L|moderate Scleroderma|Patients with Cochin hand score less than or equal to 16
62631125|NCT05171114|EXPERIMENTAL|severe Scleroderma|Patients with Cochin hand score greater than 16
62631126|NCT01878318|EXPERIMENTAL|RoActemra/Actemra|
62631127|NCT05177146|EXPERIMENTAL|Intravenous Ketamine (IV)|
62631128|NCT05602506|ACTIVE_COMPARATOR|BETAF OD arm|one tablet taken orally once daily
62631129|NCT05602506|EXPERIMENTAL|BETAF 3W arm|one tablet taken orally 3 days per week : Mondays, Wednesdays, and Fridays
62631130|NCT05602506|EXPERIMENTAL|BETAF 2W arm|one tablet taken orally 2 days per week : Mondays, and Thursdays
62631131|NCT05602506|EXPERIMENTAL|BETAF 1W arm|one tablet taken orally 1 days per week : Mondays
62631132|NCT01299818||spinal surgery|patients who undergo spinal surgery
62631133|NCT04052321|EXPERIMENTAL|3D scan arm|This is a single arm study. Patients in this arm will receive a 3D scan just prior to, 2 weeks after, as well as 6 and 12 months after Nuss bar removal.
62269809|NCT01876407|EXPERIMENTAL|Low energy laser|Administration of a low energy laser for oral mucositis.
62269810|NCT01876407|PLACEBO_COMPARATOR|Placebo|
62269811|NCT03922698||Case Group|Patients who undergo surgical intervention of carotid trombo-endo-arterectomy at the Department of Vascular Surgery of the IRCCS Neuromed, with specific inclusion/exclusion criteria
62653204|NCT02873689|EXPERIMENTAL|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
62452327|NCT03190746||No SNP|Subjects have two copies of the wild type gene
62269812|NCT00661531|EXPERIMENTAL|Estrace & Anastrozole|Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered
62269813|NCT01537757|EXPERIMENTAL|Part 1, Panel A - Severe Renal Impairment Group|
62452328|NCT03190746||SNP present|Subjects have one or two copies of the SNP
62452329|NCT04164771|EXPERIMENTAL|Moringa Group|Participants will receive 5-7g of moringa diet daily for 6 weeks.
62452330|NCT04164771|EXPERIMENTAL|Aerobic training Group|Participants will receive 5-7g of moringa diet daily and will do 30 minutes of aerobic training daily for 6 weeks.
62452331|NCT04164771|EXPERIMENTAL|Moringa and Aerobic training|Participants will do 30 minutes of aerobic training daily for 6 weeks
62452332|NCT04164771|NO_INTERVENTION|Control Group (T4)|Participants will not recieve any treatment
62452333|NCT01644890|EXPERIMENTAL|NK105|
62452334|NCT01644890|ACTIVE_COMPARATOR|Paclitaxel|
62452335|NCT02831569|EXPERIMENTAL|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
62452336|NCT05123625|NO_INTERVENTION|RC combined with lymph node dissection|When radical cystectomy was performed, pelvic lymph node dissection was also performed.
62452337|NCT05123625|EXPERIMENTAL|Only RC|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
62452338|NCT06158321|SHAM_COMPARATOR|M1 or DLPFC sham stimulation|Participants will receive M1 or DLPFC sham stimulations.
62269814|NCT01537757|EXPERIMENTAL|Part 1, Panel B - Healthy Control Group to Match Panel A|
62452339|NCT06158321|EXPERIMENTAL|M1 rTMS|Participants will receive high-frequency rTMS over M1.
62452340|NCT06158321|EXPERIMENTAL|DLPFC rTMS|Participants will receive low-frequency rTMS over DLPFC.
62269815|NCT01537757|EXPERIMENTAL|Part 2, Panel C - Moderate Renal Impairment Group|
62269816|NCT01537757|EXPERIMENTAL|Part 2, Panel D - Healthy Control Group to Match Panel C|
62269817|NCT01537757|EXPERIMENTAL|Part 2, Panel E - Mild Renal Impairment Group|
62269818|NCT01537757|EXPERIMENTAL|Part 2, Panel F - Healthy Control Group to Match Panel E|
62269819|NCT02055144||Non squamous histology|patients with advanced, non-squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and pemetrexed. Maintenance with pemetrexed is allowed.
62452341|NCT04677062|EXPERIMENTAL|GV-328|"The treatment should be carried out for 4 days. Children between 3 and 6 years old had to consume 4 pills a day, children between 7 and 10 years old 5 pills, and children between 11 and 13 years old up to 6 pills. The patient had to slowly thin the tablet in the mouth, maintaining direct contact with the area to be treated.~The study consisted of 2 visits, one initial and one final. In the initial visit , the documentation (informed consent) and the treatment were delivered. During this visit, baseline assessments of pain level, functional limitation, marginal mucosal edema, and lesion size were recorded. In addition, a photograph of the area to be treated was taken. Parents were also given a chart, in which they had to record the intensity of pain daily using the Wong-Baker face scale."
62452342|NCT04277533||Patient group|NEC preterm neonates with gestational ages are between 28-36 weeks regardless of birth weight. NEC diagnosis and staging will be according to Bell's staging criteria .
62653205|NCT02873689|EXPERIMENTAL|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
62653206|NCT04987073|EXPERIMENTAL|patients with CYP24A1 mutation|
62269820|NCT02055144||Squamous histology|patients with advanced squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and gemcitabine
62269821|NCT01944514||Ischaemic cardiomyopathy group|Patients with ischaemic cardiomyopathy attending for ICD implantation / Ventricular tachycardia stimulation testing as part of ICD risk stratification
62269822|NCT01944514||Non-ischaemic cohort|Patients attending for ICD implantation / ventricular tachycardia stimulation test who do not have ischaemic cardiomyopathy.
62269823|NCT01944514||Control group|Patients attending for electrophysiological study with no conditions that place them at risk of sudden cardiac death.
62269824|NCT02695628|EXPERIMENTAL|Diagnostic (18F-fluoromisonidazole, PET/CT, embolization)|Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.
62269825|NCT00875745|EXPERIMENTAL|Sorafenib-Vorinostat|This is a single-arm, non-randomized feasibility and safety Phase I trial of a combination of Sorafenib and Vorinostat, both administered orally.
62269826|NCT04069065|EXPERIMENTAL|Conversion to Once-daily Tacrolimus|Conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) at least one year after liver transplantation
62452343|NCT04277533||Control group|Stable preterm neonate with matched gestational and postnatal ages without infectious diseases.
62452344|NCT00058292|EXPERIMENTAL|Treatment Arm|
62452345|NCT01915732|EXPERIMENTAL|Duac™Once Daily Gel|Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
62452346|NCT01915732|ACTIVE_COMPARATOR|1% clindamycin phosphate gel|Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
62452347|NCT03874130|ACTIVE_COMPARATOR|Scopolamine|0.2 mg scopolamine HBr per dose
62452348|NCT03874130|ACTIVE_COMPARATOR|IV Scopolamine|4.0 μg/kg; 15 minute IV infusion
62064742|NCT06091462|EXPERIMENTAL|virtual reality group|"Participants in the intervention group will log into the virtual reality-based interactive therapeutic patient education program with a username and password to be defined for them on the hadi.hacettepe.edu.tr website. After completing the dementia module in this program, the participants will complete the application by switching to the virtual reality-based interactive therapeutic patient education program."
62064743|NCT06091462|NO_INTERVENTION|control group|Participants in the control group, on the other hand, will not receive any educational intervention other than standard education. In parallel with the completion of the application by the participants in the intervention group, the participants in the control group will complete the post-tests.
62452349|NCT02596334|ACTIVE_COMPARATOR|triple therapy|dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
62631134|NCT05645042|ACTIVE_COMPARATOR|Transcendental Meditation (TM):|TM treatment for PTSD is designed to reduce stress, facilitate deep rest, and increase well-being. It was originally conceptualized as an effortless technique to enable physical relaxation. The treatment will be delivered by experienced, certified TM instructors receiving weekly supervision.
62631135|NCT05645042|ACTIVE_COMPARATOR|Present Centered Therapy (PCT):|PCT is a focused time-limited treatment for PTSD that focuses on increasing adaptive responses to current life stressors and difficulties that are directly or indirectly related to trauma or PTSD symptoms. PCT was originally designed as a treatment comparator in trials evaluating the effectiveness of trauma-focused cognitive-behavioral therapies such as PE and CPT. Several clinical trials have indicated that PCT may be an effective treatment option for PTSD and that patients may drop out of PCT at lower rates relative to trauma focused forms of CBT.
62631136|NCT05828953|EXPERIMENTAL|Anlotinib|Experimental: The dosage of Anlotinib is 8mg per dose, once daily, to be taken orally before breakfast.
62269827|NCT03286985||General ICU patients|No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay \>72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
62452350|NCT02596334|EXPERIMENTAL|monotherapy|dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.
62064744|NCT01222923|ACTIVE_COMPARATOR|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
62064745|NCT01222923|EXPERIMENTAL|1|Risperidone 1 mg ODT tablets of Ranbaxy Laboratories, Ltd
62631137|NCT05828953|PLACEBO_COMPARATOR|Placebo,|control group：Placebo, take orally once daily before breakfast
62452351|NCT04987164||Feminabiane CBU Consumers|Group of consumers of Feminabiane CBU : 2 tablets of Feminabiane CBU® every day, to be swallowed with a glass of water.
62064746|NCT02579018|EXPERIMENTAL|Anorexia Nervosa (AN)|Diagnosis of anorexia spectrum disorder and stable use of all medications ≥ three months.
62064747|NCT02579018|EXPERIMENTAL|Matched Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Also age (+/- 2 years) and gender matched to AN study participant and exercise regularly.
62064748|NCT02579018|EXPERIMENTAL|Healthy Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Do not exercise regularly.
62064749|NCT05996952|EXPERIMENTAL|Adjuvant RC48-ADC|In this arm, RC48-ADC is evaluated in patients with HER2-positive high-risk non-muscle-invasive bladder cancer as an adjuvant treatment.
62064750|NCT05996952|EXPERIMENTAL|Salvage RC48-ADC|In this arm, RC48-ADC is evaluated in patients with HER2-positive non-muscle-invasive bladder cancer who failed BCG treatment as an adjuvant treatment.
62064751|NCT03597035|EXPERIMENTAL|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
62269828|NCT03124823|EXPERIMENTAL|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
62269829|NCT03202966|EXPERIMENTAL|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
62269830|NCT02187471|PLACEBO_COMPARATOR|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
62452352|NCT04987164||Control group|Control group of non consumers of Feminabiane CBU
62064752|NCT01261715|ACTIVE_COMPARATOR|Woman with previous ceasarean section - staples|
62452353|NCT04289428||A|Not currently on antiviral therapy for HBV and HBV DNA detectable
62452354|NCT04289428||B|Stable on HBV antiviral therapy for at least 3 months with HBV DNA \< 20 IU/ml
62452355|NCT05592509|ACTIVE_COMPARATOR|Supplement|This arm will take dietary supplement
62452356|NCT05592509|PLACEBO_COMPARATOR|Placebo|Placebo will take the placebo
62631138|NCT01585246|OTHER|Phase 1: The dose finding phase (DFP)|Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
62631139|NCT01585246|ACTIVE_COMPARATOR|Phase 2: RCT phase- Saw Palmetto|Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
62631140|NCT01585246|PLACEBO_COMPARATOR|Phase 2: RCT phase- Placebo|Patients received Soybean Oil Soft Gel as the placebo treatment
62064753|NCT02912468|PLACEBO_COMPARATOR|Placebo|Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
62064754|NCT02912468|EXPERIMENTAL|Dupilumab 300 mg|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.
62269831|NCT02187471|OTHER|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
62269832|NCT02187471|EXPERIMENTAL|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
62269833|NCT02187471|EXPERIMENTAL|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
62269834|NCT03970187|EXPERIMENTAL|Exposure|Phase 1 (visit 1): 60 minutes exposure-based eye contact training in VR Phase 2 (home training): 9 blocks of 20 minutes exposure-based eye contact training in VR, distributed over a total duration of maximally 2 weeks
62452357|NCT05884853|EXPERIMENTAL|ASD group|autistic adolescents with their caregiver
62452358|NCT05884853|SHAM_COMPARATOR|Control group|healthy control without their caregiver
62269835|NCT03970187|NO_INTERVENTION|Control|"Phase 1 (visit 1): waitlist. In order to prevent systematic preparation for the subsequent PST, a 60 minutes virtual reality games with fear-unrelated content will serve as the control intervention.~Phase 2 (home training): waitlist"
62269836|NCT03320122|EXPERIMENTAL|Telemedicine|Medical Direction will be provided by pediatric physiatrists using telemedicine.
62269837|NCT03320122|ACTIVE_COMPARATOR|In-Person Pediatric Physiatrist|Medical Direction will be provided by pediatric physiatrists in-person.
62269838|NCT03320122|ACTIVE_COMPARATOR|In-Person Non-Pediatric Physiatrist|Medical Direction will be provided by contracted physicians (i.e., non-pediatric physiatrists) in-person care.
62269839|NCT02071407|PLACEBO_COMPARATOR|N1(traditional treatment group)|Patients in group N1 are treated with basic therapeutic measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
62269840|NCT02071407|EXPERIMENTAL|N2(midazolam group)|Patients in group N2 was treated with intravenous infusion of midazolam on the basis of basic treatment measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
62452359|NCT04282538|ACTIVE_COMPARATOR|Group A - Active|Active rTMS for Gait Dysfunction of Hemiplegia
62452360|NCT04282538|SHAM_COMPARATOR|Group A - Sham|Sham rTMS for Gait Dysfunction of Hemiplegia
62452361|NCT04282538|ACTIVE_COMPARATOR|Group B - Active|Active tDCS for Frontal Gait Dysfunction
62452362|NCT04282538|SHAM_COMPARATOR|Group B - Sham|Sham tDCS for Frontal Gait Dysfunction
62452363|NCT01215448|NO_INTERVENTION|Lifestyle changes|Lifestyle changes(booklet and audio cassette of recommended diet, physical activity and breathing exercises)
62452364|NCT01215448|EXPERIMENTAL|Wheatgrass juice & lifestyle changes|Wheatgrass juice \& lifestyle changes
62452365|NCT01242280|ACTIVE_COMPARATOR|Self-expandable esophageal stent|"The patient will receive a self-expandable esophageal stent (SX-Ella-Danis) without endoscopical guidance but under slight sedation. An immediate X-ray will be done to assess the correct placement of the stent.~After a maximum of 7 days, the stent will be removed by using the specifically designed devices."
62631141|NCT06017622||All subjects|There is a single group consisting of all subjects who meet the eligibility criteria
62631142|NCT02360280|EXPERIMENTAL|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
62631143|NCT02360280|ACTIVE_COMPARATOR|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
62064755|NCT04848883|EXPERIMENTAL|Advanced AMS program|Three randomily assigned primary care centres in which an infectious diseases expert will be continuously in touch with primary care practitioners.
62064756|NCT04848883|ACTIVE_COMPARATOR|Standard AMS program|Three primary care centres in which a typical AMS will be promoted.
62064757|NCT01358838|ACTIVE_COMPARATOR|laser|
62269841|NCT01028846|ACTIVE_COMPARATOR|Diazoxide|1-2 mg/kg total dose given intravenously during pancreatic clamp study
62269842|NCT01028846|PLACEBO_COMPARATOR|Placebo|Intravenous normal saline during pancreatic clamp study
62631144|NCT03718390|EXPERIMENTAL|Sentinel Group 1 LYN-PLT|Sentinel dosing in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
62631145|NCT03718390|EXPERIMENTAL|Sentinel Group 2 LYN-PLT|Sentinel dosing (second) in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
62631146|NCT03718390|EXPERIMENTAL|Group 3 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind). and evaluation of gastric retention by MRI
62631147|NCT03718390|EXPERIMENTAL|Group 4 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI
62631148|NCT03718390|EXPERIMENTAL|Group 5 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI.
62631149|NCT04658979|EXPERIMENTAL|Intervention group|
62631150|NCT02412202|OTHER|patients who undergo weaning from mechanical ventilation|consecutive mechanically ventilated critical ill patients who fulfil criteria for weaning will be included
62631151|NCT05217602|EXPERIMENTAL|AC+ARwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards only if they meditate using their anchoring plan on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
62653207|NCT00070434|EXPERIMENTAL|Irinotecan + 5-FU + Leucovorin|Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.
62064758|NCT01358838|NO_INTERVENTION|no laser|
62064759|NCT02218840||Behavioral|Evaluation of cigar smoking topography
62064760|NCT04062708|EXPERIMENTAL|Treatment|Combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles.
62269843|NCT06131879|EXPERIMENTAL|Laser acupuncture|Laser acupuncture biostimulation for temporalis and masseter muscles
62269844|NCT06131879|EXPERIMENTAL|Modified physical therapy|Muscle relaxation and biofeedback for temporalis and masseter muscles
62269845|NCT01594853|EXPERIMENTAL|exercise|Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
62269846|NCT02280460||VA ECMO|Patients who are placed on VA ECMO.
62269847|NCT02280460||VV ECMO|Patients who are placed on VV ECMO.
62269848|NCT05813080|EXPERIMENTAL|CARE interventional treatment|AI-computerassisted prognosis of high risk psychosis profile and adapted study-specific therapy taking place in early-recognition centers.
62269849|NCT05813080|ACTIVE_COMPARATOR|Standard of Care Control arm|Treatment as usual (TAU) patient will receive their usual treatment from their local physicians and therapeutic personnel.
62452366|NCT01242280|ACTIVE_COMPARATOR|Sengstaken-Blakemore tube|The esophageal tamponade will be done as described elsewhere. The gastric content will be checked hourly and the correct placement of the tube will be checked by an immediate X-ray. The esophageal balloon will be inflated a maximum of 24 hours.
62631152|NCT05217602|EXPERIMENTAL|AC+RwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards if they meditate on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
62064761|NCT03906305|EXPERIMENTAL|Dry needling in a myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into trigger point spastic muscle of the shoulder.
62631153|NCT05217602|ACTIVE_COMPARATOR|Usual Calm Control (UC)|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; $20 incentive for completing the baseline, week 8, and week 16 surveys
62631154|NCT02726789|EXPERIMENTAL|Experimental|Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.
62631155|NCT03839329|EXPERIMENTAL|ACT Group Condition|The ACT group condition will receive two 90-minute group Acceptance and Commitment Training (ACT) workshops (scheduled approximately one week apart) and will complete assessments.
62631156|NCT03839329|NO_INTERVENTION|Assessment-Only Condition|The Assessment-only condition will not receive any intervention and will only complete assessments.
62064762|NCT03906305|ACTIVE_COMPARATOR|Dry needling in a non myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into a non trigger point spastic muscle of the shoulder.
62631157|NCT01416545|ACTIVE_COMPARATOR|Lifestyle counseling|Children received the same educational material for their parents and, additionaly, were exposed to a weekly educational program directed for cardiovascular prevention.
62631158|NCT01416545|PLACEBO_COMPARATOR|Control group|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
62631159|NCT03263715|EXPERIMENTAL|Tocilizumab|Tocilizumab-based regimen (Tocilizumab Prefilled Syringe \[Actemra\] 162 mg s.c. administered weekly) on top of rapidly tapered Glucocorticoid \[Glucocorticoids\]
62631160|NCT03263715|PLACEBO_COMPARATOR|Placebo|Placebo \[Placebos\] and rapidly tapered Glucocorticoid \[Glucocorticoids\] treatment
62631161|NCT06049446||Patients receiving seed localization|Patients receiving seed localization
62631162|NCT06469450|EXPERIMENTAL|Atorvastatin|atorvastatin 40 mg daily for 28 days
62631163|NCT01030016|EXPERIMENTAL|atenolol|subjects received 6 weeks of atenolol
62631164|NCT03442647|ACTIVE_COMPARATOR|Living donors|sinistrin clearance dynamic measurement
62631165|NCT03442647|ACTIVE_COMPARATOR|ADPKD patients|sinistrin clearance dynamic measurement
62631166|NCT03442647|ACTIVE_COMPARATOR|Patients with primary renal tumor|sinistrin clearance dynamic measurement
62631167|NCT03939923|ACTIVE_COMPARATOR|Neostigmine/Glycopyrrolate|Group 1: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on train of four (TOF) watch monitor reading recorded every 15 minutes. Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage).
62631168|NCT03939923|ACTIVE_COMPARATOR|Sugammadex|Group 2: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on train of four (TOF) watch monitor reading recorded every 15 minutes. Group 2 (treatment) will receive reversal with Sugammadex (2mg/kg).
62631169|NCT02472886|EXPERIMENTAL|LDV/SOF|Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
62631170|NCT02472886|EXPERIMENTAL|LDV/SOF Coinfected with HIV-1|Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
62631171|NCT02472886|EXPERIMENTAL|LDV/SOF+RBV Retreatment|Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
62631172|NCT05010746|EXPERIMENTAL|MV replacement with Innovalve MR system|MV replacement with Innovalve MR system
62631173|NCT05745545|EXPERIMENTAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|
62631174|NCT05745545|PLACEBO_COMPARATOR|Placebo|
62631175|NCT04255758|EXPERIMENTAL|Vigorous-intensity Aerobic Exercise|Vigorous-intensity aerobic exercise, single intervention
62064763|NCT04822740|EXPERIMENTAL|Novel strategy|"Inserting the CGMS device with use of the results of the device in real time by the health care team~* Insulin infusion according to the same local guidelines for insulin therapy in ACS~* Transmission of real-time data to the nurse and use of the alarms of the device~* Adaptation of insulin according to blood glucose measured by the CGMS device and according to the same protocol as the conventional arm~* Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
62064764|NCT04822740|ACTIVE_COMPARATOR|Conventional strategy|"Inserting the CGMS device without the use of the results by the health care team: blinded CGMS (use of these results only at the end of the participation to analyze the main criterion)~* Insulin infusion according to the same local guidelines for insulin therapy in ACS~* Adaptation of insulin according to the capillary blood glucose levels performed every hourly if insulin dose change, every 2 hours if stable insulin dose according to local recommendations~* Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
62631176|NCT04655508|EXPERIMENTAL|Seretide|"For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
62269850|NCT04422860|EXPERIMENTAL|Gum Arabic varnish|Gum arabic (Acacia senegal) is an exudate obtained from Acacia senegal stems and roots, and other similar African Acacia species. It consists mainly of high molecular weight polysaccharides high concentrations of calcium, magnesium, and potassium salts which can potentially increase tooth remineralization.
62269851|NCT04422860|ACTIVE_COMPARATOR|Sodium Fluoride varnish|The gold standard remineralizing agent recommended by the guidelines.
62269852|NCT04422860|ACTIVE_COMPARATOR|10% w/v CPP-ACP, 5% sodium fluoride varnish|CPP-ACP is the most studied non fluoride remineralizing agent.
62269853|NCT05716880|EXPERIMENTAL|KA+MPD|Ketosteril + Medium Protein Diet (MPD) for 12 months
62269854|NCT05716880|ACTIVE_COMPARATOR|MPD|Medium Protein Diet (MPD) for 12 months
62452367|NCT06214377|EXPERIMENTAL|Active Transcranial Direct Current Stimulation and dopaminergic medication|Active Transcranial Direct Current Stimulation (atDCS) will be applied over the Primary Motor Cortex (M1) contralateral to pain if it is unilateral, or always on the left M1 if pain is bilateral. It will consist of 1 session of 20 minutes of conventional stimulation (anode over M1) at 2 mA. It will be applied in the OFF state (i.e., \>12h after the last medication intake). Lately, patients will take its usual dopaminergic medication.
62452368|NCT06214377|SHAM_COMPARATOR|: Sham Transcranial Direct Current Stimulation and dopaminergic medication|Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex with the same procedure, during 1 session of 20 minutes of conventional stimulation. It will be applied in the OFF state (i.e., \>12h after the last medication intake). Lately, patients will take its usual dopaminergic medication.
62452369|NCT06455826|EXPERIMENTAL|Multi-ascending dose escalation study of VP-001|
62631177|NCT04655508|PLACEBO_COMPARATOR|placebo|For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
62631178|NCT05819372|EXPERIMENTAL|finite arm|
62653208|NCT00070434|EXPERIMENTAL|Irinotecan + Oxaliplatin|Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles
62269855|NCT03389035|EXPERIMENTAL|CARCIK-CD19|
62452370|NCT06364722|EXPERIMENTAL|Acupuncture group|Subjects in this group will receive real acupuncture combined with real moxibustion.
62269856|NCT03823469|ACTIVE_COMPARATOR|Intervention: Nutritional counseling + CCTP|Nutritional counseling + Culinary Coaching Telemedicine Program (CCTP)
62269857|NCT03823469|ACTIVE_COMPARATOR|Control: Nutritional counseling only|Two 30-minute nutritional counseling sessions
62269858|NCT05230186||On-Treatment Solid Tumor Responder (Tumor Biopsy)|Research tumor tissue biopsy collected at any one time point while responding to ICI therapy (radiographic regression of lesion). Tumor biopsy and companion blood sample.
62269859|NCT05230186||Pre and On-Treatment Solid Tumor Responder (Tumor Biopsy)|Tumor tissue collection prior to beginning ICI therapy (optional biopsy). If and when there is a response to ICI therapy, a second research tumor tissue biopsy is collected. Tumor biopsy and companion blood sample.
62269860|NCT05230186||On-Treatment Solid Tumor Responder (Surgical Removal Tumor)|Collection of excess tumor tissue in patients who are responding to ICI therapy and are scheduled for Surgical resection of residual disease. Excess tissue provided.
62269861|NCT05230186||Post-Treatment of patients with Melanoma who develop vitiligo|Up to 5 patients treated for melanoma that develop vitiligo - Skin Tissue Biopsy obtained at any point in time from any skin site with vitiligo (selected sites only). Tissue biopsy
62452371|NCT06364722|SHAM_COMPARATOR|Sham group|Subjects in this group will receive sham acupuncture combined with sham moxibustion.
62631179|NCT04852731|EXPERIMENTAL|Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~* According to recommendations : echocardiography, 24-hour external loop recording and exercise ECG,~* And specifically for research purposes : injected cardiac MRI and a blood collection."
62631180|NCT04852731|EXPERIMENTAL|Group A (b) : patients without mitral regurgitation with ventricular extrasystole (>10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~* According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~* And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
62631181|NCT04852731|EXPERIMENTAL|Group B : patients with Mitral valve prolapse with trivial mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~* According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~* And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
62064765|NCT03230383|EXPERIMENTAL|Cohort 1_90mg and Matching Placebo|
62269862|NCT05230186||On-Treatment Responder (Previously Frozen Tumor Tissue)|Previously Cryopreserved Tissue obtained from a Biobank or Tissue Repository, collected from patients when they were responding to ICI Therapy (clinical data required).
62631182|NCT04852731|EXPERIMENTAL|Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~* According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~* And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
62631183|NCT04852731|EXPERIMENTAL|Group D : patients with asymptomatic Mitral valve prolapse with severe mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~* According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~* And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
62269863|NCT04475055||Community sample|Participants will take part in the DIPS-interview and in an online survey.
62452372|NCT05221580||Real-world adult population of Chinese patients with T2DM|Ryzodec as per local clinical practise
62653209|NCT00070434|EXPERIMENTAL|Oxaliplatin + 5-FU + Leucovorin|Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.
62064766|NCT03230383|EXPERIMENTAL|Cohort 2_300mg and Matching Placebo|
62064767|NCT03230383|EXPERIMENTAL|Cohort 3_900mg and Matching Placebo|
62064768|NCT03230383|EXPERIMENTAL|Cohort 4_1800mg and Matching Placebo|
62064769|NCT03230383|EXPERIMENTAL|Cohort 5_3000mg and Matching Placebo|
62064770|NCT03230383|EXPERIMENTAL|Optional Cohort 6_TBD mg and Matching Placebo|
62269864|NCT03699007|EXPERIMENTAL|Graded Exposure Therapy (GET Living)|GET Living is jointly delivered by a pain psychologist and a physical therapist. The GET Living treatment was based on a published graded in-vivo exposure treatment manual for adults with adaptations to target a pediatric audience.
62452373|NCT06266377|EXPERIMENTAL|Intervention group|"Children afferent to the elementary school where Milano Ristorazione delivers meals and adolescents and young adults enrolled in the State Agricultural Technical Institute Giuseppe Garibaldi (Rome) and Institute I.P.S.E.O.A. Tor Carbone - A. Narducci."
62452374|NCT01608295|EXPERIMENTAL|Vilazodone; Viibryd|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
62064771|NCT03230383|EXPERIMENTAL|Optional Cohort 7_TBD mg and Matching Placebo|
62064772|NCT02687321||Advanced ovarian cancer patients|Patient with histologically confirmed advanced (FIGO III and IV) epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment are included into the study. The patient is regularly followed up every 3-4 months, blood sample collection is performed to determinate tumor marker found in blood, elevated by the presence of cancer recurrence. In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
62269865|NCT03699007|ACTIVE_COMPARATOR|Multidisciplinary Pain Management (MPM)|MPM is a treatment intervention that is representative of current standards of care in a multidisciplinary pain clinic setting. It consists of Cognitive Behavioral Therapy (CBT) and Physical Therapy (PT) sessions, delivered separately by a pain psychologist and a physical therapist.
62269866|NCT04293861|EXPERIMENTAL|HYMOVIS Arm|A treatment cycle consists of two injections administered at one week interval. For the purpose of this study, two treatment cycles of two injections of HYMOVIS® at baseline and 6 months will be performed per patient at V1 (Day 0), V2 (Day 7), V5 (Day 180) and V6 (Day 187).
62631184|NCT01939730|EXPERIMENTAL|Rituximab + GM-CSF|All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m\^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
62631185|NCT04001803|EXPERIMENTAL|Subjects with HIV infection|HIV-infected subjects receiving CAB LA+RPV LA will be included in this arm.
62631186|NCT06521190|ACTIVE_COMPARATOR|Active ear|An ACOU085 retard formulation is transtympanically injected into the round window niche of the middle ear.
62631187|NCT06521190|PLACEBO_COMPARATOR|Placebo ear|A matching placebo retard formulation is transtympanically injected into the round window niche of the contralateral middle ear.
62631188|NCT00540839|EXPERIMENTAL|Montelukast|Participants receive montelukast 4 mg oral granules (OG) or 4 mg chewable tablets (CT) once daily (QD) for 24 weeks and placebo to fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks. Participants aged \>6 months to \<2 years receive montelukast 4 mg packet of OG QD for 24 weeks. Participants aged \>2 years to \<64 months receive montelukast 4 mg CT QD for 24 weeks.
62631189|NCT00540839|ACTIVE_COMPARATOR|Fluticasone|Participants receive fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks and placebo to montelukast 4 mg QD for 24 weeks. Participants aged \>6 months to \<2 years receive placebo packet of OG QD for 24 weeks. Participants aged \>2 years to \<64 months receive placebo CT QD for 24 weeks.
62631190|NCT04780672|ACTIVE_COMPARATOR|Molixan|30 mg/ml solution for intravenous and intramuscular injection. Pharmacotherapeutic group: Metabolic agent. ATC code: V03AX - other medicinal products
62631191|NCT04780672|PLACEBO_COMPARATOR|Placebo|"Sol. of NaCl (Sodium chloride) - 0.9% Pharmacotherapeutic group: Regulators of water-electrolytic balance and acid-base balance.~ATC: B05CB01 Sodium chloride"
62631192|NCT05851248|EXPERIMENTAL|Buccal muco-gingival tissue graft|
62631193|NCT05851248|ACTIVE_COMPARATOR|Palatal connective tissue graft|
62631194|NCT04240951|OTHER|Study Session 1|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the laboratory
62631195|NCT04240951|OTHER|Study Session 2 (repeat of Study Session 1)|Arm Type: Validation: Regional sweat collection with prototype vs. reference patch in the laboratory
62631196|NCT04240951|OTHER|Study Session 3|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
62064773|NCT06422455|EXPERIMENTAL|Intervention Phase Arm A (PERLA)|Patients receive access to PERLA comprising pre-test genetics education and standard post-test provider-based genetic counseling over 20-60 minutes. .
62064774|NCT06422455|ACTIVE_COMPARATOR|Intervention Phase Arm B (usual care)|Patients receive access to usual care pre- and post-test provider-based genetic counseling.
62064775|NCT01985828|EXPERIMENTAL|Intermediate Risk|"Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy~OR~Short term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)"
62269867|NCT06317194|EXPERIMENTAL|Active kTMP|Participants received 2-8 V/m of active stimulation
62631197|NCT04240951|OTHER|Study Session 4 (repeat of Study Session 3)|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
62269868|NCT06317194|SHAM_COMPARATOR|Sham kTMP|Participants received 0.01 V/m of sham stimulation
62064776|NCT01985828|EXPERIMENTAL|High Risk|Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost
62064777|NCT02710786||Gastric bypass|Patients undergoing gastric bypass
62631198|NCT04240951|OTHER|Study Session 5|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
62631199|NCT04240951|OTHER|Study Session 6 (repeat of Study Session 5)|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
62631200|NCT00848900|NO_INTERVENTION|Control|
62064778|NCT03035305|EXPERIMENTAL|SMC and LNS (intervention group)|Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
62631201|NCT00848900|EXPERIMENTAL|Outdoor activity|Adding 1 hour outdoor time into school curricula
62631202|NCT06613295|ACTIVE_COMPARATOR|Separation surgery followed by stereotactic ablative body radiotherapy|Surgery will take place within 21 days after randomisation. Surgical planning is done by the treating neurosurgeon in the participating center where the patient was included. The goal of separation surgery for intraspinal MESCC is to remove intraspinal epidural disease to allow a margin between the spinal cord (or cauda equina) and the treated radiotherapy volume, and to provide histological diagnosis or confirmation of the metastasis. The decompression should be as minimal invasive as possible, i.e. only intraspinal tumour tissue should be removed, while preserving as much as possible all of surrounding spinal structures. Separation surgery must be followed by SABR after minimum 2 and maximum 4 weeks postoperatively. Image-guided fractionated SABR using a SIB technique to the high-dose PTV will be delivered in 5 fractions of 8 Gy to a total of 40 Gy and to the conventional-dose PTV delivered simultaneously in 5 fractions of 4 Gy to a total of 20 Gy.
62631203|NCT06613295|EXPERIMENTAL|Stereotactic ablative body radiotherapy|SABR will start within 21 days of randomisation. Image-guided fractionated SABR using a SIB technique to the high-dose PTV will be delivered in 5 fractions of 8 Gy to a total of 40 Gy and to the conventional-dose PTV delivered simultaneously in 5 fractions of 4 Gy to a total of 20 Gy.
62064779|NCT03035305|OTHER|SMC only (control group)|Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
62064780|NCT00603265|EXPERIMENTAL|ADL5859|2 x 50 milligrams (mg) ADL5859 capsules administered orally once in the morning and once in the evening for 28 days
62064781|NCT00603265|ACTIVE_COMPARATOR|Duloxetine|2 x 30 mg duloxetine capsules administered orally once in the morning and 2 placebo capsules filled with lactose administered orally once in the evening for 28 days
62064782|NCT00603265|PLACEBO_COMPARATOR|Placebo|2 placebo capsules filled with lactose administered orally once in the morning and once in the evening for 28 days
62064783|NCT00944658|PLACEBO_COMPARATOR|Placebo|placebo twice a day for 12 weeks, 4 weeks follow up
62064784|NCT00944658|ACTIVE_COMPARATOR|Apremilast|30 mg twice a day for 12 weeks, 4 weeks follow up
62064785|NCT01674621|EXPERIMENTAL|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
62631204|NCT05672316|EXPERIMENTAL|Treatment (botensilimab, balstilimab and regorafenib)|Patients receive botensilimab IV, balstilimab IV, and regorafenib PO on study. Patients also undergo CT and collection of blood throughout the study.
62064786|NCT01674621|EXPERIMENTAL|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
62064787|NCT01674621|EXPERIMENTAL|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
62064788|NCT01674621|ACTIVE_COMPARATOR|Abaloparatide Injection (80 mcg)|Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
62064789|NCT01674621|PLACEBO_COMPARATOR|Abaloparatide Transdermal Placebo (0 mcg)|Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months
62269869|NCT05800249|EXPERIMENTAL|Dose Escalation|"A total of 9 dose groups are expected to be evaluated in Phase Ia: 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg, 6 mg/kg, and 10 mg/kg. One subject will be enrolled in the starting dose group of 0.03 mg/kg (if any ≥ Grade 2 dose-related adverse event is observed in this group during the DLT observation period, the group will be changed to the 3 + 3 method), and 3 or 6 subjects will be enrolled in each of other dose groups. The first 2 subjects in the same dose group shall receive the first dose at an interval of at least 48 hours to avoid acute hypersensitivity reactions, and the specific interval shall be determined by the investigator based on the safety assessment of subjects in the previous dose group. Ultimately, the sponsor and the investigator will determine whether an increase in dose group or in a specific fixed dose is required according to the actual situation of the trial."
62064790|NCT06031597|EXPERIMENTAL|Cohort A: concurrent chemoradiotherapy combined with ICIs|For performance status (PS)=0-1 and both lungs V20≤20%, mean lung dose (MLD)≤11 gray(Gy), then the patient should be treated with concurrent chemo-radiotherapy and immunotherapy, and immunotherapy should be given after chemo-radiotherapy to maintain up to 1 year. Participants eligible for enrollment will receive radiotherapy within 8 weeks of the end of chemotherapy combined with Immune checkpoint inhibitors (ICIs) at a radical prescribed dose of 60 Gy ± 10% at 2 Gy once daily for 5 days per week. The chemotherapy regimen will be cisplatin at a dose of 25 mg/m2 once a week for 5-6 cycles. Marketed programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors are chosen as immunotherapy agents. Immunotherapy will be given every 3 weeks, with no more than 3 cycles of immunotherapy during radiotherapy. The dosage is recommended according to the drug insert.
62269870|NCT06340932||Standard of Care|Treatment of pain as per standard of care. Patients will receive regional anesthesia blocks, acetaminophen, and as needed opioids; tramadol and oxycodone postoperatively for pain management.
62631205|NCT05525546|EXPERIMENTAL|Group A: Full-Strength Formulation|Individuals receive one dose of full-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
62631206|NCT05525546|EXPERIMENTAL|Group B: Half-Strength Formulation|Individuals receive one dose of half-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
62631207|NCT05525546|EXPERIMENTAL|Group C: Dilutional Half-Strength Formulation|Individuals receive one dose of dilutional half-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
62631208|NCT05525546|PLACEBO_COMPARATOR|Group D: Placebo|Individuals receive one dose of placebo. Subsequent blood samples are taken for safety and immunological testing.
62631209|NCT01243515||Chronic Kidney Disease|minimum 7 subjects (male and female)
62631210|NCT01243515||Healthy subjects|minimum 3 subjects (male and female)
62269871|NCT06340932||Opioid Avoidance|Preoperatively patients will receive cryoneurolysis of 5 sensory nerves that innervate the knee 7 to 21 days before surgery. Patients will receive perioperative NSAIDs and acetaminophen along with regional anesthesia. For postoperative pain control patients will receive scheduled acetaminophen and NSAIDs and may request opioids as needed.
62269872|NCT02949752|EXPERIMENTAL|Aripiprazole Adjunct|Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
62269873|NCT04509310|EXPERIMENTAL|Active Bodysuits|The potential materials that can provide support are 3D printable rigid materials, semirigid foam padding, Velcro tape and stretchable wide waistbands. The 3D printable materials can be very versatile in terms of properties and can be further finished with an epoxy resin or thermoplastics. Different compositions and structures of knitted fabrics will be used in different areas of the proposed bodysuits to provide a close fit, high breathability and effective pain management due to extra support. The fastening system includes a magnetic zipper and pulley system that can be adjusted by pulling on knobs. The pulley system contains a microadjustable dial, super-strong lightweight lacing, and low friction lacing guides.
62269874|NCT04674592||Tibial fracture|Patients with a traumatic tibial fracture and without acute compartment syndrome.
62269875|NCT04674592||Tibial fracture complicated by acute compartment syndrome|Patients with a tibial fracture and acute compartment syndrome of fractured leg.
62452375|NCT01608295|EXPERIMENTAL|Paroxetine; Paxil|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
62452376|NCT00287118|EXPERIMENTAL|Efalizumab|
62452377|NCT04112485|OTHER|Open discectomy|This group of patients are treated by open discectomy
62452378|NCT04112485|OTHER|Microdiscectomy|This group of patients are treated by Microdiscectomy
62631211|NCT05654064|ACTIVE_COMPARATOR|Remifentanil-dexmedetomidine|
62631212|NCT05654064|ACTIVE_COMPARATOR|Dexmedetomidine- fentanyl|
62631213|NCT02749162|PLACEBO_COMPARATOR|Group A|After the spinal anesthesia regressed, the investigators performed a single shot femoral block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS \<3. After 2 h morphine was administered SC ½ of the total loading dose at request.
62452379|NCT00758849|PLACEBO_COMPARATOR|1|
62452380|NCT00758849|ACTIVE_COMPARATOR|2|
62452381|NCT05815381||Fibromyalgia patients|Female sex, age 20-65 years and fulfilling the ACR 1990 and ACR 2016 fibromyalgia diagnostic criteria.
62452382|NCT05815381||Healthy controls|Sex and age matched healthy controls.
62269876|NCT04674592||Acute compartment syndrome without fracture|Patients with acute compartment syndrome but without a fracture.
62269877|NCT05395065||SDF/FV|Topical Application of 38% silver diamine fluoride and 2.5% sodium fluoride varnish at baseline and 6 months
62269878|NCT01421550|ACTIVE_COMPARATOR|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
62269879|NCT01421550|ACTIVE_COMPARATOR|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
62452383|NCT02252679||Osteoporosis|Postmenopausal women, men \> age 50 years, or other patients with well-established causes of secondary osteoporosis (incl. glucocorticoid-induced osteoporosis, transplantation-related osteoporosis, disuse osteoporosis, etc.) N=20 treated with antiresorptive drugs N=10 treated with osteoanabolic drugs (e.g. teriparatide, Forsteo)
62064791|NCT06031597|EXPERIMENTAL|Cohort B: concurrent radiotherapy combined with ICIs|For PS=0-1 and 20%\<both lungs V20≤25% or 11Gy\<MLD≤13Gy, radiotherapy alone combined with concurrent immunotherapy, followed by immunotherapy up to 1 year. Participants eligible for enrollment will receive radiotherapy within 8 weeks of the end of chemotherapy combined with ICIs at a radical prescribed dose of 60 Gy ± 10% at 2 Gy once daily for 5 days per week. Marketed PD-1 or PD-L1 inhibitors are chosen as immunotherapy agents. Immunotherapy will be given every 3 weeks, with no more than 3 cycles of immunotherapy during radiotherapy. The dosage is recommended according to the drug insert.
62269880|NCT04655664|EXPERIMENTAL|Treatment Group|Men and women aged 18-60 years, not currently experiencing chronic pain, kidney problems, liver problems, or other hormone disorders
62631214|NCT02749162|ACTIVE_COMPARATOR|Group B|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg and 4 mg dexamethasone phosphate. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS \<3. After 2 h morphine was administered SC ½ of the total loading dose at request.
62064792|NCT06031597|EXPERIMENTAL|Cohort C: radiotherapy|For PS=2 or 25%\<both lungs V20≤30% or 13Gy\<MLD≤17Gy, radiotherapy alone, followed by immunotherapy for up to 1 year. Participants eligible for enrollment will receive radiotherapy within 8 weeks of the end of chemotherapy combined with ICIs at a radical prescribed dose of 60 Gy ± 10% at 2 Gy once daily for 5 days per week. Marketed PD-1 or PD-L1 inhibitors are chosen as immunotherapy agents. The dosage is recommended according to the drug insert.
62064793|NCT05963152|PLACEBO_COMPARATOR|Control|Habitual Physical Activity
62064794|NCT05963152|EXPERIMENTAL|Morning exercise|Exercise training between 6-10am
62064795|NCT05963152|EXPERIMENTAL|Afternoon exercise|Exercise training between 4-8pm
62269881|NCT04655664|ACTIVE_COMPARATOR|Regularly Group|Subjects who consumed vitamin D supplements regularly, were pregnant, or were breastfeeding.
62631215|NCT02749162|ACTIVE_COMPARATOR|Group C|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg+ lidocaine 1% 200 mg and 8 mg dexamethasone phosphate.After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS \<3. After 2 h morphine was administered SC ½ of the total loading dose at request.
62064796|NCT02410967|EXPERIMENTAL|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
62064797|NCT02410967|PLACEBO_COMPARATOR|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
62064798|NCT01788696|ACTIVE_COMPARATOR|Group A - Early Imaging|Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52.
62064799|NCT01788696|ACTIVE_COMPARATOR|Group B - Delayed Imaging|Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment). Scan will take place at week 26 and week 52.
62064800|NCT01161472|EXPERIMENTAL|4mg fesoterodine|
62064801|NCT01161472|EXPERIMENTAL|fesoterodine 8mg|
62064802|NCT01161472|ACTIVE_COMPARATOR|1mg alprazolam|
62269882|NCT02849795|EXPERIMENTAL|Psoriasis and arthritic psoriasis|additional blood sample for biological analyses bone densitometry questionnaires
62064803|NCT01161472|PLACEBO_COMPARATOR|Placebo|
62064804|NCT06230458|OTHER|Asthma patients without reversibility|Asthma patients without reversibility
62064805|NCT02842944|EXPERIMENTAL|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
62269883|NCT00646542|EXPERIMENTAL|1|
62269884|NCT00646542|PLACEBO_COMPARATOR|2|
62269885|NCT04951037|EXPERIMENTAL|Fully Asynchronous Online Savvy Program|Family caregivers of PLWD taking part in a fully asynchronous online caregiver education program.
62064806|NCT02842944|ACTIVE_COMPARATOR|Routine care|"* Connect and start Beacon with advice disabled~* Standardized routine care"
62064807|NCT05529784||Severe, uncontrolled CRSwNP patients in therapy with Dupilumab|
62064808|NCT02872298|EXPERIMENTAL|Treatment|Treatment: Targeted Lung Denervation (TLD)
62064809|NCT01216163|EXPERIMENTAL|Treatment A|
62064810|NCT01216163|ACTIVE_COMPARATOR|Treatment B|
62064811|NCT01216163|PLACEBO_COMPARATOR|Treatment C|
62269886|NCT05097456|ACTIVE_COMPARATOR|Laser treatment|carbon dioxide treatment
62269887|NCT05097456|SHAM_COMPARATOR|Sham treatment|sham treatment
62269888|NCT00480610|EXPERIMENTAL|1|
62452384|NCT02252679||Calcium malabsorption|N=10 Patients with clinically obvious potential causes of calcium malabsorption (incl. severe vitamin D-deficiency, Scopinaro or other bariatric surgery, exocrine pancreatic insufficiency/steatorrhea, cystic fibrosis, inflammatory bowel disease, celiac disease, anorexia nervosa/eating disorders, malnutrition, etc.), with or without bone pains, muscle weakness and other typical osteomalacia symptoms. Confirmed by 24h urine collection showing calciuria \<100 mg/24h.
62064812|NCT04652830|ACTIVE_COMPARATOR|Naprapathy training|Training program for three months
62269889|NCT00480610|PLACEBO_COMPARATOR|2|
62269890|NCT06216665|ACTIVE_COMPARATOR|Continuous insulin at 40mU/m2/min|Paricipants will receive insulin infused continuously during the hyperinsulinemic euglycemic clamp test of insulin sensitivity.
62269891|NCT06216665|EXPERIMENTAL|Pulsatile insulin at 40mU/m2/min|Participants will receive insulin infused every five minutes during the hyperinsulinemic euglycemic clamp test of insulin sensitivity
62269892|NCT05547178||Eurythmy Therapy (performed as part of the ENTAiER main study)|
62269893|NCT05547178||Tai Chi (performed as part of the ENTAiER main study)|
62269894|NCT05547178||Standard Care|
62269895|NCT04734912|OTHER|Gastroscopy in transnasal technique|All patients with indication for gastroscopy in transnasal techqiue are included.
62269896|NCT05860062|PLACEBO_COMPARATOR|calcium+topiramate/amitriptyline|Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
62269897|NCT05860062|EXPERIMENTAL|vitamin D3/calcium+topiramate/amitriptyline,|Patients with prophylactic treatment (amitriptyline, topiramate) + Vitamin D and calcium supplementation: 1 Tablet every 24 hours containing: Calcium carbonate 1666.670 mg (600 mg calcium) + Vitamin D3 6.2 mg (400 IU).
62269898|NCT05860062|ACTIVE_COMPARATOR|vitamin D+topiramate/amitriptyline|Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)
62452385|NCT02252679||Various disorders|Exploratory, heterogeneous group of calcium-related disorders (incl.hypercalcemia, hypocalcemia, primary/secondary/tertiary hyperparathyroidism, hypoparathyroidism, vitamin D deficiency, X-linked/autosomal dominant hypophosphatemic rickets, familial hypocalciuric hypocalcemia,etc.) N=20
62452386|NCT02252679||Normal control subjects|N=40 Men and women ≤ 40 years recruited from the population
62064813|NCT04652830|PLACEBO_COMPARATOR|Control group|No change of daily routines
62064814|NCT02218528|PLACEBO_COMPARATOR|Starchy meal|No Plant-based ingredient added to a starchy meal
62064815|NCT02218528|ACTIVE_COMPARATOR|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
62064816|NCT02218528|PLACEBO_COMPARATOR|Starchy meal and side dish|No Plant-based ingredient added to starchy meal and side dish
62064817|NCT02218528|ACTIVE_COMPARATOR|Low dose added to starchy meal and side dish|Plant-based ingredient in low dose added to starchy meal and side dish
62064818|NCT02218528|ACTIVE_COMPARATOR|Medium dose added to starchy meal and side dish|Plant-based ingredient in medium dose added to starchy meal and side dish
62064819|NCT02218528|ACTIVE_COMPARATOR|High dose added to starchy meal and side dish|Plant-based ingredient in high dose added to starchy meal and side dish
62064820|NCT04826328|EXPERIMENTAL|FX301 Low Dose Low Volume|65 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
62064821|NCT04826328|EXPERIMENTAL|FX301 Low Dose High Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
62064822|NCT04826328|EXPERIMENTAL|FX301 High Dose Low Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
62064823|NCT04826328|EXPERIMENTAL|FX301 High Dose High Volume|260 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
62064824|NCT04826328|PLACEBO_COMPARATOR|Normal Saline|Low or high matching volume of preservative-free normal saline given as a single injection adjacent to the sciatic nerve of the popliteal fossa
62064825|NCT05854030||advanced lung squamous carcinoma|advanced pulmonary carcinoma with pathological diagnosis of squamous cell and are applied with first line treatment of anti-PD-L1 combined with chemotherapy
62064826|NCT05854030||normol volunteers|10 normol volunteers will be enrolled in the group
62269899|NCT00786578||1|overweight runners (BMI\>25)
62269900|NCT00786578||2|lean runners (BMI\<24)
62269901|NCT05656924|EXPERIMENTAL|digital prosthetic interface technology group|Study participants randomized to this group will use the digital prosthetic interface technology developed by Bionic Skins.
62269902|NCT05656924|NO_INTERVENTION|traditional socket and liner technology group|Study participants randomized to this group will use a traditional socket-liner technology (i.e., study participants will use their own liner and socket system).
62064827|NCT04902820|EXPERIMENTAL|PrEPTECH intervention recipients|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine \[200 mg\]/tenofovir disoproxil fumarate \[300 mg\]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
62064828|NCT04902820|ACTIVE_COMPARATOR|Control resource-list only recipients|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
62452387|NCT01805609|EXPERIMENTAL|Working with the Caregiving Family (WCF) training|This is a new training curriculum for inpatient oncology providers called Working with the Caregiving Family (WCF) training, a program designed to teach MSKCC inpatient staff to address family-level concerns during acute hospitalization. The WCF training will teach staff to recognize and inquire about areas of family distress that are likely to impact the caregiving process; to provide brief, supportive interventions, and/or to transition families to specialized support services when needed. We will provide staff with skills to address especially challenging family situations (e.g., noncompliance with medical care, conflict, poor communication) in collaborative and compassionate ways. We will teach clinicians to intervene and respond more effectively when problematic relationships develop within families or between families and larger systems (e.g., medical team, institutional programs).
62452388|NCT04941664|OTHER|Levobupivacaine|Superior trunk nerve block will be done under ultrasound guidance to patients scheduled for shoulder surgeries. Local anesthetic agent (0.5% levobupivacaine) 8ml will be injected at the superior trunk of the brachial plexus in order to produce surgical anesthesia or analgesia for shoulder surgeries.
62452389|NCT01619748||Untreated OSA patients|Patients with obstructive sleep apnoea who are untreated
62452390|NCT01619748||OSA patients highly compliant with CPAP|OSA patients established on CPAP therapy (high compliance, \> 80% nightly use for ≥ 4 h per night)
62452391|NCT01619748||OSA patients poorly compliant with CPAP|OSA patients established on CPAP therapy (poor compliance, 10% \< nightly use \< 50% or \< 4 h per night)
62452392|NCT01619748||Age and BMI-matched controls|Age and BMI-matched controls without OSA
62452393|NCT03797755||Palliative Cancer Patients|Stage IV cancer patients evaluated for palliative radiotherapy.
62631216|NCT02030119|ACTIVE_COMPARATOR|Control|The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved their goal for the prior day.
62064829|NCT00894634|EXPERIMENTAL|Brompheniramine maleate|Brompheniramine maleate oral solution 1 mg/5 mL, single dose
62631217|NCT02030119|EXPERIMENTAL|Gain Framing|Participants will be told that they will earn money for each day they walk at least 7000 steps. Each participant will receive either an email or text message (based on the participant's preference) stating whether or not he/she achieved the goal for the prior day and can collect the earnings. Non-adherent participants will receive messages about how much they would have earned had they met their target step goal.
62631218|NCT02030119|EXPERIMENTAL|Loss Framing|The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
62631219|NCT02030119|EXPERIMENTAL|Daily Lottery|Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
62631220|NCT04360369|ACTIVE_COMPARATOR|Goldmann Applanation Tonometer|Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.
62631221|NCT04360369|ACTIVE_COMPARATOR|ORA G3 and ic100|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.
62631222|NCT04360369|EXPERIMENTAL|Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.
62631223|NCT02465164|OTHER|Cook catheter|Control
62631224|NCT02465164|ACTIVE_COMPARATOR|Cook catheter plus low dose oxytocin|Test group
62631225|NCT03209193|EXPERIMENTAL|Sevoflurane|Sevoflurane (2 vol%) use as a maintenance volatile anesthetic drug during the surgery
62631226|NCT03209193|EXPERIMENTAL|Desflurane|Desflurane (6 vol%) use as a maintenance volatile anesthetic drug during the surgery
62631227|NCT03419117|EXPERIMENTAL|Treatment|Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection
62064830|NCT02118337|EXPERIMENTAL|MEDI0680 0.1 mg/kg + Durvalumab 3 mg/kg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.
62269903|NCT03579355|EXPERIMENTAL|DFND Program|"Dentist Fighting Nicotine Dependence, (DFND) intervention program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills. DFND was administered over 5 weeks, at a rate of 2 sessions per week. Each session lasts an hour. Fourteen classrooms in four schools represented the experimental arm and received DFND."
62631228|NCT03419117|PLACEBO_COMPARATOR|Placebo|Patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.
62631229|NCT01581515|ACTIVE_COMPARATOR|P-E group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
62631230|NCT01581515|ACTIVE_COMPARATOR|X-P group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
62631231|NCT06170944|EXPERIMENTAL|Remote ischemic preconditioning and guideline-based treatment|5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), once or twice daily for 12 months.
62631232|NCT06170944|NO_INTERVENTION|Guideline-based treatment|Guideline-based treatment.
62631233|NCT03202446|EXPERIMENTAL|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
62631234|NCT03202446|EXPERIMENTAL|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
61978557|NCT01220882|NO_INTERVENTION|Radiographic skeletal age assessment|Participant group studied will include all pediatric patients presenting to our institution with a unilateral or bilateral SCFE. Patients with metabolic and endocrine conditions will be included.
61978558|NCT02511366|EXPERIMENTAL|ileal infusion of casein|Ileal infusion of casein
61978559|NCT02511366|PLACEBO_COMPARATOR|ileal infusion of tap water|ileal infusion of tap water
62064831|NCT02118337|EXPERIMENTAL|MEDI0680 0.1 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
62631235|NCT03202446|ACTIVE_COMPARATOR|Arm 3: Control Arm|Patients will receive the standard of care.
62631236|NCT03283930|EXPERIMENTAL|Active Intervention|Children and adolescent participants with anxiety disorder receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete the Active Attention Bias Modification Training (ABMT), computer-based attention bias modification training aimed at re-training attentional biases before a CBT session: Part 1. modified dot-probe task, where a target is always presented at the previous location of the neutral and not the simultaneously presented threatening stimulus. Part 2. visual search, where the targets are always presented distally of threatening distractors.
62064832|NCT02118337|EXPERIMENTAL|MEDI0680 0.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
62064833|NCT02118337|EXPERIMENTAL|MEDI0680 2.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
62064834|NCT02118337|EXPERIMENTAL|MEDI0680 10 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
62064835|NCT02118337|EXPERIMENTAL|MEDI0680 20 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
62064836|NCT02118337|EXPERIMENTAL|MEDI0680 20 mg/kg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
62269904|NCT03579355|NO_INTERVENTION|Informational Booklet|Fourteen classrooms in four schools represented the No Intervention arm (control). They received only an informational booklet about tobacco adverse health effects.
62269905|NCT01309074|EXPERIMENTAL|Pregabalin|Pregabalin is an antiepileptic medication which has been found in double blind placebo controlled trials to be effective and safe in the treatment of primary generalized anxiety disorder. It has an indication for the treatment of this condition in Europe \& Canada but not in the US.
62269906|NCT01309074|ACTIVE_COMPARATOR|Sertraline|Sertraline is an SSRI found to be an effective treatment of generalized anxiety disorder in controlled trials. It does not have an indication for this in this country.
62452394|NCT00981604|ACTIVE_COMPARATOR|SILS Cholecystectomy|Single Incision Laparoscopic Cholecystectomy
61978560|NCT04977583|EXPERIMENTAL|Screening|Participants in this arm will be screened for unmet social needs and receive a post card that includes a list of generic VA crisis and homeless hotlines.
61978561|NCT04977583|EXPERIMENTAL|Awareness|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, and receive a Resource Sheet tailored to the unmet needs identified in the unmet need screen. The Resource Sheet will include the names of available resources within the VA and/or local community that can help to address the identified need(s) and contact information and hours of operation.
61978562|NCT04977583|EXPERIMENTAL|Assistance|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, receive a tailored Resource Sheet, and be offered assistance from a Social Worker. If accepted, the SW will contact the participant and work with them over a period of 8 weeks to help facilitate their connection to resources than can help to address the unmet need(s) identified in the unmet need screen.
61978563|NCT05455788||Patients undergoing Cardiac valve replacement|
61978564|NCT01170507|ACTIVE_COMPARATOR|vitamin D3 1000 IU|
61978565|NCT01170507|ACTIVE_COMPARATOR|Vitamin D3 3000 IU|
61978566|NCT01170507|ACTIVE_COMPARATOR|Vitamin D3 5000 IU|
61978567|NCT01170507|PLACEBO_COMPARATOR|Placebo|
62269907|NCT03442543|EXPERIMENTAL|charcoal|
62269908|NCT03442543|EXPERIMENTAL|silver wire|
62269909|NCT01903512||arthrocentesis in TMJ internal derangement|30 patients with TMJ internal derangement and pain with history of failed conservative management.
62452395|NCT00981604|ACTIVE_COMPARATOR|Standard Laparoscopic Cholecystectomy|4 port laparoscopic cholecystectomy
62452396|NCT03820921||PATIENTS WITH PANCREATIC CANCER|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNB for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNB will be further verified during a clinical follow-up of at least 6 months.~Immunochemistry will be performed on the EUS-FNB specimens to determine PD-L1 expression and MMR status"
62269910|NCT04956159|ACTIVE_COMPARATOR|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) twice daily for two weeks (20 sessions). The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
62064837|NCT02118337|EXPERIMENTAL|MEDI0680 20 mg/kg + Durvalumab 750 mg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
62269911|NCT04956159|SHAM_COMPARATOR|Sham iTBS rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse twice daily for two weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.
62269912|NCT03762759|EXPERIMENTAL|Arm I (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
62269913|NCT03762759|ACTIVE_COMPARATOR|Arm II (68Ga-PSMA, PET/CT)|Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
62269914|NCT06141278|EXPERIMENTAL|Intervention|Stakeholder-based participatory research will be conducted after CFIR-ERIC mapping activities to focus on partnerships, engagement, co-learning, and developing interventions incorporating interventions on existing practices. Three workshops will be held to reach agreements on the intervention tools, the implementation structure, the data collection procedures and the study audit process among the research team, local policymakers, and implementers. The participants and contents of each workshop are shown in Table 1. At the end of the workshop series, the implementation team from each county prepared a proposed intervention plan describing the steps needed to achieve their goals within a set timeline. The agreed plan of action considered their constraints and how to overcome those barriers.
62269915|NCT06141278|NO_INTERVENTION|Control|Usual care
62269916|NCT05779826|EXPERIMENTAL|Play Dough Group|Play dough was played while receiving nebulizer therapy for the children in play dough group.
62631237|NCT03283930|PLACEBO_COMPARATOR|Control Intervention|Children and adolescent participants with anxiety disorder receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete the control intervention before a CBT session: Part 1. dot-probe task, where a target is equally randomly presented at the previous location of the neutral or the simultaneously presented threatening stimulus. Part 2. visual search, where the targets are equally randomly presented distal of neutral and threatening distractors.
62269917|NCT05779826|NO_INTERVENTION|Routine Treatment Group|Play dough was not used for the children in the routine treatment group. Routine nebulizer treatment was applied to this group.
62269918|NCT01707472|EXPERIMENTAL|Simtuzumab in HIV Patients|HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
62269919|NCT01707472|EXPERIMENTAL|Simtuzumab in HCV Patients|HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks.
62269920|NCT01707472|EXPERIMENTAL|Simtuzumab in HIV/HCV Co-Infected Patients|HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
62269921|NCT02298764|ACTIVE_COMPARATOR|standard + 10 psychotherapeutic sessions|- standard back pain treatment plus 10 psychotherapeutic sessions, that will include the shock-trauma method 'Somatic Experiencing'.
62269922|NCT02298764|ACTIVE_COMPARATOR|Standard back pain treatment|Standard back pain treatment
62269923|NCT04063371||Control Group 1|At least one location will serve as the control office and will continue to conduct their visits including screening for cognitive impairment as they normally do using their usual method based on the primary care provider's normal practice.
62269924|NCT04063371||Intervention Group|At least one different location will serve as the intervention office where all the providers, as their standard of care, use a standardized method for screening for cognitive impairment consisting of using the SAGE or eSAGE test and having a conversation with an individual who knows the patient well (if possible) to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
62269925|NCT04063371||Control Group 2|Control group 2 consists of patients handled by the intervention office who did not complete the SAGE or eSAGE.
62269926|NCT04204252|ACTIVE_COMPARATOR|Inhaled AAT|"Daily inhalation of 80 mg/day Kamada-AAT for Inhalation for 104 weeks"
62064838|NCT02118337|ACTIVE_COMPARATOR|Nivolumab 240 mg|Participants in dose-expansion phase will receive IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
62064839|NCT02081222||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease in 2013 at Samsung Medical Center
62269927|NCT04204252|PLACEBO_COMPARATOR|Placebo|Daily inhalation of a solution of NaCl in phosphate buffer solution with 0.01% TWEEN-80
62269928|NCT05873244|EXPERIMENTAL|Experiment arm|"* Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks"
62269929|NCT05873244|OTHER|Control arm|"Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily"
62269930|NCT00783094|EXPERIMENTAL|Tadalafil 2.5 milligrams (mg)|2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
62269931|NCT00783094|EXPERIMENTAL|Tadalafil 5 mg|5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
62269932|NCT00783094|PLACEBO_COMPARATOR|Placebo|"Placebo tablet taken by mouth once a day for 12 weeks.~Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks."
62269933|NCT01731652|EXPERIMENTAL|TMX-101|TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
62269934|NCT04640883|EXPERIMENTAL|Sprints during low-intensity cycling|
62269935|NCT04640883|ACTIVE_COMPARATOR|Low-intensity cycling|
62269936|NCT03826732|EXPERIMENTAL|Guided self-help based on ACT|Participants follow a self-help program and receive weekly support by trained facilitators
62631238|NCT01381926|EXPERIMENTAL|Exenatide then Placebo|"Study participants in phase1 will receive the study drug, exenatide, at a dose of 5mg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the dose of exenatide will be increased to 10mg subcutaneously twice daily before meals for one month. During the third month of the study, no study medication will be given and this will serve as a wash out period prior to the second phase of the study (placebo). During the fourth and fifth months, study participants will get placebo alternatives to exenatide 5mg and exenatide 10mg, respectively, subcutaneously twice daily before meals."
62631239|NCT01381926|ACTIVE_COMPARATOR|Placebo then Exenatide|"Study participants in phase1 will receive the saline placebo, at a dose of 5mcg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the saline placebo will be increased to 10mcg subcutaneously twice daily before meals for one month. During the third month of the study, no treatment will be given and this will serve as a wash out period prior to the second phase of the study. During the fourth month study participants will receive Exenatide 5mcg twice daily with meals. During the fifth month, study participants will receive exenatide 10mcg, subcutaneously twice daily before meals."
62064840|NCT03515057|EXPERIMENTAL|Atrial Fibrillation Spot-Check|For eligible patients from primary care clinics randomly selected for the Atrial Fibrillation Spot-Check arm, practice medical assistants will screen assenting patients for undiagnosed AF during regularly scheduled office visits using a single-lead handheld electrocardiogram (ECG). Single-lead handheld electrocardiogram readings detecting AF will be confirmed during the same office visit with a standard 12-lead ECG at the discretion of the primary care physician. If AF is detected, the patient's PCP will be able to address the condition with them during the clinic visit and initiate appropriate follow-up to manage the AF.
62631240|NCT00570960|EXPERIMENTAL|1: Dextran 70|antibiotic therapy in addition to dextran 70, 1.0 g/kg on days one, two and three
62631241|NCT00570960|ACTIVE_COMPARATOR|2: Standard of Care Human Albumin|antibiotic therapy in addition to human albumin, 1.5 g/kg on day one and 1.0 g/kg on day three
62631242|NCT03723863|EXPERIMENTAL|Supportive care (Occupational therapy)|Patients receive in-person occupational therapist-led work consultation
62631243|NCT06494501|EXPERIMENTAL|Inclisiran|"Participants in this arm will receive the study drug (inclisiran, for 5 years). Specific measures will be implemented to achieve the following goals: LDL-C \<55 mg/dl; blood pressure \<130/80 mmHg; and HbA1c \<6.5%. Diet and lifestyle recommendations will be recommended to all patients as a first step. Follow-up will occur every 2 months until goals are achieved. If the goal is not achieved, the subsequent recommendation will be implemented. Pharmacologic treatment may be implemented as early as the first visit at the discretion of the physician.~* Product Name: inclisiran~* Active ingredient: inclisiran sodium~* Dosage Form: Solution for Injection~* Unit Dose Inclisiran sodium 300 mg/1.5 mL vial (equivalent to 284 mg inclisiran)~* Route of Administration: SC use~* Physical Description: Clear, colorless to pale yellow solution essentially free of particulates"
62631244|NCT06494501|NO_INTERVENTION|Control Group|Participants in this group will receive guideline directed medical treatment, according to American Heart Association/American College of Cardiology guidelines. These recommendations will be provided to the primary care physicians to be followed, according to standards of care. Follow-up visits will occur every 6 months, although patients might be seen more often according to their provider´s criteria.
62631245|NCT02380404||Edentulous maxilla|Ibuprofen (600 mg - Film-coated Tablets) 3x/day before the surgery. Duration : 5 days Amoxicilline Teva (500 mg - dispersible tablets) 3x/day before the surgery. Duration : 16 days
62064841|NCT03515057|NO_INTERVENTION|Usual Care|For eligible patients from primary care clinics randomly selected for the Usual Care arm, they will receive standard care during outpatient visits without change.
62064842|NCT00480896|EXPERIMENTAL|1|
62631246|NCT04546633|EXPERIMENTAL|Run-in - KAF156 and LUM-SDF QD for 2 days in fasted condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
62269937|NCT03826732|NO_INTERVENTION|Wait-list control|Participants are informed that they will receive the intervention after the 6-month follow-up assessment
62631247|NCT04546633|EXPERIMENTAL|Run-in - KAF156 and LUM-SDF QD for 2 days in fed condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
62631248|NCT04546633|EXPERIMENTAL|Cohort 1/2 - KAF156 and LUM-SDF QD (once daily) in either a 2-day or 3-day dose regimen|KAF156 and LUM-SDF QD (once daily) in either a 2-day or 3-day dose regimen. Food recommendation will be issued after the Run-in Cohort based on efficacy, safety, tolerability and PK data).
62064843|NCT00480896|PLACEBO_COMPARATOR|2|
62064844|NCT05912478|EXPERIMENTAL|Study group|Videogame-Based Therapy Games for the Nintendo Switch (Version 2) will be used for eight weeks, three days per week, for a total of 24 sessions.
62269938|NCT02965495|EXPERIMENTAL|YYD302 2ml|YYD302 2ml
62631249|NCT04546633|ACTIVE_COMPARATOR|Cohort 1/2 - Coartem® BID (twice a day) for 3 days|Coartem® BID (twice a day) for 3 days (will be administered with food and doses will be based on patient's body weight as per product label).
62269939|NCT02965495|EXPERIMENTAL|YYD302 3ml|YYD302 3ml
62269940|NCT02965495|PLACEBO_COMPARATOR|Placebo 3ml|Phosphate buffered saline 3ml
62452397|NCT05856175||PT patients with postoperative recurrence|participants in this group undergo ultra-high resolution CT, vessel wall MR, 4D Flow MR and ASL MR imaging technology before and after surgery.
62631250|NCT05118347|EXPERIMENTAL|Buteyko Breathing Technique|Buteyko Breathing Method teaches you how to bring your breathing volume back toward normal or, in other words, reverse what's called chronic hyperventilation or chronic over-breathing. When your breathing is normal (ideally it is shown you should breathe lightly, in a calm fashion, and only through the nose, not mouth), you have better oxygenation of tissues and organs, including your brain.
62631251|NCT05118347|EXPERIMENTAL|Incentive Spirometer|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
62653210|NCT06158581|EXPERIMENTAL|The Emotion Awareness and Skills Enhancement|EASE is a 16-session mindfulness-based intervention (MBI). It emphasizes a small set of core concepts (i.e., mindfulness practices, distress tolerance, encouraging helpful thoughts, self-compassion) that are repeated with consistent language throughout. Emphasis is placed on increasing awareness of gradients of emotional arousal.
62269941|NCT01368835|EXPERIMENTAL|Ulthera treatment|
62269942|NCT04590092|NO_INTERVENTION|Control|Study Participants who do not receive a pessary. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and will continue to have standard antenatal care with their maternity provider.
62269943|NCT04590092|EXPERIMENTAL|Pessary|Study Participants who are fitted with a pessary for urinary incontinence. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and pessary use in pregnancy. They will continue to have standard antenatal care with their maternity provider.
62452398|NCT05856175||PT patients without postoperative recurrence|participants in this group undergo ultra-high resolution CT, vessel wall MR, 4D Flow MR and ASL MR imaging technology before and after surgery.
62452399|NCT04868526|EXPERIMENTAL|Control-Dietary Intervention|Control condition first, then the Dietary intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
62452400|NCT04868526|EXPERIMENTAL|Dietary intervention-Control|Dietary intervention first, then the Control condition. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
62452401|NCT04448665||patients with suspected infection|The hospitalized patients in whom, based on clinical signs and symptoms, an infection is suspected, and an administration of antimicrobial agents as empiric therapy is necessary.
62269944|NCT02686515|ACTIVE_COMPARATOR|Single-task balance training group|Participants in the single-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks. They will start walking on a treadmill with a self-selected comfortable speed for 5 minutes of warm-up and then receive an individually-progressed program of balance training aimed at improving standing balance and walking abilities.
62064845|NCT05912478|OTHER|Control Group|The participants on the waiting list will be evaluated as the control group. For eight weeks, the control group will be instructed to maintain their daily routine.
62064846|NCT02093676|EXPERIMENTAL|parents counseling|parents counseling guided by the experiment protocol
62064847|NCT06624852||Performances with AI assistance|Performances of screening coronary artery revascularization with PROPECG-TMT
62064848|NCT06624852||Performances without AI assistance|Performances of screening coronary artery revascularization without PROPECG-TMT
62064849|NCT04757818|EXPERIMENTAL|0.07% cetylpyridinium chloride (CPC) in mouthwash|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
62064850|NCT04757818|PLACEBO_COMPARATOR|Distilled water with the same colorant as the experimental product|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
62269945|NCT02686515|EXPERIMENTAL|Dual-task balance training group|Participants in the dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks. They will perform a cognitive task or motor task concurrently with the balance/gait task. The framework of progressive balance exercises in the dual-task training group will be progressed from simple to more complex tasks as outlined for the single-task training group. In addition, a variety of added tasks will be progressively integrated into the dual-task balance training program.
62269946|NCT03127371|EXPERIMENTAL|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
62064851|NCT01017978|OTHER|MRI Scan|MRI scan of soft tissue tumor
62631252|NCT06075771|EXPERIMENTAL|Carbidopa Levodopa Group|"Patients randomized to the Carbidopa Levodopa Group will receive one tablet per day of L-DOPA (150 mg levodopa administered with 37.5 mg carbidopa) for 4 weeks.~Patients that respond after the initial 4 weeks will continue on the same dose for an additional 4 weeks to determine whether clinical response at the 150 mg dose is sustained over time compared to placebo.~Patients that do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) after 4-weeks on the 150 mg dose will escalate to 450 mg L-DOPA (three tablets per day of 150 mg levodopa administered with 37.5 mg carbidopa) and studied over an additional 4 weeks (8 weeks total in the study)."
62064852|NCT05973318|EXPERIMENTAL|Patients with primary open-angle glaucoma receiving Dorzotimol eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d., 12 weeks
62064853|NCT05973318|ACTIVE_COMPARATOR|Patients with primary open-angle glaucoma receiving Cosopt eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d., 12 weeks
62064854|NCT06390514|EXPERIMENTAL|with the vibrating floor|
62064855|NCT06390514|ACTIVE_COMPARATOR|without the vibrating floor|
62064856|NCT02026232|ACTIVE_COMPARATOR|hydroxychloroquine|hydroxychloroquine twice daily for 4 weeks
62064857|NCT02026232|PLACEBO_COMPARATOR|Placebo|hydroxychloroquine placebo twice daily for 4 weeks
62064858|NCT05147727|EXPERIMENTAL|Fluconazole and Famitinib interaction|
62064859|NCT02932839|EXPERIMENTAL|Intervention|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
62064860|NCT00303563|EXPERIMENTAL|1|
61978568|NCT02883634|EXPERIMENTAL|specific manipulation|"Participants allocated to group specific manipulation, will have their lumbar spine manipulated according to the previous clinical examination."
61978569|NCT02883634|EXPERIMENTAL|non-specific manipulation|"Participants allocated to group non-specific manipulation will have their upper thoracic spine manipulated (also known as global manipulation) regardless of the previous clinical examination."
61978570|NCT04675203||Normal tooth eruption|
61978571|NCT00109889|OTHER|MRI and PET|Magnetic resonance imaging and positron emission tomography
61978572|NCT05070117|EXPERIMENTAL|Resistance/strength training|
61978573|NCT04673331||Cystic fibrosis|"Inclusion Criteria:~Having been diagnosed with cystic fibrosis Being over 18 years old The clinical condition is stable Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis~Exclusion Criteria:~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
62064861|NCT00303563|EXPERIMENTAL|2|
62064862|NCT00303563|EXPERIMENTAL|3|
62064863|NCT00303563|PLACEBO_COMPARATOR|4|
62064864|NCT04789902|EXPERIMENTAL|Hospital site 1|This site will provide usual ED care during the control period which will last for the first six months of the study. After six months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
62064865|NCT04789902|EXPERIMENTAL|Hospital site 2|This site will provide usual ED care during the control period which will last for the first 12 months of the study. After 12 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
62064866|NCT04789902|EXPERIMENTAL|Hospital site 3|This site will provide usual ED care during the control period which will last for the first 18 months of the study. After 18 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
62064867|NCT04789902|EXPERIMENTAL|Hospital site 4|This site will provide usual ED care during the control period which will last for the first 24 months of the study. After 24 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
62064868|NCT02766816|EXPERIMENTAL|Part 1 Study - BBio bOPV|
62064869|NCT02766816|ACTIVE_COMPARATOR|Part 1 Study - Licensed bOPV|
62064870|NCT02766816|EXPERIMENTAL|Part 2 Study - BBio bOPV Lot 1|
62064871|NCT02766816|EXPERIMENTAL|Part 2 Study - BBio bOPV Lot 2|
62064872|NCT02766816|EXPERIMENTAL|Part 2 Study - BBio bOPV Lot 3|
62064873|NCT02766816|ACTIVE_COMPARATOR|Part 2 Study - Licensed bOPV|
62064874|NCT00694382|EXPERIMENTAL|Semuloparin|Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
62064875|NCT00694382|PLACEBO_COMPARATOR|Placebo|Placebo (for semuloparin) once daily until change in chemotherapy regimen
62064876|NCT06505694|EXPERIMENTAL|Test Product Arm|Participants in this arm will receive the test product, which is an alcohol alternative herbal tincture. The intervention includes taking 2 ml of the test product directly onto the tongue every evening, 1-2 hours before bedtime, for a duration of 8 weeks.
62064877|NCT06505694|PLACEBO_COMPARATOR|Placebo Arm|Participants in this arm will receive a placebo. The intervention includes taking 2 ml of the placebo directly onto the tongue every evening, 1-2 hours before bedtime, for a duration of 8 weeks.
62064878|NCT01809041|EXPERIMENTAL|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
62064879|NCT01809041|ACTIVE_COMPARATOR|propofol & remifentanil|propofol (50 - 150 µg/kg/min) and remifentanil (0.1 - 0.5 µg/kg/min)
62064880|NCT01610154|EXPERIMENTAL|Sitagliptin treatment|
62269947|NCT03127371|EXPERIMENTAL|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
62269948|NCT06195800||Patients treated with aHSCT|Patients with aggressive disease treated with autologous haematopoetic stem cell transplantation.
62064881|NCT03522077|EXPERIMENTAL|RadAR EasyCLik plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (\< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
62269949|NCT06195800||Patients treated with disease modifying treatment|Patients with aggressive disease treated with high efficacy disease modifying treatment
62269950|NCT05393609||Sigmoidectomy|Patients with diverticular disease undergoing elective resection of the sigmoid colon
62269951|NCT05393609||Conservative|Patients with diverticular disease not referred to surgery, but conservative treatment
62269952|NCT02393729|OTHER|children with DCD|Children with Developmental Coordination Disorder (DCD) will have neuropsychological assessment and MRI study
62064882|NCT03522077|ACTIVE_COMPARATOR|TR BAND® plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (\< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
62064883|NCT03522077|EXPERIMENTAL|SoftSeal®-STF hemostatic|Hemostasis at the radial access site for subjects randomized to the SoftSeal®-STF hemostatic pad will be obtained by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (\< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure.
62064884|NCT03522077|ACTIVE_COMPARATOR|VascBand™ Hemostat|Hemostasis at the radial access for subjects randomized to the VascBand™ Hemostat will be obtained in accordance to the manufacturer's instructions. The VascBand™ device will be placed proximal to the puncture site and inflated slowly while simultaneously removing the sheath, and continue to inject air (max. 18 mL) into the device until hemostasis is obtained.
62269953|NCT02393729|OTHER|children with DD|Children with Developmental Dyslexia (DD) will have neuropsychological assessment and MRI study
62269954|NCT02393729|OTHER|children with DCD + DD|Neuropsychological assessment and MRI study
62269955|NCT02393729|OTHER|control children|Neuropsychological assessment and MRI study
62269956|NCT03718507|ACTIVE_COMPARATOR|GROUP Fentanyl|patients will receive atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes) before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
62269957|NCT03718507|EXPERIMENTAL|GROUP Sucrose|patients will be given atropine (0.01-0.02 mg/kg i.v. bolus) and oral sucrose 24% (0.5 ml) 2 minutes before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
62452402|NCT02933775|EXPERIMENTAL|CAR-CD19 T cells|Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
62631253|NCT06075771|PLACEBO_COMPARATOR|Placebo Group|Participants will receive placebo tablet. Placebo-treated non-responders at 4 weeks will remain on placebo but with the same instructions to increase daily pill intake.
62631254|NCT02768688|EXPERIMENTAL|Brain connectivity and physiology|Dexmedetomidine anesthesia on glymphatic flow in human subjects as visualized by diffusion tensor MRI.
62631255|NCT00934245|ACTIVE_COMPARATOR|Inactivated Polio Vaccine (IPV)|Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
62631256|NCT00934245|EXPERIMENTAL|Inactivated Trivalent Influenza Vaccine|Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
62631257|NCT00934245|NO_INTERVENTION|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
62631258|NCT05502952|EXPERIMENTAL|Alopecia areata|
62631259|NCT04826484|EXPERIMENTAL|Liposomal Bupivacaine plus 0.25% Bupivacaine|Participants will receive local wound infiltration with sequential Liposomal Bupivacaine plus 0.25% Bupivacaine
62269958|NCT04100330|EXPERIMENTAL|Ficlatuzumab with HiDAC|Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.
62631260|NCT04826484|ACTIVE_COMPARATOR|0.25% Bupivacaine alone|Participants will receive local wound infiltration with 0.25% Bupivacaine alone.
62269959|NCT04100330|ACTIVE_COMPARATOR|HiDAC alone|Cytarabine 2 g/m2 IV per day on Days 1 through 6
62631261|NCT02633969|EXPERIMENTAL|Indomethacin Capsules low dose|Indomethacin Capsules low dose twice daily for up to three days
62631262|NCT02633969|EXPERIMENTAL|Indomethacin Capsules high dose|Indomethacin Capsules high dose twice daily for up to three days
62631263|NCT00826410|EXPERIMENTAL|subcutaneous drain|"Use of subcutaneus suction drain (Redon) after laparotomy"
62631264|NCT02407847|NO_INTERVENTION|General Practitioners Care|Usual medical care provided by General Practitioners at the Primary Out-of-Hours Service.
62631265|NCT02407847|EXPERIMENTAL|Nurse Practitioners Care|Medical care provided by both Nurse Practitioners and General Practitioners at the Primary Out-of-Hours Service.
62631266|NCT03069534|EXPERIMENTAL|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
62631267|NCT03069534|NO_INTERVENTION|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
62631268|NCT01263717|EXPERIMENTAL|Tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
62631269|NCT01263717|PLACEBO_COMPARATOR|Placebo (inactive injection)|Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
62631270|NCT03397121|EXPERIMENTAL|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
62631271|NCT03397121|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
62631272|NCT04551664|EXPERIMENTAL|EVT group|Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.
62631273|NCT04551664|ACTIVE_COMPARATOR|Best medical management group|Patients in this group will receive best medical management alone.
62452403|NCT01150747||Risk of positive chlamydia|"1. current, untreated endocervical C. trachomatis infection~2. mucopurulent cervicitis on pelvic examination~3. Sexual contact with a male partner recently diagnosed with C. trachomatis, and/or non-gonococcal urethritis"
62452404|NCT06299137|NO_INTERVENTION|Control|Usual care. No changes made or recommended to patients randomized to the control arm.
62452405|NCT06299137|EXPERIMENTAL|Intervention arm (Undergoes SAPB)|Patients randomized to this arm will receive the Serratus Anterior Plane block.
62452406|NCT00706745|PLACEBO_COMPARATOR|placebo|The control oil is based on the general fat consumption in a Western population and consists of an equal amount (4 gr) of fat. It is a blend of palm (80%) and soybean oil (20%). Two capsules will be taken in the morning and two in the evening.
62452407|NCT00706745|ACTIVE_COMPARATOR|oil rich in cis9, trans11 CLA|Subjects will receive daily 4 g of CLA oil (2.6 g cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
62452408|NCT06456372|NO_INTERVENTION|Treatment as Usual|
62452409|NCT06456372|EXPERIMENTAL|Digital Health Intervention Group|
62452410|NCT04749602|EXPERIMENTAL|Cohort 1: Intrapleural Nivolumab in patients with renal cell carcinoma|Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed.
62452411|NCT04749602|EXPERIMENTAL|Cohort 2: Intrapleural Nivolumab in patients with non-small cell lung cancer|Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed.
62452412|NCT01376128||Subjects prescribed PAXIL|Pediatric subjects with panic disorder prescribed PAXIL during study period
62452413|NCT01690936|EXPERIMENTAL|Breakfast|Almonds (43g/day) were consumed with breakfast for four weeks.
62452414|NCT01690936|EXPERIMENTAL|Morning snack|Almonds (43g/day) were consumed alone as morning snacks for four weeks.
62452415|NCT01690936|EXPERIMENTAL|Lunch|Almonds (43g/day) were consumed with lunch for four weeks.
62452416|NCT01690936|EXPERIMENTAL|Afternoon snack|Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.
62452417|NCT01690936|NO_INTERVENTION|Control no nuts|Avoided all nuts and seeds
62452418|NCT04709848||Pre-screening group|Individuals undergoing bone marrow transplantation Jun 2018 - July 2020
62452419|NCT04709848||Screened group|Individuals undergoing bone marrow transplantation July 2020 - July 2021
62452420|NCT02090439|EXPERIMENTAL|standard treatment with Silodosin|Silodosin
62452421|NCT02090439|NO_INTERVENTION|standard treatment|
62452422|NCT04826588|ACTIVE_COMPARATOR|Methylprednisolone sodium succinate 10 mg/kg|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
62452423|NCT04826588|ACTIVE_COMPARATOR|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
62452424|NCT05118295|EXPERIMENTAL|SAVI Scout®|marker is accurately placed in the breast tumor
62452425|NCT05582499|EXPERIMENTAL|L1-1|If patients were hormone receptor-positive (HR+) and HER2-negative (HER2-) defined as similarity network fusion 1(SNF1) subtype
62452426|NCT05582499|ACTIVE_COMPARATOR|L1-2|If patients were HR+HER2- with SNF1 subtype
62452427|NCT05582499|ACTIVE_COMPARATOR|L2-2|If patients were HR+HER2- with SNF2 subtype
62452428|NCT05582499|ACTIVE_COMPARATOR|L3-2|If patients were HR+HER2- with SNF3 subtype
62452429|NCT05582499|ACTIVE_COMPARATOR|L4-2|If patients were HR+HER2- with SNF4 subtype
62452430|NCT05582499|EXPERIMENTAL|L4-low-1|If patients were HR+HER2-low with SNF4 subtype
62452431|NCT05582499|ACTIVE_COMPARATOR|L4-low-2|If patients were HR+HER2-low with SNF4 subtype
62452432|NCT05582499|EXPERIMENTAL|TN1-1|If patients were triple-negative breast cancer with immunomodulatory (IM) subtype
62452433|NCT05582499|ACTIVE_COMPARATOR|TN1-2|If patients were triple-negative breast cancer with IM subtype
62631274|NCT01986738||Radiation Treatment|Patients undergoing standard of care radiation treatment with Active Breathing Control (ABC)
62064885|NCT02500914|EXPERIMENTAL|SC-002|"Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability.~Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent."
62064886|NCT05988970|OTHER|Patients with Non- Small Cell Lung Cancer - NSCLC|
62064887|NCT04395183|ACTIVE_COMPARATOR|5-HTP + Placebo|5-hydroxytryptophan 100mg PO BID plus placebo matched to creatine monohydrate
62064888|NCT04395183|ACTIVE_COMPARATOR|Creatine + Placebo|Creatine 5g PO qday plus placebo matched to 5-HTP
62064889|NCT04395183|ACTIVE_COMPARATOR|Creatine + 5-HTP|Creatine 5g PO qday plus 5-hydroxytryptophan 100mg PO BID
62064890|NCT04395183|PLACEBO_COMPARATOR|Double Placebo|Creatine-matched placebo and 5-HTP-matched placebo
62064891|NCT02232841||Mechanical ventilation|Hospitalized adult patients with lung injury receiving mechanical ventilation and who also have received or will receive a CT scan as part of their standard care
62064892|NCT05030259||patients with fasciotomy|
62269960|NCT03713944|EXPERIMENTAL|Carboplatin, Pemetrexed, Atezolizumab plus Bevacizumab|"Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles.~Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities."
62269961|NCT02833103|EXPERIMENTAL|Pinaverium Bromide group|Able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.
62269962|NCT02833103|ACTIVE_COMPARATOR|Danshu group|Contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
62269963|NCT01680900|EXPERIMENTAL|experimental 1|vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks
62064893|NCT05030259||patients without fasciotomy|
62064894|NCT03733743|OTHER|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
62269964|NCT01680900|PLACEBO_COMPARATOR|placebo capsules (sugar pill)|Placebo capsules matched to the drug dose for 8 weeks
62452434|NCT05582499|EXPERIMENTAL|TN2-1|If patients were triple-negative breast cancer with basal-like immune suppressed (BLIS) subtype
62452435|NCT05582499|ACTIVE_COMPARATOR|TN2-2|If patients were triple-negative breast cancer with BLIS subtype
62452436|NCT05582499|EXPERIMENTAL|TN3-1|If patients were triple-negative breast cancer with androgen receptor positive HER2 activated (AR HER2) subtype
62452437|NCT05582499|ACTIVE_COMPARATOR|TN3-2|If patients were triple-negative breast cancer with AR HER2 subtype
61978574|NCT04673331||Healthy individuals|"Inclusion Criteria:~Being over 18 years old Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis~Exclusion Criteria:~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
62631275|NCT04306497||Cohort of western medicine|"1. Routine treatment：~   ① support treatment:maintain water and electrolyte balance .~   ②oxygen therapy: give nasal catheters to inhale oxygen.~   ③ basic treatment of traditional Chinese and western medicine: antiviral drugs and proprietary Chinese medicines with similar composition or function to the observed scheme of differentiation and treatment of traditional Chinese medicine are not included in the scope of such drugs.~2. Antiviral drugs ：Clinicians can judge according to the patient's condition according to the latest version of the diagnosis and treatment plan for COvID-19 issued by the General Office of the National Health Commission / the Office of the State Administration of traditional Chinese Medicine (currently the latest version is the sixth trial edition). Select any of the recommended antiviral drugs(for example:IFN-α、lopinavir-ritonavir、Ribavirin、Chloroquine Phosphate、Arbidol)or a combination of two antiviral drugs."
62631276|NCT04306497||Cohort of integrated TCM and western medicine|"routine treatment + Antiviral drugs + the following TCM regimens. 1.TCM regimens:① Early stage: Dampness trapped in exterior and interior. Recommended prescription: Huoxiang 15g, Suye15g, Cangzhu15g, Houpo10g, Qianhu15g, Chaihu15g, Huangqin10g, Qinghao20g, Xingren10g, JInyinhua15g, Lianqiao15g.~Take decocted or granule, one dose a day.~② Middle stage: Dampness-toxicity blocking lung Recommended prescription: Zhimahuang9g, Xingren10g, Sangbaipi30g, Tinglizi20g, Dongguazi20g, Fabanxia10g, Houpo10g, Suzi15g, Baijiezi10g, Gualoupi15g, Xuanfuhua9g, Xiangfu10g, Yujin10g, Taoren10g, Huangqi20g.~Take decocted or granule, one dose a day."
62631277|NCT03197467|EXPERIMENTAL|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
62631278|NCT02008136|EXPERIMENTAL|botulinum toxin injected|Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)
62631279|NCT02510612|EXPERIMENTAL|Dexmedetomidine|Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes， the speed in maintenance phase is 0.4μg/Kg.h
62631280|NCT02510612|PLACEBO_COMPARATOR|placebo|Patients in group P will be given normal saline during anesthesia induction and maintenance phase
62631281|NCT05933330||Danish HHT patient 18-65 years of age|
62631282|NCT02816073|ACTIVE_COMPARATOR|1,700|Patients receive 1,700 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
62631283|NCT02816073|ACTIVE_COMPARATOR|2,500|Patients receive 2,500 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
62631284|NCT02575196||Cardiac arrest|Consecutive adult cardiac arrest patients with sustained ROSC in an academic medical center
62631285|NCT04784507|EXPERIMENTAL|En Bloc Resection Bladder Tumor (Any energy source)|Patients with suspicion of NMIBC (primary or recurrent) that underwent en bloc resection (EBRT
62452438|NCT05582499|EXPERIMENTAL|TN4-1.1|If patients were HR-HER2-low
62452439|NCT05582499|ACTIVE_COMPARATOR|TN4-2|If patients were HR-HER2-low
62452440|NCT05582499|EXPERIMENTAL|TN5-1.1|If patients were triple-negative breast cancer with other subtypes
62631286|NCT04784507|ACTIVE_COMPARATOR|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Patients with suspicion of NMIBC (primary or recurrent) that underwent conventional TURBT
62064895|NCT04836117|EXPERIMENTAL|Informed|"Blood draw for SomaSignal Test and laboratory assessments at baseline, and 6 months (±30 days); SomaSignal Test results to be sent to investigators as available. Review and discussion of results with the participant from baseline and 6 months within 30 days (2-4 weeks to get SomaSignal results) after blood draw. Initiation of changes in medical management as soon as test results are known and discussed with patient.~Patients will have a blood draw performed at baseline and 6 months for lipid panel, hemoglobin A1C, CBC, and BMP."
62064896|NCT04836117|NO_INTERVENTION|Uninformed|"Blood draw for SomaSignal Test at baseline and 6 months (+30 days). However, results will not be provided to clinician and participant until study conclusion. Patients contacted within 30 days (2-4 weeks) after baseline and 6-month visits to discuss treatment strategy (nothing, add/ remove medication, etc.) made at visit. Patients will have a blood draw performed at baseline and for lipid panel, hemoglobin A1C, CBC, and BMP~SomaSignal Test results to be sent to investigators AFTER study conclusion. Patients will be provided with SomaSignal Test results after the 6 month post-test timepoint."
62064897|NCT01134601|EXPERIMENTAL|Selumetinib (AZD6244): 50 mg & Capecitabine: 825 mg/m^2|LEVEL 1 - Cycle = 49 days: AZD6244: 50 mg by mouth (PO) everyday (QD) Capecitabine: 825 mg/m\^2 by mouth (PO)
62631287|NCT06259149||Early initiation of drug prophylaxis (within 24 hours after surgery)|Patients who underwent surgery received prophylactic administration of low molecular weight heparin (nardraparin calcium injection) at a time point of 24 hours after surgery，this group carries out early initiation of drug prophylaxis (within 24 hours after surgery)
62631288|NCT06259149||Late initiation of drug prophylaxis (24 hours after surgery)|Patients who underwent surgery received prophylactic administration of low molecular weight heparin (nardraparin calcium injection) at a time point of 24 hours after surgery，this group carries out late initiation of drug prophylaxis ( 24 hours after surgery)
62631289|NCT02050139|EXPERIMENTAL|L-cysteine (Biocysan®)|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
62631290|NCT02050139|PLACEBO_COMPARATOR|Placebo|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
62631291|NCT01655719|EXPERIMENTAL|Pioglitazone Treatment|"If eligible, subjects can participate in 1 or both parts of this study as follows:~Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.~Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment."
62631292|NCT06611917||Ultrasonographic and Physical Examination Cohort|Participants in this study are patients scheduled for surgery under general anesthesia. The participants will undergo standard physical examination tests conducted by anesthesiologists before surgery and will also receive ultrasonographic measurements of the subglottic and other critical airway structures. The participants will be categorized as an observational cohort in which the ultrasonographic assessments will be compared with the results of the physical examination. The primary objective of this study is to compare the effectiveness of these two methods in predicting difficult airways.
62631293|NCT02258659|EXPERIMENTAL|Group A (radiation therapy alone)|Patients undergo radiation therapy once daily for weeks.
62064898|NCT05244148|EXPERIMENTAL|Group A|IP1 - Stérimar BLOCKED NOSE Baby nasal spray + standard of care
62269965|NCT01280136|EXPERIMENTAL|It's Your Game Tech|An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game...Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
62269966|NCT06454253||robot-assisted right colon group|Robot assisted radical surgery for right colon cancer
62269967|NCT06454253||laparoscopic-assisted right colon group|Laparoscopic assisted radical surgery for right colon cancer
61978575|NCT05354752|EXPERIMENTAL|VC005 Tablets Dose escalation groups|VC005 Tablets groups Repeat doses
61978576|NCT05354752|PLACEBO_COMPARATOR|VC005 Tablets Placebo groups|VC005 Tablets Placebo groups Repeat doses.
62064899|NCT05244148|EXPERIMENTAL|Group B|IP2 - Stérimar Stop \& Protect Cold Baby + standard of care
62064900|NCT05244148|OTHER|Group C|Standard of Care alone
62064901|NCT05891626|EXPERIMENTAL|Group intervention|Six comparable general clinics (2 for pediatric care and 4 for adult primary care) from all MultiCare facilities will be selected to participate in the study. Half of the clinics will be in the Puget Sound Region and others in the Eastern Washington Areas. Allocation to the intervention will be based on randomization: one pediatric and two adult (Internal Medicine or Family Medicine) clinics will get the comprehensive intervention.
62269968|NCT03691792|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT-SAD)|12 1.5-hour group sessions at a rate of 2 sessions per week over 8 weeks.
62653211|NCT06158581|ACTIVE_COMPARATOR|The Unified Protocol|UP is a 12-21 session cognitive behavioral therapy (CBT) based treatment. In this study, there will be 16 sessions. UP is focused on identifying emotions and building new coping strategies. It is customizable to meet the needs of the individual.
62064902|NCT05891626|NO_INTERVENTION|Standard care|The other three facilities will stay as the control under routine care. The three control group sites will have no additional interventional activities regarding vaccination, except for MultiCare's usual vaccine promotion practices (which the interventional clinics will have also).
62631294|NCT02258659|EXPERIMENTAL|Group B (combination chemotherapy, low-dose radiation therapy)|Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62269969|NCT03691792|ACTIVE_COMPARATOR|Light Therapy|6 weeks of daily light therapy at home, using a 10,000-lux light box beginning at 30 minutes upon waking, with dose subsequently adjusted per treatment algorithm.
62064903|NCT05822921|EXPERIMENTAL|In-person Psychoeducation|
62631295|NCT02258659|EXPERIMENTAL|Group C (combination chemotherapy, high-dose radiation)|"Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.\*~\*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy."
62631296|NCT03638960|ACTIVE_COMPARATOR|Bupivacaine|Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine.
62064904|NCT05822921|EXPERIMENTAL|Telehealth Psychoeducation|
62064905|NCT05822921|ACTIVE_COMPARATOR|Psychoeducation as Usual|
62269970|NCT01686620|EXPERIMENTAL|BIOD-123|BIOD-123 used as prandial insulin
62269971|NCT01686620|ACTIVE_COMPARATOR|Lispro (Humalog)|Lispro (Humalog) used as prandial insulin
62631297|NCT03638960|EXPERIMENTAL|Liposomal bupivacaine|Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.
62631298|NCT02356952|EXPERIMENTAL|Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
62631299|NCT02356952|EXPERIMENTAL|Low Glycemic Index Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
62631300|NCT02356952|EXPERIMENTAL|Low Glycemic Index Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
61978577|NCT01004133||Subjects 80 years of age or older without chronic diseases.|
62064906|NCT02384525|EXPERIMENTAL|clinical-based ultrafiltration|
62064907|NCT02384525|ACTIVE_COMPARATOR|BIA-based ultrafiltration|
62269972|NCT02294240|EXPERIMENTAL|Arm One|Energy dense biscuits will be provided throughout pregnancy after enrolment
62269973|NCT02294240|PLACEBO_COMPARATOR|Arm Two|Wheat Flour,oil, iron and folic acid will be provided fortnightly throughout pregnancy after enrolment
62269974|NCT00810979|EXPERIMENTAL|1|SLx-4090 dose #1 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
62269975|NCT00810979|EXPERIMENTAL|2|SLx-4090 dose #2 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
62269976|NCT00810979|OTHER|3|Placebo in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
62269977|NCT00896376|EXPERIMENTAL|trastuzumab|
62269978|NCT01858181|EXPERIMENTAL|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
62269979|NCT01858181|EXPERIMENTAL|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
62631301|NCT03752879||Case (Kristaller Group)|Group of kristeller maneuver applied in the second stage of labor due to clinical necessity.
62064908|NCT02991443|EXPERIMENTAL|Mindfulness based stress reduction|Parents of children with IBD will undergo mindfulness based stress reduction (MBSR) intervention consisted of 8 group sessions. The effect on stress and anxiety will be assessed using 3 validated questionnaires which will be filled prior to intervention, at the end of intervention and 3 months following intervention.
62064909|NCT05559853||Participants with Brain Metastases|Participants will have at least one untreated brain metastasis \> 1cm
62631302|NCT03752879||Control (no Kristaller Group)|The control group not required to kristeller maneuver
62064910|NCT05559853||Healthy participants|Participants will have no known cancer diagnosis. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
62631303|NCT05018702|EXPERIMENTAL|ARX788|
62269980|NCT01858181|EXPERIMENTAL|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
62631304|NCT03746639|ACTIVE_COMPARATOR|therapeutic ultrasound group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy and therapeutic ultrasound over the paravertebral low back region.
62631305|NCT03746639|OTHER|therapeutic ultrasound untreated group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy over the paravertebral low back region.Therapeutic ultrasound will not be applied to this group.
62631306|NCT03168451|EXPERIMENTAL|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
62631307|NCT03168451|NO_INTERVENTION|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
62631308|NCT03521869|ACTIVE_COMPARATOR|Compression bandage group|
62631309|NCT03521869|ACTIVE_COMPARATOR|Standard gauze group|
62631310|NCT05934916|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP) group in (Coronavirus disease 2019) patients|receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and using Continuous Positive Airway Pressure (CPAP)
62631311|NCT05934916|EXPERIMENTAL|Non-CPAP group|Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020
62064911|NCT03716674|EXPERIMENTAL|Parkinson's Disease patients|
62064912|NCT05341102|EXPERIMENTAL|LY3556050 (Part 1)|Participants will receive single ascending doses of LY3556050 orally.
62269981|NCT05087069|EXPERIMENTAL|BV100|BV100 intravenous infusion
62064913|NCT05341102|EXPERIMENTAL|Placebo (Part 1)|Participants will receive placebo orally.
62064914|NCT05341102|EXPERIMENTAL|LY3556050 (Part 2)|Participants will receive multiple ascending doses of LY3556050 orally.
62064915|NCT05341102|EXPERIMENTAL|Placebo (Part 2)|Participants will receive placebo orally.
62064916|NCT00826163|ACTIVE_COMPARATOR|stable COPD|Postbronchodilator FEV1\> or = 50% predicted
62064917|NCT00826163|SHAM_COMPARATOR|Asthma|Postbronchodilator FEV1 \> or = 50% predicted
62269982|NCT05087069|PLACEBO_COMPARATOR|Placebo|Saline intravenous infusion
62269983|NCT05331014|EXPERIMENTAL|JW0101+C2101|LivaloVA
62269984|NCT05331014|ACTIVE_COMPARATOR|JW0101+C2102|LivaloV
62269985|NCT05331014|ACTIVE_COMPARATOR|C2101|VA
62269986|NCT00874978|EXPERIMENTAL|lenalidomide|
62269987|NCT00334022|PLACEBO_COMPARATOR|Did not receive enfuvirtide|patients were randomized to either receive enfuviratide or not receive it
62269988|NCT00334022|ACTIVE_COMPARATOR|enfuvirtide|enfuvirtide 1ml BID
62269989|NCT06425003|EXPERIMENTAL|[14C] ABBV-CLS-7262|Participants will receive \[14C\] ABBV-CLS-7262 on Day 1.
62452441|NCT05582499|ACTIVE_COMPARATOR|TN5-2|If patients were triple-negative breast cancer with other subtypes
62631312|NCT05642104||Single group assignment|Patients with invasive breast cancer who need neoadjuvant therapy.
62631313|NCT01537848||post-operative collection|patients suffering from a post-operative abdominal collection
62631314|NCT04865029|EXPERIMENTAL|Treatment Arm|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission and Progesterone 200mg by mouth daily for 5 days starting at admission.
62631315|NCT04865029|OTHER|Control Arm|"Standard of Care along with placebo injection and placebo pill~Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines"
62631316|NCT03824717|OTHER|Ropivacaine dosage|Dose finding study - The volume of 0.5% ropivacaine used to achieve surgical anesthesia in infraclavicular brachial plexus block
62653212|NCT03462680|ACTIVE_COMPARATOR|niacin|Niacin 250 mg is compared to placebo tablet.
62064918|NCT05561777|NO_INTERVENTION|Pharmacist-led Evaluation|Patients randomized to the pharmacist-led arm will appear in the pharmacy-penicillin electronic health care dashboard. A pharmacist may, at their discretion and in consultation with the primary care team, perform an allergy risk-stratification and oral challenge in low-risk patients using local standard of care protocol
62064919|NCT05561777|EXPERIMENTAL|Provider-targeted Clinical Decision Support Tool|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
62064920|NCT01800695|EXPERIMENTAL|Arm A|ABT-414 in combination with radiation and temozolomide
62064921|NCT01800695|EXPERIMENTAL|Arm B|ABT-414 in combination with temozolomide
62064922|NCT01800695|EXPERIMENTAL|Arm C|ABT-414 monotherapy
62064923|NCT03108495|EXPERIMENTAL|Cohort 1 LN-145 monotherapy|Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
62064924|NCT03108495|EXPERIMENTAL|Cohort 2 LN-145 monotherapy|Patients previously treated with an antiprogrammed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor: Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
62064925|NCT03108495|EXPERIMENTAL|Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only|Patients will be administered with pembrolizumab, followed by NMA lymphodepletion, then infused with their autologous TIL (LN-145) followed by pembrolizumab every 3 or 6 weeks post IL-2 administration up to 24 months.
62064926|NCT03108495|EXPERIMENTAL|Cohort 4 - Non-enrolling Cohort|Cohort includes patient population not meeting inclusion criteria in cohort 1 and 2. Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
62064927|NCT03108495|EXPERIMENTAL|Cohort 5 Retreatment Cohort|Patients who have been previously treated with LN-145 may be given a second treatment with TIL.
62064928|NCT02986061|ACTIVE_COMPARATOR|Control Group|Patients with indwelling urinary catheter
62064929|NCT02986061|NO_INTERVENTION|Study Group|Patients without indwelling urinary catheter
62064930|NCT00675155|EXPERIMENTAL|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
62064931|NCT06326710|EXPERIMENTAL|mHealth Group|This arm of participants will be receiving 4 sessions of face-to-face or online delivered mHealth intervention.
62269990|NCT02566746|EXPERIMENTAL|Chait Trapdoor caecostomie catheter|Patients randomized in this arm will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter
62064932|NCT06326710|ACTIVE_COMPARATOR|Control Group|This arm of participants will be receiving 4 sessions of face-to-face or online exercise delivered health talks.
62064933|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
62064934|NCT02378532|EXPERIMENTAL|Radiotherapy/Temozolomide + Chloroquine|"Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM.~Chloroquine will be escalated in 3 dose-levels (200mg, 400mg and 600mg) up each containing a minimum of 3 and a maximum of 6 patients. Based on the results of the DSMB, an additional level of 300mg was added."
62064935|NCT01402596|ACTIVE_COMPARATOR|Chloral hydrate|Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
62064936|NCT01402596|ACTIVE_COMPARATOR|Midazolam|Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
62064937|NCT00515437|EXPERIMENTAL|1|1500U Myobloc
62064938|NCT00515437|EXPERIMENTAL|2|2500U Myobloc
62064939|NCT00515437|EXPERIMENTAL|3|3500U Myobloc
62064940|NCT00515437|PLACEBO_COMPARATOR|4|pooled placebo
62064941|NCT03158389|EXPERIMENTAL|Subtrial A: APG101|"* weekly application of 800 mg i.v. for 6 months or until progression~* in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
62064942|NCT03158389|EXPERIMENTAL|Subtrial B: Alectinib|"* 600 mg orally twice daily (bid) for 6 months or until progression~* in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
62064943|NCT03158389|EXPERIMENTAL|Subtrial C: Idasanutlin|"* at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle for 6 months or until progression~* in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
62064944|NCT03158389|EXPERIMENTAL|Subtrial D: Atezolizumab|"* application of 1200 mg i.v. every three weeks for 6 months or until progression~* in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
62452442|NCT05582499|EXPERIMENTAL|H1-1.1|If patients were HR+HER2+
62452443|NCT05582499|ACTIVE_COMPARATOR|H1-2|If patients were HR+HER2+
62452444|NCT05582499|EXPERIMENTAL|H2-1.1|If patients were HR-HER2+
62631317|NCT02078271|EXPERIMENTAL|FBDG group|The group received Food Based Dietary Guidelines for feeding recommendation. Monthly-session with group of mothers involving interactive activities e.g. cooking session, cooking competition and games.
62631318|NCT02078271|EXPERIMENTAL|Stimulation group|The children received psychosocial stimulation from the mothers. Mothers were taught on psychosocial module which was developed using locally existing resources and was directed at improving four aspects of child development, namely gross motoric, fine motor, language and socio-emotional developments.
62631319|NCT02078271|EXPERIMENTAL|Combined (FBDG and Stimulation)|The group received both FBDG and psychosocial stimulation
62631320|NCT02078271|OTHER|Control|The group received standard health education messages from existing health care system.
62631321|NCT02781987||CP group|Those patients with chronic pancreatitis underwent ERCP for pancreatic stone clearance, pancreatic stent placement, etc..
62631322|NCT02781987||BD group|Those patients with biliary ductal disease, such as choledocholithiasis, underwent ERCP to relieve outflow obstruction of the common bile duct.
62631323|NCT05404711|OTHER|CGM use for T2D risk evaluation|All participants will complete a standard 2-hour oral glucose tolerance test (OGTT), wear a CGM for 10 days, complete at-home glucose challenge, and provide qualitative feedback about their experiences with both OGTT and CGM use for risk evaluation.
62631324|NCT05888480|EXPERIMENTAL|Intervention group (IG)|The IG will receive the end-of-life CST between the two measurement points
62631325|NCT05888480|OTHER|Control group (CG)|The CG will be a waitlist group and receive the training after the end of data collection.
62631326|NCT02938338||Obese patients with BMI above 35|Bariatric surgery
62631327|NCT01639144|ACTIVE_COMPARATOR|Receiving PRP and PPP.|Administration of PRP and PPP to surgical site.
62631328|NCT01639144|NO_INTERVENTION|Control|Group not receiving autogenous PRP and PPP.
62064945|NCT03158389|EXPERIMENTAL|Subtrial E: Vismodegib|"* daily application of 150 mg orally for 6 months or until progression~* in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
62269991|NCT02566746|ACTIVE_COMPARATOR|Continuation of optimal medical therapy|"Patients randomized in this arm will continue this medical treatment of constipation with laxative and / or suppositories and / or enemas retrograde during 12 months.~At 12 months : patients will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter during 12 months."
62631329|NCT04563754|EXPERIMENTAL|mHRME|"5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed.~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
62064946|NCT03158389|EXPERIMENTAL|Subtrial F: Palbociclib|"* 75/100/125 mg orally once daily on 21/28 days~* in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks~* followed by a 4 weeks break (after last dose of 2nd cycle)~* and with maintenance therapy with palbociclib at 125 mg daily for 6 months or until progression"
62064947|NCT03158389|EXPERIMENTAL|Subtrial G: Temsirolimus|"* weekly application of 25 mg i.v. for 6 months or until progression~* in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
62452445|NCT05582499|ACTIVE_COMPARATOR|H2-2|If patients were HR-HER2+
62631330|NCT05005936||Ancillary-Correlative (ABUS, WBUS)|Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline, mid-treatment and pre-surgery (end of treatment).
62631331|NCT03095352|EXPERIMENTAL|Arm A: Pembrolizumab + Carboplatin|Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
62631332|NCT03095352|EXPERIMENTAL|Arm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only|Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62631333|NCT02998996|EXPERIMENTAL|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
62631334|NCT02998996|EXPERIMENTAL|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
62269992|NCT05021783||Patients|Patients with Axial SpondyloArthritis
62631335|NCT02998996|EXPERIMENTAL|Influenza antigen,|15 µg HA/strain
62631336|NCT02998996|PLACEBO_COMPARATOR|Saline (NaCl),|Placebo
62631337|NCT02998996|ACTIVE_COMPARATOR|i.m. comparator,|15 µg HA/strain
62631338|NCT02998996|ACTIVE_COMPARATOR|i.n. comparator|
62631339|NCT05122689|EXPERIMENTAL|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
62631340|NCT05122689|PLACEBO_COMPARATOR|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
62064948|NCT01121484|EXPERIMENTAL|desvenlafaxine succinate sustained-release|
62064949|NCT01121484|PLACEBO_COMPARATOR|Placebo|
62064950|NCT02048748|EXPERIMENTAL|Telemonitoring|Device: Weight and blood pressure device Device: Home telemonitoring device
62064951|NCT02048748|NO_INTERVENTION|Control|Usual care
62064952|NCT02086552|EXPERIMENTAL|Treatment (sonidegib, lenalidomide)|Patients receive sonidegib PO QD on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve sCR, CR, VGPR, PR, MR, or SD (or usCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.
62269993|NCT00957008|EXPERIMENTAL|A - GWL|Group Weight Loss Program (GWL) - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator.
62452446|NCT05582499|EXPERIMENTAL|L2-1.2|If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype
62452447|NCT05582499|EXPERIMENTAL|L3-1.2|If patients were HR+HER2- with similarity network fusion 3 (SNF3) subtype
62064953|NCT05905497|EXPERIMENTAL|Bemnifosbuvir (BEM)|oral tablet
62064954|NCT05583214|EXPERIMENTAL|Ondansetron|Patients given Ondansetron (8mg)
62064955|NCT05583214|EXPERIMENTAL|Dexamethasone|Patients given Dexamethasone (8mg)
62064956|NCT05583214|PLACEBO_COMPARATOR|Placebo|
62064957|NCT05971823|ACTIVE_COMPARATOR|Own Brand Cigarette|
62064958|NCT05971823|EXPERIMENTAL|NJOY Ace 2.4% nicotine ECIG - Menthol flavor|
62064959|NCT05971823|EXPERIMENTAL|NJOY Ace 2.4% nicotine ECIG - Classic Tobacco flavor|
62064960|NCT05971823|EXPERIMENTAL|NJOY Ace 5.0% nicotine ECIG - Menthol flavor|
62064961|NCT05971823|EXPERIMENTAL|NJOY Ace 5.0% nicotine ECIG - Classic Tobacco flavor|
62064962|NCT05971823|EXPERIMENTAL|NJOY Daily 6.0% nicotine ECIG - Menthol flavor|
62064963|NCT05971823|EXPERIMENTAL|NJOY Daily 6.0% nicotine ECIG - Extra Rich Tobacco flavor|
62064964|NCT05974995|EXPERIMENTAL|Robotic surgery|
62064965|NCT05974995|ACTIVE_COMPARATOR|Laparoscopic surgery|
62064966|NCT05020262||Test Group|Using PI/PC reconstruct raw data
62452448|NCT05582499|EXPERIMENTAL|L4-1.2|If patients were HR+HER2- with similarity network fusion 4 (SNF4) subtype
62631341|NCT04382716||PANS participants|
62631342|NCT03189355|EXPERIMENTAL|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
62631343|NCT02597179||Metastatic Breast Cancer, Young Breast Cancer|Patients with feasible biopsy site.
62631344|NCT04835064|EXPERIMENTAL|Nab-paclitaxel and Gemcitabine|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15;Gemcitabine 1000 mg/m2 was given intravenously for more than 30min on days 1, 8, and 15, and repeated every 4 weeks.
62269994|NCT00957008|EXPERIMENTAL|B - GWL+SWA|Group weight loss program plus use of the Senseware Armband - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator and wore a SenseWear Armband. The SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
62269995|NCT00957008|EXPERIMENTAL|C - SWA Alone|Use of the senseware armband alone program - The intervention for the SWA Alone group was the SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
62631345|NCT04835064|EXPERIMENTAL|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
61978578|NCT05523661|EXPERIMENTAL|Dasatinib plus anti-CD19/CD22 CAR-T cells|Administration with oral Dasatinib plus anti-CD19/ CD22 CAR-T cells in the elderly Ph-positive ALL patients.
61978579|NCT06023420|EXPERIMENTAL|Study group|Herbal formula 5g daily, and Zometa
62452449|NCT05582499|EXPERIMENTAL|TN5-1.2|If patients were triple-negative breast cancer with other subtypes
62452450|NCT05582499|EXPERIMENTAL|H1-1.2|If patients were HR+HER2+
62452451|NCT05582499|EXPERIMENTAL|H2-1.2|If patients were HR-HER2+
62452452|NCT05582499|EXPERIMENTAL|TN4-1.2|If patients were HR-HER2-low
62452453|NCT02649283|OTHER|Breast symmetrisation with OrbiSymm|Standard surgical intervention of up to 30 patients including placement of the OrbiSymm device
62452454|NCT02649283|OTHER|Breast symmetrisation without device|Standard surgical intervention of up to 30 patients without the Orbix device; only routine reduction/symmetrisation intervention
62452455|NCT06395857|EXPERIMENTAL|Intervention group|Eligible participants will be randomly assigned to receive usual care with the four-week visual arts-based intervention.
62452456|NCT06395857|NO_INTERVENTION|Control group|Eligible participants will be randomly assigned to receive receive usual stroke care.
62631346|NCT01673984|EXPERIMENTAL|Decapeptyl® SR 22.5mg (Triptorelin)|
62631347|NCT01673984|ACTIVE_COMPARATOR|Current 3-monthly LHRH agonist|One of the following: Decapeptyl® SR 11.25mg (Triptorelin), Prostap® 3 DCS 11.25mg, Zoladex® LA 10.8mg
62631348|NCT05254899|EXPERIMENTAL|Inductive and concurrent anti-PD-1 antibody combined with chemo-radiotherapy|All the enrolled patients receive 3 cycles of anti-PD-1 antibody (Tislelizumab 200mg d1) + P-GEMOX (Pegaspargase 3000u d2, Gemcitabine 1g/m2 d2, Oxaliplatin 85mg/m2 d2) systemic treatment every 14 days, followed by involved-site radiotherapy with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
62631349|NCT03072095|EXPERIMENTAL|Text-only|Text-only outreach
62631350|NCT03072095|EXPERIMENTAL|Text + Lottery|Text outreach + financial incentive
62631351|NCT01901016|EXPERIMENTAL|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
62269996|NCT00957008|NO_INTERVENTION|D - Standard Care|Standard Care - Participants in this group received a self-directed weight loss manual that focused on cognitive and behavior change principles and learning activities based on Active Living Every Day and Healthy Eating Every Day
62269997|NCT04821427|EXPERIMENTAL|Brief mHealth Intervention + mobile messaging|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages
62269998|NCT04821427|NO_INTERVENTION|Assessment Only|This is an assessment only condition. No intervention following completion of baseline surveys will be administered.
62269999|NCT04361591||COVID-19|Liver Transplant recipients
62270000|NCT02141711|EXPERIMENTAL|Cohort 1: TAK-438 10 mg|TAK-438 10 mg tablets, orally, once, daily, for 7 days.
62270001|NCT02141711|EXPERIMENTAL|Cohort 2: TAK-438 20 mg|TAK-438 20 mg tablets, orally, once, daily, for 7 days.
62631352|NCT01901016|EXPERIMENTAL|Schultz's autogenic training|Schultz's autogenic training
62631353|NCT01901016|NO_INTERVENTION|control|The CG continued to receive their standard care. After data collection at the six-month follow-up, the CG participants were invited to attend one of two relaxation interventions.
62631354|NCT06004271|ACTIVE_COMPARATOR|control group|In the control group, only the exercise program was applied and the first and last measurements will be compared.
62631355|NCT06004271|EXPERIMENTAL|experimental group|In the experimental group, kinesiology taping will be applied twice a week for 8 weeks together with exercise. Kinesiology taping was first applied by closing the malleoli from the upper part of the foot, and stretching it to the anterior capsule of the foot using the ligament technique. For the second tape, it covered the plantar area under the malleolus and was attached in the form of stirrups. During the application, the tape will be applied with full tension on the malleolus and 50-75% tension will be applied on the other parts.
62631356|NCT06004271|PLACEBO_COMPARATOR|placebo group|Tape application will be applied in the placebo group as it was in the experimental group. Kinesiology taping will be attached horizontally without tension along the Tensor Facie Late line. The application to the ankle will be attached horizontally without tension slightly above the lateral malleolus.
62631357|NCT01267929|EXPERIMENTAL|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months. The mirror neurons stimulation based VCD program that contained four volumes. The first volume includes activities activities for improving balance in sitting position. The second volume includes activities of sitting to standing. The third volume includes activities for improving balance in standing position. The last one includes activities of sideway walking. The running time of each volume is 30 minutes. The children had been practicing for two weeks per volume. Their parents were trained for practicing their children by VCD program at home and were asked to complete daily record of children's activities. The children were scheduled to meet a pediatric physical therapist once a week to monitor possible side effects.
62653213|NCT03462680|PLACEBO_COMPARATOR|placebo|placebo
62064967|NCT05020262||Control Group|Using Idose4/Cardiac Image reconstruct raw data
62064968|NCT01338922|EXPERIMENTAL|Insulin pump therapy (CSII)|Continuous subcutaneous insulin infusion therapy using different devices with marketing approval and different insulins
62064969|NCT01338922|ACTIVE_COMPARATOR|Multiple daily injection therapy (MDI)|Multiple daily injection therapy using different devices with marketing approval and different insulin types
62270002|NCT02141711|EXPERIMENTAL|Cohort 3: TAK-438 40 mg|TAK-438 40 mg tablets, orally, once, daily, for 7 days.
62270003|NCT02141711|EXPERIMENTAL|Cohort 4: TAK-438 30 mg|TAK-438 30 mg tablets, orally, once, daily, for 7 days.
62270004|NCT02141711|PLACEBO_COMPARATOR|Cohorts 1-4: Placebo|TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.
62270005|NCT03064477|EXPERIMENTAL|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
62270006|NCT03064477|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
62270007|NCT06345677|EXPERIMENTAL|ViXe Combination|This arm includes a combination of the Xeomin medication, a generic of the Botulinium Toxin A drug that is not currently approved for this indication, and the Vibe medical device, an experimental device for the delivery of Botulinium Toxin to the bladder for overactive bladder
62452457|NCT04704609||Imaging Analysis of patients with uveitis|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
62452458|NCT01072942|EXPERIMENTAL|Arm 1|
62452459|NCT01072942|PLACEBO_COMPARATOR|Arm 2|
62452460|NCT02001454||Patients in pain|There is no intervention, only questionnaires for the patient
62631358|NCT01267929|ACTIVE_COMPARATOR|The conventional physical therapy|The children receive manual physical therapy regularly at the hospital once a week for first two months and twice a month for last four months. The conventional physical therapy technique in this study derive from the manual technique including the Bobath concept, stretching exercise and functional training for 30-45 minutes at a time.
62631359|NCT00661635|ACTIVE_COMPARATOR|Arm 1|
62270008|NCT06345677|PLACEBO_COMPARATOR|Placebo + Sham|The placebo that will be used in the study is identical in its physical properties to the investigational drug and will be used in the same manner as the active drug. Sham procedure will include all the steps for device preparation and activation, without the actual transmission of ultrasound eneregy to the participant.
62270009|NCT03303950|EXPERIMENTAL|Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)|Participants receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo HSCT on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
62270010|NCT02987621|EXPERIMENTAL|Sham first, wash out 7 days, then tDCS|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
62452461|NCT02001454||Attending Physicians and Nurses|The staff physicians and nurses will also fill out a questionnaire
62631360|NCT00661635|ACTIVE_COMPARATOR|Arm 2|
62631361|NCT00661635|PLACEBO_COMPARATOR|Arm 3|
62631362|NCT03280056|ACTIVE_COMPARATOR|NurOwn® (MSC-NTF cells)|Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals
62452462|NCT02824900|EXPERIMENTAL|Vibration stimuli to neck|Vibration stimuli to contralesional neck muscles, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy \~ 45 minutes.
62452463|NCT02824900|ACTIVE_COMPARATOR|Vibration stimuli to hand|Vibration stimuli to contralesional hand, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy \~ 45 minutes.
62452464|NCT02585284||vicenarian|20 to 29 years. Five males and five females
62452465|NCT02585284||tricenarian|30 to 39 years. Five males and five females
62452466|NCT02585284||quadragenarian|40 to 49 years. Five males and five females
62452467|NCT02585284||quinquagenarian|50 to 59 years. Five males and five females
62452468|NCT02585284||sexagenarian|60 to 69 years. Five males and five females
62452469|NCT02585284||septuagenarian|70 to 79 years. Five males and five females
62452470|NCT02585284||octogenarian|80 to 89 years. Five males and five females
62452471|NCT02585284||nonagenarian|90-99 years. Five males and five females
62452472|NCT01825109|EXPERIMENTAL|6 weeks RV & normal breast feeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
62452473|NCT01825109|EXPERIMENTAL|6 weeks RV & delayed breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
62452474|NCT01825109|EXPERIMENTAL|14 weeks RV & Normal breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
62064970|NCT04102930||Retrospective|A patient who has a diagnosis of GCA or PMR
62064971|NCT04102930||Prospective|Patient with suspected GCA and PMR
62064972|NCT00023647|EXPERIMENTAL|Synchrotope TA2M, 800 micrograms|Tyrosinase peptides, 800 micrograms
62064973|NCT00023647|EXPERIMENTAL|Synchrotope TA2M, 200 micrograms|Tyrosinase peptides, 200 micrograms
62064974|NCT00023647|EXPERIMENTAL|Synchrotope TA2M, 400 micrograms|Tyrosinase peptides, 400 micrograms
62064975|NCT02328703|EXPERIMENTAL|Reiki Therapy by a Reiki Master|The Reiki Master will take approximately 30 minutes to perform a hand placement sequence that will allow the direction of energy toward the site of pain.
62064976|NCT02328703|PLACEBO_COMPARATOR|Sham Reiki Therapy by a Clinician|The Clinician, who has not trained in Reiki, will mimic the same 30 minute hand placement protocol as the Reiki Master.
62064977|NCT03908073|ACTIVE_COMPARATOR|Active transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
62064978|NCT03908073|PLACEBO_COMPARATOR|Sham transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
62064979|NCT06053554|OTHER|Sulcus|On the day baseline examination, the first eye to be operated is randomised to receive a 3p-IOL implantation in the capsular bag (group 1) or a 3p-IOL haptics in the ciliary sulcus with the IOL optic tucked in the capsular bag (group 2). The second eye to be operated receives the other method. The eye with the lower visual acuity is operated first, in case of identical visual acuity values the for the patient subjective worse eye is operated first. This procedure is clinical standard.
62064980|NCT06053554|OTHER|In the bag|On the day baseline examination, the first eye to be operated is randomised to receive a 3p-IOL implantation in the capsular bag (group 1) or a 3p-IOL haptics in the ciliary sulcus with the IOL optic tucked in the capsular bag (group 2). The second eye to be operated receives the other method. The eye with the lower visual acuity is operated first, in case of identical visual acuity values the for the patient subjective worse eye is operated first. This procedure is clinical standard.
62270011|NCT02987621|EXPERIMENTAL|tDCS first, wash out 7 days, then Sham|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
62270012|NCT01496066|EXPERIMENTAL|LAL|LAL implanted
62270013|NCT01496066|ACTIVE_COMPARATOR|Monofocal control|Monofocal control IOL implanted
62270014|NCT02560675||120 healthy subjects|"One hundred and twenty healthy subjects (range 20-79; 20 subjects per age decade, 10 M and 10 F) will participate in the first phase of the study aimed to collect normative data from healthy population.~Study design Phase I - Normative data collection for the inhibitory and excitatory pain modulation responses, a study on healthy subjects (no blood tests)"
62270015|NCT02560675||750 subjects with acute whiplash-injury|"Seven hundred and fifty acute whiplash-injury based mild TBI will participate in this study.~Phase II - Multi-modal assessment of acute mild TBI whiplash patients and follow-up"
62064981|NCT05680961||Parkinson's patients|Cohort of patients with clinical diagnosis of Parkinson's diseases with varied symptoms and severity.
62064982|NCT02885493||Falls is <or = 1 year|Patients whose number of falls is \<or = 1 year
62270016|NCT00987038|OTHER|PF-04171327 and Midazolam|
62064983|NCT02885493||falls is> 1 year|Patients whose numbers falls is\> 1 year
62631363|NCT03280056|PLACEBO_COMPARATOR|Placebo|Three Intrathecal administrations of Placebo at bi-monthly intervals
61978580|NCT06023420|ACTIVE_COMPARATOR|Control group|Zometa alone
62064984|NCT04723043|ACTIVE_COMPARATOR|v group|patients will ventilate with volume controlled mode
62064985|NCT04723043|ACTIVE_COMPARATOR|p group|patients will ventilate with pressure controlled mode
62064986|NCT02715817|ACTIVE_COMPARATOR|Virtual Rehabilitation - VR|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
62270017|NCT04179383|OTHER|Patient|"Patient presenting a Reversible Cerebral Vasoconstriction Syndrome (RCVS) :~* Questionnaires about anxiety, depression ;~* Constitution of a biobank (if specific consent) at inclusion and at 3 months"
62653214|NCT01326975||EAdi 1|babies in this group will first receive CPAP through IF-CPAP for 30 minutes. After another 45 minutes, they will be switched to HFNC for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
62270018|NCT04179383|OTHER|Volunteers|"Volunteers admitted for a non neurological or non vascular pathology or healthy volunteers accompanying a patient :~* Questionnaires about anxiety, depression ;~* Constitution of a blood biobank (if specific consent)"
62270019|NCT02078687|ACTIVE_COMPARATOR|Group 1, HM|This group received breastfeeding (human milk, HM) solely throughout the 4 month of intervention. Randomisation for group 1 or group 2. Mothers own milk.
62064987|NCT02715817|ACTIVE_COMPARATOR|Conventional Therapeutic Exercises - CTE|A program of conventional therapeutic exercises (G1) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1: 30 minutes of upper limb PNF diagonal exercise (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes of scapula PNF diagonal exercise (anterior and posterior elevation); b) protocol 2: 20 minutes of lower limb PNF diagonal exercise (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes of pelvis PNF diagonal exercise (anterior and posterior depression), and 10 minutes gait cycle training;
62064988|NCT02715817|EXPERIMENTAL|VR and CTE|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
62064989|NCT05733975|OTHER|Use of Decision Making Tool|Single Arm design, study team will deliver the tool to be used by the parent(s) to help guide them in discussion with their infant's clinicians.
62064990|NCT04866004|EXPERIMENTAL|Contingency Management - Cannabis|Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.
62064991|NCT04091724||Delirium is determined by PAED score|
62064992|NCT04091724||No delirium is determined by PAED score|
62270020|NCT02078687|ACTIVE_COMPARATOR|Group 2, HMF|This group received mothers own milk with fortification (human milk fortification, HMF) throughout the 4 month intervention period. Randomisation for group 1 og group 2. Enfamil HM fortifier, Mead Johnson.
62064993|NCT06625502|EXPERIMENTAL|Culturally Affirming Racial Equity (CARE) framework|In this single-arm study, all participants will receive the CARE protocol, which includes a) 3-4 session protocol aimed at cultivating the cross-racial/cross-cultural therapeutic alliance, b) therapist and patient collaboration on a case formulation and treatment plan, c) evidence-based approaches to treating the presenting problem, d) alliance-focused training to address ruptures, and e) cultural case consultation.
62064994|NCT05291221|PLACEBO_COMPARATOR|control|At the end of the operation by 15min, 5ml saline in a medical spray bottle was sprayed down the intratracheal tube of patients.
62064995|NCT05291221|ACTIVE_COMPARATOR|Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
62631364|NCT03446378|EXPERIMENTAL|Anodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
62631365|NCT03446378|EXPERIMENTAL|Cathodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where cathodal electrode will be on the affected hemisphere and the anodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
62631366|NCT03446378|SHAM_COMPARATOR|Sham tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
62631367|NCT03642535|EXPERIMENTAL|ALA for all face group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
62064996|NCT05291221|ACTIVE_COMPARATOR|Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
62064997|NCT03028402||Asymptomatic Controls|Individuals who have no history of neck pain, trauma or surgery, similar in age and sex to the surgical patients
62631368|NCT03642535|ACTIVE_COMPARATOR|ALA for AK lesion group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
62631369|NCT04147247|EXPERIMENTAL|1.0 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 1.0 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
62064998|NCT03028402||C5-C6 arthrodesis|Patients scheduled to undergo C5-C6 anterior cervical arthrodesis
62064999|NCT03028402||C6-C7 arthrodesis|Patients scheduled to undergo C6-C7 anterior cervical arthrodesis
62270021|NCT02078687|ACTIVE_COMPARATOR|Group 3, PF|This group received preterm formula (PF) throughout the intervention period of 4 month. This group was not randomised for ethical reasons. Enfalac Premature Formula, Mead Johnson Nutritionals
62270022|NCT04677712|ACTIVE_COMPARATOR|Cohort 1: CCH-aaes|CCH-aaes was administered without mitigation treatment (control group).
62270023|NCT04677712|ACTIVE_COMPARATOR|Cohort 2: CCH-aaes + Compression Garment|CCH-aaes was administered with compression garment.
62270024|NCT04677712|ACTIVE_COMPARATOR|Cohort 3: CCH-aaes + Instant Cold Packs|CCH-aaes was administered with instant cold packs.
62270025|NCT04677712|ACTIVE_COMPARATOR|Cohort 4: CCH-aaes + Arnica Gel Patches (OcuMend)|CCH-aaes was administered with arnica gel patches (OcuMend).
62452475|NCT01825109|EXPERIMENTAL|14 weeks RV & delayed breastfeedin|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
62452476|NCT02407444|EXPERIMENTAL|Physiotherapy treatment & leg cycling|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes. Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will have cycling training with leg cycle ergometer for 20 minutes.~This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
62452477|NCT02407444|ACTIVE_COMPARATOR|Physiotherapy treatment & music listening|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes .Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will listen to music (while sitting on a chair) for 20 minutes.This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
62452478|NCT00427492|ACTIVE_COMPARATOR|Magnesia|Medical laxative
62452479|NCT00427492|PLACEBO_COMPARATOR|Placebo|Placebo
62452480|NCT04963088|EXPERIMENTAL|TISLELIZUMAB、Anlotinib plus XELOX|
62452481|NCT02236338|ACTIVE_COMPARATOR|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
61978581|NCT00042770|ACTIVE_COMPARATOR|Arm I|Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed.
62270026|NCT04677712|ACTIVE_COMPARATOR|Cohort 5:CCH-aaes + INhance Post-Injection Serum with TriHex Technology®|CCH-aaes was administered with INhance Post-Injection Serum with TriHex Technology®
62270027|NCT04677712|ACTIVE_COMPARATOR|Cohort 6: CCH-aaes + Pulse Dye Laser Treatment (PDL)|CCH-aaes was administered with PDL.
62270028|NCT02100878||Lean adolescents|
62270029|NCT02100878||Obese adolescents|
62270030|NCT05076539|OTHER|Geospatial|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery)
62270031|NCT04992520|EXPERIMENTAL|Group 1A: S. sonnei 53G|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
62270032|NCT04992520|EXPERIMENTAL|Group 1B: S. flexneri 2a 2457T|"At least 3 months after challenging Group 1A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
62270033|NCT04992520|EXPERIMENTAL|Group 2A: S. flexneri 2a 2457T (1500 cfu)|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
62452482|NCT02236338|ACTIVE_COMPARATOR|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
62452483|NCT02514174|EXPERIMENTAL|Afatinib|afatinib starting at 30 mg daily dose
62631370|NCT04147247|EXPERIMENTAL|2.5 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 2.5 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
62270034|NCT04992520|EXPERIMENTAL|Group 2B: S. sonnei 53G|"At least 3 months after challenging Group 2A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
62631371|NCT04147247|EXPERIMENTAL|5.0 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 5.0 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
62631372|NCT04147247|EXPERIMENTAL|7.0 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 7.0 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
62631373|NCT04147247|EXPERIMENTAL|8.5 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 8.5 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
62631374|NCT04821843|EXPERIMENTAL|(Neoadjuvant chemotherapy) nCT|This arm received chemotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
62631375|NCT04821843|PLACEBO_COMPARATOR|(Neoadjuvant Chemoradiation) nCRT|This arm received chemoradiotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
62270035|NCT04186078||obstructive sleep apnea (OSA)|5 or more predominantly obstructive respiratory events \[obstructive and mixed apneas, hypopneas or respiratory effort-related arousals (RERAs)\] per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
62270036|NCT04186078||central sleep apnea (CSA)|"PSG shows all of the following:~1. 5 or more central apneas and/or central hypopneas per hour of sleep.~2. The number of central and/or central hypopneas is \> 50% of the total number of apneas and hypopneas."
62270037|NCT04186078||control|apnea-hypopnea index \< 5 per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
62653215|NCT01326975||EAdi 2|babies in this group will first receive CPAP through HFNC for 30 minutes. After another 45 minutes, they will be switched to IF-CPAP for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
62631376|NCT05897515|OTHER|Blinded, Prospective Arm|"Clinical specimens shall be collected prospectively from patients with signs or symptoms of respiratory tract infection. Nasal swab in Copan universal transport media (UTM) 3 milliliters for comparator testing should be collected by a healthcare professional.~Where subjects are willing and able, up to 40% of nasal swab for the investigational device will be self-collected under the guidance and supervision of a healthcare professional.~Nasopharyngeal (NPS) specimens (optional) should only be collected by a healthcare professional. All specimens collected from children 13 years or younger should only be collected by a trained healthcare professional. Follow the Centers for Disease Control and Prevention guidelines for collecting NPS swabs, unless otherwise specified by the sponsor."
62631377|NCT03764514||Spinal Cord Stimulator - Permanent Implantation|
62631378|NCT00624000|EXPERIMENTAL|1|IA administration of Alteplace vs. IV administration of Alteplace
62631379|NCT00624000|ACTIVE_COMPARATOR|2|IA administration of Alteplase vs.IV administration of Alteplase
62270038|NCT05808400|EXPERIMENTAL|Exosomes treatment group|Treated with umbilical cord mesenchymal stem cell-derived extracellular vesicles (EVs) preparation (Specification: 5ml, EV concentration of 1\*10\^9 particles /ml)
62631380|NCT01908712|EXPERIMENTAL|Lamazym|1 mg Lamazym/kg body weight
62631381|NCT05063578|EXPERIMENTAL|Participant|
62631382|NCT02810275|EXPERIMENTAL|Folinic Acid|Folinic acid group received 5 mg daily during four weeks
62270039|NCT05808400|NO_INTERVENTION|Non-treatment group|No treatment
62270040|NCT03678480|EXPERIMENTAL|HTD1801 500 mg BID (twice daily), or 1000 mg/day|HTD1801 tablets in double-blind capsules, 250 mg
62452484|NCT03858257|EXPERIMENTAL|High flow nasal oxygen|The gas temperature will commence at the 'High' setting (ranges 30-32º Celsius) and titrated downwards if the patient complains of irritation. The gas flow rate will commence at 30 liters per minute prior to sedation administration and be titrated up to 70 liters per minute as tolerated by the patient after sedation has been administered. The fraction of oxygen in the gas will be commenced at 50% (same as that delivered from 6 liters per minute via facemask) and can be titrated upward according to patient requirements (i.e. increased if there is evidence of hypoventilation, airway obstruction or inadequate oxygenation, decreased during use of diathermy). Anesthesia Assistants at the site will be provided with training in the use of this mode of oxygen delivery prior to study commencement.
62631383|NCT02810275|PLACEBO_COMPARATOR|Placebo|Placebo group received a tablet daily during four weeks
62631384|NCT01614002||carcinoma, Doce onkovis (Docetaxel)|treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region.
62270041|NCT03678480|ACTIVE_COMPARATOR|Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day|UDCA tablets in double-blind capsules, 250 mg
62631385|NCT06069739|EXPERIMENTAL|Guided physical activity group|Guided-exercise of moderate intensity and frecuency, and incentive of autonomous physical activity proposals by the specialist.
62270042|NCT01928381|PLACEBO_COMPARATOR|placebo capsules|Capsules to match pregabalin and AZD5213
62270043|NCT01928381|EXPERIMENTAL|AZD5213 + pregabalin|AZD5213 in combination with pregabalin
62631386|NCT06069739|ACTIVE_COMPARATOR|Standard physical activity group|Standard physical activity without guided and incentives.
62631387|NCT03004768|EXPERIMENTAL|Single dose of radiolabeled BMS-986165|
62631388|NCT02324361|EXPERIMENTAL|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
62631389|NCT02324361|EXPERIMENTAL|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
62631390|NCT05002166||Children aged less than 18 years with a confirmed diagnosis of IBD.|"All patients admitted with inflammatory bowel disease will be subjected to:~1. History: including name, age ,sex ,family history, consanguinity, history of rectal bleeding, mucus or blood in the stool, diarrhea, abdominal pain ,vomiting ,nausea and loss of appetite.~2. Examination: including general examination, chest, cardiac, abdominal and neurological examination~3. Investigation:including labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope."
62631391|NCT02959918|EXPERIMENTAL|SEL-037 Pegadricase LD (low dose) alone|Pegadricase 0.2 mg/kg intravenous (IV) every 28 days for 5 treatments
62631392|NCT02959918|EXPERIMENTAL|SEL-037 Pegadricase HD (high dose) alone|Pegadricase 0.4 mg/kg intravenous (IV) every 28 days for 5 treatments
62270044|NCT01928381|ACTIVE_COMPARATOR|pregabalin|pregabalin capsules
62270045|NCT00505466||Pre-Test Genetic Counseling + Genetic Sample|
62270046|NCT05461950||Self-breathing infants|Vigorous infants with spontaneous onset of respiration within one minute after delivery by cesarean section, receiving extra-uterine placental transfusion and physiology-based cord clamping
62270047|NCT05461950||Infants with respiratory support|Infants with no or poor spontaneous onset of respiration after delivery by cesarean section, receiving extra-uterine placental transfusion, intact-cord stabilisation (any respiratory support) and physiology-based cord clamping after transfer to resuscitation table
62270048|NCT05461950||Historical control group|Infants delivered by cesarean section in a time period when delayed cord clamping after 1-3 minutes was default procedure. Less-than-vigorous infants needing respiratory support or full resuscitation had their umbilical cords cut early (within 30 seconds)
62270049|NCT04583033|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT) Group|Participants will receive CBT intervention bi-weekly for total of six (6) sessions.
62631393|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase LD & SEL-110 (1a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
62631394|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (1b)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
62631395|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase LD & SEL-110 (2a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
62631396|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (2b)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
62631397|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (3a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
62631398|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (3b)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
62631399|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (4a)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.125 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
62631400|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (4b)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
62631401|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (5a)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
62631402|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (5b)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 5 treatments
62631403|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (6a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.10 mg/kg IV every 28 days for 1 treatment followed by pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 4 treatments
62631404|NCT02959918|EXPERIMENTAL|SEL-212, Pegadricase HD & SEL-110 (6b)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 5 treatments
62631405|NCT04512144|EXPERIMENTAL|Intervention|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. She will be provided a three month gift subscription. Headspace will be downloaded to her smartphone and she will be instructed on use. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. The number of Headspace sessions will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
62653216|NCT01030900|EXPERIMENTAL|Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin + Rituximab + Campath|Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin (EPOCH) + Rituximab + campath every 3 weeks for six cycles
62653217|NCT00988780|EXPERIMENTAL|Maraviroc|"Maraviroc 600mg po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID"
62452485|NCT03858257|OTHER|Standard oxygenation|Supplemental oxygen through a facemask with the flow rate chosen by the clinician responsible for sedation as per their standard practice. The oxygen flow rate is typically commenced at 6 liters per minute and can be titrated up to 15 liters per minute.
62452486|NCT03849313|EXPERIMENTAL|AVT02 100mg/mL|Biosimilar Adalimumab AVT02
62452487|NCT03849313|ACTIVE_COMPARATOR|EU-Humira 100mg/mL|EU Approved Adalimumab originator Humira
62452488|NCT03849313|ACTIVE_COMPARATOR|US-Humira 100mg/mL|US licensed Adalimumab originator Humira
62065000|NCT03028402||C4-C5-C6 arthrodesis|Patients scheduled to undergo C4-C5-C6 anterior cervical arthrodesis
62452489|NCT02073630|OTHER|Healthy subjects|healthy subjects will receive either sham or active cerebellar stimulation
62452490|NCT02073630|OTHER|Dystonia|dystonic patients will receive either sham or active cerebellar stimulation
62065001|NCT03028402||C5-C6-C7 arthrodesis|Patients scheduled to undergo C5-C6-C7 anterior cervical arthrodesis
62065002|NCT02294188|PLACEBO_COMPARATOR|Placebo|Spatial Repellent product without active ingredient (SHIELD)
62452491|NCT03516747|EXPERIMENTAL|investigation group|participants that suffer hypercalcemia due to primary hyperparathyroidism. include all participants in the trial
62452492|NCT02295397|EXPERIMENTAL|food provocation|open and placebo-controlled food challenges
62653218|NCT00988780|PLACEBO_COMPARATOR|Placebo|"Placebo po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID"
62631406|NCT04512144|NO_INTERVENTION|Control|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. All patients in the control group may choose to practice calming or mindfulness exercises of their own accord but will not be specifically instructed to seek out such resources as is our standard practice. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
62631407|NCT05686863|ACTIVE_COMPARATOR|P group|induction: Propofol 3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: propofol 5-10 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
62631408|NCT05686863|EXPERIMENTAL|R group|induction: Remimazolam 0.3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: Remimazolam 1-3 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
62452493|NCT06455020|EXPERIMENTAL|Catheter ablation|Patients randomized to the emergency catheter ablation arm will first undergo catheter ablation. Vasopressors, antiarrhythmic drugs, and hemodynamic mechanical support devices will be adopted as needed. All patients will be advised for ICD implantation before discharge.
62452494|NCT06455020|ACTIVE_COMPARATOR|Stepped-care strategies|Patients randomized to the stepped-care strategies arm will undergo a stepwise progressive procedure, with anti-arrhythmic drugs, sedation and anesthesia, and hemodynamic mechanical support devices, that is, the next treatment is only started when the previous sequence of treatment is ineffective, and catheter ablation is only used as the final rescue treatment. All patients will be advised for ICD implantation before discharge.
62452495|NCT00948675|EXPERIMENTAL|Pemetrexed + Carboplatin + Pemetrexed|Pemetrexed and Carboplatin followed by Pemetrexed
62452496|NCT00948675|ACTIVE_COMPARATOR|Paclitaxel + Carboplatin + Bevacizumab|Paclitaxel, Carboplatin, and Bevacizumab followed by Bevacizumab
62452497|NCT00508560|EXPERIMENTAL|Arm 1|Experimental
62452498|NCT00508560|ACTIVE_COMPARATOR|Arm 2|Active Comparator
62452499|NCT02556242|EXPERIMENTAL|Targeted indoor residual spraying|The intervention arm of the trial will receive Indoor Residual Spraying delivery through targeted spraying in the neighbourhood of recent local cases only.
62452500|NCT02556242|ACTIVE_COMPARATOR|Generalised Indoor residual spraying|The reference (control) arm of the trial will receive Indoor Residual Spraying through generalised annual spraying of all structures, as is the current standard practice.
62452501|NCT02898649|EXPERIMENTAL|IRE|The intervention group
62631409|NCT06027762||Single-Groupe|
62631410|NCT00630799|EXPERIMENTAL|1|leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)
62452502|NCT01241461|EXPERIMENTAL|LY2584702|
62452503|NCT06110039|EXPERIMENTAL|Group 1: Cervicothoracic junction mobilization with arm movement along with baseline treatment|
62452504|NCT06110039|EXPERIMENTAL|Group 2: upper thoracic manipulation woth baseline treatment|
62452505|NCT01520051|EXPERIMENTAL|Mepolizumab|
62452506|NCT01520051|PLACEBO_COMPARATOR|Saline|
62452507|NCT03752788|EXPERIMENTAL|Dual-task Training Fixed Priority|"Dual-task Training with fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
62631411|NCT04592549|EXPERIMENTAL|Cohort 1: 150 mg IM injection of active drug or placebo|"Subjects in cohort 1 will receive a 150 mg dose IM injection of either active drug or placebo.~Cohort 1 will dose 8 subjects to active drug and 2 subject to placebo"
62631412|NCT04592549|EXPERIMENTAL|Cohort 2: 300 mg IM injection of active drug or placebo|"Subjects in cohort 2 will receive 300 mg IM injection of either active drug or placebo.~Cohort 2 will dose 8 subjects to active drug and 2 subject to placebo."
62065003|NCT02294188|ACTIVE_COMPARATOR|Intervention|Spatial Repellent product with active ingredient (SHIELD)
62452508|NCT03752788|ACTIVE_COMPARATOR|Dual-task Training Variable Priority|"Dual-task Training with variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
62452509|NCT06373575|EXPERIMENTAL|Intervention group|Fluid removal with the guidance of lung and inferior vena cava ultrasound before prolonged hemodialysis
62631413|NCT04592549|EXPERIMENTAL|Cohort 3: 300 mg IM injection of active drug or placebo|"Subjects in cohort 3 will receive 300 mg IM injection of either active drug or placebo.~Cohort 3 will dose 8 subjects to active drug and 2 subject to placebo"
62631414|NCT04592549|EXPERIMENTAL|Cohort 4: 300 mg IM injection of active drug or placebo|"Subjects in cohort 4 will receive 300 mg IM injection of either active drug or placebo.~Cohort 4 will dose 8 subjects to active drug and 2 subject to placebo"
62631415|NCT04592549|EXPERIMENTAL|Cohort 5: 600 mg IM injection of active drug or placebo|"Subjects in cohort 5 will receive 600 mg IM injection of either active drug or placebo.~Cohort 5 will dose 8 subjects to active drug and 2 subject to placebo"
62065004|NCT02693301|NO_INTERVENTION|Control|Children who follow the recommendations of their pneumologist
62065005|NCT02693301|EXPERIMENTAL|Experimental|A two month intervention program 3 days/week will be carried out. The session will last \~60 minutes, and will consist of a combined training (aerobic training \~30 min, and strength \~30 min of 7 whole body exercises (3 sets x 10 repetitions).The load was gradually increased as the strength of each child improved, i.e., from 40% of five-repetition maximum (5RM) lifting ability at the start of the program to 60% of 5RM at the end of the program. All sessions were individually supervised by trained professionals.
62065006|NCT03169634|EXPERIMENTAL|short or long stemmed rTKR cemented|
62452510|NCT06373575|ACTIVE_COMPARATOR|Control group|Fluid removal with the conventional protocol
62452511|NCT02983448|PLACEBO_COMPARATOR|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
62631416|NCT03677869|EXPERIMENTAL|Pneumatic vitreolysis (PVL)|Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.
62631417|NCT00701688|EXPERIMENTAL|Dose Level 1|Palifermin 40 mcg/kg/day intravenous
62631418|NCT00701688|EXPERIMENTAL|Dose Level 2|Palifermin 60 mcg/kg/day intravenous
62631419|NCT00701688|EXPERIMENTAL|Dose Level 3|Palifermin 90 mcg/kg/day intravenous
62452512|NCT02983448|ACTIVE_COMPARATOR|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
62452513|NCT03287050|EXPERIMENTAL|Pembrolizumab + SBRT|
62452514|NCT05802680|SHAM_COMPARATOR|Sham-tPBM, non-ADHD|Participants with no medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).
62452515|NCT05802680|SHAM_COMPARATOR|Sham-tPBM, ADHD|Participants with a medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).
62452516|NCT05802680|EXPERIMENTAL|tPBM, non-ADHD|Participants with no medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).
62452517|NCT05802680|EXPERIMENTAL|tPBM, ADHD|Participants with a medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).
62452518|NCT05722509|EXPERIMENTAL|"Distal Reduction Flap Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
62452519|NCT05722509|ACTIVE_COMPARATOR|"Only Exodontia Group"|Exodontia of the 3rd molar will be performed following the different steps in the simple exodontic technique without performing any other surgical procedure.
62452520|NCT00802802|EXPERIMENTAL|Cohort I, Step 1|HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs
62452521|NCT00802802|EXPERIMENTAL|Cohort II|HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
62452522|NCT00802802|EXPERIMENTAL|Cohort I, Step 2|HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy
62452523|NCT02185612|NO_INTERVENTION|Control|Participants will be randomized to a 1 year wait list. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
62452524|NCT02185612|EXPERIMENTAL|Savings program|Participants will be randomized to the EARN.org online savings program for 6 months. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
62452525|NCT04639596|EXPERIMENTAL|MBTS|It will consist of four hours of sailing and mindfulness training at the Jordanelle Reservoir. Boats and skippers will be provided by Park City Sailing Association, a non-profit community organization.
62452526|NCT04639596|EXPERIMENTAL|SRT|SRT will occur on four separate occasions during the summer of 2019. SRT will consist of 4 hours of bowling at a community bowling alley.
62452527|NCT02046928|EXPERIMENTAL|A6|A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
62631420|NCT04394156|EXPERIMENTAL|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.~In the intervention phase the participant will be offered around five intervention sessions with a researcher. Each session the participant will choose which intrusive memory they would like to focus on and the cognitive task will be completed. The intervention includes a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants will be given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary."
62631421|NCT04964661||SpA women MRI|Women affected by spondyloarthritis and performed a sacroiliac MRI
62065007|NCT03169634|EXPERIMENTAL|Cone with short stem|
62452528|NCT02207231|EXPERIMENTAL|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter \[mL\] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
62452529|NCT02207231|PLACEBO_COMPARATOR|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
62631422|NCT01088490||critically ill|Critically ill patients admitted to ICU
62631423|NCT03934008||Historical Control Group|All pediatric patients 0-6 years of age seen in the clinic within one year prior to the start of the intervention period
62631424|NCT03934008||Post-Intervention Group|All pediatric patients 0-6 years of age seen in the clinic for one year following the implementation of the motivational interviewed based tool
62631425|NCT00953888|EXPERIMENTAL|Active|AZD5069 oral solution
62631426|NCT00953888|PLACEBO_COMPARATOR|Placebo|Placebo oral solution
62631427|NCT05637307|EXPERIMENTAL|sentinel node procedure|Participants will indergo the standard treatment for their disease ( i.e. brachytherapy) but a sentinel node procedure will be added to their treatment
62631428|NCT01881607|NO_INTERVENTION|Control|Schoolchildren aged 12-13 years in the first year of Compulsory Secondary Education (Enseñanza Secundaria Obligatoria in the Spanish educational system) in the city of Terrassa. The CONTROL arm is formed by schoolchildren in schools that willnot receive the intervention and will continue with ongoing (usual) health education sessions.
62631429|NCT01881607|EXPERIMENTAL|Intervention|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
62631430|NCT00331838|EXPERIMENTAL|Semuloparin 5 mg|Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
62065008|NCT03169634|EXPERIMENTAL|Cone with long stem|
62065009|NCT05508906|EXPERIMENTAL|OP-1250 with Ribociclib|Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation).
62065010|NCT05508906|EXPERIMENTAL|OP-1250 with Alpelisib|Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation)
62065011|NCT05508906|EXPERIMENTAL|OP-1250 with Everolimus|Treatment Group 3: OP-1250 in combination with everolimus
62065012|NCT02626858|OTHER|extra treatment planning CT-scan|Extra pre-operative CT-scan for treatment planning in RT
62065013|NCT01996215||AMD controls|
62065014|NCT01996215||AMD cases|
62452530|NCT02207231|ACTIVE_COMPARATOR|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg \[0.8 mL\] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
62452531|NCT01116375||Obese children with OSA|To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR
62065015|NCT03606122|EXPERIMENTAL|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
62065016|NCT06233643|EXPERIMENTAL|The group received acupuncture combined with intradermal sterile water|These acute renal colic patients who will received acupuncture combined with intradermal sterile water
62065017|NCT06233643|ACTIVE_COMPARATOR|The group received intramuscular inject phloroglucinol|These acute renal colic patients who will received intramuscular inject phloroglucinol.
62065018|NCT02566798|EXPERIMENTAL|Oleogrape|Patients are taking capsules of OleograpeSEED (Extract of grape and olive) 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days
62631431|NCT00331838|EXPERIMENTAL|Semuloparin 10 mg|Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
62631432|NCT00331838|EXPERIMENTAL|Semuloparin 20 mg|Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
62631433|NCT00331838|EXPERIMENTAL|Semuloparin 40 mg|Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
62452532|NCT06274606|EXPERIMENTAL|Exercise Group (EX-group)|The EX-group will complete 8 weeks of supervised aerobic exercise training. The EX-group will also continue normal care with bariatric doctors and nurses along with the exercise intervention.
62452533|NCT06274606|NO_INTERVENTION|Standard Care Only Group (SC-group)|The SC-group will only complete the orientation visit and testing visits. The participants that are randomized to this group will continue normal care with bariatric doctors and nurses. They will participate in study assessment visits only.
62452534|NCT02154529|EXPERIMENTAL|Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 150 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
62065019|NCT02566798|PLACEBO_COMPARATOR|Placebo|Patients are taking capsules of placebo (lactose) 3 times a day in the morning, at noon and in the evening during 7 days
62065020|NCT03779139|ACTIVE_COMPARATOR|Intrahepatic islets alone|
62065021|NCT03779139|EXPERIMENTAL|Intrahepatic and omental pouch islets|
62065022|NCT03779139|SHAM_COMPARATOR|Normal Volunteers|
62065023|NCT02821624|EXPERIMENTAL|Cohort 1|G1T38 or placebo
62065024|NCT02821624|EXPERIMENTAL|Cohort 2|G1T38 or placebo
62065025|NCT02821624|EXPERIMENTAL|Cohort 3|G1T38 or placebo
62065026|NCT02821624|EXPERIMENTAL|Cohort 4|G1T38 or placebo
62065027|NCT02821624|EXPERIMENTAL|Cohort 5|G1T38 or placebo
62065028|NCT02821624|EXPERIMENTAL|Cohort 6|G1T38 or placebo
62452535|NCT02154529|EXPERIMENTAL|Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 250 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
62452536|NCT02154529|EXPERIMENTAL|Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 300 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
62452537|NCT02154529|EXPERIMENTAL|Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 350 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
62452538|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
62452539|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
62452540|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
62452541|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
62452542|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
62631434|NCT00331838|EXPERIMENTAL|Semuloparin 60 mg|Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
62631435|NCT00331838|ACTIVE_COMPARATOR|Enoxaparin 40 mg|Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
62631436|NCT00331838|EXPERIMENTAL|Placebo pre-op / Semuloparin 20 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
62631437|NCT00331838|EXPERIMENTAL|Placebo pre-op / Semuloparin 40 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
62631438|NCT01427010|EXPERIMENTAL|Reirradiation of recurrent and 2nd primary head/neck cancer.|
62631439|NCT00534248|EXPERIMENTAL|Zostavax™|Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
62631440|NCT00534248|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive Placebo.
62631441|NCT04017715|EXPERIMENTAL|warm up|warm up exercises
62631442|NCT04017715|EXPERIMENTAL|cool down|cool down exercises
62631443|NCT04017715|ACTIVE_COMPARATOR|control|Following conventional protocol
62270050|NCT04583033|NO_INTERVENTION|Control Group|Participants will not receive any intervention as part of the study.
62452543|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
62452544|NCT03069274|OTHER|Control|Only general nutritional recommendations were given.
62452545|NCT03069274|EXPERIMENTAL|Intervention|General nutritional recommendations, change their drinking habits.
62452546|NCT00925249||1|The study group will consist of RA patients of the Walter Reed Army Medical Center (WRAMC) rheumatology clinic being considered for treatment with anti-TNF alpha therapy. We will enter patients into the study over a projected course of 12-24 months or until we reach the statistical requirement of 60 subjects.
62452547|NCT00925249||2|The control group will consist of healthy subjects without known immune-dysregulation or history of treatment with biologic agents who present to the WRAMC Allergy- Immunology clinic for routine screening TST as a part of current WRAMC policy.
62452548|NCT01669395|EXPERIMENTAL|Early homebased rehabilitation|After discharge from the hospital patients are offered a homebased rehabilitation program lasting 6 weeks.
62631444|NCT03925129|EXPERIMENTAL|TENS|
62631445|NCT03925129|SHAM_COMPARATOR|Sham TENS|
62631446|NCT00635544|EXPERIMENTAL|1|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
62631447|NCT00635544|ACTIVE_COMPARATOR|2|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
62452549|NCT01669395|EXPERIMENTAL|control group: Ususal care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
62452550|NCT04232150|EXPERIMENTAL|Group C (control group)|control group will receive no sedation under spinal anesthesia.
62452551|NCT04232150|EXPERIMENTAL|Group O (single dose group)|patients will receive 0.025mg/kg midazolam sedation under spinal anesthesia.
62452552|NCT04232150|EXPERIMENTAL|Group M (double dose group)|patients will receive 0.025mg/kg midazolam sedation twice under spinal anesthesia.
62452553|NCT04835948||Multiple doses of anti-thymocyte globulin (ATG)|Control group that received fractionated doses of 1.5 mg/kg adding up to a total of 6 mg/kg
62631448|NCT05391997|EXPERIMENTAL|Modified Cervical and Shoulder Retraction exercises|Cervical extension traction protocol will be added as standard treatment. Then, patients either sit or stand in an upright position while pushing their chin backward and simultaneously raising their head within the pain-free range, then, in a seated or standing position, patients will maintain an upright posture and try to pull back their shoulders and extend their neck within the pain-free range.
62452554|NCT02280629|EXPERIMENTAL|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
62631449|NCT05391997|ACTIVE_COMPARATOR|Cervical Extension Traction exercises|Here, patients will receive Cervical Extension Traction exercises as standard treatment. Cervical extension traction includes a protocol in which traction will be applied within the extension range of the cervical region in full spine position.
62631450|NCT00603603|EXPERIMENTAL|80% inhaled oxygen-non-rebreather|10 liters of oxygen via non re-breather mask during cesarean section and up to two hours post-operatively
62065029|NCT02821624|EXPERIMENTAL|Cohort 7|G1T38 or placebo
62270051|NCT05152550||Group A|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features
62631451|NCT00603603|ACTIVE_COMPARATOR|30% inhaled oxygen-nasal cannula|2 liters of oxygen via nasal cannula (standard of care) during cesarean section only
62631452|NCT02983045|EXPERIMENTAL|Dose Escalation: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels to determine the RP2D Part 1 of RP2D in patients with advanced or metastatic melanoma, RCC, NSCLC, urothelial carcinoma, or TNBC.
62631453|NCT02983045|EXPERIMENTAL|Dose Expansion: Combination of NKTR-214 + nivolumab|NKTR-214+nivolumab in patients with advanced or metastatic solid tumor malignancies to assess the efficacy of the RP2D.
62631454|NCT02983045|EXPERIMENTAL|Experimental: Combination of NKTR-214 + nivolumab + ipilimumab|To assess the safety and tolerability of NKTR 214 + nivolumab + ipilimumab triplet therapy and establish RP2D dosing schedules for Part 4 in patients with advanced or metastatic melanoma, RCC, NSCLC, or UCC in a first-line setting (1L).
62631455|NCT02983045|EXPERIMENTAL|Experimental: Dose Expansion of Part 3|To further assess the RP2D triplet combination dosing schedules from Part 3 in 1L NSCLC and 1L RCC patients.
62631456|NCT00812175||Group 1|
62631457|NCT00766597|EXPERIMENTAL|Vicriviroc in tablet form (20/30 mg) or liquid form (1 mg/ml)|HIV-1 Infected Antiretroviral Therapy Experienced Participants with CCR5-tropic Virus
62631458|NCT04710004|EXPERIMENTAL|Brain stimulation via clinically implanted electrodes|Brain will be stimulated in different patterns including synchronized or asynchronous current.
62631459|NCT03263026|ACTIVE_COMPARATOR|R-CHOP + enzastaurin hydrochloride|Subjects in the R-CHOP + enzastaurin Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus a 1125 mg loading dose of enzastaurin on Day 2 followed by 500 mg daily.
62631460|NCT03263026|PLACEBO_COMPARATOR|R-CHOP + placebo|Subjects in the R-CHOP + placebo Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus an identical number of tablets as the subjects in the enzastaurin Arm.
62631461|NCT00527826|ACTIVE_COMPARATOR|arm 1|
62452555|NCT02280629|PLACEBO_COMPARATOR|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
62631462|NCT00527826|ACTIVE_COMPARATOR|arm 2|
62631463|NCT03619655|EXPERIMENTAL|"Cohort A - SPECT CT and NaF PET"|Intervention 1: SPECT CT Intervention 2: NaF PET
62631464|NCT03619655|EXPERIMENTAL|"Cohort B - SPECT CT and 18F-DCFPyL PET/CT"|Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT
62452556|NCT02280629|ACTIVE_COMPARATOR|Mesalamine|LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily
62452557|NCT01784042|PLACEBO_COMPARATOR|No dietary energy restriction plus Placebo|No dietary energy restriction plus Placebo
62452558|NCT01784042|PLACEBO_COMPARATOR|Dietary energy restriction plus placebo|Dietary energy restriction plus placebo
62452559|NCT01784042|EXPERIMENTAL|Lovaza|Lovaza only
62452560|NCT01784042|EXPERIMENTAL|Dietary energy restriction plus Lovaza|Dietary energy restriction plus Lovaza
62452561|NCT04195165|EXPERIMENTAL|SIT|Subject will be asked to take \<3,000 steps for two intervention days prior to an oral glucose tolerance test on the third day.
62452562|NCT04195165|EXPERIMENTAL|SIT+EX|Subject will be asked to take \<3,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
62452563|NCT04195165|EXPERIMENTAL|ACTIVE+EX|Subject will be asked to take \>10,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
62452564|NCT02764008|ACTIVE_COMPARATOR|Low thoracic paravertebral block|T8-T9 Ultrasound guided paravertebral block with 20 ml %0,25 bupivacaine
62452565|NCT02764008|ACTIVE_COMPARATOR|Peritubal infiltration|Peritubal infiltration with 20 ml %0,25 bupivacaine
62452566|NCT02764008|NO_INTERVENTION|Control Group|No drug
62452567|NCT04154709|EXPERIMENTAL|CTA101|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62452568|NCT05172375|EXPERIMENTAL|The Shared Care model - intervention group|The patients are referred to outpatient clinics based on their home address. The two outpatient clinics should be comparable in terms of patients' diagnoses and staffing. The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties. The final version of the intervention can only be determined based on the results of the research steps 1+2.
62631465|NCT03619655|EXPERIMENTAL|"Cohort C - SPECT CT and WB-MRI"|Intervention 1: SPECT CT Intervention 2: WB-MRI
62631466|NCT01421641|ACTIVE_COMPARATOR|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle.
62631467|NCT01421641|ACTIVE_COMPARATOR|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip (this amount of lidocaine will be measured out prior to procedure)
62631468|NCT03321201|EXPERIMENTAL|Cauterization|
62631469|NCT03321201|ACTIVE_COMPARATOR|Fibrin glue|
62631470|NCT04554602||Patient with endometriosis or suspicion of endometriosis|"* Information and collection of the non-objection before inclusion~* Interrogation, clinical examination, EHP30 and SF36 form at inclusion~* MRI, pelvic ultrasound (coupled with fusion ultrasound)~* Laparoscopy if indicated after MRI, ultrasound and fusion ultrasound~* Monitoring by form and fusion ultrasound at 6 months and then once a year for 3 years"
62631471|NCT04554602||Patient with other gynaecological pathology|"* Information and collection of the non-opposition before inclusion~* Interrogation, clinical examination, EHP30 and SF36 form at inclusion~* MRI, pelvic ultrasound (coupled with fusion ultrasound)~* laparoscopy if indicated after MRI, ultrasound and fusion ultrasound"
62631472|NCT02600611|EXPERIMENTAL|iclaprim|iclaprim 80 mg intravenous every 12 hours
62065030|NCT02821624|EXPERIMENTAL|Cohort 8|G1T38 or placebo
62631473|NCT02600611|ACTIVE_COMPARATOR|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
62631474|NCT00152113|OTHER|1|
62631475|NCT04710680||group A|
62631476|NCT04710680||group I|
62631477|NCT03162185|EXPERIMENTAL|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
62631478|NCT03162185|PLACEBO_COMPARATOR|Control group|Half of the participants ( n= 30) will receive the placebo.
62631479|NCT05204147|EXPERIMENTAL|Treatment (Ac225-DOTA-M5A)|Patients receive Ac225-DOTA-M5A IV over 25 minutes on day 1.
62631480|NCT03897569||patellofemoral pain syndrome|twenty subjects with anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
62631481|NCT03897569||control|twenty-six asymptomatic subject will be recruited for this study and should have no pain or other relevant clinical symptoms in the lower quadrant
62631482|NCT05383417|EXPERIMENTAL|EndoClip|Clip applied to endotracheal tube.
62631483|NCT05383417|NO_INTERVENTION|No Clip|No clip applied to endotracheal tube.
62631484|NCT04210128||Breast cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of breast neoadjuvant chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
62631485|NCT04210128||Pancreatic cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of pancreatic chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
62631486|NCT05148637|ACTIVE_COMPARATOR|Group I|anesthesia maintained by sevoflurane
62631487|NCT05148637|ACTIVE_COMPARATOR|Group II|anesthesia maintained by desflurane
62065031|NCT02821624|EXPERIMENTAL|Cohort 9 - Food Effect|G1T38
62452569|NCT05172375|NO_INTERVENTION|Treatment as usual - Control group|The patients are referred to outpatient clinics based on their home address. The two outpatient clinics should be comparable in terms of patients' diagnoses and staffing. In the control group the patients will receive treatment as usual.
62631488|NCT05148637|ACTIVE_COMPARATOR|Group III|anesthesia maintained by TIVA
61978582|NCT00042770|EXPERIMENTAL|Arm II|Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed.
61978583|NCT03774511|ACTIVE_COMPARATOR|Study group 1|High Intensity Interval Excercise
61978584|NCT03774511|ACTIVE_COMPARATOR|Study group 2|Moderate Intensity Interval Exercise
62065032|NCT02821624|EXPERIMENTAL|Cohort 10|G1T38 or placebo
62065033|NCT02821624|EXPERIMENTAL|Cohort 11|G1T38 or placebo
62452570|NCT06386783|ACTIVE_COMPARATOR|Group D (N.74)|5µg Dexmedetomidine {precedexTM 200U/2ml Hospira, Inc,lake forest,iL,USA} (5 µg added by taking 50 µg in a insulin syringe) + 4ml 0.5% heavy bupivacaine HCl.
62452571|NCT06386783|ACTIVE_COMPARATOR|Group F (N.74) -|25 µg Fentanyl {fentanyl Hameln 50 u/ml Gmbh-germany} + 4ml 0.5% heavy bupivacaine HCl.
62452572|NCT02473809|EXPERIMENTAL|Liraglutide|"Liraglutide (Victoza), subcutaneous 1,8 mg once daily for 180 days"
62452573|NCT02473809|PLACEBO_COMPARATOR|Placebo|Saline, subcutaneous once daily for 180 days
62452574|NCT04414956|OTHER|Surveillance|All participants will be examined with three biomarker tests and sonography every six months and contrast-enhanced CT annually.
62452575|NCT03385473|ACTIVE_COMPARATOR|Pharmacological Adequation (PA)|Pharmacological adequation based on the Pharmacogenomic Index and therapeutic drug monitoring results.
62631489|NCT05603585|NO_INTERVENTION|Control Group|Standard care as per current ICU feeding regime.
62631490|NCT05603585|EXPERIMENTAL|Interventional Group|Optimal protein supplementation to achieve 80% protein adequacy through optimised protein supplementation. The protein supplementation will be increased/decreased based on the previous day's intake to achieve 80% adequacy each day by the dietician.
62631491|NCT06611891|EXPERIMENTAL|Performing a 68Ga-Dotatoc PET scan in patients followed for metastatic breast cancer.|"1. Prescreening of the patient followed for metastatic breast cancer during the routine care~2. V1 Selection: Patient's selection in the Nuclear Medicin or Oncology department~3. V2 Inclusion: The day of the 68Ga-Dotatoc PET scan in the Nuclear Medicin department~4. V3 End of study visit, the same day after the 68Ga-Dotatoc PET scan."
62065034|NCT02821624|EXPERIMENTAL|Cohort 12|G1T38 or placebo
62065035|NCT01550172|EXPERIMENTAL|Sleep Behavioral Therapy A and NHMS|Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
62065036|NCT01550172|ACTIVE_COMPARATOR|Sleep Behavioral Therapy B and NHMS|Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
62065037|NCT01492491|NO_INTERVENTION|standard HFR therapy|standard HFR hemodiafiltration therapy
62452576|NCT03385473|NO_INTERVENTION|Standard of Care (SOC)|Without pharmacological adequation
62452577|NCT00628823|NO_INTERVENTION|A1|Gluten-containing diet
62452578|NCT00628823|ACTIVE_COMPARATOR|A2|Gluten-free diet
62631492|NCT01911754|EXPERIMENTAL|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22
62065038|NCT01492491|ACTIVE_COMPARATOR|SUPRA-HFR therapy|SUPRA-HFR hemodiafiltration therapy
62065039|NCT02040558|EXPERIMENTAL|MNK-010|Subjects will receive 1 dose of MNK-010 followed by a 7-day post dose assessment period per treatment cycle. Dose levels will be based upon the amount of active delivered per square meter of body surface area (mg/m2). Cycles will repeat every 3 weeks (21 days) based on toxicity and response, as determined by a Safety Review Committee (SRC). Subjects will continue treatment with MNK-010 until unacceptable toxicity, documented progression of disease, another criterion for discontinuation is met, or until 4 treatment cycles have been completed.
62065040|NCT03729102|ACTIVE_COMPARATOR|Control group|Persons who had received primary immunization
62065041|NCT03729102|EXPERIMENTAL|Study group|Persons who had received primary immunization and later received booster vaccination for at least 3 times
62452579|NCT03810430|ACTIVE_COMPARATOR|intervention group|ten clusters (villages) were received health promotion activities during six months of interventions
61978585|NCT03774511|NO_INTERVENTION|Control group|No Intervention
62065042|NCT03260127|EXPERIMENTAL|CEFT-CPT|Computerized executive function training plus Cognitive Processing Therapy for PTSD
62631493|NCT02776072||dimethyl fumarate (DMF)|Participants who initiated DMF during the specified time period
62631494|NCT02776072||glatiramer acetate (GA)|Participants who initiated GA during the specified time period
62631495|NCT02776072||teriflunomide|Participants who initiated teriflunomide during the specified time period
62631496|NCT02776072||fingolimod|Participants who initiated fingolimod during the specified time period
62631497|NCT06285799|EXPERIMENTAL|Low Dose IHAT|IHAT in capsule form and carob flour in capsule form - taken as 1 x 100mg IHAT capsule (equivalent to 30mg iron) in the morning with water and 1 x placebo capsule in the evening with water
62065043|NCT03260127|ACTIVE_COMPARATOR|WT-CPT|Word game training plus Cognitive Processing Therapy for PTSD
62065044|NCT04409548|ACTIVE_COMPARATOR|Lumbar Disc Hernaition Group|The number of participants in this group is anticipated to be 153. The pain intensity of the patients was recorded by a Visual Analog Scale (VAS) immediately before performing the analysis. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
62065045|NCT04409548|ACTIVE_COMPARATOR|Healthy Control Group|The number of participants in this group is anticipated to be 54. The participants were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
62065046|NCT04409548|ACTIVE_COMPARATOR|Preoperative and Postoperative Group|The number of participants in this group is anticipated to be 59. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day, before and 15 days after surgery.
62065047|NCT01341977|EXPERIMENTAL|Alcon MPDS|Alcon Multi-Purpose Disinfecting Solution (MPDS)
62065048|NCT01341977|ACTIVE_COMPARATOR|ReNu Fresh Multi-Purpose Solution|ReNu Fresh Multi-Purpose Solution
62065049|NCT05635292|EXPERIMENTAL|Tele-CBT|
62065050|NCT05635292|NO_INTERVENTION|Control|
62065051|NCT04402164|ACTIVE_COMPARATOR|Dentally anchored Herbst group|Herbst appliance will be anchored on the mandibular dentition
62065052|NCT04402164|ACTIVE_COMPARATOR|Skeletally anchored Herst group|Herbst appliance will be anchored on mini-plates placed in the para symphesial areas
62452580|NCT03810430|NO_INTERVENTION|control group|10 clusters (villages) were not received intervention during the intervention period and by the end of study, it will be compared with the intervention group to measure the change in the primary and secondary outcomes.
62452581|NCT06288061|EXPERIMENTAL|Non-invasive Phrenic Nerve Neuromodulation|
62631498|NCT06285799|EXPERIMENTAL|High Dose IHAT|IHAT in capsule form - taken as 2 capsules (2 x 100mg IHAT, equivalent to 60mg iron total) daily with water (1 capsule in the morning and 1 capsule in the evening)
62631499|NCT06285799|PLACEBO_COMPARATOR|Carob flour|Carob flour in capsule form - taken as 2 capsules daily with water (1 capsule in the morning and 1 capsule in the evening)
62631500|NCT00642213||ischemic stroke sample with DNA|We prospectively collected 450(1999), 502(2005), and 512(2010) ischemic stroke patients who agreed to participate and also most provided a sample for DNA. The cohort data consists of a baseline interview, medical record abstraction and various timeframes of followup interviews from 3 months to 3 years. See website (www.gcnkss.com for data forms)
62631501|NCT00642213||stroke data from medical record review|The second part of the study is a retrospective medical record review of all potential ischemic strokes, TIAs, and Hemorrhagic strokes in our 5 county region that occurred in all study years.
62631502|NCT04703010|EXPERIMENTAL|All participants|All participants undergo the same measurements (longitudinal design)
62065053|NCT02698683||malnourished|low zinc, low albumin, anthropometric measures lower than percentile 5 lymphocyte count
62065054|NCT02698683||well nourished|normal zinc, normal albumin, anthropometric measures higher than percentile 5 lymphocyte count
62065055|NCT06023901|EXPERIMENTAL|85 patients with only apical periodontitis (AP group)|AP group was divided into 3 subgroups. AS-PAI 1 (mild): those having at least 1 tooth with either PAI 3 or PAI 4, AS-PAI 2 (moderate): those having only 1 tooth with a PAI 5, AS-PAI 3 (severe): those having two or more teeth with a PAI 5.
62065056|NCT06023901|EXPERIMENTAL|50 patients with only chronic periodontitis (CP group),|In this study, the CP group was divided into 4 subgroups according to the periodontitis staging system (PSS) (Tonetti). This system classifies the periodontitis from I to IV according to the interdental clinical attachment loss (CAL), radiographic bone loss (RBL) and tooth loss. This scoring is as follows: Stage 1: CAL 1 to 2 mm, RBL is at coronal third (\<15%) and no tooth loss, Stage 2: CAL 3 to 4 mm, RBL is at coronal third (15% to 33%) and no tooth loss, Stage 3: CAL \> 5 mm, RBL is extending to mid-third of root and beyond and tooth loss \< 4 teeth, and Stage 4: CAL \> 5 mm, RBL is extending to mid-third of root and beyond and tooth loss \> 5 teeth. However, Stage 1 and 2 were evaluated in the same group due to the low number of cases. As a result, the groups were designed as Stage 1-2: PSS 1-2, Stage 2: PSS 2 and Stage 3: PSS 3.
62065057|NCT06023901|NO_INTERVENTION|A healthy control group of 50 volunteers|control group. A healthy control group of 50 volunteers without periodontal pathology as well as any acute/chronic disease (muscle/joint/bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus) were included in the study.
62065058|NCT03497507|PLACEBO_COMPARATOR|Sham bracelet|Patients randomized to sham group will wear bracelets on both hands which will not apply acupressure
62065059|NCT03497507|EXPERIMENTAL|Acupressure bracelet|Patients randomized to the experimental group will wear bracelets on both hands which will apply acupressure to the P6 acupoint.
62065060|NCT04061720|EXPERIMENTAL|Enhanced Chronic Care|Enhanced Chronic Care provides ongoing, phone-based motivational interventions and interpersonal support to promote readiness to quit, with facilitated access to evidence-based smoking treatment.
62065061|NCT04061720|ACTIVE_COMPARATOR|Standard Care|Standard Care provides phone-based brief advice to quit once per year.
62065062|NCT00755014|EXPERIMENTAL|2|Forty subjects are randomized to a group (n=20) that consumed red wine (100 ml) or a group (n=20) that consumed beer (250 ml) daily for 3 weeks
62065063|NCT03517618|EXPERIMENTAL|S-1 + leucovorin|Single arm
62065064|NCT00669903|EXPERIMENTAL|1|AZD0328 low dose
62065065|NCT00669903|EXPERIMENTAL|2|AZD0328 Optimal dose
62065066|NCT00669903|EXPERIMENTAL|3|AZD0328 High dose
62631503|NCT01433419|EXPERIMENTAL|TAK-875 25 mg|
62631504|NCT01433419|EXPERIMENTAL|TAK-875 50 mg|
62631505|NCT00107562|EXPERIMENTAL|Intervention|The cohort will be comprised of up to 4 index participants and from 1-4 of their network members for a possible range of 8-16 subjects in each cohort (average of 12 per cohort). The vast majority of the intervention will be delivered to both females and males together, but it would be beneficial, and appropriate for this adolescent population, to deliver certain exercises with the two genders separated.
62631506|NCT03666416|EXPERIMENTAL|Sprint Interval Training|Participants will be scheduled for two in-lab experimental appointments: sprint interval training (SIT) and Non-SIT. During the SIT appointment, the researcher will lead the participant through a set of stretches and three minutes of low-intensity cycling on a Schwinn AD2 Airdyne leg-cycling and arm-cranking ergometer to warm up and increase blood flow to active muscles. Participants will then complete 16 minutes of SIT, consisting of eight bouts of 20 seconds of cycling followed by 100 seconds of rest. Participants will complete computer-based tests of sustained attention and working memory during both the SIT (15 minutes following the exercise) and Non-SIT appointments.
62631507|NCT03735407|EXPERIMENTAL|C-Scan procedure|Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
62631508|NCT05179746|ACTIVE_COMPARATOR|With electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
62631509|NCT05179746|PLACEBO_COMPARATOR|Without electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
62631510|NCT04330144|EXPERIMENTAL|administration of hydroxychloroquine as PEP|
62065067|NCT00669903|PLACEBO_COMPARATOR|4|Placebo Comparator
62065068|NCT04570774|EXPERIMENTAL|Facilitatory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
62065069|NCT04570774|ACTIVE_COMPARATOR|Facilitatory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and sham high-frequency rTMS over the ipsilateral cerebellar hemisphere.
62452582|NCT06288061|PLACEBO_COMPARATOR|Cervico-dorsal Massage|
62270052|NCT05137327|EXPERIMENTAL|Classroom Behavior Support (CBS) Condition|"Consultants follow the problem-solving process used in the comparison condition and attempt to address barriers to integrity using the knowledge, skills, beliefs, or stress components in the CBS manual. Consultants conduct a Values Interview, so teacher values can be used in the individual goal setting and decision making process. Consultants are trained to (a) incorporate the teacher's values into the problem-solving process, (b) elicit change talk from teachers using techniques borrowed from Motivational Interviewing, and (c) engage in Socratic questioning and cognitive restructuring for beliefs that may be barriers to integrity (e.g., should statements). Enhanced performance feedback involves highlighting connections between teacher integrity and child outcomes and using this as a catalyst for a knowledge, skills, beliefs, or stress component. Consultants use change rulers to elicit motivation to achieve the stated goals."
62631511|NCT04330144|ACTIVE_COMPARATOR|control with no PEP|
62631512|NCT04701450||conventional|consent for anaesthesia is obtained as part of a conversation with physical attendance
62270053|NCT05137327|ACTIVE_COMPARATOR|Standard Problem Solving Comparison Condition|Consultation in the comparison condition follows a 5-step problem solving approach and provide brief performance feedback procedures that mirror (in duration, content, and process) best practice procedures (Gilbertson et al., 2007; Noell et al., 1997). The guiding principles for this condition are that the performance feedback portion of the session should be limited to 5 to 10 minutes and unless the teacher initiates discussion of other content, the problem solving should remain student-focused, rather than teacher-focused. Discussion on teacher values and beliefs, and attempts to facilitate change talk, are contra-indicated. If the teacher initiates discussion of knowledge, beliefs, or skills, the consultant may answer questions, but may not use strategies associated with Motivational Interview or Cognitive-Behavioral Therapy (CBT) or strategies in CBS condition. We have separate scripts and checklists for each condition.
62270054|NCT03308656||Induced labor in term pregnancies|100 singleton nulliparous patients are planning to complete the study period. Study group constitute of third trimester pregnancies between 37-40 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
62631513|NCT04701450||telephonic|consent for anaesthesia is obtained telephonically
62631514|NCT04701450||digital|a digital survey and video information is used to inform the patient about the anaesthetic procedure
62631515|NCT03703752||Adhesive IH|Adhesive IH can further be divided into primary or secondary groups according to the history of abdominal and(or) pelvic surgery
62631516|NCT03703752||non-adhesive IH|Non-adhesive IH means the IH resulting from the abnormality of peritoneal structure.
62631517|NCT00914134|EXPERIMENTAL|Levodopa Infusion|Patients with advanced Parkinson's disease and motor fluctuations that cannot be adequately controlled with oral medication.
62631518|NCT00738491||1|Patients with stable angina pectoris and documented coronary heart disease recruited in Edinburgh
62631519|NCT00738491||2|Patients with stable angina pectoris and documented coronary heart disease recruited in London
62631520|NCT01967771|EXPERIMENTAL|DTG/CBZ|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3).
62631521|NCT02166359|ACTIVE_COMPARATOR|Glucose group|Glucose use of 2.5% or 4.25% dextrose solution at least 4 hours
62631522|NCT02166359|EXPERIMENTAL|Extraneal (Icodextrin) group|Extraneal (Icodextrin) use at least 8 hours
62631523|NCT03455712|EXPERIMENTAL|Intervention|Subjects to receive the Gestational Weight Gain Card at enrollment in addition to standard prenatal care.
62631524|NCT03455712|NO_INTERVENTION|Standard-of-Care|No intervention to be delivered. Subjects to receive standard prenatal care.
62631525|NCT01488760||Nineteen women with low back pain|
62631526|NCT01488760||Twenty pain-free women|
62631527|NCT04167189|OTHER|Observational study of prevalence in hard-to-treat ADHD|Subjects will be tested with lidocaine gel.
62631528|NCT03533231|ACTIVE_COMPARATOR|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
62631529|NCT03533231|EXPERIMENTAL|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
62065070|NCT04570774|EXPERIMENTAL|Inhibitory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
62631530|NCT03533231|ACTIVE_COMPARATOR|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
62065071|NCT04570774|ACTIVE_COMPARATOR|Inhibitory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and sham rTMS over the ipsilateral cerebellar hemisphere.
62065072|NCT04662463|EXPERIMENTAL|CBM-I assignment|Patients will receive CBM-I assignments
62065073|NCT04662463|PLACEBO_COMPARATOR|Placebo assignment|Patients will receive placebo assignments
62065074|NCT01257659|EXPERIMENTAL|STARR arm|In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
62065075|NCT01257659|ACTIVE_COMPARATOR|Elevate arm|In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.
62065076|NCT02354963|NO_INTERVENTION|Control arm|No intervention is performed. Assessment of antral follicle count. IVF treatment.
62065077|NCT02354963|EXPERIMENTAL|Experimental arm|"Perform intervention described: Laparoscopy. In vitro fragmentation of the ovarian tissue.~Assessment of antral follicle count. IVF treatment."
62065078|NCT02067390||Vancomycin|Vancomycin
62065079|NCT02067390||Linezolid|Linezolid
62065080|NCT00831363||1|minimal invasive approach
62631531|NCT03533231|EXPERIMENTAL|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
62631532|NCT03974282|OTHER|Low psychopathy distribution|Participants who score at the low end of the psychopathy distribution
62065081|NCT00831363||2|traditional transgluteal approach
62065082|NCT03511417|EXPERIMENTAL|Middle-aged adults|Participants will use an over-the-counter hearing device in one ear until asymptotic speech perception performance is noted (maximum 12 weeks). The same individuals will use over-the-counter hearing devices in each ear until asymptotic performance is noted (the order of these two phases will be randomized across participants). They will be asked to use these devices at least 4 hours/day.
62065083|NCT02698449|EXPERIMENTAL|cognitive rehabilitation + transcranial stimulation|specific cognitive rehabilitation combined to transcranial direct current stimulation
62065084|NCT02698449|EXPERIMENTAL|cognitive rehabilitation + stimulation sham|specific cognitive rehabilitation combined to transcranial direct current stimulation sham
62631533|NCT03974282|OTHER|High psychopathy distribution|Participants who score at the high end of the psychopathy distribution
62065085|NCT02698449|EXPERIMENTAL|placebo rehab + transcranial stimulation|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation
62065086|NCT02698449|EXPERIMENTAL|placebo rehab + stimulation sham|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation sham
62270055|NCT05026307|EXPERIMENTAL|Pterygium|Simple surgical excision of pterygium withe bare sclera
62631534|NCT00196105|EXPERIMENTAL|6 mm Zilver|6 mm Nitinol Zilver Stent
62065087|NCT02611050|EXPERIMENTAL|Option Grid|Patients randomized to the Option Grid arm will receive the Multi-vessel Coronary Artery Disease Option Grid at the time of enrollment. The treating physician will then discuss the patient diagnosis and treatment choice reviewing the Option Grid within the conversation to facilitate patient understanding and shared decision making
62270056|NCT01472497|EXPERIMENTAL|glymepiride|
62631535|NCT00196105|EXPERIMENTAL|10 mm Zilver|10 mm Nitinol Zilver Stent
62065088|NCT02611050|OTHER|Usual Care|Patients randomized to usual care will discuss the patient diagnosis and treatment options typical to the physician's routine care.
62065089|NCT01057030|ACTIVE_COMPARATOR|A1 (BMS-708163)|Healthy Japanese Subjects
62065090|NCT01057030|PLACEBO_COMPARATOR|A2 (Placebo)|Healthy Japanese Subjects
62065091|NCT01057030|ACTIVE_COMPARATOR|B1 (BMS-708163)|Healthy Non-Japanese Subjects
62065092|NCT01057030|PLACEBO_COMPARATOR|B2 (Placebo)|Healthy Non-Japanese Subjects
62631536|NCT00196105|ACTIVE_COMPARATOR|10 mm Wallstent|10 mm Stainless Steel Wallstent
62631537|NCT00697593|EXPERIMENTAL|Efalizumab|
62631538|NCT00765739|EXPERIMENTAL|1|The group who will get neuromuscular electrical stimulation (NMES)
62631539|NCT00765739|ACTIVE_COMPARATOR|2|The group who will do the voluntary muscle contraction
62065093|NCT00004935|ACTIVE_COMPARATOR|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
62065094|NCT00004935|ACTIVE_COMPARATOR|Herceptin™+Chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
62270057|NCT05699096||eye surgery ,Vitreoretinal Surgery and Related Ocular Inflammation|
62270058|NCT02798536|EXPERIMENTAL|A1/LMB-100 dose escalation (closed)|De-escalating doses of LMB-100 in up to 18 subjects
62270059|NCT02798536|EXPERIMENTAL|A2/LMB-100 dose expansion (closed)|Fixed dose of LMB-100 as determined in Arm A1 in up to 16 subjects
62270060|NCT02798536|EXPERIMENTAL|B1/LMB-100+ nab- paclitaxel dose escalation|De-escalating doses of LMB-100 + fixed dose of nab-paclitaxel in up to 12 subjects
62631540|NCT06134661|EXPERIMENTAL|Single Arm: Treatment with cTBS|This is a single-arm study. All participants will receive the treatment with cTBS.
62631541|NCT00685360|EXPERIMENTAL|Delamanid 100 mg BID + OBR|"Participants received delamanid 100 milligrams (mg) (two 50 mg tablets), orally, BID with two matching placebo tablets plus optimized background regimen (OBR) for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on World Health Organization (WHO) guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
62065095|NCT03129529|EXPERIMENTAL|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
62065096|NCT03129529|EXPERIMENTAL|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
62631542|NCT00685360|EXPERIMENTAL|Delamanid 200 mg BID + OBR|"Participants received delamanid 200 mg (four 50 mg tablets), orally, BID plus OBR for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
62631543|NCT00685360|PLACEBO_COMPARATOR|Placebo + OBR|"Participants received four placebo tablets matching 50-mg tablets of delamanid, orally, BID plus OBR for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
62631544|NCT02824146|NO_INTERVENTION|Control group|Patients received standard protective mechanical ventilation during all surgery, with tidal volumen 6 ml/kg and positive end-expiratory pressure (PEEP) level of 5 (centimeter of water) cmH2O.
62065097|NCT04999371|NO_INTERVENTION|Control without intervention|No information or cash incentives are provided to the participants in the control group, but it is also necessary to collect the information of the participants in the control group and perform an alcohol test. Therefore, the project team will provide a certain degree of compensation for participants in the control group (participants of the intervention group also will receive this part of compensation).
62065098|NCT04999371|ACTIVE_COMPARATOR|Mobile-based information intervention|The participants in this group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.
62631545|NCT02824146|EXPERIMENTAL|Recruitment maneuver group|"Patient received a lung recruitment maneuver after pneumoperitoneum insufflation.~The recruitment maneuver consists in 10 breaths at 30/15 cmH2O of plateau pressure and PEEP, respectively. Then, the ventilatory settings back to protective ventilation but adding 8 cmH2O of PEEP to keep the lungs open."
62631546|NCT05989204|EXPERIMENTAL|NHL Dose Level 1|7x10\^6 TmCD19-IL18 cells administered as a single intravenous (IV) infusion
62631547|NCT05989204|EXPERIMENTAL|NHL Dose Level -1|2x10\^6 TmCD19-IL18 cells administered as a single intravenous (IV) infusion
62631548|NCT05989204|EXPERIMENTAL|NHL Dose Level 2|2x10\^7 TmCD19-IL18 cells administered as a single intravenous (IV) infusion
62631549|NCT05989204|EXPERIMENTAL|NHL Dose Level 3|6x10\^7 TmCD19-IL18 cells administered as a single intravenous (IV) infusion
62631550|NCT05816382|EXPERIMENTAL|TAK-861 Dose 1|Participants will receive TAK-861 dose 1 for up to approximately 5 years.
62631551|NCT05816382|EXPERIMENTAL|TAK-861 Dose 2|Participants will receive TAK-861 dose 2 for up to approximately 5 years.
62631552|NCT06612814|EXPERIMENTAL|Cohort 1|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with Fluzoparib(Parp inhibitor) and endocrine therapy.
62631553|NCT06612814|ACTIVE_COMPARATOR|Cohort 2|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with endocrine therapy.
62631554|NCT03959046|EXPERIMENTAL|GIST|"GIST is an alternative way of speaking to patients. In order for patients to get the gist, Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved."
62065099|NCT04999371|ACTIVE_COMPARATOR|Mobile-based information intervention with performance-based incentive|The participants in this group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
62065100|NCT02773680|EXPERIMENTAL|Study cohort 1|"electrical impedance tomography"
62065101|NCT02055937|EXPERIMENTAL|immediate implant breast reconstruction|immediate implant breast reconstruction
62065102|NCT02266602|OTHER|Treatment|Patients treated with intraoperative radiation therapy at the time of partial mastectomy.
62065103|NCT01187329|EXPERIMENTAL|hyperinsulinemic normoglycemic clamp (HNC)|Patients will be randomized to receive treatment with HNC during cardiac surgery.
62065104|NCT01187329|PLACEBO_COMPARATOR|standard glucose management|Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.
62631555|NCT03959046|NO_INTERVENTION|Usual Care|These are physician and patient participants that will communicate in their normal, unchanged way.
62631556|NCT06611592|EXPERIMENTAL|Pramipexole at a dose of 0.088 mg/tid|Treatment with antidepressant and pramipexole at a dose of 0.088 mg/tid (0.125 mg of salt)
62631557|NCT06611592|EXPERIMENTAL|Pramipexole at a dose of 0.18 mg/tid|Treatment with antidepressant and pramipexole at a dose of 0.18 mg/tid (0.25 mg of salt)
62631558|NCT06611592|EXPERIMENTAL|Pramipexole at a dose of 0.35 mg/tid|Treatment with antidepressant and pramipexole at a dose of 0.35 mg/tid (0.50 mg of salt)
62631559|NCT02340143|ACTIVE_COMPARATOR|Control|Marketed partially hydrolyzed cow's milk protein infant formula
62631560|NCT02340143|EXPERIMENTAL|Investigational|Partially hydrolyzed cow's milk infant formula with a probiotic
62631561|NCT01252407|EXPERIMENTAL|tens|
62631562|NCT02554045|ACTIVE_COMPARATOR|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
62631563|NCT02554045|PLACEBO_COMPARATOR|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
62631564|NCT01941394|EXPERIMENTAL|With MSC|infusion of Mesenchymal stem cells at dose 1 mln cells per kg
62631565|NCT01941394|NO_INTERVENTION|Without MSC|Without MSC infusion
62631566|NCT04275258|EXPERIMENTAL|Intervention group|"Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge. In addition, subjects will receive:~* A face-to-face meeting prior to discharge where the PA will discuss with the subject their individualized pain management plan and individualized opioid taper plan.~* PA will contact subject on the phone within the first week after hospital discharge to ensure subject plans to follow up with PCP and to troubleshoot any subject concerns related to pain management."
62631567|NCT04275258|NO_INTERVENTION|Control group|Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge.
62631568|NCT04227418||Mental Health|
62631569|NCT04227418||Psychiatric|
62631570|NCT05395871|ACTIVE_COMPARATOR|Usual Care|A text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message will be the 'usual care' content that is currently sent by the London Breast Cancer Screening Programme. This includes a link to a YouTube hosted video.
62631571|NCT05395871|EXPERIMENTAL|Behavioural Message|A text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message has been informed by previous co-design work, and incorporate behavioural change techniques. This will include the same link to a YouTube hosted video, as the usual care arm.
62631572|NCT05395871|EXPERIMENTAL|Behavioural Message + Video|An text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message will be the same as the Behavioural text, however the link will be replaced with a weblink to an animated video. This video has been designed through an extensive co-design process involving several behavioural change techniques designed to overcome barriers highlighted in this qualitative work.
62631573|NCT05117112|EXPERIMENTAL|10g of nutritional product|All subjects will ingest 10g of a commercially available nutritional supplement one time during a study visit.
62631574|NCT03743766|EXPERIMENTAL|Relatlimab|"Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1).~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
62065105|NCT06626178|EXPERIMENTAL|High-risk screening subjects|"Ever and former male and female smokers aged over 50 years old at high risk for lung cancer, cardiovascular diseases and chronic obstructive pulmonary disease (COPD).~Additional procedures for this group:~* Spirometry~* Nurse evaluation~* Epidemiological questionnaire, Quality of Life (QoL) questionnaires~* Smoking cessation program~* Cardiovascular primary prevention~* measurement of carbon monoxide (CO)~* Blood storage~* Computed tomography (CT) scan low-dose"
62631575|NCT03743766|EXPERIMENTAL|Nivolumab|"Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks.~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
62065106|NCT06626178|EXPERIMENTAL|Previous positive high-risk screening subjects|Subjects enrolled in previous screening cohorts in this Institute with the presence of lung nodules \>4 mm. Additional procedure for this group: Computed tomography (CT) scan low-dose
62065107|NCT06626178|NO_INTERVENTION|Previous negative high-risk screening subjects|Subjects enrolled in previous screening cohorts in this Institute with negative computed tomography (CT) scan. No additional procedures for this group.
62270061|NCT02798536|EXPERIMENTAL|B2/LMB-100+ nab- paclitaxel dose expansion|Fixed dose of LMB-100 as determined in Arm B1 + fixed dose of nab-paclitaxel in up to 16 subjects
62270062|NCT05117775||Patients with all stages of HNSCC (Full analysis set)|To describe median OS by primary tumor location (oral cavity, oropharynx, larynx, and hypopharynx) in HNSCC patients after stratification for prognostic factors, including tumor stage and treatment.
62270063|NCT05117775||Patients with early and locally advanced stages|To describe clinical characteristics and treatments and to compare OS in locally advanced HNSCC patients
62631576|NCT03743766|EXPERIMENTAL|Relatlimab + Nivolumab|Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
62631577|NCT02975817|EXPERIMENTAL|Hibler's|Insert description from protocol
62631578|NCT02975817|ACTIVE_COMPARATOR|Warm Air|Insert description from protocol
62631579|NCT05728333|EXPERIMENTAL|Tirofiban|Tirofiban will be administrated intravenously before endovascular thrombectomy.
62631580|NCT05728333|ACTIVE_COMPARATOR|Alteplase|Alteplase will be administrated intravenously before endovascular thrombectomy.
62631581|NCT06024811||intervention|"Pregnant women over 18 years of age, with cervical dilatation 3 cm or more, planned for spontaneous vaginal delivery, term and singleton pregnancy, who speak Turkish, who did not have language communication problems, and who voluntarily agreed to participate in the study were included.~Pregnant women in the intervention and control groups were randomized using the www.random.org website on the computer (intervention=56 control= 56).Intervention and control groups were randomized according to some basic variables (age group, education level, body mass index, number of births and pregnancies, participation in prenatal preparation classes) considering the literature ."
62270064|NCT05117775||Patients with recurrent or metastatic disease|To describe the epidemiologic and clinical characteristics, and treatment and the impact of introducing immunotherapy in recurrent or metastatic HNSCC
62270065|NCT04427215|EXPERIMENTAL|A - Music Therapy|Two section a week of music therapy
62270066|NCT04427215|EXPERIMENTAL|B - Art Therapy|Two section a week of Art therapy
62631582|NCT06024811||control|"Pregnant women over 18 years of age, with cervical dilatation 3 cm or more, planned for spontaneous vaginal delivery, term and singleton pregnancy, who speak Turkish, who did not have language communication problems, and who voluntarily agreed to participate in the study were included.~During the data collection period of the study, 313 women were evaluated according to the inclusion and exclusion criteria. Women who did not meet the inclusion criteria (n=198) and refused to participate in the study (n=3) were not included in the study sample. Pregnant women in the intervention and control groups were randomized using the www.random.org website on the computer (intervention=56 control= 56).Intervention and control groups were randomized according to some basic variables (age group, education level, body mass index, number of births and pregnancies, participation in prenatal preparation classes) considering the literature (Taghenijad et al. 2010; Erdogan et al. 2017)."
62065108|NCT06626178|EXPERIMENTAL|Lung cancer patients|Lung cancer patients diagnosed outside screening and treated at San Raffaele Hospital. Additional procedures for this group: biobank tissue and blood storage.
62065109|NCT06321978||Study Group|Mepilex Border Flex dressing changes
62065110|NCT04315025|ACTIVE_COMPARATOR|Conditioned Medium (CM)|a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar
62065111|NCT04315025|ACTIVE_COMPARATOR|UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar
62065112|NCT04315025|ACTIVE_COMPARATOR|UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar
62270067|NCT04427215|EXPERIMENTAL|C - Dance-Movement Therapy|Two section a week of Dance-Movement Therapy
62631583|NCT03143101|EXPERIMENTAL|FluMist trivalent (2015-2016)|Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10\^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
62065113|NCT01479413||Schizophrenia|
62065114|NCT01810627||MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
62270068|NCT04427215|EXPERIMENTAL|D - Bibliotherapy|Two section a week of Bibliotherapy
62270069|NCT04427215|EXPERIMENTAL|E - Physical Activity|Two section a week of systematized physical activity
62270070|NCT00278993|ACTIVE_COMPARATOR|1|With stratification
62270071|NCT06253156|EXPERIMENTAL|virtual reality|The experimental group will be given virtual reality-based training in addition to standard training.
62270072|NCT06253156|NO_INTERVENTION|standard training|The control group will be given only standard training.
62270073|NCT04368156|NO_INTERVENTION|Control|
62270074|NCT04368156|EXPERIMENTAL|Gammacore treatment|
62270075|NCT02931058|ACTIVE_COMPARATOR|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
62270076|NCT02931058|ACTIVE_COMPARATOR|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
62452583|NCT01003132|NO_INTERVENTION|Treatment As Usual|Treatment as usual as determined by the clinical team responsible for the individual's care
62065115|NCT01138930|EXPERIMENTAL|Berberine|
62065116|NCT01138930|PLACEBO_COMPARATOR|Placebo|
62065117|NCT00802555|EXPERIMENTAL|ARQ 197|
62631584|NCT03143101|EXPERIMENTAL|FluMist Quadrivalent (2015-2016)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10\^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
62065118|NCT04315532|ACTIVE_COMPARATOR|Pregnancy Group|"GCF and saliva samples were taken from pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from pregnant periodontal healty individuals baseline and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed for pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
62065119|NCT04315532|ACTIVE_COMPARATOR|Non-Pregnancy Group|"GCF and saliva samples were taken from non-pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from periodontal healty individuals baseline and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed for non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
62065120|NCT06075563|EXPERIMENTAL|Treatment|Total lymphoid irradiation (TLI)
62065121|NCT06613126|EXPERIMENTAL|symptom management APP group|The experimental group(parents of children with TS between 6 and 12 years old) received TS symptom management APP intervention for four weeks. The experimental group recorded the patterns and treatments of tics at least twice a week and completed relevant readings on TS care information during these four weeks.
62065122|NCT06613126|ACTIVE_COMPARATOR|Health education instructions group|The control group(parents of children with TS between 6 and 12 years old) continued to receive outpatient verbal and paper health education guidance from healthcare providers.
62065123|NCT06423053|EXPERIMENTAL|Biology 3 students|This arm consists of students enrolled in Dartmouth College's Biology 3 course during Spring 2024 term, who will have access to course offerings and usual university wellness resources (as described for the control arm).
62065124|NCT06423053|NO_INTERVENTION|Biology 3 waitlisted students|This arm consists of students waitlisted for Dartmouth College's Biology 3 course during Spring 2024 term. They will receive university wellness resources as usual. These include access to wellness counselors, mental health advisors, and psychiatrists at the university's counseling center, wellness advising at the student wellness center, and campus-wide wellness programs, such as weekly group yoga and meditation sessions and a free subscription to the Headspace app. The 4-hr mindfulness retreat will also be advertised to and open to all Dartmouth students.
62065125|NCT05826015|EXPERIMENTAL|Paclitaxel + AVB-500|Patients will receive up to 9 21-day cycles of paclitaxel + AVB-500. Patients will receive AVB-500 via intravenous (IV) infusion at the assigned dose level on days 1, 8, and 15 of each cycle. Patients will receive IV paclitaxel at a dose of 175 mg/m\^2 on day 1 of each cycle. After 3 cycles, patients will be assessed for disease response. Patients who have progression will not continue on treatment. Patients who have a partial response or stable disease will continue on treatment for another 3 cycles of paclitaxel + AVB-500 at the assigned dose. Patients will be assessed for response again at the end of 6 cycles and may continue on treatment if they have partial response (PR) or stable disease (SD). Up to 9 cycles of treatment with paclitaxel + AVB-500 may be given. At the end of the 9 cycles, patients with a SD or PR can continue on maintenance AVB-500 until progression. Patients with complete response will continue single agent AVB-500 as maintenance therapy until progression.
62065126|NCT03427190|ACTIVE_COMPARATOR|Control|Phone contact with patient will be made by a professional psychologist within 21 days of hospital discharge. If contact cannot be made after 9 attempts, post-cards will be sent monthly at M2, M3, M4 and M5, asking the participant to establish contact with the designated psychologist. The phone call will determine whether or not the participant is in a state of suicidal crisis. If yes, steps will be taken to attend the crisis within 24 hours.
62270077|NCT02931058|ACTIVE_COMPARATOR|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
62270078|NCT06463600|EXPERIMENTAL|Tumour localisation with Magseed|Before preoperative chemotherapy a Magseed is inserted in the breast tumour
62270079|NCT06463600|ACTIVE_COMPARATOR|Metallic marker + guide wire|Before preoperative chemotherapy an ordinary metallic clip is inserted in the breast tumour. Before surgery a guide wire is inserted to localise the clip.
62270080|NCT00604604|NO_INTERVENTION|1|Control group (usual postpartum care)
62270081|NCT00604604|EXPERIMENTAL|2|Experimental group (usual postpartum care plus telephone-based support from an experienced mother who has participated in a 4-hour training session)
62270082|NCT05208151|ACTIVE_COMPARATOR|Creative Drama Group|
62270083|NCT05208151|NO_INTERVENTION|Control Group|
62270084|NCT01632566|PLACEBO_COMPARATOR|Placebo|Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
62270085|NCT01632566|EXPERIMENTAL|LY3031207|Daily oral administration of 25 milligrams (mg) LY3031207 up to 450 mg LY3031207 for 28 days.
62270086|NCT01632566|ACTIVE_COMPARATOR|Celecoxib|Daily oral administration of 400 mg celecoxib for 28 days. Positive control for LY3031207.
62270087|NCT01632566|OTHER|LY3031207 + Simvastatin|Daily oral administration of 75 mg LY3031207 or 225 mg LY3031207 for 28 days. Single, oral 10 mg simvastatin open-label dose administered before and after 28-day dosing of LY3031207.
62270088|NCT06446440||Group A|These group will include cases underwent laparoscopic adhesiolysis
62631585|NCT03143101|EXPERIMENTAL|FluMist Quadrivalent (2017-2018)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10\^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
62631586|NCT01766531|EXPERIMENTAL|Body bioelectrical impedance|comparison with four methods for assessing nutritional status. ; compare length of mechanical ventilation, length in ICU and energy expenditure rest between malnourished and non-malnourished patient
62270089|NCT06446440||Group B|These group will include cases underwent open adhesiolysis
62270090|NCT04011020|EXPERIMENTAL|Treatment of T1D with Stem Cell Educator therapy|Recruited T1D subjects will receive one treatment with SCE therapy.
62270091|NCT04011020|EXPERIMENTAL|Conventional insulin therapy|Control group will receive conventional insulin therapy.
62631587|NCT04587141|EXPERIMENTAL|Sucrosomial iron|One or two capsules/die of sucrosomial iron will be assumed by the participant, depending on hemoglobin (Hb) concentration and participant body weight, for 8 weeks. Each capsule contains 30 mg of iron.
62631588|NCT04587141|ACTIVE_COMPARATOR|Ferric gluconate|Ferric gluconate will be administered by iv infusion, 125 mg of elemental iron once or twice weekly for 4 or 8 weeks depending on Hb concentration and patient body weight.
62631589|NCT04587141|ACTIVE_COMPARATOR|Ferric carboxymaltose|Two or three iv infusions of 500-1000 mg of elemental iron will be given as ferric carboxymaltose, over a 4 week period. Dosage and number of infusions will be established depending on Hb concentration and patient body weight.
62631590|NCT02223351|OTHER|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir
62631591|NCT02223351|OTHER|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir
62631592|NCT03092570|EXPERIMENTAL|tDCS Post-CVA|The participants will get a 20min stimulation at a maximal intensity of 2mA
62631593|NCT03092570|SHAM_COMPARATOR|Sham Post-CVA|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
62631594|NCT03092570|EXPERIMENTAL|tDCS Young Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
62631595|NCT03092570|SHAM_COMPARATOR|Sham Young Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
62631596|NCT03092570|EXPERIMENTAL|tDCS Older Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
62631597|NCT03092570|SHAM_COMPARATOR|Sham Older Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
62270092|NCT04255056|EXPERIMENTAL|Pyrotinib|"Eligible patients will receive four cycles of epirubicin and cyclophosphamide combined with pyrotinib.~Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
62270093|NCT00980200|EXPERIMENTAL|C/E/A/B/D|GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
62270094|NCT00980200|EXPERIMENTAL|D/C/E/A/B|GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
62270095|NCT00980200|EXPERIMENTAL|A/B/C/D/E|placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
62270096|NCT00980200|EXPERIMENTAL|B/A/D/E/C|GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
62270097|NCT00980200|EXPERIMENTAL|E/D/B/C/A|GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo
62631598|NCT04814589|EXPERIMENTAL|ezetimibe Tablets|ezetimibe tablets test formulation at a single dose of 10 mg
62631599|NCT04814589|ACTIVE_COMPARATOR|ezetimibe tablets(Ezetrol ®)|ezetimibe tablets reference formulation at a single dose of 10 mg
62631600|NCT02759094|EXPERIMENTAL|Treatment with RefluxStop device|All enrolled subjects will receive treatment for their GERD using the RefluxStop device intervention
62631601|NCT01095627|OTHER|Metacholine Challenge|Exhaled breath analysis following metacholine challenge
62631602|NCT00792909|EXPERIMENTAL|Synflorix™ Group 1|Subjects previously vaccinated with the Synflorix™ vaccine according to a 2+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
62631603|NCT00792909|EXPERIMENTAL|Synflorix™ Group 2|Subjects previously vaccinated with the Synflorix™ vaccine according to a 3+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
62631604|NCT00792909|ACTIVE_COMPARATOR|Unprimed Group|Age-matched subjects not previously vaccinated with any pneumococcal vaccine receiving two doses of Synflorix™ at 36-46 and 38-48 months of age. Age-matching was ensured by the enrolment of subjects 36-46 months of age.
62631605|NCT00961779|PLACEBO_COMPARATOR|Placebo (Normal saline infusion)|
62631606|NCT00961779|EXPERIMENTAL|NNZ-2566|NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
62065127|NCT03427190|OTHER|APSOM|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
62631607|NCT03020628|EXPERIMENTAL|NBP607-QIV 0.5mL|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
62065128|NCT05201911|EXPERIMENTAL|Injection of I-124 AT03.|Single arm only, no placebo or comparator
62452584|NCT01003132|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy|Up to 10 sessions of Acceptance and Commitment Therapy plus treatment as usual
62065129|NCT05341323|ACTIVE_COMPARATOR|Group K1 Ketamine|pre-incisional submucosal infiltration of ketamine .5 mg/kg in the Peritonsillar area
62065130|NCT05341323|ACTIVE_COMPARATOR|Group B1 Bupivacaine|pre-incisional submucosal infiltration of Bupivacaine .25 % in the Peritonsillar area
62270098|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 18-30|
62270099|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 31-50|
62270100|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 51-70|
62270101|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 70+|
62452585|NCT02966379|EXPERIMENTAL|Cochlear implantation|Cochlear implantation with EVO electrode lead. This electrode lead has been specially designed for atraumatic surgery, in order to preserve the residual hearing of the patients included in the study. All patients are implanted with the same electrode lead.
62631608|NCT03020628|ACTIVE_COMPARATOR|NBP607-TIV 0.25mL|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
62631609|NCT00938665||Control Group|
62631610|NCT00938665||AD Group|
62270102|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 18-30|
62270103|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 31-50|
62631611|NCT02186977|ACTIVE_COMPARATOR|Intramuscular group|These subjects will receive one intramuscular injection of 1.0cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur-MSD) with syringe and needle in the deltoid region.
62631612|NCT02186977|EXPERIMENTAL|Intradermal group (Mantoux)|These subjects will receive one intradermal injection with mantoux technique in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur-MSD) will be injected.
62631613|NCT02186977|EXPERIMENTAL|Intradermal group (VAX-ID) A|These subjects will receive one intradermal injection with the newly developed intradermal injection device VAX-ID in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
62631614|NCT02186977|EXPERIMENTAL|Intradermal group (VAX-ID) B|These subjects will receive two intradermal injections with two newly developed intradermal injection devices VAX-ID in both forearms each 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
62631615|NCT01801488||AVM Patients|Patients receiving surgical intervention for an intracranial arterial-venous malformation.
62631616|NCT01801488||Ruptured Aneurysm|Patients receiving surgical intervention for a ruptured intracranial aneurysm.
62631617|NCT01801488||Unruptured Aneurysm|Patients receiving surgical intervention for an unruptured intracranial aneurysm.
62631618|NCT01688323||Elderly Chemorads|Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
62631619|NCT02217111|EXPERIMENTAL|voice therapy|
62631620|NCT05262335|EXPERIMENTAL|Experimental: Experimental group 1|Initial treatment: Anlotinib + Oxaliplatin + Capecitabine. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
62631621|NCT05262335|EXPERIMENTAL|Experimental: Experimental group 2|Initial treatment: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
62631622|NCT05262335|EXPERIMENTAL|Experimental: Experimental group 3|Initial treatment: Anlotinib + Standard first-line chemotherapy Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
62631623|NCT01431339|ACTIVE_COMPARATOR|Vancomycin with possible switch to oral linezolid|
62631624|NCT01431339|EXPERIMENTAL|Dalbavancin|
62631625|NCT05302375|EXPERIMENTAL|iPath*D|An online platform that connects patients screening positive for clinically significant depression in cancer settings to a range of online and inperson evidence-based treatments, facilitated by an interactive DA.
62631626|NCT06484296|ACTIVE_COMPARATOR|Education Group|"Before the training, students in all groups will be provided to take the Pretest.~The students included in the training group will be trained on good and green health practices in the conference hall of the Faculty by expert researchers and the green transformation coordinator of the university who have a certificate of Conscious Awareness training. Three weeks after the training, all students will be given the Green Culture Scale Post-Test."
62631627|NCT06484296|NO_INTERVENTION|Control Group|No application will be made to the control group. The students in this group will only fill in the questionnaires as pre-test and post-test three weeks after the pre-test.
62631628|NCT03975504|OTHER|LDCT Screening|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
62631629|NCT04500301|EXPERIMENTAL|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
62270104|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 51-70|
62270105|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 70+|
62270106|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 18-30|
62631630|NCT02988739|EXPERIMENTAL|Laser assisted epidermal application|"Laser pretreatment: 4 adjacent areas of 2 cm² each (14mm x 14 mm) will be pretreated with an Erbium Yttrium Aluminium Garnet laser (22,7 J/cm², 2 pulses, Density: 5%) generating micropores with a depth of approximately 91 µm.~0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be topically administered on the laser-treated area."
62631631|NCT02988739|ACTIVE_COMPARATOR|Intradermal application|0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be intradermally injected in the deltoid area.
62631632|NCT04988334|ACTIVE_COMPARATOR|FAST|12 weeks of FAST, 2/week 45 minute sessions with half hour per week of education, same group of men and women
62631633|NCT04988334|PLACEBO_COMPARATOR|wait control|12 weeks of usual activity prior to intervention, same group of men and women
62631634|NCT03976661||DIAPASON 92 arm|Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
62631635|NCT03976661||Control arm|Arm will be constituted by people residing at the EHPAD (retirement home)
62270107|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 31-50|
62631636|NCT00768690|OTHER|1|Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole
62270108|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 51-70|
62270109|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 70+|
62270110|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 18-30|
62631637|NCT00768690|OTHER|2|Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID
62631638|NCT00768690|OTHER|3|Healthy volunteers, receiving 600mg ABT-333 or placebo, BID
62631639|NCT00768690|OTHER|4|Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID
62631640|NCT00768690|OTHER|5|"Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID\*~\*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed."
62631641|NCT03068689|EXPERIMENTAL|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
62270111|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 31-50|
62270112|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 51-70|
62270113|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 70+|
62270114|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 18-30|
62270115|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 31-50|
62270116|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 51-70|
62270117|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 70+|
62270118|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 18-30|
62270119|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 31-50|
62270120|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 51-70|
62270121|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 70+|
62270122|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 18-30|
62270123|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 31-50|
62270124|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 51-70|
62631642|NCT03068689|PLACEBO_COMPARATOR|Placebo Control|Placebo prior to partial nephrectomy.
62631643|NCT06612138|EXPERIMENTAL|Pilates exercises|the patients will receive pilates exercise twice a week for six weeks plus traditional
62631644|NCT06612138|EXPERIMENTAL|yoga exercise|the patients will receive yoga exercise twice a week for six weeks plus traditional
62631645|NCT06612138|EXPERIMENTAL|tai chi exercises|the patients will receive tai chi exercise twice a week for six weeks plus traditional
62631646|NCT06612138|ACTIVE_COMPARATOR|traditional physical therapy|the patients will receive tradional physical therapy twice a week for six weeks
62631647|NCT02526160|EXPERIMENTAL|Burosumab 1 mg/kg|Burosumab 1 mg/kg administered subcutaneously (SC) every 4 weeks, for the duration of the study.
62065131|NCT02916797|EXPERIMENTAL|Stepping training with feedback|Subjects stand in a step standing position with placing the affected leg on the load cells of the VWTM and the non-affected leg slightly backward outside the load cells, look forward to light bars of the displayed section which will be set at their eye level. Then subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can. Subjects repetitively practice the task for 30 minutes with a period of sufficient rest as required.
62631648|NCT02526160|PLACEBO_COMPARATOR|Placebo|Placebo administered SC every 4 weeks through Week 24, followed by burosumab 1 mg/kg, for the duration of the study.
62065132|NCT02916797|NO_INTERVENTION|Stepping training without feedback|Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
62065133|NCT04713787|EXPERIMENTAL|Group A|400 mg (4 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
62065134|NCT04713787|EXPERIMENTAL|Group B|800 mg (8 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
62065135|NCT04713787|ACTIVE_COMPARATOR|Group C|400 mg (1 tablet of 400 mg) of Albendazole administered orally as a single dose on Day 1. N=83.
62065136|NCT05024422|ACTIVE_COMPARATOR|Administration of Cabergoline|one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days
62065137|NCT05024422|ACTIVE_COMPARATOR|Administration of Vitamin B6|200 mg X 3 per day for a week
62065138|NCT03815084|EXPERIMENTAL|PD-1 and DC-NK treatment group|
62065139|NCT03357367|EXPERIMENTAL|PAD patients|"Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by TiVi system"
62065140|NCT04644640|ACTIVE_COMPARATOR|Telerehabilitation|
62065141|NCT04644640|ACTIVE_COMPARATOR|In-Person Rehabilitation|
62065142|NCT03373864|EXPERIMENTAL|Unilateral spinal anesthesia|In this arm, the patients will have a hypobaric lateral spinal anesthesia. Sedation can be added for the patients comfort.
62065143|NCT03373864|ACTIVE_COMPARATOR|General anesthesia|In this arm, the patients will have a general anesthesia.
62065144|NCT01040650||Normal Controls|Normal Controls
62631649|NCT05371561|ACTIVE_COMPARATOR|Goggles + surgical mask|Dentist wearing Goggles + surgical mask will examin the patient
62065145|NCT01040650||Statin associated myopathy|subjects with statin associated myopathy
62270125|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 70+|
62270126|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 18-30|
62270127|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 31-50|
62270128|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 51-70|
62270129|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 70+|
62065146|NCT01400230||CCTA-IVUS-FFR|Patients suspected ischemic heart disease by the symptom and CCTA and undergone IVUS and FFR in the Cath Lab with CAG enrolled consecutively.
62065147|NCT03644069|EXPERIMENTAL|Nexvax2|
62065148|NCT03644069|PLACEBO_COMPARATOR|Placebo|
62065149|NCT01676948|EXPERIMENTAL|Canakinumab - Cohort 1, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
62065150|NCT01676948|EXPERIMENTAL|Canakinumab - Cohort 1, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
62065151|NCT01676948|EXPERIMENTAL|Canakinumab - Cohort 2, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
62065152|NCT01676948|EXPERIMENTAL|Canakinumab - Cohort 2, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
62065153|NCT01676948|EXPERIMENTAL|Cohort 2 - canakinumab dose reduction|
62065154|NCT01676948|EXPERIMENTAL|Cohort 1 - canakinumab dose reduction|
62065155|NCT01461330|EXPERIMENTAL|DASH diet|DASH DIET + EXERCISE
62065156|NCT01461330|ACTIVE_COMPARATOR|ADA DIET|DIET ACCORDING AMERICAN DIABETES ASSOCIATION DIETARY RECOMMENDATIONS FOR DIABETES
62065157|NCT04404478|EXPERIMENTAL|B-SWELL|Participants in the B-SWELL intervention will receive information about stress and goal setting in addition to healthy lifestyle behaviors. The intervention will take place weekly for eight weeks in groups of 11 to 13 midlife Black women for peer support. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
62270130|NCT03357627|EXPERIMENTAL|Dose Escalation: TAK-659 + Venetoclax|TAK-659 40, 60, 80, or 100 milligram (mg) (tablet, orally, once daily, up to 35 days in Cycle 1 or in different intermittent schedules \[7 days dosing followed by 7 days off or 14 days dosing followed by 7 days off or other intermittent dosing schedules\]) along with venetoclax 200, 400, 800 or 1200 mg (tablet, orally, once daily, up to 35 days in Cycle 1). After Cycle 1, TAK-659 and venetoclax will be administered once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant.
62631650|NCT05371561|ACTIVE_COMPARATOR|Face shield+ surgical mask|Dentist wearing Face shield+ surgical mask will examin the patient
62631651|NCT05371561|EXPERIMENTAL|Half face reusable respirator+ Filter|Dentist wearing Half face reusable respirator+ Filter will examin the patient
62631652|NCT05371561|EXPERIMENTAL|Full face reusable respirator+ Filter|Dentist wearing Full face reusable respirator+ Filter will examin the patient
62631653|NCT02465437|EXPERIMENTAL|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
62631654|NCT02465437|EXPERIMENTAL|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
62631655|NCT02465437|EXPERIMENTAL|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
62631656|NCT02465437|PLACEBO_COMPARATOR|Placebo|Placebo bid on Days 1-84.
62631657|NCT02465437|EXPERIMENTAL|Part B Open-label|JBT-101 20 mg bid on Days 1-364
62631658|NCT05182411||Patients with spasticity|adult neurological patients with spasticities in their lower extremities
62631659|NCT01972412|OTHER|Telephone support|Intervention type: Telephone support for four months.
62631660|NCT01290302|EXPERIMENTAL|Luitpold Azacitidine|
62631661|NCT01290302|ACTIVE_COMPARATOR|Vidaza®|
62631662|NCT00094679|ACTIVE_COMPARATOR|2hrs daily patching|2 hours patching per day to cover the sound eye
62631663|NCT00094679|ACTIVE_COMPARATOR|6hrs daily patching|6 hours per day patching to cover the sound eye
62631664|NCT02690272|EXPERIMENTAL|Psychic processes|Quantitative and qualitative approche of the psychic process for patients awaiting kidney transplant
62631665|NCT01963884||Alveolar Socket Below Basal Bone|Tooth and the alveolar socket are positioned below basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
62631666|NCT01963884||Alveolar Socket in Basal Bone (imbedded)|Tooth and alveolar socket are positioned in basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
62631667|NCT01963884||Alveolar Socket Buccal to Basal Bone|Tooth and alveolar socket are positioned buccally in relation to maxillary basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
62631668|NCT06347367|ACTIVE_COMPARATOR|Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles)|Diaphragmatic stretching technique, pectoral muscle relaxation, diaphragmatic mobilisation, thoracic mobilisation and diaphragmatic breathing.
62631669|NCT06347367|ACTIVE_COMPARATOR|Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles)|İn addition to Group 1, patients in group 2 will receive, abdominal massage, abdominal mobilisation, stabilisation exercises and pelvic floor muscle training.
62631670|NCT01735188||Living|
62631671|NCT01735188||Deceased|
62631672|NCT03923881|EXPERIMENTAL|Study group|Patients with oral squamous cell carcinoma that have been included in ICON-study and are scheduled for treatment of neck
62631673|NCT01517633|EXPERIMENTAL|A device for identifying between amniotic fluid and urine|
62631674|NCT02853045|EXPERIMENTAL|period with drug (trade name) then period with generic|Period of 6 weeks.
62631675|NCT02853045|EXPERIMENTAL|period with generic then period with drug (trade name)|Period of 6 weeks.
62631676|NCT01559038||adalimumab|Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
62270131|NCT03357627|EXPERIMENTAL|Safety Expansion: Diffuse Large B-cell Lymphoma (DLBCL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
62270132|NCT03357627|EXPERIMENTAL|Safety Expansion: Follicular Lymphoma (FL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
62270133|NCT05940792|EXPERIMENTAL|intervention group|The intervention group received 45 min of conventional physiotherapy after nonelastic taping, which provides eversion support.
62270134|NCT05940792|ACTIVE_COMPARATOR|control group|The control group received 45 min of conventional physiotherapy
62270135|NCT03956095||Ensure Surgery Immunonutrition Shake supplements|Participants will be provided with and instructed to drink three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
62270136|NCT03470415||Group A|Patients with type 2 diabetes milletus with normoalbuminuria.
62270137|NCT03470415||Group B|Patients with type 2 diabetes milletus with microalbuminuria.
62065158|NCT04404478|ACTIVE_COMPARATOR|WE|The attention control group (WE), will include education about healthy lifestyle behaviors and peer support. The attention control groups will also have weekly sessions for eight weeks in groups of 11 to 13 midlife Black women. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
62452586|NCT04808089|EXPERIMENTAL|Health Lung App. +ezOxygen|"Health Lung App. (AstraZeneca Pharmaceuticals LP) is the application for mobile phone to help asthma care and is available freely in Google Play. Health Lung can be connected to the mobile spirometry, ezOxygen (Genius Holding Co.,Ltd Taiwan Branch).~The functions of Health Lung App. include asthma control monitor, lung function monitor, controller and reliver inhaler reminder and recording, asthma educational topics in brief and information of air quality~Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~he physicians in charge will get the information about control status score by ACT, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
62065159|NCT04394845|EXPERIMENTAL|[18F]GTP1|Participants will receive a single bolus injection of radioligand \[18F\]GTP1 intravenously (IV).
62270138|NCT03470415||Group C|Patients with type 2 diabetes milletus with macroalbuminuria.
62270139|NCT03757910|EXPERIMENTAL|DPPOS Exposed to Metformin|DPPOS participants with exposure to metformin will be scanned with 18F-MK-6240 and 11C-PIB.
62270140|NCT03757910|ACTIVE_COMPARATOR|DPPOS Exposed to Placebo|DPPOS participants with no exposure to metformin but only placebo will be scanned with 18F-MK-6240 and 11C-PIB.
62452587|NCT04808089|ACTIVE_COMPARATOR|Usual care|The research assistant assess/ teach inhaler technique, offering the asthma education as the regular clinical service.
62065160|NCT01971190|SHAM_COMPARATOR|Sham injection|Sham injection at baseline, at 1 month, and at 2 month
62065161|NCT01971190|ACTIVE_COMPARATOR|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
62270141|NCT06180954|EXPERIMENTAL|Part 1: [14C]-LOXO-305|A single dose of \[14C\]-LOXO-305 oral solution will be administered
62270142|NCT06180954|EXPERIMENTAL|Part 2: LOXO-305|A single dose of LOXO-305 oral tablets will be administered
62270143|NCT06180954|EXPERIMENTAL|Part 2: [14C]-LOXO-305|A single dose of \[14C\]-LOXO-305 intravenously (IV) solution will be administered
62270144|NCT03098329|EXPERIMENTAL|Ct/GC screening|Community screening of men for Ct and GC is not normally done. We are testing to see if this intervention will impact the rates of Ct and GC among women
62270145|NCT02052271|EXPERIMENTAL|Essential tremor|cerebellar stimulation
62270146|NCT02052271|PLACEBO_COMPARATOR|Placebo arm|placebo stimulation
62270147|NCT05319392||Patients with Gastric Adenocarcinoma|Patients with origin of tumor in distal part of stomach who underwent total or partial gastrectomy after biopsy examination with availability of follow-up and archived FFPE tissue will be considered for this study.
62270148|NCT01344876|EXPERIMENTAL|OPB-51602|OPB-51602 1, 2, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle
62270149|NCT01320865||Subjects with PAH treated with nilotinib|
62631677|NCT01559038||DMARD (disease-modifying antirheumatic drugs)|Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
62631678|NCT05074524|EXPERIMENTAL|rTMS group|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
62270150|NCT05562375|EXPERIMENTAL|Patients|73 patients are to be recruited from the ones that go to the oral medicine service at the university clinic of Rey Juan Carlos in Madrid that present a compatible clinic diagnostic compatible with oral potentially malignant disorders. Each patient will receive first an intraoral exploration, taking note of location and size of the injury. After that, an exploration with the GOCCLES® device will be made, also taking note of the location and size data. Thereafter, the blue toluidine stain will be used, taking note of the size and location of the marked areas. Pictures will be taken through all the steps. Finally, a biopsy will be made of the area or areas the clinic considers and/or marked by the device or the toluidine blue.
61978586|NCT03835611|EXPERIMENTAL|Intervention group|"Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free."
62065162|NCT04632732||COVID+, SARS|patients COVID+ SARS mechanically ventilated and/or needing more than 6L/min of O2-40% FiO2 for a SpO2 equal or above 90% for more than 24hours.
62270151|NCT03189446|EXPERIMENTAL|Vaginal Cuff Brachytherapy + Chemotherapy|Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles
62270152|NCT01415427|EXPERIMENTAL|BMN 110 Weekly|BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
62270153|NCT01415427|EXPERIMENTAL|BMN 110 Every Other Week|BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.
62270154|NCT02121457|NO_INTERVENTION|Control Group|This group did not receive any intervention.
62270155|NCT02121457|EXPERIMENTAL|Treatment Group|This group took one Brazil nut daily during 6 months.
62270156|NCT04041882|EXPERIMENTAL|68Ga-DOTATATE PET/CT|Inject 68Ga-DOTATATE and then perform PET/CT scan
62270157|NCT05572775||Chronic post-surgical pain|Living kidney donor with the incidence of chronic post-surgical pain
62270158|NCT05572775||Non-Chronic Post-surgical pain|Living kidney donor without the incidence of chronic post-surgical pain
62270159|NCT02302898||Wt maintenance|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
62452588|NCT00861445|EXPERIMENTAL|1|
62452589|NCT00861445|PLACEBO_COMPARATOR|2|
62452590|NCT05638425||Group 1|
62452591|NCT05213936|EXPERIMENTAL|Scalp cooling with hairstyle|Scalp cooling with hairstyle (braids, twists, cornrows) to minimize hair volume and increase scalp cooling cap to scalp contact
62452592|NCT05213936|EXPERIMENTAL|Scalp Cooling with conditioner and water emulsion|Scalp cooling after coating hair with conditioner and water emulsion to minimize hair volume and increase scalp cooling cap to scalp contact
62452593|NCT05213936|NO_INTERVENTION|No Scalp Cooling|Control with no scalp cooling
62452594|NCT01645384|EXPERIMENTAL|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
62452595|NCT01645384|ACTIVE_COMPARATOR|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
62452596|NCT06545747|EXPERIMENTAL|MRI-based hypo-RT|Patients will receive split-course hypo-RT combined with concurrent chemotherapy and consolidative immunotherapy. The experimental arm will undergo adaptive dose-painting hypo-RT based on DCE-MRI.
62452597|NCT06545747|ACTIVE_COMPARATOR|CT-based hypo-RT|Patients will receive split-course hypo-RT combined with concurrent chemotherapy and consolidative immunotherapy. The control arm will undergo hypo-RT based on CT.
62452598|NCT00538343|EXPERIMENTAL|RTA 744|
62270160|NCT02302898||Wt Regain|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
62631679|NCT05074524|SHAM_COMPARATOR|Placebo Group|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
62631680|NCT06221371|EXPERIMENTAL|IVT with rhTNK-tPA+EVT|"rhTNK-tPA 0.25mg/kg: 1-2 vials (1.0×107 IU/16 mg per vial) Each vial of rhTNK-tPA is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. The total amount of drug will be calculated according to the subject's actual body weight and the required drug volume will be measured. The maximum dose should not exceed 25mg. rhTNK-tPA should be given as a single, intravenous bolus (drug administered over 5-10 seconds).~Endovascular treatment (EVT) should be performed as soon as possible after rhTNK-tPA administration."
62631681|NCT06221371|ACTIVE_COMPARATOR|Direct EVT|During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
62065163|NCT04632732||COVID+, nonSARS|patients COVID+ nonSARS respiratory symptomatic, with or without lung infiltrates, non mechanically ventilated, and needing less than 6L/min O2-40% FiO2 for a SpO2 equal or above 90%. They are hospitalized on floors (pulmonolgy, internal medecine or in intensives cares units).
62631682|NCT02602314|EXPERIMENTAL|Imatinib + Nilotinib|
62270161|NCT06308276|ACTIVE_COMPARATOR|Group A|Brisk walking, jogging, cycling, or low-impact aerobics
62270162|NCT06308276|ACTIVE_COMPARATOR|Group B|Full body resistance exercise targeting major muscle groups, including squats, lunges, chest presses, rows, and core exercises
62270163|NCT04223934|EXPERIMENTAL|optima4BP|"Treating physicians receive periodic (every 5-8 weeks) medication treatment recommendations intended to optimize the current patient treatment.~The recommendations are generated based on periodic remote data collected from the patient and from the Electronic Health Record. The analysis of the data allows assessment of the patient's response to current treatment and need for a treatment optimization. If a treatment optimization is needed, one is generated and sent to the treating physician for consideration."
62452599|NCT02215577|EXPERIMENTAL|In-situ split with portal vein ligature|In-situ liver split at time when portal vein ligature is performed
62452600|NCT02215577|ACTIVE_COMPARATOR|Portal embolization or ligation|Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy
62065164|NCT04632732||COVID-, ARDS|patients are in ARDS according to the Berlin definition and the lung injury is categorized in the direct form (e.g. pneumonia, aspiration).
62065165|NCT04632732||COVID-, nonARDS|patients are not in ARDS according to the Berlin definition but are respiratory symptomatic, with or without lung infiltrates and needing less than 6L O2/min-40% FiO2 for a SpO2 equal or above 90%.
62270164|NCT04223934|NO_INTERVENTION|Standard of Care (SOC)|The treating physician follows usual care practices.
62270165|NCT05069857|EXPERIMENTAL|Neoadjuvant arm|The patients received three cycles of neoadjuvant therapy, with 14 days each. Dosage and administration: 200mg Carrelizumab intravenously on the first day of each cycle; Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle. Then the patients received the standard treatment of surgery and postoperative adjuvant therapy of radiotherapy or chemoradiotherapy.
62452601|NCT00680121|PLACEBO_COMPARATOR|Control Group|Placebo
62452602|NCT00680121|EXPERIMENTAL|Benfotiamine|Benfotiamine 600 mg
62631683|NCT02602314|EXPERIMENTAL|Nilotinib|
62631684|NCT04220801|EXPERIMENTAL|Cohort 1 of Part 1 (SAD)|300 mg ZM-H1505R or placebo
62631685|NCT04220801|EXPERIMENTAL|Cohort 2 of Part 1(SAD)|450 mg ZM-H1505R or placebo
62631686|NCT04220801|EXPERIMENTAL|Cohort 3 of Part 1(SAD)|150 mg ZM-H1505R or placebo (2 periods)
62631687|NCT04220801|EXPERIMENTAL|Cohort 4 of Part 1(SAD)|75 mg ZM-H1505R or placebo
62631688|NCT04220801|EXPERIMENTAL|Cohort 5 of Part 1(SAD)|25 mg ZM-H1505R or placebo
62631689|NCT04220801|EXPERIMENTAL|Cohort 1 of Part 2 (MAD)|75 mg ZM-H1505R or placebo
62065166|NCT04632732||COVID-, control, MV+|patients hospitalized and mechanically ventilated for non-respiratory reasons (post hoc with sex-age matching).
62631690|NCT04220801|EXPERIMENTAL|Cohort 2 of Part 2 (MAD)|150 mg ZM-H1505R or placebo
62270166|NCT05069857|NO_INTERVENTION|Control arm|The patients received the standard treatment of surgery and postoperative adjuvant therapy of radiotherapy or chemoradiotherapy.
62631691|NCT04220801|EXPERIMENTAL|Cohort 3 of Part 2 (MAD)|300 mg ZM-H1505R or placebo
62631692|NCT04826159|EXPERIMENTAL|IMB-1018972 200 mg|
62631693|NCT00874159||A|
62631694|NCT02105233|EXPERIMENTAL|BMG|brain mimicking fluid
62631695|NCT03113968|ACTIVE_COMPARATOR|electroconvulsive therapy (ECT)|Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
62631696|NCT03113968|ACTIVE_COMPARATOR|ketamine infusion|Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
62631697|NCT03940196|EXPERIMENTAL|NovoTTF-100L(O)|Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel
62631698|NCT03940196|ACTIVE_COMPARATOR|Best Standard of Care|Patients receive best standard of care with weekly Paclitaxel
62631699|NCT00943397|EXPERIMENTAL|1|Montelukast
62270167|NCT06310980|EXPERIMENTAL|smartpen|patients treated by smartpen, glucose sensor and connected by a digital application
62270168|NCT03946709|OTHER|Muscle strength condition|
62270169|NCT03946709|OTHER|Muscle weakness condition|
62631700|NCT00943397|ACTIVE_COMPARATOR|2|Usual Care
62270170|NCT03946709|NO_INTERVENTION|Control|
62270171|NCT00419380|ACTIVE_COMPARATOR|dornase alfa (Pulmozyme®)|dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear.
62270172|NCT00419380|ACTIVE_COMPARATOR|Ofloxin|Ofloxin : 5 drops twice daily for 7 days to the affected ear.
62270173|NCT05558839|EXPERIMENTAL|exercise training|Physiotherapists prescribed and delivered interventions in the exercise arm. Each exercise session began with a 5-minute warm up and stretching, followed by 15-minute Aerobic exercises, 15-minute of resistance training, 10-minute of agility and balance training, and 5-minute of cooling down.
62631701|NCT05185466|EXPERIMENTAL|Experimental Group|Experimental Group
62631702|NCT05185466|NO_INTERVENTION|Control Group|Control Group
62631703|NCT03438201|ACTIVE_COMPARATOR|High-protein diet|High Protein Diet (2,0 - 2,5g/Kg body weight/day) Physical Activity protocol
62631704|NCT03438201|ACTIVE_COMPARATOR|Normoproteic diet|Standard Protein Diet (1,0 - 1,2g/Kg body weight/day) Physical Activity protocol
62631705|NCT02030262|EXPERIMENTAL|Air|The participant will undergo epiretinal membrane peeling with fluid-air exchange. The remaining of the surgery is the same in all arms.
62631706|NCT02030262|ACTIVE_COMPARATOR|Sulfur hexafluoride (SF6)|The participant will undergo epiretinal membrane peeling with fluid-SF6 exchange. The remaining of the surgery will stay the same.
62631707|NCT00438204|EXPERIMENTAL|Bevacizumab, gemcitabine hydrochloride|"Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days~Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days~Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days."
62631708|NCT01793038|ACTIVE_COMPARATOR|CC-plus uFSH|clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12
62631709|NCT01793038|EXPERIMENTAL|Aromataze inhibitor plus uFSH|Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12
62631710|NCT03159832|ACTIVE_COMPARATOR|Normal renal function|All subjects were given SHR3824 20mg only one time.
62631711|NCT03159832|ACTIVE_COMPARATOR|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
62065167|NCT04632732||COVID-, control, MV-|non mechanically ventilated patients hospitalized for non-respiratory reasons (post hoc with sex-age matching).
62065168|NCT04511416|ACTIVE_COMPARATOR|Intervention|Metformin
62631712|NCT03159832|ACTIVE_COMPARATOR|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
62631713|NCT00712894|EXPERIMENTAL|D|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
62631714|NCT00712894|ACTIVE_COMPARATOR|V|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
62631715|NCT00712894|ACTIVE_COMPARATOR|N|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.
62631716|NCT04974892||low dose aspirin|high-risk women given LDA at ≤16 weeks.
61978587|NCT03835611|ACTIVE_COMPARATOR|Control Group|Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:
62270174|NCT05558839|EXPERIMENTAL|cognitive training|"Board game teachers who have more than 5 years of community teaching experience prescribed and delivered interventions in the cognitive arm.~Each cognitive session uses different board games to strengthen training for different cognitive aspects."
62270175|NCT02958488|EXPERIMENTAL|Preterm Neonates with Respiratory Distress Syndrome|34 to 36 Weeks Preterm Neonates with Respiratory Distress Syndrome
62270176|NCT06130267|PLACEBO_COMPARATOR|control condition|same paradigm without the active agent
62270177|NCT06130267|EXPERIMENTAL|Virtual Reality condition|calming VR environment
62270178|NCT02150577|EXPERIMENTAL|Implementation|Evidence Based Quality Improvement
62270179|NCT02150577|NO_INTERVENTION|Control|Usual Quality Improvement
62270180|NCT02224859|OTHER|Safety|"Following an initial examination of the scalp and head for baseline evidence of skin integrity (intact, without breaks, lacerations, etc.) and appearance (healthy/normal, no erythema/irritation, etc.) the HCP will place the CSD on the patient and secure the attached Velcro strap to hold the device in place~At specific time points (approximately 15 minutes, 1 hour, 3 hours and 6 hours) the HCP (through human intervention)will remove the CSD for examination and completion of the Skin Assessment Scale based on the appearance of the patient's scalp and adjacent areas of the head. Additionally, the patient's head will be observed for excessive scalp sweating/moisture accumulation."
62270181|NCT03864653|OTHER|MoodGym|"Non-randomized single-arm intervention; eligible persons are newly enrolled methamphetamine use treatment service program (i.e., Getting Off) participants who will be invited to participate in the study during their enrollment, and can enroll in the study at any time during their first two weeks of program participation. Participants who enroll will take the preexisting, low-intensity MoodGym intervention."
62270182|NCT00806559|ACTIVE_COMPARATOR|Usual room|Patients in this arm will see their clinician in the usual clinical exam room
62270183|NCT00806559|EXPERIMENTAL|Re-designed room|Patients assigned to this arm will see the physician in a redesigned clinical exam room
62270184|NCT02127190|PLACEBO_COMPARATOR|CXA-10 placebo emulsion|single intravenous dose of CXA 10 placebo emulsion
62270185|NCT02127190|EXPERIMENTAL|CXA-10 Emulsion|single ascending intravenous doses of CXA-10 emulsion
62452603|NCT05072340|EXPERIMENTAL|RISE (Blended learning)|"Students will undergo a training that comprises of six sessions: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.~RISE training will be hosted via the NUS' online learning platform, LumiNUS and virtual face-to-face platform, Zoom. Each session will take approximately one to two hours per week. One session is made available each week to encourage completion before moving onto the next session. Students will be provided with materials in the form of interactive videos. Virtual face-to-face sessions, online forum, quizzes and homework will be additionally available to students."
62452604|NCT05072340|ACTIVE_COMPARATOR|RISE (Asynchronous learning)|"Students will also undergo a six-session training comprising of: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.~RISE training will be hosted via the NUS' online learning platform, LumiNUS. One session is made available each week to encourage completion before moving onto the next session. Participants will be reminded via emails and short message service (SMS) to complete the intervention. Students will be provided with materials in the form of interactive videos in LumiNUS."
62452605|NCT05382221|EXPERIMENTAL|Comprehensive Chronic Care|ongoing proactive outreach designed to provide support and information about evidence-based smoking treatment, with access to individually validated treatments that are appropriate for patients who are: 1) unwilling quit but willing to reduce; 2) ready to quit; and 3) recovering from an unsuccessful quit attempt
62452606|NCT05382221|ACTIVE_COMPARATOR|Standard Care|involves one offer of cessation treatment (8 weeks of nicotine patch plus referral to the tobacco quit line), annually
62452607|NCT02456532|PLACEBO_COMPARATOR|Placebo|Intervention: Six months of nightly placebo
62452608|NCT02456532|ACTIVE_COMPARATOR|Zolpidem CR|Intervention: Six months of zolpidem cr 12.5 mg nightly use
62452609|NCT02456532|ACTIVE_COMPARATOR|Eszopiclone|Intervention: Six months of eszopiclone 3 mg nightly use
62452610|NCT04076501|EXPERIMENTAL|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
62452611|NCT04076501|SHAM_COMPARATOR|Sham room air|Room air will be applied similarly to oxygen
62270186|NCT04865068|EXPERIMENTAL|African migrant's population located in la region New Aquitaine.|Echocardiography norms will be harvested data on SSA participants located in la region New Aquitaine, France
62270187|NCT03847701|ACTIVE_COMPARATOR|High in SDS|Balanced diet high in Slowly Digestible Starch
62270188|NCT03847701|PLACEBO_COMPARATOR|Low in SDS|Balanced diet low in Slowly Digestible Starch
62452612|NCT06189378|ACTIVE_COMPARATOR|Conventional blood pressure diary|Blood pressure diaries consisted of tables including columns for date, time as well as systolic and diastolic blood pressure respectively (1 page for 1 week) printed on the right-hand pages of an A5 (ISO 216 format) booklet.
62452613|NCT06189378|EXPERIMENTAL|Blood pressure diary including patient-provided pictures|In the interventional arm pictures chosen by patients were provided over a secure online connection by patients in this group and inserted into the left-hand-pages of the blood pressure diaries.
62452614|NCT06546267||Prostate cancer, localized disease|"Patients treated with IGRT, IMRT, SBRT, with radical intent for localized prostate cancer will be evaluated~Other Names:~Intensity Modulated Radiotherapy Stereotactic Body Radiotherapy"
62452615|NCT06546267||Prostate cancer, extensive disease|"Patients operated on for prostate cancer, treated with IGRT, IMRT, SBRT in adjuvant setting will be evaluated~Other Names:~Intensity Modulated Radiotherapy Stereotactic Body Radiotherapy"
62452616|NCT06546267||Prostate cancer, biochemical relapse|Patients operated on for prostate cancer and treated with IGRT, IMRT, SBRT for biochemical relapse will be evaluated
62631717|NCT04974892||Non responders to low dose aspirin|high-risk women who have not responded to LDA and have gone on to develop PE.
62065169|NCT04511416|PLACEBO_COMPARATOR|Placebo|Placebo
62270189|NCT01061814|EXPERIMENTAL|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) SC daily
62270190|NCT01061814|PLACEBO_COMPARATOR|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) SC daily
62270191|NCT02326415|ACTIVE_COMPARATOR|"Clinical Pathway With Fast-Track"|All the clinical performances that the health personal have to do about the patient with uncomplicated acute appendicitis is already established in a care maps since the patient comes to hospital until the discharge.
62452617|NCT06546267||Prostate cancer, oligometastatic disease ( lymph-nodal, bone, visceral)|Prostate cancer patients treated with IGRT, IMRT, SBRT, in radical setting or as salvage radiotherapy for relapse after previous treatments will be evaluated
62452618|NCT05071807|ACTIVE_COMPARATOR|Pecan Group|Participants will consume their usual diet, but replace one snack with unsalted raw pecans incorporated as a snack
62452619|NCT05071807|ACTIVE_COMPARATOR|Usual Care Group|Participants will consume their usual diet devoid of nuts
62452620|NCT01752257|OTHER|EF5 Hypoxia|EF5 administered at 21mg/kg
62452621|NCT01619826|EXPERIMENTAL|Treatment Group|Participants randomized to the physical activity-based afterschool intervention
62452622|NCT01619826|PLACEBO_COMPARATOR|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
62452623|NCT02933281|EXPERIMENTAL|Cohort 1: MTBVAC 5 x 10^3 CFU|Quantiferon (QFT) negative, 1 dose on Day 0
62452624|NCT02933281|EXPERIMENTAL|Cohort 2: MTBVAC 5 x 10^4 CFU|QFT Negative, 1 dose on Day 0
62452625|NCT02933281|EXPERIMENTAL|Cohort 3: MTBVAC 5 x 10^5 CFU|QFT Negative, 1 dose on Day 0
62452626|NCT02933281|EXPERIMENTAL|Cohort 4: MTBVAC 5 x 10^6 CFU|QFT Negative, 1 dose on Day 0
62452627|NCT02933281|EXPERIMENTAL|Cohort 5: MTBVAC 5 x 10^3 CFU|QFT Positive, 1 dose on Day 0
62452628|NCT02933281|EXPERIMENTAL|Cohort 6: MTBVAC 5 x 10^4 CFU|QFT Positive, 1 dose on Day 0
62452629|NCT02933281|EXPERIMENTAL|Cohort 7: MTBVAC 5 x 10^5 CFU|QFT Positive, 1 dose on Day 0
62452630|NCT02933281|EXPERIMENTAL|Cohort 8: MTBVAC 5 x 10^6 CFU|QFT Positive, 1 dose on Day 0
62270192|NCT02326415|ACTIVE_COMPARATOR|Postoperative Usual Protocol|The postoperative time and the clinical cares in patients with uncomplicated acute appendicitis, are defined by responsability sugery as he thinks he should be according to the literature.
62452631|NCT02933281|ACTIVE_COMPARATOR|BCG 5 x 10^5 CFU|Both QFT positive and negative, 1 dose on Day 0
62452632|NCT05052138|EXPERIMENTAL|Tactile massage|Tactile massage 1 will receivetwo 15-min tactile massages (hand massage) per week for 4 weeks
62452633|NCT05052138|NO_INTERVENTION|comparison group|The comparison group will receive regular care and activities.
62452634|NCT01600495|EXPERIMENTAL|Experimental TENS|TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
62452635|NCT01600495|NO_INTERVENTION|control Group|Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.
62452636|NCT03188081||Cohort A|Adult RA patients followed up according to local clinical practice only at the hospital wards
62452637|NCT03188081||Cohort B|Adult RA patients followed up according to local clinical practice at the Hospital wards and additionally at their home through a support program
62452638|NCT05271474|EXPERIMENTAL|Intervention Arm|Participants will be assigned to use Sibel sensor and download the ANNE ONE platform to their mobile devices. The Sibel sensors are to be worn on the sternum and index finger and can be attached using provided replaceable gel adhesive. The Sibel sensors will transmit data to the ANNE ONE platform. The ANNE ONE platform will send automated alerts to the CRC via email when a patient is flagged as uncontrolled, which will occur when a patient's vitals reach or pass one of the safety thresholds.
62452639|NCT05271474|NO_INTERVENTION|Control Arm|These patients will be followed by the Clinical Research Coordinator for CAT scores, emergency department visits and hospitalizations.
62452640|NCT01697020|EXPERIMENTAL|Arm 1|Mercaptopurine 20mg/ml Oral Suspension
62452641|NCT01697020|ACTIVE_COMPARATOR|Arm 2|Mercaptopurine 50mg tablets
62452642|NCT05698368|ACTIVE_COMPARATOR|Active comparator group|A series of educational videos and reflective questions of the same duration and required attention as the mindset intervention program. The videos are sourced videos from YouTube that educate about osteoarthritis. The content consists of information about osteoarthritis that patients would typically receive if looking for more information about the disease, including disease pathology, risks, symptoms, and treatment strategies. The included videos contain factual content with a similar format to the mindset intervention videos, including live experts sharing information with animations and supplementary b-roll footage.
62452643|NCT05698368|EXPERIMENTAL|Mindset intervention group|Four modules, each with a series of videos and reflective questions. Each module takes approximately 20-60 minutes to complete, with a total of about two hours to complete the entire program. Participants have one week to complete the program at their own pace. Participants are suggested to complete one module per day but are encouraged to go at the pace that works best for them.
62452644|NCT05698368|NO_INTERVENTION|Waitlist control group|This group will take the same surveys as the other groups at the same time points but will not receive any additional content.
62452645|NCT05894161|EXPERIMENTAL|Group-I|Group-1: Twenty-five adult patients with SCD will receive a designed exercise program of physical therapy for relief pain and improve sleep quality (experimental group). The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.
62452646|NCT05894161|NO_INTERVENTION|Group-II|Group-2: Twenty-five adult patients with SCD will participate as a control group they will not receive exercise program.
62452647|NCT01817348|EXPERIMENTAL|Lidocaine group|"1% lidocaine 5ml intra-articular injection to shoulder joint + physiotherapy three times weekly~* Injection is performed if pain during intervention equals to or greater than 7cm in a 10-cm VAS scale.~* Injection frequency is not greater than twice per week and total injection time is limited to 10 times in the whole course~* In each week, patient will receive 3 times of PT with or without intra-articular lidocaine injection."
62065170|NCT03317028|EXPERIMENTAL|high dose of CS02|Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.
62631718|NCT01918657|ACTIVE_COMPARATOR|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded.
62065171|NCT03317028|EXPERIMENTAL|middle dose of CS02|Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.
62065172|NCT03317028|EXPERIMENTAL|low dose of CS02|Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.
62065173|NCT03317028|PLACEBO_COMPARATOR|placebo control|Subjects will receive placebo combined with a stable dose of metformin monotherapy.
62065174|NCT02803060|EXPERIMENTAL|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62065175|NCT03068546||Participants providing samples|NCI employees agreeing to provide samples for microbiome sample study
62065176|NCT00920530||Real time PCR monitoring|Women giving birth at the St Etienne Teaching Hospital
62452648|NCT01817348|PLACEBO_COMPARATOR|PT group|- Apply to every patient, each by the same physical therapist, 3 times weekly for 3 months or till the patients gain satisfactory results.
62065177|NCT00462722|PLACEBO_COMPARATOR|Placebo pre and post exercise|placebo before and after musculoskeletal-loading exercise
62452649|NCT03918798|EXPERIMENTAL|Chloroprocaine 1%|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
62452650|NCT03918798|EXPERIMENTAL|Chloroprocaine 2%|All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.
62452651|NCT05759975|ACTIVE_COMPARATOR|Intraoral photobiomodulation (PBMI)|"The protocol will be performed daily by a single trained professional from the first day of conditioning until D + 5 after bone marrow transplantation or while lesions are present.~PBMI protocol will use the indium-gallium-aluminium-phosphorus diode laser (InGaAlP) (DUO® - MMOptics Ltda, São Carlos, Brazil). Four anatomical areas will be irradiated perpendicularly in the buccal mucosa through several anatomical points with a distance of approximately 1 cm between them, in order to cover the largest area per cm² by region.~Application points:~* Buccal mucosa: 9 points each side: bite line on cheeks and upper and lower internal buccal vestibule (18 points).~* Tongue: 4 points on each side, on the lateral and ventral edge (8 points).~* Floor of the mouth: 1 point on each side (2 points)~* Upper and lower lips: upper and lower lips (lip redness), bottom of upper and lower sulcus and buccal commissure, right and left sides (4 points).~* Soft palate: right and left side (2 points)"
62452652|NCT05759975|ACTIVE_COMPARATOR|Extraoral photobiomodulation (PBME)|"The protocol will be performed daily by a single trained professional from the first day of conditioning until D + 5 after bone marrow transplantation or while lesions are present.~A gallium-aluminum arsenide diode laser (Gemini® manufactured by Azena Medical, LLC, distributed by Ultradent Products, Inc.) with double wavelength 810 + 980 nm, previously standardized and calibrated for extraoral application by the measurement of potency (Coherent Inc, Santa Clara, CA). The equipment will be programmed with 1 W of power. The application points will be carried out perpendicularly on the face.~Application points:~* 4 points on each cheek (2 on the right and 2 on the left)~* 1 on lips; patients with sealed lips being possible to cover the upper and lower lip~* 5 points in the cervical region (2 in the right submandibular space and 2 in the left submandibular space and submental space in the midline)."
62065178|NCT00462722|EXPERIMENTAL|Placebo pre and ibuprofen post exercise|placebo before and ibuprofen after musculoskeletal-loading exercise
62065179|NCT00462722|EXPERIMENTAL|Ibuprofen pre and placebo post exercise|ibuprofen before and placebo after musculoskeletal-loading exercise
62065180|NCT02231229|EXPERIMENTAL|PCR-based strategy|PCR-based strategy: after testing for isoniazid and rifampin resistance using a molecular testing with PCR (GenoType ®MTB DR plus), patients will receive HRZ combination therapy (INH , RIF, PZA) if no resistance is detected
62065181|NCT02231229|ACTIVE_COMPARATOR|conventional therapy|Conventional therapy: based on the standard of care in France: initiation of the standard 4 drug regimen INH, RIF, PZA, and EMB, until drug susceptibility testing (DST) results are available.
62065182|NCT05250713|EXPERIMENTAL|tDCS|Patients receiving tDCS during SEEG investigation
62065183|NCT05250713|EXPERIMENTAL|tACS|Patients receiving tACS during SEEG intervention
62065184|NCT04505436|EXPERIMENTAL|HM15211|
62065185|NCT04505436|PLACEBO_COMPARATOR|Placebo|
62065186|NCT05918562|EXPERIMENTAL|Low fiber diet group|Subjects are allowed a low fiber diet the day of their colonoscopy prep
62065187|NCT05918562|ACTIVE_COMPARATOR|Clear liquid diet group|Subjects are allowed a clear liquid diet the day of their colonoscopy prep, as is standard of care
62065188|NCT03417921|EXPERIMENTAL|ARM A|ABTL0812 (starting 1,300 mg tid orally) in combination with gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer
62065189|NCT03417921|ACTIVE_COMPARATOR|ARM B|Gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer as standard pattern
62631719|NCT01918657|PLACEBO_COMPARATOR|placebo arm|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
62631720|NCT01945047|EXPERIMENTAL|Ketamine|During Phase 1 patients will be randomly assigned to receive ketamine or active placebo.
62631721|NCT01945047|ACTIVE_COMPARATOR|Midazolam|In phase 1 patients will be randomized to receive active placebo
62631722|NCT03452956||FTD Cohort|No intervention-observation only
62631723|NCT02608385|EXPERIMENTAL|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
62631724|NCT02608385|EXPERIMENTAL|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
62065190|NCT01686165|EXPERIMENTAL|Belinostat Yttrium Ibritumomab Tiuxetan|Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
62065191|NCT01928680|EXPERIMENTAL|Cisplatin/Capecitabine|"Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.~This is a single arm phase II clinical trial."
62065192|NCT03675451|EXPERIMENTAL|Interventional|"Injection of study drug followed by PET/CT imaging.~Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.~Followed by prostatectomy"
62270193|NCT04336631|OTHER|Routine Medical Follow Up, Counseling & Usual Care|Behavioral counseling was provided to the patients on each consecutive follow up after enrolling in this study. They were adequately followed on physical exercise, reduced salt intake, lifestyle modifications, and smoking cessation. All measurements of blood pressure and weight were maintained and recorded.
62270194|NCT04336631|NO_INTERVENTION|Routine Medical Follow Up & Usual Care|Usual routine medical care was provided to the study participants only.
62270195|NCT02336828||MEWS alarm and mortality|Reach MEWS Alarm, Not reach MEWS Alarm, With 7 day mortality, Without 7 day mortality
62452653|NCT01502566|EXPERIMENTAL|Educational Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries. This intervention will be applied at the Brazilian National Vaccination Day
62452654|NCT01502566|NO_INTERVENTION|Control group|This group will receive no intervention
62631725|NCT02608385|EXPERIMENTAL|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
62631726|NCT04522557|EXPERIMENTAL|Experimental: Participants with breast cancer enrolled in grou|
62631727|NCT03574974|EXPERIMENTAL|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
62631728|NCT03574974|PLACEBO_COMPARATOR|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
62631729|NCT05359614|EXPERIMENTAL|GROUP A=CoolSculpting Elite and CoolTone|Group A: Study subjects will have a total of 1 or 2 bilateral CoolSculpting Elite sessions to the banana roll area 6 weeks prior to four EMMS treatment sessions during the study.
62631730|NCT05359614|ACTIVE_COMPARATOR|GROUP B CoolSculpting Elite alone|Group B: Study subjects will have a total of 1 or 2 bilateral CoolSculpting Elite sessions to the banana roll area.
62631731|NCT02949882|EXPERIMENTAL|Probiotic Intervention|130 Elderly participants receiving daily 65ml Yakult for 10 consecutive weeks.
62631732|NCT02949882|ACTIVE_COMPARATOR|Non-Probiotic Intervention|130 Elderly participants receiving daily 65 ml of Dairy Peach Drink (AH Basic) for 10 consecutive weeks.
62631733|NCT04552561|EXPERIMENTAL|My MS Toolkit|10 Participants asked to use My MS Toolkit and meet weekly with a study coach via telephone.
62631734|NCT05278741|EXPERIMENTAL|Surgery for unilateral breast reconstruction|"Patients treated in oncological surgery at the Center Georges-François Leclerc (CGFL) in Dijon for unilateral breast reconstruction after therapeutic total mastectomy.~Before the surgery, 2 questionnaires will be completed by patients : BREAST-Q and DASH. Also, the isokinetic test and EMG will be performed.~After the surgery, 2 questionnaires will be completed at one month, 3 months, 6 months and 12 months. The Two tests will be performed at 3 months, 6 months and 12 months after the surgery."
62631735|NCT02052427|EXPERIMENTAL|ADRCs|"Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:~* 0.8 x 10\^6 cells/kg body weight (not to exceed 80.0 x 10\^6 cells)~* Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
62631736|NCT02052427|PLACEBO_COMPARATOR|Placebo|"Placebo - Physiological Solution~* Inactive substance (Lactated Ringers + autologous blood)~* Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
62631737|NCT05433545||Adherence to specific physiotherapy exercises|
62631738|NCT06508203|EXPERIMENTAL|study group|20 patients will be treated by arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg) (study group).
62631739|NCT06508203|ACTIVE_COMPARATOR|control|20 patients will be treated by arthrocentesis with lactate ringer only (control group).
62631740|NCT02966847|EXPERIMENTAL|CBCT Acquisition|The anesthesia and surgery will take place in the usual way. The intervention consists in the CBCT acquisition after the initiation of single-lung ventilation, after the introduction of trocars.
62631741|NCT01265160||the group of Jiangzhuo prescription|
62631742|NCT01265160||the group of fenofibrate|
62631743|NCT01265160||the group of placebo|
62631744|NCT03586050|EXPERIMENTAL|Microwave Ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
62065193|NCT00610064|OTHER|A|Baseline neuroimaging
62065194|NCT00610064|OTHER|B|Neuroimaging during sacral neuromodulation
62286845|NCT03644160|EXPERIMENTAL|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity with a physiotherapist who has training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
62452655|NCT05493007|EXPERIMENTAL|Sandbag motion style acupuncture treatment|"The MSAT group will recieve 3 sessions of MSAT; on second, third, fourth day after hospitalization.~A trained doctor of Korean medicine with at least 3 years of clinical experience will conduct the MSAT.~The MSAT group will be also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
62631745|NCT05056402|EXPERIMENTAL|9-17y (0,6m)|Subjects who aged 9-17 years old would receive 2 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
62065195|NCT00803101|EXPERIMENTAL|Beriplex® P/N|
62631746|NCT05056402|EXPERIMENTAL|9-17y (0,1,6m)|Subjects who aged 9-17 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
62631747|NCT05056402|EXPERIMENTAL|18-26y (0,1,6m)|Subjects who aged 18-26 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
62631748|NCT05098327|ACTIVE_COMPARATOR|Prostate cancer on ADT receiving pioglitazone|Subjects will receive a 12-week supply of pioglitazone 30 mg dose 1 tab daily
62631749|NCT05098327|PLACEBO_COMPARATOR|Prostate cancer on ADT receiving placebo|Subjects will receive a 12 week supply of placebo pills containing cellulose
62631750|NCT05098327|NO_INTERVENTION|Prostate cancer not on ADT|No intervention will be done in this group
62631751|NCT02608567||Preserved LV GLS|"Patients will be compared according to the level of LV global longitudinal strain (GLS) as derived from transthoracic echocardiography and speckle tracking analysis.~Two groups will be compared regarding outcome: preserved LV GLS vs. reduced LV GLS. The definition use for reduced LV GLS will be \>-16%. An optimal threshold would also be calculated and derived from the pooled data."
62631752|NCT02608567||Reduced LV GLS|The definition use for reduced LV GLS will be \>-16%. An optimal threshold would also be calculated and derived from the pooled data.
62065196|NCT00803101|ACTIVE_COMPARATOR|Fresh frozen plasma|
62065197|NCT00744328|EXPERIMENTAL|Transdermal Estradiol|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains transdermal estradiol ranging in dose from 50 to 200 mcg/day
62065198|NCT00744328|ACTIVE_COMPARATOR|Sertraline|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The skin patch contains no active ingredients, though packaging is designed to match active patches. The capsules contain sertraline ranging in dose from 25 to 200mg/day
62065199|NCT00744328|PLACEBO_COMPARATOR|Placebo|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains no active ingredients, though packaging is designed to match active patches.
62065200|NCT01347385|EXPERIMENTAL|Barbed suture|
62065201|NCT01347385|ACTIVE_COMPARATOR|Traditional suture material|
62065202|NCT00810758|EXPERIMENTAL|PF-04878691|
62065203|NCT00280826|EXPERIMENTAL|Efalizumab|
62065204|NCT03383003|EXPERIMENTAL|High dose dual therapy|Esomeprezole (Nexium)40 mg tid. and amoxicillin (Amolin) 750 mg qid. for 14 days
62631753|NCT04080830||Acute ischemic stroke/transient ischemic attack (TIA) with AF|patients with Acute ischemic stroke/TIA and Atrial fibrillation (observational -no intervention)
62631754|NCT05717712|EXPERIMENTAL|Experimental Group|Multiple intratumoral injections of Ad-TD-nsIL12.
62631755|NCT05586997|ACTIVE_COMPARATOR|Bonded Rapid Maxillary Expansion|Bonded-hyrax with a 7mm expansion screw activated a full turn twice daily
62065205|NCT03383003|ACTIVE_COMPARATOR|Non-bismuth quadruple therapy|Esomeprezole (Nexium) 40 mg bid.,clarithromycin (Klaricid) 500 mg bid., amoxicillin (Amolin) 1 g bid. and metronidazole (Flagyl) 500 mg bid. for 7 days
62452656|NCT05493007|ACTIVE_COMPARATOR|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine
62452657|NCT00978900|ACTIVE_COMPARATOR|Acesulfame K|
62452658|NCT00978900|ACTIVE_COMPARATOR|Sucralose|
62452659|NCT00978900|ACTIVE_COMPARATOR|Aspartame|
62452660|NCT00978900|ACTIVE_COMPARATOR|Glucose|
62452661|NCT00978900|ACTIVE_COMPARATOR|Fructose|
62452662|NCT00978900|PLACEBO_COMPARATOR|Water|
62452663|NCT04114669|EXPERIMENTAL|Regret lottery|"Will receive a lottery incentive (regret lottery) for 6 months"
62452664|NCT04114669|PLACEBO_COMPARATOR|Control Condition|Will complete a total of 3 in-person study visits, approximately one hour each.
62452665|NCT05863546|SHAM_COMPARATOR|Control group|(control group) It consisted of 15 subjects who received a program of 'sham' US application, so that the US device was working but not delivering any output plus traditional PT treatment for carpal tunnel syndrome which included hot packs, tendon glide and nerve glide exercises, US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
62452666|NCT05863546|EXPERIMENTAL|Low-dose group|(low-dose group) It consisted of 15 subjects who received a program of US treatments that was administered to the carpal tunnel area with pulsed mode at a frequency of 1 MHz with an intensity of 0.25 W/cm2 and a duty cycle of 1:5 plus traditional treatment.
62452667|NCT05863546|EXPERIMENTAL|Mid-dose group|(Mid-dose group) It consisted of 15 subjects who received a program of US treatments that was administered to the carpal tunnel area with pulsed mode at a frequency of 1 MHz with an intensity of 0.5 W/cm2 and a duty cycle of 1:5 plus traditional treatment.
62631756|NCT05586997|EXPERIMENTAL|Bonded Rapid Maxillary Expansion and low-Level Laser|Bonded-hyrax with a 7mm expansion screw activated a full turn twice daily with 10 sessions of Indium Gallium Arsenide Phosphoride (940nm) semiconductor diode laser
62631757|NCT02600923|EXPERIMENTAL|Palbociclib + Letrozole|palbociclib and letrozole combination
62631758|NCT03335813|EXPERIMENTAL|brachytherapy with multichannel balloon applicator|6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
62631759|NCT00642005|EXPERIMENTAL|1|Humidified and warmed carbon dioxide laparoscopic insufflation.
62065206|NCT02392611|EXPERIMENTAL|Monotherapy: Alobresib 0.6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 0.6 mg to determine the MTD.
62286846|NCT03644160|NO_INTERVENTION|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
62065207|NCT02392611|EXPERIMENTAL|Monotherapy: Alobresib 1.4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 1.4 mg to determine the MTD.
62065208|NCT02392611|EXPERIMENTAL|Monotherapy: Alobresib 2 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 2 mg to determine the MTD.
62065209|NCT02392611|EXPERIMENTAL|Monotherapy: Alobresib 3 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 3 mg to determine the MTD.
62065210|NCT02392611|EXPERIMENTAL|Monotherapy: Alobresib 4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 4 mg to determine the MTD.
62065211|NCT02392611|EXPERIMENTAL|Monotherapy: Alobresib 6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 6 mg to determine the MTD.
62286847|NCT05504200|EXPERIMENTAL|Bladder and Pelvic Floor Muscle Training|Participants randomised to the intervention group will complete an 8-week bladder and PFMT programme, both at the LSCIC and at home. They will be invited to 3 face-to-face follow up appointments over the 8-weeks, where they will meet with a physiotherapist to check their technique and monitor their progress. At home participants will receive a daily text reminder to complete their PFM training, they will also receive a weekly phone call from a member of the research team who will check how they are managing and whether they have any questions. At the end of the programme, participants will be asked to repeat the questionnaires and have their pelvic floor re-assessed. Following this, they will complete the urodynamic investigation with tSCS.
62065212|NCT02392611|EXPERIMENTAL|Combination Therapy: Alobresib 2 mg + Exemestane|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with exemestane 25 mg.
62065213|NCT02392611|EXPERIMENTAL|Combination Therapy: Alobresib 2 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with fulvestrant 500 mg.
62270196|NCT02423915|EXPERIMENTAL|Phase I: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Mesna administered on Day -8 immediately following completion of the Fludarabine.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Three (3) participants treated at cell dose level 1: 1 x 10\^6/kg fucosylated T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD transplant on Day 0.~Mycophenolate 15 mg/kg by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days."
62270197|NCT02423915|EXPERIMENTAL|Phase I: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Ten (10) participants treated with non-fucosylated T-reg cells at dose level 2: 1 x 10\^7/kg T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days."
62631760|NCT00642005|PLACEBO_COMPARATOR|2|Cold and dry carbon dioxide laparoscopic insufflation.
62065214|NCT02392611|EXPERIMENTAL|Combination Therapy: Alobresib 3 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 3 mg in combination with fulvestrant 500 mg.
62088174|NCT04596527|EXPERIMENTAL|18F-FMPP PET MPI (following off-study 13N-ammonia PET MPI)|"Imaging Procedure: 18F-FMPP PET Day 1: All subjects will receive rest and stress IV boluses of 18F-FMPP injections in a large peripheral vein. The dosages of 18F-FMPP Injection administered at rest and during stress conditions are 2.5 mCi and 6.0 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor.~Imaging Procedure: 13N-Ammonia PET All subjects will receive 2 IV boluses of 13N-ammonia Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of 13N-ammonia Injection administered at rest and during stress conditions is 20mCi and 20 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor."
62065215|NCT02542839|EXPERIMENTAL|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
62065216|NCT02542839|SHAM_COMPARATOR|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
62065217|NCT03554993|EXPERIMENTAL|CC-99677 Under Fasted Conditions|CC-99677 Under Fasted Conditions
62065218|NCT03554993|EXPERIMENTAL|Placebo|Placebo under fasted conditions
62065219|NCT03554993|EXPERIMENTAL|CC-99677 Under Fed Conditions|CC-99677 Under Fed Conditions
62065220|NCT04240990|EXPERIMENTAL|Prospective cohort|Children included in the cohort will all be in the same arm. The patients will benefit from standard-of-care TB diagnosis with additional diagnostic methods.
62065221|NCT02597790||Group A (HIV/HCV coinfected)|
62065222|NCT02597790||Group B (HIV monoinfected)|
62270198|NCT02423915|EXPERIMENTAL|Phase II: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Fucosylated T-reg cells at dose level 2: 1 x 10\^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days."
62452668|NCT05863546|EXPERIMENTAL|High-dose group|(high-dose group) It consisted of 15 subjects who received a program of the same US equipment that was set at pulsed mode at a frequency of 1 MHz, intensity of 1.0W/ cm2 and a duty cycle of 1:5 plus traditional treatment.
62452669|NCT00237549|EXPERIMENTAL|Intervention|The 334 general practices in Denmark, United Kingdom and the Netherlands have been randomised to screening for diabetes followed by routine care (RC group) according to national guidelines, or screening followed by multifactorial treatment (IT group).
62270199|NCT02423915|EXPERIMENTAL|Phase II: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Non-Fucosylated T-reg cells at dose level 2: 1 x 10\^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days."
62270200|NCT06391671||Overweight/obese|BMI-Z \> 25
62270201|NCT06391671||Normal weight|BMI-Z \< 25
62270202|NCT05034965|ACTIVE_COMPARATOR|deep injection of hyaluronic acid fillers|Each female will receive filler injection deep to the muscle (supraperiosteal) on one side of the face.
62270203|NCT05034965|ACTIVE_COMPARATOR|superficial injection of hyaluronic acid fillers|Each female will receive filler injection at superficial level to the muscle (subcutaneous) on the contralateral side(same dose and same site).
62270204|NCT06110130|ACTIVE_COMPARATOR|Placebo|Placebo 10 mg orally daily
62631761|NCT00550797|EXPERIMENTAL|No.1 ASM8 (oligonucleotide)|TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation
62270205|NCT06110130|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin 10 mg orally daily
62631762|NCT00550797|PLACEBO_COMPARATOR|Phosphate Buffer solution|Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation
62631763|NCT00998712||1|Black women in the third trimester of a pregnancy complicated by gestational diabetes.
62631764|NCT00998712||2|Black women in the third trimester of a normal, uncomplicated pregnancy.
62631765|NCT00998712||3|White women in the third trimester of a pregnancy complicated by gestational diabetes.
62270206|NCT00264706|OTHER|Participant|Internal control study
62270207|NCT01259609|EXPERIMENTAL|Diabetic Macular Edema Group|
62270208|NCT01259609|ACTIVE_COMPARATOR|Epiretinal Membrane Group|
62270209|NCT01259609|NO_INTERVENTION|Healthy Control|
62631766|NCT00998712||4|White women in the third trimester of a normal, uncomplicated pregnancy.
62631767|NCT06128421|EXPERIMENTAL|Trail Group|30 patients will receive dietary counseling and individual nutrition support treatment based on Oral nutrition supplements and supplemented by parenteral nutrition.
62631768|NCT06128421|NO_INTERVENTION|Control Group|30 patients will receive standard care food provided by the hospital kitchen according to their ability and desire, standard care food provided by the hospital kitchen.
62631769|NCT06014177|OTHER|Control|"After enrollment but before the start of their clinical visit, participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor.~At the end of the visit, the participant will complete the Patient Control Exit Survey while the provider will complete the Provider Control Exit Survey.~These participants will not receive STIckER training."
62065223|NCT05637411||Retrospective cohort|The clinical data, socioeconomical data and environmental exposure data from 800.000 asthmatic patients attended in our region from 2007 to 2021 will be analysed to train and validate a risk predictive model for exacerbation (defined as emergency visits)
62065224|NCT05637411||Prospective cohort|The same inclusion/exclusion criteria were applied prospectively. This is an external validation cohort.
62065225|NCT02734108|EXPERIMENTAL|Transcranial direct current stimulation|10 patients will be stimulated twice a day for two weeks or 20 sessions. 2 milli ampere stimulation will be applied for 25 min respecting a period of four hours between sessions.
62065226|NCT02166957||Long disruption > 5cm +/- loss of SES|
62065227|NCT02166957||Short disruption < 5cm|
62065228|NCT01279733||Microarray Analysis|
62065229|NCT04031521||Sickle cell pain crisis|
62065230|NCT04031521||Sickle cell steady-state|
62065231|NCT04712201|EXPERIMENTAL|En bloc|En bloc transurethral resection of the bladder
62065232|NCT04712201|ACTIVE_COMPARATOR|Conventional|Conventional transurethral resection of the bladder
62270210|NCT01733472|PLACEBO_COMPARATOR|RA-arm|RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
62631770|NCT06014177|EXPERIMENTAL|STIckER|"After enrollment but before the start of their clinical visit, participants assigned to a provider in the intervention arm will scan a QR code using their personal mobile phone at the start of their ED visit. If they do not have a mobile phone present, a secure password-protected tablet will be provided by the research staff. This will lead them to go through the STIckER decision aid modules. After completing the modules, participants will show the final outcome to their ED provider which may facilitate an SDM conversation about STI testing.~At the end of the visit, the participant will complete the Patient Intervention Exit Survey while the provider will complete the Provider Intervention Exit Survey."
62631771|NCT03146338|EXPERIMENTAL|Magnesium-rich mineral water (Rozana)|Patients in this arm must take 1.5 Liter by day of a mineral water rich in magnesium (Rozana) during the treatment by anti-EGFR. The mineral water is provided.
62631772|NCT03146338|NO_INTERVENTION|Standard|Patients will have the usual care (oral advice only according to the habits of the investigator)
62065233|NCT04626973|EXPERIMENTAL|Intensive-targeting group|
62065234|NCT04626973|ACTIVE_COMPARATOR|Conventional-targeting group|
62065235|NCT00988221|EXPERIMENTAL|Tocilizumab 10 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
62270211|NCT01733472|EXPERIMENTAL|GA-arm, remifentanil|GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
62065236|NCT00988221|EXPERIMENTAL|Tocilizumab 8 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
62065237|NCT00988221|EXPERIMENTAL|Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
62065238|NCT00988221|PLACEBO_COMPARATOR|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks.
62065239|NCT01038258|OTHER|No arms|No arms
62270212|NCT03106038|EXPERIMENTAL|Nerindocianine for Injection|One Arm: Nerindocianine for Injection (Initial dosing cohort: 0.06 mg/kg body weight); solution, intravenous, one time administration during surgery. the study has only one arm.
62270213|NCT03289650|ACTIVE_COMPARATOR|Standard of care tacrolimus twice-daily|
62065240|NCT06559943|PLACEBO_COMPARATOR|Traditional Physiotherapy + Placebo Kinesio Tape|Following a total of 15 sessions of electro-physical agent treatment, exercise training, 5 days a week for 3 weeks, each session lasting 45 minutes, and traditional physiotherapy 2 days a week for 3 weeks, a total of 6 times applied to the trapezius muscle in the neck area with 0% tension. Kinesiotape will be applied in the form of (I). The tape will be applied twice a week in total, staying for 3 days and leaving one day free after each application.
62270214|NCT03289650|ACTIVE_COMPARATOR|Extended-release tacrolimus once-daily|
62270215|NCT06116825|EXPERIMENTAL|Experiment group|In the experimental group, students from grades three to six in four primary schools in Chiayi County participated. Participating school children are taught the correct method of brushing their teeth, and flossing is also taught in the upper grades. The experimental group used toothpaste containing 1,450 ppm fluoride and asked students to use it at least twice a day, one of which was to clean their teeth before bed. During the pre-test and 4-week post-test, the plaque control index (Plaque Control Record; PCR) was checked and a self-administered questionnaire was filled out.
62631773|NCT02267070|EXPERIMENTAL|Cognitive Training and Exercise|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
62270216|NCT06116825|ACTIVE_COMPARATOR|Control group|In the control group, students from grades three to six in four primary schools in Chiayi County participated. All participating children receive instruction on proper tooth brushing techniques, with flossing included in higher grades. Schoolchildren in the control group were given toothpaste containing 1,000 ppm fluoride and were asked to use it at least twice a day, including once to clean their teeth before bed. During the pre-test and 4-week post-test, the plaque control index (Plaque Control Record; PCR) was checked and a self-administered questionnaire was filled out.
62270217|NCT02025335||high CMV ELISPOT results|high spot counts in ELISPOT
62631774|NCT02267070|ACTIVE_COMPARATOR|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
62631775|NCT00610181||Breast MRI|Magnetic resonance imaging (MRI) of breast for patients with invasive lobular carcinoma of the breast.
62270218|NCT02025335||low CMV ELISPOT results|low spot counts in ELISPOT
62270219|NCT04519892|EXPERIMENTAL|Receiving PDRC and coach guidance|Intervention group: Receiving PDRC + coach guidance.
62270220|NCT04519892|ACTIVE_COMPARATOR|Receiving PDRC without coach guidance|Control group: Receiving PDRC only.
62270221|NCT03868332||inflammatory bowel diease patients|
62270222|NCT03868332||normal indivuals|
62631776|NCT01341093|ACTIVE_COMPARATOR|usual care|
62631777|NCT01341093|EXPERIMENTAL|educational program+telephone follow up|
62270223|NCT02796846||CPAP prescription group|Patients with a CPAP prescription (both compliant and noncompliant)
62270224|NCT02796846||Without a CPAP prescription|Patients without a CPAP prescription to satisfy our primary goals/objectives.
62631778|NCT04002726|ACTIVE_COMPARATOR|Group Aa|Allocated to do the app-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
62270225|NCT01783327|EXPERIMENTAL|Teens-Connect|The Teens-Connect Program is an internet-based program that combines Managing Diabetes and TEENCOPE.
62270226|NCT01783327|ACTIVE_COMPARATOR|Planet D|Planet D is an internet program developed by the American Diabetes Association for children and adolescents with diabetes.
62631779|NCT04002726|ACTIVE_COMPARATOR|Group As|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
62631780|NCT04002726|ACTIVE_COMPARATOR|Group Sa|Allocated to do the slide-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
62631781|NCT04002726|ACTIVE_COMPARATOR|Group Ss|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
62270227|NCT05204264|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Intervention based on Acceptance and Commitment Therapy that promotes the acceptance and defusion of unwanted internal experiences and commitment to values of the personal life project.
62270228|NCT05204264|EXPERIMENTAL|Mindfulness-based Emotional Regulation (MER)|Intervention inspired in the Mindfulness-Based Stress Reduction program that fosters the development of a behavioral pattern made up of conscious responses in order to decrease reactivity to stressors.
62270229|NCT05284760|EXPERIMENTAL|Part A, Sequence 1: Treatment A + Treatment B + Treatment C|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270230|NCT05284760|EXPERIMENTAL|Part A, Sequence 2: Treatment A + Treatment C + Treatment B|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62286848|NCT05504200|NO_INTERVENTION|Control|Participants randomised to the control group will continue with their usual care for 8-weeks. They will return to repeat their baseline questionnaires and have their pelvic floor re-assessed. Finally, they will complete tSCS bladder filling and emptying cycles with urodynamics.
62631782|NCT05701540|EXPERIMENTAL|Tegoprazan 50mg|Tegoprazan 50mg, once daily, oral administration for two weeks
62631783|NCT05701540|ACTIVE_COMPARATOR|Esomeprazole 40mg or 20mg|"1. In case of ERD patients: Esomeprazole 40mg, qd, oral administration for two weeks~2. In case of NERD patients: Esomeprazole 20mg, qd, oral administration for two weeks"
62065241|NCT06559943|EXPERIMENTAL|Traditional Physiotherapy + Kinesio Tape Treatment with Inhibition Method|"Group 2 will receive a total of 15 sessions of electrophysical agent treatment, 45 minutes per session, 5 days a week, for 3 weeks, and kinesiotape treatment with inhibition method in addition to exercise training. Electro-physical agent therapy:~Intermittent ultrasound at 1.5 w/cm2 for 8 minutes, transcutaneous electrical nerve stimulation, 20 minutes for the trapezius muscle, and hot pack application to the neck area will be applied. Neck isometric exercises, pulley exercise and codman exercise will be applied. Kinesiotape will be applied with the inhibition technique a total of 6 times, following traditional physiotherapy application, 2 days a week for 3 weeks."
62065242|NCT04859439|EXPERIMENTAL|Mild Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
62631784|NCT00672568|EXPERIMENTAL|1|4975
62631785|NCT00672568|EXPERIMENTAL|2|4975
62065243|NCT04859439|EXPERIMENTAL|Moderate Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
62065244|NCT04859439|EXPERIMENTAL|Severe Renal function|Subjects will receive a single dose of 100 mg DBPR108
62065245|NCT04859439|EXPERIMENTAL|Kidney failure|Subjects will receive a single dose of 100 mg DBPR108
62065246|NCT04859439|EXPERIMENTAL|Normal Renal function|Subjects will receive a single dose of 100 mg DBPR108
62065247|NCT01639105|EXPERIMENTAL|treated half of the scar|
62065248|NCT01639105|NO_INTERVENTION|untreated half of the scar|
62631786|NCT00672568|EXPERIMENTAL|3|4975
62631787|NCT00672568|PLACEBO_COMPARATOR|4|Placebo
62631788|NCT00657800|EXPERIMENTAL|Group 1|Behavioral - Intensified coordinated inpatient diabetes education program (IDEP)
62631789|NCT00657800|NO_INTERVENTION|Group 2|Diabetes education as is typically provided by clinical staff
62631790|NCT02371902|ACTIVE_COMPARATOR|ESWT Group|Focused Extracorporeal Shock Wave Therapy: 3 sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2
62631791|NCT02371902|ACTIVE_COMPARATOR|Cryo-US Group|Therapeutic cryoultrasound: 12 sessions was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each.
62631792|NCT05920499|EXPERIMENTAL|Intervention group|The INTEGO practices (INTEGO is a GP morbidity registry in Flanders Belgium) that will be assigned to the intervention group will receive an extended electronic feedback report with multiple components, directly implemented in their EHR (electronic health record), on the pneumococcal vaccination coverage in adults at risk in their practice ('push system'). There will be a direct connection between the EHR of the practice and a SAS visual analytics tool in the Healthdata environment (single-sign-on connection), that will show the extended feedback. This report will be available at baseline and updated every two months based on the current situation.
62631793|NCT05920499|ACTIVE_COMPARATOR|Control group|Every GP center assigned to the control group will only have access to the clinical AUDIT to identify patients that may benefit from a pneumococcal vaccination. GP centers in the control group will not receive an extended feedback report at baseline and every 2 months afterwards.
62631794|NCT00028262|EXPERIMENTAL|Drug: Cystagon and N-acetylcysteine|
62631795|NCT01001520|PLACEBO_COMPARATOR|Placebo (Sugar Pill)|11-day placebo-controlled medication period
62631796|NCT01001520|ACTIVE_COMPARATOR|Tolcapone|11-day phase, tapered dosing scheduled (Day 1: 100mg three times daily, Days 2-8: 200mg three times daily, Day 9: 200mg twice daily, Day 10: 200mg once daily, Day 11: 100mg once daily); oral dosing; medication is encapsulated by the University of Pennsylvania's Investigational Drug Service (IDS)
62631797|NCT04020419|EXPERIMENTAL|Pediaberry group|PediaBerry™ is a proprietary blend powdered berry extracts
62065249|NCT02256644||Million Veteran Program (MVP) participants|Veterans who are currently enrolled in the Million Veteran Program.
62065250|NCT00345163|EXPERIMENTAL|1|
62065251|NCT00345163|EXPERIMENTAL|2|
62065252|NCT04011332|EXPERIMENTAL|Intervention Group|
62065253|NCT04011332|NO_INTERVENTION|Control Group|
62065254|NCT01047644|EXPERIMENTAL|3-month flushing schedule|3-month port-flushing schedule
62065255|NCT03349268|ACTIVE_COMPARATOR|Pulsed xenon ultraviolet light (PX-UV) Device Emitting Germicidal UV|Pulsed xenon ultraviolet light (PX-UV) Device to be used to disinfect rooms following post-discharge terminal cleaning
62065256|NCT03349268|SHAM_COMPARATOR|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
62065257|NCT01462162||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.
62065258|NCT06000982|EXPERIMENTAL|PTCy-40|Patients receive 40mg/kg PTCY (day+3 and +4) with tacrolimus from day+5 and low-dose ATG of 2,5mg/kg 72 hours after documentation neutrophil engraftment.
62065259|NCT06000982|ACTIVE_COMPARATOR|PTCy-50|Patients receive 50mg/kg PTCY (day+3 and +4) with tacrolimus from day+5 and low-dose ATG of 2,5mg/kg 72 hours after documentation neutrophil engraftment.
62065260|NCT02205801|ACTIVE_COMPARATOR|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
62065261|NCT02205801|PLACEBO_COMPARATOR|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
62065262|NCT02205801|ACTIVE_COMPARATOR|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
62631798|NCT04020419|PLACEBO_COMPARATOR|Placebo|Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).
62065263|NCT02205801|PLACEBO_COMPARATOR|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
62065264|NCT04247399|EXPERIMENTAL|Simulation-based learning + clinical training|
62065265|NCT04247399|NO_INTERVENTION|Clinical training|
62065266|NCT00105586|EXPERIMENTAL|Escitalopram (1)|Escitalopram
62270231|NCT05284760|EXPERIMENTAL|Part A, Sequence 3: Treatment B + Treatment A + Treatment C|Soticlestat T3 mini-tablets 300 milligram (mg), orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270232|NCT05284760|EXPERIMENTAL|Part A, Sequence 4: Treatment B + Treatment C + Treatment A|Soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270233|NCT05284760|EXPERIMENTAL|Part A, Sequence 5: Treatment C + Treatment A + Treatment B|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62631799|NCT01405495||PTSD group|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
62270234|NCT05284760|EXPERIMENTAL|Part A, Sequence 6: Treatment C + Treatment B + Treatment A|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T3 mini-tablets 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270235|NCT05284760|EXPERIMENTAL|Part B, Sequence 1: Treatment D + Treatment E + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270236|NCT05284760|EXPERIMENTAL|Part B, Sequence 2: Treatment D + Treatment F + Treatment E|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270237|NCT05284760|EXPERIMENTAL|Part B, Sequence 3: Treatment E + Treatment D + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62631800|NCT01405495||Exposed without PTSD|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
62270238|NCT05284760|EXPERIMENTAL|Part B, Sequence 4: Treatment E + Treatment F + Treatment D|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62286849|NCT04915196||Ferrous Sulphate|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Ferrous Sulphate for iron replacement
62631801|NCT01405495||Healthy Controls|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
62631802|NCT03145753|EXPERIMENTAL|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
62065267|NCT00105586|PLACEBO_COMPARATOR|Placebo (2)|Placebo
62270239|NCT05284760|EXPERIMENTAL|Part B, Sequence 5: Treatment F + Treatment D + Treatment E|Soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270240|NCT05284760|EXPERIMENTAL|Part B, Sequence 3: Treatment F + Treatment E + Treatment D|Soticlestat T4 300 mg tablets, crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
62270241|NCT05135650|EXPERIMENTAL|Prevention (Sotrovimab)|Patients receive sotrovimab IV over 30 minutes within 1-7 days prior to the start of pre-transplant conditioning. Patients also undergo blood and nasal swab sample collection throughout the trial.
62631803|NCT03145753|ACTIVE_COMPARATOR|HIV/HCV Education|In this arm only education should be provided
62631804|NCT01307891|EXPERIMENTAL|Abraxane + Tigatuzumab|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.
62270242|NCT00916253|EXPERIMENTAL|Modafinil First|Treatment by Modafinil during first condition then placebo during second condition
62270243|NCT00916253|EXPERIMENTAL|Placebo First|Treatment by Placebo during first condition then Modafinil during second condition
62270244|NCT00916253|NO_INTERVENTION|H|Healthy Volunteers
62270245|NCT06499987|ACTIVE_COMPARATOR|resection anastomosis|resection of the stenotic part of the trachea and then doing re anastomosis
62631805|NCT01307891|EXPERIMENTAL|Abraxane alone|Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.
62631806|NCT00526448|EXPERIMENTAL|1|Peginterferon alfa-2a 180 mcg/week + ribavirin 2000 mg/day + epoetin beta 450 UI/week
62631807|NCT00526448|ACTIVE_COMPARATOR|2|Peginterferon alfa-2a 180 mcg/week + ribavirin 1000-1200 mg/day
62631808|NCT01897051|EXPERIMENTAL|Combination therapy|Rifaximin(normix®)+nonselective beta-blocker(Propranolol)
62631809|NCT01897051|PLACEBO_COMPARATOR|Monotherapy|nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)
62631810|NCT03566277|EXPERIMENTAL|Single-arm trial|All participants will undergo each of three conditions during the study.
62631811|NCT03197662|EXPERIMENTAL|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
62631812|NCT03197662|PLACEBO_COMPARATOR|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
62270246|NCT06499987|ACTIVE_COMPARATOR|long term stenting with Montgomery tube|application of T shaped Montgomery tube for 6 months
62270247|NCT06076915|EXPERIMENTAL|G1 (Group 1)|"Experimental: Exergame Training, then Usual Daily Work~Participants of G1 first received the Exergame Training (integrated into their working schedule). After 6 weeks, they no longer received exergame training but followed their normal work schedule for another 6 weeks."
62270248|NCT06076915|EXPERIMENTAL|G2 (Group 2)|"Experimental: Usual Training Work, then Exergame Training~Participants of G2 first followed their normal work schedule for 6 weeks and then received the Exergame training for another 6 weeks."
62270249|NCT04791046||By CDSS (MedicBK) Analysis|
62270250|NCT04791046||General practice|
62270251|NCT00287625|ACTIVE_COMPARATOR|1|PRP
62270252|NCT00287625|NO_INTERVENTION|2|control
62270253|NCT05822687|EXPERIMENTAL|Education|Participants will complete an educational digital module and no skills-based digital modules.
62270254|NCT05822687|EXPERIMENTAL|Education + Reappraisal|Participants will complete an educational digital module and a skills-based digital module that teaches reappraisal coping.
62065268|NCT05134662|EXPERIMENTAL|ALT-801 Dose Level 1|
62270255|NCT05822687|EXPERIMENTAL|Education + Distraction|Participants will complete an educational digital module and a skills-based digital module that teaches distraction coping.
62270256|NCT05822687|EXPERIMENTAL|Education + Relaxation|Participants will complete an educational digital module and a skills-based digital module that teaches relaxation coping.
62270257|NCT05822687|EXPERIMENTAL|Education + Reappraisal + Distraction|Participants will complete an educational digital module and two skills-based digital modules, one that teaches reappraisal coping and one that teaches distraction coping.
62270258|NCT05822687|EXPERIMENTAL|Education + Reappraisal + Relaxation|Participants will complete an educational digital module and two skills-based digital modules, one that teaches reappraisal coping and one that teaches relaxation coping.
62270259|NCT05822687|EXPERIMENTAL|Education + Distraction + Relaxation|Participants will complete an educational digital module and two skills-based digital modules, one that teaches distraction coping and one that teaches relaxation coping.
62270260|NCT05822687|EXPERIMENTAL|Education + Reappraisal + Distraction + Relaxation|Participants will complete an educational digital module and three skills-based digital modules, one that teaches reappraisal coping, one that teaches distraction coping, and one that teaches relaxation coping.
62270261|NCT01052298|EXPERIMENTAL|Arm 1|
62065269|NCT05134662|EXPERIMENTAL|ALT-801 Dose Level 2|
62065270|NCT05134662|EXPERIMENTAL|ALT-801 Dose Level 3|
62065271|NCT05134662|PLACEBO_COMPARATOR|Placebo|
62270262|NCT01052298|EXPERIMENTAL|Arm 2|
62270263|NCT01052298|EXPERIMENTAL|Arm 3|
62270264|NCT01052298|PLACEBO_COMPARATOR|Arm 4|
62270265|NCT03354754|EXPERIMENTAL|LYS228|IV infusion every 6 hours for at least 5 days
62270266|NCT03354754|ACTIVE_COMPARATOR|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
62270267|NCT03346460|EXPERIMENTAL|Tongue scraper group (Group 1)|Fifteen patients will be included in this group. Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
62270268|NCT03346460|EXPERIMENTAL|aPDT group (Group 2)|Fifteen patients will be included in this group. One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
62065272|NCT06624943|NO_INTERVENTION|Control|Continue current treatment with either intermediate- and short-acting human insulin, or pre-mixed insulin, both via needle and syringe
62065273|NCT06624943|EXPERIMENTAL|Intervention|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
62065274|NCT06283797|EXPERIMENTAL|Automated insulin delivery|Participants will use an automated insulin delivery system with study CGM
62065275|NCT06283797|ACTIVE_COMPARATOR|Conventional insulin therapy|Participants will use multiple insulin daily insulin injections or insulin pump with study CGM
62065276|NCT05025501|EXPERIMENTAL|Intervention group|"Subjects in this group will receive the Famliy based Executive Function Training  program in aiming to reduce ADHD symptoms and improve the executive function."
62065277|NCT05025501|NO_INTERVENTION|Waiting group|"Subjects in this group will not receive the Famliy based Executive Function Training  program during the study period."
62065278|NCT00930943|EXPERIMENTAL|Oxymorphone ER 40 mg fed|Participants received 40 mg oxymorphone ER after a high-fat meal of approximately 1,010 kCal
62065279|NCT00930943|EXPERIMENTAL|Oxymorphone ER 40 mg fasting|Participants received 40 mg oxymorphone ER after fasting for 8-12 hours
62270269|NCT03346460|EXPERIMENTAL|Tongue scraper and aPDT (Group 3)|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
62270270|NCT04448587|EXPERIMENTAL|Sitagliptin|
62270271|NCT02706730|EXPERIMENTAL|OTO-104|12 mg dexamethasone
62270272|NCT04422249|EXPERIMENTAL|laparoscopic middle hepatic vein guidance hemihepatectomy|In theory, the advantages of anatomical hemihepatectomy guided by middle hepatic vein are as follows: 1) correctly guiding the transecting plane of the liver parenchyma can reduce the cross-sectional area of the liver and avoid damaging the vascular ducts of the pre-cut liver. so as to reduce the residue of necrotic tissue without blood supply and reduce the occurrence of postoperative complications. 2) active anatomy and exposure of hepatic vein can avoid uncontrollable bleeding after passive injury of hepatic vein, and laparoscopic anatomy has obvious advantage in exposing hepatic vein. 3) it may reduce the early recurrence rate of hepatocellular carcinoma after operation.
62270273|NCT04422249|ACTIVE_COMPARATOR|laparoscopic traditional anatomic hemihepatectomy|According to textbooks and the views of some scholars at present, traditional anatomical hepatectomy (non-hepatic vein-guided anatomical hepatectomy) has the following advantages: 1) avoiding exposure of hepatic vein can reduce the probability of injury to the trunk of hepatic vein, thus reduce the risk of massive bleeding during operation; 2) the difficulty of operation is relatively low, and a better short-term and long-term effect can be obtained.
62270274|NCT02899039|EXPERIMENTAL|IgG4-related disease|Subjects suffering from IgG4-related disease
62270275|NCT02899039|ACTIVE_COMPARATOR|Sjögren syndrome|Subjects suffering from Sjôgren syndrome
62270276|NCT02899039|ACTIVE_COMPARATOR|Healthy controls|Healthy subjects
62270277|NCT03615183|EXPERIMENTAL|Panel A: 10 mg MK-8527|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
62270278|NCT03615183|EXPERIMENTAL|Panel B: 3 mg MK-8527|Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
62270279|NCT03615183|EXPERIMENTAL|Panel C: 1 mg MK-8527|Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
62270280|NCT03615183|EXPERIMENTAL|Panel D: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
62270281|NCT03615183|EXPERIMENTAL|Panel E: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
62270282|NCT01797211|EXPERIMENTAL|diet group A|Mediterranean diet+olive oil
62270283|NCT01797211|EXPERIMENTAL|Diet Group B|Mediterranean diet+not-fried fish
62270284|NCT01797211|EXPERIMENTAL|Diet Group C|Mediterranean diet+nuts
62065280|NCT05829291|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62270285|NCT02236052|EXPERIMENTAL|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
62065281|NCT05741905|EXPERIMENTAL|Levofloxacin group|Levofloxacin 200mg twice per day is administrated.
62065282|NCT05741905|PLACEBO_COMPARATOR|Levofloxacin simulant group|Levofloxacin simulant 200mg twice per day is administrated.
62270286|NCT02236052|EXPERIMENTAL|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
62270287|NCT02236052|EXPERIMENTAL|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
62270288|NCT02236052|EXPERIMENTAL|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
62270289|NCT02236052|EXPERIMENTAL|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
62065283|NCT04989985|ACTIVE_COMPARATOR|Active Comparator|"SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
62065284|NCT04989985|EXPERIMENTAL|Experimental|"Sinitlimab + SOX； SOX: Oxaliplatin+S-1~Sinitlimab: 200mg, ivdrip, d1, q3w;~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
62270290|NCT02236052|PLACEBO_COMPARATOR|Placebo|A single dose of Placebo
62270291|NCT01778361||HIV positive|
62270292|NCT01778361||HIV negative|
62065285|NCT03899961|ACTIVE_COMPARATOR|Oxytocin|Oxytocin 2.5 U i.v.
62065286|NCT03899961|EXPERIMENTAL|Carbetocin|Carbetocin 100 µg i.v.
62270293|NCT02355561|EXPERIMENTAL|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram \[mg\] formulation 1 \[reference\] under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg formulation 2 \[test\] under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg formulation 2 under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62270294|NCT02355561|EXPERIMENTAL|Sequence 2 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62270295|NCT02355561|EXPERIMENTAL|Sequence 3 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62452670|NCT01860248|EXPERIMENTAL|Vapocoolant spray|Vapocoolant is administered in 20 centimeters distance for 20 seconds to the patients as anesthetic before ABG.
62270296|NCT02355561|EXPERIMENTAL|Sequence 4 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62631813|NCT03671655|EXPERIMENTAL|Drug-eluting stent|Drug-eluting stent is nitinol stent coated with Paclitaxel drug Other Names: Zilver PTX stent Zilver Paclitaxel stent
62065287|NCT01472562|EXPERIMENTAL|all patients|"Induction Phase (week 1 - 48):~* Lenalidomide will be given at 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~* Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance Phase (week 49 - progression of disease):~* Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.~* Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
62631814|NCT03671655|ACTIVE_COMPARATOR|Bare metal stent|Bare metal stentis Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
62631815|NCT02111174|EXPERIMENTAL|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
62631816|NCT02111174|SHAM_COMPARATOR|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
62270297|NCT02355561|EXPERIMENTAL|Sequence 5 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62631817|NCT00777868|EXPERIMENTAL|1|
62631818|NCT00777868|EXPERIMENTAL|2|
62631819|NCT00777868|EXPERIMENTAL|3|
62631820|NCT00777868|PLACEBO_COMPARATOR|4|
62065288|NCT01391325|OTHER|Allopurinol|Treatment.
62065289|NCT02088203|EXPERIMENTAL|Single Dose Sequence 1|Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.
62065290|NCT02088203|EXPERIMENTAL|Single Dose Sequence 2|Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.
62270298|NCT02355561|EXPERIMENTAL|Sequence 6 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62286850|NCT04915196||Liposomally-bound Iron|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Liposomally-bound Iron for iron replacement
62286851|NCT06287879|EXPERIMENTAL|Roxadustat|Subjects were treated with Roxadustat for renal anemia
62631821|NCT04283812|EXPERIMENTAL|D1 Stereotactic System Assessment|Participants in the clinical study will consist of subjects approved to undergo deep brain stimulation surgery for the treatment of a neurological disorder at Mayo Clinic. Subjects will have a Key secured to their skull for attachment of an MRI-compatible localizer box or D1 stereotactic frame. 3D Euclidian distance error(s), trajectory accuracy(s), operating room time, and comfort level of the system will be assessed.
62631822|NCT03866421||Kidney transplanted patients|"Number of patients: 16~Patients on the waiting list for kidney transplantation with a living donor. The patients are screened with an OGTT before participation in the study, thereby excluding patients with diabetes mellitus.~Patients in this group are examined three times (baseline (before transplantation) and after three and twelve months after transplantation).~Same interventions as in the control Group.~Including/ Exclusion criteria are listed under the section Eligibility"
62286852|NCT06287879|ACTIVE_COMPARATOR|EPO|Subjects were treated with EPO for renal anemia
62631823|NCT03866421||Control group|"Number of patients: 16~Participants in this group are matched on age and BMI according to the kidney transplanted patients.~Participants are screened with an OGTT before participation since only persons with normal glucose tolerance may be included in the study.~Furthermore, participants have to have normal kidney function.~Participants in this group are only examined once. Same interventions as in the kidney transplanted patient group"
62065291|NCT02088203|EXPERIMENTAL|Single Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.
62631824|NCT00652704|EXPERIMENTAL|A|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions
62631825|NCT00652704|ACTIVE_COMPARATOR|B|Subjects received the reference product, Monodox (Oclassen) under fed conditions
62631826|NCT00652704|EXPERIMENTAL|C|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions
62631827|NCT03654703|EXPERIMENTAL|Cyclophophamide|Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.
62631828|NCT03654703|EXPERIMENTAL|Placebo|5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline
62631829|NCT03822260||Sur1/ Trpm 4 acitivities at SAH|only after collecting sample,
62065292|NCT02088203|EXPERIMENTAL|Single Dose Sequence 4|Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.
62631830|NCT05288946|EXPERIMENTAL|local segmental control and closed kinetic chain|the patients will receive local segmental control and closed kinetic chain three times a week for four weeks
62631831|NCT05288946|EXPERIMENTAL|local segmental control and open kinetic chain|the patients will receive local segmental control and open kinetic chain three times a week for four weeks
62065293|NCT02088203|EXPERIMENTAL|Single Dose Sequence 5|Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.
62065294|NCT02088203|EXPERIMENTAL|Single Dose Sequence 6|Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.
62065295|NCT02088203|EXPERIMENTAL|Single Dose Sequence 7|Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.
62065296|NCT02088203|EXPERIMENTAL|Single Dose Sequence 8|Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.
62065297|NCT02088203|EXPERIMENTAL|Single Dose Sequence 9|Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.
62065298|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 1|Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065299|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 2|Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065300|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065301|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 4|Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065302|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 5|Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065303|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 6|Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065304|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 7|Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62452671|NCT01860248|PLACEBO_COMPARATOR|Water spray|The Patients in this arm will receive water spray as anesthetic before ABG.
62065305|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 8|Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065306|NCT02088203|EXPERIMENTAL|Multiple Dose Sequence 9|Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
62065307|NCT03372837|EXPERIMENTAL|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
62065308|NCT01247714|ACTIVE_COMPARATOR|Group 1|The group 1 will receive the experimental product T-Diet plus Diabet NP for the first month followed by a reference diet corresponding to a current marketed product (Glucerna SR, Abbott) for the second month, then the patients will receive a control product non specific for diabetic patients (T-Diet plus Standard)for the third month, and finally a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the fourth month.
62065309|NCT01247714|ACTIVE_COMPARATOR|Group 2|The group 2 will receive a reference diet corresponding to a current marketed product (Glucerna SR, Abbott)for the first month, followed by the experimental product T-Diet plus Diabet NP for the second month, then the patients will receive a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the third month, and finally a control product non specific for diabetic patients (T-Diet plus Standard)for the fourth month
62065310|NCT01789996|ACTIVE_COMPARATOR|Alternative six minute walk test|"Subjects will be given the following instructions~1. walk as fast as they can in 6 minutes~2. walk as normally as they can in 6 minutes~3. walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
62631832|NCT05288946|ACTIVE_COMPARATOR|traditional therapy|the patients will receive traditional therapy three times a week for four week
62631833|NCT02794636||IFN Treatment|Adult (age ≥ 18 years) patients identified as having stage III melanoma and no other primary or secondary cancer who initiated treatment with IFN between 1/1/2007 and 12/31/2011. Patients are required to have continuous pharmaceutical benefit enrollment for 180 days before (pre-index) and after (post-index) IFN initiation and no evidence of treatment with systemic chemotherapy during the pre- or post-index period
62631834|NCT06014086|EXPERIMENTAL|Sequential escalating doses of PH-762.|Escalating doses of PH-762 are to be tested, with an observation period between doses.
62631835|NCT04056949|OTHER|IBI308 + Paclitaxel/Albumin-Bound Paclitaxel|IBI308 Combined with Albumin-Bound Paclitaxe
62631836|NCT03975257|EXPERIMENTAL|Preventive application of EHT02|application of one Ectoin Lozenge before SLIT-initiation
62631837|NCT03975257|EXPERIMENTAL|Therapeutic application of EHT02|application of one Ectoine Lozenge after SLIT-initiation
62631838|NCT03975257|NO_INTERVENTION|No application of EHT02|SLIT-Initiation without Ectoin Lozenge
62631839|NCT04152291|EXPERIMENTAL|E-EPA-diet group|All the study participants will receive the same treatment. 3.9g of E-EPA in capsules, which include 75µg of D3-vitamin, daily for 30 days.
62631840|NCT06367946||Under 40 years old|Patients undergoing surgery with mechanical ventilation who are under 40 years old
62631841|NCT06367946||40-50 years old|Patients undergoing surgery with mechanical ventilation who are 40-50 years old
62631842|NCT06367946||50-60 years old|Patients undergoing surgery with mechanical ventilation who are 50-60 years old
62631843|NCT06367946||60-70 years old|Patients undergoing surgery with mechanical ventilation who are 60-70 years old
62631844|NCT06367946||70-80 years old|Patients undergoing surgery with mechanical ventilation who are 70-80 years old
62631845|NCT06367946||Over 80 years old|Patients undergoing surgery with mechanical ventilation who are over 80 years old
62631846|NCT05272553|EXPERIMENTAL|Narrative Exposure Therapy|This is a single case series design which focuses on assessing whether Narrative Exposure Therapy could reduce symptoms of traumatic stress in cancer survivors; no comparator will be included.
62631847|NCT03751475|EXPERIMENTAL|OptiMA|The enrolled subjects will follow the nutritional Optima strategy.
62631848|NCT03751475|ACTIVE_COMPARATOR|Control|The enrolled subjects will follow the standard nutritional protocol currently in use in the Democratic Republic of Congo
62286853|NCT04134494|EXPERIMENTAL|Intervention|Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart
62286854|NCT05684380|EXPERIMENTAL|MAZ-101|One applications in each nostril, twice a day.
62631849|NCT01869777|EXPERIMENTAL|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).
62286855|NCT05684380|ACTIVE_COMPARATOR|DYMISTA®|One applications in each nostril, twice a day.
62631850|NCT00921661|EXPERIMENTAL|AVE0005 (aflibercept)|
62631851|NCT06071117|EXPERIMENTAL|Virtual Reality Glasses (VR)|
62631852|NCT06071117|ACTIVE_COMPARATOR|White noise|
62631853|NCT06071117|SHAM_COMPARATOR|Basic behavior management techniques|
62631854|NCT03936153|EXPERIMENTAL|Abexinostat 80 mg bis in die (BID)|Abexinostat 80 mg BID
62631855|NCT01302418||Symptomatic|Individuals with signs and symptoms of an acute respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
62631856|NCT01733121|EXPERIMENTAL|NBI-98854|Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
62270299|NCT05299437|EXPERIMENTAL|Optimized therapy|"Patients with ascertained metastatic differentiated thyroid cancer will be studied with FDG PET, CT, and for genetic characterization. 100 MBq of 124-I are administered for blood and PET lesion dosimetry.~According Jentzen et al, good efficacy (Tumour Control Probability \> 80%) is obtained with absorbed dose higher than 80 Gy to soft tissue metastases, and \> 650 Gy to bone metastases. These values ae pursued with the limit of 2 Gy to blood.~Only soft tissue lesions will be considered as target for the calculation of the complete response rate.~However, for ethical reasons, therapeutic activity will be chosen in order to be effective both on soft tissue and bone lesions. Patients with too low predicted lesion absorbed dose even administering the Maximum Tolerable Activity (2 Gy to blood) will exit the protocol to receive the standard of care."
62631857|NCT01733121|PLACEBO_COMPARATOR|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
62065311|NCT01789996|PLACEBO_COMPARATOR|Standard six minute walk test|"Subjects will be given the following instruction~1. walk as far as they can in 6 minutes"
62065312|NCT02861144|OTHER|Intervention|"Patient participants in the intervention arm will receive diabetes self-management program, Ma ka hana ka ̒ike which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 4.5 months. After 4.5 months, the patient will receive 4 monthly boosters by mail that will reinforce information from the Ma ka hana ka ̒ike program. Completion of diabetes process and glycemic outcomes will trigger the modest financial incentives.~Health care provider participants in the intervention arm will receive educational resources, Hanapū Provider Toolbox to guide their patients to optimal glycemic control.They will receive modest financial incentives when their patients complete clinical tests and achieve glycemic target."
62065313|NCT02861144|NO_INTERVENTION|Usual Care|"Patient participants in the usual care arm will receive 5 mail-out diabetes self management education booklets endorsed by the American Diabetes Association (ADA) and the National Institute for Diabetes, Digestive and Kidney disease for 4.5 months. Patients will see their doctor according to usual care practice. After 4.5 months, the patients will receive 4 monthly boosters in mail reinforcing the previous mail-out diabetes self-management program materials.~Health care provider participants in the usual care arm will receive the latest ADA guidelines to use in their treatment plan of their patients."
62065314|NCT04596826|EXPERIMENTAL|healthy subjects|
62065315|NCT04596826|EXPERIMENTAL|glaucoma patients|
62270300|NCT04455373||orthopedic surgery group|Planned tumor resection
62631858|NCT04720989|EXPERIMENTAL|Bathing With Baby Cleanser|Skin cleansing products will be used in the first baths of the participants in this group.
62631859|NCT04720989|EXPERIMENTAL|Bathing With only Water|Only water will be used in the first baths of the participants in this group.
62270301|NCT04455373||traumatic surgery group|Patients with traumatic vascular injury
62270302|NCT05598372|EXPERIMENTAL|shotblocker|infant pain during vaccination and mother anxiety
62270303|NCT05598372|EXPERIMENTAL|lullaby|infant pain during vaccination and mother anxiety
62631860|NCT05684289|EXPERIMENTAL|Part 1: BMS-986278 + Sildenafil|
62065316|NCT04596826|PLACEBO_COMPARATOR|healthy volunteers|
62065317|NCT04596826|PLACEBO_COMPARATOR|Glaucoma patients|
62270304|NCT05598372|NO_INTERVENTION|CONTROL|not infant pain during vaccination and mother anxiety
62270305|NCT03183882|EXPERIMENTAL|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
62270306|NCT03183882|ACTIVE_COMPARATOR|Control Feedback|One-time summary report of their individual history of opioid prescribing
62270307|NCT05913453||Procedures corresponding to technical failure|
62270308|NCT04854681|EXPERIMENTAL|TQB2928 injection|Dose Escalation: intravenous (IV) infusion of TQB2928 as monotherapy
62286856|NCT01265836||1|
62631861|NCT05684289|PLACEBO_COMPARATOR|Part 1: Placebo + Sildenafil|
62631862|NCT05684289|EXPERIMENTAL|Part 2: BMS-986278|
62631863|NCT05684289|PLACEBO_COMPARATOR|Part 2: Placebo|
62631864|NCT02203344||Light sedation|Light sedation is defined as RASS of +1 to -2.
62631865|NCT02203344||Deep sedation|Deep sedation is defined as RASS of -3 to -5
62631866|NCT02378948|EXPERIMENTAL|Early oral feeding|Liquid oral feeding directly after esophagectomy.
62065318|NCT06054971||Group A|Group A will have Live telemedicine assessments completed prior to caregiver Asynchronous Video
62065319|NCT06054971||Group B|Group B will have Caregiver Asynchronous Video first, followed by live telemedicine
62065320|NCT05508386|OTHER|MATLAB-based interface, showing 50 EEG traces|A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
62065321|NCT05072184|ACTIVE_COMPARATOR|ESP block|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
62065322|NCT05072184|SHAM_COMPARATOR|Control|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of saline on each side
62065323|NCT04476420|ACTIVE_COMPARATOR|Steroid group|Participants in group 1 will be given corticosteroid lotion (Betamethasone valerate 0.1%) and will be advised to apply it topically (0.5 ml) on the buccal mucosa thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
62270309|NCT03393767|OTHER|prospective 1- Arm|OCT-guided high frequency intravitreal ranibizumab 0.5mg
62065324|NCT04476420|EXPERIMENTAL|Nigella Sativa oil group|Group 2 will be given commercially available, cold pressed N.sativa (Black seed) oil and will be advised to apply it topically over the buccal mucosa (1 ml) thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
62065325|NCT05228002|ACTIVE_COMPARATOR|Standard|"The monitoring criteria used will be the same as those usually used at the Nice University Hospital, according to the protocol of the department.~For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis."
62065326|NCT05228002|EXPERIMENTAL|Biomarkers|"The monitoring decision will be made based on the ratio calculation:~Ratio \< 38: Classic monitoring with one prenatal visit per month 38 ≤ Ratio ≤ 85: Close outpatient monitoring Ratio \> 85: Inpatient monitoring in Pathological Pregnancy"
62065327|NCT04318028|EXPERIMENTAL|Diagnostic (7 Tesla MRI)|Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and 6-9 months.
62631867|NCT02378948|NO_INTERVENTION|Delayed oral feeding|Liquid oral feeding 5 days after esophagectomy
62631868|NCT06309823|EXPERIMENTAL|Active treatment|
62065328|NCT02520648|ACTIVE_COMPARATOR|Neuro-lymphatic treatment|Participants were positioned in prone, with the head in neutral position and the arms beside the body. They were asked to perform conscious breathing. The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement. Neuro-lymphatic reflexes as referred to applied kinesiology, are locations on the body that are believed to affect a specific muscle and organ. Duration of the treatment is 15 minutes.
62065329|NCT02520648|EXPERIMENTAL|Articulatory spinal manual therapy.|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached. Three repetitions are performed at each vertebral level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize possible slight dysfunctions of the spine, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
62270310|NCT02271503|OTHER|Sequence 1|Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
62270311|NCT02271503|OTHER|Sequence 2|Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
62631869|NCT00696735|ACTIVE_COMPARATOR|1|standard chemotherapy arm, the CHVP (cyclophosphamide, low-dose doxorubicin, teniposide, and prednisone) regimen consisted of cyclophosphamide (600 mg/m2), doxorubicin (25 mg/m2), and teniposide (60 mg/m2), all administered intravenously on day 1, and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
62631870|NCT00696735|EXPERIMENTAL|2|VCAP (cyclophosphamide, high-dose doxorubicin, prednisone, and vincristine) regimen as a first-line therapy combining vindesine (3 mg/m2) on day 1, cyclophosphamide (1500 mg/m2) on day 2, doxorubicin (80 mg/m2) on day 2, and prednisolone (50 mg/m2) on days 1 to 5, every 3 weeks.19,31,32 Patients in CR, VGPR, or PR after the second or third VCAP cycle continued on to stem-cell harvesting and received, before transplantation, one course of IMVP16 (ifosfamide, methotrexate, and VP-16), which combined ifosfamide (1.5 g/m2) and VP16 (100 mg/m2) on days 1 through 3, and methotrexate (30 mg/m2) on days 1 and 10. Patients with less than PR after the VCAP cycles received, as salvage therapy, 2 to 3 courses of DHAP (dexamethasone, high-dose cytarabine, and cisplatin) combining cisplatine (100 mg/m2) on day 1, cytarabine (4 g/m2) on day 2, and dexamethasone (40 mg/m2) on days 1 through 4. If at least a PR was obtained after DHAP, stem cells were harvested or patients were considered as failures
62270312|NCT02271503|OTHER|Sequence 3|Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
62270313|NCT06471868|ACTIVE_COMPARATOR|A group|"Period 1 : IY-HCR21 1Tab, BID~Period 2 : IY-MIC 1Tab, QID"
62270314|NCT06471868|ACTIVE_COMPARATOR|B group|"Period 1 : IY-MIC 1Tab, QID~Period 2 : IY-HCR21 1Tab, BID"
62631871|NCT03341845|EXPERIMENTAL|axitinib and avelumab|axitinib 5MG BID and avelumab 10mg/kg Q2W
62631872|NCT05323747||Radiation with Hydrogel Spacer|Males at least 18 years of age, who will be undergoing radiation therapy with a hydrogel spacer in place.
62631873|NCT06344975|EXPERIMENTAL|Cohort1|"Cohort 1: Dose A in Younger/older Adults~Single injection of Dose A of STR-V003 or placebo on Day 0."
62065330|NCT02520648|EXPERIMENTAL|Articulatory costal Manual therapy.|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
62065331|NCT01334944|EXPERIMENTAL|Intravenous ibuprofen|Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.
62065332|NCT01380886|EXPERIMENTAL|Infant formula, alternate protein source|Experimental infant formula with alternate protein source
62065333|NCT01380886|ACTIVE_COMPARATOR|Infant formula powder|Infant formula powder
62065334|NCT03019003|EXPERIMENTAL|Oral Decitabine and Durvalumab|Oral decitabine (ASTX 727) will be administered alone in Cycle 1 and the combination of oral decitabine and durvalumab therapy will be given in Cycles 2-12.
62065335|NCT01115985|EXPERIMENTAL|single-add first group|single administration first, then concomitant administration
62631874|NCT06344975|EXPERIMENTAL|Cohort2|"Cohort 2: Dose B in Younger/older Adults~Single injection of Dose B of STR-V003 or placebo on Day 0."
62631875|NCT06344975|EXPERIMENTAL|Cohort3|"Cohort 3: Dose C in Younger/older Adults~Single injection of Dose C of STR-V003 or placebo on Day 0."
62631876|NCT06344975|EXPERIMENTAL|Cohort4|"Cohort 4: Dose B in Younger/older Adults~Two injections of Dose B of STR-V003 or placebo on Day 0 and Day21."
62631877|NCT04612283|ACTIVE_COMPARATOR|NGA-01 gel|A formulation with natural ingredients expected to be used for joint pain in Osteoarthritis
62631878|NCT04612283|PLACEBO_COMPARATOR|Placebo gel|Placebo gel with no active ingredient
62065336|NCT01115985|EXPERIMENTAL|combi-add first group|concomitant administration first, then single administration
62631879|NCT02256813|EXPERIMENTAL|BIRT 2584 XX + PK-cocktail|
62631880|NCT01664702|EXPERIMENTAL|Recommended dairy diet|Recommended servings of dairy products per day
62631881|NCT01664702|EXPERIMENTAL|Low dairy diet|One or fewer dairy servings per day
62631882|NCT01388855|EXPERIMENTAL|Cholecalciferol|Patients were given two cholecalciferol tablets (10,000 IU each) daily for 30 days.
62065337|NCT05580159|EXPERIMENTAL|SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
62065338|NCT05580159|ACTIVE_COMPARATOR|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration Intramuscular : injection Intramuscular
62065339|NCT02350920|ACTIVE_COMPARATOR|Acceptance and Committment Therapy (ACT)|This group will consist of patients who will receive ACT therapy.This intervention will run with 8-12 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
62065340|NCT02350920|NO_INTERVENTION|Control|The control group will consist of patients who will receive no ACT therapy during the 26 week st udy period
62065341|NCT06303544|EXPERIMENTAL|Wedge 1|Four villages of 12 will be randomized into Wedge 1. Four of the remaining 8 villages will be randomized to Wedge 2. The remaining 4 villages will be Wedge 3.
62065342|NCT06303544|NO_INTERVENTION|Wedge 2|While Wedge 1 is undergoing intervention, Wedges 2 \& 3 will act as controls.
62631883|NCT01388855|PLACEBO_COMPARATOR|Placebo|Patients were given two cholecalciferol placebo tablets daily for 30 days.
62631884|NCT04009187|ACTIVE_COMPARATOR|Training group|Training group will first receive 30 minutes of education about biomechanically efficient propulsion techniques. They will be tested on this knowledge to make sure participants understand the material. The participant then will be asked to come into the lab for 6 sessions of training, two times per week for three weeks. The training is an hour of the proper wheelchair propulsion techniques broken into 5 parts, 7 minutes each with breaks. Based on the motor learning principles, we gradually increase the components of the training by focusing either hand reaching toward the back of the wheel or hands reaching down toward the axle.
62631885|NCT04009187|ACTIVE_COMPARATOR|Control group|Control group will first receive 30 minutes of education about the biomechanically efficient propulsion. They will be tested on this knowledge to make sure participants understand the material. No further training will be implemented with this group.
62631886|NCT04474561|OTHER|Reduced sulfur diet intervention (INT)|"The INT group will receive conventional management plus a reduced sulfur diet and diet counselling by an RD. Implementation of the diet will be delivered directly by the RD and will provide each patient with an individualized plan. A reduced sulfur diet includes reducing foods, additives and beverages high in sulfate/sulfur.~The reduced sulfur diet eating plan, resources on reduced sulfur eating, and RD counselling session will be designed and reviewed by experts in nutrition, dietary design, education resources and dietary behaviour change"
62631887|NCT04474561|NO_INTERVENTION|Conventional management (CM)|The CM group will receive one session with RD on reduced sulfur diet at the end of 8 weeks.CM groups will receive conventional management .
62631888|NCT05118620|EXPERIMENTAL|Active Treatment|This group will receive a single injection PENG nerve block of bupivacaine 0.375% (20 mL)
62631889|NCT05118620|PLACEBO_COMPARATOR|Placebo|This group will receive a single injection PENG nerve block with normal saline (20 mL)
62631890|NCT01153607|EXPERIMENTAL|Arm 1|
62631891|NCT01153607|EXPERIMENTAL|Arm 2|
62065343|NCT06303544|NO_INTERVENTION|Wedge 3|While Wedge 1 is undergoing intervention, Wedges 2 \& 3 will act as controls.
62065344|NCT03653832|EXPERIMENTAL|Dexmedetomidine Group|For dexmedetomidine, the regimen will follow the manufacturer's guidance and regimens used in previous trials. Dexmedetomidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and documented at least daily. No loading dose will be administered. The starting dose will be 0.7 µg.kg-1.hour-1 titrated to a maximum dose 1.4 µg.kg-1 hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
62065345|NCT03653832|EXPERIMENTAL|Clonidine Group|For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2 µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
62270315|NCT01776073|EXPERIMENTAL|Patient navigation|In addition to receiving the standard of care, these patients will be connected with a patient navigator who will provide personalized assistance with regard to completion of the pre-waitlisting process
62631892|NCT01153607|EXPERIMENTAL|Arm 3|
62631893|NCT02077686|EXPERIMENTAL|Education - Diabetes and Travel|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Travel"
62631894|NCT02077686|NO_INTERVENTION|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
62631895|NCT06612060|EXPERIMENTAL|Coated circuit|Cardiac surgery with a specialized biocompatible extracorporeal circulation circuit with a hydrophobic coating.
62631896|NCT06612060|ACTIVE_COMPARATOR|Non-coated circuit|Cardiac surgery with the conventional non-coated extracorporeal circulation circuit.
62631897|NCT03937544|EXPERIMENTAL|CD19 CAR-T CELLS|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
62631898|NCT03241394||Lean|Individuals with Body Mass Index (BMI) = 18.5 - 25.0 Kg/m2
62631899|NCT03241394||Obese with MS|Individuals with BMI ≥ 30.0 Kg/m2 and metabolic syndrome (MS) MS was defined as the presence of three or more of the following criteria: 1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 2) serum triglycerides ≥ 150 mg/dL, 3) high density lipoprotein-cholesterol (HDL-C) \< 40 mg/dl in men and \< 50 mg/dl in women, 4) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg or antihypertensive drug treatment, 5) fasting glucose ≥ 100 mg/dL
62631900|NCT03241394||Obese without MS|Individuals with BMI ≥ 30.0 Kg/m2 but not MS
62631901|NCT06611904|ACTIVE_COMPARATOR|Patients receiving dulaglutide and dapagliflozin|Patients with T2DM and albuminuria receiving dulaglutide and dapagliflozin
62631902|NCT06611904|ACTIVE_COMPARATOR|Patients receiving DPP-4i|Patients with T2DM and albuminuria receiving DPP-4i
62631903|NCT05426187||Group 1|Women who received the PRIMVAC Vaccine or Placebo during the phase 1b trial in Burkina Faso
62270316|NCT01776073|NO_INTERVENTION|Standard of Care|These patients will receive the standard of care, which includes assistance from the current Emory Transplant Center team of social workers, physicians, and other support staff with regard to completion of the pre-waitlisting process
62631904|NCT05426187||Group 2|Women of the same age and nulligravid who did not participate in the phase 1b trial
62631905|NCT05426187||Group 3|Women of the same age and primigravid who did not participate in the phase 1b trial
62631906|NCT02762435|PLACEBO_COMPARATOR|control|No pressure applied to the 3 points
62270317|NCT02057783|EXPERIMENTAL|Physical activity|Obstructive sleep apnea and resistant hypertension controlled + physical activity
62270318|NCT02057783|NO_INTERVENTION|Control Group|Obstructive sleep apnea and resistant hypertension controlled
62631907|NCT02762435|SHAM_COMPARATOR|sham|Light touch applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
62631908|NCT02762435|EXPERIMENTAL|acupressure|Moderate pressure applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
62631909|NCT04649879|EXPERIMENTAL|Convalescent plasma treatment|"* Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions.~* If steroid therapy has not already been initiated, betamethasone 3 mg daily will be given concomitantly with steroid therapy or longer if clinically indicated but for a maximum of 10 days."
62631910|NCT04649879|ACTIVE_COMPARATOR|Control|Standard of care for COVID-19 patients.
62631911|NCT00478270|EXPERIMENTAL|1|
62631912|NCT03409536||SSEP Monitoring|participants will receive a brachial plexus block for their surgery and will be monitored for brachial plexus injury using the automated SSEP monitor.
62631913|NCT00333710|EXPERIMENTAL|Individual face-to-face contact|Individual face-to-face contact treatment
62631914|NCT00333710|EXPERIMENTAL|Individual telephone contact|Individual telephone contact treatment
62631915|NCT00333710|NO_INTERVENTION|Control condition/treatment as usual|Control condition/treatment as usual
62065346|NCT03653832|ACTIVE_COMPARATOR|Usual Care (Propofol) Group|Usual Care Group : Patients will continue to receive intravenous propofol according to usual current care . The sedation targets, weaning, and sedation discontinuation procedures will follow the same clinical targets as for the clonidine and dexmedetomidine groups.
62065347|NCT02820584|EXPERIMENTAL|GSC-loaded autologous dendritic cells|DC-GSC immunotherapy. Six vaccinations are envisaged. The first three vaccinations will be performed every two weeks; subsequent three vaccinations every month. The first vaccination will be performed using 20 million DC, the second and third with 10 million DC; and from the 4th vaccine 5 million DC
62631916|NCT00848406||1|30 individuals ≤ 40 years, who currently smoke ≥ 10 cigarettes/day and \> 10 packyears
62631917|NCT00848406||2|30 individuals ≤ 40 years, who have not smoked during the last year, have never smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have \< 0.5 packyear.
62631918|NCT00848406||3|30 individuals above 40 years, who currently smoke ≥ 10 cigarettes per day, and \> 20 packyears.
62631919|NCT00848406||4|30 individuals above 40 years, who have not smoked during the last year, have never smoked for as long as a year, and have \< 0.5 packyear.
62631920|NCT01247350|EXPERIMENTAL|2 mg LY3009104 (Cohort 1)|2mg administered once on day 1 (single dose)
62631921|NCT01247350|EXPERIMENTAL|5 mg LY3009104 (Cohort 2)|5mg administered once on day 1 (single dose)
62631922|NCT01247350|EXPERIMENTAL|10 mg LY3009104 (Cohort 3)|10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
62631923|NCT01247350|EXPERIMENTAL|14 mg LY3009104 (Cohort 4 )|14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
62631924|NCT01247350|PLACEBO_COMPARATOR|Placebo|administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
62631925|NCT02653911|EXPERIMENTAL|acupuncture group|"Bilateral ST25, EX-CA1, CV4 and SP6 will be selected for treatment. After routine sterilization of the local skin, bilateral ST25, EX-CA1, CV4 and SP 6 will be inserted by the needles (0.30 mm in diameter, 40 mm in length) to a depth of 25-30 mm to the abdominal muscle layer with the manipulation of lifting, thrusting and rotating until de qi. Each session will last for 30 minutes, and the manipulation of lifting, thrusting and rotating evenly three times will be used for CV 4 and SP 6 every 10 minutes. If the date of treatment is during the menstrual circle, the treatment will be continued as usual. Participants will be treated three times a week for 12 weeks with 36 sessions."
62631926|NCT02653911|SHAM_COMPARATOR|Sham-acupuncture group|The sham ST25, EX-CA1, CV4 and SP 6, which are 1 cun (25 mm) outward to ST25, EX-CA1, CV4 and SP 6, will be inserted to 2-3 mm with needles with a diameter of 0.30 mm and a length of 13 mm. The needles will be inserted without de qi or any manipulation. The treatment sessions will be the same as those in the acupuncture group.
62065348|NCT01719601||Immediate release tapentadol|Patients will be taking immediate release tapentadol hydrochloride as per the product insert approved in Philippines.
62631927|NCT06338943||Patient with the history of pregnancy|"Patient with the history of pregnancy (1 or more \> 20 weeks)~This group will further be subdivided in a subgroup with HFpEF and a group without HFpEF"
62631928|NCT02014519|OTHER|Study Group|Subjects, male and female, aged 18 years and above who had agreed to collection of blood sample.
62631929|NCT05704205|EXPERIMENTAL|NB-UVB+OTT|8-16 weeks of NB-UVB phototherapy combined with (a minimum of) 3 months of optimal topical therapy
62631930|NCT05704205|ACTIVE_COMPARATOR|Optimal topical therapy (OTT)|(a minimum of) 3 months of optimal topical therapy
62065349|NCT02471859|EXPERIMENTAL|Part A: GDC-3280|Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions.
62065350|NCT02471859|PLACEBO_COMPARATOR|Part A: Placebo|Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions.
62065351|NCT02471859|EXPERIMENTAL|Part B: GCD-3280|Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\\n
62065352|NCT02471859|PLACEBO_COMPARATOR|Part B: Placebo|Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\\n
62270319|NCT04258943|EXPERIMENTAL|Single Agent Bosutinib|Bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML). A treatment cycle is defined as 28 days
62270320|NCT05105490||Chronic Discogenic Low Back Pain|"Patient is skeletally mature and between 21 and 60 years of age.~Patient has Degenerative Disc Disease (DDD) at one or more levels~between L1 and S1 but must have a single level identified as the pain generator.~Patient has adequate disc height (6mm) at the level to be treated~Patient is not responsive to conservative, non-surgical treatment for back pain."
62270321|NCT01700556|ACTIVE_COMPARATOR|Usual Care|"150 patient-caregivers will receive a light support in the form of paper brochures and 3 preventive home visits by a nurse"
62270322|NCT01700556|EXPERIMENTAL|UP Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker and receiving 3 preventive home visits by a nurse
61978588|NCT05404373|PLACEBO_COMPARATOR|Low flow oxygen group|patients were randomized into the Low flow oxygen group and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
62065353|NCT03484338|EXPERIMENTAL|Intervention|
62065354|NCT03484338|ACTIVE_COMPARATOR|Wait list controlled|
62631931|NCT04254276||Symptomatic group|Office workers with neck and shoulder area musculoskeletal pain
62631932|NCT04254276||Asymptomatic group|Office workers without neck and shoulder area musculoskeletal pain
62631933|NCT05136235|OTHER|Extremely preterm newborns|All extremely preterm newborns in Flanders will be included, it is a single arm study
62270323|NCT01700556|EXPERIMENTAL|UP-TECH Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker, receiving an intervention based on assistive technologies and 3 preventive home visits by a nurse
62631934|NCT02597738|EXPERIMENTAL|Lung/ Head and Neck Cancer Group|Blood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five.
62631935|NCT02597738|EXPERIMENTAL|Chronic inflammatory disease|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
62065355|NCT02903134||Newborn from obese and nonobese pregnant|Obese (BMI\>30) or normal weight (BMI\<25) women at their first antenatal visit were invited to participate in the study at the moment of delivery at Sotero del Rio Hospital, Santiago. Information regarding birth outcomes, parental history, as well as environmental conditions was collected at recruitment. Follow-up questionnaires by phone were completed every 6 months. Umbilical cord blood samples were collected to measure IL-12, TNF-α, IL-10, IL-4; to evaluate metabolic status; to isolated monocytes and macrophage differentiation; and for DNA methylation status of the promoter regions of the genes coding for TNF-α, IL-12, IL-10, and IL-4Rα. Also, fasting blood samples of the mothers within 48 hours after delivery; and blood samples and skin prick test were collected.
62065356|NCT02419092||Obstructive Sleep Apnea|Subjects scheduled to undergo bariatric surgery and with Obstructive Sleep Apnea
62065357|NCT02419092||No Obstructive Sleep Apnea, controls|Subjects scheduled to undergo bariatric surgery and without Obstructive Sleep Apnea, control group
62065358|NCT05011825|EXPERIMENTAL|Pregnant Moms' Empowerment Program|The PMEP is a 5-session program, delivered prenatally. The first three sessions address violence and mental health and the final two sessions address labor/delivery, infant health and early parenting.
62065359|NCT05011825|NO_INTERVENTION|Control|Control group participants received information about community resources, but did not receive any study-related intervention.
62065360|NCT05624866|ACTIVE_COMPARATOR|Dexmeditomidine group|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
62065361|NCT05624866|ACTIVE_COMPARATOR|Triamcinolone group|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
62065362|NCT00582530||1 men with prostate cancer|Patients who have opted for radical prostatectomy as treatment for prostate cancer.
62065363|NCT01705808|EXPERIMENTAL|Protein C concentrate|
62065364|NCT01705808|PLACEBO_COMPARATOR|Placebo|
62270324|NCT05051774|EXPERIMENTAL|Intervention Group|In addition to usual care, the intervention group will receive the 12 weeks intervention consists of three monthly group education and center-based group exercise followed by 20 minutes of individualized telephone follow-up at weeks 3, 7, and 11.
62631936|NCT02597738|EXPERIMENTAL|At risk for lung cancer|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
62065365|NCT06315803|EXPERIMENTAL|Xplane ultrasound group|The lumbar interforamen puncture was performed under the guidance of Xplane ultrasound with a X6-1 volume transducer probe (frequency range 1-6MHz, center frequency 3.2MHz).
62065366|NCT06315803|NO_INTERVENTION|radiography group|The lumbar interforamen puncture was performed under the guidance of radiography with Mobile X-ray Image System (Arcadis Orbic 3D, Siemens, Germany) .
62065367|NCT02329301|EXPERIMENTAL|MDA with DHAp (Eurartesim)|All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
62270325|NCT05051774|NO_INTERVENTION|Control Group|The control group will receive the usual care provided in the study hospital included an unstructured health education conducted by a nurse on healthy lifestyle and health assessment and brief unstructured health education on their conditions, focusing on the risk factors management and stress management by the cardiologist.
62270326|NCT02797236|EXPERIMENTAL|vaccine dose 1|SF2a-TT15 vaccine, 2 μg
62270327|NCT02797236|EXPERIMENTAL|vaccine dose 1+ adjuvant|SF2a-TT15 vaccine, 2 μg + alum
62270328|NCT02797236|EXPERIMENTAL|vaccine dose 2|SF2a-TT15 vaccine, 10 μg
62270329|NCT02797236|EXPERIMENTAL|vaccine dose 2 + adjuvant|SF2a-TT15 vaccine, 10 μg + alum
62270330|NCT02797236|PLACEBO_COMPARATOR|Placebo|Tris buffer
62270331|NCT02797236|PLACEBO_COMPARATOR|Placebo + adjuvant|Tris buffer + Alum
62631937|NCT02597738|EXPERIMENTAL|Healthy people who exercise|Blood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise.
62631938|NCT02597738|EXPERIMENTAL|Lung cancer with planned resection|"Blood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits.~Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded."
62270332|NCT02161679|EXPERIMENTAL|IMMU-132|IMMU-132 infusion is administered
62270333|NCT02161679|ACTIVE_COMPARATOR|IMMU-132 plus Carboplatin|IMMU-132 infusion and Carboplatin infusion are administered to the participants in this arm of study.
62286857|NCT01299766|EXPERIMENTAL|Behavior Activation|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
62631939|NCT02597738|EXPERIMENTAL|Solid tumor cancer w/ radiation therapy|Blood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years.
62065368|NCT02329301|EXPERIMENTAL|Focal MDA with DHAp (Eurartesim)|All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
62631940|NCT03045653|EXPERIMENTAL|treatment arm|receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
62631941|NCT03728439|EXPERIMENTAL|Before|LED applications at the beginning, with a dose of 8 J/cm2, will be performed shortly after the blood collections, with a maximum period of 10 minutes, in which the participants of the other groups should remain in rest passive. At the end of these 10 minutes, a 5 minute warm up will be performed and then the tests will be started.
62631942|NCT03728439|EXPERIMENTAL|Interval|The LED therapy applied in the tests interval will be performed after the first block of tests, with a maximum duration of 10 minutes and dose of 8 J/cm2. Then the second block of maximum tests will be performed.
62065369|NCT02329301|NO_INTERVENTION|Standard of Care (Control)|The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.
62065370|NCT01139190|EXPERIMENTAL|PL3100|
62631943|NCT03728439|EXPERIMENTAL|After|LED applications at the end will be performed 10 minutes after the second battery of tests, also with 8 J/cm2 and in the same muscles irradiated in the other moments of application.
62631944|NCT03728439|NO_INTERVENTION|Baseline|On that day, participants will not receive any intervention.
62631945|NCT06424561|EXPERIMENTAL|Psychological Intervention Group|The patients in the intervention group received systematic psychological intervention on the basis of routine nursing after admission, the main steps were as follows: 1 preoperative and postoperative psychological assessment (self-rating anxiety scale (SAS) and self-rating depression scale (SDS-RRB- to assess the psychological status of patients) , this part through medical records, face-to-fAssessmentment and questionnaire survey; Timely attention to patients' psychological state. 2 at the end of the evaluation, we can start the psychological intervention, collect the pre-intervention scale and post-intervention scale, collect the data, and make records according to the collected data, so as to carry on the follow-up work in the later period. 3 the days of hospitalization, the satisfaction of hospitalization, the expenses of hospitalization and the psychological scale were recorded, and the influence of psychological intervention on the patients was compared with the routine group.
62065371|NCT01139190|ACTIVE_COMPARATOR|Naproxen|
62065372|NCT01557621|EXPERIMENTAL|Collaborative Population-Based Recall-Phone/Mail Group|Collaborative Pop-Based R/R: Phone/Mail Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
62286858|NCT01299766|PLACEBO_COMPARATOR|Supportive Therapy (ST)|ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
62286859|NCT03308188|NO_INTERVENTION|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
62631946|NCT06424561|NO_INTERVENTION|Routine care group|Routine nursing care is carried out by the regular group based on the measures for VSD drainage procedure.
62631947|NCT06363019|EXPERIMENTAL|Mothers using SMART app|The intervention will be delivered via a mobile-based application, the SMART app. The intervention consists of educational material on parenting, pregnancy and managing emotional well-being that mothers are to engage in. Mothers will also participate in the forum with other mother participants. Mothers will also engage in the chat function with a peer volunteer who is an experienced mother. The app is accessible to the mother via the Android or iOS playstore and mother can access anytime in their convenience over 6 months.
62631948|NCT06363019|NO_INTERVENTION|Standard Care|This includes routine perinatal visits and check-ups at the hospital or polyclinic the mother is assigned to.
62631949|NCT00477802|EXPERIMENTAL|Botox|Randomized into receiving Botox first. At cross-over, patients will receive placebo.
62631950|NCT00477802|PLACEBO_COMPARATOR|Placebo|Randomized to receive placebo first. At cross-over, patients will receive the active Botox.
62631951|NCT00826059|ACTIVE_COMPARATOR|Active Stimulation|"Implantation/ISS Stimulation during 5 consecutive days \& Standard of Care (SoC).~Day 1: First stimulation initiated within 24 hours from stroke onset, following implantation completion. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: ISS Stimulation treatment sessions repeated daily. Each treatment will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last ISS Stimulation treatment session, imaging performed for assessing Injectable Neuro Stimulator (INS) positioning and/or lesion. Implant removal procedure will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
62065373|NCT01557621|EXPERIMENTAL|Collaborative Population-Based Recall-Mail Only Group|Collaborative Pop-Based R/R: Mail-Only Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
62065374|NCT01557621|ACTIVE_COMPARATOR|Practice-based Recall|Practice-based Recall
62065375|NCT04530539|EXPERIMENTAL|Experimental- Melatonin|Patients will receive melatonin
62065376|NCT04530539|EXPERIMENTAL|Experimental- Vit C|Patients will receive vitamin C
62065377|NCT04530539|PLACEBO_COMPARATOR|Control|Patients will receive placebo
62065378|NCT03097861|ACTIVE_COMPARATOR|Lubiprostone Capsule|Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
62065379|NCT03097861|EXPERIMENTAL|Lubiprostone Sprinkle|Lubiprostone 24 mcg sprinkle BID for 7 days.
62065380|NCT03097861|PLACEBO_COMPARATOR|Placebo|Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.
62270334|NCT05616260|EXPERIMENTAL|Acetazolamide, then Placebo, then optional open-label CPAP-therapy|"Subjects will start with a 2-week ACETAZOLAMIDE regimen~* Day 1-13: Acetazolamide 500mg at bedtime at home~* Day 14: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 2-week PLACEBO regimen:~* Day 1-13: Placebo (matching Acetazolamide 500mg) at bedtime at home~* Day 14: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects may then undergo an OPTIONAL, OPEN-LABEL 2-week CPAP regimen:~- Day 1-14: CPAP will be used at home during sleep"
62065381|NCT01860586|EXPERIMENTAL|Bevacizumab|Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
62065382|NCT03748602|EXPERIMENTAL|TOD|Thoracic Outlet Decompression (TOD)
62065383|NCT03748602|NO_INTERVENTION|Conservative therapy|Physiotherapy and pain relief
62065384|NCT06339554||Cohort A|Male ALK-positive ANSCLC patients receiving first-line treatment with alectinib
62065385|NCT06339554||Cohort B|Female ALK-positive ANSCLC patients receiving first-line treatment with alectinib
62065386|NCT06339554||Cohort C|Male ALK-negative ANSCLC patients receiving first-line treatment according to molecular profiling
62065387|NCT01835600|ACTIVE_COMPARATOR|with PEEP|10 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
62270335|NCT05616260|EXPERIMENTAL|Placebo, then Acetazolamide, then optional open-label CPAP-therapy|"Subjects will start with a 2-week PLACEBO regimen~* Day 1-13: Placebo (matching Acetazolamide 500mg) at bedtime at home~* Day 14: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 2-week ACETAZOLAMIDE regimen:~* Day 1-13: Acetazolamide 500mg at bedtime at home~* Day 14: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects may then undergo an OPTIONAL, OPEN-LABEL 2-week CPAP regimen:~- Day 1-14: CPAP will be used at home during sleep"
62065388|NCT01835600|PLACEBO_COMPARATOR|without PEEP|0 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
62065389|NCT03716544|NO_INTERVENTION|Waiting list control group|There will be no treatment for 12 months.
62065390|NCT03716544|EXPERIMENTAL|Hearing aid group|Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
62065391|NCT03716544|ACTIVE_COMPARATOR|Customized music group|Customized music according to participants hearing level will be made available in an iPod. The iPod will deliver ear-specific therapeutic sound for asymmetrical hearing profile. Participants will have to listen to the therapeutic sound at a comfortable volume for two hours daily for 12 months.
62065392|NCT02088632|ACTIVE_COMPARATOR|Incobotulinumtoxina|Xeomin 25-100 units injected to chosen area one time.
62065393|NCT02088632|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.
62065394|NCT06160752|EXPERIMENTAL|Phase 1 Part A and Part B|TYRA-200 taken once daily by mouth in 28-day cycles
62065395|NCT06625853|EXPERIMENTAL|Mtwo R files without Xp-endo finisher file.|
62065396|NCT06625853|EXPERIMENTAL|Mtwo R files followed by Xp-Endo finisher file|
62065397|NCT02641457|EXPERIMENTAL|Aflibercept x Ranibizumab|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and 12 eyes patients received an intraocular injection of 1.25mg ranibizumab
62065398|NCT06009640|EXPERIMENTAL|Intraoperative neurophysiological monitoring for decompression surgery|we integrated intraoperative neuromonitoring system into laparoscopic lumbosacral plexus nerve decompression surgery and simultaneusly recorded nerve roots from lumbar 5 to sacral 4 during the operation. Diseases that cause pelvic nerve compression such as abnormal vascular conflict, aberrant priformis muscle, and endometriosis have settled in hard-to-reach deep areas of the pelvis. These areas can be accesed more easily with by laparoscopy, which provides better magnification and visualization. Sacral and sciatic nerves might be damaged when performing decompression surgery in these deep pelvic areas. Patients who gave informed consent and underwent surgical treatment for a proven diagnosis of lumbosacral plexus nerve entrapment were included in the study.
62065399|NCT06006923|EXPERIMENTAL|Pembrolizumab + Regorafenib|"Pembrolizumab: 200mg, Q3 weeks~Regorafenib: 60mg Cycle 1 Day 1 90 mg Cycle 2 Day 1"
62065400|NCT06006923|ACTIVE_COMPARATOR|Pembrolizumab|Pembrolizumab: 200mg, Q3 weeks
62065401|NCT06196125||Intubated mechanically ventilated patients with thoracic trauma.|Intubated and mechanically ventilated patients with thoracic trauma (with at least 2 rib fractures with or without chest tube), who are in spontaneous/ partially assisted breathing phase.
62065402|NCT02970513|EXPERIMENTAL|patients operated on for colorectal cancer|
62065403|NCT05396092|EXPERIMENTAL|Integrated mindfulness-based Tai Chi Chuan|MBTCC
62065404|NCT05396092|ACTIVE_COMPARATOR|Mindfulness-based intervention|MBI
62631952|NCT00826059|SHAM_COMPARATOR|Sham Stimulation|"Sham Implantation and Sham Stimulation during 5 consecutive days \& Standard of Care (SoC).~Day 1: First Sham stimulation initiated within 24 hours from stroke onset, following Sham implantation procedure. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: Sham Stimulation sessions repeated daily. Each Sham Stimulation will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last Sham Stimulation session, imaging performed for lesion assessment. Sham Implant removal will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
62631953|NCT02503163|EXPERIMENTAL|KCT-0809|
62631954|NCT00731796||1|Stroke victims with a visual field deficit that undergo vision restoration therapy
62631955|NCT00731796||2|Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
62631956|NCT00731796||3|Stroke victims that do not have a visual field deficit
62065405|NCT05396092|ACTIVE_COMPARATOR|Tai Chi Chuan|TCC
62065406|NCT05396092|ACTIVE_COMPARATOR|Sleep Hygiene Education|SHE
62065407|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
62631957|NCT00731796||4|Normal individuals who have not had a stroke and do not have a visual field deficit
62065408|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
62065409|NCT04093921|EXPERIMENTAL|Intervention|Receive motivational enhancement training based, telehealth-delivered 6-8 session intervention aimed at increasing readiness to engage in pain self-management, in addition to all recommended outpatient treatments.
62065410|NCT04093921|ACTIVE_COMPARATOR|Standard Care|Participate in all recommended outpatient pain treatments while awaiting PPRC admission.
62065411|NCT05120648||Immediate enrollment|
62065412|NCT05120648||Wait-list controls|
62065413|NCT02579356|EXPERIMENTAL|Part1-A|The Part1-A of groups take Telmisartan once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
62065414|NCT02579356|EXPERIMENTAL|Part1-B|The Part1-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan once a day for 6 days in period 2.
62065415|NCT02579356|EXPERIMENTAL|Part2-A|The Part2-A of groups take Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
62065416|NCT02579356|EXPERIMENTAL|Part2-B|The Part2-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Atorvastatin once a day for 6 days in period 2.
62065417|NCT06625281|ACTIVE_COMPARATOR|Interventional Group A|It includes participants receiving Epley's Maneuver combined with Brandt-daroff exercises for 6 weeks of treatment.
62270336|NCT02875639|EXPERIMENTAL|tonifying qi group|tonifying qi group:which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng,and so on)
62065418|NCT06625281|EXPERIMENTAL|Interventional Group B|This group involves participants receiving Semont-Plus Maneuver along with Brandt-daroff exercises for a period of 6 weeks.
62065419|NCT02122341|EXPERIMENTAL|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
62065420|NCT02122341|NO_INTERVENTION|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
62270337|NCT02875639|EXPERIMENTAL|activating blood group|which treated by a kind of Chinese patent medicine (major components: Honghua,Taoren,Danggui，and so on)
62270338|NCT02875639|EXPERIMENTAL|qi and blood group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，Honghua,Taoren,Danggui，and so on)
62270339|NCT02875639|ACTIVE_COMPARATOR|QISHEN YIQI DRIPPING PILLS group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，and so on)
62270340|NCT02875639|SHAM_COMPARATOR|placebo group|which treated by the simulation of Chinese patent medicine (major components:excipient)
62631958|NCT06050096||DCB group|CTO patients treated by DCB
62631959|NCT00534872|EXPERIMENTAL|SB649868|10 mg
62631960|NCT01867320|EXPERIMENTAL|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
62631961|NCT05352932||patient group|Patients with chronic pancreatitis or idiopathic recurrent acute pancreatitis are considered as study subjects.
62631962|NCT01028404|EXPERIMENTAL|Trial part 1|
62631963|NCT01028404|EXPERIMENTAL|Trial part 2|
62631964|NCT03893955|EXPERIMENTAL|Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors|Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.
62631965|NCT03893955|EXPERIMENTAL|Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.
62631966|NCT03893955|EXPERIMENTAL|Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC|Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.
62631967|NCT03893955|EXPERIMENTAL|Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.
62065421|NCT06400966|EXPERIMENTAL|Experimental|"Students in the Jigsaw technique group are divided into 5 home groups consisting of 8 people.Each student in the groups was randomly included to be an expert on a subject under 8 headings.In the home group, students assigned to different subject specializations were combined with students selected as experts in the same subject. This group was called the expert group.The experts came together a week later, explained what they had learned on the common topic, discussed the topics they had taken notes while researching and reading in expert groups, and noted any additional points or missing parts they had learned. After completing their tasks in the expert groups, students returned to their home groups. They explained the information they learned in the expert group to each other in the home group, and as a home group, they brought together different topics and reported the main topic."
62065422|NCT06400966|NO_INTERVENTION|Traditional education group|Students in the traditional education group were given training by the researchers with a powerpoint presentation. Students are divided into 5 groups of 8 people. Training was given in 3 sessions for each group, for a total of 15 sessions. The training duration was 45 minutes for each session (one lesson hour).During the training, a projector, training slides and training videos on seizure types were used. Direct explanation and question-answer techniques were used in the training.
62065423|NCT02176421|EXPERIMENTAL|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
62065424|NCT00896428|EXPERIMENTAL|1|16 patients with a diagnosis of severe asthma under gallopamil treatment
62631968|NCT03893955|EXPERIMENTAL|Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.
62631969|NCT03893955|EXPERIMENTAL|Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.
62631970|NCT03893955|EXPERIMENTAL|Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.
62631971|NCT04927897||Observational|In addition to standard workup and treatment, patients will undergo pre-operatively, after induction of general anaesthesia, an endorectal ultrasound and rigid rectoscopy as study procedures if these are not part of standard workup yet.
62631972|NCT01968187|EXPERIMENTAL|FE 992097|
62631973|NCT01968187|PLACEBO_COMPARATOR|Placebo|
62270341|NCT02329769|EXPERIMENTAL|PRO044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
62270342|NCT02329769|EXPERIMENTAL|PRO044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
62065425|NCT00896428|PLACEBO_COMPARATOR|2|16 patients with a diagnosis of severe asthma under placebo treatment
62065426|NCT00633932|EXPERIMENTAL|1|Esomeprazole 20mg
62065427|NCT00633932|EXPERIMENTAL|2|Esomeprazole 40mg
62065428|NCT00633932|ACTIVE_COMPARATOR|3|Omeprazole 20mg
62065429|NCT03501043|EXPERIMENTAL|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
62270343|NCT02329769|EXPERIMENTAL|PRO044 SC 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
62270344|NCT01477242|EXPERIMENTAL|Ondansetron|Ondansetron use group
62270345|NCT01477242|PLACEBO_COMPARATOR|Placebo|Placebo group
62270346|NCT05754346|ACTIVE_COMPARATOR|Control Group|"Patients in this group will receive Complete Decongestive Therapy for 6 weeks. 1 session each week will be supervised in a clinic. Rest of the sessions will be performed at home."
62270347|NCT05754346|EXPERIMENTAL|Study Group|"Patients in this group will receive Complete Decongestive Therapy combined with diaphragmatic breathing exercises for 6 weeks. 1 session each week will be supervised in a clinic. Rest of the sessions will be performed at home."
62452672|NCT04208659|EXPERIMENTAL|Self-administration of Auricular Acupuncture Group|There is only one arm in this pilot project, whose purpose is to determine safety of self-administration of Battlefield Acupuncture over a six month period and how well a prosthesis facilitates needle insertion. Five ASP (Aiguille D'acupuncture semi-permanente) needles will be self-inserted into each participant's ear every two weeks according to the standardized acupuncture points in Battlefield Acupuncture.
62452673|NCT04812756|EXPERIMENTAL|Texting intervention|This is a single arm study in which all participants received a pedometer and text messages for the 12 week intervention period. Participants received a content message and a message requesting them to report the number of steps from their pedometer daily.
62065430|NCT02358798|EXPERIMENTAL|Preschool aged children detected of CF in neonatal period|Preschool aged children detected of Cystic Fibrosis in neonatal period
62270348|NCT04793295|EXPERIMENTAL|MT-7117 Drug-drug interaction with test drug 1 and test drug 2|
62270349|NCT04793295|EXPERIMENTAL|MT-7117 Drug-drug interaction with test drug 3 and test drug 4|
62452674|NCT03730103|NO_INTERVENTION|Historical control group|The investigators will use data from a historical control group discharged on POD 1 after minimally invasive sacrocolpopexy to examine Aim 1 and Aim 2. This is a cohort of 60 women matching our eligibility criteria from a prospective randomized trial of two different types of lightweight polypropylene mesh (IRB #14-354). This study completed recruitment 2017. It consists of a group of women who underwent minimally invasive sacrocolpopexy using the same surgical approaches, at the same institutions
62065431|NCT01052402|EXPERIMENTAL|Dose A|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose A) followed by a heterologous booster vaccination (Dose A) on Day 360
62065432|NCT01052402|EXPERIMENTAL|Dose B|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose B) followed by a heterologous booster vaccination (Dose B) on Day 360
62065433|NCT06275425|EXPERIMENTAL|Intervention|General anesthesia is maintained with intravenous administration of Byfavo.
62065434|NCT06275425|ACTIVE_COMPARATOR|Control|
62065435|NCT01633151||20 volunteers|
62270350|NCT04793295|EXPERIMENTAL|MT-7117 Drug-drug interaction with test drug 5 and test drug 6|
62270351|NCT04793295|EXPERIMENTAL|MT-7117 Drug-drug interaction with test drug 7|
62270352|NCT01586585||post cardiac surgery patients|
62270353|NCT03740256|EXPERIMENTAL|Treatment Phase|"Seven dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.T cells 3 days later (Day 4), according to the following dose levels.~Dose Level 1 CAdVEC = 5.00E+9 HER2 specific CAR-T cells = 0~Dose Level 2 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 0~Dose Level 3 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 1.00E+06~Dose Level 4 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+06~Dose Level 5 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+07~Dose Level 6 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+07~Dose Level 7 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+08"
62452675|NCT03730103|EXPERIMENTAL|Same day discharge group|47 women will be recruited for same day discharge after laparoscopic sacrocolpopexy. We will compare aim 1 and 2 (serious adverse events and procedure-related costs) between the two groups
62452676|NCT02128048||Heavy smokers|Assessment of body composition and muscle function
62452677|NCT04053790|PLACEBO_COMPARATOR|placebo group|Patients in this group will receive placebo 1 tablet every 12 hours, during 4 weeks.
62270354|NCT05680363|ACTIVE_COMPARATOR|Standard Sperm Preparation|Sperm samples in the control group will undergo traditional processing in the lab prior to insemination.
62270355|NCT05680363|EXPERIMENTAL|HyperSperm|Sperm samples in the experimental group will undergo product-specific processing in the lab prior to insemination.
62270356|NCT02370875|EXPERIMENTAL|Real rTMS stimulation|Repetitious transcranial magnetic stimulation (rTMS) will be delivered using the Magstim RapidStim2 over each anterior cingulate cortex, using a figure-of-eight coil. The investigators will apply rTMS with 0.2 Hz frequency to the ACC. 180 stimuli will be delivered with a stimulator output of 100% active motor threshold (AMT). AMT will be assessed at the tibialis anterior muscle with the coil. The AMT will be defined as the lowest stimulation intensity required to evoke a 150 μV potential in the target muscle. To determine the stimulation site for ACC, the coil will be placed over Fz and then moved over the midline of the brain in 0.5-cm steps anteriorly, until the point of maximum motor evoked potential in the orbicularis oculi (OO) muscle. The coil position will be marked on the skin. These rTMS sessions will be repeated daily for 10 days.
62631974|NCT03363932||Perimembranous VSD with high pulmonary flow rate|"It is an observational study, no intervention or examination will be realized for the sole purpose of the study. Patient management will be at the discretion of referral cardiologists according to the practices of the centers.~As part of the usual follow-up of these patients, the participating centers collect the clinical and echocardiography data from inclusion and the following year, as well as data from a functional assessment at baseline and at one year. and the collection of cardiovascular events at 5 years and 10 years of follow-up.~Data from a possible percutaneous or surgical closure procedure will be collected. The indication of VSD closure will be left to the discretion of participating centers. There will be no recommendation for percutaneous or surgical closure of VSD for the sole purpose of this observatory."
62631975|NCT00753675|EXPERIMENTAL|A|Vandetanib 300 mg as a once daily oral dose, from Day 1
62270357|NCT02370875|SHAM_COMPARATOR|Sham rTMS Stimulation|During sham repetitious transcranial magnetic stimulation (rTMS), subjects will undergo the same procedure for identifying stimulus location as used in patients receiving real rTMS using the sham Magstim RapidStim2 coil. This coil will be placed on the patient's head in an identical manner however will not be connected to the Magstim device. Instead another coil will be connected to provide stimulation sound. In each stimulation condition, the Magstim will be placed behind the patient and not visible to him or her. Placebo sham coil which produces discharge noise and vibration similar to a real coil without stimulating the cerebral cortex. During rTMS, all patients will continue to wear ear plugs as instructed during the real stimulation sessions.
62631976|NCT00753675|EXPERIMENTAL|B|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)
62631977|NCT00753675|PLACEBO_COMPARATOR|C|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).
62631978|NCT04912492|ACTIVE_COMPARATOR|RealConsent 1.0 with Alcohol|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target breath alcohol concentration (BrAC=.08).
62631979|NCT04912492|ACTIVE_COMPARATOR|RealConsent 1.0 with Placebo|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
62270358|NCT04312009|EXPERIMENTAL|Losartan|Participants in this arm will receive the study drug, Losartan.
62270359|NCT04312009|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo treatment.
62270360|NCT04441229|EXPERIMENTAL|Treatment Group|Patients age 12-24 diagnosed with pediatric-onset Multiple Sclerosis
62270361|NCT04145414|EXPERIMENTAL|Cerebral magnetic resonance imaging x2|Cerebral MRI performed at enrolment visit and at +6 weeks (maximum)
62270362|NCT05472727||Case group (mild cognitive impairment)|geriatric population with mild cognitive impairment
62270363|NCT05472727||Control Group (healthy elderly)|healthy older adults without cognitive impairment
62270364|NCT04517188|EXPERIMENTAL|Halodine Nasal Antiseptic|"Povidone-Iodine Solution 1.25% w/w \[0.125% available iodine\] USP~Single topical administration"
62270365|NCT00881777|EXPERIMENTAL|RF Heating + CABG|Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
62270366|NCT00881777|ACTIVE_COMPARATOR|CABG Alone|Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
62270367|NCT01826552|EXPERIMENTAL|Orsiro|The Patient group who are treated with Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
62270368|NCT01826552|ACTIVE_COMPARATOR|Resolute Integrity|The Patient group who are treated with ② Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
62452678|NCT04053790|ACTIVE_COMPARATOR|LB 10000|Patients in this group will receive placebo 1 tablet containing 5,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
62631980|NCT04912492|EXPERIMENTAL|RealConsent2.0 with Alcohol|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target BrAC=.08).
62631981|NCT04912492|EXPERIMENTAL|RealConsent2.0 with Placebo|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
62631982|NCT04912492|ACTIVE_COMPARATOR|Stress Management with Alcohol|Men assigned to complete a web-based stress management program. Men assigned to alcohol intoxication arm (target BrAC=.08).
62065436|NCT03417037|EXPERIMENTAL|Arm A|BMS-986205 and Nivolumab administered in combination
62065437|NCT03417037|EXPERIMENTAL|Arm B|BMS-986205 and Nivolumab administered in combination with chemotherapy
62065438|NCT03417037|ACTIVE_COMPARATOR|Arm C|Chemotherapy administered alone
62065439|NCT01077479|EXPERIMENTAL|Metformin|
62065440|NCT02074722||Healthy Subjects|Healthy Subjects
62631983|NCT04912492|ACTIVE_COMPARATOR|Stress Management with Placebo|Men assigned to complete a web-based stress management program. Men assigned to a no-alcohol placebo control arm.
62631984|NCT01575756|EXPERIMENTAL|Octafibrin followed by Haemocomplettan® P or RiaSTAPTM|Participants received Octafibrin 70 mg/kg intravenously once followed by Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once 45 days later.
62631985|NCT01575756|EXPERIMENTAL|Haemocomplettan® P or RiaSTAPTM followed by Octafibrin|Participants received Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once followed by Octafibrin 70 mg/kg intravenously once 45 days later.
62631986|NCT05488951|EXPERIMENTAL|Otago Exercise Program Plus Usual Care|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive. Participants will also receive usual care from health care providers (e.g., specialist and local doctor visits, community nurse visits, paid care provider visits, hospitalizations as required, and any ongoing treatment for any illness and/or their comorbidities).
62631987|NCT05488951|NO_INTERVENTION|Usual Care Only|Usual care will consist of routine care from their health care providers (e.g., specialist and local doctor visits, community nurse visits, paid care provider visits, hospitalizations as required, and any ongoing treatment for any illness and/or their comorbidities).
62065441|NCT05401435|EXPERIMENTAL|Blood pressure and heart rate measurement|Resting blood pressure and heart rate measurement regularly one value in the morning and evening for 28 days. The volunteer measures the parameters simultaneously on both devices (smartwatch and digital tonometer). In total, each participant will undergo this measurement 56 times.
62270369|NCT03466177||Ab+ AD patients|"amyloid positive Alzheimer's Disease patients~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
62270370|NCT03466177||Ab+ Mild Cognitive Impairment (MCI) patients|"amyloid positive Mild Cognitive Impairment patients~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
62270371|NCT03466177||Ab+ cognitively intact volunteers|"amyloid positive cognitively intact volunteers~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
62270372|NCT03466177||Ab- cognitively intact volunteers|"amyloid negative cognitively intact volunteers~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
62631988|NCT03034837|ACTIVE_COMPARATOR|Resin sealant|"Sealing pit and fissures of the included permanent first molars using SDI conseal f resin sealant material once at the baseline of the study."
62270373|NCT03466177||Glaucoma patients|- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)
62631989|NCT03034837|EXPERIMENTAL|ART sealant|"Sealing pit and fissures of the included permanent first molars using 3M ESPE KetacTM Molar Easymix glass ionomer cement material once at the baseline of the study."
62631990|NCT03877146|NO_INTERVENTION|Usual Care Control Condition|As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
62065442|NCT01108458|EXPERIMENTAL|Pertuzumab plus Erlotinib Hydrochloride|"Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks~Erlotinib hydrochloride 150 mg/day by mouth"
62065443|NCT01433640||Contrast-enhanced Mammography|Subjects will undergo 2D imaging with iodine contrast.
62065444|NCT01433640||Contrast-enhanced Breast Tomosynthesis|Subjects will undergo 3D imaging with iodine contrast.
62065445|NCT01433640||Contrast-enhanced MRI|Each subject imaged with iodine contrast will also be imaged with contrast-enhanced MRI using gadolinium.
62065446|NCT02810067|ACTIVE_COMPARATOR|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
62065447|NCT02810067|EXPERIMENTAL|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
62065448|NCT01110083|EXPERIMENTAL|Arm 1|
62065449|NCT00345384|PLACEBO_COMPARATOR|Normal Saline|One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
62065450|NCT00345384|ACTIVE_COMPARATOR|Dexmedetomidine|The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
62270374|NCT03466177||Age-related macular degeneration patients|- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)
62631991|NCT03877146|EXPERIMENTAL|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
62631992|NCT01136252|EXPERIMENTAL|Adalimumab|
62631993|NCT00134966|EXPERIMENTAL|1|
62631994|NCT00134966|ACTIVE_COMPARATOR|2|
62631995|NCT02145208|EXPERIMENTAL|Medi-Tate iTind|TIND System
62631996|NCT03011177|EXPERIMENTAL|teneligliptin|teneligliptin 20mg qd
62065451|NCT04398615|EXPERIMENTAL|Intervention|Single arm, receiving the experimental device
62270375|NCT03466177||Diabetic retinopathy patients|- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), DVA
62270376|NCT04245020|ACTIVE_COMPARATOR|Text Message|Patients will be followed up with a series of text messages at 6-8 weeks
62631997|NCT03011177|ACTIVE_COMPARATOR|linagliptin|linagliptin 5mg qd
62631998|NCT06180122|OTHER|Symptomatic Group|Participants who are suffer from unexplained left leg swelling.
62631999|NCT06180122|OTHER|Asymptomatic Group|Participants who do not suffer from unexplained left leg swelling
61978589|NCT05404373|EXPERIMENTAL|NBO group (2h)|patients were randomized into the NBO group (2h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 2 hours.
61978590|NCT05404373|EXPERIMENTAL|NBO group (4h)|patients were randomized into the NBO group (4h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
62065452|NCT06081335|ACTIVE_COMPARATOR|Continuous Rotation group|EdgeEndo x7 continuous rotation files system (Albuquerque, New Mexico, USA)
62065453|NCT06081335|ACTIVE_COMPARATOR|Reciprocation group|EdgeOne Fire reciprocating files system (Albuquerque, New Mexico, USA)
62452679|NCT04053790|ACTIVE_COMPARATOR|LB 20000|Patients in this group will receive placebo 1 tablet containing 10,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
62065454|NCT04317014||cases|early puberty girls of Han Chinese
62065455|NCT04317014||controls|normal development girls of Han Chinese
62065456|NCT03207646|EXPERIMENTAL|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
62065457|NCT03207646|NO_INTERVENTION|Control|Standard-of-care alone.
62270377|NCT04245020|ACTIVE_COMPARATOR|Telephone|Patients will be followed with a telephone conversation at 6-8 weeks
62452680|NCT05381623|EXPERIMENTAL|Simplified suture-less approach|Infiltration of local anesthetic (articaine 4% 1:100.000 epinephrine) around the harvesting site and attendance for the establishment of a competent coagulum.
62632000|NCT00888888||Cohort: Patients with colonic resections|Colonic resections in patients submitted to appendicectomy for suspected acute appendicitis
62632001|NCT05413915|ACTIVE_COMPARATOR|Imatinib|Standard of care imatinib at 300 or 400 mg PO daily for 52 weeks
62632002|NCT05413915|EXPERIMENTAL|Imatinib and Asciminib|Asciminib (60 mg PO daily for 52 weeks) will be added to standard of care imatinib (300 or 400 mg PO daily for 52 weeks)
62632003|NCT01900041|EXPERIMENTAL|Pantovigar + Minoxidil 2%|Minoxidil 2% is given as background therapy in both arms
62632004|NCT01900041|OTHER|Minoxidil 2% only|Minoxidil 2% is given as background therapy in both arms
62632005|NCT02472158|EXPERIMENTAL|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
62632006|NCT02472158|ACTIVE_COMPARATOR|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
62065458|NCT04779905||Non-alcoholic Fatty Liver Diseases|patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital
62065459|NCT04779905||control|healthy volunteers who looks normal on ultrasonography
62065460|NCT03607201||Diabetic|History of diabetes prior to Acute Coronary Syndrome
62065461|NCT03607201||Non-diabetic|No documented history of diabetes prior to Acute Coronary Syndrome
62065462|NCT05915728|EXPERIMENTAL|Gadoquatrane - Approved Macrocyclic GBCA|Participants will receive one intravenous injection of gadoquatrane during MRI in Period 1, followed by one intravenous injection of any approved macrocyclic GBCA during MRI in Period 2.
62065463|NCT05915728|EXPERIMENTAL|Approved Macrocyclic GBCA - Gadoquatrane|Participants will receive one intravenous injection of any approved macrocyclic GBCA during MRI in Period 1, followed by one intravenous injection of gadoquatrane during MRI in Period 2.
62065464|NCT01349894||SNaP® Wound Care System|
62270378|NCT04245020|ACTIVE_COMPARATOR|In person|Patients will be followed in person in the Outpatient department at 6-8 weeks
62286860|NCT03308188|EXPERIMENTAL|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
62286861|NCT04152382|EXPERIMENTAL|LY3462817 - Intravenous (IV)|LY3462817 administered as IV infusions.
62452681|NCT05381623|ACTIVE_COMPARATOR|Conventional approach|Application of hemostatic sponges over the donor site and placement of tooth-suspended compressive sutures over the area.
62065465|NCT05959421|EXPERIMENTAL|Booster|Participants will receive ERVEBO® (rVSV∆G-ZEBOV-GP) ≥72 million pfu/mL primary immunization And a single booster immunization with the same dose of study vaccine as the primary dose (≥72 million pfu/mL) at month 6 following primary vaccination
62270379|NCT03156400|ACTIVE_COMPARATOR|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
62632007|NCT06609278|EXPERIMENTAL|THRIVE|Participants will complete pre- and post-intervention quantitative measures assessing their motivation and comfort using Narcan and FTS. In addition, participants will also participate in a semi-structured qualitative focus group after completing the intervention session to assess harm reduction needs in their community, additional barriers participants expect with the adapted intervention, feasibility of the intervention, and perceived knowledge of opioid overdose and prevention and intervention tools gained from prior to the intervention to afterwards.
62270380|NCT03156400|ACTIVE_COMPARATOR|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
62632008|NCT02870192|EXPERIMENTAL|Rectal Prolapse|Patients with rectal prolapse, who will underwent laparoscopic ventral mesh rectopexy. The implemented mesh may be synthetic or biological.
62632009|NCT06515418|ACTIVE_COMPARATOR|A: Tirzepatide Monotherapy|"* Azelaprag placebo every morning~* Azelaprag placebo every evening~* Tirzepatide 5mg once weekly"
62632010|NCT06515418|EXPERIMENTAL|B: Azelaprag once daily plus Tirzepatide|"* Azelaprag 300mg every morning~* Azelaprag placebo every evening~* Tirzepatide 5mg once weekly"
62632011|NCT06515418|EXPERIMENTAL|C: Azelaprag twice daily plus Tirzepatide|"* Azelaprag 300mg every morning~* Azelaprag 300mg every evening~* Tirzepatide 5mg once weekly"
62632012|NCT06515418|EXPERIMENTAL|D: Azelaprag Monotherapy|"* Azelaprag 300mg every morning~* Azelaprag 300mg every evening~* Tirzepatide placebo once weekly"
62632013|NCT01497548|EXPERIMENTAL|Methylphenidate add on to Mirtazapine|Methylphenidate add on to the usual treatment (Mirtazapine)
62632014|NCT01497548|PLACEBO_COMPARATOR|Placebo add on to Mirtazapine|Non active compund add on to the usual treatment (Mirtazapine)
62632015|NCT04785898|OTHER|Screening patients COVID-19 test|"As part of the patient's management, two nasopharyngeal swabs will be taken from the same nostril:~* The first swab will be sent to the microbiology laboratory for analysis with the Simplexa ™ COVID-19 Direct assay so as not to impact the patient's diagnostic result.~* The second swab taken as part of the research will be analyzed with the ID NowTM COVID-19 test located in the UAS by one of the nurses trained and authorized to use it. The choice to perform the ID Now ™ COVID-19 test in the emergency room and not in the laboratory is based on the supplier's instructions. Indeed, the nasopharyngeal swab is intended to be analyzed directly and not to be transported in a container which could hinder the quality of the sample.~The discomfort or pain felt by the patient during the first sample can possibly influence the quality of the second. This could induce a bias. To minimize this bias, staff will be specifically trained in sampling."
62632016|NCT02966132|EXPERIMENTAL|iMD|"Participants will receive interactive Mobile Doctor (iMD) intervention in English, Chinese, Korean or Vietnamese languages that delivers video education tailored to patient's responses on a computer tablet during the clinic visit to enhance patient-provider discussion of tobacco use. The iMD intervention implements the 5As (Ask, Advice, Assess, Assist, and Arrange) recommended by the Clinical Practice Guideline for treating tobacco dependence. A summary printout including provider recommendation options, brief summary of smoking status, quit intention and concerns are provided to patients to empower them to discuss tobacco use with their providers."
62632017|NCT02966132|ACTIVE_COMPARATOR|NPA|Participants will receive a video education providing nutrition and physical activity recommendations right before before seeing their providers. A printout summarizing topics presented in the education videos will be provided to the patient
62065466|NCT05959421|EXPERIMENTAL|no Booster|Participants will receive ERVEBO® (rVSV∆G-ZEBOV-GP) ≥72 million pfu/mL primary immunization only
62065467|NCT01913158|PLACEBO_COMPARATOR|Placebo suppository|Hydrogenated palm kernel oil suppositories
62065468|NCT01913158|ACTIVE_COMPARATOR|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
62065469|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
62065470|NCT06624904|EXPERIMENTAL|Losartan|50 mg single-dose losartan
62270381|NCT06047548|EXPERIMENTAL|Tirzepatide 5 milligram (mg)|Participants will receive tirzepatide subcutaneously (SC).
62270382|NCT06047548|EXPERIMENTAL|Tirzepatide Maximum Tolerated Dose|Participants will receive tirzepatide SC.
62270383|NCT06047548|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62270384|NCT05880342|OTHER|Mental fatigue group|
62270385|NCT05880342|OTHER|Physical fatigue group|
62270386|NCT05880342|OTHER|Combined group|
62270387|NCT05080010|EXPERIMENTAL|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
62270388|NCT03042208|EXPERIMENTAL|Intervention|Access to Weight Watchers in-person meetings and online tools.
62632018|NCT04016142|EXPERIMENTAL|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients~* will be registered in the first part of the study at diagnosis and will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~* will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage (no progression during Part 1 of the study and no medical contra-indication to the study treatment)."
62632019|NCT06378307||Students, families, professionals|Students with disabilities, students without disabilities, families, educational professionals, social workers and professionals/volunteers working in recreational activities
62632020|NCT00943592|EXPERIMENTAL|Treatment|
62632021|NCT05588752|NO_INTERVENTION|group 1|will receive at induction of spinal anesthesia 100 µg of morphine
62632022|NCT05588752|EXPERIMENTAL|group 2|No morphine in spinal anesthesia but will receive a bilateral TAP block with 20 ml of Bupivacaine 0.25% and dexamethasone 4 mg in the same syringe on each side
62270389|NCT03042208|OTHER|Self-Guided Control Group|Received handout with basic weight management advice.
62632023|NCT03790852|EXPERIMENTAL|KSI-301 2.5 mg|KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
62286862|NCT04152382|PLACEBO_COMPARATOR|Placebo - IV|Placebo administered as IV infusions.
62632024|NCT03790852|EXPERIMENTAL|KSI-301 5 mg|KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
62632025|NCT02945735|EXPERIMENTAL|gaze-contingent|Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
62632026|NCT02945735|PLACEBO_COMPARATOR|non-gaze contingent|Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
62632027|NCT02007720|PLACEBO_COMPARATOR|Placebo|Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
62632028|NCT02007720|EXPERIMENTAL|Serelaxin|Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
62632029|NCT04406714|EXPERIMENTAL|Trial Mailed FIT Intervention - Age Group 50-75|Subjects randomized to this arm are 50-75 years of age and eligible for CRC screening using FIT per electronic health record at either of two FQHCs. Only subjects who are 50-75 years of age are randomized to this arm. Subjects who are 50-75 cannot be randomized to Arm 3 or Arm 4.
62632030|NCT04406714|NO_INTERVENTION|Trial Usual Care - Age Group 50-75|Subjects randomized to this arm are 50-75 years of age and eligible for CRC screening using FIT per electronic health record at either of two FQHCs. Only subjects who are 50-75 years of age are randomized to this arm. Subjects who are 50-75 cannot be randomized to Arm 3 or Arm 4.
62065471|NCT06624904|PLACEBO_COMPARATOR|Placebo|Microcellulose placebo in identical capsule
62065472|NCT04426344|EXPERIMENTAL|Group A - core warming|Patients randomized to Group A will have core warming with the ensoETM device initiated in the ICU or other clinical environment in which they are being treated. The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).
62286863|NCT04152382|EXPERIMENTAL|LY3462817 - Subcutaneous (SC)|LY3462817 administered as SC injections. (SC administration is discretionary/optional.)
62286864|NCT04152382|PLACEBO_COMPARATOR|Placebo - SC|Placebo administered as SC injections. (SC administration is discretionary/optional.)
62286865|NCT04152382|EXPERIMENTAL|LY3509754|LY3509754 administered orally.
62286866|NCT04152382|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62270390|NCT05149690|EXPERIMENTAL|monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
62632031|NCT04406714|EXPERIMENTAL|Sub-study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49|Subjects randomized to this arm are 45-49 years of age and eligible for CRC screening using FIT per electronic health record at one FQHC. Only subjects who are 45-49 years of age are randomized to this arm. Subjects who are 45-49 years of age cannot be randomized to Arm 1 or Arm 2 of the main trial.
62632032|NCT04406714|ACTIVE_COMPARATOR|Sub-study Mailed FIT Comparator Plain Envelope - Age Group 45-49|Subjects randomized to this arm are 45-49 years of age and eligible for CRC screening using FIT per electronic health record at one FQHC. Only subjects who are 45-49 years of age are randomized to this arm. Subjects who are 45-49 years of age cannot be randomized to Arm 1 or Arm 2 of the main trial.
62065473|NCT04426344|NO_INTERVENTION|Group B - Control Group|Group B is serving as the control group who will not have the ensoETM device used.Control group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature \< 36°C) or antipyretic therapy for febrile patients, as requested by the treating physician.
62632033|NCT02003755|EXPERIMENTAL|Spastic CP|continuous passive motion training
62632034|NCT05452915||Chronic Pain|Patients with chronic pain, aged 18 - 50 years for the neuropsychological assessment and 18-45 years for the fMRI examination
62632035|NCT05452915||Healthy Controls|Healthy controls matched on group level in terms of gender, age, and educational level
62632036|NCT03170817||N13-ammonia Cardiac Rest/Stress PET/CT|Patients with coronary artery disease (CAD) undergo a Cardiac Perfusion Rest/Stress Digital PET/CT scan using the radiopharmaceutical N13-ammonia and Regadenoson (Lexiscan) to induce pharmacologic stress.
62632037|NCT01794962|EXPERIMENTAL|Manual therapy and exercises|Manual therapy treatment: spinal manipulation, Soft tissue treatment, muscle energy techniques. Exercises: stabilisation exercises, Mckenzie exercises and general muscle exercises.
62632038|NCT01794962|EXPERIMENTAL|Cognitive Functional Therapy|An in depth interview, including investigating the patients beliefs on back pain, fear towards movement, anxiety and distress, using reflecting questions. The physical part consists of specific and functional exercises related to the patients functional complaints.And general physical activity for 30 mins 3-4 times weekly.
62632039|NCT03459716||Systemic sclerosis patients w/ PH|Pulmonary hypertension will be defined as a mean pulmonary artery pressure≥25mmHg on right heart catheterization
62632040|NCT03459716||Systemic sclerosis patients w/o PH|Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure\<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
62632041|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
62632042|NCT06612801|EXPERIMENTAL|Experimental: REThink therapeutic game|Participants in the experimental group will received the game-based intervention called REThink Game
62270391|NCT05149690|ACTIVE_COMPARATOR|Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
62270392|NCT01210339|EXPERIMENTAL|1|Treatment A (Clopidogrel 9 days), at least 14 days wash-out, Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days)
62270393|NCT01210339|EXPERIMENTAL|2|Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days), at least 14 days wash-out, Treatment A (Clopidogrel 9 days)
62632043|NCT06612801|NO_INTERVENTION|Control: Care as usual|Participants in the control group do not receive an intervention but they have access to standard resources from the school
62632044|NCT03055247|EXPERIMENTAL|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
62632045|NCT00500578|EXPERIMENTAL|1: Standard Schedule - Ribavirin|Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
62632046|NCT00500578|EXPERIMENTAL|2: Modified Schedule - Ribavirin|Aerosolized Ribavirin 2 grams over 3 hours every 8 hours
62065474|NCT06311656|EXPERIMENTAL|LY4100511 (DC-853) Part A Fasted|Single and multiple doses of LY4100511 (DC-853) administered orally.
62065475|NCT06311656|EXPERIMENTAL|LY4100511 (DC-853) Part B|Single and multiple higher doses of LY4100511 (DC-853) administered orally.
62065476|NCT06311656|EXPERIMENTAL|LY4100511 (DC-853) Part C (Open Label)|Single dose of LY4100511 (DC-853) administered orally in fed and fasted states.
62632047|NCT02362893|EXPERIMENTAL|Direct Observed Therapy|Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
62632048|NCT02362893|NO_INTERVENTION|Control|Standard care
62632049|NCT03564769|EXPERIMENTAL|Intervention Arm 1|Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
62270394|NCT01307475||Proband Group|Patients identified with FSS or a related condition
62632050|NCT03564769|EXPERIMENTAL|Intervention Arm 2|Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
62632051|NCT02360787|EXPERIMENTAL|Energy restriction|Energy restriction (-500 kcal/day) (N=40), where participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits to support weight loss. Participants will also be asked to avoid all nuts during the intervention period.
62632052|NCT02360787|EXPERIMENTAL|Energy restriction with almonds|Energy restriction (-500 kcal/day) with dry-roasted, lightly salted almonds supplying 15% of estimated energy requirement. Participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits. Energy from almonds will be accounted for during dietary modeling so that a 500 kcal/day deficit is achieved.
62632053|NCT00889655|ACTIVE_COMPARATOR|Golytely|216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy
62065477|NCT06311656|EXPERIMENTAL|LY4100511 (DC-853) Part D|Multiple higher doses of LY4100511 (DC-853) administered orally.
62065478|NCT06311656|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62065479|NCT02539836|EXPERIMENTAL|Obesity with dietary nutrition|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
62632054|NCT00889655|EXPERIMENTAL|MiraLax|216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser
62632055|NCT00423280|ACTIVE_COMPARATOR|1|700mg/day 6R-BH4
62632056|NCT00423280|ACTIVE_COMPARATOR|2|400mg/day 6R-BH4
62065480|NCT02539836|ACTIVE_COMPARATOR|Liver fat of obese children|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
62065481|NCT06493136||questionnaire|questionnaire
62270395|NCT01307475||Family Group|Persons who are genetically or legally related to a person with FSS or related condition
62270396|NCT01307475||Other Affected Individuals Group|Persons who have had significant and meaningful contact with a person with FSS or related condition but do not qualify for family group enrolment
62270397|NCT01148446|EXPERIMENTAL|R-CHOP|R-CHOP (every 21 days) for six courses Cyclophosphamide: 750 mg/m2, IV, day 1 Doxorubicin: 50 mg/m2, IV, day 1 Vincristine: 1.4 (max 2) mg/m2, IV, day 1 Prednisone: 75 mg/m2, IV, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
62286867|NCT04031456|EXPERIMENTAL|Participants receiving PRP treatment|Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion
62632057|NCT00423280|PLACEBO_COMPARATOR|3|Placebo
62632058|NCT01885832|EXPERIMENTAL|Treatment|In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.
62632059|NCT01280526|EXPERIMENTAL|Romidepsin dose 10mg/m²|Romidepsin dose 10mg/m²
62632060|NCT01280526|EXPERIMENTAL|Romidepsin dose 12mg/m²|Romidepsin dose 12mg/m²
62632061|NCT01280526|EXPERIMENTAL|Romidepsin dose 14mg/m²|Romidepsin dose 14mg/m²
62632062|NCT01280526|EXPERIMENTAL|Romidepsin dose 8mg/m²|Romidepsin dose 8mg/m²
62632063|NCT05453110|EXPERIMENTAL|Cautionary|The group will receive a message regarding potential risk for spine injury before the tested task.
62632064|NCT05453110|EXPERIMENTAL|Reassuring|This group will receive a message regarding spine resiliency before the tested task.
62632065|NCT05453110|NO_INTERVENTION|Control|This group will not receive education before the tested task.
62632066|NCT03335319|EXPERIMENTAL|Periodized Exercise Training Regime|The ET program will be carried out 3 times a week (60 minutes per session) on non-consecutive days for 48 weeks and supervised for both groups. Exercise prescription will be gradually progressed through various combinations of duration, frequency and/or intensity of training. Over the 1st-15th exercise sessions: MCT and anatomical resistance training; from the 16th-30th session: combined ET with HIIT and hypertrophy; from the 31st-45th exercise session, after the adjustments of the respectively time point assessments: MCT and maximal strength; from the 46th-60th exercise sessions: HIIT with hypertrophy; at the end of the 60th session until the end (6 months has passed): the same exercise prescription will repeat all over again at the same order.
62632067|NCT03335319|ACTIVE_COMPARATOR|Non Periodized Exercise Training Regime|participants will do a combined ET regime (aerobic and RT). Aerobic component: combine moderate to vigorous exercises 3 d.wk-1 on nonconsecutive days, for 20 min per session, involving major muscle groups using the available ergometers to perform continuous and rhythmic activities in nature. Resistance component: RT should be performed after the aerobic component of the exercise session to allow for adequate warm-up. Initial load should be trained initially with one set of 10-15 repetitions that can be lifted without straining (\~30%-40% 1RM for the upper body; \~50%-60% 1 RM for the lower body). Each major muscle group should be trained initially with one set; multiple set regimens may be introduced later as tolerated. It will be performed 8-10 exercises of the major muscle groups.
62632068|NCT02690012|ACTIVE_COMPARATOR|Drug Magnesium oxide|Participants will be given standard dose levels of Magnesium oxide according to the level of magnesium in blood.
62632069|NCT02690012|ACTIVE_COMPARATOR|Drug Magnesium citrate|Participants will be given standard dose levels of Magnesium citrate according to the level of magnesium in blood.
62632070|NCT04270617|NO_INTERVENTION|Control arm|The control arm will involve usual care - 6 weeks of physical therapy, NSAIDs, and epidural steroid injections
62632071|NCT04270617|EXPERIMENTAL|Yoga Arm|The study arm will involve a yoga protocol devised by Eddie Stern - a renowned Ashtanga yoga practitioner, and can include NSAIDs.
62632072|NCT04530838|EXPERIMENTAL|20-valent pneumococcal conjugate vaccine (subcutaneous)|20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
62632073|NCT04530838|ACTIVE_COMPARATOR|13-valent pneumococcal conjugate vaccine (subcutaneous)|13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
62632074|NCT04530838|EXPERIMENTAL|20-valent pneumococcal conjugate vaccine (intramuscular)|20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)
62632075|NCT00666211|ACTIVE_COMPARATOR|Standard of Care|Standard pain control drugs.
62632076|NCT00666211|EXPERIMENTAL|Opioid Titration|Pain will be Monitored and Medication Titrated
62632077|NCT06612359|EXPERIMENTAL|BOOST GAIT|Participants recruited for this pilot study will undergo the BOOST GAIT program in addition to their usual inpatient rehabilitation care.
62065482|NCT04596033|EXPERIMENTAL|Multiple Low Dose (MLD)|GEN-011 is administered by IV infusion at 4-week intervals, up to 5 doses maximum. Each dose is followed by IL-2 administration. MLD patients will not undergo lymphodepletion.
62632078|NCT01293747|EXPERIMENTAL|Estradiol 0.5 mg/Progesterone 15 mg microspheres|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension
62632079|NCT01293747|EXPERIMENTAL|Estradiol 1 mg/Progesterone 20 mg microspheres|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension
62632080|NCT05113680|EXPERIMENTAL|compassion|compassion focused group based on CFT
62065483|NCT04596033|EXPERIMENTAL|Single High Dose (SHD)|GEN-011 is administered as a single IV infusion at the maximum available cell yield, after the patient completes a fludarabine/cyclophosphamide lymphodepletion regimen. The single GEN-011 dose is followed by IL-2 administration.
62065484|NCT03282279||TVOR population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all transvaginal oocyte retrieval procedures performed between 1996 and October 2016.
62632081|NCT05113680|ACTIVE_COMPARATOR|emotional competencies|emotional competencies group (based on emotional intelligence)
62632082|NCT05113680|NO_INTERVENTION|control|control group
62632083|NCT03628378|NO_INTERVENTION|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
62632084|NCT03628378|EXPERIMENTAL|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
62632085|NCT06119165|NO_INTERVENTION|Control|Participants will conduct online shopping tasks without any environmental nudges. This includes no labels, peer comparison messages, or suggested product swaps.
62632086|NCT06119165|EXPERIMENTAL|Environmental|Participants in the experimental arm will shop and receive environmental nudges in the form of labels, peer comparisons messages, and suggested product swaps.
62632087|NCT05556980|EXPERIMENTAL|totally laparoscopic distal gastrectomy|patients in this arm will receive totally laparoscopic distal gastrectomy
62632088|NCT05556980|NO_INTERVENTION|laparoscopy-assisted distal gastrectomy|patients in this group will receive laparoscopy-assisted distal gastrectomy
62632089|NCT04658433|EXPERIMENTAL|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 8 weeks.
62632090|NCT04658433|NO_INTERVENTION|Control group|
62632091|NCT01698970|EXPERIMENTAL|1 = Tested product|
62632092|NCT01698970|PLACEBO_COMPARATOR|2 = Control product|
62632093|NCT02632006|EXPERIMENTAL|PIK-PD-1 cells|PIK-PD-1 cells treatment will be performed every 3 weeks with a total of three periods.
62632094|NCT02632006|ACTIVE_COMPARATOR|DC-PMAT|DC-PMAT cells treatment will be performed every 3 weeks with a total of three periods.
62452682|NCT03408626|EXPERIMENTAL|papain chemomechenical caries removal agent (brix 3000)|papain chemomechenical caries removal agent (Birx 3000) and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action
62452683|NCT03408626|PLACEBO_COMPARATOR|conventional|conventional 330 bur
62632095|NCT02948647|NO_INTERVENTION|Control Group|Will receive standard of care, which is general dietary advice
62632096|NCT02948647|EXPERIMENTAL|Intervention Group|Will receive standard of care as well as sugar-reduction education
62632097|NCT05221697|EXPERIMENTAL|Intervention|PRESAGE Care ATIH + Nurse or GP consultation
62632098|NCT05221697|NO_INTERVENTION|Control group|usual care
62632099|NCT01369459|EXPERIMENTAL|Family Counseling with MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
62632100|NCT01369459|NO_INTERVENTION|Historical Control|
62632101|NCT02533934|EXPERIMENTAL|Treatment with Sofosbuvir based HCV Therapy|Prospective and retrospective treatment for HCV
62632102|NCT00608751|EXPERIMENTAL|IMRT|External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
62632103|NCT01608464|ACTIVE_COMPARATOR|Arm A|Arm A: will receive combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
62632104|NCT01608464|EXPERIMENTAL|Arm B|"Arm B will receive combination of cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.~PET scan will be repeated 3-4 weeks after end of concurrent chemo-radiation therapy Patients in Arm A and B will go for esophagectomy 4-6 weeks after end of concurrent chemo-radiation therapy or chemotherapy"
62632105|NCT05361967||ATK: Above-The-Knee|Subjects with claudication (Rutherford 3) or CLTI (Rutherford 4 or 5), who have undergone an endovascular procedure utilizing adjunctive therapies, other than balloon angioplasty alone, which are then followed by PTA and IVUS, and have an arterial dissection requiring repair. ATK subjects will have baseline lesions in the superficial femoral and/or proximal popliteal arteries.
62065485|NCT02287350|EXPERIMENTAL|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
62065486|NCT02359643|PLACEBO_COMPARATOR|with high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (\>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.
62632106|NCT05361967||BTK: Below-The-Knee|Subjects with CLTI (Rutherford 4 or 5), who have undergone an endovascular procedure utilizing adjunctive therapies, other than balloon angioplasty alone, which are then followed by PTA and IVUS, and have an arterial dissection requiring repair. BTK subjects will have baseline lesions in the mid/distal popliteal, peroneal and/or tibial arteries.
62632107|NCT04781296|EXPERIMENTAL|Subject's Scanned with Investigational Device|
62632108|NCT02536105|ACTIVE_COMPARATOR|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
62632109|NCT02536105|PLACEBO_COMPARATOR|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
62065487|NCT02359643|EXPERIMENTAL|Without high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) without high dose aspirin (\>50mg/kg/day) since diagnosed, then low dose aspirin (3-5mg/kg/day) when fever subside.
62065488|NCT02998021|EXPERIMENTAL|Resistance Training - Vibrating Dumbbell|Study participants who are randomized into the vibration exercise group will complete an in-home exercise program using a vibrating dumbbell.
62065489|NCT02998021|ACTIVE_COMPARATOR|Resistance Training - Standard Dumbbell|Study participants who are randomized into the control exercise group will complete an in-home exercise program using standard dumbbells.
62065490|NCT02784223|EXPERIMENTAL|PET-CT with F18-choline|PET-CT with F18-choline examination will be performed before surgery
62065491|NCT06358911|EXPERIMENTAL|Poly amido amine dendrimer (PAMAM)'s desensitizing agent|"Fourth generation with COOH terminal functional group, colorless liquid. PAMAM-succinamic acid dendrimer, 1,4-diaminobutane core, generation 4 solution. 10 wt.% in water.~The application of PAMAM 30 min according to previous studies"
62065492|NCT06358911|EXPERIMENTAL|Manufacturer's desensitizing agent, Ultra EZ|3% potassium nitrate and 0.11% fluoride (Ultra EZ), gel The application of manufacturer recommended desensitizing agent for 1hrs
62065493|NCT06358911|EXPERIMENTAL|MI paste plus, desensitizing agent|"Casein-phosphopeptide-amorphous calcium phosphate with Fluoride, topical tooth cream.~Gel contains pure water,D-sorbitol,glycerol,Carboxymethylcellulose Sodium, casein phosphopeptide amorphous calcium phosphate,propylene glycol, titanium dioxide, Silicon dioxide, Sodium Saccharin,Phosphoric acid, butyl P-hydroxy-benzoate, and ethyl hydroxyl benzoate~The application of MI paste plus according to manufacturer instructions, 3minutes"
62452684|NCT03167671|ACTIVE_COMPARATOR|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy.
62452685|NCT03167671|EXPERIMENTAL|AposTherapy|Treatment with at home AposTherapy with daily use of the shoe.
62270398|NCT01148446|EXPERIMENTAL|R-mini-CEOP|R-miniCEOP (every 21 days)for six courses Cyclophosphamide: 50 mg/m2, IV, day 1 Epirubicin: 50 mg/m2, IV, day 1 Vinblastine: 5 mg/m2, IV, day 1 Prednisone: 60 mg/m2, IV/PO, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
62452686|NCT03840733||Participants from NCT01985568 or NCT03411356|All subjects who previously enrolled in the Parent Study's behavioral weight loss intervention (NCT01985568 or NCT03411356).
62270399|NCT02435355|NO_INTERVENTION|standard support|All patients in this study underwent this procedure, which is the regular procedure in France.
62452687|NCT01835678|ACTIVE_COMPARATOR|Linagliptin|Linagliptin
62452688|NCT01835678|PLACEBO_COMPARATOR|Placebo|Placebo
62452689|NCT02004704|EXPERIMENTAL|GZ402665|GZ402665 administered intravenously once every 2 weeks at the dose each participant was receiving at the end of their previous olipudase alfa study, for 9 years or until olipudase alfa becomes commercially accessible, whichever comes first, unless the participant decides to enter another olipudase alfa clinical trial within the 9-year period prior to when olipudase alfa is commercially accessible.
62452690|NCT01195714|EXPERIMENTAL|Ofatumumab|
62452691|NCT00665041|EXPERIMENTAL|PR1|
62452692|NCT00665041|PLACEBO_COMPARATOR|PL1|
62452693|NCT03239132|EXPERIMENTAL|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks, as well as meditation educational materials.
62452694|NCT03239132|ACTIVE_COMPARATOR|Control|The control will receive meditation educational materials.
62452695|NCT03197064|OTHER|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
62452696|NCT01346332||Anesthetization|
62452697|NCT05564832|EXPERIMENTAL|Pilocarpine Therapy|The right eyes of 45 patients will be treated by Biocarpine® and Vuity® eye drops. They will be considered as the case group,
62452698|NCT05564832|NO_INTERVENTION|Without Pilocarpine Therapy|The left eyes of the patients will be defined as the controls.
62452699|NCT01265784|EXPERIMENTAL|TP-434, 1.5 mg/kg q24h|TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
62452700|NCT01265784|EXPERIMENTAL|TP-434, 1.0 mg/kg q12h|TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
62452701|NCT01265784|ACTIVE_COMPARATOR|Ertapenem, 1 g q24h|Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
62452702|NCT04799158|EXPERIMENTAL|Run-In Period|Participants will receive vonoprazan 20 mg once daily for up to 4 weeks.
62452703|NCT04799158|EXPERIMENTAL|Vonoprazan 10 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 10 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
62452704|NCT04799158|EXPERIMENTAL|Vonoprazan 20 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 20 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
62286868|NCT04031456|PLACEBO_COMPARATOR|Participants receiving Platelet Free Plasma (PFP) treatment|Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion
62452705|NCT04799158|EXPERIMENTAL|Vonoprazan 40 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 40 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
62632110|NCT02536105|ACTIVE_COMPARATOR|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
62270400|NCT02435355|EXPERIMENTAL|coached group|In the coached group (CG), patients received standard support completed by 5 sessions (day 3, 10, 30, 60, 90 with equipment at home) of telephone-based counselling session by competent staff. Sessions were performed by a qualified person in education, qualifies by a university degree (Paul Sabatier University, Toulouse, France). The dates of phone calls were planned with the patient availabilities.
62270401|NCT05136937|EXPERIMENTAL|Oncolytic virus injection(RT-01) for patients with advanced solid tumors|"Intratumoral administration of RT-01 as single agent for patients with advanced solid tumors.The injection dose of RT-01 was determined by the lesion size:~1. mL for lesion length \<1.5 cm;~2. mL for lesion length between 1.5 cm and 2.5 cm;~3. mL for lesion length between 2.5 cm and 5.0 cm;~4. mL for lesion length between \>5 cm"
62632111|NCT02536105|ACTIVE_COMPARATOR|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
62632112|NCT00527280|EXPERIMENTAL|1|
62632113|NCT03861091|EXPERIMENTAL|Risedronate|Risedronate 150 mg given once 7-21 days prior to initiation of SBRT
62632114|NCT03861091|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo, dose not applicable given once 7-21 days prior to initiation of SBRT
62632115|NCT05163262|EXPERIMENTAL|experimental|Addition of a sexuality questionnaire during patient follow-up within 3 months after inclusion, 6 months after and at one year
62632116|NCT00760721|EXPERIMENTAL|1|Educational small group session with HBV screening resources provided
62632117|NCT00760721|SHAM_COMPARATOR|2|Educational small group discussion, diet/physical activity resources provided
62632118|NCT01944748|EXPERIMENTAL|Family Mediation|Families receive FARS family mediation program after completing baseline survey.
62632119|NCT01944748|NO_INTERVENTION|Wait-list control|Families receive FARS family mediation program after completing baseline, 6-week and 12-week surveys.
62632120|NCT04033146|EXPERIMENTAL|Young Adult Exoskeleton Users|Study participants who are 18-45 year old.
62632121|NCT04033146|EXPERIMENTAL|Older Adult Exoskeleton Users|Study participants who are greater than 65 years of age.
62632122|NCT02571062|EXPERIMENTAL|experimental formulation|crossover design
62632123|NCT02571062|EXPERIMENTAL|final formulation|crossover design
62632124|NCT01772927||Very low birth weight infants,|Parenteral nutrition
62632125|NCT04643327|EXPERIMENTAL|Active arm|125mg Levetiracetam capsules taken twice daily (morning and evening) for 14 days
62632126|NCT04643327|PLACEBO_COMPARATOR|Placebo arm|125mg maize starch-based placebo capsules taken twice daily (morning and evening) for 14 days
62270402|NCT04650373||Surgical management|Underwent bariatric surgery
62270403|NCT04650373||Non-surgical management|Patients treated medically
62632127|NCT03795337|EXPERIMENTAL|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
62632128|NCT01619878|EXPERIMENTAL|Cohort 1|"One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.~Infants age \>28 days."
62632129|NCT03113110|OTHER|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG \[Jardiance\]
62632130|NCT01074177|EXPERIMENTAL|BIBW 2992|BIBW 2992 Taken orally once a day
62632131|NCT02954328|EXPERIMENTAL|tDCS|"The active tDCS condition will consist of 4 visit:~During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:~1. Sham~2. motor M1 area~3. motor M1 + Dorsolateral Prefrontal cortex~4. Dorsolateral Prefrontal cortex.~The tDCS condition will be randomized and double blinded"
62632132|NCT04657263||Person at risk of infection according to French 2019 immunization|Person at risk of infection according to French 2019 immunization
62632133|NCT01275443|EXPERIMENTAL|300mg TMC278LA|Single gluteal intramuscular injection (300mg) at day 1
62632134|NCT01275443|EXPERIMENTAL|1200mg TMC278LA|Single gluteal intramuscular injection (1200mg) at day 1
62632135|NCT01275443|EXPERIMENTAL|600mg TMC278LA|Single gluteal intramuscular injection (600mg) at day 1
62270404|NCT02148380|EXPERIMENTAL|chemotherapy group(B)|pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks
62270405|NCT02148380|EXPERIMENTAL|combination therapy group(A)|pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.
62270406|NCT02148380|EXPERIMENTAL|gefitinib group (group C)|received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death
62270407|NCT00486408|EXPERIMENTAL|1|MRKAd5 HIV-1 gag/pol/nef vaccine administered as 1 ml in either deltoid at study entry and Weeks 4 and 26
62270408|NCT01751308|EXPERIMENTAL|Phase 1: Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).
62632136|NCT01275443|EXPERIMENTAL|150mg TMC278LA|This arm was included in the adaptive design of the study, but was not recommended for use based on the review of results from 300mg and 600mg arms by the protocol steering committee
62632137|NCT05364476|EXPERIMENTAL|16 weeks digital intervention with online and offline support|This study is a single-arm, non-randomized clinical trial, which will collect participant's baseline data, apply relevant assessment scales, collect data using a comprehensive digital intervention in 16 weeks to evaluate the improvement of relevant markers post intervention.
62632138|NCT05622461|EXPERIMENTAL|Road-to-recovery group (R2R)|Usual medical care plus the R2R-TBI intervention (self-guided web-program)
62632139|NCT05622461|ACTIVE_COMPARATOR|Internet resources comparison group (IRC)|Usual medical care plus internet resources
62632140|NCT04485078||Axial spondyloarthritis patients|QST with clinical scales
62632141|NCT04485078||Healthy controls|QST
62632142|NCT06473207|EXPERIMENTAL|Remote ischemic post-conditioning (RIPOST)|Patients subjected to three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest)
62270409|NCT01751308|EXPERIMENTAL|Phase 1: Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
62270410|NCT01751308|EXPERIMENTAL|Phase 1: Cabazitaxel 30 mg/m^2|Cabazitaxel 30 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
62270411|NCT01751308|EXPERIMENTAL|Phase 1: Cabazitaxel 35 mg/m^2|Cabazitaxel 35 mg/m\^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
62632143|NCT06473207|SHAM_COMPARATOR|Sham procedure|Patients subjected to three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest)
62632144|NCT02931786|ACTIVE_COMPARATOR|propofol|body core temperature was measured from tympanic membrane after 1 mg/kg propofol administration, before and after magnetic resonance imaging
62632145|NCT02931786|ACTIVE_COMPARATOR|ketofol|body core temperature was measured from tympanic membrane after 0,1 ml/kg administration of ketamine propofol mixture of 10 mg/ml both, before and after magnetic resonance imaging
62632146|NCT02542397|EXPERIMENTAL|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
62632147|NCT00762762|ACTIVE_COMPARATOR|Total toothpaste|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste.
62632148|NCT00762762|PLACEBO_COMPARATOR|Fluoride mouthrinse|Swish whole mouth 2x/day for 12 months with fluoride mouthrinse.
62632149|NCT02997605|ACTIVE_COMPARATOR|Glucocorticoid (GC) tapering|"GC tapering group: patients will be asked to taper prednisone taken every morning at 8.00 AM by decreasing the daily dose by 1 mg every month as soon as they are in remission or Low Disease Activity (LDA). In addition they will receive a placebo of 20 mg/day of hydrocortisone (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg/day (at 8.00 AM) of hydrocortisone placebo for 3 months before discontinuing the hydrocortisone placebo."
62632150|NCT02997605|ACTIVE_COMPARATOR|Hydrocortisone replacer|"Hydrocortisone replacer group: patients will replace prednisone with 20 mg of hydrocortisone on a daily basis (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg daily (at 8.00 AM) for 3 months then stop as soon as they are in remission or LDA, as well as a prednisone placebo (at 8.00 AM) with a schedule to taper the prednisone placebo by 1mg/day every month until discontinuation."
62632151|NCT04010292|EXPERIMENTAL|Patient education card|
62632152|NCT04010292|NO_INTERVENTION|Control|
62632153|NCT04635930|EXPERIMENTAL|Taping plus Traditional exercises|"kinesio tape for improving the alignment of the scapula by inhibiting the hyperactive upper trapezius and facilitating the weak serratus anterior muscleStretching of the tight muscles of upper limb.~* Reaching forward sidewise and backward.~* Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).~* Prone lying weight bearing on elbows (four point kneeling)~* side sitting with weight bearing on the effected side, for 5 minutes.~* Wall pushups.~* Catching and throwing of ball"
62632154|NCT04635930|ACTIVE_COMPARATOR|Traditional exercises|"Stretching of the tight muscles of upper limb.~* Reaching forward sidewise and backward.~* Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).~* Prone lying weight bearing on elbows (four point kneeling)~* side sitting with weight bearing on the effected side, for 5 minutes.~* Wall pushups.~* Catching and throwing of ball"
62632155|NCT04058197|EXPERIMENTAL|Active|Deferoxamine (DFO) Intradermal Delivery Patch (DIDP), 45mg DFO daily, up to 12 weeks
62632156|NCT04058197|PLACEBO_COMPARATOR|Placebo|Placebo
62632157|NCT01405898|EXPERIMENTAL|Beetroot Juice|
62632158|NCT01405898|PLACEBO_COMPARATOR|Nitrate-free beetroot juice|
62632159|NCT00653367|EXPERIMENTAL|NS|Nerve section of intercostal nerve during surgery
62632160|NCT00653367|NO_INTERVENTION|Control|Control
62632161|NCT03793647|ACTIVE_COMPARATOR|Low Intensity EMS|Conventional Stimulation
62632162|NCT03793647|EXPERIMENTAL|High Intensity EMS|Russian Stimulation
62632163|NCT03793647|PLACEBO_COMPARATOR|Placebo|no Stimulation, supported by phone contact
62632164|NCT03212014|EXPERIMENTAL|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
62632165|NCT03212014|EXPERIMENTAL|POWER|Participants in this group would be treated with POWER for three months
62270412|NCT01751308|EXPERIMENTAL|Phase 2: Cabazitaxel 30 mg/m^2|Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m\^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
62632166|NCT03212014|ACTIVE_COMPARATOR|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
62632167|NCT00397605|EXPERIMENTAL|Crossover|
62632168|NCT03779347|EXPERIMENTAL|Schistosomiasis treated during pregnancy|Praziquantel 40mg/kg once will be given during pregnancy at second to third trimester
62632169|NCT03779347|ACTIVE_COMPARATOR|Schistosomiasis treated after pregnancy|Praziquantel 40mg/kg once will be given to parturient after delivery during lactation
62632170|NCT03779347|EXPERIMENTAL|All study participants|UCP-LF CAA and composite diagnostic reference test based on extensive egg microscopy, plus serology, plus qPCR on egg DNA, and plus POC-CC will be used to detect schistosomiasis infection in pregnant women
62632171|NCT02455505||Risk Screening tool & Cognitive Interview|
62632172|NCT01951417|EXPERIMENTAL|Adapalene/BPO Gel/Foam Wash/Moisturizer|Adapalene BPO Gel Pump (once daily) in conjunction with a Foam Wash (twice daily) and Moisturizer SPF 30 (once daily)
62632173|NCT00991289|EXPERIMENTAL|NTZ/PEG/RBV|Participants received nitazoxanide (NTZ) alone for 4 weeks followed by 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment.
62270413|NCT06309459||Low Staining|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total.
62270414|NCT06309459||High Staining|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as high staining if they constituted ≥ 10%
62270415|NCT01324232|PLACEBO_COMPARATOR|Placebo|
62270416|NCT01324232|EXPERIMENTAL|AVP-923-45|
62270417|NCT01324232|EXPERIMENTAL|AVP-923-30|
62270418|NCT01324232|EXPERIMENTAL|AVP-923-20|
62632174|NCT05602740||MINDRHYTHM HARMONY|Passive Recording of the head pulse
62632175|NCT00254553|ACTIVE_COMPARATOR|Arm 1|Testim 1% (testosterone gel)
62632176|NCT00254553|PLACEBO_COMPARATOR|Arm 2|Placebo
62632177|NCT01008839||Old age group of healthy women|Old women over 70 years old
62632178|NCT01008839||young group of healthy women|aged 25-35 years
62632179|NCT02440061|ACTIVE_COMPARATOR|Study Group: Type 2 Diabetes Mellitus (T2DM)|Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
62452706|NCT04799158|PLACEBO_COMPARATOR|Placebo: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take a placebo when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
62632180|NCT02440061|ACTIVE_COMPARATOR|Control Group|Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
62632181|NCT02051790|EXPERIMENTAL|Clinical Practice Scans|Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.
62632182|NCT03438084|EXPERIMENTAL|Interesterified|Commercially available interesterifed fat spread. 50g fat.
62632183|NCT03438084|ACTIVE_COMPARATOR|Non- interesterified|Commercially available non-interesterified fat. 50g fat.
62632184|NCT03438084|ACTIVE_COMPARATOR|Control|Rapeseed oil. 50 g fat.
62632185|NCT03438084|ACTIVE_COMPARATOR|Saturated fat control|Butter. 50g fat
62632186|NCT06171854|EXPERIMENTAL|cabozantinib|60 mg once daily. Route: per os Cycle: 28 days
62632187|NCT00118989|PLACEBO_COMPARATOR|PLACEBO|placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
62632188|NCT00118989|EXPERIMENTAL|Curcuminoids C3 Complex® to be taken orally via caps|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
62632189|NCT01711983|EXPERIMENTAL|Test Device|ASD closure with the GORE® CARDIOFORM Septal Occluder
62632190|NCT01289548|NO_INTERVENTION|control|patients (both donors and recipients) had a deflated cuff placed on the left lower limb for 30 min
62632191|NCT01289548|EXPERIMENTAL|donor|Donors receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; recipients only have a deflated blood pressure cuff around their leg for 30 minutes.
62065494|NCT06358911|EXPERIMENTAL|Hydroxyapatite and F (ReminPro), desensitizing agent|Hydroxyapatite, Fluoride and Xylitol, water-based cream The application of Hydroxyapatite and F (ReminPro) according to manufacturer instructions, 3minutes
62632192|NCT01289548|EXPERIMENTAL|recipient|recipients receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; donors only have a deflated blood pressure cuff around their leg for 30 minutes.
62632193|NCT03414333|EXPERIMENTAL|Roux-en- Y gastric bypass (RYGB)|Roux-en- Y gastric bypass (RYGB) is the most popular bariatric procedure and it has been associated with improvements in glycemic control and cognitive function. It works by decreasing the amount of food you can eat at one sitting and by changing the hormones released at the bottom of the stomach and duodenum.we propose that RYGB is a model of chronic elevation of GLP-1 providing an opportunity to explore relationship between changes in the circulating hormone and brain glucose metabolism, cognitive function and neuroplasticity.
62632194|NCT03414333|ACTIVE_COMPARATOR|GLP-1|GLP-1 is an intestinal hormone secreted in response to nutrients.
62632195|NCT03559543|EXPERIMENTAL|Ocoxin-Viusid®|
62632196|NCT01867515|ACTIVE_COMPARATOR|Younger normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~* age between 18 and 35~* individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
62632197|NCT01867515|ACTIVE_COMPARATOR|Hearing-impaired listeners|"individuals with bilateral sensorineural hearing losses with thresholds between 25 and 70 dB HL and no losses greater than 70 dB HL at frequencies of 4000 Hz or below~* age 18 to 65 Acoustic distortion of speech"
62632198|NCT01867515|ACTIVE_COMPARATOR|Older normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~* age between 36 and 65~* individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
62632199|NCT05714696|EXPERIMENTAL|Weight discrimination experience|"Participants in the experimental condition will:~1. Learn that their group mates are biased against overweight people (i.e., they have negative attitudes toward people with higher body weight),~2. Receive feedback about their personal attributes that is consistent with negative weight-based stereotypes (e.g., lacking self-discipline), and~3. Not be selected as a partner for the remaining lab tasks (i.e., this experience may prompt feelings of social exclusion)."
62632200|NCT05714696|ACTIVE_COMPARATOR|Control experience|"Participants in the control condition will:~1. Learn that their group mates are very accepting of overweight people (i.e., they have positive attitudes toward people with higher body weight),~2. Receive positive feedback about their personal attributes that is not consistent with negative weight-based stereotypes, and~3. Will be told that one of their group members had to leave early for an emergency so the pairs cannot be assembled as usual (i.e., this experience should not prompt feelings of social exclusion)."
62632201|NCT06300099|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone injection
62452707|NCT05549856|EXPERIMENTAL|Dry suction group|22G Franseen needle biopsy with dry suction technique(The puncture needle be filled with air)
62452708|NCT05549856|ACTIVE_COMPARATOR|Wet suction group|22G Franseen needle biopsy with wet suction(The puncture needle be filled with saline before sugry)
62452709|NCT00565305|EXPERIMENTAL|Healing Touch|Healing Touch + Standard Treatment Healing Touch treatments daily following standard Radiation Therapy. Standard radiation therapy is part of their medical care and is not administered as part of this study. Protocol of 4 HT techniques will be used including Pain Drain, Chakra connection, Magnetic Unruffling, and Mind Clearing. Treatments will be approximately 20-30 minutes.
62632202|NCT06300099|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine injection.
62632203|NCT04181671|EXPERIMENTAL|Low Resistance Training Group|The experimental group will receive low resistance blood flow restriction training with 30% of 1 RM.
62632204|NCT04181671|ACTIVE_COMPARATOR|High Resistance Training Group|Participants of this group will receive High resistance training (80% of 1 RM) without blood flow restriction.
62632205|NCT02408042|ACTIVE_COMPARATOR|RICE and Pembrolizumab|non-Hodgkin's lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
62632206|NCT02408042|ACTIVE_COMPARATOR|ICE and Pembrolizumab|classical Hodgkin's lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
62632207|NCT02408042|ACTIVE_COMPARATOR|brentuximab vedotin and Pembrolizumab|classical Hodgkin's lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin
62632208|NCT02541422|ACTIVE_COMPARATOR|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
62632209|NCT02541422|PLACEBO_COMPARATOR|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
62632210|NCT03574077|EXPERIMENTAL|Instant messaging|AWARD advice + NRT sampling + Active referral + Instant Messaging (IM)
62632211|NCT03574077|ACTIVE_COMPARATOR|SMS messaging|AWARD advice + NRT sampling + Active referral + SMS messaging
62065495|NCT00687336|ACTIVE_COMPARATOR|1|Empirical eradication treatment
62632212|NCT00181883|EXPERIMENTAL|Quetiapine|"2.5 - 5.0mg/kg PO BID quetiapine~Other Names:~Seroquel"
62632213|NCT05084183|EXPERIMENTAL|PermeaDerm®|N=34 Participants will receive application of PermeaDerm® as outlined in Directions for Use
62632214|NCT05084183|ACTIVE_COMPARATOR|Mepilex Ag®|Participants will receive application of Mepilex Ag® as outlined in Directions for Use.
62632215|NCT04487808|ACTIVE_COMPARATOR|Average American Diet|Diet representative of average American intake in terms of diet quality measured by the Healthy Eating Index-2015.
62632216|NCT04487808|ACTIVE_COMPARATOR|Average American Diet + Pecans|Diet that approximates average American intake in terms of diet quality measured by the Healthy Eating Index-2015, but includes 2 oz./day of pecans.
62632217|NCT04487808|ACTIVE_COMPARATOR|Healthy Diet + Pecans|High diet quality, measured by Healthy Index-2015 score \>95, and includes 2 oz./day of pecans.
62632218|NCT00507260|EXPERIMENTAL|Control Group|Control Group (Food Record)
62632219|NCT00507260|EXPERIMENTAL|Treatment Group|Treatment Group (Food Record + Nutritional Consults)
62632220|NCT04338477|EXPERIMENTAL|Nephrosolid|Acute dosis day 1: 3X2 Nephrosolid tablets 0.5 h before intake of a meal Long-term dosis days 2-28: 2x1 Nephrosolid tablets 0.5 h before intake of a meal
62632221|NCT00933504|EXPERIMENTAL|Dermacyd Silver Floral (Lactic Acid)|Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
62632222|NCT06612242||Early tracheostomy|Patients with Guillain Barre who underwent early tracheostomy
62632223|NCT06612242||Late tracheostomy|Patients with Guillain Barre who underwent late tracheostomy
62632224|NCT02706080||Antithrombotic agents|We propose to realize a single-center prospective registry of patient under Antithrombotic agent who came to the emergency unit for any reason.
62632225|NCT04691219|EXPERIMENTAL|Mulberry leaves powder plus diet control|
62270419|NCT01029067|ACTIVE_COMPARATOR|Cognitive Remediation|Computerized cognitive remediation (CogPack training). A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with group MCT, eight sessions are administered. Each session lasts approximately 45-60 minutes.
62632226|NCT04691219|OTHER|Diet control alone|
62632227|NCT02454751|EXPERIMENTAL|Pre-fentanyl dose/fentanyl dose|Crossover: 6-six minute walk test, subjective rating of dyspnea, heart rate, respiratory rate, oxygen saturation and participants' general appearance measured before and after a dose of fentanyl.
62632228|NCT05748964||Transperitoneal approach laparoscopic pyeloplasty. (TALP)|Transperitoneal approach laparoscopic pyeloplasty. (TALP)
62632229|NCT05748964||Retroperitoneal Approach laparoscopic pyeloplasty. (RALP)|Retroperitoneal Approach laparoscopic pyeloplasty. (RALP)
62632230|NCT03485794||Diagnostic (biospecimen collection)|Patients undergo collection of blood for metabolic profiling via LC/Q-TOF/MS.
62632231|NCT05940415||Patients with low-risk of prostate cancer based on USTC diagnostic model and serum PSA levels.|Patients with PSA between 4 to 10 ng/ml and USTC model predicted probability of cancer less than 0.05 (https://ustcprostatecancerprediction.shinyapps.io/dynnomapp/).
62632232|NCT05364788||All participants|Appendiceal Cancer Patients
62065496|NCT00687336|ACTIVE_COMPARATOR|2|Eradication treatment according to a diagnostic test (URT, histological test, breath test or serology).
62065497|NCT03847038|EXPERIMENTAL|Intervention|Multimodal lifestyle-interventional. Participants are disclosed their 5-year dementia risk estimate
62065498|NCT01396577|ACTIVE_COMPARATOR|3 x 2-mg perampanel|
62065499|NCT01396577|ACTIVE_COMPARATOR|6mg perampanel|
62632233|NCT05492149||Pulmonary rehabilitation group|Patients referred for a pulmonary rehabilitation program will be follow up.
62632234|NCT01124318|ACTIVE_COMPARATOR|Lactofiltrum|
62632235|NCT01124318|PLACEBO_COMPARATOR|Placebo|
62632236|NCT03153046|EXPERIMENTAL|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
62632237|NCT03153046|PLACEBO_COMPARATOR|Maltodextrin|12 week ingestion of maltodextrin
62632238|NCT05407688||ADHD group|Adolescents with ADHD
62632239|NCT05407688||Health group|Adolescents without ADHD
62632240|NCT04767113|EXPERIMENTAL|Heparin group|Continuous infusion of heparin was used to maintain the patency of CVC.
62632241|NCT04767113|PLACEBO_COMPARATOR|Control group|Continuous infusion of heparin was used at the corresponding speed.
62632242|NCT03741322||Infants ages 3-24 months with respiratory infections|
62632243|NCT02195635|EXPERIMENTAL|Period 1|Single oral dose of 500 mg telotristat etiprate on Day 1
62632244|NCT02195635|OTHER|Period 2|Subcutaneous injections of 200 µg octreotide acetate three times daily with a single oral dose of 500 mg telotristat etiprate on Day 6
62632245|NCT00156026|EXPERIMENTAL|1|Immediate Treatment - LEEP - Loop electrosurgical excision procedure
62632246|NCT00156026|NO_INTERVENTION|2|Colposcopic Follow-up
62632247|NCT00447525|EXPERIMENTAL|1|
62632248|NCT00447525|ACTIVE_COMPARATOR|2|
62632249|NCT00718094|EXPERIMENTAL|Polyphenon E treatment|Polyphenon E® therapy was given for 56 days.
62632250|NCT00718094|PLACEBO_COMPARATOR|Placebo|Oral Placebo
62632251|NCT05347810|EXPERIMENTAL|Study group|All participants in the study will receive the same investigational treatment (application of prolonged repetitive forces) and provide continuous comfort ratings.
62270420|NCT01029067|EXPERIMENTAL|Metacognitive Training|The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, \& Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt. The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions). The eight modules are presented via a video projector using pdf-converted Power-Point slides. Each group session lasts approximately 45-60 minutes. Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy. For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
62270421|NCT01703416||1|
62452710|NCT00565305|ACTIVE_COMPARATOR|Usual Care|Standard Treatment. These patients receive usual medical care but no additional intervention. Standard treatment is not administered as part of this study but as part of their medical treatment.
62632252|NCT06420817|EXPERIMENTAL|Lifestyle Interventions|Lifestyle Interventions (a prescribed whole food plant-based diet, physical activity and intermittent fasting along with monitoring of sleep and stress levels) would be carried out to the enrolled participants
62632253|NCT01062893|PLACEBO_COMPARATOR|0 mls saline injected|NO SALINE INJECTED
62632254|NCT01062893|ACTIVE_COMPARATOR|15 mls saline|15ML SALINE ADMINISTERED EPIDURALLY
62632255|NCT01437683||traumatic brain injury patients|a large group of traumatic brain injury patients
62632256|NCT05607316|EXPERIMENTAL|Oral Metformin|Treatment with metformin will be started at 500 mg twice daily and increased to 1000 mg twice daily only after they have tolerated the treatment.
62632257|NCT02992028|EXPERIMENTAL|Intravenous vitamin C injection|During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer.
62632258|NCT02992028|PLACEBO_COMPARATOR|Intravenous saline injection|During the first 30 min after beginning of the rotator cuff repair, sham group received 6 ml normal saline in 500 ml of Ringer.
62632259|NCT04875910|EXPERIMENTAL|Stroke survivors participants|"Subjects who have been diagnosed with stroke 6 months or more.~1)Either right and left hemiparesis. 2) Subjects able to walk with or without assistive device. 3) age between 40-80. 4) Subjects can understand and follow commands.~Exclusion criteria is: 1) subjects with uncontrolled Blood pressure, heart rate or breathing problems. 2) Having an orthopedic problem or"
62632260|NCT03576339|SHAM_COMPARATOR|Sham Group - Free Gingival Graft + Sham Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the SHAW Group will receive the simulation of the electrical stimulation process, thus non current will be applied.
62632261|NCT03576339|EXPERIMENTAL|Test Group - Free Gingival Graft + Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Conductive electrodes for electrical current application will be applied to the palatal donor area on each side of the wound at a distance of 3 mm from the wound edge. An alternating current of 100 microamperes (μA) at 9 kilohertz (kHz), will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, five consecutive days.
62632262|NCT04884646|EXPERIMENTAL|Virtual Reality with Routine Physical Therapy|The duration of the VR will be from 10 to 15 minutes during each session and Routine Physical Therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
62270422|NCT01056146|ACTIVE_COMPARATOR|Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
62270423|NCT01056146|EXPERIMENTAL|I-InTERACT|Participants will receive the internet-based parenting skills program.
62632263|NCT04884646|EXPERIMENTAL|Motor imagery technique with Routine Physical Therapy|Motor Imagery techniques will be given for 5 to 10 minutes along with routine physical therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
62632264|NCT04884646|EXPERIMENTAL|Routine Physical Therapy|Only routine physical therapy will be given (including warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
62632265|NCT02089802|EXPERIMENTAL|Normal plasma level patients and low plasma level patients.|"1. Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).~2. Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP)."
62632266|NCT06039319||Appropriate Growth|Pregnant individuals with normal estimated fetal weight
62065500|NCT02724722|EXPERIMENTAL|Intervention|a simple flyer in one empty bag with face-to-face health education
62065501|NCT02724722|PLACEBO_COMPARATOR|No Intervention|a simple flyer in one empty bag with no face-to-face health education
62065502|NCT03254953|EXPERIMENTAL|Sequential Intervention|"* in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet~* participants are asked to use the MyFitnessPal app for self-monitoring~* given goal to lose 5% weight by end of intervention (3 months)~* weekly personalized feedback via email~* weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~* weekly action plans via email"
62065503|NCT03254953|EXPERIMENTAL|Simultaneous Intervention|"* in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months~* participants are asked to use the MyFitnessPal app for self-monitoring~* given goal to lose 5% weight by end of intervention (3 months)~* weekly personalized feedback via email~* weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~* weekly action plans via email"
62065504|NCT03254953|EXPERIMENTAL|Control (diet-tracking only)|"* participants are asked to self-monitor their diet for 3 months~* participants are asked to use the MyFitnessPal app for self-monitoring~* given goal to lose 5% weight by end of intervention (3 months)"
62270424|NCT02238444|EXPERIMENTAL|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
62270425|NCT02238444|ACTIVE_COMPARATOR|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
62270426|NCT03258112|OTHER|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
62270427|NCT04051437|EXPERIMENTAL|Plasma exchange|The consented patients will receive standard medical management with sessions of single volume plasma exchange with fresh frozen plasma and 5% human albumin.Plasma exchange session will be done on an alternate day to a maximum of 5 procedures.
62270428|NCT04051437|ACTIVE_COMPARATOR|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections, entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
62632267|NCT06039319||Fetal Growth Restricted|Pregnant individuals with fetal growth restriction
62632268|NCT05886114|EXPERIMENTAL|Structured Multi-domain Intervention|Multi-domain structured intervention will be tailored by Chinese traditional and social norms and then conducted among the intervention group. That includes: Nutritional and dietary instruction, Cognitive training, Physical exercises, and Vascular risks monitoring and control.
62632269|NCT05886114|EXPERIMENTAL|Self-Guided Intervention|Every 6-12 months, control group will receive a regular health education campaign to encourage a healthy lifestyle and a regular health monitoring and examination of blood pressure, weight, fasting blood glucose and liposome group
62632270|NCT04244617|EXPERIMENTAL|iCBT with addition of peer-support (iCBT-PS)|Participants in the iCBT-PS, are guided by both a psychologist and a peer-support in the iCBT-program used in the study.
62270429|NCT03516760|EXPERIMENTAL|GEM333|application of GEM333, a CD33 targeted bispecific antibody engaging T-cells
62270430|NCT01727609|ACTIVE_COMPARATOR|Slower milk feed increment|Increase milk feeds by 18 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
62270431|NCT01727609|EXPERIMENTAL|Faster milk feed increment|Increase milk feeds by 30 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
62632271|NCT05641441||Stereotactic radiosurgery group|Patients with unilateral Vestibular Schwannoma treated with stereotactic radiosurgery, as proposed by the institution's skull base tumor board independently of the study.
62632272|NCT05641441||Wait and scan group|Patients with unilateral Vestibular Schwannoma followed with an MRI-based observation strategy, as proposed by the institution's skull base tumor board independently of the study.
62065505|NCT04396080|EXPERIMENTAL|Onlays behaviour depending on materials|Patients who require it as treatment option will be treated with posterior partial restorations, and will have clinical follow-up to obtain a comparison of the behavior of subsequent restorations based on the material.
62065506|NCT01294501|EXPERIMENTAL|Fever assessment and management|Medication administration educational module for low literacy subjects on how to administer common medications appropriately and safely.
62065507|NCT01586312|EXPERIMENTAL|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
62065508|NCT01586312|ACTIVE_COMPARATOR|Hyaluronic acid (Durolane)|Intraarticular injection of hyaluronic acid (60 mg)
62065509|NCT00002757|ACTIVE_COMPARATOR|Group A|All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
62270432|NCT01018498|EXPERIMENTAL|Restricted FODMAPs diet|Restricted fermentable substrate diet for 1 week
62632273|NCT02775097||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
62632274|NCT02775097||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus.
62632275|NCT01945879|EXPERIMENTAL|GFFC + LMWH|gemcitabine/ 5-flourouracil/folinic acid/ cisplatin as chemotherapeutic treatment plus enoxaparine as experimental addition
62632276|NCT01373034|EXPERIMENTAL|Soy Dietary Fiber|
62270433|NCT05218785||Botulinum toxin A injection|Patients will receive a total of 3 -three - injections of 75 IU Botulinum Toxin A in the proximal medial gastrocnemius muscle. Treatments will be performed by a specialist in neurology as a Ultra-Sound guided injection into the proximal medial gastrocnemius muscle Injections will be administered at baseline, 3 months and 6 months.
62632277|NCT01373034|PLACEBO_COMPARATOR|Rice powder|
62065510|NCT00002757|ACTIVE_COMPARATOR|Group B|Non resected stage I \& II, stage III \& st IV (CNS - ve, BM \< 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
62065511|NCT00002757|ACTIVE_COMPARATOR|Group C|Bone marrow \> 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
62065512|NCT00114634|EXPERIMENTAL|Egg yolk preparation with cholesterol|Dietary cholesterol in the form of liquid egg yolk
62065513|NCT00114634|PLACEBO_COMPARATOR|Egg yolk preparation without cholesterol|"No dietary cholesterol supplementation (egg substitute) Papetti Foods Better 'n Eggs egg substitute"
62270434|NCT02278172|ACTIVE_COMPARATOR|Vitamin D3 3000IU (75μg)|Treatment solution delivered via oral spray once daily for 12-weeks
62270435|NCT02278172|PLACEBO_COMPARATOR|Placebo|Placebo solution delivered via oral spray once daily for 12-weeks
62270436|NCT02098174|EXPERIMENTAL|Healthy participants|MP-3180 (1 µmol/kg or 0.372 mg/kg) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. The iohexol comparator (Omnipaque 300, 5 mL) was then administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
62270437|NCT02420873|EXPERIMENTAL|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
62270438|NCT02420873|EXPERIMENTAL|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
62452711|NCT01644500|EXPERIMENTAL|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
62632278|NCT06010212|EXPERIMENTAL|Treatment group|Fruquintinib,Camrelizumab, Paclitaxel liposome combined with nedaplatin
62065514|NCT03265990|EXPERIMENTAL|Group A|Conventional haemrrhoidectomy,Ferguson technique
62065515|NCT03265990|EXPERIMENTAL|Group B|Ligasure haemorrhoidectomy
62632279|NCT01693744||Dialysis patients|Patients with stage 5 chronic kidney disease undergoing haemodialysis
62632280|NCT01693744||Chronic kidney disease patients|Stage 1-4 Chronic kidney disease patients
62632281|NCT01693744||Control group|Patients with normal renal functions
62632282|NCT03191565|EXPERIMENTAL|App-Condition|In this condition the intervention is that participants enter their skills-use and mood on a smartphone. They can follow their progress on graphs on the smartphone, get reminders to train skills, get psychoeducation about what the different emotion regulation coping skills can do, and how to do the skills. therapists can watch patient progress online, and review skill use together with the patients while in psychotherapy. The intervention is using a smartphone as an adjunct to the treatment.
62632283|NCT03191565|ACTIVE_COMPARATOR|Paperdiary-condition|Patients are, weekly, given a paper diary sheet to fill out on a daily basis at home No prompting, no accumulative overview of progress. Patients are supposed to bring this paper to the weekly therapysession
62632284|NCT02090686|ACTIVE_COMPARATOR|Pulsatile Cupping|
62632285|NCT02090686|ACTIVE_COMPARATOR|Minimal Cupping|
62632286|NCT02090686|NO_INTERVENTION|No Intervention|Waiting list
62632287|NCT04789447||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT
62632288|NCT01697800|PLACEBO_COMPARATOR|Placebo|Patients received placebo capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
62632289|NCT01697800|ACTIVE_COMPARATOR|Tadalafil|Patients received 20 mg tadalafil capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
62632290|NCT03988140|EXPERIMENTAL|Implant placed at supra crestal level (SL)|Implants were placed at supra crestal level (SL)
62065516|NCT02038686|ACTIVE_COMPARATOR|Standard PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
62270439|NCT02420873|EXPERIMENTAL|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
62270440|NCT00307151|EXPERIMENTAL|Coh I: NVP|Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.
62270441|NCT00307151|EXPERIMENTAL|Coh I: LPV/r|Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.
62632291|NCT03988140|OTHER|Implant placed at crestal level (CL).|Implants were placed at crestal level (CL)
62632292|NCT00291200||1|Participants with basic symptoms of psychosis
62632293|NCT00291200||2|Control participants
62632294|NCT00643019|EXPERIMENTAL|SAFE Intervention|Behavioral Intervention
62632295|NCT00643019|OTHER|Control|Sexually Transmitted Infection Risk Reduction Counseling
62632296|NCT02752360|EXPERIMENTAL|BSA Group|Patients accept the management of Biodegradable Stenting Anastomoses for reconstruction in the surgery of Intestinal Anastomosis
62632297|NCT02752360|EXPERIMENTAL|DHS Group|Patients accept the management of Double-layer Hand Sutures for reconstruction in the surgery of Intestinal Anastomosis
62632298|NCT00664352|EXPERIMENTAL|1|
62632299|NCT00664352|EXPERIMENTAL|2|
62632300|NCT00664352|EXPERIMENTAL|3|
62632301|NCT00664352|EXPERIMENTAL|4|
62632302|NCT00664352|OTHER|5|
61978591|NCT05404373|EXPERIMENTAL|NBO group (6h)|patients were randomized into the NBO group (6h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 6 hours.
62632303|NCT00679848|EXPERIMENTAL|1|Transoral Suturing
62632304|NCT03452462|EXPERIMENTAL|Direct His Bundle Pacing|Pacing from the His bundle lead
62632305|NCT03452462|ACTIVE_COMPARATOR|Biventricular Pacing|Pacing from the right ventricular and coronary sinus leads
62632306|NCT00112918|ACTIVE_COMPARATOR|FOLFOX4|"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m\^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\^2 bolus injection, and then as a 600 mg/m\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\^2 (alone), followed by 5-FU 400 mg/m\^2 bolus injection, and 5-FU 600 mg/m\^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Observation only."
62632307|NCT00112918|EXPERIMENTAL|FOLFOX4 + Bv|"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m\^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\^2 bolus injection, and then as a 600 mg/m\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\^2 (alone), followed by 5-FU 400 mg/m\^2 bolus injection, and 5-FU 600 mg/m\^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
62632308|NCT00112918|EXPERIMENTAL|XELOX+Bv|"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m\^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m\^2 twice daily (equivalent to a total daily dose of 2000 mg/m\^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
62632309|NCT01329770|EXPERIMENTAL|Ascorbic Acid and alpha-tocopherol|Two daily doses of the combination of antioxidants, administered at breakfast and dinner
62270442|NCT00307151|EXPERIMENTAL|Coh II: NVP|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen
62270443|NCT00307151|EXPERIMENTAL|Coh II: LPV/r|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen
62270444|NCT01725009|EXPERIMENTAL|Levetiracetam IV infusions in Japanese|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects
62270445|NCT01725009|EXPERIMENTAL|Levetiracetam IV infusions in Caucasian|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects
62270446|NCT01864538|EXPERIMENTAL|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
62270447|NCT01081067||Control|Routine cow milk-based infant formula
62270448|NCT01081067||Investigational|Cow milk-based infant formula containing probiotics
62270449|NCT01653288|EXPERIMENTAL|Coping Coach|Receive access to Coping Coach online intervention at baseline for use (self-guided, with email reminders) over the next 6 weeks.
62270450|NCT01653288|EXPERIMENTAL|Coping Coach Waitlist Control|Treatment as usual from baseline to 12 week follow-up assessment. Then receive access to Coping Coach intervention after 12 week follow-up for use (self-guided, with email reminders) over the next 6 weeks.
62270451|NCT02830880|EXPERIMENTAL|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
62632310|NCT01329770|PLACEBO_COMPARATOR|Placebo|Two daily doses of placebo, administered at breakfast and dinner
62632311|NCT01690455||Cohort|
62632312|NCT05005624||Validation group 1 (VG-1)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.1 logMAR (Snellen 20/25)
62632313|NCT05005624||Validation group 2 (VG-2)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.4 logMAR (Snellen 20/50)
62632314|NCT05005624||Validation group 3 (VG-3)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.7 logMAR (Snellen 20/100)
62270452|NCT06394713|EXPERIMENTAL|QLF31907 in combination with Irinotecan|
62632315|NCT00871624|ACTIVE_COMPARATOR|Dexmedetomidine|Subjects received active dexmedetomidine 0.2 -0.7 mcg/kg/hr
62632316|NCT00871624|PLACEBO_COMPARATOR|Placebo|Subjects received placebo saline solution 0.2-0.7 mcg/kg/hr
62632317|NCT00537186|OTHER|1|Iron oligosaccharide
62632318|NCT01299883|ACTIVE_COMPARATOR|Cancer and CVD Education|Participants receive education about both cancer and CVD risk factors and their relationship to dietary and physical activity health behaviors.
62632319|NCT01299883|ACTIVE_COMPARATOR|CVD Education|Participants receive education about CVD risk factors and their relationship to dietary and physical activity health behaviors.
62270453|NCT06394713|EXPERIMENTAL|QLF31907 in combination with Docetaxel|
62270454|NCT05933369|EXPERIMENTAL|Intervention|Patients in the intervention group will receive a protocol-defined clinical pharmacist intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits.
62270455|NCT05933369|NO_INTERVENTION|Control|Patients in the control group will receive the usual pharmacist care.
62286869|NCT04058522|EXPERIMENTAL|Group Physiotherapy|1 class per week for 6 weeks (30 min length) aiming for 5-10 participants per class. Classes included advice on the nature of the condition and exercises for scapulo-humeral mobility, scapulo-humeral stability and specific rotator cuff rehabilitation exercises
62270456|NCT06203990|EXPERIMENTAL|Barre class|Barre is an exercise modality that combines elements of classical ballet with strength training. Barre involves high repetitions of low impact, isometric movements, requires little to no equipment, and is highly modifiable for different fitness levels. Barre is traditionally performed in a class setting, which promotes increased social interaction and builds community. Furthermore, interventions with dance elements exhibit high adherence rates (often \> 80%).The exercises in a barre class are also performed holding on to a fixed barre or on the floor, which may address people with PD's fear of falling.
62632320|NCT05545137|EXPERIMENTAL|Pivmecillinam hydrochloride tablets treatment group|"participants received Pivmecillinam Hydrochloride Tablets + Fosfomycin Tromethamine Granules Simulant.~Pivmecillinam Hydrochloride Tablets:oral,One tablets each time,3 times a day for five days.~Fosfomycin Tromethamine Granules Simulant :oral, 1 pack, only once for the entire course of treatment"
62270457|NCT04677244|EXPERIMENTAL|Portal vein blood sample|
62632321|NCT05545137|ACTIVE_COMPARATOR|Fosfomycin Tromethamine Granules treatment group|"participants received Fosfomycin Tromethamine Granules + Pivmecillinam Hydrochloride Tablets Simulant~Fosfomycin Tromethamine Granules:oral, 1 pack, only once for the entire course of treatment.~Pivmecillinam Hydrochloride Tablets Simulant :oral,One tablets each time,3 times a day for five days."
62065517|NCT02038686|ACTIVE_COMPARATOR|Long PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
62065518|NCT01759069|EXPERIMENTAL|treatment with microscope|treatment with microscope
62065519|NCT01759069|EXPERIMENTAL|treatment without microscope|treatment without microscope
62065520|NCT00792558|EXPERIMENTAL|Single Arm|
62065521|NCT02493049|EXPERIMENTAL|Domperidone|Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks
62065522|NCT02493049|NO_INTERVENTION|No add on treatment|No add on treatment. Control group
62065523|NCT06018909|EXPERIMENTAL|Cognitive-Behavioral Interventions Package Group|Participants received CBIP. CBIP included procedural preparation and information, distraction, suggestions, parent training and positive reinforcement.
62065524|NCT06018909|NO_INTERVENTION|Control|The control group received the routine peripheral venous cannulation procedure.
62065525|NCT01456234|ACTIVE_COMPARATOR|Patients with Oseltamivir Prescription|Patients arriving at the pharmacy with a prescription for Oseltamivir
62270458|NCT01018875|EXPERIMENTAL|Arm 1, Dose 1, ABT-288|Low Dose
62270459|NCT01018875|EXPERIMENTAL|Arm 2, Dose 2, ABT-288|High dose
62270460|NCT01018875|ACTIVE_COMPARATOR|donepezil|
62270461|NCT01018875|PLACEBO_COMPARATOR|sugar pill|
62065526|NCT01456234|EXPERIMENTAL|Patients with signs, symptoms of flu|Patients arriving at the pharmacy with signs, symptoms of flu that the pharmacist diagnoses as having flu and being suitable for pharmacist prescribing of Oseltamivir according to an algorithm.
62065527|NCT01042743|EXPERIMENTAL|RAP|individuals who underwent robot-assisted surgery for primary right-sied colon cancer
62065528|NCT01042743|ACTIVE_COMPARATOR|LAP|Individuals who underwent laparoscopic surgery for primary right-side colon cancer
62270462|NCT02179333||Subjects with Ataxia|Patients with a diagnosis of ataxia (Friedreich's ataxia or Spinocerebellar ataxia type 1-30) aged 18-80 years old will be recruited for the study.
62270463|NCT01957358|EXPERIMENTAL|Lifestyle counselling using the Grief Recovery Method|Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method.
62270464|NCT05706389|EXPERIMENTAL|Ca-AKG|Pill format, 500mg/pill, half of daily dose
62270465|NCT05706389|PLACEBO_COMPARATOR|Placebo|Pill format, indistinguishable from active pill
62065529|NCT03453827||PEX|Patients after Cataract surgery with PES
62632322|NCT04092530|EXPERIMENTAL|Intervention - Aim 2|During the intervention period, staff will capture women during the first well-baby visit (WBV) and offer to have the next visit co-scheduled for infant and contraception care. Appointments are scheduled during the discharge process at the end of each WBV. During the discharge process all women 0-6 months postpartum will be identified by clerical staff through review of each pediatric clinic beforehand and through an electronic flag alert in the infant's electronic medical record. The pre-review of pediatric clinic schedules and the use of the flag will remind staff to offer the mother a co-scheduled visit for newborn and contraceptive care at the time of the next newborn visit.
62065530|NCT03453827||Control|Patients after Cataract surgery without PES
62065531|NCT02152501|EXPERIMENTAL|Exercise Energy Expenditure 300 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 300 kcal/day.
62065532|NCT02152501|EXPERIMENTAL|Exercise Energy Expenditure 600 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 600 kcal/day.
62632323|NCT04092530|NO_INTERVENTION|Control - Aim 2|Clinics will schedule postpartum contraception using normal clinic procedures.
62065533|NCT04535336|EXPERIMENTAL|Vitality acupunch (VA)|The VA program took 40 minutes to complete and included 3 phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allowed the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands were used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group received the VA program led by the instructors, who were trained an certified by the PI, 3 times per week and 40 minutes per session for 6 months.
62270466|NCT06492096|ACTIVE_COMPARATOR|TMD Group|
62270467|NCT06492096|ACTIVE_COMPARATOR|Non_TMD Group|
62270468|NCT04220996|EXPERIMENTAL|Vortioxetine|10-20 mg vortioxetine tablets
62270469|NCT03776175|PLACEBO_COMPARATOR|Placebo|Placebo (PF 05221304) BID Placebo (PF 06865571) BID
62270470|NCT03776175|EXPERIMENTAL|PF-05221304 Monotherapy|15 mg PF-05221304 BID Placebo (PF-06865571) BID
62270471|NCT03776175|EXPERIMENTAL|PF-06865571 Monotherapy|Placebo (PF-05221304) BID 300 mg PF-06865571 BID
62270472|NCT03776175|EXPERIMENTAL|PF-05221304 and PF-06865571 Combination|15 mg PF-05221304 BID 300 mg PF-06865571 BID
62270473|NCT04793425|NO_INTERVENTION|Standard care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI.
62270474|NCT04793425|EXPERIMENTAL|Mobile app care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI. On top of that every patient will be given an access to mobile application, which will support rehab process. The application stands as a educational and coordination tool.
62270475|NCT05099692||CHD patients participating in the cardiac rehabilitation|
62270476|NCT01000662|ACTIVE_COMPARATOR|ARM 1 daily boost|Radiation Therapy
62270477|NCT01000662|ACTIVE_COMPARATOR|ARM 2 weekly boost|Radiation Therapy
62270478|NCT02556398|EXPERIMENTAL|Intervention - Educ Module and App|"Participants in this arm to be given smartphone app (Sugar Sleuth) and educational module."
62270479|NCT04336761||Child suspected of infection with COVID-19.|Child included with positive included
62286870|NCT04058522|ACTIVE_COMPARATOR|Routine Physiotherapy|Individual physiotherapy sessions: 6 sessions weekly (30 min) for 6 weeks. Treatment was based on evidence-based guidelines for the treatment of shoulder impingement (CSP 2005) and consisted of mobilisation techniques, supervised exercises and stretches.
62286871|NCT02680782|EXPERIMENTAL|X4P-001 QD|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug once daily in the first period, followed by twice daily in the second dosing period.
62632324|NCT04348097|EXPERIMENTAL|activator trigger point therapy|"The Activator adjusting instrument used had force settings ranging from 1 to 6~. For this study a force setting of 3 was used."
62632325|NCT04348097|ACTIVE_COMPARATOR|Trigger point dry needling|First, a tight band was held between the index finger and the thumb of the non-dominant hand and the needle (0.25-40 mm - Shen Long) was perpendicularly inserted into the muscle with the dominant hand.
62632326|NCT06028126|EXPERIMENTAL|0.2% ropivacaine|Intermittent superficial parasternal intercostal plane block via ultrasound-guided catheter placement. Initial bolus dosing of 20 milliliter (mL) of 0.2% ropivacaine per side at the time of catheter placement, followed by intermittent boluses of 10 mL 0.2% ropivacaine per side.
62065534|NCT04535336|ACTIVE_COMPARATOR|Control|Participants in the control group continued with their daily activities as usual.
62286872|NCT02680782|EXPERIMENTAL|X4P-001 BID|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug twice daily in the first period, followed by once daily in the second dosing period.
62632327|NCT06028126|SHAM_COMPARATOR|0.9% saline|Intermitted superficial parasternal intercostal plane block via ultrasound-guided catheter placement. Initial bolus of 20 mL of 0.9% saline per side at the time of catheter placement, followed by intermitted boluses of 10 ml of 0.9% saline per side.
62632328|NCT01541995||virtual and classic autopsy|Patients where contrast medium enhanced post mortem CT and classic autopsy will be performed.
62632329|NCT01541995||virtual autopsy only|Patients where only contrast medium enhanced post mortem CT will be performed.
62632330|NCT05438238|EXPERIMENTAL|investigational group A|during TVOR +PCB addition of Oncomfort, commercially available Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform IEC62366-1:2015, EN 62304:2006/Amd1:2015, EN 82304-1:2015, EN 82304-1:2016, ISO 13485:2016, EN ISO 14971:2019, EN 60601-1-2:2015
62632331|NCT05438238|NO_INTERVENTION|reference group|standard of care TVOR + PCB
62632332|NCT04001556|EXPERIMENTAL|Patients reporting subjective sicca symptoms|HAQ(Health Assessment Questionnaire) Score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
62286873|NCT02421887|ACTIVE_COMPARATOR|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
62065535|NCT03794258|EXPERIMENTAL|SOF+DCV+CDI-31244|Subjects will receive two weeks of sofosbuvir, daclatasvir, and CDI-31244 if they achieve HCV RNA \< 500 IU/mL on Day 2 and HCV RNA \< LLOQ (\< 25 IU/mL) on Week 1.
62065536|NCT03794258|EXPERIMENTAL|SOF+DCV+CDI-31244+ASV|Subjects will receive two weeks of sofosbuvir, daclatasvir, CDI-31244 and asunaprevir if they achieve HCV RNA \< 500 IU/mL on Day 2 and HCV RNA \< LLOQ (\< 25 IU/mL) on Week 1.
62065537|NCT05108207|PLACEBO_COMPARATOR|Control Group|will receive the standard delirium prevention measures outlined above, plus the use of a mobile device without delirium prevention software for 5 days (Control Group: nPPD package, without PREVEDEL).
62065538|NCT05108207|EXPERIMENTAL|Experimental Group|will receive the standard delirium prevention measures, plus the use of a mobile device with PREVEDEL software for 5 days (Experimental Group: nPPD package, with PREVEDEL).
62286874|NCT02421887|PLACEBO_COMPARATOR|Placebo|
62632333|NCT04001556|EXPERIMENTAL|Patients without subjective sicca symptoms|HAQ(Health Assessment Questionnaire) score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
62632334|NCT04269720|NO_INTERVENTION|Control|Participants will not receive biofeedback intervention.
62632335|NCT04269720|EXPERIMENTAL|Biofeedback|Participants will receive a biofeedback intervention daily for 8 weeks. Each biofeedback session lasts approximately 10 minutes.
62632336|NCT02247739|EXPERIMENTAL|rhC1INH twice weekly|rhC1INH administered twice weekly
62065539|NCT00925496||Standard PROMOS prosthesis|Patients receiving a standard PROMOS prosthesis
62065540|NCT00925496||Reverse PROMOS prosthesis|Patients receiving a reverse PROMOS prosthesis
62632337|NCT02247739|EXPERIMENTAL|rhC1INH once weekly|rhC1INH administered once weekly
62632338|NCT02247739|PLACEBO_COMPARATOR|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
62632339|NCT02453880|EXPERIMENTAL|Web-based Cognitive Behavioral Therapy|"Participants will be directed to a web-based CBT self-help program with weekly modules."
62065541|NCT00101660|EXPERIMENTAL|Dasatinib, 70 mg twice daily (BID)|Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.
62065542|NCT01374802|EXPERIMENTAL|BI 201335|capsule for oral administration
62270480|NCT04978207|EXPERIMENTAL|Multilevel, religiously-culturally tailored COVID-19 testing and linkage to care|Church-based COVID19 promoted with a religiously-culturally tailored Faithful Response COVID19 Toolkit delivered by church health workers (trained in an enhanced communication style) through multilevel church outlets (e.g., sermon guide, responsive reading, church bulletin inserts, automated text messages) and linkage to care delivered by community health workers who also conduct contact tracing; inclusive of 2 church-based COVID-19 testing events at each participating site.
62270481|NCT04978207|ACTIVE_COMPARATOR|Standard COVID19 information (non-tailored) attention control arm|Standard COVID-19 information that has not been tailored delivered by trained church health workers via a toolkit; inclusive of 2 church-based COVID19 testing evens at each participating site.
62270482|NCT00886301|OTHER|1|obese or overweight patients with fatty liver or ectopic fat
62270483|NCT01817309|EXPERIMENTAL|Study group|endotoxin assay in peritoneal dialysis effluent
62632340|NCT06432647|EXPERIMENTAL|ATH-1105|"Part A: ATH-1105 administered once as an oral solution.~Part B: ATH-1105 administered once daily as an oral solution for 10 days."
62632341|NCT06432647|PLACEBO_COMPARATOR|Placebo|"Part A: Placebo administered once as an oral solution~Part B: Placebo administered once daily as an oral solution"
62632342|NCT05495308||NON-DISTANT METASTASES|Those patiens who do not develop distant metastasis during the follow-up time.
62632343|NCT05495308||DISTANT METASTASES|Those patiens who develop distant metastasis during the follow-up time.
62632344|NCT04724603||patients having had avderse event after phagotherapy for bone or joint infection|
62632345|NCT03235466|ACTIVE_COMPARATOR|Voice Therapy|(Group 1) will undergo active training in behavioral cough suppression and laryngeal relaxation exercises, but will not receive HRVB. Traditional cough suppression and laryngeal relaxation exercises include pursed lip breathing, swallowing (water, lozenge, gum, ice chips), sustained semi-occluded voicing, discussion and mitigation of triggers, maintaining a cough journal, addressing muscle tension dysphonia if indicated, and developing prophylaxis suppression and laryngeal relaxation based on stimulability. Participants in Group 1 will receive handwritten guidance indicating exercises to practice at home.
62632346|NCT03235466|ACTIVE_COMPARATOR|Voice Therapy and Heart Rate Variability Biofeedback|Voice therapy as described in Arm 1. HRVB involves measure respiratory rate, heart rate, body temperature and skin conductance. Participants are guided through reduced breathing rate until a resonant frequency is attained. HRVB breathing simulates resonance between the baroreflex rhythm and respiration based rhythm, increasing heart rate variability and baroreceptor sensitivity. Evidence suggests HRVB improves autonomic regularity. We propose this novel modality to address centrally regulated hypersensitivity that perpetuates coughing.
62632347|NCT03235466|ACTIVE_COMPARATOR|Heart Rate Variability Biofeedback|HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
62632348|NCT02490826|ACTIVE_COMPARATOR|Table-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a table top material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
62632349|NCT02490826|ACTIVE_COMPARATOR|Tablet-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a tablet (digital) material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
62632350|NCT02677415|OTHER|Local anesthesia|local anesthesia and spontaneous breathing will be maintained.
62632351|NCT02677415|OTHER|General anesthesia|Intravenous anesthetics and controlled ventilation will be used .
62632352|NCT04474886|EXPERIMENTAL|Fresubin® powder fibre|2 servings of Fresubin® powder fibre per day as supplement to normal diet
62632353|NCT04474886|NO_INTERVENTION|Usual diet|Maintain usual diet
62270484|NCT05779072|OTHER|Dual Focus for 3 years|Group of subjects who completed dual focus soft contact lens wear treatment for 3 years
62270485|NCT05779072|OTHER|Dual Focus for 6 years|Group of subjects who completed dual focus soft contact lens wear treatment for 6 years
62270486|NCT01931358|EXPERIMENTAL|Group Ia|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
62270487|NCT01931358|PLACEBO_COMPARATOR|Group Ib|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
62270488|NCT01931358|EXPERIMENTAL|Group IIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12, 24 and 48
62270489|NCT01931358|PLACEBO_COMPARATOR|Group IIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12, 24 and 48
62270490|NCT01931358|EXPERIMENTAL|Group IIIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24; AIDSVAX B/E at Week 48
62065543|NCT01374802|EXPERIMENTAL|Darunavir 400 mg|tablet for oral administration
62065544|NCT01374802|EXPERIMENTAL|Ritonavir 100 mg|tablet for oral administration
62065545|NCT04844918|EXPERIMENTAL|10 Milligrams (mg) Tirzepatide|Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
62065546|NCT04844918|EXPERIMENTAL|15 mg Tirzepatide|Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
62065547|NCT04844918|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo administered SC QW.
62065548|NCT01097252|ACTIVE_COMPARATOR|weekly cisplatin|Weekly cisplatin 40mg/m2 during radiation therapy
62065549|NCT01097252|EXPERIMENTAL|tri-weekly cisplatin|cisplatin 75mg/m2 three cycles, every 3 weeks
62065550|NCT02254083|EXPERIMENTAL|BIBT 986 BS - low|
62065551|NCT02254083|EXPERIMENTAL|BIBT 986 BS - high|
62065552|NCT02254083|PLACEBO_COMPARATOR|Placebo|
62065553|NCT04200313|EXPERIMENTAL|Bionic Pancreas (BP)|Some adults and 1/2 peds will be randomized to use the Bionic Pancreas (BP) with lispro or aspart for 13 weeks
62632354|NCT03301987|EXPERIMENTAL|Therapeutic exercise|
62632355|NCT03468725|EXPERIMENTAL|XPF-008|Single oral dose
62632356|NCT03468725|ACTIVE_COMPARATOR|Placebo|Single oral dose
62632357|NCT04247165|EXPERIMENTAL|Experimental|"Nivolumab 3 mg/kg will be given on day 1 (± 2 days) of each 28-day treatment cycle until the progression of disease, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given once only on day 1 cycle 1. Nivolumab will be administered as an IV infusion over 30 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Pre-medication for chemotherapy (based on standard-of-care and local institutional standards) and chemotherapy will then be administered after a further 30 minutes rest period.~The recommended dose of nab-paclitaxel is 100 mg/m2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8, and 15 of each 28-day cycle. Gemcitabine 800 mg/m2 will be administered over 30 to 40 minutes immediately after nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle."
62065554|NCT04200313|EXPERIMENTAL|Bionic Pancreas with Fiasp (BPFiasp)|Some adults will be randomized to use the Bionic Pancreas (BP) with Fiasp for 13 weeks during RCT
62065555|NCT04200313|OTHER|Usual Care (UC)|Adults and peds will use their own diabetes insulin regimen plus continuous glucose monitoring (CGM) during the RCT
62065556|NCT04200313|EXPERIMENTAL|Bionic Pancreas Extension|Used by all participants in the EXT study
62065557|NCT04200313|EXPERIMENTAL|Transition Phase - BP Guidance|Adults and peds will use their own diabetes insulin regimen plus SMBG and blinded continuous glucose monitoring (CGM) in the Transition phase and use dosing based on guidance from the BP system
62065558|NCT04200313|OTHER|Transition- Pre-study dosing|Adults and peds will use their own diabetes insulin regimen plus SMBG and blinded continuous glucose monitoring (CGM) in the Transition phase and use dosing based on their pre-study regimen
62065559|NCT04488003|EXPERIMENTAL|Part A: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
62065560|NCT04488003|EXPERIMENTAL|Part B: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
62065561|NCT04488003|EXPERIMENTAL|Part B: Physician's choice of treatment|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice). If a patient progresses on physician's choice of treatment, crossover to the ulixertinib arm is permitted.
62065562|NCT02853266||patients KD|adults with a history of KD in childhood
62065563|NCT02853266||control group|healthy adults volunteers
62065564|NCT02914184|EXPERIMENTAL|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
62065565|NCT02914184|EXPERIMENTAL|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
62065566|NCT02914184|EXPERIMENTAL|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
62065567|NCT02914184|ACTIVE_COMPARATOR|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
62065568|NCT06010290||Parkinsonism patients|This group/cohort comprises clinically diagnosed as Parkinsonism, including Parkinson's disease and atypical Parkinsonism syndromes, and each participant is injected 18F-SMBT-1 (185-370Mbq) and underwent PET/CT scanning within 50-70 min after injection.
62065569|NCT06010290||Health control|Each participant is injected 18F-SMBT-1 (185-370Mbq) and underwent PET/CT scanning within 50-70 min after injection.
62065570|NCT03002038|EXPERIMENTAL|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
62065571|NCT03002038|EXPERIMENTAL|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
62065572|NCT03941613|EXPERIMENTAL|Anterior temporal lobectomy|surgical treatment for mTLE
62065573|NCT03941613|ACTIVE_COMPARATOR|SEEG guided RF-TC|SEEG recording and minimal invasive treatment for mTLE
62065574|NCT05157516|ACTIVE_COMPARATOR|group ESPB|Erector Spinae Plane Block
62065575|NCT05157516|ACTIVE_COMPARATOR|In group CEA|Caudal epidural block
62632358|NCT01386931||Cytopathologist present during EUS-FNA|"Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
62632359|NCT01386931||Cytopathologist absent during EUS-FNA|"In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
62632360|NCT06169306|NO_INTERVENTION|control|Following endotracheal intubation, no throath pack will inserted into the hypopharynx.
62632361|NCT06169306|EXPERIMENTAL|throath pack|Following endotracheal intubation, throath pack will inserted into the hypopharynx.
62632362|NCT06251271||Soroka University Medical Center Pulmonology Ward - 'All Comers'|In the Pulmonology Ward, the cohort will encompass 'All Comers'-any patient referred for PFTs who meets the inclusion criteria. This cross-sectional observational study will screen all eligible patients presenting at the ward, offering a comprehensive snapshot of the diagnostic accuracy of point-of-care ultrasound in this diverse patient population.
62632363|NCT06251271||Rabin Medical Center Pulmonology Ward - 'All Comers'|In the Pulmonology Ward, the cohort will encompass 'All Comers'-any patient referred for PFTs who meets the inclusion criteria. This cross-sectional observational study will screen all eligible patients presenting at the ward, offering a comprehensive snapshot of the diagnostic accuracy of point-of-care ultrasound in this diverse patient population.
62632364|NCT05199922|ACTIVE_COMPARATOR|Group M = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
62632365|NCT05199922|NO_INTERVENTION|Group C = Control group|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia."
62065576|NCT03101241|EXPERIMENTAL|CX-8998|
62065577|NCT03101241|PLACEBO_COMPARATOR|Placebo|
62065578|NCT05514574|EXPERIMENTAL|Music|Patients (listening to music group) who are taken to the intervention table and placed on their backs by the team that will perform the intervention will be monitored. The hemodynamic parameters on the monitor screen will be recorded on the data collection form before and after percutaneous coronary intervention by the researcher KY. Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale before being taken to the intervention room for percutaneous coronary intervention (while in a bed or stretcher or wheelchair). Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale after leaving the intervention room (while on the bed or stretcher). During percutaneous coronary intervention; Except for routine treatment and care interventions, the patient will listen to music during the procedure.
62065579|NCT05514574|EXPERIMENTAL|Stress ball|Patients (stress ball group) who are taken to the intervention table and placed on their backs by the team that will perform the intervention will be monitored. The hemodynamic parameters on the monitor screen will be recorded on the data collection form before and after percutaneous coronary intervention by the researcher KY. Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale before being taken to the intervention room for percutaneous coronary intervention (while in a bed or stretcher or wheelchair). Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale after leaving the intervention room (while on the bed or stretcher). During percutaneous coronary intervention; Except for routine treatment and care interventions, the patient will stress ball will be applied during the procedure.
62632366|NCT03565874|EXPERIMENTAL|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
62270491|NCT01931358|PLACEBO_COMPARATOR|Group IIIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24; AIDSVAX B/E Placebo at Week 48
62270492|NCT01931358|EXPERIMENTAL|Group IVa|ALVAC-HIV at Weeks 0, 4 and 48; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
62632367|NCT04398810|EXPERIMENTAL|the low-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~* Cholelithiasis~* Chronic cholecystitis~* Gallbladder polyps~* Gallbladder adenoma~* Porcelain gallbladder~The experimental group controls the CO2 flow that is injected into the abdominal cavity during surgery and maintains the pressure in the abdominal cavity at a low level of 5 mmHg to perform the surgery."
62065580|NCT05514574|NO_INTERVENTION|Control|Patients (control group) who are taken to the intervention table and placed on their backs by the team that will perform the intervention will be monitored. The hemodynamic parameters on the monitor screen will be recorded on the data collection form before and after percutaneous coronary intervention by the researcher KY. Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale before being taken to the intervention room for percutaneous coronary intervention (while in a bed or stretcher or wheelchair). Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale after leaving the intervention room (while on the bed or stretcher). During percutaneous coronary intervention; No intervention will be performed except for routine treatment and care interventions.
62286875|NCT01151722|NO_INTERVENTION|no injection|no bevacizumab
62632368|NCT04398810|EXPERIMENTAL|the standard-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~* Cholelithiasis~* Chronic cholecystitis~* Gallbladder polyps~* Gallbladder adenoma~* Porcelain gallbladder~In the case of the control group, surgery is performed while maintaining the pressure in the abdominal cavity at 12 mmHg as generally performed during surgery."
62632369|NCT02982889|EXPERIMENTAL|LIQ865A bupivacaine formulation|Liquidia's PRINT bupivacaine free base/PLGA (poly D,L-lactic-co-glycolic acid) suspension for subcutaneous injection at doses ranging from 150mg to 600mg
62632370|NCT02982889|EXPERIMENTAL|LIQ865B bupivacaine formulation|Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg
62452712|NCT01644500|EXPERIMENTAL|0.75 mg Dulaglutide|0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
62632371|NCT02982889|PLACEBO_COMPARATOR|Diluent for LIQ865|Negative control for subcutaneous injection. Each subject will act as his own control, receiving a LIQ865 formulation subcutaneous injection in one calf, and a diluent subcutaneous injection in his other calf
62632372|NCT02982889|ACTIVE_COMPARATOR|0.5% bupivacaine hydrochoride|Positive control arm to be used with one of the LIQ865 cohorts, with each subject acting as his own positive control (i.e., one leg will receive subcutaneous injection of LIQ865A or LIQ865B, and the other leg will receive subcutaneous injection of 0.5% bupivacaine hydrochloride).
62632373|NCT02061813|EXPERIMENTAL|Abametapir lotion 0.74% w/w|Applied 0.2 mL topically under occlusive condition
62065581|NCT02189993||Total Parenteral Nutrition Use|The cohort investigated consisted of patients with intestinal failure requiring total parenteral nutrition use.
62065582|NCT06625203||Patients diagnosed with one of the eligible cancers and having at least one archived FFPE sample|
62065583|NCT04822480||DPP Patients|UMMC Patients with prediabetes or risk for diabetes based on risk parameters referred to and enrolled in the DPP.
62632374|NCT02061813|PLACEBO_COMPARATOR|Vehicle lotion|Applied 0.2 mL topically under occlusive condition
62632375|NCT02061813|OTHER|Sodium Lauryl Sulfate|Positive control applied 0.2 mL topically under occlusive condition
62632376|NCT02061813|OTHER|Saline 0.9%|Negative control applied 0.2 mL topically under occlusive condition
62632377|NCT02459197|ACTIVE_COMPARATOR|T4P1001|
62632378|NCT02459197|SHAM_COMPARATOR|Placebo|
62632379|NCT02309957||BioMatrix CRD|All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.
62632380|NCT03828955|EXPERIMENTAL|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage.
62632381|NCT03828955|PLACEBO_COMPARATOR|Placebo|Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage.
62632382|NCT03609814||Pediatric Bone Marrow Transplantation Recipients|Children undergoing alloHCT at UCSF Benioff Children's Hospital.
62632383|NCT03871530|EXPERIMENTAL|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
62632384|NCT03871530|EXPERIMENTAL|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
62632385|NCT03871530|EXPERIMENTAL|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
62632386|NCT03871530|EXPERIMENTAL|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
62632387|NCT03871530|EXPERIMENTAL|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
62632388|NCT03871530|EXPERIMENTAL|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
62632389|NCT03871530|EXPERIMENTAL|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
62632390|NCT03871530|EXPERIMENTAL|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
62632391|NCT03871530|EXPERIMENTAL|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
62632392|NCT03871530|EXPERIMENTAL|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
62632393|NCT03871530|EXPERIMENTAL|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
62632394|NCT03871530|EXPERIMENTAL|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
62632395|NCT03871530|EXPERIMENTAL|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
62632396|NCT03871530|EXPERIMENTAL|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
62632397|NCT05619315|EXPERIMENTAL|Charcoal -based whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
62632398|NCT05619315|ACTIVE_COMPARATOR|Calcium carbonate /perlite containing whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
62065584|NCT04822480||Non-DPP Patients|Control matched UMMC patients with prediabetes or risk for diabetes based on risk parameters not enrolled in the DPP.
62065585|NCT01090310|EXPERIMENTAL|AIN457 300mg every 2 weeks|AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
62270493|NCT01931358|PLACEBO_COMPARATOR|Group IVb|ALVAC-HIV Placebo at Weeks 0, 4 and 48; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
62452713|NCT01644500|ACTIVE_COMPARATOR|Glimepiride|1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
62632399|NCT05455151|ACTIVE_COMPARATOR|Conservative therapy|This is Group 1, whose patients received electrical impulse therapy using a BTL-4000 Premium G device (BTL Medical Technologies, Czech Republic) starting from day 5-7 of menstrual cycle for 10-12 days daily.
62632400|NCT05455151|EXPERIMENTAL|PRP injection|This is Group 2, whose patients received single intraendometrial injections of autologous PRP during proliferative phase (day 6-9) of menstrual cycle.
62632401|NCT05455151|EXPERIMENTAL|Injection of PRP after conservative therapy|This is Group 3, whose patients received electrical impulse therapy identically with Group 1 during the first menstrual cycle. In the second cycle, the patients received autologous PRP injections identically with Group 2.
62632402|NCT05455151|EXPERIMENTAL|Injection of PRP with endometrial cells|This is Group 4, whose patients received single intraendometrial injections of the minimally manipulated autologous endometrial cells suspended in autologous PRP during proliferative phase (day 6-9) of menstrual cycle.
62632403|NCT02691390|EXPERIMENTAL|study group|alcoholics - dTMS group
62632404|NCT02691390|SHAM_COMPARATOR|control group|alcoholics - sham group
62065586|NCT01090310|EXPERIMENTAL|AIN457 300 mg every 4 weeks|AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
62632405|NCT01787669|ACTIVE_COMPARATOR|Avastin (bevacizumab)|Intravitreal Avastin loading doses followed by as prn for remainder of 6 months according to defined retreatment criteria
62632406|NCT01787669|ACTIVE_COMPARATOR|Ozurdex (dexamethasone)|single dose at baseline and repeat dose when required according to defined re-treatment criteria
62632407|NCT00201019|EXPERIMENTAL|1|Active intervention participants receive a physician-pharmacist collaborative intervention.
62632408|NCT00201019|NO_INTERVENTION|2|Control participants do not receive recommendations from a clinical pharmacist.
62632409|NCT00201019|NO_INTERVENTION|3|Passive intervention participants receive care by the same physicians caring for participants in the active intervention arm but are not seen by a clinical pharmacist. They are not actively enrolled in the study and do not have study visits for measuring blood pressure.
62632410|NCT05258487||VIBe Grade 1|Intraoperative bleeding of grade 1 as defined by the VIBe scale.
62632411|NCT05258487||VIBe Grade 2|Intraoperative bleeding of grade 2 as defined by the VIBe scale.
62065587|NCT01090310|EXPERIMENTAL|AIN457 150 mg every 4 weeks|AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
62065588|NCT01090310|PLACEBO_COMPARATOR|Placebo|Placebo s.c. every 2 weeks
62065589|NCT00238381|OTHER|Arm I|Patients undergo total mesorectal excision (TME) by standard methods or laparoscopically and side-to-end anastomosis rectal reconstruction.
62065590|NCT00238381|OTHER|Arm II|Patients undergo TME and colon-J-pouch anastomosis rectal reconstruction.
62065591|NCT00238381|OTHER|Arm III|Patients undergo straight coloanal anastomosis with/without temporary protective ileostomy
62632412|NCT05258487||VIBe Grade 3|Intraoperative bleeding of grade 3 as defined by the VIBe scale.
62632413|NCT05258487||VIBe Grade 4|Intraoperative bleeding of grade 4 as defined by the VIBe scale.
62632414|NCT04608331|EXPERIMENTAL|Dexmedetomidine group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
62632415|NCT04608331|PLACEBO_COMPARATOR|Placebo group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
62632416|NCT02440893||Corus CAD (ASGES) Post-metformin|Corus CAD (ASGES) second sample draw results to compare to Corus CAD (ASGES) first draw results (per patient).
62632417|NCT04978272|ACTIVE_COMPARATOR|IPTc DP 1 year|DP given from 8 weeks to 52 weeks of age; DP placebo given from 52 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
62632418|NCT04978272|ACTIVE_COMPARATOR|IPTc DP 2 years|DP given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
62065592|NCT04885114|EXPERIMENTAL|Cohort 1 Unilateral low dose|3.0 x 10\^9 (vg/mL) rAAV1-miHHT
62065593|NCT04885114|EXPERIMENTAL|Cohort 2 Bilateral low dose|3.0 x 10\^9 (vg/mL) rAAV1-miHHT
62065594|NCT04885114|EXPERIMENTAL|Cohort 3 Bilateral mid dose|1.7 x 10\^10 (vg/mL) rAAV1-miHHT
62065595|NCT04885114|EXPERIMENTAL|Cohort 4 Bilateral high dose|9.9 x 10\^10 (vg/mL) rAAV1-miHHT
62270494|NCT02286947|EXPERIMENTAL|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
62632419|NCT04978272|PLACEBO_COMPARATOR|No IPTc|DP placebo given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
62065596|NCT06336980|EXPERIMENTAL|Behavior intervention to increase inclusionary practices|Each congregation will participate in the intervention for 11-12 months
62632420|NCT02908152|ACTIVE_COMPARATOR|curcumin|curcumin
62632421|NCT02908152|PLACEBO_COMPARATOR|placebo|
62632422|NCT00657696||Group 1|Physicians and staff in VA non-contract primary care outpatient clinics and patients seen in last 12 months in the same clinics
62632423|NCT00657696||Group 2|Patients seen in last 12 months in Group 1 clinics
62065597|NCT01380301|EXPERIMENTAL|Miltefosine and Antimony|Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
62065598|NCT01380301|ACTIVE_COMPARATOR|Miltefosine alone|Miltefosine 1,5 to 2,5 mg x kg x d during 14 days
62065599|NCT00759044||AMD|Patients diagnosed with AMD
62065600|NCT00759044||DME|Patients diagnosed with DME
62065601|NCT03491345|EXPERIMENTAL|avelumab|
62065602|NCT04922996||Ongoing|Patients already on calcium dobesilate treatment
62065603|NCT04922996||New|Patients with approved indication for calcium dobesilate treatment but not already on treatment
62270495|NCT03937856|EXPERIMENTAL|Intervention group|Participant groups will include enrolled patients with rheumatic disease who use the smartphone mindfulness meditation application for 30 days.
62632424|NCT01429844|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
62632425|NCT01429844|ACTIVE_COMPARATOR|Cyclosporine|Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
62065604|NCT01729962||Agreement Cohort|All subjects in the agreement portion of the study will have a single measurement performed with each device, the Nidek optical biometer, predicate device and ultrasound reference device. Each device will be operated by a different operator.
62270496|NCT03937856|NO_INTERVENTION|Control group|Usual care participants.
62270497|NCT03900871|EXPERIMENTAL|Experimental group|
62270498|NCT03900871|PLACEBO_COMPARATOR|Control group|
62270499|NCT04797143||control group|patients in control group receive standard care
62270500|NCT04797143||intervention group|intervention group after implementation of a MCP
62632426|NCT00816777|EXPERIMENTAL|Chemoembolization|Chemoembolization with Irinotecan Bead in combination with Intravenous Chemotherapy Group (test arm)
62632427|NCT00816777|ACTIVE_COMPARATOR|Chemotherapy|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
62632428|NCT01005576|EXPERIMENTAL|Conditioning regimen|Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
62632429|NCT04087837|EXPERIMENTAL|bougie group|The bougie group: The end of the endotracheal tube was guided to the glottis using the endotracheal tube in the bougie mode under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
62632430|NCT04087837|EXPERIMENTAL|Nasogastric(NG) tube group|NG tube group: The end of the endotracheal tube is guided to the glottis by using the endotracheal tube in the nasogastric tube under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
62065605|NCT01729962||Precision Cohort|All subjects in the precision portion of the study will each be paired with one Nidek optical biometer and with one predicate device for a total of three Nidek optical biometer/predicate device pairs. Each of the three device pairs will be designated one and only one operator. All subjects in the precision portion of the study will have their measurements repeated three times on each of three Nidek optical biometer and predicate device pairs.
62065606|NCT02965755|OTHER|Genetic profiling|All participants will undergo genetic profiling. Archival tissue will be requested to undergo routine review for possible treatment recommendations. Blood samples will be obtained to study research correlates (plasma tumor DNA, ptDNA) and tissue comparison.
62065607|NCT04094337|EXPERIMENTAL|Internet-assisted treatment|The intervention group will receive internet-assisted treatment comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
62270501|NCT04004884||UPA Treatment|Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018
62270502|NCT01452399|EXPERIMENTAL|Shave Margins|
62065608|NCT04094337|NO_INTERVENTION|Control group|The control group will receive treatment as usual, which is no specific treatment. The control group can however use the general health system as they like.
62065609|NCT01005485||Group A|Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
62065610|NCT01005485||Group B|Healthy controls will be recruited from the general medical population, community.
62065611|NCT01005485||Acute Myocardial Infarction|Patients with acute myocardial infarction with or without ST segment deviation.
62065612|NCT00602680|EXPERIMENTAL|1|dose 1
62065613|NCT00602680|EXPERIMENTAL|2|dose 2
62065614|NCT00602680|EXPERIMENTAL|3|dose 3
62065615|NCT00602680|PLACEBO_COMPARATOR|4|
62065616|NCT00602680|ACTIVE_COMPARATOR|5|
62270503|NCT01452399|ACTIVE_COMPARATOR|No shave margins|
62270504|NCT00744874|EXPERIMENTAL|Ablated Patients|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
62270505|NCT01803360|EXPERIMENTAL|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
62270506|NCT01803360|PLACEBO_COMPARATOR|Placebo|Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment
62452714|NCT02009800|NO_INTERVENTION|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
62452715|NCT02009800|EXPERIMENTAL|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
62452716|NCT02788461|ACTIVE_COMPARATOR|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
62452717|NCT02788461|EXPERIMENTAL|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
62452718|NCT03652701|EXPERIMENTAL|Hair Up|
62452719|NCT03652701|PLACEBO_COMPARATOR|Placebo|
62452720|NCT05231642|EXPERIMENTAL|Low GI|Consumption of standardised low-GI mixed-macronutrient breakfast-based meal followed by a standardised low-GI mixed-macronutrient lunch meal 4 hours later.
62270507|NCT04440995|EXPERIMENTAL|PECS block(P) group|PECS group (P) received general anesthesia and pectoral nerve block(PECS block) with 025% ropivacaine after surgical resection of breast by operator.
62270508|NCT04440995|NO_INTERVENTION|Control(c) group|only received general anesthesia
62270509|NCT05721235|EXPERIMENTAL|Open Label|13.1 mg/2.6 mg SDX/d-MPH, 26.1/5.2 mg SDX/d-MPH, or 39.2 mg/7.8 mg SDX/d-MPH
62270510|NCT06500364|EXPERIMENTAL|LoopLoc Arm|The patients in this group will have the LoopLoc device used following their hip arthroscopy, to close the capsule.
62270511|NCT06500364|ACTIVE_COMPARATOR|Control Arm|This is a control group, meaning they had their hip arthroscopy done without the use of the LoopLoc device.
62270512|NCT00630630|EXPERIMENTAL|1|
62270513|NCT00630630|PLACEBO_COMPARATOR|2|
62270514|NCT05073809||Group 1|Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status
62452721|NCT05231642|EXPERIMENTAL|High GI|Consumption of a standardised high-GI mixed-macronutrient breakfast-based meal followed by a standardised high-GI mixed-macronutrient lunch meal 4 hours later.
62270515|NCT05073809||Group 2|Proven or suspected oral cavity cancer, amenable to intraoral examination
62270516|NCT01578733|EXPERIMENTAL|protein intake|different levels of protein intake
62270517|NCT05376176|EXPERIMENTAL|STN1010904 ophthalmic suspension 0.03% BID|
62270518|NCT05376176|EXPERIMENTAL|STN1010904 ophthalmic suspension 0.1% BID|
62452722|NCT05169762||transgender women|transgender women eligeble to start gender affirming hormone treatment
62632431|NCT04087837|NO_INTERVENTION|control group|Control group: The general anesthesia method of placing the endotracheal tube through the nasal cavity is used to guide the tip of the endotracheal tube to the glottis under the direct view of the electronic imaging laryngoscope.
62270519|NCT05376176|PLACEBO_COMPARATOR|Placebo Vehicle BID|
62632432|NCT02489448|EXPERIMENTAL|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
62270520|NCT04001361|SHAM_COMPARATOR|Sham|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser inserted into knee joint but not turned on.
62270521|NCT04001361|EXPERIMENTAL|Laser Only|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser fiber is inserted into knee over an 18 gauge needle and micro-channels are made into the damaged cartilage.
62270522|NCT04001361|EXPERIMENTAL|Laser plus Marrow|Under conscience sedation, a 10mL marrow aspiration is performed. Laser fiber is inserted into the knee over an 18 gauge needle and micro-channels are made into the damaged cartilage. After the channels are made, marrow aspirate is injected over the same 18 gauge needle.
62270523|NCT02997579|EXPERIMENTAL|patellar resurfacing|patellar resurfacing TKA
62270524|NCT02997579|NO_INTERVENTION|patellar non-resurfacing|patellar non-resurfacing TKA
62270525|NCT01544946|EXPERIMENTAL|sucrose po|
62452723|NCT05896631|ACTIVE_COMPARATOR|7.5 mg hyperbaric bupivacaine|Patients undergoing spinal anesthesia in the lateral decubitus position with 7.5 mg of hyperbaric bupivacaine will be included.
62632433|NCT06084702|PLACEBO_COMPARATOR|Water|Plain Water
62632434|NCT06084702|EXPERIMENTAL|Low Carb drink|Roaring Water
62632435|NCT03287076|EXPERIMENTAL|Active|Patients will receive exenatide injections
62632436|NCT03287076|NO_INTERVENTION|Standard Care|Standard care for stroke as per hospital protocol
62270526|NCT01544946|PLACEBO_COMPARATOR|placebo po|
62270527|NCT03783390|NO_INTERVENTION|Orientation|Informed consent, height, weight, and blood pressure measurement. A link to an online survey the participant and their parent can fill out at home about the participant's medical history will be given.
62270528|NCT03783390|NO_INTERVENTION|Measurement session Pre/Post Intervention|Questionnaires completed, blood draws, and fixed and ad lib meals completed to measure appetite and hormones. DXA completed.
62270529|NCT03783390|NO_INTERVENTION|Home Assessments Pre/Post intervention|24-hour dietary recalls. Physical activity measured by monitors (Actigraph, ActivPAL).
62270530|NCT03783390|NO_INTERVENTION|Physical Activity Session Pre/Post intervention|DXA, and Fitness testing to measure VO2submax and VO2max. Cognitive assessments will be administered.
62270531|NCT03783390|NO_INTERVENTION|fMRI Session Pre/Post intervention|The participant will have an fMRI completed and answer questions related to 60 food and activity images while in and out of the fMRI machine.
62270532|NCT03783390|EXPERIMENTAL|Exercise Intervention/Newsletter|After completion of the initial fMRI session the participant will be randomly assigned to intervention for 3 months and then complete another round of assessments described as above (except for the orientation session).
62632437|NCT02488018|EXPERIMENTAL|Provision of experimental honeys|Eight experimental monofloral honeys and reference glucose
62632438|NCT04579432|EXPERIMENTAL|Training Group|
62632439|NCT04579432|NO_INTERVENTION|Control Group|
62632440|NCT03996668|NO_INTERVENTION|Control|Subjects received standard operating room dress including sequential compression devices.
62632441|NCT03996668|EXPERIMENTAL|Experimental|Subjects wore thigh high compression stockings in addition to standard operating room dress including sequential compression devices.
62270533|NCT02626195|EXPERIMENTAL|nutritional support program apply|Preoperative nutritional support program is given for 5 or more days preoperatively by nutritional support program.
62270534|NCT02626195|NO_INTERVENTION|historical control group|Historical control group is that did not receiving
62270535|NCT03638232||Patients with multiple myeloma|"Data to be collected are :~* Drug exposition data~* Administrative data~* Medical data"
62270536|NCT01029366|EXPERIMENTAL|CART-19 CLL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10\^7 / 5x10\^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
62286876|NCT01151722|EXPERIMENTAL|experimental 2|bevacizumab before vitrectomy
62286877|NCT01151722|EXPERIMENTAL|experimental 3|bevacizumab after vitrectomy
62632442|NCT00614172|EXPERIMENTAL|Proton Radiotherapy|Two week course of proton radiotherapy to the breast.
62632443|NCT04214366|EXPERIMENTAL|Carbon Ion irradiation|22 x 3 Gy(RBE) Carbon Ions
62632444|NCT04214366|ACTIVE_COMPARATOR|Bimodal Arm|25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost
62632445|NCT04256564|EXPERIMENTAL|Oblique visualization linear probe|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein
62632446|NCT04256564|EXPERIMENTAL|Y-shape visualization micro-convex probe|A micro-convex endocavity ultrasound probe will be utilized to place the central catheter into the brachiocephalic vein
62632447|NCT02364297|ACTIVE_COMPARATOR|Early TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Performance of TIPS in the first 5 days following acute gastric variceal bleeding."
62065617|NCT05881876||burn groups|Inclusion criteria were as follows: male or female patients between 18 and 75 years of age, partial or full-thickness burns that healed spontaneously or required skin grafting, and limited joint ROM in the upper extremities caused by burns.
62065618|NCT01305746|EXPERIMENTAL|A-623 high dose weekly|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
62065619|NCT01305746|EXPERIMENTAL|A-623 low dose weekly|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
62065620|NCT01305746|EXPERIMENTAL|A-623 high dose every 4 weeks|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
62065621|NCT02435472|EXPERIMENTAL|Arm A: Exercise|Arm A will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test (CPET) performed at baseline) for 16 weeks. This exercise prescription will be achieved through \~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline \& week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing. Archival biopsy tissue samples from before and after the intervention will also be requested.
62065622|NCT02435472|NO_INTERVENTION|Arm B: Usual Care|"Arm B will receive print material with physical activity guidance which includes general physical activity information (e.g., Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a heart rate monitor, an individualized aerobic exercise program based on their cardiorespiratory fitness test results, and opportunity to consult with study exercise physiologist (one-time)."
62088175|NCT00112112|ACTIVE_COMPARATOR|FluMist|The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
62270537|NCT01029366|EXPERIMENTAL|CART-19 ALL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10\^7 / 5x10\^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
62270538|NCT03603496|EXPERIMENTAL|Transitional Tobacco Care Management (TTCM)|TTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call. At each contact the patient is offered a return call from the hospital-based tobacco coach for counseling, medication advice, and coordination of care with the patient's outpatient health care team.
62452724|NCT05896631|ACTIVE_COMPARATOR|5 mg hyperbaric bupivacaine|Patients undergoing spinal anesthesia in the lateral decubitus position with 5 mg of hyperbaric bupivacaine will be included.
62452725|NCT05936099|NO_INTERVENTION|Control|Participants will complete the baseline survey and receive an informational brochure
62452726|NCT05936099|EXPERIMENTAL|Intervention|Participants will complete the baseline survey, receive a behavioral health intervention supported by computerized decision support, and take an exit survey
62452727|NCT01938118|EXPERIMENTAL|Obesity Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote healthy lifestyle behaviors for prevention of excessive weight gain between birth to 15 months of life. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver to actively participate in the program with her.
62452728|NCT01938118|ACTIVE_COMPARATOR|Injury Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote automobile and home safety behaviors for prevention of childhood injury. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver, who is only asked to complete surveys/assessments.
62452729|NCT01106963||Tibial shaft fractures|Patients had tibial shaft fractures in the last 3 years. All were treated with intramedullary (IM) reamed nails with 2 or 3 interlocking screws.
62452730|NCT04825938|EXPERIMENTAL|Toripalimab + Carboplatin + Nab-paclitaxel|"* Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~* Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~* Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
62632448|NCT02364297|PLACEBO_COMPARATOR|Control|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices)."
62632449|NCT06609122|NO_INTERVENTION|Control Group|Students join the standard class at the same time slot
62065623|NCT02435472|ACTIVE_COMPARATOR|Arm C: Exploratory|Arm C is a non-randomized control group of men without cancer, which will receive all baseline and 16 week follow-up assessments (except tissue procurement) will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through \~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline \& week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing.
62065624|NCT02435472|ACTIVE_COMPARATOR|Observational Non-Randomized Group|There is also a non-randomized observational component to the study where biospecimens and survey data will be collected and one CPET will be administered. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research.
62065625|NCT05903716||Severe acne vulgaris|40 female patients aged 14-20 years, who were diagnosed with severe to moderate acne bulgaris and will be treated with isotretinoin.
62065626|NCT05903716||Healthy control|40 female patients aged 14-20 years
62065627|NCT06037174||minimally invasive surgery|undergoing thyroidectomy with endoscopy-assisted subclavian approach, robot-assisted transaxillary approach, robot-assisted transoral approach, robot-assisted retroauricular approach, etc.
62270539|NCT03603496|ACTIVE_COMPARATOR|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Quitline staff will contact patient to offer up to 5 proactive telephone calls from a tobacco coach. Patient may also be eligible for NRT sample. Feedback from the quitline will be sent back to the patient's medical chart.
62270540|NCT02135692|EXPERIMENTAL|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
62270541|NCT05687461||People at high risk for VTE|Patients who are admitted to the hospital for acute medical illness or surgery operations.
62452731|NCT04353908|ACTIVE_COMPARATOR|kabat|Rehabilitation will be started in both groups of patients and it will be carried out according to Kabat et al., i.e. a proprioceptive neuromuscular facilitation procedure, twice a week for 8 weeks, by an experienced physioptherapist
62452732|NCT04353908|EXPERIMENTAL|collagen injection|Injections of an equally-balanced solution of MD Neural, MD Matrix and MD Muscle (Guna S.p.a., Milan-Italy), containing collagen of porcine origin, will be administered subcutaneously after applying lidocaine/prilocaine cream on the affected side, by a skilled otonaryngologist in the field of injection treatments, twice a week for 8 weeks
62065628|NCT06037174||traditional open surgery|undergoing thyroidectomy with tradition open surgery
62065629|NCT02310451|EXPERIMENTAL|metastatic melanoma|Patients affected by advanced melanoma not resectable (stage IIIc) or metastatic (stage IV)
62065630|NCT02354716||EndoFLIP Measurements|To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.
62065631|NCT01458184|EXPERIMENTAL|PhoneCare system|This arm is evaluating whether utilizing the PhoneCare system aids participants with their complex health care needs.
62270542|NCT05687461||People diagnosed with VTE|Patients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism.
62270543|NCT00428974|EXPERIMENTAL|CF101 1 mg|
62270544|NCT00428974|EXPERIMENTAL|CF101 2mg|
62452733|NCT00821392|ACTIVE_COMPARATOR|1 Febuxostat 40mg|
62452734|NCT00821392|ACTIVE_COMPARATOR|2 Febuxostat 80mg|
62452735|NCT00821392|ACTIVE_COMPARATOR|3 Febuxostat 120mg|
62452736|NCT00821392|SHAM_COMPARATOR|4 Allopurinol 300mg|
62632450|NCT06609122|EXPERIMENTAL|Intervention Group|The teacher will work on the training goals with incorporation of the dog in the activity. For example, in the training of comprehension of commands, participant would be asked to take one item out of a few items, and then to pass to the dog. If correction of articulation errors is indicated (e.g. misarticulated /k/), training items would be picked under consideration of linkage to dogs. Words like '狗' /kɐu2/ and '教' /kau3/ would be used as stimuli during training.
62632451|NCT02584270|EXPERIMENTAL|Prosthesis + Articulation Therapy|This arm will receive a palatal augmentation prosthesis with standard articulation therapy, and is the study arm.
62632452|NCT02584270|OTHER|No Prosthesis; Articulation Therapy Only|This arm will not receive a palatal augmentation prosthesis, but will receive standard articulation therapy, and is the control arm.
62270545|NCT00428974|EXPERIMENTAL|CF101 4mg|
62270546|NCT00428974|PLACEBO_COMPARATOR|Placebo|
62452737|NCT00821392|PLACEBO_COMPARATOR|5 Placebo|
62452738|NCT01206309||Controls|Never develop an immune mediated disorder
62270547|NCT02634723||Previously Untreated Patients (PUPs)|PUPs in China with Moderate to Severe Hemophilia A
62270548|NCT05446545||ND-EOC or platinum-sensitive rEOC|"1. Newly diagnosed patients with advanced EOC (ND-EOC) who are eligible for radical surgery.~2. Patients relapsed from platinum-based therapy (rEOC) who are eligible for secondary cytoreductive surgery."
62270549|NCT05453331||Awake MER-guided surgical procedure under local anesthesia with intraoperative testing|Awake micro-electrode recording-guided surgical procedure under local anesthesia with intraoperative testing
62452739|NCT01206309||Immune Mediated Disorder|Develop an immune mediated disorder
62452740|NCT05413603|ACTIVE_COMPARATOR|fluoroscopic focus Shock wave lithotripsy|Shock wave lithotripsy, accurate localization of the shock waves is performed by the fluoroscope (FS) to fully focus the shock waves on the stone
62270550|NCT05453331||Asleep MRI-guided and CT-verified surgical procedure|Asleep MRI-guided and CT-verified surgical procedure
62452741|NCT05413603|ACTIVE_COMPARATOR|ultrasonic focus Shock wave lithotripsy|Shock wave lithotripsy, accurate localization of the shock waves is performed by the ultrasound (US), to fully focus the shock waves on the stone
62632453|NCT02368132|NO_INTERVENTION|Usual Care|Caregivers randomized to UC will be sent general material about VA and community resources for patients with dementia and their CGs. With the exception of this material, individuals in this group will receive usual care and will be contacted again at 3, 6, and 12 months for follow-up research assessments.
62270551|NCT01665144|EXPERIMENTAL|Siponimod (BAF312)|Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.
62452742|NCT04676438||Patients receiving surgery breast surgery for cancer at National Institute of Oncology|No intervention will be administered
62065632|NCT01458184|NO_INTERVENTION|Control Group: without PhoneCare System|Subjects in this arm will receive the usual care. Usual care is defined as receiving regular care from their physicians and no additional care or intervention from the study.
62270552|NCT01665144|PLACEBO_COMPARATOR|Placebo|Matching placebo to BAF312 was administered orally during the Core Part of the trial. Following the Core Part, eligible participants enter the Extension Part during which all receive open-label BAF312.
62065633|NCT05486442|EXPERIMENTAL|Experimental group|Participants in the experimental group received ACT training in the group setting aiming to reduce weight-related experiential avoidance. This included 6 sessions in total. Each session was completed approximately in 80 mins.
62065634|NCT05486442|NO_INTERVENTION|Control group|Participants in the control group did not receive any manipulation
62065635|NCT05479604|EXPERIMENTAL|SinuSonic Group|Subjects will use the SinuSonic device for 2 minutes twice daily for 8 weeks
62270553|NCT01113827|ACTIVE_COMPARATOR|150mg olive extract|
62270554|NCT01113827|ACTIVE_COMPARATOR|50mg olive extract|
62270555|NCT01113827|PLACEBO_COMPARATOR|Placebo control|
62270556|NCT06479655|ACTIVE_COMPARATOR|Fentanyl|Intravenous fentanyl infusion 0.5 - 1 mcg/kg/hr
62270557|NCT06479655|ACTIVE_COMPARATOR|Morphine|Intraveous morphine infusion 0.05 - 0.1 mg/kg/hr
62270558|NCT01263639|EXPERIMENTAL|Intervention Group, biosketch card|The investigators aim to improve the patient-physician relationship and improve patient satisfaction by providing a biosketch card of the attending orthopaedic trauma surgeon to the patient. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
62270559|NCT01263639|ACTIVE_COMPARATOR|Control group, standard care|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The control group will receive the usual/standard care as provided to all orthopaedic trauma admission patients without receiving a biosketch card."
62270560|NCT05104580||Group 1|High pre-PCI PPG index and high post-PCI QFR
62270561|NCT05104580||Group 2|Low pre-PCI PPG index and high post-PCI QFR
62270562|NCT05104580||Group 3|Low post-PCI QFR regardless of pre-PCI PPG index
62270563|NCT02884778|EXPERIMENTAL|NoL index in response to stimulation|"There is only one arm in this study. The intervention is not a drug, but it is the stimulus applied to the patient such as intubation and a standardized electrical stimulus applied on the forearm of the anesthetized patient. There are several stimuli that are the so-called interventions and the NoL index and the classical vital signs (heart rate, mean blood pressure, BISspectral index) are registered in response to these stimuli in an observational manner."
62286878|NCT04591054|ACTIVE_COMPARATOR|Extended Vision IOL|Vivity
62452743|NCT02717247|EXPERIMENTAL|Active tRNS treatment|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsalateral prefrontal cortex (F4).~100 (Hertz)Hz-650Hz, 2milliampere(mA), 30min, twice daily, 5 days"
62065636|NCT05479604|SHAM_COMPARATOR|Sham Group|Subjects will use the sham device for 2 minutes twice daily for 8 weeks
62065637|NCT01534884|ACTIVE_COMPARATOR|MabThera|rituximab
62065638|NCT01534884|ACTIVE_COMPARATOR|CT-P10|rituximab
62065639|NCT04483934|EXPERIMENTAL|Patients treated with dermal fibroblasts|Cultured dermal fibroblasts and LED phototherepy
62065640|NCT01356992|ACTIVE_COMPARATOR|Clexane® (enoxaparin - Sanofi)|
62065641|NCT01356992|EXPERIMENTAL|Versa® (enoxaparin - Eurofarma)|
62065642|NCT00310323|EXPERIMENTAL|1|Children with OSAS identified via sleep study
62065643|NCT02714868|EXPERIMENTAL|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
62286879|NCT04591054|ACTIVE_COMPARATOR|Neutral Aspheric Monofocal IOL|enVista \[MX60E\]
62286880|NCT03029013|EXPERIMENTAL|experimental group|Apatinib and chemotherapy
62286881|NCT04573101|NO_INTERVENTION|Before intervention|Participants answer questionnaire before any stimulus is given.
62286882|NCT04573101|NO_INTERVENTION|After intervention|Participants answer questionnaire after the series of stimulus is given.
62286883|NCT04573101|EXPERIMENTAL|N1 (Ney - Improvisation- Saba Re)|Improvisation with Ney, on Saba maqam on Re.
62065644|NCT02714868|ACTIVE_COMPARATOR|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
62632454|NCT02368132|ACTIVE_COMPARATOR|Individual Delivered TEP Arm|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
62270564|NCT05319639|EXPERIMENTAL|POFI and Tislelizumab|"This study will include a sequential evaluation of 3 subjects per cohort. Irinotecan 135 → 150 and paclitaxel 45 → 67.5 → 90 mg/m2 on day 1.~The rest of regimen is that oxaliplatin (85 mg/m2) and Lev-leucovolin (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. Tislelizumab 200mg，repeating the cycle every 14 days.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days); Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
62270565|NCT03261622|ACTIVE_COMPARATOR|Control arm|Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)
62270566|NCT03261622|SHAM_COMPARATOR|Intervention arm|"Alternation of stimulation amplitude~1. Period - Stimulation amplitude 0.05 Volts (lowest possible)~2. Period - Stimulation amplitude - 50% of sensory threshold.~3. Period - Stimulation amplitude - 90% of sensory threshold."
62270567|NCT03449212||SOD1 ALS|
62270568|NCT03449212||Sporadic ALS|
62452744|NCT02717247|SHAM_COMPARATOR|Placebo tRNS treatment|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
62270569|NCT03449212||Asymptomatic SOD1 gene carriers|
62270570|NCT00689871|EXPERIMENTAL|1|Primary augmentation
62270571|NCT00689871|EXPERIMENTAL|2|Primary reconstruction
62270572|NCT00689871|EXPERIMENTAL|3|Revision-augmentation
62270573|NCT00689871|EXPERIMENTAL|4|Revision-reconstruction
62270574|NCT01068028|PLACEBO_COMPARATOR|Placebo for ORM-12741|
62270575|NCT01068028|EXPERIMENTAL|ORM-12741|
62270576|NCT05259982|EXPERIMENTAL|Vital root resection|Root resective surgery aiming to preserve pulp vitality
62452745|NCT01900236|NO_INTERVENTION|Control|Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
62065645|NCT01735396|EXPERIMENTAL|Abiraterone Acetate|Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.
62065646|NCT02803567|EXPERIMENTAL|Intervention|Those in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education on substance use. Content in the intervention will focus on health promotion and will deliver positive messages about health.
62270577|NCT03801668|EXPERIMENTAL|Nab-P/S-1|Patients in this arm receive chemotherapy with Albumin-bound Paclitaxel plus S-1.
62270578|NCT03801668|ACTIVE_COMPARATOR|SOX|Patients in this arm receive chemotherapy with Oxaliplatin plus S-1.
62270579|NCT02733770|ACTIVE_COMPARATOR|Sleeve gastrectomy|US DOopler for Patient with BMI of 40 or more than 35 with co-morbidities underwent Sleeve gastrectomy
62270580|NCT02733770|ACTIVE_COMPARATOR|Mini Gastric Bypass|US DOopler for Patient with BMI of 40 or more than 35 wtih co-morbidities underwent mini gastric bypass
62270581|NCT03691974|EXPERIMENTAL|Fasinumab|
62270582|NCT03691974|PLACEBO_COMPARATOR|Placebo|
62270583|NCT02171585|EXPERIMENTAL|Dabigatran without Clarithromycin|
62270584|NCT02171585|EXPERIMENTAL|Dabigatran with Clarithromycin|
62270585|NCT02103569|EXPERIMENTAL|Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325|"Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days~Cycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days"
62632455|NCT02368132|ACTIVE_COMPARATOR|Group Delivered TEP Arm|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
62632456|NCT03038529|OTHER|A: Classic approach|"Intradiscal O3 injection through classic postrolateral extraarticular percutaneous approach.~The participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2. The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
62632457|NCT03038529|ACTIVE_COMPARATOR|B: Transforaminal approach (Yess approach )|"Participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach).~The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
62632458|NCT02770235|EXPERIMENTAL|DE assessment and AGE measurements|To evaluate the association between erectile dysfunction (DE) and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients
62632459|NCT06263647|EXPERIMENTAL|Houston-HVIP treatment group|
62632460|NCT06263647|ACTIVE_COMPARATOR|Case Manager group|
62632461|NCT04793646|ACTIVE_COMPARATOR|N-acetylcysteine syrup|Thirty pSS patients
62632462|NCT04793646|PLACEBO_COMPARATOR|Placebo syrup|Thirty pSS patients
62632463|NCT02380937|EXPERIMENTAL|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
62632464|NCT00198263|EXPERIMENTAL|Bleomycin|Bleomycin 4 USP Units/mL; intratumorally at dose of 0.25mL/cm\^3
62065647|NCT02803567|NO_INTERVENTION|Control|Those in the control arm will receive treatment as usual.
62065648|NCT01422369|EXPERIMENTAL|All Subjects|pitavastatin 4 mg
62065649|NCT04106843|EXPERIMENTAL|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30 minutes every 8-16 weeks. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
62632465|NCT05046015|NO_INTERVENTION|non diabetic|Control Group of 20 non-diabetics. Skin measurements, evaluation of skin dryness and sampling of skin particles will be performed
62632466|NCT05046015|EXPERIMENTAL|moderate dryness-diabetic|"Experimental: Diabetics with moderate dryness. Intervention Group of 20 diabetics with moderate dryness~10% Urea foot lotion During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
62632467|NCT05046015|EXPERIMENTAL|severe dryness- diabetic|"Intervention Group of 20 diabetics with severe dryness 10% Urea foot ointment During the course of the study participants cleanse their feet once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® Fuss Salbe 10% Urea on both feet once daily in the evening by themselves."
62632468|NCT00784719|EXPERIMENTAL|Treatment 1|
62632469|NCT00784719|EXPERIMENTAL|Treatment 2|
62632470|NCT00784719|EXPERIMENTAL|Treatment 3|
62632471|NCT00784719|EXPERIMENTAL|Treatment 4|
62632472|NCT00784719|ACTIVE_COMPARATOR|Active comparator|
62632473|NCT00784719|PLACEBO_COMPARATOR|Placebo|
62632474|NCT00160056|OTHER|Hypoglycemia|Intrerfvention is a hypoglycemic stimulus
62632475|NCT01706835|EXPERIMENTAL|Aldoxorubicin|Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
62632476|NCT04189432|EXPERIMENTAL|SCM-CGH|"* Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells~* Dose: 1x10\^6 cells/Kg"
62065650|NCT00737425|ACTIVE_COMPARATOR|1|
62065651|NCT00737425|SHAM_COMPARATOR|2|
62065652|NCT05872529|NO_INTERVENTION|BEFORE|The incidence of the POD and PND will determine before the education which consists processed EEG monitoring and SBI approach
62065653|NCT05872529|ACTIVE_COMPARATOR|AFTER|The incidence of the POD and PND will determine after the education which consists processed EEG monitoring and SBI approach
62088176|NCT00112112|PLACEBO_COMPARATOR|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
62088177|NCT01440049||Eplerenone|
62088178|NCT01403675|EXPERIMENTAL|Ovarian autotransplantation|
62088179|NCT05775796|EXPERIMENTAL|Serplulimab plus platinum doublet chemotherapy|
62270586|NCT06407180|EXPERIMENTAL|Intraarticular triamcinolone injection|receive Intraarticular triamcinolone injection
62632477|NCT04189432|PLACEBO_COMPARATOR|Placebo|3 times with 2-week intervals by IV infusion.
62632478|NCT04788095|EXPERIMENTAL|Device feasibility (app-based mindfulness program)|Patients participate in a mindfulness-based program by using the Am app for 20-30 minutes every day, a minimum of 4 days each week over 4 weeks.
62632479|NCT00370591|EXPERIMENTAL|Arm 1|
62065654|NCT04463121|EXPERIMENTAL|Acute CNT pacing signals testing|"Acute study procedure will be carried out prior to a pacemaker implantation or replacement: pacemaker Right Atrial (RA) and Right Ventricular (RV) leads will be positioned according to standard procedure for pacemaker implant and connected to a Moderato® System IPG, via a single use, sterile Pacing System Analyzer (PSA) cable. The Moderato IPG will deliver CNT signals.~Furthermore, a standard conductance catheter in the left ventricle will measure cardiac volumes and pressure. Arterial blood pressure will be obtained as well.~A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead while ventricular pressure and volume and arteial pressure signals will be assesed for cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions."
62065655|NCT05064111||All subjects|The experimental conditions will include a standard prostate biopsy using an FDA-approved ultrasound machine with application of the experimental (non-FDA approved) image fusion software.
62065656|NCT05516017|EXPERIMENTAL|Vestibular Electrical Stimulation and exercises with pinhole glasses|"For VES, which we will apply in our study, the anode will be placed on the mastoid protrusion on the sick ear and a cathode electrode is placed on the healthy ear.The skin to be treated will be cleaned and dried The electrodes are fixed to the head with the help of an elastic band. VES application per session will be applied for 30 minutes, 2 days a week, for 8 weeks. Patients will be asked to perform a bed exercise program once a day for 20-30 minutes each session, 5 days a week, for 8 weeks, including the above exercises, which they will perform in bed after the first day.These exercises are; fixation of the head and turning the eyes to the right and left, the movement of fixing the eyes and turning the head to the left and right, turning the head and eyes in one direction and focusing, hip flexor and knee extensor strengthening.~Patients in the experimental group will also wear pinhole glasses while applying VES."
62065657|NCT05516017|ACTIVE_COMPARATOR|VES and exercises without pinhole glasses|"For VES, which we will apply in our study, the anode will be placed on the mastoid protrusion on the sick side and the cathode will be placed on the healthy ear. The skin to be treated will be cleaned and dried. The electrodes are fixed to the head with the help of an elastic band. VES application per session will be applied for 30 minutes, 2 days a week, for 8 weeks.Patients will be asked to perform a bed exercise program once a day for 20-30 minutes each session, 5 days a week, for 8 weeks, including the above exercises, which they will perform in bed after the first day.These exercises are; fixation of the head and turning the eyes to the right and left, the movement of fixing the eyes and turning the head to the left and right, turning the head and eyes in one direction and focusing, hip flexor and knee extensor strengthening.~Patients in the active comparator will not wear pinhole glasses while VES is applied."
62065658|NCT06035614|ACTIVE_COMPARATOR|Tacrolimus + excimer light (group A)|group A, will be treated by Tacrolimus 0.1% ointment twice daily and excimer light 308nm twice weekly (exciplex®)
62065659|NCT06035614|ACTIVE_COMPARATOR|Tacrolimus (group B)|group B will start on Tacrolimus 0.1% ointment twice daily alone
62065660|NCT04340908|EXPERIMENTAL|Treatment|Dapagliflozin 10 mg tablet
62270587|NCT06407180|PLACEBO_COMPARATOR|placebo group|receive Intraarticular normal saline injection
62065661|NCT04340908|PLACEBO_COMPARATOR|Control|matching placebo tablet
62065662|NCT03122730|EXPERIMENTAL|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
62065663|NCT02557490|EXPERIMENTAL|Oxaliplatin by TACE|Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
62065664|NCT02557490|NO_INTERVENTION|Raltitrexed by TACE|Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
62065665|NCT04672096|EXPERIMENTAL|Neuronoff BASMATI Injectrode|Subjects will be provided with the placement of an Injectrode insert. The maximal placement duration will be 28 days.
62286884|NCT04573101|EXPERIMENTAL|O1 (Oud - Improvisation- Saba Re)|Improvisation with Oud, on Saba maqam on Re.
61978592|NCT03706781|EXPERIMENTAL|Test product CTP/BNZ with mucus adhesive polymer|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) + mucus adhesive polymer is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
62065666|NCT03963661|EXPERIMENTAL|c-SIGHT|SIGHT requires participants to grasp and lift rods with their less impaired arm.
62065667|NCT00402337|ACTIVE_COMPARATOR|72 ug linaclotide acetate|
62286885|NCT04573101|EXPERIMENTAL|Q1(Qanun - Improvisation- Saba Re)|Improvisation with Qanun, on Saba maqam on Re.
62632480|NCT03292185|EXPERIMENTAL|IDeglira-IDeg-Liraglutide|Treatment sequence first Insulin Degludec/Liraglutide, then Insulin Degludec, then Liraglutide
62270588|NCT05903846|EXPERIMENTAL|Oketani massage group|According to the Ministry of Health, the follow-up period for mothers after cesarean section in Turkey is 48 hours. After the mothers in the massage group were taken to the service, oketani massage was applied three times a day for an average of 15-20 minutes, starting before breastfeeding. Massage was applied to the Oketani massage group by a midwife working in the clinic. Before the mothers were discharged, the breast fullness and breastfeeding status of the mothers were evaluated using the breast engorgement assessment scale and the LATCH breastfeeding diagnostic scale.
62270589|NCT05903846|NO_INTERVENTION|Control group|No intervention was made in the control group and routine follow-up of mothers and babies will be performed after cesarean section. No intervention was made regarding the breastfeeding process of the mothers, other than the breastfeeding counseling given by the breastfeeding consultant according to the hospital protocol. Before the mothers were discharged, the breast fullness and breastfeeding status of the mothers were evaluated using the breast fengorgement assessment scale and the LATCH breastfeeding diagnostic scale.
62270590|NCT02426216||Group A|Group A: Subjects who fullfil all eligibility criteria of the MCS-8 protocol and consent to enroll the study.
62270591|NCT02426216||Group B|Group B: Subjects who fullfil the definition of elevated risk for prostate cancer by the MCS-8 protocol but did not sign up for the MCS-8 study.
62270592|NCT02902952|EXPERIMENTAL|Physical Exercise Condition|An eight week physical exercise intervention
62065668|NCT00402337|ACTIVE_COMPARATOR|145 ug linaclotide acetate|
62065669|NCT00402337|ACTIVE_COMPARATOR|290 ug linaclotide acetate|
62270593|NCT02902952|ACTIVE_COMPARATOR|Control Condition|An eight week control condition consisting of sedentary activities
62452746|NCT01900236|EXPERIMENTAL|Motivation Behavioral Technique|Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
62065670|NCT00402337|ACTIVE_COMPARATOR|579 ug linaclotide acetate|
62065671|NCT00402337|PLACEBO_COMPARATOR|Matching Placebo|
62452747|NCT05585996|EXPERIMENTAL|Combination therapy of CD19 CAR-T and CD19 CAR-DC|6-18 patientsare planned to be enrolled in the dose-escalation trial (0.5×10\^6/kg、1×10\^6/kg、2×10\^6/kg和4×10\^6/kg) and 52 patients in the dose-expansion trial.
62452748|NCT06485024|EXPERIMENTAL|intervention|the use of Modeling resin as the last layer applied to the NanoHybrid composite direct veneer
62452749|NCT06485024|ACTIVE_COMPARATOR|comparator|the regular application of the NanoHybrid composite as a direct anterior veneer restoration
62065672|NCT04105530|ACTIVE_COMPARATOR|Transcranial direct current stimulation (tDCS) on day 1|"One stimulation will be conducted using Anodal treatment.~The Direct Current Anodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session."
62065673|NCT04105530|ACTIVE_COMPARATOR|Transcranial direct current stimulation (tDCS) on day 2|A final stimulation will be conducted using Cathodal stimulation. Direct Current Cathodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session.
62452750|NCT01742975|EXPERIMENTAL|Arm A: Applying Ifabond|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.
62452751|NCT01742975|NO_INTERVENTION|Arm B: without Ifabond|The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.
62452752|NCT05448144||Alcohol-associated liver disease|drinking, had fatty liver, hepatitis, or hepatic cirrhosis
62452753|NCT05448144||Purely drinking|drinking, but had no fatty liver and hepatitis.
62632481|NCT03292185|EXPERIMENTAL|IDeglira-Liraglutide-IDeg|Treatment sequence first Insulin Degludec/Liraglutide, then Liraglutide, then Insulin Degludec
62065674|NCT04105530|PLACEBO_COMPARATOR|Sham treatment|"The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes.Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial:"
62452754|NCT05448144||Healthy control|no drinking and no liver diseases.
62632482|NCT03292185|EXPERIMENTAL|IDeg-Liraglutide-IDeglira|Treatment sequence first Isulin Degludec, then Liraglutide, then Insulin Degludec/Liraglutide
62270594|NCT04712929||Homogenous oral leukoplakia|"uniform, flat, thin, smooth/ wrinkled/corrugated surface throughout the white lesion.~Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days"
62270595|NCT04712929||Non-Homogenous oral leukoplakia|mixture of red and white lesions with a irregularly speckled/ nodular/ verrucous surface Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days
62270596|NCT04712929||Control group|30 healthy controls ( age and sex matched) would also be recruited from patients who are reporting for other routine dental problems.
62632483|NCT03292185|EXPERIMENTAL|IDeg-IDeglira-Liraglutide|Treatment sequence first Insulin Degludec, then Insulin Degludec/Liraglutide, then Liraglutide
62632484|NCT03292185|EXPERIMENTAL|Liraglutide-IDeg-IDeglira|Treatment sequence first Liraglutide, then Insulin Degludec, then Insulin Degludec/Liraglutide
62270597|NCT04307290|EXPERIMENTAL|DEX group|received intravenous dexmedetomidine (0.5 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg/h infusion from 10 min before the start of surgery to the end of surgery
62270598|NCT04307290|PLACEBO_COMPARATOR|CON group|received an equivalent volume of normal saline bolus and infusion as placebo until the end of surgery.
62270599|NCT00928551|EXPERIMENTAL|1|
62270600|NCT05324046||Liver metastasis|Patients with suspicion of liver metastasis and scheduled for CT
62270601|NCT04270474|EXPERIMENTAL|Active Intervention (ACT)|Pharmacist-based Deprescribing
62270602|NCT04270474|SHAM_COMPARATOR|Usual Care (UC)|Usual Care
62270603|NCT01227330|EXPERIMENTAL|Medication adherence intervention|Receives 12-week behavioral feedback intervention to improve adherence to statin medication
62270604|NCT01227330|NO_INTERVENTION|Control|No intervention
62270605|NCT01227330|ACTIVE_COMPARATOR|Attention-control|Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol
62270606|NCT03433014|ACTIVE_COMPARATOR|0.5% Levobupivacaine|The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision.
62270607|NCT03433014|OTHER|Control|The control group will not receive any local infiltrative agent.
62270608|NCT02442973||Control group (CG):|Standard practice group
62270609|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
62270610|NCT03119519|EXPERIMENTAL|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
62270611|NCT03119519|ACTIVE_COMPARATOR|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
62270612|NCT03375450||Observation|Cohort of patients with COPD
62270613|NCT05540197||Autologous islet transplantation|Arginine stimulation test: 5 grams of arginine hydrochloride intravenously. Performed at baseline after mixed meal tolerance test (MMTT), performed separately at day -1 or 0, day 1, day 3, day 7 and 3 months, and also at 3 months after MMTT.
62270614|NCT05540197||Allogeneic islet transplantation|Arginine stimulation test: 5 grams of arginine hydrochloride intravenously. Performed at day -1 or 0, day 1, day 3, day 7, 3 months and at 3 months after MMTT.
62270615|NCT04609852|EXPERIMENTAL|Cohort 1: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
62270616|NCT04609852|EXPERIMENTAL|Cohort 2: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
62270617|NCT04609852|EXPERIMENTAL|Cohort 3: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
62270618|NCT04609852|EXPERIMENTAL|Cohort 4: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
62270619|NCT02813200|EXPERIMENTAL|Group 1|
62270620|NCT02813200|EXPERIMENTAL|Group 2|
62270621|NCT02813200|EXPERIMENTAL|Group 3|
62270622|NCT00812214|EXPERIMENTAL|Eszopiclone (Lunesta) 3mg|Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. They were treated for 6 weeks with 3mg eszopiclone, followed by a 2-week runout period. Participants came in for five visits: a screening visit, a randomization visit, a compliance visit, an end-treatment visit, and an exit/early termination visit.
62270623|NCT00812214|PLACEBO_COMPARATOR|Placebo|Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. They were treated for 6 weeks with placebo, followed by a 2-week runout period. Participants came in for five visits: a screening visit, a randomization visit, a compliance visit, an end-treatment visit, and an exit/early termination visit.
62270624|NCT03621371|EXPERIMENTAL|Metacognitive therapy|
62270625|NCT03621371|EXPERIMENTAL|Intolerance of uncertainty therapy|
62286886|NCT04573101|EXPERIMENTAL|N2 (Ney - Improvisation- Saba Sol)|Improvisation with Ney, on Saba maqam on Sol.
62286887|NCT04573101|EXPERIMENTAL|O2 (Oud - Improvisation- Saba Sol)|Improvisation with Oud, on Saba maqam on Sol.
62632485|NCT03292185|EXPERIMENTAL|Liraglutide-IDeglira-IDeg|Treatment sequence first Liraglutide, then Insulin Degludec/Liraglutide, then Insulin Degludec
62632486|NCT00455000|EXPERIMENTAL|Active treatment|5 possible active doses
62632487|NCT00455000|PLACEBO_COMPARATOR|Placebo|
62632488|NCT00707057|EXPERIMENTAL|Ibuprofen 600 mg ER group|One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
62632489|NCT00707057|PLACEBO_COMPARATOR|Placebo group|Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
62632490|NCT02702843|ACTIVE_COMPARATOR|Xenon Light|Laparoscopic cholecystectomy with Xenon Light
62632491|NCT02702843|EXPERIMENTAL|Near infrared light|Laparoscopic cholecystectomy with Near infrared light
62632492|NCT02193750|PLACEBO_COMPARATOR|Placebo|1 placebo muesli bars and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
62065675|NCT04940013|OTHER|Study participants|Study participants will be persons who have late period of up to 14 days
62065676|NCT01283321|EXPERIMENTAL|Group A: RiaSTAP|Human fibrinogen concentrate
62065677|NCT01283321|ACTIVE_COMPARATOR|Group B: apheresis platelets|single apheresis unit
62065678|NCT02664701|ACTIVE_COMPARATOR|Individual supportive therapy|"Patients randomized to this arm will have individual supportive therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Individual supportive therapy~Intervention: Evaluations with a psychiatrist"
62270626|NCT05915442|EXPERIMENTAL|Treatment with quemliclustatm, etrumadenant, zimberelimab and SBRT|Subjects with metastatic prostate cancer will receive quemliclustat and etrumadenant for 4 weeks prior to metastasis-directed SBRT (Stereotactic Body Radiation Therapy). Within one week of completing SBRT, subjects will also start zimberelimab.
62270627|NCT03986489|EXPERIMENTAL|Mindfulness-based dance/movement therapy|Participants assigned to the M-DMT group condition will receive care as usual plus 12 weekly 90-minute group M-DMT sessions delivered online by a board-certified dance/movement therapist. The therapist is instructed to follow the M-DMT manualized protocol.
62270628|NCT03986489|ACTIVE_COMPARATOR|Chronic pain social support group|Participants assigned to the control condition will participate in a 12-session (90-minute session/week) online social support group.
62632493|NCT02193750|EXPERIMENTAL|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
62632494|NCT02193750|EXPERIMENTAL|High Oligosaccharide Group|1 intervention muesli bar and 1 serving intervention muesli per day (5.43 total fructans/GOS)
62632495|NCT04715282|OTHER|Epley maneuver|The Epley maneuver was performed for all patients (both EpleyM and EpleyM\&Exe groups) included in this study until nystagmus had disappeared in each position. If nystagmus/vertigo was not seen, the Epley maneuver was not performed for patients at the 1st, 3rd, and 6th week assessments.
62632496|NCT04715282|OTHER|Cawthorne-Cooksey exercises combined with the Epley maneuver|Additional Cawthorne-Cooksey exercises were prescribed to the EpleyM\&Exe group. The physiotherapist explained and demonstrated the exercises to each patient and the patients practiced the exercises until they performed them correctly. Then the exercises were prescribed twice a day and repeated 10 times for 6 weeks as a home exercise program.
62632497|NCT01472445|EXPERIMENTAL|Non-obese (Body Mass Index ≤ 25)|Non-obese participants receive Vitamin D at 400 or 10,000 IU/day
62065679|NCT02664701|EXPERIMENTAL|Cognitive behavioural group therapy|"Patients randomized to this arm will have cognitive behavioural therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Cognitive behavioural group therapy~Intervention: Evaluations with a psychiatrist"
62065680|NCT03486925|EXPERIMENTAL|oxytocin group|
62065681|NCT03486925|PLACEBO_COMPARATOR|placebo group|
62065682|NCT06109233||MRD negativity|NDMM patients who obtained MRD negativity after induction and consolidation therapy
62065683|NCT06109233||MRD positivity|NDMM patients who MRD positivity after induction and consolidation therapy and agree to adjust the treatment regimen
62065684|NCT00426322|ACTIVE_COMPARATOR|1|small particles
62065685|NCT00426322|ACTIVE_COMPARATOR|2|large particles
62065686|NCT04875364|EXPERIMENTAL|Early PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will be set up with a loaner CPAP for 8 weeks to initiate therapy right away.
62270629|NCT04096911|EXPERIMENTAL|Sintilimab and HPV Vaccine|Sintilimab 200 mg intravenously every 3 weeks ，3 doses of quadrivalent HPV vaccine intramuscularly at day 1,60,180
62632498|NCT01472445|EXPERIMENTAL|Obese (Body Mass Index > 25)|Obese participants receive Vitamin D at 400 or 10,000 IU/day
62632499|NCT03012841|EXPERIMENTAL|Treatment Arm|Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter
62632500|NCT00086450|ACTIVE_COMPARATOR|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
62632501|NCT00086450|EXPERIMENTAL|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
62632502|NCT04860479||Infants: 28 days - 12 month|inguinal sonoanatomy
62632503|NCT04860479||small children: 13 months - 36 months|inguinal sonoanatomy
62632504|NCT04860479||preschool age: 37 months - 72 months|inguinal sonoanatomy
62632505|NCT04860479||school age: 73 months - 9 years|inguinal sonoanatomy
62632506|NCT04860479||Preadolescant: >9 years - 12 years|inguinal sonoanatomy
62632507|NCT04860479||Adolescants: >12 years - 18 years|inguinal sonoanatomy
62632508|NCT02949154||Metastatic melanoma patients|All patients \>18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
62270630|NCT06463496||Heart failure group|Patients with heart failure in post-acute care program
62632509|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
62270631|NCT06463496||Healthy control group|The age- and gender-matched healthy control group
62632510|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
62632511|NCT05897866|EXPERIMENTAL|Issa3|Dr.A.Sayed Issa and his team
62632512|NCT05783947||Suspicion of autoimmune neurological disorder|Sera and CSF of patients with a suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome
62632513|NCT00280592|PLACEBO_COMPARATOR|Placebo|
62632514|NCT00280592|EXPERIMENTAL|Cranberry|Cranberry
62632515|NCT03318003|EXPERIMENTAL|Auto-PAP Therapy|
62632516|NCT03318003|NO_INTERVENTION|No Therapy|
62632517|NCT06337357|EXPERIMENTAL|Intervention group|"The intervention group receives supervised resistance training instructions and baseline treatment for sarcopenia and diabetes:~* Resistance training with elastic bands aims to increase muscle strength and muscle mass of the upper and lower limbs. Training duration 12 weeks, frequency 2 times/week, intensity gradually increases.~* Baseline treatment for diabetes and sarcopenia: Recommendations according to American Diabetes Association guidelines which include instructions to follow the diet and exercises as recommended for older type 2 diabetic patients and baseline treatment for sarcopenia (education about sarcopenia and treatment measures such as diet and exercise) and provide basic information on resistance training."
62632518|NCT06337357|NO_INTERVENTION|Control group|"The control group receives the baseline treatment for diabetes and sarcopenia:~- Recommendations according to American Diabetes Association guidelines which include instructions to follow the diet and exercises as recommended for older type 2 diabetic patients and baseline treatment for sarcopenia (education about sarcopenia and treatment measures such as diet and exercise) and provide basic information on resistance training."
62632519|NCT02895685|EXPERIMENTAL|Dyad training|Participants randomized to train in pairs during the whole 6-week course
62632520|NCT02895685|NO_INTERVENTION|Control group: individually training|If randomized to train individually, participants will be instructed to do all the training individually. Participants will be instructed not to practice with others when practising at home and will only receive feedback from the expert during the expert-guided self-training. At the training at CAMES, participants will sit at separate tables.
62632521|NCT03202290|OTHER|Gambling disorder|patients suffering from gambling disorder
62632522|NCT03202290|OTHER|Controls|healthy controls
62632523|NCT03340038|ACTIVE_COMPARATOR|Specialty Ward|Patients who have been randomized into receiving post-operative care at the Non-ICU Specialty ward (intervention) after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
62632524|NCT03340038|NO_INTERVENTION|Intensive Care Unit (ICU)|Patients who have been randomized into receiving post-operative care at the intensive care unit after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
62632525|NCT01757860|EXPERIMENTAL|CARD-024|CARD-024 oral administered: 3, 9, 27 or 81 mcg.
62270632|NCT04942925|OTHER|Precision1, then Infuse|Verofilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62270633|NCT04942925|OTHER|Infuse, then Precision1|Kalifilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62270634|NCT01948687||1. the control group|healthy adult volunteers
62270635|NCT01948687||2. patients with chronic hepatitis|patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen)
62270636|NCT01948687||3. liver cirrhosis type B or C|patients with liver cirrhosis type B or C
62632526|NCT01757860|PLACEBO_COMPARATOR|Drug Carrier|Placebo: 20% ethanol:80% propylene glycol solution oral administered.
62632527|NCT04868773|EXPERIMENTAL|Cabozantinib in Combination with TAS-102 (trifluridine/tipiracil)|Subjects will receive cabozantinib in combination with TAS-102. Patients will receive cabozantinib on Days 1 - 28 and TAS-102 on Days 1-5 and Days 8-12, for a cycle length of 28 days.
62632528|NCT02898233|ACTIVE_COMPARATOR|Deprexis and active LLLT|Participants will have access to Deprexis and will receive active low-level light therapy (4 days X 8 minutes of active LLLT)
62632529|NCT02898233|SHAM_COMPARATOR|Deprexis and sham LLLT|Participants will have access to Deprexis and will receive sham low-level light therapy (4 days X 5 seconds of active LLLT and 55 seconds of sham LLLT)
62632530|NCT02898233|OTHER|Deprexis only|Participants will have access to Deprexis but will not receive real or sham LLLT
62632531|NCT02026752||Study Population|
62632532|NCT04006470||Stannous Fluoride Dentifrice|Twice daily use
62632533|NCT04006470||Positive control dentifrice|Twice daily use
62632534|NCT04006470||Negative control dentifrice|Twice daily use
62632535|NCT06612632|EXPERIMENTAL|Combination therapy|Research drug in combination with Toripalimab
62632536|NCT06612632|EXPERIMENTAL|Sequential therapy|Toripalimab
62270637|NCT03086733|EXPERIMENTAL|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
62632537|NCT06612632|NO_INTERVENTION|RWS cohort|observation
62632538|NCT00780780|ACTIVE_COMPARATOR|1|Triamcinolone intravitreal injection + Nepafenac eye drops
62632539|NCT00780780|OTHER|2|Triamcinolone intravitreal injection
62632540|NCT03682068|EXPERIMENTAL|Durvalumab in Combination with SoC Chemotherapy|"Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~* cisplatin+ gemcitabine~* If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
62632541|NCT03682068|EXPERIMENTAL|Durvalumab in Combination with Tremelimumab+SoC Chemotherapy|"Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks~Tremelimumab will be provided for 4 cycles.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~* cisplatin+ gemcitabine~* If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
62632542|NCT03682068|ACTIVE_COMPARATOR|SoC Chemotherapy|"Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~* cisplatin+ gemcitabine~* If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
62632543|NCT03954002|EXPERIMENTAL|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
62632544|NCT02674724|EXPERIMENTAL|Gym Group|With gym equipments, twice per week for 12 weeks.
62632545|NCT02674724|ACTIVE_COMPARATOR|Free Weights Group|With dumbbells, elastics, twice per week for 12 weeks.
62632546|NCT02674724|PLACEBO_COMPARATOR|Control Group|The control group will be instructed to perform stretching exercises at home in the same 12-week period, according to an illustrated booklet.
62632547|NCT00604994||Malignant|Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina
62632548|NCT00604994||Benign|Patients without malignant gynaecological cancers
62632549|NCT06152380||Clinic-based Rehabilitation|Individualised clinic-based face-to-face sessions with a physiotherapist in public or private rehabilitation facility
62632550|NCT06152380||Knee Care @Home|Individualised synchronous internet-based remote sessions at home via conferencing software under the supervision of a certified exercise and health coach as a complement to conventional clinic-based rehabilitation sessions.
62632551|NCT01918917|ACTIVE_COMPARATOR|Levobupivacaine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml 0.9% sodium chloride administered. postoperative morphine administered for analgesia
62632552|NCT01918917|ACTIVE_COMPARATOR|Dexmedetomidine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml (100 mcg/ml) dexmedetomidine administered, postoperative morphine used for analgesia
62632553|NCT02356757|EXPERIMENTAL|Personalized Behavioral Intervention (PBI)|The PBI is a 12-month long integrated, multicomponent counseling and dermal thermometry intervention targeting foot self-care, foot self-monitoring, diet, medication and physical activity. The intervention is based on self-regulation theory, the Transtheoretical Model and
62632554|NCT02356757|PLACEBO_COMPARATOR|Current Best Practice (CBP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes and foot care, and will also receive counseling regarding preventing general health conditions.
62632555|NCT04803214|OTHER|Treatment (ReActiv8)|Market-approved ReActiv8 device
62270638|NCT04695964|OTHER|ICG-NIRF Imaging and objective perfusion rate|ICG-NIRF imaging is used to visualise the blood supply and the bowel perfusion rate in the area of the pouch anastomoses. An additional ingress and egress analysis at specific regions of interest is performed. This is to get an objective method of visualisation of the blood inflow and outflow over time and thus bowel perfusion at the anastomotic site.
62632556|NCT04803214|NO_INTERVENTION|Control (OMM)|Standard of Care
62632557|NCT06318403|EXPERIMENTAL|Transdermal estradiol patches|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
62632558|NCT06318403|PLACEBO_COMPARATOR|Placebo patches|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
62632559|NCT06422871||HeRO® / Super HeRO®|Subjects who meet all inclusion criteria and none of the exclusion criteria and treatment is attempted with the HeRO® Graft or Super HeRO® device.
62632560|NCT04718480|PLACEBO_COMPARATOR|Placebo|2 x 100 mg placebo daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
62632561|NCT04718480|EXPERIMENTAL|Fluvoxamine|2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
62632562|NCT00970645|ACTIVE_COMPARATOR|traditional mediastinoscopy/thoracoscopy|Traditional Mediastinoscopy used to detect or stage lung cancers.
62632563|NCT00970645|ACTIVE_COMPARATOR|EBUS/EUS|Minimal invasive technique for staging/detecting lung cancer.
62632564|NCT05664308||Electrocardiogram|
62632565|NCT05664308||Electrocardiogram + Connect Watch|
62632566|NCT02598739|EXPERIMENTAL|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
62632567|NCT02598739|OTHER|Control group|Waiting list for the exercises.
62632568|NCT05170646||Participants treated with upadacitinib|
62632569|NCT01799252||Doxy|Women who are prescribed a seven-day regimen of doxycycline following medical abortion
62632570|NCT01799252||No Doxy|Women who are not prescribed antibiotics following medical abortion
62632571|NCT01214668|EXPERIMENTAL|LY573636 + Liposomal Doxorubicin|
62632572|NCT03513263|ACTIVE_COMPARATOR|Scaling and polishing plus oral hygiene instruction|This arm will contain RA participants with PD who will continue with their treatment for RA and also receive the intervention of scaling and polishing plus oral hygiene instructions
62632573|NCT03513263|SHAM_COMPARATOR|only oral hygiene instructions|This arm will contain rheumatoid arthritis (RA) participants with periodontitis who will continue with their treatment for (RA) and also receive only oral hygiene instructions
62632574|NCT03450577||PCI of bifurcation lesions|Patients who have undergone bifurcation coronary artery stenting.
62632575|NCT04491461|ACTIVE_COMPARATOR|Herbal tea blend|1 cup of herbal tea blend containing Rosehip and other berry extracts.
62065687|NCT04875364|EXPERIMENTAL|Usual PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will remain untreated until they are set up with their clinically prescribed CPAP (typically takes about 8 weeks).
62065688|NCT00957164|ACTIVE_COMPARATOR|Pain Treatment Only|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
62065689|NCT00957164|ACTIVE_COMPARATOR|PTSD Treatment Only|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
62270639|NCT03837080|EXPERIMENTAL|Nutrition Education|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care will go through a series of individual and group nutrition educations. Educations are specifically tailored for chronic pain patients, based on our preliminary findings on this group of patients.
62270640|NCT03837080|NO_INTERVENTION|Control|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care. Patients will receive all treatments (e.g. physical therapy) except the nutrition education.
62270641|NCT00653003|EXPERIMENTAL|A|Subjects received Kali formulated product under fed conditions
62632576|NCT04491461|SHAM_COMPARATOR|Warm water|1 cup of warm water.
62632577|NCT06420245|ACTIVE_COMPARATOR|Standard of Care (SOC)|Standard of care DFU wound management
62632578|NCT06420245|EXPERIMENTAL|Amniotic Membrane plus Standard of Care|Biweekly application of Orion TM amniotic membrane allograft in addition to standard of care DFU wound management
62632579|NCT04368507|EXPERIMENTAL|YYB101+Irinotecan|"1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks"
62632580|NCT02571764|EXPERIMENTAL|Nutritional Oats Cookie|
62632581|NCT02740959|EXPERIMENTAL|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
62632582|NCT02740959|EXPERIMENTAL|Astragalus Polysaccharides 250 mg|PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
62632583|NCT03441685|EXPERIMENTAL|Verb strategies|"The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences."
62632584|NCT06336057||Patients|Group of patients with narcolepsy type 1.
62632585|NCT06336057||Controls|Group of control patients with Obstructive Sleep Apnea (OSA) corrected by treatments
62065690|NCT00957164|ACTIVE_COMPARATOR|Combined Pain and PTSD Treatment|This treatment arm will involve 5 sessions each of the Pain-Only and PTSD-Only treatments described above.
62632586|NCT00074815|EXPERIMENTAL|MedMgmt+CBT|Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.
62065691|NCT00957164|NO_INTERVENTION|Treatment as Usual|The treatment as usual group will complete the assessments given in each of the other study arms, but will not participate in treatment through the study. Instead, participants randomized to this group will be encouraged to seek treatment for pain and/or PTSD through existing channels. Referrals for treatment will be made for those with clinically significant symptoms for pain and/or PTSD at intake.
62065692|NCT04138199||Participants with Human Immunodeficiency Virus-1 Infection|Human Immunodeficiency Virus-1 (HIV-1) infected and clinically stable patients on dual or triple HAART including Kaletra who switched or planned to switch to generic product of lopinavir/ritonavir
62270642|NCT00653003|ACTIVE_COMPARATOR|B|Subjects received Aventis formulated products under fed conditions
62452755|NCT06412562||Major Depressive Episode|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Major Depressive Disorder (MDD) or Bipolar Disorder (BD), as determined by a psychiatrist.
62632587|NCT00074815|EXPERIMENTAL|MedMgmt+I-CBT|Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.
62632588|NCT00074815|ACTIVE_COMPARATOR|MedMgmt Only|Participants will receive the intervention SRI medication management with a psychiatrist
62632589|NCT02303639|EXPERIMENTAL|Radiofrequency catheter ablation|Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping
62632590|NCT02303639|ACTIVE_COMPARATOR|Antiarrhythmic drug therapy|Amiodarone (or sotalol) tablet by mouth for the duration of the study
62632591|NCT04878120|OTHER|Standard HCL System - HCL System with Smart Bolus Calculator|Use of standard HCL system followed by use of HCL system with smart bolus calculator informed by insulin sensitivity
62632592|NCT04878120|OTHER|HCL System with Smart Bolus Calculator - Standard HCL System|Use of HCL system with smart bolus calculator informed by insulin sensitivity followed by use of standard HCL system
62452756|NCT00991588||PCL, posterolateral reconstruction|All patients who are entered into study who receive a PCL and/or posterolateral knee ligament reconstruction
62632593|NCT06612658|EXPERIMENTAL|Capsimax|Capsules containing either 100 mg Capsimax (OmniActive Health Technologies)
62065693|NCT01659398|EXPERIMENTAL|Enhanced external counterpulsation (EECP)|
62452757|NCT02572310|EXPERIMENTAL|HV Cement|Simplex High Viscosity Bone Cement
62452758|NCT02127606|EXPERIMENTAL|Vibration with tilt-table standing|Participants in this arm will undergo alternating side-to-side, whole body vibration while standing on a tilt table for multiple treatments for a total of approximately 14 minutes for 3 sessions over 3 different days
62632594|NCT06612658|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose
62632595|NCT05377112|EXPERIMENTAL|SYNB8802v1|Dose ramp to 1 × 1011 QD and then dose ramp to 3 × 1011 TID SYNB8802v1 live cells
62632596|NCT05377112|PLACEBO_COMPARATOR|Placebo|Placebo will be administered during the dose ramp such that all subjects receive IMP dosing TID
62632597|NCT06373341|EXPERIMENTAL|VR training|The intervention group will participate in training with a VR-exergame for 4 weeks after inclusion. For this training a Meta Quest VR-headset with a game specifically designed for and with ICU patients that was previously pilot tested for feasibility and safety will be used under supervision of a researcher or caregiver until the patient feels ready to practice alone.
62065694|NCT01659398|NO_INTERVENTION|Subjects not receiving EECP|Control group to measure data from experimental group against.
62632598|NCT06373341|NO_INTERVENTION|Standard care|The control group will receive standard care rehabilitation.
62632599|NCT02546869|EXPERIMENTAL|Lebrikizumab|Participants will receive lebrikizumab SC using prefilled syringes (PFS), q4w up to Week 12.
62632600|NCT02638402||Stage I, II, III, IV ovarian cancer|Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital
62065695|NCT05168917|OTHER|Ulcerative colitis in clinical and endoscopic remission|Patients with established diagnosis of ulcerative colitis (UC) in clinical and endoscopic remission defined as clinical score = 0 at enrollment with no endoscopy flare up may participate to follow up. Proctosigmoidoscopy to document endoscopic remission has to be foreseen. The patients' inclusion/exclusion criteria are based on the established diagnostic procedures for the UC, i.e. colonoscopy at the time of diagnosis, endoscopic evidence of remission and clinical significant findings.
62632601|NCT02638402||Stage I, II, III, IV endometrial cancer|Stage I, II, III, IV endometrial cancer receive treatment in National Taiwan University Hospital
62632602|NCT01948921|PLACEBO_COMPARATOR|placebo|1 ml normal saline will be given 5 minutes before EGD
62632603|NCT01948921|ACTIVE_COMPARATOR|meperidine|25 mg intramuscular meperidine will be given 5 minutes before EGD
62632604|NCT01061541|EXPERIMENTAL|Group A|
62632605|NCT01061541|ACTIVE_COMPARATOR|Group B|
62632606|NCT01750060|ACTIVE_COMPARATOR|Fentanyl citrate IV infusion & Naltrexone|Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
62632607|NCT01750060|EXPERIMENTAL|Fentanyl Study System (170 mcAmps) & Naltrexone|Two consecutive 40 mcg fentanyl doses each delivered over 10 minutes by the Study System (170 mcAmps) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
62632608|NCT01750060|EXPERIMENTAL|Fentanyl, Study System (140 mcAmp) & Naltrexone|Two consecutive 35 mcg fentanyl doses, each delivered over 10 minutes by the Study System (140 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
62632609|NCT01750060|EXPERIMENTAL|Fentanyl, Study System (200 mcAmp) & Naltrexone|Two consecutive 50 mcg fentanyl doses, each delivered over 10 minutes by the Study System (200 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
62632610|NCT01750060|EXPERIMENTAL|Fentanyl, Study System (230 mcAmp) & Naltrexone|Two consecutive 54 mcg fentanyl doses, each delivered over 10 minutes by the Study System (230 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
62065696|NCT02204137||Completion of Questionnaires|"Participants will complete an assessment consisting of the Falls Risk Questionnaire, a primarily self-administered geriatric assessment (GA) developed by the Cancer and Aging Research Group, a quality of life scale (FACT GOG/NTX) and the Falls Efficacy Scale-International.~Each questionnaire contains approximately 150 questions and will take between 30 minutes and one hour to complete."
62270643|NCT03473496|EXPERIMENTAL|CART therapy in multiple myeloma|In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10\^6-10\^7/Kg transduced CAR T cells at one time.
62632611|NCT06083363||post-ICU with ARDS|Patients admitted to the ICU who have developed Acute Respiratory Distress Syndrome (ARDS), as defined according the new 2023 guidelines (Matthay et.al, 2023)
62632612|NCT06083363||post-ICU without ARDS|Patients admitted to the ICU who have suffered a severe pneumonia, needing advanced respiratory support, but without developing ARDS according to the new 2023 guidelines.
62632613|NCT02553824|EXPERIMENTAL|Phentermine/Topiramate-First + Placebo|Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
62632614|NCT02553824|PLACEBO_COMPARATOR|Placebo-First + Phentermine/Topiramate|Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
62632615|NCT04378686||ESKD|Patients with ESKD and on treatment with any form of dialysis
62632616|NCT01803087|ACTIVE_COMPARATOR|CHF 1535 100/6 pMDI (Foster®) TEST 1|Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
62632617|NCT01803087|ACTIVE_COMPARATOR|CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
62270644|NCT01993693|EXPERIMENTAL|Ultrasonic Diathermy Device|Therapeutic ultrasound used daily.
62270645|NCT01993693|PLACEBO_COMPARATOR|Sham Ultrasonic Diathermy Device|Sham device that does not deliver ultrasound
62270646|NCT00973076|EXPERIMENTAL|AZD8055|AZD8055 will be administered orally
62632618|NCT01803087|ACTIVE_COMPARATOR|(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)|BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
62632619|NCT01803087|ACTIVE_COMPARATOR|CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI|Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
62632620|NCT04998890|EXPERIMENTAL|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program A 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure training (one adventure day camp (2 sessions) and adventure activities in the beginning of each workshop). One session per week, 3 hours for each session. A variety of cognitive behavioral skills were taught in lectures and these skills were practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework were used in the intervention program.
62632621|NCT04998890|NO_INTERVENTION|Control group|No intervention of the adventure-based cognitive behavioral program
62632622|NCT04143191|ACTIVE_COMPARATOR|Sorafenib|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.
62632623|NCT04143191|EXPERIMENTAL|Sorafenib plus TACE|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. TACE will be performed on the fourth day after randomization. If any drug related adverse event occurred, the dosage will be reduced.
62632624|NCT01751750|OTHER|Grape|
62632625|NCT01388153|EXPERIMENTAL|Arm 1|
62632626|NCT01388153|EXPERIMENTAL|Arm 2|
62632627|NCT01388153|ACTIVE_COMPARATOR|Arm 3|
62286888|NCT04573101|EXPERIMENTAL|Q2 (Qanun - Improvisation- Saba Sol)|Improvisation with Qanun, on Saba maqam on Sol.
62632628|NCT04653831|OTHER|Standard of Care - Control|Standard of care (Soc) according to current guidelines and the discretion of treating physician.
62632629|NCT04653831|EXPERIMENTAL|Pirfenidone Treatment|"In addition to SoC, Pirfenidone 2,403 mg administered orally or per nasogastric tube as 801mg TID, for 4 weeks.~Pirfenidone dose will be 2,403mg daily, from day one of admission to the ICU, titrated over 3 days:~Day 1 - 801mg x 1/d (801mg) Day 2 - 801mg x 2/d (1,602 mg) Day 3 - 801mg x 3/d (2,403 mg) Feeding and medication delivery will be upon the discretion of the treating physician according to tolerability. Powdered 801mg tablets will be administered through the nasogastric tube: Each tablet will be crushed and dissolved in 20cc of water. The nasogastric tube will be flushed afterwards to avoid obstruction..~If the patient is able to swallow and the nasogastric tube is removed, pirfenidone will continue to be delivered orally."
62632630|NCT02896569|EXPERIMENTAL|Topical combination therapy|Application of human bone marrow stem cell derived growth factor and cytokines serum followed by a botanical lipid-based occlusive immediately post-radio-frequency treatment of the face
62286889|NCT04573101|EXPERIMENTAL|N3 (Ney - Improvisation- Kurd Re)|Improvisation with Ney, on Kurd maqam on Re.
62286890|NCT04573101|EXPERIMENTAL|O3 (Oud - Improvisation- Kurd Re)|Improvisation with Oud, on Kurd maqam on Re.
62286891|NCT04573101|EXPERIMENTAL|Q3 (Qanun - Improvisation- Kurd Re)|Improvisation with Qanun, on Kurd maqam on Re.
62286892|NCT04573101|EXPERIMENTAL|N4 (Ney - Improvisation- Kurd Sol)|Improvisation with Ney, on Kurd maqam on Sol.
62632631|NCT02896569|NO_INTERVENTION|Standard of care|No topical therapies for 24 hours post-radio-frequency treatment of the face
62632632|NCT05463497|OTHER|Group 1(N=10)|"Treatment A for Period 1 Treatment C for Period 2 Treatment B for Period 3~\*Washout period : No washout period between period 1 and 2, more than 7 days between period 2 and 3"
62632633|NCT05463497|OTHER|Group 2(N=10)|"Treatment B for Period 1 Treatment A for Period 2 Treatment C for Period 3~\*Washout period : more than 7 days between period 1 and 2, no washout period between period 2 and 3"
62632634|NCT05463497|OTHER|Group 3(N=10)|"Treatment A for Period I Treatment E Treatment D~\*Washout period : No washout period between period 1 and 2, more than 7 days between period 2 and 3"
62270647|NCT03502993||BIVA studies - children with fever and/or suspected infection|A minimum of 3,000 children will be recruited to the BIVA-ED (Biomarker Validation in Emergency Department) study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
62270648|NCT03502993||BIVA studies - control children without fever or suspicion of infection|Afebrile children \<18 years (16 years depending in the setting) of age who are having blood tests for reasons other than for investigation of infectious or inflammatory illness or whom parents give consent for bloods taken for research purposes. Controls may have a range of clinical presentations including co-morbidities without infection. One set of samples will be taken from controls, no follow up data or samples taken.
62270649|NCT02823977|EXPERIMENTAL|Ketamine / Dexmedetomidine|Ketamine 0.25 mg/kg bolus followed by 0.5 mg/kg per hour AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
62632635|NCT05463497|OTHER|Group 4(N=10)|"Treatment D for Period 1 Treatment A for Period 2 Treatment E for Period 3~\*Washout period : more than 7 days between period 1 and 2, no washout period between period 2 and 3"
62270650|NCT02823977|PLACEBO_COMPARATOR|Placebo / Dexmedetomidine|Normal saline, as a 500 mL infusion bag, to represent placebo AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
62632636|NCT04998214||control group non cirrhotic|compare liver function 1m after COVID-19 and that at beginning of infection
62632637|NCT04998214||cirrhotic patients|compare liver function 1m after COVID-19 and that at beginning of infection
62632638|NCT03593954|EXPERIMENTAL|JNJ-61393215 2 mg + Ritonavir 100 mg|Participants will receive suspension of JNJ-61393215 2 mg (Day 1 and 5) orally and tablet of Ritonavir 100 mg twice a Day (Day 4-14) orally.
62632639|NCT01649362|NO_INTERVENTION|Control group|"No prefeeding oral stimulation~Infants in the control group received neither oral stimulation nor a pacifier before or during gavage feeding."
62270651|NCT04251637||adult patients scheduled for thoracic pulmonary|"Adult patients scheduled in Louis Pradel hospital operating theater (Lyon University Hospital) for elective Lung surgery (lobectomy, bilobectomy or pneumonectomy); by thoracotomy and / or thoracoscopy.~- Having stated their non opposition to be part of this protocol"
62270652|NCT00779376|EXPERIMENTAL|1|Zidovudine 300mg tablets of Ranbaxy
62270653|NCT00779376|ACTIVE_COMPARATOR|2|Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline
62286893|NCT04573101|EXPERIMENTAL|O4 (Oud - Improvisation- Kurd Sol)|Improvisation with Oud, on Kurd maqam on Sol.
62632640|NCT01649362|EXPERIMENTAL|Oral stimulation, interventional group|"Infants in the interventional group received pre-feeding oral stimulation. The intervention started on infants born within 32 gestational weeks when the patients were stable and tube-fed, receiving more than 100 ml/kg/day of milk. On infants born after 32 weeks, the intervention started immediately after clinical stability was achieved.~The pre-feeding oral stimulation program consisted of a 15-minute stimulation program delivered by one of the eight trained nurses or one trained member from the medical staff in accordance with the stimulation program proposed by Fucile, Gisel and Lau.~The stimulation program was administered 15 to 30 minutes prior to tube feeding, once daily for at least 10 days. The program was stopped when the infants attained more than three oral feedings per day. The program was interrupted if the infants were medically unstable and/or had episodes of desaturation, apnoea and/or bradycardia during the intervention"
62632641|NCT06084910|EXPERIMENTAL|Experimental Group|Caregiver-child dyads that receive the Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) intervention
62632642|NCT06084910|ACTIVE_COMPARATOR|Treatment-As-Usual Control Group|Caregiver-child dyads that receive standard Reach Out and Read intervention without additional emphasis on cultural pride
62632643|NCT06520527|EXPERIMENTAL|Brisk Walking Exercise|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.a
62632644|NCT06520527|EXPERIMENTAL|Andrographis Paniculata|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
62632645|NCT06520527|EXPERIMENTAL|Combination|"Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.a~Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days."
62632646|NCT06520527|NO_INTERVENTION|Control|Obese with no intervention
62632647|NCT06520527|NO_INTERVENTION|Normal|Normal with no intervention
62632648|NCT05259163|EXPERIMENTAL|Group 1: LFR-260 first, then traditional phoropter|The LFR-260 was administered first in this group, followed by the traditional phoropter. The LFR-260 is a portable digital refractor which allows for determination of refractive error as well as for fully remote refractions during eye exams. The traditional phoropter is intended to be used for distance vision testing in any environment.
62632649|NCT05259163|ACTIVE_COMPARATOR|Group II: Traditional Phoropter first, then LFR-260|The traditional phoropter was administered first in this group, followed by the traditional phoropter. The traditional phoropter is intended to be used for distance vision testing in any environment. The LFR-260 is a portable digital refractor which allows for determination of refractive error as well as for fully remote refractions during eye exams.
62270654|NCT02911922|EXPERIMENTAL|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
62270655|NCT02911922|EXPERIMENTAL|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
62270656|NCT06100341|EXPERIMENTAL|Head-mounted display (HMD)|The HMD system uses a commercially available virtual headset, the Oculus/Meta Quest 2, which allows a user to view a virtual environment in 360 degrees and to interact with the environment using hand-tracking technology (i.e., when a user's hand is projected into the virtual world to be used for interactions and gestures).
62270657|NCT06100341|EXPERIMENTAL|Semi-cave automatic virtual environment (semi-CAVE)|The semi-CAVE system uses projectors and projector screens to provide a 270-degree view of the virtual environment. These projectors are connected to a powerful workstation (desktop computer), which uses HTC Vive trackers and base stations to track user movements and interactions
62286894|NCT04573101|EXPERIMENTAL|Q4 (Qanun - Improvisation- Kurd Sol)|Improvisation with Qanun, on Kurd maqam on Sol.
62452759|NCT03411005|EXPERIMENTAL|Metabolic availability of lysine in Sorghum|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked sorghum with or without lentils, which will all be provided by the investigators."
62452760|NCT06370897||Prospective Cohort|Divers admitted with suspected IEDS
62452761|NCT06370897||Retrospective Cohort|Divers diagnosed with Inner ear decompression sickness (IEDS) at Deep Diving Research Centre within past 10 years
62452762|NCT05473676|EXPERIMENTAL|Robotic Training Period|Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
62452763|NCT01621425||TAC regimen|Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol
62452764|NCT01621425||PRODOC regimen|male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol
62452765|NCT04076176|ACTIVE_COMPARATOR|L-amino Acids|"The specific amount and timing of L-amino acid consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
62452766|NCT04076176|EXPERIMENTAL|PKU Sphere|"The specific amount and timing of PKU sphere consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
62452767|NCT05909475|PLACEBO_COMPARATOR|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
62452768|NCT05909475|EXPERIMENTAL|GKEX|GKEX group. Probiotic capsules contain 10 billion CFU (colony forming units) of GKEX, , 2 caps daily use.
62452769|NCT03383744|EXPERIMENTAL|Vitamin A supplementation 1|Vitamin A status assessed at Baseline and one month after the administration of 200,000 IU of vitamin A
62452770|NCT03383744|EXPERIMENTAL|Vitamin A supplementation 3|Vitamin A status assessed at Baseline and three months after the administration of 200,000 IU of vitamin A
62452771|NCT01625156|EXPERIMENTAL|Treatment (tivantinib, temsirolimus)|Patients receive tivantinib PO BID and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 (days 8, 15, 22, and 29 of course 1). Courses repeat every 28 days (35 days in course 1) in the absence of disease progression or unacceptable toxicity.
62452772|NCT03104738|NO_INTERVENTION|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
62452773|NCT03104738|EXPERIMENTAL|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
62452774|NCT03558477|EXPERIMENTAL|Set 1(YYD601 1 & Nexium)|Set 1: YYD601 1 \& Nexium
62452775|NCT03558477|EXPERIMENTAL|Set 2(YYD601 2 & Nexium)|Set 2: YYD601 2 \& Nexium
62452776|NCT03558477|EXPERIMENTAL|Set 3(YYD601 3 & Nexium)|Set 3:YYD601 3 \& Nexium
62452777|NCT05180864|ACTIVE_COMPARATOR|Complete omentectomy|Gastrectomy with complete omentectomy
62452778|NCT05180864|EXPERIMENTAL|Omentum presevation|Gastrectomy with preservation of the omentum distal to the gastroepiploic vessels
62452779|NCT04654104||Healthy never smokers|Clinical evaluation of immune check points expression. A prospective study
62452780|NCT04654104||Smokers with normal lung function|evaluation of immune check points expression
62452781|NCT04654104||Lung cancer|evaluation of immune check points expression
62632650|NCT02475772|EXPERIMENTAL|Cisplatin and doxorubicin|Cisplatin and doxorubicin will be applied under pressure into the abdomen via laparoscopic trocars. The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
62632651|NCT00977912|EXPERIMENTAL|"Milk containing B. Lactis"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
62632652|NCT00977912|PLACEBO_COMPARATOR|"Milk containing placebo"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
62632653|NCT03649893|NO_INTERVENTION|Control Group|The control group will use conventional siiting-desk office.
62632654|NCT03649893|EXPERIMENTAL|Active Office Group|The experimental group will use active offfice, including sit-to-stand desk, bike desk, seddle chair and active breask.
62632655|NCT06175208|EXPERIMENTAL|internet-based Emotional Freedom Techniques (iEFT)|The first intervention entails emotional freedom techniques (EFT). EFT is a brief and easy to learn exposure therapy, originally developed to manage phobias and nowadays known to have many positive effects on both physiological and psychological aspects. Participants will apply EFT daily for the period of 6 weeks. During the trajectory, there is a first information session for participants (±20 minutes) and two follow-up sessions (±15 minutes). These sessions will be guided by the iEFT practitioner. This is an oncology health professional who has gone through a specific EFT training acknowledged by EFT International and is thus qualified and trained to conduct the trial.
62632656|NCT06175208|ACTIVE_COMPARATOR|internet-based mindfulness meditation intervention (iMMI)|The second intervention is a mindfulness meditation-based intervention focused on improving psychological, behavioural, and biological function in cancer survivors based on following sources: Mindfulness trainingsboek, Het achtweekse programma, stap voor stap (1), Mindfulness bij stress, burn-out en depressie, Een 8-weken-stappenplan voor hulpverleners (2), Mindfulness-based cognitive therapy for depression (3), Met radicale compassie naar de wereld kijken, De RAIN-methode (4). The mindfulness group intervention programme will be conducted once a week, for 2 hours during 6 weeks, by a trained mindfulness provider who will follow the study intervention protocol. Participants will apply mindfulness meditation daily for the period of 6 weeks.
62632657|NCT06175208|NO_INTERVENTION|Wait-list Control Group (WLC)|The third arm of the study refers to the wait-list control (WLC) group with delayed intervention offered to the participants after they have completed parallel outcome assessments alongside the participants receiving the two interventions iEFT and iMMI, but not until the end of data collection (i.e. 6 weeks after the post-intervention assessment T1 for the cohort). Patients included in the WLC group can optionally join either the iEFT or iMMI group according to their preference, after 12 weeks (T2).
62632658|NCT00101868|EXPERIMENTAL|Discharge communication software|Computerized-Physician-Order-Entry software application to facilitate communication at time of hospital discharge to patients, retail pharmacists, community physicians. Software had required fields, pick lists, standard drug doses, alerts, reminders, online reference information. Software prompted discharging physician to enter pending tests, order tests after discharge. Hospital physicians used software on day of discharge to generate four documents automatically: personalized letter to outpatient physician, legible prescriptions, and legible discharge order
62632659|NCT00101868|ACTIVE_COMPARATOR|Usual care discharge process|Hospital physicians and ward nurses completed handwritten discharge forms on the day of discharge. The forms contained blanks for discharge diagnoses, discharge medications, medication instructions, post discharge activities and restrictions, post discharge diet, post discharge diagnostic and therapeutic interventions, and appointments. Patients received handwritten copies of the forms, one page of which also included medication instructions and prescriptions
62632660|NCT01273909||Perforator Flap Breast Reconstruction|Patients who undergo perforator flap breast reconstruction with or without concomitant vascularized lymph node transfer
62632661|NCT01273909||Vascularized Lymph Node Transfer|Patients who undergo perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
62452782|NCT04654104||COPD|evaluation of immune check points expression
62452783|NCT05495542|EXPERIMENTAL|Shotblocker group|In the ShotBlocker group, ShotBlocker was placed on the previously determined injection site before vaccination, and the vaccination was performed by holding it on the surface of the skin and pressing lightly with the fingertips. All vaccinations were carried out by an experienced nurse. ShotBlocker was removed after removing the needle.
62452784|NCT05495542|NO_INTERVENTION|Control group|In the control group, the steps of administering a normal intramuscular injection were used. Except for this, no additional method was used. All vaccinations were carried out by an experienced nurse.
62452785|NCT03186911|OTHER|E-liquid Group|Participants will sample two different e-liquids.
62452786|NCT03459937|EXPERIMENTAL|Hatha Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Hatha Yoga.
62632662|NCT00539071|ACTIVE_COMPARATOR|Conventional dose|All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks (given as two injections - active 50 mg plus placebo injection).As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 3 unless symptoms warrant a quicker titration) along with the injections.Any oral risperidone the patients receive will be discontinued after Week 4.At Week 6, psychopathology will be assessed with a PANSS. Dose will remain at 50 mg q 2 weeks for those in the conventional Consta dose group.
62632663|NCT00539071|ACTIVE_COMPARATOR|High Dose group|Those who are randomized to high dose Consta will receive Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose after consent. As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 4 unless symptoms warrant a quicker titration) along with the injections. Any oral risperidone the patients receive will be discontinued after Week 4.Psychopathology will be assessed with a PANSS at Week 6. If no improvement since baseline, dose will be increased to two 50 mg injections q 2 weeks for the remainder of the study.
62632664|NCT04655781|EXPERIMENTAL|N-T group|ILM was peeled off from nasal retina to temporal retina.
62632665|NCT04655781|EXPERIMENTAL|T-N group|ILM was peeled off from temporal retina to nasal retina
62632666|NCT00649077|EXPERIMENTAL|1|Meloxicam Tablets 15 mg
62270658|NCT04360759|EXPERIMENTAL|Arm 1: Chloroquine or hydroxychloroquine|Loading dose of 4 tablets (150 mg chloroquine base per chloroquine salt tablet; 155 mg chloroquine base per hydroxychloroquine tablet) at time 0 and 6 hours, followed by a maintenance dose of 2 tablets at time 12 hours, and then twice daily for a total of 7 days.
62270659|NCT04360759|NO_INTERVENTION|Arm 2: Standard of care|This does not include specific therapy under current guidelines.
62270660|NCT02549703||Relapsing Remitting Multiple Sclerosis|Patients with Relapsing Remitting Multiple Sclerosis/Clinically Isolated Syndrome
62270661|NCT02549703||Secondary Progressive Multiple Sclerosis|
62270662|NCT02549703||Primary Progressive Multiple Sclerosis|
62632667|NCT00649077|ACTIVE_COMPARATOR|2|Mobic® Tablets 15 mg
62632668|NCT04609423|EXPERIMENTAL|Cod liver oil|supplementation for 6 months
62632669|NCT04609423|PLACEBO_COMPARATOR|Corn oil (placebo)|supplementation for 6 months
62632670|NCT02144038|EXPERIMENTAL|Phase Ib: LGH447 + BYL719|Dose-escalation, LGH447 in combinatinon with BYL719
62632671|NCT02144038|EXPERIMENTAL|Phase II: LGH447 + BYL719|LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
62632672|NCT02144038|EXPERIMENTAL|Phase II: LGH447 alone|LGH447 alone (dosing according to single-agent RDE)
62632673|NCT03200210|EXPERIMENTAL|Treatment with Febuxostat|Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
62632674|NCT03200210|PLACEBO_COMPARATOR|Treatment with placebo|Same dose and dose adjustment as the intervention arm.
62632675|NCT02630810|EXPERIMENTAL|Early oral hydration|Early oral intake of 100 ml clear unsweetened water 1 hour following the Cesarean Section, then upon patient's desire, then starting semisolid, solid food when participant passed flatus.
62632676|NCT02630810|ACTIVE_COMPARATOR|Delayed oral hydration|Oral intake of 100 ml clear unsweetened water after 6 hours from the end of CS then upon patient's request,then starting semisolid, solid food when participant passed flatus.
62632677|NCT02241525||Prospective|Twenty patients will be enrolled and scanned with the RESEARCH procedures
62065697|NCT02815787|ACTIVE_COMPARATOR|SP2086 and Glyburide|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days. In this group,the subjects was given the drugs from A sequence to the B sequence.
62065698|NCT02815787|ACTIVE_COMPARATOR|Glyburide and SP2086|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days.In this group,the subjects was given the drugs from B sequence to the A sequence.
62065699|NCT05164432|EXPERIMENTAL|High risk of preterm birth|Women at high risk of preterm birth
62065700|NCT05164432|ACTIVE_COMPARATOR|Women with low risk pregnancies|Women with uncomplicated pregnancies anticipated to deliver at term
62065701|NCT04731233|EXPERIMENTAL|PRGF Arm|The PRGF experimental group will have two cc of PRGF infused into the upper joint space after the TMJ arthrocentesis procedure.
62065702|NCT04731233|ACTIVE_COMPARATOR|Steroid Arm|Two cc containing 40 mg of triamcinolone acetonide with 5 mg bupivacaine will be infused into the upper joint space after the TMJ arthrocentesis procedure.
62270663|NCT03759535||Control group and Case group|"Control group:~The allograft kidneys function normally. The rejection of allograft kidneys are excluded. The patients have no infectious complications.~Case group:~There is obvious evidence for acute rejection of the allograft kidneys. The patients have no infectious complications."
62270664|NCT04381910|EXPERIMENTAL|LY01610|LY01610(Irinotecan Hydrochloride Liposome Injection),Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted. Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance. If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
62632678|NCT02241525||Retrospective|Patients with matching age and BMI will be selected from existing patients with a CLINICAL STANDARD of Care CTPA scan.
62632679|NCT02521792|EXPERIMENTAL|Palovarotene|The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.
62632680|NCT00970021|PLACEBO_COMPARATOR|Water with artificial colour|Placebo
62632681|NCT00970021|ACTIVE_COMPARATOR|Extract of agaricus blazei Murill|Agaricus blazei Murill
62065703|NCT03505450||Population sample|
62065704|NCT03505450||Purposive Sample|
62065705|NCT01250964|ACTIVE_COMPARATOR|Wound-assisted lens injection|Wound-assisted lens injection is considered neither superior or inferior to wound-directed lens injection.
62065706|NCT01250964|ACTIVE_COMPARATOR|Wound-directed lens injection|Wound-directed lens injection is neither considered superior nor inferior to wound-assisted lens injection.
62065707|NCT02973555|EXPERIMENTAL|PRP injection|
62065708|NCT00640796|EXPERIMENTAL|Treatment|Participants undergo haploidentical donor derived natural killer cell infusion (cells obtained from donors and selected using CliniMACS cell selection system) and chemotherapy (cyclophosphamide, fludarabine, interleukin-2, mesna).
62065709|NCT01805817|EXPERIMENTAL|Levonorgestrel releasing intrauterine device, contraception|LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year
62065710|NCT01805817|EXPERIMENTAL|YASMIN® (Drospirenone/Ethinyl Estradiol), contraception|oral, once a day, 1 year
62065711|NCT01805817|EXPERIMENTAL|Copper T 380 A , contraception|intrauterine device, once per 10 year, 1 year period
62632682|NCT03624491|NO_INTERVENTION|Standard of care mechanical ventilation|Anesthesia and surgical procedures will be performed following standard of care for mechanical ventilation during surgery.
62632683|NCT03624491|ACTIVE_COMPARATOR|Transpulmonary pressure guided mechanical ventilation|Same treatment as the control group with the addition of esophageal pressure measurements used to guide mechanical ventilation during surgery.
62632684|NCT03860298|EXPERIMENTAL|NaviFUS System|FUS treatment for 10 minutes
62632685|NCT00354965|EXPERIMENTAL|ARM 1|
62632686|NCT06434675||Polyps|Patients evaluated for nasal polyps
62632687|NCT02132143|EXPERIMENTAL|Progression-free survival&Concurrent chemoradiotherapy|"The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy, 21 days as a cycle.~Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W."
62632688|NCT02132143|ACTIVE_COMPARATOR|Progression-free survival&sequential chemoradiotherapy|Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, 21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.
62632689|NCT03249168|EXPERIMENTAL|case group|Duloxetine 60mg orally 12 hours before surgery
62632690|NCT03249168|ACTIVE_COMPARATOR|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
62632691|NCT03410992|EXPERIMENTAL|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
62632692|NCT03410992|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
62632693|NCT03410992|EXPERIMENTAL|Bimekizumab Escape arm|Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
62632694|NCT00006029|ACTIVE_COMPARATOR|vinorelbine + gemcitabine + doxorubicin - higher doses|"Patients who have not undergone prior transplantation receive vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
62632695|NCT00006029|EXPERIMENTAL|vinorelbine + gemcitabine + doxorubicin - lower doses|"Patients who have undergone prior transplantation receive lower doses of vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
62632696|NCT05105672|EXPERIMENTAL|chemoradiotherapy + Sintilimab|Participants will be given intravenous administration of sintilimab (200mg, q3w), cisplatin(75 mg/m², q3w) and Radiotherapy. After completing 2 cycles of concurrent chemoradiation, the Participants will continue to use 4 cycles of sintilimab (200mg, q3w) and cisplatin(75 mg/m², q3w) as maintenance therapy.
62632697|NCT00379899|ACTIVE_COMPARATOR|Control|Standard of care, without use of cinacalcet.
62632698|NCT02100280|EXPERIMENTAL|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
62632699|NCT02100280|NO_INTERVENTION|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
62632700|NCT03783117|EXPERIMENTAL|Magnetic field treatment|Each subject will place his/her right arm into a bore of the Magnetic Blood Pressure Lowering (MBPL) Device for magnetic treatment of 15 minutes, while the blood pressure is monitored with the left arm. The MBPL device produces a magnetic field around 1T parallel to the blood flow inside the arm. The subject's blood pressure will be lowered. The subject needs to come back to check the blood pressure 24 hours after the treatment.
62632701|NCT05691413|EXPERIMENTAL|Product X facial cleanser|Participants will used Product X facial cleanser twice daily for 5 weeks
62270665|NCT05300178||multiple vessel disease|patients with coronary artery disease will be revascularized by using different bypass configuration.
62632702|NCT02040753||Intensive Lifestyle Intervention|Former participants of intensive lifestyle intervention at Ubberup Folk High School.
62270666|NCT00096863|PLACEBO_COMPARATOR|A - placebo|per oral pill
62270667|NCT00096863|ACTIVE_COMPARATOR|B|Ziprasidone
62270668|NCT00096863|ACTIVE_COMPARATOR|C|Haloperidol
62270669|NCT01339559|EXPERIMENTAL|Brivaracetam|Brivaracetam with a maximum of 200 mg/day
62632703|NCT01236040|EXPERIMENTAL|Group A|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
62632704|NCT01236040|EXPERIMENTAL|Group B|Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.
62632705|NCT01236040|PLACEBO_COMPARATOR|Group C|Subjects will receive 2 doses of a placebo at a 21-day interval.
62632706|NCT01236040|EXPERIMENTAL|Group D|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
62632707|NCT01236040|EXPERIMENTAL|Group E|Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.
62632708|NCT01236040|EXPERIMENTAL|Group F|Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.
62065712|NCT05336201|EXPERIMENTAL|C-READY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Self-management and goal-setting cognitive remediation
62270670|NCT04325542|OTHER|HBSAG positive with rapid test|Newborns from woman who are positive with HBSAG rapid test got WHO recommended HBV vaccination at birth to avoid HBV transmission
62270671|NCT04901299|EXPERIMENTAL|NERATINIB + FULVESTRANT|"After the screening procedures confirm participation in the research study.~- Each Cycle = 28 days~* Neratinib (oral, once daily)~* Fulvestrant, injection, on 2 days for cycle 1, then one time per cycle thereafter"
62270672|NCT05018234|EXPERIMENTAL|Treatment|
62270673|NCT05417854|EXPERIMENTAL|Ultrasound Group|
62270674|NCT01440621|ACTIVE_COMPARATOR|Arm M|Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.
62270675|NCT01440621|PLACEBO_COMPARATOR|Arm P|Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.
62270676|NCT02455531||Transplant-free survivors|Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
62632709|NCT05216107||Hospital Universitario de Álava, Spain|large hospitals (\>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
62632710|NCT05216107||Hospital Universitario de Basurto, Spain|large hospitals (\>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
62632711|NCT05216107||Hospital Universitario de Cruces, Spain|large hospitals (\>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
62065713|NCT05336201|OTHER|Wait-List Control Group|Will receive the same C-READY intervention after a 4-week wait period
62065714|NCT02876172|EXPERIMENTAL|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted therapy.
62632712|NCT05216107||Hospital Universitario de Donostia, Spain|large hospitals (\>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
62632713|NCT05216107||Hospital San Pedro (Logroño), Spain|large hospitals (\>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
62632714|NCT05216107||Hospital of Navarra, Spain|large hospitals (\>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
62632715|NCT06106880|PLACEBO_COMPARATOR|Group A: Placebo Throat Spray and Placebo Tablet|"The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
62632716|NCT06106880|ACTIVE_COMPARATOR|Group B: Wintergreen Throat Spray and Aspirin Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet"
62632717|NCT06106880|ACTIVE_COMPARATOR|Group C: Aspirin Throat Spray and Placebo Tablet|"The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
62632718|NCT06106880|ACTIVE_COMPARATOR|Group D: Wintergreen Throat Spray and Placebo Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
62065715|NCT01496716||Hip Osteoarthritis|
62270677|NCT03445091|EXPERIMENTAL|Patients using investigational product|Open-label use of SANKOM Patent Socks
62270678|NCT04242082||patients with psoriasis vulgaris only|
62270679|NCT04242082||patients with psoriasis vulgaris and type 2 diabetes mellitus|
62065716|NCT04309929||Women with breast cancer|Female patients (age\> 18yrs) in ASA class \<4; candidate for a planned surgery for simple mastectomy, simple mastectomy with immediate reconstruction, mastectomy with sentinel node biopsy, modified radical mastectomy (unilateral or bilateral)
62065717|NCT04612855||Painful post-traumatic trigeminal nerve injuries|Patients presenting with painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
62065718|NCT04612855||Non-painful post-traumatic trigeminal nerve injuries|Patients presenting with non-painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
62270680|NCT04242082||healthy control|
62270681|NCT06424782|EXPERIMENTAL|Medicinal water treatment|Participants receive medicinal water treatment in bath tub once daily (30 min) on weekdays for 3 weeks.
62270682|NCT06424782|PLACEBO_COMPARATOR|Tap water (placebo) treatment|Participants receive placebo water treatment in bath tub once daily (30 min) on weekdays for 3 weeks.
62632719|NCT04019145|EXPERIMENTAL|Fiber Reinforced bulk fill resin composite|Fiber reinforced bulk fill resin composite dentine substitute, capped occlusally and proximally (closed centripetal technique) by nanohybrid resin composite.
62065719|NCT04612855||Temporary nerve injuries|Patients with a trigeminal nerve injury with symptom resolution within 3 months after data of trauma.
62065720|NCT04612855||Persistent nerve injuries|Patients with a trigeminal nerve injury and complaints persisting longer than 3 months after the trauma.
62065721|NCT04495582||Non-Interventional Study group|Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
62065722|NCT00720902|ACTIVE_COMPARATOR|A - Normal growth hormone secretion|Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) \& arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.
62065723|NCT00720902|ACTIVE_COMPARATOR|B - Growth hormone deficient|Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) \& arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.
62088180|NCT04124991|EXPERIMENTAL|Yttrium-90 Microspheres in Combination with Durvalumab|Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD. TARE will be performed 1-2 weeks (7 to 14 days) before the first dose of durvalumab and a maximum of 2 more times during the treatment period, per Investigator discretion. If additional TARE is performed, the interval between additional TARE treatments and administration of durvalumab should be at least 1 week.
62270683|NCT01332539||drug-resistant partial epilepsy|
62270684|NCT01332539||controlled partial epilepsy|
62270685|NCT01902290|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered by subcutaneous injection on day 1, week 1, week 2 and every 2 weeks thereafter for 24 weeks.
62270686|NCT01902290|EXPERIMENTAL|Brodalumab 210 mg|Participants received 210 mg brodalumab administered by subcutaneous injection on day 1, week 1, week 2, and every 2 weeks thereafter for 24 weeks.
62270687|NCT06301880|PLACEBO_COMPARATOR|Group 1: Normal saline|Patients in this group were randomly assigned to receive the topical application of normal saline (0.9% sodium chloride solution) on the LIMA graft as control
62270688|NCT06301880|ACTIVE_COMPARATOR|Group 2: Nitroglycerin|Patients were randomly assigned to receive the topical application of nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline on the LIMA graft.
62270689|NCT06301880|ACTIVE_COMPARATOR|Group 3: milrinone|Patients were randomly assigned to receive the topical application of milrinone (Baxter Pharmaceuticals, Ahmedabad, India) on the LIMA graft
62270690|NCT04363775|EXPERIMENTAL|Regurgitation|intubation in regurgitation condition
62632720|NCT04019145|ACTIVE_COMPARATOR|nanohybrid resin composite incrementation|Nanohybrid resin composite layering to fill the whole cavity, using closed centripetal technique.
62632721|NCT05888298|ACTIVE_COMPARATOR|Proximal block|GON block is performed at C2 vertebra level
62270691|NCT04363775|EXPERIMENTAL|Tongue edema|intubation in Tongue edema condition
62270692|NCT01606111|PLACEBO_COMPARATOR|0.9% NaCl, saline|
62270693|NCT01606111|EXPERIMENTAL|Cerebrolysin|
62270694|NCT04429178||women in the 1st trimester of pregnancy.|
62632722|NCT05888298|OTHER|Distal block|GON block is performed at occipital protuberence
62632723|NCT03343743|OTHER|Hydration|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C \<200 mg/L) for at least 12 months
62632724|NCT01491867|EXPERIMENTAL|Travoprost arm|All individuals receive travoprost 0.003% 1/day in both eyes after 6 weeks wash-out for 3 months
62632725|NCT04279080||1|rectal cancer patients
62270695|NCT04429178||women in the 2nd trimester of pregnancy.|
62632726|NCT04279080||2|ovarian cancer patients
62632727|NCT05930314|EXPERIMENTAL|CNCT19 cell injetion|CNCT19 administration：0.25 to 0.5 x 10\^8 CAR-positive viable
62632728|NCT02247882|EXPERIMENTAL|Patient Education|Health Education.
62632729|NCT02247882|ACTIVE_COMPARATOR|Aquatic Physical Therapy|Protocol of aquatic physical therapy exercises.
62632730|NCT01085708|EXPERIMENTAL|1|
62270696|NCT04429178||women in the 3rd trimester of pregnancy.|
62270697|NCT04429178||non-pregnant women|
62270698|NCT00978029|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet sublingual, once daily
62270699|NCT00978029|EXPERIMENTAL|SCH 39641 6 Amb a 1-U|6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
62270700|NCT00978029|EXPERIMENTAL|SCH 39641 12 Amb a 1-U|12 Amb a 1-U in an AIT, sublingual, once daily
62270701|NCT03269123|OTHER|A device to relieve Blepharospasm|The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.
62632731|NCT01085708|EXPERIMENTAL|2|
62632732|NCT01085708|EXPERIMENTAL|3|
62632733|NCT01085708|ACTIVE_COMPARATOR|4|
62632734|NCT02458560|EXPERIMENTAL|single-arm|
62632735|NCT02794298|EXPERIMENTAL|Anodal tDCS|Anodal stimulation during resting state fMRI
62632736|NCT02794298|EXPERIMENTAL|Cathodal tDCS|Cathodal stimulation during resting state fMRI
62270702|NCT04345744|EXPERIMENTAL|Test group 1|administration of a hyaluronic and 0.2% chlorhexidine mouth rinse
62270703|NCT04345744|EXPERIMENTAL|Test group 2|administration of chlorhexidine 0.2% mouth rinse
62632737|NCT02794298|SHAM_COMPARATOR|sham tDCS|Sham stimulation during resting state fMRI
62632738|NCT00650819|EXPERIMENTAL|Ezetimibe + Simvastatin|
62270704|NCT04345744|ACTIVE_COMPARATOR|Control Group|No administration of mouth rinses after surgery
62270705|NCT04807348|EXPERIMENTAL|Chiglitazar sodium 32mg QD+metformin|Chiglitazar 32mg qd+metformin
62632739|NCT00650819|ACTIVE_COMPARATOR|Simvastatin|
62632740|NCT00650819|ACTIVE_COMPARATOR|Ezetimibe|
62632741|NCT00500734||Heart Disease Patients|
62632742|NCT04754646|EXPERIMENTAL|RHA®4 - Cannula|
62632743|NCT04754646|ACTIVE_COMPARATOR|RHA®4 - Needle|
62632744|NCT01023347|ACTIVE_COMPARATOR|Paclitaxel (Genexol®) and Cisplatin|
62632745|NCT01023347|EXPERIMENTAL|Paclitaxel loaded polymeric micelle (Genexol-PM®) & Cisplatin|
62632746|NCT02033707|EXPERIMENTAL|Male volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
62632747|NCT02033707|EXPERIMENTAL|Female volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
62632748|NCT00613366|EXPERIMENTAL|Misoprostol|Cervical preparation with misoprostol prior to intrauterine device insertion
62632749|NCT00613366|PLACEBO_COMPARATOR|Placebo|Cervical preparation with placebo prior to intrauterine device insertion
62632750|NCT00535431|EXPERIMENTAL|A|AER 001
62632751|NCT00535431|PLACEBO_COMPARATOR|P|sterile saline
62632752|NCT05083910|EXPERIMENTAL|Oxytocin Group|The oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord
62632753|NCT05083910|EXPERIMENTAL|Oxytocin+Intrauterine Misoprostol|The oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity
62632754|NCT05083910|EXPERIMENTAL|Carbetocin|100-mg carbetocin was intravenously administered immediately after birth of the baby
62270706|NCT04807348|EXPERIMENTAL|Chiglitazar sodium 48 mg QD+metformin|Chiglitazar 48 mg qd+metformin
62632755|NCT02594917||Test Group|The study population will include ten patients (ages 18-60 yrs) with confirmed mutations of the iron-sulfur cluster biogenesis complex of proteins and experiencing dyspnea, heart failure, or exercise intolerance.
62632756|NCT02594917||Control Group|It will also include ten additional patients (ages 18-60 yrs) who are unaffected first-degree family members of the above subjects.
62632757|NCT05275933|PLACEBO_COMPARATOR|PC+SC|Placebo Control Capsules (PC) are provided in addition to Standard Care medications
62632758|NCT05275933|ACTIVE_COMPARATOR|LH+SC|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications.
62632759|NCT02077309|ACTIVE_COMPARATOR|Linagliptin|Patients will receive 5 mg linagliptin once daily for a period of 6 months.
62632760|NCT02077309|PLACEBO_COMPARATOR|Placebo|Patients will take placebo tablets once daily for a period of 6 months.
62632761|NCT05765357|EXPERIMENTAL|Trastuzumab for injection|4mg/kg, Single dose for intravenous infusion
62632762|NCT05765357|ACTIVE_COMPARATOR|Herceptin|4mg/kg, Single dose for intravenous infusion
62270707|NCT04807348|PLACEBO_COMPARATOR|placebo+metformin|placebo+metformin
62270708|NCT04780620|EXPERIMENTAL|Parent Intervention Group|The parent intervention group will undergo 8 weekly, manualized group sessions, with between 6 and 10 parent participants. Sessions are structured and follow an agenda including check-in and review of home practice, discussion of a skill or strategy, and review and assignment of home practice. Group sessions are held weekly for 1.5 hours and include both didactic, discussion, and practice elements, as well as assigned home practice.
62270709|NCT04780620|NO_INTERVENTION|Usual Care Group|Parents in the usual care condition will be involved in their adolescent's care as is standard in our clinical program. With adolescent consent, parents are invited to participate in a single, 2-hour orientation session for parents/caregivers that provides information about depression, as well as the role of sleep, diet, and exercise in improving mood. Based on adolescent preference, parents can also attend regular psychiatric appointments with their adolescent, in which they will receive further information about depression and may receive and provide information about their adolescent's depression symptoms and response to psychosocial and pharmacological interventions. This control condition will allow us to determine whether the parent intervention is more effective than a relevant clinical alternative.
62270710|NCT01784861|EXPERIMENTAL|Phase I Dose Level 0: X-82 + Everolimus|"* X-82 100 mg by mouth once daily~* Everolimus 10mg by mouth once daily for each cycle~* Everolimus and X-82 should be taken at the same time every day~* 28 days =1 cycle"
62270711|NCT01784861|EXPERIMENTAL|Phase I Dose Level 1: X-82 + Everolimus|"* X-82 150 mg by mouth once daily~* Everolimus 10mg by mouth once daily for each cycle~* Everolimus and X-82 should be taken at the same time every day~* 28 days =1 cycle"
62270712|NCT01784861|EXPERIMENTAL|Phase I Dose Level 2: X-82 + Everolimus|"* X-82 200 mg by mouth once daily~* Everolimus 10mg by mouth once daily for each cycle~* Everolimus and X-82 should be taken at the same time every day~* 28 days =1 cycle"
62452787|NCT03459937|EXPERIMENTAL|Vinyasa Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Vinyasa Yoga.
62452788|NCT00967642|NO_INTERVENTION|standard treatment|glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
62452789|NCT00967642|OTHER|Intravenous Insulin|intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
62452790|NCT04750187|EXPERIMENTAL|Hypo-pressive abdominal exercise program|
62452791|NCT04750187|NO_INTERVENTION|No training program|
62452792|NCT06456203|NO_INTERVENTION|Control Arm|Chest radiographs reported with AI assistance
62452793|NCT06456203|ACTIVE_COMPARATOR|AI assisted|AI assisted detection, triage and reporting of CXR
62452794|NCT02576509|EXPERIMENTAL|Nivolumab|Nivolumab specified dose on specified days
62452795|NCT02576509|ACTIVE_COMPARATOR|Sorafenib|Sorafenib specified dose on specified days
62452796|NCT05307861|ACTIVE_COMPARATOR|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
62452797|NCT05307861|ACTIVE_COMPARATOR|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
62452798|NCT02608853||Liraglutide-like Cohort|
62452799|NCT02608853||LEADER™-like Cohort|
62632763|NCT00270296|EXPERIMENTAL|Trizivir (TZV) Arm|Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
62632764|NCT00270296|EXPERIMENTAL|Kaletra Arm|Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
62632765|NCT00270296|EXPERIMENTAL|Nevirapine (NVP) Arm|Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
62632766|NCT04849663|EXPERIMENTAL|study group|Use of free fat graft to cover exposed root
62632767|NCT04849663|ACTIVE_COMPARATOR|control group|use of sub epithelial connective tissue graft to cover exposed root
62632768|NCT03297866||Incentive schemes 1|No incentive will be given after completing the follow-up survey
62632769|NCT03297866||Incentive schemes 2|Receiving $100 supermarket coupon after completing the follow-up survey
62632770|NCT03297866||Incentive schemes 3|Receiving $200 supermarket coupon after completing the follow-up survey
62632771|NCT03297866||Incentive schemes 4|Receiving $100 supermarket coupon before completing the follow-up survey and another $100 supermarket coupon after completing the follow-up survey
62632772|NCT03102957|EXPERIMENTAL|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
62632773|NCT03102957|OTHER|Healthy volunteers|1 functional MRI with memory and language tasks
62632774|NCT01243060|EXPERIMENTAL|Almorexant 100mg|Subjects will receive a one-time dose of Almorexant 100mg.
62270713|NCT01784861|EXPERIMENTAL|Phase II: X-82 + Everolimus|"* X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily~* Everolimus 10mg by mouth once daily for each cycle~* 28 days =1 cycle"
62632775|NCT01243060|EXPERIMENTAL|Almorexant 200mg|Subjects will receive a one-time dose of Almorexant 200mg.
62632776|NCT01243060|ACTIVE_COMPARATOR|Zolpidem|Subjects will receive a one-time dose of Zolpidem 10mg.
62632777|NCT01243060|PLACEBO_COMPARATOR|Placebo|Subjects will receive a one-time dose of Placebo.
62270714|NCT01784861|EXPERIMENTAL|Phase I Dose Level 3: X-82 + Everolimus|"* X-82 300 mg by mouth once daily~* Everolimus 10mg by mouth once daily for each cycle~* Everolimus and X-82 should be taken at the same time every day~* 28 days =1 cycle"
62632778|NCT02981199|ACTIVE_COMPARATOR|Micro-SCT|"patients treated with microtransplantation. \[VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation\]×4cycles; \[PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)\]×1cycle; then maintenance therapy with thalidomide 100mg/d.~microtransplantation = \[VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation\]×4cycles"
62632779|NCT02981199|ACTIVE_COMPARATOR|Auto-SCT|patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; \[PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)\]×4cycle; then maintenance therapy with thalidomide 100mg/d.
62632780|NCT03695263|EXPERIMENTAL|N-of-1 Trial|Multiple crossovers between one of the available intervention options (mindfulness meditation, gratitude journaling, physical activity, laughter therapy, or random acts of kindness) and usual activities
62632781|NCT04858308|ACTIVE_COMPARATOR|Test Group|Take both YYC506 and Placebo(Control)
62632782|NCT04858308|ACTIVE_COMPARATOR|Control Group|Take both Contral and Placebo(YYC506)
62286895|NCT04573101|EXPERIMENTAL|N5 (Ney - Known music- Kurd Re)|Known music with Ney, on Kurd maqam on Re. (El Rabii)
62632783|NCT01602796|EXPERIMENTAL|School-based intervention|
62632784|NCT01602796|NO_INTERVENTION|Control|
62632785|NCT05220514||Non-COVID-19 Diagnosis Control Group|Subjects hospitalized and receiving intensive care for diagnosis of an acute neurological disease other than COVID-19
62632786|NCT05220514||COVID-19 Diagnosis Case Group|Subjects previously hospitalized at Mayo Clinic Hospital for treatment of PCR test confirmed COVID-19
62270715|NCT01784861|EXPERIMENTAL|Phase I Dose Level 4: X-82 + Everolimus|"* Everolimus 10mg by mouth once daily for each cycle MUST BE TAKEN FIRST~* X-82 400 mg by mouth once daily 2 HOURS AFTER everolimus dose~* 28 days =1 cycle"
62632787|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction Without Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
62632788|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction With Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
62270716|NCT00704782|EXPERIMENTAL|Dimebon|20 mg by mouth 3 times a day
62270717|NCT04319328||Cefazolin|n = 20
62270718|NCT04319328||Ceftazidime|n = 20
62270719|NCT04319328||Ciprofloxacin|n = 20
62270720|NCT01762852|EXPERIMENTAL|Belimumab Arm|Subjects will receive belimumab 10 mg/kg intravenous infusion \[will last for 1 hour (hr)\] on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with \>1000 mg/mmol uPCR (\>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
62270721|NCT01762852|PLACEBO_COMPARATOR|Placebo Arm|Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with \>1000 mg/mmol uPCR (\>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
62270722|NCT06115187||Patient group|Patients with carpal tunnel syndrome
62270723|NCT05903183|EXPERIMENTAL|IVX-A12 Vaccine Formulation 1|Participants will receive a single dose of IVX-A12 intramuscular (IM) injection on Day 0.
62270724|NCT05903183|EXPERIMENTAL|IVX-A12 Vaccine Formulation 2|Participants will receive a single dose of IVX-A12 IM injection on Day 0.
62452800|NCT00096395|EXPERIMENTAL|Treatment (sorafenib tosylate, gemcitabine hydrochloride)|"Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.~Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62452801|NCT05589675|EXPERIMENTAL|Intervention arm|Invitation letter to the screening program with the FIT test
62632789|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction Without Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
62632790|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction With Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
62632791|NCT04986241||Healthy sedentary Without Statin|Sedentary and healthy participant without use of statin; Without statin in the last 6 months.
62632792|NCT04986241||Healthy sedentary With Statin|Participant with dyslipidemia and sedentary with current use of statin.
62088181|NCT03086122|NO_INTERVENTION|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
62270725|NCT05903183|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo IM injection on Day 0.
62270726|NCT02105532|ACTIVE_COMPARATOR|Restrictive Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
62270727|NCT02105532|ACTIVE_COMPARATOR|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
62270728|NCT06154057|EXPERIMENTAL|Dental Implants installed in an grafted area (sinus lifting)|Dental implants produced by additive manufacturing installed in an area grafted with synthetic bone graft (Plenum® Osshp) - sinus lifting.
62270729|NCT06154057|EXPERIMENTAL|Dental Implants installed in an grafted area (ridge augmentation)|Dental implants produced by additive manufacturing installed in an area grafted with synthetic bone graft (Plenum® Osshp) - ridge augmentation.
62632793|NCT04986241||Healthy physically active Without Statin|Healthy, physically active participant without use of statin; Without statin in the last 6 months.
62065724|NCT02578511|EXPERIMENTAL|Ixazomib (MLN9708) in combination with standard POMP/D|"Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.~Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that."
62065725|NCT03885011|EXPERIMENTAL|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
62270730|NCT06154057|EXPERIMENTAL|Dental Implants installed in an grafted area (extraction sites)|Dental implants produced by additive manufacturing installed in an area grafted with synthetic bone graft (Plenum® Osshp) - extraction sites (socket preservation or dental implant preparation/placement).
62065726|NCT03885011|ACTIVE_COMPARATOR|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
62065727|NCT03885011|ACTIVE_COMPARATOR|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
62270731|NCT03401528|EXPERIMENTAL|Single Ascending Dose - AVB-S6-500|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
62270732|NCT03401528|PLACEBO_COMPARATOR|Single Ascending Dose - placebo|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
62270733|NCT03401528|EXPERIMENTAL|Repeat Dose - AVB-S6-500|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
62270734|NCT03401528|PLACEBO_COMPARATOR|Repeat Dose - placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
62632794|NCT04986241||Healthy physically active With Statin|Participant with dyslipidemia and physically active with current use of statin.
62632795|NCT03297229|EXPERIMENTAL|Peer mentoring|Peers will be patients with hypertension that have already been adequately controlled within the last six months. They will be selected within each center by the staff of the center and invited to participate in the study.
62065728|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
62065729|NCT06577766|EXPERIMENTAL|NNC0638-0355|Participants will be randomized to receive NNC0638-0355. The study will be conducted in 4 parts. Part A: Single ascending dose (SAD) Part B, C and D: Multiple ascending dose (MAD).
62065730|NCT06577766|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive Placebo. The study will be conducted in 4 parts. Part A: Single ascending dose (SAD). Part B,C and D: Multiple ascending dose (MAD).
62065731|NCT01659658|EXPERIMENTAL|Arm A: Ixazomib + Dexamethasone|Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 and dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22 of each 28-day cycle for up to a maximum of 95.2 months. Dexamethasone was increased up to 40 mg/day after 4 weeks, if tolerated.
62065732|NCT01659658|ACTIVE_COMPARATOR|Arm B: Dexamethasone + Melphalan|Participants received dexamethasone 20 mg, orally, and melphalan 0.22 mg/kg, orally once on Days 1 through 4 of each 28-day cycle, for up to a maximum of 72.4 months.
62065733|NCT01659658|ACTIVE_COMPARATOR|Arm B: Dexamethasone + Cyclophosphamide|Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22, and cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 of each 28-day cycle for up to a maximum of 72.4 months.
62065734|NCT01659658|ACTIVE_COMPARATOR|Arm B: Dexamethasone + Thalidomide|Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle, and thalidomide daily at a starting dose of 50 mg and increased, as tolerated, to a maximum of 200 mg, orally for up to a maximum of 72.4 months.
62065735|NCT01659658|ACTIVE_COMPARATOR|Arm B: Dexamethasone + Lenalidomide|Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle and lenalidomide 15 mg, orally, once on Days 1 through 21 every 28 days for up to a maximum of 72.4 months.
62065736|NCT04268901|NO_INTERVENTION|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for the medical procedure.
62065737|NCT04268901|EXPERIMENTAL|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction.
62065738|NCT01567865|ACTIVE_COMPARATOR|Reference Lot|Lot of Vaccine produced in existing facility
62270735|NCT03436862|EXPERIMENTAL|Nivolumab|Patients will receive Nivolumab 240 mg by intravenous infusion (IV) starting Day 45-120 post-transplant (±10 days) every 2 weeks for up to a maximum of 6 months of treatment.
62270736|NCT01849874|EXPERIMENTAL|MEK162|
62065739|NCT01567865|EXPERIMENTAL|New Lot #1|First lot of vaccine produced in new facility
62065740|NCT01567865|EXPERIMENTAL|New Lot #2|Second lot of vaccine produced in new facility
62270737|NCT01849874|ACTIVE_COMPARATOR|Physician's choice chemotherapy|
62065741|NCT01567865|EXPERIMENTAL|New Lot #3|Third lot of vaccine produced in new facility
62065742|NCT02337712|EXPERIMENTAL|q.d. RT|q.d. RT (65 Gy in 26 fractions) to the chest and concurrent etoposide and cisplatin
62065743|NCT02337712|ACTIVE_COMPARATOR|b.i.d.RT|b.i.d.RT (45Gy in 30 fractions) to the chest and concurrent etoposide and cisplatin
62065744|NCT05762614||patient on invasive mechanical ventilation able to perform a SBT|
62270738|NCT04110847|ACTIVE_COMPARATOR|TCM OA1|"JING CEIH SHERN YUAN EXTRACT PILL CHUANG SONG ZONG 3 TABLET For 2 Times per day"
62270739|NCT04110847|PLACEBO_COMPARATOR|Placebo|Placebo 3 TABLET For 2 Times per day
62270740|NCT02891304||Quarterly Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive objective feedback every 3-months on trainee overall performance including learning curves on ACE tool performance, performance relative to de-identified anonymous peers on each of the individual skills (e.g. fine tip control), and the global assessment for technical and cognitive skill achievement. For those skills which are not advanced/superior - trainees will additionally receive links to online didactic videos which teach these skills.
62065745|NCT03068806||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
62065746|NCT03068806||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
62065747|NCT05266014|EXPERIMENTAL|tinlarebant|Daily, oral administration of one tinlarebant.
62065748|NCT00960921|EXPERIMENTAL|Iron group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of iron sucrose, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
62065749|NCT00960921|PLACEBO_COMPARATOR|Saline group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of normal saline, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
62270741|NCT02891304||Annual Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive learning curves at the end of each training year. Learning curves, relative to de-identified anonymous peers will be provided to program directors annually (June).
62270742|NCT01687764|EXPERIMENTAL|CBGT+ABMT(active)|
62270743|NCT01687764|EXPERIMENTAL|CBGT+ABMT(placebo)|
62270744|NCT01687764|EXPERIMENTAL|PCI+ABMT(active)|
62270745|NCT01687764|PLACEBO_COMPARATOR|PCI+ABMT(placebo)|
62270746|NCT02905565|PLACEBO_COMPARATOR|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
62270747|NCT02905565|ACTIVE_COMPARATOR|800 mg of NBP daily|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
62270748|NCT00683033|ACTIVE_COMPARATOR|A|Brief counseling based on public health service guidelines.
62270749|NCT00683033|EXPERIMENTAL|B|Brief counseling based on public health service guidelines for quitting smoking plus prize-based contingency management
62270750|NCT02608021||Amnestic mild cognitive impairment|
62270751|NCT02608021||Cognitively normal|
62270752|NCT05672342|EXPERIMENTAL|Arm I (CBD)|Patients receive CBD PO on study.
62065750|NCT03127189|EXPERIMENTAL|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) \[with different particle size distribution (PSD) as compared to Treatment A, D, C and E\] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
62632796|NCT03297229|EXPERIMENTAL|Self-monitoring|Each participant will receive a blood pressure monitor. The study nurse will teach the participant on how to use the device.
62632797|NCT03297229|NO_INTERVENTION|Control|Usual care
62632798|NCT01971567|ACTIVE_COMPARATOR|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.
62632799|NCT01971567|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.
62065751|NCT03127189|EXPERIMENTAL|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA \[with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
62065752|NCT03127189|EXPERIMENTAL|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA \[with different PSD as compared to Treatment B, C, D and E\] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
62632800|NCT05409950|ACTIVE_COMPARATOR|Study group: implants were inserted using socket shield technique at the esthetic zone|
62632801|NCT05409950|NO_INTERVENTION|Control group: implants were inserted using conventional immediate technique|
62065753|NCT03127189|EXPERIMENTAL|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA \[with different PSD as compared to Treatment A, B, D and E\] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
62088182|NCT03086122|NO_INTERVENTION|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
62088183|NCT03086122|EXPERIMENTAL|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
62632802|NCT06503068||NAFLD/NASH patients|Patients ≥ 18 years old diagnosed with NAFLD/ NASH and willing to complete the survey.
62632803|NCT06503068||Physicians|Physicians treating patients with NAFLD/NASH (hepatologists, gastroenterologists, endocrinologists, and internal medicine physicians).
62632804|NCT04452851|EXPERIMENTAL|Treadmill test with BREATHE|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with the prototype BREATHE system until they are fully recovered (Borg: 0).
62632805|NCT04452851|ACTIVE_COMPARATOR|Treadmill test with BiPAP|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a standard BiPAP machine until they are fully recovered (Borg: 0).
62632806|NCT04452851|PLACEBO_COMPARATOR|Treadmill test with placebo inhaler|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a placebo inhaler until they are fully recovered (Borg: 0).
62632807|NCT04452851|EXPERIMENTAL|Activity of Daily Living with BREATHE|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
62632808|NCT04452851|EXPERIMENTAL|Activity of Daily Living with BREATHE during recovery|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
62632809|NCT04452851|NO_INTERVENTION|Activity of Daily Living|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system will NOT be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
62632810|NCT03245320||TITAN™ Total Shoulder System Generation 1.0|Integra TITAN™ Total Shoulder System Generation 1.0
62632811|NCT00751140|EXPERIMENTAL|Lymph Node Dissection at Time of Nephroureterectomy|A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
62632812|NCT06455852|EXPERIMENTAL|Cholera Vaccine Arm|We will measure mucosal, memory B cell and circulating antibody responses to V. cholerae in the participants using an established immunoprofiling approach. We will then identify individuals who develop V. cholerae infection over a two-year period, including those with mild and asymptomatic infection. We will use a systems-serology approach to identify CoPs in the OCV (bWC) cohort and non-OCV vaccinated control (TCV) cohort. Our approach will include cross-validation and adjustments for age, sex, and baseline immunity, to identify vaccine-induced CoPs. We will also compare the performance of these CoPs with the traditional vibriocidal titer.
62632813|NCT06455852|OTHER|Typhoid Vaccine Arm|We will compare individual CoPs and immunologic signatures in the OCV and non-cholera vaccinated (TCV) control arms which are correlated with protection. This will identify individual CoPs and immunologic signatures which distinguish protective immunity derived from natural infection with V. cholerae from immunity derived from inactivated OCV response.
62065754|NCT03127189|EXPERIMENTAL|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA \[with different PSD as compared to Treatment A, B, C and D\] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
62065755|NCT01152294|NO_INTERVENTION|Control|Group not receiving the decision aid (DVD and booklet)
62065756|NCT01152294|EXPERIMENTAL|Decision Aid|Group receiving the decision aid (DVD/booklet)
62632814|NCT00763997|EXPERIMENTAL|1|Dipyrone
62632815|NCT00763997|ACTIVE_COMPARATOR|2|Ibuprofen
61978593|NCT03706781|ACTIVE_COMPARATOR|Reference product CTP/BNZ - Tantum Verde Bocca|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) Tantum Verde Bocca is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
62632816|NCT00763997|ACTIVE_COMPARATOR|3|Acetaminophen
62632817|NCT00763997|PLACEBO_COMPARATOR|4|Parecoxib/Valdecoxib
62065757|NCT00926003|EXPERIMENTAL|Full Computerized Cognitive Training|Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. Each training game become more difficult as the child gains proficiency.
62065758|NCT00926003|NO_INTERVENTION|Control|Passive Control with no intervention training (computer cognitive games) for 8 weeks.
62270753|NCT05672342|EXPERIMENTAL|Arm II (CBD + THC)|Patients receive CBD PO + THC PO on study.
62270754|NCT05672342|PLACEBO_COMPARATOR|Arm III (placebo)|Patients receive placebo PO on study.
62452802|NCT05589675|EXPERIMENTAL|Intervention arm - sub study|Prior notification to the new entrants, followed by an invitation letter to the screening program with the FIT test
62452803|NCT05589675|NO_INTERVENTION|Control arm|Invitation letter to visit its own GP who will deliver the FIT test
62632818|NCT04485728|EXPERIMENTAL|Sleep Improvement Intervention|
62632819|NCT04485728|NO_INTERVENTION|Standard of Care (Control)|
62632820|NCT00508911|EXPERIMENTAL|Healthy female subjects|Each subject will be administered a monophasic combined oral contraceptive (COC) containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms for two complete cycles (Day 8 to Day 28) in Session 1. The subjects will be administered COC on Day 8 to Day 28 and GW876008 125 milligrams on Days 1 to 35 in Session 2.
62632821|NCT06604832|PLACEBO_COMPARATOR|Treated with prabotulinumtoxinA-xvfs and placebo|Subjects will have one treatment session at week 0 and two live assessment visits at weeks 2 and 12. Approximately 20 units of prabotulinumtoxinA-xvfs will be injected into the left side of the subject's glabellar lines and forehead region, and a placebo saline treatment will be injected into the right side of the subject's glabellar lines and forehead region.
62632822|NCT06604832|ACTIVE_COMPARATOR|Treated with prabotulinumtoxinA-xvfs and incobotulinumtoxinA|Subjects will have one treatment session at week 0 and two live assessment visits at weeks 2 and 12. Approximately 20 units of prabotulinumtoxinA-xvfs will be injected into the left side of the subject's glabellar lines and forehead region, and approximately 20 units of incobotulinumtoxinA will be injected into the right side of the subject's glabellar lines and forehead region.
62632823|NCT03675360|EXPERIMENTAL|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target \<40 g net carbohydrates per day for first 3 months; \<60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
62632824|NCT03675360|NO_INTERVENTION|Usual Diet|"No dietary intervention.~At baseline, participants will receive written information with standard dietary advice and standard physical activity recommendations."
62632825|NCT05449171|NO_INTERVENTION|Control group|
62632826|NCT05449171|EXPERIMENTAL|Treatment group|
62632827|NCT06612398|NO_INTERVENTION|Standard of care|Participants received the standard care provided upon arrival and being admitted to the hospital, involving only a verbal explanation of the anaesthesia induction process.
62632828|NCT06612398|EXPERIMENTAL|Preoperative preparation video|On the night before the surgery, participants were presented with an animated video illustrating the story of a child's journey through the hospital facilities, including the anaesthesia induction, and the postoperative return home.
62632829|NCT01863290||Former inmates|Former inmates with a chronic disease condition or aged 50 years and above engaged into primary care through an innovative primary care redesign model of the Transitions Clinic Network.
62632830|NCT02688933|EXPERIMENTAL|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
62632831|NCT02688933|ACTIVE_COMPARATOR|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
62632832|NCT01342575|EXPERIMENTAL|Intra-operative maneuver group|
62632833|NCT00327717|EXPERIMENTAL|Zonisamide 100 mg tablet|
62632834|NCT00327717|PLACEBO_COMPARATOR|Placebo|
62065759|NCT00926003|ACTIVE_COMPARATOR|Limited computerized cognitive training|"Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. In this arm, however, the training games do NOT become progressively more difficult as the child gains proficiency, but rotates randomly among simpler to moderate levels of difficulty for each game. The purpose to to give children int he limited CCRT arm comparable exposure to the cognitive games training as with the full CCRT arm, with the exception of the titrating nature of the game training."
62632835|NCT06129383|ACTIVE_COMPARATOR|Control group to which serratus anterior plane block will be applied|Control group patients, accompanied by the 38 mm 6 MHz linear probe of the ultrasound device, , the patient will be placed in the lateral decubitus position and SAP block will be applied to the serratus anterior muscle fascia using 20 ml of 0.25% bupivacaine solution.
62632836|NCT06129383|OTHER|serratus anterior plane block to the pecto intercostal plane block will be applied.|SAP block will be applied to the patient's serratus anterior fascia using 20 ml of 0.25% bupivacaine solution. Then, PIFB will be applied to the patient's parasternal region using 10 ml of 0.25% bupivacaine solution.
62632837|NCT05923047|EXPERIMENTAL|Combined group|In-office nasal polypectomy group with mepolizumab
62632838|NCT05923047|EXPERIMENTAL|Medical group|(mepolizumab)
62632839|NCT05923047|ACTIVE_COMPARATOR|Surgical group|In-office nasal polypectomy
62632840|NCT02447445||Older inpatient at MOP|The group includes older patients who are admitted to one of the Medicine for Older Patients (MOP) wards. Grip strength will be part of the routine assessment of older patient when admitted to MOP.
62632841|NCT02620787|EXPERIMENTAL|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
62632842|NCT02620787|ACTIVE_COMPARATOR|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
62632843|NCT05127564|EXPERIMENTAL|DRF: Chinese Participants|Chinese participants will receive DRF Dose 1, oral capsules, twice daily (BID), from Day 1 to Day 4 and DRF Dose 1, oral capsules, once daily (QD), on Day 5.
62632844|NCT05127564|EXPERIMENTAL|DRF: Caucasian Participants|Caucasian participants will receive DRF Dose 1, oral capsules, BID, from Day 1 to Day 4 and DRF Dose 1, oral capsules, QD, on Day 5.
62632845|NCT02558764|NO_INTERVENTION|Control|No intervention; basic wound contact absorbent dressings will be used as per current standard of care.
62632846|NCT02558764|OTHER|PICO|PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.
62632847|NCT02193204|EXPERIMENTAL|Social Drinkers Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers with depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
62632848|NCT02193204|EXPERIMENTAL|Social Drinkers No Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers without depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
62632849|NCT02193204|EXPERIMENTAL|Alcohol Dependent, Non-Depressive|30 treatment-engaged 28-day abstinent, alcohol dependent (AD) smokers, without Depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
62632850|NCT02193204|EXPERIMENTAL|Alchohol Dependent Depressive Symptoms|30 treatment-engaged 28-day abstinent, alcohol dependent smokers with depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
62632851|NCT06065644|EXPERIMENTAL|Long fixation|CT in a neutral and then by provocation (anterior straight leg raise and figure-of-four).
62632852|NCT06065644|ACTIVE_COMPARATOR|One segment fixation|CT in a neutral and then by provocation (anterior straight leg raise and figure-of-four).
62632853|NCT05199792||2x dose of Dotarem|qualifying MRA
62632854|NCT06232967||Primary tumor resection (PTR group)|includes wedge resection, segmentectomy, or lobectomy.
62632855|NCT06232967||Exploratory thoracotomy (ET group)|JSimply open and close surgery.
62632856|NCT03746834|EXPERIMENTAL|Treatment arm|Patients are given NASHA/Dx as a perianal injection
62632857|NCT03870334|EXPERIMENTAL|BT-11 880 mg|Oral once daily tablet
62632858|NCT03870334|PLACEBO_COMPARATOR|Placebo|Oral once daily tablet
62632859|NCT05140889||Group 1|Children with severe asthma
62632860|NCT05140889||Group 2|Children who undergo chest CT scan for other reasons than asthma
62632861|NCT02027233|EXPERIMENTAL|Nasopharyngeal sample|Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
62632862|NCT05551390|EXPERIMENTAL|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
62632863|NCT05551390|EXPERIMENTAL|three-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
62632864|NCT03260608|EXPERIMENTAL|Intervention|Telesupport: eight weekly phone calls of psychoeducation and support on the illness of their relatives. Patients will also receive printed materials on problematic behaviors about dementia.
62632865|NCT03260608|NO_INTERVENTION|Control|No active intervention. Patients will only receive printed materials on problematic behaviors about dementia and no contact by the research team.
62632866|NCT00353223|EXPERIMENTAL|A|Participants will receive combined interpersonal and behavioral psychotherapy aimed at reducing depression in patients with heart failure.
62632867|NCT00353223|ACTIVE_COMPARATOR|B|Participants will receive the attention control condition.
62632868|NCT01158261||Vascular Surgery Subjects Treated with EVICEL|
62632869|NCT01144455|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle
62270755|NCT03449823||TTTS Cases|Cases of monochorionic / diamniotic twin pregnancies diagnosed with twin-twin transfusion syndrome.
62632870|NCT01144455|EXPERIMENTAL|240 mg/m2 TH-302 + Gemcitabine|"TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
62632871|NCT01144455|EXPERIMENTAL|340 mg/m2 TH-302 + Gemcitabine|"TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
62632872|NCT05073419|ACTIVE_COMPARATOR|Control|Post-AMI patients in this arm will receive standard of care
62632873|NCT05073419|EXPERIMENTAL|ICM|Post-AMI patients in this arm will receive standard of care and an ICM
62632874|NCT00803712|EXPERIMENTAL|Cinacalcet Group|Cinacalcet plus low dose active Vitamin D (if prescribed)
62632875|NCT00803712|ACTIVE_COMPARATOR|Control Group|Flexible active vitamin D dosing
62632876|NCT04716972||Online Survey|Online survey
62632877|NCT04716972||Interviews|Interviews
62632878|NCT00954122|EXPERIMENTAL|Quetiapine XR|Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.
62632879|NCT03169907|EXPERIMENTAL|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
62632880|NCT02843126|EXPERIMENTAL|Trastuzumab and NK immunotherapy|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62632881|NCT02843126|ACTIVE_COMPARATOR|Trastuzumab|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62632882|NCT05746169||Pregnant women and their children|The DREAM cohort will recruit from University of California, San Francisco (UCSF) Mission Bay, Zuckerberg San Francisco General Hospital, and Fresno Community Medical Center locations to enroll an economically, geographically, ethnically and racially diverse cohort of pregnant women and their children for long term follow-up.
62632883|NCT00945412|EXPERIMENTAL|Micropolysaccharide Hemospheres (MPH)|
62632884|NCT00945412|ACTIVE_COMPARATOR|Electrocautery|
62632885|NCT02282865||Visual analogue scale (VAS) >5|The degree of surgery-related anxiety assessment using VAS
62632886|NCT02282865||Visual analogue scale (VAS) ≤5|The degree of surgery-related anxiety assessment using VAS
62632887|NCT01129245|NO_INTERVENTION|Control cycle|Control menstrual cycle
62632888|NCT01129245|EXPERIMENTAL|Pre-LH surge celecoxib administration|Pre-LH surge dosing of celecoxib
62632889|NCT01129245|EXPERIMENTAL|Post-LH surge celecoxib administration|Post-LH surge dosing of celecoxib
62270756|NCT03449823||MCDA Controls|Controls of monochorionic / diamniotic twin pregnancies without a diagnosis of twin-twin transfusion syndrome.
62632890|NCT00705757|ACTIVE_COMPARATOR|Lumigan|Patients assigned to Lumigan/bimatoprost one drop before bedtime (qhs) to affected eye(s)
62632891|NCT00705757|ACTIVE_COMPARATOR|Xalatan|Patients assigned to Xalatan/latanoprost one drop before bedtime (qhs) to affected eye(s)
62632892|NCT00705757|ACTIVE_COMPARATOR|Travatan|Patients assigned to Travatan/travoprost one drop before bedtime (qhs) to affected eye(s)
62632893|NCT00816127|EXPERIMENTAL|1|DDAVP
62632894|NCT00816127|ACTIVE_COMPARATOR|2|Standard Treatment
62632895|NCT02493517|EXPERIMENTAL|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
62632896|NCT02493517|ACTIVE_COMPARATOR|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
62632897|NCT03221998|EXPERIMENTAL|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
62632898|NCT03221998|PLACEBO_COMPARATOR|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
62632899|NCT06553690|EXPERIMENTAL|Participants receiving Brain Gym Therapy.|Participants in this arm will undergo Brain Gym Therapy, which consists of a series of structured physical exercises designed to enhance cognitive function and promote relaxation.
62632900|NCT06553690|NO_INTERVENTION|Participants receiving standard care without Brain Gym Therapy|standered care
62270757|NCT02205749|OTHER|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
62270758|NCT02205749|OTHER|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
62632901|NCT01253096|EXPERIMENTAL|L19IL2|
62632902|NCT05488769||Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
62632903|NCT04762199|EXPERIMENTAL|Treatment (osimertinib, MRX-2843)|Patients receive osimertinib PO QD and MRX-2843 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62632904|NCT01366313|EXPERIMENTAL|Paracetamol|initial doses was 1.5g g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
62632905|NCT01366313|EXPERIMENTAL|Morphine|Initial doses of morphine was 5mg, with dose adjustment intervals of 1 mg .
62632906|NCT01366313|EXPERIMENTAL|Paracetamol-morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
62632907|NCT01629095||NAFLD|Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.
62632908|NCT01629095||NASH|Patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes havebeen ruled out are eligible to participate.
62632909|NCT04613739|EXPERIMENTAL|Insurance navigation|The intervention group will be offered access to AAFA's insurance chat bot and navigation services. Navigation will be provided through AAFA's existing online patient community platform that provides assistance with clinical, educational and financial questions and includes secure, personal messaging capabilities that will be supplemented with telephonic outreach.
62632910|NCT04613739|NO_INTERVENTION|Wait-list controls|Control subjects will be offered the chat bot after completion of data collection for the intervention group (after completion of the four-month follow-up surveys)
62632911|NCT01060423|EXPERIMENTAL|hepatic TACE with irinotecan eluting beads and iv cetuximab|Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
62632912|NCT01060423|ACTIVE_COMPARATOR|iv cetuximab and irinotecan|systemic treatment with intravenous cetuximab and irinotecan
62632913|NCT04538469||Group 1|Admitted prior to COVID visitation restrictions introduced
62632914|NCT04538469||Group 2|Admitted following the introductions of visitation restrictions due to COVID 19 pandemic
62632915|NCT04546750||Patients without Varicose Veins|Individuals who do not have varicose veins of lower legs: C0, C1 classes according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
62632916|NCT04546750||Patients with Varicose Veins|Individuals who have varicose veins of lower legs: C2 Ep class according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
62632917|NCT04827979|EXPERIMENTAL|Cohort 1 (N=5 Subjects)|"Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:~* Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.~* Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%."
62632918|NCT04827979|EXPERIMENTAL|Cohort 2 (N=10 Subjects)|"The enrollment of ten additional subjects is dependent on the results in Cohort 1.~Multiple intravenous infusions of daratumumab and belatacept over 14 weeks:°~* Daratumumab will be administered intravenously at a dose of 8 mg/kg for the first dose, then 16 mg/kg for subsequent given weekly for 3 weeks, then every 2 weeks for 2 doses (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.~* Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, 14, 16 and 18). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%.~  * Was modified based on the safety and efficacy analysis of Cohort 1."
62632919|NCT04806269||Thyroid dysfunction group|"Subjects with thyroid dysfunction including thyrotoxicosis and hypothyroidism Subjects who were newly diagnosed or undergoing treatment for thyroid dysfunction can be included in the study.~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
62632920|NCT04806269||Control group|"Subjects without thyroid dysfunction including thyrotoxicosis and hypothyroidism.~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
62632921|NCT01438619||representitives of Goyang city|"1. Representative population of Goyang city who were randomly selected by digit dialing (RDD) method~2. Volunteers who are reside in Goyang city"
62632922|NCT02259400|ACTIVE_COMPARATOR|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
62632923|NCT02259400|ACTIVE_COMPARATOR|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
62632924|NCT02716792|EXPERIMENTAL|Ibandronate 15-Minute Infusion|Participants will receive ibandronate IV infusions over a 15-minute interval.
62632925|NCT02716792|ACTIVE_COMPARATOR|Ibandronate 60-Minute Infusion|Participants will receive ibandronate IV infusions over a 60-minute interval.
62632926|NCT00452660|EXPERIMENTAL|evaluating the effect of -Exjade|evaluating the effect of -Exjade (Deferasirox)_on oxidative stress parameters of blood cells in patients with Low risk Mylodysplastic syndrome ( MDS) with Iron over load
62632927|NCT00738634|EXPERIMENTAL|Physical activity mediated|"Self-motivated physical activity intervention~Materials mailed to participants"
62632928|NCT00738634|ACTIVE_COMPARATOR|Nutrition control|"Nutrition attention-control arm.~Delivered by researcher."
62065760|NCT00728117|EXPERIMENTAL|ibuprofen-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
62065761|NCT00728117|EXPERIMENTAL|ibuprofen-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
62065762|NCT00728117|EXPERIMENTAL|indomethacin-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
62065763|NCT00728117|EXPERIMENTAL|indomethacin-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
62065764|NCT04424875|EXPERIMENTAL|study arm|patients will undergo surgery to remove impacted lower third molar and receive Melatonin (3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%) in the socket following removal of the impacted third molar
62632929|NCT00738634|EXPERIMENTAL|Physical activity researcher contact|"Self-motivated physical activity intervention~Delivered by researcher."
62632930|NCT04168645|EXPERIMENTAL|Presence of SUD with BCBT|Patients diagnosed with SUD who are randomly assigned to receive BCBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
62632931|NCT04168645|NO_INTERVENTION|Presence of SUD with TAU|Patients diagnosed with SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
62270759|NCT02205749|OTHER|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
62632932|NCT04168645|EXPERIMENTAL|Absence of SUD with BCBT|Patients without SUD who are randomly assigned to receive BCBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of BCBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
62632933|NCT04168645|NO_INTERVENTION|Absence of SUD with TAU|Patients without SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
62632934|NCT04917614|ACTIVE_COMPARATOR|group teas|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at Hegu (LI4), Neiguan (PC6), and Zusanli (St 36) with an electronic acupuncture device.
62632935|NCT04917614|SHAM_COMPARATOR|Control Group|In the sham group, the patients were connected to the electronic acupuncture, but electronic stimulation was not applied.
62632936|NCT00522548|ACTIVE_COMPARATOR|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) at a target dose of 720 mg orally twice daily for 6 months after transplant.
62632937|NCT00522548|ACTIVE_COMPARATOR|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent manufactured by Sandoz, at a target dose of 1000 mg orally twice daily for 6 months after transplant.
62632938|NCT00335517|EXPERIMENTAL|10mg Depodur|
62632939|NCT00335517|EXPERIMENTAL|15mg DepoDur|
62632940|NCT05801861|EXPERIMENTAL|Active 10-Hz rTMS|For the first TMS session, participants will receive 10-Hz repetitive TMS (rTMS) delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 2250 pulses. For the second TMS session, participants will receive single pulse TMS during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 200 pulses.
62632941|NCT05801861|EXPERIMENTAL|Active single-pulse rTMS|For the first TMS session, participants will receive a single TMS pulse during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 300 pulses. For the second TMS session, participants will receive single pulse TMS during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 200 pulses.
62632942|NCT05801861|SHAM_COMPARATOR|Sham 10-Hz rTMS|Identical parameters of the active 10-Hz rTMS group will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
62632943|NCT05801861|SHAM_COMPARATOR|Sham single-pulse rTMS|Identical parameters of the active single-pulse rTMS group will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
62632944|NCT01242241|OTHER|Non-obese|Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile
62632945|NCT01242241|ACTIVE_COMPARATOR|Obese children|Obese children are categorized as those with a body mass index \>95th percentile
62632946|NCT03854721|EXPERIMENTAL|VAX014|Intravesical VAX014 (dose: 3.33x10\^10 - 9.0x10\^11 recombinant bacterial minicells (rBMCs)), given once per week for Weeks 1-6
62632947|NCT04032795|EXPERIMENTAL|Lycium barbarum polysaccharide (LBP)|Experimental group takes LBP tablet (300mg/day) for 6 weeks
62270760|NCT04558814|OTHER|Systemic lupus erythematosus patients|Evaluation of serum galectin-9 level
62632948|NCT04032795|PLACEBO_COMPARATOR|Placebo|Placebo control group takes placebo 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
62632949|NCT05435469||Questionnaires assessed adolescents|① Teenagers aged 14-25. ② Chinese nationality, who has lived in China since the outbreak of the COVID-19 epidemic, and has experienced or is experiencing the epidemic and its normalization. ③ Have the normal cognitive ability, expression ability, and social participation ability.
62632950|NCT02868021|PLACEBO_COMPARATOR|NO-EX group|Subjects allocated to the No Exercise (NO-EX) group will undergo: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function and Six-minute walk (SMW) test. Intra-op muscle biopsies.
62632951|NCT02868021|EXPERIMENTAL|EX-BFR group|Subjects allocated to the EX-BFR group will undergo baseline strength testing, Short Physical Performance Battery (SPPB), Numerical pain scale, Six-minute walk (SMW), Self-assessed function, and determination of 1 Repetition Maximum (1-RM). Blood flow restriction exercise, Borg Category Ratio 10 (Borg CR10) scale. Intra-op muscle biopsies.
62270761|NCT04558814|OTHER|Control group|Evaluation of serum galectin-9 level
62286896|NCT04573101|EXPERIMENTAL|O5 (Oud - Known music- Kurd Re)|Known music with Oud, on Kurd maqam on Re. (El Rabii)
62286897|NCT04573101|EXPERIMENTAL|Q5 (Qanun - Known music- Kurd Re)|Known music with Qanun, on Kurd maqam on Re. (El Rabii)
62632952|NCT01733745|EXPERIMENTAL|SYSTANE® Family|SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
62632953|NCT01733745|ACTIVE_COMPARATOR|Standard of Care|Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
62632954|NCT01992250|OTHER|Low Risk - Age 70+|Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
62270762|NCT01140360|EXPERIMENTAL|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
62632955|NCT01992250|OTHER|Moderate Risk - Age 50-69|Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
62632956|NCT01051817|EXPERIMENTAL|AIN457|
62632957|NCT01051817|PLACEBO_COMPARATOR|Placebo|
62632958|NCT01015716|ACTIVE_COMPARATOR|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
62632959|NCT01015716|EXPERIMENTAL|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
62632960|NCT04818073|EXPERIMENTAL|Group A|Participants with undergo new FINGER robotic training with no physical assistance 3 times a week for a period of 3 weeks.
62632961|NCT04818073|EXPERIMENTAL|Group B|Participants will undergo new FINGER robotic training with physical assistance 3 times a week for a period of 3 weeks.
62632962|NCT04818073|EXPERIMENTAL|Group C|Participants will undergo new FINGER robotic training with physical assistance and proprioceptive exercises 3 times a week for a period of 3 weeks.
62632963|NCT04917848|EXPERIMENTAL|Older adults with cancer|Participants will be 70 years old or older with a diagnosis of gastrointestinal or gynecological cancer. Participants will be receiving or about to receive medical cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy, biological agents)
62286898|NCT04573101|EXPERIMENTAL|N6 (Ney - Known music- Kurd Sol)|Known music with Ney, on Kurd maqam on Sol. (El Rabii)
62286899|NCT04573101|EXPERIMENTAL|O6 (Oud - Known music- Kurd Sol)|Known music with Oud, on Kurd maqam on Sol. (El Rabii)
62452804|NCT00777829|EXPERIMENTAL|zolpidem first, then placebo|Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap.
62452805|NCT00777829|PLACEBO_COMPARATOR|Placebo first, then zolpidem|Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap.
62452806|NCT01570465||All patients enrolled in the GIMEMA AML1310 study.|"* All patients enrolled in the GIMEMA AML1310 study;~* Signed written informed consent according to ICH/EU/GCP and national local laws."
62452807|NCT01017783|OTHER|Healthy Choices|
62452808|NCT01017783|EXPERIMENTAL|Diet Substitution A|
62452809|NCT01017783|EXPERIMENTAL|Diet Substitution B|
62452810|NCT02995070|EXPERIMENTAL|CTG + LLLT|The irradiation will be performed with a GaAlAs diode laser that will continuously emits a wavelength of 660 nm with a power of 30 milliwatts. The patients allocated for the LLLT group will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 J/cm2 and a time of 20 seconds. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment will be calibrated prior to each application.
62452811|NCT02995070|SHAM_COMPARATOR|CTG + SHAM|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which will not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications.
62452812|NCT00472290|EXPERIMENTAL|Open Label Romiplostim (formerly AMG 531)|
62452813|NCT05240209|EXPERIMENTAL|Education (Intervention) Group|In the pretest phase of the research;Education group, those who signed the Informed Voluntary Consent Form and agreed to participate in the research will fill out the questionnaire.Data collection will take approximately 20-25 minutes.Afterwards,the researcher will give training to the training group about skin cancer,skin self-examination and sun protection behaviors.The tutorials are planned as a PowerPoint demonstration.The duration of the trainings is planned to take approximately 40minutes.The content of the training was prepared in line with the literature review.As a method;It will be in the form of narration,question and answer,brainstorming.Materials used in education;Colorfulbrochures on the subject will be given to reinforce the slide show and post-training information.A follow-up period of four months will be expected after the training given.At the end of the follow-up period,the training group will have to fill out the post-test questionnaires during the post-test phase.
62452814|NCT05240209|NO_INTERVENTION|Control Group|Control Group: In the pre-test phase of the study; control group parents, those who signed the Informed Consent Form and agreed to participate in the study will fill out the questionnaire. Data collection will take approximately 20-25 minutes. During the follow-up period (120 days), no intervention will be made on the control group. At the end of the follow-up period (120 days), the control group will have to fill out the post-test questionnaires during the post-test phase. Participants will be reminded of the purpose of the research. Approval of the Informed Consent Form will be received. Completing the post-test questionnaires will take approximately 20-25 minutes. A brochure training material will be distributed to the parents of the control group, in line with the principle of equality, immediately after the completion of the post-tests.
62452815|NCT04112251|PLACEBO_COMPARATOR|Placebo|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg oral placebo capsule (Cornstarch) every 12 hours for 12 weeks.
62270763|NCT06495632|ACTIVE_COMPARATOR|scheduled pain regimen|This group will receive post-operative pain medications including narcotics for 2-3 days (Oxycodone/Acetaminophen 5mg/325mg, Hydrocodone/Acetaminophen 5mg/325mg, Hydromorphone 2mg, or Tramadol 50mg) every 4 hours and 800 mg Motrin for 10 days every 8 hours on a fixed time/day schedule.
62632964|NCT01720316|ACTIVE_COMPARATOR|glycine|Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
62632965|NCT01720316|PLACEBO_COMPARATOR|Placebo|placebo, TID dosing, 6 weeks Double-blind
62632966|NCT01720316|ACTIVE_COMPARATOR|glycine, open-label|glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks
62632967|NCT03735082|EXPERIMENTAL|apatinib+Paclitaxel+Carboplatin|apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle
61978594|NCT01327950||Superficial Femoral Lesions|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions
62632968|NCT03464032|EXPERIMENTAL|BCD-135|Dose-escalation Arm (0.4, 1, 3, 10, 20 mg/kg)
62632969|NCT01754324||Methadone|All infants requiring pharmacological treatment of their NAS symptoms are treated with a standardized protocol utilizing oral methadone. This treatment protocol has been the standard of care for infants with NAS at our institution for many years. Infants enrolled in this study will have blood samples drawn at predetermined times in order to obtain information regarding the pharmacokinetics of oral methadone in this population.
62632970|NCT04380870||Chinese Herbal Medicine|Chinese Herbal Medicine for suspected COVID-19 symptoms.
62270764|NCT06495632|EXPERIMENTAL|as needed pain regimen|This group will receive post-operative pain medications including narcotics for 2-3 days (Oxycodone/Acetaminophen 5mg/325mg, Hydrocodone/Acetaminophen 5mg/325mg, Hydromorphone 2mg, or Tramadol 50mg) every 4 hours and 800 mg Motrin for 10 days every 8 hours as needed for moderate to severe pain (4-10 on numeric rating scale).
62632971|NCT05497453|EXPERIMENTAL|OTX-2002|Monotherapy: OTX-2002 (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks
62632972|NCT05497453|EXPERIMENTAL|OTX-2002 + Tyrosine Kinase Inhibitor One|"OTX-2002 + Tyrosine Kinase Inhibitor One: (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.~Tyrosine Kinase Inhibitor One will be standard per the respective fixed local approved dose"
62632973|NCT05497453|EXPERIMENTAL|OTX-2002 + Tyrosine Kinase Inhibitor Two|"OTX-2002 + Tyrosine Kinase Inhibitor Two : (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.~Tyrosine Kinase Inhibitor Two will be standard per the respective fixed local approved dose"
62632974|NCT05497453|EXPERIMENTAL|OTX-2002 + Checkpoint Inhibitor|"OTX-2002 + Immune Checkpoint Blockade: (Cycle length = 6 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.~Checkpoint Inhibitor will be standard per the respective fixed local approved dose"
62065765|NCT04424875|PLACEBO_COMPARATOR|controlled arm|patients will undergo surgery to remove impacted lower third molar and patients will receive no melatonin (2 ml of hydroxyethyl cellulose gel 2 %).
62065766|NCT00612222|EXPERIMENTAL|ALVAC plus anti-MART-1 F5 TCR PBL + HD IL-2|"ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.~Aldesleukin - 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days."
62270765|NCT02961335|EXPERIMENTAL|Patient who need to undergo bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
62270766|NCT06407310|EXPERIMENTAL|neoadjuvant pembrolizumab with carboplatin and paclitaxel in triple-negative breast cancer|"6 cycles of Pembrolizumab (Keytruda) at a dose of 200 mg given every 3 weeks for 6 cycles. The first cycle of pembrolizumab is given as a lead-in without carboplatin and paclitaxel.~Carboplatin area under the curve (AUC) 1.5 and Paclitaxel 80 mg/m2, starting with the second pembrolizumab cycle, will be given weekly for 12 weeks."
62065767|NCT04732429|EXPERIMENTAL|Active Drug|Part B is the 6-month, randomized, double-blind (Subject/Investigator/Sponsor), placebo-controlled, 2-period crossover study consisting of 2 intervention periods of 12 weeks each to evaluate the safety and efficacy of the optimal dose of HST5040 in PA and MMA subjects ≥ 2 years old (N = minimum 12) in addition to SoC determined in Part A (within-subject dose escalation).
62065768|NCT04732429|EXPERIMENTAL|Placebo|Placebo in addition to standard of care.
62065769|NCT00494260|EXPERIMENTAL|Social learning and cognitive behavioral therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
62270767|NCT03976973|EXPERIMENTAL|Intervention|Participants with inoperable pseudomyxoma peritonei or peritoneal mucinous tumour that meet the entry criteria and consent to the intervention will receive intratumoural treatment/s with the combination drug BromAc. The drug product will be injected directly into the tumour via a radiologically placed drain
62270768|NCT03695003|ACTIVE_COMPARATOR|600 mg sage/polyphenol combination|600 mg of this sage/polyphenol combination will be consumed, via capsule, per day for 29 days.
62270769|NCT03695003|PLACEBO_COMPARATOR|Placebo|The same number of aesthetically similar capsules will be consumed per day for 29 days.
62632975|NCT00237692|NO_INTERVENTION|Arm 1|Control group - a group of hypertensive patient who receive usual care
62270770|NCT03389854|SHAM_COMPARATOR|Group 1 - Control|No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
62065770|NCT00494260|ACTIVE_COMPARATOR|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
62065771|NCT01422135|EXPERIMENTAL|Abdomen, Buttock, Upper Torso|"Patch was placed on abdomen, buttock then the upper torso excluding breast.~Intervention: AG200-15 patch"
62632976|NCT00237692|EXPERIMENTAL|Arm 2|Nurse Behavioral intervention with Home BP Telemonitoring Nurse-administered tailored behavior intervention
62632977|NCT00237692|EXPERIMENTAL|Arm 3|Nurse Medication Management with Home BP Telemonitoring -- Nurse administer medication management according to hypertension decision support system
62632978|NCT00237692|EXPERIMENTAL|Arm 4|Nurse Combined intervention with Home BP Telemonitoring - Combination of the nurse administered tailored behavioral \& medication management interventions
62632979|NCT02906124||Repatha® exposed|Females with familial hypercholesterolaemia (FH) exposed to Repatha® in the 15 weeks prior to or during pregnancy or during breastfeeding
62632980|NCT02906124||Non exposed to Repatha®|Pregnant females with familial hypercholesterolaemia (FH) not exposed to Repatha® and enrolled into this study, overall and stratified by lipid lowering therapy use
62065772|NCT01422135|EXPERIMENTAL|Abdomen, Upper Torso, Buttock|"Patch was placed on abdomen, upper torso excluding breast then the buttock.~Intervention: AG200-15 patch"
62065773|NCT01422135|EXPERIMENTAL|Buttock, Abdomen, Upper Torso|"Patch was placed on the buttock, abdomen, then the upper torso excluding breast.~Intervention: AG200-15 patch"
62065774|NCT01422135|EXPERIMENTAL|Buttock, Upper Torso, Abdomen,|"Patch was placed on the buttock, upper torso excluding breast then the abdomen~Intervention: AG200-15 patch"
62065775|NCT01422135|EXPERIMENTAL|Upper Torso, Abdomen, Buttock|"Patch was placed on the upper torso excluding breast, abdomen then buttock.~Intervention: AG200-15 patch"
62270771|NCT03389854|EXPERIMENTAL|Group 2 - PTT 1x daily x 3 months|Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
62270772|NCT03389854|EXPERIMENTAL|Group 3 - PTT 2x daily x 3 months|Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
62632981|NCT00850369|EXPERIMENTAL|1|All subjects wil receive monthly RBC transfusions for 6 months
62632982|NCT02307149|EXPERIMENTAL|CAVATAK and ipilimumab|CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
62632983|NCT06357624|EXPERIMENTAL|Mulligan mobilization technique|The participants received MMT from the physiotherapist.
62632984|NCT06357624|OTHER|Self-mobilization techniques|The second group was trained only self-mobilization technique.
62632985|NCT01822834||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
62632986|NCT01822834||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
62065776|NCT01422135|EXPERIMENTAL|Upper Torso, Buttock, Abdomen|"Patch was place on the upper torso excluding breast, buttock, then abdomen.~Intervention: AG200-15 patch"
62065777|NCT06316219|NO_INTERVENTION|Control|Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
62065778|NCT06316219|EXPERIMENTAL|Intervention|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol 2.5mg/1.5mg at any time of the menstrual cycle
62065779|NCT05739435|EXPERIMENTAL|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
62270773|NCT03389854|EXPERIMENTAL|Group 4 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
62270774|NCT02091570|PLACEBO_COMPARATOR|Nutrition bar|50 g nutrition bar
62270775|NCT02091570|EXPERIMENTAL|Nutrition Bar 1|50 g nutrition bar with additional 2 g of milk-based nutrient
62270776|NCT02091570|EXPERIMENTAL|Nutrition bar 2|50 g nutrition bar with additional 3 g of milk-based nutrient
62270777|NCT03259074|EXPERIMENTAL|AIN457 150 mg/placebo|AIN457 150 mg and a matching placebo was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
62632987|NCT03832270|EXPERIMENTAL|Parents InC|Group parenting support intervention based around four pillars: 1) empowerment/ownership; 2) education on ADHD and its effect on family identity/ values; 3) positive parenting in the context of ADHD; 4) making sense of ADHD in a developmental context. It is delivered over 5 weekly 2-hour sessions, a 6 week break, and a follow-up session.
62632988|NCT03832270|ACTIVE_COMPARATOR|Incredible Years|A group parenting support intervention aimed at strengthening parent-child interactions and attachment, reducing harsh discipline and fostering parents' ability to promote children's social, emotional, and academic development. The IY programme is delivered over 14 weekly 2-hour sessions. IY facilitators are videotaped during sessions to maintain intervention fidelity. IY also includes 1-4 pre-intervention preparation sessions which may involve home visits and telephone support and reminders.
62065780|NCT05739435|EXPERIMENTAL|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
62065781|NCT00581633|EXPERIMENTAL|1|saline infusion for sodium loading
62065782|NCT03669653|ACTIVE_COMPARATOR|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
62065783|NCT03669653|PLACEBO_COMPARATOR|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
62065784|NCT02592200|EXPERIMENTAL|Lactobacillus gasseri|Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)
62065785|NCT02592200|PLACEBO_COMPARATOR|Placebo|Placebo capsules (two doses)
62065786|NCT05763953|EXPERIMENTAL|Etripamil NS 70mg|Patients will be administered by study site personnel
62065787|NCT01860014|ACTIVE_COMPARATOR|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
62065788|NCT01860014|ACTIVE_COMPARATOR|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
62065789|NCT04379037|EXPERIMENTAL|Intervention Arm|Adults over 18 years of age hospitalized because of COVID-19 infection will be treated with transcutaneous auricular vagus nerve stimulation (taVNS).
62065790|NCT00642135|ACTIVE_COMPARATOR|1|Premature newborns and neonates treated using Phenylephrine and tropicamide eyedrops
62065791|NCT00642135|ACTIVE_COMPARATOR|2|Premature newborns and neonates treated using insert Mydriasert®
62065792|NCT06102486||MCI|Participants diagnosed with or suspected to have MCI
62065793|NCT06102486||Control|Participants without MCI
62270778|NCT03259074|EXPERIMENTAL|AIN457 300 mg|AIN457 300 mg (2 x 150 mg) was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
62632989|NCT02012725||Arm 1 Mycardial Fibrosis|MRI with Intravenous administration of gadolinium
62632990|NCT02012725||Arm 2 Chronic Kidney Disease|MRI with no gadolinium administration
62065794|NCT01982877|EXPERIMENTAL|Family Support Intervention|Multifaceted family support intervention as well as ICU educational component.
62065795|NCT01982877|EXPERIMENTAL|Educational Control|ICU educational component
62065796|NCT02760758|EXPERIMENTAL|Cohort 1A HV|CDI-31244 20 mg active or placebo single dose (SD)
62065797|NCT02760758|EXPERIMENTAL|Cohort 2A HV|CDI-31244 50 mg active or placebo SD
62065798|NCT02760758|EXPERIMENTAL|Cohort 3A HV|CDI-31244 100 mg active or placebo SD
62065799|NCT02760758|EXPERIMENTAL|Cohort 4A HV|CDI-31244 200 mg active or placebo SD; food effect
62065800|NCT02760758|EXPERIMENTAL|Cohort 5A HV|CDI-31244 400 mg active or placebo SD
62270779|NCT03259074|ACTIVE_COMPARATOR|GP2017 40mg|GP2017 (adalimumab biosimilar) 40 mg was administered subcutaneously via pre-filled syringes at Baseline followed by dosing every 2 weeks until Week 102
62270780|NCT06046261|EXPERIMENTAL|General routine care and ACP board game for life|
62286900|NCT04573101|EXPERIMENTAL|Q6 (Qanun - Known music- Kurd Sol)|Known music with Qanun, on Kurd maqam on Sol. (El Rabii)
62286901|NCT04573101|EXPERIMENTAL|N7 (Ney - Known music- Saba Re)|Known music with Ney, on Saba maqam on Re. (Howa Sahih)
62286902|NCT04573101|EXPERIMENTAL|O7 (Oud - Known music- Saba Re)|Known music with Oud, on Saba maqam on Re. (Howa Sahih)
62452816|NCT04112251|EXPERIMENTAL|Supplement|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg capsule every 12 hours (100 mg / day of epicatechin) for 12 weeks.
62632991|NCT05074641|EXPERIMENTAL|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
62065801|NCT02760758|EXPERIMENTAL|Cohort 6A HV|CDI-31244 200 mg active or placebo multiple dose (MD)
62065802|NCT02760758|EXPERIMENTAL|Cohort 7A HV|CDI-31244 200 mg active or placebo MD
62065803|NCT02760758|EXPERIMENTAL|Cohort 8A HV|CDI-31244 400 mg active or placebo MD
62065804|NCT02760758|EXPERIMENTAL|Cohort 1B HCV genotype (GT) 1|CDI-31244 400 mg active or placebo MD
62065805|NCT02760758|EXPERIMENTAL|Cohort 2B HCV GT 1|CDI-31244 600 mg active or placebo MD
62065806|NCT02760758|EXPERIMENTAL|Cohort 3B HCV GT 1|CDI-31244 800 mg active or placebo MD
62065807|NCT06163053||Participants receiving immunotherapy at home|
62065808|NCT01988363|OTHER|GON injection at C2 location|A 25 gauge, 2 inch spinal needle will be inserted into the symptomatic side after locating the GON via US at the level of C2. Subjects will receive an injection of 4 ml of injectate consisting of 1 ml of 2% Lidocaine, 3 mg betamethasone and 2.5 ml of 0.25% Bupivicaine to the greater occipital nerve at the novel, proximal C2 location.
62065809|NCT00920621|EXPERIMENTAL|Vitamin D treatment|vitamin D treatment plus prenatal multivitamins
62065810|NCT00920621|PLACEBO_COMPARATOR|placebo|placebo plus prenatal multivitamins
62065811|NCT00467064|EXPERIMENTAL|Arthritis self-management workshop|Comparison of two-week, lay led, scripted self-management workshop emphasizing action planning, problem-solving, and content specific to arthritis.
62065812|NCT00467064|OTHER|Delayed treatment control|After 4 month delay, participants in Control Group receive Experimental intervention.
62065813|NCT03380663|ACTIVE_COMPARATOR|RIC - Healthy|Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
62065814|NCT03380663|ACTIVE_COMPARATOR|RIC - HF|Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
62286903|NCT04573101|EXPERIMENTAL|Q7 (Qanun - Known music- Saba Re)|Known music with Qanun, on Saba maqam on Re. (Howa Sahih)
62270781|NCT06046261|NO_INTERVENTION|General routine care|"General routine care means that when a CKD stage 4-5 patient is in critical condition or at the end of life, the renal medical team will explain the content of DNR to the patient's family (without cardiopulmonary resuscitation: including endotracheal tube intubation, extracorporeal cardiac compression, Emergency treatment items such as cardiac electric shock, emergency drug injection, and artificial cardiac pacemaker adjustment), the concept of palliative care (supportive care for end-of-life patients to relieve physical discomfort symptoms to reduce physical, mental and spiritual pain) or ACP."
62270782|NCT04392115|EXPERIMENTAL|Exercise Group|"The home-based exercise program called the PREPARE program.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
62270783|NCT04392115|NO_INTERVENTION|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
62270784|NCT04163809|NO_INTERVENTION|Control Group (no VR)|Patients will be randomly allocated to the control group, which receives no Virtual Reality (VR) during the regional anesthesia procedure.
62632992|NCT05074641|ACTIVE_COMPARATOR|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
61978595|NCT02596581|NO_INTERVENTION|diabetics with periodontally healthy group|Control group
62270785|NCT04163809|EXPERIMENTAL|Experimental Group (VR)|Patients will be randomly allocated to the the experimental group, which receives VR during the regional anesthesia procedure.
62270786|NCT01314716|EXPERIMENTAL|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
62270787|NCT01314716|PLACEBO_COMPARATOR|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
62270788|NCT03054376|ACTIVE_COMPARATOR|Immobilization|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will not be trained. After the two weeks the subjects will train both legs for four weeks.
62270789|NCT03054376|ACTIVE_COMPARATOR|Training of non-immobilized leg|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will be trained. After the two weeks the subjects will train both legs for four weeks.
62270790|NCT03670875|EXPERIMENTAL|Agave inulin|Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
62286904|NCT04573101|EXPERIMENTAL|N8 (Ney - Known music- Saba Sol)|Known music with Ney, on Saba maqam on Sol. (Howa Sahih)
61978596|NCT02596581|NO_INTERVENTION|systemically and periodontally healthy group|Control group
62632993|NCT02288702||Normal|This is the group with no neurological problems or syndrome
62065815|NCT03380663|ACTIVE_COMPARATOR|BFRE - Healthy|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
62065816|NCT03380663|ACTIVE_COMPARATOR|BFRE - HF|Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
62065817|NCT03380663|ACTIVE_COMPARATOR|TRT - Healthy|Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
62065818|NCT03380663|NO_INTERVENTION|Control - Healthy|No intervention.
62065819|NCT03380663|NO_INTERVENTION|Control - HF|No intervention.
62065820|NCT00058227|EXPERIMENTAL|Treatment (alvocidib, fludarabine phosphate, rituximab)|Patients receive fludarabine phosphate IV over 15-30 minutes on days 1-5 and rituximab IV over 3-4 hours on day 1. Alvocidib is administered IV over 60 minutes on day 1 in cohort 1; on days 1 and 2 in cohort 2; and on days 1, 2, and 3 in cohort 3. In cohorts 4 and 5, patients receive fludarabine phosphate and rituximab as above and alvocidib IV over 30 minutes and then IV over 4 hours on day 1 of courses 2-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62065821|NCT01282671|EXPERIMENTAL|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months.
62270791|NCT03670875|EXPERIMENTAL|Curcumin|Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.
62270792|NCT03670875|EXPERIMENTAL|Omega 3 Fatty Acids|O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
62632994|NCT02288702||Down syndrome|This is the group with Down syndrome
62632995|NCT04793984|EXPERIMENTAL|Inhaleen|Iota-Carrageenan inhalation
62632996|NCT04793984|PLACEBO_COMPARATOR|Placebo|NaCl inhalation
62632997|NCT00725907|EXPERIMENTAL|1|PGRF
62065822|NCT01282671|NO_INTERVENTION|Control group|No breathing exercises.
62270793|NCT03670875|OTHER|Control|Recommendations to decrease calories intake an do exercise.
62270794|NCT03220828|NO_INTERVENTION|Control|The control group will be provided standard of care, which is no use of technologies.
62632998|NCT00725907|PLACEBO_COMPARATOR|2|saline
62632999|NCT05225545|EXPERIMENTAL|Sucrosomial Iron|These patients will receive Sucrosomial Iron 30 mg + 70 mg ascorbic acid (Sideral Forte) twice daily
62633000|NCT05225545|ACTIVE_COMPARATOR|Oral Iron Therapy|These patients will receive Oral Iron therapy at a dose of 195 mg twice daily for the same period of time
62633001|NCT00447096|EXPERIMENTAL|Treatment Arm|Treatment arm will receive treatment 5 days a week for 6 weeks. Repetitive transcranial magnetic stimulation (rTMS) treatment.
62065823|NCT03912623|ACTIVE_COMPARATOR|3 weeks SPA Treatment|"3-week thermal cure:~* Spa treatment harmonized in the different stations~* Therapeutic education workshops and conferences common to all stations in the form of practical workshops during supervised lunches~* Adapted physical activity, workshops are common to all spas and use an electric bike suitable for health (VELIS) with briefing and debriefing. An APA (Adapted Physical Activity) coaching consultation at the end of the cure for personalized post-cure programs and objectives is planned as well as a telephone or internet coaching during the 5 months post-cure (objectives and adaptation, motivation)~* Maintenance of the usual treatment within 6 months post randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by the software Diascope and / or HAS~* Information booklet for inclusion (French Association of Diabetics)"
62065824|NCT03912623|SHAM_COMPARATOR|Discovery week end|"Maintenance of usual treatment within 6 months post-randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by Diascope and HAS software In addition, a discovery access to the baths of 2-3 days will be offered to patients. Finally, the information booklet on diabetes will be given at the inclusion (French Federation of Diabetics)."
62633002|NCT00447096|SHAM_COMPARATOR|Sham Arm|Sham Arm will not receive any stimulation 5 days a week for 6 weeks. Sham transcranial magnetic stimulation.
62065825|NCT05844930|ACTIVE_COMPARATOR|Intra-articular Injection of Corticosteroid Plus Lidocaine|Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc).
62065826|NCT05844930|EXPERIMENTAL|Intra-articular Injection of ActiveMatrix Plus Lidocaine|Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc).
62065827|NCT05038852|OTHER|Group 1 smartphone applications|app is designed to help you learn relaxation skills
62065828|NCT05038852|OTHER|Group 2 smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
62065829|NCT02825901|ACTIVE_COMPARATOR|Djulis-Buckwheat & Placebo|Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
62270795|NCT03220828|EXPERIMENTAL|Intervention Group VR|Interventional arm will use technology based distractions (Virtual Reality)
62633003|NCT01825304|ACTIVE_COMPARATOR|esophageal pressure ,titrated setting|
62633004|NCT01825304|OTHER|ARDSNet recommendations,peep|
61978597|NCT02596581|ACTIVE_COMPARATOR|diabetics with chronic periodontitis group|non-surgical periodontal treatment was performed
61978598|NCT02596581|ACTIVE_COMPARATOR|chronic periodontitis group|non-surgical periodontal treatment was performed
62065830|NCT02825901|ACTIVE_COMPARATOR|Buckwheat & Placebo|Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
62065831|NCT02825901|EXPERIMENTAL|Djulis-Buckwheat & Buckwheat|Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
62065832|NCT04319601|EXPERIMENTAL|rituximab combined with chidamde and lenalidomide|rituximab and chidamide, lenalidomide
62633005|NCT06380205|EXPERIMENTAL|Povorcitinib + levonorgestrel (LNG)/ethinyl estradiol (EE)|Povorcitinib and LNG/EE will be administered at the protocol defined doses.
62286905|NCT04573101|EXPERIMENTAL|O8 (Oud - Known music- Saba Sol)|Known music with Oud, on Saba maqam on Sol. (Howa Sahih)
62065833|NCT05995431|EXPERIMENTAL|PERIODONTITIS STAGE 2 AND STAGE 3 WITH BRUXISM|All the participants will undergo scaling and root planing
62065834|NCT05995431|ACTIVE_COMPARATOR|AGE MATCHED PATIENTS WITH STAGE 2 AND STAGE 3 PERIODONTITIS WITHOUT BRUXISM|All the participants will undergo subgingival instrumentation
62065835|NCT03065114||PGSno.|blastocysts from patients underwent preimplantational genetic screen (PGS) prtocols. only euploid embryos were selected to transfer.
62065836|NCT04220814|EXPERIMENTAL|Patients|
62065837|NCT04220814|OTHER|Healthy Volunteer|
62065838|NCT04564950||Control|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
62286906|NCT04573101|EXPERIMENTAL|Q8 (Qanun - Known music- Saba Sol)|Known music with Qanun, on Saba maqam on Sol. (Howa Sahih)
62286907|NCT03860948|EXPERIMENTAL|Savolitinib Test Preparation|The subjects in this arm will receive Test preparation (T). T is dry granulation savolitinib tablets.
62286908|NCT03860948|EXPERIMENTAL|Savolitinib Reference Preparation|The subjects in this arm will receive Reference preparation(R). R is wet granulation savolitinib tablets.
62633006|NCT04249362|EXPERIMENTAL|Cohort A|Patients received standard radiotherapy \[60 gray (Gy) ± 10% or hypofractionated BED\] prior to study entry.
62633007|NCT04249362|EXPERIMENTAL|Cohort B|Patients received palliative radiotherapy \[40 to \< 54 Gy or hypofractionated BED\] prior to study entry.
62633008|NCT02264808||Developmental outcomes|A developmental assessment (Bayley-III) of children 18-20 months who already enrolled in Florida Neonatal Neurologic Network. As part of this previous study, these children were born with Hypoxic Ischemic Encephalopathy (HIE) and underwent therapeutic cooling after birth.
62633009|NCT03151447|EXPERIMENTAL|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
62286909|NCT02736747|ACTIVE_COMPARATOR|Cryotherapy (ice pack)|A pack with 1000g of crushed ice without air will be placed for 20 consecutive minutes on a pre-delimited rectangular area with dimensions of 25 x 35 cm and will be fixed with a non-compressive elastic band. One strip of plastic paper will encompass the paretic leg of the subjects, avoiding direct contact from the skin with the ice pack.
62065839|NCT04564950||Periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
62065840|NCT04564950||Coronary heart disease|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
62065841|NCT04564950||Coronary heart disease + periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
62633010|NCT05828459|EXPERIMENTAL|OT-A201 monotherapy|OT-A201 administered by IV infusion on a weekly (qw) basis. An alternative dosing schedule of every 2 weeks (q2w) may be implemented based on the clinical safety and laboratory data.
62065842|NCT03820323|OTHER|Standard of Care|Participants in the Standard-of-Care control arm will receive laboratory based VL testing based on the existing Kenyan national guidelines by routine clinical staff (not study staff). DRM testing is usually done if there is a failing 2nd line ART regimen based on the current Kenyan guideline.
62065843|NCT03820323|EXPERIMENTAL|Intervention|POC VL and targeted DRM testing.
62065844|NCT01302561|PLACEBO_COMPARATOR|Sugar Pill|
62452817|NCT03365323||infectious group|Patients who met the criteria according of Periprosthetic Joint Infection were identified as the infectious group.
62633011|NCT05828459|EXPERIMENTAL|OT-A201 in combination with iMiD|OT-A201 in combination with lenalidomide or pomalidomide at the approved dose
62633012|NCT05828459|EXPERIMENTAL|OT-A201 in combination with a specific agent|OT-A201 in combination with late stage approved treatment (combination to be defined by a protocol amendment)
62633013|NCT05828459|EXPERIMENTAL|OT-A201 in combination with bevacizumab|OT-A201 in combination with bevacizumab at the approved dose
62065845|NCT01302561|EXPERIMENTAL|Galactooligosaccharide 5 g|
62065846|NCT02459093|EXPERIMENTAL|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
62065847|NCT02459093|EXPERIMENTAL|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
62065848|NCT05651360||Abdominal Pain|Participants under evaluation for an acute abdominal condition who are referred to CT of the abdomen and pelvis.
62065849|NCT04069260|EXPERIMENTAL|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
62633014|NCT05828459|EXPERIMENTAL|OT-A201 in combination with paclitaxel|OT-A201 in combination with paclitaxel at the approved dose
62065850|NCT02044458|ACTIVE_COMPARATOR|Stylette|Stylette: a thin wire inserted into a catheter to maintain rigidity, used to guide the insertion of the Foley catheter.
62065851|NCT02044458|NO_INTERVENTION|No Stylette|No Stylette: 22 French Foley catheter placed without stylette or guide.
62065852|NCT05330416|ACTIVE_COMPARATOR|Group Reference Strategy|Detailed examination of the suppuration and drainage with a seton
62065853|NCT05330416|EXPERIMENTAL|Group test strategy|Detailed examination of the suppuration without drainage via a seton
62065854|NCT04995237|EXPERIMENTAL|Prescription Produce Plan (PPP)|PPP provides access to fresh produce along with individual goal setting and education
62065855|NCT01803295|EXPERIMENTAL|40 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
62065856|NCT01803295|ACTIVE_COMPARATOR|Standard of care MMC mixed with water|40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
62270796|NCT04458142|EXPERIMENTAL|Single buccal infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine).~Injecting by a small amount of solution in the superficial mucosa. After a few seconds, the needle was slowly advanced in the mucobuccal fold toward the apex of the molar and 1.8 ml of 4% articaine using short 30-gauge needle was slowly given.~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed by inquiring about the area of numbness from the participant, no pain during pricking the palatal mucosa. The cases in which palatal anesthesia will not be reported by the patient will be given supplemental palatal infiltration with 0.2 to 0.3 mL articaine.~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
62270797|NCT04458142|ACTIVE_COMPARATOR|Buccal and intrapapillary infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine) Injecting a small amount of solution in the superficial mucosa,then needle will slowly advanced in the mucobuccal fold toward the apex of the molar and 1.5 ml of 4% articaine was slowly given. The remaining 0.3ml solution will be given equally into the distal, mesial intrapapillary and palatal sites respectively until blanching of the palate is observed extending more than halfway along the palatal gingival margin.~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed.~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
62633015|NCT02136459|EXPERIMENTAL|Small tube size|Size 6.5 ETT for female, size 7.0 ETT for male
62286910|NCT02736747|PLACEBO_COMPARATOR|Placebo (sand pack)|"For placebo application, the pack will be filled with 1000g of thin sand, in environmental temperature, so that the pressure exerted will be the same as the ice pack. All other experimental procedures will follow the same protocol as cryotherapy application."
62286911|NCT01349647|EXPERIMENTAL|Vaccine and Chemotherapy|This is a pilot trial evaluating the safety and immunogenicity of a pentavalent vaccine for patients with small cell lung cancer (SCLC). Patients with SCLC who have completed all planned initial therapy and have maintained a partial or complete response will be enrolled.
62633016|NCT02136459|ACTIVE_COMPARATOR|Large tube size|Normal tube size, size 7.5 for female, size 8 for male
62633017|NCT02721056|EXPERIMENTAL|NBTXR3, IL or IA injection +SBRT|"* Patients will receive a single intralesional (IL) injection of NBTXR3 at four increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 42% of the baseline tumor volume, activated by SBRT.~* Patients with primary and secondary nodular intra hepatic cancers only will receive a single superselective transcatheter arterial (IA) injection of NBTXR3 at five increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 45% of the baseline tumor volume, activated by SBRT."
62633018|NCT02479659|NO_INTERVENTION|Control|Facilities in this arm maintained status quo HIV testing and routine childhood immunization services
62633019|NCT02479659|EXPERIMENTAL|Simple Intervention|This included: 1) HIV testing commodity reinforcement and 2) a policy reinforcement meeting
62633020|NCT02479659|EXPERIMENTAL|Comprehensive Intervention|This arm included: 1) HIV testing commodity reinforcement, 2) a policy reinforcement meeting, 3) community sensitization, 4) Opt-out HIV testing for mothers and newborns, and 5) Operational support for service integration
62633021|NCT01025284|EXPERIMENTAL|Part A LY2523355|8 milligrams per square meter (mg/m²) per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 5, 9 of each 21-day cycle, until disease progression or unacceptable toxicity.
62065857|NCT01803295|EXPERIMENTAL|80 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
62065858|NCT04520555|EXPERIMENTAL|Laryngeal mask airway group|Flexible laryngeal mask airway is inserted for general anesthesia
62633022|NCT01025284|EXPERIMENTAL|Part B LY2523355|5 or 6 mg/m² per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 2, 3 plus granulocyte colony-stimulating factor (G-CSF) support administered subcutaneously beginning on Day 4 of each 21-day cycle, until disease progression or unacceptable toxicity.
62633023|NCT06240611||Group A (Control)|A healthy matched volunteers' group (n = 23) between 18 and 23 years of age was included in this study. For students of both genders, the body mass index was not less than 18.5 and not more than 29.5, and there was no recent or previous musculoskeletal injury or pain.
62065859|NCT04520555|ACTIVE_COMPARATOR|intubation group|Endotracheal intubation was performed for general anesthesia
62065860|NCT00829686|NO_INTERVENTION|No intervention|No antibiotic
62065861|NCT00829686|ACTIVE_COMPARATOR|Septra DS|Septra DS (800/160) two pills PO BID x 7 days
62065862|NCT03983993|EXPERIMENTAL|Treatment (niraparib, panitumumab)|Patients receive 200 or 300 mg niraparib orally once daily on days 1-28 and 6 mg/kg panitumumab intravenously over 60-90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62065863|NCT04277455|EXPERIMENTAL|Treatment arm|Patients will receive laser treatment for benign symptomatic nodules
62065864|NCT04133103|NO_INTERVENTION|First ambulation at 24 hours after operation|
62065865|NCT04133103|EXPERIMENTAL|First ambulation at 4 hours after operation|
62633024|NCT06240611||Group B (Experimental)|Participants with CNSNP (n = 22) were between 18 and 23 years of age. Patients with CNSNP For students of both genders, the duration of the non-specific neck pain was more than 3 months (for the symptomatic group with no neurological manifestations and with referral from orthopedic surgeons by diagnosis of non-specific neck pain), and for matched students, they did not have any history of neck pain. The student's age ranges from 18 to 23 years. Neck pain intensity on the numerical Pain Rating Scale was between 3 and 8, and neck pain-related disability on the Neck Disability Index was between 5 and 14 points (10-28%) for mild disability and 15-24 points (30-48%) for moderate disability. The body mass index for students was not less than 18.5 and not more than 29.5.
62633025|NCT00870467|PLACEBO_COMPARATOR|DB Placebo|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
62633026|NCT00870467|EXPERIMENTAL|DB adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
62633027|NCT00870467|EXPERIMENTAL|DB Adalimumab/OL Adalimumab|Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
62633028|NCT00870467|EXPERIMENTAL|DB Placebo/OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
62633029|NCT00870467|EXPERIMENTAL|DB Adalimumab/RE OL Adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
62633030|NCT00870467|EXPERIMENTAL|DB Placebo/RE OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
62633031|NCT02250300|EXPERIMENTAL|MLN9708 Phase II matched sibling|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, \& 22 starting on day +60 to +90 post allogeneic HCT.
62633032|NCT02250300|EXPERIMENTAL|MLN9708 Phase II matched unrelated|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, \& 22 starting on day +60 to +90 post allogeneic HCT.
62065866|NCT02733705|PLACEBO_COMPARATOR|Control|normal saline IV plus propofol infusion
62065867|NCT02733705|ACTIVE_COMPARATOR|Fentanyl|0.5 mcg/kg ideal body weight IV plus propofol infusion
62065868|NCT05268575|EXPERIMENTAL|endoscopic sclerotherapy|Patients with hemorrhoids will be treated with endoscopic sclerotherapy. Injection site is submucosa of hemorrhoid nucleus. Sclerosing agent makes the submucosal tissue fibrotic, and then fixes the hemorrhoidal tissue.
62065869|NCT05268575|EXPERIMENTAL|endoscopic rubber band ligation|Patients with hemorrhoids will be treated with endoscopic rubber band ligation. The ligature position is above the mucosa of the hemorrhoid nucleus. Ligation of hemorrhoidal tissue can lead to ischemic necrosis of the prolapsed mucosa, which in turn leads to scar fixation. At the same time, the ligature also has the effect of lifting the tissue upward.
62270798|NCT05823597|EXPERIMENTAL|Sugar Intensive Treatment|The Sugar-Intensive Intervention touched on exercise, sleep, and other aspects of healthy diet, but focused primarily on added sugar reduction. Beyond defining added sugar, the sugar-intensive intervention also included: information on how sugar is metabolized; description of health risks associated with excessive added sugar; opportunities to rehearse women's and men's recommended daily maxima; a game guessing the sugar content of various foods and beverages; information on proportion of undergraduates at their university who report being motivated to reduce their sugar intake; training in finding added-sugar information in nutritional labels; and concrete suggestions for replacing high-sugar foods and beverages with healthy options, and managing tempting situations.
62452818|NCT03365323||non-infectious group|Patients who didn't meet the criteria according of Periprosthetic Joint Infection were identified as the non-periprosthetic joint infection group.
62065870|NCT05268575|EXPERIMENTAL|endoscopic sclerotherapy combined with rubber band ligation|Patients with hemorrhoids will be treated with endoscopic sclerotherapy combined with rubber band ligation. Sclerotherapy first, followed by rubber band ligation. Sclerotherapy injection reduces the likelihood of ligature dislodgement.
62065871|NCT05439239|PLACEBO_COMPARATOR|Normoxic group females|The participants in this group (12 females) will perform a repeated sprint training in normoxia.
62065872|NCT05439239|EXPERIMENTAL|Hypoxic group females|The participants in this group (12 females) will perform a repeated sprint training in hypoxia.
62065873|NCT05439239|PLACEBO_COMPARATOR|Normoxic group males|The participants in this group (12 males) will perform a repeated sprint training in normoxia.
62065874|NCT05439239|PLACEBO_COMPARATOR|Hypoxic group males|The participants in this group (12 males) will perform a repeated sprint training in hypoxia.
62065875|NCT03528980||Bariatric surgery|
62065876|NCT03528980||standard nutritional management|
62633033|NCT02250300|EXPERIMENTAL|MLN9708 Phase I (2.3 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, \& 22 orally based on a dose escalation schema.
62633034|NCT02250300|EXPERIMENTAL|MLN9708 Phase I (3.0 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, \& 22 orally based on a dose escalation schema.
62065877|NCT05168605|EXPERIMENTAL|Home Visit|Participants will receive home visit During the course of the first home visit, patients will receive routine care for diabetes and hypertension management (outcome variables are listed below) and data will be recorded in the EHR for primary outcomes. The resident physician will also assist the patient in completing enrollment in MyChart (if interested), utilizing either the resident's computer or smartphone and an internet hotspot. MyChart is a patient health platform that allows patients to contact their healthcare doctors, log health reminders, see test results, and a list of medications. The resident physician will also review a social determinants of health (SDH) screener (included in the EHR). The research faculty (licensed medical clinician) will collect blood pressure readings during this visit.
62065878|NCT05168605|NO_INTERVENTION|Standard of care|Participants will receive a standard of care
62065879|NCT06342427||Patients with Gastric Cancer (Training)|Individuals with a pathologically confirmed diagnosis of gastric cancer
62633035|NCT02250300|EXPERIMENTAL|MLN9708 Phase I (4.0 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, \& 22 orally based on a dose escalation schema.
62065880|NCT06342427||Patients without Gastric Cancer (Training)|Individuals without cancer at the time of blood sampling
62633036|NCT06612073||Children who have kidney affection after hypovolemic shock|No intervtional drugs or devices at all.
62633037|NCT01503983|EXPERIMENTAL|Trastuzumab+Oxaliplatine+capecitabine|Patient takes Trastuzumab (initial dose 8 mg/kg and a maintenance dose 6 mg/kg) anda oxaliplatin (dose 130mg/m2) during the first day os cycle and them Capecitabine (dose 2000 mg/m2)during 14 days in cycle of 21 days.
62065881|NCT06342427||Patients with Gastric Cancer (Validation)|Individuals with a pathologically confirmed diagnosis of gastric cancer
62065882|NCT06342427||Patients without Gastric Cancer (Validation)|Individuals without cancer at the time of blood sampling
62065883|NCT00860067|EXPERIMENTAL|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson (BD) Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], B/Victoria \[B/Malaysia/2506/2004\], and B/Yamagata \[B/Florida/4/2006\]).
62633038|NCT04380376|EXPERIMENTAL|Melphalan inhalations|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 7-10 consequent days
62633039|NCT04380376|OTHER|Standard of care group|Patients assigned to the standard of care group will not receive any additional therapy.
62633040|NCT06331663|EXPERIMENTAL|Arms|Neurosurgery with fixation
62633041|NCT04569175|EXPERIMENTAL|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product)
62633042|NCT02283658|EXPERIMENTAL|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62633043|NCT04493372|EXPERIMENTAL|Individuals with spinal cord injury|
62633044|NCT04493372|EXPERIMENTAL|Individuals without spinal cord injury|
62270799|NCT05823597|ACTIVE_COMPARATOR|General Health Control|The General Health Intervention presentation covered Healthy People 2030 goals regarding physical activity (aerobic exercise, strength training), healthy eating (fruit, vegetable, and whole grain consumption; decreasing consumption of saturated fats and added sugar), and sleep (minimum of 7 hours per night), as well as healthy stress management/emotion regulation. The health benefits/risks associated with each goal were described, along with suggested strategies for achieving each goal. This version of the intervention also included a definition of added sugar and information about the recommended daily added-sugar maxima for women and men, but served mainly as an active control condition for testing the effects of the target intervention of interest.
62633045|NCT01184521||pulse CO-oximeter|
62270800|NCT03651596|ACTIVE_COMPARATOR|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
62452819|NCT00990613|OTHER|Cohort 1|
62633046|NCT05562297|EXPERIMENTAL|sintilimab + nab-paclitaxel + gemcitabine|Experimental: sintilimab + nab-paclitaxel + gemcitabine nab-paclitaxel at 125 mg/m\^2 on days 1, and 8; gemcitabine at 1000 mg/m\^2 on days 1, and 8; sintilimab at 200mg on day 1;
62065884|NCT00860067|ACTIVE_COMPARATOR|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], and B/Yamagata \[B/Florida/4/2006\])a B strain of the Yamagata lineage.
62452820|NCT00990613|OTHER|Cohort 2|
62633047|NCT00873730|EXPERIMENTAL|1|
62633048|NCT00873730|ACTIVE_COMPARATOR|2|
62633049|NCT02761018|EXPERIMENTAL|Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
62633050|NCT02761018|EXPERIMENTAL|Fitness Tracker with Group Participation|will use a fitness tracker and will be able to see other member's daily and weekly results
62633051|NCT06517498||Patients With Facioscapulohumeral Muscular Dystrophy|No intervention will be administered
62065885|NCT00860067|ACTIVE_COMPARATOR|FluMist/B/Victoria|FluMist/B/Victoria(trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10\^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 \[A/South Dakota/6/2007\], A/H3N2 \[A/Uruguay/716/2007\], and B/Victoria \[B/Malaysia/2506/2004\])a B strain of the Victoria lineage.
62065886|NCT03842553||Police officers|Police officers from the cantonal police forces in Bern, Switzerland
62065887|NCT03842553||Firefighters|Firefighters from the professional fire service of the Canton Bern, Switzerland
62270801|NCT03651596|EXPERIMENTAL|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
62270802|NCT04248413|OTHER|Standard rehabilitation protocol|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution.
62633052|NCT03493438|EXPERIMENTAL|Relaxation Group|Patients performed Jacobson relaxation technique in supine position. Respiration control and various visual imaging techniques were used during the technique. Relaxation exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
62633053|NCT03493438|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation Group|Patients exercised with proprioceptive neuromuscular facilitation technique for trunk muscles using chopping and lifting patterns with ritmic initiation PNF exercises were made by the physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
62633054|NCT03493438|EXPERIMENTAL|Core stabilization group|Patients had core stabilization exercises that involved spinal mobility. The patients performed the drawing-in maneuver within various visual imaging techniques during all exercises, especially with respiratory control. Exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
62633055|NCT03493438|OTHER|control group|Patients in the control group were told the importance of a single session exercise
62065888|NCT03842553||Ambulance personnel|Ambulance personnel of the Canton Bern, Switzerland
62065889|NCT03842553||Emergency nurses|Emergency nurses of the Emergency Unit of the University Hospital of Bern, Switzerland
62065890|NCT03842553||Psychiatric nurses|Psychiatric nurses of the University Hospital of Psychiatry, University of Bern, Switzerland
62065891|NCT02523521|NO_INTERVENTION|Bronchopylmonary Dysplasia Control|Nothing
62270803|NCT04248413|EXPERIMENTAL|Standard rehabilitation plus Blood Flow Restriction Therapy|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution in addition to the BFR therapy. Per recommendations of Owens Recovery Science, the organization responsible for certifying physical therapists in BFR therapy, the therapy will take place concurrently throughout the duration of the rehabilitation.
62270804|NCT05875870|EXPERIMENTAL|Experimental group|The rehabilitation program is composed of two parts: six-week bright-light exposure program and an exercise program.
62270805|NCT05875870|ACTIVE_COMPARATOR|Active control group|The active control group receives six weeks of a stretching exercise.
62270806|NCT03673683|ACTIVE_COMPARATOR|Usual Care|Sedation and ventilation weaning that is non-protocol-based and primarily medically-driven.
62270807|NCT03673683|EXPERIMENTAL|SANDWICH protocol|A protocol-based intervention for managing sedation and ventilation weaning.
62633056|NCT05180162|EXPERIMENTAL|Cohort 1: Liver Fibrosis|Patients with liver fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
62633057|NCT05180162|EXPERIMENTAL|Cohort 2: Pulmonary Fibrosis|Patients with pulmonary fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
62633058|NCT05180162|EXPERIMENTAL|Cohort 3: Myocardial Fibrosis|Patients with myocardial fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
62065892|NCT02523521|EXPERIMENTAL|Bronchopylmonary Dysplasia Intervention|physical activity program.
62065893|NCT02523521|NO_INTERVENTION|Healthy children|Nothing.
62270808|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
62270809|NCT06494995|EXPERIMENTAL|Hybrid RT|Patients will receive treatment of low-dose radiotherapy and cadonilimab, combined with selective lesions stereotactic radiotherapy.
62270810|NCT06494995|EXPERIMENTAL|Metronomic chemotherapy and LDRT|Patients will receive treatment of low-dose radiotherapy and cadonilimab, combined with capecitabine metronomic chemotherapy.
62270811|NCT02412800||Acute lung injury|Postoperative acute lung injury was diagnosed according to the latest 2012 Berlin definition of acute respiratory distress syndrome by the PaO2/FiO2\< 300 and acute onset of bilateral infiltrates on the chest radiograph that were not fully explained by cardiac failure during postoperative day 1 to postoperative day 3.
62452821|NCT05351164|EXPERIMENTAL|Patients with MSL|
62452822|NCT04531228|EXPERIMENTAL|Experimental: TACE-HAIC plus lenvatinib|chemo-lipiodolization, followed by FOLFOX-based chemotherapy artery infusion (HAIC). Lenvatinib was administrated two or four days after TACE-HAIC.
62452823|NCT02192736|OTHER|Intra-nasal infusion of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally
62065894|NCT05835882|EXPERIMENTAL|Liver transplant recipients receiving blood donors' transfusion|Liver transplant recipients in which donor blood was collected and intraoperatively transfused to recipients.
62065895|NCT01350895||Experimental Group|
62065896|NCT01350895||Control Group|
62065897|NCT04289701||Hypertension Cohort|"Hypertension patients recruited in the Hypertension Prevention and Control Initiative in China project."
62065898|NCT01589562|ACTIVE_COMPARATOR|Megace 800mg/20ml|Fed condition
62065899|NCT01589562|EXPERIMENTAL|DW-ES(B) 625mg/5ml|Fed condition
62065900|NCT03066622|ACTIVE_COMPARATOR|Standard of Care|IV Morphine or any medication per attending decision
62065901|NCT03066622|EXPERIMENTAL|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
62452824|NCT03828942||Hematological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
62065902|NCT05031676|EXPERIMENTAL|group 1|Intervention consists at induction : direct intravenous lidocaine 1.5 mg/kg; clonidine 2 μg/kg in 250 ml of isotonic saline, started as soon as the venous route is taken and over a period of approximately 15 minutes; magnesium sulfate 50 mg/kg in the same isotonic saline as clonidine.
62270812|NCT05564065|ACTIVE_COMPARATOR|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
62452825|NCT00337571|EXPERIMENTAL|A1|5 mg
62633059|NCT02131064|ACTIVE_COMPARATOR|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m\^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter\* minute (mg/mL\*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
62633060|NCT02131064|EXPERIMENTAL|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
62633061|NCT04712136|EXPERIMENTAL|Cardiac disease|Children aged of 6 to 18 years old with an inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or those with an inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy).
62633062|NCT04712136|SHAM_COMPARATOR|Control group|Children aged 6 to 18 years old referred to the paediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography.
62633063|NCT01492504||Subjects with chronic hepatitis C|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C
62633064|NCT02842372||Ectoin Dermatitis Cream 7%|Cream for symptomatic treatment and relief of skin redness and itching experienced with various types of inflammatory dermatoses.
62633065|NCT02791529|ACTIVE_COMPARATOR|Scalpel|Skin incision performed by scalpel
62633066|NCT02791529|EXPERIMENTAL|Electrocautery|Skin incision performed by electrocautery
62633067|NCT04474808|EXPERIMENTAL|L-arginine-containing foot cream|The participants apply one foot (randomized assignment) with the L-arginine-containing foot cream twice a day (morning and evening) over a period of six weeks.
62633068|NCT04474808|ACTIVE_COMPARATOR|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the Urea-containing foot cream twice a day (morning and evening) over a period of six weeks.
62633069|NCT02480881|EXPERIMENTAL|Single Sequence A, B, C, and D|Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
62633070|NCT01001312|EXPERIMENTAL|Daxor Blood Volume Analysis|Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
62633071|NCT01001312|ACTIVE_COMPARATOR|Clinical volume status assessment|Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.
62065903|NCT05031676|NO_INTERVENTION|group 2|In classic induction: fentanyl at a dose of 2 µg/kg. Following induction in all patients consisted of the administration of propofol 2-3 mg/kg in titration, rocuronium 0.6 mg/kg, ketamine 0.5 mg/kg, methylprednisolone 120 mg.
62065904|NCT01540565|EXPERIMENTAL|Treatment (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62065905|NCT02783222|ACTIVE_COMPARATOR|Arm B|Nab-paclitaxel 125 mg/mq weekly for 3 out of every 4 weeks
62065906|NCT02783222|EXPERIMENTAL|Arm A|Nab-paclitaxel 100 mg/mq weekly for 3 out of every 4 weeks
62065907|NCT00032344|OTHER|1|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
62065908|NCT05263999|EXPERIMENTAL|Itolizumab (EQ001)|Itolizumab (EQ001) administered in a blinded fashion by intravenous infusion every 2 weeks for a total of 7 doses.
62270813|NCT05564065|ACTIVE_COMPARATOR|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
62270814|NCT05541965|EXPERIMENTAL|Median score distributions of the reflexology groups, ICIQ-SF, IQOL and ISI|
62270815|NCT05541965|ACTIVE_COMPARATOR|Median score distributions of the kegel groups, ICIQ-SF, IQOL and ISI|
62270816|NCT05541965|ACTIVE_COMPARATOR|Median score distributions of the control groups, ICIQ-SF, IQOL and ISI|
62270817|NCT03731962|ACTIVE_COMPARATOR|Developed Contrast Induced Nephropathy|Coronary Angiography
62452826|NCT00337571|EXPERIMENTAL|A2|10 mg
62452827|NCT00337571|EXPERIMENTAL|A3|15 mg
62452828|NCT00337571|PLACEBO_COMPARATOR|B1|
62452829|NCT00946257|EXPERIMENTAL|Cohort 1|0.3 mg dose
62065909|NCT05263999|PLACEBO_COMPARATOR|EQ001 Placebo|EQ001 Placebo administered in a blinded fashion by intravenous infusion every 2 weeks for a total of 7 doses
62065910|NCT01788345|EXPERIMENTAL|non-invasive ventilation|
62065911|NCT05068739|EXPERIMENTAL|PA-EMR (Partial ampullary endoscopic mucosal resection)|Partial ampullary endoscopic mucosal resection
62270818|NCT03731962|OTHER|Without CIN|Coronary Angiography
62452830|NCT00946257|EXPERIMENTAL|Cohort 2|0.6 mg dose
62452831|NCT00946257|EXPERIMENTAL|Cohort 3|1.2 mg dose
62452832|NCT00946257|EXPERIMENTAL|Cohort 4|1.8 mg dose
62452833|NCT00946257|EXPERIMENTAL|Cohort 5|2.4 mg dose
62452834|NCT00946257|EXPERIMENTAL|Cohort 6|3.0 mg dose
62065912|NCT05068739|ACTIVE_COMPARATOR|NKF(Needle knife fistulotomy)|Needle knife fistulotomy
62065913|NCT04522180|EXPERIMENTAL|GHR-LRX 120 mg|Participants received GHR-LRX 120 mg subcutaneous (SC) injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
62065914|NCT04522180|EXPERIMENTAL|GHR-LRX 160 mg|Participants received GHR-LRX 160 mg SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
62065915|NCT00977769|EXPERIMENTAL|carbetocin 100 µg|Carbetocin injection, 100µg, single injection
62065916|NCT00977769|ACTIVE_COMPARATOR|oxytocin 5 u|Oxytocin 5U, injection, single injection
62065917|NCT00977769|PLACEBO_COMPARATOR|placebo (NaCl)|Saline single injection
62065918|NCT01566929|NO_INTERVENTION|IVF only|IVFtreatment
62065919|NCT01566929|ACTIVE_COMPARATOR|Weight reduction treatment and IVF|Dietary Supplement: Low calorie diet treatment and then IVFtreatment
62065920|NCT00639821||inflammatory bowel disease|Patients with refractory inflammatory bowel disease (ulcerative colitis and Crohn's disease) before and after treatment with infliximab.
62065921|NCT06463821||pediatric patients|pediatric patients who attended the child-parent sections of the Fangcang shelter hospitals with laboratory-confirmed COVID-19
62065922|NCT06463821||adult patients|adult patients who attended the child-parent sections of the Fangcang shelter hospitals with laboratory-confirmed COVID-19
62065923|NCT02768948|EXPERIMENTAL|telmisartan|treatment with telmisartan at doses of 80 mg / day for 6 months
62065924|NCT02768948|EXPERIMENTAL|losartan|Losartan at a dose of 100 mg / d for 6 months.
62065925|NCT04695340|EXPERIMENTAL|Familial amyloidosis patients|Familial amyloidosis patients with gastro-intestinal pain receiving Psyllium
62065926|NCT04501133|EXPERIMENTAL|Healthy Participants|Healthy participants without motor disorders and medications influencing brain functions will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG is recorded.
62065927|NCT04501133|EXPERIMENTAL|Patients|Participants with Parkinson's Disease or essential tremor will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG and EEG are recorded.
62065928|NCT02826369|EXPERIMENTAL|3.0 Tesla in Magnetic Resonance Imaging|
62065929|NCT02748694|PLACEBO_COMPARATOR|Part 1 (SRD): Placebo Cohorts 1-5|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
62065930|NCT02748694|EXPERIMENTAL|Part 1 (SRD): Cohort 1: TAK-041 5/20 mg|TAK-041 5 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 20 mg, suspension, orally, once on Day 8 in the SRD period.
62065931|NCT02748694|EXPERIMENTAL|Part 1 (SRD): Cohort 2: TAK-041 10/40 mg|TAK-041 10 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 40 mg, suspension, orally, once on Day 8 in the SRD period.
62065932|NCT02748694|EXPERIMENTAL|Part 1 (SRD): Cohort 3: TAK-041 80 mg|TAK-041 80 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
62270819|NCT06329583|OTHER|Diaphragmatic breathing protocol|All patients will undergo the diaphragmatic breathing protocol with high-resolution esophageal manometry.
62270820|NCT00769002|ACTIVE_COMPARATOR|Natural Infection|previously naturally infected
62270821|NCT00769002|ACTIVE_COMPARATOR|FluShield - influenza positivity|prior FluShield ipsilateral vaccinated
62065933|NCT02748694|EXPERIMENTAL|Part 1 (SRD): Cohort 4: TAK-041 120 mg|TAK-041 120 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
62270822|NCT00769002|ACTIVE_COMPARATOR|FluShield - influenza positivity2|prior FluShield contralateral vaccinated
62270823|NCT00769002|ACTIVE_COMPARATOR|FluMist|prior FluMist vaccinated.
62065934|NCT02748694|EXPERIMENTAL|Part 1 (SRD): Cohort 5: TAK-041 160 mg|TAK-041 160 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
62065935|NCT02748694|PLACEBO_COMPARATOR|Part 2 (MRD): Placebo Cohorts 1-4|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the multiple-rising dose (MRD) period.
62065936|NCT02748694|EXPERIMENTAL|Part 2 (MRD): Cohort 1: TAK-041 40/20 mg|TAK-041 40 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 20 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
62065937|NCT02748694|EXPERIMENTAL|Part 2 (MRD): Cohort 2: TAK-041 80/40 mg|TAK-041 80 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 40 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
62065938|NCT02748694|EXPERIMENTAL|Part 2 (MRD): Cohort 3: TAK-041 120/60 mg|TAK-041 120 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 60 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
62065939|NCT02748694|EXPERIMENTAL|Part 2 (MRD): Cohort 4: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
62065940|NCT02748694|EXPERIMENTAL|Part 3: Relative Bioavailability (RBA)/Food Effect: Regimen A|TAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1.
62065941|NCT02748694|EXPERIMENTAL|Part 3: RBA/Food Effect: Regimen B|TAK-041 40 mg, tablet, orally, once on Day 1 in fed state (Regimen B) in Cohort 2.
62270824|NCT05450146|EXPERIMENTAL|Partner in Balance (intervention group)|"Informal caregivers assigned to the intervention group will receive the 8-week online selfmanagement program Partner in Balance (Boots, 2018)."
62270825|NCT05450146|NO_INTERVENTION|Usual/standard care (control group)|"Participants in the comparison condition will continue to receive the care as usual.~The control group will be shared with another collaborating study from the 'Vrije Universiteit of Amsterdam'), which has the same goals, applies the same inclusion criteria, applies the same study procedures, and obtains the same outcomes. This implies that the data of the participants recruited for the control group for this study will be shared with the collaborating study."
62270826|NCT02658123|ACTIVE_COMPARATOR|Group A: Standard of care|"* Standard of care pre-operative education~* Standard of care home health visits~* Standard of care follow-up post-operative visits with surgeon and CWOCN~* At 30-days post hospital discharge, the participant will:~  * See the physician~ * Turn in Patient Data Collection Form~ * Turn in Healthcare Utilization Form~ * Complete The City of Hope QOL Survey for Ostomy Patients~ * Ostomy assessment with a CWOCN, including photo of ostomy site"
62270827|NCT02658123|EXPERIMENTAL|Group B: Phone call|"* Standard of care pre-operative education~* Standard of care home health visits~* Standard of care follow-up post-operative visits with surgeon and CWOCN~* Telephone call 48-72 hours post-discharge from CWOCN/PA to evaluate tolerability to foods/fluids, activity level, screen for red-flags, review/assess for medication, reviewing pouching of ostomy, review patient's ability to obtain supplies, provide continued education, discuss proper use of durable medical equipment/frequency of pouch changes, and complete Patient Assessment Form.~* At 30-days post hospital discharge, the participant will:~  * See the physician~ * Turn in Patient Data Collection Form~ * Turn in Healthcare Utilization Form~ * Complete The City of Hope QOL Survey for Ostomy Patients~ * Ostomy assessment with a CWOCN, including photo of ostomy site"
62270828|NCT01436539|EXPERIMENTAL|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
62270829|NCT01436539|ACTIVE_COMPARATOR|Adefovire Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
62270830|NCT04036708|EXPERIMENTAL|MISC and WTM|Wetting method (WTM)+ Mediational Intervention for Sensitizing Caregivers (MISC) bi-weekly for 12 months.
62065942|NCT02748694|PLACEBO_COMPARATOR|Part 4: MRD: Placebo|TAK-041 placebo-matching, suspension, orally, on Days 1, 8, 15 and 22 in participants with schizophrenia
62065943|NCT02748694|EXPERIMENTAL|Part 4: MRD: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in participants with schizophrenia.
62065944|NCT00713674|NO_INTERVENTION|1|No Treatment
62270831|NCT04036708|ACTIVE_COMPARATOR|WTM only|WTM trainings only (recommended standard of care) bi-weekly for 12 months.
62270832|NCT05101603|ACTIVE_COMPARATOR|Control|Only non surgical periodontal treatment
62270833|NCT05101603|EXPERIMENTAL|Test|Nd:YAG Laser and air abrasive combined application addition to non surgical periodontal treatment
62270834|NCT03189875||Observation|Cohort of patients with moderate-to-severe SLE
62270835|NCT00506883|EXPERIMENTAL|High Dose Colchicine|After confirmation of a gout flare, patients were to begin standard dosing of colchicine 4.8mg (two capsules (1.8mg) initially followed by additional one capsule doses (0.6mg) every hour for an additional 6 doses).
62065945|NCT00713674|EXPERIMENTAL|2|Theraworx intranasal
62065946|NCT00713674|ACTIVE_COMPARATOR|3|mupirocin antibiotic ointment intranasal
62065947|NCT03996941||seguiPrEP|MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.
62065948|NCT04780698|EXPERIMENTAL|Study Cohort|
62065949|NCT04988425|EXPERIMENTAL|TNFα monoclonal antibody group|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
62633072|NCT04617119|EXPERIMENTAL|Conventional physical therapy treatment and IMT|"The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.~In addition, the patient will receive inspiratory muscle training (IMT) by using a threshold IMT device. Patient will ask to use the device twice daily. In each time, patient will perform 3 sets of 10 breaths with 1-minute rest between sets.~Exercise intensity will start with 10 % of pre-measured maximal inspiratory pressure.~Once the patient successfully completed 30 breath twice a day, the exercise load will increase 5% more in the subsequent training session.~This treatment protocol will perform daily for 2 weeks."
62633073|NCT04617119|ACTIVE_COMPARATOR|Conventional physical therapy|The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
62270836|NCT00506883|EXPERIMENTAL|Low Dose Colchicine|Within 12 hours of a confirmed gout flare, patients were to begin the low dose colchicine regimen consisting of a total dose of 1.8 mg - two colchicine capsules initially (1.2 mg)followed an hour later by a single additional capsule of active drug(0.6 mg)then by 5 additional hourly doses of an identical looking placebo capsules
62270837|NCT00506883|PLACEBO_COMPARATOR|Placebo|
62286912|NCT01349647|EXPERIMENTAL|Vaccine Alone|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
62633074|NCT03997097|EXPERIMENTAL|sildenafil|• Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day (t.i.d.), as defined in the marketing authorization indicated for PAH in adolescent and adult patients, and for a period of 6 months.
62633075|NCT03997097|PLACEBO_COMPARATOR|placebo|• Patients in the group 2 will receive a placebo (t.i.d.), for the same period of 6 months. To guarantee the double blind, capsules will be similar in size and colour and will be differentiated only by a vial number regarding to the randomization list
62633076|NCT05627050|EXPERIMENTAL|AR Training System|The subjects follow the daily rehabilitation training program designed by clinical and healthcare team. The system will monitor their movement and provide feedbacks to the users. The clinicians/healthcare workers can provide feedbacks and guidance to correct their movements and postures.
62633077|NCT01893697||Healthy Participants|HRCT scan in a specific postural position
62270838|NCT03716349|EXPERIMENTAL|System A|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system w/Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan), informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment, clinical assessment
62270839|NCT03716349|ACTIVE_COMPARATOR|System B|ScotchBond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M) will randomly be applied to the other tooth informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment and clinical assessment at periodic timepoints.
62270840|NCT00160459|EXPERIMENTAL|1|
62270841|NCT00160459|EXPERIMENTAL|2|
62270842|NCT00160459|EXPERIMENTAL|3|
62270843|NCT00160459|PLACEBO_COMPARATOR|4|
62270844|NCT02961556|EXPERIMENTAL|AJG555|After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.
62270845|NCT00797823|PLACEBO_COMPARATOR|Insulin + Placebo|Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.
62270846|NCT00797823|ACTIVE_COMPARATOR|Insulin + Glucagon|Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.
62270847|NCT00797823|EXPERIMENTAL|Pilot Study|Pilot studies designed to assess safety of the system. Includes 6 participants undergoing 7 studies.
62270848|NCT01100437|EXPERIMENTAL|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules crushed and mixed in solution and administered orally at each patient's stable dose, given either once daily or twice daily.
62452835|NCT06401083|ACTIVE_COMPARATOR|Pre-extubational caffeine-citrate|Participants will receive 20 mg/kg loading dose of caffeine citrate on the first day of life and after that 5-10 mg/kg maintenance dose each day. On this arm, the participants will receive 20 mg/kg caffeine dose once again before the planned extubation.
62270849|NCT01100437|EXPERIMENTAL|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily
62270850|NCT00372502|ACTIVE_COMPARATOR|1|
62452836|NCT06401083|NO_INTERVENTION|Routine care|Participants will receive 20 mg/kg loading dose of caffeine citrate on the first day of life and after that 5-10 mg/kg maintenance dose each day, also on the day of the extubation.
62633078|NCT01628848|EXPERIMENTAL|SPM 962|SPM 962 transdermal patch
62633079|NCT01628848|PLACEBO_COMPARATOR|Placebo|Placebo transdermal patch
62633080|NCT02777905|EXPERIMENTAL|MBCT intervention|"Mindfulness Based Cognitive therapy (MBCT) will consist of group meditative practices, lasting 2 hours per week (or whatever the patient can tolerate). The interventions will be conducted at the centre local de services communautaires (CLSC) Benny Farm, once a week. Patients will be invited to try various techniques during sessions. The patients will be encouraged to practice the Mindfulness techniques, that includes formal mindfulness meditation and informal mindfulness practices (e.g. being in the present moment while not meditating), at home, between sessions, and will be provided with meditation compact discs to help them do so. MBCT interventions also include a cognitive therapy perspective. Specifically, the interventionists will offer education regarding depression and anxiety and will work on automatic mental processes that are believed to be at the root of the recurrence of depressive and anxious symptoms."
62065950|NCT04988425|ACTIVE_COMPARATOR|Methylprednisolone group|Injection of 500mg of methylprednisolone immediately after admission before surgery.
62270851|NCT00372502|EXPERIMENTAL|2|
62270852|NCT01535781|PLACEBO_COMPARATOR|Placebo|Patients are given saline instead of tranexamic acid in the placebo group
62270853|NCT01535781|ACTIVE_COMPARATOR|Tranexamic Acid|Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.
62452837|NCT00958243|PLACEBO_COMPARATOR|Placebo|Placebo
62452838|NCT00958243|EXPERIMENTAL|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose
62452839|NCT00958243|EXPERIMENTAL|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose
62452840|NCT04305964|EXPERIMENTAL|Nastent® users|Patients with an established diagnosis of obstructive sleep apnea with apnea/hypopnea-index (AHI) \< 20/ hour sleep who receive Nastent® as treatment modality
62452841|NCT00857636|EXPERIMENTAL|Health Literacy|
62452842|NCT01714570|EXPERIMENTAL|piperacillin/tazobactam|
62452843|NCT01714570|ACTIVE_COMPARATOR|imipenem/cilastatin|
62452844|NCT01906541|EXPERIMENTAL|ex-vivo gene-therapy|transplantation of genetically modified autologous CD34+ cells
62065951|NCT04988425|PLACEBO_COMPARATOR|Control group|Injection of the same volume of saline immediately after admission before surgery.
62065952|NCT03070509|EXPERIMENTAL|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
62065953|NCT03070509|EXPERIMENTAL|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
62065954|NCT05799937||Group-A Smokers|smoker patients will be recruited in this group
62633081|NCT02777905|NO_INTERVENTION|Control Group|Patients randomized to the control group will be offered literature on mental health promotion and will receive treatment as usual in the primary care health center setting. After the end of the study, the control group will be offered MBCT.
62065955|NCT05799937||Group-B Non-Smokers|non smokers or patients who had quit smoking will be recruited in this group
62270854|NCT06426069||Periodontally Healthy|Complete periodontal examination will be done comprising of recording pocket probing depth (PPD), clinical attachment level (CAL) at six sites per tooth, bleeding on probing (BOP), plaque index (PI) and gingival index (GI) and mobility. Objective Masticatory Performance will be evaluated using colour mixing ability of a chewing gum. Subjective masticatory performance will be calculated using The Quality of Masticatory Function Questionnaire.
62270855|NCT06426069||Stage I Periodontitis|Complete periodontal examination will be done comprising of recording pocket probing depth (PPD), clinical attachment level (CAL) at six sites per tooth, bleeding on probing (BOP), plaque index (PI) and gingival index (GI) and mobility. Objective Masticatory Performance will be evaluated using colour mixing ability of a chewing gum. Subjective masticatory performance will be calculated using The Quality of Masticatory Function Questionnaire.
62270856|NCT06426069||Stage II Periodontitis|Complete periodontal examination will be done comprising of recording pocket probing depth (PPD), clinical attachment level (CAL) at six sites per tooth, bleeding on probing (BOP), plaque index (PI) and gingival index (GI) and mobility. Objective Masticatory Performance will be evaluated using colour mixing ability of a chewing gum. Subjective masticatory performance will be calculated using The Quality of Masticatory Function Questionnaire.
62452845|NCT01870661|EXPERIMENTAL|Long axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
62452846|NCT01870661|ACTIVE_COMPARATOR|Short axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
62633082|NCT01345812|ACTIVE_COMPARATOR|urine-derived FSH|Follicle stimulating hormone
62452847|NCT03428594|EXPERIMENTAL|CKD-11101|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
62452848|NCT03428594|ACTIVE_COMPARATOR|NESP|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
62452849|NCT06073249|EXPERIMENTAL|Auricular vagus stimulation:|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear (auricle). Somatosensory innervation is provided by the auricular branch. The name of this device is vagustim device, which consists of a TENS device placed in the outer ear; headphones that can be selected to the size of the individual's ear and a TENS device in which stimulation current is given superficially. In our study, we will perform the application non-invasively by stimulating the branch of the vagus nerve in the auricle. The application time will take 20 minutes.
62065956|NCT04770753|EXPERIMENTAL|Mitapivat|"Double-blind Period: Participants will receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 24 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
62065957|NCT04770753|PLACEBO_COMPARATOR|Placebo|"Double-blind Period: Participants will receive placebo matching mitapivat, orally, BID for 24 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
62065958|NCT03739775|OTHER|Blood sampling|
62065959|NCT03072225|EXPERIMENTAL|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
62065960|NCT03072225|PLACEBO_COMPARATOR|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
62065961|NCT02133482|EXPERIMENTAL|BI 639667|single rising doses given as oral solution
62065962|NCT02133482|PLACEBO_COMPARATOR|Placebo|placebo solution
62088184|NCT00618670|EXPERIMENTAL|1|Home-based program with progressive increases in exercise duration and intensity (i.e., cadence); walking duration will be longer for the home-based group because the intensity of walking will be lower than the graded treadmill walking performed by the supervised group
62452850|NCT06073249|ACTIVE_COMPARATOR|Tibial Nerve Stimulation|The nervus tibialis approaches the surface when it approaches the medial malleolus. In this study, transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus at the point where the nervus tibialis contacts the surface and approximately bilaterally.
62633083|NCT01345812|ACTIVE_COMPARATOR|recombinant FSH|Follicle stimulation hormone
62633084|NCT04663685|EXPERIMENTAL|Single Arm|This was the only arm in the study. All participants were allocated to this arm, where they received an 8-week remotely-delivered exercise and nutrition program.
62633085|NCT03182790|EXPERIMENTAL|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
62633086|NCT03182790|EXPERIMENTAL|Group B|COSH booklet + general brief advices +Placebo Messages
62065963|NCT04306939||Case/Chronic complex disorders|Chronic complex disorders are composed of multiple population sub classifications - many of which have not been fully defined. Thus, all eligible patients should be included to maximize study power. Sufficient numbers of controls, those individuals in the general population, who may or may not have complex disorders are needed to match future comparison studies for a subset of questions, and so should also be included.
62065964|NCT04306939||Control|The number of controls that are anticipated for this study is less than patient numbers since they will not be needed for calculating the minor allele frequency of the majority of genetic polymorphism of interest in genetic association studies. This data is already available in public and research databases. Controls will be useful for evaluating case report form questions, providing assessment of the local genetic pool, and for possibly participating in future studies as provided by the consent.
62065965|NCT03241602|ACTIVE_COMPARATOR|group of Pulmonary recruitment & Intraperitoneal libocai|
62065966|NCT03241602|ACTIVE_COMPARATOR|Group of Intraperitoneal lidocaine|
62633087|NCT05504837|EXPERIMENTAL|Cohort 1 (open label)|A single administration of KB407
62065967|NCT03241602|ACTIVE_COMPARATOR|Group of pulmonary recruitment|
62633088|NCT05504837|EXPERIMENTAL|Cohort 2 (open label)|Two administrations of KB407
62065968|NCT03241602|NO_INTERVENTION|group receive passive exsufflation through port|
62065969|NCT03798834|EXPERIMENTAL|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
62452851|NCT04073147|EXPERIMENTAL|Dosing group 1|Venetoclax 600mg + Obinutuzumab 1000mg
62452852|NCT04073147|EXPERIMENTAL|Dosing group 2|Venetoclax 800mg + Obinutuzumab 1000mg
62633089|NCT05504837|EXPERIMENTAL|Cohort 3 (open label)|Four administrations of KB407
62633090|NCT05470244|ACTIVE_COMPARATOR|Therapeutic Exercise Group|This group will receive Routine Physical therapy protocol along with prescribed intra-venous regimen.
62633091|NCT05470244|EXPERIMENTAL|TENS Plus Therapeutic Exercise Group|This group will receive high frequency Transcutaneous Electrical Nerve Stimulation with routine physical therapy and prescribed intra-venous regimen.
62633092|NCT05030233|EXPERIMENTAL|Nurse-Administered Touch Intervention|Preterm infants will receive the nurse-administered touch intervention during one episode of essential nursing care.
62065970|NCT03798834|PLACEBO_COMPARATOR|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
62065971|NCT02172703|OTHER|Non-invasive ICP measurement|non-invasive ICP measurement with NON-INVASIVE ICP ABSOLUTE VALUE METER (carried out simultainusly with standard invasive ICP measurement catheter and probes)
62065972|NCT02932969|EXPERIMENTAL|Panel 1 Arm|BMS-986231 and BMS-986231 Placebo intravenously
62065973|NCT02932969|EXPERIMENTAL|Panel 2 Arm|BMS-986231 and BMS-986231 Placebo intravenously
62065974|NCT02932969|EXPERIMENTAL|Panel 3 Arm|BMS-986231 and BMS-986231 Placebo intravenously
62065975|NCT04022005|EXPERIMENTAL|Chidamide combined with R-GemOx|Chidamide, 20 mg,twice per week; Rituximab 375mg/m2, d1, intravenous drip; Gemcitabine 1000mg/m2, d2, intravenous drip; Oxaliplatin 100mg/m2, d2,intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive chidamide maintenance therapy.
62633093|NCT05030233|NO_INTERVENTION|Standard Care|Preterm infants will receive one episode of essential nursing care delivered as standard care.
62633094|NCT01951599|EXPERIMENTAL|AZD9291 20mg (oral capsule fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.
62633095|NCT01951599|EXPERIMENTAL|AZD9291 20mg (oral solution fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.
62065976|NCT03533634|EXPERIMENTAL|superior group|this group with midshaft clavicle fracture were treated with superior reconstruction plate
62452853|NCT04073147|EXPERIMENTAL|Dosing group 3|Venetoclax 1000mg + Obinutuzumab 1000mg
62633096|NCT01951599|EXPERIMENTAL|AZD9291 20mg (oral tablet fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.
62633097|NCT01951599|EXPERIMENTAL|AZD9291 20mg (oral fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.
62633098|NCT01951599|EXPERIMENTAL|AZD9291 20mg (oral fed)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.
62065977|NCT03533634|EXPERIMENTAL|anteroinferior group|this group with midshaft clavicle fracture were treated with anteroinferior reconstruction plate
62270857|NCT06426069||Stage III Periodontitis|Complete periodontal examination will be done comprising of recording pocket probing depth (PPD), clinical attachment level (CAL) at six sites per tooth, bleeding on probing (BOP), plaque index (PI) and gingival index (GI) and mobility. Objective Masticatory Performance will be evaluated using colour mixing ability of a chewing gum. Subjective masticatory performance will be calculated using The Quality of Masticatory Function Questionnaire.
62452854|NCT05435508|EXPERIMENTAL|Pain Neurosicence Education + Pre-anesthetic Assessment|Pain neuroscience education + Pre-anesthetic Assessment. Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system.
62633099|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
62633100|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
62633101|NCT03227731|ACTIVE_COMPARATOR|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
62633102|NCT03227731|NO_INTERVENTION|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation
62633103|NCT05876429|ACTIVE_COMPARATOR|Pre-Intervention: Current Transfer Process|Control: Transfer patients are admitted per usual based on existing processes for GMS, Cardiology, and Oncology services. Data collection assesses clinician reported feedback on the logistics for each patient transfer, and issues along the transfer supply chain.
62633104|NCT05876429|EXPERIMENTAL|Post-Intervention: Implementing Standardized Accept Note|Intervention Arm: After engaging stakeholders and finalizing a standardized accept note for transfer patients, appropriate staff will be trained on the use of the note and the note will be implemented in the transfer patient admission process. Data collection will assess clinician reported feedback on the logistics for each patient transfer, and issues along the transfer supply chain, post-intervention.
62633105|NCT04712409|ACTIVE_COMPARATOR|SADI-S as a primary surgery|
62633106|NCT04712409|ACTIVE_COMPARATOR|BPD-DS as a primary surgery|
62633107|NCT04712409|ACTIVE_COMPARATOR|SADI-S as a revisional procedure|
62633108|NCT04712409|ACTIVE_COMPARATOR|BPD-DS as a revisional procedure|
62633109|NCT01042821|ACTIVE_COMPARATOR|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
62065978|NCT04154865|EXPERIMENTAL|Enrolled, eligible|Single arm for eligible subjects
62065979|NCT04566588|EXPERIMENTAL|Early apical release holmium enucleation of the prostate|Early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
62065980|NCT04566588|ACTIVE_COMPARATOR|Classic holmium enucleation of the prostate|Classic holmium enucleation of the prostate (HoLEP), as a surgical treatment for benign prostatic hyperplasia
62633110|NCT01042821|ACTIVE_COMPARATOR|Group 2|The flap comprised mucosa, submucosa only
62633111|NCT04178408||Cases|Cases of inflammatory bowel disease
62633112|NCT04178408||Controls|Two controls per case. 1. Sibling or other second degree relative of similar age. 2. neighbourhood control matched for age
62633113|NCT00713271|EXPERIMENTAL|1|Low dose
62065981|NCT01238549||Spinal Cord Injury|Participants with SCI
62065982|NCT04235634||Intra-arterial Prostglandin therapy|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
62452855|NCT05435508|OTHER|Pre-anesthetic Assessment (Usual Care)|The pre-anesthetic assessment is the clinical study that allows evaluating the physical condition, personal, pathological and surgical history together with laboratory tests to be able to establish a surgical risk in order to define the best anesthetic plan that the patient requires according to the surgical event.
62633114|NCT00713271|EXPERIMENTAL|2|intermediate dose
62633115|NCT00713271|EXPERIMENTAL|3|high dose
62633116|NCT00713271|PLACEBO_COMPARATOR|4|
62633117|NCT00959348||Asthma|Asthma patients on inhaled corticosteroids
62452856|NCT01238848|EXPERIMENTAL|Hypertonic|Nebulized hypertonic saline (sodium chloride 3%) + albuterol
62452857|NCT01238848|ACTIVE_COMPARATOR|Normal|Normal saline (sodium chloride 0.9%) + albuterol
62452858|NCT04613830|ACTIVE_COMPARATOR|Erector spinae group|patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae.
62633118|NCT00959348||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
62633119|NCT04078971|EXPERIMENTAL|Ketogenic diet|Ketogenic diet: less than 30 g/day of carbohydrate. Subjects can eat beef, veal, poultry, fish, raw and cooked vegetables without restriction, cold cuts such as dried beef, eggs and seasoned cheese (parmesan), ketogenic pasta (selected with a ketogenic ratio of 4:1), fruits with the lowest glycemic index (blueberry, raspberry), raw nuts and seeds, ghee butter, plant oils and fats from avocado, coconut and olives
62633120|NCT04078971|ACTIVE_COMPARATOR|Western diet|The western diet (WD) is composed mainly of whole cereals (spelt, rye, oat) and pseudo-cereals (buckwheat, quinoa, amaranth), whole grain pasta, potatoes, meet, fish, vegetables, fruit, legumes, olive oil, milk and red wine (at most 1 glass per day). It ensure a constant energy and macronutrient balance: protein 1.8g x Kg-1 x body weight-1 x day-1, (30%), fats 20-25% and carbohydrate 50-55%.
62633121|NCT02689804|OTHER|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
62633122|NCT02689804|OTHER|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
62633123|NCT05304988||Developing and testing of EFT|It aims to develop a patient-based assessment tool by our research members for adolescents with cancer in Hong Kong.
62633124|NCT01971814|EXPERIMENTAL|Early infliximab monitoring group.|A consecutive sample of patients hospitalized with severe ulcerative colitis who are eligible to receive infliximab at 10mg/kg IV.
62452859|NCT04613830|PLACEBO_COMPARATOR|Opioid GROUP|Patient in group T will intravenously administrate dose of 1 mg/kg/8hr tramal ( opioid) to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic.
62633125|NCT05924659|EXPERIMENTAL|Neurofeedback Training|1 week of cerebral training with a neurofeedback strategy based on increased alpha EEG activity
62452860|NCT00429806|PLACEBO_COMPARATOR|Placebo|Placebo suppository; once daily for 7 days.
62452861|NCT00429806|EXPERIMENTAL|DHEA 0.50%|DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
62452862|NCT00429806|EXPERIMENTAL|DHEA 1.0%|DHEA 1.0% (13 mg) suppository; once daily for 7 days.
62452863|NCT00429806|EXPERIMENTAL|DHEA 1.8%|DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.
62633126|NCT05924659|SHAM_COMPARATOR|Control|1 week of cerebral training with a strategy based on time on task increase of performance, without neurofeedback
62270858|NCT06426069||Stage IV Periodontitis|Complete periodontal examination will be done comprising of recording pocket probing depth (PPD), clinical attachment level (CAL) at six sites per tooth, bleeding on probing (BOP), plaque index (PI) and gingival index (GI) and mobility. Objective Masticatory Performance will be evaluated using colour mixing ability of a chewing gum. Subjective masticatory performance will be calculated using The Quality of Masticatory Function Questionnaire.
62270859|NCT01423799|EXPERIMENTAL|Nutritional product|Nutritional intervention containing immuno-nutrients
62270860|NCT01423799|ACTIVE_COMPARATOR|Control Group|Isocaloric and isonitrogenous control without immuno nutrients.
62452864|NCT02253979|PLACEBO_COMPARATOR|standard double lumen tube|Intervention: Standard double lumen tube
62452865|NCT02253979|EXPERIMENTAL|VivaSight double lumen tube|Intervention: VivaSight double lumen tube
62452866|NCT01818856|EXPERIMENTAL|Telaprevir interactions|"Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.~Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours"
62452867|NCT05182632|EXPERIMENTAL|Group pelvic floor tele-rehabilitation|12 weekly treatment online sessions + daily home exercise program
62452868|NCT01032369|EXPERIMENTAL|CBT|with behavioral intervention-CBT.
62452869|NCT01032369|OTHER|Without CBT|Without behavioral intervention-CBT
62452870|NCT04438005|EXPERIMENTAL|ICP-022|
62452871|NCT01415778|EXPERIMENTAL|Active 1|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
62065983|NCT04535323|EXPERIMENTAL|Treatment of GSM (platelet rich plasma)|Patients receive platelet rich plasma via injection into the vaginal area.
62270861|NCT04839731|PLACEBO_COMPARATOR|Placebo group|10 patients will be divided into 7 and 14 day treatment groups with 5 patients each. They will apply Nourivan base cream from Pure Science Rx, twice per day for their designated time.
62270862|NCT04839731|EXPERIMENTAL|7 day medication group|The 7 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 7 days.
62270863|NCT04839731|EXPERIMENTAL|14 day medication group|The 14 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 14 days.
62270864|NCT01070264|EXPERIMENTAL|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
62270865|NCT03910556||no complication|the patients who did not develop any kind of complication and no re-craniotomy
62270866|NCT03910556||with complication (s)|the patients who developed at least one of non-neurological complication or required re-craniotomy
62270867|NCT01412593|EXPERIMENTAL|Stem cell transplant|
62270868|NCT01412593|NO_INTERVENTION|Control|
62270869|NCT01294670|EXPERIMENTAL|Vorinostat and Etoposide|This is a multi-center, open label, phase I/II trial of escalating doses of vorinostat in combination with etoposide.
62452872|NCT01415778|EXPERIMENTAL|Active 2|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
62452873|NCT01415778|EXPERIMENTAL|Active 3|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
62633127|NCT03331263|EXPERIMENTAL|Abdominal application of 2% CHG|
62633128|NCT03331263|EXPERIMENTAL|Groin application of 2% CHG|
62633129|NCT03331263|NO_INTERVENTION|Control treatment with no application|
62633130|NCT00920777|EXPERIMENTAL|8 weeks CBT|
62633131|NCT00920777|ACTIVE_COMPARATOR|Control group|
62633132|NCT00920777|EXPERIMENTAL|16 weeks CBT|
62633133|NCT03248648|ACTIVE_COMPARATOR|Neostigmine group|At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
62633134|NCT03248648|ACTIVE_COMPARATOR|ketamine group|At the end of the surgery patients receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
62270870|NCT02592850|EXPERIMENTAL|Osteopathic Manipulative Treatment|Active manipulative treatment.
62270871|NCT02592850|SHAM_COMPARATOR|Sham Osteopathic Manipulative Treatment|Sham manipulative treatment.
62633135|NCT02169505|EXPERIMENTAL|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
62065984|NCT03976453||Group A|Women who underwent caesarean hysterectomy
62065985|NCT03976453||Group B|Women who underwent lower segment caesarean section
62065986|NCT03976453||Group C|Women who underwent spontaneous Vaginal delivery
62270872|NCT03393273|EXPERIMENTAL|Elotuzumab|This is a single arm phase II trial to assess the Very Good Partial Response rate of a strategy involving autologous hematopoietic stem cell transplantation, after intensive treatment and followed by consolidation phase, with elotuzumab, dexamethasone, velcade, and thalidomide in elderly patients.
62270873|NCT06319105||Standard intervention: Offer PrEP choice|Offer pre-exposure prophylaxis choice between oral and long-acting injectable cabotegravir for pre-exposure prophylaxis across 36 study sites.
62270874|NCT00757250|EXPERIMENTAL|1|Dose Cohort 1: 50 mcg/kg/day of TXA127
62270875|NCT00757250|EXPERIMENTAL|2|Drug Cohort 2: 100 mcg/kg/day TXA127
62270876|NCT00757250|EXPERIMENTAL|3|Drug Cohort 3: 200 mcg/kg/day TXA127
62270877|NCT00757250|EXPERIMENTAL|4|Drug Cohort 4: 300 mcg/kg/day TXA127
62270878|NCT00757250|EXPERIMENTAL|5|Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.
62270879|NCT03991689|EXPERIMENTAL|the six weeks solution-focused pain management groups|
62270880|NCT05442307|EXPERIMENTAL|asthma education|The general practices in this arm will receive the education visits about asthma.
62270881|NCT05442307|PLACEBO_COMPARATOR|Other education|The general practices in this arm will receive an educational visit on another topic (PPI).
62270882|NCT06128460|EXPERIMENTAL|Concurrent themoradiotherapy Followed by Zimberelimab|"1. Radiotherapy: Intensity modulated conformal radiation therapy (IMRT) is used for external irradiation, and the pelvic target volume dose (PTV) is: 45-50 Gy/1.8Gy/25-28f; the stump margin is positive, and after the external irradiation is completed, Additional CT-guided three-dimensional conformal brachytherapy, HR-CTV: 24--30Gy/4-5f.~2. Concurrent chemotherapy: performed during external radiotherapy. Starting from the first week of radiochemotherapy, cisplatin 40 mg/m2 was given. Chemotherapy is given every 7 days, up to 5-6 times;~3. Zimberelimab injection: 240 mg/time, intravenous infusion, administered every 21 days, starting within four weeks after completing concurrent chemoradiotherapy, and maintained for 8 cycles"
62270883|NCT00950508|ACTIVE_COMPARATOR|High volume plasma exchange|3 successive plasma exchanges over 3 days
62270884|NCT00950508|PLACEBO_COMPARATOR|Standard medical treatment|
62270885|NCT03248401|EXPERIMENTAL|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
62270886|NCT03248401|ACTIVE_COMPARATOR|Aspirin group|Aspirin 100 mg
62270887|NCT02057315|EXPERIMENTAL|ELS-M11|Topical 5% ELS-M11 (3 g)
62270888|NCT02057315|PLACEBO_COMPARATOR|Placebo|A matching formulation with no active ingredient
62270889|NCT05988476|NO_INTERVENTION|Control|
62270890|NCT05988476|EXPERIMENTAL|Stretching Exercise|
62270891|NCT05988476|EXPERIMENTAL|Pulsed Electromagnetic Field|
62270892|NCT05988476|EXPERIMENTAL|Pulsed Electromagnetic Field and Stretching Exercise|
62270893|NCT00152542|EXPERIMENTAL|Inhaled nitric oxide|
62270894|NCT00152542|PLACEBO_COMPARATOR|Placebo|
62270895|NCT01430273||Planned hip or knee arthroplasty|Patients with planned hip or knee arthroplasty
62270896|NCT01430273||urgent hip or knee arthroplasty|Patients with hip or knee arthroplasty in emergency.
62270897|NCT00411554|EXPERIMENTAL|Sitagliptin 50 mg QD|sitagliptin 50 mg orally once daily (QD=once daily)
62270898|NCT00411554|ACTIVE_COMPARATOR|Voglibose 0.2 mg TID|voglibose 0.2 mg orally three times daily (TID= three times daily)
62270899|NCT00641498|NO_INTERVENTION|Control|Usual therapy
62065987|NCT03592277|EXPERIMENTAL|TREATMENT with Vitamins C and B1|Patients in the Vitamins C and B1 arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
62270900|NCT00641498|EXPERIMENTAL|Active group|Individual supportive psychotherapy initiated in the Emergency department
62270901|NCT02061865|EXPERIMENTAL|Cohorts 1 - 4|Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4.
62270902|NCT00262873|EXPERIMENTAL|Bortezomib|
62270903|NCT01856881|ACTIVE_COMPARATOR|AMG 876|
62065988|NCT03592277|NO_INTERVENTION|PLACEBO with saline only|Patients in the placebo (control group) arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
62270904|NCT01856881|PLACEBO_COMPARATOR|Placebo|
62270905|NCT03608943||Adrenal insufficiency|"Individuals who are in the process of changing their treatment from:~1. hydrocortisone to prednisolone or;~2. prednisolone to hydrocortisone"
62452874|NCT01415778|EXPERIMENTAL|Active 4|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
62065989|NCT03018301|ACTIVE_COMPARATOR|Ketamine group|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
62065990|NCT03018301|PLACEBO_COMPARATOR|Control group|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
62065991|NCT02917941|EXPERIMENTAL|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.
62065992|NCT02712593|EXPERIMENTAL|Niagen™ 100|
62065993|NCT02712593|EXPERIMENTAL|Niagen™ 300|
62065994|NCT02712593|EXPERIMENTAL|Niagen™ 1000|
62065995|NCT02712593|EXPERIMENTAL|Placebo|
62065996|NCT01351532|EXPERIMENTAL|Lifestyle counseling, smoking cessation drug|
62270906|NCT05980442||OrthoPilot® Elite|navigated / computer assisted total knee replacement surgery
62270907|NCT05980442||MAKO|robot assisted total knee replacement surgery
62270908|NCT01617460|EXPERIMENTAL|Aripiprazole|administered orally once daily
62270909|NCT04672759||Cohort 1|Cohort 1 will include patients with unresectable stage III non-small cell lung cancer. Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
62452875|NCT00625911|ACTIVE_COMPARATOR|morphine only|standard analgesia protocol
62452876|NCT00625911|EXPERIMENTAL|morphine ketamine|alterantive regimen for intravenous patient controlled analgesia
62452877|NCT03196999|ACTIVE_COMPARATOR|Personalized Attention Bias Training|Personalized version of ABM Training.
62065997|NCT01351532|ACTIVE_COMPARATOR|Lifestyle counseling|
62065998|NCT04723849|EXPERIMENTAL|Tretment group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
62065999|NCT04723849|PLACEBO_COMPARATOR|Placebo group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
62066000|NCT06626477|EXPERIMENTAL|Active (6 weeks) + Active (6 weeks)|Randomized, double-blinded, active treatment for 6 weeks, then 6 weeks of unblinded active treatment.
62066001|NCT06626477|SHAM_COMPARATOR|Sham (6 weeks) + Active (6 weeks)|Randomized, double-blinded, sham treatment for 6 weeks, then 6 weeks of unblinded active treatment.
62066002|NCT06625580|ACTIVE_COMPARATOR|ultrasound guided transverse thoracic muscle plane block and serratus anterior plane block|ultrasound guided transverse thoracic muscle plane block and serratus anterior plane block will be performed with %0.25 bupivacaine
62270910|NCT04672759||Cohort 2|Cohort 2 will enroll patients with histologically or cytologically confirmed NSCLC or SCLC who will or have received chemotherapy/radiotherapy at the physician's discretion.
62452878|NCT03196999|PLACEBO_COMPARATOR|Neutral Attention Training Condition|Non-active version of ABM training.
62452879|NCT03196999|ACTIVE_COMPARATOR|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
62066003|NCT06625580|ACTIVE_COMPARATOR|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block
62066004|NCT01080651|ACTIVE_COMPARATOR|CYP2C19 extensive metabolizer|
62066005|NCT01080651|ACTIVE_COMPARATOR|CYP2C19 poor metabolizer|
62270911|NCT04693962||Partial Nephrectomy (PN)|Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.
62270912|NCT04693962||Hemicolectomy (HC)|Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.
62270913|NCT04693962||Nephrolithotomy (NL)|Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury
62270914|NCT03377907|ACTIVE_COMPARATOR|Ketamine in hematoma block|Ketamine used in hematoma block
62270915|NCT03377907|ACTIVE_COMPARATOR|ketamine intravenous anesthesia|ketamine used in local intravenous anesthesia
62270916|NCT03377907|ACTIVE_COMPARATOR|lidocaine intravenous anesthesia|2.5 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
62270917|NCT02113059||Liver resection|Patients undergoing a hemihepatectomy.
62270918|NCT00568646|EXPERIMENTAL|1|
62633136|NCT02326272|EXPERIMENTAL|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
62633137|NCT02326272|EXPERIMENTAL|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
62633138|NCT02326272|PLACEBO_COMPARATOR|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~* PASI75 responders at Week 16 continue to receive Placebo.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
62066006|NCT02007408|PLACEBO_COMPARATOR|Placebo group|
62633139|NCT04009304|EXPERIMENTAL|In-person|OSNAP intervention delivered to afterschool sites using an in-person train-the-trainer model implementation strategy
62066007|NCT02007408|ACTIVE_COMPARATOR|Paracervical block plus lidocaine spray|Lidocaine injection+Lidocaine spray received PCB with 2 ampoules of lidocaine solution plus 2 pumps (20 mg=2 pumps) of 10% lidocaine spray
62066008|NCT02007408|ACTIVE_COMPARATOR|paracervical block plus isotonic saline spray|2 ampoules of lidocaine solution (20 mg Lidocaine HCl+0.0125 mg epinephrine/ml) plus isotonic spray
62270919|NCT02303379|ACTIVE_COMPARATOR|Continuous Endurance training|Endurance training with constant work load 31min at 65-75% maximal heart rate (HRmax)
62270920|NCT02303379|EXPERIMENTAL|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
62633140|NCT04009304|EXPERIMENTAL|Online|OSNAP intervention delivered to afterschool sites using an online training model implementation strategy
62633141|NCT04009304|NO_INTERVENTION|Control|
62066009|NCT02007408|ACTIVE_COMPARATOR|only lidocaine spray|paracervical block with saline solution plus 10% lidocaine spray
62066010|NCT01365533|ACTIVE_COMPARATOR|Roflumilast|
62066011|NCT01365533|PLACEBO_COMPARATOR|Placebo|
62066012|NCT05474729|EXPERIMENTAL|minocycline|minocycline capsule 100mg per day orally
62066013|NCT01978080|EXPERIMENTAL|Tremor reports provided|Kinesia HomeView utilized to monitor tremor at home and reports provided to treating clinician
62066014|NCT01978080|ACTIVE_COMPARATOR|Tremor reports not provided|Kinesia HomeView utilized to monitor tremor at home and reports not provided to treating clinician
62270921|NCT02303379|EXPERIMENTAL|High-intensity intervall training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
62270922|NCT03451773|EXPERIMENTAL|1/ Arm 1-Gemcitabine + de-escalating dose of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + de-escalating dose of M7824
62270923|NCT03451773|EXPERIMENTAL|2/ Arm 2-Gemcitabine + Recommended Phase 2 Dose (RP2D) of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + RP2D of M7824
62270924|NCT02242955|ACTIVE_COMPARATOR|"AD = as-usual diazepam"|Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
62270925|NCT02242955|EXPERIMENTAL|"PD = prolonged diazepam"|Diazepam will be slowly tapered to be stopped at day 30
62633142|NCT04217460|ACTIVE_COMPARATOR|Intervention for fluency difficulty (controls)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for controls.
62633143|NCT04217460|EXPERIMENTAL|Intervention for fluency difficulty (experimental)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for experimental group
62066015|NCT06304662|NO_INTERVENTION|Control Group|The control group (CG) that is not going to undergo treatment, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive general advice on the positive effects of regular physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
62633144|NCT04835727|EXPERIMENTAL|Semi-vegetarian diet|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
62633145|NCT00288418|ACTIVE_COMPARATOR|ARROWgard Blue® CVC|7-French x 20-cm, triple lumen, short-term CVC
62066016|NCT06304662|EXPERIMENTAL|Experimental Group|The experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the ERFS, for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 30-45 min per session. Once the intervention is finished, a final evaluation will be used again to see if there is a difference or not with the results obtained at the beginning.
62066017|NCT04513678|EXPERIMENTAL|ImmunOncoTool Condition|The ImmunOncoTool condition includes access to the web-based platform, routine monitoring of irAEs every week for twelve weeks and then bi-weekly for an additional eight weeks, and messages to healthcare providers and patients if a reported irAE is deemed severe enough that it warrants provider attention.
62066018|NCT04513678|NO_INTERVENTION|Control|Participants in the control condition are not assigned an intervention. They receive standard of care.
62066019|NCT02243774|NO_INTERVENTION|No letter|Individuals randomized to the control group who will not receive any of the four letters
62066020|NCT02243774|EXPERIMENTAL|Core letter signed by Surgeon General|Individuals randomized to receive only a core letter signed by the Surgeon General
62066021|NCT02243774|EXPERIMENTAL|Core letter signed by Director of the National Vaccine Program|Individuals randomized to receive only a core letter signed by the Director of the National Vaccine Program
62066022|NCT02243774|EXPERIMENTAL|Core letter signed by Surgeon General + implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General with an implementation intention prompt added in an appended P.S. tag region below the signature line
62066023|NCT02243774|EXPERIMENTAL|Core letter signed by SG + enhanced implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General (SG) with an enhanced implementation intention prompt added in an appended P.S. tag region below the signature line
62066024|NCT05145842|ACTIVE_COMPARATOR|floroscopy|28 patients who have previously been evaluated and planned for caudal epidural injections
62270926|NCT03306732|ACTIVE_COMPARATOR|Thiamine group|
62270927|NCT03306732|PLACEBO_COMPARATOR|Placebo group|
62270928|NCT05318391||Group/Cohort|Retrospective Cohort： Participants who diagnosed with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients and treated with BTK inhibitor or lenalidomide and its biosimilars.
62270929|NCT03958448|EXPERIMENTAL|Short Group|In each side of the posterior region of the maxilla, one tissue level implant, 4 mm long and 4.1 mm in diameter, will be installed
62270930|NCT03958448|EXPERIMENTAL|Standard group|sinus floor elevation with will be performed using natural bovine bone graft as filler material and porcine dermis collagen membrane to cover the antrostomy. After 4 months of healing, one bone level implant, 10 mm long and 4.1 mm in diameter, will be installed into each augmented sinus.
62270931|NCT04434274||Group A, MPFF-group|MPFF \[Detralex®, Servier, France\] 1,000 mg OD for 30 days in the postoperative period.
62270932|NCT04434274||Group B|No venoactive drug prescribed in the postoperative period.
62633146|NCT00288418|EXPERIMENTAL|Angiotech CVC|A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
62633147|NCT06117020|EXPERIMENTAL|MTR-601|Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
62633148|NCT06117020|PLACEBO_COMPARATOR|Placebo|
62633149|NCT05919082|EXPERIMENTAL|LEO 90100|The subjects will receive LEO 90100 foam once daily for 4 weeks.
62066025|NCT05145842|EXPERIMENTAL|ultrasound+fluoroscopy|28 patients who have previously been evaluated and planned for caudal epidural injections
62066026|NCT04598893||Teplizumab|Participants who received teplizumab in the PROTECT study
62270933|NCT02277509|EXPERIMENTAL|Chinese DPP|Our Chinese DPP intervention includes: 1) skills development core adapted from the DPP core curriculum, 2) stress reduction counseling and activities, 3) physical activity sessions, 4) self-monitoring tools for diet and physical activity, 5) barriers assessment linked to tool box, and 6) post-core support intervention.
62270934|NCT02277509|ACTIVE_COMPARATOR|Minimal Intervention Control|The minimal control intervention will consist of providing patients with publically available materials on diabetes prevention, which are produced in Chinese.
62633150|NCT05919082|ACTIVE_COMPARATOR|Daivobet® ointment|The subjects will receive Daivobet® ointment once daily for 4 weeks.
62633151|NCT05276102|ACTIVE_COMPARATOR|Repated exposure to antiseptic and treatment|Repeated exposure of forearm skin to antiseptic (once daily for 2 hours under occlusion, during three weeks) Emollient cream treatment 3 times a day
62633152|NCT05276102|ACTIVE_COMPARATOR|Sham irritation and treatment|Repeated exposure of forearm skin to deionized water (once daily for 2 hours under occlusion, during three weeks) Emollient cream treatment 3 times a day
62633153|NCT05276102|ACTIVE_COMPARATOR|No irritation and treatment|Intact skin on forearms Emollient cream treatment 3 times a day
62633154|NCT05276102|NO_INTERVENTION|Repated exposure to antiseptic and no treatment|Repeated exposure of forearm skin to antiseptic (once daily for 2 hours under occlusion, during three weeks) No emollient cream treatment
62633155|NCT05276102|NO_INTERVENTION|Sham irritation and no treatment|Repeated exposure of forearm skin to deionized water (once daily for 2 hours under occlusion, during three weeks) No emollient cream treatment
62270935|NCT05832281|ACTIVE_COMPARATOR|Synthetic CBD 4-Week Trial Arm|For one week they will titrate up to the maintenance dose of 600 mg/day of Purysis, a synthetic, liquid form of CBD, which they will continue for 4 weeks. Upon completion of the 4-week trial, they will be re-assessed, followed by one week of titrating down to discontinuation.
62270936|NCT05832281|PLACEBO_COMPARATOR|Placebo 4-Week Trial Arm|For one week they will titrate up to the maintenance dose of 600 mg/day of placebo for Purysis, a synthetic, liquid form of CBD, which they will continue for 4 weeks. Upon completion of the 4-week trial, they will be re-assessed, followed by one week of titrating down to discontinuation.
62270937|NCT04442230|EXPERIMENTAL|NasoVAX|Participants will receive a single intranasal dose of NasoVAX on Day 1 (enrollment).
62270938|NCT04442230|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intranasal dose of placebo on Day 1 (enrollment).
62270939|NCT03632421|EXPERIMENTAL|Intervention group|
62270940|NCT03632421|ACTIVE_COMPARATOR|Control group|
62270941|NCT03217838|EXPERIMENTAL|Group 1 Arm A (AZD2811 Dose 1)|Participants with AML will receive intevenous (IV) infusion of AZD2811 Dose 1 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270942|NCT03217838|EXPERIMENTAL|Group 1 Arm A (AZD2811 Dose 2)|Participants with AML and myelodysplastic syndrome (MDS) will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270943|NCT03217838|EXPERIMENTAL|Group 1 Arm A (AZD2811 Dose 3)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 3 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270944|NCT03217838|EXPERIMENTAL|Group 1 Arm A (AZD2811 Dose 4)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 4 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62452880|NCT01855724|EXPERIMENTAL|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
62633156|NCT05276102|NO_INTERVENTION|No irritation and no treatment|Intact skin on forearms No emollient cream treatment
62633157|NCT03141190|EXPERIMENTAL|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
62270945|NCT03217838|EXPERIMENTAL|Group 1 Arm A (AZD2811 Dose 5)|Participants with AML will receive IV infusion of AZD2811 Dose 5 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62633158|NCT03141190|ACTIVE_COMPARATOR|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
62066027|NCT04598893||Placebo|Participants who received placebo in the PROTECT study
62633159|NCT06525051||Group 1|Group 1 consisted of COPD patients not receiving any treatment ( inhaled and/or systemic steroids, long-acting inhaled beta-2 agonists alone, theophylline and combined long-acting beta-2 agonists and long-acting anticholinergic ). These patients are early stage COPD patients.
62633160|NCT06525051||Group 2|Group 2 consisted of healthy volunteers for similar age and gender.
62633161|NCT06525051||Group 3|Group 3 consisted of COPD patients of the same age and gender with receiving only handhaler Tiotropium 18 mcg for three months.
62633162|NCT04853823|EXPERIMENTAL|PDC-APB|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
62633163|NCT04853823|PLACEBO_COMPARATOR|Vehicle|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
62633164|NCT00828425||1|Diabetic patients with retinopathy
62633165|NCT02308449|PLACEBO_COMPARATOR|Iron-deficient, given placebo|Iron-deficient participants given an infusion of sodium chloride at conclusion of baseline experimental visit
62633166|NCT02308449|ACTIVE_COMPARATOR|Iron-deficient, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
62633167|NCT02308449|PLACEBO_COMPARATOR|Iron-replete, given placebo|Iron-replete participants given an infusion of sodium chloride at conclusion of baseline experimental visit
62633168|NCT02308449|ACTIVE_COMPARATOR|Iron-replete, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
62633169|NCT00198991|EXPERIMENTAL|All patients|All patients are treated upfront according to one arm
62633170|NCT01702909|EXPERIMENTAL|Interleukin-2|Interleukin-2
62066028|NCT02332018||Limb Torsion|adult patients, lower limb assessment retrospectively limb length and limb axis, torsion biplanar x-ray images
62066029|NCT02332018||Limb Length and Axis|adult patients, lower limb assessment prospectively limb length and limb axis biplanar x-ray images
62066030|NCT02332018||Spine|adult patients, spine assessment prospectively Cobb angles, plumbline biplanar x-ray images
62066031|NCT04989075|NO_INTERVENTION|Control group|The control group will continue its usual oral hygiene practice.
62633171|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between~01-Jan-2013 and 30-Sep-2016."
62633172|NCT04750018||COVID-19 2019|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed \[4\]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
62633173|NCT04750018||COVID-19 2020|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed \[4\]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
62066032|NCT04989075|EXPERIMENTAL|Oral prophylactic intervention|For the study group, the oral prophylactic intervention will consist of provision of specfic package including soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
62270946|NCT03217838|EXPERIMENTAL|Group 1 Arm B (AZD2811 Dose 2)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62452881|NCT02857842|EXPERIMENTAL|Blood eosinophil guided prednisolone treatment|Intravenous Solu-Medrol 80 mg, followed by prednisolone tablet 37.5 mg daily (maximum of 5 days in all) if the eosinophil count in the blood ≥ 0.3 x 10E9/L. Eosinophil count in the blood \<0.3 x 10E9/L results in no treatment with prednisolone. If the patient is discharged during the treatment period, given treatment from the last measured eosinophil count the remaining days.
62633174|NCT01793753||Propofol|Chronically constipated children ages 2-6 years who will receive anesthesia for anorectal manometry including propofol per standard of care
62066033|NCT05667701|EXPERIMENTAL|Soy isoflavone|Soy isoflavone powder dosed in puree or liquid twice daily
62270947|NCT03217838|EXPERIMENTAL|Group 1 Arm B (AZD2811 Dose 6)|Participants with AML will receive IV infusion of AZD2811 Dose 6 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270948|NCT03217838|EXPERIMENTAL|Group 2 Arm A (AZD2811 Dose 3 + Azacitidine 75 mg/m^2)|Participants with AML and MDS will receive Azacitidine 75 mg/m\^2 of body surface area (BSA) by subcutaneous (SC) injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 3 on Days 1 and 4 of each 28-day cycle. Participants will receive the study treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270949|NCT03217838|EXPERIMENTAL|Group 2 Arm A (AZD2811 Dose 4 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m\^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 4 on Days 1 and 4 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270950|NCT03217838|EXPERIMENTAL|Group 2 Arm B (AZD2811 Dose 2 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m\^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62633175|NCT03816553|EXPERIMENTAL|SHR-1210 + Apatinib|Participants receive SHR-1210 200mg (3mg/kg for underweight patients) intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
62066034|NCT05667701|PLACEBO_COMPARATOR|Placebo|Matching placebo powder dosed in puree or liquid twice daily
62452882|NCT02857842|ACTIVE_COMPARATOR|Standard of care|Intravenous Solu-Medrol 80 mg on the first day followed by 37.5 mg of prednisolone tablets (1 x 25 mg plus 1 x 12.5 mg) daily for 5 days
62633176|NCT06039644|EXPERIMENTAL|Probiotic group|Subjects received two probiotic sachets per day
62633177|NCT06039644|PLACEBO_COMPARATOR|Placebo group|Subjects received two placebo sachets per day
62066035|NCT02306265|OTHER|DBT and FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental).
62066036|NCT04527848|EXPERIMENTAL|small amount of undiluted C3F8|
62066037|NCT04527848|ACTIVE_COMPARATOR|large amount of diluted C3f8|
62066038|NCT04527848|ACTIVE_COMPARATOR|small amount of undiluted SF6|
62066039|NCT04527848|ACTIVE_COMPARATOR|large amount of diluted SF6|
62633178|NCT03782714|EXPERIMENTAL|Low-level laser therapy group|This group of teeth received laser irradiation after amputation of coronal pulp
62633179|NCT03782714|NO_INTERVENTION|Formocresol group|This group of teeth received the gold standard medication (formocresol) after coronal pulp amputation
62633180|NCT05141435|ACTIVE_COMPARATOR|NCPAP|
62633181|NCT05141435|ACTIVE_COMPARATOR|NHFOV|
62066040|NCT01756820|ACTIVE_COMPARATOR|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|Single-portal Endoscopic Carpal Tunnel Release (Microaire®) will be used, according to the endoscopic technique described by Agee at al.
62066041|NCT01756820|ACTIVE_COMPARATOR|Knifelight®|A mini-open technique will be performed, using the Knifelight® (Stryker).
62066042|NCT06624436|ACTIVE_COMPARATOR|Group 1: dexamethasone|This arm (n = 12) of healthy male volunteers will have two LPS challenges (day 0 and day 7) and will receive dexamethasone infusion in 1 hour on the first LPS challenge.
62066043|NCT06624436|ACTIVE_COMPARATOR|Group 2: Tocilizumab|This arm (n = 12) of healthy male volunteers will have two LPS challenges (day 0 and day 7) and will receive Tocilizumab infusion in 1 hour on the first LPS challenge.
62066044|NCT06624436|ACTIVE_COMPARATOR|Group 3: Anakinra|This arm (n = 12) of healthy male volunteers will have two LPS challenges (day 0 and day 7) and will receive Anakinra infusion in 1 hour on the first LPS challenge.
62633182|NCT04664257|EXPERIMENTAL|e-CBT|All e-CBT sessions will be administered through OPTT and will consist of approximately 30 slides per week. The content and format of each weekly online session will be designed to mirror in-person CBT for the treatment of BAD-II. Participants will complete the module and submit the assigned homework to their clinician through OPTT where the clinician will be able to provide personalized feedback. These pre-designed engaging and multimedia modules will be able to streamline the therapy process, helping care providers save time on repeating similar materials to all patients and focusing on delivering personalized feedback to each patient. The slides will highlight a different topic each week and include general information, an overview of skills, and homework that is to be completed within that week. All weekly sessions have an estimated completion time of 50 minutes. During the 12 weeks, both groups will continue with their TAU.
62066045|NCT06624436|PLACEBO_COMPARATOR|Group 4: Placebo|This arm (n = 12) of healthy male volunteers will have two LPS challenges (day 0 and day 7) and will receive a placebo infusion in 1 hour on the first LPS challenge.
62066046|NCT06624436|NO_INTERVENTION|Group 5: Control|This arm (n = 4) of healthy male volunteers won't receive an LPS challenge or any of the study treatments. This group will be used to familiarise the study team with the study procedures and to establish the effect of placement of an intrathecal catheter on systemic and neuroinflammation.
62066047|NCT03107377|ACTIVE_COMPARATOR|EVO100|A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
62452883|NCT00193609|EXPERIMENTAL|Oxaliplatin/Capecitabine|All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
62270951|NCT03217838|EXPERIMENTAL|Group 2 Arm B (AZD2811 Dose 6 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m\^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 6 on Days 1, 4, 15, and 18 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62452884|NCT02684552|EXPERIMENTAL|Non invasive ventilation|Patients perform physical test with non invasive ventilation
62452885|NCT02684552|ACTIVE_COMPARATOR|Oxygen|Patients perform physical test with oxygen with mask
62452886|NCT04549064||Patients with pancreatic cancer|Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.
62452887|NCT04549064||Healthy Control|healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors.
62452888|NCT04021537|EXPERIMENTAL|non-invasive nerve stimulation a|Electrical stimulation will be delivered to a location at the ear.
62633183|NCT04664257|NO_INTERVENTION|Treatment as Usual|Participants will continue with treatment as usual and any lifestyle activities (diet, exercise, medication, etc.)
62633184|NCT00369343|EXPERIMENTAL|A|
62633185|NCT00369343|PLACEBO_COMPARATOR|B|
62633186|NCT00048035|EXPERIMENTAL|Cohort 1 (RO0503821 [0.25/150 1x/week])|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta \[Mircera\]) intravenously (IV) using a dose conversion factor of 0.25/150 microgram (mcg)/kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 62.50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62452889|NCT04021537|ACTIVE_COMPARATOR|non-invasive nerve stimulation b|Electrical stimulation will be delivered to a location at the ear.
62452890|NCT02959905|EXPERIMENTAL|medium-dose lymphodepletion regimen|Patients will receive medium-dose lymphodepletion regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
62452891|NCT02959905|EXPERIMENTAL|low-dose lymphodepletion regimen|Patients will receive low-dose lymphodepletion regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
62452892|NCT02959905|EXPERIMENTAL|No lymphodepletion regimen|Patients will only receive TSA-CTL.
62633187|NCT00048035|EXPERIMENTAL|Cohort 2 (RO0503821 [0.25/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.25/150 mcg/kg of the previous weekly ESA dose, (equal to 62.50% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62633188|NCT00048035|EXPERIMENTAL|Cohort 3 (RO0503821 [0.4/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62452893|NCT01723995|EXPERIMENTAL|low-level laser on nipples|Application of laser light from the device in direct contact with the nipple injury, equipment connected and set up at a dose of 5J/cm2 (Epoint = 0.2J/cm2) for both groups, three consecutive doses of 5J/cm2 (ETotal = 0.6J/cm2) along the entire length of the injury.
62452894|NCT01723995|PLACEBO_COMPARATOR|low-level laser off on nipples|Laser with modified standard operation - shutdown of InGaAIP semiconductor diode and installation of a visible red light emitting diode with optical power of 0mW (LED - Light Emitting Diode - maximum power with standard nozzle).
62452895|NCT03818048|EXPERIMENTAL|Group Propofol|propofol infusion
62066048|NCT03107377|PLACEBO_COMPARATOR|Placebo|An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
62066049|NCT06178783|EXPERIMENTAL|Brensocatib Treatment Sequence ADBC|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence ADBC.
62270952|NCT03217838|EXPERIMENTAL|Group 3 Arm A (AZD2811 Dose 2 + Venetoclax 200 mg)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle and venetoclax 100 mg orally (PO) on Day 1 and 200 mg PO from Days 2 to 28 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270953|NCT03217838|EXPERIMENTAL|Group 3 Arm A (AZD2811 Dose 2 + Venetoclax 400 mg)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle and venetoclax 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
62270954|NCT04160507||Healthy black adults 50 and over|Healthy black adults age 50 and over with no known history of kidney disease will be recruited as controls in this study.
62066050|NCT06178783|EXPERIMENTAL|Brensocatib Treatment Sequence BACD|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence BACD.
62270955|NCT04160507||black adult cases with non-diabetic nephropathy|black adult cases with non-diabetic nephropathy
62270956|NCT06171438||Acute kidney injury (AKI)|Donors with AKI (acute kidney injury) defined based on the results of creatinine increase and diuresis decrease before organ harvest.
62270957|NCT06171438||no-AKI|Donors without AKI (acute kidney injury) defined based on the results of creatinine increase and diuresis decrease before organ harvest.
62633189|NCT00048035|EXPERIMENTAL|Cohort 4 (RO0503821 [0.4/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62633190|NCT00048035|EXPERIMENTAL|Cohort 5 (RO0503821 [0.6/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62066051|NCT06178783|EXPERIMENTAL|Brensocatib Treatment Sequence CBDA|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence CBDA.
62066052|NCT06178783|EXPERIMENTAL|Brensocatib Treatment Sequence DCAB|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence DCAB.
62066053|NCT06624956|PLACEBO_COMPARATOR|Standard Care|Subjects in the standard care/placebo arm will receive only regular crystalloid.
62270958|NCT06171438||delayed graft function (DGF)|Donors and the paired recipients in whom the organ was transplanted in IKEM (Institute for Clinical and Experimental Medicine) who developed delayed graft function (DGF) defined as dialysis in the 1st week after transplantation.
62270959|NCT06171438||no-DGF|Donors and the paired recipients in whom the organ was transplanted in IKEM (Institute for Clinical and Experimental Medicine) with immediate graft function (no-DGF).
62270960|NCT06171438||Recipient IFTA|Donors and the paired recipients in whom the organ was transplanted in IKEM with 3-month protocol biopsy histology finding of IFTA≥2.
62066054|NCT06624956|ACTIVE_COMPARATOR|GIK|Subjects in the glucose, insulin, and potassium (GIK) arm will receive regular crystalloid with GIK added.
62270961|NCT06171438||Recipient no-IFTA|Donors and the paired recipients in whom the was transplanted in IKEM with 3-month protocol biopsy histology finding of IFTA\<2.
62088185|NCT00618670|EXPERIMENTAL|2|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 70% of exercise capacity
62066055|NCT05942755||Subarachnoid haemorrhage with Fisher 3 or 4.|"HAS Group :~* Adults~* Hospitalized in the neurological intensive care unit for a Fisher 3 or 4 aneurysmal meningeal hemorrhage with external ventricular drain (EVD) and urinary catheter. This EVD allows the evacuation of 10-20ml/h of CSF into an external collector. CSF is usually removed daily.~* With a catheter (arterial or venous) for repeated sampling. Blood samples are taken as part of routine care on arrival of patients and then every 24 hours if an arterial catheter is in place; otherwise, every Monday, Wednesday and Friday. Samples from the EVD will be taken on Day 0 and then every 24 hours. A urine ionogram is also performed every 24 hours as part of the usual management to regulate water, sodium and potassium intake by enteral or parenteral route.~In addition, clinical data will be collected every 24 hours on the basis of a computerized medical record without additional examination."
62066056|NCT05942755||Control group, normal pressure hydrocephalus|"Control group :~* Adults~* Performing a perfusion test in the operating room in the context of normal pressure hydrocephalus.~A lumbar puncture is performed in the operating room to evacuate the chronic CSF effusion in the ventricles (hydrocephalus), before performing an intrathecal perfusion test. 1ml of the CSF thus collected will be analyzed to determine the ionic composition and thus compare it to the CSF collected from patients with SAH."
62066057|NCT00025584|EXPERIMENTAL|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62066058|NCT03872388|EXPERIMENTAL|Group I (atorvastatin)|Patients receive standard of care atorvastatin PO QD for up to 24 months.
62270962|NCT01598038|NO_INTERVENTION|Afinitor|"The recommended dose of Afinitor is 10 mg everolimus once daily, at fixed hour.Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.~In case of frail patients, treatment could be initiated at a lower daily-dose (5mg/d for example) and then increase if tolerance is acceptable."
62270963|NCT01437020|EXPERIMENTAL|Dose escalating-IV infusion of SCH708980 and Ambisome|
62066059|NCT03872388|ACTIVE_COMPARATOR|Group II (capecitabine)|Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
62270964|NCT01575067||blood pressure monitor|Cuff circumference:22cm-42cm
62270965|NCT01575067||stethoscopy|Cuff circumference: 22cm-42cm
62270966|NCT05712187|EXPERIMENTAL|ALTO-100|Participants will receive ALTO-100 tablet twice daily, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open label (OL) treatment period will receive ALTO-100 tablet twice daily from OL baseline until the end of OL period/early termination visit (Up to 7 weeks).
62270967|NCT05712187|PLACEBO_COMPARATOR|Placebo DB|Participants will receive matching placebo tablet twice daily, from Day 1 to Day 42 in double blind (DB) treatment period.
62270968|NCT01732887|OTHER|Immediate cognitive fitness training|"After the initial baseline evaluation, the immediate treatment group participants will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants in this group will switch to a 20 week no intervention period where they receive only standard of care treatment."
62270969|NCT01732887|OTHER|Delayed cognitive fitness training|"After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks (no intervention period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment."
62270970|NCT05345600|EXPERIMENTAL|MILTA|The MILTA® uses photons which are emitted with low intensity in the visible and near infrared combining 5 physical principles to reduce pain
62270971|NCT05345600|PLACEBO_COMPARATOR|placebo|
62270972|NCT04737577|EXPERIMENTAL|Supramarginal resection (intervention arm)|Planned resection beyond the Gadolinium (GAD)-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
62270973|NCT04737577|OTHER|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
62270974|NCT06288087|OTHER|MG Group|The group trained with VR Based Training with Machine Guidance will be referred as MG group.
62066060|NCT01725386||Monotherapy|Capecitabine as monotherapy according to prescribing information and normal clinical practice.
62066061|NCT01725386||Combination Therapy|Capecitabine as part of combination therapy according to prescribing information and normal clinical practice.
62066062|NCT02378519|EXPERIMENTAL|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
62088186|NCT00618670|ACTIVE_COMPARATOR|3|Light resistance training without any walking exercise
62270975|NCT06288087|OTHER|EG Group|The group trained with VR Based Training with Educators Guidance in Metaverse will be referred as EG group.
62452896|NCT03818048|EXPERIMENTAL|Group Sevoflurane|inhalation with sevoflurane
62452897|NCT05159609|ACTIVE_COMPARATOR|Stim First|Participants slept for one night while auditory sounds were played at specific points during slow wave sleep. At least one week later, an identical procedure occured with no acoustic sounds.
62088187|NCT03760315||Sepsis|All enrolled patients
62452898|NCT05159609|SHAM_COMPARATOR|Sham First|Participants slept for one night while no acoustic sounds were played. At least one week later, an identical procedure occured while acoustic sounds were played at specific points during slow wave sleep.
62452899|NCT05653596|EXPERIMENTAL|Experimental: VR restorative intervention|Individuals who are assigned to the experimental group will receive a 4-week VR-based cognitive intervention.
62066063|NCT02378519|ACTIVE_COMPARATOR|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
62066064|NCT02730221||Patients admitted during measurement 1|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period before the implementation of a new electronic patient data management system
62066065|NCT02730221||Patients admitted during measurement 2|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period after the implementation of a new electronic patient data management system
62270976|NCT02492503|ACTIVE_COMPARATOR|pacli carb 3|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
62452900|NCT05653596|NO_INTERVENTION|Control: Usual care|Individuals who are assigned to the control group will receive the usual care and then receive the same intervention as they wish.
62452901|NCT05023213|EXPERIMENTAL|Warna-Warni Waktu intervention|Participants in this condition will be asked to view six, approximately five minute videos (each with a number of associated short, interactive reinforcer activities), at a pace of one video per day, for 6 days.
62633191|NCT00048035|EXPERIMENTAL|Cohort 6 (RO0503821 [0.6/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
62066066|NCT03115554|ACTIVE_COMPARATOR|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
62088188|NCT03659487|ACTIVE_COMPARATOR|Nissen|Surgery of GERD with 360 degrees total fundoplication
62270977|NCT02492503|ACTIVE_COMPARATOR|pacli carb 1|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
62452902|NCT05023213|NO_INTERVENTION|Waitlist control condition|These participants will no be contacted during the intervention timeframe.
62270978|NCT04842084||healthy volunteers|Healthy volunteers both sex aged between 18 and 50 without personal or family history of hemorrhage, thrombosis before 45 years old,
62633192|NCT06324643|EXPERIMENTAL|Use Designed occupational therapy program in childern with erb's palsy|1st group treated by strengthening exercises , stretching ,and occupational therapy
62633193|NCT06324643|EXPERIMENTAL|Use designed occupational therapy program and sensory motor integration training|2nd group treated by strengthening exercises , stretching ,and occupational therapy and sensory motor integration training (use different textures and different temperature)
62633194|NCT05923710|ACTIVE_COMPARATOR|Primary anterior cruciate ligament repair|Investigators performed arthroscopic primary repair in 18 patients with proximal ACL tears.
62633195|NCT05923710|ACTIVE_COMPARATOR|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET)|Investigators performed arthroscopic primary repair and lateral extraarticular tenodesis (LET) with iliotibial band in 20 patients with proximal ACL tears.
62270979|NCT00179309|EXPERIMENTAL|Arm I - PANVAC + docetaxel|Patients receive vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine subcutaneously (SC) once and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) SC once daily for 4 days in week -2. Patients also receive fowlpox-CEA-MUC-1-TRICOM vaccine SC once and GM-CSF SC once daily for 4 days in weeks 1, 5, and 9. Patients also receive docetaxel intravenous (IV) over 30 minutes once weekly in weeks 1-3, 5-7, and 9-11. After week 12, patients with no disease progression continue with docetaxel once weekly for 3 weeks followed by 1 week of rest and fowlpox-CEA-MUC-1-TRICOM vaccine plus GM-CSF every 4 weeks until disease progression.
62633196|NCT05624411||A|post-placental insertion of CU T380A IUD during CS
62633197|NCT05624411||B|post-placental insertion of multiload 375 IUD during CS
62633198|NCT05342753|EXPERIMENTAL|Restylane Kysse|Hyaluronic Acid
62633199|NCT04612985|EXPERIMENTAL|Procedures with XACT Robotic System|Device: XACT Robotic System The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous lung procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
62066067|NCT03115554|ACTIVE_COMPARATOR|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
62066068|NCT02888717|EXPERIMENTAL|OSNA stadification during surgery|The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and will be analysis both by histological analysis and OSNA analysis
62066069|NCT04145037|EXPERIMENTAL|Switch Stable|Switch-stable arm: Subjects who had undergone ERT ≥15 U/kg and ≤60 U/kg every other week (or equivalent; i.e., any combination of infusions resulting in a total monthly ERT dose of \>30 U/kg and \<120 U/kg) for ≥24 consecutive months for Type 1 Gaucher disease at the time of Screening. Switch-stable subjects must have discontinued ERT at least 2 weeks before the scheduled AVR-RD-02 infusion. Switch-stable subjects who had been and substrate reduction therapy (SRT) must not have received SRT within 12 months of Screening.
62066070|NCT04145037|EXPERIMENTAL|Treatment-naïve|"Treatment-naïve arm: Subjects with Type 1 Gaucher disease who had never received either ERT or SRT for Gaucher disease or had not received either ERT or SRT for Gaucher disease within 12 months of Screening (i.e., treatment-naïve subjects). Enrollment followed a similar scheme as for the switch-stable subjects.~Note: No subjects enrolled in this arm."
62066071|NCT00568191||1|retinal thickness program Stratus OCT software 4.0
62066072|NCT00568191||2|retinal cube 200x200 program of Cirrus OCT
62066073|NCT06616311|EXPERIMENTAL|Treatment|The target population is skin of color patients with melasma. Patients will receive 5 consecutive RFMN treatments over a period of 5 months.
62066074|NCT04678622||Classic Orthrosis|Group of patients who they will wear the usual splint indicated by the servicio physicians
62066075|NCT04678622||3D Orthrosis|Group of patients who they will wear the personalized splint designed by the company OPTIMUS 3D.
62066076|NCT04929093|EXPERIMENTAL|Novel dose adjustment schedule|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with novel dose adjustment schedule.
62066077|NCT04929093|ACTIVE_COMPARATOR|Conventional dose adjustment|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with conventional dose adjustment schedule.
62066078|NCT04929093|ACTIVE_COMPARATOR|Continuous cluster SCIT schedule|The subjects had a routine cluster SCIT schedule without interrupted period.
62066079|NCT06394765|EXPERIMENTAL|Mindful Mapping|
62633200|NCT03675568|EXPERIMENTAL|study group|Non-Cultured autologous keratinocyte suspension
62633201|NCT03675568|ACTIVE_COMPARATOR|Control group|Split skin Graft
62633202|NCT04449289|ACTIVE_COMPARATOR|Intravenous lidocaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+intravenous lidocaine infusion for the first 48 hours postoperative
62066080|NCT06394765|ACTIVE_COMPARATOR|Serial Sevens|
62066081|NCT02402296|ACTIVE_COMPARATOR|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
62066082|NCT02402296|PLACEBO_COMPARATOR|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
62066083|NCT01048645|PLACEBO_COMPARATOR|P/PC arm|Patients were assigned to receive placebo (P/PC) 1 week prior to treatment until completing two cycles
62633203|NCT04449289|ACTIVE_COMPARATOR|Epidural ropivacaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+epidural ropivacaine infusion for the first 48 hours postoperatively
62633204|NCT02691546||Subjects aged 75 years or older|
62633205|NCT02093936||Healthy non exposed|Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure
62633206|NCT02093936||Healthy exposed|Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure
62633207|NCT02093936||Non-healthy exposed|Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure
62633208|NCT02093936||Non-healthy non-exposed|Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure
62633209|NCT02902042|EXPERIMENTAL|Arm A: Triple therapy|Encorafenib, binimetinib and pembrolizumab. Doses as determined in phase I
62066084|NCT01048645|EXPERIMENTAL|RA/PC arm|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two cycles
62270980|NCT00179309|EXPERIMENTAL|Arm II - Docetaxel alone|Patients receive docetaxel as in arm I. After week 12, patients with disease progression discontinue docetaxel and receive vaccinia-carcinoembryonic antigen (CEA)- mucin 1(MUC-1)-triad of costimulatory molecules (TRICOM) vaccine, fowlpox-CEA-MUC-1-TRICOM vaccine, and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) as in arm I until further disease progression. Patients with no disease progression after week 12 continue with docetaxel as in arm I until disease progression.
62270981|NCT02834468|EXPERIMENTAL|Treatment group|DEX Combined With RTX, CSA and IVIG All patients are assigned to receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
62633210|NCT02902042|EXPERIMENTAL|Arm B: Pembrolizumab alone|Pembrolizumab with a dose of 200 mg every 3 weeks.
62633211|NCT01138020|EXPERIMENTAL|Arm 1|Cognitive intervention
62633212|NCT01138020|ACTIVE_COMPARATOR|Arm 2|Educational intervention
62633213|NCT00463801|EXPERIMENTAL|Daptomycin|350 mg of Daptomycin was supplied as sterile lyophilized powder in glass vials. Each vial was to be reconstituted with 7 mL of normal saline or water for injection, to give a 50 mg/mL drug concentration. Daptomycin was to be administered as a 30-minute intravenous infusion, once daily for at least 7 days, at the dose of 4 mg/Kg, up to a maximum of 14 days.
62633214|NCT01285869|EXPERIMENTAL|Multidisciplinar intervention|Patients that will receive the multidimensional intervention during the ambulatory follow-up.
62633215|NCT01285869|NO_INTERVENTION|Conventional follow up|This is an observation only group and outpatient follow up will be indicated in accordance with usual and customary practices.
62633216|NCT04394702|EXPERIMENTAL|One Shape Single-file rotary system|
62633217|NCT04394702|ACTIVE_COMPARATOR|Manual stainless steel K-file|
62633218|NCT05401721||Ascites without SBP|Cirrhotic ascitic patients not diagnosed with SBP
62633219|NCT05401721||Ascites with SBP|Cirrhotic ascitic patients diagnosed with SBP
62066085|NCT02999425|EXPERIMENTAL|Education|Educational intervention to study participants
62066086|NCT00281034||OASIS Study Group|
62633220|NCT06008054|EXPERIMENTAL|SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody|Participants received SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62633221|NCT00715234|EXPERIMENTAL|Reminder/recall notices for vaccines|This group will receive up to 4 recall messages (both letters and computer-generated phone messages) reminding them to get their vaccines. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
62633222|NCT00715234|NO_INTERVENTION|Usual Care|This group will receive usual care. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
62633223|NCT05076604|ACTIVE_COMPARATOR|Cardioplegia|4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.
62633224|NCT05076604|ACTIVE_COMPARATOR|Microplegia|Nondiluted microplegia consists of all parts human blood.
62066087|NCT00301080|PLACEBO_COMPARATOR|Placebo (original version)|Placebo administered orally twice per day for 4 weeks.
62066088|NCT00301080|ACTIVE_COMPARATOR|D-cycloserine 200mg|D-cycloserine administered orally at a dose of 200 mg twice per day for 12 weeks.
62633225|NCT01411319|EXPERIMENTAL|LEAD Radiation Therapy|Participants in this group will receive the LEAD Radiation Therapy on Day 1 followed by 38 daily standard IMRT beginning Day 2.
62633226|NCT04624048||University population|Survey to analyze the impact of COVID-19.
62633227|NCT05547256|EXPERIMENTAL|Group A|Two doses were administered by intramuscular injection, 28 days apart
62633228|NCT05547256|EXPERIMENTAL|Group B|Two doses were administered by intramuscular injection, 28 days apart
62633229|NCT01688622|OTHER|Exercise|obese women who are volunteers for the 3 months exercise programs
62270982|NCT05700695|EXPERIMENTAL|Experiential Arm|Drug: iv Branch Chain Amino Acid + Lactulose Intravenous Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
62270983|NCT05700695|ACTIVE_COMPARATOR|Comparator Arm|Drug: Lactulose + Placebo
62270984|NCT03592446|EXPERIMENTAL|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
62270985|NCT03592446|SHAM_COMPARATOR|Sham-raVNS|Sham vagus nerve stimulation at ear.
62270986|NCT01738334|ACTIVE_COMPARATOR|Healthy subjects|"The active control group of healthy individuals was subjected to the practice of meditation for eight weeks."
62270987|NCT01738334|NO_INTERVENTION|Standby|The control group of participants (patients and healthy subjects) who was not practice anything for eight weeks.
62270988|NCT01738334|EXPERIMENTAL|Meditation|A Group of Patients with ADHD was participate of the meditation practices for eight weeks.
62270989|NCT00782769|EXPERIMENTAL|Oxybutinyn Vaginal Ring 4mg|inserted daily and replaced every 4 weeks
62270990|NCT00782769|EXPERIMENTAL|Oxybutinyn Vaginal Ring 6mg|inserted daily and replaced every 4 weeks
62270991|NCT05639855|EXPERIMENTAL|Third year students of the Bachelor's Degree in Occupational Therapy|Third-year students of the Bachelor's Degree in Occupational Therapy will receive training on a specific module on mental health and stigma in the university curriculum.
62633230|NCT03160040||Minocycline IV|Participants who received 2 doses over 48 hours if given once daily or 4 doses over 48 hours if given twice daily of minocycline intravenous (IV) as monotherapy, with or without transition to oral minocycline.
62270992|NCT05639855|NO_INTERVENTION|Students of University of A Coruña|The students of the University of A Coruña will take part in an online survey to find out the attitudes and beliefs of future professionals from different areas of knowledge regarding mental health.
62270993|NCT05639855|NO_INTERVENTION|People with mental health disorder|Users of a Psychosocial and Labor Rehabilitation Centers in the A Coruña Health Care Area will take part in interviews to find out their experiences regarding the attributions made towards them by citizens and health professionals.
62270994|NCT04892836|EXPERIMENTAL|High Intensity Training (HIT)|They have trained at 80-90% of 1RM for 12 weeks, twice per week
62270995|NCT04892836|EXPERIMENTAL|Moderate Intensity Training|They have trained at 65-75% of 1RM for 12 weeks, twice per week
62270996|NCT04892836|EXPERIMENTAL|Low Intensity Training|They have trained at 50-60% of 1RM for 12 weeks, twice per week
62270997|NCT04892836|NO_INTERVENTION|Control Group|This groups subjects did not participate in any training
62633231|NCT06001970||Adults who experience fatigue and have been through an activity pacing program|Adults with chronic conditions who experience fatigue recruited from Cresta Fatigue Clinic, Newcastle, UK
62633232|NCT06001970||Adults who experience fatigue and have not been through an activity pacing program|Adults with chronic conditions who experience fatigue recruited from the waiting list of Cresta Fatigue Clinic, Newcastle, UK
62633233|NCT06001970||Health professionals working on activity pacing|Health professionals who are working on Cresta Fatigue Clinic, Newcastle, UK
62633234|NCT05710328|EXPERIMENTAL|Diagnostic (FDG-PET/CT scan)|Patients receive FDG IV, undergo PET/CT, receive standard of care chemotherapy, and undergo standard of care surgery on study.
62633235|NCT05679115|EXPERIMENTAL|Lifestyle intervention|Participants get access to the tool and use it regularly
62633236|NCT05679115|NO_INTERVENTION|Controls on standard care|Participants who get randomized to control cannot access the tool.
62066089|NCT00301080|ACTIVE_COMPARATOR|D-cycloserine 50 mg|D-cycloserine administered orally at a dose of 50 mg twice per day for 12 weeks.
62270998|NCT01137773|EXPERIMENTAL|Intensive IV Insulin|Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
62633237|NCT00761072||1|The source of data will be from spinal surgery procedures performed at CHOP from 4/1/07 to 3/31/08 using a TIVA anesthetic technique of propofol/remifentanil infusions
62633238|NCT04753957|ACTIVE_COMPARATOR|Vaginal progesterone|200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery
62633239|NCT04753957|NO_INTERVENTION|Control|No intervention, scheduled cesarean delivery
62270999|NCT01137773|ACTIVE_COMPARATOR|Conventional Insulin Treatment|Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl
62271000|NCT04899232|EXPERIMENTAL|AT3 less than 100% with SOC plus AT3 supplement|Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
62271001|NCT04899232|NO_INTERVENTION|AT3 less than 100% with SOC only|Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
62633240|NCT01060189|EXPERIMENTAL|Ulinastatin|1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
62633241|NCT01060189|EXPERIMENTAL|Tranexamic Acid|15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
62633242|NCT01060189|PLACEBO_COMPARATOR|Placebo|50ml saline solution before skin incision; 50ml saline solution after neutralization
62633243|NCT05867667|EXPERIMENTAL|Cardiac Rehabilitation to Improve Breast Cancer Outcomes|12 weeks of Cardiac Rehab
62633244|NCT03583008|EXPERIMENTAL|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
62633245|NCT03583008|NO_INTERVENTION|Control|Providers in this arm will not receive any intervention.
62633246|NCT02587767|EXPERIMENTAL|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
62633247|NCT02587767|ACTIVE_COMPARATOR|HD-PDT|Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
62271002|NCT04899232|NO_INTERVENTION|AT3 more than 100% with SOC only|Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.
62088189|NCT03659487|ACTIVE_COMPARATOR|Toupét|Surgery of GERD with 270 degrees partial fundoplication
62271003|NCT03300466|EXPERIMENTAL|GP0045|Treatment with GP0045
62271004|NCT03300466|ACTIVE_COMPARATOR|Comparator|Treatment with active comparator
62271005|NCT02555670||BIA and CT|Patients who had a CT-scan made for diagnostic reasons.
62066090|NCT00301080|ACTIVE_COMPARATOR|D-cycloserine 250mg|This was the original active comparator arm (before the design was changed): D-cycloserine administered orally at a dose of 250 mg twice per day for 4 weeks.
62633248|NCT06074783|EXPERIMENTAL|MSC Intervention Group|"Participants will be enrolled into one of four subgroups listed below Firm connective tissue injury (Cartilage, bone, disc, and meniscus) Firm connective tissue degeneration (Cartilage, bone, disc, and meniscus) Soft connective tissue injury (Ligament, tendons, and muscles) Soft connective tissue degeneration (Ligament, tendons, and muscles)~Treatment: Eligible patients will receive 50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under ultrasound guidance along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury is not feasible. Additional dose can be administered. Minimum interval between two local doses is 2 months and systemic doses is 3 months."
62271006|NCT04048915|EXPERIMENTAL|Long live drama|Primary school students watched an interactive long live drama (90 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
62633249|NCT05859607|ACTIVE_COMPARATOR|Easy cholecystectomy|easy procedure with no complications
62633250|NCT05859607|ACTIVE_COMPARATOR|moderate severe cholecystectomy|moderate severity with prolonged time or complication .
62633251|NCT05859607|ACTIVE_COMPARATOR|difficult cholecystectomy|very prolonged time , complication or conversion to open cholecystectomy .
62633252|NCT06167785|EXPERIMENTAL|Tislelizumab|Tislelizumab 200mg intravenously every 3 weeks - initial safety run-in period
62633253|NCT06167785|EXPERIMENTAL|Zanubrutinib|Zanubrutinib 160 mg oral twice daily - initial safety run-in period
62633254|NCT06167785|EXPERIMENTAL|Tislelizumab + Zanubrutinib|"Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks~* Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle - expanded cohort"
62633255|NCT00941304|ACTIVE_COMPARATOR|Standard Opioid|Oxycodone 5-mg oral capsule and 2 buccal placebo films
62633256|NCT00941304|EXPERIMENTAL|High Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 1, buccal placebo film, and oral placebo capsule
62633257|NCT00941304|EXPERIMENTAL|Mid Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 2, buccal placebo film, and oral placebo capsule
62633258|NCT00941304|EXPERIMENTAL|Low Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.25-mg modified formulation 2, buccal placebo film, and oral placebo capsule
62633259|NCT00941304|PLACEBO_COMPARATOR|Placebo|Oral placebo capsule and 2 buccal placebo films
62633260|NCT05625724|EXPERIMENTAL|Aspirin|Low-dose Aspirin: 150mg, daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.
62633261|NCT05625724|PLACEBO_COMPARATOR|Control|Matching placebo administrated daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.
62066091|NCT00301080|PLACEBO_COMPARATOR|Placebo (revised version)|Placebo administered orally twice per day for 12 weeks.
62066092|NCT03485274|ACTIVE_COMPARATOR|Vortioxetine Arm|Oral: 5-20mg daily
62066093|NCT03485274|ACTIVE_COMPARATOR|Treatment as Usual|Any medication or Rx other than vortixoetine
62066094|NCT05324345|EXPERIMENTAL|Prehabilitation group|This is a prospective single-arm study. All patients enrolled in this study will receive the multimodal prehabilitation strategy by the network learning platform after a complete assessment.
62066095|NCT05696561|EXPERIMENTAL|Treatment with a Canaloplasty Device|Canaloplasty Device
62066096|NCT03980184|EXPERIMENTAL|Study Medication|guanfacine 3mg/day (GUA)
62633262|NCT02213315|EXPERIMENTAL|100mg arm|100mg dose
62066097|NCT03980184|PLACEBO_COMPARATOR|placebo|placebo (PBO)
62271007|NCT04048915|EXPERIMENTAL|Short live drama|Primary school students watched an interactive short live drama (60 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
62271008|NCT04048915|NO_INTERVENTION|Waitlist control|Primary school students received no intervention during the 3-month study period. After the study finished, the students watched either short or long live drama, and DVD with worksheets were distributed to students and they were invited to share with their parents.
62633263|NCT02213315|EXPERIMENTAL|150mg arm|150mg dose
62633264|NCT02213315|PLACEBO_COMPARATOR|Placebo|Placebo
62271009|NCT01923129|EXPERIMENTAL|24 hour postop catheter removal|group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)
62271010|NCT01923129|NO_INTERVENTION|72 hour postoperative catheter removal|catheter removed on postoperative day 3 (72 hours postoperatively)
62271011|NCT02757664|ACTIVE_COMPARATOR|Shock wave plus eccentric exercises|Shock wave therapy associated with eccentric exercises rehabilitation program.
62633265|NCT03857698|EXPERIMENTAL|Evaluation of pain|The patient's pain will be evaluated by VAS (visual analog scale) at the end of the treatment, at the end of the treatment and at the end of the 3 months follow-up. For this, a 10 cm long line will be drawn. 0: painless and 10: the most severe pain is described and the patient will be asked to mark the value corresponding to the pain (rest, activity and night pain) on the scale.
62633266|NCT03857698|EXPERIMENTAL|Evaluation of joint range of motion|The flexion and extension range of motion of the knee joints of the patient will be measured in the prone position using a universal goniometer before and after the training.
62633267|NCT03857698|EXPERIMENTAL|Assessment of balance|Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
62633268|NCT03857698|EXPERIMENTAL|Evaluation of functional performance|A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
62633269|NCT03857698|EXPERIMENTAL|Lumbar lordosis angle assessment|During the test, patients will be asked to stand upright in a comfortable position. In the evaluation of the lumbar lordosis, the inclinometer will first be fixed to the T12-L1 backbone and then to the L5-Sl backbone and the angular values in both measurements will be collected and recorded as lordosis angle.
62271012|NCT02757664|PLACEBO_COMPARATOR|Placebo plus eccentric exercises|Placebo associated with eccentric exercises rehabilitation program.
62271013|NCT00313209|ACTIVE_COMPARATOR|Roflumilast|"Roflumilast 500 µg~underlying medication: salmeterol 50 μg, twice daily, inhaled"
62271014|NCT00313209|PLACEBO_COMPARATOR|Placebo|"Placebo~underlying medication: salmeterol 50 μg, twice daily, inhaled"
62271015|NCT01187641||colon cancer|patients undergoing treatment for colon cancer
62271016|NCT00941265|OTHER|levodopa 100 mg and benserazide 25 mg|2 weeks with Daily CAT on list A+ levodopa and benserazide
62271017|NCT00941265|OTHER|placebo|2 weeks with Daily CAT on list B + placebo.
62271018|NCT05448872||Sacubitril/Valsartan|Heart Failure (HF) patients treated with Sac/Val
62271019|NCT05729412||Compliance|Prescription is filled for specific parameters
62271020|NCT05729412||Non-compliance|Prescription is not filled for specific parameters
62271021|NCT05729412||Not available - NA|Data not available
62066098|NCT02924389|OTHER|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada with dolutegravir.
62066099|NCT02924389|OTHER|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada with dolutegravir.
62271022|NCT04041284|EXPERIMENTAL|fremanezumab|monthly 225 mg. In the open-label extension phase starting at week 12, all participants will receive active treatment with a quarterly dose of 675 mg sc
62271023|NCT04041284|PLACEBO_COMPARATOR|Placebo|
62271024|NCT01897636|EXPERIMENTAL|EUS-guided fine-needle injection of DCs vaccinations|
62271025|NCT03344003||Wilate or Nuwiq prospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
62271026|NCT03344003||Wilate or Nuwiq retrospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
62633270|NCT03857698|EXPERIMENTAL|Evaluation of knee functionality|It will be measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). There are three subgroups, namely pain, stiffness and function. A total of 24 questions (pain 5 questions, 2 questions of malfunction and 17 questions of function) and the scale answered by patients are completed in approximately 5 minutes. The scale is a 5-point Likert-type scale (0 = none 1 = mild 2 = moderate 3 = severe 4 = very severe). The score range for the subgroup of pain is 0-20, for the subgroup group 0-8 and for the subgroup of function is 0 - 68. The total WOMAC score is obtained by the sum of these 3 points and the maximum total WOMAC score is 96. There is a linear ratio between the scores obtained from the WOMAC index and the presence of symptoms. The high scores were associated with severe symptoms, more disability and poor health status, whereas low scores indicated that symptoms, pain, and functionality were good.
62066100|NCT04444661||HIT-resistance exercise|High Intensity Resistance Exercise
62271027|NCT00606086|EXPERIMENTAL|1|GI-5005 monotherapy continuing on to triple therapy
62271028|NCT00606086|ACTIVE_COMPARATOR|2|Standard of care alone
62271029|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
62271030|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
62271031|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
62066101|NCT04444661||Non exercising control|Control group that maintained life style and physical activity habits
62066102|NCT02092246|ACTIVE_COMPARATOR|Ultrasound Machine Guided Injection|Use of ultrasound machine guidance in needle placement into the knee joint
62271032|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
62271033|NCT04029012|EXPERIMENTAL|Penthrox|methoxyflurane inhaler (Penthrox) to be used 5 minutes (+/- 1 minutes) before procedure, and continuously breathing in the inhaler throughout the procedure.
62271034|NCT02135718||Group 1|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the MDI inhaler twice daily for 5 to 9 days during the second period.
62271035|NCT02135718||Group 2|Subjects will use the MDI inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
62271036|NCT04788628|EXPERIMENTAL|Epilepsy inpatients|Epilepsy inpatients with implanted hippocampal electrodes and continuous scalp EEG monitoring
62271037|NCT05583929||Spastic Cerebral Palsy|Children with spastic cerebral palsy
62271038|NCT05583929||Healthy Developing Peers|Children with healthy developing peers
62271039|NCT04223310|EXPERIMENTAL|Virtual AAD TEST group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Preselect drug with optimal antiarrhythmic effects in the patient.~3. Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~4. Drug selection should be decided according to the guidelines.~5. A follow-up of rhythm follow-up has to be conducted according to the above study design."
62271040|NCT04223310|ACTIVE_COMPARATOR|Empirical AAD group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~3. Drug selection should be decided according to the guidelines.~4. A follow-up of rhythm follow-up has to be conducted according to the above study design."
62271041|NCT04087473||Prior 2nd generation ALKi|
62271042|NCT04087473||Prior 1st and 2nd generation ALKi|
62066103|NCT02092246|ACTIVE_COMPARATOR|Unguided Injection|Needle placement performed without ultrasound machine guidance
62066104|NCT06051487|OTHER|Titanium dioxide nanoparticles containing group|participants using twin block appliance in which titanium dioxide nanoparticles added to acrylic baseplates to evaluate its antibacterial effect
62271043|NCT03988556|EXPERIMENTAL|Cohort A1 - Head & neck cancer - Prophylactic intent|"Patients with head \& neck cancer starting radiotherapy +/- chemotherapy +/- targeted therapy (no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing both oral mucositis and radiodermatitis.~."
62271044|NCT03988556|EXPERIMENTAL|Cohort A2 - Head & neck cancer - Curative intent|"Patients with head \& neck cancer having started radiation therapy and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated whether they are oral mucositis or radiodermatitis lesions."
62271045|NCT03988556|EXPERIMENTAL|Cohort B1 - Breast cancer - Prophylactic intent|"Patients with breast cancer starting radiation therapy (i.e. no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing radiodermatitis."
62271046|NCT03988556|EXPERIMENTAL|Cohort B2 - Breast cancer - Curative intent|"Patients with breast cancer having started radiation therapy and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated."
62271047|NCT02565407|EXPERIMENTAL|Proprioceptive training|This arm will receive specialized robot-aided proprioceptive training of the wrist next to usual care.
62066105|NCT06051487|OTHER|control|participants use twin block appliance without any addition to acrylic base plates
62066106|NCT04242420|OTHER|Connexin genotype|Genotyping
62066107|NCT00812084||CAP cohort|Includes cases that were hospitalized because of a community-acquired pneumonia during the study period, and for which we had a baseline EQ-5D score from the start of the study period. These CAP cases are prospectively followed for up to one year using questionnaires for health status and (health) resources.
62271048|NCT02565407|ACTIVE_COMPARATOR|Usual care|This arm will receive what participants have been receiving from their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy at home, day rehabilitation, or outpatient visits.
62066108|NCT00812084||Controls cohort|For each CAP cases, two controls are matched based on age, sex and baseline EQ-5D score measured at the start of the study. These controls are prospectively followed for up to one year using questionnaires for health status and (health) resources.
62066109|NCT02164968||Obstructive bronchitis|1-5 year old patients who have visited the TAYS emergency room due to obstructive bronchitis and have been instructed to begin a three-month period of inhaled corticosteroid (ICS) treatment as per national guidelines.
62066110|NCT01350141|PLACEBO_COMPARATOR|Treatment A|
62066111|NCT01350141|EXPERIMENTAL|Treatment B|
62066112|NCT01350141|EXPERIMENTAL|Treatment C|
62066113|NCT06413784|EXPERIMENTAL|Morning Chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of morning chronotype individuals were examined.
62066114|NCT06413784|EXPERIMENTAL|Intermediate chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of Intermediate chronotype individuals were examined.
62066115|NCT06413784|EXPERIMENTAL|Evening chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of evening chronotype individuals were examined.
62066116|NCT02710695|ACTIVE_COMPARATOR|Control|This group will receive a 10 minute discussion
62066117|NCT02710695|ACTIVE_COMPARATOR|Intervention|This group will receive a 10 minute standardized discussion
62066118|NCT01713699|OTHER|diagnostic|Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
62066119|NCT01057615|EXPERIMENTAL|Active Fish Oil + Vitamin C Placebo|Fifteen subjects will take 10 active fish oil capsules per day and 2 vitamin C placebo capsules per day for 3 weeks.
62066120|NCT01057615|EXPERIMENTAL|Fish Oil Placebo + Active Vitamin C|Fifteen subjects will take 10 fish oil placebo capsules per day and 2 active vitamin C capsules per day for 3 weeks.
62066121|NCT01057615|EXPERIMENTAL|Active Fish Oil + Active Vitamin C|Following a 2-week washout period, all subjects from the other two arms (n=30) will take 10 active fish oil capsules per day and 2 active vitamin C capsules per day for 3 weeks.
62271049|NCT03108950|EXPERIMENTAL|Home-Based Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
62066122|NCT04141020|EXPERIMENTAL|Microsurgical Clipping Treated with Sirolimus|Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.
62066123|NCT04141020|EXPERIMENTAL|Endovascular Treatment Treated with Sirolimus|Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.
62066124|NCT04853147|EXPERIMENTAL|triple therapy|Triple combination of Fosaprepitant, Palonosetron and Dexamethasone were administered
62066125|NCT04853147|OTHER|double therapy|double combination of Palonosetron and Dexamethasone were administered
62066126|NCT02475317|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to maralixibat 10 milligram (mg), 20 mg, 50 mg once daily (QD), 50 mg twice daily (BID), 100 mg liquid formulation and volixibat 10 mg, 20 mg capsule orally for 7 days.
62066127|NCT02475317|EXPERIMENTAL|Maralixibat 10mg|Participants will receive maralixibat 10 mg liquid formulation orally QD for 7 days.
62271050|NCT01278498|EXPERIMENTAL|escitalopram|prevention of poststroke depression in patients with acute stroke.
62271051|NCT01278498|PLACEBO_COMPARATOR|placebo|prevention of poststroke depression in patients with acute stroke.
62271052|NCT05190003|EXPERIMENTAL|Study group I: The first time of patients attending single-level lumbar microdiscectomy|"Study group I:~On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises."
62271053|NCT05190003|NO_INTERVENTION|Study group II: Control healthy people|"Study group II:~40 people aged 20-65 years. Including criteria: healthy persons without lumbar spine pain for at least 6 months and without lumbar spine surgery."
62271054|NCT00107237|EXPERIMENTAL|AEE788 200 mg + RAD001 5 mg|AEE788 200 mg qd, RAD001 5 mg qd
62271055|NCT00107237|EXPERIMENTAL|AEE788 150 mg + RAD001 5mg|AEE788 150 mg qd, RAD001 5 mg qod
62066128|NCT02475317|EXPERIMENTAL|Volixibat 10mg|Participants will receive volixibat 10 mg capsule orally QD for 7 days.
62066129|NCT02475317|EXPERIMENTAL|Maralixibat 20mg|Participants will receive maralixibat 20 mg liquid formulation orally QD for 7 days.
62066130|NCT02475317|EXPERIMENTAL|Volixibat 20mg|Participants will receive volixibat 20 mg capsule orally QD for 7 days.
62271056|NCT01123863||Patient Group|"This study will administer Brigance Preschool Screen -II to 3 year old children with SCD followed at St. Jude Children's Research Hospital~Intervention: Brigance Preschool Screen -II"
62271057|NCT01123863||control group|"The control group will consist of 3-year-old children attending day care in the Memphis area and serve as a population that come from a similar socioeconomic background as the SCD patient population.~Intervention: Brigance Preschool Screen -II"
62271058|NCT02869386|EXPERIMENTAL|STEMO deployment|STEMO is a specialized stroke ambulance providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
62271059|NCT02869386|ACTIVE_COMPARATOR|Regular care|Regular prehospital care consists of an ambulance. In suspected life-threatening cases an emergency physician is sent to the emergency scene in parallel.
62271060|NCT01462266|EXPERIMENTAL|Sitagliptin|Sitagliptin 100 mg once daily
62271061|NCT01462266|PLACEBO_COMPARATOR|Placebo|Placebo to sitagliptin once daily
62271062|NCT03652532|EXPERIMENTAL|Alternate Day Fasting and Exercise|
62271063|NCT03652532|EXPERIMENTAL|Alternate Day Fasting|
62271064|NCT03652532|EXPERIMENTAL|Exercise|
62271065|NCT03652532|NO_INTERVENTION|Control|regular eating and exercise habits for 8 weeks
62271066|NCT04232579||Chronic obstructive respiratory disease|The out-patient population with chronic obstructive respiratory disease consulted at Nguyen Tri Phuong Hospital, Ho Chi Minh city, Vietnam.
62271067|NCT02870361|ACTIVE_COMPARATOR|Insulin nasal spray|160 Units of human insulin as nasal spray
62271068|NCT02870361|PLACEBO_COMPARATOR|Placebo nasal spray|Nasal spray containing placebo solution
62633271|NCT03857698|EXPERIMENTAL|Assessment of lower extremity muscle endurance|The patient will be asked to sit on the chair as fast as possible, so that the chair, which has a 46 cm height, will be crossed in the chest. The stopwatch is started with the command given to the patient and stopped in 30 seconds. The number of repetitions will be recorded.
62066131|NCT02475317|EXPERIMENTAL|Maralixibat 50mg|Participants will receive maralixibat 50 mg liquid formulation orally QD for 7 days.
62271069|NCT00862264|EXPERIMENTAL|CHF 1535 pMDI|CHF 1535 HFA pMDI aerosol (100 µg/unit dose of beclomethasone dipropionate plus 6 µg of formoterol/unit dose
62633272|NCT01000987|EXPERIMENTAL|varenicline|varenicline 1mg/day or 2mg/day
62633273|NCT01000987|PLACEBO_COMPARATOR|placebo|placebo
62271070|NCT00862264|ACTIVE_COMPARATOR|BDP pMDI|Beclomethasone dipropionate-CFC pMDI, 250 µg/unit dose
62271071|NCT05662423|ACTIVE_COMPARATOR|Expressive Writing about Childbirth|Subgroup of participants will write about their recent childbirth.
62633274|NCT05221970|OTHER|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|MBCT uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
62633275|NCT05221970|OTHER|Positive Psychology - online|Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
62271072|NCT05662423|PLACEBO_COMPARATOR|Neutral Writing|Subgroup of participants will write about neutral daily events.
62633276|NCT05221970|OTHER|Autogenic Training - online|Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
62633277|NCT05221970|NO_INTERVENTION|Waiting list|No intervention.
62633278|NCT02526485||Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
62271073|NCT02526004|ACTIVE_COMPARATOR|Standard Empiric Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin
62633279|NCT03058354||Group TIVA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
62633280|NCT03058354||Group GA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
62633281|NCT01795794|EXPERIMENTAL|LOSEC|"LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the control group of herself."
62633282|NCT03613714|ACTIVE_COMPARATOR|Intervention Group|At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
62633283|NCT03613714|NO_INTERVENTION|Usual Care|Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
62633284|NCT01583413|EXPERIMENTAL|Opt Out Protocol|
62633285|NCT03213847|OTHER|Participants with carpal tunnel syndrome|Participants diagnosed with carpal tunnel syndrome; will be evaluated with Doppler ultrasound and superb microvascular imaging (SMI) ultrasound. The results of these two evaluations will be compared between each other in according to severity of carpal tunnel syndrome (severity will be determined by electromyography studies)
62066132|NCT02475317|EXPERIMENTAL|Maralixibat 50mg BID|Participants will receive maralixibat 50 mg liquid formulation orally BID for 7 days.
62633286|NCT00734266||1 Control|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
62633287|NCT00734266||2 COPD|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
62633288|NCT01185470|EXPERIMENTAL|Subjects with Implantable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
62633289|NCT06204770|EXPERIMENTAL|groups of infants with CMPA|Administered treatment for 4 weeks during intervention period.
62633290|NCT03358823||Angelman syndrome|Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
62633291|NCT03513679|EXPERIMENTAL|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
62633292|NCT03513679|NO_INTERVENTION|Control Group|Gait and balance testing to be administered once in healthy subjects
62633293|NCT04999943|ACTIVE_COMPARATOR|Hypomemylating agent monotherapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle)
62633294|NCT04999943|EXPERIMENTAL|Combined cellular immunotherapy（eDC）with Hypomemylating agent therapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle) with Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin
62633295|NCT01000974|EXPERIMENTAL|Hiberix Group|Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
62633296|NCT01000974|ACTIVE_COMPARATOR|ActHIB Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
62066133|NCT02475317|EXPERIMENTAL|Maralixibat 100mg|Participants will receive maralixibat 100 mg liquid formulation orally QD for 7 days.
62271074|NCT02526004|EXPERIMENTAL|Microbiome Guided Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis
62633297|NCT01000974|ACTIVE_COMPARATOR|Pentacel Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
62633298|NCT02610517|OTHER|Provider Training|Training providers to offer alcohol pharmacotherapy to at-risk drinkers interested in quitting or reducing their drinking as part of overall HIV care could be an important strategy to reduce hazardous alcohol use in this medically-ill population.
62633299|NCT02610517|OTHER|Patient Intervention|Determine the effectiveness of a computer-delivered brief intervention (CBI) for reducing hazardous drinking in the HIV clinical care setting at two intervention clinics: University of Alabama at Birmingham (UAB) and the University of Washington (UW).
62633300|NCT02404610|EXPERIMENTAL|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
62633301|NCT02404610|EXPERIMENTAL|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
62633302|NCT06218446||Patients|
62633303|NCT06218446||Care team|
62633304|NCT04069884|EXPERIMENTAL|Arm I (Clinical low-risk, RecurIndex high-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
62633305|NCT04069884|ACTIVE_COMPARATOR|Arm II (Clinical low-risk, RecurIndex high-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
62633306|NCT01255072|ACTIVE_COMPARATOR|Active rTMS + placebo|Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
62633307|NCT01255072|SHAM_COMPARATOR|SHAM|Patients, free from medication at least for one week (washout of 3 weeks for fluoxetine users)receiving 20 sessions of Sham TMS delivered to the left dordolateral prefrontal cortex, at the same time this washed out of antidepressives patients start taking Citalopram 20mg/day, for 60 days.
62633308|NCT06379373|EXPERIMENTAL|Spinal manipulation|"Tuina method：(1) Cervical traction treatment (2) Relaxation techniques: Massage the neck for about 10 minutes with methods such as kneading, etc.~(3) Orthopedic manipulation; (4) Cervicothoracic dorsal extension and wrenching method; (5) Lumbar spine oblique wrenching method;"
62271075|NCT03867578|OTHER|Exploratory Phase - Standard CT Imaging and HR-MRI|The goal is to test several different novel Magnetic Resonance sequences to determine which gives the best visualization of peritoneal disease.
62271076|NCT03867578|OTHER|Testing Phase- Conventional and HR-MRI and Ultrasound|Patients will undergo conventional and HR-MRI imaging as well as abdominal ultrasound to define the performance of these methods.
62633309|NCT06379373|ACTIVE_COMPARATOR|Relaxation manipulation and medicine|Take Typride tablets (Jiangsu Enhua Pharmaceutical Co., Ltd., Guoyao Zhunzi H32025477). Methods: Oral administration half an hour after meals. Dosage: 50mg/time for 4-7 years old, 75mg/time for 7-12 years old, 100mg/time for 10-18 years old, 2 times/d) for 23 cases each, 2 consecutive weeks for 1 course of treatment.
62066134|NCT03004313|EXPERIMENTAL|Migraine|"20 subjects experiencing 1-14 migraines per month will undergo the following:~* Blood and urine samples will be collected~* Complete a series of questionnaires; some of which will be completed daily~* Quantitative Sensory Test (QST)will be performed~* Magnetic Resonance Imaging (MRI)~* PET imaging (during and outside of a migraine attack)"
62633310|NCT06379373|NO_INTERVENTION|Healthy controls|healthy people
62633311|NCT02864407||Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|Korean patients with COPD who are newly prescribed with Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination).
62633312|NCT04235426|EXPERIMENTAL|surgical group.|30 patients went to the surgical release of carpal tunnel.
62633313|NCT04235426|EXPERIMENTAL|medical group.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
62066135|NCT03004313|ACTIVE_COMPARATOR|Healthy|"20 healthy subjects will undergo the following:~* Blood and urine samples will be collected~* Complete a series of questionnaires; some of which will be completed daily~* Quantitative Sensory Test (QST)will be performed~* Magnetic Resonance Imaging (MRI)~* PET imaging"
62271077|NCT04431713|EXPERIMENTAL|Exenatide|
62271078|NCT04431713|NO_INTERVENTION|Standard of care|
62271079|NCT02161211|EXPERIMENTAL|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
62271080|NCT02161211|EXPERIMENTAL|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
62271081|NCT02161211|EXPERIMENTAL|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
62271082|NCT04479163|EXPERIMENTAL|Plasma|Convalescent plasma with an IgG titer against SARS-CoV2
62271083|NCT04479163|PLACEBO_COMPARATOR|Placebo|Normal Saline 0.9%
62452903|NCT05854758|EXPERIMENTAL|Core strengthening with conventional treatment|This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation continuous mode for 10 minutes.
62633314|NCT04235426|EXPERIMENTAL|injection group.|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
62633315|NCT04472897|EXPERIMENTAL|Part A: Participants receiving GSK2556286|Participants will be randomized to receive GSK2556286 in any of the 11 cohorts. In each dosing cohort, 6 participants will receive a single dose of GSK2556286. Following initial dosing of cohorts in the fasted state, one cohort will investigate the effect of food administration (high fat meal) on safety, tolerability and PK data of GSK2556286. One cohort may also investigate the effects of a moderate fat meal.
62066136|NCT02814474|PLACEBO_COMPARATOR|SALINE|Infusion of saline (0.9 %)
62066137|NCT02814474|EXPERIMENTAL|KETONE|Infusion of Na-3-Hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
62066138|NCT05260372||Lung transplantation recipients|Recipients aged 18 to 65 years old undergoing lung transplantation at Fondazione IRCCS Ospedale Policlinico Milano undergoing quantification of donor-derived cell-free DNA on serial plasma samples
62066139|NCT00653549|EXPERIMENTAL|A|Subjects received Par formulated product under fasting conditions
62066140|NCT00653549|ACTIVE_COMPARATOR|B|Subjects received Roche formulated product under fasting conditions
62633316|NCT04472897|PLACEBO_COMPARATOR|Part A: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 11 cohorts. In each dosing cohort, 2 participants will receive a single dose of matching placebo.
62066141|NCT00525265|EXPERIMENTAL|1|OPC-41061
62633317|NCT04472897|EXPERIMENTAL|Part B: Participants receiving GSK2556286|"Participants will be randomized to receive GSK2556286 in any of the 4 cohorts. In each dosing cohort, 6 participants will receive repeat doses of GSK2556286 under either fasting or fed conditions, dependent on the results from Part A.~Appropriate doses and dose regimens for Part B will be selected by the Dose Escalation Committee based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B."
62633318|NCT04472897|PLACEBO_COMPARATOR|Part B: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 4 cohorts. In each dosing cohort, 2 participants will receive repeat doses of matching placebo under either fasting or fed conditions, dependent on the results from Part A.
62633319|NCT05136677|EXPERIMENTAL|Arm A|
62633320|NCT05136677|EXPERIMENTAL|Arm B|
62633321|NCT00667992|ACTIVE_COMPARATOR|Budesonide Hydrofluoroalkane (HFA) 100|Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks
62066142|NCT00525265|PLACEBO_COMPARATOR|2|placebo
62633322|NCT00667992|ACTIVE_COMPARATOR|Budesonide HFA 400|Budesonide HFA 400 mcg twice daily for 2 weeks
62633323|NCT00667992|ACTIVE_COMPARATOR|Budesonide Chlorofluorocarbon (CFC) 100|Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks
62633324|NCT00667992|ACTIVE_COMPARATOR|Budesonide CFC 400|Budesonide CFC 400 mcg twice daily for 2 weeks
62633325|NCT00292552||COPD subjects|Subjects with GOLD stage II-IV COPD
62066143|NCT05177731|EXPERIMENTAL|Investigational ( venetoclax, decitabine)|"Randomized participants will receive induction as decitabine on days 1-5 and venetoclax daily on days 1-28.~Second Induction (if not reach complete remission, but the percentage of blaste cells in bone marrow decreased by more than 50%):Re-induction with pre-induction therapy.~Consolidation: If patients with favorable risk and MRD (Minimal Residual Disease) negative or refuse to allo-HSCT (Hematopoietic stem-cell transplantation), intermediate-dose (2g/m2 q12h days 1-3) for 4 cycles. If patients with intermediate or poor risk or favorable risk but MRD positive, intermediate-dose cytarabine for 1-2 cycles and follow up with allo-HSCT.~For patients with FLT3 mutation, gilteritinib can be combined with the follow-up treatment after the end of initial induction."
62088190|NCT03671538|EXPERIMENTAL|Anlotinib Plus Pemetrexed and Cisplatin|pemetrexed 500mg/m2 and Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
62633326|NCT00292552||Smoker controls|Subjects with smoking history but normal lung function
62633327|NCT00292552||Non-smoker controls|Normal healthy non-smokers
62633328|NCT06380920|EXPERIMENTAL|Case|intervened with App/CBT/MB-EAT groups by a randomized control trial design for 9 months and periodically surveyed as well as 0, 3, and 6 months after intervened
62633329|NCT06380920|PLACEBO_COMPARATOR|Control|intervened without App/CBT/MB-EAT groups by a randomized control trial design for 9 months and periodically surveyed as well as 0, 3, and 6 months after intervened
62633330|NCT05807971|EXPERIMENTAL|SAD cohort|SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of ATH-063 (capsule) under fasting conditions at the planned dose levels.
62633331|NCT05807971|EXPERIMENTAL|MAD Cohort|MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of ATH-063 (Capsule) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.
62633332|NCT05807971|EXPERIMENTAL|Food Effect|An intermediary dose level that has already been administered in this study will be selected for the food-effect evaluation based on the available PK and safety data. This will be conducted under fasting and fed conditions.
62633333|NCT05807971|PLACEBO_COMPARATOR|SAD cohort (Placebo)|SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of placebo (Capsule identical to active ATH-063) under fasting conditions at the planned dose levels.
62633334|NCT05807971|PLACEBO_COMPARATOR|MAD cohort (Placebo)|MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of placebo (Capsule identical to active ATH-063) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.
62633335|NCT03714477|ACTIVE_COMPARATOR|Treatment Arm|immediate extracorporeal shock wave lithotripsy - subject will have SWL arranged in the next available list
62633336|NCT03714477|NO_INTERVENTION|Control Arm|delayed extracorporeal shock wave lithotripsy - subject will have SWL done 6 months later
62633337|NCT02959216|EXPERIMENTAL|Aerobic Exercise|Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day up to 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
62633338|NCT02959216|PLACEBO_COMPARATOR|Stretching Exercise|Stretching exercise participants will receive a prescription to complete a standardized physical therapy stretching protocol once a day for approximately 20 minutes. Participants will wear a heart rate monitor to track their heart rate during the stretching exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
62633339|NCT00931632|EXPERIMENTAL|Inhaled Nitric Oxide|Inhaled Nitric Oxide
62633340|NCT00931632|PLACEBO_COMPARATOR|Placebo|Nitrogen Placebo
62633341|NCT03812900|EXPERIMENTAL|Formulation A|Echinacea purpurea alcoholic extract lozenges (novel formulation)
62066144|NCT05177731|EXPERIMENTAL|"Standard of Care (Conventional Induction 7+3)"|"Randomized participants will receive cytarabine and idarubicin per standard of care as follows:~Induction: cytarabine on days 1-7 and idarubicin (12mg/m2) on days 1-3 .~Second Induction (if not reach complete remission, but the percentage of blaste cells in bone marrow decreased by more than 50%): Re-induction with pre-induction therapy.~Consolidation: If patients with favorable risk and MRD negative or refuse to allo-HSCT, intermediate-dose cytarabine (2g/m2 q12h days 1-3) for 4 cycles. If patients with intermediate or poor risk or favorable risk but MRD positive, intermediate-dose cytarabine for 1-2 cycles and follow up with allo-HSCT.~For patients with FLT3 mutation, gilteritinib can be combined with the follow-up treatment after the end of initial induction."
62271084|NCT03020732|EXPERIMENTAL|test groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups.In test groups, a special centrifuge machine(Medifuge) and subjects venous blood were used to obtain Concentrated growth factor. A special compress was used to transform Concentrated growth factor membrane.
62633342|NCT03812900|EXPERIMENTAL|Formulation B|Echinacea purpurea alcoholic extract spray (novel formulation)
62633343|NCT03812900|ACTIVE_COMPARATOR|Formulation C|Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
62633344|NCT03812900|ACTIVE_COMPARATOR|Formulation D|Echinacea purpurea alcoholic extract, drops (basic formulation, reference)
62088191|NCT04802863|EXPERIMENTAL|Five doses of XNW4107 with imipenem/cilastatin|Each subject will receive a total of five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin via IV infusion administered every 6 hours with each administration infused over 60 minutes.
62088192|NCT05218122||LKD syndrome|liver and kidney deficiency syndrome
62633345|NCT05617807|EXPERIMENTAL|Nanoscopic Partial Meniscectomy|This is the experimental group. patients will have a partial meniscectomy performed using the arthrex nanoscope
62633346|NCT05617807|ACTIVE_COMPARATOR|Standard Partial Meniscectomy|Patients will have a partial meniscectomy performed using standard arthroscopic equipment which is the current gold standard
62633347|NCT04257396|EXPERIMENTAL|Arm 1 CARA Positioning|Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.
62088193|NCT05218122||PBS syndrome|phlegm and blood stasis syndrome
62271085|NCT03020732|ACTIVE_COMPARATOR|control groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups. In control groups, subepithelial connective tissue graft was taken from the palatal canine teeth-first molar teeth area with a trap door technique according to the width of the exposed root surface and the adjacent bone margins. The graft's thickness was adjusted between 1.5 and 2 mm.
62271086|NCT03933865|OTHER|Buprenorphine Maintained Patients|All participants will be maintained on buprenoprhine for the treatment of opioid use disorder. All participants will be exposed to all 8 study drug combinations
62271087|NCT01019382|EXPERIMENTAL|All patients|All patients entering the trial
62633348|NCT04257396|NO_INTERVENTION|Arm 2 Standard of Care|Arm 2 patients will not receive CARA breast support. Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre. These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD. Published rates of MD for the control arm thus pertain to a cross section of these methods. The control arm of this study will look at all of these methods combined. There may be centre specific preference for the control method and stratification by centre will be done.
62633349|NCT03066830|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received two Sotagliflozin tablets of 200 mg, orally once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
62633350|NCT03066830|PLACEBO_COMPARATOR|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
62633351|NCT03852823|EXPERIMENTAL|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
62633352|NCT06386380||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis outpatients from the National Institute of Medical Sciences
62633353|NCT01063309||Autosomal recessive CGD|Participants must have autosomal recessive CGD (p47phox, p67phox, or p22phox deficiency) as demonstrated by DHR or genetic screening.
62633354|NCT01063309||CGD carrier|Participants with confirmed as X-linked CGD carriers as demonstrated by DHR or genetic screening.
62633355|NCT01063309||Healthy Volunteer|Healthy volunteers over the age of 18, both male and female. That have not been diagnosed with CGD, Inflammatory Bowel Disease, or another primary disease of the immune system.
62066145|NCT06459830|EXPERIMENTAL|Mime Therapy with Neural Mobilization|"This group will receive mime therapy and neural mobilization session with resting intervals.~1. Self- facial massages for 10 minutes.~2. Breathing and relaxation exercises .~3. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~4. Exercises to assist with eye and lip closure.~5. Articulation Exercises.~6. Facial expression exercises~Facial Nerve Mobilization The circular movement and horizontal traction will be applied 25 times in three sets with a 5-second rest period in between a single manipulation and a 30- second rest period in between the sets.~All the participates in the experimental group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
62066146|NCT06459830|PLACEBO_COMPARATOR|Mime Therapy with placebo Mobilization|"Control group will receive mime therapy session with short resting intervals.~1. Self- facial massages for 10 minutes.~2. Breathing and relaxation exercises.~3. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~4. Exercises to assist with eye and lip closure.~5. Articulation Exercises.~6. Facial expression exercises.~Placebo Neural Mobilization Technique:~Placebo Mobilization followed all the procedures of real facial mobilization without applying horizontal and circular auricular traction. The purpose of this placebo facial nerve mobilization is not to deprived the control group from therapy.~All the participates in the control group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
62066147|NCT04406350|EXPERIMENTAL|Study group - MRI CO2 and O2 stress test|Pilot Study of Feasibility of tight control of end-tidal respiratory gases during conduct of anesthesia
62088194|NCT05218122||NC group|Normal Control group
62088195|NCT02733107|OTHER|Apatinib+Etoposide|Apatinib combined with Etoposide
62271088|NCT06307912|PLACEBO_COMPARATOR|Placebo group|The placebo intervention group will be shown an online educational VR video.
62271089|NCT06307912|EXPERIMENTAL|Nocebo group|The nocebo intervention group will be shown an online educational VR video.
62271090|NCT04864730||CT scans|No intervention Data of voxels will be integrated to the final model
62271091|NCT04749459|EXPERIMENTAL|ChapStick Moisturizer, Classic Flavor|This arm will include all the test sites on the participants back where ChapStick Classic Moisturizer (ANZ) will be applied.
62271092|NCT04749459|EXPERIMENTAL|ChapStick Moisturizer, Strawberry Flavor|This arm will include all the test sites on the participants back where ChapStick Strawberry Moisturizer (ANZ) will be applied.
62633356|NCT01063309||IFN-gamma treated CGD|Participants with CGD the have been treated with Interferon gamma.
62633357|NCT01063309||Inflammatory bowel disease|Participants with Inflammatory Bowel Disease with a well-recognized granulomatous inflammation, but normal phagocyte function and ROS production. They have not been diagnosed with CGD.
62633358|NCT01063309||Other immune system disorders|Participants with other disorders such as Chediak-Higashi Syndrome, Leukocyte Adhesion Deficiency, myeloperoxidase deficiency, Hyper- IgE (Job's) Syndrome, IRAK4-deficiency, and NEMO-deficiency
62633359|NCT01063309||X-linked Chronic Granulomatous Disease (CGD)|Participants diagnosed with X-linked CGD confirmed by DHR.
62633360|NCT01618786|EXPERIMENTAL|Compliant Flooring (CF)|Compliant flooring
62633361|NCT01618786|PLACEBO_COMPARATOR|Control (CON)|Non-compliant flooring
62633362|NCT03717779||HF/HFpEF|patients with heart failure with a preserved ejection fraction(HFpEF) perform LUS
62066148|NCT02379065|ACTIVE_COMPARATOR|Control nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
62066149|NCT02379065|EXPERIMENTAL|Treatment nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
62066150|NCT03369184|EXPERIMENTAL|Supplemental oxygen|Inhalation of oxygen 6 L/min through an open face mask
62066151|NCT03369184|SHAM_COMPARATOR|Ambient air|Breathing ambient air through an open face mask
62066152|NCT00847795|EXPERIMENTAL|1|5ng Avotermin
62066153|NCT00847795|EXPERIMENTAL|2|50ng Avotermin
62066154|NCT00847795|EXPERIMENTAL|3|100ng Avotermin
62066155|NCT00847795|PLACEBO_COMPARATOR|4|Placebo
62066156|NCT00847795|NO_INTERVENTION|5|Standard Care
62066157|NCT06006702|EXPERIMENTAL|Bioavailability Tablet vs Capsule Formulation|TYRA-300-B01 single oral dose of tablet or capsule crossover followed by twice-daily tablet dosing
62066158|NCT06006702|EXPERIMENTAL|Food Effect Tablet Formulation|TYRA-300-B01 single oral dose of tablet in the fed and fasted state
62066159|NCT06006702|EXPERIMENTAL|Pharmacokinetic Tablet Formulation|TYRA-300-B01 single oral dose
62633363|NCT03717779||HF/HFrEF|patients with heart failure with a reduced ejection fraction(HFrEF) perform LUS
62633364|NCT03521882||Stroke Symptom Participants|
62271093|NCT04749459|ACTIVE_COMPARATOR|ISO 24444:2010 P2 Standard Sunscreen|This arm will include all the test sites on the participants back where ISO 24444:2010 P2 Standard Sunscreen will be applied.
62633365|NCT03521882||Healthy Controls|
62271094|NCT05469347|EXPERIMENTAL|Alirocumab|Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive alirocumab.
62633366|NCT03216707|SHAM_COMPARATOR|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
62633367|NCT03216707|ACTIVE_COMPARATOR|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
62066160|NCT06006702|EXPERIMENTAL|Pharmacokinetic Mini-Tablet Formulation|TYRA-300-B01 multiple-dose mini-tablet formulation
62066161|NCT01373996||Wireless|Measuring of invasive arterial blood pressure through HMW10 Wireless System.
62066162|NCT01373996||Wired|Measuring of invasive arterial blood pressure through conventional wired technology.
62066163|NCT06284967||Patients|Adults aged 20 - 45 years with symptomatic isthmic spondylolysis
62066164|NCT06284967||Controls|Matched population without spondylolysis indicated for plain x-ray and CT lumbo-sacral spine. These will be recruited mainly from the Trauma Unit. This will not add any non-indicated radiation exposure to healthy individuals
62633368|NCT03216707|ACTIVE_COMPARATOR|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
62633369|NCT06013449|ACTIVE_COMPARATOR|6-week Pulsed Electromagnetic Field treatment with intravesical bupivacaine/heparin instillations|Participants will be instructed to self-administer pulsed electromagnetic field therapy (PEMF) devices immediately following each intravesical bupivacaine/heparin instillation, while they are holding the instillation solution in their bladder. PEMF therapy will be self-administered using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat dry surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control B. Box) has been pre-programmed to deliver the same energy level every time. Participants will be instructed to administer this home treatment in conjunction with their self-administered bladder instillations of bupivacaine/heparin for 8-minute sessions, three times a week over a 6 week period. At the mid way point (3 weeks) and after completion (6 weeks) participants will complete the online questionnaires. At 6 weeks the PEMF device is returned.
62066165|NCT02811757|EXPERIMENTAL|tenodesis|
62633370|NCT06013449|SHAM_COMPARATOR|6-week Sham Treatment with intravesical bupivacaine/heparin instillations|Participants will be provided with a sham B. Body and B. Pad that appears identical to the active pulsed electromagnetic field (PEMF) device. The participant will lie the sham B- Body mat on any flat dry surface and lay on the mat with with the smaller sham B. Pad placed directly over the pelvic area. The participant will be instructed to administer this sham treatment immediately following each intravesical bupivacaine/heparin instillation, while they are holding the instillation solution in their bladder. Participants will be instructed to administer this sham treatment in conjunction with their self-administered bladder instillations of bupivacaine/heparin for 8-minute sessions, three times a week over a 6 week period. At the mid way point (3 weeks) and after completion (6 weeks) participants will complete the online questionnaires. At 6 weeks the sham PEMF device is returned.
62633371|NCT01899820|ACTIVE_COMPARATOR|Artemether lumefantrine|Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.
62633372|NCT01899820|EXPERIMENTAL|Dihydroartemisinin piperaquine|Tablets, 2 paediatric tablets/1 adult tablet, OD, every 24 hours for 48 hours
62633373|NCT05157880|EXPERIMENTAL|Experimental Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily skills.
62633374|NCT05157880|ACTIVE_COMPARATOR|Control Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily educational.
62633375|NCT05554640|EXPERIMENTAL|Test/Control|Eligible subjects that are habitual contact lens wearers will be randomized into the sequence, Test/Control.
62633376|NCT05554640|EXPERIMENTAL|Control/Test|Eligible subjects that are habitual contact lens wearers will be randomized into the sequence, Test/Control.
62633377|NCT05860569|EXPERIMENTAL|Cohort 1|3.0x10\^12 vg/kg of GC304 delivered one-time intravenously (n=3)
62633378|NCT05860569|EXPERIMENTAL|Cohort 2|1.0x10\^13 vg/ kg of GC304 delivered one-time i intravenously (n=3)
62633379|NCT05860569|EXPERIMENTAL|Cohort 3|3.0x10\^13 vg/ kg of GC304 delivered one-time i intravenously (n=3)
62633380|NCT05305859|EXPERIMENTAL|venetoclax combining chidamide and azacitidine (VCA)|"28 days per cycle × at least 2 cycles；~1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7"
62633381|NCT06523140|NO_INTERVENTION|Control group|Conventional follow-up: two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of SAH and SPLF.
62653219|NCT02340949|EXPERIMENTAL|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil \[5-FU\], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
62066166|NCT02811757|ACTIVE_COMPARATOR|tenotomy|
62271095|NCT05469347|PLACEBO_COMPARATOR|Placebo|Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive a placebo to match alirocumab.
62271096|NCT00640172||Anemic Elderly|
62271097|NCT00640172||Non-anemic adults (non-elderly, without bone marrow biopsy)|
62066167|NCT02696044|EXPERIMENTAL|Participants aged 0 months to 3 years|Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.
62066168|NCT02696044|EXPERIMENTAL|Participants aged 4 to 6 years|Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.
62066169|NCT02696044|EXPERIMENTAL|Participants aged 7 to 9 years|Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.
62066170|NCT02696044|EXPERIMENTAL|Participants aged 10 to 14 years|Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.
62066171|NCT02696044|EXPERIMENTAL|Participants aged 15 to 20 years|Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.
62066172|NCT02696044|EXPERIMENTAL|Participants aged 21 years and older|Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.
62271098|NCT00640172||Non-anemic adults (non-elderly, with bone marrow biopsy)|
62271099|NCT00640172||Non-anemic Elderly (control without bone marrow biopsy)|
62271100|NCT00640172||Non-anemic Elderly (control, with bone marrow biopsy)|
62633382|NCT06523140|EXPERIMENTAL|Experimental group|Patients will receive conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. Patients are monitored daily remotely by Case Managers, who, when the BVS3-3 alarm is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then notify the pulmonologist by transmitting the information from Bora Connect and the minutes of the phone call, who, according to conventional management, decides whether or not to hospitalize the patient, or to generate an unscheduled consultation in order to prescribe drug treatment, and/or to prescribe additional examinations, and/or to adapt the patient's oxygen therapy prescription. The Case Manager re-evaluates the situation at 48h and 96h if necessary and forwards the information to the pulmonologist.
62633383|NCT02604030|EXPERIMENTAL|Upper limb function|Assessment of scapular kinematics during arm elevation, perceived function, quality of life, range of motion and muscle strength for shoulder complex after a rehabilitation program focused on upper limb.
62633384|NCT06067867||Kidney and Pregnancy clinic consultations|Patients followed at the Kidney and Pregnancy clinic pre-conception, during pregnancy and postpartum and patients subsequently referred to nephrological follow-up
62633385|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio \< 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
62066173|NCT03785457|EXPERIMENTAL|Repetitive Trunk Extension|Participants with low back pain will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds, repeated five times with 15-second rest breaks
62633386|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
62271101|NCT03755648|EXPERIMENTAL|Treadmill training|Group A: received treadmill training along with traditional physiotherapy.. The motorized treadmill was used keeping treatment parameters as 50 Hertz, 10 Ampere and 220 Volts The treadmill training was provided by giving instructions first and then warm up was given for 5 minutes prior to the training. The children were upright with the feet flat on treadmill platform. The height of handrails was adjustable according to every child thus keeping their gaze forward. The training was ended at cool down period of 5 minutes
62271102|NCT03755648|OTHER|traditional physical therapy|Traditional therapy includes use of hot packs for 15 minutes and stretching for 20 minutes which will be applied to both groups prior to actual intervention
62633387|NCT06613022|EXPERIMENTAL|IASTM First|This arm of the study received IASTM treatment on the first day and the wait/control on the second day of the study.
62633388|NCT06613022|EXPERIMENTAL|Wait/control First|This arm of the study waited (was the control) on the first day and received IASTM treatment on the second day of the study.
62633389|NCT06517433|EXPERIMENTAL|Dose Escalation|"XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.~This cohort is closed to enrollment."
62633390|NCT01264809|EXPERIMENTAL|A : immediate physical activity counseling|Participants randomized in the experimental group (group A) will receive physical activity counseling during a one-to-one consultation at both baseline and 3 months.
62633391|NCT01264809|ACTIVE_COMPARATOR|B : later physical activity counseling|Exercise consultation will be realised only at 3 months in the control group(group B). Furthermore, patients of group B will not received any physical activity counseling at baseline.
62633392|NCT02202798||Syringe device|Endotracheal tube cuff pressure measured by 2 new syringe devices.
62271103|NCT03755648|EXPERIMENTAL|Delorme Resistance exercise|Group B received delorme resistance exercise with traditional physiotherapy. Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
62633393|NCT03952572|EXPERIMENTAL|CDOP regimen|cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.
62633394|NCT03952572|ACTIVE_COMPARATOR|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
62633395|NCT01290419|EXPERIMENTAL|A: Dose 1 + adjuvant|
62633396|NCT01290419|EXPERIMENTAL|B: Dose 2 + adjuvant|
62633397|NCT01290419|EXPERIMENTAL|C: Dose 3 + adjuvant|
62633398|NCT01290419|EXPERIMENTAL|D: Dose 3 alone|
62633399|NCT01290419|PLACEBO_COMPARATOR|E: Placebo control|
62633400|NCT01290419|EXPERIMENTAL|F: Dose 4 alone|
62633401|NCT01290419|EXPERIMENTAL|G: Dose 4 +adjuvant|
62066174|NCT03785457|EXPERIMENTAL|Sustained Trunk Extension|Participants with low back pain will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks
62066175|NCT02419430|ACTIVE_COMPARATOR|MBRT ClassRoom and Phone Application|MBRT ClassRoom and Phone Application
62452904|NCT05854758|ACTIVE_COMPARATOR|Conventional treatment|This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval
62271104|NCT04019730|EXPERIMENTAL|low carbohydrate diet|less than 10 En% carbohydrates
62271105|NCT04019730|EXPERIMENTAL|high carbohydrate diet|more than 50 En%carbohydrates
62271106|NCT01465906|EXPERIMENTAL|tulobuterol combined with tiotropium bromide|
62066176|NCT02419430|ACTIVE_COMPARATOR|Phone application only|Phone application only
62271107|NCT01465906|ACTIVE_COMPARATOR|Tiotropium bromide|
62633402|NCT04824898|EXPERIMENTAL|simvastatin 1.2%gel|simvastatin 1.2%gel applied after open flap debridment in group I
62633403|NCT04824898|EXPERIMENTAL|I-prf|Injectable plasma rich fibrin will be collected from each patient in group II and the applied after open flap debridment
62633404|NCT02105935||Normative study|male and female athletes, ages 8-14.
62633405|NCT02105935||Baseline|male and female athletes, ages 8-18.
62633406|NCT04865588|ACTIVE_COMPARATOR|rotational atherectomy + cutting balloon|angioplasty with rotational atherectomy followed by cutting balloon
62633407|NCT04865588|ACTIVE_COMPARATOR|rotational atherectomy + plain old balloon|angioplasty with rotational atherectomy followed by plain old balloon
62633408|NCT02753816|EXPERIMENTAL|Tranexamic Acid|1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
62633409|NCT02753816|PLACEBO_COMPARATOR|Placebo|Placebo given over 10 minutes into the vein once prior to surgery
62271108|NCT03595553|EXPERIMENTAL|ridinilazole|ridinilazole 200mg bid
62271109|NCT03595553|ACTIVE_COMPARATOR|vancomycin|vancomycin 125 mg qid
62633410|NCT06337864|EXPERIMENTAL|LNAA supplementation, Then Low-Phe diet|"Phase 1: LNAA Treatment Period (8 weeks) Each participant will be prescribed a specific dosage of LNAA tablets to be taken three times daily.~Phase 2: Washout (2 weeks) Participants will follow a liberalized diet and refrain from taking any LNAA or amino acid supplement.~Phase 3: Low-Phe diet (8 weeks) Each participant will follow a low-phenylalanine diet. LNAA therapy will not be administered during this phase."
62633411|NCT06337864|EXPERIMENTAL|Low-Phe diet, Then LNAA supplementation|"Phase 1: Low-Phe diet (8 weeks) Each participant will follow a low-phenylalanine diet. LNAA therapy will not be administered during this phase.~Phase 2: Washout (2 weeks) Participants will follow a liberalized diet and refrain from taking any LNAA or amino acid supplement.~Phase 3: LNAA Treatment Period (8 weeks) Each participant will be prescribed a specific dosage of LNAA tablets to be taken three times daily."
62633412|NCT02106351|EXPERIMENTAL|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
62271110|NCT02826109|EXPERIMENTAL|Interventional: Cyanoacrylate Application|Application of cyanoacrylate adhesive to one quadrant of mouth
62633413|NCT02106351|EXPERIMENTAL|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
62633414|NCT02106351|EXPERIMENTAL|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
62633415|NCT03570775|EXPERIMENTAL|"Neomedlight Sleeping bag phototherapy"|Phototherapy device with LED light + fiber optic mesh
62271111|NCT02826109|NO_INTERVENTION|Control: Absence of Cyanoacrylate Application|No application of cyanoacrylate adhesive to the other quadrant of mouth
62271112|NCT04417478|ACTIVE_COMPARATOR|Normal weight|Patients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2.
62271113|NCT04417478|EXPERIMENTAL|class I Obesity|Patients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2.
62271114|NCT04417478|EXPERIMENTAL|class II Obesity|Patients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2.
62633416|NCT03570775|ACTIVE_COMPARATOR|Conventional phototherapy|LU-6T model: phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated.
62633417|NCT02752438||Survived|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation and survived.
62633418|NCT02752438||Death|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation but died.
62633419|NCT03630159|EXPERIMENTAL|Tisagenlecleucel+Pembrolizumab|
62633420|NCT05074134|EXPERIMENTAL|[14C]-TNP-2092|
62633421|NCT05088499||Experimental group:|Patients with epilepsy
62633422|NCT05088499||Control group|Patients without epilepsy
62633423|NCT03923153|ACTIVE_COMPARATOR|Inspiratory muscle training group|Inspiratory muscle training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
62633424|NCT03923153|SHAM_COMPARATOR|Sham group|Sham group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
62271115|NCT01040052|EXPERIMENTAL|Study Group|
62452905|NCT05129579|EXPERIMENTAL|MBRSEG|The group in which the mindfulness-based stress reduction intervention will be implemented.
62452906|NCT05129579|OTHER|control group|The group to which mindfulness-based stress reduction intervention will not be applied
62633425|NCT01073826|ACTIVE_COMPARATOR|Tocilizumab|Infusion of Tocilizumab and sport intervention
62633426|NCT01073826|ACTIVE_COMPARATOR|Sitagliptin|Intake of Sitagliptin and sport intervention
62633427|NCT01073826|PLACEBO_COMPARATOR|Placebo|Intake of placebo and sport intervention
62633428|NCT06612476|EXPERIMENTAL|Interleukin 6-guided antibiotic therapy (Interleukin-6 group)|After randomization, baseline blood samples will be drawn within 2 hours. Prescribing clinician are able to access the results of the IL-6 through the internal network of the hospital. Participants' antibiotic prescription decisions will made according to the results. The detailed recommendations are as follows: if Interleukin-6\<10 pg/ml，strongly discouraged；if Interleukin-6 (10-30 pg/ml) and no sputum purulence, discouraged; if Interleukin-6 (10-30 pg/ml) and sputum purulence, Recommended; Interleukin-6\>30 pg /ml, Strongly recommended.
62633429|NCT06612476|ACTIVE_COMPARATOR|GOLD-guided antibiotic therapy (GOLD group)|After randomization, baseline blood samples will also need to be drawn within 2 hours. Prescribing clinician are able to access all results through the internal network of the hospital. Participants' antibiotic prescription decisions will made according to the recommendations of GOLD guideline. The guideline recommends antibiotic therapy for the following patients: those with COPD exacerbations presenting with all three cardinal symptoms (increased dyspnea, sputum volume, and sputum purulence); those with two of the cardinal symptoms, provided that increased purulence of sputum is one of them; or those who need mechanical ventilation (either invasive or noninvasive).
62633430|NCT02923999|EXPERIMENTAL|Dose cohort 1|P2G12 0.125g
62633431|NCT02923999|EXPERIMENTAL|Dose cohort 2|P2G12 0.25g
62633432|NCT02923999|EXPERIMENTAL|Dose cohort 3|P2G12 0.5g
62633433|NCT04993209|EXPERIMENTAL|NDV-HXP-S 1μg|NDV-HXP-S 1μg with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
62633434|NCT04993209|EXPERIMENTAL|NDV-HXP-S 3μg|NDV-HXP-S 3μg with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
62066177|NCT02419430|ACTIVE_COMPARATOR|Questionnaires|Questionnaires
62066178|NCT01108757|EXPERIMENTAL|Drug|
62066179|NCT01108757|PLACEBO_COMPARATOR|Placebo|
62066180|NCT05983744|EXPERIMENTAL|Pulsatile perfusion therapy (PPT)|Application of oscillatory lower body negative pressure (LBNP) at specific target frequencies of interest.
62066181|NCT03564782|EXPERIMENTAL|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10\^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
62066182|NCT02823964|EXPERIMENTAL|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
62066183|NCT01737996|EXPERIMENTAL|All patients|For the first 9 days patients receive BI 207127 low dose or high dose, then BI 207127 high dose with faldaprevir
62066184|NCT06038890|EXPERIMENTAL|Holmium laser enculeation of the prostate|veil-sparing Holmium laser enucleation of the prostate
62271116|NCT00091832|EXPERIMENTAL|Denosumab 60 mg every 12 weeks|Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
62066185|NCT05809349|EXPERIMENTAL|DRE patients|There will be 50 drug-refractory epilepsy (DRE) patients in this study.
62271117|NCT00091832|EXPERIMENTAL|Denosumab 120 mg every 4 weeks|Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
62066186|NCT06028074|EXPERIMENTAL|Intravenous administration of GIM-122|GIM-122
62066187|NCT03264768|OTHER|control|standard care in case collateral ventilation is observed (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post allocation.
62066188|NCT03264768|EXPERIMENTAL|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post intervention.
62633435|NCT04993209|EXPERIMENTAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscularly, with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
62633436|NCT04993209|ACTIVE_COMPARATOR|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU dose (0.5 mL) with an interval of 28 days apart Intramuscular (deltoid). In the original version of protocol, the control arm consisted in placebo use. There was a changing post hoc to Adsorbed inactivated COVID-19 vaccine (CoronaVac) due to decision of Data and Safety Monitoring Board, when 219 (50% of original sample) subjects have already included in the study. Therefore, those who received a placebo at the first vaccine visit started to receive active control vaccine and those who were included from that moment forward received two doses of active control vaccine. The original study protocol provided for the inclusion of the placebo arm (10% of population of study), in order to serve as a control for safety evaluations and to assess the attack rate of natural infection to which participants will be exposed during the study.
62633437|NCT02249104|EXPERIMENTAL|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily~Cetaphil Acne Regimen:~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
62066189|NCT02372760|EXPERIMENTAL|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V).
62066190|NCT02372760|ACTIVE_COMPARATOR|BA classic anesthesia|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
62066191|NCT03600896|EXPERIMENTAL|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
62066192|NCT03600896|EXPERIMENTAL|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
62066193|NCT06082414||<28 weeks and <1000 grams|By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.
62633438|NCT02686164|EXPERIMENTAL|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
62633439|NCT03851848|EXPERIMENTAL|Joint mobilization (JM) group|The Maitland mobilization technique will target three main joints of the affected foot in order to facilitate major ankle and foot movements: (1) Talocrural joint Anterior-posterior (AP) mobilization will be performed to enhance ankle dorsiflexion ROM; (2) first metatarsal phalangeal joint (FMTP) AP glide will be performed to facilitate big toe extension ROM; (3) subtalar joint traction will be performed to increase both foot eversion and inversion ROM, and lateral glide will be performed to reinforce inversion ROM.
62633440|NCT03851848|EXPERIMENTAL|Myofascial release (MFR) group|The MFR technique will be performed as a direct trigger point release followed by deep soft tissue release for the calf muscles (gastrocnemius and soleus) and the plantar fascia .
62633441|NCT04024605|EXPERIMENTAL|Sunflower|Biscuits containing sunflower isolate intrinsically labelled with 15N and 2H
62633442|NCT04024605|EXPERIMENTAL|Rapeseed|Biscuits containing rapeseed isolate intrinsically labelled with 15N and 2H
62633443|NCT04024605|EXPERIMENTAL|Flaxseed|Biscuits containing flaxseed isolate intrinsically labelled with 15N and 2H
62633444|NCT04024605|EXPERIMENTAL|Lupin|Biscuits containing lupin flour intrinsically labelled with 15N and 2H
62633445|NCT01653145|ACTIVE_COMPARATOR|Diet A|Low Fat High Energy Density (1.6 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
62633446|NCT01653145|ACTIVE_COMPARATOR|Diet B|High Fat Low Energy Density (1.05 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
62633447|NCT01653145|ACTIVE_COMPARATOR|Diet C|High Carbohydrate Low Energy Density (1.05 kcal/g)-20% Fat, 65% Carbohydrate, 15% Protein
62633448|NCT00416819|EXPERIMENTAL|methotrexate, leucovorin calcium, rituximab, and temozolomide|Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.
62633449|NCT04385433|EXPERIMENTAL|EXPERIMENTAL GROUP|RADIOTHERAPY + PRAVASTATIN
62633450|NCT04385433|PLACEBO_COMPARATOR|CONTROL GROUP|RADIOTHERAPY + PLACEBO
62066194|NCT06082414||<28 weeks and ≥1000 grams|By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.
62066195|NCT06082414||≥28 weeks and <1000 grams|By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.
62066196|NCT00192023|EXPERIMENTAL|Atomoxetine|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO) for 1 week, 1.2 mg/kg/day QD, PO for 7 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
62271118|NCT00091832|EXPERIMENTAL|Denosumab 180 mg every 4 weeks|Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
62271119|NCT00091832|ACTIVE_COMPARATOR|IV bisphosphonates every 4 weeks|Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.
62271120|NCT00091832|EXPERIMENTAL|Denosumab 180 mg every 12 weeks|Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
62271121|NCT00091832|EXPERIMENTAL|Denosumab 30 mg every 4 weeks|Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
62271122|NCT05801380||Alzheimer's disease patients with AChE inhibitor monotherapy|This cohort includes those with the disease and given AChE inhibitor monotherapy only
62633451|NCT05441033|EXPERIMENTAL|Group-FHB|"Written and verbal consent will be obtained by explaining the purpose of the study at the first interview with the couples in the pregnant outpatient clinic. Then, from the couples, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAAS), Antenatal Father Attachment Scale (PABB), Pre-test data will be obtained through the Richard Campbell Sleep Quality Scale (RCAS) and State Anxiety Inventory (DQS). After the attempt to imagine the baby by listening to the fetal heart beats for 5 consecutive nights, the measurement tools will be obtained at the end of the 5th night by re-measurements. A total of 2 measurements, one pre-test and one post-intervention post-test, will be performed, and it is planned to take approximately 15 minutes for each couple to apply the measurement tools."
62633452|NCT05441033|EXPERIMENTAL|Group-GIT|"Written and verbal consent will be obtained by explaining the purpose of the study at the first interview with the couples in the pregnant outpatient clinic. Then, from the couples, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAAS), Antenatal Father Attachment Scale (PABB), Pre-test data will be obtained through the Richard Campbell Sleep Quality Scale (RCAS) and State Anxiety Inventory (DQS). After the attempt to imagine the baby with the guided imagery technique performed for 5 consecutive nights with the measurement tools, the data will be obtained by re-measurements at the end of the 5th night. A total of 2 measurements, one pre-test and one post-intervention post-test, will be performed, and it is planned to take approximately 15 minutes for each couple to apply the measurement tools."
62633453|NCT05441033|NO_INTERVENTION|Control group|"It is planned to conduct two interviews in total with the couples included in the control group. Written and verbal consent will be obtained by explaining the purpose of the research at the first interview to be held in the pregnant outpatient clinics with the couples to be included in the control group. Later on, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAPAS), Antenatal Father Attachment Scale BABI, Richard Campbell Sleep Scale Pre-test data will be obtained by means of the State Anxiety Scale and the State Anxiety Scale. Measurement tools will be repeated at the end of the 5th night in parallel with the experimental groups and a total of 2 measurements will be obtained together with the pre-test measurements. It is planned that the application of the measurement tools will take approximately 15 minutes for each couple."
62633454|NCT06444503||Patients suffering from growth plate or bone pathology|As part of their pathology, patients benefit from clinical monitoring and regular blood and urine tests.
62066197|NCT00192023|PLACEBO_COMPARATOR|Placebo|placebo, daily (QD), by mouth (PO) for 8 weeks, then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
62633455|NCT05869669|ACTIVE_COMPARATOR|Neflamapimod|Neflamapimod will be administered with food for 16 weeks in subjects with DLB. Subjects will receive 3 capsules per day (TID) with food (i.e., with the morning, mid-day and evening meals).
62633456|NCT05869669|PLACEBO_COMPARATOR|Placebo|Placebo will be administered with food for 16 weeks in subjects with DLB. Subjects will receive 3 capsules per day (TID) with food (i.e., with the morning, mid-day and evening meals).
62633457|NCT03797898|EXPERIMENTAL|Intervention|Parents will meet with a Parent Coach during child's routine well visits, and have access to the parent coach between visits for additional follow up and concerns, and have access to a preventive care text messaging services (Healthy Txt).
62633458|NCT03797898|NO_INTERVENTION|Control|usual care well child care
62633459|NCT03895359|ACTIVE_COMPARATOR|Transarterial Chemoembolization (TACE)|Transarterial Chemoembolization (TACE)
62633460|NCT03895359|ACTIVE_COMPARATOR|TACE Plus Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT)
62633461|NCT01676103|EXPERIMENTAL|Tyrosine|Tyrosine supplementation (500 mg 2x daily) for 7 days
62633462|NCT01676103|PLACEBO_COMPARATOR|Sugar pill|Placebo sugar pills (2x daily) for 7 days
62633463|NCT01211756|EXPERIMENTAL|Oxytocin|20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.
62633464|NCT01211756|PLACEBO_COMPARATOR|Placebo|Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.
62633465|NCT06383026||Transgender and Gender-Diverse Persons|"Breast imaging data in the form of standard screening mammography in addition to screening whole breast ultrasound will be gathered and interpretations will follow the standard Breast Imaging Reporting and Data Systems.~Insight on the perceptions and experiences of being involved in a breast cancer screening program will be gathered."
62633466|NCT06383026||Breast Imaging Stakeholders|A semi-structure focus group to explore radiology faculty and staff experiences while capturing information on the perceived screening barriers, what support and/or training staff require to ensure patients are treated equitable in the screening process, and areas for providers and healthcare systems to improve breast cancer screening for transgendered and nonbinary persons.
62633467|NCT03131115|ACTIVE_COMPARATOR|Lateral Crural Strut Graft|Lateral crura strut graft is a well described and universally used technique involves strengthening lateral crus of lower lateral cartilage of the nose with piece of cartilage.
62633468|NCT03131115|ACTIVE_COMPARATOR|Bone-Anchored suspension|Bone- Anchored suspension is a well described surgical technique which involves anchoring the nasal sidewall to the bony rim below the eye.
62271123|NCT05801380||Alzheimer's disease patients given AChE inhibitor and NMDA receptor anatgonist combination therapy|This cohort includes those with the disease, given AChE inhibitor and NMDA receptor antagonist combination therapy
62633469|NCT01158560|EXPERIMENTAL|Vitamin D and gargling|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and asked to gargle with tap water twice daily
62633470|NCT01158560|EXPERIMENTAL|Vitamin D and general health advice|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and will receive general health advice in place of gargling advice
62633471|NCT01158560|PLACEBO_COMPARATOR|Placebo and general health advice|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be given general health advice in place of gargling advice.
62633472|NCT01158560|PLACEBO_COMPARATOR|Placebo and gargling|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be asked to gargle with tap water twice daily
62633473|NCT02037815|EXPERIMENTAL|Mannitol|20% mannitol solution, 125 ml, IV infusion in 15 min
62633474|NCT02037815|EXPERIMENTAL|Hypertonic saline|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
62633475|NCT04508686|EXPERIMENTAL|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
62633476|NCT01050946|OTHER|Haploidentical/cord transplant|Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
62633477|NCT03476057||Advanced gastrointestinal tumor|200 patients with pathologically confirmed Advanced gastrointestinal tumor who never treated with chemotherapy at Fujian Cancer Hospital
62633478|NCT05682833|EXPERIMENTAL|Test|NS therapy + Chlorhexidine/Hyaluronic acid subgingival gel application
62633479|NCT05682833|PLACEBO_COMPARATOR|Control|NS therapy + Placebo gel subgingival application
62633480|NCT00571662|EXPERIMENTAL|Cohort I|Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day
62633481|NCT05722717||MIS-C|Children with a history of MIS-C: as defined according to WHO criteria, who were 0-18 at the time of MIS-C.
62633482|NCT05722717||Post COVID-Condition|Children with post-COVID condition who were 0-18 at the time of SARS-CoV-2 infection: as defined according to the WHO case definition.
62271124|NCT01195129|OTHER|MicroVention Hydrogel Coils|FDA approved and in common use for cerebral aneurysm treatment.
62271125|NCT01195129|ACTIVE_COMPARATOR|Non-hydrogel coils|Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).
62271126|NCT04500327|EXPERIMENTAL|CPAP users|The Drive app will be used by CPAP users to identify any major issues with the usability and functionality of the app when used with CPAP therapy.
62633483|NCT05722717||Control|'Exposed' control group: children with a history of proven SARS-CoV-2 infection (RT-PCR, antigen test or serology positive) who were 0-18 at the time of SARS-CoV-2 infection.
62633484|NCT03003247|EXPERIMENTAL|IDP-120 Gel|IDP-120 Gel is a combination treatment
62633485|NCT03003247|ACTIVE_COMPARATOR|IDP-120 Component A Gel|IDP-120 Monad Gel of Component A
62633486|NCT03003247|ACTIVE_COMPARATOR|IDP-120 Component B Gel|IDP-120 Monad Gel of Component B
62633487|NCT03003247|PLACEBO_COMPARATOR|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel
62633488|NCT00045799|EXPERIMENTAL|Omeprazole sodium bicarbonate immediate release PWD/FS|
62633489|NCT00045799|ACTIVE_COMPARATOR|Cimetidine IV|
62633490|NCT06612346||MINT Surgery Cohort|Cohort that includes subjects that have undergone the MINT surgical procedure.
62633491|NCT01834456|EXPERIMENTAL|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
62633492|NCT01834456|NO_INTERVENTION|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~The control group will continue to receive usual care as they did before they enrolled in this study"
62271127|NCT04797065|EXPERIMENTAL|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 6 minutes then in 9 minutes during the segmental withdrawal.~At 6-minute withdrawal, the left colon, transverse colon and right colon will take 2 minutes each. Then at 9-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 3 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
62271128|NCT04797065|ACTIVE_COMPARATOR|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 9 minutes then in 6 minutes during the segmental withdrawal.~At 9-minute withdrawal, the left colon, transverse colon and right colon will take 3 minutes each. Then at 6-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 2 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
62271129|NCT05598918|EXPERIMENTAL|early passive mobilization|ıt will begin to using an orthosis with 30\* flexion of the wrist,70\* flexion of metacarpophalangeal (MCP) joints,full extension of IF joints.Home exercises will be performed as passive flexion and active extension exercises with rubber band 10 times per hour on postoperative 3rd day for 3 weeks.Passive flexion and extension exercises will be performed ten times a day;four times a day on MCP+PIP+IF joints.3 weeks after repair and non-resistance active movement and tenodesis exercises will be started in presence of a physiotherapist.From the 6th week tendon gliding exercises and blocking exercises will be started.
62633493|NCT04878068||Rapid Antigen Saliva Test|Participants who have had a COVID-19 PCR test will self-administer the saliva test. The research team will conduct the processing of the test for the results of positive, negative or inconclusive
62633494|NCT03184311|EXPERIMENTAL|High-intensity interval training (HIT)|A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
62633495|NCT03184311|PLACEBO_COMPARATOR|Moderate-intensity continuous training (MCT)|A 12-week MCT will be performed 3 times per week on a bicycle ergometer. All sessions will consist of moderate continuous training (MCT) at 60-70% of peak heart rate (HRpeak) for 47 minutes.
62633496|NCT06014320||ESLD|All participants recruited will belong to this group. These participants will all have end stage liver disease and be listed for liver transplant with an accepted organ offer.
62633497|NCT02630563|EXPERIMENTAL|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
62286913|NCT03656302||Case offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having at least one biological parent with a lifetime or current diagnosis of bipolar disorder; 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder; 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
62633498|NCT02829047|OTHER|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
62633499|NCT03610074|EXPERIMENTAL|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
62633500|NCT05091983||Restrictive eating disorder group|Adolescents between 12 and 18 y.o. Restrictive eating disorders diagnosis (Anorexia Nervosa or ARFID) answering DSM-5 criteria
62633501|NCT05091983||Control group|Adolescents between 12 and 18 y.o. No eating disorders
62633502|NCT04613518|EXPERIMENTAL|BMS-986165|
62633503|NCT04613518|PLACEBO_COMPARATOR|Placebo|
62633504|NCT04613518|EXPERIMENTAL|Open label Extension, BMS-986165|
62633505|NCT03035513||CSWS patients|The data of CSWS patients will be statistically compared to healthy volunteers
62633506|NCT03035513||healthy volunteers|The data of CSWS patients will be statistically compared to healthy volunteers
62633507|NCT00707967|EXPERIMENTAL|Group A|Subjects receiving the candidate vaccine
62633508|NCT00707967|PLACEBO_COMPARATOR|Group B|Subjects receiving the adjuvant
62633509|NCT00707967|PLACEBO_COMPARATOR|Group C|Subjects receiving physiological saline
62633510|NCT02020369|EXPERIMENTAL|FVIIa: 75 µg/kg first, then 225 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
62633511|NCT02020369|EXPERIMENTAL|FVIIa: 225 µg/kg first, then 75 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
62271130|NCT05598918|EXPERIMENTAL|early active mobilization|ıt will begin to using an orthosis that positions wrist in neutral position,MCP joints 50\*-70\* flexion,IF joints in full extension.After flexion active extension exercises,full passive flexion of fingers with the other intact hand and then keeping fingers in flexion position for 3-5 sec for 3 weeks.Rehabilitation program applied from 3rd week is the same as the passive group:3 weeks after repair and non-resistance active movement and tenodesis exercises will be started in presence of a physiotherapist.From the 6th week tendon gliding exercises and blocking exercises will be started.
62271131|NCT00257803|EXPERIMENTAL|1|In the other group, the women will receive a small injection of oxytocin directly into the vein via their intravenous (bolus) after their baby is born.
62271132|NCT00257803|PLACEBO_COMPARATOR|2|In one group, women will receive a small injection of saline (salt water) directly into the vein via their intravenous (bolus) after their baby is born.
62271133|NCT01986543|EXPERIMENTAL|Arm 1|8 weeks R20mg/Kg + HZE and efavirenz 600mg
62271134|NCT01986543|EXPERIMENTAL|Arm 2|8 weeks R20mg/Kg + HZE and efavirenz 800mg
62633512|NCT05854485|EXPERIMENTAL|Hybrid multi-muscle FES+Robot|Participants will be receive hybrid upper extremity training involving the combination of REACH robotic device and multi-muscle FES. Water based electrodes will be positioned on the Triceps, Anconeus, wrist and finger extensors. Stimulation intensity of FES will be set at the participants tolerance level. The FES induced muscle contraction timing will be triggered in synchrony with the robotic movement. The training will be a multi-directional reach movement and hand opening re-training.
62633513|NCT05854485|ACTIVE_COMPARATOR|Robot only|Participants will receive upper extremity training with the REACH robotic device. The training will be a multi-directional reach movement re-training.
62271135|NCT01986543|ACTIVE_COMPARATOR|Standard arm|8 weeks R10mg/Kg + HZE and efavirenz 600mg
62633514|NCT03668665|ACTIVE_COMPARATOR|Conventionell Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~1st half: conventional treatment with moist dressings (mepilex and fixomull)"
62271136|NCT01942057||School Grades 1+2|Children currently enrolled in grades 1 and 2
62633515|NCT03668665|EXPERIMENTAL|Treatment with Ready Medical Post Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~2nd half: conventional treatment with moist dressings (mepilex and fixomull) and additional treatment with ready medical post treatment"
62633516|NCT02363387|EXPERIMENTAL|Incentive Group|Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
62633517|NCT02363387|OTHER|Usual Care Group|Usual Care Control participants will receive the standard HIV medical care offered in their clinic.
62633518|NCT06201039|EXPERIMENTAL|CWI Block|"Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon.~The Continuous placebo Wound Infusion (CWI) will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.~• Intervention: Drug: 0.5% lidocaine hydrochloride at 4ml/h."
62633519|NCT06201039|PLACEBO_COMPARATOR|CWI Placebo|"Control Intervention: Patients in the control arm will undergo the CWI procedure as well. The infusion will contain 0.9% normal saline + 1:400000 adrenaline at 4ml/h.~• Intervention: Drug: 0.9% normal saline at 4ml/h."
62633520|NCT04710875|ACTIVE_COMPARATOR|Na-lactate|Iv infusion of sodium D/L lactate
62633521|NCT04710875|PLACEBO_COMPARATOR|Sodium chloride|Iv infusion of Sodium chloride
62633522|NCT00974363|EXPERIMENTAL|Group A|Subjects who received GSK Biologicals' meningococcal vaccine 134612 in the primary vaccination study 109069.
62633523|NCT00974363|ACTIVE_COMPARATOR|Group B|Subjects who received MencevaxTM ACWY in the primary vaccination study 109069.
62633524|NCT02773095|EXPERIMENTAL|Intervention counties|In intervention counties, a Novartis Access portfolio of 15 medicines will be sold to local purchasers at a cost of 150 Kenyan Shillings (KES), around US$1.50, per monthly dose.
62633525|NCT02773095|NO_INTERVENTION|Control counties|Control counties not exposed to the intervention.
62271137|NCT01942057||School Grades 6+7|Children currently enrolled in grades 6 and 7
62271138|NCT01942057||School Grades 11+12|Children currently enrolled in grades 11 and 12
62271139|NCT01076582|EXPERIMENTAL|Arm 1|
62271140|NCT01076582|ACTIVE_COMPARATOR|Arm 2|
62271141|NCT04016311|EXPERIMENTAL|Mindful Drinking/Eating Group|Behavioral: Mindful Drinking/Eating Intervention Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
62271142|NCT04016311|NO_INTERVENTION|Wait list control|Usual care. Offered intervention after post-test data collected.
62271143|NCT04344587|EXPERIMENTAL|Intervention group|Participants in the intervention arm will receive a text message on their smartphones linking to the Qualtrics intervention website
62633526|NCT03742986|EXPERIMENTAL|HER2-negative, including TNBC or HR-positive|
62633527|NCT03742986|EXPERIMENTAL|HER2-positive, independent of HR status|
62271144|NCT04344587|ACTIVE_COMPARATOR|Usual care group|Participants in the usual care arm will receive a text message on their smartphone linking to the Qualtrics usual care website
62633528|NCT01667445|EXPERIMENTAL|epimorph|single dose administration of 150mcg epimorph
62633529|NCT01667445|ACTIVE_COMPARATOR|spinal analgesia|spinal alone
62633530|NCT03118817|EXPERIMENTAL|HM95573|Single arm
62633531|NCT06410651|EXPERIMENTAL|Nimotuzumab concurrent with chemordiotherapy followed by surgery|
62066198|NCT06158425||OA group|Data for consecutive OA patients with knee pain who underwent primary TKA by one senior surgeon between August 2021 and July 2023 at a single institution were analyzed retrospectively. A total of 273 patients underwent long-leg radiographs. The following 27 patients were excluded from this study: prior total hip arthroplasty, 2; obvious bony deficiency of the femur or tibia, 10; simultaneous flexion of the knee and rotation of the leg on radiographs, 15. CPAK distribution of the remaining 246 cases(unilateral, 15; bilateral, 231; totally 477 knees) was examined.
62066199|NCT06158425||healthy group|Data for consecutive visitors at outpatient clinic who underwent long-leg radiographs but without any sign of cartilage degeneration or medical history of low extremity between January 2023 and July 2023 at the same institution were analyzed retrospectively. A total of 136 visitors were recruited. The following 18 visitors were excluded from this study: extra-articular deformity of the femur or tibia, 15; simultaneous flexion of the knee and rotation of the leg on radiographs, 13; poor quality image, 1. CPAK distribution of the remaining 107 cases(214 knees) was examined.
62271145|NCT03130244|ACTIVE_COMPARATOR|Device Placement|The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
62633532|NCT00149396|EXPERIMENTAL|Safety and antitumor effects of NV1020|"Stage 1: Four escalating dose cohorts of NV1020 3x10\^6 pfu, 1x10\^7 pfu, 3x10\^7 pfu, and 1x10\^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.~Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy."
62633533|NCT05868538||Patients|
62633534|NCT05868538||control|
62633535|NCT04019717|EXPERIMENTAL|8 weeks|
62633536|NCT04019717|EXPERIMENTAL|12 weeks|
62633537|NCT02871609||Patients with longterm ureteral stent|
62066200|NCT05420441|EXPERIMENTAL|Group A (Phonophoresis with chitosan group)|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
62271146|NCT03130244|NO_INTERVENTION|Control|The patients in this arm will receive the best medical management.
62271147|NCT05748093|EXPERIMENTAL|Cohort 1: Adjusting osimertinib treatment plans with concomitant pk-boosting|Feasibility of using pharmacokinetic boosting and TDM to individualize treatment plans and dosage for osimertinib, in patients with advanced NSCLC with mutated EGFR. In this cohort, patients will receive cobicistat for pharmacokinetic boosting of standard osimertinib treatment. Afterwards, they will receive personalised treatment plans, guided by therapeutic drug monitoring.
62271148|NCT05748093|EXPERIMENTAL|Cohort 2: Improving osimertinib CNS penetration in patients with neurometastases|Assessing whether pharmacokinetic boosting can improve CNS penetration of osimertinib, in patients with advanced NSCLC with mutated EGFR with asymptomatic CNS oligoprogression. Patients who experience progressive disease intracranially, are sometimes dose-escalated to try and improve osimertinib intracranial exposure. This study will look to demonstrate the feasibility of using a PK-booster instead, potentially providing patients the benefits of higher intracranial treatment efficacy, without needing to take extra osimertinib.
62271149|NCT00356941|EXPERIMENTAL|Chemoradiation Treated Patients|Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
62633538|NCT01212094|EXPERIMENTAL|Rituximab|Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
62633539|NCT01212094|PLACEBO_COMPARATOR|Placebo|Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
62633540|NCT01212094|NO_INTERVENTION|Baseline|Patients in their first year baseline prior to study drug phase
62271150|NCT01497015|EXPERIMENTAL|memory training|memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
62271151|NCT01497015|EXPERIMENTAL|speed of processing training|Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
62271152|NCT01497015|EXPERIMENTAL|waitlist control|Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
62271153|NCT00832559|EXPERIMENTAL|CVA21|CVA21
62633541|NCT01078064||Study group|Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.
62633542|NCT06301789|PLACEBO_COMPARATOR|Control Group|receive pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
62633543|NCT06301789|EXPERIMENTAL|InterventionalGroup|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine plus 2 ml of magnesium sulfate 10 % on each side of the abdominal wall before induction of GA.
62271154|NCT03548558|EXPERIMENTAL|"Arm 1 (group sessions)"|Group meetings only (16 total)
62271155|NCT03548558|EXPERIMENTAL|"Arm 2 (group+home sessions)"|Mixed group meetings with a limited number of individual home visits (12 group meetings + 4 home visits)
62271156|NCT03548558|NO_INTERVENTION|Arm 3|This arm will serve as the control group to identify the effects of a parenting intervention and the most effective mode of delivery, as well as the sustained impacts from the intervention
62633544|NCT05701254||Type 1 Diabetics|All participants will complete 4 visits over 6-8 weeks. Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG. Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy. Visit 3 is the bone biopsy and includes a blood draw. Visit 4 is to remove the stitches.
62633545|NCT05701254||Non-Type 1 Diabetics|All participants will complete 4 visits over 6-8 weeks. Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG. Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy. Visit 3 is the bone biopsy and includes a blood draw. Visit 4 is to remove the stitches.
62066201|NCT05420441|EXPERIMENTAL|Group B (Phonophoresis with glucosamine group)|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
62633546|NCT02154932|ACTIVE_COMPARATOR|double dose misoprostol|2 doses, 3 and 1 hours, prior surgery (group B, 35 cases).
62633547|NCT02154932|ACTIVE_COMPARATOR|single dose Misoprostol|intra-vaginal single dose of 400 microgram Misoprostol 1 hour pre-operatively (group A, 34 cases)
62633548|NCT02958787|EXPERIMENTAL|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
62633549|NCT04218721|EXPERIMENTAL|eHealth application|Participants get access to the eHealth application InvolveMe
62633550|NCT02431312|EXPERIMENTAL|Group A: low dose, standard regimen|Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
62633551|NCT02431312|EXPERIMENTAL|Group A: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
62633552|NCT02431312|EXPERIMENTAL|Group A: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
62633553|NCT02431312|EXPERIMENTAL|Group B: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
62633554|NCT02431312|EXPERIMENTAL|Group B: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
62633555|NCT02431312|ACTIVE_COMPARATOR|Active Control: nucleos(t)ide analogue treatment|Participants continued treatment with nucleos(t)ide analogue treatment.
62633556|NCT06573229|EXPERIMENTAL|Aminolife Plus|Food supplement based on milk protein serum (Isolac Instant), acetyl-carnitine, hydroxy-methyl-butyrate, arginine, inositol, coenzyme Q10 and extracts of perilla, maca and mallow. Perilla supports the body's natural defences, maca has a tonic and metabolic support action and mallow has an emollient and soothing action (digestive system, urinary tract). Calcium, vitamin D and vitamin K2 complete the formulation. Calcium contributes to energy metabolism and is necessary for maintaining normal bones. Vitamin D modulates the immune system and contributes to regular muscle function. Vitamin aK2 contributes to proper blood clotting and maintenance of normal bones.
62271157|NCT03548558|EXPERIMENTAL|Arm B (Booster villages)|In one half of Arm 1 and Arm 2 villages above, after the end of the main intensive intervention, extended light-touch group booster sessions held every other month over two years between the two follow-up surveys will be held
62271158|NCT03548558|OTHER|Arm A (Non-booster villages)|In the other half of Arm 1 and Arm 2 villages, no boosters will be held during phase 2
62066202|NCT05420441|ACTIVE_COMPARATOR|Group C (Conventional physical therapy only)|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
62066203|NCT01503840|ACTIVE_COMPARATOR|Sugammadex|
62271159|NCT03548558|EXPERIMENTAL|Arm X: Fathers invited|During phase 1, fathers were invited to attend sessions in half of Arms 1 and 2 villages.
62271160|NCT03548558|OTHER|Arm Y: Fathers not invited|During phase 1, fathers were not invited in the other half of Arms 1 and 2 villages.
62271161|NCT03193398|EXPERIMENTAL|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
62633557|NCT06573229|PLACEBO_COMPARATOR|Placebo|It is an inactive substance or treatment that has no therapeutic effect and is often used as a control in clinical trials.
62633558|NCT02044757|EXPERIMENTAL|SSB withdrawal|
62633559|NCT03962621|ACTIVE_COMPARATOR|2940 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
62633560|NCT03962621|ACTIVE_COMPARATOR|1064 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 1064 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
62271162|NCT03193398|PLACEBO_COMPARATOR|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
62271163|NCT00373204|EXPERIMENTAL|Xcytrin® (motexafin gadolinium)|
62271164|NCT04332588|EXPERIMENTAL|Herceptin monotherapy cohort|Herceptin monotherapy cohort. Locally advanced HER2+ breast cancer patients receiving neoadjuvant Herceptin monotherapy prior to combination therapy will undergo three contrast-enhanced \[18F\]FMISO PET/MRI scans. Each imaging session will be identical. Imaging session one will be after diagnosis and before beginning monotherapy. Imaging session two will be within 10 days prior to beginning combination therapy with targeted HER2 agents. Imaging session three will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
62271165|NCT04332588|EXPERIMENTAL|Combination therapy cohort|Locally advanced HER2+ breast cancer patients that receiving neoadjuvant combination therapy including Herceptin will undergo two contrast-enhanced \[18F\]FMISO PET/MRI imaging. Imaging session one will be after diagnosis and before beginning combination therapy. Imaging session two will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
62633561|NCT03962621|EXPERIMENTAL|Combined treatment group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm or 1064 nm laser (Fotona, Slovenia, EU) alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
62271166|NCT01394588||Cardiac Surgery Patients|Competent Adult Patients going for elective cardiac surgery.
62633562|NCT00818155|EXPERIMENTAL|desvenlafaxine succinate SR|desvenlafaxine succinate SR
62633563|NCT00818155|PLACEBO_COMPARATOR|Placebo|
62271167|NCT03687216|EXPERIMENTAL|HVPG group|HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)
62271168|NCT03687216|ACTIVE_COMPARATOR|Routing group|Routing therapy (EVL plus NSBB)
62633564|NCT02155699|EXPERIMENTAL|Exercise 1|65% of V02 Max, 3x per week, 3 months
62633565|NCT02155699|EXPERIMENTAL|Exercise 2|85% of VO2 Max, 2x per week, 3 months
62066204|NCT01503840|PLACEBO_COMPARATOR|Sodium chloride solution|
62066205|NCT04218773|EXPERIMENTAL|Induced hypertension|The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.
62066206|NCT01909570|EXPERIMENTAL|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
62066207|NCT01909570|ACTIVE_COMPARATOR|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
62066208|NCT05520840|EXPERIMENTAL|Patient referred for screening colonoscopy or for endoscopic resection|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
62066209|NCT02105441||cochlear implant|How well patients with cochlear implants understand speech in noise with implant on, compared to implant off.
62066210|NCT05275491||Mild to moderate COVID 19 patients|"According to COVID 19 treatment guidelines of National Institutes of Health (NIH):~Mild illness that show symptoms like fever, cough, nausea, vomiting, sore throat, loss of taste \& smell but don't show dyspnea or abnormal chest imaging.~Moderate illness that show clinical or radiological lower respiratory disease with SpO2 \> 94% on room air."
62271169|NCT06264570|EXPERIMENTAL|B-TMG experimental group|Subjects with normal COMT gene and MTHFR gene polymorphism
62066211|NCT05275491||Severe to critical COVID 19 patients|"According to COVID 19 treatment guidelines of National Institutes of Health (NIH):~Severe illness that show SpO2 \< 94% on room air, (PaO2/FiO2) \<300 mm Hg \& lung infiltration \> 50% with respiratory rate \> 30 breath/min.~Critical illness that show respiratory failure, septic shock or multiorgan failure."
62271170|NCT06264570|EXPERIMENTAL|B-SAM experimental group|Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
62271171|NCT06264570|PLACEBO_COMPARATOR|B-TMG placebo group|Subjects with normal COMT gene and MTHFR gene polymorph polymorphism ysm
62271172|NCT06264570|PLACEBO_COMPARATOR|B-SAM placebo group|Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
62271173|NCT00630955|EXPERIMENTAL|1|20 mg memantine
62271174|NCT00630955|EXPERIMENTAL|2|40 mg memantine
62271175|NCT00630955|PLACEBO_COMPARATOR|3|
62271176|NCT03901950|EXPERIMENTAL|XNW7201|
62633566|NCT02155699|NO_INTERVENTION|Waitlist|Waitlist (three months)
62633567|NCT03028675||Multiple Sclerosis|
62633568|NCT03028675||Healthy Volunteer|10 age-matched control volunteers
62633569|NCT02806856|ACTIVE_COMPARATOR|Active tDCS|
62633570|NCT02806856|SHAM_COMPARATOR|Sham|
62633571|NCT04242979|OTHER|Human albumin use in liver cirrhosis|"Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5-Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6-Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7-Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians."
62633572|NCT04312243|EXPERIMENTAL|Treatment Group|Inhaled NO (160 ppm) before and after the work shift. Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
62633573|NCT04312243|NO_INTERVENTION|Control Group|Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
62633574|NCT02106780|EXPERIMENTAL|1: ASP1707|
62633575|NCT01675505||Patients|"Inclusion criteria:~Patients with first-diagnosed colon cancer. Age 18-60 y.o.~Exclusion criteria:~Metastatic colon cancer. Former psychiatric history. Substance use. Previous serious medical conditions."
62271177|NCT01171846|ACTIVE_COMPARATOR|Physiotherapy|
62633576|NCT02809924|EXPERIMENTAL|Simulation-based just-in-time training|Viewing a short video showing the neonatal glottis of similar gestational age to the patient that is being intubated followed by practice on a mannequin (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada) with supervision and feedback from a senior provider (low fidelity simulation).
62633577|NCT02809924|ACTIVE_COMPARATOR|Video training|5 minutes video regarding endotracheal intubation
62633578|NCT01736735|EXPERIMENTAL|CLP|CLP BID
62633579|NCT01736735|PLACEBO_COMPARATOR|Placebo|BID powder
62633580|NCT00763789|EXPERIMENTAL|1|Local anaesthesia and remifentanil sedation
62633581|NCT00763789|OTHER|2|Total intravenous anaesthesia
62633582|NCT02408731|EXPERIMENTAL|Single dose of 0.005 mg/kg of PMZ-2010|A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
62633583|NCT02408731|EXPERIMENTAL|Single dose of 0.01 mg/kg of PMZ-2010|A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
62633584|NCT02408731|EXPERIMENTAL|Single dose of 0.05 mg/kg of PMZ-2010|A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
62633585|NCT02408731|EXPERIMENTAL|Single dose of 0.10 mg/kg of PMZ-2010|A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
62633586|NCT02408731|EXPERIMENTAL|3 doses equivalent to MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
62633587|NCT02408731|EXPERIMENTAL|3 doses equivalent to 2*MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to 2\*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
62633588|NCT06579677||PROCESS Cohort|
62271178|NCT01171846|NO_INTERVENTION|Control|Women allocated to the Control group will only receive, by post, the same Lifestyle Advice Sheet as the intervention group.
62066212|NCT05275491||Normal male subjects (Control)|
62066213|NCT06289634|EXPERIMENTAL|Man-made sounds|Participants who listen to man-made sounds (music)
62271179|NCT01162434||Patients|Up to 8 patients who have received Deep Brain Stimulation for Treatment Resistant Depression at Frenchay Hospital (UK) will be recruited.
62271180|NCT01162434||Healthy volunteers|Up to 16 healthy volunteers, matched to the DBS patients on age, sex, handedness, and education, will be recruited.
62271181|NCT00439582|EXPERIMENTAL|1|
62271182|NCT00439582|EXPERIMENTAL|2|
62271183|NCT01791192|EXPERIMENTAL|FTY720|Fingolimod
62271184|NCT01791192|ACTIVE_COMPARATOR|Oral Corticosteroid|Oral Corticosteroid
62271185|NCT02556255|EXPERIMENTAL|B-Laser™ Atherectomy Catheter|Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
62271186|NCT05686174|ACTIVE_COMPARATOR|MBS-217|4 ml MBS-217 twice a day for 16 weeks
62271187|NCT05686174|PLACEBO_COMPARATOR|Placebo|4 ml MBS-217 placebo twice a day for 16 weeks
62633589|NCT02121171|EXPERIMENTAL|Ologen Collagen Matrix Intervention|Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
62633590|NCT02121171|ACTIVE_COMPARATOR|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
62633591|NCT01678118||minority smokers|A single arm ABA design will be used to pilot a tobacco-focused patient navigation (TPN) intervention for low income, minority smokers.
62633592|NCT06611943||Low patient food shopping coverage|In this group, participants need to give at least one dietary recommendation to a patient whose loyalty card(s) cover(s) a low percentage of food purchases.
62633593|NCT06611943||Medium patient food shopping coverage|In this group, participants need to give at least one dietary recommendation to a patient whose loyalty card(s) cover(s) a medium percentage of their food purchases.
62633594|NCT06611943||High patient food shopping coverage|In this group, participants need to give to at least one dietary recommendation to a patient whose loyalty card(s) cover(s) a high percentage of food purchases.
62633595|NCT01754064||Cardiac Rhythm Management device|Implanted with implantable defibrillator or pacemaker system
62633596|NCT04579003|EXPERIMENTAL|Mobilization|Mobilization, heat application, ultrasound, TENS
62633597|NCT04579003|ACTIVE_COMPARATOR|Mobilization with movement|Mobilization with movement, heat application, ultrasound, TENS
62633598|NCT05766774|EXPERIMENTAL|Low-added sugar, high-fat diet Arm|Patients will receive a low-added sugar, high-fat diet for 8 weeks. Study menus will be designed by registered dietitians using the Nutrient Database System for Research (NDSR) software program with a 2-wk rotation.Total kcal provided will be individually tailored to maintain body weight and adjusted throughout as needed. All foods (including snacks and drinks) for 8 wks will be delivered to participants' homes. Menus will be designed so that food will be delivered to subjects' homes every 3-4 days. It will be expected that participants consume only the foods provided by the study.
62271188|NCT05166694|EXPERIMENTAL|Group 1: Prescribing Based on Information From Both Drug-Drug and Drug-Gene Profiles|"Group one consists of subjects who will participate in the Personalized Therapeutics Clinic where in which study doctors will make recommendations based on information found in both the subject's drug-drug interaction and drug-gene profiles. These recommendations will be given to participating providers. These recommendations will be communicated to healthcare providers who are directing the subject's care. These providers may work in hospitals, primary care, oncology, geriatrics, and mental and behavioral health. Each provider will have separately agreed to participate in this study. Subjects in this group will also learn about their drug-drug interaction and drug-gene profiles during educational visits with clinic staff.~Participants will randomly (like by a flip of the coin) assigned to a group."
62271189|NCT05166694|EXPERIMENTAL|Group 2: Prescribing Based ONLY on Information From Drug-Drug Interaction Profiles|"Group two consists of subjects who will participate in the Personalized Therapeutics Clinic where study doctors will make recommendations based on information only found in the subject's drug-drug interaction profile. Subjects in this group will also learn about their drug-drug interaction and drug-gene profiles during educational visits with clinic staff.~Participants will randomly (like by a flip of the coin) assigned to a group."
62271190|NCT05166694|EXPERIMENTAL|Group 3: Prescribing Not Based on ANY Profile Information (Drug-Drug or Drug-Gene Interactions)|"Group three consists of subjects who will not participate in the Personalized Therapeutics Clinic or receive recommendations. These subjects will not have any recommendations from regarding their drug-drug interaction or drug-gene profiles. Both drug-drug interaction and drug-gene profiles will be kept hidden from all of their treating providers-regardless of whether the providers directing their care have agreed to participate in this research. Subjects in this group will not learn about their drug-drug interaction or drug-gene profiles during educational visits with clinic staff.~Participants will randomly (like by a flip of the coin) assigned to a group."
62271191|NCT00731250|PLACEBO_COMPARATOR|PART 1-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
62271192|NCT00731250|EXPERIMENTAL|PART 1-Visit 1-Capsaicin|Eligible subjects will receive incremental capsaicin doses
62271193|NCT00731250|PLACEBO_COMPARATOR|PART 1-Visit 2-Placebo|Eligible subjects will receive matching placebo tablets
62271194|NCT00731250|EXPERIMENTAL|PART 1-Visit 2-Capsaicin|Eligible subjects will receive maximum capsaicin dose
62271195|NCT00731250|PLACEBO_COMPARATOR|PART 1-Visit 3-Placebo|Eligible subjects will receive matching placebo tablets
62633599|NCT05766774|ACTIVE_COMPARATOR|Typical CF diet Arm|Patients will receive a high-added sugar, high-fat CF diet for 8 weeks. Study menus will be designed by registered dietitians using the Nutrient Database System for Research (NDSR) software program with a 2-wk rotation. Total kcal provided will be individually tailored to maintain body weight and adjusted throughout as needed. All foods (including snacks and drinks) for 8 wks will be delivered to participants' homes. Menus will be designed so that food will be delivered to subjects' homes every 3-4 days. It will be expected that participants consume only the foods provided by the study.
62633600|NCT02413957|NO_INTERVENTION|Controll-Group|Patient randomized to the Control-Group will receive the traditional care by physician and nurse on the ward.
62633601|NCT02413957|EXPERIMENTAL|MedRec-Group|Patient randomized to the MedRec-Group will receive the traditional care by physician and nurse on the ward and additional pharmacist led medication reconciliation.
62066214|NCT06289634|EXPERIMENTAL|Natural sounds|Participants who listen to natural sounds (e.g., ocean, birds, rain)
62271196|NCT00731250|EXPERIMENTAL|PART 1-Visit 3-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
62271197|NCT00731250|PLACEBO_COMPARATOR|PART 2-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
62271198|NCT00731250|EXPERIMENTAL|PART 2-Visit 1-SB-705498|Eligible subjects will receive SB-705498 tablets
62271199|NCT00731250|EXPERIMENTAL|PART 2-Visit 2-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
62271200|NCT03955133|EXPERIMENTAL|intervention|This is a single arm before and after study with data collection at 4 time points.
62452907|NCT02877251||Deep venous thrombosis|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis
62271201|NCT05427266|OTHER|Study Group - Tap Block|"Study Group: Study group: Laparoscopic Transversus Abdominis Plane in four points: above and below the umbilicus in both right and left sides; dose calculation 2.5mg per body weight.~After the appendicectomy is done and just before withdrawing port and deflating the abdomen, the operating surgeon will advance a needle into the abdominal wall to the level of the preperitoneal space. Once the needle tip is seen, it is withdrawn slowly and gently about 0.5cm above/superficial to the transversus abdominis (TA) muscle. The surgeon then infiltrates the local anaesthetic into the plane, and the right plane is confirmed by visualising a uniform protrusion downwards of the TA muscle fibres (Doyle's bulge). Seeing a preperitoneal or muscle blister laparoscopically indicates that the infiltration is deeper to this plane, and the needle should be withdrawn more superficially."
62271202|NCT05427266|OTHER|Control Group - Standard port site infiltration|Patients will be randomised after diagnosis either clinically or radiologically of appendicitis (both complicated and uncomplicated) Control Group _ standard port site infiltration using 0.25% plain bupivacaine. The dose is calculated to 2.5mg/per kg body weight. After the appendicectomy is done, after removal of ports and deflating the abdomen, the total calculated dose volume will be infiltrated into the subcutaneous plane at the umbilicus and the other 2 ports sites
62271203|NCT03759626|ACTIVE_COMPARATOR|pupils benefiting from the impulsive intervention|Secondary school pupils from general secondary schools
62271204|NCT03759626|ACTIVE_COMPARATOR|pupils benefiting from the reflective intervention|Second year students from general high schools.
62271205|NCT02575521|PLACEBO_COMPARATOR|Propofol-Dexmedetomidine group|this group is planned to receive intravenous anaesthesia only
62633602|NCT02413957|EXPERIMENTAL|AMTS-Group|Patient randomized to the AMTS-Group will receive the traditional care by physician and nurse on the ward and additional pharmaceutical care by a pharmacist.
62633603|NCT06608940|EXPERIMENTAL|BC3402 to tremelimumab plus durvalumab|The study consists of two parts: a safety lead-in study part (Phase Ib) to confirm the tolerable dose (RP2D) of BC3402 in combination with T+D followed by an efficacy study part (Phase II) to evaluate preliminary efficacy of the study regimen in a single arm, two stage Minimax design. Note that participants who are treated at the RP2D in the Phase Ib study part will automatically be part of the Phase II study part.
62633604|NCT02508376|EXPERIMENTAL|ID93 (10 mcg) + AP10-602 (10 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
62633605|NCT02508376|EXPERIMENTAL|ID93 (10 mcg) + AP10-602 (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
62633606|NCT02508376|EXPERIMENTAL|ID93 (10 mcg) + GLA-SE (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
62633607|NCT02508376|EXPERIMENTAL|ID93 (10 mcg) alone|N=10 subjects will receive intervention on Days 1, 29, 57
62633608|NCT01853293|ACTIVE_COMPARATOR|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
62633609|NCT01853293|PLACEBO_COMPARATOR|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
62633610|NCT04494295||AURORA|Aurora® Surgiscope used for MIS evacuation of supratentorial hematoma
62633611|NCT02580253|EXPERIMENTAL|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
62633612|NCT02580253|ACTIVE_COMPARATOR|mFOLFOX6|Oxaliplatin (85 mg/m2 )+Fluorouracil (2800 mg/m2 ) q2w
62653220|NCT02340949|ACTIVE_COMPARATOR|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil \[5-FU\], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
62633613|NCT06184009|EXPERIMENTAL|ALL, High risk with DI #2(Doxorubicin)|"* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported."
62633614|NCT02529254|EXPERIMENTAL|Video coaching|14 residents in general surgery from PGY-1(post graduate year-1) to PGY-4 Block randomized to the intervention group who will receive a 30 minute video coaching session as the intervention
62633615|NCT02529254|NO_INTERVENTION|Control|14 residents in general surgery from PGY-1 to PGY-4 block randomized to the control group
62633616|NCT01973686|EXPERIMENTAL|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
62633617|NCT01973686|EXPERIMENTAL|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
62633618|NCT01973686|NO_INTERVENTION|Control|Receives no intervention
62633619|NCT02001532||Diabetes type 2|Patients diagnosed with type 2 diabetes within 5 years from baseline (i.e. 10 years at follow-up)
62633620|NCT02001532||Healthy controls|Sex and age-matched healthy controls
62633621|NCT05886842||Test-retest|A group of 19 patients will be tested using the 30 seconds Sit-to-stand and Timed up and go tests. Each test will be repeated 3 times and the best score will be used. There is going to be 3 days waiting period before the re-tests.
62633622|NCT04328025|ACTIVE_COMPARATOR|Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP|"For TGW in the intervention arm, peers will deliver HIVST and PrEP medications monthly in between quarterly clinic visits. Quarterly clinic-based testing will confirm accuracy of self-tests and identify inaccurate test results. Additionally, peers will remind TGW to self-test before opening a new PrEP bottle. They will also distribute STI self-sampling kits to TGW for own use, and with regular partners as needed. They will present smart phone instructional videos showing trans women how to self-collect pharyngeal, rectal and urine specimens for Neisseria gonorrhoeae and Chlamydia trachomatis testing.~Peers will: a) motivate ongoing adherence; b) promote repeat HIV testing; and c) support PrEP use as problems arise. Self-sampling for STIs will be performed monthly by participants (with questions answered by the peer or other study staff as needed)."
62633623|NCT04328025|NO_INTERVENTION|Facility-Delivered Care|Participants will receive facility-based HIV counseling, PrEP prescriptions condoms, risk reduction counseling, and management of sexually transmitted infections as standard of care.
62633624|NCT05439421|EXPERIMENTAL|With Claim 0% Tar|Package or digital marketing advertisement containing claim of interest
62633625|NCT05439421|EXPERIMENTAL|Without Claim 0% Tar|Package or digital marketing advertisement without claim of interest
62271206|NCT02575521|ACTIVE_COMPARATOR|Sevoflurane group|this group is planned to receive sevoflurane/fentanyl anaesthesia
62271207|NCT01329393|EXPERIMENTAL|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
62633626|NCT05439421|EXPERIMENTAL|With Claim No Chemicals|Package or digital marketing advertisement containing claim of interest
62633627|NCT05439421|EXPERIMENTAL|Without Claim No Chemicals|Package or digital marketing advertisement without claim of interest
62633628|NCT05439421|EXPERIMENTAL|With Claim Apple Image|Package or digital marketing advertisement containing claim of interest
62633629|NCT05439421|EXPERIMENTAL|Without Claim Apple Image|Package or digital marketing advertisement without claim of interest
62633630|NCT05439421|EXPERIMENTAL|With Claim 100% Food Grade Glycerin|Package or digital marketing advertisement containing claim of interest
62633631|NCT05439421|EXPERIMENTAL|Without Claim 100% Food Grade Glycerin|Package or digital marketing advertisement without claim of interest
62633632|NCT05439421|EXPERIMENTAL|With Claim Ultra Light|Package or digital marketing advertisement containing claim of interest
62271208|NCT01329393|ACTIVE_COMPARATOR|Illness Management and Recovery|
62271209|NCT04299295|EXPERIMENTAL|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
62271210|NCT04299295|ACTIVE_COMPARATOR|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
62633633|NCT05439421|EXPERIMENTAL|Without Claim Ultra Light|Package or digital marketing advertisement without claim of interest
62633634|NCT05439421|EXPERIMENTAL|With Claim Fresh Hookah Tobacco|Package or digital marketing advertisement containing claim of interest
62633635|NCT05439421|EXPERIMENTAL|Without Claim Fresh Hookah Tobacco|Package or digital marketing advertisement without claim of interest
62633636|NCT05439421|EXPERIMENTAL|With Claim Lower Nicotine Tobacco|Package or digital marketing advertisement containing claim of interest
62633637|NCT05439421|EXPERIMENTAL|Without Claim Lower Nicotine Tobacco|Package or digital marketing advertisement without claim of interest
62633638|NCT05439421|EXPERIMENTAL|With Claim Premium Shisha Tobacco|Package or digital marketing advertisement containing claim of interest
62633639|NCT05439421|EXPERIMENTAL|Without Claim Premium Shisha Tobacco|Package or digital marketing advertisement without claim of interest
62633640|NCT05439421|EXPERIMENTAL|With Claim High Quality Shisha Tobacco|Package or digital marketing advertisement containing claim of interest
62633641|NCT05439421|EXPERIMENTAL|Without Claim High Quality Shisha Tobacco|Package or digital marketing advertisement without claim of interest
62633642|NCT05439421|EXPERIMENTAL|With Claim Don't blow smoke - blow clouds|Package or digital marketing advertisement containing claim of interest
62633643|NCT05439421|EXPERIMENTAL|Without Claim Don't blow smoke - blow clouds|Package or digital marketing advertisement without claim of interest
62633644|NCT05439421|EXPERIMENTAL|With Claim Contains natural, unwashed tobacco leaf|Package or digital marketing advertisement containing claim of interest
62633645|NCT05439421|EXPERIMENTAL|Without Claim Contains natural, unwashed tobacco leaf|Package or digital marketing advertisement without claim of interest
62633646|NCT05439421|EXPERIMENTAL|With Claim We only use ingredients which are FDA approved|Package or digital marketing advertisement containing claim of interest
62633647|NCT05439421|EXPERIMENTAL|Without Claim We only use ingredients which are FDA approved|Package or digital marketing advertisement without claim of interest
62633648|NCT05439421|EXPERIMENTAL|With Claim Passing flavored tobacco smoke through water cools and purifies it|Package or digital marketing advertisement containing claim of interest
62633649|NCT05439421|EXPERIMENTAL|Without Claim Passing flavored tobacco smoke through water cools and purifies it|Package or digital marketing advertisement without claim of interest
62633650|NCT05439421|EXPERIMENTAL|With Claim Natural flavor|Package or digital marketing advertisement containing claim of interest
62633651|NCT05439421|EXPERIMENTAL|Without Claim Natural flavor|Package or digital marketing advertisement without claim of interest
62633652|NCT05439421|EXPERIMENTAL|With Claim Shisha or hookah tobacco is unique and completely unlike that found in cigarettes|Package or digital marketing advertisement containing claim of interest
62653221|NCT05052840|EXPERIMENTAL|Muscle endurance training (MET)|
62066215|NCT02312401|EXPERIMENTAL|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 \& 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
62633653|NCT05439421|EXPERIMENTAL|Without Claim Shisha or hookah tobacco is unique and completely unlike that found in cigarettes|Package or digital marketing advertisement without claim of interest
62633654|NCT05439421|EXPERIMENTAL|With Claim water in the shisha effectively cools and filters the smoke, making smooth and light|Package or digital marketing advertisement containing claim of interest
62633655|NCT05439421|EXPERIMENTAL|Without Claim water in the shisha effectively cools and filters the smoke, making smooth and light|Package or digital marketing advertisement without claim of interest
62633656|NCT00014612|ACTIVE_COMPARATOR|axillary lymph node dissection|complete axillary lymph node dissection
62633657|NCT00014612|EXPERIMENTAL|axillary radiotherapy|axillary radiotherapy, daily for 5 days a week, for 5 weeks
62633658|NCT01301300|ACTIVE_COMPARATOR|Glenbrook Hospital|Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
62633659|NCT01301300|ACTIVE_COMPARATOR|Evanston, Highland Park, Skokie Hospitals|"Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.~Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)"
62633660|NCT04464967|EXPERIMENTAL|Phase 1, Cohort 1|SNK01 (low dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
62633661|NCT04464967|EXPERIMENTAL|Phase 1, Cohort 2|SNK01 (high dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
62633662|NCT04464967|EXPERIMENTAL|Phase 1, Cohort 3|SNK01 (low dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
62633663|NCT04464967|EXPERIMENTAL|Phase 1, Cohort 4|SNK01 (high dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
62633664|NCT04464967|EXPERIMENTAL|Phase 2, Expansion Cohort 1|SNK01 (TBD RP2D) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
62633665|NCT04464967|EXPERIMENTAL|Phase 2, Expansion Cohort 2|SNK01 (TBD RP2D) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
62633666|NCT01726062|EXPERIMENTAL|Motivational Interviewing plus Incentives|
62633667|NCT01726062|OTHER|Conventional Care (CC)|
62633668|NCT03458624||Not applicable-observational study|Not applicable-observational study
62633669|NCT02081378|EXPERIMENTAL|Asciminib in CML patients|Dose escalation study estimated the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of asciminib in adult patients with chronic myeloid leukemia (CML).
62633670|NCT02081378|EXPERIMENTAL|Asciminib+Nilotinib in CML patients|Dose escalation study estimated the MTD and/or RDE of asciminib in combination with Nilotinib in adult CML patients
62633671|NCT02081378|EXPERIMENTAL|Asciminib in Ph+ ALL patients|Dose escalation study estimated the MTD and/or RDE of asciminib in adult patients with Ph positive ALL patients
62066216|NCT00369681|EXPERIMENTAL|R-ABVD|ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m\^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m\^2 Cycles 2, 4, and 6 Day 1.
62633672|NCT02081378|EXPERIMENTAL|Asciminib+Imatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of asciminib in combination with imatinib in adult CML patients
62633673|NCT02081378|EXPERIMENTAL|Asciminib+dasatinib in CML patients|Dose escalation study estimated the MTD and/or RDE of asciminib in combination with dasatinib in adult CML patients
62633674|NCT04633226|EXPERIMENTAL|V114|Participants received 4 total doses of V114, administered at approximately 2, 4, 6, and 12 to 15 months of age.
62633675|NCT03127319|EXPERIMENTAL|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
62633676|NCT03127319|ACTIVE_COMPARATOR|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
62633677|NCT01222000|EXPERIMENTAL|right controlled against moisturizing cream|
62633678|NCT01222000|EXPERIMENTAL|left controlled against moisturizing cream|
62633679|NCT01008865|EXPERIMENTAL|Studer Pouch|Studer Pouch orthotopic urinary diversion
62633680|NCT01008865|EXPERIMENTAL|T-Pouch|T-Pouch orthotopic urinary diversion
62633681|NCT01136577|EXPERIMENTAL|LEDDYBLOO®|LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
62633682|NCT01136577|EXPERIMENTAL|Double BILITRON®|Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
62633683|NCT01136577|EXPERIMENTAL|Futura®|Future phototherapy device equipped with 8 fluorescent tubes
62633684|NCT00994747|ACTIVE_COMPARATOR|Group EEEEEEE|Infant is fed Enfamil from 0.5-7.5 months of life
62633685|NCT00994747|EXPERIMENTAL|Group ENEEEEE|Infant is fed Enfamil during 0.5-1.5 months of life, Nutramigen from 1.5-2.5 months of life and then Enfamil 2.5-7.5 of life.
62633686|NCT00994747|EXPERIMENTAL|Group EENEEEE|Infant is fed Enfamil 0.5-2.5 months of life, Nutramigen from 2.5-3.5 months of life and then Enfamil from 3.5 to 7.5 months of life
62633687|NCT00994747|EXPERIMENTAL|Group EEENEEE|Infant is fed Enfamil from 0.5-3.5 months of life, Nutramigen from 3.5-4.5 months of life and then Enfamil from 4.5-7.5 months of life.
62633688|NCT00994747|EXPERIMENTAL|Group ENNNEEE|Infant if fed Enfamil from month 0.5-1.5 months of life, Nutramigen from 1.5 to 3.5 months of life and then Enfamil again 3.5-7.5 months of life.
62633689|NCT00994747|EXPERIMENTAL|Group NNNNNNN|Infant is fed Nutramigen from 0.5-7.5 months of life.
62633690|NCT06283953|ACTIVE_COMPARATOR|Active Comparator Caregivers|TrachMeHome program delivered in the hospital including education, skills training and case management for caregivers
62633691|NCT06283953|EXPERIMENTAL|Intervention Caregivers|Trach Me Home and Trach Plus with additional education, outpatient care team communication and social support for caregivers.
62271211|NCT02368054|ACTIVE_COMPARATOR|Bupivacaine-adrenaline|Paracervical block. Bupivacaine 2,5 mg/ml Adrenaline 5 microg/ml; 20 ml
62066217|NCT02500563|ACTIVE_COMPARATOR|Amino acid based infant formula|
62633692|NCT06283953|ACTIVE_COMPARATOR|Active Comparator Physicians|Primary care physicians' of the enrolled participant's child receiving discharge communication
62271212|NCT02368054|ACTIVE_COMPARATOR|Bupivacaine|Paracervical block. Bupivacaine 2,5 mg/ml; 20 ml
62271213|NCT01340209|EXPERIMENTAL|Tiotropium Respimat (low dose)|Tiotropium low dose once daily delivered with Respimat inhaler
62271214|NCT01340209|EXPERIMENTAL|Tiotropium Respimat (high dose)|Tiotropium high dose once daily delivered with Respimat inhaler
62271215|NCT01340209|PLACEBO_COMPARATOR|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
62271216|NCT03912077|EXPERIMENTAL|Culturally Adapted Cognitive Behavioural Therapy|"Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) is an evidence-based psychological intervention manual developed by Devon Hinton, MD from Harvard University and Baland Jalal from University of Cambridge. It is a group therapy protocol that consists of 7 sessions.~It is a brief, feasible and culturally sensitive intervention that has a transdiagnostical approach. Detailed information about Syrian culture, idioms of stress, cultural differences, and psychological problems that Syrian refugee women have been facing and their needs, expectations and sensitivities are considered in the adaptation process. Examples, cultural metaphors and imageries that take part in the manual are adapted according to Syrian culture."
62271217|NCT03912077|NO_INTERVENTION|Treatment as Usual|Control arm participants will receive routine social support and/or care according to ordinary practice of the non-governmental organization (treatment as usual). Also, they will receive baseline and post assessments according to the study schedule.
62066218|NCT02500563|EXPERIMENTAL|Extensively hydrolyzed casein infant formula|
62066219|NCT02500563|OTHER|Mother's own breast milk|
62066220|NCT05375435|EXPERIMENTAL|experimental group|
62271218|NCT05501353||Group1|Patients with various types of metastatic colorectal cancer who had underwent the radical resection of colorectal cancer and were planning to undergo radical resection of metastasis
62066221|NCT05375435|EXPERIMENTAL|control group|
62066222|NCT00765297|EXPERIMENTAL|1|Healthy young 18-40years
62271219|NCT00648375|EXPERIMENTAL|Propranolol|Participants will take propranolol for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
62271220|NCT00648375|PLACEBO_COMPARATOR|Placebo|Participants will take placebo for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
62271221|NCT01936532|EXPERIMENTAL|assessment of treatment lenalidomide, dexamethasone,MLN9708|
62271222|NCT04348409|EXPERIMENTAL|nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
62271223|NCT04348409|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo BID for 7 days
62271224|NCT02540486|EXPERIMENTAL|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
62271225|NCT02540486|ACTIVE_COMPARATOR|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
62271226|NCT02776800|EXPERIMENTAL|Allevyn Life|Foam Dressing
62271227|NCT02776800|OTHER|Foam Dressing|Standard Care - Foam Dressing
62271228|NCT00429858|EXPERIMENTAL|Targeted therapy group|Gemcitabine monotherapy until disease progression, followed by gemcitabine + S-1
62271229|NCT02103530|EXPERIMENTAL|FLT PET/CT|Patients who had FLT PET/CT
62271230|NCT02224378|EXPERIMENTAL|peep induced CVP|
62271231|NCT02224378|ACTIVE_COMPARATOR|passive leg raising(PLR)|
62066223|NCT00765297|EXPERIMENTAL|2|Healthy elderly
62066224|NCT00713102||1|The group includes 10189 patients with on board medical or surgical emergencies.
62066225|NCT05971342|EXPERIMENTAL|Gelatin sponge-loaded apoptotic vesicle complex|4 \* 10\^10 apoptotic vesicles derived from umbilical cord mesenchymal stem cells were loaded in a gelatin sponge（Kuaikang®）. A piece of gelatin sponge-loaded apoptotic vesicle complex was placed in an extraction socket after tooth extraction.
62066226|NCT05971342|ACTIVE_COMPARATOR|Gelatin sponge only|A piece of gelatin sponge（Kuaikang®）was placed in an extraction socket after tooth extraction.
62066227|NCT03408743|EXPERIMENTAL|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
62066228|NCT03408743|EXPERIMENTAL|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
62066229|NCT03408743|EXPERIMENTAL|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks. \*Also referred to as 'benefits' in other arm descriptions\*\*
62271232|NCT02101723|ACTIVE_COMPARATOR|Micronutrient Powder (MNP) + Zn/Fe|Micronutrient Powder with 5 mg Zn and 12 mg Fe
62271233|NCT02101723|ACTIVE_COMPARATOR|MNP + Zn|Micronutrient Powder with 5 mg Zn
62271234|NCT02101723|PLACEBO_COMPARATOR|Control|Placebo sachets without micronutrients
62271235|NCT00777010|ACTIVE_COMPARATOR|Healthy high carbohydrate diet|Participants will follow a typical, higher carbohydrate dietary intervention with emphasis on lower glycemic carbohydrate foods and monounsaturated fatty acid consumption
62271236|NCT00777010|EXPERIMENTAL|Carbohydrate restricted, ketogenic diet|Paricipants will follow a carbohydrate restricted dietary intervention designed to induce ketone metabolism
62271237|NCT01330238|ACTIVE_COMPARATOR|Zoledronic acid|Single infusion of 5 mg zoledronic acid I.V.
62633693|NCT06283953|EXPERIMENTAL|Intervention Physicians|Primary care physicians' of the enrolled participant's child receiving outpatient care team communication prior to discharge
62633694|NCT02019342||Post-quality improvement cohort|Patient cohort after FACE quality improvement initiative is implemented
62271238|NCT01330238|PLACEBO_COMPARATOR|Placebo|Single infusion of 100 ml isotonic NaCl-solution I.V.
62633695|NCT02019342||Pre-quality improvement cohort|Patient cohort prior to implementation of FACE quality improvement initiative
62633696|NCT03875469|EXPERIMENTAL|CT patients_Centargo_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
62633697|NCT03875469|EXPERIMENTAL|CT-patients_Stellant_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
62633698|NCT03875469|EXPERIMENTAL|CT-patients_Centargo_2|Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)
62633699|NCT00941200||Blood collection|
62066230|NCT03408743|EXPERIMENTAL|Benefits and self-efficacy|Participants will have access to the knowledge module plus perceived benefits and self-efficacy modules for a period up to 3 weeks.
62066231|NCT03408743|EXPERIMENTAL|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
62271239|NCT05405283|ACTIVE_COMPARATOR|Comirnaty® (Pfizer-BioNTech)|
62271240|NCT05405283|EXPERIMENTAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|
62066232|NCT03408743|EXPERIMENTAL|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus injunctive norms and self-efficacy modules for a period up to 3 weeks.
62271241|NCT06130293|EXPERIMENTAL|VR training|Using VR training. 40 minutes per session, one session per week, and a total 8 weeks.
62633700|NCT02372344|EXPERIMENTAL|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
62633701|NCT02372344|EXPERIMENTAL|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
62633702|NCT02372344|EXPERIMENTAL|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
62271242|NCT06130293|NO_INTERVENTION|Waiting list group|
62066233|NCT03408743|EXPERIMENTAL|Injunctive norms and benefits|Participants will have access to the knowledge module plus injunctive norms and perceived benefits modules for a period up to 3 weeks.
62066234|NCT03408743|EXPERIMENTAL|Injunctive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62066235|NCT03408743|EXPERIMENTAL|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms modules for a period up to 3 weeks.
62066236|NCT03408743|EXPERIMENTAL|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
62633703|NCT03180203|EXPERIMENTAL|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
62633704|NCT03180203|ACTIVE_COMPARATOR|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
62633705|NCT06240481|ACTIVE_COMPARATOR|Group I|Meridol ToothPaste Brush 2 x day / 2 mins Meridol Mouthwash (AmCl+Zn +NaF) Swish 15 mL / 30 secs after brushing
62633706|NCT06240481|PLACEBO_COMPARATOR|Group II|regular fluoride ToothPaste, Brush 2 x day 2 mins
62633707|NCT03421964|ACTIVE_COMPARATOR|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, virtual sessions.
62633708|NCT03421964|EXPERIMENTAL|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
62633709|NCT05028309|EXPERIMENTAL|Interventional Arm|Older group of adults (65-75 yrs). Everyone enrolled uses the 'intervention'/ external cuirass - mechanical unloading of thorax
62066237|NCT03408743|EXPERIMENTAL|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
62066238|NCT03408743|EXPERIMENTAL|Descriptive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62066239|NCT03408743|EXPERIMENTAL|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
62066240|NCT03408743|EXPERIMENTAL|Descriptive and injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
62271243|NCT04851951||patients treated by one-shot PRP injection|
62271244|NCT00540189|OTHER|Initial appendectomy|children with complicated appendicitis will undergo initial appendectomy
62271245|NCT00540189|OTHER|Interval appendectomy|children with complicated appendicitis will undergo initial antibiotic treatment followed by an interval appendectomy
62271246|NCT05211479|EXPERIMENTAL|intervention group|Tele-nursing will be applied to adolescents in this group for 24 weeks. Weekly meeting and blood glucose monitoring will be done. The HbA1c value will be checked and the scales will be filled by meeting 3 times in total with 3 months intervals.
62271247|NCT05211479|NO_INTERVENTION|Control Group|This group will be given face-to-face training only in the first encounter. During the research, no interviews will be provided through tele nursing. Only at the 3rd and 6th months will be interviewed to measure the HbA1c value and to fill the scales.
62633710|NCT01801111|EXPERIMENTAL|Alectinib|Participants will receive alectinib treatment continuously starting from Day 1 Cycle 1 (in 28-day cycles) until disease progression, death, or withdrawal for any other reasons, whichever occurs first. After PD, participants without EGFR mutation will continue treatment with alectinib alone and participants with EGFR mutation will receive alectinib in combination with erlotinib as per discretion of the treating physician.
62633711|NCT05319496|EXPERIMENTAL|isCGM with education and feedback|Intervention subjects will receive three isCGM sensors (FreeStyle Libre 2, Abbott Laboratories) for use over weeks 1-6. They will have encounters with a diabetes educator for individualized education and coaching during weeks 1-2 and 5-6.
62633712|NCT05319496|ACTIVE_COMPARATOR|Enhanced usual care with education and feedback only|Enhanced usual care subjects will receive two encounters with a diabetes educator for individualized education and coaching, during weeks 1-2 and 5-6. They will not be provided with isCGM sensors.
62633713|NCT01936363|EXPERIMENTAL|Pimasertib (once daily) plus SAR245409|
62633714|NCT01936363|EXPERIMENTAL|Pimasertib (twice daily) plus SAR245409 placebo|
62633715|NCT06206512|EXPERIMENTAL|Investigational product|Extended release torsemide and immediate release torsemide placebo
62633716|NCT06206512|ACTIVE_COMPARATOR|Control product|Immediate release torsemide and extended release torsemide placebo
62633717|NCT01367249|EXPERIMENTAL|Bromfenac Ophthalmic Solution|Bromfenac ophthalmic solution 0.07% one drop into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
62066241|NCT03408743|EXPERIMENTAL|Descriptive and injunctive norms, and benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
62066242|NCT03408743|EXPERIMENTAL|Descriptive & injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62066243|NCT03408743|EXPERIMENTAL|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
62066244|NCT03408743|EXPERIMENTAL|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
62066245|NCT03408743|EXPERIMENTAL|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
62633718|NCT01367249|PLACEBO_COMPARATOR|Placebo|One drop of placebo into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
62066246|NCT03408743|EXPERIMENTAL|Expectancies, benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62066247|NCT03408743|EXPERIMENTAL|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
62633719|NCT04456491||Asthma|Patients with Asthma
62633720|NCT04456491||COPD|Patients with COPD
62633721|NCT04456491||Control group|Healthy volunteers
62633722|NCT03839394|EXPERIMENTAL|Educational pamphlets + telephone|
62633723|NCT03839394|ACTIVE_COMPARATOR|Educational pamphlets|
62633724|NCT03172598|EXPERIMENTAL|MT-8554 low dose|Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.
62633725|NCT03172598|EXPERIMENTAL|MT-8554 middle dose|Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.
62633726|NCT03172598|EXPERIMENTAL|MT-8554 high dose|Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.
62633727|NCT03172598|EXPERIMENTAL|MT-8554, then placebo|The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase
62633728|NCT03172598|EXPERIMENTAL|Placebo, then MT-8554|The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase
62633729|NCT04610138|EXPERIMENTAL|Active treatment with 60 ml low-dose ZnAg|(Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours
62633730|NCT04610138|EXPERIMENTAL|Active treatment with 60 ml high-dose ZnAg|(Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours;
62633731|NCT04610138|PLACEBO_COMPARATOR|60 ml matching placebo|60 ml matching placebo, po q12 hours
62633732|NCT01218542|EXPERIMENTAL|Volumetric modulated arc therapy|Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.
62633733|NCT02210520|EXPERIMENTAL|laser|3 J/cm², 2 minutes in 6 points around the back spine
62066248|NCT03408743|EXPERIMENTAL|Expectancies, injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
62066249|NCT03408743|EXPERIMENTAL|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
62066250|NCT03408743|EXPERIMENTAL|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62066251|NCT03408743|EXPERIMENTAL|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
62271248|NCT02418416|EXPERIMENTAL|Double activation|The Oocytes in this arm will undergo double activation with Ca ionophore 5 micro mol for 20 min them Strontium chloride 10 micro mol for 60 min.
62271249|NCT02418416|NO_INTERVENTION|Control arm|The Oocytes will undergo Intracytoplasmic sperm injection only
62633734|NCT02210520|EXPERIMENTAL|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine
62633735|NCT02210520|EXPERIMENTAL|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
62633736|NCT02210520|NO_INTERVENTION|control|no treatment.
62633737|NCT03568578|ACTIVE_COMPARATOR|Entecavir Group|Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.
62633738|NCT03568578|EXPERIMENTAL|Entecavir and Anluohuaxian Group|Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.
62633739|NCT02813928|EXPERIMENTAL|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.
62633740|NCT02574364|ACTIVE_COMPARATOR|traditional incision|traditional incision : McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
62633741|NCT02574364|EXPERIMENTAL|modified incision|modified incision :The application of abdomen CT before surgery provides a new approach to the incision and new perception.
62066252|NCT03408743|EXPERIMENTAL|Expectancies, descriptive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
62633742|NCT04621032||OSA +|Patients with visceral obesity and newly diagnosed Obstructive Sleep Apnea (during the study)
62271250|NCT01698346|NO_INTERVENTION|control|50 unvaccinated pregnant women
62633743|NCT04621032||OSA -|Patients with visceral obesity in whom Obstructive Sleep Apnea diagnosis have been excluded (during the study)
62633744|NCT04258124|EXPERIMENTAL|Experimental group|"Each session will last 10 minutes, taking place 3 days a week, over a period of 6 weeks. The intervention will take place at the beginning of the training session. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.~Exercise 1. In quadruped position, keeping the back flat, making an isometric contraction of the transverse muscle, and raising one arm and one leg contralaterally.~Exercise 2. Training of the deep cervical flexor muscles, supine. Players will move their heads slowly towards craniocervical flexion.~Exercise 3. In standing position, an ocular-cervical coordination exercise by means of a cranio-cervical flexion, adding a rotation, guided by an eye feedback provided by the physiotherapist by means of a laser projected on a wall."
62271251|NCT01698346|ACTIVE_COMPARATOR|Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)|50 pregnant women vaccinated with pertussis vaccine
62271252|NCT06027359|EXPERIMENTAL|Therapeutic game to reduce fear of hospital and ambulance|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
62271253|NCT06027359|EXPERIMENTAL|Therapeutic game to reduce fear of injectors and eye drops|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
62633745|NCT04258124|NO_INTERVENTION|Control group|Athletes in the control group will be asked to follow their usual warm-up routine.
62633746|NCT02143219|OTHER|FOLFIRINOX|FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU
62633747|NCT05293522|EXPERIMENTAL|NTX-001|Solution #1, Solution #2 Active, Solution #3
62633748|NCT05293522|NO_INTERVENTION|Standard of Care|Standard neurorrhaphy
62633749|NCT05317429|EXPERIMENTAL|Treatment|Carbohydrate-rich meal
62633750|NCT05317429|ACTIVE_COMPARATOR|Control|Carbohydrate-rich meal
62633751|NCT03423212|EXPERIMENTAL|Experimental Condition|Participants assigned to the experimental arm will be enrolled in the 2-session Just Do You intervention described elsewhere.
62633752|NCT03423212|NO_INTERVENTION|Treatment as Usual Condition|Participants assigned to treatment as usual will receive the PROS program that is standard in the agencies without any additional intervention.
62633753|NCT03423212|ACTIVE_COMPARATOR|Active Control Condition|Participants assigned to the active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
62633754|NCT00003483|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62271254|NCT06027359|EXPERIMENTAL|Therapeutic play to reduce fear of intrauterine and serum|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
62271255|NCT06027359|EXPERIMENTAL|Therapeutic play to reduce fear of EKG and EMG|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
62271256|NCT06349395|EXPERIMENTAL|interventional|The study conducted an online eight-session mindfulness-based stress reduction (MBSR) program for its intervention group, with each session lasting about two hours. Daily exercise adherence was monitored via phone. The control group received no intervention but followed standard hospital protocols, with an offer for MBSR training post-study.
62271257|NCT06349395|NO_INTERVENTION|controls(control group)|No intervention was provided to the control group; these participants were evaluated following the routine hospital treatment protocol. Participants who wished to receive MBSR training were offered the opportunity to do so after the completion of the study.
62271258|NCT02419287|EXPERIMENTAL|crizotinib|250mg BID
62271259|NCT02308683|EXPERIMENTAL|hsCRP, Hgba1c|Pre treatment hsCRP and hgba1c will be initially measured After 12 weeks supplementation of Moringa oleifera, post treatment hsCRP and Hgba1c will be measured
62633755|NCT05219968|EXPERIMENTAL|LYR-210|Single administration of LYR-210 drug matrix (7500 μg)
62633756|NCT05219968|SHAM_COMPARATOR|Sham procedure control|Single mock administration procedure
62633757|NCT06420037|OTHER|Individuals between 45-80 years with bilateral hearing aids (control group)|Within this control group, no changes will be made to the hearing aid settings. However, they undergo all other tests of the test protocol.
62633758|NCT06420037|EXPERIMENTAL|Individuals between 45-80 years with bilateral hearing aids (frequency compression)|Within this experimental group, a slight modification (which differs between groups) will be made to the basic hearing aid setting.
62633759|NCT06420037|EXPERIMENTAL|Individuals between 45-80 years with bilateral hearing aids (noise reduction)|Within this experimental group, a slight modification (which differs between groups) will be made to the basic hearing aid setting.
62633760|NCT01935024|NO_INTERVENTION|Normal Activity level|
62633761|NCT01935024|ACTIVE_COMPARATOR|Personalized Exercise Regimen|
62633762|NCT04576728|EXPERIMENTAL|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
62633763|NCT04576728|PLACEBO_COMPARATOR|Placebo|Human albumin 1%
62633764|NCT03421938|EXPERIMENTAL|Group 1 (Downhill Exercise Group)|This group will have downhill walking exercises with %10 slope.
62633765|NCT03421938|EXPERIMENTAL|Group 2 ( Uphill Exercise Group)|This group will have uphill walking exercises on the treadmill with %10 slope.
62633766|NCT03339817|OTHER|Patients with severe MS|polysomnography and functional pulmonary testings.
62633767|NCT03418259|EXPERIMENTAL|Active KCS Medical Device|
62633768|NCT03418259|PLACEBO_COMPARATOR|Inactive KCS Medical Device|
62271260|NCT01849861|EXPERIMENTAL|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~* TSH and FT4~* Questionnaire of Quality of life for older adults (WHOQOL-OLD)~* Mini-Mental State Examination~* Geriatric Depression Scale~* Cardiopulmonary exercise testing - cardiopulmonary capacity"
62066253|NCT03408743|EXPERIMENTAL|Expectancies, descriptive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
62271261|NCT02326805|EXPERIMENTAL|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
62271262|NCT02326805|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
62633769|NCT00631254|ACTIVE_COMPARATOR|1|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
62271263|NCT01656031|EXPERIMENTAL|high-dose cytarabine and clofarabine|high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days
62271264|NCT01966133|NO_INTERVENTION|Control|no interventions were assigned
62271265|NCT01966133|ACTIVE_COMPARATOR|TACE('Ethiodized Oil + Doxorubicin)|TACE using Ethiodized Oil + Doxorubicin mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4-6 weeks after surgery.
62271266|NCT04243330|NO_INTERVENTION|Implementation as Usual|Implementation support consisting of clinical decision support tools, trainings, technical assistance and quality assurance to support implementation of VA Suicide Risk Identification Strategy. Available to all facilities.
62271267|NCT04243330|EXPERIMENTAL|Audit and Feedback|Audit and Feedback will serve as the first stage implementation intervention for sites that do not meet the benchmark for adequate implementation following 9 months of implementation as usual.
62271268|NCT04243330|EXPERIMENTAL|External Facilitation|Audit and Feedback plus External Facilitation will serve as the second stage implementation intervention for sites that still do not meet the benchmark for adequate implementation following 9 months of implementation as usual plus audit and feedback.
62271269|NCT06063421|ACTIVE_COMPARATOR|Nicotine Replacement Therapy (NRT)|The arm will comprise participants that receive NRT. The NRT used will be combination therapy; transdermal Nicotine patches will be combined with faster-acting oral products like gum or lozenges. The strength of nicotine patches will be from 7 to 21 mg, and for gum or lozenges, the strength will be 1-4 mg. Usage will be in the form of a daily nicotine patch and ad libitum use of the faster-acting lozenge to curb nicotine cravings. Participants will be provided with a 12-week supply of NRT.
62271270|NCT06063421|EXPERIMENTAL|Electronic Cigarettes (EC)|Participants randomised to the EC group will be supplied with an EC starter kit. The kit will consist of a personal vaping device with an integrated battery. Three commonly used flavours of e-liquid (tobacco, menthol, and fruit flavours) will be provided. All e-liquids will have a nicotine concentration of 18-20 mg/ml. EC will be provided for a total of 12 weeks.
62271271|NCT04739046|EXPERIMENTAL|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and radiation therapy
62271272|NCT02206646||Metalyse|weight-adjusted dose
62271273|NCT00193895|ACTIVE_COMPARATOR|Radiotherapy alone|Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
62633770|NCT00631254|ACTIVE_COMPARATOR|2|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
62653222|NCT05052840|ACTIVE_COMPARATOR|Conventional Treatment|
62066254|NCT03408743|EXPERIMENTAL|Expectancies, descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62271274|NCT00193895|EXPERIMENTAL|Radiotherapy plus chemotherapy|Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
62271275|NCT03631836|EXPERIMENTAL|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
62271276|NCT04804189|NO_INTERVENTION|Control Group|Up to 30 4-H Shooting Sport Clubs that will not receive Guardians 4 Health intervention.
62271277|NCT04804189|EXPERIMENTAL|Intervention Group|Up to 30 Randomized 4-H Shooting Sport Clubs that will receive Guardians 4 Health intervention.
62271278|NCT04639622|OTHER|asymptomatic at-risk individual|First-degree relative of a family member affected with the frontotemporal dementia.
62271279|NCT04639622|OTHER|symptomatic individual|Patient who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum
62271280|NCT03740750|PLACEBO_COMPARATOR|control|sham heat and sham TENS
62271281|NCT03740750|EXPERIMENTAL|heat only|heat applied to the back for 4 hours with sham TENS
62271282|NCT03740750|EXPERIMENTAL|Tens only|Tens applied for 4 hours with sham heat
62271283|NCT03740750|EXPERIMENTAL|Heat and Tens continuous|Heat and Tens applied together for 4 hours
62271284|NCT03740750|EXPERIMENTAL|Tens 15|Tens applied only 15 minutes each hour for 4 hours, sham heat
62633771|NCT05630443|NO_INTERVENTION|ERAS|Ordinary ERAS treatment postoperatively without any prone position or voicetraining
62633772|NCT05630443|ACTIVE_COMPARATOR|+prone position|Ordinary ERAS treatment adding the prone position and voicetraining in short intervals
62633773|NCT01945346|EXPERIMENTAL|PRX167700|
62271285|NCT03740750|EXPERIMENTAL|Heat and Tens 15|Heat applied for 4 hours with tens only applied the last 15 minutes of each hour
62271286|NCT02269527|OTHER|Live music|1-hour live music 5 days/week
62271287|NCT05627219||Supportive care (training, education, discussion)|"AIM 1: Peer genetic coaches undergo training and education on study.~AIM 2: Patients receive an educational booklet and attend a discussion with a peer genetic coach on study."
62271288|NCT06372964|EXPERIMENTAL|Lumateperone|Lumateperone 42 mg for patient ages 13-17 years and Lumateperone 21 mg for patient ages 10-12 years.
62271289|NCT06372964|PLACEBO_COMPARATOR|Placebo|Matching placebo
62271290|NCT00267748|EXPERIMENTAL|C|
62271291|NCT00267748|EXPERIMENTAL|A|
62271292|NCT03077672||NYP-WCM|The NYP-WCM cohort will consist of patients presenting to the NewYork-Presbyterian/Weill Cornell Medicine Emergency Department with suspected sepsis.
62271293|NCT03077672||NYP-BMH|The NYP-BMH cohort will consist of patients presenting to the NewYork-Presbyterian Brooklyn Methodist Hospital Emergency Department with suspected sepsis.
62271294|NCT03343587|EXPERIMENTAL|LY3375880 Single Dose|Single dose of LY3375880 administered IV or SC
62271295|NCT03343587|PLACEBO_COMPARATOR|Placebo Single Dose|Single dose of placebo administered IV or SC
62271296|NCT03343587|EXPERIMENTAL|LY3375880 Multiple Dose|Multiple doses of LY3375880 administered IV or SC
62633774|NCT01945346|PLACEBO_COMPARATOR|Placebo|
62066255|NCT03408743|EXPERIMENTAL|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies , descriptive norms, and injunctive norms modules for a period up to 3 weeks.
62066256|NCT03408743|EXPERIMENTAL|Expectancies, descriptive & injunctive norms, efficacy|Participants will have access to the knowledge module plus the expectancies , descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
62066257|NCT03408743|EXPERIMENTAL|Expectancies, descriptive & injunctive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
62066258|NCT03408743|EXPERIMENTAL|Expectancies, descriptive & injunctive, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
62066259|NCT06133114|EXPERIMENTAL|S arm: Single drug clonazepam|Single drug clonazepam: 1 mg a day (0.5 mg twice a day) with Treatment As Usual (TAU)
62271297|NCT03343587|PLACEBO_COMPARATOR|Placebo Multiple Dose|Multiple doses of placebo administered IV or SC
62271298|NCT04495738|ACTIVE_COMPARATOR|Control Feeding Group|Ready to feed milk-based product
62066260|NCT06133114|EXPERIMENTAL|D arm: Two-drug combination clonazepam/olanzapine|Two-drug combination clonazepam/olanzapine: 1 mg a day (0.5 mg twice a day) of Clonazepam plus 2.5 mg a day of Olanzapine with Treatment As Usual (TAU)
62066261|NCT06133114|EXPERIMENTAL|T arm: Three-drug combination clonazepam/olanzapine/buprenorphine|Three-drug combination clonazepam/olanzapine/buprenorphine: 1 mg a day (0.5 mg twice a day) of Clonazepam plus 2.5 mg a day of Olanzapine plus 2mg a day of Buprenorphine with Treatment As Usual (TAU)
62066262|NCT06133114|NO_INTERVENTION|Control Group|Participants that will not receive an intervention.
62066263|NCT02948959|PLACEBO_COMPARATOR|Placebo|Placebo (for Dupilumab), subcutaneous (SC) injection every 2 weeks (q2w) for 52 weeks in combination with stable-dose background therapy of medium-dose inhaled corticosteroids (ICS) with a second controller medication (i.e., long-acting β2 agonist \[LABA\], long acting muscarinic antagonist \[LAMA\], leukotriene receptor antagonist \[LTRA\] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
62271299|NCT04495738|EXPERIMENTAL|Experimental Feeding Group|Ready to feed milk-based product with oligosaccharides
62271300|NCT04495738|OTHER|Human Milk (HM) Reference Group|HM from infant's own mother and as needed supplemental infant formula and toddler milk-based product
62066264|NCT02948959|EXPERIMENTAL|Dupilumab|Dupilumab 200 milligrams (mg) (in 1.14 milliliters \[mL\] for \>30 kilograms \[kg\] bodyweight \[BW\]) or 100 mg (in 0.67 mL for less than or equal to (\<=) 30 kg BW), SC injection q2w for 52 weeks in combination with stable-dose background therapy of medium-dose ICS with a second controller medication (i.e., LABA, LAMA, LTRA\] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
62066265|NCT00621907|EXPERIMENTAL|1|patient who received levobupivacaïne
62271301|NCT02706873|ACTIVE_COMPARATOR|Methotrexate|"Period 1: Participants will receive placebo to upadacitinib once daily and methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on placebo to upadacitinib once daily and methotrexate once weekly until the study is unblinded, after which participants will receive open-label methotrexate up to Week 260."
62633775|NCT05501392|EXPERIMENTAL|Intervention|This group received health education, P.E. classes, child nutritional services, as well as a parent component.
62633776|NCT05501392|ACTIVE_COMPARATOR|Control|This group received their usual health education and P.E. classes.
62653223|NCT04530071|EXPERIMENTAL|CordSTEM-DD(0.7x10^7 cells)|HA+saline+CordSTEM-DD(0.7x10\^7 cells)
62271302|NCT02706873|EXPERIMENTAL|Upadacitinib 7.5 mg (Japan-only)|"Period 1: Participants will receive upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 7.5 mg up to Week 260."
62452908|NCT02877251||Deep venous thrombosis and Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis and pulmonary embolism
61978599|NCT03255486|EXPERIMENTAL|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
62066266|NCT00621907|PLACEBO_COMPARATOR|2|patient who received placebo
62066267|NCT02810314|EXPERIMENTAL|Clinical measures|MS patients recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works for each group and all MS patients will also complete a comprehensive neuropsychological battery including cognitive and behavioural tests of interest in MS
62452909|NCT02877251||Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with pulmonary embolism
62452910|NCT05263648|OTHER|Virtual Reality Sessions|Patients will undergo at least two VR sessions. One prior to and one during the course of radiation treatment.
62452911|NCT04776551|OTHER|group (1)|group (1) who are complaining of acute scaphoid fractures,we will do percutaneous trans trapezial fixation of scaphoid by Herbert screw.Short arm circular cast including the thumb will be applied. After 3 weeks, cast will be removed and exercises will start.
61978600|NCT05320523|ACTIVE_COMPARATOR|GPi stimulation + NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with globus pallidus internus (GPi) stimulation using Vercise deep brain stimulation
62066268|NCT02810314|OTHER|Control measures|Healthy participants recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works
62271303|NCT02706873|EXPERIMENTAL|Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 15 mg up to Week 260."
62271304|NCT02706873|EXPERIMENTAL|Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 30 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 30 mg once daily. After implementation of Protocol Amendment 6 participants will receive upadacitinib 15 mg once daily up to Week 260."
62271305|NCT03797625|EXPERIMENTAL|Endostar Combined With IP|Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1
62271306|NCT00584480|ACTIVE_COMPARATOR|1|Active Hyperbaric Oxygen Treatment (HBOT)
62271307|NCT00596089||1|Men and women 60 years and older
62271308|NCT00596089||2|Men and women 20-30 years of age
62452912|NCT02260557|EXPERIMENTAL|Selexipag|Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.
62452913|NCT02260557|EXPERIMENTAL|Placebo|Placebo matching selexipag tablets is administered according to the same schedule as selexipag
62271309|NCT05713097||ATD withdrawal|"ATD treatment was decided to be stopped at the discretion of the attending physician. Then, patients were followed after ATD withdrawal to determine who would have relapse of GD.~Finally, patients were divided into 2 groups: Relapse and No relapse"
62271310|NCT05713097||No ATD withdrawal|Patients treated with ATD still the end of the study
62271311|NCT01238458|EXPERIMENTAL|[18F]AV-45 PET amyloid binding imaging|
62271312|NCT06457386|ACTIVE_COMPARATOR|systematic echocardiography arm|"transthoracic echocardiography (TTE) will be performed as soon as possible within 14 days following the first blood sample collection for SAB diagnosis, completed, if required, by a transoesophageal (TEE) echocardiography based on the judgment of the echocardiographist.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
62271313|NCT06457386|EXPERIMENTAL|no echocardiography arm|"no echocardiography will be performed unless occurrence of new events evocating IE (extra-cardiac events or positive Staphylococcus aureus blood culture), based on the clinical judgment of the investigator.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm.~"
62066269|NCT02672501|EXPERIMENTAL|anti-CD19-CAR-T cells|patients receive chemotherapy(CF, cyclophosphamide and Fludarabine) on day -6 to day -1, then infusied with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity.
62066270|NCT00875732|EXPERIMENTAL|1|Biventricular Pacing
62066271|NCT00875732|ACTIVE_COMPARATOR|2|Right Ventricular Pacing
62066272|NCT02139475||Colonoscopy|patients undergoing colonoscopy after colorectal cancer surgery
62271314|NCT02239939|EXPERIMENTAL|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for \>10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
62271315|NCT02239939|ACTIVE_COMPARATOR|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
62066273|NCT02643719|ACTIVE_COMPARATOR|Topiramate|
62066274|NCT02643719|ACTIVE_COMPARATOR|Behavioral intervention|
62066275|NCT02643719|ACTIVE_COMPARATOR|topiramate and behavioral intervention|
62066276|NCT02643719|ACTIVE_COMPARATOR|Standard of Care|
62271316|NCT03703973||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University \[Jiangsu China\]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.We also measure their preoperative leukocyte telomere length.
62271317|NCT03703973||control group|We enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
62271318|NCT01334034|EXPERIMENTAL|Dose levels 1-7|
62271319|NCT01493453|EXPERIMENTAL|Single Arm - aCD19z cells, interleukin 2, Chemotherapy|
62271320|NCT03328663|EXPERIMENTAL|CARE intervention|"* Six psychological intervention sessions in-person or via video conferencing conducted by a trained psychologist~* The CARE intervention contain 3 component~  * a psychoeducational component to address preparednessmanage expectations, and develop caregiving skills~ * a psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~ * a self-care component to promote caregiver health and well-being"
62066277|NCT05043402|EXPERIMENTAL|Combination navicixizumab + paclitaxel|Combination navicixizumab + paclitaxel: navicixizumab 3 mg/kg Q2W of a 28 day cycle (i.e., Days 1 and 15); paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28 day cycle
62271321|NCT03328663|ACTIVE_COMPARATOR|Standard transplant care|"* Standard Transplant Care~* Social work consults to help caregivers only upon request"
62066278|NCT05043402|ACTIVE_COMPARATOR|Paclitaxel monotherapy|Paclitaxel monotherapy: paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
62452914|NCT06542081||One grup|parents of hearing impaired children
62066279|NCT05043402|EXPERIMENTAL|Navicixizumab monotherapy|Navicixizumab monotherapy: navicixizumab 3 mg/kg Q2W of a 28-day cycle (i.e., Days 1 and 15)
62066280|NCT02183116|EXPERIMENTAL|Meloxicam|
62066281|NCT05287516|EXPERIMENTAL|Breakfast meal with 460 kcal|
62066282|NCT05287516|ACTIVE_COMPARATOR|Breakfast meal with 230 kcal|
62066283|NCT04278677|ACTIVE_COMPARATOR|Melatonin supplementation|5mg melatonin tablets to be taken for 6 weeks
62066284|NCT04278677|NO_INTERVENTION|No supplementation|
62066285|NCT01291238|EXPERIMENTAL|Healthy lifestyle habits|Increased physical activity and healthy food with decreased sugar and fat content
62066286|NCT00840008|EXPERIMENTAL|Educational intervention|see protocol
62066287|NCT00840008|NO_INTERVENTION|Standard care|distribution of guidelines and a published algorithm
62066288|NCT05844891|EXPERIMENTAL|Telehealth-Enhanced Asthma Care for Home After the Emergency Room|New model of patient-centered asthma management.
62066289|NCT05844891|ACTIVE_COMPARATOR|Enhanced Care (EC) Comparison Group|Standard emergency department care for asthma exacerbations, enhanced through a report of recent symptoms sent to PCPs, and systematic feedback on asthma management/care at intervals that parallel the TEACH-ER group's telemedicine assessments.
62066290|NCT01030978|EXPERIMENTAL|Family-based Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
62066291|NCT01030978|ACTIVE_COMPARATOR|Standard Diet & Activity Education (Control)|
62633777|NCT01639612|EXPERIMENTAL|ALD-451|Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide
62066292|NCT04902417|NO_INTERVENTION|Low Dairy Habitual Diet|Participants will follow their usual diet for 6-weeks, which includes low dairy consumption as screened for with the inclusion criteria.
62066293|NCT04902417|EXPERIMENTAL|High Dairy Diet|Participants will be provided with 3 servings of dairy per day to replace other foods within their diet (preventing weight gain over the intervention period) for 6-weeks
62271322|NCT05134961||Patients undergoing resection of primary duodenal cancer|Tumors comprised histologically confirmed adenocarcinomas in the duodenum excluding adenocarcinoma of the ampulla of Vater and adenocarcinomas with gastric and pancreato-biliary morphology and immunohistochemistry.
62271323|NCT02355288|ACTIVE_COMPARATOR|Minimally Invasive Coronary Bypass|Minimally invasive bypass surgery (MICS CABG) would be conducted to treat the left anterior descending (LAD) artery disease in diabetic patients. This would be a surgical intervention, and differs from the stent procedure arm.
62066294|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
62066295|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
62452915|NCT00930488||Group 1|
62066296|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
62066297|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
62633778|NCT01637714|EXPERIMENTAL|Multi-strain probiotics|
62633779|NCT01637714|PLACEBO_COMPARATOR|Placebo powder|
62633780|NCT02449421|EXPERIMENTAL|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
62653224|NCT04530071|EXPERIMENTAL|CordSTEM-DD(2.1x10^7 cells)|HA+saline+CordSTEM-DD(2.1x10\^7 cells)
62066298|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
62066299|NCT02066896|SHAM_COMPARATOR|Sham Comparator: Sham Lasertherapy|Sham lasertherapy in parotid, submandibular and sublingual glands for six weeks.
62066300|NCT02066896|ACTIVE_COMPARATOR|Active Comparator: Lasertherapy|Low level lasertherapy in parotid, submandibular and sublingual glands for six weeks.
62066301|NCT04068363||Matched group|Same sex of both donor and recipient
62066302|NCT04068363||Mismatched group|Sex mismatch between donor and recipient, subgroups might be added
62066303|NCT05182073|EXPERIMENTAL|Regimens A-A4|FT576 single dose monotherapy in subjects with r/r MM
62633781|NCT02449421|EXPERIMENTAL|Quality Improvement Learning Community|The Quality Improvement Learning Community arm will include clinicians who set goals related to CPT delivery, execute a plan, study results, refine plan, and continue each cycle until goals are met.
62066304|NCT05182073|EXPERIMENTAL|Regimen A1|FT576 multiple dose monotherapy in subjects with r/r MM
62452916|NCT04931667|EXPERIMENTAL|0.07 mg Lorecivivint|One intra-articular injection of 0.07 mg Lorecivivint in 2 ml vehicle in one or both knees as clinically indicated. Bilateral injection of 0.07 mg LOR are allowed.
62452917|NCT06121206|EXPERIMENTAL|Altitude-like hypoxia (12%) combined with cognitive training|Participants breathe 12% ambient oxygen in an altitude-training room, 3.5 hours daily, 5-6 days per week for 3 weeks. On iPads, they perform cognitive training, which is interleaved by short breaks.
62633782|NCT01470703|EXPERIMENTAL|ECMO arm|
62452918|NCT06121206|ACTIVE_COMPARATOR|Altitude-like hypoxia (12%) with no training|Participants breathe 12% ambient oxygen in an altitude-training room, 3.5 hours daily, 6 days per week for 3 weeks. On iPads, they perform matched control games without cognitive benefits, which is interleaved by short breaks.
62066305|NCT05182073|EXPERIMENTAL|Regimens B-B4|FT576 single dose in combination with daratumumab in subjects with r/r MM
62452919|NCT06121206|ACTIVE_COMPARATOR|Normoxia (20%) combined with cognitive training|Participants breathe 20% ambient oxygen in an altitude-training room, 3.5 hours daily, 6 days per week for 3 weeks. On iPads, they perform cognitive training, which is interleaved by short breaks.
62633783|NCT01470703|ACTIVE_COMPARATOR|conventional arm|
62633784|NCT05382546|EXPERIMENTAL|NTM-001 Treatment Arm|NTM-001 loading dose of 12.5 mg administered over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mg/h for 24h, by a pre-programmed infusion pump.
62633785|NCT01275690||subjects with PH undergoing right heart catheterization|
62271324|NCT02355288|ACTIVE_COMPARATOR|Percutenous Coronary Intervention|Percutaneous coronary intervention (PCI) with drug eluting stents would be used to treat left anterior descending (LAD) artery disease in diabetic patients. This would be an intervention induced by cardiology, and differs from the surgical intervention arm.
62452920|NCT06121206|SHAM_COMPARATOR|Normoxia (20%) combined with no training|Participants breathe 20% ambient oxygen in an altitude-training room, 3.5 hours daily, 6 days per week for 3 weeks. On iPads, they perform matched control games without cognitive benefits, which is interleaved by short breaks.
62066306|NCT05182073|EXPERIMENTAL|Regimen B1|FT576 multiple dose in combination with daratumumab in subjects with r/r MM
62066307|NCT03612427||Breastfed infants|Infants depending on breastfeeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
62066308|NCT03612427||Formula-fed infants|Infants have formula feeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
62066309|NCT03062774|EXPERIMENTAL|PB-119|intervention: PB-119 injection
62452921|NCT06121206|NO_INTERVENTION|Treatment as usual|Participants receive no additional care or intervention between baseline and end-of-treatment assessment points.
62452922|NCT04359238|ACTIVE_COMPARATOR|Intervention group with motivation messages|There are 100 patients in the intervention group with automated or observer initiated motivation messages. They receive an individualized training program with regular notifications about their training status via their SmartWatch.
62653225|NCT04530071|PLACEBO_COMPARATOR|Control group|HA + saline + placebo comparator
61978601|NCT05320523|SHAM_COMPARATOR|GPi stimulation + sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
62066310|NCT01022801|EXPERIMENTAL|Entecavir (0.01 mg)|
62066311|NCT01022801|EXPERIMENTAL|Entecavir (0.1 mg)|
62066312|NCT01022801|EXPERIMENTAL|Entecavir (0.5 mg)|
62271325|NCT00278421|ACTIVE_COMPARATOR|Interventional: 6 R-CHOP-21|Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
62271326|NCT00278421|ACTIVE_COMPARATOR|Interventional: 4 R-CHOP-21 + 2 x R|Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.
62271327|NCT03747601|EXPERIMENTAL|Temporal Interference (TI) Stimulation|Temporal Interference stimulation applied to the head via standard electrodes
62271328|NCT04583397|EXPERIMENTAL|Experimental: WiFi - Sham|first intervention WiFi, second intervention sham
62271329|NCT04583397|EXPERIMENTAL|Experimental: Sham - WiFi|first Intervention sham, second Intervention WiFi
62271330|NCT01568606|EXPERIMENTAL|Body Composition Analysis InBody Scale|
62271331|NCT04813471|EXPERIMENTAL|Endothelial Dysfunction Protocol|"Experimental: Endothelial Dysfunction Protocol~Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin(or home statin), nicorandil, l-arginine, folic acid and vitamin B complex) in critically Ill patients already on optimal medical therapy for the treatment of COVID-19 virus. Protocol will be given for a total of 14 days or until discharge from the hospital~Patients already on home statin will continue their medication or if the are eligible for statins they will recieve 40 mg tablet to be given PO once daily.~Nicorandil Nicorandil 10 mg PO BID for the first 7 days and then if no contraindications escalated to 20 mg PO BID for the remaining 7 days~Folic Acid Folic Acid 5 mg po once daily~L-Arginine L-Arginine 1 g po TID~Vitamin B complex (Becozyme) 1 ampoule IV daily"
62271332|NCT04813471|NO_INTERVENTION|Standard of care|Standard of Care
62271333|NCT04069845||liposomal doxorubicin treatment|intravenous liposomal doxorubicin
61978602|NCT05700045|EXPERIMENTAL|dexmedetomidine + ropivacaine|each side dexmedetomidine 0.5ug/kg+0.25% ropivacaine 20ml TAP block
61978603|NCT05700045|NO_INTERVENTION|ropivacaine|each side 0.25% ropivacaine 20ml TAP block
61978604|NCT05555212|EXPERIMENTAL|dose escalation (in China)|
61978605|NCT06409884|EXPERIMENTAL|Patients with a suspected amoxicillin allergy|Patients with a suspected amoxicillin allergy for which the diagnostic work-up was performed at the hospital for the possible diagnosis of amoxicillin allergy.
62066313|NCT05699122|ACTIVE_COMPARATOR|The Control Group - Persistent erythema with intact epidermis|The Control Group - Persistent erythema with intact epidermis
62271334|NCT05219188||Heart failure with preserved ejection fraction and BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
62271335|NCT05219188||Heart failure with preserved ejection fraction and BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
62271336|NCT05219188||Healthy controls with BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
62271337|NCT05219188||Healthy controls with BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
61978606|NCT05109039|EXPERIMENTAL|Creatine Supplementation|
61978607|NCT05109039|PLACEBO_COMPARATOR|Placebo Supplementation|
61978608|NCT04533347|ACTIVE_COMPARATOR|Tafenoquine|Tafenoquine two 100 mg oral tablets 1x/day on Days 1,2,3 and 10
62066314|NCT05699122|EXPERIMENTAL|The Experimental Group - Persistent erythema with intact epidermis|The Experimental Group - Persistent erythema with intact epidermis
62066315|NCT05699122|ACTIVE_COMPARATOR|The Control Group - Erythema with signs of epidermis loss|The Control Group - Erythema with signs of epidermis loss
62271338|NCT05435456|EXPERIMENTAL|Experimental Group|Performed strengthening and relaxation exercises 3 times a week for 8 weeks.
62452923|NCT04359238|ACTIVE_COMPARATOR|Intervention group without motivation messages|There are 100 patients in the intervention group without automated or observer initiated motivation messages. They receive an individualized training program without regular notifications about their training status via their SmartWatch.
62633786|NCT03653845|EXPERIMENTAL|Intevention|Patients in this group will be treated with endovascular chemical ablation of adrenal glandp by endovascular injection of dehydrated alcohol. Sequenced antihypertensvie drugs with titrated dosage(amlodipine 5-10 mg/d ; terazosin 2-6mg/d) will be prescribed if home blood pressure (HBP) exceeds ≥160/100 mmHg.
62271339|NCT05435456|NO_INTERVENTION|Control Group|There is no intervention
62271340|NCT03580421|ACTIVE_COMPARATOR|standard pathway group|this group will benefit from standard care including: one surgical consultation, one anesthesia consultation, surgery followed by 2-4 days of hospitalization and most of the time 3 post-operative consultations (M1, M6, M12) during the first operative year
62633787|NCT03653845|ACTIVE_COMPARATOR|Control|Patients in this group will be treated only with sequenced antihypertensvie drugs with titrated dosage(amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d→→plus amlodipine 10 mg/ d →plus terazosin 2-6mg / d) if home blood pressure (HBP) exceeds ≥160/100 mmHg.
62633788|NCT05104073|EXPERIMENTAL|Intervention|The intervention arm is characterized by calibrated formula feeding recommendations. The intervention group parents will be given written instructions on infant hunger and satiety cues as well as copies of videos with guidance on bottle feeding and how to soothe fussy infants without feeding. N=30 meeting inclusion/exclusion criteria
62271341|NCT03580421|EXPERIMENTAL|ambulatory pathway group|Preoperative and postoperative protocols will be applied for optimizing same-day discharge. Gynaecologists, anaesthetists, and nursing staff will work as a team. A specific anesthesia consultation will focus on ambulatory surgery management. A geriatric evaluation will be offered to women over 70 years old with a score ≤14 according to G8 screening tool. A dietetic evaluation will be offered to women with BMI ≥ 35. A nursing consultation will be offered, as patient and their family preparation prior to ambulatory surgery is important.
62633789|NCT05104073|NO_INTERVENTION|Control|The control arm will have ad lib feeds as per usual care. N=30 meeting inclusion/exclusion criteria
62633790|NCT01747356|EXPERIMENTAL|Resolute stent treatment group|"All patients will receive Resolute stent implantation to cure severe coronary atherosclerotic lesions.~RESOLUTE stent system specification (eluted zotarolimus 1.6μg/mm2):~After stent implantation, each patient will be followed up at time point of 30-day, 6-month and 12-month.~Follow-up window:~Duration of hospital stay Follow-up 1: 30days after procedure (±7 days) Follow-up 2: 6-month after procedure (±30 days) Follow-up 3: 12-month after procedure (±30 days)"
62633791|NCT06280898||nonischemic|
62633792|NCT06280898||ischemic|
62271342|NCT06081907|EXPERIMENTAL|IBI363 DL1|IBI363 + IBI325
62633793|NCT01234597|ACTIVE_COMPARATOR|Arm A: Without Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the treating physician"
62633794|NCT01234597|EXPERIMENTAL|Arm B: Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: the patients are connected to a CGM sensor. Insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the national coordinator based on the data collected in the past previous days of CGM sensor monitoring."
62633795|NCT03462784||Cases|
62633796|NCT00402792|EXPERIMENTAL|Arm 1: hydrocodone / acetaminophen extended release|
62066316|NCT05699122|EXPERIMENTAL|The Experimental Group - Erythema with signs of epidermis loss|The Experimental Group - Erythema with signs of epidermis loss
62271343|NCT06081907|EXPERIMENTAL|IBI363 DL2|IBI363 + IBI325
62271344|NCT06081907|EXPERIMENTAL|IBI363 DL3|IBI363 + Lenvatinib
62271345|NCT06081907|EXPERIMENTAL|IBI363 DL4|IBI363 + Lenvatinib
62271346|NCT06081907|EXPERIMENTAL|IBI363 DL5|Patients with histopathologically confirmed advanced melanoma, who have failed PD-1/PD-L1 treatment and CD73 ≥++ confirmed by IHC.
62271347|NCT06081907|EXPERIMENTAL|IBI363 DL6|Patients with histopathologically confirmed advanced NSCLC, who have failed PD-1/PD-L1 treatment and CD73 ≥++ confirmed by IHC.
62633797|NCT00402792|EXPERIMENTAL|Arm 2: hydrocodone / acetaminophen extended release|
62633798|NCT00402792|PLACEBO_COMPARATOR|Arm 3: Placebo|
62066317|NCT00632008|EXPERIMENTAL|1|SBG
62066318|NCT00632008|PLACEBO_COMPARATOR|2|
62066319|NCT04865211|EXPERIMENTAL|Liposomal Bupivicaine|Administration of a combination of lioposomal bupivicane 20ml/266mg mixed with 20mL of 0.375% bupivicaine
62066320|NCT04865211|ACTIVE_COMPARATOR|Bupivicane|Administration of 40 ml of 0.375% Bupivicaine with epinephrine 1:400,000
62271348|NCT06081907|EXPERIMENTAL|IBI363 DL7|Patients with histopathologically confirmed advanced NSCLC, who have failed PD-1/PD-L1 treatment, and whose best response during PD-1/PD-L1 treatment was disease stabilization for less than 6 months or disease progression.
62452924|NCT04359238|NO_INTERVENTION|Control group|100 patients are in the control group without an individualized training program.
62452925|NCT04552509|OTHER|Observation|Observational study of patient efficacy and side effects
62633799|NCT04300712|OTHER|Tracking of the children with difficulties|All parents and teachers will respond to the questionnaires and the beginning and end of school year which is not done in the routine for tracking the children in difficulty.
62271349|NCT06081907|EXPERIMENTAL|IBI363 DL8|Patients with histopathologically confirmed advanced NSCLC, who have failed PD-1/PD-L1 treatment, and whose best response during PD-1/PD-L1 treatment was partial response or complete response lasting more than 6 months.
62271350|NCT06081907|EXPERIMENTAL|IBI363 DL9|Patients with histologically confirmed advanced NSCLC, who have undergone NGS testing confirming the presence of an ALK fusion mutation and have previously failed standard treatment.
62452926|NCT01079637|EXPERIMENTAL|Midfoot Fusion Bolt|
62452927|NCT01079637|EXPERIMENTAL|Cast treatment|
62452928|NCT00000359|EXPERIMENTAL|Canalith repositioning maneuver|Repositioning treatment for posterior canal BPPV
62633800|NCT04848636||Healthy Controls|"* Age greater than or equal to 18 years~* lack of kidney disease, cardiovascular disease, diabetes, liver cirrhosis and peripheral edema"
62633801|NCT04848636||Chronic Kidney Disease Patients|"* Age greater than or equal to 18 years~* evidence of kidney disease persisting \> 3 months and no indications to start dialysis"
62633802|NCT04848636||Hemodialysis Patients|"* Age greater than or equal to 18 years~* more than 3 months duration of therapy"
61978609|NCT04533347|PLACEBO_COMPARATOR|Placebo|Placebo two tablets 1x/day on Days 1,2,3 and 10
61978610|NCT03971890|EXPERIMENTAL|DanceTherapy Group|The experimental group will receive a dance treatment.
62066321|NCT04865211|PLACEBO_COMPARATOR|Placebo|Saline injection with 40mL preservative-free saline
62066322|NCT03973866|EXPERIMENTAL|Alfapump|Implantation of Alfapump
62066323|NCT02436083|NO_INTERVENTION|control|no antibiotics
62066324|NCT02436083|ACTIVE_COMPARATOR|experimental group|drug administration (antibiotic)
62066325|NCT01771822|EXPERIMENTAL|Ibuprofen 5% topical gel|
62066326|NCT01771822|EXPERIMENTAL|Topical gel vehicle|
62066327|NCT01771822|ACTIVE_COMPARATOR|Sodium lauryl sulfate 0.2%|
62271351|NCT06081907|EXPERIMENTAL|IBI363 DL10|Patients with histological or cytological confirmation of advanced NSCLC who harboring EGFR mutation and failed standard treatment.
62271352|NCT06081907|EXPERIMENTAL|IBI363 DL11|Patients with histological or cytological confirmation of advanced NSCLC and failed standard treatment with rare mutations, including but not limited to ROS1, BRAF V600E, METex14 skipping, HER2, NTRK, and RET fusion.
62452929|NCT00000359|EXPERIMENTAL|Modified Epley maneuver|
62452930|NCT00000359|SHAM_COMPARATOR|Sham|The subject sat in a chair; the head was passively tilted downward, turned away from the involved side, turned back to center, upward, away from the involved side, twice, slowly.
62452931|NCT00000359|ACTIVE_COMPARATOR|Liberatory maneuver|The standard liberatory maneuver (also known as the Semont maneuver) was used.
62452932|NCT00000359|ACTIVE_COMPARATOR|Brandt Daroff exercise|Modified Brandt Daroff exercise performed as a self-liberatory exercise.
62452933|NCT03295721|EXPERIMENTAL|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
62452934|NCT03295721|PLACEBO_COMPARATOR|Treatment Group 2: Saline Placebo|Saline placebo
62452935|NCT03295721|ACTIVE_COMPARATOR|Treatment Group 3: Bupivacaine HCI|Bupivacaine HCl
62452936|NCT03598439|EXPERIMENTAL|Recombinant (RIV4) Influenza Vaccine|A single dose of licensed recombinant influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
62452937|NCT03598439|EXPERIMENTAL|Cell-culture (ccIIV4) Influenza Vaccine|A single dose of licensed cell-culture influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20
62452938|NCT03598439|ACTIVE_COMPARATOR|Standard (IIV4) Influenza Vaccine|A single dose of licensed standard influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
62452939|NCT02296580|EXPERIMENTAL|Nativis Voyager RFE Therapy|Subjects will be treated with Nativis Voyager therapy until tumor progression.
62633803|NCT05679245||Healthy Controls|Healthy controls without mental disorder in the general population of the Barcelona area of Catalonia, Spain to be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
62633804|NCT04710069|NO_INTERVENTION|Control/Usual Care|standard treatment of postoperative pain, which involves automatic prescription of a narcotic pain medication regimen after surgery,
62633805|NCT04710069|EXPERIMENTAL|Opt-in/POINT|An opt-in program (POINT), which requires the patient to consent to receiving a prescription for narcotics
62633806|NCT05177640|EXPERIMENTAL|99mTC-duramycin|single dose of 99mTc-duramycin in healthy volunteers who will undergo SPECT-CT scanning at different time points
62452940|NCT05667870||Newborns with CHD and their mothers|Consecutive newborns with CHD (n=100), who are diagnosed and born in the University Hospitals of Leuven and Ghent, are eligible for inclusion. Mothers (n=100) will be asked for participation in the study before delivery and written informed consent will be obtained. Umbilical cord blood of the ENVIRONAGE study (Hasselt University) will be used as a control group.
62452941|NCT05667870||(Young) adults with CHD - study 2|An age-stratified random sample of (young) adults with CHD, followed-up at the University Hospital of Leuven and the Ghent University Hospital will be included. Age strata for this study are: 18-24y; 25-34y; 35-44y; 45-54y; 55+. In total 500 patients will be included, 100 in each age stratum.
62452942|NCT05667870||(Young) adults with CHD - study 3|At the University Hospital of Leuven and Ghent University Hospital, patients with selected complex (Fontan operation; Systemic right ventricle), moderate (Tetralogy of Fallot; Coarctation of the aorta), and mild heart defects (isolated atrial septal defect; isolated ventricular septal defect) are eligible. For each type of heart defect 20 patients between the age of 30-50 years are enrolled. The overall sample will comprise 120 patients, who will be part of study 2 as well.
62633807|NCT05549583|EXPERIMENTAL|Reference group|Thirty minutes after the start of the breakfast, a single dose of the Reference formulation was administered with approximately 240 mL of water at ambient temperature
62633808|NCT05549583|EXPERIMENTAL|Test group|Thirty minutes after the start of the breakfast, a single dose of the Test formulation was administered with approximately 240 mL of water at ambient temperature
62066328|NCT01771822|SHAM_COMPARATOR|Sodium chloride solution 0.9% (saline)|
62271353|NCT00951730||Down syndrome|Adult and children with Down syndrome.
62271354|NCT00919503|EXPERIMENTAL|Regimen A (PBSCT and BMT)|"CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
62633809|NCT06453395||upper thoracic case|Cervical esophagus to lower border of the azygos vein
62633810|NCT06453395||Middle thoracic case|Cervical esophagus to lower border of the azygos vein
62633811|NCT06453395||Lower thoracic case|Lower border of the inferior pulmonary vein to the stomach, including the esophagogastric junction
62633812|NCT05627518|ACTIVE_COMPARATOR|Reference formulation (Treatment A)|100 mg linaprazan glurate reference formulation, fasting conditions
62633813|NCT05627518|EXPERIMENTAL|Test formulation (Treatment B)|100 mg linaprazan glurate reference formulation, fasting conditions
62633814|NCT05627518|EXPERIMENTAL|Test Formulation (Treatment C)|100 mg linaprazan glurate test formulation, fed conditions
62286914|NCT03656302||Control offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having no biological parent(s) with lifetime or current diagnosis of mood disorders. 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form.~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder. 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
62286915|NCT01451619|EXPERIMENTAL|Laropiprant|
62452943|NCT05667870||Healthy controls|Data on healthy controls (n=500) will be retrieved from blood donors at the blood donation service of the Belgian Red Cross-Flanders. The healthy controls will be matched to the included adult patients (in study 2 and 3) based on sex and age.
62452944|NCT04428567|EXPERIMENTAL|Treadmill Exercise + Cognitive Training (Dual-Task)|The Dual-Task group will be provided with treadmill training with added simultaneous cognitive training during treadmill exercise training.
62633815|NCT05855837|EXPERIMENTAL|Cereal Product 1|Ready to Eat Cereal Product 1 with 6 oz of skim milk
62633816|NCT05855837|EXPERIMENTAL|Cereal Product 2|Ready to Eat Cereal Product 2 with 6 oz of skim milk
62633817|NCT05855837|NO_INTERVENTION|Control|No intervention (i.e., no food provided)
62633818|NCT06257056|EXPERIMENTAL|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
62633819|NCT06257056|EXPERIMENTAL|Experimental: Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
62633820|NCT02872025|EXPERIMENTAL|CLOSED:Pembrolizumab intralesionally (IL) x 2 doses (Escalation Phase)|Participants, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The participant will then undergo the surgical treatment as determined by the surgeon and the participant (partial mastectomy or mastectomy).
62633821|NCT02872025|EXPERIMENTAL|CLOSED:Pembrolizumab IL x 4 doses (Expansion Phase)|Participants, upon diagnosis with high risk DCIS, will be offered 4 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 4th dose. The participant will then undergo the surgical treatment as determined by the surgeon and the participant (partial mastectomy or mastectomy).
62633822|NCT02872025|EXPERIMENTAL|CLOSED:Pembrolizumab IL x 2 doses + mRNA 2752 IL x 2-4 doses (Expansion Phase)|Participants, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab and intralesional mRNA 2752 injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The participant will then undergo the surgical treatment as determined by the surgeon and the participant (partial mastectomy or mastectomy).
62633823|NCT02872025|EXPERIMENTAL|mRNA-2752 Monotherapy x 2-4 doses (Escalation Cohort)|Participants will be offered up to 4 doses of mRNA-2752 injected intralesionally (IL) 3 weeks apart (+/- 1) week) with surgery or core biopsy 3 weeks (+/-1 week). The participants will proceed to biopsy, either image guided or excisional or partial mastectomy
62633824|NCT02872025|EXPERIMENTAL|mRNA-2752 x 2-4 doses with or without immune checkpoint inhibitor (Expansion Cohort)|Participants will be will be offered injections of mRNA-2752 given on up to 4 occasions, 3 weeks apart (+/- 1 week) or a combination mRNA-2752 and immune checkpoint inhibitor will be given up to 4 occasions, 3 weeks apart (+/- 1 week). The participants will proceed to biopsy, either image guided or excisional or partial mastectomy.
62633825|NCT02872025|NO_INTERVENTION|No active treatment|The control group will proceed to surgery alone within a 4 month timeframe following the diagnosis of high risk DCIS.
62452945|NCT04428567|NO_INTERVENTION|Control Group|The control group will be assessed as the intervention group at the same time intervals without the intervention.
62452946|NCT04826796|EXPERIMENTAL|Whatsapp intervention group|In addition to standard care, participants will be included into a peer support Whatsapp group on Whatsapp with other participants and trained peer supporters after study entry. Standard weekly prompt text messages will be sent to the group by peer supporters to encourage questions and discussion related to breastfeeding. Peer supporters will provide breastfeeding and emotional support. Intervention will last for 6 months after birth.
62452947|NCT04826796|NO_INTERVENTION|Control group|Participants in the control group will continue to receive standard care.
62452948|NCT00322478|OTHER|GlucoMON-ADMS enabled|Patients who are equipped with the automated technology vs. standard/conventional care
62452949|NCT04026126|EXPERIMENTAL|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline hemodynamic assessments as well as VO2max measurements. Subjects will complete 10 heat therapy treatments over the course of 14 days. Hemodynamics will be assessed with the use of the Clearsight© fingertip blood pressure cuff. Within 24-48 hours after the last heat therapy experience, hemodynamic assessments and VO2max will be performed. Blood samples will be collected pre- and post intervention and analyzed for levels of nitric oxide mediators, heat shock protein levels and pro-anti-inflammatory markers.
62452950|NCT03041766|EXPERIMENTAL|Group 1|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
62452951|NCT03041766|EXPERIMENTAL|Group 2|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
62452952|NCT01894711||Patients with HER2 positive tumors|Patients with HER2 positive tumors treated with trastuzumab or not treated with trastuzumab
62452953|NCT06121466|EXPERIMENTAL|Abdominal wall injections for abdominal wall pain|Patients with abdominal pain who are suspected of having abdominal wall pain.
62452954|NCT02304432|EXPERIMENTAL|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
62286916|NCT01451619|PLACEBO_COMPARATOR|Placebo|
62633826|NCT01442012|ACTIVE_COMPARATOR|Group A|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Pericardium 6, Heart 7 and Stomach 25
62452955|NCT02304432|EXPERIMENTAL|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
62271355|NCT00919503|EXPERIMENTAL|Regimen B (UBCT)|"CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD."
62271356|NCT03506555|ACTIVE_COMPARATOR|the arm A (Veress needle)|a standard reusable Veress needle technique was performed for laparoscopic entry
62271357|NCT03506555|ACTIVE_COMPARATOR|the arm B (Hasson)|the standard open Hasson technique was performed for laparoscopic entry
62271358|NCT04044131|EXPERIMENTAL|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
62271359|NCT04044131|PLACEBO_COMPARATOR|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
62271360|NCT03329235|EXPERIMENTAL|Intraosseous and intra-articular|injection of PRP 2 ml
62271361|NCT03329235|ACTIVE_COMPARATOR|intra-articular PRP|injection PRP 2 ml
62271362|NCT03329235|ACTIVE_COMPARATOR|Intra-articular injection of HA|injection of HA 2 ml
62271363|NCT03094871|EXPERIMENTAL|Intervention group|FACE-PC comprises 3 weekly and 2 bi-weekly sessions (total 5 sessions), delivered by a bachelors' prepared nurse care manager (CM) over 8 weeks. Over the five sessions, the nurse care manager will (1) review the patient medical history and set health goals for depression and chronic condition with the dyad, (2) review all medication, the level of adherence, challenges and facilitating factors of adherence, (3) deliver brief behavioral activation therapy.
62271364|NCT03094871|NO_INTERVENTION|Enhanced usual care group|Participants in this group will receive a typical primary care enhanced with reporting of their depression status and their goal for medical condition to their PCP for 8 weeks. Upon enrolment, a research nurse will review the patient medical history and identify goals for depression and a chronic condition with the dyad.
62271365|NCT04901208|ACTIVE_COMPARATOR|Users of Juul|Individuals who use Juul devices to vape nicotine
62271366|NCT04901208|NO_INTERVENTION|Controls|Healthy non-smokers
62633827|NCT01442012|SHAM_COMPARATOR|Group B|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Gall Bladder 34, Kidney 6 and Liver 3
62271367|NCT02564315|ACTIVE_COMPARATOR|Reduction/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62452956|NCT02304432|EXPERIMENTAL|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
62633828|NCT00988000|OTHER|Agree to the alternative study invitation|Agree with alternative of telephone consultation (instead of face to face) offered as an initial consultation to new referrals
62633829|NCT00988000|OTHER|Decline the alternative study invitation|Decline, no respond to the alternative of telephone consultation
62633830|NCT00988000|OTHER|Comparator|Choose and book
62271368|NCT02564315|ACTIVE_COMPARATOR|Reduction/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62271369|NCT02564315|ACTIVE_COMPARATOR|Reduction/Skill Counseling+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62271370|NCT02564315|ACTIVE_COMPARATOR|Reduction/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62271371|NCT02564315|ACTIVE_COMPARATOR|Recycling/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62271372|NCT02564315|ACTIVE_COMPARATOR|Recycling/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62271373|NCT02564315|ACTIVE_COMPARATOR|Recycling/Skill Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62452957|NCT01456611|EXPERIMENTAL|Diclofenac Sodium Gel|Diclofenac sodium Topical Gel 1%
62271374|NCT02564315|ACTIVE_COMPARATOR|Recycling/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
62271375|NCT02564315|PLACEBO_COMPARATOR|Preparation Phase Control/No Phase 3|"This arm includes Phase 2 (Preparation) Control Treatment and No Phase 3 (Cessation) Treatment. More specifically, treatments include the following:~Phase 2: Preparation Phase Control Treatment~Phase 3: No Treatment"
62271376|NCT04455529||ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
62271377|NCT06329037|EXPERIMENTAL|Vasopressin group|Vasopressin (20IU)
62271378|NCT06329037|PLACEBO_COMPARATOR|Placebo group|Placebo
62271379|NCT04547205|EXPERIMENTAL|AK109|
62271380|NCT06501664|EXPERIMENTAL|Experimental Group|liposomal irinotecan+5-FU/LV q2w
62452958|NCT01456611|ACTIVE_COMPARATOR|Voltaren (R) Gel|Voltaren (R) Gel 1%
62066329|NCT04065217|OTHER|Iraqi patients with face hemangioma|Diode laser 980-nm in the diseased group only while we no need the comparator group because we compared between lesion before and after. The administration of laser is scheduled to start treatment. Patients will take laser therapy as a 12 session at two week-interval. In case of intolerance, session number reduction by 10, 8, 6, 4 allowed. Adherence to treatment will be assessed at each interval for undesired side effects or complications. The intervention should continue also after complete session, or during temporary interval withdrawal due to reached maximal cumulative response or side effects from laser therapy.
62066330|NCT03613701||Moyamoya disease patients|Moyamoya disease patients/Healthy volunteers
62066331|NCT00720525||1|Patients with diastolic heart failure
62066332|NCT00720525||2|Patients without diastolic heart failure
62452959|NCT01456611|PLACEBO_COMPARATOR|Placebo|Placebo Topical Gel
62633831|NCT05036798|EXPERIMENTAL|Tislelizumab combined with Lenvatinib and GEMOX|"Chemotherapy regimen(GEMOX):~Gemcitabine 1g/m2,Oxaliplatin 100mg/m, D1, Q3W Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD~Receive at least 3 cycles of combined treatment, and perform imaging evaluation after 3 cycles of treatment. If surgical treatment is not possible, imaging evaluation will be performed every two cycles thereafter until surgical treatment is feasible. If more than 7 cycles are still not possible for surgical resection, enter Tislelizumab + Lenvatinib maintenance treatment until the disease progresses or the toxicity cannot be tolerated.~If patients undergoing R0 resection, start to receive Tislelizumab + Lenvatinib+Gemox regimen in 4-8 weeks after surgery for 7 cycles, and then entered Tislelizumab+Lenvatinib for 1 year or disease progression or toxicity cannot be tolerated"
62633832|NCT05201612|EXPERIMENTAL|Pembrolizumab plus olaparib|"Treatment cycles will be 21 days in length. All participants will receive treatment as follows:~Olaparib 300 mg, orally (po), twice a day (BID) continuously. Pembrolizumab 200 mg, intravenously (IV), every 21 days. Treatment will be continued in the absence of disease progression, unacceptable toxicity, withdrawal of consent or death. Pembrolizumab will be administered up to a maximum of 2 years (35 cycles)."
62633833|NCT02721615|ACTIVE_COMPARATOR|Laminectomy|Comparison of bone decompression versus no decompression for reducing intra spinal pressure
62633834|NCT02721615|ACTIVE_COMPARATOR|Duraplasty|Expansion duraplasty versus no duraplasty for reducing intraspinal pressure
62066333|NCT05222035|EXPERIMENTAL|G-CSF+Camrelizumab|
62066334|NCT05222035|ACTIVE_COMPARATOR|Camrelizumab|
62066335|NCT04243460|EXPERIMENTAL|CTG connective tissue graft augmentation|CTG connective tissue graft (CTG) was used for soft tissue augmentation. I
62066336|NCT04243460|ACTIVE_COMPARATOR|XCM Xenogeneic collagen matrix (XCM)graft augmentation|Xenogeneic collagen matrix (XCM) was used for soft tissue augmentation.
62066337|NCT01369238|EXPERIMENTAL|Bee Venom Acupuncture & zaltoprofen|
62066338|NCT01369238|ACTIVE_COMPARATOR|zaltoprofen|
62066339|NCT01369238|ACTIVE_COMPARATOR|Bee Venom Acupuncture|
62271381|NCT06501664|ACTIVE_COMPARATOR|Control group|Irinotecan q2w or irinotecan+5-FU/LV q2w
62452960|NCT01714648|EXPERIMENTAL|OHSS high risk patients|Triptorelin 0.2 mg
62633835|NCT02721615|ACTIVE_COMPARATOR|Hypothermia|Localised hypothermia for reducing intra spinal pressure and improving spinal cord metabolism
62066340|NCT03163576|EXPERIMENTAL|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
62066341|NCT03163576|ACTIVE_COMPARATOR|control group|patients received usual phosphate binders .
62088196|NCT04838821|EXPERIMENTAL|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
62271382|NCT03530371|EXPERIMENTAL|Dexmedetomidine Hydrochloride|sedation of patients to perform auditory test
62271383|NCT01622881|ACTIVE_COMPARATOR|Nefopam|
62271384|NCT01622881|PLACEBO_COMPARATOR|Control|
62452961|NCT05151406|ACTIVE_COMPARATOR|medical students|5th year undergraduate medical students
62633836|NCT01870986|EXPERIMENTAL|A|PF-06410293
62271385|NCT04489966|EXPERIMENTAL|Aerobic training group|The aerobic training group was performed 3 times/week for 60 minutes/session(including 5 minutes of warm-up, 50 minutes aerobic rhythmic exercise and 5 minutes to relax) for moderate(60 to 70% of participants' HRmax) aerobic rhythmic exercise. All patients received an open class, relate to diabetes health education. The intervention lasted for 6 months.
62633837|NCT01870986|ACTIVE_COMPARATOR|B|Adalimumab-EU
62271386|NCT04489966|NO_INTERVENTION|Control group|Patients in control group remained the original lifestyle unchanged. All patients received an open class, relate to diabetes health education.
62271387|NCT04489966|EXPERIMENTAL|Intervention group|The intervention was aerobic rhythmic exercise, with intensive training under the guidance and supervision of a professional.The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 5-10 minutes flexibility exercises). Participants were educated on aerobic exercises (aerobic dancing) with music.The intervention lasted for one year.
62633838|NCT01870986|ACTIVE_COMPARATOR|C|Adalimumab-US
62271388|NCT04489966|NO_INTERVENTION|Compared group|The control group was instructed to maintain their usual habits and received no structured exercise intervention. But the form, frequency and time of movement of each participant must be recorded.Participants receive an open diabetes health education class once a month, which is taught by a specially trained diabetes nurse.
62271389|NCT01355939||Abdominal surgery after prior VHR with barrier-coated mesh|
62452962|NCT05151406|ACTIVE_COMPARATOR|nursing students|4th year undergraduate nursing students
62452963|NCT05010603||Families with a history of Alzheimer's Disease|Families with two or more family members affected with Alzheimer's Disease
62633839|NCT05852314|EXPERIMENTAL|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|Participants in this arm will be offered the CMAP-SI intervention. The intervention will be delivered by trained researchers.
62452964|NCT05010603||Un-related, non-demented controls|Un-related, non-demented healthy controls over age 55
62452965|NCT05010603||Individuals with Dementia (Alzheimer's Disease)|Individuals with dementia over the age of 65
62452966|NCT05265325|EXPERIMENTAL|AND017 Dose Regimen A|AND017 will be administrated orally at dose A three times a week
62452967|NCT05265325|EXPERIMENTAL|AND017 Dose Regimen B|AND017 will be administrated orally at dose B once a week
62452968|NCT05265325|ACTIVE_COMPARATOR|Erythropoietin stimulating agent|Investigator will select an erythropoietin stimulating agent, such as epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars, for the patient under this arm with starting doses and dose adjustment rules according to the epoetin alfa USPI or SmPC.
62452969|NCT02927847|EXPERIMENTAL|BA + VLNC|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
62452970|NCT02927847|ACTIVE_COMPARATOR|VLNC Only|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus supportive counseling and health education.
62452971|NCT01578707|ACTIVE_COMPARATOR|Ofatumumab (Arm A)|An anti-CD20 monoclonal antibody
62452972|NCT01578707|EXPERIMENTAL|ibrutinib (Arm B)|A Bruton Tyrosine Kinase Inhibitor
62452973|NCT03682042|ACTIVE_COMPARATOR|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
62452974|NCT03682042|NO_INTERVENTION|Early Cord Clamping|The umbilical cord is clamped immediately after the delivery (within 60 seconds).
62633840|NCT05852314|NO_INTERVENTION|Treatment as Usual (TAU)|Local medical, psychiatric, and primary care services provide standard routine care in Pakistan. Participants will receive an initial assessment along with TAU as ascertained by their treating primary care physician (General Practitioner, GP). As part of the safety protocol, we will obtain the contact details of the participants GP. We will also obtain the details of any treatment received by each participant. Research psychologists delivering the interventions will not be involved with the participants allocated to the TAU.
62633841|NCT05155748|EXPERIMENTAL|Intervention|"Nursing staff, physicians and pharmacists will be invited to a continuous education - knowledge exchange session to inform them on the study rationale and the means of medication optimization.~Pharmacists will be asked to perform medication reviews, guided by the information and tools provided, for the participating residents.~Pharmacists' recommendations will be discussed during meetings with physician and nurses."
62633842|NCT05155748|NO_INTERVENTION|Control|Care as usual.
62452975|NCT00958256|EXPERIMENTAL|Bortezomib with Cyclophosphamide and Rituximab|Bortezomib 1.3 mg/m\^2 intravenously (IV) on Days 1, 4, 8, and 11 of the cycle; Cyclophosphamide 300 mg/m\^2 IV every 12 hours on Days 2, 3, and 4, and Rituximab 375 mg/m\^2 IV on Day 1. Mesna 600 mg/m\^2 for 3 days, G-CSF 5 micrograms/kg subcutaneously daily for 7 days after last dose of Bortezomib. Cycles repeated every 21 days for up to six cycles.
62452976|NCT03309449|OTHER|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
62452977|NCT03309449|OTHER|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
62633843|NCT00121719|EXPERIMENTAL|1|
62633844|NCT03036371|EXPERIMENTAL|High Intensity Interval Exercise|home exercise sessions
62633845|NCT04677114|EXPERIMENTAL|Outpatient Parenteral Antibiotic Therapy (OPAT)|Patients with opioid use disorder (OUD) and severe, injection-related infections (SIRI) will be treated with buprenorphine and be discharged with outpatient parenteral antibiotic therapy (OPAT).
62633846|NCT04677114|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Patients with OUD and severe, injection-related infections (SIRI) will receive usual care.
62633847|NCT03746925|ACTIVE_COMPARATOR|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
62066342|NCT01993017|EXPERIMENTAL|AHA Depression Screen & Treat|"Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (\>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized."
62633848|NCT03746925|EXPERIMENTAL|SuperPATH|SuperPATH approach surgery to replace the hip.
62066343|NCT01993017|ACTIVE_COMPARATOR|Depression Screen & Notify Arm Type :|Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (\>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
62633849|NCT04292067||patients with SPA|100 SPA patients
62271390|NCT01355939||Abdominal surgery after prior VHR with nonbarrier-coated mesh|
62271391|NCT01355939||Lap adhesiolysis during abdominal surgery after prior VHR|
62633850|NCT04292067||Healthy subjets|200 healthy subjets in control group
62633851|NCT04292067||patients with RA|100 RA patients
62633852|NCT05311826|ACTIVE_COMPARATOR|STANDARD PHYSIOTHERAPY TREATMENT - CTL GROUP|Patients aged from 12 to 24 years hospitalized for corrective arthrodesis surgery with Adolescent Idiopathic Scoliosis (AIS) diagnosis.
62633853|NCT05311826|EXPERIMENTAL|EXPERIMENTAL diaphragmatic breathing exercise - EXP GROUP|Patients aged from 12 to 24 years hospitalized for corrective arthrodesis surgery with Adolescent Idiopathic Scoliosis (AIS) diagnosis.
62633854|NCT02277275|PLACEBO_COMPARATOR|Standard protein diet with placebo|Subjects will be provided with standard protein diet for four months and corn starch pills(Placebo) for 6 months
62633855|NCT02277275|EXPERIMENTAL|Standard protein diet with BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months, standard protein diet will be provided for four months
62066344|NCT01993017|PLACEBO_COMPARATOR|No Depression Screen|Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
62271392|NCT01355939||Open adhesioloysis during abdominal surgery after prior VHR|
62633856|NCT02277275|PLACEBO_COMPARATOR|High protein diet with placebo|Subjects will be provided with high protein diet for four months and corn starch pills(Placebo) for 6 months
62271393|NCT04344678|PLACEBO_COMPARATOR|Control group|Escitalopram 20 mg tablet plus one placebo tablet
62271394|NCT04344678|EXPERIMENTAL|Sildenafil group|Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet
62271395|NCT06293612||Training cohort|The patients were randomized into a training cohort (n ＝ 211) to train the model. The patients' clinicopathological data were reviewed, including age, sex, obesity, serum carcinoembryonic antigen and cancer antigen 19-9 levels, T- and N-stages evaluated by MRI, yp-T and yp-N stages evaluated by histopathology. The MR-T/N stages of the tumors were assessed by radiologists. The tumor region of interest was manually delineated on high-resolution oblique axial T2WI and generated the VOI using ITK-SNAP. Overall, 1229 features were extracted from each VOI. Biopsy specimens from colonoscopy were sectioned into 5 μm slices and stained with H\&E. Areas with both stromal and tumor cells presented on all four sides were selected to evaluate tumor stroma ratio using an automated scoring method with the highest proportion of stromal components in all measured areas recorded.
62271396|NCT06293612||Validation cohort|The patients were randomized into a validation cohort (n ＝91) to verify the model. The patients' clinicopathological data were reviewed, including age, sex, obesity, serum carcinoembryonic antigen and cancer antigen 19-9 levels, T- and N-stages evaluated by MRI, yp-T and yp-N stages evaluated by histopathology. The MR-T/N stages of the tumors were assessed by radiologists. The tumor region of interest was manually delineated on high-resolution oblique axial T2WI and generated the VOI using ITK-SNAP. Overall, 1229 features were extracted from each VOI. Biopsy specimens from colonoscopy were sectioned into 5 μm slices and stained with H\&E. Areas with both stromal and tumor cells presented on all four sides were selected to evaluate tumor stroma ratio using an automated scoring method with the highest proportion of stromal components in all measured areas recorded.
62452978|NCT03309449|OTHER|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
62633857|NCT01693913|EXPERIMENTAL|Cognitive-behavioral|Those participating in a cognitive behaviorally supported exercise and nutrition treatment will receive a cognitive behavioral exercise and nutrition over 50 weeks
62633858|NCT01693913|ACTIVE_COMPARATOR|Nurtition education|This arm will participate in nutrition and exercise education
62633859|NCT03683836||Study Group|
62633860|NCT01476267|EXPERIMENTAL|Single Arm|
62633861|NCT01985100|EXPERIMENTAL|single group|single group of 6 patients will be treated with hyperbaric oxygen at 2 atmospheres absolute (ATA) for 90 minutes 5 days per week for 4 weeks (20 treatments) to see if the previously reported increase in cell metabolism following such treatment can be better documented by the more sensitive and precise method for assessing this, i.e. PET/MRI, than the previously reported SPECT/CT method
62633862|NCT03200561|ACTIVE_COMPARATOR|S group|IVIG (2g/Kg in 12 hours)+oral prednisolone (2mg/Kg/day for 5 days)
62633863|NCT03200561|PLACEBO_COMPARATOR|I group|IVIG (2g/Kg in 12 hours)
62066345|NCT03277378|ACTIVE_COMPARATOR|Group 1 (AB)|Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
62066346|NCT03277378|ACTIVE_COMPARATOR|Group 2 (TB)|Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
62271397|NCT02031705|ACTIVE_COMPARATOR|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
62271398|NCT02031705|PLACEBO_COMPARATOR|control group|Control group was performed no additional cavotricuspid isthmus ablation.
62452979|NCT01867242|EXPERIMENTAL|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);
62452980|NCT01867242|EXPERIMENTAL|Complete Substitution|Use snus in place of cigarettes
62633864|NCT03889249|ACTIVE_COMPARATOR|Tenecteplase (tNK-TPA)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization. Tenecteplase has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
62633865|NCT03889249|ACTIVE_COMPARATOR|Alteplase ( tPA)|The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).
62452981|NCT01867242|EXPERIMENTAL|Partial Substitution (Snus and Cigarettes)|Use snus and cigarettes how ever you like
62633866|NCT05198856|EXPERIMENTAL|Thalidomide|"The study is divided into two phases:~The first phase is a combination phase (chemotherapy +T) : Oxaliplatin (130mg/m2 iv d1) and capecitabine (1000mg/m2 d1-14 po bid) repeated every 21 days for a total of 4-6 cycles. Thalidomide tablet: 100 mg/d, qn, orally.~The second stage is maintenance stage: Patients who have obtained CR, PR or SD in the first stage enter the maintenance stage and receive maintenance treatment with thalidomide tablets: 100mg/d, qn, orally. Maintained until disease progression or adverse reactions are intolerable."
62633867|NCT03825991||Control group|Cohort 1 is a a control group matched 1:5 to the exposed group on sex and age. This group i randomly assigned via Statistics Denmark and does not have a diagnosis of back pain in the time period 2008-2013. They do however have another diseases registered in the Danish Patient Registry, which only contains information on patients having had contacts with the hospital sector i Denmark. Used for study 1.
62633868|NCT03825991||Specific back pain (unexposed)|Cohort 2 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Spinal Disc Herniation DM51.1 and Spinal stenosis DM48.0 (ICD-10 classification).
62633869|NCT03825991||Unspecific back pain (exposed)|Cohort 3 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Other intervertebral disc disorders DM51\*-51.1, Dorsalgia DM54, Other disorders of muscle DM62, Postprocedural musculoskeletal disorders not elsewhere classified DM96 and Segmental and somatic dysfunction DM99 (ICD-10 classification)
62633870|NCT03825991||Total population (DM*)|Cohort 4 is the total population including all BPD diagnosis in the time period 2008-2013 in Denmark. This cohort will be used as basis for study 2 and 3, although de definitions of the groups specific back pain (unexposed) and unspecific back pain (exposed) will used in sub-analysis.
62633871|NCT04770506||Lithiasis patients|Lithiasis patients: diagnosis of recurrent NL confirmed by URO CT with presence of idiopathic hypercalciuria and metabolic workup available.
62633872|NCT04770506||Control group|Control group: patients without NL matched for age and sex and who had a bone mineral densitometry or abdominal CT.
62633873|NCT04708080||Group E|patients who underwent thoracic epidural catheter for postoperative analgesia
62633874|NCT04708080||Group I|Patients who cannot be applied thoracic epidural catheter for postoperative analgesia
62633875|NCT03844425|ACTIVE_COMPARATOR|Conventional Vacuum-Formed Retainers|Vacuum-formed retainers constructed on conventional stone models.
62633876|NCT03844425|EXPERIMENTAL|Vacuum-Formed Retainers From SLA|Vacuum-formed retainers constructed on 3D reconstructed models using stereolitography (SLA) technique.
62633877|NCT03844425|EXPERIMENTAL|Vacuum-Formed Retainers From FDM|Vacuum-formed retainers constructed on 3D reconstructed models using fused deposition modeling technique (FDM).
62452982|NCT01483508|ACTIVE_COMPARATOR|Flavanol and procyanidins|
62452983|NCT01483508|EXPERIMENTAL|Flavanols only|
62452984|NCT01483508|EXPERIMENTAL|Procyanidins only|
62452985|NCT01601509|ACTIVE_COMPARATOR|nasal spray with tramazoline and dexamethazone|
62452986|NCT01601509|PLACEBO_COMPARATOR|Placebo|
62452987|NCT04433390|EXPERIMENTAL|Naloxegol group|naloxégol tablet by oral route
62452988|NCT04433390|PLACEBO_COMPARATOR|Placebo group|inert tablet by oral route
62633878|NCT05270980|EXPERIMENTAL|Intervention Group (Cohorting)|
62633879|NCT05270980|NO_INTERVENTION|Control Group (No Cohorting)|
62066347|NCT05763758||Healthy Control|Healthy participants will undergo multimodal neuroimaging during resting state, no-pain and painful tonic pressure presentation. At FSU, EEG and fMRI will be simultaneously acquired. At MGH, sequential MRI and MEG/EEG will be acquired.
62066348|NCT05763758||Patients with chronic low back pain|Subjects with chronic low back pain (cLBP) patients will undergo multimodal neuroimaging during resting state, no-pain and painful tonic pressure presentation. The study will only be performed at MGH, sequential MRI and MEG/EEG will be acquired.
62633880|NCT04685252|EXPERIMENTAL|Pre-Partum and Post-Partum (BL) NCC3001|One stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
62633881|NCT04685252|PLACEBO_COMPARATOR|Placebo Control|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
62633882|NCT04685252|EXPERIMENTAL|Post-Partum (BL) NCC3001 (Crossover Arm)|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily for 3 months during pre-partum, followed with switch to one stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily for 3 months post-partum.
62633883|NCT03821987|EXPERIMENTAL|BFCA regimen|"Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."
62633884|NCT06255080|EXPERIMENTAL|Intervention group|This group practiced the proficiency-based program on the LAPSIM(R) simulator using the new 2019-version of the software
62633885|NCT06255080|NO_INTERVENTION|Control Group|This group practiced the proficiency-based program on the LAPSIM(R) simulator using the original (and evidence based) 2016-version of the software
62633886|NCT00791219|EXPERIMENTAL|Test|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
62066349|NCT01445223|ACTIVE_COMPARATOR|lopinavir/ritonavir|400/100 mg BID + 2 NRTIs BID
62066350|NCT01445223|ACTIVE_COMPARATOR|atazanavir/ritonavir|300mg+100mg QD+ 2 NRTI QD
62066351|NCT01445223|ACTIVE_COMPARATOR|efavirenz|600mg QD + 2NRTI QD
62066352|NCT01729117|OTHER|Meal Replacement|Meal Replacements will be provided to participants randomized to the MR group
62066353|NCT01729117|OTHER|Standard Care|Standard Care participants will receive standard care but no meal replacements
62066354|NCT01401413|PLACEBO_COMPARATOR|1|placebo control nightly
62452989|NCT02270788|EXPERIMENTAL|Study Participants|"All participants who consent and are enrolled on the study.~Interventions: Crenolanib, sorafenib, triple intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine with leucovorin)."
62633887|NCT00791219|ACTIVE_COMPARATOR|Reference|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
62633888|NCT00791219|PLACEBO_COMPARATOR|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
62633889|NCT04749095|ACTIVE_COMPARATOR|Erector block|
62633890|NCT04749095|ACTIVE_COMPARATOR|sham block|
62633891|NCT01737307|EXPERIMENTAL|Fluoride Varnish|Fluoride varnish was used once in this group. Fluoride varnish(NaF 5%,Sultan,USA)
62633892|NCT01737307|EXPERIMENTAL|Oral hygiene|Oral hygiene followed twice daily. No F varnish or CPP-ACP applied.
62633893|NCT01737307|EXPERIMENTAL|CPP-ACP|CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
62066355|NCT01401413|ACTIVE_COMPARATOR|2|8 mg ramelteon nightly
62066356|NCT01737281|EXPERIMENTAL|Proactive outreach|Proactive outreach to deliver 7 sessions of telephone counseling and nicotine replacement therapy.
62066357|NCT01737281|ACTIVE_COMPARATOR|Usual care|Usual smoking cessation care from clinical staff
62066358|NCT01861574|EXPERIMENTAL|Both Real TMS|Participants in the Both Real TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Real TMS 4 hours after surgery.
62633894|NCT06132334|EXPERIMENTAL|Upper extremity aerobic exercise training|The training group will receive upper extremity aerobic exercise training on an arm ergometer accompanied by a physiotherapist for 6 weeks.
62066359|NCT01861574|SHAM_COMPARATOR|Sham then Real TMS|Participants in the Sham then Real TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and 20 minutes of Real TMS 4 hours after surgery.
62066360|NCT01861574|SHAM_COMPARATOR|Real then Sham TMS|Participants in the Real then Sham TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then 20 minutes of Sham TMS 4 hours after surgery.
62066361|NCT01861574|SHAM_COMPARATOR|Both Sham TMS|Participants in the Both Sham TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Sham TMS 4 hours after surgery
62066362|NCT00553098|EXPERIMENTAL|Treatment (chemotherapy, low dose radiation)|"CONDITIONING REGIMEN: \*Patients with no life-threatening viral or fungal infections within 1 month before the planned HCT receive alemtuzumab IV over 6 hours on day -10 and fludarabine phosphate IV over 30 minutes on days -4 to -2. They also undergo low-dose TBI on day 0. Patients with HLH, IPEX syndrome, DiGeorge syndrome, or life-threatening viral or fungal infections within 1 month before the planned HCT receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo 2 low doses of TBI on day 0.~HEMATOPOIETIC CELL TRANSPLANTATION: Patients undergo HCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. They also receive mycophenolate mofetil IV or PO 3 times daily beginning on day 0 and continuing until day 40 followed by a taper until day 96."
62066363|NCT05458167|EXPERIMENTAL|Device: Hedia Diabetes Assistant with physical activity module.|The participants will take part in a 45-minute moderate-intensity exercise bout on a stationary ergometer bike. Participants will use the Hedia Diabetes Assistant bolus calculator with the physical activity module (intervention) during a 24-hour period starting one hour before the bout of exercise.
62066364|NCT05458167|ACTIVE_COMPARATOR|Usual treatment|The participants will take part in a 45-minute moderate-intensity exercise bout on a stationary ergometer bike. Participants will use their habitual diabetes management approach during a 24-hour period starting one hour before the bout of exercise (control).
62066365|NCT01552122|EXPERIMENTAL|Odanacatib|
62066366|NCT01552122|ACTIVE_COMPARATOR|Alendronate|
62066367|NCT01295567|PLACEBO_COMPARATOR|placebo|
62066368|NCT01295567|EXPERIMENTAL|dipyridamole|
62066369|NCT03346213||Major surgery|"1. Adult patients undergoing elective surgery~2. Having a CPET as part of routine care~3. Patients with a Hb value of \< 130 g/L who are iron deficient, iron restricted/deplete or have functional iron deficiency.~4. Able to provide written informed consent."
62066370|NCT05622448|ACTIVE_COMPARATOR|RPD with metallic framework|removable partial denture with cobalt chromium framework
62066371|NCT05622448|EXPERIMENTAL|RPD with PEEK framework|removable partial denture with poly ether ether ketone framework
62066372|NCT00146250|EXPERIMENTAL|Nitrous oxide|Nitrous oxide 70% as balance gas in inspired mixture
62066373|NCT00146250|EXPERIMENTAL|Nitrogen|Nitrogen instead of nitrous oxide 70% as balance gas in inspired mixture
62066374|NCT00708526|EXPERIMENTAL|Phase 1 Recovery|Quick Emergence Device is in place for phase 1 anesthesia recovery
62066375|NCT00708526|OTHER|Standard of care|Tidal volume and respiratory rate are not changed during phase 1 recovery from anesthesia
62271399|NCT03091309|EXPERIMENTAL|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
62271400|NCT03091309|ACTIVE_COMPARATOR|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
62633895|NCT06132334|SHAM_COMPARATOR|Control Group|The control group will not be given any training for 6 weeks during the study period.
61978611|NCT03971890|EXPERIMENTAL|Control Group|The control group will be subjected to a educational treatment.
62271401|NCT05477290||Transverse incision|At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release
62286917|NCT05792436|EXPERIMENTAL|1-min interval oscillometric method|1-min interval blood pressure monitoring using oscillometric method during induction of anesthesia
62633896|NCT05897749|EXPERIMENTAL|Experimental group: Brucea javanica oil emulsion injection+The best supportive treatment|
62633897|NCT05897749|ACTIVE_COMPARATOR|control group:The best supportive treatment|
62633898|NCT00625456|EXPERIMENTAL|Single Arm, dose escalation|dose escalation starting dose 1e5 pfu/kg bw to 3e7 pfu/kg bw; Recombinant Vaccinia GM-CSF (JX-594)
62633899|NCT01161576|EXPERIMENTAL|Group A|The first dose cohort consists of 6 subjects who received AAVrh.10CUhCLN2 vector 9.0x10\^11 genome copies (gc) total dose. This is equal to 900,000,000,000 molecules of the drug.
62066376|NCT03942679|OTHER|PRPinjection group|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 201
62066377|NCT03942679|OTHER|physiotherapy group|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks
62066378|NCT03050645||previous GDM|Women with previous GDM
62066379|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
62066380|NCT02351323|EXPERIMENTAL|Glutamine + Lifestyle change|Glutamine 30 grams/day X 12-14 weeks, Lifestyle change
62066381|NCT02351323|PLACEBO_COMPARATOR|No glutamine + Lifestyle change|Lifestyle change
62066382|NCT04627519|NO_INTERVENTION|SoC alone|Standard of Care alone (days 1 to 9)
62066383|NCT04627519|EXPERIMENTAL|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after meal (every 12 hours) for 9 days to be provided together with Standard of Care.
62066384|NCT00852826|SHAM_COMPARATOR|1|Standard axillary lymphadenectomy
62066385|NCT00852826|EXPERIMENTAL|2|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
62633900|NCT01161576|EXPERIMENTAL|Group B|The second dose cohort consists of 10 subjects, who will receive AAVrh.10CUhCLN2 vector 2.85x10\^11 genome copies (gc) total dose. This is equal to 285,000,000,000 molecules of the drug.
62633901|NCT01418911||diabetes type 2|type 2 diabetes patients 40-70 years of age hebrew speaking members of maccabi healthcare services
62633902|NCT01158742||1|Caucasians who donated a kidney at Mayo Clinic in Rochester, Minnesota (MN)
61978612|NCT05814939|EXPERIMENTAL|VC005 Tablets Low Dose groups|
61978613|NCT05814939|EXPERIMENTAL|VC005 Tablets Medium Dose groups|
62066386|NCT03773718||Russkoe pole|400 patients
62066387|NCT05188755|ACTIVE_COMPARATOR|Healthy controls|sex and age matched healthy controls
62066388|NCT05188755|EXPERIMENTAL|young adults recovered from lymphoma or Hodgkin's disease|young adults recovered from lymphoma or Hodgkin's disease
62066389|NCT02795208|NO_INTERVENTION|Control group|Patients received standard protective ventilation along the protocol.
62271402|NCT05477290||Oblique incision|At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
62633903|NCT01158742||2|Caucasians who donated a kidney at the University of Minnesota
62633904|NCT01158742||3|African-Americans who donated a kidney at the University of Alabama
62633905|NCT02256839||non TB infection|Group tested with CST_001
62633906|NCT02256839||low exposure risk|Group tested with CST_001
62633907|NCT04610710|ACTIVE_COMPARATOR|Operation|Operation for severe endometriosis
62633908|NCT04610710|ACTIVE_COMPARATOR|Fertility treatment|Fertility treatment for women with severe endometriosis.
62633909|NCT01845597||MAKOplasty® medial UKA|Patients knees that have received a MAKOplasty® robotically guided unicompartmental knee arthroplasty (UKA) and received a medial MCK onlay implant.
62633910|NCT00078403|EXPERIMENTAL|Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA \>=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.
62633911|NCT00078403|EXPERIMENTAL|Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA \>=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).
62066390|NCT02795208|EXPERIMENTAL|Recruitment maneuver group|Patient received a lung recruitment maneuver after cardiopulmonary bypass. The recruitment maneuver consists in 10 breaths at 40/20 cmH2O of plateau pressure and PEEP, respectively. Then, the .ventilatory settings back to protective ventilation but adding 10 cmH2O of PEEP to keep the lungs open.
62271403|NCT05477290||Vertical incision|At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
62633912|NCT00078403|EXPERIMENTAL|Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)|At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA \<600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly \& RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA \>=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.
62633913|NCT03060226|OTHER|Control group|
62633914|NCT03060226|OTHER|radiosensibility group|
62633915|NCT06235710||Group 1: Nursing home residents without dementia|"* Mentally competent nursing home resident ≥ 65 years;~* No diagnosis of dementia (major neurocognitive disorder according to DSM-5 criteria);~* The nursing home resident provides informed consent to participate in the study.~In this study, nursing home residents all undergo a physical examination of the musculoskeletal system.~In addition:~- In group 1: nursing home residents provide an answer on 3 non-incriminating questions (assessment general health, severity of joint complaints and pain in general)."
61978614|NCT05814939|EXPERIMENTAL|VC005 Tablets High Dose groups|
61978615|NCT05814939|ACTIVE_COMPARATOR|Tofacitinib Citrate Tablets groups|
62286918|NCT05792436|ACTIVE_COMPARATOR|arterial catheterization method|Continuous blood pressure monitoring through arterial catheter during induction of anesthesia
62286919|NCT02859155|OTHER|Multiviceral resection colorectal cancer|Multiviceral resection surgery of 2 or more intrabdominal organs en bloc with colorectal cancer
62271404|NCT02966691|ACTIVE_COMPARATOR|Patients 'sick'|"The patients of this arm have a clinical signs of bladder cancer with :~* a positive result of bladder endoscopy~* or an negative endoscopy and a positive result of the conventional cytology~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice .This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized"
62271405|NCT02966691|ACTIVE_COMPARATOR|Patients 'healthy'|"The patients of this arm have no suspicion of bladder cancer with negative results of their bladder endoscopy and conventional cytology.~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
62286920|NCT02669979|EXPERIMENTAL|Intervention|"Intervention in the research groups is professional oral care with tooth brush, ordinary fluoridated tooth paste (1100-1450 ppm NaF), and repeated oral care instruction to participants and staff (contact person) , supra gingival depuration if necessary. The group receive treatment each month."
62633916|NCT06235710||Group 2: Nursing home residents with dementia|"* Nursing home resident with dementia (major neurocognitive disorder according to DSM-5 criteria) ≥ 65 years;~* The legal representative of the nursing home resident provides informed consent to participate in the study.~In this study, nursing home residents all undergo a physical examination of the musculoskeletal system.~In addition:~In group 2: if possible, provide an answer on 1 non-incriminating question (severity of joint complaints). If the nursing home resident cannot answer this question (reliably), we use the Pain Assessment Checklist for Seniors with Severe Dementia (PACSLAC-D)."
62633917|NCT05814315|EXPERIMENTAL|HOPE Intervention|These participants will have peer support and online support groups.
62633918|NCT05814315|NO_INTERVENTION|Control|The control will not have any support provided.
62633919|NCT00809445|EXPERIMENTAL|HIV rapid test & counseling|Participants will be offered an oral fluid HIV rapid test (via oral swab) and brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach (Project RESPECT-2 counseling). Prior to receiving testing, study participants must first provide consent for HIV testing. Consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test.
62633920|NCT00809445|EXPERIMENTAL|HIV rapid test and info|Participants will be offered an oral fluid HIV rapid test (via oral swab). Prior to receiving testing, study participants must first provide consent for HIV testing. Again, consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test. Participants will receive rapid HIV testing and test results after signing the consent to be tested. In both Groups 1 and 2, participants who test reactive (preliminary positive) will be counseled on the sexual risk behaviors associated with transmission of HIV and the acquisition of STDs, as is current clinical practice with those testing HIV positive. Confirmed positives will be linked to HIV primary care.
61978616|NCT05814939|PLACEBO_COMPARATOR|VC005 Tablets Placebo groups|
62271406|NCT02966691|ACTIVE_COMPARATOR|Patients 'monitoring'|"The patients of this arm have a history of bladder cancer, but the results of their follow up examinations (cytologic and endoscopic) are negative (no tumor).~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
62271407|NCT05655338|EXPERIMENTAL|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The patients received antimicrobial photodynamic therapy after non-surgical periodontal treatment
62066391|NCT06015555|EXPERIMENTAL|The TAMO therapy|For four months, TAMO therapy will last 30 minutes every day, twice a week. The therapist first applies light loading for a short period of time to his left hemiocciput directed toward the supporting surface.
62633921|NCT00809445|ACTIVE_COMPARATOR|HIV testing referral|Participants randomized to group 3 will receive a referral list for HIV community-testing agencies. Each CTP site will have previously prepared an extensive referral list of testing sites in the surrounding geographic area. By virtue of their status as patients in the CTPs, they will receive whatever HIV testing and HIV education referrals the CTPs normally provide to their patients. This is the standard of care at CTPs that do not provide on-site testing.
62066392|NCT06015555|EXPERIMENTAL|Postural Control exercises|For four months, posture control exercises will be taught twice a week for 30 minutes each time. Under the age of 3 months, infants were required to shift their chin as far to the affected side and upward in the supine or dominant prone posture before they could regulate their neck. Instead of passively adjusting the newborns' heads, we waited for them to actively turn toward their midline.
62271408|NCT05655338|EXPERIMENTAL|SYSTEMIC ANTIBIOTICS|The patients received systemic antibiotics after non-surgical periodontal treatment
62633922|NCT02607501|OTHER|eCLIPs BRS|Implant eCLIPs BRS at target aneurysm
62633923|NCT06128018|OTHER|EUS-guided gastrojejunostomy (EUS-GJ)|Patients on this arm will undergo the endoscopic procedure.
62633924|NCT06128018|OTHER|Surgical gastrojejunostomy (S-GJ)|Patients on this arm will undergo the surgical procedure.
62633925|NCT01829698|EXPERIMENTAL|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
61978617|NCT05516706|ACTIVE_COMPARATOR|Dynamic stretching|This group performed warm up and dynamic stretching exercise for six weeks.
62066393|NCT05606263|EXPERIMENTAL|Caldonirimab and nimotuzumab|Caldonirimab combined with nimotuzumab therapy
62066394|NCT00509002|EXPERIMENTAL|Adenoid Cystic Salivary Gland Carcinoma Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
62066395|NCT00509002|EXPERIMENTAL|Other Carcinoma of Salivary Gland Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
62066396|NCT03881930|EXPERIMENTAL|Experimental group|"Balance rehabilitation with modified visual input:~In experimental group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with modified visual input."
62271409|NCT00544609|OTHER|Sorafenib|2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
62271410|NCT00207051|EXPERIMENTAL|1|
62271411|NCT05144607|NO_INTERVENTION|Control group|Detection of patient-ventilator asynchronies through visual inspection of pressure and flow waveforms.
62286921|NCT02669979|NO_INTERVENTION|Control|Care as usual. Common oral hygiene help administered by nursing staff.
62066397|NCT03881930|ACTIVE_COMPARATOR|control group|"Balance rehabilitation with no modified visual input:~In control group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with no modified visual input."
62271412|NCT05144607|EXPERIMENTAL|Pmus group|Detection of patient-ventilator asynchronies through visual inspection of estimated inspiratory muscle pressure curves, in addition to pressure and flow waveforms.
62633926|NCT01829698|ACTIVE_COMPARATOR|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
62633927|NCT02990013|EXPERIMENTAL|Treatment arm|All patients will be in the treatment arm where they will be subject to skin testing with various cleansing agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
62633928|NCT05048043|EXPERIMENTAL|Computer-assisted Behavior Intervention|A serious game paired with teacher consultation to address common needs related to ADHD in the classroom.
62633929|NCT05048043|ACTIVE_COMPARATOR|Challenging Horizons Program, School Consultation|An established teacher consultation program to help teachers address ADHD in the classroom.
62633930|NCT05701358|ACTIVE_COMPARATOR|Physiology-guided Non-Culprit-Lesion (NCL) PCI|Patients randomized to this group will have their physiology assessment using RFR and/or FFR of all qualifying NCLs that were identified prior to randomization. Other validated non-hyperemic physiology ratios (eg. iFR) may only be used when RFR is not available.
62633931|NCT05701358|OTHER|Angiography-guided NCL PCI|Patients randomized to this group will undergo routine staged PCI of all qualifying NCLs that were identified prior to randomization.
62633932|NCT03659123|EXPERIMENTAL|Intervention|"The intervention is designed to be implemented at different times of patients' care~During the prehabilitation time:~* Nutritional care~* Total-body rehabilitation~* Pharmaceutical conciliation During peri-operative time~* Management of enhances rehabilitation of the elderly. During rehabilitation time~* Nutritional, medication conciliation and functional follow-up During hospital-home transition time~* Nutritional and functional follow-up~* Optimisation of symptoms management: abdominal pain, nausea, vomiting..."
62633933|NCT05862051|EXPERIMENTAL|Local ablative therapies (LAT) arm|"A maximum of three Local ablative therapy (LAT) modalities can be administered for each participant, with a maximum of 2 modalities per organ, provided all LAT can be delivered within 12 weeks and participant can safely resume systemic treatment within 16 weeks from randomisation.~After completing LAT, participant is to resume a further two to three months of first-line systemic treatment to a total of 6 months (including the initial 3-4 months of treatment). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion. The treating clinician may choose to discontinue systemic treatment following LAT for patients who have experienced prior intolerable toxicity."
62633934|NCT05862051|PLACEBO_COMPARATOR|Control arm|The first-line systemic treatment will be standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
62633935|NCT03362177|EXPERIMENTAL|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
62633936|NCT03362177|PLACEBO_COMPARATOR|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
62633937|NCT01664676|EXPERIMENTAL|Liraglutide|1.2 mg liraglutide sc. (single-dose)
62633938|NCT01664676|PLACEBO_COMPARATOR|Placebo-liraglutide|Placebo liraglutide sc. (single-dose)
62066398|NCT02321280|EXPERIMENTAL|Single arm single dose of denosumab|Open label = Single dose administration of single dose Denosumab 120 mg subcutaneously
62271413|NCT06162910|EXPERIMENTAL|Clinical swallowing exam|Patients with acute ischemic stroke
62271414|NCT03920670|EXPERIMENTAL|Tetragraph (TG)|TetraGraph placed on dominant hand, ToFscan placed on non-dominant hand
62452990|NCT03038113|EXPERIMENTAL|Part 1: Single-Ascending Dose (SAD)|Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
62452991|NCT03038113|EXPERIMENTAL|Part 2: Multiple Ascending Dose|Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.
62633939|NCT04156126||Infertility - Frozen Embryo Transfer|Adult females undergoing a frozen embryo transfer
62633940|NCT04156126||Spontaneous Conception|Adult females presenting with positive pregnancy test to the Obstetrics Department
62633941|NCT03485534|EXPERIMENTAL|Tenofovir Disoproxil|Tenofovir Disoproxil 245mg, a daily dose for 48 weeks
62633942|NCT03485534|PLACEBO_COMPARATOR|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks
62066399|NCT02687490|EXPERIMENTAL|Abraxane|Abraxane: 125 mg/m2, D1, D8, D15 every 28 days
62066400|NCT03216902|PLACEBO_COMPARATOR|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
62286922|NCT04831060||Case (patients with stage 3 or 4 periodontitis)|
62633943|NCT05643989|ACTIVE_COMPARATOR|Self-expandable metal stent (SEMS) endoscopic placement.|Anesthesia will include only propofol injection. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis.
62633944|NCT05643989|PLACEBO_COMPARATOR|Stoma formation.|Anesthetic care will include general endotracheal anesthesia with positioning of nasogastric tube and bladder catheterization. The diverting stoma formation will be proceed in 10 sm proximally to tumor.
62066401|NCT03216902|EXPERIMENTAL|Ultra-low dose 0.0005% DE-126|
62066402|NCT03216902|EXPERIMENTAL|Low dose 0.001% DE-126|
62633945|NCT01785537||E-cigarettes only|Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes
62633946|NCT01785537||Traditional cigarettes only|Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers.
62633947|NCT01785537||Mixed group|Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up
62633948|NCT04968093|OTHER|Group sessions of mindfulness-based therapy|Education of patients followed by seven group sessions of mindfulness-based therapy
62633949|NCT04001192|EXPERIMENTAL|exercise|exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
62633950|NCT01016145|ACTIVE_COMPARATOR|First generation antipsychotic|Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
62066403|NCT03216902|EXPERIMENTAL|Medium dose 0.002% DE-126|
62633951|NCT01016145|EXPERIMENTAL|Second generation antipsychotics|Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone
62633952|NCT00901043|EXPERIMENTAL|Walnut supplementation|Eight weeks with walnut supplementation to an ad lib diet
62633953|NCT00901043|ACTIVE_COMPARATOR|Ad lib diet|Eight weeks ad lib diet without walnut supplementation
62633954|NCT04195724|EXPERIMENTAL|Patients with decompensated ascites and receiving TIPS|Patients with decompensated ascites and receiving TIPS will be enrolled. In this study, diagnostic paracentesis will be performed to get the ascites sample before the patients receiving TIPS. Next, the blood sample from superior mesenteric vein and hepatic vein will be collected under the procedure of TIPS.
62633955|NCT03404388|EXPERIMENTAL|Experimental|Balance Training
62633956|NCT04794751|EXPERIMENTAL|senofilcon A C3/delefilcon A/delefilcon A|Subjects randomized to this arm will wear the senofilcon A C3 lens during period 1 and the delefilcon A lens during period 2 and period 3
62066404|NCT03216902|EXPERIMENTAL|High dose 0.003% DE-126|
62066405|NCT03216902|ACTIVE_COMPARATOR|0.005% Latanoprost|
62066406|NCT01562535|EXPERIMENTAL|Pronation group|In this group, participants will receive the pronation procedure. The technique is described below
62066407|NCT01562535|ACTIVE_COMPARATOR|Supination group|Participants in this group will be performed the supination technique. Description below.
62066408|NCT02291432|EXPERIMENTAL|AMDC-USR|Cell treatment
62066409|NCT03646630|ACTIVE_COMPARATOR|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, \~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
62633957|NCT04794751|EXPERIMENTAL|delefilcon A /senofilcon A C3/senofilcon A C3|Subjects randomized to this arm will wear the delefilcon A lens during period 1 and the senofilcon A C3 lens during period 2 and period 3
62633958|NCT00920959|EXPERIMENTAL|Fluticasone propionate/salmeterol combination|study drug
62633959|NCT00920959|EXPERIMENTAL|Fluticasone propionate|study drug
62633960|NCT00920959|EXPERIMENTAL|Placebo|placebo
62633961|NCT05139355|EXPERIMENTAL|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
62633962|NCT05139355|EXPERIMENTAL|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
62633963|NCT05139355|EXPERIMENTAL|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil C. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
62633964|NCT05139355|PLACEBO_COMPARATOR|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil.
62633965|NCT03847961|NO_INTERVENTION|Control Group|The control group receive routine treatment of sepsis only. All sites agree, when feasible, to follow the tenets of the Surviving Sepsis Campaign clinical practice guidelines for management of sepsis.
62633966|NCT03847961|EXPERIMENTAL|Experimental Group|The experimental group receive routine treatment of sepsis combined with hemoperfusion with cytokine adsorption column (CA330).
62633967|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
62633968|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
62633969|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
62633970|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
62633971|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
62633972|NCT00715299|OTHER|Locomotor Training Group|persons who have sustained a stroke within greater than 6 months ago and less than 5 years.
62633973|NCT01676246|ACTIVE_COMPARATOR|flupirtine per os single dose|100 mg flupirtine per os, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
61978618|NCT05516706|ACTIVE_COMPARATOR|Plyometric push up|This group performed Warm up and plyometric push up for six weeks.
62066410|NCT03646630|ACTIVE_COMPARATOR|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
62633974|NCT01676246|ACTIVE_COMPARATOR|flupirtine intravenous|100 mg flupirtine intravenous, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
62633975|NCT01676246|ACTIVE_COMPARATOR|flupirtine per os steady state|400 mg flupirtine per os, pharmacokinetics of flupirtine, electric pain measurement
62271415|NCT03920670|ACTIVE_COMPARATOR|ToFscan (TS)|ToFscan placed on dominant hand, TetraGraph (TG) placed on non-dominant hand
62271416|NCT01103674|OTHER|Numeris-AF Guided Coagulation System|
62633976|NCT02140177||Adult Medical Inpatients|Adult medical inpatients; We will enroll adult patients, ages 18 years and older, admitted to identified inpatient medical units during designated data collections days.
62633977|NCT06259214|NO_INTERVENTION|regular brushing|regular brushing
62633978|NCT06259214|ACTIVE_COMPARATOR|15% HCl gel|15% HCl gel (Icon Etch, DMG, Hamburg, Germany) was applied to the WSLs for 2 min, followed by water rinsing and drying with compressed air (each for 30 s)
62633979|NCT06259214|ACTIVE_COMPARATOR|37% H3PO4 gel|37% H3PO4 gel (Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA) was applied to the WSLs for 30 s, which were then water rinsed and dried with compressed air (each for 30 s)
62066411|NCT03720418|EXPERIMENTAL|OXB-102 Dose Level 1|OXB-102 Dose Level 1 Single Administration (Part A: open-label)
62066412|NCT03720418|EXPERIMENTAL|OXB-102 Dose Level 2|OXB-102 Dose Level 2 Single Administration (Part A: open-label)
62271417|NCT05934500|NO_INTERVENTION|Standard of Care|Opioid standard of care: Percocet (oxycodone 5mg-acetaminophen 325 mg) every 4 hours PRN postoperatively for 7 days
62271418|NCT05934500|EXPERIMENTAL|Cannabidiol Oil 100 mg/day|CDB 100mg PO liquid suspension QD starting 30 days prior to surgery and finishing 30 days post-operatively
62271419|NCT05934500|EXPERIMENTAL|Cannabidiol Oil 200 mg/day|CBD 200mg PO liquid suspension QD starting 30 days prior to surgery and finishing 30 days post-operatively.
62633980|NCT06259214|ACTIVE_COMPARATOR|Er:YAG laser|Er:YAG laser (Fotona AT Fidelis III, Ljubljana, Slovenia) was applied for 10 s with the following operating parameters: energy 300 mJ, frequency 10 Hz, wavelength 2.94 μm, short pulses of 10 pulses per second, pulse time 180 ms, distance 1 mm away from lesion, water spray cooling 80%.
62633981|NCT02390089|ACTIVE_COMPARATOR|Healthy control|Healthy age-matched adult participants with no history of Parkinson's disease Participants in this group will receive capsaicin vapor cough provocation test. The vapor will be delivered using a small hand-held nebulizer.
62633982|NCT02390089|EXPERIMENTAL|Parkinson's disease - no PA|People with Parkinson's disease without penetration or aspiration during swallowing; based on results of videofluoroscopic swallow evaluation. Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer.Participants in the group will also receive a fluoroscopic swallow evaluation.
62633983|NCT02390089|EXPERIMENTAL|Parkinson's disease - PA|People with Parkinson's disease with penetration or aspiration during swallowing;based on results of videofluoroscopic swallow evaluation.Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer. Participants in the group will also receive a fluoroscopic swallow evaluation.
62633984|NCT02815033|OTHER|Single arm|Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
62066413|NCT03720418|EXPERIMENTAL|OXB-102 Dose Level 3|OXB-102 Dose Level 3 Single Administration (Part A: open-label)
62633985|NCT02619097|EXPERIMENTAL|0.08mg/kg|Pegol-sihematide injection, 0.08mg/kg, single-dose
62633986|NCT02619097|EXPERIMENTAL|0.2mg/kg|Pegol-sihematide injection, 0.2mg/kg, single-dose
62633987|NCT02619097|EXPERIMENTAL|0.33mg/kg|Pegol-sihematide injection, 0.33mg/kg, single-dose
62633988|NCT02619097|EXPERIMENTAL|0.5mg/kg|Pegol-sihematide injection, 0.5mg/kg, single-dose
62633989|NCT02619097|EXPERIMENTAL|0.7mg/kg|Pegol-sihematide injection, 0.7mg/kg, single-dose
62633990|NCT04328909|EXPERIMENTAL|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
62633991|NCT04328909|ACTIVE_COMPARATOR|Control Group|Usual care - No E-Care app will be provided
62633992|NCT01387178||COPD patients - risk analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).
62633993|NCT01387178||COPD patients - cost analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).
62633994|NCT02501746|ACTIVE_COMPARATOR|Usual Clinical Care (UC)|This will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension.
62633995|NCT02501746|EXPERIMENTAL|Usual clinical care plus microfinance groups only (MF)|Usual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program.
62633996|NCT02501746|EXPERIMENTAL|Group medical visits only (GMV)|Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen.
62633997|NCT02501746|EXPERIMENTAL|GMV integrated into GMV-MF|Clinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit.
62633998|NCT04453761|EXPERIMENTAL|Drugs Group|Thiamine IV
62633999|NCT04453761|PLACEBO_COMPARATOR|Placebo|NaCl IV
62634000|NCT03446092|EXPERIMENTAL|Mindfulness group|Group will receive mindfulness intervention
62634001|NCT01520207|PLACEBO_COMPARATOR|Placebo group: (0.9% normal saline)|0.9% saline will be administered (IV) during the hemodialysis session at 1.25mL/kg/hour (max 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
62634002|NCT01520207|ACTIVE_COMPARATOR|Intervention: intravenous mannitol (20%)|Mannitol will be administered (IV) during the hemodialysis session at a maximum rate of 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
62634003|NCT05922644|EXPERIMENTAL|Spinal cord electrical stimulation group|According to the EDC system, patients are randomly assigned to receive 21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
62634004|NCT05922644|SHAM_COMPARATOR|Conventional treatment group|According to the EDC system, patients are randomly assigned to receive only routine brain resuscitation and rehabilitation awakening treatment.
62634005|NCT00472732||1|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
62634006|NCT00472732||2|Healthy males or females without known medical or metabolic disorder (control group)
62634007|NCT03950453|EXPERIMENTAL|Parenting Mindfully for Health Nutrition (PMH)|Parenting Mindfully for Health (PMH) + nutrition and physical activity counseling to promote healthy eating and physical activity in parent and child.
62634008|NCT03950453|ACTIVE_COMPARATOR|Contact Control Nutrition (C+N)|Contact control intervention (C) + nutrition and physical activity counseling (N).
62634009|NCT03950453|OTHER|Historical Control (WLC) non-randomized|Non-randomized, historical control group with only assessments during intervention and follow-up period.
62066414|NCT03720418|EXPERIMENTAL|OXB-102 Selected Dose|Selected Dose of OXB-102 Single Administration (Part B: double-blind)
62066415|NCT03720418|SHAM_COMPARATOR|Imitation Surgical Procedure|General anesthesia with bilateral skin incisions (Part B: double-blind)
62066416|NCT00868699|EXPERIMENTAL|lurasidone low arm|
62066417|NCT00868699|PLACEBO_COMPARATOR|Placebo|
62066418|NCT00868699|EXPERIMENTAL|lurasidone high arm|
62066419|NCT05102123|EXPERIMENTAL|Cytisine and Video Messaging|Administration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support through video messaging.
62066420|NCT05102123|PLACEBO_COMPARATOR|Placebo and Video Messaging|Administration of placebo (inactive drug) to patients on a set dose schedule with behavioural support through video messaging.
62066421|NCT05102123|ACTIVE_COMPARATOR|Cytisine and No Video Messaging|Administration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support according to standard care such as a phone number for a self-help line.
62634010|NCT00798941|EXPERIMENTAL|pain intervention|music and massage for 30 minutes
62634011|NCT00798941|EXPERIMENTAL|thirst intervention|sterile water mouth spray, lip moisturizer,mouth swab
62634012|NCT00798941|NO_INTERVENTION|control|
62634013|NCT01614015|EXPERIMENTAL|Supervision as Usual|Supervision as Usual
62634014|NCT01614015|EXPERIMENTAL|Observation Based Supervision|Behavioral
62634015|NCT04407676|EXPERIMENTAL|Experimental|Patients eligible for an investigator initiated trial are given the standard PIS by email, and are also emailed a summary PIS and access to an online set of 10 video educational modules. They are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They then present for their standard of care consent visit.
62634016|NCT04407676|PLACEBO_COMPARATOR|Control|Patients eligible for an investigator initiated trial are given the standard PIS by email and are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They will then be emailed and are also emailed a summary PIS and access to an online set of 10 video educational modules. They will then perform the QuIC-A and QuIC-B again. They will then present for their standard of care consent visit.
62634017|NCT04371055|EXPERIMENTAL|Risk-adapted ECG monitoring for atrial fibrillation|"Intervention Group with high Risk for AF:~Continuous Rhythm Monitoring using an implantable cardiac Monitor~Intervention group with low risk for AF:~7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation"
62634018|NCT04371055|OTHER|Standard of Care|Standard of care rhythm monitoring
62271420|NCT06258070|OTHER|Duration of symptoms before BTX injections|"All the participants received BTX injections. Informed consent was obtained. Doses and sessions of injections varied between them according to the time of recurrence and the duration of the primary symptoms.~The investigator carried out injections using Dysport (Ipsen Pharma, Germany). The toxin was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U. The patient received the same doses in each session, delivered to TrPs detected by carefully palpating the muscle. 0.05 ml was injected into each TrPs."
62271421|NCT05595044|EXPERIMENTAL|Vitamin D therapy and habilitation|40 ASD children receiving Vitamin D therapy and habilitation
62271422|NCT05595044|OTHER|Habilitation|40 ASD children receiving habilitation
62634019|NCT01715948|EXPERIMENTAL|CROS hearing aid|The CROS uses two hearing aids that fit behind each ear. The hearing aid fitted with a retainer earhook on the side of the poor ear houses a microphone and a transmitter. The hearing aid fitted on the normal ear side houses a receiver that is connected to a slim tube and open ear tip. The CROS does not amplify sound but rather transmits sound from the side of the unaidable ear to the contralateral ear, overcoming the head shadow effect that presents with SSD.
62634020|NCT01715948|EXPERIMENTAL|Bone-anchored hearing device (BAHD)|The BAHD (such as the Baha by Cochlear or Bone-Bridge by MED-EL) also helps to alleviate the negative effect of head shadow and the difficulty with speech perception in noise that present with SSD. Also known as an osseointegrated aural prosthesis, the BAHD is implanted in individuals with SSD to stimulate the ear with the normal cochlea. The BAHD requires that a titanium screw be surgically implanted in the temporal bone on the side of the poor ear. This titanium screw is connected to a percutaneous abutment. An electromechanical sound processor (external transducer) is coupled onto the abutment and can be removed when necessary. Sound can now be routed to the better ear by transcranial bone conduction.
62634021|NCT06080542|EXPERIMENTAL|Aerobic session|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 60 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test.
62271423|NCT04513431|EXPERIMENTAL|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
62271424|NCT03594188|EXPERIMENTAL|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
62271425|NCT03594188|ACTIVE_COMPARATOR|local anesthesia|Patients in this group will have RF ablation for treatment of HCC under local anesthesia.
62271426|NCT00935168|EXPERIMENTAL|Hydroxy-ethyl starch|Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)
62066422|NCT05102123|NO_INTERVENTION|Placebo and No Video Messaging|Administration of placebo (inactive drug) to patients on a set dose schedule behavioural support according to standard care such as a phone number for a self-help line.
62066423|NCT03748836|ACTIVE_COMPARATOR|Single Ascending Dose ALPN-101|
62066424|NCT03748836|PLACEBO_COMPARATOR|Single Dose Placebo|
62271427|NCT00935168|ACTIVE_COMPARATOR|Saline|Intravenous fluid resuscitation with saline (0.9% sodium chloride)
62271428|NCT05470907||EBP|ICU COVID-19 patients treated with hemoperfusion/hemadsorption
62271429|NCT05470907||non-EBP|ICU COVID-19 patients not treated with hemoperfusion/hemadsorption
62271430|NCT05040516||Group 1|"The planned procedures include: medical interview, physical examination with basic anthropometric measurements (age, height, body weight); biochemical tests including blood selenium, selenoproteins, renalase and creatinine levels; total antioxidant status (TAS), 24-hour Holter electrocardiography, polysomnography and echocardiography.~A 10 ml of venous blood sample will be collected by venopuncture. Laboratory tests will be performed using commercially available standardized tests."
62271431|NCT06241040|EXPERIMENTAL|Aerobic Exercise Group with Core Muscle strengthening Group|Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.
62271432|NCT06241040|ACTIVE_COMPARATOR|Aerobic Exercise without Core Muscle Strengthening Group|Participants assigned to this group will engage in aerobic exercise interventions
62271433|NCT03668483|EXPERIMENTAL|Pulmonary Rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
62271434|NCT00767377|EXPERIMENTAL|EOF5 Group|The regimen of 5-day Continuous infusion of FU combined with Epirubicin and Oxaliplatin will be used in the patients recruited in this trial.
62271435|NCT03798821|EXPERIMENTAL|Experimental|One capsule a day will be consumed. At breakfast for the six weeks.
62271436|NCT03798821|PLACEBO_COMPARATOR|Comparator|One capsule a day will be consumed. At breakfast for the six weeks.
62271437|NCT00303251|EXPERIMENTAL|TKI258|
62271438|NCT02415712||Fomepizole Intravenous Infusion|Fomepizole Intravenous Infusion
62066425|NCT03748836|ACTIVE_COMPARATOR|Multiple Ascending Dose ALPN-101|
62066426|NCT03748836|PLACEBO_COMPARATOR|Multiple Dose Placebo|
62066427|NCT00803166||Cohort Group 1|Subjects number 1 to 30
62066428|NCT00803166||Cohort Group 2|Subjects number 31 to 60
62634022|NCT06080542|EXPERIMENTAL|High-intensity interval training|Our elastic band protocol is a modification of the HIIT protocols used by previous authors changing body weight exercises by exercises with TheraBand CLX. The exercise program is chosen to involve large muscle groups simulating conventional bodybuilding exercises by applying the external load to the elastic band's resistance. Four exercises of upper limb (bench press, seated dumbbell, shoulder press, and seated row) and four of lower limb (squats, stiff-legged deadlift, hamstring curl exercise, and quadriceps curl exercise) are chosen, which are intercalated in the program without doing two consecutive exercises of the same area. All exercises are done with both arms or legs at the same time.
62066429|NCT00462254|OTHER|A|Day 1-3: placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: continue placebo.
62066430|NCT00462254|OTHER|B|Day 1-3: Placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: continue placebo. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime.
62066431|NCT04380298|EXPERIMENTAL|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
62066432|NCT04380298|ACTIVE_COMPARATOR|The control group|In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
62066433|NCT02252614|ACTIVE_COMPARATOR|Naproxen sodium codein|Preoperative Naproxen sodium codein administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
62066434|NCT02252614|EXPERIMENTAL|Paracetamol codein|Preoperative paracetamol codein administrered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
62066435|NCT02252614|PLACEBO_COMPARATOR|Placebo tablet|Preoperative placebo tablet administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
62271439|NCT00944164|EXPERIMENTAL|Healthy eating/physical activity|
62271440|NCT00944164|ACTIVE_COMPARATOR|Safety/Injury prevention|
62271441|NCT05186207||observation group|those who need clinical intervention before or after pregnancy, the experts shall formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process. And they should be confirmed intrauterine pregnancy within the study period.
62271442|NCT05186207||control group|those who need not clinical intervention before or after pregnancy, pregnancy was prepared under the clinical and health care guidance provided by experts, and intrauterine pregnancy was confirmed within the study period.
62271443|NCT05986526|ACTIVE_COMPARATOR|Pulmonary vein isolation without posterior wall ablation|Pulmonary vein isolation without left atrial posterior wall ablation
61978619|NCT05766982|NO_INTERVENTION|Xenograft only|The Kerecis® xenograft (Kerecis® Omega3 MariGen) will be applied without the application of PRP.
62066436|NCT04959760|EXPERIMENTAL|BinaxNow Covid-19 Antibody test|The BinaxNOW™ Antibody Tests measure SARS-CoV-2 S-IgG antibodies.
62634023|NCT01579513|ACTIVE_COMPARATOR|Intraoperative Methylprednisone|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass(CPB) in the first month of life that receive one dose of intravenous methylprednisolone (30 mg/kg) during anesthetic induction.
62634024|NCT01579513|PLACEBO_COMPARATOR|Placebo|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass (CPB) in the first month of life that receive one dose of placebo (normal saline) during anesthetic induction.
62634025|NCT02855489|EXPERIMENTAL|Attitudes Only|The attitudes condition targeted cognitive and affective attitudes by pairing attitudinal messages with pictures, and included an evaluative conditioning task.
62634026|NCT02855489|EXPERIMENTAL|Norms Only|The norms condition utilized a group-affirmation exercise, personalized feedback, and group norms in an attempt to greater condom use norms.
62634027|NCT02855489|EXPERIMENTAL|Perceived Behavioral Control Only|The PBC condition included a condom application video, lubrication instructions, condom negotiation videos, and a detailed description regarding purchasing condoms.
62634028|NCT02855489|EXPERIMENTAL|Intentions Only|The intentions condition utilized implementation intentions in order to create condom use intentions.
62634029|NCT02855489|EXPERIMENTAL|Three Constructs|A three construct condition, which included attitudes, norms, and perceived behavioral control represented the core components of the TPB that are thought to work through intentions to result in behavior change.
62634030|NCT02855489|EXPERIMENTAL|Four Constructs|"A four construct condition (i.e., attitudes, norms, PBC, and intentions) was designed to represent the full TPB model intervention which we expected would be more successful than either the three-construct intervention or any of the single construct interventions."
62634031|NCT02855489|NO_INTERVENTION|No-Treatment, Control|A no-treatment control condition, which solely consisted of pretest and posttest assessments, was included. This allowed us to obtain important information about how the theoretical constructs in the TPB change over time (or do not) in the absence of an experimental manipulation.
62634032|NCT05763914|EXPERIMENTAL|Group 1: Picture-based prevention education and an educational course|The participants will have access to picture-based prevention education, and at the same time, they will participate in an educational course.
62634033|NCT05763914|EXPERIMENTAL|Group 2: Picture-based prevention education only (no educational course)|The participants will only have access to picture-based prevention education and will not participate in any educational course.
62634034|NCT05763914|PLACEBO_COMPARATOR|Group 3: Placebo (control)|The participants will not have access to picture-based prevention education and do not participate in any educational course.
62634035|NCT03404986|OTHER|Standardized ureteroscopy group|
62634036|NCT03404986|OTHER|Ultrasonography ureteroscopy group|
62634037|NCT03890458|EXPERIMENTAL|Experimental|
62066437|NCT03357120|OTHER|Follow-up after neoadjuvant chemotherapy|Patients with an invasive breast cancer on neoadjuvant chemotherapy (with the exception of cT2cN0 tumors) are preselected before the surgical procedure. They are definitely included during the post-surgery visit following the analysis of the surgical specimen (only patients whose tumor did not achieve a complete pathological response are included).
62066438|NCT03966690|EXPERIMENTAL|leg curl device starters|Group A randomly assigned to start with legcurl device
62066439|NCT03966690|EXPERIMENTAL|legpress device starters|Group A randomly assigned to start with legpress device
62634038|NCT03890458|NO_INTERVENTION|Control|
62634039|NCT03414190|EXPERIMENTAL|Experimental|Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
62634040|NCT03414190|NO_INTERVENTION|No Intervention|Usual Care
62634041|NCT01817075|EXPERIMENTAL|Arm I (CHG cleansing wipe)|Patients receive CHG cleansing with topical skin wipes QD for 90 days.
62634042|NCT01817075|ACTIVE_COMPARATOR|Arm II (control)|Patients receive control cleansing with topical skin wipes QD for 90 days.
62634043|NCT02622243|EXPERIMENTAL|tiotropium|2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
62634044|NCT02622243|EXPERIMENTAL|glycopyrronium|1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge
62634045|NCT02573259|EXPERIMENTAL|Arm 1 PF-06801591|0.5 mg/kg IV every 21 days (Part 1)
62066440|NCT02571790|EXPERIMENTAL|Relaxation optimized virtual reality|six relaxation sessions with virtual reality
62271444|NCT05986526|ACTIVE_COMPARATOR|Pulmonary vein isolation with posterior wall ablation|Pulmonary vein isolation with left atrial posterior wall ablation
62271445|NCT04800536|EXPERIMENTAL|Cardiovascular effects of rapidly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with a rapidly declining plasma glucose (\>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
62634046|NCT02573259|EXPERIMENTAL|Arm 2 PF-06801591|1.0 mg/kg IV every 21 days (Part 1)
62066441|NCT02571790|EXPERIMENTAL|Classical relaxation (without Virtual Reality).|six relaxation sessions without virtual reality
62066442|NCT03090581|ACTIVE_COMPARATOR|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
62066443|NCT03090581|ACTIVE_COMPARATOR|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
62634047|NCT02573259|EXPERIMENTAL|Arm 3 PF-06801591|3.0 mg/kg IV every 21 days (Part 1)
62634048|NCT02573259|EXPERIMENTAL|Arm 4 PF-06801591|10 mg/kg IV every 21 days (Part 1)
62066444|NCT03090581|ACTIVE_COMPARATOR|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
62066445|NCT06622278|EXPERIMENTAL|Group Health Education|Participants will be complete a total of 24, 1-hour group sessions with a health educator (exercise physiologist). The group size will be 10-15 participants and will be completed via Zoom. Prior to each group meeting, participants will email their weekly self-monitoring sheets to their health educator to review diet and exercise adherence. Each group session will follow a pre-determined structure: group discussion, review of adherence, 5 to 10 minutes of physical activity, and an active learning-based activity.
62066446|NCT06319235|EXPERIMENTAL|Investigational arm|DUOFAG® (the investigational medicinal product - IMP) will be administered twice a day for two weeks. DUOFAG® will be sprayed on the surgical wound. The phage titers of each bacteriophage in DUOFAG® is ≥ 10 000 000 PFU/mL (PFU = plaque forming units).
62271446|NCT04800536|EXPERIMENTAL|Cardiovascular effects of slowly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with slowly declining plasma glucose (\<0.085 mmol/l/min). A combined hyperglycaemic and euglycaemic clamp with a slowly declining plasma glucose (\>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
62271447|NCT02851004|EXPERIMENTAL|BBI608 + Pembrolizumab|BBI608 and Pembrolizumab
62271448|NCT03155594|EXPERIMENTAL|Single arm|Patients in this trial will receive a FreeStyle Libre patch that continuously measures glucose in addition to their standard glucose monitoring.
62634049|NCT02573259|EXPERIMENTAL|Arm 5 PF-06801591|300 mg SC every 28 days (Part 1 and 2)
62634050|NCT04260997|EXPERIMENTAL|Oral Probiotic Product|
62066447|NCT06319235|PLACEBO_COMPARATOR|Control arm|Placebo (physiological saline solution - 0.9% sodium chloride solution) will be administered twice a day for two weeks. Placebo will be sprayed on the surgical wound.
62066448|NCT01062763|EXPERIMENTAL|addition of spironolactone|spironolactone is added to previous antihypertensive treatment
62066449|NCT01062763|PLACEBO_COMPARATOR|Placebo|Addition of placebo
62066450|NCT03535402|OTHER|open label treatment|single arm with patients receiving 200 mg SC twice a week of sarilumab
62066451|NCT05384665|EXPERIMENTAL|Group A (placebo + remifentanil)|
62066452|NCT05384665|EXPERIMENTAL|Group B (sufentanil + placebo)|
62634051|NCT04260997|PLACEBO_COMPARATOR|Placebo product|
62634052|NCT03756948|ACTIVE_COMPARATOR|Usual Care (Before)|No Thromboelastometry No Synthetic Factor Concentrates Usual Care
62634053|NCT03756948|EXPERIMENTAL|Thromboelastometry-Guided Therapy (After)|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
62634054|NCT04784130|EXPERIMENTAL|DHSMP core|Dietary Modification and Physical Activity
62634055|NCT04784130|EXPERIMENTAL|DHSMP core plus|Dietary Modification, physical activity and medication adherence
62634056|NCT04784130|ACTIVE_COMPARATOR|DHSMP control|enhanced usual care-3 hours of education plus materials.
62634057|NCT04332068|ACTIVE_COMPARATOR|Arm 1|Permethrin cream plus placebo tablets
62634058|NCT04332068|EXPERIMENTAL|Arm 2|Ivermectin (200 µg/kg) plus placebo cream
62271449|NCT01602692|ACTIVE_COMPARATOR|Tumescent solution with dilute epinephrine|Subjects in this arm of the study will be randomized to receive tumescent solution containing dilute epinephrine (1:1,000,000) during their breast reduction.
62066453|NCT05384665|PLACEBO_COMPARATOR|Group C (placebo + placebo)|
62066454|NCT00816387|ACTIVE_COMPARATOR|IUI|Intrauterine insemination using standard catheter
62066455|NCT00816387|EXPERIMENTAL|FSP|Fallopian tube sperm perfusion using a commercial device for hysterosalpingography and tubal hydropertubation
62066456|NCT01131117||Pregnant women|
62271450|NCT01602692|ACTIVE_COMPARATOR|Tumescent solution with dilute lidocaine and epinephrine|Subjects in this arm of the study will receive tumescent solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000).
62271451|NCT05294744|ACTIVE_COMPARATOR|Corticosteroids|Corticosteroids following Standard Clinical Practice
62271452|NCT05294744|EXPERIMENTAL|Corticosteroids + N-acetylcysteine|Corticosteroids following Standard Clinical Practice plus N-acetylcisteine
62271453|NCT00003460|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62634059|NCT04332068|EXPERIMENTAL|Arm 3|Ivermectin (400 µg/kg) plus placebo cream
62634060|NCT04332068|EXPERIMENTAL|Arm 4|Ivermectin (800 µg/kg) plus placebo cream (Kenya and The Gambia sites)
62066457|NCT01834222||1|Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting
62066458|NCT02020980||Post-stroke lower limb spasticity patients|
62066459|NCT03093740|EXPERIMENTAL|HCV treatment - no viral resistance|Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier
62066460|NCT03093740|EXPERIMENTAL|HCV treatment - viral resistance|Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir
62271454|NCT06194591|ACTIVE_COMPARATOR|Stage A - Active treatment|The medical device NephrospecTM is used to administer 6 treatments of Low-intensity extracorporeal shockwave therapy (Li-ESWT) to the kidneys during 3 weeks.
62271455|NCT06194591|SHAM_COMPARATOR|Stage A - Sham treatment|The sham group will undergo the same treatment schedule, but with an applicator with an internal barrier to prevent shockwaves to pass through to the patient.
62271456|NCT06194591|ACTIVE_COMPARATOR|Stage B - Open label active treatment|Patients that were in the placebo group of stage A and do not exhibit a significant improvement in one of the main parameters will be eligible to enter stage B where they are treated with the active device in an open-label fashion.
62066461|NCT04929808|ACTIVE_COMPARATOR|Control group|Will receive the standard institutional skin care for acute radiodermatitis
62066462|NCT04929808|EXPERIMENTAL|Experimental group|Will receive the novel, self-prepared skin care product
62066463|NCT06294912|EXPERIMENTAL|Panel A: MK-7602 Single dose Part 1|Participants are inoculated with Plasmodium falciparum (P. falciparum). Panel A participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62066464|NCT06294912|EXPERIMENTAL|Panel B: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel B participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62066465|NCT06294912|EXPERIMENTAL|Panel C: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel C participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62271457|NCT01479543|EXPERIMENTAL|Group A|Volunteers received Probiotic CNCM I-4034.
62634061|NCT04839718||Control|Patients receiving referral to specialty mental healthcare
62634062|NCT04839718||ADAPT|ADAPT
62634063|NCT03436017||ADHD|Patient with ADHD diagnosis criterion. The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach
62634064|NCT03436017||non ADHD|"Patient with symptom of hyperactivity and/or attention deficiency but without ADHD diagnosis criterion.~The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach."
62634065|NCT02589470|EXPERIMENTAL|COMETE|patients will attend a specific rehabilitation programme of memory
62271458|NCT01479543|EXPERIMENTAL|Group B|Volunteers receive Probiotic CNCM I-4035.
62271459|NCT01479543|EXPERIMENTAL|Group C|Volunteers are given Probiotic CNCM I-4036.
62271460|NCT01479543|EXPERIMENTAL|Group D|Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
62066466|NCT06294912|EXPERIMENTAL|Panel D: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel D participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62634066|NCT02589470|NO_INTERVENTION|CONTROL|the control group where patients will benefit from a standard treatment
62066467|NCT06294912|EXPERIMENTAL|Panel E: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel E participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62066468|NCT06294912|EXPERIMENTAL|Panel F: MK-7602 Multiple dose Part 2|Participants are inoculated with P. falciparum. Panel F participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62066469|NCT06294912|EXPERIMENTAL|Panel G: MK-7602 Multiple dose Part 2|Participants are inoculated with P. falciparum. Panel G participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62066470|NCT06294912|EXPERIMENTAL|Panel H: MK-7602 Multiple dose Part 2|Participants are inoculated with P. falciparum. Panel H participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
62066471|NCT03068013|EXPERIMENTAL|Managing Cancer Living Meaningfully|Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months. Sessions are reviewed to ensure treatment fidelity.
62066472|NCT03068013|ACTIVE_COMPARATOR|Supportive psycho-oncology intervention|Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
62066473|NCT06528548||participants|1000 newborns are expected to take part in step 1
62066474|NCT06528548||tios|infants resulted negative at the TREAT-panel gNBS at the step 1 and their parents
62066475|NCT06024772|EXPERIMENTAL|Diagnostic (mp-MRI, Definity, mp-US, prostate biopsies)|Patients undergo mp-MRI, receive Definity IV, and undergo transrectal mp-US and prostate biopsies on study.
62066476|NCT00879996|ACTIVE_COMPARATOR|1|Methadone 10-60 mg per day in 2-4 divided doses for 6 months
62066477|NCT00879996|EXPERIMENTAL|2|Buprenorphine 4-16 mg per day in 2-4 divided doses for 6 months (using tablets of buprenorphine/naloxone:4/1 mg)
62066478|NCT03361826|OTHER|DBT Only|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder.
62271461|NCT01479543|PLACEBO_COMPARATOR|Group E|Volunteers receive a Placebo.
62271462|NCT03919708||Enriched Population|Children between the ages of 2-8 who present to an eye clinic. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans and exam should be performed within a single visit. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
62271463|NCT03919708||Unenriched Population|Children between the ages of 2-8 who present to a general pediatric clinic, with no history of eye disorders or amblyopia. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans will be performed at a single visit, but the exam may require a follow up visit, depending on the availability of a pediatric ophthalmologist at the clinic at the time of study enrollment. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
62271464|NCT01017393|EXPERIMENTAL|ketamine|epidural ketamine added to the patient controlled epidural analgesia regimen
62271465|NCT01017393|ACTIVE_COMPARATOR|ketamine free|epidural ketamine NOT added to the patient controlled epidural analgesia regimen
62271466|NCT01347034|ACTIVE_COMPARATOR|External Beam Radiation Therapy (RT)|Arm A - University of Florida - External Beam Radiation Therapy (RT) - As outlined in Intervention Description
62634067|NCT03981146|EXPERIMENTAL|Nivolumab|Patients will receive 480mg of Nivolumab on a four weekly cycle for a maximum of two years.
62634068|NCT00189163|ACTIVE_COMPARATOR|Pioglitazone|30 mg, taken orally, once per day
62634069|NCT00189163|PLACEBO_COMPARATOR|Placebo|Sugar pill, taken orally, once a day
62066479|NCT03361826|EXPERIMENTAL|MagPro MST with Cool TwinCoil + DBT|MST treatments will be administered using the MagPro MST with Cool TwinCoil. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
62066480|NCT02139423|EXPERIMENTAL|All newborns who fail universal newborn|CMV PCR
62066481|NCT04100109|ACTIVE_COMPARATOR|Polylactose|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing polylactose
62271467|NCT01347034|EXPERIMENTAL|External Beam RT + DC Injection|Arm B - Moffitt Cancer Center - External Beam RT + Autologous Dendritic Cells (DC) Injection - As outlined in Intervention Description
62271468|NCT01451710|EXPERIMENTAL|Prednisone or Prednisolone|
62286923|NCT04831060||Control (healthy periodontium)|Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries or aesthetic surgeries
62452992|NCT05362435|EXPERIMENTAL|Participation in Makoyoh'sokoi (the Wolf Trail Program)|"This is a self-control, non-randomised intervention study. 7 locations will run a total of 10 programs (4 urban, off-reserve; 6 rural, on reserve).~Makoyoh'sokoi (The Wolf Trail Program) is a holistic health and wellness program that consists of a 12-week live phase where participants engage weekly in approximately 45 minutes of physical activity, 20 minutes of a health education module, and 20 minutes of a sharing circle. The live phase is followed by a 12-week follow-up phase where participants meet bi-weekly for approximately 30 minutes of a health education module and 30 minutes of a sharing circle."
62452993|NCT01138072|EXPERIMENTAL|Treatment A|Simvastatin 20mg (single dose) Day 1
62452994|NCT01138072|EXPERIMENTAL|Treatment B|Atorvastain 20 mg (single dose) Day 3
62452995|NCT01138072|EXPERIMENTAL|Treatment C|Rosuvastatin 10mg (single dose) Day 7
62452996|NCT01138072|EXPERIMENTAL|Treatment X|GSK2248761 200mg single dose Day 10-14, Day 16-17, Day 19-21, Day 23-24
62452997|NCT01138072|EXPERIMENTAL|Treatment D|GSK2248761 200mg + simvastatin 20 mg Day 15
62452998|NCT01138072|EXPERIMENTAL|Treatment E|GSK2248761 200mg + atorvastatin 20 mg Day 18
62452999|NCT01138072|EXPERIMENTAL|Treatment F|GSK2248761 200mg + rosuvastatin 20 mg Day 22
62453000|NCT04682041|EXPERIMENTAL|EnteraGam + standard of care|Subjects will receive EnteraGam® (oral nutritional therapy) + standard of care for COVID-19 for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
62453001|NCT04682041|OTHER|Control (standard of care)|Subjects will receive standard of care for COVID-19 alone for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
62453002|NCT06130020|EXPERIMENTAL|Self|The Self group is instructed to carry out the expressive writing exercise as if they were writing to themselves.
62453003|NCT06130020|EXPERIMENTAL|Other|The Other group is instructed to carry out the expressive writing exercise as if they were writing to someone they feel close to.
62453004|NCT06130020|PLACEBO_COMPARATOR|Control|The Control group is asked to write down a factual description of their routine that day, as if they were writing to themselves.
62286924|NCT06381661|EXPERIMENTAL|Immuno-modulation : Tocilizumab|
62286925|NCT06381661|EXPERIMENTAL|Immuno-modulation Baricitinib|
62453005|NCT00718159|EXPERIMENTAL|LY573636|
62453006|NCT04788680|EXPERIMENTAL|Experimental: Beverage 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
62453007|NCT04788680|EXPERIMENTAL|Experimental: Beverage 2|Participants receive a beverage with a defined amount of non-nutritive sweetener.
62453008|NCT04788680|EXPERIMENTAL|Experimental: Beverage 3|Participants receive a beverage with a defined amount of monosaccharide.
62453009|NCT04788680|EXPERIMENTAL|Experimental: Beverage 4|Participants receive a beverage with a defined amount of disaccharide.
62453010|NCT01173770|EXPERIMENTAL|Cohort 1: ADC3680B vs. Placebo|
62453011|NCT01173770|EXPERIMENTAL|Cohort 2: ADC3680B vs. Placebo|
62453012|NCT01173770|EXPERIMENTAL|Cohort 3: ADC3680B vs Placebo|
62453013|NCT01173770|EXPERIMENTAL|Cohort 4: ADC3680B vs. Placebo|
62453014|NCT01173770|EXPERIMENTAL|Cohort 5: ADC3680B vs. Placebo|
62453015|NCT01173770|EXPERIMENTAL|Cohort 6: ADC3680B|
62453016|NCT00738166|EXPERIMENTAL|II|organic animal manure
62453017|NCT00738166|ACTIVE_COMPARATOR|III|conventional
62453018|NCT00738166|EXPERIMENTAL|I|organic green manure
62453019|NCT00617526|EXPERIMENTAL|RDEA806 400 mg|Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
62453020|NCT00617526|EXPERIMENTAL|RDEA806 600 mg|Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
62453021|NCT00617526|EXPERIMENTAL|RDEA806 800 mg|Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
62453022|NCT00617526|EXPERIMENTAL|RDEA806 1000 mg|Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.
62066482|NCT04100109|ACTIVE_COMPARATOR|Placebo|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing cellulose, which is an inert dietary fiber, and which will act as our placebo for this project.
62271469|NCT04943705|EXPERIMENTAL|Yin and Yang Regulating Moxibustion|1.The acupoints will be selected as Shenque and Mingmen.The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Each treatment was 60min, once a week, Wenyang Yishen moxibustion and Peiyuan Guben moxibustion were performed alternately. Each patient received WenYang Yishen moxibustion and then Peiyuan Guben moxibustion for a total of 12 weeks of treatment and 12 weeks of follow-up at the end of the treatment. 2.The diet and exercise control implementation plan is as follows:Participants weighed ≤113.6 kg (250 lbs) and had a prescription diet of 1200-1499 kcal/day, including traditional foods, of which protein was about 15-20 kcal, fat was about 20-35%, and the rest came from carbohydrates. People weighing ≥113.6 kg are prescribed 1500-1800 kcal per day. They were also instructed to continue moderate-intensity physical activities (such as jogging, brisk walking) at least 5 days a week, at least 210 minutes a week, preferably ≥270 minutes a week。
62286926|NCT06381661|EXPERIMENTAL|Immuno-modulation Anakinra|
62286927|NCT06381661|EXPERIMENTAL|Cortico-steroids : Hydrocortisone|
62066483|NCT01858480|ACTIVE_COMPARATOR|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
62286928|NCT06381661|EXPERIMENTAL|Cortico-steroids :Hydrocortisone and fludrocotisone|
62453023|NCT02931474|PLACEBO_COMPARATOR|Placebo|Salt Water Solution
62066484|NCT01858480|PLACEBO_COMPARATOR|Placebo|Placebo dosage form designed to mock active.
62066485|NCT03719053|EXPERIMENTAL|Truvada|single oral dose of Truvada® (300 mg tenofovir disoproxil fumarate)
62066486|NCT04157465|OTHER|Early Empiric group|Participants will receive standard medical therapy along with the empiric strategy of treatment of invasive fungal infection (based on both risk factors and clinical suspicion of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
62286929|NCT06381661|EXPERIMENTAL|Coagulation : Heparin|
62286930|NCT06381661|EXPERIMENTAL|Coagulation : Low molecular weight heparin|
62286931|NCT06381661|EXPERIMENTAL|Coagulation : Recombinant humanThrombomodulin( rhTM)|
62286932|NCT06381661|EXPERIMENTAL|Coagulation : Sivelestat|
62453024|NCT02931474|EXPERIMENTAL|Tesamorelin|Growth Hormone-Releasing
62453025|NCT05496140|EXPERIMENTAL|CLS-R-FUERTE|Active program participation in: a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). via school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
62453026|NCT05496140|NO_INTERVENTION|Care-As-Usual|Continued participation in school care-as-usual
62453027|NCT02837965||diagnosed bullous pemphigoid|
62088197|NCT04838821|EXPERIMENTAL|Placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
62088198|NCT04850742|EXPERIMENTAL|Cryopreserved aorta|After resection of a segment of tracheal or bronchial lesion, reconstruct the airway with cryopreserved aortic allograft.
62088199|NCT04121221|EXPERIMENTAL|GA Depot|Monthly IM injection
62088200|NCT04121221|PLACEBO_COMPARATOR|Placebo|Monthly IM injection
62088201|NCT06358742|EXPERIMENTAL|ZCT toothpaste|Brush with zinc citrate trihydrate toothpaste twice per day, morning and evening, for 12 weeks
62088202|NCT06358742|PLACEBO_COMPARATOR|Control toothpaste|Brush with control toothpaste twice per day, morning and evening, for 12 weeks.
62088203|NCT02703038||Cardiogenic shock|Patient with cardiogenic shock table defined by the combination of a low cardiac output even as the filling pressures are normal or high, originally of hypoperfusion and organ suffering.
62088204|NCT00691028|EXPERIMENTAL|TA-650 3 mg/kg|
62088205|NCT00691028|EXPERIMENTAL|TA-650 6 mg/kg|
62088206|NCT00691028|EXPERIMENTAL|TA-650 10 mg/kg|
62088207|NCT03801772|ACTIVE_COMPARATOR|Metronome|This arm will be using the metronome as a pacing device during aquatic exercises.
62634070|NCT03971006||Immunocompetent ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) and no immunosuppression (excluding patients with HIV infection, solid tumor or hematological malignancies, organ transplant or taking steroids since more than 4 weeks).
62066487|NCT04157465|ACTIVE_COMPARATOR|Pre-emptive group|Participants will receive standard medical therapy along with the pre-emptive strategy of treatment of invasive fungal infection (based on risk factors, clinical suspicion and radiological or mycological evidence of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
62453028|NCT05720663||nonalcoholic steatohepatitis (NASH)|Adult patients nonalcoholic steatohepatitis (NASH)
62066488|NCT01742637|EXPERIMENTAL|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)
62453029|NCT03871608||DTM Disorders|Patient with DTM Disorders with Examination of functional etiologies on DTM Disorders and Assessment of symptoms on DTM Disorders
62453030|NCT04591626|EXPERIMENTAL|1.5 Milligrams (mg) Dulaglutide|Participants received 1.5 mg Dulaglutide administered once weekly (QW) subcutaneously (SC) as add-on to titrated treat-to-target (TTT) dose of Insulin Glargine given SC, along with metformin and/or acarbose.
62453031|NCT04591626|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered QW SC as add-on to titrated TTT dose of insulin glargine given SC, along with metformin and/or acarbose.
62453032|NCT00417274|EXPERIMENTAL|Quinacrine|Uncontrolled treatment arm
62453033|NCT00922597||Group 1|
62453034|NCT03747822|ACTIVE_COMPARATOR|autogenous fat|autogenous fat augmentation in deficient chin will be harvested from lower abdomen,inner or outer thigh
62453035|NCT03747822|ACTIVE_COMPARATOR|PEEK|Will use onlay PEEK augmentation in deficient chin.Virtual planning will be done using mimics software. A virtual osteotomy of the chin will be performed at the inferior border of the mandible same alignments as sliding genioplasty, then segmentation of the chin area will be done and according to the soft tissue analysis adjustment will be performed.
62453036|NCT03747822|OTHER|Osseous sliding genioplasty|Under general anesthesia, the preparation and the incision line will be performed same as PEEK augmentation .After complete exposure of the bone repositioning of the chin will be performed. Finally fixation will be obtained using x shape titanium plate.
62453037|NCT05447338|EXPERIMENTAL|Specific joint mobilization post muscle inhibition on C1 and C2|Experimental technique alone, with its two variants. That applies a sliding of the articular surfaces of the atlas and axis after a muscular reflex inhibition (proprioceptive neuromuscular facilitation). Between 1 and 5 mobilizations will be carried out per variant of the technique. There will be 4 treatment sessions distributed over 2 weeks.
62453038|NCT05447338|EXPERIMENTAL|Specific joint mobilization post muscle inhibition on C1 and C2 + myofascial inductions|Experimental technique alone, with its two variants. That applies a sliding of the articular surfaces of the atlas and axis after a muscular reflex inhibition (proprioceptive neuromuscular facilitation). Between 1 and 5 mobilizations will be carried out per variant of the technique. Myofascial inductions will also be applied to the cranial and cervical fascia, as well as to the suboccipital, pectoral, angular scapula, sternocleidomastoid, trapezius, internal and external pterygoid, masseter and temporal muscles. There will be 4 treatment sessions distributed over 2 weeks.
62453039|NCT05447338|ACTIVE_COMPARATOR|Maitland C2 + SNAG C1|The Maitland technique will be applied, central postero-anterior passive joint mobilization in the C2 vertebra. As well as the sustained apophyseal slip technique (SNAG) in rotation on C1. The dosage is from 1 to 5 mobilizations per technique. There will be 4 treatment sessions distributed over 2 weeks.
61978620|NCT05766982|EXPERIMENTAL|Xenograft and PRP|The Kerecis® xenograft (Kerecis® Omega3 MariGen) will be applied with the application of PRP.
61978621|NCT05715073|EXPERIMENTAL|TeaCrine and caffeine|150mg of Teacrine and 150mg of caffeine
61978622|NCT05715073|ACTIVE_COMPARATOR|Caffeine|300mg of caffeine
61978623|NCT05715073|PLACEBO_COMPARATOR|Placebo|300mg of cellulose
62453040|NCT04700449|EXPERIMENTAL|Double-Blind 0.2mg CBP-307|0.2 mg CBP-307 capsules oral administration.
62453041|NCT04700449|PLACEBO_COMPARATOR|Double-Blind Placebo|Placebo capsules oral administration.
62453042|NCT04700449|EXPERIMENTAL|Open-Label CBP-307|0.2 mg CBP-307 capsules oral administration.
62453043|NCT04700449|EXPERIMENTAL|Double-Blind 0.1mg CBP-307|0.1 mg CBP-307 capsules oral administration.
62453044|NCT05760703|EXPERIMENTAL|lowest dose treatment group|Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
62453045|NCT05760703|EXPERIMENTAL|low dose treatment group|Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
62453046|NCT05760703|EXPERIMENTAL|Intermediate dose treatment group|Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
62453047|NCT05760703|EXPERIMENTAL|A single high dose of treatment group|Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements
62453048|NCT02806921|ACTIVE_COMPARATOR|ZenLens with Low limbal clearance|Scleral contact lens designed to provide approximately 25 microns of limbal clearance.
62453049|NCT02806921|ACTIVE_COMPARATOR|ZenLens with High limbal clearance|Scleral contact lens designed to provide approximately 80 microns of limbal clearance.
62634071|NCT03971006||Immunosuppressed ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) (Berlin definition (2)) and previously known immunosuppression (as listed above). These patients will allow comparing the cell defects observed in the study population to those observed in immunosuppressed patients.
62634072|NCT03971006||Controls|(n=10) Patients undergoing a bronchoscopy with Bronchoalveolar Liquid (BAL) as part of routine care but having neither ARDS nor active lung infection, infiltrating lung disease or immunosuppression. These patients will allow quantifying normal levels of the studied biomarkers in the alveolar and blood compartments.
62634073|NCT02302846|EXPERIMENTAL|Ixazomib|Participants receive 4 mg oral dose of Ixazomib on Days 1, 8 and 15 of each 28-day cycle.
62634074|NCT02003144|EXPERIMENTAL|Eculizumab|Eculizumab intravenous infusion every two weeks.
62634075|NCT01309321|EXPERIMENTAL|Perinatal Handwashing Intervention Arm|
62066489|NCT01742637|ACTIVE_COMPARATOR|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)
62066490|NCT01742637|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)
62066491|NCT06414512|ACTIVE_COMPARATOR|control|Historical controls drawn from the AMBITION trial will be used as a comparison group, selected weighted by inclusion/exclusion criteria, baseline characteristics and therapies received.
62066492|NCT06414512|EXPERIMENTAL|Low Dose Flucytosine|HIV-infected persons in Uganda with cryptococcal meningitis
62066493|NCT05368181|EXPERIMENTAL|Prevention group|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
62066494|NCT02268617|EXPERIMENTAL|Treadmill Walking|All subjects will walk on treadmill for a total of 20 minutes.
62066495|NCT04533451|EXPERIMENTAL|Group A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62634076|NCT01309321|ACTIVE_COMPARATOR|Neonatal Health Promotion|
62634077|NCT02589080|EXPERIMENTAL|Non-invasive sensory feedback|
62634078|NCT01249417|EXPERIMENTAL|Dysport 10 U/Kg|10 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
62634079|NCT01249417|EXPERIMENTAL|Dysport 15 U/Kg|15 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
62634080|NCT01249417|PLACEBO_COMPARATOR|Placebo|Total volume to be injected per lower limb - 2ml. Either one or both lower limbs can be treated.
62634081|NCT02171429|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
62634082|NCT02171429|ACTIVE_COMPARATOR|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
62634083|NCT02171429|EXPERIMENTAL|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
62634084|NCT00336934|EXPERIMENTAL|Arm I|Patients receive oral pomegranate extract daily.
62271470|NCT04943705|ACTIVE_COMPARATOR|Mild Moxibustion|1.The acupoints will be selected as Zhongwan, Guanyuan, Sanyinjiao (double).The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Light one end of the moxa stick and hang it about 2-3cm above the skin, taking the patient's local skin redness and conscious warmth as the degree. Moxa-box moxibustion will be used for 20 minutes each treatment, once every other day, 3 times a week, for a total of 12 weeks of treatment, and 12 weeks of follow-up after the treatment. 2.Lifestyle modification:It will be performed as the same as the Yin and Yang Regulating Moxibustion group.
62271471|NCT01182428|EXPERIMENTAL|XIENCE V® / XIENCE PRIME™|
62271472|NCT01182428|ACTIVE_COMPARATOR|CYPHER SELECT|
62286933|NCT06381661|EXPERIMENTAL|Coagulation : Fresh Frozen Plasma|
62634085|NCT00336934|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo daily.
62634086|NCT05911477|EXPERIMENTAL|rhBMP-2 group|
62634087|NCT05911477|NO_INTERVENTION|No rhBMP-2 group|
62634088|NCT02720276|EXPERIMENTAL|Training after acute stroke|Intervention: Outdoor walking and strength training.
62634089|NCT00970489|EXPERIMENTAL|Omega-3 fatty acid capsules|
62634090|NCT00970489|PLACEBO_COMPARATOR|Olive Oil capsule|
62634091|NCT05468216|EXPERIMENTAL|MovIn-Lessons group|The schools which will implement the movement integration in the learning activities of primary education subjects (maths, natural science and English).
62634092|NCT05468216|NO_INTERVENTION|Control group|Schools which will continues applying the same methodology in the realization of the learning activities.
62066496|NCT04533451|EXPERIMENTAL|Group B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV per institutional guidelines on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62066497|NCT03579914|PLACEBO_COMPARATOR|Placebo group|Patients receive intravenous placebo injection.
62271473|NCT02465073|ACTIVE_COMPARATOR|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. ( NXTSC).
62453050|NCT02274298|ACTIVE_COMPARATOR|CKD feedback and tools|Physicians in these clinics/clusters will receive feedback on their performance for screening and managing CKD quality indicators as well as EMR tools to aid in their performance
62066498|NCT03579914|EXPERIMENTAL|Intravenous metoprolol group|Patients receive intravenous metoprolol injection.
62066499|NCT03579914|EXPERIMENTAL|RIC group|Patients receive RIC treatment.
62066500|NCT03579914|EXPERIMENTAL|Intravenous metoprolol and RIC group|Patients receive intravenous metoprolol injection and RIC treatment.
62066501|NCT02826590|EXPERIMENTAL|Neck passive mobilizations|Neck passive mobilizations
62271474|NCT02465073|ACTIVE_COMPARATOR|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site.( Next Science Wound Gel, plus standard of care).
62271475|NCT02465073|ACTIVE_COMPARATOR|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management intervention to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted. Determine the effect on wound treatment outcomes using standard of care treatment
62066502|NCT02826590|PLACEBO_COMPARATOR|Manual contact|Manual contact
62066503|NCT05784805|EXPERIMENTAL|Participants with ongoing non-convulsive or focal motor SE|Adult patients with ongoing non-convulsive or focal motor SE despite treatment with at least 2 ASMs and who are monitored with surface EEG will be screened and enrolled to receive up to 2 sessions of PLIFU.
62066504|NCT06624813|EXPERIMENTAL|Partial prostatectomy|Robot-assisted partial prostatectomy in patients with prostate cancer
62286934|NCT06381661|ACTIVE_COMPARATOR|Control|
62453051|NCT02274298|NO_INTERVENTION|No Intervention|Physicians in these clinics/clusters will not receive CKD feedback or tools
62634093|NCT04164368|EXPERIMENTAL|R2-CHOP|Lenalidomide combined with rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone
62634094|NCT06439108|ACTIVE_COMPARATOR|single superior symphyseal plate|15 cases undergoing single superior symphyseal plate, reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach.Anterior pelvic ring reduction and fixation was done via the classic Pfannenstiel approach
61978624|NCT03446183||Smoking cessation prospective|Smoking cessation workshops
62286935|NCT04075331|EXPERIMENTAL|Mepolizumab|Mepolizumab
62271476|NCT04103437||recreational runners|Recreational runners (minimum of 2 running session and 20km of total mileage per week), with seasonal best on half-marathon comprised between 1h20' and 2h00'. Age \> 18 and \< 60 years. Free from musculoskeletal injuries from at least three months.
62271477|NCT03597048|EXPERIMENTAL|Curriculum|Participants received only the curriculum intervention
62271478|NCT03597048|ACTIVE_COMPARATOR|Contact|Participants received only the contact intervention
62271479|NCT03597048|ACTIVE_COMPARATOR|Materials|Participants received only the materials intervention
62634095|NCT06439108|ACTIVE_COMPARATOR|double superior & anterior symphyseal plates|15 cases undergoing double superior \& anterior symphyseal plates, 15 cases undergoing double superior \& anterior symphyseal plates, reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach.Anterior pelvic ring reduction and fixation was done via the classic Pfannenstiel approach
62271480|NCT03597048|EXPERIMENTAL|Curriculum and Contact|Participants received both curriculum and contact interventions
62271481|NCT03597048|EXPERIMENTAL|Curriculum and Materials|Participants received curriculum and materials interventions
62271482|NCT03597048|ACTIVE_COMPARATOR|Contact and Materials|Participants received contact and materials intervention
62271483|NCT03597048|ACTIVE_COMPARATOR|Curriculum, Contact and Materials|Participants received curriculum, contact and materials interventions
62634096|NCT00003494|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
61978625|NCT03446183||Smoking cessation retrospective|File review of former workshop participants
62271484|NCT03597048|NO_INTERVENTION|No intervention|Participants received no intervention
62271485|NCT00084123|EXPERIMENTAL|Healing Touch|Healing Touch Therapy
62271486|NCT00084123|ACTIVE_COMPARATOR|Relaxation Therapy|Relaxation Therapy
62271487|NCT00084123|PLACEBO_COMPARATOR|Standard Care|Standard Care
62271488|NCT05522439|EXPERIMENTAL|Subjects receiving SHR-1703 dose 1|
62271489|NCT05522439|EXPERIMENTAL|Subjects receiving SHR-1703 dose 2|
62271490|NCT05522439|EXPERIMENTAL|Subjects receiving SHR-1703 dose 3|
62271491|NCT05522439|PLACEBO_COMPARATOR|Placebo|
62271492|NCT00187421|NO_INTERVENTION|1|Graft patency assessment by routine clinical assessment with/without intraluminal coronary probe
62271493|NCT00187421|EXPERIMENTAL|2|Graft patency assessment by indocyanine green angiography and transit-time flowmetry
62271494|NCT05133635|ACTIVE_COMPARATOR|Pulse methylprednisolone|250 mg methylprednisolone for 3 days
62634097|NCT05128591|EXPERIMENTAL|Arm A-Rivaroxaban|Period 1 : Reference Drug(AD-1091) Period 2 : Test Drug(AD-109)
62634098|NCT05128591|EXPERIMENTAL|Arm B-Rivaroxaban|Period 1 : Test Drug(AD-109) Period 2 : Reference Drug(AD-1091
62634099|NCT00053209|EXPERIMENTAL|Pemetrexed Disodium and Gemcitabine|Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles
62066505|NCT06626308|EXPERIMENTAL|neuroimaging assessment|visual stimulation protocol during functional MRI session
62066506|NCT05453916|EXPERIMENTAL|Nitazoxanide|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
62634100|NCT03175926|EXPERIMENTAL|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
62634101|NCT03175926|EXPERIMENTAL|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
62634102|NCT03175926|EXPERIMENTAL|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
62634103|NCT04308863|EXPERIMENTAL|Chitosan scaffold/ MTA pulp dressing material|
62634104|NCT04308863|ACTIVE_COMPARATOR|MTA pulp dressing material|
62634105|NCT05594147||TKIs treated group|Adult cancer patients with newly diagnosed COVID-19 who used Tyrosine kinase inhibitors (TKIs) within 30 days before COVID-19 diagnosis.
62634106|NCT05594147||Non-TKIs treated group|Adult cancer patients with newly diagnosed COVID-19 who used other anti-cancer therapies 30 days before COVID-19 diagnosis
62634107|NCT01178125|EXPERIMENTAL|DR-102|desogestrel/ethinyl estradiol 0.15/0.02 mg for 21 days then ethinyl estradiol 0.01 mg for 7 days
62066507|NCT05453916|ACTIVE_COMPARATOR|Rifaximin|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days.
62066508|NCT01589952|EXPERIMENTAL|Pegylated Interferon, Entecavir|'Pegylated Interferon, Entecavir' arm will consist of 20 chronic hepatitis B patients who will receive Pegylated Interferon 90 micro gms subcutaneously once weekly in combination with entecavir 0.5 mg orally once daily for 24 weeks
62066509|NCT05238064|EXPERIMENTAL|PI3Kδ inhibitor Parsaclisib plus CHOP|"Phase Ib (Explored the appropriate dose of Parsaclisib in combination with CHOP)~Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day.~CHOP was given at the standard dose, 21 days per cycle~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib day 1-14 of each cycle, as well as CHOP at standard dose for 6 cycles.~Maintain treatment: Parsaclisib maintenance (2.5mg po, qd) will be performed on CR or PR patients after 6 cycles of induction therapy until disease progression, death, unacceptable toxicity, withdrawal of informed consent, or the investigator's decision or initiation of new antitumor therapy. The maximum maintenance period of parsaclisib is 24 months."
62066510|NCT01616771|OTHER|glottis view assessment|Glottis view assessment using Macintosh laryngoscope \& GVL selected by weight \& smaller sized GVL in single patient
62066511|NCT06625749|EXPERIMENTAL|AccuraSee™ intraocular pseudophakic capsular lens (IOPCL)|
62066512|NCT02746913|EXPERIMENTAL|Urodynamics, followed by Pessary|
62066513|NCT02746913|EXPERIMENTAL|Pessary, followed by Urodynamics|
62634108|NCT03012932|OTHER|HPV Self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
62634109|NCT01566604|EXPERIMENTAL|NVA237|NVA237 50 µg once daily delivered via a single dose dry powder inhaler
62634110|NCT01566604|PLACEBO_COMPARATOR|Placebo|Placebo once daily delivered via a single dose dry powder inhaler
62634111|NCT01751321|OTHER|sitagliptin, metformin, placebo|"1. group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day~2. group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day"
62634112|NCT04634188||Meningioma Group|"This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
62634113|NCT04634188||Glioma Group|"This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
62634114|NCT04634188||Brain Metastasis Group|This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
62634115|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
62634116|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
62634117|NCT03059732||Thailand|Thai patients who diagnosed gastric cancer
62634118|NCT03059732||Japan|Japanese patients who diagnosed gastric cancer
62271495|NCT05133635|ACTIVE_COMPARATOR|Tocilizumab|Tocilizumab 400-800 mg for one time
62271496|NCT03872986|EXPERIMENTAL|SDF+Giomer|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Beautifil II restorative material
62271497|NCT03872986|EXPERIMENTAL|Giomer only|Beautifil II dental restorative material
62271498|NCT03872986|EXPERIMENTAL|SDF+GIC|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Equia forte
62271499|NCT03872986|EXPERIMENTAL|GIC only|Equia forte dental restorative material
62271500|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
62271501|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
62271502|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
62271503|NCT02457871|EXPERIMENTAL|Ecological Nurse Case Managemnt|Ecological Nurse Case Management (ENCM) group receives 6 months of ENCM services in addition to their usual primary care services at the study site.
62066514|NCT00073827|EXPERIMENTAL|1|levalbuterol MDI 90 mcg QID
62066515|NCT00073827|ACTIVE_COMPARATOR|2|racemic albuterol MDI 180 mcg QID
62271504|NCT02457871|NO_INTERVENTION|Comparison|Usual Clinical Care - is the usual primary care services delivered at the site of the study, a free clinic.
62271505|NCT04482335||Main Study|Participants complete questionnaires and agree to have their retrospective and prospective medical data used as part f this research project. All participants will take part in this arm.
62271506|NCT04482335||Biosample Sub-Study|A subset of the participants will take part of this. Participants will agree to have blood samples taken at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to provide urine samples.
62271507|NCT04482335||Synovial Biopsy and Synovial Fluid Sub-Study|A subset of the participants will take part of this. Participants will agree to synovial biopsies at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to donate waste synovial fluid.
62271508|NCT03224897|ACTIVE_COMPARATOR|Cathodal tDCS|
62066516|NCT00073827|PLACEBO_COMPARATOR|3|Placebo MDI QID
62066517|NCT00326638|OTHER|Arm A: 3D-Conformal Radiation|"Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks.~3DCRT 7800 cGY/39 Fractions/ STD Technique\*~* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~* Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
62271509|NCT03224897|ACTIVE_COMPARATOR|Anodal tDCS|
62634119|NCT06158204|EXPERIMENTAL|Immediate intervention|Participants will receive the 8-week intervention first, followed by 8 weeks of observation-only
62634120|NCT06158204|ACTIVE_COMPARATOR|Delayed intervention|Participants will receive the 8-week intervention after 8 weeks of observation-only
62634121|NCT04505852|EXPERIMENTAL|EMBRACE USERS|Embrace wristband users
62634122|NCT02938117|EXPERIMENTAL|CON : concentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
62634123|NCT02938117|EXPERIMENTAL|EXC : eccentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
62066518|NCT00326638|EXPERIMENTAL|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks.~IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16"
62066519|NCT06624826|EXPERIMENTAL|PureSee Emmetropia|Patient will receive the PureSee IOL with an emmetropic modality
62271510|NCT03224897|SHAM_COMPARATOR|Sham tDCS|
62271511|NCT06409676|EXPERIMENTAL|ERAS group|Participants will receive the ERAS protocol tailored for endoscopic procedures
62271512|NCT06409676|NO_INTERVENTION|Standard care group|Participants will receive conventional pre-endoscopic care, including basic patient education, standard bowel preparation, preoperative fasting guidelines, medication management, and routine preoperative assessment
62271513|NCT03664999||Parturients physiologic pregnancy|Parturients undergoing caesarean delivery with physiologic pregnancy
62286936|NCT04075331|PLACEBO_COMPARATOR|Placebo|Saline solution
62066520|NCT06624826|EXPERIMENTAL|PureSee Monovision|Patient will receive the PureSee IOL in a monovision modality
62066521|NCT05969821||Dysimmune manifestations with or without clonal hematopoiesis|Dysimmune manifestations with or without clonal hematopoiesis
62066522|NCT01473472|ACTIVE_COMPARATOR|Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
62066523|NCT01473472|PLACEBO_COMPARATOR|Placebo of Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
62066524|NCT02265016||Patients with CAD|Patients with stable coronary artery disease
62066525|NCT02265016||Patients with ACS|Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI
62066526|NCT02265016||healthy control group|healthy control group without clinical apparent arteriosclerosis
62066527|NCT00647634|EXPERIMENTAL|1|Alprazolam Extended-Release Tablets 3 mg;
62066528|NCT00647634|ACTIVE_COMPARATOR|2|Xanax XR® Tablets 3 mg
62066529|NCT00827593|ACTIVE_COMPARATOR|Standard behavioral weight loss|University-based behavioral weight loss treatment
62271514|NCT03664999||Parturients with risk pregnancy|Parturients undergoing caesarean with risk of complications (pre-eclampsia, HELLP syndrom, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
62271515|NCT04648384|EXPERIMENTAL|Protein Supplementation and Resistance exercise|Protein supplementation composed of 20 gram of whey protein or casein in different proportions (80:20) and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
62634124|NCT02824627|EXPERIMENTAL|Oxytocin|Subjects weighing \>40kg will receive a total of 24 IU of oxytocin delivered as 2- 6 IU puffs to each nostril once daily. Subjects weighing \< 40kg will receive a total of 12 IU of oxytocin delivered as 1- 6 IU puff to each nostril daily. Subjects will receive 14 to 21 days of daily oxytocin administration.
62066530|NCT00827593|ACTIVE_COMPARATOR|Weight Watchers|Weight Watchers program
62066531|NCT00827593|ACTIVE_COMPARATOR|Combined Treatment|University-based behavioral weight loss treatment followed by Weight Watchers
62634125|NCT02824627|PLACEBO_COMPARATOR|Placebo|Subjects weighing\>40kg will 2 puffs of placebo to each nostril daily. Subjects weighing \<40kg will receive 1 puff per day. Subjects will receive 14-21 days of placebo administration.
62066532|NCT05942352|PLACEBO_COMPARATOR|Placebo|Enrolled participants would accept intravenous administration of 250ml saline per day for 15 days, then 50 mg placebo tablet by mouth would be maintained for 1 year.
62066533|NCT05942352|EXPERIMENTAL|Ligustrazine short-term treatment|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days. Then, a 50 mg placebo tablet by mouth would be maintained for 1 year
62066534|NCT05942352|EXPERIMENTAL|Ligustrazine maintenance treatment|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days，then, a 50 mg Ligustrazine tablet by mouth would be maintained for 1 year.
62066535|NCT03059875|OTHER|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
62271516|NCT04648384|PLACEBO_COMPARATOR|Placebo Supplementation|Placebo supplementation composed of 20 gram of Maltodextrin and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
62271517|NCT04648384|EXPERIMENTAL|Resistance Training|Resistance Exercise will be performed before supplementation and is composed by 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise.
62271518|NCT02095535||Study group|All study participants
62271519|NCT01596998|ACTIVE_COMPARATOR|Levobupivacaine without epinephrine|
62271520|NCT01596998|EXPERIMENTAL|Levobupivacaine with epinephrine|
62271521|NCT02573155|EXPERIMENTAL|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
62271522|NCT02573155|EXPERIMENTAL|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
62271523|NCT02573155|EXPERIMENTAL|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
62634126|NCT02862145|EXPERIMENTAL|Treatment with MRX34|Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.
62634127|NCT06298955|EXPERIMENTAL|OMS906 study drug|OMS906 study drug repeat-dose 5 mg/kg IV administration at 8-week intervals.
62634128|NCT04754815|EXPERIMENTAL|Pembrolizumab + Pemetrexed|Pembrolizumab 200mg intravenous (IV) infusion on Day 1 of each 21 day cycle. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity + pemetrexed 500mg intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21 day cycle up to 35 cycles or until disease progression.
62634129|NCT04754815|EXPERIMENTAL|Pembrolizumab + Paclitaxel OR Paclitaxel|"Pembrolizumab 200mg intravenous (IV) infusion on Day 1 of each 21 day cycle. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity~+ Paclitaxel 100 mg/m2 intravenous (IV) infusion on days 1 and 8 of each 21 day treatment cycle~OR Paclitaxel100 mg/m2 intravenous (IV) infusion on days 1 and 8 of each 21 day treatment cycle until disease progression."
62634130|NCT00441285|ACTIVE_COMPARATOR|I. ABZ + ABZ Placebo + PZQ|Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
62634131|NCT00441285|ACTIVE_COMPARATOR|II.- ABZ + ABZ Placebo + PZQ Placebo|Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
62634132|NCT00441285|ACTIVE_COMPARATOR|III .- Albendazole + PZQ Placebo|"Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward."
62634133|NCT02212119|PLACEBO_COMPARATOR|Saline|Saline injection up to 5 cc in arm with paratonia (one time injection)
62634134|NCT02212119|ACTIVE_COMPARATOR|Botulinum Toxin|Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)
62271524|NCT02573155|EXPERIMENTAL|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
62271525|NCT02573155|EXPERIMENTAL|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
62271526|NCT02573155|EXPERIMENTAL|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
62271527|NCT02573155|EXPERIMENTAL|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
62271528|NCT02573155|EXPERIMENTAL|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
62271529|NCT02573155|EXPERIMENTAL|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
62271530|NCT02573155|EXPERIMENTAL|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
62271531|NCT02573155|EXPERIMENTAL|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
62271532|NCT02573155|EXPERIMENTAL|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
62271533|NCT02573155|EXPERIMENTAL|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
62271534|NCT02573155|EXPERIMENTAL|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
62271535|NCT02573155|EXPERIMENTAL|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
62634135|NCT00849069|EXPERIMENTAL|Group A|
62634136|NCT00849069|ACTIVE_COMPARATOR|Group B|
62634137|NCT03932461|ACTIVE_COMPARATOR|Vacuum assisted closure|The VAC® Abdominal Dressing System (KCI Vacuum Assisted Closure, San Antonio, TX, USA) will be used. Intestines, including lateral aspects, are covered by the visceral protective layer. The first layer of foam is placed in the laparostoma on the visceral protective layer and must extend below the fascia at a distance of 5 cm from the facial opening. Above this, a minimum of one piece of foam is folded and placed in the laparostoma. Finally, the laparostoma will be covered by the occlusive drape. A circular opening of approximately 5 cm in diameter will be created in the drape where the connection tubes to the vacuum pump will be placed. Simultaneously while applying the negative pressure of 125 mmHg, the wound edges are approximated manually towards the midline. Each dressing change must be performed in the operation theatre with the patient in general anesthesia and muscle relaxation.
62066536|NCT03059875|OTHER|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
62066537|NCT05199805|EXPERIMENTAL|Mindfulness-based pain management|The program consists of sessions of 150 minutes once a week over the course of 8 weeks. Treatment as usual is allowed.
62066538|NCT05199805|NO_INTERVENTION|Waiting-List|The control group will receive no active intervention in addition to treatment as usual during the study period.
62066539|NCT01103960|EXPERIMENTAL|Telmisartan80mg+Amlodipine5mg|combination therapy
62066540|NCT01103960|ACTIVE_COMPARATOR|amlodipine 5 mg|Monotherapy
62066541|NCT04998305|EXPERIMENTAL|Treatment sequence TJ-68-Placebo-Placebo-TJ-68|"Employing an N-of-1, crossover design, each participant in the TJ-68 clinical trial will serve as his/her control. The participation will last for 11 weeks - four, 2-week treatment periods with 1-week washout (WO) period between each treatment period. Participants (n=13) will be randomized to the following treatment sequences:~TJ-68, placebo, placebo, TJ-68 (1 week WO between each treatment period)"
62066542|NCT04998305|EXPERIMENTAL|Treatment sequence Placebo-TJ-68-TJ-68-Placebo|"Employing an N-of-1, crossover design, each participant in the TJ-68 clinical trial will serve as his/her control. The participation will last for 11 weeks - four, 2-week treatment periods with 1-week washout (WO) period between each treatment period. Participants (n=13) will be randomized to the following treatment sequences:~placebo, TJ-68, TJ-68, placebo (1 week WO between each treatment period)"
62066543|NCT02904902|EXPERIMENTAL|Adalimumab|Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).
62066544|NCT02117934|EXPERIMENTAL|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
62066545|NCT02117934|ACTIVE_COMPARATOR|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
62066546|NCT05141903||Arm 1|Antibiotic conditioning
62066547|NCT05141903||Arm 2|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
62066548|NCT05141903||Arm 3|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
62066549|NCT05141903||Arm 4|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
62066550|NCT05141903||Arm 5|Antibiotic conditioning and probiotic treatment.
62066551|NCT05977920|OTHER|Only one Arm|s. description
62066552|NCT06428461|ACTIVE_COMPARATOR|Total of 15 mL.|For the control group, we plan to use a mixture of 7.5 mL of 0.5% bupivacaine (BUVİCAİNE®) and 7.5 mL of 2% prilocaine (PRİLOC®) for a total of 15 mL. single shot supraclavicular brachial plexus block.
62066553|NCT06428461|ACTIVE_COMPARATOR|Total of 20 mL.|For the research group, we plan to use a mixture of 10 mL of 0.5% bupivacaine (BUVİCAİNE®) and 10 mL of 2% prilocaine (PRİLOC®) for a total of 20 mL.
62066554|NCT06428461|ACTIVE_COMPARATOR|Total of 25 mL.|For the research group, we plan to use a mixture of 12.5 mL of 0.5% bupivacaine (BUVİCAİNE®) and 12.5 mL of 2% prilocaine (PRİLOC®) for a total of 25 mL.
62066555|NCT06428461|ACTIVE_COMPARATOR|Total of 30 mL.|For the research group, we plan to use a mixture of 15 mL of 0.5% bupivacaine (BUVİCAİNE®) and 15 mL of 2% prilocaine (PRİLOC®) for a total of 30 mL.
62066556|NCT04435171||Open renal transplantation|Patients who were performed open renal transplantation due to end stage renal disease.
62066557|NCT04435171||robot assisted renal transplantation|Patients who were performed robot assisted renal transplantation due to end stage renal disease
62066558|NCT00184483|EXPERIMENTAL|Lichtenstein's operation|Patients with a primary unilateral inguinal hernia are randomized to Lichtenstein's operation to repair their groin hernia
62066559|NCT00184483|ACTIVE_COMPARATOR|Prolene Hernia System|Patients with a primary unilateral inguinal hernia are randomized to Prolene Hernia System to repair their groin hernia
62066560|NCT01014975|EXPERIMENTAL|20 mg Plasmin (Human)|20 mg of Plasmin (Human)
62066561|NCT01014975|EXPERIMENTAL|40 mg Plasmin (Human)|40 mg of Plasmin (Human)
62066562|NCT01014975|EXPERIMENTAL|80 mg Plasmin (Human)|80 mg of Plasmin (Human)
62066563|NCT00683280|ACTIVE_COMPARATOR|Standard of Care|Medication (varenicline) for 12 weeks (Day 1 through 84) and brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35).
62271536|NCT02573155|EXPERIMENTAL|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
62066564|NCT00683280|EXPERIMENTAL|Standard of Care plus Contingency Management|Medication (varenicline) for 12 weeks (Day 1 through 84), brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35), plus prize-based contingency management for carbon monoxide samples and urinary cotinine samples that meet smoking abstinence criteria.
62066565|NCT02507882|EXPERIMENTAL|HCC|This group will include patients with chronic hepatitis C (no. =135)
62066566|NCT02507882|EXPERIMENTAL|HCC with Cirrhosis|This group will include patients with chronic hepatitis C (no. =135) with cirrhosis (F4).
62066567|NCT02507882|EXPERIMENTAL|HCV related HCC patients|This group will include patients with HCV related HCC (no. =135) This is confirmed by presence of focal lesion detected by Imaging (computed tomography (CT) and ultrasound), and elevated serum AFP.
62066568|NCT01118455|EXPERIMENTAL|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
62066569|NCT01118455|EXPERIMENTAL|Anti-Epileptic Drug (AED)|This arm will supply a comparison between VNS and new AEDs which is necessary to determine an overall treatment regimen for the 30% to 40% of patients who fail to respond to 2 AEDs.
62271537|NCT02573155|EXPERIMENTAL|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
62271538|NCT02573155|EXPERIMENTAL|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
62271539|NCT04485520|EXPERIMENTAL|Carica Papaya extract|Carica Papaya at 3%
62271540|NCT04485520|ACTIVE_COMPARATOR|Chlorhexidine|0.12% chlorhexidine mouthwash formulation (commercially available)
62066570|NCT02650232|OTHER|Young Healthy Volunteers|We will evaluate in this group (18 - 40 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
62066571|NCT02650232|OTHER|Old Healthy Volunteers|We will evaluate in this group (50 - 80 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
62066572|NCT02650232|OTHER|Patients with heart failure|We will evaluate in this group (50 - 80 y + Heart failure) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
62271541|NCT04884230||Group A|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
62271542|NCT04884230||Group B|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
62066573|NCT06624397|EXPERIMENTAL|CAREFREE is a 12-session Carer's Programme|This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE programme is unique in its focus on providing a framework for understanding AN from a Schema Therapy - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.
62066574|NCT03191929|EXPERIMENTAL|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
62066575|NCT03191929|ACTIVE_COMPARATOR|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
62066576|NCT00994786|EXPERIMENTAL|pregabalin|
62066577|NCT00994786|PLACEBO_COMPARATOR|Placebo|
62066578|NCT05424224||patients with depression|patients with depression
62066579|NCT03455296|ACTIVE_COMPARATOR|central venous oxygen saturation ScVO2 normalization|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%
62066580|NCT03455296|ACTIVE_COMPARATOR|Lactate clearance|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study
62066581|NCT02467322|EXPERIMENTAL|Albumin|MVP (Moderate Volume Paracentesis) of less than 5 liters with iv albumin at a dose 8 gms/l of ascitic fluid.
62066582|NCT02467322|ACTIVE_COMPARATOR|No Albumin|MVP(Moderate Volume Paracentesis) of less than 5 liters without albumin.
62066583|NCT01802814|NO_INTERVENTION|SR-A|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
62066584|NCT01802814|ACTIVE_COMPARATOR|SR-A + Epratuzumab|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab. This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
62066585|NCT01802814|NO_INTERVENTION|SR-B|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab. This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
62066586|NCT01802814|ACTIVE_COMPARATOR|SR-B + Epratuzumab|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab. This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
62066587|NCT02420145|EXPERIMENTAL|Yoga|This group will participate in 12 weeks of yoga
62066588|NCT02420145|NO_INTERVENTION|Waitlist|No intervention
62066589|NCT03542097||Temozolomide and Irinotecan treatment|The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done
62066590|NCT01780129|EXPERIMENTAL|Polydatin Injectable (HW6)|10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
62066591|NCT01780129|PLACEBO_COMPARATOR|HW6 blank dummy (0.9%NaCl)|10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
62453052|NCT06236737|EXPERIMENTAL|Sensorimotor Exercise Group|Sensorimotor exercise group; oculomotor exercise to provide information from the visual system, laser target exercise to provide information from the proprioception system, and postural stability exercise to provide information from the vestibular system. Within the scope of oculomotor exercise, gaze stability exercise and head-body coordination exercise will be given to the participants. Laser target exercise will be given with the laser target fixed on the participant's head and 90 cm away from the target. Postural stability exercise will be given in the form of tandem exercise and standing on one leg.
62066592|NCT05761574|EXPERIMENTAL|Acetaminophen/Naproxen Sodium Fixed Combination|Participants will receive a single oral dose of two Acetaminophen/Naproxen Sodium Fixed Combination tablets.
62066593|NCT05761574|ACTIVE_COMPARATOR|Naproxen Sodium|Participants will receive a single oral dose of one Naproxen Sodium tablet with one Placebo capsule.
62066594|NCT05761574|ACTIVE_COMPARATOR|Acetaminophen|Participants will receive a single oral dose of two Acetaminophen tablets.
62066595|NCT05761574|PLACEBO_COMPARATOR|Placebo|Participants will receive a single oral dose of two Placebo capsules.
62066596|NCT03434457||Prenatal and 3 to 72 months|
62066597|NCT02238717|EXPERIMENTAL|PF-06372865 (65mg)|
62066598|NCT02238717|EXPERIMENTAL|PF-06372865 (15mg)|
62066599|NCT02238717|ACTIVE_COMPARATOR|Pregabalin|
62066600|NCT02238717|PLACEBO_COMPARATOR|Placebo|
62066601|NCT04710043|EXPERIMENTAL|Part 1 group A BNT153|Monotherapy dose escalation.
62271543|NCT00097760|EXPERIMENTAL|Group 1|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
62271544|NCT00097760|PLACEBO_COMPARATOR|Group 2|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
62271545|NCT06539923||T2DM patients|patients with definite type 2 diabetes diagnosis
62066602|NCT04710043|EXPERIMENTAL|Part 1 group B BNT152|Monotherapy dose escalation.
62271546|NCT05701332|EXPERIMENTAL|BCG|6 doses of intravesical BCG
62271547|NCT04321759|EXPERIMENTAL|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
62066603|NCT04710043|EXPERIMENTAL|Part 2A - BNT152+153|Escalating dose levels up to RP2D
62066604|NCT04710043|EXPERIMENTAL|Part 2B - BNT152+153|Escalating dose levels up to RP2D
62066605|NCT04710043|EXPERIMENTAL|Part 2C - BNT152+153|Escalating dose levels up to RP2D
62066606|NCT04710043|EXPERIMENTAL|Part 2 - BNT152+153 - biomarker cohort|
62066607|NCT02035332|EXPERIMENTAL|Aurora Treatment Arm|Endometrial Ablation
62066608|NCT01533571|ACTIVE_COMPARATOR|Immediate implant + xenogenic graft|Treatment with immediate implant and GBR using xenogenic bone graft material
62271548|NCT04321759|ACTIVE_COMPARATOR|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health..
62271549|NCT00590590|PLACEBO_COMPARATOR|3 (Placebo)|
62271550|NCT00590590|EXPERIMENTAL|1 (Lidocaine)|
62271551|NCT00590590|EXPERIMENTAL|2 (Lidocaine/Diphenhydramine)|
62286937|NCT02813772|EXPERIMENTAL|group 1|Patients with infantile colics who will receive the milk formula NAN Sensitive, Nestlè
62066609|NCT01533571|ACTIVE_COMPARATOR|Immediate implant + allogenic graft|Treatment with immediate implant and GBR using allogenic bone graft material.
62066610|NCT06623058||Infected patients with hepatitis C virus|Infected patients with hepatitis C virus
62066611|NCT02424409|ACTIVE_COMPARATOR|1: Control|
62066612|NCT02424409|EXPERIMENTAL|2: Intervention|
62066613|NCT02479516|EXPERIMENTAL|CHAPP intervention communities|"CHAPP intervention: The proposed CHAPP intervention will include:~* Diabetes risk assessment (modified FINRISK and assessment of lifestyle risk behaviours) sessions be at least every 2 weeks in accessible community locations, manned by trained volunteers of LLO~* Volunteers educate CHAPP participants regarding their diabetes risk factors and ways to practice healthy lifestyle (including referral to local resources/activities) using diabetes education materials adapted for local context~* Use of an accepted process have participant data transmitted to a central web database system through a combination of cell-phone and computer-based technology~* Have participant assessment result forwarded to the Municipal Health Officer (doctor) for follow-up and screening"
62066614|NCT02479516|NO_INTERVENTION|Delayed Intervention communities|
62066615|NCT04496141||With COVID-19 infection|Subjects with a positive SARS-CoV-2 PCR
62066616|NCT04496141||Without COVID-19 infection|Subjects with COVID-19 negative serum
62271552|NCT05520983|ACTIVE_COMPARATOR|Illinois MCHB Care Coordination|MCHB Care Coordination is funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, this is the oldest and most universal care coordination model for children with I/DD. The University of Illinois Chicago Division of Specialized Care for Children (DSCC) is the Illinois (IL) state Title V MCHB care coordination agency and has annual contact with over 19,000 families and youth in IL. MCHB (known as DSCC) Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
62271553|NCT05520983|EXPERIMENTAL|Illinois MCHB Care Coordination + CHECK tiered behavioral health|MCHB Care Coordination plus CHECK: includes all elements of MCHB care coordination, described above, plus the CHECK program. The CHECK program consists of a trained, behavioral health care team; an evidence-based treatment algorithm to classify risk for depression and anxiety (minimal, subclinical and clinical symptomatology) and guide treatment advancement \[Tier 1/selective: cognitive behavioral psycho-education; Tier 2/indicated: cognitive-behavioral prevention groups; Tier 3/treatment: individualized or group cognitive-behavioral treatment (CBT)\]; as well as structures and processes to support communication, coordination and data sharing between MCHB care coordinators and CHECK staff.
62271554|NCT05945953|EXPERIMENTAL|Incentive spirometer as visual feedback|
62453053|NCT06236737|EXPERIMENTAL|Yoga Exercise Group|Yoga group will be given yoga exercises including 14 poses. These exercises are: bridge pose, corpse pose, bharadvaja's twist, downward facing dog, downward facing hero, extended side angle, extended triangle, mountain pose, prosperous pose, reclining big toe, standing half forward bend, thunderbolt pose, upward hand
62634138|NCT03932461|ACTIVE_COMPARATOR|"Relaparotomy on-demand"|"The Isreaelsson principle includes a running suture of the fascia with a distance of 5 mm between the stitches of 5 mm and the distance to the facial edge of 5-10 mm. Monofilament PDS 2-0 or equivalent is used. The suturing is started cranially and caudally, and the sutures are tied with self-locking knots. Four times as much suture material as the length of the wound must be used. The peritoneal fluid must be cultured at closure.~The treating surgeon decides to perform a ROD and should be guided by the patient's general condition, gastrointestinal function, renal function, and inflammatory parameters at daily rounds."
62066617|NCT06203652||All enrolled patients|All patients who are eligible for participation to the study.
62066618|NCT04576819||Sepsis cohort|"Inclusion criteria~* Patients meeting the Sepsis-3 definition of sepsis or septic shock (the sequential organ failure assessment (SOFA) score will be used for organ failure assessment for Sepsis-3 criteria)~* Treatment with an institutional, evidence-based guideline management bundle for sepsis~* Within 24 hrs of sepsis recognition~Exclusion criteria:~* alternative/confounding diagnosis causing shock (e.g., myocardial infarction or pulmonary embolus),~* uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),~* advanced directives limiting resuscitative efforts,~* organ transplant recipient on immunosuppressive agents,~* known pregnancy,~* inability to obtain informed consent,~* HIV/AIDS with CD4 count \< 200,~* absolute neutrophil count \< 500"
62066619|NCT02990416|EXPERIMENTAL|A-dmDT390-bisFv(UCHT1)/Radiation/Pembrolizumab|A-dmDT390-bisFv(UCHT1): 2.5 µg/kg 2x x 4 days, Ionizing Radiation: single treatment on day five of 14-24 Gy to a tumor, Pembrolizumab: 2 mg/kg IV every 3 weeks
62066620|NCT03758014|EXPERIMENTAL|Chlorogenic Acid for Injection|3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
62066621|NCT03758014|ACTIVE_COMPARATOR|Lomustine|110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles
62066622|NCT06425926|EXPERIMENTAL|Phase 1 Single Agent|GIM-531 administered orally daily
62066623|NCT06425926|EXPERIMENTAL|Phase 2 Combination Treatment|GIM-531 administered orally daily in combination with anti-PD-1 therapy
62066624|NCT03736564|EXPERIMENTAL|68Ga-DOTATATE PET/CT|Subjects will undergo imaging by 68Ga-DOTATATE PET/CT
62066625|NCT01965158|EXPERIMENTAL|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
62066626|NCT01965158|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo orally once daily for 12 weeks.
62066627|NCT01764763||non epiaortic group|non epiaortic group ( n=1019)
62271555|NCT05945953|ACTIVE_COMPARATOR|Diaphragmatic breathing exercise (Mirror mediated therapy)|
62271556|NCT03682497|ACTIVE_COMPARATOR|Spironolactone|Spironolactone treatment for 28 days
62271557|NCT03682497|EXPERIMENTAL|AZD9977|AZD9977 treatment for 28 days
62634139|NCT06086938|ACTIVE_COMPARATOR|active TBS group|active TBS combined with speech language therapy
62066628|NCT01764763||epiaortic group|epiaortic group ( n=1273)
62271558|NCT04079270|EXPERIMENTAL|Personalized algorithm-based diet|The intervention arm will be an 'algorithm-based' arm in which patients will receive personally tailored dietary recommendations, based on their microbiome, and other clinical data such as blood tests and lifestyle features.
62286938|NCT02813772|ACTIVE_COMPARATOR|group 2|Patients with infantile colics who will receive the milk formula NAN Optipro, Nestlè
62271559|NCT04079270|ACTIVE_COMPARATOR|standard Mediterranean low-fat diet|The control arm will receive nutritional recommendations according to the standard Israeli dietary approach Mediterranean-style low-fat diet.
62271560|NCT03298022|EXPERIMENTAL|ALTB-168|intravenous doses of ALTB-168
62634140|NCT06086938|SHAM_COMPARATOR|sham TBS group|sham TBS combined with speech language therapy
62271561|NCT04937088|PLACEBO_COMPARATOR|Placebo|Soy Bean Oil identical packaging as the active arm, taken once daily by mouth for 30 days.
62453054|NCT01151813|ACTIVE_COMPARATOR|Varenicline|Varenicline, oral administration for 1 week
62634141|NCT01454011|ACTIVE_COMPARATOR|Testosterone 250mg injection,|
62634142|NCT01454011|ACTIVE_COMPARATOR|Testosterone transdermal application|
62634143|NCT06108908||Intervention Group|"1. Patients (compliance rate \<80%) received active contact to remind on regular use of medication.~2. The intervention is engaged in caring aspect behavior. None of regular asthma treatment is altered between groups."
62634144|NCT06108908||Control|Patients were not informed regardless to their compliance rate.
62634145|NCT02976610|NO_INTERVENTION|1|This is the control group where no intervention takes place. Blood sampling carried out according to routine at the emergency department.
62271562|NCT04937088|ACTIVE_COMPARATOR|Liquid ASA|Aspirin 150 mg liquid formulation (2.5%w/w) taken once daily by mouth for 30 days
62271563|NCT00467454|ACTIVE_COMPARATOR|1|Naltrexone
62271564|NCT00467454|PLACEBO_COMPARATOR|2|Placebo
62271565|NCT00548496|EXPERIMENTAL|Placebo-Controlled based on the two Intervention Groups below|Placebo-Controlled based on the two Intervention Groups below.
62453055|NCT01151813|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration for 1 week
62453056|NCT05905848|EXPERIMENTAL|RASI group|Administer RASI, with or without other antihypertensives except for CCB, and blood pressure should be controlled within the target range (140/90 mmHg). RASI intaking starts at least 5 days before stenting.
62634146|NCT02976610|EXPERIMENTAL|2|"During the blood sampling the health care professional will screen all vacuum Lithium Heparin tubes, with the Hemolysis point-of-care test (H-POCT). If the health care professional receives a negative test the bloodsample is sent to the local laboratory.~If H-POCT indicates a positive test, of free hemoglobin in plasma, the bloodsample and H-POCT will be discarded and a new sample will be collected and screened for hemolysis. This can be repeated 3 times."
62634147|NCT01704807|ACTIVE_COMPARATOR|Intervention, Custom Orthotics|Wearing custom foot orthotics
62634148|NCT01704807|SHAM_COMPARATOR|Sham Foot Orthotic|Wearing sham or flat shoe insoles
62634149|NCT04531423|EXPERIMENTAL|SSRI + golimumab|Participants will be administered with SSRI+golimumab . Golimumab will be administered at the dose of 50mg every month during the acute phase.
62271566|NCT01965262|ACTIVE_COMPARATOR|Hema-copolymer Lens|Participants were randomized to wear the Hema-copolymer lens pair for one week during the cross over study.
62271567|NCT01965262|ACTIVE_COMPARATOR|etafilcon A Lens|Participants were randomized to wear the etafilcon A lens pair for one week during the cross over study.
62271568|NCT03303794|ACTIVE_COMPARATOR|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
62271569|NCT03303794|EXPERIMENTAL|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
62453057|NCT05905848|ACTIVE_COMPARATOR|CCB group|Administer CCB, with or without other antihypertensives except for RASI, and blood pressure should be controlled within the target range (140/90 mmHg). CCB intaking starts at least 5 days before stenting.
62453058|NCT01420783|EXPERIMENTAL|SAR302503 100 mg|once daily X 28 days
62634150|NCT04531423|ACTIVE_COMPARATOR|SSRI +placebo|Participants will be administered with SSRI+placebo
62634151|NCT03157076|ACTIVE_COMPARATOR|Pacing mode with CLS|
62634152|NCT03157076|ACTIVE_COMPARATOR|Intrinsic mode|
62634153|NCT00889941|ACTIVE_COMPARATOR|small|
62634154|NCT00889941|ACTIVE_COMPARATOR|medium|
62634155|NCT00889941|ACTIVE_COMPARATOR|large|
62634156|NCT04273516|EXPERIMENTAL|Intervention|Tablet Rivaroxaban 2.5 mg 2 times daily plus ASA 80 mg daily
62634157|NCT04273516|PLACEBO_COMPARATOR|Comparator|Tab ASA 80 mg daily plus placebo ( similar to rivaroxaban tablet) 2 times daily
62271570|NCT06374823|EXPERIMENTAL|Multiple Electrolyte|Multiple Electrolytes Injection(II): contains sodium chloride 6.799g, potassium chloride 0.2984g, calcium chloride 0.3675g, magnesium chloride 0.2033g, sodium acetate 3.266g, L-malic acid 0.671, sodium hydroxide 0.200g per 1000mL.
62271571|NCT06374823|ACTIVE_COMPARATOR|Normal Saline|Sodium chloride injection: contains sodium chloride 9.0g per 1000mL.
62271572|NCT03402607|ACTIVE_COMPARATOR|Percutaneous Local Ablation (PLA)|A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
62271573|NCT03402607|ACTIVE_COMPARATOR|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
62453059|NCT01420783|EXPERIMENTAL|SAR302503 200 mg|once daily X 28 days
62453060|NCT01420783|EXPERIMENTAL|SAR302503 400 mg|once daily X 28 days
62453061|NCT01420783|EXPERIMENTAL|SAR302503 600 mg|once daily X 28 days
62453062|NCT01938950|ACTIVE_COMPARATOR|Aerobic Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals at 40-65% of VO2peak, three times per week, for 60 minutes/session.
62453063|NCT01938950|ACTIVE_COMPARATOR|Resistance Exercise|Participants will perform 2 sets (8-12 repetitions per set) of 8 exercises to the point of failure using weight stack equipment, three times per week, for 60 minutes/session. 2 sets of push-ups and sit-ups will also be performed.
62453064|NCT01938950|ACTIVE_COMPARATOR|Aerobic and Resistance Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals for 30 min at 40-65% of VO2peak and thereafter, perform 1 set of each of the above 10 resistance exercise for 30 min.
62453065|NCT00418470|EXPERIMENTAL|A|Higher concentration of antibiotic in NS
62066629|NCT06615505|ACTIVE_COMPARATOR|VIA Disc NP|
62066630|NCT06615505|SHAM_COMPARATOR|Sham Arm|
62066631|NCT00615134|EXPERIMENTAL|1|
62453066|NCT00418470|EXPERIMENTAL|B|Lower concentration of antibiotic in NS
62453067|NCT04384549|EXPERIMENTAL|BCG Arm|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
62066632|NCT00615134|ACTIVE_COMPARATOR|2|
62453068|NCT04384549|PLACEBO_COMPARATOR|PLACEBO Arm|One intradermal placebo injection.
62634158|NCT01442662|EXPERIMENTAL|pazopanib, gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
62271574|NCT01829256|EXPERIMENTAL|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
62634159|NCT03150329|EXPERIMENTAL|Vorinostat 100mg + Pembrolizumab 200mg|Patients receive Vorinostat 100mg PO BID on days 1-5 and 8-12 and pembrolizumab 200mg IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
62634160|NCT03150329|EXPERIMENTAL|Vorinostat 200mg + Pembrolizumab 200mg|Patients receive Vorinostat 200mg PO BID on days 1-5 and 8-12 and pembrolizumab 200mg IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
62634161|NCT05686447||Multiple myeloma|Multiple myeloma (MM) is a hematologic malignant tumor characterized by abnormally cloned plasma cells in bone marrow, whose growth can lead to destructive bone injury, acute kidney injury, anemia, and hypercalcemia.
62634162|NCT05686447||Healthy control|Individuals in good health without obvious disease and with normal physical examination report; Avoid people who have not suffered from major chronic diseases in recent years, such as hypertension, diabetes, chronic kidney disease, etc; controls were appropriately selected that matched cases for age and sex.
62453069|NCT01031537|OTHER|FSME-IMMUN 0.5mL Baxter|FSME-IMMUN 0.5mL Baxter is non-US licensed vaccine for tick-borne encephalitis virus. The FSME-IMMUN 0.5mL Baxter is available as 0.5mL in a pre-loaded vaccine syringe. All participants received active vaccine using a rapid immunization schedule, with vaccine administration on Days 0, 14, 161 and 245. Participants that tested seropositive for tick-borne encephalitis virus or subjects that developed positive viral neutralizer titers after the 3rd or 4th vaccine were given a booster of FSME-IMMUN 0.5mL Baxter vaccine at 3, 6 and 9 years after enrollment.
62634163|NCT03035565|EXPERIMENTAL|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
62634164|NCT03035565|ACTIVE_COMPARATOR|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
62634165|NCT03035565|NO_INTERVENTION|Usual Care|No computerized cognitive intervention
62271575|NCT01829256|NO_INTERVENTION|Education Control|Will receive educational material about management of kidney disease
62271576|NCT05047757|EXPERIMENTAL|Fava bean|The intervention consists in a test meal containing 250 g of cooked and peeled favabean, to provide 20 g protein. Fava bean are intrinsically labelled with 15N.
62271577|NCT05453617|EXPERIMENTAL|The TRE group|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
62271578|NCT05453617|EXPERIMENTAL|The 5:2 diet group|Participants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
62271579|NCT05453617|NO_INTERVENTION|Control|Participants in the control group will receive a general lifestyle counseling.
62271580|NCT06302218|ACTIVE_COMPARATOR|iPACK + ACB|"spinal anesthesia~+ ultrasound guided iPACK (20ml 0,2% ropivacaine) with ACB (10ml 0.5% ropivacaine)"
62271581|NCT06302218|ACTIVE_COMPARATOR|Erectro Spinae Plane Block|"spinal anesthesia~+ ultrasound guided ESPBk - 20ml 0,2% ropivacaine"
62271582|NCT06302218|PLACEBO_COMPARATOR|Control group|Only spinal anesthesia - No peripheral nerve block
62271583|NCT00868946|EXPERIMENTAL|Treatment with IND Ribavirin|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with IND Virazole (Ribavirin) for 7 days with multiple dosing regime based on weight and dosage day.
62271584|NCT02200380|EXPERIMENTAL|CDX-301|
62271585|NCT02200380|EXPERIMENTAL|CDX-301 and plerixafor|
62271586|NCT04687696|EXPERIMENTAL|Post Isometric Relaxation Group|The participants in this group will perform post isometric relaxation stretching in modified cross body position for 6 weeks.
62634166|NCT01932697|EXPERIMENTAL|Treatment (docetaxel, hyperfractionated IMRT)|Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID 5 days a week on days 1-12 for a total of 20 fractions.
62634167|NCT04990193|ACTIVE_COMPARATOR|Control group|Children in the control group received the conventional physical therapy protocol which was designed to improve axial stability and trunk steadiness during standing and walking.
62634168|NCT04990193|EXPERIMENTAL|Study group|The children in the study group received the conventional protocol given to the control group. Moreover, they wore TheraTog orthotic undergarment with its strapping system eight hours every day for twelve consecutive weeks.
62634169|NCT01116037|OTHER|ATS 3f Aortic Bioprosthesis|ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
62634170|NCT04464746|NO_INTERVENTION|Control|usual medical follow-up
62271587|NCT04687696|EXPERIMENTAL|Isolytic Stretching Group|The participants in this group will perform isolytic stretching in modified cross body position for 6 weeks..
62271588|NCT04687696|EXPERIMENTAL|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position for 6 weeks.
62271589|NCT05997641|EXPERIMENTAL|DF-003 (Single Ascending Dose, Part 1)|Participants will receive a single oral dose of 3 mg DF-003 (1 mg x 3).
62271590|NCT05997641|PLACEBO_COMPARATOR|Placebo (Single Ascending Dose, Part 1)|Visually matching 0 mg DF-003 capsules.
62271591|NCT05997641|EXPERIMENTAL|DF-003 (Multiple Ascending Doses, Part 2)|Participants will receive DF-003 once daily by oral administration for 14 days. The specific doses given will be based on data collected in Part 1 of the study. This part of the study may include 1 mg, 5 mg, or 25 mg capsules.
62271592|NCT05997641|PLACEBO_COMPARATOR|Placebo (Multiple Ascending Doses, Part 2)|Visually matching 0 mg DF-003 capsules.
62271593|NCT02150590|ACTIVE_COMPARATOR|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
62271594|NCT02150590|PLACEBO_COMPARATOR|Sham oxygen|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
62271595|NCT04523506|EXPERIMENTAL|the temporomandibular joint (TMJ) group|This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The TMJ group will be injected with two units of Botox into four different injection points to each masseter (16 units of Botox total) at the initial visit. No additional Botox will be injected in subsequent visits. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1
62271596|NCT04523506|EXPERIMENTAL|the perioral group|Biological/Vaccine: Botulinum toxin(Botox) This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The perioral group will be injected with two units of Botox into eight different injection points (16 units of Botox total) around the lips (in the orbicularis oris). Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3.
62634171|NCT04464746|ACTIVE_COMPARATOR|Intervention|Implementation of a specific program to improve therapeutic adherence
62634172|NCT01983215|EXPERIMENTAL|negative pressure dressing vs. standard of care|single arm study- randomized Prevena vac or standard of care
62634173|NCT05758818|PLACEBO_COMPARATOR|A = Placebo (negative control)|"Dosage Form: Capsules~Route of Administration: Oral~The placebo and milademetan will be identical in appearance."
62634174|NCT05758818|ACTIVE_COMPARATOR|B = Moxifloxacin (positive control)|"Dosage Form: Tablets~Route of Administration: Oral~Dosage: 400 mg"
62634175|NCT05758818|EXPERIMENTAL|C = Milademetan|"Drug: Milademetan~Dosage:~Part 1: 300, 330, 360 mg. Part 2: 260 mg single oral dose or higher, as determined in Part 1."
62634176|NCT03631069||Dementia|People with hospital episode statistics labels of dementia
62634177|NCT03631069||Normal|
62271597|NCT03268915|EXPERIMENTAL|patient with idiopathic pulmonary fibrosis|
62271598|NCT01256073|EXPERIMENTAL|IPH2101|
62271599|NCT06239987|EXPERIMENTAL|Care-oriented group|Care-oriented practical training intervention is a 2-hour care-oriented applied group training program for intensive care nurses in groups of 13-15 people.
62271600|NCT05820425||Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS|Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS, using PERCEPT device (Medtronic)
62634178|NCT01563328|EXPERIMENTAL|Cohort 1|DTG x 5 days followed by BCV + DTG x 10 days
62634179|NCT01563328|EXPERIMENTAL|Cohort 2|DTG x 5 days followed by TVR + DTG x 10 days
62634180|NCT00919633|EXPERIMENTAL|Group 1: interferon alfa-2b (dose 1)|continuous subcutaneous infusion for 48 weeks
62271601|NCT00898560|OTHER|Microginon®|A single oral dose of a combined oral contraceptive containing 30ug ethinyloestradiol and 150ug levonorgestrel (Microginon ®).
62271602|NCT00898560|EXPERIMENTAL|ESL and Microginon®|15-day treatment with ESL 800 mg once daily, with co administration of a single oral dose of Microginin® on Day 14 of the relevant dosing period, to assess impact of ESL on pharmacokinetics of the combined oral contraceptive.
62271603|NCT05843552||patients with GD|
62271604|NCT05843552||obligate carriers|
62634181|NCT00919633|EXPERIMENTAL|Group 2: interferon alfa-2b (dose 2)|continuous subcutaneous infusion for 48 weeks
62634182|NCT00919633|EXPERIMENTAL|Group 3: interferon alfa-2b (dose 3)|continuous subcutaneous infusion for 48 weeks
62634183|NCT00919633|ACTIVE_COMPARATOR|Group 4: peginterferon alfa-2b (1.5 μg/kg)|subcutaneous weekly for 48 weeks
62634184|NCT05460299|EXPERIMENTAL|Telko plus conventional physical therapy (CPT)|All patients received 15-minute CPT, three times a week, for four weeks. The patients in the experimental group received 15-minute Telko at the end of each CPT session.
62634185|NCT05460299|ACTIVE_COMPARATOR|Conventional physiotherapy|All patients received 15-minute CPT, three times a week, for four weeks.
62634186|NCT04195061||Cardiopulmonary exercise testing|
62634187|NCT05890417|EXPERIMENTAL|Questionnaires|Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and at 6 months after starting hormone replacement therapy.
62271605|NCT05843552||healthy volunteers|
62634188|NCT05927168|EXPERIMENTAL|TENS group|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed.
62634189|NCT05927168|NO_INTERVENTION|Control group|TENS will not be applied to the control group
62634190|NCT02133430|EXPERIMENTAL|Bispectral index (BIS) group|Bispectral index as measured by a BIS Processor is used to guide doses of anesthetic for maintaining the BIS values of 40-60
62271606|NCT03741998|NO_INTERVENTION|THRIVE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction using jaw-thrust maneuver.
62634191|NCT02133430|NO_INTERVENTION|Control group|Clinical signs is used to guide doses of anestheitics.
62634192|NCT03134729|EXPERIMENTAL|Serratus Plane Loco-regional block|"* Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~* Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours~plus~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
62271607|NCT03741998|ACTIVE_COMPARATOR|THRIVE with nasopharyngeal airway|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction with nasopharyngeal airway.
62271608|NCT01733017|EXPERIMENTAL|sodium reduction, omega-3, lycopene|combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
62634193|NCT03134729|NO_INTERVENTION|Standard of Care|"* Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~* Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
62634194|NCT04085848|EXPERIMENTAL|Groupe intervention|Usual care and music therapy
62634195|NCT04085848|NO_INTERVENTION|Groupe contrôle|Usual care
62634196|NCT02797028|PLACEBO_COMPARATOR|Placebo capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule
62066633|NCT05516368|EXPERIMENTAL|TF-CBT|16 sessions of trauma-focused CBT adapted to victims of terrorism with long-term PTSD, major depressive disorder and/or anxiety disorders
62066634|NCT05516368|NO_INTERVENTION|Waiting list control|4 months of waiting list condition
62066635|NCT02704897|EXPERIMENTAL|Intervention Arm|"Wound assessment tool - delivered via a smartphone. A link will be sent to participants on discharge, which can be accessed at any point should they have concerns about their wound.~They will also be sent the tool at 3 additional time-points."
62066636|NCT02704897|NO_INTERVENTION|Control Arm|Normal Post-operative Care
62066637|NCT05981963|EXPERIMENTAL|[14C]-BMS-986196|
62066638|NCT01126554||Critically ill patients|
62634197|NCT02797028|EXPERIMENTAL|Anthocyanidins capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule.
62634198|NCT02797028|EXPERIMENTAL|Allopurinol|The experimental group taking allopurinol.
62634199|NCT06609486|EXPERIMENTAL|Blood pressure measurement group|"In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device."
62066639|NCT01981421||Liver fibrosis|patients who had chronic liver disease
62066640|NCT03788005|ACTIVE_COMPARATOR|Intervention group|"Early mobilization as soon as possible, within a maximum of 12 hours post-surgery.~Subdural drains will be closed when the patient is allowed to mobilize and will be open during a nocturnal period of 8 hours. Subdural drains will be removed past 48 hours of surgery."
62066641|NCT03788005|NO_INTERVENTION|Control Group|Bed rest with head of bed at 0 degrees for 48h. Subdural drains will be removed past 48 hours of surgery.
62066642|NCT04506749|EXPERIMENTAL|Experimental group|"Consumption of antioxidant boiled ham, 100 grams daily to consume during the day.~Consumption time: 8 weeks."
62066643|NCT04506749|PLACEBO_COMPARATOR|control group Placebo|Consumption of extra boiled ham, 100 grams daily to consume during the day. Consumption time: 8 weeks.
62066644|NCT02863718|NO_INTERVENTION|Watch & wait|Watch \& wait
62066645|NCT02863718|PLACEBO_COMPARATOR|Placebo 420 mg/d|Placebo 420mg/d
62066646|NCT02863718|ACTIVE_COMPARATOR|Ibrutinib 420mg/d|Ibrutinib 420mg/d
62066647|NCT05598177|EXPERIMENTAL|Group D|The participant will be infused with dexmedetomidine during anesthesia to protect the myocardium.
62066648|NCT05598177|PLACEBO_COMPARATOR|Group R|The participant will use saline of the same volume as dexmedetomidine as a placebo during anesthesia.
62066649|NCT03811106|ACTIVE_COMPARATOR|NMES + PT|NMES will be applied to the back muscles with the chattanooga intelect advanced device. In addition, conventional physiotherapy and rehabilitation applications will be made.
62066650|NCT03811106|OTHER|PT|Conventional physiotherapy and rehabilitation practices will be carried out.
62066651|NCT04203537|ACTIVE_COMPARATOR|CA-008 36 mg|Single administration (0.3 mg/mL concentration)
62066652|NCT04203537|ACTIVE_COMPARATOR|CA-008 60 mg|Single administration (0.5 mg/mL concentration)
62066653|NCT04203537|ACTIVE_COMPARATOR|CA-008 90 mg|Single administration (0.75 mg/mL concentration)
62066654|NCT04203537|PLACEBO_COMPARATOR|Placebo|Single administration
62634200|NCT03916445||gynecological cancer|all patients having a consultation doctor during the recruiting time
62634201|NCT03916445||chronic gynecological disease|all patients having a consultation doctor during the recruiting time
62634202|NCT03601195||Subjects|Chinese women carrying multiple pregnancies
62634203|NCT02848664||Dysphagia retraining with device|Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device
62634204|NCT05471388|ACTIVE_COMPARATOR|case|
62634205|NCT05471388|ACTIVE_COMPARATOR|control|
62634206|NCT03925337|EXPERIMENTAL|Arm-1 Standard Colonoscopy/AI-Assisted Combined Colonoscopy|Normal scope insertion and withdrawal first, followed by a second withdrawal with the research software running on a separate screen to catch any additional polyps missed during the first withdrawal.
62634207|NCT03925337|EXPERIMENTAL|Arm-2 AI-Assisted Combined Colonoscopy/Standard Colonoscopy|Normal scope insertion but first withdrawal with the research software running on a separate screen, followed by a second withdrawal without the research software running.
62634208|NCT02907242|NO_INTERVENTION|Concealment|Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight \<p10
62634209|NCT02907242|OTHER|Revealment|Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio \<p5
62066655|NCT04530357|EXPERIMENTAL|Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62066656|NCT04530357|PLACEBO_COMPARATOR|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62066657|NCT04530357|EXPERIMENTAL|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62066658|NCT04530357|EXPERIMENTAL|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62066659|NCT04530357|EXPERIMENTAL|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder
62634210|NCT04014010||Cohort|Patients ages ≥ 45 receiving their index (i.e. first) non-cardiac surgery with an overnight stay at the Nova Scotia Health Authority Queen Elizabeth II (QEII) hospitals (Victoria General and Halifax Infirmary) Halifax, Canada, from January 1, 2013 to December 1, 2017 will be included. Patients under going cardiac surgery or deceased organ donation will be excluded. Patients without an electronic anesthetic record during surgery will also be excluded. Preliminary analysis of the intraoperative database estimates approximately 35,000 patients in this cohort.
62634211|NCT01820897|EXPERIMENTAL|Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim, placebo|Fosfomycin-Trometamol 3 grams every 10 days for 6 months Plus Sulfamethoxazole trimethoprim 800/160 mg monday, wednesday and friday for 6 months Plus Placebo of Sulfamethoxazole trimethoprim Tuesday,thursday, saturday and sunday for 6 months.
62634212|NCT01820897|ACTIVE_COMPARATOR|Sulfamethoxazole trimethoprim, placebo|Sulfamethoxazole trimethoprim 800/160 mg every day for 6 months plus Placebo of Fosfomicyn-trometamol every 10 days for 6 months
62066660|NCT04530357|EXPERIMENTAL|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
62066661|NCT02599103|PLACEBO_COMPARATOR|fat-free milkshake|
62066662|NCT02599103|ACTIVE_COMPARATOR|Olive oil|
62066663|NCT02599103|EXPERIMENTAL|soybean oil|
62271609|NCT01733017|PLACEBO_COMPARATOR|Control|Limited nutritional counseling, juice without lycopene, rice oil capsules
62066664|NCT02599103|EXPERIMENTAL|fried soybean oil|
62066665|NCT02599103|EXPERIMENTAL|palm oil|
62066666|NCT02599103|EXPERIMENTAL|fried palm oil|
62066667|NCT02599103|EXPERIMENTAL|camellia oil|
62066668|NCT02599103|EXPERIMENTAL|fried camellia oil|
62066669|NCT02599103|EXPERIMENTAL|tallow|
62634213|NCT01660867|PLACEBO_COMPARATOR|0.9% saline + oral placebo|nebulized epinephrine + 0.9% saline + placebo =\> epinephrine + 0.9% saline
62634214|NCT01660867|EXPERIMENTAL|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline
62634215|NCT01660867|ACTIVE_COMPARATOR|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline
62634216|NCT02478515|EXPERIMENTAL|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
62271610|NCT03185390|OTHER|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
62271611|NCT05988801|EXPERIMENTAL|Glass ionomer sealant|glass ionomer based sealant material
62271612|NCT05988801|ACTIVE_COMPARATOR|Resin sealant|resin-based sealant material
62271613|NCT04515732|EXPERIMENTAL|3a (apremilast intervention)|Apremilast in standard dosis (gradual increase 0-30 mg x 2 daily over the first 6 days, hereafter 30 mg x 2 daily) for 6 months, followed by 6 months observation.
62271614|NCT04515732|NO_INTERVENTION|3b (non-intervention)|Observation
62634217|NCT06404619|EXPERIMENTAL|mHealth education program|"They received 1 session every 2 weeks for 3 months using Zoom meeting (each session lasts for 1 hour). The message emphasizes the importance of quality of life and positive psychology and highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. Daily engagement with the intervention was assessed using text message replies and number of coaching calls completed. Participants were asked to reply Done via Emails, Facebook, WhatsApp, Telegram, Instagram, or Zoom meeting."
62634218|NCT06404619|ACTIVE_COMPARATOR|Traditional education program|They received 1 session every 2 weeks for 3 months at their convenience place (each session lasts for 1 hour). The same message as the Intervention group. Small group discussions and display of educational messages, posters, handout, and power point presentation lectures.
62634219|NCT03077893|EXPERIMENTAL|Active Group|Treatment with active Provant Therapy System
62271615|NCT03242837|EXPERIMENTAL|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
62271616|NCT03242837|ACTIVE_COMPARATOR|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
62453070|NCT01968382|EXPERIMENTAL|IMM 124-E 2400 mg/day|Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of powder to be mixed with water. Subjects will get 1 active drug powder and 1 placebo powder with each dosing for a total of 4 sachets daily.
62453071|NCT01968382|EXPERIMENTAL|IMM 124-E 4800 mg/day|Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 2400 mg in the form of a powder to be mixed with water. The total number daily will be 4 sachets.
62453072|NCT01968382|PLACEBO_COMPARATOR|Placebo (High protein milk powder)|Subjects will receive 2 sachets of placebo powder to be mixed with water in the morning and 2 sachets of placebo powder (to be mixed with water) in the evening for a total of 4 sachets of placebo daily.
62453073|NCT04617665|OTHER|One-handed mask ventilation|For the one-handed mask ventilation, only one hand can be used to achieve the face mask seal. The left thumb and index finger form a ''C,'' providing anterior pressure over the mask, while the third, fourth, and fifth fingers form an ''E'' to lift the jaw.
62271617|NCT02705989|PLACEBO_COMPARATOR|Single Ascending Dose (SAD)|Single ascending dose of BMS-986195 or Placebo matching BMS-986195
62271618|NCT02705989|PLACEBO_COMPARATOR|Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195
62271619|NCT02705989|PLACEBO_COMPARATOR|Japanese-Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage
62271620|NCT02705989|EXPERIMENTAL|Relative Bioavailability with Food Effects (Open Label)|
62453074|NCT04617665|OTHER|Two-handed mask ventilation|For the two-handed mask ventilation, the provider's thumb and thenar eminence of each hand are held parallel, adjacent to the mask connector, and depress each side of the mask. The second through fifth digits wrap around and elevate the mandible to draw it anteriorly into the mask establishing both a jaw-thrust and chin-lift maneuver when appropriate.
62453075|NCT06087874|EXPERIMENTAL|Probiotics|Vivomixx® is a multi-strain probiotics product.
62271621|NCT04235556||Historic cohort|Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.
62271622|NCT04235556||Prospective cohort|All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.
62271623|NCT03027739|EXPERIMENTAL|Arm 1|CART-19 cells treated
62066670|NCT02599103|EXPERIMENTAL|fried tallow|
62066671|NCT01108835|ACTIVE_COMPARATOR|comprehensive care programme|Comprehensive care involving multidisciplinary input.
62271624|NCT03277495|ACTIVE_COMPARATOR|Usual SREC pods Flavor|The liquid in the e-cigarette refills contains nicotine and comes in the following flavors: tobacco, menthol, blueberry, and watermelon. The participant will receive SREC pods in their usual flavor.
62271625|NCT03277495|ACTIVE_COMPARATOR|Choice of SREC pods Flavors|The liquid in the e-cigarette refills contains nicotine and comes in the following flavors: tobacco, menthol, blueberry, and watermelon. The participant will receive SREC pods in their choice of flavor.
62066672|NCT01108835|NO_INTERVENTION|Control group|Control arm with usual care
62066673|NCT02057744||Robotic-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive robotic-guided spinal fixation surgery.
62066674|NCT02057744||Freehand image-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive image-guided freehand or navigated spinal fixation surgery.
62271626|NCT04373031|EXPERIMENTAL|Control|Control Arm: (Pembro + ACT): Pembrolizumab induction (single-dose 200mg IV), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
62271627|NCT04373031|EXPERIMENTAL|Arm A|• Arm A: (Pembro + IRX-2 + ACT): Pembrolizumab (single-dose 200mg IV) + cyclophosphamide (single-dose 300 mg/m2 IV) + IRX-2 induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by IRX-2 re-induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
62271628|NCT05058833||Patients with cardiac diastolic dysfunction|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
62271629|NCT05058833||Patients with coronary microcirculatory dysfunction|Patients with coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
62271630|NCT05313061|ACTIVE_COMPARATOR|MTX continue|Group will continue MTX after vaccination
62453076|NCT06087874|PLACEBO_COMPARATOR|Placebo|Maltose-containing placebo product
62634220|NCT03077893|SHAM_COMPARATOR|Sham Group|Treatment with Inactive (sham) Provant Therapy System
62271631|NCT05313061|EXPERIMENTAL|MTX 1 week hold|Group will continue MTX for 1 week after vaccination
62271632|NCT01240460|EXPERIMENTAL|1|Twice-daily dosing (every 12 hours) XL765
62271633|NCT01240460|EXPERIMENTAL|2|Once-daily dosing XL147
62271634|NCT01240460|EXPERIMENTAL|3|Once-daily dosing XL765
62271635|NCT04710342|EXPERIMENTAL|CTO proximal cap crossing|To demonstrate that CapBuster breaks the proximal cap of CTO's
62271636|NCT02814630|OTHER|Open-label Xolair|"The patients will receive one subcutaneous injection of omalizumab at a dose of 300 mg on Days 1, 30, and 60.~There is no control drug."
62066675|NCT02348398|EXPERIMENTAL|Pazopanib + Topotecan|"Pazopanib 600 mg taken orally continuously while Topotecan 0.25 mg taken orally for 21 days continuously followed by 7 days off. A cycle will be defined as 28 days.~During follow up if disease gets worse, participant called by study staff every 3 months."
62271637|NCT01382693|EXPERIMENTAL|TimeSlips group storytelling program|
62271638|NCT01382693|ACTIVE_COMPARATOR|Standard care activity program|
62271639|NCT06434480|EXPERIMENTAL|Radiotherapy|"After screening procedures, suitable patients are consented and enrolled with the following treatment being given~* Continue Atezolizumab 1200mg Day 1 plus Bevacizumab 15mg/kg Day 1, given intravenously every 3 weeks, till the next progression, or death.~* Radiotherapy will start 4 to 6 weeks after consent~* For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given.~* For extrahepatic progression: an aim to give ablative dose (i.e. BED10≥100Gy) will be given (allow lower dose based on nearby OAR dose constraints and is at the discretion of the treating radiation oncologist)~* Bevacizumab will need to be withhold 4 weeks prior and after radiotherapy.~* Dose constraints to organ at risk (OAR) will take reference from RTOG-1112 and UK 2022 consensus on normal tissue dose-volume constraints"
62271640|NCT02483312|EXPERIMENTAL|IL-12|A single dose of IL-12, given intravenously.
62634221|NCT02377856|ACTIVE_COMPARATOR|intervention|40 patients will receive pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks combination treatment, followed by 24 weeks of follow-up. 'pegylated interferon alpha 2a, ribavirin'
62066676|NCT04741802|EXPERIMENTAL|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors
62066677|NCT01861821|ACTIVE_COMPARATOR|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication for labor analgesia
62066678|NCT01861821|ACTIVE_COMPARATOR|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication for labor analgesia
62271641|NCT00921700|EXPERIMENTAL|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg
62066679|NCT03697980||HVAD Left Ventricular Assist Device|"Device: HeartWare Ventricular Assist Device~Other Names:~HVAD The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD)."
62066680|NCT03739294|EXPERIMENTAL|PILOT: 4 puffs once|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms
62066681|NCT03739294|EXPERIMENTAL|PILOT: 4 puffs once a day for 7 days|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms for 7 days
62066682|NCT03739294|EXPERIMENTAL|LARGE: 4 puffs once|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) once
62271642|NCT00921700|EXPERIMENTAL|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg + codeine 60 mg
62271643|NCT00921700|ACTIVE_COMPARATOR|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg + codeine 60 mg
62634222|NCT02377856|NO_INTERVENTION|observation|40 patients without treatment will be followed for the clinical course for 1.5 year
62634223|NCT02864732|EXPERIMENTAL|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
62634224|NCT02864732|EXPERIMENTAL|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
62634225|NCT00594893|ACTIVE_COMPARATOR|1|Mini Incision Approach
62271644|NCT00921700|PLACEBO_COMPARATOR|Placebo|Single oral dose of lactose as placebo
62634226|NCT00594893|ACTIVE_COMPARATOR|2|2 Incision Approach
62634227|NCT05362370||Cohort 1|Participants will receive a Stryker PEEK Customized Implant
62634228|NCT01167400|EXPERIMENTAL|Cybercycling|cybercycling for 3 months
62634229|NCT01167400|ACTIVE_COMPARATOR|Traditional Stationary Biking|Traditional exercise on a stationary bike for 3 months.
62634230|NCT04153474|ACTIVE_COMPARATOR|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
62634231|NCT04153474|ACTIVE_COMPARATOR|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
62634232|NCT01953042|NO_INTERVENTION|Waitlist as Per Usual|Wait list as per usual with no additional information sessions
62634233|NCT01953042|ACTIVE_COMPARATOR|Waitlist and Psychoeducation|Patients remain on waitlist but also receive 4 additional educational sessions (8 hours each)
62271645|NCT04726878|PLACEBO_COMPARATOR|Controlled|Standard care without regional block. General anesthesia. After the end of the surgery, the patient-controlled analgesia with oxycodone.
62271646|NCT04726878|EXPERIMENTAL|ESP block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.375% ropivacaine will be performed. Then, the patient will be treated as in the controlled group.
62634234|NCT04215562|OTHER|patients with peripheral facial palsy|collection of data from records on the outcome of rehabilitation therapy on patients with peripheral facial palsy and types of complications associated with this therapy type
62634235|NCT01851655|EXPERIMENTAL|Plyometric Exercise - High intensity|The exercises should produce a higher peak vertical ground reaction force than those in the low group based on literature findings (e.g. single leg jumps, jumps from higher heights, higher percent effort).
62634236|NCT01851655|ACTIVE_COMPARATOR|Plyometric Exercise - Low intensity|A lower peak vertical ground reaction force will be generated in the low intensity group compared to the high intensity group based on findings in the literature (e.g. lower box heights, only two-legged jumps, lower percent effort)
62634237|NCT06008210|EXPERIMENTAL|Intervention Group|Decision Support Intervention
62634238|NCT06008210|ACTIVE_COMPARATOR|Control Group|Health coaching
62634239|NCT03900338||PWV>10|Patients with PWV \> 10 (SSphygmoCor) in two different measurements
62271647|NCT04726878|SHAM_COMPARATOR|Sham block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.9% saline will be performed. Then, the patient will be treated as in the controlled group.
62271648|NCT01849172|EXPERIMENTAL|electroacupuncture|Electroacupuncture at RN4, EX-CA1，ST25, SP6 (double sides). One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
62286939|NCT05257512|EXPERIMENTAL|Phase I/II Study of SY-3505|SY-3505 will be given orally in ascending doses (escalation cohort), until the DLT or RP2D is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose. In phase II, SY-3505 will be given at RP2D in advanced ALK-positive NSCLC patients.
62453077|NCT03392571|EXPERIMENTAL|Resectable and borderline restable|"Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed.~Patients receive 3 cycles of preoperative chemotherapy (NGC-triple regimen). The regimen consists of gemcitabine 800 mg/m2, Nab-paclitaxel 100 mg/m2and Cisplatin 25 mg/m2 given IV weekly x 2, every 3 weeks (one cycle).~Patients will be evaluated for adjuvant therapy within 12 weeks of surgery which will consist of Nab-paclitaxel, gemcitabine, and Cisplatin IV weekly x 2, every 3 weeks (one cycle) x 3 cycles."
62453078|NCT01263158|EXPERIMENTAL|Expectant group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Expectancy of standard oxytocin treatment for 3 hours.
62453079|NCT01263158|NO_INTERVENTION|Early oxytocin group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Oxytocin treatment started within 20 minutes.
62453080|NCT01252069|EXPERIMENTAL|A|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ended by a drug free period until return of menses.
62453081|NCT01252069|EXPERIMENTAL|B|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets) during 3 periods each ended by a drug free period until return of menses.
62453082|NCT02258256|EXPERIMENTAL|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
62453083|NCT01450709||Dialysis patients|
62453084|NCT02309099|EXPERIMENTAL|Cochlear Implant|Cochlear implantation of the affected ear
62453085|NCT06244654|OTHER|Standart Anesthesia management|In the non-VR group, the standard anesthesia procedure will be followed. Brachial plexus nerve block will be performed with a 50mm peripheral block needle (Vygon echoplex+ 22Gx50mm) with a mixture of 2% lidocaine and 0.5% bupivacaine (10 mL each) prepared as 20ml. After waiting for a sufficient time, the nerve block effectiveness of the patients will be measured by Modified Broomage scale and pinprick. Additional sedative agents may be applied to both groups at the discretion of the anesthesiologist and will be recorded. Anesthesia management will be applied to both groups in accordance with the standard working order of the Anesthesia clinic.
62453086|NCT06244654|EXPERIMENTAL|VR group|Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones will be used for patients to hear the sounds of the immersive environment and to block the sounds coming from the operating room environment. Brachial plexus nerve block will be performed with a 50mm peripheral block needle (Vygon echoplex+ 22Gx50mm) with a mixture of 2% lidocaine and 0.5% bupivacaine (10 mL each) prepared as 20ml. After waiting for a sufficient time, the nerve block effectiveness of the patients will be measured by Modified Broomage scale and pinprick.Additional sedative agents may be applied to both groups at the discretion of the anesthesiologist and will be recorded. Anesthesia management will be applied to both groups in accordance with the standard working order of the Anesthesia clinic.
62453087|NCT03510364|EXPERIMENTAL|Dietary intervention|All participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days.
62453088|NCT00617448|ACTIVE_COMPARATOR|I|conventional diathermy haemorrhoidectomy under spinal anaesthesia
62453089|NCT00617448|ACTIVE_COMPARATOR|II|conventional diathermy haemorrhoidectomy with local anaesthesia combined with intravenous sedation (group II)
62634240|NCT03900338||PWV<10|Patients with PWV \< 10 (SphygmoCor) in two different measurements
62634241|NCT05709288|EXPERIMENTAL|BBM-H901 administration group|Subjects will be administered with single dose intravenous infusion of BBM-H901.
62453090|NCT00617448|ACTIVE_COMPARATOR|III|Ligasure haemorrhoidectomy under spinal anesthesia
62453091|NCT00617448|ACTIVE_COMPARATOR|IV|Ligasure haemorrhoidectomy under local anesthesia
62634242|NCT06407219|ACTIVE_COMPARATOR|"Passive Endurance"|"Participants will complete a training session using the Trexo robotic gait trainer in the endurance mode with a fixed gait pattern regardless of the participant's activity."
62634243|NCT06407219|ACTIVE_COMPARATOR|"Voluntary activity Strength"|"Participants will complete a training session using the Trexo robotic gait trainer in the strength mode where the gait pattern is impacted by the participant's activity"
62634244|NCT02418793|EXPERIMENTAL|Dose Cohort 1|Lowest MOD-5014 dose tested in the study
62634245|NCT02418793|EXPERIMENTAL|Dose Cohort 2|MOD-5014 Dose cohort 2
62634246|NCT02418793|EXPERIMENTAL|Dose Cohort 3|MOD-5014 Dose cohort 3
62634247|NCT02418793|EXPERIMENTAL|Dose Cohort 4|MOD-5014 Dose cohort 4
62634248|NCT02418793|EXPERIMENTAL|Dose Cohort 5|MOD-5014 Dose cohort 5
62634249|NCT02418793|EXPERIMENTAL|Dose Cohort 6|Highest MOD-5014 dose tested in the study
62634250|NCT00553488|ACTIVE_COMPARATOR|1|Regular insulin SC at -17 mins
62634251|NCT00553488|ACTIVE_COMPARATOR|2|Regular insulin ID at -17 mins
62634252|NCT00553488|ACTIVE_COMPARATOR|3|Regular insulin ID at -2 mins
62634253|NCT00553488|ACTIVE_COMPARATOR|4|Insulin lispro given SC at -2 mins
62634254|NCT00553488|EXPERIMENTAL|5|Insulin lispro given ID at -2 mins
62634255|NCT00558987|EXPERIMENTAL|1|
62634256|NCT00558987|SHAM_COMPARATOR|2|
62271649|NCT01849172|SHAM_COMPARATOR|sham electroacupuncture|Sham electroacupuncture at non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides).Specially constructed EA apparatus were used with no skin penetration, electricity output, or de qi requirement for needle manipulation One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
62634257|NCT05816915|EXPERIMENTAL|Professional lifestyle modification counselling (behavioral therapy)|Lifestyle intervention will be based on CBT (cognitive behavioral therapy) and mindfulness, especially mindful eating by professional organisation STOB.
62634258|NCT05816915|NO_INTERVENTION|standard care|Patients will have standard care with regular visits at an outpatient Department of Hepatology. Standard recommendations of lifestyle change and weight reduction will be given by hepatologists.
61978626|NCT05319522|ACTIVE_COMPARATOR|Individuals with SCI|Male and female, Veteran and non-Veteran participants with traumatic SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
62271650|NCT02065154|EXPERIMENTAL|Cyclophosphamide (Cytoxan)|Cyclophosphamide (Cytoxan)
62286940|NCT05198713|EXPERIMENTAL|Experimental|All participants will be fit with the study hearing aid and under go the same testing conditions.
62286941|NCT02172157|EXPERIMENTAL|BI 1744 CL i.v. (intravenous) infusion|
62286942|NCT02172157|ACTIVE_COMPARATOR|BI 1744 CL Oral solution|
62634259|NCT01136018||intentional lateral caudal approach|
62634260|NCT00105742|OTHER|Arm 1|
62634261|NCT00714974|NO_INTERVENTION|1|Standard of care
62286943|NCT00971126|EXPERIMENTAL|Single Group Assignment|
62634262|NCT00714974|EXPERIMENTAL|2|Sedation based on BIS value, oer treating physician discretion.
62634263|NCT02855775|EXPERIMENTAL|Bevacizumab|Bevacizumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
62634264|NCT02855775|EXPERIMENTAL|Trastuzumab|Trastuzumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
62066683|NCT03739294|EXPERIMENTAL|LARGE: 4 puffs once a day for 7 days|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) daily for 7 days
62634265|NCT03198858|OTHER|Ablation with Carto® 3 System|Ablation with Carto® 3 System
62634266|NCT03198858|OTHER|Ablation CartoUnivu™|Ablation CartoUnivu™
62634267|NCT06325800||Controls|"Patients with~Arterial biomechanics values lower than or equal to the 50th percentile of the distribution (measured as carotid stiffness by ultrasound elastography, distensibility and stress, flow velocity and vascular resistance),~AND~Absence of vascular target organ damage (considered as carotid intima-media thickness \>0.9 mm, cholesterol plaque, carotid stenosis, carotid-femoral pulse wave velocity \>10 m/s, pulse pressure \>60 mmHg, ankle-Brachial Index \<0.9 or \>1.3, hypertensive retinopathy)~AND~Absence of cardiovascular disease (cardiovascular events, cerebrovascular events, hospital admissions, consultations, death, disability)"
62634268|NCT06325800||Cases|"Patients with~Arterial biomechanics values higher than the 50th percentile of the distribution (measured as carotid stiffness by ultrasound elastography, distensibility and stress, flow velocity and vascular resistance),~OR~Presence of vascular target organ damage (considered as carotid intima-media thickness \>0.9 mm, cholesterol plaque, carotid stenosis, carotid-femoral pulse wave velocity \>10 m/s, pulse pressure \>60 mmHg, ankle-Brachial Index \<0.9 or \>1.3, hypertensive retinopathy)~OR~Presence of cardiovascular disease (cardiovascular events, cerebrovascular events, hospital admissions, consultations, death, disability)"
62634269|NCT03319433||Group I (Perfusion Index <3.5)|Those parturient with perfusion index \<3.5 when baseline monitors are attached while the patient is being prepared for surgery.
62066684|NCT03739294|EXPERIMENTAL|LARGE: 1 puff once|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (1 puff) once
62066685|NCT03739294|EXPERIMENTAL|LARGE: 1 puff once a day for 7 days|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 (1 puff) daily for 7 days
62066686|NCT05754684|EXPERIMENTAL|Intervention|Quadruple immunotherapy
62066687|NCT03469349|EXPERIMENTAL|Actovegin 1200 mg|Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
62066688|NCT03469349|PLACEBO_COMPARATOR|Placebo|Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
62066689|NCT03486587|EXPERIMENTAL|Changfukang® group|Patients in Changfukang group will receive Changfukang® (Bacillus Cereus tablets).
62066690|NCT01777321|EXPERIMENTAL|SC HZ/su Group|Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.
62066691|NCT01777321|ACTIVE_COMPARATOR|IM HZ/su Group|Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.
62066692|NCT01008475|EXPERIMENTAL|Safety part: EMD 525797 250 mg + Standard of Care (SoC)|EMD 525797 250 mg in combination with cetuximab and irinotecan
62066693|NCT01008475|EXPERIMENTAL|Safety part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
62634270|NCT03319433||Group II (Perfusion index >3.5)|Those parturient with perfusion index \>3.5 when baseline monitors are attached while the patient is being prepared for surgery.
62634271|NCT05946226|EXPERIMENTAL|IMC002 dose 1-3|IMC002 single infusion
62066694|NCT01008475|EXPERIMENTAL|Safety part: EMD 525797 750 mg + SoC|EMD 525797 750 mg in combination with cetuximab and irinotecan
62066695|NCT01008475|EXPERIMENTAL|Safety part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg in combination with cetuximab and irinotecan
62066696|NCT01008475|EXPERIMENTAL|Randomized part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
62066697|NCT01008475|EXPERIMENTAL|Randomized Part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg (or dose as defined by safety monitoring committee (SMC)\] in combination with cetuximab and irinotecan.
62066698|NCT01008475|OTHER|Randomized Part: SoC|Cetuximab and irinotecan
62066699|NCT03808337|ACTIVE_COMPARATOR|Standare of Care|Patients with newly diagnosed metastatic non-small cell lung cancer or triple negative breast cancer may be enrolled on protocol prior to receiving any systemic therapy. If these patients are randomized to the standard of care arm (Arm 1), they will initiate appropriate therapy as determined by their oncologist. Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist.
62066700|NCT03808337|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT) + Standard of Care|Patients enrolled on Arm 2 of the study will undergo Stereotactic Body Radiotherapy/SBRT to all known metastases seen on imaging studies performed prior to enrollment. Radiotherapy will be given concurrently to all metastatic sites. Minimum BED for ablative SBRT is more than or equal to 48 Gy10. Patients can undergo systemic therapy concurrently with SBRT at the discretion of treating radiation oncologist and medical oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
62066701|NCT02283359|EXPERIMENTAL|Selinexor in Combination with Irinotecan|"The first study drug is called selinexor (KPT-330). This drug is taken by mouth on days 1, 3, 8 and 10 of each cycle. The starting dose of selinexor will be dependent on the cohort in which the patient is enrolled into. Level -1: 25 mg/m\^2; Level 1: 40 mg/m\^2; Level 2: 50 mg/m\^2; Level 3: 65 mg/m\^2.~The second drug is called irinotecan. This drug is given as intravenous (IV) infusion on days 1 and 8 of each cycle. Participants will receive the standard recommended dose: 125 mg/m\^2."
62066702|NCT05838924|EXPERIMENTAL|Physical Activity + Virtual Reality|"A program of 8 VR exercises will be applied, of a therapeutic nature, based on the applied exercises of the Back School, aimed at gaining strength, stability, mobility and flexibility of the abdomino-lumbo-pelvic region and the lower extremities. For each exercise, the VR goggles will manipulate the visual proprioceptive information by modifying the perceived degree of lumbar flexion and extension, i.e., in the VR goggles they will perceive that your movements are different from what you are actually doing."
62066703|NCT05838924|ACTIVE_COMPARATOR|Physical Activity|The same therapeutic exercise program will be applied as the experimental group, but without VR. The training methodology and progression of loads, evaluations and supervision by the physiotherapist will also be the same.
62066704|NCT00399763|PLACEBO_COMPARATOR|1|placebo plus individual cognitive behavioral therapy
62066705|NCT00399763|EXPERIMENTAL|2|atomoxetine plus individual cognitive behavioral therapy
62066706|NCT06213194|EXPERIMENTAL|Experimental Group|It combines social cognitive and executive functions skills and it will be present on the designed website and they will participate in the intervention online. After participants are assigned the experimental group the 6-week training program will start and they cannot access the next week before completing the previous week. Each week's will last about 75 minutes. The training includes social cognitive skills including cognitive and affective empathy and executive functions.
62066707|NCT06213194|NO_INTERVENTION|Control Group|This group will not take the training until the follow-up test. After the study will be done, the training program will be offered to the control group as well.
62066708|NCT05250401||patients with liver cirrhosis|
62066709|NCT05250401||control group|
62066710|NCT06382909|ACTIVE_COMPARATOR|Mix Probiotic K11T with out vitamins|"Drug-1: K11T~1 dose/day Orally"
62066711|NCT06382909|ACTIVE_COMPARATOR|Mix Probiotic K11TMAX with vitamins|"Drug-1: K11Tmax~1 dose/day Orally"
62066712|NCT06382909|PLACEBO_COMPARATOR|Placebo drugs|"Placebo~1 dose/day Orally"
62066713|NCT06243107|EXPERIMENTAL|Tai-chi|Tai Chi Chuan Intervention: There are 10 styles ,Each movement is performed for 3 minutes, repeated 10 times, totaling 30 minutes per session. participants will engage Tai Chi practice six times a week for eight weeks.
62066714|NCT06243107|NO_INTERVENTION|control|routine care
62066715|NCT01441817|OTHER|Surgery|
62066716|NCT03383159||Observation group 1|Patients who suffered metachronous adenoma after proximal colorectum cancer surgery.
62066717|NCT03383159||Control group 1|Patients who do not suffere metachronous adenoma after proximal colorectum cancer surgery.
62066718|NCT03383159||Observation group 2|Patients who suffered metachronous adenoma after distal colorectum cancer surgery.
62066719|NCT03383159||Control group 2|Patients who do not suffered metachronous adenoma after distal colorectum cancer surgery.
62066720|NCT06619730|NO_INTERVENTION|Control Arm|Conventional method: Anesthesia will not be guided by the Sedline brain function monitor during the procedure.
62066721|NCT06619730|ACTIVE_COMPARATOR|Sedline Monitor Arm|Anesthesia care guided by Sedline brain function monitor during the procedure.
62066722|NCT04515121|EXPERIMENTAL|HD-tCES & lower limb rehabilitation|The experiment group will receive HD-tCES combined with lower limb rehabilitation of affected side.
62066723|NCT04515121|SHAM_COMPARATOR|Sham HD-tCES & lower limb rehabilitation|The sham control group will receive sham HD-tCES combined with lower limb rehabilitation of affected side.
62066724|NCT04122235|EXPERIMENTAL|Intervention arm|New follow-up model
62066725|NCT04122235|NO_INTERVENTION|Control arm|Usual care
62066726|NCT06625801||IVUS-guided PCI in US minorities|Patients undergoing IVUS-guided PCI for complex coronary artery disease who self-identify within a census-defined minority in the United States
62066727|NCT01973036|ACTIVE_COMPARATOR|Oxytocin|This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
62066728|NCT01973036|EXPERIMENTAL|Foley Catheter and Oxytocin|A 30cc/16 French (16F) foley catheter will be inserted by the provider under direct visualization or by palpation, ensuring that the catheter is appropriately and adequately positioned. Oxytocin will be administered concurrently at a rate of 2 milliunits/milliliter (as noted under oxytocin active comparator). If the catheter remains in place after 12 hours, it will be deflated and removed and oxytocin infusion will continue.
62066729|NCT00152009|EXPERIMENTAL|SPD503 (Guanfacine HCl) (2 mg)|
62066730|NCT00152009|EXPERIMENTAL|SPD503 (3 mg)|
62066731|NCT00152009|EXPERIMENTAL|SPD503 (4 mg)|
62066732|NCT00152009|PLACEBO_COMPARATOR|Placebo|
62066733|NCT04877093|EXPERIMENTAL|Clonidine Phase|Participants will receive clonidine titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.
62066734|NCT04877093|PLACEBO_COMPARATOR|Placebo Phase|Participants will receive placebo titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.
62066735|NCT01654991|ACTIVE_COMPARATOR|Clinic-Based Testing|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
62066736|NCT01654991|EXPERIMENTAL|Home-Based Testing|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
62066737|NCT02581332|OTHER|Behavioral: Mindfulness Meditation|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
62066738|NCT04000594|EXPERIMENTAL|Dose level 1 of RO7234292 (RG6042)|Participants will receive dose level 1 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
62286944|NCT00002550|EXPERIMENTAL|RT + chemotherapy followed by surgery + chemotherapy|Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
62453092|NCT06325579|EXPERIMENTAL|Dysphagia patients using VR|"Day 1: Consent taken 5mins. Baseline period wearing strain gauge 5mins, it´d pick up and measure the patient's swallow movements while at rest not using the VR. IVR trial 25mins, the headset will be refitted and instructions to use two different games for up to 10 minutes with a 5-minute break in between. The SALT Assistant would be closely guide and monitor the participant. The experience will be concluded for the day if the participant shows sign of or indicates discomfort.~Days 2-4 (30-35mins) same proceed as above, minus the test experience (Baseline period (5 mins) and IVR trial (25 mins).~Day 5 (40-45mins) final day of the trial and after take part in a short semi-structured interview (10mins) in person and audio recorded by the SALT Assistant. SALT Assistant post-trial interview (25-40mins) online audio recorded by a member of the research team ."
62066739|NCT04000594|EXPERIMENTAL|Dose level 2 of RO7234292 (RG6042)|Participants will receive dose level 2 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
62286945|NCT00002550|ACTIVE_COMPARATOR|RT + chemotherapy followed by chemotherapy + RT|Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
61978627|NCT05319522|ACTIVE_COMPARATOR|Controls (No SCI)|Male and female Veterans, age and sex-matched to participants with SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
61978628|NCT02919501|EXPERIMENTAL|IV vortioxetine|
62271651|NCT02281695|ACTIVE_COMPARATOR|Arm A|"Patients that are mechanically ventilated for less than 24 hours until the weaning process can be started.~At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen."
62286946|NCT03463070|ACTIVE_COMPARATOR|preoperative misoprostol group|70 women who received 600 mg misoprostol rectally preoperatively before cesarean section
62286947|NCT03463070|ACTIVE_COMPARATOR|postoperative misoprostol group|70 women who received 600 mg misoprostol postoperatively at operating theatre after cesarean section
62286948|NCT02500693|EXPERIMENTAL|Screening|
62453093|NCT06220292|EXPERIMENTAL|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
62453094|NCT06220292|ACTIVE_COMPARATOR|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The control group receives Nasogastric Tube Feeding for enteral nutrition support
62453095|NCT02470559|EXPERIMENTAL|Treatment (aldesleukin, sargramostim, HER2Bi-aACT)|Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.
62634272|NCT02701621|ACTIVE_COMPARATOR|MIRT Group|Individuals underwent Multidisciplinary Intensive Rehabilitation Treatment. It consists of 4 weeks of physical therapy in a hospital setting with four daily sessions for five days and one hour of physical exercise on the sixth day.The duration of each session is about one hour. The first session comprises cardiovascular warm-up activities, relaxation and muscle-stretching. The second session includes aerobic exercises and the use of different devices: a stabilometric platform, treadmill plus, crossover, cycloergometer. The third is a session of occupational therapy. The last session includes one hour of speech therapy. The rehabilitation program can also include: robotic-assisted walking training, virtual reality training and meetings with a Psychologist.
62066740|NCT04000594|EXPERIMENTAL|Dose level 3 of RO7234292 (RG6042)|Participants will receive dose level 3 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
62066741|NCT04181840|EXPERIMENTAL|Impedance spectroscopy|"Maximum 56 women up to 16 weeks from a natural delivery, with at least one perinatal anal sphincter injury risk factor, such as: the extended second delivery phase, instrumental delivery (vacuum or forceps), shoulder dystocia, birth weight of the child \> 4kg, episiotomy, uncontrolled perineal laceration (in patients with crotch protection).~The planned interventions are:~* Blood and faeces tests~* Impedance spectroscopy test~* Full gynecological and proctological examination~* Transanal ultrasonography~* Anorectal manometry"
62271652|NCT02281695|ACTIVE_COMPARATOR|Arm B|Patients that are mechanically ventilated for more than 24 hours until the weaning process can be started. At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen.
62271653|NCT01618214|EXPERIMENTAL|Subject-driven titration|
62453096|NCT04622709|EXPERIMENTAL|Study drug administration: furosemide|Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant.
62453097|NCT02632877|EXPERIMENTAL|Pirfenidone with MODD|"Active ingredients: Pirfenidone 8% with modified oxide diallyl disulfide (MODD) 0.016%.~Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every eight hours for 6 months."
62453098|NCT02632877|ACTIVE_COMPARATOR|Ketanserin|"Active ingredients: Ketanserin 2%. Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 months."
62453099|NCT05310565|EXPERIMENTAL|Chiropractic|Cervical chiropractic care
62453100|NCT02132247|EXPERIMENTAL|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
61978629|NCT02919501|PLACEBO_COMPARATOR|IV placebo|
62066742|NCT03075241|EXPERIMENTAL|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
62066743|NCT03075241|EXPERIMENTAL|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
62066744|NCT03075241|PLACEBO_COMPARATOR|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
62066745|NCT06416813|NO_INTERVENTION|GDMT|
62066746|NCT06416813|EXPERIMENTAL|GDMT+DCB|
62066747|NCT03634501|EXPERIMENTAL|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
62066748|NCT04275843|ACTIVE_COMPARATOR|Traditional Diet|Unprocessed/minimally processed whole foods.
62066749|NCT04275843|ACTIVE_COMPARATOR|Modern Diet|Multi-ingredient, ultra-processed formulations of the traditional diet.
62066750|NCT05016544|EXPERIMENTAL|Inetetamab+Pyrotinib|Dose Escalation and Dose Expansion: Inetetamab in combination with Pyrotinib in HER2 mutant or amplified participants with advanced or metastatic NSCLC
62271654|NCT01618214|ACTIVE_COMPARATOR|Investigator-driven titration|
62271655|NCT05831397||Breast cancer patients candidate for neoadjuvant chemotherapy|Female patients diagnosed with breast cancer, at any TNM stage, who are candidate to neoadjuvant treatment.
62271656|NCT05831397||Healty control|Control group (sex and age matched): healthy volunteers, not affected by breast cancer (with negative mammography, breast ultrasound or breast examination within 12 months of the study enrolment).
62634273|NCT02701621|EXPERIMENTAL|MIRT-AT|"Patients underwent land-based therapy in association with aquatic therapy, three times per week for four weeks.~The land-based activities included the second and the third session of MIRT.~The water sessions were divided in 3 phases:~i) Warm Up Exercises. This phase lasted 10 minutes and comprised walking performances.~ii) Central session Training. This phase lasted 30-45 minutes and comprised trunk mobility exercises in standing position and sitting on a floating device, static and dynamic exercises. The successive balance training exercises comprised: maintaining balance with closed eyes; balance control with one leg resting on a step; postural control changing the support base.~iii) Cool-down. This phase lasted 5 minutes and comprised general stretching exercises and gentle walking."
62634274|NCT01979874|EXPERIMENTAL|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)
62634275|NCT01979874|PLACEBO_COMPARATOR|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
62634276|NCT00660296|OTHER|2|Air insufflation in colonoscopy
62634277|NCT00660296|OTHER|1|CO2 insufflation in colonoscopy
62634278|NCT02534597|EXPERIMENTAL|pctm|Receives the earliest Promotores training, followed by direct caregiver training, materials support, and technical assistance.
62634279|NCT02534597|EXPERIMENTAL|p_ctm|Receives the earliest Promotores training, followed by delayed caregiver training, delayed materials support, and delayed technical assistance.
62634280|NCT02534597|EXPERIMENTAL|_pmt|Receives the delayed Promotores training, followed by receipt of materials support and technical assistance.
62634281|NCT02534597|EXPERIMENTAL|_p_mt|Receives the delayed Promotores training, followed by delayed receipt of materials support and technical assistance.
61978630|NCT01953055|EXPERIMENTAL|Stereotactic ablative radiotherapy|40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
61978631|NCT03420469|EXPERIMENTAL|Baseline CYP2D6 activity|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
61978632|NCT03420469|EXPERIMENTAL|CYP2D6 activity with single dose of bupropion|The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
62271657|NCT03970902||Integrated Osteoporosis Care|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis in whom a complex patient-tailored intervention is provided.
62271658|NCT03970902||Care As Usual|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis receiving care as usual for the management of osteoporosis.
62271659|NCT03915223|EXPERIMENTAL|"Arm Injection corticosteroids"|Single dose of Solumedrol 2 mg/kg
62271660|NCT03915223|PLACEBO_COMPARATOR|"Arm  injection physiological serum"|Single dose of physilogical serum
62271661|NCT06475144|EXPERIMENTAL|Experimental Group|"The intervention involves an online escape room teaching experience, aimed at enhancing participants' cognition, clinical reasoning, self-efficacy, and learning satisfaction. Participants complete a pre-test survey before the online escape room teaching session, followed by a post-test and satisfaction survey after the course. The entire game intervention and testing process takes 80-90 minutes. Learning outcomes, including cognition, clinical reasoning, and self-efficacy, are reassessed four weeks later."
62271662|NCT06475144|PLACEBO_COMPARATOR|Control Group|"The intervention involves an online video-based teaching experience, offering the same instructional video content as the experimental group. Participants can review and pause the videos during the course. Before the course, participants complete a pre-test survey, followed by a post-test and satisfaction survey after the course. The entire intervention and testing process takes 80-90 minutes. Learning outcomes, including cognition, clinical reasoning, and self-efficacy, are reassessed four weeks later."
62634282|NCT02534597|EXPERIMENTAL|_pct|Receives the delayed Promotores training, followed by caregiver training and technical assistance.
62634283|NCT02534597|EXPERIMENTAL|_p_ct|Receives the delayed Promotores training, followed by delayed caregiver training and technical assistance.
62634284|NCT02534597|EXPERIMENTAL|_pt|Receives the delayed Promotores training, followed by technical assistance.
62634285|NCT02534597|EXPERIMENTAL|_p_t|Receives the delayed Promotores training, followed by delayed technical assistance.
62634286|NCT02534597|EXPERIMENTAL|_pc|Receives the delayed Promotores training, followed by a full caregiver training only.
62634287|NCT02534597|EXPERIMENTAL|_p_c|Receives the delayed Promotores training, followed by delayed caregiver training.
62634288|NCT03535857|ACTIVE_COMPARATOR|Unilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
62634289|NCT03535857|EXPERIMENTAL|Bilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
62634290|NCT04007965|EXPERIMENTAL|Opacified posterior capsule|PCO
62634291|NCT04007965|ACTIVE_COMPARATOR|Clear posterior capsule|CPC
62634292|NCT01510821|EXPERIMENTAL|Maquet Vasoshield Arm|Pressure limiting syringe
62634293|NCT01510821|ACTIVE_COMPARATOR|Non-regulated Arm|standard non-regulated syringe
62271663|NCT04324372|EXPERIMENTAL|HEC68498|HEC68498 will be administered daily
62271664|NCT01910714|ACTIVE_COMPARATOR|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
62453101|NCT03665649|OTHER|CD133+ human donors|CD133+ cells isolation
62453102|NCT03423888|EXPERIMENTAL|High-flow nasal oxygen|
62453103|NCT01267266|EXPERIMENTAL|Arm I (saracatinib)|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62453104|NCT01267266|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Upon progression, patients may crossover to arm I.
62453105|NCT06266988|EXPERIMENTAL|Test Product|Sacubitril and Valsartan Tablets 97mg/103mg to be orally administered
62453106|NCT06266988|ACTIVE_COMPARATOR|Reference product|Entresto® (97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex) to be orally administered
62453107|NCT03923764|EXPERIMENTAL|Intervention group|1.3 g protein per kg bodyweight per day for 8 weeks
62453108|NCT03923764|ACTIVE_COMPARATOR|Kontrol group|habitual diet
62453109|NCT03066453|EXPERIMENTAL|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
62453110|NCT03066453|EXPERIMENTAL|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care
62453111|NCT06114407|EXPERIMENTAL|Baricitinib|Participants of 'Baricitinib' arm will be treated with tablet baricitinib 2 mg twice daily for 12 weeks
62453112|NCT06114407|ACTIVE_COMPARATOR|Tofacitinib|Participants of 'Tofacininib' arm getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
62453113|NCT02449707|ACTIVE_COMPARATOR|Control|Lateral Window Technique Augmentation for Maxillary Sinus without the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of membrane. Placement of Purus® Cancellous Allograft, stabilized by Biomend ™ Collagen membrane. Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
62453114|NCT02449707|EXPERIMENTAL|Ultrasonic Pins|Lateral Window Technique Augmentation for Maxillary Sinus with the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of the Purus® Cancellous Allograft, and Resorb X Membrane.Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
62453115|NCT01365650|EXPERIMENTAL|Ketorolac Tromethamine|
62453116|NCT01365650|EXPERIMENTAL|Oxymetazoline Hydrochloride|
62453117|NCT01365650|EXPERIMENTAL|Fluticasone Propionate|
62634294|NCT04252677|ACTIVE_COMPARATOR|Vaping and Obesity Prevention Only|"Obesity prevention and vaping~1. Vaping:~   * Factual information about vaping devices and vaping~  * Beliefs and attitudes about nicotine products~  * Refusing and avoiding vaping~  * Recognizing addiction and getting help~2. Health information:~   • Factual information about healthy eating and activity (PA)~3. Motivation:~   * Personal: Create positive attitudes toward engagement in healthy eating and PA~  * Social: Enlisting social support to increase healthy eating and PA~  * Social: Identification of community resources that promote and support healthy eating and PA~4. Behavioral Skills~   * Tips for engaging in prevention behaviors and avoiding risk behaviors in the context of existing barriers~  * Skills for social situations around behaviors~  * Skills for making behavior part of routine~  * Build autonomy, self-efficacy and model good health decision-making for health behaviors"
62634295|NCT04252677|EXPERIMENTAL|Health Literacy and Obesity Prevention|"Obesity prevention and health literacy (HL).~1. Health Literacy~   * Functional HL: skills for reading/understanding nutrition labels and medication instructions.~  * Interactive HL: verbal skills for interacting with others on health issues.~  * Critical HL: connections between advocacy and health~  * Media HL: skills for accessing and identifying reliable source of media.~2. Health information:~   • Factual information about healthy eating and activity (PA)~3. Motivation:~   * Create positive attitudes toward engagement in healthy eating and PA~  * Enlisting social support to increase healthy eating and PA~  * Identification of community resources that promote and support healthy eating and PA~4. Behavioral Skills~   * Tips for engaging in prevention behaviors and avoiding risk behaviors~  * Skills for social situations around behaviors~  * Skills for making behavior part of routine~  * Build autonomy, self-efficacy and good health decision-making for health behaviors"
62634296|NCT06612970|ACTIVE_COMPARATOR|HB0056 dose group 1|HB0056 single dose
62634297|NCT06612970|ACTIVE_COMPARATOR|HB0056 dose group 2|HB0056 single dose
62634298|NCT06612970|ACTIVE_COMPARATOR|HB0056 dose group 3|HB0056 single dose
62634299|NCT06612970|ACTIVE_COMPARATOR|HB0056 dose group 4|HB0056 single dose
62634300|NCT06612970|ACTIVE_COMPARATOR|HB0056 dose group 5|HB0056 single dose
62634301|NCT06612970|ACTIVE_COMPARATOR|HB0056 dose group 6|HB0056 single dose
62634302|NCT06612970|ACTIVE_COMPARATOR|HB0056 dose group 7|HB0056 single dose
62634303|NCT06612970|PLACEBO_COMPARATOR|Matching placebo for each dose group|placebo, single dose
62634304|NCT01526408|PLACEBO_COMPARATOR|Placebo Arm|Treatment with 3 months of placebo
62634305|NCT01526408|ACTIVE_COMPARATOR|Active Arm|Treatment with 3 months of active drug
62634306|NCT03522116||No intervention|
62634307|NCT02636569|ACTIVE_COMPARATOR|diclofenac once daily|Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
62634308|NCT02636569|PLACEBO_COMPARATOR|placebo|The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
62634309|NCT05535374|EXPERIMENTAL|Connected soles|Number of steps recorded by the soles (activation per smartphone)
62634310|NCT05535374|ACTIVE_COMPARATOR|Gold Standard|Number of steps counted by two observers viewing the film
62634311|NCT03164447|EXPERIMENTAL|Multi-Drug Resistant|
62453118|NCT01346085|EXPERIMENTAL|CNI-free single-group|
62286949|NCT02502760|EXPERIMENTAL|Prehabilitation|"Immediately after randomization and until surgery, patients in this arm will:~1. - Receive a personalized physical exercise program~2. - Receive nutritional counselling with Whey protein isolate powder~3. - Receive relaxation techniques"
62453119|NCT00776503|EXPERIMENTAL|B|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)
62453120|NCT00776503|EXPERIMENTAL|A|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)
62453121|NCT02907996||Sofosbuvir|Adult Korean participants with genotype 1, 2, 3, and 4 chronic HCV infection and pediatric Korean participants aged 12 to \<18 years with genotype 2 and 3 chronic HCV infection who are initiating commercial Sovaldi regimens
62453122|NCT01575054|EXPERIMENTAL|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
62453123|NCT01575054|OTHER|Normal Saline (Placebo) Followed by botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
62453124|NCT01282359|OTHER|Clinical Practice Group|Patients collected in centres randomized as usual clinical practice, who will not receive the limited educational asthma program.
62634312|NCT00409279|EXPERIMENTAL|1|multi-component psychosocial intervention
62634313|NCT00409279|NO_INTERVENTION|2|
62634314|NCT04572828|ACTIVE_COMPARATOR|Group 1: Waiting 1 Minute After Paracervical Block|
62634315|NCT04572828|ACTIVE_COMPARATOR|Group 2: Waiting 3 Minute After Paracervical Block|
62634316|NCT04572828|PLACEBO_COMPARATOR|Group 3: Control Group|
62634317|NCT04572828|ACTIVE_COMPARATOR|Group 4: Waiting 60 Minute After Taking Oral NSAIDs|
62634318|NCT01042834||Air pollution|The subjects will have to live in districts where important atmospheric pollution is established
62634319|NCT00697853|ACTIVE_COMPARATOR|Group A|
62634320|NCT00697853|EXPERIMENTAL|Group B|
62634321|NCT00697853|EXPERIMENTAL|Group C|
62634322|NCT00697853|EXPERIMENTAL|Group D|
62634323|NCT00697853|EXPERIMENTAL|Group E|
62634324|NCT00823238|ACTIVE_COMPARATOR|systemic|
62634325|NCT00823238|ACTIVE_COMPARATOR|inhaled|
62634326|NCT02793765|EXPERIMENTAL|Docetaxel & Sipuleucel-T|75 mg/m2 docetaxel IV over 1-hour every 21 days x 6 cycles; 28 day rest then Sipuleucel-T IV over 1-hour every 14 days for 3 doses
62634327|NCT04256759|EXPERIMENTAL|Dupilumab|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
62271665|NCT01910714|EXPERIMENTAL|Focus on Youth Intervention (FOY)|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
62271666|NCT02167932||Breast Cancer Patients|Breast Cancer patients undergoing chemotherapy will participate in the Walk with Ease program during their treatment.
62271667|NCT03177772||LTC Facility 1|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
62453125|NCT01282359|OTHER|"Gold Standard educational group"|Patients will receive a formal program of structured and individualized education, enrolled in centres recognized by using high standard procedures in asthma education.
62066751|NCT03711474|EXPERIMENTAL|Treatment 1; Dexamethasone|"Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision."
62271668|NCT03177772||LTC Facility 2|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
62634328|NCT04297202|EXPERIMENTAL|Apatinib Combined With SHR-1210 Injection|"SHR-1210 Injection: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle; Apatinib : D1-D21 : 250 mg, orally, qd; Before surgery, the patient's surgical pathology samples still need to be collected.~D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation;~After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. The cycle of a three-week plan will be performed with a total of 8 cycles with the treatment of Apatinib combination with SHR-1210 Injection."
62634329|NCT05419297|ACTIVE_COMPARATOR|Active drug arm|Subjects who meet eligibility criteria and complete a single blind placebo lead in will be provided placebo buprenorphine buccal film that mimics the actual drug comparator and is continued by a blinded individual throughout the duration of the trial.
62453126|NCT01282359|OTHER|Intervention group|This group will receive a limited educational asthma program (minimal educational intervention)
62634330|NCT05419297|PLACEBO_COMPARATOR|Placebo arm|Subjects who meet eligibility criteria and complete a single blind placebo lead in will be provided active buprenorphine buccal film that is titrated to the effective dose and continued by a blinded individual throughout the duration of the trial.
62634331|NCT03629769|EXPERIMENTAL|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
62634332|NCT02236312|EXPERIMENTAL|Botulinum Toxin 30 units|I.M. injection
62634333|NCT02236312|EXPERIMENTAL|Botulinum Toxin 45 units|I.M. injection
62634334|NCT02236312|EXPERIMENTAL|Botulinum Toxin 60 units|I.M. injection
62271669|NCT03177772||LTC Facility 3|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
62271670|NCT04406909|EXPERIMENTAL|Training|Access to training at membership training facility
62634335|NCT02236312|PLACEBO_COMPARATOR|Placebo|I.M. injection
62634336|NCT05201846|EXPERIMENTAL|Continuous subcutaneous insulin infusion|Continuous subcutaneous insulin infusion using insulin pump (DIA:CONN G8) with continuous glucose monitoring
62634337|NCT05201846|ACTIVE_COMPARATOR|Multiple daily insulin injection|Multiple daily insulin injection with continuous glucose monitoring
62634338|NCT06273527|EXPERIMENTAL|COGENT - Cognitive Training Intervention Program|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
62634339|NCT06273527|SHAM_COMPARATOR|Non-Training Program|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials.
62271671|NCT04406909|NO_INTERVENTION|No training|No access to training at membership training facility
62453127|NCT04659538|EXPERIMENTAL|CAPTIS Embolic Protection|TAVR will be performed according to standard institutional practice under local or general anesthesia by the transfemoral approach. The investigational device will be advanced and deployed across the aortic arch covering the ostia of the 3 great vessels (innominate, left carotid, and left-subclavian arteries) at the initiation of the procedure and withdrawn at the completion of the TAVR procedure.
62271672|NCT01185405|EXPERIMENTAL|EA group|Voriconazole dosage adjustment according to the each measurements of voriconazole levels from day 1, using NONMEM program
62453128|NCT02585700|EXPERIMENTAL|Vaccine|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:~* NYMC BX-51B reassortant of B/Massachusetts/2/2012~* X-181 reassortant of H1/A/California/7/2009~* X-223A reassortant of H3/A/Texas/50/2012."
62634340|NCT02764502|EXPERIMENTAL|Pressure Gauge Manometer|Tuohy needle is introduced into intervertebral space at the level of L3-L4 up to the interspinous ligaments . The needle is advanced slowly using both hands while monitoring the manometer reading and is stopped when the pressure suddenly dropped ( the pressure usually drops by 5-10 mm Hg when the tip of the needle inters the epidural space ).
62634341|NCT05871840||Treatment duration of RLRL therapy (≥ 6 months and < 12 months)|
62634342|NCT05871840||Treatment duration of RLRL therapy (≥12 months and < 24 months)|
62634343|NCT05871840||Treatment duration of RLRL therapy (≥24 months and < 36 months)|
62634344|NCT05871840||Treatment duration of RLRL therapy (≥36 months)|
62271673|NCT01185405|ACTIVE_COMPARATOR|CA group|Voriconazole dosage adjustment according to the levels from day 5, using predefined protocol
62271674|NCT03739450|EXPERIMENTAL|Problem Solving Training + Education|Participants in this arm will receive the TBI-specific education intervention and the Problem Solving Training (PST) intervention.
62271675|NCT03739450|ACTIVE_COMPARATOR|Education|Participants in this arm will only receive the TBI-specific education intervention.
62271676|NCT00516737|EXPERIMENTAL|1|Active Drug
62634345|NCT03021317|EXPERIMENTAL|Treated Group|Open label, single arm treatment study using MRI and laboratory markers to assess efficacy of ACTHAR in MS patients who are undergoing relapses.
62271677|NCT00516737|PLACEBO_COMPARATOR|2|Matching Pbo Comparator
62271678|NCT02917889|EXPERIMENTAL|Caffeine protocol|300 mg in pills
62271679|NCT02917889|EXPERIMENTAL|Placebo protocol|300 mg in pills
62271680|NCT02222259|EXPERIMENTAL|GA and Integrated Care Plan|Participants allocated to the intervention group will be seen in the geriatric oncology clinic where they will be assessed using a geriatric assessment. Based on the issues identified in the geriatric assessment, a care plan will be developed with the participant to address the issues.
62271681|NCT02222259|NO_INTERVENTION|Standard oncology care|Participants randomized to standard oncology care will receive usual care from their oncology team.
62271682|NCT04980612|EXPERIMENTAL|Group 1|4 cohorts of 10 participants to MBPR (First 3 groups single-arm, final group of 10 randomly assigned to MBPR)
62453129|NCT02585700|PLACEBO_COMPARATOR|Placebo|0.5 mL of phosphate buffered saline
62271683|NCT04980612|ACTIVE_COMPARATOR|Group 2|The last 20 participants will be randomly assigned to MBSR or MBPR, which will results in a control group with \~10 participants undergoing MBSR
62066752|NCT03711474|PLACEBO_COMPARATOR|Treatment 0; Placebo|"Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision."
62066753|NCT04278378|ACTIVE_COMPARATOR|Riboflavin|1.6 mg riboflavin / day for 24 weeks
62066754|NCT04278378|EXPERIMENTAL|Folic Acid|0.4 mg folic acid/ day for 24 weeks
62271684|NCT04395794||Medical Employees|Asymptomatic medical employees in high-volume cardiovascular center.
62271685|NCT06299527|EXPERIMENTAL|Synchronous Exercise Group|Synchronous telerehabilitation was performed via videoconference. Patients were taken to video conference calls accompanied by a researcher and supervisor. Participants were to perform their exercises simultaneously under the guidance of the researcher. Participants were taken to video conference calls in groups of 5 with similar functional levels. Each session lasts an average of 45 minutes. It was last. The start and end date of the exercise program, the number of repetitions for each exercise, the number of sets, daily repetitions, rest time between sets and the order of the exercises were determined by the researcher.
62453130|NCT02714309|EXPERIMENTAL|Control Trial|A mixed macronutrient breakfast meal is consumed without additional protein, following a period of rest. An ad libitum lunch meal is subsequently consumed.
62453131|NCT02714309|EXPERIMENTAL|Exercise No Preload Trial|Following an exercise bout a mixed macronutrient breakfast meal is consumed without additional protein. An ad libitum lunch meal is subsequently consumed.
62066755|NCT04278378|EXPERIMENTAL|Riboflavin + Folic Acid|1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
62066756|NCT04278378|PLACEBO_COMPARATOR|Placebo|
62066757|NCT03806504|ACTIVE_COMPARATOR|high PEEP|35 cm/H2O PEEP, 2-3 ml/kg tidal volume,45 seconds, after cardiopulmonary bypass
62066758|NCT03806504|ACTIVE_COMPARATOR|control group|6 cm/H2O PEEP, 6-8 ml/kg tidal volume, continues, after cardiopulmonary bypass
62066759|NCT00621296|EXPERIMENTAL|MP-424|
62066760|NCT04404088|EXPERIMENTAL|Treatment (acalabrutinib, lenalidomide, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21 and rituximab IV on days 1, 8, 15, and 22 of cycle 2 and day 1 of subsequent cycles. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
62453132|NCT02714309|EXPERIMENTAL|Exercise With Preload Trial|Following low/moderate intensity exercise bout, whey protein (20g) administered prior to consumption of mixed macronutrient breakfast meal. An ad libitum lunch meal is subsequently consumed.
62066761|NCT02192775|EXPERIMENTAL|MV-NIS + Cyclophosphamide|
62634346|NCT04591106||Group 1|50 healthy subjects and 50 subjects with NAFLD between ages of 6-17 years old. Each subject will receive 1 MRI/MRE exam. The MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
62634347|NCT04591106||Group 2|"60 subjects with Liver Disease and Fibrosis between ages of 1 month - 40 years old.~Each subject will receive 1 MRI/MRE exam. The MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations."
62634348|NCT04591106||Group 3|15 healthy infants between 1 week - 6 months old and their mothers; 15 at-risk infants (mother had gestational diabetes) between 1 week - 6 months old and their mothers. Each infant will receive 1 MRI scan.
62634349|NCT01684514|EXPERIMENTAL|colitis, ulcerative|Enrolled patients will be examined by conventional colonoscopy and confocal laser endomicroscopy before and after initiation of topical treatment, respectively.
62634350|NCT01684514|SHAM_COMPARATOR|Control group|A control group will be examined by conventional colonoscopy and confocal laser endomicroscopy.
62634351|NCT01676701|EXPERIMENTAL|Tabalumab Auto-Injector|Tabalumab 180 milligram (mg) loading dose administered using auto-injectors at Week 0 as 2 subcutaneous (SC) injections (90 mg each), followed by a 90 mg SC injection every 2 weeks (Q2W) up to Week 12.
62634352|NCT01676701|EXPERIMENTAL|Tabalumab Prefilled Syringe|Tabalumab 180 mg loading dose administered using prefilled syringes at Week 0 as 2 SC injections (90 mg each), followed by a 90 mg SC injection Q2W up to Week 12.
62066762|NCT04437225|EXPERIMENTAL|Constant Infusion of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 5:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 7:30 am for the carbon 13 glycolate infusion which will occur at a constant rate for 10 hours, following a priming dose. From 7:30 am to 5:30 pm, urine collections will occur hourly, and from 8:30 am to 5:30 pm, IV blood collections will occur every half hour. Subjects will receive a meal at 5:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
62066763|NCT04437225|EXPERIMENTAL|Single Intravenous Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 8:30 am for a single dose of carbon-13 glycolate to be administered. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, IV blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
62453133|NCT04480398||Ayurveda|Guduchi Ghan Vati was given to Covid patients 2 tablets (500 mg each) twice daily were given orally after meal for 28 days. Guduchi ghan vati is a powdered aqueous extract of Tinospora cordifolia in tablet form and prepared in GMP certified Pharmacy of the University, following standard protocol.
62634353|NCT01814410|PLACEBO_COMPARATOR|intravenous ethanol placebo and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
62634354|NCT01814410|ACTIVE_COMPARATOR|intravenous ethanol 40% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
62634355|NCT01814410|ACTIVE_COMPARATOR|intravenous ethanol 100% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
62634356|NCT04846192||Patients|
62634357|NCT01480388|PLACEBO_COMPARATOR|Placebo|
62634358|NCT01480388|EXPERIMENTAL|JNJ-39758979 (10 mg/d)|
62634359|NCT01480388|EXPERIMENTAL|JNJ-39758979 (30 mg/d)|
62634360|NCT01480388|EXPERIMENTAL|JNJ-39758979 (100 mg/d)|
62634361|NCT01480388|EXPERIMENTAL|JNJ-39758979 (300 mg/d)|
62634362|NCT00764569||Oral Tissue measurement|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
62286950|NCT02502760|ACTIVE_COMPARATOR|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patients in the other arm but to be started after surgery.
62634363|NCT04358016|EXPERIMENTAL|terlipression|terlipression 1mg；once every 6 hours；5days
62634364|NCT04358016|ACTIVE_COMPARATOR|Control|Somatostatin，3mg， once every 12 hours; 5 days
62634365|NCT03000946|EXPERIMENTAL|Somatostatin|Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days
62634366|NCT03000946|ACTIVE_COMPARATOR|Octreotide|Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.
62634367|NCT04396132|EXPERIMENTAL|Virtual SVV|The subjects will be tested by virtual SVV. The deviation angle will be measured at 15, 30 and 45-degree head tilt to the left and right side while they are standing
62634368|NCT04157088|EXPERIMENTAL|Participants treated with darolutamide|
62286951|NCT06381830|EXPERIMENTAL|ASCT+CAR-T|Participants will receive autologous stem cell transplantation followed by chimeric antigen receptor T (CAR-T) cell therapy.
62634369|NCT04157088|EXPERIMENTAL|Participants treated with enzalutamide|
62634370|NCT05828316|EXPERIMENTAL|Intervention group|60 students (30 nursing students in alexandria- 30 nursing students in Saudi). They will participate in resilience based intervention
62634371|NCT05828316|NO_INTERVENTION|Control group|60 students (30 nursing students in alexandria- 30 nursing students in Saudi). They will not participate in resilience based intervention
62634372|NCT02584478|EXPERIMENTAL|Phase 3 -Active Treatment Arm|"Phase 3: AL3818 8 mg once daily in combination with one background chemotherapy in 21-day cycles. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~* Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~* Pegylated liposomal doxorubicin (PLD)~* Topotecan"
62271686|NCT06299527|ACTIVE_COMPARATOR|Asynchronous Exercise Group|Asynchronous telerehabilitation was carried out through the mobile application. Researchers created a record for each participant in the mobile application with the personal information of the participants. Participants were logged in to the application with an account address and password created for them. The mobile application was supervised and followed by a researcher. The principal researcher prepared an exercise program specifically for each participant. He sent the exercise program he had prepared to the relevant participants through the application. In the mobile application, all exercises are explained in video and writing.
62271687|NCT04580381||Standard Interval Dosing (SID)|Patients continuing Natalizumab treatment with standard interval dosing defined as \> 11 infusions per year
62271688|NCT04580381||Extended Interval Dosing (EID)|Patients switching to extended interval dosing defined as ≤ 10 infusions per year
62271689|NCT00749996|EXPERIMENTAL|Investigational group|Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
62271690|NCT00749996|ACTIVE_COMPARATOR|Control group|Single level herniectomy
62066764|NCT04437225|EXPERIMENTAL|Single Oral Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. At 8:30 am, subjects will ingest the carbon-13 glycolate, dissolved in to 50 ml (about 1/4 cup) of water. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, intravenous (IV) blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
62066765|NCT03560245|EXPERIMENTAL|Bryostatin 20µg|20µg Bryostatin administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
62066766|NCT03560245|PLACEBO_COMPARATOR|Placebo|"Placebo administered IV over 45 minutes every other weekafter 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.~The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
62066767|NCT06361667|EXPERIMENTAL|Active Group (AG)|This arm will receive the arts intervention (any of the arts interventions).
62066768|NCT06361667|PLACEBO_COMPARATOR|Waitlist Control (WL)|This arm will be the waitlist control and after 3 months it will be active.
62271691|NCT01780831|EXPERIMENTAL|Cohort 1|"HIV-1-exposed full-term infants. Infants received two single doses of RAL: first dose within 48 hours of birth and second dose at 7-10 days of life:~* RAL-naive: 3 or 2 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life.~* RAL-exposed: 1.5 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life."
62271692|NCT01780831|EXPERIMENTAL|Cohort 2|"HIV-1-exposed full-term infants. Daily RAL through 6 weeks of life with first dosing within 48 hours of birth and between 12-60 hours of birth for in utero RAL-naive and RAL-exposed infants, respectively.~Daily RAL through 6 weeks of life: 1.5 mg/kg once daily during Days 1-7 of life, 3.0 mg/kg twice daily during Days 8-28 of life, and 6.0 mg/kg twice daily during Days 29-42 of life."
62271693|NCT00501813|ACTIVE_COMPARATOR|surgery|initial palliative hepatectomy followed by TACE and/or local regional treatment
62271694|NCT00501813|EXPERIMENTAL|no surgery|TACE combined with local regional treatment without hepatectomy
62271695|NCT02416284|EXPERIMENTAL|NFBDG|Multi-faceted, 2 week intervention to increase compliance to the NFBDG.
62271696|NCT03911765|EXPERIMENTAL|Executive Function cognitive training|20 hours of digital cognitive training targeting executive function.
62271697|NCT03911765|ACTIVE_COMPARATOR|Games|10 hours of computer games c available online which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc), followed by 10 hours of of digital cognitive training targeting executive function.
62271698|NCT06287320||NSCLC patients received CRT plus ICIs|"For it's an observational study, locally advanced NSCLC patients received CRT with induction immunotherapy or consolidation immunotherapy will be divided into the group NSCLC patients received CRT plus ICIs."
62066769|NCT00960752|ACTIVE_COMPARATOR|Group 1: gp100 and MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
62066770|NCT00960752|ACTIVE_COMPARATOR|Group 2: gp100 and MAGE-3|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
62066771|NCT00960752|ACTIVE_COMPARATOR|Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
62066772|NCT03659253|EXPERIMENTAL|Oral Fluid Based Self Testing|All study participants that received intervention and meet inclusion criteria intervention that will be offered OFT
62271699|NCT06287320||NSCLC patients received CRT|"For it's an observational study, locally advanced NSCLC patients received CRT without immunotherapy will be divided into the group NSCLC patients received CRT."
62271700|NCT02467530|EXPERIMENTAL|AGE diet|Dietary intervention consistent of consuming low amounts of (AGEs).
62271701|NCT02467530|NO_INTERVENTION|Original diet|Patients will continue their original diet.
62634373|NCT02584478|OTHER|Phase 3-Control Treatment Arm|"Control Treatment Arm: Background chemotherapy treatment alone. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~* Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~* Pegylated liposomal doxorubicin (PLD)~* Topotecan"
62271702|NCT01052311|PLACEBO_COMPARATOR|Placebo|Placebo pills once daily
62271703|NCT01052311|ACTIVE_COMPARATOR|Active treatment|Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.
62286952|NCT04152876||Cases|Patients with rare disease
62066773|NCT03659253|NO_INTERVENTION|Control Group|All HIV Patients in the clinic that not received any intervention
62066774|NCT03659253|EXPERIMENTAL|Simplified ART Initiation|All study participants that received intervention and meet inclusion criteria intervention that will be offered SAI
62066775|NCT03659253|EXPERIMENTAL|CBO AND BROTHEL-BASED ART SERVICE|All patients coming to brothel or Community Based Organization services will be offered to get tested and received ART
62286953|NCT04152876||controls|Healthy parents and relatives
62066776|NCT03659253|EXPERIMENTAL|SMS Reminder|"All patients that recently found HIV Positive HIV Naive offered to get SMS Reminder"
62066777|NCT03659253|EXPERIMENTAL|Motivational Interviewing|PWID in Jakarta and Bandung that recently found HIV Positive or lost to follow up ARV offered MI intervention
62066778|NCT02487550|EXPERIMENTAL|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
62066779|NCT02487550|OTHER|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
62066780|NCT02536001|OTHER|One mesh Endofast reliant system|Patients with anterior compartment stage III and uterus prolapse grade II will be treated with one mesh - Anterior Endofast reliant system (fixation of posterior arms to the sacrospinous ligament)
62066781|NCT02536001|OTHER|two meshes Endofast reliant system|intervention: Patients with anterior compartment stage III and uterus prolapse grade II will be treated with 2 meshes: anterior Endofast reliant system mesh to correct the anterior compartment and posterior Endofast reliant system mesh to correct the apical prolapse (fixation to the sacrospinous ligament)
62066782|NCT00157807|NO_INTERVENTION|No Ablation|
62066783|NCT00157807|OTHER|bipolar radiofrequency ablation of persistent and permanent AF|intra operative bipolar RF ablation of persistent and permanent AF
62066784|NCT04804774|EXPERIMENTAL|WW program modified for people with Type 2 diabetes|Includes weekly Virtual Workshops and use of the WW App.
62066785|NCT05633407|EXPERIMENTAL|Efgartigimod|Receive efgartigimod IV 10mg/kg during weekly infusions during a treatment period of 24 weeks
62066786|NCT05633407|PLACEBO_COMPARATOR|Placebo|Receive a matching placebo during weekly infusions during a treatment period of 24 weeks
62066787|NCT05304715|PLACEBO_COMPARATOR|Placebo|Patients will be treated with 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
62066788|NCT05304715|ACTIVE_COMPARATOR|Bezlotoxumab|Patients will be treated with bezlotoxumab at a dose of 10mg per kg of body weight (up to maximum of 1000mg) dissolved in 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
62453134|NCT04480398||Control|Standard care for asymptomatic confirmed cases is isolation (to contain virus transmission) and clinical monitoring as per recommended Guidelines.
62634374|NCT02584478|EXPERIMENTAL|Phase 1b: AL3818 plus carboplatin and paclitaxel|Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.
62066789|NCT03355755|EXPERIMENTAL|Interventional Group|All participants will be included in the interventional group. Intervention will consist of walking exercise using the EksoGT exoskeleton for supported walking, running SmartAssist software.
62066790|NCT02076074|EXPERIMENTAL|Treatment (HG-PBI)|Patients undergo single fraction high gradient-partial breast irradiation within 8 weeks after partial mastectomy.
62271704|NCT03283800|EXPERIMENTAL|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
62066791|NCT02372864|NO_INTERVENTION|Care as usual|"All participants in the intervention and control group receive the care as usual. The care as usual consists of a clinic appointment with the research nurse. In this appointment the RRSO-induced menopausal complaints will be discussed in more detail. Depending on the complaints at hand, information, reassurance and life style advice will be offered. A leaflet with relevant information will be provided for. Furthermore, the usual medical care may include prescription of (non-)hormonal medicationsTwelve weeks after the clinic appointment, the research nurse will contact all participants per telephone to ask whether there are issues that remain to be addressed.~Participants are allowed to continue the use of all their current medication."
62066792|NCT02372864|EXPERIMENTAL|Mindfullness based stress reduction|
62066793|NCT02873026|NO_INTERVENTION|Standard care|The patient will receive the standard care given to all patients that have received a vitrectomy following open globe trauma.
62271705|NCT03283800|PLACEBO_COMPARATOR|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
62634375|NCT02584478|EXPERIMENTAL|Phase 2a: AL3818 plus carboplatin and paclitaxel|Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b.
62634376|NCT05927792|EXPERIMENTAL|Intervention Group|participants in intervention group will receive accelerated continuous theta-burst stimulation (a-cTBS) on the left primary motor cortex (M1) for 5 consecutive days.
62634377|NCT05927792|SHAM_COMPARATOR|Sham Group|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
62066794|NCT02873026|EXPERIMENTAL|Triamcinolone acetonide|Triamcinolone Acetonide 4mg/0.1ml intravitreal cavity and 40mg/1ml subtenons to be injected at the time of the vitrectomy. Patients will then receive standard care following operation.
62066795|NCT06329674|EXPERIMENTAL|AJU-A51+A51R2 placebo+A51R3|
62066796|NCT06329674|EXPERIMENTAL|AJU-A51 placebo+A51R2+A51R3|
62271706|NCT01730235||Case Group|Group receiving access to MyMediHealth web site.
62271707|NCT01730235||Control Group|Children completing baseline and week two measures, but without any additional intervention.
62271708|NCT05033496||Newborn infants|Newborn infants born in our medical center
62271709|NCT02554539|EXPERIMENTAL|Obese|Women, aged 21-45 with BMI \>30
62271710|NCT02554539|EXPERIMENTAL|Normal weight|Women, aged 21-45 with BMI \< 25
62286954|NCT03089307|ACTIVE_COMPARATOR|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
62066797|NCT02206022|EXPERIMENTAL|Remifentanil|Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion
62066798|NCT02206022|PLACEBO_COMPARATOR|Placebo|Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion
62066799|NCT06220383|EXPERIMENTAL|Hall technique|In the Hall technique method, an orthodontic separator was placed 2 days before the procedure to create distance for the crown in the mesial and distal contact areas of the tooth on which the crown will be placed. A stainless steel crown was cemented on the tooth with glass ionomer cement without local anesthesia, caries cleaning or any preparation. The participant was asked to close the teeth tightly for 2-3 minutes.
62286955|NCT03089307|ACTIVE_COMPARATOR|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
62286956|NCT03426176|EXPERIMENTAL|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
62286957|NCT03426176|EXPERIMENTAL|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
62286958|NCT03426176|EXPERIMENTAL|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
62286959|NCT03426176|PLACEBO_COMPARATOR|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
62271711|NCT03601286|EXPERIMENTAL|Lentiviral vector transduced CD34+ cells|Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
62271712|NCT05122234|EXPERIMENTAL|Secretome - mesenchymal stem cell group (n = 20)|This group will be given secretome - mesenchymal stem cell and COVID-19 standard therapy
62271713|NCT05122234|PLACEBO_COMPARATOR|Control ( n= 20)|This group will be given placebo and COVID-19 standard therapy
62271714|NCT03797469|ACTIVE_COMPARATOR|Nicotinamide and Pyruvate (N&P)|This group will receive two separate sets of tablets containing 3 x 1000 mg of Vitamin B3 (nicotinamide) and 2 x 1500 mg of Pyruvate.
62271715|NCT03797469|PLACEBO_COMPARATOR|Placebo|This group will receive an equal number of tablets as the N\&P group.
62271716|NCT05459623|ACTIVE_COMPARATOR|Manual myofascial release|Manual myofascial release as conventional treatment
62271717|NCT05459623|EXPERIMENTAL|Emmett intervention|Emmett intervention and myofascial release
62271718|NCT03099486|EXPERIMENTAL|Regorafenib + 5FU/LV Treatment Arm|
62271719|NCT00089908|EXPERIMENTAL|1|One subcutaneous vaccination with rDEN1delta30 vaccine (10\^3 PFU dose) into the deltoid region of either arm.
62271720|NCT00089908|EXPERIMENTAL|2|One subcutaneous vaccination with rDEN1delta30 vaccine (10\^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
62271721|NCT00089908|PLACEBO_COMPARATOR|3|One subcutaneous vaccination with placebo into the deltoid region of either arm.
62271722|NCT04900597|EXPERIMENTAL|Elecare - Nourish - Real Foods Blends|Elecare for first bolus, Nourish for second bolus, Real Foods Blends for third bolus
62271723|NCT04900597|EXPERIMENTAL|Nourish - Real Foods Blends - Elecare|Nourish for first bolus, Real Foods Blends for second bolus, Elecare for first bolus
62271724|NCT04900597|EXPERIMENTAL|Real Foods Blends - Elecare - Nourish|Real Foods Blends for first bolus, Elecare for second bolus, Nourish for third bolus
62271725|NCT01781221|ACTIVE_COMPARATOR|Alpha-Bio's GRAFT Natural Bovine Bone|two different bone substitutes commonly used in dental procedures.
62271726|NCT01781221|ACTIVE_COMPARATOR|Bio-Oss xenograft|two different bone substitutes commonly used in dental procedures.
62271727|NCT02486055|ACTIVE_COMPARATOR|Cohort 1|In Cohort 1, doses of BPM31510 Oral Nanosuspension 4% will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
62271728|NCT02486055|ACTIVE_COMPARATOR|Cohort 2|In Cohort 2 doses BPM31510 Oral Nanosuspension 4% will be administered three times per day before meals, with no less than 4 and no more than 6 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
62453135|NCT04071600|PLACEBO_COMPARATOR|Placebo|Type two trauma patients randomly assigned to be administered the vehicle (water) with Kurve intranasal device once and followed for up to 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
62271729|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
62271730|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
62271731|NCT03237065|EXPERIMENTAL|Iron isomaltoside/ferric derisomaltose|Administered IV
62634378|NCT02735980|EXPERIMENTAL|Prexasertib (Platinum Sensitive Disease)|105 mg/m\^2 Intravenous (IV) prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had platinum-sensitive disease (has prior platinum based therapy with subsequent progression greater or less than 90 days after last dose of platinum based therapy).
62634379|NCT02735980|EXPERIMENTAL|Prexasertib (Platinum Resistant Disease)|105 mg/m\^2 IV prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had resistant/refractory disease (did not have an objective response to platinum-based therapy or had progression greater than 90 days after the last dose of platinum).
62634380|NCT02735980|EXPERIMENTAL|Prexasertib Exploratory Addendum (Platinum Sensitive Disease)|40 mg/m\^2 IV prexasertib Day 1, 2, and Day 3 of a 14 day cycle in participants with ED-SCLC platinum sensitive disease.
62066800|NCT06220383|ACTIVE_COMPARATOR|Conventional technique|In the conventional technique, after the area to be anesthetized was dried, topical anesthetic solution (Locanest 10% spray lidocaine, Avixa, Turkey) was applied to the mucosa with a cotton pellet for one minute. For infiltrative anesthesia, 4% articaine solution (Ultracaine DS Forte ampoule, Sanofi-Aventis GmbH, Germany) containing 1 ml of 1:100,000 epinephrine was applied. Preparation was made on the mesial, distal and occlusal sides of the tooth. The decay was cleaned and the cavity was filled with glass ionomer cement (Ketac Molar Easymix, 3M™ ESPE™, St. Paul, MN, USA). The stainless steel crown was bonded with glass ionomer cement (Ketac Cem Easymix, 3M™ ESPE™, St. Paul, MN, USA).
62066801|NCT04139148|ACTIVE_COMPARATOR|True tDCS Combined With CCAT|Ture transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including drug knowledge every week, self-evaluation every two weeks and outpatient follow-up reminder every four weeks.
62634381|NCT00827515|EXPERIMENTAL|One|
62634382|NCT00827515|EXPERIMENTAL|Two|
62634383|NCT00827515|EXPERIMENTAL|Three|
62634384|NCT00827515|EXPERIMENTAL|Four|
62634385|NCT02937181|EXPERIMENTAL|open fractures type II and III|Every patients will receive Ceftaroline in an open label, single arm
62066802|NCT04139148|SHAM_COMPARATOR|Sham tDCS Combined With CCAT|Sham transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including only outpatient follow-up reminder every four weeks.
62066803|NCT04139148|NO_INTERVENTION|Control group|During the treatment, the participants in control group only received treatment such as education of psychology, health and judicature, physical training as well as vocational training as usual in the compulsory rehabilitation center.
62271732|NCT03237065|ACTIVE_COMPARATOR|Ferric carboxymaltose|Administered IV
62271733|NCT05102955||1/Observational Questionnaires|All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters(physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
62271734|NCT02240654||Dabigatran etexilate|
62271735|NCT04644809|EXPERIMENTAL|LY3561774 (Part A)|Single ascending doses of LY3561774 administered subcutaneously (SC).
62271736|NCT04644809|EXPERIMENTAL|LY3561774 (Part B)|Repeat doses of LY3561774 administered SC.
62271737|NCT04644809|EXPERIMENTAL|LY3561774 (Part C)|Single doses of LY3561774 administered SC in Japanese Participants.
62634386|NCT01255904|EXPERIMENTAL|Arm 1|Oral Chloral and intranasal placebo
62634387|NCT01255904|EXPERIMENTAL|Arm 2|oral placebo and intranasal dexmedetomidine
62271738|NCT04644809|PLACEBO_COMPARATOR|Placebo (Part A, B & C)|Placebo administered SC.
62271739|NCT03033186||Everolimus (afinitor)|Patients using everolimus as therapy for cancer: Advanced (Hormone-Receptor \[HR\]-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC)
62271740|NCT00793650|ACTIVE_COMPARATOR|Bortezomib before Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours before melphalan.
62271741|NCT00793650|ACTIVE_COMPARATOR|Bortezomib after Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours after melphalan.
62271742|NCT05747911||Migraine|
62271743|NCT05747911||Without Migraine|
62271744|NCT01090882|SHAM_COMPARATOR|Control|Sham wash, sham injection
62271745|NCT01090882|EXPERIMENTAL|Subperitoneal injection|Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
62271746|NCT01090882|ACTIVE_COMPARATOR|Topical LA|Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm
62271747|NCT04869085|EXPERIMENTAL|e-PainSupport Condition|e-PainSupport is a self-administered, digital pain application. Over the course of the two weeks, caregivers and patients will record the severity of patient's pain and how much pain medicine they use to control patient's pain in the e-PainSupport application.
62271748|NCT04869085|NO_INTERVENTION|Standard Care Condition|Patients and caregivers will be given a paper copy of the same list of resources for pain management included in the Education Module of the e-PainSupport condition at baseline.
62066804|NCT04762225|EXPERIMENTAL|RPTR-168|Escalating doses of RPTR-168 as a monotherapy in HPV-16 E6/E7 positive tumors and melanoma.
62271749|NCT02565979|ACTIVE_COMPARATOR|Resveratrol|resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
62271750|NCT02565979|PLACEBO_COMPARATOR|Placebo|placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
62271751|NCT01657409|EXPERIMENTAL|BoNT-A (10 injection)|100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body
62271752|NCT01657409|EXPERIMENTAL|BoNT-A (20 injections)|100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body
62271753|NCT01657409|EXPERIMENTAL|BoNT-A (40 injections)|100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body
62271754|NCT02723123|EXPERIMENTAL|CPAP|CPAP will be provided for a approximately 45 minutes.
62271755|NCT02723123|EXPERIMENTAL|NIPPV|NIPPV will be provided for a approximately 45 minutes.
62066805|NCT04095221|EXPERIMENTAL|Prexasertib and Irinotecan|Patients will have extent of disease scans following every 2 cycles (every 6 weeks on dose levels 0-3, and every 8 weeks on dose level -1 (if required). Patients will be allowed to continue therapy as long as they do not experience dose-limiting toxicities or progression of disease.
62271756|NCT02723123|EXPERIMENTAL|NIV-NAVA|NIV-NAVA will be provided for a approximately 45 minutes.
62271757|NCT06320483||Group with percussion massage|
62066806|NCT02820805|EXPERIMENTAL|Meal skipping|No meal given
62066807|NCT02820805|EXPERIMENTAL|Mashed potatoes|Carbohydrate Test Meal (50 g of available carbohydrates)
62271758|NCT06320483||Group with vibroacoustic massage|
62271759|NCT04513002|OTHER|Group 1: Triheptanoin and no Placebo|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.~Group 1: 10%, 20%, 35%, 35%, 35% (no placebo). Group 2: placebo, 10%, 20%, 35%, 35% Group 3: placebo, placebo, 10%, 20%, 35%"
62271760|NCT04513002|OTHER|Group 2: Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.~Group 1: 10%, 20%, 35%, 35%, 35% (no placebo). Group 2: placebo, 10%, 20%, 35%, 35% Group 3: placebo, placebo, 10%, 20%, 35%"
62271761|NCT04513002|OTHER|Group 3: Placebo, Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.~Group 1: 10%, 20%, 35%, 35%, 35% (no placebo). Group 2: placebo, 10%, 20%, 35%, 35% Group 3: placebo, placebo, 10%, 20%, 35%"
62271762|NCT03697187||Hereditary Angioedema|Patients with Hereditary Angioedema who are receiving treatment with Ruconest (rhC1INH).
62453136|NCT04071600|ACTIVE_COMPARATOR|Neuropeptide Y|The individuals in this arm will be randomly assigned to be administered intranasal NPY with Kurve intranasal device once and will be followed for at least 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
62271763|NCT00927836|EXPERIMENTAL|AX200|
62271764|NCT00927836|PLACEBO_COMPARATOR|Placebo|
62453137|NCT04071600|NO_INTERVENTION|Control|The individuals in this arm will be randomly assigned and treated the same as the other arms but with no intervention.
62453138|NCT05889338|ACTIVE_COMPARATOR|Case: adults with severe psoriasis treated by adalimumab therapy.|
62286960|NCT05238038||Healthy|EIT measurements will be performed on appendicular muscles (in the upper and lower extremities) depending on the condition, both at rest and with contraction. EIT measurements will be repeated on an intermittent basis to assess repeatability as well disease progression or improvement over time
62453139|NCT05889338|ACTIVE_COMPARATOR|Control: adults with severe psoriasis treated by methotrexate therapy.|
62453140|NCT05656742|EXPERIMENTAL|Vitamin D|5,000 IU of oral vitamin D3 in white powder form, daily for 8 continuous weeks
61978633|NCT03420469|EXPERIMENTAL|CYP2D6 activity after treatment with bupropion to steady sate|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
61978634|NCT03036761|EXPERIMENTAL|AUR+: Auriculotherapy|Patients benefit from 3 sessions of auriculotherapy at one month intervals.
61978635|NCT03036761|NO_INTERVENTION|AUR-: No auriculotherapy|Patients do not benefit from auriculotherapy.
62066808|NCT02820805|EXPERIMENTAL|French fries|Carbohydrate Test Meal (50 g of available carbohydrates)
62066809|NCT02820805|EXPERIMENTAL|Hash browns|Carbohydrate Test Meal (50 g of available carbohydrates)
62066810|NCT02820805|EXPERIMENTAL|Rice|Carbohydrate Test Meal (50 g of available carbohydrates)
62066811|NCT02820805|EXPERIMENTAL|Beans|Carbohydrate Test Meal (50 g of available carbohydrates)
62066812|NCT03862196|EXPERIMENTAL|Intervention|Participants will receive 2 tailored text messages weekly from a trained counselor during 3 months.
62066813|NCT03862196|NO_INTERVENTION|Control|Participants will receive standard of care: pre and post counseling after being diagnosed with HIV
62066814|NCT03061448|EXPERIMENTAL|Inhibitory learning based treatment|The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.
62066815|NCT03061448|ACTIVE_COMPARATOR|Habituation based treatment|The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).
62066816|NCT05431634|PLACEBO_COMPARATOR|Placebo|Placebo for ESK-001
62066817|NCT05431634|EXPERIMENTAL|Experimental Drug ESK-001|Experimental Drug ESK-001
62066818|NCT05318534|EXPERIMENTAL|GL-0719|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Single Ascending IV Dose Cohorts~* Cohort 1: 4 subjects~* Cohort 2: 8 subjects~* Cohort 3: 8 subjects~* Cohort 4: 8 subjects~* Cohort 5: 8 subjects~Subcutaneous Injection Cohort~* Cohort 6: 8 subjects~* Cohort 7: 8 subjects~* Cohort 8 (Patient Arm): Up to 6 subjects with Cold Agglutinin Disease (CAD); Placebo is not applicable."
62066819|NCT05318534|PLACEBO_COMPARATOR|Placebo|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Single Ascending IV Dose Cohorts~* Cohort 1: 4 subjects~* Cohort 2: 8 subjects~* Cohort 3: 8 subjects~* Cohort 4: 8 subjects~* Cohort 5: 8 subjects~Subcutaneous Injection Cohort~* Cohort 6: 8 subjects~* Cohort 7: 8 subjects"
62066820|NCT01992705|OTHER|Chemotherapy+SBRT prior to surgery if applicable|"FOLFIRINOX Drugs:~* Calcium Folinate (Folinic Acid) 400 mg IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles.~Stereotactic Body Radiotherapy (SBRT):~30 Gy in 5 fractions given to radiographically defined pancreatic mass alone"
62066821|NCT06172608|EXPERIMENTAL|Intervention Group (I)|Intervention group (I) will be receiving a psychoeducational intervention along with routine care they are getting in the hospital
62066822|NCT06172608|NO_INTERVENTION|Control group (C)|Comparison usual care and Leaflet of the information. At the end of the trial these also get the video and educational sessions as intervention group.
62271765|NCT00700271|EXPERIMENTAL|Morning Intake|After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP \>= 140 mmHg and/or msDBP \>= 90 mmHg or msSBP \>= 130 mmHg and/or msDBP \>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \< 140 mmHg and msDBP \< 90 mmHg or msSBP \< 130 mmHg and msDBP \< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
62453141|NCT05991739|EXPERIMENTAL|Treatment|Participants in the treatment arm will begin the FIESTA intervention immediately (Time 1).
62634388|NCT02635919|EXPERIMENTAL|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
62066823|NCT06625359|EXPERIMENTAL|Treatment arm|"Patients with histologically confirmed primary central nervous system lymphoma or secondary CNS lymphoma defined as either synchronous CNS involvement of sys- temic NHL or as a site of recurrence in a patient s with a history of systemic NHL~* Patients who achieved remission after first line chemotherapy and/or WBRT, or who experience relapse of PCNSL/SCNLS.~* Patients who have not previously received therapy with high high-dose chemotherapy and stem cell transplantatitransplantation.~* The performance st atus of the patients should be 2 or less by ECOG performance scale.~* Patients should not have major illness or organ failure incompatible with autologous stem cell transplantation."
62066824|NCT03692221|EXPERIMENTAL|MSC treatment group 1|Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution
62453142|NCT05991739|OTHER|Waitlist-Control|Participants in the waitlist-control arm will wait approximately three months for the FIESTA intervention (Time 2).
62453143|NCT01774266||Molina - Chile|Molina is one of the counties with the highest mortality rate of gastric cancer in Chile. Molina has a population of 40.000 hab mostly rural. Half of the population lives in Molina city and the other half in the suburbs. Molina is located near the Mountain Andes.
62634389|NCT02635919|NO_INTERVENTION|Control|Smokers in this group will not be given the mSMART application.
62634390|NCT04202497|EXPERIMENTAL|TAK-418 1.5 mg|TAK-418 1.5 milligram (mg), orally, once on Day 1. Participants will also receive 10 millicurie (mCi) of \[18F\]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3. Dose levels for subsequent participants may vary based on available review of imaging and pharmacokinetics (PK) data.
62634391|NCT06611709|EXPERIMENTAL|Kinesiotaping|Kinesiotaping (real) + exercises
62634392|NCT06611709|SHAM_COMPARATOR|Sham-taping|Sham-taping (non-elastic medical cloth tape) + exercises
62634393|NCT02993198|EXPERIMENTAL|Prophylactic Carvedilol|Carvedilol 3.125 mg by mouth every 12 hours, titrated to a max dose of 25 mg by mouth every 12 hours, depending on blood pressure and heart rate, until completion of study.
62634394|NCT02993198|NO_INTERVENTION|No Therapy|Standard of care monitoring without prophylactic treatment.
62634395|NCT01493050|EXPERIMENTAL|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
62634396|NCT01493050|ACTIVE_COMPARATOR|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
62634397|NCT02949947|EXPERIMENTAL|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
62634398|NCT02949947|ACTIVE_COMPARATOR|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
62634399|NCT04354415|ACTIVE_COMPARATOR|Tourniquet Group|Tourniquet application during procedures
61978636|NCT04389424||Anastrozole|Breast cancer women with anastrozole treatment
62066825|NCT03692221|ACTIVE_COMPARATOR|MSC treatment group 2|High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution
62066826|NCT03692221|ACTIVE_COMPARATOR|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
62066827|NCT03062059|PLACEBO_COMPARATOR|Normal saline|Intravesical 52.6ml normal saline instillation during radical nephroureterectomy followed by normal saline bladder irrigation
62634400|NCT04354415|EXPERIMENTAL|Non-Tourniquet group|No application of tourniquet for procedures
62634401|NCT03319316|EXPERIMENTAL|Cohort 1 - Non-squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
62271766|NCT00700271|EXPERIMENTAL|Evening Intake|After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP \>= 140 mmHg and/or msDBP \>= 90 mmHg or msSBP \>= 130 mmHg and/or msDBP \>= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP \< 140 mmHg and msDBP \< 90 mmHg or msSBP \< 130 mmHg and msDBP \< 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
62634402|NCT03319316|NO_INTERVENTION|Cohort 1 - Non-squamous - Arm B|Patients receive a maintenance treatment of pemetrexed
62066828|NCT03062059|EXPERIMENTAL|Gemcitabine|Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy followed by normal saline bladder irrigation
62066829|NCT03651063|EXPERIMENTAL|social robot group|
62066830|NCT03651063|ACTIVE_COMPARATOR|computer group|
62066831|NCT03651063|NO_INTERVENTION|contro: no intervention|This group will only be a follow up: clinical examination at the entrance and follow 5 weeks with clinical examination 5 weeks post, with no intervention.
62066832|NCT00977496||Nasal Swab|New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
62066833|NCT02128256|EXPERIMENTAL|Cerament G injection|Cerament G is injected to fill a bone defect after debridement of the infected bone.
62066834|NCT02419729|EXPERIMENTAL|CO2 laser & Estrogen|Effective fractional CO2 laser therapy and effective estrogen vaginal cream
62634403|NCT03319316|EXPERIMENTAL|Cohort 2 - Squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
62066835|NCT02419729|ACTIVE_COMPARATOR|CO2 laser & Placebo of Estrogen|Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
62066836|NCT02419729|SHAM_COMPARATOR|Placebo of CO2 laser & Estrogen|Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.
62066837|NCT03581123|EXPERIMENTAL|Supported-Self management (SSM)|Supported-Self management
62066838|NCT03581123|EXPERIMENTAL|Spinal Manipulation Therapy (SMT)|Spinal Manipulation Therapy
62066839|NCT03581123|EXPERIMENTAL|SMT + SSM|Spinal Manipulation Therapy + Supported Self-Management
62066840|NCT03581123|ACTIVE_COMPARATOR|Standard Medical Care (SMC)|Standard Medical Care
62066841|NCT05036928||HIV infection group|
62066842|NCT02568579||Breastfed|collection of blood/stool/breast milk samples and information about feeding changes and introduction of solid foods. - Cord Blood sample, stool samples monthly and blood sample at 6 month and 12 months of age
62271767|NCT04082195|EXPERIMENTAL|Fooya mobile game|An arm that receives a mobile-app-based treatment.
62271768|NCT04082195|ACTIVE_COMPARATOR|Uno board game|An arm that receives a non mobile-app-based treatment.
62271769|NCT03285997|EXPERIMENTAL|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
62634404|NCT03319316|NO_INTERVENTION|Cohort 2 - Squamous - Arm B|Patients will have observation
62634405|NCT05737264||TAVR group|The group that undergoes transcatheter aortic valve replacement
62634406|NCT03871192|EXPERIMENTAL|FACET JOINT UNDER CT GUIDANCE|Injection of the facet joint under computed tomography guidance
62066843|NCT02568579||Bottlefed|collection of blood/stool samples and information about feeding changes and introduction of solid foods. Coord blood sample, stool samples monthly and blood sample at 6 month and 12 month of age.
62634407|NCT03871192|ACTIVE_COMPARATOR|NERVE BLOCK UNDER CT GUIDANCE|Injection of the nerve under computed tomography guidance
62634408|NCT03871192|EXPERIMENTAL|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|Injection of the facet joint under fluoroscopy guidance
62634409|NCT03871192|ACTIVE_COMPARATOR|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|Injection of the nerve under ultrasound guidance
62634410|NCT03871192|EXPERIMENTAL|FACET JOINT UNDER ULTRASOUND GUIDANCE|Injection of the facet joint under ultrasound guidance
62271770|NCT03285997|ACTIVE_COMPARATOR|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
62066844|NCT01032044|ACTIVE_COMPARATOR|Standard endoscopic evaluation|Standard high-definition white light endoscopy guided evaluation
62066845|NCT01032044|EXPERIMENTAL|pCLE-guided evaluation|Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
62066846|NCT02091739|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) (100 Units)|"* Main period (1 treatment cycle): Subjects to receive 100 Units.~* Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.~* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
62271771|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
62271772|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
62286961|NCT05238038||Neuromuscular disease patients and Central neurological disease patients|EIT measurements will be performed on appendicular muscles (in the upper and lower extremities) depending on the condition, both at rest and with contraction. EIT measurements will be repeated on an intermittent basis to assess repeatability as well disease progression or improvement over time
62453144|NCT02375009|EXPERIMENTAL|Treatment Cohort|All subjects will receive bilateral 360 degree Selective Laser Trabeculoplasty therapy in a single session, but will be randomized to one of three treatment sessions at times 0, Month 3 and Month 6. Subjects will be washed out of current IOP-lowering therapy 4-6 weeks pre-SLT. Subjects continuing on meds beyond time 0 will provide a comparator to early SLT to quantify regression to the mean.
62453145|NCT01098721|PLACEBO_COMPARATOR|Group 1|A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.
62453146|NCT01098721|ACTIVE_COMPARATOR|Group 2|A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.
62453147|NCT03728842||Spontaneous regression|Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
62634411|NCT03871192|ACTIVE_COMPARATOR|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|Injection of the nerve under computed ultrasound guidance
62634412|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
62634413|NCT04560959|EXPERIMENTAL|tACS arm|The patient would receive strings of tACS stimulations in 77.5 HZ, each string would last for 1 second, followed by an interval of 5 seconds. A total of 600 strings would be sent out to the patients.
62634414|NCT04472546|OTHER|Control subject group|"Divided in 5 subgroups :~* A': associated to acne of the face subgroup~* B' : associated to atopic dermatitis of the upper limb subgroup~* C' : associated to vulgar plaque psoriasis subgroup~* D' : associated to telangiectasic erythrocouperosis papule of the face (rosacea) subgroup~* E' : associated to seborrheic dermatitis of scalp subgroup"
62634415|NCT04472546|OTHER|Subject group with dermatitis|"Divided in 5 subgroups :~* A : acne of the face subgroup~* B : Atopic dermatitis of the upper limb subgroup~* C : Vulgar plaque psoriasis subgroup~* D : Telangiectasic erythrocouperosis papule of the face (rosacea) subgroup~* E : Seborrheic dermatitis of scalp subgroup"
62634416|NCT05282368|EXPERIMENTAL|Intervention (PHM)|This pathway is intended to be a tool to enhance support for a mother/birthing person and her caregiving partner, facilitate communication with healthcare providers, and promote development of caregiving to optimize maternal-fetal, infant, and family health.
62634417|NCT05282368|NO_INTERVENTION|Usual Care Group (UC)|The control group participants will receive care as usual.
62634418|NCT01589419|EXPERIMENTAL|veliparib and capecitabine and radiation|Veliparib on days 1-7, capecitabine and radiation on days 1-5
62634419|NCT00490971|EXPERIMENTAL|Paliperidone ER|
62634420|NCT00490971|PLACEBO_COMPARATOR|Placebo|
62634421|NCT00490971|ACTIVE_COMPARATOR|Olanzapine|
62066847|NCT02091739|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) (75 Units)|"* Main period (1 treatment cycle): Subjects to receive 75 Units.~* Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.~* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
62066848|NCT02091739|PLACEBO_COMPARATOR|Placebo|"* Main period (1 treatment cycle): Subjects to receive placebo injection.~* Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.~* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
62453148|NCT01624220|EXPERIMENTAL|Hypofractionated Radiation|"All patients receive CT-guided spinal SBRT using IMRT to maximize conformality of treatment plan to target volume, while sparing normal structures. Dose given to tumor and number of treatments received determined by patient's doctor.~In second stage, characterize tolerance of esophagus to hypofractionated radiation doses through prospective constraint relaxation and toxicity monitoring. Data collected from Group 1 in first stage will give data on dose delivered to esophagus. Second stage of protocol will begin accrual once Group 1 has filled. Dose constraints used for Groups 3 allow higher dose. Dose constraints for Group 4 represent modest increase of esophageal dose maximums."
62634422|NCT04401332|EXPERIMENTAL|Intervention|
62634423|NCT04401332|NO_INTERVENTION|Usual Care|
62066849|NCT03820479||Apfel score 1|Female
62066850|NCT03820479||Apfel score 2|Female, non smoker
62066851|NCT03820479||Apfel score 3|Female, non smoker, under 40 years old
62634424|NCT02504320|EXPERIMENTAL|Treatment Sequence ABDC|Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
62634425|NCT02504320|EXPERIMENTAL|Treatment Sequence DACB|Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
62634426|NCT02504320|EXPERIMENTAL|Treatment Sequence CDBA|Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
62634427|NCT02504320|EXPERIMENTAL|Treatment Sequence BCAD|Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
62634428|NCT01725633|OTHER|Progressive Stretching Group|
62634429|NCT01725633|EXPERIMENTAL|Nonlinear Aerobic Training|
62634430|NCT05238688|EXPERIMENTAL|Thoracic Epidural Analgesia (TEA) group|Patients in this group will receive Thoracic Epidural analgesia.
62634431|NCT05238688|EXPERIMENTAL|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Patients in this group will receive Thoracic Epidural analgesia in addition to high thoracic ultrasound-guided erector spinae plane block (ESPB).
62634432|NCT05292261|EXPERIMENTAL|Team handball group|The team handball group participants were encouraged to performed at least two out of three weekly supervised team handball training sessions of 60 min each, for 36 weeks.
62634433|NCT05292261|NO_INTERVENTION|Control group|The control group participants were instructed to keep their regular daily physical activity for 36 weeks.
62066852|NCT03820479||Apfel score 4|Female, non smoker, under 40 years old, previous history of PONV
62066853|NCT04772053|EXPERIMENTAL|Participants undergoing tumor biopsy|
62271773|NCT04534660|EXPERIMENTAL|Nasolabial Fold|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.~The study treatment facial areas are the Right and Left nasolabial fold. The Treating Investigator will inject SMI-01 into the mid to deep dermis for correction of moderate to severe wrinkle and folds. The Treating Investigator will determine the appropriate volume of SMI-01 to be injected during initial and touch-up treatment(s)."
61978637|NCT04389424||Tamoxifen|Breast cancer women with tamoxifen treatment
62066854|NCT06432660||Ocular Melanoma|Patients 18 years of age or older with unilateral primary choroidal melanoma
62066855|NCT04813601|EXPERIMENTAL|Robot Asissted Gait Training|The rehabilitation sessions will be carried out by a physiotherapist trained in rehabilitation with the ATLAS 2030 exoskeleton and will also have the technical supervision of personnel specialised in the handling of the laboratory and the robotic device.
62066856|NCT01468779|PLACEBO_COMPARATOR|Sugar pill|The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period.
62286962|NCT03263559|EXPERIMENTAL|Haploidentical Transplantation|A conditioning regimen with Hydroxyurea, rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, and Mesna will be administered prior to Haploidentical Bone Marrow Transplantation.
62453149|NCT01624220|EXPERIMENTAL|ExacTrac Positioning System|Analysis performed of ExacTrac positioning system with and without fiducial guidance. Four dimensional CT datasets for simulation will allow use of data from this portion of protocol to characterize degree to which organ at risk (OAR) motion is relevant at each spinal level. 20 patients accrued in two groups of 10, with 10 patients in each rostral-caudal position in the spine (Group 1: T4-T12, Group 2: L1-L5). Imaging done with fiducial markers for this study will not impact patient management. Patients will treated with standard dose constraints to normal tissues.
62634434|NCT05136417|EXPERIMENTAL|left atrial appendage (LAA) occlusion with the WATCHMAN FLX device using (ICE)|100 patients undergoing LAA closure with the WATCHMAN FLX utilizing an intra-procedural ICE probe under moderate sedation.
62453150|NCT04245826||Low-calorie Sweetened Beverages (LCSBs)|Beverages exclusively using zero-energy (e.g., acesulfame-potassium, aspartame, cyclamate, saccharin, sucralose, advantame, neotame), and /or reduced-energy food additives (e.g., stevia, monk fruit).
62453151|NCT06126393||POLE Mut|The POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation.
62453152|NCT06126393||dMMR|The mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype
62453153|NCT06126393||P53abn|The expression of p53 was detected by immunohistochemistry. The abnormality of p53 protein expression (completely negative or diffusely strong positive in the nucleus) or expression location (cytoplasmic expression) was judged as p53abn, otherwise it was p53wt.
62634435|NCT06600412|EXPERIMENTAL|R3R01|R3R01 oral tablet (200 mg twice daily) for 12 weeks
62634436|NCT06600412|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet twice daily for 12 weeks
62634437|NCT03338764|EXPERIMENTAL|Experimental (SM-1)|Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
62634438|NCT03338764|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
62453154|NCT06126393||P53wt|The expression of p53 was detected by immunohistochemistry. The abnormality of p53 protein expression (completely negative or diffusely strong positive in the nucleus) or expression location (cytoplasmic expression) was judged as p53abn, otherwise it was p53wt.
62453155|NCT06411366|EXPERIMENTAL|Experimental|
62453156|NCT01232270|ACTIVE_COMPARATOR|fentanyl|
62634439|NCT04004312|EXPERIMENTAL|Single Fraction SBRT in the treatment of prostate cancer|Prior to treatment, a hydrogel spacer will be inserted between the recutm and prostate. A urinary catheter will also be inserted in the bladder. A single dose of 19Gy will be delivered with an IMRT technique. The treatment should last approximately 30 minutes. After the treatment, the urinary catheter will be removed.
62634440|NCT02017275|EXPERIMENTAL|BuMA group|Implant BuMA stent only
62634441|NCT02017275|ACTIVE_COMPARATOR|EXCEL group|Implant EXCEL stent
62634442|NCT05915273|EXPERIMENTAL|CAD/CAM group|
62634443|NCT05915273|ACTIVE_COMPARATOR|Lab group|
62453157|NCT01232270|PLACEBO_COMPARATOR|saline|
62453158|NCT02612636|ACTIVE_COMPARATOR|ear plug and eye mask|"* The patients will not receive the intervention in the first night (N1) from 9 pm to 6 am~* The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~* The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.~* The patients will receive the intervention (eye mask and ear plug) in the fourth night (N4) from 9 pm to 6 am."
62453159|NCT02612636|NO_INTERVENTION|control|The researcher will assess and observe the patients who are receiving the routine hospital nursing care during the four nights.
62634444|NCT05915273|ACTIVE_COMPARATOR|Chairside group|
62271774|NCT04534660|EXPERIMENTAL|Cheek Augmentation|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.~The midface constitutes the area of the face below the eyes and between the nose and the left or right ear. The study treatment facial areas are the Right and Left cheeks. The Treating Investigator will inject SMI-01 deeply (subcutaneous and/or supraperiosteal plane) for cheek augmentation to correct age-related volume deficiency in the midface, i.e., zygomaticomalar region, anteromedial cheek, and/or submalar region"
62271775|NCT02555514||Knee Osteoarthritis|The study population consists of 100 enrolled patients with different stages of knee OA and varus malalignment \>4° with respect to the mechanical loading axis of the lower extremity. A minimum of 40 patients are to be included per year, so that the study period will be planned from January 1st, 2015 to June 30th, 2017. Preliminary results will be reviewed by the end of every year and intermediate reports will be generated by the sub-study-groups
62634445|NCT05183334|PLACEBO_COMPARATOR|group 1|patients with PE
62634446|NCT05183334|EXPERIMENTAL|group2|patients with PE
62634447|NCT05183334|EXPERIMENTAL|group 3|patients with PE
62634448|NCT05183334|EXPERIMENTAL|group 4|patients with PE
61978638|NCT04389424||Exemestane|Breast cancer women with exemestane treatment
62066857|NCT01468779|ACTIVE_COMPARATOR|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
62066858|NCT04454086|EXPERIMENTAL|Supportive care (exercise program, counseling)|Patients undergo aerobic exercise over 10-30 minutes and resistance exercise comprising 1-3 sets of 8-12 repetitions of 10 different exercises over 1 hour for 24 weeks. Patients also receive behavioral activity counseling once a week and nutritional counseling over 30 minutes for 10 sessions after center-based exercise sessions during months 1-2.
62066859|NCT05434221|EXPERIMENTAL|Experiment group|interns in the experiment group receive COPE during their internship.
62066860|NCT05434221|NO_INTERVENTION|Control group|interns in the control group do not receive any specific communication training during their internship.
62066861|NCT03325205|EXPERIMENTAL|Active tDCS|Participants receive anodal tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
62066862|NCT03325205|SHAM_COMPARATOR|Sham tDCS|Participants receive sham tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
62066863|NCT01905254|OTHER|Transient elastography and liver biopsy|All patients with Autoimmune hepatitis (AIH) were investigated with Transient Elastography before liver biopsy
62271776|NCT05325905||Healthy|bleeding on probing (BoP) ≤ 10% of the sites, probing depth (PD) ≤ 3 mm and no indication of clinical attachment level (CAL) or radiographic bone loss
62271777|NCT05325905||Gingivitis|gingival inflammation (BoP ≥ 10% of the sites, red-blue discoloration of the gingiva and edema) PD ≤ 4 mm and no clinical attachment or radiographic bone loss
62271778|NCT05325905||Periodontitis|PD ≤ 5 mm, radiographic bone loss, and 3-4 mm CAL in at least 30% of the sites
62634449|NCT02683980|EXPERIMENTAL|Ablation of the prostate|ablation of the prostate will be performed using the study device: Lumenis Pulse P120H Holmium Laser
62634450|NCT02351401|EXPERIMENTAL|Education with ultrasonography|Intervention includes education of self-assessment of synovitis using ultrasonography as a feedback training tool
62634451|NCT02351401|NO_INTERVENTION|Standard Care|Normal standard care where patients are not taught how to self-assess for synovitis, without ultrasonography a training tool
62634452|NCT03258801||Pirfenidone|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are treated with Pirfenidone as bridging therapy.
62634453|NCT03258801||Control|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are not treated with Pirfenidone.
61978639|NCT04389424||Basal|Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)
61978640|NCT04389424||Recurrence|Breast cancer women luminal type with recurrence of disease during endocrine therapy
61978641|NCT02452346|EXPERIMENTAL|All Patients|Tosedostat 120 mg PO once daily will be administered.
61978642|NCT03852641|EXPERIMENTAL|Bolus gavage feeds|Bolus gavage feeds over 15-30 minutes
61978643|NCT03852641|EXPERIMENTAL|Continuous feeds|Continuous feeds over 2.0 hrs
62066864|NCT04169919|ACTIVE_COMPARATOR|Modified method|Povidone Iodine
62066865|NCT04169919|ACTIVE_COMPARATOR|Ordinary method|normal saline
62066866|NCT02974530||Stroke population|Patient with stroke will be explored during their acute phase and in 6 months of diagnosis.
62066867|NCT02974530||Healthy population|Healthy subjects will be explored in Grenoble in research laboratory
62066868|NCT02875834|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
62286963|NCT05085509|EXPERIMENTAL|Ultrasound|Ultrasound guidance and methylene blue staining
62286964|NCT05085509|ACTIVE_COMPARATOR|Open surgery|Open surgery without ultrasound guidance and methylene blue staining
62634454|NCT04245592|EXPERIMENTAL|Extra Virgin Olive Oil|Women with fibromyalgia will consume Extra Virgin Olive Oil.
62634455|NCT04245592|EXPERIMENTAL|Refined Olive Oil|Women with fibromyalgia will consume Refined Olive Oil.
62634456|NCT01683604||Rheumatoid Arthritis (RA) Participants (All Groups)|Participants with severe RA were prescribed with tocilizumab in accordance with routine clinic practice, and were observed for 6 months.
62634457|NCT01747499|EXPERIMENTAL|Cohort 1|"Conditioning treatment~Transplant on Day 0~15 mg/m\^2 azacitidine Days 7-11~15 mg/m\^2 azacitidine Days 35-39~15 mg/m\^2 azacitidine Days 63-67~15 mg/m\^2 azacitidine Days 91-95"
62634458|NCT01747499|EXPERIMENTAL|Cohort 2|"Conditioning treatment~Transplant on Day 0~30 mg/m\^2 azacitidine Days 7-11~30 mg/m\^2 azacitidine Days 35-39~30 mg/m\^2 azacitidine Days 63-67~30 mg/m\^2 azacitidine Days 91-95"
62634459|NCT01747499|EXPERIMENTAL|Cohort 3|"Conditioning treatment~Transplant on Day 0~37.5 mg/m\^2 azacitidine Days 7-11~37.5 mg/m\^2 azacitidine Days 35-39~37.5 mg/m\^2 azacitidine Days 63-67~37.5 mg/m\^2 azacitidine Days 91-95"
62453160|NCT03732846|EXPERIMENTAL|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
62634460|NCT01747499|EXPERIMENTAL|Cohort 4|"Conditioning treatment~Transplant on Day 0~45 mg/m\^2 azacitidine Days 7-11~45 mg/m\^2 azacitidine Days 35-39~45 mg/m\^2 azacitidine Days 63-67~45 mg/m\^2 azacitidine Days 91-95"
62634461|NCT01747499|EXPERIMENTAL|Phase II Cohort|"Conditioning treatment~Transplant on Day 0~Dose determined in Phase I - 45 mg/m\^2 azacitidine Days 7-11~Dose determined in Phase I - 45 mg/m\^2 azacitidine Days 35-39~Dose determined in Phase I - 45 mg/m\^2 azacitidine Days 63-67~Dose determined in Phase I - 45 mg/m\^2 attitudinize Days 91-95"
62286965|NCT05698667|EXPERIMENTAL|Oropharynx Ultrasound|Transoral and transcervical ultrasound of the oropharynx, including the tonsils and tongue base.
62453161|NCT01681030|EXPERIMENTAL|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
62066869|NCT02875834|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
62066870|NCT02875834|PLACEBO_COMPARATOR|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
62066871|NCT01556698|EXPERIMENTAL|NVN1000 Gel|NVN1000 Gel topically applied one daily at bedtime for 8 weeks
62066872|NCT01556698|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel topically applied once daily at bedtime for 8 weeks
62066873|NCT03313102|EXPERIMENTAL|Horton disease|
62453162|NCT01681030|ACTIVE_COMPARATOR|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
62066874|NCT03313102|EXPERIMENTAL|control|
62066875|NCT01377558|EXPERIMENTAL|Aerobic endurance training intervention|Aerobic endurance training
62066876|NCT01377558|EXPERIMENTAL|Strength endurance training intervention|Strength endurance training
62453163|NCT01681030|ACTIVE_COMPARATOR|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
62453164|NCT05357157||Electroacupuncture|All subjects will be administered electroacupuncture sessions Acupoints that will be used: Baihui, Yin tang, BL-10, GB21, SI13, BL-60, ST-36, LV-3, LV8, Spl 6, LI-4, LI11, Kid 3, Ren 6, Heart 7
62066877|NCT01377558|EXPERIMENTAL|Combined training intervention|Combined aerobic endurance training and strength endurance training intervention
62453165|NCT05357157||Electroacupuncture, Nutrition and Dietary supplement|All subjects will be administered electroacupuncture sessions Acupoints that will be used: Baihui, Yin tang, BL-10, GB21, SI13, BL-60, ST-36, LV-3, LV8, Spl 6, LI-4, LI11, Kid 3, Ren 6, Heart 7. Patients will be presented with the option to be prescribed a dietary supplement containing vitamin B complex, Mg, Zn, superoxide dismutase, Alpha Lipoic Acid and PalmitoylethanolamideAdditionally they will be given a specific anti-intiflamatory dietary regimen to follow.
62634462|NCT01624480|EXPERIMENTAL|Armodafinil 50 mg|In period 1, patients will receive a single 50-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose daily on days 1 through 42.
62634463|NCT01624480|EXPERIMENTAL|Armodafinil 100 mg|In period 1, patients will receive a single 100 mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1 then daily 100-mg doses on days 2 through 42.
62634464|NCT01624480|EXPERIMENTAL|Armodafinil 150 mg|In period 1, patients will receive a single 150-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1, 100-mg doses on days 2 and 3, then daily 150-mg doses on days 4 through 42.
61978644|NCT05356455|EXPERIMENTAL|EXPERIMENT- active|Motivational interview technique
62066878|NCT01377558|NO_INTERVENTION|Control group|control group
62066879|NCT01779479|EXPERIMENTAL|Cabacitaxel|
62066880|NCT01779479|ACTIVE_COMPARATOR|Paclitaxel|
62066881|NCT01119014|EXPERIMENTAL|Aripirazole|
62066882|NCT01119014|EXPERIMENTAL|Quetiapine prolong|
62066883|NCT00981396|ACTIVE_COMPARATOR|CBT|Cognitive Behavioral Therapy
62066884|NCT00981396|EXPERIMENTAL|EFT|Emotional Freedom Techniques, a novel but efficacious stress-reduction technique
62066885|NCT02111226|ACTIVE_COMPARATOR|Passive SMS Group|Passive SMS messages focused on lifestyle adjustment
62066886|NCT02111226|EXPERIMENTAL|Active SMS Group|Active SMS messages based on hypertension clinical practice guidelines including rational for taking antihypertensive medication and reminders to see the health care practioner if BP is above target.
62066887|NCT03056664|EXPERIMENTAL|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
62066888|NCT03056664|EXPERIMENTAL|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
62066889|NCT03056664|EXPERIMENTAL|Ctrl|Patient in this arm will receive routine surgery and local NS injection
62271779|NCT00603915|EXPERIMENTAL|GC Plus Erlotinib|Eligible patients are treated with cisplatin/carboplatin and gemcitabine (GC) for 6 cycles of therapy followed by maintenance erlotinib. Those patients achieving SD or PR with chemotherapy will be started on maintenance erlotinib until disease progression. Those patients achieving CR with chemotherapy will be started on erlotinib for 6 cycles of treatment and those achieving CR on erlotinib will be treated with a maximum of 6 further cycles of erlotinib. Those patients with disease progression while on chemotherapy will be offered erlotinib 2 weeks following the last dose of chemotherapy until further disease progression.
62271780|NCT04577443|ACTIVE_COMPARATOR|Adenosine|
62271781|NCT04577443|PLACEBO_COMPARATOR|Saline|
62453166|NCT05777213|EXPERIMENTAL|Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs)|Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) made as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks.
62066890|NCT06625190|EXPERIMENTAL|alpha/beta T cell and CD19+ B cell depleted stem cell graft with zoledronic acid|
62066891|NCT02122653|EXPERIMENTAL|Older WT|Older people with weight training
62066892|NCT02122653|EXPERIMENTAL|Older WT and ES|Older people with weight training combined electrical stimulation.
62066893|NCT02122653|NO_INTERVENTION|Young control group|Young people with control group
62066894|NCT03086018|EXPERIMENTAL|Successor hearing aid to Juna|The intervention is the new device which is the successor to the Juna device. The participants will use their current device as a control. The will wear the intervention device for approximately two weeks.
62453167|NCT04111744|EXPERIMENTAL|Training Group|Preoperative Exercise Training Optimal medical therapy,
61978645|NCT05356455|NO_INTERVENTION|control passive|just watched
62066895|NCT02260505|EXPERIMENTAL|Imatinib maintenance|Maintenance of Imatinib at the last dose routinely taken by the patient in the 3 years period prior to randomization (either 300 or 400 mg/day). Increase dose up to 800 mg/day if relapse according to RECIST 1.1 criteria. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib Specific Product Characteristics (SPC).
62066896|NCT02260505|NO_INTERVENTION|Imatinib Interruption|Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.
62066897|NCT03607825|EXPERIMENTAL|Neurapheresis System|CSF filtration
62066898|NCT03846414||PEG-rhG-CSF group|This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients\<45 kg is given to PEG-rhG-CSF 3 mg each time.
61978646|NCT02350725|EXPERIMENTAL|Group 1|Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
62271782|NCT00643695|EXPERIMENTAL|1|Home-based walking program
62271783|NCT00643695|OTHER|2|educational intervention
62271784|NCT04015154||T2 Alpha Femoral Nail PF|Subjects in the clinical investigation will undergo placement of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the piriformis fossa, according to the Instructions for Use and Operative Technique Manual
62271785|NCT02802891||Recruitment group|"Group of individuals (aged 6 to 18 years old) recruited for the JOIN project. Consent was obtained from legal guardians for individuals under 18.~Exclusion criteria:~* Individuals who refused to partake in the clinical assessment, despite the legal guardians consent.~* Individuals who provided an insufficient amount of sample (ex: low volume of EBC)"
62453168|NCT04111744|OTHER|Control Group|Optimal medical therapy, inactive control group
62453169|NCT00683020|ACTIVE_COMPARATOR|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support.
62453170|NCT00683020|NO_INTERVENTION|WAIT LIST Control|WAIT LIST Control: six month Wait List.
62634465|NCT05150665|EXPERIMENTAL|En-Masse Retraction|Six anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
62634466|NCT05150665|EXPERIMENTAL|two step retraction|Six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to the upper lateral incisor and a power chain
62066899|NCT03846414||rhG-CSF group|This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
62066900|NCT00621972||Observation|Chronic kidney disease patients presenting for fisulta evaluation with documented GFR\<30ml/min by abbreviated MDRD calculation.
62453171|NCT02309827|EXPERIMENTAL|Cohort 1: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453172|NCT02309827|EXPERIMENTAL|Cohort 2: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453173|NCT02309827|EXPERIMENTAL|Cohort 3: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453174|NCT02309827|EXPERIMENTAL|Cohort 4: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453175|NCT02309827|EXPERIMENTAL|Cohort 5: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453176|NCT02309827|EXPERIMENTAL|Cohort 6: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453177|NCT02309827|EXPERIMENTAL|Cohort 7: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62066901|NCT03987126|ACTIVE_COMPARATOR|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)"
62453178|NCT02309827|EXPERIMENTAL|Cohort 8: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453179|NCT02309827|EXPERIMENTAL|Cohort 9: PF-06651600 or Placebo|Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
62453180|NCT01802879|EXPERIMENTAL|Panobinostat - 10 to 40 mg/day TIW QoW|10 to 40mg/day TIW QoW (3 times/week every other week) as per parent protocol design
62453181|NCT04394754|NO_INTERVENTION|Control|Patients will receive usual care and no digital health device.
62453182|NCT04394754|EXPERIMENTAL|BodyPort|Patients will receive the BodyPort device.
62453183|NCT04394754|EXPERIMENTAL|Noom|Patients will receive a subscription to the Noom platform.
62634467|NCT04474262|ACTIVE_COMPARATOR|Albumin with placebo|Group A will be given albumin 8g/l of ascitic tap along with placebo for 7 days. Standard albumin therapy will continue (40gm/week)
62634468|NCT04474262|EXPERIMENTAL|Albumin with Midodrine|GROUP B will be given midodrine 7.5 mg to 10 mg tds (keeping the target MAP above 70 mmhg)for 7 days plus albumin same as in other group.
62634469|NCT02896764|EXPERIMENTAL|Eligible patients for cone-beam CT|A cone-beam CT will be offered to the patient undergoing a CT scan of the middle ear
62634470|NCT02952690|ACTIVE_COMPARATOR|standard curve group|The style is curved in accordance with the curve of GVL blade in this group.
62271786|NCT05741255|EXPERIMENTAL|STUDY GROUP|After random sampling and dividing patients into two groups of study and control. Patients from the study and control groups will be interviewed individually by the researcher to apply the study tools. Acceptance and Commitment Therapy will be carried out for patients in the study group
62271787|NCT05741255|ACTIVE_COMPARATOR|Control group|Those in the control group will be left without any intervention to undergo the usual unit routine care.
62066902|NCT03987126|PLACEBO_COMPARATOR|Placebo|"10 g sachet, self-administered for 3 months.~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
62066903|NCT01720784|PLACEBO_COMPARATOR|Placebo|
62066904|NCT01720784|EXPERIMENTAL|Low dose (1.5 g DF)|
62066905|NCT01720784|EXPERIMENTAL|High dose (2.25 gDF)|
62066906|NCT01751230|EXPERIMENTAL|WIC E-Moms|If picked for this group, you will receive a personalized diet and exercise plan to help you lose the weight you gained during your pregnancy. All information will be given to you using a SmartPhone, such as an iPhone. You can use your own phone or one can be loaned to you for the study. You will also be loaned a scale so you can weigh yourself at home. You will also get advice and services from your WIC clinic.
62066907|NCT01751230|NO_INTERVENTION|WIC Moms|You will get advice and services for nutrition and weight management after pregnancy from your WIC clinic.
62271788|NCT01724658|EXPERIMENTAL|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
62271789|NCT01724658|PLACEBO_COMPARATOR|placebo|placebo twice a week with progynova 1 mg oral daily
62271790|NCT02490514||Mircera|Patients with stage III-IV CKD received open-label Mircera for 12 months at a dose to be determined by the investigator.
62271791|NCT01514032|ACTIVE_COMPARATOR|Extracorporal shockwave lithotripsy|
62271792|NCT01514032|ACTIVE_COMPARATOR|Retrograde intrarenal surgery|
62271793|NCT00737659|EXPERIMENTAL|1|Concentration Controlled (CC)group will receive an individually adjusted MMF dosing regimen based on the plasma concentrations of mycophenolic acid (MPA,the active metabolite of mycophenolate mofetil).
62066908|NCT00077311|EXPERIMENTAL|Chemotherapy without BNP7787|Chemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
62271794|NCT00737659|ACTIVE_COMPARATOR|2|Fixed dose (FD) group will receive an a priori set dose of 2mg\\day MMF, the recommended dose, with a possible secondary adaptation by the clinician based on criteria of clinical efficacy, toxicity or interactions with other medications.
62271795|NCT03648697|EXPERIMENTAL|EBV-TCR-T cells(YT-E001)|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered."
62271796|NCT02223572|EXPERIMENTAL|osteoporotic hip fracture|
62271797|NCT01508728|EXPERIMENTAL|Active vibration|
62271798|NCT01508728|PLACEBO_COMPARATOR|Placebo Vibration|
62271799|NCT00845728|EXPERIMENTAL|Indacaterol|Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
62271800|NCT00845728|ACTIVE_COMPARATOR|Tiotropium|Tiotropium 18 µg o.d. delivered via the handihaler®
62271801|NCT00756145|EXPERIMENTAL|1|Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline
62271802|NCT00756145|EXPERIMENTAL|2|Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline
62066909|NCT00077311|EXPERIMENTAL|Chemotherapy + BNP7787|Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
62271803|NCT00756145|EXPERIMENTAL|3|Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline
62453184|NCT04394754|EXPERIMENTAL|Conversa|Patients will receive a subscription to the Conversa platform.
62271804|NCT04437355|ACTIVE_COMPARATOR|Control Group|Young and healthy Group of People (18-50 years) without any pathology of the lower limb
62453185|NCT05557786|ACTIVE_COMPARATOR|Real cerebellar tACS for Cerebellar Ataxia (Part Ⅰ: SCA3, Part Ⅱ: MSA-C)|Real cerebellar tACS, 70Hz, 2mA (peak to peak), 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
62453186|NCT05557786|SHAM_COMPARATOR|Sham cerebellar tACS for Cerebellar Ataxia (Part Ⅰ: SCA3, Part Ⅱ: MSA-C)|Device: Sham cerebellar tACS, 10Hz, 2mA (peak to peak) for 40s, and then no current 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
62066910|NCT03429790|EXPERIMENTAL|group intra-operative cell salvage|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) \* Hb= (Hb2-Hb1) \* blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg \* body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether the experimental group or the no intervention group."
62271805|NCT04437355|ACTIVE_COMPARATOR|Ankle Fracture Type Weber B|Young and healthy patients with an operative treated fracture of the ankle (type Weber B)
62271806|NCT04437355|ACTIVE_COMPARATOR|Ankle Fracture Weber C and complex|Young and healthy patients with an operative treated fracture of the ankle (type Weber C or complex fracture)
62271807|NCT00921232|OTHER|dyad|life-ending patient and its caregiver
62453187|NCT04596956|EXPERIMENTAL|sodium bicarbonate Ringer injection|
62453188|NCT04596956|ACTIVE_COMPARATOR|Ringer lactate solution|
62634471|NCT02952690|EXPERIMENTAL|tip-manipulated curve group|The style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree) in this group.
62453189|NCT03759821|EXPERIMENTAL|Nutrition, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
62634472|NCT04192240|EXPERIMENTAL|WB Training with external feedback|WB during sit-to-stand with external feedback for 10 minute and then, WB during stepping training with external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
62634473|NCT04192240|ACTIVE_COMPARATOR|WB Training without external feedback|WB during sit-to-stand without external feedback for 10 minute and then, WB during stepping training without external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
62453190|NCT03759821|EXPERIMENTAL|Nutrition, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and the groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
62453191|NCT03759821|EXPERIMENTAL|Nutrition+parenting, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
62453192|NCT03759821|EXPERIMENTAL|Nutrition+parenting, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
62066911|NCT03429790|ACTIVE_COMPARATOR|group allogeneic blood transfusion|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) \* Hb= (Hb2-Hb1) \* blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg \* body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether group intra-operative cell salvage or group allogeneic blood transfusion."
62453193|NCT03759821|NO_INTERVENTION|Standard of care control|Local standard of care
62453194|NCT04614961||Patients with overweight, obesity or after bariatric surgery|Patients with overweight, obesity or after bariatric surgery
62453195|NCT00638365|EXPERIMENTAL|1|KB001, a monoclonal antibody
62453196|NCT00638365|PLACEBO_COMPARATOR|2|Placebo
62453197|NCT00261196|EXPERIMENTAL|Collagenase|Collagenase Injection
62634474|NCT03003442|EXPERIMENTAL|Supradyn® Energy 3RDA|Supradyn® Energy 3RDA, 1 multivitamin/mineral tablet administered by mouth daily for 28 days
62634475|NCT03003442|PLACEBO_COMPARATOR|Placebo|Placebo, 1 tablet administered by mouth daily for 28 days
62634476|NCT05694806||patients with symptomatic Mediastinal mass syndrome|patients with symptomatic Mediastinal mass syndrome at diagnosis or at relapse of a patient with haematological malignancy admitted to the Intensive Care unit
62634477|NCT01815658||Broken humerus shaft|Patients presenting with broken humerus shaft
62634478|NCT02517957|EXPERIMENTAL|Qinzhuliangxue Keli|Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)
62634479|NCT02517957|ACTIVE_COMPARATOR|loratadine tablets|Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
62634480|NCT02517957|ACTIVE_COMPARATOR|Qinzhuliangxue and loratadine|Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
62634481|NCT05734820|EXPERIMENTAL|HD-colonoscopy + AI-HD colonoscopy|This group is comprised by patients \>45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy will be performed followed by an HD-colonoscopy with artificial intelligence assistance. The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.
61978647|NCT02350725|EXPERIMENTAL|Group 2|Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
62453198|NCT00261196|PLACEBO_COMPARATOR|Placebo|Placebo Injection
62453199|NCT01226797|PLACEBO_COMPARATOR|Placebo|
62453200|NCT01226797|ACTIVE_COMPARATOR|PF-04136309|
62453201|NCT03703063|EXPERIMENTAL|Resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m\^2 followed by leucovorin 400 mg/m\^2 followed by 5FU 2400 mg/m\^2 on days 1, 15 of the 28 day cycle.
62453202|NCT03703063|EXPERIMENTAL|Borderline resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m\^2 followed by leucovorin 400 mg/m\^2 followed by 5FU 2400 mg/m\^2 on days 1, 15 of the 28 day cycle.
62634482|NCT05734820|EXPERIMENTAL|AI-HD colonoscopy + HD-colonoscopy|This group is comprised by patients \>45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy assisted by artificial intelligence will be performed followed by an HD-colonoscopy alone.The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.
62634483|NCT01726075|EXPERIMENTAL|COLIRIOBCN070660|COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution. One drop/eye administered twice a day.
62634484|NCT01726075|PLACEBO_COMPARATOR|Placebo|Placebo Eye drops, solution. One drop/eye administered twice a day.
62634485|NCT01726075|EXPERIMENTAL|Brimonidine|Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.
62634486|NCT02962310|EXPERIMENTAL|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
62634487|NCT02962310|ACTIVE_COMPARATOR|Reference|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
62453203|NCT01684969|ACTIVE_COMPARATOR|intravenous haloperidol|intravenous haloperidol pharmacokinetics
62634488|NCT03506438|EXPERIMENTAL|ICU physician mobile app group|Clinicians and family members will receive access to versions of the needs-focused mobile app that differ in content.
62634489|NCT03506438|PLACEBO_COMPARATOR|ICU physician usual care group|Usual ICU care in an ICU as per the standards of the ICU attending
62634490|NCT02090504|EXPERIMENTAL|Sodium oxybate (SMO)|"Patients randomized to the first arm of the study will receive:~* SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is \> 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);~* placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
62634491|NCT02090504|ACTIVE_COMPARATOR|Oxazepam|"Patients randomized to the second arm of the study will receive:~* OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;~* placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is \> 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
62634492|NCT01852123|OTHER|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
62634493|NCT01852123|OTHER|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
62634494|NCT05793281||Patients with solid tumor and genome profiling results|Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
61978648|NCT01028365||No treatment|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
62453204|NCT01684969|PLACEBO_COMPARATOR|Placebo|
62453205|NCT05764044|OTHER|Control Arm (Standard of Care)|Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
62453206|NCT05764044|EXPERIMENTAL|Experimental Arm|Receive two cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days. After that, patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
62634495|NCT03789097|EXPERIMENTAL|Combination therapy|Vaccination with Flt3L, Radiation, and Poly ICLC combined with Pembrolizumab
62634496|NCT03692637|EXPERIMENTAL|anti-Mesothelin Car NK Cells|Total dose of 0.5-3 million /kg cells will be administered at day0
62271808|NCT01476657|EXPERIMENTAL|IPI-145|IPI-145 is administered orally as a capsule formulation. The IPI-145 drug product is supplied as 1 mg, 5 mg, 25 mg, and 100 mg formulated capsules. IPI-145 will be administered orally daily during each 28-day cycle. Patients will be evaluated for DLTs in the dose escalation portion of the study during Cycle 1 (28 days), after which treatment may continue for additional cycles.
62271809|NCT03881397|NO_INTERVENTION|Control (Track B assessed at Time 2)|A survey regarding tech use, health behaviors and well-being including physical activity, anxiety, and sleep
62453207|NCT04167566|OTHER|Intervention Communities|All participants confirmed using rapid diagnostic test (RDTs) to be carrying the malaria parasite will be treated using artemisinin combination therapy (ACT) following the Ghana National Malaria Treatment Guidelines and followed up on days 1, 2, 3 during treatment as DOTs (Directly observed therapy) and on day 7 post treatment. The research team together with Community volunteers will be provided the treatment guidelines which specify the dosage for each treatment regimen. Participants who receive the treatment will be observed for five minutes to ensure that they retain the drug. Those who vomit within this period will have the treatment repeated.
62453208|NCT02947009|EXPERIMENTAL|Adolescent athletes with PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index"
62634497|NCT00733278|EXPERIMENTAL|Copper IUD|Copper IUD
62634498|NCT02900248||Provider Determined Treatment|Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
62634499|NCT03801642|EXPERIMENTAL|Dapagliflozin|10 mg dapagliflozin oral tablet taken once daily for 12 weeks
62066912|NCT03555630||Post-cesarean preeclampsia|
62066913|NCT03555630||Post spontaneous vaginal delivery preeclampsia|
62066914|NCT04117269|EXPERIMENTAL|External shoe lift|Those patients allocated in the experimental group will be supplemented with a external shoe lift in the contralateral limb in their conventional shoes to compensate the differences with the affected foot (using a offloading device to active ulcer).
62066915|NCT04117269|NO_INTERVENTION|Standard of care|Those patients allocated in the control group will not be supplemented, they will be treated with a standard of care treatment.
62271810|NCT03881397|EXPERIMENTAL|Online Family Media Use Plan (Track A)|The Online Family Media Use Plan group will receive a link to American Academy of Pediatrics Family Media Use plan at the end of the survey, which describes internet safety ideas for teens and parents to review and create together.
61978649|NCT03828357||Ellipse VR with Durata|Ellipse VR single-chamber ICD with a Durata defibrillation lead
62271811|NCT03881397|EXPERIMENTAL|Media Use Resources Awareness (Track B assessed at Time 3)|Resources offered to parents and teens that include tools and data for safe technology use among teens
62271812|NCT02555735||Solid Tumor Cancer|Participants with solid tumor cancer treated with physician-choice standard of care chemotherapy.
62271813|NCT06207136|EXPERIMENTAL|Intervention healthy diet|Participants in the active intervention group will have specific diet advice delivered with motivational and behaviour-change techniques and will learn relevant cooking skills in remotely-delivered group cooking classes (via Zoom).
62271814|NCT06207136|ACTIVE_COMPARATOR|Standard diet|The active control group will focus on an energy-adequate diet considered standard-of-care but similar to the participant's baseline diet. The control dietary intervention group will receive general diet advice and standard care and will receive instruction in cooking skills delivered in remote group cooking classes (via Zoom).
62271815|NCT04395911|OTHER|SCD|Cytopheretic device
62271816|NCT01339546||Study population|All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study
62271817|NCT01265524|ACTIVE_COMPARATOR|CLP|Investigational drug: 15 g CLP per day given as capsules
62271818|NCT01265524|PLACEBO_COMPARATOR|Placebo|Placebo, capsules
62634500|NCT03801642|PLACEBO_COMPARATOR|Matching placebo|Placebo oral tablet taken once daily for 12 weeks
62271819|NCT05119712|ACTIVE_COMPARATOR|Placebo to Drug|Subjects will begin treatment on placebo then crossover to study drug.
62271820|NCT05119712|ACTIVE_COMPARATOR|Drug to Placebo|Subjects will begin treatment on study drug then crossover to placebo.
62271821|NCT02287974|EXPERIMENTAL|Autologous mononuclear stem cell from the bone marrow|Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells
62271822|NCT02287974|EXPERIMENTAL|Autologous endothelial stem cell from the bone marrow|Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells
62271823|NCT02287974|EXPERIMENTAL|Autologous mesenchymal stem cells from the adiposite tissue|Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells
62271824|NCT02287974|ACTIVE_COMPARATOR|Current medication for the disease|Current medication for the disease
62271825|NCT05113836||Any patient hospitalised in intensive care for a COVID-19 infection.|Any patient hospitalised in intensive care for a COVID-19 infection. The health emergency of this pandemic and the potential therapeutic action of HDL particles justify the choice of this population for study.
62271826|NCT05603715|OTHER|Pyridostigmine Bromide|Open Label
62271827|NCT04732741||Oral Cancer|patients diagnosed clinically and histopathologically with oral cancer who have yet to receive any treatment.
62271828|NCT04732741||Premalignant lesions|patients diagnosed clinically and histopathologically with oral potentially malignant lesions who have not yet to receive treatment or had a month wash-out period from any previous treatment.
62271829|NCT04732741||Control Group|healthy individuals who will be examined clinically through conventional visual and tactile examination to ensure no oral lesions are present and through thorough medical history
62634501|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
61978650|NCT03828357||Ellipse DR with Durata & Tendril STS|Ellipse DR dual-chamber ICD with a Durata lead in the right ventricle (RV) and a Tendril STS lead in the right atrium (RA).
62271830|NCT06187376|EXPERIMENTAL|Chinese Herbal Medicine (CHM) herbal tincture|Chinese herbal tincture
62271831|NCT06187376|PLACEBO_COMPARATOR|Placebo|Matching placebo tincture.
62271832|NCT00566930|NO_INTERVENTION|1|
62271833|NCT00566930|ACTIVE_COMPARATOR|2|spinal manipulation
62271834|NCT00566930|EXPERIMENTAL|3|Spinal manipulation + exercises
62271835|NCT03432078|ACTIVE_COMPARATOR|Individual hypnotherapy|Treatment given on a individual basis, face to face.
62271836|NCT03432078|ACTIVE_COMPARATOR|Group hypnotherapy|Treatment given in a group setting, face to face.
62271837|NCT04708275|EXPERIMENTAL|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
62271838|NCT04708275|ACTIVE_COMPARATOR|Waitlist|PaCT after a waiting period (3 months)
62271839|NCT00514865|EXPERIMENTAL|Experimental 1|1-2 mg of ONO-2333
62271840|NCT00514865|EXPERIMENTAL|Experimental 2|5-10 mg of ONO-2333
62271841|NCT00514865|PLACEBO_COMPARATOR|Placebo|placebo comparator
62271842|NCT02042937|NO_INTERVENTION|Control|No intervention
62271843|NCT02042937|EXPERIMENTAL|Exercise|Exercise to improve gluteus maximus recruitment
62271844|NCT00465595|EXPERIMENTAL|Low Dose First, High Dose Second|The Low-Dose-1st Group received the low dose of psilocybin on the first session and the high dose on the second session
62634502|NCT01859182|EXPERIMENTAL|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62066916|NCT03556358|EXPERIMENTAL|TX05 (trastuzumab)|"• Intravenous (IV) epirubicin, 75 mg/m\^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
62271845|NCT00465595|EXPERIMENTAL|High Dose First, Low Dose Second|The High-Dose-1st Group received the high dose of psilocybin on the first session and the low dose on the second session
62271846|NCT03967548|EXPERIMENTAL|0.004% single-dose|96 subjects will be treated with Germinal peptide eye drops 0.004% single dose (16 were pre-tested and 64 were formally tested).
62271847|NCT03905993||Experimental: unique group.|At V0: 1238 subjects were screened At V1: 1012 subjects (12 later withdrew) gave the following samples: blood, nasal swab,stool. 323 subjects among 1000 gave one additional sample (Skin Biopsy) At V2: 504 subjects came at V2 to perform blood, nasal swab and stool samples
62271848|NCT02027103|ACTIVE_COMPARATOR|Metformin|patients receiving fixed dose metformin 1000 mg daily
62271849|NCT02027103|ACTIVE_COMPARATOR|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
62271850|NCT00740350|EXPERIMENTAL|Experimental|Logan Basic chiropractic adjustments during pregnancy.
62271851|NCT03083340|EXPERIMENTAL|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
62634503|NCT05130827|EXPERIMENTAL|Plinabulin|In this pilot study, 15 patients age 18-75 with multiple myeloma will be admitted to the hospital and treated with a single dose of high dose melphalan. Stem cell infusion will occur per institutional standard of care. Patients will then receive plinabulin 40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0. Pegfilgrastim 6mg will be administered as per standard of care on day +1.
62634504|NCT01889368|ACTIVE_COMPARATOR|Grape Seed Extract|This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
62634505|NCT01889368|PLACEBO_COMPARATOR|Placebo|This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
62634506|NCT02402946|EXPERIMENTAL|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor but not showed to the patients; in the biofeedback group, patients will be instructed to control, abdomino-thoracic muscle activity
62634507|NCT02402946|PLACEBO_COMPARATOR|Placebo medication|Electromyography will be recorded but not shown to the patients. Patienst will take a pill of placebo and receive no instructions about controlling muscular activity.
62634508|NCT02712957|EXPERIMENTAL|NEO6860|NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.
62634509|NCT02712957|PLACEBO_COMPARATOR|Placebo|In this arm, patients will receive both placebo: oral liquid suspension (NEO6860 placebo) and capsule (naproxen placebo).
62634510|NCT02712957|ACTIVE_COMPARATOR|Naproxen|Naproxen is provided as over-encapsulated tablets using a commercially approved medication. In this arm patients will receive both naproxen and a placebo of NEO6860.
62634511|NCT01005862|EXPERIMENTAL|PF-04360365|
62634512|NCT01005862|PLACEBO_COMPARATOR|Placebo|single dose administered intravenously
62634513|NCT01534117|ACTIVE_COMPARATOR|Platelets/DDAVP|Fall on ASA/Plavix that sustained head trauma requiring administration of platelets and/or DDAVP
62634514|NCT01534117|NO_INTERVENTION|No Platelets|Those that sustain head trauma NOT requiring platelet transfusion. The investigators are evaluating platelet function in those not requiring platelet transfusion
62066917|NCT03556358|ACTIVE_COMPARATOR|Herceptin®|"• Intravenous (IV) epirubicin, 75 mg/m\^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
62066918|NCT02961881|EXPERIMENTAL|blinatumomab|
62271852|NCT03627221|EXPERIMENTAL|music listening and social network|The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
62271853|NCT03627221|NO_INTERVENTION|Control group|The control group will not receive music listening at sleep time and will not be invited to join a social network for 12 weeks. But their sleep quality, sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
62271854|NCT03607760||ECMO|severe respiratory failure with ECMO
62271855|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
62066919|NCT06525558||IBD Group|Patients with IBD disease (Crohn disease and Ulcerative Colitis) who will be subjected, as established by normal clinical practice, to any type of bowel surgery that involves resection of colon, ileum and/or rectum
62271856|NCT00476879|EXPERIMENTAL|1|12 hours of fasting and a GH bolus
62271857|NCT00476879|EXPERIMENTAL|2|36 hours of fasting and a GH bolus
62271858|NCT00476879|EXPERIMENTAL|3|36 hours of fasting and Pegvisomant
62271859|NCT00476879|EXPERIMENTAL|4|36 hours of fasting and NaCl injection
62453209|NCT02947009|ACTIVE_COMPARATOR|Adolescent athletes at-risk for PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index."
62271860|NCT02555943|ACTIVE_COMPARATOR|Prophylactic/Early anti-HBV treatment|"HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).~."
62271861|NCT02555943|EXPERIMENTAL|Deferred anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
62271862|NCT05842187|EXPERIMENTAL|Organoid generation|All patients will be included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation
62271863|NCT06170515|OTHER|BGM Evaluation|
62634515|NCT03291821|EXPERIMENTAL|DuoStim|Two controlled ovarian stimulation within the same menstrual cycle using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
62634516|NCT03291821|ACTIVE_COMPARATOR|Conventional Stimulation|Two controlled ovarian stimulation in different menstrual cycles using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
62634517|NCT03075267|EXPERIMENTAL|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
62634518|NCT03075267|EXPERIMENTAL|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
62634519|NCT03075267|EXPERIMENTAL|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
62634520|NCT03146741|EXPERIMENTAL|Zepatier (grazoprevir 100mg and elbasvir 50 mg)|
62634521|NCT02627456|EXPERIMENTAL|1A|(n=5), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (4.5x105) via DVI. All 5 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination.
62634522|NCT02627456|EXPERIMENTAL|1B|(n=S), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (9.0x10S) via DVI. All S subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination
62271864|NCT06170515|OTHER|HbA1c evaluation|
62634523|NCT02627456|EXPERIMENTAL|1C|(n=30), will be the targeted dose for the Pilot Safety Group. Subjects will receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. 15 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to each administration of PfSPZ Vaccine, while 15 will not, except prior to PfSPZ Vaccine #3 when all 30 subjects will receive antimalarial treatment with ASAQ.
62634524|NCT02627456|EXPERIMENTAL|1D|(n=15), will be the CHMI control group. Subjects will not receive any PfSPZ vaccinations but will serve as infectivity controls for CHMI. All 15 subjects will receive antimalarial treatment with ASAQ prior to PfSPZ Challenge.
62634525|NCT02627456|EXPERIMENTAL|2|(n=60), will be the targeted vaccine dose arm and receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the pilot study indicate otherwise.
62634526|NCT02627456|PLACEBO_COMPARATOR|3|(n=60), will be the placebo arm and receive vaccinations with normal saline via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the Pilot Study indicate otherwise.
62634527|NCT02627456|ACTIVE_COMPARATOR|4|(n=SS), will be group- matched (age, sex, village) controls for Arm 2 for the duration study. Subjects previously enrolled in Arm 3 may re-enroll in Arm 4. All subjects will receive antimalaria treatment at enrollment
62634528|NCT04248946|EXPERIMENTAL|MRI stream|"In this stream all patients receive 2 experimental interventions (anodal tDCS and cathodal tDCS) and a sham intervention (sham tDCS). These are delivered in randomised order, ensuring a balanced distribution of participants across possible orders. They will receive 5 sessions per condition (on consecutive days), for a total of 15 sessions.~I. Anodal, cathodal, sham II. Anodal, sham, cathodal III. Cathodal, anodal, sham IV. Cathodal, sham, anodal V. Sham, anodal, cathodal VI. Sham, cathodal, anodal"
62634529|NCT04248946|EXPERIMENTAL|Bedside stream|"In this stream all patients receive 1 experimental interventions (either anodal tDCS or cathodal tDCS) and 1 sham intervention (sham tDCS). These include only 1 session per condition and are delivered in randomised order, resulting in the following possible combinations:~I. Anodal, sham II. Cathodal, sham III. Sham, anodal IV. Sham, cathodal~Participants will be randomly assigned to the above groups ensuring a balanced distribution of participants across them."
62634530|NCT03559504||Group 1|Infant period: 1 month-1 year old
62634531|NCT03559504||Group 2|Toddler period:1-3 years old
61978651|NCT03828357||Ellipse DR with Optisure and Isoflex|Ellipse DR dual-chamber ICD with an Optisure defibrillation lead in the right ventricle (RV) and an Isoflex lead in the right atrium (RA).
62271865|NCT00722150|ACTIVE_COMPARATOR|Arm 1|"Oral Artesunate (standard dose)"
62271866|NCT00722150|ACTIVE_COMPARATOR|Arm 2|"Oral Artesunate (ARC1 dose)"
62271867|NCT00722150|EXPERIMENTAL|Arm 3|"Oral Artesunate (experimental high dose)"
62271868|NCT05167942|SHAM_COMPARATOR|Sham dTMS|29 patients will be randomly allocated into this group,they will receive sham stimulation.
62634532|NCT03559504||Group 3|Preschool age period:3-6 years old
62634533|NCT03559504||Group 4|School age period:7-18 years old
62634534|NCT03559504||Group 5|Adults:18-65 years old
62271869|NCT05167942|ACTIVE_COMPARATOR|dTMS 20Hz|29 patients will be randomly allocated into this group,they will receive real stimulation.
62271870|NCT05167942|ACTIVE_COMPARATOR|dTMS iTBS|29 patients will be randomly allocated into this group,they will receive real stimulation.
62271871|NCT04388995|EXPERIMENTAL|observed patients|
62634535|NCT03559504||Group 6|Elderly:65-80 years old
62271872|NCT01857713|ACTIVE_COMPARATOR|Reza Band UES Assist Device|Patient is own control. Compare baseline to last follow-up after using device
62634536|NCT04833517||Lu177 PSMA RLT|Lutetium-177 prostate-specific membrane antigen (Lu177 PSMA) radioligand therapy (RLT) according to standard local protocol
62634537|NCT04833517||Ac225 PSMA RLT|Actinium-225 prostate-specific membrane antigen (Ac225 PSMA) radioligand therapy (RLT) according to standard local protocol
62271873|NCT04394533|EXPERIMENTAL|Prilocaine (Intervention) Group|Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
62271874|NCT04394533|ACTIVE_COMPARATOR|Bupivacaine (Control) Group|Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
62453210|NCT03561948|EXPERIMENTAL|Experimental group|Surgery and Intraperitoneal Chemotherapy
62453211|NCT03561948|PLACEBO_COMPARATOR|Control group|only surgery
62634538|NCT04833517||Tandem Lu177 / Ac225 PSMA RLT|Combined Lu177 / Ac225 PSMA radioligand therapy according to standard local protocol
62634539|NCT04833517||Ra223 chloride|Bone-targeted Radium-223 (Ra223) radionuclide therapy in standard application
62634540|NCT04833517||Sm153 EDTMP|Bone-targeted Samarium-153 (Sm153) EDTMP radionuclide therapy in standard application
62634541|NCT04833517||Y90 microspheres|Radioembolization with yttrium-90 (Y90) microspheres, standard methodology
62634542|NCT04833517||Tb161 PSMA RLT|Terbium-161 prostate-specific membrane antigen (Tb161 PSMA) radioligand therapy (RLT) according to standard local protocol
62634543|NCT05610488|EXPERIMENTAL|Vabysmo (Faricimab) 6 mg|Vabysmo (Faricimab) 6 mg solution for intravitreal injection All consenting, enrolled patients will receive an intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits up to month 12.
62634544|NCT06521047||Standard of Care|Patients randomized in the standard of care arm in the EXCELLENT trial who have completed their 6-month follow-up visit
62271875|NCT00685126|EXPERIMENTAL|A|"Low dose levalbuterol (0.15 mg, 0.31 mg or 0.63 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
62271876|NCT00685126|EXPERIMENTAL|B|"High dose levalbuterol (0.31 mg, 0.63 mg or 1.25 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
62634545|NCT06521047||ProtheraCytes Arm|Patients randomized in the ProtheraCytes arm in the EXCELLENT trial, who received an injection of ProtheraCytes and who have completed their 6-month follow-up visit
62634546|NCT06296446||people with fibromyalgia|People with fibromyalgia in Poland. The study does not include any intervention. The collected data, in a cross-sectional study, are intended to assess the functioning and disability of people with fibromyalgia using standardized questionnaires such as: WHODAS 2.0, FIQ, BDI.
62634547|NCT03498313|EXPERIMENTAL|Transdermal Estradiol + Placebo|.1mg per 24 hours transdermal estradiol applied to the skin weekly, and sugar pill manufactured to mimic the progesterone pills taken twice daily by mouth, for 14 days.
62634548|NCT03498313|EXPERIMENTAL|Oral Micronized Progesterone + Placebo|100 mg oral micronized progesterone pill taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
62286966|NCT03110055|EXPERIMENTAL|HCV patients with un-resectable HCC|"HCV genotype 1 (a and b) cirrhotic patients (child pugh A compensated cirrhosis) with advanced and un-resectable HCC who are eligible for TACE . The patients will receive Grazoprevir/Elbasvir and Transarterial Chemoembolization.~Their outcomes will be compared to the medical records of patients who underwent Transarterial Chemoembolization only, in the past."
62271877|NCT00685126|ACTIVE_COMPARATOR|C|"Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
62271878|NCT00571350|ACTIVE_COMPARATOR|A|women with vaginal prolapse who underwent TVT O
62271879|NCT05667714|EXPERIMENTAL|Experimental Group A（ non-continuous exposure to COVID-19）|1725 participants who were non-continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
62271880|NCT05667714|PLACEBO_COMPARATOR|Control Group A（ non-continuous exposure to COVID-19）|575 participants who were non-continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day .
62271881|NCT05667714|EXPERIMENTAL|Experimental Group B (continuous exposure to COVID-19)|400 participants who were continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
62271882|NCT05667714|PLACEBO_COMPARATOR|Control Group B(continuous exposure to COVID-19)|200 participants who were continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
62271883|NCT02347176|PLACEBO_COMPARATOR|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
62271884|NCT02347176|EXPERIMENTAL|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
62271885|NCT02347176|EXPERIMENTAL|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
62271886|NCT02347176|EXPERIMENTAL|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
62271887|NCT06033820|EXPERIMENTAL|ZR2-ICE Group|All patients will receive 3 cycles of ZR2-ICE immunochemotherapy every three weeks.
62066920|NCT06525558||Non-IBD Group|Patients with other diseases that are not IBD (for example, tumor, rectal prolapse or diverticulitis) who will be subjected, as established by normal clinical practice, to any type of bowel surgery that involves resection of colon, ileum and/or rectum
62271888|NCT01617330|EXPERIMENTAL|Diesel exhaust|2 hour exposure to diesel exhaust at 100 microgram per cubic meter during intermittent exercise
62271889|NCT01617330|EXPERIMENTAL|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise
62286967|NCT01404663|EXPERIMENTAL|stem cell recipients|The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation
62271890|NCT05815303|EXPERIMENTAL|Cadonilimab + XELOX|Oxaliplatin 130 mg/m2 iv and Cadonilimab 10mg/kg iv on day 1； Capecitabine 1000mg/m2 po bid on day 1 to 14； every 21 day as a cycle, 4 cycles before surgery and 4 cycles after surgery
62271891|NCT05815303|SHAM_COMPARATOR|XELOX|Oxaliplatin 130 mg/m2 iv on day 1； Capecitabine 1000mg/m2 po bid on day 1 to 14； every 21 day as a cycle, 4 cycles before surgery and 4 cycles after surgery
62066921|NCT00005028|EXPERIMENTAL|Arm I|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
62066922|NCT04812613||Photovoice|"Three youth community peer researchers from marginalized communities will be recruited and involved in every aspect of the project.~We will recruit 20 participants from marginalized communities with a current or past history of cannabis use, who can speak English, and who are between 16 and 26 years old.~Participants will receive training on study procedures, basics of photography and disposable camera to document their experiences with mental health and substance use over the span of two weeks. Community peer researchers and research team will conduct photoanalysis and creation of the description of the five photos chosen by each participant.~Duoethnographic dialogue: 10 youth participants will be paired with an older participant of TCAY study to have an open discussion to explore their experiences with cannabis and mental health. This conversation will be facilitated by community peer researcher, recorded and transcribed verbatim."
62066923|NCT04812613||Mix-method community based participatory action research|"Phase 1 study: we will conduct 50 semi-structured questionnaires. Data from the participants and literature will then be triangulated, coded, and analyzed using NVivo software. Researchers will transcribe interviews, create a code guide, code, analyze and report the data to appropriately inform the intervention (Phase 2).~Phase 2: 6 month follow-up with a questionnaire focused on socio-demographic data, questions on participants' smoking and other substance use habits, mental health, as well as questions on participants' social networks.. Participants will be informed that they can skip any of the questions if they are uncomfortable answering them. Qualitative data will be analyzed using NVivo, and quantitative data will be analyzed using SAS or R software. Phase 2 findings will be reported and submitted to an appropriate peer-review journal."
62066924|NCT02490358||1|Healthy smoking subjects
62066925|NCT02490358||2|COPD smoking subjects
62066926|NCT02490358||3|COPD ex-smoker subjects
62088208|NCT03801772|NO_INTERVENTION|Control|The patients will be educated on proper performance of aquatic exercises following normal physical therapy procedures. Patients will start with 10-20 repetitions of the exercises depending on their physical ability and progressed as the patient's strength and endurance improve. Each session will last approximately 30 to 45 minutes. The BORG scale (a valid, subjective measure of perceived exertion) will be used as a monitoring device to ensure that a desired level of exercise intensity is reached. The desired level is a score between 12 and 16. The patients will be asked to rate their level of exertion at the end of each session. Intensity of the exercises will be adjusted the next session if the patient's reported level of exertion does not fall within the desired range. The pain rating and the BORG number will be recorded for both groups in the chart and flow
62271892|NCT06369012|ACTIVE_COMPARATOR|Group A : Mefenamic acid|"About 65 women will take Mefenamic acid tablets orally, 3 timed per day.This regiment can be repeated for at least three attacks of Abnormal Uterine Bleeding.~(Mefenamic acid manufactured by JPI pharmaceutical company)"
62271893|NCT06369012|ACTIVE_COMPARATOR|Group B: Tranexamic acid|"About 65 women will take Tranexamic acid capsules orally, 3 time per day .This regiment can be repeated for at least three attacks of Abnormal Uterine Bleeding.~(Tranexamic acid manufactured by AMOUN pharmaceutical company)"
62271894|NCT05749380|OTHER|1A(RT)|Patients (AmBisome, DKF-5122)
62271895|NCT05749380|OTHER|1B(TR)|Patients (DKF-5122, AmBisome)
62271896|NCT05749380|OTHER|2A(RT)|Healthy subjects (AmBisome, DKF-5122)
62271897|NCT05749380|OTHER|2B(TR)|Healthy subjects (DKF-5122, AmBisome)
62271898|NCT03840655||palmar hyperhidrosis|VATS R4 Sympathicotomy performed on all patients. Fluorescent thoracoscopy was used to identify the shifting mode of sympathetic ganglions.
62271899|NCT04451954|EXPERIMENTAL|Group 1: Quadrivalent RIV with H3 strain 1, without adjuvant|1 injection of quadrivalent RIV containing H3 strain 1, without adjuvant, in participants ≥ 50 years old
62271900|NCT04451954|EXPERIMENTAL|Group 2: Quadrivalent RIV with H3 strain 1, with adjuvant|1 injection of quadrivalent RIV containing H3 strain 1, with adjuvant, in participants ≥ 50 years old
62066927|NCT06625879|ACTIVE_COMPARATOR|Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15)|"Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15):~The patient will lay on her side with arm brought forward, the linear US transducer probe (10-12 MHz) will be placed in the midaxillary line and then moved caudal from second rib until the sixth intercostal space. At this point, the subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction. In-plane technique will be used until the tip of the needle placed between the serratus anterior muscle and the external intercostal muscle (deep SABP) (Blanco et al., 2013). A volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection (Lin J et al., 2020)."
62271901|NCT04451954|EXPERIMENTAL|Group 3: Quadrivalent RIV with H3 strain 2, without adjuvant|1 injection of quadrivalent RIV containing H3 strain 2, without adjuvant, in participants ≥ 50 years old
62271902|NCT04451954|EXPERIMENTAL|Group 4: Quadrivalent RIV with H3 strain 2, with adjuvant|1 injection of quadrivalent RIV containing H3 strain 2, with adjuvant, in participants ≥ 50 years old
62634549|NCT03498313|PLACEBO_COMPARATOR|Placebos|Sugar pill designed to mimic the P4 pills taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
62634550|NCT00225186|EXPERIMENTAL|Arm 1|
62271903|NCT04451954|ACTIVE_COMPARATOR|Group 5: Quadrivalent RIV Control, without adjuvant|1 injection of quadrivalent RIV containing 2018-19 Northern Hemisphere (NH) recommended H3 strain, without adjuvant, in participants ≥ 50 years old
62271904|NCT04451954|ACTIVE_COMPARATOR|Group 6: Quadrivalent RIV Control, with adjuvant|1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, with adjuvant, in participants ≥ 50 years old
62634551|NCT01604889|EXPERIMENTAL|Epacadostat 300 mg|300 mg twice daily (BID) in combination with ipilimumab
62634552|NCT01604889|PLACEBO_COMPARATOR|Placebo in combination with ipilimumab|
62634553|NCT01604889|EXPERIMENTAL|Epacadostat 25 mg|25 mg BID in combination with ipilimumab
62634554|NCT01604889|EXPERIMENTAL|Epacadostat 50 mg|50 mg BID in combination with ipilimumab
61978652|NCT03828357||Quadra Assura MP CRT-D|Quadra Assura MP CRT-D with an Optisure or Durata defibrillation lead in the RV, an Isoflex or Tendril STS lead in the RA, and a Quartet lead in the LV
62634555|NCT01604889|EXPERIMENTAL|Epacadostat 75 mg|75 mg once a day (QD) in combination with ipilimumab
62271905|NCT04451954|ACTIVE_COMPARATOR|Group 7: Quadrivalent RIV Control, without adjuvant|1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, without adjuvant, in participants 18-30 years old
62271906|NCT05157815|EXPERIMENTAL|Soluble Corn Fibre|12g compound per Sachet (providing 10g fibre) consumed twice per day
62271907|NCT05157815|PLACEBO_COMPARATOR|Maltodextrin|Calorie matched control of 2 g compound per sachet (0 g fibre), composed of: Maltodextrin, consumed twice per day
62066928|NCT06625879|ACTIVE_COMPARATOR|GroupII: (Midpoint transverse process to pleura (MTP) block group )(n=15)|"GroupII: (Midpoint transverse process to pleura (MTP) block group )(n=15):~In the lateral postion, the T4 spine will be counted by ultrasound, and high frequency linear US transducer probe (10-12 MHz) will be placed longitudinally, approximately 2.5 cm lateral to the midline the needle will be advanced in plane from cranial to caudal direction. The desired end point for the needle tip will be the midpoint of the line between the posterior border of the transverse process of T4 and the pleura(injection will be deep (anterior) to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligment),the needle tip dose not enter the paravertebral space (Chin et al., 2021), a volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection,pleural displacement and bowing of erector spinae will be observed at the side of injection (Syal et al., 2020; Pusch et al., 2000)."
62066929|NCT04114747|EXPERIMENTAL|Starting at high blood pressure|Patients in this arm are randomized to have high target blood pressure at MAP 80-90 mmHg during the first recordings, thereafter they will receive low blood pressure target 60-70 mm Hg
62066930|NCT04114747|EXPERIMENTAL|Starting at low blood pressure|Patients in this arm are randomized to have low target blood pressure at MAP 60-70 mmHg during the first recordings, thereafter they will receive high blood pressure target 80-90 mm Hg
62066931|NCT03657459|NO_INTERVENTION|usual care group|Usual care consists of patient's receiving a Heart Failure Handbook before hospital discharge + verbal education delivered by multiple care providers (including a group education class at 1 site). The handbook is consistent; however, verbal education may vary between care providers based on their knowledge and time available, and perceived patient needs
62066932|NCT03657459|ACTIVE_COMPARATOR|video education group|"Will receive usual care, plus will watch 2 short Wellflix, Inc. Danger Signs of Heart Failure videos (via iPAD) on dyspnea, fatigue + a Danger Sign edema video, when applicable. Each video describes how to recognize if the sign/symptom is new or worsening and how to self-manage at home (via diet, fluid management and activity instructions)"
62066933|NCT06369246|EXPERIMENTAL|Stereotactic Body Radiation Therapy|"Participants will then be scheduled to receive radiation therapy. Radiation will be given over 5 sessions, 2-3 times per week, for 2 weeks. Each radiation therapy session will take 15-30 minutes to complete.~Within 1 day after completing radiation therapy, blood (about 2 tablespoons) will be drawn for routine tests."
62066934|NCT01333878|EXPERIMENTAL|Open-Label Subcutaneous Abatacept|Open-Label Subcutaneous Abatacept
62271908|NCT05616936|EXPERIMENTAL|Group I|Intervention side: application of i-PRF with distalization of maxillary first molar that will be performed on intervention sides according to a standardized protocol.
62066935|NCT04492150|EXPERIMENTAL|study group|women who will receive 250 mL/hour of dextrose 5% with normal saline in a 1:1 ratio.
62271909|NCT05616936|NO_INTERVENTION|Group II|Control side: distalization of maxillary first molar that will be performed without any intervention
62271910|NCT05616936|EXPERIMENTAL|Group A|levelling and alignment assisted with Injectable Platelet-rich fibrin (i-PRF) according to a standardized protocol.
62271911|NCT05616936|NO_INTERVENTION|Group B|leveling and alignment will be commenced without Injection of Injectable platelet-rich fibrin (i-PRF)
62271912|NCT05616936|EXPERIMENTAL|Group a|Will includes 9 patients who will receive intrusive arch after leveling and alignment assisted Injectable Platelet-rich fibrin (i-PRF) according to a standardized protocol.
62271913|NCT05616936|NO_INTERVENTION|Group b|Will includes 9 patients who will receive intrusive utility arches after leveling and alignment without Injection of Injectable platelet-rich fibrin (i-PRF)
62286968|NCT01196702||CVID|Patients with common variable immunodeficiency
62286969|NCT01196702||CVID and granulomatous disease|Patients with CVID complicated with granulomatous inflammation
62286970|NCT01196702||CVID and bronchiectasis|Patients with CVID complicated by bronchiectasis
62634556|NCT00696345||1|Colorectal cancer patients, Stages I-IV
62066936|NCT04492150|ACTIVE_COMPARATOR|control group|women who will receive 250 mL/hour of normal saline for the whole duration of induction
62066937|NCT01126060|ACTIVE_COMPARATOR|Fibrin sealant|usage of fibrin sealant after surgery
62066938|NCT01126060|NO_INTERVENTION|Control|No usage of fibrin sealant
62634557|NCT00696345||2|Non colorectal cancer patients, verified by colonoscopy
62066939|NCT00750282|EXPERIMENTAL|Florbetaben (BAY94-9172)|
62066940|NCT02980003|ACTIVE_COMPARATOR|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The infusion rate will be 1 mL/kg/h in the first 5 hours they will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction \<35% or New York Heart Association (NYHA) functional class III or IV). Then, will be infused at 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h
62286971|NCT01196702||Control on Immunoglobulin|Patients on immunoglobulin long-term who do not have an immunodeficiency
62088209|NCT02942147|ACTIVE_COMPARATOR|conventional radiofrequency therapy|In the conventional radiofrequency method applied to Group 1 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
62286972|NCT01196702||Control bronchiectasis|Controls with bronchiectasis not caused by a known immunodeficiency
62286973|NCT01196702||Control with granulomatous disease|Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation.
62634558|NCT03110133|EXPERIMENTAL|CP101|Full Spectrum Microbiota Capsule
62634559|NCT03110133|PLACEBO_COMPARATOR|Placebo|Matching Placebo Capsule
62634560|NCT01638715|EXPERIMENTAL|Infliximab|Infliximab (Remicade®) will be administered i.v.at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
62066941|NCT02980003|ACTIVE_COMPARATOR|i.v. sodium bicarbonate|in the first 5 hours patients will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction \<35% or NYHA functional class III or IV). Then, a solution of 1.4% sodium bicarbonate (167 mEq/L; 334 milliosmol (mOsm/L)) will be infused: the initial intravenous bolus will be 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction \<35% or NYHA functional class III or IV) during the exposure to contrast and for 6 hours after the procedure. Later, patients will resume hydration with isotonic saline for further 6 hours.
62271914|NCT04159038|EXPERIMENTAL|Immediate Intervention Group|Parents in the immediate intervention arm sign a study consent that is integrated into the WIC Referral Form. They also complete a brief demographic survey. No consent is necessary in the delayed intervention arm as only aggregate information will be reported to the study team by EI/ECSE. EI/ECSE referrals are tracked from clinics in both arms for 6 months in ecWeb. At the end of the data collection period, the study team will meet to refine the intervention based on the experience with the immediate intervention group. Qualitative Interviews will take place with WIC staff, parents who indicate interest, EI/ECSE staff, and primary care providers during and after the post-intervention data collection period.
62271915|NCT04159038|OTHER|Delayed Intervention Group|6 months after the immediate intervention group receives their training, the delayed intervention group will receive the training. Prior to implementation of the training in the delayed intervention group, the study team will meet with the Stakeholder Advisory Board. It will review interim results and consider the efficacy of the intervention as a whole. Based on actual use patterns and stakeholder feedback, the investigators will make improvements to the intervention prior to implementing it in the delayed intervention group.
62271916|NCT05059496|EXPERIMENTAL|Hamstring stretching with Pressure Biofeedback Unit|Hot pack, Hamstring stretching with Biofeedback unit, TENS
62271917|NCT05059496|ACTIVE_COMPARATOR|Hamstring stretching with out Pressure Biofeedback Unit|Hot pack, Hamstring stretching without Biofeedback unit, TENS
62271918|NCT01536860|PLACEBO_COMPARATOR|Control Test Drink|control drink
62634561|NCT01638715|EXPERIMENTAL|Abatacept|Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: \<60 kg Body weight (BW): 500 mg; \>60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c.application at a dose of 125mg weekly.
62634562|NCT01638715|EXPERIMENTAL|Tocilizumab|Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
62634563|NCT01638715|EXPERIMENTAL|Rituximab|Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26. Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
62634564|NCT00789620|ACTIVE_COMPARATOR|1|Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h
62634565|NCT00789620|PLACEBO_COMPARATOR|2|NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h
62634566|NCT05796700|ACTIVE_COMPARATOR|Microwave Ablation|According to the shape, size and location of each patient's tumor, as well as the adjacent relationship with the surrounding organs, the individual MWA scheme was pre-established. Contrast-enhanced CT (CE-CT) or contrast-enhanced magnetic resonance imaging (CE-MRI) was used to evaluate complete ablation within 3 to 5 days after ablation. If radiography suggested incomplete ablation, supplementary ablation was performed as soon as the patient's condition permitted. A cooled-shaft MW system (KY-2000, Kangyou Medical, China) was used in the procedure.
62634567|NCT05796700|ACTIVE_COMPARATOR|Laparoscopic Hepatectomy|The optimal surgical procedure for each patient depends on the characteristics of the tumor. Patients were placed in French position and a laparoscopic-assisted partial hepatectomy was performed under CO2 pneumoperitoneum pressure 12-14 mmHg (1 mmHg =0.133 kPa). In most cases, a 4-well or 5-well method was used under general anesthesia.
62634568|NCT03421379|EXPERIMENTAL|Glucagon Nasal Powder|A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
62271919|NCT01536860|EXPERIMENTAL|Experimental Test Drink 1|control drink containing ingredient 1
62271920|NCT01536860|EXPERIMENTAL|Experimental Test Drink 2|Control drink containing ingredient 2
62271921|NCT02488122|EXPERIMENTAL|High Impact Exercise|weight bearing exercises, jumps, plyometric exercises
62271922|NCT02488122|SHAM_COMPARATOR|Low Impact Exercise|Walking, Strength training, Cycling, Yoga.
62271923|NCT03354663|EXPERIMENTAL|TactiCath SE|Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
62271924|NCT01971125||No treatment|"Patients with:~* diabetes mellitus type 2~* absence of heart disease previously reported~* age \>45 years~* Informed Consent~Patients without:~* presence of heart disease previously reported~* diabetes type 1~* serious systemic disease, with an expected lifetime lower than 2 years~* no willingness to participate to the screening~* inadequate compliance to study procedure~* participation to other study"
62271925|NCT03355508|OTHER|puncture bevel up|
62271926|NCT03355508|OTHER|puncture bevel domn|
62271927|NCT02716610|EXPERIMENTAL|INH 69 U (low)|single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)
62271928|NCT02716610|EXPERIMENTAL|INH 69 U (high)|single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
61978653|NCT05282017||Case Group|Meets the COVID-19 like case definition AND Tests positive for at least one SARS-CoV-2 RT-PCR test or Quick-Test (Antigen) with specimens collected between 14 days prior to and including within 24 hours of the day of hospital admission (day 0).
62066942|NCT02980003|EXPERIMENTAL|oral sodium bicarbonate:|"patients will start hydration with isotonic saline as well as Arm Hydration Alone. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water. The drug will be weighed with a precision balance with a sensitivity of ± 0.1 mg and placed in a labeled sterile plastic container. The label will report the lot number, expiry date of the sodium bicarbonate lot, the signature of the pharmacist carrying out the weighing process, a serial number to identify the sample and the patient identification number.~Documentation will be stored in the Laboratory of Galenic Preparations, Pharmacy Division, of the hospital."
62066943|NCT03479190|ACTIVE_COMPARATOR|Platelet rich plasma|ultrasound guided injection of Platelet rich plasma
62271929|NCT02716610|EXPERIMENTAL|INH 139 U|single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.
62271930|NCT02716610|EXPERIMENTAL|INH 208 U|single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
62271931|NCT02716610|ACTIVE_COMPARATOR|LIS 18 U|single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.
62271932|NCT01117636|EXPERIMENTAL|Arm 1|
62271933|NCT01117636|ACTIVE_COMPARATOR|Arm 2|
62271934|NCT01117636|PLACEBO_COMPARATOR|Arm 3|
62271935|NCT00166205|EXPERIMENTAL|Gastric Band|Single-arm study, all subjects banded.
62634569|NCT03421379|ACTIVE_COMPARATOR|Glucagon Hydrochloride Solution|A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)
62271936|NCT00692211|EXPERIMENTAL|Arm 1: Fecal Immunochemical Tests|Mailed fecal immunochemical tests
62271937|NCT00692211|EXPERIMENTAL|Arm 2: Fecal Occult Blood Tests|Mailed fecal occult blood tests
62271938|NCT03405948|EXPERIMENTAL|botulinum toxin|injection of Botulinum toxin
62271939|NCT03405948|PLACEBO_COMPARATOR|placebo|Injection of saline serum (placebo)
62286974|NCT01196702||Healthy Controls|
62634570|NCT00887705|NO_INTERVENTION|1: Standard rehabilitation programme|
62286975|NCT03566329|ACTIVE_COMPARATOR|Magnesium sulphate|50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion
62286976|NCT03566329|ACTIVE_COMPARATOR|lidocaine hydrochloride|1.5mg/kg loading followed by 2mg/kg/hr infusion
62634571|NCT00887705|EXPERIMENTAL|2. Additional ADL training|
62286977|NCT03566329|PLACEBO_COMPARATOR|NaCl 0.9% normal saline|Normal saline infusion with the same rate as the study drugs
62286978|NCT04925310||RSV Bronchiolitis Group|hospitalized children with confirmed RSV infection between the first month of life and second year of life
62634572|NCT05569122|EXPERIMENTAL|Aim 1: Primary Mitochondrial Disease Patients|"The participant has the interventions/study visits occur in a random order:~CPET pGz administration through pGz Bed pGz administration through Gentle Jogger"
62066944|NCT03479190|PLACEBO_COMPARATOR|Normal saline|ultrasound guided injection of Normal saline
62066945|NCT06312982|EXPERIMENTAL|Experimental group|The enrolled patients will receive a long course of NCRT (50 Gy / 25f, capecitabine 850-1000 mg / m2, BID, PO, D1-D5, QW) within the first 5 weeks. In regard to tumor immunotherapy, enrolled patients will receive tislelizumab (200 mg, iv) on the first day at week 2,5, and 8 after initiation of radiotherapy. Thereafter, patients will be treated with two 14-day cycles of the CAPOX（Q 3 w; D1 oxaliplatin, 130mg/m2,iv.gtt; D1-D14, capecitabine, 850-1000mg / m2, BID, PO）regimen. Two CAOPX regimens were treated one week apart. Eight to 8-10 weeks after the completion of radiation therapy, patients will undergo multiple examinations, including colonoscopy and MRI. Subsequent treatment options will be determined by each center physician based on their clinical experience.
62066946|NCT06312982|NO_INTERVENTION|Control group|This group required only 5 weeks of NCRT and two 14-day cycles of the CAPOX （Q 3 w; D1 oxaliplatin, 130mg/m2,iv.gtt; D1-D14, capecitabine, 850-1000mg / m2, BID, PO）regimen.
62271940|NCT03616678|EXPERIMENTAL|VenTouch System Implant|"The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have moderately severe or severe mitral regurgitation (grade 3 or 4 MR)."
62271941|NCT02111993|ACTIVE_COMPARATOR|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
62453212|NCT04765709|EXPERIMENTAL|BRIDGE single arm|"Treatment plan:~* Part 1: induction with durvalumab plus histology-based chemotherapy regimen.~* Part 2: patients with a sufficient tumor shrinkage to be considered eligible for part 2 and they will be treated concomitantly with durvalumab and radiotherapy.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for durvalumab maintenance, for up to 2 years or until disease progression or unacceptable toxicity."
62066947|NCT06153823|EXPERIMENTAL|virtual reality glasses|
62066948|NCT06153823|ACTIVE_COMPARATOR|show-tell-do technique.|
62066949|NCT01155037|EXPERIMENTAL|3.75 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
62066950|NCT01155037|EXPERIMENTAL|7.5 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 7.5µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
62066951|NCT01155037|ACTIVE_COMPARATOR|3.75 µg of the vaccine on day 0|The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine.
62066952|NCT01254864|EXPERIMENTAL|Abiraterone Acetate + Prednisone (AP)|Abiraterone Acetate at 1000 mg orally each day, given in combination with 5 mg of Prednisone orally twice daily.
62066953|NCT01254864|EXPERIMENTAL|Group 1: AP + Sunitinib|AP (Abiraterone Acetate + Prednisone) Plus Sunitinib; Randomized from AP group to receive Sunitinib if disease worsens. Assignment to crossover group AP + Dasatinib with further disease progression.
62453213|NCT01684358|EXPERIMENTAL|Immediate implant|Sino-implant (II) inserted at enrollment visit
62453214|NCT01684358|ACTIVE_COMPARATOR|Delayed implant|Sino-implant (II) inserted at 3-month follow-up visit
62453215|NCT00918437||RAUP treatment|Patients referred to the hospital for a snoring problem
62453216|NCT04730505|EXPERIMENTAL|Patient App + HCP Portal (Cohort 1)|Cohort 1 is to assess how patients will use the Patient App if connected in real time with the Healthcare professional (HCP) Portal
62453217|NCT04730505|EXPERIMENTAL|Patient App Alone (Cohort 2)|Cohort 2 is to assess how patients will use the Patient App where there is no connectivity to the Healthcare professional (HCP) Portal and thus no real-time data sharing with the HCP Portal
62453218|NCT01424722|EXPERIMENTAL|ST Monitoring Feature|ST segment continous monitoring feature enabled and programmed ON
62453219|NCT01725425|EXPERIMENTAL|Control|Participants will receive equal amounts of foods.
62453220|NCT01725425|EXPERIMENTAL|Increase Portion Size|Participants will receive increased portion sizes.
62453221|NCT01725425|EXPERIMENTAL|Decrease Portion Sizes|Participants will receive decreased portion sizes.
62453222|NCT01725425|EXPERIMENTAL|Mixed Portion Sizes|Participants will receive mixed portion sizes.
62453223|NCT02583204|NO_INTERVENTION|Control - standard care|Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.
62453224|NCT02583204|EXPERIMENTAL|Intervention - Oncolife drops|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.
62453225|NCT02583204|EXPERIMENTAL|Intervention - Nail polish|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.
62453226|NCT05964634||myopic glaucoma|Patiens who have high myopia with primary open angle glaucoma
62453227|NCT05964634||healthy myopia|Patiens who have high myopia without primary open angle glaucoma
62453228|NCT06181825|EXPERIMENTAL|COMET-BA|COMET-BA (Common Elements Toolbox- Behavioral Activation) includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
62453229|NCT06181825|NO_INTERVENTION|Waitlist Control|Thoss assigned to the waitlist control condition will complete weekly surveys but will not have access to the COMET-BA materials until the data collection period is over.
62453230|NCT06336863|EXPERIMENTAL|Immunosuppression Taper|Eligible patients who are deemed immune quiescent will undergo sequential withdrawal of immunosuppression medications over a 12-month period from a multi-drug regimen to a Belatacept monotherapy using precision medicine.
62453231|NCT06336863|OTHER|Multi-Drug Regimen|Eligible patients who are not deemed immune quiescent will continue on a multi-drug regimen.
62453232|NCT00655577|NO_INTERVENTION|2|Control group
62453233|NCT00655577|EXPERIMENTAL|1|Exercise group
62453234|NCT02467621|EXPERIMENTAL|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
62066954|NCT01254864|EXPERIMENTAL|Group 2: AP + Dasatinib|AP (Abiraterone Acetate + Prednisone) Plus Dasatinib; Randomized from AP group to receive Dasatinib if disease worsens. Assignment to crossover group AP + Sunitinib with further disease progression.
62066955|NCT02142582|ACTIVE_COMPARATOR|WHO ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
62453235|NCT02467621|PLACEBO_COMPARATOR|Normal saline|Saline (0.9%)
62066956|NCT02142582|ACTIVE_COMPARATOR|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
62066957|NCT00572338||patients with myeloma/related diseases|
62066958|NCT00476619|PLACEBO_COMPARATOR|Erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
62453236|NCT02178826|EXPERIMENTAL|Rapid Maxillary Expansion|A Rapid Maxillary Expander will be fitted and the palate will be expanded approximately 5mm.
62066959|NCT06435780|EXPERIMENTAL|Experimental group|Augmentation for their soft tissue by a novel Denuded interpositional pedicled rolled flap technique (DIPRF)
62066960|NCT06435780|ACTIVE_COMPARATOR|Control group|Will be augmented by the conventional subepithelial connective tissue graft technique.
62066961|NCT01548859|ACTIVE_COMPARATOR|Midazolam|Used for maintenance anaesthesia (0.2 mg/kg/saat continuous infusion)
62066962|NCT01548859|ACTIVE_COMPARATOR|Sevoflurane|Used for the maintenance for anaesthesia (% 0.5-8 end tidal concentration)
62066963|NCT01233609|ACTIVE_COMPARATOR|Valproic Acid|Subjects who receive valproic acid
62066964|NCT01233609|PLACEBO_COMPARATOR|Placebo|Subjects who receive placebo
62453237|NCT02178826|PLACEBO_COMPARATOR|Placebo group|A Sham appliance is fitted and activated for 10-14 days. The patients in this group will after it has been revealed they were randomized into the placebo group have a true Rapid Maxillary Expander fitted and the palate will be expanded approximately 5 mm.
62066965|NCT02768558|EXPERIMENTAL|Nivolumab|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
62066966|NCT02768558|PLACEBO_COMPARATOR|Placebo|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
62066967|NCT06376981|EXPERIMENTAL|Combination of corticosteroid and hyaluronic acid injection|An injection of 1 ml if corticosteroids and an injection of 2 ml of hyaluronic acid
62066968|NCT06376981|PLACEBO_COMPARATOR|Corticosteroid injection alone|An injection of 1 ml of corticosteroids and an injection of 2 ml of placebo (physiological serum).
62066969|NCT04183907|NO_INTERVENTION|Control group|The control group completes three questionnaires in months 1, 3 and 6, including questions on health behaviours, workaholism and work outcomes.
62066970|NCT04183907|EXPERIMENTAL|Transform|Intervention (see next page)
62066971|NCT02667886|EXPERIMENTAL|Dose Escalation (Part A): X4P-001 200 mg BID with Axitinib|Participants will receive X4P-001 200 milligrams (mg) orally twice daily (BID) with axitinib at 5 mg orally BID.
62066972|NCT02667886|EXPERIMENTAL|Dose Escalation (Part A): X4P-001 400 mg QD with Axitinib|Participants will receive X4P-001 400 mg orally once daily (QD) with axitinib at 5 mg orally BID.
62066973|NCT02667886|EXPERIMENTAL|Dose Escalation (Part A): X4P-001 600 mg QD with Axitinib|Participants will receive X4P-001 600 mg orally QD with axitinib at 5 mg orally BID.
62066974|NCT02667886|EXPERIMENTAL|Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib|Participants received X4P-001 400 mg orally QD with axitinib at 5 mg orally BID.
62634573|NCT05569122|EXPERIMENTAL|Aim 1: Healthy Controls|"The participant has the interventions/study visits occur in a random order:~pGz administration through Gentle Jogger CPET pGz administration through pGz Bed"
62634574|NCT05569122|EXPERIMENTAL|Aim 2: PICU Patients|All participants in Aim 2 will have the interventions/study visits occur in the same order: Exercise Pedal and Gentle Jogger
62066975|NCT02667886|EXPERIMENTAL|Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy|Participants will receive X4P-001 600 mg orally QD.
62271942|NCT02111993|ACTIVE_COMPARATOR|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
61978654|NCT05282017||Control Group|Meets the COVID-19 case definition AND Tests negative for all SARS-CoV-2 RT-PCR or Quick-Test (Antigen) tests with specimens collected between 14 days prior to and including a negative test the day at hospital admission (day 0).
62066976|NCT04325087|EXPERIMENTAL|Active iTBS|Active stimulation of the dlPFC directly after trauma exposure and on the following two days
62066977|NCT04325087|PLACEBO_COMPARATOR|Placebo iTBS|Same procedure as in the active stimulation group but with a placebo stimulation imitating the sensation of a real iTBS protocol.
62066978|NCT02481843||Hyperoxia|2-hours of hyperoxia (FiO2 = 1.0)
62066979|NCT02481843||Control|2-hours control without hyperoxia
62066980|NCT04619953|ACTIVE_COMPARATOR|Postural Stability group (PSg)|The Postural Stability group (PSg) will perform 30 minutes of conventional neuromotor rehabilitation and 20 minutes of dynamic postural stability training.
62271943|NCT01509352|ACTIVE_COMPARATOR|with esophageal stitches|fundoplication with crural stitches
62271944|NCT01509352|EXPERIMENTAL|without esophageal stitches|fundoplication without crural stitches.
62271945|NCT03513003|EXPERIMENTAL|Functional pacifier|Swap from the habitual pacifier to a functional pacifier
62271946|NCT03513003|ACTIVE_COMPARATOR|Stop habit|Stop the use of the habitual pacifier and or baby bottle
62271947|NCT02889796|EXPERIMENTAL|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
62271948|NCT02889796|EXPERIMENTAL|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
62271949|NCT02889796|ACTIVE_COMPARATOR|Adalimumab|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
62286979|NCT03998657|EXPERIMENTAL|Exablate Treated Arm|Treatment with Exablate Prostate 2100 Type-3 System
62634575|NCT00854672||sarcoidosis patients|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
62634576|NCT02233699|EXPERIMENTAL|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
62634577|NCT02233699|PLACEBO_COMPARATOR|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
62634578|NCT04985045||Control group|Healthy women will be included
62634579|NCT04985045||Cerebral palsy group|Women with cerebral palsy will be included
62634580|NCT04978324|EXPERIMENTAL|Autogenous Growth Factors Left Side|5-8mm pockets on the left side of the mouth will receive insertion of small treatment after deep cleaning. The right side of the mouth will receive deep cleaning only, the standard of care.
62634581|NCT04978324|EXPERIMENTAL|Autogenous Growth Factors Right Side|5-8mm pockets on the right side of the mouth will receive insertion of small treatment after deep cleaning. The left side of the mouth will receive deep cleaning only, the standard of care.
62066981|NCT04619953|ACTIVE_COMPARATOR|Cognitive-Motor group (CMg)|The Cognitive-Motor group (CMg) performed 30 minutes of conventional neuromotor rehabilitation and 20 minutes of cognitive-motor training.
62088210|NCT02942147|ACTIVE_COMPARATOR|conventional TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
61978655|NCT01806324|EXPERIMENTAL|HL040XC(Atorvastatin+Losartan)|HL040XC lag time released combination drug
62088211|NCT02942147|ACTIVE_COMPARATOR|pulse radiofrequency therapy|In the pulse radiofrequency method applied to Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
62088212|NCT02202590|EXPERIMENTAL|Imaging|Subject will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.
62088213|NCT01548443|EXPERIMENTAL|Medifoam H|"A group which treated with medifoam H on the wound."
62286980|NCT00936624|EXPERIMENTAL|SOTB07 100mg|
62286981|NCT00936624|EXPERIMENTAL|SOTB07 200mg|
62286982|NCT00936624|PLACEBO_COMPARATOR|Placebo|
62286983|NCT00936624|ACTIVE_COMPARATOR|Montelukast 10mg|
62286984|NCT02440581|NO_INTERVENTION|Control, low turnover|No intervention in low turnover osteoporosis control group.
62286985|NCT02440581|EXPERIMENTAL|Treatment, low turnover|Low turnover osteoporosis group treated with teriparatide and cinacalcet.
62066982|NCT05032118|EXPERIMENTAL|Ketamine|Intravenous ketamine will be initiated following aneurysm securement at 0.5mg/kg/h and will be titratable by 0.2mg/kg/h every 20min to a Richmond Agitation Sedation Scale (RASS) goal of 0 to -1 (or as otherwise clinically indicated). Ketamine boluses will be available at 0.5mg/kg every 1hr as needed for inadequate sedation or breakthrough agitation. An additional 0.5mg/kg bolus may be utilized prior to initiating the ketamine infusion, or as needed at the discretion of the clinician. The maximum ketamine infusion dose will be limited to 4mg/kg/h. A fixed-dose propofol infusion at 10mcg/kg/min will simultaneously be administered to minimize the potential psychomimetic side effects of ketamine. This sedation paradigm will continue for up to 10 days post-bleed or until the study participant no longer requires sedation, whichever occurs earlier. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
62066983|NCT05032118|ACTIVE_COMPARATOR|Standard of Care|Intravenous titratable propofol will be initiated as needed per current standard of care, which generally consists of initiating the infusion at 10-20mcg/kg/min with titration parameters of 5-10mcg/kg/min every 5-10min for a RASS goal of 0 to -1 (or as otherwise clinically indicated). Propofol boluses are available at 10-20mg (or higher dosages if clinically required) every 15min as needed for inadequate sedation or breakthrough agitation. The maximum infusion dose is generally limited to 50mcg/kg/min. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
62066984|NCT05899660|PLACEBO_COMPARATOR|Olive oil|Dosage form : capsule Dosage : 1000 mg oleic acid (olive oil) + 3.6 mg D-α-tocopherol (vitamin E) Frequency : 4 capsules per day Duration : 3 months
62066985|NCT05899660|ACTIVE_COMPARATOR|Omega-3|Dosage form : capsule Dosage : 330 mg EPA, 220 mg DHA, 100 mg other n-3 PUFA + 3.6 mg D-α-tocopherol (vitamin E) Frequency : 4 capsules per day Duration : 3 months
62066986|NCT01653808|EXPERIMENTAL|Elisio-210H with HD|hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer
62066987|NCT01653808|ACTIVE_COMPARATOR|Elisio-210H with on line HDF|hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer
62271950|NCT02889796|EXPERIMENTAL|Placebo to Filgotinib 200 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
62066988|NCT03329430|EXPERIMENTAL|Foot orthoses|Customize foot orthoses
62066989|NCT04107896|EXPERIMENTAL|Silodosin|8 mg daily by mouth, 12 weeks
62066990|NCT04107896|ACTIVE_COMPARATOR|Tamsulosin|0.4 mg daily by mouth, 12 weeks
62066991|NCT06617234|EXPERIMENTAL|Nurse-led Intervention Program|This intervention consists of a face-to-face educational session led by a nurse, focusing on the importance of cardiac rehabilitation. The session lasts 15-20 minutes and is tailored to the patient's medical condition and lifestyle, with follow-up reminders and personalized guidance for rehabilitation participation.
62066992|NCT06617234|EXPERIMENTAL|LINEbot Automated Robot System|This intervention uses the LINEbot system to send automated push notifications to participants, including educational messages, reminders for cardiac rehabilitation appointments, and health tracking prompts. Participants can log their daily health data through the system, which offers personalized advice on diet, exercise, and medication management.
62066993|NCT06617234|NO_INTERVENTION|Control Group (Usual Care)|Participants in this group will receive usual care. This includes clinical evaluations by cardiologists and standard rehabilitation referrals without any specialized education or reminders. Their participation in cardiac rehabilitation will not be monitored or actively encouraged beyond routine clinical care. The patients decide independently whether or not to attend cardiac rehabilitation sessions.
62066994|NCT03424486||Adolescents (14 to 17 years old)|Patients with CF
62286986|NCT02440581|NO_INTERVENTION|Control, high turnover|No intervention in high turnover osteoporosis control group.
62286987|NCT02440581|EXPERIMENTAL|Treatment, high turnover|High turnover osteoporosis group treated with alendronate.
62271951|NCT02889796|EXPERIMENTAL|Placebo to Filgotinib 100 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
62634582|NCT02750332|EXPERIMENTAL|Treatment Sequence A (Fed) - B (Fasted)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62271952|NCT02889796|PLACEBO_COMPARATOR|Placebo Never Received Filgotinib|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.
62271953|NCT04405011|EXPERIMENTAL|Entecavir 0.5mg daily for 24 weeks|Entecavir will be delivered for 24-week and will be the experimental arm
62066995|NCT03424486||Parents|Parents of adolescents (14 to 17 years old with CF (father, mother and other)
62088214|NCT01548443|ACTIVE_COMPARATOR|Duoderm THIN|"A group which treated with  Duoderm THIN  on the wound"
62271954|NCT04405011|ACTIVE_COMPARATOR|Entecavir 0.5mg daily for 12 weeks|12-week entecavir will be served as active comparator
62271955|NCT04405011|NO_INTERVENTION|Control|Control group does not receive prophylactic ETV
62634583|NCT02750332|EXPERIMENTAL|Treatment Sequence B (Fasted) - A (Fed)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62634584|NCT03970525||Venturi pump|This cohort will receive femtosecond laser cataract surgery with Venturi pump.
62271956|NCT04149067||Dapagliflozin cohort|Patients diagnosed with type 2 diabetes that started dapagliflozin treatment at least 6 months before the beginning of the study.
62066996|NCT04818697||Patients with heart rhythm disorders|Having been diagnosed with heart rhythm disorders such as atrial fibrillation, atrial tachycardia, ventricular tachycardia, and ventricular extrasystole
62066997|NCT04818697||Healthy individuals|Healthy individuals without chronic disease
62271957|NCT04149067||Sitagliptin cohort|Patients diagnosed with type 2 diabetes that started sitagliptin treatment at least 6 months before the beginning of the study.
62271958|NCT05216965|EXPERIMENTAL|9MW2821|
62066998|NCT04168372|EXPERIMENTAL|High fructose meal, with fructose label|2-13C fructose incorporated into a meal with high fructose content
62634585|NCT03970525||Peristaltic vacuum pump|This cohort will receive femtosecond laser cataract surgery with peristaltic pump.
62634586|NCT04777760||one dose of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
62634587|NCT04777760||two and more doses of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
62634588|NCT05057221|EXPERIMENTAL|Uproleselan|Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.
62634589|NCT00311688||1|Individuals will follow the schedule of the study they are participating in
62066999|NCT04168372|EXPERIMENTAL|High fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with high fructose content
62067000|NCT04168372|EXPERIMENTAL|Low fructose meal, with fructose label|2-13C fructose incorporated into a meal with low fructose content
62271959|NCT04971304||G-CSF originator receipt|Patients receiving filgrastim (Neupogen) or pegfilgrastim (Neulasta) per Health Care Procedural Coding System (HCPCS) J-codes.
62271960|NCT04971304||G-CSF biosimilar receipt|Patients receiving filgrastim biosimilars (filgrastim-aafi, filgrastim-sndz, tbo-filgrastim) or pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-bmez, pegfilgrastim-cbqv) per Health Care Procedural Coding System (HCPCS) J-codes.
62634590|NCT05216445|EXPERIMENTAL|Mindfulness Training|The participants in this group will receive the training for 8 weeks, with 60 minute online weekly sessions. The first session will be for 90 minutes.
62634591|NCT05216445|NO_INTERVENTION|Wait-list Control|The wait-list control group will not receive any intervention. Once the study has been completed they will be offered the Mindfulness Training course.
62634592|NCT04906226|EXPERIMENTAL|Intervention group|Individuals participating in the study will be divided into intervention and control groups. The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
62634593|NCT04906226|NO_INTERVENTION|Control group|There will be no additional application other than routine to the control group, data collection forms will be applied and recorded at the beginning of the study and at the end of four weeks.
62634594|NCT04848142||Primary Group (parent-child)|parents (i.e., guardians/caregivers) and children age ≥ 8 years,will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment. Optional qualitative interviews may be completed individually for participants (age ≥ 12 years with P/LP variant and aware of results, or their parent)
62067001|NCT04168372|EXPERIMENTAL|Low fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with low fructose content
62067002|NCT01099930|ACTIVE_COMPARATOR|Non-randomized control group|Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
62067003|NCT01099930|EXPERIMENTAL|Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
62067004|NCT03604757|EXPERIMENTAL|PET/CT Imaging|
62067005|NCT02819856|PLACEBO_COMPARATOR|SPI-1000 Capsule 0mg Ebselen Placebo|0mg Ebselen SPI-1000 bid po x 21d
62067006|NCT02819856|EXPERIMENTAL|SPI-1005 Ebselen 200mg Capsule x1|200mg SPI-1005 bid po x 21d Low Dose Arm
62271961|NCT01554280|EXPERIMENTAL|Oesophageal Stents|Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.
62271962|NCT02452580||Family Centered Care Unit|Cohort of premature infants and their families receiving Family Centered Care hospitalized at VVHF
62271963|NCT02452580||Open-bay Care Unit|Cohort of premature infants and their families receiving and traditional open-bay care hospitalized at HUH
62271964|NCT02989792|OTHER|Unique study arm|
62271965|NCT01146106|EXPERIMENTAL|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
62271966|NCT01146106|ACTIVE_COMPARATOR|Pravachol 80 mg Tablets|Bristol Myers Squibb
62286988|NCT03402776|NO_INTERVENTION|good resp. after 3 vacc. inject.|no randomization for a 4th dose.
62634595|NCT04848142||Parent Only Group|parents of children age \< 8 years, will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment.
62634596|NCT02585349||First-ever and recurrent ischemic and hemorrhagic stroke|First-ever and recurrent ischemic and hemorrhagic stroke patients are enrolled in the study. Recurrent strokes are only included if the patient is fully recovered from the previous event, which occurred at least 3 years ago, without obvious residual symptoms.
62271967|NCT05972460|EXPERIMENTAL|IMM2510 in Advanced Solid Tumors|"IMM2510 Phase 1a Dose Escalation: 0.007 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 6.0 mg/kg, 10 mg/kg, 20 mg/kg, or higher dose, through intravenous administration every 2 weeks up to 52 weeks.~Phase 1b Cohort Expansion: multiple cohorts are planned, including, but not limited to: non-small cell lung cancer, liver cancer, cervical cancer, cholangiocarcinoma, pancreatic cancer and renal cell carcinoma, with at least 12 patients enrolled in each cohort to further explore the safety and efficacy of IMM2510 in different tumors. The dose for expansion is given by intravenous infusion up to 52 weeks."
62271968|NCT04864444|EXPERIMENTAL|MDA with DHA-PPQ + SLD-PQ|Participants in intervention villages will be given three rounds of MDA with DHA-PPQ and SLD-PQ. Prior to the intervention, participants will have received piperonyl butoxide (PBO) treated LLINs and proactive community case management. Unlike control villages, MDA-randomized villages will not receive SMC.
62271969|NCT04864444|NO_INTERVENTION|Standard malaria control interventions|Participants in the control villages will receive standard malaria control interventions as implemented by the Senegal PNLP. This will include the distribution of PBO LLINs, proactive case management, and SMC.
62271970|NCT00645983|EXPERIMENTAL|1|Chamomile Extract
62634597|NCT03927859|ACTIVE_COMPARATOR|Mailing Letter|Patients assigned to this arm, in which a letter is mailed out will receive 2 pamphlets in the mail. One pamphlet described the teleophthalmology program and the other pamphlet was designed by the Canadian Association of Ophthalmologists and describes what DR is and why screening is important. The letter will also contain contact information about the closest TOP to the area of the PCP practice.
62453238|NCT03106584|ACTIVE_COMPARATOR|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
62067007|NCT02819856|EXPERIMENTAL|SPI-1005 Ebselen 200mg Capsule x2|400mg SPI-1005 bid po x 21d Mid Dose Arm
62067008|NCT02819856|EXPERIMENTAL|SPI-1005 Ebselen 200mg Capsule x3|600mg SPI-1005 bid po x 21d High Dose Arm
61978656|NCT01806324|ACTIVE_COMPARATOR|Losartan + Atorvastatin|Coadministration group
62067009|NCT02011425|EXPERIMENTAL|mandibular advancement appliance|mandibular advancement appliance (SomnoDent by SomnoMed)
62271971|NCT00645983|PLACEBO_COMPARATOR|2|Anxiolytic Therapy
62271972|NCT01358656|ACTIVE_COMPARATOR|Single Bundle Reconstruction|Subjects will undergo single bundle acl reconstruction
62453239|NCT03106584|EXPERIMENTAL|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
62453240|NCT05861726|ACTIVE_COMPARATOR|Exercising Group|"The exercising group shall have pre-intervention assessment of executive brain functions vide Stroop test, Trail making test \& N-Back task/2-Back by using online psytoolkit followed by intervention.~The intervention for the group being acute aerobic exercise, which will comprise of 30 minutes of treadmill walking at 60-65% of Heart Rate max with continuous recording of heart rate and ECG via Biopac MP36 Student Lab system.~This will be followed by post-intervention assessment of executive brain functions vide Stroop test, Trail making test \& N-Back task/2-Back by using online psytoolkit."
62634598|NCT03927859|ACTIVE_COMPARATOR|Phone call|"Administrative staff on site of each practice will contact all patients assigned to this arm by a phone call.~The patient will be informed that they are calling from the family health practice that the patient belongs to. The reason for the call will be that the patient has been identified as somebody who is likely overdue for a screening test. Patients will be asked if they have had a screening test done recently, and if not, they will be offered an appointment. Patients that refuse an appointment, will be politely probed for reasons and attempts will be made to provide them with information on potential solutions to these barriers (e.g. patients working 9-5 on weekdays will be informed that they can access TOP on evenings). The call will also be used as an opportunity to inform patients about the importance of screening.Three attempts will be made to reach each patient. Only a single voicemail message will be left, when the possibility is available."
62067010|NCT02011425|NO_INTERVENTION|without mandibular advancement appliance|no therapy
62067011|NCT05709158||Case: G4 neutropenia occurs after palbociclib initiation|Grade 4 neutropenia occurs after initiation of palbociclib Note that: Case patients are categorized as control before incurring grade 4 neutropenia
62067012|NCT05709158||Control: G4 neutropenia does not occur after palbociclib initiation|Grade 4 neutropenia does not occur after initiation of palbociclib
62067013|NCT02689934|EXPERIMENTAL|Lactoflorene colesterolo|Red Yeast Rice titrated in 10 mg monacolin K per daily dose plus Bifidobacterium longum 50 mg, powder form, 1 packet per day
62067014|NCT02689934|PLACEBO_COMPARATOR|Placebo Lactoflorene colesterolo|placebo, powder form, 1 packet per day
62067015|NCT00284908|EXPERIMENTAL|I STU-Na|Cross-over study with escalating doses
62067016|NCT06432413||Patients group|70 CRC Egyptian patients, admitted to the Oncology Center of the Faculty of Medicine, Ain Shams University Hospitals or the Oncological Surgery Department of Dar-El-Shafa Hospital, before surgical treatment or CRC neo-adjuvant treatment, if they were eligible and agreed to participate (signed the Informed consent) were recruited in the research.
62067017|NCT06432413||Apparently healthy control group|26 randomly-chosen, age-matched, and sex-matched healthy subjects served as the control group. Control group subjects were chosen from those who came to visit hospital workers in the hospital or from blood donors at the ASUH Blood Donation Unit. None of the control group did take any medications or have any diseases upon questioner and blood samples was taken for CBC.
62067018|NCT05013866|ACTIVE_COMPARATOR|Repair of resin Z350|Repair with Z350 on resin composite proximal
62271973|NCT01358656|ACTIVE_COMPARATOR|Double bundle reconstruction|Subjects will undergo double bundle acl reconstruction
62271974|NCT02368717|EXPERIMENTAL|Mesalazine|Mesalazine Enema
62067019|NCT05013866|EXPERIMENTAL|Repair of Tetric Evo Ceram Bulkfill|Repair with Tetric Evo Ceram on resin composite proximal
62067020|NCT00979602|EXPERIMENTAL|GSK2340274A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (\>60 years) and between 18 to 64 years of age and older (\>64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
62271975|NCT02368717|PLACEBO_COMPARATOR|Placebo|Placebo Enema
62271976|NCT02013180||prostate cancer|prostate adenocarcinoma in pathologic evaluation
61978657|NCT02371109||selftaken vs clinical taken swabs|
61978658|NCT00399360|PLACEBO_COMPARATOR|Group 1|No Lifestyle Modification and Placebo
61978659|NCT00399360|ACTIVE_COMPARATOR|Group 2|Lifestyle Modification and Placebo
61978660|NCT00399360|ACTIVE_COMPARATOR|Group 3|No Lifestyle Modification and Metformin
61978661|NCT00399360|ACTIVE_COMPARATOR|Group 4|Lifestyle Modification and Metformin
61978662|NCT00743327||1|Participants receiving ADT and pioglitazone
62067021|NCT00979602|EXPERIMENTAL|GSK2340273A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (\>60 years) and between 18 to 64 years of age and older (\>64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
62067022|NCT06091657|ACTIVE_COMPARATOR|ketamine group|"Group K (ketamine):~syringe (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.~syringe (2): saline syringe 10 ml saline in 10 ml syringe. (for double blinded technique). we will give 0.1ml/kg of the syringe."
62088215|NCT06021210|EXPERIMENTAL|mNGS detection before stem cell transplantation|Using letermovir to prevent CMV reactivation for high-risk patients with pre-existing CMV viremia based on the mNGS detection technology before HSCT
62271977|NCT02013180||control|benign prostatic diseases in pathologic evaluation
62271978|NCT00223496|EXPERIMENTAL|Aripiprazole|Aripiprazole open-label in doses ranging from 5-30mg QD adjunct to Divalproex 500-2500mg QD.
62271979|NCT00726687|EXPERIMENTAL|single|Single arm designed to elicit Maximum Tolerated Dose
62271980|NCT05173454|EXPERIMENTAL|Breastfeeding Education and Support|The intervention arm will receive antenatal and postnatal breastfeeding education and support intervention for six months starting in their third trimester pregnancy period. The intervention package is comprised of four components: Antenatal breastfeeding education, providing specific take-home print materials, Telephone call counseling and Individual home visit.
62271981|NCT05173454|NO_INTERVENTION|Usual or routine care|The routine care will be continued in the control group.
62286989|NCT03402776|EXPERIMENTAL|bad resp. after 3 vacc. inj., 4th inj|After randomization, these patients will receive a 4th dose one month after the 3rd dose.
62634599|NCT03927859|ACTIVE_COMPARATOR|Mail + Phone call|Patients assigned to this arm will first have letters mailed out to them (identical to the ones mailed out in the letter only arm). A week later, the letter will be followed up by a phone call as per the phone only arm. Patients will be asked if they have already booked, and if not, will be provided with information about the program as per the phone call script in the phone only arm.
62634600|NCT03927859|NO_INTERVENTION|Control|No intervention will be offered to patients in this arm.
62634601|NCT04296708|EXPERIMENTAL|ExerCube group|The ExerCube is an immersive fitness game setting that combines innovative soft- and hardware designs with state of-the-art training concepts. The ExerCube has three walls which serve as virtual reality projection screens and haptic interfaces. The ExerCube is a playful physical-cognitive exergame training. The user navigates a virtual environment/reality via whole body exercise. The video game navigates the user and triggers various cognitive functions. The used physical exercises are functionally and elicit the improvement of endurance and strength components. Via different monitoring systems (points and heart rate), the game adapts to the individual abilities and training level to tailor workout intensity. The ExerCube training consists of two sessions a week each session will last about 30 minutes of which 25 minutes will be pure playtime
62634602|NCT04296708|NO_INTERVENTION|Control group|The control group does not have any additional ExerCube training.
62634603|NCT02888366||1|Breath samples taken, no treatment given.
62067023|NCT06091657|ACTIVE_COMPARATOR|ketamine dexamethasone group|"Group KD (ketamine plus dexamethasone):~Syringes (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.~Syringe (2): dexamethasone syringe, 10 mg dexamethasone will be diluted with 10 ml saline in 10 ml syringe, concentration will be 1mg/ml. the dose will be 0.1 mg/kg, so we will give 0.1ml/kg of the syringe."
62634604|NCT03461198|EXPERIMENTAL|Treatment|Restylane® Silk to a defined area of mid to low cheeks.
61978663|NCT00743327||2|Participants receiving ADT only
61978664|NCT00743327||3|Participants not receiving ADT and in remission from prostate cancer
61978665|NCT01654367|EXPERIMENTAL|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
61978666|NCT02950454|EXPERIMENTAL|Intervention|8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
62634605|NCT06218615|EXPERIMENTAL|Health Services Research|Participants watch a culturally tailored decision aid video. Surveys are completed before and after the video.
62634606|NCT06611618|EXPERIMENTAL|Knee Osteoarthritis|"Elderly patients with knee osteoarthritis, without a history of falls (in the 12 months prior to enrollment).~All subjects will be followed up for 24 months, every 6 months. Muscle force and power assessments, plus a home-based mobility monitoring, will be performed at all visits. Full lower limb MRI and a gait assessment will be performed at first and last visit."
62634607|NCT03185286|EXPERIMENTAL|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
62634608|NCT02923583|EXPERIMENTAL|M834|M834 (abatacept biosimilar candidate)
62634609|NCT02923583|ACTIVE_COMPARATOR|US Orencia®|US-sourced Orencia® (abatacept)
62634610|NCT02923583|ACTIVE_COMPARATOR|EU Orencia®|EU-sourced Orencia® (abatacept)
62634611|NCT02953483|EXPERIMENTAL|Acellular first|Lung preservative solution without red blood cells will be used for perfusion in the initial 2 hours followed by addition of red blood cells for the next two hours
62271982|NCT04938258|EXPERIMENTAL|Intensive Case Management Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual."
62271983|NCT03458390|EXPERIMENTAL|HyGIeaCare and PillCam COLON|Patient will receive the HyGIeaCare colon irrigation prior to their PillCam COLON procedure
62271984|NCT00368771|ACTIVE_COMPARATOR|1|IBS Stress Management
62634612|NCT02953483|EXPERIMENTAL|Cellular first|Lung preservative solution will contain red blood cells for the first two hours followed by acellular perfusate for the next two hours
62634613|NCT03788161|EXPERIMENTAL|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
62634614|NCT03788161|PLACEBO_COMPARATOR|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
62067024|NCT04399733||Ethnicity|Patients will be segmented on a 1:1:1 ratio similar to the EMPOWER-1 study based on ethnicity (White, Black, South Asian).
62067025|NCT02220504|EXPERIMENTAL|Intervention group|Antipsychotic treatment discontinuation (DT)
62271985|NCT00368771|ACTIVE_COMPARATOR|2|IBS Symptom Management
62271986|NCT00368771|ACTIVE_COMPARATOR|3|IBS Educational Training
62271987|NCT06197828||Sepsis-associated acute kidney injury|Between May 2021 and December 2024, patients admitted to the Pediatric Intensive Care Unit (PICU) for a duration exceeding three days were included in the study. Specifically, patients diagnosed with sepsis were selected based on the 2005 international standard for childhood sepsis, the 2012 Surviving Sepsis Campaign guidelines for pediatric sepsis, and the 2015 expert consensus on sepsis criteria for Chinese children with septic shock. The age range of the patients included in the study varied from 1 month to 16 years old.
62271988|NCT06197828||Patients without sepsis In ICU|patients admitted to the Pediatric Intensive Care Unit (PICU) for a duration exceeding three days and those without sepsis were included in the study.
62271989|NCT02066272||IBD patients|IBD patients who start or re-start anti-TNF therapy
62271990|NCT01568593|EXPERIMENTAL|T2750|
62271991|NCT01568593|ACTIVE_COMPARATOR|Vismed|
62271992|NCT01376947||Nulliparous|Nulliparous women who were submitted to IUD device insertion
62634615|NCT06071741||PCI group|Patients undergoing Percutaneous Coronary Intervention
62634616|NCT01947101|EXPERIMENTAL|Ulcerative Colitis|Fecal Microbiota Transplant
62634617|NCT04778839|EXPERIMENTAL|Paclitaxel Micelles for Injection|In the First Period, Only three Participants in the first dose group were randomly assigned to 175 mg/m2 paclitaxel micelle for injection at a 1:1 rate.175 mg/m2, 260 mg/m2, 320 mg/m2, and 390 mg/m2 of paclitaxel micelle for Injection was intravenously administrated for three hours,three weeks constituted one course of treatment.
62271993|NCT01376947||Multiparous with no cesaraen section|Multiparous women with no cesarean sections that were submitted to IUD device insertion
62271994|NCT01376947||Mulitparous with cesarean section|multiparous women with a cesarean section that were submitted to IUD insertion
62634618|NCT04778839|ACTIVE_COMPARATOR|Paclitaxel Injection|three Participants were randomly assigned to 175 mg/m2 paclitaxel Injection,175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
62634619|NCT04187443|EXPERIMENTAL|MS-553 low dose|low dose of MS-553 taken orally
62634620|NCT04187443|EXPERIMENTAL|MS-553 mid dose|mid dose of MS-553 taken orally
62634621|NCT04187443|EXPERIMENTAL|MS-553 high dose|high dose of MS-553 taken orally
62067026|NCT02220504|ACTIVE_COMPARATOR|Control group|Maintenance antipsychotic treatment (MT)
62067027|NCT01211236|EXPERIMENTAL|Maggot Debridement Therapy|
62067028|NCT01211236|ACTIVE_COMPARATOR|control|
62067029|NCT03313258|ACTIVE_COMPARATOR|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
62271995|NCT06539572||Cleft lip and palate|Cleft lip and palate patients, undergone surgical treatment and received regular follow-ups in the Chang Gung Craniofacial Center; aged 10-12; after alveolar bone grafting surgery
62271996|NCT06539572||Non-cleft|Non cleft cohort as control group; recruited from various elementary schools in the Guishan district of Taoyuan City, Taiwan; aged 10-12; without craniofacial anomalies.
62271997|NCT05334186|EXPERIMENTAL|Telehealth Reasoning Training|Telehealth-delivered inductive reasoning training will focus on improving the ability to solve problems that require linear thinking and that follow a serial pattern or sequence. Participants will be taught strategies to identify patterns to solve problems. These problems involve identifying the pattern in series of numbers and letters, or recognizing patterns in everyday activities, like dosing for medications. Training will consist of ten training sessions, over 5 weeks, and will be conducted over Zoom. Each training session is 60-75 minutes long and typically consists of (a) 10 minutes of introductory training exercises for basic mental abilities, such as finding patterns in schedules, (b) training exercises for everyday tasks, such as filling out medication charts, recycling charts, and understanding medicine bottle labels, and (c) a 20-question practice assessment.
62271998|NCT02138032|EXPERIMENTAL|Gains Framed Message|gains framed visual fridge magnet and information sheet about smoking cessation (benefits of quitting smoking)
62271999|NCT02138032|EXPERIMENTAL|Loss Framed Message|loss framed visual fridge magnet and information sheet about smoking cessation (losses of continued smoking)
62286990|NCT03402776|NO_INTERVENTION|bad resp. after 3 vacc. inj., no 4th inj|After randomization, these patients will not receive a 4th dose one month after the 3rd dose.
62634622|NCT04789525|EXPERIMENTAL|Group A (high-intensity aerobic training with high protein diet )|
62634623|NCT04789525|EXPERIMENTAL|Group B(regular physical activities and taken regular diet)|
62634624|NCT03215537|NO_INTERVENTION|observation|No Intervention
62634625|NCT03215537|ACTIVE_COMPARATOR|comprehensive intervention|preoperative: exercise counseling postoperative : symptoms counseling and pulmonary rehabilitation
62634626|NCT03863847|ACTIVE_COMPARATOR|Online Neurofeedback|This intervention entails online feedback of pain-related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
62634627|NCT03863847|SHAM_COMPARATOR|Online Sham Neurofeedback|This intervention entails online sham feedback of non-pain related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
62634628|NCT05380154|EXPERIMENTAL|Test group|Botulinum Toxin A type for injection (Botulax®)
62634629|NCT05380154|ACTIVE_COMPARATOR|control group|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)
62634630|NCT00828113|EXPERIMENTAL|Extended treatment|52-week varenicline therapy + individual smoking cessation counseling
62067030|NCT03313258|EXPERIMENTAL|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
62067031|NCT05907460|NO_INTERVENTION|Control group|Perform standard advanced life support. No examination of transesophageal echocardiography during cardiopulmonary resuscitation.
62634631|NCT00828113|ACTIVE_COMPARATOR|Standard treatment|13 weeks of varenicline therapy + individual smoking cessation counseling
62634632|NCT04796766|EXPERIMENTAL|Healthy volunteers|HFS / LFS in healthy volunteers at two different points in time
62634633|NCT04796766|EXPERIMENTAL|Migraine patients|HFS / LFS in migraine patients at a single point in time
62634634|NCT04796766|EXPERIMENTAL|Patients with Botulinum toxin or CGRP-targeted therapy|HFS / LFS before and under treatment with Botulinum toxin or CGRP-targeted therapy
62634635|NCT02084901|EXPERIMENTAL|Orsiro Arm|
62634636|NCT02084901|ACTIVE_COMPARATOR|BioMatrix or BioMatrix Flex Arm|
62634637|NCT06518733||Group A|patients with fixed labial orthodontic appliance
62272000|NCT06221475|EXPERIMENTAL|Healthy male participants from Netherlands|In Part 1, participants will receive a single dose of 40 mg of BAY2927088 as oral tablets on Study Day 1 approximately 30 min after a light meal, they will then receive a single dose of a microtracer not exceeding 100 ug of \[14C\]-BAY2927088 and 37 kilo becquerel (kBq) \[1000 nano Curie (nCi)\] of 14C will be administered intravenously (IV) as a 15 min infusion ending at the expected median time to maximum concentration (tmax) for the tablet (2 hours oral post-dose). After 2 days of washout, participants will move on to Part 2. In Part 2, on Study Day 1 approximately 30 min after a light meal, all enrolled participants will receive a single dose of 40 mg BAY2927088 containing approximately 3.7 MBq (100 µCi) \[14C\]-BAY 2927088 administered as an oral solution
62272001|NCT00037609|EXPERIMENTAL|Capecitabine + Exisulind|Capecitabine 1000 mg/m\^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
62272002|NCT02274103|ACTIVE_COMPARATOR|Clinic|BFST delivered to youth with poorly controlled diabetes and their families in the clinic, face-to-face.
62634638|NCT06518733||Group B|patients with fixed labial appliance with palatal appliances
62634639|NCT06518733||Group C|patients with fixed labial appliance with miniscrews
62634640|NCT06518733||Group D|patients with fixed labial appliance with both palatal appliances and miniscrews
62634641|NCT06518733||Group E|patients with fixed retainer
62634642|NCT03967288|EXPERIMENTAL|Chloroprocaine|50 mg of 1% spinal chloroprocaine (5 mL) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
62634643|NCT03967288|ACTIVE_COMPARATOR|Bupivacaine|10.5 mg of spinal hyperbaric bupivacaine (1.4 mL of 0.75% bupivacaine hydrochloride in 8.25% dextrose) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
62634644|NCT06408337|EXPERIMENTAL|experimental|The experimental group will be implanted with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT). The implantation of this advanced therapy medication will cover the lateral defect generated by the mobilization of fibromucous flaps during standard surgery (uranostaphylorrhaphy
62634645|NCT06408337|NO_INTERVENTION|control group|These patients will be included in the control group and will receive the usual treatment for their disease (uranoestafilorrafia), without applying any type of restriction to the area used for the movement of the arms.
62634646|NCT01607216||Premature Infant|Infants born 23 0/7 weeks gestation to 35 6/7 weeks gestation.
62634647|NCT01607216||Healthy Full Term Infants|Infants born between 37 0/7 weeks gestation to 41 6/7 weeks gestation.
62634648|NCT04226781|ACTIVE_COMPARATOR|ICG|Fluorescence imaging for blood Perfusion of the gastrointestinal tissue
62634649|NCT04226781|EXPERIMENTAL|HSI|Hyperspectralimaging for blood Perfusion of the gastrointestinal tissue
62634650|NCT02240017|ACTIVE_COMPARATOR|Carboplatin/Gemcitabine|
62634651|NCT02240017|EXPERIMENTAL|Fractionated Cisplatin/Gemcitabine|
62634652|NCT03243825|EXPERIMENTAL|chemo/brachytherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) and brachytherapy before radical hysterectomy.
62634653|NCT03243825|ACTIVE_COMPARATOR|chemotherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) before radical hysterectomy.
62634654|NCT05710900|EXPERIMENTAL|Low-calorie diet group|A low-calorie diet involving will involve a commercial weight loss program (pre-packaged foods from Ideal Protein, select lean protein sources, non-starchy vegetables) and be led by the pharmacist and registered dietitian (RD) involving in-person and virtual appointments.
62634655|NCT05710900|EXPERIMENTAL|Low-carbohydrate diet group|The low-carbohydrate diet will involve an individualized whole-food diet (30-130 grams carbohydrate per day) led through virtual visits with a registered dietitian.
62067032|NCT05907460|EXPERIMENTAL|Intervention group|Perform examination of transesophageal echocardiography during cardiopulmonary resuscitation and adjust the chest compression site to avoid left ventricular outflow tract according to the result of transesophageal echocardiography
62272003|NCT02274103|ACTIVE_COMPARATOR|Skype|BFST delivered to youth with poorly controlled diabetes and their families using Skype.
62634656|NCT02004938||normal respiratory function|This will include the 40 subjects enrolled in the study
62634657|NCT05231343|EXPERIMENTAL|Dual mini-fragment plating|
62634658|NCT05231343|ACTIVE_COMPARATOR|Single precontoured plating|
62634659|NCT02895347|NO_INTERVENTION|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
62634660|NCT02895347|EXPERIMENTAL|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
62634661|NCT04739033|EXPERIMENTAL|Experimental group|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
62067033|NCT01412814|EXPERIMENTAL|Experimental|These patients will carry out the specified intervention of the study with the AposTherapy Biomechanical System in addition to the typical physical therapy regiment prescribed to them by their physician.
62067034|NCT01412814|ACTIVE_COMPARATOR|Control|The patients within this group will also carry out the typical physical therapy program for total knee replacement as prescribed by their physician. The patients will carry out a similar therapy program to the experimental group, but without the study intervention device (placebo walking shoe).
62272004|NCT01495442|ACTIVE_COMPARATOR|modified Handihaler DPI|
62272005|NCT01495442|PLACEBO_COMPARATOR|standard Handihaler DPI|
62272006|NCT01314300|EXPERIMENTAL|Efficacy of Lidocaine 5% plaster|Treatment of pain by Lidocaine 5% plaster
62272007|NCT04253275|OTHER|Ischemic stroke patients|Patients with ischemic stroke diagnosed on clinical presentation and cerebral imaging
62272008|NCT04253275|OTHER|hemorragic stroke patients|Patients with hemorragic stroke diagnosed on clinical presentation and cerebral imaging
62272009|NCT04253275|OTHER|healthy controls|Stroke-free
62067035|NCT03560258|EXPERIMENTAL|Arm A: p24CE/full-length Gag DNA|Participants received p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55\^gag pDNA vaccine at Weeks 12 and 24.
62067036|NCT03560258|EXPERIMENTAL|Arm B: Full-length Gag DNA|Participants received full-length p55\^gag pDNA vaccine at Weeks 0, 4, 12, and 24.
62272010|NCT01678183|EXPERIMENTAL|Monthly Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension, and hypercholesterolemia at the pharmacy on time. The intervention is the cash incentive.
62286991|NCT01911026|EXPERIMENTAL|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus interventional instructions from reinforcement educated nurse such as 'Reinforcement Nurse Education'
62634662|NCT04739033|ACTIVE_COMPARATOR|Control Group|The control group will receive the same webbased lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
62634663|NCT02958579||Obesity|Body mass index (BMI) score \> 25.2 kg/m2 for women and \> 27.3 kg/m2 for men or Waist circumference \> 90 cm
62634664|NCT02958579||Pre-diabetics or diabetics|"if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;~1. Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)~2. Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test~3. Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)~4. Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;~1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)"
62634665|NCT02958579||Hypertension|Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs
62634666|NCT02958579||hypertriglyceridemia|Serum triglyceride ≥150 mg/dL
62634667|NCT02958579||Low high density lipoprotein -cholesterol (HDL-c)|Serum HDL-C of \<40 mg/dL for men, \<50 mg/dL for women,
62634668|NCT00953290|EXPERIMENTAL|Treated Thigh|The thigh treated with the RF device
62634669|NCT00953290|NO_INTERVENTION|Untreated Thigh|The untreated thigh
62634670|NCT00366782|EXPERIMENTAL|1|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
62634671|NCT00366782|EXPERIMENTAL|2|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to HPIV3-seropositive children 15 to 59 months of age). This arm may enroll after Arm 1 depending on the effect of the vaccine on Arm 1.
62634672|NCT00366782|EXPERIMENTAL|3|One vaccination with rB/HPIV3 vaccine (at lower dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
62634673|NCT00366782|EXPERIMENTAL|4|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
62067037|NCT03560258|PLACEBO_COMPARATOR|Arm C: Placebo|Participants received placebo at Weeks 0, 4, 12, and 24.
62067038|NCT00714532|ACTIVE_COMPARATOR|1|Expert system only, which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months.
62088216|NCT05711329||All patients|Patients in this group will serve to validate the accuracy of the French method to detect OSA patients in comparison with PSG results.
62088217|NCT06463262||Spinal, Sacral Chordoma|
62088218|NCT05070650|EXPERIMENTAL|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
62634674|NCT00366782|PLACEBO_COMPARATOR|5|One vaccination with placebo vaccine given as nose drops to adults, HPIV3-seropositive children, or seronegative children or infants
62067039|NCT00714532|EXPERIMENTAL|2|"The intervention consists of 3 components:~* Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~* scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~* telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~* a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
62067040|NCT06625346||Naive Hypertensive patients|Naive Pakistani subjects diagnosed as the case of Hypertension prescribed Extor in routine practice.
62634675|NCT05618015|EXPERIMENTAL|Supervised progressive resistance training|Supervised PRT was conducted face-to-face at the clinic
62634676|NCT05618015|ACTIVE_COMPARATOR|Home-based progressive resistance training|Home-based PRT was conducted at home without supervision
62634677|NCT04038112|OTHER|Method of Levels (MOL)|all participants will be offered intervention
62067041|NCT01006317|NO_INTERVENTION|Control|Financial coverage of MCH care within the local reimbursement system (CMS).
62634678|NCT03363607|EXPERIMENTAL|3D printed transfer tray group|Indirect bonding using digital 3D printed transfer tray
62067042|NCT01006317|EXPERIMENTAL|Clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
62453241|NCT05861726|PLACEBO_COMPARATOR|Control Group|"The control group will also have pre-intervention assessment of executive brain functions vide Stroop test, Trail making test \& N-Back task/2-Back by using online psytoolkit.~The control group will undergo NO EXERCISE intervention. They will sit idly in laboratory for 30 minutes with continuous recording of heart rate and ECG via Biopac system.~The executive brain functions of the control group will be re-assessed vide Stroop test, Trail making test \& N-Back task/2-Back by using online psytoolkit."
62453242|NCT06324136|EXPERIMENTAL|Rare kidney diseases|Patients with rare kidney diseases
62453243|NCT00868309|EXPERIMENTAL|Anavip|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 30 minutes for Anavip
62067043|NCT01006317|EXPERIMENTAL|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
62067044|NCT01006317|EXPERIMENTAL|Financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
62067045|NCT05423327|OTHER|Single Blood Draw|
62453244|NCT00868309|ACTIVE_COMPARATOR|CroFab|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 60 minutes for CroFab, or as permitted by IV access.
62453245|NCT01208064|EXPERIMENTAL|Pazopanib|2 weeks at 600mg and then maintenance at 800mg
62453246|NCT01208064|PLACEBO_COMPARATOR|Placebo|placebo match 2 weeks at 600mg and then maintenance at 800mg
62453247|NCT04363983|ACTIVE_COMPARATOR|Located/resected colorectal cancer|
62453248|NCT04363983|ACTIVE_COMPARATOR|Advanced colorectal cancer|
62453249|NCT04363983|ACTIVE_COMPARATOR|Located/resected pancreatic cancer|
62453250|NCT04363983|ACTIVE_COMPARATOR|Advanced pancreatic cancer|
62453251|NCT04363983|ACTIVE_COMPARATOR|Located/resected biliary tract cancer|
62453252|NCT04363983|ACTIVE_COMPARATOR|Advanced biliary tract cancer|
62453253|NCT04363983|ACTIVE_COMPARATOR|Located/resected gastroesophageal cancer|
62453254|NCT04363983|ACTIVE_COMPARATOR|Advanced gastroesophageal cancer|
62453255|NCT04363983|ACTIVE_COMPARATOR|Located/resected neuroendocrine cancer|
62453256|NCT04363983|ACTIVE_COMPARATOR|Advanced neuroendocrine cancer|
62453257|NCT04725149|PLACEBO_COMPARATOR|0 ml tart cherry concentrate|Still cherry-flavored beverage, similar in appearance, taste, aroma and calories to the 30 ml and 60 ml tart cherry concentrate beverages
62453258|NCT04725149|EXPERIMENTAL|30 ml tart cherry concentrate|"Low dose tart cherry concentrate beverage"
62453259|NCT04725149|EXPERIMENTAL|60 ml tart cherry concentrate|"High dose tart cherry concentrate beverage"
62453260|NCT02334371|OTHER|MR-PET|Preoperative whole-body MR-PET with 18F-FDG
62453261|NCT02161874|EXPERIMENTAL|T3 with DCD tapered implant|T3 with DCD tapered prevail implant
62453262|NCT02161874|ACTIVE_COMPARATOR|Nanotite certain tapered implant|Nanotite Certain tapered implant
62634679|NCT03363607|ACTIVE_COMPARATOR|Thermoformed transfer tray group|Indirect bonding using Thermoformed transfer tray
62634680|NCT01417975|EXPERIMENTAL|Moderate Exercise Group|The moderate exercise condition will involve participants waking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise is defined as 40-68% of heart rate reserve (HRR). Heart rate (HR) will be monitored using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
62634681|NCT01417975|ACTIVE_COMPARATOR|Passive Sitting Group|The passive sitting condition will involve participants sitting passively in a chair for 10 minutes. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) with regards to distraction effects and researcher contact.
62067046|NCT04924686||Crohn's disease|The fecal and plasma were collected
62067047|NCT04924686||Ulcerative colitis|The fecal and plasma were collected
62067048|NCT04924686||Diabetes mellitus, type 2|The fecal and plasma were collected
62067049|NCT04924686||Atherosclerotic cardiovascular disease|The fecal and plasma were collected
62067050|NCT04924686||Colorectal cancer|The fecal and plasma were collected
62067051|NCT06280495|ACTIVE_COMPARATOR|FOLFOX only group|Oxaliplatin: 85 mg/m2 IV on day 1 Fluorouracil (FU): 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours Leucovorin: 200 mg/m2 IV on day 1 This treatment regimen is repeated every two weeks for a total of 6 cycles.
62067052|NCT06280495|EXPERIMENTAL|Serplulimab + Bevacizumab + FOLFOX|Serplulimab: 200 mg IV infusion on day 1 Bevacizumab: 5 mg/kg IV infusion on day 1 Oxaliplatin, FU, and Leucovorin as per the control arm The experimental arm follows the same treatment schedule as the standard FOLFOX regimen, with the addition of Serplulimab and Bevacizumab for the first 3 cycles only.
62067053|NCT05815901|EXPERIMENTAL|Epaminurad 6 mg|\[Main study period\] Epaminurad 6 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
62067054|NCT05815901|EXPERIMENTAL|Epaminurad 9 mg|\[Main study period\] Epaminurad 9 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
62067055|NCT05815901|ACTIVE_COMPARATOR|Febuxostat 40 mg|\[Main study period\] Febuxostat 40 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
62067056|NCT05815901|ACTIVE_COMPARATOR|Febuxostat 80 mg|\[Main study period\] Febuxostat 80 mg and three matched placebos for 20 weeks. \[Extension study period\] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
62067057|NCT02900612|EXPERIMENTAL|WA (Water Aerobics Training)|Water aerobics training.
62067058|NCT02900612|EXPERIMENTAL|WR (Water Resistance Training)|Resistance aquatic training.
62067059|NCT02900612|ACTIVE_COMPARATOR|CG (Control Group)|Control Group.
62272011|NCT01678183|EXPERIMENTAL|Monthly and Final Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension and hypercholesterolemia at the pharmacy on time, as well as an additional financial incentive for each full percentage point of decrease in their hemoglobin A1c over the eight-month course of the study. The two cash incentives are the intervention.
62067060|NCT04922190|EXPERIMENTAL|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
62067061|NCT00674323|EXPERIMENTAL|Verteporfin and Ranibizumab|Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
62067062|NCT00674323|ACTIVE_COMPARATOR|Verteporfin monotherapy|Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
62088219|NCT05070650|ACTIVE_COMPARATOR|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day
62634682|NCT04391777|EXPERIMENTAL|CV-4 group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The CV-4 technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
62272012|NCT01678183|NO_INTERVENTION|Control|These subjects will complete the enrollment process for the study but will be randomized to a group that receives usual care.
62272013|NCT01394146|EXPERIMENTAL|Subjects with healthy kidney function|
62272014|NCT02501044||Hemodialysis Patients|
62634683|NCT04391777|SHAM_COMPARATOR|Control group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The sham technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
62634684|NCT04010461|EXPERIMENTAL|TMS to dlPFC, without a concurrent task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are in a resting state
62634685|NCT04010461|EXPERIMENTAL|TMS to vertex, without concurrent task|TMS (intermittent theta burst stimulation) will be applied to the cerebral vertex, when subjects are in a resting state
62272015|NCT06222151|EXPERIMENTAL|A|Participates in intervention 1 and 2
62272016|NCT06222151|OTHER|B|Participates in intervention 1, control in intervention 2
62634686|NCT04010461|EXPERIMENTAL|TMS to dlPFC, during task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are engaged in the n-back working memory task
62272017|NCT06222151|OTHER|C|Participates in intervention 2, control in intervention 1
62634687|NCT01096953|ACTIVE_COMPARATOR|Telepsychiatry|Psychiatry provided over telehealth network
62272018|NCT06222151|ACTIVE_COMPARATOR|D|Control in both intervention 1 and 2
62453263|NCT01591707|EXPERIMENTAL|ISC+PRT Intervention|For the duration of at least one school year children will receive 45-90 minutes of intervention in the classroom in an attempt to increase social and communication skills.
61978667|NCT02950454|ACTIVE_COMPARATOR|control|8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.
61978668|NCT05991037|EXPERIMENTAL|"overdosed group"|The experimental group will be made up of falling patients recruited for whom at least one psychoactive drug has been measured in a concentration higher than the usual therapeutic ranges.
62286992|NCT01911026|NO_INTERVENTION|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
62453264|NCT01591707|NO_INTERVENTION|Instruction As Usual|For the duration of at least one year children will receive the typical classroom instruction
62453265|NCT00278694|EXPERIMENTAL|Chemoradiation|Neoadjuvant chemotherapy and chemoradiation
62453266|NCT04716660||Women receiving epidural analgesia for labor|
62453267|NCT05744609||children hospitalized with community-acquired pneumonia|
62453268|NCT04007133||Diabetic patients|Patients with non-insulin-dependent diabetes, taking statins for at least 1 month
62453269|NCT02398877|EXPERIMENTAL|Depression with early trauma|stress
62453270|NCT02398877|EXPERIMENTAL|Depression without early trauma|stress
62634688|NCT01096953|ACTIVE_COMPARATOR|Face-to-face care|Psychiatry provided in person
62067063|NCT00674323|ACTIVE_COMPARATOR|Ranibizumab monotherapy|Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
62067064|NCT04733911|EXPERIMENTAL|Eccentric 75|Participants in this arm will perform an eccentric exercise protocol consisted of 75 eccentric repetetions on an isokinetic dynamometer.
62067065|NCT04733911|EXPERIMENTAL|Eccentric 150|Participants in this arm will perform an eccentric exercise protocol consisted of 150 eccentric repetetions on an isokinetic dynamometer.
62067066|NCT04733911|EXPERIMENTAL|Eccentric 300|Participants in this arm will perform an eccentric exercise protocol consisted of 300 eccentric repetetions on an isokinetic dynamometer.
62067067|NCT04733911|NO_INTERVENTION|Control|Participants in this arm will receive no intervention.
62088220|NCT05503420|EXPERIMENTAL|exerciser|Participants will be asked to use a masticatory muscle training exerciser twice daily, 10 minutes each time, and also perform active range of motion for 4 minutes each time.
62634689|NCT02767778|EXPERIMENTAL|REAL Pulsed ELF-MF stimulation|Patients will receive REAL pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
61978669|NCT05991037|OTHER|"non-overdosed group"|The control group will be made up of falling patients recruited for whom none of the psychoactive drugs have been measured in supra-therapeutic concentrations (therefore concentrations measured therapeutic or infra-therapeutic)
61978670|NCT00714324||1|Paper screening
61978671|NCT00714324||2|Electronic screening
61978672|NCT01132131|ACTIVE_COMPARATOR|Delegation form|
62272019|NCT05250375||Primary Mitochondrial Myopathy|Patients with a mitochondrial disorder established by confirmed genetic or biochemical mutation in mtDNA or nuclear DNA or is suitable for participation in the opinion of the investigator based on clinical presentation and exhibits myopathy (exercise intolerance, muscle strength, fatigue) relating to mitochondrial disease.
62634690|NCT02767778|SHAM_COMPARATOR|SHAM Pulsed ELF-MF stimulation|Patients will receive SHAM pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
62634691|NCT01039766|EXPERIMENTAL|oxytocin|
62634692|NCT01039766|PLACEBO_COMPARATOR|Placebo|
61978673|NCT01132131|ACTIVE_COMPARATOR|Regular doctor's consultation|
62634693|NCT00424593|EXPERIMENTAL|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
62634694|NCT00424593|PLACEBO_COMPARATOR|Placebo|every day (QD), by mouth (PO), 13 weeks
62634695|NCT01495052|NO_INTERVENTION|Usual care group|The usual care group was used as control group and didn't receive any intervention except standard health advice at the beginning and the end of the study.
61978674|NCT04190615||0 to 3 months|0 (term newborns) to 3 month of age
61978675|NCT04190615||4 to12 months|infants from 4month to 12month of age
61978676|NCT04190615||13 to 24 months|children from 13month to 2years of age
62088221|NCT05503420|NO_INTERVENTION|Control|Participants in this group will receive the normal stroke rehabilitation training in the centre without additional provision of masticatory muscles training exercises.
62634696|NCT01495052|NO_INTERVENTION|diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention.
62634697|NCT01495052|EXPERIMENTAL|50g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
62634698|NCT01495052|EXPERIMENTAL|100g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
62634699|NCT01057667|EXPERIMENTAL|Arm A: With RO5024048|Patients in arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily).
62634700|NCT01057667|ACTIVE_COMPARATOR|Arm B: Standard treatment|Patients in arm B will receive standard treatment with Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
62272020|NCT05250375||Healthy Controls|Males or females age 0-100 years of age with no history of mitochondrial myopathy symptoms.
62272021|NCT01726348||Darunavir|Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
62286993|NCT05062057||Palpitations|n=15 peri- and postmenopausal women with self-reported palpitations within 2 weeks prior to enrollment
62067068|NCT01621204|EXPERIMENTAL|Eltrombopag|Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
62067069|NCT01621204|ACTIVE_COMPARATOR|IVIG infusion|Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.
62272022|NCT02424526|ACTIVE_COMPARATOR|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
62272023|NCT02424526|ACTIVE_COMPARATOR|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
62272024|NCT01768455|EXPERIMENTAL|Gemigliptin and Glimepiride|Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride
62272025|NCT01768455|EXPERIMENTAL|Glimepiride|Single administration of glimepiride
62453271|NCT02398877|EXPERIMENTAL|Healthy with early trauma|stress
62272026|NCT01931800||Presenting patients a pneumonia pneumococcique|
62272027|NCT01931800||Patients presenting a bacteremia pneumococcique|
62272028|NCT01931800||Patients affected by pneumococcique meningitis|
62453272|NCT02398877|EXPERIMENTAL|Healthy without early trauma|stress
62453273|NCT02226328|EXPERIMENTAL|Propofol sedation|"Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist.~Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation.~Maintenance with 10-20 mg of propofol in case of discomfort."
62272029|NCT02229552|OTHER|Baseline Cohort|Children completed body weight and other measures at baseline, 1-year follow up and 2-year follow up measurement periods.
62272030|NCT05797324|EXPERIMENTAL|Luminette|Patients without ocular contraindications undergo a Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian phase.
62453274|NCT02226328|ACTIVE_COMPARATOR|Midazolam and Fentanyl sedation|"1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation.~Maintenance with 1 mg Midazolam in case of discomfort."
62453275|NCT05418348|EXPERIMENTAL|Treatment A (GTX-104 IV, Test):|Nimodipine was administered by infusion over 72 hours.
62453276|NCT05418348|EXPERIMENTAL|Treatment B (NIMOTOP, RLD):|Nimodipine capsules (RS) administered orally with 240 mL of water at a dose level of 60 mg (two 30 mg capsules) q4h for 72 hours.
62453277|NCT01232673|EXPERIMENTAL|BMAC treatment active group|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC. This ammount is applied by one ml per injection into the critical limb ischemia along the calf vessels.
62453278|NCT01232673|NO_INTERVENTION|Control Study Group|Standard treatment group of patients with CLI after surgical or interventional revascularisation will serve as control.
62634701|NCT01157611|ACTIVE_COMPARATOR|Mentoring program group|type 1 diabetes patients participating in online base mentoring program
62634702|NCT01157611|NO_INTERVENTION|Control group|type 1 diabetes patients receiving regular clinic visits
61978677|NCT04190615||2 to 5 years|children from 2 to 5 years of age
62272031|NCT05797324|SHAM_COMPARATOR|Sham|Control group (white light \<100 lux equivalent).
62272032|NCT00723164|ACTIVE_COMPARATOR|FM|Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
62067070|NCT00010439|EXPERIMENTAL|1 Alendronate for 12 months|Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.
62067071|NCT01091896|NO_INTERVENTION|1 - no bevacizumab|Patients will not receive bevacizumab before nor during vitrectomy
62067072|NCT01091896|EXPERIMENTAL|2- bevacizumab before vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
62067073|NCT01091896|EXPERIMENTAL|3- bevacizumab after vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
62067074|NCT04570995|ACTIVE_COMPARATOR|fish oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing fish oil encapsulated in soft gel capsules.
62067075|NCT04570995|PLACEBO_COMPARATOR|safflower oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing a placebo oil product (safflower oil) encapsulated in soft gel capsules.
62067076|NCT00888758|EXPERIMENTAL|1|
62067077|NCT00888758|ACTIVE_COMPARATOR|2|
62067078|NCT02772575||patients with primary liver or liver metastases|A biopsy will be performed as standard of care either at time of Hepatic trans-arterial embolization (TAE) or within 4 months prior to TAE. TAE is a standard of care procedure. Within 8 weeks of TAE, patient will have a clinic visit which will include medical history, physical examination, vital signs, EKG (if one is not available), and ECOG assessment. Additionally a dedicated liver CT or MR will be obtained as well as standard of care labs. IMPACT blood test will be performed at the time of any of the standard of care labs. As IMPACT platform at MSKCC continually evolves to include more genes, we will use the platform available at the time of initiation of the protocol, therefore all patients will be subjected to the same platform. RNA-seq has been demonstrated to be superior in detecting low abundance transcripts, demonstrating a broader dynamic range, and detecting different isoforms and genetic variants.
62067079|NCT05620901|EXPERIMENTAL|Treatment Arm|Dextenza insert intraoperatively for perioperative ocular inflammation and pain. These patients will not be prescribed topical steroid drops post-operatively
62067080|NCT05620901|ACTIVE_COMPARATOR|Control Arm|Prednisolone forte 1% steroid drop taper for 28 days post-operatively to treat perioperative ocular inflammation and pain; drops four times per day (QUID) on days 0-7, three times per day (TID) on days 7-14, twice per day (BID) on days 14-21 and once per day (QD) on days 21-28.
62067081|NCT05016414|NO_INTERVENTION|Control|4 days of strict bed rest
62067082|NCT05016414|EXPERIMENTAL|Lower body negative pressure|4 days of strict bed rest with nightly lower body negative pressure at -20mmHg
62088222|NCT05051787|EXPERIMENTAL|Breastfeeding women|Mothers over 18, treated with amoxicillin alone or associated with clavulanic acid for at least 2 days, breastfeeding their child.
62088223|NCT04887961|EXPERIMENTAL|Single Arm|PLD 30 mg/mq 1 h iv + Trabectedin 1.1 mg/mq 3 h iv d1q21 up to 6 cycles or PD.
62088224|NCT04038099|PLACEBO_COMPARATOR|Water Based Lubricating Jelly|5ml of Water Based Lubricating Jelly
62088225|NCT04038099|ACTIVE_COMPARATOR|Lidocaine 2% Jelly|5ml of Lidocaine 2% Jelly
62453279|NCT05565820|EXPERIMENTAL|Vamousse Spray 'n' Go|Clinical staff will apply Vamousse Spray 'n' Go during the baseline visit (Day 0) to fully coat the hair and scalp. The treatment will be left on for 8 hours, then standard at home shampoo will be used and rinsed off with warm water, followed by combing. At day 7, if live lice are still present, a repeat treatment will be administered.
62634703|NCT03588897|NO_INTERVENTION|Normal Diet|Elderly patients receiving normal diet
62067083|NCT05303597|OTHER|diagnostic superior cluneal nerve block|Patients with low back pain will be evaluated by two physicians. The clinical history and physical examination of all patients with low back pain will be taken by the first physician. Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment. Patients who have had a diagnostic injection will be re-evaluated 1 hour later. Patients whose pain is reduced by more than 70% will be diagnosed with superior cluneal nerve entrapment.
62067084|NCT00136032|ACTIVE_COMPARATOR|1|
62067085|NCT00136032|PLACEBO_COMPARATOR|2|
62067086|NCT01959191||Low platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
62067087|NCT01959191||high platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
62067088|NCT01414426|EXPERIMENTAL|Arm I (chemoprevention)|Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
62272033|NCT00723164|PLACEBO_COMPARATOR|NaCl|A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
62286994|NCT05062057||No palpitations|n=15 peri- and postmenopausal women with no self-reported palpitations within 6 months prior to enrollment
62286995|NCT03222427|EXPERIMENTAL|LY3314814|Single 50 milligram (mg) dose of LY3314814 administered orally
62286996|NCT03222427|EXPERIMENTAL|[13C415N3] LY3314814|Single 100 micrograms (μg) intravenous (IV) dose of \[13C415N3\] LY3314814 administered as an IV infusion.
62286997|NCT03334084|EXPERIMENTAL|1|Scheme 1
62634704|NCT03588897|EXPERIMENTAL|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
62634705|NCT04733586|ACTIVE_COMPARATOR|fascia iliaca group|
62634706|NCT04733586|ACTIVE_COMPARATOR|quadratus lumborum|
62272034|NCT02825095|ACTIVE_COMPARATOR|Talc Pleurodesis|"For patients in this group, chest tube type PIGTAIL 10 - 14 Fr will be inserted by by chest ultrasound guided and under local anesthesia, allowing good draining of the hemithorax, in case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed, chest tube will be removed 24 - 48 hours later on. the patient will be admitted in the hospital during the whole procedure course.~If the patient developed non expanded - trapped lung post chest tube insertion, or if he had persistence high chest tube output for more than 10 days, then the patient will remain with the PIGTAIL as an Indwelling Pleural Catheter."
62453280|NCT05565820|ACTIVE_COMPARATOR|Nix Creme Rinse Lice Treatment|During the baseline visit (Day 0) clinical staff will first shampoo the hair and scalp using regular shampoo. They will then thoroughly rinse and towel dry the hair and scalp, and allow hair to air dry for a few minutes. Staff will shake Nix Creme Rinse Lice Treatment (1% permethrin lotion) well before applying, they will then proceed to thoroughly wet the hair and scalp with the lotion, being sure to cover the areas behind the ears and on the back of the neck. After allowing the lotion to remain in place for 10 minutes, they will rinse the hair and scalp thoroughly and dry with a clean towel. At day 7, if live lice are still present, a repeat treatment will be administered.
61978678|NCT04190615||6 to 10 years|children from 2 to 10 years of age
62272035|NCT02825095|ACTIVE_COMPARATOR|Indwelling Pleural Catheter|"All patients from this group will have Indwelling Pleural Catheter insertion type PLEURAX inserted by ultrasound guided and under local anesthesia.~the patient and his/her family will be instructed and educated about the proper way of using the catheter, and how to perform pleural draining at home.~the duration of treatment with the Pleurax depends on the rate and amount of pleural effusion draining."
62272036|NCT05166304|PLACEBO_COMPARATOR|placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
62272037|NCT05166304|EXPERIMENTAL|rebamipide|100 mg rebamipide taken orally daily plus Methotrexate 7.5 mg weekly
62272038|NCT04018911|ACTIVE_COMPARATOR|Hearing Aid standard NR_1|Hearing Aid with standard Noise Reduction (NR) serves as reference condition.
62272039|NCT04018911|EXPERIMENTAL|Hearing Aid with NR_2|NR_2: Noise Reduction principle 2
62272040|NCT04018911|EXPERIMENTAL|Hearing Aid with NR_3|NR_3: Noise Reduction principle 3
62272041|NCT04018911|EXPERIMENTAL|Hearing Aid with NR_4|NR_4: Noise Reduction principle 4
62286998|NCT03334084|EXPERIMENTAL|2|Scheme 2
62286999|NCT03334084|EXPERIMENTAL|3|Scheme 3
62272042|NCT01569685|ACTIVE_COMPARATOR|Venlafaxine|6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
62272043|NCT01569685|ACTIVE_COMPARATOR|Sertraline|6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
62272044|NCT04113772|ACTIVE_COMPARATOR|Orfandin .5 mgm/kg mgm bid|Two participant will receive .5 mgm/kg mgm of orfadin
62272045|NCT04113772|EXPERIMENTAL|Nitinosine .5 mgm/kg bid|Two participant will receive .5 mgm/kg of nitinosine
62272046|NCT01562548|EXPERIMENTAL|Arm 1|Guaifenesin 1 tablet BID
62272047|NCT01562548|EXPERIMENTAL|Arm 2|Guaifenesin 2 tablets BID
62272048|NCT01562548|PLACEBO_COMPARATOR|Arm 3|Placebo 1 tablet BID
62272049|NCT01562548|PLACEBO_COMPARATOR|Arm 4|Placebo 2 tablets BID
62272050|NCT04758585|ACTIVE_COMPARATOR|Study Group|
62272051|NCT04758585|NO_INTERVENTION|Control Group|
62272052|NCT01926483|EXPERIMENTAL|Neoadjuvant Treatment|Neoadjuvant Chemoradiotherapy
62272053|NCT02469090|EXPERIMENTAL|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
62272054|NCT02469090|PLACEBO_COMPARATOR|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
62272055|NCT01168661|NO_INTERVENTION|Control arm|Participants in this arm will be recruited from the group who applied to participate in the study and fulfilled the inclusion criteria but for various reasons (such as time constraints) could not participate.
62272056|NCT01168661|ACTIVE_COMPARATOR|Cognitive psychotherapy arm|In this arm, participants will attend a group meeting to practice cognitive psychotherapy once a week. They will also practice on their own \>= 4 times a week.
62634707|NCT01986803|EXPERIMENTAL|PCI with ABSORBTM bioresorbable vascular scaffold system (BVS)|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the Abbott Vascular ABSORB TM everolimus eluting bioresorbable vascular scaffold system (BVS)
62634708|NCT01986803|ACTIVE_COMPARATOR|PCI with XIENCE Xpedition stent|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the XIENCE Everolimus Eluting Coronary Stent System (XIENCE Xpedition) (commercial product)
62634709|NCT00662077|EXPERIMENTAL|1|Ibandronate + Lifestyle modifications
62634710|NCT00662077|OTHER|2|Lifestyle modifications
62634711|NCT04987866|EXPERIMENTAL|group Vibration|The participants who were chose an opaque envelope containing yellow paper represented the vibration group (Group V). After 1 min of pre-treatment with the vibration device on the intravenous catheter trace, we manually injected 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunterand. Also asked the patients whether they had any discomfort. After the propofol injection, pain scores were observed during propofol injection and 20 seconds after the injection, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and after 20 seconds rocuronium injection.
62634712|NCT04987866|NO_INTERVENTION|group Control|The participants who were chose an opaque envelope containing red paper represented the group control (Group C).Only propofol and rocuronium were given to these patients. propofol injection made manually 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Patients were observed during and after the injection of propofol for 20 seconds. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunter. During the injection of propofol, we also asked the patients whether they had any discomfort. After the propofol injection for 20 seconds, pain scores were observed, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and 20 seconds after the rocuronium injection.
62634713|NCT01909804|EXPERIMENTAL|SOF+VEL 25 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
62634714|NCT01909804|EXPERIMENTAL|SOF+VEL 25mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
62634715|NCT01909804|EXPERIMENTAL|SOF+VEL 100 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
62634716|NCT01909804|EXPERIMENTAL|SOF+VEL 100 mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
62634717|NCT01909804|EXPERIMENTAL|SOF+VEL 25 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
62634718|NCT01909804|EXPERIMENTAL|SOF+VEL 25 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
62634719|NCT01909804|EXPERIMENTAL|SOF+VEL 100 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
62634720|NCT01909804|EXPERIMENTAL|SOF+VEL 100 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
62634721|NCT01909804|EXPERIMENTAL|SOF+VEL 25 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
62634722|NCT01909804|EXPERIMENTAL|SOF+VEL 25 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.
62634723|NCT01909804|EXPERIMENTAL|SOF+VEL 100 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
62634724|NCT01909804|EXPERIMENTAL|SOF+VEL 100 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.
62634725|NCT03671876|ACTIVE_COMPARATOR|Intervention plus therapy|"Case group:~A population that suffered a stroke and treated to improve mobility with the Selfit system (25 patients) for twice a week, at least 30 minutes per session, for a period of 3 weeks.~Intervention with the Selfit system include a set of mobility task exercises."
62634726|NCT03671876|NO_INTERVENTION|Therapy and no intervention|"Control group:~A population that suffered a stroke and is being treated in the hospital without any interventions with the Selfit system."
61978679|NCT04190615||11 to16 years|children from 11 to 16 years of age
62634727|NCT04611542|EXPERIMENTAL|FIR Prototype Evaluation|30 fathers in recovery from opioid-use disorder will receive the prototype FIR online intervention.
62634728|NCT03204643|EXPERIMENTAL|BH-VPN|A bundle of usual care components applied consistently and completely, plus access to mental health trained patient navigators and navigation services.
62634729|NCT03204643|NO_INTERVENTION|Usual Care|The standard intervention (Control - Usual Care) is given in this population. May contain some of the BH-VPN components.
62067089|NCT01414426|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
62272057|NCT01168661|ACTIVE_COMPARATOR|Mindfulness based cog psychotherapy arm|In this arm, participants will attend a group meeting to practice mindfulness based cognitive psychotherapy once a week. They will also practice on their own \>= 4 times a week.
62272058|NCT01168661|ACTIVE_COMPARATOR|Yoga treatment group|Persons in this arm will practice yoga \>= 5 time each week (2 times in a supervised group and the other times on their own).
62272059|NCT00920660|EXPERIMENTAL|Treatment Group|"Subjects will be required to attend the research unit in a fasted state (at least 10 hours without food) on six separate occasions (treatment visits) during the study. At approximately the same time every morning, subjects will consume a standard, non-high-fat meal (approximately 650 kcal with 30% of calories derived from fat). Test material (per treatment) will be administered within 15-30 minutes following the meal. There will be at least a 7-day washout period between treatment visits.~During the first five treatment visits, subjects will receive one of the following treatments in the form of 8 capsules: 0.25g SRT2104, 0.5g SRT2104, 1g SRT2104, 2g SRT2104, or placebo.~During the last treatment visit, subjects will receive 30 mg of open-label prednisolone tablets."
62634730|NCT04361422|ACTIVE_COMPARATOR|Isotretinoin|13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally for one month
61978680|NCT01272414|EXPERIMENTAL|BoTox Treatment|Subjects receive BoTox injection to levator complex
62067090|NCT02477397|EXPERIMENTAL|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
62067091|NCT02477397|ACTIVE_COMPARATOR|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
62067092|NCT03772951|ACTIVE_COMPARATOR|Cognitive Remediation Therapy|The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300\~600 mg/d; po; duration: 12 week.
62453281|NCT03344367|EXPERIMENTAL|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10\^7, 2.5×10\^7, 5×10\^7, 1×10\^8, 1.5\^108 CAR+ T cells.
62634731|NCT04361422|SHAM_COMPARATOR|Standard COVID-19 therapy|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases
62272060|NCT03496090|EXPERIMENTAL|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
62634732|NCT04361422|ACTIVE_COMPARATOR|Standard COVID-19 therapy+ isotretinoin|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) plus 13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally forone month.
62634733|NCT04884100|OTHER|PPG recording|arrhythmia recording using PPG monitor
61978681|NCT01272414|PLACEBO_COMPARATOR|Saline injection|Saline injection to levator complex
62272061|NCT03496090|ACTIVE_COMPARATOR|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
62287000|NCT01976806|EXPERIMENTAL|Aspirin & Docosahexaenoic acid|Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
62287001|NCT01976806|ACTIVE_COMPARATOR|Aspirin & Placebo|Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
62634734|NCT01999439|EXPERIMENTAL|Eosinophilic Esophagitis with Dysphagia|To assess quantitative magnetic resonance imaging(MRI)as a potential diagnostic tool for evaluating esophageal wall thickness and stiffness and response to treatment in children and adolescents with a diagnosis of eosinophilic esophagitis (EoE) presenting with difficulty swallowing(dysphagia)and food impaction.
62634735|NCT02851459|EXPERIMENTAL|Morally Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations.
62287002|NCT02005185||6-11y/o anesthetized at 0-2y/o for >2hrs|6-11yr olds anesthetized for more than120 minutes before the age of 2.
62634736|NCT02851459|EXPERIMENTAL|Morally Non-Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations.
61978682|NCT05364931|EXPERIMENTAL|Cotadutide 300μg|
61978683|NCT05364931|PLACEBO_COMPARATOR|Placebo 300μg|
61978684|NCT05364931|EXPERIMENTAL|Cotadutide 600μg|
61978685|NCT05364931|PLACEBO_COMPARATOR|Placebo 600μg|
62287003|NCT02005185||6-11y/o anesthetized @ 0-2y/o for <30min|6-11 year olds anesthetized for \< 30min before the age of 2.
62287004|NCT02005185||6-11y/o anesthetized at 4-7y/o for >2hrs|6-11 year olds anesthetized for more than 120 min between the ages of 4-7.
62634737|NCT02851459|SHAM_COMPARATOR|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
62634738|NCT04616716|EXPERIMENTAL|1|"Drug:FMTN fasted in P1,low-fat diet in P2,high-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after low-fat diet in period 2,FMTN administration after high-fat diet in period 3"
62634739|NCT04616716|EXPERIMENTAL|2|"Drug:FMTN high-fat diet in P1,fasted in P2,low-fat diet in P3~FMTN administration after high-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after low-fat diet in period 3"
62453282|NCT03935269|EXPERIMENTAL|Intervention with Ambulatory Therapy|Caregivers of participants with high-grade glioma will undergo standard Cereset Research Office (CRO) in-office treatment for a total of five (5) treatments. Ambulatory therapy with the Cereset Research Wearable (CRW) will be available to caregivers while they are attending routine radiation therapy with glioma patients.
62453283|NCT01957488|EXPERIMENTAL|Treatment sequence 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 1 and secondly test either:~1. Coloplast Test product 1 and thereafter Coloplast SenSura~2. Coloplast Sensura and thereafter Coloplast Test product 2"
62453284|NCT01957488|EXPERIMENTAL|Treatment seqence 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 2 and secondly test either:~1. Coloplast Test product 1 and thereafter Coloplast SenSura~2. Coloplast Sensura and thereafter Coloplast Test product 1"
62453285|NCT01957488|EXPERIMENTAL|Treatment sequence 3, First Coloplast SenSura|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast SenSura and secondly test either:~1. Coloplast Test product 2 and thereafter Coloplast Test product 1~2. Coloplast Test product 1 and thereafter Coloplast Test product 2"
62067093|NCT03772951|PLACEBO_COMPARATOR|Clozapine|Clozapine, dosage, dosage form, and frequency :300\~600 mg/d; po; duration: 12 week.
62067094|NCT01678443|EXPERIMENTAL|Treatment (yttrium-90 anti-CD45 monoclonal antibody BC8)|Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
62067095|NCT02446925|EXPERIMENTAL|Surefire® Infusion System|Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
62287005|NCT02005185||6-11 y/o healthy control|6-11 year olds that have never received general anesthesia.
62634740|NCT04616716|EXPERIMENTAL|3|"Drug:FMTN low-fat diet in P1,high-fat diet P2,fasted in P3~FMTN administration after low-fat diet in period 1,FMTN administration after high-fat diet in period 2,FMTN administration in fasted condition in period 3"
62067096|NCT02446925|ACTIVE_COMPARATOR|Standard End-hole catheter|Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.
62067097|NCT03394456|EXPERIMENTAL|Intervention|Receive diabetes group visits/diabetes program
62067098|NCT03394456|NO_INTERVENTION|Control|Receive usual care in the clinic, followed by group visits (wait list control) for cohorts 1-4 case-matched comparisons via chart review for cohort 5
62067099|NCT02746042|EXPERIMENTAL|Sinupret extract coated tablets|"Sinupret extract coated tablets: one tablet three times a day orally during the 16-week treatment phase.~There will be no dose change during the trial."
62067100|NCT02746042|PLACEBO_COMPARATOR|Placebo coated tablets|Placebo coated tablets: One tablet three times a day orally during the 16-week treatment Phase.
62067101|NCT00885352|EXPERIMENTAL|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
62067102|NCT00885352|PLACEBO_COMPARATOR|Placebo|Placebo to sitagliptin orally once daily for 26 weeks.
62088226|NCT02711722|ACTIVE_COMPARATOR|PScli1|Patients are ventilated in Pressure support (PS) according to the Clinical settings for 30min.
62287006|NCT01391247||healthy age machted controls|
62287007|NCT01391247||normal tension glaucoma patients|
62287008|NCT01391247||primary open angle glaucoma patients|
62287009|NCT03585855|NO_INTERVENTION|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
62067103|NCT03781089|EXPERIMENTAL|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L.
62067104|NCT03781089|NO_INTERVENTION|Usual care arm|Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
62272062|NCT00004262|EXPERIMENTAL|Treatment (motexafin gadolinium, radiotherapy, radiosurgery)|Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
62272063|NCT02684214|EXPERIMENTAL|Food secure families|high and marginal household food security
62272064|NCT02684214|EXPERIMENTAL|Food insecure families|low and very low household food security
62272065|NCT06044116||Calculator design|5.000 patients of the entire cohort of 6.000 patients will be used for the design of the risk calculator
62272066|NCT06044116||Internal validation|1.000 patients of the entire cohort of 6.000 patients will be used for the design of the risk calculator
62272067|NCT06044116||External validation|Another surgical group from outside Spain will be contacted for external validation
62272068|NCT04433650|EXPERIMENTAL|Group 1|"The child will firstly undergo phase A without the digital reporting and communication tool.~The child will secondly undergo phase B with the digital reporting and communication tool (i.e., A, B)."
62453286|NCT00967538|EXPERIMENTAL|Etanercept|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
62453287|NCT05664464|ACTIVE_COMPARATOR|Standard of care|Radiotherapy 30 x 2 Gy with concomitant temozolomide followed by maintenance temozolomide
62634741|NCT04616716|EXPERIMENTAL|4|"Drug:FMTN fasted in P1,high-fat diet P2,low-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after high-fat diet in period 2,FMTN administration after low-fat diet in period 3"
62634742|NCT04616716|EXPERIMENTAL|5|"Drug:FMTN low-fat diet in P1,fasted P2,high-fat diet in P3~FMTN administration after low-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after high-fat diet in period 3"
62067105|NCT00805493|NO_INTERVENTION|Medication Taper|All participants begin with gradual tapering to the point of discontinuing medication
62067106|NCT00805493|NO_INTERVENTION|Random assignment to placebo|Once they are medication-free, 50% of participants are randomized to placebo
62453288|NCT05664464|EXPERIMENTAL|Standard of care plus glutamate signaling inhibitors|Radiotherapy 30 x 2 Gy with concomitant temozolomide followed by maintenance temozolomide plus combined daily gabapentin, sulfasalazine and memantine
62453289|NCT04318561|EXPERIMENTAL|Gallium-68 NODAGA-LM3 group|Patients will undergo a Gallium-68 NODAGA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
62067107|NCT00805493|ACTIVE_COMPARATOR|Random assignment to riluzole|One they are medication-free, 50% of participants are randomized to riluzole
62067108|NCT02086162|EXPERIMENTAL|Behavioral intervention|Web-based motivational decision support system
62067109|NCT02086162|ACTIVE_COMPARATOR|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
62067110|NCT01778946|EXPERIMENTAL|Nicotine|"Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)~All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).~Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.~All participants will apply a new patch daily for a total of 28 days (1 month)"
62272069|NCT04433650|EXPERIMENTAL|Group 2|"The child will firstly undergo phase B with the digital reporting and communication tool.~The child will secondly undergo phase A without the digital reporting and communication tool (i.e., B, A)."
62272070|NCT03534427|NO_INTERVENTION|Control group|No exercise intervention
62287010|NCT03585855|EXPERIMENTAL|MSC transplantation|patients with ABMR treated with MSC transplantation
62453290|NCT04318561|EXPERIMENTAL|Gallium-68 DOTA-LM3 group|Patients will undergo a Gallium-68 DOTA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
62634743|NCT04616716|EXPERIMENTAL|6|"Drug:FMTN high-fat diet in P1,low-fat diet P2,fasted in P3~FMTN administration after high-fat diet in period 1,FMTN administration after low-fat diet in period 2,FMTN administration in fasted condition in period 3"
62634744|NCT01105312|EXPERIMENTAL|panobinostat (LBH589) and letrozole|Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks. There are two phases of the study. The first phase determines the maximum tolerated dose for LBH589 in combination with letrozole. The second phase is to assess and confirm the response rate and safety profile of LBH589 in combination with letrozole.
62453291|NCT04027764|EXPERIMENTAL|Toripalimab Combined With S1 and Albumin Paclitaxel|
62634745|NCT02999334|NO_INTERVENTION|Individual ANC (standard care)|Individual ANC is the standard of care. Women arrive at the clinic and and are provided ANC services on a first come, first serve basis. While waiting women who are present listen to a health lecture. Women then complete laboratory tests, including HIV testing (at the first visit), then meet individually with a midwife for a brief one-on-one physical assessment. Four ANC visits are recommended.
62634746|NCT02999334|EXPERIMENTAL|Group ANC (intervention)|Women in CP-based group antenatal care (intervention) arrive at clinic at the scheduled appointment time and go directly to the group space. The same group of 12 women and the midwife and co-facilitator are present at each session. Women measure and record their own vital signs and weight. Each then has a brief one-on-one assessment with the midwife in the group space room. Instead of health lectures, the group engages in facilitated and interactive discussions using activities. Four ANC visits are recommended.
62634747|NCT01414478|ACTIVE_COMPARATOR|High Protein Shake|Protein shake that contain 30 grams of protein in 11 fluid ounces.
62634748|NCT01414478|NO_INTERVENTION|Ice Chips|Patients allowed consumption of ice chips only during labor.
62634749|NCT02826161|EXPERIMENTAL|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
62634750|NCT02826161|ACTIVE_COMPARATOR|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
62634751|NCT01775007|EXPERIMENTAL|Normal Healthy Subjects|Brillouin Ocular Analyser
62634752|NCT02319252|ACTIVE_COMPARATOR|Gastric tube|A gastric tube is used
62634753|NCT02319252|ACTIVE_COMPARATOR|Jejunal tube|A jejunal tube is used
62634754|NCT01407809|EXPERIMENTAL|Intervention|
62634755|NCT05581823|EXPERIMENTAL|Tavapadon Followed by Tavapadon + Carbamazepine|Participants will receive oral tavapadon tablets titrated up to a steady-state dose from Day 1 to Day 14. From Day 15, participants will receive oral carbamazepine tablets titrated up to a steady-state dose along with oral tavapadon tablets, up to Day 30.
62634756|NCT05987826|EXPERIMENTAL|Furmonertinib (AST2818) 80mg QD group|All patients enrolled into this study will receive furmonertinib 80mg for 8 weeks neoadjuvant therapy before surgery.
62634757|NCT05636813|EXPERIMENTAL|Training|Program of training of use of assistive technology
62634758|NCT00235573|EXPERIMENTAL|Vitamin B12 supplement|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12 were administered 6 hours apart.
62634759|NCT01834170|EXPERIMENTAL|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
62634760|NCT03463629|EXPERIMENTAL|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
62634761|NCT03463629|ACTIVE_COMPARATOR|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services. Data for this arm will be collected through retrospective chart review.
62634762|NCT02048124|ACTIVE_COMPARATOR|25g standard needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
62453292|NCT04862078|EXPERIMENTAL|Shared decision making group|The Study arm - shared decision making when deciding surveillance strategy
62453293|NCT04862078|OTHER|Usual surveillance group|The control arm - surveillance with usual care
62453294|NCT06159062|EXPERIMENTAL|162|"The dose-escalation stage will be conducted sequentially at 3 dose cohorts, which are 50 mg in the pre-test, 75 mg and 100 mg in the formal test.~Two subjects with chronic HBV infection will be enrolled in the 50 mg dose cohort and all will be given the investigational product 162.~Four subjects with chronic HBV infection will be enrolled in the 75 mg and 100 mg dose cohorts, respectively. Subjects in each cohort will be randomized 3:1 to receive a single ascending dose of investigational product 162 or placebo."
62634763|NCT02048124|EXPERIMENTAL|25d ProCor needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
62634764|NCT06612775|EXPERIMENTAL|CB03-154 5mg and Placebo 15mg|Participants will receive CB03-154 5mg and Placebo 15mg orally once daily for 12 weeks.
62634765|NCT06612775|EXPERIMENTAL|CB03-154 10mg and Placebo 10mg|Participants will receive CB03-154 10mg and Placebo 10mg orally once daily for 12 weeks.
62634766|NCT06612775|EXPERIMENTAL|CB03-154 20mg|Participants will receive CB03-154 20mg orally once daily for 12 weeks.
62634767|NCT06612775|PLACEBO_COMPARATOR|Placebo 20mg|Participants will receive Placebo 20mg orally once daily for 12 weeks.
62634768|NCT01047280|PLACEBO_COMPARATOR|Safflower oil|This arm of the study constitutes the control phase
62634769|NCT01047280|EXPERIMENTAL|Clarinol G-80®|
62634770|NCT01047280|EXPERIMENTAL|G-c9, t11|
62067111|NCT01761539|EXPERIMENTAL|Aggressive Hydration|Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
62453295|NCT06159062|PLACEBO_COMPARATOR|Placebo|"The dose-escalation stage will be conducted sequentially at 3 dose cohorts, which are 50 mg in the pre-test, 75 mg and 100 mg in the formal test.~Two subjects with chronic HBV infection will be enrolled in the 50 mg dose cohort and all will be given the investigational product 162.~Four subjects with chronic HBV infection will be enrolled in the 75 mg and 100 mg dose cohorts, respectively. Subjects in each cohort will be randomized 3:1 to receive a single ascending dose of investigational product 162 or placebo."
62453296|NCT01443065|ACTIVE_COMPARATOR|Arm A : simplified Folfox 4|"Every 2 weeks :~* Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1~* Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :~* 5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :~* 5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h"
62634771|NCT05911126|ACTIVE_COMPARATOR|Group A|(60 participants) will receive two oral tablets of HBB (Buscopan 10 mg, Boehringer Ingelheim) and one capsule of Celecoxib 200 mg (Celebrex 200, Pfizer, USA) simultaneously.
62634772|NCT05911126|ACTIVE_COMPARATOR|Group B|(60 participants) will receive one oral placebo capsule similar in size, structure, and color to celecoxib and two oral tablets of HBB (Buscopan 10 mg, Boehringer Ingelheim)
62634773|NCT05911126|ACTIVE_COMPARATOR|Group C|(60 participants) will receive two oral placebo tablets similar in size and color to Buscopan tablet and one capsule of Celecoxib 200 mg (Celebrex ® 200, Pfizer, USA).
62634774|NCT02595502|ACTIVE_COMPARATOR|Sequence 1: Test Control Test|Test/control/test using the Johnson \& Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
62634775|NCT02595502|ACTIVE_COMPARATOR|Sequence 2: Control Test Control|Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
62634776|NCT03522636||Treatment|Prehospital blood products resuscitation up to 2 units of blood products as follows: 1 unit of packed human plasma and 1 unit of packed red blood cells
62634777|NCT03522636||Historic control|No prehospital blood products available
62634778|NCT04596969|EXPERIMENTAL|SFD Tapioca 20g|20g soluble fiber dextrin derived from tapioca
62634779|NCT04596969|EXPERIMENTAL|SFD Tapioca 40g|40g soluble fiber dextrin derived from tapioca
62634780|NCT04596969|EXPERIMENTAL|SFD corn 20g|40g soluble fiber dextrin derived from corn
62067112|NCT01761539|ACTIVE_COMPARATOR|Moderate Hydration|Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
62067113|NCT02827318|ACTIVE_COMPARATOR|75g glucose|75g of glucose dissolved in 500ml provided in a clear plastic tumbler.
62634781|NCT04596969|EXPERIMENTAL|SFD corn 40g|
62634782|NCT04596969|PLACEBO_COMPARATOR|Control|Maltodextrin
62634783|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
62634784|NCT06150300|ACTIVE_COMPARATOR|Physical activity intervention|8 week virtual pulmonary rehab program including breathing exercises and educational messages.
62634785|NCT06150300|PLACEBO_COMPARATOR|Placebo|Breathing exercises and educational messages
62634786|NCT01976481|EXPERIMENTAL|Sunbed|sunbed exposure
62634787|NCT01976481|NO_INTERVENTION|Observation|only observation of subjects recruited after randomization
62634788|NCT00485069|EXPERIMENTAL|Ropinirole Hydrochloride|
62634789|NCT02211378|EXPERIMENTAL|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
62634790|NCT02211378|ACTIVE_COMPARATOR|Hotseat|Trainees are in the 'hotseat' actively participating during all 3 simulation sessions
62634791|NCT04131712|NO_INTERVENTION|Ambulatory Control|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. Atrophy will not be induced and massage intervention will not be applied. Ambulatory groups will be recruited following the immobilized groups.
62634792|NCT04131712|SHAM_COMPARATOR|Ambulatory Massage|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. No atrophy induction. Four massage treatments will be applied every other day until the end of the study. Ambulatory groups will be recruited following the immobilized groups.
62067114|NCT02827318|EXPERIMENTAL|75g isomaltulose|75g of isomaltulose dissolved in 500ml provided in a clear plastic tumbler.
62067115|NCT02827318|PLACEBO_COMPARATOR|Sweetened water|500ml water sweetened with sucralose provided in a clear plastic tumbler.
62067116|NCT02571946|EXPERIMENTAL|Proton beam therapy|
62067117|NCT02762838|EXPERIMENTAL|BCD-055|Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
62067118|NCT02762838|ACTIVE_COMPARATOR|Remicade®|Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
62067119|NCT06351644|EXPERIMENTAL|ON 123300 (NARAZACICLIB) + dexamethasone|Participants will continue 28-day cycles of ON 123300 (NARAZACICLIB) + dexamethasone as long as the drug shows anti-myeloma activity with a disease response ≥PR (PR, VGPR, CR) and the patient does not exhibit any DLTs and the study is open. Patients will continue the regimen until disease progression/intolerable toxicity/death, withdrawal OR for a maximum up to 2 years after enrollment.
62067120|NCT06014736|EXPERIMENTAL|XJ101 for Injection|XJ101 via intravenous(IV).
62067121|NCT06014736|PLACEBO_COMPARATOR|Placebo|Placebo via intravenous(IV).
62067122|NCT00273559||1|subjects who remain on steroids after discharge
62067123|NCT00273559||2|Subjects will be off steroids at the time of discharge
62067124|NCT05434299|EXPERIMENTAL|Dose escalation|Single agent dose escalation
62067125|NCT05434299|EXPERIMENTAL|Dose expansion|Single agent dose expansion
62067126|NCT00892190|EXPERIMENTAL|dasatinib (SPRYCEL) and all trans retinoic acid (VESANOID)|"Dasatinib DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours~ATRA 22.5mg/m2 every 12 hours"
62067127|NCT02429687|EXPERIMENTAL|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
62634793|NCT04131712|NO_INTERVENTION|Immobilization Control|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Massage intervention will not be applied.
62067128|NCT02429687|ACTIVE_COMPARATOR|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4\* courses in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
62067129|NCT01566305|EXPERIMENTAL|Buttermilk with added egg yolk|
62067130|NCT01566305|EXPERIMENTAL|Buttermilk without added egg-yolk|
62067131|NCT01566305|EXPERIMENTAL|Skimmed milk with added egg-yolk|
62067132|NCT01566305|PLACEBO_COMPARATOR|Skimmed milk without added egg yolk|
62634794|NCT04131712|EXPERIMENTAL|Immobilization Massage|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Four massage treatments will be applied every other day until the end of the study.
62634795|NCT04214574|EXPERIMENTAL|Real time ultrasound-guided Parasagittal oblique technique (RTU-PO)|In the RTU-PO group, the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. This provides a view of the paramedian interlaminar space. The ligamentum flavum and the dura form the posterior complex that can be often visualized as a single hyperechoic structure beneath which lies the hypoechoic intrathecal space. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
62634796|NCT04214574|EXPERIMENTAL|Real time ultrasound-guided paramedian tranverse technique (RTU-T)|In the RTU-T group, similar to the RTU-PO group, the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
62067133|NCT00544544|EXPERIMENTAL|Riluzole|Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.
62067134|NCT06561217||AI-alone|
62067135|NCT06561217||Human-alone|
62067136|NCT06561217||Human + AI|
62067137|NCT03708588|EXPERIMENTAL|Experimental: Chewed ticagrelor|Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline P2Y12 platelet reaction units (PRU) level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)
62067138|NCT03708588|ACTIVE_COMPARATOR|Active Comparator: Integral pill|Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline P2Y12 platelet reaction units (PRU) level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL (milliliter) of water. (180mg)
62067139|NCT02978053|EXPERIMENTAL|Bright light|10 000 lux
62067140|NCT02978053|PLACEBO_COMPARATOR|Red light|400 lux
62067141|NCT02207439|EXPERIMENTAL|Single Arm Phase 2|Single Arm, Phase II study of Nelfinavir Lead-In (Period 1) Followed by Concurrent Chemoradiation with Nelfinavir (Period 2)
62067142|NCT02379559|EXPERIMENTAL|Exercise Group|Eligible participants randomized into the intervention group will receive a mix of supervised moderate-intensity aerobic and light weight-resistance exercises.
62067143|NCT02379559|ACTIVE_COMPARATOR|Attention Control Group|Eligible participants randomized in the attention control group will be asked to maintain their current daily activities and exercise habits for 6-months.
62067144|NCT03248609|EXPERIMENTAL|Milano grapes|Unique grape varietal to test glycemic response.
62067145|NCT03248609|ACTIVE_COMPARATOR|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
62067146|NCT03248609|ACTIVE_COMPARATOR|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
62067147|NCT03248609|PLACEBO_COMPARATOR|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
62067148|NCT00308737|EXPERIMENTAL|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
62067149|NCT00308737|OTHER|Usual care|Usual care
62067150|NCT00308737|NO_INTERVENTION|Non-diabetes|Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)
62272071|NCT03534427|EXPERIMENTAL|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
62272072|NCT03725748|NO_INTERVENTION|no irrigation group|nothing used for irrigation of cs scar
62272073|NCT03725748|PLACEBO_COMPARATOR|saline irrigation group|saline used for irrigation the cs scar before closure
62272074|NCT03725748|EXPERIMENTAL|betadine irrigation group|betadine used for irrigation of cs scar
62634797|NCT00627497|EXPERIMENTAL|DIAM Group1|
62634798|NCT00627497|ACTIVE_COMPARATOR|Single-Level Posterior Decompression|
62634799|NCT00627497|EXPERIMENTAL|DIAM Group2|
62634800|NCT00627497|ACTIVE_COMPARATOR|Posterolateral Interbody Fusion|
62634801|NCT02766153||patients|
62634802|NCT02766153||healthy volunteers|intrafamily marrow donors
62634803|NCT01699334|EXPERIMENTAL|Psychoeducational video|
62634804|NCT01699334|ACTIVE_COMPARATOR|Relaxation video|
62634805|NCT06289439|EXPERIMENTAL|Green tea supplementation group|2 capsules for 10 consecutive weeks, distributed in a single daily oral intake with the main meal
62272075|NCT04381611||Primary Glaucoma|
62272076|NCT04381611||Glaucoma Surgery|
62272077|NCT04381611||Glaucoma Laser|
62272078|NCT04381611||Glaucoma Surgery Combined|
62272079|NCT04381611||Glaucoma treatment|
62272080|NCT04381611||Glaucoma imaging|
62272081|NCT04381611||Glaucoma co-morbidity|
62634806|NCT06289439|PLACEBO_COMPARATOR|Placebo supplementation group|2 capsules for 10 consecutive weeks, distributed in a single daily oral intake with the main meal
62067151|NCT04692844||Patients with essential tremor treated with Propranolol|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Propranolol in the course of routine medical practice, will be included.
62634807|NCT03062215|EXPERIMENTAL|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
62067152|NCT04692844||Patients with essential tremor treated with Primidone|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Primidone in the course of routine medical practice, will be included.
62067153|NCT03491098|PLACEBO_COMPARATOR|momestone furoate spray first group: will be given|Nasonex spray one puff in each nostril daily for 8 weeks
62067154|NCT03491098|PLACEBO_COMPARATOR|prednisolone sodium phosphate 15mg second group: will be given|Predsol fort tablet three times per day for 1 week then gradual withdrawal over 2 weeks
62067155|NCT03491098|PLACEBO_COMPARATOR|hypertonic sea water solution spray third group: will be given|Nasal spray one puff in each nostril daily for 8 weeks
62067156|NCT05531019|EXPERIMENTAL|Dietary Supplement with sea urchin egg extract|Ingestion of dietary supplement with 0,025% of Echinochrome A (ingested 3ml twice a day for 90 days), 1,5mg daily consumption from sea urchin egg extract (Arbacia dufresnii)
62067157|NCT05531019|PLACEBO_COMPARATOR|Control|Ingestion of 3ml twice a day for 90 days of placebo
62272082|NCT04381611||Glaucoma untreated|
62272083|NCT04381611||Glaucoma Suspect|
62272084|NCT04381611||Secondary Glaucoma|
62272085|NCT00643643|EXPERIMENTAL|A|
62272086|NCT00643643|EXPERIMENTAL|B|
62634808|NCT03062215|NO_INTERVENTION|Control Group|Waiting list
62272087|NCT00643643|EXPERIMENTAL|C|
62634809|NCT06145503|EXPERIMENTAL|Dance Intervention Group|"Patients within the dance intervention group (n=20) were initially required to complete a Patient Information Form and provide written informed consent following an explanation of the study. Over the course of 12 weeks, these patients (n=20) received a 60-minute dance intervention three times a week, led by a dance instructor. Assessments, including the MoCA and SS-QOL, were conducted three times: before the dance intervention (pre-test/0th week), at the 6th week (interim measurement), and after completing the 12-week study (post-test/12th week)."
62272088|NCT00643643|EXPERIMENTAL|D|
62272089|NCT00643643|PLACEBO_COMPARATOR|E|
62067158|NCT04595539|EXPERIMENTAL|Simultaneous interventions|In this condition, both interventions are proposed simultaneously. Condition 1 is spread over 5 weeks with 5 weekly laboratory sessions of 2-hours (one hour of BATD and one hour of ATT separated by a break). A 30-minutes ATT sessions at home were prescribed between sessions for a total of 5 laboratory ATT sessions and 5 at home ATT sessions.
62088227|NCT02711722|ACTIVE_COMPARATOR|NAVAcli|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to match to respiratory muscle unloading reached with PScli1. Patients are ventilated in NAVAcli for 30min.
62088228|NCT02711722|ACTIVE_COMPARATOR|NAVA40%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 40% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA40% for 30min.
62088229|NCT02711722|ACTIVE_COMPARATOR|NAVA60%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 60% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA60% for 30min.
62088230|NCT02711722|ACTIVE_COMPARATOR|PScli2|Patients return to PS ventilation, according to the Clinical settings as in PScli1 for 30min.
62088231|NCT04086173|EXPERIMENTAL|Study group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of probiotics for 16 weeks. Probiotics (LACTIPAN®) include 2.5 billion CFU of 6 different strains of live microorganisms, such as Lactobacillus acidophilus (1.0 x 109 CFU), Lactobacillus casei (1.0 x 109 CFU), Lactobacillus rhamnosus (4.4 x 108 CFU), Lactobacillus plantarum (1.76 x 108 CFU), Bifidobacterium infantis (2.76 x 107 CFU), Streptococcus thermophilus (6.66 x 105 CFU) and 50 mg of oligofructose enriched inulin.
62088232|NCT04086173|PLACEBO_COMPARATOR|Control group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of placebo for 16 weeks. Placebo presentation will have the same aspect as those of the probiotic treatment.
62088233|NCT01975350||Colistimethate sodium inhalation|"Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.~Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia"
62067159|NCT04595539|EXPERIMENTAL|Sequential interventions|In this condition, the interventions are introduced sequentially. Condition 2 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 4 with of one hour of ATT followed by one hour of BATD separated by a break). A six 30-minutes ATT sessions were prescribed between the first 4 sessions of ATT for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
62067160|NCT04595539|EXPERIMENTAL|Sequential interventions in reverse order|In this condition, the interventions are introduced sequentially in the reverse order than the condition 2. Condition 3 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 5 with of one hour of BATD followed by one hour of ATT separated by a break). A six 30-minutes ATT sessions were prescribed between the 4 last sessions for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
62634810|NCT06145503|NO_INTERVENTION|Control Group|"The control group did not receive any intervention beyond participating in data collection. Patients in this group underwent assessments with the MoCA and SS-QOL before the study (pre-test/0th week), at the 6th week of the study (interim measurement), and after the completion of the 12-week study (post-test/12th week)."
62634811|NCT04396691||Instructors group|Group of flight instructors at the reactor school.
62067161|NCT01306201||In-patient Volunteers|In-patients from the hospital who choose to participate in the study
62067162|NCT02069574|EXPERIMENTAL|severe periodontitis group|non-surgical periodontal therapy
62634812|NCT04396691||Students group|Group of students at the reactor school.
62634813|NCT04705012|EXPERIMENTAL|Test - increased frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
62634814|NCT04705012|ACTIVE_COMPARATOR|Control - conventional frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
62634815|NCT01083043||Type 2 Diabetes Mellitus|
62067163|NCT02069574|EXPERIMENTAL|Moderate periodontitis group|non-surgical periodontal therapy
62067164|NCT02069574|NO_INTERVENTION|healthy control|No treatment
62067165|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
62067166|NCT00994773|EXPERIMENTAL|Simvastatin|Simvastatin orally
62067167|NCT00994773|EXPERIMENTAL|Simvastatin and tenofovir|Simvastatin combined with tenofovir
62067168|NCT00994773|EXPERIMENTAL|Simvastatin and entecavir|Simvastatin combined with entecavir
62067169|NCT01570595|EXPERIMENTAL|Web-Based Intervention|This group will be asked to participate in the online quit smoking program. At their first visit, they will be given an ID number to log in to the quit smoking program, and they will complete their first log in with the research assistant. The online program is made up of 8 separate online sessions that are supposed to be completed approximately once per week. Each sessions is written to take an average reader 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. At the first visit, participants are asked to provide an email address and/or cell phone number so reminders can be sent, by email or text message, to complete the sessions. If participants are late completing a session, they may receive call from clinic staff as a reminder.
62067170|NCT01570595|ACTIVE_COMPARATOR|Standard Care|"This group will receive standard care for their smoking, including advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
62067171|NCT01821898|ACTIVE_COMPARATOR|Positive for food allergy: Group A|Oral Budesonide
62272090|NCT06092073|EXPERIMENTAL|RIFPB group|Patients will receive bilateral Recto-Intercostal Fascial Plane Block (RIFPB) using 20 mL of bupivacaine 0.25% on each side.
62272091|NCT06092073|NO_INTERVENTION|Control group|Patients will not receive the block.
62272092|NCT00326898|EXPERIMENTAL|Arm A (sunitinib malate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sunitinib malate PO QD for 4 weeks and placebo sorafenib tosylate PO QD or BID for 6 weeks.
62272093|NCT00326898|EXPERIMENTAL|Arm B (sorafenib tosylate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sorafenib tosylate PO QD or BID for 6 weeks and placebo sunitinib malate PO QD for 4 weeks followed.
62272094|NCT00326898|PLACEBO_COMPARATOR|Arm C (placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive placebo sorafenib tosylate as in Arm A and placebo sunitinib malate as in Arm B.
62272095|NCT00737867|EXPERIMENTAL|A|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
62272096|NCT00737867|ACTIVE_COMPARATOR|B|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert's formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
62272097|NCT00264875|EXPERIMENTAL|1|
62272098|NCT05692037|EXPERIMENTAL|Yttrium-90 carbon microspheres|Single dose of yttrium-90 carbon microspheres injection. Patients will be assessed by SPECT-CT imaging within 24 hours for yttrium-90 distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.Ten Patients will be tested for the radioactivity of yttrium-90 in blood, urine, and feces (if available).
62453297|NCT01443065|EXPERIMENTAL|Arm B : simplified FOLFOX 4 + panitumumab|"Every 2 weeks :~* Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~* Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :~* 5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :~* 5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h~* Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn."
62272099|NCT02321254|EXPERIMENTAL|The RehaARM-Robot|Receive 45 min of robot-assisted therapy for the shoulder and 1 hour of daily standard rehabilitation therapy.
62272100|NCT03464500|ACTIVE_COMPARATOR|Mitopure 500mg|
62272101|NCT03464500|ACTIVE_COMPARATOR|Mitopure 1000mg|
62272102|NCT03464500|ACTIVE_COMPARATOR|Placebo|
62272103|NCT03161756|EXPERIMENTAL|Arm A|Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintenance phase).
62272104|NCT03161756|EXPERIMENTAL|Arm B|Patients in Arm B will receive ipilimumab at 3 mg/kg combined with nivolumab at 1 mg/kg IV every 3 weeks for 4 doses with denosumab 120 mg SC given D1, D8, D15, D29, D57 (induction phase). This will be followed by nivolumab 480 mg IV and denosumab 120 mg SC ever 4 weeks for a total of 24 months (maintenance phase).
62287011|NCT01670266|EXPERIMENTAL|Experimental Arm 1|Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
62287012|NCT01670266|EXPERIMENTAL|Experimental Arm 2|Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
62634816|NCT03374475|PLACEBO_COMPARATOR|Lead-in period: Placebo|Participants who successfully complete the baseline examination visit at the clinical site/unit, will be treated with placebo (2 capsules taken orally) for the duration of the lead-in period which will last up to 3 weeks. Investigators and participants will be blinded to exact duration of each participant-specific lead-in period throughout the study.
62634817|NCT03374475|EXPERIMENTAL|Treatment period: JNJ-42847922 or Placebo|Placebo lead-in period responders and non-responders will be randomized to receive either placebo or 20 milligram (mg) JNJ-42847922 or 40 mg JNJ-42847922 for 5 Weeks. Participants will swallow JNJ-42847922 20 mg (2\*10-mg capsules) or JNJ-42847922 40 mg (2\*20-mg capsules) or 2 matching placebo capsules once daily for 5 Weeks.
62634818|NCT03374475|PLACEBO_COMPARATOR|Withdrawal period: Placebo|Participants who will complete the treatment period prior to the end of Week 8 will enter the withdrawal period where they will be treated with placebo (2 capsules taken orally) for the remaining time of the double-blind phase of the study. Investigators and participants will be blinded to exact duration of each participant-specific withdrawal period.
62272105|NCT05373147|EXPERIMENTAL|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
62272106|NCT00649532|EXPERIMENTAL|1|Ondansetron Tablets 24 mg
62272107|NCT00649532|ACTIVE_COMPARATOR|2|Zofran® Tablets 24 mg
62272108|NCT04280900|EXPERIMENTAL|cybertherapy|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
62272109|NCT04280900|OTHER|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
62272110|NCT00419328|EXPERIMENTAL|Experimental Arm A|Patients were scheduled to receive a 1 hour intravenous (iv) infusion of NGR-hTNF every 3weeks.- The dose of administered NGR-hTNF was: 0.2, 0.4, 0.8, 1.6 μg/m2 (step 1); 3.2, 6.4, 12.8 μg/m2 (step 2); 19.2, 28.8, 43.2 64.8 μg/m2 (step 3); 86.2, 114.6, 152.4 μg/m2 (step 4)
62272111|NCT00193765|ACTIVE_COMPARATOR|Wait and Watch|Therapeutic neck dissection on developing nodal relapse
62272112|NCT00193765|EXPERIMENTAL|Elective Neck dissection|Elective neck dissection in early oral cancer at the time of primary surgery
62067172|NCT01821898|ACTIVE_COMPARATOR|Positive for food allergy: Group B|Elimination diet
62067173|NCT02862041|ACTIVE_COMPARATOR|Group Echogenic|Ultrasound guided infraclavicular brachial plexus block with Pajunk sonoplex echogenic needle
62272113|NCT00902785||no drug|no drug
62272114|NCT04760665|EXPERIMENTAL|Fecal microbiota transplantation|
62067174|NCT02862041|PLACEBO_COMPARATOR|Group Nonechogenic|Non echogenic needle group, ultrasound guided infraclavicular brachial plexus block with Stimuplex Braun non echogenic needle
62272115|NCT04760665|PLACEBO_COMPARATOR|Placebo|
62067175|NCT00672958|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.
62272116|NCT05740228|EXPERIMENTAL|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
62272117|NCT05740228|EXPERIMENTAL|Anodal High-Definition (HD) tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
62272118|NCT05740228|SHAM_COMPARATOR|Sham stimulation|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
62272119|NCT05581914|EXPERIMENTAL|Treatment group|Care as Usual and the MY LIFE treatment
62453298|NCT01443065|EXPERIMENTAL|Arm C : simplified FOLFOX 4 + AMG 102|"Every 2 weeks :~* Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~* Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :~* 5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :~* 5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h~* AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn."
62453299|NCT06547190|EXPERIMENTAL|HL|High-to-Low AGEs diet
62453300|NCT06547190|EXPERIMENTAL|LH|Low-to-High AGEs diet
62453301|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
62634819|NCT05283811|OTHER|Epilepsy Monitoring Unit|Patient's behavioral and neural activity via computer tasks and questionnaires are monitored in the Epilepsy Monitoring Unit
62634820|NCT05283811|OTHER|Neuropace RNS Device|Patients are implanted with RNS device to treat their seizure activity
62067176|NCT00672958|EXPERIMENTAL|Vortioxetine|Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.
62067177|NCT03324503|EXPERIMENTAL|Glucocorticoid ≥ 30 mg/day|≥ 30 mg/day prednisone or prednisolone as per local clinical practice of sarcoidosis initial induction therapy will be taken orally preferably before, during, or immediately after meals or with food or milk, at approximately the same time of day for 8 weeks.
62067178|NCT05749601|ACTIVE_COMPARATOR|Patients without knee osteoarthritis (KOA) grade 0|Patient without knee affection
62067179|NCT05749601|EXPERIMENTAL|Patients with KOA grade I|Kellgren-Lawrence classification (KL) grade I- doubtful narrowing of the joint space and possible osteophytes
62067180|NCT05749601|EXPERIMENTAL|Patients with KOA grade II|KL grade II - definite osteophytes and possible narrowing of joint space.
62067181|NCT05749601|EXPERIMENTAL|Patients with KOA grade III|KL grade III- definite narrowing of the joint space, significant osteophytosis, and possible bone deformities.
62067182|NCT05749601|EXPERIMENTAL|Patients with KOA grade IV|KL grade IV- marked joint space narrowing accompanied by deformities, bone sclerosis, and large osteophytes
62272120|NCT05581914|ACTIVE_COMPARATOR|Waitinglist Control group|Care as Usual
62272121|NCT03602872|EXPERIMENTAL|Group 1|Subjects will receive a single intraarticular 20x10\^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
62272122|NCT03602872|EXPERIMENTAL|Group 2|Subjects will receive a single intraarticular 20x10\^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
62067183|NCT00460317|PLACEBO_COMPARATOR|Arm B|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
62453302|NCT03996512|EXPERIMENTAL|Post scaphoid fracture with screw fixation|Post surgical rehabilitation using an early active controlled wrist motion rehab protocol that limits the amount of proximal carpal row loading forces
62453303|NCT02629549|EXPERIMENTAL|OTL38|Dosage calculated by weight of individual
62067184|NCT00460317|ACTIVE_COMPARATOR|Arm A|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
62453304|NCT03997370|EXPERIMENTAL|Treatment (iohexol, standard care carboplatin, blood samples)|Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.
62453305|NCT02896088|OTHER|test tooth groups|test tooth groups
62453306|NCT02896088|OTHER|control tooth groups|control tooth groups
62453307|NCT03736109||Group I:|Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
62453308|NCT03736109||Group II:|Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
62634821|NCT02789969|EXPERIMENTAL|Hydromorphone 15mcg/kg IV|Patient randomly assigned to hydromorphone
62067185|NCT02966535|EXPERIMENTAL|1:2, 1:1 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:2 during the first one hour of laparoscopy and then switched to I:E ratio of 1:1 during the rest time of laparoscopy.
62067186|NCT02966535|ACTIVE_COMPARATOR|1:1, 1:2 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:1 during the first one hour of laparoscopy and then switched to I:E ratio of 1:2 during the rest time of laparoscopy.
62067187|NCT02671318|ACTIVE_COMPARATOR|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
62453309|NCT01805713||CF Infant Cohort|Infants with CF followed for the first two years of life.
62634822|NCT02789969|EXPERIMENTAL|Fentanyl 1.5 mcg/kg IV|Patient randomly assigned to fentanyl
62067188|NCT02671318|ACTIVE_COMPARATOR|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
62272123|NCT03602872|EXPERIMENTAL|Group 3|Subjects will receive a single intraarticular 20x10\^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
62272124|NCT00194545|EXPERIMENTAL|1|Medication diary
62634823|NCT00305227|EXPERIMENTAL|Lactin-V|Vaginal capsule containing Lactobacillus crispatus in high concentration. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
62634824|NCT00305227|PLACEBO_COMPARATOR|Placebo|Vaginal capsule - placebo. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
62634825|NCT04435808|EXPERIMENTAL|Hydroxychloroquine Arm|Group A: up to 275 health care workers who choose to take hydroxychloroquine. Will receive a 600 mg loading dose, followed by 200 mg daily (tablets).
62067189|NCT00984360|EXPERIMENTAL|A118G|
62067190|NCT00984360|EXPERIMENTAL|Wild-type|
62067191|NCT03800979|EXPERIMENTAL|Tofacitinib|All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
62067192|NCT03120208|EXPERIMENTAL|women in the nonexposed group without a hemorrhage|
62634826|NCT04435808|NO_INTERVENTION|No Intervention Arm|Group B: Up to 75 health care workers who choose not to take hydroxychloroquine.
62067193|NCT03120208|EXPERIMENTAL|women in the exposed group with a hemorrhage|
62272125|NCT00194545|NO_INTERVENTION|2|Caregivers only receive counseling which is the standard of care
62287013|NCT01670266|EXPERIMENTAL|Experimental Arm 3|Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
62634827|NCT01673581||Low risk prostate cancer|
62634828|NCT01081626|EXPERIMENTAL|Group I: Chronic Low dose Protocol|Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
62067194|NCT03120208|EXPERIMENTAL|Partners|
62067195|NCT05962320|EXPERIMENTAL|mERAS Group|"* Education and counselling of patients and their parents~* Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible~* Stimulation of intestinal motility in the postoperative period~* Initiation of oral intake in the early postoperative period~* Early removal of the patient by reducing postoperative IV fluid infusion~* Initiation of early mobilization of the patient in the postoperative period~* Reducing opioid use and ensuring pain management~* Implement nausea and vomiting prophylaxis~* Management of thirsty~* Management of fear and stress"
62067196|NCT05962320|NO_INTERVENTION|Standart Care Group|Patients in this group will receive standard care according to the practices of the clinic where the study will be conducted.
62067197|NCT00315588|EXPERIMENTAL|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
62067198|NCT06419218|EXPERIMENTAL|School meal messages|Participants will view messages focused on the benefits of children eating school meals, using text and images developed based on parent interviews. Participants will view a total of 10 messages.
62453310|NCT01805713||CF Child/Adult Cohort|CF patients \> 8 years of age followed during hospitalization for pulmonary exacerbation and when well for two years.
62453311|NCT01211548||contrast CTA of the CAP|All patients being considered for a complex aortic surgery and undergoing medically indicated contrast enhanced CT aortic angiography of the chest abdomen and pelvis will be includedRaw data from CT coronary angiography will be available from all patients.
62634829|NCT01081626|EXPERIMENTAL|Group II: Low dose Protocol|Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.
62634830|NCT04683796|EXPERIMENTAL|100% APRP|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
62634831|NCT04683796|ACTIVE_COMPARATOR|100% AS|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
62634832|NCT03076112|EXPERIMENTAL|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin~\*\* Metformin and sulfonylurea's dosages~* Metformin 500 mg - 2550 mg~* Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
62067199|NCT06419218|ACTIVE_COMPARATOR|Control (neutral) messages|Participants will view messages focused on the benefits of children reading. Messages will be matched in length to the experimental messages. Participants will view a total of 10 messages.
62067200|NCT02386917|ACTIVE_COMPARATOR|Gastric bypass|40 patients will undergo gastric bypass
62067201|NCT02386917|ACTIVE_COMPARATOR|Very low calorie diet|40 patients will undergo a very low calorie diet
62453312|NCT02932254|ACTIVE_COMPARATOR|Magnesium Sulfate|"1. After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~2. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~3. INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution)."
62272126|NCT03604965|EXPERIMENTAL|GP+CCRT|GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
62453313|NCT02932254|PLACEBO_COMPARATOR|Saline Solution|"1. After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~2. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~3. INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously 100 mL saline solution over 10 minutes."
62634833|NCT03076112|ACTIVE_COMPARATOR|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin~\*\* Metformin and sulfonylurea's dosages~* Metformin 500 mg - 2550 mg~* Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
62272127|NCT03604965|ACTIVE_COMPARATOR|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
62634834|NCT01089842|EXPERIMENTAL|Health coaching|
62287014|NCT01670266|EXPERIMENTAL|Experimental Arm 4|Experimental Eye drop, 2 sequence crossover Cohort \[1 dose; 1-30 µg/mL\]to be determined and placebo
62287015|NCT01670266|PLACEBO_COMPARATOR|Placebo Arm|Matched placebo eye drops dosed in same manner as ONO-9054
62453314|NCT06345248|ACTIVE_COMPARATOR|US-TAP group|
62453315|NCT06345248|ACTIVE_COMPARATOR|LAPTAP group|
62634835|NCT01089842|NO_INTERVENTION|Control|
62272128|NCT04064775|EXPERIMENTAL|Smart snacking intervention|In intervention 2 participants took part in a 4-week intervention on Instagram. Participants saw images of fictitious peers' snacks or beverages three times per week, and saw snack information images three times per week. Peer snack images were posted on days 2,4 and 6 of each week, and snack information images were posted on days 1,3 and 5 of each week. Images were posted between 10-11am each day. Participants also completed quizzes related to snacking at the end of weeks 1-3. Participants completed a survey at baseline and intervention end to assess their ideal portion sizes to allow for examination of the effectiveness of the intervention.
62272129|NCT04064775|NO_INTERVENTION|Control|Participants in the control received no intervention. They completed the questionnaires at the end of weeks 1, 2 and 3, and also completed the surveys at baseline and intervention end.
62272130|NCT06445868|EXPERIMENTAL|intervention group|Knowledge (information support, changing health attitudes); Motivation (motivation to change sedentary behaviour and improve exercise compliance); Capacity (development of exercise plans to improve sedentary behaviour change); Opportunities (increasing the timing of exercise and creating opportunities for sedentary behaviour change); Behaviour (monitoring and reinforcing sedentary behaviour change)
62272131|NCT06445868|NO_INTERVENTION|control group|Routine nursing education
62067202|NCT02386917|NO_INTERVENTION|Gall bladder operation|20 patients will be asked to undergo one pharmacokinetic study only, and then finish the study. They will not undergo any weight loss intervention.
62272132|NCT02741102|EXPERIMENTAL|Women with AUFI|Women with AUFI must meet criteria for uterine transplant. In vitro fertilization to obtain 6 (screened) healthy embryos for cryo-preservation precedes uterine transplant from an appropriate donor The recipient will be required to take potent anti rejection medications including Thymoglobulin, Prednisone, Tacrolimus, Mycophenolate Mofetil (MMF) , later substituted with Azathioprine to avoid birth defects. One year later, up to 6 attempts using 1 screened embryo at a time will be tried to achieve pregnancy. During pregnancy, the high risk pregnancy and transplant teams will follow the recipient. The goal is a full term baby and delivery will be by Caesarian section. A second pregnancy may be attempted. Afterward, the uterus will be explanted.
62634836|NCT01029262|EXPERIMENTAL|Arm #1 - Lenalidomide plus placebo|Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and \< 60 mL/min.
62634837|NCT01029262|PLACEBO_COMPARATOR|Arm #2 - placebo|Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.
62088234|NCT01975350||saline inhalation|saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
62088235|NCT00654238|EXPERIMENTAL|1|This is a single arm study.
62272133|NCT04190225|EXPERIMENTAL|Multi-technology physical activity intervention|Digital/social media
62272134|NCT04190225|NO_INTERVENTION|Control|Control group receives a Fitbit but none of the intervention components.
62272135|NCT03343132||Subacute SCI|
62067203|NCT05367609|OTHER|Children undergoing Spine Fusion Surgery|"This arm will include approximately 300 children undergoing spine fusion surgery~1. Pharmacokinetic (PK): collection of 10-13 serial blood samples to determine serum levels of methadone/oxycodone and its metabolites~2. Pharmacogenetic (PG): Preoperative CYP2D6 genotyping (for preferential recruitment of CYP2D6 PMs and UMs). This will be collected in the pre-operative clinic via blood if there are clinical labs needed for standard of care. If no blood is needed in the pre-op clinic, the investigators will collect this via saliva.~Postoperative Analgesia Dose and PK Sampling Schedule:~Clinical care providers are blinded to CYP2D6/CYP2B6 when prescribing oxycodone/methadone; and genetic analysis of proposed targeted genes. Results of these samples will be used to determine personalized analgesia plan."
62272136|NCT03343132||Chronic SCI|
62272137|NCT03343132||Controls|
62272138|NCT01716910|PLACEBO_COMPARATOR|Maltodextrin|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day
62272139|NCT01716910|ACTIVE_COMPARATOR|Synbiotic|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day + 10e9 CFU
62272140|NCT01801956|ACTIVE_COMPARATOR|Motivational interviewing|A one hour motivational interview
62272141|NCT01801956|EXPERIMENTAL|Physical activity|Four motivational interviews, free membership of a sport club, virtual arena to upload training data from a GPS-watch
62272142|NCT01297270|ACTIVE_COMPARATOR|PegIFN/RBV|48 weeks
62272143|NCT01297270|EXPERIMENTAL|BI 201335 for 24 weeks|BI 201 335 QD dosing in combination with IFN/RBV
62272144|NCT01297270|EXPERIMENTAL|BI201335 for 12 weeks|BI 201335 QD doing in combination with PEFG IFN/RBV
62272145|NCT01297270|PLACEBO_COMPARATOR|Placebo|
62272146|NCT06339528|EXPERIMENTAL|group stimulated according to the Vojta's Reflex Locomotion|Stimulation of trigger zones according to Vojta was applied to 20 of them by a team of licensed physiotherapists.
62272147|NCT06339528|PLACEBO_COMPARATOR|control group received a sham stimulation carried out by physicians|Control group received a sham stimulation carried out by physicians.
62272148|NCT00679705|EXPERIMENTAL|1|Ritodrine (Pre-Par)
62272149|NCT00679705|EXPERIMENTAL|2|Atosiban (Tractocile)
62272150|NCT00679705|PLACEBO_COMPARATOR|3|Placebo
62272151|NCT03524261|EXPERIMENTAL|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
62272152|NCT03524261|ACTIVE_COMPARATOR|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
62272153|NCT03524261|NO_INTERVENTION|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62272154|NCT02841215|EXPERIMENTAL|Oral ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
62272155|NCT02841215|ACTIVE_COMPARATOR|Oral ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
62067204|NCT05677802|EXPERIMENTAL|Health Services Research (stress management therapy)|Patients receive biobehavioral stress reduction intervention while on study. Patients undergo blood specimen collection at baseline and follow up and have their medical records reviewed.
62067205|NCT00715572|ACTIVE_COMPARATOR|A|
62067206|NCT00715572|ACTIVE_COMPARATOR|B|
62272156|NCT01312935|EXPERIMENTAL|Heparin and PMX-60056|
62272157|NCT03524339|PLACEBO_COMPARATOR|Placebo|
62272158|NCT03524339|EXPERIMENTAL|Tamsulosin|
62272159|NCT05872776|ACTIVE_COMPARATOR|RR2 wearable home-care: active device|Real stimulation with RR2 neuromodulation device
62272160|NCT05872776|SHAM_COMPARATOR|RR2 wearable home-care: sham control device|Mock sham stimulation with RR2 neuromodulation device
62634838|NCT00577733||obese|obese
62634839|NCT00577733||healthy volunteers|healthy volunteers
62272161|NCT03824847|ACTIVE_COMPARATOR|Intervention group|Intervention group: clarithromycin 1 tablet (250mg) twice daily for three days
62272162|NCT03824847|PLACEBO_COMPARATOR|Placebo group|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days.
62272163|NCT01902550|EXPERIMENTAL|Metoprolol plus placebo then Metoprolol plus JNJ-54452840|Metoprolol tartrate immediate-release (metoprolol IR) will be administered as single oral dose of 100 milligram (mg) tablet or capsule. After two hours, placebo (normal saline) will be administered intravenously over 1 minute on Day 1.
62634840|NCT04378569|ACTIVE_COMPARATOR|ARQ-252 cream 0.3% QD (once daily)|Active Comparator
62634841|NCT04378569|ACTIVE_COMPARATOR|ARQ-252 cream 0.3% BID (twice daily)|Active Comparator
62634842|NCT04378569|ACTIVE_COMPARATOR|ARQ-252 cream 0.1% QD (once daily)|Active Comparator
62634843|NCT04378569|PLACEBO_COMPARATOR|Vehicle cream BID (twice daily)|Placebo Comparator
62067207|NCT04588818|EXPERIMENTAL|Adalimumab plus Methotrexate|
62067208|NCT05650944||Covid-19 Survivor groups|Covid-19 survivor groups are hematological parameters
62067209|NCT05650944||Covid-19 Non-survivor groups|Hematological parameters in patients with severe COVID-19 who have died.
62067210|NCT01302938|EXPERIMENTAL|Tolterodine ER|
62067211|NCT01302938|PLACEBO_COMPARATOR|Placebo|
62067212|NCT05817435|EXPERIMENTAL|Efgartigimod PH20 SC - prefilled syringe|efgartigimod PH20 SC administered by a prefilled syringe
62272164|NCT01902550|EXPERIMENTAL|Metoprolol plus JNJ-54452840 then Metoprolol plus placebo|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule. After two hours, JNJ-54452840 (12 milliliter \[ml\] solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
62272165|NCT01975415||Experienced Meditators|Self-identified participants who confirm to having a regular meditation practice for at least 3 months and practiced at least 70 minutes per week.
62272166|NCT01975415||Novice meditators|Self-identified participant who confirm to either having never seriously tried meditation, or who have not meditated more than once a week for at least 3 months
62272167|NCT04847973|EXPERIMENTAL|12 weeks of medically-tailored meals (MTMs)|12 weeks of home-delivered medically-tailored meals (MTMs), prepared and delivered by the non-profit Community Servings. The MTM has be developed specifically for patients with heart failure, with an approximate protein intake range of 1.1-1.5 g/kg body weight/day and a maximum of 2000 mg sodium/day.
62272168|NCT04847973|EXPERIMENTAL|12 weeks of protein supplementation shakes|Participants will receive 1 bottle of Ensure Max Protein shake every day (any flavor option without caffeine, daily for 12 weeks) to take in addition to their standard diet, without MTM delivery.
62272169|NCT05625828|EXPERIMENTAL|SILVER XIII EQUILIBRE|Cognitive-motor 10 weeks program
62272170|NCT05625828|ACTIVE_COMPARATOR|VIVIFRAIL|Multifactorial 10 weeks program
62272171|NCT01914562|EXPERIMENTAL|OCA 10 mg while fasted|OCA 10 mg orally in the fasting state
62272172|NCT01914562|EXPERIMENTAL|OCA 10 mg while Fed|OCA 10 mg orally in the fed state
62272173|NCT01914562|EXPERIMENTAL|OCA 25 mg while fasted|OCA 25 mg orally in the fasting state
62272174|NCT01914562|EXPERIMENTAL|OCA 25 mg while Fed|OCA 25 mg orally in the fed state
62634844|NCT04378569|PLACEBO_COMPARATOR|Vehicle cream QD (once daily)|Placebo Comparator
62634845|NCT00687986|ACTIVE_COMPARATOR|primary surgery|primary surgical resection
62634846|NCT00687986|EXPERIMENTAL|stereotactic radiotherapy|primary stereotactic radiotherapy
62634847|NCT06421701|EXPERIMENTAL|anti-CD19 CAR-NK cells|To evaluate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus. All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by anti-CD19 CAR-NK cells infusion on Day 0, 7, and 14.
62067213|NCT05817435|ACTIVE_COMPARATOR|Efgartigimod PH20 SC - vial + syringe|efgartigimod PH20 SC administered by a vial + syringe
62067214|NCT06124742||clear aligners|The aim of this study is to assess the gustatory perception and alteration in patients using either clear aligners or fix orthodontics treatment.
62067215|NCT01916941|ACTIVE_COMPARATOR|Prazosin|Prazosin titrated to 16 mg daily x 6 weeks
62067216|NCT01916941|PLACEBO_COMPARATOR|Placebo|Placebo X 6 weeks
62067217|NCT00548067|ACTIVE_COMPARATOR|1|
62067218|NCT00548067|ACTIVE_COMPARATOR|2|
62067219|NCT00548067|ACTIVE_COMPARATOR|3|
62067220|NCT00548067|EXPERIMENTAL|4|
62067221|NCT03791203|EXPERIMENTAL|Calorie restriction (MACR)|Participants restricted 70% of their energy needs over 24 hours on a calorie restriction day alternate with a feeding day for the next 24 hours, where they were allowed eating (ad libitum). The calorie restriction and feeding days begun at 9 am each day, and on the calorie restriction day, meals were consumed between 2 pm and 8 pm to ensure that they underwent the same duration of calorie restriction. On each calorie restriction day, they were allowed energy-free beverages and sugar-free gum and encouraged to drink plenty of water. Diet plans were self-selected using detailed individualized food portion lists, meal plans, and recipes. Participants received phone calls from the investigator and four 2-weekly appointments with a dietitian. Adverse experiences were assessed every 2 weeks.
62067222|NCT03791203|NO_INTERVENTION|Control group|Participants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
62067223|NCT01392716|EXPERIMENTAL|Single arm|
62067224|NCT03659643||Retrospective MCI cohort|EEG with SPR analysis of the group from the study 2011-2013 is evaluated in relation to the status of current cognitive impairment
62067225|NCT03659643||Prospective MCI cohort|New individuals diagnosed with MCI. EEG with SPR analysis is performed during the diagnostic work-up and evaluated in relation to changes in cognitive status during the following two years.
62067226|NCT05427513|PLACEBO_COMPARATOR|placebo|will injection 10 ml of normal saline to ensure binding
62067227|NCT05427513|ACTIVE_COMPARATOR|tranexamic acid(TXA)|will inject tranexamic acid according to body weight
62067228|NCT01207323|EXPERIMENTAL|Dose Escalation (MEHD7945A)|Participants will receive intravenous (IV) infusion of MEHD7945A in escalating doses Q2W until MTD is reached or up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first. Approximately 5 dose levels between 1 and 30 mg/kg will be evaluated.
62067229|NCT01207323|EXPERIMENTAL|Dose Expansion (MEHD7945A)|Participants will receive IV infusion of MEHD7945A Q2W at or below the MTD (decided from dose escalation part) up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
62067230|NCT05690061|ACTIVE_COMPARATOR|Sequence 1: Grain-Fed, Grass-Fed, Impossible|"On the first visit, a grain-fed beef burger (250 grams) will be consumed.~On the second visit, a grass-fed beef burger (250 grams) will be consumed.~On the third visit, an Impossible BurgerTM (250 grams) will be consumed."
62067231|NCT05690061|ACTIVE_COMPARATOR|Sequence 2: Grass-Fed, Grain-Fed, Impossible|"On the first visit, a grass-fed beef burger (250 grams) will be consumed.~On the second visit, a grain-fed beef burger (250 grams) will be consumed.~On the third visit, an Impossible BurgerTM (250 grams) will be consumed."
62067232|NCT05690061|ACTIVE_COMPARATOR|Sequence 3: Impossible, Grass-Fed, Grain-Fed|"On the first visit, an Impossible BurgerTM (250 grams) will be consumed.~On the second visit, a grass-fed beef burger (250 grams) will be consumed.~On the third visit, a grain-fed beef burger (250 grams) will be consumed."
62634848|NCT06236321|EXPERIMENTAL|Rectal cancer patients|Patients with locally advanced rectal cancer who require neoadjuvant chemoradiotherapy
62067233|NCT05690061|ACTIVE_COMPARATOR|Sequence 4: Impossible, Grain-Fed, Grass-Fed|"On the first visit, an Impossible BurgerTM (250 grams) will be consumed.~On the second visit, a grain-fed beef burger (250 grams) will be consumed.~On the third visit, a grass-fed beef burger (250 grams) will be consumed."
62067234|NCT05690061|ACTIVE_COMPARATOR|Sequence 5: Grain-Fed, Impossible, Grass-Fed|"On the first visit, a grain-fed beef burger (250 grams) will be consumed.~On the second visit, an Impossible BurgerTM (250 grams) will be consumed.~On the third visit, a grass-fed beef burger (250 grams) will be consumed."
62067235|NCT05690061|ACTIVE_COMPARATOR|Sequence 6: Grass-Fed, Impossible, Grain-Fed|"On the first visit, a grass-fed beef burger (250 grams) will be consumed.~On the second visit, an Impossible BurgerTM (250 grams) will be consumed.~On the third visit, a grain-fed beef burger (250 grams) will be consumed."
62067236|NCT03027687|EXPERIMENTAL|Real transcranial Direct Current Stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for three days in one week.
62067237|NCT03027687|SHAM_COMPARATOR|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
62067238|NCT05538182|EXPERIMENTAL|Spectacles|"Based on the refraction results, spectacles will be prescribed at the baseline visit and worn throughout the study. Study participants with newly diagnosed hyperopia at baseline will undergo a reading assessment and near visual acuity check over six months, compared to age-, gender- and school-matched emmetropic controls.~Spectacle compliance will be observed among newly diagnosed hyperopic and newly diagnosed myopic school children in Grades 2 and 4 primary school children, from Mashonaland Central province of Zimbabwe, at six weeks and 14 weeks from spectacle acquisition."
62067239|NCT05538182|NO_INTERVENTION|No treatment|Age-, gender- and school-matched emmetropic controls will undergo a reading assessment at baseline and at six months.
62067240|NCT02287116|NO_INTERVENTION|nasal mask and nasal prongs|
62067241|NCT03295266|EXPERIMENTAL|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI (estimated glomerular filtration rate \[eGFR\] of ≤60mL/min/1.73m\^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
62067242|NCT03295266|EXPERIMENTAL|Severe Hepatic Impairment (Panel B)|Participants with severe HI (eGFR of ≤50 mL/min/1.73m\^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
62067243|NCT03295266|EXPERIMENTAL|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
62067244|NCT03696719|ACTIVE_COMPARATOR|Undergoing surgery under general anesthesia|Patients will undergo the surgery under general anesthesia, anesthetic regime will be according to standard clinical practice.
62634849|NCT02537951|EXPERIMENTAL|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
62067245|NCT03696719|ACTIVE_COMPARATOR|Undergoing surgery under regional anesthesia|Patients will undergo the surgery under neuroaxial anesthesia.
62067246|NCT06111144|EXPERIMENTAL|Polarized training Intensity distribution model without mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (5%), zone 3 (15%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique and strength, these will have a weekly volume of 30 min and 1 hour respectively during all 12 weeks.~In summary:~60 running sessions 24 strength sessions 24 running technique sessions"
62067247|NCT06111144|EXPERIMENTAL|Pyramidal training Intensity distribution model without mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (5%), zone 3 (15%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique and strength, these will have a weekly volume of 30 min and 1 hour respectively during all 12 weeks.~In summary:~60 running sessions 24 strength sessions 24 running technique sessions"
62634850|NCT02537951|ACTIVE_COMPARATOR|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
62067248|NCT06111144|EXPERIMENTAL|Polarized training Intensity distribution model with mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (5%), zone 3 (15%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique, strength and mindfulness these will have a weekly volume of 30 min, 1 hour and 65 min respectively during all 12 weeks.~The weekly mindfulness practice will be done in 4 different types of sessions: (life-meditation, jogging-meditation, stretching-meditation, running-meditation).~In summary:~60 running sessions 60 mindfulness sessions 24 strength sessions 24 running technique sessions"
62088236|NCT02389426|EXPERIMENTAL|Patients with Multiple Sclerosis|One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
62272175|NCT05170243|ACTIVE_COMPARATOR|9MW1911 Injection|Experimental drug administered IV infusion
62634851|NCT02537951|ACTIVE_COMPARATOR|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
62634852|NCT01806168|ACTIVE_COMPARATOR|Low-frequency (1 Hz) rTMS|Low-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
62067249|NCT06111144|EXPERIMENTAL|Pyramidal training Intensity distribution model with mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (15%), zone 3 (5%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique, strength and mindfulness these will have a weekly volume of 30 min, 1 hour and 65 min respectively during all 12 weeks.~The weekly mindfulness practice will be done in 4 different types of sessions: (life-meditation, jogging-meditation, stretching-meditation, running-meditation).~In summary:~60 running sessions 60 mindfulness sessions 24 strength sessions 24 running technique sessions"
62067250|NCT00013065||Group 1|
62088237|NCT02389426|EXPERIMENTAL|Healthy controls|Only one examination with TCD baseline and NIRS baseline will be performed, without administration of bosentan.
62088238|NCT05250479|NO_INTERVENTION|Control group|44 pregnant women won't receive mindfulness training
62272176|NCT05170243|PLACEBO_COMPARATOR|9MW1911 Injection Placebo|Placebo administered IV infusion
62272177|NCT02936141|EXPERIMENTAL|Group psychotherapy|Group psychotherapy sessions includes the following: training of social skills (such as communication, social interaction and assertive behaviors), cognitive stimulation and training of activities of daily living (such as personal hygiene, hygiene of spaces and standardized mealtimes)
62272178|NCT04198415||Venetoclax Participants|Participants prescribed and treated with venetoclax.
62272179|NCT03434405|EXPERIMENTAL|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
62272180|NCT03878511|EXPERIMENTAL|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
62272181|NCT03878511|PLACEBO_COMPARATOR|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
62272182|NCT06276803||Patients who have no risk factors for PDAC|In this study, LINFU® will be evaluated to help identify pancreatic intraepithelial neoplasia-2 (PanIn-2), pancreatic intraepithelial neoplasia-3 (PanIn-3), and early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) in patients with no risk factors and who do not display signs or symptoms of pancreatic disease.
62272183|NCT06081556||Group A|the difference between mean gestational sac diameter and crown-rump length （mGSD-CRL） ≥ 10mm
62272184|NCT06081556||Group B|10 mm \< mGSD-CRL ≤ 15 mm
62272185|NCT06081556||Group C|mGSD-CRL \>15 mm
62272186|NCT04000685|ACTIVE_COMPARATOR|Yoga exercise group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing, warm up and relaxation exercises.
62272187|NCT04000685|ACTIVE_COMPARATOR|Spinal stabilization exercise group|Spinal stabilization exercise with three different progressive phases were applied all patients in this group accompanied by physiotherapist.
62272188|NCT04000685|ACTIVE_COMPARATOR|aerobic walking exercise group|Aerobic walking exercise program applied all patients in this group accompanied by physiotherapist.
62272189|NCT02936700|OTHER|Control group|Add on relaxation group
62272190|NCT02936700|EXPERIMENTAL|Therapy ACT|Add on ACT group
62272191|NCT04880200|EXPERIMENTAL|POC NAT & Adherence Intervention|These participants will receive the POC NAT test during their study visit. The result will be conveyed to their provider, who will deliver the result and an adherence intervention.
62272192|NCT04880200|NO_INTERVENTION|Standard of Care|These participants will receive the clinical standard of care during their visit.
62634853|NCT01806168|ACTIVE_COMPARATOR|High-frequency (10 Hz) rTMS|High-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
62453316|NCT02625831||SLE patients|"165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without.~Biological analysis were performed."
62634854|NCT01806168|PLACEBO_COMPARATOR|Sham rTMS|Sham stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
62272193|NCT01614587||Cases|"1. Early, unexplained recurrence (within six months of procedure) after Sacrocolpopexy~2. The recurrence required treatment (surgery or pessary)"
62453317|NCT02625831||healthy patients|48 healthy patients. Biological analysis were performed.
62453318|NCT01379781|EXPERIMENTAL|Behavioral Intervention for PPD|Behavioral Intervention for PPD delivered over 3 in-person sessions.
62453319|NCT01379781|NO_INTERVENTION|Treatment As Usual|Referred to Treatment in the Community.
62453320|NCT00661999|EXPERIMENTAL|Arm I|Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
62453321|NCT00661999|EXPERIMENTAL|Arm II|Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
62453322|NCT00661999|EXPERIMENTAL|Arm III|Patients receive darbepoetin alfa as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
62453323|NCT02493244|EXPERIMENTAL|Treatment|Participants clean their eyelids with Cliradex wipes before going to bed at night.
62634855|NCT06444334|ACTIVE_COMPARATOR|control PRF group|controlled diabetic patients with 11 implants covered with PRF inserted in posterior maxilla or mandible, not laser irradiated
62272194|NCT01614587||Controls|"1. Sacrocolpopexy during the same period~2. No recurrence, no reoperation, no retreatment to date (minimum of 12 months from surgery)"
62272195|NCT04247425|EXPERIMENTAL|Supportive Care (resistance training, exercise counseling)|Patients complete a series of progressive resistance training exercises at home twice weekly over 1 hour and receive instructional guidance from an exercise physiologist via videoconferencing once per week during one of these sessions for up to 12 weeks.
62067251|NCT02899364|EXPERIMENTAL|Sodium thiosulfate|25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram (50mL) dissolved in 250 ml sodium chloride 0.9%. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he will receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
62067252|NCT02899364|PLACEBO_COMPARATOR|Sodium chloride 0.9%|50 ml Sodium chloride 0.9%, added to 250ml sodium chloride 0.9% is administered twice. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
62067253|NCT02687412|EXPERIMENTAL|Fast-track Surgery|Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
62067254|NCT02687412|OTHER|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
62067255|NCT05059912|EXPERIMENTAL|CD7 positive relapsed or refractory T cell lymphoma|Humanized CD7 CAR-T cells intravenously infused to patient with R/R T-NHL\[ at a dose of (0.5- 5)x10\^6 CD7 CAR-T cells/kg
62067256|NCT02221245||Patients with Esophageal Cancer|Tumor Biopsy via Ultrasound Endoscopy
62067257|NCT01619657|EXPERIMENTAL|Hypertonic Saline|Inhalation with 6% Hypertonic Saline twice daily over 1 year
62272196|NCT01899235|ACTIVE_COMPARATOR|Stent|drug eluting stent (Resolute)
62272197|NCT01899235|EXPERIMENTAL|drug eluting balloon|drug eluting balloon (Elutax)
62272198|NCT02811692||BAY86-5321|Anti-Vascular Endothelial Growth Factor (VEGF) - naive patients starting intravitreal Aflibercept injection treatment for Neovascular age-related macular degeneration (AMD), macular edema following Branch Retinal Vein Occlusion (BRVO), macular edema following central retinal vein occlusion (CRVO), and diabetic macular edema (DME)
62272199|NCT02322060||Primary ovarian insufficiency|"Primary ovarian insufficiency (POI; also known as premature ovarian failure/dysfunction/insufficiency or premature menopause) is characterised by amenorrhoea, sex hormone (oestrogen, progesterone and testosterone) deficiency and elevated gonadotrophins levels in a woman aged more than two standard deviations below the mean age of menopause estimated for her reference population. POI is defined as a disorder in ovarian function in any woman before the age of 40 years, irrespective of the cause.~In our study, we mainly recruit POI patients who also desire to have a baby of their own."
62453324|NCT02493244|NO_INTERVENTION|Control|No treatment
62634856|NCT06444334|EXPERIMENTAL|laser and PRF test group|controlled diabetic patients with 11 implants covered with PRF inserted in posterior maxilla or mandible, expoed to Diode laser irradiation
62634857|NCT04961164|EXPERIMENTAL|Resistant Potato Starch|15g RPS mixed with water will be consumed twice per day during intervention
62634858|NCT04961164|PLACEBO_COMPARATOR|Corn Starch|15 g corn starch mixed with water will be consumed twice per day during intervention
62634859|NCT02026765|OTHER|Heparin Surface Modified Aspheric Lens|Heparin Surface Modified Aspheric Lens
62634860|NCT02026765|OTHER|traditional lens|traditional Aspheric lens
62272200|NCT02322060||Ovarian resistance syndrome|We currently also include patients diagnosed with Ovarian resistance syndrome, which means that follicles exist, but do not response to FSH.
62453325|NCT05560464|EXPERIMENTAL|Cohort 1: Mild Hepatic Impairment|Participants will receive multiple doses of VX-548 every 12 hours (q12h) from Day 1 through Day 14.
62634861|NCT03074877|EXPERIMENTAL|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
62453326|NCT05560464|EXPERIMENTAL|Cohort 2: Matched Healthy Participants|Healthy participants matched to cohort 1 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
62634862|NCT03074877|EXPERIMENTAL|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
62634863|NCT03074877|NO_INTERVENTION|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
62634864|NCT06312384|ACTIVE_COMPARATOR|study|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane will be applied, in this group 3D surgical template will be applied which consist of a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.
62453327|NCT05560464|EXPERIMENTAL|Cohort 3: Moderate Hepatic Impairment|Participants will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
62634865|NCT06312384|ACTIVE_COMPARATOR|control|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane will be applied \[conventional guided tissue regeneration\].
62634866|NCT03193047|EXPERIMENTAL|bempedoic acid|Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
62634867|NCT03193047|PLACEBO_COMPARATOR|placebo|Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
62634868|NCT05909020||Patients|Approximately 150 adults referred for suspected HNC will be recruited.
62634869|NCT05909020||Staff|Approximately 15 ENT and Maxillofacial) clinicians will be recruited.
62453328|NCT05560464|EXPERIMENTAL|Cohort 4: Matched Healthy Participants|Healthy participants matched to cohort 3 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
62453329|NCT04886115|EXPERIMENTAL|Eccentric pedalling group at 15 rpm|
62453330|NCT04886115|EXPERIMENTAL|Eccentric pedalling group at 60 rpm|
62453331|NCT04886115|ACTIVE_COMPARATOR|Control|
62453332|NCT00890019|EXPERIMENTAL|1A, 2A, 3A, 4A, 5A, 6A, 7A|AdCh63 ME-TRAP
62453333|NCT00890019|EXPERIMENTAL|1B, 2B, 3B, 4B, 6B, 7B, 7C|AdCh63 ME-TRAP; MVA ME-TRAP
62453334|NCT00682084||1|Patients recently diagnosed with Cushing's syndrome
62453335|NCT00954967|NO_INTERVENTION|Usual care|The subjects in the control group will receive the usual care for smoking cessation in diabetic smokers.
62067258|NCT01619657|ACTIVE_COMPARATOR|Isotonic Saline|Inhalation with 0.9% Isotonic Saline twice daily over 1 year
62067259|NCT02128165|ACTIVE_COMPARATOR|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
62067260|NCT02128165|ACTIVE_COMPARATOR|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere)those BMI below 45
62272201|NCT05138835|ACTIVE_COMPARATOR|Group 1|Subjects will receive BTX in the glabella and forehead regions, using a traditional injection technique commonly utilized in aesthetic medicine. The traditional injection technique will deposit the neurotoxin into the targeted muscles; with up to 24 units being injected into the forehead and 20 units in the glabella.
62272202|NCT05138835|EXPERIMENTAL|Group 2|Subjects will receive the traditional, deep injection technique, in addition to a superficial intradermal injection technique, which uses micro-aliquots of toxin. The superficial technique will deposit 0.1 units of toxin at 5mm intervals, at the level of the deep dermis.
62272203|NCT05691855|EXPERIMENTAL|89Zr-NY009|
62272204|NCT04901910|EXPERIMENTAL|Physical Activity (PA) Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
62634870|NCT03539978||SM-THINk Unit|Two of the three inpatient floors will use the SM-THINk enhanced discharge method. This is part of a clinical practice change and not for research. Parents will complete a questionnaire at the time of the patient's discharge from the hospital.
62272205|NCT04901910|EXPERIMENTAL|Verdi plus PA Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
62272206|NCT04901910|NO_INTERVENTION|Attention-Control condition Social Media Group|This will be an 8 week Social Media Group available to the participant with social media topics.
62272207|NCT02950220|EXPERIMENTAL|Arm 1|
62272208|NCT04697407|EXPERIMENTAL|MS Patients|Patients with MS at any stage and for any type of MS : MS at the onset of the disease, Clinically isolated syndrome (CIS), Relapsing-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS)
62272209|NCT04697407|ACTIVE_COMPARATOR|non MS Patients|Patients with a neurological and immunological disease except MS.
62272210|NCT04697407|ACTIVE_COMPARATOR|Healthy volunteers|
62272211|NCT04011865|ACTIVE_COMPARATOR|Robotic-assisted surgery|
62272212|NCT04011865|SHAM_COMPARATOR|Laparoscopic surgery|
62272213|NCT04467307|ACTIVE_COMPARATOR|Foreign body aspiration.|Patients undergoing bronchoscopy with suspicion of foreign body aspiration. There is a foreign body in the bronchoscopy performed on these patients and it is the treated group.
62272214|NCT04467307|ACTIVE_COMPARATOR|Group with no foreign body aspiration|Patients undergoing bronchoscopy with suspicion of foreign body aspiration, but there is no foreign body in bronchoscopy.
62067261|NCT00878332||partially edentulous patients|"Adult (post growth period) patients who are interested in fixed dental rehabilitation (non- removable denture) by dental implants.~Partially edentulous patients with insufficient bone height for dental implant insertion."
62067262|NCT05942079||group receiving reiki|Individuals who will undergo Reiki for 12 weeks
62067263|NCT05942079||control group|control group
62067264|NCT02712398|EXPERIMENTAL|Phasix™ ST|Subjects treated with Phasix™ ST mesh
62067265|NCT01617317|ACTIVE_COMPARATOR|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
62067266|NCT01617317|EXPERIMENTAL|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)
62453336|NCT00954967|EXPERIMENTAL|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
62453337|NCT05458609|ACTIVE_COMPARATOR|Lemborexant plus Naltrexone|10 milligrams of Lemborexant will be given daily at nighttime and 50 milligrams of Naltrexone will be given daily for a total of 4 weeks
62634871|NCT03539978||Control Unit|One of the three inpatient floors will use the usual discharge method. Parents will also complete a questionnaire at the time of the patient's discharge from the hospital.
62067267|NCT05164497|EXPERIMENTAL|Deliberate practice training|The experimental condition consists of deliberate practice training of non-specific psychotherapy skills using role-play and Theravue, an online skill-building system with therapy videos.
62067268|NCT05164497|ACTIVE_COMPARATOR|Theoretical teaching|The control condition will consist of theoretical teaching of non-specific psychotherapy skills.
62067269|NCT06546553|EXPERIMENTAL|Part 1A: PF-07826390 Monotherapy|PF-07826390 monotherapy at prescribed dose and frequency in 28-day cycles
62067270|NCT06546553|EXPERIMENTAL|Part 1B: PF-07826390 + sasanlimab|PF-07826390 + sasanlimab at prescribed dose and frequency in 28-day cycles
62067271|NCT06546553|EXPERIMENTAL|Part 2A (Arm 1): PF-07826390 + sasanlimab|PF-07826390 + sasanlimab dose expansion in NSCLC 2L+ at prescribed dose and frequency in 28-day cycles
62453338|NCT05458609|PLACEBO_COMPARATOR|Placebo plus Naltrexone|10 milligrams of placebo will be given daily at nighttime and 50 milligrams of Naltrexone will be given daily for a total of 4 weeks
62453339|NCT05583812|EXPERIMENTAL|SAD Dose 1|Subjects will receive FB2001 or placebo for inhalation once on DAY 1
62634872|NCT04494269|ACTIVE_COMPARATOR|Subjects with normal hepatic function|Single dose of Tegoprazan 50mg
62634873|NCT04494269|EXPERIMENTAL|Subjects with mild hepatic impairment|Single dose of Tegoprazan 50mg
62634874|NCT04494269|EXPERIMENTAL|Subjects with moderate hepatic impairment|Single dose of Tegoprazan 50mg
62067272|NCT06546553|EXPERIMENTAL|Part 2A (Arm 2): PF-07826390 + sasanlimab|PF-07826390 + sasanlimab dose expansion in MSS CRC 2L+ at prescribed dose and frequency in 28-day cycles
62067273|NCT06546553|EXPERIMENTAL|Part 2A (Arm 3): PF-07826390 + sasanlimab|PF-07826390 + sasanlimab dose expansion in RCC 2L+ at prescribed dose and frequency in 28-day cycles
62067274|NCT06546553|EXPERIMENTAL|Part 2B: PF-07826390|PF-07826390 dose expansion in NSCLC 2L+ at prescribed dose and frequency in 28-day cycles
62067275|NCT06546553|EXPERIMENTAL|Part 2C: PF-07826390 + SOC|PF-07826390 + SOC (anti-PD-1 + platinum -based chemo) dose expansion for a PDx-naive NSCLC 1L at prescribed dose and frequency in 28-day cycles
62067276|NCT03311022|EXPERIMENTAL|Treatment 1|One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.
62067277|NCT03311022|ACTIVE_COMPARATOR|Treatment 2|One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.
62067278|NCT03752710||Acute primary angle closure|
62067279|NCT03752710||Acute secondary angle closure induced by LS|
62067280|NCT03752710||Cataract|
62067281|NCT03752710||Primary chronic angle closed glaucoma|
62453340|NCT05583812|EXPERIMENTAL|SAD Dose 2|Subjects will receive FB2001 or placebo for inhalation once on DAY 1
62634875|NCT04494269|EXPERIMENTAL|Subjects with severe hepatic impairment|Single dose of Tegoprazan 50mg
62634876|NCT03555487|EXPERIMENTAL|18F-choline PET|PET/CT
62067282|NCT05114694|EXPERIMENTAL|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
62067283|NCT05114694|PLACEBO_COMPARATOR|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
62067284|NCT02341287|ACTIVE_COMPARATOR|Warming hydrogel glove, then non-thermal glove|In the first two-week period, subjects will wear a warming hydrogel glove. In the second two-week period, subjects will wear a non-thermal glove. Also a actigraph to monitor sleep latency.
62067285|NCT02341287|PLACEBO_COMPARATOR|Non-thermal glove, then warming hydrogel glove|In the first two-week period, subjects will wear a non-thermal glove. In the second two-week period, subjects will wear a warming hydrogel glove. Also an actigraph to monitor sleep latency.
62272215|NCT04931992||Molecular relapse|Confirmed molecular relapse, without overt cytological relapse
62272216|NCT04931992||Cytological relapse|Overt cytological relapse, without prior molecular relapse
62272217|NCT04931992||Persistent responders|No molecular or cytological relapse during follow-up
62272218|NCT06194773|EXPERIMENTAL|Totalfil|
62067286|NCT03088358|EXPERIMENTAL|TeaRx 50 mg|TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)
62067287|NCT03088358|EXPERIMENTAL|TeaRx 100 mg|TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
62272219|NCT06194773|EXPERIMENTAL|NeoSealer|
62272220|NCT06194773|ACTIVE_COMPARATOR|AH-Plus|
62272221|NCT03958552|NO_INTERVENTION|Standard Care|Participants will receive the standard Medicare Skilled Nursing Facility care.
62272222|NCT03958552|EXPERIMENTAL|Palliative Care Consult|Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
62272223|NCT06222840||Arm 1|cases with SYN1 gene mutation
62272224|NCT06222840||Arm 2|control cases
62272225|NCT05828693|EXPERIMENTAL|Experimental group|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
62272226|NCT05828693|OTHER|Waiting group with subsequent intervention|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
62067288|NCT03088358|EXPERIMENTAL|TeaRx 150 mg|TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
62067289|NCT03088358|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)
62067290|NCT06062901|EXPERIMENTAL|Health services research (Survivorship ECHO)|Participants attend 6 sessions of Survivorship ECHO educational intervention over 1 hour each, every 2 weeks for 12 weeks. Participants may optionally participate in a one-on-one interview to give feedback about the sessions over 30 minutes.
62067291|NCT06561230||Human + AI|
62088239|NCT05250479|EXPERIMENTAL|"experimental group mindfulness education"|mindfulness education 44 pregnant women will receive mindfulness training
62272227|NCT02852512|ACTIVE_COMPARATOR|Laparoscopic sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be laparoscopic
62634877|NCT00929838|EXPERIMENTAL|Diabetes Knowledge/Information Arm|Subjects randomized to the diabetes knowledge/information arm will complete 12 diabetes education modules over a 12-week period. The educational materials were developed based on guidelines for diabetes education by the American Diabetes Association. The content is based on the principles of the Adult Learning Theory. The information is designed to be relevant, person centered, and presented in a non-threatening manner. The modules are designed to be delivered via telephone in 10-15 minutes, so that the maximum contact time per telephone call including introduction and closing would not exceed 30 minutes.
62634878|NCT00929838|EXPERIMENTAL|Motivation/Behavioral Skills Arm|The motivation/behavioral skills intervention consists of patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks. The behavioral skills training will be focused on 4 behaviors - physical activity, diet, medication adherence, and glucose self-monitoring. Guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks (4 behaviors over 12 weeks).
62634879|NCT00929838|EXPERIMENTAL|Combined Intervention Arm|The combined intervention group will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The behavioral skills training will be focused on 4 behaviors and guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks. The combined intervention group telephone sessions will last for 30 minutes.
62634880|NCT00929838|SHAM_COMPARATOR|Usual Care Arm|The usual care group will receive weekly telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention. Patients in the usual care group will continue to receive any usual diabetes education provided by the clinic staff; however, they will not receive targeted diabetes knowledge/information, activation, empowerment, or behavioral skills training.
62634881|NCT00320242|ACTIVE_COMPARATOR|1 mo baseline|1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
62634882|NCT00320242|NO_INTERVENTION|2 month baseline|Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo
62634883|NCT04658797|ACTIVE_COMPARATOR|Single Vision Spectacle for Vision correction|Single Vision Spectacle
62634884|NCT04658797|EXPERIMENTAL|somofilcon A Daily disposable contact lenses|Daily disposable contact lenses
62634885|NCT05411835|ACTIVE_COMPARATOR|Nutrition Ketogenic Supplement|The Ketone pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains a mix of D-beta-hydroxybutyrate salts, flavors and stevia.
62634886|NCT05411835|SHAM_COMPARATOR|Isocaloric Placebo Supplement|The maltodextrin pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains an isocaloric amount of maltodextrin, flavors and stevia similar to the ketone beverage.
62634887|NCT02805296|ACTIVE_COMPARATOR|Double light|"High-intensity phototherapy with blue LED light from above combined with a fiber optic, blue LED blanket from below.~Intervention: Light irradiance: 66 µW/cm2/nm + 39 µW/cm2/nm"
62634888|NCT02805296|ACTIVE_COMPARATOR|Single light|High-intensity phototherapy with blue LED light from above. Intervention: Light irradiance: 66 µW/cm2/nm
62634889|NCT02214342|EXPERIMENTAL|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
62634890|NCT02214342|NO_INTERVENTION|Control|The control group will keep their normal activity without receiving any intervention.
62634891|NCT01189877|EXPERIMENTAL|pO2 measurements|In patients meeting eligibility requirements outlined below, comparisons will be made between direct pO2 measurements using a tissue hypoximeter and IHC-assessed expression of hypoxia related proteins (HIF-1α, VEGF, CA IX and GLUT-1) in both normal and tumor tissue.
62067292|NCT00762840|EXPERIMENTAL|Apexum|the tooth is treated by a standard root canal treatment, supplemented by Apexum Ablator protocol, in which the periapical lesion tissue is minced and removed through the root canal, in a minimally invasive fashion.
62453341|NCT05583812|EXPERIMENTAL|MAD Dose 1|Subjects will receive FB2001 or placebo for inhalation twice daily during the dosing period
62453342|NCT05583812|EXPERIMENTAL|MAD Dose 2|Subjects will receive FB2001 or placebo for inhalation twice daily during the dosing period
62067293|NCT00762840|ACTIVE_COMPARATOR|Control|the tooth is subject to conventional endodontic procedure alone, (standard root canal treatment)
62067294|NCT01408758|OTHER|VCRT|This group will have 2 visits with a study physician in addition to using the VCRT.
62067295|NCT01408758|OTHER|no VCRT|This group will have 2 visits with study physician only, no VCRT.
62453343|NCT00806832||Medical clowns treatment|Patients scheduled for an elective cataract surgery will receive pre-operative conventional treatment and in addition will be exposed to medical clowns effect
62453344|NCT00806832||Conventional treatment only|Patients scheduled for elective cataract surgery will receive only conventional pre-operative treatment
62453345|NCT05476575|EXPERIMENTAL|Hydrogen inhalation group|Patients allocating to this group received hydrogen inhalation (4% hydrogen given via nasal cannula) with other normal intraoperative care throughout the whole procedure.
62067296|NCT03150927|EXPERIMENTAL|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
62067297|NCT03150927|PLACEBO_COMPARATOR|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
62272228|NCT02852512|ACTIVE_COMPARATOR|Robotic assisted Sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be robotic assisted
62272229|NCT02085434|EXPERIMENTAL|FITLINE practice-based referral program|
62272230|NCT02085434|NO_INTERVENTION|Contemporaneous control|
62634892|NCT00926757|EXPERIMENTAL|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
62634893|NCT00926757|ACTIVE_COMPARATOR|Therapeutic arm|In patients with HBV reactivation and ALT flare \> 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission
62634894|NCT05022277|EXPERIMENTAL|Phone-based intervention Plus SMS messages|
62272231|NCT01981642|EXPERIMENTAL|Patients with a LVAD implanted.|Recording of LVAD data during routine visits and daily life. Recording of daily activity using wristwatch accelerometers.
62634895|NCT05022277|EXPERIMENTAL|SMS messages only|
62634896|NCT05022277|NO_INTERVENTION|Control|
62634897|NCT01261390|PLACEBO_COMPARATOR|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide \~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
62272232|NCT04385654|EXPERIMENTAL|Neoadjuvant toripalimab plus axitinib|Toripalimab (240 mg,ivgtt,q3w) combined with Axitinib (5 mg,po,bid) was treated for 6 weeks and underwent surgery within 2-4 weeks
62272233|NCT04849039||Mechanicaly ventilated adult patients for non-pulmonary conditions|
62272234|NCT06266143|EXPERIMENTAL|Experimental group|Y101D combined with Gemcitabine and Nab-Paclitaxel
62287016|NCT05774327|EXPERIMENTAL|Foam Roller+Foot Core Exercises Group|Participants in the foam roller+exercise group underwent foam roller application, which is a self-myofascial release method, 2 days a week for 6 weeks in addition to exercises. Medium-hard foam rollers were used in the applications. Foam roller application was performed on thoracolumbar fascia, iliotibial band, hamstring, gastro-soleus, peroneals and plantar fascia for 60 seconds on each region. A metronome was used to determine the rhythm during foam roller application. The rhythm of the metronome was set to 60 beats per minute (60 rpm). When determining the amount of load on the tissue, the participants were told to give the maximum amount of load possible.
62272235|NCT04740476|EXPERIMENTAL|STK-001 multiple dose levels|Enrollment of patients after completion of Study STK-001-DS-101 or Study STK-001-DS-102 if eligible. Patients will receive IT administration of study drug STK-001 at the dose level they received while participating in Study STK-001-DS-101 or STK-001-DS-102, or at a dose level recommended by the Safety Monitoring Committee (SMC).The highest dose administered in this study may not exceed that which has already been evaluated in an STK-001 Phase 1/2 study, and doses above 45 mg/dose in this study require approval from the Food and Drug Administration (FDA). Patients will initially receive 3 doses, one every approximately 4 months (16 weeks). Patients who are tolerating treatment may continue treatment with doses approximately every 4 months, with an End of Study/Follow-up Visit 24 weeks after the last dose of study drug. Patients who do not continue treatment after the third dose will have a Follow-up Visit (V5) at Week 48 and an End of Study Visit at Week 56.
62067298|NCT02503917||Healthy volunteers|Healthy female adult volunteers
62067299|NCT02503917||Cervical cancer patients|Patients receiving radiotherapy for cervical cancer at the Royal Marsden who will receive a planning CT scan and daily CBCT scanning as part of their treatment.
62067300|NCT04671043|EXPERIMENTAL|CAF+lowCHO|A drink containing caffeine and 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
62634898|NCT01261390|SHAM_COMPARATOR|Sham PAP (Sham)|"In addition to receiving CMT, participants in this treatment arm will receive a sham-CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.~The treatment visit schedule is outlined below.~1. PAP Initial Set-Up~2. 1-week follow up~3. 1-month follow up~4. 3-month follow up~5. 6-month follow up~6. 9-month follow up (will not occur if on a 6-month follow-up protocol)~It is estimated that each in-person follow-up adherence visit with the PAP specialist would last \~30 minutes."
62067301|NCT04671043|ACTIVE_COMPARATOR|10g CHO|A drink containing 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
62067302|NCT04671043|PLACEBO_COMPARATOR|placebo|A drink containing an artificial sweetener (aspartame) dissolved in 200 mL of tap water
62634899|NCT01261390|ACTIVE_COMPARATOR|Active PAP with RT Support (Active-Beh)|"In addition to receiving CMT, participants will receive active-PAP. The treatment visit schedule is outlined below.~1. PAP Initial Set-Up~2. 1-week follow up (FU)~3. 1-month FU~4. 3-month FU~5. 6-month FU~6. 9-month FU (12-month follow-up protocol only)~All visits will take place with a PAP specialist. All follow-up visits will be anchored to the initial PAP set-up visit. At these visits, using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. Each follow-up visit with the PAP specialist will last 30 minutes."
62067303|NCT02882711|EXPERIMENTAL|ketamine|
62634900|NCT01261390|ACTIVE_COMPARATOR|Active PAP with Behavioral Modification (Active+Beh)|"In addition to receiving CMT and active-PAP, participants will have behavioral intervention sessions to promote PAP adherence. The treatment visit schedule is outlined below:~Visits with Behavioral Interventionist (in addition to active-PAP treatment visits):~1. PAP Initial Set-Up (in-person, 1-hr)~2. 1-week follow-up (FU) (in-person, 1-hr)~3. 1-month FU~4. 2-month FU~5. 3-month FU~6. 5-month FU~7. 8-month FU (12-month follow-up protocol only)~All follow-up visits will be anchored to the initial PAP set-up visit. PAP treatment visits will occur as outlined in the active-PAP arm.~All behavioral intervention visits will be 30-min phone calls, unless otherwise noted. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training."
62634901|NCT01468454|EXPERIMENTAL|(18F-DOPA) PET/CT imaging|Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion
62067304|NCT01850368|EXPERIMENTAL|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
62067305|NCT04192474|OTHER|Flexible cystoscopy|50% of the patients undergo flexible diagnostic cystoscopy; 50% of the patients undergo flexible cystoscopy intervention with endoscopic accessories.
62067306|NCT04297787|OTHER|Treatment|The treatment protocol the study team will be following is as follows for all enrolled patients. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
62067307|NCT05415033|OTHER|BREAST-Q|
62272236|NCT01140386||hospital pediatric patients 1/1/2000-12/31/2008 documented VTE|Age \<18 Hospitalized for greater than or equal to 24 hours VTE documented during hospital admission
62272237|NCT02836067|OTHER|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
62067308|NCT01744925|ACTIVE_COMPARATOR|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
62067309|NCT01744925|EXPERIMENTAL|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
62453346|NCT05476575|NO_INTERVENTION|Traditional care group|Patients allocating to this group received traditional intraoperative care.
62453347|NCT02319928|ACTIVE_COMPARATOR|Short-term surveillance|Short-term surveillance. Colonoscopy at 5+10 years in low-risk adenomas or 3+5 years in high-risk adenomas.
62067310|NCT01767935|EXPERIMENTAL|Treatment (cryosurgery and radiation therapy)|Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62453348|NCT02319928|EXPERIMENTAL|Long-term surveillance|Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.
62453349|NCT02805803|OTHER|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:~* SF12~* Beck~* WOMAC"
62453350|NCT01697722||Step-up as FDC ICS/LABA|ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).
62453351|NCT01697722||Step up as separate therapies|ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).
62453352|NCT01697722||Qvar step-up|ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate
62453353|NCT03195985|EXPERIMENTAL|Mindfulness-based Intervention|Mindfulness intervention of 4 weeks
62453354|NCT03195985|ACTIVE_COMPARATOR|"Age Well psycho-education course"|4-week active control condition
62634902|NCT03654729|EXPERIMENTAL|PledOx (2 µmol/kg)|Calmangafodipir (2 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
62634903|NCT03654729|EXPERIMENTAL|PledOx (5 µmol/kg)|Calmangafodipir (5 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
62067311|NCT02421900||group 1|Atrial fibrillation patients
62067312|NCT00201864|EXPERIMENTAL|single-arm study|Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
62634904|NCT03654729|PLACEBO_COMPARATOR|Placebo|Placebo will be given to patients as an intravenous infusion, on top of mFOLFOX6 chemotherapy.
62067313|NCT05533359|ACTIVE_COMPARATOR|Text Messaging (TM) + No Patient Navigation|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~Patients will not receive patient navigation."
62634905|NCT00800111|OTHER|Treatment|Endothelial keratoplasty procedure is performed.
62634906|NCT04999761|EXPERIMENTAL|Cohort A-1|AB122 will be given in participants with advanced or metastatic solid tumor.
62067314|NCT05533359|ACTIVE_COMPARATOR|Text Message (TM) + Request (RPN)|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a TM offering connection to testing and/or vaccination."
62067315|NCT05533359|ACTIVE_COMPARATOR|Conversational Agent (CA)+ No Patient Navigation|"Automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.~Patients will not receive patient navigation."
62453355|NCT05282654|NO_INTERVENTION|Usual Care (Arm 1)|During the 18-month Baseline Period (Arm 1, n=450) patients will be enrolled and receive usual care to develop the initial predictive model.
62634907|NCT04999761|EXPERIMENTAL|Cohort A-2|AB122 will be given in participants with advanced or metastatic solid tumor.
62634908|NCT04999761|EXPERIMENTAL|Cohort B-1|AB122 will be given in combination with TAS-116 in participants with pancreatic ductal adenocarcinoma.
62634909|NCT04999761|EXPERIMENTAL|Cohort B-2|AB122 will be given in combination with TAS-116 in participants with unresectable metastatic MSS/pMMR CRC without liver metastases.
62067316|NCT05533359|ACTIVE_COMPARATOR|Conversational Agent (CA) + Request PN (RPN)|"Automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.~RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a CA offering connection to testing and/or vaccination."
62067317|NCT05107479|EXPERIMENTAL|Treatment|The participants in the treatment group will be invited to participate in a 5-module IVR training covering an overview of available COVID-19 vaccines and best practices for vaccine administration.
62067318|NCT05107479|ACTIVE_COMPARATOR|Control|Participants in the control group will receive the intervention following a one-month delay allowing for a comparison of outcomes with the treatment group.
62067319|NCT04311541||Dexlansoprazole|Participants diagnosed with GERD and initiated treatment with dexlansoprazole MR therapy will be observed prospectively at 150 sites in Russian federation for a period of 2 months.
62067320|NCT01003600||Questionnaire|This study is a cross-sectional survey study to be administered to adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens Cancer Center (QCC) at Queens Hospital between 6 months and 2 years ago and have no evidence of disease at the time of study enrollment.
62067321|NCT05401032|ACTIVE_COMPARATOR|Control arm|tamsulosin 0.4mg (once a day) for 6 months.
62634910|NCT04999761|EXPERIMENTAL|Cohort B-3|AB122 will be given in combination with TAS-116 in participants with unresectable metastatic non-squamous NSCLC without actionable gene alterations.
62634911|NCT04999761|EXPERIMENTAL|Cohort D-1|AB122 will be given in combination with TAS-120 in participants with unresectable metastatic NSCLC with PD-L1 high expression and without actionable gene alterations.
62634912|NCT04999761|EXPERIMENTAL|Cohort E-1|AB122 will be given in combination with TAS-115 in participants with unresectable metastatic NSCLC without actionable gene alterations.
62634913|NCT04999761|EXPERIMENTAL|Cohort E-2|AB122 will be given in combination with TAS-115 in participants with unresectable metastatic ASPS, in those who received or no prior regimen for advanced disease.
62634914|NCT04999761|EXPERIMENTAL|Cohort C-1|AB122 will be given in combination with TAS-102 and Ramucirumab in participants with unresectable or recurrent gastric cancer or gastroesophageal junction cancer.
62634915|NCT04999761|EXPERIMENTAL|Cohort C-2|AB122 will be given in combination with TAS-102 and Bevacizumab in participants with unresectable metastatic CRC.
62634916|NCT04999761|EXPERIMENTAL|Cohort D-2|AB122 will be given in combination with TAS-120, Fluorouracil and Cisplatin in participants with histologically diagnosed advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus with no prior treatment for advanced cancer.
62272238|NCT02836067|OTHER|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:~Questionnaires Blood Draw Bronchoscopy"
62067322|NCT05401032|EXPERIMENTAL|Experimental arm|5-hidroxitriptophan 100 mg (3 times a day) for 6 months.
62067323|NCT03329521|EXPERIMENTAL|Multicomponent intervention|A multicomponent intervention will be provided at chronic kidney disease (CKD) programs.
62067324|NCT03329521|NO_INTERVENTION|Usual Care|CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.
62067325|NCT03690934|EXPERIMENTAL|Fistula-tract laser closure (FiLAC™)|The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.
62067326|NCT03690934|ACTIVE_COMPARATOR|Fistula monopolar cogulation|The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.
62272239|NCT03847987|EXPERIMENTAL|Part 1|Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses.
62272240|NCT03847987|EXPERIMENTAL|Part 2|Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses.
62272241|NCT02448407|EXPERIMENTAL|Platelet rich plasma|Three intraarticular injection, one each fifteen days
62272242|NCT02448407|ACTIVE_COMPARATOR|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1 % solution, administered by intraarticular injection (3 doses, one each fifteen days)
62067327|NCT00762021|EXPERIMENTAL|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT
62067328|NCT00762021|ACTIVE_COMPARATOR|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF
62067329|NCT04778514|OTHER|Sequence 1|This arm is a single, over-encapsulated DPP containing PrEP (200 mg of emtricitabine \[FTC\], 300 mg of tenofovir disoproxil fumarate \[TDF\]) and a COC (30 mcg of ethinyl estradiol \[EE\], 150 mcg of levonorgestrel \[LNG\]) taken once daily for three 28-day cycles followed by PrEP (FTC/TDF) and a COC (EE/LNG) taken daily for three 28-day cycles.
62067330|NCT04778514|OTHER|Sequence 2|This arm is two separate tablets (PrEP \[FTC/TDF\] and COC \[EE/LNG\]) taken once daily for three 28-day cycles followed by single, over-encapsulated DPP containing PrEP (FTC/TDF) and a COC (EE/LNG) taken once daily for three 28-day cycles.
62067331|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
62067332|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
62067333|NCT03243643|EXPERIMENTAL|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
62067334|NCT02040272|EXPERIMENTAL|Surgery|(Extended) pleurectomy decortication
62067335|NCT02040272|NO_INTERVENTION|no surgery|no surgery
62067336|NCT06442540|EXPERIMENTAL|Group 1|"HVLA thrust for SI Joint once per week:~Core stability exercises Intramuscular electrotherapy / 3 sessions per week 10 mins / frequency 100hz muscles( piriformis, erector spinae )"
62067337|NCT06442540|EXPERIMENTAL|Group 2|Hot pack 10 mins soft tissue / myofacial release ( piriformis, erector spinae ) Piriformis stretching core stability exercises
62067338|NCT03038984|EXPERIMENTAL|Every 3 months|screening every 3rd month: (home monitoring: FC and DA)
62067339|NCT03038984|ACTIVE_COMPARATOR|On demand|screening On demand: (home monitoring: FC and DA)
62272243|NCT06409312|EXPERIMENTAL|Akina Cloud|
62272244|NCT05009719|EXPERIMENTAL|Prophylactic|The patients with high risk of relapse of disease and full donor chimerism after allo-HSCT without signs of the disease will be include in this group.
62272245|NCT05009719|EXPERIMENTAL|Preventive|The patients with persisted minimal residual disease or cytogenetic relapse after allo-HSCT will be include in this group.
62272246|NCT04993365|EXPERIMENTAL|Experimental Group|The experimental group is also called the combined immunization group .260 participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.
62272247|NCT04993365|ACTIVE_COMPARATOR|Control Group|The control group is also called the Non-combined immunization group.260 participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
62453356|NCT05282654|NO_INTERVENTION|Usual Care (Arm 2)|During the 30-month Main Trial (RCT) Period, patients will be randomized to usual care (Arm 2, n=425). Data collection for post-discharge AE determination will occur during both periods.
62067340|NCT03967990|EXPERIMENTAL|refined-50/50-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) whole grain cornmeal flour
62067341|NCT03967990|EXPERIMENTAL|50/50-whole-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) whole grain cornmeal flour, followed by (3) refined cornmeal flour
62067342|NCT03967990|EXPERIMENTAL|whole-refined-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) refined cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
62067343|NCT03967990|EXPERIMENTAL|refined-whole-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) whole grain cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
62067344|NCT03967990|EXPERIMENTAL|50/50-refined-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) refined cornmeal flour, followed by (3) whole grain cornmeal flour
62067345|NCT03967990|EXPERIMENTAL|whole-50/50-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) refined cornmeal flour
62272248|NCT03682978|EXPERIMENTAL|Arbaclofen|"Arbaclofen is provided as orally disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg.~A flexible dose titration schedule will be utilized during the first 5 weeks of the Treatment Period. Dosing regimens will be stratified by age. The total up-titration to 15 mg TID or 20 mg TID, and dose adjustment period to the optimal dose will be 35 days. If a participant does not tolerate a dose increase, he or she should return to the previous dose level and must remain at the dose level for the remainder of the Treatment Period. No changes should be made to dosing after 5 weeks, unless for safety.~5-11 years: Week 0 (BID) 5mg; Week 1 (BID) 5mg; Week 2 (TID) 10mg; Week 3 (TID) 10mg; Week 4-16 (TID) 15mg.~12-17 years: Week 0 (QD) 5mg; Week 1 (BID) 10mg; Week 2 (BID) 10mg; Week 3 (TID) 15mg; Week 4-16 (TID) 20mg."
62272249|NCT03682978|PLACEBO_COMPARATOR|Placebo|"Placebo tablets will have similar form, colour, smell and taste compared to the Arbaclofen tablets, and will be provided in non-distinguishable packaging.~Dosage level is n/a."
62272250|NCT04567212||Male-group|in this group we will enroll only male with asthma
62272251|NCT04567212||Female-group|in this group we will enroll only female with asthma
62634917|NCT04999761|EXPERIMENTAL|Cohort D-3|AB122 will be given in combination with TAS-120 and AB154 in participants with histologically diagnosed advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus with no prior treatment for advanced cancer or who have been previously treated with one line of chemotherapy.
62634918|NCT04999761|EXPERIMENTAL|Cohort D-4|"AB122 will be given in combination with TAS-120, Fluorouracil and Cisplatin/Carboplatin in participants with histologically diagnosed advanced or metastatic squamous cell carcinoma of the head and neck (middle pharynx, oral cavity, hypopharynx, larynx) with no prior treatment for advanced cancer.~・The validity of enrollment in the cohort must be confirmed, taking into account the patient background including CPS and the guidelines for head and neck cancer treatment."
62634919|NCT04999761|EXPERIMENTAL|Cohort D-5|"AB122 will be given in combination with TAS-120 and AB154 in participants with histologically diagnosed advanced or metastatic squamous cell carcinoma of the head and neck (middle pharynx, oral cavity, hypopharynx, larynx) with no prior treatment for advanced cancer.~・The validity of enrollment in the cohort must be confirmed, taking into account the patient background including CPS and the guidelines for head and neck cancer treatment."
62634920|NCT04999761|EXPERIMENTAL|Cohort D-6|AB122 will be given in combination with TAS-120, Carboplatin and nab-Paclitaxel in participants with unresectable metastatic squamous NSCLC patients with no prior treatment for advanced cancer.
62634921|NCT04999761|EXPERIMENTAL|Cohort D-7|AB122 will be given in combination with TAS-120, Cisplatin and Gemcitabine in participants with unresectable metastatic adenocarcinoma or adenosquamous biliary tract cancer patients with no prior treatment for advanced cancer.
62634922|NCT04999761|EXPERIMENTAL|Cohort D-8|AB122 will be given in combination with TAS-120, nab-Paclitaxel and Gemcitabine in participants with unresectable metastatic Pancreatic ductal adenocarcinoma patients with no prior treatment for advanced cancer.
62634923|NCT05044247|EXPERIMENTAL|ESP block|ESP block under mixed local anesthetics, betamethasone agent
62634924|NCT06167889||Retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform|A retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform is conducted to collect data and to explore the gender differences and influencing factors of disability and cognitive impairment among the elderly.
62634925|NCT06167889||Retrospective cohort from CLHLS|The data from the China Longitudinal Healthy Longevity Survey (CLHLS) was used to further validate the results.
62634926|NCT00493012|EXPERIMENTAL|vitamin D oil|oil containing vitamin D (Vigantol oil)
62634927|NCT00493012|PLACEBO_COMPARATOR|placebo oil|oil not containg vitamin D (Migliol oil)
62634928|NCT00052078|ACTIVE_COMPARATOR|Sertraline|Participants received sertraline for 12 weeks.
62634929|NCT00052078|ACTIVE_COMPARATOR|CBT|Participants received cognitive behavioral therapy for 12 weeks
62634930|NCT00052078|ACTIVE_COMPARATOR|SRT + CBT|Participants received both sertraline and CBT for 12 weeks.
62634931|NCT00052078|PLACEBO_COMPARATOR|Placebo|Participants received a placebo pill for 12 weeks.
62634932|NCT03868189|EXPERIMENTAL|electroneuromyography|
62634933|NCT03868189|PLACEBO_COMPARATOR|control|
62634934|NCT01166750|EXPERIMENTAL|CD-ROM-treatment|
62634935|NCT01166750|ACTIVE_COMPARATOR|Wait-list Control Group|
62272252|NCT01169077|EXPERIMENTAL|Group I: 0.25 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 0.25 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
62634936|NCT01081782|EXPERIMENTAL|E1|
62634937|NCT01081782|EXPERIMENTAL|E2|
62634938|NCT01081782|EXPERIMENTAL|E3|
62634939|NCT01081782|PLACEBO_COMPARATOR|P|
62634940|NCT04424147|EXPERIMENTAL|HVA treatment|All patients with rrAML are treated with HVA regimen
62272253|NCT01169077|EXPERIMENTAL|Group II: 1.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 1.0 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
62272254|NCT01169077|EXPERIMENTAL|Group III: 4.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 4.0 mg, Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
62634941|NCT00810199|EXPERIMENTAL|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
62272255|NCT00716105|PLACEBO_COMPARATOR|Control|Standard Infant Formula
62272256|NCT00716105|EXPERIMENTAL|Test Product|Infant formula with different level of proteins
62634942|NCT00810199|PLACEBO_COMPARATOR|Tocilizumab + Placebo|Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
62634943|NCT00908414|EXPERIMENTAL|Panel 1: Single Dose Escalation|Panel 1 will receive doses of 40 milligram (mg) (Session Ia), 100 mg (Session IIa), 200 mg (Session IIIa) and 400 mg (Session IVa) of TMC589337 or placebo.
62634944|NCT00908414|EXPERIMENTAL|Panel 2: Single Dose Escalation|Panel 2 will receive doses of 40 mg (Session Ib), 100 mg (Session IIb), 200 mg (Session IIIb) and 400 mg (Session IVb) of TMC589354 or placebo.
62272257|NCT00716105|NO_INTERVENTION|Breast Milk|Breastfeeding reference group
62272258|NCT05929690|EXPERIMENTAL|Standard care plus self-acupuncture|Participants randomised to the self-acupuncture arm will be asked to attend a group workshop. All participants will be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total). Participants will be asked to needle the points 2-3 times a week throughout their cancer treatment and for 3 months post treatment.
62272259|NCT05929690|NO_INTERVENTION|Standard care|Chemotherapy patients allocated to standard care will receive no additional treatments. 'Standard care' for all patients will be consistent with current best practice.
62272260|NCT04899297||Quality of life|
62634945|NCT00908414|EXPERIMENTAL|Panel 3: Multiple dosing|AA mg (Final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. (twice daily) during 7 days (Session Va) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIa).
62634946|NCT00908414|EXPERIMENTAL|Panel 4: Multiple dosing|BB mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session Vb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIb).
62272261|NCT01778114|PLACEBO_COMPARATOR|Placebo + orange juice without vitamin D|Placebo + orange juice without vitamin D
62272262|NCT01778114|EXPERIMENTAL|Placebo + 1000 IU vitamin D3 in OJ|Vitamin D3 in orange juice
62272263|NCT01778114|EXPERIMENTAL|Placebo + 1000 IU vitamin D2 in OJ|Vitamin D2 in orange juice
62272264|NCT01778114|ACTIVE_COMPARATOR|1000 IU vitamin D3 + placebo OJ|1000 IU vitamin D3 + placebo OJ
62272265|NCT01778114|ACTIVE_COMPARATOR|1000 IU vitamin D2 + placebo OJ|1000 IU vitamin D2 + placebo OJ
62272266|NCT00557219|PLACEBO_COMPARATOR|Placebo|Control group receiving placebo
62272267|NCT00557219|EXPERIMENTAL|Ketanserin|patients receiving ketanserin infusion
62272268|NCT00557219|EXPERIMENTAL|Fenoldopam|patients receiving fenoldopam infusion
62272269|NCT04134962||Ankel surgery group|Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.
62453357|NCT05282654|EXPERIMENTAL|Intervention (Arm 3)|During the 30-month Main Trial (RCT) Period, patients will be randomized to the intervention (Arm 3, n=425). Data collection for post-discharge AE determination will occur during both periods.
62067346|NCT01191060|EXPERIMENTAL|lenalidomide, bortezomib with ASCT|"RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)~Autologous stem cell transplant:~Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)"
62067347|NCT01191060|EXPERIMENTAL|lenalidomide, bortezomib without ASCT|RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
62067348|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
62067349|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
62067350|NCT04071977|ACTIVE_COMPARATOR|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
62067351|NCT04071977|PLACEBO_COMPARATOR|Placebo group|This arm will be administered with placebo, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
62067352|NCT05258123|ACTIVE_COMPARATOR|active drug|A fixed titration to 360mg （or nine tables） daily of Ginkgo biloba extract was administered with three times daily dosage throughout the study
62067353|NCT05258123|PLACEBO_COMPARATOR|placebo|A nine tables of placebo were administered with three times daily dosage throughout the study
62067354|NCT04851496||Arm 1: MCI amyloid positive|"* Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62067355|NCT04851496||Arm 2: MCI amyloid negative|"* Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62067356|NCT04851496||Arm 3: CN amyloid positive|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62067357|NCT04851496||Arm 4: CN amyloid negative|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62067358|NCT05890625|EXPERIMENTAL|InT-mAp|
62067359|NCT05890625|ACTIVE_COMPARATOR|Control group|
62067360|NCT03762629|EXPERIMENTAL|Obese intervention group|Obese children were received exercise and diet intervention for 6 weeks.
62067361|NCT03762629|NO_INTERVENTION|Normal weight control group|Normal weight children were recruited as a control group without any intervention.
62067362|NCT01434992||H. pylori gastritis|
62067363|NCT02606955|EXPERIMENTAL|BIA REST|BIA DW assessment
62067364|NCT05196048||No Intervention|No Intervention
62067365|NCT05220007|EXPERIMENTAL|Glaucomatous arm|Mild stage glaucomatous patients age more than 18 years old, a history of uneventful phacoemulsification with MIOL implantation at least 1 month before participation, distant best-corrected visual acuity (BCVA) equal to or better than 20/30, near BCVA at least Jaeger 2.
62067366|NCT05220007|ACTIVE_COMPARATOR|Non-glaucomatous arm|Pseudophakic participants without glaucoma, age more than 18 years old, a history of uneventful phacoemulsification with MIOL implantation at least 1 month before participation, distant best-corrected visual acuity (BCVA) equal to or better than 20/30, near BCVA at least Jaeger 2.
62067367|NCT04342624|EXPERIMENTAL|Cinnamon|Consume 4g of cinnamon capsules daily. Will be randomized, double blind, cross-over to other arm after.
62067368|NCT04342624|PLACEBO_COMPARATOR|Placebo|Consume 4g of placebo daily. Will be randomized, double blind, cross-over to other arm.
62067369|NCT02702700|EXPERIMENTAL|Lipoplatin/Visudyne-mediated photodynamic therapy|200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
62067370|NCT04810039||doctor working in neuro-intensive unite care|doctor predicting the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
62067371|NCT02800603|EXPERIMENTAL|Family Check Up|FCU Intervention: All 280 participants will undergo screening and a baseline FCU assessment before randomization. Once randomized, the FCU group (n=140) will be provided with a feedback visit and up to 6 optional sessions of the EDP curriculum over 16 weeks.
62067372|NCT02800603|NO_INTERVENTION|Community Control|The Community Control group (n=140) will receive general information that includes a list of all the relevant services available in Hamilton. As such, the community control group would be provided with all the information needed to obtain standard care.
62067373|NCT03366220|EXPERIMENTAL|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
62067374|NCT03366220|ACTIVE_COMPARATOR|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
62272270|NCT04134962||control foot group|"Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.~Will be retained only results of normal aligment FAO"
62272271|NCT06351995|EXPERIMENTAL|Primary|Subjects will receive medication administration intravenously, then through a wired ION system of NEO + GEO.
62067375|NCT05309460|ACTIVE_COMPARATOR|Nifedipine|Patients randomized to Nifedipine will be started on Nifedipine XR 30mg BID. Escalation in therapy to be determined by primary provider. Maximum dose of Nifedipine is 120mg daily. All patients will be monitored for signs and symptoms of hypotension or medication side effect- severe HA, orthostasis, syncope.
62067376|NCT05309460|ACTIVE_COMPARATOR|Labetalol|Patients randomized to Labetalol will be started on 200mg TID. Escalation in therapy to be determined by primary provider. Maximum dose is 2400mg in a day. All patients will be monitored for signs and symptoms of hypotension or medication side effect- orthostasis, syncope, bradycardia.
62067377|NCT04407351|OTHER|Arm Green LED light - Red LED light|Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks, the rest of the time indoors is not limited by light. Then crossover to red light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks.
62067378|NCT04407351|OTHER|Arm Red LED light - Green LED light|Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks, and the rest of the time indoors is not restricted by light. Then crossover to green light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks.
62067379|NCT03326947|EXPERIMENTAL|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
62067380|NCT03326947|NO_INTERVENTION|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
62067381|NCT04654247|SHAM_COMPARATOR|Control group|Endoscopists in control group were informed standard quality indicators requirements and the corresponding references during informed consent.
62067382|NCT04654247|EXPERIMENTAL|Feedback group|Endoscopists in feedback group were informed standard quality indicators requirements and the corresponding references during informed consent. In addition to the quality requirements, endoscopists randomized to feedback group received customized quality reports feedback from Endo.Adm weekly.
62067383|NCT06619457|EXPERIMENTAL|Placebo Cream|
62067384|NCT06619457|EXPERIMENTAL|Active Moisturizing Cream|
62067385|NCT06207643|ACTIVE_COMPARATOR|group (A) conventional CEA|this group of patients will be subjected to carotid endarterectomy using the conventional technique of this procedure
62272272|NCT00562549|EXPERIMENTAL|1|SLx-2101
62272273|NCT00562549|PLACEBO_COMPARATOR|2|Matching Placebo Dose
62272274|NCT05042310|EXPERIMENTAL|LY3541860 (Part A)|Single doses of LY3541860 administered intravenously (IV) or subcutaneously (SC).
62272275|NCT05042310|EXPERIMENTAL|LY3541860 (Part B)|Multiple doses of LY3541860 administered either IV or SC.
62272276|NCT05042310|PLACEBO_COMPARATOR|Placebo (Part A)|Single doses of Placebo administered either IV or SC.
62067386|NCT06207643|ACTIVE_COMPARATOR|group (B) Eversion CEA|this group of patients will be subjected to carotid endarterectomy using the Eversion technique of this procedure
62067387|NCT01947595|ACTIVE_COMPARATOR|high risk non-responder, intensified lifestyle intervention|"high risk non-responder:~* A) reduced Insulin secretion (disposition index: (IGI \* ISI-Matsuda)\< 760)~* B) insulin resistance (ISI-Matsuda \< 9,2)~* C) elevated liver fat ( MRT \> 5,56%)~* A+B or A+C or B+C or A+B+C"
62088240|NCT06175663||Cross-sectional study|To examine if there are cerebral abnormalities present following hypertension before MRI markers of SVD have manifested, we will do high-resolution 3T MRI in 100 young (18-40 years) hypertensive adults.
62272277|NCT05042310|PLACEBO_COMPARATOR|Placebo (Part B)|Multiple doses of Placebo administered either IV or SC.
62272278|NCT05848154||ctDNA detection group|ctDNA detection, WES and RNA-seq will be performed on blood samples of all patients in this group.
62272279|NCT05066490|EXPERIMENTAL|endurance exercise|This group received endurance exercises only.
62272280|NCT05066490|EXPERIMENTAL|resistance exersise plus endurance exersise|This group received resistance exercises followed by endurance exercises.
62272281|NCT04485312|ACTIVE_COMPARATOR|caries preventive protocol|preventive protocol for special needs ( tooth brushing , topical fluoride and mouth wash)
62272282|NCT04485312|OTHER|chlorhexidine varnish added to the caries preventive protocol|chlorhexidine varnish preventive caries protocol for special needs
62272283|NCT05725356|EXPERIMENTAL|Experimental|Receiving physical exercise treatment (basic body awareness therapy and neck-specific training exercises) and ergonomic modification
62272284|NCT05725356|OTHER|Control|Receiving ergonomic modification only
62272285|NCT02002975||Pioglitazone 15 to 30 mg|administered orally once daily before or after breakfast for 3 years.
62067388|NCT01947595|ACTIVE_COMPARATOR|hight risk non responder, normal lifestyle intervention|"high risk non-responder:~* A) reduced Insulin secretion (disposition index: (IGI \* ISI-Matsuda)\< 760)~* B) insulin resistance (ISI-Matsuda \< 9,2)~* C) elevated liver fat ( MRT \> 5,56%)~* A+B or A+C or B+C or A+B+C"
62634947|NCT00908414|EXPERIMENTAL|Panel 5: Multiple dosing|CC mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. during 7 days (Session VIa) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXa).
62634948|NCT00908414|EXPERIMENTAL|Panel 6: Multiple dosing|DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
62067389|NCT01947595|ACTIVE_COMPARATOR|Responder, normal lifestyle intervention|"Responder:~* A) reduced Insulin secretion (disposition index: (IGI \* ISI-Matsuda)\< 760)~* B) insulin resistance (ISI-Matsuda \< 9,2)~* C) elevated liver fat ( MRT \> 5,56%)~* No A, only B or C"
62067390|NCT01947595|ACTIVE_COMPARATOR|Responder, single lifestyle advice (control group)|"Responder:~* A) reduced Insulin secretion (disposition index: (IGI \* ISI-Matsuda)\< 760)~* B) insulin resistance (ISI-Matsuda \< 9,2)~* C) elevated liver fat ( MRT \> 5,56%)~* No A, only B or C"
62067391|NCT05236621|EXPERIMENTAL|Permadomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
62067392|NCT02172300|EXPERIMENTAL|Tiotropium|Tiotropium inhalation capsules via HandiHaler
62067393|NCT02172300|PLACEBO_COMPARATOR|Placebo|Placebo inhalation capsules via HandiHaler
62067394|NCT05310201|EXPERIMENTAL|Be Well Care Well|
62067395|NCT05310201|NO_INTERVENTION|Control|
62067396|NCT06440018||Case arm|Participants newly diagnosed with cancer, belonging to one of thirteen distinct cancer types.
62067397|NCT06440018||Control arm|Healthy or benign condition participants with no cancer diagnosis subsequent to routine cancer screening tests.
62067398|NCT01354275|ACTIVE_COMPARATOR|GnRH Agonist|oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
62067399|NCT01354275|ACTIVE_COMPARATOR|GnRH Agonist Arm|Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach \>17 mm hCG will be administered.
62634949|NCT00908414|EXPERIMENTAL|Panel 7: Multiple dosing|EE mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) or YY mg TMC589354 (n=6) b.i.d. or q.d. during 7 days (Session VII) ) plus a single oral dose of 300 mg or 600mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg or 600 mg TMC310911, single dose (Session X).
62067400|NCT01112696|OTHER|Sensor|All subjects that wear sensors (all subjects)
62067401|NCT03584776|EXPERIMENTAL|Virtual Reality Post Spinal Fusion|Patients randomized to the VR group will have the opportunity to utilize VR during the post operative period, and will also experience VR during research visits each day following surgery.
62067402|NCT03584776|NO_INTERVENTION|Standard of Care|Patients randomized to the non-VR condition will experience the usual standard of care following spinal fusion surgery. This will include 15-30 minutes of movie viewing during research visits.
62272286|NCT05618379||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 60 months and the available data is collected retrospectively.
62634950|NCT05969990||case group|100 children with migraine are included into case group and we will collect the blood of them to investigate tryptophan metabolites plasma concentration
62634951|NCT05969990||control group|100 healthy children are included into control group and we will collect the blood of them to investigate tryptophan metabolites plasma concentration
62634952|NCT05996939|EXPERIMENTAL|Unstable shoes|Use of unstable shoes for 8 weeks
62634953|NCT05996939|NO_INTERVENTION|Usual sports footwear|Use of conventional shoes for 8 weeks
62634954|NCT01650467||Healthy controls|60 healthy controls with no hematological pathologies
62634955|NCT01650467||Imatinib optimal response|30 CML patients who are optimal responders to imatinib treatment
62634956|NCT01650467||Imatinib primary resistance|30 CML patients who have primary resistance to imatinib treatment
62634957|NCT00992641|EXPERIMENTAL|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
62067403|NCT03596437|EXPERIMENTAL|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
62067404|NCT03596437|EXPERIMENTAL|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
62067405|NCT05985603|EXPERIMENTAL|CIMT Group|In this group of patients CIMT technique will be used for treatment
62272287|NCT05618379||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 60 months.
62634958|NCT00992641|ACTIVE_COMPARATOR|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
62634959|NCT01587105|NO_INTERVENTION|Control|Usual Care Group
62634960|NCT01587105|EXPERIMENTAL|Comprehensive Care Management Service|Care Coordination through the Comprehensive Care Management Service at Seattle Children's Hospital
62634961|NCT04149717|EXPERIMENTAL|Changes in BP, HR and EKG with Test Solution A and Exercise|"1. Subject baseline HR, BP, EKG recorded.~2. Subject will ingest sucrose (150g):~3. 30 min later, subject will exercise on a treadmill~4. Subjects will return each week to repeat the above procedures with a different test solution."
62634962|NCT04149717|EXPERIMENTAL|Changes in BP, HR and EKG with Test Solution B and Exercise|"1. Subject baseline HR, BP, ECG recorded.~2. Subject will ingest sucrose (150g); caffeine (400 mg)~3. 30 min later, subject will exercise on a treadmill~4. Subjects will return each week to repeat the above procedures with a different test solution."
62634963|NCT04149717|EXPERIMENTAL|Changes in BP, HR and EKG with Test Solution C and Exercise|"1. Subject baseline HR, BP, ECG recorded.~2. Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)~3. 30 min later, subject will exercise on a treadmill"
62634964|NCT04149717|EXPERIMENTAL|Changes in BP, HR and EKG with Test Solution C|"1. Subject baseline HR, BP, ECG recorded.~2. Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)"
62634965|NCT03158168|EXPERIMENTAL|study group|"The first group will receive Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by insulin syringe in the largest wart at the first visit.( Only those patients who showed a positive response to the Candida test antigen).I njections will be repeated for all patients into the same lesion every 3 weeks for three treatment sessions. Follow up for next six months for any recurrences.~Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c."
62634966|NCT03158168|ACTIVE_COMPARATOR|control group|"The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis \[19\]. Injections will be repeated for all patients into the same lesion every 2 weeks for three treatment sessions.Follow up for next six months for any recurrences.~Preparation of 2% zinc sulfate: A measure of 2g. of zinc sulfate powder is to be dissolved in 100 ml of sterile distilled water and autoclaved at 95c for 20 min(20)."
62634967|NCT03235037|OTHER|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
62634968|NCT06179069|EXPERIMENTAL|Dose Escalation: Arm 1|ZL-1310 as a single-agent
62067406|NCT05985603|EXPERIMENTAL|Mirror Therapy Group|patient will perform movements in semi-reclined and sitting positions with the mirror placed between the two lower extremities.
62067407|NCT05761145||Cases - obese with metabolic syndrome|Obese subjects with metabolic syndrome
62067408|NCT05761145||Cases - obese without metabolic syndrome|Obese subjects without metabolic syndrome
62067409|NCT05761145||Controls|Normal weight subjects
62067410|NCT05258747|OTHER|Olaparib tablets, 150 mg, then Lynparza® (olaparib) tablets 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
62634969|NCT06179069|EXPERIMENTAL|Dose Expansion: Arm 1|Dose level 1 established from single-agent dose-escalation
62067411|NCT05258747|OTHER|Lynparza® (olaparib) tablets 150 mg, then Olaparib tablets, 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
62272288|NCT01365559|EXPERIMENTAL|Group A: Carfilzomib & Non-IMiD containing regimen|Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
62272289|NCT01365559|EXPERIMENTAL|Group B: Carfilzomib & IMiD containing regimen.|Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
62272290|NCT05341271|OTHER|digital reminiscence group (DRG)|Experiment group A accepted the planned digital nostalgic group activities using the official account platform of line as a medium, one class per week, 45-50 minutes each time, lasting 8 times.
62634970|NCT06179069|EXPERIMENTAL|Dose Expansion: Arm 2|Dose level 2 established from single-agent dose-escalation
62634971|NCT06179069|EXPERIMENTAL|Dose Escalation: Arm 2|ZL-1310 in combination with Atezolizumab
62634972|NCT00765531||Testing group 1 - Patients with hypercalciuria and their families|7 day diet and 44hr inpatient testing
62272291|NCT05341271|OTHER|general reminiscence group (GRG)|Experiment group B participated in a general traditional nostalgic group, using actual nostalgic objects or utensils to carry out nostalgic activities, one class per week, 45-50 minutes each time, lasting 8 times
62634973|NCT00765531||Testing group 2 - Patients with or without hypercalciuria and their families|7 day diet and outpatient testing
62634974|NCT04752839||Exposed Workers|Workers who have been exposed during COVID 19 pandemic.
62634975|NCT01476995||Controls|Men and women ages 18-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
62634976|NCT01476995||Five Diagnosis Group|Men and women ages 18-85 with at least one active medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
62634977|NCT04226300|EXPERIMENTAL|Laparoscopic-Assisted|Surgeons will place TAP block laparoscopically using a camera prior to beginning a surgical procedure.
62634978|NCT04226300|ACTIVE_COMPARATOR|Ultrasound-Guided|Anesthesiologists will use ultrasound to place TAP block prior to beginning a surgical procedure.
62634979|NCT00642226|ACTIVE_COMPARATOR|1|Grid Laser
62634980|NCT00642226|EXPERIMENTAL|2|Vitrectomy in combination with 20 mg triamcinolone
62634981|NCT03786315||Usual care|Older patients with multimorbidity and the GPs with whom they consult, from across five GP practices in Devon
62634982|NCT03850834|EXPERIMENTAL|Ammoxetine Hydrochloride Enteric-coated Tablets|
62634983|NCT03850834|PLACEBO_COMPARATOR|Placebo Enteric-coated Tablets|
62634984|NCT02638779|EXPERIMENTAL|Blood sampling|Blood sampling will be performed in all patients and healthy volunteers
62272292|NCT01692301|EXPERIMENTAL|LCZ696 (sacubitril/valsartan)|Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
62272293|NCT01692301|ACTIVE_COMPARATOR|Olmesartan|Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
62272294|NCT00663065|EXPERIMENTAL|arm 1|
62272295|NCT03557281|ACTIVE_COMPARATOR|Rifafour e-275|All participants will receive a standard-of-care therapy (rifafour e-275) tablet, orally, once daily from Day 1 to Day 14. Participants will receive the standard treatment for tuberculosis (i.e. rifafour e-275 or equivalent generic alternative) once the study treatment (Day 1 to Day 14) is completed.
62634985|NCT00219947||high risk|Blood draw from individuals known to be or at high risk for HIV-infection
62634986|NCT00219947||diagnosed|Blood draw f rom individuals diagnosed with HIV infection
62634987|NCT00369915|EXPERIMENTAL|Plac/Scop|Placebo then scopolamine
62634988|NCT00369915|EXPERIMENTAL|Scop/Plac|Scopolamine then placebo
62634989|NCT04361799|EXPERIMENTAL|Closed-loop insulin therapy|
62634990|NCT04361799|ACTIVE_COMPARATOR|Standard insulin therapy|
62634991|NCT03161041|EXPERIMENTAL|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
62634992|NCT01836562|OTHER|STEM CELL|intra thecal injection of MNC stem cell therapy
62272296|NCT03557281|EXPERIMENTAL|GSK3036656 1 mg|Participants will receive a loading dose of GSK3036656 3 milligram (mg), capsule, orally on Day 1, followed by maintenance dose of GSK3036656 1 mg, orally, once daily from Day 2 to Day 14.
62634993|NCT04525430|EXPERIMENTAL|Group 1|only childbirth education group
62272297|NCT03557281|EXPERIMENTAL|GSK3036656 5 mg|Participants will receive a loading dose of GSK3036656 15 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 5 mg, orally, once daily from Day 2 to Day 14.
62272298|NCT03557281|EXPERIMENTAL|GSK3036656 15 mg|Participants will receive a loading dose of GSK3036656 30 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 15 mg, orally, once daily from Day 2 to Day 14.
62272299|NCT03557281|EXPERIMENTAL|GSK3036656 30 mg|Participants will receive a loading dose of GSK3036656 75 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 30 mg, orally, once daily from Day 2 to Day 14.
62272300|NCT01272999||1|Otitis media cases
62272301|NCT04273178|EXPERIMENTAL|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
62287017|NCT05774327|EXPERIMENTAL|Foot Core Exercises Group|The foot core exercises in the treatment program for young adults with pes planus were taught to the participants one by one. It was checked that each exercise in the program was performed correctly by the participants. An exercise brochure was prepared and given to all participants so that the participants could learn the exercises better and perform them correctly. The exercise program follow-up of the participants and gradual progression of the difficulty levels were performed by the responsible researcher. The exercises were performed two days a week for six weeks under the supervision of the researcher. On the other days, the exercise program follow-up was checked daily via an online platform.
62287018|NCT00895830|PLACEBO_COMPARATOR|1|
62287019|NCT00895830|EXPERIMENTAL|2|0.3mg dose level
62634994|NCT04525430|EXPERIMENTAL|Group 2|childbirth education and was subjected to a birth plan group
62634995|NCT04525430|NO_INTERVENTION|Group 3|standard care group
62634996|NCT02248064|NO_INTERVENTION|Fixed flow oxygen COPD|The 6MWT will done on the patients usual fixed flow ambulatory oxygen in this arm.
62634997|NCT02248064|EXPERIMENTAL|Auto-titrating arm COPD|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
62634998|NCT02248064|NO_INTERVENTION|Fixed flow oxygen Pulmonary Fibrosis (IPF)|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
62272302|NCT04833283|EXPERIMENTAL|the intervention group intermittent hypoxic-hyperoxic training|"the intervention group is patients performing intermittent hypoxic-hyperoxic training before operation. ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)~Intervention Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s)."
62272303|NCT04833283|PLACEBO_COMPARATOR|the control group|intermittent hypoxic-hyperoxic training control group will be identical to the main group, also underwent four daily procedures before surgery using 40 min training periods with simulation of intermittent hypoxic-hyperoxic trainings by using the same equipment, whereas moistened air will be delivered through a placebo mask
62272304|NCT02767648||cholestasis|infant suffering from cholestasis proteomic urine analysis
62272305|NCT05648435||Sepsis patients|No interventions
62272306|NCT05648435||Healthy controls|No interventions
62634999|NCT02248064|EXPERIMENTAL|Auto-titrating arm Pulmonary Fibrosis (IPF)|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
62272307|NCT05537805|EXPERIMENTAL|proximal tubal occlusion|Infertile patients that were referred to our unit for uni or bilateral proximal tubal occlusion demonstrated by HyFoSy or hysterosalpingography.
62635000|NCT04232007|EXPERIMENTAL|Closed-loop|Closed-loop system to titrate vasopressor during surgery
62635001|NCT02244047|ACTIVE_COMPARATOR|Bifidobacterium breve|Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months
62287020|NCT00895830|EXPERIMENTAL|3|1mg dose level
62287021|NCT00895830|EXPERIMENTAL|4|2mg dose level
62067412|NCT01027364|EXPERIMENTAL|Fixed Weekly Interval|"50 IU/kg rFIXFc via intravenous (IV) injection once every 7 days initially, then at a dose indicated by the participant's baseline pharmacokinetic (PK) assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial weekly dose of rFIXFc (50 IU/kg) were to be made based on baseline PK assessments, occurrence of spontaneous bleeding episodes, and the trough levels, which were to be monitored at Weeks 4, 16, 26, and 39.~Prior to the first dose of rFIXFc, participants in the Sequential PK subgroup were to receive a single dose of 50 IU/kg BeneFIX administered IV in the clinic, followed by PK sampling. A single dose of 50 IU/kg rFIXFc was administered following a 120-hour washout from BeneFIX, followed by PK sampling for a baseline PK profiling. At Week 26 (±1 week) subjects were to receive a single dose of 50 IU/kg rFIXFc for repeat PK profiling."
62067413|NCT01027364|EXPERIMENTAL|Individualized Interval|100 IU/kg rFIXFc via IV injection once every 10 days initially, then at an interval derived from the baseline PK assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial 10-day interval were to be made based on baseline PK assessments and trough levels, which were monitored at Weeks 4, 16, 26, and 39.
62272308|NCT03711643|EXPERIMENTAL|Optimizing pain management|An experimental group receive a standard pain management and benefit the hypnotic mask (Hypnos pro).
62635002|NCT02244047|ACTIVE_COMPARATOR|Placebo|Placebo in the same powder packages as Bifidobacterium breve
62067414|NCT01027364|EXPERIMENTAL|On Demand|20 to 100 IU/kg rFIXFc via IV injection, or the dose indicated by the participant's baseline PK to target a plasma level of 20% to 100%, as needed for the treatment of mild to severe bleeding episodes
62067415|NCT01027364|EXPERIMENTAL|Surgery|The surgical period and dosing are dependent on the type of surgery the participant undergoes. Participants who started the study in one of the other treatment arms prior to surgery will return to the original treatment arm. Participants who joined the study in the Surgery arm will be assigned to one of the other treatment arms following post-operative rehabilitation.
62272309|NCT03711643|ACTIVE_COMPARATOR|standard pain management|
62272310|NCT01158482||IVC Filter Placement or Removal|Patients undergoing IVC filter placement and/or IVC filter removal at Stanford Medical Center.
62272311|NCT06318910|EXPERIMENTAL|CFO with W1|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Root, the forefoot angle will be determined for both the forefoot and rearfoot wedges. Previous studies recommended the posting at 60% of the measured forefoot angle, up to a maximum of 8 degrees, for extrinsic forefoot varus wedge and the posting at 50% of the measured forefoot angle, up to a maximum of 6 degrees, for extrinsic rearfoot varus wedge. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
62287022|NCT00895830|EXPERIMENTAL|5|3mg dose level
62635003|NCT02198729|ACTIVE_COMPARATOR|Endoscopic Mucosal Resection|Participants randomised to this arm will receive standard of care Endoscopic Mucosal Resection for removal of their lesions.
62635004|NCT02198729|EXPERIMENTAL|Endoscopic Submucosal Dissection|Participants randomised to this arm will receive Endoscopic Mucosal Dissection to remove their lesion.
62067416|NCT06162338|EXPERIMENTAL|A Prospective, single-center, open, single-arm study|The study is single-arm. LY-M001 injection is administered by intravenous infusion at a rate of 1 mL per minute.LY-M001 Injection is Clear and colorless liquid.According to the dose cohort of the subject, the required dosage was accurately calculated by the patient's body weight for infusion.
62635005|NCT02736448|EXPERIMENTAL|Arm Lu-PRRT-Cap|Arm Lu-PRRT-Cap: oral low dose of capecitabine in association with Lu-PRRT (at 3.7 Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
62635006|NCT02736448|EXPERIMENTAL|Arm Lu-PRRT|Arm Lu-PRRT: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
62635007|NCT06405178|EXPERIMENTAL|Metformin 1000mg|
62635008|NCT06405178|EXPERIMENTAL|Dapagliflozin 10mg|
62635009|NCT06405178|EXPERIMENTAL|Dapagliflozin-Metformin 10/1000mg|
62635010|NCT06405178|NO_INTERVENTION|control group.|
62635011|NCT01164150|EXPERIMENTAL|Arm B|Radiation: 45 Gy / 25 fractions pelvic radiotherapy using intensity modulated radiotherapy (IMRT) followed by 11 Gy / 2 fractions vaginal vault brachytherapy
62635012|NCT01164150|OTHER|Arm A Control|Radiation: 45 Gy/25 fraction external beam pelvic radiotherapy delivered using a 3-dimensional planned technique followed by 11 Gy / 2 fractions vaginal vault brachytherapy
62635013|NCT01266824|EXPERIMENTAL|Proparacaine|Infants in this group will receive 1 drop of Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) into each eye prior to receiving mydriatic eye drops
62067417|NCT06620159||Covid19(+)|Covid19 patients with a positive PCR test
62635014|NCT01266824|NO_INTERVENTION|Standard of Care|Infants in this arm will not receive Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) prior to mydriatic eye drops.
62635015|NCT01884948|ACTIVE_COMPARATOR|Omegaven™|Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).
62635016|NCT01884948|PLACEBO_COMPARATOR|NaCl 0.9%|100ml of saline is used as a placebo comparator and administered as described above.
62635017|NCT01779557|EXPERIMENTAL|Huaren peritoneal dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
62635018|NCT01779557|ACTIVE_COMPARATOR|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
62635019|NCT02574169|EXPERIMENTAL|Alveolar recruitment maneuvers Group 1|alveolar recruitment maneuvers by CPAP then alveolar recruitment maneuvers by eSigh
62635020|NCT02574169|EXPERIMENTAL|Alveolar recruitment maneuvers Group 2|alveolar recruitment maneuvers by eSigh then alveolar recruitment maneuvers by CPAP
62635021|NCT04256980|EXPERIMENTAL|Pemigatinib in patients with advanced/metastatic or surgically|Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma
62067418|NCT03101124|EXPERIMENTAL|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
62067419|NCT03101124|EXPERIMENTAL|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
62067420|NCT03101124|ACTIVE_COMPARATOR|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
62067421|NCT01375205|ACTIVE_COMPARATOR|Standard of Care|Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
62067422|NCT01375205|EXPERIMENTAL|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
62067423|NCT00421525|OTHER|Multiple Doses|Multiple Dose levels
62067424|NCT05436379|OTHER|TBS|"In this open-label trial, all participants will undergo 2 continuous TBS (cTBS) sessions per visit over 10 days (weekdays, over 2 weeks; total = 20 TBS sessions in 10 visits). The total time of each pair of sessions (including pause between sessions) will be approximately 1 hour, with each session lasting approximately 100 seconds.~There is only 1 group and 1 arm of the study. All participants will receive the treatment."
62067425|NCT04598932||1: Normal Controls|Patients with normal corneas without any prior surgery to serve as the control group
62067426|NCT04598932||2 Keratoconus|Patients with various stages of keratoconus
62067427|NCT04598932||3: LASIK|Patients with normal corneas who are undergoing laser in situ keratomileusis (LASIK)
62067428|NCT04598932||Group 4: PRK|Patients with normal corneas who are undergoing photorefractive keratectomy (PRK)
62067429|NCT04598932||5: SMILE|Patients with normal corneas who are undergoing small incision lenticular extraction (SMILE)
62635022|NCT06107647|EXPERIMENTAL|GRUP DA|Patients who will be given low-flow anesthesia during the operation and will be heated with an active air blower heater.
62635023|NCT06107647|EXPERIMENTAL|GRUP YA|Patients who will be given high current anesthesia during the operation and will be heated with an active air blower heater.
62635024|NCT06107647|EXPERIMENTAL|GRUP DR|Patients who will be given low-flow anesthesia during the operation and will be heated with a resistive heater
62067430|NCT04598932||6: CXL|Patients with keratoconus who are undergoing corneal cross-linking (CXL)
62067431|NCT05625581||Glucocorticosteroids combined with Cyclophosphamide Group|"Glucocorticoid: 0.5-1.0 mg/kg/d prednisone (or other glucocorticoids of equivalent dose) for 1 month (visit V2-V3), then reduced by 5 mg every 2 weeks, and maintained at 5-10 mg/day to visit V8.~Cyclophosphamide: intravenous infusion, once a month, 0.5-1g/m2 each time, 6 times in total, until the end of visit V7."
62635025|NCT06107647|EXPERIMENTAL|GRUP YR|Patients who will be treated with high-flow anesthesia and heated with a resistive heater during the operation
62635026|NCT05609396|NO_INTERVENTION|Usual care|Standard reminder letter only
62635027|NCT05609396|EXPERIMENTAL|Enhanced reminder letter only|Behaviorally enhanced reminder letter
62067432|NCT05625581||Glucocorticoids combined with tofacitinib Group|"Glucocorticoid: 0.5-1.0 mg/kg/d prednisone (or other glucocorticoids of equivalent dose) for 1 month (visit V2-V3), then reduced by 5 mg every 2 weeks, and maintained at 5-10 mg/day to visit V8.~Tofacitinib: oral, twice a day, 5mg each time, lasting for 6 months, until the end of visit V8."
62067433|NCT02220296|EXPERIMENTAL|Part 1 insulin 338|
62067434|NCT02220296|PLACEBO_COMPARATOR|Part 1 placebo|
62635028|NCT05609396|EXPERIMENTAL|Usual care plus test kit|Standard reminder letter plus test kit
62635029|NCT05609396|EXPERIMENTAL|Enhanced reminder plus test kit|Behaviorally enhanced reminder letter plus test kit
62635030|NCT02842476||Disposable Sensor|Adhesive based Pulse Oximeter Probes, Model S0136J
62635031|NCT02842476||Reusable Sensor|Reusable Pulse Oximeter Probes, Model S0080D
62635032|NCT02842476||Control Pulse Oximetry|Reference CO-Oximeters ABL80 Flex OSM (Radiometer), # 302125, 307205 IL682 (Instrumentation Laboratories), # 012511B (ILH), #012511A (ILG)
62067435|NCT02220296|EXPERIMENTAL|Part 2 insulin 338|
62067436|NCT02220296|ACTIVE_COMPARATOR|Part 2 insulin glargine|
62067437|NCT03861520||16-24 weeks Pregnant womes|Pregnant Women at (16-24) weeks of gestation for mid trimester anomaly scan with one sonographic fetal soft marker or more.
62635033|NCT05039697|EXPERIMENTAL|NBO group Normobaric Hyperoxia combined with endovascular mechanical thrombectomy|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30minutes after admission) at a ventilation rate of 10L/min using a sealed non-ventilating oxygen storagemask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
62635034|NCT05039697|PLACEBO_COMPARATOR|Control group Inhale air placebo plus endovascular mechanical thrombectomy|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%
62635035|NCT01275144|EXPERIMENTAL|LY2216684+lorazepam, placebo+lorazepam|Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
62635036|NCT01275144|EXPERIMENTAL|Placebo+Lorazepam, LY2216684+Lorazepam|Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
62635037|NCT02668965|NO_INTERVENTION|control|intrauterine infusion with standard embryo culture media 10 microliters before embryo transfer
62635038|NCT02668965|EXPERIMENTAL|intrauterine hCG|intrauterine infusion with hCG (500 IU) 10 microliters before embryo transfer
62635039|NCT05214469||Case Group|Individuals diagnosed with knee-osteoarthritis
62635040|NCT05214469||Control Group|Individuals who do not have a chronic disease and are not diagnosed with osteoarthritis
62635041|NCT05418439|EXPERIMENTAL|Poppi ACV prebiotic soda|Each day in the morning, for lunch, or in the afternoon, participants will drink one 12 fl oz. can of Poppi ACV prebiotic soda.
62635042|NCT02675764|EXPERIMENTAL|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
62635043|NCT02675764|ACTIVE_COMPARATOR|Placebo|"The control group will wear the vibration device with no vibration.~* Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.~* The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
62635044|NCT05436561|EXPERIMENTAL|MBF-RIC|Patients with MBF-RIC as conditioning regimen
62635045|NCT00749593||CaHASE 1|Adults with CAH
62635046|NCT04907214|EXPERIMENTAL|Empagliflozin|Individuals receive empagliflozin 25mg/day orally for 12 weeks
62635047|NCT05304845|EXPERIMENTAL|Cohort 1|Aspirin (substrate), DWP14012 (Perpetrator)
62635048|NCT05304845|EXPERIMENTAL|Cohort 2|DWP14012 (substrate), Aspirin (Perpetrator)
62635049|NCT02232204|ACTIVE_COMPARATOR|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
62088241|NCT06175663||Longitudinal study|In a cohort study, we will examine the effects of an increase and decrease in blood pressure on the brain. For this analysis, we will include hypertensive patients that are referred to the Radboudumc Department of Internal Medicine for a diagnostic work up on the cause(s) of their hypertension. The diagnostic procedure entails withdrawal of antihypertensives for approximately four weeks, as per the routine diagnostic protocol to allow for diagnosis of the cause of hypertension, and subsequent restart of treatment until the target blood pressure is reached (normotension). Measurements are performed just before antihypertensive medication is withdrawn (baseline), approximately four weeks after withdrawal (T=1), once patients have reached their target blood pressure and blood pressure is stable, estimated to occur within 2-4 months (T=2) and approximately 1 year after T=2 (T=3).
62635050|NCT02232204|NO_INTERVENTION|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive CBT-I-ICD.
62635051|NCT04678843|EXPERIMENTAL|Virtual Family-Based Treatment|Family-based treatment is the gold standard treatment for youth and adolescents with anorexia nervosa. A therapist works with the family to help parents take charge of the process of re-feeding their child, and with progress this control is gradually given back to the youth/adolescent. Other developmental issues are discussed in order to help the youth/adolescent get back to normal development.
62635052|NCT03972215|EXPERIMENTAL|Berberine treatment|
62635053|NCT03972215|PLACEBO_COMPARATOR|Placebo control|
62635054|NCT00379561|EXPERIMENTAL|Intervention PSA-PAH1|Determination of the therapeutic activity of different concentrations of PSA-PAH1 at increasing doses of per gram of prostate.
62067438|NCT01913639|EXPERIMENTAL|FOLFOX Plus Regorafenib|Regorafenib 160 mg daily on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets + mFOLFOX on Day 1 and Day 15 of each cycle. Each cycle consists of 28 days. All patients will receive systemic chemotherapy with the mFOLFOX regimen and regorafenib. The specific version of the FOLFOX regimen used at MSKCC is mFOLFOX6. mFOLFOX6 will be given on Day 1 of each cycle. Patients will receive Oxaliplatin 85 mg/m2 IV (over 120 minutes), leucovorin 400 mg/m2 IV (over 120 minutes), 5-FU 400 mg/m2 IVP, and 5-FU 1200 mg/m2/day CIVI x 2 days, every two weeks. Treatment will be performed on the scheduled day ± 7 days. In case of discontinuation of FOLFOX due to cumulative toxicity and administration as a single agent during the study, regorafenib for patient convenience will be administered 160 mg daily for 3 weeks on/1 week off. The 3 weeks on/1 week off schedule is supported by the single agent regorafenib data in colon cancer and GIST.
62272312|NCT06318910|EXPERIMENTAL|CFO with W2|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Monaghan et al., the forefoot will be posted at 50% of the measured forefoot angle, and the rearfoot will be posted at 20% of the measured rearfoot angle. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
62067439|NCT01719237|ACTIVE_COMPARATOR|Ropivacine and Cholroprocaine mixture|20 ml's of 1% ropivacaine + 10 ml's of 3% 2-chloroprocaine + 0.1 ml of 1 mg/ml epinephrine
62067440|NCT01719237|SHAM_COMPARATOR|Ropivacine only|30 ml syringe with either 20 ml's of 1% ropivacaine + 10 ml's of normal saline + 0.1 ml of 1mg/ml epinephrine
62067441|NCT01862991|PLACEBO_COMPARATOR|Dilapan-Placebo|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
62067442|NCT01862991|ACTIVE_COMPARATOR|Dilapan-Mifepristone|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
62635055|NCT01945944|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
62272313|NCT06318910|ACTIVE_COMPARATOR|CFO without wedge|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
62272314|NCT03530410||Patients with intragastric balloon|Patients who will receive an intragastric balloon placement for weight loss
62635056|NCT01945944|EXPERIMENTAL|Hypertonic Saline|Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
62635057|NCT05255094|EXPERIMENTAL|AK102 regimen 1|
62067443|NCT01862991|EXPERIMENTAL|Mifepristone|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
62088242|NCT02198456||3D echocardiography|
62088243|NCT01759992|NO_INTERVENTION|Control group|Usual care
62067444|NCT03450681|PLACEBO_COMPARATOR|No pulsed radiofrequency|Procedure consists of a mock incision at the pulsed radiofrequency needle insertion site and standard perioperative pain management by the pain clinic (femoral catheter and PCA)
62067445|NCT03450681|EXPERIMENTAL|Pulsed Radiofrequency|Procedure consists in pre-operative pulsed radiofrequency under ultrasound guidance of the saphenous nerve and standard postoperative pain management by the pain clinic (femoral catheter and PCA)
62067446|NCT06417541||Diseased patients with an indwelling central venous catheter|Sub study 1, Diseased patients with an indwelling central venous catheter
62067447|NCT06417541||Living patients with an indwelling central venous catheter|Living patients with an indwelling central venous catheter who are referred to a CT-scan without intravenous contrast
62635058|NCT05255094|EXPERIMENTAL|AK102 regimen 2|
62635059|NCT05255094|PLACEBO_COMPARATOR|Placebo 1|
62635060|NCT05255094|PLACEBO_COMPARATOR|Placebo 2|
62635061|NCT03513666|EXPERIMENTAL|treatment arm|Toripalimab 240 mg or 360 mg Q3W in combination with chemotherapy
62635062|NCT00678015|EXPERIMENTAL|1|
62635063|NCT02576262||HPV-positive women，30-65 years of age|
62635064|NCT01131559|ACTIVE_COMPARATOR|Lisdexamfetamine|Drug
62635065|NCT01131559|PLACEBO_COMPARATOR|Placebo|Drug
62272315|NCT03960281||Single implant crowns in the anterior maxilla|No drugs to be administered. Patients who have had a single implant crown placed since more than one year in the anterior maxilla (second premolar to second premolar) will be invited for a review session for dental examination and to fill the Oral Health Impact Profile (OHIP) questionnaire.
62272316|NCT04623450|EXPERIMENTAL|High Carbohydrate Meal|A smoothie including maltodextrin and low-fat strawberry yoghurt - 289 kcal, 61g carbohydrate, 6.7g protein, 1.9g fat.
62635066|NCT03049228||Type 2 Diabetic Patients|"* Obese (BMI \> 27 kg/m2 \< 35 kg/m2)~* Non-insulin dependent; they must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months~* They should have a (moderately) well-controlled diabetes (defined by a HbA1c\<8%)"
62635067|NCT03049228||Obese Subjects|"* A similar BMI as T2DM patients (BMI \> 27 kg/m2\< 35)~* Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
62635068|NCT03049228||Lean subjects|"* BMI between 20-25 kg/m2~* Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
62635069|NCT02415153|EXPERIMENTAL|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62635070|NCT00576862|EXPERIMENTAL|1|
62635071|NCT03744637|EXPERIMENTAL|Panel A: MK-5475 120 ug/165 ug/240 ug/240 ug/240 ug (Parts 1 and 2)|Participants in Panel A will receive a single inhaled dose of MK-5475 120 ug in Period 1 of Part 1, followed by MK-5475 165 ug in Period 2, followed by MK-5475 240 ug in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2 Period 2, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a right heart catheterization (RHC). In Part 2 Period 3, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a functional respiratory imaging (FRI).
62635072|NCT03744637|EXPERIMENTAL|Panel B: 300 ug/360 ug/360 ug (Part 2)|Participants in Panel B will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
62635073|NCT03744637|EXPERIMENTAL|Panel C: 300 ug/360 ug/360 ug (Part 2, Expansion)|Participants in Panel C will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
62635074|NCT03744637|EXPERIMENTAL|Panel D: 480 ug/120 ug/120 ug (Part 2)|Participants in Panel D will receive a single inhaled dose of MK-5475 480 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 120 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 120 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
62635075|NCT03744637|PLACEBO_COMPARATOR|Placebo (Part 1)|Participants will receive a single inhaled dose of matching placebo in Part 1.
62067448|NCT02548858|ACTIVE_COMPARATOR|Perineorrhaphy|Patients who are randomized to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
62067449|NCT02548858|ACTIVE_COMPARATOR|No Perineorrhaphy|Patients who are randomized not to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
62067450|NCT05660954|EXPERIMENTAL|Cabozantinib, 60 mg|Patients with advanced radioactive-iodine refractory DTC who progressed to previous TKIs (including but not limited to lenvatinib or sunitinib). Patients will have not received previously cabozantinib, selective small-molecule BRAF kinase inhibitors, immune checkpoint inhibitor therapy, or systemic chemotherapy regimens.
62067451|NCT00702416|EXPERIMENTAL|US Group|In this group, the continuous block will be performed under real-time ultrasound (US) guidance.
62067452|NCT00702416|ACTIVE_COMPARATOR|ENS Group|In this group, the continuous block will be performed with an electrical nerve stimulation (ENS) technique.
62067453|NCT00957931|EXPERIMENTAL|Mesenchymal stromal cells|
62067454|NCT05303064|EXPERIMENTAL|Group 1 OLZ/SAM|Fixed dose combination of olanzapine and samidorphan
62067455|NCT05303064|ACTIVE_COMPARATOR|Group 2 Olanzapine|Fixed dose of olanzapine
62067456|NCT05065190|EXPERIMENTAL|nintedanib|
62067457|NCT05065190|PLACEBO_COMPARATOR|Placebo|
62067458|NCT02344394|OTHER|Hybrid Ablation-cryoballoon alone|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation consisting of pulmonary vein isolation with no further catheter ablation. This will be achieved using the nContact and Medtronic cryoballoon
62067459|NCT02344394|OTHER|Hybrid ablation-cryoballoon plus RF|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation. Endocardial portion consists of pulmonary vein isolation using the cryoballoon with further catheter ablation, which may consist of ablation of complex fractionated electrograms and linear lesions. This will be achieved using the nContact and Medtronic Cryoballoon plus Thermocool Catheter.
62067460|NCT03283696|EXPERIMENTAL|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab 15 milligrams per kilogram (mg/kg) on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin and ifosfamide was administered. When the safety of the 15-mg/kg dose of olaratumab was established, a 20-mg/kg loading dose cycle of olaratumab on Days 1 and 8 of a 21-day cycle in Cycle 1 only, followed by 15 mg/kg on Days 1 and 8 of subsequent cycles in combination with doxorubicin and ifosfamide plus mesna, was administered.
62067461|NCT00791323|ACTIVE_COMPARATOR|1|Ketorolac 0.4%
62067462|NCT00791323|ACTIVE_COMPARATOR|2|Mineral Oil Emollient
62067463|NCT02958462|EXPERIMENTAL|Screening (biospecimen collection, NGS analysis)|Participants may undergo blood sample collection, a bone marrow biopsy, a skin punch biopsy, hair follicle collection, a buccal swab, and/or saliva collection for NGS analysis on study. Patients may additionally undergo clinical assessment and may receive genetic counseling on study.
62067464|NCT06205797|EXPERIMENTAL|HU-045 group|"HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each.~HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
62067465|NCT06205797|ACTIVE_COMPARATOR|Xeomin® group|"Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each.~Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
62635076|NCT01528410|EXPERIMENTAL|ALFApump removal of ascites|Removal of ascites
62635077|NCT01528410|ACTIVE_COMPARATOR|Large volume paracentesis for removal of ascites|Removal of ascites
62067466|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
62067467|NCT03841123|EXPERIMENTAL|Intervention|At the maternity wards mothers will receive dietary counseling and leaflets as a reminder to prevent the early introduction of added sugar and ultra-processed foods.
62067468|NCT03841123|NO_INTERVENTION|Control|At the maternity wards mothers assigned to control groups will have all the health assistance related to the maternity routine without any interference from the study protocol.
62067469|NCT01098149|ACTIVE_COMPARATOR|AFB stand alone|Patients are switched in AFB treatment, without blood volume control.
62067470|NCT01098149|ACTIVE_COMPARATOR|BD and BVC|Patients are switched into bicarbonate dialysis with Blood Volume Control
62067471|NCT01394484|EXPERIMENTAL|Arm 1|Four servings of dairy foods per day for 42 days, followed by washout for 42 days, followed by dietary supplements for 42 days
62635078|NCT01747096|EXPERIMENTAL|68-Ga-DOTANOC|
62635079|NCT03113370|EXPERIMENTAL|Fish Oil|4 grams of fish oil per day
62635080|NCT03113370|PLACEBO_COMPARATOR|Placebo|4 grams of olive oil capsules per day
62067472|NCT01394484|EXPERIMENTAL|Arm 2|Dietary Supplements for 42 days, followed by washout for 42 days, followed by 4 servings of dairy foods for 42 days.
62067473|NCT06158763|EXPERIMENTAL|Experimental Group|In the experimental group, a web-based application intervention will be provided.
62635081|NCT03256019|ACTIVE_COMPARATOR|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
62067474|NCT06158763|NO_INTERVENTION|Control Group|In the control group, the patients screened for depression or anxiety received treatment as usual (TAU). TAU consisted of standard care under the responsible family physician. TAU in low-income countries largely consists of pharmacological treatment with anti-depressant medication and follow-up in an outpatient clinic.
62067475|NCT04394507||Fontan Patients|Fontan patients operated at the two centres between 1991 and 2014.
62067476|NCT04394507||Control Group|Age, gender and weight matched healthy controls.
62272317|NCT04623450|EXPERIMENTAL|High Fat Meal|A smoothie including double cream and low-fat strawberry yoghurt - 312 kcal, 13.3g carbohydrate, 7g protein, 25.5g fat.
62635082|NCT03256019|ACTIVE_COMPARATOR|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
62635083|NCT02364687||Participants|Participants will have previously had an MRI scan and will undergo a CT scan.
62635084|NCT00593450|ACTIVE_COMPARATOR|1|Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.
62067477|NCT04250337|EXPERIMENTAL|Lebrikizumab + Topical Corticosteroid|"500 mg Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection of 250 mg Lebrikizumab every 2 weeks (Q2W) from Week 4 until Week 14.~Topical corticosteroid (TCS) will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response."
62453358|NCT02602184|EXPERIMENTAL|AR/101|Topically treatment with AR/101+Standard of Care once daily for up to 21 days. Daily treatment will include application of AR/101 drug to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with AR/101.
62635085|NCT00593450|EXPERIMENTAL|2|Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.
62635086|NCT00593450|EXPERIMENTAL|3|Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
62635087|NCT00593450|EXPERIMENTAL|4|Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
62635088|NCT05438979|PLACEBO_COMPARATOR|Placebo|The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.
62635089|NCT05438979|ACTIVE_COMPARATOR|Calcium Fructoborate|Calcium Fructoborate (CFB), is a proprietary, safe generally-recognized-as-safe (GRAS) supplement. The only content of the supplement is CFB - there are no excipients, binders, or flow agents, nor are there any other materials. 216mg of CFB will be administered daily for 90 days.
62635090|NCT00509899|EXPERIMENTAL|Ruxolitinib|All participants received oral ruxolitinib. Patients began treatment with either 10 mg twice a day (bid), 15 mg bid, 25 mg bid, 50 mg bid, 25 mg once a day (qd), 50 mg qd, 100 mg qd, or 200 mg qd, depending on the time period when they entered the study. The doses were titrated based on efficacy and safety to a maximum of 25 mg bid for patients who entered the study after sufficient dosing information had been obtained to define the maximum dose for patients in the study. Patients could continue receiving treatment indefinitely if receiving benefit at a dose that continues to maintain benefit but does not exceed a maximum dose of 25 mg BID.
62635091|NCT04559477|EXPERIMENTAL|Static extension endurance exercise|static back extension endurance exercise
62635092|NCT04559477|ACTIVE_COMPARATOR|Dynamic extension endurance exercise|dynamic back extension endurance exercise
62272318|NCT04623450|EXPERIMENTAL|High Protein Meal|A smoothie including whey protein and low-fat strawberry yoghurt - 307 kcal, 13.6g carbohydrate, 57g protein, 2.7g fat.
62272319|NCT02517775|ACTIVE_COMPARATOR|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
62635093|NCT04501484|EXPERIMENTAL|Treatment Group|Participants will undergo a thalamotomy contralateral to their previous treatment with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel).
62635094|NCT01570140||Web portal users|T2DM patients in the primary care setting, using the web portal.
62635095|NCT00929994||Exercise|Following a 3 month non intervention period, participants will participate in Cardiac Rehabilitation, carrying out an exercise program which will last 6 months and combine both resistance and aerobic training.
61978686|NCT02646280|EXPERIMENTAL|Massage therapy and contact experience|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading associated with a preparation to the contact phase of the massage using the typical elements of neurocognitive rehabilitation such as motor imagery, dynamic state during which a person mentally simulates an action, and language, necessary to understand the way of perceiving and organizing sensory, cognitive and phenomenological informations by the patients and so to interpretate pain in a more articulate way.
62067478|NCT04250337|PLACEBO_COMPARATOR|Placebo + Topical Corticosteroid|"Two placebo subcutaneous (SC) injections as a loading dose at Baseline and Week 2 followed by a single injection of placebo every Q2W from Week 4 until Week 14.~TCS will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response"
62067479|NCT01876563|ACTIVE_COMPARATOR|diabetes, vitamin D|patients with type 2 diabetes who receive 4000 IU/day vitamin D
62067480|NCT01876563|PLACEBO_COMPARATOR|placebo, diabetes|patients with type 2 diabetes who receive one tab placebo
62067481|NCT04464616|PLACEBO_COMPARATOR|control group|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + normal saline (0.5 ml).
62067482|NCT04464616|EXPERIMENTAL|Dexmedetomidine group):|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 5 μg dexmedetomidine in a volume of (0.5 ml).
62272320|NCT02517775|ACTIVE_COMPARATOR|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
62272321|NCT02517775|ACTIVE_COMPARATOR|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
62635096|NCT05231889|PLACEBO_COMPARATOR|Below the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located below the shoulder
62272322|NCT02517775|ACTIVE_COMPARATOR|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
62272323|NCT02517775|ACTIVE_COMPARATOR|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
62453359|NCT02602184|PLACEBO_COMPARATOR|Placebo|Topically treatment with Placebo + Standard of Care once daily for up to 21 days. Daily treatment will include application of placebo control to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with Placebo.
62453360|NCT05936944||Natural Light|Group of patients enrolled in the first ICU, with natural lighting
62635097|NCT05231889|ACTIVE_COMPARATOR|Above the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located above the shoulder
62635098|NCT01724177|EXPERIMENTAL|Lenalidomide|Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
62635099|NCT03461458|EXPERIMENTAL|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
62635100|NCT03461458|EXPERIMENTAL|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
62635101|NCT06133140||Blinded monitoring|Continuous postoperative vital sign monitoring blinded to clinicians and investigators.
62635102|NCT06133140||Unblinded monitoring|Continuous postoperative vital sign monitoring unblinded to clinicians and investigators.
62635103|NCT06314217|EXPERIMENTAL|Open-label prospective device study|Treatment of previously treated patients diagnosed with diabetic macular edema (DME)
62635104|NCT06392464||Patients with heart valve disease|The same group of patients is evaluated with a pre-test-post-test design with a randomly assigned group, utilizing a longitudinal approach with repeated measures and retrospective validation.
62272324|NCT02517775|PLACEBO_COMPARATOR|Cranberry deprived supplement|Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
62272325|NCT02084277|EXPERIMENTAL|Self-ligating brackets|Several self-ligating brackets are currently FDA-approved but have not been rigorously studied in this malocclusion patient population or in comparison to traditional brackets methods. Unlike conventional brackets, Self-ligating brackets (SLB) are bracket systems, without the wire ligature or elastic ligature, that have a tube-like device build into the bracket to close off the edgewise slot.
62453361|NCT05936944||Artificial Light|Group of patients enrolled in the second ICU, with totally artificial lighting
62453362|NCT06206356|EXPERIMENTAL|PNS Injectrode F1|
62453363|NCT05372081||Patients who will receive digital assistant|Patients will receive digital assistance (in a few words text format) for any symptoms/adverse events they will include in their profile in the digital platform.
62453364|NCT05372081||Patients who will not receive digital assistant|Patients will just include any symptoms/adverse events in their profile in the digital platform.
62453365|NCT02478307|ACTIVE_COMPARATOR|Cognitive Therapy|Eight, 2-hours sessions of group delivered cognitive therapy.
62635105|NCT01999647|ACTIVE_COMPARATOR|Perineural|Patients in this group will receive a perineural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
62635106|NCT01999647|EXPERIMENTAL|Intraneural|Patients in this group will receive an intraneural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
62635107|NCT03327389|EXPERIMENTAL|Dexmedetomidine (Group D)|Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
62635108|NCT03327389|PLACEBO_COMPARATOR|Control (Group C)|0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
62635109|NCT03361241|EXPERIMENTAL|No Physiotherapeutic Intervention|Virtual reality training without physiotherapeutic intervention
62635110|NCT03361241|ACTIVE_COMPARATOR|Physiotherapeutic Intervention|Virtual reality training with physiotherapeutic intervention
61978687|NCT02646280|ACTIVE_COMPARATOR|Massage therapy|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading.
61978688|NCT00597545|ACTIVE_COMPARATOR|Conventional Shunt|"Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt only if it is indicated by EEG, by conventional management."
62635111|NCT01820247|EXPERIMENTAL|enteral nutrition|The patients receive treatment of enteral nutrition only.
62635112|NCT01820247|EXPERIMENTAL|tripterygium glycosides|The patients receive treatment of tripterygium glycosides only.
62635113|NCT01820247|EXPERIMENTAL|tripterygium glycosides and enteral nutrition|The patients receive treatment of tripterygium glycosides and enteral nutrition.
62635114|NCT04997876||Study Group|Biomarkers from presurgical OCTs are diagnosed
62635115|NCT05965596|EXPERIMENTAL|the intervention group|Participants in the intervention group will receive a psychoeducational intervention program
62635116|NCT05965596|SHAM_COMPARATOR|the control group|those in the control group will receive the routine care provided for all gynecological cancer patients in the study setting.
62272326|NCT02084277|PLACEBO_COMPARATOR|Conventional brackets|"The conventional brackets (CB) (edgewise appliance) retain the basic principle design of a rectangular wire in a rectangular slot. Archwire are tied to the bracket once placed in the slot with either elastometric ligation ties (O-rings) or steel ligation."
62272327|NCT03799393|ACTIVE_COMPARATOR|Control Group|"The control group will receive a brief tablet-based questionnaire followed by standard, paper discharge instructions on car safety. Children ≥13 years old and above will answer questions themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
62287023|NCT01439438|ACTIVE_COMPARATOR|Test formulation|Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2
62453366|NCT02478307|ACTIVE_COMPARATOR|Mindfulness Meditation|Eight, 2-hours sessions of group delivered mindfulness meditation.
61978689|NCT00597545|EXPERIMENTAL|Prophylactic Shunt|Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt even when by standard criteria they would not need to receive one.
61978690|NCT05813795|EXPERIMENTAL|C1- XW003 Low Dosage|XW003 with low dosage once weekly
61978691|NCT05813795|PLACEBO_COMPARATOR|C1-Placebo|Matched Placebo once weekly
61978692|NCT05813795|EXPERIMENTAL|C2- XW003 Medium Dosage|XW003 with medium dosage once weekly
61978693|NCT05813795|PLACEBO_COMPARATOR|C2-Placebo|Matched Placebo once weekly
62067483|NCT04464616|EXPERIMENTAL|Dexamethasone group|spinal anaesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 2 mg dexamethasone in a volume of 0.5 ml).
62453367|NCT02478307|ACTIVE_COMPARATOR|Mindfulness-Based Cognitive Therapy|Eight, 2-hours sessions of group delivered mindfulness-based cognitive therapy
62453368|NCT00718679|EXPERIMENTAL|1|Study drug
62453369|NCT00718679|PLACEBO_COMPARATOR|2|Placebo
62453370|NCT01289652||HCV + HIV|
62453371|NCT01289652||HCV|
62272328|NCT03799393|EXPERIMENTAL|Experimental/CIAS Group|"The Experimental/CIAS Group will receive a brief tablet-based questionnaire followed by the intervention - CIAS, an interactive tablet computer program that gives educational information customized to the patient's age and size. Children ≥13 years old will answer questions and interact with the program themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
62272329|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
62453372|NCT06217809|EXPERIMENTAL|EmpowHer|The intervention curriculum is designed to address sexual activity, abstinence, and adulthood preparation topics.
62453373|NCT04868448||Vaccinated participants|Participants who received 1or 2 doses of the Covid-19 vaccines
62635117|NCT01655225|EXPERIMENTAL|Part A: LY3023414 Once Daily|LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
62067484|NCT02635724|EXPERIMENTAL|Peramivir|Single dose 600 mg IV injection
62635118|NCT01655225|EXPERIMENTAL|Part A2: LY3023414 Twice Daily|LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
61978694|NCT05813795|EXPERIMENTAL|C3- XW003 High Dosage|XW003 with high dosage once weekly
62067485|NCT01320735||Advanced PCa|Participants with advanced PCa
62067486|NCT03176446|ACTIVE_COMPARATOR|Control Group|The children anesthesia will be traditional technique
61978695|NCT05813795|PLACEBO_COMPARATOR|C3-Placebo|Matched Placebo once weekly
61978696|NCT01397032|EXPERIMENTAL|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
62453374|NCT04868448||Unvaccinated participants|Participants who have not received any dose of the Covid-19 vaccines
62453375|NCT01220206|PLACEBO_COMPARATOR|Placebo|2 placebo capsules daily
61978697|NCT01397032|PLACEBO_COMPARATOR|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
62067487|NCT03176446|ACTIVE_COMPARATOR|Computerized Group|The children anesthesia will be computerized technique
62067488|NCT03176446|ACTIVE_COMPARATOR|DentalVibe Group|The children anesthesia will be DentalVibe technique
62067489|NCT06199661|EXPERIMENTAL|APEX|Physical exercise intervention based on high-intensity interval training
62453376|NCT01220206|EXPERIMENTAL|one POMx capsule|One POMx capsule, one placebo capsule daily
62453377|NCT01220206|EXPERIMENTAL|2 POMx Capsules|2 POMx Capsules daily
62272330|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
62453378|NCT03031054|EXPERIMENTAL|hyaluronic acid hydrodissection|Ultrasound-guided hydrodissection with 2.5cc hyaluronic acid between carpal tunnel and median nerve.
62067490|NCT04049903|EXPERIMENTAL|MP0310 Part A|Enrollment will follow a standard 3 + 3 dose escalation design. Sequential Cohorts of patients will be dosed until the MTD or unacceptable toxicity is reached. Up to 12 additional patients in total may be included at selected dose levels (up to 3).
62067491|NCT04049903|EXPERIMENTAL|MP0310 Part B|weekly schedule, at least 3 and up to 24 patients evaluable for DLT assessment will be enrolled (1 to 4 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
62453379|NCT03031054|ACTIVE_COMPARATOR|Normal saline hydrodissection|Ultrasound-guided hydrodissection with 2.5cc normal saline between carpal tunnel and median nerve.
62453380|NCT04219202|ACTIVE_COMPARATOR|Proton Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Proton Treatment
62453381|NCT04219202|EXPERIMENTAL|Carbon Ion Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Carbon Ion Treatment
62635119|NCT01655225|EXPERIMENTAL|Part B1 : LY3023414 + Midazolam|LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
62635120|NCT01655225|EXPERIMENTAL|Part B2: LY3023414 + Fulvestrant|LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
62635121|NCT01655225|EXPERIMENTAL|Part B3: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.
62635122|NCT01655225|EXPERIMENTAL|Part B4: LY3023414 + pemetrexed/cisplatin|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.
62635123|NCT01655225|EXPERIMENTAL|Part B5: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.
62635124|NCT01655225|EXPERIMENTAL|Part B6: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.
62635125|NCT01655225|EXPERIMENTAL|Part B7: LY3023414 + Abemaciclib + Letrozole|LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.
62635126|NCT05528172|EXPERIMENTAL|Group A|Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 4 week follow-up period with no treatment.
62635127|NCT05528172|EXPERIMENTAL|Group B|Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 14 week follow-up period with no treatment.
62635128|NCT05528172|PLACEBO_COMPARATOR|Group C|Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 4 week follow-up period with no treatment.
62067492|NCT04049903|EXPERIMENTAL|MP0310 Part C|q3w schedule implementing B-cell depletion, at least 3 and up to 12 patients evaluable for DLT assessment will be enrolled (1 to 2 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
62067493|NCT01382966||Single group|Maintenance hemodialysis patients of minimal 6 months of hemodialysis duration; free of malignancy, infection and autoimmune disease; age over 18 years
62067494|NCT04925674|EXPERIMENTAL|HEC53856|HEC53856 Oral TIW There will be a total of 3 dose cohorts in the hemodialysis: 100mg，150mg，200mg； There will be only one dose cohort in the peritoneal dialysisp:100mg.
62067495|NCT06201221||Single-port Laparoscopy group|Single-port Laparoscopy in the Treatment of Benign Ovarian Tumors in Children and Adolescents
62067496|NCT06201221||Multiport Laparoscopy group|Multiport Laparoscopy in the Treatment of Benign Ovarian Tumors in Children and Adolescents
62272331|NCT02229071|EXPERIMENTAL|Donafenib(200mg)|Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
62272332|NCT02229071|ACTIVE_COMPARATOR|Donafenib(300mg)|Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
62272333|NCT00724997|OTHER|cohort I|dose level I: 6.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
62635129|NCT05528172|PLACEBO_COMPARATOR|Group D|Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 14 week follow-up period with no treatment.
62635130|NCT00613821|EXPERIMENTAL|Lidocaine infusion|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
62067497|NCT06295614|EXPERIMENTAL|All participants|"All participants enrolled in the study will receive the same intervention.~The first year of the study consists of the following phases: enrolment, baseline assessments, surgical implantation of the ARC-IM stimulation device, configuration sessions for stimulation, in-clinic and at-home rehabilitation, and a home-use phase. It is followed by 3 years of safety follow-up.~Assessments will be planned throughout the course of the study and at baseline, the end of the optimization phase, the end of the rehabilitation phase, and after 12 months post-surgery."
62088244|NCT01759992|EXPERIMENTAL|Treatment group|Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
62272334|NCT00724997|OTHER|cohort II|dose level II: 6.7 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
62272335|NCT00724997|OTHER|cohort III|dose level III: 7.0 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
62453382|NCT00846378|EXPERIMENTAL|Post conditioning|After 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. The balloon should be inflated to only occlude the coronary artery. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
62635131|NCT00613821|ACTIVE_COMPARATOR|Paracervical block only|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
62635132|NCT05562245|EXPERIMENTAL|Intervention arm|"1. 1st hour after cesarean section Pre-tests and motivational interviewing-based breastfeeding education~2. Postpartum 5-7th Day: When the mothers come to the hospital for control, a second motivational interviewing session will be held in the breastfeeding room and breastfeeding will be supported when necessary and a second measurement will be made.~3. Postpartum 6th Week: The third motivational interviewing session will be held by going to the mothers' homes, breastfeeding will be supported when necessary and a third measurement will be made.~4. Postpartum 3rd Month: In order to end the motivational interviewing, the fourth motivational interviewing session will be held by going to the mothers' homes and the fourth measurement will be made."
62635133|NCT05562245|NO_INTERVENTION|Control arm|1st hour after cesarean section will be made pre-tests and routine breastfeeding training of the hospital will be given to mothers in the control group. Mothers will be followed up 5-7th days postpartum, postpartum 6th week, and postpartum 3rd month
62635134|NCT06415019|EXPERIMENTAL|BAYHO06689|Topical application of BAYH006689 naproxen 10% topical gel on the intact skin
62272336|NCT00724997|OTHER|cohort IV|dose level IV: 7.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
62272337|NCT00724997|OTHER|cohort V|dose level V: 7.7 log10 TCID50/volunteer, 16 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
62453383|NCT00846378|ACTIVE_COMPARATOR|Usual Care|Usual care for treatment of thrombolysis in myocardial infarction (TIMI) 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
62067498|NCT02492113|EXPERIMENTAL|Patients with BMI > 35|"ICU patients with a BMI \> 35, on pressure support ventilation, scheduled for spontaneous breathing trial for evaluation of extubation~After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs) in randomized order. Either the patient will receive SBT at PEEP = 0-5 cmH2O, with PSV=0 and FiO2 unchanged; or the patient will perform an SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
62067499|NCT05080881|EXPERIMENTAL|Blood draw|All blood draw subjects will have baseline data collected over 15 minutes. The participants with then donate blood. For 15 minutes after the blood donation, the participant will stay in place and will continue to have data collected.
62272338|NCT03041285|EXPERIMENTAL|Group 1 NOX66 400mg and SBRT|Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
62272339|NCT03041285|EXPERIMENTAL|Group 2 NOX66 800mg and SBRT|Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
62067500|NCT02144948|EXPERIMENTAL|E.-coli-Nissle|10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd
62453384|NCT05898568|EXPERIMENTAL|experimental: virtual reality|In addition to routine hand care programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days, 20 minutes) virtual reality based movement therapy program will be applied.
62067501|NCT00941564|EXPERIMENTAL|Commercially available infant formula A|Varying fat blend from comparator product
62067502|NCT00941564|ACTIVE_COMPARATOR|Commercially available infant formula B|
62067503|NCT05232513|EXPERIMENTAL|Hand massage group|The group that received hand massage for 10 minutes before cataract surgery
62067504|NCT05232513|NO_INTERVENTION|Control group|standard care group
62067505|NCT04182880|PLACEBO_COMPARATOR|Placebo|Placebo
62067506|NCT04182880|EXPERIMENTAL|CPL-01|CPL-01
62067507|NCT05730790|EXPERIMENTAL|Cognitive-motor dual task training (DTT)|Participants attended 14 sessions (40 minutes each) of dual task cognitive-motor training, 2 times per week for 7 weeks. Each cognitive-motor training session comprised of performing a dual task activity - gameplay using a virtual reality (VR) system while walking on a treadmill, of progressive difficulty pitched to the participant's performance.
62067508|NCT05730790|ACTIVE_COMPARATOR|Cognitive single task training (CSTT)|Participants attended 14 sessions (32 minutes each) of single task cognitive training, 2 times per week for 7 weeks. Each cognitive training session comprised of game play using a virtual reality (VR) system, of progressive difficulty pitched to the participant's performance
62067509|NCT05730790|ACTIVE_COMPARATOR|Motor single task training (MSTT)|Participants attended 14 sessions (40 minutes each) of single task motor training over a period of 7 weeks. Each motor training session comprised of walking on a treadmill, of progressive difficulty pitched to the participant's performance
62272340|NCT02030743|ACTIVE_COMPARATOR|Visual training|Training in visual attention
62635135|NCT06415019|PLACEBO_COMPARATOR|Placebo|Topical application of placebo gel which contains 0% of naproxen on the intact skin
62635136|NCT06415019|PLACEBO_COMPARATOR|Negative control|Topical application of the sterile 0.9% saline (negative control) on the intact skin
62067510|NCT01760018|EXPERIMENTAL|Desflurane group|
62067511|NCT01760018|ACTIVE_COMPARATOR|TIVA(total intravenous anesthesia) group|
62067512|NCT02590692|EXPERIMENTAL|CPCB-RPE1 treatment|Subretinal implantation of CPCB-RPE1 in dry AMD patients
62067513|NCT06089174|EXPERIMENTAL|Exposed (Runners)|Ultra-endurance runners taking part in an ultra-trail of 72 km, 109 km or 165 km
62272341|NCT02030743|PLACEBO_COMPARATOR|Usual activity|Usual activity
62272342|NCT05846776|EXPERIMENTAL|elderly subjects at risk of fall|
62635137|NCT01153217|EXPERIMENTAL|Abacavir|Switch from tenofovir to abacavir
62635138|NCT01153217|NO_INTERVENTION|tenofovir|Follow same ART regimen
62453385|NCT05898568|ACTIVE_COMPARATOR|control:routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be implemented.
62453386|NCT00235456|ACTIVE_COMPARATOR|80% perioperative oxygen|Perioperative supplemental oxygen: Patients were randomly assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
62067514|NCT06089174|NO_INTERVENTION|Non-exposed (companions)|Runners' companions not running
62272343|NCT02772432|EXPERIMENTAL|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
62272344|NCT02772432|ACTIVE_COMPARATOR|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
62272345|NCT04856709|OTHER|study group|Women with stage 2 to 4 uterine prolapse. BMI from ≤ 35 kg\\m2. Women of any parity including nulliparas will be included. Age of female patients ranges from 20 to 40 years.
62453387|NCT00235456|PLACEBO_COMPARATOR|30% perioperative oxygen|Standard oxygen: Patients were randomly assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
62453388|NCT05364827|EXPERIMENTAL|CTCA prior to CTO PCI|A diagnostic CTCA will be conducted prior to CTO PCI by at a level 2 CTCA trained operator. The results will be discussed with the CTO operator prior to the CTO PCI.
62272346|NCT06096558|ACTIVE_COMPARATOR|Melatonin|
62067515|NCT01293019|EXPERIMENTAL|Experimental|Osteopathic treatment
62067516|NCT01293019|PLACEBO_COMPARATOR|Placebo|Sham osteopathic treatment
62067517|NCT01293019|ACTIVE_COMPARATOR|Usual care|Classic treatment of cystic fibrosis patients
62067518|NCT03350243|EXPERIMENTAL|CCENT Intervention group|Participants will be assigned a dedicated key worker that will support families through the child's first year, in addition to standard medical care, which involves a primary care provider and/or neonatal follow-up at routine times.
62067519|NCT03350243|NO_INTERVENTION|Control group|Participants will receive the standard medical care at their institution, which involves a primary care provider and/or neonatal follow-up at routine times.
62272347|NCT06096558|PLACEBO_COMPARATOR|placebo|
62067520|NCT00332605|EXPERIMENTAL|Naltrexone plus N-Acetyl Cysteine|"Naltrexone tablets~N-Acetyl Cysteine: 600mg tablets, daily"
62067521|NCT00332605|PLACEBO_COMPARATOR|Placebo|"Inactive placebo (sugar pill)"
62067522|NCT02673905|EXPERIMENTAL|N-TEC (tissue engineered product)|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 weeks to allow the cells to produce extracellular matrix containing cartilage specific Proteins. The IMP is implanted in the knee joint and secured by sutures.
62067523|NCT02673905|EXPERIMENTAL|N-CAM (tissue engineered product)|N-Cell activated Matrix (CAM) is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 days only to allow the cells to adhere. The IMP is implanted in the knee joint and secured by sutures.
62067524|NCT04408547||soft catheter|Patients who underwent embryo transfer with a soft catheter
62067525|NCT04408547||stiff catheter|Patients who underwent embryo transfer with a stiff catheter because soft couldn't pass
62067526|NCT05091944|EXPERIMENTAL|intervention|usual care plus web-based birth decision aid
62067527|NCT05091944|NO_INTERVENTION|control|ususal care
62067528|NCT04323228|EXPERIMENTAL|Intervention|the intervention groups will receive daily oral antioxidant supplement enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc.
62067529|NCT04323228|PLACEBO_COMPARATOR|Placebo|Placebo group will receive daily intervention in form of cellulose-containing gelatin capsules with the same color and shape.
62272348|NCT05474300||Covid-19 ARDS patients on PCV mode|No Intervention
62272349|NCT03702998||HIV-infected individuals +/- HBV/ HCV|"1 All HIV-infected individuals followed up in all public HIV clinics with and without HBV and/or HCV co-infection will be included in the analysis.~1.1 Inclusion criteria for HIV-infected individuals with and without HBV or HCV co-infection: 1.1.1 Positive HIV antibody 1.1.2 At least one visit in one of the HIV clinics 1.1.3 Subjects with positive HBsAg and/or anti-HBc will be regarded as having HBV co-infection 1.1.4 Subjects with positive HCV antibody will be regarded as having HCV co-infection"
62067530|NCT03917641|EXPERIMENTAL|Patients after Oculoplastic surgery|"Each participant will use one compression with Khat leaves and another standard compression and will decide on which eye to use which compression.~The compressions will be used for 10 minutes per every waking hour in the first 2 days post-op.~The patient will take pictures of both his eyes in days 1,3 and 7 post operative days."
62067531|NCT02678767|EXPERIMENTAL|HIV+ with neurocognitive disorder|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
62272350|NCT03702998||HBV/HCV mono-infected individuals|"2 All HBV and/or HCV-infected individuals followed up in public hospitals will be identified from the Hospital Authority electronic database.~2.1 Inclusion criteria for HBV/HCV mono-infected individuals 2.1.1 Documented diagnosis of hepatitis B or hepatitis C infection, or 2.1.2 Positive HBsAg and/or anti-HBc, or 2.1.3 Positive HCV antibody, and 2.1.4 Negative HIV antibody result, or no record of HIV diagnosis or anti-retroviral therapy prescription"
62272351|NCT02577861|EXPERIMENTAL|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
62272352|NCT03607864|EXPERIMENTAL|coral bone graft and xenograft|Extraction of upper anterior badly broken teeth with immediate implant placement with the use of coral bone and xenograft as grafting material between the implant and the labial socket bone
62453389|NCT05364827|NO_INTERVENTION|No CTCA prior to CTO PCI|Patients will be listed directly for the CTO PCI procedure without undergoing CTCA prior
62453390|NCT05480722|EXPERIMENTAL|Salt Sensitivity Assessment|1 week high salt diet and 1 week low salt diet
62453391|NCT05480722|EXPERIMENTAL|Functional Magnetic Resonance Imaging|Hypertonic saline infusion perturbation with and without NKCC2 antagonism (furosemide) to examine sodium sensing mechanisms
62272353|NCT02227680|ACTIVE_COMPARATOR|Music Therapy|Patients randomized to the music therapy group will receive 1-3 10-40 minute music therapy sessions during each of the days of their stay on the inpatient unit. Each participant randomized to the music therapy intervention will be given a personalized CD and one portable CD player with headphones which they may keep after the study has ended.
62272354|NCT02227680|ACTIVE_COMPARATOR|Massage Therapy|Patients randomized to the massage therapy group will receive 1-3 10-40 minute massage treatments during each of the days of their stay on the inpatient unit.
62272355|NCT02227680|NO_INTERVENTION|Usual Care|The control group will continue to receive usual care while on the Family Medicine Inpatient Unit.
62272356|NCT04612010|ACTIVE_COMPARATOR|Alpha frequency|Wobble oscillation will revolve the individual alpha frequency
62272357|NCT04612010|ACTIVE_COMPARATOR|Alpha frequency plus|Wobble oscillation will revolve the individual alpha frequency plus 0.5Hz
62272358|NCT04612010|SHAM_COMPARATOR|Theta frequency|Wobble oscillation will revolve the individual theta frequency
62272359|NCT01941407|EXPERIMENTAL|Association eribulin and bevacizumab|Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
62067532|NCT02678767|ACTIVE_COMPARATOR|HIV+ without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
62067533|NCT02678767|ACTIVE_COMPARATOR|HIV- without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
62272360|NCT02097147|EXPERIMENTAL|Vilazodone 20 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days.
62272361|NCT02097147|EXPERIMENTAL|Vilazodone 40 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days, followed by vilazodone 40 mg once daily for 21 days
62272362|NCT02097147|ACTIVE_COMPARATOR|Paroxetine 20 mg|Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days
62272363|NCT02097147|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 35 days
62635139|NCT05044429|EXPERIMENTAL|Intravenous Lidocaine|
62635140|NCT05044429|ACTIVE_COMPARATOR|Transversus abdominis plane (TAP) block|
62635141|NCT05044429|ACTIVE_COMPARATOR|Quadratus Lumborum (QL) Block|
62635142|NCT01617239|EXPERIMENTAL|Group 1|1 x standard dose (0.5 mL) on Day 1, Day 29, and Day 57
62635143|NCT01617239|EXPERIMENTAL|Group 2|1 x double standard dose (1.0 mL) on Day 1 and 1 x standard dose (0.5 mL) on Day 57.
62272364|NCT00455598|PLACEBO_COMPARATOR|A|Sulfonylurea + 100 mg/week ISIS 113715 or placebo
62635144|NCT01617239|EXPERIMENTAL|Group 3|1 x triple standard dose (1.5 mL) on Day 1
62272365|NCT00455598|PLACEBO_COMPARATOR|B|Sulfonylurea + 200 mg/week ISIS 113715 or placebo
62635145|NCT06531902||Patient group|A total of 60 CRC pateints' were enrolled in the study. CRC pateints' were treatment-naïve Egyptian patients' cohort admitted to the Clinical Oncology Clinic, National Cancer Institute (NCI), Cairo University, Cairo, Egypt. Male-to-female 1:1 (30/30) and their age range 24-76 years.
62635146|NCT06531902||Healthy Control|28 age-matched and sex-matched apparently healthy volunteers, randomly selected from subjects enlisted during normal check-up examination or during blood donation. The control group participants were not taking any medication or suffering from any disease. Controls age range is 40-60 years and 13:15 male-to-female.
62635147|NCT04745741||IB-positive group|Patients with level IB metastasis and histologically confirmed positive by biopsy.
62635148|NCT02403011|EXPERIMENTAL|Soft tissue mobilization group|soft tissue mobilization was applied three times in a week and home program exercises were recommended which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
62635149|NCT02403011|EXPERIMENTAL|Home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations were recommended
62635150|NCT02928796||Trainees|Registrar Cardiologists
62635151|NCT02928796||Trainers|Consultant Cardiologists
62635152|NCT05537311|EXPERIMENTAL|Social engagement using VR|Patients will receive social engagement with emphasize on meaningful conversation, cognitive engagement, and emotional support provided by trained research assistant using virtual reality as a vehicle for delivery. Subjects will receive 15-45 minutes of treatment per day for 5 days initiated after respiratory support (Intubation via mask or tube, high-flow nasal cannula) have been weaned to nasal cannula. Experimental group will also receive standard of care
62635153|NCT05537311|NO_INTERVENTION|Control|Control will receive standard of care
62635154|NCT04892732||Budesonide|Reference Group
62635155|NCT04892732||Budesonide-formoterol|Exposure Group
62635156|NCT05332041|EXPERIMENTAL|Predicta Bioactive bulk fil composite restoration|Bioactive bulk fil resin composite dental restoration material
62635157|NCT05332041|ACTIVE_COMPARATOR|High viscosity glass ionomer (Equia Fil)|High viscosity dental restoration material
62635158|NCT04974229||acute non-specific low back pain|patients with acute low back pain of (\< 6 weeks) were consecutively included with or without radiating pain, aged 18 to 60 years with a pain-free episode for at least 3 months before the onset of their current back pain. They were also required to be able to read and understand the Dutch language.
62635159|NCT00447668|EXPERIMENTAL|1|
62635160|NCT00447668|ACTIVE_COMPARATOR|2|Exercise
62635161|NCT00447668|ACTIVE_COMPARATOR|3|Self-care book recommendations
62635162|NCT02768168|EXPERIMENTAL|Group D|40 patients receive dezocine 0.1 mg/Kg
62635163|NCT02768168|PLACEBO_COMPARATOR|Group C|40 patients receive matching placebo （normal saline）
62635164|NCT01976793||patients with major depression|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week
62635165|NCT05550636|EXPERIMENTAL|BI 1015550 + midazolam treatment arm|test and reference treatment arm
62635166|NCT06131450|EXPERIMENTAL|BL-M07D1|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62635167|NCT02434874|EXPERIMENTAL|Immediate Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated immediately.
62635168|NCT02434874|OTHER|Delayed Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated after 90 days.
62635169|NCT04557735|EXPERIMENTAL|Ravulizumab plus Best Supportive Care|Participants will receive ravulizumab plus Best Supportive Care as background therapy.
62635170|NCT06354218|EXPERIMENTAL|Assigned Interventions|Treatment options Serplulimab （4.5mg/Kg every 3 weeks）combined with chemoradiotherapy (Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose 40-60mg BID, and the oral tigio course from Monday to Friday is synchronized with radiation therapy) for the treatment of locally advanced elderly esophageal cancer patients, in which the tigio regimen with good clinical tolerability was selected for chemotherapy to evaluate the short-term efficacy and toxic side effects
62635171|NCT00675987|ACTIVE_COMPARATOR|Losartan|Losartan 100 mg 1 tab po QD
62635172|NCT00675987|PLACEBO_COMPARATOR|Placebo|Placebo 1 tab po QD
62635173|NCT01557478|PLACEBO_COMPARATOR|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
62635174|NCT01557478|ACTIVE_COMPARATOR|Melatonin 20mg|20 mg melatonin gelatin capsule
62635175|NCT00983645|ACTIVE_COMPARATOR|Neoral|Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
62635176|NCT00983645|ACTIVE_COMPARATOR|Prograf|Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
62635177|NCT04058639|EXPERIMENTAL|felt relief|"custom felt relief"
62635178|NCT04058639|ACTIVE_COMPARATOR|treatment as usual|standard treatment usually provided by the Surgical Outpatient Clinic
62635179|NCT01240096|ACTIVE_COMPARATOR|Mirtazapine|mirtazapine 15 mg daily
62635180|NCT01240096|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62635181|NCT01516138|ACTIVE_COMPARATOR|GIK|glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).
62453392|NCT01048320|OTHER|Treatment|Gemcitabine plus Oxaliplatin in combination with imatinib mesylate
62067534|NCT05269784|EXPERIMENTAL|Completely Tubeless Group|minimally invasive lung surgery under ERAS with completely tubeless protocol: no intubation, no urinary catheter, move the chest drainage as fast as possible according the ERAS guideline on the premise of safety.
62453393|NCT05893056|EXPERIMENTAL|Cryoablation combined with Tislelizumab and lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab and Lenvatinib will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62453394|NCT02582970|EXPERIMENTAL|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
62453395|NCT02658084|EXPERIMENTAL|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
62067535|NCT05269784|ACTIVE_COMPARATOR|Partially Tubeless Group|minimally invasive lung surgery under ERAS with partially tubeless protocol.
62067536|NCT00068380|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62067537|NCT05403060|EXPERIMENTAL|Intervention|Educational nutritional intervention, based on the Social Cognitive Theory
62067538|NCT05403060|NO_INTERVENTION|Control|Regular school education, without educational nutritional intervention
62067539|NCT05914025|EXPERIMENTAL|Behavioral Activation Intervention|All individuals enrolled in the study will be assigned to this arm and will receive a brief behavioral activation psychoeducation module among other self-report assessments.
62067540|NCT03321006|ACTIVE_COMPARATOR|Antidepressant (AD) + full amplification hearing aids|Participant will be randomized to active comparator and will receive escitalopram or duloxetine + active hearing aid for 12 weeks.
62453396|NCT02658084|EXPERIMENTAL|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
62635182|NCT01516138|PLACEBO_COMPARATOR|Control|6.12 g/L sodium acetate, 5.85 g/L sodium chloride, 0.3 g/L potassium chloride and 0.33 g/L calcium chloride
62635183|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 \[12 ± 2 weeks\]) with a 10-14 week interval between assessments.
62635184|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
62635185|NCT06320210|EXPERIMENTAL|Children with asthma, parents/guardians of children with asthma, school staff|"Children will be recruited from two University of Chicago Charter elementary schools. Children with a diagnosis of asthma and their parents will be eligible for inclusion in the study and will specifically be targeted for study recruitment. Staff and administrators at each school will also be recruited through in-person, phone, and email communication, primarily through word of mouth and professional development days. UCCS teachers, staff, and administrators will also be included in the program evaluation and we will obtain appropriate consent.~Up to 400 families with a child/children with asthma from two UCCS schools will be added to a registry database. A total of 68 children with a diagnosis of asthma and their parents will be recruited for evaluation of the multi-component program, resulting in a total of 136 children and parents. We will also recruit 24 teachers, staff, and administrators across the two schools to participate in the evaluation of the overall program."
62635186|NCT02248467||eugonadal|50 eugonadal subjects
62635187|NCT02248467||untreated hypogonadal|25 asymptomatic hypogonadal subjects
62635188|NCT02248467||treated hypogonadal|25 symptomatic hypogonadal subjects treated - In the present study, we decided to monitor only sexual symptoms of androgen deficiency due to the fact that testosterone replacement therapy (TRT) should be expected to improve them in the time span until surgery. These patients will be treated with TRT as per clinical practice.
62635189|NCT02708550|EXPERIMENTAL|Participatory Organizational Intervention|Participatory intervention (workshops) with workers, consultants and leaders. The workshops will find solutions for increased use of assistive devices
62635190|NCT02708550|NO_INTERVENTION|Control|This group will go through the same baseline and follow-up tests as the intervention group, but will not receive any intervention.
62635191|NCT02620683|ACTIVE_COMPARATOR|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
62067541|NCT03321006|SHAM_COMPARATOR|Antidepressant (AD) + Low amplification (sham) hearing aids|Participant will be randomized to sham comparator and will receive escitalopram or duloxetine + sham hearing aid for 12 weeks.
62067542|NCT01679301|ACTIVE_COMPARATOR|Continuous dose|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator.
62067543|NCT01679301|EXPERIMENTAL|Pulse dose ('sleep mode')|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator
62067544|NCT03274219|EXPERIMENTAL|bb21217 Experimental Arm|
62067545|NCT02676193|EXPERIMENTAL|Australian Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using standard Australian marketing for three months.
62067546|NCT02676193|EXPERIMENTAL|Blank Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using blank packaging for three months. Blank packaging will indicate participants brand and will not have any brand-related images or labels.
62453397|NCT01271439|EXPERIMENTAL|cetuximab|
62453398|NCT03891719|EXPERIMENTAL|Changes in nose symmetry|- Direct anthropometric assessment (frontal, oblique, lateral and basal views) and three- dimensional observations of the nose preoperatively and postoperatively in order to evaluate the nostril symmetry, the angles, ratios of the nose and its relation to the face.
62453399|NCT02974153|EXPERIMENTAL|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
62067547|NCT02676193|NO_INTERVENTION|American Packs|Participants assigned the nonintervention group will purchase their US brand of cigarettes in the standard American packaging for three months.
62635192|NCT02620683|ACTIVE_COMPARATOR|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
62635193|NCT03562078|EXPERIMENTAL|Tai Chi Quan for Type 2 Diabetes|diabetic patients care education and Tai Chi Quan training, including 10-minute warm-up, 40-minute Tai Chi lesson, and 10-minute cool-down exercise in the training, twice a week for 12 weeks.
62067548|NCT02679521|ACTIVE_COMPARATOR|rESWT|Radial extracorporeal shock wave therapy (rESWT).
62635194|NCT03562078|NO_INTERVENTION|Control Group for Type 2 Diabetes|diabetic patients care education
62635195|NCT03718715||prospective cohort|All participants receive Metformin in accordance to the ordinary therapy practice. They will be part of one subject group/cohort. After onset of metformin treatment the subjects who develop gastrointestinal side effects will be compared with cases without gastrointestinal side effects.
62635196|NCT05467852|ACTIVE_COMPARATOR|Didroxyprogesterone treatment group|Since the first menstrual cycle after surgery, dydrogesterone was administered orally 10mg bid on the 14th to 27th day of each menstrual cycle, planned to be used for 6 menstrual cycles (if the patient conceived naturally during medication, the drug could be stopped), and the patient was instructed to try pregnancy, the observation period was 12 menstrual cycles after surgery.
62635197|NCT05467852|NO_INTERVENTION|control|No medication was used after surgery, and the observation period was 12 menstrual cycles after surgery
62635198|NCT00090896|EXPERIMENTAL|CTLA4-Blocking Monoclonal Antibody|
62635199|NCT06085521|EXPERIMENTAL|LNK01001 Dose A|Participants will receive LNK01001capsule Dose A BID orally for 12 weeks.
62067549|NCT02679521|PLACEBO_COMPARATOR|Placebo|Placebo treatment.
62272366|NCT06098235|PLACEBO_COMPARATOR|Usual diet advice|
62272367|NCT06098235|ACTIVE_COMPARATOR|ORIENT diet intervention|
62272368|NCT01039337|ACTIVE_COMPARATOR|Hip school|This group will receive hip school during the intervention period of 6 weeks.
62635200|NCT06085521|EXPERIMENTAL|LNK01001 Dose B|Participants will receive LNK01001capsule Dose B BID orally for 12 weeks.
62635201|NCT06085521|PLACEBO_COMPARATOR|placebo|Participants will receive a Placebo capsule BID orally for 12 weeks.
62635202|NCT01607593||sertraline (Zoloft)|
62635203|NCT02174224|EXPERIMENTAL|SMC + BI + Case Management|This arm will include all interventions in Standard Medical Care + Brief Intervention Arm. Case management will also be given to this arm. General needs based assessments will be conducted by the outreach worker. These assessments will be done at the hospital or at the youth's home, whichever they prefer. This assessment tool addresses education, vocational training, employment, housing, medical insurance, follow-up care and pro-social activities. Although each youth in this arm will receive the same needs-based assessment, individual youth will have variable needs, which will guide each unique and individualized case management plan.
62272369|NCT01039337|ACTIVE_COMPARATOR|Hip School and Manual Treatment|This group receives both hip school and manual treatment during the 6 weeks.
62272370|NCT01039337|ACTIVE_COMPARATOR|Minimal control intervention|An information leaflet including exercises.
62272371|NCT03504878||Patients undergoing laparoscopic appendectomy|Appendix removal via scope.
62272372|NCT03504878||Patients undergoing open appendectomy|Open operation for removal of appendix
62453400|NCT02974153|EXPERIMENTAL|ALD403 (Eptinezumab) Dose Level 2|ALD403 (Eptinezumab) Dose Level 2 (IV)
62635204|NCT02915159|EXPERIMENTAL|Abatacept|Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
62635205|NCT02915159|PLACEBO_COMPARATOR|Placebo|Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
62272373|NCT02230631||Part 1 (retrospective cross-sectional evaluation)|
62453401|NCT02974153|PLACEBO_COMPARATOR|Placebo|Placebo (IV)
62453402|NCT04172298|PLACEBO_COMPARATOR|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
62635206|NCT04758013|EXPERIMENTAL|Laparoscopic gastric surgery with Epidural injection|Patients with laparoscopic gastric surgery who received epidural injection through an thoracic epidural catheter.
62635207|NCT04758013|EXPERIMENTAL|Laparoscopic gastric surgery without Epidural injection|Patients with laparoscopic gastric surgery who don't received epidural injection through an thoracic epidural catheter.
62635208|NCT04758013|NO_INTERVENTION|Open gastric surgery|Patients with open gastric surgery.
62272374|NCT02230631||Part 2 (prospective observational evaluation)|
62272375|NCT01573715|ACTIVE_COMPARATOR|severe ARDS patients|
62272376|NCT01573715|ACTIVE_COMPARATOR|control group|
62272377|NCT01573715|EXPERIMENTAL|moderate SDRA patients|
62272378|NCT00529256|NO_INTERVENTION|2|No intervention
62272379|NCT02615444|EXPERIMENTAL|Beta-glucan enriched oatcake|Oatcakes which have been enriched with beta-glucan. Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.
62272380|NCT02615444|PLACEBO_COMPARATOR|Isocaloric control|Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content. Contains no oat-beta glucan. Each participant will consume 6.5 Krackawheats daily.
62272381|NCT01758250||Systemic Sclerosis|Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
62635209|NCT03722082|EXPERIMENTAL|Enhancing cognitive reserve intervention|This intervention focuses in the improvement of academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the hospital and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. The groups will be made with parents and children, adolescents and young adults separately being the content of the sessions the same but adapted to the age of the attendees.
62635210|NCT03722082|PLACEBO_COMPARATOR|Supportive Intervention|The participants will not receive any structured intervention focused to enhance cognitive reserve. The therapists will adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise.
62635211|NCT01040949|ACTIVE_COMPARATOR|a self help smoking cessation guide|Guia, a culturally relevant self-help smoking cessation guide in Spanish
62635212|NCT01040949|EXPERIMENTAL|couple-based counseling for smoking cessation plus Guia|couple-based counseling for smoking cessation plus Guis, culturally relevant self-help smoking cessation guide for Latinos
62635213|NCT01119521|EXPERIMENTAL|Group A: INH; BCG|6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI) (completed within no more than 7 months) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination.
62635214|NCT01119521|EXPERIMENTAL|Group B: observation; BCG; observation; INH|7 months of observation (run in period) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination followed after 6 months of observation by 6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI).
62635215|NCT05646927||Group Child Preference|The children will prefer parents (mother or father) who will accompany them in the preoperative holding area and at induction.
62635216|NCT05646927||Group None|The parent of the children who will accompany them during the perioperative period will be determined according to randomization.
62635217|NCT05074953||Adults|145184 patients with COVID-19 over 17 years of age.
62635218|NCT05074953||Children and adolescents|11950 patients with COVID-19 under 18 years of age.
62272382|NCT01758250||GVHD|Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.
62635219|NCT00543114|EXPERIMENTAL|Lenalidomide, fludarabine and rituximab|Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle
62635220|NCT02057263|EXPERIMENTAL|Alendronate and Hepatitis B Vaccine|Participants in the experimental arm will receive 4 alendronate doses during their Hepatitis B vaccination course.
62635221|NCT02057263|EXPERIMENTAL|Sugar Pill and Hepatitis B Vaccine|Participants in the experimental arm will receive placebo doses during their Hepatitis B vaccination course.
62635222|NCT04670120|EXPERIMENTAL|First group|Pyfazimine 100mg group, 12 cases.
62635223|NCT04670120|EXPERIMENTAL|Second group|Pyfazimine 200mg group, 12 cases.
62635224|NCT04670120|EXPERIMENTAL|Third group|Pyfazimine 300mg group, 12 cases.
62635225|NCT04670120|ACTIVE_COMPARATOR|Forth group|Pyrazinamide 1500mg group, 10 cases.
62635226|NCT04670120|ACTIVE_COMPARATOR|Fifth group|Pyfazimine 200mg + Pyrazinamide 1500mg group, 10 cases.
62635227|NCT05105347|EXPERIMENTAL|Medium dose group (Adalimumab plus medium dose oral glucocorticosteroid)|Patients will be given adalimumab with 30mg daily prednisone or equivalent with a fixed slow tapering plan.
62453403|NCT04172298|EXPERIMENTAL|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
62635228|NCT05105347|ACTIVE_COMPARATOR|High dose group (Adalimumab plus high dose oral glucocorticosteroid)|Patients will be given adalimumab with 60mg daily prednisone or equivalent with a fixed slow tapering plan.
62635229|NCT00387322|EXPERIMENTAL|Group 1|Patients receive oral erlotinib hydrochloride once on days 2, 9, and 16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression
62635230|NCT00387322|EXPERIMENTAL|Group 2|Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
62635231|NCT05337865||Transgender women|Well-trained transgender women.
62635232|NCT05337865||Cisgender Women|Well-trained cisgender women.
62635233|NCT05337865||Cisgender Men|Well-trained cisgender men.
62272383|NCT01758250||Undergoing HSCT|Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.
62272384|NCT01758250||Controls|Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.
62272385|NCT01758250||Sickle cell disease|Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
62635234|NCT04786691|PLACEBO_COMPARATOR|Black coffee first|12 oz of black coffee with no additives is the first intervention tested
62067550|NCT03240536|EXPERIMENTAL|Intervention Group|Ordering physicians who have referred to a rheumatologist in the St. Joseph's rheumatology clinic randomized to the intervention group will receive a brief Choosing Wisely form (for education of guidelines) faxed with the referral notice. At one and two years all ordering physicians will receive by fax a three question survey.
62272386|NCT01758250||Cutaneous fibrosing disorder|Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.
62272387|NCT06240884|EXPERIMENTAL|Infraspinatus-teres minor interfascial block|Patients will receive Infraspinatus-teres Minor Interfascial Block with 20 ml of 0.375% ropivacaine prior to induction of general anesthesia.
62635235|NCT04786691|ACTIVE_COMPARATOR|Coffee with half and half first|12 oz of black coffee with 1 oz of half and half is the first intervention tested
62635236|NCT04786691|ACTIVE_COMPARATOR|Coffee with non-dairy creamer first|12 oz of black coffee with 1 oz of liquid non-dairy creamer is the first intervention tested
62635237|NCT05988762|EXPERIMENTAL|Supramaximal Walkout|Walkout set performed at 110% 1RM
62635238|NCT05988762|EXPERIMENTAL|Control (Submaximal Walkout)|Walkout set performed at 30% 1RM
62635239|NCT01807533|EXPERIMENTAL|Family-centered intervention program|FCIP: family members were encouraged to present in all intervention sessions included 5 in-hospital intervention, 7 after-discharge interventions (0, 1, 2, 4, 6, 9, and 12 months of corrected age), and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
62635240|NCT01807533|OTHER|Usual care intervention program|UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
62635241|NCT05041556||Case-control study of clinical outcomes|These are children who live in RTS,S implementation areas aged less than 5 years and who were eligible to have received RTS,S based on their date or birth and age, will be eligible to be recruited into the study. Cases will be recruited in sentinel hospitals of the ongoing malaria Vaccine Pilot Evaluation (MVPE). Control for a case will be a child who lives outside a 100-metre radius from the case, matched on date of birth (+/- 1 month of date of birth of the case)
62635242|NCT05041556||Case-control study of mortality outcome|These will be children who died of any cause excluding accidents or trauma, who are eligible to have received the RTS,S vaccine based on their date of birth and age. Cases will be recruited from the community-based mortality surveillance of MVPE. Control for a mortality case will be a live child who lives outside a 100 metre radius from the case with date of birth +/- 1 month of the date of birth of the case who are eligible to have received the RTS,S vaccine.
62635243|NCT03119948|PLACEBO_COMPARATOR|Group 1|Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
62635244|NCT03119948|ACTIVE_COMPARATOR|Group 2|Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
62635245|NCT03119948|ACTIVE_COMPARATOR|Group 3|Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
62272388|NCT06240884|ACTIVE_COMPARATOR|interscalene block|The patient underwent an ultrasound-guided brachial plexus nerve block in the interosseous sulcus using 20 ml of 0.375% ropivacaine.
62272389|NCT06195722|NO_INTERVENTION|control|control
62272390|NCT06195722|EXPERIMENTAL|experimental|experimental
62272391|NCT01536054|EXPERIMENTAL|Treatment (vaccine, sirolimus, GM-CSF)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Patients also receive sirolimus PO QD on days 1-14 OR 15-28 OR 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive an additional course of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine only followed by ALVAC(2)-NY-ESO-I (M)/TRICOM vaccine SC 8 weeks after completion of course 4.
62287024|NCT01439438|ACTIVE_COMPARATOR|Reference formulation|Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2
62287025|NCT01936220|EXPERIMENTAL|Continuity of specialized care|Continuity of specialized inpatient and outpatient care (relapse prevention)
62287026|NCT01936220|EXPERIMENTAL|Continuity of specialized care and parent groups|Continuity of specialized care combined with Parent groups
62287027|NCT01936220|ACTIVE_COMPARATOR|Treatment as usual|Discontinuity of care, relapse prevention as usual
62453404|NCT04172298|EXPERIMENTAL|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
62453405|NCT01607775|ACTIVE_COMPARATOR|PEEK-cage|Patients will receive a PEEK-cage
62453406|NCT01607775|EXPERIMENTAL|PMMA-cage|
62453407|NCT05631626|ACTIVE_COMPARATOR|25mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. The starting dose for all subjects at Day 0 is 25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62453408|NCT05631626|ACTIVE_COMPARATOR|37.5mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62453409|NCT05631626|ACTIVE_COMPARATOR|50mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62453410|NCT05631626|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
62453411|NCT04024956|EXPERIMENTAL|Sealing Device|Sealing Device applied in hepatic resection or distal pancreatectomy
62453412|NCT05354414|EXPERIMENTAL|VR followed by SOC|Participants will receive a 20-minute (min) VR session at the first nusinersen IT (IT1), followed by SOC (local anesthesia - lidocaine or intravenous sedation) at the subsequent nusinersen IT (IT2) during the main study, later followed by 20-min VR sessions at two subsequent nusinersen ITs (IT3 and IT4) during the extension period, for up to 450 days.
62635246|NCT00956839|ACTIVE_COMPARATOR|Group A|IM Vitamin D3 3,00,000 Units single dose
62453413|NCT05354414|EXPERIMENTAL|SOC followed by VR|Participants will receive SOC (local anesthesia - lidocaine or intravenous sedation) at nusinersen IT1, followed by a 20-min VR session at the subsequent nusinersen IT (IT2) during the main study, later followed by 20-min VR sessions at two subsequent nusinersen ITs (IT3 and IT4) during the extension period, for up to 450 days.
62453414|NCT03416764|EXPERIMENTAL|EFP-NF (participants without steady menstrual cycle).|EFP-NF training, twice a week for a total of 10 sessions .
62453415|NCT03416764|NO_INTERVENTION|TAU|Participant will receive no EFP-NF training, and continue their treatment as usual (TAU).
62453416|NCT03416764|EXPERIMENTAL|EFP-NF during HIGH estrogen phase|EFP-NF training, twice a week, during high-estrogen phases only (days 7-21 of a 28-day cycle), for a total of 10 sessions.
62453417|NCT03416764|EXPERIMENTAL|EFP-NF during LOW estrogen phase|EFP-NF training, twice a week, during low-estrogen phases only (days 21-28 of a cycle and days 1-7 of the following cycle,based on a 28-day cycle), for a total of 10 sessions.
62635247|NCT00956839|ACTIVE_COMPARATOR|Group B|IM vitamin D3 6,00,000 Units single dose
62635248|NCT00956839|ACTIVE_COMPARATOR|Group C|Oral vitamin D3 500 Units/ day
62453418|NCT02715947|EXPERIMENTAL|single-arm|intervention: open registry, non-randomized, single-arm trial.Methotrexate:2.5mg per piece, oral.
62453419|NCT06261853|EXPERIMENTAL|3D-CBCT Scan|The surgeons will only utilise the 3D-CBCT scan of their patient during wisdom tooth surgery. The patient should observe no difference in their care in this arm of the trial on the day of surgery as they wouldn't typically be aware of which image was being viewed
62635249|NCT02408198|EXPERIMENTAL|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
62635250|NCT02408198|NO_INTERVENTION|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
62067551|NCT03240536|NO_INTERVENTION|Control Group|Ordering physicians who have referred to rheumatologists in the control group will not receive the Choosing Wisely form. At one and two years all ordering physicians will receive by fax a three question survey.
62067552|NCT01346514|EXPERIMENTAL|Arm 1: Addiction/Housing Case Management(AHCM)|The AHCM condition provided individual case management, delivered at the VA and in the community, designed to assist homeless Veterans with SUD issues who may be unable to take advantage of housing opportunities available in the VA due to difficulty navigating multiple services and maintaining stability with respect to SUD and co-occurring mental health conditions.
62635251|NCT03358550|EXPERIMENTAL|Accommodation in scotopic luminance|
62635252|NCT05388981|EXPERIMENTAL|Cohort 1|Intramuscular (IM) dose level 1
62635253|NCT05388981|EXPERIMENTAL|Cohort 2|IM dose level 2
62635254|NCT05388981|EXPERIMENTAL|Cohort 3|IM dose level 3
62635255|NCT05388981|EXPERIMENTAL|Cohort 4|IM dose level 4
62635256|NCT05388981|EXPERIMENTAL|Cohort 5|Intravenous (IV) dose level 1
62067553|NCT01346514|ACTIVE_COMPARATOR|Arm 2: Housing Support Group(HSG)|The HSG condition involved a weekly drop-in housing support group.
62067554|NCT02200939|EXPERIMENTAL|Partial-Thickness Tear|Intermediate or High partial-thickness tear (PTT) or very small full-thickness tear of the supraspinatus tendon surgically treated by implantation of the bioinductive implant.
62067555|NCT02200939|EXPERIMENTAL|Full Thickness Tear|Medium or large full thickness tear (FTT) of the supraspinatus tendon surgically treated with the bioinductive implant adjunctive to surgical repair.
62067556|NCT00884858|EXPERIMENTAL|Maraviroc|Subjects in this group will add Maraviroc to their current HAART.
62067557|NCT00884858|NO_INTERVENTION|2|Subjects in this group will continue their current HAART without adding Maraviroc.
62067558|NCT05157841|EXPERIMENTAL|Part A: EXPAREL 266 mg arm|subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline
62067559|NCT05157841|EXPERIMENTAL|Part A: EXPAREL 133 mg arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL mixed with 20 mL saline
62067560|NCT05157841|ACTIVE_COMPARATOR|Part A: Bupivacaine HCl arm|Subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
62067561|NCT05157841|EXPERIMENTAL|Part B: EXPAREL 133 mg arm OR EXPAREL 266 mg arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline OR 10 mL (133 mg) EXPAREL mixed with 20 mL saline. Dose will be determined following interim analysis of Part A.
62067562|NCT05157841|ACTIVE_COMPARATOR|Part B: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
62067563|NCT06626217|EXPERIMENTAL|Comparison of perfusion index monitoring using a smartwatch and a pulse oximeter|Placing the finger pulse oximeter sensor on the left middle finger and placing the Massimo Watch W1 on the volunteer's left wrist (2 cm from the processus styloideus). Four interventions subsequently follow (Resting condition, Movement artifacts and Circulation constriction, Physical Exercise).
62067564|NCT04488367|EXPERIMENTAL|Early TXA|Experimental group will receive 10 mg/kg IV TXA while in the Emergency Department, and repeat preoperative and postoperative doses.
62067565|NCT04488367|OTHER|Control|Control group will receive 100 mL 0.9% normal saline in the Emergency Department, and 10 mg/kg IV TXA before skin incision and again in post anesthesia care unit.
62067566|NCT02039661|ACTIVE_COMPARATOR|Lidocaine Spray|
62067567|NCT02039661|PLACEBO_COMPARATOR|Placebo|These patients received placebo spray.
62088245|NCT02007083|ACTIVE_COMPARATOR|Bilateral laminotomy (BL)|The multifidus muscles is detached from the spinous process bilaterally.The decompression of the spinal canal is performed by first doing a flavectomy. Thereby performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. This is performed bilaterally.
62287028|NCT04325477|EXPERIMENTAL|Nolix Device|Comparing use of device to non-treatment (pads only) phase
62287029|NCT05456425|PLACEBO_COMPARATOR|Vehicle|Emulsion eye drop without drug
62287030|NCT05456425|EXPERIMENTAL|CBT-001 Low Dose|CBT-001 eye drop
62635257|NCT03225287|EXPERIMENTAL|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
62635258|NCT01834339|ACTIVE_COMPARATOR|AlloDerm|The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
62635259|NCT01834339|EXPERIMENTAL|EVPOME|An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.
62067568|NCT02679534|EXPERIMENTAL|hand massage|"Patients will receive a 20 minute hand massage by a trained nurse in addition to the standard ICU care. Before administering the massage, a favorable environment will be created that promotes calmness such as dampening the light, reducing the alarm intensity, closing the curtains and the door and posting the notice do not disturb, and a comfortable positioning of the patient will be ensured. The interventionist will hold each hand for 5-10 seconds, and apply 5-10 ml of unscented hypoallergenic cream to both hands and wrists. Then, she will perform massage using moderate pressure, and the stroking and kneading techniques during ten minutes on the palm and back of each hand."
62067569|NCT02679534|ACTIVE_COMPARATOR|hand holding|The active control group will receive hand holding by the same trained nurse in addition to standard ICU care. The same hand hygiene and environmental adjustments will be made as for those receiving massage. Patients will have their hands held for 5-10 seconds and unscented hypoallergenic cream applied to both hands. Then, the interventionist will hold each of the patients' hand in her hand for ten minutes without performing any tissue manipulation. The hand holding procedure will last for a total of 20 minutes.
62067570|NCT02679534|OTHER|rest group|The passive control group will have a 20 minutes rest period including the same environmental adjustments as the massage and hand holding groups in addition to the standard care administered in the ICU. The standard care includes the pharmacological and non-pharmacological treatments used to promote recovery and symptom relief. In the study ICU, cardiac surgery patients are automatically prescribed a pain management protocol that includes the regular administration of morphine, unless extraordinary patient circumstances require different prescriptions. Patients might equally receive breakthrough doses of analgesia in addition to regular opioids. Of the existing non-pharmacological interventions, repositioning and back rubs are commonly employed in the study ICU to provide patient comfort.
62067571|NCT05191641|EXPERIMENTAL|İntervention group|"PVQ and PedsQL will be used to collect research data. The same measurement tools will be used in the collection of pre-test, mid-term and post-test data. After obtaining the necessary written and verbal permissions from the parents in the intervention group included in the research, 12-week individualized nursing care will be applied. It is planned to make three measurements, namely pre-test, interim evaluation and post-test, from the parents in the intervention groups.~12 Weeks of Individualized Nursing Care~* 5 individual interviews~* A interview after 2 weeks~* Telephone consultation"
62272392|NCT04770051|EXPERIMENTAL|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
62272393|NCT03066427|EXPERIMENTAL|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
62272394|NCT00609479|EXPERIMENTAL|1|Internal fixation with Micronail. 41 patients.
62272395|NCT00609479|EXPERIMENTAL|2|External fixation with Hoffmann-II-non-bridging. 41 patients.
62272396|NCT00679497|EXPERIMENTAL|1|MVA HIV-B
62635260|NCT03167554|SHAM_COMPARATOR|Sham group|Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
62272397|NCT00679497|PLACEBO_COMPARATOR|2|Placebo
62272398|NCT00852995|EXPERIMENTAL|A - Low Q7D|Low dose HP802-247, applied at each visit
62272399|NCT00852995|EXPERIMENTAL|B - Low Q14D|Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
62272400|NCT00852995|EXPERIMENTAL|C - High Q7D|High dose HP802-247, applied at each visit
62272401|NCT00852995|EXPERIMENTAL|D - High Q14D|High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
62287031|NCT05456425|EXPERIMENTAL|CBT-001 High Dose|CBT-001 eye drop
62635261|NCT03167554|EXPERIMENTAL|Experimental group 1|Electrolysis application with monopolar needle.
62635262|NCT03167554|EXPERIMENTAL|Experimental group 2|Electrolysis application with bipolar needle.
62635263|NCT01921517|EXPERIMENTAL|Low Magnitude Mechanical Stimulation|10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
62272402|NCT00852995|PLACEBO_COMPARATOR|E - Vehicle|Placebo (Vehicle), applied at each visit
62272403|NCT04794712||Study group A|"Participants group: Group A : 20 participants with chronic venous insufficiency~* 3 months exercise pre surgery~* Pre-surgery evaluation~* Venous reflux assessment by ultrasound and PPG~* Pain assessment by CHEPS,VAS QS MCGILL~* 3 months exercise post surgery~* Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
62272404|NCT04794712||Study group B|"Participants group: Group B : 20 participants with chronic venous insufficiency~* Pre-surgery evaluation~* Venous reflux assessment by ultrasound and PPG~* Pain assessment by CHEPS,VAS QS MCGILL~* Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
62272405|NCT04794712||Study Group C|"Participants group: Control Group C : 40 participants with chronic venous insufficiency SUBGROUP 1: WITHOUT EXERCISE 20 PARTICIPANTS~* VENOUS ASSESSMENT TOOLS( U/S, PPG )~* PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)~SUBGROUP 2: 3 MONTHS EXERCISE 20 PARTICIPANTS~* VENOUS ASSESSMENT TOOLS ( U/S, PPG )~* PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)"
62635264|NCT01921517|PLACEBO_COMPARATOR|Sham Low Magnitude Mechanical Stimulation|10 minutes daily of placebo treatment using a sham vibrating platform.
62272406|NCT01312597|EXPERIMENTAL|Fruit beverage|
62272407|NCT01312597|EXPERIMENTAL|Control beverage|
62635265|NCT02558842|EXPERIMENTAL|Education Strategy|Educational Strategy and Oversight Distance
62635266|NCT02558842|NO_INTERVENTION|Routine|Routine hospital assistance
62635267|NCT04633681|EXPERIMENTAL|Cake matrix|3 phases of 2-week daily consumption of cake product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
62635268|NCT04633681|EXPERIMENTAL|Biscuit matrix|3 phases of 2-week daily consumption of biscuit product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
62635269|NCT04633681|EXPERIMENTAL|Yoghurt matrix|3 phases of 2-week daily consumption of yoghurt product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
62635270|NCT04633681|EXPERIMENTAL|Chocolate matrix|3 phases of 2-week daily consumption of chocolate product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
62635271|NCT04633681|EXPERIMENTAL|Cereal matrix|3 phases of 2-week daily consumption of cereal product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
62635272|NCT04633681|EXPERIMENTAL|Universal Eating Monitor study|A sub-group of the yoghurt matrix will be selected for assessment of eating rate and microstructure of feeding using Universal Eating Monitors.
62635273|NCT04633681|EXPERIMENTAL|fMRI study|A sub-group of the chocolate matrix will be selected for assessment of neural activation to images of food using fMRI.
62635274|NCT01419314|EXPERIMENTAL|Splinting application|Participants will be asked to wear a pair of LE night splints for the duration of the study (6 weeks) at night/during sleep only.
62635275|NCT01419314|PLACEBO_COMPARATOR|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study.
62635276|NCT00523770||Group A|Non-pneumococcal infected healthy elderly volunteers
62272408|NCT01923792||Placebo|Subjects previously randomised to receive placebo in study TH002
62272409|NCT01923792||ToleroMune HMD Group 1|Subjects previously randomised to receive ToleroMune HDM in study TH002
62272410|NCT01923792||ToleroMune HDM Group 2|Subjects previously randomised to receive ToleroMune HDM in study TH002
62272411|NCT02122237|EXPERIMENTAL|Cathodal Cefaly tDCS|Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.
62272412|NCT03236558|EXPERIMENTAL|Patients with diabetes|T1D patients with blood collection
62287032|NCT01977963||Agranulocytosis|
62067572|NCT05191641|NO_INTERVENTION|Control group|Pre-test (PVQ and PedsQL) will be applied after obtaining informed consent from the parents included in the control group after randomization. In the pre-test application, an interim evaluation (PVQ and PedsQL) will be applied to the control group 1 week after and the post-test (PVQ and PedsQL) will be applied 4 weeks later. After the post-test application is completed, a five-day individual interview will be applied to the parents included in the control group.
62067573|NCT05482737||Reference group|Transfused RBC stored 8-35 days
62067574|NCT05482737||less than or equal 7 days|Transfused RBC stored =\<7 days
62067575|NCT05482737||more than 7 days|Transfused RBC stored \<7 days
62453420|NCT06261853|ACTIVE_COMPARATOR|2D-OPG X-ray|The surgeons will only utilise the 2D-OPG X-ray of their patient during wisdom tooth surgery. The patient should observe no difference in their care in this arm of the trial on the day of surgery as they wouldn't typically be aware of which image was being viewed
62453421|NCT02724683||Symptomatic ascites drainage with CVC.|Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.
62453422|NCT03066999|ACTIVE_COMPARATOR|Cystoscopy|will have catheter placement using the cystoscopy method
62453423|NCT03066999|ACTIVE_COMPARATOR|DirectVision|will have catheter placement using DirectVision.
62635277|NCT05856253||ERAS group|
62067576|NCT05482737||less that or equal 10 days|Transfused RBC stored =\<10 days
62067577|NCT05482737||more that 10 days|Transfused RBC stored \>10 days
62067578|NCT05482737||more than 35 days|Transfused RBC stored \>35 days
62067579|NCT05482737||less than or equal 35 days|Transfused RBC stored =\<35 days
62067580|NCT05482737||less than 18 days|Transfused RBC stored \<18 days
62067581|NCT05482737||more than or equal 18 days|Transfused RBC stored =\>18 days
62635278|NCT05856253||Control group|
62067582|NCT02566070|ACTIVE_COMPARATOR|Continuous Gastric Feeding (CGF)|CGF group will have total daily enteral nutrition requirement delivered at a constant rate via infusion over the entire 24 hour period.
62067583|NCT02566070|EXPERIMENTAL|Bolus Gastric Feeding (BGF)|BGF group will have total daily enteral nutrition requirement delivered in interval, finite volumes over the course of the 24 hour period.
62067584|NCT04191681|EXPERIMENTAL|Sacubitril-valsartan study arm|"1. Start medication-naïve patients on low-dose sacubitril-valsartan (24/26 mg PO BID) without a washout period per guideline and label recommendations.~2. Switch patients to equivalent dose sacubitril-valsartan if on prior ACE inhibitor (after a 36 hour washout period) or ARB therapy (after discontinuing one day prior).~3. If therapeutic range MAP (65 to 85 mm Hg), discontinue other oral vasodilator (e.g., hydralazine, isordil) or non-rate limiting dihydropyridine calcium channel blocker (non-DHP CCB, e.g., amlodipine) therapy on the day prior to sacubitril-valsartan initiation. If MAP \> 85 mm Hg, low-dose sacubitril-valsartan will be added with or without discontinuation of other oral vasodilator or non-DHP CCB per physician's discretion based on drug tolerability and maintenance of therapeutic range MAP.~4. Sacubitril-valsartan can be up-titrated every 2-4 weeks per standard practice guidelines per physician's discretion as above."
62453424|NCT04713059||patients with CPS ≥ 1 or MSI-H or TMB ≥ 10Mb/MUT|
62453425|NCT04713059||patients with CPS =0 , MSS and TMB < 10Mb/mut|
62272413|NCT01031914|EXPERIMENTAL|Paced Breathing Sleep/Wake detection|All subjects enrolled will have oobstructive sleep apnea (OSA) and will be current Continuous Positive Airway Pressur (CPAP) users.
62272414|NCT05204966|OTHER|Infant with suspected dysphagia|For newborns and infants who satisfy the inclusion and exclusion criteria, after taking a video of a bottle feeding, we try to develop an evaluation of swallowing disorder through artificial intelligence-based analysis. The developed evaluation will be verified for validity by comparing it with NOMAS (and VFSS if possible), and the correlation with future development will be analyzed through the relationship with the 1st and 2nd year correctional Bailey Developmental Evaluation.
62635279|NCT04862260|EXPERIMENTAL|Multipathway cholesterol metabolism disruption|Twelve to fifteen patients will receive a combination of daily atorvastatin 40 mg, twice daily ezetimibe 10 mg and evolocumab 420 mg subcutaneously every month. This multipathway cholesterol metabolism disruption will be combined to standard chemotherapy (FOLFIRINOX).
62272415|NCT01564862|EXPERIMENTAL|Vortioxetine (Lu AA21004) QD|Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
62453426|NCT04449653||Lupus Cases|Individuals who are diagnosed with System Lupus Erythematosus and consent to the study will be placed in this cohort. Upon enrollment they will be given the opportunity to invite a non-SLE-diagnosed friend to enroll in the study as a healthy control. These individuals will answer weekly questions and receive a smartwatch to measure their physical activity.
62635280|NCT02574663|EXPERIMENTAL|TGR-1202|TGR-1202 daily dose
62635281|NCT02574663|EXPERIMENTAL|TGR-1202 + nab-paclitaxel + gemcitabine|TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion
62635282|NCT02574663|EXPERIMENTAL|TGR-1202 + FOLFOX|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)
62635283|NCT02574663|EXPERIMENTAL|TGR-1202 + FOLFOX + Bevacizumab|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion
62635284|NCT01101750|OTHER|Liver and Kidney Transplant Patient Arm|Standard of Care Intervention: Participants on this arm receive Gardasil vaccine and have a history of liver or kidney transplant.
62635285|NCT02524340||Juvenile Idiopathic Arthritis|Children diagnosed with Juvenile Idiopathic Arthritis
62635286|NCT00411450|EXPERIMENTAL|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.
62272416|NCT01564862|ACTIVE_COMPARATOR|Duloxetine QD|Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
62272417|NCT01564862|PLACEBO_COMPARATOR|Placebo QD|Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
62272418|NCT06118060|EXPERIMENTAL|acupressure group|After surgery, the patient is placed in a supine position, exposing both calves, and the operator sits on the edge of the bed and applies acupressure with the thumb or pressing tool (homemade).
62272419|NCT06118060|NO_INTERVENTION|control group|usual care group
62272420|NCT06222125|EXPERIMENTAL|Arm 1|10 mg/kg intravenously, every 2 weeks, till tumor progression or intolerance.
62272421|NCT06222125|EXPERIMENTAL|Arm 2|20 mg/kg intravenously, every 2 weeks, till tumor progression or intolerance.
62453427|NCT06290180|EXPERIMENTAL|Healing Lodge First Face Training Evaluation Study|All participants in this evaluation will be assigned to the First Face for Mental Health training condition. The investigators will use a pre-post design to measure change in relevant outcomes from pre-training, to post-training, to 3-months post-training.
62453428|NCT01025531||patients with newly diagnosed Hepatitis C|Hepatitis C patients newly diagnosed
62453429|NCT01158365|EXPERIMENTAL|Dermacyd (different fragrances)|Day 1 until 30: Investigational Product (Dermacyd) Day 31 until 37: wash-out Day 38 until 67: Glycerine Vegetal Soap Granado Traditional
62453430|NCT01158365|ACTIVE_COMPARATOR|Glycerine Vegetal Soap Granado Traditional|Day 1 until 30: Glycerine Vegetal Soap Granado Traditional Day 31 until 37: wash-out Day 38 until 67: Investigational Product (Dermacyd)
62453431|NCT05456607|ACTIVE_COMPARATOR|Control|Online Mood Monitoring for 12 weeks
62453432|NCT05456607|EXPERIMENTAL|Single Insomnia Treatment|Cognitive-behavioral therapy for insomnia delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.
62453433|NCT05456607|EXPERIMENTAL|Single Depression Treatment|Cognitive-behavioral therapy for depression delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.
62453434|NCT05456607|EXPERIMENTAL|Sequenced Depression and Insomnia Treatment|Cognitive-behavioral therapy for depression followed by cognitive-behavioral therapy for insomnia each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the depression treatment only for 4 weeks after which the access to the insomnia treatment is also made available. Total duration of access for 12 weeks.
62453435|NCT05456607|EXPERIMENTAL|Sequenced Insomnia and Depression Treatment|Cognitive-behavioral therapy for insomnia followed by cognitive-behavioral therapy for depression each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the insomnia treatment only for 4 weeks after which the access to the depression treatment is also made available. Total duration of access for 12 weeks.
62453436|NCT06286969|EXPERIMENTAL|intensive multi-acupuncture method group|The needle entry points of the lower row are straight punctures that penetrate the muscle attachments along the medial superior margin of the posterior superior iliac spine, the medial margin of the sacroiliac joint, and a portion of the lateral iliac crest of the lumbar triangle. The entry point of the upper row of needles was made oblique, and then small lifting insertion, respectively, reached and penetrated the anterior border muscle attachments. Then subperiosteal stabbing along the bone surface was used to penetrate 1.5cm forward and downward, and the needle was retained for 15min. The needle was left in place for 15 min, and for the second puncture, the entry point was chosen to be in the middle of the two longitudinal entry points of the first puncture. The rest of the operation was unchanged. Repeat the above operation for the last 3 treatments. The treatment is performed twice a week for a total of 5 treatments.
62272422|NCT00864955|EXPERIMENTAL|phototype 2|Volunteers with cutaneous phototype 2
62635287|NCT02056418|EXPERIMENTAL|enteral nutrition|The patients receive treatment of enteral nutrition only.
62272423|NCT00864955|EXPERIMENTAL|phototype 4|Volunteers with cutaneous phototype 4
62272424|NCT01200901|EXPERIMENTAL|Melancolic depression patients|Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).
62272425|NCT06016426|ACTIVE_COMPARATOR|mass closure|infants and children whose transverse laparotomy incisions will be closed in mass closure.
62272426|NCT06016426|ACTIVE_COMPARATOR|layer by layer closure|infants and children whose transverse laparotomy incisions will be closed layer by layer.
62635288|NCT02056418|EXPERIMENTAL|Corticosteroid|The patients receive treatment of corticosteroid only.
62272427|NCT05979610|EXPERIMENTAL|Reiki Therapy|Participants randomized to Arm 1 will receive a session of Reiki therapy during the standard wait time between the placement of the brachytherapy device and their first brachytherapy treatment.
62272428|NCT05979610|NO_INTERVENTION|Standard of Care|Participants randomized to the standard of care control arm will be asked to remain in a clinic room during the standard waiting period between the placement of the brachytherapy device and the start of brachytherapy treatment. Participants may participate in any activity other than Reiki therapy during this time. Participants may be accompanied by a family member or friend.
62635289|NCT02056418|NO_INTERVENTION|Healthy control|healthy people applied with normal diet.
62635290|NCT03529253|EXPERIMENTAL|Intensive therapy group|Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
62635291|NCT03529253|ACTIVE_COMPARATOR|Standard therapy group|The standard therapy group is Rosuvastatin10mg/daily alone.
62635292|NCT03646968|EXPERIMENTAL|Cohorts|Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
62635293|NCT03590574|EXPERIMENTAL|AUTO4|Relapsed or refractory T cell non-Hodgkin Lymphoma patients
62635294|NCT02953288||Benign thyroid nodules|Benign thyroid nodules
62272429|NCT02058680|EXPERIMENTAL|PSA/IL-2/GM-CSF vaccine|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
62272430|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
62272431|NCT03881150|EXPERIMENTAL|Hybrid Cardiac Rehabilitation|"This intervention is adapted from the Cardiac Rehabilitation Delivery Model for Low-Resource Settings proposed by the International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. This program will be delivered by an exercise specialist (physiotherapist) and the principal purposes of the exercise sessions is to develop patient self-management related to the physical activity habit, and educate them how to monitor exercise intensity at home and in daily life. The program include 10 face-to-face exercise sessions and a transition to unsupervised phase using mobile technology.~Counseling is considered about physical activity, diet, smoking, and medication compliance."
62635295|NCT02953288||Thyroid Carcinoma|Thyroid Carcinoma
62067585|NCT04191681|ACTIVE_COMPARATOR|Usual care (standard-of-care) arm|"1. Continue current regimen of patients on oral vasodilator therapy (e.g., ACE inhibitor, ARB, hydralazine, isordil), allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above.~2. Start medication-naïve patients de novo on one of the oral vasodilators as below per guideline and label recommendations, allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above: i. ACE inhibitor: Enalapril 2.5 mg PO BID or Lisinopril 5 mg PO daily; ii. ARB: Valsartan 20 mg PO BID or Losartan 25 mg PO daily; iii. Other: Hydralazine 10 mg PO TID or Isordil 5 mg PO TID."
62067586|NCT06342895|EXPERIMENTAL|Interventional|
62067587|NCT06342895|OTHER|control|
62453437|NCT06286969|EXPERIMENTAL|normal needling group|"The points were selected with reference to the 2006 National Standard of the People's Republic of China (GB/T 12346-2006), Acupoint Names and Localization. The patients were placed in the prone position, the acupoints were sterilized with 75% alcohol, and the needles were inserted vertically with the conventional needling method, to the extent that there was a sensation of acidity, numbness, heaviness, distension, or radiating to the surroundings, and the needles were left in place for 15 min. The treatments were carried out twice a week for a total of five treatments."
62453438|NCT03882047|EXPERIMENTAL|Mometasone furoate nasal spray|Participants receive 200 mcg of mometasone furoate nasal spray and fluticasone propionate placebo matching nasal spray once daily.
62067588|NCT05494229|EXPERIMENTAL|Utilizing autologous whole blood for the full thickness macular hole|It is an interventional study by performing pars-plana vitrectomy
62067589|NCT00119925|ACTIVE_COMPARATOR|minimal intervention|professional audit and feedback on current practice
62067590|NCT00119925|ACTIVE_COMPARATOR|maximal intervention|multi-faceted intervention consisting of professional and patient elements
62067591|NCT04372160||Younger school age children|Equal ratio of boys and girls, age range 7-13 years (68 subjects)
62067592|NCT04372160||Older school age children|Equal ratio of boys and girls), age range 14-17 years (68 subjects)
62067593|NCT04372160||Adults|Equal ratio of adult men and women, age range 18-65 years (68 subjects).
62453439|NCT03882047|ACTIVE_COMPARATOR|Fluticasone propionate nasal spray|Participants receive 200 mcg of fluticasone propionate nasal spray and mometasone furoate placebo matching nasal spray once daily.
62067594|NCT06625736|ACTIVE_COMPARATOR|Control group|The Xenical group:60 patients will receive identical capsules of 120mg (one capsule) to be taken three times daily with meals and for 12 weeks, equaling 360mg total daily dose.
62067595|NCT06625736|EXPERIMENTAL|The dandelion extract group|The dandelion extract group: 60 patients will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals and for 12 weeks.
62067596|NCT02273297||Pregnant women and their offspring|Ethnically diverse pregnant women and their offspring
62067597|NCT01743300|ACTIVE_COMPARATOR|Grapefruit juice arm|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment
62067598|NCT01743300|ACTIVE_COMPARATOR|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment.
62067599|NCT02590328||Screened patients|SCID screening: some drops of blood are placed on a second Guthrie card when current screening is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
62067600|NCT05321706|ACTIVE_COMPARATOR|Dapagliflozin|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin (tablet) once daily for one year.
62067601|NCT05321706|PLACEBO_COMPARATOR|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching tablet once daily for one year.
62067602|NCT02443506|EXPERIMENTAL|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
62067603|NCT02443506|PLACEBO_COMPARATOR|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
62067604|NCT03386955|EXPERIMENTAL|BPI-7711 treatment|"Phase I: Patients in dose escalation group will receive single dose of BPI-7711 on day -7 and start receive the 21 days/cycle continuous treatment once a day after 7 day washout period. Patients in the extension group will receive BPI-7711 once a day with the selected doses.~Phase IIa: Patients will receive BPI-7711 capsule(recommend phase 2 dose) as the first line treatment."
62067605|NCT00610974|ACTIVE_COMPARATOR|1|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
62067606|NCT00610974|EXPERIMENTAL|2|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
62067607|NCT03555357|ACTIVE_COMPARATOR|PRP|Platelet Rich Plasma (PRP) injections into one half of the scar will be preformed. PRP is already considered an effective treatment for scar therapy.This will be randomly assigned by the clinical research coordinator .
62067608|NCT03555357|EXPERIMENTAL|PRF|Platelet Rich Fibrin (PRF) injections will be preformed the other half of the scar that is not treated with PRP. PRF has not been established as an effective scar treatment. The PRF will be considered experimental as this study seeks to evaluate if it is more effective than PRP.
62067609|NCT02887469|ACTIVE_COMPARATOR|Intermittent bolus group|"\<\<Within 6hr\>\>~* Moderately Severe : 3% saline 2ml/kg over 20min \*1 (unknown bwt 100ml)~* Severe :3% saline 2ml/kg over 20min \*2 (unknown bwt 100ml)~\<additional treatment\> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief~\<\<During 6-24hr\>\>~- Moderately Severe or Severe~: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief~\<\<During 24-48hr\>\>~* Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief"
62088246|NCT02007083|ACTIVE_COMPARATOR|Unilateral laminotomy with crossover (UL)|The multifidus muscles is detached from the spinous process unilaterally. The laminotomy is first performed ipsilaterally. The decompression of the spinal canal is performed by first doing a flavectomy. Then, performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. Dura is then retracted, and the decompression is performed contralaterally.
62635296|NCT06422169|EXPERIMENTAL|Artofill|One vial for intra-articular infiltration every 7 days, for three consecutive weeks. After the injection it is necessary to keep the infiltrated joint at rest for at least 24 hours. In addition, as with all invasive joint treatments, the patient is advised to avoid any physical activity 2-3 days after the injection. Do not repeat the treatment before 7 days from the previous one.
62635297|NCT06230731|EXPERIMENTAL|Vascular abnormality group|People with acquired vascular abnormalities in the proximal colon
62635298|NCT06230731|ACTIVE_COMPARATOR|Control group|People with healthy colon
62635299|NCT01715701|EXPERIMENTAL|Paravertebral nerve blockade|A multilevel thoracic paravertebral nerve block will be performed by the anaesthesiologist prior to the induction of general anesthesia. Prior to the block, the anaesthesiologist will locate and mark each level and then, infiltrate the skin with lidocaine 2% (0.5-1 mL). Subsequently, using a Tuohy needle 22G, 5 mL of ropivacaine 0.5% will be injected at each level between T4 and T8. At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
62635300|NCT01715701|ACTIVE_COMPARATOR|Intercostal nerve blockade|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will also infiltrate the skin with lidocaine 2% (0.5-1 mL). A multilevel intercostal nerve block will be performed by the surgeon at the end of surgery before skin closure. Five mL of ropivacaine 0.5% will be injected at each level between T4 and T8. A PCA device will be installed upon arrival in the recovery room.
62287033|NCT01756274|EXPERIMENTAL|Neonates 'Left-over' Blood Samples|Blood samples used in this study were 'left-over samples'. The blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. Two left-over samples could be obtained from a single neonate. Laboratory professionals tested the BG concentration using three Bayer Blood Glucose Monitoring Systems (BGMS): Contour® NEXT BGMS, Contour® PLUS BGMS, and Contour® Next EZ BGMS.
62067610|NCT02887469|ACTIVE_COMPARATOR|slow continuous infusion group|"\<\<Within 24hr\>\>~- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)~- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)~Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)~If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na~if △ Na inc \<0.5mmol/hr or △ Na inc \<3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped~if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr~: maintain infusion rate~\<\<During 24-48hr\>\>~- Moderately Severe and Severe~Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)~If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief~: stop 3% saline infusion regardless of △ Na~if △ Na inc \<1.5mmol/6hr~: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped~if △ Na inc ≥ 1.5mmol/6hr~: maintain infusion rate"
62067611|NCT04935723|EXPERIMENTAL|EFFECT OF REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the reiki/sham reiki group were taken to a quiet single room and reiki/sham reiki was applied for approximately 25-30 minutes. will be applied. Reiki application will be applied by a researcher who has Reiki I and Reiki II level training.
62453440|NCT03882047|PLACEBO_COMPARATOR|Placebo nasal spray|Participants receive mometasone furoate placebo matching nasal spray and fluticasone propionate placebo matching nasal spray once daily.
62067612|NCT04935723|PLACEBO_COMPARATOR|EFFECT OF SHAM REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the sham reiki group were taken to a quiet single room and sham reiki was applied for approximately 25-30 minutes. will be applied. Sham Reiki will be applied by a health professional who has not received Reiki training.
62067613|NCT04935723|NO_INTERVENTION|ANXIETY, FEAR PAIN LEVELS AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|The control group will be given routine post-operative care without any intervention and the data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
62067614|NCT01190215|EXPERIMENTAL|Fluarix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
62067615|NCT01190215|ACTIVE_COMPARATOR|Havrix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
62067616|NCT00882921||Elaprase|Idursulfase 0.5 mg/kg Weekly
62067617|NCT02342665|EXPERIMENTAL|Copanlisib (BAY80-6946)|Dose escalation/safety evaluation cohort and objective tumor response (OR) expansion cohort
62067618|NCT01508013|EXPERIMENTAL|Appearance-Focused Website Intervention|This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
62067619|NCT01508013|ACTIVE_COMPARATOR|Control Website|Control participants viewed an Internet site designed to provide drug and alcohol education for teens.
62067620|NCT02223754|ACTIVE_COMPARATOR|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
62067621|NCT02223754|EXPERIMENTAL|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
62067622|NCT01097486|ACTIVE_COMPARATOR|Allograft|Cervical Spinal Fusion with Allograft
62067623|NCT01097486|EXPERIMENTAL|NeoFuse|Cervical Spinal Fusion with NeoFuse
62287034|NCT06547957|EXPERIMENTAL|Part 1A dose escalation|EOS301984 dose escalation as monotherapy
62453441|NCT00997581|EXPERIMENTAL|apremilast|Experimental treatment for acute gout
62453442|NCT00997581|ACTIVE_COMPARATOR|indomethacin|Medication currently used for the treatment of acute gout
62067624|NCT04548271|EXPERIMENTAL|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy and had prior treatment with PD-1 antagonists. Every patients will receive apatinib 250mg orally every day starting 14 days prior to Camrelizumab. Then apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
62067625|NCT04315103|EXPERIMENTAL|the combined-injection group|patients received a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
62067626|NCT04315103|ACTIVE_COMPARATOR|the one-injection group|patients received a single injection of 3 ml PRP
62067627|NCT02544802|EXPERIMENTAL|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8\~10x10\^6 cells/injection
62067628|NCT04485715|EXPERIMENTAL|AI-aided group|
62067629|NCT04485715|NO_INTERVENTION|control group|
62067630|NCT06474858||Normal weight|COPD patients with BMI 18.5-24.99
62067631|NCT06474858||Obese|COPD patients with BMI ≥ 30
62067632|NCT03091101|EXPERIMENTAL|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
62067633|NCT01450605||Patients ≥ 13 years of age with HIV-1|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
62067634|NCT04996290|ACTIVE_COMPARATOR|PENG + LFCN block|"The participants in this group received a combined regional technique just before surgery:~* Pericapsular nerve group (PENG) block~* Lateral femoral cutaneus nerve (LFCN) block"
62067635|NCT04996290|NO_INTERVENTION|No regional anesthesia|Control group
62272432|NCT03881150|ACTIVE_COMPARATOR|Standard Cardiac Rehabilitation|The participants in the control group will receive the standard cardiac rehabilitation that is delivered in participating centers. These programs accounts with physicians, nurses, nutritionists and physiotherapists. The programs will be standardized in participating centers in accordance with currents guidelines (only 18-22 face-to-face exercise sessions). Differentially, this programs provide, group education sessions about physical activity, diet, smoking, and medication compliance (without counseling).
62453443|NCT00046865|EXPERIMENTAL|Acupressure|Arm I: Patients receive active acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied to a specific site each morning and again whenever nausea is experienced for 3-6 minutes.
62272433|NCT03934450|EXPERIMENTAL|RPQ (-) enantiomer|Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days
62272434|NCT03934450|EXPERIMENTAL|SPQ (+) enantiomer|Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days
62272435|NCT03934450|ACTIVE_COMPARATOR|Primaquine Phosphate|Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days
62272436|NCT03934450|PLACEBO_COMPARATOR|Placebo|Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days
62635301|NCT01715701|ACTIVE_COMPARATOR|Patient Controlled Analgesia (PCA)|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will infiltrate the skin with lidocaine 2% (0.5-1 mL). At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
62272437|NCT03834415|EXPERIMENTAL|Lactobacillus reuteri DSM17038|Lactobacillus reuteri DSM17038, 1x108 CFU once a day for 30 days
62067636|NCT04898712|EXPERIMENTAL|Tranexamic Acid Arm|"Participants in the experimental arm will receive tranexamic acid (TXA) during surgery for CSDH evacuation with a single 1000mg intraoperative intravenous (IV) dose. Participants with a body weight 60-100kg will also receive a post-operative dose regimen of 500 mg TXA orally, 3 times a day (TID).~Weight deviations from this body weight range will be considered with a dose adjustment of 1000mg TXA two times a day (BID) for a body weight \>100 kg, and 500 mg TXA BID for body weight \<60kg."
62067637|NCT04898712|PLACEBO_COMPARATOR|Placebo Control Arm|Participants in the control arm will placebo according to the same administration regimen.
62635302|NCT02167438|EXPERIMENTAL|Investigational|Application of the Hem-Avert device.
62635303|NCT02167438|NO_INTERVENTION|Control|No Application of the Hem-Avert device.
62067638|NCT00988546|OTHER|1|exam documentation performed using dictation
62067639|NCT00988546|EXPERIMENTAL|2|exam documentation performed using computer based template
62067640|NCT03418870|EXPERIMENTAL|Family Integrated Care (mFI-Care)|Parents of infants assigned to the Family Integrated Care (mFI-Care) intervention will be treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches. Parent training on the Canadian FI-Care Parent Curriculum will be provided during small group sessions facilitated by the study team. Parents will receive peer support from mFI-Care-trained alumni parents and can interact with other mFI-Care parents through the We3Health App secure online parent forum. mFI-Care parents will be expected to track time spent with their infant; record infant activity, feeds and output; track learning and skills acquisition; and keep a journal of the NICU experience using the We3Health app.
62272438|NCT03834415|PLACEBO_COMPARATOR|Placebo probiotics|Placebo for probiotics, pols drops similar in consistency and flavor as experimental product
62272439|NCT00006565|EXPERIMENTAL|1|HEPA Air Cleaners
62272440|NCT00006565|PLACEBO_COMPARATOR|2|Inactive (placebo) filtration unit
62272441|NCT05722665||Normal chest radiographs|X-rays without alterations in the lung parenchyma
62272442|NCT05722665||COVID-19 chest radiographs|X-rays belonging to patients with a diagnosis of COVID-19 confirmed by positive Reverse Transcriptase polymerase chain reaction (RT-PCR) and/or presence of antibodies to COVID-19 and/or positive COVID-19 viral antigen.
62272443|NCT05722665||Other pneumonia chest radiographs|X-rays belonging to patients with a diagnosis of pneumonia other than COVID-19
62272444|NCT04428424||Patients with rheumatoid arthritis|Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease
62272445|NCT00424827|EXPERIMENTAL|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
62272446|NCT03038425|PLACEBO_COMPARATOR|Saline infusion|Participants in this group will receive normal saline infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
62453444|NCT00046865|PLACEBO_COMPARATOR|Placebo Acupressure|Arm II: Patients receive placebo acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied as in arm I except at a non-specific site.
62635304|NCT02874612||Young Adults with Type 1 Diabetes Mellitus|All YA (ages 18-24) who are seen in the Cincinnati Children's Hospital Medical Center Diabetes Clinic and have recently (\< 4 months) completed the Transition Readiness assessment tool as part of their standard clinical care is eligible for the study.
62635305|NCT05558319|ACTIVE_COMPARATOR|Control arm (A)|"INDUCTION: Isatuximab + VRD, 4 cycles. Isatuximab (IV) 10 mg/Kg, 1st cycle D: 1,8,15, 22. Cycles 2-4: D 1,15. Bortezomib (SC) 1.3 mg/m2, D:1, 4, 8, 11. Lenalidomide (PO) 25mg, D:1-21. Dexamethasone (PO) 40 mg, D: 1-4, 9-12.~ASCT. The conditioning regimen is melphalan 200 mg/m2.~CONSOLIDATION: Isatuximab + VRD, 2 cycles. Isatuximab (IV) 10 mg/Kg. D 1-15. Bortezomib (SC) 1.3 mg/m2, D:1, 4, 8, 11. Lenalidomide (PO) 25mg, D:1-21. Dexamethasone (PO) 40 mg, D: 1-4, 9-12.~CONTINUOUS TREATMENT: Lenalidomide and monthly Isatuximab until progression, unacceptable toxicity, patient withdrawal, loss to follow up or death. During continuous treatment, dexamethasone 40 mg is used as a standardized premedication for Isatuximab."
62272447|NCT03038425|ACTIVE_COMPARATOR|Ropivacaine infusion|Participants in this group will receive ropivacaine 0.2% infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
62272448|NCT04090112|EXPERIMENTAL|the study group (Group A)|Patients received four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
62272449|NCT04090112|ACTIVE_COMPARATOR|Comparator group (Group B)|Patients received 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
62272450|NCT06410560|EXPERIMENTAL|Training workshop with hands-on laboratory|Participants will undergo a training course for a total of 12 hours: 4 FAD + 8 in the laboratory. They will receive theoretical narrative medicine education with 4 hours of distance education and a practice course of storytelling and creative writing whit 8 hours of distance education in small groups, enabling discussion and interaction among participants.
62272451|NCT06410560|PLACEBO_COMPARATOR|Brief training course|Participants will undergo a training course for a total of 4 FAD hours. They will receive theoretical narrative medicine education with 4 hours of distance education.
62272452|NCT03003208|OTHER|Pulmonary rehabilitation|
62287035|NCT06547957|EXPERIMENTAL|Part 1B dose escalation|EOS301984 in combination with other cancer therapies
62635306|NCT05558319|EXPERIMENTAL|EXPERIMENTAL ARM (B): Extended VRD and Early Rescue Intervention|"INDUCTION: Includes two experimental lines:~1. VRD extended to 18 cycles: Induction (VRDx6): Bortezomib (SC) 1.3 mg/m2, D: 1, 4, 8, and 11 (Q4W). Lenalidomide 25 mg (PO), D: 1-21 (Q4W). Dexamethasone 40 mg (PO) D 1 to 4 and 9 to 12 (Q4W). Isatuximab (IV) 10 mg/kg, D: 1, 8, 15, and 22 (Q4W) and D: 1-15 in subsequent cycles.~2. Early detection of treatment failure and Early Rescue Intervention (ERI): Isatuximab-Iberdomide-Dexamethasone in continuous treatment. Isatuximab (IV) 10mg/kg Cycle 1: Days 1, 8, 15, and 22 (Q4W). Cycles 2 onwards: Days 1 and 15 (Q4W). Isatuximab will be infused monthly after 1 year treatment (Day 1 Q4W) including ASCT. Iberdomide (PO) 1,6 mg. D: 1-21 (Q4W). Dexamethasone (PO) 40 mg. D: 1, 8, 15, and 22 (Q4W).~ASCT. The conditioning regimen is melphalan 200 mg/m2. CONSOLIDATION (VRDx2)- Extended VRD: VDx10, followed by lenalidomide plus dexamethasone maintenance.~CONTINUOUS TREATMENT: Lenalidomide 15 mg, D: 1-21, and dexamethasone 20 mg, D: 1-4 (Q4W)."
62635307|NCT05558319|EXPERIMENTAL|EXPLORATORY ARM (C)|"INDUCTION: Iberdomide plus Isatuximab, bortezomib and dexamethasone (four cycles). Isatuximab (IV) 10 mg/kg D 1, 8, 15, and 22 in the first Q4W; and days 1-15 in subsequent cycles. Iberdomide (PO) at 1.6 mg on days 1-21 of every 4-week cycle. Bortezomib (SC) at 1.3 mg/m2 on days 1, 4, 8, and 11 of every 4-week cycle. Dexamethasone 40 mg (PO) D 1-4, 9-12 (Q4W).~ASCT. The conditioning regimen is melphalan 200 mg/m2.~CONSOLIDATION: two cycles (Q4W) of Isatuximab, Iberdomide, Bortezomib and Dexamethasone, as in induction, starting approximately 2 months after hospital discharge or 3 months after transplantation. Isatuximab will be infused monthly since the start of continuous therapy (after the second cycle of consolidation).~CONTINUOUS TREATMENT: Iberdomide and monthly Isatuximab until progression, unacceptable toxicity, patient withdrawal, loss to follow up or death. During continuous treatment, dexamethasone 40 mg is used as a standardized premedication for Isatuximab."
62635308|NCT05944185|EXPERIMENTAL|CAR T cells|
62272453|NCT03554915||Ketamine-based Protocol|The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
62272454|NCT03554915||Midazolam-based Protocol|The second 6 month period of the study will employ a midazolam-based protocol for prehospital agitation. There will again be a tiered dosing protocol based on degree of agitation.
62272455|NCT00512798|EXPERIMENTAL|Phase I|
62635309|NCT03679559|EXPERIMENTAL|Arm I (home-based walking program, resistance training)|Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
62635310|NCT03679559|EXPERIMENTAL|Arm II (home-based Zumba program, resistance training)|Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
62635311|NCT03679559|EXPERIMENTAL|Arm III (HIIT, resistance training)|Participants wear Fitbit and attend supervised HIIT exercise sessions 3 days per week over 12 weeks. Participants receive resistance training as in Arm I.
62635312|NCT03679559|ACTIVE_COMPARATOR|Arm IV (supervised moderate intensity walking program)|Participants wear Fitbit and attend supervised moderate intensity walking sessions weekly for 50-60 each over 12 weeks. Participants undergo resistance training as in Arm I.
62635313|NCT03679559|ACTIVE_COMPARATOR|Arm V (usual physical activity)|Participants wear Fitbit and continue their usual physical activity over 12 weeks.
62635314|NCT06278948|EXPERIMENTAL|Group TP: Test Product|Subjects (aged 20-50 years) with mild to severe facial epidermal melasma for more than 1 year
62635315|NCT06278948|ACTIVE_COMPARATOR|Group CYS: Cysteamine 5%|Subjects (aged 20-50 years) with mild to severe facial epidermal melasma for more than 1 year
62635316|NCT01059773|EXPERIMENTAL|Immediate Methotrexate Cessation|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
62635317|NCT01059773|ACTIVE_COMPARATOR|Gradual Reduction of Methotrexate|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.
62635318|NCT01358292|EXPERIMENTAL|Semi-extended surgical technique|The experimental technique for implanting an intramedullary tibia nail is with the knee in 10-20 degrees of flexion.
62635319|NCT01358292|ACTIVE_COMPARATOR|Standard Surgical Technique|The standard surgical technique in intramedullary tibia nailing is with the knee in almost 90 degrees of flexion.
62272456|NCT00512798|EXPERIMENTAL|Phase II|
62635320|NCT01161810||Post-Burn Rehabilitation|Patients with an acute burn injury who are admitted to the hospital with anticipated length of stay of 5 days or greater
62272457|NCT00836212|EXPERIMENTAL|LPV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
62635321|NCT01514383|EXPERIMENTAL|Surgical Adhesive|The surgical adhesive (cyanoacrylate) will be used once to close the topical skin surgical incision created during surgical procedures.
62272458|NCT00836212|EXPERIMENTAL|EFV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
62453445|NCT00046865|SHAM_COMPARATOR|Usual Care|Arm III: Patients receive usual nausea care during the second or third course of chemotherapy.
62272459|NCT05776433||Unilateral upper extremity lymphedema women after breast cancer treatment|The study group consisted of women aged 18-50 years with unilateral upper extremity lymphedema after breast cancer treatment.
62272460|NCT02064387|EXPERIMENTAL|Schedule 1 Part 1|Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.
62272461|NCT02064387|EXPERIMENTAL|Schedule 2 Part 1|Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.
62635322|NCT00660712||1|Patients with bipolar disorder
62635323|NCT02021292|EXPERIMENTAL|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
62635324|NCT02021292|PLACEBO_COMPARATOR|Placebo|Matching placebo oral tablet, to be taken once daily.
62635325|NCT03943914|EXPERIMENTAL|"An early NIV strategy associated with HFNC-O2"|
62635326|NCT03943914|ACTIVE_COMPARATOR|"A late NIV strategy associated with COT"|
62635327|NCT01912950|EXPERIMENTAL|Prowave LX IPL|One area on forearm will receive treatment with Prowave LX IPL
62635328|NCT01912950|NO_INTERVENTION|No Treatment|No treatment administered on one area of forearm
62635329|NCT03050177|EXPERIMENTAL|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
62635330|NCT03050177|ACTIVE_COMPARATOR|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
62635331|NCT05208996|EXPERIMENTAL|siCoV/KK46|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use
62635332|NCT04891302|EXPERIMENTAL|Clevudine|Clevudine 150 mg once a day for 10 days
62635333|NCT04891302|PLACEBO_COMPARATOR|Placebo|Matching Placebo once a day for 10 days
62067641|NCT03418870|NO_INTERVENTION|Family-Centered Care (FCC)|Infants assigned to usual FCC will have NICU nurses as primary caregivers per standard NICU protocol. FCC provides parents with orientation to the NICU; individualized teaching and support; and encouragement to participate in infant care under nursing supervision. Individualized support from social workers, lactation consultants and other specialists will be offered. As part of the study, parents will be asked to use the We3Health mobile app track their time in the NICU, time learning and time spent in infant caregiving activities and to keep of a journal of their NICU experience.
62635334|NCT00715559|EXPERIMENTAL|cysteamine bitartrate|Participants received cysteamine bitartrate by mouth up to 300 mg three times daily.
62635335|NCT03227393|NO_INTERVENTION|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
62635336|NCT03227393|EXPERIMENTAL|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
62635337|NCT05269368|EXPERIMENTAL|No wicking|Absence of Wicking after intervention
62635338|NCT05269368|ACTIVE_COMPARATOR|Control|Wicking after intervention
62067642|NCT03817021|EXPERIMENTAL|All Factors On|Nutrition and Physical Activity Self-Assessment of Childcare (Core NAP SACC) will be turned on ECE Provider intervention will be turned on Parent intervention will be turned on Child intervention will be turned on
62067643|NCT03817021|EXPERIMENTAL|NAP SACC on/ECE on/Parent on|Core NAP SACC will be turned on ECE Provider intervention will be turned on Parent intervention will be turned on Child intervention will be turned off
62067644|NCT03817021|EXPERIMENTAL|NAP SACC on/ECE on/Child on|Core NAP SACC will be turned on ECE Provider intervention will be turned on Parent intervention will be turned off Child intervention will be turned on
62635339|NCT04924634||Students|Students from 4 universities, regardless of field of study and academic year
62635340|NCT02336867|EXPERIMENTAL|Experimental group|closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
62635341|NCT02336867|OTHER|Control group|advancement flap technique
62635342|NCT06111768|EXPERIMENTAL|SGLT2i administration|A 10 mg oral dose of dapagliflozin will be administered daily for three days.
62635343|NCT06111768|NO_INTERVENTION|Usual Care|Subjects continue with usual care.
62067645|NCT03817021|EXPERIMENTAL|NAP SACC on/ECE on|Core NAP SACC will be turned on ECE Provider intervention will be turned on Parent intervention will be turned off Child intervention will be turned off
62067646|NCT03817021|EXPERIMENTAL|NAP SACC on/Parent on/Child on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned on Child intervention turned on
62067647|NCT03817021|EXPERIMENTAL|NAP SACC on/Parent on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned on Child intervention turned off
62067648|NCT03817021|EXPERIMENTAL|NAP SACC on/Child on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned off Child intervention turned on
62635344|NCT03163407|ACTIVE_COMPARATOR|Norepinephrine group|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
62635345|NCT03163407|ACTIVE_COMPARATOR|Ephedrine group|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
62067649|NCT03817021|EXPERIMENTAL|NAP SACC on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned off Child intervention turned off
62067650|NCT05902221|ACTIVE_COMPARATOR|Antibiotic treatment backbone alone|Amoxicillin or moxifloxacin to the investigator's discretion
62067651|NCT05902221|EXPERIMENTAL|Antibiotic treatment backbone + rifampicin|Amoxicillin or moxifloxacin to the investigator's discretion + RIMACTAN
62067652|NCT01720134||after legislation 1st july 2003|2003-2006
62067653|NCT01720134||before legislation 1st july 2003|1999-2003
62067654|NCT04719403|EXPERIMENTAL|VIDEO|Participants receive access to video recordings of their clinic visits
62067655|NCT04719403|NO_INTERVENTION|Usual Care|Participants receive usual care (UC), which is their normal clinic visit and written after-visit summary
62067656|NCT03422263||Patients with T2DM under new therapy with SGLT-2-Inhibitors|Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
62272462|NCT02064387|EXPERIMENTAL|Schedule 1 Part 2|Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.
62272463|NCT02064387|EXPERIMENTAL|Schedule 2 Part 2|Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.
62272464|NCT02895061|EXPERIMENTAL|A: Daily|A: oral daily alfacalcidol treatments total 6 microgram/week
62272465|NCT02895061|EXPERIMENTAL|B: Pulse|B: pulse (trice a week) alfacalcidol treatments total 6 microgram/week
62272466|NCT05797701|EXPERIMENTAL|Treatment A|Single dose of SAR443820 tablet in fasted condition
62272467|NCT05797701|EXPERIMENTAL|Treatment B|Single dose of SAR443820 capsule in fasted condition
62272468|NCT05797701|EXPERIMENTAL|Treatment C|Single dose of SAR443820 tablet in fasted condition
62272469|NCT05797701|EXPERIMENTAL|Treatment D|Single dose of SAR443820 tablet in fed condition
62272470|NCT02665507|ACTIVE_COMPARATOR|LLLI|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition LLLI (low level laser irradiation) treatment performed with Gallium-Aluminium-Arsenide 808 nm laser ( GaAlAs 808nm laser ).
62272471|NCT02665507|SHAM_COMPARATOR|Sham|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition sham LLLI treatment
62272472|NCT00554125|ACTIVE_COMPARATOR|2, III ,intervention|
62067657|NCT03422263||Patients with T2DM without SGLT-2-Inhibitors.|Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
62067658|NCT03422263||Patients without T2DM manifesting similar comorbidities|Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)
62067659|NCT01836627|EXPERIMENTAL|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
62067660|NCT01836627|NO_INTERVENTION|Control|The control group will continue with their current daily care
62272473|NCT02579655|ACTIVE_COMPARATOR|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
62272474|NCT02579655|ACTIVE_COMPARATOR|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
62272475|NCT02579655|ACTIVE_COMPARATOR|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
62272476|NCT02579655|NO_INTERVENTION|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
62272477|NCT00281879|ACTIVE_COMPARATOR|Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)|
62272478|NCT00281879|ACTIVE_COMPARATOR|Busulfan and Cyclophosphamide (Cytoxan)|
62272479|NCT00281879|ACTIVE_COMPARATOR|BEAM Regimen|On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
62287036|NCT05831982|EXPERIMENTAL|Intervention (A)|Intervention focusing on strength training and nutritional optimization.
62287037|NCT05831982|ACTIVE_COMPARATOR|Control (B)|Usual care. Physiotherapy (type of training decided by the physiotherapist) without nutritional intervention.
62287038|NCT03681444|EXPERIMENTAL|Regular diet|no dietary restriction
62287039|NCT03681444|PLACEBO_COMPARATOR|Clear fluid diet|no solid material
62272480|NCT00281879|ACTIVE_COMPARATOR|Low-Dose Fludarabine and TBI(for second stem cell donation)|A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
62635346|NCT04607902|ACTIVE_COMPARATOR|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
62635347|NCT04607902|EXPERIMENTAL|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
62635348|NCT04607902|EXPERIMENTAL|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
62635349|NCT06143046|EXPERIMENTAL|mRNA-1345 Dose A|Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single intramuscular (IM) injection of mRNA-1345 Dose A.
62635350|NCT06143046|EXPERIMENTAL|mRNA-1345 Dose B|Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single IM injection of mRNA-1345 Dose B.
62635351|NCT06143046|EXPERIMENTAL|mRNA-1345 Dose C|Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single IM injection of mRNA-1345 Dose C.
62635352|NCT06143046|PLACEBO_COMPARATOR|Placebo|Participants will receive single IM injection of mRNA-1345 vaccine matching placebo in the period from 28 weeks to 36 weeks of gestation.
62272481|NCT00281879|ACTIVE_COMPARATOR|Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)|On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
62272482|NCT00281879|ACTIVE_COMPARATOR|ATG For Cord Blood Transplants|If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
62287040|NCT03681444|EXPERIMENTAL|Low residue diet|easy digestible food
62453446|NCT05116995|ACTIVE_COMPARATOR|Rivaroxaban first|Patients will be treated with rivaroxaban 2.5 mg twice a day for one week then on Day 21, will be treated with ticagrelor 60 mg twice a day for one week.
62287041|NCT05190952|ACTIVE_COMPARATOR|Group 1|Control Group (Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure).
62453447|NCT05116995|ACTIVE_COMPARATOR|Ticagrelor first|Patients will be treated with ticagrelor 60 mg twice a day for one week then on Day 21, will be treated with rivaroxaban 2.5 mg twice a day for one week.
62453448|NCT01437865|EXPERIMENTAL|Gadofosveset enhanced MRI Axilla|
62453449|NCT03775395|EXPERIMENTAL|HAIC plus Lenvatinib|
62453450|NCT03775395|ACTIVE_COMPARATOR|HAIC plus Sorafenib|
62453451|NCT04971096|EXPERIMENTAL|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
62453452|NCT04971096|EXPERIMENTAL|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
62453453|NCT04971096|PLACEBO_COMPARATOR|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
62272483|NCT00281879|ACTIVE_COMPARATOR|DLI (Donor Leukocyte Infusion)|Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
62272484|NCT00281879|ACTIVE_COMPARATOR|Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)|On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
62272485|NCT00253630|EXPERIMENTAL|Treatment (vorinostat)|Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62272486|NCT01240642|EXPERIMENTAL|ASA404|
62272487|NCT00896311|ACTIVE_COMPARATOR|1|Treatment solution consisted of 100 micrograms/mL of nitroglycerin. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
62272488|NCT00896311|PLACEBO_COMPARATOR|2|Placebo solution was saline. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
62272489|NCT03431571|OTHER|Single arm|ReLEx SMILE treatment can be done binocular or monocular, no masking and randomization used, no control group
62272490|NCT02342795|EXPERIMENTAL|cigarette substitute|The QuitSmart cigarette substitute is a plastic tube that looks like a real cigarette and is designed to provide the same draw resistance as a smoker's usual cigarette. There is no drug delivery with this product. Two cigarette substitutes and a product manual are provided to participants following randomization and replacement products are provided throughout the intervention period (24 weeks).
62272491|NCT02342795|EXPERIMENTAL|e-cigarette (with 0 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 0 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
62272492|NCT02342795|EXPERIMENTAL|e-cigarette (with 8 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 8 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
62272493|NCT02342795|EXPERIMENTAL|e-cigarette (with 36 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 36 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
62272494|NCT06343675||Cross-sectional study with sub-group interviews|Dental staff
62272495|NCT01411085|EXPERIMENTAL|Risperidone + Desipramine|All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
62272496|NCT04620460|ACTIVE_COMPARATOR|LIFUS-left DLPFC|20 patients will be treated with active LIFUS for 3 weeks on the left DLPFC.
62272497|NCT04620460|SHAM_COMPARATOR|LIFUS-SHAM|20 patients will be treated with sham LIFUS for 3 weeks on the left DLPFC.
62272498|NCT01525004|ACTIVE_COMPARATOR|Standard dose trivalent inactivated influenza vaccine|
62272499|NCT01525004|EXPERIMENTAL|High-Dose trivalent inactivated influenza vaccine|
62272500|NCT05779982||Multicenter retrospective cohort|This study included patients diagnosed with breast cancer who received neoadjuvant systemic therapy (NAST) followed by curative surgery between January 2013 and December 2018. All patients were cN1-3 breast cancer at initial presentation confirmed by any imaging studies (either ultrasonography or MRI) or pathological examination using ultrasonography-guided needle biopsy of suspicious axillary lymph nodes. The clinical nodal stage was determined based on findings from physical examination, with imaging studies such as ultrasonography or MRI taken into account, according to the American Join Committee on Cancer guidelines (7th edition). In addition, all patients underwent sentinely lymph node biopsy (SLNB) followed by axillary lymph node dissection. SLNB was performed using a radioactive marker, blue dye, or both (dual tracers).
62272501|NCT02797808|EXPERIMENTAL|Children with OCD|Children with obsessive compulsive disorder, not currently on medication for OCD
62272502|NCT02797808|ACTIVE_COMPARATOR|Healthy Control Children|Children without obsessive compulsive disorder
62272503|NCT02510768|EXPERIMENTAL|ELAPR002f|ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
62272504|NCT02510768|EXPERIMENTAL|ELAPR002g|ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
62272505|NCT02510768|PLACEBO_COMPARATOR|Saline|Saline
62272506|NCT02482129|EXPERIMENTAL|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
62272507|NCT02482129|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
62272508|NCT01759758|ACTIVE_COMPARATOR|Plaster Ulnar Gutter Splint|Patients will have their hand placed in a conventional Plaster ulnar gutter splint. This immobilizes all joints of the ring and small fingers and the wrist
62272509|NCT01759758|EXPERIMENTAL|Thermoplastic Splint|Patients will be fitted with a custom molded thermoplastic splint that stabilizes the metacarpals of the injured hand but does not immobilize any joints
62272510|NCT04659460|EXPERIMENTAL|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
62453454|NCT04971096|NO_INTERVENTION|Healthy Control|No intervention
62067661|NCT05632536|ACTIVE_COMPARATOR|GROUP ESP|Before the operation, under general anesthesia, group ESP (n=30) patients will be blocked with the sacral ESP block method. By giving the lateral decubitus position, the linear ultrasound probe will be placed in the sterilized area longitudinally on the midline of the sacrum. The erector spinae muscle and the sacral medial crest will be visualized. The 22 gauge, 50 mm needle will be advanced in the direction from cranial to caudal to reach the sacral crest. 0.25% bupivacaine from a dose of 1 mL kg-1 will be aspirated and injected every 2 mL under the erector spina muscle at the level of the median sacral crest at the level of the 4th sacral vertebra. (A test dose will be administered with 1 mL of saline.)
62067662|NCT05632536|SHAM_COMPARATOR|GROUP C|Group C (n=30) patients to whom caudal block will be applied will be placed in the lateral decubitus position and the linear ultrasound probe will be placed longitudinally in the sterilized area on the midline of the sacrum. A 2.5 cm 22 gauge needle will be inserted over the back skin of the sacral hiatus (located distal to the sacrum and formed by the two sacral cornua on its lateral edges) at a 90° position. The sacrococcygeal ligament will be crossed, the needle will be oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. After entering the sacral hiatus and confirming the location with negative aspiration method, 1 mL kg-1 0.25% bupivacaine will be injected by aspiration every 2 mL (test dose will be administered with 1 mL saline).
62272511|NCT04659460|SHAM_COMPARATOR|Sham Remote Ischemic Conditioning|RIC sham interventions will be applied to the upper extremity for a total of 20 cumulative minutes. For sham, inflation will occur.
62272512|NCT01206205|EXPERIMENTAL|Lenalidomide, Bortezomib|"3 induction cycles of bortezomib, lenalidomide and dexamethasone (VRD) followed by high dose melphalan and autologous stem cell transplantation.~Two months after haematological recovery, patients will receive 2 consolidation cycles of VRD and maintenance therapy for 1 year with lenalidomide."
62272513|NCT03544827|EXPERIMENTAL|Atropine 0.01% then atropine 0.1%|Participants will be on topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
62272514|NCT03544827|EXPERIMENTAL|Atropine 0.1% then atropine 0.01%|Participants will be on topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
62635353|NCT04893551|EXPERIMENTAL|Tilvestamab|Participants will receive tilvestamab at a low starting dose level (Cohort A) given via intravenous (IV) infusion every 2 weeks. Dose escalations to subsequent cohorts (Cohort B and Cohort C) will be decided by the Protocol Steering Committee (PSC) after review of all Cycle 1 (28 days cycle) safety and pharmacokinetics (PK) data up to Cycle 1 Day 22 for all participants in the ongoing cohort.
62635354|NCT02047279|ACTIVE_COMPARATOR|MVS + maze|"Procedure: Maze procedure, mitral valve surgery~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed."
62635355|NCT02047279|EXPERIMENTAL|MVS + maze + LA reduction|"Procedure: maze procedure, mitral valve surgery, left atrial reduction~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.~The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape."
62635356|NCT01441973|EXPERIMENTAL|Elotuzumab, 20 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1: Days 1 and 8. Cycle 2 and beyond: Day 1 only.
62635357|NCT01441973|EXPERIMENTAL|Elotuzumab, 10 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1 and 2: Days 1, 8, 15, and 22. Cycle 3 and beyond: Days 1 and 15.
62272515|NCT01703780||resistant hypertension|blood pressure remaining above goal (\< 140/90 mm Hg for the general population and \< 130/80 mm Hg for patients with diabetes or renal disease) despite using optimal doses of 3 antihypertensive agents of different classes(including a diuretic) for half to one year.
62635358|NCT03836157|EXPERIMENTAL|Mirvetuximab and Bevacizumab|"* Mirvetuximab Soravtansine 6mg/kg IV (adjusted ideal body weight), on day 1 of each 21 day cycle.~* Bevacizumab 15 mg/kg, IV, on day 1 of each 21-day cycle."
62635359|NCT04187833|EXPERIMENTAL|Nivolumab + Talazoparib|Nivolumab 480mg intravenously every 4 weeks (28 days) + Talazoparib 1mg orally daily
62635360|NCT06336317|ACTIVE_COMPARATOR|Vaccination arm|Influenza vaccine (Vaxigrip Tetra Sanofi Pasteur Europe).
62635361|NCT06336317|PLACEBO_COMPARATOR|Placebo arm|Sodium Chloride (Placebo) Solution for infusion, 9mg/ml ATC code: B05BB01
62635362|NCT04797988|EXPERIMENTAL|eon FR 1064 nm Device|Patient will be treated with the eon FR 1064 nm device.
62635363|NCT04007328|EXPERIMENTAL|methylprednisolone|20 mg of methylprednisolone IV Q12H for 5 days
62635364|NCT04007328|PLACEBO_COMPARATOR|Placebo|normal saline IV Q12H for 5 days
62635365|NCT05354518|EXPERIMENTAL|gestational diabetes management simulation|
62635366|NCT05354518|NO_INTERVENTION|no intervention will be made|
62635367|NCT01448252|ACTIVE_COMPARATOR|TCV|multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
62067663|NCT03236922|ACTIVE_COMPARATOR|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
62067664|NCT03236922|ACTIVE_COMPARATOR|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
62272516|NCT01703780||controllable hypertension|blood pressure can reach 130/80 mm Hg or less in half year by use of optimal dose of less than 3 antihypertensive agents of different classes
62287042|NCT05190952|ACTIVE_COMPARATOR|Group 2|Ketamine Group (In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes).
62635368|NCT01448252|SHAM_COMPARATOR|Placebo|saline injections subcutaneously at the same 4 time points with active treatment
62635369|NCT03808233||Spinal Muscular Atrophy Type 1|Non rolling infants or children with SMA
62635370|NCT03808233||Non Rolling Function matched control|Non rolling typically developing infant
62635371|NCT01898169|EXPERIMENTAL|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|
62635372|NCT03063736|EXPERIMENTAL|Td vaccine with entolimod|Td vaccine (4 ug) + Entolimod (1 ug) (n=25)
62067665|NCT05730530|EXPERIMENTAL|Intervention|Classroom assigned to receive the 6-week long nutrition education curriculum
62067666|NCT05730530|NO_INTERVENTION|Control|Classroom assigned to receive no intervention
62067667|NCT04962438||Tumor patients using anti-VEGF drugs|
62067668|NCT01203839|EXPERIMENTAL|Radiation treatment|This is a Phase II single-arm study of PBI with external-beam radiation therapy in which a group of select women with early-stage invasive and noninvasive breast cancer will be given radiation to the partial breast.
62635373|NCT03063736|PLACEBO_COMPARATOR|Td vaccine only|Td vaccine (4 ug) (n=15)
62635374|NCT00817622|PLACEBO_COMPARATOR|A|"Placebo, Placebo :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day) Placebo pearl + corn oil 400 mg per day for 12 weeks"
62635375|NCT00817622|ACTIVE_COMPARATOR|B|"EPA, Placebo :~EPA pearls,500 mg QID for 12 Weeks (2000 mg per day),From MINAMINUTRITION Company(Belgium)+ Placebo pearl ,corn oil 400 mg per day for 12 weeks"
62635376|NCT00817622|PLACEBO_COMPARATOR|C|"Placebo ,Vitamin E :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day)+ Vitamin E pearls, 400 mg from DANA Company(IRAN) per day for 12 weeks"
62067669|NCT04707690|ACTIVE_COMPARATOR|Intraurethral laser therapy|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic fluid (Cathejell ®) will be applied to the urethral meatus. Before laser therapy, an intraurethral swab will be taken before treatment in order to determine the intraurethral microbiome.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Incontinence mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2."
62067670|NCT04707690|PLACEBO_COMPARATOR|Intraurethral SHAM laser therapy|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
62635377|NCT00817622|ACTIVE_COMPARATOR|D|"EPA, Vitamin E :~EPA pearls,500 mg QID From MINAMINUTRITION Company(Belgium) for 12 Weeks (2000 mg EPA per day)+ Vitamin E pearls, 400 mg from DANA Company ( IRAN) per day for 12 weeks"
62635378|NCT03086629|OTHER|PCI Group|Participants who are patients of consultants randomized to this group will use the PCI during clinics.
62635379|NCT03086629|OTHER|Non PCI Group|Participants who are patients of consultants randomized to this group will not use the PCI during clinics.
62635380|NCT01776970|EXPERIMENTAL|Sativex|Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml)
62635381|NCT01776970|PLACEBO_COMPARATOR|Placebo|Placebo oromucosal spray
62635382|NCT04221919|EXPERIMENTAL|Carvedilol|
62635383|NCT04221919|EXPERIMENTAL|Bisoprolol|
62635384|NCT04221919|EXPERIMENTAL|Metoprolol tartrate|
62635385|NCT04221919|EXPERIMENTAL|Metoprolol succinate|
62635386|NCT01726296|EXPERIMENTAL|Health services research (educational intervention)|Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.
62635387|NCT04001088|EXPERIMENTAL|Probiotic|Probiotics in a capsule.
62635388|NCT04001088|PLACEBO_COMPARATOR|Placebo|Non active ingredients in a capsule.
62453455|NCT04478019|OTHER|Control > Active Intervention|Treatment is 3 weeks of standard personal protective equipment without any povidone-iodine (PI) or chlorhexidine gluconate (CHG) intervention (control), followed by a 2 weeks washout period, and 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures.
62453456|NCT04478019|OTHER|Active Intervention > Control|Treatment is 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures, followed by 2 weeks of washout, and 3 weeks of standard personal protective equipment without any PI or CHG intervention (control).
62635389|NCT05928039|ACTIVE_COMPARATOR|TNFα antagonist|"Participants will receive either:~* Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks; OR~* Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks"
62067671|NCT02617264|EXPERIMENTAL|Axillary lymph node FNA Biopsy|A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer
62067672|NCT03380793|EXPERIMENTAL|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
62067673|NCT04060225|EXPERIMENTAL|Participants|Participants will be asked to participate in a single arm study with three phases (washout phase, abstinence phase, and exposure phase). These participants will first be asked to abstain from drinking any caffeinated food or beverages for 72 hours (known as the washout phase). Following the first phase, participants will then wear a blood pressure cuff to collect diastolic and systolic blood pressure for 24 hours (abstinence phase) wherein they will be asked to refrain from caffeinated products. Participants will then drink the coffee intervention and collect blood pressure measurements for 24 hours (exposure phase).
62453457|NCT05511597|EXPERIMENTAL|SBT+CP|Split-belt training + complex task practice
62635390|NCT05928039|ACTIVE_COMPARATOR|Anti-IL12/23 or anti-IL23|"Participants will receive either:~* Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks; OR~* Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks"
62635391|NCT05928039|ACTIVE_COMPARATOR|Anti-integrin|"Participants will receive either:~* Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks; OR~* Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks"
62635392|NCT04609657|PLACEBO_COMPARATOR|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
62453458|NCT05511597|ACTIVE_COMPARATOR|SBT+PL|Split-belt training + static exercise
62453459|NCT04884893|EXPERIMENTAL|Intermittent nitrous oxide|10 minutes of 50% nitrous oxide + 10 min 100% oxygen + 10 min 50% nitrous oxide + 10 min 100% oxygen
62635393|NCT04609657|PLACEBO_COMPARATOR|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
62067674|NCT03959670||extensive TAAA|including Crawford extent I and II TAAA
62067675|NCT03959670||Crawford extent III TAAA|
62067676|NCT03959670||supra-renal aortic aneurysms|Crawford extent IV TAAA and para-renal abdominal aortic aneurysms.
62067677|NCT05334927||Medicine Overuse Headache/New Daily Persistent Headache|The first 18 months were followed up once a month,then followed up once at the 24th month,follow-up visits were made annually after 24 months
62067678|NCT05334927||Chronic Migraine|The patients were followed up at 1, 2, 3, 6, 9, 12, 18 and 24 months,then follow-up visits were made annually
62067679|NCT05334927||Patients with other types of primary headache|The patients were followed up at 3, 6, 9months
62287043|NCT05190952|ACTIVE_COMPARATOR|Group 3|Dexamethasone Group (In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes).
62453460|NCT04884893|EXPERIMENTAL|Continuous nitrous oxide|20 min 50% nitrous oxide + 20 min 100% oxygen
62453461|NCT01208012|NO_INTERVENTION|Metformin|Patients taking Metformin at individual dose
62453462|NCT01208012|EXPERIMENTAL|Metformin and Liraglutide|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
62067680|NCT04703634|EXPERIMENTAL|erector spinae group|All blocks will be done under general anesthesia. Using a 6-10 MHz linear ultrasound (Esaote my-lab 6, Italy). With the ultrasonography device of our clinic, the side of the nephrectomy surgery will be performed with the position of the nephrectomy, and the position (lateral decubitus) is given to the patient. The thoracic 10th vertebra will be found under ultrasound guidance. After the T12 transverse protrusion is seen by sliding 3 cm laterally from the midline, 30 ml of 0.25% Bupivacaine will be injected under the erector spinae muscle above it.
62453463|NCT02116712|EXPERIMENTAL|Saracatinib|"Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.~More regarding dose escalation is included in intervention below."
62067681|NCT04703634|PLACEBO_COMPARATOR|placebo group|No block transaction will be applied to this group. Only postoperative analgesia methods will be used for this group as specified in the protocol.
62067682|NCT05332977|EXPERIMENTAL|CAD-CAM fabricated provisional prothesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
62453464|NCT01113268|OTHER|1:cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
62453465|NCT05137678|EXPERIMENTAL|Experimental group|Glibenclamide was given orally or through nasogastric tube, 1.25 mg every 8 hours for 7 days
62453466|NCT05137678|NO_INTERVENTION|Control group|No glibenclamide treatment
62453467|NCT02473211|EXPERIMENTAL|SOF+DCV|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
62453468|NCT02527096|EXPERIMENTAL|dolutegravir(Tivicay®) and lamivudine(Epivir®)|
62453469|NCT02068040|EXPERIMENTAL|CocoaVia capsules|From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin
62453470|NCT05333523|EXPERIMENTAL|Sentinel lymph node biopsy guided selective elective neck irradiation|"* Sentinel lymph node biopsy~* Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with selective elective neck irradiation guided by histopathologic status of the sentinel lymph node(s)"
62453471|NCT05333523|ACTIVE_COMPARATOR|Standard elective neck irradiation|- Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with standard bilateral elective neck irradiation
62067683|NCT05332977|ACTIVE_COMPARATOR|Insertion of denture conversion (DC)|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
62067684|NCT01744860||"INCa molecular genetics laboratory in-house methods"|"BRAF V600 mutations were analysed using INCa (Institut National du Cancer \[French National Cancer Institute\]) molecular genetics laboratories using in-house methods"
62067685|NCT01744860||Cobas 4800 Mutation Test|BRAF V600 mutations were analysed using Cobas 4800 mutation test
62067686|NCT04590859||Penile block|Patients undergoing procedure with penile block
62067687|NCT04590859||caudal block|Patients undergoing procedure with caudal block
62067688|NCT02281760|EXPERIMENTAL|Combination therapy with dabrafenib and trametinib in patients with ECD|Patients with Erdheim Chester Disease (ECD) and BRAFV600E mutation received combination therapy with dabrafenib, a BRAFV600E inhibitor 150mg orally every twelve hours, and trametinib, an inhibitor of MEK, downstream of BRAF, 2mg orally daily.
62067689|NCT05425030|EXPERIMENTAL|Free LSSS Arm|Participants will receive 6 months of free low-sodium salt by delivery from a community health worker. In addition, the same educational information as provided in Arm 2 (Information Only Arm, below) will be provided.
62453472|NCT05481307|EXPERIMENTAL|Fixed Sequence|Period 1: RLD2202, Period 2 : RLD2203 -\> RLD2202+RLD2203
62453473|NCT04182971|ACTIVE_COMPARATOR|Whole fruit|Phase 1 of study is an orange, Phase 2 of study is an apple
62067690|NCT05425030|ACTIVE_COMPARATOR|Information Only Arm|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
62067691|NCT05425030|NO_INTERVENTION|No Intervention|Participants will not receive any intervention of any sort.
62067692|NCT03697382|EXPERIMENTAL|Very Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 2,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
62067693|NCT03697382|EXPERIMENTAL|Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 5,000 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
62067694|NCT03697382|EXPERIMENTAL|Moderate Steps|Subjects will be asked to undergo reduced daily stepping to a level of 7,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
62067695|NCT01966796||PSI II|PSI less than 70 or equal to 70
62067696|NCT01966796||PSI III|PSI 70-90
62067697|NCT01966796||PSI IV|PSI 90-130
62067698|NCT01966796||PSI V|PSI more than 130
62067699|NCT02082626|EXPERIMENTAL|Eribulin|All patients will receive the experimental agent eribulin. The dose will increase with subsequent cohorts of patients.
62453474|NCT04182971|ACTIVE_COMPARATOR|Juice|Phase 1 of study is orange juice, Phase 2 of study is apple juice
62453475|NCT04182971|EXPERIMENTAL|Juice plus pomace fiber|Phase 1 is orange juice with added fiber, Phase 2 is apple juice with added fiber
62453476|NCT04585321|OTHER|T-R|"Part 1 (QD) and part 2 (BID):~Period 1: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.~Period 2: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac."
62067700|NCT05021003|EXPERIMENTAL|Group A|: Core stabilization training with pressure biofeedback unit
62067701|NCT05021003|ACTIVE_COMPARATOR|Group B|: Core stabilization training without pressure biofeedback unit
62067702|NCT05660915|EXPERIMENTAL|The intermediate approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
62287044|NCT06377904||Retrospective phase|Retrospective inclusion (using data of patients who had been hospitalized between April 2020 and December 2023)
62453477|NCT04585321|OTHER|R-T|"Part 1 (QD) and part 2 (BID):~Period 1: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.~Period 2: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster."
62067703|NCT05660915|OTHER|The standard approach|The area between superior mesenteric artery and superior mesenteric vein was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
62067704|NCT06547372|EXPERIMENTAL|Intervention|Throughout the 2-month intervention period, only participants in the intervention arm will be provided with bento-styled meals for lunch and dinner daily. The meals will encompass a variety of nutrient-rich ingredients, including whole grains, lean proteins, an array of fruits and vegetables, and healthy fats. The food will be prepared by a licensed food catering service.
62067705|NCT06547372|NO_INTERVENTION|Control|The control group will not receive the meals provided by our study nor will they receive any nutritional advice. Instead, they will continue following their usual dietary habits and patterns throughout the study period.
62067706|NCT02357810|EXPERIMENTAL|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62067707|NCT03178513|EXPERIMENTAL|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
62067708|NCT03178513|NO_INTERVENTION|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
62067709|NCT01469455|EXPERIMENTAL|DT01|
62067710|NCT01777958||Cohort|
62067711|NCT01863927|EXPERIMENTAL|Research arm|Each of the participants will be randomly exposed to 4 conditions during four separate consecutive days.
62067712|NCT04279327||cases|cytology positive for malignancy
62067713|NCT04279327||controls|cytology negative for malignancy
62067714|NCT03904511|EXPERIMENTAL|Low Dose Souroubea-Platanus|190 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
62067715|NCT03904511|EXPERIMENTAL|High Dose Souroubea-Platanus|380 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
62067716|NCT03904511|PLACEBO_COMPARATOR|Placebo|Inert placebo in an identical vegicap to the experimental treatment groups. Administered once daily for 14 days.
62067717|NCT00575211||Cardiomyopathy|
62067718|NCT04478513|EXPERIMENTAL|Smokers|Pre-specified group of participants.
62067719|NCT04478513|EXPERIMENTAL|Non-smokers|Pre-specified group of participants.
62067720|NCT03456167|EXPERIMENTAL|Mobile app for follow-up care|Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op \& weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 \& 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory \& surgeon.
62287045|NCT06377904||Prospective phase|Prospective inclusion (using data of patients hospitalized between January 2024 and August 2026)
62635394|NCT04609657|ACTIVE_COMPARATOR|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
62067721|NCT03456167|NO_INTERVENTION|Conventional inperson followup care|The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 \& 6 weeks post-op and attend all scheduled follow up appointments.
62067722|NCT06047236||Observational Arm|Initial diagnosis of primary salivary gland carcinoma in the head and neck region
62067723|NCT06047236||Control Group 1|Initial diagnosis of a benign salivary gland tumor in the head and neck region
62067724|NCT06047236||Control Group 2|Healthy control group. Functional diseases of the nose or ear (patients with the indication for functional ear surgery and rhinoplasty) without salivary gland tumor.
62067725|NCT05246215||STEMI group.|60 participants of patients with STEMI treated with primary percutaneous coronary intervention (pPCI).
62067726|NCT05246215||healthy group.|15 participants of healthy people as a case control.
62067727|NCT05246215||Stable angina group.|15 participants of patients stable angina
62067728|NCT01884714|EXPERIMENTAL|High fat/high calorie meal|All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
62067729|NCT01974505|EXPERIMENTAL|intubation using optiscope|The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery.
62067730|NCT06371365||Patients underwent free flap surgery|
62067731|NCT00825032|ACTIVE_COMPARATOR|1: comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
62453478|NCT05857839|EXPERIMENTAL|Myofascial release with support belt|Group A get myofascial release on sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks with support belt and a support belt should not be worn for longer than two to three hours at a time and it will be used 4 times a week.
62635395|NCT04609657|ACTIVE_COMPARATOR|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
62635396|NCT04609657|ACTIVE_COMPARATOR|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
62635397|NCT04609657|ACTIVE_COMPARATOR|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
62635398|NCT00166868|EXPERIMENTAL|Neomycin prescribed|Interventions: 10 cases received Neomycin for 6 months
62635399|NCT00166868|EXPERIMENTAL|Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed|Interventions: 10 cases received Probiotics for 6 months
62635400|NCT00166868|NO_INTERVENTION|control|10 cases without intervention were historical control.
62635401|NCT04263246|EXPERIMENTAL|PhytoDyNAmic|Six capsules per day b.i.d.
62067732|NCT00825032|EXPERIMENTAL|2: UEET + PR|Experimental program consisting in additional 15 daily sessions of unsupported UEET over and above the same PR program used for control patients.
62453479|NCT05857839|ACTIVE_COMPARATOR|Myofascial release without support belt:|Group B get myofascial release technique to sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks but without support belt. Data will be collected and analyzed at baseline and at 4 weeks follow up.
62635402|NCT04263246|PLACEBO_COMPARATOR|Inulin|Six capsules per day b.i.d.
62635403|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
62635404|NCT02751112|EXPERIMENTAL|Couple donor / recipient|"Each couple will be treated the same way :~An additional blood sample of the donor will be taken prior GCSF mobilization. This blood sample will then be analyzed via Predictor's kit, by the immunology laboratory of the hospital where the graft will be done.~Whatever the result given by the Predictor' kit, the graft will be done for the recipient patient. No change will be done on the usual graft process."
62635405|NCT05238636||Stretta|Patients that have undergone or are to undergo the Stretta procedure
62635406|NCT05238636||LINX|Patients that have undergone or are to undergo the LINX device
62067733|NCT00847990||Pregnant women|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will receive the fetal FISH and/or karyotype results from the procedure.
62635407|NCT05238636||Laparoscopic fundoplication|Patients that have undergone or are to undergo laparoscopic fundoplication.
62635408|NCT02541331|EXPERIMENTAL|ISMIGEN|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
62635409|NCT02541331|PLACEBO_COMPARATOR|PLACEBO|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
62635410|NCT05051046|EXPERIMENTAL|Hypnosis|
62635411|NCT05051046|NO_INTERVENTION|General anesthesia|Common practice
62272517|NCT01703780||healthy control|"1. Age\>50 years old~2. Blood pressure ≤ 120/80 mm Hg( 24-hour blood pressure monitor or home blood pressure measurement at 6-9 am and 5-8pm, twice)~3. No cardiovascular diseases: coronary artery disease(coronary angiography or CTA), cerebrovascular diseases(history, MRI-Lacunar brain stem), Carotid ultrasound~4. No peripheral angiopathy (ABI\<0.9 or lower extremity vessels Doppler ultrasound)~5. No major cardiovascular risk factors:~   1. Dyslipidemia~  2. Diabetes~  3. Smoke within one year"
62272518|NCT04011280|EXPERIMENTAL|Low Dose Varenicline|0.5 mg twice daily with 0.5 mg daily titration over one full week
62272519|NCT04011280|ACTIVE_COMPARATOR|Standard Dose Varenicline|1.0 mg twice daily with standard titration
62272520|NCT05235035||health care professionals|Staff from the department of anesthesia and general resuscitation and thoracic cardiac pediatric with patient contact that regularly works in shifts including night shifts
62272521|NCT04754451|NO_INTERVENTION|Group P(placebo)|Attach two placebo patches for 12 hours, above and below the incision site.
62272522|NCT04754451|EXPERIMENTAL|Group L(lidocaine patch)|Attach two lidocaine patches for 12 hours, above and below the incision site.
62272523|NCT00065728|EXPERIMENTAL|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
62272524|NCT01060059||exenatide|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide.
62635412|NCT06018805|ACTIVE_COMPARATOR|Body Mass Index≥30 kg/m2|Pregnant women with a Body Mass Index≥30 kg/m2 will be included.
62272525|NCT01060059||basal insulin|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin.
62635413|NCT06018805|ACTIVE_COMPARATOR|Body Mass Index: 18,5 - 24,9 kg/m2|Pregnant women with a Body Mass Index between 18.5 and 24.9 kg/m2 will be included.
62635414|NCT02843464|EXPERIMENTAL|long-term RIPC group|routine treatment + once RIPC/day for a year. Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
62635415|NCT02843464|NO_INTERVENTION|control group|routine treatment.
62272526|NCT00705783|EXPERIMENTAL|Aripiprazole depot|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.
62272527|NCT00705783|PLACEBO_COMPARATOR|Placebo depot|Patients received placebo intramuscularly every 28 days for 52 weeks.
62272528|NCT04703790||Adults from the United States|Adult participants 18 years of age or older who are panelists recruited and maintained by Ipsos (KnoweledgePanel). All participants live within the United States.
62272529|NCT02948621||Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
62272530|NCT05685186||PCD Cohort|"The PCD cohort will include individuals who have a genetically confirmed diagnosis of PCD with 2 identified pathogenetic variants within 1 of 4 genetic/ultrastructural variants:~* DNAI1 ODA defect~* Other ODA defect~* IDA-MTD defect, CCDC39 or CCDC40~* Radial Spoke defect"
62272531|NCT05685186||Healthy Volunteer Cohort|The healthy volunteer cohort will include health individuals.
62272532|NCT03124784|EXPERIMENTAL|RD Disposable Sensors|All subjects are enrolled into the test group and all subjects received the RD Disposable Sensors
62272533|NCT00246428|EXPERIMENTAL|1|MI
62272534|NCT02106312|OTHER|Radiation|Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.
62272535|NCT00748579|EXPERIMENTAL|Cohort 1|0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
62635416|NCT06418113|EXPERIMENTAL|Experimental|Stereotactic biopsy will be performed on patients in the experimental group, who will then be discharged. If the histopathological diagnosis is not wildtype IDH non-mutated glioblastoma, the patient will be withdrawn from the study and receive conventional treatment. If wildtype IDH non-mutated glioblastoma is diagnosed, ten days after the biopsy, patients will undergo conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period (GEINO, 2016). Five weeks later, patients will undergo supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring. Starting from 4 weeks post-surgery, TMZ will be administered for 6 months according to the Stupp protocol.
62635417|NCT06418113|OTHER|Stupp Protocol|The Stupp protocol is a standard treatment regimen for glioblastoma, which involves a combination of radiotherapy and chemotherapy.
62635418|NCT02761590|EXPERIMENTAL|Circuit training protocol|"The CT protocol will be held in three sessions per week for 14 weeks. The volume of work is defined by the training section of time and intensity of effort by the heart rate response to exercise.~The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. that concludes in favor of the organization of training adapted to the reality of the public to be trained."
62067734|NCT04412590|EXPERIMENTAL|Vermont Family Based Approach|"The VFBA group was offered a variety of supports and services to help them achieve and maintain wellness and address emotional behavioral challenges.~All families partnered with a Family Wellness Coach (FWC) to design and implement a comprehensive program of family health and wellness with an emphasis on nutrition, exercise, music training, mindfulness, decreasing screen time, and positive parenting.~Families with a child or parent experiencing significant emotional and behavioral problems were also partnered with Focused Family Coaches (FFCs) and Family Based Psychiatrists (FBPs). FFCs and FBPs respectively provided evidence-based psychotherapy and psychiatric care from the family perspective.~Families also were also offered health promotion programs, including music lessons for all family members, behavioral parent training, yoga and mindfulness training, and nutrition coaching."
62272536|NCT00748579|EXPERIMENTAL|Cohort 2|≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
62272537|NCT02670642|EXPERIMENTAL|On demand 20 mg esomeprazole|On demand treatment with 20-mg esomeprazole once daily when needed
62272538|NCT02670642|ACTIVE_COMPARATOR|Continuous 20 mg esomeprazole|Continuous treatment with 20 mg esomeprazole once daily
62067735|NCT04412590|ACTIVE_COMPARATOR|Control|The Control Group received pediatric care as usual.
62067736|NCT02019784|ACTIVE_COMPARATOR|Rifaximin-α|Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
62067737|NCT02019784|PLACEBO_COMPARATOR|Placebo|Placebo tablets - 550mg twice daily for 90 days
62067738|NCT05801458|EXPERIMENTAL|Modeling Resin Insertion Technique|Resin Composite (Tetric® N-Ceram Nano-hybrid incremental composite) / Wetting Agent (Modeling Resin, Bisco)
62272539|NCT05852756|EXPERIMENTAL|Experimental:|pecha kucha will be practiced
62272540|NCT05852756|NO_INTERVENTION|control|Routine maintenance will be applied.
62272541|NCT04138485|EXPERIMENTAL|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
62272542|NCT04138485|PLACEBO_COMPARATOR|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
62272543|NCT01738971|NO_INTERVENTION|control (standard care)|standard verbal and written advice on contraception from pharmacy
62272544|NCT01738971|EXPERIMENTAL|rapid access|rapid access to family planning service
62272545|NCT01738971|EXPERIMENTAL|progestogen only pill|one month progestogen only pill
62635419|NCT02761590|ACTIVE_COMPARATOR|Strength training protocol|"The strength training protocol was performed in three sessions per week for 14 weeks and divided into three levels.~The initial load set for each exercise was based on the one repetition maximum test (1 RM). Strengthening exercises were performed in two sets of 15 repetitions, using 25% 1RM for hip adductors and abductors, and 50% 1RM for the quadriceps and hamstrings, using ankle weights. Exercises for the trunk were performed in 3 10-second series, increasing the duration when participants were able."
62453480|NCT05668481|ACTIVE_COMPARATOR|Constructive memory support|Participants will watch videos of a sleep expert delivering treatment components from the Transdiagnostic Sleep and Circadian Intervention (TranS-C). After each video, a team member will deliver constructive memory supports.
62453481|NCT05668481|ACTIVE_COMPARATOR|Non-constructive memory support|Participants will watch videos of a sleep expert delivering treatment components from the Transdiagnostic Sleep and Circadian Intervention (TranS-C). After each video, a team member will deliver non-constructive memory supports.
62453482|NCT06211985|ACTIVE_COMPARATOR|Bronchiolitis Group|patients admitted to the ward with a diagnosis of Bronchiolitis (Group 1)
62635420|NCT02761590|NO_INTERVENTION|Educational Protocol|In order to provide care, social interaction, and health education, an educational protocol was conducted. This protocol consisted in interactive presentations of 60 minutes, twice a month for 14 weeks, totaling 7 meetings. The topics addressed pathophysiology of osteoarthritis, and American College of Rheumatology (ACR) recommendations on nutrition, posture, and lifestyle.
62272546|NCT04561154|EXPERIMENTAL|patient hospitalized between march 1 and june 30, 2020|patient hospitalized between march 1 and june 30, 2020
62635421|NCT05667662|EXPERIMENTAL|PUR1900 40 mg|4 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
62635422|NCT05667662|EXPERIMENTAL|PUR1900 20 mg|2 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) and 2 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
62635423|NCT05667662|PLACEBO_COMPARATOR|Placebo|4 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
62635424|NCT02871141||ECT group|Patients with a major depressive episode treated with ECT. Patients will be investigated (i) prior to the 1st ECT session, (ii) after the 4th ECT session, (iii) after the 12th ECT session, and (iv) 6 months after the 1st ECT session.
62635425|NCT02871141||Antidepressant group|Patients with a major depressive episode treated with antidepressants. Patients will be investigated (i) prior to treatment, (ii) after 10 days of treatment, (iii) after 4 weeks of treatment, and (iv) after 6 months.
62635426|NCT00965237|OTHER|Multifocal CL / Single vision CL + reading glasses|Lotrafilcon B multifocal contact lenses (CL) worn first, with lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
62635427|NCT00965237|OTHER|Single vision CL + reading glasses / Multifocal CL|Lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn first, with lotrafilcon B multifocal contact lenses (CL) worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
62272547|NCT02842411||chronic constipation|patients with chronic constipation based on Rome Ⅳ
62635428|NCT04790578|EXPERIMENTAL|ZoeInsights Application Arm|Participants will receive free access to the ZI app for the 12-week intervention. After completing initial set-up, participants will be asked to record physical activity and symptoms regularly via scheduled in-app routines. Further use of ZI (eg. Custom daily routines, additional graphing, medication tracking, accessing linked health resources) during the intervention will be possible ad libitum. After the initial 12-weeks of the EXCEL+ZI intervention, participants have continued free access to the ZI app for up to 1 year.
62635429|NCT04790578|ACTIVE_COMPARATOR|Waitlist control|During the 12-week intervention the participants will only take part in an online delivered EXCEL exercise class and will not have access to the ZI app. After completion of the 24-week test, the participants will be granted access to the ZI app.
62635430|NCT06436989|EXPERIMENTAL|hot water|300ml pure water cooled to room temperature in a kettle.
62635431|NCT06436989|PLACEBO_COMPARATOR|normal temperature water|300 ml pure water without any treatment
62635432|NCT03764280|NO_INTERVENTION|MDI with Physician Adjusted Basal-Bolus Parameters|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Participants will undergo their conventional multiple daily injection (MDI) therapy.
62272548|NCT05244850||One group|Stroke patients
62272549|NCT00798746||Pyloric Drainage Procedure|Esophagectomy with pyloric drainage procedure
62635433|NCT03764280|EXPERIMENTAL|MDI with Basal-Bolus Optimization Algorithm|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Once daily, the data from the glucose sensor and injection information will be entered into a computer and the optimization algorithm will be run. Once daily, participants' parameters may be changed based on the algorithm's recommendations.
62635434|NCT04067869|EXPERIMENTAL|Single arm|Patient with confirmed HIV-1 infection
62635435|NCT05102669||vaccinated|COVID19 vaccinated subjects
62635436|NCT05102669||non vaccinated|COVID19 non vaccinated subjects
62635437|NCT06041906||Neonate, Children, Adult with CPSS|
62635438|NCT02329327|EXPERIMENTAL|Andexanet|Participants received andexanet as an intravenous bolus administered over \~15 to 30 minutes, followed immediately by a continuous infusion administered over \~120 minutes.
62635439|NCT04194489|EXPERIMENTAL|FMF Connect Intervention|
62635440|NCT02392026|EXPERIMENTAL|Metronidazole Gel|Metronidazole Vaginal Gel
62635441|NCT04302402|ACTIVE_COMPARATOR|Rifaximin|Rifaximin 550mg thrice daily for 14 days Other Name: Normix
62272550|NCT00798746||No Pyloric Drainage Procedure|Esophagectomy without pyloric drainage procedure
62272551|NCT01677715|ACTIVE_COMPARATOR|"Yili Mei Yi Tian lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
62635442|NCT04302402|PLACEBO_COMPARATOR|Placebo|Placebo thrice daily for 14 days
62635443|NCT05053269||good body weight growth|body weight growth after birth is consistent with the growth curve
62272552|NCT01677715|PLACEBO_COMPARATOR|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
62272553|NCT00023374|EXPERIMENTAL|Rifampin+PZA+Ethambutol|6 mos of intermittent (2 or 3 times weekly) therapy with REZ
62272554|NCT00865072|EXPERIMENTAL|A|Metformin HCl 750 mg Extender Release tablets, single dose
62272555|NCT00865072|ACTIVE_COMPARATOR|B|GLUCOPHAGE® XR 750 mg tablets, single dose
62272556|NCT02312492|EXPERIMENTAL|18:1 diet|Oleic Diet - volunteers will consume oleic enriched food for a period of 5 weeks.
62067739|NCT05801458|PLACEBO_COMPARATOR|Conventional Resin Composite Incremental Placement Technique|Conventional resin composite incremental placement technique (Tetric® N-Ceram Nano-hybrid incremental composite)
62067740|NCT01427192|EXPERIMENTAL|acetazolamide|1 week therapy, cross-over design
62067741|NCT01427192|PLACEBO_COMPARATOR|Placebo tablet|One week, cross-over design
62067742|NCT01427192|EXPERIMENTAL|supplemental oxygen during nights|One week, cross-over design
62067743|NCT01427192|EXPERIMENTAL|Non-invasive ventilation|One week, cross-over design
62067744|NCT01427192|SHAM_COMPARATOR|room air|room air applied via sham-oxygen-concentrator
62067745|NCT05939258||Mapo Fire Station|
62067746|NCT05936229|EXPERIMENTAL|Prevention (interferon beta-1A [FP-1201])|Patients undergo leukapheresis prior to treatment and receive FP-1201 IV for 3 days every 24 hours from day -3 through day -1 or for 5 days every 24 hours from day -5 through day -1 or on day -5, day -3, and day -1. Patients may receive lymphodepletion chemotherapy with either cyclophosphamide IV and fludarabine IV on days -5, -4, -3 followed by axi-cel IV or brexu-cel IV on day 0 or fludarabine IV over 30 minutes on days -4, -3, and -2 and cyclophosphamide IV over 60 minutes on day -2 followed by brexu-cel IV on day 0. Patients undergo x-ray imaging and ECHO or MUGA during screening. Patients also undergo CT or PET/CT as well as LP for CSF collection and/or bone marrow aspiration and biopsy as clinically indicated during screening and follow-up. Patients undergo blood sample collection on study and during follow-up as well as a tissue biopsy during screening and follow-up.
62067747|NCT01517243|EXPERIMENTAL|Alternating Sunitinib and Temsirolimus|"A cycle is defined as:~Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest"
62067748|NCT03048084|ACTIVE_COMPARATOR|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
62067749|NCT03048084|ACTIVE_COMPARATOR|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
62067750|NCT05315661|EXPERIMENTAL|Treatment Arm|injected with 3x10\^7 cells/2mL of ET-STEM to intraventricular space via an Ommaya reservoir. repeated 3 times at 4 week intervals
62067751|NCT01878123|EXPERIMENTAL|AMP-110|Escalating doses of AMP-110
62067752|NCT01878123|PLACEBO_COMPARATOR|Placebo|
62067753|NCT00981474|ACTIVE_COMPARATOR|Control|Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
62067754|NCT00981474|EXPERIMENTAL|Intervention|Blood pressure management based on cerebral autoregulation data.
62067755|NCT04446780||Women who underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery with mediolateral episiotomy
62067756|NCT04446780||Women who did not underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery without mediolateral episiotomy
62067757|NCT01199458|ACTIVE_COMPARATOR|opioid|Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
62272557|NCT02312492|EXPERIMENTAL|16:0 diet|Palmitic diet - Volunteers will consume palmitic enriched food for a period of 5 weeks.
62272558|NCT02312492|EXPERIMENTAL|18:0|Stearic Diet - Volunteers will receive Stearic enriched food for a period of 5 weeks.
62272559|NCT05913414|EXPERIMENTAL|Iron Isomaltide|Patients receive iron Isomaltide after anti-tumor therapy.
62272560|NCT05913414|ACTIVE_COMPARATOR|Oral iron supplement|Patients receive polysaccharide iron complex after anti-tumor therapy.
62272561|NCT05932550|EXPERIMENTAL|Maraviroc 300 mg/day|Open-label study
62067758|NCT01199458|PLACEBO_COMPARATOR|placebo|Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
62067759|NCT02139358|EXPERIMENTAL|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
62067760|NCT04296890|EXPERIMENTAL|Treatment|All participants will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
62067761|NCT00203151|EXPERIMENTAL|1|
62067762|NCT00203151|PLACEBO_COMPARATOR|2|
62067763|NCT02001974|EXPERIMENTAL|Group 1|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)
62067764|NCT02001974|EXPERIMENTAL|Group 2|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 100% increase to 800 mg t.i.d. if no toxicity in previous group (400 mg) three weeks on one week off (three to six patients)
62067765|NCT02001974|EXPERIMENTAL|Group 3|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 50% increase to 1200 mg t.i.d. if no toxicity in previous group (800 mg) three weeks on one week off (three to six patients).
62272562|NCT01283165||health education|This was an intervention follow up Knowledge Attitude and Practice study that investigated the distribution of polyparasitism with schistosomiasis, STHs and P. falciparum among primary schoolchildren.
62272563|NCT00181181|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin for 3 months
62272564|NCT00181181|PLACEBO_COMPARATOR|Placebo|
62272565|NCT06548906|EXPERIMENTAL|GZR4 Injection- Abdomen|Participants received GZR4 Injection by subcutaneous injection on Abdomen.
62635444|NCT05053269||poor body weight growth|body weight growth after birth is inconsistent with the growth curve
62635445|NCT00678847|PLACEBO_COMPARATOR|B|
62635446|NCT00678847|ACTIVE_COMPARATOR|A|
62067766|NCT03847467|EXPERIMENTAL|2'-Fucosyllactose|"Phase I: 36 young adult participants aged 18-25 years. Group 1: 1 gm per day n=12 (6UC/6CD) Group 2: 5 gm per day n=12 (6UC/6CD) Group 3: 10 gm per day n=12 (6UC/6CD)~Phase II (post Phase I interim safety analysis): 120 participants aged 11-25 years Group 1: 1 gm per day n=40 (20UC/20CD) Group 2: 5 gm per day n=40 (20UC/20CD) Group 3: 10 gm per day n=40 (20UC/20CD)"
62067767|NCT03847467|PLACEBO_COMPARATOR|Placebo|"Phase I: 20 young adult participants age 18-25 years dosed at 2 gm placebo per day. (10UC/10CD)~Phase II (post Phase I interim safety analysis): 40 participants age 11-25 years dosed at 2 gm placebo per day. (20UC/20CD)"
62272566|NCT06548906|EXPERIMENTAL|GZR4 Injection- Upper Arm|Participants received GZR4 Injection by subcutaneous injection on Upper Arm.
62272567|NCT06548906|EXPERIMENTAL|GZR4 Injection- Thigh|Participants received GZR4 Injection by subcutaneous injection on Thigh.
62067768|NCT01562912|ACTIVE_COMPARATOR|Control|Radiofrequency Ablation Procedure. Subjects who are undergoing AF ablation with traditional ablation technology at the same centers by the same operators. Control patients will be enrolled in a 1:2 ratio compared to the PVAC cohort. Intervention is the use of Radiofrequency Ablation.
62272568|NCT04849780|EXPERIMENTAL|ARM 1|Eligible subjects will be randomized to the TEST lens to wear in both eyes for approximately 2 weeks.
62272569|NCT04849780|EXPERIMENTAL|ARM 2|Eligible subjects will be randomized to the CONTROL lens to wear in both eyes for approximately 2 weeks. Then the subject will receive the TEST lens to wear in both eyes for approximately 2 weeks.
62272570|NCT05661773|EXPERIMENTAL|combined use of vacuum assisted suction and heat exchanger warming|The novel idea that this study proposes, is the combined use of vacuum assisted suction and heat exchanger warming. It is well known that heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
62272571|NCT05661773|NO_INTERVENTION|expectant medical management|expectant medical management will continue to the contralateral hand
62272572|NCT04775329|NO_INTERVENTION|Control arm|Standard of care
62272573|NCT04775329|ACTIVE_COMPARATOR|Treatment arm|
62272574|NCT00900770||PIB+ NC|PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
62453483|NCT06211985|ACTIVE_COMPARATOR|Mild to Moderate Pneumonia Group|patients admitted to the ward with a diagnosis of mild to moderate pneumonia (Group 2)
62453484|NCT06211985|ACTIVE_COMPARATOR|Severe Pneumonia Group|patients admitted to the ward with a diagnosis of severe pneumonia (Group 2)
62453485|NCT06211985|ACTIVE_COMPARATOR|Control Group|the control group without pneumonia (Group 4)
62453486|NCT04638166|EXPERIMENTAL|Mineral water group|The mineral water group were instructed to consume 1.25L of a commercially supplied bicarbonate rich mineral water per day at meal times, supplemented by other fluid intake up to 2.5 - 3L/day.
62453487|NCT04638166|ACTIVE_COMPARATOR|Plain water group|The plain water group consumed only plain water up to 2.5 - 3L/day.
62453488|NCT04267666|EXPERIMENTAL|Inspiratory Muscle Strength Training|in the form of: Inspiratory threshold muscle trainer in addition to traditional chest physical therapy intervention (Deep breath, cough training)
62453489|NCT04267666|EXPERIMENTAL|Incentive Spirometer|incentive spirometer, three sessions per week for six weeks
62453490|NCT00066131|ACTIVE_COMPARATOR|Scaling and root planing|Scaling and root planing delivered prior to 21 weeks of gestation.
62453491|NCT00066131|NO_INTERVENTION|Placebo|Delayed treatment group. Controls monitored clinically from baseline to 29-32 weeks of gestation. Scaling and root planing provided after delivery.
62453492|NCT02369042|EXPERIMENTAL|Cohort I|Patients admitted with the primary diagnosis of HF and are currently being assessed with clinically indicated hemodynamic monitoring.The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected through hemodynamic monitoring. The device will be worn for 60 days post hospital discharge.
62635447|NCT04052880|EXPERIMENTAL|Daratumumab with dose-attenuated VRd|SubQ Daratumumab with Dose-Attenuated VRd
62635448|NCT03907696|OTHER|Intervention|The intervention arm participate in an educational program that aimed at reducing stigma
62635449|NCT03907696|NO_INTERVENTION|control|regular curriculum with no addition educational contents
62635450|NCT04204161|EXPERIMENTAL|CAR-T19/CAR-T22|CAR-T19/CAR-T22 (autologous T cells transduced with CD19 / 22 CAR-ζ/4-1BB vector) will be administered to children with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity.
62635451|NCT03094585|NO_INTERVENTION|No information|The nurses in this group are offered no booklet or oral information
62635452|NCT03094585|EXPERIMENTAL|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
62067769|NCT01562912|EXPERIMENTAL|PVAC Ablation Procedure|Intervention is the use of PVAC technology. The PVAC is deployed in the left atrium over a 0.032-inch guidewire inside the PV and advanced until it is wedged within the antrum proximal to the ostium. Energy is delivered through selected electrode pairs with local potentials as well as adjacent electrode pairs, allowing bipolar current to flow to the target electrode(s) from both sides. Each application lasts for 60 seconds. When the temperature does not rise above 50°C within 15 seconds, the application should be discontinued to improve position. The PVAC may be manipulated within the antrum to ablate in a pattern of overlapping circular lesions.
62067770|NCT05434143|EXPERIMENTAL|Chorus Sleep|"During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises. Participants will be encouraged to complete classes every day but will be asked to complete classes at least 3 times per week in order to be considered as adhering to the intervention. Participation will be tracked based on participants self-reports in the daily sleep logs. Participants who did not adhere to the intervention will be excluded from per-protocol analyses.~Participants will complete surveys online at baseline, after 3 weeks, and after 6 weeks. The baseline questionnaires will include demographic information."
62272575|NCT00900770||PIB- NC|PIB negative, cognitively normal individuals without amyloid deposition
62272576|NCT01175902|ACTIVE_COMPARATOR|Arm 1|Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
62272577|NCT01175902|ACTIVE_COMPARATOR|Arm 2|Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day
62272578|NCT04619485|SHAM_COMPARATOR|SHAM LASER|Group A: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to zero potence.
62272579|NCT04619485|ACTIVE_COMPARATOR|EFFECTIVE LASER|Group B: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to regular potence.
62272580|NCT06106854|EXPERIMENTAL|Intervention|
62272581|NCT06106854|PLACEBO_COMPARATOR|Control|
62272582|NCT01576692|EXPERIMENTAL|Treatment|"Participants receive humanized anti-GD2 antibody, chemotherapy, cytokines, and natural killer cells.~Cells for infusion are prepared using the CliniMACS System."
62272583|NCT01916538||Cases|Individuals with a current or past diagnosis of anorexia nervosa
62272584|NCT01916538||Controls|Individuals who have never been diagnosed with an eating disorder
62272585|NCT02490293|EXPERIMENTAL|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
62272586|NCT02490293|PLACEBO_COMPARATOR|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
62272587|NCT01908101|EXPERIMENTAL|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62272588|NCT02104583|EXPERIMENTAL|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
62272589|NCT02104583|EXPERIMENTAL|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
62272590|NCT02104583|PLACEBO_COMPARATOR|Placebo|Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
62272591|NCT02188316|ACTIVE_COMPARATOR|Jumbo forceps polypectomy|89 patients were randomized to jumbo forceps arm and 120 diminutive colorectal polyps were removed by jumbo forceps polypectomy.
62272592|NCT02188316|ACTIVE_COMPARATOR|Hot biopsy electrocauterization|90 patients were randomized to hot biopsy forceps arm and 117 diminutive colorectal polyps were removed by hot biopsy electrocauterization.
62635453|NCT03094585|EXPERIMENTAL|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
62635454|NCT04214496||Postoperative Delirium Risk Patients|Preoperative cognitive function testing- EEG monitorization during surgery - Postoperative function testing
62635455|NCT02097823|EXPERIMENTAL|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~\>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses \<20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~\>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses \<20kg - 1.5-2mg/kg orally daily for 3 doses"
62067771|NCT05434143|NO_INTERVENTION|Waitlist|"Participants will be placed on a 6 week waitlist to access the chorus sleep app. There will be no daily activities for them to complete during those 6 weeks.~Participants will complete surveys online at baseline, after 3 weeks, and after 6 weeks. The baseline questionnaires will include demographic information."
62635456|NCT02097823|EXPERIMENTAL|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~\>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses \<20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~\>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses \<20kg - 1.5-2mg/kg orally daily for 3 doses"
62635457|NCT01246895||Experimental|Microfracture with BST-CarGel
62635458|NCT01246895||Control|Microfracture without BST-CarGel
62635459|NCT02039778|EXPERIMENTAL|Stem Cell Radiotherapy and Temozolomide|"One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy \[IMPT\] preferred) is an acceptable treatment modality.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
62272593|NCT04864431|ACTIVE_COMPARATOR|Vitamin D group|Daily vitamin D3 2000 IU on day 1 through day 180 Intervention: vitamin D3 2000 IU
62635460|NCT05882500||Pancreatits|Patients with pancreatitis based ont the Atlanta criteria
62453493|NCT02369042|EXPERIMENTAL|Cohort II|Patients admitted with the primary diagnosis of HF and are being assessed with or without hemodynamic monitoring. The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected while the patient is hospitalized. The device will be worn for 60 days post hospital discharge.
62453494|NCT03231956||Group 0|Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
62635461|NCT05719194|ACTIVE_COMPARATOR|Standard intervention|
62635462|NCT05719194|EXPERIMENTAL|Personalized intervention - WIPO risk factors vs no risk factors|
62635463|NCT00078286|EXPERIMENTAL|Sertraline|Participants will take sertraline for 12 weeks
62635464|NCT00078286|PLACEBO_COMPARATOR|Placebo|Participants will take placebo for 12 weeks
62635465|NCT04175132|EXPERIMENTAL|Healthy subjects|
62272594|NCT04864431|PLACEBO_COMPARATOR|Control group|Daily placebo (saccharum lactis) on day 1 through day 180 Intervention: placebo
62635466|NCT04175132|EXPERIMENTAL|PD patients|
62272595|NCT03042715||Psychological Intervention refinement|"* Eight weekly sessions in-person or via telephone~* Qualitative interviews~* Feedback from 5-10 caregivers to refine the intervention."
62635467|NCT04424225|EXPERIMENTAL|Psilocybin First|Participants in this arm will receive psilocybin first, then niacin
62272596|NCT04589104|EXPERIMENTAL|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to release \& integrate difficult emotions~* Week 3: Writing to nurture gratitude~* Week 4: Writing to enhance strengths \& resources~* Week 5: Writing to cultivate positive meaning \& savor goodness~* Week 6: Writing to invite insight, perspective, \& growth"
62453495|NCT03231956||Group 1|Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
62453496|NCT03231956||Group 2|Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
62067772|NCT02540785|EXPERIMENTAL|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
62067773|NCT02540785|EXPERIMENTAL|small-incision lenticule extraction|The patients in this group chose to receive the small-incision lenticule extraction surgery.
62067774|NCT01729234|EXPERIMENTAL|Nitrate|150µmol /Kg bodyweight /day
62453497|NCT03231956||Group 3|Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
62453498|NCT03002649|EXPERIMENTAL|Tofacitinib|All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
62453499|NCT02779036|EXPERIMENTAL|Task-oriented Exercise|Structured, progressive, task-oriented, home exercise program
62453500|NCT02779036|ACTIVE_COMPARATOR|Usual Care|Usual Physiotherapy Care
62453501|NCT01015430|PLACEBO_COMPARATOR|Placebo (for RO4917523 ascending doses)|
62453502|NCT01015430|PLACEBO_COMPARATOR|Placebo (for RO4917523 fixed dose)|
62453503|NCT01015430|EXPERIMENTAL|RO4917523 ascending doses|
62453504|NCT01015430|EXPERIMENTAL|RO4917523 fixed dose|
62453505|NCT05012345|EXPERIMENTAL|4 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 4 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
62635468|NCT04424225|EXPERIMENTAL|Niacin First|Participants in this arm will receive niacin first, then psilocybin
62635469|NCT06145126|OTHER|Start pred/End placebo|Both arms will receive both placebo and prednisone
62067775|NCT01729234|PLACEBO_COMPARATOR|PLacebo|150µmol /Kg bodyweight /day
62272597|NCT03150225|EXPERIMENTAL|Exercise group + supplementation|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily."
62635470|NCT06145126|OTHER|Start placebo/End pred|Both arms will receive both placebo and prednisone
62067776|NCT03846505|EXPERIMENTAL|Oxytocin|"A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
62067777|NCT03846505|PLACEBO_COMPARATOR|Placebo|"A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
62067778|NCT04575727|EXPERIMENTAL|Health Volunteers|In the first stage, five healthy human subjects will receive a microdose (10 µg) of \[11C\]MPC6827, immediately followed by whole body PET/CT to determine dosimetry and perform an initial safety evaluation of the radiotracer. A dose of 20 mCi \[11C\]MPC6827 will be administered and serial whole body PET scans will be acquired up to 2 hours post injection.
62272598|NCT03150225|ACTIVE_COMPARATOR|Control group + supplementation|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
62635471|NCT06328517||Patients with cirrhosis|Abdominal ultrasound, CT, or MRI showed Cirrhosis during the screening period; Fibroscan results during the screening period were\> 17.5kPa.
62635472|NCT05192317|EXPERIMENTAL|Arm Sollievo Fisiolax|Sollievo Fisiolax
62635473|NCT05192317|PLACEBO_COMPARATOR|Arm Placebo|Placebo
62635474|NCT00936455||Telemedicine|Telemedicine evaluated patients
62635475|NCT00936455||Telephone|Telephone evaluated patients
62635476|NCT03082027||ultrasonography|diagnostic tool
62635477|NCT03082027||operative release|
62635478|NCT05867056|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|SAD will be approximately 10 weeks for each participant, comprising a maximum 42-day screening period, a 1-day treatment period involving a single administration of IMC-I109V and a 28-day follow-up period, for a total of 8 visits. Visits will take place on Day -1 and Days 1, 2, 3, 8, 15, 22, and 29. Follow-up may be extended in participants who achieve a decrease in HBsAg of \> 0.5 log10 IU/mL at Day 29.
62635479|NCT05867056|EXPERIMENTAL|Part 2: Multiple Ascending Doses (MAD)|MAD will be approximately 54 weeks for each participant, comprising a maximum 42-day screening period, a 24-week treatment period involving weekly administration of IMC-I109V, and a 24-week follow-up period, with a total of 29 visits. Visits will take place on Day -1 and Days 1, 3 and 8, Weeks 3 (Day 15) through 24, Weeks 28, 36, 48 and 49. Participants who have achieved HBsAg \<100 IU/mL at end of Week 24 may be considered for further study treatments of up to Week 48 and follow-up visits every 12 weeks to Week 72. Treatment will be discontinued at Week 16 in participants who have not shown evidence of a response to IMC-I109V, in order to minimize unnecessary drug exposure in participants who are unlikely to achieve reductions in viral biomarkers with further doses.
62635480|NCT05867056|EXPERIMENTAL|Part 3: HBV HCC Module MAD|Enrollment into Part 3 may begin at the discretion of the Sponsor and will involve a maximum 42-day screening period, a treatment period comprising weekly administration of the target dose until the criteria for treatment discontinuation are met. Visits will take place on Day 1-2 and Day 8, Week 3 (Day 15), with this cycle being repeated until treatment stops, then 30 and 90 days post-last dose, then every 3 months after last dose, after which there will be a safety follow-up period of 30 days.
62635481|NCT06344169|ACTIVE_COMPARATOR|ITM group|Participants assigned to intrathecal morphine (ITM) group will receive intrathecal injection of morphine (0.15mg) for post-cesarean section pain
62272599|NCT03150225|EXPERIMENTAL|Exercise group + placebo|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive starch capsules to be taken daily."
62272600|NCT03150225|NO_INTERVENTION|Control group + placebo|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive starch capsules to be taken daily.
62272601|NCT04049045|ACTIVE_COMPARATOR|Verum arm|25 mg tablet of empagliflozin once daily for five days
62272602|NCT04049045|PLACEBO_COMPARATOR|Placebo arm|one tablet of the matching Placebo once daily for five days
62272603|NCT04858165|NO_INTERVENTION|CONTROL|without MY GERYFS
62635482|NCT06344169|EXPERIMENTAL|SDE group|Participants assigned to sebacoyl dinalbuphine ester (SDE) group will receive intramuscular injection of SDE (150mg) for post-cesarean section pain
62635483|NCT00431093|EXPERIMENTAL|1|tibolone
62635484|NCT00431093|ACTIVE_COMPARATOR|2|low-dose estradiol/noresterone
62635485|NCT05308290|EXPERIMENTAL|Blood pressure managed by cerebral autoregulation|In this arm cerebral autoregulation monitoring will be used to determine the lower and upper limits of cerebral autoregulation. Monitoring will continue throughout the surgery. Blood pressure management will be maintained to be within the limits of cerebral autoregulation.
62067779|NCT04575727|EXPERIMENTAL|Patients with Neurodegenerative Disorders|Up to 30 patients with neurodegenerative disorders will receive a microdose (10 µg) of \[11C\]MPC6827 and be imaged dynamically for up to 90 minutes using PET/CT for research purposes.
62272604|NCT04858165|OTHER|INTERVENTION|with MY GERYFS
62272605|NCT06424093|EXPERIMENTAL|Group A: Cases Group|About 25 women indicated for diagnostic hysteroscopy with using Virtual Reality Technology
62272606|NCT06424093|PLACEBO_COMPARATOR|Group B: Control Group|About 25 women indicated for diagnostic hysteroscopy without using Virtual Reality Technology
62272607|NCT04195321|ACTIVE_COMPARATOR|norepinephrine group|patients will receive NE infusion at a starting of rate of 1 ml/min of 8 mcg/ml solution (prepared by diluting 4 mg NE in 500 ml normal)
62272608|NCT04195321|ACTIVE_COMPARATOR|phenylephrine|patients will receive PE infusion at a starting rate of 1 ml/min of 100 mcg/ml solution (prepared by diluting 10 mg of PE in 100 ml normal saline)
62453506|NCT05012345|EXPERIMENTAL|6 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 6 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
62635486|NCT05308290|ACTIVE_COMPARATOR|Standard of care blood pressure management|In this arm cerebral autoregulation monitoring will be used for observation. The anesthesia provider will use usual care guidelines for blood pressure management.
62635487|NCT04823312|EXPERIMENTAL|Medtronic Duo Extended Set|These subjects will be using 4 Duo Extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
62635488|NCT03920475||TAU (treatment as usual) group|Patients with depression, meeting inclusion criteria, who needed antidepressant treatment and received either sertraline or venlafaxine.
62635489|NCT00680329||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
62635490|NCT02007317|EXPERIMENTAL|Oshadi D and Oshadi R|Anti tumor agents
62635491|NCT05767853||SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical worsening|(PaO2/FiO2\<200)
62635492|NCT05767853||SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical improvement|(PaO2/FiO2\>200)
62635493|NCT01014598|EXPERIMENTAL|Treatment (cisplatin)|Patients receive cisplatin intra-arterially via isolated lung suffusion over 2 hours. Beginning approximately 2 weeks later (6-8 weeks if indicated for patients with sarcoma undergoing surgery after cisplatin), patients receive standard chemotherapy regimen.
62635494|NCT01886508|EXPERIMENTAL|NSRH|patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)
62635495|NCT01886508|ACTIVE_COMPARATOR|RH|patients in Arm RH undergo radical hysterectomy (RH)
62635496|NCT02760719|EXPERIMENTAL|hypertonic saline|4 ml of nebulized 3 % hypertonic saline + salbutamol 0,03 ml/kg every 8 hours for the time of hospitalisation and standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
62635497|NCT02760719|NO_INTERVENTION|supportive care|Standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
62635498|NCT06073457|EXPERIMENTAL|MagGJ System|"GT Metabolic Solutions Magnet System, GJ Biofragmentable (MagGJ System)"
62635499|NCT05419713|EXPERIMENTAL|Visual scences|Lit target locations in visual environment will be varied and subjects' perceived locations will be measured.
62635500|NCT03944772|EXPERIMENTAL|Module 1: Osimertinib + Savolitinib|The patients in this group will receive osimertinib taken in combination with savolitinib
62635501|NCT03944772|EXPERIMENTAL|Module 2: Osimertinib + Gefitinib|The patients in this group will receive osimertinib taken in combination with gefitinib
62635502|NCT03944772|EXPERIMENTAL|Module 3: Osimertinib + Necitumumab|The patients in this group will receive osimertinib taken in combination with necitumumab
62635503|NCT03944772|EXPERIMENTAL|Module 4: Carboplatin + Pemetrexed + Durvalumab)|The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
62067780|NCT05402540|EXPERIMENTAL|STRAIN COUNTER STRAIN GROUP|Strain Counter Strain Technique in combination with conventional physiotherapy
62635504|NCT03944772|NO_INTERVENTION|Observational Cohort: No study drug|"Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.~With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib."
62635505|NCT03944772|EXPERIMENTAL|Module 5: Osimertinib + Alectinib|The patients in this group will receive osimertinib taken in combination with alectinib
62067781|NCT05402540|EXPERIMENTAL|ACTIVE RELEASE TECHNIQUE GROUP|Active Release Technique in combination with conventional physiotherapy
62067782|NCT03966079|EXPERIMENTAL|Intervention arm|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
62453507|NCT05501691|PLACEBO_COMPARATOR|Placebo|Laser Simulation
62635506|NCT03944772|EXPERIMENTAL|Module 6: Osimertinib + Selpercatinib|The patients in this group will receive osimertinib taken in combination with selpercatinib
62635507|NCT03944772|EXPERIMENTAL|Module 7: Etoposide + Durvalumab + Carboplatin or Cisplatin|The patients in this group will receive platinum-containing doublet (etoposide + carboplatin or cisplatin) taken in combination with durvalumab.
62635508|NCT03944772|EXPERIMENTAL|Module 8: Osimertinib + Pemetrexed + Carboplatin or Cisplatin.|The patients in this group will receive Osimertinib plus platinum-containing doublet (pemetrexed + carboplatin or cisplatin).
62067783|NCT04540484||ALGH Physicians|Attending physicians on the medical staff, fellow physicians, and resident physicians that work at Advocate Lutheran General Hospital (ALGH) from March 1st, 2020 and forward.
62635509|NCT03944772|EXPERIMENTAL|Module 9: Osimertinib + Selumetinib|The patients in this group will receive osimertinib taken in combination with selumetinib
62635510|NCT03944772|EXPERIMENTAL|Module 10: Osimertinib + datopotamab deruxtecan|The patients in this group will receive osimertinib taken in combination with datopotamab deruxtecan.
62635511|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
62635512|NCT06117696||control group|Standard announcement system
62635513|NCT06117696||video reinforced announcment group|standard announcement system reinforced by animated videos
62635514|NCT03894709|EXPERIMENTAL|The family-centered care model|Interventions include a family-centered approach to interdisciplinary care and a family caregiving-training component to enhance family caregivers' competence in providing post-operative care and handling behavioral problems of adults with cognitive impairment. The interdisciplinary care model consists of geriatric consultation, continuous rehabilitation, and discharge planning. The family-centered approach involves family caregivers using a structured guide to assess the condition of the hip-fractured patient with cognitive impairment. Habits, daily routines, preferences, behavioral problems and environmental safety and stimuli are explored. The strengths, weakness, and resources of the family are assessed. The behavioral problems and symptoms to target are identified. Both the research nurse and the caregiver will then collaborate on a tentative plan to minimize the behavioral problems.
62067784|NCT04540484||Household Members|Household members above age 18 who lived in household of ALGH physician who tested positive for COVID-19 IgG antibodies, and who lived with that physician for at least 2 consecutive weeks.
62067785|NCT00211978|EXPERIMENTAL|PhosLo|
62067786|NCT00211978|PLACEBO_COMPARATOR|placebo|
62067787|NCT02328092|ACTIVE_COMPARATOR|Real group|The real group received biphasic rSMS using a Magstim Super Rapid (Magstim, Whitland, UK) stimulator connected to a 120-mm outer diameter figure-of-8 air film cooling coil positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2). Stimulation was delivered at 15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upward. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off.
62453508|NCT05501691|EXPERIMENTAL|445 nm|445 nm Diode Laser Wavelength (SiroLaser Blue)
62453509|NCT05501691|EXPERIMENTAL|660 nm|660 nm Diode Laser Wavelength (SiroLaser Blue)
62453510|NCT05501691|EXPERIMENTAL|970 nm|970 nm Diode Laser Wavelength (SiroLaser Blue)
62635515|NCT03894709|NO_INTERVENTION|Usual care|During hospitalization, patients receive health teaching for exercise while still in bed. Physical therapy usually starts only for those who received arthroplasty of hip replacement. Physical therapists train patients to use a walker and get in/out of bed through consultation. Usually, patients are discharged from the hospital without home assessment, nor are in-home programs provided for rehabilitation or nursing care. The usual care does not involve interdisciplinary care protocols, continuity of care, or specific care for hip-fractured patients with cognitive impairment.
62635516|NCT04061278|EXPERIMENTAL|4 Cycles of Neoadjuvant Chemotherapy With Radiotherapy|Four cycles of neoadjuvant chemotherapy combined with radical radiotherapy
62635517|NCT04061278|ACTIVE_COMPARATOR|3cycles of Neoadjuvant Chemotherapy With chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy
62635518|NCT01051479|EXPERIMENTAL|C11-Choline|
62635519|NCT06611735||Retention clamp|Retention clamps applied to maxillary premolars during routine rubber dam isolation for performing anterior restorations.
62635520|NCT04518618|EXPERIMENTAL|Group F|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml).
62635521|NCT04518618|EXPERIMENTAL|Group FN|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml) plus 20 ugs naloxone.
62067788|NCT02328092|SHAM_COMPARATOR|Sham Group|The control group received sham rSMS stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
62067789|NCT00389181|EXPERIMENTAL|Medical management|Patients with unruptured BAVMs will receive symptomatic medical management alone.
62067790|NCT00389181|ACTIVE_COMPARATOR|Interventional therapy|Patients with unruptured BAVMs will receive symptomatic medical management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy).
62453511|NCT06545149|PLACEBO_COMPARATOR|Control|The group will receive the intervention with coconut wheat
62453512|NCT06545149|EXPERIMENTAL|BioNutri AR-1|The group will receive the intervention with fermented and nutritionally balanced food
62453513|NCT01226069|ACTIVE_COMPARATOR|Glycerine Magnesium Sulphate paste|
62453514|NCT01226069|ACTIVE_COMPARATOR|Hirudoid cream|Topical Mucopolysaccharide polysulphate
62453515|NCT01226069|EXPERIMENTAL|No application|Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
62453516|NCT02521441|EXPERIMENTAL|F-627, 10 mg/dose|F-627 at dose of 10 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
62635522|NCT05506969|EXPERIMENTAL|Part 1 Group 1:rF1V vaccine and CpG 1018® adjuvant co-administered|rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183
62635523|NCT05506969|EXPERIMENTAL|Part 1 Group 2:rF1V vaccine and CpG 1018® adjuvant bedside mix|Bedside mix of rF1V vaccine and CpG 1018® adjuvant and placebo will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183
62635524|NCT05506969|ACTIVE_COMPARATOR|Part 1 Group 3: rF1V vaccine and placebo|rF1V vaccine and placebo will be administered on Days 1, 29, and 183
62635525|NCT05506969|EXPERIMENTAL|Part 2 Group 1 & 3, OR Group 2 & 3|"Group 1 \& 3 (if selected): Group 1: rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183. Group 3: rF1V vaccine and placebo will be administered on Days 1, 29, and 183~OR~Group 2 \& 3 (if selected): Group 2: Bedside mix of rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29; placebo will be administered on Day 183. Group 3: rF1V vaccine will be administered on Days 1, 29, and 183"
62635526|NCT00610168|EXPERIMENTAL|BOOSTRIX I GROUP|Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
62635527|NCT00610168|EXPERIMENTAL|BOOSTRIX II GROUP|Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
62635528|NCT01839916|EXPERIMENTAL|Treatment (DLI)|Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
62635529|NCT02078193|EXPERIMENTAL|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
62635530|NCT01116752|ACTIVE_COMPARATOR|Strict control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if \>140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive strict glycemic control (80-140 mg/dL)
62635531|NCT01116752|ACTIVE_COMPARATOR|Conservative control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if \>140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive conservative control (190-220 mg/dL).
62635532|NCT02843009|PLACEBO_COMPARATOR|Safflower Oil plus Resistance Exercise Training|3.0g of safflower oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
62635533|NCT02843009|ACTIVE_COMPARATOR|Fish Oil plus Resistance Exercise Training|3.0g of fish oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
62635534|NCT03784391||Treatment|Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox
62635535|NCT03784391||Reference|Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment
62635536|NCT05869071||Healthy volunteers|Participants with no chronic disease and no acute symptoms
62067791|NCT03301727|ACTIVE_COMPARATOR|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
62272609|NCT01309178|ACTIVE_COMPARATOR|Amitriptyline|After the experience with the treatment of 18 CF-patients phase IIa study), the medication will be therefore 25 mg daily in two doses (2 x 12,5 mg). Because of a higher rate of side effects (tiredness, dry mucous membrane) the higher dose of 50 mg (2 x 25 mg) is not chosen first, but will be adapted after 2 weeks of treatment.
62635537|NCT05869071||Patients with Allergic rhinitis or Nasal Polyps|Participants with allergic rhinitis or nasal polyps
62635538|NCT05869071||Patients with asthma|Participants with asthma
62635539|NCT05869071||Patients with COPD|Participants with Chronic Obstructive Pulmonary Disease
62635540|NCT01406119|EXPERIMENTAL|ABT-806 Arm|
62635541|NCT02149407|ACTIVE_COMPARATOR|Glycerin group (GG)|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
62067792|NCT03301727|ACTIVE_COMPARATOR|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
62067793|NCT03301727|OTHER|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
62272610|NCT01309178|PLACEBO_COMPARATOR|Mannite|The placebo will be given 25 mg daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
62453517|NCT02521441|EXPERIMENTAL|F-627, 20 mg/dose|F-627 at dose of 20 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
62453518|NCT02521441|EXPERIMENTAL|Filgrastim, 5 mcg/kg/dose|Filgrastim of 5 mcg/dose administered by subcutaneous injection for up to two weeks, start from Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
62453519|NCT05412407|OTHER|Questionnaire : Taken analgesics|the patient will complete a questionnaire
62453520|NCT03010748||Chinese population|Chinese population of different nation from several provinces.
62272611|NCT01784965|PLACEBO_COMPARATOR|placebo|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
62272612|NCT01784965|ACTIVE_COMPARATOR|liraglutide|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
62272613|NCT03732300|EXPERIMENTAL|ASSIP + TAU goup|ASSIP psychotherapy intervention + treatment as usual (TAU)
62272614|NCT03732300|NO_INTERVENTION|TAU|Treatment as usual
62272615|NCT04868084|EXPERIMENTAL|Intervention group|"Physical Literacy in the early years. The intervention was delivered by an external provider and designed to provide nursery teachers, teaching assistants and others working with children under age five the knowledge, skills and confidence to deliver enjoyable and engaging lessons which focus on the development of core fundamental skills. The course was developed in conjunction with leading Physical Education (PE) consultants, Sports Scientists and Office for Standards in Education, Children's Services and Skills (Ofsted) advisors which covered both the theory about FMS and physical literacy, and practical demonstrations of age-appropriate ways to teach and develop FMS. Staff from the Intervention settings received the six-hour training session. After the training session, school nurseries which were encouraged to speak with the training provider to follow-up the understanding of the training and provide additional help for implementation of the practice learned."
62272616|NCT04868084|NO_INTERVENTION|Control|The control nurseries followed their usual practice.
62272617|NCT05564169|EXPERIMENTAL|Masitinib (4.5) & SOC|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Dose up-titration is subjected to a safety control. Masitinib will be administered as an add-on to cholinesterase inhibitor and/or memantine standard of care (SOC).
62067794|NCT06392672|NO_INTERVENTION|Control Group|Group: Group in which only observation is made by the clinical pharmacist For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received treatment for pulmonary embolism and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded.
62635542|NCT02149407|ACTIVE_COMPARATOR|Rectal stimulation group (SG)|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
62635543|NCT02149407|SHAM_COMPARATOR|Control group (CG)|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
62635544|NCT04277780|EXPERIMENTAL|CGM Sensor|Subjects will receive the Libre Pro Freestyle continuous glucose monitor (CGM) sensor that will be applied to their upper arm at the time of hospital discharge. They will be asked to peel off the sensor after 14 days and mail it to the endocrinology clinic in a stamped envelope that will be provided. They will also be provided the conventional diabetes management which will include instructions on fingerstick blood glucose monitoring and logging which they will start after the CGM sensor is removed. The sensor data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time the sensor is placed for further management of their diabetes.
62635545|NCT04277780|ACTIVE_COMPARATOR|Conventional Diabetes Care|Subjects will receive only the conventional diabetes management at the time of hospital discharge which includes instruction on fingerstick blood glucose monitoring and logging onto a blood glucose log sheet for 14 days. They will then be asked to fax/mail/call-in the blood glucose log. The log data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time of hospital discharge for further management of their diabetes.
62067795|NCT06392672|EXPERIMENTAL|Intervention Group|Intervention Group: Group to which the clinical pharmacist makes recommendations For patients in this group, intervention (i.e. recommendation) will be made to physician in charge by the clinical pharmacist. Within the intervention group, patient characteristics such as the underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received treatment for pulmonary embolism and met the inclusion criteria. Through medication reviews, evaluations were made to identify drug-related problems and provide solutions to these problems. The clinical pharmacist provided recommendations to the physicians regarding significant clinically important problems.
62067796|NCT05142982|EXPERIMENTAL|Radiotherapy|Patients randomized to the test arm will undergo radiotherapy to the residual mass. Patients will be stratified by the size of the residual mass in shortest dimension being \<3 cm or \> 3 cm.A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
62067797|NCT05142982|NO_INTERVENTION|Observation|Patients randomized to the standard arm will be observed and the status of residual mass monitored with an FDG PETCT scan done at three to six monthly intervals.
62453521|NCT06028009|EXPERIMENTAL|Platelet-rich plasma injection|
62453522|NCT06028009|SHAM_COMPARATOR|0.9% saline injection|
62453523|NCT05865197||Passive monitoring|No intervention
62453524|NCT03818945|OTHER|Sodium Fluoride Varnish|
62453525|NCT03818945|ACTIVE_COMPARATOR|PRG barrier Giomer|
62453526|NCT01000337|ACTIVE_COMPARATOR|sevoflurane|Volatile anesthetic
62453527|NCT01000337|ACTIVE_COMPARATOR|Propofol|Intravenous anesthetic
62453528|NCT01923077|PLACEBO_COMPARATOR|Conventional|Conventional treatment with simvastatin
62453529|NCT01923077|ACTIVE_COMPARATOR|Rosuvastatin|loading dose of rosuvastatin 80 mg at randomization followed by 40 mg daily in 12 month.
62453530|NCT02045121|EXPERIMENTAL|Indwelling Pleural Catheter|Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.
62453531|NCT02045121|ACTIVE_COMPARATOR|Talc Pleurodesis|Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if \>75% of visceral and parietal pleura in direct contact on chest x-ray.
62453532|NCT01792882||Cancer Subjects|
62453533|NCT05445297|OTHER|Amiodarone group|
62453534|NCT05445297|OTHER|Refralon group|
62067798|NCT02554630||Preterm Neonate|Neonates of gestational age 24-37 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
62453535|NCT04026464|ACTIVE_COMPARATOR|Ibuprofen+Acetaminophen Group|Infants with PDA randomized to the combined treatment group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) and oral acetaminophen (15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses).
62635546|NCT02092454|EXPERIMENTAL|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
62635547|NCT02092454|PLACEBO_COMPARATOR|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
62635548|NCT04331834|EXPERIMENTAL|Pre-exposure prophylaxis of SARS-CoV-2|Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
62635549|NCT04331834|PLACEBO_COMPARATOR|Control group with placebo|Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
62635550|NCT00082212|EXPERIMENTAL|1|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
62635551|NCT05286853|SHAM_COMPARATOR|Sham Procedure|Participants randomized to the Sham Comparator arm will have 2 sham procedures
62635552|NCT05286853|EXPERIMENTAL|Experimental (REACT injections)|Participants randomized to the experimental arm will receive 2 injections of REACT.
62635553|NCT01720641|NO_INTERVENTION|Control|Standardized partner notification counseling
62635554|NCT01720641|EXPERIMENTAL|Internet Notification|Standardized partner notification counseling and referral to internet-based partner referral website.
62635555|NCT01720641|EXPERIMENTAL|Referral Card|Standardized partner notification counseling and provision of 5 printed partner referral cards.
62635556|NCT01720641|EXPERIMENTAL|Internet and Referral Card|Standardized partner notification counseling and referral to internet-based partner referral website and provision of 5 printed partner referral cards.
62635557|NCT04780815|EXPERIMENTAL|myBluTM Formulation 1 Oral cavity and lungs|This group was used for measuring oral cavity and lungs endpoints after administration of Formulation 1
62635558|NCT04780815|EXPERIMENTAL|myBluTM Formulation 2 Oral cavity and lungs|This group was used for measuring oral cavity and lungs endpoints after administration of Formulation 2
62635559|NCT04780815|EXPERIMENTAL|myBluTM Formulation 1 Brain|This group was used for measuring brain endpoints after administration of Formulation 1
62635560|NCT04780815|EXPERIMENTAL|myBluTM Formulation 2 Brain|This group was used for measuring brain endpoints after administration of Formulation 2
62635561|NCT00492726|EXPERIMENTAL|Moxifloxacin (Avelox, BAY12-8039)|Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
62635562|NCT00492726|ACTIVE_COMPARATOR|Ertapenem|Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
62635563|NCT05028764||18 to 30 years of age group|Consisting of at least 13 males and 13 females
62635564|NCT05028764||31 to 50 years of age group|Consisting of at least 13 males and 13 females
62635565|NCT05648552||Stroke group|Chronic subcortical stroke participants with motor dysfunction
62067799|NCT02554630||Term Neonates|Neonates of gestational age 37-42 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
62635566|NCT05648552||Healthy controls group|Well-matched healthy controls
62635567|NCT01170325|EXPERIMENTAL|Group A|
62635568|NCT01170325|PLACEBO_COMPARATOR|Group B|
62635569|NCT04868110|NO_INTERVENTION|Usual Care|Women in the usual care group, will received standard care from the obstetrician.
62635570|NCT04868110|EXPERIMENTAL|High fiber|Women in high fiber group will receive education on consuming a high fiber diet, including weekly lessons and daily snacks.
62635571|NCT04533113|EXPERIMENTAL|VitreBond LC|VitreBond LC used as a liner after selective carious tissue removal.
62635572|NCT04533113|EXPERIMENTAL|Biodentine|Biodentine used as a liner after selective carious tissue removal.
62635573|NCT04533113|EXPERIMENTAL|Theracal|Theracal used as a liner after selective carious tissue removal.
62635574|NCT02676557||LASIK|
62635575|NCT05086588||Bio Blue 90 Plus|Patients who were underwent Macular Surgery using Bio Blue 90 Plus (Brilliant Blue G Dye; 0.25 g /l concentration in 0.5 ml BD Glass Syringe; Biotech Vision Care Pvt. Ltd., Ahmedabad, India.)
62635576|NCT05086588||ILM Blue|Patients who were underwent Macular Surgery using ILM Blue (Brilliant Blue G Dye; 0.25 g /l concentration in 0.5 ml BD Glass Syringe; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Zuidland, The Netherlands)
62635577|NCT05748132|EXPERIMENTAL|trigeminal Radiofrequency|Combined conventional and pulsed radiofrequency (CCPRF) achieved comparable pain relief to PRF treatment alone in patients with chronic pain, the combination of PRF and CRF would increase the effect of CRF and reduce the need for long-duration CRF (LCRF) and its attendant side effects.
62635578|NCT04383197|EXPERIMENTAL|Semaglutide treatment|3 months of therapeutic semaglutide treatment
62635579|NCT04383197|EXPERIMENTAL|Semaglutide and Endurance exercise|12 weeks of endurance exercise concomitant to semaglutide treatment
62635580|NCT04383197|EXPERIMENTAL|Endurance exercise|12 weeks of endurance exercise
62635581|NCT06441318|EXPERIMENTAL|Treatment Group 1|Povorcitinib and placebo will be administered at the protocol defined doses.
62635582|NCT06441318|EXPERIMENTAL|Treatment Group 2|Povorcitinib will be administered at the protocol defined doses.
62635583|NCT06441318|PLACEBO_COMPARATOR|Treatment Group 3|Placebo will be administered at the protocol defined doses.
62635584|NCT06441318|ACTIVE_COMPARATOR|Treatment Group 4|Moxifloxacin will be administered at the protocol defined doses.
62635585|NCT02296658|EXPERIMENTAL|S-1 based chemoradiotherapy|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy in a standard manner.
62635586|NCT02292459|EXPERIMENTAL|PEG 3350|Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.
62635587|NCT02292459|ACTIVE_COMPARATOR|PEG 4000|Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.
62635588|NCT01687218|ACTIVE_COMPARATOR|Group 1|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
62635589|NCT01687218|ACTIVE_COMPARATOR|Group 2|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
62635590|NCT01687218|ACTIVE_COMPARATOR|Group 3|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
62635591|NCT01687218|ACTIVE_COMPARATOR|Group 4|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
62635592|NCT01687218|ACTIVE_COMPARATOR|Group 5|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
62635593|NCT01687218|ACTIVE_COMPARATOR|Group 6|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
62635594|NCT02038556|EXPERIMENTAL|cognitive behaviorial therapy for insomnia group program|Behavioral
62635595|NCT05465369|EXPERIMENTAL|injectable flowable composite with giomer technology (beatifil flow plus x)|Injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
62635596|NCT05465369|ACTIVE_COMPARATOR|high viscosity glass ionomer (Equia Fil ) in ART|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
62635597|NCT02835859|EXPERIMENTAL|Group 1- Oral solution|Participants will be randomly assigned to drink two oral solutions made of different combinations of saccharin, lactisole, acetaminophen, 3-O-methyl glucose, or glucose.
62635598|NCT01353131||ECG Screening|1000 patients with moderate to high risk determined by stratification algorithm based on the electronic analysis of 69,088 routine 12-lead ECGs performed in a large medical institution during a 6 month period by combining previously established indices of abnormal repolarization (wide QRS-T angle) with validated measures of myocardial damage (Selvester QRS score) excluding those \> 70 years of age or with LV ejection fraction ≤ 35%, or at a high risk of dying within 3 years from cancer, end stage cardiac, pulmonary, renal, immunologic or neurologic diseases excluded on clinical data obtained through medical record.
62067800|NCT02554630||Healthy Adult Control|Healthy Adult aged 18-55 years will undergo a single blood collection by the way of vein puncture. Microfluidic techniques, utilizing whole blood, will be employed to evaluate the genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function.
62453536|NCT04026464|PLACEBO_COMPARATOR|Ibuprofen Group|Infants with PDA randomized to the control mono therapy group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) alone.
62453537|NCT01513148|EXPERIMENTAL|Superluminous Light Diode Irradiation|Application of super luminous diodes light irradiation over the superficial radial nerve
62453538|NCT01513148|PLACEBO_COMPARATOR|Sham Superluminous Light Diode Irradiation|Sham Superluminous Light Diode Irradiation over the Superficial Radial Nerve for the same time period as the intervention group
62453539|NCT05471674|EXPERIMENTAL|Treatment|
62453540|NCT05337709|EXPERIMENTAL|treatment group|Patients from the pharmacies assigned as treatment group will receive intervention. Intervention are education (aid with leaflet and video) and medication review with counselling.
62635599|NCT05780138|EXPERIMENTAL|Intervention group|Participants will receive 10 remote sessions with the curriculum
62453541|NCT05337709|NO_INTERVENTION|control group|Patients from the pharmacies assigned as control group will receive as usual care they have been provided regularly.
62067801|NCT04453215|EXPERIMENTAL|test group|SLE patients treated with infrared laser irradiation
62635600|NCT05994547|EXPERIMENTAL|Midazolam|"Patients aged \<60 years or weighing \>50 kg were randomly assigned to receive 3 mg intravenous midazolam. In contrast, those aged ≥60 years or with a body weight of \<50 kg were assigned 2 mg intravenous.~If adequate sedation was not achieved after the initial sedative administration, additional midazolam (0.5 mg) was administered at intervals of 3-4 min, at the discretion of the physician."
62635601|NCT05994547|ACTIVE_COMPARATOR|Remimazolam|"Patients aged \<60 years or weighing \>50 kg were randomly assigned to receive 5 mg remimazolam. In contrast, those aged ≥60 years or with a body weight of \<50 kg were assigned intravenous 3 mg remimazolam.~If adequate sedation was not achieved after the initial sedative administration, additional remimazolam (2.5 mg) was administered at intervals of 3-4 min, at the discretion of the physician."
62635602|NCT02543047|ACTIVE_COMPARATOR|Right Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the right region of the heart
62635603|NCT02543047|ACTIVE_COMPARATOR|Left Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the left region of the heart
62635604|NCT06219863|EXPERIMENTAL|Body weight supported harness|Harness is set up in families' homes for one month. Caregivers re asked to use the harness with their infant for 30 min/day, 5 times a week.
62635605|NCT03867175|EXPERIMENTAL|Arm 1 Stereotactic Body Radiation Therapy/Pembrolizumab|3-10 treatments of SBRT/ pembrolizumab IV for 30 minutes every 3-4 weeks for 1 year at doctor's discretion.
62635606|NCT03867175|EXPERIMENTAL|Arm 2 Pembrolizumab Only|Patients receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
62067802|NCT04453215|PLACEBO_COMPARATOR|placebo group|SLE patients treated with red laser irradiation
62067803|NCT04453215|NO_INTERVENTION|control group|no therapy group
62067804|NCT00597714|EXPERIMENTAL|Cohort A - Lymphoid Disease|Group A: Patients with a high chance of progressive lymphoid or myelomatous disease undergo Non-myeloablative Stem Cell Transplantation.
62067805|NCT00597714|EXPERIMENTAL|Cohort B - Myeloid Disease|Group B: Patients with a high chance of progressive myeloid diseases, marrow failure syndromes or myeloproliferative disorders undergo Non-myeloablative Stem Cell Transplantation.
62067806|NCT00597714|NO_INTERVENTION|Donor|Donor priming and apheresis will include filgrastim 8 mcg/kg subcutaneously twice daily for 4 days prior to stem cell collection and continuing until pheresis is completed. Alternative mobilization strategies may be employed at the investigator's discretion.
62067807|NCT05727943|EXPERIMENTAL|add - on clioquinol|"Add-on clioquinol to concomitant anti seizure medications.~Clioquinol - magistral suspension preparation (100mg/ml) - oral intake Exposure 2 weeks to low dose: 1 mg/kg/day Exposure 6 weeks to higher dose: 4 mg/kg/day"
62635607|NCT06203470|EXPERIMENTAL|Botox group|"Patients will receive a single intradermal injection of Mesobotox as a monotherapy.~Botulinum toxin injection: Botox injections will be intradermal. Concentration will be 100 U to be diluted with 5-ml sterile physiological sodium chloride solution. Each patient will receive individual injections of 1 U using a grid with points set at a distance of 1 cm apart. Up to two plaques per patient will be selected, whose diameter would not exceed 5-10 cm2. Each patient will receive a single BoNT-A injection"
62635608|NCT06203470|EXPERIMENTAL|Botox and Tacrolimus group|Patients will receive a single intradermal injection of Mesobotox of the same dilution followed by topical application of Tacrolimus 0.03% ointment twice daily for 3 months.
62635609|NCT06203470|EXPERIMENTAL|Tacrolimus group|Patients will apply Tacrolimus (0.03%) as a monotherapeutic twice daily for 3 months
62635610|NCT04951089|EXPERIMENTAL|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation i-gel supraglottic device insertion for oxygenation and ventilation
62635611|NCT04951089|EXPERIMENTAL|Air-Q SP 3G supraglottic insertion for oxygenation|Air-Q SP 3G supraglottic device insertion for oxygenation Air-Q SP 3G supraglottic device insertion for oxygenation and ventilation
62067808|NCT02917577|ACTIVE_COMPARATOR|Avaxim Pediatric®|2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
62635612|NCT05710146|EXPERIMENTAL|Tranexamic Acid|Patients will be injected with 15 mg/kg of tranexamic acid in 100mL of normal saline via IV access normally established for this procedure.
62067809|NCT02917577|ACTIVE_COMPARATOR|Avaxim ® (adult)|2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
62067810|NCT01512745|EXPERIMENTAL|apatinib|
62067811|NCT01512745|PLACEBO_COMPARATOR|placebo|
62635613|NCT05710146|PLACEBO_COMPARATOR|Placebo|Patients will be injected with 100mL of normal saline via IV access normally established for this procedure.
62067812|NCT03545373|EXPERIMENTAL|Azithromycin|Azithromycin 500mg, oral, once daily for 3 days commencing on randomization day.
62067813|NCT03545373|EXPERIMENTAL|Amoxicillin|Amoxicillin 1g, oral, 3 times daily for 5 days commencing on randomization day.
62635614|NCT01173315|EXPERIMENTAL|Group MV|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg
62635615|NCT01173315|EXPERIMENTAL|Group MVB|Group MVB: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg)plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg)
62067814|NCT03545373|NO_INTERVENTION|Standard of care|The standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment, re-evaluate with sputum results)
62067815|NCT03788902|EXPERIMENTAL|ADHD group|This group was examined twice - once after taking Ritalin and once after taking placebo
62067816|NCT03788902|NO_INTERVENTION|Healthy control|Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
62067817|NCT02724813|EXPERIMENTAL|Intervention arm|Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
62635616|NCT01173315|PLACEBO_COMPARATOR|Group P|Group P: starch (placebo
62635617|NCT05275465|EXPERIMENTAL|HH-006|
62635618|NCT05275465|PLACEBO_COMPARATOR|Placebo|
62635619|NCT03289767|EXPERIMENTAL|Curved-tube|Giving additional curve to the endotracheal tube by simple preparation.
62635620|NCT03289767|NO_INTERVENTION|Control|No other manipulation of the endotracheal tube is done.
62635621|NCT02467361|EXPERIMENTAL|Combo with Ipilimumab|
62635622|NCT02467361|EXPERIMENTAL|Combo with Nivolumab|
62635623|NCT02467361|EXPERIMENTAL|Combo with Pembrolizumab|
62635624|NCT04687410|ACTIVE_COMPARATOR|FNA|
62272618|NCT05564169|PLACEBO_COMPARATOR|Placebo & SOC|Participants receive a matched dose placebo, given orally twice daily. Placebo will be administered as an add-on to cholinesterase inhibitor and/or memantine standard of care (SOC).
62635625|NCT04687410|EXPERIMENTAL|FNB|
62635626|NCT01116947|ACTIVE_COMPARATOR|Intervention Arm|1. Treatment Arm (CASES) will receive high protein meals during thrice weekly hemodialysis in-center (each meal includes \~50 g of protein, \~850 Cal, and phos/protein ratio \<10 mg/g) PLUS dietary counseling to continue similar high protein intake with low phosphorus to protein ratio and to avoid foods with high preservative content. Fosrenol 1.0 to 1.5 g per meal will be prescribed (use of pill crusher will be recommended) and will be titrated based on bi-weekly phosphorus levels.
62635627|NCT01116947|ACTIVE_COMPARATOR|Control Arm (CONTROLS)|2. Control Arm (CONTROLS) will receive salad boxes in-center (no protein, low calorie) and routine dietary counseling and will continue pre-existing phosphorus binder regimen.
62635628|NCT00671346||1|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg and vitamin B12 0.4 mg
62635629|NCT00671346||2|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg, vitamin B12 0.4 mg and B6 40 mg.
62635630|NCT00671346||3|Participants in NORVIT and WENBIT allocated to daily oral treatment with vitamin B6 40 mg.
62635631|NCT00671346||4|Participants in NORVIT and WENBIT allocated to daily oral treatment with placebo
62635632|NCT02021214|EXPERIMENTAL|Methylphenidate/Placebo|40 mg Methylphenidate, per os, single dose Placebo, single dose
62067818|NCT02724813|ACTIVE_COMPARATOR|Wait-list arm|Participant in this arm will receive therapy 8 weeks after initial assessment. Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
62067819|NCT01231503|EXPERIMENTAL|RTS,S Neo-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62461500|NCT03025880|EXPERIMENTAL|Single arm|"Eligible patients will be enrolled and treated with Pembrolizumab (P) at a dose of 200mg as an intravenous (IV) infusion on day 1 of each 21-day cycle in combination with Gemcitabine (G) at a dose of 1,250mg/m2 or 1,000mg/m2 (this dose will be explored in combination with P in the initial exploratory run-in-phase if necessary) as a IV infusion on day 1 and 8 of each 21-day cycle.~Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. An initial exploratory run-in-phase will be performed to test the safety of the combination and determine the Recommended Phase II Dose (RP2D) of G in combination with fixed doses of P."
62635633|NCT05826210||Sarcopenic obesity group|Patients who underwent LSG with FM/FFM\>0.80 calculated from the cross-sectional CT image of L3 vertebra.
62635634|NCT05826210||Non-sarcopenic obesity group|Patients who underwent LSG with FM/FFM\<0.80 calculated from the cross-sectional CT image of L3 vertebra.
62635635|NCT04717258|EXPERIMENTAL|Main FIREFLI trial: Intervention arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) offered by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer) once randomised.
62287046|NCT01348802|EXPERIMENTAL|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
62635636|NCT04717258|NO_INTERVENTION|Main FIREFLI trial: Control arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer offered 12 months post-randomisation)
62635637|NCT04717258|EXPERIMENTAL|Recruitment SWAT: Self-Determination Theory informed invitation letter|The recruitment pack to take part in the FIREFLI study will include an invitation letter informed by Self-Determination Theory.
62635638|NCT04717258|NO_INTERVENTION|Recruitment SWAT: Standard invitation letter|The recruitment pack to take part in the FIREFLI study will include the University of York, York Trials Unit's standard invitation letter
62635639|NCT04717258|EXPERIMENTAL|Retention SWAT: Pen arm|A pen (which has the University of York logo on it) will be included with the first four-month reminder questionnaire.
62635640|NCT04717258|NO_INTERVENTION|Retention SWAT: No pen|No pen will be included with the four-month reminder questionnaire.
62635641|NCT01693679|EXPERIMENTAL|antiviral drug|Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients.
62635642|NCT02176369|EXPERIMENTAL|vinorelbine|50 mg three times a week for a three weeks cycle
62635643|NCT02176369|NO_INTERVENTION|Close observation/Best Supportive Care|Close observation/Best Supportive Care (BSC)
62088247|NCT02007083|ACTIVE_COMPARATOR|Spinous process osteotomy (SPO)|The multifidus muscles is detached from the spinous process unilaterally. An osteotomy of the superior spinous process is performed at the basis, in the actual level. The spinous process with intact interspinal and supraspinal ligaments is then retracted to the contralateral side. The decompression is first performed in the midline. Then one goes laterally on both sides too perform the decompression. About 1/3 of the lower part of the superior lamina is removed, and about 1/4 of the upper part of the inferior lamina is removed.
62461501|NCT04862702|ACTIVE_COMPARATOR|ProTaper Next rotary file system (Dentsply Sirona)|
62635644|NCT01340755|EXPERIMENTAL|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
62635645|NCT02667301|EXPERIMENTAL|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:~1. The patient is subjected to tympanometry test on the specific ear,~2. The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,~3. The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
62635646|NCT03459625|EXPERIMENTAL|Mindfulness-Based Stress Reduction (MSBR)|MSBR (Kabat-Zinn, 1990), 8-week group-based intervention where participants learn mindfulness skills to help alleviate parenting stress among parents of young children with Autism Spectrum Disorder.
62635647|NCT03459625|ACTIVE_COMPARATOR|Psychoeducational Support Group (PE)|PE is a 8-week group-based intervention to provide psychosocial support and resources for parents of young children with Autism Spectrum Disorder.
62287047|NCT01348802|PLACEBO_COMPARATOR|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
62461502|NCT04862702|EXPERIMENTAL|TruNatomy rotary system (Dentsply Sirona)|
62635648|NCT04990115|ACTIVE_COMPARATOR|rotation|root canal preparation performed using rotating instruments
62635649|NCT04990115|ACTIVE_COMPARATOR|reciprocation|root canal preparation performed using reciprocating instruments
62635650|NCT04292210|EXPERIMENTAL|CAPD handling|"A connecting device simplifying the steps during a cycle of Peritoneal dialysis. Instead of directly doing a manual connection and manually breaking a frangible, the device assist in connecting and breaking the frangible.~This study was done demonstrating a continuous ambulatory peritoneal dialysis (CAPD)"
62635651|NCT05193513|EXPERIMENTAL|group (1)|tow perpendicular miniscrews supported hybrid expanders
62635652|NCT05193513|EXPERIMENTAL|group (2)|tow angulated miniscrews supported hybrid expanders
62635653|NCT01919034||Patients undergoing abdominal surgery|Patients undergoing abdominal surgery and using morphine pain control analgesia (PCA) device will be involved. Pre- and Post- operative (after anesthesia and at the end of surgery) blood sampling (total 30 ml) plus normal liver tissue (10mm3) e will be harvested. Above protein(TM, IL-20, HD) amount change will be measured (ELISA for TM, IL-20 (serum) or flowcytometry (white cells) for TM, HD, IL-20 expression, stain or blotting for skin tissue). Patients will be included in this branch to check the correlation between morphine consumption and protein expression. Pain questionnaire (BPI, McGill) will be applied for pain evaluation. 2-D gel analysis will also be applied to screen further possible molecules.
62635654|NCT03899857|EXPERIMENTAL|Pembrolizumab|Temozolomide-based radiochemotherapy (TMZ/RT=\>TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=\>TMZ.
62287048|NCT02083458|EXPERIMENTAL|axillary vein catheterization|Catheterization of the axillary vein based on anatomical landmark.
62287049|NCT04905667|EXPERIMENTAL|GB221 group|6 mg/kg, single dose, intravenous infusion, 90-100 min
62287050|NCT04905667|ACTIVE_COMPARATOR|Herceptin group|6 mg/kg, single dose, intravenous infusion, 90-100 min
62461503|NCT00389064|EXPERIMENTAL|Quetapine XR|Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily.
62461504|NCT00389064|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets orally administered once daily.
62461505|NCT01165671|EXPERIMENTAL|Experimental Arm|Carbon Ion Radiotherapy to the Macroscopic Tumor 6 x 3 Gy E up to 18 Gy E
62461506|NCT01165671|ACTIVE_COMPARATOR|Standard Arm|Proton Radiotherapy to the Macroscopic Tumor 5 x 2 Gy E up to 10 Gy E (Standard dose) applied after 48-52 Gy photon radiotherapy
62461507|NCT02433106|EXPERIMENTAL|Intervention|GAA 15 Specific neuromuscular exercise training
62461508|NCT02433106|ACTIVE_COMPARATOR|Control|Control Usual training
62461509|NCT00214422|EXPERIMENTAL|Arm 1- 5040cGy to the lymph nodes|5040Gray (cGy) to the lymph nodes
62461510|NCT00214422|EXPERIMENTAL|Arm 2 - 5400cGy to the lymph nodes|5400Gray (cGy) to the lymph nodes
62461511|NCT00214422|EXPERIMENTAL|Arm 3 - 5900cGy to the lymph nodes|5900Gray (cGy) to the lymph nodes
62461512|NCT03977649|EXPERIMENTAL|erenumab|monthly subcutaneous erenumab 140 mg for 12 weeks
62461513|NCT03977649|PLACEBO_COMPARATOR|placebo|monthly subcutaneous masked placebo for 12 weeks.
62461514|NCT03010098|EXPERIMENTAL|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
62461515|NCT03010098|EXPERIMENTAL|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
62067820|NCT01231503|EXPERIMENTAL|RTS,S Neo-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanri xHepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62453542|NCT04997694|EXPERIMENTAL|Active Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form, Temperature Comfort Perception Scale- The form was recorded in the Shivering Level Diagnosis Form Filling.Before anesthesia was given, heating was performed with the 3M Bair Hugger Model 775 Heating Unit, which has an active heating system, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
62635655|NCT03210493|EXPERIMENTAL|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
62067821|NCT01231503|EXPERIMENTAL|RTS,S 6-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 14 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62635656|NCT03210493|NO_INTERVENTION|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
62635657|NCT01835912|PLACEBO_COMPARATOR|Flavoured water placebo for acute dosing|500 milliliters flavoured water (placebo for the acute dosing intervention of sodium citrate)
62635658|NCT01835912|EXPERIMENTAL|Sodium Citrate Dihydrate Acute|dose: 0.5 g/kg of body mass dissolved in 500 milliliters of flavoured water
62635659|NCT01835912|PLACEBO_COMPARATOR|Flavoured water placebo chronic dosing|500 milliliters flavoured water (placebo for the chronic dosing intervention of sodium citrate)
62635660|NCT01835912|EXPERIMENTAL|Sodium Citrate Dihydrate Chronic|3 days of 0.1g/kg of body mass of sodium citrate and 4th day at 0.3 g/kg of body mass of sodium citrate in 500 milliliters of flavoured water
62635661|NCT03471832|EXPERIMENTAL|stenfilcon A lens|MyDay contact lens
62635662|NCT03471832|ACTIVE_COMPARATOR|narafilcon A lens|1-Day Acuvue TruEye
62635663|NCT01766908|ACTIVE_COMPARATOR|Cord Clamp 20 Seconds After Delivery|Intervention is cord clamp at 20 seconds following vaginal or cesarean delivery
62635664|NCT01766908|ACTIVE_COMPARATOR|Cord Clamp 40 seconds After Delivery|Timing of cord clamp at 40 seconds following vaginal or cesarean delivery.
62635665|NCT01766908|ACTIVE_COMPARATOR|Cord Clamp 60 seconds After Delivery|Intervention is timing of cord clamp at 60 seconds following vaginal or cesarean delivery
62635666|NCT03719430|EXPERIMENTAL|Doxorubicin/APX005M|"Patients will be treated with doxorubicin and APX005M in 21 day cycles. All patients receive the same treatment (there is no placebo arm). After completing 8 cycles of study treatment, patients without evidence of disease progression or unacceptable toxicity may continue treatment with APX005M alone. Doxorubicin will not be continued beyond cycle 8 due to the risk for cardiac toxicity from cumulative dosing."
62635667|NCT05199467|EXPERIMENTAL|Health Coaching|Receipt of up to 12 sessions of health coaching, plus printed materials providing information on VA benefits
62635668|NCT05199467|ACTIVE_COMPARATOR|VA Benefits Information|Receipt of printed materials providing information on VA benefits
62635669|NCT01525966|EXPERIMENTAL|Treatment (carboplatin and nab-paclitaxel)|Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once weekly. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62635670|NCT01190813|ACTIVE_COMPARATOR|Levodopa/Carbidopa|Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
62635671|NCT01190813|PLACEBO_COMPARATOR|Placebo|Oral placebo tid
62635672|NCT01861769|EXPERIMENTAL|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
62088248|NCT05498311|EXPERIMENTAL|Intraoperative Radiotherapy (IORT)|Patients with diagnosis of invasive breast cancer (IBC) will be treated with conservative surgery (with or without oncoplastic surgery) and 20 Gy IORT followed by hypofractionated radiotherapy.
62287051|NCT03280251|EXPERIMENTAL|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
62635673|NCT01861769|EXPERIMENTAL|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
62635674|NCT01861769|NO_INTERVENTION|No consultation|No Consultation/Fidelity Monitoring Only. Participants assigned to this condition will receive no post-workshop expert consultation, but will be subject to the same audiorecorded session-uploading and client-outcome reporting as the other conditions. This condition allows us to assess the effect of clinicians knowing that their sessions are subject to fidelity assessment.
62635675|NCT04748289|EXPERIMENTAL|NICU patients|All patients admitted to the Neurointensive Care Unit (NICU)
62088249|NCT03713645|EXPERIMENTAL|Tacrolimus extended-release 0.13mg/kg/day|Tacrolimus extended-release is initiated within post-operative day 3 of kidney transplant
62088250|NCT06242509||Metastatic castration resistant prostate cancer (CRPC) receiving next generation hormonal therapy|
62088251|NCT05270824|EXPERIMENTAL|radical surgery after neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)|After randomization, patients received radical surgery after the neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)
62088252|NCT05270824|ACTIVE_COMPARATOR|radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)|After randomization, patients received radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)
62635676|NCT03118518|ACTIVE_COMPARATOR|Anti-arrhythmic drug|
62635677|NCT03118518|EXPERIMENTAL|Cryoablation|
62635678|NCT03188055|EXPERIMENTAL|Best Case/Worst Case communication tool|The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
62635679|NCT03188055|NO_INTERVENTION|Usual Care|Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.Usual care also consists of daily updates with patient and family, describing each new problem as it arises and what will be done to treat it, regardless of how this fits into the patient's overall prognosis or health trajectory.
62635680|NCT05078203|EXPERIMENTAL|Exercise|36 minutes of exercise
62635681|NCT05078203|PLACEBO_COMPARATOR|Rest|36 minutes of rest
62635682|NCT05761418|EXPERIMENTAL|Dinoprostone|Will receive 20 mg of Dinoprostone vaginally 2 hrs. preoperatively.
62635683|NCT05761418|EXPERIMENTAL|Misoprostol|will receive 400 μg of Misoprostol vaginally 2 hrs. preoperatively.
62635684|NCT05761418|NO_INTERVENTION|control|received a placebo vaginally 2 hrs. preoperatively.
62635685|NCT04101383|EXPERIMENTAL|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
62635686|NCT04101383|ACTIVE_COMPARATOR|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
62635687|NCT00775762|ACTIVE_COMPARATOR|aspirin|
62635688|NCT00775762|ACTIVE_COMPARATOR|clopidogrel|
62635689|NCT00775762|ACTIVE_COMPARATOR|clopidogrel plus aspirin|
62635690|NCT00541567|PLACEBO_COMPARATOR|1|
62635691|NCT00541567|EXPERIMENTAL|2|
62635692|NCT00541567|EXPERIMENTAL|3|
62635693|NCT00541567|EXPERIMENTAL|4|
62635694|NCT01398852|EXPERIMENTAL|CXL Treatment|All eyes to be treated with riboflavin and UV light
62287052|NCT03280251|EXPERIMENTAL|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
62635695|NCT04907292||Planned Cesarean delivery|Patients who have an elective Cesarean delivery at Mount Sinai Hospital
62635696|NCT04907292||Unplanned Cesarean delivery|Patients who have an unplanned Cesarean delivery at Mount Sinai Hospital
62635697|NCT03163719||Patients with generalized convulsive seizure|All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.
62635698|NCT05173077||Colorectal cancer patients|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
62635699|NCT05173077||Control group patients without colorectal cancer|Patients without colorectal malignant disease according to data obtained in colonoscopy
62635700|NCT05173077||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
62635701|NCT05173077||Colorectal cancer patients undergoing surgery|Patients with histologically confirmed colorectal cancer (adenocarcinoma) planned for surgical management
62635702|NCT05173077||Patients with polyps undergoing polypectomy|Patients with colon polyps that will perform polypectomy
62635703|NCT05545423|EXPERIMENTAL|instrumented assisted soft tissue mobilization|patients will receive IASTM three times a week for eight weeks
62635704|NCT05545423|ACTIVE_COMPARATOR|traditional therapy|patients will receive traditional therapy three times a week for eight weeks
62635705|NCT05985057||Patients with carbapenem resistant Klebsiella spp. infection|
62635706|NCT05985057||Patients with carbapenem sensitive Klebsiella spp. infection|
62635707|NCT02492893|EXPERIMENTAL|Hatha Yoga|A 12-session 90-minute weekly hatha yoga intervention, that includes asanas (physical postures), pranayama (breathing exercises) and dhyana (meditation.
62635708|NCT02492893|NO_INTERVENTION|Treatment as Usual|
62635709|NCT02104076|EXPERIMENTAL|Evolution® Biliary Stent-Fully Covered|
62635710|NCT03534167|EXPERIMENTAL|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
62088253|NCT03076359|ACTIVE_COMPARATOR|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
62635711|NCT03534167|NO_INTERVENTION|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
62635712|NCT02738359||1rst arm: optical colonoscopy (OC)|t0: optical colonoscopy; Follow-up: yearly by phone call for three years
62635713|NCT02738359||2nd arm: colon capsule endoscopy (CC)|t0: colon capsule endoscopy -\> if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years
62635714|NCT02738359||3rd arm: fecal immunological test (FIT)|"FIT yearly for two years:~t0: FIT -\> if positive : OC; t = 1 year: FIT -\> if positive : OC; t = 2 years: FIT -\> if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years"
62272619|NCT01492608|ACTIVE_COMPARATOR|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
62635715|NCT03995888|EXPERIMENTAL|Healthy Volunteers|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
62635716|NCT03995888|EXPERIMENTAL|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
62635717|NCT01519011|EXPERIMENTAL|1: A, B, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
62272620|NCT01492608|PLACEBO_COMPARATOR|Natriumchlorid|Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).
62272621|NCT02765074|EXPERIMENTAL|Roactemra|subcutaneous tocilizumab
62272622|NCT04381390|EXPERIMENTAL|Whole egg consumption|This arm involved whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
62272623|NCT04381390|EXPERIMENTAL|Egg whites consumption|This arm involved egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
62272624|NCT00857727|EXPERIMENTAL|Drug|Dexmedetomidine
62635718|NCT01519011|EXPERIMENTAL|2: B, C, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
62635719|NCT01519011|EXPERIMENTAL|3: C, A, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
62635720|NCT01519011|EXPERIMENTAL|4: B, A, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
62635721|NCT01519011|EXPERIMENTAL|5: A, C, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
62635722|NCT01519011|EXPERIMENTAL|6: C, B, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
62635723|NCT01519011|EXPERIMENTAL|Extension|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
62635724|NCT06406335|OTHER|An intervention study (a quasi-experimental design)|a quasi-experimental design pre \&post
62635725|NCT04632277|PLACEBO_COMPARATOR|Placebo|"A tap water,"
62635726|NCT04632277|EXPERIMENTAL|Expermental recieve low MG|Low Mg bottle water (50mg/l)
62635727|NCT04632277|EXPERIMENTAL|Expermental recieve high MG|high Mg bottle water (100 mg/l)
62635728|NCT01190085|ACTIVE_COMPARATOR|Ghrelin (1 microg/kg)|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
62635729|NCT01190085|ACTIVE_COMPARATOR|Ghrelin (3 microg/kg)|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
62272625|NCT00857727|PLACEBO_COMPARATOR|Control|Normal Saline IV solution
62272626|NCT05506761|NO_INTERVENTION|Group I|This group includes patients with rib fractures receiving patient-controlled analgesia.
62635730|NCT01190085|PLACEBO_COMPARATOR|Saline Solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
62635731|NCT05418803|EXPERIMENTAL|Group1|17 subjects, Cross-over, Single dose of comparator on day1, YHP1807 on day8
62635732|NCT05418803|ACTIVE_COMPARATOR|Group2|17 subjects, Cross-over, Single dose of YHP1807 on day1, comparator on day8
62635733|NCT04531748|ACTIVE_COMPARATOR|Toremifene + Melatonin|"100mg oral Melatonin on Days 1 \& 2 (40mg in the morning and 60mg in the evening), 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).~60mg oral toremifene daily days 1-14."
62635734|NCT04531748|ACTIVE_COMPARATOR|Melatonin + Placebo|100mg oral Melatonin on Days 1 \& 2 (40mg in the morning and 60mg in the evening) and 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
62067822|NCT01231503|EXPERIMENTAL|RTS,S 6-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62635735|NCT04531748|PLACEBO_COMPARATOR|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions
62635736|NCT04036721|EXPERIMENTAL|ARM A - PROLONGED|induction dose 1-4mg/kg of prednisone, prednisone 60mg q24h for 2-4wks, tapering not faster than 10mg each 14d, maintenance dose 10mg q24h for 8wks, withdraw of treatment during 4wks, summary of treatment time not shorter than 12-24wks.
62635737|NCT04036721|ACTIVE_COMPARATOR|ARM B - FAST REDUCTION|induction dose 1-4mg/kg of prednisone, prednisone 30-60 mg q24h, tapering not faster than 10mg each 7d, summary of treatment time 6-12wks.
62272627|NCT05506761|EXPERIMENTAL|Group II|This group includes patients with rib fractures receiving continuous ultrasound-guided erector spinae plane block.
62272628|NCT05506761|EXPERIMENTAL|Group III|This group includes patients with rib fractures receiving continuous ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block.
62635738|NCT04356469|EXPERIMENTAL|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
62635739|NCT05653947|EXPERIMENTAL|Vital teeth|root canal instrumentation sodium hypochlorite 2.5% irrigation
62635740|NCT05653947|OTHER|Non-vital teeth|root canal instrumentation sodium hypochlorite 2.5% irrigation
61978698|NCT06200233|EXPERIMENTAL|single arm|"Rivoceranib 700 mg once daily by mouth. Rivoceranib should be given at the same time each day, with or without meals. Swallow the tablet whole. Do not chew, crush, or split the tablet.~Receive study medication until there is evidence of disease progression, intolerable toxicity, withdrawal of consent by the patient, or in the judgment of the principal investigator that the study cannot continue due to inability to administer.~Tumor response will be assessed according to RECIST v1.1 criteria based on imaging studies (CT or MRI) measured every 8 weeks (±1 week) from C1D1 through 12 months and every 12 weeks (±1 week) after 12 months."
61978699|NCT00269282|ACTIVE_COMPARATOR|1|Self-Management (SM) (Standard Care Group)
62635741|NCT04884347|EXPERIMENTAL|Alline proMEN|The qualitative and quantitative formula is as follows: 500 mg Keratin, 225 mg Inactive dried yeast rich in vitamin (containing 200 mg Saccharomyces cerevisiae 100% inactivated, 11.218.4 mg Vitamin B3, 6.8-7.2 mg Vitamin B5, 1.6-1.8 mg Vitamin B6, 1.6-1.8 mg Vitamin B2, 1.6 -1.8 mg Vitamin B1, 0.2-0.4 mg Vitamin B9, 0.2 mg Vitamin B8, 5.6 μg Vitamin B12), 150 mg Venus hair fern extract, 117.6 mg Iron gluconate (containing 14.7 mg Iron), 84.2 mg Sodium ascorbate coated, 76.8 mg Zinc gluconate (11 mg Zinc) 24 mg Beta carotene 20%, 14.8 mg Vitamin E, 256.3 mg Acacia gum, 100 mg Microcrystalline cellulose, 11.3 mg Magnesium stearate, 78 mg White coating (containing: 23.4-39 mg Hydroxypropylmethylcellulose (E464), 15.6-23.4 mg Calcium sulfate anhydrous (E516), 15.6-23.4 mg Magnesium carbonate, light (E504), 7.8-15.6 mg Hydroxypropylcellulose (E463), 3.9-11.7 mg Stearic acid (E570)).
61978700|NCT00269282|EXPERIMENTAL|2|Motivational Interviewing plus Self-Management Training (MI+SM)
62272629|NCT05969509|EXPERIMENTAL|the group that performed relaxation exercises|patients' postoperative pain and bowel movements will be evaluated by applying relaxation exercise intermittently
62272630|NCT05969509|NO_INTERVENTION|the group that did not do relaxation exercises|patients' postoperative pain and bowel movements will be evaluated
62635742|NCT04884347|PLACEBO_COMPARATOR|Placebo|1095 mg Microcrystalline cellulose, 5 mg Magnesium stearate, 55 mg White coating (containing: 16.5-27.5 mg Hydroxypropylmethylcellulose (E464), 11.0-16.5 mg Calcium sulfate anhydrous (E516), 11.0-16.5 mg Magnesium carbonate, light (E504), 5.5-11.0 mg Hydroxypropylcellulose (E463), 2.8-8.2 mg Stearic acid (E570).
62635743|NCT02727738|EXPERIMENTAL|Methimazole plus selenium|Methimazole 5-30 mg daily for 90 days Selenium 80 bid for 90 days
62635744|NCT02727738|ACTIVE_COMPARATOR|Methimazole|Methimazole 5-30 mg daily for 90 days
62635745|NCT02717000||NASH|
62635746|NCT02717000||No NASH|
62635747|NCT01789788|PLACEBO_COMPARATOR|Placebo|
62635748|NCT01789788|EXPERIMENTAL|RO6811135|
62635749|NCT02376504|EXPERIMENTAL|Treadmill workstation|Participants will be provided with a treadmill workstation to be more active at the workplace Active Workplace
62635750|NCT02376504|EXPERIMENTAL|Sit-to-Stand workstation|Participants will be provided with a sit-to-stand workstation to be decrease sitting time at the workplace Active Workplace
62635751|NCT02376504|NO_INTERVENTION|Control|Participants will be asked to engage in three 10 min walking bouts each work day
62635752|NCT06195618|EXPERIMENTAL|Vaccine|Triple-negative breast cancer patients with specific tumor mutation, with six doses of peptide-pulsed autologous dendritic cells after surgery
62272631|NCT02497859|EXPERIMENTAL|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
62272632|NCT02497859|ACTIVE_COMPARATOR|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
62635753|NCT02462512||FNAB of Thyroid nodule|The Patients with thyroid nodule who are scheduled for FNAB
62635754|NCT04856111|ACTIVE_COMPARATOR|Pirfenidone|Pirfenidone will be started at a dose of 600 mg/day. The dose will be escalated by 600 mg/day every 3-7 days up to a targeted dose of 2400 mg/day. The subjects will be administered the maximum tolerated dose for a total period of 24 weeks from randomization.
62635755|NCT04856111|ACTIVE_COMPARATOR|Nintedanib|Subjects in this group will be administered nintedanib at a dose of 150 mg twice daily. The liver function tests will be monitored as above. The dose will be reduced to 100 mg twice daily, if there is intolerance to 300 mg/day dose.
62635756|NCT04230369|EXPERIMENTAL|Internet-CBT|The internet-CBT will comprise 8 weekly modules with therapist-support, encouraging exposure for fear of asthma symptoms while ensuring a stable asthma medication through a written medical plan on medical adherence Participants work independently from home with the treatment and receive weekly support from their psychologist through written messages online.
62635757|NCT04230369|OTHER|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment, but psychological, from pre-assessments to 2 months after treatment completion. Participants in this arm will be crossed over to Internet-CBT after the primary endpoint at to 2 months follow up.
62635758|NCT05862493|NO_INTERVENTION|Standard management|Standard preoperative management, no preoperative TTE
61978701|NCT00138476|EXPERIMENTAL|Group 4: 0.48 RT-PCR units or Placebo|Group 4: dosage group of 10 subjects will receive 0.48 RT-PCR units of Lot 42399 NV or placebo control (8 subjects will receive NV and 2 subjects will receive placebo control).
62635759|NCT05862493|EXPERIMENTAL|FOCUS optimization|Standard preoperative management AND preoperative FOCUS along with an individualized hemodynamic optimization based on FOCUS findings.
62635760|NCT04030598|PLACEBO_COMPARATOR|Part A: Placebo|Participants with hereditary angioedema type I/type II (HAE-1/HAE-2) received placebo subcutaneously (SC) every 4 weeks at Weeks 1, 5, 9, and 13.
62635761|NCT04030598|EXPERIMENTAL|Part A: Donidalorsen 80 mg|Participants with HAE-1/HAE-2 received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
62635762|NCT04030598|EXPERIMENTAL|Part B: Donidalorsen 80 mg|Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
62635763|NCT00115778|EXPERIMENTAL|First IVIG, then Placebo|Study participants will receive three doses of IVIG given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of placebo over 12 weeks.
62635764|NCT00115778|EXPERIMENTAL|First Placebo, then IVIG|Study participants will receive three doses of 0.1% albumin solution (placebo) given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of IVIG over 12 weeks.
62635765|NCT02274597||Environmental impact on epitympanic temperature measurment|volunteers exposed to different environmental factors to simulate field settings
62635766|NCT00572260|EXPERIMENTAL|A|Daptomycin as a single preoperative dose within 30 minutes prior to surgery Dosage: if creatinine clearance ≥ 30 ml/min: 6 mg/kg IV
62635767|NCT00612911||Major group|Patients with Idiopathic dilated cardiomyopathy
62635768|NCT00959465|EXPERIMENTAL|Cohort 1/Dose Level A|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
62635769|NCT00959465|EXPERIMENTAL|Cohort 1/Dose B|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
62635770|NCT00959465|EXPERIMENTAL|Cohort 2/Dose C|A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.
62635771|NCT03805737|EXPERIMENTAL|Indoor Daylight PDT Therapy|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will be exposed to natural sunlight through a window for 2 hours. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
61978702|NCT00138476|EXPERIMENTAL|Group 3: 4.8 RT-PCR units or Placebo|Group 3: dosage group of 12 subjects will receive 4.8 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
62067823|NCT01231503|EXPERIMENTAL|Engerix-B Neo/RTS,S 6-10-26 Group|Subjects received one dose of Engerix-B (HBV) when ≤ 7 days of age followed by 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E and HBV vaccines were administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62088254|NCT03076359|EXPERIMENTAL|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
62635772|NCT03805737|ACTIVE_COMPARATOR|FDA Approved Standard Light Therapy Treatment|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
62635773|NCT02348229|EXPERIMENTAL|ERAS group|ERAS protocols
62635774|NCT02348229|OTHER|conventional pathway group|using conventional pathway
62635775|NCT05308966||Patient presenting MPS treated with nivolumab and ipilimumab|Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma (MPM) treated with combination of Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of their data
62635776|NCT02361034|ACTIVE_COMPARATOR|GRC 27864|Test treatment GRC 27864
62635777|NCT02361034|PLACEBO_COMPARATOR|Placebo|Placebo treatment
62635778|NCT01096160|EXPERIMENTAL|Panel A: MK-8266 BID, 1 mg/Placebo|MK-8266 1 mg (0.7 mg in the morning \[AM\] + 0.3 mg in the evening \[PM\]), or as matching placebo BID.
62635779|NCT01096160|EXPERIMENTAL|Panel B: MK-8266 BID, 1.8 mg/Placebo|MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
62635780|NCT01096160|EXPERIMENTAL|Panel C: MK-8266 TID, 1.8 mg/Placebo|MK-8266 TID, 1.8 mg (0.6 mg every 6 hours \[q6hr\]), or as matching placebo TID.
62635781|NCT01096160|EXPERIMENTAL|Panel D: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
62635782|NCT01096160|EXPERIMENTAL|Panel E: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.
62635783|NCT03607877|ACTIVE_COMPARATOR|pedometer walking (PW)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months.
62635784|NCT03607877|ACTIVE_COMPARATOR|pedometer walking with training (PWT)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down. Exercise intensity for the first four weeks was 50-55% heart rate reserve (HRR) with training for 3 months.
62635785|NCT03607877|EXPERIMENTAL|positive education and walking (PEPWT)|PEPWT: 15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months and six sessions of positive education.
62635786|NCT05682417|EXPERIMENTAL|Patients with anorexia nervosa according to DSM-5|Patients over 15 years old, suffering from anorexia nervosa according to DSM-V with a BMI\<18.5 and without psychiatric comorbidities
62635787|NCT03768778|OTHER|Debridement|
62635788|NCT03752476||case|Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
62067824|NCT01231503|EXPERIMENTAL|RTS,S 10-14-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 10, 14 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62272633|NCT06263569||Total hip arthroplasty (THA)|Total hip arthroplasty surgery
62272634|NCT06263569||Non-Total hip arthroplasty (THA)|No total hip arthroplasty surgery performed / control group.
62272635|NCT02981758||Data Collection Phase 1|All women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x).
62272636|NCT02981758||Data Collection Phase 2|All women who delivered (vaginally) at HackensackUMC who had blood loss and measured quantitatively by Triton and qualitatively (i.e., EBL) by obstetrician.
62272637|NCT05337332|EXPERIMENTAL|Central serous chorioretinopathy group|Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide.
62272638|NCT05337332|EXPERIMENTAL|Irvine-Gass Syndrome group|Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide
62272639|NCT01666327|EXPERIMENTAL|MT-1303|
62461516|NCT03386019|EXPERIMENTAL|Sprinters|Sprinters will be recruited from the track and field team of National Taiwan Normal University (NTNU) in this study. After individuals' enrollments and baseline data collections, all subjects will receive all three different treatments (massage, cold water immersion and static stretching) in randomized orders a week apart, respectively. Outcome measures are: visual analogue scale (VAS) score, lower leg volume, pressure pain threshold and horizontal jump distance. All measurements will be recorded at baseline, immediately after exercise, immediately after treatment, and 10 minutes after treatment as the follow up.
62635789|NCT03752476||control|Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
62635790|NCT02107846|EXPERIMENTAL|50 Units|PRX-112 50 Units daily for 5 days
62635791|NCT02107846|EXPERIMENTAL|100 Units|PRX-112 100 Units daily for 5 days
61978703|NCT00138476|EXPERIMENTAL|Group 2: 48 RT-PCR units or Placebo|Group 2: dosage group of 12 subjects will receive 48 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
62088255|NCT02064621|EXPERIMENTAL|C(Candesartan 32mg)|Candesartan 32mg 1T, PO, QD for 9days
62088256|NCT02064621|EXPERIMENTAL|B(Candesartan 32mg/Amlodipine 10mg)|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
62088257|NCT03839472|EXPERIMENTAL|Continuous Bladder Irrigation (CBI)|"Each subject will have a TURBT procedure performed per standard of care procedure, which will be followed by the study intervention - Continuous Bladder Irrigation (CBI) for up to two hours after procedure.~Six samples of discarded bladder irrigation will be collected from each participant (N=20) immediately after TURBT and after the completion of each liter of normal saline 0.9% irrigation (1 to 5 L) for a total of 120 samples."
62088258|NCT05420662|EXPERIMENTAL|Vaginal Manipulator Group|In this group of patients, abdominal hysterectomy surgery will be performed with the vaginal manipulator. After cutting and suturing uterine arteries, cardinal and sacrouterine ligaments are preserved by using a vaginal manipulator. The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point of the vagina.
62088259|NCT05420662|ACTIVE_COMPARATOR|Classical Abdominal Hysterectomy Group|In this group of patients, abdominal hysterectomy surgery will be performed in a conventional way, by cutting the cardinal and sacrouterine ligaments.
62088260|NCT02992015|EXPERIMENTAL|Gemcitabine|The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.
62088261|NCT04238221|EXPERIMENTAL|Doxofylline+inhalation therapy|4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy, followed by 4-week treatment of maximal inhalation therapy only
62088262|NCT04238221|EXPERIMENTAL|Inhalation therapy|4-week treatment with maximal inhalation therapy only, followed by 4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy
62088263|NCT03428061||Intervention group|The intervention under study will be the integrated care for cardiovascular risk management (CVRM), based on the Dutch CVRM guideline. Patients with a history of cardiovascular disease (CVD), a high cardiovascular risk (CVR) (\>10%) or use of antihypertensives or lipid lowering drugs are included in the program. Patients will be invited for an intake consultation, including a blood test, an interview, physical examination and estimation of the 10-years cardiovascular risk. If indicated, treatment with medication will be started and general lifestyle advises will be given. Patients can be referred to smoking cessation therapy, dietician and exercise programs or a physiotherapist. Patients will be controlled on a regular base to evaluate and adjust their personal goals.
62067825|NCT01231503|EXPERIMENTAL|RTS,S 14-26-9M Group|Subjects received 3 doses of RTS,S/AS01E (or GSK257049) at 14 and 26 weeks of age and at 9 months of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62067826|NCT01231503|ACTIVE_COMPARATOR|Engerix-B Neo Group|Subjects in this group received one dose of Engerix-B (HBV) ≤ 7 days of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The HBV vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
62635792|NCT02107846|EXPERIMENTAL|200 Units|PRX-112 200 Units daily for 5 days
62635793|NCT02107846|EXPERIMENTAL|400 Units|PRX-112 400 Units daily for 5 days
62067827|NCT04931394|EXPERIMENTAL|Organoid-Guided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
62635794|NCT03941340|EXPERIMENTAL|[14C]-AST2818 80mg (oral solution)|Volunteers will receive 80 mg \[14C\]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.
62635795|NCT04533789|EXPERIMENTAL|the control group|Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
62635796|NCT04533789|EXPERIMENTAL|virtual reality|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min.
62635797|NCT04533789|EXPERIMENTAL|Task oriented|Group 3 the study group received the same physical therapy program 30 min. plus task oriented training for 30 min.
62635798|NCT00209001|SHAM_COMPARATOR|Sham acupuncture therapy|Sham acupuncture therapy
62635799|NCT00209001|ACTIVE_COMPARATOR|Acupuncture|Acupuncture
62635800|NCT00209001|NO_INTERVENTION|Observation|Observation
62635801|NCT01701804||integrative treatment|
62635802|NCT03701880|EXPERIMENTAL|Ivabradine group|an initial dose of 5 mg/12 hours of Ivabradine will be added to beta-blockers (bisoprolol 2.5 mg/day) and ivabradine will be increased until a dose of 7.5 mg/12 hours according to HR. The heart rate target will be at least \<70 bpm and not lower than 60 bpm. If HR decreases below 60 bpm, ivabradine and/or beta-blockers doses will be decreased to the previous dose. After discharge, beta-blockers up-titration will be continued during follow-up visit.
62635803|NCT03701880|ACTIVE_COMPARATOR|Control group|beta-blocker (bisoprolol 2.5 mg/day) and it will be doubled every 2 weeks during the admission according to the stability of HR, blood pressure and tolerability of patients. Ivabradine will be only added after reaching bisoprolol optimal dose (10mg) or maximum tolerated dose and the HR is still above 70 bpm. If HR decreases below 60 bpm, ivabradine dose will be decreased.
62067828|NCT04931394|NO_INTERVENTION|Physician-decided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
62635804|NCT05854420|EXPERIMENTAL|Modified anterior Lamellar Recession|All patients in this arm underwent a combination of ALR, blepharoplasty, suprasternal fixation, and cauterization or internal bulb extirpation of posteriorly located lashes.
62635805|NCT02219685|EXPERIMENTAL|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
62067829|NCT06189118|EXPERIMENTAL|Online Mindfulness based Cognitive Therapy|The intervention will consist of 8 online weekly sessions (90-min each) of Mindfulness based Cognitive Therapy, plus daily home practice.
62635806|NCT02219685|PLACEBO_COMPARATOR|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
62635807|NCT02219685|EXPERIMENTAL|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
62635808|NCT04214522||Acute stroke patients|Acute stroke patients
62635809|NCT02582333||Tenofovir|Chronic hepatitis B patients who receive tenofovir as their first anti-HBV therapy and are indicated for stopping tenofovir therapy
62635810|NCT02582333||Entecavir|Chronic hepatitis B patients who receive entecavir as their first anti-HBV therapy and are indicated for stopping entecavir therapy
62635811|NCT04284683|EXPERIMENTAL|Normal and overweight participants|"Healthy males and female, age 6 to 30. BMI range for participants age 6 to 18 is between 5th percentile to 85th percentile, overweight BMI between the 85 and 95th percentile, and obese, above the 95th percentile.~BMI range for participants age 18 to 30 is between 18.5 to 24.9 for normal weight, 25-30 for overweight and above 30 for obese."
62635812|NCT00302536|EXPERIMENTAL|Tacrolimus|
62067830|NCT06189118|ACTIVE_COMPARATOR|Online Health Education Program|The active control will consist of 8 online weekly sessions (90-min each) of Health Education Program, plus daily home practice.
62635813|NCT01481558|SHAM_COMPARATOR|Sham tDCS|sham-tDCS application every 2 days for 2 weeks (total of 6 applications)
62635814|NCT01481558|EXPERIMENTAL|Transcranial direct current stimulation|tDCS application every 2 days for 2 weeks (total of 6 applications)
62067831|NCT01335503|ACTIVE_COMPARATOR|AN-PEP with low caloric meal|
62067832|NCT01335503|ACTIVE_COMPARATOR|AN-PEP with high caloric meal|
62067833|NCT01335503|PLACEBO_COMPARATOR|Placebo with low caloric meal|
62067834|NCT01335503|PLACEBO_COMPARATOR|Placebo with high caloric meal|
62067835|NCT01290822|EXPERIMENTAL|BiVP Pacing|BIVP optimize AVD, VVD, and LVPS parameters and assess the effect on cardiac output.
62067836|NCT01290822|ACTIVE_COMPARATOR|AAI Pacing|Traditional atrial (AAI) pacing
62635815|NCT06540560|EXPERIMENTAL|My Pelvic Plan|This is a web-based self-guided program.
62635816|NCT01841970|OTHER|HET Arm|Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
62067837|NCT06327763|NO_INTERVENTION|inguinal hernioplasty with ilioinguinal nerve preservation|
62461517|NCT04751669|EXPERIMENTAL|Micronutrient dietary supplement effervescent tablet|"Tablet containing:~* Retinol (Vitamin A) 700 mcg~* Cholecalciferol (Vitamin D3) 10 mcg~* Alpha-Tocopherol (Vitamin E) 45 mg~* Ascorbic acid (vitamin C) 1000 mg~* Pyridoxine (Vitamin B6) 6.5 mg~* Cyanocobalamin (Vitamin B12) 9.6 mg~* Folic acid 400 mg~* Iron 5 mg~* Zinc 10 mg~* Selenium 110 mg~* Copper 0.9 mg~* Excipients"
62067838|NCT06327763|EXPERIMENTAL|inguinal hernioplasty with ilioinguinal nerve section|
62067839|NCT03405272|EXPERIMENTAL|recombinant anti-EGFR monoclonal antibody（SCT200）|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
62067840|NCT05799664|EXPERIMENTAL|Experimental group|Patients will be treated with TLD and standard of care (per GOLD guideline).
62067841|NCT05799664|SHAM_COMPARATOR|Control group|Patients will undergo sham TLD procedure and be treated with standard of care (per GOLD guideline).
62067842|NCT01286220|ACTIVE_COMPARATOR|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
62067843|NCT01286220|PLACEBO_COMPARATOR|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
62067844|NCT04458116|EXPERIMENTAL|Tumeric Group|participants will receive capsules containing 1.5 grams of turmeric 95% curcumin
62067845|NCT04458116|PLACEBO_COMPARATOR|Placebo Group.|will receive capsules containing corn starch.
62067846|NCT02482272|ACTIVE_COMPARATOR|Lamivudine plus Adefovir or Adefovir|Lamivudine+Adefovir or Adefovir for 48 weeks
62067847|NCT02482272|EXPERIMENTAL|Entecavir plus Adefovir|Entecavir+Adefovir for 48 weeks
62272640|NCT00412750|EXPERIMENTAL|LdT+ PEG-INF|Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
62272641|NCT00412750|EXPERIMENTAL|LdT Monotherapy|Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
62272642|NCT00412750|ACTIVE_COMPARATOR|PEG-INF Monotherapy|Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
62272643|NCT01179958|EXPERIMENTAL|aerobic training|24 weeks of aerobic training, 4 times/week
62272644|NCT01179958|PLACEBO_COMPARATOR|stretching/toning|stretching/toning condition, 24 weeks to parallel the active intervention group
62272645|NCT05946473|EXPERIMENTAL|Experimental gum formulation|Participants will be asked to chew 2 pieces of chewing gum containing additives 2 times a day for a four-week period
62272646|NCT05946473|PLACEBO_COMPARATOR|Placebo|Participants will be asked to chew 2 pieces of pure gum base with no additives chewing gum 2 times a day for the same four-week period.
62272647|NCT00421668|EXPERIMENTAL|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate, and B12
62272648|NCT00421668|EXPERIMENTAL|Multivitamins + Zinc|Vitamins C, E, B1, B2, niacin, B6, folate and B12, and zinc
62272649|NCT00421668|EXPERIMENTAL|Zinc|zinc
62272650|NCT00421668|PLACEBO_COMPARATOR|Placebo|placebo
62272651|NCT05626530|OTHER|single arm|This is an open label single arm study
62272652|NCT04349423|EXPERIMENTAL|No Social Media Use|Participants will be asked to refrain from using all social media
62272653|NCT04349423|EXPERIMENTAL|Maximum 30 minutes of use|Participants will be asked to only use social media at most 30 minutes a day.
62272654|NCT04349423|EXPERIMENTAL|Maximum 1 hour of use|Participants will be asked to only use social media at most 60 minutes a day.
62272655|NCT04349423|EXPERIMENTAL|Control|Control Group
62461518|NCT04751669|PLACEBO_COMPARATOR|Placebo dietary supplement effervescent tablet|"Effervescent tablet with only the excipients.~* Sucralose 13 mg~* Sodium Chloride 20 mg~* Potassium Acesulfam 22.5 mg~* Orange P 55 mg~* Sodium Carbonate 70 mg~* Betacarotene 100 mg~* Malic Acid 800 mg~* Citric Acid 960 mg~* Sodium bicarbonate 1,000 mg~* Isomalt 1,459.50 mg"
62067848|NCT04727476||Children with attention deficit disorders|children aged 7-13 years who have attended a specialised outpatient clinic treating children with attention deficit disorders i in the period from 1 April 2013 to 5 November 2019.
62067849|NCT05429658|EXPERIMENTAL|Thrombectomy|Aspiration of clot with large bore catheter in acute ischemic stroke patients
62067850|NCT01879423|EXPERIMENTAL|Lamotrigine (Lamictal) D/C 5mg*5, Crossover|Single dose of lamotrigine dispersible/chewable (D/C)5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
62067851|NCT01879423|EXPERIMENTAL|Lamotrigine (Lamictal) Compressed 25mg, Crossover|Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
62067852|NCT03661034|EXPERIMENTAL|Cohort 1, Arm A|Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)
62067853|NCT03661034|EXPERIMENTAL|Cohort 1, Arm B|Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)
62067854|NCT03661034|EXPERIMENTAL|Cohort 2, Arm C|Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
62272656|NCT04103801|EXPERIMENTAL|Sucrose group|This group received the 2 ml of sweet solution (sucrose)
62272657|NCT04103801|PLACEBO_COMPARATOR|Water group|This group received the 2 ml of water
62272658|NCT01659320|EXPERIMENTAL|Minocycline|Open label treatment using minocycline.
62272659|NCT04797832|ACTIVE_COMPARATOR|Treatment|100 patients receiving IV Iron during index hospitalisation.
62272660|NCT04797832|NO_INTERVENTION|No treatment|100 patients not receiving IV Iron above standout treatment.
62453543|NCT04997694|EXPERIMENTAL|Pasive Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form ,Vital Signs Follow-up Form, Temperature Comfort Perception Scale. The form was recorded in the Shivering Level Diagnosis Form . Before anesthesia was given, heating was performed with a wool blanket, which is a passive heating method, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
62453544|NCT04997694|NO_INTERVENTION|Control Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form , Temperature Comfort Perception Scale The form was recorded in the Shivering Level Diagnosis Form the participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form , Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
62453545|NCT03020602|EXPERIMENTAL|Treatment (BPM31510)|Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62453546|NCT00633282|EXPERIMENTAL|Lifestyle intervention|Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
62453547|NCT00633282|EXPERIMENTAL|Life style intervention, pioglitazone|Life style intervention with pioglitazone 15mg qd for 16 weeks
62453548|NCT00633282|EXPERIMENTAL|Life style intervention, berberine|Life style intervention with berberine 0.5g tid for 16 weeks
62453549|NCT05014308|EXPERIMENTAL|piezocision group|piezocision surgical procedure was done according to Dibart's et al,
62453550|NCT05014308|EXPERIMENTAL|fiberotomy group|the fiberotomy procedure followed Edward's et al
62453551|NCT05014308|NO_INTERVENTION|control group|no intervention
62453552|NCT01743157|EXPERIMENTAL|Biochemo + Bevacizumab then Ipilimumab|Single arm: Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.
62453553|NCT03876561|EXPERIMENTAL|Prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 sessions per week before stoma closure and 1 sessions per week during 6 weeks following stoma closure. Complementary sessions are allowed if necessary.
62453554|NCT03876561|NO_INTERVENTION|No intervention|No pelvic floor prehabilitation will be proposed before stoma closure. The pelvic floor prehabilitation will be proposed to patients suffering from LARS
62453555|NCT03396133|EXPERIMENTAL|Snap group|individuals in this arm used Snap according to the instruction on time and screened at the symptomatic
62453556|NCT03396133|NO_INTERVENTION|RC group|patients in the RC arm accepted normal methods
62453557|NCT03025607|NO_INTERVENTION|Control|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight.
62453558|NCT03025607|EXPERIMENTAL|JOOL-Only|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, and will receive the JOOL Health mobile phone application.
62453559|NCT03025607|EXPERIMENTAL|JOOL-Plus|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, the JOOL Health mobile phone application, a digital scale, and a Fitbit.
62453560|NCT00493272|PLACEBO_COMPARATOR|Placebo|Nacl
62453561|NCT00493272|ACTIVE_COMPARATOR|Fibrinogen|Fibrinogen
62067855|NCT03661034|EXPERIMENTAL|Cohort 2, Arm D|Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
62272661|NCT01148537|EXPERIMENTAL|BTDS|Buprenorphine transdermal patches 5, 10, 20, and 2 \* 20 mcg/h.
62272662|NCT01148537|PLACEBO_COMPARATOR|Placebo TDS|Matching placebo transdermal patches 5, 10, 20 and 2 \* 20.
62272663|NCT01148537|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin hydrochloride 400 mg tablets
62272664|NCT00452699|ACTIVE_COMPARATOR|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
62272665|NCT00452699|ACTIVE_COMPARATOR|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
62635817|NCT03281746|ACTIVE_COMPARATOR|Group I (standard prevention education)|Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
62453562|NCT00322491|EXPERIMENTAL|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
62453563|NCT00322491|EXPERIMENTAL|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
62453564|NCT04619810|OTHER|Intervention arm|quasi-experimental pre-post study
62635818|NCT03281746|EXPERIMENTAL|Group II (standard and one-on-one education, consultation)|Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.
62635819|NCT01705938|ACTIVE_COMPARATOR|Group 1|SP-333 0.1 mg \& Placebo, one tablet by mouth, single dose
62635820|NCT01705938|ACTIVE_COMPARATOR|Group 2|SP-333 0.3 mg \& Placebo, 3 tablets by mouth, single dose
62635821|NCT01705938|ACTIVE_COMPARATOR|Group 3|SP-333 1 mg \& Placebo, one tablet by mouth, single dose
62635822|NCT01705938|ACTIVE_COMPARATOR|Group 4|SP-333 3 mg \& Placebo, 3 tablets by mouth,single dose
62635823|NCT01705938|ACTIVE_COMPARATOR|Group 5|SP-333 10 mg \& Placebo, 1 tablet by mouth, single dose
62635824|NCT01705938|ACTIVE_COMPARATOR|Group 6|SP-333 30 mg \& Placebo, 3 tablets by mouth, single dose
62635825|NCT01705938|ACTIVE_COMPARATOR|Group 7|SP-333 60 mg \& Placebo, 6 tablets by mouth, single dose
62635826|NCT02318030||Solid organ transplant|
62635827|NCT02318030||Hematopoietic Stem Cell Transplant|
62635828|NCT03625596|ACTIVE_COMPARATOR|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
62635829|NCT03625596|EXPERIMENTAL|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
62635830|NCT03625596|EXPERIMENTAL|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
62635831|NCT03625596|EXPERIMENTAL|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
62635832|NCT03625596|PLACEBO_COMPARATOR|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
62635833|NCT01309295||Cohort|
62635834|NCT05384002||Retrospective (training model)|
62635835|NCT05384002||Prospective (validation model)|
62635836|NCT04078711|EXPERIMENTAL|losartan & qianyangyuyin|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Chinese Medicine (Qianyangyuyin granule) 20g by mouth, bid for 6 months.
62635837|NCT04078711|PLACEBO_COMPARATOR|Losartan & Placebo|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Qianyangyuyin placebo 20g by mouth, bid for 6 months.
62635838|NCT03748134|EXPERIMENTAL|Randomized Part: Experimental: Sintilimab + chemotherapy|"Sintilimab in combination with investigator's choice of chemotherapy~TP regimen: Cisplatin + paclitaxel~or~CP regimen: Cisplatin + fluorourcil"
62635839|NCT03748134|ACTIVE_COMPARATOR|Randomised Part: Active Comparator: Placebo + chemotherapy|Placebo in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil
62635840|NCT03748134|EXPERIMENTAL|Open-label part: Sintilimab+ chemotherapy|Sintilimab in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil
62635841|NCT03334357|NO_INTERVENTION|Control|Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
62635842|NCT03334357|EXPERIMENTAL|PAR group|"The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity).~Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM.~Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training.~Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks).~Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol"
62635843|NCT03334357|EXPERIMENTAL|HIIT group.|"The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be \>95% VO2max and HIIT with short intervals (Type B session), \>120% VO2max.~Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session.~Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol"
62652914|NCT04937868||Blunt trauma patients undergoing abdominopelvic computed tomographic imaging|"The study will be observational and not alter the care or management of blunt injury victims. Medical decisions will be made by treating physicians using current standards of care. Thus, to reduce the potential for bias, the study will seek to enroll all blunt injury victims who undergo A/P imaging as part of their ED trauma evaluation. This may include children, the elderly, all races, both sexes, and any other demographic or social groups that may present among blunt injury patients. An individual will become eligible for the study when the treating physician determines that A/P CT imaging is needed for their trauma evaluation. Inclusion or exclusion will not be based on age, gender, pregnancy or child-bearing potential, or racial/ethnic origin.~There will be no exclusion criteria."
62067856|NCT04221282||Epileptic elderly patients|Elderly patients with partial-onset seizures
62453565|NCT04148313||Patients|Patients with diagnosis of Multiple Sclerosis.
62635844|NCT03334357|EXPERIMENTAL|WB-EMS group.|"WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT.~Electrical parameters:~We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session.~Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec).~Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%.~RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale 5 of 9"
62635845|NCT02915224||Obinutuzumab|Participants will receive obinutuzumab as per Summary of Product Characteristics in daily practice along with chlorambucil for 24 months.
62635846|NCT00875563|EXPERIMENTAL|1|Zenith(R) Fenestrated AAA Endovascular Graft
62635847|NCT00514618|ACTIVE_COMPARATOR|1|patients will be treated with misoprostol 50 mcg PO
62635848|NCT00514618|PLACEBO_COMPARATOR|2|patients will receive placebo (Vitamin C)
62635849|NCT05704400|EXPERIMENTAL|single arm|
62635850|NCT04743934|EXPERIMENTAL|Flibanserin + ADT|Flibanserin at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
62635851|NCT04743934|PLACEBO_COMPARATOR|Placebo + ADT|Placebo at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
62635852|NCT05682547|EXPERIMENTAL|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 8 weeks.
62635853|NCT05682547|ACTIVE_COMPARATOR|HA group|Participants in HA group will be administered one drop of 0.1% Sodium hyaluronate artificial tears (preservative free) six times per day for 8 weeks
62635854|NCT04528134|EXPERIMENTAL|Extended Contact RMGI Varnish/5% Sodium Fluoride Varnish|This group will receive extended contact (XT) varnish on their upper left and lower right teeth, and traditional 5% sodium fluoride varnish on their upper right and lower left teeth.
62635855|NCT04528134|EXPERIMENTAL|Placebo Varnish/Extended Contact RMGI Varnish|This group will receive placebo varnish on their upper left and lower right teeth, and extended contact (XT) varnish on their upper right and lower left teeth.
62635856|NCT04528134|ACTIVE_COMPARATOR|5% Sodium Fluoride Varnish/Placebo Varnish|This group will receive traditional 5% sodium fluoride varnish on their upper left and lower right teeth, and placebo varnish on their upper right and lower left teeth.
62635857|NCT01124747|EXPERIMENTAL|ASP1585 and 14C-Labeled ASP1585|
62635858|NCT03834025|EXPERIMENTAL|Phase 1 Condition 1, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 1.
62635859|NCT03834025|EXPERIMENTAL|Phase 1 Condition 1, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 2.
62635860|NCT03834025|EXPERIMENTAL|Phase 1 Condition 1, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 3.
62635861|NCT03834025|EXPERIMENTAL|Phase 1 Condition 2, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 1.
62635862|NCT03834025|EXPERIMENTAL|Phase 1 Condition 2, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 2.
62635863|NCT03834025|EXPERIMENTAL|Phase 1 Condition 2, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 3.
62635864|NCT03834025|EXPERIMENTAL|Phase 1 Condition 3, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 1.
62635865|NCT03834025|EXPERIMENTAL|Phase 1 Condition 3, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 2.
62635866|NCT03834025|EXPERIMENTAL|Phase 1 Condition 3, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 3.
62652915|NCT05489042|EXPERIMENTAL|Active rTMS|5 sessions of active rTMS
62652916|NCT05489042|SHAM_COMPARATOR|Sham rTMS|5 sessions of sham rTMS
62067857|NCT04116528|OTHER|Ketamine|Every eligible participant will receive 0.5mg/kg IV given over 40 minutes
62067858|NCT04116528|ACTIVE_COMPARATOR|Buprenorphine or Placebo|Buprenorphine or placebo once daily for 4 weeks
62067859|NCT02415374|PLACEBO_COMPARATOR|Low-AVA oat flour cookies|Three low-AVA oat flour cookies
62067860|NCT02415374|EXPERIMENTAL|High-AVA oat flour cookies|Three high-AVA cookies
62067861|NCT04924972||Intracutaneous Suture|
62067862|NCT04924972||running Suture|
62453566|NCT01661270|PLACEBO_COMPARATOR|Placebo|Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m\^2 IV infusion and leucovorin 400 mg/m\^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m\^2 followed by continuous IV infusion 2400 mg/m\^2.
62453567|NCT01661270|EXPERIMENTAL|Aflibercept|Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m\^2 IV infusion and leucovorin 400 mg/m\^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m\^2 followed by continuous IV infusion 2400 mg/m\^2.
62453568|NCT02952495|EXPERIMENTAL|Online alcohol educational class|Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults.
62453569|NCT02952495|NO_INTERVENTION|No intervention|Participants will NOT Participate in the online alcohol education class.
62453570|NCT02532764|EXPERIMENTAL|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
62453571|NCT02532764|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
62453572|NCT05616208|EXPERIMENTAL|Implantation|This is a non-randomized, single group treatment study with a single arm and is not subject or investigator masked or blinded. BioSphincters will be implanted in every study subject.
62453573|NCT04856345|EXPERIMENTAL|Music with synchronising|walking to music that one can synchronise to
62453574|NCT04856345|ACTIVE_COMPARATOR|Music without synchronising|walking to music that one cannot synchronise to
62453575|NCT04856345|SHAM_COMPARATOR|No music|walking without music.
62453576|NCT02564263|EXPERIMENTAL|Pembrolizumab|Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).
62453577|NCT02564263|ACTIVE_COMPARATOR|Chemotherapy|Participants received Investigator's choice of paclitaxel 80-100 mg/m\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).
62453578|NCT02586259||Cortiment®|Treatment according to routine clinical practice.
62453579|NCT02016300|EXPERIMENTAL|Unloader Bracing|This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
62067863|NCT01774318|OTHER|preterm cohort|preterm infants born at medical university of vienna and born at gestational age 23+0 - 28+6 weeks of gestation intervention: aEEG and conventional EEG measurements will be performed every two weeks untill 36 weeks of gestation
62453580|NCT02016300|ACTIVE_COMPARATOR|Non-Bracing Arm|This group will be randomly selected and assigned to wear no brace post-operatively.
62453581|NCT03519828||Patients with post-stroke cognitive impairment|
62453582|NCT03519828||Patients without post-stroke cognitive impairment|
62453583|NCT01808664|EXPERIMENTAL|Standardized Patient Instructor Intervention|"Primary care physicians (PCPs) randomized to intervention will receive over a three month run-in period two visits by standardized patient instructors portraying: 1) a 48 year-old patient with low back pain for less than six-weeks and no red flags for immediate spinal imaging; and 2) a 50 year-old recently menopausal woman establishing care with concerns about osteoporosis risk."
62067864|NCT04856943|EXPERIMENTAL|smartconsent group|Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.
62453584|NCT01808664|ACTIVE_COMPARATOR|Control|"In the latter half of visits with control PCPs, standardized patient instructors (SPIs) will share information regarding low back pain or bone health that are unrelated to diagnostic testing, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
62453585|NCT06111911|EXPERIMENTAL|Urine Specimen|
62453586|NCT06111911|EXPERIMENTAL|Cervical Swab Specimen|
62652917|NCT04581915|EXPERIMENTAL|Interventional|Participants to receive Triazavirin 250mg po 8 hourly for 5 days
62272666|NCT00106171|EXPERIMENTAL|Immediate Treatment Arm|Participants will receive immediate HAART for 1 year; then HAART will stopped until clinically indicated.
62067865|NCT04856943|PLACEBO_COMPARATOR|control group|Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.
62067866|NCT04937426|EXPERIMENTAL|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|During gastroscopy additional biopsies are taken in cases where infection with helicobacter pylori is suspected. It will then undergo laboratory analysis with fluorescent-labeled urease inhibitor marker. Results will be compared to standard analysis to determine efficacy.
62272667|NCT00106171|NO_INTERVENTION|Deferred Treatment Arm|Participants will receive no immediate HAART, but will receive HAART when HAART is clinically indicated.
62453587|NCT04292561|EXPERIMENTAL|light general anesthesia|During anesthesia maintenance, patients were received with low concentration sevoflurane to maintain a target of 0.8 MAC.
62652918|NCT04581915|PLACEBO_COMPARATOR|Control|Participants to receive placebo po 8 hourly for 5 days
62272668|NCT01503255|EXPERIMENTAL|cognitive behavioral group therapy|
62272669|NCT01503255|ACTIVE_COMPARATOR|health education group|
62272670|NCT02519166|OTHER|Patients with chronic wounds|
62272671|NCT01870401|EXPERIMENTAL|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
62272672|NCT01870401|ACTIVE_COMPARATOR|PTA Catheter|Standard Uncoated PTA Catheter
62272673|NCT03700307|EXPERIMENTAL|pulmonary vein isolation|patients will receive circumferential pulmonary vein isolation using cryoballoon ablation
62067867|NCT05017324|EXPERIMENTAL|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an individualised RR-TB treatment recommendation
62067868|NCT05017324|NO_INTERVENTION|Standard of Care|Standard of care diagnosis of the drug resistance profile and individualised treatment
62067869|NCT06299514|ACTIVE_COMPARATOR|Pharmacological Therapy|Patients randomized to pharmacology rate control will receive guideline-directed HF management across all ranges of LVEF, including appropriate rate control medications. ICD will be inserted in those patients who have LVEF ≤35%
62453588|NCT04292561|EXPERIMENTAL|deep general anesthesia|During anesthesia maintenance, patients were received with high concentration sevoflurane to maintain a target of 1.0 MAC.
62067870|NCT06299514|EXPERIMENTAL|P&A-CSP|Patients randomized to P\&A-CSP will receive a CSP and ICD if LVEF ≤35% within 10 working days of randomization. Catheter AVNA will be performed within 4 weeks.
62067871|NCT05613283||Accuracy verification group|Assessment reagent urine sample HPV-PCR test result Assessment reagent vaginal secretion sample HPV-PCR test result Comparative Methods NGS Nucleic Acid Sequencing Results
62067872|NCT05613283||Consistency verification group|Assessment reagent urine sample HPV-PCR test result Assessment reagent vaginal secretion sample HPV-PCR test result ApprovedListed Reagent Cervical Sample HPV-PCR Test Result
62067873|NCT05613283||Efficacy and safety verification group|Thin-layer liquid-based cytology (TCT) results panel Colposcopy results Tissue biopsy pathological diagnosis result
62453589|NCT04503330|EXPERIMENTAL|Patients with iatrogenic PUJO|patients with iatrogenic PUJO or long segment ureteric stricture disease for safety and efficacy of using buccal graft for repair
62453590|NCT01367275|EXPERIMENTAL|Brivanib + Irinotecan|Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m\^2 on Day 1.
62652919|NCT05033132|EXPERIMENTAL|Balstilimab|Balstilimab monotherapy: approximately 147 patients.
62067874|NCT00812188|ACTIVE_COMPARATOR|Medium Dose UVA-1|Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
62453591|NCT05634109|EXPERIMENTAL|Whole Blood|Leukoreduced whole blood with a platelet-sparing filter. Participants will be transfused with 3 whole blood units. If the participant requires, an additional transfusion pack composite by 3 whole blood units will be administered.
62453592|NCT05634109|ACTIVE_COMPARATOR|Blood Components Therapy|1:1:1 ratio of red blood cells unit, plasma unit, and platelets unit. Participants will be transfused with 3 red blood cell units, 3 fresh frozen plasma units, and 3 platelets units. A second intervention with the same ratio can be transfused to participants if they require it.
62453593|NCT01186588|EXPERIMENTAL|001|Canagliflozin One 300-mg dose of canagliflozin on Day 1
62635867|NCT03834025|EXPERIMENTAL|Phase 1 Condition 4, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 1.
62635868|NCT03834025|EXPERIMENTAL|Phase 1 Condition 4, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 2.
62635869|NCT03834025|EXPERIMENTAL|Phase 1 Condition 4, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 3.
62635870|NCT05722262|EXPERIMENTAL|Sequence A|Three period alternative intervention and fed/fasted sequence
62635871|NCT05722262|EXPERIMENTAL|Sequence B|Three period alternative intervention and fed/fasted sequence
62635872|NCT05722262|EXPERIMENTAL|Sequence C|Three period alternative intervention and fed/fasted sequence
62635873|NCT05722262|EXPERIMENTAL|Sequence D|Three period alternative intervention and fed/fasted sequence
62635874|NCT05722262|EXPERIMENTAL|Sequence E|Three period alternative intervention and fed/fasted sequence
62453594|NCT05861648|EXPERIMENTAL|Drug group 1|Dietary Supplement: Folic acid 2.5 mg/day
62453595|NCT05861648|PLACEBO_COMPARATOR|Control group 2|Dietary Supplement: Placebo
62635875|NCT05722262|EXPERIMENTAL|Sequence F|Three period alternative intervention and fed/fasted sequence
62635876|NCT03307928|EXPERIMENTAL|Cardiopulmonary Exercise Test Protocol|All subjects performed an incremental cardiopulmonary exercise test (CPET) to maximum exercise tolerance. All the procedures were performed in agreement with the American Thoracic Society/American College of Chest Physicians guidelines for cycle ergometer tests.
62067875|NCT00812188|ACTIVE_COMPARATOR|High Dose UVA-1|High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
62453596|NCT05505812|EXPERIMENTAL|HS-IT101 monotherapy|1x10\^9-6x10\^10 in vitro expanded autologous TIL (HS-IT101) will be infused i.v. to patients with advanced breast cancer after lymphodepletion treatment with fludarabine and cyclophosphamide, and then followed by the administration of a regimen of IL-2.
62453597|NCT01247259|ACTIVE_COMPARATOR|SLIT-mono|
62453598|NCT01247259|ACTIVE_COMPARATOR|SLIT-poly|
62453599|NCT04849988|EXPERIMENTAL|ABP-450 - Low Dose|ABP-450 Low Dose - Intramuscular injections into affected neck muscles.
62453600|NCT04849988|EXPERIMENTAL|ABP-450 - Medium Dose|ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.
62635877|NCT03307928|EXPERIMENTAL|Polysomnography Assessment|All hypertensive subjects were submitted to a polysomnography exam to diagnose OSA. The OSA diagnose was confirmed by the apnea/hypopnea index (AHI) and classified as follows: AHI \< 5 events/h, absence of OSA; 5 ≤ AHI ≤ 15 events/h, low OSA; 15 ≤ AHI ≤ 30 events/h, moderate OSA; AHI \> 30 events/h, severe OSA.
62635878|NCT03796312|EXPERIMENTAL|Tub Bathing|In this group, preterm infants were given tub bathing.
62635879|NCT03796312|ACTIVE_COMPARATOR|Sponge Bathing|Separate cotton cloths were prepared for each body area in the sponge bath. The room temperature was set to 26-27°C to prevent hypothermia. The temperature of the water used for sponge bathing was set to 37-38°C. Alongside the bath, the infant was placed on a flat, protected surface and washed from a bowl of water, using the same mild cleanser. The eyes, face, and head were wiped and dried while the baby was wrapped in a blanket. The wrap was opened so that body parts could be washed, dried, and then immediately rewrapped, after which infants were diapered.
62635880|NCT02318849|EXPERIMENTAL|First initiation site|University randomized to receive intervention after 1 baseline assessment. Duration of intervention was 3 semesters. This was University of Hawaii at Manoa (UHM).
62635881|NCT02318849|EXPERIMENTAL|Second initiation site|University randomized to receive intervention after 3 baseline assessments. Duration of intervention was 2 semesters. This was University of Hawaii at Hilo (UHH).
62635882|NCT02318849|EXPERIMENTAL|Third initiation site|University randomized to receive intervention after 5 baseline assessments. Duration of intervention was 2 semesters. This was Hawaii Pacific University (HPU).
62453601|NCT04849988|EXPERIMENTAL|ABP-450 - High Dose|ABP-450 High Dose - Intramuscular injections into affected neck muscles.
62635883|NCT01575171||"Intervention/Nudge"|"Individuals will be analyzed according to their assigned intervention group, to compare the effectiveness of an opt-out EHR decision support system to enhance the prescription of statins to those patients with an elevated LDL-C and to subsequently titrate the medication dose until LDL-C control is obtained. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
62652920|NCT05033132|EXPERIMENTAL|Balstilimab + Zalifrelimab|Balstilimab in combination with Zalifrelimab (combination therapy): approximately 30 patients.
62453602|NCT04849988|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.
62453603|NCT02288832|EXPERIMENTAL|Innovative strategy (group A):|these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique; if the test is found to be positive, an appropriate treatment will be prescribed. The POC (point-of-care) test will be considered positive if: A. vaginae is detected at a threshold \> 105.copies per ml and/or G. vaginalis \> 105 copies per ml. The women with vaginosis will be screened monthly for recurrences through 28 weeks, and recurrence will be treated.
62453604|NCT02288832|OTHER|Standard strategy (group B):|This group will be followed according to the usual practices of the physicians seeing them.
62453605|NCT03922438|EXPERIMENTAL|Cleft margin flap with anterior palatal closure|Usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.
62453606|NCT05815069|EXPERIMENTAL|[18F]AlF-NOTA-pentixather|No special preparation such as fasting and fasting is required before the examination. The radiotracer 18F-AlF-NOTA-pentiaxther PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight, and the drug was synthesized by the Department of Nuclear Medicine of Sichuan Provincial People's Hospital immediately before the examination. Before the examination, patients were instructed to urinate as many times as possible to reduce the possible influence of the residual radiotracer in the renal pelvis and calyces on the image quality. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were reconstructed iteratively.
62067876|NCT03748238|EXPERIMENTAL|Injury group|Endometrial injury with hysteroscopy
62067877|NCT03748238|NO_INTERVENTION|Control group|No hysteroscopy
62067878|NCT06249490|EXPERIMENTAL|The experimental group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.
62067879|NCT06249490|ACTIVE_COMPARATOR|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.
62453607|NCT04240938|OTHER|Lacrimal sac mucocele|Adult patients with lacrimal sac mucocele
62453608|NCT01180244|ACTIVE_COMPARATOR|Active treatment|Subjects in this group will receive the noninvasive cortical stimulation signal from the treatment device
62635884|NCT02513004|EXPERIMENTAL|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
62652921|NCT02902926|EXPERIMENTAL|Low FODMAPs Diet|"1. Instructed to low FODMAPs diet when patients signed the informed consent.~2. Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food."
62067880|NCT03084497|EXPERIMENTAL|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
62067881|NCT03084497|NO_INTERVENTION|Group without intervention|The subjects of this group won´t receive any intervention.
62067882|NCT03942380|OTHER|Cell-free tumor DNA|The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.
62067883|NCT03942380|OTHER|Identifying recurrence|The aim is to identify recurrence through serial monitoring patients with blood samples.
62453609|NCT01180244|PLACEBO_COMPARATOR|Placebo group|Subjects in this group will be provided the same experience as those in the active treatment arm, but will not receive the noninvasive cortical stimulation signal from the treatment device
62453610|NCT02578550|EXPERIMENTAL|Treatment Sequence (AB)|Participant will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination \[FDC\]) (Treatment A) in period 1, then 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 2
62067884|NCT00774449||1|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion
62088264|NCT03428061||Control group|Usual care will be based on the Dutch CVRM guideline, describing how to calculate the CVR and advices to lower this risk by lifestyle intervention and/or medication. However systematic identification of patients eligible for CVRM, actively inviting patients for a visit, regular follow-up and standardized collaboration with other disciplines in the health care chain are not necessarily part of usual care.
61978704|NCT00138476|EXPERIMENTAL|Group 1: 4800 RT-PCR units or Placebo|Group 1: dosage group of 11 subjects will receive 4800 reverse transcription polymerase chain reaction (RT-PCR) units of Lot 42399 Norwalk Virus (NV) or placebo control (9 subjects will receive NV and 2 subjects will receive placebo control).
62272674|NCT03700307|EXPERIMENTAL|pulmonary vein and left atrial roof linear isol|patients will receive circumferential pulmonary vein and left atrial roof linear isolation using cryoballoon ablation
62272675|NCT06255457||Arrhythmogenic mitral valve prolapse versus non-arrhythmogenic mitral valve prolapse|Surgical repair or replacement of the mitral valve due to significant mitral regurgitation according to standard of care.
62635885|NCT02513004|ACTIVE_COMPARATOR|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
62272676|NCT03628014|OTHER|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
62272677|NCT02188030|ACTIVE_COMPARATOR|Group Exercise Training (GET).|Group Exercise Program. The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum 12. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
62067885|NCT02970032|ACTIVE_COMPARATOR|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
62272678|NCT02188030|ACTIVE_COMPARATOR|Individual Exercise Training|Individual Exercise Program. The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al. and Sundstrup et al . During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
62272679|NCT04709783|EXPERIMENTAL|Implementation Arm|Participants will receive the 3-Step Workout for Life program and other rehabilitation services based on the plan of care.
62272680|NCT03375190|EXPERIMENTAL|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
62272681|NCT03375190|EXPERIMENTAL|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM, Devon, UK) at insertion site
62272682|NCT03375190|EXPERIMENTAL|Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
62272683|NCT03375190|EXPERIMENTAL|Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
62272684|NCT03375190|EXPERIMENTAL|Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
62272685|NCT03375190|EXPERIMENTAL|Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
62272686|NCT00985205|EXPERIMENTAL|Enteral Glutamine|0.5 g/kg/day mixed in water and given via nasogastric or feeding tube as boluses q 4 hrs or TID or QID if po
62272687|NCT00985205|PLACEBO_COMPARATOR|Placebo|Mixed in with water and given via nasogastric or feeding tube as boluses q 4hrs or TID or QID if po
62272688|NCT01961700|EXPERIMENTAL|Physiotherapy|Physiotherapy (breathing exercises, mobilisation, exercises for upper limbs, advice on physical activity and exercise) provided daily during hospitalization.
62272689|NCT01961700|NO_INTERVENTION|Control group|No physiotherapy.
62272690|NCT02500628|EXPERIMENTAL|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
62272691|NCT02500628|EXPERIMENTAL|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
62272692|NCT05240755|NO_INTERVENTION|Standard of Care|Opioid standard of care: Tramadol 50 mg PO PRN #30, Hydrocodone/Acetaminophen 5/325 PO PRN #30
62272693|NCT05240755|EXPERIMENTAL|Cannabidiol Oil 100 mg|CBD 100 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
62272694|NCT05240755|EXPERIMENTAL|Cannabidiol Oil 200 mg|CBD 200 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
62272695|NCT03270865|EXPERIMENTAL|Usability and Ergonomic Evaluation of Self-Positioning System|
62272696|NCT03773042|EXPERIMENTAL|HSK3486|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg
62272697|NCT03773042|ACTIVE_COMPARATOR|Propofol|1.0mg/kg, 2.0mg/kg
62272698|NCT03250403|EXPERIMENTAL|PRP injection|
62272699|NCT03250403|ACTIVE_COMPARATOR|medical treatment|
62272700|NCT05396742|EXPERIMENTAL|Cohort 1|Participants received a single dose of ravulizumab SC 400 (milligrams) mg .
62272701|NCT05396742|EXPERIMENTAL|Cohort 2|Participants received a single dose of ravulizumab SC 500 mg/rHuPH20 10000 units.
62635886|NCT05983796|EXPERIMENTAL|18F-HER2 PET|
62272702|NCT05396742|EXPERIMENTAL|Cohort 3|Participants received a single dose of ravulizumab SC 1000 mg/rHuPH20 20000 units.
62635887|NCT04001010|EXPERIMENTAL|inhaled THC/CBD (PPP011)|PPP011 (synthetic THC/CBD) inhalation with mighty medic device
62635888|NCT04001010|PLACEBO_COMPARATOR|Placebo|Placebo inhalation with mighty medic device
62067886|NCT02970032|EXPERIMENTAL|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
62453611|NCT02578550|EXPERIMENTAL|Treatment Sequence (BA)|Participant will receive 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 1, then a single oral tablet of D/C/F/TAF (800/150/200/10 mg) FDC (Treatment A) in period 2
62272703|NCT05396742|EXPERIMENTAL|Cohort 4|Participants received a single dose of ravulizumab SC 2000 mg/rHuPH20 40000 units.
62272704|NCT05396742|EXPERIMENTAL|Cohort 5|Participants received a single dose of ravulizumab intravenously (IV) 400 mg.
62272705|NCT02849132|EXPERIMENTAL|Treatment group|entecavir oral，0.5mg daily for 8 years
62272706|NCT02952222|ACTIVE_COMPARATOR|Propofol (Group P)|Propofol only
62453612|NCT05639634|EXPERIMENTAL|Chlorella Supplementation and Exercise|Supplementation with Chlorella (1.5 g/d) with a physical exercise program for 12 weeks
62453613|NCT05639634|EXPERIMENTAL|Chlorella Supplementation|Supplementation with Chlorella (1.5 g/d) only for 12 weeks. No exercise programme
62635889|NCT05459909|EXPERIMENTAL|Synbiotic supplementation|Synbiotic supplementation
62067887|NCT05307328|EXPERIMENTAL|SPI-62|Active drug by mouth each morning for up to 12 weeks
62067888|NCT05307328|PLACEBO_COMPARATOR|Placebo|Placebo by mouth each morning for up to 12 weeks
62635890|NCT05459909|EXPERIMENTAL|Dietary intervention|Dietary intervention
62067889|NCT02989272|PLACEBO_COMPARATOR|saline group|Control group (30 patients), who will receive Treatment by venous infusion of saline solution
62272707|NCT02952222|ACTIVE_COMPARATOR|Propofol with Dexmedetomidine (Group DP)|Propofol with Dexmedetomidine
62272708|NCT03099928||Qualitative Interviews|
62272709|NCT02070614||rs2242480 wild-type homozygote|\*1/\*1 Grouped by rs2242480 polymorphism genotyping
62272710|NCT02070614||rs2242480 mutant heterozygote|\*1/\*1G Grouped by rs2242480 polymorphism genotyping
62272711|NCT02070614||rs2242480 mutant homozygote|\*1G/\*1G Grouped by rs2242480 polymorphism genotyping
62272712|NCT04603573|EXPERIMENTAL|(intervention)|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
62272713|NCT04603573|ACTIVE_COMPARATOR|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
62272714|NCT01958801|ACTIVE_COMPARATOR|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
62453614|NCT05639634|PLACEBO_COMPARATOR|Placebo Supplementation and Exercise|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) with a physical exercise program for 12 weeks
62453615|NCT05639634|PLACEBO_COMPARATOR|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) only for 12 weeks. No exercise programme
62453616|NCT01088126|ACTIVE_COMPARATOR|Focal ablation|PV isolation + CFAE-targeted focal ablation
62453617|NCT01088126|ACTIVE_COMPARATOR|Linear ablation|PV isolation + CFAE-guided linear ablation
62453618|NCT03361371|EXPERIMENTAL|Interventional group|"Intervention Group: in addition to receiving the aforementioned bronchiolitis discharge instructions, this group will undergo nasal suctioning prior to each feeding as needed for 72 hours post discharge home, using exclusively the Zo-Li study device (see above under study device), with saline nose drops. Families in this group will be given the Zo-Li device at no cost and instructed in the appropriate technique and importance of using this tool.~We shall not reveal the identity of the study devices to the ED physicians in order to minimize contamination of the control group. The ED treating physicians will also be blinded to which device the infant had been randomized to. We shall also ask the ED treating physicians not to recommend specific suctioning devices to the study patients."
62635891|NCT05459909|EXPERIMENTAL|Synbiotic supplementation & dietary intervention|Synbiotic supplementation \& dietary intervention
62635892|NCT05225025|EXPERIMENTAL|ROSE Intervention|
62635893|NCT05225025|ACTIVE_COMPARATOR|Standard of Care|
62635894|NCT00922116|EXPERIMENTAL|1|
62067890|NCT02989272|EXPERIMENTAL|Sulfate group|magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg
62272715|NCT01958801|EXPERIMENTAL|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
62272716|NCT02469766|ACTIVE_COMPARATOR|Extracorporeal Shockwaves|Patients in this arm will undergo SWL
62272717|NCT02469766|ACTIVE_COMPARATOR|Semirigid URS|Patients in this arm will undergo Semirigid Ureteroscopy
62635895|NCT04630223||intrauterine growth retardation|Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
62635896|NCT04630223||healthy fetuses|Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
62635897|NCT00616746|EXPERIMENTAL|1|Three test days, within-subject design.
62635898|NCT05724342||rhTNK-tPA Thrombolysis|
62067891|NCT06076356|ACTIVE_COMPARATOR|Group A|Foam Rolling Group
62067892|NCT06076356|ACTIVE_COMPARATOR|Group B|Kinesio Taping Group
62067893|NCT00610701|EXPERIMENTAL|Anterior pin placement|Anterior pin placement
62272718|NCT02469766|ACTIVE_COMPARATOR|Flexible URS|Patients in this arm will undergo Flexible Ureteroscopy
62461519|NCT04320173|EXPERIMENTAL|Lidocaine Patch (Sequence ABC)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied in Period 1, and 3 lidocaine 5% patches were applied in Period 2, and 3 lidocaine 5% medicated plasters were applied in Period 3.
62635899|NCT05411393|EXPERIMENTAL|Experimental arm|Research participants in this arm will receive the ADL-enhanced program and usual home health care rehabilitation. The ADL-enhanced program consists of six home visits delivered by a study occupational therapist.
62635900|NCT05411393|OTHER|Control arm|Research participants in this arm will receive usual home health care rehabilitation.
62635901|NCT01625871|EXPERIMENTAL|artemether-lumefantrine|tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
62067894|NCT00610701|EXPERIMENTAL|Lateral pin placement|Lateral pin placement
62067895|NCT00613288|EXPERIMENTAL|A|
62067896|NCT04482829|EXPERIMENTAL|Experimental Group|On the basis of PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with one dose daily.
62272719|NCT03961087|ACTIVE_COMPARATOR|case group|patients with liver cirrhosis and frequent hepatic encephalopathy received coenzyme Q10 and Meclofenoxate in addition to usual hepatic support
62272720|NCT03961087|NO_INTERVENTION|control group|patients with liver cirrhosis and frequent hepatic encephalopathy received usual hepatic support only
62635902|NCT02415192||Patients treated with Levacalm|"In this group, the patients will be enrolled treated with Levacalm tab. as an anti-hypertensive drug.~The number of this group will be double than the control group to get more information about safety and efficacy."
62067897|NCT04482829|OTHER|Control Group|All the patients in control group will receive PC chemotherapy and symptomatic treatment without other treatment.
62067898|NCT06167551|EXPERIMENTAL|mother lullaby group|group listening to mother's lullaby
62067899|NCT06167551|EXPERIMENTAL|white noise group|group listening to white noise
62067900|NCT06167551|EXPERIMENTAL|classical music group|group listening to classical music
62272721|NCT05578742|EXPERIMENTAL|Strategy A: PEEP 15 cmH2O → PEEP 5 cmH2O|
62067901|NCT06167551|OTHER|Control group|No intervation
62067902|NCT02168543|EXPERIMENTAL|Alendronate|1% Alendronate gel once in periodontal pocket (Gums)
62067903|NCT02168543|PLACEBO_COMPARATOR|Placebo|Placebo gel once in periodontal pocket (Gums)
62067904|NCT02400437|EXPERIMENTAL|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity~* Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.~* Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase~* Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase~* Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
62067905|NCT03266185|EXPERIMENTAL|45-minutes|45-minutes post-infusion cooling time
62067906|NCT03266185|EXPERIMENTAL|20-minutes|20-minutes post-infusion cooling time
62272722|NCT05578742|ACTIVE_COMPARATOR|Strategy B: PEEP 5 cmH2O → PEEP 15 cmH2O|
62272723|NCT06185673|EXPERIMENTAL|BB-301 Treatment|"The phase 1b component of the study is the dose escalation phase which will enroll up to 18 subjects in up to 3 dosing cohorts.~The phase 2a component of the study is the dose expansion phase which will enroll up to 12 subjects."
62272724|NCT00891605|EXPERIMENTAL|Paclitaxel and ABT-263|
62272725|NCT04652271||Patients undergoing pancreatic surgery|Patients undergoing any type of pancreatic surgery.
62272726|NCT01861405||Cerebral metastases subjects|Prior to each subject's radiation treatment (either whole brain radiation therapy or stereotactic radiosurgery), he/she will have fMRI scanning and neuropsychological testing and conduct a quality of life assessment. Each subject will then have standard of care WBRT or SRS treatment. Following WBRT or SRS treatment, subjects will have 4 month follow up fMRI scanning, and have neuropsychological testing and a quality of life assessment 4 months and 12 months post treatment.
62272727|NCT01861405||Healthy participants|Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
62272728|NCT00399165|ACTIVE_COMPARATOR|1|Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
62635903|NCT02415192||Patients treated with Valsartan/amlodipine|In this group, the patients will be enrolled treated with Valsartan/amlodipine combination drug as an anti-hypertensive drug.
62067907|NCT03266185|NO_INTERVENTION|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
62272729|NCT00399165|ACTIVE_COMPARATOR|2|Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
62067908|NCT05958329|EXPERIMENTAL|HRV Biofeedback|5 minute daily sessions of HRV biofeedback
62067909|NCT03857412|SHAM_COMPARATOR|Non capsular polishing|No capsular polishing taking place during cataract surgery
62067910|NCT03857412|ACTIVE_COMPARATOR|Capsular polishing|Capsular polishing taking place during cataract surgery
62067911|NCT00818103|EXPERIMENTAL|Atorvastatin, β-interferon, EPO|
62272730|NCT02026609||TIPS|Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
62272731|NCT02468791|EXPERIMENTAL|MabionCD20®|A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
62272732|NCT02468791|ACTIVE_COMPARATOR|MabThera®|A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
62272733|NCT01453855|EXPERIMENTAL|Travoprost 0.003%|Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
62272734|NCT01453855|ACTIVE_COMPARATOR|TRAVATAN|Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
62272735|NCT03110900|ACTIVE_COMPARATOR|haloperidol + lorazepam|IM haloperidol 5mg + IM lorazepam 2mg + placebo inhaler
62272736|NCT03110900|EXPERIMENTAL|loxapine|Inhaled loxapine 10mg + IM normal saline
62272737|NCT00793481||Diagnostic tool|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
62272738|NCT02537171|ACTIVE_COMPARATOR|Apatinib 750mg group|Apatinib mesylate tablets(ATAN) is taken 750mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.The dose of the study drug may be modified following the occurence of a clinically significant adverse event(AE).
62272739|NCT02537171|ACTIVE_COMPARATOR|Apatinib 500mg group|Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.
62272740|NCT01459250|EXPERIMENTAL|AGO178C|
62635904|NCT06136468|EXPERIMENTAL|Experimental|"Exercise program using the virtual coach projected through head-mounted display"
62635905|NCT06136468|NO_INTERVENTION|No Intervention|Usual exercise program
62067912|NCT02641249|NO_INTERVENTION|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
62067913|NCT02641249|EXPERIMENTAL|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
62067914|NCT03615521|EXPERIMENTAL|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
62067915|NCT03615521|EXPERIMENTAL|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.~3 Session for 6 weeks."
62067916|NCT03615521|EXPERIMENTAL|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.~3 session for 6 weeks."
62067917|NCT02120664|EXPERIMENTAL|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie \[mCi\]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
62088265|NCT01316692|EXPERIMENTAL|MLN8237|Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62088266|NCT01079455|ACTIVE_COMPARATOR|HA|Coxarthrosis
62272741|NCT01493336|EXPERIMENTAL|Capecitabine RTD|
62272742|NCT01493336|ACTIVE_COMPARATOR|Xeloda|
62272743|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
62272744|NCT05393466|EXPERIMENTAL|Phase Ia Dose Escalation|The number of patients enrolled will be determined based on the maximum number required to establish the RP2D according to a Bayesian Optimal Interval (BOIN) method and will depend on the true DLT rate. Up to 24 patients will be enrolled for the dose-finding part.
62272745|NCT05393466|EXPERIMENTAL|Phase Ib Expansion Study|Based on clinical data obtained from Part 1a, up to 24 patients with advanced NSCLC harboring EGFR C797S mutation will be enrolled in this dose expansion part of the study. One or more dose levels may be investigated dependent on emerging data. The sample size will be determined based on practical considerations.
62635906|NCT06239610|OTHER|feeding tube migration|Use of an EMPD to assess for FT migration in all eligible critical care patients requiring the use of a feeding tube during admission.
62067918|NCT02120664|EXPERIMENTAL|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
62067919|NCT06128174|EXPERIMENTAL|Patients with longstanding persistent atrial fibrillation (AF)|All subjects will undergo Pulmonary vein isolation (PVI) and Posterior wall isolation (PWI) with the Farapulse catheter.
62635907|NCT03905837|EXPERIMENTAL|Lidocaine IV|Group 1: intravenous lidocaine and paravertebral saline (SF). In this group during intraoperative anesthetic maintenance, a continuous intravenous infusion of lidocaine at 1.5mg/kg/h until the end of surgery and perfusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1ml/kg/h will be administered.
62635908|NCT03905837|EXPERIMENTAL|Lidocaine PV|Group 2: intravenous SF and paravertebral lidocaine. During anesthesia maintenance, a continuous intravenous infusion of 0.9% SF and an infusion of 2% lidocaine will be administered through the intraoperative paravertebral catheter at a rate of 0.1 ml/kg/h.
62635909|NCT03905837|ACTIVE_COMPARATOR|no lidocaine|Group 3: intravenous remifentanil and paravertebral SF. During the maintenance of anesthesia, a continuous intravenous infusion of remifentanil at a rate of 0.1 mg/kg/min until the end of surgery and an infusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1 ml / kg / h.
62635910|NCT02479074|ACTIVE_COMPARATOR|Montelukast (high FeNO)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
62635911|NCT02479074|ACTIVE_COMPARATOR|Prednisolone, Montelukast (high FeNO)|Prednisolone 5 mg and montelukast 10 mg. Patients to take Prednisolone 5 mg, 4 tablets per day for 14 days patients to take Montelukast 10 mg film-coated tablet per day for another 14 days Prednisolone is a Class A medicine Montelukast is a Class B medicine
62635912|NCT02479074|ACTIVE_COMPARATOR|Montelukast|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
62635913|NCT03296969|ACTIVE_COMPARATOR|rectus muscle approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
62652922|NCT02902926|PLACEBO_COMPARATOR|Diet Instruction|1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
62652923|NCT03555799||Labor analgesia patients|Patients with clinical indication of labor epidural will have IVC diameter measurement with ultrasound before and after the epidural placement
62067920|NCT04746651|EXPERIMENTAL|Guided Self Help|"Four guided self-help booklets were used; Why do I feel so bad? covered formulation/understanding feelings, I can't be bothered doing anything centred on activity scheduling, Why does everything always go wrong? focused on thought-challenging, and How to fix almost everything incorporated problem solving. Linked worksheets were adapted following feedback from Prison Officers."
62652924|NCT03527264|EXPERIMENTAL|Cohort 1A|Nivolumab during Chemo/RT with whole pelvic RT
62652925|NCT03527264|EXPERIMENTAL|Cohort 1B|Nivolumab during Chemo/RT with extended field
62067921|NCT02778399|EXPERIMENTAL|OBE2109 50 mg|
62067922|NCT02778399|EXPERIMENTAL|OBE2109 75mg fixed dose (FD)|
62272746|NCT05393466|EXPERIMENTAL|Phase II Study|The phase II part will be conducted using a Bayesian Optimal Phase 2 (BOP2) method with efficacy monitoring based on cumulative information on Objective Response Rate (ORR). The BOP2 method will consist of 2 interim looks occurring when the number of evaluable patients reaches the pre-specified values of 10 and 20 and a final analysis when a total of 30 patients are evaluable.
62272747|NCT01317433|EXPERIMENTAL|Arm A|Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
62272748|NCT01317433|ACTIVE_COMPARATOR|Arm B|Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.
62272749|NCT01054742||Standard of Care PegIntron Plus Ribavirin [Part 2]|Participants who had relapsed during Part 1 of the study, had detectable HCV-RNA on Day 1 of Part 2 of the study, and who were re-treated during Part 2 of the study with standard of care PegIntron plus ribavirin for 48 weeks.
62453619|NCT03361371|PLACEBO_COMPARATOR|Control group|Control Group: this group will receive standardized routine discharge instructions describing information about bronchiolitis, expected course of illness, recommended management strategies such as fever control, augmented air humidification, need for frequent feeding and warning signs prompting return for care. This group will be suctioned prior to feeds via bulb suction (with saline drops) which is expected to provide minimal effect, due to non-sustained negative pressures generated during bulb release. Since the benefit of nasal suction in bronchiolitis is unknown, this design is ethically reasonable. However, the use of no suction would likely meet with parental resistance and enrollment would be difficult. Families in the control group will be given the bulb device at no cost and instructed in the appropriate technique of using this tool prior to feeds.
62287053|NCT03280251|EXPERIMENTAL|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
61978705|NCT00138476|EXPERIMENTAL|Validation Group: 4.8 and 0.48 RT-PCR units|Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
62067923|NCT02778399|EXPERIMENTAL|OBE2109 75mg titrated dose (TD)|
62067924|NCT02778399|EXPERIMENTAL|OBE2109 100mg|
62453620|NCT00143819|ACTIVE_COMPARATOR|1|bilateral comparison
62067925|NCT02778399|EXPERIMENTAL|OBE2109 200 mg|
62272750|NCT02630758|EXPERIMENTAL|Mindfulness-based Yoga|"Participants in the 12-week mindfulness-based yoga condition were guided by a gentle yoga DVD that included postures (asanas), pranayama (breathing exercises), and relaxation (meditation). Participants were asked to complete 60-75 minutes of the DVD twice per week and were encouraged to do more if they were interested.~Following the initial baseline assessment and randomization telephone interview, participants in the yoga group completed weekly 15-minute telephone sessions for the first month and bi-weekly telephone sessions for the second and third for a total of eight sessions over the 12 weeks. The mindfulness telephone sessions were modified from the Mindfulness-Based Stress Reduction."
62067926|NCT02778399|PLACEBO_COMPARATOR|Placebo / OBE2109 100mg|Participants received placebo for the first 12 weeks and were then crossed-over to active treatment with OBE2109 100mg for a further 12 weeks.
62067927|NCT02185885|EXPERIMENTAL|Increased bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted according to department guidelines with the modification that MAP is kept between 70 and 80 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
62635914|NCT03296969|ACTIVE_COMPARATOR|rectus muscle non approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
62635915|NCT02267915|EXPERIMENTAL|subcutaneous rituximab|MabThera 1400 mg solution for subcutaneous injection
62067928|NCT02185885|NO_INTERVENTION|Regular bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted in accordance with departmental guidelines, where MAP is sought to be ≥ 45 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
62272751|NCT02630758|ACTIVE_COMPARATOR|Walking Control Group|"The 12-week walking control condition included twice-weekly home practice with a 65-minute walking DVD (Sansone, 2008) and eight telephone sessions with the telephone counselor.~Participants were asked to complete 60 minutes of the DVD (or other walking) twice weekly and encouraged to do more if they were interested.~Participants received telephone sessions on the same schedule as the yoga condition. The education sessions covered a variety of health and wellness related topics."
62272752|NCT04529759|ACTIVE_COMPARATOR|Control Infant Formula|Feed ad libitum
62272753|NCT04529759|EXPERIMENTAL|Experimental Infant Formula|Feed ad libitum
62635916|NCT00248651|ACTIVE_COMPARATOR|Amitriptyline|Amitriptyline capsule (50 mg) plus a placebo escitalopram tablet will be taken at night half an hour before bedtime. To maximize patient tolerability, in the first 2 weeks the dose of amitriptyline will be 25 mg and then the dose will be increased to 50 mg, but the 25 mg and 50 mg capsules will be indistinguishable to maintain blinding.
62272754|NCT03022773|OTHER|Carotenoid measurements|Subjects are asked to have carotenoid levels measured in the eye, skin and/or blood.
62635917|NCT00248651|ACTIVE_COMPARATOR|Escitalopram|Escitalopram tablet (10 mg) plus a placebo amitriptyline capsule will be taken by mouth at night half an hour before bedtime for 12 weeks.
62652926|NCT03527264|EXPERIMENTAL|Cohort 2|Chemoradiation followed by Nivolumab Maintenance
62635918|NCT00248651|PLACEBO_COMPARATOR|Placebo|Placebo escitalopram tablets and placebo amitriptyline capsules will be taken by mouth half an hour before bedtime for 12 weeks.
62635919|NCT02435303|EXPERIMENTAL|Sildenafil|Sildenafil 20mg tid for six months (\* consider open-label extension study for 1 year)
62453621|NCT00143819|PLACEBO_COMPARATOR|2|bilateral comparison
62453622|NCT00859664||Neuroleptics|Children with autistic spectrum disorder, treated with neuroleptics
62453623|NCT01578083||Cognitive Impairment|With self-report cognitive impairment.
62453624|NCT01578083||No Cognitive Impairment|Without self-report cognitive impairment.
62453625|NCT04635423|EXPERIMENTAL|V503|Participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
62453626|NCT04635423|PLACEBO_COMPARATOR|Placebo|Participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.
62453627|NCT00699257||Oxford® Partial Knee System|
62453628|NCT02737215|ACTIVE_COMPARATOR|CPAP group|patients will receive CPAP therapy for the first 7 days after extubation from CABG
62067929|NCT06250647|EXPERIMENTAL|VK INTERVENTION|administration of a menu diet containing 500mcg of vitamin K (in the food selected) durinf 6 weeks.
62067930|NCT06250647|NO_INTERVENTION|DIETARY RECOMMENDATIONS|No menu administration but only recommendations for correct diet.
62067931|NCT04337086|EXPERIMENTAL|T4k|
62067932|NCT04337086|ACTIVE_COMPARATOR|Twin block|
62453629|NCT02737215|NO_INTERVENTION|Control Group|Patients will receive usal care
62453630|NCT04567342|EXPERIMENTAL|Arm 1|
62088267|NCT01079455|ACTIVE_COMPARATOR|Corticosterone|Coxarthrosis
62453631|NCT04567342|EXPERIMENTAL|Arm 2|
62453632|NCT04567342|EXPERIMENTAL|Arm 3|
62453633|NCT04567342|EXPERIMENTAL|Arm 4|
62453634|NCT05585658|ACTIVE_COMPARATOR|Erythropoietin alpha Eprex®|Group/cohort/Arm 1 (participating 21 volunteers): Eprex® injection 4,000 IU will be administered subcutaneously on Day 1; and wash out for 4 weeks. GBPD002 injection 4,000 IU/1 mL will be administered subcutaneously on Day 29.
62453635|NCT05585658|EXPERIMENTAL|Erythropoietin alpha, GBPD002|"Group/cohort/Arm 2 (participating 21 volunteers):GBPD002 PFS (Pre-Filled Syringe) 4,000 IU/ 1 mL (Erythropoietin alfa 4,000 IU) will be administered subcutaneously on Day 1.And wash out for 4 weeks (28 days from the 1st injection day). Eprex® inj. (Injection) 4,000 IU (Erythropoietin alfa 4,000 IU) will be administered subcutaneously on Day 29.~Total 42 volunteers participated in the clinical trial."
62453636|NCT01540032|NO_INTERVENTION|Control|
62453637|NCT01540032|EXPERIMENTAL|Diet|
62453638|NCT03444038|EXPERIMENTAL|Valbenazine|Valbenazine administered once daily for up to 24 weeks
62453639|NCT01790165|EXPERIMENTAL|TDT067|Active treatment
62453640|NCT01790165|PLACEBO_COMPARATOR|Placebo|Placebo
62453641|NCT05275400|EXPERIMENTAL|Insulin Efsitora Alfa|Participants will be given insulin efsitora alfa subcutaneously (SC).
62453642|NCT05275400|ACTIVE_COMPARATOR|Insulin Degludec|Participants with be given insulin degludec SC.
62635920|NCT02435303|PLACEBO_COMPARATOR|Placebo|Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
62635921|NCT01151345|EXPERIMENTAL|diltiazem|
62652927|NCT03527264|EXPERIMENTAL|Cohort 3|Nivolumab during chemoradiation and then as maintenance
62652928|NCT03752892|EXPERIMENTAL|intervention -1-leg cycle training|Primary aerobic training component one-legged, partitioned, cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
62067933|NCT01381874|EXPERIMENTAL|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
62067934|NCT01381874|EXPERIMENTAL|Abiraterone acetate + Prednisone/Prednisolone + Exemestane|Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
62453643|NCT05666349|EXPERIMENTAL|Niraparib and re-irradiation (re-RT)|"Patients will be treated with IMRT-based re-RT for a total dose of 35 Gy in 10 daily fractions over approx. 2 weeks. Patients will take niraparib daily from the first day of re-RT until documented progression or discontinuation due to unacceptable treatment-related toxicity or any other cause (whichever occurs sooner).~Patients will be recruited in cohorts of 3. Following the completion of each dosing cohort and once the patients have completed the dose limiting toxicity (DLT) assessment window, the independent data monitoring committee (IDMC) will review the data for each patient. In conjunction with the statistical recommendations from the continual reassessment method (CRM), the IDMC will advise whether the dose for the next cohort should be escalated, de-escalated or stay at the current niraparib dose."
62067935|NCT01381874|EXPERIMENTAL|Exemestane|Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
62067936|NCT02826525|EXPERIMENTAL|Treatment|Subjects in this arm will receive AZD4076
62067937|NCT02826525|PLACEBO_COMPARATOR|Control|Subjects in this arm will receive placebo
61978706|NCT01040897|ACTIVE_COMPARATOR|Active Control Arm|At Active Comparative Sites, Pediatric Residents will be trained to address injury prevention issues using The Injury Prevention Program (TIPP) approach
62453644|NCT05817799|EXPERIMENTAL|intervention|"L-Carnitine 500mg thrice daily~1g L-Carnitine IV three times a week"
62453645|NCT05817799|NO_INTERVENTION|control|no intervention given
62088268|NCT01079455|PLACEBO_COMPARATOR|Bupivacaine|Coxarthrosis
62453646|NCT02285140|EXPERIMENTAL|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
62088269|NCT00590980||Observation|Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.
62453647|NCT02285140|EXPERIMENTAL|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
62088270|NCT03564275|EXPERIMENTAL|Prospective Treatment Group|Proton Boost
62067938|NCT02756832||Alogliptin Benzoate|Participants with diabetes mellitus type 2 (T2DM) who received alogliptin benzoate tablets, orally, as prescribed by physician according to Russian summary of product characteristics (SmPC) were observed for approximately 6 months.
62067939|NCT04172493|EXPERIMENTAL|Diagnostic|Patients undergo standard of care white light endoscopy (WLE) and hyperspectral endoscopy (HySE) during routine colonoscopy procedure.
62067940|NCT05477706|EXPERIMENTAL|Personalized Support for Progress (PSP)|PSP includes an initial 60-minute video or phone appointment and then follow-up tailored to the Veteran's preferences. The Peer Specialist guides the Veteran through a card-sorting task to prioritize concerns and then create a personalized care plan. The Peer then provides up to six months of outreach and support to implement the care plan. At the end of the six months, the Veteran and peer review the plan, determine next steps and consider other supports and resources to sustain progress made.
62453648|NCT02285140|EXPERIMENTAL|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
62453649|NCT02285140|EXPERIMENTAL|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
62652929|NCT03752892|ACTIVE_COMPARATOR|usual care - 2-leg cycle training|Primary aerobic training component conventional two-legged cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
62652930|NCT05793658|ACTIVE_COMPARATOR|Sedation with standard capnography|37 patient Sedation using midazolam + propofol for colonoscopy
62067941|NCT05477706|ACTIVE_COMPARATOR|Tailored Referral (TR)|The Tailored Referral (TR) comparator will be comprised of written or emailed information describing resources and contact information for VHA and local social and mental health resources. Examples include information about the appropriate office/person to reach within the local VA or area, help scheduling an appointment, or information for a same-day Primary Care - Mental Health Integration (PCMHI) assessment.
62067942|NCT02348853|EXPERIMENTAL|Healthy Weight For Living (HWL)|HWL is a behavioral intervention designed to effectively facilitate hunger suppression with several concurrent approaches. Hunger suppression is a core behavioral goal of the intervention, and strategies will be used to support that goal, for example increasing meal frequency and encouraging the use of highly satiating low-energy foods to reduce hunger acutely. A unique combination of healthy dietary goals will be recommended that support hunger suppression and/or maintenance of satiety: high total dietary fiber, moderately high protein, moderately low glycemic load (GL) and low energy density.
62067943|NCT02348853|EXPERIMENTAL|Current Best Practice (CBP)|This intervention is an adapted version of Group Lifestyle Balance which is a validated weight loss program for community groups and military populations that is an official adaptation of the gold standard Diabetes Prevention Program Lifestyle Balance intensive research intervention. It has both training programs for interventionists and program material available on the web and is also slightly modified from the Diabetes Prevention Program study to take into account changing national nutrition recommendations.
62067944|NCT02401308|ACTIVE_COMPARATOR|Awake DBS Surgery|"Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation"
62067945|NCT02401308|ACTIVE_COMPARATOR|Asleep DBS Surgery|Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.
62652931|NCT05793658|ACTIVE_COMPARATOR|Sedation with modified capnography|37 patients in Sedation using midazolam + fentanyl + propofol for colonoscopy
62652932|NCT02253264|EXPERIMENTAL|Intrathecal rituximab|25 mg of rituximab will be administered intrathecally by direct infusion over 10 minutes at two time points, two weeks apart.
62635922|NCT02718911|EXPERIMENTAL|LY3022855 + Durvalumab (Dose Escalation)|"Cohort D1A: LY3022855 (25 mg,QW)+Durvalumab (750mg,Q2W):~25 mg LY3022855 administered once weekly (QW) intravenously (IV) in combination with 750 mg durvalumab administered every 2 weeks (Q2W) IV. Treatment may continue until disease progression or discontinuation.~Cohort D2A: LY3022855 (50 mg,QW)+Durvalumab (750mg,Q2W) 50 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation.~Cohort D3A: LY3022855 (75 mg,QW)+Durvalumab (750mg,Q2W) 75 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation.~Cohort D4A: LY3022855 (100 mg,QW)+Durvalumab (750mg,Q2W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation."
62635923|NCT02718911|EXPERIMENTAL|LY3022855 + Tremelimumab (Dose Escalation)|"Cohort T1A: LY3022855 (50 mg,QW) +Tremelimumab (75mg,Q4W):~50 mg LY3022855 administered QW intravenously (IV) in combination with 75 mg tremelimumab administered every 4 weeks (Q4W) IV. Treatment may continue until disease progression or discontinuation.~Cohort T2A: LY3022855 (100 mg,QW) +Tremelimumab (75mg,Q4W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 75 mg tremelimumab administered Q4W IV. Treatment may continue until disease progression or discontinuation.~Cohort T3A: LY3022855 (100 mg,QW) +Tremelimumab (225 mg,Q4W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 225 mg tremelimumab administered Q4W IV. Treatment may continue until disease progression or discontinuation.~Cohort T4A: LY3022855 (100 mg,QW) +Tremelimumab (750 mg,Q4W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg tremelimumab administered Q4W IV. Treatment may continue until disease progression or discontinuation."
62635924|NCT02718911|EXPERIMENTAL|LY3022855 + Durvalumab (Expansion)|"Cohort B-1: NSCLC LY3022855+ Durvalumab:~100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation.~Cohort B-1: OVARIAN LY3022855+ Durvalumab:~100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation."
62635925|NCT01450813|SHAM_COMPARATOR|Group 1|Saline 0.06 ml/kg
62635926|NCT01450813|ACTIVE_COMPARATOR|Group 2|Rocuronium 0.2 mg/kg
62635927|NCT01450813|ACTIVE_COMPARATOR|Group 3|Rocuronium 0.4 mg/kg
62635928|NCT01450813|ACTIVE_COMPARATOR|Group 4|Rocuronium 0.6 mg/kg
62635929|NCT03043742|EXPERIMENTAL|Phase I Open Label|"open label bone marrow derived autologous CD133+ selected stem cell application in patients receiving trans-myocardial laser revascularization to improve regional myocardial function as detailed below:~Drug: CD133+ selected stem cells Dosage: Single injection of 0.1-0.2 ml around each laser channel Frequency: 10-20 channels Duration: Trans-Myocardial Revascularization"
62635930|NCT03639857|EXPERIMENTAL|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
62635931|NCT03639857|EXPERIMENTAL|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
62635932|NCT03639857|ACTIVE_COMPARATOR|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
62635933|NCT00437476|EXPERIMENTAL|A|LPV/r + selected NRTIs for 26 weeks, followed by LPV/r monotherapy and anti HCV drugs for 48 weeks. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
62652933|NCT06393231|EXPERIMENTAL|observation group|Sunnybrook score ≥83 points
62453650|NCT00623103|EXPERIMENTAL|Rivastigmine capsule|Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
62453651|NCT00623103|EXPERIMENTAL|Rivastigmine patch|Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm\^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm\^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm\^2 patch or the highest well tolerated dose was maintained until week 76.
62453652|NCT05089123|EXPERIMENTAL|Flu-M|160 volunteers were vaccinated with the Flu-M inactivated split influenza vaccine with a preservative
62453653|NCT05089123|ACTIVE_COMPARATOR|Ultrix|160 volunteers were vaccinated with the Ultrix (Inactivated split influenza vaccine)
62453654|NCT05177627|EXPERIMENTAL|Fundamental of Care Framework implementation|Educational interventions related to introduction of FoC framework and taking charge of patients and their fundamental needs will be realized during theoretical, simulation and internship learning.
62652934|NCT06393231|ACTIVE_COMPARATOR|control group|Sunnybrook score ≥95 points
62635934|NCT00437476|ACTIVE_COMPARATOR|B|LPV/r+ selected NRTIs for 24 weeks, followed by the same HAART and anti-HCV drugs for 48 weeks. At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decision. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
62635935|NCT03747848|EXPERIMENTAL|CBT group|Subjects will participate in group treatment sessions (once a week for six weeks).
62635936|NCT02511925||ICU Cluster 1|Adult Intensive Care Unit - Royal Brompton Hospital
62272755|NCT01787357|EXPERIMENTAL|Sequence 1 (ADBC)|Each volunteer will receive Treatment A on Day 1 of Treatment Period 1, followed by Treatment D on Day 1 of Treatment Period 2, followed by Teatment B on Day 1 of Treatment Period 3, and followed by Treatment C on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
62635937|NCT02511925||ICU Cluster 2|Paediatric ICU - Royal Brompton Hospital
62453655|NCT05177627|NO_INTERVENTION|No Fundamental of Care Framework implementation|the participants of no intervention group will receive the standard training as scheduled on the curriculum
62635938|NCT02511925||ICU Cluster 3|Adult Intensive Care Unit - Harefield Hospital
62453656|NCT03015090|EXPERIMENTAL|theophylline|
61978707|NCT01040897|EXPERIMENTAL|Health Communication and Obesity Prevention|Pediatric Residents will be training in effective health communication skills and given a toolkit of literacy/numeracy sensitive educational materials to use with families with children age 2 months to18 months during each well child visit
62067946|NCT04651114|EXPERIMENTAL|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
62067947|NCT01024790|EXPERIMENTAL|Exercise group|
62067948|NCT01024790|NO_INTERVENTION|Usual care|
62067949|NCT02340702||Patient with COPD and those without COPD|The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
62067950|NCT02478021|EXPERIMENTAL|Hydrocortisone|10 mg hydrocortisone
62067951|NCT02478021|PLACEBO_COMPARATOR|Placebo|1 pill Placebo
62453657|NCT02495324|EXPERIMENTAL|Fimasartan|Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks
62453658|NCT02495324|ACTIVE_COMPARATOR|Valsartan|Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks
62453659|NCT02495324|OTHER|Olmesartan medoxomil|Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks
62453660|NCT03706196||high incidence crohn's disease area|subjects living in high incidence crohn's disease area coming in dentist for dental extraction linked to medical indication
62635939|NCT00095979|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62635940|NCT04331691|ACTIVE_COMPARATOR|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
62453661|NCT03706196||low incidence crohn's disease area|subjects living in low incidence crohn's disease area coming in dentist for dental extractionlinked to medical indication
61978708|NCT05931939|EXPERIMENTAL|Ileal Interposition|Interposition ileal surgery group Procedure/Surgery: Bariatric surgery
62067952|NCT00245856|EXPERIMENTAL|Treatment of Upper Extremity DVT|Participants received dalterparin followed by warfarin or received dalterparin monotherapy for the treatment of upper extremity DVT
62067953|NCT04613882|EXPERIMENTAL|Soft Toric Custom Made contact lenses|Subjects will be randomized to wear Soft Toric custom made contact lenses for 30 minutes in one eye with other eye patched.
62067954|NCT04613882|ACTIVE_COMPARATOR|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lens for 30 minutes in one eye with other eye patched
62287054|NCT03280251|EXPERIMENTAL|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
62453662|NCT06495814|NO_INTERVENTION|Cross sectional group of newly diagnosed obese type 2 diabetes mellitus|No intervention conducted
62453663|NCT06495814|NO_INTERVENTION|Cross section group of healthy individuals|No intervention conducted
62453664|NCT06495814|EXPERIMENTAL|Intervention group of high-risk obese impaired glucose tolerance|General lifestyle intervention+1/bag of Jinlida granules, 3 times/day, taken with hot water.
62453665|NCT06495814|NO_INTERVENTION|Observation group of high-risk obese impaired glucose tolerance|General lifestyle intervention
62453666|NCT06495814|NO_INTERVENTION|Observation group of low-risk obese impaired glucose tolerance|General lifestyle intervention
62635941|NCT04331691|EXPERIMENTAL|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
62635942|NCT06008119|EXPERIMENTAL|Experimental|Tunlamatinib plus Vemurafenib
62635943|NCT06008119|ACTIVE_COMPARATOR|Control|Investigators' choice
62652935|NCT01879267|OTHER|Exercise Training: HD subjects|Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
62453667|NCT06495814|NO_INTERVENTION|Cross sectional group and observation group of obese impaired glucose tolerance|General lifestyle intervention
62272756|NCT01787357|EXPERIMENTAL|Sequence 2 (BACD)|Each volunteer will receive Treatment B on Day 1 of Treatment Period 1, followed by Treatment A on Day 1 of Treatment Period 2, followed by Treatment C on Day 1 of Treatment Period 3, and followed by Treatment D on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
62453668|NCT01952249|EXPERIMENTAL|Demcizumab|Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
62453669|NCT01952249|EXPERIMENTAL|Taxol|demcizumab combined with weekly paclitaxel
62453670|NCT06007391|EXPERIMENTAL|nicotinamide|
62453671|NCT01712880|ACTIVE_COMPARATOR|open debridement with modular exchange|
62453672|NCT01712880|ACTIVE_COMPARATOR|one stage exchange|
62453673|NCT04471675|EXPERIMENTAL|Experimental: solid tumors|Albumin-bound docetaxel by intravenous infusion.Patients receive albumin-bound docetaxel once every three weeks (a Cycle), starting at a dose of 50mg/m2.
62453674|NCT02770950|ACTIVE_COMPARATOR|High dose group|"High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day."
62652936|NCT01879267|OTHER|Exercise Training: healthy subjects|6 months of exercise training (2 times 30 min per week)
62652937|NCT05081687|EXPERIMENTAL|Total neoadjuvant therapy (TNT)|"4 cycles of mFOLFIRINOX every 14 days:~* Oxaliplatin 85 mg/m2~* Irinotecan 150mg/m2~* 5-FU 2.400mg/m2~* Dexamethasone 12mg~* Atropine 0.5mg~* Netupitant/palonosetron"
62272757|NCT01787357|EXPERIMENTAL|Sequence 3 (CBDA)|Each volunteer will receive Treatment C on Day 1 of Treatment Period 1, followed by Treatment B on Day 1 of Treatment Period 2, followed by Treatment D on Day 1 of Treatment Period 3, and followed by Treatment A on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
62067955|NCT04613882|ACTIVE_COMPARATOR|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
62287055|NCT01222650|EXPERIMENTAL|KSO-0400 Low Dose|
62287056|NCT01222650|EXPERIMENTAL|KSO-0400 High Dose|
62453675|NCT02770950|ACTIVE_COMPARATOR|Low dose group|"Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day."
62287057|NCT01222650|EXPERIMENTAL|Silodosin|
62287058|NCT01222650|PLACEBO_COMPARATOR|Placebo|
62453676|NCT02770950|ACTIVE_COMPARATOR|Controlled group|Indometacin Cataplasms will be used topically on the knee for 24h per day
62453677|NCT02623088||PAP therapies|Patients with sleep apnea syndrome treated by CPAP after respiratory and vascular assessment and followed 5-7 years, as part of a clinical research.
62453678|NCT05296915|EXPERIMENTAL|tVNS + CBT-E group|N=10 Interventional group with transcutaneous stimulation of the auricular branch of the vagus nerve associated with targeted cognitive-behavioral therapy (following the CBT-E protocol, CG Fairburn - 2010.
62453679|NCT05296915|EXPERIMENTAL|rTMS + CBT-E group|N=10 Interventional group with repetitive transcranial magnetic stimulation associated with targeted cognitive-behavioral therapy (following the CBT-E protocol, CG Fairburn - 2010.).
62453680|NCT05296915|EXPERIMENTAL|Only CBT-E group|N=10 Group with only cognitive-behavioral therapy of eating disorders.
62453681|NCT03231475|EXPERIMENTAL|SPH1188-11|SPH1188-11 dose escalation, 50mg/100mg/200mg/300mg/450mg/600mg
62067956|NCT00965003|EXPERIMENTAL|MRI scan with surface coil|Patients with known laryngeal cancer, with suspected cartilage involvement by conventional computed tomography scanning, who undergo high resolution magnetic resonance imaging enhanced with a surface coil placed over the larynx.
62067957|NCT04930770|EXPERIMENTAL|Renal/renopancreatic transplant's patients with a verified seronegativity|
62635944|NCT04718870|EXPERIMENTAL|Atopic Dermatitis Participants|Pediatric participants with moderate-to-severe atopic dermatitis (AD) and with baseline body weight more than or equal to (\>=) 15 kilograms (kg) and less than (\<) 30 kg received a subcutaneous (SC) loading dose of dupilumab 600 milligrams (mg) (2 injections of dupilumab 300 mg) on Day 1 (Week 0) followed by dupilumab 300 mg SC injection every 4 weeks (Q4W), from Week 4 to Week 12. Pediatric participants with body weight \>=30 kg and \<60 kg received SC loading dose of dupilumab 400 mg (2 injections of dupilumab 200 mg) on Day 1 (Week 0), followed by dupilumab 200 mg SC injection every 2 weeks (Q2W), from Week 2 to Week 14.
62272758|NCT01787357|EXPERIMENTAL|Sequence 4 (DCAB)|Each volunteer will receive Treatment D on Day 1 of Treatment Period 1, followed by Treatment C on Day 1 of Treatment Period 2, followed by Treatment A on Day 1 of Treatment Period 3, and followed by Treatment B on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
62635945|NCT04718870|NO_INTERVENTION|Healthy Volunteers|Healthy volunteers with age, gender, location of targeted skin lesion area and study site matched to selected AD participants, received no treatment, but were monitored in a similar way as AD participants.
62635946|NCT04801251|OTHER|Resident|Full history.complete systemic and cardiac physical examination
62635947|NCT04801251|OTHER|Assistant Lecturer|Echocardiographic examination
62635948|NCT04614298|EXPERIMENTAL|KHK4827 210 mg SC (Subcutaneous)|Single SC administration
62635949|NCT04614298|PLACEBO_COMPARATOR|Placebo SC|Single SC administration
62635950|NCT05235360|EXPERIMENTAL|Condition 1|1) Episodic future thinking; 2) Positive affect imagery; 3) Action planning; 4) High intervention dose
62635951|NCT05235360|EXPERIMENTAL|Condition 2|1) Episodic future thinking; 2) Positive affect imagery; 3) Action planning; 4) Low intervention dose
62635952|NCT05235360|EXPERIMENTAL|Condition 3|1) Episodic future thinking; 2) Positive affect imagery; 3) High intervention dose
62635953|NCT05235360|EXPERIMENTAL|Condition 4|1) Episodic future thinking; 2) Positive affect imagery; 3) Low intervention dose
62635954|NCT05235360|EXPERIMENTAL|Condition 5|1) Recent thinking; 2) Positive affect imagery; 3) Action planning; 4) High intervention dose
62635955|NCT05235360|EXPERIMENTAL|Condition 6|1) Recent thinking; 2) Positive affect imagery; 3) Action planning; 4) Low intervention dose
62635956|NCT05235360|EXPERIMENTAL|Condition 7|1) Recent thinking; 2) Positive affect imagery; 3) High intervention dose
62635957|NCT05235360|EXPERIMENTAL|Condition 8|1) Recent thinking; 2) Positive affect imagery; 3) Low intervention dose
62635958|NCT05235360|EXPERIMENTAL|Condition 9|1) Episodic future thinking; 2) Neutral imagery; 3) Action planning; 4) High intervention dose
62272759|NCT00623480|EXPERIMENTAL|Recombinant Factor VIII prophylaxis treatment|Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
62272760|NCT00623480|EXPERIMENTAL|Recombinant Factor VIII on-demand treatment|Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
62272761|NCT04457427|NO_INTERVENTION|Tracheostomy, no DPS|5 patients undergoing tracheostomy for failure to wean will receive no additional intervention.
62272762|NCT04457427|EXPERIMENTAL|Trachesotomy with immediate DPS stimulation and monitoring|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate stimulation and monitoring.
62272763|NCT04457427|ACTIVE_COMPARATOR|Trachesotomy with DPS monitoring, stimulation on day 5|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate monitoring followed by stimulation on day 5 post-procedure.
62635959|NCT05235360|EXPERIMENTAL|Condition 10|1) Episodic future thinking; 2) Neutral imagery; 3) Action planning; 4) Low intervention dose
62635960|NCT05235360|EXPERIMENTAL|Condition 11|1) Episodic future thinking; 2) Neutral imagery; 3) High intervention dose
62272764|NCT04847661|ACTIVE_COMPARATOR|Mefloquine arm|"Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.~* 30kg≤BW\<45kg: 825mg followed by 275mg after 6-8 hours~* 45kg≤BW\<60kg: 825mg followed by 550mg after 6-8 hours~* 60kg≤BW: 825mg followed by 550mg after 6-8 hours and then 275mg 6-8 hours after the second dose"
62635961|NCT05235360|EXPERIMENTAL|Condition 12|1) Episodic future thinking; 2) Neutral imagery; 3) Low intervention dose
62635962|NCT05235360|EXPERIMENTAL|Condition 13|1) Recent thinking; 2) Neutral imagery; 3) Action planning; 4) High intervention dose
62635963|NCT05235360|EXPERIMENTAL|Condition 14|1) Recent thinking; 2) Neutral imagery; 3) Action planning; 4) Low intervention dose
62635964|NCT05235360|EXPERIMENTAL|Condition 15|1) Recent thinking; 2) Neutral imagery; 3) High intervention dose
62635965|NCT05235360|EXPERIMENTAL|Condition 16|1) Recent thinking; 2) Neutral imagery; 3) Low intervention dose
62635966|NCT03878823|EXPERIMENTAL|ODM-209 Part 1 Dose escalation|
62635967|NCT03878823|EXPERIMENTAL|ODM-209 Part 2 Dose expansion|
62635968|NCT00984932|EXPERIMENTAL|Rosuvastatin|
62652938|NCT05081687|NO_INTERVENTION|Standard of care|Standard post-radiation care
62067958|NCT01535274|EXPERIMENTAL|Desflurane|Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
62453682|NCT02716129|ACTIVE_COMPARATOR|Group 1|Morphine group
62635969|NCT02899065|EXPERIMENTAL|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
62635970|NCT02899065|NO_INTERVENTION|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
62635971|NCT02381613|ACTIVE_COMPARATOR|Baked beef|A meal based on baked beef
62635972|NCT02381613|EXPERIMENTAL|Baked herring|A meal based on baked herring
62635973|NCT02381613|EXPERIMENTAL|Pickled herring|A meal based on pickled herring
62635974|NCT03060304|EXPERIMENTAL|study group|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
62652939|NCT02982759|OTHER|Comparison Arm|The comparison group will receive 2 generic newsletters
62652940|NCT02982759|EXPERIMENTAL|Intervention Arm|The intervention arm will receive the multi-level intervention.
62272765|NCT04847661|PLACEBO_COMPARATOR|Control arm|A similar tablet of non-active gradients was specifically manufactured for the study by EVA Pharma company. The placebo tablets exactly resemble the active treatment mefloquine tablets (the same shape, size and color).
62652941|NCT02991807|EXPERIMENTAL|RAD001|RAD001 is formulated as tablets of 5.0 mg or 2.5mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
62652942|NCT02991807|PLACEBO_COMPARATOR|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
62067959|NCT01535274|EXPERIMENTAL|Propofol|Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
62067960|NCT03312686||Eosinophilic Esophagitis patients|PPI treatment
62067961|NCT00811421|ACTIVE_COMPARATOR|Trial 1: IPTp-SP+LLITNs|HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)
62272766|NCT05491993|EXPERIMENTAL|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study. One arm was for obtaining data on the Rapid Antigen Test for Covid-19. The comparator arm was to obtain data from the RT-PCR.
62272767|NCT06542913||right lobe|cases underwent LDLT for right lobe with borderline GRWR
62287059|NCT04674462|EXPERIMENTAL|CpG-adjuvanted HBV Vaccine|
62453683|NCT02716129|ACTIVE_COMPARATOR|Group 2|Morphine plus Nalbuphine group
62453684|NCT04905433|EXPERIMENTAL|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
62453685|NCT04905433|ACTIVE_COMPARATOR|cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
62453686|NCT06438874|EXPERIMENTAL|GLP-1 Treatment|Individuals diagnosed with type 2 diabetes mellitus (T2DM) who are currently receiving treatment with a glucagon-like peptide 1 (GLP1) agonist.
62067962|NCT00811421|EXPERIMENTAL|Trial 1: IPTp-MQ (full dose) + LLITNs|HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
62635975|NCT03060304|ACTIVE_COMPARATOR|control group|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If endometrial thickness \<7mm and E2\<100pg/ml, the dose of estradiol valerate can increase or combine other estradiol. Endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before endometrium transformation. The embryo transfer day is decided according embryo development. Serum levels of E2, P are tested on the day before embryo transfer.
62635976|NCT04464291|EXPERIMENTAL|Patients with pneumococcal infection|There will be assessing the prevalence of Streptococcus pneumoniae serotypes in the nasopharynx in healthy people; in middle ear liquid in patients with acute otitis media; in sputum and epithelial lining fluid in patients with community-acquired pneumonia; in spinal fluid in patients with invasive pneumococcal indection
62635977|NCT01877200||Subjects with diabetes (type 2)|
62635978|NCT03450759|EXPERIMENTAL|Treatment sequence 1|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate)"
62635979|NCT03450759|EXPERIMENTAL|Treatment sequence 2|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 oral suspension (reference)"
61978709|NCT05931939|ACTIVE_COMPARATOR|Traditional surgical technique|Conventional revisional surgery group Procedure/Surgery: Bariatric surgery
61978710|NCT03692364|ACTIVE_COMPARATOR|Metal-on-conventional polyethylene|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a CoCr prosthetic femoral head and an acetabular liner made of intermedially cross-linked polyethylene polyethylene (Duration, Stryker, Mahwah, NJ, US).
62067963|NCT00811421|EXPERIMENTAL|Trial 1: IPTp-MQ (split dose)+LLITNs|HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs
62067964|NCT00811421|EXPERIMENTAL|Trial 2: CTX+IPTp-Placebo+LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)
62067965|NCT00811421|EXPERIMENTAL|Trial 2: CTX + IPTp-MQ+ LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
62067966|NCT03946514|EXPERIMENTAL|losartan/hydrochlorothiazide group|
62067967|NCT03946514|ACTIVE_COMPARATOR|amlodipine/hydrochlorothiazide group|
62453687|NCT02172248|EXPERIMENTAL|Sequence ABC|"1. Treatment A: BI 10773 once daily from day 1 to 5~2. Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4~3. Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4"
62067968|NCT03492892|EXPERIMENTAL|Acupuncture|Use real acupuncture treatment for blood pressure management in patients with hypertension
62067969|NCT03492892|SHAM_COMPARATOR|Sham Acupuncture|Use non-acupoint as the stimulating site in acupuncture for the treatment of hypertension
62067970|NCT06041958|ACTIVE_COMPARATOR|General rehabilitation therapy|Conducting a general rehabilitation program for lymphedema, three times a week, continuing until the end of the experiment.
62067971|NCT06041958|EXPERIMENTAL|ESWT therapy group|Participants are randomly assigned to receive either shockwave therapy or electromagnetic pulse therapy. Once assigned, the treatment method is fixed and continues for 12 weeks. From week 1 to week 12, participants receive either extracorporeal shockwave therapy or electromagnetic pulse therapy three times a week, totaling 36 sessions. After the completion of the 12-week treatment, the general rehabilitation program for lymphedema continues, conducted three times a week.
62067972|NCT06041958|EXPERIMENTAL|PEMFT therapy group|Participants are randomly assigned to receive either shockwave therapy or electromagnetic pulse therapy. Once assigned, the treatment method is fixed and continues for 12 weeks. From week 1 to week 12, participants receive either extracorporeal shockwave therapy or electromagnetic pulse therapy three times a week, totaling 36 sessions. After the completion of the 12-week treatment, the general rehabilitation program for lymphedema continues, conducted three times a week.
62067973|NCT01370603|ACTIVE_COMPARATOR|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 40 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
62067974|NCT01370603|EXPERIMENTAL|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/40 mg, placebo to ezetimibe, and placebo to atorvastatin.
62272768|NCT06542913||left lobe|cases underwent LDLT for left lobe with borderline GRWR
62272769|NCT04569721|EXPERIMENTAL|CT guided splanchnic cryoablation|Obese patients with type 2 diabetes receiving CT guided splanchnic cryoablation.
62272770|NCT05196659|NO_INTERVENTION|CONTROL Group|"* Regular current system of care~* Treating physicians provided current cardiovascular disease management guidelines~* Patients provided a leaflet (printed information) on healthy lifestyle"
62287060|NCT04674462|ACTIVE_COMPARATOR|Traditional HBV Vaccine|
62067975|NCT06159374|NO_INTERVENTION|Control|Control group
62067976|NCT06159374|EXPERIMENTAL|normoxia-thermoneutral|Training performed under normoxia (200 m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%);
62067977|NCT06159374|EXPERIMENTAL|hypoxia-thermoneutral|Training performed under normobaric hypoxia (3000 m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%);
62453688|NCT02172248|EXPERIMENTAL|Sequence CAB|"1. Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4~2. Treatment A: BI 10773 once daily from day 1 to 5~3. Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4"
62635980|NCT03450759|EXPERIMENTAL|Treatment sequence 3|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule"
62635981|NCT03450759|EXPERIMENTAL|Treatment sequence 4|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate)"
62635982|NCT01997034||Intensive Lifestyle Intervention|Former participants of Ubberup Folk High Schools intensive lifestyle intervention programme.
62635983|NCT06291766|OTHER|Continous glucose measurement|Use of FreeStyle Libre 3, with Libre Link app and Glooko app for measurement and review of glucose measurements.
62635984|NCT06291766|NO_INTERVENTION|Capillary glucose measurement|Standard care, including capillary glucose measurements and Glooko app for review of glucose measurements.
62635985|NCT03414944|EXPERIMENTAL|SMART-Brain|selective brain radiotherapy based on SIB and hippocampus, inner ear avoidance.
62635986|NCT04916717|OTHER|Counseling|Quasi-experimental design. Face-to-face and telephone counseling were applied to individuals in the intervention group.
62287061|NCT06370416|EXPERIMENTAL|Trilaciclib group|240mg/m2, intravenous infusion for 30 minutes, and administration completed within 4 hours before daily chemotherapy;
62067978|NCT06159374|EXPERIMENTAL|normoxia-heat|training performed under normoxia (200 m above sea level) and high ambient temperature (31°C) and constant humidity (40%);
62287062|NCT02664116|EXPERIMENTAL|Cambia|Diclofenac postassium powder for oral solution and placebo injection
62287063|NCT02664116|ACTIVE_COMPARATOR|ketorolac|ketorolac intramuscular injection and placebo oral solution
62635987|NCT03175614|ACTIVE_COMPARATOR|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
62067979|NCT06159374|EXPERIMENTAL|hypoxia-heat|training performed under normobaric hypoxia (3,000 m above sea level) and high ambient temperature (31°C) and constant humidity (40%);
62067980|NCT06159374|EXPERIMENTAL|normoxia-cold|Training performed in normoxia (200 m above sea level) and low ambient temperature (-11°C) and constant humidity (40%).
62067981|NCT06159374|EXPERIMENTAL|hypoxia-cold|training performed under normobaric hypoxia (3,000 m above sea level) and low ambient temperature (-11°C) and constant humidity (40%);
62067982|NCT06159374|EXPERIMENTAL|hypoxia-heat-humidity|training performed under normobaric hypoxia (3,000 m above sea level) and high ambient temperature (31°C) and high humidity (70%);
62067983|NCT03082833|EXPERIMENTAL|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
62453689|NCT04518774|EXPERIMENTAL|Allogeneic γδT cell immunotherapy|Patients will receive 3 cycles of ex-vivo expanded allogeneic γδT cells treatments, at four-weeks' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
62453690|NCT03346564|EXPERIMENTAL|Ritual training program|ritual training program for 8 weeks, biweekly
62287064|NCT03417050||Randomized CABG patients|Patients which were randomized to undergo CABG.
62453691|NCT03346564|PLACEBO_COMPARATOR|Routine care|Routine care following hospital
62453692|NCT00101608|EXPERIMENTAL|1|
62635988|NCT03175614|EXPERIMENTAL|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
62067984|NCT02080195|EXPERIMENTAL|Nonmyeloablative Conditioning and BMT|Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
62067985|NCT04851860|OTHER|allergic rhintis children|sublingual immunotherapy is used for allergic rhintis children by dosing Allergen immunotherapy extract as sublingual drops which were kept under the tongue for a couple of minutes and then swallowed. The sublingual drops were administered in the morning on an empty stomach .
62067986|NCT01603563|EXPERIMENTAL|Stepped Care TF-CBT|Patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
62088271|NCT03564275|NO_INTERVENTION|Retrospective Comparison Group|Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.
62287065|NCT03417050||Randomized PCI patients|Patients which were randomized to undergo PCI.
62287066|NCT03417050||Registry CABG|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the CABG registry for PCI-ineligible patients.
62067987|NCT01603563|ACTIVE_COMPARATOR|Standard TF-CBT|Patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, \& trauma narrative etc.).
62635989|NCT02930057|EXPERIMENTAL|Celestone|all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
62067988|NCT03020329|EXPERIMENTAL|Paclitaxel liposome, Cisplatin, 5-Fu,|Patients receive paclitaxel liposome(135mg/m2 on day 1), cisplatin (75mg/m2 on day 1,Separate injection on day 1 to 3) and fluorouracil (3750mg/m2 CIV 120h) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
62272771|NCT05196659|ACTIVE_COMPARATOR|INTERVENTION Group|"1. Electronic Health Record-Decision Support Software (EHR-DSS):~   * Electronic patient health record storage~  * Management prompts to the clinical team (following algorithms)~  * Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~2. Non-physician health worker-led continuity of care:~   - individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~3. Text-message based reminders for a healthy lifestyle~4. Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~5. Quarterly audit and feedback to the clinical team"
62067989|NCT02560935|ACTIVE_COMPARATOR|Moderate Dose Hydroxyurea|Hydroxyurea at 20 mg/kg/day (range 17.5 to 26 mg/kg/day) for primary stroke prevention.
62635990|NCT02930057|OTHER|Control|all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
62635991|NCT00205101||1|Triad allograft
62635992|NCT00205101||2|other anterior lumbar interbody fusion (ALIF)
62067990|NCT02560935|ACTIVE_COMPARATOR|Low Dose Hydroxyurea|Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention.
62067991|NCT03835936|ACTIVE_COMPARATOR|Manual maneuvers physiotherapy|The protocol of physiotherapy treatment techniques consists of 20 minutes of FR based on prolonged slow expiration and cough provoked.
62635993|NCT00205101||3|transforaminal lumbar interbody fusion (TLIF)
62635994|NCT00205101||4|posterior lumbar interbody fusion (PLIF)
62067992|NCT03835936|EXPERIMENTAL|High frequency compression chest wall|The protocol consists in the application of the Smart Vest® device for high frequency compression of the chest wall, with a fixed frequency of 13 Hz and a time of 15 minutes. Then during 20 minutes will apply the same protocol as in the manual maneuvers group.
62067993|NCT02766179|ACTIVE_COMPARATOR|CPAP Therapy|Continuous Positive Airway Pressure
62067994|NCT02766179|EXPERIMENTAL|Somnoguard|Somnoguard
62067995|NCT04805463|EXPERIMENTAL|control group|After gingivectomy and released into the secondary wound healing gingivoplasty group.
62067996|NCT04805463|EXPERIMENTAL|PRF group|The group in which PRF was applied to the wound surface after gingivectomy and gingivoplasty.
62067997|NCT04805463|EXPERIMENTAL|CGF group|The group in which CGF was applied to the wound surface after gingivectomy and gingivoplasty.
62067998|NCT04805463|EXPERIMENTAL|AFG group|The group in which AFG was applied to the wound surface after gingivectomy and gingivoplasty.
62272772|NCT02790151|ACTIVE_COMPARATOR|Standard Therapy|Learning and practicing memory strategies
62272773|NCT02790151|EXPERIMENTAL|Experimental Intervention|Computerbased working memory training and Recollection training
62272774|NCT00887237|EXPERIMENTAL|TRIV|Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)
62272775|NCT00887237|ACTIVE_COMPARATOR|BIV|Conventional cardiac resynchronization
62067999|NCT02922790|ACTIVE_COMPARATOR|Control|"Subjects will review standard health information on the health consequences of smoking.~Subjects will have blood drawn but it will not be tested for DNA damage."
62068000|NCT02922790|ACTIVE_COMPARATOR|Biomarker feedback|"Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.~Subjects will have blood drawn and the feedback will be presented at Visit 2."
62068001|NCT02922790|ACTIVE_COMPARATOR|Biomarker feedback plus|"Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.~Subjects will have blood drawn and the feedback and images will be presented at Visit 2."
62068002|NCT06160622|EXPERIMENTAL|Experimental 1: participants with severe renal impairment|8 participants with severe renal impairment will be given 400mg of Leritrelvir
62068003|NCT06160622|EXPERIMENTAL|Experimental 2: healthy participants|8 participants with normal renal function will be given 400mg of Leritrelvir
62068004|NCT02225977||Gilenya treated - 1 month|Patient's taking continuous oral Gilenya at prescribed dose for 1 month.
62272776|NCT05056025|EXPERIMENTAL|postbiotics with vitamins|postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)
62635995|NCT03383991|EXPERIMENTAL|Reverse Total Shoulder Arthroplasty|
61978711|NCT03692364|EXPERIMENTAL|Ceramic-on-ceramic|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a prosthetic femoral head and an acetabular liner made of alumina ceramic (Biolox Forte, Ceramtec, Plochingen, Germany).
62068005|NCT02225977||Gilenya treated - 3 months|Patient's taking continuous oral Gilenya at prescribed dose for 3 months.
62068006|NCT02225977||Gilenya treated - 6 months|Patient's taking continuous oral Gilenya at prescribed dose for 6 months.
62068007|NCT02225977||Gilenya treated - 12 months|Patient's taking continuous oral Gilenya at prescribed dose for 12 months.
62068008|NCT02225977||Gilenya qualified - untreated|Patient's qualifying to start treatment with oral Gilenya at prescribed dose but still as yet untreated.
62272777|NCT05056025|PLACEBO_COMPARATOR|vitamins|vitamins (AREDS formulation and recommended daily dose)
62272778|NCT03048422|EXPERIMENTAL|Arm 1: Maternal DTG+FTC/TAF|Mothers randomized to receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
62272779|NCT03048422|EXPERIMENTAL|Arm 2: Maternal DTG+FTC/TDF|Mothers randomized to receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
62272780|NCT03048422|ACTIVE_COMPARATOR|Arm 3: Maternal EFV/FTC/TDF|Mothers randomized to receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
62272781|NCT03048422|NO_INTERVENTION|Arm 1 Infants|Infants born to women in Arm 1. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
61978712|NCT00137423|EXPERIMENTAL|SU011248 (sunitinib)|Single-arm study
61978713|NCT02428660|OTHER|Controls (no analysis or testing)|MTM alone (i.e. Treatment As Usual)
61978714|NCT02428660|EXPERIMENTAL|Group 1|MTM + software-based drug \& gene interaction risk analysis + pharmacogenetic testing
61978715|NCT02428660|ACTIVE_COMPARATOR|Group 2|MTM + software-based drug \& gene interaction risk analysis only
62068009|NCT06215651|EXPERIMENTAL|Cadonilimab and lenvatinib|the combination therapy of Cadonilimab and Lenvatinib for conversion treatment in unresectable hepatocellular carcinoma
62635996|NCT03383991|ACTIVE_COMPARATOR|Hemiarthroplasty|
61978716|NCT04417881||patients with acurate heart failure|
62068010|NCT01339598|SHAM_COMPARATOR|Sham transcranial direct current stimulation|
62068011|NCT01339598|ACTIVE_COMPARATOR|Transcranial direct current stimulation|
62453693|NCT01801670||MF patients for blood & biopsy|Participants who are cared for at Boston Medical Center will first be assessed by physicians of the CTCL multi-specialty clinic if vorinostat, administered per standard of care, is an appropriate therapy for their CTCL. The decision to invite patients to participate in this study is (1) separate from the above described clinical decision to utilize vorinostat, and (2) will be offered subsequent to the clinical decision to utilize vorinostat. Vorinostat (Zolinza) will be administered as follows: each subject will receive each month for the first 3 months (cycle 1 to 3) 3 capsules of vorinostat 100 mg po daily. For months 4-6 (cycles 4 to 6), subjects will receive each month for 4 capsules of vorinostat 100 mg po daily.
62453694|NCT04687163|EXPERIMENTAL|OXA 130|Patients received sorafenib or lenvatinib Plus HAIC of 130 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
62453695|NCT04687163|ACTIVE_COMPARATOR|OXA 85|Patients received sorafenib or lenvatinib Plus HAIC of 85 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
62453696|NCT01501942|EXPERIMENTAL|Active|The active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
62453697|NCT01501942|PLACEBO_COMPARATOR|Inactive product|The matching placebo is an oral solution of phosphate buffered saline
62453698|NCT04822870|EXPERIMENTAL|quadratus lumborum block|Parturients receive ultrasound-guided quadratus lumborum block as post-operative analgesia.
62453699|NCT04822870|EXPERIMENTAL|iliohypogastric/ilioinguinal nerve block|Parturients receive ultrasound-guided iliohypogastric/ilioinguinal nerve block as post-operative analgesia.
62453700|NCT04822870|ACTIVE_COMPARATOR|epidural analgesia|Parturients receive epidural morphine via epidural catheter placed during anesthesia as post-operative analgesia.
62453701|NCT03901014|ACTIVE_COMPARATOR|Baseline diet|1 week baseline diet
62453702|NCT03901014|EXPERIMENTAL|Very low carbohydrate diet|2 week very low carbohydrate ketogenic diet
62635997|NCT04552132|EXPERIMENTAL|GentleWave|Patients randomly assigned to the GentleWave group will receive irrigation and activation of irrigants with the GentleWave device (multisonic energy) by Sonendo.
62635998|NCT04552132|ACTIVE_COMPARATOR|EndoActivator|Patients randomly assigned to the EndoActivator group will receive irrigation via a side-vented needle and activation using the EndoActivator (sonic energy) by Dentsply Sirona.
62635999|NCT00327223|EXPERIMENTAL|imexon|Dose escalation of imexon
62636000|NCT01407991|EXPERIMENTAL|Length or graph method|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
62636001|NCT01407991|ACTIVE_COMPARATOR|NEM method for NG/OG tube placement|Standard method- measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length. Nose to ear to mid-xiphoid-umbilicus (NEM).
62068012|NCT01339598|ACTIVE_COMPARATOR|Different transcranial direct current stimulation montage|
62453703|NCT02252562|NO_INTERVENTION|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
62453704|NCT02252562|EXPERIMENTAL|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system \[(SAGE Products Inc., Cary, Il),
62068013|NCT04561882|EXPERIMENTAL|Transcatheter exclusion of atrial septal aneurysm|Transcatheter reconstruction of atrial septum might be achieved with PFO occluder through transseptal perforation in patients with ASA.
62068014|NCT02703207|ACTIVE_COMPARATOR|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
62068015|NCT02703207|NO_INTERVENTION|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
62068016|NCT02703207|NO_INTERVENTION|OSA and comorbid COPD|Eligible elderly (age \>/=60yrs) Veterans with moderate to severe Overlap Syndrome.
62453705|NCT01245790|EXPERIMENTAL|1|Healthy subjects (Stage 1)
62453706|NCT01245790|EXPERIMENTAL|2|Mild renal impairment (Stage 2)
62453707|NCT01245790|EXPERIMENTAL|3|Moderate renal impairment (Stage 2)
62453708|NCT01245790|EXPERIMENTAL|4|Severe renal impairment (Stage 2)
62453709|NCT01245790|EXPERIMENTAL|5|End stage renal disease (Stage 1)
62453710|NCT06123507|EXPERIMENTAL|Full educational intervention condition|The Full intervention condition included a perspective-taking workshop plus independent practice and video-feedback
62453711|NCT06123507|ACTIVE_COMPARATOR|Partial intervention condition|The Partial intervention condition involved video-feedback alone. In this condition, participants were provided with a link to the perspective-taking workshop after the study was complete.
62453712|NCT05626595|EXPERIMENTAL|Control|Outdoor play is an essential component of childhood development, including supporting children's cognitive, physical, emotional, and social growth. Currently, the early learning and childcare centres (ELCCs) host children within childcare settings, with outdoor playtime governed by institutional regulations.
62068017|NCT05635136||The DIVAT cohort|"patient \> 18 years of age who received renal transplant are registered in the DIVAT cohort (standing for computerized and validated data in transplantation, Données Informatisées VAlidées Transplantation). It comprises more than 300 clinical and biological parameters collected at the time of transplant, at 3 months, 6 months and at each anniversary of the transplant. The DIVAT cohort and network is accredited by the CNIL (standing for Commission Nationale de l'Informatique et des Libertés)"
62068018|NCT04707911|EXPERIMENTAL|Vaping Intervention|The vaping intervention will be implemented on Instagram. Participants in the treatment condition will be assigned to groups on Instagram, where they will receive up to 3 posts per day for 30 days. Groups are facilitated by a trained Guide, working with the Principal Investigator, Co-Investigators and a Pediatrician on demand if additional expertise or clinical advice is needed. Participants will be educated about signs of nicotine dependence and if they express interest in pharmacotherapy will be encouraged to access this through their personal healthcare providers. The Instagram groups will provide educational and social support, troubleshooting and advice about nicotine replacement therapy (NRT) or other forms of treatment.
62068019|NCT04707911|NO_INTERVENTION|Control Condition|Participants in the control condition will be directed to the Truth Initiative e-cigarette texting quit program. This innovative and free text message program was created with input from teens, college students and young adults who have attempted to, or successfully, quit e-cigarettes using text coaching methods
62068020|NCT03781765|ACTIVE_COMPARATOR|Methylphenidate|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
62068021|NCT03781765|ACTIVE_COMPARATOR|Atomoxetine|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
62068022|NCT06625840|EXPERIMENTAL|Panel A|Participants receive a loading dose of MK-1167 or Placebo orally on day 1, followed by a once daily (QD) maintenance dose orally on days 2 to 16.
62068023|NCT06625840|EXPERIMENTAL|Panel B|Participants receive a loading dose of MK-1167 or Placebo orally on days 1 to 3, followed by a QD maintenance dose orally on days 4 to 16.
62272782|NCT03048422|NO_INTERVENTION|Arm 2 Infants|Infants born to women in Arm 2. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
62272783|NCT03048422|NO_INTERVENTION|Arm 3 Infants|Infants born to women in Arm 3. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
62272784|NCT00743379|EXPERIMENTAL|A|TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
62453713|NCT05626595|SHAM_COMPARATOR|Project|"The PRO-ECO project to increase the quality of outdoor play involves four primary components:~1. Modifying ELCC's outdoor play policies: the ELCC policy on outdoor play requirements and procedures will be modified in conjunction with ELCC management.~2. ECE training and mentorship:~   ECEs will undergo the Learning Outside Together (LOT) program, which incorporates traditional wisdom into training on Indigenous ways of knowing, learning and experiencing the land as teacher.~3. ELCC outdoor space modification:~   This includes designing and implementing tailored modifications for each centre's outdoor play space developed by landscape architecture students.~4. Parent engagement:~ELCCs will host parent-engagement events and opportunities to increase knowledge of the importance of outdoor play."
62453714|NCT04908826|ACTIVE_COMPARATOR|Group A (standard cholangiography during surgery)|All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
62652943|NCT03168945|ACTIVE_COMPARATOR|Novel diagnostics arm|The intervention is to screen a sputum specimen collected on a participant with suspected TB in the community at the point-of-contact in a mobile van using an on-site GeneXpert MTB/RIF machine
62272785|NCT00743379|EXPERIMENTAL|B|TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
62272786|NCT00743379|EXPERIMENTAL|C|TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
62272787|NCT02164981|ACTIVE_COMPARATOR|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
62272788|NCT02164981|OTHER|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
62272789|NCT02164981|PLACEBO_COMPARATOR|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
62272790|NCT03714945||Case Group with Allergic Rhinitis|"- Inclusion Criteria~1. Both genders of 11-14 years, diagnosed with allergic rhinitis on basis of screening instruments, medical history, clinical assessment (by general ORL examination including nasal endoscopy)~2. Chinese in ethnicity~3. Positive skin prick test with wheal diameter \>= 3mm~4. Ability to understand the nature, scope, and possible consequences of the study~5. Capability and willingness to comply with the requirements of the protocol"
62272791|NCT03714945||Control Group without Allergic Rhinitis|"- Inclusion Criteria~1. Both genders of 11-14 years~2. Chinese in ethnicity~3. Subjects who have not been diagnosed with a long term medical or psychiatric problem~4. Subjects who are not currently undergoing any long term medical treatment."
62636002|NCT05360407|EXPERIMENTAL|Intervention Group|The mobile information application was downloaded from the Android market and installed on the patients' phones, and the patients were taught about how to use it. The patients were given a short information brochure on the use of the mobile application. One week after the surgery, the patients were called and reminded about the use of the application. Three weeks after the surgery, data were collected through telephone interviews using the Patient Follow-up Form, Anxiety, Distress and Quality of Life measurement tools, the Patient Information Satisfaction Questionnaire, and the Mobile Application Evaluation Form.
62068024|NCT05675865|EXPERIMENTAL|VT Cryoablation|all enrolled patients will have a ablation procedure using the Adagio VT Cryoablation System for SMVT
62068025|NCT05124041|EXPERIMENTAL|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis
62272792|NCT00733707|EXPERIMENTAL|1|Text messaging reminders
62272793|NCT00733707|NO_INTERVENTION|2|No text messaging reminder
62272794|NCT02953535|EXPERIMENTAL|T test|Test drug (Magicbuvir)1 tablet contains 400 mg Sofosbuvir
61978717|NCT00103142|EXPERIMENTAL|PANVAC-V + PANVAC-F + DC|Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic cells (DC). Patients then receive autologous DC loaded with vaccinia-CEA-MUC-1-TRICOM (PANVAC-V) vaccine subcutaneously (SC) and intradermally (ID) on day 1 and autologous DC loaded with fowlpox-CEA-MUC-1-TRICOM (PANVAC-F) vaccine SC and ID on days 28, 56, and 84.
62068026|NCT05124041|ACTIVE_COMPARATOR|Control-arm|Treatment of significant blood loss conventionally, ie. using clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma
62453715|NCT04908826|ACTIVE_COMPARATOR|Group B (cholangiography with iv administration of icg prior to surgery)|All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).
62636003|NCT05360407|NO_INTERVENTION|Control Group|The patients received routine care and training in the clinic, and no additional intervention was applied. Three weeks after the surgery, data were collected through telephone interviews using the Patient Follow-up Form, Anxiety, Distress and Quality of Life measurement tools, and the Patient Information Satisfaction Questionnaire
62068027|NCT00295438|EXPERIMENTAL|Robot-Based Tele-Echography (TER)|ultrasound performed according to the method Tele-Echography
62068028|NCT00295438|ACTIVE_COMPARATOR|ultrasound method FAST|ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)
62068029|NCT05711888|EXPERIMENTAL|Semantic information in Alzheimer Disease|To observe the semantic information processing in early stages of Alzheimer Disease is the main aim of the study. A paper-pencil neuropsychological assessment battery will be used. For memory testing FCSRT (free and cued selective reminding test) will be used. The patients are going to be assessed while in clinical diagnosis routine.
62272795|NCT02953535|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
62272796|NCT02953535|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
62272797|NCT01233973|NO_INTERVENTION|control subjects|verbal narrative of advance care planning
62272798|NCT01233973|EXPERIMENTAL|intervention group|video decision aid viewed by subjects
62636004|NCT04190862|EXPERIMENTAL|Cell Therapy Treatment|Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
62068030|NCT04581200|EXPERIMENTAL|Lift mobile mindfulness program|Will receive standard dose Lift mobile mindfulness program intervention content, app-based response to elevated symptoms, and no introductory call from a therapist. This program lasts 1 month and includes 4 unique weeks' worth of audio, video, and text content.
62272799|NCT03926221|EXPERIMENTAL|PBC_I plus TranS-C|The Parent Behavior Change Intervention (PBC-I) is a behavioral intervention intended to teach parent behavior change techniques to better support their adolescents to improve sleep health behavior. The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
62272800|NCT05287009|EXPERIMENTAL|ILM nonpeeling|
62272801|NCT05287009|OTHER|ILM peeling|
62272802|NCT04029519|EXPERIMENTAL|PN40082|All subjects in this study will receive one open-label treatment with PN40082.
62272803|NCT02542761|EXPERIMENTAL|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
62272804|NCT02542761|EXPERIMENTAL|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
62652944|NCT03168945|PLACEBO_COMPARATOR|Routine screening arm|The control arm is to send a sputum specimen collected on a participant with suspected TB at the mobile van for routine smear microscopy at a laboratory
61978718|NCT00103142|EXPERIMENTAL|PANVAC-V + PANVAC-F + GM-CSF|Patients receive PANVAC-V SC on day 1 and PANVAC-F SC on days 28, 56, and 84. Patients also receive sargramostim (GM-CSF) SC into the same injection site once daily on days 0-3, 28-31, 56-59, and 84-87.
62068031|NCT04581200|NO_INTERVENTION|Usual care control|Usual care.
62272805|NCT05199259||HCC positive Group|Multi-analyte blood test screen in participants with a recent confirmed untreated diagnosis of HCC by CT scan, MRI or biopsy.
62272806|NCT05199259||HCC negative Group: Sub-Group 1|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by CT or MRI (No lesion, LR-1 or LR-2)
62272807|NCT05199259||HCC negative Group: Sub-Group 2|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by ultrasound. Participants will be scheduled for a 6 month visit (at least 5 months but no more 9 months form enrollment) for a confirmatory ultrasound.
62453716|NCT04908826|ACTIVE_COMPARATOR|Group C (cholangiography with direct administration of icg to the bile duct system during surgery)|All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
62636005|NCT04190862|EXPERIMENTAL|Cell Therapy Treatment Part B1|Adult subjects with simple perianal fistula who meet all eligibility criteria to participate in Part B of the study will be treated in the outpatient setting with curettage and E-CEL UVEC cells without fistulotomy. E-CEL UVEC cells will be injected along the two sides (180 degrees apart from each other) of the whole length of the curetted anal fistula tract.
62636006|NCT04190862|EXPERIMENTAL|Cell Therapy Treatment Part B2-S|Subjects in Part B2-S will have the same eligibility criteria and would undergo the same procedure as described in Part B1, except that B2-S subjects will also have suturing and injection of the internal opening.
62636007|NCT04190862|EXPERIMENTAL|Cell Therapy Treatment Part B2-M|Subjects in Part B2-M will have the same eligibility criteria and would undergo the same procedure as described in Part B1, except that B2-M subjects in this cohort are eligible for up to 4 treatments (versus 1 in Part B2-S).
62636008|NCT02762448||Daclatasvir + Asunaprevir|Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
62636009|NCT02361112|EXPERIMENTAL|pyrotinib combined with capecitabine|
62636010|NCT00729716|EXPERIMENTAL|A|BioCart™II treatment
62636011|NCT00729716|ACTIVE_COMPARATOR|B|Microfracture procedure
62636012|NCT06346847|EXPERIMENTAL|Postbiotic|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
62636013|NCT06346847|PLACEBO_COMPARATOR|Placebo|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
62636014|NCT04250116|EXPERIMENTAL|NOAC monotherapy|
62636015|NCT04250116|ACTIVE_COMPARATOR|Dual antithrombotic therapy|
62636016|NCT03930095|EXPERIMENTAL|Acceptance-Based Behavior Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
62636017|NCT03930095|ACTIVE_COMPARATOR|Non-directive Supportive Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
62636018|NCT02403050||Fiducial Markers Prospective cohort|2 fiducial markers (Visicoils) to be placed in the tumor area at the routine endoscopic ultrasound (EUS) appointment.
62636019|NCT02403050||Retrospective cohort|Images and clinical data from a retrospective group of patients without fiducial markers
62088272|NCT05375565|EXPERIMENTAL|weight bearing exercises|weight bearing exercises
62088273|NCT05375565|EXPERIMENTAL|non weight bearing exercises|non weight bearing exercises
62453717|NCT00797108|EXPERIMENTAL|1|Loading dose of IV sulopenem with switch to oral PF-03709270
62453718|NCT00797108|EXPERIMENTAL|2|IV sulopenem with switch to oral PF-03709270
62453719|NCT00797108|ACTIVE_COMPARATOR|3|IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator
62453720|NCT04259840||Peri-implantitis|Patients who underwent resective surgical treatment for peri-implantitis at the University of Michigan Graduate Periodontics clinic from January 1, 1990 through July 1, 2018
62636020|NCT01858038|NO_INTERVENTION|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
62636021|NCT01858038|EXPERIMENTAL|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
62636022|NCT00334789|EXPERIMENTAL|Treatment (belinostat, isotretinoin)|"Patients receive belinostat IV over 30 minutes on days 1-5 and isotretinoin PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of belinostat until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.~Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies.~All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies."
62068032|NCT05085821|EXPERIMENTAL|Experimental 1: HEART - Placebo - HEART - Placebo|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after \>24hour washout) Week 2: HEART, Placebo (after \>24hour washout)"
62272808|NCT06173193|EXPERIMENTAL|multicomponent exercise group|8 months of multicomponent exercise (3 sessions/week).
62272809|NCT06173193|ACTIVE_COMPARATOR|Reference group|8 months of standard rehabilitative care based home exercises.
62272810|NCT00687362|EXPERIMENTAL|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
62652945|NCT05474001|ACTIVE_COMPARATOR|Fentanyl group|"Patients will receive 10 mg hyperbaric Bupivacaine ( 2ml ) and 20 μg (0.5 mL) fentanyl IT.~1 mL IV normal saline immediately after the placement of the spinal."
62272811|NCT00777569|EXPERIMENTAL|Extra-low nicotine cigarettes|
62272812|NCT00777569|EXPERIMENTAL|Nicotine-free cigarettes|
62272813|NCT00777569|ACTIVE_COMPARATOR|Medicinal Nicotine|
62272814|NCT00488982|EXPERIMENTAL|Docetaxel + Observation|Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy
62088274|NCT01077674||Entropy - BIS|Patients undergoing surgery in sevoflurane anaesthesia.
62088275|NCT01019356|EXPERIMENTAL|Rosiglitazone|Lean and obese PCOS women
62272815|NCT00488982|EXPERIMENTAL|Docetaxel + GM-CSF|Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)
62068033|NCT05085821|EXPERIMENTAL|Experimental 2: HEART - Placebo - Placebo - HEART|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after \>24hour washout) Week 2: Placebo, HEART (after \>24hour washout)"
62068034|NCT05085821|EXPERIMENTAL|Experimental 3: Placebo - HEART - Placebo - HEART|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: Placebo, HEART (after \>24hour washout) Week 2: Placebo, HEART (after \>24hour washout)"
62068035|NCT05085821|EXPERIMENTAL|Experimental 4: Placebo - HEART - HEART - Placebo|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after \>24hour washout) Week 2: Placebo, HEART (after \>24hour washout)"
62068036|NCT00989586|EXPERIMENTAL|Phase I|Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
62068037|NCT00989586|EXPERIMENTAL|Phase II|Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
62068038|NCT00975988||TYKERB® tablets|There is only one group. This group includes patients administrated TYKERB® tablets
62453721|NCT05451836|EXPERIMENTAL|Group 1|Group 1 (Two emergency departments) will receive patient education leaflets for 6 months and will receive physician feedback for the next 6 months on top of the patient education.
62652946|NCT05474001|ACTIVE_COMPARATOR|Granisetron group|"Patients will receive 10 mg hyperbaric Bupivacaine ( 2ml ) and 0.5 mL normal saline IT.~1 mg (1 mL) IV granisetron after spinal placement."
62068039|NCT06434597|EXPERIMENTAL|SPH5030|
62068040|NCT05015764|EXPERIMENTAL|Reprieve Cardiovascular System|
62068041|NCT05015764|ACTIVE_COMPARATOR|Standard of Care|
62068042|NCT05414097||Phase 1: 24 Women - FGDs|Focus groups enrolling HIV-positive, previously screened for cervical cancer; HIV-positive, not previously screened for cervical cancer; HIV-negative, previously screened for cervical cancer; HIV-negative, not previously screened for cervical cancer.
62068043|NCT05414097||Phase 1: 16 Men - FGDs|Focus groups enrolling male partners referred by women previously screened or treated for cervical cancer and by women not previously screened for cervical cancer.
62453722|NCT05451836|EXPERIMENTAL|Group 2|Group 1 (Two emergency departments) will receive physician feedback for 6 months and will receive patient education leaflets for the next 6 months on top of the physician feedback.
62453723|NCT05586425|EXPERIMENTAL|Emotion Regulation Skills + Treatment as Usual|Emotion Regulation Skills (ERS), a version of Dialectical Behaviour Therapy Skills Training, is a type of skills-focused therapy for individuals who experience severe emotion dysregulation.
62453724|NCT05586425|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
62453725|NCT02641964||ARDS group|patients with acute necrotizing pancreatitis complicated by ARDS
62068044|NCT05414097||Phase 1: 12 Key Stakeholders - IDIs|Stakeholder interviewers with women's groups, women's health providers, laboratory personnel, NGOs, and public health organizations.
62068045|NCT05414097||Phase 2: 300 women - DCE|Discrete Choice Experiment enrolling women 18 years of age and older.
62068046|NCT05414097||Phase 3: 36 Women, women's health providers, and policy makers|Stakeholder groups comprising individuals 18 years and older who participated in Phase 1 will be eligible.
62068047|NCT00706225|EXPERIMENTAL|1|Bazedoxifene and Conjugated Estrogens (BZA \& CE)
62068048|NCT00218803|EXPERIMENTAL|1|
62068049|NCT00218803|OTHER|2|
62068050|NCT03387241|EXPERIMENTAL|Fluticasone/ Formoterol (Flutiform)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled"
62068051|NCT03387241|ACTIVE_COMPARATOR|Fluticasone/ salmeterol (Seretide)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled"
62068052|NCT02387216|EXPERIMENTAL|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
62068053|NCT02387216|ACTIVE_COMPARATOR|Arm B: Comparator Arm|Docetaxel alone
62088276|NCT01019356|ACTIVE_COMPARATOR|Acarbose|Obese PCOS women
62453726|NCT02641964||non-ARDS group|acute necrotizing pancreatitis patients without ARDS
62453727|NCT02398188|EXPERIMENTAL|LIPO-202|Experimental arm
62453728|NCT02398188|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62652947|NCT05474001|PLACEBO_COMPARATOR|Control group|"10 mg hyperbaric Bupivacaine ( 2ml ) IT and normal saline 0.5 ml~1 ml normal saline IV after spinal placement."
62652948|NCT00797758|EXPERIMENTAL|1|Umbilical cord blood transplantation after reduced intensity conditioning
62068054|NCT00879580||Non-ruptured aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have one or more non-ruptured or late ruptured (\>30days), intracranial aneurysm.
62068055|NCT00879580||Acute ruptured Aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have a on or more acute ruptured (\<30Days) aneurysms
62068056|NCT02281526|OTHER|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
62068057|NCT02281526|OTHER|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
62272816|NCT01107431|ACTIVE_COMPARATOR|Sucrose with Dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
62652949|NCT06296511|EXPERIMENTAL|Exercise|Participants were asked to arrive at the lab at 8.30 am, having fasted overnight for 10 hours. After resting in the lab for 30 minutes, participants were asked to exercise at an intensity of 70 percent of their peak oxygen uptake for an hour before resting in the lab for a further 2.5 hours. Ad libitum energy intake was assessed 1 h after exercise completion.
62068058|NCT01842737|EXPERIMENTAL|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
62068059|NCT01842737|ACTIVE_COMPARATOR|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
62636023|NCT05986981|EXPERIMENTAL|MUC1 Vaccine|"Enrollment by cohort from the starting dose of the trial and proceed to the next higher dose level if no one of the first 3 subjects develops DLT. If 1 of the 3 subjects develops DLT, then 3 additional subjects will be added to that dose level for a total of 6 subjects.~If only 1 of 6 subjects develops DLT, proceed to the next higher dose level. If no fewer than 2 of the 6 subjects develop DLT, no more subjects will be added to that dose level and dose escalation will cease. The Safety Monitoring Committee (SMC) decides whether to use the intermediate dose as the next dose level for the study. Until the maximum sample size specified in the protocol or the SMC decides to terminate the dose increment.each subject receives only one dose group of study drug (during the incremental period, subjects may receive a reduced dose to continue treatment after the investigator has assessed the risk-benefit for safety reasons; dose increments are not permitted for the same subject)."
62636024|NCT01265186||Ventilated term newborns|Ventilated newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
62636025|NCT01265186||Control group: healthy term newborns|Control group: healthy newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
62636026|NCT05159557|EXPERIMENTAL|In-Home Technology System|"The full system \[(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 1 Apple Watch to detect falls and activity outside the home\] will be self-installed by caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
62636027|NCT05159557|SHAM_COMPARATOR|Limited In-Home Technology System|"The full system \[(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights\], with the exception of the Apple Watch that those in the experimental condition receive will be self-installed by caregivers (N=60) in their homes. Only monitoring of the water leak and associated warnings will be activated remotely for those participants who have been randomly assigned to this limited (sham comparator) arm."
62636028|NCT00238407|ACTIVE_COMPARATOR|Arm I|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
62636029|NCT01676051||Chloraprep|
62636030|NCT01676051||Duraprep|
62636031|NCT01676051||Betadine only|
62636032|NCT05160844||Diseased|young Egyptian patients with premature myocardial infarction
62636033|NCT05160844||Control|healthy young Egyptians
62636034|NCT01804088|EXPERIMENTAL|Stent|
62636035|NCT03961763|ACTIVE_COMPARATOR|omega-3 supplement|This group will receive a daily dose of 4g EPA+DHA (which is the recommended safe tolerable upper intake level of omega-3 supplements for healthy individuals) for eight weeks.
62636036|NCT03961763|PLACEBO_COMPARATOR|Placebo|This group will receive a daily dose of 4g olive oil placebo for eight weeks.
62068060|NCT06624462|ACTIVE_COMPARATOR|Treatment in the Meta Care Clinic|The patients who after randomization are allocated to the treatment arm will receive 12 months of treatment in a pragmatic metabolic clinic. Patients will receive measurements/monitoring at least 3 times during the study period: Upon enrolment, after 6 months and after 12 months.
62068061|NCT06624462|ACTIVE_COMPARATOR|Standard care with general practitioner and/or outpatient clinics|The patients who after randomization are allocated for standard care will continue with their current psychiatric out-patient clinic and/or contact with their general practitioner. Patients will receive measurements/monitoring upon enrolment and after 12 months.
62068062|NCT03195465|EXPERIMENTAL|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
62636037|NCT06203509|EXPERIMENTAL|THRIVE Intervention|"THRIVE Intervention~1-month intensive post discharge case management and care coordination"
62636038|NCT06203509|NO_INTERVENTION|Usual Care|Discharge to home without intensive post-acute case management or care coordination.
62068063|NCT03047772|PLACEBO_COMPARATOR|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
62453729|NCT04089709|EXPERIMENTAL|Study arm|Patients randomized to this group will be provided exercises to perform with the uninjured arm once daily for 3 months.
62636039|NCT01057355|EXPERIMENTAL|Cyst ethanol lavage|Subjects receiving the study intervention
62636040|NCT04074434||All Participants|
62636041|NCT00132080|PLACEBO_COMPARATOR|1|Patients with acute Kawasaki disease
62636042|NCT00081887|EXPERIMENTAL|Weekly Clofarabine|
62068064|NCT03047772|EXPERIMENTAL|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
62636043|NCT01598610|EXPERIMENTAL|Intended Users of the Monitoring System|Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.
62453730|NCT04089709|NO_INTERVENTION|Control arm|"Patients randomized to this group will not be provided exercises for the well-arm and will be managed according to the current standard of care."
62068065|NCT03047772|EXPERIMENTAL|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
62636044|NCT04753294|EXPERIMENTAL|Avance Solo NPWT System|Treatment with negative pressure wound therapy for Venous leg ulcers, Diabetic foot ulcers, and Pressure ulcers.
62636045|NCT04753294|EXPERIMENTAL|Avance Solo Adapt NPWT System|Treatment with negative pressure wound therapy for Pressure ulcers.
62068066|NCT03047772|EXPERIMENTAL|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
62068067|NCT03047772|PLACEBO_COMPARATOR|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
62068068|NCT03047772|ACTIVE_COMPARATOR|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
62068069|NCT03047772|PLACEBO_COMPARATOR|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
62068070|NCT03047772|EXPERIMENTAL|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
62068071|NCT05581615|ACTIVE_COMPARATOR|Pure inulin|2 x 5 g/d inulin
62068072|NCT05581615|EXPERIMENTAL|Shortbread containing inulin|2 x per day shortbread containing 5 g inulin per serving
62272817|NCT01107431|ACTIVE_COMPARATOR|Sucrose without Dietary Supplement|Consumed 70 grams of sucrose without simultaneously taking the dietary supplement
62453731|NCT05291078|EXPERIMENTAL|Experimental Group A|Tinnitus patients(n=12 people)
62453732|NCT05291078|EXPERIMENTAL|Experimental Group B|Tinnitus patients(n=12 people)
62453733|NCT05291078|SHAM_COMPARATOR|Control Group|Tinnitus patients(n=12 people)
62453734|NCT01890382|PLACEBO_COMPARATOR|Control|alanine as placebo to leucine (same dosage); corn starch as placebo to protein and/or creatine (same dosage)
62453735|NCT01890382|EXPERIMENTAL|whey protein|
62453736|NCT01890382|EXPERIMENTAL|soy protein|
62453737|NCT01890382|EXPERIMENTAL|leucine supplementation|
62453738|NCT01890382|EXPERIMENTAL|whey plus creatine|
62636046|NCT01703390|EXPERIMENTAL|ERCC-1 low|modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
62636047|NCT01703390|EXPERIMENTAL|ERCC-1 high|FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
62636048|NCT04904471|EXPERIMENTAL|Experimental|Three doses of recombinant SARS-CoV-2 vaccine (Sf9 Cell) on Day 0, Day 21and Day 42.
62636049|NCT04904471|PLACEBO_COMPARATOR|Placebo Comparator|Three doses of placebo on Day 0, Day 21and Day 42.
62068073|NCT05581615|EXPERIMENTAL|Rice drink containing inulin|2 x per day rice drink containing 5 g inulin per serving
62272818|NCT03098836|EXPERIMENTAL|Caucasian|
62272819|NCT03098836|EXPERIMENTAL|African American|
62068074|NCT05581615|EXPERIMENTAL|Milk chocolate containing inulin|2 x per day milk chocolate containing 5 g inulin per serving
62068075|NCT04187820|EXPERIMENTAL|Acupuncture group|Participants receiving acupuncture and mild moxibustion.
62068076|NCT06568744|EXPERIMENTAL|Intervention|This group will follow a resuscitation algorithm aimed at macrohemodynamic stabilization and improvement of tissue hypoperfusion. Fluid administration will be tailored according to fluid responsiveness status, fluid intolerance signals, and hypoperfusion signals such as capillary refill time. Mechanical ventilation and sedation will follow standard management as per current recommendations.
62068077|NCT06568744|ACTIVE_COMPARATOR|Standard of Care|This group will follow a resuscitation algorithm aimed at macrohemodynamic stabilization and improvement of tissue hypoperfusion. Fluid administration will be tailored according to fluid responsiveness status, and hypoperfusion signals such as capillary refill time. Mechanical ventilation and sedation will follow standard management as per current recommendations.
62272820|NCT02944630|EXPERIMENTAL|Experimental:|Receiving psychotherapy and medical treatment.
62272821|NCT02944630|NO_INTERVENTION|Control|Awaiting group: Receiving medical treatment.
62272822|NCT01127165|EXPERIMENTAL|Zonisamide Low Dose Group|
62272823|NCT01127165|EXPERIMENTAL|Zonisamide High Dose group|
62453739|NCT01890382|EXPERIMENTAL|creatine|
62453740|NCT02624843|EXPERIMENTAL|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
62453741|NCT02624843|ACTIVE_COMPARATOR|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
62453742|NCT02624843|PLACEBO_COMPARATOR|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
62272824|NCT02686593|OTHER|Clofarabine, AraC, mitoxantrone (CLAM)|This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone
62272825|NCT04934787|EXPERIMENTAL|ENMS-BSF assisted gait training|The participants will receive the full assistance of the ENMS-BSF during a 20-session gait rehabilitation.
62272826|NCT04934787|ACTIVE_COMPARATOR|Partial ENMS-BSF assisted gait training|The participants will receive a partial assistance of the ENMS-BSF during a 20-session gait rehabilitation.
62272827|NCT04934787|SHAM_COMPARATOR|Sham ENMS-BSF assisted gait training|The participants will only wear the device without assistance during a 20-session gait rehabilitation.
62272828|NCT02199197|EXPERIMENTAL|Radium Ra 223 Dichloride and Enzalutamide|Radium Ra 223 Dichloride and Enzalutamide administered concurrently for 6 28-day cycles.
62068078|NCT02790073|OTHER|SNF472|SNF472 for calciphylaxis
62068079|NCT03383796|EXPERIMENTAL|3D approach|Three dimensional laparoscopic resection for pCCA
62068080|NCT03383796|EXPERIMENTAL|open approach|Open resection for pCCA
62068081|NCT04538989|EXPERIMENTAL|RZ358 Cohort 1|
62068082|NCT04538989|EXPERIMENTAL|RZ358 Cohort 2|
62272829|NCT02199197|ACTIVE_COMPARATOR|Enzalutamide alone|Enzalutamide administered as a single agent for 6 28-day cycles.
62272830|NCT06437678|OTHER|Recurrent/Refractory Advanced Gastric Cancer|
62068083|NCT04538989|EXPERIMENTAL|RZ358 Cohort 3|
62068084|NCT04538989|EXPERIMENTAL|RZ358 Cohort 4|
62068085|NCT00857805|ACTIVE_COMPARATOR|Transarterial Chemoembolization|Transarterial Chemoembolization
62068086|NCT00857805|ACTIVE_COMPARATOR|Proton Beam Radiotherapy|Proton Beam Radiotherapy
62068087|NCT06493123|EXPERIMENTAL|Group I|Group I/Control group: Conventional cardiopulmonary rehabilitation will be applied in the postoperative period.
62068088|NCT06493123|EXPERIMENTAL|Group II|Group II/ Bottle P.E.P.: Conventional cardiopulmonary rehabilitation and bottle-PEP therapy will be applied in the postoperative period.
62068089|NCT06493123|EXPERIMENTAL|Group III|Group III/Early Mobilization: Early mobilization program will be started in conventional cardiopulmonary rehabilitation in the postoperative period.
62068090|NCT05357937|ACTIVE_COMPARATOR|Obese group|Received standard physiotherapy program
62068091|NCT05357937|ACTIVE_COMPARATOR|Non-Obese group|Received standard physiotherapy program
62272831|NCT05754840|EXPERIMENTAL|Arm 1. High-CBD arm (MPL-001)|High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD.
62272832|NCT05754840|EXPERIMENTAL|Arm 2. Medium-CBD arm (MPL-005)|Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD.
62272833|NCT05754840|EXPERIMENTAL|Arm 3. Balanced arm (MPL-009)|Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD.
62272834|NCT05593900|EXPERIMENTAL|Intervention|Parents have the option to use telehealth to virtually connect with the nurse before transfer
62272835|NCT05593900|NO_INTERVENTION|Control|Standard of care
62272836|NCT01965132||Biologic or targeted synthetic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biolsimilars) or a targeted synthetic DMARD
62272837|NCT02069171||early ovarian cancer group|
62272838|NCT02069171||locally advanced cervical cancer group|
62272839|NCT02069171||primary endometrial cancer group|
62272840|NCT05954442|EXPERIMENTAL|Arm A|Everolimus plus Investigator's Choice of Chemotherapy
62272841|NCT05954442|ACTIVE_COMPARATOR|Arm B|Investigator's Choice of Chemotherapy
62272842|NCT02806323|EXPERIMENTAL|Yoga Practice|12 week yoga intervention; 45 minutes/weekly practice Participants will be encouraged to practice their prescribed program of yoga at home, daily, for 20 minutes each day.
62272843|NCT03428165|OTHER|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
62068092|NCT03885804|SHAM_COMPARATOR|Quadratus lamborum dexmedetomidine intravenous group|Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
62068093|NCT03885804|ACTIVE_COMPARATOR|Quadratus lamborum dexmedetomidine perineural group|Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
62068094|NCT05282849|ACTIVE_COMPARATOR|Group F: ultrasound guided fascia iliaca block group|
62272844|NCT03428165|NO_INTERVENTION|spontaneous|
62272845|NCT04462952|EXPERIMENTAL|Adavosertib (AZD1775) monotherapy|Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
62272846|NCT04462952|EXPERIMENTAL|Adavosertib (AZD1775) in combination with gemcitabine|Dose escalation of adavosertib in combination with gemcitabine for patients with advanced solid tumours
62272847|NCT02918773|EXPERIMENTAL|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
62636050|NCT05332314|EXPERIMENTAL|NSAIDs|This arm is given NSAIDs perioperatively and after discharge
62636051|NCT05332314|NO_INTERVENTION|Opioids|This arm will be given the standard opioids treatment to control pain perioperatively and at discharge.
62068095|NCT05282849|ACTIVE_COMPARATOR|Group Q: ultrasound guided quadratus lumborum block group|
62068096|NCT01476488|NO_INTERVENTION|Advagraf|single group, conversion of prograf to advagraf
62068097|NCT01706419|NO_INTERVENTION|no school meal|control group receiving no school meal
62068098|NCT01706419|PLACEBO_COMPARATOR|normal school meal|school meal without fortified rice, placebo group
62068099|NCT01706419|EXPERIMENTAL|cold extruded fortified rice|school meal with fortified rice using cold extrusion kernels
62068100|NCT01706419|EXPERIMENTAL|warm extrusion|school meal with fortified rice using warm extrusion kernels
62068101|NCT01706419|EXPERIMENTAL|hot extruded|school meal with fortified rice using hot extrusion kernels
62636052|NCT02475434|EXPERIMENTAL|Cream Supplement group|Infants randomized to the cream supplement group will receive an exclusive HM-based diet with the addition of a HM-derived cream caloric supplement.
62636053|NCT02475434|NO_INTERVENTION|Control Group|Infants randomized to the Control group will receive the standard regimen of an exclusive HM-based diet (no cream supplement).
62068102|NCT01381627|ACTIVE_COMPARATOR|Remifentanil|
62068103|NCT01381627|EXPERIMENTAL|Dexmedetomidine|
62088277|NCT01019356|NO_INTERVENTION|Control|Obese and lean healthy women evaluated only at baseline
62272848|NCT02918773|ACTIVE_COMPARATOR|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
62272849|NCT04091997||endometriosis|laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay
62272850|NCT04091997||control|diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay
62287067|NCT03417050||Registry PCI|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the PCI registry for CABG-ineligible patients.
62636054|NCT06017401|ACTIVE_COMPARATOR|Group OSTAP|The investigator will perform oblique subcostal transversus abdominis plane block to that patient group for postoperative analgesia
62068104|NCT02873130|EXPERIMENTAL|Behavioral: Telepractice Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) through West Chester University's Desire 2 Learn (D2L) software program. Synchronous and asynchronous learning opportunities are provided through D2L over a four week period. The GVPM includes vocal hygiene, vocal education, and vocal training.
62068105|NCT02873130|EXPERIMENTAL|Behavioral: In-person Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) at West Chester University in-person. The GVPM will meet for 2 hours once a week for four weeks. The GVPM includes vocal hygiene, vocal education, and vocal training.
62068106|NCT02873130|SHAM_COMPARATOR|Behavioral: Telepractice, Vocal Hygiene and Vocal Education|Participants will complete Vocal Hygiene and Vocal Education through West Chester University's Desire 2 Learn (D2L) software program. Asynchronous learning opportunities are provided through D2L over a one week period.
62636055|NCT06017401|ACTIVE_COMPARATOR|Group TQLB|The investigator will perform transmuscular quadratus lumborum block to that patient group for postoperative analgesia
62636056|NCT00528307|ACTIVE_COMPARATOR|1|First 3 months of biventricular pacing, second 3 months right ventricular apical pacing
62636057|NCT00528307|ACTIVE_COMPARATOR|2|First 3 months of right ventricular apical pacing, second 3 months biventricular pacing
62636058|NCT02985112||Patients with FFR > 0.80|Group of patients with physiologically non-significant coronary stenoses who will not undergo coronary revascularization
62636059|NCT02985112||Patients with FFR < 0.80|Group of patients with physiologically significant coronary stenoses who will undergo coronary revascularization
62636060|NCT03050827|ACTIVE_COMPARATOR|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
62636061|NCT03050827|PLACEBO_COMPARATOR|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
62636062|NCT00091468|PLACEBO_COMPARATOR|Placebo Group|Placebo for first six months of study; moved to open-label active nicotine for second six months
62636063|NCT00091468|EXPERIMENTAL|Active Nicotine Group|Blinded active nicotine for first six months of study; open-label active nicotine for second six months
62636064|NCT01348724|EXPERIMENTAL|[14C] NKTR-118|
62636065|NCT00570375|EXPERIMENTAL|Single Arm|All patients will receive 150 mg of Erlotinib
62636066|NCT05738746|EXPERIMENTAL|Pasteurized Akkermansia muciniphila|pasteurized A.muciniphila (Pasteurized, 3x10\^10 bacteria per day) as supplement for 3 months,
62636067|NCT05738746|PLACEBO_COMPARATOR|Placebo|placebo administered for 3 months once a day
62636068|NCT02562586|ACTIVE_COMPARATOR|Closed Suction Drainage System|Group 1: patients undergoing total hip replacement received a Closed Suction Drainage System for 24 hours after the surgical procedure
62636069|NCT02562586|NO_INTERVENTION|No Closed Suction Drainage System|Group 2: patients undergoing total hip replacement have not received a Closed Suction Drainage System after the surgical procedure
62636070|NCT00777166|ACTIVE_COMPARATOR|1|oxytocin 5 units
62068107|NCT04919174|ACTIVE_COMPARATOR|Control group|Patients receive dexmedetomidine for sedation
62068108|NCT04919174|EXPERIMENTAL|Test group|Patients receive remimazolam for sedation
62272851|NCT02706808|EXPERIMENTAL|resistance starch for CKD|- Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
62636071|NCT00777166|ACTIVE_COMPARATOR|2|oxytocin, 10 units
62636072|NCT00808067|EXPERIMENTAL|dabigatran dose 1|dabigatran high dose twice daily
62636073|NCT00808067|EXPERIMENTAL|dabigatran dose 2|dabigatran low dose twice daily
62636074|NCT03621033|OTHER|non-transparent cap-assisted endoscopic intubation|we do not use transparent cap-assisted endoscopic intubation.
62636075|NCT03621033|OTHER|transparent cap-assisted endoscopic intubation|we use transparent cap-assisted endoscopic intubation in the second insertion.
62636076|NCT01372631|EXPERIMENTAL|Pressure assessment|30 patients undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled to assess the ideal pressure that should be applied when taking optical measurements.
62636077|NCT01372631|EXPERIMENTAL|Random and Systematic Errors|40 patients undergoing lumpectomy or mastectomy will be enrolled to assess the random and systematic errors of the miniature spectral imaging system.
62636078|NCT01372631|EXPERIMENTAL|Sensitivity and Specificity Assessment|150 patient undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled in order to determine the sensitivity and specificity of the miniature spectral imaging system.
62636079|NCT02340000|ACTIVE_COMPARATOR|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
62636080|NCT02340000|EXPERIMENTAL|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
62652950|NCT06296511|NO_INTERVENTION|Control|Participants replicated all the procedures of the exercise trial except they rested for 1 h as the exercise counterpart.
62636081|NCT05564481|EXPERIMENTAL|Immediate intervention|Participants randomized to the immediate intervention group will participate in 3 video-conferencing sessions with a Certified Diabetes Care and Education Specialist (CDCES) interventionist and connect with a peer parent consultant immediately post randomization (expected intervention duration: 3 months).
62636082|NCT05564481|ACTIVE_COMPARATOR|Wait-list/delayed intervention|Participants randomized to the delayed intervention group will receive no intervention for 6 months post-randomization; after the 6-month follow-up period, the delayed intervention group also will participate in 3 video conferencing sessions with a CDCES interventionist and connect with a peer parent consultant (expected intervention duration: 3 months).
62068109|NCT05041816|EXPERIMENTAL|Focal vibration group|The Myovolt device used in our previous study will be used for focal vibration delivery during week three to six. Participants will wear Myovolt secured by an elastic band, at a location based on therapist and participants preference. During the four weeks of the FV therapy, participants will be asked to use the Myovolt device for up to 0.5-hour per session (each site 10 minutes per session, with one-minute intersession between sites), once in the morning and once in the evening each day, for five days a week. The dosing paradigm was chosen based on the safety and potential effectiveness of the FV therapy, and our preliminary study.
62068110|NCT00288028|EXPERIMENTAL|Bortezomib|Bortezomib is administered as a 5 second IV bolus on days 1, 4, 8,11 or 1,8 and 15 of a 21-35 days cycle (Depending on the Dosing schedule). The dosage will be calculated based on actual weight of the patient unless the actual weight is greater than 40% above the ideal body weight. In this instance the dosage will be based on the adjusted ideal body weight. The Adjusted IBW (kg) = IBW + 0.25 x (actual body weight - IBW). The dosage will be adjusted based on the safety and toxicity profile, until a MTD is determined.
62068111|NCT02690077|ACTIVE_COMPARATOR|Method 1 by Preference 1|Delivery through the Family-Centered Cesarean for patients with known Family-Centered preference.
62068112|NCT02690077|ACTIVE_COMPARATOR|Method 1 by Preference 2|Delivery through the Family-Centered Cesarean for patients with known Traditional Cesarean preference.
62068113|NCT02690077|ACTIVE_COMPARATOR|Method 2 by Preference 1|Delivery through the Traditional Cesarean for patients with known Family-Centered preference.
62272852|NCT02706808|EXPERIMENTAL|cross-over period|intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
62272853|NCT03938805|EXPERIMENTAL|I-CBT|Internet-based cognitive behavioral therapy program including 1-week introduction, 2 weeks psycho education on Cardiovascular disease/insomnia, 6 weeks of sleep hygiene, stimulus control and sleep restriction
62272854|NCT03938805|ACTIVE_COMPARATOR|Control group|3 weeks internet-based sleep hygiene education
62272855|NCT00603759|ACTIVE_COMPARATOR|1|
62453743|NCT03467568|ACTIVE_COMPARATOR|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
62453744|NCT03467568|ACTIVE_COMPARATOR|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
62453745|NCT03467568|ACTIVE_COMPARATOR|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
62453746|NCT03467568|PLACEBO_COMPARATOR|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
62453747|NCT02704351||Sugammadex group|sugammadex to reverse neuromuscular blockade following cardiac surgery
62453748|NCT00998699|ACTIVE_COMPARATOR|XOMA 052|
62636083|NCT01649882|EXPERIMENTAL|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (\< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
62272856|NCT00603759|PLACEBO_COMPARATOR|2|
62272857|NCT05067842||Locally advanced esophageal or gastroesophageal adenocarcinoma|Subjects with diagnosed locally advanced esophageal or gastroesophageal adenocarcinoma.
62453749|NCT00998699|PLACEBO_COMPARATOR|Placebo|
62453750|NCT01200472|EXPERIMENTAL|Apremilast capsules|Apremilast in 10 mg capsules
62453751|NCT01200472|PLACEBO_COMPARATOR|Placebo|
62453752|NCT00602329|EXPERIMENTAL|Arm I|Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
62453753|NCT00602329|EXPERIMENTAL|Arm II|Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
62453754|NCT00602329|ACTIVE_COMPARATOR|FOLFOX alone (control)|Patients receive FOLFOX as in arm I.
62453755|NCT01834963|EXPERIMENTAL|Interferon Alfa、Fluorouracil|"Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
62652951|NCT04084015|EXPERIMENTAL|Early axillary Impella®|Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO
62636084|NCT03656627|EXPERIMENTAL|Nivolumab: Autoimmune Diseases Cohort 1|"Arms determined by autoimmune type. First cohort consists of patients with:~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
62636085|NCT03656627|EXPERIMENTAL|Nivolumab: Autoimmune Diseases Cohort 2|"Arms determined by autoimmune type. Second cohort consists of patients with:~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
62272858|NCT05102643|EXPERIMENTAL|Test Product|SARS-CoV-2 DNA Vaccine at 1mg and 2mg, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
62272859|NCT05102643|PLACEBO_COMPARATOR|Reference Product|Matching placebo, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
62636086|NCT04413344|ACTIVE_COMPARATOR|Active|
62636087|NCT04413344|PLACEBO_COMPARATOR|Placebo|
62636088|NCT05736328||Subjects admitted for percutaneous needle tenotomy of the knee flexor muscles|Postoperative lower extremity traction.
62636089|NCT04135482||CD|patients with severe crohn's disease
62636090|NCT01715233|EXPERIMENTAL|Metastatic Esophageal, Gastroesophageal & Gastric Cancer|Participants receive Modified Docetaxel 40mg/m2, Leucovorin 400mg/m2 and Fluorouracil 400mg/m2 on day 1, Fluorouracil 1000mg/m2 per day on days 1 and 2 and Cisplatin 40mg/m2 (or Carboplatin) on day 3 in Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
62636091|NCT06607900|EXPERIMENTAL|hUC-MSC-sEV-001 group|hUC-MSC-sEV-001 nasal drops treatment
62453756|NCT01834963|EXPERIMENTAL|Cisplatin、Fluorouracil|"Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
62636092|NCT05137717|EXPERIMENTAL|Maribavir|Maribavir 400 milligrams (mg), tablets, orally twice a day (BID) for up to 8 weeks.
62636093|NCT02121860|EXPERIMENTAL|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
62636094|NCT02121860|EXPERIMENTAL|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
62272860|NCT01992783|EXPERIMENTAL|Hi-maize resistant starch|13.5 g/day
62068114|NCT02690077|ACTIVE_COMPARATOR|Method 2 by Preference 2|Delivery through the Traditional Cesarean for patients with known Traditional Cesarean preference.
62453757|NCT04815902|EXPERIMENTAL|Active Fisetin and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 \& 33, 61 \& 62 and 90 \& 91).
62453758|NCT04815902|ACTIVE_COMPARATOR|Active Fisetin and Losartan Placebo|Losartan Placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 \& 33, 61 \& 62 and 90 \& 91).
62453759|NCT04815902|ACTIVE_COMPARATOR|Fisetin Placebo and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 \& 33, 61 \& 62 and 90 \& 91).
62453760|NCT04815902|PLACEBO_COMPARATOR|Control|Losartan placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 \& 33, 61 \& 62 and 90 \& 91).
62453761|NCT01586858||RAVE subjects|
62636095|NCT02121860|EXPERIMENTAL|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
62636096|NCT02121860|EXPERIMENTAL|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
62272861|NCT01992783|PLACEBO_COMPARATOR|Maltodextrin|13.5 g/day
62068115|NCT04430413|NO_INTERVENTION|Group A|50 Participants who underwent a total excision of the pilonidal sinus and the wound remained open for secondary healing.
62068116|NCT04430413|ACTIVE_COMPARATOR|Group B|50 Participants who underwent the same operation with secondary healing intention but on postoperative days 4 and 12 the platelet rich plasma was injected to the surgical wound.
62068117|NCT04904081|EXPERIMENTAL|Treatment Arm (Indocyanine Green [ICG])|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
62453762|NCT01202747|EXPERIMENTAL|LipiFlow Treatment|Treatment with LipiFlow device
62453763|NCT00585780|ACTIVE_COMPARATOR|High Alcohol Withdrawal on Prazosin|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
62636097|NCT02443831|EXPERIMENTAL|CD19/22 CAR T-cells|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19/22CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19/22CAR T-cells.
62453764|NCT00585780|PLACEBO_COMPARATOR|High Alcohol Withdrawal on PLA|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
62652952|NCT01369433|EXPERIMENTAL|tivozanib renal cell carcinoma (RCC)|Subjects who participated in a Phase 2 monotherapy study in RCC and showed tolerability and clinical benefit will be allowed access to tivozanib (AV-951).
62068118|NCT04904081|NO_INTERVENTION|Control Arm (Standard Care)|The Standard Care group will have no change to the medical and surgical care they receive while in the hospital. The surgeon will perform the surgery as they normally would outside of this study. This involves a laparoscopic-assisted transanal pullthrough surgery.
62068119|NCT05232474|OTHER|Control group: no access to KomPas+|Therapists in the control group will not have access to KomPas+ and will continue to deliver usual care by using the KNGF guideline. They will also maintain access to KomPas. As with KomPas+, therapists are free to choose whether to use KomPas or not. The use of KomPas will also be encouraged.
62068120|NCT05232474|EXPERIMENTAL|Experimental group: access to KomPas+|KomPas+ will be implemented within the experimental group. The use of KomPas+ in the physiotherapeutic treatment of patients with intermittent claudication will not be mandatory but will be encouraged through an implementation strategy. Therapists are free to choose whether to use it or not.
62068121|NCT01486134|EXPERIMENTAL|procedure|
62068122|NCT02751918|EXPERIMENTAL|Anetumab ravtansine|Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.
62068123|NCT01090908||Ages 6-11 years|
62068124|NCT01090908||Ages 12-17 years|
62068125|NCT02732093|ACTIVE_COMPARATOR|stellate block|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml of lidocaine 2% after routine induction of general anesthesia and before endotracheal intubation
62453765|NCT00585780|ACTIVE_COMPARATOR|Low Alcohol Withdrawal on Prazosin|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. Low AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
62068126|NCT02732093|PLACEBO_COMPARATOR|control|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml normal saline (Na.Cl 0.9%) (control group) after routine induction of general anesthesia and before endotracheal intubation
62068127|NCT00405353|EXPERIMENTAL|crossover treatment with Androgel|6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone
62068128|NCT03949088|EXPERIMENTAL|Linear descending UF profile|2-step descending Na profile, linear descending UF profile 3 weeks (9 sessions)
62453766|NCT00585780|PLACEBO_COMPARATOR|Low Alcohol Withdrawal on PLA|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment.Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
62453767|NCT04128007|EXPERIMENTAL|ARQ-154 foam 0.3%|active
62453768|NCT04128007|PLACEBO_COMPARATOR|ARQ foam VehicleRQ-154 foam Vehicle|placebo
62453769|NCT06250595||Inherited Rare Anaemia Disorders, including inherited Bone Marrow Failures|Patients with Inherited Rare Anemia Disorders, including inherited Bone Marrow Failures, stratified by gender, age, and/or variants/types if applicable.
62453770|NCT06250595||Acquired Bone Marrow Failures|Patients with Acquired Bone Marrow Failures, stratified by gender, age, and/or variants/types if applicable.
62453771|NCT06250595||Rare bleeding-coagulation disorders and related diseases|Patients with Rare bleeding-coagulation disorders and related diseases, stratified by gender, age, and/or variants/types if applicable.
62453772|NCT06250595||Hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis|Patients with hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis, stratified by gender, age, and/or variants/types if applicable.
62453773|NCT06250595||Myeloid malignancies|Patients with Myeloid malignancies, stratified by gender, age, and/or variants/types if applicable.
62068129|NCT03949088|EXPERIMENTAL|Run-in & washout phases|constant Na concentration, constant UF rate 3 weeks (6+3 sessions)
62068130|NCT03949088|EXPERIMENTAL|Ascending/descending UF profile|2-step descending Na profile, ascending/descending UF profile 3 weeks (9 sessions)
62068131|NCT00244374|EXPERIMENTAL|AIC, Hepatitis A & B vaccine|Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC), for administration of viral hepatitis immunizations at Month 1, 2, 6.
62068132|NCT00244374|EXPERIMENTAL|AIC, Outreach, Hepatitis A & B vaccine|AIC + outreach: Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC)) for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
62068133|NCT00244374|EXPERIMENTAL|SEP, Hepatitis A & B vaccine|SEP only: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6.
62068134|NCT00244374|EXPERIMENTAL|SEP, Outreach, Hepatitis A & B vaccine|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
62272862|NCT04010500|EXPERIMENTAL|Rugby Players|
62453774|NCT06250595||Lymphoid malignancies|Patients with lymphoid malignancies, stratified by gender, age, and/or variants/types if applicable.
62453775|NCT00147381|EXPERIMENTAL|Campath-1H 20 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 20 mg IV infusion over 3-6 hours.~Day 1: Same protocol of Campath-1H and methylprednisolone as on Day 0.~Day 2: No treatment~Day 3: Initial dose of Tacrolimus 0,1 mg/kg/d (0,05 mg/kg/bid)~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
62453776|NCT00147381|ACTIVE_COMPARATOR|Tacrolimus|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
62453777|NCT00147381|EXPERIMENTAL|Campath-1H 30 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment.~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
62453778|NCT01512043|EXPERIMENTAL|1. Breathing control|Description ...
62453779|NCT01512043|ACTIVE_COMPARATOR|2. Listening to music|Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
62453780|NCT01512043|SHAM_COMPARATOR|3. Silence|Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
62652953|NCT01369433|EXPERIMENTAL|tivozanib + temsirolimus|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + temsirolimus combination.
61978719|NCT03219489|EXPERIMENTAL|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
61978720|NCT03219489|NO_INTERVENTION|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
61978721|NCT00608283||Live Kidney Donors|People who are going to donate a kidney at one of the three transplant centers from August 2007 until June 2011
62068135|NCT03096171|NO_INTERVENTION|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
62068136|NCT03096171|EXPERIMENTAL|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
62068137|NCT06422403|ACTIVE_COMPARATOR|Cohort A (SOC)|Nivolumab, XELOX/FOLFOX
62272863|NCT01469858|EXPERIMENTAL|study group|fMRI
62272864|NCT02349698|OTHER|Acute Lymphoblastic Leukemia|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells targeting CD19.
62272865|NCT02349698|OTHER|Chronic Lymphcytic Leukemia|Chronic lymphocytic leukemia with chimeric antigen receptor modified T cells targeting CD19.
62272866|NCT02349698|OTHER|Non-Hodgkin Lymphoma|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells targeting CD19.
62272867|NCT01060358||healthy|Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury.
62287068|NCT03315351|EXPERIMENTAL|Study Procedure|Brachytherapy. PET-scan.
62287069|NCT00836550|ACTIVE_COMPARATOR|Control|The participants spoke with a live counselor prior to answering the knowledge measure
62068138|NCT06422403|EXPERIMENTAL|Cohort A (EDI)|Nivolumab, XELOX/FOLFOX
62068139|NCT06422403|ACTIVE_COMPARATOR|Cohort B (SOC)|Bevacizumab, Atezolizumab
62068140|NCT06422403|EXPERIMENTAL|Cohort B (EDI)|Bevacizumab, Atezolizumab
62068141|NCT06422403|ACTIVE_COMPARATOR|Cohort C (SOC)|Pembrolizumab
62068142|NCT06422403|EXPERIMENTAL|Cohort C (EDI)|Pembrolizumab
62068143|NCT00477477|EXPERIMENTAL|1|Low glycemic load diet
62068144|NCT00477477|ACTIVE_COMPARATOR|2|Low fat diet
62068145|NCT03360877|OTHER|Health-care associated infection|
62068146|NCT04023097|EXPERIMENTAL|Toothwave contraindicated subject|"the Toothwave toothbrush is contraindicated for people in certain conditions, e.g. pregnant or nursing women, people with pacemaker and more.~This arm is assembled from contraindicated subject, who should exclude themselves from use of the device, based on the user manual and box sleeve."
62068147|NCT04023097|ACTIVE_COMPARATOR|potential users of the Toothwave device|The control arm is assembled from people who can use the toothbrush and should recognize themselves as potential users.
62068148|NCT00542841|EXPERIMENTAL|1|
62068149|NCT06017674|EXPERIMENTAL|Group 1|Intra-articular Pulsed Radiofrequency and Steroid Injection
62068150|NCT06017674|EXPERIMENTAL|Group 2|Only Intra-articular Steroid Injection
62272868|NCT05970263|EXPERIMENTAL|Breztri|"1. Interventional Arm: patients receive :~1. First dose of Breztri during hospitalization and discharge with 7-day Breztri inhaler~2. Breztri refills to cover 12-month follow-up period, mailed in 90-day supply from a central pharmacy. Emergency resupply is also available if needed."
62068151|NCT04696718|EXPERIMENTAL|Traitement 1|Lactobacillus salivarius
62068152|NCT04696718|EXPERIMENTAL|Traitement 2|Lactobacillus Rhamnosus GG
62068153|NCT04696718|EXPERIMENTAL|Traitement 3|Bifidobacterium lactis
62068154|NCT00708721|EXPERIMENTAL|All patients|All participants enrolled.
62068155|NCT04341155|ACTIVE_COMPARATOR|Dexamethasone|"Sixty nine patients will be administered randomly dexamethasone 20 mg IV for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
62068156|NCT04341155|PLACEBO_COMPARATOR|Placebo|"Sixty nine patients will be administered randomly Normal Saline 0,9% IV (4 cc) for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
62068157|NCT00936481||Healthy controls|18 years or older with body mass index between 25-45
62068158|NCT00936481||Obstructive Sleep Apnea Group|Age 18 years or older with body mass index between 25 and 45
62272869|NCT05970263|OTHER|External Comparator - Non-Triple|2. External Comparator Arm: patient who receive any non-triple inhaled therapy following a hospitalization for severe COPD exacerbation. This arm will be constructed of de-Identified patient.
62272870|NCT03546075|EXPERIMENTAL|500 mg Resveratrol|
62272871|NCT03546075|EXPERIMENTAL|250 mg Resveratrol|
62272872|NCT03546075|PLACEBO_COMPARATOR|Placebo|
62272873|NCT06392880|EXPERIMENTAL|Floss Band|A floss band will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
62068159|NCT00864526|EXPERIMENTAL|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
62068160|NCT00864526|ACTIVE_COMPARATOR|B|COMBONOX® tablets, single dose
62068161|NCT06172491||No Delirium Severity|Patients who did not experience a level of delirium severity (subsyndromal, mild, moderate, severe)
62068162|NCT06172491||Delirium Severity|Patients who did experience a level of delirium severity (subsyndromal, mild, moderate, severe)
62068163|NCT02047565|EXPERIMENTAL|Part 1 - 60mg edoxaban|Treatment A: single oral dose of 60 mg edoxaban (1 × 60 mg tablet)
62453781|NCT01785836|EXPERIMENTAL|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
62453782|NCT01785836|EXPERIMENTAL|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
62636098|NCT04609683|EXPERIMENTAL|Hydrostasis group|"50 study subjects scheduled for an EP procedure will have AleriTM sensors on subject's bicep, forearm, or wrist, to start data collection.~Measurements will be made from the subject for a period of approximately 1 hours prior to the EP procedure. . Measurements will continue as patient is moved to the operating room. Once the EP procedure is complete, the subject will be transferred from the operating room to a hospital room, where they will stay overnight. Measurements will be made for 3-5hours post-operation.Detailed analysis will investigate how does AleriTM data correlate with known measures such as saline volume/rate, urine production volume, USG, Blood osmolality and body weight;"
62636099|NCT03685097||Cardiac surgery patients|Patients undergoing elective cardiac surgery requiring cardiopulmonary bypass.
62068164|NCT02047565|EXPERIMENTAL|Part 1 - 180mg edoxaban|Treatment B: single oral dose of 180 mg edoxaban (3 × 60 mg tablet)
62068165|NCT02047565|EXPERIMENTAL|Part 2 - 60mg edoxaban and 50 IU/kg Beriplex P/N|Dose cohort 1: 60 mg edoxaban + 50 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
62068166|NCT02047565|EXPERIMENTAL|Part 2 - 60mg edoxaban and 20 IU/kg Beriplex P/N|Dose cohort 2: 60 mg edoxaban + 25 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
62068167|NCT02047565|EXPERIMENTAL|Part 2 - 60mg edoxaban and 10 IU/kg Beriplex P/N|Dose cohort 3: 60 mg edoxaban + 10 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
62068168|NCT00260819|EXPERIMENTAL|1|Experimental and Placebo Comparator administered in random order during to successive experimental phase
62068169|NCT00260819|PLACEBO_COMPARATOR|2|Experimental and Placebo Comparator administered in random order during to successive experimental phase
62068170|NCT02163655|PLACEBO_COMPARATOR|PLACEBO|PLACEBO: placebo, oral, every 24 hours for maximum 5 days
62068171|NCT02163655|EXPERIMENTAL|FUROSEMIDE|FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days
62068172|NCT01923896|EXPERIMENTAL|Behavioral Intervention & DCS|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and D-cycloserine (0.7mg/kg DCS) to be taken acutely one hour prior to the onset of the first treatment session each day
62068173|NCT01923896|ACTIVE_COMPARATOR|Behavioral Intervention & Placebo|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and placebo (lactose powder) by method of intake (bottle; formula; tube)
62068174|NCT03939247|OTHER|"Conventional PT treatment (CPT)"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching;
62068175|NCT03939247|EXPERIMENTAL|"CPT + Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an active Tecaretherapy is also provided during the sessions
62068176|NCT03939247|SHAM_COMPARATOR|"CPT + Placebo Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an inactive Tecaretherapy is also provided during the sessions
62068177|NCT02576782|ACTIVE_COMPARATOR|perineural dexamethasone group|21 patients received perineural dexamethasone plus bupivacaine 0.5%
62068178|NCT02576782|ACTIVE_COMPARATOR|systemic dexamethasone group|21 patients received systemic (intravenous) dexamethasone plus perineural bupivacaine 0.5%
62068179|NCT02576782|SHAM_COMPARATOR|control group|21 patients received only perineural bupivacaine 0.5% plus intravenous saline
62068180|NCT01468532|EXPERIMENTAL|Treatment (chemotherapy, receptor agonist)|Patients receive pasireotide IM, 40 mg on day 1, docetaxel 75mg/m2 IV over 1 hour, and prednisone 5mg PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62272874|NCT06392880|EXPERIMENTAL|Mulligan mobilization|Mulligan mobilization will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
62272875|NCT06392880|OTHER|Control|Participants will practice various weight-bearing active ankle motions.
62287070|NCT00836550|EXPERIMENTAL|Video|
62453783|NCT01785836|EXPERIMENTAL|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
62068181|NCT01362556|PLACEBO_COMPARATOR|Sodium Chloride|Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
62068182|NCT01362556|ACTIVE_COMPARATOR|Sodium Bicarbonate|Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
62068183|NCT02111837|PLACEBO_COMPARATOR|Standard infant formula|Standard infant formula fed ad libitum
62068184|NCT02111837|EXPERIMENTAL|Standard infant formula with PL1|Standard infant formula enriched with PL1 lipid fraction fed ad libitum
62068185|NCT02111837|EXPERIMENTAL|Standard infant formula with PL2|Standard infant formula enriched with PL2 lipid fraction fed ad libitum
62068186|NCT00332332|EXPERIMENTAL|etanercept|Open label etanercept 50 mg twice weekly subcutaneously (SC) for 3 months followed by 50 mg twice a week week SC for 9 months, for a total treatment period of 12 months.
62068187|NCT00251927|ACTIVE_COMPARATOR|1|Surgery
62068188|NCT00251927|EXPERIMENTAL|2|Esomeprazole (NEXIUM) therapy
62068189|NCT02829333|OTHER|Group GA|22 patients receive general anesthesia and patient controlled intravenous analgesia
62068190|NCT02829333|OTHER|Group SA|22 patients receive spinal anesthesia and continuous postoperative epidural analgesia
62068191|NCT05666687|EXPERIMENTAL|Cohort 1|MIJ821, starting dose
62272876|NCT02123485|EXPERIMENTAL|low frequency rTMS|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
62453784|NCT01785836|ACTIVE_COMPARATOR|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
62453785|NCT00560235|EXPERIMENTAL|1|
62453786|NCT02048865|ACTIVE_COMPARATOR|Apixaban|2.5 mg BID for 6 months
62453787|NCT02048865|PLACEBO_COMPARATOR|Placebo drug|2.5 mg BID for 6 months
62453788|NCT03056274|ACTIVE_COMPARATOR|Metformin arm|Metformin
62453789|NCT03056274|ACTIVE_COMPARATOR|Ursodeoxycholic acid|Ursodeoxycholic acid
62453790|NCT04572100|EXPERIMENTAL|Group A - Low Risk|Participants who have low-risk cancer and significant reduction (greater than 50%) in tumor size following induction therapy will be assigned to this group.
62068192|NCT05666687|EXPERIMENTAL|Cohort 2|MIJ821, dose will be defined based on the results of the previous cohort(s).
62068193|NCT05666687|EXPERIMENTAL|Cohort 3|MIJ821, dose will be defined based on the results of the previous cohort(s).
62068194|NCT05666687|EXPERIMENTAL|Cohort 4|MIJ821, dose will be defined based on the results of the previous cohort(s).
62068195|NCT05666687|EXPERIMENTAL|Cohort 5|MIJ821, dose will be defined based on the results of the previous cohort(s).
62068196|NCT05919147|EXPERIMENTAL|Pioglitazone|
62068197|NCT05919147|PLACEBO_COMPARATOR|Placebo|
62068198|NCT00332683|ACTIVE_COMPARATOR|Control|Patients randomly assigned to this group will have no changes in the ETT during surgery
62068199|NCT00332683|EXPERIMENTAL|Treatment group|Patients in this group will undergo same surgery as control group but with a monitoring and manipulation of ETT pressure
62272877|NCT02123485|SHAM_COMPARATOR|Sham-rTMS|Sham right prefrontal rTMS 2 times a week
62272878|NCT05988151||New surgical approach (Fibonacci ratio)|Agroup of 60 patients who underwent VaGinoplasti+ labioplasty ( wedge resection) with fibonacci ratio surgical ratio.
62272879|NCT05988151||Classical surgical approach (control group)|A group of 30 patients who underwent Vaginoplasty + Labioplasty( wedge resection) with classical surgical approach.
62272880|NCT01489514||Peanut allergic subjects|
62453791|NCT04572100|EXPERIMENTAL|Group B - Intermediate Risk|Participants who have low-risk cancer and intermediate reduction (30-50%) in tumor size or high-risk cancer with significant reduction (greater than or equal to 50%) in tumor size following induction therapy will be assigned to this group.
62453792|NCT04572100|EXPERIMENTAL|Group C - High-Risk|Participants who have high-risk cancer and less than a 50% reduction in their tumor size following induction therapy will be assigned to this group.
62453793|NCT04572100|EXPERIMENTAL|Induction Therapy (Carboplatin and Paclitaxel)|All study participants will be assigned to this group to first receive induction therapy using a combination of carboplatin and paclitaxel. Participant response to this phase of therapy will determine which group (low-risk, intermediate risk or high-risk) the participant will be in.
62068200|NCT02442635|EXPERIMENTAL|Condition 1|Yoga Breathing
62068201|NCT02442635|EXPERIMENTAL|Condition 2|Static Yoga
62068202|NCT02442635|EXPERIMENTAL|Condition 3|Flowing Yoga
62068203|NCT02176681|ACTIVE_COMPARATOR|Insulin alone|Use the usual frequency and dose
62068204|NCT02176681|EXPERIMENTAL|Insulin and Vildagliptin|vildagliptin 50 mg/day during 3 months
62068205|NCT01806740|EXPERIMENTAL|Gadoterate meglumine|there is one single arm of patients (no comparative arm)
62068206|NCT05241561|EXPERIMENTAL|Cabozantinib|
62068207|NCT06624046|OTHER|Single arm|Sleep stability intervention
62272881|NCT06344078||patients operated for acute diverticulitis|patient with acute diverticulitis which are operated in urgency setting
62272882|NCT00085371|EXPERIMENTAL|Treatment (triapene)|Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62272883|NCT05654129|OTHER|F1-F2 NAFLD|Patients with NAFLD stage 1 or 2 confirmed by a biopsy less than 1 year old
62272884|NCT05654129|OTHER|F3-F4 NAFLD|Patients with NAFLD stage 3 or 4 confirmed by a biopsy less than 1 year old
62453794|NCT02222428|EXPERIMENTAL|BI 1744 CL/BI 54903 XX FDC|
62453795|NCT02222428|ACTIVE_COMPARATOR|BI 54903 XX|
62453796|NCT02222428|ACTIVE_COMPARATOR|BI 1744 CL|
62453797|NCT02314338|EXPERIMENTAL|Pulmonary rehabilitation|Multi-disciplinary pulmonary rehabilitation
62461520|NCT04320173|EXPERIMENTAL|Lidocaine Patch (Sequence CAB)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 2, 3 lidocaine 5% medicated plasters were applied in Period 1, and 3 lidocaine 1.8% patches were applied in Period 2, and 3 lidocaine 5% patches were applied in Period 3.
62272885|NCT02926209|ACTIVE_COMPARATOR|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
62636100|NCT04092738|EXPERIMENTAL|Intervention Group|"In the intervention group, subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2. In addition, participants will be provided with an external movement sensor that will be linked to the Walk@WalkApp-Diab for Android and iOS. This App will monitor the time participants spend sitting, walking and standing during working hours. It will also provide participants with strategies to sit less and move more at work throughout 13 weeks. This mHealth intervention aims to change occupational sitting by replacing desk-based activities by active tasks."
62272886|NCT02926209|ACTIVE_COMPARATOR|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
62636101|NCT04092738|NO_INTERVENTION|Control Group|Subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2.
62272887|NCT05449600|EXPERIMENTAL|Participant|Tegaderm™ tape, Kind™ removal tape, and Thermotape will be applied to both of the participant's forearms.
62272888|NCT05449600|NO_INTERVENTION|Researcher|
62068208|NCT01679236|ACTIVE_COMPARATOR|Mindfulness Training for Smokers|Mindfulness Training for Smokers (MTS) is a 7-week intervention that provides instruction in mindfulness very similar to the way it is taught in Mindfulnes-Based Stress Reduction. In addition MTS provides mindfulness training targeted to specific smoking relapse challenges. The MTS intervention was designed around a weekly curriculum that provides instruction to help participants learn practices including mindfulness meditation, mindful walking and mindful eating. MTS participants are instructed to practice meditation 30 minutes per day with a guided meditation CD.
62272889|NCT01016639|EXPERIMENTAL|Chemoradiotherapy|
62272890|NCT01920204|EXPERIMENTAL|Midostaurin|Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.
62272891|NCT01687712|EXPERIMENTAL|AFOLIA|One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
62272892|NCT01687712|ACTIVE_COMPARATOR|Gonal-f® RFF|One subcutaneous injection of 225IU Gonal-f® RFF (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
62636102|NCT03323112||Influenza vaccine recipients|Health care workers vaccinated by their occupational health care according to the routine praxis.
62272893|NCT02937350|EXPERIMENTAL|Study Population|D6-25-hydroxyvitamin D3
62272894|NCT01489527|ACTIVE_COMPARATOR|Gardasil Vaccine Administration|Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
62272895|NCT01489527|PLACEBO_COMPARATOR|Placebo Administration|Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
62068209|NCT01679236|ACTIVE_COMPARATOR|Interactive Learning for Smokers|Interactive Learning for Smokers (ILS) is a 7-week intervention that provides a closely matched active control group for MTS, but with substantive education and skills training for smoking cessation. To this end, ILS combines elements of two smoking cessation programs, the American Lung Association, Freedom from Smoking program and The Mayo Clinic Nicotine Dependence Center program. ILS participants were asked to practice 30 minutes of silent non-directed walking per day throughout the intervention and were instructed to use non-directed walking for relaxation, stress reduction and as a strategy for managing urges and withdrawal symptoms.
62068210|NCT02841293|EXPERIMENTAL|Arm with biological mesh|The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm)
62068211|NCT02841293|ACTIVE_COMPARATOR|Arm with primary perineal wound closure|The intervention consists of perinal reconstruction by primary perineal wound closure
62272896|NCT02158780|EXPERIMENTAL|Scrotal Orchidopexy|Single incision
62068212|NCT04904068||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease.
62068213|NCT04904068||Healthy|Healthy individuals with no known neurological disorders.
62068214|NCT04022837|EXPERIMENTAL|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
62068215|NCT04022837|EXPERIMENTAL|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
62272897|NCT02158780|OTHER|Inguinal Orchidopexy|Double Incision (Standard)
62272898|NCT02800200|EXPERIMENTAL|Platelet rich plasma|The ultrasoud-guided injection with Platelet rich plasma (3cc) was perfomed in both groups.
62272899|NCT02800200|EXPERIMENTAL|Active shock wave|One-session active shock wave 2 weeks later after PRP injection was performed in intervention group.
62272900|NCT02800200|PLACEBO_COMPARATOR|Sham shock wave|One-session sham shock wave 2 weeks later after PRP injection was performed in control group.
62453798|NCT04438356|EXPERIMENTAL|M-health|After the acute myocardial infarction, patients will be randomly assigned to the intervention group. Give the intervention group mobile health care programs and given Garmin monitoring hands ring. In order to give patients clear walking goals and exercise intensity, the intervention group will use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
62453799|NCT04438356|EXPERIMENTAL|wait list control|wait list control for 3 months and then use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
62636103|NCT02550743|EXPERIMENTAL|Dose 1|BYL719, capectabine and radiation Dose BYL719: 200mg/day
62636104|NCT02550743|EXPERIMENTAL|Dose 2|BYL719, capectabine and radiation Dose BYL719: 250mg/day
62272901|NCT01819779|ACTIVE_COMPARATOR|Exforge tab. 10/160mg|"* amlodipine besylate (10mg as amlodipine)~* valsartan 160mg"
62272902|NCT01819779|EXPERIMENTAL|Lodivixx tab. 5/160mg|"* S-amlodipine nicotinate (5mg as S-amlodipine)~* valsartan 160mg"
62287071|NCT06298071|EXPERIMENTAL|Group 1|Injection; strength: 4mg.
62272903|NCT02190851|EXPERIMENTAL|electrical nerve stimulation (TENS)|"Two electrodes are attached around the internal malleolus and connected to the TENS unit, by UROSTIM 2.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
62272904|NCT02190851|PLACEBO_COMPARATOR|Control group|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
62272905|NCT03178487|EXPERIMENTAL|Upadacitinib 15 mg|Participants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
62272906|NCT03178487|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
62272907|NCT04208477|EXPERIMENTAL|BSG patients|
62636105|NCT02550743|EXPERIMENTAL|Dose 3|BYL719, capectabine and radiation Dose BYL719: 300mg/day
62453800|NCT05450770|ACTIVE_COMPARATOR|HIV+ GROUP|"Subjects included in the ANRS EP 46 NOVAA trial:~• 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \> 350/mm3 and a viral load \<50 copies / mL for at least 6 months)."
62636106|NCT02550743|EXPERIMENTAL|Dose -1|BYL719, capectabine and radiation Dose BYL719: 150mg/day
62272908|NCT04492683|EXPERIMENTAL|Disease group|One active patch and one control patch applied to subjects with clinical symptoms suggestive of non-IgE mediated CMA
62272909|NCT04492683|EXPERIMENTAL|Control group|One active patch and one control patch applied to subjects without any history of allergic disease
62272910|NCT04824586|EXPERIMENTAL|Insulin infusion regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin infusion regimen.~Fast-acting human insulin (Actrapid®) was used in this group."
62287072|NCT06298071|EXPERIMENTAL|Group 2|Injection; strength: 8mg.
62636107|NCT01493895|ACTIVE_COMPARATOR|control group,|The control group will be treated with a sham B-cure laser machine, emitting only green indicator light and no 808nm laser.
62636108|NCT01493895|EXPERIMENTAL|study, LLLT-808 B-cure laser machine|The study group will be treated with the LLLT-808 B-cure laser machine, emitting the 808nm laser beam together with a green indicator light.
62068216|NCT03363659|EXPERIMENTAL|DSF-Cu with temozolomide and radiation|Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles
62068217|NCT01758874|NO_INTERVENTION|Non phlebotomy group (control group)|"• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation.~We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups.~Non phlebotomy arm has no phlebotomy treatment."
62068218|NCT01758874|EXPERIMENTAL|PH (study group)|"The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.~Procedures for therapeutic phlebotomy~1. Inject heparin 5000 units to prevent blood clot during phlebotomy~2. Inject volume expander equivalent to 5% of blood volume~3. Remove 5% of whole blood~4. Monitor the vital sign of the patient during the phlebotomy~They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc.~We will compare amputation and mortality between control and study groups."
62272911|NCT04824586|EXPERIMENTAL|Insulin bolus regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin bolus regimen.~Fast-acting human insulin (Actrapid®) was used in this group."
62287073|NCT06298071|EXPERIMENTAL|Group 3|Injection; strength: 12mg.
62068219|NCT05204641|ACTIVE_COMPARATOR|Fecal microbiota transplant|"Pretreatment with rifaximin 3x 400 mg PO for 7 days Fecal Microbiota Transfer from healthy donor during colonoscopy. Assessments in clinical scales: 30 days, 90 days and 12 months: Unified Parkinson Disease Rating Scale, Constipation Assessment Scale, Parkinson Disease Questionnaire-39, Non- Motor Symptoms Questionnaire, Gastrointestinal Dysfunction Scale for Parkinson Disease.~Assessment of levodopa/benserazide 200+50 mg tablet before and 30 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention"
62636109|NCT01985503||Phase 1 group|Subjects were studied in 2009 and their follow-up is in 2014.
62272912|NCT02686086|PLACEBO_COMPARATOR|Standard hospital jet nebuliser|"Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a standard hospital jet nebuliser.~Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation."
62636110|NCT01985503||Phase 2 group|Subjects were studied in 2011 and their follow-up is in 2016.
62636111|NCT06344715|EXPERIMENTAL|Cohort S1|SL-T10 (3mg, multiple injections, IM), GX-I7 (320 ug 2 injections, IM)
62636112|NCT06344715|EXPERIMENTAL|Cohort S2|SL-T10 (6mg, multiple injections, IM), GX-I7 (320 ug 2 injections, IM)
62636113|NCT06344715|EXPERIMENTAL|Cohort a'|SL-T10 (3mg, multiple injections, IM), GX-I7 (320 ug 2 injections, IM), Pembrolizumab
62636114|NCT06344715|EXPERIMENTAL|Cohort A|SL-T10 (6mg, multiple injections, IM), GX-I7 (320 ug 2 injections, IM), Pembrolizumab
62636115|NCT06344715|EXPERIMENTAL|Cohort B|SL-T10 (6mg, multiple injections, IM) GX-I7 (720 ug 2 injections, IM) Pembrolizumab
62636116|NCT06344715|EXPERIMENTAL|Cohort C|SL-T10 (6mg, multiple injections, IM), GX-I7 (960 ug 2 injections, IM), Pembrolizumab
62636117|NCT01699724|ACTIVE_COMPARATOR|JZoloft|Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft ® tablet) 50 mg as a single oral dose under fasted conditions
62636118|NCT01699724|EXPERIMENTAL|ODT without water|sertraline ODT 50 mg without water as a single oral dose under fasted conditions
62636119|NCT01699724|EXPERIMENTAL|ODT with water|sertraline ODT 50 mg with water as a single oral dose under fasted conditions
62068220|NCT05204641|PLACEBO_COMPARATOR|Autotransplant of patients microbiota|"Pretreatment with rifaximin 3x 400 mg PO for 7 days Autotransplant of patients own microbiota collected in screening period during colonoscopy.~Assessments in clinical scales: 30 days, 90 days and 12 months: Unified Parkinson Disease Rating Scale, Constipation Assessment Scale, Parkinson Disease Questionnaire-39, Non- Motor Symptoms Questionnaire, Gastrointestinal Dysfunction Scale for Parkinson Disease.~Assessment of levodopa/benserazide 200+50 mg tablet before and 30 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention"
62068221|NCT00612157|ACTIVE_COMPARATOR|OSA CPAP|
62068222|NCT00612157|PLACEBO_COMPARATOR|Placebo|
62068223|NCT03655990||Treatment with the JUVORA™ Dental Disc|Subjects receive the device as per normal standard practice, there are no other treatment arms for this prospective study.
62068224|NCT04446715|EXPERIMENTAL|Sufentanil Group|Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia
62068225|NCT04446715|EXPERIMENTAL|Meperidine Group|Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia
62068226|NCT03924713||Community Health Worker|"1. initial comprehensive health, behavioral, and social needs assessment;~2. development of an individualized 'action plan' to address identified needs;~3. linkage to necessary services and work with neighborhood-based health care and social services organization to address each individual's unique needs; and 4) provide follow-up support as needed."
62068227|NCT03924713||Usual Health Plan Services|1) receipt of other plan services besides the CHW program for which they are eligible.
62636120|NCT02631317||rt-PA|patients treated with rt-PA, followed strategies were used: advance hospital notification by EMS, stroke team notification, key performance indicators feedback form, standard informed consent procedures, performance of thrombolysis at CT-room.
62636121|NCT02884739||schizophrenia|
62068228|NCT02751463|EXPERIMENTAL|BAY987519|All subjects are patched .
62068229|NCT00819403|ACTIVE_COMPARATOR|simvastatin|Simvastatin 40 mg daily
62068230|NCT00819403|ACTIVE_COMPARATOR|simvastatin/ezetimibe|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
62068231|NCT00154310|EXPERIMENTAL|Everolimus + Mycophenolate sodium|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued throughout the first year. Cyclosporine withdrawal started from Month 4.5 post-transplant.
62068232|NCT00154310|ACTIVE_COMPARATOR|Cyclosporine + Mycophenolate sodium|Cyclosporine tablets orally twice a day to achieve protocol specific target levels and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
62068233|NCT02835846|EXPERIMENTAL|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
62068234|NCT00234156|ACTIVE_COMPARATOR|renal disease|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
62068235|NCT00234156|ACTIVE_COMPARATOR|normal|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
62068236|NCT00877903|EXPERIMENTAL|Prochymal®|Participants will receive Prochymal® single intravenous (IV) infusion at a dose of 200 x 10\^6 human mesenchymal stem cells (hMSC), reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10\^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.
62068237|NCT00877903|PLACEBO_COMPARATOR|Placebo|Participants will receive Prochymal® placebo-matching single IV infusion at a dose of of 200 x 10\^6 hMSC, reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10\^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.
62068238|NCT02302066|EXPERIMENTAL|Group 1 (TDV 2-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 91. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 365.
62453801|NCT05450770|OTHER|HIV- GROUP|"Subjects included in the ANRS EP 46 NOVAA trial:~• 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals."
62068239|NCT02302066|EXPERIMENTAL|Group 2 (TDV 1-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Day 1. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 91 and 365.
62272913|NCT02686086|ACTIVE_COMPARATOR|Vibrating mesh nebuliser|Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a vibrating mesh nebuliser (Aerogen Solo) rather than the standard hospital nebuliser Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.
62287074|NCT04957186|ACTIVE_COMPARATOR|Patient Focus Group|Group consisting of 10 patients who have undergone breast cancer surgery (tumorectomy, mastectomy, lymph node dissection).
62453802|NCT05390346|EXPERIMENTAL|college athletes|Screening Program of RED-S in College Athletes and Establish Diagnosis and Intervention Model
62453803|NCT03500848|ACTIVE_COMPARATOR|Tacrolimus-based group|Tacrolimus-based immunosuppression regimen: Tacrolimus+MMF and/or steroids
62453804|NCT03500848|EXPERIMENTAL|Sirolimus-based group|Sirolimus-based immunosuppression regimen: Tacrolimus (Tacrolimus elimination 30 (± 5) days post LT)+Sirolimus+MMF and/or steroids
62453805|NCT05717699|EXPERIMENTAL|Experimental Group|Multiple intratumoral injections of Ad-TD-nsIL12.
62636122|NCT02884739||chronic psychiatric disorder other than schizophrenia|
62636123|NCT04213391|EXPERIMENTAL|sulforaphane group|The patients will take sulforaphane for 24 weeks, 2550mg once a day.
62068240|NCT02302066|EXPERIMENTAL|Group 3 (TDV 1-Dose + Booster)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 365. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 91.
62068241|NCT02302066|PLACEBO_COMPARATOR|Group 4 (Placebo Control)|Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 1, 91 and 365.
62068242|NCT03562455|EXPERIMENTAL|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
62068243|NCT03562455|ACTIVE_COMPARATOR|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
62068244|NCT04031430|EXPERIMENTAL|telemonitoring group (TM)|telemonitoring group (TM)
62068245|NCT04031430|ACTIVE_COMPARATOR|Patient self-monitoring group (PSM)|Patient self-monitoring group (PSM)
62068246|NCT04031430|NO_INTERVENTION|control group (CC)|No intervention
62068247|NCT04031430|EXPERIMENTAL|CAPROM - Group 1|pregnant women randomly assigned to the TM group of PREMOM II
62068248|NCT04031430|EXPERIMENTAL|CAPROM - Group 2|pregnant women followed-up via TM group as part of their usual care
62068249|NCT00684762|EXPERIMENTAL|Cilostazol|A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
62068250|NCT00684762|EXPERIMENTAL|Pletal® (cilostazol)|A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
62068251|NCT00781066|EXPERIMENTAL|1|Controlled cord traction (CCT)
62068252|NCT00781066|ACTIVE_COMPARATOR|2|No CCT
62068253|NCT04235101|EXPERIMENTAL|SYD985 + Niraparib|SYD985, Intravenous, every 3 weeks (Q3W) Niraparib taken orally and either 100 mg, 200 mg or 300 mg once daily for either 1, 2 or 3 weeks.
62068254|NCT03734991|EXPERIMENTAL|Ibrexafungerp (SCY-078)|300 mg orally every 12 hrs for 1 day (2 doses in 1 day)
62068255|NCT03734991|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62068256|NCT06381011|SHAM_COMPARATOR|Sham Local Vibration Group|In addition to conventional treatment program the placebo local vibration application will be applied bilaterally to the cervicothoracic region of the patients in the placebo group. For the application, the patient will be placed in an upright sitting position, and the local vibration device will be moved without touching the patient's skin while it is operational.
62272914|NCT03453983|EXPERIMENTAL|Anodal tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
62272915|NCT03453983|SHAM_COMPARATOR|Sham tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
62272916|NCT04669834|OTHER|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program based on a recent systematic review in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators using clamshell exercise . No emphasis will be placed on stabilizing the core musculature before initiating any of those exercises.
62272917|NCT04669834|EXPERIMENTAL|group B|Patients in this group will receive the same program as group (A) plus core stability exercise , but the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
62453806|NCT04669210|ACTIVE_COMPARATOR|PTCY tacrolimus MMF|"Conditioning:~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os~GVHD prophylaxis:~cyclophosphamide 50 mg/kg day+3, +4 tacrolimus 0.03 mg/kg from day+5 to 100 mycophenolate mofetil 30 mg/kg from day+5 to 35"
62453807|NCT04669210|EXPERIMENTAL|PTCY ruxolitinib|"Conditioning:~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os ruxolitinib 5 mg tid days -7 to -2~GVHD prophylaxis:~cyclophosphamide 50 mg/kg day+3, +4 ruxolitinib 5 mg tid days +5 to +21 ruxolitinib 5 mg bid days +22 to +150"
62453808|NCT01694485|PLACEBO_COMPARATOR|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62453809|NCT01694485|EXPERIMENTAL|Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62453810|NCT01694485|EXPERIMENTAL|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62453811|NCT01694485|EXPERIMENTAL|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62453812|NCT01694485|EXPERIMENTAL|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
62453813|NCT01850290||Dopamine Imaging|
62453814|NCT05097872|ACTIVE_COMPARATOR|Real diet|Diet excluding the trigger nutrient identified by an acute mucosal reaction in CLE
62453815|NCT05097872|SHAM_COMPARATOR|Sham diet|Diet excluding a sham nutrient without acute mucosal reaction in CLE
62453816|NCT05097872|ACTIVE_COMPARATOR|Wheat exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
62453817|NCT05097872|ACTIVE_COMPARATOR|Soy exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
62453818|NCT06544304|EXPERIMENTAL|Experimental|PMMA (polymethylmethacrylate) 30% Biosimetric
62453819|NCT02184728|NO_INTERVENTION|EMMA(TM)|"A small capnograph for measuring ET-CO2 - the EMMA capnometer~1"
62453820|NCT02041702|EXPERIMENTAL|Cardiac MRI Scan Group|
62453821|NCT02041702|NO_INTERVENTION|Control Group|
62068257|NCT06381011|EXPERIMENTAL|Local Vibration Intervention Group|In addition to conventional treatment program the patients in this group will receive bilateral local vibration application on the cervicothoracic region, utilizing two different frequency values, 50 Hz and 100 Hz. Initially, a flat attachment will be placed on the device, and application will be performed on the neck and back regions for 5 minutes at a frequency of 50 Hz. Then, the other attachment of the device will be used, the frequency value will be increased to 100 Hz, and application will be performed on a total of 5 sensitive points specified by the manufacturer in the neck and back regions, with one minute per point for a total of 5 minutes. Local vibration will be applied to each side for ten minutes, totaling 20 minutes, and this will be conducted for five consecutive days. To determine which side to start the application from, a coin toss will be performed.
62636124|NCT04213391|PLACEBO_COMPARATOR|Placebo group|The patients will take placebo for 24 weeks, 2550mg once a day.
62068258|NCT03572855|EXPERIMENTAL|Scoliosis Brace|The Peak Scoliosis Brace designed to alleviate pain in adult patients with chronic pain secondary to scoliosis.
62068259|NCT02254421|EXPERIMENTAL|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
62068260|NCT02254421|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
62068261|NCT04997044|OTHER|control group|control group
62068262|NCT04997044|EXPERIMENTAL|Experimental group|selective dorsal rhizotomy group
62068263|NCT01918319|EXPERIMENTAL|Lifestyle intervention|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
62068264|NCT01918319|NO_INTERVENTION|Control|
62068265|NCT06446219||Upadacitinib(UPA)|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in Crohn's Disease at a cellular level by selectively inhibiting Janus kinase(JAK)1, a pathway integral to inflammatory cytokine production. This study focuses on its use as main therapy for Chinese patients unresponsive to conventional Crohn's Disease treatments, such as tumor necrosis factor-α inhibitor. Rinvoq is the marketed drugs for clinical use, whose oral dosage is 45 mg per day during the induction period and 15 mg/30 mg per day during maintenance period, and the induction period would last for 8 weeks.
62068266|NCT06446219||Vedolizumab(VDZ)|Vedolizumab, a monoclonal antibody targeting integrin α4β7, is used to inhibit recruitment of inflammatory cells. This drug is always used as second-line treatment for patients with moderate-to-severe active stage Crohn's Disease who fail to respond to conventional treatments such as tumor necrosis factor-α inhibitor. This study uses Vedolizumab as control group to illustrate the efficacy and safety of Upadacitinib in second-line treatment for Crohn's Disease. Entyvio is the marketed drugs for clinical use, should be given intra-arterially in week 0, 2, 6 and every subsequent 8 weeks.
62068267|NCT00526383|EXPERIMENTAL|A|antidepressant versus medical dispositive
62068268|NCT00526383|PLACEBO_COMPARATOR|B|
62068269|NCT04515667|EXPERIMENTAL|Mindfulness|
62068270|NCT04515667|PLACEBO_COMPARATOR|Control|
62068271|NCT01740102|EXPERIMENTAL|RIPC|Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
62068272|NCT01740102|NO_INTERVENTION|No RIPC|Patients in the control group will not receive remote ischemic preconditioning before the surgery.
62068273|NCT01976364|EXPERIMENTAL|Tofacitinib|
62068274|NCT01904214|EXPERIMENTAL|severe renal impairmnt|
62068275|NCT01904214|EXPERIMENTAL|moderate renal impairment|
62068276|NCT01904214|EXPERIMENTAL|mild renal impairment|
62068277|NCT01904214|EXPERIMENTAL|healthy subjects|
62068278|NCT01852656|ACTIVE_COMPARATOR|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
62272918|NCT02669017|EXPERIMENTAL|Part 1: ADCT-402 dose escalation|In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.
62272919|NCT02669017|EXPERIMENTAL|Part 2: ADCT-402 dose expansion|"In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.~Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W)."
62272920|NCT03368651|EXPERIMENTAL|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
62272921|NCT03368651|NO_INTERVENTION|control group|no neo-adjuvant treatment before operation
62068279|NCT01852656|ACTIVE_COMPARATOR|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
62068280|NCT01852656|ACTIVE_COMPARATOR|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
62068281|NCT01610232|EXPERIMENTAL|LED Group|Phototherapy associated with treadmill training
62068282|NCT01610232|ACTIVE_COMPARATOR|Exercise Group|Treadmill training
62068283|NCT01610232|NO_INTERVENTION|Sedentary Group|Neither physical training nor phototherapy
62068284|NCT02777996|ACTIVE_COMPARATOR|Screening arm|Low Dose Computed Tomography offered at baseline and for 3 repeated rounds
62068285|NCT02777996|NO_INTERVENTION|Passive Arm|Eligible subjects were randomized to follow up in usual care (in Europe lung cancer screening is not raccomended), according with the GP.
62272922|NCT02901288|EXPERIMENTAL|experimental group1|"The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily)."
62272923|NCT02901288|EXPERIMENTAL|experimental group2|The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.
62272924|NCT02901288|ACTIVE_COMPARATOR|Control regimen group|"The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily).~."
62272925|NCT03927105|EXPERIMENTAL|Nivolumab + Cabiralizumab|Nivolumab 240mg IV + Cabiralizumab 4mg/kg on day 1 of every 14 day cycle.
62272926|NCT02204696||Tonsillectomy|All participants will undergo baseline sleep study, a second preoperative sleep study after a period of watchful waiting, and a postoperative sleep study.
62068286|NCT04000932|EXPERIMENTAL|Platelet rich plasma (PRP) -T lab PRP kit|A single 1ml PRP extract injection will be will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel. performed once into the carpal tunnel in the wrist . PRP will be obtained by centrifugation of autologous anticoagulated whole blood.
62068287|NCT04000932|ACTIVE_COMPARATOR|Diprospan ®, Schering Plough|A single steroid injection (1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel.
62068288|NCT00877578|EXPERIMENTAL|1|Nutri-Energie ®, a cake of high caloric density and palatability, twice a day for 4 weeks, in addition to an enriched diet.
62068289|NCT00877578|ACTIVE_COMPARATOR|2|Clinutren 1.5 ® standard isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet.
62636125|NCT06434194|ACTIVE_COMPARATOR|Serrantor|Subjects randomized to the Serranator Arm of the study will be treated with the Serranator PTA Serration Balloon
62068290|NCT02762734|EXPERIMENTAL|MEDIA|"The patient will benefit of the usual care with additional text message (SMS or mail or other new media). The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt."
62068291|NCT02762734|NO_INTERVENTION|CLASSIC|The patient will benefit of the usual care.
62068292|NCT00545363|EXPERIMENTAL|Bone Marker Feedback (BMF) Participants|"Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A BMF-form will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake."
62068293|NCT00545363|ACTIVE_COMPARATOR|No BMF Participants|Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants will be supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
62068294|NCT00847821||Bazedoxifene 10 mg/CE 0.625 mg|
62068295|NCT00847821||Bazedoxifene 20 mg/CE 0.625 mg|
62068296|NCT00847821||Bazedoxifene 40 mg/CE 0.625 mg|
62068297|NCT00847821||Bazedoxifene 10 mg/CE 0.45 mg|
62068298|NCT00847821||Bazedoxifene 20 mg/CE 0.45 mg|
62636126|NCT06434194|ACTIVE_COMPARATOR|PTA|Subjects randomized to the PTA Arm of the study will be treated with a standard of care percutaneous transluminal angioplasty (PTA) balloon.
62068299|NCT00847821||Bazedoxifene 40 mg/CE 0.45 mg|
62068300|NCT00847821||Raloxifene 60 mg|
62068301|NCT00847821||Placebo|
62068302|NCT04607824||Duchenne Muscular Dystrophy group|Forty-five male subjects were included in the Duchenne Muscular Dystrophy (DMD) group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer.
62068303|NCT04607824||Typical Development group|Forty-five male subjects were included in the healthy Typical Development (TD) control group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer
62068304|NCT00278590|EXPERIMENTAL|allogeneic stem cell transplantation|allogeneic stem cell transplantation will be performed
62068305|NCT02568332|EXPERIMENTAL|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10\^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10\^8 pfu at week 8.~Subjects: 20 HIV seropositive individuals"
62068306|NCT01084967||Healthy lean control group|"The healthy lean controls consisted of age-, sex- and geography-matched young volunteers, or golden standard lean controls from China Cardiometabolic Disease and Cancer Cohort Study (4C Study).~Healthy volunteers:~1. BMI:18.5-22.9kg/m2;~2. Age:14-30 years old;~3. To be proved normal by the examinations of liver and kidney function,blood lipids profile,FBG, PBG, fasting insulin and HbA1c.~Controls from 4C Study:~1. 17.0≤BMI≤23.0kg/m2 and waist circumference \<85cm for males and \<80cm for females;~2. 1.8≤LDL-c≤3.4mmol/l;~3. FBG\<6.1, PBG\<7.8;~4. HOMA-IR\<2.5;~5. BP \<140/90mmHg;~6. eGFR\>60mL/(min·1.73 m2), ALT\<40IU/L, AST\<40IU/L;~7. Excluding the history of hyperthyroidism, digestive system diseases, malignant tumors, infectious diseases (hepatitis B) and other systemic wasting diseases; Severe dysfunction of heart, lung and kidney;~8. Not using antihypertensive, hypoglycemic and lipid-lowering drugs；~9. No history of smoking."
62636127|NCT00700375|EXPERIMENTAL|Sodium bicarbonate|
62636128|NCT00700375|EXPERIMENTAL|Sodium chloride|
62636129|NCT03141112||early CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy up to 48 hours after reaching criteria of severe sepsis.
62636130|NCT03141112||late CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy after 48 hours after reaching criteria of severe sepsis.
62636131|NCT01961414|EXPERIMENTAL|Aflibercept|All patients will receive aflibercept 2.0mg intravitreal injection
62636132|NCT05893862|EXPERIMENTAL|Sequence 1: MK-8189 (Treatment A)→Moxifloxacin (Treatment B)→Placebo (Treatment C)|Participants receive a sequence of Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3; there will be a 5-day washout between periods. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2.
62636133|NCT05893862|EXPERIMENTAL|Sequence 2: Moxifloxacin (Treatment B) →Placebo (Treatment C) →MK-8189 (Treatment A)|Participants receive a sequence of Treatment B in Period 1 followed by Treatment C in Period 2 followed by Treatment A in Period 3; there will be a 5-day washout between periods. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2.
62272927|NCT01425203|EXPERIMENTAL|RGT BOC + PR|Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
62272928|NCT01425203|PLACEBO_COMPARATOR|PBO + PR (Control)|Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
62272929|NCT01425203|EXPERIMENTAL|Crossover Arm|Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.
62636134|NCT05893862|EXPERIMENTAL|Sequence 3: Placebo (Treatment C) →MK-8189 (Treatment A) →Moxifloxacin (Treatment B)|Participants receive a sequence of Treatment C in Period 1 followed by Treatment A in in Period 2 followed by Treatment B in Period 3; there will be a 5-day washout between periods. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2.
62636135|NCT05893862|EXPERIMENTAL|Sequence 4: Moxifloxacin (Treatment B) → MK-8189 (Treatment A) → Placebo (Treatment C)|Participants receive a sequence of Treatment B in Period 1 followed by Treatment A in Period 2 followed by Treatment C in Period 3; there will be a 5-day washout between periods. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2.
62636136|NCT05893862|EXPERIMENTAL|Sequence 5: MK-8189 (Treatment A) →Placebo (Treatment C) →Moxifloxacin (Treatment B)|Participants receive a sequence of Treatment A in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3; there will be a 5-day washout between periods. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2.
62636137|NCT05893862|EXPERIMENTAL|Sequence 6: Placebo (Treatment C) →Moxifloxacin (Treatment B) → MK-8189 (Treatment A)|Participants receive a sequence of Treatment C in Period 1 followed by Treatment B in Period 2 followed by Treatment A in Period 3; there will be a 5-day washout between periods. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2.
62636138|NCT01380418||Study group|Obese BMI\>30 18-85 years old
62636139|NCT00419757|ACTIVE_COMPARATOR|Symbicort|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
62636140|NCT00419757|ACTIVE_COMPARATOR|Budesonide|budesonide HFA pMDI 160 μg x 2 actuations twice daily
62636141|NCT01439243|EXPERIMENTAL|Investigational Test Product|Donepezil 10 mg Tablets
62636142|NCT01439243|ACTIVE_COMPARATOR|Reference Listed Drug|Aricept® 10 mg Tablets
62636143|NCT06258434||high risk CRC screening group|Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer or CRC patients
62272930|NCT02651363||Patients treated with Dolocordralan|
62272931|NCT04953312|EXPERIMENTAL|COVID-19 patients (group 1)|Patients with a recent diagnosis (\<7 days since first symptoms) of moderate or severe COVID-19
62272932|NCT04953312|EXPERIMENTAL|Chronic myeloid malignancies (group 2)|Adults with chronic myeloid malignancies including myelodysplastic syndromes with low risk MDS ; high risk MDS according to IPSS-R or with dysplastic or proliferative chronic myelomonocytic leukemia according to WHO2016
62272933|NCT04953312|OTHER|Control group (group 3)|Age-matched healthy donors
62272934|NCT01637233||NRTI + PI|This is the randomisation of the main study, Arm 1
62272935|NCT01637233||maraviroc + PI|this is the randomisation of the main study, Arm 2
62272936|NCT01637233||maraviroc + NRTI|this is the randomisation of the main study, Arm 3
62272937|NCT02859935|NO_INTERVENTION|Control group|The control group will receive standard care - 3 monthly STI screening, motivational interviewing and counselling. Both groups will get questionnaires on mental health problems: ADHD, depression, anxiety disorder, alexithymia and sex and drug addiction.
62272938|NCT02859935|OTHER|Intervention group|The intervention group will receive -besides standard care- additional questionnaires depending on their baseline questionnaires and in case of an indication for mental health problems, feedback and referral to relevant mental health and addiction care will be provided.
62272939|NCT03252483|ACTIVE_COMPARATOR|HIV Only|Those randomized to the control group were offered only an HIV test.
62272940|NCT03252483|EXPERIMENTAL|Bundled HCV/HIV|Those randomized to the intervention group were offered both HCV and HIV test.s
62272941|NCT00653822|EXPERIMENTAL|1a|IV
62272942|NCT00653822|PLACEBO_COMPARATOR|1b|IV
62272943|NCT00653822|EXPERIMENTAL|2a|Lower SC dose
62272944|NCT00653822|PLACEBO_COMPARATOR|2b|SC to match lower dose
62272945|NCT00653822|EXPERIMENTAL|3a|Higher SC dose
62272946|NCT00653822|PLACEBO_COMPARATOR|3b|SC to match higher dose
62272947|NCT05512533|EXPERIMENTAL|BF-UC290F for diagnosing PPLs|Thin EBUS endoscope is inserted and used to visualize peripheral pulmonary lesions, and biopsies will be conducted by EBUS-TBNA.
62272948|NCT00381771||Objective salivary function|"Based on the salivary scintigraphy,~1. Objective salivary normo-function~2. Objective salivary dysfunction"
62272949|NCT06149858|EXPERIMENTAL|sublay|patients with ventral hernia operated as sublay mesh repair positioning of mesh under sheath
62636144|NCT06258434||CRC group|Prospective enrollment of subjects with confirmed colorectal cancer
62636145|NCT01801709|EXPERIMENTAL|AAVrh.10cuARSA|intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.
62636146|NCT04953195|EXPERIMENTAL|levothyroxine sodium|levothyroxine sodium
62636147|NCT00227539|EXPERIMENTAL|Neoadjuvant therapy, PET scan and surgery|
62636148|NCT05943470|ACTIVE_COMPARATOR|daily|daily use of one exchange of icodextin as long dwell
62068307|NCT01084967||obesity group|"1. BMI ≥30kg/m2;~2. Age:14-30 years old; obesity group 4000, lean healthy control group 4000"
62068308|NCT03354130|ACTIVE_COMPARATOR|Tofu control|Volunteers will consume a vegetarian diet containing tofu during 3 days for 5 meals in total
62068309|NCT03354130|EXPERIMENTAL|Non-processed pork diet|Volunteers will consume a diet containing non-processed pork during 3 days for 5 meals in total
62068310|NCT03354130|EXPERIMENTAL|Bacon diet|Volunteers will consume a diet containing bacon during 3 days for 5 meals in total
62068311|NCT03354130|EXPERIMENTAL|Sausage diet|Volunteers will consume a diet containing sausage during 3 days for 5 meals in total
62068312|NCT03354130|EXPERIMENTAL|Dry-cured sausage diet|Volunteers will consume a diet containing dry-cured sausage during 3 days for 5 meals in total
62068313|NCT04178538|EXPERIMENTAL|25 years and older- ACL recon with DBM, Internal brace|Patients in this arm will be 25 years of age and over and receive ACL reconstruction augmented with demineralized bone matrix, bone marrow, and internal brace
62272950|NCT06149858|EXPERIMENTAL|laparoscopic|patients with ventral hernia operated as laparoscopic repair positioning TAPP mesh
62272951|NCT02672566|EXPERIMENTAL|Experimental group : enoxaparin|Experimental group will take enoxaparin (4000 Ui / Day) and will benefit from the usual care.
62272952|NCT02672566|ACTIVE_COMPARATOR|Control group|The control group will only benefit from the usual care.
62272953|NCT01736579|EXPERIMENTAL|IGIV, 10% at 0.2 g/kg body weight|IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
62272954|NCT01736579|EXPERIMENTAL|IGIV, 10% at 0.4 g/kg body weight|IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months
62272955|NCT01635114|ACTIVE_COMPARATOR|resVida (resveratrol)|
62272956|NCT01635114|PLACEBO_COMPARATOR|Placebo|
62636149|NCT05943470|EXPERIMENTAL|alternative day|alternative day use of one exchange of icodextin as long dwell
62636150|NCT01944436||Parkinson's Disease Dementia|"Participants in the Parkinson's Disease Dementia group:~* Must be taking a stable parkinsonian medication~* Must have a diagnosis of clinically definite Parkinson's disease \>1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.~* Response to cholinesterase inhibitor over a period of six months will be monitored."
62636151|NCT01944436||Dementia with Lewy Bodies|"Participants in the Dementia with Lewy Bodies group:~* Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.~* Response to cholinesterase inhibitor over a period of six months will be monitored."
62636152|NCT01519817|EXPERIMENTAL|Yeast-Brachyury vaccine|Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
62068314|NCT04178538|ACTIVE_COMPARATOR|25 years and older- Standard ACL reconstruction|Patients in this arm will be 25 years of age and over will receive an allograft All-Inside ACL reconstruction
62068315|NCT04178538|EXPERIMENTAL|24 years and younger- ACL recon with DBM, Internal brace|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft augmented with demineralized bone matrix, bone marrow, and internal brace
62068316|NCT04178538|ACTIVE_COMPARATOR|24 years and younger- Standard ACL reconstruction|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft standard all inside technique
62068317|NCT00103337|EXPERIMENTAL|Arm I (500 mg cilengitide)|Patients receive lower dose cilengitide IV over 1 hour twice a week for 6 weeks.
62068318|NCT00103337|EXPERIMENTAL|Arm II (2000 mg cilengitide)|Patients receive higher dose cilengitide IV over 1 hour twice a week for 6 weeks.
62068319|NCT01332396||Patients prescribed TYKERB|Patients with HER2 overexpressing inoperable or recurrent breast cancer
62272957|NCT00940355|EXPERIMENTAL|Intervention pulmonary nurse|group III: intervention conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, increasing motivation to engage in additional treatment, and improving health status.
62272958|NCT00940355|NO_INTERVENTION|Usual care|group II: usual care as delivered by the outpatient clinic.
62652954|NCT01369433|EXPERIMENTAL|tivozanib + paclitaxel|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + paclitaxel combination.
62068320|NCT04559282|EXPERIMENTAL|New SP followed by Baha 5 SP followed by single blinded SP|Aided hearing with new Sound Processor followed by aided hearing with the Baha 5 sound processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
62068321|NCT04559282|EXPERIMENTAL|Baha 5 SP followed by the New SP followed by single blinded SP|Aided hearing with Baha 5 sound processor followed by aided hearing with the new Sound Processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
62068322|NCT05067946|EXPERIMENTAL|GX-19N|GX-19N will be intramusculary administered via EP on day 1 and day 29.
62636153|NCT05681013|EXPERIMENTAL|Laughter Therapy Group|A pre-test was administered to all students. In the pre-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index and Perceived Stress Scale were applied. Experimental and control groups were formed randomly among the students who filled all the scales. Communication groups were established for the students in both groups without being told which group they belonged to. Considering the hours suitable for the experimental group, 8 sessions of laughter therapy were applied for an average of 45 minutes. At the end of the therapy in the last session, a post-test was administered to all of the students. In the post-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied.
62636154|NCT05681013|NO_INTERVENTION|Control Group|In the pre-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied. At the end of the therapy in the last session, a post-test was administered to all students. In the post-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied.
62636155|NCT03172728|EXPERIMENTAL|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
62652955|NCT01369433|EXPERIMENTAL|tivozanib solid tumors - QTC|Subjects who participated in a Phase 1 and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951).
62652956|NCT01369433|EXPERIMENTAL|tivozanib + capecitabine|After Ph 1b study tolerable to Tivo + Xeloda®
62652957|NCT01369433|EXPERIMENTAL|tivozanib Advanced RCC|After biomarker study tolerable to Tivo
62068323|NCT05067946|PLACEBO_COMPARATOR|Placebo|Placebo will be intramusculary administered via EP on day 1 and day 29
62068324|NCT01433393|EXPERIMENTAL|TAK-875 25 mg|
62068325|NCT01433393|EXPERIMENTAL|TAK-875 50 mg|
62068326|NCT01433393|PLACEBO_COMPARATOR|Placebo|
62068327|NCT04015700|EXPERIMENTAL|Vaccine (GNOS-PV01 + INO-9012)|"* Standard radiation therapy will be administered per standard of care and is outside the scope of this study.~* GNOS-PV01 + INO-9012 will be given on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle beginning with Cycle 2."
62068328|NCT04707339||Acute Appendicitis pre-COVID management|Audit of Acute appendicitis management in 2017-18
62068329|NCT04707339||Acute Appendicitis during COVID management|Audit of Acute appendicitis management in 2020
62068330|NCT01364974|EXPERIMENTAL|Group A|low dose, all male
62068331|NCT01364974|EXPERIMENTAL|Group B|medium dose, all male
62068332|NCT01364974|EXPERIMENTAL|Group C|high dose, all male
62068333|NCT01364974|EXPERIMENTAL|Group D|medium dose, all female
62068334|NCT01364974|PLACEBO_COMPARATOR|Placebo|
62068335|NCT03614338|EXPERIMENTAL|Core Participants Weight Loss Program|Small changes weight loss program
62068336|NCT01651273|EXPERIMENTAL|Arm 1: BMS-852927 (0.25 mg)|
62068337|NCT01651273|EXPERIMENTAL|Arm 2: BMS-852927 (1.0 mg)|
62068338|NCT01651273|EXPERIMENTAL|Arm 3: BMS-852927 (2.5 mg)|
62068339|NCT01651273|PLACEBO_COMPARATOR|Arm 4: Placebo|
62068340|NCT01946581||Cataract Surgery|
62068341|NCT05425849|NO_INTERVENTION|control group|No attempt was made to reduce pain in the patients in the control group. Standard PIVC insertion procedure was applied.
62068342|NCT05425849|EXPERIMENTAL|rose oil group|After the patients in the rose aromatherapy group were placed in a sitting position, a face mask with 1-2 drops of rose oil was placed on the nose area. Then, the standard PIVC insertion procedure was applied. After the procedure, the patient's rose-scented mask was replaced with a standard mask.
62068343|NCT05425849|EXPERIMENTAL|hand holding group|After the patients in the hand-holding group were placed in a sitting position, the patient's family was asked to hold the patient's hand and not let it go until the procedure was over. Standard PIVC insertion procedure was applied.
62068344|NCT00764374|EXPERIMENTAL|1|
62272959|NCT02133989|EXPERIMENTAL|Ticlopidine+Ginko biloba|Switch to ticlopidine + ginko biloba
62068345|NCT04581473|EXPERIMENTAL|CT041 autologous CAR T-cell injection|Two stages: Phase 1b: dose escalation and dose expansion; Phase 2: verify CT041 efficacy and safety
62068346|NCT04581473|ACTIVE_COMPARATOR|Physician's Choice|Participants will receive physician's choice of treatment in Phase II
62272960|NCT02133989|ACTIVE_COMPARATOR|Clopidogrel|Keep clopidogrel
62272961|NCT04111874|EXPERIMENTAL|Low-Intensity Therapist Assistance (LTA)|Parents will receive four 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
62636156|NCT03172728|NO_INTERVENTION|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
62636157|NCT03912740|ACTIVE_COMPARATOR|Remifentanil Analgesia|Continuous intraoperative analgesia with remifenanil + 0.9% sodium chloride
62636158|NCT03912740|ACTIVE_COMPARATOR|Remifentanil and Dexmedetomidine Analgesia|Continuous intraoperative analgesia with remifenanil + dexmedetomidine
62636159|NCT03565757|EXPERIMENTAL|SMART intervention|90-minute SMART small group session
62068347|NCT04745494|ACTIVE_COMPARATOR|OT administration|All participants will receive a single dose of 24IU OT (40.32µg, Syntocinon) delivered via a nasal spray.
62068348|NCT04745494|PLACEBO_COMPARATOR|Placebo administration|All participants will receive a single dose of a placebo delivered via a nasal spray.
62068349|NCT05231265||Patients with Low Back Pain|
62068350|NCT06273982|EXPERIMENTAL|STEP-UP|
62068351|NCT06273982|ACTIVE_COMPARATOR|ARC|
62068352|NCT00905502|EXPERIMENTAL|1: Restricted protocol (RG) group|Received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period.
62068353|NCT00905502|ACTIVE_COMPARATOR|2: Liberal protocol (LG) group|Received 10 ml/kg•hr of RL solution intraoperatively.
62068354|NCT01583023|EXPERIMENTAL|Wellbutrin + Lithium a/o Epival + Sham rTMS|
62272962|NCT04111874|ACTIVE_COMPARATOR|Standard Therapist Assistance (STA)|Parents will receive ten 60-minute supportive video calls with a therapist over the 12 weeks of treatment.
62272963|NCT05120310|EXPERIMENTAL|Intervention|"Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge).~- Calm Coaching for sleep Subsample (N=100): A random subsample of eligible participants, based on their ISI scores, will be invited to use the Calm Coaching for Sleep Program (using Healthie platform)."
62272964|NCT05120310|OTHER|Waitlist Control|"Participants will be instructed to not participate in any mindfulness meditation activities for eight weeks. The research team will send the participant study instructions. At the end of eight weeks participants will be given access to the Calm app and will be able to schedule one live 20-minute coaching session with a Calm Coach.~- Calm Coaching for sleep Subsample (N=100): A random subsample of eligible participants, based on their ISI scores, will be invited to use the Calm Coaching for sleep Program. The Calm Coaching for sleep program is administered by Calm for six weeks."
62272965|NCT04596475|EXPERIMENTAL|Treatment Arm|
62068355|NCT01583023|EXPERIMENTAL|Placebo + Lithium a/o Epival + Active rTMS|
62068356|NCT01583023|EXPERIMENTAL|Wellbutrin + Lithium a/o Epival + Active rTMS|
62068357|NCT01346618||children ages 4-17 years|Participants are children and youth ages 4-17 years (inclusive) who performed or will perform a X-ray of the left hand for bone age assessment as part of any clinical work up, within 2 months of enrollment in this study.
62068358|NCT03184090|EXPERIMENTAL|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
62068359|NCT03184922|ACTIVE_COMPARATOR|Fixed suspensory loop|Non-adjustable femoral cortical fixation device to be used
62068360|NCT03184922|EXPERIMENTAL|Adjustable suspensory loop|Adjustable femoral cortical fixation device to be used
62068361|NCT02354924|EXPERIMENTAL|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
62068362|NCT02354924|ACTIVE_COMPARATOR|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
62068363|NCT02042638||16 treatment naive Hypogonadotropic hypogonadism patients|Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
62272966|NCT02569762|EXPERIMENTAL|Sucralose-Aspartame|Generic name: sucralose or aspartame, Dosage form: powder, Duration:seven days.
62636160|NCT02752815|ACTIVE_COMPARATOR|6R-CHOP+2R|"6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
62636161|NCT02752815|EXPERIMENTAL|4R-CHOP+4R|"4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
62636162|NCT02926105|EXPERIMENTAL|T&E Home-based exercise programme|Individually tailored home-based test and exercise programme
62636163|NCT02926105|EXPERIMENTAL|Otago|Individually tailored exercise programme
62636164|NCT02926105|ACTIVE_COMPARATOR|Helsana booklet|Helsana recommendations and exercises
62636165|NCT05874102|ACTIVE_COMPARATOR|Sidelying, then Upright|Positioning in sidelying on radiology table for assessment, then will be positioned upright in tumbleform. Same bottle and liquid viscosities will be assessed in both positions.
62068364|NCT03679767|EXPERIMENTAL|Melanoma: retifanlimab 500 mg|Participants with melanoma received retifanlimab 500 milligrams (mg) every 4 weeks (Q4W), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle.
62068365|NCT03679767|EXPERIMENTAL|NSCLC: retifanlimab 500 mg|Participants with non-small cell lung cancer (NSCLC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.
62068366|NCT03679767|EXPERIMENTAL|UC: retifanlimab 500 mg|Participants with urethelial carcinoma (UC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.
62068367|NCT03679767|EXPERIMENTAL|RCC: retifanlimab 500 mg|Participants with renal cell carcinoma (RCC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.
62068368|NCT01625923|EXPERIMENTAL|Olanzapine|An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
62068369|NCT04683809|EXPERIMENTAL|Exercise group|Patients in this group will attend telerehabilitation sessions.
62068370|NCT04683809|NO_INTERVENTION|Control group|Patients in this arm will be subject to routine follow up.
62068371|NCT01240954|ACTIVE_COMPARATOR|OSIRIS|
62068372|NCT01240954|EXPERIMENTAL|OSIRIS other concentration 1|
62068373|NCT01240954|EXPERIMENTAL|OSIRIS other concentration 2|
62068374|NCT05790213|EXPERIMENTAL|Focal Prostate Ablation + Androgen Deprivation + Novel Hormonal Therapy|"A. Apalutamide 240 mg by mouth daily for a total of 6-months B. ADT therapy will consist of any generic luteinizing hormone-releasing hormone agonist which will provide either 6-months of treatment or two injections every 3-months. (e.g., one injection with a treatment period of 6 months or two injections, one at drug start and one 3-months later).~C. Focal therapy to be completed within 8- to 12-weeks of the initiation of apalutamide but after the completion of the 8-week mpMRI to allow for it to be used in FT planning"
62636166|NCT05874102|ACTIVE_COMPARATOR|Upright, then Sidelying|Positioned upright in tumbleform, then will be positioned sidelying on radiology table for assessment. Same bottle and liquid viscosities will be assessed in both positions.
62636167|NCT03113669|OTHER|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
62068375|NCT02918734|EXPERIMENTAL|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
62636168|NCT01168921|EXPERIMENTAL|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle.
62068376|NCT02918734|ACTIVE_COMPARATOR|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
62068377|NCT01893827|ACTIVE_COMPARATOR|XR-NTX|Xr-NTX 380mg IM injection monthly x 6 months
62068378|NCT01893827|ACTIVE_COMPARATOR|Oral Naltrexone|Oral naltrexone 50mg/day x 6 months
62636169|NCT03175081|EXPERIMENTAL|Test group|Patients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
62636170|NCT03175081|EXPERIMENTAL|Control group|Patients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure.
62636171|NCT02168491|EXPERIMENTAL|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
62272967|NCT02569762|EXPERIMENTAL|Aspartame-Sucralose|Generic name: aspartame or sucralose, Dosage form: powder, Duration:seven days.
62068379|NCT05023967|EXPERIMENTAL|Arm I (fasting, glucose monitoring, counseling, metformin)|Patients fast for \>= 16 hours every night and use the continuous glucose monitoring system for 4-6 weeks. Patients also receive nutritional counseling sessions on days 0 and 10. Beginning week 2, patients also receive metformin hydrochloride extended release PO QD until the day of surgery. Treatment continues for 4-6 weeks (until surgery) in the absence of disease progression or unacceptable toxicity. Patients undergo the collection of blood samples at baseline and at the final study visit (days 28-43), and the collection of tissue at the time of surgery (days 28-43).
62272968|NCT03299920|ACTIVE_COMPARATOR|Intervention|Patients will receive standardized instruction from a study nurse, tailored to understanding pain management after nerve blocks and maximizing utilization of non-opioid analgesics.
62272969|NCT03299920|OTHER|Control|Patient will receive conventional instructions on postoperative pain management.
62272970|NCT04732507|ACTIVE_COMPARATOR|One to two needle passes|Receive 1-2 needle passes for needling at each trigger point
62272971|NCT04732507|ACTIVE_COMPARATOR|Ten needle passes|Receive 10 needle passes for needling at each trigger point
62272972|NCT04732507|ACTIVE_COMPARATOR|Twenty needle passes|Receive 20 needle passes for needling at each trigger point
62272973|NCT00813423|EXPERIMENTAL|Treatment (sunitinib malate, hydroxychloroquine)|Patients receive sunitinib malate PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-42 (beginning day 4 of course 1). Treatment repeats every 42 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62636172|NCT02076620|EXPERIMENTAL|L19TNFα + doxorubicin|"Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design:~cohort 1 --\> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --\> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --\> 17 μg/kg L19TNFα + doxorubicin."
62272974|NCT01148277|ACTIVE_COMPARATOR|Propofol and Remifentanyl|Propofol, colonoscopies, liver diseases, cirrhosis
62272975|NCT01148277|ACTIVE_COMPARATOR|midazolam and fentanyl|midazolam and fentanyl, colonoscopies, liver diseases
62272976|NCT01148277|EXPERIMENTAL|control midazolam anf fentanyl|midazolam anf fentanyl
62272977|NCT02870855|EXPERIMENTAL|HCG group|intrauterine injection of HCG before blastocyst transfer
62272978|NCT02870855|NO_INTERVENTION|Control group|blastocyst transfer
62287075|NCT04957186|ACTIVE_COMPARATOR|Caregiver Focus Group|Group consisting of 10 caregivers composed of 3 surgeons, 3 algologists, 3 oncologists and one study coordinator.
62287076|NCT04479904|EXPERIMENTAL|famitinib|
62287077|NCT04574596||3GCR ceftriaxone-resistant-E. coli|Positive blood culture for above resistant e coli. Observational there will be no intervention
62287078|NCT04574596||3GCS ceftriaxone-susceptible-E. coli|Positive blood culture for above susceptible e coli. Observational there will be no intervention
62287079|NCT02820467|EXPERIMENTAL|patients with suspicion of CLI|patients presenting with peripheral artery disease and suspicion of critical limb ischemia as assessed by TASK II consensus 30 patients will be enrolled and will benefit of measures of TcPO2, too systolic blood pressure and skin perfusion pressure and in the same time angiography with fluorescence (Indocyanine grey 0.05 mg/kg by intravenous injection
62636173|NCT03983408|ACTIVE_COMPARATOR|KRG group|"* Enrollment: 60 patients~* Drug: Korean Red Ginseng (KRG) 2,000 mg/day for total 24 weeks (2 Korean Red Ginseng extract tablet twice a day, ginsenoside Rg1+Rb1+Rg3 7.0 mg/g per each tablet)"
62453822|NCT03333226|EXPERIMENTAL|ARM lymph node preservation|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node preservation will be performed.
62453823|NCT03333226|ACTIVE_COMPARATOR|ARM lymph node removal|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node removal will be performed.
62453824|NCT03919942|EXPERIMENTAL|OxyFlower gel|pericoronitis treatment with oxyflower gel.
62636174|NCT03983408|PLACEBO_COMPARATOR|Placebo group|"* Enrollment: 60 patients~* Drug: Placebo for 12 weeks, following Korean Red Ginseng 2,000mg/day for another 12 weeks"
62287080|NCT03079479||Two Years Group|
62287081|NCT03079479||Five Years Group|
62287082|NCT03079479||Ten Years Group|
62287083|NCT03079479||Control Group|
62287084|NCT05680233|EXPERIMENTAL|OA-235i (4-40 mg)|"Single ascending dose (SAD): OA-235i (4-40 mg) administered subcutaneously (SC) once to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis.~Multiple dose (MD): OA-235i (dose level to be determined from SAD) administered subcutaneously (SC) once daily for 7 days to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis."
62287085|NCT02022605|EXPERIMENTAL|Hands-on EMS training group|
62287086|NCT02022605|ACTIVE_COMPARATOR|Standard training group|
62287087|NCT01086436|EXPERIMENTAL|Rotavirus Group|Subjects will receive Rotarix™
62287088|NCT01086436|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo.
62287089|NCT05667324|EXPERIMENTAL|Group 1: Ropivacaine plus Dexamethasone|The group 1 injection procedure will be performed as follows: after preparation of the skin using appropriate skin preparation solution and using aseptic technique, a small-gauge spinal needle will be advanced into the pterygopalatine fossa under ultrasound guidance. Once the needle is properly positioned, 0.5% ropivacaine will be administered at a dose of 20 mg plus 4 mg dexamethasone and the needle will be removed. This procedure will be performed bilaterally
62272979|NCT04104438|ACTIVE_COMPARATOR|Basiliximab with Delayed TAC|"Basiliximab~* Dose #1: 20mg IV within 2 hours of transplant~* Dose #2: 20mg IV Post-operative day #4~Tacrolimus (with basiliximab induction) o Beginning day #5 post-transplant or when SCr \< 1.8 mg/dl (subjects off dialysis) to six months: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol~Post-operative taper:~* Post-op day 1- methylprednisolone 50mg IVP Q6H~* Post-op day 2- methylprednisolone 40mg IVP Q6H~* Post-op day 3- methylprednisolone 30mg IVP Q6H~* Post-op day 4- methylprednisolone 20mg IVP Q6H~* Post-op day 5- methylprednisolone 20mg IVP Q12H~* Post-op day 6- methylprednisolone 10mg IVP Q12H until taking PO, then change to: prednisone 20mg PO QAM"
62272980|NCT04104438|ACTIVE_COMPARATOR|Basliximab, Delayed TAC with Everolimus|"Basiliximab~Tacrolimus (with basiliximab induction)~o Beginning day #5 post-transplant or when SCr \< 1.8 mg/dl (subjects off dialysis) to POD 30: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil o 1000 mg po bid up to POD 30: reduce mycophenolate mofetil following achievement of steady state everolimus (POD 35) as clinically indicated~Corticosteroids (SOC): Per UCLA protocol~Everolimus (delayed)~o Add by POD 30: 1 mg po bid and adjusted to maintain whole blood trough concentrations of 3-8 ng/ml."
62068380|NCT05023967|ACTIVE_COMPARATOR|Arm II (glucose monitoring)|Patients continue their usual dietary pattern and use the continuous glucose monitoring system for 4-6 weeks (until surgery). Patients undergo the collection of blood samples at baseline and at the final study visit (days 28-43), and the collection of tissue at the time of surgery (days 28-43).
62272981|NCT04104438|NO_INTERVENTION|Control: standard TAC with steroids and MMF|"Tacrolimus (without basiliximab induction)~* Beginning day #1 post-transplant to six months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 5-12ng/mL~* Six months to one year: maintain whole blood trough concentration of 5-10ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol"
62272982|NCT00954044|EXPERIMENTAL|Exercising Together|Partnered progressive resistance exercise
62272983|NCT00954044|PLACEBO_COMPARATOR|Usual Care|Usual Care Control
62272984|NCT04369066|OTHER|Subjects who are not showing active SARS-Cov2 infection|
62272985|NCT04740047||Pulmonary Nodule|Pulmonary nodule is suitable for elective bronchoscopy with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease.
62272986|NCT01962051||Delivery system Entry|
62272987|NCT03067272|EXPERIMENTAL|FemBloc® Permanent Contraceptive System|Treatment of women who desire permanent birth control (female sterilization) by occlusion of the fallopian tubes.
62068381|NCT02527837|ACTIVE_COMPARATOR|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
62272988|NCT06519019|EXPERIMENTAL|Hydrophilic Dental Implant Group|One dental implant placed will have hydrophilic properties.
62272989|NCT06519019|ACTIVE_COMPARATOR|Conventional Dental Implant Group|This Conventional Dental implant group will act as control.
62272990|NCT01834729|EXPERIMENTAL|Alfuzosin|"In Part A, subjects randomized to this arm will receive a single dose of oral alfuzosin immediate release (IR) 2.5 mg.~In Part B, only constipated patients will receive oral alfuzosin (10 mg extended release (ER)) capsules."
62272991|NCT01834729|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive a single placebo capsule identical to the study drug.
62272992|NCT04204174|EXPERIMENTAL|Tyrosine loading|
62272993|NCT02929264|EXPERIMENTAL|ABX-1431|ABX-1431, capsules, 40 mg, single dose
62272994|NCT02929264|PLACEBO_COMPARATOR|Placebo|Placebo, capsules, single dose
62272995|NCT02929264|NO_INTERVENTION|Control|No Intervention
62272996|NCT01061463||Exposed group|French coronary interventional cardiologists and cardiologists specializing in cardiac arrhythmias treatments (electrophysiologists), occupationally exposed to X-Rays
62272997|NCT01061463||Unexposed group|French non-interventional cardiologists and non medical workers, not occupationally exposed to X-Rays
62453825|NCT03919942|EXPERIMENTAL|Chlorhexidine gel|pericoronitis treatment with chlorhexidine gel.
62068382|NCT02527837|PLACEBO_COMPARATOR|Placebo|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
62068383|NCT01299064||Buddhist Clergy and Laypersons|
62068384|NCT03705455|ACTIVE_COMPARATOR|ISAP SMS|ISAP SMS will be sent to enrolled caregivers
62068385|NCT03705455|NO_INTERVENTION|No ISAP SMS|No ISAP SMS will be sent to enrolled caregivers
62068386|NCT02556437|EXPERIMENTAL|Group A|24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia
62068387|NCT02556437|EXPERIMENTAL|Group B|24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia)
62068388|NCT04684082||Single Group Assignment|Patients will receive colonic irrigation as bowel preparation prior to colonoscopy.
62068389|NCT06291662|EXPERIMENTAL|Pelvic bone neoplasm|Patients with primary tumor of the pelvic bone; Primary meta-diaphysial tumor of the long bones; squamous cell carcinoma of the oral cavity involving the maxillary upper and/or lower.
62068390|NCT06291662|EXPERIMENTAL|Sarcoma pediatric patients|Patients with primary sarcoma of bone and soft parts involving the scapula, the pelvis and upper and lower limbs; brain tumor.
62272998|NCT01356914|EXPERIMENTAL|Treatment A: BMS-914392|
62272999|NCT01356914|EXPERIMENTAL|Treatment B: BMS-914392|
62273000|NCT01356914|EXPERIMENTAL|Treatment C: BMS-914392|
62273001|NCT01356914|PLACEBO_COMPARATOR|Treatment D: Placebo|
62273002|NCT01286246|EXPERIMENTAL|Vaginal progesterone|
62273003|NCT01286246|PLACEBO_COMPARATOR|Placebo|
62273004|NCT05997875|EXPERIMENTAL|Education|
62273005|NCT05997875|EXPERIMENTAL|Education-Plus|
62453826|NCT03919942|PLACEBO_COMPARATOR|Placebo gel|pericoronitis treatment with placebo gel.
62453827|NCT05241535|EXPERIMENTAL|Sequence 1 (starting with MT-7117 or Placebo)|"Treatment A or B (a single oral dose of MT-7117 or Placebo), Treatment C (a single oral dose of moxifloxacin), then Treatment A or B (a single oral dose of placebo or MT-7117)."
62636175|NCT04295798|EXPERIMENTAL|Traditional tDCS|At the beginning of stimulation, the current will be increased manually from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. Participants will be instructed to notify study personnel if and when they feel any uncomfortable sensation. The ramp-up will be stopped at this point and for the remainder of the session tDCS will be delivered at an intensity of 0.1 mA below the highest level reached. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
62636176|NCT04295798|SHAM_COMPARATOR|Traditional Sham|A traditional sham will be used to maximize blinding of traditional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration as described with the Traditional tDCS will be used; however, current will automatically be ramped down 60 seconds after ramp-up.
62652958|NCT02888054|EXPERIMENTAL|Sequence ABBA|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
62273006|NCT05997875|OTHER|Usual Care|
62273007|NCT03224273|EXPERIMENTAL|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
62273008|NCT03224273|ACTIVE_COMPARATOR|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
62273009|NCT04926272|EXPERIMENTAL|18F-92, PET/CT|PET/CT perform after injecting 18F-92
62453828|NCT05241535|EXPERIMENTAL|Sequence 2 (starting with MT-7117 or Placebo)|Treatment A or B (a single oral dose of placebo or MT-7117), Treatment A or B (a single oral dose of MT-7117 or Placebo), then Treatment C (a single oral dose of moxifloxacin).
62273010|NCT05051007|ACTIVE_COMPARATOR|fentanyl group|
62273011|NCT05051007|ACTIVE_COMPARATOR|lidocaine group|
62453829|NCT05241535|EXPERIMENTAL|Sequence 3 (starting sequence with Moxifloxacin)|Treatment C (A single oral dose of moxifloxacin), Treatment A or B (a single oral dose of placebo or MT-7117), then Treatment A or B (a single oral dose of MT-7117 or Placebo).
62453830|NCT04897802|EXPERIMENTAL|Experimental: GLP1-RA administration|A single dose of 10 mcg of GLP1-RA (exenatide) will be injected subcutaneously and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after GLP1-RA:placebo administration to assess OT secretory patterns
62453831|NCT04897802|PLACEBO_COMPARATOR|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than GLP1-RA (exenatide) administration
62453832|NCT03129477|EXPERIMENTAL|Telemonitoring in NonInvasiveVentilation|"Tele-monitoring in noninvasive ventilation with Lumis 150 and others Resmed equipments with AirView monitoring system, in COPD patients.~• Education and adaptation of the patient to NIV."
62453833|NCT03129477|NO_INTERVENTION|2- conventional monitoring group|"Conventional monitoring group~• Education and adaptation of the patient to NIV."
62453834|NCT02968888|PLACEBO_COMPARATOR|Milk|Participants performed a bout of strength training and consumed 20g of milk protein
62453835|NCT02968888|EXPERIMENTAL|Whey protein concentrate 80|Participants performed a bout of strength training and consumed 20g of whey protein concentrate 80
62652959|NCT02888054|EXPERIMENTAL|Sequence BABA|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
62273012|NCT06193512|EXPERIMENTAL|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU)
62453836|NCT02968888|EXPERIMENTAL|Native whey|Participants performed a bout of strength training and consumed 20g of native whey
62273013|NCT06193512|ACTIVE_COMPARATOR|Oral care treatment as usual|Oral care Treatment as usual (TAU)
62273014|NCT04690400|EXPERIMENTAL|Active care group|Participants will practice stretching exercises twice a week, at a distance and under the supervision of a professional, for 12 weeks. In addition, the experimental group will receive the same written guide and video of the comparator group.
62273015|NCT04690400|ACTIVE_COMPARATOR|Self-care group|Participants will receive stretching advice by written guide and video with stretching exercises, to be performed individually, without distance supervision, for 12 weeks. Participants will be able to resolve questions about the protocol at any time, via telephone.
62453837|NCT01968252||Intraoperative Patient|All patients in the cohort will be scheduled to undergo a planned surgical procedure in which the subject will undergo general anesthesia and the procedure and/or the patient will require transesophageal echocardiographic monitoring for the procedure.
62453838|NCT00148564|ACTIVE_COMPARATOR|Olanzapine|
62453839|NCT00148564|ACTIVE_COMPARATOR|Zpirasidone|
62273016|NCT05280678|EXPERIMENTAL|SH2018-10 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
62273017|NCT05280678|EXPERIMENTAL|SH1514-08 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
62453840|NCT05209945|EXPERIMENTAL|Vibration|Vibration (WBV, heel, and tendon vibration) was applied to participants
62636177|NCT04295798|EXPERIMENTAL|Personalized tDCS|Baseline MRI's will enable personalization of tDCS via current flow modeling and optimized to each participant with the goal of generating an average nE over the dlPFC of the same size as the one delivered by a traditional montage using sponges in an average subject at 1.5 mA of current. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
62636178|NCT04295798|SHAM_COMPARATOR|Personalized Sham|An active sham will be used in which very low-level currents (0.5mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
62636179|NCT04192721|EXPERIMENTAL|Cognitive Behavioral Therapy-Based Group Counseling|The CBT-based group counseling provided to the intervention group was carried out as a group intervention with structured sessions in which various techniques and methods of CBT, having mainly educational content, were applied, including an experiential interaction process. The counseling was performed in a total of six 60- to 90-minute sessions, comprising one session per week for four groups consisting of six to 10 members each.
62273018|NCT06501287||Group I (control group):|patients with normal coronary angiography and normal postprandial triglycerides
62273019|NCT06501287||Group II|: patients with abnormal coronary angiography and high level of postprandial triglycerides more than 200mg/dl. They will be divided into subgroups according to severity of coronary artery disease (mild, moderate and severe) according to (Syntax score)
62453841|NCT01924130|EXPERIMENTAL|One Healthy Breakfast Program|Classroom feeding, nutrition education lessons, social marketing, and parent outreach.
62453842|NCT01924130|NO_INTERVENTION|Control|Only receive assessments.
62453843|NCT02206659|EXPERIMENTAL|Telmisartan|2-week placebo run-in period followed by 6 weeks of treatment with telmisartan
62453844|NCT05963100|EXPERIMENTAL|Experimental 1*10^6/kg|
62453845|NCT05963100|EXPERIMENTAL|Experimental 1*10^7/kg|
62453846|NCT05963100|EXPERIMENTAL|Experimental 3*10^6/kg|
62453847|NCT05963100|EXPERIMENTAL|Experimental 2*10^7/kg|
62636180|NCT04192721|NO_INTERVENTION|Control group|No counseling was given to the control group during the study.
62068391|NCT06291662|EXPERIMENTAL|Intracranial oncologic pathology|Patients with intracranial oncologic pathology with bone involvement and lesions of the skull theca primary or secondary.
62636181|NCT01278602|EXPERIMENTAL|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
62273020|NCT06501287||Group III|: patients with abnormal coronary angiography and normal postprandial triglycerides.
62273021|NCT00634491|ACTIVE_COMPARATOR|1|150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
62273022|NCT00634491|ACTIVE_COMPARATOR|2|Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
62453848|NCT05583071|EXPERIMENTAL|combination of Tafasitamab (Minjuvi®), Lenalidomide, Rituximab and Methotrexate|All patients will receive tafasitamab (Minjuvi®) 12 mg/KG body weight and rituximab 375 mg/m² on days 0 and 5, followed by methotrexate 3,5 g/m² on day 1 as an intravenous infusion. Lenalidomide will be administered orally at 20 mg/day during the first cycle and at 25 mg/day during subsequent cycles on days 4-17 of each 21-day cycle for a total number of 4 cycles. The treatment duration per patient will be 84 days.
62453849|NCT00988624|EXPERIMENTAL|Period 1|
62453850|NCT00988624|EXPERIMENTAL|Period 2|
62636182|NCT01657162|EXPERIMENTAL|Alendronate|Participants received 70 milligrams (mg) of alendronate orally once per week beginning on Day 2 for up to 24 months after participating in Study BA058-05-003 during which participants received abaloparatide 80 micrograms (mcg) SC or abaloparatide-matching placebo daily for 18 months.
62636183|NCT00689689|ACTIVE_COMPARATOR|Fully Coated Prodigy Stem (AML)|Total hip arthroplasty with fully coated prodigy stem (AML)
62636184|NCT00689689|ACTIVE_COMPARATOR|Cemented Endurance Hip Stem|Total hip arthroplasty with cemented Endurance hip stem component
62068392|NCT01784432|ACTIVE_COMPARATOR|Low-level laser therapy and training|Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
62273023|NCT00634491|ACTIVE_COMPARATOR|3|normal salin 1cc/kg/hr before and after angiography
62273024|NCT05409339|EXPERIMENTAL|"Caffeine-Caffeine (Condition Caffeine)"|Through the 9-day pre-ambulatory, 2-day laboratory, and 7-day post-ambulatory parts, participants received 150 mg caffeine x 3 times daily.
62273025|NCT05409339|EXPERIMENTAL|"Caffeine-Placebo (Condition Withdrawal)"|During the 9-day ambulatory part, participants received 150 mg caffeine x 3 times daily, followed by a switch to placebo (150 mg mannitol) from the 2nd intake of the 9th day onward, through the laboratory and the post-ambulatory parts.
62453851|NCT00988624|EXPERIMENTAL|Period 3|
62453852|NCT00988624|EXPERIMENTAL|Period 4|
62453853|NCT00988624|EXPERIMENTAL|Period 5|
62453854|NCT05911373|PLACEBO_COMPARATOR|group serratus|preoperative superficial serratus block with local anaesthetics and parasternal block with saline
62453855|NCT05911373|ACTIVE_COMPARATOR|group serratus and parasternal|preoperative superficial serratus block and parasternal block with local anaesthetics
62453856|NCT05562310|EXPERIMENTAL|Phenylalanine, methionine, histidine requirement|
62453857|NCT00409019|EXPERIMENTAL|1|Study cancelled: Withdrawn before enrollment of any participants
62453858|NCT00409019|EXPERIMENTAL|2|Study cancelled: Withdrawn before enrollment of any participants
62068393|NCT01784432|ACTIVE_COMPARATOR|Training without low-level laser therapy|Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
62068394|NCT02409550||113 patients with concomitant asthma and allergic rhinitis|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of Pediatric Allergology \& Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
62068395|NCT02790723|EXPERIMENTAL|Low Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{11} viral genomes.
62068396|NCT02790723|EXPERIMENTAL|Medium Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{12} viral genomes.
62068397|NCT02790723|EXPERIMENTAL|High Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{13} viral genomes.
62068398|NCT05281432||Pes planus individuals|The aim of this study was to evaluate the static and dynamic balance status of male individuals diagnosed with pes planus.
62068399|NCT01280734|ACTIVE_COMPARATOR|Melatonin|Circadin(R) 2 mg tablet 2 hours at 23:00
62068400|NCT01280734|ACTIVE_COMPARATOR|Zolpidem|Stilnox (R) 10 mg tablet at 23:00
62453859|NCT00409019|EXPERIMENTAL|3|Study cancelled: Withdrawn before enrollment of any participants
62453860|NCT00676871|EXPERIMENTAL|1|MEDI-538
62453861|NCT00676871|EXPERIMENTAL|2|MEDI-538
62453862|NCT00676871|EXPERIMENTAL|3|MEDI-538
62453863|NCT00676871|EXPERIMENTAL|4|MEDI-538
62453864|NCT00676871|EXPERIMENTAL|5|MEDI-538
62453865|NCT00676871|EXPERIMENTAL|6|MEDI-538
62453866|NCT00676871|EXPERIMENTAL|7|MEDI-538
62453867|NCT05713500||PD patients with chronic pain|Parkinsonian patient with pain
62453868|NCT05713500||PD patients without pain|Parkinsonian patient without pain
62453869|NCT05713500||non-PD patients with chronic pain|Non-PD with fibromyalgia and non-PD with chronic headache
62453870|NCT00465686|EXPERIMENTAL|A|
62453871|NCT00514254||case|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
62636185|NCT05483868|EXPERIMENTAL|Intratumoral and intramural injection of AU-011 prior to TURBT (1b)|Intratumoral (50 μg) and intramural (50 μg) injection of AU-011 prior to the standard of care (TURBT) in patients with NMIBC.
62068401|NCT01280734|PLACEBO_COMPARATOR|Placebo|
62068402|NCT04500860|ACTIVE_COMPARATOR|Group A Tadalafil 5 mg|30 patients subjected to Daily dose of tadalafil 5mg
62068403|NCT04500860|ACTIVE_COMPARATOR|Group B Tolterodine|30 patients subjected to tolterodine 4 mg daily
62068404|NCT04500860|PLACEBO_COMPARATOR|Group C placebo|30 patients subjected to placebo daily
62068405|NCT04169711|EXPERIMENTAL|ARO-HIF2|
62068406|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
62068407|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
62068408|NCT00749216|EXPERIMENTAL|QW|IV infusion of 400mg once each week for 2 months
62068409|NCT00749216|EXPERIMENTAL|Q4W|IV infusion of 400mg once every four weeks for 2 months
62068410|NCT00749216|EXPERIMENTAL|Q8W|IV infusion of 400mg once every eight weeks for 2 months
62068411|NCT01208155|EXPERIMENTAL|1|Fostamatinib 50 mg tablet x 2
62068412|NCT01208155|EXPERIMENTAL|2|Fostamatinib 100 mg tablet (batch 1)
62068413|NCT01208155|EXPERIMENTAL|3|Fostamatinib 100 mg tablet (batch 2)
62068414|NCT01208155|EXPERIMENTAL|4|Fostamatinib 100 mg tablet (batch 4)
62068415|NCT01222468|ACTIVE_COMPARATOR|nabilone|nabilone 0.5 mg tablets dose-titrated over an 11-week period to a maximum of 3mg po daily. Subjects are allowed to drop back to the previous dose following a dose increase once if required
62068416|NCT01222468|PLACEBO_COMPARATOR|placebo|look-alike 0.5 mg placebo tablets titrated to a maximum daily dose of 3.0 mg daily over an 11-week phase. Subjects are allowed to drop back to the previous dose following a dose increase once during the 11-week phase if required
62068417|NCT05883761||HIV-positive DTG preconception|HIV status defined as a documented positive result in the perinatal and/or maternity register or other clinical source record. Preconception drug exposure determined using date of DTG initiation and LMP date or gestational age at delivery (if LMP not available). ART at conception is defined as maternal ART that started up to 8 weeks after the calculated LMP date, which would be up to 6 weeks after the estimated date of conception. As this is the group of interest, sample size target was determined as 10,000.
62068418|NCT05883761||HIV-negative|Women with the last HIV test result recorded during pregnancy or labor and delivery as negative.
62068419|NCT05883761||HIV-positive on non-DTG ARV preconception|HIV status defined as a documented positive result in the perinatal and/or maternity register or other clinical source record. Preconception drug exposure determined using date of ARV initiation (e.g., efavirenz) and LMP date or gestational age at delivery (if LMP not available). ART at conception is defined as maternal ART that started up to 8 weeks after the calculated LMP date, which would be up to 6 weeks after the estimated date of conception. Other groups to be included as informed by the data (e.g., HIV+ not on ART a conception, unknown ART at conception, etc).
62068420|NCT01900574|EXPERIMENTAL|Golimumab|
62273026|NCT05409339|PLACEBO_COMPARATOR|"Placebo (Condition Placebo)"|Through the 9-day ambulatory and 2-day laboratory, and 7-day post-ambulatory parts, participants received 150 mg mannitol x 3 times daily.
62453872|NCT00514254||control|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
62068421|NCT02294474|EXPERIMENTAL|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
62068422|NCT02294474|ACTIVE_COMPARATOR|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
62068423|NCT05905419|EXPERIMENTAL|Female adults with chronic pain who take prescribed opioid medications|"Opioid taking participants will undergo two study visits, one for each opioid phase (peak or trough)"
62068424|NCT05905419|NO_INTERVENTION|Female adults with chronic pain who do not take opioid medications|Participants with chronic pain who are not taking opioids will undergo one study visit
62068425|NCT05905419|NO_INTERVENTION|Healthy controls|Healthy female participants who are not taking opioids will undergo one study visit
62068426|NCT00747123|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection on days 1, 29, 57 and 85.
62068427|NCT00747123|EXPERIMENTAL|ACE-011 0.1 mg/kg|Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
62068428|NCT00747123|EXPERIMENTAL|ACE-011 0.3 mg/kg|Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
62068429|NCT00747123|EXPERIMENTAL|ACE-011 0.5 mg/kg|Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
62068430|NCT06625996|EXPERIMENTAL|Study|
62068431|NCT06625996|PLACEBO_COMPARATOR|control|No intervention
62068432|NCT01083147||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
62068433|NCT01596218|EXPERIMENTAL|Treatment Arm|Treatment Arm for all participants - Brentuximab vedotin
62068434|NCT00335686|NO_INTERVENTION|1|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
62068435|NCT00335686|NO_INTERVENTION|2|Nevirapine (Viramune): 1 comp (200mg)/12h
62068436|NCT03430063|EXPERIMENTAL|SDREGN2810|
62068437|NCT03430063|EXPERIMENTAL|SDREGN2810/ipi|
62068438|NCT03430063|EXPERIMENTAL|HDREGN2810|
62068439|NCT01338558|EXPERIMENTAL|K-RAS mutated|
62068440|NCT01338558|EXPERIMENTAL|K-RAS native A|
62068441|NCT01338558|ACTIVE_COMPARATOR|K-RAS native B|
62068442|NCT04717973||patients undergo sleeve gasterectomy|
62068443|NCT04717973||patients undergo gasteric bypass|
62273027|NCT00670592|OTHER|HCD122|
62273028|NCT02406807|EXPERIMENTAL|HVLA manipulation|Osteopathic high velocity, and low amplitude spinal lumbar manipulation
62273029|NCT02406807|SHAM_COMPARATOR|Sham Spinal lumbar manipulation|Just position in the side lying and not performed the high velocity and low amplitude
62287090|NCT05667324|ACTIVE_COMPARATOR|Group 2: Placebo plus Dexamethasone|In group 2 the same procedure will be performed, but the injectate will consist of 5 mL of a balanced crystalloid intravenous solution (4 ml of normal saline) plus 4 mg dexamethasone (each side). This procedure will be performed bilaterally.
62287091|NCT01225562|EXPERIMENTAL|1|Oral Treatment
62068444|NCT04824248|EXPERIMENTAL|Experimental intervention|10 weeks online therapy delivered using a blended approach. The online therapy consists of instructive video's, challenges to complete, 1-on-1 video calls with the therapist, online quizzes, online booklets, and online diaries/workbooks. . The experimental group will receive a behavioral weight reduction program combined with pain neuroscience education plus cognition-targeted exercise therapy. The combined therapy will adhere to guidelines for patient-centered care
62636186|NCT05483868|EXPERIMENTAL|Intratumoral and intramural injection of AU-011 with laser application before TURBT (4a)|Intratumoral (50 μg) and intramural (50 μg) injection of AU-011 with laser application before standard of care (TURBT) in patients with NMIBC.
62636187|NCT05483868|EXPERIMENTAL|Intratumoral injection of AU-011 with laser application before TURBT (4b)|Intratumoral injection of AU-011 (100 μg) with laser application before standard of care (TURBT) in patients with NMIBC.
62068445|NCT04824248|ACTIVE_COMPARATOR|Control intervention|Identically to the experimental intervention, the therapy is provided online within 10 weeks. Also identical to the experimental intervention, the control intervention will adhere to guidelines for patient-centered care. The control group will receive pain neuroscience education in combination with cognition-targeted exercise therapy alone.
62068446|NCT02732613|EXPERIMENTAL|Actual weight Group|Patients in Actual weight Group: The selection of Laryngeal Mask Airway classic will be based on actual body weight, followed the recommendations of manufacturer (size 3 for weight \< 50 kg, size 4 for weight 50-70 kg, and size 5 for weight \> 70 kg ).
62287092|NCT01225562|EXPERIMENTAL|2|Oral Treatment
62453873|NCT02188797|EXPERIMENTAL|Group MI risk reduction program|Participants receive four 1-hour group motivational interviewing sessions focused on reducing substance use and sexual risk behavior. They also receive an HIV information brochure and Community Resource Guide.
62453874|NCT02188797|NO_INTERVENTION|Usual care control|Participant receive HIV information brochure and Community Resource Guide.
62636188|NCT05483868|EXPERIMENTAL|Intratumoral injection of AU-011 with laser application before TURBT (4c)|Intratumoral injection of AU-011 (200 μg) with laser application before standard of care (TURBT) in patients with NMIBC.
62636189|NCT05483868|EXPERIMENTAL|AU-011 intratumoral injection with laser application prior to cystectomy (5a)|Intratumoral injection of AU-011 (100 μg) with laser application followed by standard of care (cystectomy) in patients with NMIBC or MIBC.
62636190|NCT05483868|EXPERIMENTAL|AU-011 intratumoral injection with laser application prior to cystectomy (5b)|Intratumoral injection of AU-011 (200 μg) with laser application followed by standard of care (cystectomy) in patients with NMIBC or MIBC.
62273030|NCT04032990|EXPERIMENTAL|Transcutaneous spinal stimulation - Acute and Training|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while upper extremity function is assessed at 3 time points (acute) and/or in combination with activity-based upper extremity training (40 sessions, 1.5 hours/day, 5 days/week); stimulation will be applied intermittently for no more than 10 minutes at a time. Upper extremity training is based on usual care activities to challenge use of the hands and arms, e.g. reaching, grasping, manipulating objects.
62273031|NCT01050400||Observant|Individuals within this group will receive pharmacotherapy according to the established institutional guidelines.
62273032|NCT01050400||Prospective CYP2D6 genetic screening|Individuals within the prospective group will receive their CYP2D6 genotype results prior to pharmacotherapy and their analgesic regimen will be tailored to their genetic results.
62273033|NCT04882891|EXPERIMENTAL|MS patients|Ambulant patients with multiple sclerosis
62273034|NCT01058343|EXPERIMENTAL|IFN-K 1|IFN kinoid dose 1
62273035|NCT01058343|EXPERIMENTAL|IFN-K-2|IFN kinoid dose 2
62273036|NCT01058343|EXPERIMENTAL|IFN-K 3|IFN kinoid dose 3
62273037|NCT01058343|EXPERIMENTAL|IFN-K 4|IFN kinoid dose 4
62273038|NCT01058343|PLACEBO_COMPARATOR|Saline|saline at same dose as IFN K
62273039|NCT05979571|EXPERIMENTAL|Experimental|
62273040|NCT03947814|EXPERIMENTAL|Part A: Normal renal function (control group)|Participants with normal renal function (glomerular filtration rate \[GFR\] greater than or equal to \[\>=\] 90 milliliters per minute \[mL/min\]) will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
62273041|NCT03947814|EXPERIMENTAL|Part A: Severe renal impairment or ESRD|Participants with severe renal impairment (GFR \>=15 to less than \[\<\]30 mL/min) who are not on dialysis or end stage renal disease (ESRD) (GFR \<15 mL/min) not yet on dialysis will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
62273042|NCT03947814|EXPERIMENTAL|Part B (Optional): Mild renal impairment|Participants with mild renal impairment (GFR \>=60 mL/min to \<90 mL/min) will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
62273043|NCT03947814|EXPERIMENTAL|Part B (Optional): Moderate renal impairment|Participants with moderate renal impairment (GFR \>=30 to \<60 mL/min) will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
62273044|NCT01345331|EXPERIMENTAL|Real Stimulation|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain.
62273045|NCT01345331|SHAM_COMPARATOR|Sham|The sham treatment will use the same equipment as the real treatment, but the participant will not receive any real stimulation to the ear.
62273046|NCT04053738|NO_INTERVENTION|Baseline|Participants slept in the anti-snoring bed in the laboratory, but the bed did not provide any intervention
62273047|NCT04053738|EXPERIMENTAL|Anti-snoring Intervention|Participants slept in the anti-snoring bed in the laboratory, and the bed moved the trunk of the participant
62273048|NCT01356589||Cohort|
62273049|NCT00907400|EXPERIMENTAL|1|PN400
62273050|NCT00907400|ACTIVE_COMPARATOR|2|Naprosyn E
62273051|NCT00938314|EXPERIMENTAL|NTx®-265 Low Dose|hCG 385 µg (10,000 international unit \[IU\]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
62273052|NCT00938314|EXPERIMENTAL|NTx®-265 Medium Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
62273053|NCT00938314|EXPERIMENTAL|NTx®-265 High Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
62273054|NCT00938314|PLACEBO_COMPARATOR|Saline Placebo|
62273055|NCT00880815|EXPERIMENTAL|Treatment (chemotherapy, stem cell transplant, rituximab)|Participants receive rituximab IV over 5-7 hours on days -13 and -6, fludarabine IV over 1 hour and bendamustine IV over 1 hour on days -5 to -3, and tacrolimus IV starting on day -2 and PO after hospital discharge for 6 to 8 months. Participants with MUD receive thymoglobulin on days -2 and -1. Participants undergo allogenic stem cell transplant over 30-45 minutes on day 0. Participants receive rituximab IV over 5-7 hours on days 1 and 8 and methotrexate IV over 30 minutes on days 1, 3, and 6. Participants with MUD also receive methotrexate IV on day 11. Participants receive G-CSF SC once daily starting on day 7 until white blood cell counts recover.
62273056|NCT05738850|EXPERIMENTAL|Part 1: ABBV-932|Participants will receive ABBV-932 on Day 1 and followed for 30 days.
62273057|NCT05738850|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive placebo on Day 1 and followed for 30 days.
62273058|NCT05738850|EXPERIMENTAL|Part 2: Sequence 1|Participants will receive ABBV-932 on Day 1 in Period 1 under fasting conditions and followed for 30 days. Participants will receive ABBV-932 with food on Day 1 in Period 2 and followed for 30 days.
62273059|NCT05738850|EXPERIMENTAL|Part 2: Sequence 2|Participants will receive ABBV-932 with food on Day 1 in Period 1 and followed for 30 days. Participants will receive ABBV-932 on Day 1 in Period 2 under fasting conditions and followed for 30 days.
62273060|NCT05738850|EXPERIMENTAL|Part 3: Japanese Participants: ABBV-932|Japanese participants will receive ABBV-932 on Day 1 in Period 1 and followed for 30 days.
62273061|NCT05738850|PLACEBO_COMPARATOR|Part 3: Japanese Participants: Placebo|Japanese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
62636191|NCT02316639|EXPERIMENTAL|Neuromuscular Training - No Exercise|Subjects will participate in 5 weeks of neuromuscular training followed by 5 weeks of no exercise intervention
62636192|NCT02316639|EXPERIMENTAL|No Exercise - Neuromuscular Training|No exercises will be administered for 5 weeks, followed by 5 weeks of neuromuscular Training.
62636193|NCT05236907|PLACEBO_COMPARATOR|Control Group|Patients in this group received nothing for sedation.
62636194|NCT05236907|ACTIVE_COMPARATOR|Midazolam group|7.5 mg of Midazolam were given orally the night before operation. Another dose 90 min. preoperatively.
62636195|NCT05236907|EXPERIMENTAL|Melatonin group|5 mg of Melatonin were given orally the night before operation. Another dose 90 min. preoperatively
62636196|NCT02073526||Anti-TNF|Inflammatory bowel patients age 18 and over treated with anti-TNF agents
62273062|NCT05738850|EXPERIMENTAL|Part 3: Han-Chinese Participants: ABBV-932|Han-Chinese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
62273063|NCT01285908|NO_INTERVENTION|Baseline|Baseline values measured at various tilt angles, so that each participant may serve as their own control.
62453875|NCT02276677|EXPERIMENTAL|Oxytocin|Oxytocin 24 IU x 1
62453876|NCT02276677|PLACEBO_COMPARATOR|Placebo|Placebo 24 IU x 1
62453877|NCT04971551|EXPERIMENTAL|Jaktinib treatment|Participants began oral administration of Jaktinib at 75mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 100mg BID Or continue 75mg BID treatment .
62636197|NCT01171157||Group 1|Subjects with influenza like illness
62636198|NCT01781104|ACTIVE_COMPARATOR|RM-131|
62636199|NCT01781104|PLACEBO_COMPARATOR|Placebo|
62636200|NCT02182401|EXPERIMENTAL|BI 207127 NA|fixed sequence
62636201|NCT03174015|EXPERIMENTAL|Intervention|"Landlords on selected plots will receive the Bauleni Secret intervention. Landlords and selected tenants will be surveyed in baseline/end-line data collection."
62636202|NCT03174015|NO_INTERVENTION|Control|Landlords and selected tenants will be surveyed in baseline/end-line data collection only.
62636203|NCT06203821|EXPERIMENTAL|Treatment|Patient receive two doses of the study drug, NP137, approximately two weeks apart. This will be followed by surgery. After the surgery if feasible, patients will begin post-surgical treatment with a standard-of-care chemotherapy regimen called FOLFIRINOX, combined with the study drug, NP137, for a total duration of about 6 months. Upon completing this phase, patients will receive an additional 6 months of treatment with only the study drug NP137.
62636204|NCT06202144|EXPERIMENTAL|Personalized Noninvasive support|Helmet noninvasive support, with positive end-expiratory pressure (PEEP)=12 cmH2O and the minimal pressure-support level capable of generating inspiratory effort between 5 and 10 cmH2O
62636205|NCT06202144|ACTIVE_COMPARATOR|Continuous positive airway pressure|Helmet CPAP will be delivered through a high-flow generator and PEEP valve set at 12 cmH2O
62273064|NCT01285908|PLACEBO_COMPARATOR|Saline infusion|Subjects received a saline IV infusion as a placebo, while measurements were taken at various tilt angles.
62273065|NCT01285908|ACTIVE_COMPARATOR|Norepinephrine Infusion|Subjects were given an norepinephrine infusion at various tilt angles, while measurements were taken.
62068447|NCT02732613|EXPERIMENTAL|Ideal weight Group|Patients in Ideal weight Group: The selection of Laryngeal Mask Airway classic will be based on ideal body weight, followed the recommendations of manufacturer ( size 3 for weight \< 50 kg, size 4 for weight 50-70 kg, and size 5 for weight \> 70 kg ).
62068448|NCT03997058|NO_INTERVENTION|Control group|
62068449|NCT03997058|EXPERIMENTAL|Auricular acupoint pressing group|
62068450|NCT03997058|ACTIVE_COMPARATOR|Oral estazolam group|
62068451|NCT03997058|ACTIVE_COMPARATOR|Combined treatment group|
62068452|NCT06399367||Lipedema/MSOT Cohort|"MSOT measurements are carried out on 50 subjects with changes in the subcutaneous fatty tissue (e.g. lipedema). In these studies, adult patients (\>18 years, \<80 years) are included with the indicators mentioned below, after risk information and voluntary consent.~1. Typical tenderness in the calf, back of the knee or lateral thigh~2. Tendency to hematoma in areas affected by edema~3. Typical appearance of fatty tissue distribution with dent formation, asymmetry in lateral comparison and increased circumference~4. Tendency to edema throughout the day with typical feeling of pressure/pain~5. Unsuccessful conservative therapy attempts and weight loss attempts"
62068453|NCT06399367||Non-Lipedem/MSOT Cohort|"MSOT measurements are carried out on 50 subjects with clinically healthy subcutaneous fatty tissue. In these studies, adult patients (\>18 years, \<80 years) are included after exclusion of the indicators mentioned below, after risk information and voluntary consent.~1. Typical tenderness in the calf, back of the knee or lateral thigh~2. Tendency to hematoma in areas affected by edema~3. Typical appearance of fatty tissue distribution with dent formation, asymmetry in lateral comparison and increased circumference~4. Tendency to edema throughout the day with typical feeling of pressure/pain~5. Unsuccessful conservative therapy attempts and weight loss attempts."
62068454|NCT01720823|EXPERIMENTAL|home polysomnography and standard polysomnography|home polysomnography (GETEMED) and standard polysomnography (BRAINNETII) are both carried out in children during 1 night.
62068455|NCT00747526|EXPERIMENTAL|Rabeprazole sodium 5 mg|
62068456|NCT00747526|EXPERIMENTAL|Rabeprazole sodium 10 mg|
62068457|NCT05943275|OTHER|Patient with an indication for right heart catheterization|During the preparation of the subject on the cardiac catheterization table, a person specifically trained to the measurements of the medical device under test will be dedicated to this study. Once the skin has been cleaned with alcohol the device (magnet and micro-sensor encapsulated in the plastic support) will be placed on the subject's uninjured skin of the subject, on the path of the jugular vein. A second device will be placed at the level of the radial artery radial artery with the help of a bracelet. The signals will be recorded and observed on a screen for the duration of the invasive hemodynamic measurements, i.e. approximately 15 minutes.
62273066|NCT05993637||High Tibial Osteotomy|patients who were diagnosed with medial gonarthrosis and underwent HTO surgery
62273067|NCT05993637||Unicompartmantal Knee Arthroplasty|patients who were diagnosed with medial gonarthrosis and underwent UKA surgery
62068458|NCT04748419|EXPERIMENTAL|Hypofractionated radiation therapy (hfRT) with Durvalumab|Combining consolidative radiation therapy (RT) using a hypofractionated regimen (hfRT) of 10Gy x 2 fractions for boosting the residual primary lung cancer with adjuvant anti-PD-L1 therapy (durvalumab), dose of 10 mg/kg infusion every two weeks concurrently for up to 12 months or disease progression.
62068459|NCT01416701|ACTIVE_COMPARATOR|Vitamin D (D3, cholecalciferol)|
62068460|NCT01416701|PLACEBO_COMPARATOR|Placebo (cellulose)|
62068461|NCT03100994|NO_INTERVENTION|Group A|without nerve block
62068462|NCT03100994|ACTIVE_COMPARATOR|Group B|Ultrasound guided transmuscular quadratus lumborum block with 0.125% bupivacaine 30ml
62068463|NCT03100994|ACTIVE_COMPARATOR|Group C|Ultrasound guided quadratus lumborum type 2 block with 0.125% bupivacaine 30ml
62273068|NCT06449638|ACTIVE_COMPARATOR|Standard of Care|Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.
62273069|NCT06449638|EXPERIMENTAL|Revita|Revita is an opaque, lyophilized dehydrated complete human placental membrane (dCHPM) allograft.
62273070|NCT06449638|EXPERIMENTAL|Relese|Relese is a fenestrated dehydrated complete human placental membrane (dCHPM) allograft.
62273071|NCT06449638|EXPERIMENTAL|Cogenex|Cognenex is a fenestrated dehydrated complete human placental membrane (dCHPM) allograft.
62273072|NCT06449638|EXPERIMENTAL|Enverse|Enverse is a translucent dehydrated complete human placental membrane (dCHPM) allograft.
62273073|NCT06095856|EXPERIMENTAL|Lf-La-Ks|"On the first day, baseline muscle activity will be measured by the sEMG, then, the leaf gauge will be used till centric relation is located, then, muscle activity will be recorded once more. On the second day, baseline muscle activity will be measured by the sEMG, then, the Lucia jig will be used till centric relation is located, then, muscle activity will be recorded once more.~On the third day, baseline muscle activity will be measured by the sEMG, then, the Kois deprogrammer will be used till centric relation is located, then, muscle activity will be recorded once more.~Patient satisfaction questionnaire will be handed-out to the participants and filled-out at the end of the third day."
62287093|NCT01225562|PLACEBO_COMPARATOR|3|Oral Treatment
62636206|NCT06202144|ACTIVE_COMPARATOR|Noninvasive ventilation|Helmet NIV will be delivered in the pressure-support mode, with PEEP=12 cmH2O and pressure support=12 cmH2O
62636207|NCT03030625|OTHER|IGRT/VMAT focal therapy boost to DIL|Localized prostate cancer (PCa) of intermediate and high risk according to NCCN criteria
62068464|NCT02478125|ACTIVE_COMPARATOR|burixafor hydrobromide|Four daily doses of burixafor hydrobromide alone
62068465|NCT02478125|ACTIVE_COMPARATOR|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
62273074|NCT06095856|EXPERIMENTAL|La-Ks-Lf|"On the first day, baseline muscle activity will be measured by the sEMG, then, the Lucia jig will be used till centric relation is located, then, muscle activity will be recorded once more. On the second day, baseline muscle activity will be measured by the sEMG, then, the Kois deprogrammer will be used till centric relation is located, then, muscle activity will be recorded once more. On the third day, baseline muscle activity will be measured by the sEMG, then, the leaf gauge will be used till centric relation is located, then, muscle activity will be recorded once more.~Patient satisfaction questionnaire will be handed-out to the participants and filled-out at the end of the third day."
62273075|NCT06095856|EXPERIMENTAL|Ks-Lf-La|"On the first day, baseline muscle activity will be measured by the sEMG, then, the Koid deprogrammer will be used till centric relation is located, then, muscle activity will be recorded once more. On the second day, baseline muscle activity will be measured by the sEMG, then, the leaf gauge will be used till centric relation is located, then, muscle activity will be recorded once more. On the third day, baseline muscle activity will be measured by the sEMG, then, the Lucia jig will be used till centric relation is located, then, muscle activity will be recorded once more.~Patient satisfaction questionnaire will be handed-out to the participants and filled-out at the end of the third day."
62287094|NCT00964431|EXPERIMENTAL|Indomethacin Test (lower dose)|
62453878|NCT03202836|EXPERIMENTAL|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
62453879|NCT03202836|OTHER|no medication|only tocolysis plus corticosteroid for 48 hours
62453880|NCT06056388|ACTIVE_COMPARATOR|Deep-threaded implants|Straumann BLX implants
62636208|NCT03534947|EXPERIMENTAL|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
62636209|NCT03534947|EXPERIMENTAL|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
62453881|NCT06056388|PLACEBO_COMPARATOR|Regular-threaded implants|Straumann BLT implants
62636210|NCT03534947|OTHER|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
62068466|NCT02478125|EXPERIMENTAL|Docetaxel|"Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2"
62068467|NCT02140710|ACTIVE_COMPARATOR|Osteopathic treatment group|visceral osteopathic treatment algorithm
62068468|NCT02140710|NO_INTERVENTION|Control group|no intervention
62068469|NCT01411501|EXPERIMENTAL|Acupuncture at ST25 and BL25|the points formula of back-shu point combination with front-mu point.
62068470|NCT01411501|EXPERIMENTAL|Acupuncture at LI11 and ST37|the points formula of He-points
62068471|NCT01411501|EXPERIMENTAL|Acupuncture at ST25, BL25, LI11 and ST37|the formula of He-point,back-shu point and front-mu point
62453882|NCT01469546|EXPERIMENTAL|Axitinib (AG-013736)|A prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma who have received no more than two prior lines of systemic therapy for recurrent or metastatic head and neck cancer.
62453883|NCT02148302|EXPERIMENTAL|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.~A run-in period of two weeks followed by twelve weeks of active treatment"
62068472|NCT01411501|ACTIVE_COMPARATOR|medicine|oral use of mosapride citrate
62636211|NCT01575418|EXPERIMENTAL|Rectal specific formulation (RF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
62068473|NCT01932294||MedaMACS participants|All participants who have met the inclusion criteria.
62068474|NCT05636150|EXPERIMENTAL|Fruquintinib plus S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w."
62068475|NCT04245085|ACTIVE_COMPARATOR|Arm A|"* Atezolizumab (1200 mg) Q3W, until PD~* Bevacizumab (15 mg/kg), Q3W, until PD~* Carboplatin (AUC5) Q3W, 4-6 cycles~* Paclitaxel (175-200 mg/m2), Q3W, 4-6 cycles"
62068476|NCT04245085|ACTIVE_COMPARATOR|Arm B|"* Atezolizumab (1200 mg), Q3W, until PD~* Bevacizumab (15 mg/kg), Q3W, until PD~* Pemetrexed (500 mg/m2), Q3W, until PD"
62068477|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
62068478|NCT01582789|ACTIVE_COMPARATOR|enfilcon A/senofilcon A|Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.
62636212|NCT01575418|ACTIVE_COMPARATOR|Vaginal formulation (VF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
62636213|NCT01575418|ACTIVE_COMPARATOR|Reduced glycerin vaginal formulation (RGVF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
62068479|NCT01582789|ACTIVE_COMPARATOR|senofilcon A/enfilcon A|Subjects were randomized to wear senofilcon A then enfilcon A for two weeks
62068480|NCT02024035||Tomotherapy|
62068481|NCT02024035||Arc'therapy Vmat|
62068482|NCT02024035||Arctherapy Rapid'Arc|
62068483|NCT00152971|EXPERIMENTAL|Dabigatran Dose 1|low dose regimen taken once daily
62068484|NCT00152971|EXPERIMENTAL|Dabigatran Dose 2|high dose regimen taken once daily
62068485|NCT00152971|ACTIVE_COMPARATOR|Enoxaparin|30 mg subcutaneously twice daily
62068486|NCT01167283|ACTIVE_COMPARATOR|Electrostimulation|Neuromuscular electrical stimulation
62068487|NCT01167283|SHAM_COMPARATOR|Sham stimulation|Sham stimulation
62068488|NCT02012192|EXPERIMENTAL|Ganetespib + Paclitaxel|Drug: ganetespib, dose will depend on phase I results, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle); Drug: paclitaxel, 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression.
62287095|NCT00964431|EXPERIMENTAL|Indomethacin Test (upper dose)|Single dose
62068489|NCT02012192|ACTIVE_COMPARATOR|Paclitaxel|Drug: paclitaxel: 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression
62273076|NCT04673786|EXPERIMENTAL|CT-P43|All patients who were initially randomized to the CT-P43 group on Day 1 (Week 0) will continue their treatment with CT-P43 until Week 40.
62273077|NCT04673786|ACTIVE_COMPARATOR|Stelara|Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.
62273078|NCT04080622|PLACEBO_COMPARATOR|Placebo|Usual care
62273079|NCT04080622|ACTIVE_COMPARATOR|Selenium|Usual care + selenium 300 µg/day (IV infusion)
62273080|NCT00713700|EXPERIMENTAL|Device|
62273081|NCT04751162||Phase I|Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones for tracking PA, SQ and symptoms for 3 weeks The ECOG-PS will be assessed by clinician at both, baseline and subsequent visit after the 3 weeks.
62273082|NCT04751162||Phase II|"Participants will be equipped with both devices (wearable and mobile application) for further monitoring during the following 9 weeks. Study participants will undergo scheduled visits according to local standard practice. The study will progress to Phase II just in case any of the following conditions are met at the end of Phase I:~* The average time of use of the wearable device is equal or over 96 hours/week/participant, OR~* The average SUS score is equal or above 68, OR~* The average adherence to the app is equal or above 80%, measured as the rate of submitted ePROMs through the app."
62273083|NCT02797886|EXPERIMENTAL|FES+VOL|Electrical stimulation (FES) in concert with volitional effort. The subject is visually cued to initiate the movement and when they begin the movement (as ascertained by EMG response), the stimulation is immediately applied until the completion of the trial.
62273084|NCT02797886|ACTIVE_COMPARATOR|FES|Electrical stimulation alone. The subject is asked to do nothing as electrical stimulation initiates and completes the movement for them.
62273085|NCT02797886|ACTIVE_COMPARATOR|VOL|Volitional effort alone. When cued, the subject initiates and completes the movement on their own until the completion of the trial. There is no electrical stimulation in this group.
62273086|NCT03105570|EXPERIMENTAL|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
62273087|NCT03406065|EXPERIMENTAL|Sodium bicarbonate supplementation|Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
62273088|NCT03406065|PLACEBO_COMPARATOR|Placebo treatment|Group taking oral supplementation with placebo (maltodextrin with NaCl) in a similar tablet form prepared by the same producer as NaHCO3 tablets.
62273089|NCT04146610|EXPERIMENTAL|Dp303c|Multiple dose grouping
62273090|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
62273091|NCT02179957||CT and FFR|Coronary stenoses which have been analysed with both CT and FFR
62287096|NCT00964431|ACTIVE_COMPARATOR|Celecoxib 400 mg|
62287097|NCT00964431|PLACEBO_COMPARATOR|Placebo|
62453884|NCT02148302|NO_INTERVENTION|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
62273092|NCT03979274|EXPERIMENTAL|Reference Eutirox®, then Test Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (mcg) (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
62068490|NCT00675415|ACTIVE_COMPARATOR|Capnography|"Capnography: Subjects randomized to capnography-titration arm: The endoscopy team would be made aware of the capnographic abnormalities as they arise.~In this arm, the endoscopy team will have the graphic representation of respiratory activity (capnography) as well as end-epxiratory levels of carbon dioxide in addition to the normal physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography.~This observation phase would take place for a baseline prior to sedation, during the administration of sedation as well as throughout the procedure. Monitoring for the study would stop upon completion of the endoscopic procedure."
62287098|NCT04428047|EXPERIMENTAL|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
62273093|NCT03979274|EXPERIMENTAL|Test Eutirox®, then Reference Eutirox®|Participants received single oral dose of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Reference Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
62273094|NCT02090400|OTHER|Bazedoxifene & Calcium/Vit D|Bazedoxifene 20mg oral once a day and calcium 500mg and 400 IU vitamin D (OSTINE)
62273095|NCT02090400|OTHER|Calcium/Vit D|Calcium 500mg and 400 IU vitamin D (OSTINE )daily.
62273096|NCT01034995|EXPERIMENTAL|SSR125543 20 mg|1 capsule of SSR125543 20 mg + 1 capsule of placebo
62068491|NCT00675415|NO_INTERVENTION|Standard Monitoring|Subjects randomized to capnography-blinded arm: In this arm, the endoscopy team will not have the graphic representation of respiratory activity (capnography) as well as end-expiratory levels of carbon dioxide available. Only a standard of care physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography at the disposal of the endoscopy team to titrate the sedative medications.
62068492|NCT02732626|ACTIVE_COMPARATOR|pulmonary vein isolation alone|patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map
62068493|NCT02732626|EXPERIMENTAL|pulmonary vein isolation + low voltage area guided ablation|patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any
62068494|NCT04599738|PLACEBO_COMPARATOR|Wheat muffin|Muffin made with 100% wheat flour
62636214|NCT06265090|EXPERIMENTAL|ball and balloon exercises|"Ball and balloon exercise exercises:~The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Instructions~1. supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~2. Insert a ball measuring between four and six inches in diameter in the space between your knees.~3. Put your left hand upon a balloon and your right arm above your head.~4. Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~5. drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle."
62068495|NCT04599738|EXPERIMENTAL|Finger millet grain muffin|Muffin made with 50% wheat flour and 50% finger millet crushed grain
62068496|NCT01849432||Control|Healthy Controls
62068497|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
62068498|NCT01849432||Panic Disorder|Participants with Panic Disorder
62273097|NCT01034995|EXPERIMENTAL|SSR125543 50 mg|1 capsule of SSR125543 50 mg + 1 capsule of placebo
62273098|NCT01034995|EXPERIMENTAL|SSR125543 100 mg|2 capsules of SSR125543 50 mg
62273099|NCT01034995|ACTIVE_COMPARATOR|escitalopram 10 mg|1 capsule of escitalopram 10 mg + 1 capsule of placebo
62068499|NCT01849432||Specific Phobia|Participants who have specific phobias
62068500|NCT03413254|ACTIVE_COMPARATOR|2nd look DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up according to the Dutch colorectal cancer guideline until 5 years.
62273100|NCT01034995|PLACEBO_COMPARATOR|placebo|2 capsules of placebo
62453885|NCT03150836|EXPERIMENTAL|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
62453886|NCT03150836|EXPERIMENTAL|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
62461521|NCT04320173|EXPERIMENTAL|Lidocaine Patch (Sequences BCA)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 3, 3 lidocaine 5% patches were applied in Period 1, and 3 lidocaine 5% medicated plasters were applied in Period 2, and 3 lidocaine 1.8% patches were applied in Period 3.
62273101|NCT05490420|SHAM_COMPARATOR|Control|17 participants who meet the inclusion criteria will be applied conventional exercise which includes nerve gliding and tendon gliding exercises. And also sham (placebo) upper extremity manual lymphatic drainage will be applied. Sham (placebo) manual lymphatic drainage will include only classical massage not manual lymphatic drainage techniques. Participants will be treated for a total of 6 weeks, 2 days a week. Each session will last approximately 20-30 minutes, and the exercises will be performed in 3 sets with 10 repetitions.
62273102|NCT05490420|EXPERIMENTAL|experimental|17 participants who meet the inclusion criteria will be applied both conventional exercise and upper manual lymphatic drainage (MLD). MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions. Within the scope of this research, an application will be made to cover the entire upper extremity lymphatic system. MLD will last approximately 20-30 minutes. Conventional exercise, which includes nerve gliding and tendon gliding exercises, will be performed in 3 sets with 10 repetitions. Participants will be treated for a total of 6 weeks, 2 days a week.
62273103|NCT02693587||Misodel group in Holbæk|Misodel for induction of labour in Holbæk
62273104|NCT02693587||Angusta group in Roskilde and Næstved|Angusta for induction of labour in Roskilde and Næstved
62273105|NCT05088707|EXPERIMENTAL|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
62652960|NCT02888054|EXPERIMENTAL|Sequence ABAB|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
62273106|NCT05088707|ACTIVE_COMPARATOR|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
62273107|NCT02975843|EXPERIMENTAL|CHF5993|99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
62273108|NCT06367296|EXPERIMENTAL|Normal Weight|All volunteers Normal Weight: BMI=18.5 kg/m2 to 24.9 kg/m2 and % fat \<25.9%, n=16
62273109|NCT06367296|EXPERIMENTAL|Obese|All volunteers Obesity: BMI= 30.0 kg/m2 to 39.9 kg/m2 m2 and % fat \> 32%, n=16.
62273110|NCT02028195|EXPERIMENTAL|Health check|The intervention consists of invitation for a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up.
62273111|NCT02028195|NO_INTERVENTION|No invitation|The persons randomised to the control arm does not get invitation to a health care examination before time for follow up in the intervention group.
62273112|NCT05841095|ACTIVE_COMPARATOR|ISA104|
62273113|NCT05841095|PLACEBO_COMPARATOR|Placebo|
62273114|NCT04634214||COVID 19 positive patients without diabetes|COVID 19 positive patients without diabetes
62273115|NCT04634214||COVID 19 positive patients with diabetes|COVID 19 positive patients with diabetes
62068501|NCT03413254|EXPERIMENTAL|2nd and 3rd DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up and third look DLS after negative CT abdomen at 18 months and normal CEA. Third look DLS is not performed in patients with evidence of disease that is not curable, or in those already diagnosed with PM in the preceding period.
62068502|NCT00659594|ACTIVE_COMPARATOR|1|Ciclesonide 200µg
62068503|NCT00659594|PLACEBO_COMPARATOR|2|Placebo
62068504|NCT04990206|EXPERIMENTAL|Intervention|TranS-C
62068505|NCT05989373|EXPERIMENTAL|nerve stimulation|The test in currently used to search for a nerv compression
62068506|NCT02529878|EXPERIMENTAL|conversion treatment|after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent
62636215|NCT06265090|ACTIVE_COMPARATOR|core stability exercises|"Core stability exercises (CSE): Subjects in this group were handled with core stability exercises that targeted deep abdominal muscles. This included a series of exercises as well as a baseline therapeutic management of ultrasonic as well as TENS. A physiotherapist supervised these exercises.~For four weeks, all groups did core stability exercises for 30 minutes three times per week.exercises. Based on the patient's success, the intensity of the individual training steadily increased with decreasing therapist support. Patients were told to contract their abdominal muscles and hold the contraction while continuing to breathe normally during each repetition of each exercise."
62636216|NCT05083663|EXPERIMENTAL|Group I|received bupivacaine 0.375 % 15 mL + normal saline 4ml +hyaluronidase 800 IU in 1 ml.
62273116|NCT00413361|PLACEBO_COMPARATOR|A|placebo
62636217|NCT05083663|NO_INTERVENTION|Group II|received bupivacaine 0.375% 15 mL + normal saline5 ml.
62636218|NCT03639246|EXPERIMENTAL|Phase 1b: AVB-S6-500+PLD|
62636219|NCT03639246|EXPERIMENTAL|Phase 1b: AVB-S6-500+Pac|
62273117|NCT00413361|EXPERIMENTAL|B|versus hydroxychloroquine
62636220|NCT03639246|EXPERIMENTAL|Phase 2: AVB-S6-500+PLD|
62273118|NCT02867761|ACTIVE_COMPARATOR|Indacaterol/Glycopyrrolate|indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily for 12 weeks
62273119|NCT02867761|PLACEBO_COMPARATOR|Placebo|Placebo 27.5/15.6 mcg inhaled twice daily for 12 weeks
62636221|NCT03639246|EXPERIMENTAL|Phase 2: AVB-S6-500+Pac|
62636222|NCT03639246|ACTIVE_COMPARATOR|Phase 2: Placebo+PLD|
62636223|NCT03639246|ACTIVE_COMPARATOR|Phase 2: Placebo+Pac|
62636224|NCT04307134||R/R ALL|Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia (ALL)
62068507|NCT02527070|EXPERIMENTAL|Red LED|Light emitting diodes, 670 nm, 50 mW/cm2, Quantum Warp10 (Quantum Devices Inc, Barneveld, WI, USA); RESPeRATE; Heat/cold provocation
62068508|NCT02527070|ACTIVE_COMPARATOR|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/cm2, Omnilux new-U (Photomedex, Horsham, PA, USA); RESPeRATE; Heat/cold provocation
62068509|NCT02681705|EXPERIMENTAL|Study Treatment|All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with Temozolomide. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as Temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
62068510|NCT04180735||Perforation|Perforation
62068511|NCT04180735||No perforation|No perforation
62273120|NCT00388908|EXPERIMENTAL|A|Multifaceted intervention
62273121|NCT00388908|ACTIVE_COMPARATOR|B|Usual Care
62273122|NCT01844895|EXPERIMENTAL|Abatacept (Autoinjector and Prefilled Syringe)|"Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months~Abatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
62636225|NCT05544591|EXPERIMENTAL|611 Q2W|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 1, followed by two 150 mg injections (for a total of 300 mg) q2w from Week 2 to Week 14 (7 cycles).
62636226|NCT05544591|EXPERIMENTAL|611 Q4W|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on week 0 Day 1, followed by two 150 mg injections (for a total of 300 mg) q4w on week 4, 8, 12 and two injections of placebo on week 2, 6, 10, 14.
62636227|NCT05544591|PLACEBO_COMPARATOR|placebo|Four subcutaneous injections of placebo as a loading dose on week 0 Day 1, followed by two injections q2w from Week 2 to Week 14 (7 cycles).
62636228|NCT03445000|EXPERIMENTAL|Trial treatment|"Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.~Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision."
62636229|NCT05429541||Otitis Media (OM) Case Group|"Case definition:~1. Acute otitis media (AOM)~   AOM will be diagnosed by pneumatic otoscopy by validated otoscopists, when children with acute onset of otalgia had tympanic membranes (TMs) that were:~  1. bulging or full; and~  2. a cloudy or purulent effusion was observed, or the TM was completely opacified; and~  3. TM mobility was reduced or absent~2. Otitis media with effusion (OME)~   Collection of fluid within the middle ear without signs of acute inflammation, fever or otorrhea. Otoscopic findings include:~  1. dull tympanic membrane (TM)~  2. retraction of TM~  3. fluid level or air bubble~  4. TM colour change~  5. restricted TM mobility with pneumatic otoscopy~3. Chronic suppurative otitis media (CSOM)~Otoscopic findings:~1. Perforated TM~2. Mucopurulent discharge"
62068512|NCT04199533||Classroom Observation|The investigators will use day-long observational and interview procedures with eight staff from four schools. The classroom observation will focus on documenting episodes of classroom disruptive behavior, including antecedents and consequences to the behaviors. The interview will involve discussing with staff decision-making processes and current needs around classroom behavioral management.
62068513|NCT04199533||RUBI Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing adaptation or pruning needs related to RUBI content and structure to ensure the redesigned curriculum (RUBIES) is contextually appropriate for schools.
62068514|NCT04199533||RUBIES Collaborative Design|Eight staff from 4 schools will attend one of four 2-hour in-person feedback sessions to support collaborative feedback around RUBI redesign, including feasibility and appropriateness and methods supporting implementation.
62273123|NCT01890421|EXPERIMENTAL|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
62273124|NCT05006885|EXPERIMENTAL|ALT-801 Dose Level 1|Administered once a week for 12 weeks
62273125|NCT05006885|EXPERIMENTAL|ALT-801 Dose Level 2|Administered once a week for 12 weeks
62273126|NCT05006885|EXPERIMENTAL|ALT-801 Dose Level 3|Administered once a week for 12 weeks
62273127|NCT05006885|PLACEBO_COMPARATOR|Placebo|Administered once a week for 12 weeks
62068515|NCT04199533||RUBIES Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing final RUBIES adaptation or pruning needs.
62068516|NCT01998490|EXPERIMENTAL|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
62068517|NCT01998490|EXPERIMENTAL|Robot-assisted activity|30 minutes group session with robot-assisted activity with the robot seal Paro twice a week for 12 weeks in groups of 4-6 participants
62453887|NCT03150836|EXPERIMENTAL|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
62453888|NCT03150836|EXPERIMENTAL|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
62453889|NCT03150836|EXPERIMENTAL|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
62068518|NCT01998490|NO_INTERVENTION|Control|Control group with treatment as usual
62273128|NCT03317756|EXPERIMENTAL|Patient Variation 1|Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys.
62636230|NCT05306717||Epidemiology|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year.
62273129|NCT03317756|EXPERIMENTAL|Patient Variation 2|Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys.
62273130|NCT03923569|OTHER|Alzheimer's Disease patients group|This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease
62273131|NCT03923569|OTHER|Healthy control group|This group contains the 31 (anticipated) age and sex -matched healthy controls
62273132|NCT01843218|OTHER|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
62273133|NCT03865693|EXPERIMENTAL|scarmbler treatment group|Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The experimental participants were received scarmbler therapy 10 times for 2 weeks. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
62273134|NCT03865693|SHAM_COMPARATOR|sham treatment group|conservative management without scarmbler therapy
62273135|NCT02692209||FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
62273136|NCT02692209||Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
62273137|NCT00294307||Advanced Practice Nurse Care (APNC)|Hospital to Home
62273138|NCT00294307||Augmented Standard Care (ASC)|Hospital only
62273139|NCT00294307||Resource Nurse Care (RNC)|Hospital only
62273140|NCT04270097||Emirati Genetic T2D cohort|
62273141|NCT06484790|EXPERIMENTAL|NW-301V|NW-301V monotherapy in patients with Solid Tumors with KRAS G12V mutation
62068519|NCT01962701||OCT-group|OCT prior to C-section
62273142|NCT06484790|EXPERIMENTAL|NW-301D|NW-301D monotherapy in patients with Solid Tumors with KRAS G12D mutation
62273143|NCT03690765||Endometriosis/Dydrogesterone|Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®
62273144|NCT00955630|ACTIVE_COMPARATOR|Monthly injections|3 monthly injections of ranibizumab followed by prn injections
62273145|NCT00955630|ACTIVE_COMPARATOR|PRN injections|injections of ranibizumab on a prn basis from the start of the study
62068520|NCT01962701||None-OCT-group|No OCT prior to C-section
62273146|NCT03335332|EXPERIMENTAL|High intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.
62068521|NCT00911313|EXPERIMENTAL|Letrozole|
62068522|NCT00911313|ACTIVE_COMPARATOR|Metformin-CC|
62273147|NCT03335332|ACTIVE_COMPARATOR|Moderate intensity exercise|
62273148|NCT03678402|EXPERIMENTAL|Palarum Fall Prevention System|The Study site, the OSU Wexner Center Brain and Spine Hospital, is located on three contiguous floors with each floor being made up of two units or Pods designated East and South. Following commencement of the study, and throughout its duration, Pods assigned to the Study will only utilize the Palarum Fall Prevention System and a monitored PUP™ sock, i.e., (Patient is Up) System as the standard of care intervention for fall prevention in accordance with its operating instructions and procedures.
62636231|NCT04633746||sepsis with AKI|Patients admitted with the diagnosis of sepsis associated with elevation of renal function tests
62636232|NCT04633746||Sepsis without AKI|Patients admitted with the diagnosis of sepsis with no elevation of renal function tests
62636233|NCT05701982|EXPERIMENTAL|Every Step Counts-Tai Chi|The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
62273149|NCT01325428|EXPERIMENTAL|Afatinib once daily (OD)|Patients receive afatinib monotherapy once daily until progression of their disease
62636234|NCT05701982|ACTIVE_COMPARATOR|Usual Care|Usual Care
62453890|NCT03150836|EXPERIMENTAL|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
62453891|NCT05272358||strategy 1: sarcoma MDTB before surgery and initial management in the NETSARC network|Patients who had a sarcoma-specialized multidisciplinary tumour board (MDTB) before the initial surgery and complete initial management (including surgery) in the network (also including patients who had a sarcoma-specialized MDTB after the initial surgery and complete initial management in the network) (strategy 1)
62453892|NCT05272358||strategy 2: sarcoma MDTB before surgery and initial management outside the NETSARC network|Patients who had a sarcoma-specialized MDTB before the initial surgery and initial management (including surgery) outside the network (strategy 2)
62453893|NCT05272358||strategy 3: sarcoma MDTB after surgery and initial management outside the NETSARC network|Patients who had initial management (including surgery) outside the network and a sarcoma-specialized MDTB after initial surgery (strategy 3)
62453894|NCT05272358||strategy 4: No sarcoma MDTB and initial management outside the NETSARC network|Patients who had an initial management (including surgery) outside the network, without sarcoma-specialized MDTB neither before nor after the initial surgery (strategy 4).
62453895|NCT02129023|EXPERIMENTAL|exergame|Participants were asked to use exergame (Xbox 360) half hour for three times per week in the 12-week study period.
62068523|NCT02611830|EXPERIMENTAL|Maintenance Phase: Induction IV + Vedolizumab 108 mg SC|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
62273150|NCT05853614|EXPERIMENTAL|Nurse-Led Quality of Life Intervention|"Participants and caregivers will complete study procedures as outlined:~* Completion of surveys at four timepoints (baseline, one month, two months, and three months)~* Three visits on-site with trained clinical research nursing staff.~* Semi-structured exit interviews with participants and caregivers."
62068524|NCT02611830|EXPERIMENTAL|Maintenance Phase: Induction IV + Vedolizumab 300 mg IV|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
62068525|NCT02611830|EXPERIMENTAL|Maintenance Phase: Induction IV + Placebo|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
62273151|NCT04977180|EXPERIMENTAL|Treatment arm (beta blocker and ACE inhibitor)|Participants will receive a beta blocker (either metoprolol or carvedilol) and an ACE inhibitor (lisinopril) at standard doses based on tolerance starting from when they start induction therapy for AML through 90 days after the first day of the last cycle of therapy that includes an anthracycline (whether that is in the induction, re-induction, or consolidation phase of treatment). They will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
62273152|NCT04977180|NO_INTERVENTION|Standard Clinical Care|Participants will receive standard clinical care, but will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
62636235|NCT05649670|EXPERIMENTAL|Intervention (MSU)|Deployment of MSU + conventional ambulance
62636236|NCT05649670|NO_INTERVENTION|Control (usual care)|Deployment of conventional ambulance
62636237|NCT01906242|PLACEBO_COMPARATOR|Water|Patients' dentures are treated with water (placebo) once a week for 10 min.
62636238|NCT01906242|ACTIVE_COMPARATOR|sodium hypochlorite|Patients' dentures are treated with a solution of sodium hypochlorite 0.5% once per week for 10 min
62636239|NCT01906242|ACTIVE_COMPARATOR|0.5% chlorhexidine|Patients' dentures are treated with 0.5% chlorhexidine once a week for 10 min.
62636240|NCT01906242|ACTIVE_COMPARATOR|0.12% sodium bicarbonate|Patients' dentures are treated with sodium bicarbonate 0.12% once a week for 10 min.
62273153|NCT05151055|EXPERIMENTAL|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
62453896|NCT02129023|NO_INTERVENTION|control|Participants were not asked to use exergames.
62453897|NCT00394056|OTHER|Period 1|
62453898|NCT00394056|OTHER|Period 2|
62273154|NCT05151055|PLACEBO_COMPARATOR|Placebo|
62273155|NCT02090712||Reperfusion strategies|Patients submitted to thrombolysis with tenecteplase after acute myocardial infarction will be transferred to a tertiary center and angiography with the intention to treat the culprit artery will be performed in 3 - 48 hours (preferably first 24 hours).
62273156|NCT02090712||Primary PCI|Patients with contra-indication to thrombolytics or able to reach the catheterization laboratory within 90 minutest will be transferred for primary angioplasty, according to current guidelines.
62273157|NCT01569802||screening|
62453899|NCT00394056|OTHER|Period 3|
62636241|NCT00994110|EXPERIMENTAL|SOM230|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
62636242|NCT00994110|PLACEBO_COMPARATOR|placebo|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
62636243|NCT02130947|EXPERIMENTAL|Exercise Intervention Arm|The exercise intervention will consist of a combination of aerobic (cardiovascular exercise) and strength training (emphasis of the intervention) 3 times per week for 12 weeks with each session lasting \~1.5 hours.
62636244|NCT02130947|NO_INTERVENTION|Non-Exercise Control Arm|Participants in the Non-Exercise Control Arm will not exercise for 12 weeks.
62636245|NCT06116578|ACTIVE_COMPARATOR|A: Pembrolizumab before surgery|Before surgery: Pembrolizumab 200 mg two intravenous (IV) infusions q3w (2 injections: at C1D1 and C1D21)
62273158|NCT05552911||De novo coronary lesions: cutting balloon group|De novo coronary lesions were pretreated with a cutting balloon and then treated with a drug-coated balloon.
62636246|NCT06116578|ACTIVE_COMPARATOR|B: Pembrolizumab + olaparib before surgery|Before surgery: Pembrolizumab 200 mg two IV infusions q3w (2 injections: at C1D1 and C1D21) + concomitant full dose olaparib (300 mg per os b.i.d) during four weeks
62273159|NCT05552911||De novo coronary lesions: non-cutting balloon group|De novo coronary lesions were pretreated with a non-cutting (Compliance balloon or/and non-compliant balloon) balloon and then treated with a drug-coated balloon.
62273160|NCT05552911||In-stent restenosis: Type-I|Body stenosis: restenosis of the stent body, not beyond the edge of the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
62273161|NCT05552911||In-stent restenosis: Type-II|Marginal stenosis type: restenosis at the edge of the stent, stenosis ≥50% within 5mm of the stent edge, which can continue into the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
62273162|NCT05552911||In-stent restenosis:Type-III|Diffuse proliferative type: the lesion extends to the whole scaffold body and beyond the edge of both ends.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
62273163|NCT05552911||In-stent restenosis:Type-IV|Complete occlusion type: complete occlusion in the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
62453900|NCT02497456|EXPERIMENTAL|Follow-up counselling|Participants in the experimental arm will receive home-based HIV counselling and testing and referral for HIV care if found to have HIV infection. Additionally, participants will receive home-based follow-up counselling at 1 and 2 months after HIV diagnosis.
62453901|NCT02497456|NO_INTERVENTION|Standard of care|Participants in this arm will receive only home-based HIV counselling and testing and referral for HIV care if found to have HIV infection.
62453902|NCT06170268||Not Applicable/Open Label Registry|ALZ-NET is a growing network of sites that follow participants over time with an expandable platform, allowing for the collection of real-world data from enrolled patients being evaluated for or receiving any novel FDA-approved Alzheimer's disease therapies. ALZ-NET is treatment agnostic. Drug treatment dosage, frequency and duration will be guided by FDA label and clinician judgment as part of treatment and patient management.
62636247|NCT03225170|EXPERIMENTAL|Self-affirmation (SA) group|"Immediately prior to the scheduled cancer genetic counseling appointment, clients:~1. completed standardized questionnaires on self-affirmation (SA) intervention that focused on positive values of personal importance. The SA intervention required clients to rank 11 items (artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity) from most important to least important and to elaborate on one that was most important to them and why;~2. 6-item standardized measure of anxiety questionnaire;~3. after the genetic counseling session, clients were required to fill out a post session questionnaire"
62652961|NCT02888054|EXPERIMENTAL|Sequence BAAB|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
62652962|NCT03000972|ACTIVE_COMPARATOR|Standard Nail|Hip fracture surgery with a PFN-A Nail (Proximal Femoral Nail Augmentation).
62273164|NCT02268058|ACTIVE_COMPARATOR|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
62273165|NCT02268058|ACTIVE_COMPARATOR|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
62273166|NCT02268058|ACTIVE_COMPARATOR|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency Department."
62273167|NCT02268058|NO_INTERVENTION|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
62273168|NCT04222452||Hypophosphatasia patients (HPP)|Patients with known hypophosphatasia (HPP) as diagnosed using genetic testing.
62273169|NCT04222452||Controls|Healthy individuals (controls) matched to the cases by gender and age.
62273170|NCT04218253|EXPERIMENTAL|nutritional intervention|300 or 500 calories nutritional support before operation according to the level of malnutrition
62273171|NCT04218253|OTHER|control group|Dietary education was conducted according to preoperative nutritional requirements
62273172|NCT03477708||Study group|TCCO2 monitoring
62273173|NCT03477708||Control group|Routine monitoring
62273174|NCT02971670|EXPERIMENTAL|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
62273175|NCT02971670|EXPERIMENTAL|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
62652963|NCT03000972|EXPERIMENTAL|Augmented Nail|Hip fracture surgery with a PFN-A Nail with Cement augmentation with TraumaCemV+
62273176|NCT02971670|EXPERIMENTAL|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
62273177|NCT02971670|PLACEBO_COMPARATOR|Dose Group 0|Control: Al(OH)3 Adjuvant
62273178|NCT02474082|EXPERIMENTAL|Secukinumab|Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
62273179|NCT02474082|ACTIVE_COMPARATOR|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
62273180|NCT06364085|EXPERIMENTAL|Participant Group|Participants who meet eligibility criteria and provide informed consent.
62273181|NCT02979665||Ranibizumab Ophthalmic|DME consults requiring anti-VEGF treatment
62273182|NCT02979665||Control|DME consults not requiring anti-VEGF
62273183|NCT03378908|NO_INTERVENTION|Conventional Treatment 6 meals|Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
62273184|NCT03378908|EXPERIMENTAL|Intervention Treatment 3 meals|Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
62273185|NCT04890210|EXPERIMENTAL|Early Diet Group|"* 1st diet: 100 ml of clear fluid (1 hour after esophageal variceal ligation)~* 2nd diet: 100 ml of clear fluid (4 hours after the 1st diet)~* 3rd diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 4 hours after the 2nd diet~* 4th diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 3rd diet~* 5th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 4th diet~* 6th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 5th diet~* 7th diet: soft rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 6th diet~* 8th diet: regular rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 7th diet"
62273186|NCT04890210|ACTIVE_COMPARATOR|Late Diet Group|"* 1st diet : 100 ml of clear fluid (6 hours after esophageal variceal ligation)~* After the 1st diet (Day 1): 6x100 ml of clear fluid for 24 hours~* Day 2: soft porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~* Day 3: porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~* Day 4: soft rice (the amount will be calculated according to patient's caloric needs) for 24 hours~* Day 5: regular rice (the amount will be calculated according to patient's caloric needs) for 24 hours and beyond"
62273187|NCT01112046|EXPERIMENTAL|Endoscopic submucosal dissection|
62273188|NCT01112046|ACTIVE_COMPARATOR|Laparoscopic resection|
62273189|NCT04930055||Group 1|Patients with solid tumors receiving courses of cytotoxic therapy.
62273190|NCT04930055||Group 2|Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
62068526|NCT03590665|OTHER|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
62068527|NCT03590665|OTHER|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
62068528|NCT03447730|EXPERIMENTAL|Part 1: SYNB1020|Part 1 comprised a sentinel open-label cohort of subjects enrolled sequentially to receive SYNB1020, which was administered orally at a dose of 5 × 10\^11 colony-forming units (CFU) 3 times daily (TID) given immediately after meals from Days 1 through 6.
62068529|NCT03447730|EXPERIMENTAL|Part 2: SYNB1020|Subjects randomized to receive SYNB1020 in Part 2 received SYNB1020 administered orally at a dose of 5 × 10\^11 CFU TID given immediately after meals from Days 1 through 6.
62068530|NCT03447730|PLACEBO_COMPARATOR|Part 2: Placebo|Subjects randomized to receive control in Part 2 received matching placebo (100 mL masking solution) administered orally TID given immediately after meals from Days 1 through 6.
62273191|NCT04930055||Group 3|Patients with solid tumors receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
62636248|NCT03225170|SHAM_COMPARATOR|Control group|"Immediately prior to the scheduled cancer genetic counseling appointment, clients:~1. completed similar standardized questionnaire as the SA group, with a non-affirming exercise. The non-intervention required clients to rank 11 items (artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity) from most important to least important and to elaborate on the 9th ranked item and why it might be important to someone else;~2. 6-item standardized measure of anxiety questionnaire;~3. after the genetic counseling session, clients were required to fill out a post session questionnaire"
62636249|NCT00362947|PLACEBO_COMPARATOR|A|A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days
62636250|NCT00362947|ACTIVE_COMPARATOR|B|B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days
62068531|NCT03491423|EXPERIMENTAL|Patients|
62068532|NCT01947660|EXPERIMENTAL|Continuous regional anesthesia|
62068533|NCT01947660|ACTIVE_COMPARATOR|Systemic analgesia|
62068534|NCT04549311|ACTIVE_COMPARATOR|Antibiotic 1 arm (amoxicillin + clavulanic acid)|"Patients will undergo I\&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~Patients randomized to the antibiotic 1 arm will receive a prescription for amoxicillin + clavulanic acid (875 mg amoxicillin and 125 mg clavulanic acid BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
62273192|NCT04930055||Group 4|Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
62273193|NCT04930055||Group 5|Patients receiving immune checkpoint inhibitors.
62273194|NCT04930055||Group 6|Patients who underwent allogeneic stem cell transplant within 12 months.
62273195|NCT04930055||Group 7|Patients who underwent cellular therapy, including CAR-T cells or T cells with engineered TCRs within 12 months.
62273196|NCT04930055||Group 8|Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches
62461522|NCT04875793|EXPERIMENTAL|List of health centers that randomly allocated to receive the intervention|The intervention is the integrated system which is composed of psychologist, endoscopy physician, family physician, community outreach, and audiovisuals in the waiting area. In addition to text messages of information, education and communication (IEC) delivered to the participants at the outreach, and education campaigns to mobilize individuals going for screening.
62636251|NCT00362947|ACTIVE_COMPARATOR|C|C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days
62273197|NCT04930055||Group 9|Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
62636252|NCT01076543|EXPERIMENTAL|Treatment (lenalidomide, temsirolimus)|Patients receive lenalidomide PO on days 1-21 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 2 courses may continue therapy for up to 52 weeks.
62461523|NCT04875793|NO_INTERVENTION|List of health centers that randomly allocated to receive routine care|The comparators will be individuals with an average risk of colorectal cancer of both genders attending the randomly selected health centres
62636253|NCT06175286|EXPERIMENTAL|POWERBreath|Subjects will train with the POWERBreath twice per day, for 30 continous breaths
62636254|NCT06175286|NO_INTERVENTION|Control|Subjects will carry on with their normal daily life
62273198|NCT04930055||Group 10|Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
62273199|NCT04930055||Group 11|Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
62636255|NCT02616783|EXPERIMENTAL|E/C/F/TAF|Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
62068535|NCT04549311|ACTIVE_COMPARATOR|Antibiotic 2 arm (ciprofloxacin + metronidazole)|"Patients will undergo I\&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~Patients randomized to the antibiotic 2 arm will receive a prescription for ciprofloxacin + metronidazole (ciprofloxacin 500 mg and metronidazole 500 mg BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
62068536|NCT04549311|NO_INTERVENTION|No antibiotics|"Patients will undergo I\&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~In the comparator arm, patients will not receive any antibiotics. Otherwise, all participants will be treated identically according to the institution's standard practices."
62068537|NCT06279572||Observational (blood collection, bone marrow aspirate)|Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.
62636256|NCT02616783|ACTIVE_COMPARATOR|Remain current regimen|Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
62461524|NCT03227198|EXPERIMENTAL|Intramyocardial injection of stem cell|Intramyocardial injection of autologous bone marrow mononuclear cells in patients with Heart Failure
62636257|NCT06390657||Phase A: retrospective planning study|Simulation CTs of up to ten patients with bulky (\>6cm) tumors will be selected. This will be used for optimization of contouring and planning strategy.
62068538|NCT00879320||1|Adults with ADHD
62068539|NCT00879320||2|Healthy adults without ADHD
62273200|NCT04930055||Group 12|Patients who have a cancer diagnosis but do not fall into group 1-11
62636258|NCT06390657||Phase B: prospective planning study|Ten patients with bulky tumors (\>6cm) recommended to receive RT with CT and MRI planning will be accrued. MRI DCE sequence (20-30mins) will be added if not requested for clinical use. They will be treated with standard clinical plans. Every effort will be made to include equal numbers of patients (2-3) from head and neck, thorax, abdomen and pelvis. Planning images will be used for the purpose of dosimetric comparison between SBRT-PATHY and CARBON-PATHY radiation plans.
62636259|NCT01562977|OTHER|no arms|no arms were present for the study, only 2 different cohorts:MCL and LDCGB
62273201|NCT01119248||Children undergoing MRI|120 children ages of 6 months and 8 years for MRI and axillary temperature before MRI and after the MRI with MRI compatible device
62461525|NCT03227198|PLACEBO_COMPARATOR|Placebo|Placebo intramyocardial injection in patients with Heart Failure
62461526|NCT03470220||Ultrasound|All included patients will be examined with ultrasound
62636260|NCT01635829|EXPERIMENTAL|Panel 1|Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
62636261|NCT01635829|EXPERIMENTAL|Panel 2|"Part 1 of Panel 2: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 2: Participants will receive carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
62636262|NCT05739487||IAT therapy|patients with central retinal artery occlusion received selective intra-arterial thrombolysis
62636263|NCT00970905|EXPERIMENTAL|Aprepitant & Ondansetron|
62273202|NCT02387580|ACTIVE_COMPARATOR|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
62453903|NCT05278806|EXPERIMENTAL|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|After the step in which the primary care providers are randomized to receiving intervention, one group of providers will receive the equity dashboard data and complete an equity huddle where they will review their list of eligible patients (Black, Indigenous and People of Color \[BIPOC\] patients and patients with limited English proficiency \[LEP\]) with a population health coordinator (PHC). The goal of the equity huddle will be to develop a plan to improve eligible patients' hypertension control. One of the options will be to refer patients to a community health worker (CHW) program focused specifically on addressing hypertension.
62453904|NCT05278806|EXPERIMENTAL|Equity Dashboard and Population Health Coordinator Support|After the step in which the primary care providers are randomized to receiving intervention, a second group of providers will receive the equity dashboard data and complete an equity huddle where they will review their list of eligible patients (Black, Indigenous and People of Color \[BIPOC\] patients and patients with limited English proficiency \[LEP\]) with a population health coordinator (PHC). The goal of the equity huddle will be to develop a plan to improve eligible patients' hypertension control.
62453905|NCT05278806|NO_INTERVENTION|Delayed intervention|Black, Indigenous and People of Color (BIPOC) patients and patients with limited English proficiency (LEP) before their primary care providers are randomized to receiving the intervention. (By the end of the 12 steps, all BIPOC/LEP patients will be assigned to an experimental group)
62453906|NCT05278806|NO_INTERVENTION|Usual Care|Patients who are not eligible for additional clinical support (i.e. White and English speaking patients).
62453907|NCT00648518|EXPERIMENTAL|1|Metformin Hydrochloride ER Tablets 750 mg
62453908|NCT00648518|ACTIVE_COMPARATOR|2|Glucophage® XR Tablets 750 mg
62453909|NCT01513551|EXPERIMENTAL|V114|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
62453910|NCT01513551|ACTIVE_COMPARATOR|PNEUMOVAX® 23|Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
62453911|NCT01513551|ACTIVE_COMPARATOR|PREVNAR 13®|Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.
62453912|NCT04278469|ACTIVE_COMPARATOR|Patients with chemotherapy|
62636264|NCT06063928||Observational (stool, blood, tissue, genetic testing, questionnaires)|Patients undergo stool sample collection, blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.
62636265|NCT06139250||hypoxic-ischemic encephalopathy group|Photoacoustic/ultrasound imaging will be used for neonates with hypoxic ischemic encephalopathy
62273203|NCT02387580|EXPERIMENTAL|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
62273204|NCT02387580|EXPERIMENTAL|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
62273205|NCT02387580|ACTIVE_COMPARATOR|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
62273206|NCT02387580|EXPERIMENTAL|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
62273207|NCT02387580|EXPERIMENTAL|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
62273208|NCT02260843|NO_INTERVENTION|Control|Subjects in this group do not received any intervention.
62273209|NCT02260843|ACTIVE_COMPARATOR|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
62273210|NCT02260843|PLACEBO_COMPARATOR|Generic Fitness Intervention|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
62453913|NCT04278469|NO_INTERVENTION|Patients without chemotherapy|
62453914|NCT03318692|EXPERIMENTAL|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
62453915|NCT03318692|ACTIVE_COMPARATOR|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
62453916|NCT02832856|PLACEBO_COMPARATOR|Control|"Control group members will receive a job readiness curriculum entitled Beginning to Work it Out (BWIO) that assists at-risk youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
62453917|NCT02832856|EXPERIMENTAL|Full Relationship Smarts Curriculum|This group receives the behavioral intervention of the healthy relationship education in the form of the full, 12-lesson RS+ curriculum over approximately 12 weeks.
62636266|NCT06139250||control group|Photoacoustic/ultrasound imaging will be used for neonates without brain disease
62273211|NCT01394939|EXPERIMENTAL|Single Agent_ Cohort 1|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: Recombinant Vaccinia Granulocyte-Macrophage Colony-Stimulating Factor (RAC VAC GM-CSF) Cohort 1: JX-594 3 x 10\^8 plaque forming unit (pfu), Days 1, 8,15, 22, and 29"
62273212|NCT01394939|EXPERIMENTAL|Single Agent_Cohort 2|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: RAC VAC GM-CSF Cohort 2: JX-594 1 x 10\^9 pfu, Days 1, 8,15, 22, and 29"
62273213|NCT01394939|EXPERIMENTAL|Combination_Cohort 3|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF Irinotecan: 180 mg/m2 IV every 2 weeks. JX-594 3 x 10\^8 pfu Day 1,8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
62273214|NCT01394939|EXPERIMENTAL|Combination_Cohort 4|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF JX-594 1 x 10\^9 pfu Day1, 8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
62273215|NCT02535533|EXPERIMENTAL|Study Treatment|"During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined as 4000 mcg SLM. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Pilot Phase, dosing will begin at dose level 3 (4000, 5000, or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days. Each cohort will enroll 2 evaluable patients."
62273216|NCT02365168|EXPERIMENTAL|Food Challenge with cod|
62273217|NCT02365168|EXPERIMENTAL|Food Challenge with salmon|
62273218|NCT02365168|EXPERIMENTAL|Food Challenge with mackerel|
62273219|NCT02365168|PLACEBO_COMPARATOR|Food Challenge with placebo|
62273220|NCT00782457|ACTIVE_COMPARATOR|OPEN SURGERY|
62273221|NCT00782457|EXPERIMENTAL|LAPAROSCOPIC SURGERY|
62273222|NCT05804708|EXPERIMENTAL|GH001 Individualized Dosing Regimen|"Drug: 5-Methoxy-N,N-Dimethyltryptamine~GH001 is administered via inhalation, as an IDR (individualized dosing regimen) consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience \[PE\]) at the previously administered dose"
62273223|NCT01446419|EXPERIMENTAL|Intracept Treatment|
62273224|NCT01446419|SHAM_COMPARATOR|Sham Treatment|
62273225|NCT01849770|ACTIVE_COMPARATOR|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 12 weeks.
62273226|NCT01849770|ACTIVE_COMPARATOR|Mexiletine, 900 milligrams|Mexiletine, 900 milligrams by mouth per day for 12 weeks.
62273227|NCT01849770|PLACEBO_COMPARATOR|Placebo|Placebo, by mouth per day for 12 weeks.
62273228|NCT00847366|EXPERIMENTAL|Perifosine 201|"Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer.~Perifosine dosage:~Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week."
62273229|NCT00847366|EXPERIMENTAL|Perifosine 206|"Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab.~Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle."
62068540|NCT06251739|ACTIVE_COMPARATOR|Tablet Ivermectin|A cumulative dose of 60 mg Oral Ivermectin monotherapy (12 mg/day) on five consecutive days (day 1 - day 5) for three consecutive months (180 mg in total)
62273230|NCT00847366|EXPERIMENTAL|Perifosine 207|Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food.
62068541|NCT06251739|ACTIVE_COMPARATOR|Capsule Miltefosine|Oral Miltefosine monotherapy for 12 weeks. 50 mg in the morning and 50 mg in the evening with meal x 84 days (Total 100 mg/day)
62273231|NCT00847366|EXPERIMENTAL|Perifosine 208|Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
62453918|NCT02832856|EXPERIMENTAL|Abridged Relationship Smarts Curriculum|"This group receives the behavioral intervention of the healthy relationship education in the form of the summary 8-lesson version of the RS+ curriculum - as well as four lessons on career planning and job readiness over approximately 12 weeks."
62453919|NCT02744352|ACTIVE_COMPARATOR|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
62068542|NCT04956978|EXPERIMENTAL|Patient Decision Support Tool|Patient decision support tool to be used in conjunction with physician counseling to discuss the risk and benefits of systemic oral anticoagulation.
62068543|NCT04956978|NO_INTERVENTION|Usual Healthcare Counseling|Traditional physician counseling regarding the risk and benefits of systemic oral anticoagulation
62068544|NCT02778620||Aortic Valve Replacement|Post Anaesthetic Care Unit (PACU) patients treated with aortic valve replacement (AVR) are highly eligible for this study.These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
62068545|NCT00830141||1|50 children with GH deficiency
62453920|NCT02744352|ACTIVE_COMPARATOR|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
62453921|NCT03735446|EXPERIMENTAL|Prexasertib+MEC|"* Cytarabine is administered intravenously on days 1-5.~* Etoposide is administered intravenously on days 1-5.~* Mitoxantrone is administered intravenously on days 1-5.~* Prexasertib is administered intravenously on days 1, 3, and 5."
62068546|NCT00830141||2|50 children with ISS
62068547|NCT00830141||3|50 children with FTT
62273232|NCT00847366|EXPERIMENTAL|Perifosine 209|Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval).
62273233|NCT00870064|OTHER|Formal Operative Treatment|Children randomized to the formal operative management arm will be taken to the Operating Room within 24 hours for irrigation and debridement and appropriate bone management.
62273234|NCT00870064|OTHER|Emergency Department Treatment|Children in the Emergency Department Treatment arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
62453922|NCT04051970|EXPERIMENTAL|Strategy TRI-BI|
62453923|NCT04051970|ACTIVE_COMPARATOR|Strategy Immediate BI|
62453924|NCT04826510|ACTIVE_COMPARATOR|Lithium carbonate group|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
62453925|NCT04826510|EXPERIMENTAL|Perospirone hydrochloride group|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
62453926|NCT04826510|EXPERIMENTAL|Lithium carbonate + perospirone hydrochloride group|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
62453927|NCT05375149||LTx rejection|Lung transplanted patients with acute or chronic rejection
62068548|NCT00830141||4|50 children with obesity
62068549|NCT00830141||5|50 children without short stature or obesity will serve as controls
62068550|NCT06314490|EXPERIMENTAL|Open label|
62273235|NCT03721094|OTHER|Immersive virtual reality|Completing the procedures in immersive virtual reality
62453928|NCT05375149||LTx non-rejection|Lung transplanted patients without any form of rejection
62453929|NCT01868841|ACTIVE_COMPARATOR|Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging|SPECT imaging of 10 millicurie of Adreview
62273236|NCT03721094|NO_INTERVENTION|Conventional virtual reality|Completing the procedures in conventional virtual reality
62273237|NCT00662103|ACTIVE_COMPARATOR|progressive, aerobic exercise program|Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
62273238|NCT00662103|ACTIVE_COMPARATOR|progressive, resistance exercise program|Patients undergo resistance exercise training 3 days a week for 18 months.
62273239|NCT00662103|ACTIVE_COMPARATOR|flexibility and relaxation training [control]|Patients perform a series of whole body flexibility (stretching) and relaxation (guided imagery, progressive neuromuscular relaxation, focused breathing) exercises 3 days a week for 18 months.
62453930|NCT01868841|ACTIVE_COMPARATOR|AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging|SPECT imaging of 10 millicurie of Adreview
62453931|NCT00689013|NO_INTERVENTION|1|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the first month of observation. These patients have not been exposed to pharmacist-driven interventions utilized in this study. This group serves as the control group.
62453932|NCT00689013|EXPERIMENTAL|2|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the second month of observation. These patients may or may not have been exposed to pharmacist-driven interventions utilized in this study. This group serves as the study/intervention group.
62273240|NCT06400888|ACTIVE_COMPARATOR|needle free subcutaneous injector of mecobalamin|
62453933|NCT04450745|EXPERIMENTAL|Exercise in hypoxia|Patients randomized to this arm will have training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above see level( indoor air composition: 15,4% of O2 and 84,7% of N)
62453934|NCT04450745|EXPERIMENTAL|Exercise in normoxia|Patients randomized to this arm will have the same training program in normoxic conditions
62453935|NCT05647486||EVAR|Patients with AAA, treated electively by EVAR. The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed.
62453936|NCT01849042|OTHER|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
62453937|NCT01849042|ACTIVE_COMPARATOR|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
62273241|NCT06400888|ACTIVE_COMPARATOR|intramuscular injection of Mecbl|
62273242|NCT00868283|EXPERIMENTAL|Cerebrolysin|
62453938|NCT02745002|EXPERIMENTAL|navigated bronchoscopy|
62273243|NCT00868283|PLACEBO_COMPARATOR|0.9% Saline Solution|
62273244|NCT00595712|ACTIVE_COMPARATOR|A|Using Iliac crest allograft in high tibial osteotomy
62273245|NCT00595712|ACTIVE_COMPARATOR|B|Using iliac crest autograft in high tibial osteotomy
62273246|NCT05700903|ACTIVE_COMPARATOR|Prostate Cancer|Men undergoing androgen deprivation therapy via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for the treatment of prostate cancer
62273247|NCT05700903|ACTIVE_COMPARATOR|Healthy + ADT|Healthy men undergoing gonadal suppression via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for 9 weeks
62273248|NCT05700903|PLACEBO_COMPARATOR|Healthy + Placebo|Healthy men undergoing placebo for 9 weeks.
62273249|NCT01482364|EXPERIMENTAL|HOTMAN-driven therapeutic approach arm|"Hotman-driven therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System."
62273250|NCT01482364|PLACEBO_COMPARATOR|Control arm|Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
62273251|NCT05815589|EXPERIMENTAL|experimental|screw retained prosthesis group this group will received a mandibular screw retained hybrid prosthesis over four inra-foraminal implant
62273252|NCT05815589|ACTIVE_COMPARATOR|active comparator|this group received a mandibular telescopic attached overdenture.
62273253|NCT05671939||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
62273254|NCT05671939||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
62453939|NCT01141465||IPDA FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at ≥twice the equivalent BDP-equivalent dose
62068551|NCT06202183|EXPERIMENTAL|Group A: Exercise Group|"42 participants will be enrolled using a permuted blocked design with varying block size and will complete study procedures as follows:~* Baseline in-office visit.~* Completion of exercise sessions 3x weekly.~* Post-intervention in-office visit."
62273255|NCT05588570|EXPERIMENTAL|CAT|Participants will receive behavioral treatment for anxiety.
62453940|NCT01141465||IPDA FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at ≥twice the equivalent BDP-equivalent dose
62068552|NCT06202183|NO_INTERVENTION|Group B: Waitlist Control Group|"42 participants will be enrolled using a permuted blocked design with varying block size and will complete study procedures as follows:~* Baseline in-office visit.~* Participants will be asked to maintain baseline exercise behavior and/or usual, daily activities.~* Post-intervention in-office visit. Participants will be offered to participate in the exercise program upon the completion of post-intervention assessments."
62068553|NCT05930418|EXPERIMENTAL|Cardiac MRI after sepsis|Participants who meet the eligibility criteria of severe sepsis.
62287099|NCT02410694|EXPERIMENTAL|Ixazomib-Thalidomide-Dexamethasone|"Combination therapy of:~Ixazomib 4.0mg at days 1, 8, 15, Thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), Dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle.~After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months."
62636267|NCT05863650|EXPERIMENTAL|Hybrid Education|100 volunteer students participating in the study will start face-to-face training after preliminary evaluations are made. Afterwards, a randomized group of 20 people will be included in the simulation training every two weeks. In the face-to-face education group, a case analysis will be applied by the students themselves together with the educators in the classroom environment. In the simulation group, one case analysis will be made every week on the website designed under the supervision of researchers.
62636268|NCT05863650|ACTIVE_COMPARATOR|Face to Face Education|100 volunteer students participating in the study will start face-to-face training after preliminary evaluations are made. Afterwards, a randomized group of 20 people will be included in the simulation training every two weeks. In the face-to-face education group, a case analysis will be applied by the students themselves together with the educators in the classroom environment. In the simulation group, one case analysis will be made every week on the website designed under the supervision of researchers.
62636269|NCT02067520|OTHER|IT hydromorphone dose|dose response study
62461527|NCT00715065||2|Healthy control subjects (who do not faint at the sight of blood)
62068554|NCT02198053||Ticagrelor2|Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
62068555|NCT02198053||Ticagrelor1|Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
62461528|NCT00715065||1|People who faint at sight of blood
62273256|NCT06303934|EXPERIMENTAL|systemic therapy+Intermittent Oro-Esophageal Tube Feeding|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
62636270|NCT03489343|EXPERIMENTAL|Sym023 0.03 mg/kg|Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion
62636271|NCT03489343|EXPERIMENTAL|Sym023 0.1 mg/kg|Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion
62636272|NCT03489343|EXPERIMENTAL|Sym023 0.3 mg/kg|Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion
62636273|NCT03489343|EXPERIMENTAL|Sym023 1.0 mg/kg|Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion
62636274|NCT03489343|EXPERIMENTAL|Sym023 3.0 mg/kg|Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion
62636275|NCT03489343|EXPERIMENTAL|Sym023 10.0 mg/kg|Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion
62636276|NCT03489343|EXPERIMENTAL|Sym023 20.0 mg/kg|Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion
62636277|NCT02874313|EXPERIMENTAL|CPAP treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin plus continuous positive airway pressure (CPAP)
62636278|NCT02874313|ACTIVE_COMPARATOR|Control treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin
62636279|NCT02810418|EXPERIMENTAL|Arm A1, Dose Level 1 (Phase 1, short infusion) 100µg/kg LMB-100|"Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 +125mg/m\^2 nab-paclitaxel~Dose level 1 (DL1) Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving short infusion LMB-100+nabpaclitaxel"
62287100|NCT02870725|NO_INTERVENTION|Control Group (Treatment As Usual)|Individuals randomized into the control condition will not receive any active treatment but will have access to customary, community-based supportive services. These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of comparison for those in the other arm of the study.
62461529|NCT03589534|OTHER|pregnancy test|pregnancy tests
62461530|NCT05463653|EXPERIMENTAL|Experimental telemedicine|Patient's rehabilitation and compliance with the standard exercices will be guided and monitored through an ad hoc device developed specifically for this trial.
62461531|NCT05463653|ACTIVE_COMPARATOR|Control|Patient's rehabilitation and compliance with the standard exercices will be monitored in the usual manner, at the monthly visits to the physical therapy clinic
62461532|NCT06140264|ACTIVE_COMPARATOR|Acupuncture dry needle|This group received acupuncture dry needle over trigger points of back muscles followed by stretching and strengthening exercises for back muscles, 2 sessions per week for 2 weeks.
62461533|NCT06140264|NO_INTERVENTION|Stretching and strengthening exercises|This group received only stretching and strengthening exercises for back muscles.
62461534|NCT01405222||Acute COPD exacerbation|Patients admitted in to hospital with an acute exacerbation of COPD
62461535|NCT02256293|EXPERIMENTAL|Group Therapy|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).
62461536|NCT02533362|EXPERIMENTAL|ANF-Rho|pegfilgrastim Anti-Neutropenic Factor (ANF)
62461537|NCT02629757|EXPERIMENTAL|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.
62461538|NCT02195245|NO_INTERVENTION|Control|Control - Observational (non interventional) data is collected from current state of the art absorber devices.
62461539|NCT02195245|EXPERIMENTAL|memsorb|New CO2 filter - data is collected using the new CO2 absorber.
62461540|NCT01539915|EXPERIMENTAL|BCT194|
62461541|NCT01410630||FLT-PET/CT and FDG-PET/CT scan|Patients will have FLT-PET/CT and FDG-PET/CT scans performed 18-24 days after the second cycle of R-CHOP.
62461542|NCT03626649|EXPERIMENTAL|DiamondTemp Cardiac Ablation System|Cardiac ablation procedure
62461543|NCT00481520|EXPERIMENTAL|1|
62461544|NCT00481520|PLACEBO_COMPARATOR|2|
62461545|NCT01268865||HBV-infected|
62461546|NCT01268865||HCV-infected|
62461547|NCT02392364|ACTIVE_COMPARATOR|Variable Treatment Dosing Arm|Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
62461548|NCT02392364|ACTIVE_COMPARATOR|Monthly Treatment Arm|Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
62461549|NCT03476980|ACTIVE_COMPARATOR|Randomized to Umbilical Cord Milking at birth|Milking the umbilical cord towards the infant at a speed of 20cm/2seconds at birth.
62461550|NCT03476980|ACTIVE_COMPARATOR|Randomized to Delayed Cord Clamping at birth|Delayed clamping of the umbilical cord at birth.
62461551|NCT00941837|EXPERIMENTAL|Olive Oil|
62461552|NCT00941837|EXPERIMENTAL|Coconut oil|
62461553|NCT00941837|EXPERIMENTAL|Palm Olein|
62461554|NCT01384461||Cohort|
62461555|NCT01743508|ACTIVE_COMPARATOR|Misoprostol by physician|Misoprostol treatment by midwife
62461556|NCT01743508|EXPERIMENTAL|Misoprostol by midwife|Misoprostol treatment by midwife
62461557|NCT02084004|EXPERIMENTAL|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
62461558|NCT02084004|EXPERIMENTAL|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
62461559|NCT02084004|NO_INTERVENTION|lifestyle counseling|
62273257|NCT06303934|ACTIVE_COMPARATOR|systemic therapy+Persistent Nasogastric Tube Feeding|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
62273258|NCT01221428|EXPERIMENTAL|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
62273259|NCT03264430|ACTIVE_COMPARATOR|The ketamine group|The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
62273260|NCT03264430|PLACEBO_COMPARATOR|The control group|group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
62453941|NCT01141465||IPDI FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at equivalent BDP-equivalent dose
62453942|NCT01141465||IPDI BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at equivalent BDP-equivalent dose
62453943|NCT01141465||IPDI FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at equivalent BDP-equivalent dose
62273261|NCT04560088|EXPERIMENTAL|Mindfulness|Mindfulness using an individual mobile health mindfulness-based intervention training. These sessions are intended to act as a general introduction to mindfulness meditation and incorporate techniques such as breath awareness and body scanning.
62273262|NCT04560088|ACTIVE_COMPARATOR|Breathing|Breathing control intervention will use an individual breathing app. The intervention is designed to be structurally equivalent to the mindfulness-based study intervention on key common factors of psychosocial interventions: (a) the number of sessions, (b) the length of sessions, and (c) delivery format.
62273263|NCT05522166|ACTIVE_COMPARATOR|Digital Storytelling Group|After the digital storytelling group teacher candidates are determined, forms and digital stories will be prepared to be used as pre-test, post-test and retention test. Afterwards, the skill assessment, in which the pre-test form will be applied, will be observed without intervention and evaluated by the researcher. Then, digital stories about TYD will be uploaded to social media for teacher candidates to watch. After watching these applications for two months, one-to-one applications will be made with teacher candidates in face-to-face education models. One month after the last test, the posttest and permanence test will be held in the same environment.
62453944|NCT01141465||IPDA BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at ≥twice the equivalent BDP-equivalent dose
62453945|NCT03294863|EXPERIMENTAL|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive will be applied to 1/2 of the cutaneous wound
62453946|NCT03294863|PLACEBO_COMPARATOR|Standard of Care|Another 1/2 of cutaneous wound will be treated per standard of care
62453947|NCT05817916|ACTIVE_COMPARATOR|ESP Block|
62453948|NCT05817916|ACTIVE_COMPARATOR|LP block|
62636280|NCT02810418|EXPERIMENTAL|Arm A1, Dose Level-1 (Phase 1, short infusion) 65µg/kg LMB-100|Arm A1, DL-1, Ph I Short Infusion 65µg/kg LMB-100 +125mg/m\^2 nab-paclitaxel
62636281|NCT02810418|EXPERIMENTAL|Arm A2 (Phase 2, short infusion) 65µg/kg LMB-100|"Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 +125mg/m\^2 nab-paclitaxel~Efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel"
62636282|NCT02810418|EXPERIMENTAL|Arm B1, Dose Level 2 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL2, 48-hr Continuous Infusion Single Agent Lead-in 100µg/kg/day LMB-100 Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving continuous infusion LMB-100 as single agent
62273264|NCT05522166|NO_INTERVENTION|Face to Face Applied Training Group|After the teacher candidates of the face-to-face application group are determined, the seminar training and program will be prepared. Then, the forms developed by the researcher will be applied as a pre-test. Pre-test skills of teacher candidates will be evaluated by the researcher with a skill evaluation form by making face-to-face observations on the model without any intervention. After the 8-week training of the teacher candidates is over, knowledge and skills will be given as a post-test. One month after the last test, retention tests will be done in a similar way.
62453949|NCT02688556|EXPERIMENTAL|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
62453950|NCT02688556|PLACEBO_COMPARATOR|Vehicle|vehicle of OTX-101
62636283|NCT02810418|EXPERIMENTAL|Arm B1, Dose Level 1 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL1, 48-hr Continuous Infusion Single Agent Lead-in 65µg/kg/day LMB-100
62636284|NCT02810418|EXPERIMENTAL|Arm B1, Dose Level 3R Phase I (Continuous infusion single agent lead-in)|Arm B1, DL3R, 24-hr Continuous Infusion Single Agent Lead-in 100µg/kg LMB-100
61978722|NCT06084403|ACTIVE_COMPARATOR|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
62068556|NCT05800808|EXPERIMENTAL|High Intensity Exercise|Vigorous cycling
62068557|NCT05800808|ACTIVE_COMPARATOR|Continuous Moderate Exercise|Leisurely cycling
62273265|NCT01564615|EXPERIMENTAL|AgION catheter|Patients in this arm received an AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
62453951|NCT05437965||isolated coronary arteritis|
62453952|NCT05437965||coronary artery disease|
62461560|NCT04271722|EXPERIMENTAL|Mifepristone|Mifepristone 200mg 24hours before the induction day
62273266|NCT01564615|ACTIVE_COMPARATOR|Non-impregnated polyurethane catheter|Patients in this arm received a non-impregnated polyurethane umbilical catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
62273267|NCT01954693|EXPERIMENTAL|Everolimus (RAD001)|2x2.5mg daily
62636285|NCT02810418|EXPERIMENTAL|Arm B2 Phase I (continuous infusion combination therapy)|Subjects with pancreatic cancer receiving continuous infusion LMB-100 combination therapy
62453953|NCT04351009|EXPERIMENTAL|Indocyanine green sentinel lymph node mapping|Indocyanine green dye is injected in the submucosa or subserosa around the tumor to identify sentinel lymph nodes intra-operatively with near infrared fluorescence imaging.
62636286|NCT05874362|OTHER|Group with complications at 3 month|Group composed with participants who develop a psychiatric complication (depressive episode or post traumatic stress disorder) 3 month after the death of their loved one.
62273268|NCT01954693|PLACEBO_COMPARATOR|Placebo|2x2.5mg daily
62273269|NCT01936545|EXPERIMENTAL|propofol|The anesthesia was maintained with propofol during liver transplantation.
62636287|NCT05874362|OTHER|Group without complication at 3 month|Group composed with participants who do not develop a psychiatric complication (depressive episode or post traumatic stress disorder) 3 month after the death of their loved one.
62636288|NCT00001322|EXPERIMENTAL|Phase 1 - Lupron|Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
62636289|NCT00001322|EXPERIMENTAL|Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
62273270|NCT01936545|ACTIVE_COMPARATOR|Desflurane|The anesthesia was maintained with desflurane during liver transplantation.
62273271|NCT02155998||PREVENT study patients|Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation.
62273272|NCT00511355|EXPERIMENTAL|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
62273273|NCT00511355|ACTIVE_COMPARATOR|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets (LNG-EE), 150 mcg LNG and 30 mcg EE
62273274|NCT01934283|NO_INTERVENTION|operated patients|small bowel obstrucion patients who needed surgery for treatment of obstruction.
62273275|NCT01745146|EXPERIMENTAL|Anger Self-Management Training (ASMT)|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
62273276|NCT01745146|ACTIVE_COMPARATOR|Personal Readjustment and Ed (PRE)|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment. Significant other (friend or relative) invited to participate in 3 of 8 sessions
62273277|NCT01384578|EXPERIMENTAL|pentoxiphylline and Vitamin E|
62273278|NCT01384578|ACTIVE_COMPARATOR|Vitamin E|
62453954|NCT00919308||Control, traditional bedside training|Postgraduate year 1 and 2 residents who are trained in central venous catheter insertion according to the traditional, bedside apprenticeship model.
62461561|NCT04271722|ACTIVE_COMPARATOR|Balloon catheter|Balloon catheter with 40ml placed 24hours before the induction day
62273279|NCT02070042|EXPERIMENTAL|Omega- 3 Fatty Acid|The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
62636290|NCT00001322|EXPERIMENTAL|Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
62636291|NCT03435588|ACTIVE_COMPARATOR|EUS-FNA with ROSE|EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
62636292|NCT03435588|EXPERIMENTAL|EUS-FNB alone|EUS-FNB is performed with a 22 or 25 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.
62273280|NCT02070042|PLACEBO_COMPARATOR|Placebo|Seagate® Extra Virgin Olive oil capsules
62636293|NCT01546051|EXPERIMENTAL|BCI-838 Food Effect Dosing Arm 1|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
62636294|NCT01546051|EXPERIMENTAL|BCI-838 Fasted Dosing (100 & 300 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
62273281|NCT02876887|ACTIVE_COMPARATOR|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
62453955|NCT00919308||Simulation training|Postgraduate year 1 and 2 residents who complete a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by: the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous cannulator on a partial task training simulator with no technical errors.
62636295|NCT01546051|EXPERIMENTAL|BCI-1038, BCI-1206 & BCI-1283|Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
62636296|NCT01546051|EXPERIMENTAL|BCI-838 Fasted Dosing (900 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
62636297|NCT00844090|PLACEBO_COMPARATOR|Arm 1|placebo tablets
62636298|NCT00844090|EXPERIMENTAL|Arm 2|methylphenidate tablets
62636299|NCT00533819|EXPERIMENTAL|1|
62636300|NCT00533819|NO_INTERVENTION|2|would have routine physical activity
62636301|NCT00990002||Control|A children's milk-based beverage
62636302|NCT00990002||experimental probiotic 1|children's milk-based beverage containing a bioactive ingredient
62273282|NCT02876887|PLACEBO_COMPARATOR|Placebo|Three servings per day of placebo beverages for six months.
62636303|NCT00990002||experimental probiotic 2|children's milk-based beverage containing a different bioactive ingredient
62636304|NCT03204617|EXPERIMENTAL|DDDMM + CCM|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20. At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
62636305|NCT03204617|PLACEBO_COMPARATOR|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since fifth placebo administration, administration of 0.9% sterile normal saline solution at weeks 0, 12 and 24.
62636306|NCT01316575|EXPERIMENTAL|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
62636307|NCT01316575|ACTIVE_COMPARATOR|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
62273283|NCT05344456|EXPERIMENTAL|PVC response ''Off''|
62273284|NCT05244265|EXPERIMENTAL|Mindfulness-based stress reduction (MBSR)|The 9 session MBSR program following the manual (Kabat-Zinn, 1982).
62273285|NCT05244265|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants take part in their treatment as usual in outpatient habilitation and other services.
62453956|NCT00725439|EXPERIMENTAL|A|Talarozole
62453957|NCT01205607|EXPERIMENTAL|ITPR -9 & then -5 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
62453958|NCT01205607|EXPERIMENTAL|ITPR -5 & then _9 mm HG|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
62461562|NCT00769041|PLACEBO_COMPARATOR|placebo|
62461563|NCT00769041|ACTIVE_COMPARATOR|moxifloxacin|
62461564|NCT00769041|EXPERIMENTAL|avanafil therapeutic|avanafil 100mg - therapeutic dose
62636308|NCT01235065|ACTIVE_COMPARATOR|direct laryngoscope|emergency intubation with direct laryngoscopy technique
62068558|NCT02019134|ACTIVE_COMPARATOR|usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
62461565|NCT00769041|EXPERIMENTAL|avanafil supratherapeutic|avanafil 800mg - supratherapeutic dose
62636309|NCT01235065|ACTIVE_COMPARATOR|video laryngoscope|emergency intubation with video laryngoscopy technique
62636310|NCT02200679||Autism Spectrum Disorders|Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R
62636311|NCT05662748||Pro Star|patient received Pro Star Device
62636312|NCT05662748||MANTA|Patient received MANTA Device
62636313|NCT02922153|EXPERIMENTAL|Cryoanalgesia + Standard of Care (SOC)|Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
62636314|NCT02922153|ACTIVE_COMPARATOR|Standard of Care|Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.
62636315|NCT03186144|EXPERIMENTAL|No arm : descriptive study|
62636316|NCT06342713|EXPERIMENTAL|Part A (Single Ascending Dose)|Part A is designed to assess the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic profile of BGB-45035 following single-ascending doses (SAD) in healthy participants.
62636317|NCT06342713|EXPERIMENTAL|Part B (Multiple Ascending Dose)|Part B is designed to assess safety, tolerability, PK, and pharmacodynamic profile after repeated dosing of BGB-45035 in healthy participants.
62636318|NCT06342713|EXPERIMENTAL|Part C (Chinese Substudy)|Part C is designed to assess safety, tolerability, PK, and pharmacodynamic profile after repeated dosing of BGB-45035 in healthy Chinese participants.
62636319|NCT06342713|EXPERIMENTAL|Part D (Food Effect)|Part D is designed to assess the effect of food on BGB-45035 exposure.
62636320|NCT01893112|EXPERIMENTAL|Unity Workshop|The intervention is a workshop facilitated by a peer advocate (an African American woman who is also HIV positive) and a social worker. It has exercises, videos and group discussions intended to equip participants with coping skills to overcome HIV related stigma and the negative outcomes related to stigma. The workshop will last about 8 hours total across 2 two days (4 hours per day). The researcher in the current study has done a lot of work in adapting this intervention for African American women. The workshop has been piloted in Seattle and had promising results. Based on results in the pilot study, a 2 hour booster session has been added 6 months after the initial workshop
62636321|NCT01893112|OTHER|Breast Cancer Screening|The time and attention control group workshop will be facilitated by a research coordinator. The control group program is based on another program that is designed explore issues related to breast cancer screening among African American women. The program has the same format as the Unity Workshop, with video and group discussion. Although breast cancer may be associated with stigma, we anticipated that breast cancer stigmas would not be related to HIV-associated stigma, which is our primary outcome of interest. The control groups will be held during the same week as the Unity Workshops, and control group participants will complete assessments on the same schedule as the Unity Workshop participants.
62636322|NCT00268983|EXPERIMENTAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
62636323|NCT00268983|ACTIVE_COMPARATOR|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
62636324|NCT03166787|EXPERIMENTAL|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
62636325|NCT03166787|EXPERIMENTAL|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
62636326|NCT03166787|EXPERIMENTAL|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
62636327|NCT03328247|NO_INTERVENTION|Control|Control group will attend their routine melanoma follow-ups
62636328|NCT03328247|EXPERIMENTAL|Intervention|The intervention group will use the ASICA app in addition to their routine follow-ups
62636329|NCT01018758|EXPERIMENTAL|palonosetron|
62636330|NCT02288104|OTHER|needle based confocal endomicroscopy|The patient, scheduled for a standard liver or kidney percutaneous biopsy or ablation will undergo a needle-based confocal laser endomicroscopy procedure during the procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
62636331|NCT04198831|EXPERIMENTAL|acupuncture group|Receiving acupuncture and moxibustion treatment
62273286|NCT00913029|ACTIVE_COMPARATOR|Stent|One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
62636332|NCT04198831|SHAM_COMPARATOR|sham acupuncture group|Receiving sham acupuncture and sham moxibustion treatment
62273287|NCT00913029|ACTIVE_COMPARATOR|Medication|One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.
62636333|NCT03065686|EXPERIMENTAL|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
62273288|NCT05558956|EXPERIMENTAL|Low Dose|3 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.
62273289|NCT05558956|EXPERIMENTAL|High dose|7 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.
62287101|NCT02870725|EXPERIMENTAL|CBT Individual Psychotherapy (Treatment)|Behavioral Intervention (Individual Psychotherapy). These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of determining whether or not the intervention was effective compared to the control arm.
62636334|NCT06323785|ACTIVE_COMPARATOR|Active whole-body hyperthermia|
62636335|NCT06323785|SHAM_COMPARATOR|Sham whole-body hyperthermia|
62636336|NCT00823264|EXPERIMENTAL|Multiple Doses of Activated Charcoal|Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc
62273290|NCT04094220|EXPERIMENTAL|Lateral lumbar interbody fusion|Patients in this group received lateral lumbar interbody fusion alone. Patients who suffered residual neurologic symptoms postoperatively will received conservative treatment for at least 3 months.Patients were considered to have unsuccessful indirect decompression if they had less than 20% improvement according to the Oswestry Disability Index (ODI) by 3 months postoperatively.
62273291|NCT04094220|EXPERIMENTAL|Lateral lumbar interbody fusion plus posterior decompression|Patients in this group received lateral lumbar interbody fusion plus posterior decompression.
62273292|NCT03750266||Congenital Diaphragmatic Hernia referred for fetal MRA|
62273293|NCT04884048||Benign bone tumors|Patients with benign lesions confirmed either by histology or imaging follow-up showing lesion stability.
62273294|NCT04884048||Malignant bone tumors|Patients with malignant lesions confirmed by histology.
62273295|NCT00691483|PLACEBO_COMPARATOR|placebo|
62273296|NCT00691483|EXPERIMENTAL|varenicline|
62273297|NCT02112370|PLACEBO_COMPARATOR|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
62273298|NCT02112370|EXPERIMENTAL|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
62273299|NCT00328770|EXPERIMENTAL|Sirolimus based immunosuppression|Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
62273300|NCT01764074|EXPERIMENTAL|Brief Sleep Intervention|Every participant in the study will complete a 3-session sleep intervention with a clinician to improve sleep problems such as insomnia or hypersomnia.
62273301|NCT00711100|EXPERIMENTAL|Camel Snus|Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
62273302|NCT00711100|EXPERIMENTAL|Marlboro Snus|Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.
62273303|NCT00711100|EXPERIMENTAL|Stonewall|Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
62273304|NCT00711100|EXPERIMENTAL|Ariva|Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.
62273305|NCT00711100|EXPERIMENTAL|General Snus|General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.
62287102|NCT01047202|EXPERIMENTAL|Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
62636337|NCT00823264|NO_INTERVENTION|Control|Will not receive activated charcoal. Serum levels will be followed.
62636338|NCT01222208|ACTIVE_COMPARATOR|Oral Nutrition|Subjects will receive an oral nutrition regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as pressurized whey protein
62636339|NCT01222208|PLACEBO_COMPARATOR|Peripheral Parenteral Nutrition|Subjects will receive a peripheral parenteral nutrition (PPN) regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as amino acids.
62636340|NCT03983200|SHAM_COMPARATOR|Control group|Mecobalamine 0.5mg, tid
62636341|NCT03983200|EXPERIMENTAL|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min,bid + Mecobalamine 0.5mg, tid
62636342|NCT03052881|EXPERIMENTAL|Robot assisted surgery|To investigate use of an intraocular robotic system to assist the surgeon in performing one of two operation: i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage.
62636343|NCT03052881|NO_INTERVENTION|Control|A control group of patients underwent either i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage without the use of a robot i.e. the surgery was done in the standard manner.
62636344|NCT05686655||diabetes children|
62636345|NCT05619471|EXPERIMENTAL|VIO Imaging|Subjects with skin conditions that are candidates for biopsy
62636346|NCT04904627||Polyehtylene vs Poliìycarbonate|super rigid vs rigid material
62636347|NCT04904627||Free pelvis vs classic pelvis|fixed pelvis versus free pelvis, allowing adjustment in the sagittal plane.
62636348|NCT03310216|EXPERIMENTAL|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
62636349|NCT03310216|ACTIVE_COMPARATOR|Order II of visual inspection|Participants in group II are provided EDTRS first and AI visual inspection system later.
62273306|NCT05926726|EXPERIMENTAL|CAR-GPC3 T cells|The safety and efficacy of JWATM214 will be evaluated in a 'BOIN'-designed dose escalation approach. 3 CAR-T dose levels will be tested in this study: 1×10\^8, 3×10\^8, and 10×10\^8, whereas the dosage 0.5×10\^8 and 30×10\^8 CAR-T cells will be selected as optional back-up doses for potential escalation or de-escalation.
62273307|NCT02447848|EXPERIMENTAL|sufentanil sublingual tablet 30 mcg|Patients may be administered one tablet every 60 minutes as needed during the study period
62273308|NCT03372031|EXPERIMENTAL|Active-Passive|Active Piano training (8 sessions in two weeks) followed by listening to piano training (8 sessions in 2 weeks) (Passive condition)
62273309|NCT03372031|EXPERIMENTAL|Passive-Active|Passive piano training listening (8 sessions in two weeks) followed by active piano training (8 sessions in two weeks)
62273310|NCT00701545||1|Patients with von Willebrand disease treated with Humate P® ivr in Canada
62273311|NCT04538794|EXPERIMENTAL|CDX-0159|CDX-0159 every 4-8 weeks
62273312|NCT04538794|PLACEBO_COMPARATOR|Normal Saline|Normal saline every 4-8 weeks
62636350|NCT01571960|EXPERIMENTAL|Group 1: study vaccine|Participants in this arm will receive a 0.3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 224.
62636351|NCT01571960|PLACEBO_COMPARATOR|Group 1: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 224.
62636352|NCT01571960|EXPERIMENTAL|Group 2: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 303.
62068559|NCT02019134|EXPERIMENTAL|relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
62273313|NCT03470493|EXPERIMENTAL|Participants|ApneaLink Air
62273314|NCT03824665|ACTIVE_COMPARATOR|Nalbuphine Group|Nalbuphine Group (Nalbuphine) 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 4mg nalbuphine
62273315|NCT03824665|ACTIVE_COMPARATOR|Fentanyl Group|Fentanyl Group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 20 μg fentanyl
62461566|NCT01887145|ACTIVE_COMPARATOR|Open surgery|Open surgery is Open carpal tunnel release
62636353|NCT01571960|PLACEBO_COMPARATOR|Group 2: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 303.
62636354|NCT01571960|EXPERIMENTAL|Group 3: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112 and 224.
62636355|NCT01571960|PLACEBO_COMPARATOR|Group 3: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112 and 224.
62068560|NCT05027399|ACTIVE_COMPARATOR|Intervention Group|Consultations will be carried out via video call, every 15 days for a period of 3 months, with a total of 6 telephone consultations that will have in order to clarify doubts about the CI, the monitoring of possible clinical signs of instability and help in adapting or creating strategies for better adherence to therapy.
62068561|NCT05027399|NO_INTERVENTION|Control Group|Will be composed by the participants who will have no intervention and will continue to monitor according to the institution's routine.
62273316|NCT03824665|ACTIVE_COMPARATOR|Control group|Control group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml normal saline
62273317|NCT02018627|EXPERIMENTAL|Xeris glucagon|Xeris glucagon 50 micrograms, subcutaneous injection
62273318|NCT02018627|ACTIVE_COMPARATOR|Lilly glucagon|Lilly glucagon 30 micrograms, subcutaneous injection
62273319|NCT01934088|EXPERIMENTAL|Propofol|Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
62273320|NCT01934088|ACTIVE_COMPARATOR|Fentanyl and Midazolam|0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition
62461567|NCT01887145|EXPERIMENTAL|Endoscopic surgery|Endoscopic surgery is 2-portal endoscopic carpal tunnel release
62636356|NCT01552226|ACTIVE_COMPARATOR|Continuous Preperitoneal Analgesia|Continuous Preperitoneal Analgesia for pain management
62636357|NCT01552226|ACTIVE_COMPARATOR|Continuous Epidural Analgesia|Continuous Epidural Analgesia for pain management
62636358|NCT06166017||Full-arch implant-supported restorations for fully edentulous patients|No interventions will be administered. Instead, clinical parameters will be collected (see detailed description) as well as radiographs of the implants.
62636359|NCT04527029||limb deformity children|the imaging of limb deformity diagnosis by AI
62068562|NCT01155661|EXPERIMENTAL|LY2216684 (edivoxetine) + SSRI|
62273321|NCT01558661|EXPERIMENTAL|AG-013736 (AXITINIB)|This is a single-arm phase II study evaluating the clinical efficacy of axitinib in the treatment of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (ACC).
62273322|NCT03195907||PPT group|Those participated in pulmonary rehabilitation program
62636360|NCT02993861||Levetiracetam|Children with epilepsy who are treated with levetiracetam per local standard of care
62068563|NCT04968262||Sepsis|Patients receive sepsis therapy.
62068564|NCT04968262||Sepsis-related acute kidney injury|Patients receive sepsis and sepsis-related acute kidney injury therapy.
62068565|NCT00591123|EXPERIMENTAL|FOLFOX, plus 5-FU and Erlotinib|single arm
62273323|NCT03195907||Control group|Those served as control group
62273324|NCT02230280|OTHER|The intervention cohort.|A community transition and rehabilitation intervention that includes a mobile health solution
62273325|NCT06471270|OTHER|healthy controls|healthy controls
62273326|NCT06471270|OTHER|patients having OPMDs with dysplasia|patients having OPMDs with dysplasia
62273327|NCT06471270|OTHER|patients having OPMDs without dysplasia|patients having OPMDs without dysplasia
62636361|NCT02993861||Valproic Acid|Children with epilepsy who are treated with valproic acid per local standard of care
62636362|NCT02993861||Topiramate|Children with epilepsy who are treated with topiramate per local standard of care
62068566|NCT01420263|ACTIVE_COMPARATOR|Re-feeding gastric residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
62068567|NCT01420263|ACTIVE_COMPARATOR|Fresh feeding breastmilk/formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
62068568|NCT01930630|EXPERIMENTAL|Extraesophageal saline injection (ESI)|Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
62273328|NCT06471270|OTHER|oral cancer patients|oral cancer patients
62273329|NCT01816243|EXPERIMENTAL|Transdermal Therapeutic System (TTS)-fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. Oral morphine syrup is allowed to titrate the dose of TTS-fentanyl. The study duration will be 30 days after first patch application.
62273330|NCT01084070|EXPERIMENTAL|Early oral feeding|
62273331|NCT01084070|ACTIVE_COMPARATOR|Traditional Care|
62287103|NCT01047202|EXPERIMENTAL|Group 2 : 15 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
62461568|NCT03991494|EXPERIMENTAL|Pamiparib|
62636363|NCT02993861||Oxcarbazepine|Children with epilepsy who are treated with oxcarbazepine per local standard of care
62636364|NCT02485327|EXPERIMENTAL|Afrezza®|"Two-period, replicate single dose, euglycemic clamp study. There will be 2 treatment periods with a replicate administration of 1 dose of Afrezza TI (40U) in both periods.~Each patient will be given a replicate administration of 1 dose level of Afrezza TI with washout duration between treatment periods (5-19 days between periods, ie, 7 to 21 days between dosing occasions)."
62636365|NCT03714464|EXPERIMENTAL|Whole Apple|"Participants will be given 350g of whole apple and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
62068569|NCT06379256||Radiotherapy|Definitive photon or proton radiotherapy
62068570|NCT01083420|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 0.01% mouthwash
62273332|NCT01088074|ACTIVE_COMPARATOR|Histoacryl Tissue Adhesive|Histoacryl Blue (HAB) Tissue Adhesive (n-butyl-2 cyanoacrylate; B. Braun Corp., Melsungen, Germany). Histocryl is a FDA-approved sterile liquid skin adhesive that has been utilized as a substitute for sutures for wound closure for approximately 40 years.
62273333|NCT01088074|ACTIVE_COMPARATOR|Dermabond|Dermabond High Viscosity Tissue Adhesive (2-ocytl cyanoacrylate; Ethicon, Somerville, NJ). Dermabond is also a FDA-approved liquid bonding agent that has been utilized for wound closure for approximately 10 years and proven as effective as sutures.
62273334|NCT01088074|ACTIVE_COMPARATOR|Staples|Visistat 35W Stapler (Teleflex Corp, Limerick, PA). The FDA-approved Weck staple system with stainless steel staples has been proven over years of use and remains the standard accepted closure approach due to speed of insertion as well as removal.
62273335|NCT01088074|ACTIVE_COMPARATOR|Running Subcuticular with Monocryl|Monocryl 4-0 Suture (Ethicon, Somerville, NJ). Monocryl is an FDA-approved absorbable, synthetic, suture indicated for soft tissue approximation.
62273336|NCT01097863|EXPERIMENTAL|nelfilcon A, modified inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
62273337|NCT01097863|EXPERIMENTAL|nelfilcon A, no inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
62636366|NCT03714464|EXPERIMENTAL|Apple Puree|"Participants will be given 384g of apple puree and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
62068571|NCT01083420|EXPERIMENTAL|Minocycline|Minocycline 0.2% mouthwash
62636367|NCT03714464|EXPERIMENTAL|Apple Juice|"Participants will be given 338g of apple juice and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes"
62636368|NCT01309412|EXPERIMENTAL|Siltuximab|Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
62636369|NCT04166604|EXPERIMENTAL|trifluridine/tipiracil|35mg/m² BID (PER OS) (one cycle every 4 weeks)
62636370|NCT05761353|EXPERIMENTAL|Group A (endermologie group)|This group includes 34 patients who will receive 30 min Endermologie 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks.
62636371|NCT05761353|EXPERIMENTAL|Group B (Negative pressure therapy group)|This group includes34 patients who will receive 30min negative pressure therapy 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks
62636372|NCT02298972|NO_INTERVENTION|Comparison group|The comparison group will receive standard care.
62068572|NCT02085538|EXPERIMENTAL|Normal Renal Function|
62068573|NCT02085538|EXPERIMENTAL|Mild Renal Impairment|
62068574|NCT02085538|EXPERIMENTAL|Moderate Renal Impairment|
62068575|NCT02085538|EXPERIMENTAL|Severe Renal Impairment|
62068576|NCT02608905|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
62273338|NCT01097863|ACTIVE_COMPARATOR|nelfilcon A, inversion indicator|Nelfilcon A commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for one week.
62068577|NCT02608905|PLACEBO_COMPARATOR|Placebo|Placebo tablets by mouth daily for 12 weeks
62068578|NCT04821271|EXPERIMENTAL|1|Individuals in Arm 1 will receive daily double-blinded TS-161 for three weeks during Test Session 1 and daily double-blinded placebo for three weeks during Test Session 2.
62068579|NCT04821271|EXPERIMENTAL|2|Individuals in Arm 2 will receive daily double-blinded placebo for three weeks during Test Session 1 and daily double-blinded TS-161 for three weeks during Test Session 2.
62068580|NCT02005315|EXPERIMENTAL|Vanctictumab (OMP-18R5)|Vantictumab will be administered by intravenous (IV) infusion.
62068581|NCT02005315|EXPERIMENTAL|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
62068582|NCT02005315|EXPERIMENTAL|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
62068583|NCT04610216||Bilateral users: two implant systems|For bilateral CI users two Naida CI M sound processors (one per ear) will be used during the study.
62636373|NCT02298972|ACTIVE_COMPARATOR|Intervention group|After completion of the comparison group, new patients starting chemotherapy treatment will be offered this study. Study participants will receive the nurse support and selfmanagement intervention.
62636374|NCT02939209|EXPERIMENTAL|Hydromorphone|Patients will be given 2 mg hydromorphone (immediate release) in the post anesthetic care unit.
62636375|NCT02939209|PLACEBO_COMPARATOR|Placebo|Patients will be given placebo in the post anesthetic care unit.
62068584|NCT04610216||Bimodal users: hearing aid contralateral|For bimodal subjects there will be one Naida CI M sound processor on the implanted ear as well as one hearing aid on the contralateral ear.
62068585|NCT01935921|EXPERIMENTAL|Treatment (cetuximab, IMRT, and ipilimumab)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
62068586|NCT01312987|EXPERIMENTAL|Nutrition intervention|Receives a month's supply of the nutrition supplement, Plumpy'doz®, in addition to food voucher for each month. Participants were also allowed to attend monthly educational sessions.
62068587|NCT01312987|NO_INTERVENTION|Control|Receives food vouchers each month.
62068588|NCT04112940||Adults with oropharyngeal cancer|Adult participants who have completed radiation therapy for oropharyngeal cancer within the past 3 months will undergo a swallowing x-ray study in which they will swallow up to 15 liquid stimuli prepared to different consistencies using starch and gum based thickeners.
62068589|NCT04154215|EXPERIMENTAL|Dementia with Lewy Body (DLB) patients|
62068590|NCT03679195|EXPERIMENTAL|NO Ultra (Nitric Oxid Ultra Capsules)|764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline. Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
62461569|NCT05719090|ACTIVE_COMPARATOR|Autoregulated blood flow restriction|Autoregulated BFR expands as the muscle progresses into the stretch-shortening cycle.
62636376|NCT03040401|EXPERIMENTAL|Cohort 1: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 1 will receive only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4."
62068591|NCT03679195|PLACEBO_COMPARATOR|Placebo (Cellulose Capsules)|Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
62636377|NCT03040401|EXPERIMENTAL|Cohort 2: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 2 will receive Ceplene® in combination with Proleukin® during all treatment cycles (1-4)."
62068592|NCT01678820|EXPERIMENTAL|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of \>=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
62273339|NCT03064139|EXPERIMENTAL|MCG - Mindful Walking|Participants will be trained in mindful walking technique
62273340|NCT03064139|ACTIVE_COMPARATOR|SCG - Education and Self-Care|Participants will receive education in self-management of knee OA
62636378|NCT03040401|EXPERIMENTAL|Cohort 3: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2."
62636379|NCT06613204|ACTIVE_COMPARATOR|Control Group|Control group, receives information and support in a group setting (n=160 Care Partners)
62636380|NCT06613204|EXPERIMENTAL|Test Group|Test group, receives information and support in a group setting, but program is different from control (N=160 Care Partners)
62636381|NCT06613204|NO_INTERVENTION|Care Recipients with FTD|Care recipients are consented to inform them of their rights, but they do not take part in any activities.
62636382|NCT04235400||patient with dry eye disease|
62636383|NCT03107910|OTHER|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
62636384|NCT03107910|OTHER|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
62636385|NCT04088669|EXPERIMENTAL|Intervention group|A home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist.
62636386|NCT04088669|ACTIVE_COMPARATOR|Control group|A training session about the disease and the correct inhaler use, booklets that include breathing exercises and aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks.
62636387|NCT00372632|PLACEBO_COMPARATOR|placebo|
62636388|NCT00372632|EXPERIMENTAL|sulfadoxine-pyrimethamine|
62068593|NCT01678820|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin 100 mg plus placebo to simvastatin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of \>=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
62453959|NCT03702621|ACTIVE_COMPARATOR|Liposomal Bupivacaine|"LB (Liposomal Bupivacaine) group - This group will be receiving 20 mL EXPAREL (266mg) and 40 mL of 0.125% bupivacaine in total, 30ml on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
62453960|NCT03702621|ACTIVE_COMPARATOR|Standard Bupivacaine|"SB (Standard Bupivacaine) group - This group will be receiving 60 mL of 0.25% bupivacaine in total, 30 mL on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
62636389|NCT02521363|EXPERIMENTAL|Upfront Breast Surgery|Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy
62453961|NCT05529511||Phase 1 - Preoperative|"Interviews to be completed with approximately 12 participants at three time points:~1. Prior to anterior cruciate ligament surgery~2. 3-month after anterior cruciate ligament surgery~3. 12-months anterior cruciate ligament surgery"
62636390|NCT02521363|EXPERIMENTAL|Neoadjuvant Therapy|Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.
62636391|NCT03082729|OTHER|Apremilast|Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.
62636392|NCT06044818||Healthy|
62453962|NCT05529511||Phase 2 - Nominal Group Technique panel|Consensus meeting with up to 12 participants (clinicians, patients and stakeholders) to develop the prehabilitation intervention
62453963|NCT01695109|PLACEBO_COMPARATOR|Placebo|
62453964|NCT01695109|ACTIVE_COMPARATOR|Liraglutide|
62636393|NCT06044818||Depression|
62461570|NCT05719090|ACTIVE_COMPARATOR|Non-autoregulated blood flow restriction|Non-autoregulated BFR does not expand as the muscle progresses into the stretch-shortening cycle.
62636394|NCT02936375|EXPERIMENTAL|Iguratimod|Patients will receive iguratimod over the whole follow-up, combined with steroids, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
62636395|NCT02936375|ACTIVE_COMPARATOR|Cyc+AZA|Patients will receive cyclophosphamide in the first half of study (usually to 24 weeks), followed with azathioprine till the end of follow-up. Patients will also receive steroids as combinational therapy, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
62636396|NCT03073486|EXPERIMENTAL|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
62461571|NCT05719090|ACTIVE_COMPARATOR|No blood flow restriction|This group serves as the control group for this study
62636397|NCT03073486|PLACEBO_COMPARATOR|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
62636398|NCT01023204|EXPERIMENTAL|Paclitaxel|
62636399|NCT04578171||Study population|Subjects with severe asthma treated with mepolizumab
62636400|NCT00752089|EXPERIMENTAL|Sodium fluoride/potassium nitrate/Isopentane dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice containing active ingredients: 1450 ppm F as sodium fluoride (NaF) and 5% potassium nitrate (KNO3) and isopentane as an excipient ingredient.
62636401|NCT00752089|EXPERIMENTAL|NaF/KNO3 Dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice, containing as active ingredients: 1450 ppm NaF and 5% KNO3 but no isopentane.
62068594|NCT01678820|ACTIVE_COMPARATOR|Simvastatin|Simvastatin 40 mg plus placebo to sitagliptin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of \>=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
62068595|NCT03620643|ACTIVE_COMPARATOR|Crizotinib Oral Capsule [Xalkori] monotherapy|Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule \[Xalkori\] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
62068596|NCT03620643|ACTIVE_COMPARATOR|Crizotinib Oral Capsule [Xalkori] plus Fulvestrant injection|Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule \[Xalkori\] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe \[Faslodex or generic\] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
62068597|NCT04780724|EXPERIMENTAL|Hypoxic|Participants inhale ambient air, the hypoxic gas mixture, and ambient air.
62068598|NCT04780724|EXPERIMENTAL|Hypercapnic|Participants inhale ambient air, the hypercapnic and hypoxic gas mixture, and the ambient air.
62068599|NCT01265589|PLACEBO_COMPARATOR|I=surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
62273341|NCT00853697|EXPERIMENTAL|testosterone with the 5α-reductase inhibitor dutast|This trial is a multi-center, open-label, phase II trial of the combination of exogenous testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride in patients with castration-resistant metastatic prostate cancer.
62273342|NCT03424447|NO_INTERVENTION|Non stimulated|Prospective data obtained from non stimulated patients
62273343|NCT03424447|EXPERIMENTAL|Stimulated|Prospective data obtaied from stimulated patients
62273344|NCT00640471|ACTIVE_COMPARATOR|Brivanib|
62068600|NCT01265589|EXPERIMENTAL|II=surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
62068601|NCT06325137||Patients with steroid-resistant nephrotic syndrome|Identification of a possible molecular signatures at t0 by whole transcriptome analysis from PBMCs
62068602|NCT06325137||Patients with steroid sensitive nephrotic syndrome|Identification of a possible molecular signatures at t0 by whole transcriptome analysis from PBMCs
62068603|NCT02958618|EXPERIMENTAL|"Duration for 30 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 30 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
62273345|NCT00640471|ACTIVE_COMPARATOR|Placebo|
62273346|NCT04033835|EXPERIMENTAL|MBT-I|12 sessions of MBT
62273347|NCT04033835|ACTIVE_COMPARATOR|Waiting list control|Treatment as usual
62273348|NCT03116646|EXPERIMENTAL|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
62273349|NCT04163445|ACTIVE_COMPARATOR|Depuy Attune|Subjects will have been implanted with the Depuy Attune PCR TKA
62273350|NCT04163445|ACTIVE_COMPARATOR|MicroPort Medial Pivot|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
62636402|NCT00752089|ACTIVE_COMPARATOR|NaF Dentifrice|Participants to brush their teeth for one timed minute twice daily with a dentifrice containing 1450 ppm F as NaF.
62636403|NCT00752089|PLACEBO_COMPARATOR|Placebo Dentifrice|Participants to brush their teeth for one timed minute twice daily with a fluoride free dentifrice (0 ppm F).
62273351|NCT04743947||Patients with kidney failure receiving dialysis|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in dialysis patients (hemodialysis or peritoneal dialysis).
62273352|NCT04743947||Kidney transplant patients|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in kidney transplant patients.
62273353|NCT04743947||age-matched controls in non-dialysis, non-kidney transplant patients|Historical cohort of aged matched non-dialysis and non-kidney transplanted patients who received a SARS-CoV-2 vaccination.
62273354|NCT01353742|ACTIVE_COMPARATOR|Lamivudine and Adefovir dipivoxil|One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
62636404|NCT04122118|EXPERIMENTAL|Hearth services research (pharmacist-led education)|"PHASE I: Patients' medical records are reviewed.~PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider."
62636405|NCT05946200|ACTIVE_COMPARATOR|Low flow|It will be used low-flow (0.75 l/min) to manage the general anesthesia.
62273355|NCT01353742|EXPERIMENTAL|Fixed dose combination|One capsule (100mg lamivudine and 10mg adefovir dipivoxil)
62636406|NCT05946200|SHAM_COMPARATOR|Normal flow|It will be used normal-flow (1.5 l/min) to manage the general anesthesia.
62636407|NCT01615705||Blood Draw|"SOX Subjects:~The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study."
62273356|NCT03754244|EXPERIMENTAL|TQB3456|p.o. qd
62273357|NCT02467933|PLACEBO_COMPARATOR|Placebo|The placebo arm receives a placebo letter unrelated to Seroquel
62273358|NCT02467933|EXPERIMENTAL|Informative Letter|The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
62273359|NCT02911532|EXPERIMENTAL|Optical Coherence tomography|
62273360|NCT03899662|EXPERIMENTAL|Cognitive and Physical Training|24 sessions (8 weeks, 3 times per week) of computer based 45 minute cognitive and 45 minute physical training.
62636408|NCT06612021|EXPERIMENTAL|HEMA free universal adhesive group|
62636409|NCT06612021|ACTIVE_COMPARATOR|HEMA containing universal adhesive group|
62636410|NCT05538013||obese women|The study will consist of 70 obese women volunteers aged between 18-65 years.
62636411|NCT00954265|ACTIVE_COMPARATOR|Urinary-HCG group|These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
62636412|NCT00954265|EXPERIMENTAL|Recombinant HCG group|These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
62636413|NCT06548282|EXPERIMENTAL|Experimental|Who receives intervention i.e. Acceptance and Commitment Therapy
62636414|NCT06548282|ACTIVE_COMPARATOR|Waitlist Control|Who would receive intervention after study completion
62636415|NCT03943498|EXPERIMENTAL|Treatment (Fingolimod)|"Patients receive 0.5 mg dose of Fingolimod PO QD for 4 weeks.~Take your Fingolimod approximately every 24 hours"
62068604|NCT02958618|EXPERIMENTAL|"Duration for 60 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 60 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
62068605|NCT02958618|EXPERIMENTAL|"Duration for 180 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 180 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
62068606|NCT01305278|NO_INTERVENTION|Control|No Wii balance gaming undertaken
62636416|NCT06034093|EXPERIMENTAL|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
62636417|NCT06034093|NO_INTERVENTION|Manual muscle ultrasound|Manual segmentation and size measurement for the RFCSA
62636418|NCT03756415|EXPERIMENTAL|mask plus CO2 removal device|"a traditional mask with inserted a new CO2 removal device that is called DiMax Zero Total face mask R,"
62636419|NCT03756415|ACTIVE_COMPARATOR|traditional face mask|Traditional mask without a CO2 clearance device inserted
62068607|NCT01305278|ACTIVE_COMPARATOR|Wii during vestibular rehab only|To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
62068608|NCT01305278|ACTIVE_COMPARATOR|Wii whilst on waiting list and rehab|Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.
62068609|NCT03594903|EXPERIMENTAL|Expectation violation (positive outcome of therapy)|Experimental: patients' report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
62068610|NCT03594903|OTHER|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
62068611|NCT03305224|OTHER|Ra-223 + Enzalutamide|
62068612|NCT03239873|EXPERIMENTAL|VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II®|VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
62636420|NCT01028729|EXPERIMENTAL|Endostar with chemotherapy|All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression.
62636421|NCT02670746||Nab-paclitaxel in combination with gemcitabine (AG)|The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).
62636422|NCT04486508|EXPERIMENTAL|Intermediate dose anticoagulation|Intermediate dose anticoagulation will be the the tested regimen. The anticoagulation regimen will be modified according to weight/ body mass index, and creatinine clearance level (Cl Cr). Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according to Cockcroft-Gault Formula.
62273361|NCT03232515|EXPERIMENTAL|Intervention group|Evaluation,estimation and modification of the dry weight by BIVA.
62273362|NCT00180310|EXPERIMENTAL|1|XIENCE V® Everolimus Eluting Coronary Stent System
62273363|NCT00180310|ACTIVE_COMPARATOR|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
62453965|NCT06496763||Normal Group:|(1)Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable). (2)IOP ≤ 21 mmHg bilaterally; BCVA 20/40 or better bilaterally. (3) No history of corneal, glaucoma, or retinal diseases. (4)No history of ocular surgeries, including laser refractive surgery, cataract surgery, glaucoma surgery and retinal surgery. (5)Subjects without any current ocular pathology other than cataract in the normal eye(s), as determined by self-report and/or investigator assessment at the study visit.
62453966|NCT06496763||Glaucoma Group|(1) With a current BCVA of 20/40 or better in the glaucoma study eyes. (2) History of visual field defects within the previous six months from the study visit or measured on the day of the study visit that is consistent with glaucomatous optic nerve damage. (3) Subjects who have been diagnosed with glaucoma in the glaucoma study eyes based on the presence of visual field defects, regardless of the optic nerve head and RNFL appearance. (4) Subjects without retinal disease or cornea condition in the glaucoma study eyes, as determined by self-report and/or investigator assessment at the study visit.
62636423|NCT04486508|ACTIVE_COMPARATOR|Standard Prophylaxis|Standard prophylaxis dose anticoagulation will be the anticoagulation of choice in the control arm. Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according Cockcroft-Gault Formula.
62636424|NCT04486508|EXPERIMENTAL|Atorvastatin 20|Atorvastatin 20 mg daily will be the statin therapy of choice in the intervention arm
62636425|NCT04486508|PLACEBO_COMPARATOR|Atorvastatin 20 mg Matched placebo|Matching placebo will be used for the control arm
62636426|NCT04743089|EXPERIMENTAL|Spyglass arm|Patients who underwent IHD/EHD stone removal by ERCP with SpyGlass™ DS Direct Visualization System.
62636427|NCT04743089|OTHER|PTCS arm (historical cohort)|Patients who underwent IHD/EHD stone removal by PTCS
62273364|NCT02674438|EXPERIMENTAL|Active Intervention|"Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic~Intervention #1 - Clinical algorithm: the EHMRG30-ST risk score which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation during a short stay hospital admission (3 days or less), or emergency department discharge.~Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48-72 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge."
62273365|NCT02674438|NO_INTERVENTION|Control|Usual care without access to the EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.
62273366|NCT02216461|EXPERIMENTAL|Low dose of BIBW 2948 BS|
62273367|NCT02216461|EXPERIMENTAL|Medium dose of BIBW 2948 BS|
62636428|NCT03798418|ACTIVE_COMPARATOR|exercise group|elastic band strengthening exercise
62636429|NCT03798418|EXPERIMENTAL|exercise combine diet counseling group|elastic band strengthening exercise combined diet counseling.
62636430|NCT03569098|EXPERIMENTAL|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
62636431|NCT03569098|EXPERIMENTAL|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
62273368|NCT02216461|EXPERIMENTAL|High dose of BIBW 2948 BS|
62273369|NCT02216461|PLACEBO_COMPARATOR|Placebo|
62273370|NCT03060070|PLACEBO_COMPARATOR|control group,|saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
62068613|NCT03239873|ACTIVE_COMPARATOR|VARIVAX® 2016 Commercial Process + M-M-R II®|VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
62068614|NCT01382485|ACTIVE_COMPARATOR|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
62068615|NCT01382485|EXPERIMENTAL|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
62068616|NCT06125743|OTHER|Usual Care|
62068617|NCT06125743|EXPERIMENTAL|In-Person LEF-SMP|
62068618|NCT06125743|EXPERIMENTAL|Telehealth LEF-SMP|
62068619|NCT01949597||Patients with symptomatic endometriosis|
62068620|NCT03764423|EXPERIMENTAL|Salmon fishmeal|7,5 g fishmeal and 7,5 g microcrytalline cellulose per day in capsules by mounth for 8 weeks
62068621|NCT03764423|PLACEBO_COMPARATOR|Microcrystalline cellulose|7,5 g microcrystalline cellulose per day in capsules by mounth for 8 weeks
62068622|NCT01754454|EXPERIMENTAL|Human Umbilical Cord Derived MSC|"Human Umbilical Cord Derived MSC:~Patients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
62068623|NCT02396537|EXPERIMENTAL|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
62068624|NCT02396537|PLACEBO_COMPARATOR|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
62636432|NCT03569098|PLACEBO_COMPARATOR|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
62636433|NCT03871153|OTHER|Treatment|Neoadjuvant chemotherapy(Durvalumab, Paclitaxel, Carboplatin), radiation and immunotherapy (durvalumab) followed by surgical resection followed by adjuvant immunotherapy (durvalumab)
62068625|NCT02835456|ACTIVE_COMPARATOR|Group A: Sharklet Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
62068626|NCT02835456|ACTIVE_COMPARATOR|Group B: Silicone Foley Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
62068627|NCT05349721|EXPERIMENTAL|PTC857|"Participants will receive PTC857 during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants who enter the Long-term Extension (LTE) Period, will receive open-label PTC857 for 28 weeks. Following completion of the LTE period, participants who enter the Continued LTE Period will receive open-label PTC857 for an additional 108 weeks."
62068628|NCT05349721|ACTIVE_COMPARATOR|Placebo|"Participants will receive matching placebo during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants who enter the LTE Period, will receive open-label PTC857 for 28 weeks. Following completion of the LTE period, participants who enter the Continued LTE Period will receive open-label PTC857 for an additional 108 weeks."
62068629|NCT03337191|ACTIVE_COMPARATOR|ultrasound guided caudal block|Caudal block was performed by ultrasound guided with %0,125 levobupivacaine + 10 mq/kg morphine
62068630|NCT03337191|ACTIVE_COMPARATOR|conventional caudal block|Caudal block was performed by conventional method with %0,125 levobupivacaine + 10 mq/kg morphine
62068631|NCT05033080|ACTIVE_COMPARATOR|ELX/TEZ/IVA|Following elexacftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) run-in period of 4 weeks, participants received ELX 200 milligram (mg) once daily (qd) /TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 52 weeks.
62636434|NCT03861780|EXPERIMENTAL|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
62636435|NCT03861780|EXPERIMENTAL|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.
62636436|NCT03861780|ACTIVE_COMPARATOR|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.
62636437|NCT01819727|ACTIVE_COMPARATOR|BMN 165, 20mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and \> 900 μmol/L).
62636438|NCT01819727|ACTIVE_COMPARATOR|BMN 165, 40mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and \> 900 μmol/L).
62636439|NCT01823471|EXPERIMENTAL|I-scan first group|After the caecum is reached patients will be first examined with high definition i-scan endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass white light will be used.
62636440|NCT01823471|ACTIVE_COMPARATOR|White light first group|After the caecum is reached patients will be first examined with high definition white light endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass i-scan will be used.
62636441|NCT01557673|ACTIVE_COMPARATOR|NG bolus feeding over 5 min|Tube bolus (TB): feed administered via syringe through NG tube over 5 min.
62636442|NCT01557673|PLACEBO_COMPARATOR|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.
62636443|NCT06011694||No Intervention|Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
62636444|NCT04771013|EXPERIMENTAL|Daily oral dose of thymic peptides|Patients will receive a daily oral dose of 250 mg of lyophilized thymic peptides dissolved in 50 mL of water (one hour before or two hours after a meal) in addition to the standard treatment, for up to 20 days or until medical discharge.
62636445|NCT06398236|EXPERIMENTAL|SE5-OH tablets|The product under investigation is a food supplement that contains SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup. The food supplement is presented in sealed bottles, each bottle contains 120 tablets with the recommended daily dose of 4 tablets per day administrated orally with a glass of water. The 4 tablets can be administrated together in a unique intake or in 2 separated intakes (2 tablets/intake) along the day.
62636446|NCT04899115|PLACEBO_COMPARATOR|Placebo|
62636447|NCT04899115|EXPERIMENTAL|VE303|VE303 is a live biotherapeutic product comprising 8 nonpathogenic commensal strains of Clostridia.
62636448|NCT00053885|EXPERIMENTAL|PTK787/ZK 222584|"Patients receive oral PTK787/ZK 222584 daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year."
62068632|NCT05033080|EXPERIMENTAL|VX-121/TEZ/D-IVA|Following ELX/TEZ/IVA run-in period of 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/D-IVA 250 mg qd in the treatment period for 52 weeks.
62068633|NCT05777954||Systemic Sclerosis patients|
62068634|NCT05777954||Healthy subjects|
62068635|NCT04303312|ACTIVE_COMPARATOR|Benzydamine Hydrochloride|"Control Group:Benzydamine Hydrochloride spray by mouth three times daily for 20 days.~Follow up: The patients will be recalled at one week interval for 20 days."
62068636|NCT04303312|EXPERIMENTAL|90%solcoseryl and 10% pumpkin seed oil|Intervention group: 90% solcoseryl and 10% pumpkin seed oil spray by mouth three times daily for 20 days
62273371|NCT03060070|ACTIVE_COMPARATOR|ketamine group,|ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
62636449|NCT02732808|EXPERIMENTAL|poor ovarian responder|The women with diagnose of poor ovarian responder after IVF/ICSI treatments underwent ovulation stimulation and egg collection in the same IVF/ ICSI cycle ( Shanghai protocol)
62636450|NCT00295165|EXPERIMENTAL|Arm 1|
62636451|NCT00295165|PLACEBO_COMPARATOR|Arm 2|
62636452|NCT04951908||control group|NORMAL TMJ
62636453|NCT04951908||Study group|Patients with TMJ internal derangement
62636454|NCT05563545|EXPERIMENTAL|CAR-NK-CD19 Cells|After preconditioning with chemotherapy, CAR-NK-CD19 Cells will be evaluated.
62636455|NCT00514878||1|Adult same-day outpatients scheduled for general anesthesia
62636456|NCT04553172||Affected family members|Affected family members
62636457|NCT04553172||Affected PM|Affected PM
62636458|NCT01735318|EXPERIMENTAL|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
62636459|NCT01735318|ACTIVE_COMPARATOR|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
62636460|NCT05209230|EXPERIMENTAL|Continuous renal replacement therapy arm|Echocardiographic evaluation (with 2D speckle tracking analysis of left ventricular segmental function) 1 hour before and 3 hours after the initiation of continuous renal replacement therapy (continuous veno venous hemofiltration) initiation
62636461|NCT05209230|OTHER|Control arm|Two echocardiographic evaluations (with 2D speckle tracking analysis of left ventricular segmental function) at an interval of 4 hours, before the continuous renal replacement therapy initiation.
62636462|NCT03247777|ACTIVE_COMPARATOR|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
62636463|NCT03247777|ACTIVE_COMPARATOR|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
62636464|NCT02162160|EXPERIMENTAL|Probiotic creme|Women receing probiotic creme
62636465|NCT02162160|PLACEBO_COMPARATOR|placebo|Women receiving a moisturizer
62636466|NCT00814138|ACTIVE_COMPARATOR|1|Methotrexate
62636467|NCT00814138|PLACEBO_COMPARATOR|2|Placebo
62636468|NCT03874013|EXPERIMENTAL|MOD-4023 Treatment Arm|MOD-4023 (investigational treatment): weekly MOD-4023 SC injections for 12 months; initially over the first 6 weeks, MOD-4023 will be administered in 3 stepwise escalating doses (0.25 mg/kg/week, 0.48 mg/kg/week and 0.66 mg/kg/week), each for two weeks sequentially. For the remaining 46 weeks, patients will continue to receive MOD-4023 at a dose of 0.66 mg/kg/week.
62636469|NCT03874013|ACTIVE_COMPARATOR|Genotropin Treatment Arm|Genotropin® (reference treatment): daily Genotropin® (0.025 mg/kg/day).
62636470|NCT02228005|EXPERIMENTAL|Depression|Sertraline 50- 200mg
62636471|NCT02228005|NO_INTERVENTION|Comparison group (non-depressed)|No intervention
62636472|NCT01296412|EXPERIMENTAL|Sitagliptin +/- glimepiride|Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
62636473|NCT01296412|ACTIVE_COMPARATOR|Liraglutide|Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
62636474|NCT00924846|ACTIVE_COMPARATOR|HFOV plus iNO|HFOV plus iNO: high frequency oscillatory ventilation plus inhaled nitric oxide
62636475|NCT00924846|ACTIVE_COMPARATOR|CMV plus iNO|CMV (conventional mechanical ventilation) iNO (inhaled nitric oxide)
62636476|NCT05042817|ACTIVE_COMPARATOR|Morphine|50 mg prilocaine + 2.5 mcg sufentanil + 100 mcg morphine (0.1ml)
62636477|NCT05042817|PLACEBO_COMPARATOR|NaCl 0.9%|50 mg prilocaine + 2.5 mcg sufentanil + 0.1 ml saline
62636478|NCT04211350|EXPERIMENTAL|NightBalance Sleep Position Therapy|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
62636479|NCT04211350|EXPERIMENTAL|Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
62636480|NCT03771963|EXPERIMENTAL|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously (SC), once on Day 1 (first dose) and Day 90 (second dose).
62636481|NCT00405418|EXPERIMENTAL|1|Insulin Glargine
62636482|NCT00405418|ACTIVE_COMPARATOR|2|Insulin Detemir
62273372|NCT03060070|ACTIVE_COMPARATOR|dexmedetomidine group|dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
62636483|NCT03200353|EXPERIMENTAL|Active|Each patient included receive the experimental device system NATROX during 3 to 4 weeks
62636484|NCT03498729||Persistent AF|
62461572|NCT01924078|EXPERIMENTAL|Metronomic Capecitabine and AI|Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o；or Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o.
62636485|NCT03498729||Paroxysmal AF|
62636486|NCT03498729||Psoriasis|
62273373|NCT00272038|EXPERIMENTAL|Tarceva|Tarceva 150 mg QD
62273374|NCT03234530||WTC responders|WTC Health Program participants
62636487|NCT03498729||Healthy Controls|
62636488|NCT02622152|ACTIVE_COMPARATOR|Right lateral position group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for 30 minutes period on the supine position Repositioning the patients for 30 minutes period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
62636489|NCT02622152|ACTIVE_COMPARATOR|Routine hospital care group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for two-hours period on supine position Repositioning the patients for two-hours period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
62636490|NCT00299819|ACTIVE_COMPARATOR|1|MEDI-545
62636491|NCT00299819|ACTIVE_COMPARATOR|2|MEDI-545
62636492|NCT00299819|ACTIVE_COMPARATOR|3|MEDI-545
62273375|NCT03234530||Urban workers|Control group of urban workers in NYC not exposed to the dust from the WTC
62273376|NCT03406221|EXPERIMENTAL|Intervention arm|
62273377|NCT03406221|ACTIVE_COMPARATOR|Control Arm|
62636493|NCT00299819|ACTIVE_COMPARATOR|4|MEDI-545
62636494|NCT00299819|ACTIVE_COMPARATOR|5|MEDI-545
62636495|NCT00657423|EXPERIMENTAL|1|
62636496|NCT00657423|ACTIVE_COMPARATOR|2|
62636497|NCT03383224|EXPERIMENTAL|Genotype-guided (A allele carriers)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (A allele carriers will be given pharmacologic therapy (nicotine replacement therapy --NRT; nicotine patch used according to FDA labelling).)
62636498|NCT03383224|EXPERIMENTAL|Genotype-guided (GG homozygotes)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (GG homozygotes will be given smoking cessation counseling)
62636499|NCT03383224|ACTIVE_COMPARATOR|Standard (non-genotype guided) - NRT|1/2 of patients in this arm will be given nicotine replacement therapy (NRT; nicotine patch used according to FDA labeling) but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
62636500|NCT03383224|ACTIVE_COMPARATOR|Standard (non-genotype guided)- counseling|1/2 of patients in this arm will be given smoking cessation counseling but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
62636501|NCT00445471|OTHER|A|Mifne Approach to PDD
62636502|NCT00445471|OTHER|B|Treatment as usual
62068637|NCT04485130|EXPERIMENTAL|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
62636503|NCT00988104|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|
62273378|NCT06093061|EXPERIMENTAL|MAINTENANCE STUDY TREATMENT|EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA detectable after 3 cycles of IC.
62636504|NCT00988104|ACTIVE_COMPARATOR|Supportive Counseling|
62636505|NCT02227277|EXPERIMENTAL|Conditional 12-week ART interruption|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
62636506|NCT02227277|EXPERIMENTAL|Continuous ART|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
62636507|NCT02227277|NO_INTERVENTION|Control with continuous ART|18 participants will continue their current ART regimens and be observed for 20 weeks.
62636508|NCT05597995|EXPERIMENTAL|Treatment with 1.5% sodium tetradecyl sulfate foam|each subject will have cyst contents aspirated through an 18g needle followed by an injection of 1.5% STS solution foamed 1:4 with air until foam is flowing out of the injection site.
62636509|NCT04574453|EXPERIMENTAL|Iracross|1 course of IRACROSS (crosslinked 2% Hyaluronic Acid) at baseline, consisting of a mono-dose intra-articular administration (2ml).
62273379|NCT06195020|EXPERIMENTAL|Experimental Group|This group will be informed by sharing and using educational videos prepared in the Metaverse universe on mobile.
62273380|NCT06195020|ACTIVE_COMPARATOR|Control Group|This group will be informed through routine outpatient clinic service.
62273381|NCT04756037|EXPERIMENTAL|Relugolix/E2/NETA|Participants will receive relugolix combination therapy for 1 year (13 consecutive 28-day treatment cycles).
62273382|NCT03444285|ACTIVE_COMPARATOR|Warm Up|
62273383|NCT03444285|ACTIVE_COMPARATOR|Hot Pack|
62273384|NCT02417272|EXPERIMENTAL|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
62636510|NCT04574453|ACTIVE_COMPARATOR|Iraline|1 course of IRALINE (linear 2% Hyaluronic Acid); each course consists of 3-5 intra-articular administrations (2ml) at weekly intervals (from week 1 to 3, 4 or 5, depending on each patient's need)
62636511|NCT02876796|EXPERIMENTAL|50 mg GS-0976 (Cohort 1)|"Sequence 1:~Period 1 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 2:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution"
62636512|NCT02876796|EXPERIMENTAL|200 mg GS-0976 (Cohort 2)|"Sequence 3:~Period 1 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 4:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution"
62636513|NCT02876796|EXPERIMENTAL|20 mg GS-0976 (Cohort 3)|"Sequence 5:~Period 1 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 6:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution"
62636514|NCT00545623|ACTIVE_COMPARATOR|ACU+RR|acupuncture + relaxation response CD
62068638|NCT04485130|PLACEBO_COMPARATOR|Placebo|This study will provide placebo comparator for disulfiram. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days.
62636515|NCT00545623|ACTIVE_COMPARATOR|SHAM+RR|sham acupuncture + relaxation response CD
62636516|NCT00545623|ACTIVE_COMPARATOR|ACU+EDU|acupuncture+control CD
62636517|NCT00545623|SHAM_COMPARATOR|SHAM+EDU|sham acupuncture+control CD
62636518|NCT01167569|ACTIVE_COMPARATOR|A-Ascorbic Acid (Vitamin C)|Ascorbic Acid (Vitamin C) 10mg/kg x 2 in the operating room followed by Ascorbic Acid (Vitamin C) 5mg/kg every 4 hours x 48 hours.
62636519|NCT01167569|PLACEBO_COMPARATOR|B-5% Dextrose Water or Normal Saline|5% Dextrose Water or Normal Saline (placebo) x 2 in the operating room followed by 5 % Dextrose Water or NS (placebo) every 4 hours X 48 hours.
62636520|NCT05252741|ACTIVE_COMPARATOR|Group 1: patients with psoriasis|
62636521|NCT05252741|PLACEBO_COMPARATOR|Group 2: age-, sex-, BMI-, and weight-matched control subjects.|
62636522|NCT00588146|EXPERIMENTAL|Pegylated Interferon Alpha2b, then Standard Care|Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months, then standard care for 6 months.
62636523|NCT00588146|EXPERIMENTAL|Standard Care, then Pegylated Interferon Alpha2b|Standard care for 6 months, then weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months.
62636524|NCT00249873|EXPERIMENTAL|Clopidogrel + ASA|Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
62636525|NCT00249873|PLACEBO_COMPARATOR|Placebo + ASA|Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
62636526|NCT00145769|ACTIVE_COMPARATOR|Short Course Radiotherapy|Short Course (SC) pre-operative radiotherapy, followed by surgery and adjuvant chemotherapy
62636527|NCT00145769|ACTIVE_COMPARATOR|Long Course Radiotherapy|Long Course (LC) radiotherapy delivered with concurrent chemotherapy, followed by surgery and adjuvant chemotherapy
62636528|NCT00145769|ACTIVE_COMPARATOR|Surgery|Patients will receive initial surgery followed by post-operative management according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Adjuvant therapy for rectal cancer.
62636529|NCT05370898|EXPERIMENTAL|Traditional Chinese medicine|On the basis of general symptomatic treatment of caltrate D，patients in experimental group use the traditional Chinese medicine application prescription.
62636530|NCT05370898|PLACEBO_COMPARATOR|Comparator: placebo|On the basis of general symptomatic treatment of caltrate D，patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
62636531|NCT03847740|EXPERIMENTAL|Right Isometric Thumb Force (ITF) handle|
62636532|NCT03847740|EXPERIMENTAL|Left Isometric Thumb Force (ITF) handle|
62636533|NCT04288934|ACTIVE_COMPARATOR|patients with complete transection of the spinal cord|This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.
62636534|NCT04288934|ACTIVE_COMPARATOR|patients with SCI without total transaction.|This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla.
62636535|NCT05375500|EXPERIMENTAL|Digital Therapeutic Arm|measure the treatment effects of digital therapeutic intervention
62068639|NCT02281175|NO_INTERVENTION|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
62068640|NCT02281175|ACTIVE_COMPARATOR|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
62636536|NCT02123719||Patients post liver transplantation|Patients after liver transplantation
62636537|NCT02123719||Control group|Patients with an abdominal incisional hernia without a history of immunosuppresion
62636538|NCT01644097|EXPERIMENTAL|Arm I (probiotic mix)|Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
62636539|NCT01644097|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity.
62636540|NCT00827710|ACTIVE_COMPARATOR|1|patients who received point-of-care report cards and were listed on provider performance report card
62636541|NCT00827710|ACTIVE_COMPARATOR|2|Patients who received point-of-care diabetes report cards but were not listed on provider performance report card
62068641|NCT02281175|EXPERIMENTAL|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
62068642|NCT06480682||Dance|Age: 16-45yrs old Sex: Female and male Activity: Dance (ballet, contemporary, musical theatre); Level: Full-time training at either a dance company, vocational dance school Status: Engaged in full-time training at start of project without activity limiting injury
62273385|NCT02417272|EXPERIMENTAL|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
62636542|NCT00827710|ACTIVE_COMPARATOR|3|Patients who did not receive point-of-care report card but who were listed on provider performance report card
62636543|NCT00827710|NO_INTERVENTION|4|Patients who did not receive point of care report card and who did were not listed on provider performance report card
62636544|NCT03957486|EXPERIMENTAL|Same group|arterial cannulation on same arm of continuous hemoglobin monitoring
62636545|NCT03957486|PLACEBO_COMPARATOR|Different group|arterial cannulation on different arm of continuous hemoglobin monitoring
62636546|NCT02601079|ACTIVE_COMPARATOR|Conventional biopsy|"4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
62636547|NCT02601079|ACTIVE_COMPARATOR|Endodrill biopsy|"4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
62636548|NCT05052853|EXPERIMENTAL|NMDAE|An NMDA enhancer
62636549|NCT05052853|PLACEBO_COMPARATOR|Placebo|Placebo
62636550|NCT01156688|ACTIVE_COMPARATOR|Sublingual Misoprostol|
62636551|NCT01156688|ACTIVE_COMPARATOR|Buccal misoprostol|
62636552|NCT05469529|NO_INTERVENTION|Bupivacaine|Participants to be given 2ml of 0.5% bupivacaine intrathecally for elective cesarean section deliveries.
62636553|NCT05469529|ACTIVE_COMPARATOR|Bupivacaine + Dexmedetomidine|Participants to be given 5mcg dexmedetomidine in addition to 2ml of 0.5% bupivacaine intrathecally for elective cesarean section deliveries.
62636554|NCT06377293|EXPERIMENTAL|Study diet|4-week therapeutic diet intervention as experimental group
62636555|NCT06377293|NO_INTERVENTION|Usual diet|4-week usual diet as control group, no dietary intervention in this group, participants consumed their habitual diet
62636556|NCT02224612|ACTIVE_COMPARATOR|Children 4-5 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
62636557|NCT02224612|ACTIVE_COMPARATOR|Children 6-9 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
62068643|NCT06480682||Combat Sports|Age: 16-45yrs old Sex: Female and male Activity: Combat sports (judo, karaté, taekwondo); Level: Full-time training at either a NGB centre Status: Engaged in full-time training at start of project without activity limiting injury
62636558|NCT02224612|ACTIVE_COMPARATOR|Children 10-12 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
62636559|NCT01496313|ACTIVE_COMPARATOR|300mg vandetanib|
62636560|NCT01496313|ACTIVE_COMPARATOR|150mg vandetanib|
62068644|NCT06480682||Gymnastics|Age: 16-45yrs old Sex: Female and male Activity: Gymnastics (artistic) Level: Full-time training at either a NGB centre or academy Status: Engaged in full-time training at start of project without activity limiting injury
62068645|NCT03774602|EXPERIMENTAL|MCSP package of interventions|MCSP package of interventions for health promotion and provision of RMNCH services
62068646|NCT00735644|EXPERIMENTAL|JE-CV GPO MBP (Lot 1)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
62068647|NCT00735644|EXPERIMENTAL|JE-CV GPO MBP (Lot 2)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
62068648|NCT00735644|EXPERIMENTAL|JE-CV GPO MBP (Lot 3)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
62068649|NCT00735644|ACTIVE_COMPARATOR|JE-CV WRAIR (Group 4)|Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
62068650|NCT00735644|SHAM_COMPARATOR|Hepatitis A (Group 5)|Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine
62636561|NCT01542138|ACTIVE_COMPARATOR|Niacinamide|4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.
62636562|NCT01542138|ACTIVE_COMPARATOR|Desonide|Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation
62068651|NCT02618720|EXPERIMENTAL|ornidazole|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
62068652|NCT02618720|PLACEBO_COMPARATOR|placebo|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
62636563|NCT01542138|PLACEBO_COMPARATOR|Placebo|Humectant placebo cream
62636564|NCT00325819|ACTIVE_COMPARATOR|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
62636565|NCT00325819|PLACEBO_COMPARATOR|Placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
62636566|NCT05908396|EXPERIMENTAL|IGM-2644 Dose Escalation|Participants will receive IGM-2644 via intravenous (IV) infusion weekly.
62636567|NCT05908396|EXPERIMENTAL|IGM-2644 Dose Expansion|Participants will receive IGM-2644 via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data.
62636568|NCT02581683|EXPERIMENTAL|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine via adductor canal block
62068653|NCT03331185|ACTIVE_COMPARATOR|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
62068654|NCT03331185|EXPERIMENTAL|L-PRF Clot|Socket filled with L-PRF Clot
62273386|NCT00848354|EXPERIMENTAL|Phase 1 Etanercept + methotrexate|Phase 1: Etanercept + methotrexate
62636569|NCT02581683|ACTIVE_COMPARATOR|Non-magnesium|Participants in this arm will receive ropivacaine via adductor canal block
62636570|NCT02581683|SHAM_COMPARATOR|Sham|Participants in this arm will receive a sham adductor canal block
62068655|NCT01115543|ACTIVE_COMPARATOR|calcitriol|The subjects were randomized to receive calcitriol in a dose-escalating fashion for up to 24 weeks.
62453967|NCT06496763||Retinal Disease Group|(1)Subjects with a current BCVA of 20/400 or better in the retinal disease study eye(s) at the study visit. (2)Subjects diagnosed with retinal pathology including but not limited to any one of following criteria: a. Non Exudative Macular Degeneration (dry AMD), Diabetic Macular Edema, Macular Hole, Epiretinal Membrane, Cystoid Macular Edema, or other retinal disease in the study eye(s) as confirmed within the past six months, who exhibit structural lesions in the study eye; b. Neovascular Macular Degeneration (wet AMD), Diabetic Retinopathy, Retinal Artery Occlusion, Retinal Vein Occlusion or other retinal disease in the study eye(s) as confirmed within the past six months, who exhibit vascular and/or ischemic lesions in the study eye. (3) Subjects without glaucoma or cornea condition in the retinal disease study eye(s), as determined by self-report and/or investigator assessment at the study visit.
62636571|NCT00113295|ACTIVE_COMPARATOR|Paroxetine CR and Placebo|Eleven individuals were randomized to plaecbo augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly titrated up to a maximum of 62.5 mg/day by week 10. Individuals who did not achieve remission and were randomized into the placebo group received placebo augmentation of continued paroxetine CR at the week 10 dose level.
62453968|NCT06496763||Cornea Condition Group|History of refractive surgery, contact lens (wear contact lens more than 6 months), dry eye or keratoconus.
62453969|NCT05832463|EXPERIMENTAL|Experimental arm|"In cohort 1, participants will receive either a 250 mg mulberry leaf extract CBS dose (1 supplement capsule t.i.d. + 1 placebo capsule to preserve blinding) or a 500 mg mulberry leaf extract CBS dose (2 supplements t.i.d.) in the experimental arm and will cross over to or from the placebo arm.~In cohort 2, participants will receive a 500 mg mulberry leaf extract CBS dose (2 supplement capsules t.i.d.) in the experimental arm and will cross over to or from the placebo arm."
62453970|NCT05832463|PLACEBO_COMPARATOR|Placebo arm|In Cohorts 1 and 2, participants will receive 2 placebo capsules in the placebo arm and will cross over to or from the experimental arm.
62453971|NCT05228314|EXPERIMENTAL|Standard dose SCB-2020S with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-2020S with CpG/alum adjuvant
62453972|NCT05228314|EXPERIMENTAL|Low dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with low dose squalene based adjuvant
62453973|NCT05228314|EXPERIMENTAL|Low dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with standard dose squalene based adjuvant
62453974|NCT05228314|EXPERIMENTAL|Standard dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with low dose squalene based adjuvant
62453975|NCT05228314|EXPERIMENTAL|Standard dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with standard dose squalene based adjuvant
62453976|NCT05228314|ACTIVE_COMPARATOR|Standard dose SCB-2019 with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-20219 with standard CpG/alum adjuvant
62453977|NCT03961464|EXPERIMENTAL|d-cycloserine|oral, capsule, 250 mg
62453978|NCT03961464|EXPERIMENTAL|Placebo|oral, capsule, lactose
62453979|NCT01179919|EXPERIMENTAL|Oseltamivir Dosed Group|Oseltamivir 75 mg by mouth every 12 hours for 9 doses
62453980|NCT04465188|EXPERIMENTAL|Experimental arm|Surgical procedure to prevent retinal detachment in the unaffected eye
62453981|NCT04465188|NO_INTERVENTION|Control arm|Standard procedure of clinical practice without any surgical procedure for the unaffected fellow eye.
62453982|NCT00794742||Burn Wounds|Patients with burn wounds
62453983|NCT05754047||HER2-low|patients with HER2 IHC1+ and HER2 IHC2+/ISH-negative in their pathology
62453984|NCT05754047||HER2-negative|patients with HER2-zero in their pathology
62453985|NCT05754047||HER2-positive|patients with HER2 IHC2+/ISH-positive and HER2 IHC 3+ in their pathology
62453986|NCT02447900|OTHER|Treatment|
62453987|NCT04958980|NO_INTERVENTION|Placebo|The control group will be evaluated in 2 stages: at the beginning and at the end of the study and will be accompanied only with scheduled medical consultations (also simulating the reality of basic health units with a traditional model of care) and the intervention group will undergo evaluations with the multiprofessional team on two occasions (at the beginning and at the end of the study)
62453988|NCT04958980|ACTIVE_COMPARATOR|Specific and educational guidelines on pathology care (diabetes mellitus)|"Multiprofessional educational guidelines and analysis of the following exams:~* Periodontal record, bleeding rate on and visible plaque;~* Body mass index (BMI): weight (kg) divided by height squared (m²);~* Serum glucose values;~* Glycated hemoglobin;~* Blood count: hemoglobin;~* Urea: male:~* Creatinine male;~* Uric acid;~* Oxalacetic glutamic transaminase;~* Glutamic pyruvic transaminase;~* Total cholesterol and fractions: Cholesterol, Non HDL, LDL, VLDL;~* Triglycerides;~* Type I urine;~* Vitamin D3 25OH;~* Microalbuminuria;~* Blood pressure: systolic;~* Abdominal circumference."
62453989|NCT04349605|EXPERIMENTAL|Meditation|This is a daily 15 minute meditation with guided breathing. Accessible through an app.
62453990|NCT04349605|EXPERIMENTAL|Kundalini Yoga|This is a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
62453991|NCT04349605|NO_INTERVENTION|Treatment as Usual|This group will serve as the comparison to assess the efficacy of the active treatments in that no study treatment will be provided. The participants will be asked to not start new treatments during the 8 weeks of the study.
62453992|NCT03319420|EXPERIMENTAL|LO2A|1 drop of sodium hyaluronate instilled into each eye 4 times daily
62453993|NCT03319420|ACTIVE_COMPARATOR|Systane Ultra UD|1 drop of Systane Ultra UD instilled into each eye 4 times daily
62461573|NCT05723445|EXPERIMENTAL|Low Glycemic Load Diet|Feeding study with dietary composition (approximately) 50% fat, 20% protein, 30% carbohydrate.
62461574|NCT06440447||Day program attendees|Older adults (65+ years) attending an adult day program in Alberta, British Columbia, or Manitoba
62461575|NCT06440447||Non-attendees|Older adults with an initial Resident Assessment Instrument - Home Care (RAI-HC), who are not attending a day program in Alberta, British Columbia, or Manitoba
62068656|NCT01115543|EXPERIMENTAL|alfacalcidol|
62068657|NCT05097768|ACTIVE_COMPARATOR|Dexamethasone|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive Dexamethasone 0.5 mg.
62068658|NCT05097768|ACTIVE_COMPARATOR|Ketorolac|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive ketorolac 10 mg.
62068659|NCT05097768|ACTIVE_COMPARATOR|Meloxicam|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive meloxicam 7.5 mg.
62636572|NCT00113295|EXPERIMENTAL|Quetiapine and continued paroxetine CR|Eleven individuals were randomized to quetiapine augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly tirated up to a maximum of 62.5 mg/day by week 10. Individuals who did not receive remission and were randomized to receive quetiapine started at 25 mg at bedtime for the first week, then flexibly dosed based on response and tolerability to a maximum of 200 mg BID by week 16.
62636573|NCT06203535|EXPERIMENTAL|Aerobic training (group a)|In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities ranging from 60 to 75 per cent of heart rate reserve during a 35-minute group cumulative exercise session.
62068660|NCT05097768|ACTIVE_COMPARATOR|Ibuprofen|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive ibuprofen 600 mg.
62068661|NCT05097768|PLACEBO_COMPARATOR|Placebo|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive placebo.
62068662|NCT00341380||Patients|Undergoing resection of lung tumor
62068663|NCT05765084|EXPERIMENTAL|Single arm|Standard of care chemotherapy, complemented with atezolizumab and WT1/DC vaccination
62068664|NCT06177236|EXPERIMENTAL|randomıze|Assuming that a t-test between two independent groups with 80% power, d=0.5 effect size, and t-test between two independent groups will be used in the study, it was found that there should be at least 102 women in total, including 51 self-sampling and 51 clinician sampling groups. Considering the losses that may occur during the study, it was planned to include 110 women in the sample for this phase. These women will be randomly assigned to Self-Sampling (n=55) or Clinician Sampling (n=55) groups in a 1:1 ratio using https://randomizer.org/. The self-sampling group will be trained on the subject and will be provided with a self-sampling HPV DNA test kit, while the HPV DNA test
62068665|NCT01515904||Control|Approximately 50% of attendees choose not to book into the STOMP program, for reasons including difficulty attending the frequent appointments due to distance or inability to leave work early. This population will serve as the control group for the evaluation. Control participants will be recruited from the community through posters in the hospital
62273387|NCT00848354|ACTIVE_COMPARATOR|Phase 1 Conventional DMARD (SSZ or HCQ) + MTX|Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate
62273388|NCT02937714|EXPERIMENTAL|School mental health training|Teachers Training workshop Workshop based on local adaptation of WHO-EMRO school mental health manual will be conducted in school. The duration of the workshop will be 3 days. Teachers can decline to participate or withdraw at any stage.
62273389|NCT02937714|NO_INTERVENTION|Wait list control group|Wait list control group of teachers in same schools. Half of teachers in the same school will be the wait list control group.
62453994|NCT02991625|EXPERIMENTAL|Placebos|Chronic Back Pain participants will enter an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
62453995|NCT02991625|OTHER|Waitlist|Chronic Back Pain participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar.
62453996|NCT02991625|OTHER|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
62461576|NCT02032888|EXPERIMENTAL|Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks|Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
62636574|NCT06203535|EXPERIMENTAL|control group (group B)|twenty participants have idiopathic chronic fatigue will received only traditional physical therapy exercise program (flexibility and balance activities)
62636575|NCT01712828|EXPERIMENTAL|Lenalidomide plus Quinidine|
62636576|NCT01712828|EXPERIMENTAL|Lenalidomide plusTemsirolimus and Diphenhydramine|
62636577|NCT03643510|EXPERIMENTAL|Fulvestrant in Combination with Abemaciclib|Eligible patients will take Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28. Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles. Each cycle will be 28 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.
62068666|NCT01515904||STOMP|12-17 yrs. Patients in the program have severe complex obesity defined as children and youth who have a BMI \>95th %ile for their age and gender in addition to one of the following: at least one significant obesity-related co-morbidity requiring specialty care (e.g. type 2 diabetes), other co-existing chronic illness impacted by obesity (e.g. CNS tumor, post-organ transplant), or a BMI ≥99th percentile for their age and gender
62068667|NCT04706741|EXPERIMENTAL|Izokibep and maintenance corticosteroid dose|Izokibep+ Prednisolon/Prednisone
62273390|NCT01261156|EXPERIMENTAL|Study Arm 1|
62273391|NCT01261156|EXPERIMENTAL|Study Arm 2|
62273392|NCT01708759||Sepsis|Forty patients developed septic complication during ICU stay (sepsis group).
62273393|NCT01708759||SIRS|Forty patients were critically ill without evidence of infectious organism (SIRS group).
62287104|NCT01047202|SHAM_COMPARATOR|Group 3 : 7.5 μg seasonal trivalent vaccine|60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart
62287105|NCT03684135|EXPERIMENTAL|Use of cosmetics during chemotherapy and thermal cure|Use of cosmetics during chemotherapy and post-treatment thermal cure
62273394|NCT04564586|OTHER|Enhanced Intervention Group (EIG)|The Enhanced Intervention Group was a subgroup of the participants that were invited for voluntary weekly meet-n-greet sessions in the Primary Care Clinic. These sessions were information and not educational sessions for the intervention. The entire EIG concept was to test a social component of participants by providing an informal opportunity for a DPPFit social group. The group sessions were terminated after only 5 weeks as a result of the Covid-19 pandemic. They were the only component of the DPPFit study that were face-to-face.
62273395|NCT05465356||New patients|All new referrals seen in the rheumatology outpatients department, completing pre-appointment digital questionnaires
62273396|NCT05465356||Follow-up patients|Patient with inflammatory arthritis completing ePROMs \[electronic Patient Reported Outcome Measures\] through the remote monitoring platform
62273397|NCT00781456|EXPERIMENTAL|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
62273398|NCT00781456|PLACEBO_COMPARATOR|Placebo|Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
62273399|NCT04074928|EXPERIMENTAL|QIVc|Cell-derived Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
62273400|NCT04074928|ACTIVE_COMPARATOR|Comparator QIV|Comparator Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
62273401|NCT05419089|EXPERIMENTAL|Robotic surgery only|"* Complete resection to negative frozen section margins (pT1-2)~* \< 4 nodes, ≤ 2 mm extranodal extension (ENE), no supraclavicular nodes"
62636578|NCT00281697|EXPERIMENTAL|Standard chemotherapy + bevacizumab|Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
62636579|NCT00281697|PLACEBO_COMPARATOR|Standard chemotherapy + placebo|Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
62636580|NCT02951832||observational group|Observational Study about Lymphocytes Change during Menstrual Cycle in Women of Child-bearing Age
62636581|NCT03278496|EXPERIMENTAL|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
62636582|NCT03278496|EXPERIMENTAL|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
62636583|NCT03278496|ACTIVE_COMPARATOR|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
62636584|NCT06436079|EXPERIMENTAL|Audiovisual educational program on treatment in a hyperbaric chamber|The experimental group will receive a nursing educational intervention with an explanation, with audiovisual support, of the operation of the hyperbaric chamber.
62636585|NCT06436079|ACTIVE_COMPARATOR|Usual intervention|The control group will undergo the same procedure that is currently carried out, some basic explanations before entering the hyperbaric chamber.
62636586|NCT00698815|EXPERIMENTAL|Arm I (pemetrexed)|Patients receive pemetrexed disodium 500 mg/m\^2 IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive sunitinib malate as in Arm II as third-line therapy.
62636587|NCT00698815|EXPERIMENTAL|Arm II (sunitinib)|Patients receive sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive pemetrexed disodium as in Arm I as third-line therapy.
62636588|NCT00698815|EXPERIMENTAL|Arm III (pemetrexed and sunitinib)|Patients receive pemetrexed disodium 500 mg/m\^2 IV over 10 minutes on day 1 and sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive third-line therapy at the discretion of the treating physician.
62636589|NCT00583908|ACTIVE_COMPARATOR|Group 1: lotrafilcon B/senofilcon A/balafilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. Period 1: lotrafilcon B /period 2: senofilcon A / period 3: balafilcon A / period 4: omafilcon A
62273402|NCT02499068|EXPERIMENTAL|COPD, Telehealth|Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
62273403|NCT02499068|NO_INTERVENTION|COPD, Normal clinical practice|Patients would do the usual clinical practice.
62273404|NCT05246137|EXPERIMENTAL|Experimental: COVID-19 Vaccine HIPRA 40 ug/dose|COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA
62273405|NCT03917602|EXPERIMENTAL|Patients with large macular holes|Patients suffering from large macular holes as documented by spectral domain OCT will undergo pars plan vitrectomy with human amniotic membrane insertion into the macular hole.
62273406|NCT05798260||Healthy Volunteers|Healthy Volunteers
62068668|NCT04229030|ACTIVE_COMPARATOR|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL RZL-012 (5mg).~Lipomas in the size of:~2-3.9 cm will be dozed with 0.4mL RZL-012 (20mg). 4-5.9 cm will be dozed with 0.8mL RZL-012 (80mg). 6-7.9 cm will be dozed with 1 mL RZL-012 (100mg). 8-10 cm will be dozed with 1.2 mL RZL-012 (120mg)."
62068669|NCT04229030|PLACEBO_COMPARATOR|Vehicle of RZL-012|"A single-treatment injection, multiple subcutaneous injections of vehicle administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL vehicle.~Lipomas in the size of:~2-3.9 cm will be dozed with 0.4mL vehicle. 4-5.9 cm will be dozed with 0.8mL vehicle. 6-7.9 cm will be dozed with 1 mL vehicle. 8-10 cm will be dozed with 1.2 mL vehicle."
62273407|NCT05798260||COVID-19 positive admitted to the ICU and on the ventilator|COVID-19 positive admitted to the ICU and on the ventilator
62068670|NCT00583232|ACTIVE_COMPARATOR|Corticosteroid|Subjects receiving corticosteroid therapy (1-2 mg/kg/day up to 60mg/day) with taper.
62068671|NCT00583232|ACTIVE_COMPARATOR|infliximab|Subjects receiving infliximab therapy (5 mg/kg at 0, 2 and 6 weeks, followed by every 8 week therapy)
62068672|NCT05824390|EXPERIMENTAL|Group A ( ACEi and / or ARB + rituximab group )|Patients in the experimental group were treated with the maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and / or angiotensin II receptor blocker ( ARB ) combined with rituximab. The specific usage and dosage are as follows : On the basis of the use of ACEI and / or ARB, rituximab was used on D1 and D31 days, 1 g each time, intravenous drip, twice in total. Add 1 g rituximab at 6 months. All patients who received rituximab were given oral acetaminophen ( 1g ), diphenhydramine hydrochloride ( 50mg ) and intravenous methylprednisolone ( 40mg ) 30-60min before the beginning of infusion. ACEI and / or ARB were given daily maximum tolerable dose according to individual factors of subjects.
62068673|NCT05824390|NO_INTERVENTION|Group B ( ACEi and / or ARB )|According to the individual factors of the subjects, the maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and / or angiotensin II receptor blocker ( ARB ) were used daily.
62068674|NCT03180879|EXPERIMENTAL|1|Treatment Order: Test, Reference, Comparator
62068675|NCT03180879|EXPERIMENTAL|2|Treatment Order: Test, Comparator, Reference
62068676|NCT03180879|EXPERIMENTAL|3|Treatment Order: Reference, Test, Comparator
62068677|NCT03180879|EXPERIMENTAL|4|Treatment Order: Reference, Comparator, Test
62068678|NCT03180879|EXPERIMENTAL|5|Treatment Order: Comparator, Test, Reference
62068679|NCT03180879|EXPERIMENTAL|6|Treatment Order: Comparator, Reference, Test
62068680|NCT05981313||Hemophilia Group|The viscoelastic properties (tone, stiffness, elasticity) of the lower extremity muscles (Vastus Medialis Obliquus, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Tibialis Anterior, Gastrocnemius) of hemophilia patients who meet the study criteria will be evaluated with the MyotonPro device (Myoton Ltd).
62068681|NCT05981313||Control Group|The viscoelastic properties (tone, stiffness, elasticity) of the lower extremity muscles (Vastus Medialis Obliquus, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Tibialis Anterior, Gastrocnemius) of healthy children meeting the study criteria will be evaluated with the MyotonPro device (Myoton Ltd).
62068682|NCT01519024||Women with breast hypertrophy|Fourteen women with breast hypertrophy
62068683|NCT01519024||Women without breast hypertrophy.|Fourteen women without breast hypertrophy for de control group (CG).
62068684|NCT03290560|EXPERIMENTAL|Recombinant human tissue kallikrein|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
62068685|NCT03290560|PLACEBO_COMPARATOR|Placebo|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
62273408|NCT03800654|OTHER|Mindful Action for Pain (MAP) Development|In the first arm, MAP will be fully developed.
62068686|NCT00299195|EXPERIMENTAL|1|sulindac
62068687|NCT00299195|PLACEBO_COMPARATOR|2|placebo
62068688|NCT03303586|ACTIVE_COMPARATOR|Asthma group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
62273409|NCT03800654|ACTIVE_COMPARATOR|MAP vs. CBT-CP|In the second arm, MAP will be compared to CBT-CP to establish feasibility of a larger, future trial.
62273410|NCT05079607|EXPERIMENTAL|Mitopure Topical Formula|
62273411|NCT02098564|ACTIVE_COMPARATOR|strong sense of coherence control group|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
62273412|NCT02098564|EXPERIMENTAL|strong sense of coherence intervention|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
62273413|NCT02098564|ACTIVE_COMPARATOR|weak sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
62068689|NCT03303586|ACTIVE_COMPARATOR|Healthy group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
62068690|NCT06332950|EXPERIMENTAL|Adebrelimab plus Irinotecan Liposome (II)|"Adebrelimab: 1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W"
62068691|NCT06332950|EXPERIMENTAL|Adebrelimab plus Irinotecan Liposome (II) and Famitinib|"Adebrelimab: 1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD"
62068692|NCT04437147|PLACEBO_COMPARATOR|Placebo|a) Control placebo (P1) Component Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
62068693|NCT04437147|ACTIVE_COMPARATOR|3 Billion CFU strains of probiotics|b) 3 Billion CFU (P2) Component Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
62068694|NCT04437147|ACTIVE_COMPARATOR|8 Billion CFU strains of probiotics|c) 8 Billion UFC (P3) Component Lactobacillus paracasei LPC 00 ID 1076 1 billion CFU;Bifidobacterium longum BL 03 ID 1152 1 billion CFU; Bifidobacterium lactis BS 01 ID 1195 1 billion CFU;Lactobacillus casei LC 03 ID 1872 1 billion CFU; Bifidobacterium animalis LMG 10508 1 billion CFU; Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
62068695|NCT06259734|EXPERIMENTAL|Transfusion Camp Rwanda course participants|This group will participate in a 3 day course on best practices in Transfusion Medicine in Rwanda. They will participate in testing before and after the course to ascertain knowledge gained. They will then begin to work in hospitals ordering blood for their patients. Data collectors will access their blood product orders and determine the level of appropriateness of their orders based on the Rwanda Biomedical Centre National Transfusion Guidelines.
62068696|NCT06259734|NO_INTERVENTION|Intern Physicians not participating in Transfusion Camp|Blood product ordering practices with be assessed for appropriateness in physicians who did not participate in Transfusion Camp.
62068697|NCT04773639|EXPERIMENTAL|Multi-Modal Acceptance and Commitment Therapy (M-ACT)|M-ACT consists of five 2-hour group sessions (plus booster) that alternate with self-paced online modules and check-ins that participants complete on their own, between the group sessions. The intervention addresses distress associated with coping with metastatic cancer and supports engagement in advance care planning. The intervention is based on Acceptance and Commitment Therapy, an intervention model that aims to help people cope with life challenges and difficult thoughts/feelings in a manner that helps them to live fuller and more meaningful lives.
62068698|NCT04773639|OTHER|Control: Usual Care|Patients in the control arm will have access to usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request. After completion of study procedures, including FU, the UC participants will be offered M-ACT free of cost.
62088278|NCT02821520|EXPERIMENTAL|Initial PDT combination with Conbercept|"1. Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~2. PDT: PDT with verteporfin is administered at baseline and then PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
62453997|NCT03082781|EXPERIMENTAL|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
62273414|NCT02098564|EXPERIMENTAL|weak sense of coherence intervention|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
62273415|NCT02098564|EXPERIMENTAL|medium sense of coherence intervention|Patients with a medium sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
62273416|NCT02098564|ACTIVE_COMPARATOR|medium sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
62273417|NCT00288093|EXPERIMENTAL|Treatment (triapine, radiation therapy)|Patients undergo radiotherapy once daily, 5 days a week, for approximately 5.5 weeks (a total of 28 fractions). Patients also receive 3-AP (Triapine) IV over 2 hours 3 days a week every other week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine) until the maximum tolerated dose (MTD) is determined.
62636590|NCT00583908|ACTIVE_COMPARATOR|Group 2 lotrafilcon B/omafilcon A/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: omafilcon A / period 3: senofilcon A / period 4: balafilcon A
62273418|NCT05300516|EXPERIMENTAL|vagus nerve-guided group|Procedure/Surgery: vagus nerve-guided group The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
62636591|NCT00583908|ACTIVE_COMPARATOR|Group 3 lotrafilcon B/balafilcon A/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: balafilcon A / period 3: senofilcon A / period 4: omafilcon A
62068699|NCT03146832|EXPERIMENTAL|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
62453998|NCT03082781|EXPERIMENTAL|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
62453999|NCT05512000|EXPERIMENTAL|Contrast A|Feedback vs no feedback with massed trials
62454000|NCT05512000|EXPERIMENTAL|Contrast B|Feedback vs no feedback with spaced trials
62636592|NCT00583908|ACTIVE_COMPARATOR|Group 4 senofilcon A/lotrafilcon B/omafilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: balafilcon A
62636593|NCT00583908|ACTIVE_COMPARATOR|Group 5 senofilcon A/omafilcon A/balafilcon A/lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: omafilcon A / period 3: balafilcon A / period 4: lotrafilcon B
62068700|NCT03146832|EXPERIMENTAL|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
62068701|NCT03146832|NO_INTERVENTION|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
62068702|NCT03173781|EXPERIMENTAL|droxidopa|"Droxidopa will be supplied in 100 and 200 mg pill sizes. The subject should administer the three doses 4 hours apart with the last dose prior to 4:00 pm (example: 8:00 am, 12:00 pm, and 4:00 pm). The proposed dosing is 100mg TID at baseline, then titrate slowly up to 600 mg TID. During titration, droxidopa or placebo, initiated at 100 mg TID was titrated upward in 100-mg TID increments every 48 hours until the subject:~1. Reaches the maximum permitted dosage of 600 mg TID;~2. Has a systolic blood pressure≥160mmHg or diastolic blood pressure ≥100mmHg after 10 minutes supine on 3 consecutive measurements; or~3. Experiences intolerable adverse events (AEs)."
62068703|NCT03173781|PLACEBO_COMPARATOR|placebo|sugar pill
62068704|NCT01929174||Controls|Patients undergoing catheterization for other reasons who have a normal biventricular heart.
62273419|NCT05300516|NO_INTERVENTION|Conventional group|Every patient of conventional group will receive the conventional Robotic-assisted azygoportal disconnection procedure.
62068705|NCT01929174||Single ventricle Fontan|"Patients with a single functional ventricle (excluding hypoplastic left heart syndrome) palliated with a Fontan type operation involving passive blood flow to the lungs."
62068706|NCT05236413|EXPERIMENTAL|High Intensity Interval Exercise|Enrolled patients will perform supervised exercise on 3 nonconsecutive days of the week for 4 weeks.
62068707|NCT05236413|EXPERIMENTAL|Dietary Approaches to Stop Hypertension (DASH) Diet|Enrolled patients will have all of their food prepared for them by a registered dietician for the duration of the study period. The diet will consist of a high fiber content DASH diet.
62068708|NCT05236413|EXPERIMENTAL|Exercise + DASH Diet|Enrolled subjects will undergo both the exercise training visits and be provided with the DASH diet.
62068709|NCT01045122|OTHER|Propofol|Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
62068710|NCT01045122|OTHER|Dexmedetomidine|Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
62068711|NCT05527730|ACTIVE_COMPARATOR|Screening, intake and first fit (either PRO-FIT or SELF-FIT fitting )|This multi-center, prospective, randomized cross-over clinical trial compares two methods of fitting individuals with hearing loss with a therapeutic amplification device (i.e., hearing aids). Subjects will wear the Whisper Hearing System for the PRO-FIT and SELF-FIT for two weeks each, totalling to approximately 1 month of wear throughout the trial. At the first visit, all individuals will go through intake procedures and a basic audiologic evaluation. After this is completed, individuals are randomized into one of two arms of the study Individuals in the first visit of the study will receive the conventional PRO-FIT method for the first two weeks, then will switch to the experimental SELF-FIT method for the last half of the study.
62273420|NCT03777683|EXPERIMENTAL|Dietary Supplement (OLIGOPIN)|Intervention group will receive French maritime pine bark extract supplement (OLIGOPIN) in the form oral capsules containing 50 mg French maritime pine bark extract plus 130 mg Microcrystalline Cellulose. OLIGOPIN powder of each capsule are dissolved in 10 ml deionized water and given to patients via gavage (3 capsule per day) for 10 days
62454001|NCT05512000|EXPERIMENTAL|Contrast C|Spaced vs massed trials without feedback
62454002|NCT05512000|EXPERIMENTAL|Contrast D|Spaced vs massed trials with feedback
62454003|NCT04351178|EXPERIMENTAL|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0)
62454004|NCT04351178|ACTIVE_COMPARATOR|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
62273421|NCT03777683|PLACEBO_COMPARATOR|Placebo|Control group will receive oral capsules containing 130 mg Microcrystalline Cellulose with 10 ml of deionized water via gavage (3 capsule per day) for 10 days.
62273422|NCT06156085|EXPERIMENTAL|VA14|Vonoprazan-Amoxicillin Dual Therapy for 14days
62454005|NCT01045590|ACTIVE_COMPARATOR|glibenclamide + Rosiglitazone|glibenclamide plus rosiglitazone
62454006|NCT01045590|PLACEBO_COMPARATOR|glibenclamide + placebo|
62454007|NCT05368623||Sequential Enrollment|Patients aged 22yrs or older who have diabetes will be recruited from primary care settings.
62454008|NCT04324008|EXPERIMENTAL|Constic|Constic (DMG, Hamburg, Germany)
62454009|NCT04324008|EXPERIMENTAL|G-ænial Universal Flo|G-ænial Universal Flo (GC Corporation, Tokyo, Japan) in combination with G-Premio Bond (self-etch mode)
62454010|NCT04324008|EXPERIMENTAL|Tetric N-Flow (self-etch)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (self-etch mode)
62454011|NCT04324008|EXPERIMENTAL|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (etch\&rinse mode)
62454012|NCT04390854|ACTIVE_COMPARATOR|Induced blood clot scaffold|
62454013|NCT04390854|EXPERIMENTAL|Induced blood clot scaffold combined with Platelet rich fibrin|
62461577|NCT02032888|EXPERIMENTAL|Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks|Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
62068712|NCT05527730|SHAM_COMPARATOR|Second fit (either PRO-FIT or SELF-FIT fitting )|Conversely, individuals in the second visit of the study will receive the experimental SELF-FIT method for the first two weeks, then will switch to the conventional PRO-FIT method for the last two weeks. The two fitting methods (PRO-FIT and SELF-FIT) will be compared to evaluate the efficiency and reliability of the Whisper hearing system self-fitting algorithm.
62068713|NCT05351645|ACTIVE_COMPARATOR|Treatment|Participants in the Treatment arm were assigned to read one each day during the two-week trial period. These articles described a personal experience suicide from a first-person perspective, and included positive messages. Before and after reading these articles, participants in the Treatment arm answered brief questions assessing current suicidal thoughts and other constructs. Participants in the Treatment group were administered follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs.
62068714|NCT05351645|NO_INTERVENTION|Control|Participants in the Control arm answered questionnaires one time per day assessing suicidal thoughts and among other constructs (the same items as the Treatment group) during the two-week trial. Control participants did not receive the positive suicide related stories during the two-week trial period. Participants in the control group completed follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs (the same items as the Treatment group). After the follow-up phase was complete, participants in the Control group received the same intervention as those in the Treatment group.
62068715|NCT01435434|EXPERIMENTAL|sepax, ignite, fracture healing|the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
62068716|NCT04774822||Sequential Enrollment|Enrollment based on default inclusion criteria listed below
62454014|NCT03868709|EXPERIMENTAL|Penehyclidine group|Penehyclidine inhalation is administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
62068717|NCT04774822||Enrichment Enrollment|Enrollment based periodic statistician-activated inclusion criteria adjustment to attain statistically adequate distribution
62068718|NCT00702182|EXPERIMENTAL|Conventional Vinorelbine, Erlotinib|Escalating doses of vinorelbine on Day 1 and Day 8 of 21 Day cycle; Erlotinib 100 mg OD
62068719|NCT00702182|EXPERIMENTAL|Metronomic Vinorelbine, Erlotinib|Escalating doses of vinorelbine TIW; erlotinib 100 mg OD
62068720|NCT05790564|ACTIVE_COMPARATOR|Almonds|Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
62068721|NCT05790564|PLACEBO_COMPARATOR|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
62068722|NCT05039762|ACTIVE_COMPARATOR|Extracorporeal anastomosis|Laparoscopic right hemicolectomy with Extracorporeal anastomosis in patients with colon cancer.
62068723|NCT05039762|EXPERIMENTAL|Intracorporeal anastomosis|Laparoscopic right hemicolectomy with Intracorporeal anastomosis in patients with colon cancer.
62068724|NCT02799303|EXPERIMENTAL|Multi-parametric MRI|Patients from the general population without history of previous prostate biopsy will be allocated to receive mpMRI in order to evaluate for risk of prostate cancer.
62068725|NCT02799303|ACTIVE_COMPARATOR|PSA Only|"Patients from the general population without history of previous prostate biopsy will be allocated to receive serum PSA testing in order to evaluate for risk of prostate cancer.~Patients with a serum PSA level less than 4.0 ng/mL will be managed expectantly with results provided to their primary care physician."
62273423|NCT06156085|ACTIVE_COMPARATOR|S14|Sequential therapy for 14 days
62273424|NCT03662425|EXPERIMENTAL|schizophrenia with oxytocin|Participants self-administered the oxytocin twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of oxytocin.
62454015|NCT03868709|PLACEBO_COMPARATOR|Placebo group|Placebo inhalation is administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
62454016|NCT06124196||Case - DMD|40 male individuals with DMD
62454017|NCT06124196||Controls|40 matched controls (gender, age ± 1 year, BMI category, self-reported race/ethnicity).
62454018|NCT05346055|OTHER|Engage Prism 2.0|Engage Prism is a 9-week program that integrates Engage- a form of behavioral talk therapy treating depression, and guided use of Prism technology- a software that aims to improve social support and interaction of older adults.
62454019|NCT02788422|EXPERIMENTAL|Video|Video discharge instructions developed using Easy Sketch Pro3TM software (Easy Sketch Pro, United Kingdom). It was created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
62454020|NCT02788422|ACTIVE_COMPARATOR|Standard of care|This is a one-page paper handout created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
62454021|NCT02535507|EXPERIMENTAL|Pyrotinib treatment arm|pyrotinib treatment arm
62068726|NCT03128437|EXPERIMENTAL|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
62068727|NCT03128437|NO_INTERVENTION|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.~Assessments will take place at baseline, week 2, week 4, and week 8."
62068728|NCT01070823||Relapsing Multiple Sclerosis|Participants receiving or considering treatment with Tysabri® (natalizumab).
62068729|NCT03465449|ACTIVE_COMPARATOR|usual care|
62068730|NCT03465449|EXPERIMENTAL|CKD-EDU arm|
62068731|NCT05596422||Cohort 1: Participants With Biologics Discontinuation|Participants with IBD (UC or CD) who had received biologic treatments for at least 6 months after the initial confirmed diagnosis of IBD, and with at least 3 months follow-up period after biologics discontinuation will be observed retrospectively.
62068732|NCT05596422||Cohort 2: Participants Treated With Biologics|Participants with IBD (UC or CD) who had any dose of biologic for IBD treatment after the initial confirmed diagnosis of IBD will be observed retrospectively.
62068733|NCT04186403|EXPERIMENTAL|Prior Brexpiprazole 2-3 Milligrams Per Day|Participants who received blinded brexpiprazole 2 to 3 milligrams per day (mg/day) in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
62068734|NCT04186403|EXPERIMENTAL|Prior Placebo|Participants who received blinded brexpiprazole matching placebo in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
62068735|NCT02146222|EXPERIMENTAL|Arm I (high dose X-82, docetaxel)|Patients receive high dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15. Beginning course 2, patients also receive docetaxel IV over 60 minutes on day 1.
62068736|NCT02146222|EXPERIMENTAL|Arm II (low dose X-82, docetaxel)|Patients receive low dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15 and docetaxel IV as in Arm I.
62273425|NCT03662425|PLACEBO_COMPARATOR|schizophrenia with Placebo|Participants self-administered the placebo twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of placebo.
62273426|NCT00651092|ACTIVE_COMPARATOR|A1|since the two methods of turbinectomy are in used on a regular basis there is no way to perform double blind study- both the surgeon and the patients are well aware of the operation they are about to go. we just compare several parameters in patients who are anyway about to undergo an operation in a specific method that is used by their surgeon
62273427|NCT00651092|ACTIVE_COMPARATOR|A2|the resection of the inferior turbinates will be performed endonasally with an endoscopical instruments
62273428|NCT04700176|EXPERIMENTAL|Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Len + Dex (Cohort A) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
62068737|NCT03580213|EXPERIMENTAL|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
62068738|NCT03580213|EXPERIMENTAL|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
62273429|NCT04700176|EXPERIMENTAL|Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Pom + Dex (Cohort B) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
62273430|NCT01641406|EXPERIMENTAL|ER- (Triple Neg. and ER- PR+ Her 2 -)|Experimental chemotherapy using neoadjuvant approach
62068739|NCT03580213|NO_INTERVENTION|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
62068740|NCT03580213|NO_INTERVENTION|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
62068741|NCT02496403|EXPERIMENTAL|Standard Medical Management|Standard Medical Management (SMM) is a relatively brief (1.5 hour per week for 9 weeks), medically-focused behavioral intervention for opioid dependence. The experimental arm does not involve an investigational drug, device, or biologic.
62273431|NCT01641406|EXPERIMENTAL|Her 2 +|Experimental chemotherapy using neoadjuvant approach
62273432|NCT01641406|EXPERIMENTAL|ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)|Experimental chemotherapy using neoadjuvant approach
62273433|NCT06211231|EXPERIMENTAL|Self-guided digital intervention|The program consists of 10 online sessions that teach and guide different endometriosis-related themes. The sessions include mindfulness-meditation, yoga, written assignments and patient-education, that are accessed through the digital platform. Participants continue medical treatment as usual.
62273434|NCT06211231|EXPERIMENTAL|Therapist-guided digital intervention|The program consists of 10 online sessions that teach and guide different endometriosis-related themes. The sessions include mindfulness-meditation, yoga, written assignments and patient-education, that are accessed through the digital platform. This arm includes 11 online video-consultations with a therapist (one prior to starting and one for each session.) Participants continue medical treatment as usual.
62273435|NCT06211231|NO_INTERVENTION|No-treatment control group (waiting list)|Participants randomized to the waiting list will be offered one of the two experimental treatments. Participants continue medical treatment as usual.
62273436|NCT00612638|EXPERIMENTAL|1|Pts receiving Dilantin, Tegretol or Phenobarbital
62273437|NCT00612638|EXPERIMENTAL|2|Pts on anti-convulsants other than Dilantin, Tegretol / Phenobarbital / pts not on any anti-convulsants
62273438|NCT01450033|NO_INTERVENTION|Control group|Standard of care
62068742|NCT02496403|NO_INTERVENTION|Intensive Outpatient Treatment|The Intensive Outpatient Treatment (IOT) arm is considered usual care and is a predominant model of care in specialty treatment. It incorporates psychosocial support, education, and relapse-prevention approaches and requires attendance at 12-step program. It is a group-based treatment, with individual counseling available as needed. During the initial, 3-week phase, treatment consists of 4-6 hours a day, 7 days a week. In weeks four through 9, treatment consists of 1.5 hours, four days each week. After 9 weeks, patients attend one-hour weekly group meetings for one year. Services include supportive therapy, psycho-education, relapse prevention, and family-oriented therapy. The program emphasis is on abstinence and is similar to many public and private intensive outpatient programs.
62068743|NCT06081374|EXPERIMENTAL|simulation intervention|simulation will be implemented.
62068744|NCT06081374|ACTIVE_COMPARATOR|education implication|education will be implemented.
62454022|NCT00838552||1 Asthma subjects|Children with asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
62068745|NCT06081374|NO_INTERVENTION|control group|no intervention will be made.
62273439|NCT01450033|EXPERIMENTAL|Mentoring group|Subjects in this group will participate in the following intervention activities: medical record review; questionnaires including the Hollingshead Socioeconomic Status Survey, modified Medication Adherence Module, Peds QL Transplant Module, Medical Outcomes Study Social Support Scale, and self-efficacy scale; in-person meetings with mentor; e-communication with mentor (i.e. texts, Facebook, phone calls, etc); and collection of pharmacy refill data and clinical data.
62273440|NCT00781716|ACTIVE_COMPARATOR|Cypher Stent|Cypher Sirolimus-Eluting Coronary Stent System
62454023|NCT00838552||2 Non-asthma subjects|Children with other respiratory diseases than asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
62454024|NCT02066675|EXPERIMENTAL|Trabectedin|Trabectedin administered at the dose of 1.5 mg/mq-1.3 mg/mq a 24-hour continuous infusion via a central venous access, every 3 weeks
62454025|NCT04195295|EXPERIMENTAL|periosteal membrane and egg shell graft|Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material and periosteal pedicle as barrier membrane.
62273441|NCT00781716|ACTIVE_COMPARATOR|Endeavor Stent|Endeavor Zotarolimus-Eluting Coronary Stent System
62068746|NCT05242016|EXPERIMENTAL|structured individual reminiscence|Sessions, in chronological order; Starting with birth, it is planned to progress through life years by focusing on important events. In the sessions, considering the age and individual characteristics of the patients, the house and region where they were born and raised, childhood and school memories, childhood and school friends, youth years and friends, business life, if any, marriage process, birth of the first child, happy memories about children, successful events, old holidays It is talked about subjects such as unforgettable people or events, happy places to visit, old meals, old items, old songs. In each session, different sensory stimuli (visual, auditory, tactile, smelling, tasting) are used according to the subject.
62068747|NCT05242016|PLACEBO_COMPARATOR|unstructured social interview|Unstructured social interviews are conducted on topics such as current events not related to recollection, information specific to the individual patient wants to share, illness/diseases, hobbies, and activities.
62068748|NCT05242016|NO_INTERVENTION|Control|There is no intervention other than standard nursing care.
62068749|NCT04246515|EXPERIMENTAL|Blood Flow Restriction Training|As from week 2 in the rehabilitation proces, this experimental group will receive exercises in combination with blood flow restriction. While occluding the vascular flow of the limb (startpoint = above the injury site), participants will perform 3 exercises: wall squat, leg press and bridge (3 sets of 30 repetitions). These blood flow restricted exercises are always on top of the classic rehabilitation.
62068750|NCT04246515|SHAM_COMPARATOR|Sham Blood Flow Restriction Training|The same description as the experimental arm is applicable here. However, The Blood Flow restriction material will be attached to the injured limb without occluding the vascular blood flow.
62068751|NCT04246515|ACTIVE_COMPARATOR|Classic rehabilitation|This group will undergo the classic rehabilitation program.
62273442|NCT02631330|EXPERIMENTAL|Falls prevention group|"Intervention group that will receive a monthly talk (individual or collective) of 30 minutes on the advantages of having a free fall hazards environment and multiple physical exercise component: balance,muscle strength and aerobic capacity and risk polypharmacy and abuse of drugs, especially benzodiazepines). In the same monthly meeting, subjects will be train Multicomponent physical activity program during 60 minutes. 15 minutes of gait and balance training; 15 minutes of endurance training; 30 minutes of aerobic training according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459"
62273443|NCT02631330|NO_INTERVENTION|Control group|Subjects will receive the same information provided at the beginning to Falls prevention group. They will not receive further information during the follow-up period.
62273444|NCT03039842|EXPERIMENTAL|30 mg DM|30mg dextromethorphan+valproate
62273445|NCT03039842|EXPERIMENTAL|5 mg MM|5mg memantine+valproate
62454026|NCT04195295|EXPERIMENTAL|only egg shell graft|Only Egg shell derived nano hydroxyapatite (EnHA) as graft material.
62454027|NCT04195295|ACTIVE_COMPARATOR|open flap debridement|open flap debridement procedure only.
62454028|NCT06428448|EXPERIMENTAL|Subjects with REMEDY Spectrum IM Spacer Nail|This is the REMEDY Spectrum IM Spacer Nail treatment group.
62454029|NCT04978025|EXPERIMENTAL|Silver Group|"* Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~* By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
62454030|NCT04978025|PLACEBO_COMPARATOR|Placebo Group|"* Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days~* By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days."
62273446|NCT03039842|EXPERIMENTAL|DM+MM|dextromethorphan+memantine+ valproate
62273447|NCT03039842|PLACEBO_COMPARATOR|placebo|Placebo+valproate
62273448|NCT00791271|EXPERIMENTAL|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
62454031|NCT03455166|OTHER|Psoriasis|
62454032|NCT03455166|OTHER|Psoriatic arthropathy|
62454033|NCT02850068|EXPERIMENTAL|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
62454034|NCT00818623|EXPERIMENTAL|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
62454035|NCT00818623|EXPERIMENTAL|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
62454036|NCT00818623|EXPERIMENTAL|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
62454037|NCT00818623|EXPERIMENTAL|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
62454038|NCT00818623|EXPERIMENTAL|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
62454039|NCT00818623|EXPERIMENTAL|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
62454040|NCT00818623|EXPERIMENTAL|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
62454041|NCT00818623|EXPERIMENTAL|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
62068752|NCT06474689|EXPERIMENTAL|EMDR|The EMDR intervention is based on the standard protocol of EMDR, a therapeutic approach used for the treatment of trauma and stress-related disturbances. It focuses on the memory of traumatic experiences and is a comprehensive methodology that uses eye movements or other forms of dual attentional bilateral stimulation to treat disorders related directly to traumatic or particularly stressful experiences.
62636594|NCT00583908|ACTIVE_COMPARATOR|Group 6 senofilcon A/balafilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: balafilcon A / period 3: lotrafilcon B / period 4: omafilcon A
62068753|NCT06474689|ACTIVE_COMPARATOR|CBT|The CBT intervention is based on the core principles of both the Enhanced Cognitive Behavioral Therapy (CBT-E), an evidence-based treatment for eating disorders, and the Cognitive Behavioral Therapy for Obesity (CBT-OB). CBT-E is based on the transdiagnostic theory for eating disorders. CBT-OB combines the principal strategies of the traditional behavioral therapy for obesity (self-monitoring, goal setting, stimulus control) with more specific cognitive strategies and procedures helping patients to address the cognitive processes involved with treatment discontinuation, the amount of weight lost and long-term weight-loss maintenance.
62068754|NCT04646200|EXPERIMENTAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
62068755|NCT04646200|ACTIVE_COMPARATOR|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
62068756|NCT04041440|EXPERIMENTAL|Auditory Training|Pre- and post assessments of auditory training intervention
62068757|NCT02040987|EXPERIMENTAL|AZD3293 dose A|AZD3293 therapeutic dose oral solution (low dose)
62636595|NCT00583908|ACTIVE_COMPARATOR|Group 7 omafilcon B/lotrafilcon B/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: omafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: balafilcon A
62636596|NCT00583908|ACTIVE_COMPARATOR|Group 8 balafilcon A/lotrafilcon B/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: omafilcon A
62068758|NCT02040987|EXPERIMENTAL|AZD3293 dose B|AZD3293 supratherapeutic dose oral solution (high dose)
62068759|NCT02040987|PLACEBO_COMPARATOR|Placebo|Placebo oral solution
62068760|NCT02040987|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin tablet
62068761|NCT01376960|ACTIVE_COMPARATOR|single shot popliteal fossa block|
62068762|NCT01376960|ACTIVE_COMPARATOR|ankle blocks|
62068763|NCT03719365|EXPERIMENTAL|NAVAPSV|Each patient enrolled in the study will be submitted to 3 ventilation trials during PSV and NAVA ventilation modes, assigned in a randomized order.
62068764|NCT00790153|ACTIVE_COMPARATOR|1|AZD1656
62273449|NCT06311474|NO_INTERVENTION|Waitlist Control|Participants randomized to the waitlist control (or delayed treatment) condition will receive written and verbal feedback after the baseline assessment visit. These families will participate in follow-up visits at 3 months, 6 months, and 12 months after the baseline visit. They will receive the same treatment (PCIT) after the 6-month assessment.
62636597|NCT00583908|ACTIVE_COMPARATOR|Group 9 balafilcon A/lotrafilcon B/omafilcon A/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: senofilcon A
62273450|NCT06311474|EXPERIMENTAL|Immediate Treatment|Participants randomized to the immediate treatment condition will receive written and verbal feedback after the baseline assessment visit. These families will begin PCIT shortly after this visit. These families will participate in follow-up visits at 3 and 6 months after the baseline visit.
62273451|NCT02461992|EXPERIMENTAL|Intravenous infusion of Xyntha|observation arm
62273452|NCT05571787|EXPERIMENTAL|Treatment A|Subjects in treatment A will fast overnight for at least 10 hours prior to HMPL-523 dosing.
62068765|NCT00790153|ACTIVE_COMPARATOR|2|Insulin
62068766|NCT03278886|EXPERIMENTAL|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
62068767|NCT03278886|EXPERIMENTAL|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
62068768|NCT01086605|EXPERIMENTAL|Arm I|Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62068769|NCT01086605|EXPERIMENTAL|Arm II|Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62068770|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
62068771|NCT03218332||Healthy controls|Active Comparator
62068772|NCT01569035|ACTIVE_COMPARATOR|warfarin|oral anti coagulant
62068773|NCT05417334|ACTIVE_COMPARATOR|ON Radiofrequency treatment|Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with activated RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.
62068774|NCT05417334|SHAM_COMPARATOR|Sham Radiofrequency treatment|Application of the technique in the intervention group (inactive resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with inactive RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.
62068775|NCT03813342|EXPERIMENTAL|Multichannel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 4 channels of visual information, each of which represents a joint angle (right and left hips, right and left knees).
62273453|NCT05571787|EXPERIMENTAL|Treatment B|Subjects in treatment B will receive a standardized high-fat meal approximately 30 minutes before HMPL-523 administration
62273454|NCT05571787|EXPERIMENTAL|Treatment C|Subjects in treatment C will receive a standardized low-fat meal approximately 30 minutes before HMPL-523 administration
62636598|NCT00583908|ACTIVE_COMPARATOR|Group 10 balafilcon A/senofilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: lotrafilcon B / period 4: omafilcon A
62068776|NCT03813342|EXPERIMENTAL|Single Channel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 1 channel of visual information that encompasses information from 4 lower limb joint angles (right and left hips, right and left knees).
62273455|NCT05571787|EXPERIMENTAL|Treatment D|Subjects in treatment D will receive rabeprazol 1 hour prior to receiving a standardized low-fat meal. On Day 26 subjects will also receive HMPL-523 approximately 30 minutes after the standardized low-fat breakfast
62287106|NCT03544112||ED and OUD treatment providers and staff|"* ED patients will be recruited to participate in interviews or focus groups.~* ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.~* Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc."
62454042|NCT01082653|EXPERIMENTAL|Safety|infusion of autologous bone marrow-derived stem cells
62454043|NCT00761592|ACTIVE_COMPARATOR|1|
62454044|NCT00761592|ACTIVE_COMPARATOR|2|
62068777|NCT03077620|EXPERIMENTAL|Poor sleep group treatment 1|10mg Suvorexant tablet h.s. for two consecutive nights
62636599|NCT00583908|ACTIVE_COMPARATOR|Group 11 balafilcon A/senofilcon A/omafilcon A//lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: omafilcon A / period 4: lotrafilcon B
62636600|NCT00583908|ACTIVE_COMPARATOR|Group 12 balafilcon A/omafilcon A/lotrafilcon B/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: omafilcon A / period 3: lotrafilcon B / period 4: senofilcon A
62068778|NCT03077620|PLACEBO_COMPARATOR|Poor sleep group control|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
62068779|NCT03077620|PLACEBO_COMPARATOR|Good sleep group|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
62273456|NCT02682901|ACTIVE_COMPARATOR|Cycloset (Bromocriptine-QR)|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
62273457|NCT02682901|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus placebo. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (1 matching placebo tablet) per day on a weekly basis until a maximal tolerated dose of at least two tablets (2 placebo tablets) and no more than four tablets (4 placebo tablets) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (2 to 4 placebo tablets) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
62636601|NCT01559805|EXPERIMENTAL|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
62068780|NCT03077620|EXPERIMENTAL|Poor sleep group treatment 2|20mg Suvorexant tablet h.s. for two consecutive nights
62068781|NCT05406960|EXPERIMENTAL|Tea infusion|The aerial parts of each plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. the powder of the mixture was added to 100 ml of boiling water and the tea infusion was taken three times a day for three consecutive days and it was repeated for three consecutive months
62636602|NCT01559805|ACTIVE_COMPARATOR|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
62636603|NCT06148103|OTHER|D group|Patients who received Dexmedetomidine. The starting dose of dexmedetomidine was 1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
62068782|NCT05817305||Cardiac outpatients|Patients with stable cardiovascular disease who have been referred to the service by their general practitioner or cardiologist
62273458|NCT02200185|PLACEBO_COMPARATOR|IV titrated morphine|"patient will receive 2 mg morphine each 5 min, associated to continuous nebulisation of saline serum (placebo).~Morphine administration is stopped when VAS becomes under 50% and treatment failure is defined as VAS \> 50%, 30 minutes after the beginning of the protocol."
62273459|NCT02200185|EXPERIMENTAL|Low dose nebulised morphine|"patient will receive 10 mg of morphine prepared with 4 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo"
62273460|NCT02200185|EXPERIMENTAL|High dose nebulised morphine|"patient will receive 20 mg of morphine prepared with 3 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo."
62273461|NCT06159595|ACTIVE_COMPARATOR|Active Direct electrical stimulation (DES)|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
62454045|NCT05101174|EXPERIMENTAL|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised program and multiple online sessions, for 6 months.~Intervention: aerobic exercise, resistance exercise, coordinative exercise, flexibility, social interaction, and meditation."
62636604|NCT06148103|OTHER|PF group|Patients who received Propofol-Fentanyl infusions. Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
62636605|NCT05210439|EXPERIMENTAL|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment from the date of the last positive blood culture
62636606|NCT05210439|ACTIVE_COMPARATOR|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment from the date of the last positive blood culture
62068783|NCT01676532||Students attending SBHC|Students who attend the SBHC from either Sprucecourt Public School or any other participating schools.
62068784|NCT05393271|EXPERIMENTAL|Part 1 (SAD): Participants receiving VH4011499|
62068785|NCT05393271|PLACEBO_COMPARATOR|Part 1 (SAD): Participants receiving placebo|
62068786|NCT05393271|EXPERIMENTAL|Part 2 (MAD) Drug-Drug Interaction (DDI) cohort: Participants receiving VH4011499 + Midazolam|
62273462|NCT06159595|SHAM_COMPARATOR|Sham Direct electrical stimulation (DES)|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
62454046|NCT05101174|OTHER|Control Group|"The control group is invited to attend one 60-min online educational course per week for 6 months.~Intervention: 60-min online educational program."
62454047|NCT01734772|EXPERIMENTAL|Reference (Part 1/A, Part 2/C)|multiple doses of dabigatran (alone)
62454048|NCT01734772|EXPERIMENTAL|Test 1 (Part 1/Treatment B)|concomitant administration of dabigatran and ticagrelor
62454049|NCT01734772|EXPERIMENTAL|Test 2 (Part 2/Treatment D)|staggered administration of ticagrelor and dabigatran
62454050|NCT02309125|EXPERIMENTAL|implant A|will include implants with immediate progressive loading using gingival formers of different sizes
62068787|NCT05393271|PLACEBO_COMPARATOR|Part 2 (MAD) DDI cohort: Participants receiving placebo + Midazolam|
62068788|NCT05393271|EXPERIMENTAL|Part 2 (MAD) Non DDI cohort: Participants receiving VH4011499|
62068789|NCT05393271|PLACEBO_COMPARATOR|Part 2 (MAD) Non DDI cohort: Participants receiving placebo|
62273463|NCT05583266|PLACEBO_COMPARATOR|Pentoxifylline sustained- release tablets placebo group|This group will receive Pentoxifylline sustained-release tablets placebo, 1 tablet twice a day, from the day of randomization to 6 months.
62273464|NCT05583266|EXPERIMENTAL|Pentoxifylline sustained- release tablets group|This group will receive Pentoxifylline sustained-release tablets, 1 tablet twice a day, from the day of randomization to 6 months.
62454051|NCT02309125|OTHER|implant B|The implants will remain submerged from surgery time till loading time 2 month.(submerged healing)
62454052|NCT05135442|EXPERIMENTAL|bortezomib group|On the basis of standard single membrane plasma exchange (2L/d) and hormone therapy (1mg/kg prednisone or equivalent methylprednisolone), bortezomib was given intravenous injection of 1.3mg/m2 d1, 4, 8, 11 (total 4 doses).
62454053|NCT02498548|NO_INTERVENTION|Control|Individuals with no spinal cord injury or other neurological deficits.
62068790|NCT05393271|EXPERIMENTAL|Part 3 (Single dose): Participants receiving VH4011499 (new formulation)|
62068791|NCT04642586|EXPERIMENTAL|Hypertensive participants|diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure;
62273465|NCT00993811|EXPERIMENTAL|Circumcision|Males undergoing circumcision
62273466|NCT05847998|EXPERIMENTAL|measurement of capillary refill time|measurement in a cohort of ICU adult patients with acute circulatory failure
62273467|NCT05347433||Tube baby pregnancy group|18-24-week pregnant women with in vitro fertilization
62454054|NCT02498548|NO_INTERVENTION|Unexercised SCI Knee or Hip|"Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. This group will serve as unexercised control for the Trained SCI Knee group or trained SCI Hip group"
62636607|NCT02764437||MRI-Bronch, PET-WLAC (Stress vs Control)|Subjects will have a functional MRI scan 24 hours before a bronchoscopy with segmental allergen challenge. 48 hours post segmental allergen challenge, the subject will have another MRI and bronchoscopy. 4-6 weeks later, subjects will have a PET scan and whole lung antigen challenge under a stress condition or control condition. 4-6 weeks later, subject will have another PET scan and whole lung antigen challenge under a stress condition or control condition (whatever they did not have the first time).
62636608|NCT01810562|EXPERIMENTAL|Specific treatment + std stroke care|Specific treatment in addition to standard stroke care
62636609|NCT01810562|NO_INTERVENTION|Std stroke care|Patients receive only standard stroke treatment and no specific treatment.
62636610|NCT00631982|EXPERIMENTAL|Group I|patients with PCO undergoing in vitro maturation and subsequently IVF and embryo transfer
62636611|NCT04158219|EXPERIMENTAL|Treatment|Behavioral activation for health and depression (BA-HD)
62636612|NCT02956538|EXPERIMENTAL|thalidomide|thalidomide 100mg tablet by mouth, every night for 8 weeks
62636613|NCT02956538|ACTIVE_COMPARATOR|placebo|placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks
62068792|NCT04642586|EXPERIMENTAL|Normotensive participants|absence of HTA confirmed by Ambulatory Blood Pressure Measure
62068793|NCT00976469|EXPERIMENTAL|Dose A (3.75 µg HA antigen, 0.25 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.
62068794|NCT00976469|EXPERIMENTAL|Dose B (7.5µg HA antigen, 0.5 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.
62273468|NCT05347433||Spontaneous pregnancy group|18-24-week pregnant women with spontaneous
62273469|NCT01316172|EXPERIMENTAL|5 Cs|Educational intervention
62273470|NCT01316172|NO_INTERVENTION|Control|
62636614|NCT02068976||Women with Primary Ovarian Insufficiency|
62636615|NCT04435938|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|The dose prescribed in the study will be 45Gy in 5 fractions, delivered once every 3-4 days, such that treatment is completed within 15 days. (e.g. treatment given on Monday/Thursday/Mon/Thurs/Mon) (Exceptions: treatment duration of up to 18 days will be allowed to account for cancer centre closures and unforeseen patient issues.)
62068795|NCT02069769|EXPERIMENTAL|communication with oncology team|oncology team will be prompted to contact family caregiver and/or patient twice weekly while the patient is receiving hospice care.
62068796|NCT04567693|EXPERIMENTAL|Early 1|Advance to spaced-out appointments at month 6 after a single viral load is measured.
62273471|NCT02207933|EXPERIMENTAL|AP shifting group|
62068797|NCT04567693|EXPERIMENTAL|Early 2|Advance to spaced-out appointments at month 6 after two viral loads are measured.
62068798|NCT04567693|NO_INTERVENTION|Usual Care|Do not advance to spaced-out appointments during study period
62273472|NCT02207933|ACTIVE_COMPARATOR|gait training group|
62273473|NCT05946408|EXPERIMENTAL|Supervised Antenatal Exercises|Supervised antenatal exercises twice a week an antenatal education
62068799|NCT00005881||Quality of life forms|Completion of the development of an instrument \[Minneapolis-Manchester Quality of Life (MM-QOL)\] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
62068800|NCT01464021||Adalimumab|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
62068801|NCT02308332|ACTIVE_COMPARATOR|Intervention|patients switching from Atripla to Eviplera
62068802|NCT02308332|NO_INTERVENTION|Control|patients remaining on Atripla
62068803|NCT06017388|ACTIVE_COMPARATOR|Control|The control group will simply receive a reading of the mystical experience suggestion without hypnosis.
62068804|NCT06017388|EXPERIMENTAL|Experiemental|The experiemental group will receive a suggestion of the mystical experience in hypnosis.
62273474|NCT05946408|ACTIVE_COMPARATOR|Antenatal Education|Antenatal education only
62273475|NCT02981875|EXPERIMENTAL|experimental|oculomotor training
62273476|NCT02981875|PLACEBO_COMPARATOR|control|placebo vision training exercises
62273477|NCT04086550|EXPERIMENTAL|Investigational arm|Application of LIQOSEAL after closure of dura mater
62273478|NCT04086550|ACTIVE_COMPARATOR|Control arm|Application of Adherus or DurSeal after closure of dura mater
62636616|NCT01038687|EXPERIMENTAL|A3309 15 mg|Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.
62636617|NCT01038687|EXPERIMENTAL|A3309 20 mg|Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.
62636618|NCT01038687|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.
62636619|NCT02154438|EXPERIMENTAL|ketamine|ketamine 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
62636620|NCT02154438|PLACEBO_COMPARATOR|Placebo|normal saline 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
62636621|NCT04221269|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
62273479|NCT05273827||neoadjuvant immunotherapy group|Anti-PD-1 monoclonal antibody (Nivolumab，Pembrolizumab, Sintilimab, or Sugemalimab) 200 mg intravenously in combination with cis-platinum and paclitaxel/pemetrexed
62273480|NCT05273827||control group|platinum-containing dual-agent chemotherapy(cis-platinum and paclitaxel/pemetrexed)
62273481|NCT06485154|EXPERIMENTAL|TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir|"The IMP is defined as any investigational marketed product to be administered to a study participant according to the study protocol.~Participants will all receive TLD as detailed below. Treatment will be open-label, and drugs will be dispensed at intervals as specified in the Schedule of Events.~Investigational Product Tenofovir disoproxil fumarate / lamivudine / dolutegravir Dosage Formulation 300 mg / 300 mg / 50 mg fixed dose combination tablet Route of Administration Oral Dosing Instructions 1 tablet (300/300/50 mg TDF/3TC/DTG) daily"
62636622|NCT04221269|EXPERIMENTAL|Coping Long-term with Active Suicide Program for Schizophrenia|Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
62636623|NCT00538941|ACTIVE_COMPARATOR|1|daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
62068805|NCT06625697|EXPERIMENTAL|Respiration Biosignal Feedback Condition|Participants will complete guided seated Equa training lessons on a laboratory smartphone device while physiological measures are tracked. After training lessons, a respiration biosignal feedback chart will appear.
62636624|NCT00538941|PLACEBO_COMPARATOR|2|Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
62636625|NCT04819165||COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with confirmed COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
62636626|NCT04819165||non COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with negative COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
62636627|NCT01540513|EXPERIMENTAL|I124-NM404 brain metastases or GBM imaging|injection of I-124NM404 for imaging
62068806|NCT04498247|EXPERIMENTAL|Panel A|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Day 1 and Day 57) of 1x10\^5 50% tissue culture infectious dose (TCID50) V591 or placebo
62068807|NCT04498247|EXPERIMENTAL|Panel B|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Days 1 and 57) of 1x10\^6 TCID50 V591 or placebo
62273482|NCT01078831||ARDS / ALI patients|
62454055|NCT02498548|EXPERIMENTAL|Trained SCI Knee or Trained SCI Hip|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will specifically focus on rehabilitation of the knee joint or the hip joint.
62454056|NCT03353909|EXPERIMENTAL|Treatment|At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
62454057|NCT03353909|NO_INTERVENTION|Control|At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
62454058|NCT02439008|EXPERIMENTAL|Blood samples collection|"Nine blood samples will be collected in each patient before, during and after radiotherapy treatment.~Interventions :~* Blood samples collection before radiotherapy (T0)~* Blood samples collection during radiotherapy (T1-T3)~* Blood samples collection after radiotherapy (T4-T8)"
62454059|NCT01029938|ACTIVE_COMPARATOR|Covered stent|The Willis covered stent specifically designed for intracranial vasculature was developed by our institution and the MicroPort Medical Company (Shanghai, China), and coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
62454060|NCT01029938|ACTIVE_COMPARATOR|Coil|Coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
62636628|NCT06431334|EXPERIMENTAL|Masters Level Cyclists|Participants are to be randomly assigned varying levels of amino acid intakes ranging between 0.5 to 2.8 g/kg/d
62636629|NCT01438112|EXPERIMENTAL|CG0070 oncolytic virus|Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes
62636630|NCT01438112|ACTIVE_COMPARATOR|Chemotherapy or Interferon|"Quadruple Choice as interventions~1. Mitomycin C~2. Interferon~3. Valrubicin~4. Gemcitabine"
62636631|NCT03175887|EXPERIMENTAL|Intervention Arm|Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.
62636632|NCT03175887|OTHER|Treatment Arm|"After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.~If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment."
62636633|NCT02438189|ACTIVE_COMPARATOR|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
62068808|NCT04498247|EXPERIMENTAL|Panels C, G|Participants in this 18 to 55 year old cohort (Panel C) or \>55 year old cohort (Panel G) will receive 1 dose of 1x10\^5 TCID50 V591 or placebo.
62068809|NCT04498247|EXPERIMENTAL|Panels D, H|Participants in this 18 to 55 year old cohort (Panel D) or \>55 year old cohort (Panel H) will receive 1 dose of 1x10\^6 TCID50 V591 or placebo.
62068810|NCT04498247|EXPERIMENTAL|Panel E|Participants in this 18 to 55 year old cohort will receive 1 dose of 1x10\^7 V591 or placebo.
62273483|NCT06395727|EXPERIMENTAL|• Traditional balanced anaesthesia (control group)|Analgesia will be offered by fentanyl 3-5 mic/kg in induction
62068811|NCT04498247|EXPERIMENTAL|Panel F|Participants in this 18 to 55 year old cohort will receive 2 doses (Days 1 and 169) of V591 or placebo. Day 1 will be 1x10\^4 TCID50 V591 or placebo and Day 169 will be 1x10\^5 TCID50 V591 or placebo.
62068812|NCT04498247|EXPERIMENTAL|Panel I|Participants in this \>55 year old cohort will receive 2 doses (Days 1 and 57) of 1x10\^5 TCID50 V591 or placebo
62273484|NCT06395727|EXPERIMENTAL|• Airway topical anaesthesia|Patient will be given lidocaine nebulizer (5 ml of lidocaine 2% with oxygen flow 8 l/m) after radial arterial catheter insertion that will be complemented by topical application of lidocaine spray 10 % not to exceed 200mg per dose on mouth with encouraging to move it in mouth then gargling with it before swallowing targeting reaching difficult swallowing.
62454061|NCT04117607|EXPERIMENTAL|BA1|100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
62636634|NCT02438189|NO_INTERVENTION|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
62636635|NCT05947604|OTHER|Dextromethorphan and Midazolam|"Drug drug interaction Dextromethorphan and Midazolam administrations~* Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1~* Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8"
62068813|NCT04498247|EXPERIMENTAL|Panel J|Participants in this \>55 year old cohort will receive 2 doses (Days 1 and 57) of 1x10\^6 TCID50 V591 or placebo
62068814|NCT04498247|EXPERIMENTAL|Panel K|Participants in this \>55 year old cohort will receive 2 doses (Days 1 and 169) of 1x10\^5 TCID50 V591 or placebo
62068815|NCT04498247|EXPERIMENTAL|Panel L|Participants in this \>55 year old cohort will receive 2 doses (Days 1 and 169) of 1x10\^6 TCID50 V591 or placebo
62068816|NCT01541618||Tysabri Group|Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
62273485|NCT03655964|EXPERIMENTAL|Olmesartan|20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)
62454062|NCT04117607|EXPERIMENTAL|BA2|100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
62068817|NCT06523738||Reversible Group|Left atrial volume (LAV) decreased by 15% 3 to 6 months after electrical/pharmacological cardioversion compared to baseline. Consequently, patients in the group will receive pulmonary vein isolation only.
62068818|NCT06523738||Irreversible Group|Left atrial volume (LAV) decreased by less than 15% 3 to 6 months after electrical/pharmacological cardioversion compared to baseline. Patients in the group will receive pulmonary vein isolation only.
62068819|NCT05967676|EXPERIMENTAL|Patient group|athletes who have suffered a sports injury
62273486|NCT03655964|EXPERIMENTAL|Nebivolol|20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)
62273487|NCT03655964|EXPERIMENTAL|No antihypertensive treatment|20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke
62273488|NCT01149265|EXPERIMENTAL|Online support group|
62273489|NCT01149265|ACTIVE_COMPARATOR|Expressive writing|
62636636|NCT05947604|OTHER|Acoziborole, Dextromethorphan and Midazolam|"Drug drug interaction Acoziborole, Dextromethorphan and Midazolam administrations~* Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12~* Dextromethorphan 15 mg syrup in fasted condition Period 2: Single oral dose of 15 mg administered on Day 14~* Midazolam 5 mg syrup in fasted condition Period 2: Single oral dose of 5 mg administered on Day 21"
62636637|NCT02025283||Group Decompression|Group Decompression: Patients assigned to Group Decompression. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) were advanced inside the trochar needle towards the disc and decompression was performed. After being sure of achieving sufficient decompression inside the disc, the decompression device were removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
62636638|NCT02025283||Group Nucleoplasty|Group Nucleoplasty : Patients assigned to Group Nucleoplasty. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\] were advanced inside the trochar needle towards the disc and nucleoplasty was performed. After being sure of achieving sufficient decompression inside the disc, the nucleoplasty probe was removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
62273490|NCT02211274|EXPERIMENTAL|Study Group|Individuals who want to leave the CLC will be allowed to participate in the study, there will be no assignment to groups. Individuals who want to leave the CLC will undergo transition care planning using the investigators' standardized toolkit. The investigators will compare outcomes to administrative data from other similar VA nursing homes.
62273491|NCT04660162|EXPERIMENTAL|Arm-1: Laser speckle contrast imaging|(Perimed AB, Järfälla, Sweden)
62068820|NCT02081456|ACTIVE_COMPARATOR|Therapeutic Ultrasound|Therapeutic ultrasound applied for a period of 5 minutes to the most painful region of the neck, then a second 5 minute dose at the most painful region of the upper extremity
62068821|NCT02081456|EXPERIMENTAL|Soft Tissue Mobilization|Passive soft tissue mobilization to the neck and upper extremity
62068822|NCT03375580|PLACEBO_COMPARATOR|TLC group|transform life custom (TLC) group
62068823|NCT03375580|ACTIVE_COMPARATOR|TLC + metformin group|transform life custom (TLC) combined with 0.5g metformin, PO tid
62273492|NCT04660162|EXPERIMENTAL|Arm-2: Laser Doppler perfusion imaging|(Moor Instruments, Devon, UK)
62273493|NCT04904289||Sepsis with MODS|Patients with sepsis occurred MODS.
62273494|NCT04904289||Sepsis without MODS|Patients with sepsis did not occur MODS.
62068824|NCT03375580|EXPERIMENTAL|TLC + CZT capsules group|transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid
62068825|NCT03375580|ACTIVE_COMPARATOR|TLC + simvastatin group|transform life custom (TLC) combined with 20mg simvastatin, PO qn
62068826|NCT06229704||Children with delayed gross motor development and/or with dizziness/balance problems|Children in the age of 6 months to 10 years with delayed gross motor development and/or with dizziness/balance problems are recruited at The Pediatric Department at Gødstrup Hospital, Denmark.
62068827|NCT05545241|EXPERIMENTAL|Neurofeedback and BART-EEG assessment|Healthy subjects realized 10 sessions of emotional neurofeedback. Before (Baseline, Day 0), and after (at the study completion (after 10 neurofeedback sessions, Week 5)) neurofeedback sessions, the BART, assessing risk-taking behavior, coupled with an EEG record is realized by the subjects.
62273495|NCT02627820|EXPERIMENTAL|Experimental Drug|Isis 420915/GSK 299872, an antisense oligonucleotide. Administered subcutaneously three times per week for the first week, and then weekly for 18 months. Each dose shall contain 300 mg of active drug.
62273496|NCT04720326|EXPERIMENTAL|Envarsus®|Participants take prolonged-release tacrolimus tablets orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
62273497|NCT04720326|ACTIVE_COMPARATOR|Advagraf®|Participants take prolonged-release tacrolimus capsules orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
62068828|NCT05545241|SHAM_COMPARATOR|BART-EEG assessment without neurofeedback|At the same times (Baseline, Day 0), and at the study completion (after 10 neurofeedback sessions, Week 5), healthy subjects realized the BART, assessing risk-taking behavior, coupled with an EEG record.
62068829|NCT02279147|EXPERIMENTAL|raceanisodamine & neostigmine|Patients receive immediately raceanisodamine（10mg）by intramuscular injection after operation.Then the patients will be receive 50mg raceanisodamine and 0.15mg neostigmine within 24hs by slow injection into vein for three consecutive days.
62068830|NCT02279147|NO_INTERVENTION|blank|Patients do not receive special treatment after operation.
62068831|NCT01028079|ACTIVE_COMPARATOR|Arm 2|
62068832|NCT01028079|PLACEBO_COMPARATOR|Arm 3|
62068833|NCT01028079|EXPERIMENTAL|Arm 1|
62068834|NCT06087562|EXPERIMENTAL|preop iPACK block|Patients will receive a preoperative ultrasound-guided Interspace between the Popliteal Artery and Capsule of the Posterior Knee (iPACK) block with 20 mL 0.5% ropivacaine. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindray TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the distal femoral shaft and popliteal artery. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in-plane, from the anteromedial aspect of the knee, toward the space between the popliteal artery and femur. 20 mL 0.5% ropivacaine is injected into the space between the popliteal artery and femur. The needle is withdrawn, and the needle entry site is wiped clean.
62068835|NCT06087562|EXPERIMENTAL|preop placebo block|Patients will receive a preoperative ultrasound-guided Interspace between the Popliteal Artery and Capsule of the Posterior Knee (iPACK) block with 20 mL 0.5% ropivacaine. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindray TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the distal femoral shaft and popliteal artery. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in-plane, from the anteromedial aspect of the knee, toward the space between the popliteal artery and femur. 20 mL 0.9% normal saline is injected into the space between the popliteal artery and femur. The needle is withdrawn, and the needle entry site is wiped clean.
62636639|NCT06240117|EXPERIMENTAL|Standard of care with intraoperative cell salvage|Participants for elective surgery with anemia randomized to standard of care with intraoperative cell salvage.
62636640|NCT06240117|NO_INTERVENTION|Standard of care without intraoperative cell salvage|Standard of care for cesarean sections as per the policy of the anesthesiology department.
62068836|NCT05126459|ACTIVE_COMPARATOR|Regimen 1|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Meperidine (1.5 -2 mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)
62068837|NCT05126459|EXPERIMENTAL|Regimen 2|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration- Meperidine (1.5 -2 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) -
62068838|NCT05126459|EXPERIMENTAL|Regimen 3|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation- Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)
62068839|NCT03327402|EXPERIMENTAL|SHP465|Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.
62068840|NCT01409681||Observational Group|NSCLC subject undergoing bronchoscopy
62068841|NCT02703545||Peutz-Jeghers syndrome|
62068842|NCT02703545||Familial pancreas cancer|"at least 2 close relatives affected with pancreas cancer on same side of family~1. first degree relative and 1 second degree relative(1st degree link) or~2. first degree relatives or~1 first degree relative and 2 or more second degree relatives"
62273498|NCT00987363|EXPERIMENTAL|Low dose (1x10 E8)|Dose of 1x10 E8 autologous bone marrow-derived mononuclear cells
62273499|NCT00987363|EXPERIMENTAL|Intermediate dose (5x10 E8)|Dose of 5x10 E8 autologous bone marrow-derived mononuclear cells
62273500|NCT00987363|EXPERIMENTAL|High dose (1x10 E9)|Dose of 1x10 E9 autologous bone marrow-derived mononuclear cells
62636641|NCT04346199|EXPERIMENTAL|Arm 1|Acalabrutinib+ Best Supportive Care
62068843|NCT02703545||Germline mutation Carrier 10 % risk|BRCA2 mutation carrier with family history of pancreas cancer or, PALB2 mutation carrier or, FAMMM (p16/CDKN2A) mutation carrier
62068844|NCT02703545||Germline mutation carrier 5 % risk|BRCA1 mutation carrier with family history of pancreas cancer or, HNPCC (Lynch Syndrome) with family history of pancreas cancer or, ATM gene mutation
62068845|NCT02703545||Hereditary pancreatitis|PRSS1, PRSS2, CTRC gene mutations
62068846|NCT04942860|ACTIVE_COMPARATOR|Methotrexate 1% gel|1% methotrexate gel applied onto a predefined limb
62068847|NCT04942860|ACTIVE_COMPARATOR|Methotrexate 0.5% gel|0.5% methotrexate gel applied onto a predefined limb
62068848|NCT04942860|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel applied onto a predefined limb
62273501|NCT00987363|NO_INTERVENTION|Control|Conventional treatment established by the good clinical practice
62273502|NCT04173429|EXPERIMENTAL|nadroparin calcium-warfarin sequential therapy group|nadroparin calcium every 12 hours for 1 month followed by an oral administration of warfarin for 5 months
62273503|NCT04173429|NO_INTERVENTION|Control group|No anticoagulation therapy.
62273504|NCT00962832|PLACEBO_COMPARATOR|Part 1 - Placebo intravenously|Participants received placebo intravenously every 4 weeks for 24 weeks.
62636642|NCT04346199|NO_INTERVENTION|Arm 2|Best Supportive Care
62636643|NCT01114009|EXPERIMENTAL|Lung recruitment maneuver|The maneuver briefly increases the alveolar pressure to open recruitable lung (50 cmH2O), sustained with adequate positive end-expiratory pressure(PEEP) after lung recruitment, to avoid derecruitment.
62068849|NCT00742820|EXPERIMENTAL|1|Calcium Acetate Oral Solution 667 mg per 5 mL
62068850|NCT00742820|ACTIVE_COMPARATOR|2|Calcium Acetate 667 mg Gelcaps
62068851|NCT00742820|OTHER|3|Calcium Citrate 950 mg Caplets
62068852|NCT04953013||sodium bicarbonate group|Sodium bicarbonate was initiated within 48 hours after ICU admission.
62068853|NCT04953013||non-sodium bicarbonate group|Patients were not infused with sodium bicarbonate.
62068854|NCT02841267|ACTIVE_COMPARATOR|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
62068855|NCT02841267|ACTIVE_COMPARATOR|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
62068856|NCT02841267|ACTIVE_COMPARATOR|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
62068857|NCT05724264|EXPERIMENTAL|Low-dose CT of the Chest (LDCT) + Blood sampling|
62273505|NCT00962832|EXPERIMENTAL|Part 1 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 24 weeks.
62454063|NCT04117607|EXPERIMENTAL|MAD1|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
62068858|NCT04879758|NO_INTERVENTION|Control Group|The control group will receive a Fitbit device and general lifestyle advice e-leaflet, which includes information about T2D, health impacts of T2D and lifestyle advice on 4 major risk markers of T2D (e.g., PA, diet, smoking, weight management) as recommended by the World Health Organization.
62068859|NCT04879758|EXPERIMENTAL|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk of T2D in addition to the Fitbit and e-leaflet.
62068860|NCT04879758|EXPERIMENTAL|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
62454064|NCT04117607|EXPERIMENTAL|MAD2|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
62068861|NCT05722847||Low risk|Subjects will be considered low risk if they have non-small cell histology, a length of hospital stay \<= 8 days, no or low comorbidity, no emergency department use or hospitalization in the 6 months prior, no wheelchair requirement when hospital discharge, or other than Black and/or Hispanic race.
62068862|NCT05722847||High risk|Subjects will be considered high risk if they have small cell histology, a length of hospital stay \> 8 days, high comorbidity, emergency department use or hospitalization in the 6 months prior, prescription of a wheelchair when hospital discharge, or Black and/or Hispanic race.
62068863|NCT05722847||Health Care Providers Group|Thoracic medical oncology physicians, advance practice providers, and nurse navigators respond to the survey that assess acceptability.
62068864|NCT00715663||A|
62068865|NCT02454036|EXPERIMENTAL|BBI Intervention|Biobehavioral Intervention
62068866|NCT04432532||Neuroendocrine Tumor|
62068867|NCT04432532||Adrenal Tumor|
62068868|NCT02179372|EXPERIMENTAL|Eicosapentaenoic acid|Subject with Cronn's Disease and/or Ulcerative colitis in clinical remission will receive 2 g/day of eicosapentaenoic acid for 6 months
62068869|NCT02179372|PLACEBO_COMPARATOR|Medium chain fatty acid (placebo)|Subjects with Crohn's Disease and/or Ulcerative colitis will be receive 2 g/day of medium chain fatty acid for 6 months
62068870|NCT00518128|ACTIVE_COMPARATOR|1|Surgical OSA Treatment Group: Moderate to Severe OSA patients who are unable to tolerate PAP (Positive Airway Pressure) and elect to proceed with surgical treatment (surgical cohort).
62068871|NCT00518128|ACTIVE_COMPARATOR|2|Positive Airway Pressure Therapy Comparison Group: Moderate to Severe OSA patients who tolerate PAP (Positive Airway Pressure).
62068872|NCT03792321|ACTIVE_COMPARATOR|Testosterone|Testosterone arm patients were receiving testosterone undecanoate 1000 mg intramuscular injections two years; according to the protocol every 10 weeks
62068873|NCT03792321|PLACEBO_COMPARATOR|Placebo|Placebo arm patients were receiving placebo throughout the first year of this study and testosterone undecanoate 1000 mg intramuscular injections during second year.
62068874|NCT02851966|OTHER|TEX101|This is a single arm study. All patients will be asked to provide multiple semen samples and all samples will be tested with TEX101 ELISA assay. Timing of mTESE maybe changed according to the assay results.
62068875|NCT01914809|EXPERIMENTAL|group with a preeclampsia before 34 SA|
62068876|NCT01914809|OTHER|group with a normal pregnancy|
62068877|NCT05619510|OTHER|Wait List Control Group|This group will be randomized to wait list control. They will serve as a control for the intervention at time points 1 and 2. However after a 2-3 month period they will receive the intervention.
62068878|NCT05619510|EXPERIMENTAL|Intervention Group|Individuals randomized to this group will start the intervention immediately and have outcomes measured at three time points.
62068879|NCT00545350|NO_INTERVENTION|1|Usual activity / care
62068880|NCT00545350|EXPERIMENTAL|2|"Physical exercise classes plus home exercises:~Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home. The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
62068881|NCT04116944|EXPERIMENTAL|Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults with analogue-Generalized Anxiety Disorder
62068882|NCT04116944|OTHER|Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
62068883|NCT04116944|EXPERIMENTAL|Non-Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults without analogue-Generalized Anxiety Disorder
62273506|NCT00962832|PLACEBO_COMPARATOR|Part 2 - Placebo subcutaneously|Participants received placebo subcutaneously every 2 weeks for 24 weeks.
62454065|NCT04117607|EXPERIMENTAL|MAD3|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
62454066|NCT04117607|EXPERIMENTAL|MAD4|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
62068884|NCT04116944|OTHER|Non-Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
62068885|NCT01598402|NO_INTERVENTION|No prophylactic treatment|When a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics).
62068886|NCT01598402|EXPERIMENTAL|prophylactic treatment|Administration of prophylactic amoxicillin/clavulanic acid suspension, 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT. If a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics)
62068887|NCT03270813|EXPERIMENTAL|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
62068888|NCT03270813|SHAM_COMPARATOR|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
62273507|NCT00962832|EXPERIMENTAL|Part 2 - Rontalizumab 300 mg subcutaneously|Participants received rontalizumab 300 mg subcutaneously every 2 weeks for 24 weeks.
62273508|NCT00962832|EXPERIMENTAL|Part 3 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 120 weeks.
62273509|NCT01098071|EXPERIMENTAL|mometasone furoate nasal spray|
62273510|NCT05915312||BD group|patients with bipolar disorder for the first stage
62273511|NCT05915312||MDD group|patients with major depressive disorder for the first stage
62273512|NCT05915312||healthy control|participants without psychosis for the first stage
62273513|NCT05915312||BD group II|patients with bipolar disorder for the second stage
62273514|NCT05915312||MDD group II|patients with bipolar disorder for the second stage
62273515|NCT03439150|OTHER|Study arm|The study arm will undergo absolute flow and resistance measurements immediately after PPCI of the culprit artery
62273516|NCT02687399|EXPERIMENTAL|TT-173|It will be sprayed using this syringe and a nozzle tip couplet to it one time over the surgical lesion surfaces on the exposed tissues of the knee
62273517|NCT02687399|PLACEBO_COMPARATOR|placebo|It will be sprayed over the surgical lesion surfaces on the exposed tissues of the knee
62273518|NCT03891589|EXPERIMENTAL|Optimized CF with Taburia|The intervention groups consisted of promotion of optimized complementary feeding with home fortification (taburia) one sachet per week
62068889|NCT03607513|EXPERIMENTAL|Single Ascending Dose (SAD)|The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.
62068890|NCT03607513|EXPERIMENTAL|Multiple Ascending Dose (MAD)|The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.
62068891|NCT05124834|EXPERIMENTAL|Subject glucometer measurement|Blood glucose measurement BGM for personal use
62068892|NCT05970380||Local anesthesia|Local anesthesia with 0.25% 20 mL bupivacaine will be given extrapedicular part of the fractured vertebra by the surgeon. At the same time, intravenous 0.1 mg/kg midazolam, 0.3 mg/kg ketamine and 25-100 mcg/kg/min propofol will be administered to achieve sedation and analgesia.
62068893|NCT05970380||ESP Block|Bilateral erector spinae plane block will be performed at the level of fractured vertebra with totally 40 mL 0.25% bupivacaine under ultrasound imaging by the anesthesiologist. Intravenous 0.1 mg/kg midazolam will be administered for sedation.
62068894|NCT06445387|EXPERIMENTAL|Virtual Reality Glasses Gruop|The procedure was tested for five minutes, one hour before application, to evaluate the patients' compliance and to detect any possible problems after wearing the glasses. In patients who did not experience any problems after the test, glasses were put on the patient just before the femoral sheath and remained on for 20 minutes.
62068895|NCT06445387|EXPERIMENTAL|Ice Application Group|Before taking the femoral sheath, the researcher applied cold to the area where the femoral sheath was located with an ice pack for 20 minutes. A femoral sheath was performed immediately after the ice bag was removed.
62068896|NCT06445387|OTHER|Control Group|The general procedure of the clinic was applied to the control group. Femoral sheath was removed without any invasive procedure.
62068897|NCT04032379||Certain IIH or IIH-WOP|According to revised diagnostic criteria, Friedmann, 2013.
62068898|NCT04032379||Suspected IIH|IIH is suspected, does not fulfill diagnostic criteria.
62068899|NCT04032379||IIH ruled out|Patients in whom another diagnosis is made.
62068900|NCT02779023|EXPERIMENTAL|ICHP + CBT-I|Participants in this arm will receive the usual care (ICHP program) plus 6 Cognitive-Behavior Therapy for Insomnia (CBT-I) treatment sessions. Four of the treatment sessions will be in person and two will be over the phone.
62068901|NCT02779023|NO_INTERVENTION|ICHP Only|Participants in this arm will receive the usual care (ICHP program).
62068902|NCT03813628|EXPERIMENTAL|polished celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
62068903|NCT03813628|EXPERIMENTAL|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
62068904|NCT03813628|ACTIVE_COMPARATOR|contralateral natural teeth|the poilshed and glazed all ceramic crowns will be compared by the contralateral natural teeth
62068905|NCT03340558|EXPERIMENTAL|Monotherapy Cohort|The first 10 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 of each 28-day cycle. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2. No study treatment is administered while subjects are healing after surgery.
62068906|NCT03340558|EXPERIMENTAL|Combination Cohort|The next 15 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 and Cobimetinib 60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.
62068907|NCT00790920|EXPERIMENTAL|Desmoteplase|
62273519|NCT03891589|EXPERIMENTAL|Optimized CF only|The intervention groups consisted of promotion of optimized complementary feeding without home fortification (taburia)
62068908|NCT00790920|PLACEBO_COMPARATOR|Placebo|
62068909|NCT06026319|EXPERIMENTAL|CD79b-19 CAR T cells|"Prior to receiving CD79b-19 CAR T cells, participants will undergo two preparatory processes:~* Leukapheresis: During Week -3 white blood cells will be collected.~* Lymphodepletion: On days, -5 to -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~CD79b-19 CAR T cells will be administered intravenously on day 0 only. The dose you will receive will depend on the number of participants who have been enrolled prior and how well the dose was tolerated. The CD79b-19 CAR T cells will be administered over approximately 1 hour."
62068910|NCT06205641|PLACEBO_COMPARATOR|Xuanfei Baidu Granule Placebo group|
62273520|NCT03891589|EXPERIMENTAL|Taburia|The intervention groups consisted of provision taburia home fortification three sachet per week
62273521|NCT03891589|NO_INTERVENTION|Control|No intervention but gave a standard education from primary health center
62454067|NCT04117607|EXPERIMENTAL|SAD1|1 mg (1 injection of 0.1 ml diluted 1:10 in 5% Dextrose Injection, USP) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=3 (no sentinel dosing), or matching placebo, n=1 (no sentinel dosing), on Day 1 in a double-blind manner.
62068911|NCT06205641|EXPERIMENTAL|Xuanfei Baidu Granule group|
62068912|NCT06205641|ACTIVE_COMPARATOR|Baloxavir Marboxil Tablet group|
62068913|NCT06205641|ACTIVE_COMPARATOR|Combination group|
62068914|NCT00366301|PLACEBO_COMPARATOR|Placebo pill|Placebo pill
62068915|NCT00366301|ACTIVE_COMPARATOR|Metformin Pill|Metformin pill
62068916|NCT00366301|ACTIVE_COMPARATOR|Insulin Glargine plus placebo pill|Insulin glargine plus placebo pill
62068917|NCT00366301|ACTIVE_COMPARATOR|Insulin Glargine plus metformin pill|Insulin Glargine plus metformin pill
62068918|NCT01024959|EXPERIMENTAL|PCA3 Assay|
62068919|NCT05883917|EXPERIMENTAL|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
62068920|NCT06320873|OTHER|Results of sports performance parameters values in archers|Sociodemographic and physical characteristics, Pulmonary function test (PFT), respiratory muscle strength, shooting performance test, Moberg-pickup collection test, Nelson hand reaction test, and Fatigue Severity Scale (FSS)
62273522|NCT03302754|OTHER|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
62273523|NCT01913392||morbidly obese, chronic renal disease|adult patients (\> 18 years) who have stage 4 or 5 chronic renal disease (CrCl \< 30 ml/min) who are being considered for possible future kidney transplantation. The study inclusion criteria are an indication for laparoscopic sleeve gastrectomy (BMI \> 40 kg/m2, or BMI \> 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes)
62068921|NCT04699227|SHAM_COMPARATOR|Control group not receiving RIC|Those randomised to the control group will have the blood pressure cuff placed on the arm, but it will not be inflated.
62068922|NCT04699227|EXPERIMENTAL|Interventional group receiving RIC|RIC will consist of 3-4 cycles of cuff inflations to 200 mmHg for 5 min with deflation to 0 mmHg for another 5 min, which is automatically administered by the pre-programmed cuff.
62068923|NCT03875079|EXPERIMENTAL|Part I Safety Run in: RO6874281 + Pembrolizumab|"Cohort 1.1 (CPI naive and experienced melanoma participants):~Participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2 (CPI experienced melanoma participants only):~Participants will receive RO6874281 in combination with Pembrolizumab via an induction and maintenance schedule for RO6874281: QW three times (D1, D8, D15) followed by Q3W dosing (D22 and subsequent). Pembrolizumab is to be administered Q3W, starting on Day 1. Participants will be observed for 2 pembrolizumab cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part III of this study."
62068924|NCT03875079|EXPERIMENTAL|Part II Expansion: RO6874281 + Pembrolizumab|Part II will start once all participants in Part I Cohort 1.1 have completed the observation period. Approximately 34 participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks).
62068925|NCT03875079|EXPERIMENTAL|Part III Expansion: RO6874281 + Pembrolizumab|Part III will start once all participants in Part I Cohorts 1.1 and 1.2 have completed the observation period. Approximately 80 participants will be randomised to receive RO6874281 in combination with Pembrolizumab in either a Q3W or QW/Q3W schedule.
62068926|NCT04939636|ACTIVE_COMPARATOR|Vitamin D3 capsules 4000IU/100µg|Get Vitamin D3 capsules 4000IU/100µg.
62068927|NCT04939636|ACTIVE_COMPARATOR|Vitamin D3 capsules 600IU/15µg|Get Vitamin D3 capsules 600IU/15µg.
62068928|NCT02757222|ACTIVE_COMPARATOR|Standard dose|Patients receive a radiation dose of 66Gy in 30 fractions to the planning target volume 1 (PTV1) and 54 Gy in 30 fractions to the PTV2 concurrent with platinum chemotherapy weekly
62068929|NCT02757222|EXPERIMENTAL|Escalated dose|Patients receive a radiation dose of 73.5 Gy in 30 fractions to the boost target volume (BTV), 63Gy in 30 fractions to PTV1 and 54 Gy in 30 fractions to PTV2 concurrent with platinum chemotherapy weekly
62068930|NCT03145467|EXPERIMENTAL|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
62068931|NCT03145467|EXPERIMENTAL|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
62068932|NCT05266105|EXPERIMENTAL|Dose Escalation|This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily with Palbociclib in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
62068933|NCT05266105|EXPERIMENTAL|Dose Expansion|This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 in combination with Palbociclib and estimates preliminary data of anti-tumor efficacy
62068934|NCT01526811||AAA patients|Subjects presenting with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and requiring endovascular treatment with Endurant™ Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional study
62068935|NCT04855292|EXPERIMENTAL|TG103 injection 15 mg|TG103 injection (15 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
62273524|NCT02576743||Healthy subjects|Subjects with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning. 7 Tesla MRI
62273525|NCT02576743||Patients|Patients with an unruptured brain aneurysm or an unruptured arteriovenous malformation (AVM) with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning 7 Tesla MRI
62068936|NCT04855292|EXPERIMENTAL|TG103 injection 22.5 mg|TG103 injection (22.5 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
62273526|NCT01380457|EXPERIMENTAL|A|Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions
62273527|NCT01380457|ACTIVE_COMPARATOR|B|Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.
62273528|NCT05730465|NO_INTERVENTION|Standard of Care|Participants will receive routine stroke discharge education which is standard of care. A stroke nurse will provide and review with the patient a short informational pamphlet on the importance of blood pressure monitoring.
62273529|NCT05730465|EXPERIMENTAL|Access to Blood Pressure Monitoring|Participants will also receive the teaching administered to the control group. In addition, they will be given an Omron Home Blood Pressure Cuff furnished by the study. The nurse will provide additional education on on how to use the cuff, and how to record values in a blood pressure log.
62273530|NCT03477864|EXPERIMENTAL|Arm A (REGN2810, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 IV over 30 minutes on day 1 of week 1 and in week 4, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
62273531|NCT03477864|EXPERIMENTAL|Arm B (ipilimumab, SBRT, surgery)|Participants receive ipilimumab via intraprostatic injection on day 1 of week 1, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
62273532|NCT03477864|EXPERIMENTAL|Arm C (REGN2810, ipilimumab, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 as in Arm A and ipilimumab as in Arm B. Participants also undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
62273533|NCT06101615|ACTIVE_COMPARATOR|Group A|IASTM Group
62273534|NCT06101615|ACTIVE_COMPARATOR|Group B|Foam Rolling Group
62273535|NCT02841371||chronic kidney disease (CKD)|chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.
62273536|NCT02841371||no CKD|Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.
62273537|NCT02025387|EXPERIMENTAL|Experimental|Patients will receive physical activity feedback and be encouraged to achieve the daily goals of physical activity
62273538|NCT02025387|SHAM_COMPARATOR|Control|Physical activity will be measured but not be informed to patients. She will receive usual care.
62273539|NCT05416853|ACTIVE_COMPARATOR|Transradial artery|Carotid stent implantation via radial artery approach
62273540|NCT05416853|ACTIVE_COMPARATOR|Transfemoral artery|Carotid stent implantation via femoral artery approach
62273541|NCT01789814|ACTIVE_COMPARATOR|Prasugrel|Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
62273542|NCT01789814|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention
62273543|NCT06459245|NO_INTERVENTION|Routine rehabilitation training|Starting from the first day after surgery, progressive progress was carried out according to the functional exercise table of the affected limb in the ward Functional exercise of affected limb; Pneumatic pressure pump physiotherapy during hospitalization: once a day, 30min each time;
62454068|NCT04117607|EXPERIMENTAL|SAD2|10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
62068937|NCT04855292|EXPERIMENTAL|TG103 injection 30 mg|TG103 injection (30 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
62273544|NCT06459245|EXPERIMENTAL|Resistance training|Bend the dumbbell, hold a dumbbell in each hand, put it on the side of the body, bend the arm to lift the dumbbell, the front wall and the upper arm as close as possible; Hold the dumbbells flat on the side, with the back straight, stand with feet, arms perpendicular to the side of the body, hold the dumbbells with both hands, and lift the dumbbells to the side above shoulder level, elbows slightly bent; Stand with your feet straight, hold the dumbbells, and extend your arms back as far as possible. You can feel your upper arms and lower back being stretched. With your feet open, hold the dumbbells with both hands and extend your arms naturally in front of you. Lift them up until your elbows are above shoulder height and hold for 1-2 seconds.The training frequency is 2 to 3 times a week, 2 to 3 sets each time
62273545|NCT02122978|ACTIVE_COMPARATOR|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
62273546|NCT02122978|EXPERIMENTAL|MBSCT 8 week course|Mindfulness Based Self Compassion Therapy
62273547|NCT02122978|ACTIVE_COMPARATOR|Mindfulness Based Self-Compassion - Audio guided|MBSC - minimal contact
62273548|NCT01227902|EXPERIMENTAL|Retigabine IR|Open Label flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
62273549|NCT02191943|ACTIVE_COMPARATOR|Control (fluoride varnish)|
62273550|NCT02191943|EXPERIMENTAL|resin infiltration (Icon)|
62273551|NCT03887351||JGH Cohort|This cohort will not be subjected to any intervention.
62273552|NCT03887351||RVH Cohort|This cohort will not be subjected to any intervention.
62273553|NCT05386329|EXPERIMENTAL|Therapist-guided smartphone-delivered CBT|Participants will complete app-based cognitive-behavioral therapy (CBT) treatment for major depressive disorder (MDD) through their personal mobile smartphone. They will also be assigned a therapist, who will provide brief virtual treatment sessions (up to 25 minutes via a video platform) over the course of the same treatment period.
62273554|NCT02491255|EXPERIMENTAL|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
62454069|NCT04117607|EXPERIMENTAL|SAD3|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
62068938|NCT02490618|EXPERIMENTAL|Test|Probiotic tablet
62068939|NCT02490618|PLACEBO_COMPARATOR|Control|Control tablet
62273555|NCT03575858|EXPERIMENTAL|Barrel shaped interdental brushes|test group
62273556|NCT03575858|ACTIVE_COMPARATOR|Tapered interdental brushes|control group
62273557|NCT01120496|EXPERIMENTAL|hypertonic saline|hypertonic saline (HS)
62273558|NCT01120496|PLACEBO_COMPARATOR|normal saline (NS)|normal saline (NS)
62454070|NCT04117607|EXPERIMENTAL|SAD4|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
62068940|NCT05603988|PLACEBO_COMPARATOR|Placebo group|• Mock laser application (Placebo group): The fiber optic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated
62068941|NCT05603988|OTHER|Diode Laser group|Intracanal Diode laser application
62068942|NCT02387437|EXPERIMENTAL|SI recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
62273559|NCT05089500|EXPERIMENTAL|Endoscopic injection sclerotherapy|
62273560|NCT05089500|EXPERIMENTAL|Endoscopic Band Ligation|
62273561|NCT05146570|EXPERIMENTAL|Aseptic Meningitis|"In all patients cerebrospinal (CSF) fluid will be aspirated following the routine diagnostic procedure. After aspiration CSF will be tested with standard diagnostic tests and experimental diagnostic test (D-lactate).~Immediately after aspiration, 0.5-1 ml of cerebrospinal fluid will be transferred into each of the following vials:~* native vial for conventional culture (agar plate \& broth)~* EDTA vial for the determination of leukocyte count and differential~* pediatric blood culture bottle (BacTec PedsPlus/F)~* native vial for biomarker detection (D-Lactate)"
62273562|NCT05146570|EXPERIMENTAL|Infective meningitis|"In all patients cerebrospinal (CSF) fluid will be aspirated following the routine diagnostic procedure. After aspiration CSF will be tested with standard diagnostic tests and experimental diagnostic test (D-lactate).~Immediately after aspiration, 0.5-1 ml of cerebrospinal fluid will be transferred into each of the following vials:~* native vial for conventional culture (agar plate \& broth)~* EDTA vial for the determination of leukocyte count and differential~* pediatric blood culture bottle (BacTec PedsPlus/F)~* native vial for biomarker detection (D-Lactate)"
62273563|NCT04545346|NO_INTERVENTION|Wait-listed control|Participants continue care as usual. All all medications must be kept constant during the study period, unless medically necessary.
62273564|NCT04545346|EXPERIMENTAL|Low Glutamate diet|Participants are put on the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
62273565|NCT04336995|OTHER|Exercise|Everyone is in this arm
62068943|NCT02387437|EXPERIMENTAL|IP recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
62068944|NCT02387437|EXPERIMENTAL|PCV recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
62068945|NCT03975426||conservative group|received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture.
62068946|NCT03975426||absorbable screws|received open reduction and internal fixation with fixation by absorbable screws.
62068947|NCT06251037|EXPERIMENTAL|Intervention|"The participants in this group will:~Participate in the initial survey; Undergo the YAM program; Participate in the final survey (follow-up)."
62273566|NCT02986230|EXPERIMENTAL|CP-CDS|The CP-CDS group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
62273567|NCT02986230|EXPERIMENTAL|CP-CDS + SDMT|The CP-CDS + SDMT group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The CP-CDS + SDMT arm also provides shared decision making tools to patient and provider at the time of the visit.
62273568|NCT02986230|NO_INTERVENTION|Usual Care|The usual care group will have no access to the CP-CDS, or the CP-CDS + SDMT.
62636644|NCT01114009|ACTIVE_COMPARATOR|Lung protective strategy|Lung protective strategy group received lung protective strategy without recruitment maneuver
62636645|NCT02511327||Preterm born infants of vaccinated women|Preterm born infants (\< 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
62068948|NCT06251037|NO_INTERVENTION|No intervention|"The participants in this group will:~Participate in the initial survey; Participate in the final survey (follow-up)."
62068949|NCT04109638|ACTIVE_COMPARATOR|Active PEMF Group|Participants will have a 1 in 2 chance to get the active treatment device post-operatively. The device will be attached to the post-operative dressing. The device is an Endonovo SofPulse that emits a pulsed electromagnetic field (PEMF). Single blind randomization.
62068950|NCT04109638|SHAM_COMPARATOR|Placebo PEMF Group|Participants will have a 1 in 2 chance to get the placebo treatment device post-operatively. The device will be attached to the post-operative dressing. The Endonovo SofPulse placebo device does not emit a pulsed electromagnetic field (PEMF). Single blind randomization.
62636646|NCT02511327||Term born infants vaccinated women|Term born infants (\>= 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
62636647|NCT02511327||Term born infants unvaccinated women|Term born infants (\>= 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy. Infant vaccination against pertussis is performed according to the national recommended schedule.
62273569|NCT03789227|PLACEBO_COMPARATOR|Group C|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 4 ml saline in a total volume 12 ml.
62454071|NCT04117607|EXPERIMENTAL|SAD5|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
62068951|NCT02875301|EXPERIMENTAL|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
62068952|NCT02875301|EXPERIMENTAL|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
62068953|NCT02875301|ACTIVE_COMPARATOR|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
62068954|NCT02626221||Single|Single Cohort Study
62068955|NCT03075956|EXPERIMENTAL|5 mg E4 single-dose|Group A: a single 5 mg E4 dose will be administered under fasted conditions during period 1.
62068956|NCT03075956|EXPERIMENTAL|15 mg E4 single-dose|Group B: a single 15 mg E4 dose will be administered under fasted conditions during period 1.
62068957|NCT03075956|EXPERIMENTAL|45 mg E4 single-dose|Group C: a single 45 mg E4 dose will be administered under fasted conditions during Period 1.
62068958|NCT03075956|EXPERIMENTAL|15 mg E4 multiple-dose|15 mg E4 dose will be administered once daily for 14 consecutive days during Period 2.
62068959|NCT01274065||Psychiatric illnesses|Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.
62273570|NCT03789227|ACTIVE_COMPARATOR|Group D|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 8 mg dexamethasone with 4 ml saline in a total volume 12 ml.
62273571|NCT03789227|ACTIVE_COMPARATOR|Group K|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 15 mg ketorolac with 4 ml saline in total volume 12 ml.
62454072|NCT04117607|EXPERIMENTAL|SAD6|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
62454073|NCT01986036|SHAM_COMPARATOR|CONTROL|Control breakfast low in protein and calcium. Porridge-based breakfast.
62454074|NCT01986036|ACTIVE_COMPARATOR|PROTEIN|High-protein breakfast.
62454075|NCT01986036|ACTIVE_COMPARATOR|CALCIUM|High-calcium breakfast.
62454076|NCT01986036|EXPERIMENTAL|PRO-CAL|High-protein and calcium breakfast.
62454077|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
62068960|NCT04002219|EXPERIMENTAL|Active arm|Subjects will receive treatment with active beverage containing the active ingredient
62068961|NCT04002219|PLACEBO_COMPARATOR|Placebo arm|Subjects will receive treatment with placebo beverage not containing the active ingredient
62068962|NCT02926235|EXPERIMENTAL|Amino Acid|Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.
62068963|NCT02926235|PLACEBO_COMPARATOR|Placebo|Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.
62068964|NCT00584701|EXPERIMENTAL|Risperidone|Risperidone was started at 0.5mg at bedtime for 4 days. If that dosage was tolerated and there were continued behavioral symptoms, the dose was increased to 1mg at bedtime for an additional 4 days. If tolerated and indicated, 0.5mg was added in the morning for a daily total of 1.5 mg.
62068965|NCT00068874|ACTIVE_COMPARATOR|1|Educational comparison group
62068966|NCT00068874|EXPERIMENTAL|2|Group receiving coping intervention designed to enhance coping and psychological adjustment
62068967|NCT00068874|NO_INTERVENTION|3|Comparison control group with no active intervention
62068968|NCT05774899|EXPERIMENTAL|Experimental: Cohort 1A - CB-103 + Abemaciclib|"A modified 3+3 dose escalation design will be used. 3-9 participants will receive:~* Standard of care Abemaciclib.~* Cycle 1 - End of Treatment~  --Days 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week.~* A safety review will be performed by primary investigation after completion of the ramp-up phase."
62068969|NCT05774899|EXPERIMENTAL|Experimental: Cohort 1B - CB-103 + Abemaciclib|"Participants will receive:~* Cycle 1 - End of Treatment~  --Days 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week and predetermined dose of Abemaciclib 1x daily.~* Therapy will continue until disease progression, therapy intolerance, or participant withdrawal.~* End of Treatment (EOT) visit within 30 days of last administration of study treatments."
62068970|NCT05774899|EXPERIMENTAL|Experimental: Cohort 2A- Lenvatinib + CB-103|"A modified 3+3 dose escalation design will be used. 3-9 participants will receive:~* Standard of care VEGFR TKI.~* Cycle 1 - End of Treatment~  --Days 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week.~* A safety review will be performed by primary investigation after completion of the ramp-up phase."
62068971|NCT05774899|EXPERIMENTAL|Experimental: Cohort 2B- Lenvatinib + CB-103|"Participants will receive:~* Continue standard of care VEGFR TKI at prior dose and schedule.~* Cycle 1 - End of Treatment~  --Day 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week.~* Therapy will continue until disease progression, therapy intolerance, or participant withdrawal.~* End of Treatment (EOT) visit within 30 days of last administration of study treatments."
62068972|NCT01263106|EXPERIMENTAL|Theophylline, LY2216684 + Theophylline|Period 1: single 200-milligram (mg) theophylline oral dose on Day 1; Washout period of at least 7 days; Period 2: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3
62068973|NCT01263106|EXPERIMENTAL|LY2216684 + Theophylline, Theophylline|Period 1: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3; Washout period of at least 7 days; Period 2: single 200-mg theophylline oral dose on Day 1
62068974|NCT05245604|EXPERIMENTAL|TJO-087|
62068975|NCT05245604|ACTIVE_COMPARATOR|Cyclosporine 0.05%|
62068976|NCT02309177|EXPERIMENTAL|nab-Paclitaxel and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle.
62068977|NCT02309177|EXPERIMENTAL|nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle.
62068978|NCT02309177|EXPERIMENTAL|nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1.
62068979|NCT02309177|EXPERIMENTAL|nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3.
62068980|NCT02309177|EXPERIMENTAL|nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3.
62068981|NCT02309177|EXPERIMENTAL|nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC|nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3.
62273572|NCT04646759|EXPERIMENTAL|Fulvestrant Combined With Pyrotinib|Fulvestrant, 500 mg, was injected intramuscularly on D1, D15, D28, D28, once every 28 days； Pyrotinib, 400mg, orally administered daily.
62273573|NCT04646759|ACTIVE_COMPARATOR|Capecitabine Combined With Pyrotinib|Capecitabine, 1000mg / m\^2, twice daily; Pyrotinib, 400mg, orally administered daily.
62273574|NCT02983682|EXPERIMENTAL|Lidocaine Infusion|All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.
62273575|NCT01524354|ACTIVE_COMPARATOR|Control|Patients received maintenance of anesthesia with continuous infusion of propofol according to recommendations of the manufacturer.
62273576|NCT01524354|ACTIVE_COMPARATOR|cerebral state index|Patients received continuous infusion of propofol with rate maintaining cerebral state index (CSI) between 40 and 60 points.
62068982|NCT05183217|ACTIVE_COMPARATOR|Online continence promotion program without tailoring|Participants will be allocated to the online continence promotion program without tailoring.
62068983|NCT05183217|EXPERIMENTAL|Online continence promotion program with tailoring|Participants will be allocated to the online continence promotion program with tailoring.
62068984|NCT03361787|EXPERIMENTAL|Parentship coaching intervention|
62068985|NCT01230606||overnight|Subjects that stay overnight at the hospital.
62068986|NCT01230606||Next Day Discharge|Subjects that are discharged on the same day of the procedure.
62068987|NCT04944394||hospital professionals|all professionals working in hospitals in France
62068988|NCT02538770|EXPERIMENTAL|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
62068989|NCT02538770|ACTIVE_COMPARATOR|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
62068990|NCT02276391|EXPERIMENTAL|Telmisartan/HCTZ fixed-dose combination|
62273577|NCT04365465|EXPERIMENTAL|Active device|Participants in this arm will receive an active NSS-Bridge device placed immediately following their cesarean section.
62273578|NCT04365465|SHAM_COMPARATOR|Placebo device|Participants in this arm will receive an inactive (sham) NSS-Bridge device placed immediately following their cesarean section.
62273579|NCT04365465|ACTIVE_COMPARATOR|Active Control|Participants in this arm will receive no device, only the standard postpartum pain control.
62068991|NCT02276391|ACTIVE_COMPARATOR|Telmisartan|
62068992|NCT02771730|EXPERIMENTAL|Vaccine A|Receive Ad4-mgag three times at 0,2,and 6 months with a boost at 8months
62273580|NCT06549374||Adults in Intensive care|Patient included will be adult patients admitted to intensive care after severe trauma, high-risk surgery, or presenting with acute respiratory distress
62273581|NCT01679210|EXPERIMENTAL|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
62273582|NCT01679210|NO_INTERVENTION|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
62273583|NCT03109171|OTHER|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
62068993|NCT02771730|EXPERIMENTAL|Vaccine B|Receive Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
62068994|NCT02771730|EXPERIMENTAL|Vaccine A & B|Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
62068995|NCT02771730|PLACEBO_COMPARATOR|Placebo|Receive placebo three times at 0,2,and 6 months with a boost at 8 months
62273584|NCT03109171|OTHER|Non-expert rater|"* Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.~* Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
62273585|NCT00846014|EXPERIMENTAL|Asthmatics|All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
62273586|NCT05148975||Mild ARDS due to Covid- 19 pneumonia|Adults with SARS-CoV-2 PCR positivity in the last 21 days on mechanical ventilation for Covid-19 pneumonia, fulfilling criteria for mild acute respiratory distress syndrome (ARDS) definition.
62273587|NCT03353857|EXPERIMENTAL|levonorgestrel|levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
62273588|NCT03353857|EXPERIMENTAL|norethindrone|norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
62068996|NCT02771730|EXPERIMENTAL|Vaccine A & B (previously received study vaccine)|People who have previously had a study vaccine: Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
62068997|NCT04885387|OTHER|Standard protocol using chest CT|
62068998|NCT04885387|EXPERIMENTAL|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|
62068999|NCT04190147||Moderate-to-late preterm group|
62069000|NCT04190147||Full-term group|
62069001|NCT03707444||Scrambler Therapy|All participants get the same device treatment with the Scrambler Therapy device, up to 10 treatments.
62069002|NCT05712161|EXPERIMENTAL|DurAVR™ THV System|TAVR procedure
62069003|NCT05962593|PLACEBO_COMPARATOR|Telephone call|A postoperative telephone call
62069004|NCT05962593|NO_INTERVENTION|No telephone call|No telephone call
62069005|NCT05971160|ACTIVE_COMPARATOR|Usual Care|Monthly financial education videos and one-time microgrant
62273589|NCT03353857|EXPERIMENTAL|desogestrel|desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
62636648|NCT02511327||Preterm born infants unvaccinated women|Preterm born infants (\< 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy.Infant vaccination against pertussis is performed according to the national recommended schedule.
62636649|NCT03069235|ACTIVE_COMPARATOR|Standard of Care|group/individual counselling.
62636650|NCT03069235|EXPERIMENTAL|Family member / peer support|Structured family member / peer support.
62636651|NCT03069235|EXPERIMENTAL|Special infant feeding counselor support|Enhanced intervention with counselor support
62636652|NCT05722730|EXPERIMENTAL|Pilates|The Pilates exercise protocol was designed based on protocols contained in previously published clinical trials whose objective had been muscle strengthening or improvement of muscle fatigue. Thus, the protocol will perform exercises from the classic repertoire of the Pilates Method, using equipment exclusive to the Method - such as Cadillac, Lader Barrel, Chair and Reformer. The sessions will take place twice a week, in a group of up to 3 participants, always in the morning lasting 60 minutes, with 10 minutes of warm-up, 40 minutes of load exercises and 10 minutes of relaxation exercises and calm down. All sessions were carried out by a physiotherapist specialized in the method, in a specific outpatient clinic. The professional who conducted the Pilates sessions, performed the proposed protocol, is unaware of the outcomes studied by the project.
62636653|NCT05722730|NO_INTERVENTION|Control|Only follow-up of the clinical evolution will be carried out
62636654|NCT03614403|EXPERIMENTAL|Vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
62636655|NCT03614403|NO_INTERVENTION|control|Control patients will not be received any intervention
62636656|NCT00976326|EXPERIMENTAL|A: Healthy volunteers|
62069006|NCT05971160|ACTIVE_COMPARATOR|Monthly microgrants|Monthly financial education videos and monthly microgrants
62636657|NCT00976326|EXPERIMENTAL|B: Subjects with mild liver impairment|
62069007|NCT05971160|ACTIVE_COMPARATOR|Monthly microgrants plus peer mentoring|Monthly financial education videos, monthly microgrants, and peer mentoring support
62069008|NCT02881008|EXPERIMENTAL|Arm A|Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period
62069009|NCT02881008|EXPERIMENTAL|Arm B|Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period
62273590|NCT03353857|EXPERIMENTAL|dienogest|dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
62273591|NCT03353857|EXPERIMENTAL|Drospirenone/ ethinylestradiol|"drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.~rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29."
62636658|NCT00976326|EXPERIMENTAL|C: Subjects with moderate liver impairment|
62636659|NCT00976326|EXPERIMENTAL|D: Subjects with severe liver impairment|
62636660|NCT05995938|EXPERIMENTAL|Experimental|1
62636661|NCT05995938|NO_INTERVENTION|Control|1
62636662|NCT06608121|EXPERIMENTAL|Experimental|
62069010|NCT02881008|EXPERIMENTAL|Arm C|Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period
62636663|NCT01241708|EXPERIMENTAL|Tandem Transplantation with Melphalan and Bortezomib|Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma
62636664|NCT04313517|EXPERIMENTAL|Yoga@Work|Yoga session were developed to practice at work anytime feasible.
62636665|NCT04313517|NO_INTERVENTION|Wait list Control group|Control group with no intervention. After Intervention period, group was offered same sessions.
62069011|NCT02881008|ACTIVE_COMPARATOR|Arm D|Entecavir 0.5 mg daily for 24 weeks
62273592|NCT01031446|EXPERIMENTAL|Treatment|
62273593|NCT06312072||MEIRU rural population cohort|"Adults aged \>=18 living in MEIRU's rural health demographic surveillance area (Karonga district)~No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples."
62636666|NCT04406922|EXPERIMENTAL|Intervention group|Cold exposure in the morning and evening.
62636667|NCT02126215||Study group - MRI CO2 and O2 stress test|This is a pilot study to assess feasibility of using MRI CO2 and O2 stress testing to predict POD.
62636668|NCT05914818|EXPERIMENTAL|EXPLORER V2|1 session with the exoskeleton EXPLORER V2 in healthy subjects 3 sessions with the exoskeleton EXPLORER V2 in subjects with disease
62636669|NCT04572776|EXPERIMENTAL|Resiniferatoxin|Single dose of Resiniferatoxin (25 mcg in 3 mL) injected epidurally
62636670|NCT04572776|ACTIVE_COMPARATOR|Standard of Care|Standard of care treatment as determined by the investigator
62636671|NCT04639557|EXPERIMENTAL|Virtual Intervention|Mothers in this group will participate in 16, once per week, scheduled 2-hour virtual group therapy sessions through Zoom for Healthcare. These sessions will include both visual media (e.g., presentations, recorded examples of skills), and discussions. A technician will be present in the virtual group therapy session to manage the technical component. These sessions will be supplemented with a 1-hour drop-in session moderated by a facilitator each week in which participants will be able to clarify topics for that week, discuss the material in more depth, and/or connect with other participants to share about the skill practice.
62069012|NCT02881008|EXPERIMENTAL|Arm E|Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period
62069013|NCT02881008|EXPERIMENTAL|Arm F|Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period
62069014|NCT05342103|ACTIVE_COMPARATOR|High flow nasal cannula (HFNC) group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. The flow rate will be set at 60 L/min
62069015|NCT05342103|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP) group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. Pressure will be set to 3 cm H2O for 5 minutes, then titrated according to patient comfort and tolerance, as well as clinical observation
62069016|NCT02149602||oropharyngeal and hypopharyngeal HNSCC|Intensity Modulated Radiotherapy HPV positive and HPV negative
62069017|NCT02451501|EXPERIMENTAL|Lying|Nebulization in lying position
62273594|NCT06312072||MEIRU urban population cohort|"Adults aged \>=18 living in MEIRU's urben demographic surveillance area (Lilongwe Area 25)~No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples."
62273595|NCT01568814|PLACEBO_COMPARATOR|High volume PEG|Patients who are scheduled colonoscopy ingest high volume PEG(4L) for bowel preparation.
62273596|NCT01568814|ACTIVE_COMPARATOR|Low volume PEG with low residual meals|Patients who are scheduled colonoscopy ingest low volume PEG(2L) and have a prepackaged low residual meals for bowel preparation.
62273597|NCT00903149||MITP exposure or not|Mothers of children born preterm and term.
62273598|NCT06008990||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 20 mothers with Opioid Use Disorder who are on Buprenorphine at the time of screening.
62273599|NCT06008990||Pregnant Mothers|Planned recruitment of 20 mothers who do not have any history of opioid use disorder.
62273600|NCT06537115|OTHER|Control group|After enrollment, professional doctors will conduct a comprehensive assessment of their basic conditions and provide routine interventions, mainly including basic nutrition intervention program guidance, progressive resistance exercise intervention program guidance, safety protection advice, and symptomatic treatment for different complications, with a total intervention period of 24 weeks.
62273601|NCT06537115|OTHER|experimental group 1|On the basis of the control group, whey protein powder was given to supplement for 12 weeks.60 grams of protein per day is taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.
62273602|NCT06537115|OTHER|experimental group 2|"On the basis of the control group, whey protein powder and eldecalcitol were given for supplementation for 12 weeks.~(Supplementing whey protein powder: The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.~Supplementing eldecalcitol: eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.)"
62069018|NCT02451501|ACTIVE_COMPARATOR|Sitting|Nebulization in sitting position
62069019|NCT03221504|ACTIVE_COMPARATOR|Antibiotic therapy for 10 days|After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
62069020|NCT03221504|EXPERIMENTAL|Antibiotic therapy for 7 days|After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
62069021|NCT03837392|EXPERIMENTAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) - participants in this arm will take part in an online ACT + psychoeducation intervention. The intervention will provide psychoeducation surrounding perinatal anxiety and depression as well as on engaging social support and coping strategies. The ACT portion of the intervention will focus on developing psychological flexibility, which is defined as behaviorally pursuing one's values even in the presence of barriers (e.g., thoughts, emotions). Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
62069022|NCT03837392|ACTIVE_COMPARATOR|Supportive Psychoeducation|Control group - participants in this arm will take part in an online psychoeducation and support intervention. This intervention will focus on psychoeducation surrounding perinatal anxiety and depression, as well as on engaging social support and coping strategies. Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
62069023|NCT02695602|EXPERIMENTAL|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|Turbinoplasty using microdebrider turbinate blade (2.9mm inferior turbinate blade, Medtronic, 5000 Hz)
62069024|NCT02695602|EXPERIMENTAL|Submucous Resection (SMR)|Turbinoplasty using non-powered instruments
62069025|NCT01454453|EXPERIMENTAL|Patients - dose titration|Amisulpride 50-200mg, 4-12 weeks, with brain imaging
62069026|NCT02267720|ACTIVE_COMPARATOR|Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
62273603|NCT03548051|EXPERIMENTAL|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
62273604|NCT03548051|EXPERIMENTAL|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
62273605|NCT01675960|EXPERIMENTAL|Gabapentin, then placebo|Participants first receive gabapentin 3 times per day, with varying dosing based on the protocol. After 34-38 days, a washout period of 3 days occurs, before then receiving the placebo dose for 32 days.
62069027|NCT02267720|EXPERIMENTAL|Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
62069028|NCT05362682||Case|
62069029|NCT05362682||Test Negative Control|
62069030|NCT02676752||Skin/soft tissue elasticity assessment|Participants will be evaluated for LEF status using the HN-LEF Grading Criteria and neck range of motion using the Cervical Range of Motion Device. Participants also complete study questionnaires, including VHNSS and LSIDS-H\&N. Participants undergo ultrasound shear wave elastography over 20-25 minutes. Participants' cancer disease and treatment information will be gathered from their medical records.
62069031|NCT05158478|EXPERIMENTAL|Subject glucometer measurement|
62069032|NCT05226260|EXPERIMENTAL|Intervention|Intervention clinics receiving fully functional Epic order panel with set default \[short\] duration by diagnosis: for cellulitis and drained abscess, 5 days. For impetigo and undrained abscess, 7 days.
62069033|NCT05226260|NO_INTERVENTION|Control|Control clinics receiving basic Epic order panel with antibiotic doses by diagnosis but duration free text (must be entered manually by clinician prescriber).
62069034|NCT04227496|ACTIVE_COMPARATOR|Noise1|A sound will be played while moving a body part through range of motion
62069035|NCT04227496|ACTIVE_COMPARATOR|Noise2|A sound (different from Noise 1) will be played while moving a body part through range of motion
62069036|NCT04227496|NO_INTERVENTION|No noise|No sound will be played while moving a body part through range of motion
62069037|NCT01597505|EXPERIMENTAL|Surotomycin|250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
62069038|NCT01597505|ACTIVE_COMPARATOR|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
62069039|NCT01455792|EXPERIMENTAL|MRI and soft image fusion biopsy|Preoperative MRI and soft image ultrasound guided biopsy.
62069040|NCT01455792|ACTIVE_COMPARATOR|Gold standard biopsy|Gold standard TRUS biopsy
62069041|NCT04219618|EXPERIMENTAL|Off-Pump|
62069042|NCT04219618|ACTIVE_COMPARATOR|On-Pump|
62069043|NCT00119262|EXPERIMENTAL|Arm I (combination chemotherapy, 18 courses of bevacizumab)|See detailed description.
62069044|NCT00119262|ACTIVE_COMPARATOR|Arm II (combination chemotherapy, 22 courses of bevacizumab)|See detailed description.
62069045|NCT02411305||PCRC Palliative Care Clinicians|
62069046|NCT02215733||Patients prescribed antihypertensives|
62069047|NCT01411722|OTHER|EADIWEANING|Patients mechanically ventilated for more than 48 hours during the weaning process.
62069048|NCT05929508|ACTIVE_COMPARATOR|Ischemic Preconditioning at High Pressure|In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 225mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).
62069049|NCT05929508|SHAM_COMPARATOR|Ischemic Preconditioning at Low Pressure|In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 25mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).
62069050|NCT04702880|EXPERIMENTAL|Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012|
62069051|NCT04702880|EXPERIMENTAL|Arm B: Carboplatin + Etoposide + Nivolumab|
62069052|NCT00278382|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.
62069053|NCT03344822|EXPERIMENTAL|68Ga-PSMA PET-CT|
62069054|NCT04676126|EXPERIMENTAL|Experimental|Subjects in the experimental arm will consume 1.5 Tbsp (22.2 mL) of a commercial macular pigment-containing medical food (liquid) once per day and use a carbonic anhydrase inhibitor topical eye drop (2% dorzolamide ophthalmic solution) three times per day in both eyes for 3 months.
62069055|NCT04676126|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will consume 1.5 Tbsp (22.2 mL) of a placebo liquid which resembles the commercial macular pigment-containing medical food (liquid) in taste once per day and use a lubricating eye drop (0.5% sodium + 0.9% glycerin ophthalmic solution) three times per day in both eyes for 3 months.
62069056|NCT00642629|ACTIVE_COMPARATOR|1|STA-5326 mesylate
62069057|NCT00642629|PLACEBO_COMPARATOR|2|Placebo
62069058|NCT03562546|EXPERIMENTAL|Structured Resistance Exercise|12 week at home structured resistance exercise programme ('Strength From Within') using resistance bands. Under the supervision of an experienced exercise specialist.
62069059|NCT05112211|EXPERIMENTAL|doxycycline|patients administrated with doxycycline tablets 100mg orally per day
62069060|NCT06319768|ACTIVE_COMPARATOR|- In group A (PTX group) (n:25):|Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection.
62088279|NCT02821520|ACTIVE_COMPARATOR|Delayed PDT combination with Conbercept|"1. Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~2. PDT:PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
62088280|NCT02567474|NO_INTERVENTION|control|no intervention
62088281|NCT02567474|EXPERIMENTAL|intervention|self management intervention based on 5A model
62636672|NCT04639557|EXPERIMENTAL|Therapy Intervention Pre-recorded|Mothers in this group will have access to short pre-recorded videos of the presentations with facilitator commentary (i.e., 10-12 minutes) with additional video material as warranted each week (e.g., recorded examples of skill practice) for a maximum of 30-minutes of material per week. This arm will also have a 1-hour drop-in session each week with a group facilitator to moderate homework check-ins and discussion of the material.
62636673|NCT02958371|EXPERIMENTAL|fMRI|The study consists in a fMRI experiment intended to observe the effect of the presence of choice on brain activity following consumption of a fruit-flavored drink, compared to the brain activity when the same drink is consumed without choice.
62636674|NCT02187549|EXPERIMENTAL|HYMOVIS|HYADD(TM) 4 Hydrogel Intra-Articular Injection
62636675|NCT02187549|PLACEBO_COMPARATOR|Placebo|Saline Intra-Articular Injection
62454078|NCT04960488|EXPERIMENTAL|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
62273606|NCT01675960|EXPERIMENTAL|Placebo, then Gabapentin|Participants first receive placebo 3 times per day. After 34-38 days, a washout period of 3 days occurs, before then receiving Gabapentin, with varying dosing based on the protocol, for 32 days.
62636676|NCT01533116|EXPERIMENTAL|5 mg BIA 9-1067|5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
62636677|NCT01533116|EXPERIMENTAL|Placebo|Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
62636678|NCT01533116|EXPERIMENTAL|15 mg BIA 9-1067|15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
62636679|NCT01533116|EXPERIMENTAL|30 mg BIA 9-1067|30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
62636680|NCT02288819|EXPERIMENTAL|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
62273607|NCT02956993|ACTIVE_COMPARATOR|Vonapanitase|Vonapanitase administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
62273608|NCT02956993|PLACEBO_COMPARATOR|Placebo|Placebo administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
62273609|NCT04377737|OTHER|RT-PCR Covid-19|
62273610|NCT01315262|ACTIVE_COMPARATOR|Viagra 100 mg daily|
62273611|NCT01315262|ACTIVE_COMPARATOR|Viagra 100mg on demand|
62454079|NCT04960488|ACTIVE_COMPARATOR|carotid endarterectomy|carotid endarterectomy
62461578|NCT02032888|EXPERIMENTAL|Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks|Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
62636681|NCT03718429|EXPERIMENTAL|aspirin|Patients on aspirin 81 mg daily will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
62636682|NCT03718429|EXPERIMENTAL|aspirin and clopidogrel|Patients on aspirin (81 mg daily) plus clopidogrel (75 mg daily) will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
62069061|NCT06319768|ACTIVE_COMPARATOR|- In group B(PRP group) (n:25):|Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP.
62454080|NCT05420051|EXPERIMENTAL|Positive Psychology + Motivational Interviewing|Each week, participants in the PP-MI intervention group will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. Each phone session will include PP and goal setting portions. In the PP portion, the study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. In the goal-setting portion, the trainer will (a) review the participant's physical activity goal from the prior week, (b) discuss techniques for improving physical activity (e.g. tracking activity), and (c) help the participant to set a physical activity goal for the next week. Participants also will receive supplemental text messages throughout the 8 weeks of the intervention and during the initial follow-up period (Week 9-16).
62069062|NCT06319768|ACTIVE_COMPARATOR|- In group C (combined PTX & PRP) (n:25):|Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes.
62069063|NCT06286540|EXPERIMENTAL|Lymphoblock|Patients from this group received Lymphoblock.
62069064|NCT06286540|PLACEBO_COMPARATOR|Placebo|Patients from this group received placebo.
62069065|NCT06488183|OTHER|group p|laparoscopic preperitoneal local anesthetic infiltration
62069066|NCT06488183|OTHER|group Q|ultrasound guided quadratus lamborum block
62088282|NCT04365413|EXPERIMENTAL|Imaging of Tumor or Lymph node|"Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery.~The temperature of their skin prior to and after MSOT imaging will also be measured."
62088283|NCT01920776|EXPERIMENTAL|Rutine treatment group, Ultrasound group|
62636683|NCT03718429|EXPERIMENTAL|aspirin and ticagrelor|Patients on aspirin (81 mg daily) and ticagrelor (90 mg bid) will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
62636684|NCT03718429|NO_INTERVENTION|rivaroxaban|A control cohort of subjects with atrial fibrillation on full dose rivaroxaban (20 mg daily) as per standard of care will be recruited and will undergo a single PD assessment.
62636685|NCT05515133||Observation group of newly diagnosed glioblastoma patients with high-level psychological stress|The patients had high threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
62636686|NCT05515133||Observation group of newly diagnosed glioblastoma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
62636687|NCT01063855|EXPERIMENTAL|Dapoxetine + PDE5I|Dapoxetine 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
62636688|NCT01063855|PLACEBO_COMPARATOR|Placebo + PDE5I|Placebo tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
62636689|NCT04578704|EXPERIMENTAL|Vacuum formed retainer group|It will be constructed following manufacturer's instructions for the thickness.
62636690|NCT04578704|EXPERIMENTAL|Fixed bonded retainer group|fixed bonded wire will be bonded on individual tooth extended distal to extraction space that were previously closed by fixed appliances treatment.
62636691|NCT04578704|EXPERIMENTAL|Vacuum formed retainer and fixed bonded retainer|Double regime retainer that will be consisted of bonded retainer and vacuum formed retainer for upper and lower arch.
62636692|NCT01062308|EXPERIMENTAL|Taping|The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
62636693|NCT01062308|ACTIVE_COMPARATOR|Sham Taping|This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.
62636694|NCT01328470|ACTIVE_COMPARATOR|clopidogrel 75 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
62069067|NCT05426382|EXPERIMENTAL|Digital solution group|"Participants will be instructed to download a lifestyle-changing mobile application to which they will have access for 9 months. The program aims to provide remote symptom monitoring by a health coach and by having participants enter data (on diet, exercise, weight, stress and energy levels, etc) and patient reported outcomes (PROs) via the SidekickHealth platform to empower positive lifestyle changes.~The intervention consists of a 12-week digital behavioral change program with an additional 6-month maintenance program, during which time the patient still has access to the application but with limited features compared to the first 12 weeks. During the total 9-month study period all participants will also receive standard of care."
62069068|NCT04380337|EXPERIMENTAL|Radiation/FOLFOXIRI|Treatment will comprise 6 daily fractions of radiotherapy at 5 Gy per fraction followed by 4 months of FOLFOXIRI. Patients who have performance status or conditions that may preclude use of FOLFOXIRI may be treated with FOLFOX or XELOX. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard of care total mesorectal excision (TME).
62636695|NCT01328470|ACTIVE_COMPARATOR|clopidogrel 150 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
62636696|NCT01328470|ACTIVE_COMPARATOR|adjunctive cilostazol|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; \[group 3, 20 patients\]) for 14 days.
62636697|NCT01328470|ACTIVE_COMPARATOR|75mg clopidogrel|control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).
62636698|NCT03380871|EXPERIMENTAL|NEO-PV-01/Adjuvant + pembrolizumab + chemotherapy|Pembrolizumab at a dose of 200 mg administered by intravenous infusion (IV) plus chemotherapy with carboplatin (AUC 5) + pemetrexed (500 mg/m2) every 3 weeks for 4 cycles. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with pembrolizumab.
62636699|NCT03573596|OTHER|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
62069069|NCT00423293|OTHER|5-FU + Mitomycin + IMRT|5-FU + Mitomycin + IMRT
62069070|NCT01998594|ACTIVE_COMPARATOR|Arthroplasty without HADM|Three - five (3 - 5) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure without using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of twenty-five (25) similar subjects who received the arthroplasty procedure with the use of the HADM spacer.
62273612|NCT05348655||Pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2019-2020 winter epidemic"
62273613|NCT05348655||Per Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, and 2023-2024 epidemic. The need for continuation of the study will be reassessed after each season"
62273614|NCT02178488|ACTIVE_COMPARATOR|Cholecalciferol|150 patients with MRSA resistent Cholecalciferol 4000 international units (IU)/day for 12 month
62273615|NCT02178488|PLACEBO_COMPARATOR|Sugarpill|150 patients with MRSA resistent Placebo daily 12 month
62273616|NCT01477931|EXPERIMENTAL|Wellbutrin XL|
62273617|NCT03814980|EXPERIMENTAL|Pilot Study|Participants will be shown how to use a mindful breathing software application. The software will be used for 1 week. At the end of the week, participants will evaluate the software.
62273618|NCT03602287|ACTIVE_COMPARATOR|2% lignocaine|In the Lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril, which would act as a control.
62636700|NCT04030169|EXPERIMENTAL|Experimental: MDMA-assisted psychotherapy|Two sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
62636701|NCT03892226||1, no myocardial injury|normal troponin level (hs-troponin T ≤ 99. percentile, i.e. 14ng/ml)
62636702|NCT03892226||2, chronic myocardial injury|elevated, but stable troponin level; (hs-troponin T\> 99. percentile and rise/fall ≤ 20% in the control)
62069071|NCT01998594|EXPERIMENTAL|Arthroplasty with HADM|Twent-five (25) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure with an interposition arthroplasty technique using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of three - five (3 - 5) similar subjects who received the arthroplasty procedure without the use of the HADM spacer.
62273619|NCT03602287|PLACEBO_COMPARATOR|Normal saline|In the Normal saline group, 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril.
62069072|NCT02145078|EXPERIMENTAL|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
62273620|NCT06095765|EXPERIMENTAL|Colchicine|Colchicine 0.5 mg oral once daily, in addition to SOC
62273621|NCT06095765|PLACEBO_COMPARATOR|Placebo|Placebo oral once daily, in addition to SOC
62273622|NCT01521273|EXPERIMENTAL|high iron bean with native phytic acid concentration|
62273623|NCT01521273|EXPERIMENTAL|normal iron bean with native phytic acid concentration|
62273624|NCT01521273|EXPERIMENTAL|high iron bean partially dephytinized|
62273625|NCT01521273|EXPERIMENTAL|normal iron bean partially dephytinized|
62636703|NCT03892226||3, acute myocardial injury|dynamic troponin elevation; (hs-troponin T\> 99. percentile and rise/fall \>20% in the control)
62069073|NCT01662531|EXPERIMENTAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
62069074|NCT00960674|EXPERIMENTAL|Tactile massage|A gentle form of massage given once a week for three weeks
62273626|NCT01521273|EXPERIMENTAL|high iron bean totally dephytinized|
62273627|NCT01521273|EXPERIMENTAL|normal iron bean totally dephytinized|
62273628|NCT06208020||LMS patients|The demographic characteristics will be collected, including sex, age, stroke duration, and lesion side; Penetration-aspiration (PAS) scale will be used to evaluate swallowing function. fNIRS will be used to detect changes in oxyhemoglobin (HbO) and deoxyhemoglobin (HbR) during rest and voluntary swallowing.
62273629|NCT06208020||healthy subjects|The demographic characteristics will be collected, including sex and age. fNIRS will be used to detect changes in oxyhemoglobin (HbO) and deoxyhemoglobin (HbR) during rest and voluntary swallowing.
62273630|NCT00394459|ACTIVE_COMPARATOR|A|Perifix Standard
62273631|NCT00394459|EXPERIMENTAL|B|Perifix New
62273632|NCT02247193|EXPERIMENTAL|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
62273633|NCT02247193|PLACEBO_COMPARATOR|Saline|Injection of normal saline into cleft lip at time of surgical repair.
62273634|NCT02344888|ACTIVE_COMPARATOR|Clomiphene citrate-Prednisolone group|Women will receive clomiphene citrate and prednisolone
62273635|NCT02344888|ACTIVE_COMPARATOR|Clomiphene citrate-placebo group|Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
62636704|NCT03414853||With algorithm use|
62636705|NCT03414853||No algorithm use|
62636706|NCT00908271|OTHER|Dapagliflozin|PO and IV
62636707|NCT00689338|EXPERIMENTAL|Treatment Group|Option to treat with oral azole therapy following treatment with anidulafungin
62636708|NCT05119127|EXPERIMENTAL|vivity toric IOL implantation arm|vivity toric intraocular lens will be implanted in one eye and undergo digital imaging intra op and post op to evaluate for toric intraocular lens rotational stability.
62636709|NCT00861666|OTHER|Forgiveness-based Writing|
62636710|NCT05184348|ACTIVE_COMPARATOR|Narrow band Ultraviolet B phototherapy group|Patients will be treated with Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose of 1400 mJ/cm2.
62273636|NCT06264115||Three ports Laparoscopic Cholecystectomy group|
62273637|NCT06264115||Four ports Laparoscopic Cholecystectomy group|
62273638|NCT03278132|EXPERIMENTAL|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
62636711|NCT05184348|ACTIVE_COMPARATOR|Acitretin group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally for 3 months
62069075|NCT00960674|EXPERIMENTAL|Relaxation|Relaxation (by the use of a CD with relaxation exercises used at least once a week for 10 weeks)
62069076|NCT02929550||Well-controlled cohort (LDL-C ≤ 1.8 mmol/L)|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation with well-controlled LDL-cholesterol
62636712|NCT05184348|ACTIVE_COMPARATOR|Acitretin plus Narrow band Ultraviolet B phototherapy group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally plus NB-UVB phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
62069077|NCT02929550||Non-controlled cohort|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation and with not well-controlled LDL-C
62069078|NCT01051063|EXPERIMENTAL|Partial Remission Group|Adult patients in partial remission post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
62069079|NCT01051063|EXPERIMENTAL|Complete Remission Group|Adult patients in complete remission with incomplete blood count recovery post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
62069080|NCT05833243|EXPERIMENTAL|Interventional Group|"Baseline measurement will be done in the rehabilitation center. Participants will receive modified diaphragmatic training using modified diaphragmatic training with increased load every week for strength training (60% from inspiratory muscle strength).~Weekly follow-up will be taken to reassure the respiratory muscle strength. Prescription for intervention will be determined based on the result of baseline measurement.~After 4 weeks post-intervention measurement will be taken."
62069081|NCT05833243|ACTIVE_COMPARATOR|Control Group|"Baseline measurement will be done in the rehabilitation center. Participants will receive standard diaphragmatic training using a sitting position.~Weekly follow-ups will be taken to remeasure the respiratory muscle strength and training procedure.~After 4 weeks post-intervention measurements will be taken."
62069082|NCT00764192|EXPERIMENTAL|1|14 HD patients are studied before and after a single HD using a polysulphone dialyser.
62069083|NCT00562978|EXPERIMENTAL|Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg|"* Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10\^6 /kg) proceed to radioimmunotherapy.~* Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~* Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~* AHSCT: Patients undergo reinfusion of PBSCs.~* Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
62069084|NCT00562978|EXPERIMENTAL|Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg|"* Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10\^6 /kg) proceed to radioimmunotherapy.~* Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~* Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~* AHSCT: Patients undergo reinfusion of PBSCs.~* Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
62069085|NCT05082142|EXPERIMENTAL|TXA intraoperatively|Patients will receive intraoperative 1g TXA during the HoLEP procedure.
62069086|NCT05082142|NO_INTERVENTION|No TXA intraoperatively|Patients will not receive intraoperative TXA during the HoLEP procedure.
62069087|NCT04944030|EXPERIMENTAL|SCLC (small cell lung cancer)|"At each disease progression, patient will have specific interventions :~* Metastasis biopsy~* Biomarkers blood, urine and microbiota samples~* Patient Reported Outcome (PRO)"
62069088|NCT04944030|EXPERIMENTAL|NSCLC (no small cell lung lung cancer) without oncogenic addiction:|"At each disease progression, patient will have specific interventions :~* Metastasis biopsy~* Biomarkers blood, urine and microbiota samples~* Patient Reported Outcome (PRO)"
62636713|NCT05184348|NO_INTERVENTION|Control group|30 healthy individuals un related , age, sex , BMI matched with volunteers.
62636714|NCT03161730|EXPERIMENTAL|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
62636715|NCT03161730|EXPERIMENTAL|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
62636716|NCT03161730|ACTIVE_COMPARATOR|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
62636717|NCT02315144|EXPERIMENTAL|TV48108 - Healthy Volunteers|Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg
62069089|NCT04944030|EXPERIMENTAL|NSCLC (no small cell lung lung cancer) with oncogenic addiction|"At each disease progression, patient will have specific interventions :~* Metastasis biopsy~* Biomarkers blood, urine and microbiota samples~* Patient Reported Outcome (PRO)"
62069090|NCT04378660|EXPERIMENTAL|Intervention arm|Colonoscopy with AI
62069091|NCT00885989|EXPERIMENTAL|1|
62636718|NCT02315144|PLACEBO_COMPARATOR|Placebo - Healthy Volunteers|Placebo
62636719|NCT02315144|EXPERIMENTAL|TV48108 15 µg COPD|Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.
62636720|NCT02315144|EXPERIMENTAL|TV48108 60 µg COPD|Stage 2
62636721|NCT02315144|EXPERIMENTAL|TV48108 120 µg COPD|Stage 2 .
62636722|NCT00874185||Questionnaire|filling in questionnaires
62636723|NCT03327324|EXPERIMENTAL|F1U1|Sequence 1 (Facility 1/Unit 1): Baseline, then 3 Month SLUMBER Intervention, then 39 Month Sustainability.
62636724|NCT03327324|EXPERIMENTAL|F1U2|Sequence 2 (Facility 1/Unit 2): Baseline, then 3 Month SLUMBER Intervention, then 33 Month Sustainability
62069092|NCT00885989|PLACEBO_COMPARATOR|2|
61978723|NCT06084403|ACTIVE_COMPARATOR|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
62069093|NCT05278052|ACTIVE_COMPARATOR|ARM A: Standard maintenance therapy alone|Maintenance systemic therapy/ observation
62069094|NCT05278052|EXPERIMENTAL|ARM B: Local consolidative radiation therapy (LCRT)|Radiation therapy to all oligometastatic sites including primary loco-regional disease
62069095|NCT05146960|EXPERIMENTAL|Temporal summation|"Temporal summation will be evoked in ECRL muscle origin, ECRB muscle belly, Brachioradialis. Pressure pain thresholds (PPTs) will be identified two times with a 30 s interval for each predetermined area. The average of two measurements will be used as a PPTs value. Temporal summation was induced two minutes after last PPTs was recorded. To evoke temporal summation at the lateral elbow, the probe will be applied with the pressure of the predefined PPT threshold at the rate of approximately 2 kg/s where it will be maintained for 1 s before being released with a 1 s interstimulus interval (ISI). This procedure will be repeated 10 times in each predetermined area. Pain intensity will be asked to participants at first, fifth and tenth pulse using a Visual Analog Scale range from 0 indicate no pain to 10 most painful"
62069096|NCT05146960|PLACEBO_COMPARATOR|Placebo|pressure pain threshold will be evaluated once in each predetermined region with a 30 second interval.
62069097|NCT04147182|EXPERIMENTAL|Patient with low grade TCC|"1. Patients of 18 years or older able to sign informed consent~2. A previous diagnosis of low grade bladder cancer~3. A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography) showing normal upper urinary tract in the 12 months prior to inclusion~4. Serum creatinine levels ≤ 2.0 mg/dl~5. Serum sodium levels \<146 mg/ml~6. Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months~7. Patient is candidate for TURBT"
62636725|NCT03327324|EXPERIMENTAL|F2U2|Sequence 3 (Facility 2/Unit 2): Baseline, then 3 Month SLUMBER Intervention, then 27 Month Sustainability
62069098|NCT04479605||Patients with advanced cancer|Patient and caregiver coaching is facilitated by a booklet titled Our Cancer Care (Appendices E \& F) that includes a Question Prompt List (QPL) and resources for a Values Affirmation Exercise (Appendices G \& H). The QPL and Values Affirmation Exercises will be provided with a cover letter (Appendix I). The QPL consists of example questions to discuss with oncologists about diagnosis, prognosis, treatments, symptom management, transitions in care, self-care, family needs, and life goals. Patients and caregivers meet over video-conferencing with a study interventionist for one hour to review the QPL. The interventionist makes three follow-up phone calls to each dyad bi-weekly to evaluate use of the QPL.
62069099|NCT04479605||Caregivers|Caregivers will participate in three 45-minute sessions with the interventionist over the telephone or video-conferencing (per caregiver preference) approximately bi-weekly. These sessions take place while the patient and caregiver are completing the three follow-up dyadic sessions. Efforts will be made to schedule the caregiver support sessions during weeks that fall between dyadic coaching sessions to minimize intervention burden on caregivers (i.e., avoiding scheduling two sessions for the caregiver in the same week).
62069100|NCT04479605||Oncologists|The Oncologist training will be conducted online using Bridge, an internet-based platform designed to facilitate communication between instructors and learners. The training includes written information on and videos demonstrating target communication skills (Table 1) and knowledge acquisition checks. Five of the online modules are required and the remaining six modules are optional. The required modules are estimated to take oncologists approximately one hour to complete; the optional modules are estimated to take 90 minutes total (i.e., for all modules) to complete. Oncologists' logging history will be tracked in Bridge.
62069101|NCT03108729|EXPERIMENTAL|eslicarbazepine acetate|elicarbazepine acetate, once daily flexible dosing
62454081|NCT05420051|ACTIVE_COMPARATOR|Motivational Interviewing|Each week, participants in the MI-alone group will complete an activity related to a health behavior (e.g., thinking about the pros and cons of changing the behavior), then complete a phone session with a study trainer. During the phone session, the trainer will (a) review the prior week's topic, (b) discuss techniques for improving adherence to health behaviors (e.g. tracking activity), and (c) problem-solve barriers and encourage the use of resources. Participants also will receive supplemental text messages throughout the 8 weeks of the intervention and during the initial follow-up period (Week 9-16).
62636726|NCT03327324|EXPERIMENTAL|F2U3|Sequence 4 (Facility 2/Unit 3): Baseline, then 3 Month SLUMBER Intervention, then 21 Month Sustainability
62636727|NCT03327324|EXPERIMENTAL|F2U4|Sequence 5 (Facility 2/Unit 4): Baseline, then 3 Month SLUMBER Intervention, then 15 Month Sustainability
62636728|NCT03327324|EXPERIMENTAL|F3U1|Sequence 6 (Facility 3/Unit 1): Baseline, then 3 Month SLUMBER Intervention, then 9 Month Sustainability
62636729|NCT00448214|EXPERIMENTAL|1|Low dose
62636730|NCT00448214|EXPERIMENTAL|2|Middle dose
62636731|NCT00448214|EXPERIMENTAL|3|High dose
62636732|NCT00448214|ACTIVE_COMPARATOR|4|
62636733|NCT04654715||Localized prostate cancer treatment induced rectourethral fistula|Every patient over 18 years old operated for closure of a rectourethral fistula with gracilis flap interposition after localized prostatic cancer treatment (Radiotherapy, surgery, cryotherapy and HIFU).
62069102|NCT06023004||Controls|Patients diagnosed with diverticulitis through CT scan and scheduled for a colonoscopy. The colonoscopy must result in no detection of colorectal cancer.
62636734|NCT04033978|EXPERIMENTAL|Cognitive remediation arm|Participants will be enrolled in a cognitive remediation group. The program will last 10 weeks and be composed of 10 participants. This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
62636735|NCT04033978|ACTIVE_COMPARATOR|Control group|Participants will be enrolled in an information control group. They will receive information about psychosocial rehabilitation and recovery process. The program lasts 10 weeks.
62636736|NCT00765856|EXPERIMENTAL|Oxymorphone ER|
62636737|NCT01999985|EXPERIMENTAL|Dose Escalation and Dose Expansion|"Dose escalation followed by dose expansion. Escalation cohort: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end.~Expansion cohort:: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B."
62069103|NCT06023004||Cases|Patients diagnosed with CRC immediately after an episode of diverticulitis.
62069104|NCT02721641|EXPERIMENTAL|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
62069105|NCT03918954|ACTIVE_COMPARATOR|Physical sensory room|In the inpatient ward there is a specifically designed room for calming down which a patient can request access to. In the room there is calming music, soft mats, nature themed wallpaper and calming visual lighting.
62454082|NCT02791100|NO_INTERVENTION|No promotion of chicken eggs|The community receives no chickens and therefore has no additional eggs or egg shell powder for children
62636738|NCT01089283||LRRK2 mutation|Parkinson patients that carry mutation on LRRK2 gene
62636739|NCT01089283||GBA mutation|Parkinson patients that carry mutation on GBA gene
62636740|NCT01089283||no mutation|Parkinson patients that don't carry mutation on LRRK2 or GBA genes
62636741|NCT01089283||healthy|Healthy volunteers
62069106|NCT03918954|EXPERIMENTAL|Virtual sensory room|The patients will have access to wireless virtual reality glasses during a session. The glasses will have a specially made protection that will be disinfected between each user, all users will also have the opportunity to choose a disposable cover for the glasses. The VR glasses are adjustable and adaptable to all types of head sizes and can be used with regular glasses. The application accessable in the VR glasses is called Calm Place, a virtual natural environment with day and night cycles, dynamic weather and associated soundscapes.
62636742|NCT04967807|OTHER|Cohort A - Symptomatic|Those with clinical findings suggestive of myocarditis/myocardial injury after COVID-19 vaccination
62636743|NCT04967807|OTHER|Cohort B - Asymptomatic|Those without signs or symptoms suggestive of myocarditis after COVID-19 vaccination
62636744|NCT02830412|EXPERIMENTAL|PONV Reminder|After patient has non-cardiac surgery, the subject will have Post-Operative Nausea and Vomiting Reminder display
62636745|NCT02830412|NO_INTERVENTION|No PONV Reminder|After patient has non-cardiac surgery, the subject will not have Post-Operative Nausea and Vomiting Reminder display
62636746|NCT03669549|EXPERIMENTAL|Nevanimibe hydrochloride|Ascending dose level of oral nevanimibe hydrochloride beginning with 500 mg BID up to 2000 mg BID
62069107|NCT04855110|ACTIVE_COMPARATOR|Day 2 warfarin group|warfarin will be administered on day 2 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
62069108|NCT04855110|ACTIVE_COMPARATOR|Day 5 warfarin group|warfarin will be administered on day 5 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
62069109|NCT05437822|EXPERIMENTAL|TXA group|Tranexamic acid, a topic dose of 2 g diluted in 50 mL saline solution infused in shoulder joint
62069110|NCT05437822|NO_INTERVENTION|Control group|In the control group will not be administered TXA or any other drugs.
62636747|NCT03924388|EXPERIMENTAL|Short-term transcutaneous spinal cord stimulation|"In Project 1, we will measure the immediate effects of one-hour mid-thoracic and/or lumbosacral transcutaneous stimulation on autonomic function.~In mid-thoracic stimulation, the self-adhesive cathode electrode with a diameter of 30 mm will be placed on the skin between the TVII and TVIII spinous processes (approximately corresponding to the T8 spinal segment) at the midline over the vertebral column. For lumbosacral stimulation, the cathode will be placed on the skin between the LI and LII spinous processes (approximately corresponding to the L2/3 to S4/5) at the midline over the vertebral column. Two self-adhesive anode electrodes with a size of 5 × 9 cm will be symmetrically located on the skin over the iliac crests. Before and immediately after the stimulation, the outcomes will be measured in 2 positions, supine and \~ 70° upright (adjusted by tilt-up table)."
62636748|NCT03924388|EXPERIMENTAL|Long-term transcutaneous spinal cord stimulation|"In Project 2, we will measure the effects of one-month stimulation (five one-hour stimulation sessions per week) of mid-thoracic and lumbosacral transcutaneous spinal cord stimulation on autonomic function.~The electrode placement and duration of stimulation will be identical to Project 1. The outcomes at each time point will be measured in two positions, supine and \~ 70° upright (adjusted by tilt-up table). The cardiovascular outcomes will be measured before, after the last stimulation session. Bladder and bowel function will be assessed weekly."
62069111|NCT00318149|EXPERIMENTAL|Fluarix 18-40 Y Group|Subjects (aged 18-40 years \[Y\]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
62069112|NCT00318149|EXPERIMENTAL|Fluarix ≥65 Y Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
62636749|NCT03924388|EXPERIMENTAL|Project 3|For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.
62636750|NCT03832647|EXPERIMENTAL|Salicylic acid & Epiduo 0.1%-2.5% Topical Gel|"Salicylic acid: Once-a-day, on the morning, during 12 weeks.~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
62069113|NCT00318149|EXPERIMENTAL|Fluarix-AS25 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.
62069114|NCT00318149|EXPERIMENTAL|Fluarix-AS50 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.
62636751|NCT03832647|PLACEBO_COMPARATOR|Hydréane légère & Epiduo 0.1%-2.5% Topical Gel|"Hydréane légère: Once-a-day, on the morning, during 12 weeks.~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
62069115|NCT00318149|EXPERIMENTAL|Fluarix- AS01B Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.
62069116|NCT00318149|EXPERIMENTAL|Fluarix- AS01E Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.
62069117|NCT02340754|EXPERIMENTAL|Mindfulness-base Stress Reduction|Mindfulness-based stress reduction is a formalized, experiential, 8-week stress-management program. Participants attend weekly two-hour classes and a half-day retreat during which they learn mindfulness meditation, breath work, yoga postures, self-reflection and awareness.
62069118|NCT02340754|ACTIVE_COMPARATOR|MS Education Control|The MS Education Control program is matched to MBSR for time and attention yet has no overlap with intervention content. Each two-hour class uses a pamphlet published by the National MS Society to present information about a different MS topic such as Fatigue; Bowel and Bladder Problems; Diet; Spasticity; and Nutritional Supplementation: Vitamins, Minerals, and Herbs.
62069119|NCT04249219|EXPERIMENTAL|E-Cigarette Ads|All individuals in the study will see the same e-cigarette advertisements presented in a random order.
62069120|NCT01356667|ACTIVE_COMPARATOR|Treatment-As-Usual|Substance Abuse treatment typically received
62069121|NCT01356667|EXPERIMENTAL|DARTNA|12-week DARTNA program
62069122|NCT06438419|EXPERIMENTAL|Recruited patient|Patient with idiopathic Parkinson's disease and having a STN DBS with a PERCEPT™ for less than a year or being candidate for subthalamic nucleus deep brain stimulation with the PERCEPT™ device (first-implantation)
62069123|NCT04932005|EXPERIMENTAL|DZD2269|This study includes two parts. In Part A, a single dose of DZD2269 at different dose levels will be given. In Part C, DZD2269 at selected dose levels will be given twice daily for 7 days.
62069124|NCT04932005|PLACEBO_COMPARATOR|Placebo|In Part A, a single oral dose of placebo will be given. In Part C, placebo will be given twice daily for 7 days.
62069125|NCT02827942|EXPERIMENTAL|Dual therapy|Patients assigned to this group are treated with dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week. The eradication rate attained with this regimen is measured.
62069126|NCT02827942|ACTIVE_COMPARATOR|Triple therapy|Patients assigned to this group are treated with the triple therapy with vonoprazan 20 mg bid, clarithromycin 200 mg bid and amoxicillin 750 mg bid for 1 week as the first line therapy or the triple therapy with vonoprazan 20 mg bid, metronidazole 250 mg bid and amoxicillin 750 mg bid for 1 week as the second line therapy. The eradication rates attained with these regimens are measured.
62069127|NCT03141710|EXPERIMENTAL|12 type 2 diabetes patients|Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
62069128|NCT03609554|EXPERIMENTAL|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
62636752|NCT05704855|EXPERIMENTAL|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) items each week. Participants will also participate in bi-weekly, 30-40 minute, remotely-delivered behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). The program will be taught by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
62636753|NCT05704855|ACTIVE_COMPARATOR|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
62069129|NCT03609554|NO_INTERVENTION|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
62069130|NCT00098163|EXPERIMENTAL|1|
62069131|NCT00098163|PLACEBO_COMPARATOR|2|
62273639|NCT03278132|EXPERIMENTAL|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
62636754|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:~* The Mologic Biomarker Panel~* PCT~* CRP~* Other inflammatory markers or pathogen detection that may augment the panels accuracy~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
62636755|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:~* Patients being managed for potential infection~* Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
62636756|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
62636757|NCT02727049|EXPERIMENTAL|injured athlete for OMM|Participating athletes who sustain an injury will receive standard of care with the Intervention osteopathic manipulative medicine (OMM)
62069132|NCT01486602|EXPERIMENTAL|Concurrent therapy + consolidation therapy|"Concurrent Therapy (1 cycle = 14 days, Cycles 1-3): Patients will receive paclitaxel 45 mg/m\^2 by IV over 1 hour weekly followed by carboplatin AUC 2 by IV over 30-60 minutes for 4 weeks (there will be no chemotherapy during Cycle 3). Patients will receive radiotherapy concurrently for up to 5.5 weeks, depending on the cohorts the patient is registered defined per the protocol.~Consolidation Therapy (1 cycle = 21 days, Cycles 4-5): Four weeks following the end of radiotherapy patients will receive paclitaxel 200 mg/m\^2 by IV over 3 hours followed by carboplatin AUC 6 by IV over 30-60 minutes on day 1 of each 21 day cycle for a total of 2 cycles (days 1 and 22)."
62636758|NCT02727049|NO_INTERVENTION|injured athlete no OMM|Participating athletes who sustain an injury will receive standard of care withOUT osteopathic manipulative medicine (OMM)
62069133|NCT01798186|EXPERIMENTAL|Cannabis 5% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 5% THC and in a room with no ventilation.
62069134|NCT01798186|EXPERIMENTAL|Cannabis 11% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC and in a room with no ventilation.
62069135|NCT01798186|EXPERIMENTAL|Cannabis 11% THC, Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC in a room with active ventilation.
62069136|NCT02461927|EXPERIMENTAL|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular naltrexone once a month (a total of 2 injections).
62069137|NCT02461927|EXPERIMENTAL|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
62069138|NCT02461927|PLACEBO_COMPARATOR|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous placebo treatment (psychoactive placebo midazolam) once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
62069139|NCT04078035|EXPERIMENTAL|Socio-evaluative Speech Stress, then Control|Participants will attend two laboratory sessions. At the first session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated. At the second session, participants will rest quietly for the same period as the speech task, in the absence of the stressor.
62069140|NCT04078035|EXPERIMENTAL|Control, then Socio-Evaluative Speech Stress|Participants will attend two laboratory sessions. At the first session, participants will rest quietly for 5 minutes. At the second session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated.
62636759|NCT05237115|EXPERIMENTAL|Clostridium butyricum group|given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
62273640|NCT03278132|EXPERIMENTAL|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
62273641|NCT00495651|ACTIVE_COMPARATOR|I|Standard of care
62273642|NCT00495651|EXPERIMENTAL|II|Standard of care+Isoniazid Prophylaxis:
62273643|NCT00495651|EXPERIMENTAL|III|Early Antiretroviral therapy
62636760|NCT05237115|EXPERIMENTAL|Bacillus clotting group|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
62636761|NCT05237115|ACTIVE_COMPARATOR|bismuth quadruple therapy|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
62636762|NCT03502538|EXPERIMENTAL|Curaprox 5460 Ultra Soft|Brushing with a Curaprox Ultra Soft 5460 toothbrush for one minute timed without orientations about brushing techniques and without supervision
62273644|NCT00495651|EXPERIMENTAL|IV|Early Antiretroviral therapy + Isoniazid prophylaxis
62273645|NCT05269290|EXPERIMENTAL|Ingavirin®, syrup, 30 mg/5 ml|Ingavirin®, syrup, 30 mg/5 ml will be administered on top of standard therapy
62273646|NCT05269290|PLACEBO_COMPARATOR|Placebo|Placebo will be administered on top of standard therapy
62636763|NCT03502538|ACTIVE_COMPARATOR|Oral-B Indicator Plus|Brushing with a Oral-B Indicator Plus toothbrush for one minute timed without orientations about brushing techniques and without supervision
62636764|NCT01142934|OTHER|TegaDerm CHG|TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).
62273647|NCT00612443|EXPERIMENTAL|1|non-contact Healing Touch treatment for 20-30 minutes once a week during the course of radiation therapy
62273648|NCT00612443|SHAM_COMPARATOR|2|A RN graduate assistant will provide a sham treatment of 20-30 minutes of presence.
62273649|NCT00855114|EXPERIMENTAL|Patients Treated with Everolimus|Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.
62273650|NCT00887393|OTHER|Low carbohydrate|Low carbohydrate pre-bariatric surgery diet
62273651|NCT00887393|OTHER|Low fat|Low fat pre-bariatric surgery diet
62273652|NCT04799587|ACTIVE_COMPARATOR|P6 Accupressure Group|The pressure point will be stimulated by the presence of the magnet when positioned properly on the P6 acupressure point. Additional pressure may be applied as desired by the study subject but is not necessary for P6 stimulation.
62273653|NCT04799587|SHAM_COMPARATOR|Sham Pressure Point|The sham pressure point (distal to the P6 acupressure point).
62273654|NCT05460039|NO_INTERVENTION|Usual activities|This group will receive no intervention.
62273655|NCT05460039|EXPERIMENTAL|DanceMove|This group will perform dance sessions mediated by technology (a dance mat and a web platform).
62273656|NCT03175549|ACTIVE_COMPARATOR|Apremilast (Otezla)|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
62273657|NCT03175549|PLACEBO_COMPARATOR|Placebo|Identical placebo pills taken orally for 14 days
62273658|NCT01441752|EXPERIMENTAL|Chemotherapy + TCM group|"The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.~Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number."
62273659|NCT01441752|PLACEBO_COMPARATOR|Chemotherapy + placebo group|The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
62273660|NCT02307370|EXPERIMENTAL|Turbo-Elite Atherectomy|
62273661|NCT01785134|SHAM_COMPARATOR|Control|Gastric bypass operation without omentectomy.
62273662|NCT01785134|ACTIVE_COMPARATOR|Omentectomy|Gastric bypass operation in conjunction with removal of greater omentum
62273663|NCT03152682|EXPERIMENTAL|Consume GoodIdea at Visit 2 and Placebo at Visit 3|
62273664|NCT03152682|EXPERIMENTAL|Consume Placebo at Visit 2 and GoodIdea at Visit 3|
62273665|NCT00581295||trauma|Diffuse optical spectroscopy measurment
62273666|NCT02001376|EXPERIMENTAL|Intensive exercise & home exercise|Intensive exercise group Home exercise group
62273667|NCT02001376|EXPERIMENTAL|Intensive exercise & control|Intensive exercise group Control group
62273668|NCT02001376|EXPERIMENTAL|Home exercise & control group|Home exercise Control group
62273669|NCT02872623|EXPERIMENTAL|experimental group|patients clinically suspected of having a tumor of the small intestine
62273670|NCT01405261|EXPERIMENTAL|NNC 0113-0987 (gastro)|
62273671|NCT01405261|EXPERIMENTAL|NNC 0113-987 (coated)|
62273672|NCT01405261|EXPERIMENTAL|NNC 0113-987 (i.v)|
62636765|NCT03898193|OTHER|Sequence Test-Reference (TR)|17 participants (total number of enrolled volunteers - 34) assigned to sequence TR will receive a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 1 and a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62273673|NCT06377826|ACTIVE_COMPARATOR|aerobic exercises|Aerobic exercises i-e treadmill walking, bicycle ergometer, Treadmill
62273674|NCT06377826|EXPERIMENTAL|resistance training|resistance exercise training gluteal bridge, calf raises, squats, seated shoulder press,
62273675|NCT06377826|PLACEBO_COMPARATOR|medication|only on drugs no exercise is given
62273676|NCT01487759|ACTIVE_COMPARATOR|Prebiotic|
62273677|NCT01487759|PLACEBO_COMPARATOR|Placebo|
62273678|NCT01065688|ACTIVE_COMPARATOR|Roux-en Y|Roux-en Y reconstruction after distal gastrectomy
62273679|NCT01065688|EXPERIMENTAL|Billroth-I|Billroth-I reconstruction after distal gastrectomy
62273680|NCT05639972|EXPERIMENTAL|E7 TCR-T cells|Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.
62273681|NCT06045338|EXPERIMENTAL|Mind Body Intervention #1|
62273682|NCT06045338|ACTIVE_COMPARATOR|Mind Body Intervention #2|
62273683|NCT06045338|NO_INTERVENTION|Usual Care|
62273684|NCT04093531|EXPERIMENTAL|Ustekinumab|All subjects will receive an intravenous loading dose of 6 mg/kg at their baseline visit. 650mg acetaminophen and 60mg allegra will be given as premedication to the infusion. All patients will receive 90mg ustekinumab by a subcutaneous injection at all subsequent dosing visits. Subcutaneous injections do not require any premedication. Drug will be administered by qualified personnel.
62273685|NCT00584194|EXPERIMENTAL|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to \< 1:40.
62273686|NCT00640328|EXPERIMENTAL|Cohort 1.1|100mg ofatumumab then placebo
62273687|NCT00640328|EXPERIMENTAL|Cohort 1.2|placebo then 100mg ofatumumab
62273688|NCT00640328|EXPERIMENTAL|Cohort 2.1|300mg ofatumumab then placebo
62273689|NCT00640328|EXPERIMENTAL|Cohort 2.2|placebo then 300mg ofatumumab
62273690|NCT00640328|EXPERIMENTAL|Cohort 3.1|700mg ofatumumab then placebo
62273691|NCT00640328|EXPERIMENTAL|Cohort 3.2|placebo then 700mg ofatumumab
62273692|NCT04161131|EXPERIMENTAL|ONBOARD Intervention|ONBOARD consists of four 60-minute sessions over 3 months. Each session will target a key barrier to CGM use: physical, data, social, and trust. Sessions will be delivered individually to participants by a doctoral level psychologist with diabetes expertise. Each session will include relevant first-person digital stories told adults to with T1D, recounting how they managed relevant CGM barriers.
62069141|NCT03965819|EXPERIMENTAL|Randomized to consume Pain Bloc-R, Acetaminophen, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Investigational Natural Health Product in Study Period 1, Comparator in Study Period 2, and Placebo in Study Period 3.
62069142|NCT03965819|EXPERIMENTAL|Randomized to consume Acetaminophen, Placebo, then Pain Bloc-R|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Comparator in Study Period 1, Placebo in Study Period 2, and the Investigational Product in Study Period 3.
62273693|NCT00006089|EXPERIMENTAL|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62273694|NCT01002378|EXPERIMENTAL|Arm 1|
62273695|NCT01002378|EXPERIMENTAL|Arm 2|
62273696|NCT01002378|EXPERIMENTAL|Arm 3|
62273697|NCT03861676|EXPERIMENTAL|Focal brachytherapy|"Drug: 18F-DCFPyl Other names: PET, PSMA~Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy"
62273698|NCT03413020|EXPERIMENTAL|Tailored Therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.
62273699|NCT06394687|ACTIVE_COMPARATOR|MPC/FP to MCI/SP|Participants ingest the MPC/FP protein product for their first intervention period, then MCI/SP for their second intervention period.
62273700|NCT06394687|ACTIVE_COMPARATOR|MCI/SP to MPC/FP|Participants ingest the MCI/SP protein product for their first intervention period, then MPC/FP for their second intervention period.
62273701|NCT00465959|EXPERIMENTAL|400 mg TrIP|
62273702|NCT00465959|EXPERIMENTAL|800 mg TrIP|
62273703|NCT00465959|PLACEBO_COMPARATOR|Placebo|
62273704|NCT02799069|ACTIVE_COMPARATOR|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
62069143|NCT03965819|EXPERIMENTAL|Randomized to consume Placebo, Pain Bloc-R, then Acetaminophen|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Investigational Product in Study Period 2, and Comparator in Study Period 3.
62636766|NCT03898193|OTHER|Sequence Reference-Test (RT)|17 participants (total number of enrolled volunteers - 34) assigned to sequence RT will receive a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 1 and a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62273705|NCT02799069|ACTIVE_COMPARATOR|MAL Cream|Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
62273706|NCT02799069|PLACEBO_COMPARATOR|Vehicle|Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
62273707|NCT01992887||In-depth Interview|Up to 20 in-depth interviews will be conducted among adult ART naïve patients, balanced by gender, site and reason for ART naiveté (determined ineligible or eligibility not yet determined) as much as possible. Up to 4 in-depth interviews will be conducted with health care providers.
62273708|NCT01992887||Focus Group Participants|Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
62273709|NCT01992887||Prospective Cohort|Based on historical patient data from the four study CTCs, we expect that approximately 1,000 patients will enroll in HIV care at these clinics during the study period and be determined not eligible for ART or of unknown eligibility. Assuming a 10% refusal rate, approximately 900 patients would then enroll in this study and complete baseline interviews. These 900 patients will be prospectively monitored using routinely collected patient care data for up to 24 months. Outreach workers will attempt to trace all of the enrolled patients who are observed to be LTF during the study period, and complete a defaulter tracing survey.
62273710|NCT06212245|EXPERIMENTAL|Inebilizumab|Participants will receive IV inebilizumab 300 mg
62636767|NCT02089048|EXPERIMENTAL|Cohort 1|15 subjects receive 6mg of auranofin once every 24 hours for 7 days
62636768|NCT03590171|NO_INTERVENTION|Arm HR-A|Induction: Backbone ALL R3
62069144|NCT00965835||DS|Those with Down syndrome
62069145|NCT00965835||Non-DS|Healthy controls
62069146|NCT02349464|ACTIVE_COMPARATOR|Intervention|For infants receiving pediatric care at one of the seven intervention practices, mothers will receive the Specialized Preterm Infant/Mother Dyad Lactation Support which includes home equipment and pediatric clinic-lactation support to support lactation for four months post-hospital discharge.
62069147|NCT02349464|NO_INTERVENTION|Control|For infants receiving pediatric care at one of the seven control practices, mothers will receive standard support.
62636769|NCT03590171|EXPERIMENTAL|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
62636770|NCT00938353|EXPERIMENTAL|BDP UDV|
62069148|NCT03709290||1st group|30 patients were diagnosed with MS according to revised MacDonald's criteria 2017 \& collected from Neuropsychiatry department in Assuit university hospital
62069149|NCT03709290||2nd group|30 healthy volunteers subjects matched with age, sex \& education level were recruited from outpatient clinic neuropsychiatry department and included only if they had no current or previous history of any neurological illness and their neurological examination was free
62069150|NCT01732146|ACTIVE_COMPARATOR|Erythropoietin beta|1000 to 1500 U/kg/dose X 3 every 24 hours
62069151|NCT01732146|PLACEBO_COMPARATOR|Placebo|0.2 ml saline solution X 3 given every 24 hours
62273711|NCT03448588||group with normal T4 level or T4/T3|participants with T4 within 4.3-12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) ≤7.52, which are considered to be normal T4 level and T4/T3.
62273712|NCT03448588||group with elevated T4 level or T4/T3|participants with T4 more than 12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) \> 7.52, which are considered to be elevated T4 level and T4/T3.
62273713|NCT01428817|ACTIVE_COMPARATOR|Carbetocin 20mcg|
62069152|NCT04733196|EXPERIMENTAL|Essential oils|Mouthwash based on essential oils - menthol, eucalypts oil, thymol, alcohol
62069153|NCT04733196|EXPERIMENTAL|Essential oils in combination with clorhexidine 0,12%|Mouthwash based on essential oils - mentol, eucalypt oil, thymol, alcohol, and 0,12% chlorhexidine
62069154|NCT04733196|PLACEBO_COMPARATOR|Placebo mouthwash|Water, colorant, sweetener
62273714|NCT01428817|ACTIVE_COMPARATOR|Carbetocin 40mcg|
62273715|NCT01428817|ACTIVE_COMPARATOR|Carbetocin 60mcg|
62273716|NCT01428817|ACTIVE_COMPARATOR|Carbetocin 80mcg|
62273717|NCT01428817|ACTIVE_COMPARATOR|Carbetocin 100mcg|
62636771|NCT00938353|PLACEBO_COMPARATOR|Placebo|
62069155|NCT04733196|EXPERIMENTAL|Clorhexidine 0,20% in combination with aroma oils|Mouthwash based on 0,20% chorhexidine without alcohol in combination with aroma oils of rose and lavender
62273718|NCT02751840|EXPERIMENTAL|Caffeine|Caffeine capsule (200 mg) is taken prior to RMR measurement
62273719|NCT02751840|PLACEBO_COMPARATOR|Placebo|Placebo (starch) capsule is taken prior to RMR measurement
62273720|NCT02751840|EXPERIMENTAL|Coffee|Black coffee (9 grams) is consumed prior to RMR measurement
62636772|NCT05794815|EXPERIMENTAL|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
62636773|NCT05794815|PLACEBO_COMPARATOR|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
62636774|NCT00606307|EXPERIMENTAL|ITF2357|Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity.
62069156|NCT04733196|EXPERIMENTAL|Prebiotic|Mouthwash based on prebiotic
62069157|NCT04733196|EXPERIMENTAL|Hydrogen peroxide|Mouthwash based on 0,8% hydrogen peroxide in combination with menthol and eucalypts oil
62069158|NCT03605160|ACTIVE_COMPARATOR|traditional group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents. All operations are videotaped during the whole operation. The total polish time is recorded as the time of all polish procedures.
62273721|NCT02751840|PLACEBO_COMPARATOR|Decaffeinated|Decaffeinated Black coffee (9 grams) is consumed prior to RMR measurement
62088284|NCT02419547|OTHER|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
62273722|NCT01411748|EXPERIMENTAL|S. boulardii|The patients in this group will be given 5 million unit/day S. boulardii until discharge.
62273723|NCT01411748|ACTIVE_COMPARATOR|nystatin|
62273724|NCT01816581|ACTIVE_COMPARATOR|Targin/OxyNorm|Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
62273725|NCT01816581|ACTIVE_COMPARATOR|PCA|Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
62273726|NCT01780025||Mixed hearing loss|
62273727|NCT03686397|EXPERIMENTAL|SVT-15652|1 vial twice daily
62636775|NCT00308789|EXPERIMENTAL|1|Biphasic NCPAP
62636776|NCT00308789|ACTIVE_COMPARATOR|2|Continuous CPAP
62636777|NCT06467604||Semaglutide|eligible patients who are prescribed semaglutide for their obesity-management
62273728|NCT03686397|PLACEBO_COMPARATOR|Placebo|1 vial twice daily
62273729|NCT02822066|EXPERIMENTAL|IRE for refractory neoplasms in liver and pancreas|To evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.
62273730|NCT03640039|EXPERIMENTAL|study group: 3d strut plate fixation without post op IMMF.|Open reduction and internal fixation with 3d strut plate without post operative IMMF.
62273731|NCT03640039|ACTIVE_COMPARATOR|control group: 3d srut plate fixation with post op IMMF.|Open reduction and internal fixation with 3d strut plate with post operative IMMF for 15 days.
62636778|NCT06467604||Tirzepatide|eligible patients who are prescribed tirzepatide for their obesity-management
62636779|NCT04144959||Patients with lower extremity acute limb ischemia|
62636780|NCT05429671|ACTIVE_COMPARATOR|Group A (Control-negative group)|include participants undergoing total knee arthroplasty with Stryker Surgical Simplex P cement containing no antibiotic
62636781|NCT05429671|ACTIVE_COMPARATOR|Group B (tobramycin group)|includes participants undergoing total knee arthroplasty with Stryker Surgical Simplex P cement with tobramycin antibiotic.
62636782|NCT05429671|ACTIVE_COMPARATOR|Group C (gentamicin group)|Include participants undergoing total knee arthroplasty with Huraeus Palacos R+G cement containing gentamicin antibiotic.
62273732|NCT04741724|EXPERIMENTAL|transcutaneous electrical diaphragmatic stimulation (TEDS)|"Subjects received daily TEDS (30min/day, 5days/week ) until the end of the weaning trial.~During TEDS, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was performed by applying biphasic waves at a stimulation frequency of 30 Hz, pulse width of 400 μs. TEDS intensity was gradually increased until visible muscle contraction was observed. Each session lasts for 30 min day."
62636783|NCT05429671|ACTIVE_COMPARATOR|Group D (Control-positive group)|Include participants undergoing the first of a two-stage exchange arthroplasty for confirmed infection, using an antibiotic-loaded cement spacer. These patients will have a spacer implant made of vancomycin and tobramycin antibiotics using Huraeus Palacos non-antibiotic loaded cement
62636784|NCT06090968|EXPERIMENTAL|Umbilical cord milking|20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds
62636785|NCT06090968|ACTIVE_COMPARATOR|Immediate cord clamping|clamping the umbilical cord as soon as possible (average 30 seconds)
62636786|NCT01591798|EXPERIMENTAL|Robotic surgery|Proctectomy using robot
62273733|NCT04741724|NO_INTERVENTION|Control group|Subjects in the control group did not received TEDS program. Subjects in the control group received the same pre- and post-measurement as those in TEDS group. The control group received medical treatment as those in TEDS group. The pulmonary function was measured at the beginning and end of the intervention.
62636787|NCT01591798|ACTIVE_COMPARATOR|Laparoscopic surgery|Conventional laparoscopic rectal resection
62636788|NCT04483466|EXPERIMENTAL|Treatment with methotrexate|100 participants will be treated with methotrexate
62636789|NCT04483466|PLACEBO_COMPARATOR|Placebo methotrexate|50 will receive placebo
62636790|NCT00877318|NO_INTERVENTION|Control|Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
62636791|NCT00877318|EXPERIMENTAL|telemedicine|Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months
62636792|NCT04987463|EXPERIMENTAL|Vigabatrin arm|Vigabatrin in capsules co-administered with placebo in liquid.
62636793|NCT04987463|EXPERIMENTAL|Rapamycin arm|Rapamycin in liquid co-administered with placebo in capsules.
62636794|NCT02752672||Psoriasis|Psoriasis patients treated with dithranol
62273734|NCT06233071|EXPERIMENTAL|Sequence 1-Drospirenone+ Ethinyl Estradiol test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) test product, treatment 2= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) reference product.
62273735|NCT06233071|EXPERIMENTAL|Sequence 2-Drospirenone+ Ethinyl Estradiol reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) test product, treatment 2= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) reference product.
62273736|NCT02085993||single arm|single arm study
62273737|NCT03023943|EXPERIMENTAL|IASTM group|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
62273738|NCT05105178|EXPERIMENTAL|Orientation|Information of orientation (time, place, patient's own name) is repeatedly provided during emergence.
62636795|NCT02752672||Non-Psoriasis|Non-Psoriasis patients undergoing surgery for skin lesions. Tumor-adjacent skin is collected for control purposes.
62636796|NCT03800316|EXPERIMENTAL|Synchronous Video Consultation|Testing the feasibility of a synchronous video consultation in the field prior to emergency department arrival.
62636797|NCT00632567|EXPERIMENTAL|1|caesarean section
62636798|NCT00632567|ACTIVE_COMPARATOR|2|vaginal delivery
62273739|NCT05105178|ACTIVE_COMPARATOR|Name|As usual, patient is recovered from general anesthesia with his/her name called.
62273740|NCT05381246|EXPERIMENTAL|Acupressure group|A total of 18 minutes of compression will be applied to each point for three minutes, as the Heart Meridian is at the 7th point (HT7), the Large Intestine Meridian is at the 4th point (LI4) and the pericardial meridian is at the 6th point (PC6).
62636799|NCT05923918|EXPERIMENTAL|test 1|PBK_M2101, 2-Day Regimen
62636800|NCT05923918|EXPERIMENTAL|test 2|PBK_M2101, 1-Day Regimen
62636801|NCT05923918|ACTIVE_COMPARATOR|active Comparator|active Comparator, 2-Day Regimen
62273741|NCT05381246|EXPERIMENTAL|Reiki group|In the reiki group the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
62273742|NCT05381246|NO_INTERVENTION|Control group|
62273743|NCT05043467||Duvie(Lobeglitazone)|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
62273744|NCT04358679|ACTIVE_COMPARATOR|Conventional Treatment|Conventional Treatment: Deep breathing, Assisted coughing, Sustained stretching, Splinting, Bracing and Functional mobility
62273745|NCT04358679|EXPERIMENTAL|Upper Limb ergometer training|Conventional Treatment + Upper Limb (UL) ergo-meter exercise
62273746|NCT05489978|EXPERIMENTAL|Intervention Arm|"Randomization will allocate women to intervention and control arm in 1:1 ratio; with 6 wards in each group. The intervention arm will consist of 153 women who will receive Cervical Cancer Stigma Reduction Intervention."
62273747|NCT05489978|NO_INTERVENTION|Control Arm|The control arm will consist of 153 women who would not be given any intervention.
62273748|NCT01212185|PLACEBO_COMPARATOR|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin.
62636802|NCT02221648|PLACEBO_COMPARATOR|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
62636803|NCT02221648|ACTIVE_COMPARATOR|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
62636804|NCT01252771|EXPERIMENTAL|PKM report and algorithm|Phosphate kinetic modeling was performed and displayed in graphical form laboratory results and an estimated phophorus protein ratio
61978724|NCT06084403|ACTIVE_COMPARATOR|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
62636805|NCT06122389|EXPERIMENTAL|Treatment group A|
62636806|NCT06122389|EXPERIMENTAL|Treatment group B|
62636807|NCT05861414|EXPERIMENTAL|Experimental group|21 days of emotional working memory training
62636808|NCT05861414|NO_INTERVENTION|control group|
62636809|NCT02365935|EXPERIMENTAL|Group A to administer 4 cycles|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
62636810|NCT02365935|EXPERIMENTAL|Group B to administre 6 cycles|In Group B, all patients received instead 6 cycles of adjuvant chemotherapy every three weeks according to the same chemotherapic regimen.
62636811|NCT01804517||Physician based approach|Patients will be managed as usual at the clinic without the intervention of the nurse.
62273749|NCT01212185|EXPERIMENTAL|intranasal oxytocin spray|Twice daily intranasal oxytocin spray
62636812|NCT01804517||Physician and nurse|Patients will be managed with the help of the nurse for education and follow-up.
62273750|NCT00316563|ACTIVE_COMPARATOR|1|
62273751|NCT00316563|PLACEBO_COMPARATOR|2|
62273752|NCT01515774|ACTIVE_COMPARATOR|Group 1|Give QD dose first then BID dosing
62636813|NCT02717728|ACTIVE_COMPARATOR|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
62636814|NCT02717728|SHAM_COMPARATOR|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
62273753|NCT01515774|ACTIVE_COMPARATOR|Group 2|Give BID dosing and then QD dosing
62273754|NCT00697567|EXPERIMENTAL|Group A|HSV seropositive subjects
62273755|NCT00697567|EXPERIMENTAL|Group B|HSV seronegative subjects
62273756|NCT00697567|EXPERIMENTAL|Group C|HSV seropositive subjects
62273757|NCT00697567|EXPERIMENTAL|Group D|HSV seronegative subjects
62273758|NCT00528762||Focus Group|Mexican American or African American females (aged 6-12 years old) and their parents
62273759|NCT03187665||1-6 years|12 subjects in the age range of 1-6 years old.
62273760|NCT03187665||6-10 years|12 subjects in the age range of 6-10 years old.
62273761|NCT03187665||11-17 years|12 subjects in the age range of 11-17 years old.
62273762|NCT03025958|EXPERIMENTAL|Nimotuzumab|Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).
62273763|NCT04124146||Patients with Surgery more than 10 years|Patients with surgery for spinal lumbar stenosis between 2006 and 2008 will be purposed to participate to the study.
62273764|NCT02518009||Men with gender dysphoria|Genetic men treated with estrogen
62273765|NCT02518009||Women with gender dysphoria|Genetic women treated with androgen
62273766|NCT03034395|OTHER|Wide Local Excision 1cm|
62273767|NCT03034395|OTHER|Wide Local Excision 2cm|
62273768|NCT02618304|EXPERIMENTAL|moderate to severe meibomian gland dysfunction|
62273769|NCT01870154|EXPERIMENTAL|Intervention group|The intervention consists of 16 hours of training, to be held at the subject's health center. The workshop involves mixed learning, comprising 4 sessions, each 2 hours long, in addition to personal work previous to and after each session of reading relevant bibliography and performing exercises, self-evaluation, and case studies (8 hours of individual work).
62273770|NCT01870154|ACTIVE_COMPARATOR|Control group|Usual care
62273771|NCT01096563|EXPERIMENTAL|1|AZD9164
62636815|NCT01223404|EXPERIMENTAL|Placebo, Nicotine, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
62069159|NCT03605160|EXPERIMENTAL|fluid-jet group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule. All operations are videotaped during the whole operation. The total time of all jet procedures recorded in the videotape is the total time of jet.
62069160|NCT02743715|ACTIVE_COMPARATOR|Active tDCS|Electric current of 2mA delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
62069161|NCT02743715|SHAM_COMPARATOR|Sham tDCS|In this group, the cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
62069162|NCT06152523|EXPERIMENTAL|MSI/dMMR tumors across all solid tumor types in adult patients|
62069163|NCT06400680|EXPERIMENTAL|Healthy subjects|Subjects without spine disease
62069164|NCT06400680|EXPERIMENTAL|Scoliotic subjects|Subjects with a scoliosis diagnosis
62069165|NCT03792217|EXPERIMENTAL|1.3% NaOCl|Root canal irrigation done using 1.3% NaOCl.
62273772|NCT01096563|PLACEBO_COMPARATOR|2|
62273773|NCT00028990|ACTIVE_COMPARATOR|Paclitaxel + Bevacizumab|
62273774|NCT00028990|ACTIVE_COMPARATOR|Paclitaxel|
62273775|NCT05838391|EXPERIMENTAL|Chemotherapy and Adaptive Radiation Treatment Planning|Subjects will receive concurrent chemotherapy and radiation as part of their treatment for anal cancer. Subjects will receive standard of care 54 Gy of radiation, 5 days a week for 6 weeks. In addition, subjects will receive standard of care chemotherapy, with mitomycin C (10mg/meters squared IV on Day 1) and 5-Fluorouracil (1000mg/meters squared via IV on days 1-4 and 29-32) or capecitabine (825 mg/meters squared in two divided doses by mouth on days of radiotherapy).
62273776|NCT01999283|ACTIVE_COMPARATOR|Yoga Group Exercise|Yoga group exercise will be taught by a licensed Physical Therapist. Groups consist of 4-8 individuals with 12 sessions once weekly over 12 weeks.
62454083|NCT02791100|EXPERIMENTAL|Promotion of Chicken eggs for children|The community receives chickens so that each study child receives 2 eggs a day and also receives some egg shell daily (1/4 bottle cap which provides 500 mg Ca). The community receives information on using the egg and eggshell, and has help in caring for the chickens.
62454084|NCT02220465|EXPERIMENTAL|PA+ Smoking Cessation (LMPA)|This intervention integrates low-to-moderate physical activity (PA) with evidence based smoking cessation programming. Over the 4-week treatment period, the intervention (1 in-person and 3 phone counseling sessions) focuses on (a) gradually increasing routine PA during the pre-quit period and maintaining PA post quit day (b) increasing daily PA (steps/day) using a weekly tailored algorithm with the goal of achieving 10,000 steps by Week 4 (quit day) and (c) training participants to use PA as a primary urge management strategy, thereby embedding PA within evidence-based smoking cessation counseling. Other components include additional smoking urge management skills, increasing motivation to quit, overcoming barriers and maintaining PA for quitting and staying smoke-free .
62636816|NCT01223404|EXPERIMENTAL|Nicotine, Placebo, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
62273777|NCT01999283|ACTIVE_COMPARATOR|Pilates Group Mat Exercise|Pilates mat exercise will be taught by a licensed Physical Therapist with additional Rehabilitation Pilates certification.
62273778|NCT01999283|NO_INTERVENTION|Control|Wait Listed control group. Participants complete the same testing and were offered the option of attending the exercise classes on completion. The controls were not included in the exercise groups after completion.
62273779|NCT01573273|EXPERIMENTAL|TSST Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
62273780|NCT01573273|PLACEBO_COMPARATOR|TSST Women Placebo|Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
62273781|NCT01573273|EXPERIMENTAL|MRI 1 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
62273782|NCT01573273|PLACEBO_COMPARATOR|MRI 1 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
62273783|NCT01573273|EXPERIMENTAL|MRI 2 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
62273784|NCT01573273|PLACEBO_COMPARATOR|MRI 2 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
62636817|NCT01223404|EXPERIMENTAL|Placebo, Mecamylamine, Nicotine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
62636818|NCT01223404|EXPERIMENTAL|Nicotine, Mecamylamine, Placebo|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
62636819|NCT01223404|EXPERIMENTAL|Mecamylamine, Placebo, Nicotine|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
62069166|NCT03792217|ACTIVE_COMPARATOR|5.25% NaOCl|Root canal irrigation done using 5.25% NaOCl.
62636820|NCT01223404|EXPERIMENTAL|Mecamylamine, Nicotine, Placebo|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
62636821|NCT03198845|ACTIVE_COMPARATOR|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
62636822|NCT03198845|SHAM_COMPARATOR|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
62636823|NCT00510341|ACTIVE_COMPARATOR|1|CMP program
62636824|NCT00510341|NO_INTERVENTION|2|Control group
62636825|NCT00914225||Intervention|Cohort 1 is the intervention group who received long-lasting insecticide treated bednets and a water filtration device
62069167|NCT03501693||DBT plus S-View|Breast images utilizing DBT plus S-View
62069168|NCT03501693||FFDM alone|FFDM alone images
62069169|NCT02737020|EXPERIMENTAL|Rhodiola|Rhodiola rosea 200mg up to four times a day for 28 days
62069170|NCT02737020|PLACEBO_COMPARATOR|Placebo|Placebo pill manufactured to mimic Rhodiola rosea 200mg, up to four times a day for 28 days
62273785|NCT01573273|EXPERIMENTAL|TSST Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
62273786|NCT01573273|PLACEBO_COMPARATOR|TSST Men Placebo|Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
62273787|NCT01573273|EXPERIMENTAL|MRI I Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
62069171|NCT04876651|EXPERIMENTAL|Group A|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care
62069172|NCT04876651|ACTIVE_COMPARATOR|Group B|Participants will receive the Standard of Care
62273788|NCT01573273|PLACEBO_COMPARATOR|MRI I Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
62273789|NCT01573273|EXPERIMENTAL|MRI 2 Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
62273790|NCT01573273|PLACEBO_COMPARATOR|MRI 2 Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
62273791|NCT00005648|EXPERIMENTAL|001|Gemcitabine with R115777 R115777 200 mg oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
62273792|NCT00005648|PLACEBO_COMPARATOR|002|Gemcitabine with Placebo Placebo oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
62273793|NCT03885128|EXPERIMENTAL|Vest arm|high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients
62273794|NCT03885128|EXPERIMENTAL|Quake arm|Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients
62273795|NCT00809770|EXPERIMENTAL|1|Contingency management
62273796|NCT00809770|OTHER|2|Non Contingent Control Condition
62273797|NCT05901818|EXPERIMENTAL|Autologous induced neural stem cell-derived DA precursor cells|The patients will receive transplantation of autologous induced neural stem cell-derived DA precursor cells.
62069173|NCT04876651|EXPERIMENTAL|Biodistribution and Dosimetry Sub-Study|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care
62069174|NCT00617721||1|patients with unexplained bleeding disorder
62069175|NCT00617721||2|healthy volunteers
62069176|NCT03428126|EXPERIMENTAL|Durvalumab + Trametinib|"Participants take Trametinib tablets by mouth every day. Trametinib taken alone for the first 7 days of the study then participants begin receiving it in combination with Durvalumab.~Participants receive Durvalumab by vein every 4 weeks.~Each cycle is 28 days."
62069177|NCT03954457|EXPERIMENTAL|A-CWS Intervention|Participants received A-CWS Intervention.
62273798|NCT03583190|EXPERIMENTAL|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
62273799|NCT03583190|ACTIVE_COMPARATOR|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
62273800|NCT05707923|EXPERIMENTAL|Utterance Type|This study uses a within-participant experimental manipulation. All participants will be exposed to all utterance types (across trials).
62273801|NCT01047774|EXPERIMENTAL|Soy protein|
62273802|NCT01047774|PLACEBO_COMPARATOR|Milk protein|
62273803|NCT05677074|EXPERIMENTAL|Tolerance test of fish oil, cod oil, and krill oil|All participants will have their tolerance of three different dietary supplements tested (fish oil, cod oil, and krill oil) using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
62273804|NCT05428150|ACTIVE_COMPARATOR|Regimen A|Esbriet® 801 mg (267 mg oral capsule x 3), three times daily (TID) with meals (6 hours apart) for 3 days, total daily dose of 2403 mg, given under fed conditions. Subjects will receive a single dose on Day 4 after breakfast.
62273805|NCT05428150|EXPERIMENTAL|Regimen B|EXCL-100, 1200 mg (600 mg oral tablet x 2), twice daily with meals (BID, every 12 hours) for 3 days, total daily dose of 2400 mg, given under fed conditions. Subjects will receive a single dose on Day 4 after breakfast.
62273806|NCT04735094|EXPERIMENTAL|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|
61978725|NCT04838756|EXPERIMENTAL|Intervention arm|AI-integrated mammography screening
62069178|NCT03954457|ACTIVE_COMPARATOR|Standard Care Control|Participants received standard care.
62069179|NCT04665310|ACTIVE_COMPARATOR|Group 1 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
62273807|NCT04735094|NO_INTERVENTION|Endobronchial biopsy without the use of a balloon attached to the echo-bronchoscope|
62273808|NCT00524823||1|10 diagnosed men in age 60 - 90 with Prostate Cancer
62273809|NCT00524823||2|10 patients with benign growth
62273810|NCT00524823||3|10 health volunteers
62273811|NCT00524823||4|10 patients diagnosed with other cancer
62273812|NCT03047980|EXPERIMENTAL|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
62273813|NCT03771742|ACTIVE_COMPARATOR|transverse TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
62273814|NCT03771742|EXPERIMENTAL|paramedian sagittal TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the para-sagittal scan, in-plain, caudal to cephalic approach.0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
62273815|NCT03483480|EXPERIMENTAL|Non powered-NPWT|
62273816|NCT03483480|ACTIVE_COMPARATOR|Open Technique|
62273817|NCT03527563|OTHER|Internet Medical Model|Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
62636826|NCT00914225||Comparison|"Cohort 2 is the comparison group included from the control arm of the study, Empiric therapy of helminth coinfection to reduce HIV-1 disease progression ClinicalTrials.gov identifier: NCT00507221~As part of the RCT (NCT00507221), we have enrolled 948 HIV infected ART naïve individuals to compare HIV disease progression in those receiving standard of care versus empiric deworming. Subjects are followed for 24 months and have serial measurements of HIV disease progression, and are evaluated serially for evidence of malaria, diarrhea and other co-morbidities. Participants in this study will have been consented for the collection of data on the frequency of malaria and diarrheal disease, their use of a bednet and water filtration and their compliance with TMP/SMX."
62273818|NCT03527563|NO_INTERVENTION|Conventional Medical Model|Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
62454085|NCT02220465|ACTIVE_COMPARATOR|Standard Care Smoking Counseling (SCC)|The control intervention parallels the format of the LMPA intervention with focus only on behavioral and cognitive urge management strategies (avoiding/escaping high-risk situations, stimulus control) and minimizing the probability that participants in the control group would increase increase/use PA during the intervention period. Participants are provided a pedometer without any instructions or encouragement around increasing walking/steps during the 8-week intervention period.
62273819|NCT06420973|EXPERIMENTAL|RC48+carboplatin±bevacizumab|RC48 (2.5mg/kg iv on d1 , every 21d for 6 cycles) + Carboplatin (AUC5 iv on d1 every 21d for 6 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for 6 cycles) for treatment followed by RC48 (2.5mg/kg iv on d1 , every 21d for 8 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for progress ) maintenance therapy.
62069180|NCT04665310|ACTIVE_COMPARATOR|Group 1 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
62069181|NCT04665310|ACTIVE_COMPARATOR|Group 1 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
62069182|NCT04665310|ACTIVE_COMPARATOR|Group 2 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
62069183|NCT04665310|ACTIVE_COMPARATOR|Group 2 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
62273820|NCT06413862|EXPERIMENTAL|Ciprofol group (ciprofol combined with alfentanil)|
62273821|NCT06413862|ACTIVE_COMPARATOR|Propofol group (propofol combined with alfentanil)|
62273822|NCT03874377|EXPERIMENTAL|Mindfulness|The mindfulness intervention consists of 6 weekly sessions, blending material from the evidence-based Learning to BREATHE and Mindfulness-Based Eating Awareness Training manualized interventions. Sessions will focus on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.Participants in this arm will also receive the usual care provided by the weight management clinic.
62454086|NCT01624766|EXPERIMENTAL|Arm I (everolimus, anakinra)|Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
62069184|NCT04665310|ACTIVE_COMPARATOR|Group 2 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
62273823|NCT03605680|EXPERIMENTAL|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
62454087|NCT01624766|EXPERIMENTAL|Arm II (everolimus, denosumab)|Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
62454088|NCT01403766||Pediatric post-kidney transplant|Patients having standard of care surviellance biopsies.
62636827|NCT04009603|ACTIVE_COMPARATOR|Metformin|Group no 1(26 patients) Metformin tablets at a dose of 500mg BD for 12 weeks
62636828|NCT04009603|EXPERIMENTAL|Probiotic|Group no 2(26 patients): will be given probiotics alone at a dose of 180mg B.D for 12 weeks
62636829|NCT04009603|EXPERIMENTAL|Metformin and Probiotic|Group no 3(26 patients): will be given metformin 500mg B.D and probiotics 180mgram O.D. for 12 week
62636830|NCT01056393|EXPERIMENTAL|ibalizumab 800mg Q2Weeks|Subject will receive 800mg of ibalizumab every 2 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
62069185|NCT01291225|OTHER|Playground|"The playground arm of the study will consist of playground audits and KAP surveys about playground safety in both Chillicothe and Circleville, Ohio.~The intervention is Playground Safety Renovations and Development."
62069186|NCT01291225|OTHER|Farms|The Farm Arm will consist of farm audits with safety checklists and KAP surveys about farm safety. The intervention is a Safety Educational Campaign.
62636831|NCT01056393|EXPERIMENTAL|ibalizumab 2000mg Q4Weeks|Subject will receive 2000mg of ibalizumab every 4 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
62636832|NCT01701544|SHAM_COMPARATOR|NBM DBS Off|NBM DBS switched off
62273824|NCT03605680|EXPERIMENTAL|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
62273825|NCT03605680|EXPERIMENTAL|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
62636833|NCT01701544|ACTIVE_COMPARATOR|NBM DBS On|NBM DBS Switched On
62636834|NCT04754893|EXPERIMENTAL|Group A|Healthdot directly after surgery and leave the hospital on the same day (evening) (group A)
62636835|NCT04754893|NO_INTERVENTION|Group b|Standard of care by staying one night in the hospital before returning home (group B)
62636836|NCT00947310|EXPERIMENTAL|A|Standard ICD Programming
62636837|NCT00947310|EXPERIMENTAL|B|High rate cutoff
62636838|NCT00947310|EXPERIMENTAL|C|Long ICD duration delay
62636839|NCT04777058||Patients|Patients admitted to the intensive care unit, treated with isavuconazole intravenously for treatment of invasive fungal infections
62636840|NCT04113941|EXPERIMENTAL|Neuronox®|Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites
62273826|NCT03605680|PLACEBO_COMPARATOR|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
62273827|NCT05506059|OTHER|Healthy Volunteer|Healthy volunteers over the age of 18 who consent to two ultrasounds.
62273828|NCT05506059|EXPERIMENTAL|ED patient with planned heart echocardiogram|Patients in emergency department (ED) who have a heart echocardiogram scheduled as part of their routine clinical care
62273829|NCT04717674|EXPERIMENTAL|Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA)|Participants will undergo two PET/CT scans with the tracer \[18F\]Fluoropivalate (\[18F\]Fluoro-2,2-Dimethylpropionic Acid) (FPIA), referred to as \[18F\]FPIA, on 2 separate visits.
62273830|NCT05855265|EXPERIMENTAL|study group (SG)|The patients in study group treated with photon therapy (3x/week) for 6 weeks with a total of 18 sessions and Routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent .The severity of skin reactions was assessed by the criteria of the Radiation Therapy Oncology Group (RTOG) and dermoscopy for both groups were recorded.
62273831|NCT05855265|EXPERIMENTAL|control group (CG)|Routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent for control groups CG.The severity of skin reactions was assessed by the criteria of the Radiation Therapy Oncology Group (RTOG) and dermoscopy for both groups were recorded.
62069187|NCT01930435|EXPERIMENTAL|Sterile Humidification Device, MyPurMist|Sterile Humidification Device Twice a day, 15 minutes each 12 weeks
62069188|NCT02751736|EXPERIMENTAL|Intervention|"* 2 g sachet (CJLP 243) once a day for 3 weeks~* 10 billion lactic acid bacteria(lactobacillus plantarum CJLP243), maltodextrin, glucose(anhydrous)"
62069189|NCT02751736|PLACEBO_COMPARATOR|Control|"* 2g sachet (near identically appearing placebo) once day for 3 weeks~* maltodextrin, glucose(anhydrous)"
62069190|NCT01100060|EXPERIMENTAL|Group 1|Co-administer the test chloroquine (CQ) formulation (620 mg CQ base) plus microsphere azithromycin (AZ) (2000 mg) on Day 1.
62069191|NCT01100060|ACTIVE_COMPARATOR|Group 2|Co-administer the individual tablets of CQ 2 x 500 mg (600 mg CQ base) tablets plus AZ IR 4 x 500 mg tablets on Day 1.
62273832|NCT03705715|EXPERIMENTAL|PET with radiotracer [11C]PBR-28 or [11C]ER176|PET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
62273833|NCT03705715|EXPERIMENTAL|PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge|PET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
62273834|NCT03612986|ACTIVE_COMPARATOR|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)~1 tablet/day, oral administration"
62273835|NCT03612986|PLACEBO_COMPARATOR|B: Placebo|"Placebo~1 tablet/day, oral administration"
62273836|NCT06103032||a consecutive cohort of women with asymptomatic screen-detected non-palpable breast cancer|a consecutive cohort of women with asymptomatic screen-detected non-palpable breast cancer treated in Dept. Breast Surgery, PUMC Hospital from January 2003 to December 2017
62287107|NCT03544112||Community Stakeholders|"* Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.~* Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups."
62069192|NCT01082146|EXPERIMENTAL|Lurasidone|LURASIDONE 40mg
62069193|NCT04652141|ACTIVE_COMPARATOR|AsthmaTuner field tests|Trail treatment with AsthmaTuner up to 3 months. Objective asthma criteria: Positive reversibility test, FEV1 \>12% and 200 ml or positive periodic variability PEF/FEV1 \>20%. Treatment recommendation is prescribed individually by treating physician.
62273837|NCT01225679||polysomnography|Overnight supervised polysomnography (Embla System®) was performed in a sleep laboratory, which included capnometry. Arterial blood gas analysis was performed by radial arterial puncture. Ventilatory response to progressive hypercapnia was measured using the Read breathing technique. Briefly, subjects rebreathed into an air tight 5-L bag containing a mixture of 8% carbon dioxide (CO2) and 40% oxygen (O2). The spirometer technology used to monitor ventilation was based on a bi-directional rotating vane principle (flow sensitive). A continuous record of CO2 concentration in the expired gas was obtained by a CO2 analyzer within the circuit. The ventilatory hypercapnic drive was calculated from the slope produced by changes in ventilation (L. min-1) and changes in end-tidal PCO2.
62636841|NCT04113941|PLACEBO_COMPARATOR|Placebo|Normal saline, same volume with Experimental arm
62636842|NCT04520217|EXPERIMENTAL|4% Imipramine Cream on UVB-Treated Areas|"* 2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.~* 2g of base cream will be applied to the UVB-treated areas on volar forearm and back.~* No cream will be applied to a UVB-treated area on the back"
62636843|NCT02571556|EXPERIMENTAL|Dexamethasone Phosphate Ophthalmic Solution|
62273838|NCT03729492|OTHER|CTEPH/CTED work-up|
62273839|NCT04714541|EXPERIMENTAL|Ketogenic Diet Adoption Followed by Ketamine Infusion|All 5 Participants Will Be Educated to Adopt a Ketogenic Diet, As Outpatient. After at Least 4 Weeks on the Diet, They Will Have A Series of Titrated Intravenous Ketamine Infusions Over A 2 Week Period
62273840|NCT00903929|EXPERIMENTAL|Eltrombopag|
62273841|NCT02558374|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)
62273842|NCT02558374|ACTIVE_COMPARATOR|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) \& evening (PM) in both eyes (OU)
62273843|NCT01106846|PLACEBO_COMPARATOR|Group A: Saline group|Group A: Saline group , infusion of saline intravenously
62273844|NCT01106846|ACTIVE_COMPARATOR|Group B: 1% Ketamine group|Group B: Infusion of ketamine 1% intravenously
62273845|NCT02524353|EXPERIMENTAL|cardiac surgery|cardiac surgery
62273846|NCT03186235||Group I : 18 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
62287108|NCT03544112||Patients|ED patients will be recruited to participate in interviews or focus groups.
62636844|NCT01214993|EXPERIMENTAL|Treatment A|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
62069194|NCT04652141|NO_INTERVENTION|Traditional trial treatment|Treatment recommendation is prescribed individually to patient by treating physician. The treatment plan is transferred to patient on printed paper and/or oral communication.
62636845|NCT01214993|EXPERIMENTAL|Treatment B|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q12h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
62636846|NCT01214993|PLACEBO_COMPARATOR|Treatment C|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive placebo q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
62069195|NCT03214510|EXPERIMENTAL|Arm I (TAE)|Patients undergo placement of thoracic epidural catheter before surgery. Patients receive hydromorphone hydrochloride and bupivacaine via thoracic epidural catheter every 10 minutes or 3 hours as needed. Patients may receive fentanyl and bupivacaine or plain bupivacaine via thoracic epidural catheter.
62273847|NCT03186235||group II : 16 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
62636847|NCT06378424|EXPERIMENTAL|Cold Application Group|Before peripheral intravenous catheterization, dry cold was applied to the application area using a cold gel pack. For this purpose, a 11 x10 cm pack of non-toxic gel was frozen solid in the refrigerator. Because this pack is reusable, it was disinfected before and after each use, and left in the service refrigerator to freeze solid. Attention was paid that it was used in solid form with all individuals.
62636848|NCT06378424|EXPERIMENTAL|Heat Application Group|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
62636849|NCT06378424|EXPERIMENTAL|Vibration Application Group|With individuals in this group, device was used to provide vibration. The device, at room temperature, was placed by the researcher on the peripheral intravenous catheterization application area before the application was performed. For one minute before the application, a slight, non-discomforting vibration was applied to the intervention area.
62636850|NCT06378424|NO_INTERVENTION|The control group|No intervention was performed on the control group before the peripheral intravenous catheterization procedure, and the standard peripheral intravenous catheterization procedure was performed.
62636851|NCT04608071||M group|In M group, patients underwent modified post-pyloric feeding tube bedside placement
62636852|NCT04608071||C group|In C group, patients underwent conventional Corpak protocol
62636853|NCT04608071||EM group|In EM group, patients received standard electromagnetic guided tube placement.
62636854|NCT05897671||study group|retrospective data analysis of patients that underwent after foveal sparing ILM peeling with ILM flap transposition for macular hole repair
62636855|NCT02972983|PLACEBO_COMPARATOR|Placebo|51 patients receiving a daily placebo infusion for five days on top of standard of care treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia
62273848|NCT03186235||group III:18 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
62069196|NCT03214510|EXPERIMENTAL|Arm II (TAP)|Patients undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block. Patients receive plain bupivacaine and liposomal bupivacaine via TAP block.
62273849|NCT03186235||group IV: 18 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
62273850|NCT03186235||Group V:18 patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
62636856|NCT02972983|EXPERIMENTAL|Daptomycin|51 patients receiving daily daptomycin infusion for five days on top of standard of care treatment for MSSA bacteremia
62636857|NCT02317991|EXPERIMENTAL|nab-paclitaxel and ramucirumab|"All patients will receive 125 mg/m\^2 of nab-Paclitaxel intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle (weekly for 3 weeks, with 1 week of rest).~Patients will receive ramucirumab 8mg/kg IV in combination with nab-paclitaxel on Days 1 and 15 of the 28-day cycle."
62273851|NCT05321979|EXPERIMENTAL|MBA-P01|MBA-P01 will be injected into GL:
62273852|NCT04161833|EXPERIMENTAL|OPERA|Women receiving adjuvant aromates-inhibitor with arhtralgia grade ≥ 1 (CTACAE 4.03)
62273853|NCT06151171|EXPERIMENTAL|Lipomicel Q10|Lipomicel Q10 (Natural Factors, Burnaby, BC, Canada). One soft gel capsule contains: 100 mg ubiquinone (oxidized form of CoQ10)
62273854|NCT06151171|ACTIVE_COMPARATOR|CoQ10 NOW® Ubiquinol|CoQ10 (NOW® Ubiquinol, Bloomingdale, IL, USA). One soft gel capsule contains: 100 mg ubiquinol (reduced form of CoQ10).
62273855|NCT06151171|ACTIVE_COMPARATOR|Qunol Ultra CoQ10|Qunol Ultra CoQ10 (Quten Research Institute, LLC, USA). One soft gel contains: 100 mg ubiquinone.
62273856|NCT01049763|EXPERIMENTAL|Regimen A|oseltamivir 75 mg single dose
62273857|NCT01049763|ACTIVE_COMPARATOR|Regimen B|oseltamivir 150 mg single dose
62636858|NCT03006237|EXPERIMENTAL|IV IS-001 drug|IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System
62636859|NCT01878903||i-pad VAS|All patients will be in one arm and they will be asked for post-operative pain using verbal NRS and visual VAS with i-pad
62636860|NCT06332196|OTHER|Patient with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL)|Patient with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL)
62069197|NCT05416996||Shared Medical Appointments|
62273858|NCT02677155|EXPERIMENTAL|Intranodal immunotherapy and anti-PD1|"Induction phase: 3 cycles of sequential intranodal immunotherapy (SIIT), every second week:~Radiotherapy 8 Gy single dose day 2, Rituximab 5 mg intranodal day 1 and 3, Autologous dendritic cells 1x 10 e8 intranodal day 4 and 5, GM-CSF 50 ug subcutaneously day 4 and 5, Pembrolizumab 200 mg intravenous day 5,~Consolidation phase:~Pembrolizumab 200 mg intravenous every third week for 8 cycles"
62273859|NCT03636243|OTHER|Group of obese patients with type-2 diabetes|
62273860|NCT03636243|OTHER|Group of non-diabetic obese patients|
62273861|NCT01464476|EXPERIMENTAL|Azimilide|Azimilide 75 mg film coated tablets
62273862|NCT01464476|PLACEBO_COMPARATOR|Placebo|
61978726|NCT04838756|EXPERIMENTAL|Control arm|Conventional mammography screening (standard of care)
61978727|NCT02932033|ACTIVE_COMPARATOR|Tack fixation|consecutive patients with bilateral inguinal hernias will be recruited for TEP repair. Mesh fixation methods with spiral tack is randomly assigned to one side, then comparative fixation method to the contralateral side. In group of active comparator, after randomization, the target inguinal hernia side of the patient has the mesh fixed with titanium spiral tacks.
61978728|NCT02932033|EXPERIMENTAL|Synthetic glue fixation|The same patient, his contralateral side of inguinal hernia, has the mesh fixed with synthetic glue.
62636861|NCT04776928|EXPERIMENTAL|Provider-level push report notifications|Push reports will be sent via using a secure email client. The email will be sent to the email address provided to the study team by the surgeon or site.
62636862|NCT04776928|NO_INTERVENTION|No intervention|Sites who did not sign Exhibit B-1.
62636863|NCT03108612|EXPERIMENTAL|Study group|Intervention: Análisis de carga de trabajo (ACT)
62636864|NCT03228641|EXPERIMENTAL|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
62636865|NCT04064203|EXPERIMENTAL|Totally pancreatectomized patients|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
61978729|NCT02295150|EXPERIMENTAL|Nadroparin|patients above 140 kg will receive a dose of 2850 IU nadroparine pre-operatively, anti-Xa factor will be determined 3 days after nadroparin use. After surgery patients receive 5700 IU nadroparin (our standard treatment). Three days after surgery and 4 weeks after surgery anti-Xa factor will be measured again.
62069198|NCT05416996||Usual Care Appointments|
62636866|NCT04064203|EXPERIMENTAL|Healthy controls|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
62636867|NCT03487770|EXPERIMENTAL|Aripiprazole Oral Solution|1 mg/mL, 2 \~ 15 mg/day (2 \~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;
62636868|NCT03487770|PLACEBO_COMPARATOR|Placebo Oral Solution|2 \~ 15 mg/day (2 \~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.
62636869|NCT03328234|EXPERIMENTAL|SIB-IMRT combined chemotherapy with IFI|
62636870|NCT03328234|EXPERIMENTAL|SIB-IMRT with IFI|
62636871|NCT03281941|OTHER|Patients without BT|
62069199|NCT06080932|EXPERIMENTAL|Ketogenic Diet|The KD will follow general principles as we have described with the aim to achieve blood ketones \>0.5 mM, which will require most participants to consume \<50 g/day carbohydrate and \~1.5 g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
62636872|NCT03281941|OTHER|Post BT|
62636873|NCT05833126|EXPERIMENTAL|Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab|"Hepatic arterial infusion chemotherapy: percutaneous introduction of a standard hepatic arterial catheter through the femoral artery. FOLFOX was sequentially transfused by a fixed catheter. Drugs:FOLFOX regimen: oxaliplatin, calcium folinate, and 5-FU.~Atezolizumab: About 3 to 7 days after HAIC treatment, when liver function is stable (TBILI\<2 times the upper limit of normal), Atezolizumab therapy can be started. The dosage was 1200mg and was given intravenously for at least 1 hour, once every 3 weeks. The longest course of treatment is 24 months.~Bevacizumab: About 3 to 7 days after HAIC treatment, when liver function is stable (TBILI\<2 times the upper limit of normal), bevacizumab therapy can be started. The dosage was 15mg/kg and was given intravenously for no less than 1 hour, once every 3 weeks. The longest course of treatment is 24 months."
62069200|NCT01305928|ACTIVE_COMPARATOR|Fax|
62069201|NCT01305928|EXPERIMENTAL|Warm Hand-off|
62636874|NCT05569798|NO_INTERVENTION|Standard care|Thirty patients will receive standard care (regular ICU treatment without any restriction to usual medical care). INSIGHT scans will not be performed on these patients. However, other forms of ultrasound scanning will be permitted in this group. For example, departmental ultrasound scans (full echocardiography, liver, or vascular ultrasound assessment); transoesophageal echocardiography; transcranial doppler; any form of PoCUS other than the INSIGHT scan.
62636875|NCT05569798|EXPERIMENTAL|Standard care + the INSIGHT intervention|Thirty patients will receive standard care + the INSIGHT intervention. The INSIGHT intervention is described in detail in section 5.7.1. INSIGHT scans will be performed by staff trained in the INSIGHT Training and Competency Programme on days 1 (0-36 hours), 3 (72-96 hours) and 7 (6 to 8 days) from ICU admission. Scans will only be performed at these timepoints if the patient is still admitted to the ICU.
62636876|NCT01316224||Moderate or severe plaque psoriasis|Participants with moderate or severe plaque psoriasis treated with adalimumab
62636877|NCT02199769|EXPERIMENTAL|Clinical Decision Support|Visit-based, EMR-enabled case identification and real-time decision support to identify patients without diabetes who have a RBG\>= 125mg/dL and no resulted diabetes screening.
62636878|NCT02199769|NO_INTERVENTION|Usual care|Diabetes screening/testing and diagnosis per usual care at the discretion of the treating physician.
62636879|NCT04812184|EXPERIMENTAL|Surgical Tape to bridge of nose|placed a piece of tape to the bridge of the nose, adhering a face mask to the patient's face
62273863|NCT02743832|EXPERIMENTAL|High-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection (CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
62273864|NCT02743832|EXPERIMENTAL|High-level tumor budding group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
62273865|NCT02743832|EXPERIMENTAL|Low-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection (CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
62273866|NCT02743832|EXPERIMENTAL|Low-level tumor budding group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
62273867|NCT04139876|ACTIVE_COMPARATOR|Minimal open hemorrhoidectomy|Patients randomized to Minimal open hemorrhoidectomy
62636880|NCT04812184|NO_INTERVENTION|Standard of care|Patients given a mask with no intervention to the mask
62636881|NCT01368510|EXPERIMENTAL|OCD Active CBT|Adults with obsessive-compulsive disorder (OCD) will be treated with cognitive-behavioral therapy (CBT) from the time of enrollment.
62636882|NCT01368510|ACTIVE_COMPARATOR|OCD Waitlist|Adults with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
62273868|NCT04139876|ACTIVE_COMPARATOR|LigaSure hemorrhoidectomy|Patients randomized to LigaSure hemorrhoidectomy
62273869|NCT02079987|EXPERIMENTAL|ED-to-home care transition intervention|The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
62273870|NCT02079987|EXPERIMENTAL|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
62273871|NCT02972164|NO_INTERVENTION|Control|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the control group. Control children are assessed for the same measures as the intervention group at the beginning and end of the intervention but receive none of the intervention modules.
62636883|NCT01368510|NO_INTERVENTION|Healthy Control|Healthy control adults will be given no intervention.
62636884|NCT03368313|EXPERIMENTAL|Compression arm|The compression arm will receive an adjustable velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
62636885|NCT03368313|NO_INTERVENTION|Control arm|No compression
62636886|NCT04017767|EXPERIMENTAL|Moderate to Severe Obstructive Sleep Apnea (OSA)|Individuals with moderate to severe OSA defined as having an Apnea-hypopnea Index (AHI) that is greater than or equal to 15.
62636887|NCT04017767|ACTIVE_COMPARATOR|Without OSA|Individuals without OSA defined as having AHI less than 5.
62636888|NCT02974933|EXPERIMENTAL|apatinib|combined with pemetrexed
62069202|NCT01107743||Amlodipine and Atorvastatin Combination Tablet|Subjects taking Amlodipine and Atorvastatin Combination Tablets
62069203|NCT00753883|ACTIVE_COMPARATOR|1|simvastatin 20 mg/qd for 8 weeks, and then add on ezetrol 10mg (if ldl-c . 160mg/dl) for another 8 weeks.
62273872|NCT02972164|EXPERIMENTAL|Weight loss program for school children|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the intervention group. The intervention children take part in the integrated approach for weight management consisting of (1) intensive weight loss camp (2) twelve weeks of after school clubs for consolidation purposes, and (3) social media and wearable sensors for support and monitoring.
62636889|NCT00887614|EXPERIMENTAL|MBSR|Participation will involve online completion of a questionnaire survey before and after the Mindfulness-Based Stress Reduction (MBSR) intervention. Specifically, research study participants will complete validated self-report measures to assess mindfulness, cognitive-emotional processes, sleep quality, symptoms of stress, sense of spirituality, and quality of life before and after the MBSR intervention.
62636890|NCT00231790|EXPERIMENTAL|MK-0634 50 mg|All participants will receive placebo for the 1 week prior to randomization
62636891|NCT00231790|EXPERIMENTAL|MK-0634 125 mg|All participants will receive placebo for the 1 week prior to randomization
62636892|NCT00231790|EXPERIMENTAL|MK-0634 375 mg|All participants will receive placebo for the 1 week prior to randomization
62636893|NCT00231790|PLACEBO_COMPARATOR|Placebo|All participants will receive placebo for the 1 week prior to randomization
62636894|NCT00356447|ACTIVE_COMPARATOR|Arm 1|
62636895|NCT00356447|PLACEBO_COMPARATOR|Arm 2|
62636896|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
62636897|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
62636898|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
62636899|NCT01935089|EXPERIMENTAL|Interferon alpha|pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks
62636900|NCT02912221|NO_INTERVENTION|Control|Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals
62636901|NCT02912221|ACTIVE_COMPARATOR|Incentive|An incentive will be used for this arm to encourage participants to meet their step goals
62636902|NCT06477744|EXPERIMENTAL|Low Dose Group|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Study group : 6 subjects~3. Dosage: 3.15X10\^6 cells/body (6 tracks in total, 52.5X10\^4 cells per track)"
62636903|NCT06477744|EXPERIMENTAL|High Dose Group|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Study group : 6 subjects~3. Dosage: 6.30X10\^6 cells/body (6 tracks in total, 105X10\^4 cells per track)"
62636904|NCT00732069|ACTIVE_COMPARATOR|Placebo, then ramipril, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
62069204|NCT00753883|ACTIVE_COMPARATOR|2|ezetrol 10 mg/qd for 8 weeks, and then add on simvastatin 20 mg qd (if ldl-c . 160mg/dl) for another 8 weeks
62636905|NCT00732069|ACTIVE_COMPARATOR|Placebo, then valsartan, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
62636906|NCT00732069|ACTIVE_COMPARATOR|Ramipril, then placebo, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
62069205|NCT02443922|EXPERIMENTAL|Glimepiride|Glimepiride 2mg qam
62069206|NCT02443922|EXPERIMENTAL|Sitagliptin|Sitagliptin 100mg qam
62069207|NCT02443922|ACTIVE_COMPARATOR|Metformin|Metformin as prescribed
62636907|NCT00732069|ACTIVE_COMPARATOR|Valsartan, then placebo, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
62636908|NCT00732069|ACTIVE_COMPARATOR|Ramipril, then valsartan, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
62636909|NCT00732069|ACTIVE_COMPARATOR|Valsartan, then ramipril, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
62069208|NCT04577313|ACTIVE_COMPARATOR|Continuous Counseling|Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.
62069209|NCT04577313|ACTIVE_COMPARATOR|Fixed Counseling|Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.
62069210|NCT05966961||Novosyn®|Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine
62069211|NCT05966961||Polyglactin 910|Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine
62069212|NCT03746743||Preterm neonates|Neonates born between 32 and 37 weeks gestation
62069213|NCT03746743||Fullterm neonates|Neonates born at or after 37 weeks gestation
62636910|NCT00802646|EXPERIMENTAL|1|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of preservative-free normal saline will be administered through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
62636911|NCT00802646|ACTIVE_COMPARATOR|2|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of combined spinal epidural anesthetic through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
62636912|NCT01789047|ACTIVE_COMPARATOR|Topiramate|Topiramate as adjunct to amantadine.
62636913|NCT01789047|PLACEBO_COMPARATOR|Placebo (sugar pill)|Placebo
62636914|NCT00484471|EXPERIMENTAL|1|
62636915|NCT00484471|PLACEBO_COMPARATOR|2|
62636916|NCT00913081|EXPERIMENTAL|Quercetin 500 mg|Quercetin 500 mg once, administered one hour before 500 mg immediate-release niacin
62636917|NCT00913081|EXPERIMENTAL|Quercetin 1000 mg|Quercetin 1000 mg once, administered one hour before 500 mg immediate-release niacin
61978730|NCT01502189|EXPERIMENTAL|Representational approach|The Representational approach as described in the detailed description.
62273873|NCT01972893|EXPERIMENTAL|ZYD1|Tablet ZYD1 5 to 50 mg subcutaneously Once a day (OD) or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
62069214|NCT00210522|EXPERIMENTAL|001|RWJ 333369 Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
62069215|NCT01516203|EXPERIMENTAL|Arm 1|AZD5847 500 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
62069216|NCT01516203|EXPERIMENTAL|Arm 2|AZD5847 500 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
62069217|NCT01516203|EXPERIMENTAL|Arm 3|AZD5847 1200 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
62273874|NCT01972893|PLACEBO_COMPARATOR|Placebo|Tablet Placebo 5 to 50 mg subcutaneously OD or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
62454089|NCT02594462|OTHER|ENG-group|"Twenty-five women with homozygous sickle cell anemia (hemoglobin SS), aged between 18-40 years-old, who had at least one episode of sickle cell pain crisis in the last three months pre- enrollment; whom desire to use etonogestrel-releasing implant contraceptive without contraindications will be invited to inserted etonogestrel implant.~Etonogestrel implant is a single implant progestogen-only, with 4 cm in length and 2 mm diameter containing 68 mg etonogestrel (3- ketodesogestrel), the active metabolite of desogestrel, involved in a ethylene vinyl acetate membrane (Huber, 1998), which is released continuously in bloodstream for three years. It will be inserted subdermal, on the inner face of non-dominant arm between the first and seventh day of the menstrual cycle."
62069218|NCT01516203|EXPERIMENTAL|Arm 4|AZD5847 800 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
62069219|NCT01516203|ACTIVE_COMPARATOR|Arm 5|Rifafour e-275 mg tablets given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
62454090|NCT04025879|EXPERIMENTAL|Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo|
62636918|NCT00913081|EXPERIMENTAL|Quercetin 2000 mg|Quercetin 2000 mg once, administered one hour before 500 mg immediate-release niacin
62636919|NCT00913081|PLACEBO_COMPARATOR|Placebo|Placebo once, administered one hour before 500 mg immediate-release niacin
62636920|NCT05657366|EXPERIMENTAL|low and medium risk（a-FRS）lavage|alternative pancreatic fistula risk score system，a-FRS Low risk group (0\~5%), medium risk group (\>5%\~20%), lavage
62069220|NCT02896816|EXPERIMENTAL|Parkinson's subjects|"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.~Surface EMG, MRI and PET scan will be performed at baseline."
62069221|NCT02896816|ACTIVE_COMPARATOR|Control subjects|Participants not affected by neurological disorders. Surface EMG will be performed at baseline.
62636921|NCT05657366|NO_INTERVENTION|low and medium risk（a-FRS） no lavage|alternative pancreatic fistula risk score system，a-FRS Low risk group (0\~5%), medium risk group (\>5%\~20%), no lavage
62636922|NCT05657366|EXPERIMENTAL|high risk（a-FRS）lavage|alternative pancreatic fistula risk score system，a-FRS high risk group (\>20%) lavage
62636923|NCT05657366|NO_INTERVENTION|high risk（a-FRS）no lavage|alternative pancreatic fistula risk score system，a-FRS high risk group (\>20%) no lavage
62069222|NCT06321432|EXPERIMENTAL|Intensive weight loss intervention|The intensive weight loss intervention (IWL) includes total dietary replacements, behavioural support, and weight loss medication. The intervention consists of three phases: induction, weight loss continuation, maintenance, and it will lasts two years in total.
62273875|NCT05170711|EXPERIMENTAL|hypotensive anesthesia|hypotensive anesthesia group
62069223|NCT06321432|ACTIVE_COMPARATOR|Usual care|Denmark: usual care offered by the GP or local municipality. The UK: usual care in primary care, Tier 2 weight management services.
62069224|NCT02305381|EXPERIMENTAL|Semaglutide 0.5 mg/Week|
62069225|NCT02305381|EXPERIMENTAL|Semaglutide 1.0 mg/Week|
62273876|NCT05170711|ACTIVE_COMPARATOR|normotensive anesthesia|normotensive anesthesia group
62273877|NCT01530750||Post cardiac surgery|
62273878|NCT06437873||Total Thyroidectomy (TT) Group|Patients with T3 or T4 stage follicular thyroid carcinoma who underwent total thyroidectomy
62454091|NCT04025879|PLACEBO_COMPARATOR|Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac.|
62454092|NCT06135532|NO_INTERVENTION|Non-Periodontitis|Only received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.
62454093|NCT06135532|NO_INTERVENTION|Non-Peridontitis with T2DM|Only received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.
62636924|NCT05628246|ACTIVE_COMPARATOR|In-person|Face to face at OPD
62636925|NCT05628246|EXPERIMENTAL|Telemedicine|Telemedicine
62636926|NCT00185315|EXPERIMENTAL|Arm 1|
62636927|NCT03045939|OTHER|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\\h)
62636928|NCT03045939|ACTIVE_COMPARATOR|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\\h)
62636929|NCT00712257|OTHER|Spectranetics Laser plus Gore Viabahn Endoprosthesis|Spectranetics Laser for optimal debulking followed by adjunctive PTA plus GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface placement
62069226|NCT02305381|PLACEBO_COMPARATOR|Semaglutide Placebo 0.5 mg/Week|
62069227|NCT02305381|PLACEBO_COMPARATOR|Semaglutide Placebo 1.0 mg/Week|
62069228|NCT05240378||Pre covid|Cases operated one year prior to the date of declaration of corona pandemic in India
62069229|NCT05240378||post covid|cases operated from the date of declaration of corona pandemic to one year after
62069230|NCT04795817||Single arm|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA
62069231|NCT06150989||Observational Group|Black women enrolled in this study will complete a series of lab-based assessments that evaluate their vascular health, followed by a 10-day free-living monitoring period with mobile and wearable devices.
62636930|NCT03139734|OTHER|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
62636931|NCT00910598|EXPERIMENTAL|glatiramer acetate|glatiramer acetate 20 mg s.c. daily for 1 year
62069232|NCT03508999|EXPERIMENTAL|Metronidazole Gel|Group A subjects will be given standard oral hygiene instructions on the visit with a standard 0.8 % metronidazole gel instructed to apply topically on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
62069233|NCT03508999|OTHER|SMS Text Reminder|Subjects will be provided biweekly reminder via SMS in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
62636932|NCT00910598|NO_INTERVENTION|no treatment|No disease modifying treatment allowed
62636933|NCT02762084|EXPERIMENTAL|Patidegib gel 2%|Patidegib gel 2%, applied topically, twice daily for 26 weeks
62454094|NCT06135532|ACTIVE_COMPARATOR|Periodontitis|"The patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.~The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks."
62636934|NCT02762084|EXPERIMENTAL|Patidegib gel 4%|Patidegib gel 4%, applied topically, twice daily for 26 weeks
62636935|NCT02762084|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel, applied topically, twice daily for 26 weeks
62636936|NCT05318989||Premenopausal women (PREM)|Control group
62273879|NCT06437873||No Total Thyroidectomy (No-TT) Group|Patients with T3 or T4 stage follicular thyroid carcinoma who did not undergo total thyroidectomy.
62636937|NCT05318989||Postmenopausal women (POSMA)|Test group A : postmenopausal women not treated with topical estrogens
62636938|NCT05318989||Postmenopausal women (POSMB)|Test group B: postmenopausal women treated with topical estrogens
62636939|NCT01714544|EXPERIMENTAL|Cloderm Cream|Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
62636940|NCT03615261|EXPERIMENTAL|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy \& attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing \& strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
62636941|NCT05191719|ACTIVE_COMPARATOR|Botox|
62636942|NCT05191719|EXPERIMENTAL|Neurotomy|
62636943|NCT04037124||Cervical procedure abandoned|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is abandoned due to intraoperatively reported lymph node matestasis. Patient is referred for primary (chemo)radiation.
62069234|NCT03508999|PLACEBO_COMPARATOR|Placebo|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
62069235|NCT01306175|EXPERIMENTAL|Digoxin alone (Reference)|Tablet, oral administration with 240 mL water
62069236|NCT01306175|EXPERIMENTAL|Digoxin plus BI 10773 (Test)|Tablets, oral administration with 240 mL water
62069237|NCT02781896|ACTIVE_COMPARATOR|Right ventricular pacing|Rapid pacing during TAVI is provided by a temporary pacing catheter placed in the right ventricle. An additional venous vascular access is required.
62069238|NCT02781896|EXPERIMENTAL|Left ventricular pacing|Rapid pacing during TAVI is provided by the valve delivery guidewire inserted into the left ventricle using two alligator clamps. One clamp is attached directly to the skin at the femoral entry site, the other is attached to the body of the valve delivery guidewire. No additional venous vascular access is required.
62069239|NCT01960790||Participants who received Humira®|Humira® 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
62069240|NCT01356641|EXPERIMENTAL|Antibiotic treatment alone|"Intravenous administration:~Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily~Oral administration of:~Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)"
62069241|NCT01356641|ACTIVE_COMPARATOR|Appendectomy|Routine appendectomy either laparoscopic or open depending on the surgeon's preference
62069242|NCT03222544|EXPERIMENTAL|Photodynamic Therapy|The photosensitizer, methylene blue, is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of seven times.
62273880|NCT06437873||Radioactive Iodine Therapy (RAIT) Group|Patients in the No-TT group who received radioactive iodine therapy.
62636944|NCT04037124||Cervical procedure completed|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is completed. Patient is referred for adjuvant chemoradiation.
62069243|NCT03222544|ACTIVE_COMPARATOR|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of seven times.
62273881|NCT06437873||No Radioactive Iodine Therapy (No-RAIT) Group|Patients in the No-TT group who did not receive radioactive iodine therapy.
62069244|NCT02131038||Ectoin group|Ectoin Allergy Nasal Spray
62636945|NCT05582278|EXPERIMENTAL|HAIC+lenvatinib+tislelizumab|Hepatic Arterial Infusion Chemotherapy Combined With lenvatinib and tislelizumab
62273882|NCT03787472|EXPERIMENTAL|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
62273883|NCT03787472|EXPERIMENTAL|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
62273884|NCT02940275||Hypertension|
62636946|NCT05582278|EXPERIMENTAL|D-TACE+lenvatinib+tislelizumab|Transarterial chemoembolization with drug-eluting beads Combined With lenvatinib and tislelizumab
62636947|NCT01348139|EXPERIMENTAL|1|AZD3199 800 µg inhaled via single inhaler device (SID), single dose
62636948|NCT01348139|EXPERIMENTAL|2|AZD3199 880 µg inhaled via SID, single dose
62069245|NCT02131038||Cromolyn group|Cromolyn sodium
62069246|NCT02943889|EXPERIMENTAL|Mesenchymal stem cell transplantation|This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.
62636949|NCT01348139|EXPERIMENTAL|3|AZD3199 1400 µg inhaled via SID, single dose
62636950|NCT01348139|EXPERIMENTAL|4|AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose
62636951|NCT01348139|EXPERIMENTAL|5|AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose
62069247|NCT02943889|NO_INTERVENTION|Control group|This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
62069248|NCT02682212|EXPERIMENTAL|Physiotherapy intervention|Intensive pelvic floor muscle training (PFMT) given by a physiotherapist with vaginal/rectal pressure feedback once a week for 12 weeks.
62069249|NCT02682212|NO_INTERVENTION|No intervention|Standard care
62069250|NCT01278875||Acute Coronary Syndrome|Subjects with ACS within 72 hours of clinical presentation
62069251|NCT01278875||Stable CAD subjects|Patients with stable, chronic CAD
62069252|NCT01278875||Control subjects|Healthy individuals
62273885|NCT02940275||Diabetes mellitus|
62273886|NCT02940275||Hypertension and diabetes mellitus|
62273887|NCT02940275||End stage kidney disease|
62636952|NCT01348139|PLACEBO_COMPARATOR|6|Placebo inhaled via Turbuhaler inhaler and SID, single dose
62636953|NCT02849743|EXPERIMENTAL|Syntocinon (= Oxytocin), then Placebo|"Week 0 to Week 7: Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Week 8 to Week 11: Washout~Week 12 to Week 20: Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~\*Dose Escalation, as appropriate, at 2 Weeks"
62069253|NCT04102436|EXPERIMENTAL|1/Sleeping Beauty|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Sleeping Beauty Transposed PBL + high- or low-dose aldesleukin.
62069254|NCT02486549|EXPERIMENTAL|Supraclavicular Block|Ultrasound guided supraclavicular block with 20 ml of 0.25% bupivacaine will be performed
62069255|NCT02486549|ACTIVE_COMPARATOR|Interscalene block|Ultrasound guided inter scalene block with 20ml of 0.25% bupivacaine will be performed.
62273888|NCT02940275||Kidney transplant recipient|
62273889|NCT02940275||Coronary artery disease|
62273890|NCT02940275||Peripheral arterial occlusive disease|
62636954|NCT02849743|EXPERIMENTAL|Placebo, then Syntocinon (= Oxytocin)|"Week 0 to Week 7: Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Week 8 to Week 11: Washout~Week 12 to Week 20: Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)"
62273891|NCT03534700|ACTIVE_COMPARATOR|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
62636955|NCT02492165|EXPERIMENTAL|Age 9 Months through 4 Years Group|Participants age 9 Months through 4 Years old at enrollment
62069256|NCT02674932|EXPERIMENTAL|Signature Strengths|"Patients will complete the Values in Action Youth Survey (VIA-Youth) and will receive a list of his/her top character strengths (signature strengths). The patient will then participate in the Identifying and Using Signature Strengths Intervention."
62273892|NCT03534700|EXPERIMENTAL|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
62273893|NCT02343471|EXPERIMENTAL|20 g whey protein|20 g whey protein dissolved in 200 milliliter (mL) water is consumed as a pre-meal 15 min prior to the main meal. Additionally, 200 mL water is consumed as a part of the main meal.
62636956|NCT02492165|EXPERIMENTAL|Age 5 Years through 11 Years Group|Participants age 5 Years through 11 Years old at enrollment
62636957|NCT02492165|EXPERIMENTAL|Age 12 Years through 17 Years Group|Participants age 12 Years through 17 Years old at enrollment
62636958|NCT02492165|EXPERIMENTAL|Age 18 Years through 60 Years Group|Participants age 18 Years through 60 Years old at enrollment
62069257|NCT02674932|ACTIVE_COMPARATOR|Coping Skills + Memory Aid|Patients will complete the VIA-Youth but will not receive any results. The patient will then participate in the Identifying and Writing Down Coping Skills Intervention.
62069258|NCT02674932|OTHER|Coping Skills (Treatment as Usual)|Patients will complete the VIA-Youth but will not receive any results. After completing the VIA-Youth, the study team member and patient will have a treatment-as-usual discussion about coping skills. (This is equivalent to treatment as usual that is already provided on the psychiatric unit-doctors and nurses on the unit already have this a discussion about coping skills with patients).
62069259|NCT05373134|EXPERIMENTAL|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
62069260|NCT05373134|PLACEBO_COMPARATOR|Placebo|Placebo will be given in a same manner as experimental drug
62273894|NCT02343471|PLACEBO_COMPARATOR|Water|200 milliliter (mL) water consumed as pre-meal 15 min prior to the main meal. 20 g whey protein dissolved in 200 mL water is consumed as a part of the main meal.
62273895|NCT01035905|EXPERIMENTAL|Nelfilcon A|Nelfilcon A contact lens
62273896|NCT01035905|ACTIVE_COMPARATOR|Narafilcon A|Narafilcon A contact lens
62273897|NCT01357369||Ondansetron/Cefazolin treatment|Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
62069261|NCT02891239|EXPERIMENTAL|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
62069262|NCT06112639|EXPERIMENTAL|DANCEREX Treatment|Multidimensional dance-based program with motivational support integrated into applied game. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
62273898|NCT02510287|ACTIVE_COMPARATOR|Continuous Epidural Infusion|"1. An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~2. A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.~3. Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~4. If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered."
62636959|NCT01914237|EXPERIMENTAL|Castor Stent Graft|To study the safety and efficacy of Castor single-branched stent graft system in endovascular repair of aortic dissection.
62273899|NCT02510287|EXPERIMENTAL|Programmed Intermittent Epidural Bolus|"1. An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~2. A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.~3. Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~4. If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered ."
62636960|NCT02157519|EXPERIMENTAL|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
62273900|NCT02499432|EXPERIMENTAL|Motivational Enhancement|Motivational Interviewing/Enhancement is a form of collaborative discussion for strengthening motivation and commitment to change.
62636961|NCT02157519|NO_INTERVENTION|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
62636962|NCT02699996|EXPERIMENTAL|self-management + peer mentoring|Participants complete the self-management + peer mentoring intervention comprising 5 online educational modules and 6 videoconference or phone calls with the peer mentor.
62636963|NCT01475903||sleeve gastrectomy|
62636964|NCT05863819||Mobocertinib|Participants with EGFR ex20ins positive locally advanced or metastatic NSCLC who have received mobocertinib in China's routine clinical practice setting will be observed in this study. The observation period for each participant is planned to be 18 months, starting from the participant who received mobocertinib enrolled in this study and ending at the earliest occurrence of the completion of 18 months of follow-up, death, loss to follow-up, or withdrawal from the study.
62636965|NCT00525837|OTHER|varenicline|open label varenicline
62636966|NCT03018314||Group 1|The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.
62636967|NCT03018314||Group 2|The second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility.
62636968|NCT03018314||Group 3|The third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility \<%32 and Kruger morphology \<4%.
62273901|NCT02499432|NO_INTERVENTION|Standard training|Training as usual
62636969|NCT00738647|ACTIVE_COMPARATOR|Ceram X|Fillings made with a traditional composite material (Ceram X)
62273902|NCT01916265|EXPERIMENTAL|Glucagon level: 0,11 and 1 mg|Glucagon level: 0,11 and 1 mg
62273903|NCT01916265|EXPERIMENTAL|Glucagon level: 0,22 and 0,66 mg|Glucagon level: 0,22 and 0,66 mg
62636970|NCT00738647|EXPERIMENTAL|Filtek Silorane|Fillings made with a new composite material (Filtek silorane)
62636971|NCT06331507|EXPERIMENTAL|CMR in CIED|Patients at Michigan Medicine who come in for cardiac imaging procedures and who have CIEDs.
62636972|NCT02068911||Monitoring of ETCO2 and PTCO2|All neuromuscular patients
62636973|NCT04632459|EXPERIMENTAL|pembrolizumab plus ramucirumab|"* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles"
62636974|NCT00750802|EXPERIMENTAL|1|
62069263|NCT06112639|ACTIVE_COMPARATOR|Multidimensional dance-based program|Multidimensional dance-based program without motivational support. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
62069264|NCT06112639|PLACEBO_COMPARATOR|Educational Program|Educational/informative videos on managing of clinical conditions.The program will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
62069265|NCT04230460|PLACEBO_COMPARATOR|0% THC/ 0% CBD|
62273904|NCT01916265|EXPERIMENTAL|Glucagon level: 0,44 and 0,33 mg|Glucagon level: 0,44 and 0,33 mg
62273905|NCT04099303|EXPERIMENTAL|Vaccine 1A|Subjects received one dose of DTaP aged 4 to 6 years.
62273906|NCT04099303|ACTIVE_COMPARATOR|Vaccine 1B|Subjects received one dose of DT aged 4 to 6 years.
62273907|NCT04099303|EXPERIMENTAL|Vaccine 2A|Subjects received one dose of DTcP aged 18 to 24 months.
62636975|NCT00750802|EXPERIMENTAL|2|
62069266|NCT04230460|EXPERIMENTAL|THC (5-10% [37.5 mg]) / Low CBD (<1% [2.5 mg])|
62069267|NCT04230460|EXPERIMENTAL|THC (>10% [62.5 mg]) / Low CBD (<1% [2.5 mg])|
62069268|NCT04230460|EXPERIMENTAL|0.065% BAC|
62273908|NCT04099303|ACTIVE_COMPARATOR|Vaccine 2B|Subjects received one dose of DTaP aged 18 to 24 months.
62273909|NCT04099303|EXPERIMENTAL|Vaccine 3A|Subjects received three doses of DTcP at 3,4,5 months of age.
62636976|NCT00750802|ACTIVE_COMPARATOR|3|
62636977|NCT00750802|PLACEBO_COMPARATOR|4|
62069269|NCT02471885|EXPERIMENTAL|Remote ischaemic conditioning|Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10\^9/L, skip remote ischaemic conditioning (RIC) if platelets \< 50 x 10\^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
62069270|NCT02471885|PLACEBO_COMPARATOR|Control|Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes
62069271|NCT00054964|EXPERIMENTAL|Albuterol HFA-BOI|
62069272|NCT00054964|ACTIVE_COMPARATOR|Albuterol HFA-MDI|
62069273|NCT00914290|OTHER|IPX056-Baclofen IR-IPX056|Following 2 weeks of run-in period, subjects were randomized to IPX056 and Placebo IR for 2 weeks and then to Baclofen IR and Placebo IPX056 for 2 weeks.
62636978|NCT00263198|EXPERIMENTAL|Letrozole + PTK787/ZK222584|"Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)~Start cycle 1 with:~* Letrozole 2.5 mg PO once daily~* PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.~Subsequent cycles:~* PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily~* Letrozole 2.5 mg PO once daily"
62636979|NCT04329429|EXPERIMENTAL|RC48-ADC|Participants will be treated with RC48-ADC 2.5 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
62636980|NCT01773083|EXPERIMENTAL|unfractionated heparin|25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)
62636981|NCT01773083|PLACEBO_COMPARATOR|placebo|Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)
62636982|NCT02864069|EXPERIMENTAL|Walking Intervention|
62069274|NCT00914290|ACTIVE_COMPARATOR|IPX056-IPX056-Baclofen IR|Following 2 weeks of run-in period, subjects were randomized to Baclofen IR and Placebo IPX056 for 2 weeks and then to IPX056 and Placebo IR for 2 weeks.
62069275|NCT02508922|EXPERIMENTAL|Vitamin D3|2000iu vitamin D will be taken daily for 20 weeks.
62069276|NCT02508922|PLACEBO_COMPARATOR|Placebo|Matching placebo drops will be taken daily for 20 weeks
62069277|NCT03864601|EXPERIMENTAL|14C-JNJ-56136379|Participants will receive a single oral 25 milligram (mg) dose of 14C-JNJ-56136379 on Day 1 under fed conditions.
62069278|NCT02134210|ACTIVE_COMPARATOR|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
62273910|NCT04099303|ACTIVE_COMPARATOR|Vaccine 3B|Subjects received three doses of DTaP at 3,4,5 months of age.
62636983|NCT02864069|EXPERIMENTAL|Cognitive Training Intervention|
62636984|NCT02864069|EXPERIMENTAL|Combined Intervention|
62636985|NCT01023594|ACTIVE_COMPARATOR|External stent|Feeding tube insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
62636986|NCT01023594|ACTIVE_COMPARATOR|Internal stent|short(5cm)internal stent insertion at pancreatojejunostomy site
62636987|NCT05931536||Low fibre consumers|Healthy adults consuming less than or equal to 18 grams of fibre per day.
62636988|NCT05931536||Moderate fibre consumers|Healthy adults consuming between 18.1-24.9 grams of fibre per day.
62636989|NCT05931536||High fibre consumers|Healthy adults consuming greater than or equal to 25 grams of fibre per day.
62636990|NCT06492447||HER2 low-expressing|
62636991|NCT05687097||Individuals without sleep apnea after spinal cord injury|No significant sleep apnea is defined as an apnea-hypopnea index (AHI) \< 5 events per hour of sleep
62636992|NCT05687097||Individuals with mild sleep apnea after spinal cord injury|Mild sleep apnea is defined as an apnea-hypopnea index (AHI) ≥ 5 events per hour of sleep, but an AHI \<15 events.
62069279|NCT02134210|EXPERIMENTAL|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
62069280|NCT00641758|PLACEBO_COMPARATOR|Placebo|
62069281|NCT00641758|ACTIVE_COMPARATOR|Pycnogenol|
62069282|NCT00655330|ACTIVE_COMPARATOR|1|Valsartan (160mg/day)is given in combination with Placebo
62069283|NCT00655330|EXPERIMENTAL|2|Valsartan (160mg/day) + Probucol (750mg/day)
62069284|NCT00871403|EXPERIMENTAL|Arm 1|Investigational treatment (pazopanib and pemetrexed)
62069285|NCT00871403|ACTIVE_COMPARATOR|Arm 2|Standard treatment (pemetrexed and cisplatin)
62069286|NCT02021539||The study population|"The study population consists of pregnant women presenting between the 24th and 34th week of pregnancy, with uterine contractions associated with cervical changes objectified by ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both single or multiple pregnancies can be included).~Intervention : Cervical ultrasound +elastography 1 Intervention : Vaginal fibronectin measurement Intervention : Tocolytic treatment for 2 hours Intervention : Cervical ultrasound +elastography 2"
62069287|NCT03936140|EXPERIMENTAL|Iloprost 10|"Iloprost 10μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
62069288|NCT03936140|EXPERIMENTAL|Iloprost 20|"Iloprost 20μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
62069289|NCT03936140|PLACEBO_COMPARATOR|Distilled water|"Distilled water~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
62069290|NCT00345813|EXPERIMENTAL|Arm I|Patients receive oral soy supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy supplementation.
62069291|NCT00345813|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of placebo supplementation.
62069292|NCT03219268|EXPERIMENTAL|Tebotelimab: 1 mg|
62069293|NCT03219268|EXPERIMENTAL|Tebotelimab 3 mg|
62273911|NCT04099303|ACTIVE_COMPARATOR|Vaccine 3C|Subjects received three doses of DTaP-IPV-Hib at 3,4,5 months of age.
62069294|NCT03219268|EXPERIMENTAL|Tebotelimab: 10 mg|
62273912|NCT04099303|EXPERIMENTAL|Vaccine 4A|Subjects received three doses of DTcP at 2,3,4 months of age.
62273913|NCT04099303|ACTIVE_COMPARATOR|Vaccine 4B|Subjects received three doses of DTaP-IPV-Hib at 2,3,4 months of age.
62273914|NCT04099303|EXPERIMENTAL|Vaccine 4C|Subjects received three doses of DTcP at 2,4,6 months of age.
62273915|NCT06372132|OTHER|G-POEM|
62273916|NCT06372132|ACTIVE_COMPARATOR|PEG-J|
62636993|NCT05687097||Individuals with moderate sleep apnea after spinal cord injury|Mild sleep apnea is defined as an apnea-hypopnea index (AHI) ≥ 5 events per hour of sleep but an AHI \<15 events.
62069295|NCT03219268|EXPERIMENTAL|Tebotelimab: 30 mg|
62069296|NCT03219268|EXPERIMENTAL|Tebotelimab: 120 mg|
62069297|NCT03219268|EXPERIMENTAL|Tebotelimab: 400 mg|
62069298|NCT03219268|EXPERIMENTAL|Tebotelimab: 600 mg|
62069299|NCT03219268|EXPERIMENTAL|Tebotelimab: 800 mg|
62069300|NCT03219268|EXPERIMENTAL|Tebotelimab: 1200 mg|
62069301|NCT03219268|EXPERIMENTAL|Combination cohort 1|Tebotelimab and margetuximab
62069302|NCT03219268|EXPERIMENTAL|Combination Cohort 2|Tebotelimab and margetuximab
62069303|NCT03219268|EXPERIMENTAL|Monotherapy Cohort Expansion|Monotherapy expansion at 600 mg
62069304|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
62069305|NCT02292810|EXPERIMENTAL|Inspiratory muscle exercise|Patients will exercise the inspiratory muscle using a load of 60% of maximum inspiratory mouth pressure (MIP 60%).
62069306|NCT02292810|PLACEBO_COMPARATOR|Inspiratory muscle exercise placebo|Patients will exercise the inspiratory muscle using a load of 2% of maximum inspiratory mouth pressure (MIP 2%).
62069307|NCT04096521||East Jakarta Cohort Study|One group included in the study was originated from mothers who participated in the first data collection pregnancy. The follow-up study included mothers and their children born as the subject in the follow-up in the study. This study also includes peer of the subjects that lived in the same neighbourhood since the first cohort study and have children in the same age with cohort participant
62069308|NCT05358587|EXPERIMENTAL|PENG (20 mL)|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %)
62273917|NCT02085603|ACTIVE_COMPARATOR|Saracatinib|Saracatinib at a dose of 125mg orally will be administered daily for four weeks.
62273918|NCT02085603|PLACEBO_COMPARATOR|Placebo|Placebo tablet to be orally administered daily for four weeks.
62273919|NCT04451915|EXPERIMENTAL|Early management GDM group|defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
62636994|NCT05687097||Individuals with severe sleep apnea after spinal cord injury|Severe sleep apnea is defined as an apnea-hypopnea index (AHI) \> 30 events per hour of sleep.
62636995|NCT01289327|ACTIVE_COMPARATOR|propofol|
62636996|NCT01289327|ACTIVE_COMPARATOR|midazolam+alfentanil|
62636997|NCT00456872|EXPERIMENTAL|buffered lidocaine|Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
62636998|NCT00456872|EXPERIMENTAL|unbuffered lidocaine|lidocaine is injected without sodium bicarbonate added
62273920|NCT04451915|EXPERIMENTAL|Late management GDM group|early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.
62454095|NCT06135532|ACTIVE_COMPARATOR|Periodontitis with well-controlled T2DM|"The patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.~The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks."
62454096|NCT06135532|ACTIVE_COMPARATOR|Periodontitis with poorly-controlled T2DM|"The patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.~The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks."
62454097|NCT03236766|OTHER|No intervention|
62273921|NCT01827033|OTHER|meditation training|
62273922|NCT06163612||Healthy controls, or people who do not have depression.|
62273923|NCT06163612||People diagnosed with MDD and a history of suicide attempt|
62273924|NCT06163612||People diagnosed with MDD without a history of suicide attempt|
62273925|NCT00969449|EXPERIMENTAL|Arm 1|
62273926|NCT00969449|ACTIVE_COMPARATOR|Arm 2|
62273927|NCT00892411||All study participants|Patients With Acute Low Back Pain
62454098|NCT05631366|ACTIVE_COMPARATOR|Spaced AAT|AAT-S participants will receive 4 AAT sessions totalling 1200 trails but spaced out over four weeks (one AAT session per week)
62636999|NCT01441128|EXPERIMENTAL|Arm 1|The starting doses will be 200 mg by mouth, twice a day of PF 02341066 in tablet form and 30 mg by mouth once a day of PF 0029804 in tablet form. Thedose of each drug in the combination will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
62637000|NCT01441128|EXPERIMENTAL|Arm 2|45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
62637001|NCT00692380|EXPERIMENTAL|A|Fractionated Radiation Therapy followed by Carboplatin and Taxol
62637002|NCT04426097|EXPERIMENTAL|Cervical Vagal Blockade|
62273928|NCT04065529|EXPERIMENTAL|Gelatin tannate (GT)|Gelatin tannate (GT)
62273929|NCT04065529|PLACEBO_COMPARATOR|Placebo|Placebo
62273930|NCT03485833|EXPERIMENTAL|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography during end expiratory and end inspiratory occlusion test to predict volume responsiveness.Responders are defined by an increase in velocity time integral over 15% after infusion of 5ml/kg of crystalloid solution.
62273931|NCT01908660||Antiretroviral drugs|Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
62273932|NCT02579980|EXPERIMENTAL|DCE and DWI MRI group|Patients will undergo a baseline MR exam at enrollment within 4 weeks prior to scheduled surgery, which will include DW-MRI and DCE-MRI prior to surgery and tumor tissue collection.
62273933|NCT02645175|EXPERIMENTAL|TW1025|TW1025 oral solution, 20ml, 3 times per day (daily dose: 60 ml)
62273934|NCT02645175|PLACEBO_COMPARATOR|Placebo|TW1025 oral solution matched placebo, 20ml, 3 times per day
62273935|NCT03505229|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|"Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks.~Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT."
62273936|NCT05121532|ACTIVE_COMPARATOR|non segmental vitiligo|serum analysis
62637003|NCT04426097|PLACEBO_COMPARATOR|Without Blockade|
62273937|NCT05121532|ACTIVE_COMPARATOR|normal volunteer|serum analysis
62273938|NCT03649399|EXPERIMENTAL|Patients with pancreatic stent|abdominal ultrasound and x-ray for stent detection.
62273939|NCT01373983|OTHER|ziconotide|
62273940|NCT04880577|EXPERIMENTAL|TAF|25 mg of daily TAF
62273941|NCT04880577|PLACEBO_COMPARATOR|Placebo|Placebo pill
62273942|NCT01826747|EXPERIMENTAL|experimental|Luteal Phase support
62273943|NCT01826747|NO_INTERVENTION|control|No luteal Phase support
62273944|NCT05066243||focus group|15 service users for focus group
62273945|NCT05066243||questionnaire|150 patients to test questionnaire
62069309|NCT05358587|EXPERIMENTAL|PENG (30 mL)|In this group, US guided PENG block will be performed with 30 ml of Bupivacaine solution (0.25 %)
62273946|NCT02691780|EXPERIMENTAL|Sorafenib|Sorafenib 200mg bid will be administered orally daily every 3weeks
62637004|NCT02383069|EXPERIMENTAL|Intervention Group|The intervention group will have supervised rehabilitation program held twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Each session will consist of three parts: aerobic training, strength training and respiratory physiotherapy. The aerobic training will be held for 35 minutes (10 min of warm up, 20 min on target load and 5 min of slowdown) with initial intensity of 60% of the maximum load obtained in the maximal cardiopulmonary exercise testing or in incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 80%, so that fatigue or dyspnea values are kept between 4 and 6, according to the modified Borg scale.
62637005|NCT02383069|ACTIVE_COMPARATOR|Control Group|The control group will be subjected to supervised respiratory physiotherapy and stretching exercises twice a week, each session with duration of 60 minutes, with minimum interval of 24 hours, for a period of 8 weeks. The oral high-frequency oscillation device (Flutter®) will be used for 10 minutes, 5 minutes in each lateral decubitus, followed by the stretching of upper and lower limbs for 40 minutes. All exercises will be active, performed in sitting and lying positions without increasing the heart rate. The remaining 10 minutes will be used to discuss doubts about the disease and the use of the booklet.
62637006|NCT01991353|EXPERIMENTAL|With PRP|Standardized meniscal repair with PRP (platelet rich plasma) in the meniscal healing bed.
62637007|NCT01991353|ACTIVE_COMPARATOR|Without PRP|Standardized meniscal repair without PRP (platelet rich plasma).
62637008|NCT04994561|EXPERIMENTAL|Subjects receiving study drugs and nutritional supplements|All eligible and consented subjects will receive study drugs and nutritional supplements as described in the intervention.
62637009|NCT00944710|ACTIVE_COMPARATOR|Intensified treatment|Weekend atropine 1% with plano lens over the sound eye
62637010|NCT00944710|ACTIVE_COMPARATOR|Control|Weekend atropine 1%
62637011|NCT02852460|EXPERIMENTAL|Experimental group|rapid recovery
62637012|NCT02852460|NO_INTERVENTION|Controlled group|non-rapid recovery
62637013|NCT01749956|EXPERIMENTAL|FOLFOX6/Aflibercept/Radiation/Surgery|"Preoperative Chemoradiation: (6 weeks)~* 5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;~* Radiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;~* Aflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.~Surgery at least 6 weeks after last day of aflibercept: Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.~Postoperative Chemotherapy and Aflibercept Treatments (four 28-day cycles):~* Aflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.~* Modified FOLFOX6:~  * Leucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~ * Oxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~ * 5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle."
62637014|NCT03289247|NO_INTERVENTION|Regular|"Regular closure:~The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure."
62273947|NCT01520571|ACTIVE_COMPARATOR|Non-Computer Assistance TKA|Non-Computer Assistance TKA
62637015|NCT03289247|EXPERIMENTAL|Additional tissue adhaesive|The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds
62273948|NCT01520571|EXPERIMENTAL|Computer Assistance TKA|Computer Assistance TKA
62273949|NCT03959722|EXPERIMENTAL|Probiotics:Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a multispecies probiotics: Ecologic® PERFORMANCE ( 1\*1010 CFU(Colony forming units)/daily dose, Winclove Probiotics B.V., Amsterdam).
62273950|NCT03959722|PLACEBO_COMPARATOR|Placebo: Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a placebo comparator (Winclove Probiotics B.V., Amsterdam)
62273951|NCT04925895|EXPERIMENTAL|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization (DSTM) is a soft tissue mobilization technique use to treat tight spasm using progressive muscle activation.
62273952|NCT04925895|ACTIVE_COMPARATOR|Proprioceptive neuromuscular facilitation stretching|PNF stretching technique, a type of flexibility training that is effective in improving muscle flexibility and restore functional ranges using a wide array of techniques.
62273953|NCT01407783|EXPERIMENTAL|Problem Solving Tools|The home visitation nurse will teach and utilize the problem solving tools to help low-income depressed mothers. It is a brief treatment with the a non-pathologizing intervention being done in 4-8 sessions.
62069310|NCT04653636||Adhesive capsulitis|Patients presenting to the physical medicine and rehabilitation department \[tertiary care\] of Cochin Hospital with a clinically diagnosis of severe adhesive capsulitis for whom first-line medical treatment is not effective.
62454099|NCT05631366|ACTIVE_COMPARATOR|Massed AAT|AAT-M participants will receive 4 AAT sessions (each with 300 trials) within the space of 8 days (which totals 1200 trails).
62637016|NCT03099460|EXPERIMENTAL|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
62637017|NCT03099460|EXPERIMENTAL|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
62637018|NCT03099460|SHAM_COMPARATOR|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
62637019|NCT06366646|OTHER|group of head nurses|Head nurses received competency-based intervention
62454100|NCT00136201|EXPERIMENTAL|1|armDesc1
62637020|NCT06366646|OTHER|group of assistant head nurses|assistant head nurses received competency-based intervention
62637021|NCT01589367|EXPERIMENTAL|Arm1_ Metformin|Letrozole with concurrent metformin
62069311|NCT01330693|ACTIVE_COMPARATOR|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
62069312|NCT01330693|PLACEBO_COMPARATOR|Placebo|Sugar pill
62069313|NCT02920151|EXPERIMENTAL|BALANCE EXERCISES CIRCUIT|balance exercises circuit for three months, twice weekly, 50 minutes per day.
62637022|NCT01589367|PLACEBO_COMPARATOR|Arm 2_ Letrole alone|Letrozole with placebo
62637023|NCT04778852|EXPERIMENTAL|EksoGT|Device: EksoGT. EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
62637024|NCT04778852|ACTIVE_COMPARATOR|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
62637025|NCT00689962|EXPERIMENTAL|1|Patients with unstable Lisfranc foot fracture-dislocations that receive bioabsorbable screw fixation through surgery.
62637026|NCT00689962|ACTIVE_COMPARATOR|2|Patients with unstable Lisfranc fracture-dislocations of the foot that receive steel screw fixation through surgery.
62637027|NCT03547024|EXPERIMENTAL|Part 1: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail on Day 1 followed by JNJ-55308942 high dose once daily from Day 3 to Day 14 and a single dose of drug cocktail on Day 12.
62637028|NCT03547024|EXPERIMENTAL|Part 2: JNJ-55308942 + Levonorgestrel/Ethinyl Estradiol|Participants will receive a single dose of levonorgestrel/ethinyl estradiol alone on Day 1 followed by JNJ-55308942 high dose once daily on Days 5 to 18 and a single dose of levonorgestrel/ethinyl estradiol on Day 14.
62637029|NCT03547024|EXPERIMENTAL|Part 3: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail alone on Day 1 followed by JNJ-55308942 low dose once daily on Days 3 to Day 14 and a single dose drug cocktail on Day 12.
62637030|NCT00713843|EXPERIMENTAL|1 Manual Therapy Utrecht|"Manual Therapy Utrecht (MTU) During the first consultation the manual therapist enquires about the complaints of the patient. The manual therapist conducts a number of measurements according to protocol. During treatment preferred movements are executed by the manual therapist in the patient's joints. The treatment techniques used by the manual therapist are very gentle mobilizations, without high velocity thrust techniques and are in general painless. In Manual Therapy Utrecht (MTU) it is common to give advices and recommend exercises.~A treatment session lasts between 30 and 60 minutes (repeated after one or two weeks). The maximum number of sessions is six.~The manual therapist has a minimum of five years of working experience."
62069314|NCT02920151|NO_INTERVENTION|CONTROL GROUP|usual routine
62637031|NCT00713843|ACTIVE_COMPARATOR|2 Physical Therapy - Exercise Therapy|"The physical therapist conducts a complaint related function examination. Treatment consist of active exercises, manual traction or stretching and massage. The aims of active exercises are improvement of strength, mobility and movement coordination. Specific mobilization techniques are not a part of physiotherapeutic treatment. Treatment sessions take place no more than twice a week with a maximum of nine sessions (approximately 30 minutes) with a minimum of twenty minutes on active exercise therapy combined with instruction.~To prevent overlap with MTU (experimental arm), physical therapists are selected who are not (also) trained as manual therapists or have started this education.~The physical therapist has at least five years of working experience."
62637032|NCT02298348|OTHER|Sorafenib and Cyclophosphamide/Topotecan|Sorafenib and Cyclophosphamide/Topotecan with growth factor support.
62637033|NCT05991011|EXPERIMENTAL|I2WE (Immersive and interactive wall exergames)|
62069315|NCT06436963|EXPERIMENTAL|narrative medicine training combined with CBL training|The experimental group received narrative medicine training combined with CBL training
62069316|NCT06436963|ACTIVE_COMPARATOR|CBL training|The control group received normal CBL training
62069317|NCT03691948|EXPERIMENTAL|ROPEs|
62454101|NCT05608161||Patients with unilateral sudden deafness with complete recovery of peripheral hearing|The patients who recovered from sudden deafness underwent speech recognition rate tests under different masking conditions and different signal-to-noise ratio conditions within 2 weeks after complete recovery of peripheral hearing and were followed up 3 times at 1, 6, and 12 months after recovery. The test content is the same as the first time.
62637034|NCT05991011|EXPERIMENTAL|2CMA (Complex Cognitive and Motor Activities)|
62637035|NCT05991011|EXPERIMENTAL|EXER|
62637036|NCT05991011|ACTIVE_COMPARATOR|VG (video games)|
62637037|NCT05991011|ACTIVE_COMPARATOR|BIKE (bike)|
62637038|NCT05991011|ACTIVE_COMPARATOR|VG-bike (Video games + bike)|
62637039|NCT05991011|NO_INTERVENTION|CON (control group)|
62637040|NCT01178905|OTHER|Mother CMV positive|
62637041|NCT05417412|EXPERIMENTAL|STEP-UP (brief behavioral therapy)|Intervention arm of open trial
62637042|NCT04054544|EXPERIMENTAL|Gluten challenge|Participants will receive a gluten 4 g powder twice daily (BID), for 13 consecutive days
62637043|NCT04961437||Patients with de novo acute respiratory failure|"The following tests will be performed as part of the research (these tests are usually performed as part of routine care but not routinely and comprehensively):~* A diaphragmatic ultrasound in the half-seated position. Diaphragmatic excursion and thickening fraction will be measured in the right hemi-diaphragm.~* A 10-minute reference acquisition. They will be performed at inclusion, H2, H4 and H48."
62637044|NCT05545176||out of hospital cardiac arrest patients in Asia countries|
62637045|NCT06519838|ACTIVE_COMPARATOR|Maxillary infiltration at room temperature|
62637046|NCT06519838|ACTIVE_COMPARATOR|Inferior alveolar nerve block at room temperature|
62637047|NCT06519838|EXPERIMENTAL|Maxillary infiltration pre-warmed to 37°C|
62637048|NCT06519838|EXPERIMENTAL|Inferior alveolar nerve block pre-warmed to 37°C|
62069318|NCT03691948|ACTIVE_COMPARATOR|Control|
62069319|NCT02433548|EXPERIMENTAL|Fascia iliaca block|Fascia iliaca block (Injection of 30 mLs of bupivacaine 0.5% with epinephrine 5 mcg/mL below the fascia iliaca, Carbostesin®)
62637049|NCT06519838|EXPERIMENTAL|Maxillary infiltration pre-warmed to 40°C|
62637050|NCT06519838|EXPERIMENTAL|Inferior alveolar nerve block pre-warmed to 40°C|
62637051|NCT04693429|EXPERIMENTAL|PRO-172|PRO-172 Ophthalmic Solution QID (four times per day). Single arm.
62637052|NCT01781208|EXPERIMENTAL|Ultrasound-based Acoustic Radiation Force Imaging|The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI).
62637053|NCT02320708|EXPERIMENTAL|Test Acetaminophen (ACE) (1000 mg) and placebo|
62637054|NCT02320708|ACTIVE_COMPARATOR|Commerical ACE (1000 mg) and placebo|
62069320|NCT02433548|SHAM_COMPARATOR|Sham injection|No fascia iliaca block (Sham injection = Subcutaneous injection of 5 cc of normal saline, no intervention)
62069321|NCT04418713|EXPERIMENTAL|exercise group with active video-games|exergaming exercise: A combination of traditional exercise and exercise through active video games performed 3 days a week for one hour during 7 months. As well, it will be including some session about nutritional advice.
62273954|NCT01407783|NO_INTERVENTION|Enhanced Referral|
62273955|NCT00689949|OTHER|folic acid|
62637055|NCT02320708|ACTIVE_COMPARATOR|Commerical Ibuprofen (IBU) (400 mg) and placebo|
62637056|NCT02320708|PLACEBO_COMPARATOR|Placebo|
62637057|NCT02104024||Kidney transplant recipients|CEUS in Kidney Transplant recipients
62637058|NCT02104024||Pancreas transplant recipients|CEUS in pancreas transplant recipients
62637059|NCT00503893||Wilm's Tumor PO1|Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.
62637060|NCT05978518|EXPERIMENTAL|Study Group|The study group will use the device one time daily (in the morning). The data will be reviewed and sent to the provider as detailed by the protocol.
62637061|NCT05978518|SHAM_COMPARATOR|Control Group|The control group will use the device one time daily (in the morning). The data will not be reviewed or acted upon.
62637062|NCT01429662|SHAM_COMPARATOR|Lifestyle Education (LE)|Lifestyle Education (LE) Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
62637063|NCT01429662|EXPERIMENTAL|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
62637064|NCT02694133|EXPERIMENTAL|Aphasia group|Aphasia
62637065|NCT02353026|EXPERIMENTAL|Intravenous Artesunate|Intravenous Artesunate administered on Day 1 and 8 every 3 weeks
62637066|NCT02993848||Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
62273956|NCT03881995|ACTIVE_COMPARATOR|iGlarLixi|Subjects will receive premixed Insulin glargine + lixisenatide once daily for 12 weeks
62273957|NCT03881995|ACTIVE_COMPARATOR|Insulin glargine|Subjects will receive Insulin glargine once daily for 12 weeks
62273958|NCT06541054|NO_INTERVENTION|control group|Body temperature, pulse, arterial blood pressure, SPO2 will be measured and recorded every fifteen minutes in the control group one hour before the operation. The patients in the control group will not be dressed in warm socks and general preparations will be made. During the operation, the patient's body temperature, pulse, arterial blood pressure, SPO2 values will be monitored every fifteen minutes and the total amount of drainage during the operation will be recorded in the same department. Body temperature, pulse, arterial blood pressure, SPO2 values, tremors, and total drainage in the postoperative care unit will be recorded every fifteen minutes. Body temperature, heart rate, arterial blood pressure, SPO2 values will be measured after transferring to the bed and every fifteen minutes for a total of 180 minutes, chills, shivering states, and 24-hour total drainage amount will be recorded in the same section.
62273959|NCT06541054|EXPERIMENTAL|experiment group|One hour before the operation,warm socks will be put on the experimental group,body temperature,heart rate,blood pressure,SPO2 will be measured and recorded every fifteen minutes.During the surgery,body temperature,heart rate,blood pressure,SPO2 value, drainage amount will be measured and recorded every fifteen minutes.The patient will be transferred to the postoperative care unit with warm socks and will stay on his feet in the postoperative care unit.Body temperature, heart rate,blood pressure,SPO2 values will be recorded every fifteen minutes.He will be transferred from the postoperative care unit to the clinic with socks.will stay. After transferring to the bed,body temperature,heart rate, arterial blood pressure, SPO2 will be recorded every fifteen minutes for a total of 180minutes.Chills,chills and the total drainage amount for 24hours will be recorded in the same section.
62273960|NCT06322875|EXPERIMENTAL|Test Side|Each subject will randomly formulate the face on one side as the test side
62637067|NCT02993848||Non-Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
62273961|NCT06322875|PLACEBO_COMPARATOR|Control Side|Each subject will randomly formulate the face on one side as the control side
62637068|NCT01656395|EXPERIMENTAL|MK-1029 10 mg|Participants receive MK-1029 10 mg tablets once daily (QD) for 12 weeks
62637069|NCT01656395|EXPERIMENTAL|MK-1029 30 mg|Participants receive MK-1029 30 mg tablets QD for 12 weeks
62637070|NCT01656395|EXPERIMENTAL|MK-1029 60 mg|Participants will receive MK-1029 two 30 mg tablets QD for 12 weeks
62637071|NCT01656395|EXPERIMENTAL|MK-1029 150 mg|Participants will receive MK-1029 150 mg tablets QD for 12 weeks
62069322|NCT04418713|NO_INTERVENTION|control group|no physical intevention will be provided, but it will be included some sessions on nutritional advice.
62273962|NCT02235532|EXPERIMENTAL|Foramen Herbal Aloe toothpaste|test group was asked to brush the teeth with Foramen Herbal Aloe toothpaste for 30 days once a day.
62273963|NCT02235532|ACTIVE_COMPARATOR|use of fluoride toothpaste (signal)|use of a fluoride toothpaste (signal) in control group once a day for 30 days .
62273964|NCT01418976|EXPERIMENTAL|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
62273965|NCT05687084|EXPERIMENTAL|Total hysterectomy with a uterine manipulator|Total hysterectomy with bilateral salpingo-oophorectomy performed with the use of a uterine manipulator during surgery.
62273966|NCT05687084|NO_INTERVENTION|Total hysterectomy without a uterine manipulator|Total hysterectomy with bilateral salpingo-oophorectomy performed without the use of a uterine manipulator during surgery.
62273967|NCT00294112|EXPERIMENTAL|High dose|High dose (8 million cells per kg of body weight)
62273968|NCT00294112|EXPERIMENTAL|Low dose|Low dose: 2 million cells per kg body weight
62637072|NCT01656395|ACTIVE_COMPARATOR|Montelukast 10 mg|Participants will receive Montelukast 10 mg tablets QD for 12 weeks
62637073|NCT01656395|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo tablets QD for 12 weeks
62069323|NCT02441946|EXPERIMENTAL|Abemaciclib + Anastrozole|"Abemaciclib (150 milligrams \[mg\]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
62069324|NCT02441946|EXPERIMENTAL|Abemaciclib|"Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
62069325|NCT02441946|ACTIVE_COMPARATOR|Anastrozole|"Anastrozole (1 mg) is given orally QD for 2 weeks.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
62273969|NCT02438709|EXPERIMENTAL|COX-2 Inhibitor|Patients who take COX-2 inhibitor
62454102|NCT05608161||Healthy control group|Age-, gender-, and educational-matched healthy controls were enrolled as healthy control group to test speech recognition rates under different masking conditions and different signal-to-noise ratio conditions.
62454103|NCT04876378||Diagnostic (questionnaires, MRI)|Patients complete a series of questionnaires over 15 minutes about knee function and pain, as well as physical activity. Patients also undergo an MRI over 60 minutes.
62637074|NCT01656395|EXPERIMENTAL|MK-1029 1 mg or 3 mg|Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
62637075|NCT01656395|EXPERIMENTAL|Montelukast 10 mg + MK-1029|Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
62069326|NCT00847301||Renal Impairment|
62069327|NCT03693274|EXPERIMENTAL|Mindfulness Course|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center and will also be given access to BreatheAware for Pain Management, a 16- week web-based mindfulness course.
62069328|NCT03693274|NO_INTERVENTION|Usual Care|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center.
62069329|NCT01393041|OTHER|Angio-Seal VIP|
62069330|NCT00547690|EXPERIMENTAL|1|Acupuncture and strength training
62273970|NCT04420598|EXPERIMENTAL|Trastuzumab deruxtecan (DS-8201a)|"* Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);~* Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;~* Cohort 3: HER2-positive BC with progressing BMs after local treatment;~* Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;~* Cohort 5: HER2-positive or HER2-low expressing BC with LMC."
62273971|NCT03657251||CureCloud Direct to Patient|
62273972|NCT04539730|ACTIVE_COMPARATOR|Ropivacaine Standard of Care Group|Participants undergoing elective Total Knee Arthoplasty (TKA) surgery that are randomized to the control group will undergo an ultrasound-guided Adductor Canal Block (ACB) with standard of care (SoC) Ropivacaine post TKA surgery.
62273973|NCT04539730|EXPERIMENTAL|Liposomal Bupivacaine Intervention Group|Participants undergoing elective TKA surgery that are randomized to the intervention group will undergo an ultrasound-guided ACB with Liposomal Bupivacaine post TKA surgery.
62273974|NCT05500625|EXPERIMENTAL|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|
62273975|NCT05500625|EXPERIMENTAL|Ballon-occluded retrograde transvenous obliteration|
62273976|NCT03995615|NO_INTERVENTION|Group I (Control)|• Group I (Control) - 15 periodontally healthy patient with probing depth\< 3mm and ≤ 10% sites with bleeding on probing.
62273977|NCT03995615|NO_INTERVENTION|• Group II|• Group II - 15 systemically healthy chronic periodontitis patient who had presented \>25% of sites with gingival bleeding ,surface demonstrating supra-gingival plaque accumulation and an absence of probing depth ≥ 4mm and clinical attachment level ≥3mm
62454104|NCT05411536||high reinvestor group (HRG)|The participants were divided into two groups, the high reinvestor group (HRG) and the low reinvestor group (LRG), using the conventional median split of their scores on the MSRS-C (Chu \& Wong, 2019; Mak et al., 2020).
62454105|NCT05411536||low reinvestor group (LRG)|The participants were divided into two groups, the high reinvestor group (HRG) and the low reinvestor group (LRG), using the conventional median split of their scores on the MSRS-C (Chu \& Wong, 2019; Mak et al., 2020).
62454106|NCT01261884|NO_INTERVENTION|Routine prenatal care|
62454107|NCT01261884|EXPERIMENTAL|Exercise support|
62454108|NCT01261884|EXPERIMENTAL|Exercise intervention|
62454109|NCT02545946|ACTIVE_COMPARATOR|Traditional|cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
62454110|NCT02545946|ACTIVE_COMPARATOR|Minimally Invasive|Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
62637076|NCT05798715|EXPERIMENTAL|T test|1 tablet contains 1000 mg Metformin HCl \& 50 mg Sitagliptin orally administrated with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing
62069331|NCT00547690|OTHER|2|Strength training
62273978|NCT03995615|NO_INTERVENTION|• Group III|• Group III - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28\[DAS-28\] ≥3.2 to ≤5.1with out scaling and root planing
62273979|NCT03995615|ACTIVE_COMPARATOR|• Group IV|• Group IV - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28\[DAS-28\] ≥3.2 to ≤5.1 with scaling and root planing. Periodontal clinical parameters will be assessed
62273980|NCT01387893|EXPERIMENTAL|Immediate & Delayed Instruction|Male patients with mild to moderate lower urinary tract symptoms will alternately be assigned to either immediate intervention or delayed intervention groups. Statistical assessments will be performed to establish comparability of baseline characteristics in the two groups.
62273981|NCT01902966|EXPERIMENTAL|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
62273982|NCT06062862|ACTIVE_COMPARATOR|The Incentive Spirometer group|The respiratory muscle training program has the following parameters: Duration: 20 minutes per session, Intensity: Clinical adjustment of training intensity based on actual participants' status across session time, holding time, and repetitions. Frequency: 30 per set, with each is 5-6 times. The procedure for the respiratory muscle training program is as follows: a deep slow inspiration while lips fitted around mouthpiece. Visual feedback is provided to the patient, such as a ball rising to a preset marker, to motivate them during the exercise. The patient is instructed to get the planned flow at preset amount. The patient is asked to maintain breathing in along 2-3 seconds. These guidelines should be followed during respiratory muscle training
62273983|NCT06062862|ACTIVE_COMPARATOR|The Breather Respiratory Muscle Trainer group|Utilizing a pre-session checklist can improve the success rate of using the breather for respiratory muscle training. The following items should be included in the checklist: Check the patient's posture, ensuring that they are in a comfortable crook lying or sitting position, initial easiest resistances by manipulating both dials to one, ensure the patient is using the diaphragmatic breathing technique, as this is crucial for the proper use of the breather, and make sure that the patient secures lips on mouthpiece.
62069332|NCT05562063|EXPERIMENTAL|Sotagliflozin|Daily administration of sotagliflozin (2x200 mg, orally, once a day) for 6 months.
62273984|NCT04453293|EXPERIMENTAL|BCG vaccine|Freeze-dried Glutamate Bacillus Calmette-Guérin (BCG) (Tokyo 172) vaccine
62273985|NCT04453293|PLACEBO_COMPARATOR|Placebo|Vaccine diluent \[sodium glutamate\]
62454111|NCT03619031|EXPERIMENTAL|LONG LEAVENING|Acute test meal
62454112|NCT03619031|EXPERIMENTAL|SHORT LEAVENING|Acute test meal
62069333|NCT05562063|PLACEBO_COMPARATOR|Placebo|Daily administration of placebo (2 tablet identical in appearance and color to sotagliflozin tablets, orally, once a day) for 6 months.
62454113|NCT03619031|ACTIVE_COMPARATOR|TRADITIONAL|Acute test meal
62454114|NCT02474264|OTHER|male BRCA mutations carriers|Endothelial function assessment and Cardiovascular biomarkers
62454115|NCT02474264|OTHER|healthy males - control group|Endothelial function assessment and Cardiovascular biomarkers
62454116|NCT04172870||Group I|Healthy group ( No generalised periodontitis and no CAD)
62454117|NCT04172870||Group II|Generalised periodontitis patients without CAD
62454118|NCT04172870||Group III|CAD patients without generalised periodontitis
62454119|NCT04172870||Group IV|Generalised periodontitis with CAD
62454120|NCT04556214|EXPERIMENTAL|Liver Transplant|The patients will be transplanted according to standard procedures by the institutional protocol. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
62454121|NCT01556009|ACTIVE_COMPARATOR|Drug (Vismodegib)|Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
62454122|NCT01556009|ACTIVE_COMPARATOR|Aminolevulinic acid %20 topical solution|Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
62454123|NCT03951337|EXPERIMENTAL|64Cu ATSM|pretherapeutic 64Cu-ATSM PET/CT scan
62454124|NCT04796909|EXPERIMENTAL|Parent coaching|The parent-coaching intervention consists of up to 8 weekly/fortnightly sessions, and each session will last up to one hour.
62454125|NCT04796909|ACTIVE_COMPARATOR|Parent consultation|The parent consultations are given for up to 8 weekly/fortnightly sessions, and each session may last up to one hour.
62454126|NCT01552096|PLACEBO_COMPARATOR|Placebo|The placebo group (n=30) will receive a submucosal infiltration with 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
62454127|NCT01552096|ACTIVE_COMPARATOR|lidocaine|will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.
62273986|NCT05628220|OTHER|Cohort of motion sickness|one group of patient
62454128|NCT01552096|EXPERIMENTAL|Tramadol|(n=30) will receive a submucosal infiltration with 2 mg kg-1 tramadol in 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
62454129|NCT03030196|ACTIVE_COMPARATOR|Denosumab|subcutaneous injection with 60 mg Denosumab once
62454130|NCT03030196|PLACEBO_COMPARATOR|Placebo|subcutaneous injection with NaCl once
62273987|NCT00825565|EXPERIMENTAL|Alwextin cream|8 subjects enrolled in this single study arm. All 8 subjects completed the study.
62273988|NCT02005757|EXPERIMENTAL|Bredinin tablet 150mg|dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
62273989|NCT02005757|ACTIVE_COMPARATOR|Bredinin tablet 50mg|dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
62454131|NCT05380635|EXPERIMENTAL|HyBryte (0.25 % Hypericin)|HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 18-24 hours later starting at 5 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 8 weeks.
62454132|NCT03654196|EXPERIMENTAL|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
62454133|NCT03654196|ACTIVE_COMPARATOR|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
62454134|NCT05375175|EXPERIMENTAL|Hybrid Snack|Hybrid Snack: combination of legumes, in the highest proportion, and lean meat.
62454135|NCT05375175|ACTIVE_COMPARATOR|Meat snack|Meat snack: composed of meat from loin tape
62454136|NCT01279525|EXPERIMENTAL|Multifactorial intervention|Multifactorial intervention to prevent falls
62454137|NCT03816657||Cohort1|Cohort1 (PD-L1+/low NLR)
62454138|NCT03816657||Cohort2|Cohort 2 (PD-L1-/High NLR)
62454139|NCT01217242||Children with cerebral palsy (CP)|ages 2 to \< 10 years who are able to walk with or without an assistive device
62454140|NCT01373970|PLACEBO_COMPARATOR|Placebo|
62454141|NCT01373970|ACTIVE_COMPARATOR|PPI + Placebo|PPI followed by cross over to placebo
62454142|NCT00929539|EXPERIMENTAL|Dose 1 JTT-130|
62454143|NCT00929539|EXPERIMENTAL|Dose 2 JTT-130|
62454144|NCT00929539|EXPERIMENTAL|Dose 3 JTT-130|
62454145|NCT00929539|PLACEBO_COMPARATOR|Placebo|
62454146|NCT01383525|EXPERIMENTAL|Direct Selective Trabeculoplasty|Treatment by an Direct Selective Trabeculoplasty device
62454147|NCT02679677|SHAM_COMPARATOR|Control|Whole body vibration training as sham procedure (5Hz) 3 times a week, 3x2 minutes, for 6 weeks.
62454148|NCT02679677|EXPERIMENTAL|Intervention|Whole body vibration training (12 Hz up to 30 Hz) 3 times a week, 3x2 minutes, for 6 weeks.
62454149|NCT03683407||Chemotherapy Group|All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy.
62637077|NCT05798715|ACTIVE_COMPARATOR|R Reference|1 tablet contains 1000 mg Metformin HCl \& 50 mg Sitagliptin orally administrated with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing
62637078|NCT04571047||Colorectal cancer patients|Patients diagnosed with colonrectal cancer between 2008-2016
62637079|NCT01421498|EXPERIMENTAL|5.0% Lifitegrast|Lifitegrast
62637080|NCT01421498|PLACEBO_COMPARATOR|Placebo|Placebo
62637081|NCT00533715||>100|"The study included healthy children (2.5-6.5 years old) from a number of public kindergartens. An initial screening questionnaire based on the ATA-DLD-78-A for adults, adapted for children and translated into Hebrew, concerning the child's birth, past and present health status, was completed by the parents.~Exclusion criteria: Previous symptoms or treatment for asthma, current respiratory symptoms or other present respiratory diseases."
62273990|NCT05086471|EXPERIMENTAL|NaviCam SB|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
62273991|NCT05086471|OTHER|PillCam SB3|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
62273992|NCT04654208||HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)|Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)
62273993|NCT04654208||HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant|Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)
62454150|NCT00436007|EXPERIMENTAL|GSK 257049 1 Group|"Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib, Polio Sabin™ and GSK 257049 vaccines at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ vaccines at Month 7.~The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania."
62454151|NCT00436007|EXPERIMENTAL|GSK 257049 2 Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, 3 doses of GSK 257049 vaccine at Months 0, 1 and 7, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. Stamaril™ was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
62454152|NCT00436007|ACTIVE_COMPARATOR|Tritanrix™ HepB/Hiberix™ Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
62454153|NCT04330937|EXPERIMENTAL|experimental group|volunteers consume 1 capsule per day for 3 months. (500 mg citrolive).
62454154|NCT04330937|PLACEBO_COMPARATOR|control group Placebo (sucrose)|volunteers consume 1 capsule per day for 3 months. (saccharose).
62069334|NCT04170868|OTHER|Video 1|Ten-day exposure to one of two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
62069335|NCT04170868|NO_INTERVENTION|Video 1 Washout|Ten-day washout period between access to the first and second videos.
62273994|NCT02073773|EXPERIMENTAL|Virtual Reality based therapy, levodopa|"The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
62273995|NCT02073773|ACTIVE_COMPARATOR|occupational therapy, levodopa|"The control group will receive and additional half an hour per working day of standard occupational therapy.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
62273996|NCT01515787|EXPERIMENTAL|Group 1|"Patients will receive FOLFOX chemotherapy once every two weeks for 6 cycles total over a period of 12 weeks. After completing FOLFOX chemotherapy, the patient will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor. If the tumor has not decreased in size by at least 20%, the patient will receive 5FUCMT (radiation with chemotherapy). If the tumor has decreased in size by 20%, then the patient will proceed directly to surgery.~If all borders of the tumor are normal post surgery, then the patient receives six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal then the patient receives chemoradiation therapy for 5.5 weeks after surgery. After chemoradiation, additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization."
62273997|NCT01515787|ACTIVE_COMPARATOR|Group 2|Patients receive 5FUCMT including chemotherapy and radiation therapy for 5.5 weeks. Patients will be given either 5-fluorouracil or capecitabine and radiation therapy. After the chemoradiation therapy is completed, patients will proceed directly to surgery. Post-surgery, patients will receive FOLFOX chemotherapy once every two weeks for 8 cycles total over a period of 16 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization.
62273998|NCT04955392|EXPERIMENTAL|Intervention group|Group of patients that will receive the 4 techniques proposed to evaluate the changes on sleep quality
62273999|NCT04955392|SHAM_COMPARATOR|Control group|Group of patients that will receive a sham technique
62637082|NCT01298700|EXPERIMENTAL|Bimatoprost 0.01% Ophthalmic Solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
62637083|NCT01298700|ACTIVE_COMPARATOR|Bimatoprost 0.03% Ophthalmic Solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
62637084|NCT01831219||ROBODOC|The ROBODOC group received total hip arthroplasty using the ROBODOC Surgical system for preparation of the femoral canal for a femoral stem implant.
62069336|NCT04170868|OTHER|Video 2|Ten-day exposure to the second of the two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
62069337|NCT02340520|EXPERIMENTAL|thophylline and roflumilast|Theophylline for one week, followed by the addition of Roflumilast for a further one week.
62069338|NCT04760730|EXPERIMENTAL|Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29|Subjects will receive 1 intramuscular (IM) injection of 5 × 10\^10 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10\^11 viral particles (vp) (nominal) on Day 29
62274000|NCT02531646|EXPERIMENTAL|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
62274001|NCT02531646|EXPERIMENTAL|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
62274002|NCT02531646|EXPERIMENTAL|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
62274003|NCT00393575|EXPERIMENTAL|Community Mobilization|The intervention population is defined as the community each site is attempting to mobilize.
62274004|NCT02326558|EXPERIMENTAL|microwave enucleation|zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor
62274005|NCT02326558|ACTIVE_COMPARATOR|laparoscopic partial nephrectomy|conventional laparoscopic partial nephrectomy with clamping of the renal artery
62274006|NCT05551832|PLACEBO_COMPARATOR|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months|Placebo beginning day of hospital discharge following PPPD for 6 months
62274007|NCT05551832|EXPERIMENTAL|Esmesol 40mg after PPPD for 6 months|Esmesol 40mg beginning day of hospital discharge following PPPD for 6 months
62274008|NCT06267833|ACTIVE_COMPARATOR|Control group|Receiving the Otago exercise program
62274009|NCT06267833|EXPERIMENTAL|Study group 1|Receiving additional trunk and upper extremity exercises with traditional methods added to the Otago exercise program
62274010|NCT06267833|EXPERIMENTAL|Study group 2|Receiving additional trunk and upper extremity exercises with mobile game method added to the Otago exercise program
62274011|NCT04124588|EXPERIMENTAL|Test group|"After achieving initial hemostasis only with the standard-of-care, endoscopic hemostatic therapie(s)"
62274012|NCT04124588|ACTIVE_COMPARATOR|Control gruop|"After achieving initial hemostasis only with the standard-of-care, Wrap up the first endoscopy without adding an additional procedure."
62274013|NCT06538883|EXPERIMENTAL|Ciprofol|
62274014|NCT06538883|ACTIVE_COMPARATOR|Propofol|
62637085|NCT01831219||Conventional|The conventional group received total hip arthroplasty using the conventional manual tools including a broach to prepare the femoral cavity for femoral stem replacement.
62274015|NCT03594890|EXPERIMENTAL|OVX836 (Intramuscular)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
62274016|NCT03594890|PLACEBO_COMPARATOR|Placebo (Intramuscular)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
62274017|NCT03594890|EXPERIMENTAL|OVX836 (Intranasal)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
62274018|NCT03594890|PLACEBO_COMPARATOR|Placebo (Intranasal)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
62069339|NCT04760730|EXPERIMENTAL|Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29|Subjects will receive 1 intramuscular (IM) injection of rAd26-S (1.0±0.5) х 10\^11 viral particles (vp) (nominal) on Day 1 followed by AZD1222 5 × 10\^10 vp (nominal) on Day 29.
62069340|NCT04176159|EXPERIMENTAL|Motor imagery and task-oriented training group|Two modules. A first module of motor imagery. A second module of task-oriented training and the incorporation of collective activities.
62069341|NCT04176159|NO_INTERVENTION|Usual school routines group|Children continue with the usual school routine. Once the study is completed and the corresponding measurements have been made, the subjects included in this group will be subjected to the same program detailed in the intervention, to not deprive them of their benefits.
62069342|NCT02254837|EXPERIMENTAL|Zilver PTX|
62069343|NCT04551196|ACTIVE_COMPARATOR|Alternating Regimen|A regimen of acetaminophen and ibuprofen alternating doses every 3 hours.
62274019|NCT04066075|EXPERIMENTAL|Telerehabilitation with low vision provider|
62274020|NCT04066075|EXPERIMENTAL|Telerehabilitation w/ low vision provider plus tele-extender|
62637086|NCT01214889|EXPERIMENTAL|Study Group A|Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
62637087|NCT01214889|ACTIVE_COMPARATOR|Study Group B|Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.
62637088|NCT06018155||Single cohort|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
62637089|NCT01535677|EXPERIMENTAL|1|5 mg dapagliflozin and 850 mg Glucophage in fasted state
62069344|NCT04551196|ACTIVE_COMPARATOR|Combined Regimen|A regimen of acetaminophen and ibuprofen dosed together every 6 hours.
62274021|NCT04066075|ACTIVE_COMPARATOR|Usual Care (active control)|
62274022|NCT00705939|EXPERIMENTAL|Naive 30 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
62274023|NCT00705939|EXPERIMENTAL|Naive 60 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
62274024|NCT00705939|EXPERIMENTAL|Switchover|Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)
62274025|NCT03640871|EXPERIMENTAL|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing (AWC=Advanced Wound Care)
62274026|NCT02543528|EXPERIMENTAL|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
62637090|NCT01535677|EXPERIMENTAL|2|dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted
62637091|NCT01535677|EXPERIMENTAL|3|5 mg dapagliflozin and 850 mg Glucophage in fed state
62637092|NCT01535677|EXPERIMENTAL|4|dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state
62637093|NCT01301261|ACTIVE_COMPARATOR|sugammadex 2 mg/kg|2 mg/kg of sugammadex are given when a response of two counts of train of four are present
62637094|NCT01301261|ACTIVE_COMPARATOR|4 mg/kg of sugammadex|4 mg/kg of sugammadex are given when a posttetanic count 1-3 appears
62637095|NCT01301261|ACTIVE_COMPARATOR|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg are given three minutes after the injection of cis-atracurium
62637096|NCT04458675|EXPERIMENTAL|Active|Active capsule
62637097|NCT04458675|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62637098|NCT03717103|EXPERIMENTAL|IBI188|Part A : Initial dose escalation, Part B : Maintenance dose escalation
62637099|NCT04184557|EXPERIMENTAL|"App Staying Calm in the OR"|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) or Mindfulness Self Compassion (MSC)."
62637100|NCT04184557|NO_INTERVENTION|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) arm will not download the app until the study is completed.
62637101|NCT00580411||Alcohol Problem First|Alcohol Problem precedes Insomnia
62637102|NCT00580411||Insomnia First|Insomnia Precedes Alcohol Problem
62069345|NCT01899066|EXPERIMENTAL|Lucentis; chemotherapy|"Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.~Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
62274027|NCT02543528|EXPERIMENTAL|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
62274028|NCT02543528|EXPERIMENTAL|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
62454155|NCT02438878|EXPERIMENTAL|Baby Behavior|"The intervention is comprised of 2 components: HCP and medical staff training and participant education. The trainings will be video-based and aim to build providers' knowledge and skills to support parents' recognition and understanding of common healthy infant behaviors that may be misinterpreted by parents. The intervention does not include any specific recommendations for infant feeding, nor does it include any information related to the assessment, diagnosis or treatment for any medical condition.~After completion of the intervention trainings, health care providers and medical staff will be asked to use what they learned with the mothers of infants in their care. Short handouts for mothers will be provided as tools to reinforce the verbal education. All educational materials will be focused only on supporting parents' abilities to recognize and understand common, healthy infant behaviors."
62069346|NCT01899066|ACTIVE_COMPARATOR|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
62069347|NCT02108145|ACTIVE_COMPARATOR|unilateral metal stent insertion|unilateral metal stent insertion was performed either left or right hepatic lobe as can be drainage more liver volume
62069348|NCT02108145|EXPERIMENTAL|bilateral metal stent insertion|percutaneous transhepatic biliary drainage plus bilateral metal stent.The bare stents were used for PTBS
62069349|NCT04662671|EXPERIMENTAL|RD-X19 Device|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
62069350|NCT04662671|SHAM_COMPARATOR|Sham Device|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
62069351|NCT01523340||Erlotinib treatment|
62069352|NCT02075021|EXPERIMENTAL|lenalidomide and nab-paclitaxel|100 mg/m\^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
62069353|NCT05449886|EXPERIMENTAL|Tidal volume challenge|
62069354|NCT05097118|EXPERIMENTAL|Group of Ketamine injection|Ketamine infiltration for post operative analgesia
62069355|NCT05097118|EXPERIMENTAL|Group of Bupivacaine injection|Bupivacaine infiltration for post operative analgesia
62069356|NCT00401102|OTHER|Interpersonal psychotherapy|All participants received interpersonal psychotherapy adapted for self-injury
62069357|NCT04096573|EXPERIMENTAL|LC51-0255 low dose|Oral, daily, low dose for induction period, high dose for OLE period
62069358|NCT04096573|EXPERIMENTAL|LC51-0255 middle dose|Oral, daily, middle dose for induction period, high dose for OLE period
62454156|NCT02438878|NO_INTERVENTION|Control|The control arm will continue with standard well-baby visit practices during the intervention period and will be offered the option to complete the Baby Behavior online trainings for continuing education credits.
62454157|NCT06485401|EXPERIMENTAL|ADC189 to Child-Pugh Class A|Subjects with Child-Pugh Class A received a single dose once of ADC189 (45 mg/1 tablet).
62069359|NCT04096573|EXPERIMENTAL|LC51-0255 high dose|Oral, daily, high dose for induction period, high dose for OLE period
62069360|NCT04096573|PLACEBO_COMPARATOR|placebo|Oral, daily, placebo for induction period, high dose for OLE period
62069361|NCT02774603|ACTIVE_COMPARATOR|Aquatic Locomotor Training|Aquatic Locomotor Training is a Locomotor Training technique utilizing an underwater treadmill to help increase a patient's independence and function. Aquatic Locomotor Training may require up to three people to obtain desirable gait kinematics: one at each of the patient's legs, and one at the patient's pelvis; however, typically with ambulatory patients, only one therapist is utilized. Therapists are highly trained, using their legs and feet to provide properly timed underwater cues throughout the gait cycle.
62069362|NCT02774603|ACTIVE_COMPARATOR|Land Locomotor Training|Locomotor Training encompasses a variety of interventions ranging from BWSTT to overground gait training to robotic-assisted walk training. Overground Locomotor Training, depending upon the technique used, can require up to four people to complete the intervention (one at each participant's leg, one at the participant's trunk and/or pelvis, and one monitoring the computer and/or treadmill).
62274029|NCT02543528|EXPERIMENTAL|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
62454158|NCT06485401|EXPERIMENTAL|ADC189 to normal haptic function (A)|"Healthy subjects who marched with Group Child-Pugh Class A, that received a single dose of ADC189 (45 mg/1 tablet)."
62454159|NCT06485401|EXPERIMENTAL|ADC189 to Child-Pugh Class B|Subjects with Child-Pugh Class B received a single dose once of ADC189 (45 mg/1 tablet).
62454160|NCT06485401|EXPERIMENTAL|ADC189 to normal haptic function (B)|"Healthy subjects who marched with Group Child-Pugh Class B, that received a single dose of ADC189 (45 mg/1 tablet)."
62069363|NCT06379113|EXPERIMENTAL|Obese EEC group|"This group including 29 EEC cases. Interventional Study Model was Simon two-stage optimal design. Eleven patients were needed for the first stage, and if eight or more patients achieved CR at 28 weeks, the trial can enter into the second stage.~Then every 12 to 16 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded."
62069364|NCT01110343|ACTIVE_COMPARATOR|mindfulness intervention group|Mindfulness intervention is a formatted curriculum based on Mindfulness based stress reduction techniques which have proven effective in reducing stress related to pain, everyday living and medical and psychiatric disorders.
62069365|NCT01110343|ACTIVE_COMPARATOR|conventional parent support group|a 6 week behavioral program, with weekly 1.5 hour sessions with a trained parent mentor, 3 monthly booster sessions and follow-up.
62069366|NCT02117232|EXPERIMENTAL|Visualization balloon|"Colonoscopy performed with the use of Visualization balloon"
62069367|NCT02117232|ACTIVE_COMPARATOR|Traditional CO2-insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
62069368|NCT05546541||subjects normal weight undergo to PRP treatment|subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment.
62069369|NCT05546541||subjects overweight undergo to PRP treatment|subjects with BMI values that exceed the normal weight range (BMI\>25) undergo to PRP treatment.
62069370|NCT05546541||subjects with normal weight undergo to microfragmented adipose tissue treatment|subjects with BMI within the considered normal weight range (≥18.5 e ≤25) and undergo to microfragmented adipose tissue treatment.
62069371|NCT05546541||subjects overweight undergo to microfragmented adipose tissue treatment|subjects with BMI values that exceed the normal weight range undergo to microfragmented adipose tissue treatment. (BMI\>25).
62069372|NCT02733302|EXPERIMENTAL|Hope theory|
62069373|NCT04453241|EXPERIMENTAL|NBP615|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
62069374|NCT04453241|ACTIVE_COMPARATOR|GARDASIL|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
62069375|NCT02409303|EXPERIMENTAL|Screen-Refer-Treat Intervention|PCPs and EI Providers receive training workshops on validated, evidence-based practices (i.e., Online M-CHAT-R/F, STAT, and RIT) and then receive TA (i.e., Screen-Refer-Treat Intervention). At the county level, providers are randomized to the order/timing at which they will receive this system intervention
62069376|NCT02409303|NO_INTERVENTION|Control|No intervention received.
62454161|NCT01375322|ACTIVE_COMPARATOR|Co-Diovan® Group|The starting dose of Co-Diovan® was 1 capsule (contains 1/2 tablet) (valsartan/ hydrochlorothiazide 40 mg/ 6.25 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (valsartan/ hydrochlorothiazide 160 mg/ 25.0 mg) every morning if patients did not achieve the criteria of SBP\<130 mmHg and DBP\< 80 mmHg during treatment period
62454162|NCT01375322|EXPERIMENTAL|Amtrel® Group|The starting dose of Amtrel® was 1 capsule (contains 1/2 tablet) (amlodipine / benazepril hydrochloride 2.5 mg/ 5 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (amlodipine / benazepril hydrochloride 10 mg/ 20 mg) every morning if patients did not achieve the criteria of SBP\<130 mmHg and DBP\< 80 mmHg during treatment period
62454163|NCT01722981|ACTIVE_COMPARATOR|Direct laryngoscopy|Performing percutaneous tracheostomy as accepted in our institute: By placing the tube higher up near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
62454164|NCT01722981|ACTIVE_COMPARATOR|Real time sonography|"Percutaneous tracheostomy will be guided by real time sonography (with the visualization of the needle path) using acoustic shadows of the cricoid and the tracheal rings.~In both methods, in order to identify the anatomic location of the needle prick- after passing the guide wire, the front elevation will be verified by optical means, which will be drawn out immediately afterwards."
62069377|NCT05699915|OTHER|Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors|Patients are treated as standard of care
62069378|NCT05531474|ACTIVE_COMPARATOR|Medical Weight Management|MWM corresponds to standard medical practice for weight loss that is available at the local participating centre, and thus reflects the local standard of care. MWM will typically consist of dietary, lifestyle and/or behavioral modification counseling, which may include nutritional counseling, safe weight management and/or making healthy lifestyle changes. MWM may also include the implementation of a low caloric diet, which may comprise the use of adjuvant meal replacements and/or anti-obesity mediations at the discretion of the treating physician and according to local practice guidelines.
62274030|NCT05048875|EXPERIMENTAL|JNJ-64281802|"There are two cohorts and three groups in each cohort. Cohort 1 consists of Group 1a, Group 1b and Group 2. Cohort 2 consists of Group 3, Group 4, and Group 5. Within each group, participants will either be randomized to receive study drug or placebo.~Four participants will be enrolled in Group 1a before enrolling the remaining participants to Group 1b (12 participants) and Group 2 (14 participants) in Cohort 1.~Based on the interim analysis results of Cohort 1, three groups for Cohort 2 were created. Eight participants will be enrolled in each of the three groups (Group 3, Group 4, and Group 5)."
62637103|NCT05441228|EXPERIMENTAL|Group A|Group A receives virtual reality through Oculus Quest 2. Beat saber application will be used to improve upper limb's motor function of stroke patients. Total 1 hour session will be provided to each patient for 5 days a week. Total period 4 weeks
62069379|NCT05531474|EXPERIMENTAL|Bariatric Surgery|The bariatric surgery procedures performed in BRAVE include either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards. Sleeve gastrectomy will be performed as a stand-alone procedure, but may also be performed as part of a planned duodenal switch. Gastric banding is not permitted. Patients may receive a low fat, high protein meal replacement preceding surgery to reduce the size of the liver. Perioperative use of aspirin, thienopyridines (clopidogrel, ticagrelor or prasugrel), and anti-thrombotic therapy (compression stockings and subcutaneous heparin) should follow local guidelines and will be left at the discretion of the individual surgeons. .
62274031|NCT05048875|PLACEBO_COMPARATOR|Placebo|"There are two cohorts and three groups in each cohort. Cohort 1 consists of Group 1a, Group 1b and Group 2. Cohort 2 consists of Group 3, Group 4, and Group 5. Within each group, participants will either be randomized to receive study drug or placebo.~Four participants will be enrolled in Group 1a before enrolling the remaining participants to Group 1b (12 participants) and Group 2 (14 participants) in Cohort 1.~Based on the interim analysis results of Cohort 1, three groups for Cohort 2 were created. Eight participants will be enrolled in each of the three groups (Group 3, Group 4, and Group 5)."
62274032|NCT00870753|EXPERIMENTAL|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
62274033|NCT00870753|NO_INTERVENTION|Controls|Control group are offered the yoga intervention after finishing the study
62274034|NCT05485948|EXPERIMENTAL|Treatment with P1101|Subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria will start treatment with P1101. The study drug will be subcutaneously injected once every 2 weeks, with the target dose being 500 µg. Subjects will receive an initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg from the subsequent week until Week 52. If the dose needs to be adjusted due to safety or tolerability consideration, it is allowed to be adjusted to the previous dose, but the target dose is preferred to be maintained during the treatment period.
62274035|NCT00826124|ACTIVE_COMPARATOR|I|Two epidural steroid injections two weeks apart based on history and physical exam alone
62274036|NCT00826124|ACTIVE_COMPARATOR|II|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
62069380|NCT03958240|OTHER|Patient with local and/or metastatic solid malignant tumor|Patient receiving an anticancer treatment in the context of their standard care.
62454165|NCT01722981|ACTIVE_COMPARATOR|Bronchoscopy|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
62454166|NCT02674334|ACTIVE_COMPARATOR|NIRS Monitored Not Treated|Anesthesiologist blinded to Near Infrared Spectroscopy (NIRS)
62454167|NCT02674334|ACTIVE_COMPARATOR|NIRS Monitored and Treated|Anesthesiologist treats based on Near Infrared Spectroscopy (NIRS)
62637104|NCT05441228|OTHER|Group B|Group B receives mirror therapy through mirror therapy box. Total 1 hour session will be provided to each patient for 5 days a week. Total period 4 weeks
62637105|NCT00846053|OTHER|Stable lung function|\* Group S (n = 14) will consist of CF patients, aged 12-21 years old, who underwent FDG-PET with stable lung function during the past 4 years, defined as less than 2% decline per year. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
62454168|NCT02483975|EXPERIMENTAL|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
62069381|NCT01305096|EXPERIMENTAL|Yoga group|Participants in this group will take part in six to eight weeks of yoga classes. The classes will be held once a week and each class will be approximately one hour long. The classes will consist of yoga inversions, sun salutations and other yoga postures with deep breathing.
62069382|NCT01305096|NO_INTERVENTION|Control group|Matched control
62069383|NCT01872637|EXPERIMENTAL|Progressive Multi-Component Intervention|Patients in this exercise group will receive 10-18, 45-60 minute, physical therapy visits in their home. This group will consist of progressive resistance exercises for the upper and lower extremity with a portable training device, a motor control-based program of gait/balance training, Activities of Daily Living (ADL) training, and mobility training.
62274037|NCT04868812|EXPERIMENTAL|Patient|All participants will be screened to ensure inclusion/exclusion criteria are met. A biopsy will be taken from each patient one month before the first laser treatment and one month after the last laser treatment. The MonaLisa treatment will be performed monthly for 3 months. A clinical evaluation will be recorded for each patient using validated questionnaires at baseline and one month after the last procedure.
62274038|NCT01171456|PLACEBO_COMPARATOR|Metformin Placebo|
62274039|NCT01171456|ACTIVE_COMPARATOR|Metformin|
62454169|NCT02483975|PLACEBO_COMPARATOR|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
62637106|NCT00846053|OTHER|Rapidly deteriorating lung function|\* Group R (n = 14) will contain CF patients, aged 12-21 years old, who underwent FDG-PET with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
62637107|NCT03351543|EXPERIMENTAL|Exposed group|these volunteers receive microbial inoculate
62637108|NCT03351543|NO_INTERVENTION|control|these volunteers do not receive microbial inoculate
62637109|NCT05658471|EXPERIMENTAL|Usual Brand E-Cigarette (EC) then SREC|Participants will be admitted to hospital research ward within 32 hours of the orientation visit and begin a standardized session of product use using the usual brand of e-cigarette that participants utilize for nicotine use, and will provide expired carbon dioxide samples, pharmacokinetic (PK) blood samples, urine samples, and have cardiovascular and vital signs monitored. Participants will also be asked to complete nicotine-related questionnaires. Participants will then return within 2 weeks to repeat the procedures using the SREC.
62637110|NCT05658471|EXPERIMENTAL|SREC then Usual Brand E-Cigarette (EC)|Participants will be admitted to hospital research ward within 32 hours of the orientation visit and begin a standardized session of product use using the SREC, and will provide expired carbon dioxide samples, pharmacokinetic (PK) blood samples, urine samples, and have cardiovascular and vital signs monitored. Participants will also be asked to complete nicotine-related questionnaires. Participants will then return within 2 weeks to repeat the procedures using the usual brand of e-cigarette that participants utilize for nicotine use.
62637111|NCT05002595||Modified quadruple therapy|pantoprazole 40mg bid, amoxicillin 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 14 days
62069384|NCT01872637|ACTIVE_COMPARATOR|Usual Care Group|"The patients in this group will receive approximately five visits of usual home care but the total number of visits will be determined by the therapist as part of usual care. These visits will likely occur at 1-2 times per week for 3-4 weeks. This group will receive intervention as determined by the physical therapist's initial examination. Interventions may include patient education, home exercises, low intensity strengthening exercise, training in gait, balance and transfers; home safety and assistive device assessment."
62069385|NCT00758160|EXPERIMENTAL|OROS methylphenidate|Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
62454170|NCT02329652|EXPERIMENTAL|Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for hand, arm, and trunk function. Undergoes functional training and assessment.
62454171|NCT05530109||Patients with idiopathic generalised epilepsy|
62637112|NCT05002595||Tailored eradication|pantoprazole 40mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid or pantoprazole 40mg bid, tetracycline 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 7 days
62637113|NCT03268343|EXPERIMENTAL|Schedule A: Fed Then Fasted|"Schedule A (12 subjects):~* Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).~* Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
62069386|NCT05724056|EXPERIMENTAL|Idroflog®|Patients randomized in this group will be treated with Sodium Hyaluronate 2 mg/ml and Hydrocortisone 10 μg/ml.
62069387|NCT05724056|ACTIVE_COMPARATOR|Sodium Hyaluronate 0.18% (Vismed®)|Patients randomized in this group will be treated with Sodium Hyaluronate 0.18%.
62274040|NCT04469478|EXPERIMENTAL|Virtual Reality for imaging review|Each participant (patient and caregiver(s)) will undergo standard 2D imaging review on a computer screen, followed by 3D imaging review in virtual reality during their radiation oncology consultation
62274041|NCT05174000|EXPERIMENTAL|Sequence 1:Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®|Participants will receive single oral dose of Test Euthyrox® on in treatment period 1, followed by single oral dose of Reference Euthyrox® in treatment period 2, followed by single oral dose of Test Euthyrox® in treatment period 3, followed by single oral dose of Reference Euthyrox in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period.
62454172|NCT05530109||healthy controls|age- and sex-matched healthy controls
62454173|NCT03260764|EXPERIMENTAL|group A|
62454174|NCT03260764|PLACEBO_COMPARATOR|group B|
62454175|NCT03260764|EXPERIMENTAL|group C|
62454176|NCT03260764|PLACEBO_COMPARATOR|group D|
62454177|NCT00263809|EXPERIMENTAL|1|Treatment, Mirasol-treated platelets
62069388|NCT02494921|EXPERIMENTAL|Treatment (Phase 1b)|The starting cohort dose level (1) for docetaxel will be 75 mg/m2, administered on day 1 of each cycle. Prednisone will be fixed at 5 mg twice a day. The starting dose level and schedule for ribociclib will begin at 200 mg orally once daily, starting on day 1 of the 21-day cycle. If dose level 1 is not tolerated, then alternative dosing schedules of docetaxel will be evaluated, starting with dose level 1A of 60mg/m2 docetaxel.
62069389|NCT02494921|EXPERIMENTAL|Treatment (Phase 2)|Participants in Phase 2 will receive the Recommended Phase 2 Dose for docetaxel and ribociclib
62637114|NCT03268343|EXPERIMENTAL|Schedule B: Fasted Then Fed|"Schedule B (12 subjects):~* Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).~* Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
62069390|NCT05059054|EXPERIMENTAL|Strengthening group|Strengthening exercise
62274042|NCT05174000|EXPERIMENTAL|Sequence 2:Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® in treatment period 1, followed by single oral dose of Test Euthyrox® in treatment period 2, followed by single oral dose of Reference Euthyrox® in treatment period 3, followed by single oral dose of Test Euthyrox® in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period.
62274043|NCT03215966|EXPERIMENTAL|Sequence A/B|Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
62274044|NCT03215966|EXPERIMENTAL|Sequence B/A|Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
62274045|NCT05185609||Healthy volunteers|Healthy volunteers aged 18-to 65
62454178|NCT00263809|NO_INTERVENTION|2|Reference, Untreated platelets
62454179|NCT04882293|EXPERIMENTAL|Group A: Atorvastatin / Fenofibrate in fixed dose|Group A: Atorvastatin / Fenofibrate in fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg /160 mg Adminstration way: Oral
62637115|NCT03724357|EXPERIMENTAL|Vaccination with Oral Cholera Vaccine (Vaxchora)|Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.
62637116|NCT03432481|EXPERIMENTAL|Knee Arthroplasty using BUKS|Unicompartmental Knee Arthroplasty Surgery
62637117|NCT03569397|EXPERIMENTAL|Music Therapy|Administer music therapy during the operation
62069391|NCT05059054|ACTIVE_COMPARATOR|Insole group|Insole application
62454180|NCT04882293|ACTIVE_COMPARATOR|Group B: Atorvastatin (Lipitor ®)|Group B: Atorvastatin (Lipitor ®) Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
62637118|NCT03569397|NO_INTERVENTION|Non-Music Therapy|No headphones or music therapy during the operation
62637119|NCT06320418||Patients group|A total of 39 female patients in their age range (13-75 years) diagnosed with primary malignant ovarian tumors were enrolled in the study. OC patients were a treatment-naïve Egyptian patients' cohort admitted to the Gynecology and Obstetrics Department or the Oncology Dept., Ain Shams University Hospitals, Cairo, Egypt. Ovarian cancer tissue samples were collected during surgical resection and confirmed by postoperative pathological examinations.
62637120|NCT06320418||Control group|A total of 17 normal ovarian tissue samples were collected from patients with benign uterine diseases, such as myoma, who underwent uterine and ovarian resection. The control's age range is 45-62 years
62637121|NCT03124160|EXPERIMENTAL|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
62069392|NCT02941068|EXPERIMENTAL|Prophylactic group|Patients would received intravenous fluconazole (loading dose 800 mg, then 400 mg/day) or caspofungin (loading dose 70 mg, then 50 mg/day) if patients had organ failure or renal or liver dysfunction during the immediately surgery. The antifungal treatment would continue for 5 to 7 days.
62069393|NCT02941068|NO_INTERVENTION|Empirical group|
62274046|NCT05185609||Asymptomatic patients with quiescent IBD|Asymptomatic patients with IBD in remission.
62274047|NCT05185609||Symptomatic patients with quiescent UC|Symptomatic patients with UC in remission
62274048|NCT05185609||Symptomatic patients with quiescent CD with anorectal involvement|Symptomatic patients with CD with distal involvement of the colon or perianal disease
62069394|NCT05920525|EXPERIMENTAL|Electrical stimulation|In this group of patients, retraction of upper anterior teeth will be done using backward traction, and the remodeling will be enhanced by very light electrical stimulation by a specific device.
62069395|NCT05920525|ACTIVE_COMPARATOR|Traditional retraction of the front teeth|In this group of patients, traditional traction of the front teeth will be employed without any acceleration method.
62637122|NCT03124160|ACTIVE_COMPARATOR|ParaGard® TCu380A|ParaGard® TCU380A containing 380mm2 of copper surface inserted into the uterine cavity.
62637123|NCT03255694|EXPERIMENTAL|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
62637124|NCT04492423||Prasugrel|Patients taking prasugrel
62637125|NCT04492423||Ticagrelor|Patients taking ticagrelor
62069396|NCT05828849|EXPERIMENTAL|Low SES Population - Intervention|Participants receive the study intervention, composed of navigation, compensation, and personalization for study participants. The intervention will be administered in person to the participants recruited for the study and will be administered by peer navigators who will be trained on Motivational Interviewing (MINT) techniques.
62637126|NCT01542450|EXPERIMENTAL|Treatment period 1|
62637127|NCT01542450|ACTIVE_COMPARATOR|Treatment period 2|
62637128|NCT02359110|EXPERIMENTAL|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
62637129|NCT02359110|PLACEBO_COMPARATOR|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
62069397|NCT05828849|NO_INTERVENTION|Low SES Population - No Intervention|Participants receive no intervention components of navigation, compensation, and personalization. Participants will receive their normal medical care through regular doctor visits without any intervention or personalization.
62069398|NCT04859894||Covid19|Patients aged \>18 years with confirmed Covid19 disease with symptoms \>12 weeks, not better explained by other disease
62274049|NCT03695068|EXPERIMENTAL|RISE Intervention|Reading Instruction for Students who are English Learners (El) with Reading Difficulties (RISE): The RISE intervention is a multi-phase treatment that first accelerates basic skills through an emphasis on word reading (e.g., multi-syllable words, morphology, high-frequency words commonly misread; Phase 1), and then provides a longer-term emphasis on fluency and comprehension through systematically varying text difficulty and genre (Phase 2). To assure that students have minimal loss during the summer, RISE adds a summer Book Club that includes provision of books with comprehension activities for students in the RISE intervention arm (Phase 3). This entire approach takes two full academic years and two summers to be replicated across two cohorts.
62454181|NCT00821834|EXPERIMENTAL|Clopidogrel|"Patients received:~* clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose,~* ticlopidine matching placebo twice daily."
62637130|NCT02948712|EXPERIMENTAL|Survivor Distress|This intervention will use the NCCN Distress Screening Thermometer to score each participant on their level of distress. Depending on the score the intervention will be tailored to the participant based on the Overview of Evaluation and Treatment Schema DIS-4 per the NCCN Distress Guidelines V1.0, 2016.
62454182|NCT00821834|ACTIVE_COMPARATOR|Ticlopidine|"Patients received:~* ticlopidine 100 mg twice daily,~* clopidogrel matching placebo once daily."
62454183|NCT02333370|EXPERIMENTAL|LEE011 +Letrozole|LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
62454184|NCT02333370|EXPERIMENTAL|LEE011 + Tamoxifen|LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
62637131|NCT06010797|EXPERIMENTAL|Orthodontic patients who are shown pre-treatment photographs|Group A included 30 patients who were shown their pre-treatment extra-oral and intra-oral photographs.
62637132|NCT06010797|NO_INTERVENTION|Orthodontic patients who were not shown pre-treatment photographs|Group B included 30 patients who were not shown their pre-treatment extra-oral and intra-oral photographs.
62637133|NCT05849038|EXPERIMENTAL|Baricitinib|Participants will be randomized to receive 10 weeks of treatment with baricitinib.
62637134|NCT05849038|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive 10 weeks of treatment with placebo.
62069399|NCT06547398|ACTIVE_COMPARATOR|Adaptive radiotherapy +/- margin reduction|"Phase 1 and 2: Treating Radiation Therapists (RTs) on the treatment machine will review the treatment target and organs at risk contours that are automatically generated on the plan of the day. They will modify these safely, as required, and then also approve the computer generated re-plan of the day, within the bounds of departmental protocols and decision guides (RT led).~Phase 2 only: Margin reduction facilitated by adaptive radiotherapy."
62637135|NCT00811694||a|15 male and 15 female patients with glaucoma
62274050|NCT03695068|NO_INTERVENTION|Business as Usual Comparison Condition|Participants assigned to the Business as Usual (BAU)or comparison condition will participate in an elective class that includes such options as music, cooking, film, study time, or high stakes test preparation.
62637136|NCT00811694||b|30 sex matched healthy volunteers
62274051|NCT03616938|EXPERIMENTAL|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
62637137|NCT06334263||Conservative managment|No intervention for splenic injury other than supportive care
62069400|NCT06547398|ACTIVE_COMPARATOR|Standard radiotherapy|Patients will receive standard image guided radiotherapy
62069401|NCT04861870|EXPERIMENTAL|Intervention|See intervention description
62069402|NCT04861870|NO_INTERVENTION|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but did not receive any intervention.
62069403|NCT04386226|EXPERIMENTAL|2 grams Ambrotose LIFE|2 grams daily for 8 weeks
62069404|NCT04386226|EXPERIMENTAL|4 grams Ambrotose LIFE|4 grams daily for 8 weeks
62069405|NCT04386226|ACTIVE_COMPARATOR|2 grams Advanced Ambrotose|2 grams daily for 8 weeks
62637138|NCT06334263||Splenic embolisation|Interventional radiology guided splenic artery embolisation
62637139|NCT06334263||Splenectomy|Surgical splenectomy
62637140|NCT01429467|OTHER|Continuous Glucose Monitoring (CGM)|10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5. After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
62637141|NCT00849563|ACTIVE_COMPARATOR|SRA+genetic test|patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
62069406|NCT04386226|ACTIVE_COMPARATOR|4 grams Advanced Ambrotose|4 grams daily for 8 weeks
62069407|NCT04386226|PLACEBO_COMPARATOR|Placebo|4 grams Maltodextrin daily for 8 weeks
62069408|NCT03103230|EXPERIMENTAL|Motor Evoked Potentials|Patients with aphasia after a stroke
62069409|NCT03015116|ACTIVE_COMPARATOR|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
62069410|NCT03015116|EXPERIMENTAL|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
62069411|NCT03015116|EXPERIMENTAL|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
62069412|NCT06285942|EXPERIMENTAL|Edoxaban|This arm will receive Edoxaban via PEG
62274052|NCT03616938|EXPERIMENTAL|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
62274053|NCT03616938|EXPERIMENTAL|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
62274054|NCT06419140|EXPERIMENTAL|The rehabilitation group|Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation care
62274055|NCT06419140|NO_INTERVENTION|The control group|Standard SOX/XELOX adjuvant chemotherapy without multimodal rehabilitation care
62637142|NCT00849563|NO_INTERVENTION|SRA only|Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
62274056|NCT04604808||Non hypocalcemic group|Patients that don't develop post-thyroidectomy hypocalcemia
62069413|NCT06285942|ACTIVE_COMPARATOR|No Edoxaban|This arm will receive other DOACs through PEG or subcutaneous heparin or LMWH
62069414|NCT01832103|EXPERIMENTAL|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
62069415|NCT06487819|EXPERIMENTAL|Group 1 - Short Duration Rubber Dam Application|Patients undergoing dental procedures with rubber dam isolation for 30 to 60 minutes. This group will help assess the impact of short-term mouth opening on temporomandibular joint (TMJ) condition.
62637143|NCT00849563|NO_INTERVENTION|no testing control|Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
62069416|NCT06487819|EXPERIMENTAL|Group 2 - Medium Duration Rubber Dam Application|Patients undergoing dental procedures with rubber dam isolation for 60 to 90 minutes. This group will help evaluate the effects of medium-term mouth opening on TMJ condition.
62069417|NCT06487819|EXPERIMENTAL|Group 3 - Long Duration Rubber Dam Application|Patients undergoing dental procedures with rubber dam isolation for more than 90 minutes. This group will provide insights into the impact of long-term mouth opening on TMJ condition.
62069418|NCT02397265|EXPERIMENTAL|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
62069419|NCT02397265|ACTIVE_COMPARATOR|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
62274057|NCT04604808||Hypocalcemic group|Patients that develop post-thyroidectomy hypocalcemia
62637144|NCT06064058|EXPERIMENTAL|Interventional group|This group were assigned to 6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
62637145|NCT06064058|PLACEBO_COMPARATOR|Control group|Ordinary painkillers given
62069420|NCT02397265|PLACEBO_COMPARATOR|Insulin only|Insulin only closed loop
62069421|NCT02468934|EXPERIMENTAL|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
62069422|NCT00194480|EXPERIMENTAL|PegInterferon|Arm 1: 24 weeks of weekly injections of peginterferon Arm 2: control (no treatment)
62274058|NCT02788864|ACTIVE_COMPARATOR|Arterakine|Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinin; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
62274059|NCT02788864|PLACEBO_COMPARATOR|Placebo|Placebo (visually matched to Arterakine for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
62454185|NCT02333370|EXPERIMENTAL|LEE011 + Fulvestrant|LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1
62069423|NCT02043262|EXPERIMENTAL|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to older adults, although there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the older person on a daily basis focusing on self-help.
62069424|NCT02043262|ACTIVE_COMPARATOR|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
62069425|NCT04977518||Patients diagnosed during 2008-2011|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2008-2011
62069426|NCT04977518||Patients diagnosed during 2012-2015|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2012-2015
62069427|NCT01694810|EXPERIMENTAL|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
62637146|NCT06064058|NO_INTERVENTION|No Placebo, no intervention group|Nothing was given to them neither 6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction nor painkillers.
62069428|NCT01694810|EXPERIMENTAL|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel once daily for 4 weeks
62069429|NCT01694810|PLACEBO_COMPARATOR|Vehicle Topical Gel|Vehicle Topical Gel once daily for 4 weeks
62069430|NCT01694810|EXPERIMENTAL|8% NVN1000 Topical Gel|8% NVN1000 8% Topical Gel applied once daily for 4 weeks
62069431|NCT05158881||Neonates delivered by normal vaginal delivery|
62069432|NCT05158881||Neonates delivered by elective cesarean section.|
62069433|NCT02107248|ACTIVE_COMPARATOR|Sleep position: supine|Subjects will be instructed to sleep in a supine position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
62069434|NCT02107248|EXPERIMENTAL|Sleep position: no restrictions|Patients do not have any restrictions in sleeping position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
62069435|NCT00708305|EXPERIMENTAL|NaF toothpaste (1450 parts per million [ppm] fluoride [F])|Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
62637147|NCT05252715|EXPERIMENTAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 20 µg/dose. Primary vaccination at 0, 1 and 2 months of age, respectively. Booster vaccination at 18 months of age.
62637148|NCT05252715|ACTIVE_COMPARATOR|Meningococcal A and C Polysaccharide Conjugate Vaccine|Meningococcal A and C Polysaccharide Conjugate Vaccine, 20 µg/dose. Primary vaccination at 0, 1 and 2 months of age, respectively.
62069436|NCT00708305|ACTIVE_COMPARATOR|NaF toothpaste (1400ppmF)|Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
62069437|NCT00708305|ACTIVE_COMPARATOR|Sodium monofluorophosphate (NaMFP)/ NaF toothpaste (1450ppmF))|Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
62069438|NCT00708305|PLACEBO_COMPARATOR|Placebo toothpaste (0ppmF)|Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
62069439|NCT03246243||Preterm infants|Group A will consist of preterm infants born \< 37 weeks gestational age. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
62274060|NCT00521846||1|As part of their routine care, patient's will receive Biomet modular radial head replacement. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
62454186|NCT05190510||Patient with atheromatous stenosis of the internal carotid artery|
62637149|NCT04078009|EXPERIMENTAL|Aquagen (Starts with Aquagen and finish with Grazax)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
62069440|NCT03246243||Term infants with HIE or at risk of brain injury|Group B will consist of term infants admitted to the NICU for therapeutic hypothermia who are at risk of HIE; admitted with concern for neonatal stroke; seizures of unknown etiology; and those admitted who are at risk of abnormal neurodevelopment such as those with hypoglycemia or NAS. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
62637150|NCT04078009|EXPERIMENTAL|Grazax (Starts with Grazax and finish with Aquagen)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
62454187|NCT01567956|EXPERIMENTAL|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine
62637151|NCT06209073|EXPERIMENTAL|virtual reality exercise|the patients will receive virtual reality and conventional therapy three times a week for six weeks
62637152|NCT06209073|EXPERIMENTAL|conventional treatment|the patients will receive conventional treatment three times a week for six weeks
62637153|NCT00846586|EXPERIMENTAL|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62454188|NCT01567956|PLACEBO_COMPARATOR|Placebo|Modified release tablets containing inert substances
62069441|NCT03246243||Term infants healthy at birth|Group C will consist of healthy term infants from the community and term infants admitted to who had an initial uncomplicated postnatal course that will serve as the control group. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
62069442|NCT05012449|EXPERIMENTAL|Arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with the arthrography-assisted joystick technology.
62069443|NCT05012449|NO_INTERVENTION|No arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with open or close reduction .
62637154|NCT00846586|ACTIVE_COMPARATOR|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62637155|NCT02029222||25 NSCLC patients|25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment.
62637156|NCT02532335|ACTIVE_COMPARATOR|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
62637157|NCT02532335|PLACEBO_COMPARATOR|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
62637158|NCT02532335|ACTIVE_COMPARATOR|Healthy Volunteers OCA|Obeticholic acid Obeticholic acid 25 mg/day in three weeks
62637159|NCT02532335|PLACEBO_COMPARATOR|Healthy volunteers Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
62637160|NCT00251134|ACTIVE_COMPARATOR|1|omega-3-acid ethyl ester 90
62637161|NCT00251134|PLACEBO_COMPARATOR|2|olive oil
62637162|NCT03502499|EXPERIMENTAL|Half-normal saline|
62637163|NCT03502499|ACTIVE_COMPARATOR|Normal saline|
62637164|NCT05702437||MetS Group|it consists of volunteer participants diagnosed with MetS between the ages of 18 and 50. All assessments will be applied to the participants by two different researchers at the same time.
62069444|NCT04359030||Freestyle group|Patients treated with a Freestyle aortic valve bioprosthesis
62069445|NCT04359030||Perimount group|Patients treated with a Perimount aortic valve bioprosthesis
62069446|NCT01333540|EXPERIMENTAL|Active|Escalating Doses of TD-1211
62637165|NCT05702437||Control Group|it will consist of healthy individuals aged 18-50 who do not have any health problems and have volunteered to participate in the study who have undergone a health check within the last 6 months.
62637166|NCT05916989||Leukocyte DNA Samples|Leukocyte DNA specimens extracted from participants enrolled in a completed NIH funded trial will be examined to determine if prior exposure to different behavioral interventions modifies DNA methylation patterns over 6 months.
62637167|NCT04797507|EXPERIMENTAL|Treatment Group|SHR-1210 plus Anlotinib
62069447|NCT01333540|PLACEBO_COMPARATOR|Placebo|
62069448|NCT03075501|ACTIVE_COMPARATOR|Paired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in only one room.
62274061|NCT06241612|ACTIVE_COMPARATOR|Standard group|Upper-neck irradiation at the uninvolved neck
62069449|NCT03075501|OTHER|Unpaired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in both rooms.
62069450|NCT00819065|ACTIVE_COMPARATOR|1-BTA Lanzhou/Allergan|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
62069451|NCT00819065|ACTIVE_COMPARATOR|2. BTA Allergan/Lanzhou|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.
62069452|NCT05863286|EXPERIMENTAL|botulinum toxin type A injection in lateral pterygoid muscle|"Botulinum toxin type A vial will be reconstituted with normal saline to obtain a 10 U/0.1 ml solution, 0.25 ml of this solution containing 25 U BTX-A will be loaded in a 1-ml insulin syringe attached to a needle with 27 Gauge and 31 mm length.~The Lateral pterygoid muscle will be approached extra orally through the space formed by the zygomatic arch and the sigmoid notch of the mandible below the center of the zygomatic arch. The needle will be advanced perpendicular to the skin with the mouth closed. The muscle is approximately 3 to 4 cm deep. Aspiration will be carried out to avoid unintentional intravascular injection. According to the assigned group, the inferior head of Lateral pterygoid muscle will be injected with BTX-A"
62069453|NCT05863286|PLACEBO_COMPARATOR|"Placebo Saline 0.9% injection in lateral pterygoid muscle"|"0.25 ml of normal saline will be loaded in a 1-ml insulin syringe attached to a needle with 27 Gauge and 31 mm length.~The Lateral pterygoid muscle will be approached extra orally through the space formed by the zygomatic arch and the sigmoid notch of the mandible below the center of the zygomatic arch. The needle will be advanced perpendicular to the skin with the mouth closed. The muscle is approximately 3 to 4 cm deep. Aspiration will be carried out to avoid unintentional intravascular injection. According to the assigned group, the inferior head of Lateral pterygoid muscle will be injected with normal saline"
62069454|NCT01793974||Latent Autoimmune Diabetes in Adult|Individuals who meet criteria for Latent Autoimmune Diabetes in Adult
62069455|NCT01793974||Without Latent Autoimmune Diabetes in Adult|Individuals who do not meet criteria for Latent Autoimmune Diabetes in Adult
62069456|NCT05429164|ACTIVE_COMPARATOR|Self Myofascial Release|Self Myofascial Release only
62637168|NCT03627793|ACTIVE_COMPARATOR|High load non-frail|Non-frail participants who will receive resistance training at 70% of their maximal strength
62637169|NCT03627793|ACTIVE_COMPARATOR|low load non-frail|Non-frail participants who will receive resistance training at 30% of their maximal strength
62637170|NCT03627793|EXPERIMENTAL|high load frail|Frail participants who will receive resistance training at 70% of their maximal strength
62069457|NCT05429164|ACTIVE_COMPARATOR|Myofascial Release|Myofascial Release with Physical Therapist Only
62069458|NCT05429164|ACTIVE_COMPARATOR|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization Only
62069459|NCT03976895|OTHER|Supine position (SP)|Supine position (SP) combined with HFNC
62069460|NCT03976895|EXPERIMENTAL|Prone position (PP)|Prone position (SP) combined with HFNC
62069461|NCT00077636|EXPERIMENTAL|1|
62069462|NCT00077636|EXPERIMENTAL|2|
62069463|NCT00997256|EXPERIMENTAL|Verum|Neurapas balance, film-coated tablets
62069464|NCT00997256|PLACEBO_COMPARATOR|Placebo|Film-coated sugar-pill
62274062|NCT06241612|EXPERIMENTAL|Experimental group|The low-risk clinical target volume would be reduced to two vertebral levels below the vertebral level of the metastatic level II-V nodes.
62274063|NCT03718143|EXPERIMENTAL|Arm A: Elderly Newly diagnosed AML|"Combination AZD1775 with AraC~Elderly, newly diagnosed AML"
62637171|NCT03627793|EXPERIMENTAL|low load frail|Frail participants who will receive resistance training at 30% of their maximal strength
62637172|NCT04420728|EXPERIMENTAL|Early auto-mode enabled|Auto mode continuous glucose monitoring enabled 2-10 days post-partum
62274064|NCT03718143|EXPERIMENTAL|Arm B:Relapsed AML and MDS|"Combination AZD1775 with AraC~Relapsed/Refractory AML \& HMA failure AML/ MDS"
62637173|NCT04420728|ACTIVE_COMPARATOR|Delayed auto mode enabled|Auto mode continuous glucose monitoring enabled 12 weeks post-partum
62637174|NCT06499194|ACTIVE_COMPARATOR|intervention group|Participants will taken a medical history review, anthropometric assessments, and waist circumference measurements. Tests included hemoglobin levels, kidney and liver function tests, fasting blood glucose, and lipid profiles. Baseline antihypertensive medications will be recorded in an Excel sheet and taken DASH diet .
62069465|NCT03853317|EXPERIMENTAL|Treatment with avelumab, haNK™ and N-803|The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
62069466|NCT01844115|PLACEBO_COMPARATOR|Placebo|Dose-matched placebo tablets, oral administration
62069467|NCT01844115|EXPERIMENTAL|Vilazodone|Vilazodone tablets, oral administration
62069468|NCT02796963|EXPERIMENTAL|Immediate Intervention|Men will be exposed immediately to a comprehensive intervention promoting HIV testing.
62069469|NCT02796963|EXPERIMENTAL|Delayed Intervention|Men will be exposed to a comprehensive intervention promoting HIV testing after a delay period.
62069470|NCT02261090|EXPERIMENTAL|Formulation B|Slow release (SR) tablet
62069471|NCT02261090|EXPERIMENTAL|Formulation C|SR tablet
62454189|NCT06497387|EXPERIMENTAL|BCMA-targeting CAR T cells therapy|"The study was divided into two phases: dose exploration phase and dose extension phase. Three dose levels (35×10\^6 CAR-T, 100×10\^6 CAR-T, 300×10\^6 CAR-T) were planned for the dose-exploration phase, and 3 to 6 LN or IgG4-RD subjects were included in each dose group. When 1 out of 3 subjects in a dose group showed DLT, 3 subjects were re-enrolled at that dose level. If DLT occurs in ≥2 of 6 subjects, dose reduction or study termination should be considered.~The safe and effective fixed dose of PRG-1801 was determined through the dose-exploration phase, and after evaluation by the investigators, the dose-expansion phase was conducted, in which an additional 3-6 subjects were included in the safe and effective fixed dose for each of the two indications (Lupus Nephritis and IgG4-Related Disease) to further determine the safety and efficacy of this dose for each indications."
62274065|NCT03718143|ACTIVE_COMPARATOR|Arm C: Relapsed AML, MDS and MF|"AZD1775 only~Relapsed/Refractory AML \& HMA failure AML/ MDS and Relapsed/Refractory Primary \& Secondary MF"
62274066|NCT01281462|EXPERIMENTAL|Ceftaroline fosamil and NXL104 (q8h)|
62069472|NCT02261090|EXPERIMENTAL|Formulation D|SR tablet
62069473|NCT02261090|EXPERIMENTAL|Formulation E|SR tablet
62069474|NCT02261090|EXPERIMENTAL|Formulation F|SR tablet
62069475|NCT02261090|EXPERIMENTAL|Formulation G|SR tablet
62069476|NCT02261090|EXPERIMENTAL|Formulation H|SR tablet
62069477|NCT02261090|ACTIVE_COMPARATOR|immediate release (IR) formulation|
62069478|NCT03355963|PLACEBO_COMPARATOR|Group A|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
62069479|NCT03355963|ACTIVE_COMPARATOR|Group B|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
62069480|NCT03355963|ACTIVE_COMPARATOR|Group C|"The treatment group C:~intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test."
62069481|NCT02674490|EXPERIMENTAL|A-tDCS & SALT|A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
62069482|NCT02674490|SHAM_COMPARATOR|Sham-tDCS & SALT|Sham-tDCS plus SALT for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SALT will be a computer delivered oral naming + picture naming task.
62274067|NCT01281462|EXPERIMENTAL|Ceftaroline fosamil and NXL104 (q12h)|
62274068|NCT01281462|ACTIVE_COMPARATOR|Doripenem|
62274069|NCT01446354||Cardiac surgery with HCA|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
62454190|NCT01018706||STEMI patients treated with PCI|Four hundred patients with STEMI treated with primary PCI or rescue PCI.
62637175|NCT06499194|PLACEBO_COMPARATOR|control group|Participants will taken a medical history review, anthropometric assessments, and waist circumference measurements. Tests included hemoglobin levels, kidney and liver function tests, fasting blood glucose, and lipid profiles. Baseline antihypertensive medications will be recorded in an Excel sheet and without taken DASH diet .
62637176|NCT03566095|ACTIVE_COMPARATOR|Coaching and Voices for Food Kit|The treatment communities received community coaching from an Extension Professional or Educator in the use of the Voices for Food kit.
62637177|NCT03566095|SHAM_COMPARATOR|Voices for Food Kit|The comparison community received the Voices for Food kit.
62637178|NCT01796028|PLACEBO_COMPARATOR|Arm A : TAXOTERE® + Metformin placebo|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
62637179|NCT01796028|EXPERIMENTAL|Arm B : TAXOTERE® + Metformin|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
62637180|NCT04035824|ACTIVE_COMPARATOR|Gastrodia and Uncaria granule|Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
62069483|NCT00553202|EXPERIMENTAL|Treatment (chemotherapy and allogeneic SCT)|"Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.~Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.~Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives"
62069484|NCT05436964|PLACEBO_COMPARATOR|Placebo group|Use 250 ml of saline as placebo group.
62069485|NCT05436964|EXPERIMENTAL|Experimental group|Use dexmedetomidine as experimental group
62069486|NCT01403441|EXPERIMENTAL|Radiosurgical Neuromodulation|Bilateral Radiosurgical Neuromodulation using the Cyberknife
62069487|NCT01058434|EXPERIMENTAL|TKI258|
62069488|NCT05472337|EXPERIMENTAL|Colchicine|Subjects allocated to the intervention group will receive colchicine + standard of care for 6 weeks.
62274070|NCT05134272||mCIMT plus NMES|"Phase 1: Infants will receive therapy 1 hour/day, 1 day/week for 3 weeks while wearing a sock 1 hour/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks.~Phase 2:Infants will receive therapy 2 hours/day, 3 days/week for 3 weeks while wearing a splint 24 hours/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks.~Phase 3:Infants will receive therapy 1 hour/day, 1 day/week for 3 weeks while wearing a sock 1 hour/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks."
62274071|NCT00502216|EXPERIMENTAL|1|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
62274072|NCT00502216|PLACEBO_COMPARATOR|2|Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
62274073|NCT01583621|NO_INTERVENTION|Placebo|Placebo group
62274074|NCT01583621|EXPERIMENTAL|Supplementation arm 1|cholecalciferol 18000 U/month for 4 months
62274075|NCT01583621|EXPERIMENTAL|supplementation arm 2|cholecalciferol 60000 U/month for 4 months
62069489|NCT05472337|NO_INTERVENTION|Standard of Care - Control|Subjects allocated to the control group will receive only standard of care for 6 weeks.
62069490|NCT06436937|EXPERIMENTAL|Honey Chlorella|The subjects ingest a single meal: a drink including 40 g of honey chlorella intrinsically labelled with 15N, to provide 20g protein from chlorella
62069491|NCT06436937|EXPERIMENTAL|Faba bean meat analogue|The subjects ingest a single meal: a mixed meal including 80 g of faba bean meat analogue intrinsically labelled with 15N, to provide 20g protein from faba bean
62274076|NCT01583621|EXPERIMENTAL|Supplementation arm 3|cholecalciferol 120000 U/month for 4 months
62274077|NCT02200315|EXPERIMENTAL|No Antimicrobial prophylaxis|No use of antimicrobial prophylaxis during surgery
62274078|NCT00038350|EXPERIMENTAL|1|8 week lingual strengthening exercise protocol
62637181|NCT04035824|PLACEBO_COMPARATOR|Placebo|Placebo of Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
62274079|NCT03979092|EXPERIMENTAL|IP-ACLS|
62274080|NCT03979092|OTHER|Waitlist|
62274081|NCT00184145|EXPERIMENTAL|EMDR|The experimental group was treated for animal phobia by EMDR, control group received an attention placebo (relaxation plus breathing exercises). Afterwards, both groups were treated by exposure therapy (therapy of choice for animal phobia).
62637182|NCT03983954|EXPERIMENTAL|Naptumomab estafenatox 2 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 2 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637183|NCT03983954|EXPERIMENTAL|Naptumomab estafenatox 5 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 5 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637184|NCT03983954|EXPERIMENTAL|Naptumomab estafenatox 10 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637185|NCT03983954|EXPERIMENTAL|Naptumomab estafenatox 15 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637186|NCT03983954|EXPERIMENTAL|Naptumomab estafenatox 20 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62069492|NCT04719663|EXPERIMENTAL|1. Congruent Rationale & Treatment: Biological/Pharmacol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
62069493|NCT04719663|EXPERIMENTAL|2. Incongruent Rationale & Treatment: Psychological/Pharmacol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
62069494|NCT04719663|EXPERIMENTAL|3. Congruent Rationale & Treatment: Psychological/Psychol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
62274082|NCT05012293|EXPERIMENTAL|Experimental: Fatigue Manipulation|
62274083|NCT03992937|EXPERIMENTAL|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
62274084|NCT03992937|ACTIVE_COMPARATOR|LNG-IUS|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.
62069495|NCT04719663|EXPERIMENTAL|4. Incongruent Rationale & Treatment: Biological/Psychol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
62274085|NCT03988335|EXPERIMENTAL|RIST4721|RIST4721 as once-daily 300mg oral solution for 28 days.
62274086|NCT03988335|PLACEBO_COMPARATOR|Placebo|Placebo as once-daily 300mg oral solution for 28 days.
62274087|NCT05528627|OTHER|Pectoral Nerve (PECS) block|Pectoral Nerve (PECs) block was performed at the surgical side 30 min before the procedure
62274088|NCT05248438||Multiple sclerosis patients|patients affected by multiple sclerosis based on McDonald Criteria 2017
62274089|NCT00934349||Patient|Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli) fulfilling the clinical definition of the dry beriberi.
62637187|NCT03983954|EXPERIMENTAL|Dose escalation, obinutuzumab pretreatment followed by NAP 10 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637188|NCT03983954|EXPERIMENTAL|Dose escalation, obinutuzumab pretreatment followed by NAP 15 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637189|NCT03983954|EXPERIMENTAL|MTD expansion, obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at 15mcg/kg and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637190|NCT03983954|EXPERIMENTAL|MTD expansion, obinutuzumab pretreatment with NAP, at the previous dose level, and durvalumab|NAP, at the previous dose level (10mcg/kg), and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62274090|NCT00934349||Control|Native to the Comoro Archipelago, living in the same household as the patient, sharing the same meals. Free from beriberi and with normal neurological examination.
62637191|NCT03983954|EXPERIMENTAL|MTD expansion, abbreviated regimen of obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at MTD (10 mcg/kg/day) and durvalumab (1120 mg) will be given for 6 cycles after a single dose of pre-treatment of obinutuzumab (1000 mg/day) on D-7. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
62637192|NCT02936778||PICU (= case group)|Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.
62637193|NCT02936778||MC (= control group)|Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.
62274091|NCT05512741||Group Ileus|"Patients that experience POI after colorectal surgery. POI is defined by the presence of 2 of the 5 criteria of Vather from the first postoperative day.~The first 10 consecutive patients experiencing POI will be included in the study."
62637194|NCT02380365||Outpatients on the Waiting List and after Lung Transplantation|Electrocardiography
62274092|NCT05512741||No POI group|Patients that do not experience POI. The 10 patients having the fastest recovery of gastro-intestinal functions after surgery during the period of inclusion will be included in the study
62454191|NCT03565809||Case : ADRS group|"Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: F00-F03, G30, or G31), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine or donepezil) or memantine."
62454192|NCT03565809||Control : non ADRS Group|Incidence analysis in non ADRS group. Each incident ADRS case was paired (1:1) to a beneficiary without any ADRS criteria, matched on age (same birth year), sex, residence area (based on of the 100 administrative 'départements') and insurance scheme.
62069496|NCT04719663|NO_INTERVENTION|5. Natural course control|Participants receive no intervention and remain on the psychotherapy waiting list. Participants who are recruited externally and are not on a waiting list, will be offered the option to join the waiting list.
62274093|NCT04429620||Positive group|Subjects are diagnosed with SARS-CoV2 by qPCR assay.
62274094|NCT04429620||Negative group|Subject were 2 times proved negative SARS-CoV2 by qPCR assay.
62274095|NCT02435849|EXPERIMENTAL|Single dose of CTL019|Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).
62274096|NCT04193917|OTHER|conjunctival swab|A conjunctival swab of both eyes will be taken
62274097|NCT05689411|EXPERIMENTAL|Musical Toy Group|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
62637195|NCT01463787|EXPERIMENTAL|inguinal group|
62637196|NCT01463787|ACTIVE_COMPARATOR|sub-inguinal group|
62637197|NCT02246738||Cohort1|
62637198|NCT02246738||Cohort 2|
62454193|NCT02602379||Tetanic stimulation|Single arm study. See Study description for a through description of the intervention.
62454194|NCT04627506|NO_INTERVENTION|Control Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design.~Standardized anesthesia and surgical management will be conducted according to routine institutional practice."
62637199|NCT02246738||Cohort 3|
62637200|NCT02246738||Cohort 4|
62637201|NCT02246738||Cohort 5|
62069497|NCT00974701|EXPERIMENTAL|Patients to undergo PillCam procedure|Patients presenting to ER with acute overt upper GI bleeding
62069498|NCT01688960|EXPERIMENTAL|Cohort 1|
62069499|NCT01688960|EXPERIMENTAL|Cohort 2|
62637202|NCT02246738||Cohort 6|
62637203|NCT02246738||Cohort 7|
62069500|NCT01688960|EXPERIMENTAL|Cohort 3a|
62637204|NCT02246738||Cohort 8|
62637205|NCT02246738||Cohort 9|
62637206|NCT02216383|EXPERIMENTAL|Carbetocin|One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby
62637207|NCT02216383|ACTIVE_COMPARATOR|Syntocinon|One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby
62637208|NCT02216383|ACTIVE_COMPARATOR|Syntometrine|One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby
62069501|NCT01688960|EXPERIMENTAL|Cohort 3b|
62069502|NCT01688960|EXPERIMENTAL|Cohort 4|
62069503|NCT02300285|EXPERIMENTAL|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
62069504|NCT02300285|PLACEBO_COMPARATOR|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
62069505|NCT03017144||Resuscitation team|Resuscitation pit crew model is educated to the resuscitation team.
62069506|NCT04499339|EXPERIMENTAL|All eligible patients|
62069507|NCT03091673|EXPERIMENTAL|G-Pen (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
62274098|NCT05689411|NO_INTERVENTION|Control Group|No distraction technique was applied to the children in the control group before the vascular access procedure. After the procedure was explained according to the child's developmental level, the researcher applied the procedure to open a vascular access in accordance with the institutional policies.
62069508|NCT03091673|EXPERIMENTAL|G-Pen (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
62069509|NCT01633216|ACTIVE_COMPARATOR|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
62637209|NCT05668897|EXPERIMENTAL|Single-dose ascending group|SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 6 subjects receive study drug.
62069510|NCT01633216|ACTIVE_COMPARATOR|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
62069511|NCT01633216|ACTIVE_COMPARATOR|Monovalent OPV 2week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
62069512|NCT01633216|ACTIVE_COMPARATOR|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
62069513|NCT01633216|ACTIVE_COMPARATOR|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
62454195|NCT04627506|EXPERIMENTAL|Study Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
62637210|NCT05668897|PLACEBO_COMPARATOR|SAD placebo comparator group|SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 2 subjects receive placebo.
62637211|NCT05668897|EXPERIMENTAL|Multi-dose ascending group|MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 6 subjects receive study drug.
62637212|NCT05668897|PLACEBO_COMPARATOR|MAD placebo comparator group|MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive placebo.
62637213|NCT05668897|EXPERIMENTAL|Food effect study|FE study cotains at least 1 cohort which were evaluated in SAD study to be tolerated . Each cohort enrolls 12 subjects receive study drug on fast or fed condition.
62637214|NCT02821429||Patient with mechanical ventilation|Patient will be followed with combined Thoracic Echography Record
62637215|NCT01844037|OTHER|Renal denervation|Patients will be treated with the OneShot ablation system
62637216|NCT03708445|EXPERIMENTAL|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
62637217|NCT01055015|EXPERIMENTAL|1|Q8003, Flexible dose
62637218|NCT01055015|EXPERIMENTAL|2|Q8003, Low dose
62637219|NCT03660748|EXPERIMENTAL|Lower BMI|Use of MET-2 in subjects with BMI of 30.0 to 34.9
62637220|NCT03660748|EXPERIMENTAL|Higher BMI|Use of MET-2 in subjects with BMI of 35 to 39.9
62637221|NCT05430425||body weight|(grup VA; igel=n:40 clasic lma n=40),
62637222|NCT05430425||thyromental distance|grup T; igel=n:40 clasic lma n=40)
62637223|NCT05430425||resize with 3 fingers|grup p; igel=n:40 clasic lma n=40
62637224|NCT00500448|NO_INTERVENTION|No Treatment|No treatment was delivered to this arm. Participants went about activities of daily living
62069514|NCT03951935||sLSS|patients diagnosed with sLSS scheduled for decompression surgery
62069515|NCT03951935||control subjects|healthy, age-matched control subjects
62069516|NCT01212406|PLACEBO_COMPARATOR|Placebo|Olive oil
62454196|NCT00684671|EXPERIMENTAL|Twinrix Group|Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
62454197|NCT00684671|ACTIVE_COMPARATOR|Engerix + Havrix Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
62637225|NCT00500448|EXPERIMENTAL|Electrical Stimulation|Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
62637226|NCT06324877|OTHER|Single arm (full group)|Single arm, open-label. Dose will be via oral capsule supplementation Nicotinamide Riboside at 25mg/kg/day divided into 3 doses (max 300mgs 3 times per day). Dosing will occur via 3 equal doses 3 times a day for 12 months.
62637227|NCT03507855|EXPERIMENTAL|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
62637228|NCT03507855|ACTIVE_COMPARATOR|Control|Normal operating room environment.
62637229|NCT06379152||DB≤6.8µmol/L|heart failure with preserved ejection fraction patients with direct bilirubn ≤6.8µmol/L
62637230|NCT06379152||DB>6.8µmol/L|heart failure with preserved ejection fraction patients with direct bilirubn \>6.8µmol/L
62274099|NCT05765539|EXPERIMENTAL|Pregnant women benefitting ultrasound examination|This is the unique arm of the study. This arm is made of eligible pregnant women, with a pregnancy of at least 37 weeks.
62454198|NCT00684671|ACTIVE_COMPARATOR|HB VAX PRO + Vaqta Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).
62637231|NCT00508950|OTHER|All subjects|All subjects
62637232|NCT03007303||schizophrenia|"15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT.~The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated."
62637233|NCT03007303||health controls|15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
62637234|NCT05914350|EXPERIMENTAL|Group 1|40 mg methylprednisolone acetate and 1 mL lidocaine will be injected in sacroiliac joint in first week by ultrasound. While the second and third injections in the second and third weeks will be done by sham injection
62069517|NCT01212406|EXPERIMENTAL|Vitamin D|Addition of D-cure (100.000U) to standard care
62069518|NCT06522243|EXPERIMENTAL|immediate intervention|Start with the 8-week intervention immediately/soon after recruitment
62454199|NCT04260503||Biliary Atresia|Disease group
62454200|NCT04260503||Choledochal cyst|Disease control
62454201|NCT04260503||Neonatal hepatitis|Disease control
62454202|NCT04260503||Healthy baby|Healthy control
62454203|NCT04118478|EXPERIMENTAL|Multi-component phased training program|"The intervention of the program consists of conducting a multi-component training in a neighborhood unit.~The intervention will consist of the realization of a multi-component program in a training center adapted for the elderly. The duration of the program will be 27 weeks with a frequency of two weekly sessions and an intervention duration of 45 to 60 minutes"
62454204|NCT04118478|NO_INTERVENTION|CONTROL|Older people assigned to the GC do not do any training programming. Only attend the measurement dates.
62454205|NCT01968265|PLACEBO_COMPARATOR|Placebo|
62454206|NCT01968265|ACTIVE_COMPARATOR|ISIS-GCCRRx|
62637235|NCT05914350|EXPERIMENTAL|Group 2|3 mL PRP and 1 mL lidocaine will be injected in sacroiliac joint by ultrasound once/week for 3 weeks
62637236|NCT05914350|EXPERIMENTAL|Group 3|10 ml of medical ozone of 20 μg/ml will be injected in sacroiliac joint by ultrasound once/week for 3 weeks
62454207|NCT04820868||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
62454208|NCT04820868||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
62454209|NCT01856088|EXPERIMENTAL|Inspiron Stent|Stent Inspiron with Sirolimus
62454210|NCT01856088|ACTIVE_COMPARATOR|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
62454211|NCT00356200|EXPERIMENTAL|Fluphenazine treated|Treated with fluphenazine
62454212|NCT00356200|PLACEBO_COMPARATOR|Placebo|Treated with Placebo
62454213|NCT02008903||EoE active disease|Inflammation as defined by \>15 eos / HPF
62454214|NCT02008903||EoE remission|No inflammation in EoE patients after treatment
62454215|NCT02008903||normal control|No inflammation
62454216|NCT01187862|OTHER|Basel cocktail|
62454217|NCT02879019|SHAM_COMPARATOR|Stretching exercise group|Patients will receive two session per week of stretching classes.
62454218|NCT02879019|EXPERIMENTAL|Walking training group|Patients will perform two walking sessions per week.
62454219|NCT03838653||Left main bronchus (LMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the left main bronchus (correct placement).
62274100|NCT05506449|ACTIVE_COMPARATOR|Control Arm|Subjects randomized to the Control Arm will be treated based on recommendations for cardiogenic shock in the contemporary AHA/ACC/SCAI and ESC Practice Guidelines for STEMI and Heart Failure Management and local standard of care.
62637237|NCT04656613|EXPERIMENTAL|Vaccine|a study group of 750 subjects receiving the Gam-COVID-Vac combined vector vaccine against the SARS-СoV-2-induced coronavirus infection
62637238|NCT04656613|PLACEBO_COMPARATOR|Placebo|a reference group of 250 subjects receiving placebo
62637239|NCT05591157|EXPERIMENTAL|CSF-3 and ECG Holter|At least 40 healthy subjects with no relevant or cardiac medical history and negative cardiac symptoms. Subjects will perform an ECG spot-check measurement using the CSF-3 Device while simultaneously being connected to an ECG Holter. Recording duration for both ECG Holter and CSF-3 device will be at least 7 minutes.
62637240|NCT02529930|EXPERIMENTAL|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
62637241|NCT02529930|EXPERIMENTAL|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
62637242|NCT03740763|ACTIVE_COMPARATOR|Spinal Cord Stimulation (SCS)|"Spinal Cord Stimulation (SCS)~1. Pharmacological analgetic treatment and treatment with SCS for 3 months~2. Add-on physiotherapy for 6 months to SCS and pharmacological analgetic treatment~3. Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
62637243|NCT03740763|ACTIVE_COMPARATOR|Physiotherapy|"Physiotherapy~1. Pharmacological analgetic treatment for 3 months~2. Physiotherapy for 3 months and pharmacological analgetic treatment~3. Add-on SCS in combination with physiotherapy and pharmacological analgetic treatment for 3 months~4. Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
62637244|NCT05121610||CABG group|CABG group
62637245|NCT05121610||HCR group|HCR group
62637246|NCT05121610||PCI group|PCI group
62637247|NCT04504110|EXPERIMENTAL|Epithelial ovarian cancer|68Ga-FAPI-04 and 18F-FDG PET/CT
62637248|NCT04575220|EXPERIMENTAL|tele-exercise|Subjects will perform three sessions/week of home exercise using bicycles for 12 weeks
62637249|NCT00483535|EXPERIMENTAL|Sequence ABC|All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
62637250|NCT05756881|ACTIVE_COMPARATOR|Serum containing 1.5 % w/w of palm-oil derived vitamin E concentrate|Serum containing 1.5 % w/w of palm-oil derived vitamin E concentrate
62274101|NCT05506449|EXPERIMENTAL|Treatment Arm|Subjects randomized to the Treatment Arm will receive hemodynamic support using an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI).
62637251|NCT05756881|PLACEBO_COMPARATOR|Serum (placebo)|Serum (placebo)
62637252|NCT02975180|EXPERIMENTAL|FES|Unilateral and bimanual activities are performed with FES applied to the hemiparetic arm.
62637253|NCT02975180|EXPERIMENTAL|Conventional|Unilateral and bimanual activities are performed with no FES applied to the hemiparetic arm.
62637254|NCT04851132|EXPERIMENTAL|Exprimental Arm|IMRT plus Durvalumab
62274102|NCT05832294|SHAM_COMPARATOR|Sham Stimulation|15 Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of sham rTMS
62637255|NCT06102317|EXPERIMENTAL|Intervention group|In the study, mobile application will be installed on the phones of the mothers in the initiative group and individual information will be provided about how the patients will use the smartphone application. . Information will be provided to patients for subsequent follow-ups. After the application is started to be used, notifications of the applications developed in Smart Mobile for the disease management process will be made to the mothers of the Initiative Group every two weeks for six months. In addition, the Initiative Group will continue to receive standard care practices such as examinations, examinations, tests, treatment, medical care and rehabilitation offered by the Home Health Services unit.
62274103|NCT05832294|ACTIVE_COMPARATOR|Active Stimulation|15 Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of active rTMS
62274104|NCT05315466|EXPERIMENTAL|Non-surgical treatment|Different types of non-surgical treatments
62637256|NCT06102317|NO_INTERVENTION|control group|No attempts will be made to the control group. The control group will continue to receive the standard care practices offered by the Home Health Services unit.
62637257|NCT02050334|EXPERIMENTAL|CC100 (3 single doses)|CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
62274105|NCT05315466|EXPERIMENTAL|Surgical treatment|Surgical treatment for spinal stenosis
62274106|NCT05497466||Subjects who are male or female outpatients aged 18 years and scheduled for CCTA to rule out CAD|300 patients scheduled for coronary CTA examination to rule out CAD in PUMCH. Each subject will be selected and assigned in a specific tube-voltage arm by the scanner based on the patient's body habitus for individualized CTA scans, without any intervention
62274107|NCT01381783|OTHER|Topical anesthesia|
62274108|NCT03551743|EXPERIMENTAL|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
62274109|NCT03551743|EXPERIMENTAL|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at \~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
62274110|NCT03551743|EXPERIMENTAL|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
62637258|NCT02050334|EXPERIMENTAL|CC100 (2 single doses) & placebo(1 dose)|CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
62637259|NCT01839747|EXPERIMENTAL|Imaging|PET-MRI PET-CT
62069519|NCT06522243|NO_INTERVENTION|waitlist control|No intervention while being assessed but will receive the intervention after the assessments
62637260|NCT01741246||Control|Headache-free subjects.
62637261|NCT01741246||Episodic migraine|Patients with less that 15 headache days per month that fulfill International Classification of Headache Disorders 2R (ICHD-2nd edition Revised)- criteria for Episodic Migraine.
62274111|NCT03551743|PLACEBO_COMPARATOR|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
62069520|NCT02784470|EXPERIMENTAL|gastrojejunostomy arm|
62274112|NCT03643874|EXPERIMENTAL|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
62454220|NCT03838653||Right main bronchus (RMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the right main bronchus (incorrect placement).
62069521|NCT02784470|ACTIVE_COMPARATOR|gastroduodenal stent placement|
62274113|NCT03643874|ACTIVE_COMPARATOR|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
62274114|NCT06233370|EXPERIMENTAL|Over ground walking exercise|Participants will walk around a square hallway at a step rate of \~100 steps per minute for 20 minutes while wearing a Fitbit around the waist for measuring steps.
62274115|NCT06233370|EXPERIMENTAL|Treadmill walking exercise|Participants will walk on a motor-driven treadmill at a step rate of \~100 steps per minute for 20 minutes while wearing a Fitbit around the waist for measuring steps.
62274116|NCT00130832|EXPERIMENTAL|1|RotaTeq and OPV concomitantly
62274117|NCT00130832|EXPERIMENTAL|2|RotaTeq and OPV on staggered schedule
62274118|NCT02851173|EXPERIMENTAL|LLLT|Six weekly sessions of LLLT. The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each laser stimulation session will consist of total 8 min, with eight 1 min/cycle treatments alternating between two locations on the right forehead.
62274119|NCT02851173|ACTIVE_COMPARATOR|Placebo|The control group will undergo the same procedure as the treatment group, but will receive brief (5-s) stimulation to the intended site on the forehead, followed by 55 s of no stimulation, for each 1-min cycle. Thus the control group will receive approximately 1/12th of the cumulative energy density as the treatment group. This is sufficient to provide a brief sensation of slight heat (as active placebo) at the onset of each one-minute cycle, using a fraction of the energy received by the experimental group.
62274120|NCT05557760|EXPERIMENTAL|Cognitive Control Training Group|
62274121|NCT05557760|EXPERIMENTAL|Cognitive Control Training + Booster Sessions Group|
62274122|NCT03825965|EXPERIMENTAL|MPL-001 (CBD: THC 25:1)|125mg CBD/5 mg THC oil for oral use
62274123|NCT03825965|PLACEBO_COMPARATOR|Placebo|Visually identical placebo (medium chain triglyceride oil)
62274124|NCT03070158|EXPERIMENTAL|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
62454221|NCT04091126|EXPERIMENTAL|Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.9 milligram /kilogram (mg/kg) Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
62637262|NCT01741246||Chronic migraine|Patients that fulfill International Classification of Headache Disorders (ICHD)-2R criteria for chronic migraine (more than 15 days per month).
62637263|NCT05200273|EXPERIMENTAL|Intervention/treatment|Experimental
62637264|NCT02214030|ACTIVE_COMPARATOR|Assiut Femoral Compression Device|the sheaths were removed 2 hours after PCI instead of conventional 6hours. To standardize compression times, AFCD were applied to patient and complete femoral artery compression were applied for 5 minutes, followed by a gradual release of pressure over the ensuing 8 minutes. Therefore each patient received a minimum of 13 minutes of compression, with further compression applied only if full hemostasis had not been achieved at that point with maximum of 30 minutes.
62637265|NCT02214030|PLACEBO_COMPARATOR|Manual compression|The intra-arterial sheaths were removed 6 hours after PCI in the MC group according to the standard local protocols.
62069522|NCT00549887||Rapid acting to short acting|Patients on rapid-acting analog insulins who switch to short-acting human insulin
62069523|NCT00549887||Short acting to rapid acting|Patients on short-acting human insulins who switch to rapid-acting analog insulin
62069524|NCT05208619|ACTIVE_COMPARATOR|thoracic epidural analgesia|A thoracic epidural catheter is placed before induction of general anaesthesia. Sufentanil 10 µg and Ropivacaine are applied via the catheter.
62069525|NCT05208619|ACTIVE_COMPARATOR|paravertebral block|A single-shot paravertebral block (Ropivacaine 0,5%) is placed before induction of general anaesthesia.
62274125|NCT03070158|NO_INTERVENTION|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
62069526|NCT04872244|EXPERIMENTAL|patients with isthmosele that mirena ( levonorgestrel releasing intrauterine device) was applied|outcome measures of patients suffering from postmenstruel spotting due to ısthmosele whom mirena ( levonorgestrel releasing intrauterine device) was applied
62069527|NCT03150524|ACTIVE_COMPARATOR|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
62069528|NCT03150524|ACTIVE_COMPARATOR|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
62069529|NCT06140563|EXPERIMENTAL|Normal anticoagulation dosing|Patients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, the normal amount of anticoagulation is administered.
62069530|NCT06140563|EXPERIMENTAL|Reduced anticoagulation dosing|Patients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, only one quarter of the normal amount of anticoagulation is administered.
62069531|NCT00965796|EXPERIMENTAL|Lidocaine, pain intensity and Saline|(2 mg/kg/h) and patients of group 2 (n = 20) received 0.9% saline infusion throughout the surgical procedure
62069532|NCT02084719|EXPERIMENTAL|Group A|Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test
62069533|NCT02084719|ACTIVE_COMPARATOR|Group B|Patients will be tested only with the standard algorithm
62069534|NCT05185596|EXPERIMENTAL|Trans-esophageal echocardiography|Transesophageal Echocardiography during advanced life support for out of hospital cardiac arrest will be performed.
62069535|NCT04362657|EXPERIMENTAL|Computer aided diagnosis|Using CAD to assist in completeness of the examination during OGD
62274126|NCT01877083|EXPERIMENTAL|Lenvatinib|
62274127|NCT06182488|EXPERIMENTAL|ERAS Group|According to the ERAS guidelines, the ERAS group received ERAS protocol.
62274128|NCT06182488|OTHER|Conventional group|Conventional perioperative interventions
62274129|NCT05650983|EXPERIMENTAL|1.Aerobic exercise|play balloon volleyball for Aerobic exercise and aimed at maximizing the strain on the cardiovascular system (60-70% of heart rate recovery). Aerobic exercise intervention five times a week, one hour each time，for three months.
62274130|NCT05650983|EXPERIMENTAL|2.Resistance exercise|Resistance strength training for Resistance exercise and aimed at promoting the greatest hypertrophy response(65% of 1 repetition maximum and repeated up to 15 times). Resistance exercise intervention five times a week, one hour each time,for three months.
62274131|NCT04682080|ACTIVE_COMPARATOR|Needle-free injection group|In needle-free injection techniques, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using the Comfort-In system. Pain intensity and anxiety levels of patients were measured.
62274132|NCT04682080|ACTIVE_COMPARATOR|Dental injection group|In the conventional dental-injection method, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using a 27G, 50-mm, disposable syringe with a needle. Pain intensity and anxiety levels of patients were measured.
62274133|NCT03382847|EXPERIMENTAL|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
62637266|NCT02575417|EXPERIMENTAL|Patient Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Patient Only Groups:~1. are 18 years or older~2. speak and read English~3. have at least one chronic illness (cancer, chronic pulmonary disease, coronary artery disease, congestive heart failure, peripheral vascular disease, severe chronic liver disease, diabetes with end organ damage, renal failure)~4. have not completed an advance directive within the past 18 months~5. are able to sit for about 2.5-3 hours~6. are able to focus on the game for about 1.5-2 hours~7. can complete required surveys"
62637267|NCT02575417|EXPERIMENTAL|Caregiver Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Caregiver Only Groups:~1. are 18 years or older~2. speak and read English~3. have been an unpaid caregiver for an adult over the age of 18 in the last 12 months. Being an unpaid caregiver may include helping with personal needs or household chores, managing a person's finances, arranging for outside services, or visiting regularly to see how they are doing. This person need not live with participants in order for them to identify as caregivers;~4. are able to sit for about 2.5-3 hours~5. are able to focus on the game for about 1.5-2 hours~6. can complete required survey~7. care recipient is capable of discussing medical issues~8. care recipient has not completed an AD in past 18 months"
62637268|NCT02575417|EXPERIMENTAL|Surrogate Decision Maker with Patient|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Surrogate Decision Maker and Patient Group:~1. considers themselves a surrogate decision maker for an adult with a chronic illness (defined in Patient Only Group)~2. are 18 years or older~3. speak and read English~4. are able to sit for about 2.5-3 hours~5. are able to focus on the game for about 1.5-2 hours~6. can complete required surveys~7. both patient and surrogate decision maker are able to attend study session together~8. patient must meet eligibility criteria defined in Patient Only group"
62637269|NCT00975377|NO_INTERVENTION|No hair removal|Patients randomized to the no hair removal cohort will not undergo any preoperative hair removal.
62274134|NCT01110200|ACTIVE_COMPARATOR|ADVAIR DISKUS 250/50 mcg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
62069536|NCT02674360|ACTIVE_COMPARATOR|SDM Online Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of a web-based SDM online Training (intervention group I). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The SDM online training works on the modeling principle.
62274135|NCT01110200|ACTIVE_COMPARATOR|Serevent 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
62274136|NCT03529773|EXPERIMENTAL|Sentinel Arm 1|Low dose formulation A
62274137|NCT03529773|EXPERIMENTAL|Sentinel Arm 2|Mid dose formulation A
62274138|NCT03529773|EXPERIMENTAL|Sentinel Arm 3|High dose formulation A
62274139|NCT03529773|EXPERIMENTAL|Sentinel Arm 4|Low dose formulation B
62274140|NCT03529773|EXPERIMENTAL|Sentinel Arm 5|Mid dose formulation B
62274141|NCT03529773|EXPERIMENTAL|Sentinel Arm 6|High dose formulation B
62274142|NCT03529773|PLACEBO_COMPARATOR|Sentinel Arm 7|Placebo
62274143|NCT03529773|EXPERIMENTAL|Expanded Arm 8|Low dose formulation A and SIIV
62274144|NCT03529773|EXPERIMENTAL|Expanded Arm 9|Mid dose formulation A and SIIV
62274145|NCT03529773|EXPERIMENTAL|Expanded Arm 10|High dose formulation A and SIIV
62637270|NCT00975377|ACTIVE_COMPARATOR|Hair clipping|Patients in the clipping cohort undergo hair removal at the surgical site. Hair removal will occur on the day of surgery immediately prior to the scheduled operation.
62069537|NCT02674360|ACTIVE_COMPARATOR|Face-to-Face SDM Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of an individualized, context-based SDM individual face-to-face training at the workplace of the participants (intervention group II). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The individual training works on the coaching principle.
62069538|NCT02674360|NO_INTERVENTION|Control Group|The Control Group receives no SDM Training. All participants of the Control Group will be offered to participate in the SDM Online Training after T2.
62069539|NCT01183650|EXPERIMENTAL|Tadalafil|5 mg, administered orally, daily for 10 days
62069540|NCT00844740|EXPERIMENTAL|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood and urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
62069541|NCT04389333|EXPERIMENTAL|Non-contact MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination. In order to simplify the examination procedure, the data recorder was put on the examination bed. The patient lay down after swallowing the capsule under the remote guidance of the endoscopist.
62069542|NCT04389333|ACTIVE_COMPARATOR|MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of an endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient was instructed to assume the supine or left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist face to face, the subject turned over on the bed to complete the examination.
62274146|NCT03529773|EXPERIMENTAL|Expanded Arm 11|Low dose formulation B and SIIV
62637271|NCT03925142|ACTIVE_COMPARATOR|Controlled healthy vegetarian diet|Subjects will be randomized and assigned to consume the controlled Healthy Vegetarian Eeating Pattern for 5 weeks.
62637272|NCT03925142|EXPERIMENTAL|Controlled beef diet|Subjects will be randomized and assigned to consume the beef diet for 5 weeks, which will substitute predominantly starchy vegetables and refined grains with 6 oz. of lean unprocessed beef/day.
62637273|NCT03528551|EXPERIMENTAL|N8-GP, once weekly|All participants will receive turoctocog alfa pegol (N8-GP) once weekly.
62637274|NCT03528551|EXPERIMENTAL|N8-GP, twice weekly|All participants will receive N8-GP twice weekly.
62274147|NCT03529773|EXPERIMENTAL|Expanded Arm 12|Mid dose formulation B and SIIV
62274148|NCT03529773|EXPERIMENTAL|Expanded Arm 13|High dose formulation B and SIIV
62274149|NCT03529773|EXPERIMENTAL|Expanded Arm 14|Low dose formulation A and placebo
62637275|NCT03528551|EXPERIMENTAL|N8-GP, three times weekly|All participants will receive N8-GP three times weekly.
62637276|NCT06305975|EXPERIMENTAL|Blunt fascial entry|The blunt fascial entry technique will be used for patients in this arm
62637277|NCT06305975|ACTIVE_COMPARATOR|Veress needle entry technique|The Veress needle entry technique will be used for patients in this arm
62637278|NCT00676403|PLACEBO_COMPARATOR|1|Placebo
62637279|NCT00676403|EXPERIMENTAL|2|investigational treatment
62637280|NCT00676403|EXPERIMENTAL|3|investigational treatment
62637281|NCT00676403|EXPERIMENTAL|4|investigational treatment
62069543|NCT01351428|EXPERIMENTAL|NICOM group|Vasodilator therapy begins when SVR increases by 20% or greater than baseline. Therapy is titrated according to hemodynamic profile and clinical signs and symptoms.
62637282|NCT00676403|EXPERIMENTAL|5|investigational treatment
62637283|NCT00676403|EXPERIMENTAL|6|investigational treatment
62069544|NCT01196884||Asymptomatic ITP patients|
62069545|NCT01196884||ITP patients treated with Rituximab|
62274150|NCT03529773|EXPERIMENTAL|Expanded Arm 15|Mid dose formulation A and placebo
62637284|NCT01825200|ACTIVE_COMPARATOR|Flublok|Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
62069546|NCT01196884||ITP patients treated with steroids|
62637285|NCT01825200|PLACEBO_COMPARATOR|Afluria|Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
62637286|NCT00510614|ACTIVE_COMPARATOR|A|1 gram tinidazole twice weekly for 12 weeks
62637287|NCT00510614|PLACEBO_COMPARATOR|B|Placebo twice weekly for 12 weeks
62274151|NCT03529773|EXPERIMENTAL|Expanded Arm 16|High dose formulation A and placebo
62274152|NCT03529773|EXPERIMENTAL|Expanded Arm 17|Low dose formulation B and placebo
62274153|NCT03529773|EXPERIMENTAL|Expanded Arm 18|Mid dose formulation B and placebo
62637288|NCT01001910|EXPERIMENTAL|Treatment (pemetrexed disodium, carboplatin)|Patients receive pemetrexed disodium IV over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
62637289|NCT01877161|EXPERIMENTAL|Middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
62069547|NCT04130334|ACTIVE_COMPARATOR|horizontal meridian of donor's cornea sutured to horizontal|horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
62069548|NCT04130334|ACTIVE_COMPARATOR|horizontal meridian of donor's cornea sutured to vertical|horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
62069549|NCT00282815|ACTIVE_COMPARATOR|1|CPAP
62069550|NCT00282815|SHAM_COMPARATOR|2|sham CPAP (placebo)
62069551|NCT03676920|EXPERIMENTAL|Intervention Arm|This feasibility study includes only one arm. All enrolled patients will be asked to use the intervention.
62069552|NCT04080310|ACTIVE_COMPARATOR|combination therapy group|The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.
62274154|NCT03529773|EXPERIMENTAL|Expanded Arm 19|High dose formulation B and placebo
62637290|NCT01877161|SHAM_COMPARATOR|Control group|Repetitive magnetic stimulation (Sham)
62637291|NCT01877161|EXPERIMENTAL|Superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
62637292|NCT05208333|OTHER|Albendazole treatment|"Treatment drugs: Albendazole (Zentel) tablets 200mg, Glaxo Wellcome Production France manufacturer .~Dose: 15 mg/kg divided into 2 times/day x 5 days, orally after meals. Procedure: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection Advice on preventing re-infection according to Vietnam Ministry of Health disease prevention guidelines"
62637293|NCT04565548|EXPERIMENTAL|Intervention|Participants will receive the newly developed theory-guided program for 12 weeks.
62637294|NCT04565548|ACTIVE_COMPARATOR|Control|Participants will receive the usual care and non-hypertension related text messaging for 12 weeks.
62637295|NCT04474964|EXPERIMENTAL|Low Dose Craniospinal Irradiation|WNT subgroup medulloblastoma patients accrued in the study will be treated with Low-dose Craniospinal Irradiation (18Gy/10fx) plus focal conformal tumor-bed boost (36Gy/20fx) for total primary-site dose of 54Gy/30fx over 6-weeks. Followed by adjuvant multi-agent systemic chemotherapy which will be initiated 4-6 weeks after completion of radiotherapy provided the ANC \>1500 and platelet count \>1,00,000. A total of 6 cycles of alternating chemotherapy every 4-weekly will be planned as per our standard practice using CET protocol.
62637296|NCT04243629|EXPERIMENTAL|Rapid Insulin-Plus-Pramlintide|Rapid insulin and pramlintide infusion in two insulin pumps
62637297|NCT04243629|PLACEBO_COMPARATOR|Rapid Insulin-Plus-Placebo|Rapid insulin and placebo (saline) infusion in two insulin pumps
62069553|NCT04080310|OTHER|intensive statin group|The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.
62637298|NCT02590055|EXPERIMENTAL|Intervention arm|D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr
62637299|NCT01105520||intralspinal processes|Patients with intralspinal processes
62637300|NCT03040167|PLACEBO_COMPARATOR|Control group|PEC 1 block with injection of 0.4 mL/kg of normal saline under echoguidance.
62637301|NCT03040167|ACTIVE_COMPARATOR|Treatment group|PEC 1 block with injection of 0.4 mL/kg of 0.25% bupivacaine with 1/400 000 epinephrine under echoguidance.
62637302|NCT05592938|EXPERIMENTAL|rPBI|26Gy in 5 daily fractions over 1-week
62637303|NCT04009265|EXPERIMENTAL|Chemotherapy|Docetaxel 75mg/m2, 3w, 2cycles. DDP 75mg/m2, 3wl, 2cycles.
62637304|NCT04009265|EXPERIMENTAL|Chemoradiotherapy|5040cGy, 180cGy/d, 28F Concurrent Docetaxel 60mg/m2, 3w, 2cycles DDP 60mg/m2, 3w, 2cycles
62637305|NCT04009265|NO_INTERVENTION|Surgery alone|Surgery alone, no adjuvant treatment.
62637306|NCT05399199|EXPERIMENTAL|study group|
62069554|NCT01619046|ACTIVE_COMPARATOR|PK substudy|A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).
62069555|NCT01619046|EXPERIMENTAL|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.
62069556|NCT01619046|EXPERIMENTAL|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.
62069557|NCT01619046|EXPERIMENTAL|Surgical substudy|Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects
62069558|NCT00406419|PLACEBO_COMPARATOR|Placebo × 2 IV + MTX|Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
62637307|NCT05399199|NO_INTERVENTION|control group|
62637308|NCT02539017|EXPERIMENTAL|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
62637309|NCT02539017|ACTIVE_COMPARATOR|Chemo|Control group: Chemo Therapy group
62637310|NCT02239640||Medtronic NV market-released device|Patients experiencing an acute ischemic stroke due to a large vessel occlusion treated with a Medtronic Neurovascular market-released neurothrombectomy device.
62637311|NCT01553110||Cold Population|Male and female subjects 12 years of age and older with acute nasal discharge fewer then 7 days. Patients must be symptomatic at screening.
62637312|NCT01553110||Allergic Rhinitis|Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
62637313|NCT03255356||Cohort|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
62637314|NCT03618446||Survivors|Patients whose pelvic fracture and survived till time of discharge from the hospital.
62637315|NCT03618446||Non-Survivors|Patients whose pelvic fracture and died while in hospital.
62637316|NCT06086379|EXPERIMENTAL|CCT-C|10-week Compensatory Cognitive Training Group
62637317|NCT06086379|ACTIVE_COMPARATOR|HCE|10-week Holistic Cognitive Education Group
62637318|NCT03852589|ACTIVE_COMPARATOR|C-MAC Videolaryngoscope|C-MAC Videolaryngoscope: An intubating device that is used for endotracheal intubation. Proseal laryngeal mask airway will be inserted with C-MAC Videolaryngoscope
62637319|NCT03852589|ACTIVE_COMPARATOR|Blind|Proseal laryngeal mask airway will be inserted with digital finger
62637320|NCT05577728||New use of semaglutide injection|Exposure group
62637321|NCT05577728||"New initiation of standard of care"|(SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) Reference group
62637322|NCT02373150|EXPERIMENTAL|Group A1|Dose 1 or placebo
62637323|NCT02373150|EXPERIMENTAL|Group A2|Dose 2 or placebo
62637324|NCT02373150|EXPERIMENTAL|Group A3|Dose 3 or placebo
62637325|NCT02185417|ACTIVE_COMPARATOR|Hydrochlorothiazide|Participants remained on the existing hydrochlorothiazide treatment regimen (a daily dose of 25 or 50 mg).
62637326|NCT02185417|ACTIVE_COMPARATOR|Chlorthalidone|Participants switched to an equivalent dose of chlorthalidone (a daily dose of 12.5 or 25 mg).
62274155|NCT03529773|PLACEBO_COMPARATOR|Expanded Arm 20|placebo and placebo
62637327|NCT02185417|NO_INTERVENTION|Providers|Providers were enrolled in order to contact their potentially eligible patients and were not included in the results
62069559|NCT00406419|EXPERIMENTAL|Ocrelizumab 200 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
62069560|NCT00406419|PLACEBO_COMPARATOR|Ocrelizumab 500 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
62069561|NCT04180241|ACTIVE_COMPARATOR|total division of the muscle layer|POEM- total division of the circular muscle layer into the gastroesophageal junction
62069562|NCT04180241|ACTIVE_COMPARATOR|partial division of the muscle layer|POEM - partial division of the circular muscle layer into the gastroesophageal junction
62069563|NCT03804190||1-5years experience|1-5years of experience working as otorhinolaryngologist
62274156|NCT02195505||Synvisc®|
62274157|NCT02195505||Usual treatment of knee|nonsteroidal antiinflammatory drugs, antalgics
62637328|NCT05007119|ACTIVE_COMPARATOR|Control Group|"It includes participants receiving conventional physical therapy for low back pain female patients for a period of 6 months.~McKenzie extension exercise Protocol Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
62637329|NCT05007119|EXPERIMENTAL|Experimental Group|"Group (A) Involves participants receiving cupping therapy along with conventional physicla therapy for a period of 6 months .~Moist Heat Pack for 10 mins McKenzie Extension Exercise Protocol"
62637330|NCT04206345|EXPERIMENTAL|Blood Flow Restriction Group|Elbow bending exercises with resistance exercise band (%20 of 1 maximum repetition) for one session. Blood flow restriction band will be placed during exercise session. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
62069564|NCT03804190||5-10 years experience|5-10years of experience working as otorhinolaryngologist
62069565|NCT03804190||10-15years experince|10-15years of experience working as otorhinolaryngologist
62069566|NCT03804190||15_20years experience|15-20years of experience working as otorhinolaryngologist
62069567|NCT01472913|ACTIVE_COMPARATOR|Fibrin Sealent|
62069568|NCT01472913|PLACEBO_COMPARATOR|Saline water|
62069569|NCT03539367|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62637331|NCT04206345|EXPERIMENTAL|Exercise Group|Elbow bending exercises with resistance exercise band (%70 of 1 maximum repetition) will be performed for one session.
62637332|NCT04206345|NO_INTERVENTION|Control Group|10 minutes resting period will be given between evaluation.
62637333|NCT02104895|ACTIVE_COMPARATOR|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
62637334|NCT02104895|EXPERIMENTAL|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
62637335|NCT03087838||delirium group|CAM-ICU is positive within the first 24 hours after operation
62637336|NCT03087838||non-delirium group|CAM-ICU is negative within the first 24 hours after operation
62637337|NCT05033249||Normal|Alvarado Score 4 - 7 Normal according to the initial computed tomographic evaluation
62637338|NCT05033249||Patient|Alvarado Score 4 - 7 Acute appendicitis according to the initial computed tomographic evaluation
62069570|NCT03539367|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62069571|NCT05806268||Dab/tram|Patients received dabrafenib and trametinib treatment
62069572|NCT05806268||Enco/bini|Patients received encorafenib and binimetenib treatment
62274158|NCT04764760|OTHER|Phase 1:Study role tissue tensile strength|The tensile strength of the orifice of Frauchad was augmented by implantation of a Accordion fold shaped prosthesis.
62274159|NCT04764760|OTHER|Phase 2:Curative implantation of a custom designed bio-mechanically compatible Tensiflex prosthesis|The wing shaped custom designed tensiflex prosthesis in the groin was impanted as a curative technique since it provided seamless augmenation of the tensile tissue strength.
62274160|NCT01134965|EXPERIMENTAL|Digoxin plus Flibanserin|Flibanserin 100 mg tablets once daily for 7 days plus Digoxin 0.5 mg (2 tables of 0.25 mg) as single dose
62454222|NCT04091126|EXPERIMENTAL|Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.4 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
62274161|NCT01134965|EXPERIMENTAL|Digoxin|Digoxin 0.5 mg as single dose
62454223|NCT04091126|EXPERIMENTAL|Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
62454224|NCT04091126|EXPERIMENTAL|Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
62069573|NCT05145946|EXPERIMENTAL|Video Game Training Group 1 - High Frequency Hearing Loss|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have high frequency hearing loss.
62637339|NCT01425736|PLACEBO_COMPARATOR|Chemotherapy|"Chemotherapy~:Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)"
62637340|NCT01425736|EXPERIMENTAL|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment: Docetaxel(75mg/m²,1 time/21d, 6times，);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times),Nimotuzumab treatment:(200mg/w,18weeks )."
62069574|NCT05145946|ACTIVE_COMPARATOR|Video Game Training Group 1 - Normal Hearing|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have normal hearing.
62069575|NCT05145946|SHAM_COMPARATOR|Video Game Training Group 2 - High Frequency Hearing Loss|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have high frequency hearing loss.
62069576|NCT05145946|SHAM_COMPARATOR|Video Game Training Group 2 - Normal Hearing|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have normal hearing.
62637341|NCT02436863||Surgical perfomance (Laminoplasty)|After the lesions inside the spinal canal were surgical removed by laminectomy, the lamina and spinous process were replanted with titanium plates and screws.
62637342|NCT02436863||Surgical perfomance (Internal fixation)|After the lesions inside the spinal canal were surgical removed by laminectomy, the pedicle screws (Thoracic and lumbar vertebra) or lateral mass (Cervical vertebra) and sticks were used for internal fixation.
62069577|NCT03826511|ACTIVE_COMPARATOR|Tiszasüly mud-pack|Patients in the Tiszasüly mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
62069578|NCT03826511|ACTIVE_COMPARATOR|Kolop mud-pack|Patients in the Kolop mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
62069579|NCT05296096|ACTIVE_COMPARATOR|Standard protein and exercise|All enrolled patients randomized to this arm will receive a baseline nutrition and nurse-driven mobility pathway and other evidence-based bundled strategies as standard of care.
62274162|NCT01727895|EXPERIMENTAL|Beta-glucan|Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
62069580|NCT05296096|EXPERIMENTAL|High protein plus exercise|"High protein nutrition: To achieve the prescribed age-appropriate high protein target, dietitians will use EN preferentially, or if EN is contraindicated, PN may be used. High-protein EN formulas and/or protein supplements (powder or liquid) will be added to formula/breast milk feedings or administered separately in divided bolus doses. Dietitians routinely employ and customize these solutions in their scope of practice. When EN is insufficient to meet protein targets, PN may be prescribed to make up the deficit on or after the end of PICU day 3. Energy and protein delivery adequacy (% of prescribed goal) will be monitored daily by the study team.~Patients in this arm will also be prescribed the age-appropriate highest-level of mobility by the rehabilitation team with a goal of 30 minutes duration, twice daily."
62069581|NCT03917810|ACTIVE_COMPARATOR|MODSUG|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
62274163|NCT01727895|NO_INTERVENTION|Control group|
62069582|NCT03917810|EXPERIMENTAL|LOWSUG|Diet consisting of 50% carbohydrate (\<5% sugar), 15% protein, 35% fat
62069583|NCT03917810|EXPERIMENTAL|LOWCHO|Diet consisting of \<8% carbohydrate (\<5% sugar), 15% protein, \>77% fat
62069584|NCT02885727|EXPERIMENTAL|Durvalumab + Radiation therapy|"Durvalumab (MEDI4736) 750 mg (or 10mg/kg if the patient weighs \<30 kg) IV Q2W over 1 hour for all patients + Radiation therapy~* First lesion to receive 25 Gy / 5 daily consecutive fractions of 5 Gy~* Second lesion to receive15 Gy / 5 daily consecutive fractions"
62069585|NCT00079456|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62069586|NCT03221062|EXPERIMENTAL|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
62069587|NCT03221062|EXPERIMENTAL|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
62069588|NCT03221062|EXPERIMENTAL|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
62069589|NCT04735042||SGLT2 and DPP-4 inhibitors|Patients undergoing SGLT2i and DPP4i.
62274164|NCT04917211|EXPERIMENTAL|virtual reality mask|During the prior anesthesia consultation, the patient is informed of the possibility within the framework of the study of benefiting from analgesia with disconnection by a virtual reality mask, associated with local anesthesia. The patient will be explained that in the event of pain despite the virtual reality mask and local anesthesia, administration of remifentanil will be possible
62454225|NCT04091126|EXPERIMENTAL|Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
62454226|NCT04091126|EXPERIMENTAL|Cohort 6: belantamab mafodotin 1.4mg/kg cycle 1, 1.0 mg/kg Q9/12W Cycle 4+VRd/Rd|Based on emerging data from Cohort 2-5, participants will receive 1.4 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1, followed by 1.0 mg/kg dose on Day 1 of every third cycle from cycle 4 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
62454227|NCT04091126|EXPERIMENTAL|Cohort 7: belantamab mafodotin 1.9 mg/kg Cycle 1, 1.4 mg/kg Q9/12W Cycle 4+VRd/Rd|Based on emerging data from Cohort 2-5, participants will receive 1.9 mg/kg dose of belantamab mafodotin of cycle 1, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 4 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
62069590|NCT04735042||SGLT2 inhibitors only|Patients undergoing SGLT2i alone.
62069591|NCT01155830||Infants with CHD|Infants with Congenital Diaphragmatic Hernia (CHD)
62069592|NCT01155830||Infants with sepsis|Infants who are culture positive for sepsis and require vasopressor support
62069593|NCT01155830||Infants treated with ECMO|Infants suffering cardiopulmonary failure significant enough to require heart/lung bypass treatment with extracorporeal membrane oxygenation (ECMO)
62069594|NCT00786890||no treatment|observational, no treatment needed
62069595|NCT03395834|EXPERIMENTAL|O3 monitor|tissue oxygenation comparison of O3 \& INVOS
62069596|NCT06626048|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia (CBT-I) and Passive Body Heating (PBH)|Participants will receive both digital Cognitive Behavioral Therapy for Insomnia (CBT-I) and Passive Body Heating (PBH) using a sauna blanket.
62069597|NCT00014196|EXPERIMENTAL|chemo/RT followed by consolidation chemo|cisplatin docetaxel radiation therapy
62069598|NCT02714101|EXPERIMENTAL|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
62069599|NCT01393080|EXPERIMENTAL|Nimotuzumab and TP regimen|"1. TP Regimen ：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
62454228|NCT04091126|EXPERIMENTAL|Cohort 8a : belantamab mafodotin 1.9 mg/kg Cycle 1,4; 1.4 mg/kg Q9/12W from Cycle 7 +VRd/Rd|Based on emerging data from Cohort 6-7, participants will receive 1.9 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 4, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 7 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
62454229|NCT04091126|EXPERIMENTAL|Cohort 8b: belantamab mafodotin 1.4 mg/kg Cycle 1,3; 1.0 mg/kg Q9/12W from Cycle 6 +VRd/Rd|Based on emerging data from Cohort 6-7, participants will receive 1.4 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 3, then 1.0 mg/kg on Day 1 of every third cycle from cycle 6 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
62274165|NCT03954600|OTHER|NPT520-34 - SAD Cohort 1, Dose 1 (Unfed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Unfed.
62637343|NCT03166020|EXPERIMENTAL|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
62069600|NCT01393080|PLACEBO_COMPARATOR|TP Regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
62274166|NCT03954600|OTHER|NPT520-34 - SAD Cohort 1, Dose 1 (Fed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Fed.
62274167|NCT03954600|OTHER|NPT520-34 - SAD Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT520-34: 250 mg OR Single dose of orally administered placebo capsule(s) to match dose.
62069601|NCT01113658|EXPERIMENTAL|SNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
62274168|NCT03954600|OTHER|NPT520-34 - SAD Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT520-34: 500 mg OR Single dose of orally administered placebo capsule(s) to match dose.
62274169|NCT03954600|OTHER|NPT520-34 - SAD Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT520-34: 1000 mg OR Single dose of orally administered placebo capsule(s) to match dose.
62274170|NCT03954600|OTHER|NPT520-34 - MAD Cohort 1, Dose 1|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
62274171|NCT03954600|OTHER|NPT520-34 - MAD Cohort 2, Dose 2|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
62454230|NCT04091126|EXPERIMENTAL|Cohort 8c: belantamab mafodotin 1.0 mg/kg Cycle 1,5;1.0 mg/kg Q9/12W from Cycle 9 +VRd/Rd|Based on emerging data from Cohort 6-7, participants will receive 1.0 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 5, then 1.0 mg/kg on day 1 of every third cycle from cycle 9 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
62454231|NCT04333706|EXPERIMENTAL|Experimental: Phase I|A dose finding study of sarilumab plus capecitabine in patients with metastatic TNBC and metastatic HER2/neu-negative and hormone resistant breast cancer.
62454232|NCT04333706|EXPERIMENTAL|Phase 2 single arm study|Study of adjuvant sarilumab plus capecitabine in stage I to III TNBC with less than a pCR
62454233|NCT04333706|OTHER|Parallel Baseline Arm|Study of standard adjuvant capecitabine in stage I to III TNBC with less than a pCR. This Arm will be open in parallel with both Phases 1 and 2. Blood samples will be obtained during the course of the study. Bone marrow samples are optional.
62069602|NCT03534765||Retrospective arm|Retrospective multicentre cohort with 1 year outcomes available following emergency surgery for NELA eligible gastrointestinal pathology. Please refer to WP1 inclusion and exclusion criteria for eligibility.
62069603|NCT03534765||Prospective, multicentre arm|10 centre prospective observational arm. Please refer to WP2 inclusion and exclusion criteria for eligibility.
62069604|NCT04930237||Experimental Group|Patients who receive RELISTOR
62069605|NCT04930237||Observational Group|Patients that receive standard of care
62069606|NCT05404880||EDWARDS INSPIRIS RESILIA Aortic Valve|Subjects who were treated with the INSPIRIS RESILIA aortic heart valve.
62454234|NCT00323947|ACTIVE_COMPARATOR|1|Participants will take OROS-MPH then switch to placebo
62454235|NCT00323947|PLACEBO_COMPARATOR|2|Participants will take placebo then switch to OROS-MPH
62454236|NCT03737955|EXPERIMENTAL|Treatment (gemtuzumab ozogamicin)|Patients receive gemtuzumab ozogamicin IV on days 1, 4, 7. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Responders and non-responders, without significant adverse events during the first course, may receive a second course of gemtuzumab ozogamicin within 60 days after course 1.
62461579|NCT05701670|EXPERIMENTAL|Intervention|"The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the student and support in-the-moment soothing -- see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)~The Single Session Intervention has been co-produced with university students and clinical experts (Prof Jessica Schleider and Prof James Gross), combining the theories of emotion regulation with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~1. Initial guided reflection exercise~2. Short interactive psychoeducation~3. Personalised action plan~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
62069607|NCT05081505|EXPERIMENTAL|Community-based physical fitness exercise course|Included 12-week structural exercise course (0-12 weeks) and 12-week autonomous group class (12-24 weeks).
62069608|NCT02561143|EXPERIMENTAL|Intervention group|Patients in the intervention group will be given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
62069609|NCT02561143|PLACEBO_COMPARATOR|Control group|Patients in the control group will be given whole wheat flour (100 g) daily along with nutritional counseling and physical activity counseling for six months.
62088285|NCT03396419||Acute Isch. Stk pts treat. w/SPG stimul.|"Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol.~Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed.~Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle.~The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol."
62274172|NCT03954600|OTHER|NPT520-34 - MAD Cohort 3, Dose 3|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
62274173|NCT03414580||Ulcerative colitis|Patients with ulcerative colitis whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
62274174|NCT03414580||Crohn's disease|Patients with crohn's disease whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
62637344|NCT03166020|ACTIVE_COMPARATOR|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
62637345|NCT06223295|ACTIVE_COMPARATOR|Focal therapy|Patients in this group will receive focal therapy, i.e. TULSA, IRE or Hifu.
62637346|NCT06223295|ACTIVE_COMPARATOR|Usual care|Patients in this group will receive usual care for prostate cancer, i.e. radical prostatectomy or radiotherapy
62637347|NCT00763360|EXPERIMENTAL|DisCoVisc®|DisCoVisc® Ophthalmic Viscosurgical Device
62637348|NCT00763360|ACTIVE_COMPARATOR|Healon|Healon
62637349|NCT00763360|ACTIVE_COMPARATOR|Amvisc Plus|Amvisc Plus
62637350|NCT03041389|EXPERIMENTAL|CCBT-I Group|The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.
62637351|NCT03041389|ACTIVE_COMPARATOR|Control Group|"The patients who will be randomized control group will be given a reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. The control group will have access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.~To identify PD-specific barriers to Internet usage and CCBT-I, all patients at the end of the study or at the time of drop out will have a questionnaire on the barriers to CCBT-I."
62088286|NCT04619680|EXPERIMENTAL|Nintedanib|150 mg PO twice a day, taken with food, (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
62088287|NCT04619680|PLACEBO_COMPARATOR|Placebo|placebo equivalent 150mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
62088288|NCT05357807|ACTIVE_COMPARATOR|Standard RYGB|127 patients undergo a standard Roux-en-Y gastric bypass
62637352|NCT05056961|OTHER|Large tidal volumes without respiratory distress symptoms|Large tidal volumes (\> 10 mL.kg-1 of predicted body weight) despite low pressure support, without respiratory distress symptoms
62637353|NCT05056961|OTHER|Large tidal volumes with respiratory distress symptoms|Large tidal volumes (\> 10 mL.kg-1 of predicted body weight) despite low pressure support, with respiratory distress symptoms (for example, supra-clavicular and thoracic-abdominal asynchronies...)
62637354|NCT02490774|EXPERIMENTAL|Arm 1: BAY1007626, low relase|Intrauterine device with a low in vitro release rate
62637355|NCT02490774|EXPERIMENTAL|Arm 2: BAY1007626, low to medium release|Intrauterine device with a low to medium in vitro release rate
62637356|NCT02490774|EXPERIMENTAL|Arm 3: BAY1007626, medium release|Intrauterine device with a medium in vitro release rate
62637357|NCT02490774|EXPERIMENTAL|Arm 4: BAY 1007626, high release|Intrauterine device with a high in vitro release rate
62637358|NCT02490774|ACTIVE_COMPARATOR|Arm 5: Levonorgestrel, Jaydess|Intrauterine device releasing levonorgestrel (Jaydess)
62637359|NCT02490774|ACTIVE_COMPARATOR|Arm 6: Levonorgestrel, Mirena|Intrauterine device releasing levonorgestrel (Mirena)
62088289|NCT05357807|EXPERIMENTAL|Extended Pouch RYGB|127 patients undergo a Roux-en-Y gastric bypass with an extended pouch.
62088290|NCT05357807|EXPERIMENTAL|Banded Extended RYGB|127 patients undergo a Roux-en-Y gastric bypass with a minimizer around the extended pouch.
62274175|NCT03414580||Healthy control|Subject with no intestinal symptoms or no known gastrointestinal disorders. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
62274176|NCT01951469|EXPERIMENTAL|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) chemotherapy or Pemetrexed (D1)+nedaplatin (D1) chemotherapy, every 28 days
62274177|NCT01951469|ACTIVE_COMPARATOR|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
62274178|NCT03105687|NO_INTERVENTION|Control|"Participants in the Control group will receive standard Pharmaceutical Care according to the principles of Good Pharmaceutical Practice and national Slovak legislation requirements only.~Participants in the control group will also receive a welcome SMS one day after enrollment and an end-of-trial SMS three months after the enrollment. Additionally, prior to their scheduled follow-up visit (Visit 2), three months following the enrollment, trial pharmacists will call the participants to remind them of their follow-up visit."
62274179|NCT03105687|EXPERIMENTAL|Intervention|Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
62274180|NCT03506295|OTHER|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
62274181|NCT03506295|EXPERIMENTAL|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
62274182|NCT06144983|EXPERIMENTAL|Alvogyl paste|Application of 0.2 gm of Alvogyl paste inside the extraction socket filling it entirely, and suturing the flap interrupted suture following impacted mandibular third molar surgery.
62274183|NCT06144983|EXPERIMENTAL|Cholrhexidine gel|Application of 1 ml of Chlorhexidine gel inside the extraction socket filling it entirely, and suturing the flap interrupted suture following impacted mandibular third molar surgery.
62274184|NCT06144983|NO_INTERVENTION|control|no dressing material was applied following the impacted mandibular third molar surgery.
62088291|NCT05470062|EXPERIMENTAL|experimental group|wear the insoles for at least 4-h every day for 1-month
62637360|NCT01023607|ACTIVE_COMPARATOR|Group A:|Atorvastatin 20mg
62274185|NCT02611154|EXPERIMENTAL|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
62274186|NCT04132791|OTHER|aspirin after awakening + placebo before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study."
62274187|NCT04132791|EXPERIMENTAL|placebo after awakening +aspirin before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study."
62274188|NCT05327465|EXPERIMENTAL|Aerobic and resistance exercise|"Virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom.~The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer."
62637361|NCT01023607|EXPERIMENTAL|Group B:|Atorvastatin 60mg
62637362|NCT01023607|ACTIVE_COMPARATOR|Group C:|Rosuvastatin 10mg
62637363|NCT01783743|EXPERIMENTAL|Intervention arm|"Community treatment assistants (CTA ) will receive usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.~In addition to the usual training, these CTA's will also receive an additional modest half day training for TT case recognition which is called the TT training program and TT Screening Card to help them identify TT cases and refer them for surgery."
62637364|NCT01783743|NO_INTERVENTION|Usual Assessment arm|Community treatment assistants will receive only usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.
62088292|NCT05470062|NO_INTERVENTION|control group|not wear insoles for at least 4-h every day for 1-month
62637365|NCT01048541|ACTIVE_COMPARATOR|SpeediCath catheter|Standard treatment
62637366|NCT01048541|EXPERIMENTAL|Test product|
62088293|NCT04463953|EXPERIMENTAL|ZID regimen|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15.
62088294|NCT03172117|EXPERIMENTAL|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
62274189|NCT05327465|ACTIVE_COMPARATOR|Usual care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise program after 16 weeks.
62637367|NCT00732927|EXPERIMENTAL|1|parnaparin, low molecular weight heparin
62088295|NCT03172117|EXPERIMENTAL|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10\^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
62454237|NCT05779449|EXPERIMENTAL|Pre-Pro group|"Patients with RRMS under dimethyl fumarate or Ocrelizumab treatment according to the good clinical practice, who will recieve the following dietary supplementation with pre- and probiotics:~1st-15th days: One capsule containg 6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM® (Probactiol Duo cps, Metagenics) One packet with 4 g of prebiotics including inulin enriched with oligofructose (Probactiol Stips bustine Metagenics).~16th-365th days:~Two capsules, each containg 7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose (Probactiol HMO Combi cps, Metagenics)."
62088296|NCT03172117|PLACEBO_COMPARATOR|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
62454238|NCT05779449|PLACEBO_COMPARATOR|Placebo group|"Patients with RRMS under dimethyl fumarate or Ocrelizumab treatment according to the good clinical practice, who will receive only starch, the probiotic bacteria carrier:~1st-15th days: One capsule and one packet only with starch.~16th-365th days: Two capsules containg starch."
62454239|NCT05624164|EXPERIMENTAL|Lateralized microfracture group|Participants with medium to larger size rotator cuff tears will be treated with arthroscopy rotator cuff repair with microfracture at the lateral side of the footprint immediately.
62454240|NCT05624164|NO_INTERVENTION|No microfracture group|Participants with medium to larger size rotator cuff tears will be treated with arthroscopy rotator cuff repair without microfracture.
62454241|NCT01599338|EXPERIMENTAL|Liraglutide|Single Arm study. T2DM patients are studied before and after 3 months of Liraglutide treatment (1.2 mg/day).
62454242|NCT03316729|EXPERIMENTAL|DS-9231|In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
62454243|NCT03316729|PLACEBO_COMPARATOR|Placebo|In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
62454244|NCT00925314|EXPERIMENTAL|Transgenic Lymphocyte Immunization|Open Label, Single Arm
62454245|NCT01166568|EXPERIMENTAL|Implantation-Non Randomized|Subjects are not participants in the randomized sub-study. PresView Scleral Implants surgical placed in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
62454246|NCT01166568|EXPERIMENTAL|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. PresView Scleral Implants surgical placed in the eye(s)Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
62454247|NCT01166568|NO_INTERVENTION|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have PresView Scleral Implants surgically placed in the eye(s) and become part of the overall study experimental group.
62454248|NCT00789425|ACTIVE_COMPARATOR|1|a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
62454249|NCT00789425|PLACEBO_COMPARATOR|2|Placebo (starch) + 1000 mg of calcium per day.
62454250|NCT04051242|EXPERIMENTAL|XenMatrix AB Surgical Graft|This study proposes to use XenMatrix™ AB Surgical Graft which has 510(k) approval \[#K162193\] intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue. This trial proposes to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after trauma
62637368|NCT00732927|ACTIVE_COMPARATOR|2|aspirin
62088297|NCT03477942|EXPERIMENTAL|Osteoarthritis|The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.
62274190|NCT02129946|ACTIVE_COMPARATOR|Resistant Starch Bagels|Bagels made from high-resistant starch flour (provides 24g resistant starch per day)
62637369|NCT05013216|EXPERIMENTAL|Cohort A: Patients at high risk of developing pancreatic cancer.|"Patients will include those who have undergone pancreatic imaging with MRI or CT or EUS and found to have one or more pancreatic imaging abnormalities such as a pancreatic cyst consistent with an intraductal papillary mucinous neoplasm (IPMN) or parenchymal changes consistent with pancreatic intraepithelial neoplasia (PanIN). additionally patients with:~1. familial pancreatic cancer relatives~2. germline mutation carriers with an estimated lifetime risk of pancreatic cancer of \~10% or higher~3. germline mutation carriers with an estimated lifetime risk of pancreatic cancer of \~5%, all detailed in Section 3.1.1. These patients must also (as defined in Section 3.1.2)."
62637370|NCT05013216|EXPERIMENTAL|Cohort B: Patients must have evidence of a pancreatic cystic neoplasm|Patients must have clinical, radiographic, or histologic evidence of a pancreatic cystic neoplasm with high-risk features warranting surgical resection per the discretion of the treating hepatobiliary surgeon. In addition, cyst fluid analysis must demonstrate the presence of one of the six KRAS mutations included in the study vaccine. Germline mutation testing or a positive family history of pancreatic cancer is not required for enrollment in Cohort B.
62637371|NCT06522815|EXPERIMENTAL|Level 1 polysomnography patient|For patients undergoing Level 1 polysomnography, simultaneous collection of photoplethysmography (PPG) signals and polysomnography data is performed using the CART-I PLUS device.
62637372|NCT04438408||severe asthma patient|Adult patients (≥ 18 years) with diagnosis of severe asthma for at least 12 months
62637373|NCT04178304|EXPERIMENTAL|G1 patients receive prolotherapy|Intra and extra articular dextrose 25%
62637374|NCT03345381|EXPERIMENTAL|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) plus usual care
62637375|NCT03345381|ACTIVE_COMPARATOR|Usual Care|Treatment as usual
62637376|NCT03936088|EXPERIMENTAL|Intervention with Mindfulness App (Headspace)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the mindfulness (intervention) app.
62637377|NCT03936088|ACTIVE_COMPARATOR|Control with Water App (My Water Balance)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the My Water Balance (control) app and provided an in-person demonstration on how to use it.
62637378|NCT01824888|ACTIVE_COMPARATOR|Control|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
62637379|NCT01824888|EXPERIMENTAL|JUC solution|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by pouring 1.5 ml of JUC into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
62637380|NCT00607776|ACTIVE_COMPARATOR|1|Systane
62637381|NCT00607776|EXPERIMENTAL|2|Blink tears
62637382|NCT03202420|EXPERIMENTAL|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
62637383|NCT04564001|EXPERIMENTAL|A ( Infliximab)|Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
62637384|NCT04564001|EXPERIMENTAL|B (Tocilizumab)|Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
62637385|NCT05554497|EXPERIMENTAL|Mindfulness training|8 week virtual mindfulness-based stress reduction curriculum. Weekly 2.5 hour sessions over zoom.
62637386|NCT06047639||Bone Anchored Hearing Implants(BAHI) Patient|Patients with chronic otitis media whose hearing could not corrected with surgery and also could not use conventional and got bone-anchored hearing implants as a standard of care were included.
62637387|NCT00973258|EXPERIMENTAL|Nutritional Intervention|Nutritional intervention
62637388|NCT00973258|EXPERIMENTAL|Physical Exercise|Physical exercise training intervention
62637389|NCT00973258|EXPERIMENTAL|Cognitive Training|Cognitive training intervention
62088298|NCT03477942|EXPERIMENTAL|Cartilage|The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI.
62088299|NCT02203097|EXPERIMENTAL|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
62274191|NCT02129946|PLACEBO_COMPARATOR|Control Bagels|Bagels made from wheat flour
62274192|NCT04283695|EXPERIMENTAL|Part 1|IM: GX-I7 60 µg/kg IV: \[14C\]-GX-I7 40 µg
62637390|NCT00973258|EXPERIMENTAL|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
62637391|NCT00973258|PLACEBO_COMPARATOR|Control Group|Participants will receive their usual diet and placeboes.
62274193|NCT04283695|EXPERIMENTAL|Part 2|IV: \[14C\]-GX-I7 40 µg
62274194|NCT04283695|EXPERIMENTAL|Part 3|IM: GX-I7 60 µg/kg, \[14C\]-GX-I7 40 µg
62274195|NCT04356183|OTHER|Counseling Health As Treatment (CHAT)|CHAT is a control arm designed to reflect traditional clinical counselling.
62274196|NCT04356183|EXPERIMENTAL|Supervised Weight loss and Exercise Training (SWET)|SWET includes supervised aerobic (3x/w) and resistance (2x/w) training plus a weekly weight loss session.
62637392|NCT06235112|EXPERIMENTAL|Notification of Coronary Artery Calcification|"Notification to providers of the presence of coronary artery calcification automatically detected by AI based device (software) on chest CT.~Recommendation of preventive therapy."
62637393|NCT06235112|NO_INTERVENTION|Non-notification of Coronary Artery Calcification|"No notification to providers of the presence of coronary artery calcification on chest CT automatically detected by AI based device (software) on chest CT.~No recommendation of preventive therapy."
62637394|NCT03224793|EXPERIMENTAL|BIIB059 20 mg|Participants will receive single subcutaneous (SC) dose of 20 milligram (mg) BIIB059 or matching placebo on Day 1.
62637395|NCT03224793|EXPERIMENTAL|BIIB059 50mg|Participants will receive single SC dose of 50 mg BIIB059 or matching placebo on Day 1.
62637396|NCT03224793|EXPERIMENTAL|BIIB059 150mg|Participants will receive single SC dose of 150 mg BIIB059 or matching placebo on Day 1.
62637397|NCT03224793|EXPERIMENTAL|BIIB059 450mg|Participants will receive single SC dose of 450 mg BIIB059 or matching placebo on Day 1.
62637398|NCT01045005|ACTIVE_COMPARATOR|Type 1 Diabetes|Subjects with type 1 diabetes mellitus who are administered oxygen and carbon dioxide
62637399|NCT01045005|ACTIVE_COMPARATOR|Control Subjects|Healthy volunteers administered oxygen and carbon dioxide via respiratory apparatus
62069610|NCT06130813|EXPERIMENTAL|Increased perioperative communication program|The sample of the research is; it was determined as 70 patients by G. Power analysis based on the correlation coefficients in a sample study. 35 of the patients will be assigned to the intervention group (IG) and 35 to the control group (CG). Patients in the CG will receive routine perioperative care, while patients in the IG will be included in the IPCP. All patients will be followed for one month after discharge. IPCP consists of 8 informative contents such as preoperative preparations, surgical procedure, pain management, first mobilization, knee joint movements, exercise, discharge process, wound care, showering, nutrition, daily living activities, driving, sexual life, postoperative routine control, unexpected situations and etc. These informative contents will send to patients on days 7th, 4t and 1th days before the surgery and on days 1th, 2th, 3th, 5th an 7th days after surgery via whatsapp. Additionally, all participants will follow postoperative one month.
62274197|NCT04702646||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
62069611|NCT06130813|NO_INTERVENTION|Standart of care|Patients in the control group will receive routine perioperative care and will follow postoperative for one month.
62069612|NCT05194189|EXPERIMENTAL|Megadose vitamin C group|12 g vitamin C (48 ml) will intravenously injected by a infusion pump every 12 h for 4 days or until ICU discharge
62274198|NCT00927771|EXPERIMENTAL|Azelaic Acid|
62274199|NCT00927771|ACTIVE_COMPARATOR|Hydroquinone|
62461580|NCT05701670|NO_INTERVENTION|Control|Wait-list control (access to services as usual)
62637400|NCT05885451|EXPERIMENTAL|Arm 1: AMG 592 Dose 1|Participants will receive AMG 592 dose 1 subcutaneously
62637401|NCT05885451|EXPERIMENTAL|Arm 2: AMG 592 Dose 2|Participants will receive AMG 592 dose 2 subcutaneously
62637402|NCT05885451|PLACEBO_COMPARATOR|Arm 3: Placebo|Participants will receive placebo subcutaneously
62637403|NCT01119690|ACTIVE_COMPARATOR|Rapeseed oil|
62637404|NCT01119690|ACTIVE_COMPARATOR|Milk fat|
62637405|NCT01622933|EXPERIMENTAL|Vaccine + IFN|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines. Approximately 30 days after the last vaccine subjects will receive IFN intravenously 5 days a week for 4 weeks.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and after the IFN treatment."
62637406|NCT01622933|EXPERIMENTAL|Vaccine only|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and again approximately 2 months after the last vaccine."
62637407|NCT02277327|EXPERIMENTAL|Intervention|"Subjects randomized to the intervention group will participate in a bundled intervention that includes action planning and care transitions (for those hospitalized during the study period)"
62637408|NCT02277327|PLACEBO_COMPARATOR|Routine Care|"Subjects randomized to the routine care group will continue to receive their usual care from the Pediatric Medical Home Program at UCLA"
62274200|NCT04754100|EXPERIMENTAL|Allogeneic iNKT Cells|3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks (each cycle is 14 days \[2 weeks\]).
62274201|NCT01073566|EXPERIMENTAL|Finesse|Finesse Insulin Delivery Patch
62274202|NCT01073566|ACTIVE_COMPARATOR|Usual injection device|Pen/Syringe
62069613|NCT05194189|PLACEBO_COMPARATOR|Placebo group|5% glucose solution 48 ml every 12 h for 4 days or until ICU discharge.
62274203|NCT04872114|EXPERIMENTAL|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
62069614|NCT05534880|ACTIVE_COMPARATOR|Virtual Reality|Condition 01 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video, lasting 10 minutes, there will be 03 sessions on alternate days with a 24-hour interval between each session, before and after each session will be applied the SSQ questionnaire subjective assessment and EEG objective assessment.
62274204|NCT02281019||Indeterminate strictures or undefined filling defects|
62274205|NCT02281019||Biliary stone cases|
62274206|NCT02281019||Other indications|
62637409|NCT04428385|NO_INTERVENTION|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
62274207|NCT01019447|ACTIVE_COMPARATOR|Study group|The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used.
62274208|NCT01019447|ACTIVE_COMPARATOR|Control group|The control group in which polyglactin 910 antimicrobial sutures will be used.
62454251|NCT06145815||MIC RCR patients|Patients who improved their SANE score beyond the minimal important change one year after arthroscopic rotator cuff repair
62454252|NCT06145815||No-MIC RCR patients|Patients who did not improve their SANE score beyond the minimal important change one year after arthroscopic rotator cuff repair
62274209|NCT00763139|EXPERIMENTAL|Placebo First|Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
62274210|NCT00763139|EXPERIMENTAL|Pioglitazone First|Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.
62274211|NCT03884582||HealthyVolunteers|
62274212|NCT05355142|EXPERIMENTAL|Group PM+|Intervention once a week for a total of 5 weeks
62274213|NCT05355142|NO_INTERVENTION|control group|Just daily observation
62274214|NCT06301178|ACTIVE_COMPARATOR|vitamin D deficiency|patients with vitamin D deficiency or insufficiency (\<12 ng/ml and 12-19 ng/ml, respectively) received systemic and intralesional vitamin D injections
62274215|NCT06301178|ACTIVE_COMPARATOR|vitamin D sufficiency|Patients with vitamin D sufficiency (20 and greater ng/mL) of vitamin D received only intralesional injections of vitamin D on hypertrophic scars and keloids.
62637410|NCT04428385|EXPERIMENTAL|Arm 2 (consumer-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
62637411|NCT02507492|EXPERIMENTAL|RM-493 Once Daily|Dose once daily in the morning
62274216|NCT02956382|EXPERIMENTAL|Phase I - Dose Level 0|"Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
62274217|NCT02956382|EXPERIMENTAL|Phase I - Dose Level 1|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
62274218|NCT02956382|EXPERIMENTAL|Phase I - Dose Level 2|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg~Each medication is taken daily. Treatment cycles are 28 days long."
62274219|NCT02956382|EXPERIMENTAL|Phase I - Dose Level 3|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg~Each medication is taken daily. Treatment cycles are 28 days long."
62274220|NCT02956382|EXPERIMENTAL|Phase II Dose|The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
62274221|NCT04354350||Ramipril|Reference group
62069615|NCT05534880|EXPERIMENTAL|Virtual reality and binaural beats|Condition 02 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video associated with audio with binaural beat, lasting 10 minutes, there will be 03 sessions on alternate days with a 24-hour interval between each session, before and after each session, the SSQ subjective assessment questionnaire and the objective assessment EEG will be applied.
62069616|NCT02467413|ACTIVE_COMPARATOR|BAC treatment group|BAC, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
62069617|NCT02467413|PLACEBO_COMPARATOR|BAC Matched vehicle|BAC Matched vehicle, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
62274222|NCT04354350||Telmisartan|Exposure group
62274223|NCT03290495|ACTIVE_COMPARATOR|isonly|This arm will receive spinal anesthesia. then this arm will receive saline during isoflurane anesthesia. this arm will serve as a control group.
62274224|NCT03290495|ACTIVE_COMPARATOR|isoket|this arm will receive spinal anesthesia. then will receive isoflurane inhalation. during isoflurane inhalation, this arm will receive single injection of ketamine. at end of anesthesia, effect of ketamine on recovery will be monitored.
62274225|NCT04852120||Compound Sodium Picosulfate Granules|
62274226|NCT05162482|ACTIVE_COMPARATOR|Heterologous 1|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
62274227|NCT05162482|ACTIVE_COMPARATOR|Heterologous 2|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
62069618|NCT00779584|EXPERIMENTAL|MK-8776 10mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 10 mg/m\^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62069619|NCT00779584|EXPERIMENTAL|MK-8776 20mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 20 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62069620|NCT00779584|EXPERIMENTAL|MK-8776 40mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 40 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62069621|NCT00779584|EXPERIMENTAL|MK-8776 80mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62274228|NCT05162482|ACTIVE_COMPARATOR|Heterologous 3|"CanSinoBIO (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
62274229|NCT05162482|ACTIVE_COMPARATOR|Heterologous 4|"CanSinoBIO (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
62637412|NCT03698292|ACTIVE_COMPARATOR|First group|Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days
62637413|NCT03698292|ACTIVE_COMPARATOR|Second Group|Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days
62637414|NCT06397430|EXPERIMENTAL|Arm 1 - enteral nutrition|patients receiving enteral nutrition (EN) after surgery
62637415|NCT06397430|EXPERIMENTAL|Arm 2 - parenteral nutrition|patients receiving parenteral nutrition (PN)
62637416|NCT06397430|EXPERIMENTAL|Arm 3 - mixed nutrition|patients receiving mixed nutrition (MF)
62637417|NCT05835661||Observation on the application of nasopharyngeal airway|Patients eligible for inclusion were selected, and after fully explaining the advantages and disadvantages of the two ways of nasopharyngeal airway, the patients were allowed to choose to be enrolled by themselves, and then subsequent observation was started
62637418|NCT01904890|EXPERIMENTAL|CRC Prevention and Screening Education|Intervention Lay Health Workers (LHWs) will be taught to teach their participants about CRC screening through 2 outreach sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
62637419|NCT01904890|ACTIVE_COMPARATOR|Nutrition Education|LHWs and participants in the comparison group will receive a bilingual CRC brochure as well as 2 lectures on healthy nutrition for cardiovascular health delivered by a health educator and an optional post- intervention LHW outreach session on CRC screening.
62637420|NCT03485599||HIV infected people|Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
62069622|NCT00779584|EXPERIMENTAL|MK-8776 112mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62274230|NCT05162482|ACTIVE_COMPARATOR|Heterologous 5|"AstraZeneca ChAdOx (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV(0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
62637421|NCT03902613|EXPERIMENTAL|Lurasidone|Open-label treatment with lurasidone within the dose range of 20-60 mg daily
62637422|NCT01982695|ACTIVE_COMPARATOR|Lisinopril|
62637423|NCT01982695|ACTIVE_COMPARATOR|Losartan|
62637424|NCT03278821|EXPERIMENTAL|Self Match|The patient must choose between the five possible treatment options.
62274231|NCT05162482|ACTIVE_COMPARATOR|Heterologous 6|"AstraZeneca ChAdOx (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
62454253|NCT02495558|EXPERIMENTAL|Patients with Tracheostomy|Assessment of reflex cough Assessment of the deccanultation outcome (follow-up)
62637425|NCT03278821|ACTIVE_COMPARATOR|Expert Match|The Patient is referred to treatment by standard procedure which is Expert Match based on patient data.
62637426|NCT04318704|OTHER|Single Arm Active|Ifenprodil
62637427|NCT06070090|EXPERIMENTAL|Treatment Group|This is the group of participants who will receive group acupuncture after a ketamine experience.
62637428|NCT02029131|EXPERIMENTAL|Exercise|
62454254|NCT01737671|EXPERIMENTAL|Methotrexate Infusion|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle is 4 consecutive daily doses of intraventricular methotrexate with minimum 2 weeks between cycles. If any serum methotrexate level is \> 0.3 micromolar, then Leucovorin therapy administered (5 mg/square meter per dose) every 6 hours by vein or mouth.
62454255|NCT06316609||participants from birth cohort with AD|The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the incidence of atopic dermatitis in their offspring.
62461581|NCT02290171|ACTIVE_COMPARATOR|Intervention group|The intervention groups start the intervention 6 months ahead of the control group.
62637429|NCT02029131|NO_INTERVENTION|Controls|
62637430|NCT05975814|EXPERIMENTAL|concave abutment vs. straight abutment|After implant is placed a randomization will determine if the implant receives a straight or a concave abutment. If a patient requires 2 implants, one of them will be straight and the other will be concave. A patient can therefore have both abutments.
62637431|NCT05235152|ACTIVE_COMPARATOR|Usual individual physiotherapy care|Participants with either low back pain, rotator cuff related pain, patellofemoral pain syndrome or lateral ankle sprain will received usual/individual physiotherapy care over a period of 12-weeks for the treatment of their musculoskeletal conditions if randomized in this group.
62637432|NCT05235152|EXPERIMENTAL|Group-supervised physiotherapy training programs|Participants with either low back pain, rotator cuff related pain, patellofemoral pain syndrome or lateral ankle sprain will received group-supervised physiotherapy training programs over a period of 12-weeks for the treatment of their musculoskeletal condition if randomized in this group.
62274232|NCT05162482|ACTIVE_COMPARATOR|Homologous 7|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
62454256|NCT06316609||participants from birth cohort without AD|The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the reduced incidence of atopic dermatitis in their offspring.
62454257|NCT02000856|ACTIVE_COMPARATOR|Nitrate rich beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
62637433|NCT00666302|EXPERIMENTAL|1|
62637434|NCT00666302|ACTIVE_COMPARATOR|2|
62637435|NCT00902577|EXPERIMENTAL|Diagnostic (MRI and PET using FMISO)|Two weeks before initiation of chemoradiotherapy with temozolomide, patients undergo MRI (DSC, DCE,DWI and MRS) and PET scan using FMISO. A subset of 15 patients undergo FMISO PET scans approximately 1 week before chemoradiotherapy.
62637436|NCT04110431|EXPERIMENTAL|LBBP group|In this arm, An right artrial (RA) lead and an implantable cardioverter defibrillator (ICD) lead are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed. If LBBP failed, a left ventricular(LV) pacing lead is implanted instead.
62637437|NCT04110431|ACTIVE_COMPARATOR|BivP group|In this arm, an RA lead , an ICD lead and a LV pacing lead are placed. If the implantation of LV pacing lead is unsuccessful due to unavailable coronary sinus branches(venae cordis magna or venae cordis media is not recommended), capture above 3.5V/0.5ms or refractory phrenic nerve stimulation,a LBBP lead is placed instead.
62637438|NCT05782803|EXPERIMENTAL|Exercises Group|As stated in the literature, 20 sessions of KSF training will be given to the study group for 4 weeks.
62069623|NCT00779584|EXPERIMENTAL|MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 80 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62461582|NCT02290171|NO_INTERVENTION|Delayed intervention group|The control groups will start intervention with 6 months delay
62461583|NCT01965522|EXPERIMENTAL|Melatonin and Vitamin D|
62637439|NCT05782803|NO_INTERVENTION|Control Group|Participants in the control group will not receive intervention throughout the study.
62637440|NCT05670743|EXPERIMENTAL|Silver diamine fluoride|Silver diamine fluoride, 38%, topical, single application
62637441|NCT05443373||experimental group (narcolepsy Type 1)|experimental group (narcolepsy Type 1, 300 subjects)
62637442|NCT05443373||experimental group (narcolepsy Type 2)|experimental group (narcolepsy Type 2, 100 subjects)
62637443|NCT05443373||experimental group (KLS)|experimental group (KLS, 100 subjects)
62274233|NCT05162482|ACTIVE_COMPARATOR|Homologous 8|"CanSinoBIO (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
62461584|NCT01965522|EXPERIMENTAL|Placebo and Vitamin D|
62637444|NCT05443373||experimental group (IH)|experimental group (IH,50 subjects)
62637445|NCT05443373||healthy control group|healthy control group (age and gender matched healthy subjects,50 subjects)
62637446|NCT01967459|ACTIVE_COMPARATOR|High dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml
62637447|NCT01967459|ACTIVE_COMPARATOR|Low dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml
62461585|NCT01965522|EXPERIMENTAL|Melatonin and Placebo|
62461586|NCT01965522|PLACEBO_COMPARATOR|Placebo and Placebo|
62274234|NCT05162482|ACTIVE_COMPARATOR|Homologous 9|"AstraZeneca ChAdOx (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
62274235|NCT03868683|OTHER|Glucose Reference 1|Glucose solution containing 30 g of glucose
62274236|NCT03868683|OTHER|Glucose Reference 2|Glucose solution 2 containing 30 g of glucose
62274237|NCT03868683|OTHER|Glucose Reference 3|Glucose solution 3 containing 30 g of glucose
62274238|NCT03868683|EXPERIMENTAL|Sucrose|Sucrose solution containing 30 g of sucrose
62274239|NCT03868683|EXPERIMENTAL|Regular Bake beans in tomato sauce|Bake bean in tomato sauce with high levels of sucrose (37%)
62274240|NCT03868683|EXPERIMENTAL|Bake beans in tomato sauce, reduced sugar|Bake bean in tomato sauce with medium levels of sucrose (29.9%)
62069624|NCT00779584|EXPERIMENTAL|MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 112 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62274241|NCT03868683|EXPERIMENTAL|Bake beans in tomato sauce, low GI|Bake bean in tomato sauce with low levels of sucrose (18.5%)
62274242|NCT03305107|EXPERIMENTAL|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of chocolate milk"
62637448|NCT04528316|ACTIVE_COMPARATOR|Control Group/Pilates Core Stability Exercises program Group|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~* Stage I: Warm-up: consists of four Pilates motions:~  1. Breathing:~ 2. Rolling back:~ 3. Coccyx-curl:~ 4. Hundred breathing:~* Stage II: Work-out: consists of twelve Pilates motions:~  1. Single leg stretch:~ 2. Straight leg raise:~ 3. Basic bridge:~ 4. Bridging variation:~ 5. Quadruped:~ 6. Clap with seal motion~ 7. Mermaid twist:~ 8. Swimming:~ 9. Double leg stretch:~ 10. Shoulder bridge:~ 11. Swan dive:~ 12. Leg full front:~* Stage III: Cool-down: consists of three Pilates motions:~  1. Rest position:~ 2. Cat with arm/leg extension:~ 3. Breathing:"
62637449|NCT04528316|EXPERIMENTAL|Balance Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Balance Program
62637450|NCT04528316|EXPERIMENTAL|Coordination Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Coordination Exercises.
62637451|NCT04161235||Treatment|Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
62637452|NCT01686945|EXPERIMENTAL|Healthy - 20 mg|
62637453|NCT01686945|EXPERIMENTAL|Healthy - 40 mg|
62637454|NCT01686945|EXPERIMENTAL|Healthy - 60 mg|
62637455|NCT01686945|EXPERIMENTAL|T2D - 20/40/60 mg|
62637456|NCT00628563||1|Asthma patients
62274243|NCT03305107|EXPERIMENTAL|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of water"
62274244|NCT03305107|EXPERIMENTAL|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
62274245|NCT03305107|EXPERIMENTAL|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
62637457|NCT04213664||non-metastatic renal cell carcinoma|Pretreatment lymphocyte to monocyte ratio in non-metastatic patients with renal cell
62637458|NCT05060575|EXPERIMENTAL|EDUTC|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
62637459|NCT05060575|ACTIVE_COMPARATOR|Control Group|Routine hospital care.
62637460|NCT01122069||Contrast echocardiography|110 patients with acute non-ST elevation myocardial infarct were examined with contrast echocardiography prior to coronary angiography.
62637461|NCT05865223|EXPERIMENTAL|Mckenzie exercise program|"Group A Week 0 : Hot pack for 15 minutes, mackenzie extension exercise program for cervical regions and mobilization with movement at cervical regions for improving flexion, extension, side flexion and rotation. 3 sets of painless glides of 10 repetitions were given, with 1 minute rest between sets.~* Week 2 \& 4: Hot pack for 15 minutes, mckenzie exercise program at cervical region with the progression in repetition and MWM at cervical regions and then we will add progression.5 sets of painless glides of 10 repetitions were given, with 3 minute rest between sets.~* Week 3 \& 6: Hot pack for 15 minutes, mckenzie exercise program for cervical region and MWM at cervical region . 5 sets of painless glides for 10 repetitions were given. Progression can be introduced by increasing number of repetitions performed exercises for 3 weeks."
62637462|NCT05865223|ACTIVE_COMPARATOR|conventional physical therapy|A routine physical therapy(joint mobilization,hot pack and home exercise program) treatment and hot pack for 15 minutes.
62637463|NCT03119597|PLACEBO_COMPARATOR|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
62637464|NCT03119597|EXPERIMENTAL|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
62637465|NCT00917826|EXPERIMENTAL|Arginine Butyrate + Ganciclovir/Valganciclovir|
62637466|NCT01754519|EXPERIMENTAL|Treatment (radiation therapy)|Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained.
62274246|NCT00986700|OTHER|different types of bad time food|Different types of bad time food
62274247|NCT05847894||Test group|Individuals with one or more pulmonary diseases
62274248|NCT05847894||Control group|Individuals who do not suffer from pulmonary diseases
62274249|NCT02296398||Romidepsin therapy|Patients who received romidepsin per standard of care practice or included in other clinical trials (when receiving romidepsin therapy).
62637467|NCT03977012||Patients with CRPS Type I|"Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care.~-drug name: norspan patch 5\~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks"
62637468|NCT00913341|EXPERIMENTAL|1|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
62637469|NCT00913341|ACTIVE_COMPARATOR|2|Alprazolam Tablets, 1 mg (The Upjohn Company)
62274250|NCT04989101|ACTIVE_COMPARATOR|Nigelle Group|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
62274251|NCT04989101|NO_INTERVENTION|Placebo Group|Follow-up should be done weekly for 1 month.
62274252|NCT04378608|OTHER|2 DAA (OBV/PTV/r) ± ribavirin (RBV)|Administering Ombitasvir/Paritaprevir/Ritonavir/ tablets plus RBV tablets to HCV GT4 in the treatment of Egyptian naïve patients
62637470|NCT03641261|EXPERIMENTAL|Therapeutic Patient Education program|All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose
62637471|NCT05178823|ACTIVE_COMPARATOR|Corsodyl|Chlorhexidine
62637472|NCT05178823|EXPERIMENTAL|Solumium Oral|Chlorine dioxide
62637473|NCT05178823|EXPERIMENTAL|Listerine Total Care|Essential oils, sodium fluoride, zinc chloride
62637474|NCT05178823|EXPERIMENTAL|BioGate Si*CLEAN|Microsilver
62637475|NCT04375163|EXPERIMENTAL|Massage group (ME)|A sport massage was applied between the sets of an intense isokinetic exercise protocol for knee extensor muscles
62637476|NCT04375163|ACTIVE_COMPARATOR|Control|the break between the sets of an intense isokinetic exercise protocol for knee extensor muscles was passive
62637477|NCT05293782|ACTIVE_COMPARATOR|Kinesiotaping on trunk flexor muscles|Kinesiotaping
62637478|NCT05293782|ACTIVE_COMPARATOR|Kinesiotaping on trunk extensor muscles|Kinesiotaping
62637479|NCT05293782|PLACEBO_COMPARATOR|Placebo Kinesiotaping on trunk flexor muscles|Kinesiotaping
62637480|NCT05293782|PLACEBO_COMPARATOR|Placebo Kinesiotaping on trunk extensor muscles|Kinesiotaping
62637481|NCT04022317|EXPERIMENTAL|Biocon Insulin R|0.3 IU/kg Dose per administration, subcutaneous Route of administration
62637482|NCT04022317|ACTIVE_COMPARATOR|Humulin® R (regular insulin human)|0.3 IU/kg Dose per administration, subcutaneous Route of administration
62637483|NCT04851106||Patient with a solid pancreatic lesion of an undetermined nature|Patient with a solid pancreatic lesion of an undetermined nature
62637484|NCT00338741||1|Rebif exposed pregnancies
62637485|NCT00338741||2|Non-Rebif exposed pregnancies
62637486|NCT01681758|ACTIVE_COMPARATOR|PPV|use PPV to guide fluid therapy
62637487|NCT01681758|PLACEBO_COMPARATOR|standard care|fluids according to standard care
62637488|NCT03478371|SHAM_COMPARATOR|Marketed Tampon D|Regular absorbency tampon
62637489|NCT03478371|SHAM_COMPARATOR|Marketed Tampon M|Regular absorbency tampon
62637490|NCT03478371|SHAM_COMPARATOR|Marketed Tampon T|Regular absorbency tampon
62637491|NCT03478371|SHAM_COMPARATOR|Marketed Tampon V|Regular absorbency tampon
62637492|NCT00103285|EXPERIMENTAL|Group 0 Induction Therapy|All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) \< 0.1% OR MRD \>= 0.1% and \< 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD \>= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.
62637493|NCT00103285|ACTIVE_COMPARATOR|Group 1-SR-low ALL, Arm I (combination chemotherapy)|Patients receive standard consolidation therapy, standard interim maintenance therapy, and standard delayed intensification (DI) therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years
62637494|NCT00103285|EXPERIMENTAL|Group 1-SR-low ALL, arm II (combination chemotherapy)|Patients receive experimental consolidation therapy, experimental interim maintenance therapy, and standard DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
62637495|NCT00103285|ACTIVE_COMPARATOR|Group 2-SR-avg ALL, arm I (combination chemotherapy)|Patients receive standard consolidation therapy, standard interim maintenance therapy, and standard DI therapy as in group 1, arm I, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
62637496|NCT00103285|EXPERIMENTAL|Group 2-SR-avg ALL, arm II (combination chemotherapy)|Patients receive standard consolidation therapy, augmented interim maintenance therapy, augmented DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
62637497|NCT00103285|ACTIVE_COMPARATOR|Group 2-SR-avg ALL, arm III (combination chemotherapy)|Patients receive intensified consolidation therapy, standard interim maintenance therapy, and standard DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
62637498|NCT00103285|ACTIVE_COMPARATOR|Group 2-SR-avg ALL, arm IV (combination chemotherapy)|Patients receive intensified consolidation therapy, augmented interim maintenance therapy, and augmented DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
62637499|NCT00103285|EXPERIMENTAL|Group 3-SR-high ALL, combination chemotherapy|Patients receive intensified consolidation therapy, augmented interim maintenance therapy (2 courses), and augmented DI therapy (2 courses), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
62637500|NCT00059228|EXPERIMENTAL|Estradiol|Experimental
62637501|NCT00059228|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62637502|NCT03513016|EXPERIMENTAL|Part A: UBX0101|Part A: UBX0101, single intra-articular injection, ascending dose
62637503|NCT03513016|PLACEBO_COMPARATOR|Part A: Placebo|Part A: Placebo, single intra-articular injection, ascending dose
62637504|NCT03513016|EXPERIMENTAL|Part B: UBX0101|Part B: UBX0101, single intra-articular injection, fixed dose
62637505|NCT03513016|PLACEBO_COMPARATOR|Part B: Placebo|Part B: Placebo, single intra-articular injection, fixed dose
62637506|NCT01828970|EXPERIMENTAL|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
62637507|NCT04758195|EXPERIMENTAL|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
62069625|NCT00779584|EXPERIMENTAL|MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 150 mg/m\^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62069626|NCT00779584|EXPERIMENTAL|MK-8776 200mg+Gemcitabine 1000mg/m^2|Participants received MK-8776 200 mg given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m\^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
62069627|NCT06391216|EXPERIMENTAL|Probiotic|Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 combination probiotic - encapsulated
62069628|NCT06391216|PLACEBO_COMPARATOR|Placebo|Mixture of potato starch and magnesium stearate (the excipients that are present in the tested product) - encapsulated
62637508|NCT04758195|ACTIVE_COMPARATOR|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
62637509|NCT05934474||IBIS-PSY patients|
62637510|NCT01716663||Experimental: Catheter Ablation|These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
62637511|NCT02665247|EXPERIMENTAL|C-SIP|Participants assigned to the C-SIP group will attend sessions where information about sleep is presented. In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
62637512|NCT02665247|OTHER|Control Session|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
62069629|NCT00741715|PLACEBO_COMPARATOR|1|
62069630|NCT00741715|EXPERIMENTAL|2|AVE5530 25mg
62069631|NCT00741715|EXPERIMENTAL|3|AVE5530 50mg
62069632|NCT00741715|ACTIVE_COMPARATOR|4|atorvastatin 10mg
62069633|NCT00741715|EXPERIMENTAL|5|atorvastatin 10mg + AVE5530 25mg
62274253|NCT04201925||blepharoplasty|Patients will undergo blepharoplasty surgery
62274254|NCT01720537|EXPERIMENTAL|Cohort 1|
62637513|NCT05778474||Healthy participants|At least 10 healthy participants aged from 18 to 60 years old with symmetric walking at visual analysis. Participants will be excluded if pregnant, if they present with pharmacologic therapies which could affect balance and walking, and if they suffered from (or presently present with) orthopedic or neurologic conditions potentially impairing walking.
62069634|NCT00741715|EXPERIMENTAL|6|atorvastatin 10mg + AVE5530 50mg
62274255|NCT01720537|EXPERIMENTAL|Cohort 2|
62637514|NCT05778474||Pathologic group|At least 15 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled. Participants will present a unilateral motor impairment, not preventing passive oscillation of the upper limbs.
62637515|NCT05659147|EXPERIMENTAL|Imaging markers of exocrine and endocrine insufficiency|"We will prospectively enroll 85 participants; 40 with known or suspected EPI and 45 controls (no known organic gastrointestinal pathology and no history of pancreatic disease) in this aim.~Participants will be undergoing clinically-indicated endoscopy and will have endoscopic pancreatic function tests (ePFTs) collected for research during the clinically-indicated endoscopy examination. A research blood draw and a research stool collection will also be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin within 2 weeks of their clinical endoscopy but no sooner than 2 hours before or after endoscopy."
62637516|NCT05659147|EXPERIMENTAL|Imaging markers of diabetes and prediction of progression to diabetes|"We will prospectively enroll 30 participants; 10 with a single episode of acute pancreatitis, 10 with acute recurrent pancreatitis, and 10 with pancreatitis-related diabetes in this aim.~Participants will undergo a research MRI examination. Participants will also undergo a research blood draw for laboratory analysis and to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes."
62637517|NCT05659147|EXPERIMENTAL|Imaging stratification of stages of pancreatitis|"We will prospectively enroll 60 participants; 15 healthy controls, 15 participants with a single episode of acute pancreatitis, 15 participants with acute recurrent pancreatitis, and 15 participants with chronic pancreatitis.~A research blood draw and a research stool collection will be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin."
62069635|NCT00741715|ACTIVE_COMPARATOR|7|atorvastatin 20mg
62069636|NCT00741715|EXPERIMENTAL|8|atorvastatin 20mg + AVE5530 25mg
62069637|NCT00741715|EXPERIMENTAL|9|atorvastatin 20mg + AVE5530 50mg
62069638|NCT00741715|ACTIVE_COMPARATOR|10|atorvastatin 40mg
62274256|NCT01720537|EXPERIMENTAL|Cohort 3|
62274257|NCT01720537|EXPERIMENTAL|Cohort 4|
62274258|NCT01720537|EXPERIMENTAL|Cohort 5|
62274259|NCT01720537|EXPERIMENTAL|Cohort 6|
62274260|NCT01594021|EXPERIMENTAL|High pre-emptive volume loading|
62274261|NCT01594021|ACTIVE_COMPARATOR|Low pre-emptive volume loading|
62274262|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
62069639|NCT00741715|EXPERIMENTAL|11|atorvastatin 40mg + AVE5530 25mg
62069640|NCT00741715|EXPERIMENTAL|12|atorvastatin 40mg + AVE5530 50mg
62069641|NCT00741715|ACTIVE_COMPARATOR|13|atorvastatin 80mg
62069642|NCT00741715|EXPERIMENTAL|14|atorvastatin 80mg + AVE5530 25mg
62069643|NCT00741715|EXPERIMENTAL|15|atorvastatin 80mg + AVE5530 50mg
62069644|NCT01121172||obese|obese subjects according to International Obesity Task Force criteria
62069645|NCT01121172||lean|
62069646|NCT01710917||Targinact® (oxycodon/naloxon)|
62069647|NCT01478113|ACTIVE_COMPARATOR|WBT + amphetamine/dextroamphetamine|In the active group, participants will receive treatment with Well-being therapy and amphetamine-dextroamphetamine.
62069648|NCT01478113|PLACEBO_COMPARATOR|WBT + placebo|In the placebo group, participants will receive treatment with Well-being therapy and pill placebo.
62069649|NCT01044342|EXPERIMENTAL|A|Single dose of AZD1446 10 mg
62069650|NCT01044342|EXPERIMENTAL|B|Single dose of AZD1446 80 mg
62069651|NCT01044342|ACTIVE_COMPARATOR|C|Single Dose of Donepezil 5 mg
62069652|NCT01044342|PLACEBO_COMPARATOR|D|Single dose of placebo to match AZD1446
62069653|NCT06609499|EXPERIMENTAL|Flexible-tip Bougie Group|Paramedics using the flexible-tip bougie (the STIG)
62454258|NCT02000856|PLACEBO_COMPARATOR|Nitrate depleted beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
62637518|NCT05659147|EXPERIMENTAL|Imaging reproducibility|"We will prospectively enroll up to 20 participants enrolled in Aims 1 or 3 (up to 5 controls and 15 patients with pancreatic disease) to undergo repeat research MRI imaging between 24 hours and 14 days after their first research MRI.~Participants will undergo a research MRI examination with administration of intravenous secretin, identical to the research MRI performed under Aims 1 or 3. MRI images will be quantitatively analyzed and agreement between the two MRI examinations (1st and repeat MRI) will be assessed."
62637519|NCT05659147|NO_INTERVENTION|Automated or semi-automated image analysis|We will use images prospectively collected under Aims 1-3, as well as existing images that had been obtained for clinical care of children with pancreatitis at CCHMC to develop and optimize image processing pipelines for MRI images. Performance of these pipelines will be benchmarked against manual segmentation performed by multiple observers.
62637520|NCT00037986|OTHER|1|
62454259|NCT00891475|EXPERIMENTAL|Arm 1|38 patients
62454260|NCT00891475|EXPERIMENTAL|Arm 2|38 patients
62454261|NCT00891475|EXPERIMENTAL|Arm 3|38 patients
62454262|NCT00219297|EXPERIMENTAL|Single Arm|
62454263|NCT01616810||observation|Healthy participants
62274263|NCT02712515||Parkinson's disease and dystonia|Participants in this group with Parkinson's disease and/or dystonia will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
62069654|NCT06609499|ACTIVE_COMPARATOR|Gum-elastic bougie Group|Paramedics using the gum-elastic bougie
62069655|NCT04686279|EXPERIMENTAL|TFV Medicated Douche|Once enrolled, participants will complete a baseline sampling session and then a single dose of study product administration. Post-dose observations and data collection will follow at 1, 6, 24, and 72 hours, using a sparse PK sampling design in which plasma and peripheral blood mononuclear cells (PBMC) are collected at each designated time. Between sampling windows, YMSM will complete a web-survey examining their perceived reactions and comfort using the study douche, factors influencing product use in the future, and comfort with the trial procedures. The survey will be administered after dosing but scheduled not to interfere with other study assessments. Sampling for safety, PK, PD, and acceptability assessments will be collected according to the schedule of events. Phase I Trial participants will complete an in-depth interview as part of their Termination visit.
62069656|NCT04261660||fresh|NO INTERVENTION
62069657|NCT04261660||Frozen embro transfer natural|NO INTERVENTION
62274264|NCT05055193||Preterm infants who received postnatal corticosteroid for bronchopulmonary dysplasia|Corticosteroids used are hydrocortisone (as first-line therapy) and betamethasone (in situations of particular severity)
62274265|NCT05055193||Preterm infants who did not receive postnatal corticosteroid for bronchopulmonary dysplasia|No corticosteroids
62274266|NCT00345670|EXPERIMENTAL|1|MEDI-534
62274267|NCT00345670|EXPERIMENTAL|2|MEDI-534
62274268|NCT00345670|EXPERIMENTAL|3|MEDI-534
62274269|NCT05877482|EXPERIMENTAL|Experimental Group|Short foot exercises with internal shoe modification (a medial longitudinal arch support) will be performed daily for six weeks.
62274270|NCT05877482|NO_INTERVENTION|Control Group|Only internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe.
62274271|NCT04769011|EXPERIMENTAL|Clinical, neuropsychological, neurophysiological, and genetic evaluations|Clinical, neuropsychological, neurophysiological, and genetic evaluations
62274272|NCT00244023|EXPERIMENTAL|1|Testosterone gel (intervention)
62274273|NCT00244023|PLACEBO_COMPARATOR|2|one sachet of placebo gel once a day, possibly titrated to 2 sachets if insufficient efficacy
62274274|NCT01302808|EXPERIMENTAL|Cohort 1 (Erlotinib plus Romidepsin (8 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m\^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
62274275|NCT01302808|EXPERIMENTAL|Cohort 2 (Erlotinib plus Romidepsin (10 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m\^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
62274276|NCT01302808|EXPERIMENTAL|Cohort 3 (Erlotinib plus Romidepsin (10 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m\^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
62274277|NCT01302808|EXPERIMENTAL|Cohort 4 (Erlotinib plus Romidepsin (8 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m\^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
62454264|NCT05060900|EXPERIMENTAL|Hand and Wrist Ligament Reconstruction with Allograft Ligament|Participants will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
62637521|NCT02996071|ACTIVE_COMPARATOR|low waist to height ratio|laparoscopic sleeve gastrectomy
62637522|NCT02996071|ACTIVE_COMPARATOR|high waist to height ratio|laparoscopic sleeve gastrectomy
62274278|NCT04993378||GC patients receiving immunotherapy|
62274279|NCT04466800|EXPERIMENTAL|Intervention group_rehabilitation program|multidisciplinary and personalized rehabilitation program
62454265|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
62454266|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
62637523|NCT02881658|EXPERIMENTAL|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
62637524|NCT02881658|PLACEBO_COMPARATOR|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
62274280|NCT04466800|NO_INTERVENTION|Control group|Usual care of each site, including delivery of an information sheet concerning recommended physical activity (based on WHO recommendations) and nutrition. One month after inclusion, patients of this group will be offered a rehabilitation program (as described in the intervention group, but with only one session with a physical activity educator at home) and one dietitian consultation.
62637525|NCT03154580|PLACEBO_COMPARATOR|N-acetylcysteine 0mg X Cue Exposure (neutral)|
62637526|NCT03154580|PLACEBO_COMPARATOR|N-acetylcysteine 0mg X Cue Exposure (marijuana)|
62637527|NCT03154580|ACTIVE_COMPARATOR|N-acetylcysteine 2400mg X Cue Exposure (neutral)|
62637528|NCT03154580|ACTIVE_COMPARATOR|N-acetylcysteine 2400mg X Cue Exposure (marijuana)|
62637529|NCT01131715||Study group|Patients who are included in the pharmacist follow-up procedure
62637530|NCT02955953|EXPERIMENTAL|LY2963016 U-200 Formulation (Test)|LY2963016 test formulation administered as a subcutaneous (SC) injection in one of two or two of four study periods.
62637531|NCT02955953|EXPERIMENTAL|LY2963016 U-100 Formulation (Reference)|LY2963016 reference formulation administered as a SC injection in one of two or two of four study periods.
62637532|NCT01464190|EXPERIMENTAL|PA21|
62637533|NCT01464190|ACTIVE_COMPARATOR|Sevelamer carbonate|
62637534|NCT02052986|EXPERIMENTAL|Vascazen|Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.
62637535|NCT00608400|EXPERIMENTAL|1|CLA 1.5 g/d
62637536|NCT00608400|EXPERIMENTAL|2|CLA 3.0 g/d
62637537|NCT00608400|PLACEBO_COMPARATOR|3|
62637538|NCT02209363|EXPERIMENTAL|Positive airway pressure (PAP)|Auto-adjusting positive airway pressure
62274281|NCT02349178|EXPERIMENTAL|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
62637539|NCT02209363|SHAM_COMPARATOR|nasal dilator strips|Sham treatment
62069658|NCT04261660||Frozen embro transfer hormonal|NO INTERVENTION
62069659|NCT06503679|EXPERIMENTAL|LY4100511 Dose 1 + Midazolam + Repaglinide (Cohort 1)|Participants will receive an oral dose 1 of LY4100511 and single dose of midazolam and repaglinide.
62069660|NCT06503679|EXPERIMENTAL|LY4100511 Dose 2 + Midazolam + Repaglinide (Cohort 2)|Participants will receive up to an oral dose 2 of LY4100511 and single dose of midazolam and repaglinide. Dosing will not proceed until a satisfactory review of the safety and tolerability data from lower dose level is performed.
62274282|NCT01515657|EXPERIMENTAL|PL2200 Aspirin Capsules|Investigational drug arm; crossover design
62274283|NCT01515657|ACTIVE_COMPARATOR|Immediate-Release Aspirin Tablets|Active comparator; crossover design
62637540|NCT02137941|ACTIVE_COMPARATOR|techniques to optimize potential (TOP)|
62274284|NCT01515657|ACTIVE_COMPARATOR|Enteric-coated aspirin caplets|Active comparator; crossover design
62274285|NCT06037330|EXPERIMENTAL|Nalbuphine group|40 mg of nalbuphine was diluted into 50 mL solution, the load dose was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was \<2, and the daily maximum dose was 160mg.
62274286|NCT06037330|ACTIVE_COMPARATOR|Sufentanil group|0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points.
62274287|NCT02544932|EXPERIMENTAL|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
62454267|NCT03715270||breast reconstruction surgery patients|Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
62069661|NCT06503679|EXPERIMENTAL|LY4100511 Dose 3 + Digoxin and Rosuvastatin (Cohort 3)|Participants will recive an oral dose 3 of LY4100511 and single dose of digoxin and rosuvastatin.
62069662|NCT00477906|EXPERIMENTAL|1|"MVax + BCG + cyclophosphamide + IL2~2:1 randomization - MVax:Control"
62069663|NCT00477906|PLACEBO_COMPARATOR|2|Placebo Vaccine + BCG + cyclophosphamide + IL2
62274288|NCT02544932|EXPERIMENTAL|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
62274289|NCT02544932|ACTIVE_COMPARATOR|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
62274290|NCT03340610|OTHER|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
62454268|NCT02467036|EXPERIMENTAL|Family Based Behavioral Treatment Egg|The FBT+Egg group will participate in group-based FBT and will be assigned to eat eggs a minimum of 5 days a week for breakfast. Families are provided eggs each week to facilitate compliance, along with recipes
62454269|NCT02467036|ACTIVE_COMPARATOR|Family Based Behavioral Treatment Cereal|The FBT+Cereal group will participate in group-based FBT and will be assigned to eat cereal a minimum of 5 days a week for breakfast. Families are provided cereal each week to facilitate compliance.
62454270|NCT05240677|PLACEBO_COMPARATOR|Group 1|Chronic kidney diseases patients with iron deficiency anemia and eGFR ≥ 60 ml/min/1.73 m2
62637541|NCT02137941|ACTIVE_COMPARATOR|heart coherence (HC)|
62637542|NCT02137941|PLACEBO_COMPARATOR|controls|
62637543|NCT05943353|OTHER|non-randomized trials|
62637544|NCT05418465|EXPERIMENTAL|Huangqi Guizhi Wuwu decoction group|Huangqi Guizhi Wuwu decoction
62637545|NCT05418465|ACTIVE_COMPARATOR|Dapagliflozin group|Dapagliflozin
62637546|NCT01608880|PLACEBO_COMPARATOR|Polysporin Control|Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
62637547|NCT01608880|ACTIVE_COMPARATOR|Nitroglycerin|Patients in treatment group will receive nitroglycerin ointment application
62637548|NCT06080516|EXPERIMENTAL|30-SEC|Participants will execute each exercise for 30 seconds
62637549|NCT06080516|EXPERIMENTAL|45-SEC|Participants will execute each exercise for 45 seconds
62637550|NCT03936569|EXPERIMENTAL|Marketed Stannous Fluoride Toothpaste|Brush twice daily
62637551|NCT03936569|PLACEBO_COMPARATOR|Marketed Cavity Protection Toothpaste|Brush twice daily
62637552|NCT02115100|ACTIVE_COMPARATOR|pulmonary vein+renal artery denervation|Procedure: pulmonary vein and renal artery denervation
62069664|NCT02049710|ACTIVE_COMPARATOR|Sexual Behavior Intervention|Video based intervention based on changing risky behavior associated with sexual behavior.
62274291|NCT02575287||NERD group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux
62637553|NCT02115100|ACTIVE_COMPARATOR|Pulmonary vein isolation|Procedure: Pulmonary vein isolation
62274292|NCT02575287||Control group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux
62274293|NCT00280761||1|Single Arm Trial
62274294|NCT00739154||1|glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment
62274295|NCT00739154||2|glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin
62274296|NCT00739154||3|glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment
62274297|NCT04187885|ACTIVE_COMPARATOR|Group/Cohort 1 : CTL|"Label : control~Type : comparator~Description: Outside academic stress period (represented by exams), without the physical activity program (no Intervention)."
62274298|NCT04187885|EXPERIMENTAL|Group/Cohort 2: PAP|"Label : physical activity program without stress Type : experimental~Description: outside academic stress period (exams), with the physical activity program:60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday."
62274299|NCT04187885|EXPERIMENTAL|Group/Cohort 3: AS|"Label : academic stress Type : experimental~Description: during academic stress period (exams), without the physical activity program (no Intervention)"
62274300|NCT04187885|EXPERIMENTAL|Group/Cohort 4: ASPAP|Label : academic stress and physical activity program Type : experimental Description: during academic stress period (exams), with the physical activity program: 60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday.
62274301|NCT02105454|EXPERIMENTAL|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
62274302|NCT06152822|EXPERIMENTAL|treatment group|pyrotinib+capecitabine+bevacizumab
62274303|NCT00996099|ACTIVE_COMPARATOR|CGM-eMPC|
62454271|NCT05240677|EXPERIMENTAL|Group 2|Chronic kidney diseases patients with iron deficiency anemia and eGFR \< 60 ml/min/1.73 m2.
62454272|NCT02053532||Positron emission tomography/magnetic resonance imaging|
62637554|NCT01707641|ACTIVE_COMPARATOR|CD#2|patients will be asked to melt slowly in the mouth 6 lozenges per day, containing Lactobacillus brevis CD2
62637555|NCT01707641|ACTIVE_COMPARATOR|bicarbonate sodium mouthwash|patients will be asked to wash their mouth with bicarbonate several times per day
62069665|NCT02049710|ACTIVE_COMPARATOR|Driving behavior intervention|Video based intervention based on changing risky behavior associate with driving
62274304|NCT00996099|OTHER|Control|
62274305|NCT02511652|ACTIVE_COMPARATOR|Ambu AuraGain|Insertion of the supraglottic device and evaluation of its clinical performance
62274306|NCT02511652|ACTIVE_COMPARATOR|LMA Supreme|Insertion of the supraglottic device and evaluation of its clinical performance
62274307|NCT02012478|NO_INTERVENTION|No intervention|baseline session - with surveys and HbA1C only
62637556|NCT05857722|EXPERIMENTAL|Entrepreneurship and Jóvenes Capibara group|Participants in the experimental arm will receive a 10-day intervention, which consists of an entrepreneurship program, plus Jóvenes Capibara, an intervention that aims to improve emotion regulation and mental health symptoms among youth impacted by violence.
62454273|NCT03437083||Eribulin|Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m\^2) (as eribulin 1.23 mg/m\^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
62461587|NCT06171139|EXPERIMENTAL|Stage 1: Tool Development|Participants will participate in a semi-structured qualitative interview either by phone, video conference or in-person. A trained interviewer will interview eligible, consenting participants using a semi-structured interview guide to meet objectives. The interview guide is based on The Patient Education Materials Assessment Tool (PEMAT) and the COM-B (capability (C), opportunity (O), and motivation (M))/Behaviour Change Wheel (BCW) framework and will be used to determine an implementation strategy. The interview will be audio-recorded, transcribed verbatim, and analyzed.
62637557|NCT05857722|OTHER|Control waitlist condition|Participants in the control waitlist condition will will be eligible to receive the intervention after 6-month follow-up data collection, which will take place approximately 10 to 12 months after the Entrepreneurship and Jóvenes Capibara group receives the intervention.
62637558|NCT02300623|ACTIVE_COMPARATOR|Control|Antiretroviral therapy alone
62274308|NCT02012478|EXPERIMENTAL|MI-informed SMS intervention|Baseline session with surveys \& HbA1C MI baseline session Technology tutorial Intervention x 3 months
62274309|NCT06075693||Longitudinal|We will ask eligible volunteers to provide a CSF sample by a lumbar puncture procedure, a urine sample, undergo a cognitive assessment, and to undergo an MRI scan once per year for two years.
62454274|NCT03129269|EXPERIMENTAL|neuroimaging amyloid diagnosis by MRI and PET scan|"There is only one arm. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. MRI and PET Scan.~* Visits at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.~* At 6 and 18 months in consultation by a Geriatrician and research assistant for a medical check.~* one PET-Scan in the 2 months following inclusion for amyloid measurements and one MRI, depending on the clinical relevance~* A blood sample for biobank at visit 2 and at visit 5.~Extension study (CogFrail-Plus): additional 2 years follow-up of the COGFRAIL study participants, following the initial 2 years period of the study:~* 2 Visits at at 36 and 48 months for a full neuropsychological, functional and physical evaluation~* At 30 and 42 months in consultation by a Geriatrician and research assistant for a medical check~* A blood sample at 36 and 48 months."
62454275|NCT01137695|ACTIVE_COMPARATOR|Symlin Naive, Usual Dose|Symlin 120 mcg three times daily in patients not previously treated with pramlintide before the study.
62637559|NCT02300623|EXPERIMENTAL|Treatment|Antiretroviral therapy plus Interleukin-2'
62637560|NCT01759706|EXPERIMENTAL|Enhanced Recovery After Surgery (ERAS)|Patients treated with enhanced recovery after surgery protocol: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia with naropin + sufentanil, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV prophylaxis with ondansetron + dexamethasone, hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, postoperative mobilization program, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
62274310|NCT06075693||Single|We will ask eligible volunteers to provide a CSF sample by a lumbar puncture procedure, a urine sample, undergo a cognitive assessment, and to undergo an MRI scan once.
62274311|NCT02990442|EXPERIMENTAL|rTMS|treatment with repetitive transcranial magnetic stimulation for 30 days
62274312|NCT00756873|PLACEBO_COMPARATOR|1|
62274313|NCT00756873|EXPERIMENTAL|2|Etoricoxib 90 mg qd.
62274314|NCT00756873|EXPERIMENTAL|3|Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)
62274315|NCT03177083|ACTIVE_COMPARATOR|peginterferon beta-1a|
62274316|NCT03177083|ACTIVE_COMPARATOR|Current Therapy|
62287109|NCT01709331|EXPERIMENTAL|Corifollitropin alfa 150 μg + hCG|During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
62454276|NCT01137695|EXPERIMENTAL|Symlin Naive, Dose Escalation|Escalation of pramlintide dose to 360 mcg three times daily in patients not taking pramlintide prior to study.
62454277|NCT01137695|ACTIVE_COMPARATOR|Symlin treated, Usual Dose|pramlintide 120 mcg three times daily in patients who have been treated with pramlintide 120 mcg prior to the trial.
62454278|NCT01137695|EXPERIMENTAL|Symlin Treated, Dose Escalation|pramlintide 360 mcg three times daily in patients previously treated with 120 mcg prior to the study.
62454279|NCT01767064|EXPERIMENTAL|Posted commitment letter|The poster-sized (18x24 inches) commitment letter, written at the 8th grade reading-level and displayed in English and Spanish, emphasize clinician commitment to guidelines for appropriate antibiotic prescribing and explain why antibiotics are not appropriate in many cases. These letters, featuring clinician photographs and signatures, are displayed in clinician exam rooms for a 16-week period.
62454280|NCT01767064|NO_INTERVENTION|Control|Usual care with no posted letters.
62454281|NCT04894513|EXPERIMENTAL|study group|the study group received the conventional selected program in addition to Kabat motor control re-education
62637561|NCT01759706|ACTIVE_COMPARATOR|Standard perioperative care (Control)|Patients treated with standard care perioperative protocol: epidural analgesia with naropin + sufentanil, pre-anesthetic medication with diazepam, Preoperative bowel preparation with sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
62274317|NCT01641614|EXPERIMENTAL|Beating heart surgery|Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
62274318|NCT01641614|ACTIVE_COMPARATOR|heart surgery Group B|Group B (arrested heart) surgery was performed under moderate hypothermia (32⁰C) as technique requirement (3). After cardiac arrest, during the period of cross clamping, the aortic root was perfused through the cardioplegias's cannula with oxygenated blood at a rate between 200 mL/min to 300 mL/min for 2 minutes with 15 minutes intervals.Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
62069666|NCT06286514||Paper Validation|validate the paper version of the Home Food Inventory
62069667|NCT06286514||electronic validation|validate the electronic version of the Home Food Inventory
62069668|NCT02384967|EXPERIMENTAL|Darunavir 400mg/d|Tri-therapy containing Darunavir at dose of 400 mg/d.
62069669|NCT03008720|ACTIVE_COMPARATOR|tDCS active|Transcranial stimulation ( tDCS ) active will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle.
62069670|NCT03008720|PLACEBO_COMPARATOR|tDCS sham|Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
62069671|NCT03008720|ACTIVE_COMPARATOR|FES active|Functional electrical stimulation (FES) active will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 μs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold.
62274319|NCT01978093|EXPERIMENTAL|HibCY Group|Subjects received 4 doses of Hib-MenCY-TT (MenHibrix®) vaccine at Day 0, Month 2, Month 4 and Month 10-13 , 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
62274320|NCT01978093|ACTIVE_COMPARATOR|PedHIB Group|Subjects received 3 doses of PedvaxHIB® vaccine at Day 0, Month 2 and Month 10-13, 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
62069672|NCT03008720|PLACEBO_COMPARATOR|FES sham|Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA.
62637562|NCT03434210|EXPERIMENTAL|LAT-treated Community Model|The subjects in experimental group are on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
62637563|NCT03434210|OTHER|Care as usual|"The subjects in control group are on  cared as usual Which means Patients will be managed follow the request of National Continuing Management and Intervention Program for Psychoses. Patients will managed by community mental health professionals, get education information and rehablitation guidence from them."
62069673|NCT02970253|ACTIVE_COMPARATOR|Capsular resection|Capsular resection
62069674|NCT02970253|ACTIVE_COMPARATOR|Capsular retention|Capsular retention
62069675|NCT00393523|ACTIVE_COMPARATOR|5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose)."
62069676|NCT00393523|ACTIVE_COMPARATOR|10 µg ENGERIX-B™ Booster (Group 2)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)"
62069677|NCT00393523|ACTIVE_COMPARATOR|5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose)."
62069678|NCT00393523|ACTIVE_COMPARATOR|10 µg ENGERIX-B™ Booster (Group 4)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose)."
62454282|NCT04894513|EXPERIMENTAL|control group|the control group received the conventional selected program
62637564|NCT00371956|ACTIVE_COMPARATOR|1|raloxifene
62637565|NCT00371956|PLACEBO_COMPARATOR|2|placebo arm
62637566|NCT01307813|EXPERIMENTAL|Endoscopic suturing device|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
62637567|NCT01374022|EXPERIMENTAL|ART Strategy|maximum alveolar recruitment plus PEEP titration
62637568|NCT01374022|ACTIVE_COMPARATOR|ARDSNet Strategy|standard strategy (ARDSNet)
62637569|NCT03286218|PLACEBO_COMPARATOR|Placebo|Placebo was administered orally in one of five treatment periods
62637570|NCT03286218|ACTIVE_COMPARATOR|Alprazolam 2 milligram (mg)|2 mg of alprazolam was administered orally in one of five treatment periods
62637571|NCT03286218|EXPERIMENTAL|Lasmiditan 100 mg|100 mg of lasmiditan was administered orally in one of five treatment periods
62637572|NCT03286218|EXPERIMENTAL|Lasmiditan 200 mg|200 mg of lasmiditan was administered orally in one of five treatment periods
62637573|NCT03286218|EXPERIMENTAL|Lasmiditan 400 mg|400 mg of lasmiditan was administered orally in one of five treatment periods
62637574|NCT04071782|EXPERIMENTAL|SELUTION Drug Coated Balloon|Study participants will undergo lower limb angioplasty using SELUTION DCB, which is coated with sirolimus.
62637575|NCT03669601|EXPERIMENTAL|Continuous AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily for 21 days of a 28 day cycle. Dose range from 40mg to 120mg."
62637576|NCT03669601|EXPERIMENTAL|Intermittent AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily and intermittently for up to 12 days of a 28 day cycle. Dose range from 40mg to 120mg."
62637577|NCT01393145|EXPERIMENTAL|Group 1|
62637578|NCT01393145|ACTIVE_COMPARATOR|Group 2|
62637579|NCT05468255|EXPERIMENTAL|Metabolic|Metabolic: Participants will have their blood glucose levels measured via continuous glucose monitoring for 3 days while participating in their normal exercise routines (EX). Participants will also have their blood glucose levels measured for 3 days while not exercising (NOEX), following immediately by 3 days of a return to normal activity(REX). Participants will be randomized to participate in the EX or NOEX/REX phases first. The EX and NOEX/REX phases will be separated by at least 1 week
62274321|NCT00004001|EXPERIMENTAL|Docetaxel and Estramustine|Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
62274322|NCT00004001|ACTIVE_COMPARATOR|Mitoxantrone and Prednisone|Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days
62274323|NCT01352806|EXPERIMENTAL|fluoroscopy, palpation, ultrasound|in the same subject we will compare the accuracy of identifying the intralaminar space by three technique, fluoroscopy, ultrasound, palpation.
62274324|NCT04656873||ICI treatment|Adult cancer patients starting ICI monotherapy or combination therapy at UNC Chapel Hill per clinical standard of care and willing to allow specimens from surplus tissue to be banked for research purposes (in the case of resections) AND willing to have additional specimens taken for research purposes (in the case of biopsies). Patients will be followed for samples and clinical data from medical records from before starting ICI therapy until 2 years after the end of ICI treatment.
62274325|NCT03847610|EXPERIMENTAL|Healthy volunteer|
62274326|NCT05707091|EXPERIMENTAL|Low level laser therapy|Patients assigned to experimental group received low level laser therapy and conventional therapy. Treatment frequency was five sessions/week for 4 weeks. . For laser therapy, Omega laser system used with infrared probes of 830 nm wavelength and 100 mW output power, average energy density of 10 J/cm2 , frequency of 1 KHz, and a duty cycle of 80 % in one group. In all cases, the laser was in direct contact with the superficial roots of the facial nerve on the affected side. And was applied for 2 min and 5 s per point for 8 points.
62637580|NCT05468255|EXPERIMENTAL|Vascular|Vascular: Participants will have their blood vessel health measured while performing their normal exercise routines (EX) and while undergoing 1, 3, 5 days of no exercise (NOEX) followed immediately by 1 and 3 days of return to exercise (REX).
62637581|NCT02823353|EXPERIMENTAL|Fenofibrate + UDCA|Fenofibrate (200 mg/day) in combination with ursodeoxycholic acid (13-15 mg/kg/day)
62637582|NCT02823353|ACTIVE_COMPARATOR|Monotherapy|UDCA 13-15mg/kg/day
62274327|NCT05707091|EXPERIMENTAL|Conventional therapy|Group B was treated with conventional therapy. The interrupted galvanic electrical impulses with the duration of 3-30 milliseconds, the tolerable intensity was applied over the motor points of each facial muscle. A total of 30-60 electrical twitch induced muscle contractions will be maintained for each muscle. The facial muscles exercise training with mirror-visual feedback was progressed to resisted exercises by self and/or therapist-assistance. All exercises were demonstrated to participants by the therapist's efforts and instructed the participants to continue the exercises twice a day for 10-15 minutes. A pictorial leaflet of facial expressions exercises with appropriate instructions to perform exercises. Treatment frequency was five sessions/week for 4 weeks.
62274328|NCT04549701|EXPERIMENTAL|CAVAL US group|Patients assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to the treating medical team, in addition to standard care. Diuretic titration: There will not be a specific treatment protocol, but clinicians will be encouraged to tailor treatment, particularly with the use of diuretics, according to the number of B-lines and dilation in the IVC. The therapeutic objective will be discharge patients normal CAVAL US, with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory alterations that contraindicate discharge.
62454283|NCT04690777|EXPERIMENTAL|VESTIBULAR EXERCISE at home telerehabilitation|"1. The vestibular exercises were performed with the indications of a physical therapist, in sessions of about 20 minutes with 5 times per week (Monday to Friday) consisting of 5 repetitions ensuring the following were not overworked:~1. Head and eye movements while sitting.~2. Head and body movements while sitting.~3. Paused exercises.~4. Combined exercises of modifications on rungs, unstable surfaces and walking exercises."
62274329|NCT04549701|ACTIVE_COMPARATOR|Standard of care group|Patients assigned to this group will receive standard care, and diuretic titration will be based on standard practice (physical examination, symptoms, and laboratory results). The therapeutic objective will be discharge patients with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory abnormalities that contraindicate discharge.
62274330|NCT05840081|EXPERIMENTAL|Full-fat milk beverage|Beverage made with full-fat milk
62274331|NCT05840081|EXPERIMENTAL|Fat-free milk beverage|Beverage made with fat-free milk
62274332|NCT05840081|EXPERIMENTAL|Full-fat yogurt beverage|Beverage made with full-fat yogurt
62454284|NCT04690777|EXPERIMENTAL|MULTICOMPONENT EXERCISE at home telerehabilitaion|"1. A 6-week multi-component therapeutic physical exercise program was carried out. The ministerial guide and the Vivifrail consensus was followed (25, 26). There were 5 daily sessions per week (Monday to Friday), each lasting approximately 45 minutes. These sessions were conducted following the instructions of a physical therapist. VIVIFRAIL exercises are intended to be used over a progression period of up to 12 weeks, with combined exercises by days in cardiovascular aerobic balance strength and flexibility."
62274333|NCT05840081|EXPERIMENTAL|Fat-free yogurt beverage|Beverage made with fat-free yogurt
62454285|NCT04690777|EXPERIMENTAL|VESTIBULAR EXERCISE in clinic|"1. The vestibular exercises were performed with the indications of a physical therapist, in sessions of about 20 minutes with 5 times per week (Monday to Friday) consisting of 5 repetitions ensuring the following were not overworked:~1. Head and eye movements while sitting.~2. Head and body movements while sitting.~3. Paused exercises.~4. Combined exercises of modifications on rungs, unstable surfaces and walking exercises."
62454286|NCT04690777|EXPERIMENTAL|multi component exercise in clinic|"1. A 6-week multi-component therapeutic physical exercise program was carried out. The ministerial guide and the Vivifrail consensus was followed (25, 26). There were 5 daily sessions per week (Monday to Friday), each lasting approximately 45 minutes. These sessions were conducted following the instructions of a physical therapist. VIVIFRAIL exercises are intended to be used over a progression period of up to 12 weeks, with combined exercises by days in cardiovascular aerobic balance strength and flexibility."
62637583|NCT06301919||Included patients|All patients referred to our hospital and treated by TAE with NBCA, based on clinical decisions in emergency and CT scan.
62637584|NCT02118103|EXPERIMENTAL|Spinal Manipulation|bilateral lumbar spine manipulation
62637585|NCT02118103|NO_INTERVENTION|No Intervention - control|no intervention
62637586|NCT02488226|EXPERIMENTAL|Gaze Contingent|Participants will view social videos using Gaze-contingent eye-tracking technology . If the participants looking patterns deviate from a normative pattern, they will be redirected to the normative point of regard using gaze-contingent cues.
62274334|NCT02133859||Chronic Heart Failure patients using ASV|Patients with chronic heart failure who are using or willing to use adaptive servo ventilation (ASV) therapy will be enrolled. Respiratory data will be collected from this group every 3 months over a 12 month period
62274335|NCT03188952|ACTIVE_COMPARATOR|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
62274336|NCT03188952|EXPERIMENTAL|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
62069679|NCT00393523|EXPERIMENTAL|5 µg Modified Process Hepatitis B Vaccine (Group 5)|"Participants did not receive a prior vaccination with a hepatitis B vaccine.~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine."
62274337|NCT03987854|EXPERIMENTAL|complete diet and lifestyle program|
62274338|NCT02852317||Spina bifida patient|
62274339|NCT02852317||Patients with multiple sclerosis|
62274340|NCT02852317||Patients with spinal cord injury|
62274341|NCT02852317||Patients with overactive bladder|
62274342|NCT03838679||Cohort 1|80 participants with neovascular AMD and a minimum history of 12 months of anti- VEGF therapy will be included in cohort 1 and examined only once (1 study visit).
62274343|NCT03838679||Cohort 2|40 participants with treatment-naive neovascular AMD receiving standardized anti- VEGF therapy will be included in cohort 2 and followed for 12 months (6 study visits).
62274344|NCT05196945|EXPERIMENTAL|VA-dual|"14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
62274345|NCT05196945|ACTIVE_COMPARATOR|EACP - quadruple|14days(Esomeprazole 20mg/ time, 2 times/day, oral+Amoxicillin 1g/ time, 2 times/day, oral+Clarithromycin 0.5g/ time, 2 times/day, oral+Bismuth potassium citrate 220mg/ time, twice a day, orally)
62274346|NCT05181527|PLACEBO_COMPARATOR|Control group|Patients in the control group will get an identical-looking capsule containing placebo (starch) once daily in addition to SSRI.
62637587|NCT02488226|NO_INTERVENTION|Control Condition|Participants will view unaltered social videos which do not change based on where the participant is looking.
62274347|NCT05181527|EXPERIMENTAL|Test group|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment.
62274348|NCT04711707|EXPERIMENTAL|Community navigator|This group is guided through the resources and provided bi-monthly support with a community navigator
62274349|NCT04711707|OTHER|Self-Navigation|This group receives the social needs resources to self-navigation
62274350|NCT06367881|ACTIVE_COMPARATOR|Group 1: Low dose Alveofact without steroids|"After obtaining parental consent, preterm neonates diagnosed with respiratory distress syndrome will be randomly administered a low dose of Intratracheal Alveofact (50 mg/kg) once without Budesonide. The clinical improvement of ventilatory settings, oxygen requirement, Assessment of Neutrophil Extracellular Trap (NET) formation, and Reactive Oxygen Species (ROS) will then be assessed before and 48 hours after treatment.~The patient who will receive low-dose alveofact retreatment will be considered if the fraction of inspired oxygen (FiO2) was \> 0.4 (does 50 mg/kg birth weight) 6 hours after treatment."
62274351|NCT06367881|EXPERIMENTAL|Group 2: Low dose Alveofact with steroids|"After obtaining parental consent, preterm neonates diagnosed with respiratory distress syndrome will be randomly administered a low dose of Intratracheal Alveofact (50 mg/kg) once with Budesonide (0.25 mg/kg). The clinical improvement of ventilatory settings, oxygen requirement, Assessment of Neutrophil Extracellular Trap (NET) formation, and Reactive Oxygen Species (ROS) will then be assessed before and 48 hours after treatment.~The patient who will receive low-dose alveofact retreatment will be considered if the fraction of inspired oxygen (FiO2) was \> 0.4 (does 50 mg/kg birth weight) 6 hours after treatment."
62274352|NCT06367881|ACTIVE_COMPARATOR|Group 3: High dose Alveofact without steroids|After obtaining parental consent, preterm neonates diagnosed with respiratory distress syndrome will be randomly administered a High dose of Intratracheal Alveofact (100 mg/kg) once without Budesonide. The clinical improvement of ventilatory settings, oxygen requirement, Assessment of Neutrophil Extracellular Trap (NET) formation, and Reactive Oxygen Species (ROS) will then be assessed before and 48 hours after treatment.
62274353|NCT06367881|EXPERIMENTAL|Group 4: Group 1: High dose Alveofact with steroids|After obtaining parental consent, preterm neonates diagnosed with respiratory distress syndrome will be randomly administered a High dose of Intratracheal Alveofact (100 mg/kg) once with Budesonide(0.25 mg/kg). The clinical improvement of ventilatory settings, oxygen requirement, Assessment of Neutrophil Extracellular Trap (NET) formation, and Reactive Oxygen Species (ROS) will then be assessed before and 48 hours after treatment.
62274354|NCT03368261|OTHER|HTAP/ clinical complications in the sickle cell disease|Supply epidemiological data on this detected HTAP, and allow the characterization of the clinico-biological paintings and the mortality which are associated to them.
62274355|NCT05060588|EXPERIMENTAL|Sacubitril/Valsartan|Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
62274356|NCT05060588|ACTIVE_COMPARATOR|Valsartan|1 tablet of Valsartan every 24 hours for 6 months
62454287|NCT01774474|ACTIVE_COMPARATOR|Non diabetics: bromfenac|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
62637588|NCT03993483|EXPERIMENTAL|Higher Load|One arm and one leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
62637589|NCT03993483|EXPERIMENTAL|Lower Load|The other arm and leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
62274357|NCT03650192|EXPERIMENTAL|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
62274358|NCT05402423|EXPERIMENTAL|JDome rehabilitation group|Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with the JDome System
62637590|NCT06278805||Stroke patients|Participants with chronic stroke who have more than 1 year after stroke onset and who fulfill the inclusion/exclusion criteria will be included in this single-arm study.
62274359|NCT05402423|ACTIVE_COMPARATOR|control group|Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with standard exercise bike
62274360|NCT05183503||TMD group|Patients diagnosed with TMD
62274361|NCT01348646|OTHER|Lifestyle counseling|
62274362|NCT05498688|EXPERIMENTAL|Low carbohydrate|The intervention meal is a low-carbohydrate meal composed of 15 E% carbohydrates, 20 E% protein and 65 E% fat
62454288|NCT01774474|ACTIVE_COMPARATOR|Non diabetics: dexamethasone|dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
62454289|NCT01774474|ACTIVE_COMPARATOR|Non diabetics: bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
62274363|NCT05498688|NO_INTERVENTION|Control meal|The control meal is a regular diabetes meal according to the official Danish dietary guidelines composed of 50 E% carbohydrates, 20 E% protein and 30 E% fat
62274364|NCT03803644|EXPERIMENTAL|Administration of CC-92480 - Part 1|dose escalation
62274365|NCT03803644|EXPERIMENTAL|Administration of CC-92480 under fasted conditions - Part 2|Food effect
62274366|NCT03803644|EXPERIMENTAL|Administration of CC-92480 under fed conditions - Part 2|food effect
62274367|NCT02481973|EXPERIMENTAL|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy, prescribed according to their characteristic symptoms and confirmed my their miasmatic facial features. Although different individualised remedies may be dispensed, each remedy will be homoeopathic and prepared in accordance with the German Homoeopathic Pharmacopoeia. Each prescription will be in a potency of 30CH which will be taken once daily, according to the GBM. Sucrose pillules will used as the vehicle for each remedy.
62454290|NCT01774474|ACTIVE_COMPARATOR|Diabetics: eye drops|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
62454291|NCT01774474|ACTIVE_COMPARATOR|Diabetics: eye drops & TA|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~\& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)"
62454292|NCT01774474|ACTIVE_COMPARATOR|Diabetics: eye drops & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~\& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)"
62637591|NCT00735345|EXPERIMENTAL|Treatment Arm|Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy
62637592|NCT03472131|EXPERIMENTAL|Septic spondylodiscitis|A unilateral posterolateral approach and debridement with titanium cage insertion supplemented by screw fixation for severe sick patients suffering from septic spondylodiscitis
62637593|NCT03262779|EXPERIMENTAL|combination nivolumab and ipilimumab - primary|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks in patients with primary resistance.
62637594|NCT03262779|EXPERIMENTAL|combination nivolumab and ipilimumab - acquired|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks in patients with acquired resistance.
62637595|NCT02048150|EXPERIMENTAL|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
62274368|NCT01028807|EXPERIMENTAL|1. Experimental group: Early feeding:|After 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
62274369|NCT01028807|ACTIVE_COMPARATOR|Control group : Obligatory 5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
62274370|NCT00751868|EXPERIMENTAL|ARM 1|FEC e Ixabepilone. A goal of 48 patients will be enrolled in this study by 16 Italian centres of the GIM (Gruppo Italiano Mammella) Group. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled in the study
62274371|NCT03049904|NO_INTERVENTION|Wait List Control|Participants wait 3 weeks before receiving the intervention.
62274372|NCT03049904|EXPERIMENTAL|Experimental Vr2L 2Spirit|Participants immediately begin their participation in the virtual world.
62274373|NCT01479712|ACTIVE_COMPARATOR|Irrigation|This is the arm that will receive irrigation.
62274374|NCT01479712|NO_INTERVENTION|No Irrigation|This is the arm that will not receive irrigation.
62274375|NCT05332483|EXPERIMENTAL|Arm 1 - Megestrol|All study participants will receive Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
62274376|NCT04963257|EXPERIMENTAL|sertraline combined with fluvoxamine|Sertraline combined with fluvoxamine treatment group: Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
62637596|NCT04912843|EXPERIMENTAL|NR082 injection|0.5E9 viral genomes (vg), 0.05 mL eye/dose ,single-dose,only one eye per subject; 1.5E9 viral genomes (vg), 0.05 mL eye/dose single-dose,only one eye per subject; 4.5E9 viral genomes (vg) , 0.05 mL eye/dose single-dose,only one eye per subject Part 1: Dose-Finding；The recommended dose (safe and effective dose) of the Part 2 study will be determined jointly by the SRC, IDMC, sponsor and the drug regulatory authority after the interim analysis in Part 1 is completed.
62637597|NCT04912843|SHAM_COMPARATOR|sham-injection|Part2.Second Stage: randomized, double-blind, sham-injection control study One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
62637598|NCT00980824|EXPERIMENTAL|therapy|Cognitive behavioural therapy. Six sessions of structured focused therapy.
62637599|NCT00980824|ACTIVE_COMPARATOR|Standard treatment|referral to specialised or generic mental health service
62274377|NCT04963257|ACTIVE_COMPARATOR|sertraline combined with aripiprazole|sertraline combined with aripiprazole treatment group:Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
62274378|NCT06466889||Mastocytosis|Diagnosed mastocytosis according to WHO criteria
62274379|NCT06466889||Hypertryptasemia|Repeated elevated serum tryptase with no underlying mastocytosis or no bone marrow biopsy performed
62274380|NCT01367522|EXPERIMENTAL|Arm 1|
62274381|NCT04728685|ACTIVE_COMPARATOR|Group A|One-fifth of body weight traction force will be given
62637600|NCT00433550|EXPERIMENTAL|Group 1 (6/6 UGT1A1 genotype)|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
62637601|NCT00433550|EXPERIMENTAL|Group 2 (6/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
62274382|NCT04728685|ACTIVE_COMPARATOR|Group B|One-third of body weight traction force will be given
62274383|NCT04728685|ACTIVE_COMPARATOR|Group C|One-half of body weight traction force will be given
62274384|NCT02559466|EXPERIMENTAL|Patients stimulated with a H-TMS (deep)|20 sessions navigated with Deep Transcranial Magnetic Stimulation
62274385|NCT02559466|OTHER|Patients stimulated with a conventional TMS|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
62274386|NCT01514682|PLACEBO_COMPARATOR|Placebo|Placebo pills to be assigned using a permuted randomization system
62274387|NCT01514682|EXPERIMENTAL|Anti-inflammatory Combination Therapy|Salsalate, statin and omega-3-fatty acid combination therapy
62274388|NCT03158870||Pheochromocytoma|Patient who underwent surgical procedure for pheochromocytoma
62274389|NCT00215605|EXPERIMENTAL|1|
62274390|NCT01977781|EXPERIMENTAL|Tacrolimus|Topical tacrolimus suspension will be formulated and aseptically prepared from commercially available intravenous tacrolimus, PROGRAF® (Astellas Pharma US, Inc), and transferred into a sterile dropper container by the MEEI pharmacy. A formulation of 0.05% (5mg/10ml) concentration of tacrolimus with diluting solvent, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
62274391|NCT01977781|ACTIVE_COMPARATOR|Methylprednisolone Sodium Succinate|Topical methylprednisolone sodium succinate suspension will be formulated and aseptically prepared from commercially available sterile dry powder vial preservative-free for intravenous use, SOLU-MEDROL® (Pfizer, Inc.). A formulation of 0.5% (5mg/1ml) concentration of methylprednisolone with diluting solvents, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
62637602|NCT00433550|EXPERIMENTAL|Group 3 (7/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
62637603|NCT03449355||vaginal group|
62637604|NCT03449355||cesarean section group|
62637605|NCT05434455|EXPERIMENTAL|RIPC|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
62637606|NCT05434455|NO_INTERVENTION|Con|The control group had a deflated cuff placed on the upper arm for the same time.
62637607|NCT01200706|ACTIVE_COMPARATOR|Amoxicillin given twice a day|
62637608|NCT01200706|ACTIVE_COMPARATOR|Amoxicillin given three times a day|
62274392|NCT05726344|EXPERIMENTAL|Lactulose group|"Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed.~The day before the study, the group receiving lactulose shall take 4 tablets of Bisacodyl (5 mg) the day before the study at 6pm. Then, at 8pm a bottle of 250 mL (162.5g lactulose) of lactulose shall be dissolved in 600 mL of water and all contents (850 mL) shall be taken in 2 hours. At 10pm they have to drink 2 liters still water."
62274393|NCT05726344|EXPERIMENTAL|Polyethylene glycol group|"Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed.~The day before the study, the group receiving polyethylene glycol (PEG) should take 4 tablets of Bisacodyl (5 mg) at 4pm. Then, at 6pm, 3 bottles of PEG (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) shall be dissolved in 3 liters of water (1 bottle per liter) and they shall take half the preparation, that is 1 liter and a half in 2 hours. At 10pm they shall take the remaining contents in 2 hours."
62274394|NCT05537922||Retrospective Cohort|This cohort includes the analysis of a multicentric retrospective cohort of more than 2,000 patients. This cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model). All available clinical data will be collected. Also, CT and PET scans will be collected and a first radiomic signature.
62274395|NCT05537922||Prospective Cohort|The prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients.
62274396|NCT04196868|EXPERIMENTAL|Experimental arm|
62454293|NCT01774474|ACTIVE_COMPARATOR|Diabetics: eye drops, TA & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~\& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)~\& a peroperative intravitreal injection of 1.25 mg bevacizumab"
62454294|NCT05743920|EXPERIMENTAL|Self-help Forest Bathing Group|Participants in the FB group will perform forest bathing activity at the Chinese University of Hong Kong for two session.
62454295|NCT05743920|OTHER|Wait List Group|
62274397|NCT04196868|PLACEBO_COMPARATOR|Control arm|
62274398|NCT05688943|ACTIVE_COMPARATOR|General Anesthesia|This arm will receive general anesthesia for vNOTES surgery.
62274399|NCT05688943|EXPERIMENTAL|Spinal Anesthesia|This arm will receive spinal anesthesia for vNOTES surgery.
62454296|NCT03738332|OTHER|Low-level laser therapy|Single arm
62454297|NCT01550211||Students|Healthy students from Bar-Ilan University
62454298|NCT01550211||Schizophrenic patients' relatives|Healthy family members (parents or siblings) of the schizophrenic participants (chronic and naive)
62454299|NCT01550211||Naive schizophrenic patients|Naive patients with a diagnosis of schizophrenia, a history of only one psychotic episode and un-medicated
62274400|NCT05010356|EXPERIMENTAL|Healthy control subjects|Healthy control subjects undergoing a hyperinsulinemic euglycemic clamp
62454300|NCT01550211||Chronic schizophrenia patients|Chronic patients with a diagnosis of schizophrenia and a history of more than one psychotic episode
62637609|NCT02244671|EXPERIMENTAL|fat, PRP, botulinum toxin|Fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
62274401|NCT05010356|EXPERIMENTAL|Breast cancer survivors|Breast cancer survivors undergoing a hyperinsulinemic euglycemic clamp
62274402|NCT01609842|EXPERIMENTAL|Phone reminders and pharmacist|An alerted inpatient pharmacist or a designated study team member will bring the clopidogrel medication to the patient who has received a coronary stent. The patient will return home and receive IVR refill reminder calls.
62274403|NCT01609842|OTHER|Usual Care|The sites will have no interaction with the study personnel. The investigators will use database information to compare with the intervention sites
62454301|NCT01093209|SHAM_COMPARATOR|Conventional Laser Therapy|
62274404|NCT01932957|OTHER|Laparotomy arm|Standard treatment
62274405|NCT01932957|EXPERIMENTAL|Laparoscopy arm|Treatment by laparoscopy
62454302|NCT01093209|ACTIVE_COMPARATOR|Interferential Laser Therapy|
62274406|NCT00703638|EXPERIMENTAL|Sorafenib/Pemetrexed/Cisplatin|Patients receiving a dose escalation scheme of daily oral sorafenib (200 mg or 400 mg bid) when given in combination with fixed dose intravenous pemetrexed and cisplatin for the treatment of solid tumors.
62454303|NCT03508713||early RA patients|patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.
62461588|NCT06171139|EXPERIMENTAL|Stage 1: Tool Implementation (Pilot Study)|Participants will receive the tumor genetic pre-test counseling tool informed by results and themes identified in Stage 1. Participants will receive the non-therapeutic intervention, a pre-TGT counseling tool, and complete pre- and post-intervention surveys and a attend a brief post-intervention interview.
62461589|NCT01474122|ACTIVE_COMPARATOR|Macitentan 3 mg|Oral macitentan 3 mg, once daily
62461590|NCT01474122|ACTIVE_COMPARATOR|Macitentan 10 mg|Oral macitentan 10 mg, once daily
62637610|NCT04987112|EXPERIMENTAL|CAN1012 single agent|CAN1012 intratumoral injection given alone
62637611|NCT00746226|ACTIVE_COMPARATOR|A|Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
62274407|NCT04492280|ACTIVE_COMPARATOR|1. Group H|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®, E.I.P.I.co. under license of Pfizer) at dose 50mg every 6 hours by Intra venous route.
62274408|NCT04492280|ACTIVE_COMPARATOR|2. Group HF|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®) at dose of 50mg every 6 hours by Intra venous route and Fludrocortisone (Cortilon®, Amoun) 50 Microgram once daily by nasogastric tube for one week
62274409|NCT04492280|PLACEBO_COMPARATOR|3. Group C|These patients will receive standard therapy for sepsis.
62274410|NCT06458933|EXPERIMENTAL|Sage|Immediately receives 12 sessions of a couple psychotherapy designed to treat borderline personality disorder (BPD) and enhances relationship functioning simultaneously.
62069680|NCT06226428|EXPERIMENTAL|Cyclo-ergonometry program group|"* Mobility activities in bed (turning, pelvic elevation and sitting), standing, transfers and walking.~* Progressive strength training of upper and lower limbs (2 days/week), by performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.~* Cycloergometry, using the MotoMed Letto 2 device, with a progressive pattern, starting with 5 minutes and lasting up to 30 minutes. It will be performed once a day, during working days (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light)."
62274411|NCT06458933|ACTIVE_COMPARATOR|SIP|Immediately receives 12 individual sessions each (12 for people with borderline personality disorder (BPD), 12 for partners) of Supportive Individual Psychotherapy (SIP).
62454304|NCT02728037|EXPERIMENTAL|Magnesium-Based Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
62461591|NCT01474122|PLACEBO_COMPARATOR|Placebo|Oral placebo, once daily
62637612|NCT00746226|PLACEBO_COMPARATOR|B|"Numbers 612-624 and 800-811~Microcrystalline cellulose"
62637613|NCT02262910|EXPERIMENTAL|ES414|Cohorts 1-3 of the dose escalation stage of the study (Stage 1) will test weekly doses of 0.2 mcg/kg to 2 mcg/kg. Cohorts 4-9 of the dose escalation stage of the study (Stage 1) will test continuous infusion at flat doses of 25 mcg to 300 mcg per day delivered continuously over 24 hours. The maximum tolerated dose from Stage 1 of the study will be further examined in Stage 2. Patients in cohorts 1-3 will receive ES414 weekly via intravenous (IV) infusion during the first three 28-day cycles and then on Day 1 and 15 of each subsequent cycle until disease progression, intolerable toxicity occurs, or the patient withdraws consent. Patients in cohorts 4-9 will receive ES414 as a continuous IV infusion for 6 months until disease progression, intolerable toxicity occurs, or the patient withdraws consent.
62274412|NCT02001233||EV71 Vaccine|Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
62274413|NCT02001233||Placebo|placebo in 5000 infants aged 6-35 months old on day0,28
62274414|NCT00490568|EXPERIMENTAL|Rosiglitazone XR|Investigational drug
62274415|NCT04819737|EXPERIMENTAL|Spinal Cord MRI|
62274416|NCT04680611||Patients with severe eosinophilic asthma Phase 1|Patients with severe eosinophilic asthma on Nucala(R) treatment
62274417|NCT04680611||Patients with severe eosinophilic asthma Phase 2|Patients with severe eosinophilic asthma to start Nucala(R) treatment
62069681|NCT06226428|ACTIVE_COMPARATOR|Usual treatment group|"* Mobility activities in bed (turning, pelvic elevation and sitting), standing, transfers and walking.~* Progressive strength training of upper and lower limbs (2 days/week), by performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells."
62069682|NCT00507221|EXPERIMENTAL|1|Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.
62274418|NCT04680611||Partners of patients with severe eosinophilic asthma Phase 2|Partners of patients with severe eosinophilic asthma to start Nucala(R) treatment
62274419|NCT04680611||Phase 3: Patients with severe eosinophilic asthma from Phase 2|A sub-group of patients who participate in Phase 2
62274420|NCT04680611||Phase 3: Partners of patients in Phase 3|Partners of the sub-group of patients who participate in Phase 3
62274421|NCT03592095|EXPERIMENTAL|DN group|The intervention group will receive real dry needling (DN) (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
62274422|NCT03592095|PLACEBO_COMPARATOR|Placebo needle|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
62274423|NCT05320900||Severance hospital|Cardiovascular disease patients
62274424|NCT05320900||Yongin Severance hospital|Cardiovascular disease patients
62274425|NCT05320900||Soon Chun Hyang University Hospital Bucheon|Cardiovascular disease patients
62274426|NCT00915343|EXPERIMENTAL|Novel once daily modified release|"Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state"
62461592|NCT04702971|EXPERIMENTAL|patients with migraine|patient with migraine will be prescribed with flunarizine or routine clinical care per clinician's decision based on the condition of each individual patient
62637614|NCT05656170|EXPERIMENTAL|Stellate ganglion block arm|This arm will receive a one time bilateral stellate ganglion block with 20 cc bupivacaine (10 cc per side).
62637615|NCT05656170|SHAM_COMPARATOR|Placebo arm|This arm will receive a one time bilateral injection with 20 cc normal saline(10 cc per side).
62637616|NCT06428266|ACTIVE_COMPARATOR|Closed dacryointubation|Patients undergoing conventional closed dacryointubation with Crawford's tube
62637617|NCT06428266|EXPERIMENTAL|Bicanalicular Intubation|Patients undergoing bicanalicular intubation with Self-Stable Intubation Set II FCI
62637618|NCT01439113|NO_INTERVENTION|Standard of care|In this arm, patients who have difficult IV access will undergo the standard of care. The options include a) repeated attempts by a primary nurse, b) new attempts by a second nurse, c) central line placement by a physician, d) intraosseous line placement by a physician, e) physician use of ultrasound for peripheral IV placement
62637619|NCT01439113|EXPERIMENTAL|Ultrasound-guided IV|In this arm, the emergency nurse will apply the ultrasound machine to locate and cannulate a patient's peripheral veins
62637620|NCT03273959|NO_INTERVENTION|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
62637621|NCT03273959|EXPERIMENTAL|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
62637622|NCT04362202|EXPERIMENTAL|experimental|8 individual experimental rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
62069683|NCT00507221|ACTIVE_COMPARATOR|2|Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.
62069684|NCT01254890|EXPERIMENTAL|Azacitidine + Sorafenib|Azacitidine (AZA) 75 mg/m\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days; Sorafenib 200 mg orally twice a day.
62069685|NCT00730314|EXPERIMENTAL|1|Unrelated donor
62274427|NCT00915343|ACTIVE_COMPARATOR|Conventional TID hydrocortisone|Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.
62274428|NCT04608695|NO_INTERVENTION|Control ovary|
62274429|NCT04608695|EXPERIMENTAL|Punctured ovary|
62274430|NCT01938144|EXPERIMENTAL|Treatment A|IBU 200 mg/ PE 10 mg
62274431|NCT01938144|EXPERIMENTAL|Treatment B|IBU 200 mg/ PE 10 mg/CHLOR 4 mg
62274432|NCT01938144|ACTIVE_COMPARATOR|Treatment C|Acetaminophen 500 mg
62461593|NCT04702971|OTHER|healthy control|healthy control
62069686|NCT00730314|EXPERIMENTAL|2|Cord Blood
62069687|NCT00932334|EXPERIMENTAL|TALK Plus|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
62069688|NCT00932334|EXPERIMENTAL|TALK Standard|Participants receive and educational video and booklet about living kidney donation
62274433|NCT00487539|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
62274434|NCT00487539|EXPERIMENTAL|Golimumab 100 mg -> 50 mg|Golimumab 100 milligram (mg) subcutaneous injection administered at Week 0 and dose is decreased to 50 mg at Week 2.
62274435|NCT00487539|EXPERIMENTAL|Golimumab 200 mg -> 100 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 and dose is decreased to 100 mg at Week 2.
62274436|NCT00487539|EXPERIMENTAL|Golimumab 400 mg -> 200 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 and dose is decreased to 200 mg at Week 2.
62274437|NCT01088035|EXPERIMENTAL|Carboplatin|
62274438|NCT02727335||patients ALK + who received crizotinib|patients with ALK rearrangement who started treatment with crizotinib (250 mg twice a day) between the 18/11/2010 and the 31/12/2013 (will include patients from the ATU programs and patients treated after the marketing of crizotinib)
62274439|NCT03772626|EXPERIMENTAL|Heated humidified high-flow|Heated Humidified High-flow Nasal Cannula
62637623|NCT04362202|ACTIVE_COMPARATOR|control|8 individual of standard aquatic rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
62274440|NCT04565678|EXPERIMENTAL|Treatment Sequence 1: ABCD|Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
62274441|NCT04565678|EXPERIMENTAL|Treatment Sequence 2: BDAC|Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
62274442|NCT04565678|EXPERIMENTAL|Treatment Sequence 3: CADB|Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
62274443|NCT04565678|EXPERIMENTAL|Treatment Sequence 4: DCBA|Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
62637624|NCT06122402|EXPERIMENTAL|SECURE Care Bundle|The SECURE Care Bundle has been developed by researchers based on the latest evidence to prevent medical adhesive-related skin injuries associated with central venous catheter fixation in children. The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, correctly applying and removing medical adhesives and registering medical adhesive related skin injury.
62637625|NCT06122402|ACTIVE_COMPARATOR|Standart Care|No intervention will be applied to this group. No intervention will be applied to this group. The care provided in the clinic will continue to be provided in the same way.
62637626|NCT03838939|EXPERIMENTAL|interventional group|"M3 (group with 3 to 10 patients) Intensification Biotherapy Education Workshops : Subcutaneous injection education and biotherapy management"
62637627|NCT03838939|PLACEBO_COMPARATOR|Control group|"M3 (individual) Intensification Biotherapy Education: Subcutaneous injection education and biotherapy management."
62069689|NCT00932334|OTHER|Usual Care|Participants receive their usual medical care
62274444|NCT01394081|EXPERIMENTAL|Enhanced Engagement and Enrollment (EEE)|Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
62274445|NCT01394081|ACTIVE_COMPARATOR|Administrative Outreach (AO)|Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).
62637628|NCT03249428|ACTIVE_COMPARATOR|Nicotine Replacement Therapy & One-on-One Counseling|Standard NRT such as the nicotine patch, gum, inhaler, and/or lozenge as per participant liking and clinical indication deemed necessary by the expert smoking cessation nurse. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
62637629|NCT03249428|ACTIVE_COMPARATOR|Electronic Nicotine Delivery Systems & One-on-One Counseling|Electronic Nicotine Delivery Systems with nicotine. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
62069690|NCT04049292|EXPERIMENTAL|RTS and rehabilitation tool|Six months after ACLR, athletes will commence a standardized RTS assessment. The athlete will follow a standardized, sport-specific progression protocol designed to increase athletic confidence and trust in the knee during sports. Readiness to return to full, unrestricted practice will be determined based on 7 time-based, load-based, clinical and functional criteria. If the athlete fails any of the criteria, he or she will continue to participate in restricted practice. Depending on which of the specific criteria the athlete fails, a targeted treatment plan will be developed. Standardized protocols for effusion management, knee control and strength training will be triggered if the athlete fails the criteria for knee joint effusion, hopping and muscle strength, respectively. The RTS assessment and development of the targeted treatment plan will be repeated every 2 months until the athlete is cleared to RTS, up to a maximum of 12 months after ACLR.
62069691|NCT04049292|ACTIVE_COMPARATOR|Usual care|Athletes will receive usual care as determined by their treating health care professional
62274446|NCT00119522||Group 1|cohort is of individuals with a spinal cord injury who use a wheelchair as their primary means of mobility
62274447|NCT03786549|NO_INTERVENTION|Control|Patients included in this arm wil have usual follow-up.
62274448|NCT03786549|EXPERIMENTAL|Care transitional program|"Patients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~* Educative, family (patient and parent), at home~* Psychological, with the patient individually~* Medico-social orientation, group of patients"
62637630|NCT04043429|EXPERIMENTAL|Vision Restoration Training (VRT)|home-based rehabilitation program which applies intense light stimulation via a PC-monitor to areas of residual vision with a duration of 1 hour daily/six days a week, subjects are asked to respond via button press upon appearance of light stimuli without eye movements
62637631|NCT04043429|ACTIVE_COMPARATOR|Vision Exploration Training (VET)|home-based rehabilitation program to train eye movements upon visual stimuli presented via a PC-monitor with a duration of 1 hour daily/six days a week, subjects are asked to shift their gaze towards targets and respond via button press upon detection of targets
62637632|NCT02160912||Ectoin Mund- & Rachenspray|treatment with Ectoin Mund- \& Rachenspray 1%
62069692|NCT06459895||diseased group|bronchial asthma diseased group
62069693|NCT06459895||control group|healthy person
62069694|NCT01205321|EXPERIMENTAL|Arm 1|
62274449|NCT03501030|EXPERIMENTAL|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
62274450|NCT03501030|NO_INTERVENTION|No activity restriction|Women in the control group will not receive any reccomandation regarding activity restriction. Bed rest and abstain from sexual intercourse will also not recommended.
62274451|NCT04118816||Control|Healthy subjects, 7-75 y/o
62637633|NCT02160912||Emser Pastillen|treatment with Emser Pastillen
62274452|NCT04118816||Study|7-75 y/o, diagnosed with Prader-Willi syndrome.
62637634|NCT03981016|EXPERIMENTAL|Biological collection|"For the patients include in the study :~* blood samples collected at different times : Before surgery and during the post-operative visit and~* frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
62637635|NCT06100536|EXPERIMENTAL|Treatment group|Music-with-movement intervention supported by the stand-alone music-with-movement system.
62637636|NCT02260960|EXPERIMENTAL|Omega-3|Reesterified Triglyceride form omega 3
62637637|NCT02260960|PLACEBO_COMPARATOR|Placebo|safflower oil
62069695|NCT01205321|EXPERIMENTAL|Arm 2|
62637638|NCT00484770|OTHER|Congestion Score Strategy|
62274453|NCT00754910||Group 1|Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
62637639|NCT00484770|OTHER|BNP Strategy|
62637640|NCT03128450|EXPERIMENTAL|h-NSC arm|"human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel，produced by Shanghai Angecon Biotechology Cooperate.~One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time."
62637641|NCT05259826|EXPERIMENTAL|patients with food hypersensitivity|
62637642|NCT05259826|EXPERIMENTAL|healthy controls|
62637643|NCT01484080|EXPERIMENTAL|Arm I: BIBF1120+Paclitaxel|2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
62637644|NCT01484080|ACTIVE_COMPARATOR|Arm II: Paclitaxel|Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
62637645|NCT03854331|EXPERIMENTAL|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
62637646|NCT03854331|NO_INTERVENTION|Standard care|Danish antenatal standard care is 3 visits at the general practitioner, 5 midwife controls and 2 ultrasound scans
62637647|NCT04652557|EXPERIMENTAL|Fampridine SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 82 days depending on the individual scheduling of each subject."
62274454|NCT02137954|ACTIVE_COMPARATOR|lidocaine|Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day
62274455|NCT02137954|PLACEBO_COMPARATOR|placebo|
62274456|NCT00767897||CKD stage 3 or 4|Girls and Boys age 9-18 with CKD stage 3 or 4
62274457|NCT00767897||On dialysis|Girls and Boys age 9-18 who are on dialysis
62637648|NCT04652557|PLACEBO_COMPARATOR|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
62637649|NCT01328639|ACTIVE_COMPARATOR|Usual Care|Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.
62637650|NCT01328639|EXPERIMENTAL|TeamCare Depression Intervention|Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.
62637651|NCT01838239|EXPERIMENTAL|Fish oil|
62637652|NCT04534517|EXPERIMENTAL|TEST Lens|Eligible subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age will be recruited. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
62637653|NCT04249947|EXPERIMENTAL|P-PSMA-101 CAR-T cells (Single Dose - Part 1a)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
62637654|NCT04249947|EXPERIMENTAL|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)|Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
62637655|NCT04249947|EXPERIMENTAL|P-PSMA-101 CAR-T cells (Single Dose - Part 1c)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
62274458|NCT00767897||Transplanted|Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
62274459|NCT00767897||Healthy|Girls and Boys age 9-18
62287110|NCT03885778|EXPERIMENTAL|A-fasted dosing followed by fed dosing|Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing
62069696|NCT05738460||Reproductive tract GBS colonization group of mothers during pregnancy|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
62069697|NCT05738460||No reproductive tract GBS colonization group in mothers during pregnancy|No reproductive tract GBS colonization group in mothers during pregnancy
62069698|NCT02277470||Golimumab|Patients who are eligible for golimumab therapy.
62069699|NCT03298503|ACTIVE_COMPARATOR|early stage or non-freezers PD|"early stage defined as modified Hoehn and Yahr scale 1, 1.5 and 2, means that symptoms involved unilateral or bilateral without impairment of balance.~non-freezers defined as without freezing of gait, means that patients without transient inability to generate effective stepping."
62274460|NCT03875144|EXPERIMENTAL|association of PIPAC and systemic chemotherapy|4 PIPAC of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks alternating with standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
62274461|NCT03875144|ACTIVE_COMPARATOR|systemic chemotherapy alone|6 cycles of Cisplatin 75mg/m² + Pemetrexed 500mg/m²
62274462|NCT03408795|OTHER|JORS-LDG Group|Participants in JORS-LDG Group score the performance of procedure after LDG.
62274463|NCT04870879|EXPERIMENTAL|Study arm|Liver transplant
62274464|NCT04870879|OTHER|Parallel arm|Chemotherapy
62454305|NCT02728037|ACTIVE_COMPARATOR|Lidocaine-Only Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
62637656|NCT04249947|EXPERIMENTAL|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)|Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
62637657|NCT04852250||FOLFOXIRI plus bevacizumab and centralized tumour board|
62069700|NCT03298503|EXPERIMENTAL|moderate stage or freezers PD|"moderate stage defined as modified Hoehn and Yahr scale 2.5 and 3, means that symptoms involved unilateral or bilateral without impairment of balance.~freezers defined as with freezing of gait, means that patients have transient inability to generate effective stepping."
62274465|NCT04732182|EXPERIMENTAL|Standard of care medication for early Alzheimer's disease and BrightGo device cognitive training|Participants randomized to the experimental group will have standard of care and 8 weeks of experimental computer-based therapy on the device. Then they will cross over in the control arm. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
62274466|NCT04732182|OTHER|Standard of care medication for early Alzheimer's disease|Wait list controls will have standard of care only, before they cross over into the experimental group for BrightGo therapy. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
62274467|NCT00992316||Pf-04531083|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects
62069701|NCT06158308||Laparoscopic Appendicectomy|
62069702|NCT06158308||Open Appendicectomy|
62069703|NCT04346550|ACTIVE_COMPARATOR|Drain Group|Suction drain was placed in sub hepatic region through 5 mm lateral trocar site.
62069704|NCT04346550|NO_INTERVENTION|Without Drain Group|No drain was placed
62274468|NCT05984238|ACTIVE_COMPARATOR|ReCET procedure|"Patients receive ReCET (Re-Cellularization via Electroporation Therapy), which is performed using the ReCET device.~After which a 2 week isocaloric diet is followed, and then semaglutide, a GLP-1 receptor agonist is started."
62069705|NCT02447835|ACTIVE_COMPARATOR|Olanzapine|Olanzapine administration
62274469|NCT05984238|SHAM_COMPARATOR|Sham procedure|"Patients receive sham procedure, this consists of placing an Endogenex catheter, or a catheter with a similar circumference at the endoscopists discretion in the stomach and leaving it in place for 30 minutes.~After which a 2 week isocaloric diet is followed, and then semaglutide, a GLP-1 receptor agonist is started"
62274470|NCT01052584|EXPERIMENTAL|Chloroquine-P. vivax|P. vivax randomized to receive chloroquine 3-day regimen
62274471|NCT01052584|EXPERIMENTAL|Artemether-Lumefantrine: P. vivax|
62274472|NCT01052584|EXPERIMENTAL|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
62274473|NCT05292105||Coronary Artery Disease (CAD)|
62069706|NCT02447835|PLACEBO_COMPARATOR|Placebo|Placebo administration
62637658|NCT04852250||FOLFOXIRI plus bevacizumab but no centralized tumour board|
62637659|NCT00480090|EXPERIMENTAL|Cytarabine|eligible patients will receive cytarabine, starting at 075g/m2 and escalating to a maximum of 1.25g/m2, BID IV for 2 days every three weeks for 6 or more cycles if tolerated.
62637660|NCT02948829|EXPERIMENTAL|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
62637661|NCT04106908||Eqwilate|
62637662|NCT01676493|EXPERIMENTAL|Codeine|Codeine Sulfate Oral Solution and Tablet
62274474|NCT06228222||patients|patients with lupus nephritis who will be admitted to Rheumatology and Nephrology Units, Internal Medicine Department, Assuit university hospitals, Egypt. (classified according to the 1997 American College of Rheumatology or Systemic Lupus Collaborating Clinics criteria) with biopsyproven LN (classified according to The revised ISN/RPS 2018mhistopathological classification system).
62069707|NCT05788276|ACTIVE_COMPARATOR|Active treatment|165 patients
62069708|NCT05788276|PLACEBO_COMPARATOR|Control group|165 patients
62069709|NCT01532817|EXPERIMENTAL|alphacore|noninvasive neurostimulation of the vagus nerve
62069710|NCT01949376||HT Patients|any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
62637663|NCT06455657|EXPERIMENTAL|Prisoner women receiving breast cancer training|Questionnaires and scales will be administered to the participants as a pre-test. Breast cancer education will be provided in groups and their feedback will be received. Reminder training will be repeated 1 month after the training. The survey and scales will be administered to the participants as a posttest 1 month after the second training.
62637664|NCT05811988||Direct Laryngoscopy|
62274475|NCT01664780||Patients after liver transplantation|
62274476|NCT03937583|NO_INTERVENTION|Limited screening|Complete clinical history, along with routine physical, analytical examination (creatinine, sodium, potassium, red series, white series, liver and calcium profile) and chest x-ray.
62274477|NCT03937583|EXPERIMENTAL|Extended screening|Limited screening plus positron emission tomography / computed tomography with 18 FDG (18FDG PET-CT).
62274478|NCT01378312|PLACEBO_COMPARATOR|Placebo Arm|
62274479|NCT01378312|ACTIVE_COMPARATOR|AERAS 402 Arm|
62637665|NCT05811988||Video Laryngoscopy|
62637666|NCT05947253|EXPERIMENTAL|BUTYEKO BREATHING TECHNIQUE|First Group A 20 participants received Buyteko breathing technique while will be given 5 days per week
62637667|NCT05947253|EXPERIMENTAL|active cycle of breathing technique|Group B 20 participants received active cycle of breathing technique and session of 35min will be given 5 days per week
62069711|NCT01949376||CT and HT Patients|any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
62069712|NCT01949376||CT Patients|any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
62069713|NCT01949376||RT or NT Patients|any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
62069714|NCT01949376||Controls|healthy, cognitively normal subjects
62069715|NCT03389607||diabetic|the patients must have diabetic disease
62069716|NCT03389607||control|the patients must not have diabetic
62069717|NCT01496534|ACTIVE_COMPARATOR|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
62069718|NCT01496534|ACTIVE_COMPARATOR|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
62069719|NCT03075904|EXPERIMENTAL|Cohort 1: ALXN1830|Participants received 5 doses of ALXN1830 10 mg/kg administered weekly.
62069720|NCT03075904|EXPERIMENTAL|Cohort 2: ALXN1830|Participants were to receive 3 doses of ALXN1830 30 mg/kg administered weekly (loading) followed by 5 doses of ALXN1830 10 mg/kg administered every other week or 10 weekly doses of ALXN1830 IV (maintenance).
62069721|NCT00694421||1|"adults who participate in study, Social and Psychological Risks for Infectious Disease here at Children's Hospital of Pittsburgh"
62274480|NCT05493943|ACTIVE_COMPARATOR|PEMF low power|PEMF therapy using a device with low pulse intensity.
62274481|NCT05493943|ACTIVE_COMPARATOR|PEMF medium power|PEMF therapy using a medium pulse intensity.
62274482|NCT05493943|SHAM_COMPARATOR|PEMF Sham control|Control arm using a sham PEMF device.
62637668|NCT03293745|ACTIVE_COMPARATOR|Face to Face CBT-I (F2F)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered in-person, one-on-one with a qualified and experienced therapist.
62652964|NCT03555162|OTHER|Tool Use|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when using tools. Here only the fMRI experimental session is necessary. Tasks proposed to the participants within the fMRI scanner will be related to tool use. They will have to solve mechanical problems, to judge the appropriateness of hand postures for using tools, and to judge if tools presented share the same context of use, the same functional goals, the same hand postures for using them.These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use tools.
62274483|NCT02973737|EXPERIMENTAL|arm 1|pyrotinib plus capecitabine pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
62274484|NCT02973737|ACTIVE_COMPARATOR|arm 2|placebo plus capecitabine placebo(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
62069722|NCT00694421||2|"children 2-6 years who participate in Role of Virus and Genetic Susceptibility study here at Children's Hospital of Pittsburgh"
62637669|NCT03293745|EXPERIMENTAL|Telemedicine CBT-I (TM)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via the American Academy of Sleep Medicine (AASM) Sleep Telemedicine system. This telemedicine system provides an online videoconference platform in which a qualified and experienced therapist will deliver CBT-I to participants who will call in to the video therapy sessions with their provider from their homes using a webcam. All aspects of the treatment will remain identical to standard CBT-I delivered face-to-face, as described above, with the exception that the telemedicine technology will be used to deliver the treatment via video conference.
62637670|NCT05529537|ACTIVE_COMPARATOR|control|
62637671|NCT05529537|EXPERIMENTAL|MLD|
62637672|NCT06523959|EXPERIMENTAL|Apixaban|Apixaban 2.5mg (i.e Eliquis® 2,5mg tablet) orally twice daily for 28 days (with standard of care mechanical prophylaxis)
62637673|NCT06523959|NO_INTERVENTION|No anticoagulation|No anticoagulation (with standard of care mechanical prophylaxis)
62069723|NCT02475525|EXPERIMENTAL|Arginine enriched oral nutritional supplement group|Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
62069724|NCT02475525|NO_INTERVENTION|Control|This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.
62069725|NCT01252121|OTHER|Systane, Hialid, Unisol|1 drop Systane in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
62274485|NCT04979507|EXPERIMENTAL|Experimental Group|
62274486|NCT04979507|ACTIVE_COMPARATOR|Control group|
62274487|NCT01112098|EXPERIMENTAL|Educational Pamphlet and letter|Letter invites patient to self-schedule a DXA; educational pamphlet includes information about DXA scans
62274488|NCT03441178|EXPERIMENTAL|Colectomy/Gynecological/Thoracic|Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
62274489|NCT02383914||Subscapularis rupture|
62637674|NCT05239663|EXPERIMENTAL|experimental group|standard (neo)adjuvant chemotherapy plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
62069726|NCT01252121|OTHER|Systane, Unisol, Hialid|1 drop Systane in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
62274490|NCT01926782|PLACEBO_COMPARATOR|Placebo Q2W|Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
62637675|NCT05239663|OTHER|Control group|standard (neo)adjuvant chemotherapy plus 250ml normal saline (NS)
62637676|NCT04352309||Participants Treated With Glecaprevir/Pibrentasvir (GLE/PIB)|Participants will receive GLE/PIB over 8 weeks of therapy as prescribed by their physicians.
62637677|NCT06311058|EXPERIMENTAL|Protein Supplement Group|Participants in this group will receive 25g of whey protein isolate twice a day for 12 weeks.
62637678|NCT06311058|EXPERIMENTAL|Protein + Amino Acid Supplement Group|"* Protein drink - 25g of whey protein isolate~* Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)~Twice a day for 12 weeks"
62069727|NCT01252121|OTHER|Hialid, Systane, Unisol|1 drop Hialid in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
62274491|NCT01926782|EXPERIMENTAL|Alirocumab 75 mg/ Up 150 mg Q2W|One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
62274492|NCT01926782|EXPERIMENTAL|Alirocumab 300 mg/ Up 150 mg Q4W|Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
62461594|NCT02086188|EXPERIMENTAL|Mirabegron|Mirabegron - 25mg (one tablet) taken by mouth daily with option to up-titrate to 50mg daily (two tablets) taken by mouth daily
62069728|NCT01252121|OTHER|Hialid, Unisol, Systane|1 drop Hialid in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
62069729|NCT01252121|OTHER|Unisol, Systane, Hialid|1 drop Unisol in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
62069730|NCT01252121|OTHER|Unisol, Hialid, Systane|1 drop Unisol in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
62274493|NCT04421625|EXPERIMENTAL|Diagnostic test for SARS-Cov2 for patients and health staff|"* Blood test (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens)~* Nasal swab test (only if the patient has symptoms)~* Questionnaires"
62274494|NCT04314440|EXPERIMENTAL|Music therapy|After the initial warm up session music therapy will be delivered three times a week for 15-20 minutes. All babies in the experimental group will be exposed to three weeks of music therapy sessions that is a total of 9 music therapy session prior to discharge from the hospital. The baby will be placed at the bassinet 15 minutes before music therapy begins. The baby will be in the bassinet during music therapy and 15 minutes post music therapy to allow measurement of physiological indicators. If parents are present during music therapy they will not engage in kangaroo care during the music therapy session or when physiological measurements are being taken pre and post music therapy, but can do so at other times.
62274495|NCT04314440|NO_INTERVENTION|Control|Infants in this group will not receive any music therapy but will receive all other standard care provided to infants at the Regina General Hospital (RGH). All measurements will be carried out for all the infants in this group at the time when observations are carried out for infants in the music therapy group.
62637679|NCT06311058|PLACEBO_COMPARATOR|Placebo Group|"• isocaloric-matched (25g) maltodextrin supplement~Twice a day for 12 weeks"
62637680|NCT02260817|EXPERIMENTAL|Expanded Access for 11C-Choline|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
62637681|NCT02260817|EXPERIMENTAL|11C-Choline Comparison of Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
62637682|NCT06474156||short-stay residents juvenile justice center|"For the first group (first series case studies), ten short-stay residents will be included who enter residential MDFT and, after 1-3 months in the facility, continue MDFT on an outpatient basis.~MDFT is a systemic intervention for juveniles and young adults exhibiting delinquent behavior and/or experiencing disorders related to alcohol and/or drug use. MDFT for short-term residents is indicated by a behavioral scientist following multidisciplinary consultation if there are serious concerns about the parent-child relationship and/or the family situation"
62637683|NCT06474156||long-stay residents juvenile justice center|For the second group (second series of case studies), six long-term residents will be included. For long-term residents, MDFT is routinely recommended, provided that the inclusion criteria are met.
62637684|NCT01090180|EXPERIMENTAL|Arm 1: Dexamethasone|Dexamethasone (oral)
62637685|NCT01090180|PLACEBO_COMPARATOR|Arm 2: Placebo|Placebo (inactive)
62637686|NCT03024983|ACTIVE_COMPARATOR|Control|Glucose monohydrate (isoglucidic portion -50 g of available carbohydrates-)
62637687|NCT03024983|EXPERIMENTAL|Semolina|Semolina soup (isoglucidic portion -50 g of available carbohydrates-)
62637688|NCT03024983|EXPERIMENTAL|Bread|Bread (isoglucidic portion -50 g of available carbohydrates-)
62637689|NCT03024983|EXPERIMENTAL|Short pasta (fresh)|Fresh penne (isoglucidic portion -50 g of available carbohydrates-)
62637690|NCT03024983|EXPERIMENTAL|Short pasta (dry)|Short pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
62069731|NCT05386251|EXPERIMENTAL|Behavioral Parent Training/Organization Skills Training|Parents will receive 8 weeks of a 90 minute behavioral parent training protocol that focuses on supporting academic and behavioral success in adolescents with ADHD. Teens will receive a simultaneous 8 weeks of a 90 minute organization skills training group. Both groups will be delivered via telehealth.
62069732|NCT05386251|SHAM_COMPARATOR|Peer support|Parents and teens will each participate in 8 weeks of a 90 minute peer support group focused on exchange of shared experience and group problem-solving difficulties. Both groups will be delivered via telehealth.
62069733|NCT02652182||1|patients with acute ST (S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Huai'an first people's hospital
62274496|NCT00907101|EXPERIMENTAL|Study Treatment|"Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)~Other Names:~Epiduo® Gel Apply once daily"
62069734|NCT02652182||2|patients with acute ST(S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Nanjing Drum Tower hospital
62274497|NCT06005961|ACTIVE_COMPARATOR|MBP intervention arm|The MBP intervention has two modules: the core and the tailor-made modules. The core module focuses on emotional management, while the five tailor-made modules include anxiety management, mood and depression management, anger management, sleeping well, and managing self-expectation and compassion.
62069735|NCT03324711|OTHER|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
62274498|NCT06005961|OTHER|Waitlist control arm|Participants allocated to the waitlist control group will wait for 6 plus 4 weeks before receiving the MBP intervention.
62069736|NCT04745299|EXPERIMENTAL|Single cycle administration group|Study drug injections twice in a 26-day interval followed by three times comparator injections every three months.
62069737|NCT04745299|EXPERIMENTAL|Multiple administation group|Study drug injections twice in a 26-day interval followed by repeated three times study drug injections every three months.
62069738|NCT04745299|PLACEBO_COMPARATOR|Control group|Comparator injections twice in a 26-day interval followed by three times comparator injections every three months.
62069739|NCT01868035|EXPERIMENTAL|Single Arm|tositumomab and iodine I-131 tositumomab
62069740|NCT00641173|EXPERIMENTAL|1|paroxetine v placebo
62274499|NCT04788043|EXPERIMENTAL|Magrolimab (Hu5F9 G4) and pembrolizumab|All subjects will have a baseline PET CT and excisional or core needle biopsy within 1 month of study enrollment and baseline electrocardiogram and laboratory studies within 1 week of study enrollment. All subjects will receive treatment with magrolimab and pembrolizumab according to the dosing schedule. Magrolimab IV given on cycle 1, 2 and 3. Pembrolizumab 200 mg IV given on Cycle 1, 2 and 3. Patients may continue to receive treatment on the study for a maximum of 24 months or until progression of disease, unacceptable toxicity, or bridge to stem cell transplantation (SCT).
62274500|NCT05743465||Ponatinib Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others \[imatinib, dasatinib, or nilotinib\]) drug used on index date, stratified by prior TKI use. Participants with a ponatinib prescription identified as the index drug prior TKI use will be stratified in this cohort.
62287111|NCT03885778|EXPERIMENTAL|B-fed dosing followed by fasted dosing|Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing
62069741|NCT00641173|PLACEBO_COMPARATOR|2|placebo
62274501|NCT05743465||Bosutinib Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others \[imatinib, dasatinib, or nilotinib\]) drug used on index date, stratified by prior TKI use. Participants without ponatinib use and with bosutinib identified as the index drug prior TKI use will be stratified in this cohort.
62069742|NCT06457100|EXPERIMENTAL|Esmolol|In the esmolol group, esmolol(2ml:0.2g) 0.5 mg/kg was given intravenously, pumped 1 min before induction of anesthesia, and then infused intravenously at 3.0 mg-kg-1 h-1 until the end of surgery.
62274502|NCT05743465||Other TKI Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others \[imatinib, dasatinib, or nilotinib\]) drug used on index date, stratified by prior TKI use. Participants without ponatinib or bosutinib use and with imatinib, dasatinib, or nilotinib identified as the index drug after prior TKI use will be stratified in this cohort.
62274503|NCT02190773||Chronic periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment
62274504|NCT02190773||Agressive periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment.
62637691|NCT03024983|EXPERIMENTAL|Long pasta (dry)|Long pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
62274505|NCT02190773||Control group|Periodontally healthy individuals
62637692|NCT04416997||Rheumatoid arthritis patients|Blood and serum samples
62637693|NCT00097214|EXPERIMENTAL|1|"Cetuximab 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8. Carboplatin AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.~Therapy will continue for four cycles (12 weeks)for combination therapy"
62637694|NCT01445249|ACTIVE_COMPARATOR|Landmark guided ankle block|This group will receive a landmark guided ankle block.
62637695|NCT01445249|ACTIVE_COMPARATOR|This group will be given a PNS guided ankle block|Peripheral nerve stimulation will be used in this group to guide local anaesthetic infiltration. The technique is termed medial forefoot block.
62637696|NCT05881655|EXPERIMENTAL|Study Group 1|With 1.2mW lighting power of red light at wavelenth of 650nm and wearing H.A.L.T lens to control myopia.
62637697|NCT05881655|EXPERIMENTAL|Study Group 2|With 0.6mW lighting power of red light at wavelenth of 650nm and wearing H.A.L.T lens to control myopia.
62637698|NCT05881655|PLACEBO_COMPARATOR|Control Group|Wearing H.A.L.T lens to control myopia only.
62637699|NCT00798811|OTHER|KSPNO-S-081|Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor
62637700|NCT00798811|OTHER|KSPNO-S-082|High-dose Chemotherapy and Autologous Stem Cell Rescue in Infants and Young Children with Newly Diagnosed High-risk Brain Tumor To Avoid or Reduce Craniospinal Radiation
62637701|NCT00798811|OTHER|KSPNO-S-083|High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Recurrent Brain Tumor or Non-germinomatous Germ Cell Tumor with Inadequate Response to Conventional Treatment
62637702|NCT00818584|EXPERIMENTAL|1. micafungin lower dose|
62637703|NCT00818584|EXPERIMENTAL|2. micafungin higher dose|
62637704|NCT04659707|EXPERIMENTAL|COVID-19 Survivors|Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.
62637705|NCT05348720||COVID-19 ICU survivor|COVID-19 patients admitted to ICU between the 1st of March 2020 and the 30rd of May 2021, who survived ICU stay and still alive 18 months after ICU discharge.
62637706|NCT05348720||Relatives|Relative of those COVID-19 patients enrolled in the 'COVID-19 ICU survivor' cohort
62637707|NCT01845779|EXPERIMENTAL|patients in complete response|
62637708|NCT01553565|ACTIVE_COMPARATOR|Conventional polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed with electrocautery. Submucosal injection of some solution before the removal are not performed.
62637709|NCT01553565|EXPERIMENTAL|Cold polypectomy|
62637710|NCT01655316|EXPERIMENTAL|Verapamil|40 mg Verapamil Per Oral
62637711|NCT04131920||Phase 1 and 2|10 male patients with severe Hemophilia A from the Washington Center for Bleeding Disorders
62454306|NCT02728037|NO_INTERVENTION|Wait-Listed Patients|This arm is a non-randomized, no-treatment arm consisting of women who are on the waiting list for the chronic pain clinic.
62637712|NCT04131920||Phase 3|20 subjects who are also participating in the EmiMSKUS study
62637713|NCT02053493|ACTIVE_COMPARATOR|Isosorbide Mononitrate|Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
62637714|NCT02053493|PLACEBO_COMPARATOR|Isosorbide Mononitate Placebo|Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
62637715|NCT03999502|EXPERIMENTAL|Intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
62637716|NCT01474850|ACTIVE_COMPARATOR|open lung|The lung recruitment maneuver (RM) immediately after intubation using pressure controlled ventilation, increase in peak inspiratory pressure up to 30 cm H2O during tidal ventilation, respiratory rate 4/min and positive end expiratory pressure (PEEP) 15 cm H20. PEEP 7 cm H2O until extubation. Inspiratory oxygen concentration (FiO2) 40% during recovery from anesthesia.
62637717|NCT01474850|NO_INTERVENTION|control|No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
62637718|NCT04020653|PLACEBO_COMPARATOR|Placebo + ACT|Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
62637719|NCT04020653|EXPERIMENTAL|5 ALA/SFC+placebo+ACT BID|"5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.~Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14)."
62637720|NCT04020653|EXPERIMENTAL|5-ALA/SFC+placebo+ACT QD|5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).
62454307|NCT02546973||Patients with anal cancer|All patients with anal cancer during 2011-2013 will be asked to participate
62454308|NCT00159965|ACTIVE_COMPARATOR|sertraline|flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
62454309|NCT00159965|PLACEBO_COMPARATOR|placebo|flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
62461595|NCT02086188|PLACEBO_COMPARATOR|Placebo|Placebo - one tablet taken by mouth daily and two tablets taken by mouth daily if subject chooses up-titration
62274506|NCT03216356|EXPERIMENTAL|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
62637721|NCT03234036|EXPERIMENTAL|Treatment sequence ABC: Part 1|"A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.~Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
62637722|NCT03234036|EXPERIMENTAL|Treatment sequence BAC: Part 1|"A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
62637723|NCT03234036|EXPERIMENTAL|GSK2838232 tablet without RTV: Part 2|In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
62637724|NCT03234036|PLACEBO_COMPARATOR|Placebo without RTV: Part 2|In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
62637725|NCT06611982|EXPERIMENTAL|Intervention arm|Participants assigned to the intervention arm receive $1000/month for 12 months
62637726|NCT06611982|OTHER|Control arm|Participants assigned to the control arm receive information on financial toxicity and the contact information for their social workers and financial counselors
62274507|NCT03216356|ACTIVE_COMPARATOR|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
62069743|NCT06457100|ACTIVE_COMPARATOR|Lidocaine|In the lidocaine group, lidocaine(5ml:0.1g) 2.0 mg/kg was given intravenously, pumped 10 min before induction of anesthesia and then infused intravenously at 2.0 mg-kg-1 h-1 until the end of surgery.
62069744|NCT04797325|ACTIVE_COMPARATOR|vedolizumab|
62069745|NCT04797325|ACTIVE_COMPARATOR|Standard treatment|
62274508|NCT03216356|ACTIVE_COMPARATOR|CBT + I.E. + study pill|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
62274509|NCT06010966|SHAM_COMPARATOR|sham group|receive sham itbs
62637727|NCT06446414|EXPERIMENTAL|Choose to Move|"CTM (adapted Phase 4) is a 3-month, flexible, choice-based health-promoting program for low active older adults. CTM includes:~1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by an activity coach. Meetings cover a health-related discussion topic and provide time for social connection among participants. Meetings can be held online or in-person.~Community-based seniors' services organizations that deliver CTM may adapt the program (e.g., deliver in a different language, adapt for cultural or geographical factors) to fit the needs of the older adults they serve but the two components listed above will be retained."
62069746|NCT05878782|EXPERIMENTAL|Occupational therapy intervention associated with MCRO assesment.|the experimental care of this group will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
62069747|NCT05878782|EXPERIMENTAL|MCRO assessment without intervention|This experimental group will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
62069748|NCT05878782|NO_INTERVENTION|Usual care|this group will have the usual cancer management care combining specific treatments and supportive care.
62274510|NCT06010966|ACTIVE_COMPARATOR|low-dose group|receive low dose of itbs
62274511|NCT06010966|ACTIVE_COMPARATOR|high-dose group|receive high dose of itbs
62274512|NCT05697458||Kidney transplant recipients|"In kidney transplant recipients the investigators will perform pretransplant computerized tomography for assessment of iliac arteries calcifications.~From their blood, the bone remodeling biomarkers will be determined in the perioperative period.~The one year patient and graft survival will be determined for included patients."
62274513|NCT05268926|PLACEBO_COMPARATOR|Placebo|
62274514|NCT05268926|ACTIVE_COMPARATOR|Dapagliflozin 10mg/day|
62274515|NCT03622827|EXPERIMENTAL|Chemoradiotherapy + Endostar|"Chemoradiotherapy with Endostar：~* Chemoradiotherapy: pelvic radiotherapy with concurrent chemotherapy that consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day,civ, day 1-4) for 2 cycles every 3 weeks.~* Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the chemotherapy every 3 weeks, total of two cycles during chemoradiotherapy course."
62274516|NCT04470700||subjects with greater than 3years delay|Subjects with delay in treatment of Urinary incontinence greater than three years
62274517|NCT04470700||subjects with less than three years delay|Subjects with delay in treatment of Urinary incontinence lesser than three years
62274518|NCT04476238|EXPERIMENTAL|Inosine|2 grams of inosine dissolved in 250 ml of tap water
62637728|NCT02584283|EXPERIMENTAL|Dual hypothermic oxygenated perfusion|The liver is procured with a segment of supratruncal aorta. The intervention is restricted to the liver graft after arrival in the transplant center and before implantation. The donor liver is subjected to 2 hours of hypothermic oxygenated perfusion via the portal vein and the supratruncal aorta applied by the Liver Assist®. Before perfusion, the liver is flushed via the portal vein with 1 L Belzer machine perfusion solution. The perfusion is pressure controlled and set to a mean of 25 mmHg (arterial) and 5 mm Hg (portal). The perfusion fluid is 4 L Belzer machine perfusion solution with additional 3 mmol/L glutathione. The perfusion fluid is 12°C, when the temperature is set at 10°C. The oxygen flow is set at 0.5 mL/min of 100% oxygen on each of the two membrane oxygenators.
62637729|NCT02584283|NO_INTERVENTION|Care as usual|The donor liver is procured with a segment of 5 cm circular supratruncal aorta left attached to the coeliac trunc. The patients randomized to the control group will receive a liver graft preserved by conventional SCS without any further intervention.
62637730|NCT03041636|EXPERIMENTAL|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
62637731|NCT04662112|EXPERIMENTAL|NASOX|Liposomal irinotecan+S-1+oxaliplatin
62637732|NCT02782741|EXPERIMENTAL|avalglucosidase alfa (GZ402666)|Administered intravenously every 2 weeks
62069749|NCT00720174|EXPERIMENTAL|Treatment (cixutumumab and doxorubicin hydrochloride)|Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
62069750|NCT02918240|EXPERIMENTAL|4 week interval|Patients will be seen every 4 weeks to adjust their orthodontic braces
62274519|NCT04476238|PLACEBO_COMPARATOR|Water|250 ml of tap water only
62274520|NCT02432768|ACTIVE_COMPARATOR|Triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
62637733|NCT02782741|ACTIVE_COMPARATOR|alglucosidase alfa (GZ419829)|Administered intravenously every 2 weeks
62637734|NCT01274351|EXPERIMENTAL|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
62637735|NCT04622917|ACTIVE_COMPARATOR|Methylprednisolone|Depo-Medrol (Methylprednisolone) 40 milligrams/milliliter, 2 milliliters as a single dosage
62637736|NCT04622917|PLACEBO_COMPARATOR|Sodium Chloride (NaCl)|NaCl 0,9 milligrams/milliliter, 2 milliliters as a single dosage
62637737|NCT01372046|EXPERIMENTAL|Enhanced|A external consultant works with the team to develop skills and trains an in-house coach
62069751|NCT02918240|EXPERIMENTAL|6 week interval|Patients will be seen every 6 weeks to adjust their orthodontic braces
62069752|NCT02918240|EXPERIMENTAL|8 week interval|Patients will be seen every 8 weeks to adjust their orthodontic braces
62069753|NCT02918240|EXPERIMENTAL|10 week interval|Patients will be seen every 10 weeks to adjust their orthodontic braces
62069754|NCT01241253|NO_INTERVENTION|Cross-over study|beans and rice in a 50 gram carbohydrate dose
62069755|NCT05684562||Fontan group|Cardiopulmonary exercise test Pulmonary function test respiratory muscle strength test
62274521|NCT02432768|PLACEBO_COMPARATOR|Placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day.
62274522|NCT03726645|ACTIVE_COMPARATOR|Study group|Allogeneic fecal microbiota transplantation (from donor)
62274523|NCT03726645|PLACEBO_COMPARATOR|Control group|Autologous fecal microbiota transplantation (own stool)
62287112|NCT02574104||Institution 1|"McGill University Health Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
62069756|NCT05684562||Control Group|Cardiopulmonary exercise test Pulmonary function test respiratory muscle strength test
62069757|NCT06354335||Employees|Persons employed at the hospital during 2011-2020
62637738|NCT01372046|EXPERIMENTAL|Trainer|External consultant provides booster session
62637739|NCT01372046|EXPERIMENTAL|Standard|Receive agency training
62637740|NCT01756989|EXPERIMENTAL|Thalidomide, etoposide, celecoxib|Single arm study,phase II
62637741|NCT06310811|EXPERIMENTAL|Cell injection|
62637742|NCT01437618||BRAF mutant mCRC|
62637743|NCT00971867|EXPERIMENTAL|Paclitaxel|
62637744|NCT04936503|EXPERIMENTAL|High-level athletes|"High level athletes are rugby players, intervention unit agents of the National Police, sports students.~Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality.~The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects."
62069758|NCT04771338|EXPERIMENTAL|Treatment group|Job interview training protocol for 12 sessions
62069759|NCT04771338|NO_INTERVENTION|Control group|No participation in any intervention protocol
62069760|NCT00766896|ACTIVE_COMPARATOR|Aspirin Sensitive|"* For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time \>= 150 seconds~* Chrono-Log Model 700 Whole-Blood: \< 1Ω with 0.75 mM of arachidonic acid~* Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) \> 0.50~* Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L \< 10Ω~* Plateletworks: aggregation \<60% with arachidonic acid will be considered sensitive~* VerifyNow Aspirin Assay (Accumetrics): \< 550 aspirin reaction units (ARUs)~* Impact-R (Diamed) \< 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
62069761|NCT00766896|ACTIVE_COMPARATOR|Platelet with hyperreactivity to aspirin|"* For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time \< 150 s~* Chrono-Log Whole-Blood: above or = 1Ω with 0.75 mM of AA~* Chrono-Log Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) below 0.50~* Chrono-Log Whole-Blood: with collagen 1 mg/L above or = 10Ω~* Plateletworks: aggregation of more than 60% with arachidonic acid will be considered resistant~* VerifyNow Aspirin Assay (Accumetrics): ≥ 550 aspirin reaction units (ARUs)~* Impact-R (Diamed) \> 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
62287113|NCT02574104||Institution 2|"Rochester University Medical Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
62637745|NCT02049736|EXPERIMENTAL|Telbivudine|
62637746|NCT04253340|EXPERIMENTAL|Bone mineral analyser|"Diagnostic Test: Bone mineral analyser~high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12"
62637747|NCT00346749|EXPERIMENTAL|Arm 1|
62637748|NCT03239678|ACTIVE_COMPARATOR|group A|100% Oxygen
62637749|NCT03239678|EXPERIMENTAL|group B|30% Oxygen.
62637750|NCT03239678|EXPERIMENTAL|group C|21% Oxygen
62637751|NCT03239678|EXPERIMENTAL|group D|40% Oxygen
62637752|NCT03239678|EXPERIMENTAL|group E|60% Oxygen
62637753|NCT03239678|EXPERIMENTAL|group F|80% Oxygen
62637754|NCT05919550||Patients presenting a possible drug-induced adverse effects|
62637755|NCT01081613||AUY922|Patients with estrogen receptor (ER) positive, hormone therapy refractory breast cancer.
62637756|NCT02554760|EXPERIMENTAL|All Study Participants|This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
62637757|NCT06173479|EXPERIMENTAL|HeBSaPU|HeBSaPU is an acronym for educational interventions for safe pesticide use based on the health belief model. The HeBSaPU arm will get interventions for 12 weeks. HeBSaPU include educational posters, free personal protective equipment (PPE) incentives, reminder short messages, and demonstration components about correct PPE usage.
62637758|NCT06173479|ACTIVE_COMPARATOR|Control|The control arm will not take any interventions.
62637759|NCT04153279|EXPERIMENTAL|CMV-TCR-T cells|The patients will receive one dose of CMV-TCR-T.The dosage ranges from 0.1×10\^6 to 1×10\^6 TCR+T/Kg.
62637760|NCT05720559|EXPERIMENTAL|Conventional treatment group|Conventional treatment was performed according to the NCCN Guidelines for Colorectal Cancer 2023 Edition
62069762|NCT00569803|ACTIVE_COMPARATOR|Belatacept 50 mg Subcutaneous Injection|Belatacept 50 mg subcutaneous (SC) injection
62274524|NCT00288080|ACTIVE_COMPARATOR|Androgen suppression + Radiation Therapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
62274525|NCT00288080|EXPERIMENTAL|Androgen suppression + Radiation Therapy + Chemotherapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of RT. Following completion of RT, 6 cycles of docetaxel (premedicated with dexamethasone) and prednisone are delivered concurrently with androgen suppression.
62454310|NCT01061164||HIV-infected infants, children, and adolescents|Infants, children, and adolescents with HIV infection who have participated in PACTG 219C and/or select IMPAACT studies.
62454311|NCT01611090|EXPERIMENTAL|Ibrutinib + BR|Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
62454312|NCT01611090|PLACEBO_COMPARATOR|Placebo + BR|Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
62454313|NCT03978403|EXPERIMENTAL|ABDC|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
62454314|NCT03978403|EXPERIMENTAL|BCAD|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
62454315|NCT03978403|EXPERIMENTAL|CDBA|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
62637761|NCT05720559|EXPERIMENTAL|Quintuple method treatment group|SOX regimen chemotherapy, low dose cetuximab targeted therapy, and folic acid, vitamin A, metronidazole three-drug regimen were combined. Specific drug dosages were as follows: SOX regimen was administered every three weeks, d1 was given oxaliplatin intravenously, the dosage was 130mg/ m2 \* patient's body surface area, d2-d15 was taken orally by S1, 20mg three times a day each time. Cetuximab combined with chemotherapy was administered intravenously, once every three weeks, before oxaliplatin, and the dosage was 250mg/ m2 \* patient's body surface area. Metronidazole 0.4g/ time, once a day; Vitamin A 25,000 units/time, once a day; Folic acid 0.4mg/ time, once a day. The last three drugs were continued until the end of all chemotherapy cycles. These regimens last for 6 to 8 sessions.
62454316|NCT03978403|EXPERIMENTAL|DACB|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
62454317|NCT06062771|EXPERIMENTAL|FIDIAL PLUS|Solution of NaHA 20 mg/1.1 ml pre-filled syringe for intraocular use. 1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
62454318|NCT06062771|ACTIVE_COMPARATOR|IAL®-F|Solution of NaHA 20 mg/1.1 ml pre-filled syringe for intraocular use. Animal derived 1.8% sodium hyaluronate OVD.
62454319|NCT00663871|ACTIVE_COMPARATOR|Fish Oil|Participants will take fish oil supplements daily for 4 months.
62454320|NCT00663871|PLACEBO_COMPARATOR|Placebo|Participants will take soybean oil (placebo) supplements daily for 4 months.
62461596|NCT02495857|EXPERIMENTAL|Hyaluronate Injectable Viscosupplement|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
62461597|NCT02495857|ACTIVE_COMPARATOR|Euflexxa IA injection|Euflexxa IA injection to the knee once weekly for 3 weeks
62069763|NCT00569803|ACTIVE_COMPARATOR|Belatacept 100 mg Subcutaneous Injection|Belatacept 100 mg SC injection
62069764|NCT00569803|ACTIVE_COMPARATOR|Belatacept 125 mg Subcutaneous Injection|Belatacept 125 mg SC injection
62069765|NCT00569803|ACTIVE_COMPARATOR|Belatacept 150 mg Subcutaneous Injections|2 SC injections of 75 mg Belatacept
62069766|NCT00569803|ACTIVE_COMPARATOR|Belatacept 200 mg Subcutaneous Injections|2 SC injections of 100 mg Belatacept
62069767|NCT00569803|ACTIVE_COMPARATOR|Belatacept 250 mg Subcutaneous Injections|2 SC injections of 125 mg Belatacept
62069768|NCT00569803|ACTIVE_COMPARATOR|Belatacept 125 mg Intravenous Infusion|125 mg Belatacept intravenous (IV) injection
62069769|NCT00569803|PLACEBO_COMPARATOR|Placebo|SC injection of placebo solution
62274526|NCT01487512|EXPERIMENTAL|Sequence 1: Treatment A-D-B-C|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
62069770|NCT03054688|EXPERIMENTAL|Somnotouch NIBP|Blood pressure measurement with Somnotouch-NIBP device in addition to standard cuff based device
62069771|NCT04444687||SARS-CoV-2-positive 01|SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
62069772|NCT04444687||SARS-CoV-2-positive 02|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
62069773|NCT04444687||SARS-CoV-2-positive 03|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
62069774|NCT04444687||Control|Control patients, SARS-CoV-2-negative
62069775|NCT00692406|EXPERIMENTAL|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
62069776|NCT01077726|EXPERIMENTAL|1|
62069777|NCT02101918|EXPERIMENTAL|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
62069778|NCT01629056|ACTIVE_COMPARATOR|Contact ECI active|Contact ECI active
62637762|NCT03103191||Case|"* 50 subjects with fibrosing interstitial lung disease.~* 50 subjects with pulmonary fibrosis secondary to collagen diseases."
62069779|NCT01629056|PLACEBO_COMPARATOR|Contact information deactivated|RF ablation without contact data
62069780|NCT03298620|EXPERIMENTAL|Intervention|Electric toothbrush
62069781|NCT03298620|ACTIVE_COMPARATOR|Control|New standard manual toothbrush
62069782|NCT04905108|ACTIVE_COMPARATOR|Riboflavin drop every 2 minutes|Administration of one drop of Riboflavin every 2 minutes during UV exposure
62069783|NCT04905108|ACTIVE_COMPARATOR|Riboflavin drop every 10 minutes|Administration of one drop of Riboflavin every 10 minutes during UV exposure
62069784|NCT02314988|ACTIVE_COMPARATOR|Intervention|Subjects will receive tranexamic acid on the surgical wound.
62069785|NCT02314988|PLACEBO_COMPARATOR|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
62069786|NCT03987230|ACTIVE_COMPARATOR|Oust™ Demodex® Wipes™|Participant cleans eyelids with Oust™ Demodex® Wipes™
62069787|NCT03987230|ACTIVE_COMPARATOR|I-LID N LASH PLUS® Eyelid Cleanser|Participant cleans eyelids with I-LID N LASH PLUS® Eyelid Cleanser
62069788|NCT03987230|ACTIVE_COMPARATOR|Blephadex Lid Wipes|Participant cleans eyelids with Blephadex Lid Wipes
62069789|NCT03987230|ACTIVE_COMPARATOR|Eye Cleanse Lid Wipes|Participant cleans eyelids with Eye Cleanse Lid Wipes
62461598|NCT02495857|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
62069790|NCT03987230|ACTIVE_COMPARATOR|Blephademodex|Participant cleans eyelids with Blephademodex
62069791|NCT03987230|PLACEBO_COMPARATOR|Sensitive Eyes® Plus Saline Solution|Participant cleans eyelids with Sensitive Eyes® Plus Saline Solution
62069792|NCT03777865|EXPERIMENTAL|13vPnC provided as a 0.5-mL dose in a prefilled syringe|All subjects receive a single dose (0.5mL) of 13vPnC
62461599|NCT04714307||Symptomatic|Molecularly diagnosed SCA3/MJD Symptomatic subjects.
62461600|NCT04714307||Non-related Controls|Controls matched with symptomatic by age and educational level.
62637763|NCT03103191||Control|"* 75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.~* 75 subjects with collagen disease without pulmonary fibrosis."
62274527|NCT01487512|EXPERIMENTAL|Sequence 2: Treatment B-A-C-D|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
62637764|NCT04838847|EXPERIMENTAL|Participants / Healthy Participants Aged ≥65 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62637765|NCT04838847|EXPERIMENTAL|Participants / Healthy Participants Aged 18-45 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
62637766|NCT04691128|EXPERIMENTAL|Desflurane inhalational anesthesia|
62637767|NCT04691128|ACTIVE_COMPARATOR|Propofol total intravenous anesthesia|
62637768|NCT01124812|EXPERIMENTAL|131I-L19SIP|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy: Treatment dose of 131I-L19SIP RIT is titrated in cohorts of 3 patients.
62637769|NCT00498680|ACTIVE_COMPARATOR|Viagra 100mg|
62637770|NCT00498680|ACTIVE_COMPARATOR|Levitra 20mg|
62637771|NCT00498680|ACTIVE_COMPARATOR|Viagra 50mg+ Levitra 10mg|
62637772|NCT00616551|EXPERIMENTAL|A|
62069793|NCT01186614|EXPERIMENTAL|Novel treatment paradigm|treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
62274528|NCT01487512|EXPERIMENTAL|Sequence 3: Treatment C-B-D-A|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
62637773|NCT00616551|ACTIVE_COMPARATOR|B|
62637774|NCT02700048|PLACEBO_COMPARATOR|Placebo|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
62287114|NCT02574104||Institution 3|"Parkland Memorial Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
62637775|NCT02700048|EXPERIMENTAL|Treatment with intra-nasal Naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
62637776|NCT03335800|EXPERIMENTAL|Apple Heart Study App|
62637777|NCT04567940|EXPERIMENTAL|Intervention group|Behavioural multicomponent intervention
62637778|NCT04567940|NO_INTERVENTION|Control group|Usual care
62637779|NCT01368263|EXPERIMENTAL|Group 1 (Ki67 <10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.
62637780|NCT01368263|EXPERIMENTAL|Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
62637781|NCT01368263|EXPERIMENTAL|Group 3 (E2 > 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
62637782|NCT05353088|EXPERIMENTAL|Scapular stabilization exercises|Group A performed scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II).
62637783|NCT05353088|ACTIVE_COMPARATOR|Thoracic extension exercises|Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
62069794|NCT03893825|EXPERIMENTAL|TV-46000 q1m|Participants will receive a subcutaneous (SC) injection of TV-46000 at baseline and every 4 weeks (q4w) thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
62637784|NCT06354322||patients to be studied|
62637785|NCT06354322||Control patients|
62637786|NCT03721224||Children with psychogenic cough|children who were examined by Pediatric Respiratory Disease specialist and diagnosed as having a psychogenic cough.
62637787|NCT03721224||control subjects|children who were referred to pediatrics clinics and do not have a chronical disease.
62637788|NCT03686072|OTHER|Cataract surgery with goniosynechialysis|
62637789|NCT01439646||Non neutropenic, ICU, empiric ,antifungals|
62637790|NCT05093556|EXPERIMENTAL|iCHART - Interactive CBT for Headache And Relaxation Training|10 week interactive-voice response technology (IVR) based cognitive behavioral therapy for headache
62637791|NCT02322749|EXPERIMENTAL|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
62637792|NCT02322749|EXPERIMENTAL|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
62069795|NCT03893825|EXPERIMENTAL|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
62274529|NCT01487512|EXPERIMENTAL|Sequence 4: Treatment D-C-A-B|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
62637793|NCT02322749|EXPERIMENTAL|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate \[TPGS\] variant) administered orally
62637794|NCT05133323|EXPERIMENTAL|Lu AG09222 High Dose|Participants will receive a single high dose of Lu AG09222 by intravenous (IV) infusion.
62637795|NCT05133323|EXPERIMENTAL|Lu AG09222 Low Dose|Participants will receive a single low dose of Lu AG09222 by IV infusion.
62637796|NCT05133323|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo matching to Lu AG09222 by IV infusion.
62637797|NCT02653157||Burn patients with VAT or VAP with MDR-GNB|Adult patients with burn and/or inhalation injury requiring intubation
62637798|NCT00186342|EXPERIMENTAL|CIK cell|The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
62637799|NCT01409239|ACTIVE_COMPARATOR|Subcutaneous Insulin|
62637800|NCT01409239|EXPERIMENTAL|Intravenous insulin|
62637801|NCT06193174|EXPERIMENTAL|Recurrent Malignant Glioma|"Participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1)"
62637802|NCT00002610|EXPERIMENTAL|STRATUM A|Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
62637803|NCT00002610|EXPERIMENTAL|Stratum B|All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
62637804|NCT00002610|EXPERIMENTAL|STRATUM C|All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
62069796|NCT02247804|EXPERIMENTAL|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
62637805|NCT00002610|EXPERIMENTAL|STRATUM D|Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.
62637806|NCT01882296|EXPERIMENTAL|AGSPT_10|tablet, 10mg, QD, 7days
62637807|NCT01882296|EXPERIMENTAL|AGSPT_20|tablet, 20mg, QD, 7days
62637808|NCT01882296|EXPERIMENTAL|AGSPT_40|tablet, 20mg x 2, QD, 7days
62069797|NCT02247804|EXPERIMENTAL|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
62454321|NCT02580630|ACTIVE_COMPARATOR|Training and glucocorticosteroid|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with glucocorticosteroid: 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
62069798|NCT02247804|ACTIVE_COMPARATOR|Timolol 0.5%|Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
62069799|NCT02110524|EXPERIMENTAL|CVI Drug Coated Balloon|
62069800|NCT03457272|EXPERIMENTAL|New risk assessment|New risk assesment
62069801|NCT03457272|NO_INTERVENTION|Standard|Standard risk assessment
62637809|NCT01882296|ACTIVE_COMPARATOR|Pantoprazole_20|tablet, 20mg, QD, 7days
62637810|NCT01882296|ACTIVE_COMPARATOR|Pantoprazole_40|tablet, 40mg, QD, 7days
62069802|NCT05731284|ACTIVE_COMPARATOR|Adjunct Platelet rich plasma (PRP) therapy|Study Interventions: PRP will be injected in a systematic grid like fashion into the fibromuscular connective tissue of the anterior compartment following vaginal incision and dissection.
62637811|NCT04710719|ACTIVE_COMPARATOR|TAC only|Participants will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
62637812|NCT04710719|ACTIVE_COMPARATOR|TAC + 5FU|Participants will be treated with adjuvant intralesional TAC and 5FU at a dose of 0.1mg TAC for every 0.9mg 5FU 7-10 days post-op then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
62637813|NCT01571180||Gastric Bypass|Obese patients who have scheduled a gastric bypass
62637814|NCT01239394|OTHER|ofatumumab|single-arm, open-label, interventional
62069803|NCT05731284|PLACEBO_COMPARATOR|Normal saline|Placebo: Normal saline will be injected in a systematic grid like fashion into the fibromuscular connective tissue of the anterior compartment following vaginal incision and dissection.
62069804|NCT05202990|EXPERIMENTAL|Fecal Microbiota Transplantation by Stool capsules|Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool capsules
62637815|NCT04536662|EXPERIMENTAL|Group hydrocortisone|
62637816|NCT04536662|EXPERIMENTAL|Group Prednisone|
62637817|NCT04536662|EXPERIMENTAL|Group Dexamethasone|
62454322|NCT02580630|ACTIVE_COMPARATOR|Training and local anesthetic|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with local anaestethic: 1ml Lidocain 5 mg/ml and 1 ml intralipid (for blinding) in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
62637818|NCT06376487|EXPERIMENTAL|flow rate sequence|Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.
62637819|NCT06612008||Stepwise titration|Patients will receive a MAD with an individualized stepwise titration protocol. Initially, the device is set at 60% advancement of the maximum protrusion. Over the first 3 months, the advancement is adjusted incrementally (to 75% or 90%) based on subjective improvement in OSA symptoms and side effects. If side effects occur, the advancement is decreased.
62454323|NCT03717064|EXPERIMENTAL|Pitavastatin|"Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.~Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4."
62454324|NCT01493479|EXPERIMENTAL|Fractionated Initial Zevalin|
62454325|NCT03199729|EXPERIMENTAL|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
62637820|NCT06612008||Personalized titration|Patients will receive a MAD set to baseline settings. Instead of following a standard titration process, personalized titration will use both objective data and subjective patient feedback to determine the optimal advancement. This approach takes into account individual factors such as the patient's oral anatomy, sleep study results, and specific symptoms. The goal is to achieve a personalized, optimal setting that maximizes symptom improvement and comfort.
62637821|NCT01803659|EXPERIMENTAL|b-carotene|600 ug RAE/d as b-carotene, 6 d/wk for 3 weeks
62637822|NCT01803659|ACTIVE_COMPARATOR|retinyl palmitate|600 ug retinol equivalent/d, 6 d/wk for 3 weeks
62637823|NCT01803659|PLACEBO_COMPARATOR|placebo (corn oil)|0 ug RAE/d as corn oil
62637824|NCT00710255||Asthmatics|Asthmatics with exercise induced bronchospasm
62637825|NCT00026780||Cohort 1|Children and young adults who are being evaluated for protocols within the Pediatric Oncology Branch.
62637826|NCT03492437|EXPERIMENTAL|Dabigatran Etexilate|
62637827|NCT03492437|EXPERIMENTAL|Tepotinib + Dabigatran|
62637828|NCT02871674|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive behavioural training by psychologists in three sessions over three weeks
62637829|NCT02871674|NO_INTERVENTION|Control group - usual care|Participants in the control group will receive usual care. They will also attend their usual appointments with the psychiatrists. They will not receive any intervention.
62637830|NCT03169478|NO_INTERVENTION|multiple myoma control group|The control group will not have any balloon therapy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
62637831|NCT03169478|EXPERIMENTAL|multiple myoma IUB dilatation group|The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
62637832|NCT00356109|EXPERIMENTAL|1|
62637833|NCT00356109|ACTIVE_COMPARATOR|2|
62637834|NCT02151617|EXPERIMENTAL|Cohort 1-PF-06743649 or placebo|Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
62637835|NCT02151617|EXPERIMENTAL|Cohort 2-PF-06743649 or placebo|
62637836|NCT02151617|EXPERIMENTAL|Cohort 3-PF-06743649 or placebo|
62637837|NCT02151617|EXPERIMENTAL|Cohort 4-PF-06743649 or placebo|
62637838|NCT02151617|EXPERIMENTAL|Cohort 5-PF-06743649 or placebo|
62637839|NCT02410863|EXPERIMENTAL|Cohort A (BRAFi naïve)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily.
62069805|NCT05202990|EXPERIMENTAL|Fecal Microbiota Transplantation by enema|Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool enemas.
62637840|NCT02410863|EXPERIMENTAL|Cohort B (BRAFi / MEKi rechallenge)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily
62069806|NCT00595972|EXPERIMENTAL|A|patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar
62069807|NCT02057289|EXPERIMENTAL|Micafungin|"Subjects will be administered 5 mg/kg of micafungin intravenously as a ONE TIME dose.~For patients undergoing Hematopoietic Stem Cell Transplant (HSCT), Micafungin will be given on during rest days (i.e. days when no chemotherapy is administered) and blood for pharmacokinetic measurements will be drawn over next 96 hours.~Following this, further anti-fungal coverage will be at the discretion of the patient's attending physician. (I.e. other antifungal agent(s) or Micafungin at a standard clinical dose; repeat doses of 5mg/kg will NOT be administered.)"
62637841|NCT01569126|EXPERIMENTAL|5 milligrams (mg) LY110140 (SD)|5 mg administered once in the fasted state on Day 1
62637842|NCT01569126|EXPERIMENTAL|20 mg LY110140 (SD)|20 mg administered once in the fasted state on Day 1
62069808|NCT03671733|EXPERIMENTAL|Liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
62069809|NCT03671733|EXPERIMENTAL|Exenatide|Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
62069810|NCT03671733|EXPERIMENTAL|Exenatide Microspheres for Injection|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
62069811|NCT03218696|EXPERIMENTAL|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
62069812|NCT03218696|PLACEBO_COMPARATOR|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
62274530|NCT01175798|NO_INTERVENTION|No treatment (standard of care)|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
62274531|NCT01175798|EXPERIMENTAL|Vitamin D repletion|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
62274532|NCT01246791|EXPERIMENTAL|NPC-01|Single oral administration of NPC-01
62274533|NCT04726371|ACTIVE_COMPARATOR|Generic Best Practices (GBP)|The \~200 group homes randomized into this arm will receive the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consists of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings.
62274534|NCT04726371|EXPERIMENTAL|Tailored Best Practices (TBP)|The \~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents.
62274535|NCT01069497|EXPERIMENTAL|Intervention Nursing Homes|Comprising 24 nursing homes implementing a specific infection prevention program
62274536|NCT01069497|NO_INTERVENTION|Usual care Nursing Homes|
62274537|NCT02163018|EXPERIMENTAL|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1.
62454326|NCT03199729|EXPERIMENTAL|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
62637843|NCT01569126|EXPERIMENTAL|40 mg LY110140 (SD)|40 mg administered once in the fasted state on Day 1
62637844|NCT01569126|PLACEBO_COMPARATOR|Placebo (MD)|Placebo once daily oral dosing for 28 consecutive days
62637845|NCT01569126|EXPERIMENTAL|20 mg LY110140 (MD)|20 mg once daily oral dosing for 28 consecutive days
62637846|NCT01569126|EXPERIMENTAL|40 mg LY110140 (MD)|40 mg once daily oral dosing for 28 consecutive days
62069813|NCT01348776|EXPERIMENTAL|Hair2Go (Mē)|Subjects treated with Hair2Go (Mē) Device
62069814|NCT01267981|PLACEBO_COMPARATOR|Preparation 1|Standard diet: the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
62069815|NCT01267981|ACTIVE_COMPARATOR|Preparation 2|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~500 ml of polyethylene glycol 30 minutes after the ingestion of video-capsule endoscopy."
62274538|NCT02163018|PLACEBO_COMPARATOR|Placebo|Subcutaneous administration of placebo
62274539|NCT04195828|EXPERIMENTAL|Camrelizumab + Apatinib + nab-paclitaxel +S-1|Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
62454327|NCT03199729|NO_INTERVENTION|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
62454328|NCT03199729|EXPERIMENTAL|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
62454329|NCT03213210|OTHER|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
62454330|NCT02187042||All patients|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
62454331|NCT03094910|OTHER|123I-MIBG|Only the group of participants with primary Raynaud's phenomenon (Raynaud's disease) is also scheduled for this intervention, the 123I-MIBG.
62454332|NCT03094910|OTHER|All participants|Examination of vibration perception threshold in fingertips, thermography, Ewing's test, tilt table test, blood samples.
62637847|NCT06249516|EXPERIMENTAL|The experimental group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Based on this, this group was given Active Breathing Exercises"
62069816|NCT01267981|ACTIVE_COMPARATOR|Preparation 3|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~2 liters of polyethylene glycol between 7 pm and 9 pm.~500 ml of polyethylene glycol, 30 minutes after the ingestion of video-capsule endoscopy."
62069817|NCT04868643|OTHER|In-Center arm|Subjects undergo In-Center treatment in Phase 2 as defined.
62069818|NCT04868643|OTHER|In-Home arm|"Subjects undergo In-Home treatments in Phase 4 as defined.~Subjects in Phase 2 and Phase 4 will be the same."
62069819|NCT01413672||person with ostomy|Community dwelling subject with either colostomy or ileostomy and at least 3 months post-surgery.
62069820|NCT00543660|EXPERIMENTAL|Intervention arm DSEK|Intervention: DSEK
62069821|NCT01837290|ACTIVE_COMPARATOR|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
62069822|NCT01837290|PLACEBO_COMPARATOR|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
62069823|NCT05639621|EXPERIMENTAL|Meaningful accompaniment|Patient who is going to undergo an endoscopic procedure and who will have a significant accompaniment by a person freely chosen by the patient and who will escort him in a visual and tactile way during the pre-procedure, intra-procedure, and post-procedure endoscopic stage.
62069824|NCT05639621|NO_INTERVENTION|Usual care|Patient who is going to undergo an endoscopic procedure and who receives regular care provided by the service during the pre-procedure, intra-procedure and post-procedure stage.
62454333|NCT05803746|EXPERIMENTAL|Imaging cohort|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-Mirc415 PET/CT scan.
62069825|NCT03214289|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|"Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.~Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.~Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected."
62069826|NCT02712671||Enrolled subjects|Subjects attending the Ian Charleson Centre and agreeing to be tested for latent, subclinical and active tuberculosis using Chest radiograph, Blood interferon gamma release assay, Tuberculin skin testing, Sputum induction for mycobacterial microscopy and culture with spirometry, and Mycobacterium tuberculosis polymerase chain reaction testing.
62069827|NCT03684720|EXPERIMENTAL|Discover followed by direct instruction [DD]|The intervention group which will be taught suturing using guided-discovery-learning
62069828|NCT03684720|NO_INTERVENTION|Instruction followed by practice [IP]|The control group which will be taught suturing using traditional instructional teaching.
62069829|NCT06489691|EXPERIMENTAL|Assessments at 3200 m and 760 m, respectively|Participants will have a 6-minute walk distance (6MWD) assessment near their resident altitude at 3200 m and after relocation to 760 m after 1 and 7 days.
62069830|NCT01672203||PE peripheral with fibrinolysis|Patients with peripheral PE who received fibrinolysis therapy
62069831|NCT01672203||PE peripheral, no fibrinolysis|Patients with peripheral PE who did not receive fibrinolysis
62461601|NCT04714307||At 50% risk for SCA3/MJD group|The offspring of affected individuals with SARA\<3. This group will be comprised of two subpopulations: pre-symptomatic individuals and related controls. The determination will be made upon molecular diagnosis to be done in a double-blind manner.
62461602|NCT05841225|EXPERIMENTAL|experimental group|
62461603|NCT05841225|PLACEBO_COMPARATOR|control group|
62461604|NCT05685979||Patients undergoing robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|Patients with ASA( American Society of Anesthesiologists) physical status 1-3 who underwent robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.
62069832|NCT01672203||PE central with fibrinolysis|Patients with central PE who received fibrinolysis therapy
62069833|NCT01672203||PE central, no fibrinolysis|Patients with central PE who did not receive fibrinolysis
62069834|NCT00344006|EXPERIMENTAL|Arm 1|
62069835|NCT00147225|EXPERIMENTAL|1 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~1. Carboplatin \[area under the concentration curve (AUC) = 11\]; or~2. Adriamycin - Ifosfamide (AI) regimen \[Adriamycin 75-90 mg/m\^2 intravenous (IV), Ifosfamide 10-14 gm/m\^2 IV\]; or~3. High dose Ifosfamide: 14 gm/m\^2."
62069836|NCT00147225|EXPERIMENTAL|3 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~1. Carboplatin \[area under the concentration curve (AUC) = 11\]; or~2. AI regimen \[Adriamycin 75-90 mg/m\^2 intravenous (IV), Ifosfamide 10-14 gm/m\^2 IV\]; or~3. High dose Ifosfamide: 14 gm/m\^2."
62069837|NCT00147225|EXPERIMENTAL|10 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~1. Carboplatin \[area under the concentration curve (AUC) = 11\]; or~2. AI regimen \[Adriamycin 75-90 mg/m\^2 intravenous (IV), Ifosfamide 10-14 gm/m\^2 IV\]; or~3. High dose Ifosfamide: 14 gm/m\^2."
62069838|NCT00147225|EXPERIMENTAL|10 mcg/kg Pre/Post Chemotherapy|"Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.~Chemotherapy :~1. Carboplatin \[area under the concentration curve (AUC) = 11\]; or~2. AI regimen \[Adriamycin 75-90 mg/m\^2 intravenous (IV), Ifosfamide 10-14 gm/m\^2 IV\]; or~3. High dose Ifosfamide: 14 gm/m\^2."
62069839|NCT00147225|EXPERIMENTAL|5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~1. Carboplatin \[area under the concentration curve (AUC) = 11\]; or~2. AI regimen \[Adriamycin 75-90 mg/m\^2 intravenous (IV), Ifosfamide 10-14 gm/m\^2 IV\]; or~3. High dose Ifosfamide: 14 gm/m\^2."
62274540|NCT04195828|ACTIVE_COMPARATOR|nab-paclitaxel +S-1|nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
62461605|NCT00322465|EXPERIMENTAL|Doxycycline|Doxycycline 100 mg orally twice daily (2 pills/day = 200 mg/day) for 7 days plus placebo azithromycin orally single dose and placebo tinidazole.
62274541|NCT02570633|EXPERIMENTAL|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
62637848|NCT06249516|ACTIVE_COMPARATOR|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
62274542|NCT02570633|PLACEBO_COMPARATOR|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
62274543|NCT05493020||Questionnaires assessed children with cancer|Children with cancer who received at least one radiotherapy and chemotherapy during hospitalization
62274544|NCT03355183|EXPERIMENTAL|Healthy athletes|Muscular strength of healthy athletes who are not physically disabled and doing sports for 3 years as a professional will be measured by isokinetic dynamometer.
62287115|NCT02574104||Institution 4|"Eastern Maine Medical Center NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
62287116|NCT02574104||Institution 5|"Brigham and Women's Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
62637849|NCT06080009|EXPERIMENTAL|Patients diagnosed with Ca sebaceous of the ocular adnexa.|adult patients diagnosed with Ca sebaceous of the ocular adnexa.
62454334|NCT06394102|EXPERIMENTAL|A Group|Is a group that accepts natural color mode processing and then accepts natural color mode closing. In this group, subjects will first be exposed to an environment using a natural color pattern, which applies a specific light source to adjust the color temperature of the ambient light, and the phone color temperature will change with the ambient light color temperature. To evaluate the effects of natural color patterns on visual fatigue and visual function, including but not limited to measures of adjustment function, assembly function, reading efficiency, blink detection, and retinal fundus blood flow.
62637850|NCT02464137|EXPERIMENTAL|Radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
62088300|NCT05821413|EXPERIMENTAL|Data to Care|Clinics randomized to the intervention arm will implement the data to care strategy, which includes a 5-step process: (1) identify not-in-care PLWH using the a medical information system, (2) verify eligibility criteria, (3) contact patients and invite to visit the clinic, (4) determine care status and reengage into care, and (5) provide case management services and confirm engagement in care.
62274545|NCT05269394|EXPERIMENTAL|E2814 plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
62287117|NCT02574104||Institution 6|"Centre hospitalier universitaire Sainte-Justine NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
62454335|NCT06394102|EXPERIMENTAL|B Group|Is the group that accepts the natural color mode off first, and then accepts the natural color mode on. In group B, the subjects will first be in the condition of changing ambient light, and the color temperature of the phone will not change with the ambient light color temperature. Then the experiment was performed on different days to open the natural color mode. The aim is to provide a benchmark against which to compare the effects of natural color pattern treatment in the experimental group.
62454336|NCT05108623|EXPERIMENTAL|Part 1: Monotherapy with agenT-797|3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.
62454337|NCT05108623|EXPERIMENTAL|Part 2: agenT-797 in Combination with approved ICIs|Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care
62454338|NCT01612390||group 1|receive 400 Mg sublingual misoprostol.
62637851|NCT01145664|ACTIVE_COMPARATOR|Western therapy|
62637852|NCT01145664|EXPERIMENTAL|Herbal concentrate-granules plus western therapy|
62637853|NCT01145664|EXPERIMENTAL|Reduning Injection plus western therapy|
62637854|NCT02427854|NO_INTERVENTION|No training|Incidence of obstetric perineal injuries in the participating hospitals before implementation of the manual perineal protection method.
62637855|NCT02427854|ACTIVE_COMPARATOR|Education by animated training video|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video only.
62637856|NCT02427854|ACTIVE_COMPARATOR|Interactive hands on bedside training|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video and additionally by an interactive hands-on bedside training.
62088301|NCT05821413|ACTIVE_COMPARATOR|Standard of Care|Participants in the standard of care sites will receive existing case management and supportive services from the HIV clinic.
62637857|NCT02935569|EXPERIMENTAL|Compression Headband|a compression headband, placed only at the time of irradiation
62088302|NCT04108689|EXPERIMENTAL|I-ACT|I-ACT is short for Internet-Acceptance and Commitment Training
62088303|NCT01755689|EXPERIMENTAL|Nimenrix+Cervarix (1,2,7-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 1, Month 2 and Month 7. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
62274546|NCT05269394|PLACEBO_COMPARATOR|Matching placebo (E2814) plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
62274547|NCT05493319|EXPERIMENTAL|Hypopresive, strength and resistance exercises|Participants will perform 3 types of hypopresive exercises in the end of strength and resistance exercises intervention.
62637858|NCT06225973|EXPERIMENTAL|TL-925 Arm|TL-925 will be administered OU BID
62088304|NCT01755689|EXPERIMENTAL|Nimenrix+Cervarix (0,1,6-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
62274548|NCT05493319|ACTIVE_COMPARATOR|Strength and resistance exercises|Participants will perform strength and resistance exercises intervention.
62274549|NCT01345071||RA patients|RA patients with active disease or current use of anti-TNF. Treatment is according to treat to target principles.
62274550|NCT04082000|EXPERIMENTAL|BOL-DP-o-04|
62274551|NCT04082000|PLACEBO_COMPARATOR|Placebo|
62274552|NCT04450485|ACTIVE_COMPARATOR|Medial para-patellar approach|Fast track protocol applied total knee arthroplasty patients operated by using medial para-patellar approach
62274553|NCT04450485|ACTIVE_COMPARATOR|Mini mid-vastus approach|Fast track protocol applied total knee arthroplasty patients operated by using mini mid-vastus approach
62274554|NCT05713643|ACTIVE_COMPARATOR|ESPB group|
62637859|NCT06225973|PLACEBO_COMPARATOR|Vehicle Arm|Vehicle will be administered OU BID
62274555|NCT05713643|ACTIVE_COMPARATOR|TPVB group|
62274556|NCT05713643|ACTIVE_COMPARATOR|QLB group|
62274557|NCT05534932|ACTIVE_COMPARATOR|Treatment Arm|35 Subjects will be placed in the sub-study treatment arm. These subjects will receive the remote patient monitoring program therapy offered by the University of Chicago heart failure program.
62274558|NCT05534932|NO_INTERVENTION|Observational Arm|35 Subjects will be placed in the sub-study Obervational arm. These subjects will not reveive the remote patient monitoring program and will continue with thier standard of care treatment for the duration of the study.
62274559|NCT02956668|EXPERIMENTAL|Blindsight training associated to tDCS|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.~tDCS stimulation start at the beginning of the rehabilitation session, and continue for 30 min, during treatment.~Anode is placed over the parieto-occipital cortex. The cathode is placed in the contralateral supraorbital position."
62274560|NCT02956668|ACTIVE_COMPARATOR|Blindsight training alone|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time."
62274561|NCT02542475|EXPERIMENTAL|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
62274562|NCT04750551|EXPERIMENTAL|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
62274563|NCT04750551|EXPERIMENTAL|EStim|EStim is transcutaneous electrical nerve stimulation.
62274564|NCT04152096|EXPERIMENTAL|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
62274565|NCT04152096|ACTIVE_COMPARATOR|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
62637860|NCT01904110|EXPERIMENTAL|Risenex M|Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months
62637861|NCT01904110|ACTIVE_COMPARATOR|Risenex Plus|Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months
62274566|NCT03225300|EXPERIMENTAL|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
62274567|NCT03665285|EXPERIMENTAL|NC318 8mg|Phase 1 Dose Escalation (Cohort -1): Subjects received NC318 IV at 8mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62454339|NCT01612390||group 2|receive 600 Mg sublingual misoprostol.
62454340|NCT01612390||group 3|receive 5IU of intravenous oxytocin.
62454341|NCT04360811|OTHER|Unexposed group : COVID 19 negatif pregant woman|COVID-19 negative women (not immunize
62637862|NCT02307903||End-stage renal failure (ESRF)|end-stage renal failure (ESRF)
62637863|NCT02000050|EXPERIMENTAL|Single Arm|"* Neoadjuvant therapy: FOLFOX4 2 cycles + Tomotherapy + FOLFOX4 2 cycles~* Surgery~* Adjuvant therapy: FOLFOX4 8 cycles~* TME (Total Mesorectal Excision)"
62454342|NCT04360811|OTHER|Exposed group : COVID 19 positif pregant woman|Women positive for COVID-19 (symptomatic and asymptomatic) COVID-19 negative women with long-standing immunity
62454343|NCT06464328|EXPERIMENTAL|Tai Chi Combined with Music Therapy Intervention|Tai Chi combined with music therapy Intervention, the effect was achieved by replacing the school's physical education classes with Tai Chi of the researchers' choice, and then by playing music of the researchers' choice during class.
62637864|NCT01654770|ACTIVE_COMPARATOR|video capsule endoscopy|Video capsule endoscopy is performed every recruited patient.
62069840|NCT00147225|EXPERIMENTAL|10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"10 mcg/kg AMG 531 + Pre/Pre/Post/Post Chemotherapy Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~1. Carboplatin \[area under the concentration curve (AUC) = 11\]; or~2. AI regimen \[Adriamycin 75-90 mg/m\^2 intravenous (IV), Ifosfamide 10-14 gm/m\^2 IV\]; or~3. High dose Ifosfamide: 14 gm/m\^2."
62069841|NCT02593305|EXPERIMENTAL|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
62069842|NCT02593305|EXPERIMENTAL|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
62069843|NCT02593305|NO_INTERVENTION|Young Comparison|Young control group, used for age-related comparisons. This group did not go through any intervention.
62069844|NCT02891044|EXPERIMENTAL|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62069845|NCT00416260|EXPERIMENTAL|HFO-TGI|Patients with severe Acute Respiratory Distress Syndrome receiving sessions of high frequency oscillation and tracheal gas insufflation according to the study protocol
62069846|NCT00416260|NO_INTERVENTION|CMV|Patients with severe Acute Respiratory Distress Syndrome receiving only conventional mechanical ventilation according to the study protocol
62069847|NCT04111523|EXPERIMENTAL|SY-007 dose 1|The study will be intiated in healthy subjects at a 1mg dose. Six subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 2:1.
62069848|NCT04111523|EXPERIMENTAL|SY-007 dose 2|The study will be intiated in healthy subjects at a 4mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
62069849|NCT04111523|EXPERIMENTAL|SY-007 dose 3|The study will be intiated in healthy subjects at a 10mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
62069850|NCT04111523|EXPERIMENTAL|SY-007 dose 4|The study will be intiated in healthy subjects at a 20mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
62069851|NCT04111523|EXPERIMENTAL|SY-007 dose 5|The study will be intiated in healthy subjects at a 30mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
62069852|NCT04111523|EXPERIMENTAL|SY-007 dose 6|The study will be intiated in healthy subjects at a 45mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
62274568|NCT03665285|EXPERIMENTAL|NC318 24mg|Phase 1 Dose Escalation (Cohort 1): Subjects received NC318 IV at 24mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274569|NCT03665285|EXPERIMENTAL|NC318 80mg|Phase 1 Dose Escalation/Safety Expansion (Cohort 2): Subjects received NC318 IV at 80mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274570|NCT03665285|EXPERIMENTAL|NC318 240mg|Phase 1 Dose Escalation/Safety Expansion (Cohort 3): Subjects received NC318 IV at 240mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274571|NCT03665285|EXPERIMENTAL|NC318 400mg|Phase 1 Dose Escalation/Safety Expansion (Cohort 4): Subjects received NC318 IV at 400mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274572|NCT03665285|EXPERIMENTAL|NC318 800mg|Phase 1 Dose Escalation (Cohort 5): Subjects received NC318 IV at 800mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274573|NCT03665285|EXPERIMENTAL|NC318 1600mg|Phase 1 Dose Escalation (Cohort 6): Subjects received NC318 IV at 1600mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274574|NCT03665285|EXPERIMENTAL|Dose Expansion: 400mg Q2W|Phase 2 Dose Expansion (400mg): Subjects received NC318 IV at 400mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274575|NCT03665285|EXPERIMENTAL|Dose Expansion: 800mg QW|Phase 2 Dose Expansion (800mg): Subjects received NC318 IV at 800mg QW for 8 weeks, then Q2W thereafter until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
62274576|NCT03665402|ACTIVE_COMPARATOR|Rapid metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
62274577|NCT03665402|ACTIVE_COMPARATOR|Slow metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
62274578|NCT03665402|EXPERIMENTAL|Slow metabolizer (PGx treatment)|Decreased isoniazid dose regimen (200 mg qd)
62274579|NCT01787916|EXPERIMENTAL|Liraglutide|Liraglutide, s.c., 1.8 mg, die, 24 weeks
62274580|NCT01787916|PLACEBO_COMPARATOR|Placebo|Liraglutide placebo (visually identical to study drug) will be given s.c. 1.8 mg for 24 weeks
62274581|NCT03046355|EXPERIMENTAL|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
62274582|NCT03046355|ACTIVE_COMPARATOR|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
62274583|NCT00191451|EXPERIMENTAL|HER2+|Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin.
62637865|NCT01654770|ACTIVE_COMPARATOR|double balloon enteroscopy|Double balloon enteroscopy is performed after video capsule endoscopy in every recruited patient. (Tandem study)
62069853|NCT02384655|EXPERIMENTAL|Fenugreek|Mothers will take fenugreek for 14 days
62274584|NCT00191451|EXPERIMENTAL|HER2- (Taxane-)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients).
62274585|NCT00191451|EXPERIMENTAL|HER2- (Taxane+)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients).
62274586|NCT06383923||pregnant women|pregnant women without prior cesarean section（CS） who had prenatal check-ups and gave birth at the Obstetrics Department of Peking University Third Hospital from January 1, 2023 to December 31, 2024.
62274587|NCT02948803|EXPERIMENTAL|Intervention group|smartphone based intervention with Active Coach app: participants in the intervention group will use a newly developed smartphone app in combination with a Fitbit Charge activity tracker for 9 weeks. The app aims to promote an active lifestyle.
62274588|NCT02948803|NO_INTERVENTION|control group|participants in the control groups only receive a flyer with standard information about an active lifestyle
62454344|NCT06464328|EXPERIMENTAL|Music intervention only|Music only (the fast tempo of 120-130 bpm music will be selected) The effect was achieved by playing music selected by the researchers during originally physical education classes in school.
62454345|NCT06464328|EXPERIMENTAL|Tai Chi intervention only|Tai Chi intervention only The effect was achieved by replacing the school's originally physical education classes with Tai Chi of the researchers' choice.
62454346|NCT03856970|EXPERIMENTAL|Part 1: Healthy Volunteers|Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).
62637866|NCT01505413|EXPERIMENTAL|Tarceva, Gemcitabine, Oxaliplatin|"* Erlotinib 100 mg po qd daily AND~* Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1~* Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2 weeks~Each two weeks is a cycle. If at end of 12 cycles response continues, will administer Gemcitabine and erlotinib until progression."
62637867|NCT00163865||Clinical Group|clinical adolescent group
62637868|NCT00163865||Community Group|community adolescent group
62637869|NCT01162889|PLACEBO_COMPARATOR|Placebo - SC injection|
62069854|NCT04639089|EXPERIMENTAL|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure
62069855|NCT04639089|PLACEBO_COMPARATOR|We will apply 10cm saline on the sternal edge before sternal closure|We will apply 10cm saline on the sternal edge before sternal closure
62274589|NCT00737451||skin itching|
62274590|NCT02105415|ACTIVE_COMPARATOR|Etomidate|weight based dose of 0.15mg/kg
62274591|NCT02105415|EXPERIMENTAL|Ketamine / Propofol Admixture|weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
62274592|NCT01357486|EXPERIMENTAL|A|patients receiving sorafenib 400 mg - twice a day
62274593|NCT01357486|EXPERIMENTAL|B|patients receiving pravastatin 40 mg - once a day
62274594|NCT01357486|EXPERIMENTAL|C|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
62274595|NCT01357486|OTHER|D|patients receiving best supportive care
62637870|NCT01162889|EXPERIMENTAL|Drug dose level 1 - SC injection|
62637871|NCT01162889|EXPERIMENTAL|Drug dose level 2 - SC injection|
62637872|NCT01162889|EXPERIMENTAL|Drug dose level 3- SC injection|
62274596|NCT04141709|EXPERIMENTAL|local ablative radiotherapy|The therapy is performed for all patients in the intervention arm using high-dose radiation therapy, either as conventional fractional irradiation with 2 Gy/fraction up to a total dose of 50 Gy or as hypofractional irradiation with a single dose of 10 Gy up to a total dose of 30 Gy.
62274597|NCT04141709|NO_INTERVENTION|Observational group|"Effectiveness is measured as the rate in patients with PSA progression one year after randomization (defined as PSA nadir after randomization +2 ng/ml).~There is a 2:1 randomization between intervention and observation group."
62274598|NCT00739414|EXPERIMENTAL|LBH589 (Panobinostat)|
62274599|NCT04830670||Large sinus|same patient, sinus width \> 12mm measured at 10mm from the alveolar crest at the planned implant site
62274600|NCT04830670||narrow sinus|same patient, sinus width \< 12mm measured at 10mm from the alveolar crest at the planned implant site
62637873|NCT01162889|EXPERIMENTAL|Drug dose level 4 - SC injection|
62069856|NCT05198193|EXPERIMENTAL|Control - Older Adults|Participants age 60 years old or above.
62069857|NCT05198193|EXPERIMENTAL|Positive - Older Adults|Participants age 60 years old or above.
62069858|NCT05198193|EXPERIMENTAL|Negative - Older Adults|Participants age 60 years old or above.
62069859|NCT05198193|EXPERIMENTAL|Control - Younger Adults|Participants age between 30 and 59 years old.
62274601|NCT05210179|ACTIVE_COMPARATOR|TURKOVAC-Koçak|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
62274602|NCT05210179|ACTIVE_COMPARATOR|TURKOVAC-Dollvet|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
62274603|NCT00488891||Paliperidone extended release (ER)|Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
62274604|NCT00488891||Atypical antipsychotics agent (AAP)|AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
62274605|NCT05430100|EXPERIMENTAL|Breast Milk Pacifiers Group|To determine the effectiveness of breast milk pacifier in reducing pain caused by Orogastric Tube (OGT) insertion in preterm newborns by monitoring behavioral and physiological changes in infants.
62637874|NCT01162889|EXPERIMENTAL|Drug dose level 5 - SC injection|
62274606|NCT05430100|EXPERIMENTAL|Sucrose Pacifiers Group|To determine the effectiveness of sucrose pacifier in reducing pain caused by Orogastric Tube (OGT) insertion in preterm newborns by monitoring behavioral and physiological changes in infants.
62637875|NCT01162889|EXPERIMENTAL|Drug dose level 6 - IV Infusion|
62069860|NCT05198193|EXPERIMENTAL|Positive - Younger Adults|Participants age between 30 and 59 years old.
62637876|NCT01162889|EXPERIMENTAL|Drug dose level 7 - IV Infusion|
62637877|NCT01162889|EXPERIMENTAL|Drug dose level 8 - IV infusion|
62637878|NCT01162889|PLACEBO_COMPARATOR|Placebo - IV infusion|
62637879|NCT01162889|EXPERIMENTAL|Drug dose level 9 - IV infusion|
62069861|NCT05198193|EXPERIMENTAL|Negative - Younger Adults|Participants age between 30 and 59 years old.
62069862|NCT04471779|EXPERIMENTAL|Disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity, family history of Alzheimer's disease, and their APOE genotype.
62069863|NCT04471779|NO_INTERVENTION|Non-disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity and family history of Alzheimer's disease alone.
62069864|NCT00985543|ACTIVE_COMPARATOR|LPV/r 400/100 mg|Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
62637880|NCT02214940|EXPERIMENTAL|BI 11634|multiple rising dose
62637881|NCT02214940|PLACEBO_COMPARATOR|Placebo|
62637882|NCT01014247|ACTIVE_COMPARATOR|Arm 1|
62637883|NCT01014247|PLACEBO_COMPARATOR|Arm 2|
62454347|NCT03856970|EXPERIMENTAL|Part 2: Healthy Volunteers|Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).
62637884|NCT04013295|EXPERIMENTAL|Prize-linked savings intervention|Participants in the intervention group will be assisted with opening bank accounts at the partner bank and will be eligible for monetary rewards linked to the amount they save in these project accounts. During the intervention period, information about participants' savings activities will be shared with the study team at regular intervals by the bank. Winners will learn of their prize via text message and will have their prize money deposited into their accounts. Respondents who did not win the lottery will also receive a text message, which will remind them to save.
62637885|NCT04013295|NO_INTERVENTION|Control|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
62637886|NCT02987296|ACTIVE_COMPARATOR|Immunonutrition with arginine|Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
62637887|NCT02987296|PLACEBO_COMPARATOR|Immunonutrition without arginine|This group of patients will also receive a nutritional drink but containing no arginine for 5 days before surgery and for 5 days after surgery.
62637888|NCT06229223|EXPERIMENTAL|PALOMA|Parents/guardians of youth who have been referred to and agree to participate in the intervention by the child's primary care provider will participate in a 2-month program consisting of 5-7 phone sessions with a community health worker focusing on safety planning, information/education, program solving and self-care. Research participants will be asked to complete a survey via phone at the beginning of the program and another at the end of the program. The participants may also be asked to participate in an additional interview about the participants experience during the study.
62637889|NCT02412124|EXPERIMENTAL|Supportive care (W2W program)|Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
62637890|NCT04838002|ACTIVE_COMPARATOR|Focus ESWT|
62637891|NCT04838002|ACTIVE_COMPARATOR|Radial ESWT|
62637892|NCT04838002|SHAM_COMPARATOR|Sham ESWT|
62069865|NCT00985543|EXPERIMENTAL|LPV/r 200/150 mg|Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
62069866|NCT00985543|EXPERIMENTAL|LPV/r 200/50 mg|Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)
62069867|NCT01197820|EXPERIMENTAL|Arm 1|30 patients with liver tumour and 15 patients with kidney tumour will be enrolled.
62069868|NCT05351619|EXPERIMENTAL|An intervention group|An intervention group: will include 41 patients who will receive the oral care bundle.
62069869|NCT05351619|NO_INTERVENTION|A control group|A control group: will include 41 patients who will receive the traditional oral care.
62454348|NCT03856970|EXPERIMENTAL|Part 3: Healthy Volunteers|"Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).~Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42)."
62069870|NCT04910815|EXPERIMENTAL|Primary recruitment|Capsules will be ingested within 30 minutes prior to endoscopy pre- and post-antimicrobial intervention (if the patients has had a treatment) to determine if it can be used to identify increased microbial load through gas detection, and to identify responders to therapy.
62069871|NCT04910815|ACTIVE_COMPARATOR|Active SIBO Arm - Rifaximin|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of Rifaximin (550g) 1 capsule twice a day for 14 days. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
62274607|NCT05430100|EXPERIMENTAL|Pacifiers Group|To determine the effectiveness of pacifier in reducing pain caused by Orogastric Tube (OGT) insertion in preterm newborns by monitoring behavioral and physiological changes in infants.
62637893|NCT05864534|EXPERIMENTAL|Blood-brain barrier opening with concomitant BAL, BOT, DOX|Patients will undergo implantation of Sonocloud-9 after completion of radiotherapy. Within 21 days after implant, ultrasound-based BBB opening with concomitant administration of DOX (30 mg) + BAL (450 mg) every 3 weeks, and BOT (dose 1mg/kg) every 6 weeks will be initiated.
62637894|NCT05458986|EXPERIMENTAL|Arm 1 (educational video)|Patients watch an educational video about the importance of abnormal FIT results, the implications if follow-up colonoscopy is not completed, and demonstrate the steps to complete a colonoscopy.
62637895|NCT05458986|ACTIVE_COMPARATOR|Arm 2 (usual care)|Patients receive usual care and do not watch the educational video.
62637896|NCT05694858|EXPERIMENTAL|Lignocaine-Embedded Microneedle Patch|A biodegradable maltose microarray needle (MAN) patch loaded with 12.5 mg lignocaine will be applied on the dorsum of the participant's hand for 30 minutes. Intravenous cannulation will be carried out after 30 minutes.
62637897|NCT05694858|ACTIVE_COMPARATOR|EMLA 5% Patch|1 finger-tip unit (FTU) of EMLA containing 12.5 mg lignocaine and 12.5 mg prilocaine will be applied on the dorsum aspect of the participant's hand. This will then be covered by a Polyvinyl Alcohol (PVA)-Polyethylene Terephthalate (PET) adhesive and left in place for 30 minutes. Intravenous cannulation will be carried out after 30 minutes.
62274608|NCT05430100|NO_INTERVENTION|Control Group|The camera recording will be started 5 minutes before the OGT insertion procedure and the routine OGT placement process will be performed. No pain-related procedures are performed during routine OGT in the NICU.
62637898|NCT02571140|ACTIVE_COMPARATOR|Active Comparator|Subcutaneous injection of Teriparatide
62088305|NCT01755689|EXPERIMENTAL|Cervarix Group|Subjects in this group received 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6, administered intramuscularly (IM) in the deltoid region of the arm.
62088306|NCT01755689|EXPERIMENTAL|Nimenrix+Cervarix+Boostrix Group|Subjects in this group received 1 dose each of Nimenrix and Boostrix vaccines at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. All vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
62088307|NCT01755689|EXPERIMENTAL|Boostrix+Cervarix Group|Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
62088308|NCT00590993||1 - MRSI / MRI|
62274609|NCT03429192||N2 non-small cell lung cancer|Chinese patients with N2 non-small cell lung cancer
62274610|NCT01109784|EXPERIMENTAL|prasugrel|prasugrel per os 10mg/day
62637899|NCT02571140|EXPERIMENTAL|Oral PTH (1-34)|Oral administration of pill with API with different optimizations
62637900|NCT01026948||Propess and Monica AN24 care package|Women who are eligible and consent to recruitment will receive the Propess and Monica AN24 care package for outpatient induction of labour
62637901|NCT06523010|PLACEBO_COMPARATOR|Placebo Talocrural Joint Manipulation Group|In this group, patients will receive placebo talocrural joint manipulation. The application will be similar to that in the experimental group, however, hands will be positioned to avoid creating traction or manipulation force, and this position will be maintained for 20 seconds.
62637902|NCT06523010|EXPERIMENTAL|Talocrural Joint Manipulation Group|In this group, talocrural joint manipulation will be applied. After positioning the patient, high velocity low amplitude traction will be applied.
62637903|NCT05499884|EXPERIMENTAL|Experimental group|
62637904|NCT04868019|EXPERIMENTAL|Group A|Groups A will receive solution A .i.e fenofibrate suspension
62637905|NCT04868019|PLACEBO_COMPARATOR|Group B|Group B will receive solution B i.e placebo.
62637906|NCT01921803|EXPERIMENTAL|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
62637907|NCT01921803|EXPERIMENTAL|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
62069872|NCT04910815|PLACEBO_COMPARATOR|Active SIBO Arm - Placebo|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of placebo capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
62069873|NCT00967213|EXPERIMENTAL|Ranibizumab|three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
62069874|NCT04395859||Patients treated with IVT before COVID19 pandemia|Treatment started at least 6 months before the French confinement for COVID19 (15th march 2020)
62069875|NCT03767634||Neonatal population (Project A)|Neonates born between 1st January 2012 and 31st December 2017 and admitted to a neonatal unit in England, Scotland and Wales).
62069876|NCT03767634||No PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who did not receive any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
62069877|NCT03767634||PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who received any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
62069878|NCT02952664|EXPERIMENTAL|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
62637908|NCT04965181|EXPERIMENTAL|Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol, iQuit Mindfully text messages, and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke \>10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
62637909|NCT04965181|EXPERIMENTAL|iQuit Mindfully|"Participants will receive iQuit Mindfully text messages and nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke \>10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
62069879|NCT00517075|EXPERIMENTAL|A|high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
62069880|NCT00517075|ACTIVE_COMPARATOR|B|Active high frequency rTMS to the left dorsolateral prefrontal cortex
62069881|NCT00517075|SHAM_COMPARATOR|C|Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
62069882|NCT00517075|EXPERIMENTAL|Open cross over high frequency rTMS|Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --\> open phase DLPFC and vice versa)
62069883|NCT03661996|EXPERIMENTAL|Breg Cooling Control Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Breg ice water pump.
62454349|NCT02060006|PLACEBO_COMPARATOR|Placebo 7.5 mg daily for 8 weeks|Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
62274611|NCT01109784|ACTIVE_COMPARATOR|clopidogrel|clopidogrel per os 150mg/day
62069884|NCT03661996|EXPERIMENTAL|Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
62274612|NCT06501755|SHAM_COMPARATOR|Sham tACS|Intensity: 2 mA (peak-to-peak), localisation: F4/P4, phase-shift between the electrodes: 0°,duration: 20s at the begin and the end of the task (adaptive spatial n-back) with additionally each time 15 s fade-in and fade-out, frequency: 6Hz.
62274613|NCT06501755|EXPERIMENTAL|Individualized Theta-Frequency tACS|Intensity: 2 mA (peak-to-peak), localisation: F4/P4, phase-shift between the electrodes: 0°, duration: 27 min with 15 s fade-in and fade-out, frequency: peak theta-frequency at the baseline measurement during the execution of the spatial 2-, 3-, and 4-back.
62274614|NCT00049673|EXPERIMENTAL|Arm I|Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.
62274615|NCT00049673|NO_INTERVENTION|Arm II|Patients undergo observation.
62274616|NCT05392491||Control group (without coronary lesions)|Cohort control group. No interventions.
62274617|NCT05392491||Coronary Lesion < 30%|Participants with coronary lesion under 30%. No interventions.
62274618|NCT05392491||Coronary Lesion > 30% and < 50%|Participants with coronary lesions greater than 30% and under 50%. No interventions.
62274619|NCT01850056|EXPERIMENTAL|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
62274620|NCT01850056|ACTIVE_COMPARATOR|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
62274621|NCT03639714|EXPERIMENTAL|Phase 1|"* GRT-C901~* GRT-R902~* nivolumab~* ipilimumab"
62274622|NCT03639714|EXPERIMENTAL|Phase 2 Cohorts|"* GRT-C901~* GRT-R902~* nivolumab~* ipilimumab"
62274623|NCT03011957||Group 1|HIV positive viral load \< 200 copies/ml 50-65 years old CD4 \> 350 cells/ml Male or Female
62274624|NCT03011957||Group 2|HIV negative 50-65 years old CD4 \> 350 cells/ml Male or Female
62652965|NCT03555162|OTHER|Tool Evolution|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when we improve tools. Here the fMRI experimental session will be complemented by a cognitive psychology experiment, where participants will be given a tool to improve. Tasks proposed to the participants within the fMRI scanner will be related to cognitive functions that could be implicated in improving tools : creativity, technical reasinoning, logic, empathy. The BOLD measures realted to these experimental condfitions will be related to the ability of the participant to improve a tool, through General Linear Modeling.
62454350|NCT02060006|EXPERIMENTAL|Meloxicam 7.5 mg once-daily|Meloxicam 7.5mg once-daily for 8 weeks
62454351|NCT00148915|EXPERIMENTAL|Ibandronate|Participants will receive 150 milligrams (mg) ibandronate tablet orally once monthly for one year.
62454352|NCT00148915|PLACEBO_COMPARATOR|Placebo|Participants will receive ibandronate matched placebo tablet orally once monthly for one year.
62454353|NCT03493126|EXPERIMENTAL|Estradiol|Estrace: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
62274625|NCT04427631|EXPERIMENTAL|Single arm study|The family will complete questionnaires before and after each childs intervention. Therefore each child will act as their own control.
62637910|NCT04965181|EXPERIMENTAL|Mindfulness-based Addiction Treatment (MBAT)|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke \>10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
62069885|NCT03661996|EXPERIMENTAL|Shortened Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
62637911|NCT04965181|ACTIVE_COMPARATOR|Usual Care|"Participants in the usual care condition are provided with nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke \>10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
62069886|NCT03661996|EXPERIMENTAL|Single Needle Injection Gel Pack Cooling Group - 2% Lidocaine|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
62069887|NCT03661996|EXPERIMENTAL|Single Needle Injection Gel Pack Cooling Group - 1% Lidocaine|Subject receives 1% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
62069888|NCT03326817|ACTIVE_COMPARATOR|Control Group|This group will receive standard care.
62274626|NCT06267027|ACTIVE_COMPARATOR|Exercise|All study groups will be trained on a home exercise program that includes stretching and eccentric strengthening exercises.
62274627|NCT06267027|EXPERIMENTAL|Kinesiotaping and exercise|This study groups will be trained on a home exercise program and kinesiotaping. Kinesiotaping, muscle inhibition and fascia correction techniques will be applied in the forearm as described by Kase et al.
62274628|NCT06267027|EXPERIMENTAL|High intensity laser therapy and exercise|This study groups will be trained on a home exercise program and high intensity laser therapy.
62274629|NCT05714683||Participants with T2DM|All participants will be treated with Rybelsus for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by Ministry of Food and Drug Safety (MFDS).
62274630|NCT03709381|EXPERIMENTAL|ACTH stim test arm|Cosyntropin 1 mcg IV (low dose) will be given to subjects at t=0 minutes, and Cosyntropin 250 mcg (high dose) IV will be given to subjects at t=60 minutes. (All subjects were in the same arm and had the same protocol).
62069889|NCT03326817|EXPERIMENTAL|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
62069890|NCT02391441||Pulmonary arterial hypertension|Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.
62274631|NCT03943212|EXPERIMENTAL|Blood Flow Rate Reduction|Participants will have their hemodialysis blood flow rate reduced on their regular schedule.
62069891|NCT02391441||Control group|Control patients without increased pulmonary artery pressure (i.e. RV peak pressure \<35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.
62637912|NCT01573000|EXPERIMENTAL|Open-label, two-arm, Arm A and Arm B Crossover|Arm A Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 milliCurie (mCi) (35 mg) of I-131 TST infused over 30 minutes (inclusive of a 10-minute flush).• Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by a subject-specific mCi activity (35 mg) of I-131 TST to deliver the desired total body dose (TBD) infused over 30 minutes (inclusive of a 10-minute flush). The desired TBD was 65 cGy for subjects with a baseline platelet count of 100,001-149,999 cells/mm3 and 75 cGy for subjects with a baseline platelet count ≥150,000 cells/mm3. Obese subjects (subjects weighing more than 137% of their calculated lean body weight) were dosed based upon 137% of their calculated lean body mass
62637913|NCT01573000|EXPERIMENTAL|Arm B Crossover|Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
62069892|NCT02638623|ACTIVE_COMPARATOR|Drug Lactated Ringer|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
62637914|NCT04396626||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
62637915|NCT02903342|EXPERIMENTAL|Intervention|Parents will be asked to read a leaflet. They will then complete a survey and re-complete the survey via telephone two weeks later.
62637916|NCT02903342|NO_INTERVENTION|Control|Parents will be asked to complete a survey and re-complete the survey via telephone two weeks later.
62637917|NCT04260516|ACTIVE_COMPARATOR|N-acetylcysteine group|Patients received oral n-acetylcysteine syrup on dose of 10 mg/kg/day as single dose for 3 months
62637918|NCT04260516|NO_INTERVENTION|Non n-acetylcysteine group|Thalassemia major patients on regular chelation therapy who didn't receive n-acetylcysteine and served as controls
62637919|NCT02405767|EXPERIMENTAL|Foot ulcer impedance|Diabetic patients with a diabetic foot ulcer
62069893|NCT02638623|PLACEBO_COMPARATOR|Placebo|Covered empty bag with no hydration supplement
62637920|NCT02085200|OTHER|Horizontal adduction stretch without scapular stabilization|Scapular stabilization is not provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
62637921|NCT02085200|OTHER|Horizontal adduction with scapular stabilization|Scapular stabilization is provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
62637922|NCT02725658|OTHER|DOSI|
62637923|NCT01759953|ACTIVE_COMPARATOR|InsuOnline game|Playing the InsuOnline game, on the web, in the player´s own time and rhythm, until its end, as already described previously.
62274632|NCT03943212|SHAM_COMPARATOR|Control|Participants will continue to receive regularly-scheduled hemodialysis without any changes to the prescription.
62274633|NCT01317589|ACTIVE_COMPARATOR|fentanyl|active pain treatment with fentanyl patch
62637924|NCT01759953|ACTIVE_COMPARATOR|Traditional CME|Traditional learning session as used for Continuing Medical Education, on insulin therapy, including a short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
62637925|NCT00874913|EXPERIMENTAL|Laser Doppler Flowmetry|
62274634|NCT01317589|EXPERIMENTAL|methadone|active pain treatment with methadone
62637926|NCT00917124|ACTIVE_COMPARATOR|INVOS|INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
62274635|NCT02447315|EXPERIMENTAL|Treatment Sequence ABCDD|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence ABCDD. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
62274636|NCT02447315|EXPERIMENTAL|Treatment Sequence BDACC|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence BDACC. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
62088309|NCT05414721|ACTIVE_COMPARATOR|Low flow desflurane anesthesia (Group D)|All patients were preoxygenated for three minutes. Midazolam 0.03 mg/kg, fentanyl 1.5 mcg/kg , propofol 2 mg/kg and rocuronium 0.6 mg/kg were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50% O2+50% air + 6-7% desflurane in a 4 L/min fresh gas flow until the MAC value reached 1. When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air) in Group D. Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
62637927|NCT00917124|NO_INTERVENTION|CONTROL|The CONTROL arm did not have INVOS or any other cerebral oxygenation monitoring, so interventions to control cerebral oxygenation were not performed.
62637928|NCT01898247|NO_INTERVENTION|Traditionally-trained Procedures|Patients who undergo thoracentesis procedures by traditionally-trained residents who have not undergone simulation-based mastery learning.
62274637|NCT02447315|EXPERIMENTAL|Treatment Sequence CADBB|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence CADBB. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
62454354|NCT03493126|PLACEBO_COMPARATOR|Placebo|Placebo: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
62637929|NCT01898247|EXPERIMENTAL|Simulator-trained Procedures|Patients who undergo thoracentesis procedures by residents who have undergone simulation-based mastery learning.
62637930|NCT01132183|EXPERIMENTAL|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
62069894|NCT05268484|EXPERIMENTAL|TBI Intervention Group|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
62069895|NCT05268484|NO_INTERVENTION|TBI Control Group|No intervention is provided
62069896|NCT05268484|NO_INTERVENTION|Healthy Control|No intervention is provided
62069897|NCT04765241|EXPERIMENTAL|mHealth Physical Activity Intervention|The intervention arm will receive a 12 month mobile health (mHealth) physical activity intervention with a goal of increasing their moderate-vigorous intensity physical activity levels by 90 minutes per week above baseline
62069898|NCT04765241|NO_INTERVENTION|Control|Controls will receive general health education materials
62069899|NCT05289284||Female soccer cohort|A female soccer cohort will be followed for 10 month regarding injuries
62069900|NCT01337830|EXPERIMENTAL|Ariva® Silver Wintergreen|Subjects allow study product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
62069901|NCT01337830|ACTIVE_COMPARATOR|Silver Wintergreen|Subjects allow comparator product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
62069902|NCT00814996||1: employment|
62069903|NCT00814996||2: unemployment|
62274638|NCT02447315|EXPERIMENTAL|Treatment Sequence DCBAA|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence DCBAA. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
62274639|NCT00699517|EXPERIMENTAL|1|
62274640|NCT00699517|PLACEBO_COMPARATOR|2|
62274641|NCT05785312|EXPERIMENTAL|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The standard Face to Face Eye Movement Desensitization \& Reprocessing Therapy will be applied by a trained clinical psychologist through in person face to face sessions.
62274642|NCT05785312|ACTIVE_COMPARATOR|Online Eye Movement Desensitization & Reprocessing Therapy|The Online Eye Movement Desensitization \& Reprocessing Therapy will be applied by a trained clinical psychologist through computer system by connecting through internet. For this purpose the online EMDR therapy application software will be installed
62274643|NCT02364128|NO_INTERVENTION|Control|Potential bariatric surgery patients who receive both the baseline questionnaire and follow-up questionnaire.
62454355|NCT05456074||Patients with TRCC|
62637931|NCT01132183|ACTIVE_COMPARATOR|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
62637932|NCT01507116||People with Diabetes|
62637933|NCT01507116||Family Members|
62637934|NCT01507116||Healthcare Professionals|
62637935|NCT06410716|EXPERIMENTAL|Valve-regulated pleural drainage system|Patients using valve-regulated pleural drainage system.
62637936|NCT06410716|NO_INTERVENTION|Closed chest tube drainage|Patients using traditional closed chest tube drainage
62069904|NCT01904851||Stent|The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.
62274644|NCT02364128|OTHER|Decision Aid|Potential bariatric surgery patients who receive both the baseline questionnaire decision aid/conjoint analysis and follow-up questionnaire.
62637937|NCT05200585|EXPERIMENTAL|Healthy Liver/Hígado Sano program|
62637938|NCT05200585|ACTIVE_COMPARATOR|Control Group|
62637939|NCT01494805|EXPERIMENTAL|Low Dose rAAV.sFlt-1|
62637940|NCT01494805|EXPERIMENTAL|High Dose rAAV.sFlt-1|
62637941|NCT01494805|ACTIVE_COMPARATOR|Control - ranibizumab only|
62637942|NCT05460546|EXPERIMENTAL|Jincaopian Tablets high-dose group|Patients receive high dose Jincaopian Tablets 0.6g/day for 12 weeks.
62274645|NCT06133283|EXPERIMENTAL|High intensity endurance exercise and virtual reality (experimental)|The exercise group will perform high intensity interval exercise and VR-based games 3 times a week for 8 weeks.
62637943|NCT05460546|EXPERIMENTAL|Jincaopian Tablets low-dose group|Patients receive low dose Jincaopian Tablets 0.3g/day for 12 weeks.
62069905|NCT01904851||Non-Stent|The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.
62069906|NCT02208570|EXPERIMENTAL|P(+)V(+)|PPV\>14% before anesthesia induction, HES 6ml/kg infused
62069907|NCT02208570|EXPERIMENTAL|P(+)V(-)|PPV\>14% before anesthesia induction, no additional volume infused
62454356|NCT05456074||Patients with other rare kidney tumors|
62454357|NCT00614549||Levetiracetam|Patients treated with Levetiracetam
62454358|NCT03093909|EXPERIMENTAL|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
62454359|NCT01204580|EXPERIMENTAL|Amaryl-M (Glimepiride + Metformin)|"Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets.~Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test."
62454360|NCT04015232|EXPERIMENTAL|INTP5 biosimilar product|INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
62454361|NCT04015232|ACTIVE_COMPARATOR|US Neulasta reference product|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
62454362|NCT03883607|EXPERIMENTAL|Elafibranor 80 mg|Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.
62069908|NCT02208570|EXPERIMENTAL|P(-)V(+)|PPV\<14% before anesthesia induction, HES 6ml/kg infused
62069909|NCT02208570|EXPERIMENTAL|P(-)V(-)|PPV\<14% before anesthesia induction, no additional volume infused
62069910|NCT00383240|EXPERIMENTAL|MF/F MDI 200/10 mcg BID|
62069911|NCT00383240|EXPERIMENTAL|MF MDI 200 mcg BID|
62069912|NCT00383240|EXPERIMENTAL|F MDI 10 mcg BID|
62069913|NCT00383240|PLACEBO_COMPARATOR|Placebo BID|
62454363|NCT03883607|EXPERIMENTAL|Elafibranor 120 mg|Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.
62461606|NCT00322465|EXPERIMENTAL|Doxycycline + Tinidazole|Doxycycline 100 mg orally twice daily for 7 days plus placebo azithromycin single dose plus tinidazole 2 gm orally single dose (4 tablets at 500 mg each).
62454364|NCT05991661|ACTIVE_COMPARATOR|XKH001 Injection|Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.
62454365|NCT05991661|PLACEBO_COMPARATOR|XKH001 Placebo Injection|Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.
62454366|NCT03034226|ACTIVE_COMPARATOR|Single episode of hypoglycemia|Day 1: Hyperinsulinemic hypoglycemic clamp 30 min Day 2: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
62274646|NCT06133283|OTHER|Stretching and virtual reality (control)|The stretching group will perform stretching exercises and VR-based games 3 times a week for 8 weeks.
62454367|NCT03034226|ACTIVE_COMPARATOR|Two episodes of hypoglycemia|Day 3: No intervention (normal blood glucose) Day 4: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
62454368|NCT06014411|ACTIVE_COMPARATOR|Delayed Bathing|Delayed bathing-- patients will be told to begin showering after wound exam and suture removal (10-20 day postoperative).
62274647|NCT01535573|ACTIVE_COMPARATOR|Citalopram low dose|Citalopram 20 mg
62274648|NCT01535573|ACTIVE_COMPARATOR|Citalopram high dose|Citalopram 40 mg
62274649|NCT01535573|PLACEBO_COMPARATOR|Placebo|Placebo
62274650|NCT01002807|OTHER|FDC of dapagliflozin/metformin XR|
62274651|NCT01002807|OTHER|FDC of dapagliflozin/reduced mass metformin XR|
62274652|NCT01002807|OTHER|dapagliflozin and Glucophage® XR|
62287118|NCT02574104||Institution 7|"Golisano Children's Hospital of Southwest Florida NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
62454369|NCT06014411|ACTIVE_COMPARATOR|Early Bathing|Early bathing--Patients will be told to remove dressings and begin showering with body soap on postoperative day 3.
62454370|NCT02837822|ACTIVE_COMPARATOR|Stimulation Off|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn Off during the experiment."
62637944|NCT05460546|PLACEBO_COMPARATOR|Placebo group|Patients receive a matching placebo for 12 weeks.
62637945|NCT03955510|OTHER|"Right-time eating / no alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will be asked to not drink alcohol for 1 week. Subjects will randomly be assigned to each eating pattern during the study period."
62637946|NCT03955510|OTHER|"Right-time eating / with alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
62637947|NCT03955510|OTHER|"Delayed-eating / no alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Subjects will be asked to not drink alcohol for 1 week."
62069914|NCT02770508|EXPERIMENTAL|Darunavir/ritonavir plus lamivudine|Darunavir/ritonavir 800/100 mg, 1 coformulated tablet QD and lamivudine 300 mg, 1 tablet QD
62069915|NCT02770508|ACTIVE_COMPARATOR|Darunavir/ritonavir plus emtricitabine/tenofovir(FTC/TFD)|Darunavir/ritonavir 800/100 mg1 coformulated tablet QD (FDC) plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
62287119|NCT02574104||Institution 8|"Florida Hospital for Children NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
62454371|NCT02837822|ACTIVE_COMPARATOR|Stimulation On|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn On during the experiment."
62454372|NCT01493908|ACTIVE_COMPARATOR|High price|
62454373|NCT01493908|ACTIVE_COMPARATOR|Low price|
62454374|NCT01493908|ACTIVE_COMPARATOR|Low price participants aware paying part|
62637948|NCT03955510|OTHER|"Delayed-eating / with alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
62637949|NCT02262650|ACTIVE_COMPARATOR|Telmisartan alone|
62637950|NCT02262650|EXPERIMENTAL|Telmisartan + Clopidogrel (concomitantly)|
62637951|NCT02262650|EXPERIMENTAL|Telmisartan + Clopidogrel (consecutively)|
62637952|NCT02262650|ACTIVE_COMPARATOR|Clopidogrel alone|
62637953|NCT02825914|ACTIVE_COMPARATOR|Casein glycomacropeptide (CGMP)|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of CGMP-protein-shake during 12 weeks.
62287120|NCT02574104||Institution 9|"Memorial Hospital of South Bend NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Pending"
62454375|NCT01493908|ACTIVE_COMPARATOR|No price|
62454376|NCT01493908|ACTIVE_COMPARATOR|Free of charge|
62454377|NCT03712722||rCDI|Adult patients with recurrect Clostridium difficile infection
62274653|NCT03961282|EXPERIMENTAL|Parkinson Disease Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
62454378|NCT04047095|EXPERIMENTAL|Intervention|"Normal daily meals plus one sachet three times a day of immune nutrients for five days after the surgery.~8 a.m. - normal meal plus one sachet immune nutrients~1 p.m - normal meal plus one sachet immune nutrients 6 p.m. - normal meal plus one sachet immune nutrients"
62637954|NCT02825914|PLACEBO_COMPARATOR|Placebo|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of placebo-shake consisting of milk powder during 12 weeks.
62637955|NCT02480738|EXPERIMENTAL|Mild cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
62637956|NCT02480738|EXPERIMENTAL|Subjective cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
62637957|NCT02480738|ACTIVE_COMPARATOR|Normal controls|Intervention: Computerized Cognitive Training Apparatus
62637958|NCT02552108|EXPERIMENTAL|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
62274654|NCT03961282|EXPERIMENTAL|Healthy Participant Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
62274655|NCT00556660|EXPERIMENTAL|1|SPECT imaging
62274656|NCT01762280|EXPERIMENTAL|Famitinib Malate|Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily
62274657|NCT02357498|ACTIVE_COMPARATOR|microscopic|Microscopic transsphenoidal surgery, including endoscopic-assisted approach (350 subjects)
62274658|NCT02357498|ACTIVE_COMPARATOR|endoscopic|Fully endoscopic transsphenoidal surgery (350 subjects)
62274659|NCT06107075|EXPERIMENTAL|Bioactive whey protein concentrate containing phospholipids|Bioactive whey protein concentrate containing phospholipids 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day.
62274660|NCT06107075|PLACEBO_COMPARATOR|Placebo|Placebo powder matched for macronutrient and caloric content containing pea protein around 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day.
62274661|NCT05838638|EXPERIMENTAL|Intervention|This intervention is a serious game which allows older adults under treatment for cancer to practice making self-care decisions for an avatar that is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with the research assistant about choices related to managing nausea and vomiting at home
62274662|NCT05838638|ACTIVE_COMPARATOR|Control|The control group will receive standard education related to managing nausea and vomiting and will have the opportunity to participate in the intervention at the end of the study
62274663|NCT05812989|ACTIVE_COMPARATOR|Social Engage Coaching|Social Engage Coaching involves psychoeducation on the importance of social connections for health as well as structured goal setting and problem solving for increasing social connectedness.
62274664|NCT05812989|ACTIVE_COMPARATOR|Social Engage Coaching with Connect for Caregivers|Social Engage Coaching involves psychoeducation on the importance of social connections for health as well as structured goal setting and problem solving, guided by use of a digitized prioritization tool, for increasing social connectedness.
62274665|NCT05112783|EXPERIMENTAL|Henan Tuoren Endotracheal Tube group|Uses the Henan Tuoren endotracheal tube to assist the nasal tracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
62274666|NCT05112783|EXPERIMENTAL|Smiths Portex Tracheal tubes group|Uses the Smiths Portex endotracheal tube to assist the nasal tracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
62454379|NCT04047095|ACTIVE_COMPARATOR|Control|"Normal daily meals. 8 a.m. - normal meal~1 p.m. - normal meal 6 p.m. - normal meal"
62637959|NCT02552108|NO_INTERVENTION|Waiting list|12 week wait (with assessments) before being transferred to the experimental condition.
62637960|NCT03578627|NO_INTERVENTION|Assessment-only|
62637961|NCT03578627|EXPERIMENTAL|Intervention|
62274667|NCT01717365||OTs|Occupational therapists
62287121|NCT02574104||Institution 10|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
62287122|NCT02574104||Institution 11|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
62287123|NCT02574104||Institution 12|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
62287124|NCT02574104||Institution 13|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
62454380|NCT02815969||Healthy volunteers|If no material of healthy volunteers of the SERT study can be used, then other matched volunteers are asked for a vena punction and urine collection
62069916|NCT05988164|EXPERIMENTAL|Eye mask Group|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier. Researchers or nurses will assist patients who cannot wear an eye mask at night. To measure patients' perception of sleep quality, we will use the Richard-Campbell Sleep Scale. The following morning, we will complete the post-test Richard-Campbell Sleep Scale to assess sleep quality.
62069917|NCT05988164|NO_INTERVENTION|control Group|The control group will undergo no intervention, and their sleep quality will be measured in the hospital setting using the Richard-Campbell Sleep Scale.
62069918|NCT02914379|EXPERIMENTAL|20mg [¹⁴C]-LY3337641|Participants received 20 milligrams (mg) oral dose of LY3337641 containing 120 microcuries of radioactivity.
62069919|NCT01112514|EXPERIMENTAL|ICG Injection|These participants underwent a colonoscopy after having an ICG injection.
62274668|NCT01789970|PLACEBO_COMPARATOR|Placebo|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets twice a day that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
62274669|NCT01789970|EXPERIMENTAL|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets twice a day at the dosage deemed successful for managing their pain during the titration period.
62454381|NCT02815969||Patients|Patients are asked for a vena punction and urine collection, if not already done because of medical care.
62461607|NCT00322465|EXPERIMENTAL|Azithromycin|Azithromycin 1 gram (gm) orally single dose (2 tablets at 500 milligrams (mg) each) plus doxycycline placebo twice daily for 7 days plus tinidazole placebo single dose.
62637962|NCT03207191|EXPERIMENTAL|F16IL2 + BI 836858|"Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.~Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months."
62637963|NCT04694001|OTHER|Hemiplegia due to Cerebrovascular Accident (CVA)|
62461608|NCT00322465|EXPERIMENTAL|Azithromycin + Tinidazole|Azithromycin 1 gm orally single dose (2 tablets at 500 mg each) plus doxycycline placebo twice daily for 7 days plus tinidazole single dose (4 tablets at 500 mg each).
62069920|NCT02317224|EXPERIMENTAL|"3-Hole subxiphorid and subcostal approach"|The patient were in the supine position with legs apart at about 45°, made a 2.0 cm incision below xiphoid process as the observation hole. Then made two 0.5cm operation holes along bilateral rib arch at midclavicular line, two trocars were inserted into the two holes under the guidance of B-ultrasound.After that, carbon dioxide was pumped into the anterior mediastinum, the pressure was maintained at 8 mmH2O, ultrasound scalpel and a grasping forceps were inserted through the operating ports respectively. Retrosternal space including bilateral lower poles of thymus, internal mammary arteries and phrenic nerves were exposed by both blunt and sharp dissection. Then ultrasound scalpel were used to separate the thymus and its surrounding fat tissue, cut off thymic veins by ultrasound scalpel.For patients with myasthenia gravis, bilateral mediastinal pleurae and the affected adipose tissues had been thoroughly removed.
62069921|NCT02317224|EXPERIMENTAL|Trans sternal approach|
62069922|NCT02317224|EXPERIMENTAL|VATS approach|
62069923|NCT03415958||Open reduction internal fixation|Patients with displaced midshaft clavicle fractures will be offered operative treatment which involves open reduction and internal fixation.
62069924|NCT03415958||Conservative care|Patients will be treated in a sling for the acute phase of two weeks with progressive physiotherapy.
62069925|NCT06121960|EXPERIMENTAL|Interventionnal|Measure DEP, DEM25, DEM 50, DEM 75, FVC, Inspiratory capacity, SpO2, Respiratory rate before, during, or after the state of self-induced cognitive trance Evolution of the feeling of self-efficacy, assessed by questionnaire.
62069926|NCT04658186|EXPERIMENTAL|UCB0599 High Dose Arm|Participants will be randomized to receive a predefined high dosage of UCB0599 during the Treatment Period.
62069927|NCT04658186|PLACEBO_COMPARATOR|Placebo Arm|Participants will be randomized to receive a predefined dosage of Placebo during the Treatment Period.
62069928|NCT04658186|EXPERIMENTAL|UCB0599 Low Dose Arm|Participants will be randomized to receive a predefined low dosage of UCB0599 during the Treatment Period.
62069929|NCT01025934|ACTIVE_COMPARATOR|7 days|
62069930|NCT01025934|ACTIVE_COMPARATOR|20 days|
62069931|NCT01025934|SHAM_COMPARATOR|sham|
62069932|NCT00580996|EXPERIMENTAL|1|16 oz water in AM
62069933|NCT00580996|ACTIVE_COMPARATOR|2|water 1 oz in AM
62069934|NCT03855410|EXPERIMENTAL|S4E App intervention|Participants in the S4E group will receive the tobacco modules via iPads in a private room. The intervention will last approximately 20 minutes. Content includes the theoretically driven components of S4E: (a)Storytelling scenarios, (b) an introduction video, tobacco use knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent tobacco use, (e) clinician-youth communication, and (f) highlighting prevention principles. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
62069935|NCT03855410|EXPERIMENTAL|Attention-Matched Control|Participants in the Attention-Matched Control group will receive a portable document format (PDF) version of the tobacco module content, an enhancement to the care they would receive should they not join the study. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
62069936|NCT03860038|EXPERIMENTAL|TJ202|
62069937|NCT06163352|EXPERIMENTAL|Patients with pressure injury|The intervention is vasopressor infusion. In this am, 64 surgical and medical patients treated with vasopressor agents in the intensive care unit and developed pressure injury were included.
62069938|NCT06163352|ACTIVE_COMPARATOR|Patients without pressure injury|The intervention is vasopressor infusion. In this arm, 84 surgical and medical patients treated with vasopressor agents in the intensive care unit and did not develop pressure injury were included.
62274670|NCT00150592|EXPERIMENTAL|SPD503 (Guanfacine HCl)|
62069939|NCT04263298|EXPERIMENTAL|Fulvestrant Group|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
62069940|NCT04263298|ACTIVE_COMPARATOR|Capecitabine Group|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
62069941|NCT02289989|ACTIVE_COMPARATOR|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
62069942|NCT02289989|EXPERIMENTAL|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
62069943|NCT02654093|EXPERIMENTAL|Group A|A → B → C / A: Cholecalciferol, B: Raloxifene, C: Cholecalciferol+Raloxifene
62069944|NCT02654093|EXPERIMENTAL|Group B|A → C → B
62069945|NCT02654093|EXPERIMENTAL|Group C|B → A → C
62274671|NCT00150592|PLACEBO_COMPARATOR|Placebo|
62274672|NCT00293579|EXPERIMENTAL|Pemetrexed|pemetrexed 500 mg/m2 administered iv, every three weeks, for 6 cycles
62274673|NCT03726684|EXPERIMENTAL|Coding strategy for cochlear implants|Measure neural responses of cochlear implant recipient Use measured values of refractoriness, spread of excitation and facilitation as parameters for a bioinspired coding strategy perform listening tests to compare new coding strategy with standard clinical coding strategy
62274674|NCT00229307|ACTIVE_COMPARATOR|1|
62274675|NCT00229307|ACTIVE_COMPARATOR|2|
62274676|NCT04609189|EXPERIMENTAL|Pearlium®/EffectiCal®|
62274677|NCT04609189|ACTIVE_COMPARATOR|Calcium Carbonate/Vitamin D3|
62274678|NCT04192578|EXPERIMENTAL|Unilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62274679|NCT04192578|EXPERIMENTAL|Bilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62274680|NCT04192578|EXPERIMENTAL|Unilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62069946|NCT02654093|EXPERIMENTAL|Group D|B → C → A
62069947|NCT02654093|EXPERIMENTAL|Group E|C → A → B
62069948|NCT02654093|EXPERIMENTAL|Group F|C → B → A
62069949|NCT00983489|ACTIVE_COMPARATOR|counselling|counselling: Breast feeding counselling will be done to mothers
62069950|NCT00983489|ACTIVE_COMPARATOR|Video demonstration|Video demonstration to mothers on the advantages of exclusive breast feeding
62069951|NCT00983489|NO_INTERVENTION|Standard Care|Standard care includes the routine care provided to the neonates as per hospital protocol
62274681|NCT04192578|EXPERIMENTAL|Bilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62454382|NCT05984771|ACTIVE_COMPARATOR|Active group|10-element combination tablet (n=30) Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet for 6 months
62454383|NCT05984771|PLACEBO_COMPARATOR|Placebo|usual care
62274682|NCT04192578|EXPERIMENTAL|Unilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62287125|NCT02574104||Institution 14|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
62454384|NCT03378700|EXPERIMENTAL|Brief Hope Intervention Group|In addition to the pre-dialysis educational programme on self-care and treatment options for ESRF patients as per the control group, brief hope intervention will be offered: a four-weeks individual intervention. Two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between. A booklet modified from the goal worksheet in Lopez et al. (2000) will be prepared for the participants for reviewing their planned goals, recording achieved targets and successful experiences.
62461609|NCT01538251|EXPERIMENTAL|Propionyl-L-carnitine|modified release tablets 500 mg
62069952|NCT02890238|ACTIVE_COMPARATOR|sildenafil citrate|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd - 7th day of the cycle and sildenafil citrate 20mg tab from 7th-11th day of the same cycle orally 3times/day
62069953|NCT02890238|PLACEBO_COMPARATOR|placebo group|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd- 7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day
62069954|NCT01671748|ACTIVE_COMPARATOR|Standard Care|Standard treatment for VLUs is administered once a week, i.e. compression bandaging and non-adherent dressing, with debridement if required.
62069955|NCT01671748|EXPERIMENTAL|MIST and Standard Care|MIST ultrasound therapy is applied for between 3 and 12 minutes (depending on wound size) 3 times a week in combination with standard treatment for VLUs of compression bandaging and non-adherent dressing change 3 times a week, with debridement as required.
62069956|NCT05544552|EXPERIMENTAL|Phase 1 Part A - dose escalation|TYRA-300 taken once daily by mouth in 28-day cycles starting at 10 mg daily.
62069957|NCT05544552|EXPERIMENTAL|Phase 1 Part B - dose expansion|TYRA-300 taken once or twice daily by mouth in 28-day cycles.
62069958|NCT05544552|EXPERIMENTAL|Phase 2|TYRA-300 taken once or twice daily by mouth in 28-day cycles at doses determined during Phase 1.
62069959|NCT00634985|EXPERIMENTAL|A|
62461610|NCT01538251|PLACEBO_COMPARATOR|Placebo|Modified release tablet 500 mg
62069960|NCT01225913|OTHER|Asthma observational study arm|Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg/salmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg/formoterol 4.5mcg bid)or Dulera 100-200mcg mometasone/5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.
62637964|NCT00577772|ACTIVE_COMPARATOR|Healthy Participants|Healthy Participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
62069961|NCT01129531|EXPERIMENTAL|AGN-214868 3.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.
62069962|NCT01129531|EXPERIMENTAL|AGN-214868 16.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.
62274683|NCT04192578|EXPERIMENTAL|Bilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62274684|NCT04192578|EXPERIMENTAL|Unilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62274685|NCT04192578|EXPERIMENTAL|Bilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
62652966|NCT00942136|EXPERIMENTAL|Cohort 1, Sequence 1|Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
62274686|NCT00935558|EXPERIMENTAL|Aromatase inhibitor and DC vaccination|the HLA-A2 positive patients will be treated with AI, DC vaccines, Zadaxin and IL-2
62274687|NCT00935558|ACTIVE_COMPARATOR|Aromatase inhibitor|the HLA-A2 negative patients will receive AI only
62069963|NCT01129531|PLACEBO_COMPARATOR|Placebo|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
62069964|NCT03879603|EXPERIMENTAL|Group 1: 6 mcg WEVEE vaccine|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
62069965|NCT03879603|EXPERIMENTAL|Group 2: 6 mcg WEVEE vaccine + alum|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
62069966|NCT03879603|EXPERIMENTAL|Group 3: 30 mcg WEVEE vaccine|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
62069967|NCT03879603|EXPERIMENTAL|Group 4: 30 mcg WEVEE vaccine + alum|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
62069968|NCT03879603|EXPERIMENTAL|Group 5: 60 mcg WEVEE vaccine|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
62069969|NCT03879603|EXPERIMENTAL|Group 6: 60 mcg WEVEE vaccine + alum|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
62069970|NCT00596024|EXPERIMENTAL|1|Daily Lutein/zeaxanthin supplementation with a meal
62069971|NCT00596024|PLACEBO_COMPARATOR|2|
62069972|NCT00697008||GERD patients|Patients with typical GERD symptoms
62069973|NCT06268444|EXPERIMENTAL|New born|
62274688|NCT01898065|EXPERIMENTAL|PET imaging, 18 F-miso|Single Arm study
62274689|NCT01507272|EXPERIMENTAL|NNC 90-1170 (liraglutide)|
62069974|NCT05168813|EXPERIMENTAL|Group 1|This arm will assess the relative vaccine efficacy (RVE) of a 3- vs. 2-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed, symptomatic COVID-19 in adult people living with HIV who are SARS-CoV-2 negative at baseline.
62069975|NCT05168813|EXPERIMENTAL|Group 2|This arm will assess the relative vaccine efficacy (RVE) of a 2- vs. 1-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed symptomatic COVID-19 in adult people living with HIV who are SARS-CoV-2 positive at baseline.
62274690|NCT01507272|PLACEBO_COMPARATOR|Placebo|
62274691|NCT00699907|ACTIVE_COMPARATOR|Treatment Arm|Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
62274692|NCT00699907|NO_INTERVENTION|High Risk Arm|High risk patients underwent risk-reducing salpingo-oophorectomy.
62454385|NCT03378700|ACTIVE_COMPARATOR|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
62069976|NCT05168813|EXPERIMENTAL|Group 3|This arm will assess the relative vaccine efficacy (RVE) of a 3- vs. 2-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed, symptomatic COVID-19 in HIV negative adults who are SARS-CoV-2 negative at baseline.
62069977|NCT05168813|EXPERIMENTAL|Group 4|This arm will assess the relative vaccine efficacy (RVE) of a 2- vs. 1-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed symptomatic COVID-19 in HIV negative adults who are SARSCoV-2 positive at baseline.
62274693|NCT00699907|NO_INTERVENTION|Low Risk Arm|Low risk patients underwent salpingo-oophorectomy for a medical indication.
62274694|NCT01975168|EXPERIMENTAL|Group 1|arrange laser acupuncture intervention for 12 weeks, then cross over to sham laser acupuncture intervention for 12 weeks
62274695|NCT01975168|SHAM_COMPARATOR|Group 2|arrange sham laser acupuncture for 12 weeks, then cross over to laser acupuncture for 12 weeks
62274696|NCT01353703|EXPERIMENTAL|INFANRIX HEXA 6-10-14 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.
62454386|NCT03209570|EXPERIMENTAL|TENA Identifi with sensor wear data|All individuals in this arm will receive care planning using TENA Identifi sensor wear data
62274697|NCT01353703|ACTIVE_COMPARATOR|INFANRIX HEXA 2-4-6 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.
62637965|NCT00577772|ACTIVE_COMPARATOR|Symptomatic Participants|"Subjects with symptoms suggestive of small bowel bacterial overgrowth (SBBO) (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months will be divided into 2 groups based on the results of their previous testing for SBBO (5 SBBO positive patients, 5 SBBO negative patients).~The symptomatic participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.~After the capsule has been demonstrated to be passed from the subject, the subjects with SBBO present will then enter into an open-label treatment using Rifaximin (400 mg PO TID) for 7 days."
62637966|NCT04253158|EXPERIMENTAL|Educational standard|The aim of this arm is to increase knowledge about alcohol and other drug use.
62274698|NCT04775277||cases|pregnant female with idiopathic pulmonary fibrosis
62454387|NCT03209570|ACTIVE_COMPARATOR|TENA Identifi without sensor wear data|All individuals in this arm will receive care planning without using TENA Identifi sensor wear data
62454388|NCT00824265|EXPERIMENTAL|Ofatumumab, Fludarabine, Cyclophosphamide|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
62637967|NCT04253158|EXPERIMENTAL|Educational standard and Harm prevention|The aim of this arm is to increase knowledge about alcohol and other drug use and increase intentions for the use of harm prevention strategies.
62637968|NCT04253158|EXPERIMENTAL|Educational standard and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use and shift alcohol-related expectancies.
62274699|NCT04775277||control group|pregnant female with bronchial asthma
62274700|NCT01262846|ACTIVE_COMPARATOR|Fluzone SD|Fluzone® Standard dose
62274701|NCT01262846|EXPERIMENTAL|Fluzone® High dose|Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
62287126|NCT02574104||Institution 15|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
62454389|NCT00824265|ACTIVE_COMPARATOR|Fludarabine, Cyclophosphamide|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
62461611|NCT02562365|EXPERIMENTAL|A: three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
62461612|NCT02562365|NO_INTERVENTION|B: Follow-up|No interevention
62637969|NCT04253158|EXPERIMENTAL|Expectancies and Harm prevention|The aim of this arm is shift alcohol-related expectancies and increase intentions to use harm prevention strategies.
62637970|NCT04253158|EXPERIMENTAL|Educational standard and Normative perceptions|The aim of this arm is to increase knowledge about alcohol and other drug use and correct erroneous alcohol-related normative perceptions.
62637971|NCT04253158|EXPERIMENTAL|Normative perceptions and Harm prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions and increase intentions to use harm prevention strategies.
62274702|NCT06095739|EXPERIMENTAL|DA-OTC-002|A 1mL topical application of DA-OTC-002 solution was applied to a 10cm x 10xm target area of the left side of the scalp of each subject.
62274703|NCT00353418|EXPERIMENTAL|PEG-IFN Alfa-2a 180 μg + Ribavirin 800 mg|
62069978|NCT00946868||Intermittent claudication patients|Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
62274704|NCT00353418|ACTIVE_COMPARATOR|PEG-IFN Alfa-2a 180 μg + Ribavirin 1000 or 1200 mg|
62274705|NCT02979431|EXPERIMENTAL|ALX-0171 3.0 mg/kg|Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days
62274706|NCT02979431|EXPERIMENTAL|ALX-0171 6.0 mg/kg|Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days
62274707|NCT02979431|EXPERIMENTAL|ALX-0171 Dose 9.0mg/kg|Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days
62637972|NCT04253158|EXPERIMENTAL|Educational standard, Normative Perceptions, and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use, correct erroneous alcohol-related normative perceptions, and shift alcohol-related expectancies.
62637973|NCT04253158|EXPERIMENTAL|Normative perceptions, Expectancies, and Harm Prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions, shift alcohol-related expectancies, and increase intentions to use harm prevention strategies.
62637974|NCT03871036|EXPERIMENTAL|Tremelimumab 75 (R1)|"Run-in phase-1 (R1): n=3 patients will be treated with:~* paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~* tremelimumab 75 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
62637975|NCT03871036|EXPERIMENTAL|Tremelimumab 225 (R2)|"Run-in phase-2 (R2): n=3 patients will be treated with:~* paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~* tremelimumab 225 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
62454390|NCT02363790|OTHER|Bridging LVHR|"Laparoscopic ventral hernia repair without closure of central defect (bridging repair)~Upon completion of the lysis of adhesions, the margins of the hernia defect will be measured and marked. The hernia defect size will be measured with the abdomen completely desufflated and insufflated at 15 mm Hg externally (on the skin).~A coated mesh with at least four cm of overlap on all sides will be placed. Mesh will be secured with at least four but no more than eight trans-fascial sutures. Titanium tacks will be placed in a double crown technique where tacks are placed every 1 cm on the periphery and every 3 cm along the fascial edge (bridged or closed)."
62637976|NCT03871036|EXPERIMENTAL|Tremelimumab vs Tremelimumab+Durvalumab (R3)|"Run-in phase-3 (R3): n=2 x 3 patients will be randomized over 2 arms:~* paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~* tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45~OR~* paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~* tremelimumab 75 mg on day 1 of cycles 2-5~* durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
62637977|NCT03871036|EXPERIMENTAL|Tremelimumab 300 (R4)|"Run-in phase-4 (R4): n=3 patients will be treated with:~* paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~* tremelimumab 300 mg once on day 1 of cycle 2~* durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
62461613|NCT06328348|EXPERIMENTAL|supplementation group|
62637978|NCT03871036|EXPERIMENTAL|Tremelimumab 750 (A)|"Arm A:~* paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~* tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
62637979|NCT03871036|EXPERIMENTAL|Tremelimumab+Durvalumab (B)|"Arm B:~* paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~* tremelimumab 300 mg once on day 1 of cycle 2~* durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
62637980|NCT03871036|EXPERIMENTAL|Tremelimumab without paclitaxel (C)|"Arm C (control arm):~• tremelimumab 750 mg on day 1 of cycles 1-5 and then every 12 weeks until week 41"
62637981|NCT03664115|EXPERIMENTAL|Itraconazole Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles + itraconazole 200 mg oral tablet daily, on a 21-day cycle.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
62637982|NCT03664115|ACTIVE_COMPARATOR|Control Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
62069979|NCT03457285|EXPERIMENTAL|Physiotherapy via the Salaso Apllication Intervention|"All participants' physiotherapy- prescribed exercise programmes will be monitored via the Salaso application. Telehealth appointments will occur monthly and modifications to exercises will be made as required.~This will continue for the 6-month duration of the intervention."
62069980|NCT01547520|EXPERIMENTAL|meperidine|25 mg of meperidine is injected intramuscularly before EGD
62069981|NCT01547520|PLACEBO_COMPARATOR|placebo|placebo was given intramuscularly before EGD
62274708|NCT02979431|PLACEBO_COMPARATOR|Placebo|Inhalation of Placebo once daily for 3 consecutive days
62274709|NCT01056250|OTHER|SILS cholangiography|Performing cholangiography in all patients undergoing SILS cholecystectomy.
62461614|NCT06328348|PLACEBO_COMPARATOR|placebo group|
62461615|NCT04173754||MSAT Group|"The MSAT group who are treated with korean medical treatment including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
62274710|NCT04732286|EXPERIMENTAL|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62274711|NCT02117765|EXPERIMENTAL|Treatment|"Four cohorts of 5 subjects will be recruited:~Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks.~Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks.~Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks.~Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks."
62274712|NCT00809107|EXPERIMENTAL|1|HCG GROUP
62274713|NCT00809107|NO_INTERVENTION|2|LH pick
62287127|NCT02863341|EXPERIMENTAL|naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
62287128|NCT02863341|NO_INTERVENTION|naive Wait-list Control arm|
62274714|NCT04606459|ACTIVE_COMPARATOR|Optimal medical therapy|"Optimal medical therapy consisting of acetyl salicylic acid, statins, beta-blockers, calcium channel-antagonists, ranolazine will be administered at the discretion of the physician as recommended by the most recent European Society of Cardiology (ESC) guidelines.~Long-acting nitrates will not be administered unless for patients with fractional flow reserve (FFR)\<0.8 or with previously reported good response. Short-acting nitrates may be administered in patients in whom concomitant epicardial spasm is suspected, but they have no documented effect on microvascular angina."
62461616|NCT04173754||Control Group|"The control group who are treated with Korean medical treatment not including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
62069982|NCT02014090|ACTIVE_COMPARATOR|half supine bicycle Exercise|60 minutes of half supine bicycle exercise with submaximal workload
62274715|NCT04606459|EXPERIMENTAL|Coronary sinus reducer|The device being studied is the Neovasc Reducer™ System. Each patient in the Reducer group will be implanted with a single Reducer according to the instructions for use.
62461617|NCT01488630|NO_INTERVENTION|Treatment as Usual|Chart review only.
62637983|NCT06234540|EXPERIMENTAL|aPRP 1|a-PRP intrauterine instillation on Menstruation Cycle Day 8 during frozen thaw cycle procedure
62637984|NCT06234540|EXPERIMENTAL|aPRP 2|a-PRP intrauterine instillation on Menstruation Cycle Day 8 and Day 10 during frozen thaw cycle procedure
62637985|NCT06234540|EXPERIMENTAL|Controlled|Standard treatment of frozen thaw cycle
62637986|NCT02955303|EXPERIMENTAL|TECH protocol|Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
62637987|NCT00922870|ACTIVE_COMPARATOR|Standard treatment|
62461618|NCT01488630|EXPERIMENTAL|STaRS|Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
62637988|NCT00922870|EXPERIMENTAL|Cascade|
62637989|NCT01705977|PLACEBO_COMPARATOR|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
62637990|NCT01705977|EXPERIMENTAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
62069983|NCT02014090|ACTIVE_COMPARATOR|ECP|90 minutes of ECP
62069984|NCT04538924|OTHER|MINOCA (group I) - conventional MI treatment|Traditional MI treatment with optimal doses of statin, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), beta-blockers (BB) and dual antiplatelet therapy (DAPT).
62069985|NCT04538924|OTHER|MINOCA (group II)|Treatment with a low-dose statin and ACEI/ARB. In case of vasospasm, calcium channel blockers.
62274716|NCT03187769|EXPERIMENTAL|ALKS 3831|Coated bilayer tablet
62274717|NCT03187769|ACTIVE_COMPARATOR|Olanzapine|Coated bilayer tablet
62069986|NCT05147519||Step 1|Step 1 will enroll participants aged 14-55 years who are vulnerable to contracting HIV. They will be evaluated every 12 weeks for HIV and other sexually transmitted infections (STIs).
62069987|NCT05147519||Step 2|Participants who are diagnosed with HIV will proceed to Step 2, with evaluation of viral load and other HIV-related tests every four weeks for 12 weeks and then every 12 weeks for a total of 48 weeks.
62274718|NCT00911989|OTHER|Transvaginal Sleeve Gastrectomy|Transvaginal Sleeve Gastrectomy using Steerable Flex Trocar (SFT) for transvaginal endoscope placement (endoscopic visualization)
62274719|NCT04674631||Case group 1|52 patients with score of 12 or more on Leeds assessment of neuropathic symptoms and signs (LANSS) questionnaire will be included in the neuropathic pain group.
62637991|NCT04608045|EXPERIMENTAL|CPX-POM, 900 mg/m2 by 20 minute IV infusion|
62274720|NCT04674631||Case group 2|46 patients with scores less than 12 on LANSS will be included in the group without neuropathic pain.
62274721|NCT03839459|EXPERIMENTAL|Denosumab|
62454391|NCT02363790|OTHER|LVHR PFC|Ventral hernia repairs in the primary fascial group will be performed similarly except prior to placement of the mesh, the defect will be closed. After the defect size is measured, the mesh will be chosen based upon the unclosed defect size and size will not be adjusted. The hernia defect will be closed as described previously 9,10 with 0-prolene transfascial sutures placed every 1-2 cm. The two caudal-most and cranial-most sutures will be placed. The abdomen will be desufflated and these sutures will be secured. The abdomen will be reinsufflated to 15 mm Hg and the defect progressively closed. Upon completion of fascial closure, the mesh will be placed in the standard fashion as describe above. The lateral overlap will be increased due to the fascial closure.
62637992|NCT04809441|EXPERIMENTAL|Weight loss group|Participants were rigorously evaluated by the same endocrine doctor and podiatrist at baseline (Session 1) and at the end of the study after weight loss intervention (Session 2), when each participant had lost between 11-12% of its corporal weight. Therefore, we obtained 2 weight related with the two sessions: Session 1 - Weight 1; Session 2 - Weight 2.
62637993|NCT05875740||septic patients|patients with sepsis defined based on Sepsis 3.0 criteria within 24 hours after admission
62637994|NCT05875740||non-septic patients|patients without sepsis defined based on Sepsis 3.0 criteria within 24 hours after admission
62069988|NCT05147519||Step 3|Participants who achieve and maintain viral suppression in Step 2 will proceed to Step 3 for continued HIV monitoring every 24 weeks to document maintenance of viral suppression and maintain engagement with the study site for potential future recruitment into interventional studies, including clinical trials of novel strategies to achieve HIV remission.
62069989|NCT05083260|EXPERIMENTAL|NE3107|orally administered NE3107 20 mg twice daily (BID)
62069990|NCT05083260|PLACEBO_COMPARATOR|placebo|orally administered placebo, twice daily
62069991|NCT01280318|OTHER|1|patients with operable head and neck squamous cell carcinoma
62069992|NCT01280318|OTHER|2|patients treated by neck ansd head surgery for a non-oncological disease
62274722|NCT03506542|EXPERIMENTAL|Ologen (OLO)|Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy
62274723|NCT03506542|ACTIVE_COMPARATOR|Mitomycin C (MMC)|Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)
62274724|NCT03665142|EXPERIMENTAL|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm\*5m) is used. 36 participants were taped for the TTH.50-mm wide and 0.5-mm thick KT was applied to the upper trapezius muscle with one I-shaped tape. The tape was measured from the acromion to the hairline at the back, and the upper trapezius fibers were extended in the extended position, ie the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation position.
62274725|NCT03665142|PLACEBO_COMPARATOR|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
62274726|NCT01119456|EXPERIMENTAL|IMC-RON8|A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).
62274727|NCT05261620|EXPERIMENTAL|SoC + WISE|Candidates for surgery and habitual consumers of alcohol-containing beverages (7-21 alcohol-containing beverages per week) with a body mass index between 18 and 30 kg/m2. Subjects assigned to the Experimental Arm will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men.
62274728|NCT05261620|NO_INTERVENTION|SoC|Control Arm subjects adhere to diet free of any alcohol-containing beverages, as normally recommended by surgeons in their clinical practice
62637995|NCT05875740||healthy control group|healthy adults
62069993|NCT01280318|EXPERIMENTAL|3|patients treated before surgery with 3 doses of neoadjuvant cetuximab
62274729|NCT06282120||Study Arms|Drug: Irinotecan Hydrochloride Liposome Injection The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
62274730|NCT04797845|EXPERIMENTAL|telemonitoring of non invasive ventilation at home|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months. Ventilation machines make it possible to carry out remote monitoring, with the help of healthcare providers.
62274731|NCT00883714|EXPERIMENTAL|Supervised exercise|
62637996|NCT02634073|EXPERIMENTAL|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
62069994|NCT02058290|ACTIVE_COMPARATOR|IV Morphine Sulfate or Sponsor-approved Equivalent|Standard of Care (SOC)
62069995|NCT02058290|EXPERIMENTAL|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
62637997|NCT02634073|EXPERIMENTAL|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
62637998|NCT02634073|EXPERIMENTAL|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
62637999|NCT02634073|EXPERIMENTAL|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
62069996|NCT00539643|ACTIVE_COMPARATOR|Bead Arm|Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.
62069997|NCT00539643|ACTIVE_COMPARATOR|Bead + Dox Arm|Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
62069998|NCT01880372|EXPERIMENTAL|Alpha Lipoic Acid Assignment Group|Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
62069999|NCT01880372|NO_INTERVENTION|Alpha Lipoic Acid Control Group|The control group will follow routine care alone.
62070000|NCT01161693|NO_INTERVENTION|Standard pillow under head|Control (C) - Standard pillow under head (figure 1) as is the usual practice at BC Women's Hospital
62070001|NCT01161693|ACTIVE_COMPARATOR|Troop Elevation Pillow in horizontal position-HERP|TROOP® elevation pillow (designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table)
62070002|NCT01161693|ACTIVE_COMPARATOR|Troop Elevation Pillow in horizontal position-HERP-H|Operating table tilted in Trendelenberg position so angle of Troop pillow is parallel to floor (figure 3) until establishment of adequate block and then the bed levelled to horizontal i.e. to the same position as group (HERP) (figure 2)
62274732|NCT00883714|ACTIVE_COMPARATOR|Control group|
62274733|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
62274734|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
62274735|NCT05813509|EXPERIMENTAL|Platinum resistant ovarian cancer|Advanced-stage epithelial ovarian cancer (stage III or above) that has received more than 2 lines of chemotherapy and recurred within 6 months after the chemotherapy is stopped;
62274736|NCT03294018||Bradycardia during sugammadex administration|Recording any heart rate changes during planned administration of sugammadex.
62274737|NCT01780883|PLACEBO_COMPARATOR|Placebo|5 tablets of placebo once a day, an hour before falling asleep, for 6 weeks.
62070003|NCT03001232|EXPERIMENTAL|Movement-oriented Dementia Care|The experimental group received movement-oriented dementia care for a period of twelve months.Movement-oriented dementia care is a multidisciplinary approach in which all involved disciplines focus on stimulating physical activity and independence as much as possible. This way physical activity is stimulated at all times for the participants.
62638000|NCT00991081|ACTIVE_COMPARATOR|Standard treatment|"* Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling.~* A self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail~* A standard 8-week course of genetically-tailored pharmacotherapy~  * Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~ * Participants with the A2 allele (CC) were assigned to receive bupropion"
62070004|NCT03001232|NO_INTERVENTION|Care as usual|The control group received care as usual
62070005|NCT06004596|OTHER|Reference Range determination|13C-Spirulina Gastric Emptying Breath Test (GEBT) administered to healthy participants
62070006|NCT06004596|ACTIVE_COMPARATOR|Biological Variability|13C-Spirulina GEBT administered a second time to subset of participants to determine pediatric biological variability.
62070007|NCT04373915|NO_INTERVENTION|Standard Bedside Rounding|
62070008|NCT04373915|EXPERIMENTAL|Remote Bedside Rounding|Parents of infants on one care team will have the opportunity to participate in rounds via secure remote video software.
62070009|NCT05847322|OTHER|Contact|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A 3 day course of Azithromycin will be administered on week 6 if colonised.
62070010|NCT05847322|EXPERIMENTAL|Challenge|Challenge volunteers will receive a nasal inoculation containing Bordetella pertussis on Day 0. They will return to the Clinical Research Facility weekly to monitor safety, colonisation and immune responses. A 3 day course of Azithromycin will be administered on week 6 if colonised.
62070011|NCT01040767|ACTIVE_COMPARATOR|Class|
62652967|NCT00942136|EXPERIMENTAL|Cohort 2|Subjects will receive a single dose of either GSK1349572 250 mg or placebo as a suspension. Subjects will have a screening visit within 30 days prior to the dose of study medication and a follow up visit 7-14 days after the dose of study medication.
62274738|NCT01780883|EXPERIMENTAL|2 mg melatonin|1 tablet of 2mg melatonin and 4 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
62274739|NCT01780883|EXPERIMENTAL|4 mg melatonin|2 tablets of 2mg melatonin and 3 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
62274740|NCT01780883|EXPERIMENTAL|10 mg melatonin|5 tablets of 2mg melatonin once a day, an hour before falling asleep, for 6 weeks.
62638001|NCT00991081|EXPERIMENTAL|Genetic feedback plus standard treatment|"In addition to the standard treatment, participants in this arm received the following interventions:~* Genetic feedback, verbal - During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment~* Genetic feedback, printed - After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype"
62638002|NCT01204203|EXPERIMENTAL|Zometa|Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.
62638003|NCT00324922|ACTIVE_COMPARATOR|Trimethoprim-sulfamethoxazole|trimethoprim-sulfamethoxazole, double strength, 2-3 tabs twice a day by mouth for 6-12 weeks
62070012|NCT01040767|ACTIVE_COMPARATOR|Web|
62070013|NCT01040767|NO_INTERVENTION|Control|
62638004|NCT00324922|ACTIVE_COMPARATOR|Vancomycin|Vancomycin, dosage to be determined by serum levels, medication provided by vein and duration 6-12 weeks
62274741|NCT01848535|PLACEBO_COMPARATOR|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
62274742|NCT01848535|PLACEBO_COMPARATOR|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
62274743|NCT05771298|OTHER|Potassium Titanyle Phosphate (KTP) Laser|Subjects will be treated with a KTP laser in 1 - 3 sessions at intervals of 4 - 6 weeks.
62070014|NCT06296914|EXPERIMENTAL|POTSapp|Participants will receive a smart watch and Bluetooth blood pressure monitor and attend a virtual Zoom meeting to learn how to install and use the app with devices.
62274744|NCT05771298|OTHER|Pulsed Dye Laser|Subjects will be treated with a PDL in 1 - 3 sessions at intervals of 4 - 6 weeks.
62274745|NCT01665118|EXPERIMENTAL|Treated Thigh|Trusculpt (Radio Frequency) Device
62274746|NCT01665118|NO_INTERVENTION|Untreated Contra-lateral Thigh|To be used as the self control in this split body study.
62274747|NCT03563937||Phenprocoumon|Patients with NVAF who initiated the treatment of Phenprocoumon.
62274748|NCT03563937||Apixaban|Patients with NVAF who initiated the treatment of Apixaban.
62274749|NCT03563937||Rivaroxaban (Xarelto, BAY59-7939)|Patients with NVAF who initiated the treatment of Rivaroxaban.
62638005|NCT03541291|EXPERIMENTAL|SMART-SYNC LM03|All participants
62274750|NCT03563937||Edoxaban|Patients with NVAF who initiated the treatment of Edoxaban.
62274751|NCT00667615|EXPERIMENTAL|1|vorinostat in combination with cyclophosphamide, etoposide,prednisone and rituximab,peg-filgrastim or filgrastim
62274752|NCT04057625|OTHER|lung ultrasound|using lung ultrasound in diagnosis and follow up of vap measuring the largest area of consolidation according to intercostal space and the direction of the probe
62274753|NCT01571115|ACTIVE_COMPARATOR|Insomnia Stretching Exercise|This group will realize stretching exercise
62274754|NCT01571115|NO_INTERVENTION|Control|This group will not realize any type of intervention.
62274755|NCT01571115|ACTIVE_COMPARATOR|Insomnia Physical Exercise|This group will realize resistance physical exercise
62274756|NCT06345300|EXPERIMENTAL|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab
62274757|NCT06345300|EXPERIMENTAL|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
62638006|NCT04804176|ACTIVE_COMPARATOR|5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation|The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.
62274758|NCT03622099||The study group|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
62274759|NCT03279003|EXPERIMENTAL|Light-emitting diode therapy|Exposure to LED light
62274760|NCT03093038|ACTIVE_COMPARATOR|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem and the Delta-TT cup with polyethylene insert
62274761|NCT03093038|EXPERIMENTAL|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem and the Delta-TT cup with ceramic insert
62274762|NCT03093038|EXPERIMENTAL|C2 stem & Delta-TT cup + ceramic|C2 femoral stem and the Delta-TT cup with ceramic insert
62274763|NCT05495893|EXPERIMENTAL|Cyclophosphamide|Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day
62274764|NCT05495893|EXPERIMENTAL|Mycophenolate mofetil|Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day
62274765|NCT05066256|EXPERIMENTAL|Fluid responsive test|Measure cardiac output, inferior vena cava (IVC) diameter variation and LV diastolic function (E/e') baseline Fluid challenge Measure cardiac output, IVC diameter variation and LV diastolic function (E/e') after fluid challenge
62274766|NCT06431061|EXPERIMENTAL|Lens A (omafilcon B)|All participants will wear lens A for 15 minutes (Period 1).
62274767|NCT06431061|EXPERIMENTAL|Lens B (comfilcon A)|All participants will wear lens B for 15 minutes (Period 2).
62274768|NCT03847142|EXPERIMENTAL|ASTHMAXcel arm|The ASTHMAXcel arm represents the study intervention, which is a patient-facing mobile application for adult patients with asthma.
62274769|NCT03847142|ACTIVE_COMPARATOR|Usual care arm|This arm represents usual care delivered in the outpatient primary care setting at the study sites.
62274770|NCT03550066|EXPERIMENTAL|Values affirmation|In the values affirmation condition, the health outreach message contained a prompt asking participants to reflect on important personal values.
62638007|NCT04804176|ACTIVE_COMPARATOR|GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation|The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS
62274771|NCT03550066|ACTIVE_COMPARATOR|No affirmation|"In the no affirmation condition, the health outreach message appeared alone, with no values affirmation."
62287129|NCT02863341|EXPERIMENTAL|non-naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
62638008|NCT04804176|SHAM_COMPARATOR|the control group|The instrument is not working, only in exhaust mode.
62070015|NCT06296914|ACTIVE_COMPARATOR|Waitlist Control|Participants will receive an emailed information sheet containing online support information on POTS. After the initial 4- month period is over, participants will receive a smart watch and Bluetooth blood pressure monitor and attend a virtual Zoom meeting to learn how to install and use the app with devices.
62070016|NCT03176589|SHAM_COMPARATOR|sham PEP|3 cycles of 10 deep inspiration and expiration in a sham tube without expiratory resistance
62274772|NCT02848196|EXPERIMENTAL|Stereotactic body radiation therapy|Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.
62274773|NCT00798226|ACTIVE_COMPARATOR|1|n-3 fatty acid
62274774|NCT00798226|PLACEBO_COMPARATOR|2|Olive oil
62287130|NCT02863341|NO_INTERVENTION|non-naive Wait-list Control arm|
62070017|NCT03176589|ACTIVE_COMPARATOR|PEP|3 cycles of 10 deep inspiration followed by expiration with positive expiratory pressure (PEP) device or PEP bottle of 10-15 cm of water pressure
62070018|NCT03176589|EXPERIMENTAL|deep breathing maneuvers|3 cycled of 10 deep breathing maneuvers without PEP or sham PEP
62070019|NCT01233882|EXPERIMENTAL|Healthy Volunteers|
62070020|NCT01233882|EXPERIMENTAL|Mild Renal Impairment|
62070021|NCT01233882|EXPERIMENTAL|Moderate Renal Impairment|
62070022|NCT01233882|EXPERIMENTAL|Severe Renal Impairment|
62070023|NCT02053025|ACTIVE_COMPARATOR|mycoprotein|3 levels of mycoprotein will be consumed
62070024|NCT02053025|ACTIVE_COMPARATOR|control protein|3 levels of a control protein will be consumed
62070025|NCT04441723|ACTIVE_COMPARATOR|lag screw with dynamic mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
62070026|NCT04441723|ACTIVE_COMPARATOR|lag screw with static mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
62070027|NCT01332890|EXPERIMENTAL|Sequence 1|
62070028|NCT01332890|EXPERIMENTAL|Sequence 2|
62070029|NCT01332890|EXPERIMENTAL|Sequence 3|
62070030|NCT01332890|EXPERIMENTAL|Sequence 4|
62274775|NCT00538720|EXPERIMENTAL|Vitamin D|Vitamin D starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
62274776|NCT00271323|EXPERIMENTAL|1|Induction chemotherapy followed by concurrent chemoradiotherapy
62070031|NCT01332890|EXPERIMENTAL|Sequence 5|
62070032|NCT01332890|EXPERIMENTAL|Sequence 6|
62070033|NCT02569359|EXPERIMENTAL|Shea nut oil|100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
62070034|NCT02569359|PLACEBO_COMPARATOR|Placebo|placebo which comprised 100% canola oil or starch mixed soybean oil
62070035|NCT00811746|EXPERIMENTAL|1|Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG
62638009|NCT06387758|EXPERIMENTAL|Low systemic strength training|8-week (3 times per week; 45-minute sessions) home-based telehealth strengthening exercise program
62638010|NCT06387758|EXPERIMENTAL|Moderate systemic exercise|8-week (3 times per week; 45-minute sessions) home-based telehealth walking protocol
62274777|NCT00271323|ACTIVE_COMPARATOR|2|Concurrent chemo-radiotherapy followed by consolidation chemotherapy
62274778|NCT03082365||pre-dialysis|
62274779|NCT03082365||end stage renal disease|
62274780|NCT04219150|EXPERIMENTAL|Electrical cardiometry (EC)|
62274781|NCT04219150|EXPERIMENTAL|"Fluid and Catheter Treatment Trial FACTT Lite"|
62638011|NCT01973218|EXPERIMENTAL|rMenB|Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
62638012|NCT01973218|ACTIVE_COMPARATOR|Placebo/MenACWY|Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.
62638013|NCT03353324|ACTIVE_COMPARATOR|intravitreal injection of bevacizumab|
62638014|NCT03353324|ACTIVE_COMPARATOR|intravitreal injection of bevacizumab+ targeted laser|Intervention intravitreal bevacizumab injection + targeted laser photocoagulation of retinal non perfused areas
62070036|NCT00811746|ACTIVE_COMPARATOR|2|Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG
62070037|NCT00811746|OTHER|3|Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.
62070038|NCT04097405|ACTIVE_COMPARATOR|D-0120 Dose Ascending Cohorts 1-4|D-0120 dose daily for up to 7 days.
62070039|NCT04097405|PLACEBO_COMPARATOR|Placebo Dose Ascending Cohorts 1-4|Placebo dose daily for up to 7 days
62070040|NCT04097405|EXPERIMENTAL|D-0120/Uric Acid Lowering Agent Cohort 6|D-0120 in combination with a uric acid lowering agent for up to 7 days of combination therapy
62070041|NCT01982214|SHAM_COMPARATOR|sedentary|No intervention
62070042|NCT01982214|EXPERIMENTAL|Vibration|Subjects in this group will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week while 12 months. The training included light squats at 35-50 Hz and ended up by stretching and relaxation exercises.
62070043|NCT03380780|EXPERIMENTAL|Emicizumab|
62070044|NCT03806868|ACTIVE_COMPARATOR|Intervention group|The Intervention group will receive a voucher for ordering foods (ONLY omega-3 rich foods) weekly (4 times).
62070045|NCT03806868|SHAM_COMPARATOR|Control group|The Control group will receive a voucher for ordering foods in general (any type of foods) weekly (4 times). Participants will NOT be limited to purchasing foods rich in omega-3.
62070046|NCT04408027|EXPERIMENTAL|Virtual-Care Cognitive Behavioural Therapy|
62070047|NCT01550835|EXPERIMENTAL|Distal Embolic Protection Only|Carotid stenting with distal embolic protection only
62070048|NCT01550835|ACTIVE_COMPARATOR|Distal embolic protection and aspiration thrombectomy|Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection
62070049|NCT05867485|NO_INTERVENTION|Control Group:|"Initially, the Patient Diagnostic Information Form was completed. Patients were informed about the discharge process according to the regular ward procedure and were informed about their participation in the study after discharge.~One month later, patients were contacted by phone, and the Daily Life Activities Scale (DLAS) and Quality of Life Scale (SF-12) forms were completed during 10-15 minute conversations."
62274782|NCT05381064|EXPERIMENTAL|novices with AI-assisted system, Then experts without AI-assisted system|The patient is first scanned by a novice endoscopist with the assistance of a deep learning-based bile duct scanning system during the examination, and then rescanned by a specialist without the assistance of AI.
62274783|NCT05381064|EXPERIMENTAL|experts without AI-assisted system, Then novices with AI-assisted system|The patient is first scanned by a specialist without the assistance of AI and then rescanned by a novice endoscopist with the assistance of a deep learning-based bile duct scanning system during the examination.
62274784|NCT06216444|EXPERIMENTAL|Remimazolam Tosilate for Injection（5mg）|
62274785|NCT06216444|EXPERIMENTAL|Remimazolam Tosilate for Injection（10mg）|
62274786|NCT01799915||REM sleep behavior disorder, RBD|Patients that have rapid eye movement sleep behavior disorder.
62638015|NCT01950299|EXPERIMENTAL|Anakinra (standard dose)|Anakinra 100 mg daily for 14 days
62638016|NCT01950299|EXPERIMENTAL|Anakinra (high dose)|Anakinra 100 mg twice daily for 14 days
62274787|NCT01799915||multiple system atrophy|is a neurodegenerative disorder charaterized by abnormal alpha-synuclein deposition in the cytoplasm of oligodendroglial cells in the CNS, and typically sparing peripheral autonomic nerves.
62274788|NCT01799915||Pure Autonomic failure|A neurodegenerative disorder characterized by loss of peripheral noradrenergic fibers, with low levels of plasma norepinephine.
62274789|NCT01799915||Parkinson disease|A degenerative disorder of the central nervous system that leads to termors, difficulty walking, movement and coordination.
62274790|NCT01799915||Dementia with Lewy bodies|A neurodegenerative disorder similar to PAF and PD with the accumulation of Alpha-synuclein in the CNS however DLB patients develop dementia.
62274791|NCT06438172|EXPERIMENTAL|Experimental|HCP1803-3
62274792|NCT06438172|ACTIVE_COMPARATOR|Active Comparator|RLD2001-1
62274793|NCT00626938||sarcoidosis|sarcoidosis patients
62274794|NCT00626938||controls|healthy volunteers and other interstitial lung disease (ILD) patients
62274795|NCT02501278|EXPERIMENTAL|Arm A: Immunotherapy during and after CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy plus immunotherapy dosing after chemoradiotherapy in an adjuvant setting and vaccine boost one year after last vaccine dosing.
62274796|NCT02501278|EXPERIMENTAL|Arm B: Immunotherapy during CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy, and vaccine boost one year after last vaccine dosing.
62274797|NCT02501278|ACTIVE_COMPARATOR|CRT without immunotherapy|Standard chemoradiotherapy without immunotherapy
62274798|NCT06093139|ACTIVE_COMPARATOR|Active|Probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules alongside additional potato starch as a filler).
62638017|NCT01950299|PLACEBO_COMPARATOR|Placebo|Placebo for 14 days
62274799|NCT06093139|PLACEBO_COMPARATOR|Placebo|Placebo capsule (placebo consisted of the same capsules filled with potato starch)
62274800|NCT04188184|ACTIVE_COMPARATOR|tranexmic acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
62274801|NCT04188184|ACTIVE_COMPARATOR|Epinephrine roup|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
62274802|NCT05350826|EXPERIMENTAL|Ambulatory medical assistance|Patient benefiting from the ambulatory medical assistance nurse program in addition to conventional care for patients chronic lymphoid leukemia under targeted therapy
62274803|NCT05350826|NO_INTERVENTION|Conventional care|Patient benefiting from conventional care for patients chronic lymphoid leukemia under targeted therapy
62274804|NCT01090401|EXPERIMENTAL|Patients with Linox smart S DX lead|
62274805|NCT04329195|EXPERIMENTAL|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
62274806|NCT04329195|ACTIVE_COMPARATOR|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
62274807|NCT01662895|ACTIVE_COMPARATOR|Deferoxamine|Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
62274808|NCT01662895|PLACEBO_COMPARATOR|Normal Saline|0.9% sodium chloride
62274809|NCT02472132|EXPERIMENTAL|Intervention|Prospective implantation of POC US for CVC tip placement.
62274810|NCT02472132|NO_INTERVENTION|Control|Retrospective data collection for CVC placement in the medical and surgical ICUs, before the initiation of the study and without the use of POCUS for CVC tip placement.
62274811|NCT04446364|EXPERIMENTAL|Aloe vera group|Gel cavity disinfection
62274812|NCT04446364|ACTIVE_COMPARATOR|Chlorohexidine group|2% cavity disinfection
62274813|NCT04597879||Severe traumatic brain injury|
62274814|NCT04597879||Severe trauma without brain trauma|
62274815|NCT04597879||Healthy controls|
62274816|NCT05409547|EXPERIMENTAL|PEG-G-CSF|6 mg, single dose
62274817|NCT05409547|ACTIVE_COMPARATOR|rhG-CSF|5 μg/kg, twice a day
62274818|NCT06148558|OTHER|Single-Cell|
62274819|NCT05143073|NO_INTERVENTION|No educational materials|No educational materials will be provided.
62274820|NCT05143073|ACTIVE_COMPARATOR|Alcohol use disorder and strategies to reduce risk|The information provided to participants will be related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies. The content is based on information from National Institute of Alcohol Abuse and Alcoholism websites, Mayo Clinic websites, and the National Survey on Drug Use and Health.
62274821|NCT05143073|ACTIVE_COMPARATOR|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk|The information provided to participants will explain polygenic risk scores by discussing genetic variation, risk variants, how polygenic scores are created, and how they can be interpreted. The participants will also receive the same information related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies.
62274822|NCT05813197|EXPERIMENTAL|Intervention|This group will receive the test intervention My Choice-My Way!
62274823|NCT05813197|ACTIVE_COMPARATOR|Control|This group will receive usual services
62274824|NCT01178658|EXPERIMENTAL|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
62274825|NCT04934761|EXPERIMENTAL|capacity shock|2ml/kg succinylateol gelatin
62274826|NCT04934761|OTHER|routine management|conventional strategy
62274827|NCT06268691|NO_INTERVENTION|Control arm|The study was conducted in 20 clusters of 2000 dwellings each, where 10 clusters were randomly assigned to the control arm and 10 clusters to the intervention arm
62274828|NCT06268691|EXPERIMENTAL|Intervention arm|The study was conducted in 20 clusters of 2000 dwellings each, where 10 clusters were randomly assigned to the control arm and 10 clusters to the intervention arm
62274829|NCT06277388||Impedance cardiography(ICG)|The ICG during 6MWT was performed before induction chemo-immunotherapy, before CCRT, and before consolidative immunotherapy for patients with locally advanced NSCLC.
62274830|NCT00772668|EXPERIMENTAL|RCVELP|"Rituximab, Cyclophosphamide, Bortezomib, Prednisone (RCVELP):~* Rituximab~  * Induction: 375 mg/m2 IV infusion on Day 1 of every 21 days cycle for 8 cycles~ * Maintenance: 375/m2 Days 1, 8, 15, 22 every 6 months for up to 4 cycles~* Cyclophosphamide: 750 mg/m2 intravenous piggyback (IVPB) on Day 1 of every 21 day cycle for 8 cycles~* Bortezomib: 1.6 mg/m2 IV push on Days 1 and 8 of every 21 days cycle for 8 cycles~* Prednisone: 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles"
62274831|NCT00622986|EXPERIMENTAL|A1|perimenopausal women
62274832|NCT00622986|PLACEBO_COMPARATOR|A2|perimenopausal women
62274833|NCT00622986|EXPERIMENTAL|B1|early staged postmenopausal women
62274834|NCT00622986|PLACEBO_COMPARATOR|B2|early staged postmenopausal women
62638018|NCT04619784|EXPERIMENTAL|Treatment Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Patients will receive 12 sessions of pilates. Patients will be evaluated before treatment, after treatment, at the 3rd and 6th months.
62638019|NCT04619784|OTHER|Control Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Their routine medical treatments were continued
62274835|NCT01393197|ACTIVE_COMPARATOR|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
62274836|NCT01393197|EXPERIMENTAL|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
62274837|NCT01393197|EXPERIMENTAL|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
62274838|NCT01393197|EXPERIMENTAL|TACE-KMG(without chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
62274839|NCT05354986|PLACEBO_COMPARATOR|Control-Control|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse."
62287131|NCT03684109|EXPERIMENTAL|IDH-Mutant Glioma Patients|Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain.
62287132|NCT02631707|NO_INTERVENTION|Control Standard Protein Diet|Control Arm Ministry of Health guidelines percentage energy from carbohydrate (50-55%), protein (10-15%) and fat (30%).
62287133|NCT02631707|EXPERIMENTAL|Intervention High Protein Diet|Intervention Arm Percentage energy from carbohydrate (40%), protein (30%) and fat (30%).
62638020|NCT03902769|EXPERIMENTAL|No allogeneic SCT|For standard or intermediate risk AML patients who achieved good rapid response, allogenic SCT will be excluded from treatment plan
62070050|NCT05867485|EXPERIMENTAL|Study Group:|"After obtaining informed consent from the patients, they were enrolled in the study.~The COVID-19 Discharge Education Brochure, prepared by the researchers, was provided to the patients face-to-face within 10-15 minutes.~One month after the discharge education, patients were contacted by phone, and the Daily Life Activities Scale (DLAS) and Quality of Life Scale (SF-12) forms were completed."
62070051|NCT02936713|EXPERIMENTAL|1=Functional Gastro-Intestinal Disorder (FGID)|1=FGID study group: 40 evaluable FGID subjects with a functional gastrointestinal disorder (FGID) complaining of excessive gas evacuation per anus (i.e excessive flatulence), aged from 18 to 75 years that will consume a 3-day specific and controlled mild flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
62070052|NCT02936713|EXPERIMENTAL|2=Non-FGID|2=Non-FGID study group: 60 evaluable non-FGID subjects aged from 18 to 75 years that will consume a 3-day specific controlled high flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
62070053|NCT04015115|EXPERIMENTAL|Youth Opioid Recovery Support service model|The components of the Youth Opioid Recovery Support service model includes 1) home-delivery of standard-of-care medication and individual/family counseling services; 2) assertive outreach efforts by the treatment team; and 3) contingency management incentives upon receipt of medication treatment.
62070054|NCT04557527|OTHER|control|Pars plana vitrectomy, retinopexy with laser or cryotherapy, and intravitreal gas tamponade.
62070055|NCT04557527|ACTIVE_COMPARATOR|treatment|Pars plana vitrectomy, laser retinopexy, suprachoroidal viscobuckle.
62070056|NCT05904860|OTHER|Experimental Group|The experimental group will be receiving a 30-minute backward gait training using parallel bars, a mirror, and on a firm surface. Patients will receive training for 4 days per week with a total time period of 4 weeks. Balance, fall risk, and spatiotemporal gait parameters will be quantified and evaluated before the commencement of treatment, after 2 weeks, and at the end of the last session.
62070057|NCT05904860|OTHER|Control group|The control group will be receiving a 30-minute forward gait training using parallel bars, a mirror and on a firm surface. Patients will receive training for 4 days per week with a total time period of 4 weeks. Balance, fall risk, and spatiotemporal gait parameters will be quantified and evaluated before the commencement of treatment, after 2 weeks, and at the end of the last session.
62274840|NCT05354986|EXPERIMENTAL|Control-test|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
62274841|NCT05354986|EXPERIMENTAL|Test-control|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse."
62070058|NCT00132379|EXPERIMENTAL|1|
62070059|NCT03622203||Real life patients|Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)
62070060|NCT03622203||Difficult coronary lesions|Patients with bifurcation and multivessel disease, that is those with an increased risk of ST
62070061|NCT03622203||STEMI|Patients with STEMI
62070062|NCT02542540|EXPERIMENTAL|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
62070063|NCT02542540|NO_INTERVENTION|Children with OI without training|No training
62070064|NCT01086566|EXPERIMENTAL|Multiple Boost Group-15 mcg|25 healthy adults who have previously received both Clade 1 and Clade 3 vaccines as a participant in study DMID 05-0043 will receive a single dose of 15 mcg of A/Indonesia/5/05.
62070065|NCT01086566|EXPERIMENTAL|Primed Group-15 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 15 mcg of A/Indonesia/5/05.
62274842|NCT05354986|EXPERIMENTAL|Test-test|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
62274843|NCT03570112||Pregnant Women with Hep C|SOF/VEL Therapy-sofosbuvir 400mg, velpatasvir 100mg, once daily for 12 weeks at 24 weeks post partum
62274844|NCT03308396|EXPERIMENTAL|Single Arm|"This is a non-randomized, single arm, open label Phase Ib/II study.~Phase Ib:~Days 1-5~Guadecitabine:~* Dose 0: 60 mg/m\^2~* Dose -1: 45 mg/m\^2~Phase II:~Days 1-5 Guadecitabine (at Ph II dose)~Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)"
62274845|NCT02301403|ACTIVE_COMPARATOR|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
62274846|NCT02301403|EXPERIMENTAL|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
62274847|NCT01692548|EXPERIMENTAL|Neurofeedback|Neurofeedback: two sessions per week, 30 sessions total.
62274848|NCT01692548|NO_INTERVENTION|Control|
62274849|NCT04831333||Active CMVR|The UWF images of cytomegalovirus retinitis (CMVR) included various patterns: hemorrhagic necrotizing lesion, granular lesion, frosted branch angiitis, and optic neuropathy lesion. Active CMVR lesion was defined as obvious opacity (mild, moderate, severe, very severe)
62274850|NCT04831333||Inactive CMVR|Inactive CMVR lesion was defined as a lack of opacity or questionable/equivocal activity.
62274851|NCT04831333||Non-CMVR|The non-CMVR images included normal retina and other retinopathies such as HIV-related microvascular retinopathy, diabetic retinopathy, retinal detachment, vitreous hemorrhage.
62274852|NCT04036409|EXPERIMENTAL|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP \<120 mm Hg.
62274853|NCT04036409|ACTIVE_COMPARATOR|Standard Control of Systolic Blood Pressure|Participants randomized into the Standard arm will have a goal of SBP \<140 mm Hg
62274854|NCT04894656|EXPERIMENTAL|Gastroparesis patients|
62638021|NCT03902769|ACTIVE_COMPARATOR|Standard post induction therapy|For slow responding AML patients, post induction therapy will be provided according to treating physician discretion
62638022|NCT04386902||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
62274855|NCT04894656|ACTIVE_COMPARATOR|Healthy volunteers|
62638023|NCT03158961|EXPERIMENTAL|TOETVA|a new approach in surgery which can treat the thyroid disease
62638024|NCT03017222|ACTIVE_COMPARATOR|Ondansetron group|
62274856|NCT02678858|EXPERIMENTAL|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) shall target expressive and interactional behavior skills together with those social cognitive domains (facial and prosodic affect recognition, social perception, theory-of-mind) known to be most impaired (Savla, 2012) and most closely associated with functional outcome (Fett, 2012) in schizophrenia.
62274857|NCT02678858|ACTIVE_COMPARATOR|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Therapy (NCRT) shall target impairments in attention, memory, and executive functions as an active comparator to the ISST.
62274858|NCT06370455|ACTIVE_COMPARATOR|Septal advancement flap group|Fifteen patients will undergo septal advancement flap technique The mucoperichondrial flaps are elevated over the cartilaginous septum and the caudal perpendicular plate of the ethmoid. investigator will take L shape flap of the dorsal and anterior end of cartilaginous septum then advance them and suture the flap at certain points so can support the nasal tip.
62274859|NCT06370455|ACTIVE_COMPARATOR|Columellar strut group|fifteen patients will undergo columellar strut technique. investigator will extract columellar strut from septal cartilage then insert it between the two medial crura n the intercrural space and sutured to nasal spine so can support nasal tip.
62274860|NCT06247891|OTHER|Control Group|
62274861|NCT05956106|EXPERIMENTAL|Metabolic syndrome patients|Dried Mulberry fruit powder is used for preventing symptoms in Metabolic Syndrome patients Dietary intervention: Black Mulberry fruit powder Dosage: 45g per day
62274862|NCT01662583|EXPERIMENTAL|Educational Text Message|Educational text message reminder
62454392|NCT06056479|ACTIVE_COMPARATOR|external oblique intercostal block after induction|"After induction of general anesthesia, external oblique intercostal blocks will be performed with patients positioned in the supine position with their ipsilateral arm abducted.~Initially the probe is placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle identified at the level ribs 6 and 7 in line with the xiphoid process. To confirm correct identification of the external oblique muscle, With 17gauge echogenic ultrasound needle will be advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle.30 ml of bupivacaine 0.25% will be administered incrementally."
62638025|NCT03017222|EXPERIMENTAL|Ramosetron group|
62638026|NCT00468117|EXPERIMENTAL|Islet transplantation|Up to three separate islet transplants will occur and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG) and etanercept throughout study.
62638027|NCT00003677|EXPERIMENTAL|Dolastatin 10|Dolastatin 10 IV bolus once every 21 days.
62638028|NCT05398406|EXPERIMENTAL|Subcostal TAP Block|In the supine position, the US probe was placed on the imaginary line connecting the anterior superior iliac spine (SIAS) and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml (20+20 ml) of local anesthetic was infiltrated around the nerve bilaterally with a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA).
62638029|NCT05398406|EXPERIMENTAL|ESP Block|In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
62638030|NCT05398406|EXPERIMENTAL|Paravertebral block|In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
62638031|NCT03547323|EXPERIMENTAL|Theranova 400 Dialyzer|One treatment session in an in-center setting.
62638032|NCT03547323|ACTIVE_COMPARATOR|FX80 Dialyzer|One treatment session in an in-center setting.
62638033|NCT04414852|EXPERIMENTAL|mild renal impairment|
62638034|NCT04414852|EXPERIMENTAL|moderate remal impairment|
62638035|NCT04414852|ACTIVE_COMPARATOR|normal renal impairment|
62638036|NCT04281082||ICP|To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives
62638037|NCT00269152|EXPERIMENTAL|A: Pemetrexed + Cisplatin|
62638038|NCT00269152|EXPERIMENTAL|B: Pemetrexed + Carboplatin|
62638039|NCT01837251|NO_INTERVENTION|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 \& 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
62638040|NCT01837251|EXPERIMENTAL|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 \& 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
62638041|NCT01987180||Usual standard care|Parents will be provided with the usual standard of care in the NICU. Discharge information will be provided to parents as is typically done in the NICU for VLBW infants getting ready to go home. Typical handouts are given to parents that describe their child's care and needs specifically as well as general guidelines. The project coordinator for the research study will verify that parents received information prior to discharge from the NICU staff. Parents will determine how you use this information.
62274863|NCT01662583|EXPERIMENTAL|Plain Text Message|plain text message reminder
62638042|NCT01987180||NICU-2-Home mobile app user|Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
62638043|NCT02114619|ACTIVE_COMPARATOR|Low dose of I-131|Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight
62274864|NCT01662583|OTHER|Written reminder only|written reminder at time of vaccination
62274865|NCT04081194||case group, Melanoma Patients|"15 patients of with Melanoma, Age between 40 and 90 years.~-Withdrawal of Blood sample, Isolation of Exosomes:~1. Bradford protein assay And Qubit protein assay.~2. Bioanalyzer.~3. Real time PCR."
62274866|NCT04081194||control group|"10 Persons without Melanoma, age \> 40 years~-Withdrawal of Blood sample, Isolation of Exosomes:~1. Bradford protein assay And Qubit protein assay.~2. Bioanalyzer.~3. Real time PCR."
62070066|NCT01086566|EXPERIMENTAL|Unprimed Group-90 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 90 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
62454393|NCT06056479|NO_INTERVENTION|postoperative morphine per patient request|In this group no block will be done only morphine will be given intraoperatively- according to hemodynamic change and postoperative by morphine per patient request
62454394|NCT03676803|EXPERIMENTAL|Mixed spices intervention group|healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
62454395|NCT03676803|PLACEBO_COMPARATOR|placebo group|healthy participants consume placebo capsule containing 5 g of maltodextrin
62454396|NCT01802502|ACTIVE_COMPARATOR|Rifampicin 600 mg|Subjects in this arm receive 600 mg rifampicin intravenously
62638044|NCT02114619|ACTIVE_COMPARATOR|Intermediate dose|Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.
62638045|NCT02114619|ACTIVE_COMPARATOR|High dose|Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.
62638046|NCT02025192|EXPERIMENTAL|Tucatinib (ONT-380) in combination with capecitabine|
62638047|NCT02025192|EXPERIMENTAL|Tucatinib (ONT-380) in combination with trastuzumab|
62638048|NCT02025192|EXPERIMENTAL|Tucatinib (ONT-380) combined with capecitabine and trastuzumab|
62454397|NCT01802502|EXPERIMENTAL|rifampicin 750 mg|Subjects in this arm receive 750 mg rifampicin orally
62454398|NCT01802502|EXPERIMENTAL|rifampicin 900 mg|Subjects in this arm receive rifampicin 900 mg orally
62070067|NCT01086566|EXPERIMENTAL|Unprimed Group-15 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 15 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
62638049|NCT04182958|EXPERIMENTAL|(14C)-OPC-61815|
62638050|NCT02077998|EXPERIMENTAL|Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)|"PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1.~PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
62638051|NCT03969940||Thermo|Buruli ulcer patients receiving thermotherapy
62070068|NCT01086566|EXPERIMENTAL|Primed Group-90 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 90 mcg of A/Indonesia/5/05.
62070069|NCT06053060|OTHER|Standard Dynacup|Hip arthroplasty with a standard Dynacup cup
62454399|NCT03991156||Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|
62638052|NCT03969940||Chemo|Buruli ulcer patients receiving chemotherapy
62070070|NCT06053060|OTHER|Dynacup One C|Hip arthroplasty with a cup Dynacup One C
62070071|NCT00997724|EXPERIMENTAL|a-VATS|Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
62070072|NCT01177839||Intussusception cohort|Subjects with Intussusception
62070073|NCT01361620|OTHER|Aspirin|All subjects took 7-10 days of 81 mg aspirin
62638053|NCT00857662|EXPERIMENTAL|Onyx|
62638054|NCT00857662|ACTIVE_COMPARATOR|TRUFILL|
62638055|NCT04086810|EXPERIMENTAL|DCCR|25 - 450 mg DCCR
62638056|NCT05943366|EXPERIMENTAL|KOKU-Nut|Participants will be helped to download KOKU-Nut onto their ipad or tablet during the baseline visit and will receive training. In cases where participants do not have the necessary devices or data to join the intervention, a tablet with KOKU-Nut installed will be provided for the duration of the intervention. Participants will be asked to engage with KOKU-Nut at least 3 times a week throughout the 12-week period.
62638057|NCT05943366|NO_INTERVENTION|Usual care|Participants will continue with usual care and will receive a leaflet developed by Age UK about the importance of a healthy lifestyle including information on the importance of staying active and nutrition.
62638058|NCT06432478|EXPERIMENTAL|Gynaecological HDR brachytherapy patients|Using 3D-printed custom applicators to treat gynaecological HDR brachytherapy patients
62638059|NCT00246454||1|People with delayed sleep phase syndrome (DSPS).
62638060|NCT00246454||2|People with advanced sleep phase syndrome (ASPS).
62638061|NCT00246454||3|Control group (people with intermediate sleep patterns).
62070074|NCT01551316|EXPERIMENTAL|MN-221|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
62070075|NCT01551316|EXPERIMENTAL|PLACEBO|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
62070076|NCT03580616|EXPERIMENTAL|L-Serine|L-Serine 15 grams orally twice a day as tolerated for 6 months
62638062|NCT04390646|ACTIVE_COMPARATOR|Pulsatile GnRH pump treatment|
62638063|NCT04390646|PLACEBO_COMPARATOR|Pulsatile placebo pump treatment|
62638064|NCT04441346||patients with recent hemodialysis(less than 6 month|
62274867|NCT04481776|EXPERIMENTAL|Breakfast consumption|Participants will be asked to consume a standardised breakfast at home before 09:00 for seven consecutive days. The energy content of the breakfast will be 25% of individual measured resting metabolic rate. Prior to the experimental conditions, the participants will select one wholegrain, high-fibre ready-to-eat cereals (with the option of adding raisins) and fruit juice from a limited selection. Thus, breakfast composition will be controlled within participants, but not between participants to account for individual preferences. To ensure that the correct amount of each breakfast item is consumed, food items will be provided to the participants in pre-packaged containers and the participants will be provided with a marked beaker to measure their milk and juice each morning. The only exception is that parents will be asked to provide the 1.8% milk.
62638065|NCT04441346||patients on hemodialysis more than 6 months and l|
62638066|NCT04441346||patients on hemodialysis more than 5 years|
62638067|NCT00914407|EXPERIMENTAL|Healthy subjects|
62638068|NCT04915560|EXPERIMENTAL|ORTEC Employee|ORTEC professional employees performing an industrial cleaning task.
62638069|NCT01369264|EXPERIMENTAL|True Left High Frequency|True left high frequency repetitive transcranial magnetic stimulation
62638070|NCT01369264|PLACEBO_COMPARATOR|Passive sham left high frequency|Passive sham left high frequency repetitive transcranial magnetic stimulation
62274868|NCT04481776|EXPERIMENTAL|Breakfast omission|Participants were asked to abstain from all energy-providing nutrients before 10:30 for seven consecutive days.
62274869|NCT05195697||Mild acute pancreatitis|Patients treated with mild acute pancreatitis during the study period
62274870|NCT05195697||Moderate acute pancreatitis|Patients treated with moderate acute pancreatitis during the study period
62638071|NCT00789503|EXPERIMENTAL|Bread fortified with vitamin D3 and calcium|
62638072|NCT04321577||Residual disease|Participants with incidental gallbladder cancer with presence of residual disease in the re-resection specimen or in intra-operative findings.
62638073|NCT04321577||No residual disease|Participants with incidental gallbladder cancer with absence of residual disease in the re-resection specimen or in intra-operative findings.
62638074|NCT05476393|ACTIVE_COMPARATOR|Erector spinae block (Group ESPB)|ESP block will be applied in Group ESPB. The US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. Three muscles from top to bottom; Trapezius at the top, rhomboid major in the middle, and the erector spina muscle at the bottom will be displayed over the hyperechoic transverse process. Using the in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spina muscle and the block location will be confirmed. After the block location is confirmed, 40 ml of 0.25% bupivacaine will be administered (20 ml in each side).
62070077|NCT03643146|EXPERIMENTAL|Wedge 1- Step 1|
62070078|NCT03643146|EXPERIMENTAL|Wedge 1-Step 2|
62070079|NCT03643146|EXPERIMENTAL|Wedge 1-Step 3|
62070080|NCT03643146|EXPERIMENTAL|Wedge 1-Step 4|
62070081|NCT03643146|EXPERIMENTAL|Wedge 1-Step 5|
62070082|NCT03643146|EXPERIMENTAL|Wedge 2- Step 1|
62070083|NCT03643146|EXPERIMENTAL|Wedge 2-Step 2|
62070084|NCT03643146|EXPERIMENTAL|Wedge 2-Step 3|
62638075|NCT05476393|ACTIVE_COMPARATOR|Thoracal paravertebral block group (Group TPVB)|After visualizing the T5 spinous process sagittally with the US probe, the probe will be placed 2-3 cm laterally. The ribs and transverse processes will be displayed as hyperechoic structures. Superiorly, the costotransverse ligament and anteriorly the pleura will be visualized. With the in-plane technique, the block needle will be advanced in the cranio-caudal direction until the costotransverse ligament is passed. 5 ml of saline will be injected and the block location will be confirmed. After confirming the location of the needle, negative aspiration is performed, and after observing the absence of CSF, blood and air, 40 ml of 0.25% bupivacaine will be administered, and it will be seen that the pleura is pushed down as the drug is administered (20 ml in each side).
62274871|NCT05195697||Severe acute pancreatitis|Patients treated with severe acute pancreatitis during the study period
62274872|NCT05195697||Acute gastrointestinal bleeding|Patients treated with acute gastrointestinal bleeding during the study period
62274873|NCT05195697||Perforated ulcer|Patients treated with perforated ulcer during the study period
62274874|NCT05195697||Older than 70 years|Patients older than 70 years
62274875|NCT05195697||Less than 70 years|Patients younger than 70 years
62274876|NCT05195697||Prothrombotic medications|Patients on prothrombotic medications
62274877|NCT05195697||Frail patients|Patients with increased frailty score
62274878|NCT05195697||Reintervention group|Patients in need of reintervention
62274879|NCT04451629|EXPERIMENTAL|Exercises group|intervention group çalışma grubundaki kadın öğrencilere 8 hafta süresince haftada 4 kez 40 dakika boyunca pelvik taban ve core egzersizleri uygulatılacak
62274880|NCT04451629|NO_INTERVENTION|control group|students will be watched without any intervention
62274881|NCT06391697|EXPERIMENTAL|eOPRA Implant System for Transtibial Amputees and Magnetic Bead Tracking System|Implantation of e-OPRA Implant System and Magnetic Bead Tracking System in lower limb.
62274882|NCT04057339|PLACEBO_COMPARATOR|SOC (Standard of Care)|Everyone in this arm will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
62638076|NCT03427710|EXPERIMENTAL|Cohort A1|CiVi007 dose 1
62638077|NCT03427710|EXPERIMENTAL|Cohort A2|CiVi007 dose 2
62070085|NCT03643146|EXPERIMENTAL|Wedge 2-Step 4|
62274883|NCT04057339|EXPERIMENTAL|TRE + SOC|Everyone in this arm will receive standard of care nutritional behavioral counseling and will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
62454400|NCT01798069|EXPERIMENTAL|Behavioral intervention|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
62638078|NCT03427710|EXPERIMENTAL|Cohort A3|CiVi007 dose 3
62638079|NCT03427710|EXPERIMENTAL|Cohort A4|CiVi007 dose 4
62638080|NCT03427710|EXPERIMENTAL|Cohort A5|CiVi007 dose 5
62070086|NCT03643146|EXPERIMENTAL|Wedge 2-Step 5|
62070087|NCT03643146|EXPERIMENTAL|Wedge 3-Step 1|
62070088|NCT03643146|EXPERIMENTAL|Wedge 3- Step 2|
62274884|NCT04947488|ACTIVE_COMPARATOR|Bioarginina C|vials based on L-arginine and liposomal vitamin C
62274885|NCT04947488|PLACEBO_COMPARATOR|Placebo|vials without L-arginine and liposomal vitamin C
62274886|NCT03099889|EXPERIMENTAL|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
62274887|NCT03099889|NO_INTERVENTION|Control arm|Receive general health mailings
62274888|NCT05261269|EXPERIMENTAL|Dose Escalation (DAN-222)|The starting dose of DAN-222 will be administered IV every week (QW) to subjects in the first cohort.
62274889|NCT05261269|EXPERIMENTAL|Dose Escalation (DAN-222 + niraparib)|The starting dose of DAN-222 will be administered IV every week (QW), in combination with daily oral niraparib.
62274890|NCT05069987|EXPERIMENTAL|VR-immersion|
62274891|NCT05069987|NO_INTERVENTION|Non-VR control|
62274892|NCT01317810||Subjects with Overactive Bladder (OAB)|Combination of new OAB subjects and existing subjects on OAB medication
62274893|NCT03201185|EXPERIMENTAL|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
62274894|NCT03201185|NO_INTERVENTION|No intervention|Conventional treatment after transcatheter aortic valve implantation
62274895|NCT00513032||methylene blue|
62274896|NCT00513032||C|
62070089|NCT03643146|EXPERIMENTAL|Wedge 3- Step 3|
62274897|NCT06202300||Patients with high inflammation level|CAD patients undergoing multimodality imaging with high inflammation burden
62454401|NCT01798069|ACTIVE_COMPARATOR|behavoral intervention|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading medical publication workshops. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
62638081|NCT03427710|PLACEBO_COMPARATOR|Combined placebo group|group response from placebo subsets of dosing cohorts
62638082|NCT04149444|EXPERIMENTAL|ARM 1|"Dose escalation cohort - First 10 patients enrolled on study.~Trifluridine/Tipiracil 30mg/m2 - to start, if no significant dose limiting side effects the dose will be increased to 35mg/m2 for the duration of the trial.~After first 10 patients enrolled on study - Trifluridine/Tipiracil 35mg/m2~Each cycle is 28 days. Two doses per day during days 1-5 with a two day rest for days 6 and 7. Then two doses per day for days 8-12, followed by a rest period for days 13-28 with the next cycle starting the day after day 28."
62070090|NCT03643146|EXPERIMENTAL|Wedge 3- Step 4|
62070091|NCT03643146|EXPERIMENTAL|Wedge 3- Step 5|
62070092|NCT03643146|EXPERIMENTAL|Wedge 4-Step 1|
62070093|NCT03643146|EXPERIMENTAL|Wedge 4- Step 2|
62274898|NCT06202300||Patients with low inflammation level|CAD patients undergoing multimodality imaging with low inflammation burden
62274899|NCT03671031||isolated roux loop|isolated roux loop reconstruction following pancreaticoduodenectomy as the first group.
62274900|NCT03671031||single loop|single loop reconstruction following pancreaticoduodenectomy as the second group.
62274901|NCT04304027|EXPERIMENTAL|Tailored exercise intervention|8 weeks of aerobic interval training at moderate intensity which is modified according to the levels of self-reported fatigue
62274902|NCT04304027|ACTIVE_COMPARATOR|Standard exercise intervention|8 weeks of aerobic interval training at a moderate intensity
62638083|NCT05916898||S-IVL Intervention|"Patients with the presence of a highly calcified, resistant lesion or a significantly under-expanded, previously implanted stent (regardless of the time of implantation) were part of the study cohort. The lesion was defined as resistant after an unsuccessful high-pressure NC balloon inflation (at least 20% under-expansion; whit at least 16 atm.). The decision regarding initial lesion preparation was left to the operators' dissertation and did not imply a recruitment process.~There were no angiographic exclusion criteria regarding lesion anatomy regarding the length, tortuosity, severity, or prior stent placement. Operators supported by angiography assessment with optional intravascular imagining (IVUS/OCT) determined the size of the S-IVL catheter and an appropriate number of pulses for optimal vessel preparation or management of an under-expanded coronary stent."
62638084|NCT01750658||COPD|"COPD patients admitted in any of the participating ECOS hospitals due to a COPD exacerbation.~1. - External factors. The episodes of COPD exacerbations are associated to exogenous factors (pollution, change of ambient temperature, humidity, infections). The prevalence of environmental contamination and infections is higher than expected.~2. - Endogenous factors. These factors (hyperinflation, pulmonary embolism, cardiac dysfunction, mucus hypersecretion) are present in a proportion higher than expected~3. - During exacerbations of COPD serum markers of inflammation and autoimmunity are high relative to baseline in COPD and decrease progressively during the follow-up, after controlling the acute episode"
62638085|NCT01064271|EXPERIMENTAL|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
62638086|NCT01064271|ACTIVE_COMPARATOR|Risperdal®|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
62652968|NCT00942136|EXPERIMENTAL|Cohort 1, Sequence 2|Subjects in Cohort 1, Sequence 2 will receive a single dose of GSK134972 50 mg after a a high fat meal in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after fast of 10 hours in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
62638087|NCT04645563||Whatsapp Group|"This group includes 54 patients who have consulted via whatsapp. The ID physician will be consulted for all the subjects once laboratory results and CT reports were complete. All the consultations were performed with the same smartphone, and every Whatsapp consultation held since the very beginning of the pandemic was evaluated.~In this type of consultation, Thorax CT images of the patient were turned into a video of approximately 30-35 seconds, and during this video recording, the patient's clinical condition and laboratory results were also transferred to the ID physician. The ID physician, on the other hand, will state his/her admission-discharge decision via Whatsapp as hospitalization or discharge. Eventually the consultation result will be recorded in the patient's folder. The moment the video was sent will be recorded as the beginning of the patient's consultation period and response time to whatsapp video will be saved as consultation response time."
62638088|NCT04645563||Bedside Consultation Group|"This group includes 90 patients who have consulted bedside. The patients that has problems which are concerning multiple consultation will be excluded.~The ED physician wrote a consultation note over the hospital information system by specifying the patient's clinical status, history and laboratory parameters. A physician will be consulted for all the eligible subjects after their laboratory results and CT reports were complete. The ID physician examined the subjects at the bedside within 30 minutes (the legal response time in Turkey) of seeing the consultation request. Consultation response time will be saved as time between entering consultation information through the system to completion of the consultation note Although the consultant ID physicians will be informed via Whatsapp, they held the consultation at the bedside for the subjects they deemed appropriate."
62638089|NCT05867758|EXPERIMENTAL|intervention group|Group of participants (9 to 12) participating in the psychosocial group intervention (8 sessions, one per week) and receiving the self-help digital materials each week.
62638090|NCT05867758|NO_INTERVENTION|Control group - waiting list|Group of participants (9 to 12) receiving the self-help digital materials each week, who will take part in the psychosocial group intervention once the data collection will be over
62638091|NCT06312865||study group|patients diagnosed with 8 prism diopters or more exodeviation at distant or near fixation, regardless of age or fusion control (including intermittent exotropia, and constant exotropia).
62638092|NCT03933449|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to \~2 years). Participants who complete the first course of up to 35 administrations of pembrolizumab (\~2 years) but progress after discontinuation, may be eligible for a second course of pembrolizumab at the investigator's discretion, at the same dose and schedule at 200 mg IV on Day 1 of each 3-week cycle for up to 17 cycles (up to \~1 year).
62638093|NCT03933449|ACTIVE_COMPARATOR|Chemotherapy|Participants receive Investigator's choice of chemotherapy: paclitaxel 80-100 mg/m\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\^2 IV on Day 1 of every 14-day (2-week) cycle (up to \~2 years).
62638094|NCT06140433|OTHER|VSC-MEDlib|SaMD: Data collection study. Software to be applied after data collection.
62638095|NCT05329857|EXPERIMENTAL|Metformin and Vildagliptin 1000/50 mg Tablet|1 tablet of Metformin and Vildagliptin 1000/50 mg as single-dose administration
62638096|NCT05329857|ACTIVE_COMPARATOR|EUCREAS® 50/1000 mg Tablet|1 tablet of EUCREAS® 50/1000 mg (each film-coated tablet contains Vildagliptin 50 mg and Metformin hydrochloride 1000 mg) as single-dose administration
62638097|NCT05620589||Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
62070094|NCT03643146|EXPERIMENTAL|Wedge 4-Step 3|
62070095|NCT03643146|EXPERIMENTAL|Wedge 4-Step 4|
62070096|NCT03643146|EXPERIMENTAL|Wedge 4-Step 5|
62070097|NCT00786201|PLACEBO_COMPARATOR|Placebo|
62070098|NCT00786201|EXPERIMENTAL|CNTO 888 1 mg/kg|
62070099|NCT00786201|EXPERIMENTAL|CNTO 888 5 mg/kg|
62070100|NCT00786201|EXPERIMENTAL|CNTO 888 15 mg/kg|
62070101|NCT01024647|ACTIVE_COMPARATOR|Loss of Reponse Reinduction Responders|Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks
62070102|NCT01024647|ACTIVE_COMPARATOR|Response loss Reinduction Non-Responders|Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks
62070103|NCT01024647|ACTIVE_COMPARATOR|Responders|Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks
62070104|NCT01024647|ACTIVE_COMPARATOR|Non-Responders|Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks
62274903|NCT04304027|NO_INTERVENTION|Usual care control|Participants in the usual care control group will continue to receive their standard care independent of this study
62274904|NCT04871529|EXPERIMENTAL|Arm A (avelumab, gemcitabine, carboplatin, surgery)|Patients receive avelumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up 4 in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks after final systemic therapy, patients undergo standard of care surgery.
62638098|NCT05620589||Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
62638099|NCT05620589||Amoxicillin + Tetracycline 5+ Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegoprazan 50mg bid
62274905|NCT04871529|EXPERIMENTAL|Arm B (surgery)|Patients undergo standard of care surgery.
62274906|NCT02865382|ACTIVE_COMPARATOR|Group A|white light was used for both insertion and withdrawal of the colonoscope
62274907|NCT02865382|EXPERIMENTAL|Group B|Insertion to cecum was performed under white light and once the cecum was reached,the OE mode was swithed on during withdrawal of endoscope for complete colonic examination
62274908|NCT05097807|EXPERIMENTAL|The impact of word-picture-based shallow reading in social media|Use Microblog on their smartphone, a word-picture-based social media service similar to twitter.
62274909|NCT05097807|EXPERIMENTAL|The impact of short video-based shallow reading in social media|Use Tiktok on their smartphone, a short video-based social media service.
62274910|NCT05097807|ACTIVE_COMPARATOR|The impact of full-length sci-fi novel reading|Read a full-length sci-fi novel (Three body) on their own smartphone.
62274911|NCT05097807|ACTIVE_COMPARATOR|The impact of film/TV series|Watch a film on their own smartphone.
62454402|NCT04194866|OTHER|Day group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group ( 8:00-12:00)
62274912|NCT03783520|EXPERIMENTAL|Er,Cr:YSGG Laser|In laser group, each root canal was dried with paper points and then Er,Cr:YSGG (Biolase™, Waterlase™, San Clemente, CA, USA) was used for intracanal disinfection with the following parameters: panel output power of 0,75 W, pulse frequency of 20 Hz, and 1% water pressure to 10% air pressure ratio laser with RFT3 tips (415 µm diameter radial firing tip RFT3 Endolase, Biolase Technology, Inc; calibration factor of 0.85). The fiber was placed at 1mm short of the WL. Irradiation was delivered along the entire length of the root canal with helicoradial movements, 1mm per seconds in speed. This procedure was repeated three times and kept for 20 seconds between each irradiation.
62274913|NCT03783520|ACTIVE_COMPARATOR|Sodium hypochlorite|In control group, each canal were irrigated with 6 ml of 2,5% NaOCl. For the final irrigation, 5 ml of sterile saline were used. During irrigation, needle was inserted 1 mm short of the WL.
62274914|NCT00993031|EXPERIMENTAL|Group A|ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
62274915|NCT00993031|ACTIVE_COMPARATOR|Group B|ZDV 300mg/3TC 150mg/EFV 600mg
62274916|NCT00209339|EXPERIMENTAL|MitraClip|Percutaneous mitral valve repair (MitraClip Implant)
62274917|NCT04505228|EXPERIMENTAL|Research group|The patients receiving Atropine and the extra Chinese herb formulas treatment
62274918|NCT04505228|ACTIVE_COMPARATOR|Control group|The patients receiving the basic treatment of atropine
62274919|NCT02834637|ACTIVE_COMPARATOR|3 doses 2valent|3 doses of bivalent HPV vaccine (Cervarix) given at M0, M1 and M6
62638100|NCT04902781|EXPERIMENTAL|Experimental: AT-007|AT-007 The starting dose in Part A will be 5 mg/kg for all age groups. For each age group, Part B of the study will not start until the optimum dose evaluated in Part A has been identified
62070105|NCT04404608||Asymptomatic or mild symptoms patients patients|Patients with no or mild symptoms and need no respiratory support.
62070106|NCT04404608||Severe symptoms patients|Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.
62070107|NCT04404608||Critically ill patients|Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients
62070108|NCT03568721|EXPERIMENTAL|ibuprofen|ibuprofen (400 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
62274920|NCT02834637|ACTIVE_COMPARATOR|2 doses 2valent|2 doses of bivalent HPV vaccine (Cervarix) given at M0 and M6
62274921|NCT02834637|ACTIVE_COMPARATOR|1 dose 2valent|1 dose of bivalent HPV vaccine (Cervarix) given at M0
62638101|NCT04902781|PLACEBO_COMPARATOR|Placebo|Placebo given orally
62638102|NCT02970383|EXPERIMENTAL|10 group|Initial prescription for 10 narcotic tabs
62454403|NCT04194866|OTHER|Night group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
62454404|NCT04714658|EXPERIMENTAL|Immediate PTE|
62454405|NCT04714658|OTHER|6-month deferred PTE|
62638103|NCT02970383|ACTIVE_COMPARATOR|30 group|Initial prescription for 30 narcotic tabs
62638104|NCT04918654||Study Subjects|
62274922|NCT02834637|ACTIVE_COMPARATOR|3 doses 9valent|3 doses of nonavalent HPV vaccine (Gardasil9) given at M0, M2 and M6
62274923|NCT02834637|ACTIVE_COMPARATOR|2 doses 9valent|2 doses of nonavalent HPV vaccine (Gardasil9) given at M0 and M6
62070109|NCT03568721|EXPERIMENTAL|acetaminophen|acetaminophen (500 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
62070110|NCT03568721|EXPERIMENTAL|chewing gum|chewing gum (01 tablet) immediately after insertion of the initial archwire and 6/6 hs of chewing gum for a week if there is any orthodontic pain.
62070111|NCT03568721|NO_INTERVENTION|control|control (no reliever for orthodontic pain)
62070112|NCT05756452|EXPERIMENTAL|Partecipants with ACS and obstructive CAD|The study is to identify a difference in the correlation between HRV and CRP parameters in ACS patients with or without obstructive CAD
62070113|NCT05756452|EXPERIMENTAL|Partecipants with ACS without CAD, in a 1:1 ratio|Evaluate whether cardiac autonomic dysfunction is associated with low-grade systemic inflammation, inflammasome-dependent activation of IL-18 and IL-1β, and Th1/Treg frequency, in patients with ACS with or without obstructive CAD on angiography
62070114|NCT03836508|ACTIVE_COMPARATOR|Medium cut-off|Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.
62274924|NCT02834637|ACTIVE_COMPARATOR|1 dose 9valent|1 dose of nonavalent HPV vaccine (Gardasil9) given at M0
62274925|NCT00586573|EXPERIMENTAL|Namenda|
62274926|NCT01550497|EXPERIMENTAL|Home Exercise Group|Perform home exercises of unsupervised spinal stabilization exercises for 8 weeks
62274927|NCT01550497|EXPERIMENTAL|Weeky Physical Therapy Group|weekly physical therapy of supervised spinal stabilization exercises for 8 weeks
62274928|NCT02462473|EXPERIMENTAL|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
62274929|NCT02462473|EXPERIMENTAL|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
62638105|NCT00315445|PLACEBO_COMPARATOR|Placebo|Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
62638106|NCT00315445|ACTIVE_COMPARATOR|OXY/APAP|5 mg oxycodone/325 mg acetaminophen tablets
62454406|NCT00265733|EXPERIMENTAL|paclitaxel + capecitabine|"Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for up to 5 years."
62454407|NCT03803865|ACTIVE_COMPARATOR|Headspace|30-day smartphone based mindfulness training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
62454408|NCT03803865|ACTIVE_COMPARATOR|Recharge|30-day smartphone based reflection and problem solving training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
62454409|NCT02554864|ACTIVE_COMPARATOR|Adductor Canal Block- Injection -Site A|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site A - after the sartorius muscle crosses over the femoral artery
62638107|NCT00315445|EXPERIMENTAL|BTDS|Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
62638108|NCT02957357||National Cancer Data Base|Patients within the National Cancer Database with newly diagnosed prostate cancer between 2004 and 2010. Participating institutions each provided a random of sample of 10 patients to be included in the final cohort.
62070115|NCT03836508|ACTIVE_COMPARATOR|High-flux|High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.
62070116|NCT00688090|EXPERIMENTAL|Low-Dose Peptide Cohort|
62287134|NCT04948008|EXPERIMENTAL|Treatment group 1|The subjects received IBI306 150 mg Q2W subcutaneously injected into the abdomen each time for 12 weeks;
62454410|NCT02554864|ACTIVE_COMPARATOR|Adductor Canal Block - Injection -Site B|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site B - before the sartorius muscle crosses over the femoral artery
62638109|NCT02957357||NC ProCESS|The North Carolina Prostate cancer Comparative Effectiveness \& Survivorship Study (NC ProCESS) is a prospective population-based cohort of \>1,000 patients with newly diagnosed prostate cancer, enrolled from January 2011 through June 2013.
62638110|NCT00757393|ACTIVE_COMPARATOR|1|
62638111|NCT00757393|EXPERIMENTAL|2|
62638112|NCT02346708|EXPERIMENTAL|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
62070117|NCT00688090|EXPERIMENTAL|High-Dose Peptide Cohort|
62274930|NCT02462473|EXPERIMENTAL|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
62274931|NCT02037659||Gastric Varices treatment|DermaBond (glue) treatment of Gastric Varices.
62287135|NCT04948008|EXPERIMENTAL|Treatment group 2|The subjects received IBI306 300 mg Q4W subcutaneously injected into the abdomen each time for 12 weeks;
62454411|NCT02554864|ACTIVE_COMPARATOR|Adductor Canal Block -Injection -Site C|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site C - as the sartorius muscle crosses over the femoral artery
62454412|NCT04043065|EXPERIMENTAL|LEAP-2|Liver-enriched antimicrobial peptide 2
62454413|NCT04043065|PLACEBO_COMPARATOR|Placebo|Saline
62454414|NCT01955590|EXPERIMENTAL|Metacognitive therapy|The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
62454415|NCT01955590|ACTIVE_COMPARATOR|EMDR|Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
62454416|NCT01955590|ACTIVE_COMPARATOR|Treatment as usual|A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.
62454417|NCT02697903|EXPERIMENTAL|9 elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Natural Pomegranate Juice supplementation during and 48h following the first weightlifting training session."
62454418|NCT02697903|PLACEBO_COMPARATOR|9elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Placebo Juice supplementation during and 48h following the second weightlifting training session."
62454419|NCT00444145|EXPERIMENTAL|Patients with documented GERD or laryngopharyngeal reflux|Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
62454420|NCT02184130|EXPERIMENTAL|TMS|
62454421|NCT03956264|EXPERIMENTAL|VR|"VR Installation 5 min before the drain removal and stop 10 min after the procedure.~If Pain assessed by numerical rating scale (NRS) \> 4, administration of morphine."
62454422|NCT03956264|ACTIVE_COMPARATOR|Kalinox®|"Start of Kalinox® administration by inhalation with a facial mask 1 min before the drain removal and stop after the procedure according to the usual procedure of the service.~If Pain NRS \> 4, administration of morphine."
62274932|NCT04397094|EXPERIMENTAL|Theracal LC|Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
62274933|NCT04397094|ACTIVE_COMPARATOR|Formocresol|Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
62274934|NCT03589404|EXPERIMENTAL|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
62454423|NCT05293990|OTHER|Contrast-enhanced fluid attenuated inversion recovery|Confirmation of the difference between FLAIR contrast enhancement and T1 contrast enhancement patterns--\>PACS monitor shows the maximum dimension of FLAIR and T1 contrast enhancement by two neurology radiologists on FLAIR and T1 contrast enhancement images. In addition, the maximum diameter of the T2 high-signal lesion around the tumor is obtained using FLAIR images before contrast in the same plane. (Dt2)
62454424|NCT06364670|EXPERIMENTAL|The acupuncture group|Subjects in the acupuncture group will undergo acupuncture treatment, which is administered 3 times a week for 4 weeks.
62454425|NCT00604071||1|subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
62454426|NCT00495326|EXPERIMENTAL|1|Nevirapine-based ART
62454427|NCT00495326|ACTIVE_COMPARATOR|2|Efavirenz-based ART
62454428|NCT04581538|NO_INTERVENTION|Control group|This arm is being provided with continued home care as it was before
62454429|NCT04581538|EXPERIMENTAL|E-learning platform & networking platform|This arm is being provided with the e-learning platform and networking platform as components of the 24-h-quAALity package
62454430|NCT04581538|EXPERIMENTAL|Entire intervention|This arm is being provided with the entire intervention (e-learning platform, networking platform and digital care documentation)
62454431|NCT06193395|EXPERIMENTAL|Patients referred due to Pelvic Floor Disorders including anal incontinence|all patients with PFDs are eligible
62454432|NCT01143857|ACTIVE_COMPARATOR|Varenicline|
62454433|NCT01143857|PLACEBO_COMPARATOR|Placebo|
62454434|NCT00692653|EXPERIMENTAL|P4|Participant uses P4 program before meeting with his clinician to discuss treatment options.
62454435|NCT00692653|NO_INTERVENTION|Usual care+|Usual care plus participant is directed to reputable websites highly rated in research literature to learn more about prostate cancer treatments.
62454436|NCT02756325|EXPERIMENTAL|MRI|
62638113|NCT02346708|SHAM_COMPARATOR|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
62454437|NCT06367309|EXPERIMENTAL|eTEP (Extended totally extraperitoneal repair)|The anterior rectus sheath is incised and the retromuscular space is entered through the rectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the retromuscular space is performed. Two additional laparoscopic ports are established 8-10cm lateral to the linea alba caudally to the initial port. The medial border of the rectus sheath is incised and the preperitoneal space below the linea alba is dissected. The hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The medial border of the right retromuscular space is then incised and blunt dissection is performed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed on the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh is fixed non-traumatically using glubran glue or no fixation at all.
62638114|NCT01621386|EXPERIMENTAL|All Participants|Participants (male or female) that are between 18-65 years of age with a clinical diagnosis of asthma will take montelukast for 2 weeks (treatment period 1) and then take prednisone for 2 weeks (treatment period 2)
62638115|NCT01808274|EXPERIMENTAL|TAVR|with CENTERA self-expanding valve
62638116|NCT04522648|EXPERIMENTAL|Intervention (INT)|INT participants will be asked to perform self-measurements of arm circumference at five points along the arm at home every three months. Additional measurements can be performed if the participants experience signs of BCRL. Participants will report the self-measurements in cm and mm in an online questionnaire, or over the phone to a physiotherapist navigator, along with reporting sign and symptoms of BCRL.
62638117|NCT04522648|NO_INTERVENTION|Control (CON)|The CON group will follow the usual post-operative care. CON participants will be prompted every 6 months by an online questionnaire to report if they have been diagnosed with BCRL and if so, month of initiation of treatment.
62461619|NCT00304083|EXPERIMENTAL|Chemotherapy and local control by radiotherapy and surgery|Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.
62652969|NCT02990000|NO_INTERVENTION|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
62070118|NCT05721443|EXPERIMENTAL|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
62274935|NCT05537714||Vaccine hesitant|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC)
62274936|NCT05537714||Trusted community leaders|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve medical underserved individuals living in rural eastern North Carolina (ENC) .
62274937|NCT02085499|OTHER|NIMV followed by S-NIMV|During the study infants assigned to this arm will undergo a 2-hour period of non-synchronized NIMV followed by a 2-hour period of Synchronized-NIMV.
62638118|NCT02391025|EXPERIMENTAL|Gallium-68 citrate, PET|Participants will receive a single scan obtained on a single day, followed by optional tumor biopsy within 6 weeks of scan. There will be optional follow up gallium-68 citrate PET scan to assess response to treatment received outside this study that will be completed within 12 weeks of baseline scan.
62274938|NCT02085499|OTHER|S-NIMV followed by NIMV|During the study infants assigned to this arm will undergo a 2-hour period of synchronized NIMV followed by a 2-hour period of non-synchronized NIMV.
62274939|NCT01617837|ACTIVE_COMPARATOR|P6 acupressure group|"In the end of the operation Sea-Band®, a single-sized elastic acupressure band with a plastic button, was placed unilaterally at the place of P6 (the P6 Neiguan acupoint, located about 3 cm proximal to the distal wrist, between the tendons of the flexor carpi radialis and the palmaris longus)to apply acupressure."
62638119|NCT05150431|EXPERIMENTAL|Parecoxib|Parecoxib 40mg will be administered to this group 15 minutes before the end of the surgery.
62638120|NCT05150431|PLACEBO_COMPARATOR|Placebo|2ml normal saline will be administered to this group 15 minutes before the end of the surgery.
62638121|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
62454438|NCT06367309|ACTIVE_COMPARATOR|IPOM (intraperitoneal onlay mesh)|Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three laparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's left side. The peritoneum is incised and detached from the umbilical and supraumbilical linea alba. The peritoneum including the hernia sac and preperitoneal fat is resected. The hernia orifice is then closed using a barbed suture. A coated mesh is than placed to the ventral abdominal wall covering the closed hernia orifices (intended mesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and several absorbable tackers placed in double crown technique around the hernia orifice. The capnoperitoneum is released, the trocars removed and the fascia closed with an absorbable suture. The skin is sutured with absorbable sutures.
62638122|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
62070119|NCT02712697|EXPERIMENTAL|WM Group|Shentong Granules, two packs, bid, P.O., 48weeks; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
62454439|NCT04919421|ACTIVE_COMPARATOR|Virtual reality|Participants will wear a virtual reality headset during the dental injection in which a video is playing.
62454440|NCT04919421|ACTIVE_COMPARATOR|Topical gel|Participants will receive application of topical anesthetic gel on the site of dental injection.
62454441|NCT04162626|EXPERIMENTAL|Intervention|Supportive home visits by public health nurses to new parents from 28 weeks in pregnancy until the child is two years.
62638123|NCT02965404|EXPERIMENTAL|Experimental Group|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~* Intervention: investigational live attenuated varicella vaccine."
62638124|NCT02965404|ACTIVE_COMPARATOR|Positive Control Group|"* Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~* Intervention: control live attenuated varicella vaccine."
62070120|NCT02712697|PLACEBO_COMPARATOR|Hormone Group|Placebo ; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
62274940|NCT01617837|PLACEBO_COMPARATOR|Placebo group|In the end of the operation an identical Sea-Band® with no button and thereby no acupressure was placed unilaterally at the place of P6.
62274941|NCT04503577||Bladder cancer patients|
62274942|NCT01789450|EXPERIMENTAL|Section of Periareolar Dermis|Section of Periareolar Dermis
62274943|NCT05898958|NO_INTERVENTION|I.v morphine infusion|A loading i.v. dose of 0.15 mg/kg morphine sulphate diluted in 10 ml of normal saline was given slowly over4-5 min. Then, the morphine infusion will be started bysyringe pump in a dose of 0.05 mg/kg/h that wastitrated to keep the VAS less than 3 at rest andRamsay Sedation Scale (RSS) up to 4
62454442|NCT04162626|OTHER|Control|Follow up as usual at the Child health center
62454443|NCT00719966||Group 1 (hormone receptor-positive)|Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity.
62454444|NCT00719966||Group 2 (hormone receptor-negative)|Patients do not receive adjuvant treatment.
62454445|NCT05507619|ACTIVE_COMPARATOR|Control|
62454446|NCT05507619|EXPERIMENTAL|Intervention|
62454447|NCT06365723|EXPERIMENTAL|Green Walking then Gray Walking|Prediabetics randomized to Green walk first then Gray walk.
62454448|NCT06365723|EXPERIMENTAL|Gray Walking then Green Walking|Prediabetics randomized to Gray walk first then Green walk.
62454449|NCT02678832||Cancer patients|breast cancer prostate cancer colorectal cancer
62638125|NCT02965404|SHAM_COMPARATOR|Negative Control Group|"* Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~* Intervention: diluent of lyophilized vaccine."
62638126|NCT01601769|ACTIVE_COMPARATOR|Colposcopy|a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
62638127|NCT01601769|EXPERIMENTAL|Vitom|The VITOM system, consisting of the VITOM scope, xenon light source, HD camera system, AIDA HD documentation system, 1 monitor, and a mechanical support arm (all Karl Storz, Tuttlingen, Germany) is used for video exocolposcopy.
62638128|NCT05486416|EXPERIMENTAL|HSK3486 for general anesthesia induction|HSK3486 for induction of general anesthesia
62454450|NCT02678832||Physicians|working in in- and outpatient care
62454451|NCT02678832||Oncology nurses|working in in- and outpatient care
62638129|NCT05486416|ACTIVE_COMPARATOR|Propofol for general anesthesia induction|Propofol for induction of general anesthesia
62638130|NCT00902070||1|Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation
62070121|NCT04316390|EXPERIMENTAL|Hesperidin (A)|study drink without hesperidin and without vitamin C compared to study drink with hesperidin
62070122|NCT04316390|EXPERIMENTAL|Hesperidin + Vitamin C (B)|study drink with vitamin C compared to study drink with hesperidin and vitamin C
62070123|NCT02235701|EXPERIMENTAL|170 mg/m2 aldoxorubicin|
62070124|NCT02235701|EXPERIMENTAL|250 mg/m2 aldoxorubicin|
62454452|NCT06233266|EXPERIMENTAL|Sequence 1-Ticagrelor test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Ticagrelor Tablets 90 mg test product, treatment 2= Ticagrelor Tablets 90 mg reference product.
62070125|NCT05264233|ACTIVE_COMPARATOR|Meal rich in coconut oil|Participants will be asked to consume a breakfast (0 minute) and lunch (330 minute) rich in coconut oil
62454453|NCT06233266|EXPERIMENTAL|Sequence 2-Ticagrelor reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Ticagrelor Tablets 90 mg test product, treatment 2= Ticagrelor Tablets 90 mg reference product.
62454454|NCT05318651|EXPERIMENTAL|mobile app users|
62454455|NCT02044783|EXPERIMENTAL|Behavioral Intervention|Behavioral Counseling Intervention: 6 telephone calls that include physical activity goal-setting, tracking,and problem-solving of barriers
62454456|NCT02044783|NO_INTERVENTION|Usual Care|Monthly mailed print materials on aging topics (that would generally be administered by subjects' primary care clinic). No behavioral counseling.
62070126|NCT05264233|ACTIVE_COMPARATOR|Meal rich in butter|Participants will be asked to consume a breakfast (0 minute) and lunch (330 minute) rich in butter
62070127|NCT05264233|ACTIVE_COMPARATOR|Meal rich in vegetable oil|Participants will be asked to consume a breakfast (0 minute) and lunch (330 minute) rich in vegetable oil
62070128|NCT01166490|EXPERIMENTAL|1|ASG-5ME
62070129|NCT04866862|EXPERIMENTAL|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+ Camrelizumab 200mg d1; Repeated every 4 weeks
62070130|NCT05115019|EXPERIMENTAL|Group A (RUTI)|Participants will receive one dose of RUTI® vaccine at the baseline visit, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 m
62070131|NCT05115019|PLACEBO_COMPARATOR|Group B (Placebo)|Participants will receive one dose of sterile physiological serum at the baseline visit, which will be administered subcutaneously in the deltoid region.
62070132|NCT04296474|ACTIVE_COMPARATOR|Active ILIT treated|Patients that have received ILIT with birch and grass allergen 5-6 years previously
62070133|NCT04296474|PLACEBO_COMPARATOR|Non- AIT treated|Patients that have received placebo ILIT 5-6 years previously and patients with birch and grass pollen induced allergic rhinitis that have not previously been treated with allergen immunotherapy (AIT).
62070134|NCT03857841|EXPERIMENTAL|20 pmol phospholipid/kg body weight|UNEX-42 administered at 20 pmol phospholipid/kg body weight
62070135|NCT03857841|EXPERIMENTAL|60 pmol phospholipid/kg body weight|UNEX-42 administered at 60 pmol phospholipid/kg body weight
62070136|NCT03857841|EXPERIMENTAL|200 pmol phospholipid/kg body weight|UNEX-42 administered at 200 pmol phospholipid/kg body weight
62070137|NCT03857841|PLACEBO_COMPARATOR|Placebo|Phosphate-buffered saline
62638131|NCT04751695|EXPERIMENTAL|CoronoVac Vaccine Group|
62070138|NCT01122004|ACTIVE_COMPARATOR|Gabapentin|
62070139|NCT01122004|ACTIVE_COMPARATOR|Pregabalin|
62274944|NCT05898958|EXPERIMENTAL|Thoracic paravertebral block(TPVB)|Procedure/Surgery: thoracic paravertebral block The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
62274945|NCT05898958|EXPERIMENTAL|Rhomboid Intercostal , subserratus block (RISSB)|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
62638132|NCT01666561|EXPERIMENTAL|Breakfast Test Cereal 1, Oat based|"Test cereal 1, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
62070140|NCT01100047|EXPERIMENTAL|1|
62070141|NCT01100047|PLACEBO_COMPARATOR|2|
62070142|NCT04097834||PrEP Prescription at Enrollment|
62070143|NCT04097834||No PrEP Prescription at Enrollment|
62070144|NCT01141270|EXPERIMENTAL|AFOLIA|225 IU sc
62070145|NCT01141270|ACTIVE_COMPARATOR|Gonal-f|225 IU sc
62070146|NCT00220961|PLACEBO_COMPARATOR|Placebo|Placebo tablet similar to pioglitazone tablet
62454457|NCT01871467|EXPERIMENTAL|Sargramostim administration|Subjects will receive sargramostim.
62638133|NCT01666561|EXPERIMENTAL|Breakfast Test Cereal 2, Oat-based|"Test Cereal 2, Oat-based breakfast cereal. You will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat oat brand cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
62638134|NCT01666561|EXPERIMENTAL|Ready-to-eat cereal|"Ready-to-eat cereal, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~one Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
62454458|NCT04595981|EXPERIMENTAL|Chemo-embolization|Intra-arterial Cisplatin suspension 150-300 mg is infused into the tumor pedicle(s)
62454459|NCT05376566|ACTIVE_COMPARATOR|Intervention group|Hydrochloric acid (2 M)
62070147|NCT00220961|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone tablet similar to placebo tablet
62454460|NCT05376566|PLACEBO_COMPARATOR|Control group|Normal saline
62274946|NCT01338415|EXPERIMENTAL|bosentan 2mg/kg b.i.d.|Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
62274947|NCT01338415|EXPERIMENTAL|bosentan 2mg/kg t.i.d.|Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
62638135|NCT01360723||urothelial carcinoma|Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
62638136|NCT01360723||Healthy controls group|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
62274948|NCT04407559||Groupe 1|Group 1: Rheumatoid arthritis seropositive for RF (+)
62638137|NCT06187831||Before the change of the departmental pre-procedural platelet transfusion trigger for CVC placement|Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study
62638138|NCT06187831||After the change of the departmental pre-procedural platelet transfusion trigger for CVC placement|Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study
62274949|NCT04407559||Groupe 2|Group 2: Rheumatoid arthritis seronegative for RF (-)
62274950|NCT03403205|EXPERIMENTAL|ALXN1840|"ALXN1840 was administered orally for 48 weeks at doses ranging from 15 milligrams (mg) every other day (QOD) up to a titrated dose of 60 mg daily.~Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period."
62274951|NCT03403205|ACTIVE_COMPARATOR|Standard of Care (SoC) Medication|SoC medication was administered for 48 weeks. Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.
62274952|NCT06042933|EXPERIMENTAL|Group A|early oral intake 6 hours postoperative.
62274953|NCT06042933|ACTIVE_COMPARATOR|Group B|delayed oral intake after 72 hours
62274954|NCT03756038|EXPERIMENTAL|Drug: Oral Lorazepam (1mg)|Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
62454461|NCT05065645|ACTIVE_COMPARATOR|APN01|Angiotensin Converting Enzyme 2: 1.25 mg/ml, 2.5 mg/ml or 5 mg/ml
62638139|NCT04008225||ARDS group|Inpatients hospitalized in medical intensive care with a table of ARDS defined according to the Berlin criteria and requiring an BAL for a diagnostic purpose under a suspicion of pneumopathy acquired under mechanical ventilation.
62638140|NCT04008225||Control group|The control group will be made up of patients with an BAL considered normal (endoscopy patients from the pneumology department). The normality of the BAL is defined by a normocellular wash with cellularity: \< 150,000 to 200,000 cells/mL Cell composition (formula): macrophages: 80-90%, lymphocytes 5 to 10% (\< 20%), neutrophils: \< 5%, eosinophils: \< 2%.
62638141|NCT06135844|EXPERIMENTAL|Treatment Group (Hand Sanitizer)|Participants with an early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion will be invited to participate in the study. Participants will apply a large drop of hand sanitizer in an unmarked container to a Q-tip and will hold the Q-tip on the lesion for 10 seconds. The hand sanitizer will be administered every waking hour in the same manner.
62652970|NCT02990000|EXPERIMENTAL|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
62652971|NCT04113694|EXPERIMENTAL|Extended Wear Infusion Set|Each subject is given 12 Extended Wear Infusion Sets to wear.
62274955|NCT03756038|PLACEBO_COMPARATOR|Drug: Oral Placebo|
62274956|NCT03473431|EXPERIMENTAL|ketamine|single infusion of 0.5 mg / kg ketamine
62274957|NCT03473431|SHAM_COMPARATOR|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
62274958|NCT00928538|NO_INTERVENTION|Usual NFP Care|Usual NFP care includes pregnancy planning and contraceptive advice during nurse home visits, with the prescription and dispensing of contraceptives provided through the women's primary care settings.
62274959|NCT00928538|EXPERIMENTAL|Enhanced NFP Care|Enhanced NFP intervention includes usual NFP care plus the intervention that includes contraceptive administration and distribution in the home
62454462|NCT05065645|PLACEBO_COMPARATOR|NaCl|Sodium Chloride: 0.9% NaCl solution
62638142|NCT06135844|PLACEBO_COMPARATOR|Control Group (Medical Grade Mineral Oil)|Participants with an early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion will be invited to participate in the study. Participants will apply a large drop of Medical Grade Mineral Oil in an unmarked container to a Q-tip and will hold the Q-tip on the HSV-1 lesion for 10 seconds. The medical grade mineral oil will be administered every waking hour in the same manner.
62638143|NCT06163001|EXPERIMENTAL|Exercise Group|
62638144|NCT06163001|ACTIVE_COMPARATOR|Dietary supplementation|
62638145|NCT03589807|EXPERIMENTAL|Heterologous Arm 1|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=30
62638146|NCT03589807|EXPERIMENTAL|Heterologous Arm 2|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
62638147|NCT03589807|EXPERIMENTAL|Heterologous Arm 3|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
62638148|NCT03589807|EXPERIMENTAL|Homologous Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 22. PBS diluent may be used to achieve targeted dosages. N=30
62638149|NCT03589807|EXPERIMENTAL|Homologous Arm 2|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 121. PBS diluent may be used to achieve targeted dosages. N=30
62638150|NCT03589807|EXPERIMENTAL|Homologous Arm 3|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 Adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
62274960|NCT03598166|NO_INTERVENTION|Control|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Patients who call will speak to a research assistant who is trained in patient navigation and can facilitate referrals for colonoscopy or FIT. Patients will receive a follow-up telephone call that reiterates information in the letter.~Patients will also be asked to complete a questionnaire about their beliefs and attitudes regarding CRC screening. The questionnaire will be mailed with the invitation letter and will also be administered over the telephone by the research assistant."
62638151|NCT01832181||Metformin|
62638152|NCT01832181||Control|
62638153|NCT04958876|EXPERIMENTAL|SP-104 crossover to naltrexone immediate release|SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration
62287136|NCT03623724|EXPERIMENTAL|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
62638154|NCT04958876|EXPERIMENTAL|Naltrexone immediate release crossover to SP-104|Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration
62638155|NCT04449965|EXPERIMENTAL|PVP-I sinus rinses and throat gargles|Participants will dilute 7 mL of 10% PVP-I into 300 mL of saline for a final concentration of 0.23% available iodine. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
62638156|NCT04449965|PLACEBO_COMPARATOR|Placebo sinus rinses and throat gargles|Participants will dilute 7 mL of PVP-I placebo into 300 mL of saline. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
62638157|NCT04449965|EXPERIMENTAL|PVP-I gel forming nasal spray|0.6% PVP-I gel forming nasal spray will come prepared and ready for participants to use. They will be instructed to use two sprays to each nostril each time they administer the spray.
62638158|NCT04776408|ACTIVE_COMPARATOR|Control group_Use Lung recruitment|Use the Lung recruitment,
62638159|NCT04776408|EXPERIMENTAL|Study group_Use Lung recruitment combined inhaled Nitric oxide|Use the Lung recruitment combined inhaled Nitric oxide,
62638160|NCT01967160||XGEVA inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
62638161|NCT01967160||Zoledronic acid inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
62638162|NCT01967160||XGEVA-switch cohort|Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (\<24 IV infusions or \<24 monthly oral prescriptions)
62638163|NCT03736655|EXPERIMENTAL|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
62638164|NCT04789408|EXPERIMENTAL|KITE-222|"Dose Escalation: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-222 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-222 to determine the maximum tolerated dose (MTD) of KITE-222.~Dose Expansion: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose (at the MTD determined) of KITE-222."
62638165|NCT03810157|EXPERIMENTAL|Laser-assisted hatching system|Embryos were exposed to a dose of laser energy focused outside the zona pellucida by aser-assisted hatching system.
62638166|NCT03810157|NO_INTERVENTION|Control group|Nothing is done.
62638167|NCT01105104|OTHER|MedMinder System|
62638168|NCT01105104|OTHER|MedMinder System - deactivated|
62638169|NCT00705094||1|Testicular cancer patients who have received surgery and are scheduled for surveillance
62638170|NCT00705094||2|Testicular cancer patients who have received surgery and are scheduled for chemotherapy
62638171|NCT05447065|EXPERIMENTAL|Participants using vitamin D supplements|Participants in the experimental group were given 150,000 IU (10 ml) of vitamin D3 supplementation, and it was used regularly for 2 months. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
62638172|NCT05447065|NO_INTERVENTION|Participants not using vitamin D supplements|No supplement was given to the control group. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
62638173|NCT05554029|EXPERIMENTAL|Study group|Patients with rheumatic diseases
62638174|NCT03666442|EXPERIMENTAL|chemotherapy group|patients receive 4 cycles of Xelox
62638175|NCT04152681|EXPERIMENTAL|Assigned Interventions|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
62638176|NCT02479555|ACTIVE_COMPARATOR|Treatment Group: Dexamethasone Delivery|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy.~Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm."
62638177|NCT02479555|NO_INTERVENTION|Control Group|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy. Control Group: Standard endovascular revascularization therapy consisting of angioplasty with or without stent placement. No specific distribution of gender regarding enrollment or randomization is intended. There will also be a separate randomization of patients with Rutherford 6 score to a maximum of 20 enrolled patients."
62638178|NCT01299350|NO_INTERVENTION|Usual|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged according to routine clinical practice based on symptoms, physical examination and other data that the cardiologist deems appropriate, except for Nt-proBNP.
62638179|NCT01299350|EXPERIMENTAL|Nt-proBNP guided|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
62638180|NCT06276374|EXPERIMENTAL|Single antiplatelet therapy (SAPT) group with aspirin or clopidogrel|1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)
62638181|NCT06276374|ACTIVE_COMPARATOR|Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel|1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)
62638182|NCT04018495|EXPERIMENTAL|Interventional - Fitbit tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
62638183|NCT01598805|EXPERIMENTAL|roll out of eAlerts|Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
62638184|NCT00856791|EXPERIMENTAL|ON 01910.Na|3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle
62638185|NCT04620577||Antibiotic group|Infusion of ceftriaxone sodium needle (2g, solvent 100ml normal saline) within 1h before and 12h after PTCD.
62638186|NCT04620577||No-antibiotic group|Infusion of Normal saline within 1h before and 12h after PTCD.
62461620|NCT00304083|EXPERIMENTAL|Chemotherapy and local control by surgery|Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.
62638187|NCT05010213|NO_INTERVENTION|Control group|There will be no intervention to the control group.
62638188|NCT05010213|EXPERIMENTAL|Experimental group|The experimental group will be given training based on the roy adaptation model.
62638189|NCT04362124|EXPERIMENTAL|vaccine BCG|"A single dose intradermal application of 0.1 ml of between 1 x 105 to 33 x 105 CFU of BCG, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
62638190|NCT04362124|PLACEBO_COMPARATOR|Placebo|"A single dose intradermal application of 0.1ml of normal saline solution, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
62638191|NCT05660096|NO_INTERVENTION|Patient with Cerebral Palsy, no intervention|Gait analysis of cerebral palsy patients without any intervention.
62070148|NCT05165953||Group 1: COVID-19 positive with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control \[8\], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
62070149|NCT05165953||Group 2: COVID-19 positive with no asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
62070150|NCT05165953||Group 3: COVID-19 negative with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control \[8\], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
62070151|NCT01751815|EXPERIMENTAL|Acu-TENS|
62638192|NCT05660096|ACTIVE_COMPARATOR|Patient with Cerebral Palsy, with sleeve|Gait analysis of cerebral palsy patients while wearing neural sleeve.
62070152|NCT01751815|SHAM_COMPARATOR|Placebo-TENS|
62070153|NCT00144872|EXPERIMENTAL|Subjects receiving lamotrigine|Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.
62070154|NCT00823420|EXPERIMENTAL|in-vitro maturation of oocytes|
62070155|NCT00632164||1|Cervical adjustments
62070156|NCT00632164||2|Thoracic adjustments
62461621|NCT05607238|ACTIVE_COMPARATOR|Ultrasound Guided Peripheral IV|Placement of 4-5cm angiocath under ultrasound guidance
62461622|NCT05607238|EXPERIMENTAL|Ultrasound Guided Midline Catheter|Placement of 10-15cm midline catheter under ultrasound guidance
62461623|NCT04332627|ACTIVE_COMPARATOR|sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
62638193|NCT05362708|EXPERIMENTAL|Experimental group - VRH|Patients will receive VRH during port-a-cath (Port) placement
62287137|NCT03623724|ACTIVE_COMPARATOR|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
62461624|NCT04332627|PLACEBO_COMPARATOR|neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
62638194|NCT05362708|NO_INTERVENTION|Control Group|Patients who do not want to receive the VRH but who accept to answer the questionnaires will be considered as a control group.
62638195|NCT00987168|EXPERIMENTAL|Sandostatine LP|
62461625|NCT00617305|EXPERIMENTAL|Ambrisentan|Patients were assigned ambrisentan at open-label enrollment or randomization, and received at least one dose of ambrisentan plus an approved phosphodiesterase type-5 (PDE-5) inhibitor (PDE-5i; sildenafil or tadalafil).
62638196|NCT05707416|ACTIVE_COMPARATOR|Experimental group|Will includes 9 patients who will receive intrusive arche after leveling and alignment assisted with laser with wavelength 635 nm, 6.5J/cm2,The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
62638197|NCT05707416|ACTIVE_COMPARATOR|Control group|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
62638198|NCT02926963|EXPERIMENTAL|Chronic Granulomatous Disease|Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.
62638199|NCT00989222|OTHER|Volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
62638200|NCT00989222|OTHER|External fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
62454463|NCT02769208|ACTIVE_COMPARATOR|Group A: Pre-Filter Only Intervention|Subjects in Group A start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which both the HEPA and ESP are removed, leaving only a pre-filter. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
62070157|NCT02440594|EXPERIMENTAL|Enhanced Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
62638201|NCT02136537|ACTIVE_COMPARATOR|Best medical therapy|Claudicants treated according to local protocol - no added treatment
62638202|NCT02136537|EXPERIMENTAL|Best medical therapy plus NMES|In addition to best medical therapy, subjects will receive bilateral neuromuscular stimulation of their legs, 4 hours per day.
62274961|NCT03598166|EXPERIMENTAL|Septin9|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Letters will also include an option to participate in the blood test, with instructions to call the study number to schedule the blood draw. This option will not appear in the letters sent to the control group. Patients will also receive a follow-up telephone call and a questionnaire.~Participants who choose to the blood test (Septin9) will undergo phlebotomy. The blood sample will be run by an off-site commercial laboratory. The study team will notify patients and their primary care physicians of blood test results and will facilitate a colonoscopy referral for those with positive tests."
62274962|NCT02381119|EXPERIMENTAL|Personalized advice|Dietitian provides Personalized dietary advice (based on genetic, blood and food intake profiles) (the type of advice is the intervention)
62638203|NCT05743153|EXPERIMENTAL|Patients with ulcerative colitis|Patients participate in multimodal intervention
62274963|NCT02381119|ACTIVE_COMPARATOR|Regular care|Dietitian provides regular care for diabetes type 2 (regular advice is the control condition)
62274964|NCT05399459|EXPERIMENTAL|Rimegepant 25 mg|Single dose of 25 mg orally disintegrating tablet of rimegepant
62274965|NCT05399459|EXPERIMENTAL|Rimegepant 75 mg|Single dose of 75 mg orally disintegrating tablet of rimegepant
62274966|NCT05399459|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet
62454464|NCT02769208|ACTIVE_COMPARATOR|Group B: Pre-filter + HEPA Intervention|Subjects in Group B start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which the ESP is removed, leaving a pre-filter + HEPA combination. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
62454465|NCT02141256|EXPERIMENTAL|Protein enriched products|Protein enriched products will be given to elderly residents of a care home for 10 days. Does this lead to an increased protein intake or do elderly compensate for the extra amount of protein?
62454466|NCT04109170||Dry Eye Group|This group of subjects were diagnosed with dry eye.
62454467|NCT04109170||Normal Control Group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
62454468|NCT04786652|EXPERIMENTAL|Assessment of fluid responsiveness|
62638204|NCT03280407|ACTIVE_COMPARATOR|A, capecitabine|Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy
62638205|NCT03280407|EXPERIMENTAL|B, FOLFOX or CAPOX|Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice
62638206|NCT02709148|EXPERIMENTAL|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
62070158|NCT02440594|ACTIVE_COMPARATOR|Standard Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
62454469|NCT00337077|EXPERIMENTAL|Eribulin mesylate|Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62454470|NCT06158269|EXPERIMENTAL|DVRd group|Daratumumab combined with bortezomib, lenalidomide and dexamethasone
62274967|NCT01188083|EXPERIMENTAL|Fructose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
62274968|NCT01188083|EXPERIMENTAL|Glucose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
62454471|NCT06482489||Healthy volunteers for protocol optimization|The commencement of the study involves the formulation of the 0.55T MRI protocol. For this purpose, a cohort of 23 male volunteers will undergo a 0.55T MRI. The objective is to achieve the same spatial resolution and coverage as observed at 3T.
62274969|NCT00713583|EXPERIMENTAL|Levodopa pharmacotherapy|Levodopa pharmacotherapy (800mg levodopa and 200mg carbidopa per day), cognitive behavioral therapy (CBT), and contingency management (CM).
62274970|NCT00713583|PLACEBO_COMPARATOR|Placebo|Placebo, cognitive behavioral therapy (CBT), and contingency management (CM).
62070159|NCT02440594|EXPERIMENTAL|Enhanced Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Enhanced BHL Program Services, which for this group include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Monitoring via a one-time BHP follow-up call with the enrollee after 6 weeks to discuss continuing versus discontinuing the medication.
62070160|NCT02440594|ACTIVE_COMPARATOR|Standard Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
62274971|NCT04293770|EXPERIMENTAL|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
62274972|NCT05339672||Morphine|The participating patients are treated with morphine before start of enzalutamide (according to label).
62274973|NCT05339672||Edoxaban|The participating patients are treated with edoxaban before start of enzalutamide (according to label).
62274974|NCT03726164|ACTIVE_COMPARATOR|Remote Conditioning group|Patients will receive a standard remote ischaemia preconditioning protocol comprising a blood pressure cuff placed on arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle repeated three times, prior to the PCI procedure.
62274975|NCT03726164|PLACEBO_COMPARATOR|Control Group|Patients will receive a standard sham remote ischaemia preconditioning protocol with an un-inflated cuff be placed on the arm in this group of patients for 30 minutes. This is the sham intervention for this group.
62274976|NCT04327388|EXPERIMENTAL|Sarilumab 200 mg|"Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]):~* Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~* Increase/recurrence of fever or~* Increase/no change in fraction of inspired oxygen (FiO2) requirement or~* Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction."
62638207|NCT01268852|ACTIVE_COMPARATOR|Damon|Standard self ligating orthodontic Damon brackets
62638208|NCT01268852|EXPERIMENTAL|Insignia|Innovative self ligating orthodontic bracket
62638209|NCT06426667||posterior tibial nerve radiofrequency|posterior tibial nerve pulsed radiofrequency treatment
62638210|NCT06426667||plantar fasciitis radiofrequency|calcaneal spur thermocoagulation radiofrequency treatment
62274977|NCT04327388|EXPERIMENTAL|Sarilumab 400 mg|"Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]):~* Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~* Increase/recurrence of fever or~* Increase/no change in FiO2 requirement or~* Required vasopressors, ECMO or development of multi-organ dysfunction."
62274978|NCT04327388|PLACEBO_COMPARATOR|Placebo|"Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 \[dated 08-Apr-2020\]):~* Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~* Increase/recurrence of fever or~* Increase/no change in FiO2 requirement or~* Required vasopressors, ECMO or development of multi-organ dysfunction."
62287138|NCT01292967|PLACEBO_COMPARATOR|Low flavanol|Low-flavanol chocolate contained 48 mg of cocoa flavanols. macro- and micro-nutrient matched with active comparator
62287139|NCT01292967|ACTIVE_COMPARATOR|High-flavanol with sugar|High-flavanol chocolate made with added sugar containing 251 mg of cocoa flavanols
62454472|NCT06482489||Study of 0.55T Prostate MRI in Adult Men with Metal Implants.|The second phase of the research will be carried out to compare the MRI image quality between 0.55T and 3T MRI. The study will involve 20 adult men, who on 3T prostate MRI, have DWI reported as sub-diagnostic (PI-QUAL \< 3) due to the presence of metallic implant(s).
62454473|NCT06482489||Evaluation of 0.55T Prostate MRI in Adult Men with Suspicious Lesions.|The third phase includes 31 patients whose 3T MRIs detected lesions classified as PI-RADS 4/5 and who are scheduled for targeted prostate biopsy.
62638211|NCT06426667||posterior tibial nerve and plantar fasciitis radiofrequency|posterior tibial nerve pulsed radiofrequency and calcaneal spur thermocoagulation radiofrequency treatment
62638212|NCT02396225|EXPERIMENTAL|Inhaled voriconazole|12 patients inhale voriconazole 40 mg b.i.d for two days
62070161|NCT02440594|EXPERIMENTAL|Enhanced Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
62070162|NCT02440594|ACTIVE_COMPARATOR|Standard Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
62070163|NCT02440594|EXPERIMENTAL|Caregiver TEP Intervention|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Enhanced BHL Program Services which include: 1) a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services, and 2) the Telehealth Education Program (TEP) - BHPs provide manual and workbook-guided psychoeducation, support, and skills training.
62070164|NCT02440594|ACTIVE_COMPARATOR|Caregiver Control|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Standard BHL Program Services, which include a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services
62070165|NCT05083624|EXPERIMENTAL|Rehabilitation group|
62070166|NCT05083624|NO_INTERVENTION|control group|adhere to standardized management guidelines for anticoagulation, ventilation, sedation specific to the MICU ECMO population
62070167|NCT06356727|EXPERIMENTAL|Microvascular assessment|Coronary microvascular assessment
62070168|NCT02285595|OTHER|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
62070169|NCT00947037|EXPERIMENTAL|Extension|Open label extension, 1 arm
62070170|NCT02798029|EXPERIMENTAL|Treatment (FFSRT)|Patients undergo FFSRT daily over 30 minutes for 3-5 days.
62070171|NCT05095129||Experimental group:|patients with idiopathic scoliosis
62070172|NCT05095129||Control group|patients without idiopathic scoliosis
62454474|NCT06003920|EXPERIMENTAL|Process Group|Medical students enrolled in the small process group, led by psychiatrist.
62454475|NCT06003920|NO_INTERVENTION|Control Group|Medical students from the same cohorts, not enrolled in the small process group.
62274979|NCT04607083||Patients with at least one diminutive rectosigmoid polyp|"Consecutive adult (\>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected.~Exclusion criteria:~* patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~* patients with inadequate bowel preparation~* patients in which caecal intubation was not achieved or scheduled for partial examinations~* polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment~* patients undergoing urgent colonoscopy."
62274980|NCT03649295|EXPERIMENTAL|Functional Electrical Stimulation|"- Functional electrical stimulation device obeying the following steps: Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure. Conventional therapy should be performed in conjunction with functional electrostimulation~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
62274981|NCT03649295|PLACEBO_COMPARATOR|Placebo|"Sham.The electrodes are placed at 0 Hz~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
62274982|NCT03315767|OTHER|cirrhosis patients|"ARFI-elastography and portal vein flow measurement: Liver and spleen of patients with a scheduled HVPG-investigation will be examined by an ARFI-elastography-investigation. Additionally the portal vein flow will be assessed.~This examination will be done at d0 before the start of beta-blocker-administration and repeated as monitoring for portal hypertension treated by beta-blocker after 6 and 12 weeks, respectively.~HVPG-measurement: HVPG-values will be assessed at d0, after 6 and after 12 Weeks, respectively."
62274983|NCT01841333|EXPERIMENTAL|PF-04449913|Beginning 80 days after allogeneic stem cell transplant, patients receive PF-04449913 (100mg) orally once daily on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62638213|NCT02396225|ACTIVE_COMPARATOR|Oral Voriconazole|12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day
62638214|NCT05291624||Patients with preoperative suspicion of endometriosis|Consecutive patients undergoing ultrasonographic preoperative assessment and subsequent surgical approach for deep endometriosis
62638215|NCT02894333||Patients with Parkinson's disease|
62638216|NCT02314858|EXPERIMENTAL|Brief Personalized Video (BPV)|Our BPV intervention focuses on augmenting risk perception and reducing optimistic bias by showing the patient a dramatic video of his/her own apnea (which shows them struggle to breathe), as well as by explaining the physiological processes involved in an apneic event. Specific apneic events are highlighted and associated decreases in blood oxygen levels are demonstrated via oxygen saturation recording superimposed on the video. This group will receive educational information about OSA, its consequences and the need for treatment.
62274984|NCT02837315|EXPERIMENTAL|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS was described to participants as the College Adjustment Session and the session was conducted using an MI plus personalized feedback approach."
62287140|NCT01292967|ACTIVE_COMPARATOR|High flavanol Maltitol|High-flavanol chocolate made with the sugar substitute maltitol containing 266 mg cocoa flavanols
62287141|NCT02109159|EXPERIMENTAL|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
62638217|NCT02314858|ACTIVE_COMPARATOR|Non-Personalized Video (NPV)|NPV will include a video of someone having apnea, but it will not be personalized. This group will receive educational information about OSA, its consequences and the need for treatment.
62638218|NCT02314858|PLACEBO_COMPARATOR|Treatment As Usual (TAU)|The TAU group will receive no special treatment from study interventionist team and will not view a video.
62638219|NCT06238024|EXPERIMENTAL|Tocilizumab group|Intravenously for more than 1 hour.
62638220|NCT06238024|PLACEBO_COMPARATOR|Control group|Intravenously for more than 1 hour.
62638221|NCT02233218|EXPERIMENTAL|telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 40 subjects. Telmisartan80mg + Amlodipine 10mg 9 days, Telmisartan80mg + Amlodipine 10mg , Rosuvastatin 20mg 5days Total 14days administration of investigational products to healthy male volunteers
62070173|NCT00346801|EXPERIMENTAL|CPT-11 + Celecoxib/Cisplatin with RT|CPT-11 + Celecoxib + Cisplatin + Radiation Therapy (RT)
62274985|NCT02837315|ACTIVE_COMPARATOR|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, students were asked about their reaction to the relaxation techniques and were provided with relaxation training handouts.
62274986|NCT02837315|NO_INTERVENTION|Assessment|Participants fill out a battery of measures and receive no intervention.
62274987|NCT01030510|ACTIVE_COMPARATOR|group R|In group R, remifentanil was infused first before administrating propofol and rocuronium
62274988|NCT01030510|ACTIVE_COMPARATOR|group P|in group P, remifentanil was administered last after the propofol and rocuronium injection
62274989|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
62638222|NCT02233218|EXPERIMENTAL|Telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 20 subjects. Rosuvastatin 20mg 5 days, Rosuvastatin 20mg , Telmisartan80mg + Amlodipine 10mg 9days, Total 14days administration of investigational products to healthy male volunteers
62638223|NCT05901337|ACTIVE_COMPARATOR|Cupping therapy with Convential medical treatment|Cupping therapy with Convential medical treatment
62638224|NCT05901337|ACTIVE_COMPARATOR|Convential medical treatment|Convential medical treatment
62638225|NCT05974566||HFrEF patients who accept finerenone therapy|Patients with HFrEF receive finerenone 10mg or 20mg daily treatment for 3 months in addition to other medications.
62638226|NCT05974566||HFrEF patients who accept Spironolactone or eplerenone therapy|Patients with HFrEF receive spironolactone or eplerenone treatment daily treatment for 3 months in addition to other medications.
62274990|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
62274991|NCT03887754|ACTIVE_COMPARATOR|The Hyperbaric oxygen therapy group|This group consists of twenty autistic children received forty sessions of HBOT, the time of the session is one hour. The sessions were done at pressure 1.5 ATA (atmosphere absolute) and with 100% oxygen concentration, either in multiplace or monoplace chamber. The number of sessions per week allowed is five sessions per week, all participants were required to complete forty sessions within two months. After six months from the last session, another forty sessions would be taken in the same manner
62274992|NCT03887754|ACTIVE_COMPARATOR|The Risperidone group|"This group consists of twenty autistic children received Risperidone (dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more) for eight months.~The medication schedule in the initial 2 months was based on the child's weight and clinical response. Adjusting the total daily dose according to response and/or adverse effects, at the end of these eight months of treatment we began the discontinuation phase. In this phase, gradual placebo substitution occurs. The discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the last week in the eight months for the first week, followed by 50% of the last week for the second week, 25% of the last week for the third week, and placebo only by the fourth week."
62274993|NCT03887754|ACTIVE_COMPARATOR|The HBOT and Risperidone group|This group consists of twenty autistic children received HBOT as the HBOT group in addition to Risperidone as the Risperidone group in the same manner and duration
62638227|NCT05726487|EXPERIMENTAL|ACTION Intervention|Orientation (week 0): 1 group session Induction phase (weeks 1-12): 8 weekly then 2 bi-weekly goal setting via text with health coach + 2 group sessions (week 5, 9) Adoptive phase (weeks 13-24): 2 monthly goal setting with remote health coach + 3 group sessions (week 13, 17, 21) Maintenance phase (weeks 25-48): 1 group session Outcome assessment (12-, 24-, and 48-weeks)
62638228|NCT05726487|OTHER|Education Control|Orientation (week 0): 1 individual asthma education session Education texts: weekly (weeks 1-8), then bi-weekly (week 9-12), then monthly (weeks 13-24) Outcome assessments (12-, 24-, 48-weeks)
62274994|NCT03887754|PLACEBO_COMPARATOR|The Control group|This group consists of twenty autistic children received placebo in the form of multivitamins
62638229|NCT01981668|EXPERIMENTAL|Cabazitaxel, Eligard and Radiotherapy|This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
62638230|NCT05344222|EXPERIMENTAL|Photobiomodulation|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
62070174|NCT05304923|EXPERIMENTAL|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
62070175|NCT05304923|PLACEBO_COMPARATOR|nasal cannula oxygen supply|Oxygen supplementation is delivered via a nasal cannula to the participants during sedation.
62454476|NCT01456481|ACTIVE_COMPARATOR|midodrine hydrochloride pills|
62454477|NCT01456481|PLACEBO_COMPARATOR|oral placebo or sugar pill|
62638231|NCT05344222|SHAM_COMPARATOR|Sham Photobiomodulation|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
62070176|NCT04978259|EXPERIMENTAL|Standard of care plus remdesivir|Local standard of care plus daily remdesivir infusion for up to 10 days (or until discharge)
62070177|NCT04978259|NO_INTERVENTION|Standard of care|Local standard of care
62638232|NCT00799084|EXPERIMENTAL|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
62638233|NCT00799084|EXPERIMENTAL|AVR|Receives symptom management assistance from an Automated telephone system
62638234|NCT02481076|EXPERIMENTAL|compression therapy|"Intervention arm: administration of~* Flowtron Hydroven boot in the Emergency Department~* Coban2 Lite after surgery~* Flowtron Hydroven boot after surger, before discharge"
62070178|NCT00049400|EXPERIMENTAL|treatment|Single-arm, dose-escalation of BMS-247550
62070179|NCT00902941|EXPERIMENTAL|Rasagiline|
62070180|NCT00902941|PLACEBO_COMPARATOR|Placebo|
62454478|NCT05936710|OTHER|Control group|Using acetate-based dialysate
62454479|NCT05936710|EXPERIMENTAL|Experimental group|Using citrate-based dialysate
62454480|NCT06224400|EXPERIMENTAL|ENC1018 for SAD|6 of out 8 subjects per cohort will be randomized to receive ENC1018
62454481|NCT06224400|PLACEBO_COMPARATOR|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
62454482|NCT06224400|EXPERIMENTAL|ENC1018 for MAD|6 of out 8 subjects per cohort will be randomized to receive ENC1018
62454483|NCT06224400|PLACEBO_COMPARATOR|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
62454484|NCT02642666|EXPERIMENTAL|Yoga intervention|While in the yoga intervention arm of the study participants will practice yoga at home and at school for six weeks with the goal of practicing yoga daily during that time period. Yoga classes will be held twice a week at school. On the days that the children do not practice yoga at school, they will practice yoga at home with the use of a children's yoga video that mirrors the yoga class that they attend at school.
62454485|NCT02642666|NO_INTERVENTION|Normal school and home activities|While in the wait-list group the children will continue with their regular activities both at home and at school.
62454486|NCT03314025|EXPERIMENTAL|Tamsulosin|The patients in the Experimental group will receive Tamsulosin Hydrochloride 0.4 MG (milligrams) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
62454487|NCT03314025|PLACEBO_COMPARATOR|Placebo|The patients in the Placebo group will receive a placebo oral capsule (sugar) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
62454488|NCT00417209|EXPERIMENTAL|Larotaxel (XRP9881)|
62454489|NCT00417209|ACTIVE_COMPARATOR|5-Fluorouracil or capecitabine|Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
62454490|NCT00963209|EXPERIMENTAL|Tamoxifen|
62070181|NCT01091623|ACTIVE_COMPARATOR|strength training|
62454491|NCT01728012||eGFR >=60ml/min/1.73m2|Patients with an estimated glomerular filtration rate of \>=60 ml/min/1.73m2.
62454492|NCT01728012||eGFR 45-60ml/min/1.73m2|Patients with estimated glomerular filtration rate \>=45 ml/min/1.73m2 and \<60ml/min/1.73m2.
62454493|NCT03409601|EXPERIMENTAL|100% Portion Size|Test meal consists of baseline (100%) portion size of meal.
62454494|NCT03409601|EXPERIMENTAL|125% Portion Size|Test meal consists of food portion size that is 125% the size of baseline portion.
62454495|NCT03409601|EXPERIMENTAL|150% Portion Size|Test meal consists of food portion size that is 150% the size of baseline portion.
62454496|NCT03409601|EXPERIMENTAL|175% Portion Size|Test meal consists of food portion size that is 175% the size of baseline portion.
62461626|NCT00617305|ACTIVE_COMPARATOR|Placebo|Patients were assigned placebo at randomization and received at least one dose of placebo plus an approved PDE-5i (sildenafil or tadalafil).
62461627|NCT03260465|EXPERIMENTAL|seleXys PC|seleXys PC cup combined with the optimys stem
62461628|NCT03260465|ACTIVE_COMPARATOR|RM|RM Pressfit vitamys cup combined with the optimys stem
62461629|NCT01879137||healthy adults|
62461630|NCT01879137||Patients with a polyuria-polydipsia syndrome|
62461631|NCT01376102||BONVIVA(ibandronate)|Patients administrated ibandronate injection with postmenopausal osteoporosis
62461632|NCT02648620|EXPERIMENTAL|SurVeil Drug Coated Balloon catheter|Paclitaxel Coated Balloon catheter for angioplasty
62461633|NCT05070611|EXPERIMENTAL|Recurrent chalazia with IPL-MGX|The patients whose lesions had failed to respond to warm compresses and antibiotic and steroid treatment underwent incision and curettage. One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid. After removal of the ultrasound gel, meibomian gland expression (MGX) was performed with forceps-shaped meibomian gland compressor.
62461634|NCT06213844|PLACEBO_COMPARATOR|Placebo|Single dose of Placebo administered subcutaneously on Day 1
62461635|NCT06213844|EXPERIMENTAL|IBI3002|Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6) administered subcutaneously on Day 1
62461636|NCT00176306|EXPERIMENTAL|Levofloxacin|Patients receiving levofloxacin 750mg IV
62461637|NCT01833052|OTHER|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
62461638|NCT01833052|OTHER|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
62461639|NCT01696097|OTHER|Dietary Counseling|Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure
62461640|NCT02337309|OTHER|SF1126|Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.
62461641|NCT04849520|EXPERIMENTAL|High flow|Application of high flow nasal cannula during apnea
62070182|NCT01091623|ACTIVE_COMPARATOR|endurance training|
62070183|NCT01091623|ACTIVE_COMPARATOR|combined training|
62070184|NCT03695341||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
62638235|NCT02481076|OTHER|controle|"The leg is elevated on a Braun frame. This is the old fashioned conservative treatment to prevent swelling."
62070185|NCT03695341||Everolimus plus Exemestane|Everolimys 10 mg or 5 mg daily; Exemestane 25mg per day
62274995|NCT00132132|EXPERIMENTAL|Intervention|This is a long term randomized controlled study looking at the effect of a Behavioral program on BMI in a population 10-20years old with a BMI greater than or equal to 85%. The intervention is a Behavioral education program which meets monthly for 4 hour session and includes exercise, education, empowerment and incentives. Both groups are referred to a dietician. The primary outcome is change in BMI and the secondary outcome is improvement in fasting metabolic parameters (lipid panel, insulin, glucose).
62274996|NCT00132132|NO_INTERVENTION|Standard of Care/Control|Education on physical activity and nutrition in a primary care office setting
62274997|NCT05072132|EXPERIMENTAL|Inefficient metabolizers|Participants will be selected based on being inefficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are inefficient metabolizers and at increased risk for arsenic toxicities).
62274998|NCT05072132|EXPERIMENTAL|Efficient metabolizers|Participants will be selected based on being efficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are efficient metabolizers and at decreased risk for arsenic toxicities).
62638236|NCT03690713||Patient and Vessels underwent physiologic evaluation|The total 1397 patients (1694 vessels) which evaluated using pressure-temperature sensor wire and measured FFR, CFR, and IMR.
62638237|NCT05988567|PLACEBO_COMPARATOR|Placebo candy|
62638238|NCT05988567|EXPERIMENTAL|melon and oil olive pressed candy|
62070186|NCT05713760|EXPERIMENTAL|5 Day treatment course 1 with Tirbanibulin Ointment 1%|10 Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
62070187|NCT05713760|EXPERIMENTAL|5 Day treatment course 2 with Tirbanibulin Ointment 1%|Subjects with unresolved lesion will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
62638239|NCT04226417|ACTIVE_COMPARATOR|Dual-tDCS & home program exercise|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered for 20 minutes before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
62070188|NCT01989286||Plagiocephaly group-Assessment|Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
62652972|NCT00658853|ACTIVE_COMPARATOR|1|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a 5% graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
62652973|NCT00658853|ACTIVE_COMPARATOR|2|4 times 4 minutes interval training in hyperoxia - 100% oxygen
62652974|NCT00658853|ACTIVE_COMPARATOR|3|One leg at a time training 4 times 4 minutes interval training using cycling ergometer
62274999|NCT05072132|ACTIVE_COMPARATOR|Control group|The control group will consist of a random sample of HEALS participants. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. No information on arsenic metabolism efficiency will be provided during the study period (option to receive after the study)
62275000|NCT02816918|EXPERIMENTAL|Extraluminal use of Univent Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
62275001|NCT02816918|EXPERIMENTAL|Innerluminal use of Univent Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
62275002|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
62275003|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
62275004|NCT00243659|EXPERIMENTAL|A|
62275005|NCT00243659|EXPERIMENTAL|B|
62275006|NCT03536455|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62652975|NCT04132765||Patients with cerebral palsy|Patients with cerebral palsy at between the ages of 4-16 years and at Gross Motor Function Classification Levels of 3,4,5
62070189|NCT03472573|EXPERIMENTAL|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62275007|NCT03536455|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62275008|NCT00993746|ACTIVE_COMPARATOR|Bupivacaine plus lidocaine|Group 1: bupivacaine 20 ml plus lidocaine 10 ml
62275009|NCT00993746|EXPERIMENTAL|Bupivacaine alone|Group 2: bupivacaine 30 ml
62275010|NCT02921971|PLACEBO_COMPARATOR|Placebo|Placebo (for SAR156597), single subcutaneous (SC) injection once in a week (QW) up to Week 24.
62275011|NCT02921971|EXPERIMENTAL|SAR156597|SAR156597 200 milligram (mg), single SC injection QW up to Week 24.
62275012|NCT00513760|EXPERIMENTAL|1|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
62275013|NCT00513760|ACTIVE_COMPARATOR|2|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
62275014|NCT00513760|PLACEBO_COMPARATOR|3|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
62275015|NCT02977169|EXPERIMENTAL|Arm I (PORT)|Participants in the Arm I will receive four cycles of adjuvant chemotherapy and after that, sequential adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered. PORT begins within 2-4 weeks after chemotherapy.
62275016|NCT02977169|PLACEBO_COMPARATOR|Arm II (no PORT)|Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, do not undergo adjuvant thoracic conformal radiotherapy.
62070190|NCT03949660|EXPERIMENTAL|Epidural stimulation for blood pressure without stand|To assess whether epidural stimulation, used for regulating blood pressure without standing, is neuromodulatory for bowel motility after motor complete SCI
62275017|NCT02896595|ACTIVE_COMPARATOR|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
62638240|NCT04226417|SHAM_COMPARATOR|Sham-tDCS & home program exercise|Sham transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered only 30 seconds before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
62070191|NCT03949660|EXPERIMENTAL|Epidural stimulation for blood pressure with stand|To assess whether epidural stimulation, used for regulating blood pressure with standing, is neuromodulatory for bowel motility after motor complete SCI
62070192|NCT03949660|EXPERIMENTAL|Epidural stimulation for trunk and core without stand|To assess whether epidural stimulation, used for activating the trunk and core musculature without standing, is neuromodulatory for bowel evacuation after motor complete SCI
62638241|NCT05959265|EXPERIMENTAL|Arm1|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
62652976|NCT04456686|EXPERIMENTAL|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 milligram (mg) as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses.
62652977|NCT04456686|PLACEBO_COMPARATOR|Placebo|Participants received placebo every 2 weeks by IV infusion for a total of 4 doses.
62275018|NCT02896595|ACTIVE_COMPARATOR|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
62287142|NCT02109159|ACTIVE_COMPARATOR|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
62070193|NCT03949660|EXPERIMENTAL|Epidural stimulation for trunk and core with stand|To assess whether epidural stimulation, used for activating the trunk and core musculature with standing, is neuromodulatory for bowel evacuation after motor complete SCI
62287143|NCT01634932|EXPERIMENTAL|regular-iron millet|
62287144|NCT01634932|EXPERIMENTAL|iron-biofortified millet|
62454497|NCT01992055|EXPERIMENTAL|Goal Management Training|The modified GMT intervention will consist of seven group sessions and, similar to van Hooren et al (2007), an individual session with a neuropsychologist on Session 5. Sessions will be held twice weekly. The manualized group sessions will include: (1) structured psychoeducation introducing participants to the brain and executive functioning, the relationship between stress and cognitive functioning, and relaxation training; (2) stepwise learning of GMT, including education regarding attentional lapses and goal neglect, as well as in-session practice targeting individual everyday functional deficits with the goal of maximizing generalization. Homework assignments targeting individual functional deficits will be assigned following each session.
62070194|NCT02388074|EXPERIMENTAL|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent \[ie, cancer\] cells (RFCs) from deep-lung sputum samples.
62638242|NCT05959265|NO_INTERVENTION|Arm2|Patients in the control group will receive standard cancer treatment and will not be instructed to avoid exercise. They will also be provided with fitness trackers to record their daily average heart rate and step count to evaluate their daily activity level. Furthermore, participants will be retrospectively asked about their physical activity during the intervention period at the end of the intervention phase.
62638243|NCT04191889|EXPERIMENTAL|TRIPLET|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
62638244|NCT01289886|OTHER|Arm A|BR-A-657 20mg or placebo
62638245|NCT01289886|OTHER|Arm B|BR-A-657 60mg or placebo
62638246|NCT01289886|OTHER|Arm C|BR-A-657 120mg or placebo
62638247|NCT01289886|OTHER|Arm D|BR-A-657 240mg or placebo
62275019|NCT05132244|EXPERIMENTAL|Intensive Glucose Intervention|Participants will receive standard anti-hyperglycemic treatment as guided by an endocrinologist using a combination of data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Treatment will aim to maintain glucose levels between 4 and 10 mmol/L. Participants will have real-time access to their glucose data via the CGM.
62275020|NCT05132244|OTHER|Standard Care|Participants will receive standard anti-hyperglycemic treatment only if blood glucose level is above 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a CGM but will not be able to view their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
62275021|NCT02991092|EXPERIMENTAL|the experimental group|After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h
62275022|NCT02991092|OTHER|the control group|"patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
62638248|NCT01289886|OTHER|Arm E|BR-A-657 480mg or placebo
62638249|NCT05036213|ACTIVE_COMPARATOR|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
62638250|NCT05036213|PLACEBO_COMPARATOR|concentrated beet root juice with depleted nitrate content|The placebo treatment is also beetroot juice provide by the same company (BEET IT, James White Drinks, Ipswich, UK), but it does not contain any inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
62638251|NCT03988933|EXPERIMENTAL|Intervention Arm 1|Two months of daily self-administered rifampin at 20 mg/kg (maximum 1200 mg/day).
62638252|NCT03988933|EXPERIMENTAL|Intervention Arm 2|Two months of daily self-administered rifampin at 30 mg/Kg (maximum 1800 mg/day).
62638253|NCT03988933|ACTIVE_COMPARATOR|Control Arm|Four months of daily self-administered rifampin at a dose of 10mg per kg per day (maximum 600mg per day).
62638254|NCT02546648|EXPERIMENTAL|Tranexamic Acid vs. matching placebo|Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.
62638255|NCT02546648|EXPERIMENTAL|Rosuvastatin vs. matching placebo|Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery
62638256|NCT05998681|EXPERIMENTAL|Breastfeeding and Basic Maternal-Neonatal Care and mobile messages group|"In the study, education on Breastfeeding and Basic Maternal-Neonatal Care was given to the women in the experimental group within the first 24 hours after the birth, and the training topics were sent as a mobile message for 6 weeks after the birth.~Education on Breastfeeding and Basic Maternal-Neonatal Care was given in 2 postpartum sessions. In the first session, breastfeeding education was given to women in practice, together with the first postpartum breastfeeding. At the beginning of the second session, breastfeeding training was repeated and then Basic Maternal-Neonatal Care training was given. The first session was given at the first breastfeeding time, and the second session was given between 20-24 hours after birth. Each session lasted approximately 20-25 minutes. In order to solve the problems of the mothers, questions, and answers were made before discharge, and breastfeeding of the mothers was observed."
62652978|NCT05759572|EXPERIMENTAL|Cohort 1|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with Apatinib and endocrine therapy.
62070195|NCT05310396|EXPERIMENTAL|Powdered cow's milk-based infant formula containing uniquely processed whey protein|Starter and follow up formula containing combination of an HMO blend, myelin nutrient blend, and MOS
62638257|NCT05998681|NO_INTERVENTION|Routine checks|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(A sociodemographic questionnaire including questions about age, educational level, employment, income level, whether the pregnancy was planned and the gender of the baby, as well as the personal phone numbers of the women, Breastfeeding Self-Efficacy Scale (BSES), IOWA-Infant Feeding Attitude Scale (IIFAS), and Being a Mother Scale (BaM-13) . The BSES, IIFAS, and BaM-13 were re-administered to all participants at postpartum 6 weeks as post-tests. In addition, the method by which the participants continued to feed their babies, their use of bottles or pacifiers, and their nipple problems were recorded in the form created by the researchers. Post-test data were collected by the researchers by contacting the participants by phone.
62638258|NCT02557399|EXPERIMENTAL|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
62638259|NCT02557399|ACTIVE_COMPARATOR|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
62638260|NCT03934671|EXPERIMENTAL|Antioxidant dressing (active product)|
62638261|NCT03934671|ACTIVE_COMPARATOR|Usual care dressing (standard clinical practice)|
62275023|NCT01197287|EXPERIMENTAL|QAK423A Arm A|
62275024|NCT01197287|EXPERIMENTAL|QAK423A Arm B|
62638262|NCT02043288|EXPERIMENTAL|NC-6004 and Gemcitabine combination|NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively
62638263|NCT02043288|ACTIVE_COMPARATOR|Gemcitabine monotherapy|Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15
62638264|NCT04025541|OTHER|COHORT 1 BREAST TUMOR/PALBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by palbociclib~BLOOD SAMPLING"
62638265|NCT04025541|OTHER|COHORT 2 BREAST TUMOR / RIBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by ribociclib~BLOOD SAMPLING"
62275025|NCT01197287|EXPERIMENTAL|QAK423A Arm C|
62275026|NCT00942474|EXPERIMENTAL|Research Arm|Facilitate nerve stimulation lead placement with the nerve access tool
62275027|NCT04693000|EXPERIMENTAL|Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|"An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.~Keratotic nodular size observation after 12 weeks"
62275028|NCT01375764|ACTIVE_COMPARATOR|Ezetimibe|Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
62638266|NCT04145856|PLACEBO_COMPARATOR|Placebo|- Control arm
62275029|NCT01375764|EXPERIMENTAL|Evolocumab + Ezetimibe|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
62287145|NCT01634932|EXPERIMENTAL|Post-harvest iron-fortified millet|
62638267|NCT04145856|EXPERIMENTAL|Probiotic|- Arm with active probiotic alone
62638268|NCT04145856|EXPERIMENTAL|Probiotic + Antispasmodic/Antifoam|- Arm with active probiotic combined to antispasmodic/antifoam drug
62638269|NCT06492434|EXPERIMENTAL|Peer decision coaching arm|All participants will engage in the Peer Decision Coaching intervention.
62638270|NCT04637841|ACTIVE_COMPARATOR|Diabetes Mellitus Kinesiology Taping Group|Kinesiology tape will be applied to the left foot of the participants in diabetes mellitus group.
62454498|NCT01992055|ACTIVE_COMPARATOR|Education & relaxation training|Education and relaxation training control group
62275030|NCT01375764|EXPERIMENTAL|Evolocumab 280 mg|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62275031|NCT01375764|EXPERIMENTAL|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62638271|NCT04637841|ACTIVE_COMPARATOR|Kinesiology Taping Control Group|Kinesiology tape will be applied to the left foot of the healthy participants in the control group.
62638272|NCT04637841|ACTIVE_COMPARATOR|Diabetes Mellitus Myofascial Release Group|Myofascial Release Technique will be applied to the right foot of the participants in diabetes mellitus group.
62638273|NCT04637841|ACTIVE_COMPARATOR|Myofascial Release Control Group|Myofascial Release Technique taping will be applied to the right foot of the healthy participants in the control group.
62638274|NCT01854749|EXPERIMENTAL|S1 combined with cisplatin|
62070196|NCT05310396|ACTIVE_COMPARATOR|Powdered infant fortified cow's milk|Standard Starter and follow up formula without added HMOs or MOS containing lower levels of myelin nutrients
62275032|NCT01375764|EXPERIMENTAL|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62454499|NCT04806308|EXPERIMENTAL|Intervention group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
62454500|NCT04806308|NO_INTERVENTION|Control group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
62454501|NCT01986582|ACTIVE_COMPARATOR|Group A|One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning \& evening, for 8 days.
62454502|NCT01986582|PLACEBO_COMPARATOR|Group B|One puff of oxymetazoline immediately followed by one puff of placebo, morning \& evening, for 8 days.
62461642|NCT04849520|ACTIVE_COMPARATOR|Buccal|Application of buccal oxygenation during apnea
62638275|NCT03744442|ACTIVE_COMPARATOR|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
62638276|NCT03744442|ACTIVE_COMPARATOR|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
62652979|NCT05759572|ACTIVE_COMPARATOR|Cohort 2|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with endocrine therapy.
62652980|NCT01732952||regions,hospitals,age, gender, risk levels, comorbidity,|
62275033|NCT04750538|EXPERIMENTAL|BreEStim 120, then BreEStim 240|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
62275034|NCT04750538|EXPERIMENTAL|BreEStim 240, then BreEStim 120|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
62275035|NCT04926974|EXPERIMENTAL|Seeing AI Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
62275036|NCT04926974|EXPERIMENTAL|Supervision+ Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
62638277|NCT03744442|ACTIVE_COMPARATOR|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
62638278|NCT01896193|EXPERIMENTAL|SOF+RBV 16 Weeks|SOF+RBV for 16 weeks
62638279|NCT01896193|EXPERIMENTAL|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
62638280|NCT03049878|ACTIVE_COMPARATOR|analgesic group|preoperative oral dose of paracetamol-codeine
62638281|NCT03049878|PLACEBO_COMPARATOR|placebo group|preoperative placebo (starch)
62638282|NCT02417753|EXPERIMENTAL|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
62638283|NCT03904420|EXPERIMENTAL|Group A - New Model|Standardized programming and testing method
62638284|NCT03904420|ACTIVE_COMPARATOR|Group B - Traditional Model|Traditional clinical model which is not standardized across clinical sites
62638285|NCT03136718||First-time hearing aid users|Individuals using hearing aids for the first-time (or if previous users, have not having worn hearing aids for more than 3 years) will have access to the mobile-enabled RLOs (mRLOs) intervention, which will be given to the participants shortly after their hearing aid is fitted.
62638286|NCT02862080|EXPERIMENTAL|no intervention; then no intervention; then cathode tsDCS + Ekso; then Ekso; then cathode tsDCS+Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
62638287|NCT02862080|EXPERIMENTAL|no intervention; then no intervention; then Ekso; then cathode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
62638288|NCT02862080|EXPERIMENTAL|no intervention; then no intervention; then anode tsDCS + Ekso; then Ekso; then anode tsDCS + Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
62638289|NCT02862080|EXPERIMENTAL|no intervention; then no intervention; then Ekso; then anode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
62638290|NCT04381780|EXPERIMENTAL|Assessing clinical outcomes|Nutritional support with Recovery Factors
62638291|NCT01361750|EXPERIMENTAL|gastirc tube group|conduit will be perfomed by narrowed gastric tube
62638292|NCT01361750|NO_INTERVENTION|control group|conduit will be traditional subtotal stomach without any surgical modification
62275037|NCT04926974|EXPERIMENTAL|Aira Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
62638293|NCT05989022|OTHER|Imaging Breast Diagnostic|Imaging breast diagnostic where patients receive both modalities MRI and B-CT to compare the resolution of the two different diagnostic devices in the same patient
62275038|NCT03213873|EXPERIMENTAL|HiBalance|The HiBalance program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in PD. The training will be conducted as a progressive individually adjusted group program in order to challenge the specific balance disorder of every participant and endorse progression. The intervention will be performed for an hour, 2 times/week in groups of six to eight participants for a total of 10 weeks and one home training session on their own.
62638294|NCT02175225|EXPERIMENTAL|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
62638295|NCT02175225|PLACEBO_COMPARATOR|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
62070197|NCT03717662|EXPERIMENTAL|Brief counseling and NRT|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers (including all types of tobacco products such as shisha, electronic cigarettes and heat-not-burn (HNB) which are available in the market) who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
62070198|NCT00874653||Group 1|
62070199|NCT06255821|EXPERIMENTAL|One week follow-up assessment|Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment one week after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.
62070200|NCT06255821|EXPERIMENTAL|Six weeks follow-up assessment|Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment six weeks after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.
62070201|NCT06255821|EXPERIMENTAL|Three months follow-up assessment|Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment three months after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.
62070202|NCT00671632|EXPERIMENTAL|Ramelteon, triazolam, and placebo (56 poss. combinations)|Ramelteon, triazolam, and placebo (56 possible combinations total)
62070203|NCT00747318|EXPERIMENTAL|1|
62070204|NCT04293523||Hemophilia A patients|All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.
62638296|NCT00432900|ACTIVE_COMPARATOR|Healthy Volunteer|Healthy Volunteers
62638297|NCT00432900|EXPERIMENTAL|Patient|Multiple Sclerosis Patients
62638298|NCT03658551||Liver cirrhosis|Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
62070205|NCT06175273|ACTIVE_COMPARATOR|Control|Standard of Care who have either weight gain, weight maintenance, or weight loss \<10%.
62638299|NCT03658551||Control group|Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.
62070206|NCT06175273|EXPERIMENTAL|Oral Nutrition Supplements|Those receiving ONS will be prescribed a standard ONS (1.0 kcal per mL) that will meet a minimum of 50% of estimated energy needs to promote weight gain but allow for continued regular dietary intakes. The ONS will be prescribed as 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs.
62454503|NCT04168346|EXPERIMENTAL|Intervention|IV-iron substitution: The intravenous iron formulation used in the study is ferric carboxymaltose and it will be administered two to four weeks before the surgery, aiming at four weeks. The dose of intravenous iron will be calculated according to the weight and haemoglobin level of the patients, however so that all the patients receive minimum 1000mg iv iron and the maximum dose is 20 mg/kg per day.
62454504|NCT04168346|PLACEBO_COMPARATOR|Placebo|Placebo is NaCl 0.9% solution, which is administrated in the same way as the study drug
62638300|NCT03740269||oral health educational program|poster for oral health education program for a group of egyptian school girls
62638301|NCT04657939|ACTIVE_COMPARATOR|Liraglutide-Pioglitazone|Participants randomised to receive liraglutide treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with pioglitazone.
62638302|NCT04657939|ACTIVE_COMPARATOR|Pioglitazone-Liraglutide|Participants randomised to receive pioglitazone treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with liraglutide.
62070207|NCT06175273|EXPERIMENTAL|Enteral Nutrition|Those randomized to EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs to allow for continued regular dietary intakes during the day.
62070208|NCT06175273|EXPERIMENTAL|Appetite Stimulants|Those receiving age-appropriate appetite stimulants will be provided either cyproheptadine or olanzapine. Subjects will be given cyproheptadine if they fall between the ages of 2-12 years of age and olanzapine if they are \>12 years of age or older.
62275039|NCT03213873|ACTIVE_COMPARATOR|Speech therapy|The control group will receive a group treatment (2 times/w for 10 w + 1 home training session) consisting of speech and communication therapy performed by a speech therapist. This intervention will be performed in a sitting position. The speech and communication treatment will aim at increasing vocal loudness and improving articulatory precision. Level of difficulty is gradually increased by progressing from using loud voice and clear speech in short and automatized utterances, to using the same technique in more complex sentences and situations. The group format is used to practice techniques in communicative situations and also to introduce increasing level of multitasking by combining speech training with cognitively more challenging tasks in the group training.
62638303|NCT01623921|OTHER|control|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
62275040|NCT03405623|ACTIVE_COMPARATOR|Dynamic needle tip positioning|In DNTP, SAX is used, and additionally, when the needle tip is imaged in the screen as an hyper-echoic point, the practitioner (a) moves the US probe proximally a bit, and (b) the needle is advanced until the needle tip reappears in the screen. In this manner, the practitioner repeats (a) and (b) until the needle is inserted 1 cm into the lumen of vessel, and then the catheter is inserted to finish the procedure.
62275041|NCT03405623|ACTIVE_COMPARATOR|Conventional long-axis|
62275042|NCT03678805|EXPERIMENTAL|Acceleration|The impacted canines will undergo acceleration by corticotomy accompanied with traditional traction techniques.
62275043|NCT03678805|ACTIVE_COMPARATOR|Traditional Traction|"Traditional traction will be employed in this group of patients with impacted canines.~Traditional withdrawal techniques will be used."
62275044|NCT02474329||Cohort 1|"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~1. PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~2. Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
62287146|NCT02427113|ACTIVE_COMPARATOR|Self-Select Music|Participants will be randomized to two groups. Self-select music will be used as treatment for managing pain. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
62638304|NCT01623921|ACTIVE_COMPARATOR|Celecoxib|Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
62638305|NCT01623921|ACTIVE_COMPARATOR|rosuvastatin|Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
62638306|NCT01623921|ACTIVE_COMPARATOR|Combined therapy|Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
62638307|NCT05421065|EXPERIMENTAL|Psilocybin Group (Arm 1)|receives individual psychotherapy sessions plus a (25 mg) psilocybin session.
62638308|NCT05421065|ACTIVE_COMPARATOR|Ketamine Group (Arm 2)|receives individual psychotherapy sessions plus a (200 mg) ketamine session with open-label access option at the end of their study involvement.
62638309|NCT06514079|EXPERIMENTAL|refractory benign esophageal strictures patients|Pediatric patients aged less than 14 years, with refractory benign esophageal strictures and received a dilatation therapy without triamcinolone injections
62638310|NCT04148547|EXPERIMENTAL|transcranial direct current stimulation|
62638311|NCT04148547|PLACEBO_COMPARATOR|Sham transcranial direct current stimulation|
62638312|NCT05343663|EXPERIMENTAL|Education|In the COVID-19 Pandemic, the Self-Management Program with Tele-Nursing Developed Based on the Roper Logan Tierney Model will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
62638313|NCT05343663|NO_INTERVENTION|Control|It will not change the Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients of the Self-Management Program Conducted by Tele-Nursing, Developed Based on the Roper Logan Tierney Model in the COVID-19 Pandemic.
62638314|NCT02291029|EXPERIMENTAL|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
62638315|NCT02291029|PLACEBO_COMPARATOR|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
62638316|NCT02291029|EXPERIMENTAL|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
62638317|NCT02291029|PLACEBO_COMPARATOR|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
62638318|NCT02291029|EXPERIMENTAL|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
62638319|NCT02291029|EXPERIMENTAL|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
62070209|NCT03427489||Coronary heart disease|Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
62070210|NCT03427489||Controls|Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
62070211|NCT04216979|EXPERIMENTAL|randomization|Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. Group (B):- The umbilicus is the primary entry site.
62638320|NCT05029687|EXPERIMENTAL|Intervention Arm|The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
62638321|NCT03049826|EXPERIMENTAL|Stem cell transplantation (SCT)|Children undergoing stem cell transplantation (SCT)
62638322|NCT03049826|NO_INTERVENTION|Home parenteral nutrition (HPN)|Children receiving home parenteral nutrition
62638323|NCT03049826|NO_INTERVENTION|Healthy reference group|Healthy children
62638324|NCT04073719|EXPERIMENTAL|Apple Cider Vinegar + Coconut Water|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
62638325|NCT04073719|EXPERIMENTAL|Apple Cider Vinegar + Citric Soda|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
62638326|NCT04073719|EXPERIMENTAL|Apple Cider Vinegar + Lemonade|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
62638327|NCT04073719|EXPERIMENTAL|Coconut Water + Apple Cider Vinegar|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
62638328|NCT04073719|EXPERIMENTAL|Coconut Water + Citric Soda|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
62638329|NCT04073719|EXPERIMENTAL|Coconut Water + Lemonade|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
62638330|NCT04073719|EXPERIMENTAL|Citric Soda + Apple Cider Vinegar|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
62638331|NCT04073719|EXPERIMENTAL|Citric Soda + Coconut Water|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
62638332|NCT04073719|EXPERIMENTAL|Citric Soda + Lemonade|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
62638333|NCT04073719|EXPERIMENTAL|Lemonade + Apple Cider Vinegar|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
62070212|NCT04216979|EXPERIMENTAL|group A|these are the patient with palmars point as primary entry site
62638334|NCT04073719|EXPERIMENTAL|Lemonade + Coconut Water|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
62070213|NCT04216979|EXPERIMENTAL|group B|these are the patient with umbilicus as primary entry site
62287147|NCT02427113|ACTIVE_COMPARATOR|Sound Oasis Vibrating Chair|Participants will be randomized to two groups. Vibroacoustic therapy will be administered in the form of a vibrating chair. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
62638335|NCT04073719|EXPERIMENTAL|Lemonade + Citric Soda|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
62638336|NCT02361775|EXPERIMENTAL|Paravertebral catheter|a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively
62638337|NCT02361775|ACTIVE_COMPARATOR|IV PCA|opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit
62638338|NCT03492229|EXPERIMENTAL|tDCS+AMT|TDCS in combination with movement training before treadmill training
62638339|NCT03492229|ACTIVE_COMPARATOR|tDCS|tDCS only before treadmill training
62638340|NCT03492229|ACTIVE_COMPARATOR|AMT|Movement training only before treadmill training
62638341|NCT03492229|SHAM_COMPARATOR|Control|No priming before treadmill training
62638342|NCT00317746|PLACEBO_COMPARATOR|Placebo|Placebo + PEG-interferon-alfa2b + ribavirin
62070214|NCT02959671|EXPERIMENTAL|Lower Anterior EXD-952 Self-ligating Brackets|
62070215|NCT05950269|EXPERIMENTAL|Walking aid (WA) group|Participants will receive the walking aid and training in the use of the device.
62638343|NCT00317746|EXPERIMENTAL|Citalopram|Citalopram + PEG-interferon-alpha2b + ribavirin
62638344|NCT02121795|EXPERIMENTAL|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
62638345|NCT02121795|ACTIVE_COMPARATOR|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
62638346|NCT06109389|EXPERIMENTAL|infusion of saline|infusion saline for 4 successive weeks once weekly over 45 min
62638347|NCT06109389|ACTIVE_COMPARATOR|lidocaine infusion|infusion of lidocaine 3 mg per kg for 2 successive weeks then 4 mg per kg for 2 successive weeks
62638348|NCT05426408|OTHER|Patients with MINOCA undergoing CMR|Patients will be their own controls
62638349|NCT03179735|EXPERIMENTAL|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
62638350|NCT03179735|EXPERIMENTAL|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
62638351|NCT03179735|PLACEBO_COMPARATOR|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
62638352|NCT04321902|EXPERIMENTAL|The experimental group in acute cholecystitis|"inclusion criteria~1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~3. Gallbladder with surrounding organs due to gallbladder inflammation~4. Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used as before and during surgery."
62275045|NCT02474329||Cohort 2|"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~1. PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~2. Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
62275046|NCT02474329||Cohort 3|"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~1. PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~2. Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
62638353|NCT04321902|EXPERIMENTAL|The controled group in acute cholecystitis|"1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~3. Gallbladder with surrounding organs due to gallbladder inflammation~4. Patients over 19 years of age~Sencond-generation cephalosporin (Shincef inj., 750mg, Cefuroxime sodium, Shin-poong pharm.co.) was used as before and during surgery."
62638354|NCT05628701|EXPERIMENTAL|IPAA CRUISE|Patients eligible for both operations choosing ileal pouch anal anastomosis.
62638355|NCT05628701|EXPERIMENTAL|IRA CRUISE|Patients eligible for both operations choosing ileorectal anastomosis.
62638356|NCT05628701|ACTIVE_COMPARATOR|IRA Control|Patients only eligible for ileorectal anastomosis.
62638357|NCT05628701|ACTIVE_COMPARATOR|IPAA Control|Patients only eligible for ileal pouch anal anastomosis.
62638358|NCT05628701|ACTIVE_COMPARATOR|Ileostomy Control|Patients who decline reconstruction.
62638359|NCT04294537|EXPERIMENTAL|TAP block|Bilateral ultrasound-guided single-shot TAP block with 0,15% levobupivacaine 0,75 mg/kg per side.
62638360|NCT04294537|ACTIVE_COMPARATOR|LIA - local wound infiltration|Wound infiltration with 0,5% levobupivacaine 1.5 mg/kg
62638361|NCT06449469|EXPERIMENTAL|Sinus rhythm - DOAC treatment|
62638362|NCT06449469|ACTIVE_COMPARATOR|Sinus rhythm - Anti-platelet treatment|
62070216|NCT05950269|EXPERIMENTAL|Walking aid with telemonitoring (WAT) group|Participants will receive the walking aid and training in the use of the device associated with telemonitoring.
62070217|NCT05950269|OTHER|Control group|Participants will receive verbal guidance and printed material.
62070218|NCT00157651|ACTIVE_COMPARATOR|1|Receiving warfarin
62070219|NCT00157651|PLACEBO_COMPARATOR|2|Receiving matching placebo
62070220|NCT02761889|EXPERIMENTAL|IGRT 45 Gy in 5 fractions of 9 Gy|Patients will be treated using volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
62070221|NCT05325957||Norepinephrine variation|Patients with septic shock, cardiac output monitoring device with the PICCO2 system or swan ganz catheter and decision by the physician in charge to modify the norepinephrine dose.
62070222|NCT05325957||Fluid infusion|Patients with septic shock, cardiac output monitoring device with the PICCO2 system or swan ganz catheter and decision by the physician in charge to give fluid infusion
62070223|NCT02997839|NO_INTERVENTION|group 2|no intervention
62070224|NCT02997839|OTHER|group 1|sleep disruption
62070225|NCT04004572|EXPERIMENTAL|LEAP Regimen|Pegaspargase, 2500IU/m2, im, day 1 Sintilimab, 200mg, iv day1 Anlotinib, 8mg, oral, day 1-14 The LEAP regimen will be repeated every 3 weeks.
62070226|NCT06385002|NO_INTERVENTION|Sevoflurane group, S group|The control group will maintain oxygen-air (O2-Air) at 2 L/min and adjust the concentration of sevoflurane to maintain the depth of anesthesia with a bispectral index (BIS) of 40-60.
62070227|NCT06385002|ACTIVE_COMPARATOR|Remimazolam/Sevoflurane group, RS group|After tracheal intubation, the experimental group will maintain oxygen-air (O2-Air) at 2 liters/minute, and remimazolam will be infused at 1.0mg/kg/h, while adjusting the concentration of sevoflurane to maintain the depth of anesthesia with a bispectral index (BIS) of 40-60.
62070228|NCT00633737|EXPERIMENTAL|1|Stress reduction intervention
62070229|NCT00633737|NO_INTERVENTION|2|Standard care
62070230|NCT03855163|EXPERIMENTAL|Inspection visits|Regulatory tool to ensure enterprise compliance with legal requirements
62070231|NCT03855163|EXPERIMENTAL|Guidance workshops|Regulatory tool applied to inform and advise enterprises on legal requirements and how to realize compliance with such requirements
62070232|NCT03855163|EXPERIMENTAL|Online risk assessment tool|Regulatory tool applied to aid enterprises in conducting written objectives concerning health, environment and safety activities
62287148|NCT02107755|EXPERIMENTAL|Treatment (ipilimumab, stereotactic radiosurgery)|Patients receive ipilimumab IV over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician.
62638363|NCT05588986||with IUGR|Pregnant women who received antenatal corticosteroid therapy and complicated with intrauterine growth retardation
62070233|NCT03855163|NO_INTERVENTION|Control group|The Labour Inspection Authority will not preform any intervention activities in enterprises assign to the control group
62070234|NCT01234649|EXPERIMENTAL|Metformin XR plus liraglutide|Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
62070235|NCT01234649|ACTIVE_COMPARATOR|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
62070236|NCT02459184|EXPERIMENTAL|Early intervention|Participants will meet with the Income Security Health Promoter immediately.
62070237|NCT02459184|ACTIVE_COMPARATOR|Late intervention|Participants will meet with the Income Security Health Promoter at 6 months.
62070238|NCT02892682|OTHER|Arm 1 AE-Bk|Arm of the recurring angiodeme medié by the bradykinine: blood test
62070239|NCT02892682|OTHER|Arm 2 AE-Mast|Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
62070240|NCT02892682|OTHER|ARM 3 AEI|Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
62070241|NCT02892682|OTHER|ARM 4 US|Arm of superficial nettle rashes: blood test
62070242|NCT04278417|EXPERIMENTAL|Brolucizumab 6 mg|Intra-vitreal injection. 3 x q6w loading injections, followed by q12w maintenance through Week 90
62070243|NCT04278417|ACTIVE_COMPARATOR|Panretinal photocoagulation laser Arm|Initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
62070244|NCT02307513|EXPERIMENTAL|Placebo / Apremilast|Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
62070245|NCT02307513|EXPERIMENTAL|Apremilast|Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
62070246|NCT06624410|NO_INTERVENTION|Control Arm|"Pre-operative anxiety levels will be assessed with the mYPAS-SF6-12 (below). Subjects will be observed for behaviors and then given a score out of possible 5 across 5 domains that corresponds with demonstrated behaviors, specified in the figure below. The 5 domains include Activity, Vocalization, Emotional Expressivity, State of Arousal, and Use of Parent. Note that the Vocalization domain differs in that It's possible scores range from 1-7. Pilot data collection will involve mYPAS scoring in isolation to demonstrate existing anxiety burden at Doernbecher Children's Hospital."
62070247|NCT06624410|EXPERIMENTAL|Educational Intervention Arm|The educational intervention, an informational video to prepare the child for what to expect in the perioperative period, will be delivered within one week of the scheduled surgery assuming parental consent has been confirmed. They will watch the video prior to coming in for surgery and then proceed to have standard care provided as they are assessed for anxiety scores.
62070248|NCT03207217|EXPERIMENTAL|Phase I Knowledge Assessment|
62070249|NCT03207217|EXPERIMENTAL|Phase II Efficacy|
62070250|NCT03207217|EXPERIMENTAL|Phase II Acceptability|
62070251|NCT04801745|EXPERIMENTAL|Healthy Vegan Diet|Education on healthy vegan diet
62070252|NCT04801745|EXPERIMENTAL|Healthy Vegan Diet with Amla fruits|Education on healthy vegan diet, 3g of powdered amla fruits per day
62638364|NCT05588986||without IUGR|Pregnant women who received antenatal corticosteroid therapy and were not complicated by intrauterine growth retardation
62638365|NCT03603197|EXPERIMENTAL|BP-C1|Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
62070253|NCT04801745|ACTIVE_COMPARATOR|My Plate - Low Purine|"Education on My Plate diet with emphasis on choosing low purine protein options."
62070254|NCT04801745|EXPERIMENTAL|My Plate - Low Purine with Amla Fruits.|"Education on My Plate diet with emphasis on choosing low purine protein options and with an addition of 3g of amla powder per day."
62070255|NCT05484583|EXPERIMENTAL|Radiotherapy combined with Durvalumab, etoposide, and cisplatin/carboplatin|Radiotherapy combined with Durvalumab, etoposide, and cisplatin/carboplatin
62070256|NCT00579982|EXPERIMENTAL|Arm 1|Lamictal orally disintegrating tablet (ODT)
62070257|NCT02888067|ACTIVE_COMPARATOR|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
62070258|NCT02888067|ACTIVE_COMPARATOR|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
62070259|NCT00335725|EXPERIMENTAL|Fostimon|Fostimon is an highly purified FSH preparation.
62070260|NCT00335725|ACTIVE_COMPARATOR|Gonal-F|Gonal-F is a recombinant FSH preparation.
62070261|NCT05445856|EXPERIMENTAL|Methadone|Single-shot intravenous methadone 0.2 mg/kg administered intraoperatively
62070262|NCT05445856|ACTIVE_COMPARATOR|Fentanyl|Single-shot intravenous fentanyl 3 microgram/kg administered intraoperatively
62070263|NCT03948087|EXPERIMENTAL|Vacuum Removable Rigid Dressing (VRRD)|Application of a Vacuum Removable Rigid Dressing (VRRD)
62070264|NCT03948087|NO_INTERVENTION|Soft Dressing Control Group|Application of standard of care soft dressing (SD) intra-operatively.
62070265|NCT06450574|EXPERIMENTAL|Chemoradiotherapy+TEM|Preoperative chemotherapy: capecitabine 825 mg/m2 every 12 hours orally, plus Radiotherapy (50.4 Gy). After 10 weeks, transanal endoscopic microsurgery (TEM) is done
62070266|NCT06450574|ACTIVE_COMPARATOR|ransanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM)
62287149|NCT02066714||Healthy Cohort|These children will be recruited from district 8, Ho Chi Minh City where most HFMD admissions to the Hospital for Tropical Diseases occur. We wil recruit healthy children from three kindergartens and ask for volunteers from participants enrolled in an Oxford University Clinical Research Unit Dengue birth cohort study (OXTREC approval 02-09) in District 8, HCMC. This birth cohort is an observational study.
62638366|NCT03603197|PLACEBO_COMPARATOR|Placebo|Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
62070267|NCT05855902||Adults with OCD|Adults with OCD in an intensive treatment program will participate in weekly Art Therapy sessions during their enrollment in the program. Each group is 1.5 hours long. Each participant will be asked to fill out one survey after their first Art Therapy group, and one at the end of the time in the program. Both surveys pertain to their perceptions of the value of Art Therapy within the program.
62070268|NCT06131996|ACTIVE_COMPARATOR|Volar-assisted splint group|Participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
62070269|NCT06131996|ACTIVE_COMPARATOR|Elastic splint group|Participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
62070270|NCT06447064||Cases|Participants diagnosed with cancer.
62070271|NCT06447064||Controls|Participants not diagnosed with cancer.
62070272|NCT03152045|EXPERIMENTAL|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
62070273|NCT03152045|NO_INTERVENTION|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
62070274|NCT03923010|EXPERIMENTAL|Itraconazole|Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
62070275|NCT05742230|EXPERIMENTAL|Henagliflozin 10 mg|Single 10 mg tablet, administered orally once daily for 12 weeks
62275047|NCT02474329||Cohort 4|"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~1. PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~2. Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
62275048|NCT02474329||Cohort 5|"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~1. PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~2. Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
62275049|NCT06221163||Young transgender|"Transgender patients consulting the Reproductive Medicine Department for a request related to the preservation of their fertility or hormone therapy, as well as parents/family members present at the time of the appointment.~The ceiling is 20 interviews and 80 hours."
62275050|NCT06538701|EXPERIMENTAL|Anterolateral advancement pharyngoplasty|Starting with bilateral tonsillectomy, The palatopharyngeal muscle (PPM) raised and advanced to be fixed to the pterygomandibular raphe, The posterior part of the PPM, together with its attached mucosa, was then advanced superolaterally behind the palatoglossus muscle to be hooked up to the levator veli palatini muscle
62638367|NCT06524986|EXPERIMENTAL|Self-efficacy promoting program|The self-efficacy promotion program, inspired by Bandura's principles (1997, 2001) and employing computer games, extends across 5 weeks with 30-minute sessions conducted 10 minutes.The program involved activities such as motivation, modeling, and enactive mastery experiences. Weekly sessions covered collaborative planning, video demonstrations, interactive gaming, and follow-up calls to ensure active participation and address concerns related to physiological and affective states.
62638368|NCT06524986|EXPERIMENTAL|Standard nursing care|The control group received standard nursing care, which included providing dietary recommendations for pediatric patients. The recommended daily intake consisted of 0.8 grams of protein per kilogram of the child's weight, low-sodium foods, and low-fat options. This personalized guidance was communicated through informational brochures.
62638369|NCT05510258|EXPERIMENTAL|experimental group|core-stability exercises therapy given with conventional therapy
62638370|NCT05510258|OTHER|control group|only conventional therapy given
62070276|NCT05742230|OTHER|blank control|standard treatment
62070277|NCT05100719|ACTIVE_COMPARATOR|alverine-citrate + simethicone and lactase|Patients diagnosed with irritable bowel syndrome based on the ROME IV criteria will go through a lactase intolerance test (LTT) and (lactose H2 breath test) LHBT. Those who have positive LTT and LHBT will receive alverine-citrate + simethicone and lactase.
62070278|NCT05100719|PLACEBO_COMPARATOR|alverin-citrate + simethicone with placebo|Patients diagnosed with irritable bowel syndrome based on the ROME IV criteria will go through a lactase intolerance test (LTT) and (lactose H2 breath test) LHBT. Those who have positive LTT and LHBT will receive alverine-citrate + simethicone with placebo.
62070279|NCT02870504|EXPERIMENTAL|corneoscleral limbus group|Laser spot locates on the corneoscleral limbus.
62070280|NCT02870504|EXPERIMENTAL|One spot group|Laser spot locates on one spot away from the corneoscleral limbus
62638371|NCT06359262|EXPERIMENTAL|Hope@School|The universal prevention program Hope@School. A digital platform with a number of tools that target mental health and wellbeing in children and adolescents.
62638372|NCT06359262|ACTIVE_COMPARATOR|Treatment as usual|Regular student health care in the schools
62638373|NCT01102712|EXPERIMENTAL|BTVA|
62638374|NCT04891666|EXPERIMENTAL|Lactobacillus plantarum DSM 33464|1 sachet of Lactobacillus plantarum DSM 33464 (2 g) and 1 sachet of supplement YingKangWei per day for 12 weeks
62070281|NCT02870504|EXPERIMENTAL|Two spots group|Laser spot locates on two spots away from the corneoscleral limbus
62638375|NCT04891666|PLACEBO_COMPARATOR|placebo|1 sachet of placebo (2 g) and 1 sachet of supplement YingKangWei per day for 12 weeks
62638376|NCT03286387|EXPERIMENTAL|Memory for naturalistic episodes|Encoding of episode in real life situations (using Smartphones) or in a virtual environment, followed by memory retrieval (either behavior only or with fMRI, in successive studies)
62275051|NCT01698528|EXPERIMENTAL|Intervention Group|The experimental arm will be provided with a tablet computer with a newly designed software to help manage his or her diabetes care. This arm will communicate with his or her provider through the tablet computer to initiate and titrate basal insulin dose based on the 303 protocol. The individuals in this arm will also track their glucose values and medication adherence using the tablet computer by documenting when medication was taken or insulin was injected.
62638377|NCT00144599|EXPERIMENTAL|1|
62638378|NCT00144599|PLACEBO_COMPARATOR|2|
62638379|NCT02597517||Intervention group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and positive stool antigen test for H pylori in whom gastric body mucosal will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
62638380|NCT02597517||Control group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and negative stool antigen test for H pylori in whom gastric mucosal body will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
62638381|NCT03901846|OTHER|ColdZyme|"The study is intended to verify the method used to measure the duration of ColdZyme®.~Each participant will be his own control as samples are taken before application of ColdZyme and used as an internal control."
62638382|NCT03310242|EXPERIMENTAL|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
62638383|NCT03310242|EXPERIMENTAL|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
62638384|NCT03310242|PLACEBO_COMPARATOR|Placebo|Intake of placebo for 8 weeks
62638385|NCT02133391|ACTIVE_COMPARATOR|Practice-based reminder/recall or Usual care arm|"Practices participating in state immunization registry invited to reminder/recall (R/R) webinar trainings and provided educational materials to encourage immunization within their practices (child and adolescent trials only)~Patients not randomized to the collaborative centralized R/R arm will receive usual care from their provider, which does not include R/R (adult trials only)"
62638386|NCT02133391|EXPERIMENTAL|Collaborative centralized R/R|Collaborative centralized reminder/recall (R/R) effort will be conducted by state immunization registry in collaboration with accountable care organizations and practices
62638387|NCT04030741|ACTIVE_COMPARATOR|Meronem and flagyl|Children in Non-operative treatment (group A) Children in non-operative treatment group will be given intravenous meropenem (10 mg/kg/dose x IV x TDS) and metronidazole (20 mg/kg/day divided into 3 doses) for at least 48 hours. Once the child starts tolerating oral intake and becomes clinically improved, the treatment will be changed to oral ciprofloxacin (20 mg/kg/day) divided into 2 divided doses) and metronidazole (20 mg/kg/day divided into 3 doses for another 8 days.
62638388|NCT04030741|ACTIVE_COMPARATOR|Surgery (appendectomy)|"Children in group B: appendectomy will b done and post operative single dose of antibiotics.~discharge after 24hour and Follow up after 1 week."
62638389|NCT00165503|EXPERIMENTAL|Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT|Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.
62638390|NCT04121338|EXPERIMENTAL|Test group|10 patients with presumptive diagnosis of dysautonomia with chronic nausea, vomiting and food intolerance
62638391|NCT00129441|EXPERIMENTAL|Merck L-830982|
62070282|NCT03290573|ACTIVE_COMPARATOR|Dorsum of hand group|short peripheral venous catheter place in the dorsum of the hand
62070283|NCT03290573|EXPERIMENTAL|Forearm group|short peripheral venous catheter place in the forearm
62070284|NCT02762344||ACT < 150 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal below 150 sec
62638392|NCT00129441|PLACEBO_COMPARATOR|Sugar pill|
62638393|NCT00741312|EXPERIMENTAL|I|
62638394|NCT00741312|ACTIVE_COMPARATOR|II|
62638395|NCT03572673|ACTIVE_COMPARATOR|Flexima 3S|Flexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
62638396|NCT03572673|EXPERIMENTAL|New 2-piece ostomy appliance|New 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
62638397|NCT00379145|EXPERIMENTAL|Trabectedin|Trabectedin IV over 24 hours every 3 weeks
62638398|NCT00806845||HIV infected individuals, HIV controllers|CD4+ T cell count \> 350/µl, HIV load \< 1000 copies/ml
62638399|NCT00806845||HIV infected individuals, early progressors|CD4+ T cell count \> 350/µl, HIV load \> 1000 copies/ml
62638400|NCT00806845||HIV infected individuals, late progressors|CD4+ T cell count \< 200/µl
62275052|NCT01698528|NO_INTERVENTION|Control Group|The individuals in the control group will receive usual care from the study Clinic as they always have. These individuals will be tracking their diabetes in the same way they have been by communicating with their health care provider and his or her office via fax/phone/e-mail. These individuals will not be provided with a tablet computer.
62275053|NCT05168358|NO_INTERVENTION|Control group|This arm will include 55 patients, their parents will be taught the timed voiding regimen every 2 hours.
62275054|NCT05168358|EXPERIMENTAL|OCD group|This arm will include 55 patients, their parents will be taught the timed voiding regimen every 2 hours, in addition to placing an overnight catheter to drain the urinary bladder during night.
62275055|NCT03269760|NO_INTERVENTION|Control|Current practice of postoperative care without sleep medicine measures
62638401|NCT00806845||HIV infected individuals, late progressors with therapy|CD4+ T cell count \< 200/µl, under ART
62638402|NCT00806845||Healthy individuals|Uninfected
62638403|NCT00964028|EXPERIMENTAL|INFANRIX-IPV/HIB M2-M3-M4 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age (M2-M3-M4), administered intramuscularly into the upper right side of the thigh.
62638404|NCT00964028|EXPERIMENTAL|INFANRIX-IPV/HIB M3-M4-M5 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age (M3-M4-M5), administered intramuscularly into the upper right side of the thigh.
62070285|NCT02762344||ACT between 150 and 249 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal between 150 and 249 sec
62275056|NCT03269760|EXPERIMENTAL|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
62275057|NCT04992728||Male Prostate Patients|Adult male patients with fair to good performance status and who (1) have undergone an MRI of the prostate for suspected or known prostate cancer and/or (2) are planning to undergo radical prostatectomy for prostate cancer.
62275058|NCT03715283|EXPERIMENTAL|Home Lower Extremity Strengthening|Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing.
62275059|NCT03715283|EXPERIMENTAL|No intervention|In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs.
62275060|NCT02394977|EXPERIMENTAL|Compression with Feedback|CPR performed according to established international standards with chest compressions performed with the assistance of the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) compression feedback device.
62638405|NCT05728138|EXPERIMENTAL|CMAP Plus FEP|Participants with First episode of psychosis, Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT)
62638406|NCT05728138|NO_INTERVENTION|treatment as usual|Participants in this group will continue their routine treatment as prescribed by their responsible clinician. In Pakistan TAU mostly comprise of antipsychotics with few patients having access to psychological therapies. Research staff will record the nature and intensity of the TAU for each participant
62638407|NCT01428843|ACTIVE_COMPARATOR|Ferrisat|Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
62638408|NCT01428843|PLACEBO_COMPARATOR|Placebo|Infusion of placebo at inclusion visit
62070286|NCT02762344||ACT >= 250 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal above 250 sec
62275061|NCT02394977|ACTIVE_COMPARATOR|Standard chest compression|CPR performed according to established international standards with standard manual chest compression
62275062|NCT03784014|NO_INTERVENTION|Arm No NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. Thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment.~Note that for these participants and under specific conditions, subsequent NGS analyses may be allowed within the scope of the trial"
62638409|NCT00750763|ACTIVE_COMPARATOR|1|PEG (Colonlytely) - 4 litres
62638410|NCT00750763|ACTIVE_COMPARATOR|2|Picosulphate (Picolax/Picoprep) - 2 sachets
62638411|NCT00750763|ACTIVE_COMPARATOR|3|Sodium Phosphate (Fleet) - 2 bottles
62638412|NCT02743364|EXPERIMENTAL|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
62638413|NCT02743364|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
62638414|NCT00678353||1|Follow-up to S01-01US, conducted to expand information
62638415|NCT02343367|ACTIVE_COMPARATOR|Standard Care|Brief patient-centered behavioral counseling using the Healthy Lifestyle Prescription, health education materials and a community resource guide. Follow-up visits scheduled at 1, 6, and 12 months. Parent receives weekly general health education cell phone text messages for 12 months
62638416|NCT02343367|EXPERIMENTAL|Pediatric Obesity Management|All elements of standard care plus a family-based face to face counseling session with a health educator, telephone counseling, mailed newsletters and regularly scheduled cell phone text messages with tips and motivational messages for healthy eating and PA, as well as information on community events and resources.
62070287|NCT02779595||Lung surgery|26 patients (up to 36) undergoing lung surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
62070288|NCT02779595||Flail chest|8 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
62070289|NCT01915433|EXPERIMENTAL|Wahls Paleo Plus|Wahls Paleo Plus diet (ketogenic diet)
62070290|NCT01915433|EXPERIMENTAL|Wahls Diet|Wahls Diet (modified paleolithic diet)
62275063|NCT03784014|EXPERIMENTAL|Arm NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. After tumor assessment at the end of first-line systemic treatment and regardless of tumor response as per RECIST v1.1, participants will be discussed within a multidisciplinary tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant.~Patients for whom a targetable genomic alteration has been highlighted will be proposed to enter in a subsequent single-arm phase II sub-trials. Otherwise, thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment"
62275064|NCT03784014|EXPERIMENTAL|Arm NGS - Targeted therapy|Targeted therapy from a list of 10 targeted treatment strategies, guided by the genomic analyses: Nilotinib capsule per os 400 mg bd, continuous dosing ; Ceritinib capsule per os 450 mg od, continuous dosing; Capmatinib tablet per os 400 mg bd, continuous dosing; Lapatinib tablet per os 1500 mg od, continuous dosing; Trametinib tablet per os 2 mg od, continuous dosing; association of Trametinib tablet per os 2 mg od and Dabrafenib capsule per os 150 mg bd, continuous dosing; association of Olaparib tablet per os 300 mg bd, continuous dosing and Durvalumab intra-veinous 1500 mg on day 1, Q4W; Palbociclib capsule 125 mg od, 3 weeks on/1 week off; Glasdegib tablet per os 300 mg od, continuous dosing; TAS-120 tablet per os 20 mg od, continuous dosing.
62275065|NCT01216436|EXPERIMENTAL|Vaccine plus untransfected DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.
62275066|NCT01216436|EXPERIMENTAL|Vaccine plus GITRL RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.
62275067|NCT01216436|EXPERIMENTAL|Vaccine plus antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.
62275068|NCT01216436|EXPERIMENTAL|Vaccine plus GITRL/ antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.
62275069|NCT03315923|EXPERIMENTAL|Rituximab|Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
62275070|NCT03315923|EXPERIMENTAL|Glatiramer acetate|Patients in this group will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection.
62275071|NCT03790683|EXPERIMENTAL|EnsoETM|Participants receive esophageal warming. Original study design anticipated esophageal warming in addition to standard of care surface warming from the time they enter the OR until released to the PACU. After 7 patients, protocol was adjusted to specify only esophageal warming unless addition of surface warming was warranted.
62275072|NCT03790683|ACTIVE_COMPARATOR|Standard of Care|Participants receive standard of care surface warming from the time they enter the OR until released to the PACU.
62275073|NCT03923205|ACTIVE_COMPARATOR|Control meal|The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.
62070291|NCT01915433|NO_INTERVENTION|Usual Care|Control - usual care only.
62070292|NCT03758027|EXPERIMENTAL|CARESS|"The proposed intervention for this study has three stages: communicate alternatively (CA), release endorphins (RE), and self-soothe (SS) (CARESS)~CARESS is a combined skill of three activities. Each section is timed and has specific activities:~CA - will last eight (8) minutes, and will be expression of emotion with drawing with crayons.~RE - will last six (6) minutes, and will be a butterfly hug with a blanket. SS - will last six (6) minutes, and will be a pre-recorded music selection."
62275074|NCT03923205|ACTIVE_COMPARATOR|The test meal|The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.
62275075|NCT04223960|EXPERIMENTAL|Part A: SAD, EA1080 Formulation A in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
62070293|NCT03758027|ACTIVE_COMPARATOR|ISOMETRIC|This is a one time five-minute isometric circuit involving contracting muscles in different parts of the body. In order to be equivalent in time spent with the experimental intervention, this circuit will be performed three times with a five-minute break between each instance
62070294|NCT03581877|EXPERIMENTAL|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
62275076|NCT04223960|EXPERIMENTAL|Part A: SAD, EA1080 Formulation B in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
62275077|NCT04223960|EXPERIMENTAL|Part A: SAD, EA1080 Formulation C in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
62275078|NCT04223960|EXPERIMENTAL|Part A: SAD, EA1080 Formulation D in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
62638417|NCT02770911|EXPERIMENTAL|"without Dog Ear group"|Before anastomosis, the surgeon made a laparoscopic suturing on the two dog ears by using 3-0 monofilament sutures, and pull two dogears of staple line around the trocar by a tied suture through two dog ears. By this way, the staple line was kept within the circular knife when the circular stapler was closed. Then a true end-to-end anastomosis was performed after stapler firing.
62638418|NCT02770911|ACTIVE_COMPARATOR|"with Dog Ear group"|traditional double-stapled anastomosis was used for laparoscopic anterior resection
62638419|NCT01098084|EXPERIMENTAL|Decitabine|
62638420|NCT02104427|EXPERIMENTAL|TG-0054 combined with G-CSF|1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
62638421|NCT02397941||non-pregnant women|20 non-pregnant women, BMI \< 30 kg/m2, Nulligravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound
62638422|NCT02397941||pregnant women|40 pregnant women, BMI \< 30 kg/m2 before pregnancy, Primigravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, consecutive measurement during the course of pregnancy
62638423|NCT02397941||women who deliverd|20 pregnant women, BMI \< 30 kg/m2 before pregnancy, Primiparas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, measurement after delivery (10 after spontaneous delivery, 10 after elective cesarean section)
62638424|NCT05618314|EXPERIMENTAL|Group A-Mild Renal Impairment|single dose AT-527
62638425|NCT05618314|EXPERIMENTAL|Group B-Moderate Renal Impairment|single dose AT-527
62638426|NCT05618314|EXPERIMENTAL|Group C-Severe Renal Impairment (optional)|single dose AT-527
62638427|NCT05618314|EXPERIMENTAL|Group D-End-Stage Renal Disease (optional)|single dose of AT-527 pre- and post-dialysis
62275079|NCT04223960|EXPERIMENTAL|Part A: SAD, EA1080 in Healthy Japanese Participants (Optional)|Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 of SAD part of the study. There will be a maximum of six dose levels (three planned and three optional cohorts) per formulation.
62638428|NCT05618314|EXPERIMENTAL|Group E-Matched Healthy Subjects|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
62638429|NCT00039624|EXPERIMENTAL|Brachy|brachytherapy
62652981|NCT02857504|OTHER|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
62275080|NCT04223960|EXPERIMENTAL|Part A: FE and Optional BA in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to eight- way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.
62275081|NCT04223960|EXPERIMENTAL|Part A: FE and Optional BA, in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to four-way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.
62275082|NCT04223960|EXPERIMENTAL|Part A: MAD, EA1080 Formulation A in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
62275083|NCT04223960|EXPERIMENTAL|Part A: MAD, EA1080 Formulation B in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
62275084|NCT04223960|EXPERIMENTAL|Part A: MAD, EA1080 Formulation C in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
62275085|NCT04223960|EXPERIMENTAL|Part A: MAD, EA1080 Formulation D in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional).
62275086|NCT04223960|EXPERIMENTAL|Part A: MAD, EA1080 in Healthy Japanese Participants (Optional)|Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional) per formulation.
62275087|NCT04223960|EXPERIMENTAL|Part B: SAD, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
62275088|NCT04223960|EXPERIMENTAL|Part B: SAD, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
62275089|NCT04223960|EXPERIMENTAL|Part B: SAD, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
62275090|NCT04223960|EXPERIMENTAL|Part B: SAD, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
62638430|NCT03139552|ACTIVE_COMPARATOR|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
62275091|NCT04223960|EXPERIMENTAL|Part B: SAD-FE, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
62638431|NCT03139552|EXPERIMENTAL|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
62275092|NCT04223960|EXPERIMENTAL|Part B: SAD-FE, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
62275093|NCT04223960|EXPERIMENTAL|Part B: SAD-FE, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
62652982|NCT02857504|OTHER|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
62070295|NCT03581877|ACTIVE_COMPARATOR|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
62070296|NCT03485430|ACTIVE_COMPARATOR|Intervention|Receives tapering of opioid dose at baseline
62070297|NCT03485430|NO_INTERVENTION|Control|Waiting-list. Receives tapering after 4 months.
62070298|NCT01216293|PLACEBO_COMPARATOR|Placebo|Placebo-matching capsules, orally, once daily for up to 26 weeks. Participants had the option to participate in the calcium absorption sub study to receive calcium isotope 42 calcium (42 Ca) 3 milligram (mg), intravenously and 44 calcium (44 Ca) 8 mg, orally, once on Day-1 and Week 26.
62070299|NCT01216293|EXPERIMENTAL|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once daily for up to 26 weeks. Participants had the option to participate in the calcium absorption sub study to receive calcium isotope 42 Ca 3 mg, intravenously and 44 Ca 8 mg, orally, once on Day-1 and Week 26.
62070300|NCT01216293|ACTIVE_COMPARATOR|Esomeprazole 40mg|Esomeprazole 40 mg, capsules, orally, once daily for up to 26 weeks. Participants had the option to participate in the calcium absorption sub study to receive calcium isotope 42 Ca 3 mg, intravenously and 44 Ca 8 mg, orally, once on Day-1 and Week 26.
62454505|NCT05231109|OTHER|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The exercise program was arranged 3 times a day for 6 months, and each exercise was 10 repetitions. The patients were called for physiotherapist control once every 2 weeks.
62454506|NCT06159270||Cohort of patients presenting infectious diseases|
62454507|NCT04853459|EXPERIMENTAL|Retention|After Border modeling by traditional and light cure. Amount of force required to dislodge.
62275094|NCT04223960|EXPERIMENTAL|Part B: SAD-FE, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
62454508|NCT04853459|EXPERIMENTAL|Vestibular depth measurement|Casts By using Ney Surveyor
62454509|NCT04228952||Smokers with very low or no CYP2A6 activity|Japanese American smokers (daily \> 5 cigarettes) with little or no CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of \<0.6).
62454510|NCT04228952||Smokers with high CYP2A6 activity|Japanese American smokers (daily \> 5 cigarettes) with high CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of \> 3.0)
62454511|NCT02776709||Bile duct Stricture|Patients referred for the evaluation of indeterminate strictures.
62454512|NCT02776709||Common bile duct Stones|Patients referred for the removal of difficult stones.
62454513|NCT06330870|EXPERIMENTAL|WGS/TME evaluation|This is not intervention clinical trial design. We explore whole genome sequencing and tumor microenvironment evaluation for brain metastasis specimen in breast cancer patients.
62454514|NCT06176287|ACTIVE_COMPARATOR|High insertion torque group|Fifteen patients (eight females and seven males) with a single-tooth deficiency bilaterally in the molar region of the lower jaw were included in the study. Implant placement with high insertion torque was planned on one side of the jaw. The implant drills were applied as recommended by the company. To achieve high insertion torque, the single-use final drill from the implant box was not used in the high torque group.
62652983|NCT03389165|EXPERIMENTAL|Elderly adults|Stair climbing with and without a wearable hip assist robot
62638432|NCT03139552|EXPERIMENTAL|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
62638433|NCT04823780||early enteral nutrition support group|Nutrient solution is provided through oral nutrient solution within 4-48 hours after endoscopic treatment
62638434|NCT04823780||parenteral Nutrition Group|Intravenous nutrition is provided within 48 hours after endoscopic treatment
62638435|NCT02812589|EXPERIMENTAL|Diffusion tensor imaging (DTI) in breast MRI|
62275095|NCT04223960|EXPERIMENTAL|Part B: FE/BA, in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.
62275096|NCT04223960|EXPERIMENTAL|Part B: FE/BA, in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.
62638436|NCT01331369|ACTIVE_COMPARATOR|Control|Usual care. It means routine medical care that include free demand consultation and free medicines.
62638437|NCT01331369|EXPERIMENTAL|Intervention|Intensification of care. Besides routine medical care that include free demand consultation and free medicines, subjects were invited to have 6 structured medical encounters based on a social-psychological approach. Doctors must follow a protocol to conduct the encounter that have around 30 minutes each.
62638438|NCT01938196|EXPERIMENTAL|KWA-0711 Dose1|
62638439|NCT01938196|EXPERIMENTAL|KWA-0711 Dose2|
62638440|NCT01938196|EXPERIMENTAL|KWA-0711 Dose3|
62638441|NCT01938196|EXPERIMENTAL|KWA-0711 Dose4|
62638442|NCT01938196|PLACEBO_COMPARATOR|Placebo|
62638443|NCT02410447|EXPERIMENTAL|Treatment Group|"Defocused shock waves were provided by an electromagnetic generator (DUOLITH® SD1 - Storz Medical AG, Tägerwilen, Switzerland).~The protocol consisted of a series of 3 sessions in 2 weeks, 2 treatments a week. For each patient, a different number of impulses per session was delivered, depending on wound size (300 impulses + 100 impulses per cm2 wound-surface), at an energy flux density of 0.15 mJ/mm2 and a frequency of 5 pulses/s."
62638444|NCT06350734||Observational|Patients complete surveys and also have their medical records reviewed on study.
62638445|NCT01031303|EXPERIMENTAL|Study Group|
62638446|NCT02731378|EXPERIMENTAL|EPO plus sustained iron dextran|Group 1, EPO treatment at the original dose plus IV iron dextran 200 mg every three weeks (Q3W) for 15 weeks
62638447|NCT02731378|EXPERIMENTAL|EPO plus aggressive iron dextran|Group 2, EPO treatment at the original dose plus IV iron dextran 100 mg, twice a week (BIW) for five weeks
62638448|NCT02731378|ACTIVE_COMPARATOR|Double EPO|Group 3, the control group, doubling the EPO dose without preplanned iron supplementation
62638449|NCT03573037|EXPERIMENTAL|1-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 1 month after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation.
62638450|NCT03573037|ACTIVE_COMPARATOR|2-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 2 months after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation
62638451|NCT05262816|EXPERIMENTAL|sanyinjiao group|Perpendicular insertion about 0.8-1.2cun at bilateral sanyinjiao(SP6) acupoint.Then,bilateral SP6 were connected with Electronic Acupuncture Treatment Instrument (KWD-808-I,Yingdi, China). The frequency of the pulse was 20 Hz with a pulse duration of 200 us.Intensity of stimulus was depending on patient's tolerance.
62275097|NCT04223960|EXPERIMENTAL|Part B: MAD, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
62275098|NCT04223960|EXPERIMENTAL|Part B: MAD, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
62070301|NCT02095795|EXPERIMENTAL|Technological Rehabilitation|Patients in the experimental group received a multimodal treatment intervention consisting of 60 minutes of conventional treatment according to the Bobath approach (Bobath B. Adult hemiplegia: evaluation and treatment. Oxford: Butterworth-Heineman, 1990) followed by 30 minutes of robotic gait training on the Lokomat robotic system with the supervision of an expert rehabilitator. Patients started the first session with 50% weight unload and 1.5 Km/h gait speed, performances increments are allowed only in the following sessions. Each patient received 20 sessions over a period of 4 weeks (5 sessions per week).
62275099|NCT04223960|EXPERIMENTAL|Part B: MAD, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
62638452|NCT05262816|ACTIVE_COMPARATOR|guanyuan group|Perpendicular insertion about 0.8-1.2cun at bilateral Guanyuan(CV4), Zhongji (CV3) acupoints.Then,the two acupoints were connected with Electronic Acupuncture Treatment Instrument (KWD-808-I,Yingdi, China). The frequency of the pulse was 20 Hz with a pulse duration of 200 us.Intensity of stimulus was depending on patient's tolerance.
62638453|NCT05251350||An incarcerated right inguinal hernia containing sigmoid colon|
62638454|NCT01491425|EXPERIMENTAL|rhBMP-2/ACS|
62070302|NCT02095795|ACTIVE_COMPARATOR|Control Rehabilitation|Patients in the control group received the same number of treatment sessions of a similar duration as those in the experimental group but they received activities of overground walking exercises targeted to improve walking in substitution of the robotic gait trainer.
62070303|NCT02852018||Appropriate treatment|Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation
62070304|NCT02852018||No event|Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study.
62070305|NCT03259529|EXPERIMENTAL|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
62454515|NCT06176287|ACTIVE_COMPARATOR|Low insertion torque group|Fifteen patients (eight females and seven males) with a single-tooth deficiency bilaterally in the molar region of the lower jaw were included in the study. Implant placement with low insertion torque was planned on the otherside of the jaw. The implant drills were applied as recommended by the company. To achieve low insertion torque, the single-use final drill was applied two times.
62454516|NCT06495658|EXPERIMENTAL|Prebiotic at Week 0|
62275100|NCT04223960|EXPERIMENTAL|Part B: MAD, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
62638455|NCT01491425|ACTIVE_COMPARATOR|Autogenous Bone|The control group of patients from another study (Protocol ID: C-9702 Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic DDD).
62638456|NCT01099358|EXPERIMENTAL|Cetuximab and Cisplatin (D)|"Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.~100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.~After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
62638457|NCT01099358|EXPERIMENTAL|Cetuximab and Cisplatin (C)|"Cycle 1 (4 weeks, combination therapy):~100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks combination therapy):~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
62070306|NCT03259529|EXPERIMENTAL|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
62275101|NCT04222595|NO_INTERVENTION|1- naive|Group 1: up to 10 children aged 4-6 years that never received LAIV before.
62454517|NCT06495658|ACTIVE_COMPARATOR|Prebiotic at Week 8|
62070307|NCT03259529|EXPERIMENTAL|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
62638458|NCT01099358|EXPERIMENTAL|Cetuximab on Cisplatin (B)|"Cycle 1:~400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.~Cycle 2:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~Cycle 3 + :~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
62638459|NCT01099358|EXPERIMENTAL|Cisplatin on Cetuximab (A)|"Cycle 1:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.~Cycle 2 +:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.~After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
62638460|NCT05313724|EXPERIMENTAL|Mind-Body Online Therapy|
62070308|NCT01561092|ACTIVE_COMPARATOR|Escitalopram|
62070309|NCT01561092|PLACEBO_COMPARATOR|Non active drug|
62070310|NCT05510635|EXPERIMENTAL|interactive bibliotherapy|All adolescents enrolled in the experimental group will receive two times of interactive bibliotherapy with an interval of 7 to 14 days. The researcher will read the story to the participant and then discuss it with him/her.
62070311|NCT05510635|ACTIVE_COMPARATOR|reading bibliotherapy|All adolescents enrolled in the comparison group will receive two times of reading bibliotherapy with an interval of 7 to 14 days. The participant will read the story alone.
62638461|NCT05313724|NO_INTERVENTION|TAU (treatment as usual)|
62638462|NCT00750113|EXPERIMENTAL|Arm 1|
62638463|NCT00750113|EXPERIMENTAL|Arm 2|
62638464|NCT00750113|EXPERIMENTAL|Arm 3|
62070312|NCT00592319|EXPERIMENTAL|PDL+Celebrex|endoscopic treatment with once-time PDL radiation at 6.0-8.0 J on laryngeal papilloma, followed by oral taking of 9-month Celebrex (100mg, BID), in 15 subjects
62638465|NCT00667329|EXPERIMENTAL|2CdA + Cyclophosphamide + Rituximab|2CdA 1.5 mg/m\^2 subcutaneous injection three times daily x 7 days. Cyclophosphamide 40 mg/m\^2 PO twice daily x 7 days. Rituximab 375 mg/m\^2 IV once weekly x 4 weeks.
62638466|NCT00012025|EXPERIMENTAL|fulvestrant|"Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years."
62070313|NCT00592319|ACTIVE_COMPARATOR|standard surgery|"once-time and routine surgery, with either of carbon dioxide (CO2) laser radiation at 10.0-20.0 W or cold surgery with microinstruments, in 15 subjects"
62070314|NCT01537679|OTHER|Meditation Intervention|
62070315|NCT01537679|OTHER|Relaxation Intervention|
62070316|NCT01581697|EXPERIMENTAL|Oat bran|
62070317|NCT02936037|PLACEBO_COMPARATOR|GROUP 1|Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
62070318|NCT02936037|EXPERIMENTAL|GROUP 2|MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
62070319|NCT02041247|ACTIVE_COMPARATOR|VAC-3S 16µg/administration|VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
62070320|NCT02041247|PLACEBO_COMPARATOR|VAC-3S Placebo|VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
62070321|NCT02041247|ACTIVE_COMPARATOR|VAC-3S 32 µg/administration|VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
62070322|NCT02041247|ACTIVE_COMPARATOR|VAC-3S 64 µg/administration|VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.
62275102|NCT04222595|ACTIVE_COMPARATOR|2- Fluenz Tetra nasal spray suspension|Group 2: up to 10 children aged 4-6 years that received LAIV once before. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
62275103|NCT04222595|ACTIVE_COMPARATOR|3- Fluenz Tetra nasal spray suspension|Group 3: up to 10 children aged 4-6 years that were vaccinated twice before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
62275104|NCT04222595|ACTIVE_COMPARATOR|4- Fluenz Tetra nasal spray suspension|Group 4: up to 10 children aged 4-6 years that were vaccinated 3 or 4 times before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
62275105|NCT02228863|EXPERIMENTAL|Early Inmotion and Botox|Concomitant use of Inmotion and botulinum toxin from the baseline
62275106|NCT02228863|ACTIVE_COMPARATOR|Botox, then Inmotion|Inmotion training 4 weeks after botulinum toxin injection
62275107|NCT02228863|ACTIVE_COMPARATOR|Inmotion, then Botox|From the baseline Inmotion, then Botox injection at 4 weeks after baseline
62275108|NCT02228863|ACTIVE_COMPARATOR|Late Inmotion and Botox|No intervention, then Inmotion and Botox injection at 4 weeks from the baseline
62275109|NCT03618511|EXPERIMENTAL|Financial Incentive Group|
62070323|NCT02106013||Low HDL-C|Study participants with HDL-C levels below the 10th percentile (HDL-C ≤32 mg/dL)
62070324|NCT02106013||Intermediate HDL-C|Study participants with HDL-C levels between 40th and 60th percentiles (40≤HDL-C≤67 mg/dL)
62070325|NCT02106013||High HDL-C|Study participants with HDL-C levels above the 90th percentile (HDL-C ≥78mg/dL)
62070326|NCT05417451|EXPERIMENTAL|Acupuncture|All subjects will receive active acupuncture. The acupuncture intervention will consist of 10 acupuncture sessions, twice weekly for 5 weeks. There will be at least 1 day in between session.
62070327|NCT05668936|EXPERIMENTAL|Arm 1|Participants will receive cotadutide and will receive a single dose of moxifloxacin-placebo on Day 1 and Day 93.
62275110|NCT03618511|EXPERIMENTAL|Reminders Group|
62454518|NCT02698800|EXPERIMENTAL|Blue blocking (BB)|Wearing of BB lenses.
62638467|NCT01149655|EXPERIMENTAL|Phase 1|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
62070328|NCT05668936|EXPERIMENTAL|Arm 2A|Participants will receive a single dose of moxifloxacin (Day 1) prior to initiating treatment with cotadutide-placebo for up to 13 weeks, followed by a single dose of moxifloxacin-placebo on Day 93.
62638468|NCT01149655|EXPERIMENTAL|Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
62638469|NCT01149655|PLACEBO_COMPARATOR|Phase 3|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
62275111|NCT03618511|EXPERIMENTAL|Financial Incentive and Reminders Group|
62275112|NCT03618511|NO_INTERVENTION|Control Group|
62275113|NCT03618511|EXPERIMENTAL|Information Group|
62275114|NCT03618511|EXPERIMENTAL|Stigma-relieving Group|
62275115|NCT03618511|EXPERIMENTAL|Information and Stigma-relieving Group|
62275116|NCT02113631|ACTIVE_COMPARATOR|Telaprevir|Telapravir was administer with Peg-IFN and Ribavirin as per package insert Dose Telaprevir : PO, tablet 1125 mg BID for 12 weeks
62275117|NCT02113631|ACTIVE_COMPARATOR|Boceprevir|Boceprevir was administer with Peg-IFN and Ribavirin as per package insert Dose Boceprevir PO capsule, 800mg TID for up to 44 weeks
62275118|NCT02163473||Septic patients|Blood Draw Biological samples: The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
62275119|NCT02163473||Healthy Control|The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
62275120|NCT05086445|EXPERIMENTAL|LY3502970 (Part A)|Single doses of LY3502970 administered orally.
62275121|NCT05086445|EXPERIMENTAL|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally.
62638470|NCT01610037|EXPERIMENTAL|QVA149|
62070329|NCT05668936|EXPERIMENTAL|Arm 2B|Participants will receive a single dose of moxifloxacin-placebo (Day 1) prior to initiating treatment with cotadutide-placebo for up to 13 weeks, followed by a single dose of moxifloxacin on Day 93.
62070330|NCT03083392|EXPERIMENTAL|Treatment|treatment of chronic maxillary sinusitis using DIVA system
62070331|NCT04062435|EXPERIMENTAL|Interventional Group|"Peschke®TE 0.25 % application in the INFERIOR FORNIX~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
62275122|NCT05086445|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally.
62275123|NCT05086445|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered orally.
62275124|NCT03011333|EXPERIMENTAL|Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 60 mg/1.8 mg via nerve block.
62275125|NCT03011333|EXPERIMENTAL|Group 2: HTX-011|HTX-011(bupivacaine/meloxicam), 120 mg/3.6 mg via nerve block.
62454519|NCT02698800|PLACEBO_COMPARATOR|Clear|Wearing of clear lenses
62454520|NCT03080649|ACTIVE_COMPARATOR|Rotary bur|Device rotary bur
62275126|NCT03011333|EXPERIMENTAL|Group 3: HTX-011|HTX-011(bupivacaine/meloxicam), 240 mg/7.2 mg via nerve block.
62275127|NCT03011333|EXPERIMENTAL|Group 4: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via nerve block.
62275128|NCT03011333|EXPERIMENTAL|Group 5: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/ 12 mg via instillation.
62070332|NCT04062435|ACTIVE_COMPARATOR|Control Group|"Peschke®TE 0.25 % application on the CORNEA~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
62070333|NCT01515189|EXPERIMENTAL|Arm 1: Ipilimumab (3 mg/kg)|Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
62070334|NCT01515189|EXPERIMENTAL|Arm 2: Ipilimumab (10 mg/kg)|Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
62070335|NCT05992714|EXPERIMENTAL|Virtual Reality Glasses|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device
62070336|NCT05992714|EXPERIMENTAL|White Noise|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be listened using phone
62070337|NCT05992714|NO_INTERVENTION|control group|Patients of the control group, will not receive any intervention except for applied routine hospital arthroscopy surgery procedures
62454521|NCT03080649|EXPERIMENTAL|Er:YAG laser|Device Er:YAG laser
62454522|NCT06029036|EXPERIMENTAL|Darolutamide + ADT|Duration of treatment: 28-day cycle of darolutamide treatment and 6 cycles of neoadjuvant therapy.
62070338|NCT05523245||complete response|Patients receiving neoadjuvant therapy achieved pathological complete response before LARC.
62070339|NCT05523245||non complete response|Patients receiving neoadjuvant therapy did not achieve pathological complete response before LARC.
62275129|NCT03011333|ACTIVE_COMPARATOR|Group 6: Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
62275130|NCT03011333|PLACEBO_COMPARATOR|Group 7: Saline Placebo|Saline placebo via nerve block.
62275131|NCT04415476|OTHER|Sirolimus and Tacrolimus and prednisone|Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)
62275132|NCT04415476|EXPERIMENTAL|Standard of Care|"Arm1:) sirolimus and tacrolimus and prednisone group:~Tacrolimus, The patient will receive 0.1-0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 5-12 ng/ml.~Mycophenolate mofetil (NA )Stopped upon sirolimus initiation Sirolimus:1-5 mg/day PO if \>40 kg / 1 mg/m²/day if \<40 kg trough blood levels 5-12 ng/ml Prednisone:20 mg/day PO if \>40 kg and 10 mg/day if \<40 kg, adjust based on adverse effects.~Arm 2) Standard Therapy Tacrolimus:0.1 to 0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 8-12 ng/ml Mycophenolate mofetil:750-1250 mg bid PO and adjust to tolerance (WBCs and GI side effects Sirolimus: NA Prednisone: Prednisone dose 20 mg/day PO if \>40 kg and 10 mg/day if \<40 kg, adjust based on adverse effect"
62454523|NCT02218164|EXPERIMENTAL|Capecitabine or 5-FU with Pegylated Interferon alpha-2b|"Participants will start the Capecitabine pills on day 1 thru day 14 and be off for 7 days (day 15-day 21).~Participants will receive 5-FU days 1-4 of each 21 day cycle.~Participants will receive the Interferon alpha-2b injection weekly every week. The three week period is referred to as one cycle.~After three cycles, new imaging studies will be performed that will measure how the disease is responding to treatment. Participants whose disease is stable or improved will undergo an additional 3 cycles of therapy and the imaging studies will be repeated. Again, participants whose disease is stable or improved will undergo a final 3 cycles of treatment (a total 27 weeks of treatment)."
62454524|NCT05522270|EXPERIMENTAL|revitalization by concentrated growth factor|modified platelet concentrate
62454525|NCT05522270|ACTIVE_COMPARATOR|revitalization by platelet rich fibrin|platelet concentrate
62275133|NCT04278612|EXPERIMENTAL|Intervention|"Provision of comprehensive care including the following:~Baby:~Measure weight and length Plot on appropriate growth charts in Road to Health Card (RTHC) Discuss with mother about the growth of the baby Identification of malnutrition and appropriate management Age-appropriate nutrition counselling Immunisation Developmental screening Vitamin A supplementation Deworming HIV Care: If mother is HIV positive -~* Polymerase chain reaction (PCR) test for the baby repeated at 10 weeks~* Nevirapine for the baby for six weeks~Mother:~Cervical cancer screening Provide family planning Screening tuberculosis (TB) and sexually transmitted infections (STIs)~HIV Care:~* HIV positive mothers - provide ART for the mother and adherence support~* HIV negative mothers- HIV test every three months while breastfeeding"
62454526|NCT05898204|EXPERIMENTAL|Ketogenic diet arm|Ketogenic diet for a month, or a longer period if clinically necessary
62454527|NCT05898204|ACTIVE_COMPARATOR|Balanced diet arm|Balanced diet for a month, or a longer period if clinically necessary
62454528|NCT06426056|EXPERIMENTAL|Experimental group|Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week. Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
62070340|NCT04121039|EXPERIMENTAL|Apatinib plus POF|Participants will receive apatinib in combination with POF,total 9-12 cycles.Then receive apatinib plus S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62070341|NCT04121039|ACTIVE_COMPARATOR|POF|Participants will receive POF,total 9-12 cycles.Then receive S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62454529|NCT05530681|EXPERIMENTAL|Participants|
62070342|NCT00152763|EXPERIMENTAL|Cognitive Behavior Therapy - males|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the males.
62070343|NCT00152763|EXPERIMENTAL|Cognitive Behavior Therapy - females|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the females.
62275134|NCT04278612|ACTIVE_COMPARATOR|Control|Routine maternal and child care service delivery
62275135|NCT03017053|EXPERIMENTAL|Radiotherapy|Primary surgery \& Radiotherapy
62454530|NCT00163449|ACTIVE_COMPARATOR|1|Ciclesonide 40 µg
62454531|NCT00163449|ACTIVE_COMPARATOR|2|Ciclesonide 80 µg
62454532|NCT00163449|ACTIVE_COMPARATOR|3|Ciclesonide 160 µg
62454533|NCT00163449|PLACEBO_COMPARATOR|4|Placebo
62454534|NCT05123456|EXPERIMENTAL|Patient operated with isolated ACL knee reconstruction|
62454535|NCT05123456|EXPERIMENTAL|Patient operated with ACL and ALL knee reconstruction|
62454536|NCT01907009|EXPERIMENTAL|Registration.|"MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately.~Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count.~Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient).~The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days.~Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy."
62454537|NCT05946148||Empagliflozin group|Oral Empagliflozin 10mg daily, as add-on to their previous treatment regimen.
62454538|NCT05946148||Dulaglutide group|Subcutaneous Dulaglutide 1.5mg weekly, as add-on to their previous treatment regimen.
62638471|NCT01610037|ACTIVE_COMPARATOR|Tiotropium|
62275136|NCT03017053|ACTIVE_COMPARATOR|Elective neck dissection|Primary surgery \& Elective neck dissection
62638472|NCT01610037|PLACEBO_COMPARATOR|placebo|
62070344|NCT00152763|ACTIVE_COMPARATOR|Usual Cardiac Care - Males|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was just for males randomized.
62070345|NCT00152763|ACTIVE_COMPARATOR|Usual Cardiac Care - females|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was for females randomized.
62070346|NCT04714437|ACTIVE_COMPARATOR|F-R/L-A1/A3/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5)
62070347|NCT04714437|ACTIVE_COMPARATOR|F-R/L-A1/A5/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3)
62070348|NCT04714437|ACTIVE_COMPARATOR|F-R/L-A3/A1/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5)
62070349|NCT04714437|ACTIVE_COMPARATOR|F-R/L-A3/A5/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1)
62070350|NCT04714437|ACTIVE_COMPARATOR|F-R/L-A5/A1/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3)
62070351|NCT04714437|ACTIVE_COMPARATOR|F-R/L-A5/A3/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1)
62070352|NCT01391351|OTHER|Taxol and carboplatin|blood samples in patients receiving Taxol and carboplatin chemotherapy
62070353|NCT01391351|OTHER|Taxol, carboplatin and avastin|blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
62070354|NCT01821430|EXPERIMENTAL|Pregabalin|Pregabalin 400mg / Day
62070355|NCT01821430|PLACEBO_COMPARATOR|Placebo Control|Placebo Tablet
62454539|NCT05946148||Control group|Optimal anti-diabetic treatment (apart from agents of the GLP1-ras or SGLT2-is families), targeting glycemic control.
62070356|NCT03930134|EXPERIMENTAL|sparse uterine suture|women who had a french ambulatory casarean section including a sparse uterine closure
62454540|NCT00944879||HPV vaccine|Those choosing to receive the HPV vaccine
62454541|NCT00944879||no HPV vaccine|Those choosing not to receive the HPV vaccine
62275137|NCT05370859||Mme Study Participants|Participants will complete a baseline survey, 11 weekly surveys, and a follow-up survey at 12 weeks
62275138|NCT01473797|EXPERIMENTAL|cladribine|
62275139|NCT03771365||Standard-PCNL|Perform PCNL with ≥24 Fr access tract for the treatment of ≥2 renal stones
62275140|NCT03771365||Mini-PCNL|Perform PCNL with 12-20 Fr access tract for the treatment of ≥2 renal stones
62275141|NCT03771365||Super-mini PCNL|Perform SMP for the treatment of ≥2 renal stones
62275142|NCT04690972||Hepato-bilio-pancreatic surgery|Patients whom hepato-bilio-pancreatic surgery is indicated as part of the care
62275143|NCT04690972||biopsy of the hepatic parenchyma|Patients whom a biopsy of the hepatic parenchyma, one or more hepatic nodules or a loco-regional treatment is indicated as part of the care
62275144|NCT04690972||Viral chronic infection|Patients with a viral chronic liver disease
62275145|NCT01770925|ACTIVE_COMPARATOR|n-CPAP|"* The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~* CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~* If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
62275146|NCT01770925|ACTIVE_COMPARATOR|n-BiPAP|"* The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~* The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
62275147|NCT01770925|ACTIVE_COMPARATOR|NIPPV|o The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water, peak inspiratory pressure of 15cm of water, RRof35 and Ti of 0.32
62275148|NCT03136315|EXPERIMENTAL|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
62070357|NCT03930134|ACTIVE_COMPARATOR|one layer uterine closure|women who had a misgav ladach caesarean section section, including a one layer classical uterine closure
62275149|NCT02184871||intrahepatic cholangiocarcinoma|Patients committed to surgery and stratified according to exposure to different risk factors for ICC, basing on modified ReNaM questionnaire.
62275150|NCT00974987|EXPERIMENTAL|Treatment group|BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment) and TMZ(temozolomide) treatment
62275151|NCT00725075|EXPERIMENTAL|MK-8435 (Org 25935) 8-16 mg per day|Participants will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and receive 4-8 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
62275152|NCT00725075|EXPERIMENTAL|MK-8435 (Org 25935) 24-32 mg per day|Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
62638473|NCT05108701|EXPERIMENTAL|I-MBCT|"Participants randomized to I-MBCT (Mindfulness-Based Cognitive Therapy) receive 12 weekly 60- minute sessions of I-MBCT according to the protocol of Segal et al. (2002), integrated with the theme, rationale, intention and practice skills (TRIP) protocol (Woods et al. 2016, 2019). The original MBCT protocol, created for eight group sessions lasting two hours, is adapted to twelve individual sessions."
62275153|NCT00725075|PLACEBO_COMPARATOR|Placebo|Participants will be maintained on a stable dose of SGA and receive matching placebo for MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days.
62275154|NCT06436378|EXPERIMENTAL|Musical intervention|This arm will receive a personalized music intervention.
62275155|NCT06436378|NO_INTERVENTION|No musical intervention|This arm will carry out its daily activities and will be assessed using the same measures at the beginning of each session and after a delay comparable to the duration of the intervention administered in the experimental group.
62275156|NCT03938493||endotracheal intubation under general anesthesia|Adults who require endotracheal intubation for head and neck surgery under general anesthesia
62275157|NCT01845038|EXPERIMENTAL|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of \~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
62275158|NCT01845038|EXPERIMENTAL|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of \~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
62275159|NCT01845038|ACTIVE_COMPARATOR|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
62275160|NCT06269445|EXPERIMENTAL|Icaritin Combined With Bevacizumab and FOLFIRI|"Icaritin: 600 mg orally, bid; Bevacizumab: Intravenous infusion, 5 mg/kg per dose, every 14 days; FOLFIRI: ①Irinotecan: Irinotecan should be given on the first day of chemotherapy at a dose of 180mg/m2 by intravenous drip.The infusion time should be \>30-90min.~②Calcium folinate: give irinotecan at a dose of 400mg/m2 by intravenous drip in conjunction with irinotecan infusion, and the infusion time should be up to 2h.~③5-fluorouracil: give intravenous infusion at a dose of 400mg/m2 on the first day of chemotherapy, then give an intravenous drip at a dose of 1200mg/m2 for 2 days, the total amount of 2400mg/m2 , and continue to be infused for 46-48h."
62275161|NCT04983160|ACTIVE_COMPARATOR|Allopurinol|
62275162|NCT04983160|PLACEBO_COMPARATOR|Placebo|
62275163|NCT00857870|ACTIVE_COMPARATOR|Metformin|
62275164|NCT00857870|ACTIVE_COMPARATOR|Insulin glargine|
62275165|NCT02116166||Young|Young (20-35 years old)
62638474|NCT05108701|ACTIVE_COMPARATOR|CBT|Participants randomized to Individual Cognitive Behavioural Therapy (CBT) receive 12 weekly 60-minute individual sessions of standard CBT strategies following Beck et al. (1979). Participants receive a copy of Greenberger and Padesky's Mind over Mood (The Guilford Press, 1995) for use during the intervention.
62638475|NCT01102309|EXPERIMENTAL|Experimental Group (EG)|Group assigned to robot plus conventional therapy
62638476|NCT01102309|ACTIVE_COMPARATOR|Control Group (CG)|Group assigned to conventional therapy only
62638477|NCT00652912|EXPERIMENTAL|A|Subjects received the Kali formulated products under fasting conditions
62638478|NCT00652912|ACTIVE_COMPARATOR|B|Subjects received the Roche's product under fasting conditions
62638479|NCT01367015|EXPERIMENTAL|Early Feeding|Early feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours after randomization followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
62638480|NCT01367015|ACTIVE_COMPARATOR|Late feeding|Late feeding group was kept NPO for a period of 48 hours after randomization followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
62275166|NCT02116166||Old|Older (70-99 years old)
62275167|NCT03115151|EXPERIMENTAL|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
62275168|NCT03115151|SHAM_COMPARATOR|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
62275169|NCT04111029||Unresectable HCC undergoing locoregional therapy|Patients with unresectable HCC who have no curative option like tumour ablation, resection or transplantation and are being taken for locoregional therapy will be recruited
62275170|NCT01903837|EXPERIMENTAL|Low Dose|Olanzapine + low dose samidorphan tablets taken once daily
62275171|NCT01903837|EXPERIMENTAL|Medium Dose|Olanzapine + medium dose samidorphan tablets taken once daily
62638481|NCT03255369||Child exposed Zika virus proved|child born to mothers with proved zika virus in pregnancy by RT-PCR
62638482|NCT03255369||Child exposed to zika virus suspected|Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
62638483|NCT03255369||Normal Child|Normal child from mothers without Zika (IgG and IgM negative)
62638484|NCT04232930|ACTIVE_COMPARATOR|Music group|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
62638485|NCT04232930|NO_INTERVENTION|Non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
62454542|NCT02627742|EXPERIMENTAL|METANEB|Patients will receive standard care with the addition of therapy with The MetaNeb® System.
62454543|NCT01880073|EXPERIMENTAL|FemVue device|FemVue would be used in conjunction with the laparoscopic chromopertubation to determine if it is as effective.
62454544|NCT02401282|EXPERIMENTAL|ABM|Attention bias modification
62454545|NCT02401282|PLACEBO_COMPARATOR|Placebo|Dot-probe task
62454546|NCT04229849|EXPERIMENTAL|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
62638486|NCT05246891||Rehabilitation nursing intervention|Functional respiratory rehabilitation exercise plan. Motor exercise plan. Cardiorespiratory optimization. Early diagnosis of potential problems associated.
62638487|NCT05246891||Rehabilitation nursing not intervention|General nursing care
62638488|NCT04936516|ACTIVE_COMPARATOR|McGrath Video Laryngoscope|
62638489|NCT04936516|ACTIVE_COMPARATOR|C-MAC Video Laryngoscope|
62638490|NCT03205293|EXPERIMENTAL|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
62638491|NCT03205293|NO_INTERVENTION|Control Group|Regular school curriculum
62638492|NCT04845334|EXPERIMENTAL|Clinical RR intervention|Clinical RR intervention
62638493|NCT04845334|NO_INTERVENTION|Standard care|Standard care
62638494|NCT05474183|ACTIVE_COMPARATOR|Group (K)|Group (K): (n=30) will receive ketamine infusion 1-2 μg/kg/min (0.12 mg/kg/h) titrated to desired level of sedation.
62638495|NCT05474183|ACTIVE_COMPARATOR|Group (D)|Group (D): (n=30) will receive Dexmedetomidine infusion 0.1- 0.2 μg/kg/hour titrated to desired level of sedation.
62638496|NCT05474183|PLACEBO_COMPARATOR|Group (C)|Group (C): (n=30) will receive fentanyl only.
62275172|NCT01903837|EXPERIMENTAL|High Dose|Olanzapine + high dose samidorphan tablets taken once daily
62275173|NCT01903837|PLACEBO_COMPARATOR|Placebo|Olanzapine + placebo tablets taken once daily
62275174|NCT04951687|EXPERIMENTAL|Active: Ecologic Barrier©|"Dietary supplement: Ecologic Barrier©~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate, and probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58).~Subjects will consume 2g (5 billion CFU)/day of Ecologic Barrier©. The intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
62454547|NCT04229849|ACTIVE_COMPARATOR|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
62454548|NCT00102908|EXPERIMENTAL|1|Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
62454549|NCT00102908|PLACEBO_COMPARATOR|2|Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
62454550|NCT05836077|EXPERIMENTAL|Pecha kucha method|Patients will be trained by pecha kucha method using computer with powepoint presentation.
62454551|NCT05836077|NO_INTERVENTION|Control group|Routine maintenance will be applied
62454552|NCT02297451|NO_INTERVENTION|Brachial artery inflow|Elbow fistula created with brachial artery as inflow (ie. either brachiocephalic or brachiobasilic fistulas)
62638497|NCT03902093|EXPERIMENTAL|Hearing Aid|Actual Patients in the clinic will be evaluated by their Audiologist, if they are candidates to use the Lyric Hearing aid they will be asked if they want to participate in the study which will include imaging of the ear canal with a device similar to the regular ear device used in the clinic to check if there are any changes to the morphology of the ear canal.
62638498|NCT00564941|EXPERIMENTAL|Deferasirox|
62454553|NCT02297451|ACTIVE_COMPARATOR|Proximal radial/ulnar artery as inflow|Elbow fistula created with either proximal radial or ulnar artery as inflow
62638499|NCT04503967|EXPERIMENTAL|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line treatment of Gastric and Esophageal Cancer patients
62454554|NCT02463149|EXPERIMENTAL|Youth Chef Academy|Receives intervention
62638500|NCT05282628|EXPERIMENTAL|Building Better Brains and Behavior program (B4 Preterm)|Online learning modules completed sequentially and in conjunction with live coaching sessions led by a trained therapist.
62638501|NCT05837273|EXPERIMENTAL|Fully immersive leisure-based virtual reality|
62638502|NCT05837273|EXPERIMENTAL|Conventional cognitive training|
62638503|NCT05837273|NO_INTERVENTION|control group|
62070358|NCT01709305|ACTIVE_COMPARATOR|Metformin + Sitagliptin + Glimepiride|During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
62275175|NCT04951687|PLACEBO_COMPARATOR|Placebo|"Dietary supplement: placebo powder~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate.~As with the active treatment, the intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
62275176|NCT02096341|EXPERIMENTAL|RRx-001|RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses-16 and 27 mg/m2- will be tested.
62275177|NCT03891901|EXPERIMENTAL|Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid|Participants will receive 50 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
62275178|NCT03891901|EXPERIMENTAL|Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid|Participants will receive 100 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
62275179|NCT03891901|EXPERIMENTAL|Cohort 1c: Imatinib (200 mg) + Rifabutin + Isoniazid|Participants will receive 200 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
62275180|NCT03891901|EXPERIMENTAL|Cohort 1d: Imatinib (400 mg) + Rifabutin + Isoniazid|Participants will receive 400 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
62275181|NCT03891901|EXPERIMENTAL|Cohort 2a: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
62638504|NCT04810988|ACTIVE_COMPARATOR|Unsupported|"Participants in this arm will receive a 12-week Unified Protocol intervention delivered via the same web platform. Each week, participants will complete the following content:~1. depression survey,~2. anxiety survey,~3. information about their symptom change over time,~4. psychoeducational text~5. practice exercises,~6. home practice instructions,~7. writing exercise,~8. home practice worksheets.~In the first week, participants will receive an emailed welcome message followed by a link to the first week's content. For every following week, participants will receive an email at the start of the week with automatically generated feedback on intervention usage, behavior change, and symptom change, as well as the link to the new week's intervention content."
62638505|NCT04810988|EXPERIMENTAL|Partially Supported|Participants in the partially supported arm will receive all aspects of the intervention described above, with no differences between arms for the first seven weeks of the intervention (Modules 1-6). Participants will be introduced to their study therapist in week 8, at the start of Module 7 via email. During Module 7 (exposure; weeks 8-11), participants will receive four video therapy sessions. Session content will be based on principles of exposure therapy (developing a personalized exposure hierarchy, live demonstrations of exposure exercises, in-session exposure practices, post-exposure processing, home practice assignments, and therapist feedback).
62638506|NCT00737100|EXPERIMENTAL|Tiotropium Respimat 2.5 mcg|patient to receive low dose tiotropium once daily
62638507|NCT00737100|EXPERIMENTAL|Tiotropium Respimat 5 mcg|patient to receive high dose tiotropium once daily
62638508|NCT00737100|PLACEBO_COMPARATOR|Placebo Respimat|patient to receive placebo once daily
62070359|NCT01709305|EXPERIMENTAL|Metformin + Sitagliptin + Repaglinide|During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
62070360|NCT01709305|EXPERIMENTAL|Metformin + Sitagliptin + Acarbose|During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
62070361|NCT01709305|EXPERIMENTAL|Metformin + Sitagliptin + Gliclazide|During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
62070362|NCT05423522|EXPERIMENTAL|NanoLithium® NP03|"Description: Homogeneous yellow oily liquid. Dosage: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Duration of treatment: Approximately one year (12 weeks for the double-blind period and 36 weeks for the subsequent open-label period)."
62070363|NCT05423522|PLACEBO_COMPARATOR|Placebo|"Description: Homogeneous yellow oily liquid. Dosage: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Duration of treatment: 12 weeks during the double-blind period."
62070364|NCT02960763|EXPERIMENTAL|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
62070365|NCT02960763|EXPERIMENTAL|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
62070366|NCT02960763|EXPERIMENTAL|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
62638509|NCT01137513||Chest Pain|Acute Myocardial ischemia
62275182|NCT03891901|EXPERIMENTAL|Cohort 2b: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
62275183|NCT03891901|EXPERIMENTAL|Imatinib (100 mg)|Participants will receive 100 mg imatinib daily for 28 days.
62638510|NCT06119230|NO_INTERVENTION|Sensors only|Participants will only wear the sensors for a one week period during the 4 different time points.
62638511|NCT06119230|EXPERIMENTAL|Sensors and Activity Counselling|Participants will wear the sensors for a one week period and receive a goal setting session with a physiotherapist at baseline, 3-and 7-weeks post discharge.
62070367|NCT02960763|EXPERIMENTAL|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
62638512|NCT02245815|EXPERIMENTAL|use probiotics boucardii|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
62070368|NCT02960763|EXPERIMENTAL|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
62070369|NCT02169037|EXPERIMENTAL|FIRM ablation|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM) alone.
62070370|NCT02169037|ACTIVE_COMPARATOR|Conventional AF ablation with PVI|These patients will treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
62070371|NCT04737772|ACTIVE_COMPARATOR|Standard Quitline Treatment As Usual (TAU)|State quitline treatment as usual
62070372|NCT04737772|EXPERIMENTAL|QL Marijuana Check-Up intervention (QL-MJCU).|Newly developed intervention for co-users of marijuana and tobacco.
62070373|NCT03458559|ACTIVE_COMPARATOR|Radium-223-chloride|Radium-223-chloride 50kBg/kg, every 4 weeks intravenously, for a total of 6 administrations.
62070374|NCT03458559|EXPERIMENTAL|Rhenium-188-HEDP|Rhenium-188-HEDP 40MBq/kg, every 8 weeks intravenously, for a total of 3 administrations.
62070375|NCT03037879|EXPERIMENTAL|SPT|Speed of Processing Training
62070376|NCT03037879|ACTIVE_COMPARATOR|Control Group SPT|Control group to SPT treatment group
62070377|NCT03037879|EXPERIMENTAL|mSMT|Story Memory Technique
62070378|NCT03037879|ACTIVE_COMPARATOR|Control mSMT|Control group to mSMT treatment group
62070379|NCT05443087|EXPERIMENTAL|Regorafenib - mCRC, GIST, HCC|"3 x 30 = 90 patients~Patients with mCRC, GIST or HCC treated with Regorafenib"
62070380|NCT05443087|EXPERIMENTAL|Everolimus - gepNET|"60 patients~Patients with gepNET treated with Everolimus"
62638513|NCT02245815|EXPERIMENTAL|use probiotics Multi-species|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
62070381|NCT05443087|EXPERIMENTAL|Sunitinib - pNET, GIST|"2 x 30 = 60 patients~Patients with pNET and GIST, treated with Sunitinib"
62070382|NCT05443087|EXPERIMENTAL|Cabozantinib - HCC|"60 patients~Patients with HCC treated with Cabozantinib"
62638514|NCT04511897|EXPERIMENTAL|Experimental group|oral An'ningpai Enteric Soft Capsules (300 mg,three times daily) for 12 months.
62638515|NCT04511897|NO_INTERVENTION|Control group|No experimental durgs used.
62638516|NCT02895269|EXPERIMENTAL|Collaborative shared care|Conventional primary health care providers (PHCP) are trained to collaborate with and support traditional and faith healers (complementary alternative providers, CAPs) in the care of patients with psychosis. The PHCP are purposively trained to deliver evidence-based treatment for psychosis and to conduct scheduled and on-request visits to the facilities of the CAPs to collaborate in the treatment of patients with psychosis through joint decision making and clinical management. The overall care of the patients remains the responsibility of the healers. The role of the PHCP is to support the healers deliver safe and acceptable care to patients, including the promotion of and respect for human rights and avoidance of harmful practices in the care of patients.
62070383|NCT05443087|EXPERIMENTAL|Encorafenib - Cetuximab - mCRC|"60 patients~Patients with mCRC treated with the association Encorafenib - Cetuximab"
62070384|NCT01920503||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
62070385|NCT06109090||Adopted children|"Patients included in the study must meet the following inclusion criteria:~* Signing the informed consent~* Age between 6 and 10 years~* Adopted after the first year of life~The exclusion criteria for this study are:~* Comorbidity with other pathologies~* Children adopted from birth~* Cognitive impairment (IQ\<85)"
62070386|NCT05535140||Cancer patients who are 65 years of age or older|An online self-reported G8 screening tool. The tool will have content including: 1) the purpose and benefit of the G8, 2) explanations of each question with examples and probes to help with recall, and 3) next steps after the G8 assessment is completed and how the results might impact their cancer treatments. New established older cancer patients will be invited to interact with the tool.
62275184|NCT03891901|EXPERIMENTAL|Imatinib (200 mg)|Participants will receive 200 mg imatinib daily for 28 days.
62275185|NCT03891901|EXPERIMENTAL|Imatinib (400 mg)|Participants will receive 400 mg imatinib daily for 28 days.
62275186|NCT00695565|PLACEBO_COMPARATOR|Placebo Gel|Placebo Gel is vehicle without clonidine
62454555|NCT02463149|NO_INTERVENTION|Control|Usual classroom curriculum
62454556|NCT03256968|EXPERIMENTAL|ataluren administration|dose of the drug administered (mg/kg body weight)
62638517|NCT02895269|ACTIVE_COMPARATOR|Usual care|Complementary alternative providers deliver intervention for patients with psychosis without active or formal collaboration with conventional primary health care providers. The primary health care providers in this arm nevertheless receive training on evidence-based treatment of psychosis.
62638518|NCT05550350|EXPERIMENTAL|DEXYCU|DEXYCU, 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
62638519|NCT05550350|PLACEBO_COMPARATOR|Placebo|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
62638520|NCT04980014||NesinaAct® Tablet|Participants with a diagnosis of Type 2 Diabetes who took NesinaAct® tablet, a fixed dose combination of alogliptin along with pioglitazone, as prescribed by the physician, are observed in this study.
62638521|NCT06336421|EXPERIMENTAL|Experimental Group|virtual reality glasses were used in primiparous pregnant women undergoing cesarean section. The video, in which baby pictures will be shown accompanied by virtual reality music, was prepared by the researcher and a faculty member in the music department. During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes.
62275187|NCT00695565|ACTIVE_COMPARATOR|Clonidine Topical Gel (ARC-4558)|Clonidine Topical Gel contains 0.1% clonidine hydrochloride
62638522|NCT06336421|NO_INTERVENTION|Control group|"* Written consent was obtained from pregnant women who agreed to participate in the study.~* 10 minutes before cesarean section; A personal information form was filled out to determine the descriptive characteristics of the pregnant women.~* The pregnant woman's anxiety level before the procedure was determined using the State Anxiety Scale.~* Before the procedure, blood pressure, pulse, respiratory rate and saturation in the patient follow-up form were recorded.~* Routine practice was performed during cesarean section.~* 10 minutes after cesarean section; In order to determine the anxiety level, the parameters in the State Anxiety Scale and the Patient Follow-up Form were measured again and the process was completed."
62638523|NCT03159936|EXPERIMENTAL|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
62638524|NCT04423471||Group 1|Psoriasis patients who will receive systemic treatment (mainly methotrexate)
62638525|NCT04423471||Group 2|Psoriasis patients who will receive a biological treatment
62638526|NCT04423471||Group 3|Patients with major depression who will receive an antidepressant treatment
62638527|NCT02498678|NO_INTERVENTION|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min \[\< 5% variation in the first response (T1) in the TOF\]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
62638528|NCT02498678|EXPERIMENTAL|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min \[\< 5% variation in the first response (T1) in the TOF\]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
62638529|NCT03804268|PLACEBO_COMPARATOR|Vehicle|Participants received one drop of vehicle in each eye, once daily, for up to 30 days.
62638530|NCT03804268|EXPERIMENTAL|Pilocarpine HCl Ophthalmic Solution|Participants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.
62638531|NCT03741374|EXPERIMENTAL|Minimally-invasive non-surgical therapy|Intrabony defects treated with Minimally-invasive non-surgical therapy (MINST)
62638532|NCT00983502||Integrative Medicine|Patients of MD practitioners trained in Complementary and Alternative Medicine
62638533|NCT00983502||Naturopath Doctors|Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
62638534|NCT00983502||Chronic Fatigue Specialists|Patients of MD's who specialize in treating Chronic Fatigue and related conditions
62638535|NCT00983502||Control Group|Patients treated by primary care MDs in practice-based research networks
62638536|NCT03539094|EXPERIMENTAL|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
62638537|NCT03539094|NO_INTERVENTION|Western diet|The subjects randomized to this group will eat a standard western style diet.
62275188|NCT01678144|EXPERIMENTAL|Medtentia Annuloplasty Ring (MAR)|All eligible patients underwent surgical mitral valve repair using annuloplasty device - Medtentia Annuloplasty Ring (MAR)
62275189|NCT02177760|EXPERIMENTAL|Sirolimus|Sirolimus (0.05 mg/kg/day) day -5 for aGVHD prophylaxis through day +100 or until T-regulatory cells \>9% of CD4 effector cells; whichever comes first.
62275190|NCT00875355|EXPERIMENTAL|Arm I|Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
62275191|NCT00875355|EXPERIMENTAL|Arm II|Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
62275192|NCT02482454|OTHER|RFA alone|Patients undergo radiofrequency ablation alone.
62638538|NCT05598060|EXPERIMENTAL|neoadjuvant stereotactic body radiation therapy followed by hepatectomy|Experimental: Phase1(Cohort 1): neoadjuvant stereotactic body radiation therapy (24Gy/3Fr) followed by hepatectomy Experimental: Phase1(Cohort 2): neoadjuvant stereotactic body radiation therapy (30Gy/3Fr) followed by hepatectomy Experimental: Phase1(Cohort 3): neoadjuvant stereotactic body radiation therapy (36Gy/3Fr) followed by hepatectomy
62275193|NCT02482454|EXPERIMENTAL|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA
62638539|NCT00821275|ACTIVE_COMPARATOR|pregnancy expectation|The patients who desire for future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
62638540|NCT00821275|ACTIVE_COMPARATOR|No pregnancy expectation|The patients who don't desire for reserving uterus and/ or future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
62638541|NCT03366857|ACTIVE_COMPARATOR|30%|Participants allocated to these groups will receive a FiO2 of 0.3 during the operation and for two hours postoperatively.
62070387|NCT01566630|EXPERIMENTAL|RLX030|"In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030.~In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1."
62070388|NCT01566630|PLACEBO_COMPARATOR|Placebo|"In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts.~In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours"
62070389|NCT05664139|EXPERIMENTAL|Experimental Arm|"* Recombinant Human Adenovirus Type 5 Injection: 1ml or 2ml, d1, q3w, 4 cycles;~* Camrelizumab: 200mg, d2, q3w;~* Nab-paclitaxel: 260mg/m2, d1, q3w, 4-6 cycles;"
62070390|NCT02887989|EXPERIMENTAL|Virtual Reality|Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
62070391|NCT02887989|SHAM_COMPARATOR|'Health and Wellness Channel'|Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
62070392|NCT00390455|EXPERIMENTAL|Arm I (lapatinib)|Patients receive lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 and 15 of course 1 and on day 1 of each subsequent course. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62275194|NCT03842826||Athlete|Male athletes performing sports ≥ 1x/week Age: 18-40 years
62070393|NCT00390455|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 and fulvestrant as in Arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62275195|NCT02758158|EXPERIMENTAL|Tri-modal imaging|Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes
62275196|NCT05821283|EXPERIMENTAL|Physical Activity Group|The Physical Activity (PAG) was included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking).
62275197|NCT05821283|ACTIVE_COMPARATOR|Control Group|The Control Group (CG) was included in the program consisting of only supervised exercises.
62638542|NCT03366857|ACTIVE_COMPARATOR|80%|Participants allocated to these groups will receive a FiO2 of 0.8 during the operation and for two hours postoperatively.
62638543|NCT02886923|EXPERIMENTAL|Test/Control Sequence|Subjects will wear the Hioxifilcon A Test contact lens and then the Hioxifilcon A with Cosmetic Ring Control contact lens for approximately three to four hours at each of the two measurement visits.
62638544|NCT02886923|ACTIVE_COMPARATOR|Control/Test Sequence|Subjects will wear the Hioxifilcon A with Cosmetic Ring Control contact lens and then the Hioxifilcon A Test contact lens for approximately three to four hours at each of the two measurement visits.
62638545|NCT02532374|EXPERIMENTAL|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
62638546|NCT04834401||Natalizumab|Natalizumab (minimum of 6 doses at standard interval)
62638547|NCT04834401||Fumarates|Fumarates (dimethyl fumarate or diroximel fumarate)
62638548|NCT04834401||Interferon Beta 1a|Interferon Beta 1a (or pegylated Interferon Beta-1a)
62638549|NCT04834401||Ocrelizumab|Ocrelizumab (minimum of 2 full cycles of 600mg)
62638550|NCT03747393|ACTIVE_COMPARATOR|DoD/VA CPG Core Set|The standard core set of interventions recommended by the DoD/VA clinical practice guidelines for non-surgical management of knee OA.
62070394|NCT01759615|EXPERIMENTAL|Early enteral feeding|Early enteral feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
62070395|NCT01759615|ACTIVE_COMPARATOR|Late enteral feeding|Late enteral feeding group was kept NPO for a period of 48 hours followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
62275198|NCT01490619|EXPERIMENTAL|Healthy Thinking in Teens|Group-based, manualized program, based on cognitive behavioral therapy techniques.
62275199|NCT01490619|ACTIVE_COMPARATOR|Advanced Diabetes Education|Group-based, manualized program designed to provide diabetes education, focused on adolescent-specific topics.
62275200|NCT06170398|OTHER|Interventional|Electrophysiological tests
62638551|NCT03747393|EXPERIMENTAL|DoD/VA CPG Core Set + PT|In addition to DoD/VA clinical practice guidelines, patients will be referred to physical therapy (PT). Physical therapy will consist of evidence-based interventions that can be provided by a PT (exercise, manual therapy, education).
62638552|NCT02245165|EXPERIMENTAL|Nitric oxide synthase (NOS) inhibition|After a control period of 4 hours, intervention with L-NMMA (10 mg/kg IV) is done and recording continued for 4 hours.
62638553|NCT02245165|SHAM_COMPARATOR|Saline|After a control period of 4 hours, intervention with saline is done and recording continued for 4 hours.
62638554|NCT02982863||All Patients|
62638555|NCT03330509|EXPERIMENTAL|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
62638556|NCT03330509|EXPERIMENTAL|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
62638557|NCT03330509|EXPERIMENTAL|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
62638558|NCT03330509|EXPERIMENTAL|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
62638559|NCT03395626|EXPERIMENTAL|ID-JPL934|probiotics 20%, corn starch 80%
62638560|NCT03395626|PLACEBO_COMPARATOR|placebo|corn starch 100%
62638561|NCT05530772|EXPERIMENTAL|Immediate endoscopic Necrosectomy|"The subject will have endoscopic necrosectomy at the time of the EUS-guided transmural stent placement.~The necrotic collection is identified with endoscopic ultrasonography (EUS). Transmural placement of stent under EUS guidance is performed. The type of stent is at the discretion of endoscopist. It could be either lumen apposing metallic stent or double pigtail plastic stent. Immediately after stent placement, the cystoenterostomy track is dilated with a 15 mm through the scope (TTS) balloon. Then, direct endoscopic necrosectomy is performed with CO2 insufflation. The duration of necrosectomy will be 30 to 90 minutes. If complete clearance of the cavity is achieved before 30 minutes, the duration of necrosectomy may be less than 30 minutes in the given session. Also, if any complication occurs during necrosectomy, appropriate management will be done, and the procedure may be concluded earlier."
62638562|NCT05530772|ACTIVE_COMPARATOR|On-demand endoscopic necrosectomy|The subject will have EUS-guided transmural drainage of the necrotic collection The necrotic collection is identified with endoscopic ultrasonography (EUS). Transmural placement of stent under EUS guidance is performed. The type of stent is at the discretion of endoscopist. It could be either lumen apposing metallic stent or double pigtail plastic stent. In this group, endoscopic necrosectomy is not performed at the time of index procedure. Such patients may undergo endoscopic necrosectomy during follow up if clinically indicated.
62638563|NCT05968144|EXPERIMENTAL|Time-restricted eating|Participants will meet with a nutritionist to discuss dietary recommendations for patients with prostate cancer undergoing ADT. Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times).
62638564|NCT05968144|ACTIVE_COMPARATOR|Unrestricted eating|Participants will meet with a nutritionist to discuss dietary recommendations for patients with prostate cancer undergoing ADT. Participants will try to follow recommendations will no suggestion for meal timing.
62638565|NCT03606564||paediatric patients undergoing day care surgery|
62275201|NCT03984305|EXPERIMENTAL|PKG+ Group|"For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is controlled or uncontrolled based on scores provided by the PKG."
62275202|NCT03984305|PLACEBO_COMPARATOR|PKG- Group|For subjects in the PKG- Group (SOC control group), participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
62275203|NCT03949270|NO_INTERVENTION|Usual Care|Patients in the usual care arm will not receive any text messages.
62275204|NCT03949270|EXPERIMENTAL|BETA-Text Intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
62638566|NCT00962312|EXPERIMENTAL|Capecitabine and Lapatinib|
62638567|NCT00866905|EXPERIMENTAL|Ixabepilone/Cyclophosphamide|Systemic Therapy followed by surgery and possible radiation therapy
62638568|NCT02421692|NO_INTERVENTION|Usual Care|SNF rehabilitation therapists provide all patients with usual standard of care.
62638569|NCT02421692|EXPERIMENTAL|Progressive Rehabilitation|SNF rehabilitation therapists have been trained on principles of progressive rehabilitation strategies and will implement to all eligible patients as new standard of care.
62638570|NCT00791999|EXPERIMENTAL|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks
62275205|NCT01166230||Patients with Ta/T1, randomized to white light cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
62638571|NCT00791999|EXPERIMENTAL|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks
62638572|NCT00791999|EXPERIMENTAL|CDP870 400mg|400mg CDP870 given every 2 weeks
62638573|NCT00791999|PLACEBO_COMPARATOR|Placebo|Placebo given every 2 weeks
62638574|NCT05194462|ACTIVE_COMPARATOR|Pelvic Floor Physical Therapy (PFPT)|6 sessions of PFPT over a 12 week period with planned home exercises as per physical therapist's recommendation.
62638575|NCT05194462|ACTIVE_COMPARATOR|Biofeedback device|Pericoach® by Analytica is a vaginal device with recommendation for daily use during the 12 week period.
62638576|NCT03275207|PLACEBO_COMPARATOR|control group|an equal volume of saline
62638577|NCT03275207|EXPERIMENTAL|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
62070396|NCT05408143|ACTIVE_COMPARATOR|usual CC (with conventional telemedicine)|
62070397|NCT05408143|EXPERIMENTAL|comprehensive care (CC) augmented with enhanced telemedicine (ETM)|
62275206|NCT01166230||Patients with Ta/T1 randomized to Hexvix cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
62275207|NCT01610765|ACTIVE_COMPARATOR|Novel Antiviral Drug|Subjects will be randomized to receive one of 3 oral doses of a Novel Antiviral Drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
62275208|NCT01610765|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive one of 3 oral doses of placebo matched in volume to active drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
62638578|NCT04414007|EXPERIMENTAL|Internet+ home-based cardiac rehabilitation group|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
62638579|NCT04414007|ACTIVE_COMPARATOR|conventional care group|The UC-assigned patients will maintain standard of care.The conventional rehabilitation group received routine medical care and traditional home-based cardiac rehabilitation based on the rehabilitation manual and exercise diary, followed up by telephone and outpatient.
62638580|NCT06442605|EXPERIMENTAL|Experimental group|Conventional laparoscopic myomectomy with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids.
62638581|NCT06442605|ACTIVE_COMPARATOR|Control group|Conventional laparoscopic myomectomy with the use of a multi-channel specimen retrieval bag and a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.
62638582|NCT03008811|ACTIVE_COMPARATOR|Cryoballoon|Pulmonary vein isolation with cryoballoon catheter.
62638583|NCT03008811|ACTIVE_COMPARATOR|Radiofrequency|Pulmonary vein isolation with radiofrequency ablation catheter.
62638584|NCT01587885|EXPERIMENTAL|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
62638585|NCT01587885|ACTIVE_COMPARATOR|Omeprazole 20 mg|Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
62638586|NCT02357225|EXPERIMENTAL|Acute Dose of Pyridostigmine|Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
62638587|NCT02357225|EXPERIMENTAL|Prolonged Use of Pyridostigmine|This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.
62638588|NCT01417468|EXPERIMENTAL|CLSI - Known|Participants will be assigned to a specific learning group via the Canfield Learning Style Inventory (CLSI).
62638589|NCT01417468|ACTIVE_COMPARATOR|CLSI - Unknown|Participants will be assigned to a traditional learning group (Control).
62070398|NCT03160300|EXPERIMENTAL|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
62070399|NCT03160300|SHAM_COMPARATOR|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
62070400|NCT01031472|EXPERIMENTAL|Part A|Subjects will be randomized in a three way crossover design to either a single dose of GSK2248761 100mg Gelucire capsule administered with food and a single dose of 100mg of formulation 1 or a single dose of 100mg of formulation 3 administered in the fed and fasted state
62275209|NCT03296046||PPBL patients|
62638590|NCT00956085|EXPERIMENTAL|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
62638591|NCT05580484||Purified starch/Control group|Patients who were willing to receive purified starch at their own expense during this first surgery were included in the purified starch group, and patients who did not re-ceive purified starch or other anti-adhesion products were included in the control group.
62638592|NCT00535652|EXPERIMENTAL|Ertapenem|Administration of 1 gram ertapenem I.V.
62638593|NCT04825665|EXPERIMENTAL|Continuous force|A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar on one side
62638594|NCT04825665|EXPERIMENTAL|Intermittent force|A buccally directed tipping force of 150 g removed every 21 days for a 7-day rest period applied to the maxillary first premolar on one side
62638595|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
62275210|NCT05047276|EXPERIMENTAL|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
62275211|NCT01888042|EXPERIMENTAL|Everolimus|Everolimus will be administered per os every day at the same hour immediately after a meal with a glass of water 10 mg (1 tablet of 10 mg)
62638596|NCT05733663||Adult patients diagnosed with coeliac disease|A group of paediatric or adult patients diagnosed with CD and started on a strict GFD, with baseline and a follow-up intestinal biopsy to assess histological and intraepithelial lymphogram at least 1-year after starting the GFD, and with increased γδ+ T-cells at baseline.
62638597|NCT06520813||Nail Group|
62638598|NCT04102293|EXPERIMENTAL|Rotary instrumentation using MM files 1|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
62638599|NCT04102293|ACTIVE_COMPARATOR|Manual instrumentation using K-files 1|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
62638600|NCT04102293|EXPERIMENTAL|Rotary instrumentation using MM files 2|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Disposable syringe technique.
62638601|NCT04102293|ACTIVE_COMPARATOR|Manual instrumentation using K-files 2|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Disposable syringe technique
62638602|NCT05684341|EXPERIMENTAL|Device Intervention arm|Connected Solution with H2S app which connects with blood glucose meter (BGM) to support glycemic control in T2DM participants
62638603|NCT05684341|NO_INTERVENTION|No Device Control arm|Physician-recommended routine management (usual care) to support glycemic control in T2DM participants
62638604|NCT03495063|EXPERIMENTAL|Natural Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of natural caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
62638605|NCT03495063|EXPERIMENTAL|Synthetic Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of synthetic caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
62638606|NCT03905083|EXPERIMENTAL|Exercise rehab|Investigators aim to evaluate how exercise training may provide beneficial effects on the skeletal muscle and/or pulmonary vasculature in select subjects with pulmonary arterial hypertension, scleroderma or mixed connective tissue disease or patients with exercise pulmonary arterial hypertension
62638607|NCT03905083|NO_INTERVENTION|No exercsie rehab|Some participants will not be assigned to do exercise rehab so we would be using them as a control arm to intervention group
62275212|NCT06500247|EXPERIMENTAL|experimental group|Androgen Deprivation Therapy+Darxicilib+Abiraterone Acetate（II）+Prednisone
62275213|NCT04467580|EXPERIMENTAL|Patients with stenosing CD|Patients with stenosing CD will be recruited in each investigation center, during a preoperative consultation for an already decided and planned intestinal resection (digestive surgery or hepato-gastro department) -enterology).
62275214|NCT05229146|EXPERIMENTAL|Episodic Future Thinking|"Mothers will receive episodic future thinking (EFT). Mothers will meet with a peer mother who will administer the EFT intervention, including generation of several specific future events reflecting positive interactions with their child. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, mothers will receive daily text messages over the course of two weeks including a reminder cue generated as part of the EFT and a prompt to remember these episodes in vivid detail."
62275215|NCT03777644|EXPERIMENTAL|TPVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
62275216|NCT03777644|PLACEBO_COMPARATOR|placebo TPVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with morphine
62638608|NCT02937480|EXPERIMENTAL|Experimental group|Task-specific training
62638609|NCT02937480|SHAM_COMPARATOR|Control group|Global stretching, memory exercises, health care orientation
62638610|NCT02713178|ACTIVE_COMPARATOR|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
62638611|NCT02713178|ACTIVE_COMPARATOR|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
62638612|NCT02713178|PLACEBO_COMPARATOR|Placebo|Normal saline (20 mL).
62275217|NCT01496885||Nonhemorrhagic Ischemic Stroke|Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke
62275218|NCT05321836|ACTIVE_COMPARATOR|control group|chondritin sulfate 1500/1200mg
62275219|NCT05321836|EXPERIMENTAL|experimental group|chondritin sulfate plus physiotherapy
62638613|NCT01895803||smoking woman 18-60 years old|
62638614|NCT05681117|NO_INTERVENTION|control group|No intervention will be made in the control group.
62638615|NCT05681117|EXPERIMENTAL|Experimental group|Class-based nutrition education, online intervention (SMS reminders with tips for healthy eating), distribution of brochures prepared in accordance with the educational content, and a controversial supermarket tour were organized in the experimental group as multiple interventions. Class-based nutrition education was given as a 40-minute session once a week for 4 weeks. Nutrition education content has been prepared as 4 modules in line with the current literature.
62638616|NCT00350883|OTHER|Treatment as Usual|
62275220|NCT05272033|ACTIVE_COMPARATOR|GROUP TEAS|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at PC-5, PC-6, and ST-36 with an electronic acupuncture device.
62275221|NCT05272033|SHAM_COMPARATOR|Sham TEAS|In the sham TEAS group, the gel electrodes will be applied at the same anatomical points without stimulation.
62454557|NCT04462263|EXPERIMENTAL|Single Dose HTL0014242|The study consists of up to 5 dosing groups, with 2 to 3 subjects per dosing group. Each subject will receive a single oral dose of HTL0014242 in the form of solid suspension capsules (1, 5, 10, and 30mg) as required. HTL0014242 will be administered in up to 5 single dose groups, with 120mg administered in the first dosing group.
62454558|NCT01617954||Subjects with MammaPrint Result|
62454559|NCT02449876|EXPERIMENTAL|Neuroscience Education|"Subjects will have 2 sessions of education 2 weeks apart. After the first session subjects will be given a 50 page book Why Do I Hurt by Adriaan Louw. Session 1 will last approximately 60 minutes and session approximately 30 minutes."
62454560|NCT03660839|EXPERIMENTAL|Ferroquine 400 milligram (mg)|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.
62454561|NCT03660839|EXPERIMENTAL|Ferroquine 400 mg + Artefenomel 300 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.
62638617|NCT00350883|EXPERIMENTAL|Cognitive Therapy|
62638618|NCT04737525|EXPERIMENTAL|Test group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and porcine-derived membrane.
62638619|NCT04737525|EXPERIMENTAL|Control group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and connective tissue grafting (CTG).
62638620|NCT05358899|EXPERIMENTAL|Real stimulation|Participants in the real stimulation group will receive accelerated cTBS with 1800 stimulation per session for 10 consecutive days, 5 sessions per day with a gap at least one hour, 50 sessions in total. The stimulation will be conducted at left M1 area.
62638621|NCT05358899|SHAM_COMPARATOR|Sham stimulation|Participants in the sham stimulation group will receive the stimulation with coil vertical to the surface with other settings same as the real stimulation group.
62638622|NCT00327340|EXPERIMENTAL|OGX-011 / mitoxantrone/prednisone|OGX-011 / mitoxantrone/prednisone: OGX-011 administered in combination with mitoxantrone and prednisone
62638623|NCT00327340|EXPERIMENTAL|OGX-011/docetaxel/prednisone|OGX-011/docetaxel/prednisone: OGX-011 administered in combination with docetaxel and prednisone
62070401|NCT01031472|EXPERIMENTAL|Part B|A total of twelve subjects who complete Part A will participate in Part B. Subjects from Part A will be asked to participate on a first come first serve basis until there are 12 subjects, at which time enrolment to Part B will be closed. Part B will be a 2 way cross over study design. Subjects will be randomized to one of a single dose of GSK2248761 100mg Formulation 2 or 4 (based on the evaluation of Part A data) administered with food or in the fasted state. Subjects in Part B will not receive the reference formulation since they previously received this in Part A
62070402|NCT04976595|EXPERIMENTAL|Natesto|Participants will administer Natesto, gel, intranasally, three times daily up to Day 120. A multiple-dose dispenser will be used for gel deposition into the nasal cavity.
62638624|NCT05001607|OTHER|Study trial|All participants will perform pulmonary blockade on an intubating manikin using 4 different methods: Endobronchial intubation with an endotracheal tube; Bronchial blocker attached to the outside of an endotracheal tube; Double lumen endotracheal tube; and Intraluminal placement of bronchial blocker.
62652984|NCT02854462|EXPERIMENTAL|Language comprehension intervention|The intervention will run for 4 weeks. Caregivers will be provided with storybooks (e.g., Percy the Park Keeper) that have been amended to include inference-eliciting questions. Caregivers will be trained (with a video) to ask these questions and respond to their children's answers during shared reading sessions. They will be asked to read one book per day. Caregivers will keep a reading diary.
62070403|NCT04544228|EXPERIMENTAL|ketamine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml ketamine
62070404|NCT04544228|EXPERIMENTAL|Neostigmine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml neostigmine
62070405|NCT04544228|ACTIVE_COMPARATOR|Control|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml normal saline.
62070406|NCT02872727||Air France Company's Employees Working|Observational cohort : Air France Company's Employees Working in the Marseilles and Paris Airports having Respiratoy health, biological investigations
62638625|NCT01997008|EXPERIMENTAL|Intervention|"Participants receive a five week intervention providing the following activities:~EMA:~Ecological Momentary Assessment (EMA) of Emotion throughout the day.~Intervention:~Positive Events: Participants identify a positive event and then describe how they capitalized on this event.~Gratitude: Participants identify one more more things that make them feel grateful.~Mindfulness: Participants participate in a 30 minute guided mindfulness/meditation practice.~Positive Reappraisal: Participants identify how they reappraised a negative event making it into a positive event.~Personal Strengths: Participants identify one more more personal strengths. Attainable goals: Participants identify a short-term attainable goal. Participants will outline what they did that day to work toward attaining their week's goal.~Acts of Kindness: Participants will identify one more more acts of kindness that they engaged in and how it made them feel."
62652985|NCT02854462|ACTIVE_COMPARATOR|Counting intervention|The intervention will run for 4 weeks. Caregivers will be provided with a book 'At home with counting' that is made up of age appropriate maths exercises. Caregivers will trained (with a video) to work through one page of the book per day. This should take the same amount of time as the activity in the language intervention condition. Caregivers will keep a counting diary.
62652986|NCT03287544|EXPERIMENTAL|Combined rehabilitation|Linguistic training as well as communication training.
62070407|NCT05943314|EXPERIMENTAL|CLL1/+CD33 CAR-T|The target dose range for subjects was set to be 1.00\~2.50x10\^6/kg CAR-positive T cells.
62070408|NCT05149781||patients with EH|patients with endocrine hypertension
62070409|NCT05149781||patients with PH|patients with primary hypertension
62070410|NCT03335930|EXPERIMENTAL|Morning exercise|To exercise at morning (08:00-10:00)
62070411|NCT03335930|ACTIVE_COMPARATOR|Afternoon exercise|To exercise at afternoon (14:00-16:00)
62070412|NCT03335930|ACTIVE_COMPARATOR|Evening exercise|To exercise at evening (18:00-20:00)
62070413|NCT05050266|ACTIVE_COMPARATOR|REP|Replicating Effective Practices (REP) is a lower-intensity implementation strategy with explicit process framework for local tailoring
62070414|NCT05050266|EXPERIMENTAL|EBQI|Evidence-Based Quality Improvement (EBQI) is a higher-intensity implementation strategy that entails external facilitation and formal training in quality improvement.
62070415|NCT01727492|PLACEBO_COMPARATOR|sugar pill|
62454562|NCT03660839|EXPERIMENTAL|Ferroquine 400 mg + Artefenomel 600 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.
62454563|NCT03660839|EXPERIMENTAL|Ferroquine 400 mg + Artefenomel 1000 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.
62638626|NCT01997008|NO_INTERVENTION|Emotion reporting and EMA notification|"Participants report emotions and receive EMA (ecological momentary assessment) text messages on the same regular basis as intervention participants, but receive no interventions.~EMA detail:~Ecological Momentary Assessment (EMA) of Emotion throughout the day. We will assess current emotions via email or text message 4 times per day, 2 days per week (one randomly selected week/work day and one randomly selected weekend/non-work day) during the 8 week study period, for a total of 16 days of EMA reporting. Participants will be asked to rate how much they are currently feeling several positive and negative emotions that have been associated with mortality and health: happy, excited, content, appreciative, sad, worried, and fearful."
62638627|NCT04327921|EXPERIMENTAL|peer navigation social support for smoking cessation|36 HIV-positive smokers will have a 30-minute session with the study nurse to discuss smoking cessation. They will also discuss the importance of social support for quitting and the role of a Peer Navigator. Those participants who set a quit date will choose medication/s in collaboration with the nurse and/or physician. The Peer Navigator will be introduced and will reinforce adherence to medication. The Peer Navigator will ensure that the patient picks up the medication, and will help to manage side effects via physician/nurse consultation. The Peer Navigator will provide social support for quitting via weekly phone calls for 12 weeks.
62638628|NCT04327921|ACTIVE_COMPARATOR|Standard Condition|36 HIV-positive smokers will receive standard care. Participants will meet for a 30-minute session with a study nurse. They will receive counseling based on the 5A's. The nurse will ask about current smoking habits, advise the participant to quit, assess readiness to quit, and assist by providing resources (community programs, Quit line phone number). The nurse will calculate Lung Age which will serve as a motivation tool to encourage smokers to quit. Those willing to set a quit date will be instructed to call their physician for cessation medication and will provided with the National Cancer Institute self-help pamphlet. Those participants not willing to set a quit date will be instructed to contact their physician when they are ready.
62638629|NCT01127100|EXPERIMENTAL|Transdermal fentany matrix|Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
62638630|NCT01127100|ACTIVE_COMPARATOR|gabapentin|Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
62638631|NCT04321772|EXPERIMENTAL|High Intensity Interval Resistance Training (HIIRT)|"HIIRT technique consisted of three sets of: 6 repetitions at 80% 1RM (1 repetition maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30 rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets."
62638632|NCT04321772|ACTIVE_COMPARATOR|Traditional Resistance Training (TRT)|"TRT protocol performed 3 series of 15 repetitions at 60% 1RM with 75 of rest between sets."
62638633|NCT05245383|OTHER|Single arm|
62638634|NCT05684848|ACTIVE_COMPARATOR|Resveratrol + CMG|Medical device: nasal spray based on resveratrol associated with carboxymethylbetaglucan in isotonic solution
62454564|NCT02159716|EXPERIMENTAL|Metastatic Pancreatic (ductal) adenocarcinoma (PDA)|
62638635|NCT05684848|PLACEBO_COMPARATOR|Isotonic solution|Medical Device with isotonic solution
62652987|NCT03287544|ACTIVE_COMPARATOR|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
62652988|NCT02301455|NO_INTERVENTION|Control, Not hypertensive|Participants who after 3 weeks do not have high blood pressure or are not responsive to text messages.
62638636|NCT05357846|EXPERIMENTAL|NCRT+IO group|"• NCRT+IO group consists of the PD-1 inhibitor combined with concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks.PD-1 inhibitor is given by intravenous infusion on days 1 and 22. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~* Radiation: (40 or 45 Gy/20 fractions)~* Drug: Sintilimab~* Drug: Paclitaxel~* Drug: Cisplatin"
62638637|NCT05357846|ACTIVE_COMPARATOR|NCRT group|"• NCRT group consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~* Radiation: (40 or 45 Gy/20 fractions)~* Drug: Paclitaxel~* Drug: Cisplatin"
62070416|NCT01727492|ACTIVE_COMPARATOR|Antioxidantia|Dosage: 600mg n-acetylcystein and 200mg magnesium intake: 1 hour before leisure noise exposure above 100dB of at least 30 minutes frequency: 4 separate events (2x placebo, 2x antioxidants)
62070417|NCT04020159||Participants with COL6-related dystrophy|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
62275222|NCT05788939|EXPERIMENTAL|intervention group|The sample of this cluster randomized controlled experimental study consisted of 2nd year university students (n=116) training in Faculty of Economics and Administrative Sciences (FEAS) and Hasan Ferdi Turgutlu Faculty of Technology (HFTFT) from the faculties of Manisa Celal Bayar University (MCBU) between February-Semptember 2019. Among the faculties in MCBU, simple random sampling was used to draw lots, with the first lot being assigned to FEAS as the intervention group (IG), and the second lot being assigned to HFTFT as the control group (CG) . Among seven departments in FEAS and four departments in the HFTFT, simple random sampling was used to draw lots again. The Department of Econometrics from the FEAS was assigned as the IG and Mechatronics Engineering from HFTFT was assigned as the CG. The planned visual education based Health Belief Model was given.
62454565|NCT02159716|EXPERIMENTAL|Serious Epithelial Ovarian Cancer|
62638638|NCT00924924|EXPERIMENTAL|Act Healthy!|Immediate treatment group of six-weeks of classes in self-management training for healthy behaviors
62638639|NCT00924924|ACTIVE_COMPARATOR|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
62638640|NCT05909540||Goel A Type Basilar Invagination|1) ADI\>3mm in adults, or ADI\>5mm in child.
62275223|NCT05788939|NO_INTERVENTION|Control group|No attempt was made by researcher during the study. Only data were collected. At the end of the study, the planned visual education based Health Belief Model was given and all students continued in the study were given key rings with pictures about sun protection designed by the researchers.
62275224|NCT01526512|EXPERIMENTAL|metroCX|metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
62275225|NCT06128447|ACTIVE_COMPARATOR|Treatment A|ZP5-9676 600 mg dose
62275226|NCT06128447|PLACEBO_COMPARATOR|Treatment B|Placebo
62454566|NCT02159716|EXPERIMENTAL|Malignant Epithelial Pleaural Mesothelioma|
62454567|NCT04216043|EXPERIMENTAL|RUSF skimmed milk powder|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
62638641|NCT05909540||Goel B Type Basilar Invagination|"1. ADI\<3mm in adults, or ADI\<5mm in child.~2. The stabilization in atlantoaxial could can be found.~3. The tip of odontoid can exceed the Chamberlian's line， but not exceed the Wackenheim's line and Mcrae's line."
62638642|NCT01861132||Healthy pregnant women|Healthy pregnant women for C-section under spinal anesthesia
62638643|NCT02063113|NO_INTERVENTION|NA/NA|
62638644|NCT01089127|EXPERIMENTAL|Indacaterol 18.75 μg|Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
62638645|NCT01089127|EXPERIMENTAL|Indacaterol 37.5 μg|Patients inhaled indacaterol 37.5 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
62638646|NCT01089127|EXPERIMENTAL|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
62638647|NCT01089127|EXPERIMENTAL|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
62638648|NCT01089127|ACTIVE_COMPARATOR|Salmeterol 50 μg|Patients inhaled salmeterol 50 μg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
62638649|NCT01089127|PLACEBO_COMPARATOR|Placebo|Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
62638650|NCT02619617|EXPERIMENTAL|SOM230 0.9mg|cohort 2
62638651|NCT02619617|EXPERIMENTAL|SOM230 1.5 mg|cohort 1
62638652|NCT05235932|EXPERIMENTAL|Robotic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received robotic radical total gastrectomy with D2 lymphadenectomy
62638653|NCT05235932|ACTIVE_COMPARATOR|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received laparoscopic radical total gastrectomy with D2 lymphadenectomy
62638654|NCT00275171|ACTIVE_COMPARATOR|rhTSH|proceeded by 0.1 mg rhTSH
62638655|NCT00275171|PLACEBO_COMPARATOR|Placebo|1 ml isotonic saline
62638656|NCT05178472|EXPERIMENTAL|Arm I (vertebroplasty)|Patients undergo vertebroplasty and, 2-4 weeks later, undergo SRS over 1-3 fractions depending upon the number of affected vertebral bodies. Patients also receive standard of care immunotherapy IV every 2 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
62275227|NCT03434977|EXPERIMENTAL|TAK-536 10 mg (fasted) + TAK-536 10 mg (fed)|TAK-536 10 milligram (mg) granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) in the morning under fasted condition, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) after starting breakfast.
62454568|NCT04216043|EXPERIMENTAL|RUSF milk protein concentrate and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
62638657|NCT05178472|ACTIVE_COMPARATOR|Arm II (no vertebroplasty)|Patients receive standard of care immunotherapy IV every 2 weeks for up to 6 months and undergo SRS over 1-3 fractions depending upon the number of affected vertebral bodies in the absence of disease progression or unacceptable toxicity.
62638658|NCT04113291|EXPERIMENTAL|DASH diet group|Participants randomized to receive the DASH diet will be prescribed an isocaloric DASH diet using meals (lunch, dinner, snacks) prepared by a Clinical Research Metabolic Kitchen under the direction of a registered dietician. Participants will prepare their own breakfast from a menu. The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
62638659|NCT04113291|ACTIVE_COMPARATOR|Attention Control Group|Participants randomized to attention control will continue their usual diet, but they will be instructed to limit their sodium intake to 2300 mg/day. They will be requested and voluntarily agree to not make additional diet or exercise changes during the 12-week study.
62454569|NCT04216043|EXPERIMENTAL|RUSF soy protein and whey permeate|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
62638660|NCT01333423|EXPERIMENTAL|Doxil + Seliciclib|Doxil (Liposomal doxorubicin) 40 mg/m2 intravenous (IV) over 2 -3 hours on Day 4 and Seliciclib starting dose 200 mg orally twice a day on Days 1 - 3 of 28 day cycle
62638661|NCT01324947|EXPERIMENTAL|Pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
62638662|NCT02276963|EXPERIMENTAL|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
62638663|NCT02557724||liver transplant patients|5 blood samples at time points as described in protocol
62638664|NCT02557724||Liver resection patients|3 blood samples at time points described in protocol
62638665|NCT01753713|EXPERIMENTAL|Anti-angiogenic Therapy Naive Patients|Patients who have progressed without anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62638666|NCT01753713|EXPERIMENTAL|Anti-angiogenic Therapy Patients|Patients who have progressed on anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62638667|NCT01551966|EXPERIMENTAL|video capsule endoscopy|
62638668|NCT05406700|EXPERIMENTAL|Arm A Treatment with Niraparib|Patients randomized to arm A will receive niraparib daily and undergo tumor resection after 28 days (+/- 7 days) of treatment. The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery . Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent
62275228|NCT03434977|EXPERIMENTAL|TAK-536 10 mg (fed) + TAK-536 10 mg (fasted)|TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) after starting breakfast, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) in the morning under fasted condition.
62275229|NCT01047657|EXPERIMENTAL|weight loss|
62275230|NCT01047657|NO_INTERVENTION|Control|
62275231|NCT01510678|EXPERIMENTAL|Decrease Condition|In the Decrease Snack Foods condition participants will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to \< 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
62638669|NCT05406700|ACTIVE_COMPARATOR|Arm B No Treatment with Niraparib|Subjects in arm B will not receive niraparib prior to surgery. The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery . Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent.
62638670|NCT03880136|EXPERIMENTAL|Sequence 1|Period 1: CTP-543 with meal Period 2: CTP-543 without meal
62638671|NCT03880136|EXPERIMENTAL|Sequence 2|Period 1: CTP-543 without meal Period 2: CTP-543 with meal
62638672|NCT06420388|EXPERIMENTAL|Lidocaine Gel|"Description: Patients in this group received 5 mL of 2% lidocaine gel applied to the perianal region three times per day postoperatively. The gel was self-administered by the patient or applied by a nurse if the patient was unable to do so. Treatment continued for 7 days after the haemorrhoidectomy procedure.~Arm Sample Size: 200"
62638673|NCT06420388|PLACEBO_COMPARATOR|Controlled|"Description: Patients in this group received 5 mL of a non-anaesthetic, water-based lubricant gel (K-Y gel) applied to the perianal region three times per day postoperatively. The gel was self-administered by the patient or applied by a nurse if the patient was unable to do so. Treatment continued for 7 days after the haemorrhoidectomy procedure. This group served as a control to compare the efficacy of 2% lidocaine gel in reducing postoperative pain and analgesic consumption.~Arm Sample Size: 200"
62070418|NCT01762423|EXPERIMENTAL|Active Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with Velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Active Devices The device will be activated at the time of placement. The active devices are programmed to automatically deliver treatment. Each treatment duration is 15 minutes. The active device delivers treatment every 2 hours. A light will flash on the device when the PEMF begins and will continue to flash every second until the end of the treatment. Between treatments the device will be in sleep mode and the light will flash every 5 seconds."
62275232|NCT01510678|EXPERIMENTAL|Increase + Decrease Condition|Families will be encouraged to increase fruits and vegetables and decrease snack foods.
62275233|NCT01510678|EXPERIMENTAL|Increase Condition|A parent and child will be encouraged to increase fruits and vegetables. Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F\&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables.
62275234|NCT05118256|NO_INTERVENTION|No intervention - standard of care|A group of patients with PMF will be treated per standard of care on site
62275235|NCT05118256|EXPERIMENTAL|Experimental - Pirfenidone plus standard of care|A group of patients with PMF will be treated with pirfenidone plus standard of care on site
62275236|NCT02989519|NO_INTERVENTION|no progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation
62275237|NCT02989519|EXPERIMENTAL|oral progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received oral progesterone (dydrogesterone 10 mg; Duphaston™) per oral three times a day
62454570|NCT04216043|EXPERIMENTAL|RUSF soy and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
62454571|NCT04533607|ACTIVE_COMPARATOR|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
62454572|NCT04533607|NO_INTERVENTION|Waitlist control|Services as usual.
62454573|NCT00185523||CML in first Chronic Phase or Accelerated Phase|Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs\*\* Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion
62454574|NCT00185523||AML and ALL in first or second remission|FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions\* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion
62454575|NCT00650936|OTHER|AMPLATZER Septal Occluder|Subjects were enrolled if the implant of the AMPLATZER Septal Occluder device was completed or was attempted (delivery system entered the subject's body).
62454576|NCT02103738||Arm 1 (Monthly)|0.5 mg intravitreal injections of Ranibizumab monthly for the duration of the study.
62638674|NCT05459415|EXPERIMENTAL|Reducing Excision Margins|In resectable HPV-negative locally advanced head and neck squamous cell carcinoma, 3 cycles of preoperative neoadjuvant chemotherapy combined with immunotherapy are proposed, in patients with significant tumor shrinkage (≥50%) as assessed by imaging, to conduct research on narrowing the scope of surgery, preserve the patient's organ function, improve or improve the quality of life, and achieve a curative effect that is not inferior to traditional radical surgery
62275238|NCT02989519|EXPERIMENTAL|vaginal progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received vaginal progesterone (micronized progesterone 200 mg; Utrogestan™) at bed time.
62275239|NCT01785212|OTHER|Stapler-hepatectomy|The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
62454577|NCT02103738||Arm 2 (Treat and Extend)|Three consecutive months of 0.5 mg Ranibizumab intravitreal injections (Day 1, Month 1, and Month 2). Monthly injections will continue until evidence of disease stability is observed. Specifically, monthly treatment will continue until visual acuity is deemed stable as indicated by a gain in visual acuity of ≤ 3 ETDRS letters from the prior month, no clinical evidence of lesion growth, fluid or blood, and no intraretinal or subretinal fluid on OCT. When this is achieved, the intervals between each subsequent injection will be extended by 2 weeks (intervals of 6 weeks, 8 weeks, 10 weeks, to a maximum of 12 weeks) until clinical or diagnostic evidence of disease instability is observed based on OCT findings and/or BCVA ETDRS.
62454578|NCT01505257|EXPERIMENTAL|END-DSD Intervention|
62454579|NCT01505257|NO_INTERVENTION|Control|
62454580|NCT01131858|PLACEBO_COMPARATOR|Placebo|Placebo
62454581|NCT01131858|ACTIVE_COMPARATOR|Vitamin D|Vigantol (cholecalciferol) 4000 IE/day
62454582|NCT05875818|OTHER|Tele-rehabilitation|
62454583|NCT05875818|EXPERIMENTAL|In-clinic Rehabilitation|
62454584|NCT04782609|EXPERIMENTAL|20 mg Icapamespib cohort|Icapamespib will be administered orally once daily for each 28-day cycle. The initial dose in this trial will be 20 mg
62454585|NCT04782609|EXPERIMENTAL|dose expansion cohort|dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D)
62454586|NCT02517801|EXPERIMENTAL|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily)
62454587|NCT02517801|PLACEBO_COMPARATOR|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily)
62454588|NCT04790448|EXPERIMENTAL|VIC regimen|"Patients will receive VIC regimen every 2 weeks:~Cetuximab 500mg/m2 IV on Day 1; Irinotecan 180mg/m2 IV on Day 1 (If patient carries UGT\*28 7/7 or UGT\*6 A/A or UGT\*28 6/7 and UGT\*6 A/G variants, use Irinotecan IV 150mg/m2 instead); Vemurafenib PO BID on Days 1 to 14 (Dosage: 480mg; 720mg; 960mg, determined by the maximum tolerated dose (MTD) in Phase Ia trial)."
62638675|NCT01677741|EXPERIMENTAL|Part 1: Dabrafenib treatment|Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg \[+1\] and may be further to 4.5 mg/kg \[+2\] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg \[-1\] and may be further to 1.5 mg/kg \[-2\]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
62652989|NCT02301455|EXPERIMENTAL|Text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to receive text messages.
62070419|NCT01762423|SHAM_COMPARATOR|Sham Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Sham Devices The sham devices mirror the active device with the exception of the delivery of the PEMF. The sham device will be activated at the time of placement. A light will flash on the device when the SHAM PEMF begins and will continue to flash every second until the end each treatment interval. While in sleep mode the device will not deliver treatment and the light will flash every 5 seconds."
62454589|NCT00576901|EXPERIMENTAL|1|
62070420|NCT01381952|EXPERIMENTAL|Reduced radiation dose (ClarityIQ)|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology
62275240|NCT01785212|OTHER|CUSA-hepatectomy|The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
62275241|NCT00874120|EXPERIMENTAL|Phenylephrine HCl Extended-Release tablets 30 mg|Phenylephrine HCl Extended Release tablets 30 mg
62454590|NCT05003648|PLACEBO_COMPARATOR|Placebo|Participants will be on the placebo arm for 2 months and will then cross over to the pramipexole arm for 2 months
62070421|NCT01381952|ACTIVE_COMPARATOR|Normal radiation dose (AlluraXper)|Normal dose DSA with conventional X-ray technology.
62275242|NCT00874120|PLACEBO_COMPARATOR|Placebo|Placebo
62275243|NCT04421495|EXPERIMENTAL|delamanid containing regimen arm|the only one arm to be studied with delamid-containing regimen.
62275244|NCT02326779|EXPERIMENTAL|Experimental Arm|Experimental Arm: acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
62275245|NCT02326779|NO_INTERVENTION|Comparator Arm|Non-aspirin use arm as comparator
62275246|NCT01972074|EXPERIMENTAL|Memantine|"Participants in the placebo arm will receive placebo (no active ingredients) in capsule form twice daily. It will be administered twice daily for 12 weeks. Participants will undergo neuroimaging before and after the 12-week treatment phase.~Placebo: Capsule"
62275247|NCT01972074|PLACEBO_COMPARATOR|Placebo|"Participants in the memantine arm will receive memantine in capsule form twice daily. It will be administered twice daily for 12 weeks (including a 4-week titration phase to a maximum dose of 20 mg per day). Participants will undergo neuroimaging before and after the 12-week treatment phase.~Memantine: Capsule"
62275248|NCT01972074|NO_INTERVENTION|Control Group|Healthy controls will undergo neuroimaging twice (12 weeks apart) and will receive no intervention during the 12-week window.
62638676|NCT01677741|EXPERIMENTAL|Part 2: Cohort 1 Low-Grade Gliomas with BRAF V600 mutations|Subjects with low-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
62652990|NCT02301455|NO_INTERVENTION|No text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to not receive text messages.
62275249|NCT03379662|EXPERIMENTAL|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
62275250|NCT03379662|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
62275251|NCT01175291|ACTIVE_COMPARATOR|Arm A - FOLFOX 7 + MK-0646|
62070422|NCT05492812|EXPERIMENTAL|Chloral Hydrate|Chloral hydrate was administered orally to children at a dose of 25-50 mg/kg/dose. After the sedative drug administration, the child was taken to a quiet and dark sleep room in the polyclinic environment with his parents in order to enable the child to fall asleep. In this process, the child was evaluated by the nurse every 5 minutes with the Ramsay Sedation Score. Children with a Ramsay Sedation Score of 4-6 were taken to the EEG room for recording. During the sedation, the child's blood pressure, oxygen saturation and pulse were checked every 5 minutes. EEG electrodes were placed in accordance with the international 10-20 electrode positioning system. An average of 30 minutes of EEG recording was made for each patient. The awakening process of children whose EEG recordings were completed was evaluated with the Steward Recovery Score. Individuals with a score of 6 were accepted as awake, and the child's procedure was completed.
62275252|NCT01175291|PLACEBO_COMPARATOR|Arm B - FOLFOX 7 + Placebo|
62275253|NCT04612998|SHAM_COMPARATOR|Comparator group|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
62275254|NCT04612998|ACTIVE_COMPARATOR|Active control group|Active control group consisted of patients performing CSEA in the sitting position.
62275255|NCT01294800|EXPERIMENTAL|Preladenant 2 mg|Participants will receive preladenant 2 mg taken orally twice daily (BID), one tablet in the morning and one tablet in the evening, for 12 weeks.
62275256|NCT01294800|EXPERIMENTAL|Preladenant 5 mg|Participants will receive preladenant 5 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
62275257|NCT01294800|EXPERIMENTAL|Preladenant 10 mg|Participants will receive preladenant 10 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
62275258|NCT01294800|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo to preladenant tablet taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
62275259|NCT02237430|ACTIVE_COMPARATOR|Manuel compression|Conventional manual compression
62275260|NCT02237430|EXPERIMENTAL|MynxGrip closure device|Closure device for femoral artery access closure
62275261|NCT00300638||1- MRI and interviews|In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using Magnetic Resonance Imaging (MRI) scans, we observe how the brain works when people purposefully respond to the words and pictures. Interviews, cognitive tests, and emotional measurements will also be done. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
62652991|NCT04152499|EXPERIMENTAL|Phase I: Dose Escalation|Five dose levels have been selected for evaluation in the Phase I part of the study: 2, 4, 6, 9, and 12 mg/kg of SKB264
62638677|NCT01677741|EXPERIMENTAL|Part 2: Cohort 2 High-Grade Gliomas with BRAF V600 mutations|Subjects with high-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
62638678|NCT01677741|EXPERIMENTAL|Part 2: Cohort 3 LCH with BRAF V600 mutations|Subjects with LCH with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
62638679|NCT01677741|EXPERIMENTAL|Part 2: Cohort 4 Melanoma and PTC with BRAF V600 mutations|Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
62638680|NCT03984344|EXPERIMENTAL|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
62652992|NCT04152499|EXPERIMENTAL|Phase II: Triple Negative Breast Cancer|Histologically documented or cytologically , incurable, locally advanced or metastatic cancer
62454591|NCT05003648|ACTIVE_COMPARATOR|Pramipexole|Participants will be on the pramipexole arm for 2 months and will then cross over to the placebo arm for 2 months
62638681|NCT03984344|EXPERIMENTAL|Active cTBS|Continuous TBS will be delivered at 80% of RMT and will be applied as 600 pulses in a 40-second train of uninterrupted 50Hz bursts to the right dorsolateral prefrontal cortex.
62638682|NCT03984344|SHAM_COMPARATOR|Sham TBS|Sham stimulation will be given at the right or left dorsolateral prefrontal cortex (counterbalanced) for 40 seconds or 3 minutes and 9 seconds (counterbalanced), at the same frequency as active TBS (50Hz), however a sham coil will be used.
62275262|NCT02216838|EXPERIMENTAL|botulinum toxin A|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
62275263|NCT02216838|PLACEBO_COMPARATOR|Saline Control|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
62638683|NCT01691378|EXPERIMENTAL|WtoH Intervention|Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
62638684|NCT01691378|OTHER|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
62638685|NCT00032448|OTHER|1|Open and laparoscopic herniorrhaphy
62638686|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
62638687|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
62638688|NCT03361852|EXPERIMENTAL|Neo Vax|"* Neo Vax is injected into up to 4 different anatomic site.~* NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~* Within +/-3 days of the scheduled administration date for days 15 and 22~* Within +/-7 days of days 78 and 134.~* Participants will receive Rituximab weekly x 4 weeks per institutional standard"
62652993|NCT04152499|EXPERIMENTAL|Phase II: Epithelial Ovarian Cancer|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
62275264|NCT01665963|ACTIVE_COMPARATOR|TopClosure(c) Treated Wound|Pressure Bandage using the TopClosure(C) System
62275265|NCT01665963|ACTIVE_COMPARATOR|Traditional Wound Closure Treatment|Pressure Bandage
62275266|NCT00305656|EXPERIMENTAL|Arm I|Patients receive oral AZD2171 once daily on days 1-28.
62638689|NCT03361852|EXPERIMENTAL|NeoVax and pembrolizumab|"* Neo Vax is injected into up to 4 different anatomic site.~* NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~* Within +/-3 days of the scheduled administration date for days 15 and 22~* Within +/-7 days of days 78 and 134.~* Patients will receive pembrolizumab every 3 weeks starting on day 78~* Participants will receive Rituximab weekly x 4 weeks per institutional standard"
62652994|NCT04152499|EXPERIMENTAL|Phase II: Non-Small Cell Lung Cancer|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
62275267|NCT05559827|EXPERIMENTAL|Isatuximab arm|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
62275268|NCT05559827|NO_INTERVENTION|comparator arm|No treatment, supportive care will be allowed.
62275269|NCT04763070|OTHER|Ciprofloxacin|
62275270|NCT04411550|EXPERIMENTAL|HLX11 group|HLX11 are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
62275271|NCT04411550|ACTIVE_COMPARATOR|CN-Perjeta group|CN-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
62652995|NCT04152499|EXPERIMENTAL|Phase II: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma|Histologically or cytologically documented, incurable, locally advanced or metastatic cancer
62652996|NCT04152499|EXPERIMENTAL|Phase II: Extensive-stage Small Cell Lung Cancer|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
62652997|NCT04152499|EXPERIMENTAL|Phase II: HR+/ HER2- Breast Cancer|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
62275272|NCT04411550|ACTIVE_COMPARATOR|EU-Perjeta group|EU-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
62275273|NCT04411550|ACTIVE_COMPARATOR|US-Perjeta group|US-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
62275274|NCT02933697|ACTIVE_COMPARATOR|Apixaban|2.5 mg apixaban twice daily for 1 to 60 months
62070423|NCT05492812|EXPERIMENTAL|Hydroxyzine|Hydroxyzine was administered orally to children at a dose of 1-2 mg/kg/dose. After the sedative drug administration, the child was taken to a quiet and dark sleep room in the polyclinic environment with his parents in order to enable the child to fall asleep. In this process, the child was evaluated by the nurse every 5 minutes with the Ramsay Sedation Score. Children with a Ramsay Sedation Score of 4-6 were taken to the EEG room for recording. During the sedation, the child's blood pressure, oxygen saturation and pulse were checked every 5 minutes. EEG electrodes were placed in accordance with the international 10-20 electrode positioning system. An average of 30 minutes of EEG recording was made for each patient. The awakening process of children whose EEG recordings were completed was evaluated with the Steward Recovery Score. Individuals with a score of 6 were accepted as awake, and the child's procedure was completed.
62275275|NCT02933697|ACTIVE_COMPARATOR|Vitamin-K antagonists (Phenprocoumon)|Phenprocoumon by INR (Target: 2.0-3.0) treatment for 1 to 60 months
62275276|NCT02432235|EXPERIMENTAL|3 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
62275277|NCT02432235|EXPERIMENTAL|5 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles.
62275278|NCT02432235|EXPERIMENTAL|8 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
62638690|NCT04214210|EXPERIMENTAL|Tailored Family Gene Toolkit|"The tailored FGT will include 5 modules designed to increase knowledge of cancer genetics (1); provide decisional support for genetic testing (2); increase active coping to challenges faced by HBOC families (3); provide a 5-steps, skills-building communication training (4); and provide information about management of hereditary cancer risk (5).~Messages will involve shallow tailoring (e.g. sex of mutation carrier), and deep tailoring with complex elements of relevance (e.g. coping style). Tailoring will be based on personalization, tailored feedback, and content matching, based on Swiss and Korean languages and legislation, health insurance policy, and cultural values.~Participants will be asked to complete the 5 modules within 4 weeks after they first engage with the intervention. The 4-week interval will enable learning new information while having time to reflect and act. They will receive email alerts to complete the 5 modules with the URL link directing them to the FGT."
62275279|NCT02432235|EXPERIMENTAL|13 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles.
62275280|NCT02432235|EXPERIMENTAL|20 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
62275281|NCT02432235|EXPERIMENTAL|30 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
62275282|NCT02432235|EXPERIMENTAL|45 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
62638691|NCT04214210|ACTIVE_COMPARATOR|Targeted intervention|The comparator will provide targeted information about HBOC and enable sharing genetic test results. The Korean team will define the contents of the comparator that will mimic the structure and function of an existing website, already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and the three Swiss national languages. Both trial arms the tailored and the targeted platform will be technically implemented in the same system, in order to track access and usage of the platform and provide a user-friendly experience to participants. The Swiss team will also provide the implementation of the comparison website.
62638692|NCT02766348|EXPERIMENTAL|DC-CTL|After accepting chemotherapy of gGemcitabine and Cisplatin according to National comprehensive Cancer Network(NCCN) guidelines, patients will receive 3 cycles of DC-CTL treatment
62638693|NCT02766348|ACTIVE_COMPARATOR|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
62070424|NCT05492812|EXPERIMENTAL|Melatonin|Melatonin was administered orally 3 mg up to 15 kilograms, and 6 mg after 15 kilograms.After the sedative drug administration, the child was taken to a quiet and dark sleep room in the polyclinic environment with his parents in order to enable the child to fall asleep. In this process, the child was evaluated by the nurse every 5 minutes with the Ramsay Sedation Score. Children with a Ramsay Sedation Score of 4-6 were taken to the EEG room for recording. During the sedation, the child's blood pressure, oxygen saturation and pulse were checked every 5 minutes. EEG electrodes were placed in accordance with the international 10-20 electrode positioning system. An average of 30 minutes of EEG recording was made for each patient. The awakening process of children whose EEG recordings were completed was evaluated with the Steward Recovery Score. Individuals with a score of 6 were accepted as awake, and the child's procedure was completed.
62275283|NCT02432235|EXPERIMENTAL|60 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles.
62275284|NCT02432235|EXPERIMENTAL|80 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles.
62275285|NCT02432235|EXPERIMENTAL|100 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles.
62275286|NCT02432235|EXPERIMENTAL|150 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
62638694|NCT04179877|EXPERIMENTAL|Individual placement and support|Group of patients receiving IPS to increase workforce participation.
62638695|NCT04179877|NO_INTERVENTION|Control|Group of patients receiving treatment as usual.
62638696|NCT00577317|EXPERIMENTAL|Arm 1|Patients receive standard home maintenance therapy and perform self-manual lymphatic drainage once daily for 60 minutes for 24 weeks.
62638697|NCT00577317|EXPERIMENTAL|Arm II|Patients receive Flexitouch® home maintenance therapy once daily for 60 minutes for 24 weeks
62638698|NCT05357534|EXPERIMENTAL|"Type 1 diabetes group"|"type 1 diabetes group: patients with type 1 diabetes"
62638699|NCT05357534|ACTIVE_COMPARATOR|"healthy group"|"healthy group : subjects without type 1 diabetes"
62638700|NCT02692807|ACTIVE_COMPARATOR|Hip arthroscopy surgical procedures (HIPARTI Study)|Surgery is performed under general anaesthesia. Traction and joint access is controlled by fluoroscopy. A diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented. Any labral, chondral and bony pathology (cam or pincer) is treated. Labrum may be debrided, sutured, detached and refixed if needed to treat a pincer lesion. Labrum is secured with suture anchors. Pincer and cam resection is performed using an arthroscopic burr. Cartilage lesions maybe left untreated or treated with debridement or microfracture.
62638701|NCT02692807|PLACEBO_COMPARATOR|Sham surgery (HIPARTI Study)|The same arthroscopic procedures as stated above are preformed, but no surgical interventions related to Cam, Pincer, or labral tear are performed, only diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented.
62652998|NCT04152499|EXPERIMENTAL|Phase II: Head and Neck Squamous Cell Carcinoma|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
62652999|NCT04152499|EXPERIMENTAL|Phase II: Endometrial carcinoma|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
62275287|NCT02432235|EXPERIMENTAL|300 μg/kg|A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles).
62275288|NCT01913483|EXPERIMENTAL|Bivalirudin|Bivalirudin was administered as an intravenous (IV) bolus and infusion for the duration of the procedure (mean duration of 48.6 minutes). The bolus (0.75 milligrams (mg)/kilogram \[kg\]) was administered via systemic IV administration. Immediately after the bolus, an IV infusion of bivalirudin was initiated at a dose of 1.75 mg/kg/hour (h) (or 1 mg/kg/h for participants with an estimated glomerular filtration rate \[eGFR\] \<30 milliliters/minute \[mL/min\]).
62638702|NCT02692807|ACTIVE_COMPARATOR|Prospective Cohort (HARP Study)|Those that are not willing to be included in the RCT (HIPARTI Study), will be asked if they are willing to be included in the prospective cohort, or ongoing in countries were ONLY the surgery is performed (Australia). They will sign an informed concent and will undergo surgical interventions as part of usual care. Outcomes collected and follow-ups will be the same as for the RCT (HIPARTI).
62638703|NCT04866966|EXPERIMENTAL|Intervention Group|The group undergoing the intervention will participate in 90-minute group visits occurring weekly for 4 weeks, then biweekly for a total of 26 weeks/15 visits. Each visit will focus on intensive lifestyle changes. Further, these patients will each have the opportunity to meet one-on-one with a member of the research team at the end of each visit in order to discuss individual goals and progress. Pharmacotherapy therapy changes will be recommended to reduce or avoid use of medication which may contribute to weight gain and medications for weight loss will be prescribed as an individualized treatment strategy during one-on-one time with the pharmacist or physician if the patient can afford it and no contraindications exists.
62275289|NCT01913483|ACTIVE_COMPARATOR|Unfractionated Heparin|UFH was administered as an IV bolus for the duration of the procedure (mean duration of 48.6 minutes). UFH was administered via weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg. Additional bolus doses were administered per standard-of-care use.
62275290|NCT06252272|OTHER|Biopsy sample in an area of liver macroscopically free from parenchymal alterations|Patients undergoing abdominal surgery for primary or secondary liver tumors (liver metastases from colorectal, pancreatic, or breast), from which we proceed to the preparation of organotypic cultures of liver (hLSC) derived from liver biopsies taken from patients undergoing abdominal surgery for primary or secondary liver tumors for the molecular characterization of liver fibrosis.
62638704|NCT04866966|NO_INTERVENTION|Control Group|The control group will have their measurements done at the beginning and end of the study. They will continue with usual medicare care during the study and will not receive any education from the investigators during the study. They will be offered the option of a delayed intervention after the completion of the study.
62638705|NCT01908868|EXPERIMENTAL|EBUS-TBNA|EBUS-TBNA (with endobronchial and transbronchial lung biopsy)
62638706|NCT01908868|ACTIVE_COMPARATOR|Conventional TBNA|Conventional TBNA (with endobronchial and transbronchial lung biopsy)
62070425|NCT05176782|ACTIVE_COMPARATOR|Group A (HTK cardioplegia)|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
62275291|NCT04600908||Non-physician staff|All non-physician staff who have had commuting accidents
62275292|NCT02838849|SHAM_COMPARATOR|Fiber|Participants were treated with 2 sachets of fiber orally a day for 14 days, after baseline characterization of bowel habit and stool features.
62638707|NCT02155192||Cohort 1|Participants who participated in NCT01483599 (X-PLORE) study.
62275293|NCT02838849|ACTIVE_COMPARATOR|Fiber and Water|Participants were treated with 2 sachets of fiber orally a day and ingested 2 liters of water a day for 14 days, after baseline characterization of bowel habit and stool features.
62638708|NCT02155192||Cohort 2|Participants who participated in NCT00267969 (PHOENIX 1) study.
62638709|NCT02155192||Cohort 3|Participants who participated in NCT00307437 (PHOENIX-2) study.
62638710|NCT02155192||Cohort 4|Participants who participated in NCT00454584 (ACCEPT) study.
62638711|NCT05989555||I/adjuvant|15 patients with thyroid carcinoma that are treated with radioacitive iodine in an adjuvant setting
62638712|NCT05989555||II/structutral disease|15 patients with thyroid carcinoma that are treated with radioactive iodine with the indication of persistent structural disease
62638713|NCT04758728|ACTIVE_COMPARATOR|Group A|Group A - great saphenous vein stripping with local adrenaline use for hemostasis
62638714|NCT04758728|SHAM_COMPARATOR|Group B|Group B - great saphenous vein stripping with local normal saline use for hemostasis
62638715|NCT04758728|SHAM_COMPARATOR|Group C|Group C - great saphenous vein stripping with traditional hemostatic practice
62638716|NCT05355285|EXPERIMENTAL|Baseline Euglycemia|"Subjects with T1DM (Groups 1 and 2): 1) receive a low dose insulin infusion to reduce their plasma glucose to euglycemia; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min to maintain euglycemia during a Baseline MRI scanning period.~Subjects without diabetes (Groups 3 and 4) are scanned during a Baseline MRI scanning period (no intervention is needed to maintain euglycemia in these subjects)."
62070426|NCT05176782|ACTIVE_COMPARATOR|Group B ( Cold Cardioplegia)|will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
62070427|NCT05763082|EXPERIMENTAL|Padagis active product|
62275294|NCT05827029|EXPERIMENTAL|Preoperative carbohydrate drink|
62275295|NCT05827029|PLACEBO_COMPARATOR|Water|
62275296|NCT00246532|PLACEBO_COMPARATOR|1: Placebo Pill|This arm contains placebo medication.
62070428|NCT05763082|ACTIVE_COMPARATOR|Reference product|
62638717|NCT05355285|EXPERIMENTAL|Hyperglycemic Clamp|"Subjects with T1DM (Groups 1 and 2): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min.~Subjects without diabetes (Groups 3 and 4): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L."
62638718|NCT05355285|EXPERIMENTAL|Hyperinsulinemic Euglycemic Clamp|Subjects without diabetes or depression (Group 3) have a second study visit at least 15 days after the Hyperglycemic Clamp visit. They receive a variable insulin infusion to match individual insulin levels to the levels attained during the Hyperglycemic Clamp and they receive a variable glucose infusion to maintain euglycemia.
62070429|NCT05763082|PLACEBO_COMPARATOR|Padagis placebo product|
62275297|NCT00246532|ACTIVE_COMPARATOR|2: Morphine|Patients will receive oral morphine therapy.
62454592|NCT03254251|EXPERIMENTAL|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
62454593|NCT03254251|NO_INTERVENTION|No Exercise (CON)|N=21, No exercise for 12 weeks
62454594|NCT01989728|ACTIVE_COMPARATOR|care as usual|
62638719|NCT04195711||blinq screened|Patients screened by new birefringent screener
62070430|NCT02280057|ACTIVE_COMPARATOR|Metformin|Metformin 850 mg x 2 in six months
62070431|NCT02280057|PLACEBO_COMPARATOR|Placebo|Placebo 2 tablets daily for six months
62070432|NCT04381260||2016-2019 STEMI Registry|Retrospective data will be collected to develop a well-characterized registry of patients treated from 2016-2019 by any of 14 local rural EMS agencies and transported to a facility capable of performing Percutaneous Coronary Intervention. This registry will be used to determine the time to PCI performance for each of the EMS agencies. Time will be adjusted for patient distance from a PCI center using a linear mixed model with a random effect for center and a fixed effect for distance. This process will allow qualitative methods to identify organizational culture, structure, and clinical processes that impact STEMI care from the two highest and lowest performing rural EMS agencies. (n=750)
62454595|NCT01989728|EXPERIMENTAL|psychiatric examination and feedback|
62454596|NCT00950872|EXPERIMENTAL|Duet TRS|Subjects receive Duet TRS
62454597|NCT03788525|EXPERIMENTAL|Reduced recreational screen time|Reducing recreational screen-based media use for a period of 2 weeks
62454598|NCT03788525|EXPERIMENTAL|Timed recreational screen time|Reduced and timed recreational screen-based media use for a period of 2 weeks
62454599|NCT04814745|ACTIVE_COMPARATOR|morphine|morphine 150 mcg will be administered intrathecally before surgery by using a 25 Gauge with acre spinal needle
62638720|NCT03587064|ACTIVE_COMPARATOR|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
62638721|NCT03587064|EXPERIMENTAL|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
62638722|NCT05739604||Survivors|Patients hospitalized in the Department of Anaesthesiology and Intensive Care with sepsis or septic shock, undergoing continuous renal replacement therapy due to acute kidney injury, in whom the outcome of treatment was survival.
62070433|NCT04381260||Key Informant Interviews|After identifying the two highest and lowest performing rural EMS agencies in the 2016-2019 STEMI Registry, key employees from each of those agencies will be recruited to participate in semi-structured key informant interviews. The interviews will assess current clinical care, organizational culture and opportunities for improvement. (n=32)
62070434|NCT04381260||Stakeholder Surveys|Employees at all local EMS agencies will be invited to participate in stakeholder surveys to quantify each agency's use of the care strategies identified during Key Information Interviews. (n=240)
62638723|NCT05739604||Nonsurvivors|Patients hospitalized in the Department of Anaesthesiology and Intensive Care with sepsis or septic shock, undergoing continuous renal replacement therapy due to acute kidney injury, in whom the outcome of treatment was fatal.
62638724|NCT05757817|EXPERIMENTAL|Patient with an ORL Cancer|
62638725|NCT03686553||infected, with SSI|patients with SSI
62638726|NCT03686553||non-infected|patients without SSI
62638727|NCT03980262|EXPERIMENTAL|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
62638728|NCT03980262|ACTIVE_COMPARATOR|MoneySmart|A financial education program available through the Federal Deposit Insurance Corporation. Money Smart includes programs for adults and school-aged children, a parent/caregiver guide and a train-the-trainer program. MoneySmart is an Extension-approved program designed to improve money-management practices and financial confidence for parents MoneySmart involves eight weekly sessions that includes one-to-two hour modules with take-home guides for adults. For children, there are eight sessions that include take-home worksheets and a parent/caregiver guide.
62287150|NCT02066714||Hand Foot and Mouth Disease|The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
62287151|NCT01109940|EXPERIMENTAL|AIN457|
62638729|NCT03776474||Allergic|Minors allergic to cow's milk and/or eggs
62638730|NCT03776474||Non-allergic|Minors without history of allergy to cow's milk and/or eggs
62287152|NCT00234039|EXPERIMENTAL|Intravesical Gemcitabine|
62638731|NCT03776474||Acquired tolerance|Minors formerly allergic to cow's milk and/or eggs
62638732|NCT01466738|EXPERIMENTAL|HRV-16 (100 TCID50)|
62638733|NCT01466738|EXPERIMENTAL|HRV-16 (1000 TCID50)|
62638734|NCT04028726|ACTIVE_COMPARATOR|Cluster set Resistance Training Protocol|Cluster set configuration is the new training approach that it is being tested.
62638735|NCT04028726|SHAM_COMPARATOR|Traditional Resistance Training Protocol|Traditional is commonly used in training sessions.
62638736|NCT02882126|EXPERIMENTAL|Subcutaneous Treprostinil|Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003. Dose modification will be based according to clinical response and tolerability.
62638737|NCT03021811|OTHER|LumiHeal|Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
62638738|NCT03464435|EXPERIMENTAL|tacrolimus and loteprednol etabonate/tobramycin|topical eye drops
62638739|NCT05876325|EXPERIMENTAL|Financial Navigation and Insurance Assistance (FINassist)|FINassist is a comprehensive oncology financial and legal navigation program in oncology care
62638740|NCT02844166|EXPERIMENTAL|viscoelastic group|viscoelastic surface support
62638741|NCT02844166|ACTIVE_COMPARATOR|pyramidal foam group|pyramidal foam surface support
62638742|NCT01028781|OTHER|Thalidomide|Thalidomide was administered and pain reports were recorded over the course of 6 months.
62275298|NCT05864976||Standard of care rsfMRI using the Support Vector Machine algorithm|"* Once enrolled, clinical pre-surgical MRI will be done on Siemens 3T Prisma or Skyra scanners using a standard pre-surgical tumor protocol. Resting-state functional MRI (rsfMRI) will be acquired. The Support Vector Machine (SVM) algorithm will be used on this pre-surgical MRI.~* Patients will undergo post-operative MRI at approximately 8-12 weeks following surgical resection to evaluate extent of resection. Patients will then undergo subsequent MRI imaging every 2-3 months as part of routine clinical care to monitor for recurrence. The following MR sequences will be acquired: pre-and post-contrast T1-weighted, T2-weighted FLAIR, diffusion weighted imaging. MRI scans will be reviewed by a board-certified neuroradiologist to determine date of radiographic progression/recurrence. Imaging features at recurrence including location, multifocality, and presence of diffuse or distant recurrence will also be recorded."
62454600|NCT04814745|ACTIVE_COMPARATOR|tramadol|tramadol 400 mg will be administered by using an elastomeric pump for 24 hours after surgery
62454601|NCT04814745|ACTIVE_COMPARATOR|ropivacaine|at the end of surgery transversus abdominis plane block will be performed bilaterally and ropivacaine 80 mg will be used
62454602|NCT02531984|EXPERIMENTAL|Withdrawal of Azithromycin treatment|
62454603|NCT02531984|OTHER|ongoing Azithromycin treatment|
62454604|NCT01627366|EXPERIMENTAL|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
62454605|NCT01627366|NO_INTERVENTION|Usual care|Receipt of usual medical care.
62638743|NCT01005953||Professionals treating autistic children|Special educators, occupational therapists, speech pathologists, behavior analysts who work with children on the spectrum.
62638744|NCT01005953||Families with autistic children (3-10)|
62638745|NCT05568134||OGTT Cohort|All enrolled participants will complete an OGTT.
62275299|NCT04668352|EXPERIMENTAL|Dactolisib 10mg once daily|
62275300|NCT04668352|PLACEBO_COMPARATOR|Placebo|
62275301|NCT02926950|EXPERIMENTAL|Sotagliflozin 400 mg + Metformin|Following a 2-week run-in period, sotagliflozin 400 mg was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
62275302|NCT02926950|PLACEBO_COMPARATOR|Placebo + Metformin|Following a 2-week run-in period, matching placebo was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
62275303|NCT04840680||Participants With MM|Participants with MM who are newly prescribed and will start treatment with ixazomib citrate in a real-world clinical practice setting will be observed prospectively for up to 6 years 11 months.
62275304|NCT05206526|EXPERIMENTAL|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
62454606|NCT04818242|ACTIVE_COMPARATOR|POC testing with Blinded CGM (Standard of Care)|Patients in the standard of care study arm will wear a blinded CGM and receive POC testing before meals and bedtime, with providers adjusting oral agents or insulin dose based on POC results.
62638746|NCT05460949|EXPERIMENTAL|HOLD RELAX STRETCHING OF ILIOPSOAS|"10-second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20-second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
62454607|NCT04818242|EXPERIMENTAL|Dexcom CGM with Glucose Telemetry System (CGM-GTS)|Patients in the intervention CGM study arm will have a single daily fasting POC testing and will wear a real-time Dexcom G6 with GTS, and providers will adjust oral or insulin therapy based on CGM-GTS profile information.
62454608|NCT02403752|EXPERIMENTAL|exercise intervention|"Exercise protocol based on the PLIÉ protocol, developed in consultation with experts worldwide, incl. traditional strength-building exercises, yoga, Tai Chi and Feldenkrais, that engage the muscles most needed to maintain independence--including lower body strength, balance, upper body strength, fine motor exercises , and pelvic floor exercises- combined them into a unique integrative exercise program, to be purposeful and to build procedural ('muscle') memory.~To be practiced at home in dyads of affected individuals and caregivers, called Paired PLIE Program."
62454609|NCT03309956|OTHER|Holter Monitor and Zio Patch|All subjects will wear the Holter monitor and Zio patch for a total of 48 hours.
62454610|NCT03050632|EXPERIMENTAL|Working Memory Intervention (N-back)|Participants will complete the working memory priming task either for the first 3 days of the intervention or the last 3 days of the intervention, with order counterbalanced across participants. The working memory prime is the N-back test, a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back) (Jaeggi et al., 2010).
62638747|NCT05460949|EXPERIMENTAL|• WILLIAM'S PROTOCOL|"* Pelvic tilt~* Single Knee to chest~* Double knee to chest~* Partial sit-up~* Hamstring stretch~* Hip Flexor stretch~* Squat~* Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols."
62638748|NCT03514719|EXPERIMENTAL|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-avelumab PET
62275305|NCT05206526|ACTIVE_COMPARATOR|Control|12 weeks of home-based training, without supervision, to perform 3 time per week composed by ten total body exercise.
62638749|NCT02938572|EXPERIMENTAL|NNC0143-0406|
62638750|NCT02938572|ACTIVE_COMPARATOR|Insulin aspart|
62275306|NCT05816980|OTHER|Single|Re-irradiation consisting of hyperfractionated IMRT, 40.8 Gy in 1.2 fractions twice daily 5/7 days weekly, with oral capecitabine 825 mg/m2 BID on radiotherapy treatment days. Re-staging performed 4-6 weeks after the last dose, followed by surgery, when feasible.
62638751|NCT03628118||open radical hysterectomy|"The patients who would undergo open radical hysterectomy procedure."
62275307|NCT00022529|EXPERIMENTAL|Treatment (BMS-214662, trastuzumab)|Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62638752|NCT01640548||Cohort|
62454611|NCT03050632|PLACEBO_COMPARATOR|"White Bear Task"|Participants will complete this non-working-memory control task either for the first 3 days of the intervention or the last 3 days of the intervention, depending on counterbalanced order. The task consists of a procedure developed by Wegner and colleagues (1987) in a study of thought suppression, which instructs participants to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
62454612|NCT03325530||Focus Group|
62275308|NCT00608985|EXPERIMENTAL|1|almorexant 200 mg
62275309|NCT00608985|EXPERIMENTAL|2|almorexant 100 mg
62275310|NCT00608985|PLACEBO_COMPARATOR|3|Placebo
62638753|NCT02364388|ACTIVE_COMPARATOR|Imagio IUS gray-scale ultrasound|Imagio gray-scale ultrasound
62638754|NCT02364388|OTHER|Imagio OA/US|Imagio OA/US (opto-acoustic+gray-scale ultrasound)
62638755|NCT01393873||Bariatric surgery pts with Type 2 DM|Primary bariatric surgery pts with Type 2 DM
62275311|NCT00608985|ACTIVE_COMPARATOR|4|zolpidem 10 mg
62275312|NCT04665830|ACTIVE_COMPARATOR|Group 1|Evolocumab group, patients who are receiving this therapy for 12 months.
62275313|NCT04665830|PLACEBO_COMPARATOR|Group 2|The Statin group includes patients who are maintained on statin therapy.
62461643|NCT06125483|EXPERIMENTAL|38 patients with hematological malignancies who received TBI/Flu/Bu/Mel combined with secondary UCBT|Treatment stage : ( 1 ) conditioning : -7d, total body irradiation (TBI), 4Gy, 2 times ; -7d, semustine ( MECCNU ) 250mg / m2 ; -6d \~ -3d ; fludarabine ( Flu ) 30mg / m2 / d, ivgtt ; -6d \~ -5d, busulfan ( Bu ) 2.4mg / kg / d, 3 times a day, ivgtt ; -4d \~ -3d, melphalan ( Mel ) 40mg / m2 / d, ivgtt. ( 2 ) Transplantation : On day 0, unrelated umbilical cord blood ( TNC ≥ 2.3 × 107 / kg or CD34 + ≥ 1 × 105 / kg ) was transplanted, and the donor-recipient HLA matching degree was ≥ 6 / 10.
62461644|NCT05440539|EXPERIMENTAL|Written Group|Participants received only written handouts with information about pelvic floor disorders, including risk factors, prevention strategies, and information about possible treatments. They receive these handouts at the time of recruitment during pregnancy and again after delivery.
62275314|NCT03232476|OTHER|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
62275315|NCT03183674|EXPERIMENTAL|oxytocin spray|oxytocin nose spray dose 0,4IU/kg, once unique dose
62275316|NCT03183674|PLACEBO_COMPARATOR|placebo|saline nose spray, 0,9 %, once unique dose
62275317|NCT01008280|EXPERIMENTAL|Baclofen|baclofen 10 mg po tid
62461645|NCT05440539|EXPERIMENTAL|Workshop Group|Participants received written handouts and attend a virtual interactive workshop with information about pelvic floor disorders, including risk factors, prevention strategies, and information about possible treatments. They receive the handouts at the time of recruitment during pregnancy and again after delivery. The workshop is conducted prior to completion of pregnancy.
62461646|NCT02589964|ACTIVE_COMPARATOR|Probiotic|"Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The treatment is Florajen-3. The ingredients in Florajen-3 are:~Lactobacillus acidophilus-over 7.5 billion Bifidobacterium lactis-over 6.0 billion Bifidobacterium longum-over 1.5 billion"
62461647|NCT02589964|PLACEBO_COMPARATOR|Placebo|"Placebo will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The ingredients in the placebo are:~Rice maltodextrin"
62461648|NCT00360360|EXPERIMENTAL|Bevacizumab/Paclitaxel/Carboplatin/Erlotinib|Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily
62461649|NCT04181190||Mepolizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL-5 monoclonal antibody (Mepolizumab)
62461650|NCT04181190||Benralizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL5 receptor monoclonal antibody (Benralizumab)
62638756|NCT00431301||Case|PSP Cases
62638757|NCT00431301||Control|Healthy Controls
62638758|NCT03535363|EXPERIMENTAL|Maximum Tolerated Dose of Osimertinib with standard of care|For patients with 1-10 brain metastases, begin daily Osimeritinib 0-7 days prior to stereotactic radiosurgery (SRS), provide daily Osimeritinib concurrently with radiotherapy, followed by maintenance Osimeritinib until disease progression, withdrawal, or unacceptable toxicity. Dose Level 1: 80mg daily. Dose Level -1: 40mg daily
62275318|NCT01008280|PLACEBO_COMPARATOR|Placebo|placebo given tid
62638759|NCT03940872|EXPERIMENTAL|3PDQ self-questionnaire validation|200 patients will be included for this step in 10 French Parkinson expert centers.
62275319|NCT02381665|EXPERIMENTAL|Group A|Patient enrolled in this group will receive a device for effective interferential current stimulation.
62638760|NCT03191552|EXPERIMENTAL|SPIO 2 hours|"All children will be hospitalized for 2 weeks and will receive conventional exercise therapy including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks 2 hours a day.~SPIO 2 hours group will receive conventional exercise therapy with the garment on for 2 hours."
62275320|NCT02381665|PLACEBO_COMPARATOR|Group B|Patient enrolled in this group will receive a device that does not deliver current stimulation
62275321|NCT05841758|EXPERIMENTAL|Hydroxychloroquine|prednisone (scheduled protocol) + hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period, then according to the treating the physician for an additional open period of 12 months)
62638761|NCT03191552|EXPERIMENTAL|SPIO 6 hours|SPIO 6 hours group will receive conventional exercise therapy with the garment on for 2 hours and worn SPIO 4 hours more in addition to 2 hour of wear during exercise therapy.
62638762|NCT03191552|ACTIVE_COMPARATOR|Control(conventional exercises)|Control group will only receive conventional exercise therapy (for two hours a day) including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks
62638763|NCT01724151||Healthy adults|Healthy adults, over 45 years old
62638764|NCT01724151||Mild cognitive impairment|subjects with mild cognitive impairment
62638765|NCT01724151||Alzheimer's disease|subjects with Alzheimer's disease
62638766|NCT02892617||Group 1|Patients with low back pain lasting for more than 6 months, debilitating, with the presence of type 1 Modic disc disease on MRI at the operated disc, eligible for a disc prosthesis or arthrodesis anterior approach
62638767|NCT02892617||Group 2|Patients underwent surgery for nerve root pain by disc herniation on MRI viewable with a radio-clinical concordance with or without Modic 1 disc disease in the operated disc
62638768|NCT05055726|EXPERIMENTAL|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|"Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A., is assigned to the patients for radiation-induced oromucositis.~The patients take at home 15 ml (1 tablespoon) of concentrated or diluted (with water) mouthwash 2-3 times a day, but not more than 5 times a day, washing the mouth and throat for 20-30 seconds, according to the Investigator's indications and the local product's SmPC.~In Hungary, the therapy should started with diluted product (15 ml of water + 15 ml of concentrated solution). After that, gargling can be continued with 15 ml (1 tablespoon) of concentrated mouthwash, generally 2-3 times a day, but not more than 5 times a day.~In Poland, the solution is used 2 to 3 times daily; at a single time, it should be used approximately 15 ml of concentrated or diluted mouthwash with a small amount of water and wash the mouth and throat for 20 to 30 seconds."
62638769|NCT03551847|EXPERIMENTAL|Oral antibiotic therapy group|This group will receive preoperative oral antibiotic therapy tailored to the infecting organism (if identified) for two weeks before the time of revision surgery
62275322|NCT05841758|PLACEBO_COMPARATOR|Placebo arm|prednisone (scheduled protocol) + placebo (1-2 tablets/day during a 12 months double blind placebocontrolled period, then the treatment is left to the physician's discretion until M24)
62638770|NCT03551847|ACTIVE_COMPARATOR|No antibiotic therapy group|This group will not receive preoperative oral antibiotic therapy.
62638771|NCT04916652||S-26 GOLD/ULTIMA GUM-fed group:|"Parent(s) to continue feeding their child S-26 GOLD or ULTIMA GUM during the course of the study.~We will collect information from parents on the S-26 GOLD/ ULTIMA GUM for a maximum of 2 months prior to the study start and during the course of the study."
62638772|NCT04916652||Cow's milk-fed group:|"Parent(s) to continue feeding their child cow's milk during the course of the study.~We will collect information from parents on the cow's milk consumed for a maximum of 2 months prior to the study start and during the course of the study."
62638773|NCT02339103|NO_INTERVENTION|Shivering only|Pt placed in sleeping bag and warmed by shivering only
62638774|NCT02339103|EXPERIMENTAL|Warmed IV fluids|2 Liter of 42 degree celsius normal saline
62638775|NCT02339103|EXPERIMENTAL|Warmed perfusion pads|Warmed perfusion pads placed to palms and soles to rewarm through arteriovenous anastomoses
62638776|NCT02892396||COPD patients & conventional cigarettes|COPD patients regular smokers of conventional cigarettes with no desire to quit smoking habit.
62638777|NCT02892396||COPD patients & electronic cigarettes|COPD patients who had been users of electronic cigarettes for at least 8 weeks. They will be provided with an specific type of electronic cigarette and the same dosage of inhaled nicotine.
62638778|NCT03442725|EXPERIMENTAL|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
62638779|NCT03442725|ACTIVE_COMPARATOR|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
62638780|NCT03442725|EXPERIMENTAL|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
62638781|NCT03442725|EXPERIMENTAL|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
62638782|NCT04477369|OTHER|Sequence A|7 subjects assigned to Sequence A will receive a single dose of 300mg DWJ1439 in period 1, 300mg DWC202003 in period 2 and 300mg DWJ1464 in period 3.
62638783|NCT04477369|OTHER|Sequence B|7 subjects assigned to Sequence B will receive a single dose of 300mg DWJ1464 in period 1, 300mg DWC202004 in period 2 and 300mg DWC202003 in period 3.
62638784|NCT04477369|OTHER|Sequence C|7 subjects assigned to Sequence C will receive a single dose of 300mg DWC202003 in period 1, 300mg DWJ1439 in period 2 and 300mg DWC202004 in period 3.
62275323|NCT02844114|EXPERIMENTAL|Ganoderma lucidum spore & Chemotherapy|Ganoderma lucidum spore 1500mg tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
62275324|NCT02844114|PLACEBO_COMPARATOR|Placebo & Chemotherapy|Placebo tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
62275325|NCT02213601|EXPERIMENTAL|Yoga|8-week Gentle Vinyasa Flow yoga intervention
62275326|NCT02213601|NO_INTERVENTION|Wait-list Control Group|
62638785|NCT04477369|OTHER|Sequence D|7 subjects assigned to Sequence D will receive a single dose of 300mg DWC202004 in period 1, 300mg DWJ1464 in period 2 and 300mg DWJ1439 in period 3.
62638786|NCT04930926||INFECTION DISEASE PATIENTS WITH PNEUMONIA OR SARHS COVID19|NO SPECIFIC INTERVENTION
62638787|NCT04266899|EXPERIMENTAL|FDS+Treadmill gait training|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Treadmill gait training during two weeks.
62638788|NCT05775601|EXPERIMENTAL|18F-LY3950321 Whole Body Dosimetry|
62638789|NCT01351818||Growth hormone|Patients with a condition
62638790|NCT00006015|EXPERIMENTAL|Combination Chemotx|Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy
62461651|NCT01606605||Diffuse large B-cell lymphoma|Patients diagnosed and treated at the Samsung Medical Center
62638791|NCT03760224|EXPERIMENTAL|Intervention|WhatsApp group will receive at least 3 messages each week and allow real-time group discussion for the intervention period (8 weeks).
62638792|NCT03760224|ACTIVE_COMPARATOR|Control|The control group will receive 3 mobile phone text messages each week in the 8 weeks after recruitment. This will be a one way message and no real-time discussion will be available.
62638793|NCT03723434|ACTIVE_COMPARATOR|Healthy Participants|Healthy participants without disorders or medications influencing brain function will be scanned with MRI and undergo single-pulse TMS and PAS during several visits, each with a different asynchrony, while EEG and MEPs are recorded.
62638794|NCT03723434|EXPERIMENTAL|Patients|Participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) will be scanned with MRI and undergo single-pulse TMS and paired associative stimulation during several visits while EEG is recorded.
62638795|NCT06107998|EXPERIMENTAL|Stethoscope|Patients whose endotracheal tube cuff is inflated via a stethoscope
62070435|NCT01588990|EXPERIMENTAL|Bevacizumab: Phase A and Phase B|The trial will consist of 2 phases of treatment. Phase A: Participants will receive bevacizumab 7.5 mg/kg intravenous (IV) infusion on Day 1 every 3 weeks in combination with XELOX (capecitabine and oxaliplatin) or bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluouracil) until first disease progression or occurrence of unmanageable toxicity. Phase B: Upon documented first disease progression, participants will continue receiving bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluouracil) until second disease progression or occurrence of unmanageable toxicity. Phase B treatment should commence within 4 weeks of the date of documented first disease progression.
62070436|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
62070437|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
62070438|NCT03377868|OTHER|Patients with Amyotrophic lateral sclerosis|Patients diagnosed with amyotrophic lateral sclerosis
62070439|NCT03377868|OTHER|Control|Parallel cohort of healthy age and sex matched subjects
62070440|NCT01261143|EXPERIMENTAL|BK-C-0701, diabetic neuropathy|
62070441|NCT01261143|ACTIVE_COMPARATOR|alpha lipoic acid, diabetic neuropathy, capsule|
62070442|NCT00773058|ACTIVE_COMPARATOR|glucocorticoid+RAI|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI
62070443|NCT00773058|PLACEBO_COMPARATOR|placebo + RAI|no glucocorticoid But ATCH test hints RAI
62638796|NCT06107998|ACTIVE_COMPARATOR|Audible leak/Balloon palpation|Patients whose endotracheal tube cuff is inflated via audible leak/balloon palpation method.
62653000|NCT04152499|EXPERIMENTAL|Phase II: Urothelial carcinoma|Histologically or cytologically documented, incurable, locally advanced or metastatic cancer
62653001|NCT04152499|EXPERIMENTAL|Phase II: Cervical Cancer|Histologically or cytologically documented, incurable, locally advanced or metastatic cancer
62070444|NCT00773058|ACTIVE_COMPARATOR|glucocorticoid|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI
62070445|NCT00773058|PLACEBO_COMPARATOR|placebo|no glucocorticoid But ATCH test does not hint RAI
62275327|NCT03365466||Group A|Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.
62275328|NCT03365466||Group B|Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.
62275329|NCT03365466||Group C|Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.
62461652|NCT01513070|EXPERIMENTAL|Quick-Acting Heart Reliever group|Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets
62461653|NCT01513070|ACTIVE_COMPARATOR|Isosorbide Dinitrate group|Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets
62461654|NCT02635243|EXPERIMENTAL|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin\^®R will be used to induce hypoglycemia.
62461655|NCT02635243|ACTIVE_COMPARATOR|Glucagon|Single dose of glucagon given SC under fasting conditions and under induced hypoglycemia. Novolin\^®R will be used to induce hypoglycemia.
62461656|NCT02635243|EXPERIMENTAL|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin\^®R will be used to induce hypoglycemia.
62275330|NCT03365466||Group D|Patients who did not receive any treatment.
62454613|NCT01135641|EXPERIMENTAL|Rituximab, ciclosporine and corticosteroids|As soon as the diagnosis of chronic GVHD requiring systemic immunosuppressive therapy is confirmed, patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.Rituximab should be administered within 14 days of starting prednisone. Follow-up dates for response assessment and laboratory tests relate to the date of Rituximab infusion.Patients having a partial response after the 1st cycle of Rituximab will be eligible to receive a second cycle of 4 infusions during 4 weeks. A delay of 8 weeks (from the first infusion of Rituximab) will be observed between the two cycles of Rituximab therapy.Patients who relapse after an initial treatment with one cycle of 4 infusions of Rituximab will be eligible to receive a second cycle of Rituximab therapy.
62461657|NCT02324803|EXPERIMENTAL|pazopanib once daily|Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.
62070446|NCT01452984||Single Retrospective Interviews|Each retrospective interview will be conducted by the Principal Investigator and/or Project Manager to collect denmographic information and experiential narratives from the patient, using open-ended questions and structured probes based on individual responses. Retrospective interviews will be recorded and scheduled at the patients' convenience either in the clinic, at the home, or at a place that is convenient to them.
62070447|NCT01452984||Prospective Observations|Prospective Observations of clinic visits will be combined with informal interview to document conversations with their treating physicians about concerns emerging from appearance, function, and other factors that may impinge on clinical decision making and experience including quality of life. The Project Manager will be present for the clinical visit during which the Mohs surgery takes place and record field observations as well as informal interview notes in a notebook.
62070448|NCT01719224|ACTIVE_COMPARATOR|Elevated body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
62070449|NCT01719224|ACTIVE_COMPARATOR|supine body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
62070450|NCT05822843|EXPERIMENTAL|ESG206 dose level 1|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
62070451|NCT05822843|EXPERIMENTAL|ESG206 dose level 2|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
62070452|NCT05822843|EXPERIMENTAL|ESG206 dose level 3|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
62070453|NCT05822843|EXPERIMENTAL|ESG206 dose level 4|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
62275331|NCT01430442|EXPERIMENTAL|Treatment A: Rimegepant, 10 mg|Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
62070454|NCT04766814||Patient Group|10 women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
62275332|NCT01430442|EXPERIMENTAL|Treatment B: Rimegepant, 25 mg|Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
62275333|NCT01430442|EXPERIMENTAL|Treatment C: Rimegepant, 75 mg|Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
62653002|NCT01331564|EXPERIMENTAL|electronic intervention group 2|(e-intervention 2) receives a behavioral intervention through a website during pregnancy and until 18 months postpartum
62070455|NCT04766814||Control Group 1|10 healthy women subjects between the ages of 50-80 year
62070456|NCT04766814||Control Group 2|10 healthy women subjects between the ages of 20-30 years
62070457|NCT02586337|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
62275334|NCT01430442|EXPERIMENTAL|Treatment D: Rimegepant, 150 mg|Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
62070458|NCT02586337|PLACEBO_COMPARATOR|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
62070459|NCT01392222||patients who have had surgery or have scheduled surgery|In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey \[13\] and Morgan \[14\]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
62275335|NCT01430442|EXPERIMENTAL|Treatment E: Rimegepant, 300 mg|Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
62275336|NCT01430442|EXPERIMENTAL|Treatment F: Rimegepant, 600 mg|Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
62287153|NCT05492955|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants will receive clinic-based standard of care
62461658|NCT05567874||SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the first period|SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in April 2021
62653003|NCT01331564|EXPERIMENTAL|electronic intervention group 1|(e-intervention 1) receives a behavioral intervention through a website during pregnancy. During the postpartum period this arm receives the same non-weight-related information as the control arm
62653004|NCT01331564|PLACEBO_COMPARATOR|Control|
62653005|NCT05106907|EXPERIMENTAL|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
62454614|NCT06200701|EXPERIMENTAL|Intervention Program application of a Job Crafting|job crafting training program designed for this study was implemented through twelve sessions, from which three theory and nine practical sessions were held in a room at the worksite. The sessions were conducted outside of working hours in the hospital These sessions lasted 21 hours; 3 theory hours (one hour for each theoretical session); and 9 practical sessions (two hours for each practical session). Having the whole number of nurses at the same time was difficult, so the nurses were classified into five groups each group consisting of about 16 nurses. All sessions were repeated to the five main groups until 80 nurses completed the entire 21-hours instruction period
62454615|NCT06200701|NO_INTERVENTION|non Intervention Program application|non Intervention Program application
62638797|NCT01219712|ACTIVE_COMPARATOR|Preoperative Optimization|"Patients with proximal femur fracture who are \> 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management.~The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively.~* Hb would be optimized to \> 90 g/l~* SaO2 \> 96%~* Stroke volume index (SVI) \> 30~* Heart rate should ideally be \< 80~Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal."
62638798|NCT01219712|NO_INTERVENTION|Standard treatment|Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.
62638799|NCT01484951|EXPERIMENTAL|AZARGA|Brinzolamide 1% and timolol 0.5% fixed combination eye drops, one drop administered to the study eye(s) twice daily (8:00 am and 8:00 pm) for up to 8 weeks.
62638800|NCT00766324|EXPERIMENTAL|A|
62638801|NCT00766324|EXPERIMENTAL|B|
62070460|NCT01392222||who chose to not have immediate surgery|In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey \[13\] and Morgan \[14\]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
62070461|NCT02168790|EXPERIMENTAL|Amniotic membrane ring|Application of amniotic membrane device for 6-7 days.
62275337|NCT01430442|PLACEBO_COMPARATOR|Treatment P: Rimegepant Placebo-Matching Capsules|Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
62275338|NCT01430442|ACTIVE_COMPARATOR|Treatment G: Sumatriptan 100 mg|Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
62638802|NCT06326190|ACTIVE_COMPARATOR|Control group: local standard of care (LOC)|"According to local standard practice, treatment in the control arm is left to the investigator's discretion.~* Hydroxyurea~* Bevacizumab~* Sunitinib~* Octreotide (Sandostatin LAR)~* Everolimus~* No treatment (observation with regular follow-up and best supportive care)"
62638803|NCT06326190|EXPERIMENTAL|Experimental group: 177Lu-DOTATATE|Patients will receive 177Lu-DOTATATE with a total dose of 7.4 GBq/cycle every six weeks for four cycles as an IV infusion
62638804|NCT00887484|EXPERIMENTAL|Clindoxyl Gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
62638805|NCT00887484|ACTIVE_COMPARATOR|Epiduo gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
62070462|NCT05088837|EXPERIMENTAL|muscle energy technique|muscle energy technique was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles, it was done 3 times per session for 12 sessions.
62070463|NCT05088837|EXPERIMENTAL|ice and heat packs|Alternating ice and heat (20 min , 10 heat,10 cold),3times per week for 12sessions.
62070464|NCT01672164||Liver Transplant Recipients|
62070465|NCT01083940|EXPERIMENTAL|Reminders to providers|
62638806|NCT00505050|NO_INTERVENTION|1|Standard follow-up medical visits and treatment for control group were performed during the study period by the same cardiologist team that was not informed of the randomization.
62638807|NCT05781867|PLACEBO_COMPARATOR|control|26patients will be included in this group and will receive conventional physiotherapy in form of pursed lip breathing, diaphragmatic breathing exercise and Active Range of Motion of both upper extremities
62638808|NCT05781867|EXPERIMENTAL|manual therapy|26patients will be included in this group and will receive manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor and major, scaleni ) and conventional physiotherapy
62638809|NCT00465517|EXPERIMENTAL|ganaxolone|active study drug
62638810|NCT00465517|PLACEBO_COMPARATOR|non-active drug|placebo
62638811|NCT04378712|EXPERIMENTAL|Intervention Group|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
62070466|NCT01083940|NO_INTERVENTION|usual care|
62275339|NCT02918019|EXPERIMENTAL|MSTT1041A 210 mg|Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
62454616|NCT03823300|EXPERIMENTAL|Arm A: Faricimab|
62454617|NCT03823300|ACTIVE_COMPARATOR|Arm B: Aflibercept|
62454618|NCT05369871|EXPERIMENTAL|Closed-loop system followed by open-loop system|"An interventional cross-over study:~* six weeks in closed-loop system with Accu-Chek Insight pump and continuous glucose monitoring (CGM) :consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~* followed by six weeks in open-loop system with usual pump and CGM : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks ,~Followed by an optional additional study: 4 weeks in closed-loop system."
62638812|NCT04378712|OTHER|Control Group|Usual care referred to the standard-of-care (including oxygen therapy) recommended by Chinese National Health Commission.
62638813|NCT04789382|OTHER|Sequence 1|LID018869+RepleniSH in the right eye and Biofinity+RepleniSH in the left eye (first wear period), followed by PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (second wear period). Each wear period will be 2 hours.
62638814|NCT04789382|OTHER|Sequence 2|Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (first wear period), followed by LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (second wear period). Each wear period will be 2 hours.
62638815|NCT04789382|OTHER|Sequence 3|LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (first wear period), followed by Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (second wear period). Each wear period will be 2 hours.
62638816|NCT04789382|OTHER|Sequence 4|PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (first wear period), followed by LID018869+RepleniSH in the right eye and Biofinity+RepleniSH the left eye (second wear period). Each wear period will be 2 hours.
62454619|NCT05369871|EXPERIMENTAL|Open-loop system followed by closed-loop system|"An interventional cross-over study:~* six weeks in open-loop system with usual pump and CGM : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~* followed by six weeks in closed-loop system with Accu-Chek Insight pump and CGM (including two weeks of adaptation) : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~Followed by an optional additional study: 4 weeks in closed-loop system."
62638817|NCT02702089||IAPE|Intersphincteric AP excision
62638818|NCT02702089||HP|Hartmann's procedure
62638819|NCT03759080|ACTIVE_COMPARATOR|intervention of PNF|PNF group: 30 individuals, these subjects received proprioceptive neuromuscular facilitation training.
62638820|NCT03759080|EXPERIMENTAL|MP|PNFMP group:30 individuals, these subjects received mental practice.
62638821|NCT03169569|EXPERIMENTAL|Hemostatic powder group (Endo-clot™ group)|Patients who will undergo ESD with Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) after hemostasis on the post-resection ulcer using conventional method and removal of specimen.
62638822|NCT03169569|ACTIVE_COMPARATOR|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|For patients in the control group, hemostasis with conventional method (electrical coagulation and/or clip, Coagrasper®, Olympus, Japan) will be done.
62638823|NCT03227718||athletic background|ex-gymnasts
62638824|NCT03227718||control|age-matched non-gymnastics background
62638825|NCT01403558|EXPERIMENTAL|Cognitive behavioral therapy|Ten weekly individual cognitive behavioral therapy sessions before bariatric surgery
62638826|NCT01403558|NO_INTERVENTION|Control group|Usual preoperative care consisting of up to three voluntary sessions with nutritionist and physiotherapist before bariatric surgery
62638827|NCT04478318|EXPERIMENTAL|uEXPLORER/mCT|Each patient will undergo a scan on a total-body PET/CT scanner (uEXPLORER) and then undergo an additional scan on a conventional PET/CT scanner (mCT). The first scan will take place 60 minutes after injection with 18F-FDG and the second scan will be 90 minutes after injection with 18F-FDG.
62638828|NCT04478318|EXPERIMENTAL|mCT/uEXPLORER|Each patient will undergo a scan on a conventional PET/CT scanner (mCT) and then undergo an additional scan on a total-body PET/CT scanner (uEXPLORER) . The first scan will take place 60 minutes after injection with 18F-FDG and the second scan will be 90 minutes after injection with 18F-FDG.
62638829|NCT02068638|EXPERIMENTAL|IHE first, CONT second, CSII and MDI therapy|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
62638830|NCT02068638|EXPERIMENTAL|CONT first, IHE second,CSII and MDI therapy|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
62070467|NCT05800782|EXPERIMENTAL|Memory Training|Participants will perform 6 weeks of face memory training (5 x 40 min sessions/week) that targets enhancing encoding to improve face recollection. As training progresses, the repetition lags (spaces between repeated foil faces) and number of faces will increase.
62070468|NCT05800782|ACTIVE_COMPARATOR|Perception Training|Participants will perform 6 weeks of face perception training (5 x 40 min sessions/week) that require discriminating faces based on internal features (e.g., eyebrow-eye distance). As training progresses, the faces will become more challenging and the face sizes will vary.
62070469|NCT05800782|PLACEBO_COMPARATOR|Active Control Training|Participants will perform 6 weeks of face perception training (5 x 40 min sessions/week) that require discriminating faces based on external facial features (e.g., hair). As training progresses, the faces will become more challenging and the face sizes will vary.
62638831|NCT02068638|EXPERIMENTAL|GLU first, GLUFRU second, CSII and MDI therapy|GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
62638832|NCT02068638|EXPERIMENTAL|GLU-FRU first, GLU second, CSII therapy|GLU-FRU : ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): ingestion of a 10% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
62070470|NCT01048606|ACTIVE_COMPARATOR|Placeco + exercise|Placebo (no phytoestrogen): Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) Exercise (three 1h-sessions/week)
62275340|NCT02918019|EXPERIMENTAL|MSTT1041A 490 mg|Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
62275341|NCT02918019|EXPERIMENTAL|MSTT1041A 70 mg|Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
62275342|NCT02918019|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
62275343|NCT01306227|PLACEBO_COMPARATOR|water|Oral treatment with water for 6 weeks
62638833|NCT05031442|OTHER|low waist arm (investigational product RH1 first)|Investigational product RH1 (low waist) will be used for 5 consecutive days at the start before switching to the control product (low waist) for 5 days after cross-over.
62638834|NCT05031442|OTHER|high waist arm (Investigational product RC2 first)|Investigational product RC2 (high waist) to be used for 5 consecutive days at the start before switching to the control product (high waist) for 5 days after cross-over.
62070471|NCT01048606|ACTIVE_COMPARATOR|Phytoestrogens without exercise|Phytoestrogens (70mg/day of soy isoflavone) Without exercise (no structured exercise session)
62638835|NCT05031442|OTHER|low waist arm (Control product first)|Control product (low waist) to be used for 5 consecutive days at the start before switching to the investigational product RH1 for 5 days after cross-over.
62638836|NCT05031442|OTHER|high waist (Control product first)|Control product (high waist) to be used for 5 consecutive days at the start before switching to the investigational product RC2 for 5 days after cross-over.
62638837|NCT04222816|ACTIVE_COMPARATOR|Lithium carbonate|Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
62638838|NCT04222816|EXPERIMENTAL|Add-on Sodium chloride|Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.
62638839|NCT06106230|EXPERIMENTAL|Group A:Bee venom phonophoresis + Conservative care|Bee venom phonophoresis + Conservative care (32 patients)
62070472|NCT01048606|EXPERIMENTAL|Phytoestrogens + exercise|Phytoestrogens (70 mg/day soy isoflavone) Exercise (1h-sessions 3 times/week)
62070473|NCT01048606|NO_INTERVENTION|Placebo without exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) No exercise
62275344|NCT01306227|EXPERIMENTAL|L-Thyroxine|Oral treatment with L-Thyroxine for 6 weeks
62275345|NCT00144482|EXPERIMENTAL|1|
62275346|NCT00144482|PLACEBO_COMPARATOR|2|
62275347|NCT02585011|EXPERIMENTAL|Ropivacaine|Local infiltration anesthesia, single shot during surgery. 150 ml Ropivacaine (2mg/ml), added 0.5 ml Epinephrine (1mg/ml)
62275348|NCT02585011|PLACEBO_COMPARATOR|Placebo|Single shot during surgery.150 ml saline
62275349|NCT05396274|ACTIVE_COMPARATOR|standard nasal therapy|"nasal oxygen was applied for procedure~%40 inspired oxygen fraction five minutes preoxygenation"
62275350|NCT05396274|ACTIVE_COMPARATOR|high flow nasal cannula|"High Flow Nasal Oxygen was applied for procedure~%40 inspired oxygen fraction five minutes preoxygenation"
62275351|NCT03521505|EXPERIMENTAL|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
62275352|NCT03521505|ACTIVE_COMPARATOR|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
62454620|NCT05111470|EXPERIMENTAL|kayak polo players|Having a level of expertise greater than or equal to the national level 4
62454621|NCT00977106|EXPERIMENTAL|1|
62454622|NCT00977106|PLACEBO_COMPARATOR|2|
62454623|NCT00977106|EXPERIMENTAL|3|
62454624|NCT03421860|ACTIVE_COMPARATOR|ephedrine|will receive ephedrine :a bolus of 9 mg after SA once intervention: will receive complementary doses of ephedrine 6 mgto maintain systolic blood pressure above 80 % of baseline
62454625|NCT03421860|ACTIVE_COMPARATOR|phenylephrine|will receive Phenylephrine : a bolus of 100 mcg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
62454626|NCT03421860|ACTIVE_COMPARATOR|ondansetron|will receive ondansetron: a bolus of 8 mg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
62454627|NCT03421860|ACTIVE_COMPARATOR|norepinephrine|will receive noradrenaline (norepinephrine) a bolus of 0,25 mcg/kg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
62454628|NCT02761980|EXPERIMENTAL|Ibuprofen 250 mg / Acetaminophen 500 mg|Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
62454629|NCT02761980|ACTIVE_COMPARATOR|Ibuprofen 250 mg|Single dose of 2 caplets of IBU 125 mg by mouth
62454630|NCT02761980|ACTIVE_COMPARATOR|Acetaminophen 500 mg|Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
62454631|NCT02761980|PLACEBO_COMPARATOR|Placebo|Single dose of 2 caplets of Placebo by mouth
62275353|NCT02780882|EXPERIMENTAL|Pasireotide|Each patient will be treated with pasireotide at an initial dose of 600 μg twice daily for one month. The dose will be further increased to 900 μg twice daily for month 2 and 3. After month 3, patients who continue to meet the inclusion and exclusion criteria will be entered into an additional 3 months of treatment.
62275354|NCT00976066|EXPERIMENTAL|GSK1521498|Subjects will receive a dose of the experimental compound GSK1521498
62638840|NCT06106230|EXPERIMENTAL|Group B:Bee venom topical application + Conservative care|Bee venom topical application + Conservative care (32 patients)
62638841|NCT06106230|SHAM_COMPARATOR|Group C:Conservative care|Control group Conservative care only (32 patients) Plain gel instead of BV gel plus off ultrasound (sham ultrasound) with medical treatment
62638842|NCT01162044|NO_INTERVENTION|No intervention|Subjects will be assessed, but no active intervention given
62275355|NCT00976066|ACTIVE_COMPARATOR|Naltrexone|Subjects will receive a dose of the licensed pharmaceutical product, Naltrexone
62275356|NCT03239717|PLACEBO_COMPARATOR|Whey protein powder|Participants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
62275357|NCT03239717|EXPERIMENTAL|Experimental|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
62275358|NCT01972230|EXPERIMENTAL|Bilanced group|"Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.~Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
62461659|NCT05567874||SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the second period|SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville from June to September 2021
62461660|NCT05567874||SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the third period|SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in December 2021
62638843|NCT01162044|EXPERIMENTAL|Computer game|Subjects will play with computer game while in the Emergency Room
62638844|NCT04425070|EXPERIMENTAL|ATG-010 + ICE|ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11
62638845|NCT04425070|EXPERIMENTAL|ATG-010 + GEMOX|ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9
62638846|NCT04425070|EXPERIMENTAL|ATG-010 + Tislelizumab|ATG 010 40mg/once, will be given on Days 1, 8, and 15 of each cycle
62638847|NCT02979782||Endo-CABG, surgical group|the minimal invasive cardiac surgery group
62638848|NCT02979782||PCI, comparative surgical group|a comparative minimal invasive procedure
62638849|NCT02979782||Healthy volunteer, control group|to exclude any learning effect or natural variation in neurological testing
62638850|NCT00694525||1|Women in this group will have 21-OHD CAH.
62638851|NCT00694525||2|Women in this group will be healthy controls and will not have 21-OHD CAH.
62638852|NCT04058509|EXPERIMENTAL|focused shockwave therapy|3 sessions of shock wave treatment.(Focused Shockwave Therapy).
62638853|NCT02904044||Injured/Case|Secondary school pupil injured during a physical activity lesson between 2012-2014 in south of Reunion Island
62638854|NCT02904044||Control|Same age and gender than case in the same classroom and during the same physical activity lesson
62638855|NCT00248209|PLACEBO_COMPARATOR|Wellbutrin XL or placebo|1 arms - Wellbutrin XL or placebo
62638856|NCT01534273|PLACEBO_COMPARATOR|Placebo|Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days
62638857|NCT01534273|EXPERIMENTAL|35 mg LY2886721|QD oral dosing for 14 consecutive days
62638858|NCT01534273|EXPERIMENTAL|70 mg LY2886721|Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days
62070474|NCT06380634|EXPERIMENTAL|Experimental Group (Randomize)|The sample size was determined as at least 64 people for each of the experimental and control groups, with 80% power, 0.05 margin of error and 0.5 effect level. Considering the possibility of data loss later on, 70 pregnant women (140 in total) were included in each group. The groups were randomized into 2 groups using a web-based randomization program (http://www.randomizer.org). 357 pregnant women were evaluated for suitability for the study. 68 women did not meet the inclusion criteria and 149 women were not included because they did not agree to participate in the study. The pre-test of the study was completed with 70 experimental and 70 control groups (140 in total), and the post-test was completed with a total of 130 people, 69 experimental and 61 control groups.
62070475|NCT00748124|EXPERIMENTAL|PleuraSeal Sealant Device|
62070476|NCT00748124|OTHER|Control|
62070477|NCT02366936|EXPERIMENTAL|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
62070478|NCT04930328||Retrospective Data Collection|Retrospective Data Collection
62070479|NCT05092243|EXPERIMENTAL|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
62638859|NCT01534273|EXPERIMENTAL|140 mg LY2886721|Single oral dose
62638860|NCT03011866|EXPERIMENTAL|Experimental|"Loading dose: 100ml 0.9% normal saline(NS) intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 5ml/hr 0.9% NS intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 500mg TXA in 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
62638861|NCT03011866|OTHER|Control|"Loading dose: 10mg/kg tranexamic acid(TXA) in 100ml 0.9% NS intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 1mg/kg/hr TXA intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
62638862|NCT05390008|EXPERIMENTAL|Group 1: Pelvic Floor Muscle Training|volunteer elderly women with SUI
62070480|NCT05092243|SHAM_COMPARATOR|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
62070481|NCT00807521|ACTIVE_COMPARATOR|1|High dose bolus of dexamethasone before surgery
62070482|NCT00807521|PLACEBO_COMPARATOR|2|Placebo control
62070483|NCT01715337|OTHER|pulmonary rehabilitation|
62070484|NCT04890717||ASD and/or ADHD children (Case group)|Suspected or confirmed cases of ASD and/or ADHD children (Case group); no intervention(s) to be administered.
62070485|NCT04890717||Parent group|Parents of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
62070486|NCT04890717||Sibling group|Typically developed siblings of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
62070487|NCT04890717||Control group|Typically developed children not related to the case group ; no intervention(s) to be administered.
62070488|NCT00956696||Topiramte|single arm, flexible dosing
62070489|NCT01464008||chronic hepatitis C|
62070490|NCT01397435||Gaucher|We will enroll 15 children who have a confirmed diagnosis of Gaucher disease.
62638863|NCT05390008|EXPERIMENTAL|Group 2: Modified Pilates Exercises|volunteer elderly women with SUI
62638864|NCT02626598||Treated patients|Patients treated with blended Belotero for etched-in fine lines of the cutaneous lip, and/or radial cheek area, and/or nasolabial folds, and/or melolabial folds, and/or forehead area will be evaluated with photographs, physician ratings, and patient improvement assessments.
62638865|NCT00621101|ACTIVE_COMPARATOR|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
62070491|NCT01397435||Healthy volunteers|We will enroll 15 age and gender matched controls.
62638866|NCT00621101|ACTIVE_COMPARATOR|B|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
62070492|NCT03786120||1|First 25 subjects
62638867|NCT00621101|EXPERIMENTAL|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
62070493|NCT03786120||2|Second cohort of 25 subjects
62070494|NCT04023149|EXPERIMENTAL|experimental group|Patients will receive rhIL-2 solution oral gargle twice per day (2 million units of rhIL-2 dissolved in 5ml normal saline for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
62070495|NCT04023149|PLACEBO_COMPARATOR|control group|Patients will receive placebo solution oral gargle twice per day (5ml for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
62070496|NCT03444935|EXPERIMENTAL|Intervention|Participants randomized to the intervention group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the control group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
62638868|NCT00734292|PLACEBO_COMPARATOR|I|"* Period 1 Treatment Regimen A: FlutiForm 250/10 ug~* Period 2 Treatment Regimen B: FlutiForm 100/10 ug~* Period 3 Treatment Regimen C: placebo"
62638869|NCT00734292|PLACEBO_COMPARATOR|II|"* Period 1 Treatment Regimen B: FlutiForm 100/10 ug~* Period 2 Treatment Regimen C: placebo~* Period 3 Treatment Regimen A: FlutiForm 250/10 ug"
62638870|NCT00734292|PLACEBO_COMPARATOR|III|"* Period 1 Treatment Regimen C: placebo~* Period 2 Treatment Regimen A: FlutiForm 250/10 ug~* Period 3 Treatment Regimen B: FlutiForm 100/10 ug"
62275359|NCT01972230|ACTIVE_COMPARATOR|TCI group|Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI
62638871|NCT00767572|EXPERIMENTAL|atorvastatin|Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
62638872|NCT00767572|PLACEBO_COMPARATOR|sugar pill|See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.
62638873|NCT06164977|OTHER|Chronic total coronary occlusion|Participants who underwent percutaneous coronary intervention for chronic total coronary occlusion revascularization with bioresorbable scaffold.
62638874|NCT02515903|EXPERIMENTAL|Intra-endoscopy|This intervention arm will receive intra-endoscopic evacuation surgery for ICH.
62638875|NCT02515903|PLACEBO_COMPARATOR|Stereotactic Aspiration|This arm will receive stereotactic aspiration surgery for ICH evacuation.
62638876|NCT05225948|ACTIVE_COMPARATOR|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
62638877|NCT05225948|PLACEBO_COMPARATOR|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
62275360|NCT00758745|ACTIVE_COMPARATOR|Model SN60WF|Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
62638878|NCT02786992|ACTIVE_COMPARATOR|Misoprostol + Oxytocin|400 ug sublingual misoprostol + 10 IU Oxytocin IVI
62638879|NCT02786992|ACTIVE_COMPARATOR|Carbetocin|100 ug Carbetocin IV
62638880|NCT02672176|SHAM_COMPARATOR|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
62638881|NCT02672176|ACTIVE_COMPARATOR|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
62638882|NCT02269839|ACTIVE_COMPARATOR|theta-burst rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
62638883|NCT02269839|SHAM_COMPARATOR|Control arm|The control (sham) stimulation will consist of stimulating with the rTMS coil held at right angles to the participants' head. This will result in no active stimulation of brain tissue but would feel similar to the patient. Each treatment session will therefore last approximately 20 minutes.
62638884|NCT01436487|EXPERIMENTAL|Cohort 1|Low dose MultiStem or Placebo
62638885|NCT01436487|EXPERIMENTAL|Cohort 2|High dose MultiStem or Placebo
62275361|NCT00758745|ACTIVE_COMPARATOR|Model MA60AC|Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
62275362|NCT01394107||Pregnant|"50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.~Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent."
62275363|NCT01394107||Control|50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
62287154|NCT05492955|EXPERIMENTAL|Community Health Worker Care Model (CHW)|Participants will be given a standard blood pressure cuff (Omron) for at-home BP monitoring, and will be assigned to a CHW for follow-up visits and medication delivery.
62638886|NCT01436487|EXPERIMENTAL|Cohort 3|Highest, safe MultiStem dose (from Cohorts 1 and 2) or Placebo
62638887|NCT00057291|EXPERIMENTAL|caregiving intervention|One group received caregiving intervention, another received only training, and a third was business as usual. These were the interventions.
62070497|NCT03444935|OTHER|Control|Participants randomized to the control group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the intervention group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
62275364|NCT03959280|EXPERIMENTAL|Tailored intervention|"In this group, participants will receive a comprehensive lifestyle program in addition to CPAP therapy which will include a supervised exercise program, diet interventions and behavioural counselling during 12 weeks.~Then, participants will follow a real-world maintenance program from weeks 12 to 24. It will include one telephone-based contact per month with the study coordinator. Participants will be encouraged to maintain their lifestyle modification during this phase."
62070498|NCT01468896|EXPERIMENTAL|Treatment (cetuximab and recombinant interleukin-12)|Patients receive cetuximab IV over 1-2 hours on day 1 and recombinant interleukin-12 SC on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
62275365|NCT03959280|ACTIVE_COMPARATOR|Control|Participant in this group will benefit from routine CPAP therapy management from week 0 to 24.
62275366|NCT04776590|EXPERIMENTAL|Tislelizumab arm|Radiotherapy: PTV 41.4Gy in 23 Fractions，5 days per week; Chemotherapy: Paclitaxel (Albumin bound) (100mg per square meter of body-surface area weekly) and Caboplatin (area under the curve of 2 mg per milliliter per minute weekly) for 5 weeks, concurrent with radiotherapy; Immunotherapy: Tislelizumab (200mg per 3 weeks)
62275367|NCT01700933|ACTIVE_COMPARATOR|High-dosage-group|
62070499|NCT02761460|EXPERIMENTAL|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy,
62275368|NCT01700933|ACTIVE_COMPARATOR|Low-dosage-group|
62275369|NCT01726751|OTHER|Early off-stimulation (group B)|Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
62638888|NCT01082744|ACTIVE_COMPARATOR|Continuous paravertebral block with ropivacaine|
62638889|NCT01082744|EXPERIMENTAL|Continuous paravertebral block with ropivacaine and sufentanil|
62638890|NCT04554589|ACTIVE_COMPARATOR|intervention group|receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .
62638891|NCT04554589|PLACEBO_COMPARATOR|placebo group|receive normal saline 2 ml IV every 8 hours daily .
62638892|NCT02937623|EXPERIMENTAL|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
62638893|NCT02937623|NO_INTERVENTION|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
62070500|NCT01926522|EXPERIMENTAL|Technological Rehabilitation|Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).
62638894|NCT06141785|EXPERIMENTAL|Nutritional Intervention|Patients with Cancer treated with palliative chemotherapy.
62638895|NCT06141785|NO_INTERVENTION|Historical control|"Patients with Cancer treated with palliative chemotherapy.~Historical Control cohort following current clinical practise, where nutritional treatment is not systematically implemented but patients can be referred to a clinical dietitian after clinical assessment by the treating physician or nurse."
62638896|NCT01217827|EXPERIMENTAL|Clinical Reminder|Reminder of potential candidacy for an implantable cardioverter defibrillator. The reminder is placed in the medical record with copy to the primary provider and any cardiologist managing the patient.
62638897|NCT01217827|NO_INTERVENTION|Control|This group does not receive an intervention.
62638898|NCT00159315|EXPERIMENTAL|Nebulised ATP|
62638899|NCT00159315|ACTIVE_COMPARATOR|Inhaled Adenosine|
62638900|NCT05355467|EXPERIMENTAL|Ricovir® group|
62070501|NCT01926522|ACTIVE_COMPARATOR|Control Rehabilitation|Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
62638901|NCT05355467|OTHER|Historical Control Group|
62638902|NCT03337815|ACTIVE_COMPARATOR|Treatment of MTX and TwHF placebo|Patients were treated with Methotrexate (MTX) and Tripterygium wilfordii Hook F（TwHF）placebo.
62638903|NCT03337815|EXPERIMENTAL|Treatment of TwHF and MTX placebo|Patients were treated with Tripterygium wilfordii Hook F（TwHF）and Methotrexate (MTX) placebo.
62070502|NCT04091360|EXPERIMENTAL|RPL554 100 mcg|"Part A: Patients receive 1 dose of either RPL554 100mcg via metered dose inhaler.~Part B: not applicable"
62638904|NCT04264780||Younger than 50 years of age|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently less than 50 years of age
62638905|NCT04264780||50 years of age or older|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently 50 years of age or more
62638906|NCT03123081|EXPERIMENTAL|Umbilical Cord Milking|Umbilical Cord Milking involves milking 30 cm length of cord at birth, after initiation of ventilation.
62638907|NCT03123081|NO_INTERVENTION|Immediate Umbilical Cord Clamping|Procedure: No Intervention: Immediate Umbilical Cord Clamping or Immediate Cord Clamping.
62638908|NCT06244368|EXPERIMENTAL|GVM±R|Patients with relapsed or refractory aggressive NHL will undergo GVM±R therapy
62638909|NCT03957785|EXPERIMENTAL|Alter G treatment|All participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.
62638910|NCT03957785|ACTIVE_COMPARATOR|Traditional Gait Training|All participants practiced one session a day TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using FAC-tailored physiotherapist assistance, to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). Physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions.
62275370|NCT01726751|OTHER|Early on-stimulation (group A)|Early SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group A starting with SCS for a period of six weeks (A) followed by a period of no SCS (off-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
62638911|NCT03957785|ACTIVE_COMPARATOR|Healthy Control|ll participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.The HC initially practiced the device at the same BWS and S administered to the patients. BWS and S were reduced progressively and increased, respectively, across the AlterG sessions in keeping with patients progresses.
62638912|NCT03318198|ACTIVE_COMPARATOR|Intervention Arm|Attendings on the interventional arm attended daily work rounds with the resident teams in addition to established work rounds on the previously admitted patients on the care team.
62638913|NCT03318198|PLACEBO_COMPARATOR|Control Arm|Attendings crossed over to the control arm in which they did not attend work rounds with the team and only say new admissions with the resident team. This was usual care.
62638914|NCT03429101|EXPERIMENTAL|Poziotinib|"* Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~* Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD."
62638915|NCT06160336|EXPERIMENTAL|TENS group|
62638916|NCT01560247||Treatment Group|Subjects in whom a MindFrame Device was employed for restoration of flow and clot removal
62070503|NCT04091360|EXPERIMENTAL|RPL554 300 mcg|Part A: Patients receive 1 dose of RPL554 300mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 300mcg via metered dose inhaler in crossover fashion.
62070504|NCT04091360|EXPERIMENTAL|RPL554 1000 mcg|Part A: Patients receive 1 dose of RPL554 1000mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
62638917|NCT00467519|EXPERIMENTAL|Group 1|DAPTACEL primed participants
62638918|NCT00467519|EXPERIMENTAL|Group 2|Pentacel primed participants
62070505|NCT04091360|EXPERIMENTAL|RPL554 3000 mcg|"Part A: Patients receive 1 dose of either RPL554 3000mcg via metered dose inhaler.~Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion."
62070506|NCT04091360|EXPERIMENTAL|RPL554 6000 mcg|"Part A: Patients receive 1 dose of either RPL554 6000mcg via metered dose inhaler.~Part B: not applicable"
62275371|NCT04316585|EXPERIMENTAL|Participants receiving GSK2982772 960 mg|Participants will receive GSK2982772 960 mg oral tablets once daily for 12 weeks.
62070507|NCT04091360|PLACEBO_COMPARATOR|RPL554 Placebo|Part A: Patients receive 1 dose of RPL554 placebo via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 placebo via metered dose inhaler in crossover fashion.
62638919|NCT02783612|EXPERIMENTAL|glucose application|Regular high risk pregnancy clinic surveillance in addition to a Smart phone application for registering the Blood glucose levels and submitting via email every 3-5 days to the High risk Doctor involved in the trial.
62638920|NCT02783612|NO_INTERVENTION|Regular monitoring|Regular high risk pregnancy clinic surveillance
62070508|NCT05256693|EXPERIMENTAL|Vancomycine|Oral vancomycine 125 mg twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
62070509|NCT05256693|PLACEBO_COMPARATOR|Placebo|Vancomycine placebo, twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
62638921|NCT04743622|EXPERIMENTAL|Monoprost (preservative-free latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
62638922|NCT04743622|ACTIVE_COMPARATOR|Xalatan (preserved latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
62070510|NCT01057108|ACTIVE_COMPARATOR|ESRD: FOSTRAP Chewing Gum|
62070511|NCT01057108|ACTIVE_COMPARATOR|CKD: FOSTRAP Chewing Gum|
62070512|NCT01057108|PLACEBO_COMPARATOR|ESRD Matching Placebo|
62070513|NCT01057108|PLACEBO_COMPARATOR|CKD Matching Placebo|
62638923|NCT00426881|EXPERIMENTAL|1|Twice weekly resistance training for 52 weeks.
62638924|NCT00426881|EXPERIMENTAL|2|Once weekly resistance training for 52 weeks.
62638925|NCT00426881|EXPERIMENTAL|3|Twice weekly balance and tone training for 52 weeks.
62638926|NCT05648799|EXPERIMENTAL|GP30341 capsules 200 mg|4 capsules containing 200 mg of molnupiravir p.o. twice a day during 5 days (daily dose 1600 mg) in combination with Standard therapy in accordance with the current version of the guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019 (COVID-19).
62275372|NCT04316585|PLACEBO_COMPARATOR|Participants receiving placebo|Participants will receive GSK2982772 matching placebo oral tablets once daily for 12 weeks.
62275373|NCT01445678|EXPERIMENTAL|CXA-201 and Metronidazole as treatment for cIAI|
62638927|NCT05648799|ACTIVE_COMPARATOR|Standart therapy|Standard therapy in accordance with the current version of the guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019 (COVID-19).
62638928|NCT03279809|EXPERIMENTAL|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
62638929|NCT03279809|PLACEBO_COMPARATOR|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
62638930|NCT05401565|EXPERIMENTAL|Balovaptan|
62275374|NCT01445678|ACTIVE_COMPARATOR|Meropenem as treatment for cIAI|
62275375|NCT05244681|OTHER|People with chronic non-specific neck pain|Group of people with chronic non-specific neck pain who agreed to participate in a semi-structured interview about their experience using an immersive virtual reality serious game at home
62638931|NCT05401565|PLACEBO_COMPARATOR|Placebo|
62638932|NCT03241095|NO_INTERVENTION|Control|
62638933|NCT03241095|SHAM_COMPARATOR|Sham OMT|
62638934|NCT03241095|ACTIVE_COMPARATOR|OMT|
62070514|NCT00810082|ACTIVE_COMPARATOR|Group A|Standard physical therapy for fall prevention
62070515|NCT00810082|EXPERIMENTAL|Group B|Physical therapy for fall prevention that includes ActiveStep
62070516|NCT01634074||OSA patients|Patients with Obstructive Sleep Apnea (OSA), or suspected OSA
62070517|NCT04192630|EXPERIMENTAL|CVisc50 Ophthalmic Viscosurgical Device (OVD)|CVisc50 OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to Intraocular Lens (IOL) implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
62275376|NCT02945631|EXPERIMENTAL|Reduced Dose Radiation|All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
62454632|NCT05897580|EXPERIMENTAL|Heart Rate Variability-Biofeedback (HRV-BF)|"Heart Rate Variability-Biofeedback (HRV-BF) is a process by which physiological markers such as heart rate, respiration, and HRV are measured and fed back to the person on a computer screen. Guided paced slowed breathing, a skill taught in HRV-BF, maximizes the natural acceleration of heart rate with inspiration and deceleration with expiration and produces a rhythmic stimulation of the vagus nerve, providing the basis for the overall increase in parasympathetic/vagal tone over time if practiced regularly."
62454633|NCT05897580|ACTIVE_COMPARATOR|Health Promotion (HP)|The Health Promotion (HP) active control group was originally developed utilizing community-based participatory research elements, including the establishment of a Community Advisory Board (CAB), with community stakeholders, social service providers and academicians and a manualized program was developed for the HP program. The 8-week program focused on the most common physical chronic diseases PEH experience, and included discussions of hypertension, diabetes, heart disease and arthritis; total over eight weeks, along with full discussion and referrals provided based on needs expressed by PEH.
62638935|NCT02909790|EXPERIMENTAL|CURVE LLLT treatment|Up to 20 subjects are randomly selected to receive Curve Low Level Laser Therapy
62638936|NCT02909790|SHAM_COMPARATOR|SHAM device treatment|Up to 20 subjects assigned to the sham group will be treated with a device that is designed to have the same physical appearance as the treatment group, except that the interlock fuse (grey fuse holder back of device) will be removed prior to treatment. The laser screen will still be active and show to the subject that the treatment time will still be counting down, but will not activate lasers in the treatment paddles
62638937|NCT05090202||"HFrEF  Heart failure with reduced ejection fraction"|"chronic heart failure with echocardiographic finding of LVEF Left ventricular ejection fraction equal or less than 40%"
62638938|NCT05090202||"HFmrEF Heart failure with mildly reduced ejection fraction"|chronic heart failure with echocardiographic finding of LVEF between 41% and 49%
62070518|NCT04192630|ACTIVE_COMPARATOR|ProVisc OVD|ProVisc OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to IOL implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
62070519|NCT05250258||telephone peer support|Telephone peer support from experinenced father to father
62070520|NCT05250258||Routine care|Standard care as usual in child health care, one visit for fathers and nothing added
62070521|NCT00798031|OTHER|1|a minimum of two dental implants, but up to 3 dental implants, will be placed in each of 20 subjects. All surgical procedures will be performed as outpatient procedures at the College of Dentistry and implant placement will follow a one-stage procedure under local anesthesia. Placement of the 2-3 dental implants is the only intervention.
62070522|NCT03467308||Colorectal cancer patients|50 Patients confirmed histopathologically to have early stages of colorectal cancer.
62070523|NCT03467308||Risky group|20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
62275377|NCT02824744|ACTIVE_COMPARATOR|treatment by 2l/min/kg in HFNC|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
62638939|NCT05090202||"HFpEF  Heart failure with preserved ejection fraction"|chronic heart failure with echocardiographic finding of LVEF equal or more than 50%
62638940|NCT03025113|EXPERIMENTAL|EMS association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
62070524|NCT03096301|EXPERIMENTAL|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
62070525|NCT03096301|ACTIVE_COMPARATOR|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
62454634|NCT06291688|EXPERIMENTAL|Game group|An educational game regarding common EGFR-related cutaneous adverse drug reactions on a mobile APP
62070526|NCT03096301|PLACEBO_COMPARATOR|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
62070527|NCT06367387|ACTIVE_COMPARATOR|Usual Care + Standard Buprenorphine Dosing|"Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions.~Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care."
62275378|NCT02824744|EXPERIMENTAL|treatment by 3l/min/kg in HFNC|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
62275379|NCT06322771||Refusal|A questionnaire will be given to patients who have refused to participate in the RANSPRE trial
62275380|NCT06322771||Acceptance|A questionnaire will be given to patients who have agreed to participate in the RANSPRE trial
62454635|NCT06291688|PLACEBO_COMPARATOR|Text group|An educational text regarding common EGFR-related cutaneous adverse drug reactions on a mobile APP
62454636|NCT02922868|EXPERIMENTAL|EndoSheath CST-5000 Scope|Cogentix Medical CST-5000 Flexible Video Cystoscope with Slide-On® EndoSheath® Technology. EndoSheath CST-5000 Scope.
62454637|NCT02922868|ACTIVE_COMPARATOR|Olympus Visera Elite OTV-S190 Scope|Olympus HD Flexible Cysto-Nephro Videoscope (CYF-VH) with Olympus Visera Elite Platform, including OTV-S190 Video Processor CLV-S190 Xenon Light Source. Olympus Visera Elite OTV-S190 Scope.
62454638|NCT04101149||Group 1|Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.
62454639|NCT03441581|EXPERIMENTAL|Eluxadoline 100 mg with BAM|IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.
62454640|NCT03441581|EXPERIMENTAL|Eluxadoline 100 mg without BAM|IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.
62454641|NCT01328730|EXPERIMENTAL|Firebird 2 stent group|patients who were implated with Firebird 2 SES
62454642|NCT01328730|ACTIVE_COMPARATOR|Cypher Stent Group|patients who were implanted with Cypher SES
62638941|NCT03025113|ACTIVE_COMPARATOR|Miosan®|The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
62638942|NCT06046677||Sepsis cohort|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection."
62638943|NCT06046677||Elective cohort|Elective pre-operative upper GI surgical patients or elective stem cell transplant patients will be consented and enrolled at baseline, immediately prior to these procedures. If they go on to develop sepsis within 60 days of their surgery, they will go on to be sampled as per the sepsis cohort
62638944|NCT06211556|EXPERIMENTAL|Very-low calorie diet|Two weeks of \~800kcal/day
62638945|NCT06211556|NO_INTERVENTION|Free-living control|No intervention control group
62638946|NCT01145365|ACTIVE_COMPARATOR|Combination Therapy Group|Patients in this arm will have surgically established drainage of their Crohns perianal fistulas and/or abscesses (exam under anesthesia (EUA)) done BEFORE beginning medical therapy with Cimzia.
62638947|NCT01145365|NO_INTERVENTION|Control Group|Patients in this group will begin medical therapy with Cimzia regardless of status of surgically established drainage.
62638948|NCT03973580|ACTIVE_COMPARATOR|Attentional Bias Modification (ABM) group|Participants in this arm will participate in a six-session ABM task, one session per week.
62638949|NCT03973580|PLACEBO_COMPARATOR|Control group|Participants in this arm will participate in a six-session control task, one session per week.
62638950|NCT02358148||STEMI / NSTEMI|All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
62638951|NCT02358148||Elective / Non-emergent Cardiac Cath|This group will include both admitted and outpatients, with possible diagnoses of Unstable Angina (UA), Low Risk Chest Pain (LRCP), and those having cardiac catheterization for any other reason (eg: elective, medical clearance for surgery, failed stress test, etc.). To maintain integrity of the study, these patients will be randomly selected, with written consent obtained, prior to cardiac catheterization.
62275381|NCT05389878||Stroke group|Patients with stroke addressing intensive inpatient rehabilitation, including and treatment, delivered according to an Individual Rehabilitation Project (IRP), defined according AHA ASA Stroke rehabilitation Guidelines (2016. The IRP was defined by an interdisciplinary team, coordinated by a physiatrist and designed according to patients' and caregivers' needs. The team included internists, physiotherapists, occupational therapists, nurses, speech therapists, and psychologists. The assessment protocol aimed to provide a reliable and synthetic assessment of patients' clinical conditions and function at admission and discharge. Each patient received at least three hours of specific rehabilitation per day. All patients received clinical observation and management, nurse management, physiotherapy. Speech, neuropsychological, and occupational therapy treatment were prescribed by physiatrist.
62275382|NCT05040308|ACTIVE_COMPARATOR|Participants in PrEP and MAT programs|Integrated PrEP and MAT program
62275383|NCT05040308|ACTIVE_COMPARATOR|Participants in PrEP and NSP programs|Integrated PrEP and NSP program
62275384|NCT05438316|OTHER|Sequence TR|25 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Ramipril (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Tritace® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken. /
62275385|NCT05438316|OTHER|Sequence RT|25 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Tritace® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Ramipril (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62275386|NCT05593887|ACTIVE_COMPARATOR|Hip Reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur and internal fixation.
62275387|NCT05593887|ACTIVE_COMPARATOR|Proximal femoral resection|This group will undergo PFR as described by resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur.
62454643|NCT03342495|EXPERIMENTAL|Patient Navigator Arm|"Patient Navigator (Social Worker) will assist youth adapt and attach to adult delivered healthcare for up to 24 months.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences.~Up to 100 participants will be provided the opportunity to be interviewed at baseline and end of study about their transition experience."
62638952|NCT02576392|EXPERIMENTAL|Intervention|Informational letter mailed approximately 2 weeks prior to surgery, informational letter mailed approximately 2 weeks post surgery, pharmacist call if refill opioid medicine more than 28 days after surgery
62638953|NCT02576392|NO_INTERVENTION|Control|Usual Care
62070528|NCT06367387|EXPERIMENTAL|Usual Care + Patient-Oriented Dosing (POD)|"Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions.~Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone for treating participants with both opioid use disorder (OUD) and chronic pain. POD allows titration of buprenorphine or buprenorphine/naloxone dosing up to 32mg/day, split into four doses per day, based on the participant's pain level."
62638954|NCT00727376||Observation|Esophageal cancer patients
62275388|NCT05593887|ACTIVE_COMPARATOR|Proximal femur valgus osteotomy|This group will undergo McHale Procedure.The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate.
62275389|NCT04951258|EXPERIMENTAL|Multicomponent exercise group|
62275390|NCT04951258|ACTIVE_COMPARATOR|Video home exercise group|
62275391|NCT01392820|EXPERIMENTAL|TC-5214|
62275392|NCT01392820|PLACEBO_COMPARATOR|Placebo|
62638955|NCT04723459|ACTIVE_COMPARATOR|Ivermectin mask group|Contacts who will use ivermectin masks
62638956|NCT04723459|NO_INTERVENTION|ordinary mask group|Contacts who will use regular masks
62638957|NCT01848574|NO_INTERVENTION|Usual procedure|Investigators will give medical information to their patients as usual.
62638958|NCT01848574|EXPERIMENTAL|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.~Deliver the following information in the orde of the items below:~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection~Briefly additional tests:~* Radio show~* Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
62070529|NCT06367387|EXPERIMENTAL|Pain Self-Management (PSM) + Standard Buprenorphine Dosing|"Pain self-management (PSM) is a manualized behavioral intervention tailored for patients in outpatient-based addiction treatment (OBAT) programs. PSM consists of 12 intervention sessions, comprising 6 group sessions and 6 individual sessions.~Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care."
62070530|NCT06367387|EXPERIMENTAL|Pain Self-Management (PSM) + Patient-Oriented Dosing (POD)|"Pain self-management (PSM) is a manualized behavioral intervention tailored for patients in outpatient-based addiction treatment (OBAT) programs. PSM consists of 12 intervention sessions, comprising 6 group sessions and 6 individual sessions.~Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone for treating participants with both opioid use disorder (OUD) and chronic pain. POD allows titration of buprenorphine or buprenorphine/naloxone dosing up to 32mg/day, split into four doses per day, based on the participant's pain level."
62070531|NCT04334421||Mesh group|After resection, pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) and covered with subcutaneous flap.
62070532|NCT03780270|ACTIVE_COMPARATOR|Control|"Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application at Day 0 and Day180.~=\> Group: Fluoride Varnish"
62070533|NCT03780270|EXPERIMENTAL|Test1|"Single application of Curodont Repair (P11-4) at Day 0 followed by a Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application. Another fluoride Varnish application at Day180.~=\> Group: Curodont Repair + Fluoride Varnish"
62275393|NCT05531669|EXPERIMENTAL|Study group|the study group will receive 12 months of Play Project + Parental Education intervention
62275394|NCT05531669|ACTIVE_COMPARATOR|control group|the control group will receive Parental Education intervention in the first 6 months, and then receive Play Project + Parental Education intervention in the next 6 months
62638959|NCT02447419|EXPERIMENTAL|Gefitinib|Gefitinib 250 mg will be administered orally daily
62638960|NCT03744897|EXPERIMENTAL|Hypnotic analgesia|"Intervention:~- Subjects will receive hypnotic analgesia"
62275395|NCT05357300|ACTIVE_COMPARATOR|Peripheral Nerve Stimulation|Implant of percutaneous leads and impulse generator for peripheral nerve stimulation
62275396|NCT05357300|NO_INTERVENTION|Best Medical Treatment|Physical therapy and therapy with analgetic medication
62275397|NCT01871454|EXPERIMENTAL|radiotherapy (SABR) plus pentoxifylline|standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
62275398|NCT05462431|EXPERIMENTAL|web-based deep relaxation exercise intervention|
62275399|NCT05462431|NO_INTERVENTION|control|
62275400|NCT04123899|EXPERIMENTAL|IGAD→GSTD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
62275401|NCT04123899|EXPERIMENTAL|GSTD→IGAD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
62275402|NCT01463098|EXPERIMENTAL|Part A: E2006 1.0 mg|
62275403|NCT01463098|EXPERIMENTAL|Part A: E2006 2.5 mg|
62275404|NCT01463098|EXPERIMENTAL|Part A: E2006 5.0 mg|
62275405|NCT01463098|EXPERIMENTAL|Part A: E2006 10.0 mg|
62275406|NCT01463098|EXPERIMENTAL|Part A: E2006 25.0 mg|
62275407|NCT01463098|EXPERIMENTAL|Part A: E2006 50.0 mg|
62275408|NCT01463098|EXPERIMENTAL|Part A: E2006 100 mg|
62275409|NCT01463098|EXPERIMENTAL|Part A: E2006 200 mg|
62638961|NCT03744897|EXPERIMENTAL|a-tDCS|"Intervention: transcranial direct current stimulation - tDCS~* active tDCS stimulation~* montage: bilateral DLPFC anodal/left and cathodal/right~* current:2 milliamps~* time: 20 minutes"
62638962|NCT03744897|SHAM_COMPARATOR|s-tDCS|"Sham comparator: transcranial direct current stimulation - tDCS~* sham tDCS stimulation~* montage: bilateral DLPFC anodal/left and cathodal/right~* current: 0 milliamps~* time: 20 minutes"
62275410|NCT01463098|EXPERIMENTAL|Part B: Zolpidem 10 mg|
62275411|NCT01463098|EXPERIMENTAL|Part B: E2006 Matched Placebo or Zolpidem Matched Placebo|
62638963|NCT03744897|EXPERIMENTAL|Hypnotic analgesia + a-tDCS|"Intervention:~* hypnotic analgesia~* active tDCS stimulation~* montage: bilateral DLPFC anodal/left and cathodal/right~* current:2 milliamps~* time: 20 minutes"
62638964|NCT01493245|EXPERIMENTAL|JNS020QD|
62070534|NCT03780270|EXPERIMENTAL|Test2|"Single application of Curodont Repair (P11-4) at Day 0. Curodont Protect (tooth gel containing P11-4 matrix) is handed out and subjects are asked to apply it 2x weekly at home after regular teeth cleaning in the evening for the whole study period (Day 360).~=\> Group: Curodont Repair + Curodont Protect"
62070535|NCT03648593|EXPERIMENTAL|behavioral|work recovery intervention
62454644|NCT03342495|OTHER|Usual Care Arm|"Youth will receive usual care from their pediatric clinics in preparation and transfer to adult care.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences."
62454645|NCT06162923|NO_INTERVENTION|Control group|
62454646|NCT06162923|EXPERIMENTAL|On-site video group|
62454647|NCT06162923|EXPERIMENTAL|Remote video group|
62638965|NCT06392035|NO_INTERVENTION|Control Group|No intervention will be made to the participants in the control group. A pre-test will be administered before the study and a post-test will be administered after the study.
62070536|NCT03648593|EXPERIMENTAL|waiting list control|work recovery intervention after 6 months
62275412|NCT01463098|EXPERIMENTAL|Part A: E2006 Matched Placebo|
62275413|NCT01463098|EXPERIMENTAL|Part B: E2006 2.5 mg|
62275414|NCT01463098|EXPERIMENTAL|Part B: E2006 10 mg|
62070537|NCT04258085||Screening plus EMR|Individuals in this group are those residing in districts where health facilities have implemented a breast cancer screening program integrated with cervical cancer screening, the Women's Cancer Early Detection Program (WCEDP).
62275415|NCT01463098|EXPERIMENTAL|Part B: E2006 25 mg|
62275416|NCT03404011|EXPERIMENTAL|Propylene glycol and Glycerol intake|One gram intake of a Propylene glycol/Glycerol mix (50:50)
62454648|NCT01434966|EXPERIMENTAL|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
62638966|NCT06392035|EXPERIMENTAL|Intervention Group|"Secondary schools located in Karaman city center will be visited. The researcher will introduce himself and explain the purpose of the research.~A research inclusion form will be applied to those who agree to participate in the research.~Sociodemographic Data Form, Nutrition Behavior Scale, Parental Questionnaire and Tool for Measuring the Health Promotion Model Related to Breakfast Consumption will be applied as pre-test forms to the participants who meet the inclusion criteria. Participants will be assigned randomization by someone other than the researcher. After randomization assignment, a 6-week web-based training based on PENDER's Health Promotion Model, prepared in line with the literature, will be applied."
62275417|NCT03404011|PLACEBO_COMPARATOR|Mimicking intake|Mimicking Propylene glycol/Glycerol intake with the device turns off
62638967|NCT01800045|EXPERIMENTAL|Pitolisant|Pitolisant at 5, 10, 20 or 40mg
62638968|NCT01800045|PLACEBO_COMPARATOR|Placebo|Capsules of placebo containing lactose
62638969|NCT05970250|EXPERIMENTAL|Whole body vibration group|In this group (the first study group) fifteen breast cancer patients after receiving chemotherapy within 3-6 months and complaining from osteoporosis were received the whole body vibration, 20 minutes 3 times per week for 2 months and drug therapy (vitamin D supplements and calcium).
62070538|NCT01442272|NO_INTERVENTION|Habitual medication withuot additional|
62070539|NCT01442272|ACTIVE_COMPARATOR|Habitual medication plus Hidroferol®|
62275418|NCT01791608|ACTIVE_COMPARATOR|Zinc sulphate|Preschool children healthy enrolled in FAN Foundation of Medellin, which will be supplied with zinc sulphate
62275419|NCT01791608|EXPERIMENTAL|Zinc Amino Acid Chelate|Preschool children healthy enrolled in FAN Foundation of Medellin , which will be supplied with zinc amino acid chelate
62454649|NCT01434966|EXPERIMENTAL|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
62638970|NCT05970250|EXPERIMENTAL|Weight bearing exercises group|In this group (the second study group) fifteen breast cancer patients after receiving chemotherapy within 3-6 months and complaining from osteoporosis were received aerobic exercise on treadmill as form of weight bearing exercise 20 minutes 3 times per week for 2 months and drug therapy (vitamin D supplements and calcium).
62638971|NCT05970250|OTHER|drug therapy group|In this group (control group) fifteen breast cancer patients after receiving chemotherapy within 3-6 months and complaining from osteoporosis were received only drug therapy (vitamin D supplements and calcium. Measurements were conducted before starting the treatment as a first record, at end of the second month of treatment as second record and make follow up after 3 months as final record.
62638972|NCT03160391|EXPERIMENTAL|Music Training|Music Training
62638973|NCT03160391|ACTIVE_COMPARATOR|Dance Training|Dance Training
62638974|NCT03160391|NO_INTERVENTION|Passive control group|Passive control group
62638975|NCT02799147|EXPERIMENTAL|280 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.
62638976|NCT02799147|EXPERIMENTAL|200 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv
62638977|NCT02799147|EXPERIMENTAL|140 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4: Bendamustine 70 mg/m2/day iv.
62638978|NCT02731300|ACTIVE_COMPARATOR|Active tDCS|2 mA of cathodal tDCS placed over M1 for 20 mins
62275420|NCT01791608|PLACEBO_COMPARATOR|Milk without fortification|Milk without zinc
62275421|NCT03754309|EXPERIMENTAL|KY1005 lower dose|Low dose KY1005
62275422|NCT03754309|EXPERIMENTAL|KY1005 higher dose|High dose KY1005
62275423|NCT03754309|PLACEBO_COMPARATOR|Placebo|Matched placebo
62275424|NCT03445078|ACTIVE_COMPARATOR|A|Participants will be administered firstly selenium-rich corn powder 20g/d for 1 month and ordinary corn powder 20g/d for another month subsequently with a month washout period.
62638979|NCT02731300|SHAM_COMPARATOR|Sham tDCS|0 mA of sham tDCS placed over M1 for 20 mins
62070540|NCT01442272|ACTIVE_COMPARATOR|Habitual medication plus Zemplar®|
62070541|NCT04597502|PLACEBO_COMPARATOR|Oral Placebo, Topical Placebo|Oral Placebo, Topical Placebo on both forearms and dorsal hands
62070542|NCT04597502|EXPERIMENTAL|Oral Placebo, Topical TC|Oral Placebo, Topical TC on both forearms and dorsal hands
62070543|NCT04597502|EXPERIMENTAL|Oral TC, Topical Placebo|Oral TC, Topical Placebo on both forearms and dorsal hands
62070544|NCT04597502|EXPERIMENTAL|Oral TC, Topical TC|Oral TC, Topical TC on both forearms and dorsal hands
62070545|NCT01033292|EXPERIMENTAL|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
62638980|NCT04295577||Cohort 1: Retrospective Cohort|"This cohort will include:~* Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib but in whom quality of life data are not available.~* Patients who have previously commenced Niraparib prior to the MONITOR Study opening at the site but are now deceased but will be eligible for retrospective data collection without the need for informed consent.~* Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site but have discontinued treatment.~* Data in respect of AEs, SAEs, ADRs and AESIs will be recorded in Case Report Forms and be identified via the patient's medical records. There is no requirement to complete trial specific SAE reporting forms in this cohort."
62638981|NCT04295577||Cohort 2: Prospective Cohort|"This cohort will include:~* Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib and in whom quality of life data is available.~* Patients who are due to commence maintenance Niraparib treatment."
62638982|NCT02931760|ACTIVE_COMPARATOR|subcutaneous pacemaker|The patients who are randomized to receive a subcutaneously implanted pacemaker
62070546|NCT03767985|ACTIVE_COMPARATOR|Occlusion therapy|Participants are prescribed 2 hours of occlusion therapy per day, 7 days a week.
62070547|NCT03767985|EXPERIMENTAL|Dichoptic video game therapy|Participants receive dichoptic video game therapy: 1 hour per week at the out-patient clinic under direct supervision.
62454650|NCT01434966|EXPERIMENTAL|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
62454651|NCT00497796|EXPERIMENTAL|1|
62454652|NCT00497796|ACTIVE_COMPARATOR|2|
62454653|NCT01705873||LPV/r|LPV/r based HAART
62454654|NCT01705873||Efavirenz|EFV first line based HAART
62454655|NCT04940455|EXPERIMENTAL|Educational digital platforms|"Nursing students from the Experimental Group (GE), will participate in educational activities made available on digital platforms on nursing care for patients with signs and symptoms of sepsis"
62454656|NCT04940455|ACTIVE_COMPARATOR|High-Fidelity Simulation|Nursing students in the Control Group (GC) will be exposed to high-fidelity simulation in the intensive care setting, where they must solve situations and procedures related to the nurse's performance in recognizing the signs and symptoms of sepsis.
62454657|NCT01725451|EXPERIMENTAL|Testosterone Unshaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each unshaved axilla in 1 of 6 treatment periods.
62454658|NCT01725451|EXPERIMENTAL|Testosterone Unshaved + Deodorant Spray|Deodorant spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
62454659|NCT01725451|EXPERIMENTAL|Testosterone Unshaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
62454660|NCT01725451|EXPERIMENTAL|Testosterone Unshaved + Deodorant Antiperspirant Stick|Deodorant antiperspirant combination stick applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
62454661|NCT01725451|EXPERIMENTAL|Testosterone Shaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each shaved axilla in 1 of 6 treatment periods.
62454662|NCT01725451|EXPERIMENTAL|Testosterone Shaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to shaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
62454663|NCT01569451|ACTIVE_COMPARATOR|(Placebo and) Glatiramer Acetate|Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
62070548|NCT05281003|EXPERIMENTAL|Pembrolizumab + Chemo|"Neoadjuvant setting (Pembrolizumab in combination with chemotherapy): Up to 4 cycles concurrent administrations of (1) Paclitaxel, which are administrated intravenously at 150 mg/m\^2 dosage on Day 1 of each 3-week cycle; (2) Cisplatin, which are administrated intravenously at 80 mg/m\^2 dosage on Day 1 of each 3-week cycle; (3) Pembrolizumab, which are administrated intravenously at 200 mg dosage on Day 1 of each 3-week cycle.~Adjuvant setting (Pembrolizumab in combination with chemotherapy): All participants who are assessed as ineligible or unnecessary for surgery after neoadjuvant treatment may be eligible for up to an additional 17 cycles (approximately 1 year) of Pembrolizumab treatment in combination with chemotherapy."
62070549|NCT03331627|ACTIVE_COMPARATOR|STR001-IT/STR001-ER|
62070550|NCT03331627|ACTIVE_COMPARATOR|STR001-IT/STR001-ER Placebo|
62070551|NCT03331627|PLACEBO_COMPARATOR|STR001-IT placebo/STR001- ER placebo|
62638983|NCT02931760|ACTIVE_COMPARATOR|intramuscular pacemaker|The patients who are randomized to receive an intramuscular implanted pacemaker
62638984|NCT03984084||externally recruited participants|Self-referred affected and non-affected participants responding to advertisements
62070552|NCT04878016|EXPERIMENTAL|ZKAB001＋carboplatin+etoposide|"The induction phase will consist of four cycles of ZKAB001 plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, patients will receive drug infusions in the following order:~ZKAB001 → carboplatin → etoposide"
62070553|NCT04878016|PLACEBO_COMPARATOR|placebo + carboplatin + etoposide|"The induction phase will consist of four cycles of placebo plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, all eligible patients will receive drug infusions in the following order:~placebo → carboplatin → etoposide"
62070554|NCT01440127|EXPERIMENTAL|Metformin|Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
62070555|NCT01440127|NO_INTERVENTION|Observation|No metformin will be given prior to the scheduled surgery or biopsy.
62638985|NCT03984084||In-house patients|Patients seeking treatment in the outpatient clinic of the Max-Planck-institute of Psychiatry
62070556|NCT03470714|EXPERIMENTAL|Kinesiotaping Group|The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
62070557|NCT03470714|ACTIVE_COMPARATOR|Control group|The group in which the participants only perform the the force irradiation experiment.
62454664|NCT01569451|EXPERIMENTAL|Rituximab and Glatiramer Acetate (R-GA)|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
62454665|NCT03699267||UBR TRAM / GBA|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
62638986|NCT04534998|EXPERIMENTAL|Robotic-assisted partial nephrectomy|Partial nephrectomy will be performed using a robotic-assisted laparoscopic approach.
62454666|NCT03699267||UBR TRAM / GBA + TAP|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
62454667|NCT03699267||M + UBR TRAM / GBA|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
62454668|NCT03699267||M + UBR TRAM / GBA + TAP|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
62454669|NCT00855842|EXPERIMENTAL|osmotic dilator|osmotic dilator
62454670|NCT04079907|EXPERIMENTAL|Ketone|This arm will receive a supplement with 25g ketone ester. It is a commercially available supplement and will be provided as a standard dose.
62454671|NCT04079907|PLACEBO_COMPARATOR|Placebo|This arm will receive an isocaloric supplement.
62454672|NCT02847806|EXPERIMENTAL|Estradiol|dosage used in the study: 1 patch / 3-4 days dosed at 25, 37.5 or 50 mg / 24h titration according to the plasma level, with the objective of a physiological level of estradiol (25-40 pg / ml ) - During 4 weeks
62454673|NCT02847806|EXPERIMENTAL|Testosterone|dosage used : from 25 to 75 mg / day of testosterone (ie 2.5 to 7.5 g / day transdermal gel) according to the plasma level, with the goal of a physiological level of testosterone (5-8 ng / ml) - During 4 weeks
62454674|NCT02847806|EXPERIMENTAL|Testosterone + Estradiol|Testosterone + Estradiol During 4 weeks
62638987|NCT04534998|ACTIVE_COMPARATOR|Open partial nephrectomy|Partial nephrectomy will be performed using an open retroperitoneal approach.
62638988|NCT04010409||ASD Group|Autism spectrum disorder participants, no intervention
62638989|NCT04010409||TD Group|Typically developmental controls,no intervention
62638990|NCT03215069|EXPERIMENTAL|Empagliflozin|Empagliflozin 10 mg PO daily
62638991|NCT03215069|PLACEBO_COMPARATOR|Placebo|Matched placebo PO daily
62070558|NCT03350659|EXPERIMENTAL|Atomoxetine|Atomoxetine 18mg once a day.
62070559|NCT03350659|ACTIVE_COMPARATOR|Midodrine|midodrine 2.5mg twice a day (increase to 5mg three times a day if necessary)
62275425|NCT03445078|PLACEBO_COMPARATOR|B|Participants will be administered firstly ordinary corn powder 20g/d for 1 month and selenium-rich corn powder 20g/d for another month subsequently with a month washout period.
62638992|NCT00619788|EXPERIMENTAL|1|Patients receiving 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use
62638993|NCT03212040|ACTIVE_COMPARATOR|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
62638994|NCT03212040|ACTIVE_COMPARATOR|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
62638995|NCT03428334|EXPERIMENTAL|Oral roflumilast|oral roflumilast 500 microgram daily for 4 weeks
62638996|NCT01151306|PLACEBO_COMPARATOR|Lactose tablet|
62070560|NCT05240833|EXPERIMENTAL|VExUS-Guided Arm|VExUS results will be available for the treating physician. Patients will be treated according to current clinical practice. The use of diuretic and diuretic dosage will depend on treating physician's criteria.
62070561|NCT02319733|EXPERIMENTAL|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
62070562|NCT00235443|EXPERIMENTAL|1|Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day
62070563|NCT06109506||Patients with diverticular abscess classified as Hinchey 2b (Subgroup)|
62070564|NCT06109506||Patients with diverticular abscess >5 cm (Subgroup)|
62070565|NCT03609125|EXPERIMENTAL|CBS eyedrop|The product is prepared from cord blood serum (CBS) analyzed in advance with regard to the content of specific neurotrophic growth factors.
62070566|NCT00734214|EXPERIMENTAL|0.9% NaCl|
62070567|NCT00734214|ACTIVE_COMPARATOR|0.45% NaCl|
62275426|NCT04536883|EXPERIMENTAL|Microscopy confocal|"The fibroscopy is carried out according to the usual procedure of the service. During the fibroscopy, for all patient, the confocal microscopy procedure begins.~After the end of confocal procedure, 5 to 6 transbronchial biopsies are performing"
62275427|NCT05665270|EXPERIMENTAL|Dextenza|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8).
62275428|NCT05665270|ACTIVE_COMPARATOR|Prednisolone Acetate|Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.
62275429|NCT04555122|EXPERIMENTAL|Intervention Group|Advertisements will be sent to participants to attempt to increase adherence to stay-at-home orders and social distancing. There are 3 types of advertisements. This will occur for 7 days.
62275430|NCT04555122|NO_INTERVENTION|Control Group|Control Group will be people who will not receive any advertisements.
62275431|NCT04696588|EXPERIMENTAL|Kinesiotherapy group|This is the group (n=59) receives treatment i.e complex set of neck exercises and massage
62454675|NCT04670432|EXPERIMENTAL|Treatment group|Hydroxyethylrutoside oral tablet twice daily for 8 weeks starting at the time of randomization, in addition to usual care.
62638997|NCT01151306|ACTIVE_COMPARATOR|Simvastatin 20mg|
62638998|NCT04022330|OTHER|Blood sampling|
62638999|NCT03612466|EXPERIMENTAL|Dose Escalation Arm|"Dose Levels 1-3 will consist of treatment with radiopharmaceutical (153Sm-DOTMP) alone. If the maximally tolerated dose (MTD) has not been reached at Level 3, external beam radiotherapy will be added to each of Levels 4-6. Participants enrolled on Dose Levels 4-6 will be treated with external beam radiotherapy to all radiographically evident sites of disease. If an MTD has not been determined at Level 6, the study will end and Dose Level 6 will be declared the Recommended Phase 2 Dose.~Participants will be given prophylactic / supportive treatment protocols including Calcium Carbonate, mozobil, and neupogen injectable product."
62639000|NCT03117634|ACTIVE_COMPARATOR|Fixed dosing group (2Q8)|Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.
62639001|NCT03117634|EXPERIMENTAL|Treat and Extend group (T&E)|Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and indocyanine green angiography (ICGA). Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.
62639002|NCT04065243|ACTIVE_COMPARATOR|Control group|Subjects in this group will have a daily energy intake equivalent of 100 % of their calculated normal daily energy intake.
62639003|NCT04065243|EXPERIMENTAL|Overfed group|Subjects in this group will have a daily energy intake equivalent of 150 % of their calculated normal daily energy intake.
62639004|NCT01635660|ACTIVE_COMPARATOR|C-MAC System|
62639005|NCT01635660|ACTIVE_COMPARATOR|AP Advance|
62639006|NCT01635660|ACTIVE_COMPARATOR|King Vision|
62639007|NCT00941850|EXPERIMENTAL|Triple site CRT|These patients will continue to receive CRT via existing device but will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced
62639008|NCT00941850|NO_INTERVENTION|Optimised medical and device therapy|These patients will receive optimised medical and device therapy.
62639009|NCT04685993|EXPERIMENTAL|Treatment A|LPCN 1144
62639010|NCT04583605||PREVENA|A vacuum wound closure therapy like PREVENA is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
62639011|NCT04583605||NON PREVENA|A conventional wound closure is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
62639012|NCT05897242|EXPERIMENTAL|Arm I (Act on Vaping app)|Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.
62639013|NCT05897242|ACTIVE_COMPARATOR|Arm II (Incentivized text message check-ins)|Participants receive incentivized text messages check-ins assessing their vaping status.
62275432|NCT04696588|NO_INTERVENTION|Waiting List group|Individuals registered in the waiting list for receiving the treatment specified for kinesiotherapy group (n=59).These patients receive no treatment for tinnitus.
62639014|NCT05800756|EXPERIMENTAL|cohort 1|patients with stage II-III HR+/HER2+ breast cancer
62275433|NCT01100944|EXPERIMENTAL|Therapy in Thymic Malignancies|PXD101 (Belinostat) will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression. A conventional 3+3 dose escalation design was used with up to 3 additional patients added if one patient exhibited a dose limiting toxicity (DLT). Dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT.
62454676|NCT04670432|NO_INTERVENTION|Control group|Usual care, consisting of anticoagulant treatment and elastic compression therapy for full study duration.
62639015|NCT03303495|EXPERIMENTAL|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1; l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1; 5-FU - bolus 400 mg/m2 IV bolus Day 1; 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
62639016|NCT03303495|EXPERIMENTAL|CPT-11 +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1
62070568|NCT05464576|OTHER|Comparison between MRI versus anatomopathology report in bladder cancer|Comparison of MRI and anatomopathology on urinary bladder tumour after transurethral resection of the bladder or cystectomy (for patients with an invasive bladder cancer.
62275434|NCT00948870|EXPERIMENTAL|Shugan Decoction|
62275435|NCT00948870|PLACEBO_COMPARATOR|low does of Shugan decoction|
62454677|NCT01385033|EXPERIMENTAL|Part I, Healthy Elderly (HE) and AD Participants|HE and AD participants will receive a single intravenous (IV) dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part I of the study
62639017|NCT04089254|ACTIVE_COMPARATOR|Inpatient Psychiatry|Child and adolescent inpatient treatment
62639018|NCT04089254|ACTIVE_COMPARATOR|Outpatient Crisis Intervention Clinic|OCIC is outpatient crisis intervention clinic
62639019|NCT03906812|ACTIVE_COMPARATOR|Unmonitored floor admission|Participants in this arm will be admitted to an unmonitored floor bed.
62639020|NCT03906812|ACTIVE_COMPARATOR|Floor admission with telemetry|Participants in this arm will be admitted to a telemetry bed.
62639021|NCT03177148|ACTIVE_COMPARATOR|Usual Care|"* 1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar~* NO active enrollment of parents~* Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
62639022|NCT03177148|EXPERIMENTAL|Intervention by Clinicians|"* Pediatric Clinicians complete surveys during enrollment and end of the intervention~* 1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.~* Enroll 35 eligible parents per practice~* Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.~Dietitians will provide up to 6 telephone counseling sessions.~•Parents will complete surveys after enrollment and at the end of intervention"
62070569|NCT04959149|EXPERIMENTAL|face-to-face intubation|intubation approach from front of the patient
62639023|NCT04767464|OTHER|Compass Course|Virtual Compass Course
62639024|NCT04828031|EXPERIMENTAL|Vitamin D 50,000 IU PO every week|Vitamin D 50,000 IU PO every week for 12 weeks
62639025|NCT02277028|EXPERIMENTAL|Bilateral Priming|"Bilateral priming a priming technique which is non-invasive and free of side effects. The technique described in this study uses bilateral, symmetrical, rhythmic movement bilateral priming and its purpose is to ready the motor cortex for functional limb training. A rocker is used so that the less affected limb can drive the affected one in symmetrical wrist flexion and extension.~There are 2 parts to this behavioral intervention. Bilateral priming and task specific training Dosage: 15 minutes of bilateral priming per day 3/days per week for 5/wks. Also 45 minutes of task specific training is delivered 3/days per week for 5/wks. The total of 30 hours of a combination of bilateral priming and task specific training can be completed within 6 weeks.~Dosage frequency 2 times per day. Dosage type: Research participant must perform activities with hands as directed by an occupational therapist"
62639026|NCT02277028|ACTIVE_COMPARATOR|Health Education|"The group with no priming will receive stroke related health education via a website from the American Heart Association (15 minutes). They will use their affected hand (as they are able) This will be followed by 45 minutes of the same task specific arm training protocol described in the bilateral priming group. This group will follow the same schedule as experimental.~There are 2 parts to this behavioral intervention. Computerized health education training and task specific training Dosage: 15 minutes of health education per day 3/days per week for 5/wks. Also 45 minutes of task specific training is delivered 3/days per week for 5/wks. A total of 30 hours of a combination of computerized stroke health education and task specific training can be completed within 6 weeks.~Dosage frequency 2 times per day. Dosage type: Research participant must perform computerized health education activities with hands as well as task specific training directed by an occupational therapist"
62639027|NCT03535961|OTHER|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
62639028|NCT00879801||Subjects with IGR|Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
62639029|NCT02500316|EXPERIMENTAL|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
62639030|NCT02374320|EXPERIMENTAL|Exparel|20 mL liposomal bupivacaine injected once
62070570|NCT04959149|ACTIVE_COMPARATOR|standard position intubation|intubation approach from behind the head of the patient
62070571|NCT05505253|ACTIVE_COMPARATOR|Alfacalcidol|Alfacalcidol 0.5 mcg orally given for 3 months
62070572|NCT05505253|PLACEBO_COMPARATOR|Control|Placebo given orally for 3 months
62070573|NCT03771157|EXPERIMENTAL|Shingrix shingles vaccine treatment|On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
62070574|NCT02318719|PLACEBO_COMPARATOR|Placebo|Placebo (14-weeks)
62070575|NCT02318719|EXPERIMENTAL|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
62070576|NCT02318719|EXPERIMENTAL|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
62070577|NCT02318719|EXPERIMENTAL|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
62070578|NCT01296490|EXPERIMENTAL|Stress test|The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
62070579|NCT02569450||Intervention arm|Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
62070580|NCT02569450||Hospitals in control arm|Hospitals randomly assigned to the control arm without surgical outcome monitoring
62070581|NCT03329820||1 Uncomplicated CHB|Patients with chronic CHB infections but normal liver function and without cirrhosis or hepatocellular carcinoma
62639031|NCT05695742||Active smokers|Having smoked at least 1 cigarette per day for at least 2 years.
62639032|NCT05695742||Pasive smokers|Being exposed to secondhand smoke for more than 15 minutes at home, school, office or anywhere in the past year, once a week.
62070582|NCT03329820||2 CHB with impaired liver function (LF) or CC w/o tx|CHB with impaired liver function or compensated cirrhosis, not on anti-viral treatment
62070583|NCT03329820||3 CHB with impaired LF or CC with tx|CHB with impaired liver function or compensated cirrhosis, on anti-viral treatment.
62070584|NCT03329820||4 Decompensated cirrhosis|Patients with CHB infection and cirrhosis complicated by one or more of the following: variceal bleeding, hepatic encephalopathy or ascites.
62070585|NCT03329820||5 Hepatocellular carcinoma|Patients with confirmed diagnosis of hepatocellular carcinoma
62070586|NCT06155084|EXPERIMENTAL|Part 1 - Dose Escalation, 400mg/d (Cohort1)|Oral tablet(s), once daily in 28-day cycles
62070587|NCT06155084|EXPERIMENTAL|Part 1 - Dose Escalation 500mg/d (Cohort 2)|Oral tablet(s), once daily in 28-day cycles
62639033|NCT05695742||Non-smokers|Not being an active or passive smoker.
62639034|NCT04238377|ACTIVE_COMPARATOR|Stellate Group|will receive pre-operative ultrasound guided stellate ganglion block one hour before surgery and multimodal analgesia and will be followed for 6 months for neuropathic pain as the Stellate Group
62639035|NCT04238377|PLACEBO_COMPARATOR|Control Group|will receive multimodal analgesia only and will be followed for 6 months for neuropathic pain as the control Group
62070588|NCT06155084|EXPERIMENTAL|Part 2 - Dose Expansion Oral tablet(s)|Oral tablet(s), once daily in 28-day cycles
62070589|NCT06211387|EXPERIMENTAL|Resistance exercise + joint mobilization|
62070590|NCT06211387|ACTIVE_COMPARATOR|Resistance Exercise|
62639036|NCT04419857|EXPERIMENTAL|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
62639037|NCT04419857|NO_INTERVENTION|Standard calorie formula|Infant randomly assigned to standard-calorie formula for 14 days
62639038|NCT00452439|ACTIVE_COMPARATOR|Actonel|Actonel (Risedronate) + Vitamin D + Calcium
62639039|NCT00452439|PLACEBO_COMPARATOR|Placebo|Placebo + Vitamin D + Calcium
62639040|NCT04846270|EXPERIMENTAL|Investigational Device|TENA SmartCare Change Indicator
62639041|NCT06532981||Ambulatory children with spastic CP|Ambulant children with cerebral palsy between 6 and 17 years old with a consistent gait pattern. They have prescribed ankle-foot orthoses by the medical team as part of the standard care.
62639042|NCT02371681|EXPERIMENTAL|1|TB drugs
62639043|NCT05504096|OTHER|Single-Arm: Healthy Participants|All participants will be administered with the In-Ear and Wearable devices concurrently for 8 minutes while the application records the readings from the devices. Participants with the first glucometer reading of less than 11.1 mmol/L will be required to return one-hour post sugary drink consumption for a second reading with both devices.
62639044|NCT00575354|ACTIVE_COMPARATOR|1|Sevoflurane: induction 3-6%, maintenance 2-3%
62639045|NCT00575354|ACTIVE_COMPARATOR|2|Isoflurane: induction 3-6%, maintenance 2-3%
62639046|NCT02525016|EXPERIMENTAL|assessment of plasmatic lidocaine rate|Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
62639047|NCT01919164|PLACEBO_COMPARATOR|Placebo|Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
62639048|NCT01919164|EXPERIMENTAL|Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles|Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
62639049|NCT01919164|EXPERIMENTAL|Sprifermin (AS902330) 30 mcg- 4 Cycles|Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
62639050|NCT01919164|EXPERIMENTAL|Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
62639051|NCT01919164|PLACEBO_COMPARATOR|Sprifermin (AS902330) 100 mcg- 4 Cycles|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
62639052|NCT04751760||People with sensitization or allergy|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
62639053|NCT02821494|EXPERIMENTAL|Hespecta|Four dose groups of Hespecta
62070591|NCT02380508|EXPERIMENTAL|Group 1|32 BCG-naïve subjects receiving BCG SSI or BCG Sii at standard dose (2-8x10\^5 cfu) via Intradermal route.
62070592|NCT02380508|EXPERIMENTAL|Group 2|8-16 control volunteers receiving no vaccination.
62070593|NCT02859467|EXPERIMENTAL|Kinesio Taping and Inhibitory Treatment Techniques|"During each session participants will receive the application kinesio taping in trapezius, infraspinatus and paravertebral muscles.~Inhibitory Treatment Techniques:~* Release Technique of the trapezius muscle.~* Release Technique for scalene muscles.~* Technique suboccipital inhibition.~* Technique hands crossed for induction dorsal superficial fascia."
62070594|NCT02859467|ACTIVE_COMPARATOR|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
62454678|NCT01385033|EXPERIMENTAL|Part II, Healthy Young, HE and AD Participants|Healthy Young, HE and AD participants will receive a single IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part II of the study
62639054|NCT02204670||Overweight Adolescents Performing Resistance Training|Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period. Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training. This will be the primary exposure variable. After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks. During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
62639055|NCT05271565|EXPERIMENTAL|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
62639056|NCT05271565|ACTIVE_COMPARATOR|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
62639057|NCT02457195|EXPERIMENTAL|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
62070595|NCT03523182|EXPERIMENTAL|Spirulina (SP)|Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.
62070596|NCT03523182|ACTIVE_COMPARATOR|Control (CON)|Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.
62070597|NCT03675074|EXPERIMENTAL|Treatment|A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device.
62070598|NCT01781260||Young. Fit. Minor neurosurgical operation. Prone position.|18-65 year old patients, without serious medical co-morbidities (assessed as ASA I/II status) who are having minor to moderate severity neurosurgical operations in the prone position.
62070599|NCT05928715|EXPERIMENTAL|Experimental group|It is the group that will receive breast milk or formula by finger feeding.
62454679|NCT01385033|EXPERIMENTAL|Part III, Participants with aMCI|Participants with aMCI will receive a single IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part III of the study
62639058|NCT03248869|ACTIVE_COMPARATOR|Current Daily Survey|need description
62454680|NCT01977469|EXPERIMENTAL|Low intensity resistance training|Low intensity resistance training + aerobic training
62639059|NCT03248869|EXPERIMENTAL|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
62070600|NCT05928715|NO_INTERVENTION|Control group|No Intervention: control group attempt will not be implemented
62070601|NCT02587559|NO_INTERVENTION|Control|usual medical advice regarding symptomatic control and activity modification
62070602|NCT02587559|EXPERIMENTAL|Experimental|Six visits of physical therapy to provide manual therapy and therapeutic exercise
62070603|NCT01696318|NO_INTERVENTION|Educational program|Educational Program with Professional Physical Education, Pharmacist and Nutritionist
62070604|NCT01696318|EXPERIMENTAL|Educational program and individual care|Educational program and individual care with professional Physical Education; Pharmacist and Nutritionist
62454681|NCT01977469|EXPERIMENTAL|High intensity resistance training|High intensity resistance training + aerobic training
62454682|NCT05704556|EXPERIMENTAL|Cohort 1: Severe Renal Impairment|Participants will receive a single dose of VX-548 in a fasted state.
62454683|NCT05704556|EXPERIMENTAL|Cohort 2: Matched Healthy Participants|Healthy participants matched to cohort 1 will receive a single doses of VX-548 in a fasted state.
62275436|NCT02995616|EXPERIMENTAL|Lokomat training|Patients will be tested in 3 Lokomat training sessions on 3 separate days. During the first session patients will walk in the Lokomat according to their regular therapy settings. During the second and third session patients will walk in the Lokomat with 2 different levels of guidance force (100% guidance force and 60% guidance force).
62454684|NCT05704556|EXPERIMENTAL|Cohort 3: Moderate Renal Impairment|Participants will receive a single dose of VX-548 in a fasted state.
62454685|NCT05704556|EXPERIMENTAL|Cohort 4: Matched Healthy Participants|Healthy participants matched to cohort 3 will receive a single dose of VX-548 in a fasted state.
62639060|NCT05385198|EXPERIMENTAL|VOICE care|"The VOICE conversations contain minimal 5 consecutive conversations with parents. The conversations are not rigid or strictly protocolized but rather focus on issues related to the situation of the admission period of the infant and the conversations should be individualized based on the parent needs. Thus, depending on the situation of the infant and the home situation of the parents.~The content of the VOICE conversations is built up based on the admission pathway of the infant. Every VOICE conversation has its own focus, and these are presented in the 5 VOICE conversation guides. Basically, every VOICE conversation is about the support of parents and infant.~The principles of the VOICE conversations are Values, Opportunities, Integration, Control and Evaluation. The VOICE program focuses on a systematic and planned communications with parents during the NICU admission and follow-up 2-4 weeks after NICU discharge."
62070605|NCT05261503|EXPERIMENTAL|Homeostasis-Enrichment-Plasticity|HEP group will receive an environmental enrichment-based intervention.
62070606|NCT05261503|EXPERIMENTAL|Traditional Physical Therapy|TPT group will receive traditional physiotherapy intervention.
62070607|NCT00240526|EXPERIMENTAL|Engerix 4D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
62070608|NCT00240526|EXPERIMENTAL|Engerix 3D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
62070609|NCT00240526|EXPERIMENTAL|Engerix 4D|Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, 6 and 60.
62070610|NCT00240526|EXPERIMENTAL|Engerix 3D Group|Subjects received Engerix™ (hepatitis B vaccine \[HBV\]) at Month 0, 1, and 6.
62070611|NCT06488521|EXPERIMENTAL|"Complarate (JSC GENERIUM, Russia)"|tocilizumab biosimilar
62070612|NCT06488521|ACTIVE_COMPARATOR|Actemra® (F. Hoffmann-La Roche Ltd., Switzerland)|tocilizumab
62275437|NCT02361216|EXPERIMENTAL|Ingenol mebutate gel|Treatment once daily for 3 days
62070613|NCT05859633||patients with acute pancreatitis|any patient suffers from acute pancreatitis
62275438|NCT02361216|PLACEBO_COMPARATOR|Vehicle|Treatment once daily for 3 days
62275439|NCT01889979|EXPERIMENTAL|Tramadol|100 mg of tramadol SC (single dose) = 2 mL
62275440|NCT01889979|PLACEBO_COMPARATOR|Placebo|2 mL of a sterile solution SC
62275441|NCT04248738|EXPERIMENTAL|SocNSuppR|Inpatient teams systematically provided with information about patients' social needs and supportive resources.
62639061|NCT05385198|NO_INTERVENTION|Standard care|Standard care is defined as the standard family centered care (FCC) practices currently implemented in the NICU. Parents are allowed to visit the NICU for 3 hours every day and provide basic care to their infant. Standard care involves meetings with the doctors three times a week and the content is mainly directed to the medical condition and treatments of the infant. No other meetings between parents and doctors/nurses exists. The FCC principles implicate that parents and NICU staff work closely together on the NICU. This also involves unscheduled information and communication contact moments where short questions of parents will be addressed.
62639062|NCT04422938||Manuel compression|Manuel chest compressions will be handled by clinicians
62070614|NCT04070677|EXPERIMENTAL|Ziverel arm|Patients included will receive treatment with ZIVEREL®, initially 10 mL every 8 hours, 30 minutes after meals, to avoid physical entrainment by food, during a minimum of 8 weeks, recruited during a period of 12 months. The treatment will be indicated when the patient develops a radiation-induced esophagitis of degree ≥ 2.
62070615|NCT05964881|ACTIVE_COMPARATOR|PDS - resorbable suture|Operation through vaginal route, high posterior colpotomy is made towards the posterior cervix. Blunt preparation towards the right Spina ischiadica to visualise right sacrospinous ligament. PDS (0) sutures will be placed through the ligament (ca. 2 cm medial of the spina). This suture will then be placed through the posterior cervical wall, but not yet knotted. First, colpotomy will be closed via 2/0 vicryl, then pre-laid fixation sutures will be tied, whereby the portio will come to lie about 4-6 cm cranial of the level off the vulva towards the sacrospinous ligament.
62639063|NCT04422938||Mechanical compression|Mechanical chest compressions will be handled via mechanical chest compression device
62639064|NCT05026944|EXPERIMENTAL|Group A|Percussive massage and static stretching exercises
62639065|NCT05026944|OTHER|Group B|Static stretching exercises
62639066|NCT03964389|EXPERIMENTAL|Intervetion group|"A sessions of Pain Neuroscience Education (PNE) joint a physical exercises programs"
62639067|NCT03964389|NO_INTERVENTION|Control group|Only a therapeutic physical exercises programs
62275442|NCT00142883|ACTIVE_COMPARATOR|pregabalin|pregabalin compared to placebo
62275443|NCT00142883|PLACEBO_COMPARATOR|Placebo|Placebo compared to pregabalin
62275444|NCT02236455|EXPERIMENTAL|Audio Relaxation technique|Relaxation is a process that decreases the effects of stress on your mind and body. Relaxation techniques can help you cope with everyday stress and with stress related to various health problems, such as cancer and pain.
62275445|NCT02236455|EXPERIMENTAL|Medical Music Intervention|Music intervention is use to assist with relaxation and reduce stress levels in patients.
62275446|NCT02236455|EXPERIMENTAL|Nature Therapy without Music|Ecotherapy is the use of nature to reduce stress and to increase levels of well-being in patients.
62639068|NCT00969228|EXPERIMENTAL|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 or 2-month schedule.
62639069|NCT00969228|PLACEBO_COMPARATOR|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 or 2-month schedule.
62639070|NCT05242237||HCC patients|HCC patients with initial diagnosis
62639071|NCT05242237||Liver cirrhosis patients|Liver cirrhosis patients
62639072|NCT01832337|EXPERIMENTAL|precondition|
62639073|NCT00780975|EXPERIMENTAL|Arm 1|Aplidin (Plitidepsin)
62275447|NCT02236455|EXPERIMENTAL|Nature Therapy with Music|Nature therapy videos were produced with and without music for surgical patients.
62639074|NCT01328964||Children Ages 4-11 with asthma|Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy
62639075|NCT04833777|ACTIVE_COMPARATOR|Lidocaine|Administration of subcutaneous lidocaine as local anesthetic prior to carpal tunnel release (lidocaine intervention)
62639076|NCT04833777|EXPERIMENTAL|Bupivacaine|Administration of subcutaneous bupivacaine + lidocaine as local anesthetic prior to carpal tunnel release (bupivacaine intervention)
62639077|NCT04502446|EXPERIMENTAL|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
62639078|NCT00712452|OTHER|1|systemic lupus erythematosus
62639079|NCT00712452|OTHER|2|breast cancer
62639080|NCT00712452|OTHER|3|Hodgkin disease
62639081|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
62639082|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
62639083|NCT05190874||Device: Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler Interference Screw System
62639084|NCT03984396|EXPERIMENTAL|Intervention - Patient and Clinician|Intervention educational materials provided to patient and family and clinician
62639085|NCT03984396|NO_INTERVENTION|Delayed Intervention|Usual care
62639086|NCT00781053|EXPERIMENTAL|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months.
62639087|NCT02779569|EXPERIMENTAL|Ultra-low-dose group|decitabine was subcutaneously administered at 5 to 7 mg/m2 once daily for successive 3 days at the first week, and once daily at weeks 2 to 4, with a total dose of 60 mg in a 4-week cycle.
62639088|NCT02779569|ACTIVE_COMPARATOR|Low-dose group|decitabine was subcutaneously given at 20 mg/m2 once daily for successive 3 days, with a total dose of 60 mg/m2 in a 4-week cycle.
62070616|NCT05964881|EXPERIMENTAL|Prolene - non-resorbable sutures|Operation through vaginal route, high posterior colpotomy is made towards the posterior cervix. Blunt preparation towards the right Spina ischiadica to visualise right sacrospinous ligament. Prolene (2-0) sutures will be placed through the ligament (ca. 2 cm medial of the spina). This suture will then be placed through the posterior cervical wall, but not yet knotted. First, colpotomy will be closed via 2/0 vicryl, then pre-laid fixation sutures will be tied, whereby the portio will come to lie about 4-6 cm cranial of the level off the vulva towards the sacrospinous ligament.
62639089|NCT02757729|EXPERIMENTAL|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 8 weeks
62639090|NCT02757729|EXPERIMENTAL|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 8 weeks
62639091|NCT02757729|EXPERIMENTAL|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 8 weeks
62639092|NCT02757729|PLACEBO_COMPARATOR|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 8 weeks
62639093|NCT01077323||Exenatide Initiators|
62639094|NCT01077323||Other Antidiabetic Drug Initiators|
62639095|NCT01077323||Non-Diabetes Cohort|
62639096|NCT01259947|EXPERIMENTAL|Lippia alba|
62639097|NCT00377637|EXPERIMENTAL|Induction Phase: Mycophenolate mofetil|Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
62639098|NCT00377637|ACTIVE_COMPARATOR|Induction Phase: Cyclophosphamide|Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
62639099|NCT00377637|EXPERIMENTAL|Maintenance Phase: Mycophenolate mofetil|Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
62639100|NCT00377637|ACTIVE_COMPARATOR|Maintenance Phase: Azathioprine|Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.
62639101|NCT01953562||Intubated infants|
62639102|NCT02667340|EXPERIMENTAL|Superstarch|Supplementation with Superstarch before a simulated soccer game
62639103|NCT02667340|PLACEBO_COMPARATOR|Placebo|Supplementation with placebo before simulated soccer game.
62639104|NCT00480571|EXPERIMENTAL|1|BL 1020 low dose
62639105|NCT00480571|EXPERIMENTAL|2|BL 1020 High Dose
62639106|NCT06293274|EXPERIMENTAL|Discharge education|"Participants assigned to the discharge education group will receive discharge education about postpartum blues and postpartum depression. A Personal Information Form will be used. Discharge training and data collection are expected to take approximately 15-20 minutes. 5-7 days postpartum after the mothers are discharged. The 32-item Motherhood Sadness Scale will be administered by the researcher by telephone during the following days. In the 6th week of the postpartum period, the mothers will be contacted by the researcher by telephone and the 10-item Edinburgh Postpartum Depression Scale will be administered."
62639107|NCT06293274|NO_INTERVENTION|Routine discharge training|"Participants assigned to the routine discharge training group will receive routine discharge training. A personal information form will be used. Discharge training and data collection are expected to take approximately 15-20 minutes. 5-7 days postpartum after mothers are discharged. The 32-item Motherhood Sadness Scale will be administered by the researcher by telephone during the following days. In the 6th week of the postpartum period, the mothers will be contacted by the researcher by telephone and the 10-item Edinburgh Postpartum Depression Scale will be administered."
62639108|NCT02667925|EXPERIMENTAL|Intervention arm|Patients will receive an intraperitoneal chemotherapy (cisplatin) combined to a radiotracer (nanocis) in order to assess the intraperitoneal distribution of the chemotherapy
62639109|NCT03001947||IgAN patients|Biopsy-proven primary IgAN patients
62639110|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
62639111|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
62639112|NCT04448119|EXPERIMENTAL|Chemoprophylaxis|Participants of LTCH units allocated to the chemoprophylaxis arm receive favipiravir for 25 days. Residents in the LTCH unit diagnosed with COVID- 19 at enrollment will be offered treatment with favipiravir for 14 days.
62639113|NCT04448119|PLACEBO_COMPARATOR|Placebo|Participants of LTCH units allocated to the control arm receive placebo for 25 days. Residents in the LTCH unit diagnosed with COVID-19 at enrollment will be offered treatment with placebo for 14 days.
62639114|NCT03040271|EXPERIMENTAL|Intervention group- Health-E-PALS|Group of students receiving the school-based intervention: Health-E-PALS, it consists of in class activities and lessons.
62639115|NCT03040271|NO_INTERVENTION|Control group|Group of students not receiving any intervention
62639116|NCT03851770|OTHER|refractory epilepsy patients|All patients belong to the refractory epilepsy group. Intervention: Characterization of Vagus nerve stimulation: Evoked potentials (EP) are recorded using an EEG/EP digital acquisition system
62653006|NCT03803826|EXPERIMENTAL|CRT-D re-programming|"The ineffective previously implanted CRT-D is reprogrammed under supervision of transthoracic echocardiography to:~1. adjust the atrioventricular interval so that E and A waves do not overlap~2. the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.~Transthoracic echocardiography is performed prior to optimization and 3 months after optimization (i.e., 3 and 6 months after the CRT implantation) and and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods re-programming of the interventricular interval"
62070617|NCT04514471|EXPERIMENTAL|Unventilated Filter Cigarette|Conventional cigarette with approximately 6-7% (non-menthol) and 5-6% filter ventilation (menthol).
62639117|NCT05735704||Patients with Hematological Malignancies - Discovery stage|"The first stage (discovery phase) will include at least 30 patients from each of the following groups: MM, pre-MM conditions (SMM and MGUS), HL, aggressive NHL (DLBCL, HGL, FL, MZL, AML, MDS.~NOTE: Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, that were treated for their primary disease (FL/MZL/MDS/MPN) prior to study enrollment, are eligible.~For patients, it is expected, after signing the informed consent, that the serial samplings will be performed during the disease follow-up according to the standard clinical practice and/or recommended schedule and disease assessment plan.~Bone marrow samples will be obtained at Tel-Aviv Sourasky Medical Center (TASMC) from up to 50 MM patients and up to 50 AML patients that undergo bone marrow aspiration as part of the standard care procedure."
62639118|NCT05735704||Patients with Hematological Malignancies - Second stage|In the second stage, at least 250 patients with MM and 250 patients with NHL and at least 100 patients with each of the remaining hematological malignancies mentioned above will be tested. Out of these patients, AML, lymphoma and MM patients will be followed-up at the clinical sites. Periodic sampling will be defined according to disease type and progression rate. Blood and plasma samples will be stored in the clinical sites until relapse diagnosis. At this stage, blood samples will be analyzed retrospectively on the HemaChip. The screening, enrollment, and sample collection can begin in the first stage of the trial, in order to allow a maximum follow-up period for at-risk subjects as part of the study and to meet the recruitment goals.
62639119|NCT05735704||subjects at risk of developing MM / lymphoproliferative disorder - Third stage|"The last stage consists of screening of a larger group of subjects at risk of developing MM / lymphoproliferative disorder. This stage will include 400 elderly patients (\>65 years old) and 500 first-degree relatives of patients (and in particular siblings). The screening, enrollment, and sample collection can begin in the first stage of the trial, in order to meet the recruitment goals.~Follow-up patients, at-risk individuals for MM, and at-risk first-degree relatives will donate blood periodically according to the follow-up plan."
62639120|NCT05735704||Control subjects with no malignant disease- Discovery stage|"Control subjects with no malignant disease that serve as controls are expected to donate blood a single time. Following this donation, their participation will end.~At Tel-Aviv Sourasky Medical Center (TASMC) up to 50 bone marrow samples will be taken from healthy volunteers that will undergo hip or knee replacement surgery."
62639121|NCT05673447|EXPERIMENTAL|anti-CD19 CAR NK cells|CD19-CAR-NK is an allogenic CD19-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
62639122|NCT00847600|EXPERIMENTAL|1 Pregnenolone|50 mg/day
62639123|NCT00847600|PLACEBO_COMPARATOR|2 Placebo|1 caps.
62639124|NCT04668417|ACTIVE_COMPARATOR|Reminders with direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with a link enabling direct scheduling
62639125|NCT04668417|ACTIVE_COMPARATOR|Reminders with no direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with no direct scheduling link
62070618|NCT04514471|ACTIVE_COMPARATOR|Ventilated Filter Cigarette|Conventional cigarette with approximately 22-26% (non-menthol) and 35-38% filter ventilation (menthol).
62070619|NCT01154894|EXPERIMENTAL|Placebo-controlled trial|
62275448|NCT02339493|EXPERIMENTAL|Alert Group|If the patient is randomized to the alert group, their ordering provider will receive a computer electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy.
62070620|NCT03240341|EXPERIMENTAL|Patient Activation Measure (PAM)|completion of the PAM questionnaire
62275449|NCT02339493|NO_INTERVENTION|Control Group|If the patient is randomized to the control group, the computer program will not issue an on-screen electronic alert.
62639126|NCT03512522|EXPERIMENTAL|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Online Group will receive access to the course on the computer (online). A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
62639127|NCT03512522|EXPERIMENTAL|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Workbook Group will receive access to the course in a printed (workbook) format. A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
62639128|NCT03512522|NO_INTERVENTION|Wait List Control Group|Participants who are randomly allocated to the wait list control group will be provided access to the course after the twelve-week period has passed.
62639129|NCT05793021|OTHER|Single arm|
62070621|NCT01562002|EXPERIMENTAL|Bone Marrow mesenchymal stem cell|Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant
62070622|NCT01562002|ACTIVE_COMPARATOR|Allogenic limbal stem cell Transplant|Stem Cell with Amniotic Membrane Transplant
62639130|NCT03308422||Parents of 2-6-years-old children|Parents of preschool children in Nancy agglomeration
62639131|NCT04773223||Open surgery group|Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm
62639132|NCT04773223||Endovascular group|Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc.
62639133|NCT00827788|ACTIVE_COMPARATOR|iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
62639134|NCT00827788|ACTIVE_COMPARATOR|iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
62639135|NCT01334294||1. Received therapy for CNV|
62639136|NCT02605200|OTHER|Participants|Participants will complete tests of glucose tolerance and psychosocial assessments, and will undergo medical history screening. Those children identified with diabetes and/or abnormal glucose tolerance will receive both diabetes self-management education and psychosocial support from a pediatric Certified Diabetes Educator (CDE) and a psychologist, respectively.
62639137|NCT00170209|ACTIVE_COMPARATOR|Isoniazid|The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
62639138|NCT00170209|ACTIVE_COMPARATOR|Rifampin|The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).
62639139|NCT02861508|ACTIVE_COMPARATOR|Usual care|Usual care as determined by treating team. Ultrasound may still be part of the workup per the treating team's discretion.
62639140|NCT02861508|EXPERIMENTAL|Early POCUS|Point-of-care ultrasound protocol will involve cardiac views (for pericardial effusion, left ventricular function, left and right ventricular equality, aortic root dilation, and inferior vena cava status), lung views (for pneumothorax, signs of alveolar interstitial syndrome), abdominal views for free fluid, and a view of the abdominal aorta for aneurysm.
62639141|NCT05556148|EXPERIMENTAL|Otrivine Congestion Relief|Participants will be instructed to use the product per label and leaflet instructions: 1 spray in each nostril up to 3 times per day until resolution of symptoms or up to a maximum of 7 days, whichever occurs first.
62639142|NCT04454359|EXPERIMENTAL|EXP|EXP group will ingest a supplement consisting of 1) flavored whey protein isolate with added pure leucine (3 g) diluted in water, twice daily, before breakfast and before bedtime; doses are adjusted per body weight as follows: 20 g, 25 g or 30 g per category of \<65 kg, 65-75 kg and \>75 kg of body weight respectively. 2) fish oil containing vitamin D, provided as 7.5 mL liquid oil providing 1500 IU vitamin D3 + 1125 mg EPA + 750 mg DHA, to be ingested once daily.
62070623|NCT04711070||Patients with sepsis|Muscle velocity recovery cycles, electromyography, nerve conduction studies, direct musclestimulation, blood test
62070624|NCT04711070||Patients with chronic renal failure|
62070625|NCT04711070||Healthy control|
62275450|NCT02491164|EXPERIMENTAL|BAC TWO administration|All participants in this clinical study will be dosed on one occasion with BAC TWO. The final dosage will be 80 µg (± 25%).
62275451|NCT06344845|EXPERIMENTAL|Experimental: 18F-PBB3 PET/CT|Inject18F-PBB3 and then perform PET/CT scan.
62070626|NCT06241690|EXPERIMENTAL|the cold applications in post-suture pain reduces the child's pain|The population of the study consists of children aged 12-17 who were treated in the pediatric emergency departments of the designated hospitals between December 2021 and July 2022 and met the working criteria. The sample consists of 300 children who applied to the pediatric emergency service between December 2021 and July 2022 and met the research criteria. Socio-Demographic presentation form and Visual Analog Scale were used as data collection tools. Statistical analysis of the data was made in SPSS 22 package program.
62070627|NCT02394041|EXPERIMENTAL|acupuncture|"The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.~One or more additional session will be performed in the delivery room."
62070628|NCT02394041|SHAM_COMPARATOR|Sham acupuncture|The same as active arm but with sham needles.
62070629|NCT02394041|NO_INTERVENTION|control group|Standard care, no acupuncture session.
62070630|NCT03790514|EXPERIMENTAL|Heat Wrap Group|
62070631|NCT03790514|PLACEBO_COMPARATOR|Control Group|
62070632|NCT02450864|EXPERIMENTAL|patient with ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
62070633|NCT02450864|SHAM_COMPARATOR|patient without ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
62070634|NCT02761174|ACTIVE_COMPARATOR|Brimonidine (Mirvaso cream)|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face (control) and 0.5 g of brimonidine (Mirvaso cream) to the randomized side of the face.
62070635|NCT02761174|OTHER|IPL+air-cooling|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face and IPL+air-cooling (control) are thereby compared to IPL+air-cooling+brimonidine (Mirvaso cream).
62070636|NCT02430818|EXPERIMENTAL|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
62070637|NCT02430818|EXPERIMENTAL|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
62070638|NCT05671367||Artery without microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR\<2.5 mmHg\*s/cm is defined as no microvascular resistance.
62070639|NCT05671367||Single artery with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg\*s/cm is defined as microvascular resistance. There is only one of three major coronary arteries in 3 that meets this condition.
62275452|NCT01913080|ACTIVE_COMPARATOR|Health Log|Patients who have a billing diagnosis RA (714.0)or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS)will be given the Health Log health management tool.
62070640|NCT05671367||Multiple arteries with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg\*s/cm is defined as microvascular resistance. Two of the three major coronary arteries meet this condition.
62275453|NCT01913080|NO_INTERVENTION|Control Pill Box|Controls will be BRASS patients who continue to receive regular care and are also given a pill box instead of the Health Log health management tool.
62275454|NCT04230863|EXPERIMENTAL|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation.
62639143|NCT04454359|PLACEBO_COMPARATOR|CTR|Control will ingest an isocaloric placebo consisting of 1) 30 g maltodextrin, twice daily, following the same schedule, and 2) 7.5 mL corn oil, once daily.
62639144|NCT03006536|EXPERIMENTAL|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
62070641|NCT05671367||Three arteries with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg\*s/cm is defined as microvascular resistance. All three major coronary arteries meet this condition.
62070642|NCT05671367||Significant microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg\*s/cm is defined as microvascular resistance. The sum of AMR of the three main arteries is greater than 7.5mmHg\*s/cm
62070643|NCT01247519|NO_INTERVENTION|observation|
62070644|NCT01247519|EXPERIMENTAL|Intervention|
62070645|NCT02822560|ACTIVE_COMPARATOR|pEVAR|percutaneous femoral access using a suture-mediated closure system
62070646|NCT02822560|ACTIVE_COMPARATOR|open femoral access|cutdown to femoral artery and surgical closure
62070647|NCT04867876|EXPERIMENTAL|Intervention Cohort|Physical Therapy
62070648|NCT05605717||Pre specified group|Fibroscan Abdominal ultrasound Lab investigation
62070649|NCT05276063|PLACEBO_COMPARATOR|Placebo|Placebo Arm
62070650|NCT05276063|ACTIVE_COMPARATOR|Low Dose|Active Arm Low Dose Linsitinib
62070651|NCT05276063|ACTIVE_COMPARATOR|High Dose|Active Arm High Dose Linsitinib
62070652|NCT04736017|EXPERIMENTAL|Verum|The device records EEG and other biosignals throughout the night and scans these signals for slow waves associated with deep Non-Rapid Eye Movement (NREM) sleep. Upon recognition of such slow waves and fulfilment of other criteria, a tone is played via the headphones to stimulate and enhance slow waves without waking up the patient.
62070653|NCT04736017|SHAM_COMPARATOR|Sham|Playing no tones during NREM sleep but wearing the device and recording the biosignals over a period of 2 weeks, every night.
62070654|NCT05713812|ACTIVE_COMPARATOR|Active Comparator|"* IFC + Hot pack for 20 minutes~* MDT (prone positioning) for 10 minutes.~* Lumbar SNAGs + lumbar rotation mobilization.~* Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.~* Sham Kinesiotape will be applied"
62070655|NCT05713812|EXPERIMENTAL|Experimental Group|"* IFC + Hot pack for 20 minutes~* MDT (Prone positioning) for 10 minutes.~* Lumbar SNAGs + lumbar rotation mobilization.~* Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.~* Kinesiotape will be applied"
62070656|NCT05697549|EXPERIMENTAL|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of CBT. And it is focused on the treatment of speech-language related problems. CBLT helped the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. The main aim of CBLT is to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and AAC.
62461661|NCT03621800|EXPERIMENTAL|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
62070657|NCT02810730|OTHER|Single arm|Pancreatic MRI in the 6 months following the first consultation
62070658|NCT04071119|ACTIVE_COMPARATOR|Oxytocin nasal spray|
62070659|NCT04071119|PLACEBO_COMPARATOR|Placebo|
62070660|NCT00380120|EXPERIMENTAL|1|Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
62070661|NCT00380120|ACTIVE_COMPARATOR|2|Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)
62070662|NCT06320522|ACTIVE_COMPARATOR|Fed - Ketone Monoester|Ketone monoester drink (573 mg∙kg-1 body weight) provided 1 hour after a 2 g∙kg-1 bodyweight of carbohydrate mixed nutrient breakfast meal
62070663|NCT06320522|PLACEBO_COMPARATOR|Fed - Placebo|Placebo drink provided 1 hour after a 2 g∙kg-1 bodyweight of carbohydrate mixed nutrient breakfast meal
62070664|NCT06320522|ACTIVE_COMPARATOR|Fasted - Ketone Monoester|Ketone monoester drink (573 mg∙kg-1 body weight) provided whilst fasted
62070665|NCT06320522|PLACEBO_COMPARATOR|Fasted - Placebo|Placebo drink provided whilst fasted
62070666|NCT06323811|EXPERIMENTAL|MINOCA|Patients with myocardial infarction with non-obstructive coronary artery disease (MINOCA) prospectively investigated with advanced CMR
62070667|NCT06323811|EXPERIMENTAL|Myocarditis|Patients with suspected myocarditis prospectively investigated with advanced CMR
62070668|NCT06323811|EXPERIMENTAL|Takotsubo cardiomyopathy|Patients with suspected Takotsubo cardiomyopathy prospectively investigated with advanced CMR
62070669|NCT06323811|EXPERIMENTAL|Spontaneous coronary artery dissection (SCAD)|Patients with suspected/diagnosed spontaneous coronary artery dissection prospectively investigated with advanced CMR
62070670|NCT06323811|ACTIVE_COMPARATOR|NSTEMI|Patients with confirmed non-ST elevation myocardial infarction on coronary angiography prospectively investigated with advanced CMR
62070671|NCT01287637|EXPERIMENTAL|Early reversal group|Early reversal of temporary ileostomy
62070672|NCT01287637|ACTIVE_COMPARATOR|Control group|Standard reversal of temporary ileostomy
62070673|NCT00957788|EXPERIMENTAL|Cohort 0|
62070674|NCT00957788|EXPERIMENTAL|Cohort 1|
62070675|NCT00957788|EXPERIMENTAL|Cohort 2|
62070676|NCT00957788|EXPERIMENTAL|Cohort 3|
62070677|NCT04636606|ACTIVE_COMPARATOR|Home Exercise|Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.
62070678|NCT04636606|ACTIVE_COMPARATOR|Manual Therapy Combined with Home Exercise|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
62070679|NCT04636606|ACTIVE_COMPARATOR|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|"Orofacial Myofunctional therapy includes stretching the tongue muscles, tongue rotation exercises, isometric and isotonic strengthening of the tongue, special maneuver, effortful swallow exercise, strengthening exercise of hyoidal muscles.~Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
62070680|NCT01293188||Biopresthetic aortic valve replacement.|
62070681|NCT01828190|EXPERIMENTAL|Hyperbaric oxygen|hyperbaric oxygen therapy will be given for 2 months. TNF alpha blocker therapy will remain the treatment received before recruitment.
62070682|NCT05576363||Maternal|Second trimester
62070683|NCT02335086||Stable angina patients|"Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.~Clinical and angiographic exclusion criteria as stated in the study protocol."
62639145|NCT03006536|SHAM_COMPARATOR|Sham|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
62275455|NCT02325908||Hemodialysis patients|Dialysis patients will have their estimated dry weight measured with calf segmental bioimpedance. Based on these measurements, their dry weight will be adjusted and the amount of fluid removed during subsequent dialysis treatments will be increased by 200-300mL. The additional fluid removal will occur during 3 consecutive hemodialysis sessions. In addition, these subjects will also use VStim during these treatments. to prevent common intradialytic symptoms by promoting vascular refilling.
62639146|NCT00831116||LipiScan|Subjects who have at least one native coronary artery imaged with the LipiScan CIS.
62639147|NCT03320707|EXPERIMENTAL|Daratumumab|Participants will receive a single subcutaneous (SC) dose of daratumumab in each of first 7 dose cohorts. Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort. Participants in Cohort 8 will receive single SC daratumumab formulation containing recombinant human hyaluronidase (rHuPH20).
62639148|NCT03320707|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo as a single SC dose in each of first 7 cohorts.
62639149|NCT00631293|EXPERIMENTAL|1|administration of lactisole
62639150|NCT00631293|PLACEBO_COMPARATOR|2|administration of placebo
62639151|NCT04060953|EXPERIMENTAL|Health-Related Quality of Life Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report.
62639152|NCT04060953|NO_INTERVENTION|Wait List to Receive the Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report following completion of the study.
62639153|NCT02907567|ACTIVE_COMPARATOR|Active Treatment-Low|6 subjects randomized to 280 mg (Low) CT1812
62639154|NCT02907567|ACTIVE_COMPARATOR|Active Treatment-High|6 subjects randomized to 560 mg (High) CT1812
62639155|NCT02907567|PLACEBO_COMPARATOR|Placebo|4 subjects randomized to matching placebo of CT1812
62639156|NCT03511677|EXPERIMENTAL|Intervention Group|Customized insole with metatarsal support
62639157|NCT03511677|PLACEBO_COMPARATOR|Control Group|Placebo flat insole
62639158|NCT01061606|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62639159|NCT03983538||Patients receiving chemotherapy|Patients receive a protocol-approved chemotherapy regimen containing Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel) based on the patient and/or physician preference.
62639160|NCT01460732|OTHER|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
62275456|NCT02325908||Healthy Controls|No Intervention was administered. Both groups had their hydration status measured with segmental bioimpedance The group of healthy subjects was studied in order to obtain a range of values for normal hydration status.
62639161|NCT00637403|ACTIVE_COMPARATOR|I|Megestrol acetate concentrated suspension in subjects with normal renal function
62639162|NCT00637403|EXPERIMENTAL|II|Megestrol acetate concentrated suspension in subjects with mild renal impairment
62639163|NCT00637403|EXPERIMENTAL|III|Megestrol acetate concentrated suspension in subjects with moderate renal impairment
62639164|NCT00637403|EXPERIMENTAL|IV|Megestrol acetate concentrated suspension in subjects with severe renal impairment
62639165|NCT00637403|EXPERIMENTAL|V|Megestrol acetate concentrated suspension in subjects with end stage renal disease
62639166|NCT01159574|EXPERIMENTAL|all patients|"ClaPd therapy:~Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.~Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day."
62639167|NCT06402383|EXPERIMENTAL|Vaccination starting from visit 1|Vaccination will be provided at the first visit and then at 6 months for HPV negative women and 12 months for HPV positive women.
62639168|NCT06402383|EXPERIMENTAL|Vaccination starting at follow up|Vaccination will be provided after HPV results obtained - immediately for HPV negative women and again after 3 months. For HPV positive women this will be offered at 12 months after testing and again at 15 months.
62639169|NCT05415189||Patients|Patients with mental illness according to Danish health registers
62070684|NCT02335086||NSTEMI patients|"Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :~Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:~* Symptoms of ischaemia~* Development of pathologic Q waves in the electrocardiogram (ECG)~* New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.~* Identification of an intracoronary thrombus by angiography.~* Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality."
62070685|NCT03621722|EXPERIMENTAL|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
62070686|NCT03621722|EXPERIMENTAL|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
62070687|NCT03621722|NO_INTERVENTION|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
62070688|NCT03621722|NO_INTERVENTION|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
62070689|NCT02749058|OTHER|Capsulectomy|Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty
62070690|NCT02749058|OTHER|Capsulotomy|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty
62275457|NCT02796378|ACTIVE_COMPARATOR|Training+Simvastatin+Q10-placebo|Training+Simvastatin+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day and Q10-placebo.
62275458|NCT02796378|PLACEBO_COMPARATOR|Training+Simvastatin-placebo+Q10-placebo|Training+Simvastatin-placebo+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week, Simvastatin-placebo and Q10-placebo.
62070691|NCT05634720|EXPERIMENTAL|PDAC with HA Chemotherapy|On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies.
62275459|NCT02796378|ACTIVE_COMPARATOR|Training+Simvastatin+Q10|Training+Simvastatin+Q10. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day in combination with 400 mg of oral supplementation with Q10.
62275460|NCT03198208||Reference group|No fentanyl dose administered during surgery
62275461|NCT03198208||Comparative group|Fentanyl dose administered during surgery
62275462|NCT02861040|EXPERIMENTAL|Treatment (volasertib, vincristine sulfate liposome)|Patients receive volasertib IV over 1 hour on day 1 and vincristine sulfate liposome IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression, development of an inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw or treating investigator determines that the patient should be taken off treatment for any reason.
62070692|NCT04835896|EXPERIMENTAL|Study treatment|
62070693|NCT04192513|ACTIVE_COMPARATOR|Cohort 1 DBI-001 Gel and placebo|Cohort 1 DBI-001 Gel with low dose CFU's of J. lividum and placebo
62070694|NCT04192513|ACTIVE_COMPARATOR|Cohort 2 mid dose DBI-001 Gel and placebo|Cohort 2 DBI-001 Gel with mid dose CFU's of J. lividum and placebo
62070695|NCT04192513|ACTIVE_COMPARATOR|Cohort 3 high dose DBI-001 Gel and placebo|Cohort 3 DBI-001 Gel with high dose CFU's of J. lividum. Drug: J. lividum and placebo
62639170|NCT05415189||Control individuals from the general population|Control individuals from the general population matched according to the data of diagnosis/ psychotropic medication, year of birth, sex and calendar year.
62639171|NCT02819570|EXPERIMENTAL|cefuroxime|I.V cefuroxime 750 mg\*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg\*2/d for 7 days
62639172|NCT02819570|ACTIVE_COMPARATOR|ampicillin|I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg\*2/d for 7 days
62639173|NCT03539276|NO_INTERVENTION|Pre-intervention|Usual care
62639174|NCT03539276|EXPERIMENTAL|Post-intervention|One 90-minute interdisciplinary knowledge exchange including the provision of a validated list of appropriate and inappropriate medications for severe dementia long-term care residents.
62639175|NCT02992925|EXPERIMENTAL|Cohort 1: BK1310-High|
62639176|NCT02992925|EXPERIMENTAL|Cohort 1: BK1310-Low|
62639177|NCT02992925|EXPERIMENTAL|Cohort 2: BK1310-High or -Low|Either BK1310-High or -Low will be chosen based on the result of cohort 1
62639178|NCT02992925|ACTIVE_COMPARATOR|Cohort 2: ActHIB® and Tetrabik|
62461662|NCT03621800|NO_INTERVENTION|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
62461663|NCT06260488|OTHER|transfemoral amputation|Subject with a planned transfemoral amputation in the vascular surgery department of the Hôpitaux Universitaires de Strasbourg as standard care
62639179|NCT03200548|EXPERIMENTAL|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
62639180|NCT03200548|EXPERIMENTAL|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
62639181|NCT03200548|SHAM_COMPARATOR|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
62639182|NCT03200548|PLACEBO_COMPARATOR|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
62639183|NCT00209391|EXPERIMENTAL|Gadodiamide Injection|All subjects will receive a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide injection) at a dose of 0.1 mmol/kg.
62639184|NCT00634478|EXPERIMENTAL|1|preleminiscal radiation deep brain stimulation
62639185|NCT00634478|ACTIVE_COMPARATOR|2|VIM deep brain stimulation
62639186|NCT01321671|EXPERIMENTAL|Pregabalin controlled release, 330 mg, 600- 750 calorie|
62639187|NCT01321671|EXPERIMENTAL|Pregabalin controlled release, 330 mg, fasted|
62639188|NCT01321671|OTHER|Pregabalin immediate release, 300 mg|
62639189|NCT04606303|EXPERIMENTAL|Toripalimab Combined With Platinum-containing Dual-agent.|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer.
62639190|NCT02717195|EXPERIMENTAL|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
62639191|NCT02717195|EXPERIMENTAL|Double-blind Treatment (DBT) Period, Lu AF35700 10 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
62639192|NCT02717195|EXPERIMENTAL|DBT Period, Lu AF35700 20 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
62639193|NCT02717195|EXPERIMENTAL|DBT Period, Continued treatment from PC Period|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
62639194|NCT06508086|ACTIVE_COMPARATOR|group (A) LASER ABLATION|
62639195|NCT06508086|ACTIVE_COMPARATOR|group (B) KARYDAKIS TECHNIQUE|
62639196|NCT02042469||Survey|Cross-sectional survey will be carried out using an interview questionnaire composed of close-ended questions to be completed by trained research coordinator.
62639197|NCT05759637||T2D|patients with Type2 diabetes (T2D)
62639198|NCT05759637||obese without T2D|obese patients without Type 2 diabetes (T2D)
62275463|NCT05507866|EXPERIMENTAL|CSNEI|Schools randomized to receive the CSNEI intervention arm will receive help in addressing childhood obesity by modifying meal/menu items, changing school cafeteria environments, and making changes to purchasing and procurement practices.
62275464|NCT05507866|NO_INTERVENTION|Control|Schools randomized to the control arm will follow their existing nutritional practices.
62275465|NCT01716572|ACTIVE_COMPARATOR|gastric lavage|gastric lavage by nasogastric tube with 1 liter saline before the endoscopy
62275466|NCT01716572|ACTIVE_COMPARATOR|erythromycin|administration of 250mgr of erythromycin before the endoscopy
62461664|NCT06346223|EXPERIMENTAL|Mindfulness and psychoeducation|
62461665|NCT06346223|ACTIVE_COMPARATOR|Psychoeducation|
62639199|NCT02837926|EXPERIMENTAL|women attending for cervical cancer screening|
62639200|NCT03110354|EXPERIMENTAL|DS-3201b 100 mg|Participants who received 100 mg DS-3201b administered orally to participants with AML or ALL.
62639201|NCT03110354|EXPERIMENTAL|DS-3201b 150 mg|Participants who received 150 mg DS-3201b administered orally to participants with AML or ALL.
62070696|NCT05343117||Palbociclib based-therapy as initial endocrine therapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy as initial endocrine therapy from August 1, 2018 to December 31, 2023.
62070697|NCT05343117||Palbociclib based-therapy after chemotherapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy after chemotherapy from August 1, 2018 to December 31, 2023.
62639202|NCT03110354|EXPERIMENTAL|DS-3201b 250 mg|Participants who received 250 mg DS-3201b administered orally to participants with AML or ALL.
62639203|NCT03110354|EXPERIMENTAL|DS-3201b 500 mg|Participants who received 500 mg DS-3201b administered orally to participants with AML or ALL.
62639204|NCT03110354|EXPERIMENTAL|DS-3201b 700 mg|Participants who received 700 mg DS-3201b administered orally to participants with AML or ALL.
62639205|NCT01585337||patients with lumbar fusion|
62070698|NCT04033172|EXPERIMENTAL|Pyrotinib plus Fulvestrant|
62070699|NCT01243073|EXPERIMENTAL|imetelstat|Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.
62070700|NCT02532959||Diagnostic Breath Analysis|Patients at risk of SIRS
62070701|NCT05561062|NO_INTERVENTION|Control Group|This group will take 1 g mesalamine three times daily
62070702|NCT05561062|ACTIVE_COMPARATOR|Atorvastatin group|This group will take 1 g mesalamine three times daily and atorvastatin 80 mg once daily
62275467|NCT06000293|EXPERIMENTAL|Treatment Group|"At baseline, the eligible infant aged 6 months old will undergo clinical oral examination and their primary caregivers will be given the pre-evaluation questionnaires for 6-9 months old. The primary caregivers will then be given the strengthened MOH AG intervention for 6-9 months old infants.~Following three months, at evaluation 1, the 9-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 6-9 months old and pre-evaluation questionnaires for 9-12 months old. The primary caregivers will then be given the strengthened MOH AG intervention for 9-12 months old infants.~After three months, at evaluation 2, the 12-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 9-12 months old."
62639206|NCT02737761|EXPERIMENTAL|Optimal Adherence|"Participants will all undergo a qualitative interview and adherence measurements at baseline and 12 weeks after hospital discharge.~In person the participants will receive a MEMSCaps device and an Actigraph accelerometer. They will be asked to begin wearing the accelerometer after their initial interview and to begin using the MEMSCaps device once they arrive at home. Participants will use the MEMSCap throughout the entire study and will wear the Actigraph for 2 weeks at baseline and again at 12 weeks."
62639207|NCT01559662|EXPERIMENTAL|Sugared Chewing Gum|Patient asked to chew sugared chewing gum postoperative day 1 to 7, 3 times a day, 45 minutes at a time
62639208|NCT01559662|NO_INTERVENTION|No Gum|No gum given, routine postoperative care provided
62639209|NCT02329847|EXPERIMENTAL|Cohort A1|Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62639210|NCT02329847|EXPERIMENTAL|Cohort A2|Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62639211|NCT02329847|EXPERIMENTAL|Cohort B1|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62639212|NCT02329847|EXPERIMENTAL|Cohort B2|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62639213|NCT02329847|EXPERIMENTAL|Cohort B3|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62639214|NCT02329847|EXPERIMENTAL|Cohort B4|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
62275468|NCT06000293|NO_INTERVENTION|Control Group|"At baseline, the eligible infant aged 6 months old will undergo clinical oral examination and their primary caregivers will be given the pre-evaluation questionnaires for 6-9 months old. The primary caregivers will be allowed to receive the conventional MOH AG given by oral healthcare providers from the nearest dental clinic.~Following three months, at evaluation 1, the 9-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 6-9 months old and pre-evaluation questionnaires for 9-12 months old.~After three months, at evaluation 2, the 12-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 9-12 months old."
62639215|NCT04020211||HF10|SCS stimulation with HF10 therapy
62639216|NCT00842634|EXPERIMENTAL|Cohort 1|Patients who have failed two more HAART regimens
62639217|NCT00842634|EXPERIMENTAL|Cohort 2|Patients doing well on a stable antiretroviral medication
62639218|NCT00842634|EXPERIMENTAL|Cohort 3|Patients who have an undetectable viral load on HAART who have exhibited suboptimal CD4+ T cell gains during long term antiretroviral therapy. This group will not participate in the structured treatment interruption.
62639219|NCT03262077|EXPERIMENTAL|MB 1 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
62639220|NCT03262077|EXPERIMENTAL|MB 3 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
62639221|NCT03262077|EXPERIMENTAL|MB 5 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
62639222|NCT03262077|EXPERIMENTAL|MBS 1 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
62639223|NCT03262077|EXPERIMENTAL|MBS 3 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
62639224|NCT03262077|EXPERIMENTAL|MBS 5 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
62639225|NCT01810224|ACTIVE_COMPARATOR|Angio-guided arm|In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.
62639226|NCT01810224|EXPERIMENTAL|FFR-guided arm|In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.
62639227|NCT00614874|EXPERIMENTAL|1|Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks
62454686|NCT04985422|EXPERIMENTAL|Experimental group: Smartphone-based daily ecological momentary intervention (EMI)|"The experimental group receives 4 weeks of smartphone-based daily EMI. Participants are prompted 6 times a day (with an interval of at least 30 minutes between each digital prompt), on a daily basis over the 4-week period. Within 15 minutes of the digital prompt, participants are to first complete a brief (1-2 minutes) momentary survey (ecological momentary assessment \[EMA\]), and subsequently select 1 out of 5 personalised intervention actions of interest to complete in the moment (time to complete spans from 1 minute to 5 minutes).~The interventions are brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done in the moment. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).~Participants could also use the platform at any other times to redo intervention actions when preferred. Individualised reports for the EMI completed are provided."
62454687|NCT04985422|OTHER|Control group: Smartphone-based weekly-delivered information|"The control group receives 4 weeks of smartphone-based weekly-delivered information. The smartphone system (SMS + Qualtrics) as well as the contents of the interventions are identical to those provided to the EMI group. Rather than interventions delivered in the moment on a daily basis over the 4-week period, participants in the control group are provided with a new set of information on a weekly basis over the 4-week period (4 sets in total, 1 new set each week). Participants in the control group are also required to complete a brief 5-minute assessment within 3 days.~The information includes brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done anytime. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).~Participants could complete any intervention of interest in the information provided at any time throughout the 4-week period."
62639228|NCT04212767|EXPERIMENTAL|Test group|Post-extraction sockets covered with Platelet-Rich Fibrin membrane (n=16)
62639229|NCT04212767|NO_INTERVENTION|Control Goroup|Post-extraction sockets left to spontaneous healing/clot and primary closure (n=16).
62454688|NCT00418184|EXPERIMENTAL|1|
62454689|NCT00418184|PLACEBO_COMPARATOR|2|
62454690|NCT02969837|EXPERIMENTAL|E-KRd regimen|Participants will receive elotuzumab, carfilzomib, lenalidomide, and dexamethasone.
62454691|NCT02969837|EXPERIMENTAL|E-Rd Regimen|Participants will receive elotuzumab, lenalidomide, and dexamethasone.
62639230|NCT02147613|EXPERIMENTAL|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
62454692|NCT05309421|EXPERIMENTAL|EVX-01 in combination with pembrolizumab|EVX-01 is administered im. Pembrolizumab is administered according to label
62454693|NCT02907203|EXPERIMENTAL|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
62454694|NCT00699504|EXPERIMENTAL|Lead in Phase|Supratherapeutic dose of cangrelor
62639231|NCT02147613|ACTIVE_COMPARATOR|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
62639232|NCT04190355|ACTIVE_COMPARATOR|5.25% NaOCl solution|5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation
62639233|NCT04190355|ACTIVE_COMPARATOR|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water will be used as irrigation solution at every file change during root canal preperation
62639234|NCT02977793||Non-pathologic young adults|18-28 years old
62639235|NCT02977793||Non-pathologic adults|29-80 years old
62639236|NCT02977793||Pathologic adults|29-80 years old
62639237|NCT02723188|SHAM_COMPARATOR|Sham|Sham electrical stimulation
62639238|NCT02723188|EXPERIMENTAL|DC: Direct current|Direct current electrical stimulation
62639239|NCT02723188|EXPERIMENTAL|AC: Alternating current|Alternating current electrical stimulation
62639240|NCT02083796|EXPERIMENTAL|Shoulder impingement_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times.
62454695|NCT00699504|EXPERIMENTAL|A|therapeutic dose cangrelor treatment
62454696|NCT00699504|EXPERIMENTAL|B|supratherapeutic dose cangrelor treatment
62454697|NCT00699504|ACTIVE_COMPARATOR|C|active comparator treatment
62454698|NCT00699504|PLACEBO_COMPARATOR|D|placebo treatment
62454699|NCT04432948||Maternal Group|Pregnant women administered into a maternity public hospital in labour (vaginal delivery, caesarean section)
62454700|NCT01361477||patient|"1. Prolonged ICU stay~2. Unplanned ICU admission~3. Complication/adversel during ICU admission~4. Result of intraoperative complications and admission to ICU 5 Result of early postoperative (within 7 days) and ICU admission"
62454701|NCT02534493|EXPERIMENTAL|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
62454702|NCT03510559|ACTIVE_COMPARATOR|Brachial Plexus Block|It will be at the discretion of the anesthesiologist performing the block to choose a supraclavicular, infraclavicular or axillary block to achieve adequate surgical anesthesia of the operative arm. After sterile skin preparation with chlorhexidine, a linear array transducer probe is placed on the skin and the appropriate nerve structures are identified. Local anesthetics (30 mL of 50:50 mix of 0.5% bupivacaine and 2% lidocaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the brachial plexus. Patients who have a failed brachial plexus block may undergo a rescue forearm block, and will be recorded as requiring supplemental local anesthetic.
62639241|NCT02083796|SHAM_COMPARATOR|Shoulder impingement_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
62461666|NCT01888263|EXPERIMENTAL|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
62070703|NCT05407532|EXPERIMENTAL|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
62070704|NCT05407532|EXPERIMENTAL|Group with oral management|The investigators taught and monitored patients or caregivers to oral health care plus oral exercises such as salivary glands massage methods after meals and before sleep.
62070705|NCT05407532|NO_INTERVENTION|Group with standard of care|Only provided oral care education.
62070706|NCT03786796|EXPERIMENTAL|Olaparib|Participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L that have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy with measureable disease on CT imaging according to RECIST 1.1 criteria. Participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose will be increased to 300mg by mouth twice daily provided there are no grade 3 or greater adverse events experienced. Reassessment will occur at least monthly for toxicity. Radiological scans will be performed every 3 months to assess disease response. Treatment will be continued until clinical and/or radiographic progression according to RECIST 1.1 criteria or unmanageable toxicity requiring cessation.
62070707|NCT04177381|ACTIVE_COMPARATOR|interrupted closure of subcutaneous tissue with drain|consist of 89 patients that will be allocated for interrupted closure of subcutaneous tissue with drain
62070708|NCT04177381|ACTIVE_COMPARATOR|interrupted closure of subcutaneous tissue without dra|consist of 88 patients that will be allocated for interrupted closure of subcutaneous tissue without drain
62070709|NCT04177381|ACTIVE_COMPARATOR|non closure of subcutaneous tissue with drain|In the drain group,a closed non vacuum drain will be inserted in the tissue and exit from the skin through a separate opening and stitch to the skin
62070710|NCT04177381|ACTIVE_COMPARATOR|non closure of subcutaneous tissue and no drain|87 women without subcutanous sutures and without drain
62070711|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
62070712|NCT02257255|ACTIVE_COMPARATOR|Pfannenstiel cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by Pfannenstiel technique. Pain assessment on postoperative hours 6, 12 and 24.
62070713|NCT02257255|EXPERIMENTAL|Misgav-Ladach cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by minimally invasive technique. Pain assessment on postoperative hours 6, 12 and 24.
62070714|NCT03959592|ACTIVE_COMPARATOR|Lutein, zeaxanthin and mesozeaxanthin|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
62070715|NCT03959592|PLACEBO_COMPARATOR|Placebo|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).
62070716|NCT04563390|EXPERIMENTAL|Projection-based augmented reality exposure therapy|Intervention group that receives the projection-based augmented reality to carry out the exposure therapy for cockroach phobia.
62070717|NCT04563390|EXPERIMENTAL|In vivo exposure|Intervention group that receives traditional in vivo exposure therapy for cockroach phobia.
62070718|NCT04563390|NO_INTERVENTION|WL Control|Waiting list control group.
62639242|NCT02083796|ACTIVE_COMPARATOR|Asymptomatic_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times
62639243|NCT02083796|SHAM_COMPARATOR|Asymptomatic_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
62070719|NCT03320460|EXPERIMENTAL|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
62070720|NCT03320460|ACTIVE_COMPARATOR|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
62070721|NCT02384317|EXPERIMENTAL|CCX168 (Avacopan)|CCX168 (Avacopan) plus stable dose of RAAS blocker
62639244|NCT00871156|ACTIVE_COMPARATOR|Part 1|Tafenoquine + Chloroquine vs. Chloroquine alone
62639245|NCT00871156|PLACEBO_COMPARATOR|Part 2|Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
62639246|NCT02471573|ACTIVE_COMPARATOR|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
62461667|NCT01888263|ACTIVE_COMPARATOR|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
62639247|NCT02471573|ACTIVE_COMPARATOR|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
62639248|NCT00707044|EXPERIMENTAL|A|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
62639249|NCT00707044|ACTIVE_COMPARATOR|B|control group, care as usual, 24 hours intensive care stay
62639250|NCT04052607|EXPERIMENTAL|Dydrogesterone Suppression|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH.
62639251|NCT04052607|EXPERIMENTAL|Dydrogesterone Suppression with minimal stimulation|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH.
62639252|NCT04052607|ACTIVE_COMPARATOR|Antagonist Suppression|cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH.
62639253|NCT05702580|EXPERIMENTAL|Standard thoracentesis followed by pre-aspiration fluid agitation|Participants will undergo the standard thoracentesis followed by the experimental pre-aspiration fluid agitation technique
62275469|NCT04971005|EXPERIMENTAL|Intervention (aHSCT)|Autologous Hematopoietic Stem Cell Transplantation. Mobilisation will be performed with 2 g/m2 cyclophosphamide and 10 μg/kg G-CSF from day 5 until apheresis is completed. Conditioning will be 200 mg/kg cyclo-phosphamide and Anti-T-lymphocyteglobuline (Grafalon®, Neovii) with cu-mulative doses of 20 mg/kg given on day +1 (10 mg/kg) and day +2 (10 mg/kg).
62639254|NCT04385498|EXPERIMENTAL|BREATHE Intervention|Five session program, with additional sessions provided based on the individual's learning style and needs. Sessions are designed to be 20 to 30 minutes long, to accommodate the needs of the primary health care centers. Sessions will ideally be conducted once per week, but may be conducted as infrequently as once per month.
62639255|NCT04385498|ACTIVE_COMPARATOR|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the End of the trial participants will be able to receive the BREATHE Ethiopia PTSD treatment
62070722|NCT06471244|EXPERIMENTAL|EEG/MEG data collection and processing with high density recording techniques|
62070723|NCT05805683|EXPERIMENTAL|Calcitonin group|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
62275470|NCT04971005|ACTIVE_COMPARATOR|Control|In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).
62275471|NCT01244880|EXPERIMENTAL|Saline/PF-02545920|Treatments are co-administered
62275472|NCT01244880|EXPERIMENTAL|Ketamine/PF-02545920|Treatments are co-administered
62275473|NCT01244880|PLACEBO_COMPARATOR|Saline/Placebo|Treatments are co-administered
62639256|NCT02993835|ACTIVE_COMPARATOR|Labeled iron salt (Fe54)|Labeled iron salt (Fe54) with bouillon
62639257|NCT02993835|ACTIVE_COMPARATOR|Labeled iron salt (Fe57)|Labeled iron salt (Fe57) with bouillon
62639258|NCT02993835|EXPERIMENTAL|Labeled iron salt (Fe58)|Labeled iron salt (Fe58) with bouillon
62639259|NCT06433167||Idiopathic Scoliosis|The patient group for this research comprises patients diagnosed with idiopathic scoliosis, a condition characterized by abnormal lateral curvature of the spine of unknown cause.
62639260|NCT06433167||Healthy control|Healthy control group is healthy individuals without any diagnosed disease.
62070724|NCT05805683|PLACEBO_COMPARATOR|Placebo group|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
62070725|NCT04691713|EXPERIMENTAL|Targeting CD276 autologous chimeric antigen receptor T cells|
62070726|NCT00406458|EXPERIMENTAL|SB-509|60 mg SB-509 injected IM into lower limbs every 2 months
62070727|NCT00406458|PLACEBO_COMPARATOR|Normal Saline|Normal saline injected IM into lower limbs every 2 months
62070728|NCT05518760||Case|A COVID-19 confirmed case is a patient with an acute respiratory illness and RT-PCR confirmation of SARS-CoV-2 infection (i.e. any positive RT-PCR results obtained prior to admission or after enrolment in the study). In case the patient has any inconsistent RT-PCR results (e.g. a positive followed by a negative or a negative followed by a positive result), he/s he/she will be considered as a COVID-19 confirmed case if he/she has at least one positive result during his/her illness under consideration.
62070729|NCT05518760||Test-negative control|A COVID-19 negative case is a patient with an acute respiratory illness, in whom all RT-PCR tests are negative for SARS-CoV-2
62070730|NCT05960383||Lung transplant patients|53 patients who receive lung transplant and undergo microbiologic assessment with BioFire Pneumonia Panel Plus and conventional culture
62070731|NCT03586206||Mild-moderate C.difficile infection|
62070732|NCT03586206||severe C.difficile infection|
62275474|NCT01244880|EXPERIMENTAL|Ketamine/Placebo|Treatments are co-administered
62275475|NCT05178875||NDNS participants|Random participants from all the UK (including England, Scotland, Wales and North Ireland)
62275476|NCT02198807|EXPERIMENTAL|Fosmidomycin-Piperaquine|Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days
62275477|NCT05355350|EXPERIMENTAL|piperacillin tazobactam|
62275478|NCT05355350|ACTIVE_COMPARATOR|meropenem|
62275479|NCT00701753||Olanzapine|Subjects treated with olanzapine as part of their routine clinical care
62454703|NCT03510559|EXPERIMENTAL|Forearm Nerve Block|Patients allocated to the forearm block will have it performed in the semi-setting position. After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a linear array transducer probe is placed at the distal forearm to visualize each peripheral nerve (radial, ulnar, median, and lateral antebrachial cutaneous). A 5 cm 22 G insulated needle is then used to target each nerve individually and infiltrate 7.5mL of the 50:50 mixture (similar to the brachial plexus block group) at each nerve to a total of 30mL.
62070733|NCT03586206||severe complicated/fulminant C.difficile infection|
62275480|NCT00701753||Risperidone|Subjects treated with risperidone as part of their routine clinical care
62275481|NCT00701753||Quetiapine|Subjects treated with quetiapine as part of their routine clinical care
62275482|NCT03628170|EXPERIMENTAL|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
62275483|NCT03628170|ACTIVE_COMPARATOR|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
62454704|NCT02997319||Night Shift-Workers|
62639261|NCT04470973||Cefuroxime/Amikacin|20 patients will be included in the cefuroxime cohort and 20 patients in the amikacin cohort.
62070734|NCT01572246||Non-cardiac above-the-waist surgery|Subjects with an implanted ICD who present for a non-cardiac above-the-waist surgical procedure involving monopolar electrocautery
62070735|NCT01572246||Cardiac surgery|Subjects with an implanted ICD who present for a cardiac surgical procedure involving monopolar electrocautery
62070736|NCT01572246||Below-the-waist surgery|Subjects with an implanted ICD who present for a below-the-waist surgical procedure involving monopolar electrocautery
62070737|NCT03678259|EXPERIMENTAL|124I-p5+14 Injection|A single-injection dose of 124I-p5+14 adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic amyloidosis of several sub-types.
62275484|NCT04431115||Stakeholders|"Academic experts, Politicians and officials of state ministries of health and education and teachers.~1. Interviews will be conducted for academic experts, politicians and officials of state ministries of health and education.~2. Headteachers and physical education teachers will be administered questionnaires."
62275485|NCT04431115||Parents|Parents of the primary school children to be recruited for the study. Focus group discussion in a group of 3 of ten in each group.
62275486|NCT04431115||Primary school children aged 6-12 yrs.|"A cross sectional survey of the biographical data, socio economic status, physical activity level through appropriate questionnaires will be done.~A pedometer will be attached to the waist of each of the participants for a consecutive 7 days to objectively determine the level of their physical activity."
62275487|NCT06434831|EXPERIMENTAL|ANI will be recorded during the SNM.|
62454705|NCT02997319||Day Workers|
62454706|NCT02428699|EXPERIMENTAL|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
62639262|NCT01088633|OTHER|Exhaled particle analysis|
62639263|NCT01660009|EXPERIMENTAL|Hypoglycemia First|Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
62639264|NCT01660009|EXPERIMENTAL|Euglycemia First|Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
62639265|NCT01630135|EXPERIMENTAL|GW685698X|GW685698X 55mcg/day
62639266|NCT01630135|PLACEBO_COMPARATOR|Placebo|Placebo
62070738|NCT01925261|PLACEBO_COMPARATOR|TPX-100 Cohort 1|Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
62275488|NCT01986478||Normal|Normal results from clinical exam and free of ocular pathology
62275489|NCT01394705|NO_INTERVENTION|Standard of Care|standard of care (office provider exercise counseling)
62275490|NCT01394705|EXPERIMENTAL|Intervention|The intervention group received a personalized exercise prescription (using the FITT principles) and wore an accelerometer up to 7days/week (most waking hours) and logged their activity by regularly (3 times a week) uploading the device for a period of 3 months, use of the internet was supervised by a parent or guardian. Their activity was monitored via the online BodyMedia site on a regular basis by study personnel and feedback was provided at least once a week through email and/or phone calls
62639267|NCT06431464||Nanosecond laser|Patients with unwanted tattoos who plan a nanosecond laser treatment will be recruited for measurements using a multiphoton-tomography system.
62070739|NCT01925261|PLACEBO_COMPARATOR|TPX-100 Cohort 2|Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee
62275491|NCT04019132||Older adults|Older adults aged \>65 years
62275492|NCT04019132||Young group|Younger adults between the age of 20 and 40 years
62275493|NCT04019132||Middle-aged group 1|Adults between the age of 40 and 55 years
62275494|NCT04019132||Middle-aged group 2|Adults between the age of 55 and 65 years
62275495|NCT03138876|OTHER|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
62454707|NCT02428699|ACTIVE_COMPARATOR|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
62639268|NCT06431464||Picosecond laser|Patients with unwanted tattoos who plan a picosecond laser treatment will be recruited for measurements using a multiphoton-tomography system.
62639269|NCT04771845||EEG-grid-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using electroencephalogram grid guided navigation
62639270|NCT04771845||MRI-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using MRI guided navigation
62639271|NCT04771845||NACC controls|National Alzheimer's Coordinating Center matched controls
62639272|NCT02437578||Infertile couples|Infertile couples referred to Dansk fertilitetsklinik (Danish Fertility clinic) for IUI, IVF and ICSI treatment
62639273|NCT02365350|EXPERIMENTAL|STEINER-TAN Needle®|All visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
62639274|NCT02365350|ACTIVE_COMPARATOR|17G single lumen needle|In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
62639275|NCT04601740||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62639276|NCT01766362|EXPERIMENTAL|A session|
62639277|NCT01766362|OTHER|Four sessions|Every session are spaced out of month
62275496|NCT00428597|EXPERIMENTAL|A|
62275497|NCT00428597|PLACEBO_COMPARATOR|B|
62275498|NCT02448732|EXPERIMENTAL|ACM-1 team|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
62454708|NCT03206710||smokers who received Vitamin C|
62454709|NCT03206710||smokers who received placebo|
62454710|NCT03206710||control group non-smokers|
62454711|NCT01025037|OTHER|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement at the rotator cuff repair site
62639278|NCT01537237||intra-procedure 3DATG|Patients who will undergo intra-procedure 3DATG rotational angiography to guide their ablation procedure
62070740|NCT01925261|PLACEBO_COMPARATOR|TPX-100 Cohort 3|Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee
62070741|NCT01925261|PLACEBO_COMPARATOR|TPX-100 Cohort 4|Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
62275499|NCT04823949|NO_INTERVENTION|Standard care|Patient will be scheduled for a blood pressure check in the office 7-10 days postpartum
62454712|NCT02090829|PLACEBO_COMPARATOR|Placebo Group|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
62639279|NCT01537237||pre-procedure CT|Patients who will undergo pre-procedure CT scan to guide their ablation procedure
62639280|NCT02012400|EXPERIMENTAL|Intervention group|
62639281|NCT02012400|NO_INTERVENTION|Control group|
62639282|NCT01699048|OTHER|Hybrid group|Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with the left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50)
62454713|NCT02090829|ACTIVE_COMPARATOR|Experimental Group|"Intranasal oxytocin (Trade name: Syntocinon) Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril). Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
62070742|NCT01925261|PLACEBO_COMPARATOR|Part B|Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
62070743|NCT01529671|EXPERIMENTAL|Cohort 1: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
62070744|NCT01529671|EXPERIMENTAL|Cohort 2: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
62070745|NCT01529671|EXPERIMENTAL|Cohort 3: Experimental intervention: PF-05089771 or placebo|Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
62070746|NCT01529671|EXPERIMENTAL|Cohort 4: Experimental intervention: PF-05089771 or placebo|Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
62070747|NCT01529671|EXPERIMENTAL|Cohort 5: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
62275500|NCT04823949|EXPERIMENTAL|Intervention|Patient will receive a Babyscripts blood pressure cuff(brand: A\&D Medical) and Babyscripts MyJourney phone app with which to monitor their blood pressures twice daily for 16 days after discharge
62275501|NCT04460235|OTHER|Vaccination|All patients will be vaccinated according to national guidelines
62275502|NCT05514964|EXPERIMENTAL|Intervention Arm|The experimental arm were provided an intervention program based on John Forsyth \& Georg Eifert (2016) The Mindfulness \& Acceptance Workbook for Anxiety: A Guide to Breaking Free from Anxiety, Phobias \& Worry Using Acceptance \& Commitment Therapy, New Harbinger Publications. However, the initial treatment was adapted for the LGBT community using the suggestions from APA Guidelines for Psychological Practice With Lesbian, Gay and Bisexual Clients (2012) and Pachankis, J. E. (2014). Uncovering Clinical Principles and Techniques to Address Minority Stress, Mental Health, and Related Health Risks Among Gay and Bisexual Men. Clinical Psychology: Science and Practice, 21(4), 313-330. doi:10.1111/cpsp.12078.
62454714|NCT05036603|NO_INTERVENTION|1/routin medical care and neonatal intensive care unit's daily care|Group 1 (n=20) routine medical treatment for newborns on mechanical ventilator respiratory support and CPAP; Appropriate antibiotics given according to the needs of the baby, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care will be provided.
62275503|NCT02288338|EXPERIMENTAL|1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®)|"Three treatment~1. atorvastatin calcium 40mg will be administration to healthy volunteers during 7days~2. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~3. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
62461668|NCT03515967|EXPERIMENTAL|Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) after injury using the I-PAS goggles
62639283|NCT01699048|OTHER|PCI|Multi-vessel PCI with DES (MV-PCI group, n=50)
62639284|NCT01699048|OTHER|CABG|Coronary artery bypass graft (CABG) treatment (CABG group, n=50)
62639285|NCT01513993|NO_INTERVENTION|Control group|Treatment as usual
62639286|NCT01513993|EXPERIMENTAL|Telemonitoring for patients with Congestive Heart Failure|
62639287|NCT02530112||Phase 1|First round of survey respondents.
62639288|NCT02530112||Phase 2|Second round of survey respondents.
62639289|NCT02530112||Phase 3|Third round of survey respondents.
62653007|NCT03803826|NO_INTERVENTION|Control Group|Only trans-thoracic echocardiography is performed during follow-ups at 3 and 6 months from CRT implantations performed and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods
62653008|NCT04432480||Children|0-15 years old children undergoing surgery under general anesthesia
62275504|NCT02288338|EXPERIMENTAL|2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®)|"Three treatment~1. ezetimibe 10mg will be administered to healthy volunteers during 7days~2. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~3. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
62275505|NCT02288338|EXPERIMENTAL|3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®)|"Three treatment~1. atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~2. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~3. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
62275506|NCT02288338|EXPERIMENTAL|4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®)|"1. atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~2. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~3. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
62275507|NCT02288338|EXPERIMENTAL|5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®)|"1. ezetimibe 10mg will be administered to healthy volunteers during 7days~2. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~3. after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
62275508|NCT02288338|EXPERIMENTAL|6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®)|"1. atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~2. after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~3. after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
62275509|NCT01708460|EXPERIMENTAL|Ulthera-treated subjects|All enrolled subjects will receive one Ultherapy treatment to one side of the body in the lateral buttock region. Following study completion, subjects may elect to receive a balancing treatment to the other side of the body.
62275510|NCT05172739|ACTIVE_COMPARATOR|Opioid-Based Anaesthesia Analgesia|Premedication: IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg and Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/ kg. Anesthesia maintenance: Desflurane set at approximately 1 MAC, Morphine 0.1-0.12mg/kg, Fentanyl 1-2mcg/kg during induction and 50-100mcg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, along with Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. Surgical ward: PCA pump with Morphine for the first 3 postoperative days. Additional postoperative analgesia: Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
62275511|NCT05172739|ACTIVE_COMPARATOR|Opioid-Free Anesthesia Analgesia|Premedication: Pregabalin 150mg 1x2, IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Dexmedetomidine 0.5-1mcg/kg, Lidocaine 1mg/kg, Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg, Cisatracurium 0.2mg/ kg or alternatively Rocuronium 0.6-1.2mg/kg, Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg. Anesthesia maintenance: Desflurane set at \~1 MAC, Dexmedetomidine 0.5-1.2mcg/kg/h, Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, and Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. Surgical ward: PCA pump with Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam for the first 3 postoperative days. Additionally, Pregabalin 50mg per os 1x1 and 25mg 1x1, Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
62275512|NCT01839864|EXPERIMENTAL|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
62275513|NCT02905175||Rheumatoid arthritis|blood sample specimen and synoviocytes from synovial tissue
62275514|NCT02905175||Osteoarthritis|blood sample specimen and synoviocytes from synovial tissue
62287155|NCT05492955|EXPERIMENTAL|Enhanced Community Health Worker + Mobile Health Monitoring (eCHW+)|Participants will be given a blood pressure cuff with cellular capability (Blipcare) for at-home BP monitoring which automatically transmit BP data to our server for nurse review. These participants will also be assigned to a CHW for follow-up visits and medication delivery.
62287156|NCT04665557|EXPERIMENTAL|Dove Confident Me Indonesia - Single Session|Dove Confident Me Indonesia Single Session is school-based, body image curriculum.
62287157|NCT04665557|NO_INTERVENTION|Lessons As Usual Control|School lessons as usual.
62639290|NCT03505372|EXPERIMENTAL|Contrast enhanced mammography|"* The CESM images will be performed according to clinical protocol~* Images will be acquired within approximately 2-12 minutes of contrast injection~* A total of four images per breast will be acquired with low and high energy~* Two radiologists will prospectively review the CESM, and will use a third as tie-breaker~* The CESM will be evaluated for the biopsy site and up to two additional findings in either breast~* The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement"
62639291|NCT04552600|EXPERIMENTAL|NuvastaticTM 1000 mg|NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months.
62639292|NCT04552600|ACTIVE_COMPARATOR|Placebo|NuvastaticTM (without active) will be given orally, three times per day for 12 months
62639293|NCT05793749|EXPERIMENTAL|Prophylactic lymphedema treatment|"Prophylactic lymphedema treatment：The lymphedema prophylaxis treatment consists of four parts:manual lymphatic drainage, skin care, functional exercise, and wearing lymphedema preventive compression stockings.~The prophylactic lymphedema treatment group receives lymphedema prophylaxis twice a week for a total of 10 sessions, each requiring an interval of at least 48 hours but no more than 2 weeks."
62639294|NCT05793749|NO_INTERVENTION|Standard of care|Standard of care，includeIn knowledge education and telephone follow-up were routinely conducted.
62639295|NCT04438525|ACTIVE_COMPARATOR|early maintenance phase|patients who reached the maintenance dose of venom immunotherapy one week (max. +3 weeks) before recruitment will be sting challenged
62070748|NCT04105972|ACTIVE_COMPARATOR|TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.
62070749|NCT04105972|EXPERIMENTAL|ELX/TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
62275515|NCT05568342|EXPERIMENTAL|Roy Group|"The population of the research consisted of 80 patients receiving outpatient dialysis treatment in the hemodialysis unit of a university hospital. In the sample of the study, those patients who came to the dialysis session on Monday-Wednesday-Friday were randomly assigned to the Roy group (experimental) (40 patients).~Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices."
62275516|NCT05568342|NO_INTERVENTION|Clinic Group|"The population of the research consisted of 80 patients receiving outpatient dialysis treatment in the hemodialysis unit of a university hospital. In the sample of the study, those patients who came to the dialysis session on Tuesday-Thursday-Saturday were included in the Clinical group (control) (40 patients).~Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices."
62639296|NCT04438525|ACTIVE_COMPARATOR|maintenance phase|patients who reached the maintenance dose of venom immunotherapy one year (+/- 2 months) before recruitment will be sting challenged
62639297|NCT04438525|ACTIVE_COMPARATOR|after stopping VIT|patients who finished venom immunotherapy two years (+/- 6 months) before recruitment (duration of VIT: at least 3 years) will be sting challenged
62639298|NCT04438525|OTHER|blood donors|patients with confirmed vespid venom allergy who have not undergone venom immunotherapy (blood donation necessary to perform BAT Inhibition test)
62639299|NCT00260988|ACTIVE_COMPARATOR|Dalteparin|Dalteparin 200 IU/kg/day for three days prior to surgery and dalteparin 5000IU daily for 3-5 days post-surgery
62639300|NCT00260988|ACTIVE_COMPARATOR|Tinzaparin|Tinzaparin 175 IU/kg/day for three days prior to surgery and Tinzaparin 4500 IU for 3-5 days post surgery
62275517|NCT02883751|ACTIVE_COMPARATOR|Control group|Control group - gold standard: Conventional ulcer treatment with Rayon® and essential fatty acids (Dersani®). Cleaning of the surgical wound will be performed with saline solution. The wound will then be covered with a sterile polyethylene film, over which the LED plate will be positioned for placebo treatment (emission of sound, but with the device switched off). After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
62639301|NCT02037724|OTHER|supplement containing 60 mg iron sulfate|nutrient supplement containing 60 mg of iron as ferous sulfate
62639302|NCT02037724|EXPERIMENTAL|iron rich food supplement (60 mg iron)|contains 60 mg Iron
62275518|NCT02883751|EXPERIMENTAL|LED group|LED group: Cleaning of the surgical wound will be performed with saline solution and the wound will be covered with a sterile polyethylene film, over which the LED plate will be positioned for active treatment with the device switched on. After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
62461669|NCT03515967|ACTIVE_COMPARATOR|Non-Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) with no injury using the I-PAS goggles
62639303|NCT02037724|EXPERIMENTAL|iron rich food supplement (10 mg iron)|contains 10 mg of iron
62639304|NCT02037724|OTHER|supplement containing 10 mg iron sulfate|nutrient supplement containing 10 mg of iron as ferous sulfate
62070750|NCT01827254||Non-Interventional Study|
62070751|NCT01391143|EXPERIMENTAL|MGA271|Fc-optimized, humanized monoclonal antibody
62639305|NCT00918983|EXPERIMENTAL|NX-1207|
62639306|NCT00918983|PLACEBO_COMPARATOR|Placebo|
62639307|NCT02254772|EXPERIMENTAL|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
62639308|NCT06164457|NO_INTERVENTION|Control Group|Patients in this group will attend their cardiology appointment as normal. No intervention present.
62639309|NCT06164457|EXPERIMENTAL|Intervention Group|Patients in this group will complete the ePROM patient survey in advance of their care visit.
62639310|NCT03708263|ACTIVE_COMPARATOR|532nm KTP Laser|Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.
62639311|NCT03708263|EXPERIMENTAL|585 nm yellow laser|PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.
62639312|NCT03734393|EXPERIMENTAL|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 40
62639313|NCT03734393|NO_INTERVENTION|HIVD-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and are randomized to participate in the full study arm, which includes research sample collection -enrollment 40
62070752|NCT02238197||Chronic Obstructive Pulmonary Disease|
62070753|NCT03103022|EXPERIMENTAL|Interventional Group|Preterm infants who met the eligibility criteria will receive both oral acetaminophen and ibuprofen. Oral acetaminophen \[160 mg/5ml concentration\] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses and oral ibuprofen \[100 mg/5 ml\] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
62639314|NCT03734393|NO_INTERVENTION|HIVD-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group with limited data collection - enrollment 120
62639315|NCT01827969|EXPERIMENTAL|ablathermy focused ultrasound|ablathermy focused ultrasound
62639316|NCT03787823|OTHER|Retzius-sparing RARP|Arm B randomizes men with an indication for radical robotic Prostatectomy (RARP) to retzius-sparing transdouglas RARP
62639317|NCT03787823|OTHER|anterior transperitoneal RARP|Arm A randomizes men with an indication for radical robotic Prostatectomy (RARP) to anterior transperitoneal RARP
62639318|NCT05344846|EXPERIMENTAL|Guided imagery Group|Guided imagery after cesarean
62639319|NCT05344846|NO_INTERVENTION|Standard care|The participants in the control group will perform routine care of the clinic.
62639320|NCT03457389|EXPERIMENTAL|Experimental group|Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.
62639321|NCT03457389|ACTIVE_COMPARATOR|Control group|Serum prolactin level is adjusted to normal range during cabergoline administration.
62639322|NCT00596271|ACTIVE_COMPARATOR|IC51 and Placebo|6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
62639323|NCT00596271|ACTIVE_COMPARATOR|HAVRIX and placebo|HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
62639324|NCT00596271|ACTIVE_COMPARATOR|IC51 and HAVRIX|IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)
62639325|NCT04105179|EXPERIMENTAL|Implant Groups|Group will receive the Smith \& Nephew Journey II knee implant or the Zimmer NexGen LPS-Flex knee implant
62070754|NCT00095823|PLACEBO_COMPARATOR|A1|
62070755|NCT00095823|ACTIVE_COMPARATOR|A2|
62070756|NCT00095823|NO_INTERVENTION|A3|
62639326|NCT04105179|NO_INTERVENTION|Healthy Control Group|Control group that will not be undergoing a total knee arthroplasty
62653009|NCT05155319|ACTIVE_COMPARATOR|Cohort 1, 1A|Low dose (Day 1) plus placebo (Day 22)
62070757|NCT01996072|EXPERIMENTAL|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
62275519|NCT01826682|PLACEBO_COMPARATOR|Medical treatment|29 people are being recruited in order to the inclusion criteria for the study. Placebo controlled.
62454715|NCT05036603|EXPERIMENTAL|2/active chest physiotherapy in modified drainage positions|Group 2 (n=20) newborns on mechanical ventilator respiratory support and CPAP; A single session of active chest physiotherapy (CP) will be applied using modified drainage positions (avoiding the trendelenburg position, excessive position change and avoiding hand contact in babies younger than 30 weeks or who are sensitive to position change). Active CP in various modified drainage positions; It will consist of percussion and vibration methods with proprioceptive replacement stimulations. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
62639327|NCT04847024|EXPERIMENTAL|Parecoxib|Parecoxib 40 mg reconstituted in 2ml of saline solution, to pass IV as a bolus, every 12hrs + acetaminophen 1g in 100cc of saline solution to pass IV in 15 minutes, every 6hrs.
62639328|NCT04847024|EXPERIMENTAL|Dexketoprofen|Dexketoprofen 50 mg in 100 cc of saline solution, protected from sunlight, to be given IV in 15 minutes, every 8hrs + acetaminophen 1g in 100 cc of saline solution to be given IV in 15 minutes, every 6hrs.
62639329|NCT00380536|EXPERIMENTAL|1|Participants will participate in peer-led medical illness self-management group sessions.
62070758|NCT04261179|OTHER|Lymphoseek + Nanocoll|Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams
62070759|NCT04545216||UT4M 40|athletes participating to the 40 km mountain race.
62070760|NCT04545216||UT4M 160|athletes participating to the 160 km mountain race.
62070761|NCT04545216||UTV 55|athletes participating to the 55 km mountain race.
62070762|NCT04021992|EXPERIMENTAL|GVD with or without R|Gemcitabine 1000mg/m2, d1,d8, intravenous drip; Vinorelbine 50mg/m2, d1,d8, oral; Doxorubicin liposomes 30mg/m2, d1,intravenous drip; With or without rituximab 375 mg/m2, d0,intravenous drip; All patients received up to 6 treatment cycles of 21 days.
62070763|NCT03933332||Ventilator length of use|measured in days
62070764|NCT04100460|EXPERIMENTAL|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
62070765|NCT04100460|EXPERIMENTAL|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
62070766|NCT04100460|PLACEBO_COMPARATOR|Control - No Arabinoxylan (Maltodextrin)|Participants are given no Arabinoxylan
62275520|NCT01826682|ACTIVE_COMPARATOR|Physiotherapy program+medical treatment|29 people are recruited in order to the inclusion criteria for the study. Experimental group
62275521|NCT03359876||Rivaroxaban|NVAF patients with renal dysfunction newly initiated on rivaroxaban 15 mg for stroke prevention
62275522|NCT03359876||Warfarin|NVAF patients with renal dysfunction newly initiated on vitamin K antagonist (warfarin) for stroke prevention
62639330|NCT00380536|NO_INTERVENTION|2|Participants will receive treatment as usual.
62639331|NCT00179140|NO_INTERVENTION|1|control period
62070767|NCT01325649||advanced rectal cancer|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low rectal carcinoma, and with cT4 Tumors Arm 1 Long course radiochemotherapy before total mesorectal excision Arm 2 total mesorectal excision without radiochemotherapy
62070768|NCT01267253|EXPERIMENTAL|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62070769|NCT01642082|EXPERIMENTAL|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62070770|NCT02109198|EXPERIMENTAL|Active CN-NINM PoNS|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
62070771|NCT02109198|PLACEBO_COMPARATOR|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
62070772|NCT01493960|EXPERIMENTAL|Cobitolimod|2 doses 4 weeks apart
62070773|NCT01493960|PLACEBO_COMPARATOR|Placebo|2 doses 4 weeks apart
62070774|NCT03452605|EXPERIMENTAL|high cocoa flavanol drink|high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI
62070775|NCT03452605|PLACEBO_COMPARATOR|low cocoa flavanol drink|low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI
62070776|NCT05444400|EXPERIMENTAL|Strengthening of lower limbs|The participants of this group will carry out their training following the protocol described. The participants work with strength of lower limbs.
62070777|NCT05444400|ACTIVE_COMPARATOR|Conventional protocol|The participants of this group will carry out their rehabilitation following the conventional protocol.
62275523|NCT03556930|EXPERIMENTAL|Movie Induced Sedation Effect|Pediatric Radiation Oncology with Movie Induced Sedation Effect monitored by an AlignRT system (VisionRT LTD, UK).
62275524|NCT00941460|EXPERIMENTAL|one week on one week off|One week on temozolomide is followed by a week without temozolomide.
62639332|NCT00179140|ACTIVE_COMPARATOR|2|protein supplementation plus resistance exercise
62639333|NCT00179140|ACTIVE_COMPARATOR|3|protein supplementation only
62639334|NCT05739318|EXPERIMENTAL|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial during the cuff is collapsed
62070778|NCT01642069||Observational|Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or MLL-rearrangements, and other gene expression profiling by RT-PCR and karyotyping or FISH. Results are then compared with each patient's outcome data.
62070779|NCT04940182|EXPERIMENTAL|XC221|XC221 100 mg orally. 1 tablet of XC221 100 mg 2 times a day during 14 full days of treatment period
62275525|NCT00941460|EXPERIMENTAL|three weeks on, one week off|Temozolomide is given over 3 weeks, followed by a week without temozolomide.
62639335|NCT05739318|EXPERIMENTAL|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial during the cuff is inflated
62639336|NCT01406093||Candidemia patients|Patients with diagnosis of candidemia
62070780|NCT04940182|PLACEBO_COMPARATOR|Placebo|Placebo orally. 1 tablet of Placebo 2 times a day during 14 full days of treatment period
62639337|NCT00230048|NO_INTERVENTION|Assessment only|
62639338|NCT00230048|EXPERIMENTAL|Brief intervention|
62275526|NCT00666458|EXPERIMENTAL|1|saxagliptin add-on to metformin
62639339|NCT06274970|EXPERIMENTAL|ERAS Group|Those patients who follow ERAS protocols preoperatively, intraoperatively and post operatively
62639340|NCT06274970|ACTIVE_COMPARATOR|Conventional Group|Those patients who conventional protocols preoperatively, intraoperatively and post operatively
62070781|NCT06468072|EXPERIMENTAL|Children with autism|The experimental group consists of 10 children diagnosed with autism who voluntarily attend the CNR-IRIB in Messina. The sample is aged between 7 and 11 years with severity level 1 (minimum support required)
62070782|NCT06468072|OTHER|Non-autistic children|The comparison group consists of 10 non-autistic children with no other diagnosis, who voluntarily attend the CNR-IRIB in Messina. The sample is between 7 and 11 years old.
62639341|NCT01042418|EXPERIMENTAL|Whole kernel breakfast|
62070783|NCT01255943||prevalent hemodialysis patients|These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients
62070784|NCT03239405||SCS|Treated via suction callibrated system
62070785|NCT03239405||Bougie|Treated with multiple tubes \& bougie
62275527|NCT00666458|ACTIVE_COMPARATOR|2|sitagliptin add-on to metformin
62275528|NCT04479566|EXPERIMENTAL|lithium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
62275529|NCT04479566|PLACEBO_COMPARATOR|calcium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
62275530|NCT03447626||Prospective Group- Robotic UKA Arm|Robotic UKA with the MAKO machine.
62639342|NCT01042418|PLACEBO_COMPARATOR|Wheat reference breakfast|
62275531|NCT03447626||Control- Fixed and Mobile UKA Arm|Patients who have received fixed or mobile bearing UKA
62639343|NCT01042418|ACTIVE_COMPARATOR|Milled kernel breakfast|
62639344|NCT02842047|EXPERIMENTAL|End of Life Care with Meditation|The intervention has two content components: end of life planning education (using end of life planning videos) and strategies and kindness based meditation (using the Stop, Breathe \& Think™ app). The activities comprising these components work together to improve both analytic neural processing (e.g. improving knowledge about goal setting and EOL planning, learning self-monitoring of EOL values and goals of care, and self-regulation skills of monitoring symptoms of distress and anxiety) and emotional neural processing (e.g. teaching participants to experience the moment non-judgmentally and directing thoughts to think positive thoughts and feel positive feelings like kindness and compassion.
62639345|NCT02842047|ACTIVE_COMPARATOR|Meditation Only|This arm has the single content component of kindness based meditation delivered by using the Stop, Breathe \& Think™ application. This group will also be instructed to view 3 caregiver wellness videos.
62653010|NCT05155319|ACTIVE_COMPARATOR|Cohort 1, 1B|Low dose (Day 1) plus low dose (Day 22)
62275532|NCT03447626||Control-Total Knee Arthroplasty|Patients who have had cemented or cementless total knee arthroplasty
62454716|NCT05036603|EXPERIMENTAL|3/active chest physiotherapy in prone positions|Group 3 (n=20) newborns on mechanical ventilator respiratory support and CPAP; a single session of active chest physiotherapy treatment to be applied only in the prone position; Starting with proprioceptive stimulation, percussion and vibration methods will be applied. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
62070786|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
62070787|NCT05126979|EXPERIMENTAL|Flu-M (without a preservative)|15 volunteers were treated with the Flu-M inactivated split influenza vaccine without a preservative
62070788|NCT05126979|EXPERIMENTAL|Flu-M (with a preservative)|15 volunteers were treated with the Flu-M inactivated split influenza vaccine with a preservative
62275533|NCT01985672||Vitamin D deficient patients|Serum 25-OH Vitamin D levels \<20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
62639346|NCT02614989|EXPERIMENTAL|MRI guided Focused Ultrasound treatment|"MRI guided focused ultrasound thalamotomy~Patients will undergo unilateral thalmotomy using MRI guided Focused Ultrasound intervention for the treatment of the tremor"
62070789|NCT05126979|PLACEBO_COMPARATOR|Placebo|15 volunteers were treated with a placebo
62275534|NCT01985672||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels \>20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
62275535|NCT00361595|EXPERIMENTAL|open label|5 mg zoledronic acid in a single 15 minute IV
62639347|NCT01656083||SM intervention + varenicline|In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.
62639348|NCT01656083||Non-SM intervention group: varenicline|varenicline only
62639349|NCT06165211|EXPERIMENTAL|Nature Sound Group|During hemodialysis, 30 minutes with an Mp3 player and headphones (to minimize the effect of surrounding noise). Nature sounds consisting of bird, wind and tree sounds will be played.
62275536|NCT06541873||Patients with ALS or other motor neuron disease phenotype|Patients with ALS and other MND phenotypes will undergo gait evaluation using wearable sensors in different conditions (single-task vs dual-task conditions).
62639350|NCT06165211|PLACEBO_COMPARATOR|Routine Care|Patients will watch the program they want on the bedside TV during hemodialysis.
62639351|NCT05038930|EXPERIMENTAL|Intervention protocol|"Phase 1. The patient will be positioned in a supine position for 20 minutes on the Sara Combilizer®. When necessary, the head of the patient can be elevated to a maximum of 30 degrees during the 20 minutes baseline measurements.~Phase 2. The patient will be positioned in a seated position for 10 minutes with the trunk and head elevated to at least 70 degrees.~Phase 3. The patient will be moved to the standing position for 20 minutes with an elevation angle of the Sara Combilizer of at least 70 degrees. If patients become haemodynamically unstable during the seated or standing position, they will be returned to the supine position, and the intervention will be terminated.~Phase 4. The patient is returned to the phase 1 position (supine). Further measurements are made for at least 20 minutes."
62639352|NCT05038930|NO_INTERVENTION|Sedentary protocol|The sedentary protocol will follow the same four phases as the intervention protocol only the patient will remain in the supine position on the Sara Combilizer®. Ideally, no interventions will occur during the 70-minute protocol. If medications are given or other interventions are necessary, this will be registered.
62639353|NCT01228591|OTHER|Acuvue Advance Plus/ Acuvue Advance|Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.
62639354|NCT01228591|OTHER|Acuvue Advance/Acuvue Advance Plus|Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.
62639355|NCT02456194|EXPERIMENTAL|Calcium Sulfate + Antibiotics + Internal Fixation|
62639356|NCT04125979|EXPERIMENTAL|Preservation of pulmonary vagus nerve|Preservation of pulmonary branches of vagus nerve in minimally invasive surgery for lung cancer
62639357|NCT04125979|EXPERIMENTAL|No pulmonary vagus nerve preservation|In minimally invasive surgery for lung cancer, the pulmonary branches of vagus nerve were severed
62639358|NCT06396949||Patient group|Volunteer men and women diagnosed with fibromyalgia to ACR (American College of Rheumatology) 2016 criteria between the ages of 18 and 50 who applied to our clinic will be included in our study
62639359|NCT06396949||Control group|Healthy,volunteer men and women between the ages of 18-50 who applied to our clinic will be included in our study
62639360|NCT05868590|EXPERIMENTAL|Active Magnesium Containing Toothpaste-ROCS|The participants will ask not to eat for 4 hours and not to brush for 24 hours in advance of the test.In the first stage, the preliminary plaque in the children will record by the first researcher using plaque dye.After plaque disclosing the researcher brush children's teeth with ROCS active magnesium toothpaste for 1 minute with a standard toothbrush then the plaque staining will apply again.Also remaining plaque measurements will made using the Gc D lite Pro curring light on detection mode.Dental plaque on the upper anterior incisors will photograph intra-orally before and after brushing under standardized conditions.
62653011|NCT05155319|PLACEBO_COMPARATOR|Cohort 1, 1C|Placebo (Day 1) plus Placebo (Day 22)
62653012|NCT05155319|ACTIVE_COMPARATOR|Cohort 2, 2A|High dose (Day 1) plus placebo (Day 22)
62653013|NCT05155319|ACTIVE_COMPARATOR|Cohort 2, 2B|High dose (Day 1) plus high dose (Day 22)
62275537|NCT06541873||Healthy controls|30 healthy controls with similar age and sex distribution will undergo the same evaluations as patients
62275538|NCT00959816|EXPERIMENTAL|Single Dose (Part 1)|
62275539|NCT00959816|EXPERIMENTAL|Multiple Dose (Part 2)|
62639361|NCT05868590|EXPERIMENTAL|Fluoride Toothpaste-COLGATE|After 2 weeks, the same participants will ask not to eat for 4 hours and not to brush for 24 hours in advance of the retest.Initial, the preliminary plaque in the children will record by the first researcher using plaque dye. After plaque disclosing the researcher brush children's teeth with Colgate fluoride toothpaste for 1 minute with a standard toothbrush then the plaque staining will apply again.Also remaining plaque measurements will made using the Gc D lite Pro curring light on detection mode.Dental plaque on the upper anterior incisors will photograph intra-orally before and after brushing under standardized conditions.
62070790|NCT04573413|EXPERIMENTAL|r-TMS group|The interventions have a total administration time of 75 minutes per day. For rTMS stimulation, the coil will be positioned tangentially on the target area. Each rTMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The CCT (i.e. visual scanning treatment) involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities.Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the rTMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
62070791|NCT04573413|SHAM_COMPARATOR|SHAM group|SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the experimental group.
62639362|NCT03658291|EXPERIMENTAL|Sanjin tablets group|Sanjin tablets+ levofloxacin simulants
62070792|NCT00172081|PLACEBO_COMPARATOR|placebo|Daily subcutaneous injection into thigh or abdomen with 700 mg Calcium and 400 IU Vitamin D daily
62070793|NCT00172081|EXPERIMENTAL|PTH(1-84) 100 mcg|Subcutaneous injection of PTH(1-84) with 700 mg Calcium and 400 IU Vitamin D daily
62070794|NCT01421485|EXPERIMENTAL|Integrated treatment Program|
62070795|NCT01421485|ACTIVE_COMPARATOR|Treatment as Usual|
62070796|NCT01085565|EXPERIMENTAL|Exablate treatment|
62070797|NCT01684995|ACTIVE_COMPARATOR|Minimal|Brief physician advice to quit smoking plus nicotine patch
62070798|NCT01684995|EXPERIMENTAL|Tailored|
62070799|NCT03696875|EXPERIMENTAL|Multilevel Guided Discharge Planning|
62070800|NCT03696875|ACTIVE_COMPARATOR|Standard of care|
62275540|NCT00923117|EXPERIMENTAL|Bevacizumab resistant patients|Patients who had tumor progression while treated with bevacizumab.
62275541|NCT00923117|EXPERIMENTAL|Bevacizumab naive patients|Patients with progressive tumor who have not been treated with bevacizumab.
62275542|NCT04848922|EXPERIMENTAL|Intervention Group|Took a hot shower intervention and usual care.
62275543|NCT04848922|NO_INTERVENTION|Control Group|No intervention other than usual care.
62275544|NCT04405050|ACTIVE_COMPARATOR|Restrata|Treated with Restrata
62639363|NCT03658291|PLACEBO_COMPARATOR|Levofloxacin group|Sanjin tablets simulants +levofloxacin
62639364|NCT03658291|ACTIVE_COMPARATOR|Sanjin tablets+ Levofloxacin group|Sanjin tablets+ levofloxacin
62639365|NCT02567383|EXPERIMENTAL|Hyperthermia|Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
62653014|NCT05155319|PLACEBO_COMPARATOR|Cohort 2, 2C|Placebo (Day 1) plus Placebo (Day 22)
62653015|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 125mg/m2|"NUC-3373 125mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62653016|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 250mg/m2|"NUC-3373 250mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62639366|NCT03021746|EXPERIMENTAL|Parish Nurse plus Peer Leader|The focus of this approach is for Peer Leaders (PL) to provide Diabetes Self Management Support (DSMS) with the oversight of Parish Nurses (PN). The first component starts with group-based Diabetes Self Management Education (DSME) provided by Certified Diabetes Educators (CDE), co-facilitated by PN and PL and held at the church. PL will also facilitate activities including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit, with oversight of PN. As the study progresses, PL and PN will have progressive leadership responsibilities. Following DSME, participants will be invited to attend 12 months of monthly DSMS support groups led by the PL, with oversight from the PN. This approach allows for PN to provide direct supervision to PL in areas of clinical content, educational methods, and group facilitation and communication skills.
62653017|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 500mg/m2|"NUC-3373 500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62070801|NCT03393338|EXPERIMENTAL|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
62070802|NCT03393338|NO_INTERVENTION|Usual Medical Care|Usual medical care
62454717|NCT04566809|EXPERIMENTAL|Experimental group: FES+CBA|FES+CBA participants executed FES and CBA treatment which means that during the stimulation they manipulated different tools. In particular, for the first ten sessions the participants were invited to manipulate specific objects: squares, rectangles and pyramids of different sizes; touch on plastic test tubes coated with materials of different consistency; these two exercises were performed both with open and closed eyes. Finally, for the last ten sessions the participants were asked to execute specific tasks, depending on person's life before the lesion.
62454718|NCT04566809|ACTIVE_COMPARATOR|Control Group: FES|FES participants received only FES to improve their manipulating skills without the interaction with objects, but only with the muscle contraction induced by the devices.
62070803|NCT03085251|EXPERIMENTAL|Blood glucose measurement|
62275545|NCT04405050|ACTIVE_COMPARATOR|NPWT|Treated with NPWT (Negative Pressure Wound Therapy)
62275546|NCT03912129|OTHER|pediatric Evans Syndrome|Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
62454719|NCT04107870|EXPERIMENTAL|Virtual Reality Exposure Therapy|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
62454720|NCT04107870|ACTIVE_COMPARATOR|Psychomotor Therapy|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
62454721|NCT03825809|EXPERIMENTAL|Post-Operative Non Opioid Pain Protocol|"Patients will be administered a post-operative non-opioid pain protocol consisting of:~Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam"
62454722|NCT03825809|ACTIVE_COMPARATOR|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
62454723|NCT06165900|EXPERIMENTAL|adebrelimab plus stereotactic radiotherapy and chemotherapy|
62454724|NCT06165900|ACTIVE_COMPARATOR|adebrelimab plus nab-paclitaxel + carboplatin|
62454725|NCT01134081|EXPERIMENTAL|CelTx™|Living bilayered cell therapy product
62454726|NCT01134081|ACTIVE_COMPARATOR|Free Gingival Grafts|Harvested tissue from palate
62454727|NCT04988386|EXPERIMENTAL|AG10|Open-label study all participants will receive AG10 during this study.
62454728|NCT02613923|EXPERIMENTAL|GO! To Sleep|Participants in the intervention group will be provided with a code and website address to participate in this program. This program includes reminder emails and is 6 weeks in duration. Participants will be given a blood draw to measure biomarkers.
62639367|NCT03021746|EXPERIMENTAL|Peer Leader Only|This approach will contain the same elements as the PN plus PL approach, except that a PN will not be used. Rather, PL will provide all aspects of DSMS, including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. This approach will be delivered in a group setting. DSME will be provided by CDEs and co-facilitated by a PL to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 monthly DSMS groups led by PL. Following the group sessions, participants will transition into a period of ongoing support. During this time, participants and PL will be encouraged to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. If needed, PL may contact the CDE for additional information
62639368|NCT03021746|EXPERIMENTAL|Parish Nurse Only|The main focus of this approach will contain all of the same elements as the PN plus PL approach, except that PL will not be used. Rather, the PN will provide all aspects of Diabetes Self Management Support (DSMS), including facilitation of goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. Diabetes Self Management Education (DSME) will be provided by CDEs and co-facilitated by a PN to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 months of monthly, DSMS support groups led by the PN. Following support sessions, participants will transition into a period of ongoing support, where the participants and PN will be encouraged to continue to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. The PN may answer clinical questions and may contact the CDE for additional information if needed.
62070804|NCT04422639|EXPERIMENTAL|Arm I (pre-operative SRS/SRT)|Patients undergo SRS or SRT within 15 days of randomization followed by surgery within 15 days of radiation completion. Patients may undergo additional SRS or SRT if disease returns after treatment.
62275547|NCT06213909||eosinophil group|Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly eosinophils
62639369|NCT03714763|EXPERIMENTAL|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
62639370|NCT03714763|EXPERIMENTAL|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
62639371|NCT05282511||Patients with acute myocardial infarction|Patients with acute myocardial infarction
62639372|NCT05282511||Healthy controls|Healthy controls
62639373|NCT05282511||Patients with vasospastic angina|Patients with vasospastic angina
62639374|NCT03065647|NO_INTERVENTION|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
62639375|NCT03065647|EXPERIMENTAL|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
62639376|NCT04155463|EXPERIMENTAL|Organic Diet, Then Conventional Diet:|"These participants first received an organic diet for one week. During that week, daily first morning void urine samples were collected. After a washout period of one day, these participants then received a conventional (non-organic) diet for one week. During that week, daily first morning void urine samples were collected.~For each week, participants ordered all food they anticipated eating that week (up to $150) from a unique account with a local grocery store in accordance with either the organic diet or conventional diet. Study staff verified all food items corresponded with the dietary intervention that week, and then ordered the groceries to be delivered to the participant's home, when possible. For participants living in areas in which delivery was not available (generally rural areas), study staff picked up the food at the grocery store and delivered it to the participant's home."
62653018|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 750mg/m2|"NUC-3373 750mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62275548|NCT06213909||neutrophil group|Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly neutrophil
62275549|NCT06213909||lymphocyte group|Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly lymphocyte
62653019|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 1125mg/m2|"NUC-3373 1125mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62275550|NCT00356278|EXPERIMENTAL|A|Participants will receive VRE therapy and D-cycloserine
62275551|NCT00356278|ACTIVE_COMPARATOR|B|Participants will receive VRE therapy and alprazolam
62070805|NCT04422639|ACTIVE_COMPARATOR|Arm II (post-operative SRS/SRT)|Patients undergo surgery within 15 days of randomization followed by standard-of-care SRS or SRT within 30 days of surgery. Patients may undergo additional SRS or SRT if disease returns after treatment.
62070806|NCT05813626|EXPERIMENTAL|Toripalimab Combined with Induction Chemotherapy|Induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1); Toripalimab, 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.
62639377|NCT04155463|EXPERIMENTAL|Conventional Diet, Then Organic Diet|"These participants first received a conventional (non-organic) diet for one week. During that week, daily first morning void urine samples were collected. After a washout period of one day, these participants then received an organic diet for one week. During that week, daily first morning void urine samples were collected.~For each week, participants ordered all food they anticipated eating that week (up to $150) from a unique account with a local grocery store in accordance with either the organic diet or conventional diet. Study staff verified all food items corresponded with the dietary intervention that week, and then ordered the groceries to be delivered to the participant's home, when possible. For participants living in areas in which delivery was not available (generally rural areas), study staff picked up the food at the grocery store and delivered it to the participant's home."
62275552|NCT00356278|PLACEBO_COMPARATOR|C|Participants will receive VRE therapy and placebo
62639378|NCT05677711||Ultimaster|Ultimaster stent
62639379|NCT04036487|EXPERIMENTAL|IH group|Inhalation anesthesia will be given during transaxillary endoscopic breast augmentation.
62639380|NCT04036487|ACTIVE_COMPARATOR|TIVA group|Total intravenous anesthesia will be given during transaxillary endoscopic breast augmentation.
62639381|NCT02168959|ACTIVE_COMPARATOR|Femoral nerve block|bupivacaine
62639382|NCT02168959|NO_INTERVENTION|No femoral nerve block|No block
62639383|NCT01394289|EXPERIMENTAL|Biological/Vaccine: Lolium allergen extract|Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
62639384|NCT05116917|EXPERIMENTAL|Experimental Arm|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days).
62639385|NCT04822714|EXPERIMENTAL|Mobile Career Competencies Intervention|The intervention protocol has five main components and is designed in English language. The first component consists of an educational session. The second component focuses on one's reflection on motivation and qualities. The third component assists users in working out strategies with others. The fourth component prompts users to reflect on and narrate their emerging career stories through goal-setting identification activities. The fifth component includes the government's human resource practices, training programs offered, and policies. The fourth and fifth component require users to reflect on their work exploration and career control career competencies.
62639386|NCT04822714|NO_INTERVENTION|Waitlist control|Waitlist control group attended work and basic training from the organization as usual. They only receive the mobile intervention after the intervention group completing of the intervention.
62287158|NCT03072160|EXPERIMENTAL|Cohort 1: Participants that had an immune stimulating cancer vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 1: cancer vaccine"
62287159|NCT03072160|EXPERIMENTAL|Cohort 2: Participants that have had no vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 2: had no previous vaccine"
62639387|NCT00274742|EXPERIMENTAL|Blinatumomab|Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.
62639388|NCT03118934|EXPERIMENTAL|AOA MF|Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 10 ± 3 days
62639389|NCT03118934|EXPERIMENTAL|DACP MF|Nelfilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
62639390|NCT03118934|EXPERIMENTAL|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
62639391|NCT01956890|OTHER|diagnostic accuracy|diagnostic accuracy of PET and MRI for breast cancer diagnosis.
62653020|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 1500mg/m2|"NUC-3373 1500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62639392|NCT03898622|ACTIVE_COMPARATOR|Group with levothyroxine|Patients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. That meet the inclusion criteria. Levothyroxine 25 mcg (1/4 tablet of 100mcg) was administered in fasting the first month, the doctor evaluated with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 uim / L the second month increase to a dose of 50 mcg (1/2 tablet of 100mcg fasting, or similarly if the patient had a TSH \<1 u / L was suspended in medication and it was valued restart the next month the medication if TSH\> 2.5u / L ) to complete three months of intervention.
62070807|NCT02183870|EXPERIMENTAL|Crizotinib|Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
62454729|NCT02613923|ACTIVE_COMPARATOR|informational control|Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
62070808|NCT00676975|ACTIVE_COMPARATOR|Traditional Chinese Medicine|Traditional Chinese Medicine 17g herbal extract
62070809|NCT00676975|PLACEBO_COMPARATOR|Traditional Chinese Medicine Placebo|Placebo
62287160|NCT01901835|EXPERIMENTAL|Arm I (humorous followed by non-humorous movies)|Participants are provided headphones and a tablet and choose among a selection of humorous movies. Upon the third course of chemotherapy, participants are provided a selection of non-humorous movies.
62639393|NCT03898622|PLACEBO_COMPARATOR|Group Placebo|"atients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. that meet the inclusion criteria.~Placebo (1/4 tablet) was administered in fasting the first month, the doctor assessed with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 UM / L the second month increase at a dose (1/2 tablet fasting, or similarly if the patient had TSH \<1 u / L was suspended in medication and it was valued restart the next month the medication if TSH\> 2.5 / month) to complete three months of intervention."
62639394|NCT01590108|EXPERIMENTAL|Apelin|Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.
62639395|NCT01590108|PLACEBO_COMPARATOR|Control|Subject will take cardiopulmonary exercise testing with receive placebo
62639396|NCT01943981||Optimal/inappropriate exercise response|
62070810|NCT00953914|EXPERIMENTAL|Pyridostigmine|
62070811|NCT00953914|PLACEBO_COMPARATOR|Placebo|If a subject is randomized to placebo, he will receive placebo pills 3 times daily for 1 day.
62070812|NCT03961113||assessment by questionnaire|
62070813|NCT05591560|PLACEBO_COMPARATOR|Group I Placebo group|Group I (Placebo group; n=33) which will be treated with chemotherapy which includes paclitaxel 60 mg/m2 IV over 1 hour followed by carboplatin area under the curve 2 (AUC 2) IV over 30 minutes Day 1, 8, and 15 which will be repeated every 21 days for 6 cycles 12 plus 4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy).
62070814|NCT05591560|ACTIVE_COMPARATOR|Group II Itraconazole group|Group II: (Itraconazole group; n=33) which will be treated with chemotherapy which includes paclitaxel 60 mg/m2 IV over 1 hour followed by carboplatin AUC 2 IV over 30 minutes Day 1, 8, and 15 repeated every 21 days for 6 cycles 12 plus oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy).
62070815|NCT03032874||Training set|All the patients with rectal bleeding who had colonoscopy performed at Obafemi Awolowo University Teaching Hospitals Complex
62070816|NCT03032874||Validation set|All the patients with rectal bleeding who had colonoscopy performed at University College Hospital, Ibadan and University of Ilorin Teaching Hospital
62287161|NCT01901835|EXPERIMENTAL|Arm II (non-humorous followed by humorous movies)|Participants are provided headphones and a tablet and choose among a selection of non-humorous movies. Upon the third course of chemotherapy, participants are provided a selection of humorous movies.
62287162|NCT02288884|ACTIVE_COMPARATOR|Silver containing dressing|Subjects will have a silver containing dressing (Acticoat PostOp) applied at the time of elective cesarean section.
62454730|NCT00636896|EXPERIMENTAL|1|Olanzapine 10 mg plus modafinil 200 mg
62454731|NCT00636896|PLACEBO_COMPARATOR|2|Olanzapine plus Placebo
62454732|NCT03491449|EXPERIMENTAL|Group A: pressure ≥140 and ≤160mmHg|Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.
62639397|NCT03131167|EXPERIMENTAL|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
62639398|NCT03131167|PLACEBO_COMPARATOR|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
62070817|NCT05394233|EXPERIMENTAL|tislelizumab combined with bevacizumab and platinum plus pemetrexed|"Drug:~Induction Phase:~Bevacizumab: 7.5 mg/kg administered as an IV infusion on Day 1 of each 3-week cycle for 4 cycles Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours every 3 weeks for 4 cycles.~Pemetrexed, 500 mg/m2, intravenously, every 3 weeks for 4 cycles~Maintenance phase:~Tislelizumab, 200 mg IV every 3 weeks;until disease progression or intolerance Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle;until disease progression or intolerance"
62454733|NCT03491449|ACTIVE_COMPARATOR|Group B: Keep systolic pressure <185mmHg|Intensive management of blood pressure, maintaining systolic blood pressure \<185 mm Hg for 72 hours.
62639399|NCT06160089|ACTIVE_COMPARATOR|Gravitational group|Participants will have to perform a 6-week programme based on three exercises: front lunge, side lunge, and front lunge with hand grip pull, that will be the basis of each session. Exercices will be performed with the gravitational device.
62639400|NCT06160089|EXPERIMENTAL|Isoinertial group|Participants will have to perform a 6-week programme based on three exercises: front lunge, side lunge, and front lunge with hand grip pull, that will be the basis of each session. Exercices will be performed with the isoinertial device.
62639401|NCT04479839||Microcuff ETT|Patients intubated with microcuff ETT
62639402|NCT04479839||Non-microcuff ett|Patients intubated with regular ETT
62639403|NCT04996420|EXPERIMENTAL|Clearsight|hemodynamic monitoring and goal directed fluid therapy guided by clearsight
62070818|NCT02969031|EXPERIMENTAL|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
62454734|NCT03106870|ACTIVE_COMPARATOR|oral metformin and insulin|Intervention 'Insulin Mixtard' and Intervention 'metformin' had included
62639404|NCT04996420|OTHER|Control|hemodynamic monitoring blinded and silenced, no goal directed fluid therapy. Fluid therapy based on clinical evaluation and mean arterial pressure by non-invasive monitoring
62639405|NCT05362812||Patients with systemic lupus erythematosus|Diagnostic Test: Flow cytometry analysis of urine samples. Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and B cell panel with fluorochromes. T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD38, CD279; B cell panel: CD19, CD20, CD27, CD38, CD21, IgD, CXCR5
62639406|NCT04619017|EXPERIMENTAL|Segmental allergen challenge|Allergic individuals with and without asthma will be enrolled.
62639407|NCT00967577|EXPERIMENTAL|J591|
62639408|NCT02438280|EXPERIMENTAL|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
62454735|NCT03106870|ACTIVE_COMPARATOR|insulin therapy only|Intervention 'Insulin Mixtard' had included
62454736|NCT05928780|EXPERIMENTAL|LAR|Coelomofacial androgen receptor
62454737|NCT05928780|EXPERIMENTAL|IM|Immunoregulatory type
62454738|NCT05928780|EXPERIMENTAL|BLIS|Basal type and immunosuppressive type
62454739|NCT05928780|EXPERIMENTAL|MES|Interstitial type
62639409|NCT02438280|ACTIVE_COMPARATOR|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
62639410|NCT03403907|EXPERIMENTAL|Probiotic|Probiotic administration
62639411|NCT01093846|EXPERIMENTAL|AIN457 300 mg every 2 weeks|
62639412|NCT01093846|EXPERIMENTAL|AIN457 300 mg monthly|
62639413|NCT01093846|PLACEBO_COMPARATOR|Placebo|
62639414|NCT03769649|EXPERIMENTAL|Treatment arm|Subjects receive CelluTite treatment followed by Morpheus8 treatment
62639415|NCT01704755|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
62639416|NCT01704755|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
62639417|NCT00971477|EXPERIMENTAL|Teledermatology|Online Telemedicine Group
62070819|NCT02969031|ACTIVE_COMPARATOR|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
62070820|NCT02010697|EXPERIMENTAL|Messages targeting nonsmokers|Messages targeting nonsmokers include 10 mailings for nonsmokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
62070821|NCT02010697|EXPERIMENTAL|Messages targeting smokers|Messages targeting smokers include 10 mailings for smokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
62639418|NCT00971477|ACTIVE_COMPARATOR|Usual Care|Conventional in-office care
62070822|NCT02010697|NO_INTERVENTION|Usual care|one time mailing with a self-help quit kit
62454740|NCT00430079|EXPERIMENTAL|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.
62639419|NCT01768325|ACTIVE_COMPARATOR|EUS-Guided biopsy needle (ProCore)|"Comparison of ProCore core biopsy needle to QuickCore core biopsy needle.Cook Medical core biopsy needle.~* The number of needle passes requiring to acquire adequate specimen~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
62639420|NCT01768325|ACTIVE_COMPARATOR|EUS-TCB needle (Quick-Core)|"Comparison of core biopsy needles.~* The number of needle passes requiring to acquire adequate specimen~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
62639421|NCT04988204|EXPERIMENTAL|Treatment Arm|Patients enrolled in 1 year program
62454741|NCT00899964|ACTIVE_COMPARATOR|1|automated tailored feedback per E-mail
62639422|NCT06195436|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy for people with depression|Acceptance and Commitment Therapy for people with depression
62639423|NCT06195436|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy for people without depression.|
62639424|NCT02164955||Relapsed and Refractory Multiple Myeloma Patients|Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)
62639425|NCT02102048|ACTIVE_COMPARATOR|Atazanavir|patients that switch cART to boosted or unboosted ATV
62639426|NCT02102048|NO_INTERVENTION|other Protease Inibithors|patients that continue the previous cART without changes.
62639427|NCT05366595|ACTIVE_COMPARATOR|Treatment group|who received oral zinc sulfate supplementation on dose doses ranging from 10 mg (infants) to 20 mg (under-five children) of elemental zinc per day, a dosage that is safe in these children
62639428|NCT05366595|NO_INTERVENTION|Control group|who didn't receive zinc sulfate supplementation.
62070823|NCT02498379|EXPERIMENTAL|Cu[64]-25%CANF-Comb|Single IV injection of 4-8 mCi Cu\[64\]-25%CANF-Comb followed by PET-CT scan at 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours post injection.
62454742|NCT00899964|ACTIVE_COMPARATOR|2|1 + active contact per E-mail possible
62070824|NCT00781534|ACTIVE_COMPARATOR|1. Ginseng|Ginseng group
62454743|NCT00899964|ACTIVE_COMPARATOR|3|2 + active contact by trainer in case of exercise-related problems
62454744|NCT00899964|ACTIVE_COMPARATOR|4|3 + regular active contact by trainer
62454745|NCT04659109|EXPERIMENTAL|glenzocimab 1000 mg|
62070825|NCT00781534|ACTIVE_COMPARATOR|2. Ginsenosdie RE|Ginsenoside RE (a metabolite of ginseng) group
62070826|NCT00781534|PLACEBO_COMPARATOR|3. Placebo|"placebo (sugar pill) group"
62070827|NCT02221856|EXPERIMENTAL|Motion View|
62454746|NCT04659109|PLACEBO_COMPARATOR|Placebo|
62454747|NCT00543478|ACTIVE_COMPARATOR|1|Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.
62454748|NCT00543478|PLACEBO_COMPARATOR|2|Placebo will be given twice a day for 10 weeks
62454749|NCT00309972|ACTIVE_COMPARATOR|Sequential arm (SEQ)|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
62639429|NCT04545450|ACTIVE_COMPARATOR|Testosterone Undecanoate plus dutasteride|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day
62639430|NCT04545450|PLACEBO_COMPARATOR|Testosterone Undecanoate plus placebo|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill
62639431|NCT00972959|EXPERIMENTAL|Bortezomib/Dexamethasone/Zoledronic Acid|"For this study, Velcade will be administered at the standard dose of 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle.~Dexamethasone will be administered at a dose of 12 mg/m2 p.o., on days 1-2, 4-5, 8-9 and 11-12 of the same cycle.~Zoledronic acid will be administered at a dose of 4 mg, iv (15-minute infusion), every 28 days for up to 8 cycles, and then every 28 days for the next 18 months"
62070828|NCT02221856|ACTIVE_COMPARATOR|Conventional Orthodontic Treatment|
62639432|NCT03705702|ACTIVE_COMPARATOR|Intervention Group (IG)|The intervention of active comparator will be education program plus behavioral intervention through physical activity counseling program combined with a monitoring-and-feedback tool.
62639433|NCT03705702|SHAM_COMPARATOR|Control Group (CG)|The intervention of sham comparator will be an education program in asthma and physical activity recommendations.
62639434|NCT01799447|OTHER|Early intervention|Early intervention. Quasiexperimental study. Inclusion of 150 first times families in intervention and matched with 150 families from control group.
62639435|NCT06225492|EXPERIMENTAL|DaxibotulinumtoxinA 20 units|Subjects will receive 20 units of daxibotulinumtoxinA per platysmal band, up to 2 anterior bands and 2 lateral bands.
62070829|NCT01127906|OTHER|Randomized cross-over sequence|Randomized unbalanced sequence of incomplete block design with replicates within sequence
62070830|NCT04837001|EXPERIMENTAL|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
62070831|NCT04837001|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) will be administered as a single IV bolus injection.
62070832|NCT03812211|ACTIVE_COMPARATOR|Active Supplement|Participants will be allocated in a randomized, double-masked manner to receive a multi-faceted supplement for the 12-week duration of the study
62639436|NCT06225492|EXPERIMENTAL|DaxibotulinumtoxinA 15 units|Subjects will receive 15 units of daxibotulinumtoxinA per platysmal band, up to 2 anterior bands and 2 lateral bands.
62639437|NCT02553343|EXPERIMENTAL|QIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)
62070833|NCT03812211|PLACEBO_COMPARATOR|Placebo|Participants will be allocated in a randomized, double-masked manner to receive a placebo supplement (the placebo will be made of microcrystalline cellulose, and will be matched in size, appearance, taste and caloric value) for the 12-week duration of the study
62070834|NCT04542408|EXPERIMENTAL|Intensive anticoagulation strategy|In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC
62287163|NCT02288884|PLACEBO_COMPARATOR|Standard dressing|Subjects will have a standard dressing (OpSite PostOp) applied at the time of elective cesarean section.
62639438|NCT02553343|EXPERIMENTAL|QIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)
62639439|NCT02553343|ACTIVE_COMPARATOR|TIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine
62639440|NCT02553343|ACTIVE_COMPARATOR|TIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine
62639441|NCT02309086|EXPERIMENTAL|Single arm|Autologous dendritic cells transduced with Ad encoding NS3
62070835|NCT04542408|OTHER|Moderate anticoagulation strategy|In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban
62070836|NCT04421742||43 COPD|COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks
62070837|NCT03491748|EXPERIMENTAL|Part A (SAD): Cohort 1, 100 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) of oral ETX0282. Participants will be treated with a single oral dose of 100 milligrams (mg) ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
62070838|NCT03491748|EXPERIMENTAL|Part A (SAD): Cohort 2, 200 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
62070839|NCT03491748|EXPERIMENTAL|Part A (SAD): Cohort 3, 400 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
62639442|NCT03795480|EXPERIMENTAL|MOOD|"The online program MOOD is based on methods of cognitive behavior therapy (KVT) and contains elements of mindfulness and metacognition. Participants can contact a moderator (trained psychologists) if they have any questions. However, this function is optional. The program consists of nine interactive modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention."
62639443|NCT03795480|NO_INTERVENTION|Control|The wait-list control group does not receive additional treatment. However, previously started therapies (psychotherapy/ psychopharmacotherapy) may be continued during the study. Individuals of the wait-list control group receive access to MOOD after completion of the post-assessment.
62639444|NCT04627194||Mild and asymptomatic COVID-19 patients|Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.
62639445|NCT04627194||Moderate severity COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity \[including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia\] at the time of hospitalization.
62639446|NCT04627194||Severe-to-critical COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation \[including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) \< 90% on room air\] or for critical COVID-19 disease presentation \[including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium\] at the time of hospitalization.
62070840|NCT03491748|EXPERIMENTAL|Part A (SAD): Cohort 4, 800 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 800 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
62639447|NCT04627194||COVID-19 survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who survived.
62639448|NCT04627194||COVID-19 non-survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.
62639449|NCT01350817|ACTIVE_COMPARATOR|Docetaxel|
62639450|NCT01350817|EXPERIMENTAL|Erlotinib|
62639451|NCT03765060|EXPERIMENTAL|Small Stitch|"Patients requiring an urgent emergency laparotomy. The Small Stitch closure technique will be perform using a Monomax® 2/0 HR26 (Half-circle Round body):~* It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle (Half-circle Round body).~* In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
62653021|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 1875mg/m2|"NUC-3373 1875mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62070841|NCT03491748|EXPERIMENTAL|Part A (SAD): Cohort 5, 600 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
62639452|NCT03765060|ACTIVE_COMPARATOR|Large Stitch|"The intervention will be the classic large Stitch closure technique using a Monomax® 1 HR48 (Half-circle Round body).~* It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle (Half-circle Round body).~* In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
62639453|NCT02148393|ACTIVE_COMPARATOR|Control|In the control group, following oocyte retrieval, intensified luteal phase support for fresh embryo transfer (with Pregnyl®, Utrogestan® and Progynova®) will be performed. Fresh ET in the uterine cavity will be performed on the 5th day of embryo development at blastocyst stage under ultrasound guidance whenever possible.
62070842|NCT03491748|EXPERIMENTAL|Part A (SAD): Cohort 6 (Elderly), 300 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Elderly participants (aged 65 years or older) will be treated with a single oral dose of 300 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
62653022|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 2500mg/m2|"NUC-3373 2500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62639454|NCT02148393|EXPERIMENTAL|Intervention|"Elective vitrification with subsequent-cycle embryo thawing/transfer (CryoBioSystem®) will be performed. Hence, no luteal phase support will be provided immediately after oocyte retrieval. Instead, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.~On the day of embryo transfer, blastocyst(s) will be warmed one by one until one or two blastocysts are suitable for transfer. ET to the uterine cavity will be performed under ultrasound guidance whenever possible."
62070843|NCT03491748|EXPERIMENTAL|Part B (Food Effect): Cohort 7, 100 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 100 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 100 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
62639455|NCT02491138|PLACEBO_COMPARATOR|Standard information|In this arm, participants will receive standard information pamphlets about the benefits of good sleeping habits.
62639456|NCT02491138|EXPERIMENTAL|Appearance-based information|In this arm, participants will receive information about how sleep modifies their physical appearance. This will involve a computer transformation that morphs their face according to hours of sleep obtained.
62639457|NCT03194009|ACTIVE_COMPARATOR|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
62639458|NCT03194009|ACTIVE_COMPARATOR|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
62639459|NCT03577249|EXPERIMENTAL|Single arm|
62639460|NCT05032144|EXPERIMENTAL|Cohort 1:2mg/kg|All participants (fasted) received either 2mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62639461|NCT05032144|EXPERIMENTAL|Cohort 2:5mg/kg|All participants (fasted) received either 5mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62070844|NCT03491748|EXPERIMENTAL|Part C (MAD): Cohort 9, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed three times a day (TID) beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
62070845|NCT03491748|EXPERIMENTAL|Part C (MAD): Cohort 10, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed TID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
62275553|NCT04509466|EXPERIMENTAL|dose escalation (part 1)|"dose escalation (part 1):Patients with treatment-naïve, relapsed or refractory extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles. The starting dose of liposomal mitoxantrone hydrochloride is 12mg/m2.dose expansion, treatment-naïve patients (part 2):Patients with treatment-naïve extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles.~dose expansion, relapsed or refractory patients (part 2):Patients with relapsed or refractor extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles."
62275554|NCT00522587|EXPERIMENTAL|1|Fixed sevoflurane dose 1
62275555|NCT00522587|EXPERIMENTAL|2|Fixed sevoflurane dose 2
62275556|NCT00522587|EXPERIMENTAL|3|Fixed sevoflurane dose 3
62639462|NCT05032144|EXPERIMENTAL|Cohort 3:10mg/kg|All participants (fasted) received either 10mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62639463|NCT05032144|EXPERIMENTAL|Cohort 4:20mg/kg|All participants (fasted) received either 20mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62639464|NCT05032144|EXPERIMENTAL|Cohort 5:30mg/kg|All participants (fasted) received either 30mg/kg of STSA-1002 as a single dose or dose-matched placebo.
62275557|NCT00522587|EXPERIMENTAL|4|Fixed sevoflurane dose 4
62275558|NCT00522587|EXPERIMENTAL|5|Fixed sevoflurane dose 5
62639465|NCT00583310|NO_INTERVENTION|Control|Subjects receive standard written educational information at baseline, but do not receive the telephone-based intervention. Subjects may participate in the intervention following completion of the study.
62639466|NCT00583310|EXPERIMENTAL|Intervention|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
62639467|NCT03934216|EXPERIMENTAL|BMS-986165|
62639468|NCT03934216|PLACEBO_COMPARATOR|Placebo|
62070846|NCT03491748|EXPERIMENTAL|Part D: Cohort 12, ETX0282/Placebo plus Cefpodoxime Proxetil|Part D of the study will explore the safety, tolerability, and PK of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil tablets to healthy participants in a fed state. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fed state on Day 1, with a single oral dose of 400 mg cefpodoxime proxetil in a fed state on Day 4, and with a single oral dose of 600 mg ETX0282 or placebo plus a single oral dose of 400 mg cefpodoxime proxetil dosed at the same time in a fed state on Day 7. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 7 dose assessments (Day 10).
62070847|NCT03491748|EXPERIMENTAL|Part B (Food Effect): Cohort 14, 300 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 300 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 300 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
62070848|NCT03491748|EXPERIMENTAL|Part G: Cohort 17, 300 mg ETX0282/Placebo|Part G of the study will explore the tolerability and PK profile of oral ETX0282 when administered either as a single dose (i.e., 300 mg as a single dose) or in 4 equal, divided doses over a 6 hour period (i.e., 75 mg every 2 hours for 4 doses \[a 300 mg total dose\]) when administered in a fasted state. Participants will receive the 2 treatments in a cross-over design according to one of 2 randomized sequences: AB or BA. Treatment A: 0 hours, 4 × 75 mg ETX0282/placebo; 2, 4, and 6 hours, 1 × 75 mg placebo. Treatment B: 0 hours, 1 × 75 mg ETX0282/placebo and 3 × 75 mg placebo; 2, 4, and 6 hours, 1 × 75 mg ETX0282/placebo. Participants will be confined to the Study Unit from Day -1 and discharged following collection of the 24 hours post Day 4 dose assessments (Day 5).
62070849|NCT01598428|OTHER|cataract|
62275559|NCT00522587|EXPERIMENTAL|6|Fixed sevoflurane dose 6
62275560|NCT00522587|EXPERIMENTAL|7|Fixed remifentanil dose 1
62275561|NCT00522587|EXPERIMENTAL|8|Fixed remifentanil dose 2
62275562|NCT00522587|EXPERIMENTAL|9|Fixed remifentanil dose 3
62275563|NCT00522587|EXPERIMENTAL|10|Fixed remifentanil dose 4
62275564|NCT00522587|EXPERIMENTAL|11|Fixed remifentanil dose 5
62275565|NCT00522587|EXPERIMENTAL|12|Fixed remifentanil dose 6
62275566|NCT00318760|EXPERIMENTAL|ARM 1|
62275567|NCT00318760|PLACEBO_COMPARATOR|ARM 2|
62275568|NCT04600895|EXPERIMENTAL|Favipiravir|Favipiravir 200mg tablet
62275569|NCT04600895|PLACEBO_COMPARATOR|Placebo|Placebo 200mg tablet
62639469|NCT05358691|EXPERIMENTAL|AN0025: Dose level one: 250 mg daily|Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
62275570|NCT05336071|EXPERIMENTAL|Treatment group A|T - R(T: new formulation, R: old formulation)
62275571|NCT05336071|EXPERIMENTAL|Treatment group B|R -T(T: new formulation, R: old formulation)
62275572|NCT00813397|EXPERIMENTAL|Sepraspray|Receive Sepraspray
62275573|NCT00813397|NO_INTERVENTION|Control|No Treatment, No Placebo
62639470|NCT05358691|EXPERIMENTAL|AN0025: Dose level two: 375 mg daily|Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
62639471|NCT04880109|EXPERIMENTAL|APX-115|Oral administration of APX-115 100mg, daily for 14 days
62639472|NCT04880109|PLACEBO_COMPARATOR|Placebo|Oral administration of Placebo, daily for 14 days
62639473|NCT04861844|EXPERIMENTAL|Mindfulness training|
62639474|NCT04861844|ACTIVE_COMPARATOR|Active listening|
62070850|NCT03804996|EXPERIMENTAL|TG-1801|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. Subjects who experience disease progression after completing 6 months of single agent TG-1801 will be eligible for TG-1801 single-agent re-treatment at the discretion of the investigator.
62070851|NCT03804996|EXPERIMENTAL|TG-1101|"Arm Description: TG-1801 and ublituximab will be administered once every 4 weeks (28-day cycle) for up to 6 cycles followed by TG-1801 monotherapy.~To explore the safety of TG-1801 in combination with ublituximab will be explored at doses below and up to the RP2D. TG-1801 intrapatient dose escalation will not be permitted in combination therapy."
62070852|NCT01430767||Depression|Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
62070853|NCT01430767||ADHD|Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
62275574|NCT05275062|EXPERIMENTAL|IM92 CAR-T cells|
62454750|NCT00309972|EXPERIMENTAL|Experimental arm (CON)|Concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
62454751|NCT05997407|EXPERIMENTAL|Organic Conceptions intervention group|Will complete Organic Conceptions intervention.
62454752|NCT05997407|NO_INTERVENTION|Control group|Will not complete Organic Conceptions intervention.
62454753|NCT01586741|ACTIVE_COMPARATOR|Polypropylene mesh|Reconstruction of the abdominal wall diastasis with insertion of a polypropylene mesh on 30 patients.
62454754|NCT01586741|ACTIVE_COMPARATOR|quill suture|Reconstruction of the abdominal wall diastasis with double row absorbable suture ( Quill Self-retaining system) on 30 patients.
62454755|NCT01586741|NO_INTERVENTION|conservative treatment|Regular abdominal exercises workout for three months for 30 patients.
62454756|NCT04913896||Single Group Assignment|Patients with AGC who underwent neoadjuvant immunotherapy and/or chemotherapy would recieve MRI and CT examination before and after 3 cycles treatment.
62454757|NCT04014322|EXPERIMENTAL|E-cigarette|All participants will be instructed to switch completely from combustible cigarettes to e-cigarettes for the next 8weeks. They will be assessed at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks.
62275575|NCT01347736|EXPERIMENTAL|Treatment (pain therapy)|Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
62275576|NCT06379581||Patients with suspected skin tumors|With the help of photoacoustic imaging (PAI), determine the border between healthy tissue and tumor by determining the difference in chromophoric composition by their difference in absorption spectral features.
62275577|NCT02448511|EXPERIMENTAL|Ozone|this group received local application of ozone gas in addition to conventional treatment.
62275578|NCT02448511|SHAM_COMPARATOR|Placebo|This group received sham treatment in addition to conventional treatment
62275579|NCT01831960|EXPERIMENTAL|Cortexolone 17α-Propionate|Topical cream, 1.0% concentration, applied every twelve hours
62275580|NCT03680495||AECOPD with Respiratory Failure|The AECOPD cohort will be hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure requiring invasive or non-invasive mechanical ventilation. We will be following patients from admission through to discharge, and during a follow-up visit (\~2 months from discharge). During the follow-up visit we will be administering 60mg of methylprednisolone once to study possible steroid resistance.
62454758|NCT05903326||traditional treatment group|patients receiving bilateral myringotomy tube placement with the use of midazolam and intraoperative ketorolac
62653023|NCT02723240|EXPERIMENTAL|Part 1 (weekly administration) NUC-3373 3250mg/m2|"NUC-3373 3250mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62070854|NCT05443425|EXPERIMENTAL|Treatment of aGVHD (steroid therapy, leflunomide)|Patients receive steroid therapy at the discretion of the treating physician. Beginning within 3 days of starting steroids, patients receive leflunomide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Patients who respond to leflunomide treatment will be tapered off from day 29 until day 56.
62454759|NCT05903326||New standard of care|patients receiving bilateral myringotomy tube placement with the use of dexmedetomidine alone
62070855|NCT01803841|ACTIVE_COMPARATOR|Transradial access|Coronary angiography and intervention via radial artery approach
62070856|NCT01803841|ACTIVE_COMPARATOR|Transfemoral access|Coronary angiography and intervention via femoral artery approach
62070857|NCT03176095|ACTIVE_COMPARATOR|Probiotic Group|"The participants in the Probiotic group were provided with dietary supplements in the form as sachets with freeze dried bacteria (active lactobacilli culture) mixed with maltodextrin for daily intake (1 per day). The powder was dissolved in water or other non-alcoholic cold drink mixed with fruit before ingestion.~The probiotic product consisted of two different bacterial strains."
62275581|NCT03680495||Stable COPD|The Stable COPD cohort will not have had an AECOPD within the past 6 months and will be frequency matched to the AECOPD cohort. The Stable COPD cohort will have one research visit where we will administer 60mg of methylprednisolone once to study possible steroid resistance.
62275582|NCT04779203||Osseodensification|Osseodensification is a novel, biomechanical osteotomy preparation technique that preserves bone through a non-excavating drilling process utilizing specially designed burs with a tapered geometry and specially designed flutes progressively expand the osteotomy whilst compacting bone into its walls and apex.
62275583|NCT04779203||Standard Drilling|Utilizing conventional drilling technique with standard bone drilling techniques.
62070858|NCT03176095|PLACEBO_COMPARATOR|Placebo Group|The participants in the Placebo group were provided with dietary supplements in the form as sachets with maltodextrin for daily intake (1 per day).
62275584|NCT01456676|EXPERIMENTAL|Nilotinib + LDE225|The planned dose of nilotinib 400 mg b.i.d (twice a day) was selected for the combination as this is the dose approved for the treatment of the patient population that will be included in the present study. The starting dose for LDE225 chosen for the current study is 400 mg once daily(q.d.). The maximum dose of LDE225 that will be tested in combination with nilotinib is 800 mg once dail.y
62275585|NCT00464178|EXPERIMENTAL|Bortezomib and bevacizumab|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
62070859|NCT06312293|EXPERIMENTAL|In-Ear stimulation|Participants in this group underwent intra-ear transcutaneous vagus nerve simulation.
62275586|NCT01964352|EXPERIMENTAL|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
62275587|NCT01964352|EXPERIMENTAL|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
62275588|NCT01964352|ACTIVE_COMPARATOR|tiotropium|Once daily 2 puffs solution for inhalation Respimat
62275589|NCT01964352|PLACEBO_COMPARATOR|placebo|Once daily 2 puffs solution for inhalation Respimat
62275590|NCT02841969|ACTIVE_COMPARATOR|Normal care - Prontosan|Patient wounds will be irrigated using the in-use product (Prontosan)
62639475|NCT02570347|ACTIVE_COMPARATOR|Routine use arm|"All participants allocated to this arm will be given~* Injection Tetanus toxoid 0.5 ml intramuscularly Stat~* Antibiotic (Co-amoxiclav) will be given to all patients for a minimum duration of 5 days.~* Daily clinical assessment would be done. Change of antibiotics is allowed if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
62070860|NCT06312293|EXPERIMENTAL|Behind the ear stimulation|Participants in this group underwent transcutaneous vagus nerve simulation behind the ear.
62275591|NCT02841969|EXPERIMENTAL|Investigational arm - Electrolysed water|Patient wounds will be irrigated using electrolysed water
62275592|NCT04995393|ACTIVE_COMPARATOR|Glove|A heated glove containing water.
62454760|NCT03427970|ACTIVE_COMPARATOR|control group|Control subjects will receive observation for 6 months.
62454761|NCT03427970|EXPERIMENTAL|experimental group|Experimental group will perform three-dimensionally integrated exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 20-min period per day under the supervision of the parents at home.The treatment regimens lasted for 6 months.
62070861|NCT06312293|PLACEBO_COMPARATOR|In-Ear stimulation (device switched off)|In order to see the placebo effect of in-ear simulation in participants in this group, the electrode was placed inside the ear with the device closed and the results were evaluated.
62275593|NCT04995393|ACTIVE_COMPARATOR|Blanket|A heated blanket.
62275594|NCT04995393|ACTIVE_COMPARATOR|Gel pack|A heated gel pack.
62275595|NCT05429138||Immunotherapy cohort|Patient that received adjuvant immunotherapy
62275596|NCT05429138||Targeted therapy|Patient that received adjuvant targeted therapy
62275597|NCT01545700|PLACEBO_COMPARATOR|Control, saline 0-4 hours|2 cc of saline
62275598|NCT01545700|ACTIVE_COMPARATOR|Dexamethasone 4 mg, 0-4 hours|Dexamethasone 4 mg administered intraoperatively
62275599|NCT01545700|ACTIVE_COMPARATOR|Dexamethasone 8 mg, 0-4 hours|Dexamethasone 8 mg administered intraoperatively
62275600|NCT01545700|PLACEBO_COMPARATOR|Placebo Comparator saline 8-24 hours|placebo, 2 cc saline
62275601|NCT01545700|ACTIVE_COMPARATOR|Dexamethasone 4 mg, 8-24 hours|Dexamethasone 4 mg administered intraoperatively
62639476|NCT02570347|EXPERIMENTAL|Clinically-directed use arm|"Participants allocated to this arm will be given~* Injection Tetanus toxoid 0.5 ml intramuscularly Stat~* Daily clinical assessment would be done. Antibiotic (Co-amoxiclav) will be started only if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
62070862|NCT06312293|PLACEBO_COMPARATOR|Behind the ear stimulation (device switched off)|In order to see the placebo effect of behind-ear simulation in participants in this group, the electrode was placed inside the ear with the device closed and the results were evaluated.
62070863|NCT05374759||Group 1|Patients with sepsis who develop AKI
62070864|NCT05374759||Group 2|Patients with sepsis who do not develop AKI
62275602|NCT01545700|ACTIVE_COMPARATOR|Dexamethasone 8 mg, 8-24 hours|Dexamethasone 8 mg administered intraoperatively
62275603|NCT03068156|EXPERIMENTAL|excimer laser|
62275604|NCT03068156|NO_INTERVENTION|Control|
62275605|NCT05942287|EXPERIMENTAL|Diet intervention|Diet intervention (in addition to standard clinical care)
62275606|NCT05942287|NO_INTERVENTION|Standard clinical care|Standard clinical care only
62275607|NCT03363633|NO_INTERVENTION|Observation|
62275608|NCT03363633|EXPERIMENTAL|Injection + Compression|
62275609|NCT03363633|ACTIVE_COMPARATOR|Compression|
62275610|NCT01282229|ACTIVE_COMPARATOR|LANAP Quadrant|Treated with LANAP
62275611|NCT01282229|NO_INTERVENTION|Modified Widman Flap|Quadrant treated with Modified Widman Flap surgery
62275612|NCT01282229|NO_INTERVENTION|Scaling and Root Planing|Quadrant treated with scaling and root planing alone
62275613|NCT01282229|NO_INTERVENTION|Coronal Debridement|Quadrant treated with coronal debridement
62275614|NCT01337076|OTHER|cochlear implant|
62275615|NCT02570269|ACTIVE_COMPARATOR|AuraGain|The patient will get a fiberoptic Intubation via the AuraGain larynxmask
62275616|NCT02570269|PLACEBO_COMPARATOR|Slotted Guedeltubus|The patient will get a fiberoptic intubation via the slotted Guedeltubus
62275617|NCT03747146|ACTIVE_COMPARATOR|Continuous Adductor Canal Catheter (ACC)|Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter
62454762|NCT05945641|EXPERIMENTAL|Low Load Resistance Training|LLRET - 12 weeks (2-3 times/week) 3 sets of Knee extension exercise (single leg) done at 30%1- RM. Performed to failure with 3 minutes of rest between sets, weight lifted will be adjusted throughout the study to keep repetitions completed in a 20-30 repetition range.
62070865|NCT02831829|ACTIVE_COMPARATOR|Water-based exercise training group|"Intervention: Patients randomized to the water-based exercise training group will undergo water-based exercise training. The immersed exercise will include two session of aerobic (water-based) and calisthenic exercise per day, six days of a week, each lasting 30 minutes."
62070866|NCT02831829|ACTIVE_COMPARATOR|Land-based exercise training group|"Patients randomized to the land-based exercise training group will undergo exercise training which will include two aerobic and calisthenic exercise session per day, six days of a week, lasting 30 minutes"
62070867|NCT02831829|NO_INTERVENTION|Control group (usual care)|Control group: patients randomized in control group will have usual care with no exercise
62070868|NCT02275247|EXPERIMENTAL|Intervention 'Stellate Ganglion Block'|Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 6-8mL on the right side at the level of the sixth cervical vertebrae (C6) before surgery.Then the catheter will be attached to a single use patient-controlled analgesia pump containing 0.2% ropivacaine 150 mL, which will be infused at 2 mL/h.
62070869|NCT02275247|NO_INTERVENTION|without 'Stellate Ganglion Block'|In the control group, every thing will be conducted as a matter of routine without intervention.
62070870|NCT00611117|EXPERIMENTAL|1|High intensity exercise and high fat diet
62070871|NCT00611117|EXPERIMENTAL|2|Low intensity exercise and high fat diet
62070872|NCT00624325|EXPERIMENTAL|1|12 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
62070873|NCT00624325|EXPERIMENTAL|2|9 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
62070874|NCT00624325|EXPERIMENTAL|3|6 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
62070875|NCT01908673|ACTIVE_COMPARATOR|HRV biofeedback|heart rate variability biofeedback
62070876|NCT01908673|ACTIVE_COMPARATOR|ASTM|Automatic Self Transcedental Meditation
62653024|NCT02723240|EXPERIMENTAL|Part 2 (two weekly administration) NUC-3373 1500mg/m2|"NUC-3373 1500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 15 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62070877|NCT01630590|EXPERIMENTAL|Cabozantinib + Androgen Ablation Therapy|Patients receive Cabozantinib at starting dose of 60 mg by mouth every day. Study cycles 3 weeks in duration. Patients stay on treatment as long as they are benefitting. Patients receive androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration. Study doctor will decide what hormone therapy patient will receive.
62070878|NCT04173312|ACTIVE_COMPARATOR|Infused analgesic|Patients will be assigned to receive local anesthetic through continuous infusion by pump.
62070879|NCT04173312|PLACEBO_COMPARATOR|Infused saline|Patients will be assigned to receive saline through continuous infusion by pump.
62070880|NCT06451315||Abdominal Aortic Aneurysm (AAA) treated with EndoVascular Aneurysm Repair (EVAR)|Male or female ≥18 years of age with AAA treated with EVAR between ≥50mm or ≥5mm increase in 6 months. The subject is legally competent, has been informed of the nature, the scope, and the relevance of the study and has not manifested an opposition to participate. He is available for set-up and proper implementation of follow-up visits (standard of care) throughout the duration of the registry
62275618|NCT03747146|SHAM_COMPARATOR|Adductor Canal block with sham catheter|Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.
62275619|NCT03090126||Alveolar hypoventilation|
62275620|NCT03287258|ACTIVE_COMPARATOR|three program|200 patients are subjected to educational Pelvic floor dysfunction prevention program with perineal massage and Pelvic floor muscle exercise.
62275621|NCT03287258|ACTIVE_COMPARATOR|one program|200 patients are subjected to educational Pelvic floor dysfunction prevention program
62287164|NCT03002974|EXPERIMENTAL|Anakinra 100 mg|1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
62070881|NCT06234488||Transgender and Gender-Diverse Persons with Breast Cancer|Patients who had a breast cancer diagnosis (including those with ductal carcinoma in situ (DCIS)), who were age ≥18 years at the time of diagnosis and identify as a gender and/or sex that is different from their sex assigned at birth (e.g., transgender, nonbinary, genderqueer, etc.) between 1/1/1990 - 7/1/2023.
62070882|NCT01596283|ACTIVE_COMPARATOR|Standard fluid management|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
62275622|NCT03804684|EXPERIMENTAL|Healthy Controls|Healthy subjects between 21 and 80 years of age with no eye diseases (normal appearing optic nerve and retina, intraocular eye pressure less than 19 millimeters of mercury, normal and reliable standard automatic perimetry, and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
62639477|NCT06522464|EXPERIMENTAL|Group A: mCIMT with cross-education|"For ten weeks, Group A will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of constraint.~In addition, the student will receive extra cross-education, which will involve practicing reaching tasks, wrist flexion and extension, and non-paretic hand opening and closing for 30 minutes. Activities include building a tower out of cubes in various colors, sorting cubes of similar colors and forms together (square cubes in a column, cylindrical cubes together), gripping a hammer, and various cube and triangular shapes. putting balls in their column, placing various-sized circular forms in their proper locations, and moving items between both hands. We'll utilize weight cuffs for every activity."
62639478|NCT06522464|ACTIVE_COMPARATOR|Group B: mCIMT without cross-education|For ten weeks, Group B will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of confinement.
62639479|NCT06385171||Single Group Assignment|"Experimental: Botulinum Toxin Type A:~Patients will receive their first treatment on Day 1 after screening, with baseline facial muscle assessment on Day 0. Touch-up treatments will be given every 3 weeks until the sixth month. At Week 3, primary efficacy assessment will be conducted by evaluating facial movement control. Longevity assessment will occur at Month 6, with additional evaluation of immune response. This cycle will repeat for the second dose after six months until one year, and the same cycle will repeat for the 2nd dose."
62287165|NCT03002974|EXPERIMENTAL|Anakinra 200 mg|2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
62287166|NCT03002974|ACTIVE_COMPARATOR|Triamcinolone 40 mg|2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
62275623|NCT03804684|EXPERIMENTAL|Mild and Moderate Glaucoma|Subjects between 21 and 80 years of age with Mild or Moderate Glaucoma. Eyes will have a reliable standard automatic perimetry with no more than -6 mean deviation (Mild) and between -6 mean and -12 mean deviation (Moderate). Spherical refraction will be less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
62454763|NCT05945641|EXPERIMENTAL|Sprint/High Intensity Interval Training|"SIT/HIIT- 12 weeks (2-3 times/week), mix of SIT and HIIT (8-15 sets/session). SIT -30 second Super Maximal Wingate style intervals performed on a Kicking ergometer (single leg) with 4 minutes rest provided between sets (number of interval ranges from 4-5), load determined from DEXA leg lean mass and will not be altered throughout training.~HIIT - 1-minute Submaximal efforts (90% single leg kicking ergometer VO2Peak Wattage) performed on a kicking ergometer (single leg) with 1 minute rest provided between sets (number of interval ranges from 8-10), if all sets completed wattage will be increased by 5watts for the next training session."
62275624|NCT02708953|EXPERIMENTAL|Treatment (thoracic manipulation)|Patients in the initial manipulation group will attend physical therapy two sessions per week for 3 weeks for a total of 6 sessions. Each treatment session will last for a total of 15 minutes. After the initial manipulation group receives 3 weeks of treatment they will wait for 1-week, be retested, and then crossover into the other group.
62275625|NCT02708953|ACTIVE_COMPARATOR|Wait-list (thoracic manipulation)|When individuals are assigned to the wait-list control group they will serve as the control for 3 weeks while the initial manipulation group receives treatment. After serving as the wait-list control condition for 3 weeks, this group will then return for testing and will receive the manipulation package as described below at 4 weeks.
62454764|NCT04159909|EXPERIMENTAL|VNS transcutaneous stimulation|"5 minutes of stimulation (VNS) twice a day for 4 days. Patients will receive transcutaneous stimulation (30 Hz, 300 msec.) on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days. Due to the theoretical risk that right vagus nerve stimulation could affect the heart, and to ensure consistency of the intervention, all subjects randomized to receive transcutaneous vagus nerve stimulation will receive stimulation of the auricular branch of the left vagus nerve. The subject will be blinded to their treatment arm.~The device to be used will include a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide stimulation to the auricular branch of the afferent vagus nerve."
62070883|NCT01596283|ACTIVE_COMPARATOR|Goal directed fluid therapy|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
62070884|NCT04000659|EXPERIMENTAL|Episealer Knee System|The experimental arm will comprise of subjects that will be treated with the Episealer Knee System.
62070885|NCT04000659|PLACEBO_COMPARATOR|Microfracture|The control arm will comprise of subjects that will receive a Microfracture surgery.
62275626|NCT03618108|ACTIVE_COMPARATOR|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
62070886|NCT00872014|EXPERIMENTAL|15mg/ kg cohort|AMG 386 15mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
62454765|NCT04159909|SHAM_COMPARATOR|Sham stimulation|"5 minutes of sham stimulation (no electrical stimulation) twice a day for 4 days Patients will receive sham stimulation on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days.~The subject will be blinded to their treatment arm. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide sham stimulation (no electrical current) to the auricular branch of the afferent vagus nerve."
62454766|NCT04770623|EXPERIMENTAL|Chemotherapy|"Second line treatment will be as follows~* Docetaxel at 30 mg/m2 over 500 cc normal saline over 1 hour infusion~* Irinotecan at 185 mg/m2 with a maximum of 300 mg given over 500 cc normal saline over 2 hours infusion~* The whole regimen is to be cycled every 2 weeks for a maximum of 6 months with interim and end of treatment evaluation"
62454767|NCT01305070|ACTIVE_COMPARATOR|Standart balloon angioplasty|Admiral Xtreme, Invatec
62639480|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
62639481|NCT03301402|ACTIVE_COMPARATOR|Filter|
62070887|NCT00872014|EXPERIMENTAL|10 mg/kg cohort|AMG 386 10mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
62070888|NCT02252458|EXPERIMENTAL|Fentanyl high dose|Fentanyl 10mcg/kg of bodyweight
62070889|NCT02252458|ACTIVE_COMPARATOR|Fentanyl low dose|Fentanyl 1mcg/kg of bodyweight
62070890|NCT04316728|OTHER|negative Patients|Adult HCWs with no signs or symptom of coronavirus infection and no known previous history of contact with patients positive for COVID-19, working in a primary care setting and Adult patients with at least 2 chronic medical conditions routinely attending a General Practioner (GP) practice or an outpatients departments or a primary care facility
62070891|NCT03013686|ACTIVE_COMPARATOR|Interval Appendectomy|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~Interval appendectomy is performed at two months after the primary treatment, all patients also undergo colonoscopy prior to appendectomy."
62070892|NCT03013686|ACTIVE_COMPARATOR|Follow-up with MRI|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~The patients undergo abdominal magnetic resonance imaging at two months after the primary treatment, all patients also undergo colonoscopy right after the MRI."
62639482|NCT03301402|NO_INTERVENTION|No filter|
62639483|NCT02567188||Cohort of CKD Participants|Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
62639484|NCT03064113|EXPERIMENTAL|Sequence 1|Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
62639485|NCT03064113|EXPERIMENTAL|Sequence 2|Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
62070893|NCT06099951|EXPERIMENTAL|Serplulimab+FOLFOXIRI|
62275627|NCT03618108|PLACEBO_COMPARATOR|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
62639486|NCT03064113|EXPERIMENTAL|Sequence 3|Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
62454768|NCT01305070|ACTIVE_COMPARATOR|Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec
62454769|NCT01104207|EXPERIMENTAL|Arm 1|Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.
62454770|NCT01104207|SHAM_COMPARATOR|Arm 2|Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.
62454771|NCT03409757||hemodialysis patients with hyperphosphatemia|"* dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool~* Velphoro® medication"
62639487|NCT03064113|EXPERIMENTAL|Sequence 4|Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo
62639488|NCT05952921|EXPERIMENTAL|Hypochlorous acid|Thirty-two voluntary participants were randomly assigned to receive one of two post-surgical protocols after periodontal surgery: a high concentration rinse with 0.05% HOCl (7 days), followed by 0.025% HOCl /(14 days)
62070894|NCT01803230|PLACEBO_COMPARATOR|placebo|placebo (dextrose)
62070895|NCT01803230|EXPERIMENTAL|creatine|creatine supplementation
62070896|NCT01782040|NO_INTERVENTION|Control Group|Control Group didn't receive any treatment and it was evaluated at the same time and the same way of interventions group
62275628|NCT05029154|EXPERIMENTAL|Exercise|Patients in the exercise group will perform interval training 3 days per week.
62275629|NCT05029154|PLACEBO_COMPARATOR|Attention Control|Physical activity education and physical activity monitoring.
62275630|NCT03678597|EXPERIMENTAL|Handling Medium Supplemented with Latrunculin B|
62275631|NCT03678597|NO_INTERVENTION|handling Medium as it is.|
62275632|NCT03183362|EXPERIMENTAL|Barbed suture ( STRATAFIX™ )|Cesarean section incision is closed using barbed sutures
62454772|NCT03409757||control group|- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
62454773|NCT04088838||Patients undergoing abdominal surgery|All adult patients undergoing elective abdominal surgery are eligible. Abdominal surgery includes each operation in which the peritoneal cavity is openen, i.e. laparotomy or laparoscopy.
62454774|NCT06229925|EXPERIMENTAL|Experimental Stimulation|Active direct current stimulation for 20 minutes.
62639489|NCT05952921|ACTIVE_COMPARATOR|Chlorhexidine|Thirty-two voluntary participants were randomly assigned to receive one of two post-surgical protocols after periodontal surgery: a high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
62639490|NCT03663296|EXPERIMENTAL|Interventional|Additional 30 minutes of self-directed learning and practice using the mobile application, after conventional training session
62639491|NCT03663296|NO_INTERVENTION|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
62639492|NCT05035251||experimental|patients with a condition
62639493|NCT05035251||control|patients without condition
62070897|NCT01782040|EXPERIMENTAL|Auriculotherapy group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.It was used 6 points: Kidney, Liver, Stomach, Brain Stem, Ovary and Uterus point with semi-permanent needles one time per week for 8 sessions
62275633|NCT03183362|ACTIVE_COMPARATOR|Conventional suture (VICRYL™)|Cesarean section incision is closed using conventional sutures
62070898|NCT04394520|NO_INTERVENTION|Control|No change will be made to the introduction content or the consent mode (active opt-in and active opt-out) from other related trials
62275634|NCT03589378|EXPERIMENTAL|PEAF|Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
62275635|NCT03589378|NO_INTERVENTION|Control group|HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.
62275636|NCT00529971|EXPERIMENTAL|1|Participants in the first arm participate in an 8-week MBSR group
62070899|NCT04394520|EXPERIMENTAL|Modified Intro, Standard Consent|Modified introductory language will be used, but the consent structure (active opt-in and active opt-out) will remain the same.
62275637|NCT00529971|ACTIVE_COMPARATOR|2|Participants assigned to the control arm do not receive the MBSR program but may or may not be receiving current psychotherapy or counselling
62275638|NCT03041558|EXPERIMENTAL|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
62275639|NCT03041558|ACTIVE_COMPARATOR|SafeCare (SC)|SafeCare intervention as usual
62275640|NCT03698006|EXPERIMENTAL|Tibial nerve block|Adductor canal and tibial nerve blocks performed by the anesthetist under ultrasound guidance before spinal block.
62275641|NCT03698006|ACTIVE_COMPARATOR|Local infiltration analgesia|Adductor canal block by the anesthetist under ultrasound guidance before spinal block. Infiltration of the knee by the surgeon with local anesthetic at the end of the surgery.
62275642|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
62275643|NCT01942759||Histologic grade|According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
62275644|NCT01942759||Axillary metastasis|Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
62639494|NCT05534139||Healthy controls|Partner/spouse of a patient not at risk of HD OR sibling with genetic test results available that show a normal CAG repeat length for both HTT alleles (\<36); No other known cognitive, neurological or psychiatric disorders.
62275645|NCT01942759||Modified Nottingham prognostic index|"NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)~The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (\>5.4) prognostic groups"
62275646|NCT01942759||Oestrogen receptor status|Negative Positive
62275647|NCT01942759||Progesterone receptor status|Negative Positive
62275648|NCT01942759||HER-2 neu status|Negative Positive
62639495|NCT05534139||Premanifest HD expanded gene carrier|HDGEC before clinical onset: TMS \<5, DCL \<4, TFC = 13. No other major comorbidity.
62275649|NCT06099587|EXPERIMENTAL|SCD+|"Patients with subjective cognitive decline-plus due to Alzheimer's disease (or DCS in french)"
62275650|NCT06099587|EXPERIMENTAL|MCI|"Patients with mild neurocognitive impairment due to Alzheimer's disease (or TCL in french)"
62454775|NCT06229925|SHAM_COMPARATOR|Sham Stimulation|Sham direct current stimulation for 20 minutes.
62639496|NCT05534139||Early Manifest HD patient|HDGEC after clincial onset: TMS \>5, DCL = 4. Early stage of disease: TFC 11-13. No other major comorbidity.
62454776|NCT04188821|ACTIVE_COMPARATOR|output based group|Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days with no further signs of infection, fluid collection or impaired wound healing
62454777|NCT04188821|EXPERIMENTAL|early-removal group|Investigators remove the drains at hospital discharge, 3-4 days after surgery, regardless of the output at that time
62639497|NCT05534139||Moderate Manifest HD patient|HDGEC after clincial onset: TMS \>5, DCL = 4. Moderate stage of disease: TFC 7-10. No other major comorbidity.
62639498|NCT01769677|EXPERIMENTAL|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~* Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).~* Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test)."
62639499|NCT01769677|EXPERIMENTAL|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~* Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).~* Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference)."
62639500|NCT01305564|EXPERIMENTAL|Denali inferior vena cava filter|All subjects enrolled will receive the Denali vena cava filter.
62639501|NCT00713804|EXPERIMENTAL|GC|Genetic counseling (GC): One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
62639502|NCT00713804|ACTIVE_COMPARATOR|EB|Educational Booklet (EB): One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
62639503|NCT00713804|NO_INTERVENTION|WT|Waitlist (WT)
62639504|NCT00532363||Obese asthmatics|Obese subjects with asthma (on inhaled corticosteroids)
62639505|NCT00532363||Non obese asthmatics|Non obese subjects with asthma (on inhaled corticosteroids)
62639506|NCT04518917|OTHER|Parkinson disease plus dementia|Participants will have a diagnosis of Parkinson disease plus dementia.
62639507|NCT05990725|EXPERIMENTAL|Lebrikizumab|Participants will receive lebrikizumab 250 milligrams (mg) subcutaneous (SC) injection, once every two weeks (Q2W) on Day 1 for up to Week 16. A loading dose of lebrikizumab 500 mg (2 injections) SC will be administered on Day 1 and at Week 2, further followed by lebrikizumab 250 mg (1 injection), SC, once every four weeks (Q4W) after Week 16 for up to Week 24.
62639508|NCT01491022|EXPERIMENTAL|Ampyra|Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
62639509|NCT01491022|SHAM_COMPARATOR|Placebo|placebo 4 weeks followed by Ampyra 10 mg po BID
62639510|NCT01811537|EXPERIMENTAL|Experimental: premeasured Neochordae|Transthoracic echocardiography(TTE) is done for all patients. The new device will be setup using the TTE measurements.The artificial Chordae loops will be made at the operation room before starting the surgery. These loops will be attached to the respective papillary muscle's head and the free edge of respective prolapsed scallop.
62639511|NCT05486884|EXPERIMENTAL|high MAP threshold|"Norepinephrine will be titrated to maintain MAP ≥ 90 mmHg. This threshold will be maintained for the 24 hours following inclusion by the perfusion of norepinephrine at an appropriate dose.~From 24 hours after inclusion until ICU discharge, a MAP ≥ 65 mmHg will be targeted"
62639512|NCT05486884|ACTIVE_COMPARATOR|standard MAP threshold|"Norepinephrine will be titrated to maintain MAP ≥ 65 mmHg. This target MAP will be maintained for 24 hours after randomization through the perfusion of norepinephrine at an appropriate flow rate.~From 24 hours after inclusion until ICU discharge, a MAP ≥ 65 mmHg will be targeted"
62639513|NCT01043978|EXPERIMENTAL|Novel nipple|
62639514|NCT01043978|ACTIVE_COMPARATOR|Coventional nipple|
62639515|NCT04536714|EXPERIMENTAL|Intervention group|34 participants. Received Pythagorean Self-Awareness program
62639516|NCT04536714|NO_INTERVENTION|Control group|35 participants. Received usual care
62639517|NCT02605759|EXPERIMENTAL|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation for the treatment of esophageal squamous cell dysplasia
62070900|NCT04394520|EXPERIMENTAL|Modified Intro, Active Opt-in|Modified introductory language will be used, and the consent mode will be changed to active opt-in only.
62639518|NCT04996966|PLACEBO_COMPARATOR|control|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
62070901|NCT04394520|EXPERIMENTAL|Modified Intro, Active Opt-out|Modified introductory language will be used, and the consent mode will be changed to active opt-out only.
62070902|NCT04394520|EXPERIMENTAL|Modified Intro, Passive Opt-in|Modified introductory language will be used, and the consent mode will be changed to passive opt-in only.
62454778|NCT02888171|EXPERIMENTAL|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
62454779|NCT02888171|ACTIVE_COMPARATOR|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
62461670|NCT02726230|EXPERIMENTAL|Ananya Intervention|"1. Strengthen enumeration and mapping of areas to ensure reach of front line workers (FLWs: auxiliary nurse midwives- ANMs; community health workers- ASHAs; anganwadi workers- AWWs).~2. Convene monthly FLW meetings to build skills and get trained in job kits to increase the quantity and quality of household visits.~3. Train FLWs on communication skills and use of mobile kunji, a job-aid tool, to improve FLWs' communication with households.~4. A mass media campaign inclusive of street theatre, tv and radio, and a mobile van.~5. Community mobilization linking mass media efforts with self-help groups.~6. Quality improvement activities at public health facilities.~7. Facility-based skills training to staff delivering infants to improve quality of care"
62639519|NCT04996966|EXPERIMENTAL|MSCs injection|In the MSCs injection group, 1×10\^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
62639520|NCT04561648|EXPERIMENTAL|High Dose of Unfractionated Heparin|100 IU/Kg of Unfractionated Heparin
62639521|NCT04561648|ACTIVE_COMPARATOR|Standard Dose of Unfractionated Heparin|5000 IU of Unfractionated Heparin.
62639522|NCT04752371|EXPERIMENTAL|Cohort 1: Camoteskimab 7 mg/kg|6 participants will be administered camoteskimab at a dose of 7 mg/kg (500 mg maximum) at Baseline, Week 4, and Week 8.
62639523|NCT04752371|EXPERIMENTAL|Cohort 2: Camoteskimab Dose escalation/reduction|Cohort 2 dose will be determined based on a review of Cohort 1 data. 6 participants will be administered camoteskimab at the determined dose at Baseline, Week 4, and Week 8.
62639524|NCT00232557|EXPERIMENTAL|TLC-Asthma|Telephone-based home education and asthma monitoring
62639525|NCT00232557|ACTIVE_COMPARATOR|TLC-health education|Telephone-based home education
62639526|NCT00993551|EXPERIMENTAL|12 month surgery|Infants will receive primary surgery at age 12 months using Sommerlad technique
62639527|NCT00993551|EXPERIMENTAL|6 month surgery|Infants will receive primary surgery at age 6 months using Sommerlad technique.
62639528|NCT00661089|EXPERIMENTAL|Intramuscular OnabotulinumtoxinA|Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
62639529|NCT00661089|ACTIVE_COMPARATOR|Intramuscular Placebo (Saline)|Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
62639530|NCT02033759|ACTIVE_COMPARATOR|Traditional circumferential measurements|Traditional screening with volumetric analysis Patient Anxiety Questionnaire
62639531|NCT02033759|EXPERIMENTAL|Bio-Impedance Testing|Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire
62639532|NCT01619865|EXPERIMENTAL|68Ga-DOTATOC PET/CT|68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors
62639533|NCT04486118|ACTIVE_COMPARATOR|CA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
62639534|NCT04486118|PLACEBO_COMPARATOR|nonCA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
62639535|NCT06413966|EXPERIMENTAL|Partially absorbable mesh coverage group|- This group of patient will receive partially absorbable mesh coverage (ULTRAPRO size 15 x 15 cm, Ethicon) as an additional procedure after VATs to blebectomy/bullectomy.
62454780|NCT05531409|EXPERIMENTAL|Intervention Arm|Students from 6th and 7th grades from two schools were randomized to receive the RBYC curriculum. The RBYC curriculum has eight core content sessions, each of which lasts approximately 45 minutes. These include sessions that address: 1) Developmental differences between children versus teenagers; 2) Perspective-taking of and empathic responding to younger children; 3) and 4) Healthy versus unhealthy teenage-younger child relationships; 5) Misconceptions versus facts about child sexual abuse and legal ramifications; 6) Why adolescents may engage in harmful sexual behaviors; 7) Peer sexual harassment, what it is and how to avoid or address it; and 8) Being a good bystander or upstander when you have concerns that another child or peer has been or may be harmed. The RBYC curriculum was integrated into each school's existing health education curriculum.
62639536|NCT06413966|ACTIVE_COMPARATOR|Apical pleurectomy group|- This group of patient will receive standard surgical treatment that is used at Maharaj Nakorn Chiangmai Hospital, which is blebectomy or bullectomy with apical pleurectomy under video-assisted thoracoscopic approach
62639537|NCT02349035|EXPERIMENTAL|TMR surgery to evaluate pattern recognition control|Perform Targeted Muscle Reinnervation (TMR) surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
62639538|NCT01508988|EXPERIMENTAL|Eye drops 0.3 µg/mL|
62639539|NCT01508988|EXPERIMENTAL|Eye drops 1 µg/mL|
62639540|NCT01508988|EXPERIMENTAL|Eye drops 3 µg/mL|
62639541|NCT01508988|EXPERIMENTAL|Eye drops 10 µg/mL|
62639542|NCT01508988|EXPERIMENTAL|Eye drops 20 µg/mL|
62639543|NCT01508988|EXPERIMENTAL|Eye drops 30 µg/mL|
62639544|NCT01508988|EXPERIMENTAL|Eye drops placebo|
62639545|NCT00789321|EXPERIMENTAL|1|amlodipine
62639546|NCT00789321|PLACEBO_COMPARATOR|2|Placebo to amlodipine
62639547|NCT06529341|EXPERIMENTAL|High-definition transcranial direct current stimulation|HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
62639548|NCT06529341|ACTIVE_COMPARATOR|High-definition transcranial direct current stimulation pseudo-stimulation control group|The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
62639549|NCT01682824||Group I (questionnaire, nutritional assessment)|Patients complete the TFEQ-R18v2 questionnaire, a dietary intake assessment, and the EQ-EMA questionnaire online.
62639550|NCT01682824||Group II (questionnaire, nutritional assessment)|Patients complete the EQ-EMA questionnaire, a dietary intake assessment and the TFEQ-R18v2 questionnaire.
62639551|NCT02671851||Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs at the level of T3-T4 with 20 mL bupivacaine 0.375% as an adjunct to general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
62639552|NCT02671851||IV metamizole sodium, paracetamol|Patients received only standardized general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
62639553|NCT01204736||Group 1|Subjects with posterior deltoid-to-triceps tendon transfers
62070903|NCT03273140|EXPERIMENTAL|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
62639554|NCT01204736||Group 2|Subjects with biceps-to-triceps tendon transfers
62639555|NCT01204736||Group 3|Subjects with cervical SCI who have not had tendon transfers
62275651|NCT03391947|EXPERIMENTAL|semilunar coronally positioned flap|A semilunar incision will be done following the curvature of the gingival margin and ending about 2 to 3 mm short of the tip of the papillae. The most apical distance of this incision to the gingival margin will be obtained by adding the bone sounding measurement to the recession height. Perform a split-thickness dissection coronally from the incision, and connect it to an intrasulcular incision. The tissue will be collapsed coronally, covering the denuded root. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite. Finally, the area will be covered with a periodontal dressing. This is called semilunar coronally positioned flap.
62275652|NCT03391947|ACTIVE_COMPARATOR|coronally advanced flap|Coronally positioned flap will be initiated with two vertical incisions, extending from a mesial and distal linear angle at the cementoenamel junction (CEJ) and go beyond the mucogingival junction. A split thickness flap will be prepared by sharp dissection mesial and distal to the recession and connected with an intra crevicular incision. On the facial aspect of the tooth, a full thickness flap, approximately 3-4 mm apical to crest of alveolar bone. Then, the flap will be returned and sutured it at 1 mm coronal to the CEJ after de-epithelize the papillae. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite and sutured in the papilla region and releasing incision. Finally, the area will be covered with a periodontal dressing.
62454781|NCT05531409|NO_INTERVENTION|Waitlist Control|Students from 6th and 7th grades from the two schools that were randomized to the waitlist control condition received the RBYC curriculum once the study was completed (i.e., baseline and post-assessment data were collected).
62454782|NCT03767088|ACTIVE_COMPARATOR|WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
62454783|NCT03767088|ACTIVE_COMPARATOR|partial WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
62461671|NCT02726230|NO_INTERVENTION|Control Condition|standard of care public health services in India
62639556|NCT01204736||Group 4|Unimpaired control subjects
62454784|NCT03767088|SHAM_COMPARATOR|control|active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns
62639557|NCT00141518|EXPERIMENTAL|Duodopa Naïve|Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
62639558|NCT00141518|EXPERIMENTAL|Duodopa Non-naïve < 2 Years|Duodopa non-naïve participants treated with Duodopa for \< 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
62639559|NCT00141518|EXPERIMENTAL|Duodopa Non-naïve ≥ 2 years|Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
62639560|NCT05003544|ACTIVE_COMPARATOR|PENG BLOCK ( Group A)|A regional block will be applied while the patient is in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) will initially be placed in a transverse plane on the AIIS and then rotate the probe approximately 45 degrees counterclockwise to align with the pubic ramus. In this view, IPE, iliopsoas muscle and tendon, femoral artery and pectineus muscle will be observed. A 22 gauge, 80 mm needle will be inserted from lateral to medial in an in-plane approach to place the psoas tendon anteriorly and posteriorly in the musculofacial plane between the pubic ramus. Following negative aspiration, a local anesthetic solution (20ml bupivacaine 0.5%) will be injected.
62639561|NCT05003544|ACTIVE_COMPARATOR|Intra-articular( Group B)|It will be applied to the intra-articular region by the surgeon at the end of the operation. A volume of 60 ml (30 ml of 0.5% bupivacaine and 30 ml of 0.9% NaCl)
62275653|NCT02566304|EXPERIMENTAL|RIC HSCT, GVHD prophylaxis|"RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -6.~TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
62275654|NCT04240977|EXPERIMENTAL|Treatment Group|
62275655|NCT02062658|EXPERIMENTAL|Ketamine, Exposure & Response Prevention|0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
62639562|NCT05003544|ACTIVE_COMPARATOR|Quadratus lumborum block ( Group C)|The patient will be in the lateral position. A low-frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in-plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.5 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
62639563|NCT02242123||Study group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of mild intestinal histology damage (grade 1-2) at first evaluation.
62639564|NCT02242123||Control group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of intestinal villous atrophy (intestinal histology damage grade 3) at first evaluation.
62639565|NCT02787577|EXPERIMENTAL|Sleep Lengthening|The intervention group will receive a personalised sleep consultation session to lengthen sleep by 1-1.5 hours per night by targeting sleep hygiene using behaviour change techniques for 4 weeks.
62639566|NCT02787577|NO_INTERVENTION|Control|The control group will be asked to resume their normal lifestyle.
62653025|NCT02723240|EXPERIMENTAL|Part 2 (two weekly administration) NUC-3373 1875mg/m2|"NUC-3373 1875mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 15 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62275656|NCT00924937|ACTIVE_COMPARATOR|Low Fat Diet|Dietary Intervention with a Low fat diet: \<30% fat (12% monounsaturated fatty acids; 6-8%polyunsaturated fatty acids; \<10% saturated fatty acids)
62275657|NCT00924937|EXPERIMENTAL|Mediterranean Diet|Dietary Intervention with a Mediterranean Diet: 35-38% fat (22% monounsaturated fatty acids; 6% polyunsaturated fatty acids; \<10% saturated fatty acids).
62275658|NCT02681016|EXPERIMENTAL|"Sirolimus-eluting stent Calypso"|"Commercially approved coronary stent system Calypso (Angioline, Russia) Coating - Sirolimus(rapamicine) Stent diameters: 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 4.5 mm. Stent lengths: 8, 13, 15, 18, 23, 28, 33, 38 mm."
62275659|NCT02681016|ACTIVE_COMPARATOR|"Everolimus-eluting stent Xience Prime"|Commercially approved XIENCE PRIME, (Abbott Vascular, USA) Coating - Everolimus with concentration Stent diameters: 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm. Stent lengths: 8, 12, 15, 18, 23, 28, 33, 38 mm.
62454785|NCT03811080|EXPERIMENTAL|DWP14012 A mg|DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks
62454786|NCT03811080|EXPERIMENTAL|DWP14012 B mg|DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks
62454787|NCT03811080|PLACEBO_COMPARATOR|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
62454788|NCT02083315|EXPERIMENTAL|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
62454789|NCT02083315|EXPERIMENTAL|TRV130 3 mg|TRV130 3 mg IV x 1 dose
62454790|NCT02083315|EXPERIMENTAL|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
62275660|NCT05697510|EXPERIMENTAL|SILTUXIMAB|
62275661|NCT04201483|ACTIVE_COMPARATOR|DCE group|DCE exercise without RUSI feedback
62275662|NCT04201483|EXPERIMENTAL|DCE + RUSI group|DCE exercise with RUSI feedback
62275663|NCT03396965|EXPERIMENTAL|Mini-c-arm|Fluoroscopically aided reductions
62275664|NCT03396965|NO_INTERVENTION|Standard|
62454791|NCT02083315|ACTIVE_COMPARATOR|Morphine|Morphine 10 mg IV x 1 dose
62639567|NCT04350827|ACTIVE_COMPARATOR|Platelet Rich Plasma|Procedure will be carried out with excellent sterile technique. 54ml of whole blood will be drawn. 54ml will be processed by centrifugation using the GPS III system (Zimmer Biomet, Warsaw, IN) and 1 ml will undergo a complete blood count (for a baseline comparison to determine the fold increase in platelets). The resultant PRP (5ml) will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) into the patellar tendon using ultrasound guidance to accurately direct the injection to the site of the tendon abnormality. The patient will rest after the injection for 15 minutes and then be dismissed.
62088310|NCT05414721|NO_INTERVENTION|Normal flow desflurane anesthesia (Group N)|All patients were preoxygenated for three minutes. Midazolam 0.03 mg/kg, fentanyl 1.5 mcg/kg , propofol 2 mg/kg and rocuronium 0.6 mg/kg were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50% O2+50% air + 6-7% desflurane in a 4 L/min fresh gas flow until the MAC value reached 1. When the MAC value of desflurane was 1, fresh gas flow was decreased to 2 L/min (40% O2+60% air) in Group N. Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
62454792|NCT02083315|PLACEBO_COMPARATOR|Placebo|Dextrose 5% in water IV x 1 dose
62454793|NCT00449150|EXPERIMENTAL|Treatment Group A: CET 78 mg + 78 mg|"Treatment course 1: Cetrorelix 78 mg + 78 mg~* Week 0: 52 mg CET (2 injections)~* Week 2: 26 mg CET (1 injection)~Treatment course 2:~* Week 26: 52 mg CET (2 injections)~* Week 28: 26 mg CET(1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
62639568|NCT04350827|ACTIVE_COMPARATOR|Platelet Rich Plasma plus IGF|The PRP preparation and blood draw will be identical to the above. 55ml of whole blood will be drawn (1ml will undergo a CBC and the remaining 54ml will be used to make PRP). In addition to preparing the PRP, the resultant PPP (instead of discarding it) will be placed into the Plasmax device (Zimmer Biomet, Warsaw, IN) and concentrated via a second centrifugation cycle. The plasmax concentrate (concentrated IGF) will be added to the PRP (3ml of PRP + 2ml of plasmax concentrate for a total of 5ml) and then will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) under ultrasound guidance followed by the same rest period.
62639569|NCT00296855|EXPERIMENTAL|Arm 1|
62454794|NCT00449150|EXPERIMENTAL|Treatment Group B: CET 78 mg + 52 mg|"Treatment course 1: Cetrorelix 78 mg + 52 mg~* Week 0: 52 mg CET (2 injections)~* Week 2: 26 mg CET (1 injection)~Treatment course 2:~* Week 26: 52 mg CET (2 injections)~* Week 28: Placebo (1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
62454795|NCT00449150|PLACEBO_COMPARATOR|Treatment Group C: Placebo|"Treatment course 1:~* Week 0: placebo (2 injections)~* Week 2: placebo (1 injection)~Treatment course 2:~* Week 26: placebo (2 injections)~* Week 28: placebo (1 injection)~  4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
62088311|NCT01246648|ACTIVE_COMPARATOR|chronic periodontitis|
62275665|NCT04352439|EXPERIMENTAL|Aspirin|Patients with a Khorana risk score of 1 receive 81 mg aspirin daily while receiving neoadjuvant chemotherapy for ovarian cancer.
62454796|NCT05153265||Residents|We plan to distribute a survey to the Stanford anesthesiology residents to determine their assessment of the bleeding risk of nerve blocks. The survey will list the most common nerve blocks and ask the resident anesthesiologists at Stanford whether the block is low/intermediate/high risk based on a scoring system of location relative to critical structures, compressibility, and whether bleeding or hematoma would be readily apparent.
62639570|NCT06139172|EXPERIMENTAL|Functional Behavioral Training|
62639571|NCT06139172|ACTIVE_COMPARATOR|Positive Parenting Strategies-Treatment As Usual|
62639572|NCT03301636|EXPERIMENTAL|Pembrolizumab + Indoximiod|
62639573|NCT03301636|EXPERIMENTAL|Nivolumab + Indoximiod|
62088312|NCT01246648|ACTIVE_COMPARATOR|agressive periodontitis|
62088313|NCT01246648|ACTIVE_COMPARATOR|healthy patients|
62088314|NCT01461616|EXPERIMENTAL|NPH insulin injection|NPH insulin will be injected in random order in one of three seperated visit days.
62275666|NCT01877135||Anal AIN3|patients \> 18 years, with anal AIN3, without history of anal carcinoma
62275667|NCT03430648||Cognitively and metabolically normal|This group has been defined as being cognitively and metabolically normal.
62275668|NCT03430648||Cognitively normal with prediabetes|This group has been defined as being cognitively normal but showing signs of prediabetes.
62275669|NCT03430648||Persons with Mild Cognitive Impairment|This group has been defined as being mildly cognitively impaired.
62639574|NCT04623866|ACTIVE_COMPARATOR|Huaiqihuang Group|Huaiqihuang granules 60g/1.73m2 bid 24 weeks
62070904|NCT03273140|NO_INTERVENTION|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
62070905|NCT04789213||Patients with Living Donor Liver Transplantation|
62454797|NCT05153265||Attending physicians|We plan to distribute a survey to the Stanford anesthesiology attending physicians to determine their assessment of the bleeding risk of several different nerve blocks. The survey will list the most common nerve blocks and ask Stanford anesthesiologists whether the block is low/intermediate/high risk based on their experience with nerve blocks.
62454798|NCT03501680|EXPERIMENTAL|Group A: intensive insulin|Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)
62454799|NCT03501680|ACTIVE_COMPARATOR|Group B: standard insulin|Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),
62070906|NCT04789213||Patients with Deceased Donor Liver Transplantation|
62070907|NCT02132533|EXPERIMENTAL|Nifedipine|Women with preterm labor will receive nifedipine.
62070908|NCT02132533|EXPERIMENTAL|Placebo|Women with preterm labor will receive placebo.
62070909|NCT03176043|EXPERIMENTAL|Thirst Driven infusion|Subjects who are self administering fluid will be instructed when (at any point in the experiment) they are experiencing thirst to request a fluid bolus with an electronic trigger. In response to this trigger the researcher will then deliver a 200ml bolus of IV fluid. After delivery of the fluid bolus, a lockout period is set for 15mins within which the researcher will not deliver another bolus in response to the trigger.
62070910|NCT03176043|ACTIVE_COMPARATOR|NICE infusion|Subjects receiving standard fluid maintenance will receive a baseline infusion rate of 30 mL/kg/24hr (1.25 mL/kg/hr). In addition to this a 500 mL bolus will be delivered if any of the following clinical signs, indicating hypovolaemia, are observed on regular examination: low peripheral perfusion, heart rate \>90 /min, systolic BP \<100 mmHg, respiratory rate \>20, peripheral capillary refill \>2sec. A maximum of 2000 mL of fluid will be delivered by additional boluses.
62070911|NCT05392140|EXPERIMENTAL|intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
62070912|NCT05392140|ACTIVE_COMPARATOR|non-intervention group|standard care practice will continue
62070913|NCT03389841|ACTIVE_COMPARATOR|Intervention|Education of the caregiver
62454800|NCT03501680|ACTIVE_COMPARATOR|Group C: plasmapheresis|Group C: plasmapheresis
62454801|NCT01806090|ACTIVE_COMPARATOR|Clopidogrel|Continue clopidogrel for 7 days prior to the endoscopic procedure
62454802|NCT01806090|PLACEBO_COMPARATOR|Placebo|Placebo daily for 7 days prior to the endoscopic procedure
62070914|NCT03389841|NO_INTERVENTION|No intervention|Usual care
62088315|NCT01461616|EXPERIMENTAL|detemir insulin injection|insulin detemir will be injected in random order in one of three seperated visit days.
62454803|NCT06441396|ACTIVE_COMPARATOR|Telerehabilitation|It is a group that performs the given exercise program mutually with the physiotherapist via video connection.
62454804|NCT06441396|ACTIVE_COMPARATOR|Video-based rehabilitation|This is the group that does the given exercises by watching the video.
62454805|NCT02490709|EXPERIMENTAL|Local excision|Local excision for rectal cancer with good response
62454806|NCT01759199|EXPERIMENTAL|The six minute Stepper Test|Experimental : The six minute Stepper Test with a Conventional respiratory rehabilitation
62639575|NCT04623866|ACTIVE_COMPARATOR|Valsartan group|Valsartan granules 80mg/1.73m2 based qd 24 weeks
62639576|NCT00194129|EXPERIMENTAL|Lithium plus Divalproex|Patients assigned to the combination group were continued on lithium and blinded divalproex.
62454807|NCT02885337|ACTIVE_COMPARATOR|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
62070915|NCT06217887|EXPERIMENTAL|loxenatide Group|loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but loxenatide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
62070916|NCT06217887|EXPERIMENTAL|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/ day every morning until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Gliclazide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
62070917|NCT00125593|PLACEBO_COMPARATOR|Placebo|Placebo = Arm 1. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 1 patients taking 2 tablets (placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) during the first year. After the first year, all Arm 1 patients took one tablet (placebo simvastatin plus ezetimibe tablet).
62070918|NCT00125593|ACTIVE_COMPARATOR|Simvastatin 20mg plus Ezetimibe 10mg|Simvastatin 20mg plus ezetimibe 10mg = Arm 2. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 2 patients taking 2 tablets during the first year (active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet). After the first year, all Arm 2 patients took one tablet (active simvastatin 20mg plus ezetimibe 10mg tablet).
62070919|NCT00125593|OTHER|Simvastatin 20mg|Simvastatin 20mg alone = Arm 3. After 1 year, those initially allocated to Arm 3 were re-randomized to simvastatin 20mg plus ezetimibe 10mg (Arm 3b) daily or placebo (Arm 3a). A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with Arm 3 patients taking 2 tablets (a placebo simvastatin plus ezetimibe tablet with an active simvastatin tablet) during the first year. After the first year, all Arm 3a and Arm 3b patients took one tablet (active or placebo simvastatin plus ezetimibe tablet).
62639577|NCT00194129|PLACEBO_COMPARATOR|Lithium plus placebo|Patients assigned to lithium monotherapy underwent divalproex-placebo substitution at a rate of 250 mg decrements every week until discontinued.
62639578|NCT05186129|EXPERIMENTAL|Clopid® 75 mg(Clopidogrel)Tablet of Ferozsons Laboratories Ltd. Pakistan|Single dose of Clopid® 75 mg Tablet administered under fasting condition
62639579|NCT05186129|ACTIVE_COMPARATOR|Plavix® 75mg Tablet of Sanofi Winthrop Industrie France for Sanofi Pakistan.|Single dose of Plavix® 75 mg Tablet administered under fasting condition
62639580|NCT03567473|EXPERIMENTAL|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine OR Oral dexamethasone and inhaled epinephrine given by MDI
62639581|NCT03567473|PLACEBO_COMPARATOR|Control Arm|"Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.~OR Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and inhaled placebo given by MDI."
62639582|NCT03312374||stage II CRC|Patients with stage II colorectal cancer
62639583|NCT03312374||stage III CRC|Patients with stage III colorectal cancer
62639584|NCT06401707|ACTIVE_COMPARATOR|Perampanel|Perampanel oral load of 24mg upon randomization followed by 8mg oral dose daily for four more days (second dose one day after load and total treatment duration is 5 days)
62639585|NCT06401707|PLACEBO_COMPARATOR|Placebo|Placebo oral load upon randomization followed by daily placebo oral dose administration for four more days (second dose one day after load and total placebo administration duration is 5 days)
62070920|NCT00098254|EXPERIMENTAL|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
62070921|NCT05412459||The tested injected doses of 99mTc-DARPinG3 3000 μg (SPECT)|"Maximum (15) evaluable subjects with HER2-positive status in primary tumour before, after 2 and 4 courses of chemo+targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
62275670|NCT03430648||Persons with early Alzheimer's disase|This group has been defined as having early Alzheimer's disease.
62275671|NCT05495555||High IOP setting|Cataract removal with high IOP setting
62275672|NCT05495555||Low IOP setting|Cataract removal with low IOP setting
62275673|NCT02475642|ACTIVE_COMPARATOR|PVI-ADT|discontinue antiarrhythmic drugs at 3 months post PVI
62275674|NCT02475642|ACTIVE_COMPARATOR|PVI+ADT|discontinue antiarrhythmic drugs at 12 months post PVI
62275675|NCT00132067|EXPERIMENTAL|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62639586|NCT01702467|EXPERIMENTAL|GSK2647544|The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).
62639587|NCT01702467|PLACEBO_COMPARATOR|Placebo|Matching placebo
62639588|NCT05532215|EXPERIMENTAL|Misoprostol|400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.
62639589|NCT05532215|PLACEBO_COMPARATOR|Placebo|Two sublingual placebo tablets similar to the misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.
62639590|NCT03400527|EXPERIMENTAL|Exercise|Participant will be pedaling a stationary exercise bicycle
62639591|NCT02652663||ECA-MRI group|ECA-MRI group (patients who underwent conventional MRI using extracellular contrast agent \[ECA\])
62639592|NCT02652663||Gd-EOB-MRI group|Gd-EOB-MRI group (patients who underwent gadoxetic acid-enhanced MRI)
62275676|NCT01608412|ACTIVE_COMPARATOR|Tacrolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Tacrolimus"
62275677|NCT01608412|ACTIVE_COMPARATOR|Everolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Everolimus"
62275678|NCT03939507|EXPERIMENTAL|Intervention group|AEP score results were made available to the treating physician at each assessment visit.
62275679|NCT03939507|NO_INTERVENTION|Control group|AEP scores were only made available at the end of follow-up.
62275680|NCT02988583|EXPERIMENTAL|low viscosity silicone oil|Retinal detachment surgery using low viscosity silicone oil
62454808|NCT02885337|EXPERIMENTAL|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with patients at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
62454809|NCT02327195|EXPERIMENTAL|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
62639593|NCT06086990|EXPERIMENTAL|Telemonitoring Platform|"Patients assigned to the active intervention group will have access to a smartphone application named Contigo. This application is designed to identify signs and symptoms of oncology drug toxicity while providing educational content. It equips patients with the necessary tools to manage typical clinical situations associated with the diagnosis and treatment of their disease."
62639594|NCT06086990|NO_INTERVENTION|Traditional Follow-Up|Individuals designated to the traditional follow-up group will undergo standard care, including in-person check-ups as determined by their attending physician.
62639595|NCT02361866|EXPERIMENTAL|GC1107|0.5ml, intramuscular, a single dosing
62275681|NCT02988583|ACTIVE_COMPARATOR|high viscosity silicone oil|Retinal detachment surgery using high viscosity silicone oil
62275682|NCT01659645|EXPERIMENTAL|FACBC|
62275683|NCT01777152|ACTIVE_COMPARATOR|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
62275684|NCT01777152|EXPERIMENTAL|A+CHP|brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
62275685|NCT05279846|EXPERIMENTAL|MOB015B|Applied at bedtime daily for 8 weeks and then reduced to once weekly for 40 weeks
62454810|NCT02327195|PLACEBO_COMPARATOR|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
62454811|NCT05216536||Long COVID|Adults who contracted COVID-19 and present at least one physical or cognitive long COVID-19 symptom for more than 12 weeks following the initial diagnosis.
62639596|NCT02361866|ACTIVE_COMPARATOR|Tetanus and Diphtheria(Td vaccine)|0.5ml, intramuscular, a single dosing
62639597|NCT02238730|ACTIVE_COMPARATOR|Ultrabrief Right Unilateral|Ultrabrief (0.25 ms) Right Unilateral Electroconvulsive Therapy
62639598|NCT02238730|ACTIVE_COMPARATOR|Brief Pulse Bitemporal|Brief Pulse (0.5 ms) Bitemporal Electroconvulsive Therapy
62070922|NCT05913284|EXPERIMENTAL|Methadone group|Upon induction of anaesthesia, intravenous methadone 0.2mg/kg (maximum dose 20mg) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists
62639599|NCT05036941|EXPERIMENTAL|Arm 1|Acteev™ system (Acteev™ N95 masks YQD8008 during shifts+ Acteev™ fabric masks in community)
62639600|NCT05036941|ACTIVE_COMPARATOR|Arm 2|Standard system (standard N95 masks during shifts+ fabric masks in community)
62275686|NCT05279846|PLACEBO_COMPARATOR|Control Arm|Applied at bedtime daily for 8 weeks and then reduced to once weekly for 40 weeks
62275687|NCT01290965|PLACEBO_COMPARATOR|Placebo comparator|
62275688|NCT01290965|ACTIVE_COMPARATOR|SCY-635 30 mg once daily|
62275689|NCT01290965|ACTIVE_COMPARATOR|SCY-635 100 mg once daily|
62454812|NCT05216536||Acute COVID|Adults who contracted COVID-19 but did not experience persistent symptoms for more than 4 weeks following the initial diagnosis.
62070923|NCT05913284|ACTIVE_COMPARATOR|Morphine group|Upon induction of anaesthesia, intravenous morphine that is of equipotent dose as 0.2mg/kg methadone or 20mg methadone if maximum dose of interventional drug is reached) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists
62639601|NCT03999255|EXPERIMENTAL|Patients undergoing intrarenal surgery|
62639602|NCT03159585|EXPERIMENTAL|TAEST16001|Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.
62070924|NCT02906202|EXPERIMENTAL|LentiGlobin BB305 Drug Product|Participants aged less than or equal to (\<=) 50 years received a single intravenous (IV) infusion of LentiGlobin BB305 Drug Product at a dose of greater than or equal to (\>=) 5.0\*10\^6 CD34 plus (+) cells per kilogram (cells/kg) following myeloablative conditioning with busulfan (termed the Transplant population).
62070925|NCT04823559|NO_INTERVENTION|Usual practice|Usual practice
62070926|NCT04823559|EXPERIMENTAL|Intervention|Receives educational workshop
62070927|NCT00630214|NO_INTERVENTION|C|No supplements after total thyroidectomy and central neck dissection
62070928|NCT00630214|NO_INTERVENTION|D|No central neck dissection group (total thyroidectomy alone)
62070929|NCT00630214|ACTIVE_COMPARATOR|A|Oral calcium plus vitamin D supplements after total thyroidectomy and central neck dissection
62070930|NCT00630214|ACTIVE_COMPARATOR|B|Oral calcium alone supplement after total thyroidectomy and central neck dissection
62275690|NCT01290965|ACTIVE_COMPARATOR|SCY-635 300 mg once daily|
62639603|NCT02250313||Case|All patients will have the tissue from their previous negative biopsy tested with the assay. Cases are defined as those subjects who receive the ConfirmMDx assay results.
62639604|NCT02250313||Control|All patients will have the tissue from their previous negative biopsy tested with the assay. Controls are defined as subjects who will be blinded to the ConfirmMDx assay results.
62639605|NCT01914393|EXPERIMENTAL|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
62070931|NCT06210451|EXPERIMENTAL|Gel group|Speculum insertion using sterile water-based gel
62070932|NCT06210451|NO_INTERVENTION|Sterile water group|Speculum insertion using sterile water
62639606|NCT04157010|EXPERIMENTAL|TCZ monotherapy|Tocilizumab (TCZ) monotherapy 8mg/kg 4-weekly for a total of 48 weeks.
62639607|NCT04157010|EXPERIMENTAL|TCZ+MTX combination therapy|Tocilizumab (TCZ) and methotrexate (MTX) combination therapy 8mg/kg 4-weekly for a total of 48 weeks.
62639608|NCT04735705|EXPERIMENTAL|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation.
62070933|NCT00739895||Athletes|high performing athletes
62070934|NCT02501213|NO_INTERVENTION|A : observation|Clinical monitoring and best supportive care.
62070935|NCT02501213|ACTIVE_COMPARATOR|B : diuretics|Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.
62070936|NCT02529397|EXPERIMENTAL|Adaptive Working Memory Training|The experimental group will receive working memory training through a commercial computerized program: five weeks of adaptive working memory training concurrently with a behavioral weight loss program. Adaptive working memory training becomes progressively more challenging depending on an individual's performance on a given task. They will attend weekly classes of a behavioral weight loss program.
62275691|NCT01290965|ACTIVE_COMPARATOR|SCY-635 100 mg three times daily|
62275692|NCT01290965|ACTIVE_COMPARATOR|SCY-635 200 mg three times daily|
62275693|NCT01290965|ACTIVE_COMPARATOR|SCY-635 300 mg three times daily|
62275694|NCT03509350|EXPERIMENTAL|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
62454813|NCT05216536||Control|Adults who did not contract COVID-19.
62275695|NCT03509350|PLACEBO_COMPARATOR|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
62454814|NCT05586061|EXPERIMENTAL|RC48 Plus Tislelizumab and S-1(RCTS)|Disitamab Vedotin: 2.5mg/kg, ivdrip, d1, (every 3 weeks) Q3W； Tislelizumab: 200mg, ivdrip, d1, (every 3 weeks) Q3W； S-1: 40-60mg(according to patients' body surface area), po, bid, d1-14 and discontinued for 7 days in each cycle; until progressive disease (PD) or intolerable toxicity
62275696|NCT02302963|EXPERIMENTAL|AP System (DiAs or inControl) with USS Virginia|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then proceed through 7 weeks of training and use of the AP System with USS Virginia and study pump. The inpatient testing will be repeated after wearing the AP System at home.
62275697|NCT02302963|PLACEBO_COMPARATOR|Sensor-Augmented Pump Therapy|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then wear a continuous glucose monitor and their own insulin pump at home for 5 weeks. The inpatient testing will be repeated at the completion of the 5 weeks at home.
62275698|NCT03370497|ACTIVE_COMPARATOR|Whey protein hydrolysate|Whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
62454815|NCT00868400|EXPERIMENTAL|1|High-carbohydrate
62639609|NCT00003039|EXPERIMENTAL|Arm I|Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs.
62639610|NCT05324319|ACTIVE_COMPARATOR|homologous 3rd vaccination (mRNA vaccine)|Participants will receive a third SARS-CoV-2 vaccination with the same mRNA vaccine they received for the initial prime-boost vaccination (BNT162b2 or mRNA-1273 )
62639611|NCT05324319|EXPERIMENTAL|heterologous 3rd vaccination (vector vaccine)|participants will receive a third SARS-CoV-2 vaccination with a vector vaccine (Ad26COVS1 or ChAdOx1-S)
62070937|NCT02529397|PLACEBO_COMPARATOR|Non-adaptive Working Memory Training|The control group will receive five weeks of non-adaptive (placebo) cognitive training concurrent with the identical behavioral weight loss program as in the experimental group. Non-adaptive cognitive training remains at a constant level.
62275699|NCT03370497|EXPERIMENTAL|Whey protein hydrolysate plus milk mineral supplement|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
62454816|NCT00868400|PLACEBO_COMPARATOR|2|Placebo
62454817|NCT00868400|NO_INTERVENTION|3|Control
62454818|NCT03215108|EXPERIMENTAL|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
62454819|NCT03215108|EXPERIMENTAL|Conventional-CSEMS|Conventional-CSEMS (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
62454820|NCT01432977|ACTIVE_COMPARATOR|comparateur|paracetamol / droperidol
62454821|NCT01432977|EXPERIMENTAL|Eperimental|paracetamol / ondansetron
62454822|NCT01649622|EXPERIMENTAL|Bendamustine|"Patients receive Bendamustine at dose of 75 mg/m2 by vein over 30 minutes twice daily for four days (Days 1-4). Bendamustine dose based on actual body weight.~Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses."
62454823|NCT00214279|NO_INTERVENTION|1|Remain on 3-drug standard of care immunosuppression including prednisone
62454824|NCT00214279|EXPERIMENTAL|2|Corticosteroid withdrawal / prednisone taper over 14 weeks
62639612|NCT03308669|EXPERIMENTAL|Lasmiditan Alone|Lasmiditan administered orally, alone
62639613|NCT03308669|PLACEBO_COMPARATOR|Placebo Alone|Placebo administered orally, alone
62639614|NCT03308669|EXPERIMENTAL|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
62639615|NCT03308669|EXPERIMENTAL|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
62639616|NCT04045756|EXPERIMENTAL|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
62639617|NCT02564276|EXPERIMENTAL|Indocyanine Green on the right side|Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
62639618|NCT02564276|EXPERIMENTAL|Methylene Blue on the right side|Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
62639619|NCT02391051|EXPERIMENTAL|Focal Brachytherapy|HDR-Brachytherapy, 2 fractions within at least 24 but max. 30 hours, each 13,5 Gy
62639620|NCT05485922|EXPERIMENTAL|Investigational device - intermittent catheter with a micro-hole zone|A ready-to-use, sterile, hydrophilic-coated male catheter for intermittent catheterisation with a flexible tip and a micro-hole zone for urinary drainage in sizes CH12 and CH14. The catheterization was performed by a trained nurse.
62275700|NCT01731678|EXPERIMENTAL|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
62639621|NCT05485922|ACTIVE_COMPARATOR|Comparator device - VaPro intermittent catheter|Hollister VaPro, a single-use hydrophilic sleeved soft/flexible catheters in the sizes CH12 or CH14. The catheterization was performed by a trained nurse.
62639622|NCT05554107|ACTIVE_COMPARATOR|Group A - Supervised exercise first|"All POTS patients will continuously be randomized into two groups (Group A and B). Group A will first start the training program and when the training program is finished group B will start the training program. While each group is not performing the training program the patients will be encouraged to physical activity according to their own abilities.~Results from questionnaires, orthostatic tests and maximal biking tests will be compared between group A and B as well as within each group."
62639623|NCT05554107|ACTIVE_COMPARATOR|Group B - Self-instruction exercise first|See above.
62639624|NCT03908788|EXPERIMENTAL|Intplex test|In vitro diagnostic device
62639625|NCT06338306||De novo heart transplant patients|Twenty-five de-novo heart transplant recipients will be enrolled, male and female, aging 18-70 years, receiving TAC in combination with steroids and antiproliferative drugs (MMF; EC-MPS) or m-TOR inhibitors (Everolimus; Sirolimus).
62639626|NCT04604834|EXPERIMENTAL|PFAT first|1 eyedrop of PFAT every 2 hours in study eye.
62639627|NCT04604834|EXPERIMENTAL|APRP first|1 eyedrop of APRP every 2 hours in study eye.
62639628|NCT04604834|EXPERIMENTAL|APRP+PFAT first|1 eyedrop of PFAT and APRP every 2 hours in study eye.
62639629|NCT04797208|EXPERIMENTAL|Real-Time CGM|This group will have a subcutaneous RT-CGM inserted by a member of the research team. CGM's low and high glucose alerts will be activated. The treating clinical team will be able to remotely monitor glucose data and be notified of low glucose alerts through the linked handset. Hyper- and hypo-glycemia management including insulin dose adjustments by the treating clinical team, will be guided by sensor glucose levels and trends according to written guidelines during the study. Glucose level during and post-hypoglycaemia treatment will be confirmed by capillary blood glucose (CBG) measurements (using the NovaStat® glucometer or similar CE-marked glucose meter).
62639630|NCT04797208|ACTIVE_COMPARATOR|Capillary blood glucose with masked CGM|This group will have their glucose monitored in hospital using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted by a member of the research team to collect glucose values (glucose values will not be displayed and no glucose alerts will be available). This will removed at the end of the study by the research team.
62639631|NCT00838097||Darbepoetin alfa|Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.
62070938|NCT02127320|EXPERIMENTAL|Sequence 1|Rosuvastatin 20mg → Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg
62639632|NCT03988153|EXPERIMENTAL|Probiotic Milk Formula (PMF)|Twenty subjects should drink 200 mL of PMF (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
62639633|NCT03988153|PLACEBO_COMPARATOR|Skimmed Milk Formula|Twenty subjects should drink 200 mL of skimmed milk drink (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
62639634|NCT06360328|NO_INTERVENTION|direct Laryngoscopy|The resident intubates using direct laryngoscopy .
62639635|NCT06360328|EXPERIMENTAL|video Laryngoscopy|The resident intubates using video laryngoscopy
62639636|NCT05237726|ACTIVE_COMPARATOR|Unfractionated Heparin (UFH) 5000 U q8 hours|Severely burn injuries (BSA≥20%) will receive Unfractionated Heparin (UFH) 5000 U q8 hours as pharmacological VTE prophylaxis
62639637|NCT05237726|ACTIVE_COMPARATOR|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will receive Enoxaparin 40 mg q24 hours as pharmacological VTE prophylaxis
62639638|NCT05237726|ACTIVE_COMPARATOR|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will receive Enoxaparin 30 mg q12 hours as pharmacological VTE prophylaxis
62639639|NCT02946359|EXPERIMENTAL|Patients with ALK translocation|Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
62639640|NCT02946359|EXPERIMENTAL|Patients with ROS1 translocation|Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
62639641|NCT02946359|EXPERIMENTAL|Patients with MET amplification|Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
62275701|NCT03322059|ACTIVE_COMPARATOR|Control|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.~Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values."
62275702|NCT03322059|EXPERIMENTAL|Intervention|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit. Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values.~Participants will be in the form of a charitable donation in their name to a cancer charity."
62275703|NCT01318044|ACTIVE_COMPARATOR|Propofol group: propofol|
62275704|NCT01318044|ACTIVE_COMPARATOR|Thiopental group: thiopental|
62275705|NCT03730805|EXPERIMENTAL|Intervention + open mindset|ASSIST-linked Brief Intervention plus prior induction of deliberative mindset
62275706|NCT03730805|EXPERIMENTAL|Intervention + closed mindset|ASSIST-linked Brief Intervention plus prior induction of closed mindset
62275707|NCT03730805|EXPERIMENTAL|Intervention alone|ASSIST-linked Brief Intervention without prior induction of any mindset
62275708|NCT03730805|EXPERIMENTAL|Control + open mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of an open mindset is conduced.
62275709|NCT03730805|EXPERIMENTAL|Control + closed mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of a closed mindset is conduced.
62275710|NCT03730805|NO_INTERVENTION|Control alone|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) without prior induction of any mindset is conduced.
62275711|NCT05152797|EXPERIMENTAL|TILs infusion|Enrolled patients will be infused with their autologous TILs followed by IL-2 administration after post- NMA lymphodepletion
62639642|NCT03087734|ACTIVE_COMPARATOR|Perpendicular stabilizer|Implantation of regular bar with perpendicular stabilizers
62639643|NCT03087734|EXPERIMENTAL|Oblique stabilizer|Implantation of new model of bar with oblique stabilizers
62275712|NCT05941598|EXPERIMENTAL|Electroacupuncture|After skin disinfection, acupuncture needles will be inserted into the acupoints. All needles will be manipulated to achieve deqi. Then, an electroacupuncture apparatus will be connected. The stimulation parameters will be continuous wave, 2 Hz, and the current intensity will be adjusted according to the participant's comfort level.
62275713|NCT05941598|SHAM_COMPARATOR|Sham acupuncture|After skin disinfection, acupuncture needles will be inserted into acupoints that are unrelated to the treated syndromes. The needles will be inserted to a depth of 3 to 5 mm, without any manipulation or deqi. Then, the electronic acupuncture apparatus will be connected, with a continuous wave of 2 Hz. However, the intensity of electrical stimulation will be set to a minimum level that participants can perceive, and the apparatus will be turned off after 30 seconds of stimulation.
62275714|NCT05401305|EXPERIMENTAL|Hib vaccine|"Volunteers will be vaccinated with Vaccine for the prevention of infections caused by Haemophilus influenza type b once intramuscularly at a dose of 0.5 mL.~Stage I: 5 volunteers Stage II: 25 volunteers"
62275715|NCT05401305|PLACEBO_COMPARATOR|Placebo|Volunteers will receive a placebo once intramuscularly at a dose of 0.5 mL. Stage I: 5 volunteers Stage II: 25 volunteers
62639644|NCT02296489||Healthy volunteers|
62275716|NCT01673321|EXPERIMENTAL|Non-fat Yogurt-Plain flavored|Protein to carbohydrate ratio: 2.30
62275717|NCT01673321|EXPERIMENTAL|Skim milk|Protein to carbohydrate ratio: 0.69
62275718|NCT01673321|EXPERIMENTAL|Non-fat Yogurt with honey-Plain flavored|Protein to carbohydrate ratio: 1.24
62275719|NCT01673321|EXPERIMENTAL|Orange juice|Protein to carbohydrate ratio: 0.07
62275720|NCT01673321|EXPERIMENTAL|Non-fat Yogurt-Strawberry flavored|Protein to carbohydrate ratio: 0.79
62275721|NCT01617941|EXPERIMENTAL|BGG492|At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).
62275722|NCT01617941|PLACEBO_COMPARATOR|Placebo|At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).
62639645|NCT02296489||Asthma patients|
62070939|NCT02127320|EXPERIMENTAL|Sequence 2|Rosuvastatin 20mg and Ezetimibe 10mg→ Rosuvastatin 20mg → Ezetimibe 10mg
62275723|NCT04009044|EXPERIMENTAL|Treatment (afimoxifene)|Patients apply afimoxifene gel topically QD to both breasts for 3 to 5 weeks and then undergo core needle biopsies of both breasts.
62275724|NCT00803179|EXPERIMENTAL|Growth Hormone Therapy|"Nutropin Aqueous (AQ):~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d"
62275725|NCT01625754||Cardiac rehabilitation|This study recruits individuals that are currently participating in a cardiac rehabilitation exercise program.
62275726|NCT05037110|EXPERIMENTAL|Physical activity group|
62275727|NCT05037110|EXPERIMENTAL|Chemosensory training group|
62275728|NCT05037110|NO_INTERVENTION|Control group|For 12 weeks, continue the participant's routine (no intervention). This is done remotely. Then, every two weeks, complete an online follow-up questionnaire (15 minutes each).
62275729|NCT01126775||group non-high-risk|
62639646|NCT01705080||A - EnligHTN for Severe Resistant HTN|"* Office systolic Blood Pressure ≥160 mmHg~* Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~* Patient has an estimated GFR ≥45 mL/min per 1.73 m\^2 using the Modification of Diet in Renal Disease (MDRD) formula"
62639647|NCT01705080||B - EnligHTN for Resistant HTN|"* Office systolic Blood Pressure ≥140 mmHg~* Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~* Patient has an estimated GFR ≥45 mL/min per 1.73 m\^2 using the Modification of Diet in Renal Disease (MDRD) formula"
62639648|NCT01705080||C - EnligHTN for Resistant HTN & CKD|"* Office systolic Blood Pressure ≥140 mmHg~* Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~* Patient has an estimated ≥15 GFR \<45 mL/min per 1.73 m\^2 using the Modification of Diet in Renal Disease (MDRD) formula"
62639649|NCT00190424|NO_INTERVENTION|control|
62639650|NCT00190424|EXPERIMENTAL|CpG-ODN|
62639651|NCT00756626|EXPERIMENTAL|1|Intervention group receives bottle weaning intervention from WIC nutritionist
62275730|NCT01126775||group high risk|
62639652|NCT00756626|NO_INTERVENTION|2|Control standard of care
62639653|NCT00826553|EXPERIMENTAL|GABA agonist|
62639654|NCT00826553|EXPERIMENTAL|Alpha 2 agonist|
62275731|NCT00918151||A|
62639655|NCT01518647|EXPERIMENTAL|Group Therapy|ACT given as conventional group therapy in groups of 7-8 patients 3,5 hours each session, 9 sessions during 3 month
62275732|NCT00785330|OTHER|A|Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
62275733|NCT00785330|EXPERIMENTAL|B|rituximab in addition to standard GVHD prophylaxis
62275734|NCT05298137|NO_INTERVENTION|IV Cannulation Without Passive Leg Raise|"Patients will be randomized to either the passive leg raise (PLR) group or standard care (control group). In both groups baseline measurements of a peripheral vein diameter using ultrasound will be undertaken at the level of the left antecubital fossa with and without a proximally placed venous tourniquet.~Those in the control group will then have a peripheral IV (PIV) placed in the ipsilateral arm as the baseline measurements, the number of attempts to successful PIV placement will be recorded. A repeat diameter assessment of the previously assessed vein, number of PIV attempts, and time to successful IV cannulation (measured as the time from skin puncture to successful IV cannulation) will be recorded."
62275735|NCT05298137|EXPERIMENTAL|IV Cannulation With Passive Leg Raise|"Patients will be randomized to either the passive leg raise (PLR) group or standard care (control group). In both groups baseline measurements of a peripheral vein diameter using ultrasound will be undertaken at the level of the left antecubital fossa with and without a proximally placed venous tourniquet.~Those in the passive leg raise (PLR) group will have their legs elevated to 45 degrees until successful peripheral IV (PIV) placement. A repeat diameter assessment of the previously assessed vein, number of PIV attempts, and time to successful IV cannulation (measured as the time from skin puncture to successful IV cannulation) will be recorded."
62275736|NCT02059200|EXPERIMENTAL|MBCL + TAU|This cohort receives the Mindfulness Based Compassionate Living program in addition to treatment as usual.
62275737|NCT02059200|NO_INTERVENTION|TAU|This cohort receives treatment as usual of any nature, e.g. psychotherapy, antidepressant medication etc.
62639656|NCT01518647|EXPERIMENTAL|Workshop|ACT given as a one-day workshop with 15 patients with a following individual consultation
62639657|NCT01518647|ACTIVE_COMPARATOR|Standard treatment|Standard treatment is one single advisory consultation given 2 weeks after randomization
62639658|NCT05251272||Training cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
62639659|NCT05251272||Validation cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
62639660|NCT05030649|EXPERIMENTAL|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
62639661|NCT05030649|ACTIVE_COMPARATOR|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
62070940|NCT02127320|EXPERIMENTAL|Sequence 3|Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg → Rosuvastatin 20mg
62070941|NCT02127320|EXPERIMENTAL|Sequence 4|Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg → Rosuvastatin 20mg
62070942|NCT02127320|EXPERIMENTAL|Sequence 5|Ezetimibe 10mg → Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg
62275738|NCT01355705|EXPERIMENTAL|Amrubicin + Lenalidomide + Dexamethasone|"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.~Concurrent therapeutic medications:~* Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14~* Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)~Other drugs:~* Aspirin: 81 or 325 mg daily oral~* Pegfilgrastim subcutaneous on Day 2"
62454825|NCT03125200|EXPERIMENTAL|ADCT-502|"Part 1 (dose escalation): Participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined.~Part 2 (expansion): Participants were due to be assigned to the recommended dose level of ADCT-502 as identified in Part 1 by the Dose Escalation Steering Committee."
62070943|NCT02127320|EXPERIMENTAL|Sequence 6|Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg
62275739|NCT00782366||Genetic Testing Group|Those who will receive predictive genetic risk assessments
62454826|NCT06242756|EXPERIMENTAL|Bladder catheterization|Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post Cesarean section.
62454827|NCT06242756|NO_INTERVENTION|Non-use of bladder catheterization|Participants in the non-catheterized group would be encouraged to empty their bladders just prior to transfer to the operating room where they will undergo surgery without an indwelling catheter.
62070944|NCT04599686|ACTIVE_COMPARATOR|ADT|Evaluating men with oligometastatic prostate cancer lesions randomized to ADT.
62070945|NCT04599686|EXPERIMENTAL|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
62070946|NCT04529603|EXPERIMENTAL|Arm 1|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
62070947|NCT04848181|ACTIVE_COMPARATOR|cyproterone acetate|20 patients received cyproterone acetate 50 mg twice per day for two weeks before TURP
62070948|NCT04848181|ACTIVE_COMPARATOR|finasteride group|20 patients received finasteride 5 mg once per day for two weeks before TURP
62275740|NCT00782366||Control|Those who will receive standard of care
62275741|NCT01162330||Babies referred for further hearing tests|Babies referred for further hearing tests after their neonatal hearing screening tests
62070949|NCT04848181|PLACEBO_COMPARATOR|control group|20 patients received no treatment before TURP
62070950|NCT02394899|NO_INTERVENTION|Control|The control dyad will receive usual care.
62070951|NCT02394899|EXPERIMENTAL|Intervened|Parents receive training in problem solving skills and play therapy with their infants.
62070952|NCT01613027||Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
62070953|NCT03008421|EXPERIMENTAL|Study group (GBS positive w/o infection)|Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)
62070954|NCT03008421|PLACEBO_COMPARATOR|Placebo group (GBS positive w/o infection)|Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)
62070955|NCT03900377|EXPERIMENTAL|Lg-B-NHL or MCL|For previously untreated patients with Lg-B-NHL or MCL, rituximab will be intravenously administered at 375 mg/m\^2 on Day 0 (the day before Day 1 only in Cycle 1), and SyB L-0501RI will be intravenously administered at 90 mg/m\^2/day on Day 1 and Day 2 of each 28-day cycle with up to 6 cycles.
62070956|NCT03900377|EXPERIMENTAL|DLBCL|For patients with recurrent or refractory DLBCL, rituximab will be intravenously administered at 375 mg/m\^2 on Day 1, and SyB L-0501RI will be intravenously administered at 120 mg/m\^2/day on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles.
62070957|NCT00974519|ACTIVE_COMPARATOR|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
62070958|NCT00974519|ACTIVE_COMPARATOR|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
62070959|NCT00974519|PLACEBO_COMPARATOR|Placebo|Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
62070960|NCT02495896|EXPERIMENTAL|Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62070961|NCT02495896|EXPERIMENTAL|Arm B (sEphB4-HSA, docetaxel)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62070962|NCT02495896|EXPERIMENTAL|Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62070963|NCT03053921|PLACEBO_COMPARATOR|recession coverage|30 recession defects treated with Zucchelli's technique.
62070964|NCT03053921|ACTIVE_COMPARATOR|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
62454828|NCT02534779|EXPERIMENTAL|Placebo Vaginal Insert|Placebo insert
62070965|NCT03791385|EXPERIMENTAL|Study subjects|Children with ASD and their parents/caregivers were trained on tooth-brushing twice, two weeks apart using Picture Exchange Communication System (PECS) PECS as a pictures/cards series showing a structured tooth-brushing method.
62454829|NCT02854280|ACTIVE_COMPARATOR|Chronic Obstructive Pulmonary Disease (COPD)|18 patients
62454830|NCT02854280|ACTIVE_COMPARATOR|Sleep Apnea Obstructive (OSA)|18 patients
62639662|NCT06297512|EXPERIMENTAL|pGBM patients therapy|"* Whole therapy radiation therapy~* Temozolomide concomitant~* After 1 month adjuvant Temozolomide,~* After 3 months Doxorubicine~* adjuvant Temozolomide"
62070966|NCT04650971|EXPERIMENTAL|"Vaccine UniFluVec 6.7 log EID50/dose"|"Cohort 1 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 6.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
62070967|NCT04650971|EXPERIMENTAL|"Vaccine UniFluVec 7.7 log EID50/dose"|"Cohort 2 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 7.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
62639663|NCT01219543|EXPERIMENTAL|Part A|Daily dosing of AZD1480 to the patients with solid tumours excluding HCC
62070968|NCT04650971|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm consists of 20 subjects (10 subject in each Сohort).
62070969|NCT06187571|EXPERIMENTAL|MWM Group|This group received treatment with the Mulligan technique.
62070970|NCT06187571|ACTIVE_COMPARATOR|CT Group|This group received treatment with the conventional therapy.
62070971|NCT05115409|EXPERIMENTAL|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL
62070972|NCT01863979||Acute Atrial Fibrillation|
62070973|NCT01413217||Egg Breakfast|This group will be given a breakfast consisting of eggs. A breakfast consisting of eggs induces greater satiety and reduces Lunch Time intake.
62070974|NCT01413217||Cereal Breakfast|This breakfast will consist of a breakfast that will include cereal. A breakfast cereal or white bread increases lunchtime energy intake.
62070975|NCT02364232|EXPERIMENTAL|Home-based|"Participants in home-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the home-based training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
62088316|NCT01461616|EXPERIMENTAL|glargine insulin injection|insulin glargine will be injected in random order in one of three seperated visit days.
62454831|NCT02854280|ACTIVE_COMPARATOR|Healthy Volunteers|36 control patients
62454832|NCT02567968|PLACEBO_COMPARATOR|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
62454833|NCT02567968|ACTIVE_COMPARATOR|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
62639664|NCT01219543|EXPERIMENTAL|Part B|BID dosing of AZD1480 to the patients with advanced HCC (Child-Pugh A to B7)
62639665|NCT01219543|EXPERIMENTAL|Part C|BID dosing of AZD1480 to the patients with solid tumours excluding HCC
62639666|NCT01219543|EXPERIMENTAL|Expansion|BID dosing of AZD1480 to the patients with EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available.
62639667|NCT05089578||Individuals with Covid-19|Interviews were conducted with individuals who had Covid-19, and their experiences with the integrative methods they used were determined.
62639668|NCT00372424|EXPERIMENTAL|1|Combination of SU011248 (37.5 mg once daily \[Schedule 2/1\]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
62653026|NCT02723240|EXPERIMENTAL|Part 2 (two weekly administration) NUC-3373 2500mg/m2|"NUC-3373 2500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 15 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
62070976|NCT02364232|ACTIVE_COMPARATOR|Clinic-based|"Participants in clinic-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the home-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
62070977|NCT06495255|EXPERIMENTAL|Intervention|HMO bolus administration
62070978|NCT06495255|EXPERIMENTAL|Control|bolus administration
62070979|NCT04874376|EXPERIMENTAL|IOL retrospective data collection|Experimental arm: Premium Monofocal intraocular lens.
62070980|NCT05730738|ACTIVE_COMPARATOR|dalfampridine|patients received dalfampridine ER 10mg twice daily
62070981|NCT05730738|PLACEBO_COMPARATOR|Placebo|patients received placebo
62070982|NCT04151875|EXPERIMENTAL|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
62070983|NCT04151875|ACTIVE_COMPARATOR|Non-extraction orthodontic treatment|non-extraction orthodontic treatment
62070984|NCT02354859|ACTIVE_COMPARATOR|5 day of infusion of gallium nitrate|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device () using an ambulatory infusion pump infused over 24 hours for 5 sequential days.
62070985|NCT02354859|PLACEBO_COMPARATOR|5 day of infusion of normal saline|Placebo with be dispensed as 1,000 milliliters of 0.9% sodium chloride to match the reconstitution volume of the IV Ga
62070986|NCT06236360|EXPERIMENTAL|Mediterranean diet intervention|The intervention study will involve scheduled communications (via phone, video call, and/or email) with a trained nutritionist based on protocol-determined parameters and recommendations, organized weekly in the first month, every other week in the second month, and once a month in the third month. Each patient will receive general guidance and information about the MD. Additionally, a personalized nutritional plan based on the MD will be prepared for each patient, considering their initial dietary habits, preferences, food accessibility, and financial constraints. Throughout the 12-week period, patients will be motivated to adhere to the prescribed dietary regimen.
62070987|NCT06236360|NO_INTERVENTION|Continuing with previous diet|The control group will continue with their usual/current diet, with the exception of supplementation of those in whom low serum vitamin D level (in accordance with current medical recommendations)
62070988|NCT04380896||SARS-CoV-2 Seropositive Cases|"It will be formed of approximately N= 200 to 350 staff members~Core Group of PCR Confirmed Cases N \~ 150 to 250:~A) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive N \~ 150 to 250 OR~Other SARS-CoV-2 Sero-positives N \~ 50 to 100:~B) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases. OR C) No symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases"
62454834|NCT06004102|EXPERIMENTAL|reminder text message|"At the baseline of the study, the Sociodemographic and Descriptive Characteristics Form and IMAS were administered to patients in the intervention groups as a pretest. Short text messages to remind the use of immunosuppressive medication and educational text messages were sent to patients in the intervention group four times a day, every day for three months. The intervention group also received educational text messages three days a week, in addition to such text message reminders.~The text message contents prepared for the intervention group were sent automatically to patients at specified times via the purchased program. At the end of the study, intervention groups of participants completing the 9-month follow-up were administered the IMAS questionnaire as a posttest."
62639669|NCT00928434|EXPERIMENTAL|DI (Degarelix Intermittent)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.~During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered."
62653027|NCT05457959|PLACEBO_COMPARATOR|Cohort I Arm A (ppDC, placebo)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive ppDC ID in both arms with poly ICLC IM on day -10 and placebo IV on day -9 prior to standard of care surgical resection.
62070989|NCT04380896||SARS-CoV-2 Seronegative Comparison Group|"It will be formed of approximately N= 800 to 900 staff members~Core Comparison Group N \~ 800 A) Have not had clinical symptoms consistent with SARS-CoV-2 infection OR~Other Seronegatives N \~ 100 B) Have had sympoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days"
62070990|NCT02223247|EXPERIMENTAL|TVB-2640|Oral TVB-2640 capsules or tablets of various dose strengths administered QD for 21 - 28 day dosing cycles, alone or in combination with certain standard chemotherapy agents
62070991|NCT03403777|EXPERIMENTAL|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks. Courses will be repeated every 14 days until progression or unacceptable toxicity. AVELUMAB will be administered as a 1-hour (-10 minutes / +20 minutes, i.e., 50-80 minutes) intravenous (i.v.) infusion. The dose of AVELUMAB will be calculated based on the weight of the subject determined on the day prior to or the day of each drug administration.
62088317|NCT01398761|EXPERIMENTAL|Intervention|nurses, residents, PAs, and attendings from the two pilot services
62070992|NCT02141958|EXPERIMENTAL|Fenretinide|Fenretinide will be administrated orally once per day for 21 consecutive days, in up to three treatment cycles of ascending doses, with a minimum of 7-day drug-free period between cycles. Twelve (12) patients will be on Fenretinide.
62454835|NCT06004102|NO_INTERVENTION|no intervention|At the baseline of the study, the Sociodemographic and Descriptive Characteristics Form and IMAS were administered to patients in the control groups as a pretest. The control group did not receive any such intervention. At the end of the study, control groups of participants completing the 9-month follow-up were administered the IMAS questionnaire as a posttest.
62454836|NCT03164603|EXPERIMENTAL|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
62454837|NCT04860492|ACTIVE_COMPARATOR|Renalof|Patients will be given and, advised to take Renalof tablets 325mg three times a day for 90 days
62070993|NCT02141958|PLACEBO_COMPARATOR|Placebo|Four (4) patients will be on Placebo.
62070994|NCT05889819|EXPERIMENTAL|Treatment group|Intervention group received almond orange potato cookies during 4 weeks.
62070995|NCT05889819|PLACEBO_COMPARATOR|Control group|Control group received orange potato cookies during 4 weeks.
62070996|NCT01360567|PLACEBO_COMPARATOR|B formula|placebo
62070997|NCT01360567|EXPERIMENTAL|A formula|Green tea extract
62070998|NCT03835637|EXPERIMENTAL|Regimen A|
62070999|NCT03835637|EXPERIMENTAL|Regimen B|
62071000|NCT03835637|EXPERIMENTAL|Regimen C|
62071001|NCT03835637|EXPERIMENTAL|Regimen D|
62071002|NCT03835637|EXPERIMENTAL|Regimen F|
62071003|NCT03835637|EXPERIMENTAL|Regimen H|
62454838|NCT04860492|PLACEBO_COMPARATOR|Placebo|Patients will be given and, advised to take Placebo three times a day for 90 days
62454839|NCT05293353||Breast Milk Fortification with NeoKare|Prospective cohort, 50 infants
62454840|NCT05293353||No Breast Milk Fortification|Retrospective, historical cohort, approx 50 infants
62454841|NCT01624519|OTHER|1|
62454842|NCT02946385|EXPERIMENTAL|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
62071004|NCT03835637|EXPERIMENTAL|Regimen I|
62454843|NCT02946385|EXPERIMENTAL|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
62653028|NCT05457959|PLACEBO_COMPARATOR|Cohort I Arm B (placebo, nivolumab, ipilimumab)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive placebo ID in both arms with poly ICLC IM on day -10 and nivolumab IV and ipilimumab IV on day -9 prior to standard of care surgical resection.
62071005|NCT01097915||PROP taste sensitivity|"PROP Sensitive and non sensitive individuals are defined as Tasters and Non-tasters, respectively. Taster are further divided in Super-taster who perceived PROP as extremely bitter and Medium tasters who perceived PROP as moderately bitter."
62071006|NCT01382940|EXPERIMENTAL|Rituximab|Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
62071007|NCT03119610|EXPERIMENTAL|Oxytocin nasal spray|Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
62071008|NCT03119610|EXPERIMENTAL|Placebo nasal spray|Placebo nasal spray, 4x a day for 8 weeks, self administered
62071009|NCT03001713|ACTIVE_COMPARATOR|Arm 1: Immediate implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system at the start of study year 2. Arm 1 CHCs will receive implementation support that will be pragmatically iterated to address any barriers to adoption / sustained use of the CDS that are identified through study activities. The investigators will apply these learnings to improve adoption rates in Arm 2.
62071010|NCT03001713|ACTIVE_COMPARATOR|Arm 2: Delayed implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system 18 months later than Arm 1. The investigators will measure the intervention's impact on CVD risk factor control in CHCs.
62071011|NCT01463293|EXPERIMENTAL|High-dose probiotic|Capsule containing 10 billion cfu B. lactis HN019
62071012|NCT01463293|EXPERIMENTAL|Low dose probiotic|Capsule containing 1 billion cfu B. lactis HN019
62071013|NCT01463293|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62071014|NCT01432015|ACTIVE_COMPARATOR|Fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3
62071015|NCT01432015|ACTIVE_COMPARATOR|Aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1
62088318|NCT02366585|EXPERIMENTAL|Treatment with Ciclosporin|Treatment of two periodontal pockets with ciclosporin gel Non-treatment of two periodontal pockets in same patient as comparator
62088319|NCT04789200|EXPERIMENTAL|NX9 oral contrast agent|Subjects will be given a 9% w/w HBGM concentration of NX9 provided as 1.2L of liquid.
62454844|NCT02946385|EXPERIMENTAL|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
62071016|NCT05534321|ACTIVE_COMPARATOR|Standard of Care Systemic Therapy or Surveillance|Patients randomized to arm 1 will undergo appropriate systemic therapy as determined by their oncology team. These patients will either continue the current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to arm 1, these patients may also undergo palliative radiation therapy for progressive or painful lesions (a skeletal related event as defined in the study) at the time of symptom development\*(not upfront palliative radiation therapy)
62275742|NCT04930575|EXPERIMENTAL|Muscle Energy Technique group|"Patients in the group (B) will receive muscle energy technique on tonic muscles in the neck (sternocleidomastoid, scalenes, levator scapulae, and upper trapezius) in addition to strengthening exercise for deep cervical flexors and advice to correct positions three times per week for 4 weeks.~The aim of the Muscle Energy Technique in the context of NP is to decrease pain, improve movement, motor control, and function and thereby reduce disability.~A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body thus alleviating the patient's signs and symptoms."
62275743|NCT04930575|EXPERIMENTAL|Mulligan Technique group|Patient in group A will receive specialized SNAGs technique adapted from Mulligan (2005), in addition to strengthening exercise for DNF muscles and advice to correct position three times per week for 4 weeks.
62275744|NCT00268242|EXPERIMENTAL|Gemcitabine + Mitoxantrone|Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m\^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m\^2/day I.V. on days 1, 2, and 3.
62275745|NCT05020600||Patients with fibromyalgia|Patients diagnosed with fibromyalgia according to American College of Rheumatology 2016 criteria
62275746|NCT03310970|ACTIVE_COMPARATOR|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
62275747|NCT03310970|ACTIVE_COMPARATOR|Lidoderm® 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
62071017|NCT05534321|EXPERIMENTAL|Prophylactic Radiation Therapy|"Patients randomized to Arm 2 of the study will undergo upfront prophylactic radiotherapy to ≤ 5 highest risk bone metastases followed by standard of care, as defined by:~1. Bulkiest sites of disease ≥ 2cm (can include paraspinal disease extension)~2. Disease in junctional spine (Occ-C2, C7-T1, T12-L1, L5-S1)~3. Disease with posterior element involvement (facet(s), interspinous)~4. Compression Deformity \> 50%"
62071018|NCT05833516||Hyperadducted Right Radial Arm (HARRA)|The primary operators will wear real time radiation dose monitoring at the left eye, right eye, thorax and abdomen level. At the end of each diagnostic procedure the cumulative radiation dose (measured in µSv) data at each level will be collected. The radiation dose exposure in patients randomized to hyperadducted right radial arm will be recorded for primary outcome.
62275748|NCT03310970|ACTIVE_COMPARATOR|Intravenous lidocaine|A single intravenous dose of 0.5 mg/kg lidocaine hydrochloride will be administered to each subject.
62275749|NCT00799877||1|This registry will evaluate the long-term safety and effectiveness of HUMIRA® as used in routine clinical practice.
62639670|NCT00928434|EXPERIMENTAL|DC (Degarelix Continuous)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall"
62071019|NCT05833516||Left Arm Drag over technique|The primary operators will wear real time radiation dose monitoring at the left eye, right eye, thorax and abdomen level. At the end of each diagnostic procedure the cumulative radiation dose (measured in µSv) data at each level will be collected. The radiation dose exposure in patients randomized to Left Arm drag over technique will be recorded for primary outcome.
62275750|NCT06076577|NO_INTERVENTION|Standard of Care Group|
62275751|NCT06076577|EXPERIMENTAL|Prehabilitation Exercise Group|The exercise arm participants will be asked to complete weekly questionnaires which will take around 10 minutes each week and the exercise program which takes 30 minutes each day.
62275752|NCT06501651|EXPERIMENTAL|Experimental|"Initial Dose: The starting dose of Sacubitril/Valsartan is 200 mg once daily. Dose Adjustment: If blood pressure targets (SBP \< 130 mmHg and DBP \< 80 mmHg) are not achieved after 2 weeks of treatment, the dose of Sacubitril/Valsartan should be doubled to 400 mg once daily.~Additional Treatment: If blood pressure targets are still not met after an additional 2 weeks of treatment, Nifedipine controlled-release tablets (30 mg once daily) should be added to the regimen."
62275753|NCT06501651|ACTIVE_COMPARATOR|Comparator|"Initial Dose: The starting dose of Valsartan is 80 mg once daily. Dose Adjustment: If blood pressure targets (SBP \< 130 mmHg and DBP \< 80 mmHg) are not achieved after 2 weeks of treatment, the dose of Valsartan should be doubled to 160 mg once daily.~Additional Treatment: If blood pressure targets are still not met after an additional 2 weeks of treatment, Nifedipine controlled-release tablets (30 mg once daily) should be added to the regimen."
62454845|NCT02946385|EXPERIMENTAL|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
62653029|NCT05457959|EXPERIMENTAL|Cohort I Arm C (ppDC, nivolumab, ipilimumab)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive ppDC ID divided in both arms with poly ICLC IM on day -10 and nivolumab IV and ipilimumab IV on day -9 prior to standard of care surgical resection.
62275754|NCT02560610|ACTIVE_COMPARATOR|OC000459|Once daily dose of 50mg OC000459 tablets orally for 12/24 weeks
62275755|NCT02560610|PLACEBO_COMPARATOR|Placebo|Once daily dose of placebo tablets orally for 12/24 weeks
62275756|NCT03714529|EXPERIMENTAL|Treatment arm|"The vaccine consists of 500µl of 100µg PD-L1 peptide, dissolved in DMSO and PBS reconstituted with 500 µl Montanide ISA-51.~Patients will be vaccinated Q2W for 10 weeks, and a further 12 weeks if a clinical response is measured."
62275757|NCT03400800|EXPERIMENTAL|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
62275758|NCT03400800|PLACEBO_COMPARATOR|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
62275759|NCT03849339|EXPERIMENTAL|Group 1|"* Period 1: D635~* Period 2: CKD-387"
62275760|NCT03849339|EXPERIMENTAL|Group 2|"* Period 1: CKD-387~* Period 2: D635"
62275761|NCT04850209|OTHER|Control group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg , amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education
62071020|NCT04294394||rhomboid block|With a 6-13 Mhz linear USG probe, at the thoracal level of 6-7 vertebra in the sagittal position, in the cranio-caudal direction with a 22 G and 100 mm block needle in the medial of the scapula, after entering the facial plane between the rhomboid muscle and the intercostal muscle, 0.25% bupivacaine 20 ml of the local anesthetic solution will be given.
62071021|NCT04294394||erector spinae group|After the patient is taken in the lateral position, the probe T5 is 3 cm lateral to the spinous process, 22 G and 100 mm block needle with 6-13 Mhz linear ultrasonography and the facial plane between the transverse proces and the erector spina muscle is entered, and 20 ml of a local anesthetic solution consisting of 0.25% bupivacaine will be given.
62071022|NCT04294394||control group|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
62071023|NCT04152850|EXPERIMENTAL|Lifestyle Medicine Group|
62071024|NCT04152850|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
62071025|NCT01426282|NO_INTERVENTION|control|
62275762|NCT04850209|EXPERIMENTAL|Wechat group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg ,amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education. And patients will be invited into a Wechat group to obtain interactive education through question and answer,which is provided by medical professionals.
62275763|NCT06454331|EXPERIMENTAL|Active tDCS|The dosage of anodal tDCS will be 20 minutes with an intensity of 2mA. It's administered before exercise therapy sessions over a period of 8 weeks and 3 times a week
62275764|NCT06454331|SHAM_COMPARATOR|Sham tDCS Group|sham tDCS, task-oriented training (i.e. placing cones on another cone, inserting needles into a box
62071026|NCT01426282|EXPERIMENTAL|nurse education|
62071027|NCT04938115|EXPERIMENTAL|CD7 CAR-T|
62275765|NCT05416294|EXPERIMENTAL|Active Device|Participants in this arm will receive an active Primary Relief device placed following the total knee replacement surgery.
62275766|NCT05416294|SHAM_COMPARATOR|Placebo Device|Participants in this arm will receive an inactive (sham) Primary Relief device placed following the total knee replacement surgery.
62275767|NCT02175680|EXPERIMENTAL|PRO 140|PRO 140 350mg weekly SQ injection.
62454846|NCT02946385|ACTIVE_COMPARATOR|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study
62071028|NCT00799734|ACTIVE_COMPARATOR|alternative medicine|Intake of prepacked Chinese herbal medicine (EXD), one sachet of granules (15g extracted granules) twice a day
62071029|NCT00799734|PLACEBO_COMPARATOR|placebo|placebo therapy of 15g granules with similar colour and taste.
62071030|NCT04930107|ACTIVE_COMPARATOR|Recurrent Infection Cohort - symptomatic|Participants with a history of recurrent vulvovaginal candidiasis infections who have an active symptomatic infection when they come to clinic
62071031|NCT04930107|NO_INTERVENTION|Asymptomatic Cohort|Participants with no history of vulvovaginal candidiasis
62071032|NCT04930107|NO_INTERVENTION|Recurrent Infection Cohort - asymptomatic|Participants with a history of recurrent vulvovaginal candidiasis infections who do not have an active symptomatic infection when they come to clinic
62071033|NCT02735837|ACTIVE_COMPARATOR|doxycycline gel|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
62275768|NCT01908647|EXPERIMENTAL|Exp RT fMRI/Exp Cognitive Training|Both experimental conditions.
62275769|NCT01908647|EXPERIMENTAL|Exp RT fMRI/Ctrl Cognitive training|Experimental real-time fMRI and control cognitive training.
62275770|NCT01908647|EXPERIMENTAL|Ctrl RT fMRI/Exp Cognitive Training|Control RT fMRI (real-time functional MRI) and experimental cognitive training.
62275771|NCT01908647|SHAM_COMPARATOR|Ctr RT fMRI/Ctr Cognitive Training|Control real-time fMRI and control cognitive training.
62275772|NCT03350217|ACTIVE_COMPARATOR|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
62275773|NCT03350217|ACTIVE_COMPARATOR|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
62071034|NCT02735837|PLACEBO_COMPARATOR|placebo gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
62071035|NCT01544582||Boceprevir + PR|CHC genotype-1 participants included in study and prescribed boceprevir plus PR as routine clinical management.
62071036|NCT01544582||Telaprevir + PR|CHC genotype-1 participants included in study and prescribed telaprevir plus PR as routine clinical management.
62071037|NCT01544582||PR Alone|CHC genotype-1 participants included in study and prescribed PR alone as routine clinical management.
62071038|NCT04005937|EXPERIMENTAL|H-reflex|H-reflex with different interstimulus interval of the plegic side soleus muscle were tested
62071039|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
62071040|NCT02017808||OCT|Healthy controls
62071041|NCT04780217|EXPERIMENTAL|Phase 1|T3011 Single Agent Dose Escalation in participants with solid tumors
62071042|NCT02365974|ACTIVE_COMPARATOR|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps (mA) will be adjusted depending on the sensitivity of each individual patient. The arrangement thereof will be parallel on each side of the C7 (channel 1) and T4 (channel 2) vertebral spinous processes.
62071043|NCT02365974|SHAM_COMPARATOR|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment without be submitted to stimulation.
62275774|NCT00968851|ACTIVE_COMPARATOR|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 84 days
62454847|NCT02946385|ACTIVE_COMPARATOR|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study
62454848|NCT00658398|EXPERIMENTAL|ICP to prevent alcohol misuse.|Interactive Computer Program (ICP) to prevent alcohol misuse.
62454849|NCT00658398|SHAM_COMPARATOR|ICP to enhance balanced diet|2. Interactive Computer Program to enhance balanced diet (sham intervention)
62454850|NCT00777426||Thai HAD individuals (25 cases)|
62454851|NCT00777426||Thai Non-HAD individuals (25 cases)|
62639671|NCT00928434|ACTIVE_COMPARATOR|LC (Leuprolide Continuous)|"Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer's labeling directions.~One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer's labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).~On Investigator's discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels."
62639672|NCT04864743|EXPERIMENTAL|Arm 1-ADVATE+FRSW117(25 IU/kg)|Subjects received two treatments: 25 IU/kg ADVATE in the first period, followed by 25 IU/kg FRSW117 in the second period, with a washout period before each treatment.
62071044|NCT02137291||Left-sided double-lumen tube|Lung isolation with a left-sided double-lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland)
62071045|NCT02137291||Modified right-sided double-lumen tube|Right-sided double-lumen tube modified in accordance with Bussières et al. in Can J Anesth 2007
62071046|NCT03487718|ACTIVE_COMPARATOR|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
62275775|NCT00968851|ACTIVE_COMPARATOR|EVP-6124 1.0 mg|one 1.0 mg capsule every day for 84 days.
62275776|NCT00968851|PLACEBO_COMPARATOR|Placebo|Placebo every day for 84 days
62275777|NCT03008395|EXPERIMENTAL|EMMA|These participants will receive diabetes self-management education using the dialogue tools, which emphasize empowerment and use the principles of motivational communication and behaviour modification. There will be a series of four visits using the dialogue tools to guide the patient toward meaningful self-management tasks. This is not the typical approach, where providers tell the patient the behaviours they, not the patient, consider priorities. This intervention will evaluate if medical outcomes (A1c) and adherence are improved using a patient-centered not a clinician-cantered approach in individuals with poor diabetes control.
62454852|NCT00777426||Thai Non-infected individuals (10 cases)|
62454853|NCT02899390|EXPERIMENTAL|Lifestyle Intervention|All the participants will be offered group and individual sessions to help them accomplish weight loss and also increase physical activity.
62454854|NCT00582400|EXPERIMENTAL|I|
62454855|NCT01098123||Diet counseling, nutritional index|Lightweight as athletes with weight limit
62454856|NCT01098123||nutritional index|Heavyweight athletes without weight limit
62088320|NCT05969106||rtCGM + MDI|Real-time CGM Dexcom G6 used in parallel to Multiple Daily Injections (MDI)
62454857|NCT03288766||PICC Placement with Study Device|PICC Placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
62639673|NCT04864743|EXPERIMENTAL|Arm 2-ADVATE+FRSW117( 50 IU/kg)|Subjects received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW117 in the second period, with a washout period before each treatment.
62071047|NCT03487718|EXPERIMENTAL|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
62071048|NCT06476626|EXPERIMENTAL|Maternal Reflective Functioning intervention group|Will participate in a 4 session online psycho-educational workshop during pregnancy and after birth, focused on MRF.
62071049|NCT06476626|NO_INTERVENTION|Wiat-list control group|group will undergo same measurements points with no intervention
62071050|NCT04932382|OTHER|Misoprostol group|400 µg misoprostol vaginally ; these tablets will be introduced by the principal investigator, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position
62071051|NCT04932382|OTHER|No misoprostol group|will not receive any pre-insertion medications.
62071052|NCT01216891|EXPERIMENTAL|Team-based treatment|
62275778|NCT03008395|ACTIVE_COMPARATOR|Treatment as Usual|The participants will receive standard diabetes education via group and individual sessions with certified diabetes educators. In this method the patient is provided structured education in which there is an emphasis on covering clinician-determined aspects of diabetes knowledge and self-management. The emphasis vis on diabetes educator recommendations.
62275779|NCT06030843|EXPERIMENTAL|Empagliflozin|Empagliflozin 10 mg po OD
62275780|NCT06030843|PLACEBO_COMPARATOR|Placebo|Matching placebo
62275781|NCT00430508|EXPERIMENTAL|4|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
62275782|NCT00430508|EXPERIMENTAL|1|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
62653030|NCT05457959|EXPERIMENTAL|Cohort II Arm A (ppDC, placebo)|Within 30 days of surgical resection, patients receive ppDC ID in both arms with poly ICLC IM and placebo IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
62071053|NCT06026722|EXPERIMENTAL|interventional group|patient will follow cognitive behavioral therapy for insomnia 1 per week during 1 month. this therapy will start a month after inclusion.
62071054|NCT06026722|OTHER|control group (waiting list)|patient will follow cognitive behavioral therapy for insomnia 1 per week during 1 month. this therapy will start 7 month after inclusion.
62071055|NCT01146574|EXPERIMENTAL|0.1mg/kg Sotatercept|Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
62071056|NCT01146574|EXPERIMENTAL|0.3mg/kg Sotatercept|Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days
62071057|NCT01146574|EXPERIMENTAL|0.5mg/kg Sotatercept|Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days
62071058|NCT01146574|EXPERIMENTAL|0.7mg/kg Sotatercept|Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days
62071059|NCT01146574|PLACEBO_COMPARATOR|Placebo|The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.
62071060|NCT04358796|EXPERIMENTAL|HBOT environment|Cognitive testing in 2ATA, 100% oxygen in breathing-masks
62275783|NCT00430508|EXPERIMENTAL|3|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
62275784|NCT00430508|EXPERIMENTAL|2|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
62275785|NCT02025426|ACTIVE_COMPARATOR|Phenylephrine|Phenylephrine for maintaining blood pressure within 10 % of baseline
62071061|NCT04358796|SHAM_COMPARATOR|Control environment|Cognitive testing in 1ATA, air in breathing-masks
62088321|NCT05969106||rtCGM + CSII|Real-time CGM Dexcom G6 used in parallel to freestanding Continuous Subcutaneous Insulin Infusion (CSII)
62275786|NCT02025426|ACTIVE_COMPARATOR|Ephedrine|Ephedrine for maintaining blood pressure within 10 % of baseline
62275787|NCT03872804|EXPERIMENTAL|Vitiligo patient|Patient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
62275788|NCT05980520|EXPERIMENTAL|Taurine treatment group|Taurine combined with behavioral rehabilitation therapy
62275789|NCT05980520|PLACEBO_COMPARATOR|Placebo group|Placebo combined with behavioral rehabilitation therapy
62275790|NCT03273166|EXPERIMENTAL|INVSENSOR00001 sensor|This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
62275791|NCT01182831|ACTIVE_COMPARATOR|percutaneous fluoro guided celiac plexus neurolysis|
62275792|NCT01182831|ACTIVE_COMPARATOR|EUS guided neurolysis|
62639674|NCT02664142|EXPERIMENTAL|BIS Group|"BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)~* GA induction (Phase 1):~  1. inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~ 2. intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~* anaesthesia (Phase 2, Phase 3):~  1. hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~ 2. analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~ 3. relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
62639675|NCT02664142|EXPERIMENTAL|Non-BIS Group|"BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)~* GA induction (Phase 1):~  1. inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~ 2. intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~* anaesthesia (Phase 2, Phase 3):~  1. hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~ 2. analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~ 3. relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
62275793|NCT02041377|EXPERIMENTAL|Intended Users of the Monitoring System|"Subjects with diabetes used the Karajishi TS Investigational Blood Glucose Monitoring System with no training. The criteria for the intended use population:~1. At least 60% of subjects will be younger than age 65~2. At least 10% of subjects will have type 1 diabetes"
62275794|NCT04814693|EXPERIMENTAL|Interventional arm|Subjects randomized to the control device arm will undergo treatment with the EndoRotor System, which is a powered debridement tool intended for use in endoscopic procedures to resect and remove necrotic debris during direct endoscopic necrosectomy (DEN) for walled-off necrosis. The system consists of capital components including a power console, roll stand, vacuum pump, and foot control; as well as disposable components including a single-use catheter, purge kit, and suction bag. The EndoRotor System has CE-Mark 613797 and is cleared for use by the FDA in the United States.
62275795|NCT04814693|ACTIVE_COMPARATOR|Control arm|Subjects randomized to the control device arm will undergo conventional DEN as per the standard of care. Investigators will choose conventional DEN instruments according to their preference.
62639676|NCT00163566|PLACEBO_COMPARATOR|Placebo gel|Placebo gel twice per day
62639677|NCT00163566|ACTIVE_COMPARATOR|0.7% DHT gel, Dose 1|0.7% DHT gel twice per day, 35 mg/day
62071062|NCT03333174|EXPERIMENTAL|Servo-controlled Oxygen Environment|Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
62071063|NCT03333174|ACTIVE_COMPARATOR|Nasal Cannula Oxygen|Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
62071064|NCT01698086|EXPERIMENTAL|Experimental group|Participants who are randomized to the Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions (Figure 1). The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report.
62071065|NCT01698086|NO_INTERVENTION|Wait-listed Control group|The Wait-listed Control group will not receive treatment; however, participants in the Wait-listed Control group will undergo the same outcome measurement plan as the Experimental group. If interested, participants from this group will be placed on a wait-list and will have the opportunity to receive instructions in how to perform the vestibular rehabilitation program following their completion of the study.
62071066|NCT00064025|EXPERIMENTAL|Treatment (medroxyprogesterone)|"Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.~A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays."
62071067|NCT03136835|EXPERIMENTAL|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
62275796|NCT01478854|EXPERIMENTAL|Neural Progenitor Cell Sparing Radiation with Temozolomide|All subjects are treated with neural progenitor cell sparing radiation to 60 Gy in 2 Gy per day, 30 fractions Concurrent and adjuvant temozolomide chemotherapy
62639678|NCT00163566|ACTIVE_COMPARATOR|0.7% DHT gel, Dose 2|0.7% DHT gel twice per day, 70 mg/day
62275797|NCT03841357|EXPERIMENTAL|Abatacept and Usual Care (Part I)|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
62071068|NCT02300337|EXPERIMENTAL|Reduce Cuff Pressure|Cuff Pressure difference between inspiration and expiration is measured.
62639679|NCT03565354|ACTIVE_COMPARATOR|Treatment arm|intravenous iron isomaltose 3-10 weeks before operation date. The dose will be determined by the patient's body weight: \> 50kg: 1000mg; \<50kg: 20mg/kg body weight, to be infused over 30 minutes. 2 weeks after intravenous iron isomaltoside administration, blood test for hemoglobin level and iron profile would be repeated. Subjects with hemoglobin level less than 10g/dL will receive a second dose of intravenous iron isomaltoside. The second dose would be identical to the first dose
62639680|NCT03565354|NO_INTERVENTION|Control arm|Patient randomized to the control arm will follow the standard perioperative care and the perioperative management they received will be identical to the treatment arm except no intravenous iron isomaltoside will be given.
62639681|NCT01500798|PLACEBO_COMPARATOR|Placebo|
62639682|NCT01500798|EXPERIMENTAL|Bardoxolone methyl|
62639683|NCT05743530|EXPERIMENTAL|TENS - transcutaneous electrical nerve stimulation|
62639684|NCT05743530|PLACEBO_COMPARATOR|Placebo|
62071069|NCT03412162|EXPERIMENTAL|Ethnic and Racial Identity Promotion|Students will participate in 8, 1 hour and 15 minute classroom based intervention sessions at their local high school, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to promote a positive ethnic and racial identity (positive feelings about ones' ethnic and racial heritage and ethnic and racial group membership).
62275798|NCT03841357|ACTIVE_COMPARATOR|Active Comparator: Usual Care (Part I)|Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
62639685|NCT01091922|PLACEBO_COMPARATOR|Low Flavanol|Low flavanol drink containing 23 mg of total flavanols. Macro- and micro-nutrient matched with active comparator
62639686|NCT01091922|ACTIVE_COMPARATOR|High Flavanols|High Flavanol drink containing 495 mg of total flavanols
62639687|NCT05705830|EXPERIMENTAL|Pulse Magnetotherapy+medication group|150 patients with anxiety disorder and insomnia who met the inclusion criteria received pulse magnetic therapy and conventional antianxiety drugs
62639688|NCT05705830|SHAM_COMPARATOR|medication group|150 patients with anxiety disorder and insomnia who met the inclusion criteria received sham magnetic therapy and conventional antianxiety drugs
62639689|NCT05705830|OTHER|Healthy control|100 healthy controls who met the inclusion criteria received sham magnetic therapy
62639690|NCT03781466|ACTIVE_COMPARATOR|Cervical cerclage|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm
62071070|NCT03412162|ACTIVE_COMPARATOR|Academic Skills Promotion|Students in this active comparison group will participate in an 8-week, 1 hour and 15 minute classroom based intervention, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to provide information regarding college and career planning, and promote college and career planning as well as study skills and strategies. This condition receives the same amount of facilitator time and attention as the Experimental condition.
62071071|NCT04806230||Observed|
62071072|NCT03285295|EXPERIMENTAL|Screening|All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
62275799|NCT03841357|EXPERIMENTAL|Abatacept and Usual Care (Part II)|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
62275800|NCT01420146|EXPERIMENTAL|Zr89-trastuzumab PET/CT|Zr89-trastuzumab PET/CT single arm
62275801|NCT00575809||Obsevational|
62275802|NCT05069584|EXPERIMENTAL|transperineal biopsy|The strategy evaluated is based on performing targeted and systematized prostate biopsies performed by the transperineal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
62275803|NCT05069584|ACTIVE_COMPARATOR|transrectal biopsy|The comparison strategy is based on performing targeted and systematized prostate biopsies performed by the transrectal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
62275804|NCT00280007|EXPERIMENTAL|1|bevacizumab infusion evey 2 weeks
62275805|NCT00280007|PLACEBO_COMPARATOR|2|placebo infusion
62275806|NCT00398463|EXPERIMENTAL|1|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
62275807|NCT00398463|PLACEBO_COMPARATOR|2|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo
62275808|NCT02282592||Cases|newly diagnosed (within 6 months) breast cancer patients, before adjuvant or neoadjuvant treatment.
62275809|NCT02282592||Controls|patients without any malignant disease, matched for age an menopausal status with cases.
62275810|NCT06196086||HFpEF|Patients who diagnosed with heart failure with preserved ejection fraction based on symptoms, serum biomarker and test according to 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management at the First Affiliated Hospital of Shandong First Medical University from December 20, 2023 to December 20, 2026.
62639691|NCT03781466|ACTIVE_COMPARATOR|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
62639692|NCT03781466|ACTIVE_COMPARATOR|Cervical cerclage plus vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm plus Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
62639693|NCT03013400|ACTIVE_COMPARATOR|Ebselen|Three Ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
62639694|NCT03013400|PLACEBO_COMPARATOR|Placebo|Three Placebo capsules each containing 200mg taken orally twice a day for 3 weeks
62639695|NCT03191851|ACTIVE_COMPARATOR|Standard Device|Standard device
62639696|NCT03191851|EXPERIMENTAL|Melody Device|Melody device without Pump
62639697|NCT03191851|EXPERIMENTAL|Melody Device with pump|Melody Catheter device with Andromeda Pump
62639698|NCT05822817|EXPERIMENTAL|sevoflurane|Anesthesia is maintained with sevoflurane.
62639699|NCT05822817|EXPERIMENTAL|propofol|Anesthesia is maintained with continuous infusion of propofol.
62639700|NCT05648903|EXPERIMENTAL|One-to-one|All participants are offered a choice of three dietary approaches.
62639701|NCT05648903|EXPERIMENTAL|Group|All participants are offered a choice of three dietary approaches.
62639702|NCT03080740|ACTIVE_COMPARATOR|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
62071073|NCT02482636|OTHER|Group 1|"Group 1 will receive the following interventions:~* DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~* 13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months~* Rotavirus vaccine oral 1.5ml at 2 and 3 months~* 4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~* Meningococcal C/Hib vaccine IM 0.5ml at 12 months~* Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
62071074|NCT02482636|OTHER|Group 2|"Group 2 will receive the following interventions:~* DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~* 13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 3 and 12 months (instead of current routine schedule of 2,4 and 12 months)~* Rotavirus vaccine oral 1.5ml at 2 and 3 months~* 4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~* Meningococcal C/Hib vaccine IM 0.5ml at 12 months~* Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
62071075|NCT00514046|EXPERIMENTAL|Vandetanib|Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m\^2/day.
62639703|NCT03080740|ACTIVE_COMPARATOR|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
62071076|NCT02699541|EXPERIMENTAL|Intervention group|Intervention group participants will receive the educational intervention based on the Information, Motivational, Behavioral change model.
62071077|NCT02699541|NO_INTERVENTION|Control group|Control group participants will receive usual care treatment and referral to diabetes educational consultation if required.
62639704|NCT02981940|EXPERIMENTAL|Abemaciclib with Surgery|"* Abemaciclib will be administered on a continuous twice daily dosing schedule~* Patients who require re-operation will receive a short preoperative course of Abemaciclib~* Tissue will be used to investigate the ability of Abemaciclib to pass through the blood brain barrier.~* After recovery from surgery, participants will resume Abemaciclib. Each cycle lasts 28 days.~* NOTE: enrollment to this arm is complete"
62639705|NCT02981940|EXPERIMENTAL|Abemaciclib without Surgery|"* Abemaciclib will be administered on a continuous twice daily dosing schedule. Each Cycle last 28 days.~* NOTE: enrollment to this arm is complete"
62639706|NCT02981940|EXPERIMENTAL|Cohort 1 Surgery Arm|Participants who require reoperation will be treated with abemaciclib for 10-14 days prior to surgery. Tissue will be used to further investigate the abilities of Abemaciclib. After surgery participants will come off study and pursue standard of care treatments at their treating physician's discretion.
62088322|NCT05969106||Tandem Control-IQ|Realtime CGM Dexcom G6 used as part of the Automated Insulin Delivery (AID) system
62088323|NCT03407040||1/Cancer Patients|Patients with a cancer diagnosis enrolled on protocol 03-C-0277
62088324|NCT03219437|ACTIVE_COMPARATOR|Methotrexate|Participants to receive double-blind methotrexate.
62088325|NCT03219437|EXPERIMENTAL|Risankizumab|Participants to receive double-blind risankizumab.
62639707|NCT03065491|ACTIVE_COMPARATOR|Active treatment|Combined nutraceutical
62639708|NCT03065491|PLACEBO_COMPARATOR|Placebo|Placebo
62639709|NCT05406414|EXPERIMENTAL|Transdiagnostic sleep and circadian treatment|The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks.
62639710|NCT05406414|ACTIVE_COMPARATOR|Active waitlist control group|The control group receives sleep hygiene education
62275811|NCT06196086||Control|Healthy volunteers with no history of heart disease who matched for age, sex, and risk factors with HFpEF group.
62275812|NCT04593654||low dose thromboprophylaxis|Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin
62071078|NCT02374190||Hospital Admitted STEMI Patients|The analytical cohort for this study consisted of STEMI patients aged over 18 years admitted directly to '24/7' PPCI-capable hospitals for PPCI. STEMI patients were identified based on their discharge diagnoses and were selected as having received PPCI according to their initial reperfusion strategy. Hospitals performing only sporadic PPCI procedures, which we defined as less than 20 procedures per year, and only performing PPCIs during regular hours were not included in the analysis. Interhospital transfers were not included in the analysis, and we limited our analysis to PPCIs conducted within 6 hours on hospital arrival on the assumption that patients with a DTB time beyond this did not receive PCI as a primary reperfusion strategy. The analysis was conducted for the time period for which data were available-1 January 2007 to 31 December 2012. We conducted a complete-case analysis.
62071079|NCT02324764|EXPERIMENTAL|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
62275813|NCT04593654||medium dose thromboprophylaxis|Daily dose of \>4500 IU but \<175 IU/kg of body weight tinzaparin or \>5000 IU but \<200 IU/kg of body weight dalteparin
62639711|NCT01024114||Positive MBI scan|Women who are previously enrolled in an MBI study that present with a positive MBI scan.
62071080|NCT02324764|ACTIVE_COMPARATOR|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
62071081|NCT05468515||High altitude group|altitude level range from 2500 to 4500 meters
62071082|NCT05468515||mild altitude group|altitude level range from 500 to 2500 meters
62071083|NCT04290065|EXPERIMENTAL|Experimental group|The intervention will take place over a period of 4 weeks, with 2 weekly sessions, with an estimated execution time of 1.50 to 3 minutes each. A manual therapy technique of inhibition of the suboccipital musculature and an axial traction of the upper hemiarchy will be performed
62071084|NCT04290065|NO_INTERVENTION|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
62275814|NCT04593654||high dose thromboprophylaxis|Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin
62639712|NCT04460326|ACTIVE_COMPARATOR|Group 1 insulin glargine and Novolog|Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal blood glucose (BG) is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.
62639713|NCT04460326|EXPERIMENTAL|Group 2 insulin glargine and Fiasp|Group 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.
62639714|NCT02076204|EXPERIMENTAL|Home visiting|Home visiting group: Women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group. Home visiting for low-income, pregnant women - whereby individualized in-home services (including direct education, assessments, and referrals to community resources) are provided to families - has been identified by the Strong Start initiative as one promising method for reaching women who are vulnerable to poor birth outcomes.
62071085|NCT03072381|ACTIVE_COMPARATOR|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
62071086|NCT03072381|PLACEBO_COMPARATOR|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
62071087|NCT02009696||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
62071088|NCT03431051|ACTIVE_COMPARATOR|Healthy Beverage Initiative|A Healthy Beverage Initiative and health education will be implemented at two hospital campuses.
62071089|NCT03431051|NO_INTERVENTION|Control Arm|No change in beverages or education at two hospital campuses.
62071090|NCT05095090||Hospitalised Patients|Participants admitted to hospital with an acute respiratory condition including exacerbation of an underlying physician diagnosed chronic lung disease.
62071091|NCT05095090||Matched Controls|The study will include matched controls (non-hospitalised patients with stable chronic respiratory conditions or healthy volunteers) to compare the exploratory endpoints. The number of the matched controls will not exceed 25% of the main study recruitment.
62088326|NCT06334536||Medical staff|Medical staff who work at the Department of Obstetrics and Gynecology or Women Health Units in Asia and Oceania countries.
62275815|NCT05196854|OTHER|Group 1: Standard Blood Pressure measurement at home|Standard home blood pressure measurement at home
62275816|NCT05196854|EXPERIMENTAL|Group 2. Hypnosis script prior to Home Blood Pressure measurement|Participant listens to a pre-recorded hypnosis script (approx 5 mins long) prior to standard home blood pressure measurement.
62275817|NCT01141595|EXPERIMENTAL|Kuvan®|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
62275818|NCT03206697||Aneuploid mitochondria|Mitochondrial DNA content and metabolic parameters
62275819|NCT06339879|ACTIVE_COMPARATOR|High Whole Grain, Low Sugar|6 servings of whole grain and \<13% energy from added sugars.
62275820|NCT06339879|ACTIVE_COMPARATOR|Low Whole Grain, Low Sugar|3 servings of whole grain and \<13% energy from added sugars.
62275821|NCT06339879|ACTIVE_COMPARATOR|High Whole Grain, High Sugar|6 servings of whole grain and \>13% energy from added sugars.
62275822|NCT06339879|ACTIVE_COMPARATOR|Low Whole Grain, High Sugar|3 servings of whole grain and \>13% energy from added sugars.
62275823|NCT00835315||3|patients with psoriasis , patients with atopic dermatitis and healthy patients.
62639715|NCT02076204|NO_INTERVENTION|Non-Home Visiting|Control group: As described above, women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group.The home visiting program will provide control group families with referrals to other appropriate services in the community.
62639716|NCT04817332|EXPERIMENTAL|Brensocatib|Brensocatib oral tablet, 25mg once per day for 28 days
62071092|NCT05819853|EXPERIMENTAL|Untreated PCOS|"Participants with PCOS who are not on metformin or hormonal therapy, will receive 10-months of semaglutide intervention.~Participants will get either semaglutide as either:~Wegovy: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and 1.7mg for the remainder of the study.~or~Ozempic: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and Wegovy for 1.7mg for the remainder of the study."
62071093|NCT05819853|EXPERIMENTAL|PCOS on Metformin|"Participants with PCOS who are currently on metformin and still not having regular menses, will receive 10-months of semaglutide intervention. Participants in this arm will continue to take their metformin throughout the trial.~Participants will get either semaglutide as either:~Wegovy: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and 1.7mg for the remainder of the study.~or~Ozempic: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and Wegovy for 1.7mg for the remainder of the study."
62454858|NCT02837757|EXPERIMENTAL|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.~Available tumor tissues samples will be collected."
62639717|NCT04817332|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet, 25mg once per day for 28 days
62639718|NCT02048722|EXPERIMENTAL|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62071094|NCT02406209|EXPERIMENTAL|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
62454859|NCT06344338|EXPERIMENTAL|tDCS treatment group|In the real tDCS stimulation group, direct cathodal current at 2 mA was delivered by a tDCS device over the seizure onset zone. Anode was on the contralateral forehead. Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10.
62275824|NCT00961883|EXPERIMENTAL|1|Thirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
62275825|NCT00961883|EXPERIMENTAL|2|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
62071095|NCT02406209|EXPERIMENTAL|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
62071096|NCT02406209|ACTIVE_COMPARATOR|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
62275826|NCT00961883|EXPERIMENTAL|3|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
62639719|NCT05525351||NI-VATS (Non-intubated video-assisted thoracoscopic surgery)|"This is a purely observational study of the routine anesthetic practice involving the simultaneous use of three drugs. Types of surgery (non-intubated video-assisted thoracoscopic surgery or video-assisted thoracoscopic surgery) are discussed and decided totally by patients and surgeons independently.~NI-VATS: induction and maintenance are achieved by propofol, alfentanil and dexmedetomidine. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), arterial blood pressure (ABP) and bispectral index (BIS) or Patient State Index (PSI) monitor. Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
62071097|NCT03292146|EXPERIMENTAL|Active Denosumab 60mg Injection|Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
62275827|NCT00961883|EXPERIMENTAL|4|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
62275828|NCT02440815|OTHER|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
62275829|NCT03875261|EXPERIMENTAL|Study arm|Participants are treated with the investigational medical product
62071098|NCT03292146|PLACEBO_COMPARATOR|Placebo|Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
62275830|NCT01079481|EXPERIMENTAL|taxol plus everolimus|
62071099|NCT00405704|ACTIVE_COMPARATOR|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
62071100|NCT00405704|PLACEBO_COMPARATOR|Placebo|Cherry-flavored liquid suspension matched to active comparator.
62071101|NCT06481449||High dose radiotherapy (≥60Gy)|Patients who received 60 Gy or more than 60Gy radiation dose for radical radiation therapy for the primary tumor.
62071102|NCT06481449||Low dose radiotherapy (50-<60Gy)|Patients who received 50-\<60Gy radiation dose for radical radiation therapy for the primary tumor.
62071103|NCT04469699|EXPERIMENTAL|Treatment arm|Stereotactic biopsy followed by stereotactical photodynamic therapy
62071104|NCT04469699|OTHER|Control arm|Stereotactic biopsy
62071105|NCT06489665||Mammowave|
62071106|NCT06489665||Bellona|
62071107|NCT03903679|ACTIVE_COMPARATOR|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway supreme during the septal surgery.
62071108|NCT03903679|SHAM_COMPARATOR|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
62071109|NCT05371119|EXPERIMENTAL|Blood Flow Restriction|Use of the BFR cuff during the training intervention
62071110|NCT05371119|ACTIVE_COMPARATOR|control|No use of inflated cuff
62071111|NCT00004221|EXPERIMENTAL|Treatment (Combination chemotherapy, PBSC)|See detailed description.
62071112|NCT00829608|EXPERIMENTAL|Human Papillomavirus Vaccine|There are 9 participants currently being followed in the faculty sponsor's clinic that carry the clinical and histologic diagnosis of RRP. The 9 participants meet one or more of the following criteria: Surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and rapid regrowth of papilloma disease with airway compromise.
62071113|NCT01231243|ACTIVE_COMPARATOR|35% hydrogen peroxide control|The tooth bleaching will be performed using a high hydrogen peroxide concentration (35%) without light-activation with LED/light device
62071114|NCT01231243|ACTIVE_COMPARATOR|20% hydrogen peroxide|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) without light activation with a LED/laser device
62071115|NCT01231243|EXPERIMENTAL|35% hydrogen peroxide + light|The tooth bleaching will be performed with a high hydrogen peroxide concentration (35%) associated with LED/laser light activation
62071116|NCT01231243|EXPERIMENTAL|20% hydrogen peroxide + light|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) associated with LED/laser light activation
62071117|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
62071118|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
62071119|NCT03508336||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
62071120|NCT04076020|EXPERIMENTAL|Intervention|Receive the relational agent and the AliveCor Kardia for use for 120 days. Participants are directed to use these interventions daily.
62071121|NCT04076020|ACTIVE_COMPARATOR|Usual Care|"Receive a brochure on atrial fibrillation that is published by the American Heart Association and a smartphone with the WebMD application.~Participants are directed to use the WebMD application as often as they would like."
62071122|NCT02743286|NO_INTERVENTION|Control condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
62275831|NCT00939198|EXPERIMENTAL|Na-ASP-2 Hookworm Antigen Skin Test|All participants will be skin tested with Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
62275832|NCT01407094|ACTIVE_COMPARATOR|Sertraline|SSRI monotherapy
62275833|NCT01407094|PLACEBO_COMPARATOR|Placebo|Placebo control
62275834|NCT01407094|ACTIVE_COMPARATOR|Bupropion|BupropionXL
62653031|NCT05457959|PLACEBO_COMPARATOR|Cohort II Arm B (placebo, nivolumab)|Within 30 days of surgical resection, patients receive placebo ID in both arms with poly ICLC IM and nivolumab IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
62275835|NCT03146572|EXPERIMENTAL|Intervention|Parent of child to receive intervention, Sit Down and Play
62275836|NCT03146572|ACTIVE_COMPARATOR|Control|Parent will receive handout to promote positive behavior
62275837|NCT00185393|EXPERIMENTAL|Arm 1|
62275838|NCT00185393|OTHER|Arm 2|
62275839|NCT00796315|EXPERIMENTAL|Doxylamine Succinate (USP)|Doxylamine Succinate United States Pharmacopeia (USP)
62275840|NCT02491814|EXPERIMENTAL|1% M.F. Milk and Breakfast Cereal|Breakfast meal: 250 ml 1% M.F. Milk, 54 g Cheerios breakfast cereal, 100 mL water
62275841|NCT02491814|EXPERIMENTAL|Yogurt Beverage and Breakfast Cereal|Breakfast meal: 250 ml Yogurt Beverage, 54 g Cheerios breakfast cereal, 100 mL water
62275842|NCT02491814|EXPERIMENTAL|Soy Beverage and Breakfast Cereal|Breakfast meal: 250 ml Soy Beverage, 54 g Cheerios breakfast cereal, 100 mL water
62275843|NCT02491814|EXPERIMENTAL|Almond Beverage and Breakfast Cereal|Breakfast meal: 250 ml Almond Beverage, 54 g Cheerios breakfast cereal, 100 mL water
62275844|NCT02491814|EXPERIMENTAL|Water (control) and Breakfast Cereal|Breakfast meal: 250 ml Water, 54 g Cheerios breakfast cereal, 100 mL water
62071123|NCT02743286|EXPERIMENTAL|Frequent sit-to-stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 15 2-minute standing interruptions, 3 per hour, and a mid-point bathroom break.
62071124|NCT02743286|EXPERIMENTAL|Walking breaks (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 2-minute walking interruptions, 3 per hour, and a mid-point bathroom break.
62275845|NCT05449678|NO_INTERVENTION|Control diet|Usual diet (45% of daily energy intake from CHO)
62275846|NCT05449678|EXPERIMENTAL|Low carb diet|Low-carb diet (25% of daily energy intake from CHO)
62275847|NCT02164656|EXPERIMENTAL|mindfulness training|8 week course in mindfulness for smokers
62275848|NCT01604070||Nextra fusion|group that has the nextra device
62275849|NCT01604070||k wire fixation|control group fixated with k wire
62275850|NCT05744739|EXPERIMENTAL|Treatment (tomivosertib)|Tomivosertib will be dosed continuously on days 1-28 of each 28-day cycle.
62275851|NCT01517477|EXPERIMENTAL|First Arm: One iStent|Device: One iStent
62275852|NCT01517477|EXPERIMENTAL|Second Arm: Two iStents|Device: Two iStent devices
62275853|NCT01517477|EXPERIMENTAL|Third Arm: Three iStents|Device: Three iStent devices
62454860|NCT06344338|SHAM_COMPARATOR|TDCS sham-stimulation group|The duration and frequency of tDCS treatments in the sham-stimulation group are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation.
62639720|NCT05525351||VATS (video-assisted thoracoscopic surgery)|"This is a purely observational study of the routine anesthetic practice involving the simultaneous use of three drugs. Types of surgery (non-intubated video-assisted thoracoscopic surgery or video-assisted thoracoscopic surgery) are discussed and decided totally by patients and surgeons independently.~NI-VATS: induction and maintenance are achieved by propofol, alfentanil and dexmedetomidine. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), arterial blood pressure (ABP) and bispectral index (BIS) or Patient State Index (PSI) monitor. Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
62275854|NCT00778037|EXPERIMENTAL|1|Cyclobenzaprine hydrochloride 10 mg tablet of ranbaxy
62275855|NCT00778037|ACTIVE_COMPARATOR|2|Flexeril® 10 mg tablets
62275856|NCT05019131|EXPERIMENTAL|Intervention arm|"1. Training: The investigators will develop a training for providers that addresses the following topics: Stress \& positive coping mechanisms; Unconscious bias awareness and mitigation; Person-centered maternity care; Dealing with difficult situations; and Teamwork and communication;~2. Peer support and mentorship: The investigators will identify what works best for these groups in terms of group composition, size, and how the groups want to interact.~3. Leadership engagement: To ensure leadership buy in, support and sustainability of the intervention, the investigators will engage leadership of the County.~4. Embedded champions: To facilitate ongoing engagement, the investigators will identify local leaders, and invite them to training where they will be taught how to facilitate peer support groups and serve as champions."
62275857|NCT05019131|NO_INTERVENTION|Control arm|Will not receive any training during the intervention period
62275858|NCT01238809||1|
62275859|NCT02229344||Newly Diagnosed Moderate to Severe Ulcerative Colitis|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
62275860|NCT02889432|EXPERIMENTAL|Melatonin|Oral Melatonin 10mg Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
62639721|NCT01935999|OTHER|One piece closed pouch|One piece closed pouch
62071125|NCT02743286|EXPERIMENTAL|Stand More (Protocol D)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 10-minute standing breaks, 1 per hour, and a mid-point bathroom break.
62088327|NCT00997243|EXPERIMENTAL|5-azacytidine and Lintuzumab|"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC(subcutaneous)daily on days 1-7.~Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7."
62088328|NCT06042985|ACTIVE_COMPARATOR|RYGB arm: calcium citrate and calcium carbonate|The absorption effect between calcium citrate and calcium carbonate in patients with a RYGB
62275861|NCT02889432|PLACEBO_COMPARATOR|Placebo|Placebo tabs Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
62275862|NCT06501443|ACTIVE_COMPARATOR|Usual Care|Patients will receive what is the usual care in their respective countries. Usual care includes physical activity, diet modification, pharmacological therapy as: statin therapy (rosuvastatin, atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin), ezetimibe, cholestyramine or bempedoic acid.
62275863|NCT06501443|EXPERIMENTAL|Inclisiran + Usual Care|Patients will receive what is usual care in their countries plus inclisiran 284 mg at baseline, 90 days, and 270 days.
62275864|NCT04851600||Early introduction|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
62275865|NCT04632498|EXPERIMENTAL|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
62275866|NCT04632498|NO_INTERVENTION|Wait-list Control (WL)|Patient Control receiving no treatment
62275867|NCT04632498|NO_INTERVENTION|Healthy Control (HC)|Healthy Control receiving no treatment
62275868|NCT01408147|ACTIVE_COMPARATOR|Treatment Group|This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
62275869|NCT01408147|NO_INTERVENTION|Standard WIC care|The control group will received Standard Care as provided through WIC.
62275870|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
62639722|NCT04625335|EXPERIMENTAL|Group 1: Intervention First|Adult, healthy volunteers will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test. Following the crossover, these participants will then complete the Cold Pressor Test without prior massage.
62639723|NCT04625335|EXPERIMENTAL|Group 2: Intervention Last|Adult, healthy volunteers will complete the Cold Pressor Test without prior massage. After crossover, they will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test.
62639724|NCT02986464|ACTIVE_COMPARATOR|Standard pharmacological treatment|
62275871|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
62071126|NCT00924469|EXPERIMENTAL|Abiraterone plus leuprolide plus prednisone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
62071127|NCT00924469|ACTIVE_COMPARATOR|Leuprolide then abiraterone plus leuprolide plus prednisone|Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.
62071128|NCT00419653|EXPERIMENTAL|1|
62275872|NCT01442883||treatment resistant hypertensives with CKD 3-5|
62275873|NCT02077088|EXPERIMENTAL|Galactooligosaccharides|addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula
62275874|NCT02077088|NO_INTERVENTION|Only HA formula|only standard HA starter formula
62275875|NCT04239625|EXPERIMENTAL|ALK-001|
62275876|NCT02956161|EXPERIMENTAL|Up phase stimulation|Auditory stimulations are delivered in synchrony with the up phase of slow oscillations during N3 sleep stage.
62275877|NCT02956161|EXPERIMENTAL|Random phase stimulation|Auditory stimulations are randomly delivered during N3 sleep stage.
62275878|NCT02956161|SHAM_COMPARATOR|No stimulation|The device is worn without any auditory stimulations delivered.
62275879|NCT04206449|EXPERIMENTAL|Infrared thermography system|Therapeutic decision taken with infrared thermography system, integrated in an expert diagnostic algorithm (TIS), to determine the sleep stages and Apnea-Hypopnea Index (AHI).
62275880|NCT04206449|ACTIVE_COMPARATOR|Standard Polysomnography (PSG)|Therapeutic decision taken with Standard Polysomnography (PSG), to determine the sleep stages and Apnea-Hypopnea Index (AHI)
62275881|NCT00009971|EXPERIMENTAL|Arm I|Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
62275882|NCT03978559|EXPERIMENTAL|CAS with TMP/SMZ|
62275883|NCT03978559|ACTIVE_COMPARATOR|TMP/SMZ|
62275884|NCT00704964||All participants|Each site will be evaluated by a site questionnaire and assigned as either a high or low participant management site. Participants are not randomized to a group. However, treatment completion rates will be evaluated based on the high vs low participant management sites.
62275885|NCT01864278||Lutonix Drug Coated Balloon|Paclitaxel coated ballooncatheter
62275886|NCT00758355||M2A magnum|Consecutive series of patients received Total Hip Resurfacing with ReCap/Magnum
62275887|NCT00758355||Recap Magnum|Consecutive series of patients received Total Hip Replacement with ReCap/Magnum
62275888|NCT01555203|EXPERIMENTAL|liveWell: A healthy foundation for life|
62639725|NCT02986464|EXPERIMENTAL|Virtual Reality distraction|
62639726|NCT05209659||Low Back Pain|Pragmatic Mobilization The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment)
62639727|NCT04839744|EXPERIMENTAL|TG103 produced by the modified manufacturing process|A single dose of TG103 (15mg) produced by the modified manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
62639728|NCT04839744|ACTIVE_COMPARATOR|TG103 produced by the original manufacturing process original manufacturing process|A single dose of TG103 (15mg) produced by the original manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
62071129|NCT00419653|ACTIVE_COMPARATOR|2|
62071130|NCT00419653|ACTIVE_COMPARATOR|3|Haloperidol
62071131|NCT04874324|EXPERIMENTAL|WCK 2349|"WCK 2349 800mg, 1000mg, and 1200mg . 1 dose given orally twice daily at 12 hourly interval for five days.~Dosage form : Oral"
62071132|NCT04874324|PLACEBO_COMPARATOR|Placebo|Matching Placebo administered as Oral
62071133|NCT01973491|EXPERIMENTAL|ATX-MS-1467|
62071134|NCT01855581||sedation group|Children requiring sedation for MRI/CT
62071135|NCT02079584||Warfarin|A study group taken from existing anticoagulant clinics treated with warfarin.
62071136|NCT02079584||Rivaroxaban|A group seen in the rivaroxaban clinic under study.
62275889|NCT01157039|EXPERIMENTAL|Dietary Supplement|Arm A: At cycle 2, patients will be randomized to receive for 6 days- Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3
62275890|NCT01157039|EXPERIMENTAL|Dietary supplement|Arm B: At cycle 2, patients will be randomized to receive for 6 days: Glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3.
62275891|NCT03433170|EXPERIMENTAL|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
62275892|NCT03433170|ACTIVE_COMPARATOR|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
62639729|NCT02643641|EXPERIMENTAL|BM32-3|2 placebo injections will be given followed by 3 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
62639730|NCT02643641|EXPERIMENTAL|BM32-4|1 placebo injections will be given followed by 4 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
62275893|NCT05599490|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
62275894|NCT01781494|ACTIVE_COMPARATOR|Immobilization|Immobilization followed by protected range of motion
62275895|NCT01781494|EXPERIMENTAL|Immediate range of motion|Immediate motion after anterior submuscular ulnar nerve transposition
62275896|NCT01526668|ACTIVE_COMPARATOR|No contact after discharge|In Arm A: The patient do not have planned contacts with the study nurse or doctor after discharge. All patients are seen by the study nurse six weeks postoperatively.
62275897|NCT01526668|ACTIVE_COMPARATOR|Single telephone contact|In Arm B: The patient has one planned telephone contact with the study nurse the day after discharge. All patients are seen by the study nurse six weeks postoperatively.
62275898|NCT01526668|ACTIVE_COMPARATOR|Telephone contacts regularly|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively.
62275899|NCT01526668|ACTIVE_COMPARATOR|Telephone contact using CBT-inspired strategy|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively. At these telephone contacts the study nurse uses a cognitive behavior therapy (CBT)-inspired strategy in counselling and support.
62275900|NCT02911428||dosages of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.25 ml, during the study under Protocol 02-E-2015 in October-November 2015.
62275901|NCT02911428||dosages of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.
62275902|NCT00717600|EXPERIMENTAL|1|Oral probiotics
62639731|NCT02643641|EXPERIMENTAL|BM32-5|5 injections with 20 micrograms each of BM321, BM322, BM325 and BM326 will be given
62639732|NCT02643641|PLACEBO_COMPARATOR|Placebo|5 placebo injections (alhydrogel only) will be given
62639733|NCT03250689|EXPERIMENTAL|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
62639734|NCT03250689|EXPERIMENTAL|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
62639735|NCT01288599|EXPERIMENTAL|Single port access laparoscopy|Single port access laparoscopy for benign adnexal disease.
62275903|NCT04583371|NO_INTERVENTION|GROUP CONTROL|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the control group, patients will be ventilated for 1 minute with 100% inspired oxygen (FiO2), followed by three aspirations for 15 seconds and with an interval of 30 seconds."
62639736|NCT01288599|ACTIVE_COMPARATOR|Conventional laparoscopy|Conventional laparoscopy for benign adnexal disease.
62639737|NCT03529500||Adequate nutritional status|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
62275904|NCT04583371|ACTIVE_COMPARATOR|INTERVENTION GROUP|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the supine position, the headboard elevated to 30º in assisted pressure-controlled ventilatory mode, increasing 10 cmH2O in inspiratory pressure and in assisted ventilation mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, with Ppeak not exceeding 40 cmH2O and drive pressure not exceeding 15 cmH2O in both ventilation modes, and then a new aspiration in the same way as the control group."
62454861|NCT04415125|EXPERIMENTAL|elite male ice hockey players|The subjects were 50 elite men's ice hockey players playing in the super league from Turkish clubs subject to Turkey Ice Hockey Federation. All ice hockey players had practicing training programs after warming up for 10 minutes for at least 3 days a week and 1 hour in a day during the season. They also played a match at least 1 day a week. The inclusion criteria were; being a member of Turkish Ice Hockey Federation and to be subject to any of the licensed athletes who played in the super league team, to be over 18, to be male. Exclusion criteria were; being under the age of 18, being a woman, having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.
62639738|NCT03529500||Mild malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
62639739|NCT03529500||Moderate malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
62639740|NCT03529500||Severe malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
62071137|NCT05151042|EXPERIMENTAL|Group I|Distal segments repositioning using osteotomy/plate locating bone-borne surgical guide (wafer-less approach).
62071138|NCT05151042|ACTIVE_COMPARATOR|Group II|Distal segments repositioning using preoperative and final wafers.
62071139|NCT05808530|EXPERIMENTAL|Intervention arm|It is te intervention grup.
62071140|NCT05808530|NO_INTERVENTION|no intervention arm|It is the non intervention group.
62071141|NCT02302950||women that picked up raltegravir 2013|minority women that picked up raltegravir at Thomas street Health Center 2013
62454862|NCT00028665|EXPERIMENTAL|Arm I: with rituximab IV|
62454863|NCT00028665|ACTIVE_COMPARATOR|Arm II: without rituximab IV|
62071142|NCT01143532||Kidney transplant donor of black African descent.|Kidney transplant donor of black African descent.
62071143|NCT01143532||Kidney transplant recipient of black African descent|Kidney transplant recipient of black African descent.
62071144|NCT06280456|EXPERIMENTAL|Tranexamic Acid 4-hour group|10 mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 4 hours.
62071145|NCT06280456|EXPERIMENTAL|Tranexamic Acid 8-hour group|10 mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 8 hours.
62071146|NCT02653040|EXPERIMENTAL|Dynamic lighting|Indoor lighting with low-lux no-blue wavelengths at night.
62071147|NCT02653040|NO_INTERVENTION|Treatment as usual|Characterized by full white light with little variation through a day cyclus.
62071148|NCT02405117|EXPERIMENTAL|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
62454864|NCT05895552|EXPERIMENTAL|Part 1 RTA 901 Dose 1|Participants will receive study drug, once daily (QD), during the 2-week Run-in Period. Following randomization, the participants will receive a dose of RTA 901, QD, for a 12-week treatment duration.
62639741|NCT05430165||Aim 1 Prospective Cohort|All eligible admitted trauma patients in the trauma registry and a qualitative study of 110 in-depth interviews (IDIs).
62639742|NCT01848106|ACTIVE_COMPARATOR|Bivalirudin|Bivalirudin bolus and infusion
62639743|NCT01848106|EXPERIMENTAL|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
62071149|NCT02405117|NO_INTERVENTION|Treatment As Usual|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will be asked to provide limited self-report data via the phone.
62071150|NCT06199947|EXPERIMENTAL|Samples|
62071151|NCT05542407|EXPERIMENTAL|Obese|Subjects with BMI \> 30 kg/m2
62071152|NCT05542407|EXPERIMENTAL|Non-Obese|Subjects with BMI ≤ 29.9 kg/m2
62639744|NCT02667600||Cesarean Section Group|Patients undergoing cesarean section
62639745|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
62639746|NCT03592888|EXPERIMENTAL|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
62639747|NCT01492348|EXPERIMENTAL|STEPS UP Intervention|STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
62071153|NCT05713734||Patients|Patients with bleeding of unknown cause
62071154|NCT05713734||Controls|Healthy voluntaries without bleeding tendency
62071155|NCT06341426|ACTIVE_COMPARATOR|Two Doses of Psilocybin|Two psychedelic doses (25mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
62071156|NCT06341426|PLACEBO_COMPARATOR|Single Dose of Psilocybin|One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
62071157|NCT01874106|EXPERIMENTAL|Diet therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
62071158|NCT01874106|OTHER|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
62071159|NCT03804515|EXPERIMENTAL|14C-labeled Poziotinib|
62071160|NCT05433402|ACTIVE_COMPARATOR|Control|
62071161|NCT05433402|EXPERIMENTAL|Chloropromazine|
62071162|NCT06062940||Primary Care Practice|We recruited 10 primary care practices from across Colorado, from all regions of the state (e.g., Eastern Plains, Mountain West, Front Range), and a mix of rural and urban practices of varying sizes. We recruited both practice staff and patients for this cohort.
62071163|NCT06062940||Cardiology Practice|We recruited 2 cardiology practices from across Colorado, from all regions of the state (e.g., Eastern Plains, Mountain West, Front Range), and a mix of rural and urban practices of varying sizes. We recruited both practice staff and patients for this cohort.
62071164|NCT03475719|ACTIVE_COMPARATOR|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
62454865|NCT05895552|EXPERIMENTAL|Part 1 RTA 901 Dose 2|Participants will receive study drug, QD, during the 2-week Run-in Period. Following randomization, the participants will receive a dose of RTA 901, QD, for a 12-week treatment duration.
62071165|NCT03475719|EXPERIMENTAL|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
62639748|NCT01492348|ACTIVE_COMPARATOR|Optimized Usual Care (OUC)|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system.
62275905|NCT06287034||Salvage total laryngectomy STL primary suture|Patients in both groups will then undergo salvage total laryngectomy STL surgery with primary suturing.The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)31. It would be preferable for all centers to use a homogeneous pharyngeal suture technique, such as the T-shaped with Connell suture.
62639749|NCT05447143|OTHER|Control Group (CG)|The control group will be queued to be included in the exercise program and participants' routine treatment will continue.
62639750|NCT05447143|EXPERIMENTAL|Video Group (VG)|The exercise will be given as a video and participants will be asked to continue the exercises for 8 weeks, 3 days a week. Patients will be contacted by phone every week to ask if participants have any problems with the exercise program and their compliance.
62639751|NCT05447143|EXPERIMENTAL|Brochure Group (BG)|Exercise will be given as a brochure and participants will be asked to continue the exercises given for 8 weeks, 3 days a week. Visual feedback will be provided by asking participants to mark the exercise tracking chart on the exercise brochures.
62275906|NCT06287034||Salvage total laryngectomy STL primary suture + onlay flap|Patients in both groups will then undergo salvage total laryngectomy STL surgery with primary suturing, but in the patients of the second group, in addition, the positioning of a free/pedunculated covering flap will also be carried out with the onlay technique. Reconstruction with the onlay technique can be performed using a pedicled pectoralis major myofascial flap or anterolateral thigh myofascial free flap at the surgeon's discretion (pharyngeal suture unchanged). The flap will be positioned with an onlay technique to reinforce the pharyngeal suture and in turn sutured to the prevertebral fascia or residual surrounding tissues.
62454866|NCT05895552|PLACEBO_COMPARATOR|Part 1 RTA 901-Matching Placebo|Participants will receive study drug, QD, during the 2-week Run-in Period. Following randomization, the participants will receive a dose of RTA 901-matching placebo, QD, for a 12-week treatment duration.
62639752|NCT03869372|EXPERIMENTAL|Study subjects|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink. Based on responses to symptom surveys (IBS-SSS and PAGI-SYM), study subjects will be characterized as healthy or as having functional dyspepsia and/or IBS."
62454867|NCT05895552|EXPERIMENTAL|Part 2 RTA 901 Dose 1|Participants will receive study drug, QD, during the 2-week Run-in Period. Following randomization, the participants will receive a dose of RTA 901, QD, for a 12-week treatment duration.
62454868|NCT05895552|EXPERIMENTAL|Part 2 RTA 901 Dose 2|Participants will receive study drug, QD, during the 2-week Run-in Period. Following randomization, the participants will receive a dose of RTA 901, QD, for a 12-week treatment duration.
62639753|NCT04577105||Suspected, probable, or confirmed COVID-19 case|Patients who come to the emergency room with symptoms compatible with a suspected, probable, or confirmed case of SARS-CoV2 infection, in which a chest computed tomography (CT) scan was requested for suspected COVID-19 pneumonia, will be evaluated. On April 1 and August 28, 2020.
62454869|NCT05895552|PLACEBO_COMPARATOR|Part 2 RTA 901-Matching Placebo|Participants will receive study drug, QD, during the 2-week Run-in Period. Following randomization, the participants will receive a dose of RTA 901-matching placebo, QD, for a 12-week treatment duration.
62275907|NCT03742037|EXPERIMENTAL|Cenerimod 0.5 mg|Participants will receive cenerimod 0.5 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 0.5 mg for a further 6 months and end study treatment at the Month 12 visit.
62639754|NCT04938076|EXPERIMENTAL|tDCS group|"tDCS stimulation~* affected side :~  1. primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)~ 2. 2mA anode (+) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)~* contralateral unaffected side~  1. primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)~ 2. 2mA cathode (-) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)"
62639755|NCT04938076|SHAM_COMPARATOR|Sham group|". Sham stimulation~1) the current ramps up to 2mA and slowly decreased over 30 s to ensure the typical initial tingling sensation"
62639756|NCT02745652|EXPERIMENTAL|pulsed electromagnetic field (PEMF)|patients in this group received the pulse electromagnetic field with frequency 50 Hz and intensity 80 gauss for 30 min.The patient was in sitting position, while the forearm was rested on the bed inside the solenoid in supination position
62639757|NCT02745652|EXPERIMENTAL|Therapeutic ultrasound (US)|Pulsed mode US was applied over the volar surface of the forearm (the carpal tunnel area) 15 min per session with a frequency of 1 MHz and intensity of 1.0 W/cm2
62639758|NCT02534168|EXPERIMENTAL|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
62639759|NCT01634646|PLACEBO_COMPARATOR|Overweight, elevated total cholesterol|All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
62071166|NCT03408834|ACTIVE_COMPARATOR|pulse variability index|fluid management performed by pulse variability index
62071167|NCT03408834|PLACEBO_COMPARATOR|conventional fluid management|fluid management performed by conventional fluid management
62071168|NCT06115850|NO_INTERVENTION|No Music intervention|Anxiety assessment questionnaires were administered before the treatment began and after 2 weeks of treatment. Physiological parameters, including heart rate, systolic and diastolic blood pressure, and blood oxygen levels, were monitored before and after 2 weeks of treatment.
62639760|NCT03070795|EXPERIMENTAL|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
62639761|NCT03070795|ACTIVE_COMPARATOR|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
62071169|NCT06115850|EXPERIMENTAL|Music intervention|Anxiety assessment questionnaires were administered before the treatment began and after 2 weeks of treatment. Physiological parameters, including heart rate, systolic and diastolic blood pressure, and blood oxygen levels, were monitored before and after 2 weeks of treatment.
62071170|NCT02726061|EXPERIMENTAL|Internet Based psychological support|The internet-based psychological support intervention (PATH) is an internet based Problem Solving Therapy, stress management training and conflict management training program.
62071171|NCT03135704|ACTIVE_COMPARATOR|"Re Spine Mattress"|"Adults suffering low back pain will treat their low back pain using the Re Spine mattress"
62071172|NCT03135704|ACTIVE_COMPARATOR|Physiotherapy|Adults suffering low back pain will treat their low back pain using conventional physiotherapy protocols
62639762|NCT01561417|ACTIVE_COMPARATOR|CP-rFVIIa|
62639763|NCT01561417|EXPERIMENTAL|VII25|
62071173|NCT02089581|ACTIVE_COMPARATOR|Drug|MR2XXX
62639764|NCT00904007|EXPERIMENTAL|SE Game Cohort|Will receive ISE intervention.
62639765|NCT00904007|NO_INTERVENTION|Control Cohort|The control cohort will receive identical content online (with no ISE)
62639766|NCT03397784||fluid responders|Patients whose stroke volume index increase by ≥15% in response to a 500-ml fluid bolus was defined as fluid responders.
62639767|NCT03397784||fluid non-responders|Patients whose stroke volume index increase by \<15% in response to a 500-ml fluid bolus was defined as fluid non-responders.
62639768|NCT00869505||Case Group|Intensive Residential Treatment with memantine augmentation
62071174|NCT02089581|EXPERIMENTAL|MRXXX|MRXXX capsule 12 hourly
62071175|NCT02089581|EXPERIMENTAL|MR1XXX|MR1XXX capsule, 12 hourly
62071176|NCT02089581|EXPERIMENTAL|Experimental|Experimental Fed
62071177|NCT02951351|ACTIVE_COMPARATOR|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection will then proceed.
62639769|NCT00869505||Control Group|Intensive Residential Treatment without memantine augmentation
62639770|NCT00678418|EXPERIMENTAL|VIVITROL® 380 mg|
62639771|NCT00678418|PLACEBO_COMPARATOR|Placebo|
62639772|NCT00778596|EXPERIMENTAL|Prednisolone priming|Prednisolone priming 4 weeks, then treated with telbivudine.
62639773|NCT00778596|PLACEBO_COMPARATOR|Placebo priming|Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.
62639774|NCT00580957|EXPERIMENTAL|Blocked|Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
62639775|NCT00580957|PLACEBO_COMPARATOR|Intact|Saline will be used instead of trimethaphan during insulin clamp
62071178|NCT02951351|EXPERIMENTAL|Proparacaine + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
62071179|NCT03240939|ACTIVE_COMPARATOR|Dutasteride&Tadalafil|Dutasteride 0.5 mg capsule and Tadalafil 5 mg Tablet, single dose
62071180|NCT03240939|EXPERIMENTAL|YY-201|YY-201 capsule, singe dose
62071181|NCT00723424|EXPERIMENTAL|1|AZD5672 + Digoxin (single dose on day 12)
62639776|NCT01954849|EXPERIMENTAL|Probiotic formulation|Probiotic dissolving lozenge, at least 1 billion total CFU, taken at a certain prescribed regimen for 28 days.
62071182|NCT00723424|EXPERIMENTAL|2|AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)
62071183|NCT06161805|EXPERIMENTAL|Esketamine|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour).
62071184|NCT06161805|PLACEBO_COMPARATOR|Placebo|8 hours infusion with saline (NaCl 0.9%)
62071185|NCT01350622|EXPERIMENTAL|Pennsaid|Active Pennsaid and oral placebo
62071186|NCT01350622|ACTIVE_COMPARATOR|Oral Diclofenac|Oral diclofenac and placebo lotion (2.3% DMSO solution)
62071187|NCT05185518|EXPERIMENTAL|Use of novel insulin injection port|subjects inject insulin through a glucose sensing port
62071188|NCT05185518|NO_INTERVENTION|use of standard SC injections|subjects inject insulin through standard rotating subcutaneous sites.
62071189|NCT05284305||Patients with history of pregnancy|Patients with DT diagnosed during pregnancy; patients with DT with macroscopic disease in situ at the time of pregnancy (including previous partial resection, recurrent disease, primary disease followed with active surveillance); resected DT without clinical evidence of residual or recurrent disease at the onset of pregnancy.
62071190|NCT05284305||Patients without history of pregnancy|Patients with DT without history of pregnancy
62454870|NCT04297228|EXPERIMENTAL|Step by Step Program|"Thirteen 1.5 hour weekday educational sessions, five 1-hour weekday fitness classes and seventeen 1 hour weekend walks/farmer's market trips were scheduled over 22 weeks. The planned total contact time was 41.5 hours, above the minimum effective amount and recommended by the USPSTF. Children participated in all activities. Weekly text messages with motivational messages and reminders were planned.~Educational Topics included:~Intro and Goal Setting How to Read Nutrition Labels How to Build a Healthy Meal Choose My Plate/Walking for Fitness Healthy Fast Food Add More Fruits/Vegetables to Meals Add More Physical Activity Each Day Healthy Snacks and Drinks Healthy Desserts Circuit Training at Home Favorite Recipe Makeover Step by Step Jeopardy Celebration of Completion"
62454871|NCT04909437|EXPERIMENTAL|Mycobiotic group|
62454872|NCT04909437|PLACEBO_COMPARATOR|Placebo group|
62639777|NCT01954849|PLACEBO_COMPARATOR|Placebo|Placebo dissolving lozenge, with the exact same appearance as the treatment lozenge (including flavour, colour, shape and texture), and formulated with all the same ingredients except for the live bacteria, taken for 28 days at the same prescribed regimen as the probiotic lozenge.
62639778|NCT02379013|EXPERIMENTAL|Volunteer with MRI|All volunteer will be included in the arm MRI
62071191|NCT02693834|EXPERIMENTAL|PLS AFO first then DA AFO|Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
62071192|NCT02693834|EXPERIMENTAL|DA AFO first then PLS AFO|Participants will be assigned to practice with Double adjustable AFO for a week, then they will be assigned to practice with Posterior Leaf spring AFO for another week
62071193|NCT03681795|EXPERIMENTAL|patient|patients with Gilles de la Tourette syndrome
62071194|NCT03681795|EXPERIMENTAL|Control|healthy control
62071195|NCT03044262|EXPERIMENTAL|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
62071196|NCT00038441|EXPERIMENTAL|DTI-015|
62088329|NCT06042985|ACTIVE_COMPARATOR|LSG arm: calcium citrate and calcium carbonate|The absorption effect between calcium citrate and calcium carbonate in patients with a LSG
62275908|NCT03742037|EXPERIMENTAL|Cenerimod 1 mg|Participants will receive cenerimod 1 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 1 mg for a further 6 months and end study treatment at the Month 12 visit.
62275909|NCT03742037|EXPERIMENTAL|Cenerimod 2 mg|Participants will receive cenerimod 2 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 2 mg for a further 6 months and end study treatment at the Month 12 visit.
62639779|NCT01943487|EXPERIMENTAL|1: verapamil + EC905|
62639780|NCT05673356|EXPERIMENTAL|Main arm of the study|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients.
62639781|NCT03308240|EXPERIMENTAL|Magic Therapy Group|"Medical student magicians who have completed MagicAid training will provide the therapy.~Three or four tricks will be performed per patient at the discretion of the magician to cater to patient age and cognition capabilities. Patients in the experimental group may be given the opportunity to learn a magic trick that has been presented to them as well."
62639782|NCT03308240|NO_INTERVENTION|Standard Child Life Therapy Group|Stony Brook Child Life Specialists will provide standard therapies available to all patients, such as pet therapy, art therapy, music therapy.
62639783|NCT02672098|EXPERIMENTAL|HIPEC|A procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
62639784|NCT04369833||continuous glucose monitoring group|all participants wearing a continuous glucose monitoring device
62639785|NCT05222555|EXPERIMENTAL|Treatment (Tafasitamab + Lenalidomide)|"Treatment:~Tafasitamab will be combined with lenalidomide in R/R DLBCL patients.~Dose:~Cohort 1: The dose of tafasitamab will be level 1 high dose in combination with the approved dose~Cohort 2: The dose of tafasitamab will be level 2 high dose in combination with the approved dose~Expansion Cohort: The dose of tafasitamab will be the dose that is deemed safe and tolerable as determined from cohort 1 \& cohort 2~Treatment consisting of tafasitamab and lenalidomide combination will be administered until disease progression, unacceptable toxicity, or discontinuation for any other reason, whichever comes first. Lenalidomide can be given for up to 12 cycles in total, after which patients can continue with tafasitamab as monotherapy until progression or unacceptable toxicity."
62071197|NCT02676323|EXPERIMENTAL|Treatment|Participants will be given panobinostat in combination with fludarabine and cytarabine. Treatment consists of one course of therapy given over 12 days. Participants will also receive intrathecal triples and leucovorin
62275910|NCT03742037|EXPERIMENTAL|Cenerimod 2 mg (Ex-4mg)|Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to cenerimod 2 mg once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.
62275911|NCT03742037|PLACEBO_COMPARATOR|Placebo (Ex-4mg)|Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to placebo (matching cenerimod) once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.
62639786|NCT01781962||All Participants|Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
62639787|NCT05563337|EXPERIMENTAL|Denervation treatment|
62639788|NCT05563337|SHAM_COMPARATOR|Control|
62639789|NCT02749344|EXPERIMENTAL|FET after endometrial preparation|Natural cycle/progesterone fortified endometrial preparation before embryo transfer
62639790|NCT03148262|EXPERIMENTAL|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
62639791|NCT03148262|PLACEBO_COMPARATOR|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
62639792|NCT05175781|ACTIVE_COMPARATOR|Dexmedetomidine|"patients will receive two NIV sessions during which intravenous continuous infusion of dexmedetomidine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. Dexmedetomidine will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions accounting for 1-h contextual half-life of dexmedetomidine. Patients received neither tested drug nor NIV during this 6-h interval."
62071198|NCT05290610|OTHER|Research IESM|Functional mapping for research application
62275912|NCT03742037|EXPERIMENTAL|Cenerimod 4 mg|"Participants will received cenerimod 4 mg once daily in addition to background SLE therapy for up to 6 months in Treatment Period 1. The participants randomized to the 4 mg treatment who were still on treatment at Month 6 were re-randomized in a 1:1 ratio to placebo or cenerimod 2 mg to enter Treatment Period 2. The participants who did not complete 6 months of cenerimod 4 mg treatment will be analyzed in the Non Re-randomized (Ex-4mg) treatment group."
62275913|NCT03742037|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (matching cenerimod) once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with placebo (matching cenerimod) for a further 6 months and end study treatment at the Month 12 visit.
62454873|NCT03679741|EXPERIMENTAL|TEST/CONTROL/CONTROL|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
62639793|NCT05175781|ACTIVE_COMPARATOR|Ketamine|"patients will receive two NIV sessions during which intravenous continuous infusion of ketamine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, infusion of ketamine will be at the dose of 0.20 mg/kg/h (or 3.3 mg/kg/min). to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of the infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
62071199|NCT00869882|EXPERIMENTAL|1|Posterolateral fusion with instrumentation combined to transforaminal lumbar interbody fusion
62071200|NCT00869882|ACTIVE_COMPARATOR|2|Posterolateral fusion with instrumentation
62071201|NCT01628627|EXPERIMENTAL|FREMS|Frequency Modulated Neural Stimulation (FREMS)
62071202|NCT01628627|SHAM_COMPARATOR|Control|
62071203|NCT03301688|EXPERIMENTAL|A group (JS001 20161002)|The subjects of A group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161002.
62071204|NCT03301688|EXPERIMENTAL|B group (JS001 20161108)|The subjects of B group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161108.
62071205|NCT02631421||Pulmonary Arterial Hypertension|Clinical diagnosis of pulmonary arterial hypertension
62071206|NCT02631421||Healthy subjects and patients with other causes of PH|Patients referred for right heart catheterization who do not have PAH
62071207|NCT06106815|EXPERIMENTAL|The Graded Repetitive Arm Supplementary Program|
62071208|NCT06106815|ACTIVE_COMPARATOR|Usual Care|
62071209|NCT05707013|EXPERIMENTAL|HP Arize 3D-Printed Orthotics|Patients will receive the HP Arize 3D-printed orthotics for treatment of plantar fasciitis.
62071210|NCT05707013|ACTIVE_COMPARATOR|Traditional Orthotics|Patients will receive traditionally fabricated orthotics for treatment of plantar fasciitis.
62071211|NCT01800708|ACTIVE_COMPARATOR|Triamcinolone acetonide|The study group will receive an intraoperative intracameral injection of triamcinolone acetonide
62639794|NCT05175781|PLACEBO_COMPARATOR|Placebo|"patients will receive two NIV sessions during which intravenous continuous infusion of placebo (0.9% sodium chloride solution) will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of any infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
62639795|NCT01508247|EXPERIMENTAL|vaccine against EV71|Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
62639796|NCT01508247|PLACEBO_COMPARATOR|placebo|0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
62071212|NCT01800708|ACTIVE_COMPARATOR|Prednisolone syrup|The control group will receive prednisolone syrup postoperatively
62275914|NCT05154695|ACTIVE_COMPARATOR|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
62275915|NCT05154695|ACTIVE_COMPARATOR|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
62275916|NCT01887977|EXPERIMENTAL|Computational modeling|
62639797|NCT01414998|ACTIVE_COMPARATOR|Stress Ball|This is the active comparator for study 1
62639798|NCT01414998|EXPERIMENTAL|De-nicotinised Cigarette|This will be the experimental arm for study 2
62071213|NCT04057911|EXPERIMENTAL|Real NIBS|In Real NIBS arm, active Noninvasive brain stimulation (NIBS) will be given for 20 mins.
62071214|NCT04057911|SHAM_COMPARATOR|Sham NIBS|In Sham NIBS arm, sham Noninvasive brain stimulation (NIBS) will be given for 20 mins.
62071215|NCT00738452|EXPERIMENTAL|Treatment (chemo, monoclonal antibody therapy, radiation)|CHEMORADIOTHERAPY: Patients undergo external beam radiation therapy 5 days a week for 45 days. Beginning within 24 hours of the start of radiation therapy, patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 OR cisplatin IV over 60 minutes on days 1, 8, 29, and 36 and etoposide IV over 60 minutes on days 1-5 and 29-33. CONSOLIDATION RADIOIMMUNOTHERAPY: Beginning 6-10 weeks after completion of chemoradiotherapy, patients with stable disease, partial response, or complete response receive a therapeutic dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV. Treatment continues in the absence of disease progression or unacceptable toxicity.
62071216|NCT01448954|EXPERIMENTAL|ADC3680B oral|
62071217|NCT01448954|PLACEBO_COMPARATOR|Placebo oral|
62275917|NCT04421274|EXPERIMENTAL|BM-MSCs group|Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )
62275918|NCT04421274|SHAM_COMPARATOR|Control group|Receive the best medication, percutaneous coronary intervention
62275919|NCT01091701|EXPERIMENTAL|Ex vivo cultured adult allogenic MSCs|
62275920|NCT01091701|PLACEBO_COMPARATOR|Plasmalyte-A|
62275921|NCT03609307|ACTIVE_COMPARATOR|injection Combined Intravitreal bevacizumab and propranolol|patients receive two injections at each session Bavacizumab
62275922|NCT03609307|ACTIVE_COMPARATOR|injection Intravitreal bevacizumab|patients receive only Bevacizumab
62275923|NCT05877976|EXPERIMENTAL|Registered Nurses|Participants will receive an intervention of museum educator-led workshops that introduce nurses to arts appreciation skills to improve their practice and overall wellbeing.
62275924|NCT04762628|EXPERIMENTAL|MAF capsules|MAF capsules 148 mg TID for 14 days + Standard of care
62275925|NCT04762628|EXPERIMENTAL|M capsules|M capsules 148 mg TID for 14 days + Standard of care
62071218|NCT03954158|EXPERIMENTAL|Crisaborole ointment 2% once daily (QD) vs vehicle QD|intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
62071219|NCT03954158|EXPERIMENTAL|Crisaborole ointment 2% twice daily (BID) vs vehicle BID|Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
62071220|NCT01324479|EXPERIMENTAL|INC280|
62071221|NCT00836173|EXPERIMENTAL|RICE followed by GARD|"1. RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, for 3 cycles.~2. GaRD treatment: After RICE treatment, gallium nitrate will be given continuously over a 7 day period. In addition rituximab will be given on day 1 of each cycle. Dexamethasone will be given for the first 4 days of each cycle. The length of each cycle is 21 days."
62071222|NCT02543021|ACTIVE_COMPARATOR|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
62071223|NCT02543021|EXPERIMENTAL|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
62071224|NCT01336881||Correlative (tissue analysis)|Archived tumor tissue samples are analyzed for hepatoblastoma and other liver tumor biomarkers by microRNA array profiling and exome sequencing. Results are then compared with patients' clinical data.
62071225|NCT02581176|EXPERIMENTAL|Apixaban|Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.
62071226|NCT03179943|EXPERIMENTAL|Atezolizumab + Guadecitabine|
62454874|NCT03679741|EXPERIMENTAL|CONTROL/TEST/TEST|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
62454875|NCT00826774|ACTIVE_COMPARATOR|Ususal Care|
62454876|NCT00826774|EXPERIMENTAL|Breif Lifestyle Counseling|
62454877|NCT00826774|EXPERIMENTAL|Enhanced Brief Lifestyle Counseling|
62071227|NCT05905991|EXPERIMENTAL|ESRT Intervention|Five 1-hour weekly ESRT sessions
62071228|NCT05905991|OTHER|Waitlist Control|The control group will receive ESRT after the intervention group finishes the 5-week ESRT program.
62071229|NCT03247374|EXPERIMENTAL|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
62275926|NCT04762628|ACTIVE_COMPARATOR|Comparison|Standard of care
62275927|NCT02962050||ALS|Participants enrolled will complete the following tests: Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, reflexive cough testing, Pulmonary Function Testing; Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
62275928|NCT04789486|EXPERIMENTAL|AGUIX + SMART Phase 1|"Dose escalation of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).~Central lung tumor cohort will receive:~* five fractions of stereotactic body radiation therapy (SBRT)~* AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation and for patients receiving radiation over a two (2) week period with the 4th fraction of radiation .~Locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC cohort, will receive:~five fractions of stereotactic body radiation therapy (SBRT)~* AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation."
62454878|NCT04442776|EXPERIMENTAL|Intervention group|The intervention group will complete the Dual Integrated Attention Program (D-AIP) The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made.
62454879|NCT04442776|NO_INTERVENTION|Control group|The control group will complete the usual treatment. One session per day voluntary during admission and discharge, nursing consultations only to put injectable medication
62639799|NCT01414998|EXPERIMENTAL|Nicotine-free Electronic Cigarette (1)|This will be the experimental arm for study 1
62639800|NCT01414998|ACTIVE_COMPARATOR|Nicotine-free Electronic Cigarette (2)|This will be the active comparator for study 2
62639801|NCT06076031|NO_INTERVENTION|Routine care|Analgesic use
62639802|NCT06076031|EXPERIMENTAL|lntervention|streaming media (video and audio) use
62639803|NCT05232552|EXPERIMENTAL|anlotinib|3 cycles of anlotinib (12mg, d1-14)was given concurrently with docetaxel plus cisplatin chemotherapy as induction , then 2 additional cycles of anlotinib concurrent with definitive chemoradiation (IMRT with conccurent cisplatin)
62071230|NCT03247374|ACTIVE_COMPARATOR|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
62639804|NCT01232790|EXPERIMENTAL|Group A: Intervention/Placebo|Group A first receives the commercially available sustained release form of N-acetylcysteine, then the matching placebo capsules both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
62071231|NCT02294110||diabetes mellitus|spinal anesthesia
62639805|NCT01232790|PLACEBO_COMPARATOR|Group B: Placebo/Intervention|Group B first receives the placebo and then receives a commercially available sustained release form of N-Acetylcysteine. In each arm, the capsules are both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
62639806|NCT05481801||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Covid-19, Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
62639807|NCT05763927|EXPERIMENTAL|Fruquintinib& Toripalimab& SRT|"Induction treatment:~Fruquintinib 5mg d1-d14； Toripalimab 240 mg intravenously d1；~Consolidation treatment:~SRT: 25 Gy in 5 fractions d22-d26； Fruquitinib 5mg d22-d35，43-56,64-77； Toripalimab 240 mg intravenously d22、43、64；~Surgery: Surgical resection will be performed according to the principles of TME(total mesorectal excision) 2-4 weeks after the last dose administration of Fruquintinib；~Adjuvant chemotherapy: Standard chemotherapy or observation according to the judgement of Principle Investigator and patients' willing."
62639808|NCT00183651|EXPERIMENTAL|S-DBT|Participants receive standard dialectical behavior therapy
62639809|NCT00183651|ACTIVE_COMPARATOR|DBT-I|Participants receive individual dialectical behavior therapy plus activities group
62639810|NCT00183651|ACTIVE_COMPARATOR|DBT-S|Participants receive dialectical behavior therapy group skills plus case management
62088330|NCT06042985|ACTIVE_COMPARATOR|OAGB arm: calcium citrate and calcium carbonate|The absorption effect between calcium citrate and calcium carbonate in patients with a OAGB
62088331|NCT02207361|EXPERIMENTAL|Paclitaxel, Carboplatin，injection|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
62639811|NCT04687852|EXPERIMENTAL|Focused Pelvic Floor Exercise with Motor ImageryTechnique Group|5 minute-Meditation Therapy 10 minute-Progressive Relaxation training ( Bernstein-Borkovec Method) 5 min - Breathing Exercises (Diaphragmatic Breathing Exercise, Pursed lip breathing Exercise) 35 min -Motor Imagery Technique Focused Pelvic Floor Exercises-MOPEXE 5 min - Meditation Therapy Twice a week for 60 minutes 12 weeks Participants will be evaluated online at the beginning of the research and at the end of the 12-week program.
62639812|NCT04687852|ACTIVE_COMPARATOR|Nonsteroidal Anti-Inflammatory Drug(NSAID) Group|Naproxen Sodium 550 mg film-coated tablet prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the pain of the patient. Treatment time; 12 weeks.
62454880|NCT05608512||hospice care nurses|nurses who have worked in a palliative care or hospice unit
62454881|NCT04000503|EXPERIMENTAL|Community Health Worker Self-Collection|Door-to-door recruitment of women for self-collected HPV testing
62639813|NCT04687852|OTHER|Diosmin Group|Diosmin (90%) 500 mg film-coated tablets prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the patient's pain. Treatment time; 12 weeks.
62639814|NCT04687852|EXPERIMENTAL|Acupressure Group|"4 acupuncture points will be applied twice a day for 12 weeks. These points are; LI4, CV4, CV6, SP6~."
62639815|NCT04687852|NO_INTERVENTION|Control Group|Participants will not be treated.
62071232|NCT05351060|EXPERIMENTAL|3D model splinting intervention group|The researcher will scan the participant's forearm, wrist, and hand with an iPhone camera through the Comb O\&P Scan App. Scans will be completed individually to maintain privacy. The entire Comb O\&P platform is HIPAA compliant. The data is de-identified encrypted when it moves from the iPhone app to the computer through the cloud. Precision Valve Automation (PVA) will use the de-identified scans to print the 3D models which are a precise replica of the participant's hand. Once the researcher obtains the 3D models, resting hand splints will be fabricated on the 3D models to provide custom-made hand splint(s) to each participant. The participants will receive the splint(s) to wear during the hours of sleep for six weeks.
62639816|NCT04521556|ACTIVE_COMPARATOR|Epidural anesthesia and analgesia|"Epidural catheter insertion: Th 9 - Th 10 or Th 10 - Th 11 using the midline approach.~Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml).~Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml)."
62639817|NCT04521556|ACTIVE_COMPARATOR|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
62639818|NCT00417664||Dexmedetomidine|
62454882|NCT04000503|EXPERIMENTAL|Community Health Meeting Self-Collection|Community health meeting recruitment of women for self-collected HPV testing
62454883|NCT02134756|EXPERIMENTAL|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
62639819|NCT00417664||Propofol|
62639820|NCT00417664||Midazolam|
62639821|NCT01339039|EXPERIMENTAL|Part 1|Maximum Tolerated Dose Determination of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
62639822|NCT01339039|EXPERIMENTAL|Part 2|Surgical Arm: Safety evaluation of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
62639823|NCT01339039|EXPERIMENTAL|Part 3|Safety and tolerability of Plerixafor (daily) at MTD dose from Part 1 and Bevacizumab (every 2 weeks)
62639824|NCT00667563|EXPERIMENTAL|Gardasil Vaccination|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
62639825|NCT03025633|OTHER|Group A - PEARL|Group A will receive a combination of verbal and visual pre-treatment information via the use of PEARL.
62639826|NCT03025633|NO_INTERVENTION|Group B - NON PEARL|Group B will receive verbal only pre-treatment information.
62639827|NCT05456204|OTHER|Refralone group|Patients with recurrent AF/AFL after catheter interventions to restore SR will be cardioverted with refralon
62639828|NCT02060500|EXPERIMENTAL|Cardiaplication|
62639829|NCT01611623|EXPERIMENTAL|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation based on safety outcomes
62639830|NCT06172231|ACTIVE_COMPARATOR|Group A ( Conventional physiotherapy)|5 min moist Hot pack ,Patellar joint mobilizations and Tibiofemoral ,Maitland grades III and IV (5 oscillations in first week) ,PROMs of knee joint ( 5 reps) ,Quad sets ( 5 reps with 5 sec hold)Progression: 5 repetition of each exercise would be add in every week ,Frequency: 4 sessions in 4-week period Duration: 15_ 35 min each session.
62071233|NCT01073839|EXPERIMENTAL|Cisplatin plus Gemcitabine|Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.
62071234|NCT00794001|EXPERIMENTAL|Data Feedback|The intervention is systematic feedback on performance (using predefined quality indicators) to cardiology, ED, and EMS-stakeholders and staff.
62639831|NCT06172231|EXPERIMENTAL|Group B ( IASTM along with conventional physiotherapy))|rst conventional Physiotherapy same as group A thenIASTM protocol.The treatment processes consist of Four phases: warm up (heat), Graston Technique®, passive stretching and cryotherapy.6_10 long strokes on Hamstring and Rectus femoris by using G1 instrument .Brief bouts (30 - 60 s) of deeper and more specific.Frequency: 4 sessions in 4-week period.Duration: 15_35 min each session.
62639832|NCT01438138||Correlative studies|Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay, the My Profile™ AML Risk of Relapse Assay. Molecular markers analyzed include Flt3-ITD, NPM1, and MRA. Results are then correlated with each patient's clinical data including patient's age, race/ethnic background, gender, treatment received, and outcomes.
62071235|NCT06170736|ACTIVE_COMPARATOR|Doppler-Guided Haemorrhoidal Artery Ligation|Patients will be treated by DGHAL procedure.
62071236|NCT06170736|EXPERIMENTAL|Radiofrequency Ablation|Patients will be treated by radiofrequency ablation.
62071237|NCT00595829|EXPERIMENTAL|1|
62275929|NCT04789486|EXPERIMENTAL|AGUIX + SMART Phase 2|Randomized participants will receive recommended phase 1 dose established for their disease group (central lung tumor or locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC) of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
62275930|NCT04789486|EXPERIMENTAL|SMART Phase 2|Randomized participants will receive standard of care SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
62275931|NCT00654862|EXPERIMENTAL|1|Subjects with stage 1 hypertension
62639833|NCT00072410|EXPERIMENTAL|Cohort 1|Patients received a single intraperitoneal (IP) dose of 10 mg of hu3S193 radiolabeled with 10 millicuries (mCi) 90Y and 5mCi 111In-hu3S193 to enable imaging after dosing.
62639834|NCT00072410|EXPERIMENTAL|Cohort 2|Patients received a single intraperitoneal (IP) dose of 10 mg of hu3S193 radiolabeled with 15 millicuries (mCi) 90Y and 5mCi 111In-hu3S193 to enable imaging after dosing.
62639835|NCT01967680|ACTIVE_COMPARATOR|Sedation with daily wake-up trial|The control group is sedated with continuous infusion to Ramsay score 3-4. During daytime, the patient is awakened as the intravenous infusion of sedatives is discontinued. After a successful wake-up, the infusion of sedative is resumed, starting on half of the pre-wake-up dose. If the patient becomes uncomfortable or agitated during the awakening, sedation is resumed, again starting with half the dosage. The infusion of sedatives is then adjusted to Ramsey score 3-4.
62639836|NCT01967680|EXPERIMENTAL|Non-sedation|"This group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants in the non-sedated group are awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium are treated with haloperidol according to the U.S. guidelines, 2002 and the Danish national guidelines.~If, despite these measures, it is necessary to sedate an agitated patient more than twice, or where sedation might be necessary to ensure sufficient oxygenation or prone position, the patient is sedated and treated like the control-group. Every day during the wake-up trial it is evaluated whether the patient is able to continue the intervention of non-sedation."
62639837|NCT02355717||Prospective Cohort|400 otherwise healthy children and adolescents aged 9-15 years will be recruited to participate in a 2-year longitudinal study.
62639838|NCT04348708||Dose Level Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
62639839|NCT04348708||Dose Level Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
62639840|NCT04348708||Dose Level Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
62071238|NCT00852670|EXPERIMENTAL|A|
62071239|NCT00852670|PLACEBO_COMPARATOR|B|
62071240|NCT03644355|EXPERIMENTAL|Diet and Nutrition Education|Lifestyle counseling plus nutrition education and counseling and protein sparing modified fast diet plus supplementation of vitamins and minerals, followed by a balanced, hypo-caloric diet and nutrition education provided by a registered dietician
62071241|NCT03644355|ACTIVE_COMPARATOR|Exercise Instruction|Lifestyle counseling plus moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
62071242|NCT03644355|ACTIVE_COMPARATOR|Combined Diet and Exercise|Lifestyle counseling plus dietary intervention including nutrition education and counseling and a protein sparing modified fast diet and nutrition education combined with the exercise intervention including a moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
62071243|NCT03644355|NO_INTERVENTION|Control|Delayed intervention (waiting list) group receives no intervention for 12 weeks followed by the Diet plus Exercise intervention.
62071244|NCT03747770|NO_INTERVENTION|Cross-sectional baseline survey|This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students
62071245|NCT03747770|ACTIVE_COMPARATOR|Single Dose HPV vaccination|Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
62088332|NCT02207361|ACTIVE_COMPARATOR|Paclitaxel, Epirubicin，injection|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
62275932|NCT00654862|EXPERIMENTAL|2|Subjects with optimal blood pressure
62639841|NCT03994978||Surgical group|Patients with uncomplicated recurrent diverticulitis undergoing elective sigmoid resection
62071246|NCT03747770|ACTIVE_COMPARATOR|Two-dose HPV vaccination|Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
62071247|NCT03747770|NO_INTERVENTION|Cross-sectional survey at Year 2|This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students
62275933|NCT02798796|EXPERIMENTAL|MRI Group|MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI
62275934|NCT02798796|NO_INTERVENTION|Control Group|Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.
62275935|NCT05532410|OTHER|Fundus Camera|
62639842|NCT03994978||Conservative group|Patients with uncomplicated recurrent diverticulitis with conservative treatment
62071248|NCT03747770|NO_INTERVENTION|Cross-sectional survey at Year 4|Cross-sectional survey at Year 4 post vaccination
62071249|NCT01912781|EXPERIMENTAL|FID 120974A|FID 120947A contact lens disinfecting solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
62275936|NCT01042600|ACTIVE_COMPARATOR|Endotracheal intubation|Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication
62275937|NCT01042600|EXPERIMENTAL|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
62275938|NCT01602445||Cancer patients|All cancer patients with a diagnosed acute symptomatic VTE episode.
62275939|NCT02113735|EXPERIMENTAL|Group 1|H.P. Acthar® Gel , 64 U, 0.8 mL daily
62275940|NCT02113735|PLACEBO_COMPARATOR|Group 2|Placebo, 0.8 mL, daily
62275941|NCT02113735|EXPERIMENTAL|Group 3|H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily
62275942|NCT02113735|PLACEBO_COMPARATOR|Group 4|Placebo, 0.4 mL, 2x daily
62275943|NCT02113735|EXPERIMENTAL|Group 5|H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily
62454884|NCT02134756|PLACEBO_COMPARATOR|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
62639843|NCT03615313|EXPERIMENTAL|PD-1 antibody expressing mesoCAR-T cells|Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (±3days).
62639844|NCT02697643|EXPERIMENTAL|BHCDS-based recommendations|The Experimental condition will use the BH-CDS tool and receive tailored recommendations in addition to treatment as usual.
62071250|NCT01912781|ACTIVE_COMPARATOR|Boston Simplus|Boston Simplus multi-action solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
62071251|NCT02293837|EXPERIMENTAL|Tocilizumab (TCZ) + SOC|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight \<30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
62071252|NCT02293837|PLACEBO_COMPARATOR|Tocilizumab Placebo Group + SOC|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
62071253|NCT01311362||CYP2C19 wild type|"CYP2C19 wild type =extensive metaboliser~* Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
62071254|NCT01311362||CYP2C19 mutant|"CYP2C19 \*2/\*2 or \*2/\*3 or \*3/\*3 = poor metaboliser~* Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
62071255|NCT00721656|PLACEBO_COMPARATOR|Placebo|
62071256|NCT00721656|EXPERIMENTAL|KLS-0611|
62071257|NCT00840372||1|Chronic hemodialysis patients, native arterio-venous fistula
62071258|NCT00840372||2|Chronic hemodialysis patients, native arterio-venous fistula
62071259|NCT01646684|EXPERIMENTAL|SOM230|
62071260|NCT00227760|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62071261|NCT05645289|EXPERIMENTAL|minodronate|Patients will take 1 mg of minodronate tablets orally in the morning.
62071262|NCT05645289|ACTIVE_COMPARATOR|alendronate|Patients will be orally given 10 mg alendronate tablets daily in the morning.
62071263|NCT00717678|EXPERIMENTAL|Prograf-XL + MMF|
62454885|NCT00958178|EXPERIMENTAL|Rebreathing method of preoxygenation|Subjects will breathe Oxygen through a close fitting mask, but the flow will be low so that they rebreathe some of their expired air. After 30 seconds, the flow will be turned up so that they will breathe 100% Oxygen.
62639845|NCT02697643|PLACEBO_COMPARATOR|Non-tailored recommendations|The Control condition will use the BH-CDS tool and receive non-tailored recommendations in addition to treatment as usual.
62639846|NCT01791595|EXPERIMENTAL|AZD3965 Cohort 1 (5 mg OD)|
62639847|NCT01791595|EXPERIMENTAL|AZD3965 Cohort 2 (10 mg OD)|
62639848|NCT01791595|EXPERIMENTAL|AZD3965 Cohort 3 (20 mg OD)|
62071264|NCT00717678|ACTIVE_COMPARATOR|Prograf + MMF|
62071265|NCT04707131|EXPERIMENTAL|LEM-S401|
62071266|NCT04707131|PLACEBO_COMPARATOR|Placebo|
62071267|NCT05493982|EXPERIMENTAL|Receives Stanford vaping prevention curriculum (pilot phase)|Stanford vaping prevention curriculum is administered as pilot arm preceding main experimental intervention.
62071268|NCT05493982|EXPERIMENTAL|Receives Stanford vaping prevention curriculum (randomized phase)|Stanford vaping prevention curriculum is administered.
62639849|NCT01791595|EXPERIMENTAL|AZD3965 Cohort 4 (30 mg OD)|
62071269|NCT05493982|NO_INTERVENTION|Does not receive Stanford vaping prevention curriculum (randomized phase)|Receives another curriculum or no vaping prevention education.
62071270|NCT06448455||Lung cancer patients|Through convenience sampling, lung cancer patients who were hospitalized and outpatients in the cancer chemotherapy Department of Peking University Third Hospital were selected as the research objects of this study.
62071271|NCT01560260|EXPERIMENTAL|Treatment (linsitinib)|Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62071272|NCT00726349||Observation|Patients undergoing isolated elective total hip or knee arthroplasty (primary or revision surgery for a non-malignant condition), aged 60 years or older and able to walk prior to surgery.
62071273|NCT01791634|EXPERIMENTAL|proximal open wedge osteotomy with LPS system|Proximal open wedge osteotomy with Low profile plate and screws
62071274|NCT01791634|ACTIVE_COMPARATOR|proximal wedge osteotomy|Proximal wedge osteotomy procedure
62275944|NCT02113735|PLACEBO_COMPARATOR|Group 6|Placebo, 0.2 mL, 2x daily
62639850|NCT01791595|EXPERIMENTAL|AZD3965 Cohort 5 (15 mg BD)|
62639851|NCT01791595|EXPERIMENTAL|AZD3965 Cohort 6 (10 mg BD)|
62639852|NCT01791595|EXPERIMENTAL|AZD3965 Expansion Cohort (10 mg BD)|
62639853|NCT05721664|EXPERIMENTAL|Evidence-based nursing practices training program|Evidence-based nursing practices training program for nurses caring mechanically ventilated patients
62639854|NCT05721664|ACTIVE_COMPARATOR|control group taking the traditional education|control group taking the traditional education related to caring of mechanically ventilated patients
62639855|NCT03949595||cases|women suffering from severe/massive obesity
62639856|NCT05222165|EXPERIMENTAL|Infigratinib (BGJ398)|"Generic name: infigratinib. Dosage forms: 18mg and 25mg sprinkle capsules and 25mg, 75mg, 100mg capsules.~Phase 1b Three dose levels escalation until RP2D is determined.~Phase 2~* Pediatric patients: dose defined in the phase 1b (RP2D);~* Adults: 125 mg.~Frequency: once daily for 21 days in each 28-day treatment cycle.~Duration: Treatment duration will last up to 26 cycles unless progression, death or unacceptable toxicity occur."
62071275|NCT02069756||Duchenne and Becker Muscular Dystrophy|Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.
62071276|NCT04361032|EXPERIMENTAL|Tocilizumab|ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)
62071277|NCT04361032|ACTIVE_COMPARATOR|Deferoxamine|DESFERAL: 500 mg, powder, and solvent for IV solution
62071278|NCT02265081|ACTIVE_COMPARATOR|nulliparous women|internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
62071279|NCT02265081|EXPERIMENTAL|parous women|those who had vaginal delivery in the past; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
62071280|NCT02265081|EXPERIMENTAL|parous women - VBAC|those with previous LSCS and no vaginal births; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
62071281|NCT05315284|OTHER|Patients with fresh non-comminuted fracture mid-shaft clavicle|
62071282|NCT03229434|EXPERIMENTAL|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h \[uphill\], 5.2km/h \[downhill\]) in a widely pristine area with moderate intensity (Rating of perceived exertion: \~ 11-15).
62639857|NCT04530045||critically ill patients|Critically ill patients receiving continuous infusion of piperacillin/tazbactam or cefepim and dosage of plasma concentration of the B lactam administered
62639858|NCT04488445|EXPERIMENTAL|Strength Training|The intervention group performs a resistance training based on a resistance exercise of 3 sets of 3 to 5 repetitions (90% of an estimated 1 RM) and 3 minutes of resting time between sets.
62639859|NCT04488445|PLACEBO_COMPARATOR|Stretching|The control group performs 3 exercises of stretching and balance during one minute each and three sets. One minute of resting time between sets.
62639860|NCT03794492|EXPERIMENTAL|Mycophenolate mofetil|One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
62639861|NCT01241422|EXPERIMENTAL|Treatment A: JNJ 40929837|
62639862|NCT01241422|PLACEBO_COMPARATOR|Treatment B: Placebo|
62071283|NCT03229434|ACTIVE_COMPARATOR|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h \[uphill\], 5.2km/h \[downhill\]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: \~ 11-15).~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
62639863|NCT01241422|OTHER|Treatment C: Montelukast|
62071284|NCT06267443|ACTIVE_COMPARATOR|Group 1|in this group erector spina plane block will be performed before surgery for post operative analgesia
62639864|NCT01716806|EXPERIMENTAL|Part A: Brentuximab Vedotin in HL Patients|
62639865|NCT01716806|EXPERIMENTAL|Part B: Brentuximab Vedotin + Dacarbazine in HL Patients|
62639866|NCT01716806|EXPERIMENTAL|Part C: Brentuximab Vedotin + Bendamustine in HL Patients|
62639867|NCT01716806|EXPERIMENTAL|Part D: Brentuximab Vedotin + Nivolumab in HL Patients|
62639868|NCT01716806|EXPERIMENTAL|Part E: Brentuximab Vedotin in HL Patients|
62639869|NCT01716806|EXPERIMENTAL|Part F: Brentuximab Vedotin in PTCL Patients|
62639870|NCT06237933|EXPERIMENTAL|Enhanced intervention|Enhanced intervention features of using social-networking-site site and personalized feedback, plus standard intervention
62639871|NCT06237933|ACTIVE_COMPARATOR|Control|Standard intervention with regular in-person consultation
62639872|NCT02461537|ACTIVE_COMPARATOR|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
62639873|NCT02461537|EXPERIMENTAL|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
62639874|NCT03645642|EXPERIMENTAL|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
62639875|NCT03645642|ACTIVE_COMPARATOR|Albumin with diuretics|Albumin(20g/l) and diuretics.
62639876|NCT00532545|EXPERIMENTAL|A|Teriparatide
62639877|NCT01816321|EXPERIMENTAL|Corifollitropin alfa followed by hpHMG|
62639878|NCT01816321|ACTIVE_COMPARATOR|recombinant FSH|
62639879|NCT02404051|EXPERIMENTAL|ARM 1|Everolimus plus Exemestane -\> progression disease (PD) -\> fulvestrant (ARM 1)
62071285|NCT06267443|ACTIVE_COMPARATOR|Group 2|in this group after endotracheal intubation bilateral parasternal block will be performed and to the chest tube sides local anesthetic infiltration will be performed
62071286|NCT03462706|EXPERIMENTAL|Cold Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold snare techniques.
62071287|NCT03462706|EXPERIMENTAL|Hot Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot snare techniques.
62071288|NCT03462706|EXPERIMENTAL|Cold EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold EMR techniques.
62071289|NCT03462706|EXPERIMENTAL|Hot EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot EMR techniques.
62071290|NCT02095964||Cardiac Syndrome X|
62071291|NCT02095964||Control Group|
62071292|NCT00986115|ACTIVE_COMPARATOR|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
62639880|NCT02404051|EXPERIMENTAL|ARM 2|Fulvestrant -\> progression disease (PD) -\> everolimus plus exemestane (ARM 2)
62639881|NCT02378389|EXPERIMENTAL|Pyrotinib/Pyrotinib with Docetaxel|Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
62639882|NCT06459310|EXPERIMENTAL|Metformin hydrochloride|1000 mg/day Metformin hydrochloride extended-release tablets
62071293|NCT00986115|PLACEBO_COMPARATOR|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
62071294|NCT04536571|EXPERIMENTAL|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
62071295|NCT04536571|ACTIVE_COMPARATOR|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
62071296|NCT04996199|EXPERIMENTAL|Oxcarbazepine GROUP|Oxcarabazepine 150mg BD starting dose \& will be increased if the patient is not relieved
62454886|NCT00958178|ACTIVE_COMPARATOR|T method of preoxygenation|Tidal breathing of 100% oxygen through a well fitting facemask, for 4 minutes.
62639883|NCT06459310|PLACEBO_COMPARATOR|Placebo group|1000 mg/day placebo
62639884|NCT01231477||Volunteers|Healthy volunteers not submitted to anesthesia nor surgery.
62639885|NCT01231477||Sevoflurane Group|This group was submitted to inhalational anesthesia with sevoflurane and otorhinolaryngological surgery.
62639886|NCT01462630|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62639887|NCT00261755|EXPERIMENTAL|Acupuncture Group|Acupuncture treatment during labor
62639888|NCT00261755|ACTIVE_COMPARATOR|TENS Group|Transcutaneous Electric Nerve Stimulation (TENS treatment)during labor
62639889|NCT00261755|ACTIVE_COMPARATOR|Traditional Group|Traditional pain treatment during labor
62639890|NCT06044103|NO_INTERVENTION|Control|Clinical routine
62639891|NCT06044103|EXPERIMENTAL|Patient-controlled sedation with propofol|PCS group
62639892|NCT02898857||down-staging of a KRAS|Six with demonstrated down-staging of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
62639893|NCT02898857||no down-staging of a KRAS|Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
62639894|NCT02898857||non-staging and triple negative adenocarcinoma|Six with or without non-staging and triple negative adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
62275945|NCT01332071|ACTIVE_COMPARATOR|Avandamet test product|Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2
62275946|NCT01332071|ACTIVE_COMPARATOR|Avandamet reference product|Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2
62275947|NCT01699555|EXPERIMENTAL|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
62275948|NCT01699555|PLACEBO_COMPARATOR|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
62275949|NCT01400451|EXPERIMENTAL|Ipilimumab + Vemurafenib|
62275950|NCT01512264|EXPERIMENTAL|rTMS|3 weeks of nerTMS
62275951|NCT01512264|SHAM_COMPARATOR|1 week of Sham Treatment + 2 weeks of nerTMS|1 week of Sham Treatment + 2 weeks of nerTMS
62639895|NCT02306369|NO_INTERVENTION|Treatment as usual|A wait-list control.
62275952|NCT01512264|SHAM_COMPARATOR|2 weeks of Sham Treatment +1 week of nerTMS|2 weeks of Sham Treatment +1 week of nerTMS
62275953|NCT01512264|PLACEBO_COMPARATOR|Control Group|3 weeks of Sham Treatment
62275954|NCT03132181|EXPERIMENTAL|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
62639896|NCT02306369|EXPERIMENTAL|Internetdelivered exposure-based CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
62639897|NCT01439035|EXPERIMENTAL|MGH OFDI imaging|OFDI imaging
62275955|NCT03132181|PLACEBO_COMPARATOR|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
62639898|NCT01960101|EXPERIMENTAL|Lactoxeros milk product|Patient will take the milk product orally for 14 days as many times as needed per day(but not more than 6 times daily).
62639899|NCT01960101|OTHER|Aequasyal|Patients will take the oral spray for 14 days. The Aequasyal ® Oral Spray is a solution of oxidized glycerol triesters. The oral spray is applied by spraying on the inside of each cheek, 3-4 times per day. After each administration, users are instructed to gently spread the product around the mouth with the tongue. The Aequasyal ® Oral Spray is a Class I medical device, and is CE-marked.
62639900|NCT04581434|EXPERIMENTAL|Trauma-Focused Therapy|Patients randomized to Trauma Focused Therapy will receive either Prolonged Exposure (PE) or Cognitive Processing Therapy (CPT). According to standard VA practice, assignment will be determined according to which trauma-focused therapy the assigned provider is verified to provide; if the assigned therapist is verified in both PE and CPT, the provider will decide which treatment to deliver. PE and CPT are both recommended as frontline treatments by all published PTSD guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted.
62639901|NCT04581434|EXPERIMENTAL|Non-Trauma-Focused Therapy|"Those randomized to non-trauma-focused therapy will receive present centered therapy (PCT). Originally designed as a strong comparator for psychotherapy research that included the components of good therapy, PCT is now a bona-fide PTSD treatment suggested at the second tier in multiple clinical practice guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted."
62639902|NCT05751798|EXPERIMENTAL|OSE-279 100 mg|Dose Level 1: OSE-279 100 mg
62639903|NCT05751798|EXPERIMENTAL|OSE-279 300 mg|Dose Level 2: OSE-279 300 mg
62639904|NCT05751798|EXPERIMENTAL|OSE-279 500 mg|Dose Level 3: OSE-279 500 mg
62071297|NCT04996199|ACTIVE_COMPARATOR|Carbamzepine GROUP|carbamazepine 100mg BD initial dose \& will be increased if the patient is not relieved
62639905|NCT03865030|ACTIVE_COMPARATOR|psoriatic patients|psoriatic patients that are recruited from the dermatology clinic. This arm will undergo audiovestibular evaluation.
62071298|NCT05680675|EXPERIMENTAL|Arm 1|Single-Tracer FDG (F18 Fluorodeoxyglucose) PET/CT exam + Single-Tracer Cu64-DOTATATE PET/CT
62275956|NCT05410288|EXPERIMENTAL|Acu-TENS+SHP|Participants in the Acu-TENS group will receive Acu-TENS coupled with a sleep hygiene program (SHP). 4 weeks and comprise thrice-weekly 30-min sessions.
62275957|NCT05410288|EXPERIMENTAL|acupressure+SHP|The acupressure group will receive acupressure and SHP. 4 weeks and comprise thrice-weekly 30-min sessions.
62071299|NCT05680675|EXPERIMENTAL|Arm 2|Single-Tracer FDG PET/CT exam + Single-Tracer Ga68-DOTATATE PET/CT exam
62275958|NCT05410288|PLACEBO_COMPARATOR|placebo stimulation+SHP|The placebo group will receive a placebo stimulation and SHP. 4 weeks and comprise thrice-weekly 30-min sessions.
62275959|NCT02072031|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62275960|NCT02072031|ACTIVE_COMPARATOR|Sunitinib maleate|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
62275961|NCT04409873|PLACEBO_COMPARATOR|Control (Distilled Water)|Over the counter: Distilled water
62275962|NCT04409873|EXPERIMENTAL|Oral-B Mouth Sore (H2O2) mouthwash|Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)
62275963|NCT04409873|EXPERIMENTAL|Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash|Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)
62071300|NCT05680675|EXPERIMENTAL|Arm 3|Single-Tracer FDG PET/CT exam + Single-Tracer PSMA (prostate-specific membrane antigen) PET/CT exam
62275964|NCT04409873|EXPERIMENTAL|CloSYS (ClO2) mouthwash|Over the counter: CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)
62071301|NCT01002664|ACTIVE_COMPARATOR|MCS-2|Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
62071302|NCT01002664|PLACEBO_COMPARATOR|Placebo|Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
62275965|NCT04409873|EXPERIMENTAL|Listerine Mouthwash|Over the counter: Listerine Zero (Alcohol-Free)(Johnson and Johnson, USA) (C30H52O3)
62275966|NCT03965559||plasmapheresis group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the plasmapheresis during January 2006 to October 2015
62275967|NCT03965559||double filtration plasmapheresis (DFPP) group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the double filtration plasmapheresis (DFPP) during January 2006 to October 2015
62275968|NCT04702165|EXPERIMENTAL|VATS resection with J-bar|Each patient with a lung nodule meeting criteria will undergo a lung resection which could be one of three approaches: iVATS with Dyna-CT, VATS, or open. Each approach will use a the experimental device the Lung Resection Marker Locator Kit
62275969|NCT03899454|EXPERIMENTAL|Extract administration|administration of a mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
62275970|NCT03899454|PLACEBO_COMPARATOR|Control|Placebo
62639906|NCT03865030|ACTIVE_COMPARATOR|healthy volunteers|Healthy volunteers that are members of the hospital staff and will be recruited from the hospital. This arm will undergo audiovestibular evaluation.
62639907|NCT05817162|PLACEBO_COMPARATOR|Placebo Group: PRP|Temporomandibular joint arthrocentesis, Ringer lactate for washing, and 1ml PRP infiltration in each temporomandibular joint
62639908|NCT05817162|ACTIVE_COMPARATOR|PRP + Ropivacaine|Temporomandibular joint arthrocentesis, Ringer lactate for washing, and 1ml PRP + ropivacaine infiltration in each temporomandibular joint
62639909|NCT03561896|EXPERIMENTAL|IGRT|Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
62639910|NCT03561896|EXPERIMENTAL|SRS|Stereotactic Radiosurgery of the resection cavity (SRS)
62071303|NCT02035813|EXPERIMENTAL|Ribociclib in combination with standard endocrine therapy|Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
62071304|NCT02035813|EXPERIMENTAL|Eriubulin|Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
62275971|NCT05256498|EXPERIMENTAL|Amber UI Stimulation|Short-duration pudendal nerve stimulation
62275972|NCT01654510|EXPERIMENTAL|Cognitive Behavioral Therapy Group|
62275973|NCT01654510|ACTIVE_COMPARATOR|Vocational Services as Usual Control|Vocational services typically present in a comprehensive vocational service center.
62071305|NCT01200030|EXPERIMENTAL|electrical stimulation with exercises|The TENS + TRTT group received TENS simultaneously with the TRTT at home under the instruction of a physical therapist.
62071306|NCT01200030|PLACEBO_COMPARATOR|placebo stimulation with exercises|The TENS + TRTT group received placebo-simultaneously with the TRTT at home under the instruction of a physical therapist.
62275974|NCT04372927|EXPERIMENTAL|Treatment (chemotherapy, durvalumab, radiation therapy)|Patients with squamous cell cancer receive standard of care chemotherapy consisting of cisplatin on days 1, 8, 29, and 36, and etoposide on days 1-5 and 29-33. Cycles repeat every 4 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell cancer receive standard of care chemotherapy consisting of cisplatin and pemetrexed on days 1, 22, and 43. Cycles repeat every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. All patients receive durvalumab IV over 1 hour Q4W. Radiation to the primary tumor will be given over 8-15 fractions during weeks 1-3 of chemotherapy. For patients who have residual disease in the mediastinal lymph nodes at week 9, radiation will be given to the lymph nodes starting week 11. Durvalumab is given for 2 years after completion of radiation in the absence of disease progression or unacceptable toxicity.
62275975|NCT01418001|EXPERIMENTAL|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|This will be a multicenter single arm phase IB/II trial to evaluate the clinical safety and efficacy of gemcitabine/docetaxel and pazopanib in the neoadjuvant treatment of soft tissue sarcoma.
62639911|NCT04881344|EXPERIMENTAL|The laser hemorrhoidoplasty (laser group, intervention group)|
62639912|NCT04881344|ACTIVE_COMPARATOR|The hemorrhoidopexy (mucopexy group, control group)|
62639913|NCT02548377|EXPERIMENTAL|Remote ischemic preconditioning|Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.
62639914|NCT02548377|SHAM_COMPARATOR|Sham|The tourniquet will be attached to the patient's upper extremity but never inflated.
62639915|NCT00457730|EXPERIMENTAL|Duloxetine|subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
62639916|NCT00457730|PLACEBO_COMPARATOR|placebo|matched placebo medication
62071307|NCT01200030|NO_INTERVENTION|Control|Subjects in this group did not receive any active training. Home safety advice and health education including diet control and blood pressure monitoring were given to the subjects during the home-visit and telephone follow-up.
62275976|NCT06549569||TFS|thermal burn coverage with Tilapia fish skin
62639917|NCT05192265|EXPERIMENTAL|Pyramax™|Artesunate-pyronaridine is indicated for the blood-stage treatment of the two dominant strains of malaria: P. falciparum and P. vivax. The medicine is also available in a child-friendly granule formulation to enhance palatability in this vulnerable population. Dosing was administered according to body weight: 5 - \<8kg - one sachet daily for 3 days; 8 - \<15Kg - two sachets daily for 3 days; 15 - \<20 Kg - three sachets daily for 3 days; 20 - \<24 Kg - one tablet daily for 3 days; and 24 - \<45 Kg - two tablets daily for 3 days.
62639918|NCT05192265|ACTIVE_COMPARATOR|Coartem™|"We used the standard six-dose regimen of artemether-lumefantrine dispersible tablets twice daily according to body weights. Each dispersible tablet contains 20mg of artemether/120mg of lumefantrine) and the patients were dosed as follows: 5 -\<15Kg one tablet, 15 - \<25 Kg two tablets, 25 - \<35 Kg three tablets, and ≥35 Kg four tablets at the following dosing intervals:~* 0 hour - 1st dose;~* 8 hours - 2nd dose;~* 24 hours - 3rd dose;~* 36 hours - 4th dose;~* 48 hours - 5th dose~* 60 hours - 6th dose."
62639919|NCT02670369|EXPERIMENTAL|Sitting time prompt|All participants will receive a prompting device (one-arm intervention).
62071308|NCT03672513|PLACEBO_COMPARATOR|Placebo Supplemented Group|Placebo control
62071309|NCT03672513|EXPERIMENTAL|Magnesium Supplemented Group|Magnesium Group
62071310|NCT03672513|EXPERIMENTAL|Zinc Supplemented Group|Zinc Group
62071311|NCT04337060|ACTIVE_COMPARATOR|Group LB|Ultrasound-guided bilateral erector spinae plane block (10 ml 1% lidocaine + 10 ml 0.5% bupivacaine) + intravenous morphine patient-controlled analgesia.
62071312|NCT04337060|SHAM_COMPARATOR|Group S|Ultrasound-guided bilateral erector spinae plane block. block (20 ml Normal Saline) + intravenous morphine patient-controlled analgesia.
62071313|NCT01278108|EXPERIMENTAL|1|single ascending doses
62071314|NCT01278108|PLACEBO_COMPARATOR|2|single dose placebo
62275977|NCT06549569||regular dressing|thermal burn coverage with regular dressing
62275978|NCT03981783|ACTIVE_COMPARATOR|Best available care (BAC)|
62275979|NCT03981783|EXPERIMENTAL|Telerehabilitation (TH)|
62639920|NCT03440619|EXPERIMENTAL|INVSENSOR00013 Test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00013 investigational device.
62071315|NCT01278108|EXPERIMENTAL|3|multiple dose, 7 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
62071316|NCT01278108|PLACEBO_COMPARATOR|4|multiple dose, capsules, 7 days; scheme to match that of Study Arm 3.
62071317|NCT03847623|EXPERIMENTAL|Curcumin|Capsules, taken orally, 8g per day (Bi-daily dosing)
62071318|NCT03847623|PLACEBO_COMPARATOR|Placebo|Capsules, taken orally, bi-daily dosing
62071319|NCT03550586||Parturients suffering from a PDPH|Parturients suffering form a PDPH following an accidental dural puncture between the years 2007-2017 will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
62088333|NCT03112122|ACTIVE_COMPARATOR|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
62275980|NCT01763450|EXPERIMENTAL|Bevacizumab plus chemotherapy|"1. Bevacizumab:~   7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~2. Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~3. Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
62639921|NCT00164138|EXPERIMENTAL|Pelvic Floor Training Group|Pelvic floor training, biofeedback.
62639922|NCT04585802||Suicide Attempters (1)|patients with a suicide attempt
62088334|NCT03112122|EXPERIMENTAL|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
62275981|NCT03602079|EXPERIMENTAL|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
62275982|NCT03602079|EXPERIMENTAL|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
62275983|NCT03602079|EXPERIMENTAL|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
62275984|NCT03602079|EXPERIMENTAL|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
62275985|NCT03602079|EXPERIMENTAL|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
62275986|NCT02799680|EXPERIMENTAL|allogeneic CART-33|infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
62275987|NCT05530993||Have considered use of PrEP|
62275988|NCT05530993||Have not considered use of PrEP|
62275989|NCT03770065||Group A|
62275990|NCT03770065||Group B|
62639923|NCT04585802||Suicide Ideators (2)|patients with suicidal ideation
62639924|NCT04585802||Clinical Control Group (3)|patients without suicide attempt and without suicide ideation
62275991|NCT04783636|OTHER|A|After a single administration of PT105R (leuprorelin acetate 3.75mg), a single administration of PT105 (leuprorelin acetate 3.75mg)
62275992|NCT04783636|OTHER|B|After a single administration of PT105 (leuprorelin acetate 3.75mg), a single administration of PT105R (leuprorelin acetate 3.75mg)
62639925|NCT04585802||Healthy Control Group (4)|persons without suicide attempt and without suicide ideation, who do not have a psychiatric disorder
62639926|NCT03498521|EXPERIMENTAL|Molecularly-Guided Therapy|Participants will be assigned to molecularly-guided therapy based on genomic profile.
62088335|NCT03112122|EXPERIMENTAL|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
62275993|NCT01975012|EXPERIMENTAL|Cohort 1: 6 to less than 12 years of age|Participants in this arm will be at least 6 but younger than 12 years of age; they will receive the study drug RPV together with 2 other NRTIs.
62275994|NCT01975012|EXPERIMENTAL|Cohort 2: 2 to less than 6 years of age|Participants in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug RPV together with 2 other NRTIs.
62275995|NCT02490085|ACTIVE_COMPARATOR|Multiple daily injections|Subjects will use multiple daily injections to regulate glucose levels. Subject's usual insulin analog will be used.
62639927|NCT03498521|ACTIVE_COMPARATOR|Platinum-Based Chemotherapy|Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).
62639928|NCT03165773|EXPERIMENTAL|Oatmeal|87 grams oatmeal
62639929|NCT03165773|ACTIVE_COMPARATOR|Corn grits|67 grams corn grits
62639930|NCT05191966|ACTIVE_COMPARATOR|Group S-QLB3|S-QLB3 block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
62639931|NCT05191966|ACTIVE_COMPARATOR|Group TPVB|TPVB block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
62639932|NCT01205347|EXPERIMENTAL|Simvastatin 80mg|Simvastatin 80mg once a day
62639933|NCT01205347|ACTIVE_COMPARATOR|Simvastatin 10mg|Simvastatin 10mg once a day
62639934|NCT05181098||Robotic-guided surgery group|Any pediatric, adolescent or adult patient undergoing robotic-guided spine surgery, ages 12-80.
62639935|NCT04940156|OTHER|Patients implanted with the Abbott Confirm Rx ICM|Patient with cardiac implantable electronic devices with an atrial lead will have Confirm Rx Implantable Cardiac Monitor injected in the anterior chest wall.
62639936|NCT04940156|OTHER|Patients implanted with the Medtronic LINQ ICM|Patient with cardiac implantable electronic devices with an atrial lead will have LINQ Implantable Cardiac Monitor injected in the anterior chest wall.
62275996|NCT02490085|ACTIVE_COMPARATOR|Closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
62275997|NCT02163174|ACTIVE_COMPARATOR|Pentoxyfilline arm|Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
62275998|NCT02163174|PLACEBO_COMPARATOR|Placebo arm|Intravenous saline as a Placebo 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
62275999|NCT00393874|ACTIVE_COMPARATOR|Medication|Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
62276000|NCT00393874|ACTIVE_COMPARATOR|Behavioral|"Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES)."
62276001|NCT00393874|PLACEBO_COMPARATOR|Placebo|Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.
62276002|NCT03584867|EXPERIMENTAL|study Group|refresher CPR
62639937|NCT03946059|EXPERIMENTAL|iTBS then cTBS|"Participants in this arm first receive the iTBS brain stimulation in week 1, then have a one-week washout period and then receive cTBS brain stimulation in week 2.~intermittent Theta-Burst-Stimulation (iTBS) entails a 2 second train of stimuli (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). Each 2 second train is followed by an 8 second pause, followed by another 2 second train. In total, 20 trains will be delivered, for a total of 200 bursts and 600 total pulses.~continuous Theta-Burst-Stimulation (cTBS) consists of a continuous stimulus train (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). In total, 200 bursts and 600 total pulses will be delivered."
62639938|NCT03946059|EXPERIMENTAL|cTBS then iTBS|Participants in this arm first receive the cTBS brain stimulation in week 1, then have a one-week washout period and then receive iTBS brain stimulation in week 2.
62639939|NCT03374839|EXPERIMENTAL|TIL + IL-2 + Nivolumab|"A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.~For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL."
62639940|NCT04703985||Patients under the protocol of Enteral Nutrition|Patients put under the protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
62088336|NCT04420689|EXPERIMENTAL|Dose Escalation/De-Escalation Cohorts|This arm of the study will include Dose Escalation/De-Escalation cohorts of ALM-488.
62071320|NCT03550586||Parturients not suffering from a PDPH|This group will consistent of a control group of women receiving epidural analgesia on the same day as those women who suffered an ADP. This participants will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
62071321|NCT00944281|EXPERIMENTAL|LNS-Zn5|Daily intake of 20 g LNS containing 5 mg of zinc and a daily placebo supplement
62071322|NCT00944281|EXPERIMENTAL|LNS-Zn10|Daily intake of 20 g LNS containing 10 mg of zinc and a daily placebo supplement
62071323|NCT00944281|PLACEBO_COMPARATOR|LNS-Zn0|Daily intake of 20 g LNS containing 0 mg of zinc and a daily placebo supplement
62071324|NCT00944281|EXPERIMENTAL|Suppl-Zn5|Daily intake of zinc supplement containing 5 mg of zinc and 20 g LNS containing 0 mg of zinc
62071325|NCT00944281|NO_INTERVENTION|Delayed intervention group|Standard care from age 8 to 18 months. Daily consumption of LNS from age 18 to 28 months.
62071326|NCT00325936|ACTIVE_COMPARATOR|Nifedipine|parrallel design
62071327|NCT00325936|EXPERIMENTAL|Cilnidipine|
62071328|NCT05854212|EXPERIMENTAL|Behavioral economics-enhanced user interface|Food agencies will see the behavioral economics (BE)-enhanced interface by default; food items will be sorted with green-labeled items listed first, followed by yellow, then red. If users search for a specific item type (e.g., chicken) the results returned for that item type will also be sorted so that green-labeled items are listed first. At any time during the ordering episode, users will have the option to switch from the BE-enhanced default to an alternate sorting or filtering choice, such as alphabetical or cost. Users will be shown the percent of items (by weight) that are labeled green in a prominent location on the ordering screen. The percent green-labeled items in the order will appear alongside messaging reporting the average percent green-labeled items ordered by GBFB pantries that rank in the top 10% based on this metric.
62071329|NCT05854212|NO_INTERVENTION|Usual user interface|When agency staff log on to the food bank platform, by default, foods are listed in alphabetical order. If they wish, users can change how items are sorted or filtered using pull-down menus and check-boxes, including the ability to have items sorted or filtered based on traffic light labels. As orders are created, an information section at the top of the page is updated with details on the order weight and cost.
62088337|NCT04420689|EXPERIMENTAL|Dose Timing Cohorts|This arm of the study will include Dose Timing cohorts of ALM-488.
62071330|NCT01414413|EXPERIMENTAL|Home assessment and initiation of ART|"Participants with a positive home-based HIV test result will receive a home visit from a study nurse who will complete the following on the first home visit:~* Confirmatory fingerprick HIV testing~* TB symptom screening~* ART eligibility assessment (Word Health Organization clinical staging, sampling of blood for measurement of CD4 count and treatment education)~At a second home visit (within 5 days), participants who are ART eligible (as defined in National ART guidelines) will be initiated onto ART (using National Treatment Programme ART regimens).~Following home initiation of ART, participants in the intervention arm will receive detailed counselling from the study nurse about the need to attend their first 2-week follow-up appointment at the primary health care clinic that serves their household's residence. They will receive a referral slip detailing the date, time and place of their appointment."
62071331|NCT01414413|OTHER|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor. HIV care, including ART, will be started from the primary care clinic.
62071332|NCT06624501||Children and adults|Children with symptoms of TB and adults with smear-positive or smear-negative pulmonary TB.
62071333|NCT04299477|EXPERIMENTAL|Patients with periodontitis and osteoporosis|Group 1 : Patients who have periodontitis and osteoporosis prescribed with bisphosphonates
62071334|NCT04299477|EXPERIMENTAL|Systemically healthy patients with periodontitis|Group 2: Patients who have no systemic diseases but diagnosed as periodontitis
62071335|NCT04299477|NO_INTERVENTION|Systemically and periodontally healthy individuals|Group 3: Healthy controls
62071336|NCT02947698||Acute kidney injury patients admitted on weekday|All patients with acute kidney injury requiring dialysis admitted on week day (Monday to Friday) between 1st April 2003 and 31st March 2015
62071337|NCT02947698||Acute kidney injury patients admitted on weekend|All patients with acute kidney injury requiring dialysis admitted on weekend (Saturday or Sunday) between 1st April 2003 and 31st March 2015
62071338|NCT00575068|EXPERIMENTAL|1|
62071339|NCT06072820|OTHER|Research Planning|"Study population will be composed of subject with a confirmed or ruled-out diagnosis of endometriosis. The subject diagnosis could be ascertained through imaging and/or surgery with or without biopsies.~After a first assessment during a routing care visit, the subject will be asked to come back for a day, or half a day depending on the impact of the circadian cycle."
62071340|NCT01317290|EXPERIMENTAL|linseed oil; young|ALA rich linseed oil to younger subjects (18-35 years)
62071341|NCT01317290|EXPERIMENTAL|linseed oil; older|ALA rich linseed oil to older, normalweight subjects (BMI \<25, age 49-69 years)
62071342|NCT01317290|EXPERIMENTAL|linseed oil older, overweight|ALA-rich linseed oil to older, normalweight subjects (BMI \>25, age 49-69 years)
62071343|NCT01317290|EXPERIMENTAL|olive oil|n3-PUFA free control oil to normalweight subjects (BMI \<25)
62088338|NCT01454856||Surgical cancer patients|No modification of the treatment
62276003|NCT03584867|NO_INTERVENTION|control|NO refresher
62639941|NCT02740842|ACTIVE_COMPARATOR|Non-intensive group|Essential Health Care (EHC) only This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
62639942|NCT02740842|EXPERIMENTAL|Intensive group|"Interpersonal behavioral change communication This arm will have a behavior change communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.~In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm."
62071344|NCT05009706|EXPERIMENTAL|Self Care group|Patients who are randomized to the intervention Self Care group will get advice and support on physical excercise, nutrition and symptom management to perform at home for 12 weeks. Once a week, patients will come to the hospital for follow-up and to exercise with a physiotherapist.
62071345|NCT05009706|NO_INTERVENTION|Control group|Patients who are randomized to the Control group will receive ordinary health care (from an outpatient clinic), but will also be encouraged to follow recommendation of 150 minutes/week of moderate physical activity (12 weeks). To compensate for the extra attention received by the intervention group by the advice/support, the patients in the control group will be dialed with a nurse at 3, 6 and 9 weeks to discuss their current activity.
62639943|NCT04265521|EXPERIMENTAL|Biocool Footcare|"Treatment regime:~During week 1: Once daily for 7 days (7 doses) During week 2 and 3: Once every second day for 14 days (7 doses)"
62639944|NCT02410408|ACTIVE_COMPARATOR|Control|Information package about patient safety certification or how to conduct Root Cause Analysis
62639945|NCT02410408|EXPERIMENTAL|Experimental|Apps: Root Cause Analysis or patient safety ISO certification
62071346|NCT02390843|EXPERIMENTAL|simvastatin + topotecan/cyclophosphamide|During dose escalation (phase I), standard 3+3 design will be followed.
62639946|NCT01153919|ACTIVE_COMPARATOR|Arm I|Patients receive romiplostim subcutaneously once weekly for 8 weeks in the absence of disease progression or unacceptable toxicity.
62639947|NCT01153919|PLACEBO_COMPARATOR|Arm II|Patients receive placebo subcutaneously once weekly for 8 weeks. Patients failing to achieve a platelet count of \&gt; 100,000/L cross over to arm I.
62639948|NCT03856372|EXPERIMENTAL|Hypofractionated|42.5 Gy / 16 fractions, 2.66 Gy per fraction, 5 fractions weekly
62639949|NCT03856372|ACTIVE_COMPARATOR|Conventional|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
62639950|NCT00898430||Head and neck squamous cell carcinoma patients (HNSCC)|
62639951|NCT05944575|ACTIVE_COMPARATOR|Active Intervention|Participants will self-administer active taVNS for 30 min per day for 7 days.
62071347|NCT00561444||Quality of Life Study|Prostate cancer patients
62071348|NCT01200537|ACTIVE_COMPARATOR|Estradiol Patch|This group of patients will receive estradiol patches prior to the IVF cycle.
62071349|NCT01200537|ACTIVE_COMPARATOR|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
62639952|NCT05944575|SHAM_COMPARATOR|Sham Intervention|Participants will self-administer sham-taVNS for 30 min per day for 7 days.
62071350|NCT01267591||control|
62071351|NCT01267591||type 1 diabetes|
62071352|NCT01267591||obesity|
62071353|NCT06437730|EXPERIMENTAL|Group: 1|MTrPs points will be released with ischemic compression, position of ease will be acquired, and in the last METs will be performed. Ischemic compression applied through thumb on trigger point present in any muscle around the knee joint.
62276004|NCT04927728|EXPERIMENTAL|Audio MP|Participants of the audio mental practice (MP) group will complete MP via audio-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
62276005|NCT04927728|EXPERIMENTAL|Video MP|Participants of the video mental practice (MP) group will complete MP via video-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
62276006|NCT04927728|EXPERIMENTAL|Repetitive-Task Practice|Participants of the repetitive-task practice group will complete repetitive practice of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each participant completed at least 20 repetitions of the task.
62071354|NCT06437730|EXPERIMENTAL|Group: 2|Dry needle will be targeting trigger points (TrPs) using in-and-out techniques such as 'pistoning' or 'sparrow pecking'. 0.25x25mm needle is inserted.
62071355|NCT02887417||patients|glioblastoma patients
62071356|NCT02887417||controls|healthy controls
62276007|NCT04927728|ACTIVE_COMPARATOR|Traditional Therapy|The control group received traditional occupational therapy stroke rehabilitation.
62276008|NCT00702078|OTHER|usual care|follow-up according to todays best practice.
62276009|NCT00702078|EXPERIMENTAL|cooperation|Follow-up from the hospital and the primary healthcare in cooperation
62276010|NCT00931398|EXPERIMENTAL|Methylphenidate HCl (Concerta)|
62639953|NCT01991964|EXPERIMENTAL|laryngeal ultrasound stridor|During the study period, infants referred for FLB and bronchoscopy due to congenital stridor at the Department of Pediatric Pulmonology, Critical Care and Sleep Medicine at the Tel Aviv Sourasky Medical Centre will undergo an awake US of the larynx prior to performing the Flexible bronchoscopy.
62071357|NCT04048252||Focus group|
62071358|NCT04048252||Workshop|
62088339|NCT01454856||Non-surgical cancer patients|No modification of the treatment
62088340|NCT01454856||Surgical non-cancer patients|No modification of the treatment
62088341|NCT01454856||Non-surgical non-cancer patients|No modification of the treatment
62088342|NCT02259920|ACTIVE_COMPARATOR|Treatment A|KUC 4783 CL, immediate release tablets
62088343|NCT02259920|EXPERIMENTAL|Treatment B|KUC 4783 CL delivered as a particulate formulation to the distal small bowel
62088344|NCT02259920|EXPERIMENTAL|Treatment C|KUC 4783 CL delivered as a particulate formulation to the ascending colon
62276011|NCT00931398|PLACEBO_COMPARATOR|Placebo|
62276012|NCT03870555|EXPERIMENTAL|Sequence 1|"Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
62071359|NCT02153359|EXPERIMENTAL|Air cleaner then sham air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the experimental arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the sham comparator arm.
62071360|NCT02153359|SHAM_COMPARATOR|Sham air cleaner then air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the sham comparator arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the experimental arm.
62071361|NCT00412035|ACTIVE_COMPARATOR|Botox|Botulinum toxin A injection
62071362|NCT00412035|PLACEBO_COMPARATOR|Placebo|saline injection
62071363|NCT00749801|ACTIVE_COMPARATOR|A|nattokinase-mono formula (3500FU)
62071364|NCT00749801|EXPERIMENTAL|B|Nattokinase compound-multiple formulae
62639954|NCT01991964|OTHER|laryngeal ultrasound -control|Infants matched for age referred for flexible bronchoscopy for reasons other than stridor will undergo an awake US of the larynx.
62071365|NCT00749801|PLACEBO_COMPARATOR|C|Placebo
62088345|NCT02259920|EXPERIMENTAL|Treatment D|KUC 4783 CL delivered as a solution formulation to the ascending colon
62639955|NCT04622566|EXPERIMENTAL|Lenvatinib and Pembrolizumab in Resectable mucosal Melanoma.|
62071366|NCT03585491|EXPERIMENTAL|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
62276013|NCT03870555|EXPERIMENTAL|Sequence 2|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
62276014|NCT03870555|EXPERIMENTAL|Sequence 3|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period."
62276015|NCT00060346|EXPERIMENTAL|Rituximab + CHOP|"Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by:~Cyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily"
62276016|NCT03719157|ACTIVE_COMPARATOR|Unilateral ESP Block|Before general anaesthesia, Ultrasound guided unilateral ESP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
62276017|NCT03719157|ACTIVE_COMPARATOR|Unilateral OSTAP block|Under general anaesthesia, Ultrasound guided unilateral OSTAP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
62287167|NCT01814787|EXPERIMENTAL|CHICA Type 2 Diabetes Module|Children treated at the two intervention clinic sites will have be treated using the CHICA system AND will be provided access to the newly developed CHICA Type 2 Diabetes Module. The CHICA Type 2 Diabetes Module will assist pediatricians in identification of those children 10 years of age or older who are at increased risk for type 2 diabetes, it will provide pediatric physicians guidelines to screen for type 2 diabetes, and it will coordinate the diagnosis and long-term management of the condition.
62454887|NCT03256110|EXPERIMENTAL|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
62454888|NCT03256110|NO_INTERVENTION|Control|Patients and providers in this arm receive usual care.
62071367|NCT03585491|EXPERIMENTAL|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
62071368|NCT00291655|EXPERIMENTAL|Levetiracetam (LEV)|
62639956|NCT04817306||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
62276018|NCT03719157|ACTIVE_COMPARATOR|Injection of Local Anesthetic to Trocar Insertion|After the laparoscopic surgery was completed, the trocar incision sites were closed. Following the infiltration rules, local anesthetic (15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine) was applied to the trocar sites of skin, fascia, muscle, and preperitoneal area by the surgical team after the operation. A total of 20 mL of local anesthetic was used, with 6 mL for trocar sites of 10 mm, and 4 mL for trocar sites of 5 mm .Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
62276019|NCT03719157|SHAM_COMPARATOR|multimodal analgesia|Perioperative and postoperative routine analgesic protocol will be performed with no additional regional anesthesia method.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
62276020|NCT01857869|EXPERIMENTAL|GSK257049-0,1,7M Group|Subjects receiving 2 doses of GSK257049 vaccine given at 0 and 1 months and followed 6 months later (At Month 7) by another dose of GSK257049 vaccine.
62276021|NCT01857869|EXPERIMENTAL|GSK257049-0,1,2M Group|Subjects receiving 3 doses of GSK257049 vaccine given one month apart (0,1 and 2 months).
62276022|NCT01857869|EXPERIMENTAL|Infectivity Control Group|Volunteers who did not receive any immunization but underwent sporozoite challenge
62276023|NCT03984058|OTHER|Study Arm 1|All enrolled participants will have participants' PAP usage monitored by Fusion Health using the ResMed AirView Remote Monitoring system. Fusion Health will provide individual care for each participant by monitoring daily PAP usage by all study participants. This assessment ensures routine follow-up of PAP adherence during the study. The responsibility for patient care during the study, however, will fall on clinical site staff with any needed assistance by the Fusion Health staff. An intervention will be required when PAP adherence decreases or if any other issues are identified that require a face-to-face visit.
62276024|NCT00866138|EXPERIMENTAL|1|masitinib (AB1010)
62276025|NCT02740478||Volunteers|20 volunteer subjects, no selection criteria
62276026|NCT04072458|EXPERIMENTAL|BP1002 monotherapy|L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m\^2.
62276027|NCT04340973|ACTIVE_COMPARATOR|Anodal|Anodal tDCS: Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
62276028|NCT04340973|ACTIVE_COMPARATOR|Bilateral|Bilateral : Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation, 5 days a week for 4 weeks
62276029|NCT04340973|ACTIVE_COMPARATOR|Cathodal|Cathodal : Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
62276030|NCT04340973|ACTIVE_COMPARATOR|Extracephalic|Extracephalic : Anode placer over the affected primary motor cortex, cathode over right shoulder. 2 mA, 20min stimulation, 5 days a week for 4 weeks
62639957|NCT04817306||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
62639958|NCT04817306||Non-tumor (Healthy) Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
62639959|NCT04421040|EXPERIMENTAL|Biomonitor 3|Placement of Biotronik Biomonitor 3 Device for a 6 month period. After the 6 month monitoring period, the patient will have the Biotronik Biomonitor 3 device removed.
62276031|NCT04340973|PLACEBO_COMPARATOR|Placebo|Placebo : anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
62276032|NCT06025435|EXPERIMENTAL|SAIA-SSP-HIV|SAIA-SSP-HIV is an intervention that facilitates an organizational, SSP-level analysis of the delivery of HIV services by assigning a trained SAIA specialist to apply tools and techniques and engage staff to define barriers, identify solutions, and evaluate their success in cycles until achieving desired change regarding HIV service delivery. The scientific premise of this RCT is that SAIA will effectively boost and extend HIV service delivery cascades within SSPs assigned to the SAIA-SSP-HIV intervention condition (relative to IAU). SAIA specialists will meet with SSP staff biweekly for the first 3 months and then once monthly for the remaining 9 months during the 12-month intervention period.
62276033|NCT06025435|NO_INTERVENTION|Implementation as usual|SSPs randomized to the IAU arm will not receive support from a SAIA specialist. Though many SSPs in the US already offer HIV services, the investigators are testing the ability of SAIA-SSP-HIV to optimize the delivery of HIV services within SSPs. As such, the IAU condition is characterized by the absence of SAIA-SSP-HIV with the goal of comparing whether SAIA-SSP-HIV improves SSPs' HIV service delivery cascades.
62639960|NCT01721538|EXPERIMENTAL|Therapy arm|Non-drug therapeutic weight reduction program (15 weeks)
62639961|NCT01721538|PLACEBO_COMPARATOR|Control arm|Lecture on healthy nutrition (1 hour)
62639962|NCT02299440|EXPERIMENTAL|Ketamine|"Patients randomized to this group will be treated via Ketamine infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions"
62639963|NCT02299440|PLACEBO_COMPARATOR|Placebo/Control|"Patients randomized to this group will be treated via saline solution infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions"
62639964|NCT01505777|EXPERIMENTAL|Probiotics(Medirac) 10/mosapride 10mg|
62639965|NCT01505777|EXPERIMENTAL|Probiotics(Medirac) 15/mosapride 10mg|
62639966|NCT01505777|EXPERIMENTAL|Probiotics(Medirac) 15/mosapride 15mg|
62639967|NCT01505777|EXPERIMENTAL|Probiotics(Medirac) 30/mosapride 15mg|
62639968|NCT01505777|PLACEBO_COMPARATOR|Probiotics(Medirac) placebo/mosapride placebo|
62639969|NCT01765296|ACTIVE_COMPARATOR|Celecoxib|Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
62639970|NCT01765296|PLACEBO_COMPARATOR|Placebo|Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
62276034|NCT04568226|EXPERIMENTAL|ConquerFear Intervention|Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.
62639971|NCT01765296|EXPERIMENTAL|CG100649|CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)
62639972|NCT04210986|EXPERIMENTAL|Fisetin|Fisetin 100 mg capsules (\~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
62276035|NCT04568226|ACTIVE_COMPARATOR|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.
62276036|NCT02942667||Subjects undergoing high quality MRI Scans|
62276037|NCT01558362|EXPERIMENTAL|123I-CMICE-013|Administration and analysis of alternative MPI radiotracer
62639973|NCT04210986|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
62639974|NCT06470490|EXPERIMENTAL|a psychoeducational program and relaxation training|a psychoeducational program and relaxation training
62276038|NCT06539546|EXPERIMENTAL|Yttria stabilized multilayered (YML) zirconia restorations|Full coverage Yttria stabilized multilayered (YML) zirconia restorations will be fabricated on a tooth requiring full coverage in the esthetic zone.
62276039|NCT06539546|EXPERIMENTAL|Lithium disilicate restorations|Full coverage Lithium disilicate restorations will be fabricated on a tooth requiring full coverage in the esthetic zone.
62276040|NCT01237366|EXPERIMENTAL|Reslient Affective Processing Therapy (RAPT)|
62276041|NCT01237366|NO_INTERVENTION|Attention-Control|Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
62276042|NCT04031703|EXPERIMENTAL|6 cycles of PC adjuvant chemotherapy|6 cycles of PC (Paclitaxel 80 mg/m2 ivgtt d1,8,15+ Carboplatin Auc = 2 ivgtt d1,8,15, 28 days per cycle).
62639975|NCT06470490|NO_INTERVENTION|routine care without the psychoeducational program|routine care without the psychoeducational program
62639976|NCT03028142|EXPERIMENTAL|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
62639977|NCT03028142|EXPERIMENTAL|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
62639978|NCT03028142|PLACEBO_COMPARATOR|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
62639979|NCT03160716|OTHER|Treatment|
62276043|NCT04031703|ACTIVE_COMPARATOR|3 cycles of FEC followed by 3 cycles of Docetaxel|3 cycles of FEC (epirubicin100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
62454889|NCT05889871|EXPERIMENTAL|Standard endocrine therapy plus Apatinib|5 to 10 years of endocrine therapy (e.g., aromatase inhibitors, tamoxifen, LHRH agonists, etc.) and 2 years of CDK4/6 inhibitors, depending on clinical indications. plus Apatinib, 250mg orally once a day;
62639980|NCT00870454|EXPERIMENTAL|001|Carisbamate 800 mg/d 200 mg/d twice daily titrated up to 400 mg twice daily as tolerated by Week 3
62639981|NCT00870454|EXPERIMENTAL|002|Carisbamate 1 200 mg/d 200 mg/d twice daily titrated up to 600 mg twice daily as tolerated by Week 3
62639982|NCT00870454|ACTIVE_COMPARATOR|003|Pregabalin 300 mg/d 75 mg/d twice daily for Week 1 followed by 150 mg twice daily for the remainder
62639983|NCT00870454|PLACEBO_COMPARATOR|004|Placebo Placebo capsules twice daily
62639984|NCT00999505|ACTIVE_COMPARATOR|Amantadine|Amantadine 200mg twice a day
62639985|NCT00999505|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice a day
62639986|NCT01150630|EXPERIMENTAL|adjuvant PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
62454890|NCT05889871|ACTIVE_COMPARATOR|Standard endocrine therapy|5 to 10 years of endocrine therapy (e.g., aromatase inhibitors, tamoxifen, LHRH agonists, etc.) and 2 years of CDK4/6 inhibitors, depending on clinical indications.
62639987|NCT01150630|EXPERIMENTAL|perioperative PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
62639988|NCT01150630|ACTIVE_COMPARATOR|Adjuvant Gemcitabine|Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months
62639989|NCT02360514|EXPERIMENTAL|hantaan virus vaccine|
62639990|NCT04241549|EXPERIMENTAL|Part 1 (Dose Finding): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
62639991|NCT04241549|EXPERIMENTAL|Part 2 (Dose Expansion): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) will receive cusatuzumab intravenously (IV) at the recommended Phase 2 dose (RP2D) determined in Part 1 in combination with azacitidine subcutaneously (SC) or IV.
62639992|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
62639993|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
62071369|NCT05716841|NO_INTERVENTION|Control Group|It was treated with stretching and simple baseline strengthening of the upper limb through any regular mean (like TheraBand) in a moderate manner with 10 to 20 repetitions for 3 days per week for six weeks.
62088346|NCT02259920|EXPERIMENTAL|Treatment E|KUC 4783 CL delivered as a solution formulation to the descending colon
62088347|NCT01725997|ACTIVE_COMPARATOR|Operative treatment|Operative treatment with hook plate.
62088348|NCT01725997|ACTIVE_COMPARATOR|Conservative treatment|Physiotherapy
62276044|NCT03423342|EXPERIMENTAL|Nicotinamide Riboside|Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
62276045|NCT03423342|PLACEBO_COMPARATOR|Placebo|Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
62276046|NCT04743557|EXPERIMENTAL|Cohort 1|Weekly infusions of DYN101 at the starting dose level
62639994|NCT04263259|EXPERIMENTAL|Attentional Bias Modification|Participants complete attentional bias modification using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
62639995|NCT04263259|NO_INTERVENTION|Attentional Bias Control|Participants complete attentional bias assessment-only using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
62088349|NCT03914339|EXPERIMENTAL|Test group|Eighteen periodontally compromised patients who will be given both orthodontic and periodontal treatment .
62276047|NCT02173795|EXPERIMENTAL|Berodual® Respimat® - Berodual® MA HFA|"randomized sequence~1. Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)~2. Berodual® MA HFA (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per puff for 49 days)"
62276048|NCT01228123|ACTIVE_COMPARATOR|CVVH arm|
62276049|NCT01228123|ACTIVE_COMPARATOR|IHD arm|
62454891|NCT03296475|EXPERIMENTAL|Midline Ventral Hernia|"Main inclusion criteria:~* Patients with midline hernia defects.~* Patients with either a maximal ventral hernia axial width of greater than 5cm or a loss of domain of greater then 20%.~* Patients aged ≥ 18 years old.~* Midline hernias closed in the midline with primary fascial closure with or without mesh augmentation.~* Midline ventral hernias of VHWG grade 2 or 3."
62454892|NCT00543309|EXPERIMENTAL|I- nesiritide|Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
62639996|NCT05581147||Klinefelter syndrome|Males affected by 47,XXY non-mosaic Klinefelter syndrome. Subgroups according to pubertal stage: pre-pubertal, pubertal and adults. Subgroups according to gonadal status: eugonadal, hypogonadal and receiving testosterone replacement therapy (TRT).
62639997|NCT05581147||Healthy controls|Euthyroid, age- and pubertal stage-matched males Subgroups according to pubertal stage: pre-pubertal, pubertal and adults.
62639998|NCT05581147||Chronic lymphocytic thyroiditis|Adult males affected by chronic lymphocytic thyroiditis
62639999|NCT05023122|EXPERIMENTAL|vitamin D3 + calcium|vitamin D3 (cholecalciferol) 800 IU QD and calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
62640000|NCT05023122|ACTIVE_COMPARATOR|calcium only|only calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
62640001|NCT01316718|EXPERIMENTAL|Mesalazine Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
62640002|NCT01316718|PLACEBO_COMPARATOR|Placebo Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
62071370|NCT05716841|EXPERIMENTAL|Experimental group|This experimental group was treated with stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30 sec gap between sets, 3 sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
62071371|NCT01536145|EXPERIMENTAL|Single agent CP-751,871|dose escalation design
62071372|NCT03942913||dual therapy|including 1 antiplatelet treatment aspirin or clopidogrel associated with 1 anticoagulant treatment VKA or NOAC.
62071373|NCT03942913||triple therapy|"including 2 antiplatelet treatments (aspirin and clopidogrel) associated with 1 anticoagulant treatment VKA or NOAC.~In VKA class, 2 different drugs are commonly prescribed: warfarin and fluidinione. In NOAC class, 3 different drugs are commonly prescribed: rivaroxaban, apixaban, dabigatran."
62071374|NCT00012181|EXPERIMENTAL|Treatment (alvocidib)|Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62071375|NCT06108089||patients treated with CRT|Two hypoxia MR scans will be performed, one at pre-treatment and one at 2 weeks into CRT. Patients receive FMISO-PET/CT scans prior to the initiation of CRT.
62071376|NCT06108089||patients treated with primary surgical resection.|Hypoxia MR scan and FMISO-PET/CT scan will be performed prior to the treatment (surgery). Surgical specimen of excised primary tumor will undergo IHC staining.
62071377|NCT00350701|EXPERIMENTAL|androgel 5g|androgel 5g
62640003|NCT03147872|NO_INTERVENTION|5% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol).
62640004|NCT03147872|EXPERIMENTAL|2% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria).
62640005|NCT00314158|EXPERIMENTAL|Brinzolamide +Timolol|
62640006|NCT00314158|ACTIVE_COMPARATOR|Brinzolamide|
62071378|NCT00350701|EXPERIMENTAL|androgel 10g|androgel 10g
62640007|NCT00314158|ACTIVE_COMPARATOR|Timolol|
62640008|NCT04191707||Outpatients with Inflammatory Bowel Disease|This study was performed with plasma samples from IBD patients recruited in a previous study after informed consent. (1) IBD outpatients attending the Hospital de Sabadell Gastroenterology Day-care unit were consecutively included for analytical monitoring of immunosuppressant treatment or infliximab infusion
62640009|NCT03798743|EXPERIMENTAL|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
62640010|NCT05070013|EXPERIMENTAL|Adaptive DBS stimulation|Subjects experience adaptive stimulation during one week of at-home night sleep.
62640011|NCT05070013|ACTIVE_COMPARATOR|Open-loop DBS stimulation|Subjects experience open-loop stimulation (standard clinical stimulation therapy based on DBS programming for the treatment of motor symptoms) during one week of at-home night sleep.
62640012|NCT05070013|NO_INTERVENTION|No DBS Stimulation|DBS stimulation is turned off (control) during one week of at-home night sleep.
62640013|NCT05954052|EXPERIMENTAL|Glutathione Oral Supplementation|Glutathione will be the only study medication dispensed to subjects for this study. Subjects will be told to take the first dose of study medication after breakfast each day and the second dose in the evening after dinner. The proposed dose range for Glutathione in this study will be 1000mg-3000mg/day based on the subject's weight.
62071379|NCT00350701|PLACEBO_COMPARATOR|placebo|placebo
62071380|NCT01937637|OTHER|Behavioral Intervention for Dyspnea|"In the first intervention session, enrolled participants will learn breathing and relaxation exercises designed to relieve breathlessness. The nurse practitioner will also provide handouts with directions for these exercises, an audio-recording with the relaxation exercises, and worksheets for daily home practice. During the second session, participants will again meet with the nurse practitioner to review the study exercises and to address any difficulties participants may have experienced in practicing the skills.~All participants will complete questionnaires before and after the study intervention as well as a brief follow-up interview with the research assistant to obtain feedback about ways to improve the intervention to relieve breathlessness in patients with lung cancer."
62071381|NCT02556905||Korean patients|All Korean patients intended to be treated with REVLIMID® according to the approved package insert
62071382|NCT03869515||chILD|The chILD syndrome exists when a child with DLD has had the common causes of DLD excluded as the primary diagnosis and has at least three of the following four criteria: (1) respiratory symptoms (e.g., cough, rapid and/or difficult breathing, or exercise intolerance); (2) respiratory signs (e.g., resting tachypnea, adventitious sounds, retractions, digital clubbing, failure to thrive, or respiratory fail- ure); (3) hypoxemia; and (4) diffuse abnormalities on CXR or a CT scan.
62088350|NCT03914339|ACTIVE_COMPARATOR|control group|Eighteen periodontally compromised patients will receive periodontal treatment alone .
62276050|NCT05558540|EXPERIMENTAL|Implantation with spinal cord stimulator|Women participating in the trial will receive a spinal cord stimulator (SCS). Women will first undergo a trial implantation period of 14 days. When the trial period is considered successfull (at least 50 percent reported pain reduction) women will receive definitive placement of the SCS. Normal lead placement( bilateral TH8-12) and different stimulation types will be used (FAST, subthresholdand/orCombination). When participating in the trial, women will be asked to complete a set of questionnaires on several occasions, i.e. at baseline, 3 months after implantation, 6 months after implantation and 12 months after implantation.
62276051|NCT06260280||First-year medical residents|All first-year residents entering our department for any of the different specialties will undergo a nuclear magnetic resonance scan before starting their shifts and a control scan 2 months into their residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
62276052|NCT06405464||Swiss HIV Cohort Study participants on CAB+RPV LA regimen|Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen
62640014|NCT04448275|EXPERIMENTAL|study group|received conventional selected exercise program and in addition to Neurodynamics Nerve flossing for femoral nerve
62640015|NCT04448275|EXPERIMENTAL|control group|received conventional selected exercise program in form of: Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps in heamophilic patient The iliopsoas \& quadriceps muscles strength exercise
62640016|NCT03197948||Health Services Research (electronic patient reported outcome)|Patients complete questionnaires over 15 minutes once a week over 3 months via a smartphone application. Patients rate urinary function, bowel habits, sexual function, hormonal function, and overall satisfaction. Patients with advanced disease also answer questions related to pain, fatigue/lack of energy, weight loss, and worry domains.
62640017|NCT00773357|EXPERIMENTAL|Guanfacine|guanfacine 3mg/day
62640018|NCT00773357|PLACEBO_COMPARATOR|Placebo|placebo control
62640019|NCT02779491|EXPERIMENTAL|Intervention for two weeks|Receipt of the mobile phone application for two weeks
62640020|NCT02779491|NO_INTERVENTION|Control for two weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
62640021|NCT02779491|EXPERIMENTAL|Intervention for four weeks|Receipt of the mobile phone application for four weeks
62088351|NCT04055896|NO_INTERVENTION|Control Group|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
62276053|NCT06405464||Swiss HIV Cohort Study participants on a standard of care oral regimen|Matched control population on a standard of care oral regimen
62276054|NCT03321097|EXPERIMENTAL|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
62276055|NCT03321097|EXPERIMENTAL|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
62276056|NCT04277845|EXPERIMENTAL|Group 1|"Group 1: 1 cycle will be repeated every 4 weeks~Bortezomib 1.3mg/m2 SC D1, 8, 15 - Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15~Lenalidomide 25mg/d D1-21~- Dose adjustment for more than 75 : 15mg/d D1-21~Dexamethasone 40mg D1, 8, 15, 22 - Dose adjustment for more than 75 years old: 20mg If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1.~\<for patients with old age or frail\>~Bortezomib 1.0mg/m2 SC D1, 8, 15~: Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15 Lenalidomide 15mg/d D1-21 Dexamethasone 20mg D1, 8, 15, 22"
62640022|NCT02779491|NO_INTERVENTION|Control for four weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
62640023|NCT02395068|EXPERIMENTAL|Single-dose PK|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation. 1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
62640024|NCT02395068|EXPERIMENTAL|Weekly fixed dose|Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks.
62640025|NCT02395068|EXPERIMENTAL|Bioweekly fixed dose PK|Nimotuzumab 600mg, administered once every 2 weeks for 8 weeks. Dosing regimens can be adjusted according to the results of preliminary experiments. Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
62640026|NCT03361462|EXPERIMENTAL|Intervention group|Two joyful adventure days in the form of physical activities and competitions with adventure games and short interactive talk on SME.
62640027|NCT03361462|NO_INTERVENTION|Waitlist control group|The intervention won't be provided during evaluation period and will be provided after the evaluation period
62640028|NCT00948090|EXPERIMENTAL|IV Busulfan|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
62640029|NCT05781672|EXPERIMENTAL|Anthra2|"Patient will have an echocardiography with speckle tracking analysis 5 years after the end of their participation to SpeckleAnthra study (NCT02893787)"
62640030|NCT05781672|ACTIVE_COMPARATOR|Control|Cardiac ultrasound analysis with speckle tracking of age- and sex-matched healthy patients in the Anthra2 group
62640031|NCT01157845|EXPERIMENTAL|Laboratory assay|
62640032|NCT04549662|EXPERIMENTAL|Group A|Powdered formula containing whey protein and arginine (Active A) and lipid bolus containing omega 3 fatty acids. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
62640033|NCT04549662|ACTIVE_COMPARATOR|Group B|Powdered formula containing whey protein and arginine (Active A) and placebo oil. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
62071383|NCT03869515||Control|Healthy subjects were recruited from participants of an ongoing prospective birth cohort study: 'The Pulmonary Function Assessment for Bronchopulmonary Dysplasia (BPD) and Recurrent Lower Respiratory Tract Infections (LRTI) in Chinese Children'. Exclusion criteria were major birth defects, upper airway pathology, cardiac or neurological diseases, failure to thrive, a history of severe respiratory disease with intensive care unit admission, previous physician-diagnosed LRTI, gestational age (GA) \<37 weeks or birthweight (BW) \<2.5 kg.
62276057|NCT04277845|ACTIVE_COMPARATOR|Group 2|"Group 2: 1 cycle will be repeated every 4 weeks~Lenalidomide 25mg/d D1-21~* Dose adjustment for more than 75: 15mg Dexamethasone 40mg D1, 8, 15, 22~* Dose adjustment for more than 75: 20mg~\<for patients with old age or frail\>~1. Lenalidomide 15mg/d D1-21~2. Dexamethasone 20mg D1, 8, 15, 22"
62071384|NCT02894996|OTHER|Pediatric patient for general anesthesia|Pediatric patients for general anesthesia elected for scheduled surgery Patients weight between 8 and 30 kilograms
62276058|NCT02897895|EXPERIMENTAL|new strategy of immunosuppression monitoring|evaluation of calcineurin activity (CN-a) in combination with CNI blood levels
62276059|NCT02897895|ACTIVE_COMPARATOR|strategy of reference|CNI (inhibitor of Calcineurin) blood levels alone
62276060|NCT06549829|EXPERIMENTAL|Nutritional optimization-led triple prehabilitation Intervention|Nutritional optimization-led triple prehabilitation
62640034|NCT04549662|PLACEBO_COMPARATOR|Comparator|Powdered formula containing whey protein (Active B) and placebo oil. Participants will mix the powder (Active B) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
62640035|NCT02177929|EXPERIMENTAL|adapted canoeing, handbike, conventional physiotherapy|Individuals are divided into three groups: one group adapted canoeing, one group of handbike and one grup of conventional physiotherapy.
62640036|NCT00952666|EXPERIMENTAL|Device|Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.
62276061|NCT06549829|OTHER|Conventional triple prehabilitation Intervention|Conventional triple prehabilitation
62640037|NCT01753960||Control group|Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
62071385|NCT03740880|ACTIVE_COMPARATOR|Late trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
62071386|NCT03740880|EXPERIMENTAL|Early trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm
62071387|NCT03066570|EXPERIMENTAL|Single case study|Single case study using Graded exposure.
62071388|NCT05532241|EXPERIMENTAL|metal + OH|fixed metal orthodontic appliance with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)
62071389|NCT05532241|EXPERIMENTAL|metal + CHX|fixed metal orthodontic appliance with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)
62640038|NCT01753960||SpHb group|Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
62640039|NCT01820663|EXPERIMENTAL|Modified Atkins Diet|Patients will receive a 14 day menu consisting of the Modified Atkins diet, a low-carbohydrate, high protein, high fat diet.
62640040|NCT01820663|PLACEBO_COMPARATOR|Control Diet|Patients will receive a diet (e.g. regular, low cholesterol, diabetic) determined by the attending physician.
62640041|NCT01661738|EXPERIMENTAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5 ml/ vial
62640042|NCT05626309|EXPERIMENTAL|Qizhu Yuling Prescription|Qizhu Yuling Prescription
62640043|NCT05626309|PLACEBO_COMPARATOR|Placebo Comparator|Simulation agent of Qizhu Yuling Prescription Group
62640044|NCT04998864||Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2.0 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
62640045|NCT06051526||Critically ill in-patients|All adult inpatients in hospitals across Africa that are critically ill.
62640046|NCT02198846|EXPERIMENTAL|Insulin pump|insulin pump
62640047|NCT02198846|ACTIVE_COMPARATOR|conventional treatment|intensification of conventional treatment
62276062|NCT00526682|ACTIVE_COMPARATOR|1|Comparison of actives for synergy
62640048|NCT02432885|EXPERIMENTAL|ACE inhibitor|ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
62640049|NCT02432885|NO_INTERVENTION|Control|Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance
62640050|NCT03476421||R0 hepatectomy|Those HCC patients operated with standard R0 hepatectomy
62640051|NCT03476421||R1par hepatectomy|Those HCC patients operated with R1par hepatectomy
62640052|NCT03476421||R1vasc hepatectomy|Those HCC patients operated with R1vasc hepatectomy
62640053|NCT03476421||R1par+R1vasc hepatectomy|Those HCC patients operated with both R1par and R1vasc hepatectomy
62276063|NCT05439499|EXPERIMENTAL|FCN-437c+Letrozole/anastrozole ± Goserelin acetate|
62640054|NCT02597777|PLACEBO_COMPARATOR|Side of face receiving placebo vehicle|One half of the face (left or right side) will be randomized to receive the placebo lotion. Subjects will be asked to apply a pea-sized amount of the lotion to half of the face at twice daily application for 4 weeks.
62640055|NCT02597777|EXPERIMENTAL|Side of face receiving AH8 lotion|One half of the face (left or right side) will be randomized to receive the 10% Acetyl Hexapeptide-8 containing (AH8) lotion. Subjects will be asked to apply a pea-size amount of the lotion to the half of the face twice daily application for 4 weeks.
62640056|NCT00901342|EXPERIMENTAL|Sipuleucel-T|Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
62640057|NCT00555074|EXPERIMENTAL|1|Sodium Tungstate
62640058|NCT00555074|PLACEBO_COMPARATOR|2|
62276064|NCT05439499|PLACEBO_COMPARATOR|Placebo+Letrozole/anastrozole ± Goserelin acetate|
62640059|NCT06215235||Persons involved in BLT|Persons with ID and staff who are involved in BLT. Either by receiving BLT, or by prescribing or facitating BLT.
62276065|NCT00599859|ACTIVE_COMPARATOR|1|Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
62276066|NCT00599859|ACTIVE_COMPARATOR|2|Arm 2 are lactose maldigesters: 2 interventions are a. withdrawal from lactose for 2 weeks and b. consumption of 50g lactose in divided doses mixed in water for a 2 week period.
62640060|NCT03434639||1 - Ophthalmology patients|Ophthalmology patients who are receiving an intravenous dose of either fluorescein or indocyanine green (ICG) as part of their routine ophthalmic care (e.g. as part of a fluorescence angiography examination) will be recruited to the first stage of this study. These patients will take part in preliminary studies aimed at determining whether it is possible to detect fluorescein and ICG in the blood using transcutaneous fluorescence measurements.
62071390|NCT05532241|PLACEBO_COMPARATOR|non-metal + OH|fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)
62071391|NCT05532241|ACTIVE_COMPARATOR|non-metal + CHX|fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)
62640061|NCT03434639||2a - Healthy subjects|Healthy subjects with no known issues of increased gut permeability. These subjects will act as negative controls in all gut permeability studies.
62640062|NCT03434639||2b - Healthy subjects (gastric emptying)|A subset of healthy volunteers will be recruited to take part in experiments to help in understanding the impact of gastric emptying rate as a confounding factor in measurements of gut permeability.
62276067|NCT02068547|ACTIVE_COMPARATOR|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
62276068|NCT02068547|EXPERIMENTAL|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
62454893|NCT00543309|ACTIVE_COMPARATOR|II- Milrinone|Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
62640063|NCT03434639||3 - Increased permeability|Gastro-intestinal (GI) and non-GI patients who are expected to exhibit increased gut permeability (e.g. patients with celiac disease, inflammatory bowel disease (IBD), liver disease, HIV or another condition in which increased intestinal permeability is common). The more extreme cases in this group will act as positive controls.
62640064|NCT00221013|EXPERIMENTAL|Higher intensity CRRT regimen|
62640065|NCT00221013|ACTIVE_COMPARATOR|Lower intensity CRRT regimen|
62640066|NCT02805283||Dapagliflozin, dapagliflozin/met ER|Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
62640067|NCT02805283||Sulfonylurea|Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
62640068|NCT03976752|NO_INTERVENTION|Pre-drug|Participants enrolled in the pre-drug arm will not receive any drug. At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
62640069|NCT03976752|EXPERIMENTAL|Genvoya - 2 and 48 hours specimen collection|Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
62640070|NCT03976752|EXPERIMENTAL|Genvoya - 4 and 72 hours specimen collection|Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
62640071|NCT03976752|EXPERIMENTAL|Genvoya - 24 and 96 hours specimen collection|Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96 hours after taking the medication in the clinic (visit 5).
62640072|NCT03976752|EXPERIMENTAL|Genvoya - Single time point specimen collection|Specimen collection 8 hours after taking the medication in the clinic (visit 4).
62454894|NCT00543309|PLACEBO_COMPARATOR|III- placebo|Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
62454895|NCT04637997|OTHER|Study group 1|Wearing of compression stockings class I between Investigation day 28 to 56. Wearing of compression stockings class II between Investigation day 56 to 84.
62454896|NCT04637997|OTHER|Study group 2|Wearing of compression stockings class II between Investigation day 28 to 56. Wearing of compression stockings class I between Investigation day 56 to 84.
62640073|NCT02473185|EXPERIMENTAL|Methylphenidate|Methylfenidate 20 mg Tablet single-dose per os
62640074|NCT02473185|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg Tablet single-dose per os
62640075|NCT03793569|NO_INTERVENTION|Control group|Participants will be recruited and asked to complete Edinburgh Postnatal Depression Scale (EPDS) at specific timepoints postpartum.
62454897|NCT03561883|EXPERIMENTAL|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
62640076|NCT03793569|EXPERIMENTAL|Intervention group|Participants will be recruited, asked to complete Edinburgh Postnatal Depression Scale at specific timepoints postpartum, and attend a peer discussion group.
62640077|NCT04163848||Desflurane|desflurane administration based on a BIS index kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator and its econometer for an optimized fresh gas flow as low as the O2 consumption allows
62640078|NCT04163848||Sevoflurane|sevoflurane administration based on a BIS kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator with a fixed fresh gas flow of 2L/min as requested in the gas monography
62276069|NCT02485145|EXPERIMENTAL|A/B|In this crossover trial, the A/B group will receive the test product (A) and then the placebo (B). The topical product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the test product for 7 days, applying the topical product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the placebo cream, which will be used for 7 days, applying the topical placebo to the hands twice a day.
62454898|NCT03561883|PLACEBO_COMPARATOR|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
62640079|NCT05397197|OTHER|Longitudinal follow-up|Follow-up of children at 40 weeks of corrected age for all children and then regularly until 24 months
62640080|NCT01477762|ACTIVE_COMPARATOR|PTSD Negative|Participants who do not have PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
62454899|NCT00401778|ACTIVE_COMPARATOR|1|RAD001 5 mg/day for 21 days sequentially.
62454900|NCT00401778|ACTIVE_COMPARATOR|3|RAD001 10 mg/day for 21 days sequentially.
62454901|NCT00401778|NO_INTERVENTION|Control|Patients who are eligible for the study but choose not to receive RAD001 treatment.
62454902|NCT05607914|ACTIVE_COMPARATOR|percussion massage group|Applying the hypervolt device to the hamstring muscle with the hard ball head for 5 minutes
62640081|NCT01477762|EXPERIMENTAL|PTSD Positive|Participants with PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
62640082|NCT01010737|EXPERIMENTAL|Multimeric-001 250 mcg|250mcg of Multimeric-001 was administered twice at an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
62640083|NCT01010737|ACTIVE_COMPARATOR|Adjuvant: Montonide isa 51 VG|Adjuvanted PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
62640084|NCT01010737|ACTIVE_COMPARATOR|Placebo|PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
62640085|NCT01010737|EXPERIMENTAL|Multimeric-001 500 mcg|500mcg of M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
62071392|NCT00599989|EXPERIMENTAL|APBI|
62454903|NCT05607914|ACTIVE_COMPARATOR|static stretching group|Static stretching of the hamstring muscle for 5 minutes
62454904|NCT05607914|NO_INTERVENTION|control group|no intervention
62454905|NCT05733247|ACTIVE_COMPARATOR|Copenhagen adductor exercise|"The modified Copenhagen adductor exercise consists of 6 levels through which the participant will progress when able to complete one level adequately (able to complete the exercise in the given timeframe with adequate control). The first 5 levels are isometric contractions progressing in difficulty with the 6th level including concentric and eccentric components.~1. Participants perform a supported isometric adduction hold off a 30cm support in a short-lever side-lying position. The participants then raise their pelvis from the floor, keeping their lower knee on the ground for support and hold for 20 seconds, repeating it twelve times on each side.~2. Participants progressed level 1 by lifting their supporting leg, bringing their knees together and holding position for 20 seconds, repeating it twelve times on each side."
62454906|NCT05733247|EXPERIMENTAL|adduction and abduction partner exercise|"Participants are in a sitting position with their knees extended and hips abducted, supporting themselves with their hands behind their trunks, facing each other. For the adduction exercise, the participant will place his feet and lower leg on the outside of his partner's lower legs and feet. He will then adduct his hips, bringing his feet slowly together while his partner slowly resists this movement.~For the abduction exercise, the participant will place his feet and lower legs on the inside of his partner's feet and lower legs. The participant will slowly abduct the hips while the partner resists this movement.~Both exercises are performed over 6 seconds (a three second concentric and three second eccentric contraction) with as maximal effort."
62454907|NCT03832179|ACTIVE_COMPARATOR|Anti-vascular endothelial growth factor|Intravitreal Bevacizumab, Ranibizumab, or Aflibercept
62454908|NCT03832179|EXPERIMENTAL|Ozurdex|Intravitreal Ozurdex
62454909|NCT05584475|EXPERIMENTAL|Mindfulness Treatment|This arm consists of the mindfulness treatment that will be administered to all participants in the single-arm open trial.
62454910|NCT03937453||New-Onset Diabetes Mellitus|Diabetes Mellitus diagnosed within the past 12 months
62454911|NCT03937453||Deteriorating Diabetes Mellitus|History of Diabetes Mellitus with recent deteriorating within the past 6 months confirmed with repeat testing and not associated with weight gain or diabetes medication non-compliance
62276070|NCT02485145|EXPERIMENTAL|B/A|In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
62276071|NCT05624060|ACTIVE_COMPARATOR|Control Group|Pelvic Floor Dysfunction Prevention Training
62276072|NCT05624060|EXPERIMENTAL|Experimental Group 1|Pelvic Floor Dysfunction Prevention Training and Perineal Massage
62454912|NCT05608421|EXPERIMENTAL|1MoreStep Intervention|The intervention arm is 8 sessions (7 group and one individual) that meet weekly with a community health educator who is a Black woman and has experience implementing prior behavioral interventions with people who have experienced trauma and/or are LWH.
62640086|NCT01010737|EXPERIMENTAL|Adjuvanted Multimeric-001 500mcg|5000mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
62640087|NCT01010737|EXPERIMENTAL|Adjuvanted Multimeric-001 250mcg|250mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
62640088|NCT02799563|EXPERIMENTAL|Cohort A: Coach, Preselected number of cases|Cohort A completed the DKA simulator cases during two one-hour coached sessions. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
62640089|NCT02799563|EXPERIMENTAL|Cohort B: Coach, Self-selected number of cases|Cohort B completed the DKA simulator cases during two one-hour coached sessions. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
62640090|NCT02799563|EXPERIMENTAL|Cohort C: No coach, Preselected number of cases|Cohort C completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
62640091|NCT02799563|EXPERIMENTAL|Cohort D: No coach, Self-selected number of cases|Cohort D completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
62640092|NCT03788694|EXPERIMENTAL|Intranasal Ketamine|Subjects will receive study medication, intranasal ketamine.
62640093|NCT04360460|EXPERIMENTAL|Experimental|Virtual reality followed by translation into related functional tasks in a real life setting for 2 weeks + conventional therapies
62640094|NCT04360460|ACTIVE_COMPARATOR|Control|Virtual reality followed by translation into non-related functional tasks in a real life setting for 2 weeks + conventional therapies
62640095|NCT00433472|OTHER|MRI -|"MRI scan to be complete to look at RSR13 on measurement of T2 and T2\* on MRI~Procedure/surgery magnetic resonance imaging (MRI)"
62640096|NCT06213558|ACTIVE_COMPARATOR|Evaluation of rectangular archwire on maxillary canine retraction|Evaluation of rectangular archwire on maxillary canine retraction
62640097|NCT06213558|ACTIVE_COMPARATOR|Evaluation of square archwire on maxillary canine retraction|Evaluation of square archwire on maxillary canine retraction
62640098|NCT06160765||1.5 kcal/ml High Density Formula|This group consist of patients who are able to consume 300-400 kcal of solid food and given 400 cc High Density Formula 1.5 kcal/ml equivalent to 600 kcal
62640099|NCT06160765||1 kcal/ml High Density Formula|This group consist of patients who are able to consume 500-600 kkal of solid food and given 400 cc High Density Formula 1 kcal/ml equivalent to 400 kcal
62640100|NCT01826942|EXPERIMENTAL|Thin skin|Single fractional CO2 treatment at surgical area closure procedure on thin skin
62640101|NCT01826942|EXPERIMENTAL|Thick skin|Single fractional CO2 treatment at surgical area closure procedure on thick skin
62640102|NCT01276158|ACTIVE_COMPARATOR|Ultrasound|Arterial line placed with Ultrasound guidance.
62640103|NCT01276158|ACTIVE_COMPARATOR|Doppler|Arterial line placed with doppler guidance
62640104|NCT03912038||Null or low consumption|No-intervention. The group consists of women who have reported a null or low consumption of non-caloric sweeteners during late pregnancy.
62276073|NCT05624060|EXPERIMENTAL|Experimental Group 2|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise
62276074|NCT02494531|OTHER|Positon Emission Tomographic (PET)-scan|2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
62640105|NCT03912038||Moderate consumption|No-intervention. The group consists of women who have reported a moderate consumption of non-caloric sweeteners during late pregnancy.
62640106|NCT03912038||High consumption|No-intervention. The group consists of women who have reported a high consumption of non-caloric sweeteners during late pregnancy.
62640107|NCT05638282|EXPERIMENTAL|Cendakimab|
62640108|NCT05638282|PLACEBO_COMPARATOR|Placebo|
62640109|NCT00533871||Normotensive|Pregnant women in the third trimester with normal blood pressure this pregnancy and no history of HTN or pre-eclampsia in a previous pregnancy
62640110|NCT00533871||Chronic Hypertensive|Pregnant women in their third trimester with known hypertension prior to the current pregnancy
62640111|NCT00533871||Pre-eclampsia|Pregnant women in their third trimester who meet ACOG diagnostic criteria for pre-eclampsia
62640112|NCT00804453|ACTIVE_COMPARATOR|1|Standard blood line
62276075|NCT02014064|EXPERIMENTAL|Atomoxetine|Double-blind, Placebo controlled, 2-phase study the safety \& efficacy of Atomoxetine
62276076|NCT02014064|PLACEBO_COMPARATOR|Placebo|"Control Group Schedule:~Day 1: 40mg @ 8:00am Day 2: 40mg @ 8:00am Day 3: 40mg @ 8:00am, 40mg @ 8:00pm Day 4: 40mg @ 8:00am, 40mg @ 8:00pm Day 5: 40mg @ 8:00am, 40mg @ 8:00pm Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)"
62276077|NCT02290795||healthy subjects|Healthy subjects (not diagnosed with any eye disease affecting the vitreous or optic nerve head).
62276078|NCT02290795||Glaucoma patients|Glaucoma patients visiting the glaucoma consultation.
62276079|NCT02290795||Patients scheduled for trabeculectomy|Glaucoma patients scheduled for filtering surgery (=trabeculectomy)
62276080|NCT02290795||Vitreomacular traction patients|Patients with symptomative vitreomacular adhesion scheduled for treatment with Ocriplasmin
62276081|NCT01578980|EXPERIMENTAL|Outpatient Control-to-Range|Outpatient Control-to-Range: Testing system connectivity
62276082|NCT02792842|EXPERIMENTAL|ART-123 (3-day ART)|
62276083|NCT02792842|EXPERIMENTAL|ART-123 (1-day ART)|
62276084|NCT02792842|PLACEBO_COMPARATOR|Placebo|
62640113|NCT00804453|EXPERIMENTAL|2|Cartridge blood line
62640114|NCT03920085|EXPERIMENTAL|LifeScan BGMSs|OneTouch Verio, OneTouch Select Plus and OneTouch Ultra Blood Glucose Monitoring Systems (BGMSs) tested using subject capillary blood and compared to a reference instrument (YSI 2900).
62640115|NCT04956471||hospitalized patients with swallowing disorder after stroke,.|
62640116|NCT02635308|EXPERIMENTAL|Experimental|"High-Intensity, Unilaterally-Biased Resistance training 3x/wk x 12wk MOVE"
62640117|NCT04798157|EXPERIMENTAL|Children with Hemoglobinopathies|children from 2-18 years old , diagnosed to have hemoglobinopathy disease
62276085|NCT02757170|EXPERIMENTAL|I|Thromboelastography Acute on chronic liver failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
62640118|NCT03173417|EXPERIMENTAL|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
62640119|NCT05665868|EXPERIMENTAL|Experimental group based on integrated care mode|① Obtain the health records of patients receiving targeted treatment of gastric stromal tumors in the big data platform; ② Patients upload health data, disease symptoms, complete questionnaires, health consultation and other functions; ③ The platform can regularly send audit reminders, automatically analyze the data uploaded and saved by patients, automatically and intelligently intervene when abnormal results occur, and remind medical staff to intervene manually; ④ Researchers can view the recent health status of patients through the terminal, and members of corresponding disciplines can give targeted health guidance according to the existing health problems of patients; Remind patients with complex conditions to have outpatient reexamination; ⑤ Push disease related knowledge every week for patients to learn independently.
62640120|NCT05665868|ACTIVE_COMPARATOR|Control group based on conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
62640121|NCT05078983||HIGH RISK|HIGH RISK MEANS PATIENTS HAVE ASA SCORE OVER 2
62640122|NCT05078983||LOW RISK|LOW RISK MEANS PATIENTS HAVE ASA SCORE BELOW 3
62640123|NCT02849587|PLACEBO_COMPARATOR|Placebo Cannabis|Subjects will smoke cannabis with placebo THC (.02%) ad libitum
62640124|NCT02849587|EXPERIMENTAL|Cannabis with 5.9% THC|Subjects will smoke cannabis cigarettes with 5.9% THC ad libitum
62640125|NCT02849587|EXPERIMENTAL|Cannabis with 13.4% THC|Subjects will smoke cannabis cigarettes with 13.4% THC ad libitum
62640126|NCT00930462|NO_INTERVENTION|Conventional colonoscopy|No cap fitted on the colonoscopes for this group.
62640127|NCT00930462|EXPERIMENTAL|Cap-assisted colonoscopy|
62640128|NCT00370500|EXPERIMENTAL|A|There is only one arm in this study. All probands receive quetiapine.
62640129|NCT01222104||Angio-Seal|Angio-Seal attempted and/or deployed
62276086|NCT02757170|ACTIVE_COMPARATOR|Group II|Thromboelastography Healthy Controls: Healthy persons' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation.
62640130|NCT01222104||Not deployed|Other method of closure
62640131|NCT02651870|EXPERIMENTAL|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
62640132|NCT02651870|EXPERIMENTAL|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
62640133|NCT02651870|ACTIVE_COMPARATOR|Candesartan 16mg|Candesartan 16mg, po, q.d.
62640134|NCT05306847|EXPERIMENTAL|Experimental arm|"Sintilimab will be given intravenously at a dose of 200mg every 21 days. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.~Tumor evaluation will be conducted after treatment of the tested regimen every 2 cycles. Subsequent treatment will be determined based on the evaluation results: If the patients are not suitable for radical surgery, but the result of efficacy evaluation is CR, PR, or SD, they can continue to receive the tested regimen. If the patients are still not suitable for radical surgery after 6 cycles of the tested regimen, the standard first-line or immunotherapy after chemoradiotherapy or radiotherapy will be given. If patients are eligible for radical surgery, surgery will be performed within 4 weeks after completion of the last tested regimen."
62640135|NCT04577638|EXPERIMENTAL|Nivolumab and accelerated IMRT|
62640136|NCT05282147|OTHER|Babies undergoing newborn eye screening|Babies having newborn eye screening with the intervention (Digital Imaging) technique in addition to the standard ophthalmoscopic technique.
62640137|NCT02869763|EXPERIMENTAL|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
62276087|NCT02757170|EXPERIMENTAL|Group III|Thromboelastography Chronic Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
62640138|NCT02869763|EXPERIMENTAL|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
62640139|NCT02869763|PLACEBO_COMPARATOR|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
62640140|NCT03506048|EXPERIMENTAL|Treatment (lenvatinib)|Patients receive lenvatinib PO QD for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive radioactive iodine (RAI) I-131 orally as standard of care.
62640141|NCT01507181|EXPERIMENTAL|Ketamine|single dose IV ketamine, .5mg/kg
62640142|NCT01507181|PLACEBO_COMPARATOR|Midazolam|single dose IV midazolam, .45mg/kg
62640143|NCT03563573|ACTIVE_COMPARATOR|Lidocaine-effective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
62640144|NCT03563573|PLACEBO_COMPARATOR|Lidocaine-effective ADHD: Placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
62640145|NCT03563573|ACTIVE_COMPARATOR|Lidocaine-ineffective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
62640146|NCT03563573|PLACEBO_COMPARATOR|Lidocaine-ineffective ADHD: placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
62640147|NCT02765152|ACTIVE_COMPARATOR|Conventional Physical Therapy|Usual therapy: joint mobility exercises, stimulating joint movement of the main active components of the upper limb; major muscle groups stretching, especially in the affected muscles by tone impairment; manual resistance training according to the degree of the patient's muscle strength, prioritizing the functional specificity of the upper limb, so the majority of the exercises will be held in open chain; motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks.
62640148|NCT02765152|EXPERIMENTAL|discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
62640149|NCT02765152|EXPERIMENTAL|rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
62640150|NCT01767818||Previously treated PD patients|220 subjects with PD treated and responsive to dopaminergic medication
62640151|NCT01767818||Previously untreated PD|20 subjects with de-novo, previously untreated PD confirmed by I-123 Ioflupane SPECT
62640152|NCT01767818||Healthy age-matched controls|46 age-matched healthy controls will be studied.
62640153|NCT06022328||Patients with ET|"45 patients with ET:~* 15 without thrombotic event (neither at diagnosis nor during follow-up)~* 15 with thrombotic events (thrombosis at diagnosis or within 2 years of diagnosis)~* 15 who progressed to myelofibrosis or AML during follow-up"
62640154|NCT06022328||Patients with PV|"45 patients with PV~* 15 without thrombotic event (neither at diagnosis nor during follow-up)~* 15 with thrombotic event (thrombosis at diagnosis or within 2 years of diagnosis)~* 15 who progressed to myelofibrosis or AML during follow-up"
62640155|NCT06022328||Patients with PMF|"20 patients with PMF:~* 10 without transformation into AML~* 10 patients who progressed to AML"
62640156|NCT06022328||Patients without MPN|10 patients without MPN
62640157|NCT00026091|EXPERIMENTAL|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62640158|NCT05662020|EXPERIMENTAL|The Group of Investigational Vaccine|0.5 mL suspension for injection, each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein.
62640159|NCT05662020|ACTIVE_COMPARATOR|The Group of Active Control Vaccine|0.5-mL suspension for injection, each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein.
62640160|NCT05401994|ACTIVE_COMPARATOR|conventional Erich's arch bar|• Patients will receive conventional Erich's arch bar
62640161|NCT05401994|EXPERIMENTAL|Screw Retained Arch Bar|patients will receive modified screw retained arch bar.
62640162|NCT01758497|ACTIVE_COMPARATOR|Ropivacaine|US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
62276088|NCT02757170|EXPERIMENTAL|Group IV|Thromboelastography Acute Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
62276089|NCT02700737|ACTIVE_COMPARATOR|Group A|"Interventional cardiologists presented with limited dataset including only information that is available from imaging parameters currently recommended by clinical practice guidelines."
62640163|NCT01758497|SHAM_COMPARATOR|Saline|US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
62640164|NCT01711112|EXPERIMENTAL|docetaxel|Days 1 \& 8 Docetaxel 35 mg/m2 IV
62640165|NCT02569892|EXPERIMENTAL|Laser Arm|Participants receive treatment with sub-threshold macular laser photocoagulation
62640166|NCT02569892|SHAM_COMPARATOR|Sham Laser Arm|Participants receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)
62640167|NCT03875001|EXPERIMENTAL|BI 1358894|
62640168|NCT03875001|PLACEBO_COMPARATOR|Placebo|
62640169|NCT01975493||Amoxicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
62640170|NCT01975493||Ampicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)"
62640171|NCT01975493||Benzylpenicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
62640172|NCT01975493||Co-amoxiclav|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
62640173|NCT01975493||Flucloxacillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
62640174|NCT01975493||Piperacillin/tazobactam|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
62640175|NCT01786057|ACTIVE_COMPARATOR|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
62640176|NCT01786057|PLACEBO_COMPARATOR|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
62640177|NCT06444750||ICU patients without lung injury with transfusion|ICU patients who receive a transfusion and without lung injury. This will give an overview of the proteome of critical ill patients who received a transfusion but without lung injury. This way specific proteome changes caused by transfusion can be identified
62640178|NCT06444750||ICU patients with ARDS (indirect) with transfusion|ICU patients who receive a transfusion and have ARDS caused by indirect lung injury (e.g. pancreatitis, trauma, non-pulmonary sepsis). This will give an overview of the proteome of critical ill patients who receive a transfusion and have lung injury not caused by TRALI.
62640179|NCT06444750||ICU patients with pneumonia with transfusion|ICU patients who receive a transfusion and have infectious lung injury (locally). This will give an overview of the proteome of patients with local lung injury.
62640180|NCT06444750||ICU patients with ARDS (indirect) without transfusion|ICU patients without transfusion and with ARDS caused by indirect lung injury. This will give an overview of the proteome of ICU patients with a systemic cause of lung injury. Proteins that are specifically involved in a systemic reaction can be identified.
62640181|NCT06444750||ICU patients with pneumonia without transfusion|ICU patients without transfusion and with infectious pneumonia. This will give an overview of proteins involved in local lung injury.
62640182|NCT06444750||Healthy volunteers|Healthy volunteers.
62640183|NCT00412841|EXPERIMENTAL|Atorvastatin|Atorvastatin 40mg
62640184|NCT00412841|PLACEBO_COMPARATOR|Placebo|Tablets identical to atorvastatin 40mg
62640185|NCT03016169|OTHER|Treatment|All subjects will receive the Trifecta GT valve
62640186|NCT01876108|EXPERIMENTAL|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
62640187|NCT01876108|NO_INTERVENTION|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
62640188|NCT00596908||1|Subjects with Parkinsonian Tremor (PT)
62640189|NCT00596908||2|Subjects with non Parkinsonian Tremor (nPT)
62640190|NCT00458003|EXPERIMENTAL|Phenylephrine|Subject will receive a phenylephrine infusion to prevent and to treat hypotension associated with spinal anesthesia
62640191|NCT00458003|ACTIVE_COMPARATOR|Ephedrine|Subject will receive an ephedrine infusion to prevent and to treat hypotension associated with spinal anesthesia
62640192|NCT03885414|EXPERIMENTAL|OST-VRET + in-vivo transition program|One-session treatment (OST) VRET on-location with clinical psychologist (3 hours), followed by a therapist-guided, four-week online program encouraging transition to real-world, in-vivo exposure exercises.
62640193|NCT05157659|EXPERIMENTAL|[18F]F-AraG PET procedures|Within one week prior to resection two \[18F\]F-AraG PET-scans will be performed.
62640194|NCT04718597||Open hernia repair|Patients who underwent inguinal hernia repair via an open Liechtenstein procedure
62640195|NCT04718597||Robotic assisted hernia repair|Patients who underwent inguinal hernia repair via robotic assisted laparoscopy
62640196|NCT04268407|EXPERIMENTAL|2-day prophylactic antibiotics|use prophylactic antibiotic for 2 days after transoral thyroidectomy
62640197|NCT04268407|OTHER|7-day prophylactic antibiotic|use prophylactic antibiotic for 7 days after transoral thyroidectomy
62640198|NCT06205784|EXPERIMENTAL|Prehab|
62640199|NCT06205784|NO_INTERVENTION|NoTrain|
62640200|NCT01911416|EXPERIMENTAL|All participants|All participants on study
62640201|NCT03100409|EXPERIMENTAL|Dietary modification|Personalized dietary intervention, low residue diet
62276090|NCT02700737|EXPERIMENTAL|Group B|Interventional cardiologists presented with the full dataset, including imaging parameters currently recommended by clinical practice guidelines and image-based simulation modelling.
62276091|NCT00892632|EXPERIMENTAL|1|1. To compare confocal image characteristics of benign vs. malignant biliary strictures
62276092|NCT03277976||ThermoCool SmartTouch 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
62276093|NCT03277976||ThermoCool SmartTouch 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
62640202|NCT03100409|NO_INTERVENTION|Control|Dietary recommendations currently used in the INCan
62640203|NCT05218200|EXPERIMENTAL|experimental group|In addition to the routine care in the hospital, the patient will be given deep breathing and coughing exercises.
62640204|NCT05218200|NO_INTERVENTION|Control group|There will be no intervention other than routine nursing care practices in the hospital.
62640205|NCT05852093|ACTIVE_COMPARATOR|Drug: Celecoxib+Buprenorphine Transdermal Patch|
62640206|NCT05852093|EXPERIMENTAL|Drug: Celecoxib+Buprenorphine Transdermal Patch+Tizanidine|
62640207|NCT06448962|EXPERIMENTAL|Experimental 1|AD-2021, AD-2022
62640208|NCT06448962|ACTIVE_COMPARATOR|Active Comparator 1|AD-2021, AD-2022 placebo
62640209|NCT06448962|ACTIVE_COMPARATOR|Active Comparator 2|AD-2022, AD-2021 placebo
62640210|NCT06355661|ACTIVE_COMPARATOR|ParActin®: 300 mg + MCC: 100 mg (± 10%)|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner).
62640211|NCT06355661|PLACEBO_COMPARATOR|MCC: 400 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner).
62640212|NCT03720678|EXPERIMENTAL|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal or colorectal cancer.
62640213|NCT03720678|EXPERIMENTAL|Dose Expansion-GE|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal cancer
62640214|NCT03720678|EXPERIMENTAL|Dose Expansion-CRC|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with colorectal cancer
62640215|NCT00937963|EXPERIMENTAL|Palm Oil|Traditional palm oil normally used in foods
62640216|NCT04028362||Neuromuscular blockade|Patients who will receive neuromuscular blockade during their ICU length stay will be follow until day 28 or their hospital discharge.
62640217|NCT05583097|NO_INTERVENTION|Selective cytology according to EU-TIRADS|All thyroid nodules are evaluated according to EU-TIRADS and cytology is performed according to EU-TIRADS criteria.
62640218|NCT05583097|ACTIVE_COMPARATOR|Non-selective cytology|All thyroid nodules are evaluated according to EU-TIRADS and cytology is performed on all nodules \>1 cm. Cytology will also be performed on EU-TIRADS 5-nodules measuring between 0.5 and 1 cm.
62640219|NCT03151382|EXPERIMENTAL|Experimental group|
62640220|NCT03151382|OTHER|Control group|
62640221|NCT03924323|EXPERIMENTAL|Escitalopram 10 mg/day|Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion
62640222|NCT03924323|PLACEBO_COMPARATOR|Placebo|Matching oral administration of placebo once daily
62640223|NCT03003234|OTHER|Duodenal fluid aspiration|
62640224|NCT06195644|EXPERIMENTAL|GVS group|Galvanic Vestibular Stimulation in addition to the Conventional Physical Therapy program of moderate intensity aerobic training on cyclic ergometer for upper limb and task oriented training for hand dexterity.
62640225|NCT06195644|ACTIVE_COMPARATOR|CPT group|Conventional Physical Therapy program of moderate intensity aerobic training on cyclic ergometer for upper limb and task oriented training for hand dexterity.
62640226|NCT01359930|ACTIVE_COMPARATOR|Naltrexone and Bupropion SR|
62640227|NCT01359930|PLACEBO_COMPARATOR|Placebo|
62640228|NCT06225843|EXPERIMENTAL|Sotevtamab and FOLFOX|Sotevtamab at 800 mg IV infusion once weekly on Days 1 and 8 for 6 cycles combined with FOLFOX (oxaliplatin 85 mg/m² IV infusion + leucovorin 400 mg/m² IV infusion + 5-Fluorouracil (5-FU) 400 mg/m² IV bolus + 5-FU 2400 mg/m² continuous IV infusion over 46 hours) once every 2 weeks on Day 1 for the first 4 cycles.
62640229|NCT05821387|EXPERIMENTAL|Lucid-21-302|Single-ascending dose cohorts
62640230|NCT05821387|PLACEBO_COMPARATOR|Placebo|Single-ascending dose cohorts
62640231|NCT02763774|EXPERIMENTAL|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
62276094|NCT03277976||ThermoCool SmartTouch SF 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
62640232|NCT02763774|EXPERIMENTAL|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
62640233|NCT02763774|EXPERIMENTAL|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
62640234|NCT04042571|EXPERIMENTAL|Cerebral oxymetry monitoring (NIRS)|Cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools
62640235|NCT00739648|PLACEBO_COMPARATOR|Placebo|Placebo inhaled twice daily via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
62640236|NCT00739648|EXPERIMENTAL|MP-376 240 mg Twice Daily (BID)|MP-376 240 mg BID inhaled via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
62640237|NCT03332186|EXPERIMENTAL|Mild Renal Impairment|Mild renal impairment defined as eGFR 60 to \<90 mL/min/1.73 m\^2
62640238|NCT03332186|EXPERIMENTAL|Moderate renal impairment|Moderate renal impairment defined as eGFR 30 to \<60 mL/min/1.73 m\^2
62640239|NCT03332186|EXPERIMENTAL|Severe renal impairment|Severe renal impairment defined as eGFR \<30 mL/min/1.73 m\^2, not requiring dialysis
62640240|NCT03332186|EXPERIMENTAL|Normal renal function|Normal renal function defined as eGFR ≥90 mL/min/1.73 m\^2
62640241|NCT03504618||Metastatic colon cancer patients|Colon cancer patients with metastase at the diagnostic time, impossibility of radical resection, adenocarcinoma, treated by at least 3 cycles of FOLFOXIRI in the first-line in the Oncology and Palliative Care Department
62640242|NCT06367088|EXPERIMENTAL|Experimental Arm|
62640243|NCT01645150|EXPERIMENTAL|Strength training group|12 weeks of progressive strength training
62640244|NCT01645150|NO_INTERVENTION|Control group|No intervention
62640245|NCT00692575|EXPERIMENTAL|1: Experimental|Problem-solving, education based telephone counseling.
62640246|NCT00692575|SHAM_COMPARATOR|2: No intervention|Standard of care control group
62640247|NCT04995068||Included patients|See inclusion and exclusion criteria
62640248|NCT02779140|EXPERIMENTAL|0.033 mg/kg NTM-1632|N=6 administered 0.033 mg/kg NTM-1632 IV, N=2 administered placebo IV
62640249|NCT02779140|EXPERIMENTAL|0.165 mg/kg NTM-1632|N=6 administered 0.165 mg/kg NTM-1632 IV, N=2 administered placebo IV
62640250|NCT02779140|EXPERIMENTAL|0.33 mg/kg NTM-1632|N=6 administered 0.33 mg/kg NTM-1632 IV, N=2 administered placebo IV
62640251|NCT05719896|PLACEBO_COMPARATOR|Placebo tablets|Posology: oral administration of 3 placebo tablets three times per day for 8 weeks.
62640252|NCT05719896|EXPERIMENTAL|DT01 tablets|Posology: oral administration of 3 DT01 tablets three times per day for 8 weeks.
62071393|NCT02283437|EXPERIMENTAL|Problem-solving Based Bibliotherapy|The Problem-solving Based Bibliotherapy Program (PSBPF) using a self-help manual based on problem-solving therapy defined by D'Zurilla and Nezu (2007) to be 'a self-directed cognitive-behavioral process by which a person attempts to identify/discover effective/adaptive solutions for specific problems encountered in everyday living' (p.11).
62071394|NCT02283437|ACTIVE_COMPARATOR|Behavioral Management and Education Program|The Behavioral Management and Education group program will be guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) psycho-education and McFarlane et al.'s (2003) family behavioral management programs for schizophrenia.
62071395|NCT02283437|NO_INTERVENTION|Routine Outpatient Service|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
62640253|NCT05719896|EXPERIMENTAL|DT01-Placebo tablets|Posology: oral administration of 2 DT01 tablets and 1 placebo tablet, three times per day for 8 weeks.
62640254|NCT02553642|EXPERIMENTAL|Melanoma Cancer Patients|All eligible patients with melanoma will receive ipilimumab at a dose of 3 mg/kg combined with nivolumab at a dose of 1 mg/kg. The ipilimumab and nivolumab will be dosed every 3 weeks for 4 doses. Thereafter, patients may be eligible to continue to receive nivolumab monotherapy at a dose of 240 mg administered every 2 weeks OR nivolumab at dose of 480mg every 4 weeks for up to 2 years.
62071396|NCT06374537|EXPERIMENTAL|Investigate the effects of an exercise intervention on clinically debilitated dialysis patients.|150 patients from UI Health (≥ 18 years of age), who are on dialysis, or have chronic kidney disease stage 4 (CKD 4 = GFR between 15 and 29), or have chronic kidney disease stage 5 (CKD 5 = GFR below 15) and are considered clinically debilitated by their direct healthcare professional. After the initial baseline visit, subjects will come twice weekly, for roughly 1 hour each session, for 12 months (96 visits total). Subjects will also come in for data collection visits at baseline (prior to starting the exercise program), 6 months, and 12 months. Each of those visits will take about 2-3 hours. All testing done in the 3 test visits will help assess the patient's cardiovascular and functional responses and/or changes to the exercise intervention.
62276095|NCT03277976||ThermoCool SmartTouch SF 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
62276096|NCT03390062|EXPERIMENTAL|apatinib|apatinib 500 mg orally daily until the untolerabale toxicities、desease progress or death
62640255|NCT02553642|EXPERIMENTAL|Bladder Cancer Patients|All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years. All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years.
62640256|NCT04542980||SARS-CoV2 Positive|"Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus.~A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus."
62640257|NCT04542980||Control|Control tear and serum samples will be selected from Namida Lab's own biorepository.
62640258|NCT02310217||1|Hypertensive
62276097|NCT02436850|EXPERIMENTAL|Intervention group|The intervention group will receive large volume thoracentesis.
62640259|NCT02310217||2|Normotensive
62640260|NCT01431248||Azithromycin|Azithromycin 1gm PO once
62640261|NCT01431248||Erythromycin 250mg|Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
62640262|NCT05124522|EXPERIMENTAL|MSPA eClass|
62640263|NCT05124522|NO_INTERVENTION|Waiting list|
62640264|NCT04151069||At home group|Participants with allergy to tree nuts who follow the introduction procedure A (at home)
62640265|NCT04151069||At the hospital group|Participants with allergy to tree nuts who follow the introduction procedure B (at the hospital)
62640266|NCT04151069||Control group|Participants with allergy to tree nuts who follow strict avoidance of the offending nuts.
62640267|NCT03533751|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to etokimab, administered subcutaneously (SC) every 4 weeks (Q4W) for up to 16 weeks.
62640268|NCT03533751|EXPERIMENTAL|Etokimab 20 mg SC Q4W|Participants received etokimab 20 milligrams (mg) administered SC Q4W for up to 16 weeks.
62640269|NCT03533751|EXPERIMENTAL|Etokimab 300 mg load + 150 mg SC Q8W|Participants received a 300 mg loading dose of etokimab on Day 1 then 150 mg etokimab administered SC every 8 weeks (Q8W) for up to 16 weeks. At Weeks 4 and 12 participants received placebo.
62640270|NCT03533751|EXPERIMENTAL|Etokimab 300 mg load + 150 mg SC Q4W|Participants received a 300 mg loading dose of etokimab on Day 1 then 150 mg etokimab administered SC Q4W for up to 16 weeks.
62276098|NCT02436850|NO_INTERVENTION|Control group|The control group will be taped with an 18 gauge and 20 gauge venflons and drain will not be placed.
62454913|NCT05608421|ACTIVE_COMPARATOR|Equal Attention Control|The Equal Attention Control consists of 8 sessions (7 group and one individual) that meet weekly for 60-90 minutes. The control sessions provide equal attention and psychotherapeutic experience of a support group where participants can address issues important in their lives.
62454914|NCT03577509|EXPERIMENTAL|ABCD|Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg
62454915|NCT04108325|EXPERIMENTAL|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
62640271|NCT03533751|EXPERIMENTAL|Etokimab 600 mg load + 300 mg SC Q4W|Participants received a 600 mg loading dose of etokimab on Day 1 then 300 mg etokimab administered SC Q4W for up to 16 weeks.
62640272|NCT01526785|EXPERIMENTAL|Alglucosidase alfa|Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.
62640273|NCT05701813|EXPERIMENTAL|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
62640274|NCT05701813|PLACEBO_COMPARATOR|PLACEBO|Cellulose 4.3 grams once a day for 90 days.
62640275|NCT03276598|ACTIVE_COMPARATOR|Amlodipine|One of the four monotherapy treatment periods.
62640276|NCT03276598|ACTIVE_COMPARATOR|Bisoprolol|One of the four monotherapy treatment periods.
62640277|NCT03276598|ACTIVE_COMPARATOR|Hydrochlorothiazide|One of the four monotherapy treatment periods.
62640278|NCT03276598|ACTIVE_COMPARATOR|Losartan|One of the four monotherapy treatment periods.
62640279|NCT03276598|PLACEBO_COMPARATOR|Placebo|Placebo treatment period.
62640280|NCT05350020|EXPERIMENTAL|Solu-Cortef® in deltoid muscle|Solu-Cortef® in deltoid muscle
62640281|NCT05350020|EXPERIMENTAL|Solu-Cortef® in thigh muscle|Solu-Cortef® in thigh muscle
62640282|NCT05350020|EXPERIMENTAL|Hydrocortisone 100mg/ml in deltoid muscle|Hydrocortisone 100mg/ml in deltoid muscle
62640283|NCT05350020|EXPERIMENTAL|Hydrocortisone 100mg/ml in thigh muscle|Hydrocortisone 100mg/ml in thigh muscle
62640284|NCT01831895|EXPERIMENTAL|MobiusHD™|MobiusHD™
62640285|NCT02174757|EXPERIMENTAL|Inersan|Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2.
62640286|NCT02174757|EXPERIMENTAL|Inersan and Doxycycline together|"Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.~Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2."
62640287|NCT02174757|ACTIVE_COMPARATOR|Doxycycline|Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
62640288|NCT01518569|PLACEBO_COMPARATOR|placebo|normal saline, same amount, iv
62640289|NCT01518569|ACTIVE_COMPARATOR|ulinastatin|5000 unit/kg iv
62640290|NCT03515863||Grave's disease with TAO|Patients with Grave's disease and TAO
62640291|NCT03515863||Grave's disease without TAO|Patients with Grave's disease but without TAO
62640292|NCT03790410|ACTIVE_COMPARATOR|Control group-Complex pulmonary rehab.|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings."
62640293|NCT03790410|ACTIVE_COMPARATOR|Inspiratory muscle training group|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.~Inspiratory muscle training~The training program contains strengthening exercises on the diaphragm muscle."
62640294|NCT03883243|NO_INTERVENTION|Control|Patients will only receive a brochure explaining the importance of physical activity with recommendations to improve it.
62071397|NCT06374537|NO_INTERVENTION|Control|The control arm will receive no exercise intervention. Subjects will also come in for data collection visits at baseline (prior to starting the exercise program), 6 months, and 12 months. Each of those visits will take about 2-3 hours. All testing done in the 3 test visits will help assess the patient's cardiovascular and functional responses.
62276099|NCT02407678|EXPERIMENTAL|Treatment|Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
62640295|NCT03883243|EXPERIMENTAL|Telecoaching|Patients will receive a brochure explaining the importance of physical activity with recommendations to improve it. Next to this patients will receive the telecoaching intervention in which a coaching application linked to a step counter is installed on the patients smartphone, which will weekly give a new physical activity goal to improve the amount of steps per day for 8 weeks.
62640296|NCT03026946|ACTIVE_COMPARATOR|Alitretinoin|Patients with severe recurrent vesicular hand eczema, randomized to treatment with alitretinoin.
62276100|NCT02407678|NO_INTERVENTION|Control|Untreated eye
62071398|NCT04355559||conventional oxygen therapy|Continuous use of current oxygen therapy
62276101|NCT04949100|EXPERIMENTAL|Microcurrent|
62071399|NCT04355559||high flow nasal cannula|change the oxygen therapy to high flow nasal cannula
62071400|NCT04355559||Noninvasive ventilation|change the oxygen therapy to noninvasive ventilation
62276102|NCT04949100|PLACEBO_COMPARATOR|Placebo|
62276103|NCT02266693|EXPERIMENTAL|ICBT Group|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
62276104|NCT02266693|NO_INTERVENTION|Waitlist Group|Upon completion of the 8-week study wait-list period (i.e. their study participation), the opportunity to participate in iCBT, outside the study framework will be provided.
62276105|NCT05556499||HPT patients|Patients with primary hyperparathyroidism at diagnosis (HPT) treated with parathyroidectomy (HPT-PTX)
62276106|NCT06189937|EXPERIMENTAL|Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)|Participants in the experimental group will receive an 8-session group CA-CBT.
62454916|NCT02036372|EXPERIMENTAL|BR (bolus regimen)|"* Day before surgery: half evening dose long acting insulin~* Day of surgery:~  * patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets~ * patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets~* Measure blood glucose every 60 minutes, start 30 min prior to surgery~* Give bolus of insulin according to treatment algorithm"
62454917|NCT02036372|EXPERIMENTAL|LG (Liraglutide)|"* Day before surgery: half dose of long acting and mealtime insulin from start liraglutide~* Day of surgery: withhold own insulin, stop oral glucose lowering tablets~* Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.~* In case of nausea graded higher than minimal, the patient will be excluded from the study~* Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.~* Measure glucose every 60 minutes, start 30 min prior to surgery~* Adjust according to bolus algorithm of BR group"
62640297|NCT03026946|ACTIVE_COMPARATOR|Cyclosporin A|Patients with severe recurrent vesicular hand eczema, randomized to treatment with cyclosporin A.
62640298|NCT02310074|EXPERIMENTAL|Pulsatile Gonadotropin Releasing Hormone|Pulsatile Gonadotropin Releasing Hormone: subjects in the GnRH group initiated a regimen of pulsatile GnRH administered subcutaneously via a portable infusion pump for 18 months.
62640299|NCT02310074|ACTIVE_COMPARATOR|combination gonadotropin therapy|combined human chorionic gonadotropin (hCG)/urinary Follicle-Stimulating Hormone (uFSH) therapy:HCG treatment was maintained alone for 6 months and then uFSH was added for the next 12 months
62640300|NCT03545945|EXPERIMENTAL|Study arm|Patients having office diagnostic hysteroscopy and endometrial biopsy
62640301|NCT03545945|OTHER|Control arm|Patients having only endometrial biopsy
62640302|NCT03020485|EXPERIMENTAL|Isomaltulose|50g of isomaltulose dissolved in 250ml of water
62640303|NCT03020485|EXPERIMENTAL|Sucrose|50g of sucrose dissolved in 250ml of water
62640304|NCT04805671|EXPERIMENTAL|ADG20 IM|Participants will be dosed on Day 1 with ADG20 IM
62640305|NCT04805671|PLACEBO_COMPARATOR|Placebo IM|Participants will be dosed on Day 1 with placebo IM
62640306|NCT02144701|EXPERIMENTAL|Lactobacillus rhamnosus GG|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
62276107|NCT06189937|NO_INTERVENTION|Enhanced Care as Usual (E-CAU)|Participants in the control group will receive pamphlets containing information on mental health issues following earthquakes, coping strategies, and free psychological support centers. After completing all assessments, CA-CBT will be offered to these participants.
62276108|NCT05483530|EXPERIMENTAL|HLX60 combined with HLX10|
62276109|NCT01249352|ACTIVE_COMPARATOR|STANDARD CHEMORADIATION|"Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
62276110|NCT01249352|EXPERIMENTAL|CHEMORADIATION + NIMOTUZUMAB|"Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
62640307|NCT02144701|NO_INTERVENTION|No intervention|Patients receive no intervention.
62640308|NCT05006378|PLACEBO_COMPARATOR|Placebo Capsule|
62640309|NCT05006378|EXPERIMENTAL|Chamomile Tea|Subjects will consume three servings of chamomile tea throughout the day for the one-week treatment period. Each tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
62640310|NCT05006378|EXPERIMENTAL|Chamomile Extract Capsule|Subjects will consume three chamomile capsules throughout the day for the one-week treatment period. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
62640311|NCT02314728|ACTIVE_COMPARATOR|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
62640312|NCT02314728|ACTIVE_COMPARATOR|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
62640313|NCT01262144||Case group|
62640314|NCT02547753||Transplanted group|patients who are kidney receptors for at least 6 months and need tooth extraction
62640315|NCT02547753||Control group|healthy patients who need tooth extraction
62276111|NCT01726946|EXPERIMENTAL|VX-135 High Dose with ribavirin|12 weeks of a high dose of VX-135 in combination with ribavirin
62640316|NCT00297648|EXPERIMENTAL|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg
62640317|NCT03772808|EXPERIMENTAL|Lycocomfort|The once-daily supplement LycoComfort™ is a combination of lycopene and beta-sitosterol, a chemically defined extract of phytosterols with beta-sitosterol as the main component,
62640318|NCT06077344||Wide - Awake Local Anesthesia No Tourniquet|"WALANT solution used in our institution is prepared by mixing 20 ml of 2% lidocaine, with 0,4 ml 1:1000 (1 mg/ml) adrenaline in addition to 20 ml of 0,9% normal saline as described by Barros~In the study, perop parameters to be checked are perop Visual Analogue Scale (VAS; at regular intervals (every 15 minutes, etc.) VAS evaluation, the highest value will be recorded), the time spent in the operating room~Early postoperative parameters; Morphine consumption in PCA (in PCA device) the amount of morphine used in the postoperative 24 hours), the postoperative VAS (the postoperative 24th hour VAS) evaluation;)."
62640319|NCT06077344||Applied Under Spinal Anesthesia|"Applied Under Spinal Anesthesia~Early postoperative parameters; Morphine consumption in PCA (in PCA device) the amount of morphine used in the postoperative 24 hours), the postoperative VAS (the postoperative 24th hour VAS) evaluation;)."
62640320|NCT04214587||baseline assessment group|n=150 patiënts for baseline assessment
62640321|NCT04214587||clinical need for reintervention group|n=20-30 patiënts for re-bronchoscopy
62454918|NCT02036372|ACTIVE_COMPARATOR|GIK (glucose -insulin - potassium) infusion|"* Day before surgery: half evening dose long acting insulin~* Day of surgery: stop oral glucose lowering tablets and withhold own insulin.~* GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.~* Calculate the insulin amount in the GIK infusion according to the formula:~I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg~* Measure blood glucose every 60 minutes, start 30 min prior to surgery~* Adjust glucose \> 8 mmol/l according to treatment algorithm"
62071401|NCT01465503|PLACEBO_COMPARATOR|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparin (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
62454919|NCT04541719|ACTIVE_COMPARATOR|Patient-controlled remifentanil analgesia|Patients will received Patient-controlled remifentanil analgesia starting from labour pain until delivery
62071402|NCT01465503|ACTIVE_COMPARATOR|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR \<30 ml/min/1.73 m2.
62071403|NCT04879316||adult patients with NSCLC initiating nivolumab or pembrolizumab|Patients underwent a multidisciplinary evaluation including consultation with an oncologist and a dietitian. Such an assessment includes subjective and objective parameters such as medical history, weight loss, current dietary intake (including energy and protein balance), physical examination and anthropometric measurements, functional and mental assessment, medications, Resting Energy Expenditure measurement using indirect calorimetry and laboratory values.
62071404|NCT02735733|ACTIVE_COMPARATOR|Room temperature arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at room temperature.
62071405|NCT02735733|EXPERIMENTAL|Cold arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at approximately 32 degrees F for the study group.
62276112|NCT01726946|EXPERIMENTAL|VX-135 Low Dose with ribavirin|12 weeks of a low dose of VX-135 in combination with ribavirin
62454920|NCT04541719|PLACEBO_COMPARATOR|Epidural analgesia|Patients will received continuous epidural analgesia starting from labour pain until delivery
62454921|NCT03307239|EXPERIMENTAL|cold application (experimental group)|subjects in the experimental group (n = 30) received cold application of 600 g ice packs 15 minutes before CTR
62276113|NCT03063580|EXPERIMENTAL|SAR439954 with or without rifampicin|Period 1: single oral dose of 400 mg sotagliflozinon Day 1 morning Period 2: once-daily oral doses of 600 mg rifampicin from Days 1 to 10 and a single oral dose of 400 mg sotagliflozin
62276114|NCT04438174|EXPERIMENTAL|Amniotic Fluid Injection|Processed Amniotic Fluid. Dose is 1ml/5cm2; Route: injected directly into wound; Limited to two injections. The wound will then be dressed according to standard of care.
62287168|NCT01814787|NO_INTERVENTION|Usual Care|Those patients who are assigned to the control group will have the CHICA system but will NOT be cared for using the CHICA Type 2 Diabetes Module. The CHICA system will notify the physician of the child's BMI percentile on the physician worksheet. However, the CHICA system will not ask for any additional information related to risk factors for type 2 diabetes on the pre-screening form, no advice will be provided to the physician on the physician worksheet, nor will just-in-time documents or automated reminder calls be made available. Identification of patients at risk for type 2 diabetes and care of those patients will occur through routine practices for that clinic.
62454922|NCT03307239|SHAM_COMPARATOR|tap water packs application (sham group)|subjects in the sham group (n = 30) received tap water packs.
62454923|NCT02551497|EXPERIMENTAL|Other drug|Other drug BID
62454924|NCT02551497|EXPERIMENTAL|placebo|Placebo to match BID
62454925|NCT03164395|EXPERIMENTAL|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
62454926|NCT03164395|ACTIVE_COMPARATOR|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
62640322|NCT04214587||clinical stable controls|n=20 stable treated control patiënts
62640323|NCT02100046|EXPERIMENTAL|ethosuximide|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
62640324|NCT02100046|OTHER|control group|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
62640325|NCT04727957||Dataset for development and testing|
62640326|NCT04727957||Dataset for external validation|
62640327|NCT00313729|EXPERIMENTAL|Temozolomide|Temozolomide
62640328|NCT00629031|ACTIVE_COMPARATOR|2|Paromomycin for 21 days @ 11mg/kg
62640329|NCT00629031|EXPERIMENTAL|1|Paromomycin for 14 days @ 11mg/kg
62640330|NCT02365662|EXPERIMENTAL|Arm 1|Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
62640331|NCT01022333|EXPERIMENTAL|DIM group (BRCA1 carriers)|This group will have up to 100 women who are carriers of a BRCA1 deleterious mutation. To ensure safety, women in this group will not be able to participate in the study if they are under medications with warfarin, theophylline, or anticonvulsants; or if they are pregnant, breast-feeding or planning to become pregnant within 6 months of the research project. Women in this group will receive 300 mg per day of Rx Balance BioResponse DIM for six weeks. Supplements will be given free of charge. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be during the six weeks of DIM supplementation (4-6 weeks after the first clinic visit).
62071406|NCT04110366|EXPERIMENTAL|Live attenuated influenza vaccine|Participants receiving live attenuated influenza vaccine (LAIV)
62640332|NCT01022333|NO_INTERVENTION|No DIM group (BRCA1 carriers)|This group will have up to a 100 women who are carriers of a BRCA1 deleterious mutation. This group will not receive DIM. Women that choose not to take DIM will be in this group. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be 4-6 weeks after the first clinic visit.
62640333|NCT01022333|NO_INTERVENTION|General Control Group|This group will have up to 100 women who do not carry a BRCA1 mutation but who come from BRCA1 carrier family (a family with at least one individual that has tested positive for a BRCA1 mutation). A control subject is considered negative for a BRCA1 mutation if she has been confirmed by direct DNA sequencing to not be a carrier of this gene. A blood sample (20cc) and a urine sample (20cc) will be collected from these women at a single clinic visit.
62640334|NCT04584515|EXPERIMENTAL|IMP4297 40 mg|Sequential treatments of IMP4297 alone, followed by Itraconazole + IMP4297, with a washout period in between.
62640335|NCT04584515|EXPERIMENTAL|IMP4297 100 mg|Sequential treatments of IMP4297 alone, followed by Rifampin + IMP4297, with a washout period in between.
61978731|NCT02812147|ACTIVE_COMPARATOR|L-DOPS|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.
62071407|NCT04110366|EXPERIMENTAL|Mucosal immune stability cohort|Participants receiving a vehicle control nasal challenge
62640336|NCT01635452||Patients treated with Esmya|
62640337|NCT04708158|EXPERIMENTAL|Active|Inhaled Novaferon, given 20 ug BID, daily for 7 days
62071408|NCT00210119|EXPERIMENTAL|Imatinib mesylate|Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.
62454927|NCT05075564|EXPERIMENTAL|Part 1 dose escalation|ES002023 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
62071409|NCT04639778|ACTIVE_COMPARATOR|Control Group|In the control group, patients will follow a care pathway respecting the current recommendations : a systematic clinical visit scheduled each year with the multidisciplinary team.
62071410|NCT04639778|EXPERIMENTAL|Experimental Group|In the intervention group, patients will follow a new care pathway with visits triggered by weight evolution
62071411|NCT00602186|EXPERIMENTAL|1|taking Tamsulosin
62071412|NCT00602186|ACTIVE_COMPARATOR|2|taking prasosin
62071413|NCT02085343|EXPERIMENTAL|EXP + SBF + AA|Exposure therapy (EXP) with safety behavior fading (SBF) and anti-phobic action (AA)
62640338|NCT04708158|PLACEBO_COMPARATOR|Placebo|Inhaled saline (placebo), given BID, daily for 7 days
62640339|NCT02823470|EXPERIMENTAL|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
62640340|NCT02823470|EXPERIMENTAL|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
62640341|NCT02730611||Patients|Patients with morbid obesity and vertical sleeve gastrectomy
62640342|NCT01613261|EXPERIMENTAL|TAK-733 and alisertib|
62640343|NCT05057689|EXPERIMENTAL|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 200 mcg.
62640344|NCT05057689|EXPERIMENTAL|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 100 mcg.
62071414|NCT02085343|ACTIVE_COMPARATOR|EXP + SBF|Exposure therapy (EXP) with safety behavior fading (SBF)
62071415|NCT02085343|ACTIVE_COMPARATOR|EXP|Standard therapist-guided in vivo exposure therapy (EXP)
62071416|NCT02085343|NO_INTERVENTION|Wait-list control|Subjects assigned to this arm will undergo assessments at Weeks 0, Week 1, and Week 5, but will not receive any interventions.
62276115|NCT04438174|ACTIVE_COMPARATOR|Standard of Care Wound Treatment Regimen|Primary dressings are variable and based on the moisture content and microorganism load. In general, wounds respond differently to various topical treatments. Through our clinical practice, we have found that wounds plateau with the same topical for greater than 4 weeks, hence changing antimicrobial topical helps to manage the bacterial overgrowth. We will start with our application of our slurry, a 1:1:1 ratio of Nystatin ointment, Mupirocin Ointment, and Bacitracin Ointment. This slurry will be applied directly to the cleansed wound, followed by silver gauze/foam product to all wounds. Types of silver product- site and comfort predict use of Restore, Mepilex-AG, or Mepitel-AG. If allergies to the above slurry occurs, we will use medical honey with or without bacitracin. If ointment related rash present with transition to silver product only or silver product plus medical honey.
62276116|NCT03064841||Outpatient with confirmed T2DM|subjects with confirmed T2DM
62640345|NCT05057689|EXPERIMENTAL|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart. The maximum dose will be 10 mg
62640346|NCT05830760|EXPERIMENTAL|patients with aortic valve stenosis with heart failure|
62071417|NCT00657514|ACTIVE_COMPARATOR|A|Drug arm - 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
62071418|NCT00657514|PLACEBO_COMPARATOR|P|Placebo arm - 1 tablet po bid up to 2 tablets po bid if tolerated
62276117|NCT03830710||Group A|30 patients diagnosed with oral leukoplakia
62640347|NCT05830760|EXPERIMENTAL|patients with aortic valve stenosis without heart failure|
62640348|NCT05874232|EXPERIMENTAL|Heartfulness Group|Participants were asked to practice relaxation tools for 15 minutes a day using the calendar and HeartBot app, and participate in once a weekly webinar for 30 minutes during the four weeks. The GAD, SWLS, and UCLA Loneliness scale was recorded prior to the start of the study, at the end of the program at Week 4, and after the duration of 4 weeks at Week 8. The score was reviewed to see the changes in anxiety, satisfaction with life, and loneliness scale.
62640349|NCT05874232|NO_INTERVENTION|Control Group|The control group had no change in their daily routines.
62276118|NCT03830710||Group B|30 patients diagnosed with oral lichen planus
62640350|NCT01719549|EXPERIMENTAL|Dovitinib|
62640351|NCT02992119|EXPERIMENTAL|Group 1|RTS,S/AS01B Fractional dose
62071419|NCT03677882|NO_INTERVENTION|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
62640352|NCT02992119|EXPERIMENTAL|Group 2|Double RTS,S/AS01E Fractional dose
62071420|NCT03677882|EXPERIMENTAL|Treatment As Usual with Mind-Body Bridging (TAU + MBB)|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
62640353|NCT02992119|EXPERIMENTAL|Group 3|RTS,S/AS01E Standard dose
62276119|NCT03830710||Group C|30 patients having oral squamous cell carcinoma with the tongue being the most commonly affected site
62640354|NCT02992119|EXPERIMENTAL|Group 4|RTS,S/AS01E + DHA-PIP+PQ Standard dose
62071421|NCT04114240||Xybilun: mild erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with mild ED (score IIEF-6 between 22 and 25) and begin treatment at 50 mg
62071422|NCT04114240||Xybilun: moderate erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with moderate ED (score IIEF-6 between 11 and 21) and begin treatment at 50 mg
62071423|NCT04114240||Xybilun: severe erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with severe ED (score between 6 and 10) and begin treatment at 50 mg
62276120|NCT03830710||Group D|30 age and gender matched individuals having no oral mucosal lesions acting as a control group
62640355|NCT02992119|EXPERIMENTAL|Group 5|RTS,S/AS01E Fractional dose
62640356|NCT02992119|EXPERIMENTAL|Group 6|RTS,S/AS01E + DHA-PIP+PQ Fractional dose
62071424|NCT04114240||Xybilun switch|Substitution dose to dose of previous treatment by Xybilun whatever the severity of ED.
62088352|NCT04055896|EXPERIMENTAL|TAPER|"The intervention is medication reduction. This arm is comprised of:~1. Medication reconciliation~2. Identification of patient priorities for care~3. Identification of medications that are potentially appropriate for discontinuation/dose reduction~4. Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~5. Identification of medications for trial of discontinuation/dose reduction (shared decision making) Pause of medication and clinical monitoring"
62276121|NCT03861143|EXPERIMENTAL|BT-11 low-dose (440 mg)|Oral, once daily tablet
62640357|NCT02992119|EXPERIMENTAL|Group 7|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
62640358|NCT02421354|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks for 8 doses and then once every 12 weeks thereafter. Treatment may continue for up to 4 years in the absence of disease progression or unacceptable toxicity.
62640359|NCT05341024|EXPERIMENTAL|Intervention Group|16 weeks home-based PFM training program with weekly follow-up by a physiotherapist
62640360|NCT05341024|NO_INTERVENTION|Control Group|No intervention
62276122|NCT03861143|EXPERIMENTAL|BT-11 high-dose (880 mg)|Oral, once daily tablet
62276123|NCT03861143|PLACEBO_COMPARATOR|Placebo|Oral, once daily tablet
62287169|NCT03160014|EXPERIMENTAL|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
62287170|NCT03160014|EXPERIMENTAL|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
62640361|NCT05455827|EXPERIMENTAL|Intervention A|Enhancing condition differences between guilt and indignation BOLD activations of subgenual anterior cingulate cortex.
62640362|NCT05455827|ACTIVE_COMPARATOR|Intervention B|Minimising condition differences between guilt and indignation BOLD activations of subgenual anterior cingulate cortex.
62640363|NCT02486692|EXPERIMENTAL|Phase II- Experimental Group|Participants were provided with instructions and a web link for accessing the AboutFace website after the baseline assessment.
62640364|NCT02486692|NO_INTERVENTION|Phase II- Usual Care Group|Participants were provided with instructions and a web link for accessing some online PTSD education materials after the baseline assessment.
62071425|NCT02732860||Triple Negative Breast Cancer|"Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).~After the screening procedures confirms patient eligibility:~* Molecular Profiling will be performed on clinical sample~* pPDX generation for in vivo drug testing~* In vitro organoid culture generation (if sufficient fresh tissue available)~* Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
62071426|NCT02732860||Colorectal Cancer|"Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).~After the screening procedures confirms patient eligibility:~* Molecular Profiling will be performed on clinical sample~* pPDX generation for in vivo drug testing~* In vitro organoid culture generation (if sufficient fresh tissue available)~* Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
62640365|NCT01730807|EXPERIMENTAL|IntellaTip XP MiFi|Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
62640366|NCT04238936||study group ; Patients with gestational diabetes|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
62071427|NCT02732860||High Grade Serous Ovarian Cancer|"High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).~After the screening procedures confirms patient eligibility:~* Molecular Profiling will be performed on clinical sample~* pPDX generation for in vivo drug testing~* In vitro organoid culture generation (if sufficient fresh tissue available)~* Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
62276124|NCT06286748|ACTIVE_COMPARATOR|Intervention|Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.
62640367|NCT04238936||control group ; healthy pregnant women|Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
62640368|NCT00890448||Lapaquistat acetate participants|
62640369|NCT03154086|EXPERIMENTAL|Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg|Subjects will receive single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640370|NCT03154086|EXPERIMENTAL|Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640371|NCT03154086|EXPERIMENTAL|Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640372|NCT03154086|EXPERIMENTAL|Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640373|NCT03154086|EXPERIMENTAL|Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed|Subjects will receive single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640374|NCT03154086|EXPERIMENTAL|Part A: Cohort 2: Placebo Fasted/Placebo Fed|Subjects will receive single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640375|NCT03154086|EXPERIMENTAL|Part A:Cohort 3: GSK3352589 150 mg/Placebo|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62071428|NCT02732860||Other tumor types|"Other selected tumor types at the discretion of the PI (n= up to 30)~After the screening procedures confirms patient eligibility:~* Molecular Profiling will be performed on clinical sample~* pPDX generation for in vivo drug testing~* In vitro organoid culture generation (if sufficient fresh tissue available)~* Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
62640376|NCT03154086|EXPERIMENTAL|Part A:Cohort 3: Placebo/GSK3352589 400 mg|Subjects will receive single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640377|NCT03154086|EXPERIMENTAL|Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
62640378|NCT03154086|EXPERIMENTAL|Part B: GSK3352589|Subjects will receive repeat oral doses of GSK3352589 of 5 mg, 15 mg, 50 mg, 100 mg or 200 mg twice daily administered for 14 days.
62640379|NCT03154086|PLACEBO_COMPARATOR|Part B: Placebo|Subjects will receive repeat oral doses of placebo twice a day tablet administered for 14 days.
62640380|NCT02589145|EXPERIMENTAL|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.~Melphalan administered at 60 mg/m2 on days -3 and -2.~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
62640381|NCT00455169||1|Premature infants
62640382|NCT00455169||2|Full term infants
62071429|NCT05348408|ACTIVE_COMPARATOR|platelet rich plasma|patients will be injected perineural platelet rich plasmawith 1.5 to 3 ml around each affected nerve
62071430|NCT05348408|SHAM_COMPARATOR|contact group|only medical treatment in form of opioid and NSAIDs will be used
62640383|NCT04549493|ACTIVE_COMPARATOR|Trauma Management Therapy|1. Trauma Management Therapy (TMT; Turner, Beidel, \& Frueh, 2005): TMT is a multicomponent behavioral treatment program designed to target various aspects of chronic PTSD - reducing emotional and physiological reactivity to traumatic cues, reducing intrusive symptoms and avoidance behavior, improving interpersonal skills and emotion modulation (e.g., anger control), and increasing the range of enjoyable social activities. In this investigation and in line with our previous publications, TMT will include virtual-reality augmented exposure (i.e. olfactory stimulation, heart rate, and skin conductance); group therapy to address sleep, anger, depression, and social isolation; homework assignments; and programmed practice. In the 3-week treatment program, each participant receives virtual-reality assisted exposure in the morning followed by in vivo exposure and group therapy (SER) each afternoon for a total of 29 sessions.
62276125|NCT06286748|PLACEBO_COMPARATOR|Placebo|Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
62640384|NCT04549493|ACTIVE_COMPARATOR|Prolonged Exposure|2. Standard Prolonged Exposure (PE; Foa, Hembree, \& Rothbaum, 2007) consists of psychoeducation, imaginal exposure to trauma memories, in vivo exposure to situations that are avoided due to their association with the trauma, and emotional processing. The standard protocol consists of 12 imaginal exposure sessions, along with in vivo exposure/homework assignments and listening to a recording of the imaginal sessions at home during the evening.
62640385|NCT04549493|ACTIVE_COMPARATOR|Compressed Prolonged Exposure|3. Compressed PE consists of 10 standard PE sessions delivered on consecutive work days. The imaginal exposure sessions take place in the morning, with in vivo exposures assigned (not therapist accompanied) for the afternoons. Patients are instructed to listen to the recordings of the imaginal exposure each night. Being most concerned with having enough time for in vivo practice, Session 1 does not start on a Monday, allowing for two full weekends in order to maximize in vivo exposures. Both versions of PE average 36 total treatment hours.
62640386|NCT04353726|EXPERIMENTAL|Intervention group|Eligible participants will be in an intervention group led by a registered dietitian
62640387|NCT01535924|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1 and 2. Treatment repeats every 21-28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62071431|NCT05951725|EXPERIMENTAL|Experimental vaccine group A，3 months old|4 doses of DTcP vaccine (0.5 ml) on Day 0 and Month 1,2,15\~21
62276126|NCT03766880|EXPERIMENTAL|Single arm study|Participants will receive MR imaging, transjugular HVPG measurement, and analysis per protocol.
62276127|NCT04163068||Interview with researcher|All participants will participate in an interview with a researcher
62071432|NCT05951725|ACTIVE_COMPARATOR|Control vaccine group B，3 months old|4 doses of DTaP vaccine (0.5 ml) on Day 0 and Month 1,2,15\~21
62071433|NCT05951725|ACTIVE_COMPARATOR|Control vaccine group C，3 months old|4 doses of DTaP-IPV-Hib vaccine (0.5 ml) on Day 0 and Month 1,2,15\~21
62071434|NCT05951725|EXPERIMENTAL|Experimental vaccine group D，2 months old|4 doses of DTcP vaccine (0.5 ml) on Day 0 and Month 1,2,16\~22
62071435|NCT05951725|ACTIVE_COMPARATOR|Control vaccine group E，2 months old|4 doses of DTaP-IPV-Hib vaccine (0.5 ml) on Day 0 and Month 1,2,16\~22
62287171|NCT03160014|EXPERIMENTAL|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
62640388|NCT01401595|EXPERIMENTAL|Night Eaters|Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
62640389|NCT01401595|NO_INTERVENTION|Control Subjects|"At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls."
62640390|NCT04381078|EXPERIMENTAL|Intervention|Standardised Verbal Instructions Standardised Written Instructions Audiovisual Guide
62640391|NCT04381078|NO_INTERVENTION|Control|Standardised Verbal Instructions Standardised Written Instructions
62640392|NCT00954681|EXPERIMENTAL|quetiapine treatment|Open label treatment with quetiapine
62640393|NCT05514730|EXPERIMENTAL|Experimental Treatment|The experimental treatment is Phase-Based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children, an innovative intervention demonstrating promise in preliminary testing.
62640394|NCT05514730|ACTIVE_COMPARATOR|Control Treatment|The Control Treatment will utilize a Treatment-as-Usual (TAU) condition designed to mimic the types of treatment generally provided in the community for mental health concerns of children.
62640395|NCT02833896||endometrial cancer|
62640396|NCT02833896||Control|
62640397|NCT02001701|EXPERIMENTAL|Intravitreal Gas|Intravitreal injection of sulfahexafluoride gas
62640398|NCT05117060|EXPERIMENTAL|LEO 152020 tablet - Dose regimen 1|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
62640399|NCT05117060|EXPERIMENTAL|LEO 152020 tablet - Dose regimen 2|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
62640400|NCT05117060|EXPERIMENTAL|LEO 152020 tablet - Dose regimen 3|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
62071436|NCT05951725|EXPERIMENTAL|Experimental vaccine group F，2 months old|4 doses of DTcP vaccine (0.5 ml) on Day 0 and Month 2,4,16\~22
62287172|NCT03160014|EXPERIMENTAL|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
62640401|NCT05117060|PLACEBO_COMPARATOR|LEO 152020 placebo tablet|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
62640402|NCT05968313||NSSI|
62640403|NCT05968313||HC|
62640404|NCT05433467|EXPERIMENTAL|CT-guided localization for micro hepatocellular carcinoma before surgical resection|fter preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
62640405|NCT02509377|EXPERIMENTAL|BMI 35.0 to 40.0|"Mothers who meet all inclusion exclusion criteria for open fetal repair of myelomeningocele except BMI.~These mothers have a BMI between 35.0 and 40.0"
62640406|NCT04085601|NO_INTERVENTION|Standard of Care (SOC) excluding complement inhibitors|
62640407|NCT04085601|EXPERIMENTAL|1,080mg APL-2 administered subcutaneously twice weekly|
62640408|NCT03745053|EXPERIMENTAL|XLIMUS DES|Xlimus DES Implantation during coronary angioplasty
62640409|NCT03745053|ACTIVE_COMPARATOR|Synergy DES|Synergy DES Implantation during coronary angioplasty
62640410|NCT04772066||Non adherent patients|Non adherent patients
62640411|NCT04772066||Adherent patients|Adherent patients
62640412|NCT05556603||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a blood sample will be collected.
62640413|NCT05556603||Benign disease arm|Participants with benign pancreatic diseases, from whom a blood sample will be collected.
62640414|NCT05556603||Healthy arm|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
62640415|NCT05556603||High risk for pancreatic cancer arm|Participants with high risk for pancreatic cancer, from whom a blood sample will be collected.
62640416|NCT00699777|EXPERIMENTAL|1|One risedronate 150 mg tablet administered orally after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
62640417|NCT00699777|ACTIVE_COMPARATOR|2|Two risedronate 75 mg tablets administered as a single oral dose after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
62640418|NCT03708471|EXPERIMENTAL|Two-stage hybrid abltaion|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will receive percutaneous catheter ablation and recommendations about cardiovascular risk control.
62640419|NCT03708471|ACTIVE_COMPARATOR|Thoracosopic surgical ablation|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will only receive recommendations about cardiovascular risk control.
62640420|NCT02599532|OTHER|Nephrotic syndrome|Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
62640421|NCT02599532|OTHER|Non-nephrotic syndrome|Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
62640422|NCT04247516|NO_INTERVENTION|Standard Control Group|The standard control group (CG) will not have access to the self-regulatory (SR) intervention program.
62640423|NCT04247516|EXPERIMENTAL|Online-intervention group I (IGI)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration."
62071437|NCT00630058|EXPERIMENTAL|Group A (MP-424 High)|
62071438|NCT00630058|EXPERIMENTAL|Group B (MP-424 Low)|
62071439|NCT03241524|EXPERIMENTAL|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
62276128|NCT05304507|EXPERIMENTAL|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
62071440|NCT03377790|ACTIVE_COMPARATOR|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% \[w/v\] cantharidin) solution.
62071441|NCT03377790|PLACEBO_COMPARATOR|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
62287173|NCT05808036|OTHER|DOMINO app - DOMINO app|The patients start with the DOMINO diet (8 weeks). Patients that experienced symptom improvement, will continue with the DOMINO diet (6 weeks).
62454928|NCT05075564|EXPERIMENTAL|Part 2 dose expansion|Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
62640424|NCT04247516|EXPERIMENTAL|Online-intervention group II (IGII)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration; iii) the program includes gamification strategies with the purpose of promoting engagement in participants."
62640425|NCT02307227|EXPERIMENTAL|Locally advanced HER2+ breast cancer pts|"HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision"
62640426|NCT02307227|EXPERIMENTAL|Locally advanced HER2- breast cancer pts|"HER2 negative:~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision."
62640427|NCT05438277|EXPERIMENTAL|methylprednisolone acetate (MPA)|subacromial or glenohumeral shoulder injection
62276129|NCT05304507|ACTIVE_COMPARATOR|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
62276130|NCT01088581|NO_INTERVENTION|Observation group|No adjuvant chemotherapy after resection
62640428|NCT05438277|ACTIVE_COMPARATOR|triamcinolone acetonide (TA)|subacromial or glenohumeral shoulder injection
62640429|NCT05775627|EXPERIMENTAL|Sleep Restriction First|"Equivalent to obtaining 5.5.h of sleep per 24h; n=10. Participants live on a 20h-day and will experience 15.33h wake episodes followed by sleep episodes of 4.67h long.~Ad libitum food is provided during this time and participants will be fed \~130-150% of their daily caloric needs across three meals a day."
62276131|NCT01088581|ACTIVE_COMPARATOR|Adjuvant group|Adjuvant chemotherapy after resection
62640430|NCT05775627|NO_INTERVENTION|Controlled Condition First|"Equivalent to obtaining 8h sleep per 24h; n=10. Participants live on a 20h-day and will experience 13.33h wake episodes followed by 6.67h sleep opportunities.~Ad libitum food is provided during this time and participants will be fed \~130-150% of their daily caloric needs across three meals a day."
62640431|NCT03722706|EXPERIMENTAL|Handbook|handbook provided as an adjunct to standard AD management with a healthcare provider at BCH
62640432|NCT03722706|NO_INTERVENTION|Control|standard management alone
62640433|NCT01690507|OTHER|DCAG plus HLI|
62276132|NCT05878652|EXPERIMENTAL|Experimental Arm|Participants will utilize a 3D printed knee extension device and an at-home prehabilitation program designed to be used with the 3D printed knee extension device.
62640434|NCT02586376|SHAM_COMPARATOR|0J LLLT|The intervention will be made with the machine off.
62276133|NCT05878652|OTHER|Control Arm|Participants will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
62640435|NCT02586376|EXPERIMENTAL|4J LLLT|The Laser radiation will be made with 4J by spot.
62640436|NCT02586376|EXPERIMENTAL|6J LLLT|The Laser radiation will be made with 6J by spot.
62640437|NCT02586376|EXPERIMENTAL|8J LLLT|The Laser radiation will be made with 8J by spot.
62640438|NCT01753609|EXPERIMENTAL|Tulip capsule|swallowing Tulip capsule for up to 29 days
62276134|NCT02750787|EXPERIMENTAL|Nutritional Study Product|A ready-to-drink peptide-based liquid formula for patients with impaired gastro-intestinal function.
62640439|NCT05932758|OTHER|no excisional biopsy|Patients in this arm underwent to an initial sequence of sampling (less than 4 g of tissue sampled)
62640440|NCT05932758|EXPERIMENTAL|excisional biosy|Patients in this arm will undergo a second sequence of biopsy samples (at least 4g sampled)
62640441|NCT01128296|EXPERIMENTAL|Hydroxychloroquine + Gemcitabine (HcGc)|Hydroxychloroquine orally twice daily in combination with gemcitabine for 31 days prior to surgical resection
62640442|NCT01663402|PLACEBO_COMPARATOR|Placebo|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.
62071442|NCT04353193|EXPERIMENTAL|Terlipressin IV bolus|Terlipressin 1mg IV bolus
62276135|NCT02527980||dual users|Individuals who at the point of study enrollment are using both electronic cigarettes (ecig) and commercial cigarettes (CCs)
62276136|NCT02527980||commercial cigarette (CC) only users|Individuals who at the point of study enrollment are using exclusively commercial cigarettes
62276137|NCT02561091|PLACEBO_COMPARATOR|Placebo|Placebo gel for intratympanic use
62276138|NCT02561091|EXPERIMENTAL|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
62640443|NCT01663402|EXPERIMENTAL|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels \>=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were \<25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were \<15 mg/dL (0.39 mmol/L).
62640444|NCT00742911|EXPERIMENTAL|1|
62640445|NCT04787367|EXPERIMENTAL|Early-operative TAP block|The TAP block will be administered after the placement of the camera port.
62276139|NCT02561091|EXPERIMENTAL|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
62640446|NCT04787367|EXPERIMENTAL|Late-operative TAP block|The TAP block will be administered at the completion of the case just before removing the camera port.
62640447|NCT06330376|ACTIVE_COMPARATOR|arm 1|Participants randomized to usual care
62071443|NCT04353193|EXPERIMENTAL|Terlipressin IV continuous infusion|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
62640448|NCT06330376|EXPERIMENTAL|arm 2|participants randomize to diaphragmatic breathing (DB) program
62640449|NCT01450319|EXPERIMENTAL|Cetuximab|
62276140|NCT04808856|EXPERIMENTAL|ACTH|Adrenocorticotropic Hormone
62276141|NCT04808856|ACTIVE_COMPARATOR|Methylprednisolone|Methylprednisolone
62276142|NCT02613598|EXPERIMENTAL|Bortezomib and Ruxolitinib|Bortezomib on days 1, 4, 8, and 11 of a 21 day cycle in combination with Ruxolitinib (5, 10, 15, 20, or 25 mg) twice daily.
62071444|NCT04353193|EXPERIMENTAL|Octreotide IV bolus plus continuous infusion|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
62276143|NCT01179074|ACTIVE_COMPARATOR|Oesophageal stent alone|Patients of inoperable oesophageal cancer in this arm underwent oesophageal stenting with self expandable metal stents
62276144|NCT01179074|ACTIVE_COMPARATOR|Oesophageal stent followed by EBRT|Patients in this arm underwent oesophageal stenting with self expandable metal stents followed by external beam radiotherapy (30Gy/10#/2weeks)
62276145|NCT05276479||Healthy subjects|Healthy subjects aged 18-30 years
62640450|NCT05229328||Control group|Healthy volunteers
62640451|NCT05229328||Patients within the acute phase of disease|Patients within 24 hours after onset
62640452|NCT05229328||Recovery phase of disease|Inflammation was controlled, shock was corrected, and the patient remained fever free for 3 consecutive days.
62640453|NCT02692586|EXPERIMENTAL|FlowTriever System|
62640454|NCT02644278|EXPERIMENTAL|VX-984 120 mg + PLD 40 mg/m^2|
62640455|NCT02644278|EXPERIMENTAL|VX-984 240 mg + PLD 40 mg/m^2|
62640456|NCT02644278|EXPERIMENTAL|VX-984 480 mg + PLD 40 mg/m^2|
62640457|NCT02644278|EXPERIMENTAL|VX-984 720 mg + PLD 40 mg/m^2|
62640458|NCT05397353|EXPERIMENTAL|Sleepio|Participants will receive the SleepioTM app
62640459|NCT05731700|EXPERIMENTAL|Drug eluting balloon|Treatment of a single in-stent restenosis coronary artery lesion with drug eluting balloon
62640460|NCT03573635|OTHER|Supratube|Patient with orotracheal intubation and supratube device
62640461|NCT03503279|NO_INTERVENTION|Macintosh Laryngoscope|
62640462|NCT03503279|ACTIVE_COMPARATOR|McGrath MAC® Video Laryngoscope|
62640463|NCT03863860|EXPERIMENTAL|Fluzoparib capsules, 50mg per capsule|Fluzoparib capsules, PO
62640464|NCT03863860|PLACEBO_COMPARATOR|Placebo capsules, 50mg per capsule|Placebo capsules, PO
62640465|NCT03429348|NO_INTERVENTION|No additional rehabilitation|No additional rehabilitation will be done
62276146|NCT01414257||Methotrexate (MTX)|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis.
62276147|NCT00789529|ACTIVE_COMPARATOR|1|Opti-Free® RepleniSH® MPDS
62276148|NCT00789529|ACTIVE_COMPARATOR|2|Renu MultiPlus®
62276149|NCT04067063||Milpa Alta inhabitants|Population among 15 and 70 years old
62276150|NCT00883337|EXPERIMENTAL|Teriflunomide 7 mg / 14 mg|Teriflunomide 7 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
62640466|NCT03429348|OTHER|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
62640467|NCT05390606|NO_INTERVENTION|Control arm|Women follow routine care only, including prescribed medications and recommended techniques and supplements for attempting to become pregnant at home for up to three months.
62640468|NCT05390606|EXPERIMENTAL|Flourish HEC + BioGenesis arm|In addition to routine care followed by women in control arm, women in this arm also use the Flourish HEC (Hydroxyethylcellulose) vaginal care system and BioGenesis fertility lubricant for up to three months.
62640469|NCT05868317|EXPERIMENTAL|Induction CT followed by short course RT|Induction chemotherapy with modified 5 fluorouracil, oxaliplatin and irinotecan followed by short course radiotherapy ( 5x5 Gy), then 5 fluorouracil and oxaliplatin based chemotherapy. Surgery will be performed 6 to 8 weeks after completion of RT.
62276151|NCT00883337|EXPERIMENTAL|Teriflunomide 14 mg / 14 mg|Teriflunomide 14 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extension treatment period).
62454929|NCT06357338||non invasive mammary carcinoma|35 cases with non invasive breast cancer with low and high nuclear grades and co existing microfoci of invasion
62640470|NCT02652637|EXPERIMENTAL|Mechanical and oral antibiotic bowel preparation|Mechanical bowel preparation using PEG, neomycin 2g p.o. (single-dose), and metronidazole 2g p.o. (single dose) are given the day before surgery.
62640471|NCT02652637|NO_INTERVENTION|No bowel preparation|No mechanical bowel preparation or oral antibiotics.
62653032|NCT05457959|EXPERIMENTAL|Cohort II Arm C (ppDC, nivolumab)|Within 30 days of surgical resection, patients receive ppDC ID in both arms with poly ICLC IM and nivolumab IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
62653033|NCT01515839|EXPERIMENTAL|Supplement intervention|Dietary Supplement: Multivitamin, Omega 3 Supplement, Brain and Memory Formula
62276152|NCT00883337|ACTIVE_COMPARATOR|IFN-β-1a / 14 mg|Interferon β-1a 3 times a week (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
62276153|NCT02318472|EXPERIMENTAL|Early mobilization|Functional mobilization initiated directly post-operative with a weight-bearing VACOped orthosis with adjustable range of motion of the ankle
62276154|NCT02318472|ACTIVE_COMPARATOR|Immobilization|Treatment as usual using plaster cast immobilization
62276155|NCT05397990|EXPERIMENTAL|Exercise|12 weeks exercise intervention. 3 times a week, 45 minutes per session, 30 minutes of exercise.
62276156|NCT05397990|NO_INTERVENTION|Control|Continue with habitual routine. Take part in weekly online socials with others in the control group.
62276157|NCT01131000|EXPERIMENTAL|Ibuprofen|
62276158|NCT01131000|PLACEBO_COMPARATOR|Saline|Normal Saline
62276159|NCT00291447|EXPERIMENTAL|Cohort 1|Patients received a single infusion of 5 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
62276160|NCT00291447|EXPERIMENTAL|Cohort 2|Patients received a single infusion of 10 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
62276161|NCT00291447|EXPERIMENTAL|Cohort 3|Patients received a single infusion of 20 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
62276162|NCT00291447|EXPERIMENTAL|Cohort 4|Patients received a single infusion of 40 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
62276163|NCT06038786|EXPERIMENTAL|Resilience Training|Participants obtained Resilience Training, a 4 session, 1.5 hour group intervention delivering the following skills: mindfulness, mentalization, and self-compassion.
62276164|NCT06038786|PLACEBO_COMPARATOR|Waitlist|A 4-6 week waitlist during which participants did not receive any treatment. They would then obtain Resilience Training following their waitlist period.
62454930|NCT06357338||invasive mammary carcinoma|35 cases of invasive breast cancer undergone MRM and classify them according grading, staging and luminal subtypes
62454931|NCT00605748|ACTIVE_COMPARATOR|1|Segmental PV-Isolation of the arrhythmogenic vein(s)
62454932|NCT00605748|ACTIVE_COMPARATOR|2|Segmental PV-Isolation of all veins
62454933|NCT02286128||Non-diabetic controls|Age-matched non-diabetic subjects
62454934|NCT02286128||Type 2 diabetes|Type 2 diabetes with metformin monotherapy failure
62454935|NCT00842842|ACTIVE_COMPARATOR|1: tacks|mesh fixation with tacks
62454936|NCT00842842|EXPERIMENTAL|2: glue|mesh fixation with glue
62454937|NCT00695266||1|
62454938|NCT00487227|PLACEBO_COMPARATOR|Placebo|
62454939|NCT00487227|EXPERIMENTAL|2.5mg caffeine|
62454940|NCT00487227|EXPERIMENTAL|5mg caffeine|
62454941|NCT00487227|EXPERIMENTAL|10mg caffeine|
62454942|NCT02295956|EXPERIMENTAL|Home Based Exercise and Nutrition Program|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete. Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Exercise instructional booklet given to all participants describing all exercises. Participants to walk 20-30 minutes at least 3 times a week. Nutrition program discussed with participants. Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
62640472|NCT05704868|EXPERIMENTAL|UniVRse + TAU|UniVRse is a Virtual Reality (VR) intervention targeting social anxiety in students using cognitive behavioural therapy (CBT) techniques - specifically graded exposure. Participants will have access to UniVRse for a month post-randomisation and it is recommended they complete 6 sessions each 30-minutes long over this period. Exposure to the intervention will be reached if participants complete 2 30-minute sessions. UniVRse is a self-help intervention meaning that participants can engage in the intervention independently. Participants will be supported to progress through the UniVRse programme by a virtual mentor called Sam that will take on the role traditionally undertaken by the 'therapist'. Sam's function will be to provide psychoeducation, provide instruction on how to use the VR kit and interact with the virtual environment, and provide support and encouragement. Participants will be able to complete the intervention either on campus or at home.
62640473|NCT05704868|NO_INTERVENTION|Waitlist + TAU|We will be using a wait list control group. The wait list control group will receive treatment as usual for the duration of the trial. Treatment as usual may include active monitoring, meetings with academic advisors, psychiatric medication, and/or support from an NHS mental health team. We will not withhold treatment from the control group, but prospective participants may not be eligible to take part if they have current or confirmed plans to receive a psychology therapy (see exclusion criteria). Once the trial has ended, the participants in the control arm will be the first to be offered UniVRse when it is taken up by university support services.
62640474|NCT03962608|EXPERIMENTAL|Yaq-001|Standard medical treatment + Yaq-001 (8 g/ day)
62640475|NCT03962608|PLACEBO_COMPARATOR|Placebo|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
62640476|NCT00916552|EXPERIMENTAL|Erythropoeitin|40.000 IU, epoetin alfa; Janssen-Cilag
62640477|NCT00974311|EXPERIMENTAL|Enzalutamide|Formerly MDV3100
62640478|NCT00974311|PLACEBO_COMPARATOR|Placebo|
62640479|NCT05793515||FB_001|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62276165|NCT01823679|EXPERIMENTAL|Capecitabine 1000 mg/m²|"Participants will receive oral capecitabine twice-a-day (BID) as 500 mg/m² doses on days 1 to 14.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62276166|NCT06099938||Group S|intrathecal injections of sufentanil
62454943|NCT02234466|ACTIVE_COMPARATOR|Oral Dexamethasone|"Oral dexamethasone- two 4mg tabs and one 2mg tab contained within a gelatin capsule Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
62454944|NCT02234466|PLACEBO_COMPARATOR|Gelatin pill|"Gelatin capsule contained within second gelatin capsule. Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
62640480|NCT05793515||FB_002|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640481|NCT05793515||FB_003|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640482|NCT05793515||FB_004|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640483|NCT05793515||FB_005|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640484|NCT05793515||FB_006|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640485|NCT05793515||FB_007|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640486|NCT05793515||FB_008|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62276167|NCT06099938||Group R|intrathecal injections of ropivacaine
62276168|NCT05868850|NO_INTERVENTION|Routine care group|The control group receives routine nursing, including admission education, routine nursing of adverse reactions to chemotherapy, diet guidance for chemotherapy patients, precautions for various examinations, discharge guidance and follow-up.
62276169|NCT05868850|EXPERIMENTAL|Auricular point sticking group|Auricular point sticking therapy is performed on the basis of control group. The acupoint intervention group is established, and the research team consists of 2 graduate students, 1 graduate supervisor, 1 head nurse, 1 chief physician of traditional Chinese medicine, and 1 nursing expert. The nursing expert is responsible for the overall design of the project, and the director of traditional Chinese medicine is responsible for the selection of acupoints and the training of nurses for massage. The supervisor of graduate students and the head nurse are responsible for the overall quality control of the intervention process, while the graduate students are responsible for the preliminary and final screening of research objects, the implementation of intervention programs, the organization, coordination and recording of the entire intervention process and the collection of data.
62454945|NCT04598243|EXPERIMENTAL|Treatment of CFS/FMS with the nutritional combination|
62454946|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
62454947|NCT04483583|ACTIVE_COMPARATOR|ABCD-GENE >10 - Clopidogrel|Patients with an ABCD-GENE\>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
62276170|NCT02997995|EXPERIMENTAL|Immune-attractant/lymphocyte activation|After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
62071445|NCT01073410||Healthy, non-asthmatic controls|People who are non-asthmatic and non-smokers.
62276171|NCT02059083|ACTIVE_COMPARATOR|Cognitive behavioral therapy (CBT) alone|
62071446|NCT01073410||Asthmatics|People who have been diagnosed with asthma.
62071447|NCT02406989|EXPERIMENTAL|MS-553|MS-553 oral tablet BID x 14 days
62276172|NCT02059083|EXPERIMENTAL|Cognitive behavioral therapy plus HRV biofeedback|
62276173|NCT05322239|EXPERIMENTAL|Intermittent Theta Burst Stimulation|TBS. A Magventure MagPro 100X stimulator with a B65 figure-8 coil will be used for the TBS sessions. On each of the 3 stimulation days, 5 iTBS sessions will be administered at 30 min intervals.
62276174|NCT05322239|EXPERIMENTAL|Continuous Theta Burst Stimulation|TBS. A Magventure MagPro 100X stimulator with a B65 figure-8 coil will be used for the TBS sessions. On each of the 3 stimulation days, 5 cTBS sessions will be administered at 30 min intervals.
62276175|NCT05994378|EXPERIMENTAL|Experimental group|
62276176|NCT05994378|ACTIVE_COMPARATOR|Control group|
62276177|NCT03644238|EXPERIMENTAL|Experimental intervention|Oral Glucose Tolerance Test and physical activity
62276178|NCT03644238|OTHER|Control intervention|Oral Glucose Tolerance Test and inactivity.
62276179|NCT04377451|NO_INTERVENTION|Control arm|The control group will be formed of 60 overweight or obese dengue patients receiving standard of care
62071448|NCT02406989|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet BID x 14 days
62276180|NCT04377451|EXPERIMENTAL|Intervention arm|Two cohorts receive a 5-day course of metformin treatment. In the initial phase (cohort 1), 5 young adults and 5 children (age \<16) will receive a low dose of metformin. In the second phase (cohort 2), 25 adult and 25 paediatric patients will receive a weight-based dose of metformin.
62276181|NCT05328037||Acute diarrhea cases|Children with acute diarrhea defined as at least 3 loose or watery stools per day for at least 3 consecutive days and up to 10 consecutive days
62276182|NCT05328037||Chronic diarrhea cases|Children with chronic diarrhea defined as 3 or more loose or liquid stools per day for at least 4 weeks
62276183|NCT05328037||Controls|Children without fever or signs of infection or ongoing diarrhea
62276184|NCT04418700|EXPERIMENTAL|Breath Stacking technique|"The intervention group will receive routine physical therapy associated with the Breath Stacking technique in 2 daily sessions of up to 20 minutes.~The technique consists of an Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes."
62071449|NCT01342185|EXPERIMENTAL|Medical ozone therapy with tianyi|
62071450|NCT01342185|ACTIVE_COMPARATOR|medical ozone therapy with humares|
62071451|NCT01342185|PLACEBO_COMPARATOR|Diammonium glycyrrhizinate Capsules|
62071452|NCT01931579|EXPERIMENTAL|confocal endo-microscopy|confocal endo-microscopy : CELLVIZIO endo-microscopy procedure is performed in every patient using the same extended working channel as for navigational bronchoscopy.
62071453|NCT01783353|PLACEBO_COMPARATOR|Corn starch pill|Two (2) corn starch pills will be taken three (3) times a day for 60 days.
62071454|NCT01783353|EXPERIMENTAL|Zinc gluconate|Two (2) zinc gluconate 50 mg capsules will be taken three (3) times a day for 60 days.
62071455|NCT04970095|EXPERIMENTAL|cleft lip and palate patient|Clefts patient with transverse maxillary constriction and anteroposterior deficiency
62071456|NCT01989559|EXPERIMENTAL|Treatment (vaccine therapy)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine with Montanide ISA 51 VG or Montanide ISA 51 SC on day 1 and between days 25-30. After 6 months, patients free of disease receive booster injections every 6 months for 3 years in the absence of unacceptable toxicity or disease progression.
62071457|NCT05125393|EXPERIMENTAL|Linear stapler group|In the experimental group, indocyanine green was injected for development during the operation after ileocolic vessel and the middle colonic vessel were dissected. The tributary vessels of the Henle trunk were disconnected with a linear stapler if there was no obvious lymph node development, which means ligated not in the root. Otherwise, they were transferred to the experimental group.
62276185|NCT04418700|NO_INTERVENTION|Routine physical therapy|The control group will receive only routine physical therapy. Routine physiotherapy consists of breathing exercises, using techniques bronchial hygiene and pulmonary reexpansion, and motor physiotherapy through exercise passive, active-assisted or active mobilization, stretching, training activities of daily living, positioning and removal of the bed and guidelines for post-discharge.
62276186|NCT01307969|EXPERIMENTAL|Anesthetic efficacy|Local anesthetics were injected at the apex of the maxillary right canine.
62276187|NCT04651387|EXPERIMENTAL|Intervention group|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered"
62071458|NCT05125393|NO_INTERVENTION|Conventional group|The branches of Henle trunk were dissected according to the conventional method and clamped at the root.
62640487|NCT05793515||FB_009|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640488|NCT05793515||FB_0010|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640489|NCT05793515||FB_0011|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62276188|NCT04651387|NO_INTERVENTION|Control group|For the control group, the placebo will be not considered and they will follow the routine standard treatments for COVID-19.
62071459|NCT02476214|EXPERIMENTAL|Intervention group|Group prenatal care- receiving prenatal care through a group
62640490|NCT05793515||FB_0012|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640491|NCT05793515||FB_0013|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640492|NCT05793515||FB_0014|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640493|NCT05793515||FB_0015|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640494|NCT05793515||FB_0016|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640495|NCT05793515||FB_0017|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640496|NCT05793515||FB_0018|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62071460|NCT02476214|NO_INTERVENTION|Control group|Individual prenatal care - receiving regular individual prenatal care
62276189|NCT00878280||1|1:control(healthy subjects)
62276190|NCT00878280||2|2:case(dementia patients)
62276191|NCT00540254|ACTIVE_COMPARATOR|Arm 1|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
62454948|NCT04483583|EXPERIMENTAL|ABCD-GENE >10 - Ticagrelor|Patients with an ABCD-GENE\>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
62454949|NCT04483583|ACTIVE_COMPARATOR|ABCD-GENE <10 - Clopidogrel|Patients with an ABCD-GENE\<10 will be treated with clopidogrel (75 mg/qd) for 30 days.
62640497|NCT05793515||FB_0019|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640498|NCT05793515||FB_0020|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640499|NCT05793515||FB_0021|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640500|NCT05793515||FB_0022|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640501|NCT05793515||FB_0023|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640502|NCT05793515||FB_0024|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62071461|NCT05539196||Post Exablate Neuro Pallidotomy for Parkinson's Disease with Motor Complications|The population enrolled in this registry will be comprised of male and female patients that plan to be treated using the Exablate Neuro system for advanced, idiopathic Parkinson's disease with medication-refractory moderate to severe motor complications. No intervention is performed under this registry protocol.
62071462|NCT01953770|ACTIVE_COMPARATOR|Cranial irradiation|Consolidation therapy with cranial irradiation in intermediate risk group patients
62071463|NCT01953770|EXPERIMENTAL|Additional TIT|Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients
62071464|NCT01953770|EXPERIMENTAL|MTX 2,000 mg/m2|Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients
62071465|NCT01953770|ACTIVE_COMPARATOR|MTX 30 mg/m2|Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients
62071466|NCT01953770|EXPERIMENTAL|PEG-asp 1,000 U/m2|Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients
62071467|NCT01953770|ACTIVE_COMPARATOR|L-asp 5,000 U/m2|Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients
62071468|NCT01953770|ACTIVE_COMPARATOR|PEG-DNR+|Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients
62276192|NCT00540254|ACTIVE_COMPARATOR|Arm 2|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
62276193|NCT00598416|EXPERIMENTAL|Psychoeducation|
62071469|NCT01953770|EXPERIMENTAL|PEG+DNR+|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients
62071470|NCT01953770|EXPERIMENTAL|PEG+DNR-|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients
62071471|NCT02215330|PLACEBO_COMPARATOR|Sugar pill|"Maltodextrin filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~* If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~* If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~* If no subretinal fluid is present and the patient takes no medication everything stays the same.~* If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
62071472|NCT02215330|EXPERIMENTAL|Eplerenone|"Eplerenone 25mg pills triturated and filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~* If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~* If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~* If no subretinal fluid is present and the patient takes no medication everything stays the same.~* If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
62071473|NCT01035333|EXPERIMENTAL|orlistat 60mg|Patients assigned to treatment group for up to 6 months of therapy.
62088353|NCT04857450|SHAM_COMPARATOR|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
62276194|NCT02232386|EXPERIMENTAL|Treatment|"Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Treatment duration with Ibrutinib will be based on what comes first of the following three options:~* Treatment until progression or toxicity~* Treatment until MRD negativity for 6 months~* Treatment for 6 years. Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1."
62276195|NCT03400722|EXPERIMENTAL|DUOSTIM group|Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
62088354|NCT04857450|ACTIVE_COMPARATOR|Ketamine-Etomidate|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
62276196|NCT03400722|EXPERIMENTAL|Modified Shanghai Protocol group|Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
62276197|NCT02903680|ACTIVE_COMPARATOR|Dexamethasone group|Dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED.
62276198|NCT02903680|PLACEBO_COMPARATOR|Placebo group|The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
62276199|NCT04582578|NO_INTERVENTION|Control Group|The control group will be treated with practice guideline optimal medical therapy for HF.
62071474|NCT02054312|EXPERIMENTAL|Family Based Interpersonal Psychotherapy (FB-IPT)|Family Based Interpersonal Psychotherapy for Depressed Preadolescents (FB-IPT) is a promising psychosocial treatment for preadolescent depression. It is conceptually rooted in an interpersonal model of depression that focuses on how stress in interpersonal relationships is often related to the onset or maintenance of depressive symptoms. In keeping with adult and adolescent models of IPT, FB-IPT focuses on improving the interpersonal functioning of individuals as a means to improve their depressive symptoms. FB-IPT addresses two domains of interpersonal impairment in depressed preadolescents, parent-child conflict and interpersonal avoidance, and focuses on family relationships, the primary context for children's social and emotional development.
62071475|NCT02054312|ACTIVE_COMPARATOR|Client Centered Therapy (CCT)|Child Centered Therapy (CCT), a supportive and nondirective treatment that closely approximates the standard of care for pediatric depression in community mental health. CCT is a manualized treatment for children between the ages of 8-14 based on a Rogerian counseling model. In that model, changes in children's mood and behavior are initiated through their experience of a therapeutic relationship marked by unconditional positive regard, empathic understanding, and therapeutic genuineness.
62071476|NCT02439177|EXPERIMENTAL|Omnitest 3|Blood glucose monitoring system
62071477|NCT02439177|EXPERIMENTAL|Omnitest 5|Blood glucose monitoring system
62071478|NCT01022073||Globus Pallidus interna Group|Cohort of subjects who received DBS-GPi as part of the CSP 468 intervention trial, and still have their device working and in place.
62071479|NCT01022073||Subthalamic Nucleus Group|Cohort of subjects who received DBS-STN as part of the CSP 468 intervention trial, and still have their device working and in place.
62071480|NCT00110760|EXPERIMENTAL|S-Caine Peel|
62276200|NCT04582578|EXPERIMENTAL|BiV-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
62276201|NCT04582578|EXPERIMENTAL|CS-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
62276202|NCT03962205|EXPERIMENTAL|Cognitive Behavioral life-style and well-being intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification and then 4 group-based 2-hour weekly sessions of the well-being intervention in addition to the treatment as usual.
62276203|NCT03962205|PLACEBO_COMPARATOR|Cognitive Behavioral life-style intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification in addition to the treatment as usual.
62287174|NCT05808036|ACTIVE_COMPARATOR|DOMINO app - low FODMAP diet|The patients start with the DOMINO diet (8 weeks). Patients that experienced no symptom improvement, will switch to the strict low FODMAP diet (6 weeks).
62640503|NCT05793515||FB_0025|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62071481|NCT00110760|PLACEBO_COMPARATOR|Placebo Peel|
62071482|NCT03438240|ACTIVE_COMPARATOR|Group BF|Bupivacaine plus Fentanyl
62071483|NCT03438240|ACTIVE_COMPARATOR|Group BD|Bupivacaine plus Dexmedetomidine
62071484|NCT04827134|EXPERIMENTAL|Cohort 1: TRIUMEQ Fed followed by TRIUMEQ Fasted|Participants received TRIUMEQ (dolutegravir \[DTG\] 5 milligram \[mg\]/abacavir \[ABC\] 60 mg/lamivudine \[3TC\] 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment A) in treatment period 1 followed by TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment B) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
62071485|NCT04827134|EXPERIMENTAL|Cohort 1: TRIUMEQ Fasted followed by TRIUMEQ Fed|Participants received TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment B) in treatment period 1 followed by TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment A) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
62088355|NCT03952065|EXPERIMENTAL|PD1/PDL1/CTLA4 inhibitor or their combinations infusion via neck artery|Interventional technique is used to localize neck artery to infuse the inhibitor or their combinations directly into tumor.
62071486|NCT04827134|EXPERIMENTAL|Cohort 2: DOVATO Fed followed by DOVATO Fasted|Participants received DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment C) in treatment period 1 followed by DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment D) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
62640504|NCT05793515||FB_0026|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640505|NCT05793515||FB_0027|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640506|NCT05793515||FB_0028|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640507|NCT05793515||FB_0029|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62640508|NCT05793515||FB_0030|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
62276204|NCT03238287|ACTIVE_COMPARATOR|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
62276205|NCT03238287|ACTIVE_COMPARATOR|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
62276206|NCT06398041|EXPERIMENTAL|Patients|Patients will undergo 8x a BFRT session and will be asked about their feelings and thoughts using a VAS an 7 points Likert Scale
62276207|NCT06398041|OTHER|Physiotherapists|Physiotherapists involved in the practical application of BFRT will be asked about their thoughts using a 7 point Likert Scale
62276208|NCT06467890||Educational programme on vital pulp therapy|An educationnal programme based on the latest AAPD and AAE guidelines will be given to the participants after responding to the questionnaire for the first time.
62276209|NCT05408754|EXPERIMENTAL|Pulsed Field Ablation (PFA) group|PsAF patients treated by PFA
62276210|NCT05408754|EXPERIMENTAL|Pulsed Field CryoAblation (PFCA) group|PsAF patients treated by PFCA
62276211|NCT01317342|ACTIVE_COMPARATOR|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour
62276212|NCT01317342|NO_INTERVENTION|Control group: no intervention|Conventional cold storage (IGL-1)
62276213|NCT03017170|EXPERIMENTAL|Cranberry|500mg Dried Cranberry
62276214|NCT03017170|PLACEBO_COMPARATOR|Placebo Oral Capsule|Color Matching Placebo
62276215|NCT05178732|EXPERIMENTAL|Protein dose 1 and early|
62276216|NCT05178732|EXPERIMENTAL|Protein dose 1 and late|
62276217|NCT05178732|EXPERIMENTAL|Protein dose 2 and early|
62276218|NCT05178732|EXPERIMENTAL|Protein dose 2 and late|
62276219|NCT05178732|EXPERIMENTAL|Protein dose 3 and early|
62276220|NCT05178732|EXPERIMENTAL|Protein dose 3 and late|
62276221|NCT05458414|EXPERIMENTAL|Endoscopic Breast Conserving Surgery With Intra-operative Navigation System|Surgerons will use Intra-operative navigation system during the surgery to delineate the margins of tumor.
62276222|NCT04593069|OTHER|COVID-19 patients|Neurocognitive impairment in COVID-19 patients
62276223|NCT01660074|EXPERIMENTAL|Test food, reference food|Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
62276224|NCT03582670|EXPERIMENTAL|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
62276225|NCT03582670|ACTIVE_COMPARATOR|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
62276226|NCT03582670|OTHER|Control Group|Study participants do not attend any strategy training sessions.
62276227|NCT00865865|OTHER|1|Conventional total knee arthroplasty
62276228|NCT00865865|ACTIVE_COMPARATOR|2|Computer aided total knee arthroplasty
62071487|NCT04827134|EXPERIMENTAL|Cohort 2: DOVATO Fasted followed by DOVATO Fed|Participants received DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment D) in treatment period 1 followed by DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment C) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
62071488|NCT00452413|EXPERIMENTAL|Enzastaurin and erlotinib combination therapy|"Enzastaurin:~* Phase 1, Dose Level 1: 500 milligram (mg) oral loading dose Day 1, 250 mg oral, daily Day 2-28, 28-day cycle until disease progression~* Phase 1, Dose Level 2: 1125 mg oral loading dose Day 1, 500 mg oral, daily until disease progression~* Phase 2: Dose determined from Phase 1, oral, daily, 28-day cycles until disease progression~Erlotinib:~• 150 mg, oral, daily, 28-day cycles until disease progression"
62071489|NCT01474460|PLACEBO_COMPARATOR|Control group|The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
62276229|NCT01751217|EXPERIMENTAL|Funct Family Tx/Video Teleconf (FFT-V)|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Adolescents and parents assigned to the FFT-V condition will receive a Verizon netbook laptop computer equipped with the Microsoft Windows 7 operating system, webcam, and VTC software for use in the family home. The VTC software is designed to stream live video between therapists and participants, to record video, and to store recorded videos as digital mpeg files. All family sessions will take place via video teleconference.
62454950|NCT06304389|EXPERIMENTAL|Patients with refractory epilepsy|Patients will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
62640509|NCT03240419|EXPERIMENTAL|Probiotics|Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
62071490|NCT01474460|EXPERIMENTAL|Phytonadione|Patients receiving 200mcg of phytonadione.
62071491|NCT02381743|NO_INTERVENTION|Group 1|Weekly non-medical SMS messages
62454951|NCT06304389|EXPERIMENTAL|Healthy subjects|Subjects will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
62454952|NCT03270007|EXPERIMENTAL|Chemotherapy|
62454953|NCT03270007|NO_INTERVENTION|Control|
62071492|NCT02381743|EXPERIMENTAL|Group 2|Receipt of a daily SMS text message describing various aspects of clinical practice
62071493|NCT02381743|EXPERIMENTAL|Group 3|Receipt of a daily SMS text message describing various aspects of clinical practice, but phrased as multiple choice question
62071494|NCT01040286|EXPERIMENTAL|Flurbiprofen Chip|
62071495|NCT01040286|ACTIVE_COMPARATOR|Chlorhexidine chip|
62071496|NCT04451343||Patients|Patients with a diagnosis of colorectal cancer before 65 years.
62454954|NCT02026453|NO_INTERVENTION|Usual care|Physicians and nurses obtain admission medication history.
62071497|NCT04451343||Family|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
62071498|NCT04278430|EXPERIMENTAL|Real tDCS group|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 1.5 mA intensity
62071499|NCT04278430|SHAM_COMPARATOR|Sham tDCS|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 0 mA intensity.
62071500|NCT04278430|ACTIVE_COMPARATOR|Control|The normal heathy children age matched undergo the same activity and brain stimulation as the real tDCS group.
62071501|NCT04809792|EXPERIMENTAL|Head and neck cancer|In this arm patients with head and neck cancers treated with SBRT are recruited.
62071502|NCT05341375|OTHER|Group C|The general anesthesia was used.In this group, cognitive function was evaluated by MMSE scale on one day before surgery, one day after surgery, and three months after surgery
62071503|NCT05341375|EXPERIMENTAL|Group TA|Group TA received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction
62071504|NCT05341375|EXPERIMENTAL|Group TE|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
62071505|NCT05341375|OTHER|Non-surgical controls|Age and sex-matched community people are included for three sessions of MMSE test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCD incidence to rule out learning effect
62071506|NCT02151019|EXPERIMENTAL|Experimental Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT
62071507|NCT02151019|NO_INTERVENTION|Control Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique
62071508|NCT03230422|EXPERIMENTAL|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
62071509|NCT03230422|EXPERIMENTAL|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
62071510|NCT00315913|EXPERIMENTAL|IV Propranolol|IV dose propranolol
62071511|NCT00315913|PLACEBO_COMPARATOR|IV Placebo|IV Placebo of saline solution equal to propranolol in volume
62071512|NCT01014221|EXPERIMENTAL|Acupuncture group|acupuncture administered in 8 sessions over 4 weeks
62071513|NCT01014221|ACTIVE_COMPARATOR|Steroid group|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
62640510|NCT03240419|PLACEBO_COMPARATOR|Placebo|Participants in this group will take one capsule containing microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate (all ingredients listed in the probiotic capsules except the culture) . Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
62640511|NCT02791854||Registry participant|This is a registry study, the same information is collected from all participants.
62640512|NCT03179358|EXPERIMENTAL|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
62640513|NCT02031523|ACTIVE_COMPARATOR|Sanjie analgesic capsule|every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
62640514|NCT02031523|PLACEBO_COMPARATOR|placebo|every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
62640515|NCT01975558||Control group A|Control group. The group will undergo blood, urine, sebum, and saliva sampling.
62640516|NCT01975558||Breast cancer B|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling within the irradiation field.
62640517|NCT01975558||Breast cancer C|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling outside of the irradiation field, e.g. at the arm.
62640518|NCT05211440|PLACEBO_COMPARATOR|Placebo (Maltodextrin)|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days.
62640519|NCT05211440|EXPERIMENTAL|BC-006|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days.
62640520|NCT03114293|NO_INTERVENTION|Waiting group|Waiting group
62071514|NCT04324294|EXPERIMENTAL|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
62071515|NCT03729921|ACTIVE_COMPARATOR|gastric variceal obturation|gastric variceal obturation
62071516|NCT03729921|EXPERIMENTAL|gastric variceal ligation|gastric variceal ligation
62071517|NCT01988896|EXPERIMENTAL|Dose-Escalation: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days \[14-day run-in period + 28-day concomitant dosing period\]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.
62071518|NCT01988896|EXPERIMENTAL|Dose-Expansion: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.
62454955|NCT02026453|EXPERIMENTAL|Pharmacist obtains home med hx|Pharmacist obtains admission medication history, although usual care practices may also continue.
62454956|NCT02026453|EXPERIMENTAL|Pharm tech obtains home med hx|Pharmacy technician obtains admission medication history, although usual care practices may also continue.
62640521|NCT03114293|EXPERIMENTAL|Smartphone intervention|Smartphone bases behavioural intervention
62640522|NCT01775670|EXPERIMENTAL|Off-the-Shelf Splint|Subjects in this arm will be managed with off-the-shelf splints for TMC arthrosis.
62640523|NCT01775670|ACTIVE_COMPARATOR|OT Splint|Subjects in this arm will be managed with a custom-made splint made by the Massachusetts General Hospital Occupational Therapists.
62640524|NCT00965107|EXPERIMENTAL|Thiopental|Thiopental for induction of anaesthesia.
62640525|NCT00965107|ACTIVE_COMPARATOR|Propofol|Propofol for induction of anaesthesia.
62640526|NCT01558219|EXPERIMENTAL|acitive anticancer drug|single cytostatic agent, cabazitaxel every second week in the treatment of castration resistant metastatic prostate cancer after docetaxel
62071519|NCT02921373|EXPERIMENTAL|Prostate Cancer Patients|"Up to 6 Male prostate cancer patients with metastatic, castration resistant prostate cancer will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
62071520|NCT02921373|EXPERIMENTAL|Healthy Volunteers|"Up to 6 male or female healthy volunteers will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
62071521|NCT02973360|EXPERIMENTAL|Dose Level 1|Target dose 20 mg/kg Docosahexaenoic acid
62071522|NCT02973360|EXPERIMENTAL|Dose Level 2|Target dose 36 mg/kg Docosahexaenoic acid
62071523|NCT02973360|EXPERIMENTAL|Dose Level 3|Target dose 60 mg/kg Docosahexaenoic acid
62071524|NCT02973360|PLACEBO_COMPARATOR|Placebo|Soybean oil
62071525|NCT06176820|ACTIVE_COMPARATOR|Arm 1|Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
62071526|NCT06176820|ACTIVE_COMPARATOR|Arm 2|Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
62071527|NCT05246319||Patients with small intestine neuroendocrine tumors|Evaluation of preoperative abdominal imaging in patients who underwent an a resection for neuroendocrine tumors
62071528|NCT00519636|ACTIVE_COMPARATOR|FFNS, FPNS|fluticasone furoate nasal spray, fluticasone propionate nasal spray
62071529|NCT00519636|ACTIVE_COMPARATOR|FPNS, FFNS|fluticasone propionate nasal spray, fluticasone furoate nasal spray
62071530|NCT00519636|PLACEBO_COMPARATOR|placebo FFNS, placebo FPNS|placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
62071531|NCT00519636|PLACEBO_COMPARATOR|placebo FPNS, placebo FFNS|placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
62454957|NCT05404035|EXPERIMENTAL|Family Connections for relatives of people with eating disorders and personality disorders|The intervention lasts 3 months and includes 14 two-hour sessions with a group format on a weekly basis. The FC program is divided into 7 modules: 2 of Psychoeducation (ED and PD criteria, explanatory theories, available treatments, comorbidity with PD, etc.) and 5 modules of Dialectical Behavioral Therapy skills training (Relationship mindfulness, effective communication, aceptation, validation, problem management and meaning of life).
62640527|NCT02311829|EXPERIMENTAL|Telephone follow-up device (DST)|"An external independent clinical psychologist is responsible for calling regular the patient included in DST-arm.~Telephone follow-up device(DST) consists of telephone calls at 15 day, 2 month and then every 2 months until 12 months. The clinical psychologist is designed to inform the patient about its pathology, promote acceptance of diagnosis, support the patient in his approach to care encouraging psychiatric observation. The device does not replace psychiatric counseling recommended."
62640528|NCT02311829|NO_INTERVENTION|Group control ; usual care|"- Usual care: After diagnosis of PNES: orientation psychiatric care or CMP liberal and meeting biannually with the neurologist~- For patients in both groups: in addition, quotation questionnaires of quality of life and evaluation by a neuropsychologist biannual for 24 months after the appointment with the neurologist."
62640529|NCT04831034|EXPERIMENTAL|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
62071532|NCT03267290|EXPERIMENTAL|Sonazoid- CEUS+CEMRI or CECT+CEMRI|Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
62071533|NCT06364241||Individuals with lived experience of psychosis|Individuals with lived experience of psychosis
62071534|NCT06364241||Carers of individuals with lived experience of psychosis|Carers of individuals with lived experience of psychosis
62071535|NCT05422456||Chronic pain group|children are diagnosed with chronic headache by pediatric neurologist
62071536|NCT05422456||Health group|children without chronic pain
62071537|NCT06014619||Mohs Micrographic Surgery|Patients treated with Mohs Micrographic Surgery in the dermatology department of Maastricht University Medical Center +, Maastricht, the Netherlands
62640530|NCT05439746|EXPERIMENTAL|Matrix Comparison|Qualified subjects are randomly assigned Microlyte Matrix in an open label fashion to half of a randomized similar depth donor site areas within a subject and determining percent healing at Day 14.
62640531|NCT05793593|ACTIVE_COMPARATOR|Colorectal Cancer (CRC) education alone|All participants will be educated, on a simplified clinical and medical background of CRC; causes and risk factors for CRC; eligibility criteria for screening; lifestyle modifications to lower risk of developing CRC; screening methods for CRC, including FIT and colonoscopy; addressing myths and misconceptions about CRC; and information about resources for low-cost and no-cost screening, screening for the uninsured and screening for those without legal immigration documentation. Participants will also be educated on elements of fecal immunochemical testing (detects signs of cancer in the stool, can be done at home and sent to a laboratory for analysis, needs to be done yearly to ensure maximal effectiveness for cancer screening). Follow-up Assessment at 8 months complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
62640532|NCT05793593|EXPERIMENTAL|FITx3 intervention and CRC education|Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
62640533|NCT06040359|EXPERIMENTAL|Thriving Mama programme|Nine meetings delivered in either group (5 meetings), individual (1 meeting), or family group (2 meetings) formats over 10 weeks with an additional individual meeting 10-12 weeks postpartum by a trained mother in the community. Each meeting focuses on the girl's physical and mental health, taking care of a newborn, life skills, future-planning and social support and community-based services. Meetings will take place in a mixture of private settings in health facilities, community facilities, and participant homes. Adolescents will also receive usual perinatal care.
62276230|NCT01751217|EXPERIMENTAL|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Families in the FFT condition will not be provided with the laptop and internet access described above. Instead, adolescents and parents in this condition will receive the FFT intervention face-to-face from an FFT therapist who will travel to the family home for each session.
62454958|NCT05404035|ACTIVE_COMPARATOR|Optimized Treatment As Usual|Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, with 3 two-hour psychoeducation sessions in group format each week (ED and PD, explanatory theories, available treatments, comorbidity with PD).
62454959|NCT05201690|EXPERIMENTAL|VV116 200 mg Group|VV116 200 mg Group
62454960|NCT05201690|EXPERIMENTAL|VV116 400 mg Group|VV116 400 mg Group
62454961|NCT05201690|EXPERIMENTAL|VV116 600 mg Group|VV116 600 mg Group
62640534|NCT06040359|ACTIVE_COMPARATOR|Usual perinatal care|"Each visit includes care that is appropriate to the overall condition and stage of pregnancy and should include four main categories of care:~1. Identification of pre-existing health conditions (e.g., check for weight and nutrition status, anemia, hypertension, syphilis, HIV status);~2. Early detection of complications arising during pregnancy (e.g., check for pre-eclampsia, gestational diabetes);~3. Health promotion and disease prevention (e.g., tetanus vaccine, prevention and treatment of malaria, nutrition counseling, micronutrient supplements, family planning counseling); and~4. Birth preparedness and complication planning (e.g., birth and emergency plan, breastfeeding counseling, antiretrovirals for HIV positive women and reducing mother-to- child transmission of HIV)"
62071538|NCT06014619||Slow Mohs|Patients treated with Slow Mohs in the dermatology department of Maastricht University Medical Center +, Maastricht, the Netherlands
62071539|NCT03337321||ETvalid|Pregnant women attending maternal care services and having access to computational device
62071540|NCT00885573|OTHER|Sleep apnea subjects|"Patients with suspected sleep apnea syndrome will have nocturnal polysomnography. According to the number of respiratory events per hour of sleep, patients will be classified as sleep apnea or controls. All the patients will be blindly assessed for pharyngeal sensitivity the morning following the nocturnal recording."
62454962|NCT05201690|PLACEBO_COMPARATOR|Placebo|VV116 Matching placebo tablets; Multiple doses
62454963|NCT06348693||Glioma|Patients affected by brain tumors undergoing surgical resection; hypomethylation or hypermethylation of MGMT assessed post-surgery for patients affected by GBM; adult patients (≥18 years), both sexes; Patients undergoing Stupp protocol including patients aged \> 70 years performing the hypofractionated protocol and three weeks of chemotherapy; Karnofsky Performance Status (KPS)\> 60 assessed post-surgery; freely given written informed consent prior to any activity related to the study.
62640535|NCT04799925||Intervention group|Hyperuricemic group will be treated with uric acid lowering drug (febuxostat 80 mg once daily for 6 months).
62640536|NCT04799925||Placebo group|Hyperuricemic group will take placebo pills.
62071541|NCT05046535||Smokers|Individuals with MS who are current tobacco smokers: Either cigarettes, hookah pipe, E-cigarettes or other forms of tobacco. This group will perform all the assessments including surveys about nicotine dependence and smoking behavior.
62071542|NCT05046535||Non-smokers|Individuals with MS who are non-smokers of any form of tobacco. This group will perform all the assessments except for the surveys related to nicotine dependence and smoking behavior.
62454964|NCT02747745|NO_INTERVENTION|Control Group|Group receive no intervention
62071543|NCT03716622|ACTIVE_COMPARATOR|bismuth-clarithromycin-containing group|Patients in bismuth-clarithromycin-containing group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 500mg po bid for 14d
62276231|NCT01751217|ACTIVE_COMPARATOR|Services as Usual|The main CYFD service provider for adjudicated youth in both Sandoval and Valencia counties is Youth Development Incorporated (YDI) which is a private not-for-profit youth service organization serving adolescents in New Mexico . YDI provides an array of services for youth including tutoring, after-school activities, gang intervention, school drop-out prevention, family counseling services, an emergency teen shelter, parenting skills training, youth leadership development, community corrections services, GED studies, substance abuse and AIDS education, etc. The YDI juvenile corrections services include intensive supervision, educational and employment assistance, community service, victim restitution, and institutional transition services.
62276232|NCT03934983||Trauma patients|Subject experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
62640537|NCT05728736|EXPERIMENTAL|treatment|20 participants will be randomized to take lemborexant 25mg at h.s for two consecutive nights
62640538|NCT05728736|PLACEBO_COMPARATOR|placebo|10 participants will be randomized to take placebo at h.s. for two consecutive nights.
62276233|NCT01233778|EXPERIMENTAL|Canola Oil|
62276234|NCT01233778|EXPERIMENTAL|High Oleic Acid Canola + DHA|
62276235|NCT01233778|EXPERIMENTAL|High Oleic Canola Oil|
62276236|NCT01233778|EXPERIMENTAL|Flax & Safflower Oil (60:40)|
62276237|NCT01233778|EXPERIMENTAL|Safflower & Corn Oil (75:25)|
62276238|NCT02916420|EXPERIMENTAL|Treatment|Pomalidomide plus low-dose Dexamethasone
62276239|NCT01665807|EXPERIMENTAL|Nurse-administered IM|Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
62640539|NCT01461642|EXPERIMENTAL|Asthma - ICT support.|
62071544|NCT03716622|EXPERIMENTAL|bismuth-furazolidone-containing quadruple group|patients in bismuth-furazolidone-containing quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 240mg po bid, and furazolidone (Liteling) 100mg po bid for 14d
62071545|NCT00692640|EXPERIMENTAL|1|
62276240|NCT01665807|EXPERIMENTAL|Self-administered intradermal|Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
62640540|NCT01461642|NO_INTERVENTION|Asthma, comparator - no ICT support|
62640541|NCT02224625|EXPERIMENTAL|2% CHG Cloth|Chlorhexidine Gluconate 2%
62640542|NCT02224625|PLACEBO_COMPARATOR|Vehicle Cloth|Excipients on cloth
62640543|NCT02224625|ACTIVE_COMPARATOR|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
62276241|NCT01665807|ACTIVE_COMPARATOR|Repeat self-administration intradermal|Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
62276242|NCT04638569|ACTIVE_COMPARATOR|Ultrasound-guided obturator nerve block group|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle.
62276243|NCT04638569|ACTIVE_COMPARATOR|obtutaror nerve block with anatomical landmarks|In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL.
62276244|NCT03188237|EXPERIMENTAL|AfyaJamii facility|Facilities using AfyaJamii
62276245|NCT03188237|NO_INTERVENTION|Referent facility|Facilities using Focused Antenatal Care Individual Model
62454965|NCT02747745|EXPERIMENTAL|Interventional Group|Four risk areas reflecting the great needs of FCGs of PWDs: depressive symptoms, burden, distress to problematic behaviors of PWDs and healthy behaviors.
62640544|NCT02224625|SHAM_COMPARATOR|Saline|0.9% sodium chloride
62071546|NCT00437021|ACTIVE_COMPARATOR|Group C|Dryvax® vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
62276246|NCT02172859|ACTIVE_COMPARATOR|lumiVida™|lumiVida™ (2 x 0.5 g sachets to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days.
62276247|NCT02172859|PLACEBO_COMPARATOR|Placebo|Placebo (2 x 0.5 g sachets of casein hydrolysate to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days
62276248|NCT04507984||Children with hypercholesterolemia (Slovenia)|Children (aged 5 years) with total cholesterol measurement at primary care pediatricians at the programed visit prior to school entry.
62276249|NCT04507984||Children with hypercholesterolemia (Lower Saxony, Germany)|Children (aged 2-6 years) with LDL-cholesterol measurement during the compulsory routine check-ups and at any voluntary visits to the primary care pediatricians.
62276250|NCT04507984||Children referred for FH genetic analysis (Slovenia and LS)|Children referred for familial hypercholesterolemia genetic analysis to the tertiary center, according to the screening algorithm.
62454966|NCT01526538|EXPERIMENTAL|50 mg d-cycloserine|active drug condition
62454967|NCT01526538|PLACEBO_COMPARATOR|Sugar pill|Inactive placebo
62454968|NCT00796900|EXPERIMENTAL|Dantrolene|
62071547|NCT00437021|EXPERIMENTAL|Group D|Standard dose IMVAMUNE® vaccine or placebo on Day 0 and Dryvax® vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
62071548|NCT00437021|EXPERIMENTAL|Group E|Dryvax® vaccine and standard dose IMVAMUNE® vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
62071549|NCT00437021|EXPERIMENTAL|Group F|Standard dose IMVAMUNE® vaccine or placebo on Day 0.
62276251|NCT04507984||Parents and siblings of children with confirmed FH (Slovenia)|Parents or siblings of index cases with completed familial hypercholesterolemia genetic analysis, according to the screening algorithm.
62454969|NCT00796900|PLACEBO_COMPARATOR|Placebo|
62276252|NCT03017560|EXPERIMENTAL|Computerized cognitive treatment|Chosen exercises from the rehabilitation package of a commercially available, computerized, cognitive training program called Happy Neuron Pro will be used. This program was designed by a team of neurologists, neuropsychologists and cognitive psychologists, and has been successfully adapted for varying conditions of cognitive dysfunction.
62276253|NCT03017560|NO_INTERVENTION|Wait list control|Participants assigned to the wait list control arm will receive no treatment while the experimental arm is participating in the computerized treatment. However, the computerized treatment program will be made available for these participants to utilize at the end of the study period.
62454970|NCT02287532|EXPERIMENTAL|DIABEO software alone|Patient will have an introductory training session in the use of DIABEO by the investigating physician an will return for an on site consultation at 6 mounths (optional), 12 mounths and 24 mounths
62454971|NCT02287532|EXPERIMENTAL|DIABEO+paramedical telemonitoring|"Patient will have an on site introductory training session in the use of DIABEO, by his/her telemedicine nurse from his/her region. The nurse will then follow up the patient according to a delegated tasks protocol written by the investigating physician with the nurse. Patient will be asked to return to see the investigator at 6 mounths (optional), 12 mounths and 24 mounths"
62640545|NCT02224625|ACTIVE_COMPARATOR|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
62640546|NCT05945238|EXPERIMENTAL|Thrower's Ten|
62640547|NCT05945238|NO_INTERVENTION|Control|
62640548|NCT04966286|PLACEBO_COMPARATOR|conventional education service program|received only standard enterostomy care brochure
62071550|NCT00437021|EXPERIMENTAL|Group B|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 28.
62640549|NCT04966286|EXPERIMENTAL|multimedia education service program|received multimedia education service program introduction
62640550|NCT02923765|ACTIVE_COMPARATOR|combined training (CT)|additional aerobic training by a stepper : 35 minutes/session, 5 sessions/week and 4-5 weeks
62640551|NCT02923765|NO_INTERVENTION|usual rehabilitation (UR)|Usual rehabilitation, without additional aerobic training
62640552|NCT02923765|NO_INTERVENTION|healthy participant (HP)|healthy control
62071551|NCT00437021|EXPERIMENTAL|Group A|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 7.
62071552|NCT02377960|ACTIVE_COMPARATOR|Usual care (Reference group)|Treatment is leaded by treating physician according to national guide lines with no study-specific medication or clinical appointment protocol.
62071553|NCT02377960|EXPERIMENTAL|An IMB model-based initiation of medication|"In addition to usual care, participants allocated to intervention group will receive~An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time"
62071554|NCT02377960|EXPERIMENTAL|Tailored SMS-text message support|"Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication.~After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments."
62071555|NCT00538096|EXPERIMENTAL|1|MEDI-538
62276254|NCT05561790|EXPERIMENTAL|Intervention|Administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy.
62276255|NCT05561790|NO_INTERVENTION|Control|Waitlist control (sleep diary only); access to treatment after final measurement
62276256|NCT00637260|EXPERIMENTAL|A|
62276257|NCT00637260|SHAM_COMPARATOR|B|
62276258|NCT04434144||Group A:|Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10days
62276259|NCT04434144||Group B|Hydroxychloroquine 400mg first day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days.
62276260|NCT02439125|EXPERIMENTAL|Eltoprazine HCl 2.5 mg|Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
62276261|NCT02439125|EXPERIMENTAL|Eltoprazine HCl 5.0 mg|Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
62454972|NCT02287532|NO_INTERVENTION|Usual Follow up|Patient will continue his/her usual follow up and return to see the investigator at 6 mounths (optional) and at the one year end of follow up for the study
62640553|NCT04251078||Myelodysplastic Syndromes - Progression cohort|According to the literature (Greenberg et al, Blood. 2012), around 5-15% are expected to progress to high/very high-risk MDS subtype or to acute myeloid leukemia (AML). According to the total cohort of patients, it is expected that 20 of them would comprise this group and will be studied by targeted deep sequencing.
62640554|NCT04251078||Myelodysplastic Syndromes - Non Progression cohort|20 patients without progression will be analyzed by targeted deep sequencing in order to find out if there are any differences in the mutational spectrum compared with those disease progression cases.
62640555|NCT03259152|EXPERIMENTAL|Pre-Denosumab GctB|Specimens obtained during biopsy
62640556|NCT03259152|EXPERIMENTAL|Post-Denosumab GctB|Specimen after administration of Denosumab
62640557|NCT02570386|ACTIVE_COMPARATOR|Control arm|Women allocated to the control arm will either undergo fresh embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
62640558|NCT02570386|ACTIVE_COMPARATOR|Intervention arm|Fresh embryo transfer will not be undertaken in this group. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
62640559|NCT02230891|ACTIVE_COMPARATOR|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
62640560|NCT02230891|ACTIVE_COMPARATOR|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
62640561|NCT02230891|OTHER|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
62640562|NCT06524388|EXPERIMENTAL|adaptive cognitive training|The intervention lasted for 6 months. Participants willrevieve 30 minutes of training per day, at least three days per week. In each task, once a high accuracy (e.g. \>80%) is achieved, the task is automatically upgraded to the next difficulty level.
62640563|NCT06524388|PLACEBO_COMPARATOR|placebo cognitive training|The intervention lasted for 6 months. Participants will revieve 30 minutes of training per day, at least three days per week. The tasks will be set to a fixed level of difficulty.
62640564|NCT02733718|OTHER|Group 1: no enteral feeding|intervention: NIRS (near-infrared spectroscopy)
62640565|NCT02733718|OTHER|Group 2: Feeding is reduced by %50|intervention: NIRS (near-infrared spectroscopy)
62640566|NCT02733718|OTHER|Group 3: Feeding will be continued|intervention: NIRS (near-infrared spectroscopy)
62071556|NCT00538096|EXPERIMENTAL|2|MEDI-538
62071557|NCT00538096|EXPERIMENTAL|3|MEDI-538
62640567|NCT02655003|EXPERIMENTAL|INH (Intervention Nursing Homes)|TIME consists of a manual based multicomponent program which includes a rigorous assessment, the treatment, and the evaluation of NPS. The staff, physicians and nursing home managers in the intervention nursing homes will receive a one-day education program. Three nurses from each unit will receive further education including practical and theoretical training for three hours.
62640568|NCT02655003|ACTIVE_COMPARATOR|CNH (Control Nursing Homes)|A brief two hours education-only intervention about dementia and NPS will be given to the staff in for the control nursing homes (CNH). The staff and physicians in the control nursing homes continue practice as usual.
62640569|NCT01937897|EXPERIMENTAL|Left-Sided Massage|Unilateral massage on the left side of the body.
62640570|NCT01937897|ACTIVE_COMPARATOR|Right-Sided Massage|Unilateral massage on the right side of the body.
62071558|NCT00466674|EXPERIMENTAL|Allogenic Transplant|
62276262|NCT02439125|EXPERIMENTAL|Eltoprazine HCl 7.5 mg|Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
62454973|NCT04418141|EXPERIMENTAL|Single Arm|"Five planned CN1 dose levels of 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.~Subjects will receive CN1 by intravenous infusion (IV) on Day 1 (D1) of each cycle (once every 3 weeks per cycle)."
62640571|NCT01937897|SHAM_COMPARATOR|Bi-Lateral Massage|Traditional massage on the back of the body.
62071559|NCT04403958|EXPERIMENTAL|PRC|Total wrist arthrodesis with PRC and dorsal plate
62276263|NCT02439125|PLACEBO_COMPARATOR|Placebo|Placebo capsules to be taken orally b.i.d. for 3 weeks
62276264|NCT00726466|EXPERIMENTAL|I|This is an open-label, study of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg/kg/wk subcutaneous dose of Efalizumab in in subjects with AMD.
62640572|NCT00128661|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
62640573|NCT00128661|ACTIVE_COMPARATOR|Havrix Group|Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
62640574|NCT03479112|EXPERIMENTAL|Flashcards|Study participants in this arm of the trial received bleeding control flashcards that contain diagrams and figures to correctly identify the severity of the injury and visual instructions on the appropriate application of pressure dressing, hemostatic packing, and tourniquet.
62640575|NCT03479112|EXPERIMENTAL|Audio-kit|Study subjects in this arm received a commercially available audio bleeding control kit. The kit included a diagram and visual aids to identify the correct severity of the injury and determine the appropriate method of bleeding control. The kit also had buttons on it to play stepwise audio instructions on the application of compression dressing, hemostatic packing and tourniquet application in two languages (English and Spanish). The audio kits were bought at the market price and the name of the manufacturer was not mentioned in the manuscript to avoid conflict of interest.
62454974|NCT03102580|EXPERIMENTAL|OA Care Plan Intervention|For intervention sites, the patient and surgeon will receive the OA Care Plan (currently under development). The OA Care plan with have Patient Reported Outcomes, feedback reports, and risk factors for shared decision making.
62640576|NCT03479112|EXPERIMENTAL|Bleeding Control (B-Con) training|Study subjects in this arm were given the American College of Surgeons Bleeding Control Basic (B-Con) in-person training course by qualified instructors. This curriculum was developed by a collaboration between American College of Surgeons and the Hartford Consensus. The session included a multimedia presentation in a class format that included some background information about extremity hemorrhage and potential benefits of immediate first-response and hemorrhage control, steps to take in a mass casualty scenario and instructional videos on hemorrhage control modalities and their appropriate use. This was followed by hands-on training in hemorrhage control, with 1:4, instructor to trainee ratio.
62640577|NCT03479112|NO_INTERVENTION|Control|Study subjects in this arm of the trial received no intervention (no training or access to point-of-care prompts) to assess baseline competence in hemorrhage control.
62640578|NCT03479112|EXPERIMENTAL|Retention of B-Con course|Control, Audio-kit, and flashcard arms undergo B-Con training at the completion of the initial evaluation, and the B-Con arm completed training prior to testing in order that all participants obtain training and then can be evaluated at retention testing. a. 3-9 months after the trial, investigators planned to test all study subjects with a simulated mass causality scenario for retention of knowledge and skills. This test will be the same as the initial test for competence at tourniquet placement in the trial and the same evaluation form will be used to evaluate the study subjects.
62640579|NCT03540693||RYGB-longitudinal|Longitudinal group of subjects studied before and after Roux-n-Y gastric bypass surgery
62640580|NCT03540693||SG_longitudinal|Longitudinal group of subjects studied before and after sleeve gastrectomy surgery
62640581|NCT03540693||LAGB_longitudinal|Longitudinal group of subjects studied before and after laparoscopic gastric banding surgery
62640582|NCT03540693||Weight-loss success|Subjects who lost ≥40% body weight by 2-5 years post-surgery
62640583|NCT03540693||Weight-loss failure|Subjects who lost \<25% body weight (or lost more but then regain weight so that now are at \<25%) by 2-5 years post-surgery
62640584|NCT04062695|ACTIVE_COMPARATOR|Tofacitinib|5 mg oral BID
62276265|NCT06194396|ACTIVE_COMPARATOR|50 neonates using alcohol|Alcohol will be used as skin disinfectant before insertion of the central venous catheter, PICC line, and umbilical venous catheter and during its routine care
62454975|NCT03102580|NO_INTERVENTION|Usual care|As collection of Patient Reported Outcomes (PROs) is considered standard of care in orthopedics (CMS mandate, Bundled Payment requirements, and reporting for Qualified Clinical Data Registry requirement for example), usual care patients and surgeons will have the ability to see PRO scores.
62640585|NCT04062695|PLACEBO_COMPARATOR|Placebo|matching Placebo BID
62454976|NCT05367908||Cohort 1: MMM (Moderna Vaccine Series)|Participants who have only received Moderna COVID-19 vaccines (that is, the 2-shot series and a booster).
62640586|NCT03319771|EXPERIMENTAL|Treadmill Walking Exercise Training|12 weeks of supervised, progressive treadmill walking exercise training
62640587|NCT03319771|ACTIVE_COMPARATOR|Stretching-and-toning Exercise Training|12 weeks of supervised, stretching-and-toning exercise training
62454977|NCT05367908||Cohort 2: PPP (Pfizer Vaccine Series)|Participants who have only received Pfizer COVID-19 vaccines (that is, the 2-shot series and a booster).
62640588|NCT06550843||conventional group|In the conventional group, the cutting line was approximately 2cm proximal to the macroscopic lesion where the mucosa and intestinal wall appeared macroscopically normal, regardless of the adjacent mesentery.
62071560|NCT04403958|ACTIVE_COMPARATOR|TWA|Total wrist arthrodesis with dorsal plate
62071561|NCT01483157|EXPERIMENTAL|low intensity with vascular occlusion|
62071562|NCT01483157|EXPERIMENTAL|high intensity resistance training|
62071563|NCT01483157|NO_INTERVENTION|no exercise training|
62276266|NCT06194396|EXPERIMENTAL|50 neonates using chlorhexidine|Chlorhexidine will be used as skin disinfectant prior to insertion of the central venous catheter, PICC line, and umbilical venous catheter and during its routine care
62276267|NCT01442259|EXPERIMENTAL|All study subjects|
62276268|NCT02568046|EXPERIMENTAL|Sym004 12 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level 1
62276269|NCT02568046|EXPERIMENTAL|Sym004 9 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level -1
62640589|NCT06550843||mesentery-guided group (Mes-G)|In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
62640590|NCT04249427|ACTIVE_COMPARATOR|Erenumab|140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
62071564|NCT02692950|OTHER|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
62071565|NCT03303677|ACTIVE_COMPARATOR|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
62276270|NCT02568046|EXPERIMENTAL|Sym004 (RP2D) + FOLFIRI|Phase 2a, Dose-Expansion: Sym004 in the RP2D in combination with FOLFIRI
62276271|NCT04502407|EXPERIMENTAL|De-intensified Cisplatin-based Chemoradiation|This is a non-randomized study, with all patients undergoing de-intensified post-operative cisplatin-based chemoradiation. Dosage level and duration of administration will be determined by whether the patient is high risk or not as assessed by the treating investigator.
62640591|NCT04249427|PLACEBO_COMPARATOR|Placebo|Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
62640592|NCT02262897|EXPERIMENTAL|Nab-paclitaxel single agent|Nab-paclitaxel single agent, either in 130mg/m2 weekly regimen, d1,8,15 every 4 weeks or in 230mg/m2 d1 every 3 weeks
62640593|NCT01155817|EXPERIMENTAL|Nilotinib|
62640594|NCT04389528|EXPERIMENTAL|tDCS active arm|
62640595|NCT04389528|PLACEBO_COMPARATOR|tDCS placebo|
62640596|NCT03685604|ACTIVE_COMPARATOR|Cardiothoracic surgery - PI disinfection|
62640597|NCT03685604|ACTIVE_COMPARATOR|Cardiothoracic surgery - CHX disinfection|
62640598|NCT03685604|ACTIVE_COMPARATOR|Abdominal surgery - PI disinfection|
62640599|NCT03685604|ACTIVE_COMPARATOR|Abdominal surgery - CHX disinfection|
62640600|NCT01537224|OTHER|neurostimulation|
62088356|NCT03952065|EXPERIMENTAL|PD1/PDL1/CTLA4 inhibitor or their combinations infusion via peripheral vein|Routine peripheral vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations is performed.
62088357|NCT03952065|EXPERIMENTAL|PD1/PDL1/CTLA4 inhibitor or their combinations infusion via intra-tumor penetration|Interventional technique is used to intra-tumor injection of the inhibitor or their combinations directly into tumor.
62088358|NCT05843630||Training cohort|Model construction based on training cohort
62088359|NCT05843630||Validation cohort 1|Model validation in an independent validation cohort 1
62640601|NCT03691636|EXPERIMENTAL|Eyelash Prostheses|Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
62088360|NCT05843630||Validation cohort 2|Model validation in an independent validation cohort 2
62088361|NCT03497182|EXPERIMENTAL|Breath sample collection|
62088362|NCT00906503|EXPERIMENTAL|PET/Computed Tomography (CT)|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan; Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
62088363|NCT01293162||placebo|
62088364|NCT05790239|EXPERIMENTAL|MDMA-Assisted Therapy|Participants will receive a flexible divided-dose of MDMA plus therapy at Experimental Sessions.
62088365|NCT05790239|ACTIVE_COMPARATOR|Low Dose D-Amphetamine Assisted Therapy|Participants will receive a flexible divided dose plus therapy at Experimental Sessions.
62088366|NCT02143674|EXPERIMENTAL|INTERVENTION|Muscle stretching and Strength Training
62088367|NCT02143674|EXPERIMENTAL|Educated about physical exercises|
62088368|NCT03255941|ACTIVE_COMPARATOR|Clinic Provider - Urban|Urban Clinic Provider providing DMPA or Sayana Press
62088369|NCT03255941|ACTIVE_COMPARATOR|Lay Provider - Urban|Urban Lay Provider providing DMPA or Sayana Press
62088370|NCT03255941|ACTIVE_COMPARATOR|Clinic Provider- Rural|Rural Clinic Provider providing DMPA or Sayana Press
62088371|NCT03255941|ACTIVE_COMPARATOR|Lay Provider- Rural|Rural Lay Provider providing DMPA or Sayana Press
62640602|NCT03691636|ACTIVE_COMPARATOR|5.0% Lifitegrast Ophthalmic Solution|Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
62640603|NCT02895035|ACTIVE_COMPARATOR|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
62640604|NCT02895035|ACTIVE_COMPARATOR|Omidria|Omidria is the intracameral additive during cataract surgery.
62276272|NCT03355989|EXPERIMENTAL|Low Flat Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.80 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62276273|NCT03355989|EXPERIMENTAL|Low Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $4.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62071566|NCT03303677|EXPERIMENTAL|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
62071567|NCT03303677|EXPERIMENTAL|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
62071568|NCT05230979|EXPERIMENTAL|Normal weight|People with normal weight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
62276274|NCT03355989|EXPERIMENTAL|Low Sharp Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.75 on the BCG/Penta-1/Penta-2 vaccine and $1.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62276275|NCT03355989|EXPERIMENTAL|Low Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $3.75 on the BCG/Penta-1/Penta-2 vaccine and $5.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62276276|NCT03355989|EXPERIMENTAL|High Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62276277|NCT03355989|EXPERIMENTAL|High Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62276278|NCT03355989|EXPERIMENTAL|High Sharp Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.25 on the BCG/Penta-1/Penta-2 vaccine and $3.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62276279|NCT03355989|EXPERIMENTAL|High Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $11.25 on the BCG/Penta-1/Penta-2 vaccine and $15.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
62276280|NCT03355989|EXPERIMENTAL|Easypaisa Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
62276281|NCT03355989|EXPERIMENTAL|Easypaisa Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
62071569|NCT05230979|EXPERIMENTAL|Overweight|People with overweight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
62071570|NCT05230979|EXPERIMENTAL|Glycemic index|Determination of glycemic index under the ISO 26642:2010.
62071571|NCT02299258|ACTIVE_COMPARATOR|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
62071572|NCT02299258|EXPERIMENTAL|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
62276282|NCT03355989|EXPERIMENTAL|SMS Reminder Only|The intervention consists of only sending 3 SMS reminders before, at and after the due date.
62276283|NCT03355989|NO_INTERVENTION|Control|No intervention will be provided either in the form of cash incentive or reminder SMS. Vaccination facilities will be provided as per usual.
62276284|NCT03782935|EXPERIMENTAL|prenatal multivitamin mineral supplement|received prenatal multivitamin mineral supplement at time of enrollment TheraVit multivitamin/mineral prenatal supplement with instructions to take 1 per day through the remainder of pregnancy
62071573|NCT04398693|NO_INTERVENTION|Normotensive Patients|40 normotensive patients with systolic BP (SBP) \< 140 mmHg and diastolic BP (DBP) \< 90 mmHg at the office, without the use of antihypertensive drugs and evaluated through ambulatory blood pressure monitoring (ABPM) to confirm normotension (BP \< 130/80 mmHg) and the exclusion of possible masked hypertension.
62071574|NCT04398693|NO_INTERVENTION|Controlled Hypertensive Patients|40 controlled hypertensive patients using up to three antihypertensive drugs with SBP \< 130 mmHg and DBP \< 80 mmHg evaluated through 24 hours ambulatory blood pressure monitoring (ABPM).
62071575|NCT04398693|ACTIVE_COMPARATOR|Resistant Hypertensive Patients|The study will be double-blinded, randomized, placebo-controlled crossover Initially, 20 individuals of the resistant hypertensive group will take prebiotic for 4 weeks, while other 20 individuals this group will use placebo. After a washout period of 4 weeks, the study protocol will be repeated in the other arm.
62071576|NCT02518724|ACTIVE_COMPARATOR|RIPC intervention group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after RIPC intervention exposure at the beginning of every meeting."
62071577|NCT02518724|PLACEBO_COMPARATOR|false exopsure group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after placebo intervention exposure at the beginning of every meeting."
62071578|NCT04282213||Control samples|For each case, neuromuscular measurements gathered with GE CARESCAPE B450 monitor (E-NMT module).
62276285|NCT03782935|EXPERIMENTAL|prenatal multivitamin mineral supplement plus choline|received prenatal multivitamin mineral supplement plus additional choline supplemental vitamin TheraVit multivitamin mineral supplement plus 750 mg. choline with instructions to take1 multivitamin mineral supplement and 750 mg. per day of choline through the remainder of pregnancy
62276286|NCT03782935|NO_INTERVENTION|Comparison|Advised to follow obstetrics standard of care which is to take a prenatal vitamin/mineral supplement
62454978|NCT05367908||Cohort 3: V (Other Combination of Vaccines)|Participants who have received any other combinations of boosters authorized in the United States, such as the 2-shot Pfizer series and a Moderna booster (PPM), the 2-shot Moderna series and a Pfizer booster (MMP), or the 1-shot Johnson and Johnson vaccine with either a Moderna or Pfizer booster.
62071579|NCT04282213||Case samples|For each case, neuromuscular measurements gathered with TOFCuff monitor.
62071580|NCT00674115|EXPERIMENTAL|Single Dose Zegerid for 1 or 7 days|Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension
62071581|NCT00674115|ACTIVE_COMPARATOR|Single Dose Prilosec 1 or 7 days|Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet
62071582|NCT00674115|ACTIVE_COMPARATOR|Sodium Bicarbonate|Sodium Bicarbonate 1680 mg Oral Suspension
62276287|NCT04461470||London|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
62276288|NCT04461470||All United Kingdom|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
62454979|NCT01925313|EXPERIMENTAL|CJ-30044|
62454980|NCT01925313|ACTIVE_COMPARATOR|TALION TAB. 10mg|
62071583|NCT04397523|OTHER|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
62071584|NCT05391321|EXPERIMENTAL|administration of quality of sexual life questionnaires|
62071585|NCT06183086||Linovera|Apply Linovera under clinical routine practice
62454981|NCT01051193|EXPERIMENTAL|TRI476|TRI476
62276289|NCT01765673||Vibrotactile Stimulation in Dysphagia|A Vibrotactile stimulation device will be evaluated in patients with chronic moderate to severe dysphagia for more than 6 months post onset due to stroke or following radiation treatment for head and neck cancer to assess which frequency, mode, pressure characteristics are most helpful in increasing the rate of swallowing, increasing the urge to swallow, assisting with the initiation of swallowing and not affecting discomfort.
62276290|NCT00917449|ACTIVE_COMPARATOR|L-arginine|L-arginine (3.2 gr bid) plus lifestyle counselling vs placebo plus lifestyle counselling
62276291|NCT00917449|PLACEBO_COMPARATOR|placebo|placebo plus lifestyle counselling for 18 months
62454982|NCT01783171|EXPERIMENTAL|Arm A (dinaciclib, Akt inhibitor MK2206)|"Patients receive dinaciclib IV over 2 hours on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62640605|NCT02405819|OTHER|Patient Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The research team will direct patients to their assigned condition by providing a hand-out directing them to the planning tool. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
62640606|NCT02405819|OTHER|Clinician Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The provider will be provided a hand-out with their patient's assigned condition and is responsible for implementing the survivorship care plan process. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
62071586|NCT02274376||Cohort|
62071587|NCT05818059|OTHER|ARM 1: without computer-aided detection (CAD)|Diagnosis of tuberculosis without the aid of CAD
62276292|NCT01256437|EXPERIMENTAL|ointment Threolone|Treatment with topical application of combined anti inflammatory and anti bacterial agent.
62071588|NCT05818059|OTHER|ARM 2: with computer-aided detection (CAD)|Diagnosis of tuberculosis with the aid of CAD
62071589|NCT02534532||Cohort 1|Females and males ≥65 years old, attending to the primary care centers, located in three different major cities in Colombia, that are willing to participate in the study, and do not present any exclusion criteria
62071590|NCT04219722|ACTIVE_COMPARATOR|Desirial only group|Administration of DESIRIAL® at Day 0 (Visit 1)
62071591|NCT04219722|PLACEBO_COMPARATOR|Placebo and Desirial group|Administration of placebo at Day 0 (Visit 1). If still eligible 12 weeks (Visit 3) after placebo injection, patient will be treated with DESIRIAL®
62276293|NCT01256437|ACTIVE_COMPARATOR|ointment Synthomycine|ointment once daily for 1 month
62276294|NCT01256437|PLACEBO_COMPARATOR|Aqua cream|
62276295|NCT05586633|ACTIVE_COMPARATOR|deep paravertebral- periforaminal ozone injection|
62276296|NCT05586633|ACTIVE_COMPARATOR|transforaminal steroid injeciton|
62276297|NCT02353533|OTHER|EMR|Standard EMR technique
62276298|NCT02353533|EXPERIMENTAL|FTRD|
62454983|NCT01783171|EXPERIMENTAL|Arm B (Akt inhibitor MK2206, dinaciclib)|"Patients receive Akt inhibitor MK2206 PO on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62640607|NCT02295072|NO_INTERVENTION|Control group|2 Usual Physical Education sessions/week
62640608|NCT02295072|EXPERIMENTAL|Intervention Group|A 5-months physical exercise-based program (3-5 Physical Education after school sessions/week + 2 Usual Physical Education sessions/week)
62071592|NCT01266447|EXPERIMENTAL|Treatment (veliparib, topotecan hydrochloride, filgrastim)|Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62071593|NCT01289041|EXPERIMENTAL|All Patients|
62071594|NCT01643941|EXPERIMENTAL|1|SA4Ag vaccine low dose
62071595|NCT01643941|EXPERIMENTAL|2|SA4Ag vaccine mid dose
62071596|NCT01643941|EXPERIMENTAL|3|SA4Ag vaccine high dose
62071597|NCT01643941|EXPERIMENTAL|4|SA3Ag vaccine
62071598|NCT01643941|PLACEBO_COMPARATOR|5|Placebo
62454984|NCT02070237|ACTIVE_COMPARATOR|Enoxaparin Once Daily|This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
62454985|NCT02070237|ACTIVE_COMPARATOR|Enoxaparin Twice Daily|This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.
62071599|NCT05150587|ACTIVE_COMPARATOR|Rifaximin 250 mg TID|
62071600|NCT05150587|ACTIVE_COMPARATOR|Rifaximin 500 mg TID|
62276299|NCT03233854|EXPERIMENTAL|Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. On Day 14 after CAR-T, eligible patients will be given NKTR-255 IV over 30 minutes, and it will be repeated every 28 days for up to 6 cycles. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
62276300|NCT04863703||One group with HBV/HDV coinfection|Measurement of HVPG before antiviral treatment of HBV/HDV coinfection and one year after treatment initiation with Bulevirtide. Administration of Bulevirtide and HVPG measurement is independent from this study.
62071601|NCT05150587|PLACEBO_COMPARATOR|Placebo|
62276301|NCT04077905|EXPERIMENTAL|DEP regimen|pegylated liposomal doxorubicin, etoposide and methylprednisolone administered in 2 week cycles for 2 cycles
62276302|NCT05583942|EXPERIMENTAL|Intervention Group|The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 3.
62276303|NCT05583942|SHAM_COMPARATOR|Sham Group|The sham device will be altered internally so that electrical stimulation is not delivered, but the device will appear to function. Externally, the sham device will look identical to the taVNS device. The participant will be told to increase the intensity until tolerated if a sensation is felt, but will be asked to stop at a maximum level of 3.
62071602|NCT04963673||DFG> 40 ml / min|Kidney transplant population followed at CHU Amiens (group 1 ⇾ DFG\> 40 ml / min).
62071603|NCT04963673||DFG < 40 ml / min|Kidney transplant population followed at CHU Amiens (group 2 ⇾ DFG \< 40 ml / min).
62071604|NCT02934113|NO_INTERVENTION|Control|
62071605|NCT02934113|EXPERIMENTAL|iOTA and HWPP|
62071606|NCT02934113|EXPERIMENTAL|HWPP|
62071607|NCT05553158|ACTIVE_COMPARATOR|Pelvic Vein Embolization (PVE)|Patients will have their pelvic veins embolized in accordance with their personalised treatment plan, based on their trans-vaginal ultrasound scan. These patients form the control group.
62071608|NCT05553158|EXPERIMENTAL|Compression Therapy|Patients will wear compression pants (with leg compression if patients also have symptomatic leg varicose veins).
62071609|NCT03984032|EXPERIMENTAL|LMA Protector Cuff Pilot|
62071610|NCT03984032|ACTIVE_COMPARATOR|LMA Supreme|
62071611|NCT04785326|EXPERIMENTAL|DMB-3115|Patients randomized to receive DMB-3115 at the beginning of the study will continue to receive the same treatment
62071612|NCT04785326|ACTIVE_COMPARATOR|Stelara|Patients randomized to receive Stelara at the beginning of the study will be re-randomized at Week 28 in a 1:1 ratio to either continue on Stelara or will be transitioned to receive DMB-3115
62071613|NCT01213173|ACTIVE_COMPARATOR|1|
62071614|NCT01213173|EXPERIMENTAL|2|
62454986|NCT06495983||Primary aldosteronism|Patients with suspected and/or confirmed primary aldosteronism, aged 18-70 years
62640609|NCT02974868|EXPERIMENTAL|Cohort 1|PF-06651600
62071615|NCT05739032|EXPERIMENTAL|Exercise group|Exercise group received aerobic exercise (30-min walking) and upper and lower extremity strength training for 12 weeks for 3 days/week.
62071616|NCT05739032|NO_INTERVENTION|Control group|Control group continued only routine follow-up.
62640610|NCT02974868|EXPERIMENTAL|Cohort 2|PF-06700841
62454987|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
62071617|NCT01802463||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
62640611|NCT02974868|PLACEBO_COMPARATOR|Cohort placebo|placebo
62640612|NCT05327582|EXPERIMENTAL|PLENA regimen|Subject received PLENA regimen every 3 weeks until achieving a second assessable complete response or up to a maximum of 8 cycles. Treatment continued until progressive disease or intolerable toxicity, or withdrawal of consent.
62640613|NCT06268834|EXPERIMENTAL|Using PPI|Group receiving a long-term PPI (omeprazole, lansoprazole, pantoprazole, esomeprazole and rabeprazole) every day for at least 6 months or at least twice a week for at least 2 years.
62640614|NCT06268834|EXPERIMENTAL|Control|A control group was formed from individuals who had never used PPI.
62640615|NCT05296707|EXPERIMENTAL|Inspiratory muscle training group|Threshold IMT was given this group. Applied for 7 days 6 weeks.
62640616|NCT05296707|ACTIVE_COMPARATOR|Used routine medicine group|Followed 6 weeks
62640617|NCT05296707|ACTIVE_COMPARATOR|Control Group|Health children
62071618|NCT01802463||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of \>21 mmHg required
62071619|NCT01802463||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of \< 21 mmHg
62640618|NCT05107219|EXPERIMENTAL|Arm I (plecanatide, EGD)|Patients receive a single dose of plecanatide (3 mg) PO 60-120 minutes prior to standard of care EGD with biopsy and luminal fluid collection.
62640619|NCT05107219|EXPERIMENTAL|Arm II (linaclotide, EGD)|Patients receive a single dose of linaclotide (145 mcg) PO 60-120 minutes prior to standard of care EGD with biopsy and luminal fluid collection.
62071620|NCT02546154||CKD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
62071621|NCT02546154||IBD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
62071622|NCT05781893||BALCoS w/o DiLCoS|Patients of the cohort that are not enrolled in the DiLCoS substudy
62071623|NCT05781893||BALCoS w/ DiLCoS|Patients of the cohort that are additionnaly enrolled in the DiLCoS substudy
62454988|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
62640620|NCT05107219|ACTIVE_COMPARATOR|Arm III (EGD)|Patients undergo standard of care EGD with biopsy and luminal fluid collection.
62640621|NCT02344316|ACTIVE_COMPARATOR|Melatonin|Group randomized to melatonin 3 mg orally nightly
62640622|NCT02344316|PLACEBO_COMPARATOR|Placebo|Group randomized to placebo orally nightly
62640623|NCT03477292|EXPERIMENTAL|Long duration of antibiotics|14 days of Colistin
62640624|NCT03477292|ACTIVE_COMPARATOR|Short duration of antibiotics|7 days of Colistin
62640625|NCT05240235|ACTIVE_COMPARATOR|Education, compression and exercise therapy|Patients will be given exercise therapy every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do home exercise at home for 10 minutes.
62640626|NCT05240235|ACTIVE_COMPARATOR|Education, compression,exercise therapy and manual lymph drainage|Patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
62640627|NCT04426942||Spontaneous pregnancy|
62640628|NCT04426942||Assisted reproduction pregnancy|
62640629|NCT06167941||lung cancer|adenocarcinoma and squamous carcinoma
62640630|NCT05493293|EXPERIMENTAL|NBI-921352 Treatment|Treatment for up to 107 weeks.
62071624|NCT05016037|OTHER|Lexically Based Speech Intelligibility Recast|Speech recasts are likely to improve speech intelligibility in Down Syndrome. The goal of this study is to induce change in speech intelligibility in order to study phonological, acoustic and suprasegmental sequelae of improvements in speech.
62071625|NCT01229982|EXPERIMENTAL|L-PPDS|
62071626|NCT02461875|ACTIVE_COMPARATOR|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
62088372|NCT03083743|EXPERIMENTAL|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
62640631|NCT06223230|EXPERIMENTAL|Study group|First-line treatment received standard antitumor therapy and nutritional psychological interventions with and without vomit management
62640632|NCT06223230|NO_INTERVENTION|Control group|First-line treatment receives standard antitumor therapy
62088373|NCT03083743|PLACEBO_COMPARATOR|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
62088374|NCT00922844|ACTIVE_COMPARATOR|Sevoflurane|Administration of the volatile anesthetic Sevoflurane.
62088375|NCT00922844|ACTIVE_COMPARATOR|Isoflurane|Administration of the volatile anesthetic Isoflurane.
62088376|NCT04374929|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|
62088377|NCT04374929|ACTIVE_COMPARATOR|Anti-Inflammatory Glucocorticoid|
62088378|NCT04374929|ACTIVE_COMPARATOR|Increased Electrode Spacing|
62088379|NCT04374929|OTHER|Control|
62071627|NCT02461875|EXPERIMENTAL|GnRH antagonist rescue & cabergoline group|Converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) and Cabergoline is administered starting on the day of HCG administration.
62640633|NCT06125093|EXPERIMENTAL|Intervention group|"Those in the intervention group will participate in a weekly group-based online intervention for approximately 6 months (Incredible Years-Autism Spectrum and Language Delays Parent Program, IY-ASLD®).~Families allocated to the intervention group will also receive treatment as usual (TAU)."
62640634|NCT06125093|NO_INTERVENTION|Treatment as usual (TAU) group|"The TAU condition involves outpatient appointments with different paediatric specialists in the hospitals of the 3 sites of the study.~Depending on the patients' needs, some cases will be assisted in early years centers or child mental health centers based in the community."
62640635|NCT05032014|EXPERIMENTAL|probiotics group|"The oral probiotic (Lactobacillus rhamnosus Probio-M9,one times a day during the whole treatment) was isolated from healthy women's breast milk samples in 2017 and was identified as Lactobacillus rhamnosus by physiological and biochemical and 16S rRNA. It is listed as the List of Probiotics for Health Food in my country's List of Bacteria Available for Food, which can be directly applied to food production."
62640636|NCT05032014|PLACEBO_COMPARATOR|placebo group|Immunotherapy with placebo alone
62287175|NCT01912625|EXPERIMENTAL|Treatment (trametinib, chemotherapy, radiation therapy)|"CONCURRENT CHEMOTHERAPY: Patients undergo IMRT or 3D-CRT QD 5 days a week for 6 weeks. Patients receive trametinib PO QD and carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiation proceed to consolidation chemotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning 3 weeks after completion of concurrent chemoradiation, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on days 1 and 22. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
62640637|NCT05032014|NO_INTERVENTION|healthy control group|healthy control group
62640638|NCT04054401|EXPERIMENTAL|DRG Neurostimulation with Spinal Fusion|
62640639|NCT02527629||Decellularized human valves|Aortic heart valve replacement
62640640|NCT05407285|EXPERIMENTAL|0 mg CBD, ingested placebo|Ingested placebo containing 0 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
62640641|NCT05407285|EXPERIMENTAL|20 mg CBD, ingested CBD|Ingested cannabis containing 20 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
62640642|NCT05407285|EXPERIMENTAL|50 mg CBD, ingested CBD|Ingested cannabis containing 50 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
62640643|NCT05407285|EXPERIMENTAL|100 mg CBD, ingested CBD|Ingested cannabis containing 100 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
62640644|NCT05407285|EXPERIMENTAL|200 mg CBD, ingested CBD|Ingested cannabis containing 200 mg CBD Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
62640645|NCT01209403|NO_INTERVENTION|No treatment|
62071628|NCT04711603|EXPERIMENTAL|MR13A9/MR13A9|Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
62071629|NCT04711603|PLACEBO_COMPARATOR|Placebo/MR13A9|Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
62071630|NCT01811940|EXPERIMENTAL|Adderall-ER and Topiramate|Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
62071631|NCT01811940|PLACEBO_COMPARATOR|Placebo|Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
62071632|NCT01074749|ACTIVE_COMPARATOR|Optisense lead|Patients with an Accent pacemaker and an OptiSense atrial lead
62640646|NCT01209403|ACTIVE_COMPARATOR|Glukose-infusion|Glucose-infusion during hemodialysis
62640647|NCT01209403|ACTIVE_COMPARATOR|Glucose-insulin infusion|Glucose-insulin infusion during hemodialysis
62640648|NCT03545750||Regional citrate anticoagulation (RCA)|Those receiving regional citrate anticoagulation for CRRT
62071633|NCT01074749|ACTIVE_COMPARATOR|Tendril lead|Patients with an Accent pacemaker and a Tendril atrial lead
62071634|NCT06175117|EXPERIMENTAL|compound E Jiao Jiang(cEJJ)|20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
62071635|NCT06175117|PLACEBO_COMPARATOR|compound E Jiao Jiang(cEJJ) placebo|20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
62071636|NCT05317546|EXPERIMENTAL|Cannabidiol, Then Placebo|
62071637|NCT05317546|EXPERIMENTAL|Placebo, Then Cannabidiol|
62071638|NCT02468609|OTHER|Ultralow-Dose-CT|Additional Ultralow-Dose-CT of the chest
62071639|NCT04459559|EXPERIMENTAL|Intervention|Using the Tactile Cueing Device
62640649|NCT03545750||Systemic heparin anticoagulation (SHA)|Those receiving systemic heparin anticoagulation for CRRT
62071640|NCT05295563||Group 1|Children who had been injected once or twice before were included in Group 1.
62071641|NCT05295563||Group 2|Children who received 3 or more injections were included in Group 2.
62640650|NCT00863915|EXPERIMENTAL|A|Ramipril10 mg Capsules, single dose
62640651|NCT00863915|ACTIVE_COMPARATOR|B|Atlace® 10 mg capsules, single dose
62276304|NCT04219423|EXPERIMENTAL|multimodal physical therapy|The multimodal intervention is 75 minutes in duration and meets two days per week for two weeks, then once per week for six weeks, followed by weekly phone calls to determine adherence to home-exercise program (HEP) for four weeks. The total duration of the intervention is twelve weeks. The intervention will be led in a group format with a ratio of one physical therapist to two participants and groups never exceeding 4 participants. All verbal and written communications in the intervention will be conducted in Spanish. The multimodal intervention consists of progressive lower extremity strengthening training targeting the quadriceps and gluteal groups in both legs, progressive stationary bicycle exercise, self-management training and education, manual therapy and home exercise program (HEP) instruction. Participants are asked to do their strengthening exercises at least three days per week for the 12-week study duration including sessions in the clinic
62276305|NCT06365073||survival group|Patients who survived in 28 days/90 days
62640652|NCT04042584|EXPERIMENTAL|Visio conference device evaluation|Neurological tele-evaluation by a neurologist
62640653|NCT01396083|EXPERIMENTAL|Ranibizumab|
62640654|NCT01396083|ACTIVE_COMPARATOR|Standard of Care|
62640655|NCT03081247|EXPERIMENTAL|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
62640656|NCT03081247|EXPERIMENTAL|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
62071642|NCT03870178|ACTIVE_COMPARATOR|Active tDCS|Anodal tDCS over trunk motor cortex representation. Intensity: 2mA Time: 20 minutes
62071643|NCT03870178|SHAM_COMPARATOR|Sham tDCS|Anodal tDCS over trunk motor cortex representation. Itensity: 2mA Time: 20 minutes (30s ON)
62640657|NCT00913549|EXPERIMENTAL|1|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
62071644|NCT04572919|ACTIVE_COMPARATOR|group A|Patients were randomly assigned to undergo lateral advancement flap
62276306|NCT06365073||death group|Patients who survived in 28 days/90 days
62276307|NCT04422080||Keratoconus patient|Patient with keratoconus disease diagnosed on videotopography
62071645|NCT04572919|ACTIVE_COMPARATOR|group B|Patients were randomly assigned to undergo classic Limberg flap
62071646|NCT06386029|EXPERIMENTAL|Power Down pilot arm|All participants will engage in a 2-week pilot intervention trial with baseline and post-intervention testing.
62276308|NCT04422080||Healthy patient|Patient consulting for keratoconus screening with no keratoconus on videotopography
62640658|NCT00913549|EXPERIMENTAL|2|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
62640659|NCT01223833||tamoxifen|100 postmenopausal women with early breast cancer treated with tamoxifen in the adjuvant setting
62071647|NCT01324219|ACTIVE_COMPARATOR|Staff|
62071648|NCT01324219|EXPERIMENTAL|Resident|
62071649|NCT01614977|EXPERIMENTAL|Methylprednisolone|"1. Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~2. Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~3. Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days."
62071650|NCT01614977|NO_INTERVENTION|Placebo|"1. Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~2. Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~3. placebo pills with an identical outward appearance and volume prescribed according to the same schedule."
62071651|NCT01168063|EXPERIMENTAL|Helicobacter pilory triple treatment|Triple treatment on this arm is based on results of molecular detection of resistance to antibiotics
62071652|NCT01168063|ACTIVE_COMPARATOR|Helicobacter pilori standard recommended treatment|H.Pylori Eradication rate with empirical treatment
62071653|NCT04658303||Pimonidazole|Single dose of 0.5 gm/m\^2 of pimonidazole (approximately 13 mg/kg)
62071654|NCT02385578|NO_INTERVENTION|The control group|no intervention
62071655|NCT02385578|EXPERIMENTAL|The experimental group|an educational intervention
62640660|NCT01223833||aromatase inhibitors|200 postmenopausal women with early breast cancer treated with an aromatase inhibitor in the adjuvant setting
62640661|NCT00475137|EXPERIMENTAL|Lamotrigine Plus Antidepressant|Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
62640662|NCT00475137|ACTIVE_COMPARATOR|2. Lamotrigine Monotherapy|Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.
62640663|NCT03187743|EXPERIMENTAL|Pharmacokinetics/dynamics|Blood samples at 3 visits
62640664|NCT03825588|EXPERIMENTAL|ASAP + BRITE + TAU (treatment as usual)|Participants in this arm receive the ASAP (As Safe As Possible) intervention, during their transition from inpatient to outpatient care, as well as the BRITE smart phone app for distress tolerance/emotion regulation and safety planning. Participants will also receive usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
62071656|NCT03341650|EXPERIMENTAL|High Pasta|Habitual pasta consumption equal or higher than 5 times/week.
62071657|NCT03341650|EXPERIMENTAL|Low Pasta|Habitual pasta consumption equal or lower than 3 times/week.
62071658|NCT00700674||1|Entropy group
62071659|NCT00700674||2|Control
62071660|NCT04096989|NO_INTERVENTION|Control group|Routine care.
62071661|NCT04096989|EXPERIMENTAL|Experimental group|The participants accept TCM regimen-based lifestyle mobile health application intervention.
62071662|NCT04096989|SHAM_COMPARATOR|Sham comparator group|The participants accept mobile health application intervention.
62071663|NCT04147767|EXPERIMENTAL|Phytosterols Arm|"The investigational food product Cholesterol Reducing Strawberry Yogurt Drink (Tesco) is a strawberry yogurt drink with added plant sterols. A 100g bottle (one serving) of cholesterol lowering strawberry yogurt drink contains 2g of free plant sterols. The magnitude of the effect given by this enriched food product, providing a daily intake of 1,5-2,4 g plant sterols/stanols, refers to the lowering/reducing blood cholesterol effects in the range 7 % to 10 % within 2 to 3 weeks of treatment, as specified by Commission Regulation (EU) 384/2010 of 05/05/2010.~The dietary intervention will consist in 8 weeks consumption of PSS enriched Yogurt Drink, which provide a daily PSS intake of 3.4g/100g bottle plant sterols ester equivalent to 2g/100g bottle of free plant sterols."
62071664|NCT04147767|PLACEBO_COMPARATOR|Placebo Arm|"The investigational food product Low Fat Strawberry Yogurt Drinks (Morrisons) is a strawberry flavoured yogurt drink with sweetener and sugar, vitamin C, B6 and D, British milk.~Placebo intervention consists in 8 weeks consumption of PSS non-enriched Yogurt Drinks. The placebo intervention is needed for the study design chosen (randomized double-blind placebo-controlled cross-over clinical trial). Placebo will be used in order to determine the efficacy of PSS intervention, comparing the effects of the two compounds (PSS and placebo) in the same experimental conditions and then avoiding bias."
62071665|NCT02099435||Hemospray to treat lower GI bleeds|
62071666|NCT03710213|NO_INTERVENTION|Usual Care|Usual care includes (1) bowel preparation instructions that are delivered via mail or through a secure online messaging portal, (2) a phone call from the endoscopy staff in the week prior to colonoscopy, and (3) the option to call the endoscopy staff during business hours to have any questions answered on demand.
62287176|NCT02069002|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT)|"There will be ten (10) manualized session, fist 90 minutes and nine (9) 45-minute individual sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after the treatment. Sessions include psychoeducation about indoor air related symptoms and personal health behavior factors integrated on patients individual symptomatology, cognitive restructuring, behavioral experiments of patients health promoting behavior, imagery rescripting and relapse prevention.~Intervention: Behavioral: Psychotherapy (CBT)"
62640665|NCT03825588|EXPERIMENTAL|BRITE + TAU (treatment as usual)|Participants in this arm will receive the BRITE smart phone app for distress tolerance/emotion regulation and safety planning as they proceed from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
62640666|NCT03825588|EXPERIMENTAL|ASAP + TAU (treatment as usual)|Participants in this arm will receive the ASAP (As Safe As Possible) intervention during their transition from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
62276309|NCT05562986|EXPERIMENTAL|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator (Aquapick, AQ-300, Aquapick Co, Ltd, Korea). All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth. All clinical parameters were evaluated on each of the six regions of the teeth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). GCF (gingival crevicular fluid) samples was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites for the evaluation of interleukin (IL)-1β, IL-10, matrix metalloproteinase (MMP)-1, MMP-8 mediators. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
62276310|NCT05562986|EXPERIMENTAL|Interdental brush group|Fifteen patients using toothbrush and interdental brush. All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth. All clinical parameters were evaluated on each of the six regions of the teeth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). GCF (gingival crevicular fluid) samples was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites for the evaluation of interleukin (IL)-1β, IL-10, matrix metalloproteinase (MMP)-1, MMP-8 mediators. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
62640667|NCT03825588|ACTIVE_COMPARATOR|TAU (treatment as usual) alone|Participants in this grouping are studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
62276311|NCT05582642|ACTIVE_COMPARATOR|Diaphragm Strength Training|
62640668|NCT04756622|EXPERIMENTAL|N acetyl cysteine|NAC dissolved in water at a dose of 600 mg three times per day from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
62640669|NCT04756622|NO_INTERVENTION|Control|No intervention
62640670|NCT00303030|ACTIVE_COMPARATOR|1. Anal injection|
62276312|NCT05582642|SHAM_COMPARATOR|Diaphragm Endurance Training|
62276313|NCT03622697|EXPERIMENTAL|Mindfulness Meditation Arm|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation phone application intervention.
62640671|NCT00303030|ACTIVE_COMPARATOR|2. Biofeedback|
62640672|NCT02144870|ACTIVE_COMPARATOR|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
62640673|NCT02144870|ACTIVE_COMPARATOR|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
62640674|NCT04929899|OTHER|Bright Ideas- CIN Training|"The PSST will be delivered by a trainer in a minimum of three 30-minute to 1-hour sessions with a parent and patient (if developmentally appropriate).~During the first session, the study team member will build rapport by understanding relevant personal background and medical information; introduce PSST and the Bright IDEAS paradigm; review the patients experience with nausea as reported in Phase 1 and at other times during treatment; promote problem-solving strategies and skills; and develop an anti-nausea action plan. During the second session, the trainer will discuss how well the prior action plan worked and reinforce successful outcomes or, if unsuccessful, return to the problem-solving steps to generate a new action plan. The third session will review progress on CINV control, assist in problem-solving as needed, and discuss how to continue to use the Bright IDEAS framework to resolve future issues with CINV or symptom management more broadly."
62071667|NCT03710213|EXPERIMENTAL|Text Message-based Intervention|In addition to usual care, the text message-based intervention consists of the subject receiving text messages per a pre-determined protocol starting 7 days prior to the date of scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program. Of note, if a patient in the intervention arm cancels or reschedules their colonoscopy after randomization, they will not receive any additional protocol text messages as part of this trial.
62071668|NCT04925596|EXPERIMENTAL|Intervention|general practitioners randomized to intervention group will be given access to ePrimaPrescribe online program
62071669|NCT04925596|ACTIVE_COMPARATOR|Control|general practitioners randomized to control group will be given access to an online program concerning doctor-patient communication
62071670|NCT04661475|EXPERIMENTAL|Dexmedetomidine adjunctive to ECT arm|
62640675|NCT06139926|OTHER|Dexmedetomidine administered intravenously|Dexmedetomidine was administered intravenously 15 min prior to patient induction (concentration 4 μg/ml; loading dose 1 μg/kg for 15 min; maintenance dose: 0.2 μg/(kg.h) until surgical specimen removal).
62640676|NCT06139926|EXPERIMENTAL|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (original solution) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
62640677|NCT00910234|ACTIVE_COMPARATOR|Drug: rhEpo, low dose|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
62640678|NCT00910234|ACTIVE_COMPARATOR|Drug: rhEpo, high dose|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
62640679|NCT00910234|PLACEBO_COMPARATOR|Control Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
62640680|NCT00960193|ACTIVE_COMPARATOR|Colchicine Alone|baseline colchicine pharmacokinetics
62640681|NCT00960193|EXPERIMENTAL|Colchicine with Seville Orange Juice|colchicine pharmacokinetics in presence of Seville orange juice
62640682|NCT03692429|EXPERIMENTAL|CYAD-101 with FOLFOX|Infusion after standard FOLFOX chemotherapy
62071671|NCT04661475|PLACEBO_COMPARATOR|Normal Saline adjunctive to ECT arm|
62640683|NCT03692429|EXPERIMENTAL|CYAD-101 with FOLFIRI|Infusion after standard FOLFIRI chemotherapy
62640684|NCT01555658|EXPERIMENTAL|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to Bivalirudin
62640685|NCT01555658|EXPERIMENTAL|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to Unfractioned Heparin.
62640686|NCT02897557|EXPERIMENTAL|Single Cohort in CRC|This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
62640687|NCT01940965|EXPERIMENTAL|Lixisenatide + Biguanide|52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
62640688|NCT01940965|EXPERIMENTAL|Lixisenatide + TZD|52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
62640689|NCT01940965|EXPERIMENTAL|Lixisenatide + alpha-GI|52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
62640690|NCT01940965|EXPERIMENTAL|Lixisenatide + Glinide|52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
62653034|NCT06351046|EXPERIMENTAL|MBSR program|Participants will attend online group class/week for eight consecutive weeks. The MBSR will be based on the program adapted by the Multidisciplinary Pain Centre at Rigshospitalet (DK), which is tailored to patients with chronic pain. Each session has duration of 1.5 hours. Content is composed by meditation techniques and physical exercises, which focus on increasing awareness and acceptance of moment-to-moment experiences, including physical discomfort and difficult emotions.Two groups of 11-12 patients will be composed. However, individual meetings may be organized if the recruitment process shows difficulties to gather patients in groups. It will be delivered by a certified MBSR therapist and via Teams platform.
62071672|NCT04443179||Infants a family history of ASD/ADHD|
62071673|NCT04443179||Infants without a family history of ASD/ADHD|
62640691|NCT00669318|EXPERIMENTAL|Treatment (Pentostatin, Alemtuzumab, Rituximab)|"Course 1: Patients receive:~* 2 mg/m\^2 pentostatin IV on days 8 and 22;~* 3 mg alemtuzumab subcutaneously (SC) on day 3;~* 10 mg alemtuzumab SC on day 4;~* 30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~* 20 mg/m\^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~* 6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.~Courses 2 and 3: Patients receive:~* 2 mg/m\^2 pentostatin IV on days 1 and 15;~* 30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~* 20 mg/m\^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~* 6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3)."
62640692|NCT05775419|SHAM_COMPARATOR|Group A: radical chemoradiotherapy group;|Concurrent chemotherapy (2 courses): Lipusu (T) + Cisplatin (DDP) scheme: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles; Radiotherapy scheme: intensity modulated radiotherapy PTV50-54Gy, PGTV 56-60Gy, conventional fractionation.
62640693|NCT05775419|EXPERIMENTAL|Group B: radical chemoradiotherapy combined with consolidation chemotherapy group|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen; Radiotherapy scheme: intensity modulated radiotherapy PTV50-54Gy, PGTV 56-60Gy, conventional fractionation.
62640694|NCT02419807|EXPERIMENTAL|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
62640695|NCT02945826|EXPERIMENTAL|uPAR PET/MRI|One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
62640696|NCT05062096|OTHER|Group 1: BRAF-mutated metastatic patients treated with 1st line targeted therapy|BRAF-mutated metastatic patients treated with 1st line targeted therapy
62640697|NCT05062096|OTHER|Group 2: Metastatic patients treated with 1st line immunotherapy|Metastatic patients treated with 1st line immunotherapy
62640698|NCT05062096|OTHER|Group 3: BRAF-mutated patients treated with adjuvant targeted therapy|BRAF-mutated patients treated with adjuvant targeted therapy
62071674|NCT06382285|EXPERIMENTAL|Treatment group|ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after the surgery
62071675|NCT06382285|PLACEBO_COMPARATOR|Control group|Saline according to a protocol 8-10 cc per hour up to 24 hours after the surgery
62071676|NCT02459249|EXPERIMENTAL|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
62071677|NCT02459249|PLACEBO_COMPARATOR|Treatment of Mexican Health Minister|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
62640699|NCT05062096|OTHER|Group 4: Patients treated with adjuvant immunotherapy|Patients treated with adjuvant immunotherapy
62640700|NCT06515899||HDF patients|ESRF patients who are receiving renal replacement therapy in the form of HDF
62640701|NCT02909010|ACTIVE_COMPARATOR|BIS™ Brain Monitoring System|BIS monitoring to adjust sedation in order to maintain values between 50-60
62071678|NCT02140346|EXPERIMENTAL|28 day repeat dose (low dose)|
62276314|NCT03622697|NO_INTERVENTION|Non-Intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
62640702|NCT02909010|PLACEBO_COMPARATOR|RASS Monitorization|sedation was adjusted with the exclusive useof Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2.
62640703|NCT04830566|EXPERIMENTAL|Myofascial release technique group|
62640704|NCT04830566|SHAM_COMPARATOR|Simulated myofascial release technique group|
62071679|NCT02140346|EXPERIMENTAL|28 day repeat dose (high dose)|
62071680|NCT02106689|EXPERIMENTAL|Needle free system|"Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle"
62276315|NCT03694925||Primary total knee arthroplasty|Primary TKA patients included in the study, to provide a baseline level for calprotectin.
62640705|NCT03163641|EXPERIMENTAL|Treatment 1|Ocular Bandage Gel
62640706|NCT03163641|EXPERIMENTAL|Treatment 2|Ocular Bandage Gel
62640707|NCT03163641|ACTIVE_COMPARATOR|Control Group|Artificial tears with Acuvue Oasys
62640708|NCT02171546|ACTIVE_COMPARATOR|Dabigatran etexilate capsules|
62071681|NCT02106689|ACTIVE_COMPARATOR|Standard needle injection system|Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections
62640709|NCT02171546|EXPERIMENTAL|Dabigatran etexilate capsules and quinidine sulfate tablets|
62640710|NCT02171546|ACTIVE_COMPARATOR|Fexofenadine tablets|
62071682|NCT05983926|EXPERIMENTAL|Differences in conditions before and after surgical treatment of constipation|
62071683|NCT04992936|EXPERIMENTAL|Extract from the wine industry|Participants will consume the extract from the wine industry for 5 weeks.
62071684|NCT04992936|PLACEBO_COMPARATOR|Placebo|Participants will consume maltodextrin for 5 weeks.
62071685|NCT00517465|EXPERIMENTAL|1|
62071686|NCT00517465|EXPERIMENTAL|2|
62071687|NCT00517465|EXPERIMENTAL|3|
62071688|NCT00517465|PLACEBO_COMPARATOR|4|
62071689|NCT05885113|EXPERIMENTAL|Intervention|NIDCAP developmental care group receiving intervention
62071690|NCT05885113|NO_INTERVENTION|standard of care|NO intervention, control group, receiving standard of care
62071691|NCT02678689|EXPERIMENTAL|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|An age-appropriate dose of BMN 190 administered via intracerebroventricular (ICV) infusion every other week (qow) for a duration of 144 weeks.
62071692|NCT06317064|NO_INTERVENTION|Control Group|10 females with no dysmenorrhea participated as controls.
62071693|NCT06317064|EXPERIMENTAL|NSAIDs and Aprepitant group (Sequential)|"All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."
62071694|NCT00808301|OTHER|A/B|This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.
62276316|NCT03694925||Aseptic revision total knee arthroplasty|Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
62640711|NCT02171546|EXPERIMENTAL|Fexofenadine and quinidine sulfate tablets|
62640712|NCT06448052|EXPERIMENTAL|UC-MSC transplantation|Participants will receive two intravenous infusions of 100 million umbilical cord mesenchymal stem cells on days 0 and 90.
62071695|NCT03161119|EXPERIMENTAL|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
62071696|NCT03161119|ACTIVE_COMPARATOR|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
62071697|NCT02490891|EXPERIMENTAL|PET scan with RGD K5 imaging|PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
62071698|NCT03934632|ACTIVE_COMPARATOR|Postabsorptive|Saline infusion to mimic postabsorptive circulating amino acid concentrations
62276317|NCT03694925||Revision septic total knee arthroplasty|Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
62276318|NCT02433600|ACTIVE_COMPARATOR|Cow's milk-based infant formula|
62276319|NCT02433600|EXPERIMENTAL|Cow milk-based infant formula with enriched protein fractions|
62276320|NCT03099720|EXPERIMENTAL|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
62640713|NCT03570216|EXPERIMENTAL|Exercise|All participants will perform 3 exercise sessions: one session to assess their cardiorespiratory fitness, one session on moderate-intensity continuous exercise and one session of high-intensity interval exercise
62640714|NCT04997603|OTHER|Athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
62640715|NCT04997603|OTHER|Non-athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
62640716|NCT01706562||Itraconazole|
62640717|NCT01362764|OTHER|001|Abiraterone acetate tablets Type=exact unit=mg number= 250 form=tablet route=oral use as a single dose
62640718|NCT01362764|OTHER|002|Abiraterone acetate suspension Formulation 1 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
62640719|NCT01362764|OTHER|003|Abiraterone acetate suspension Formulation 2 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
62640720|NCT01996371|OTHER|Group 1|Unilateral pedicle screws
62640721|NCT01996371|OTHER|Group 2|Ipsilateral pedicle screws, contralateral facet screw
62640722|NCT01996371|OTHER|Group 3|Bilateral pedicle screws
62640723|NCT00953030|EXPERIMENTAL|COACH|"web-based risk assessments with an action plan that is negotiated with a Coach who provides personalized follow-up reinforcement"
62640724|NCT00953030|EXPERIMENTAL|RealAge|a web-based health risk assessment and risk profile with disease-specific follow-up reinforcement modules
62071699|NCT03934632|ACTIVE_COMPARATOR|Postprandial|Amino acid infusion to mimic postprandial circulating amino acid concentrations
62071700|NCT03313219|EXPERIMENTAL|Gentuximab Injection|Patients are assigned to a dose level at the time of study entry and scheduled to receive i.v. of a single dose. The patient enter the subsequent multiple dose i.v. in a 7-day cycle if no DLT in 21 days after the first dose. The study period of each subject will be up to 4 cycles until the tumor progression or unacceptable toxicity. The MTD will be determined by assessing DLT in each cohort from cohort 1 to 6, using a 3+3 dose escalation model. Cohort A begin at 4mg/kg IV and the dose escalated in separate cohorts from 8mg/kg IV, 12mg/kg IV，16mg/kg IV and 20mg/kg IV. If there is no DLT observe in any of these 3 patients in 7 weeks, then the trial proceeds to enroll 3 patients into the next higher dose cohort. If one subject develops a DLT at a specific cohort, an additional 3 patients are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 patients in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
62640725|NCT00953030|NO_INTERVENTION|light health education control|
62640726|NCT04517292|EXPERIMENTAL|Eribulin,cisplatin|EP (Eribulin and cisplatin combination)
62640727|NCT04517292|ACTIVE_COMPARATOR|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
62071701|NCT00890058||Cases|Postmenopausal breast cancer patients with hand pain receiving aromatase inhibitors
62071702|NCT00890058||Controls|Postmenopausal breast cancer patients with hand pain not receiving aromatase inhibitors
62640728|NCT06368310|EXPERIMENTAL|Intervention Arm|Patients with suspected gliomas (intrinsic primary brain tumors) in whom surgical resection under general anesthesia with neurophysiological monitoring or under awake conditions where language mapping is planned.
62640729|NCT02731196|EXPERIMENTAL|Early exercise intervention group|Education, stabilization and neurodynamic level one exercises will be provided to the intervention group within one to two weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will be provided with education, stabilization and neurodynamic level two exercises and a pedometer to monitor step count between week 4 and week 10 following the surgery.
62640730|NCT02731196|ACTIVE_COMPARATOR|Late exercise intervention group|Education, stabilization and neurodynamic level one and two exercises will be provided to the active comparator group within 4-6 weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will also be given instructions and a pedometer to monitor step count between week 4 and week 10 following the surgery.
62071703|NCT02186509|EXPERIMENTAL|Alisertib, fractionated stereotactic radiosurgery|"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.~MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
62071704|NCT04737213|EXPERIMENTAL|SGM-101|Patients included with colorectal lung metastases, SGM-101 7.5-12.5mg, 3-5 days prior to surgery
62071705|NCT03987256|EXPERIMENTAL|ECRB needling with adjuvant PRP infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with PRP"
62640731|NCT04454008|EXPERIMENTAL|Intervention|The intervention group will receive 12 sessions of executive function family training, including executive function training for children and parenting guidance for parents.
62640732|NCT04454008|ACTIVE_COMPARATOR|waiting|The waiting group will receive routine clinical intervention, including health education, family support and guidance from outpatient clinic.
62640733|NCT02189668|EXPERIMENTAL|Non-operative Management|Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
62640734|NCT02189668|NO_INTERVENTION|Surgery|Usual care with urgent appendectomy
62276321|NCT03099720|PLACEBO_COMPARATOR|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
62071706|NCT03987256|ACTIVE_COMPARATOR|ECRB needling with adjuvant NaCl 0.9% infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with Saline solution"
62276322|NCT05598892|EXPERIMENTAL|Robot-assisted Rehabilitation|Participants will receive rehabilitation based on hand robotic exosqueleton (ROBHAND, ITAP Valladolid, Spain) Patients will perform upper limb exercises assisted by the device. Training involve 16 sessions, 2 sessions per week for 8 weeks, each lasting about 60 minutes.
62640735|NCT00229671|EXPERIMENTAL|Patients with prescriptions under 21|Pediatric visits with prescriptions. These patients parents will be given survey 1.
62640736|NCT00229671|EXPERIMENTAL|Patients who completed Survey 1|Patients with prescriptions under 21 whose parents complete survey 1 will be given survey 2
62640737|NCT05716347|EXPERIMENTAL|the 5 μg recombinant SARS-CoV-2 S-Trimer vaccine booster group|
62640738|NCT05716347|EXPERIMENTAL|the 10 μg recombinant SARS-CoV-2 S-Trimer vaccine booster group|
62640739|NCT05716347|EXPERIMENTAL|the 30 μg recombinant SARS-CoV-2 S-Trimer vaccine booster group|
62640740|NCT05716347|ACTIVE_COMPARATOR|ICV booster group|
62640741|NCT05815134|EXPERIMENTAL|patients with endometriosis|
62640742|NCT05815134|ACTIVE_COMPARATOR|others infertility causes|
62071707|NCT00003458|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62640743|NCT00572091|EXPERIMENTAL|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
62640744|NCT02981030|EXPERIMENTAL|Simplified medical abortion|Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.
62640745|NCT01346865|EXPERIMENTAL|cilostazol|cilostazol 100mg
62640746|NCT01346865|PLACEBO_COMPARATOR|dual therapy group|Placebo
62071708|NCT02872961||SIBO Positive|Positive small bowel aspirate culture and/or positive glucose breath test
62071709|NCT02872961||SIBO Negative|Negative small bowel aspirate culture and negative glucose breath test
62071710|NCT01209481|EXPERIMENTAL|Nutritional education|
62071711|NCT01209481|NO_INTERVENTION|control|
62071712|NCT05238532|EXPERIMENTAL|Single Arm|CT303
62071713|NCT00665990|OTHER|Treatment|All participants will receive bevacizumab, sorafenib, and cyclophosphamide until maximum tolerated dose is reached.
62640747|NCT03603522|EXPERIMENTAL|BioGaia-DSM17938 then Placebo Comparator|28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.
62640748|NCT03603522|PLACEBO_COMPARATOR|Placebo Comparator then BioGaia DSM17938|28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.
62640749|NCT04806022|EXPERIMENTAL|Mental Fatigue Task first|"* First appointment :~  1. Pre-fatigue assessment~ 2. mental fatigue task~ 3. post-fatigue assessment~* 7 resting days~* second appointment~  1. Pre-fatigue assessment~ 2. Muscle fatigue task~ 3. post-fatigue assessment"
62640750|NCT04806022|EXPERIMENTAL|Muscle fatigue task first|"* First appointment :~  1. Pre-fatigue assessment~ 2. Muscle fatigue task~ 3. post-fatigue assessment~* 7 resting days~* second appointment~  1. Pre-fatigue assessment~ 2. mental fatigue task~ 3. post-fatigue assessment"
62640751|NCT04658264|EXPERIMENTAL|Treatment Arm|The Treatment group shall receive 2 Kg of the composite flour every week, sufficient for 21 chapattis, and shall eat chapattis made from this flour instead of their usual wheat flour chapattis. The participants shall continue to receive the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study.
62071714|NCT02020499||Acromegalic patients|Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
62071715|NCT02138747|EXPERIMENTAL|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
62640752|NCT04658264|NO_INTERVENTION|Control Group|This group shall receive only the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study. They will continue to eat their usual diet as before their enrollment. They shall however receive usual counseling on lifestyle modifications including diet
62071716|NCT02138747|EXPERIMENTAL|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
62071717|NCT02138747|EXPERIMENTAL|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
62071718|NCT02138747|EXPERIMENTAL|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
62071719|NCT04978610|EXPERIMENTAL|Intervention (Immediate)|Participants in the intervention group will begin their 6-week vACT sessions first and complete baseline, the weekly surveys during intervention, post, one month follow-up, and three month follow-up.
62276323|NCT02022982|EXPERIMENTAL|Palbociclib and PD-0325901|"* Palbociclib by mouth once a day, every day for 3 weeks every 4 in each cycle.~* PD-0325901 by mouth twice a day, every day for 3 weeks every 4 in each cycle. ."
62276324|NCT00784966|ACTIVE_COMPARATOR|1|Two weeks etanercept post islet transplant
62276325|NCT00784966|ACTIVE_COMPARATOR|2|Two months etanercept treatment post islet transplant
62640753|NCT06029881||Obstructive sleep apnea patients|"Patients admitted for complaints of sleep disturbances with no prior significant cardiovascular disease.~Inclusion criteria:~* 18 \< age \<70~* BMI \< 35 kg/m2~Exclusion criteria:~* Being under any kind of OSA treatment (cPAP therapy, etc.)~* Having been diagnosed with Atrial fibrillation, significant valvular heart disease, or ventricular dysfunction~* Age \<18 or age \> 70~* BMI \> 35 kg/m2"
62640754|NCT06139848|EXPERIMENTAL|Maitland, Mackenzie Techniques and Conventional Treatment|posterior-anterior spinal mobilization and prone press up along with conventional treatment as Heating pad for 10 minutes Bridging exercises (10 rep, 3 sets) Paraspinal muscle stretch
62640755|NCT06139848|ACTIVE_COMPARATOR|Maitland Mobilization Techniques and Conventional Treatment|Posterior-anterior spinal mobilization along with conventional treatment as Heating pad for 10 minutes Bridging exercises (10 rep, 3 sets) Paraspinal muscle stretch
62640756|NCT06139848|ACTIVE_COMPARATOR|Meckinzie Techniques and Conventional Treatment|"Prone press up technique will be given along with conventional treatment as:~Heating pad for 10 minutes Bridging exercises (10 rep, 3 sets) Paraspinal muscle stretch"
62640757|NCT01086670|OTHER|1|Subjects will be randomly assigned to use one of two novel lower extremity exercise devices: a motor-assisted cycle or an elliptical trainer.
62640758|NCT01909700|EXPERIMENTAL|Single Incision Mesh|intervention: single incision mesh implantation
62640759|NCT05340335|EXPERIMENTAL|Remimazolam|A loading dose of remimazolam is administered for sedation
62640760|NCT06327412|ACTIVE_COMPARATOR|Hospital Exercise Group|According to the Cardiopulmonary Exercise test (CPET), the patients should exercise on the treadmill (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) for 40 minutes (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) at an exercise intensity of 50-60% of the individually recorded VO2 max (the maximum amount of oxygen that an individual can utilize during intense or maximal exercise) level in the patients. Aerobic exercise therapy will be organized to include treadmill.
62640761|NCT06327412|PLACEBO_COMPARATOR|Home Exercise Group|Patients will be asked to walk 40 minutes a day, 5 days a week, for 4 weeks. Training will be given for the first session in the hospital to ensure that the patient's walking pace is between 12-13 RPE (The Borg Rating of Perceived Exertion) according to the Modified Borg scale.
62640762|NCT05562869|EXPERIMENTAL|Experimental: transient belatacept|IV, 5mg/Kg days 1, 15, 30, 45 and 60 then every months
62640763|NCT02718664|NO_INTERVENTION|A (fasting)|Fasting condition
62640764|NCT02718664|EXPERIMENTAL|B (fed)|Fed condition (test meal)
62640765|NCT04486261|EXPERIMENTAL|High-intensity strength training|"16 weeks of high-intensity strength training two times per week.~Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient)~Interventions:~Other: high-intensity strength training Drug: Usual care"
62640766|NCT04486261|NO_INTERVENTION|Control|"Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient).~Intervention:~Drug: Usual care"
62640767|NCT06417970||Volleyball Players|
62640768|NCT00683423|EXPERIMENTAL|A|
62454989|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
62640769|NCT00683423|PLACEBO_COMPARATOR|B|
62454990|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
62454991|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
62454992|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
62640770|NCT02976311|ACTIVE_COMPARATOR|Misgav-Ladach|cesarean section(C/S) via the modified 'Misgav-Ladach' technique
62640771|NCT02976311|ACTIVE_COMPARATOR|Pfannenstiel-Kerr|cesarean section(C/S) via the 'Pfannenstiel-Kerr' technique
62640772|NCT03101150|ACTIVE_COMPARATOR|400 IU Vitamin D3|400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
62640773|NCT03101150|EXPERIMENTAL|4000 IU Vitamin D3|4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
62640774|NCT01265498|ACTIVE_COMPARATOR|Obeticholic acid|obeticholic acid
62640775|NCT01265498|PLACEBO_COMPARATOR|Placebo|Placebo
62640776|NCT04240808|EXPERIMENTAL|UCD19 CAR T Cells|Participants will receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector \[LV\] Transduced Autologous Peripheral Blood Lymphocytes
62276326|NCT04735055||Artificial intelligence (AI) machine learning group|"90% machine learning part has also been divided into 2 parts as 70% for AI learning and 30% for testing the learning.~70% of the acute pancreatitis patients (approximately 840 pts) will form the model training group of the study. 30% of the acute pancreatitis patients (approximately 360 pts) will form the testing group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
62640777|NCT03137810|EXPERIMENTAL|placental cord drainage|In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
62640778|NCT03137810|ACTIVE_COMPARATOR|Non placental cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
62640779|NCT01944358||Taiwan AIDS study group|
62640780|NCT03474796|EXPERIMENTAL|Novice|
62640781|NCT03474796|EXPERIMENTAL|Expert|
62640782|NCT05572645||PyroH|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
62640783|NCT05572645||PertH|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
62640784|NCT02725320||Female Rotator Cuff Surgical Group|Females, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
62640785|NCT02725320||Male Rotator Cuff Surgical Group|Males, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
62088380|NCT04075981|EXPERIMENTAL|Botulinum toxin|"All patients from the experimental group will receive botulinum toxin (Xeomin®, incobotulinumtoxin A, Merz Pharma GmbH \& Co KGaA, Germany; 200 U dissolved in 4 mL of 0.9% normal saline and 50 U/1 mL will be injected at each fat pad).~Botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.~The whole estimated dosage would be therefore 200 units of incobotulinumtoxin A,"
62276327|NCT04735055||Validation group|"10% of the acute pancreatitis patients (approximately 134) will form the validation group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
62276328|NCT01918670||Pasteur|
62276329|NCT01918670||Grenoble|
62276330|NCT01918670||Nantes|
62276331|NCT01918670||Parly|
62276332|NCT01918670||Rennes|
62276333|NCT01918670||Rouen|
62640786|NCT02266446|EXPERIMENTAL|Attention & Interpretation Modification|The final product will be web-delivered, so it may be completed at the clinic or home. Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session
62640787|NCT00236002|PLACEBO_COMPARATOR|placebo|
62640788|NCT03059914|EXPERIMENTAL|InterOss|Maxillary sinus augmentation using ABBM Inteross ( Xenograft)
62640789|NCT03059914|ACTIVE_COMPARATOR|Bio-oss|Maxillary sinus augmentation using ABBM Bio-oss ( Xenograft)
62640790|NCT02900352|EXPERIMENTAL|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 7 weeks, then 9 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
62640791|NCT02900352|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
62640792|NCT01703494|ACTIVE_COMPARATOR|Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal Microbiota Transplant (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
62640793|NCT01703494|SHAM_COMPARATOR|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute severe C. difficile infection, subjects will receive a 300 mL infusion of a sham (autotransfusion) fecal solution at colonoscopy.
62640794|NCT04928781|EXPERIMENTAL|Smoking Cessation Counseling - Intervention Arm|Intervention arm. All patients enrolled in the study will be provided with smoking cessation counseling.
62454993|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
62071720|NCT04978610|OTHER|Control (Waitlist)|Upon the intervention group's completion of the 6-week long vACT, the control group will then enroll into their own 6-week long ACT intervention. The research protocol for the second 6-week long ACT intervention will mirror the protocol with the original 6-week long ACT intervention, except for one change: participants will NOT complete an additional baseline questionnaire prior to starting the 6-week ACT therapy group. The rest of the protocol remains the same. Namely, before each session, each participant will be required to fill out a short survey on their stress and pain throughout previous week. At the conclusion of the final session, participants will follow the complete post-intervention battery of surveys, which mirrors the baseline measures plus the inclusion of satisfaction surveys assessing the effectiveness of the virtual therapy intervention. Participants will complete the post-intervention follow up battery of questionnaires at 1 and 3 months post-intervention.
62454994|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
62454995|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
62276334|NCT05043415|ACTIVE_COMPARATOR|Immediate endoscopic necrosectomy|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Then in this group, endoscopic necrosectomy will be performed immediately following index EUS-guided drainage of the necrotic collection, during the same session
62640795|NCT04928781|NO_INTERVENTION|Retrospective Chart Review - Control Arm|Control arm. A retrospective chart review will be conducted to create a randomly selected cohort of patients that meet inclusion and exclusion criteria and did not receive smoking cessation counseling to serve as the control arm.
62640796|NCT03799614|EXPERIMENTAL|Lower dose vibration|RMBand lower dose vibration
62640797|NCT03799614|EXPERIMENTAL|Higher dose vibration|RMBand higher dose vibration
62640798|NCT01401322|EXPERIMENTAL|Lenalidomide 50 mg/day x 28 days|Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.
62071721|NCT01292174|EXPERIMENTAL|Group 1 - lowest dosage|120 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
62276335|NCT05043415|ACTIVE_COMPARATOR|Step-up endoscopic intervention|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. In this group, only EUS-guided drainage of the necrotic collection will be performed, and endoscopic necrosectomy will be performed at a separate session at a later time as needed.
62640799|NCT01100853|ACTIVE_COMPARATOR|Extended release VIVITROL injection 380 mg, 24 weeks|Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
62640800|NCT01100853|PLACEBO_COMPARATOR|VIVITROL placebo injection, 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
62640801|NCT06251141|ACTIVE_COMPARATOR|Study group gum Health gel|Study group we fill the sockets with gel foam immersed with Gum Health gel
62454996|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
62454997|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
62454998|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
62071722|NCT01292174|EXPERIMENTAL|Group 2 - middle dosage level|240 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
62071723|NCT01292174|EXPERIMENTAL|Group 3 - highest dosage level|480 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
62071724|NCT04103424|NO_INTERVENTION|Pre-training Metabolic Study Visit|Participants will first complete a pre-training metabolic study visit.
62071725|NCT04103424|EXPERIMENTAL|Post-training Metabolic Study Visit|Participants will complete a second, identical metabolic study visit following 2-weeks of exercise training.
62640802|NCT06251141|PLACEBO_COMPARATOR|Control group gel foam|Control group we fill the sockets with gel foam only
62640803|NCT01129401|OTHER|Stonewall Project Participants|
62640804|NCT04779424||Primary Health Care Providers (PHCPs)|Any Belgian general practitioner (GP) (including those in professional training) currently working in primary care and any other primary health care providers (PHCPs) from the same GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP).
62640805|NCT06087770|EXPERIMENTAL|Phase Ia Dose escalation|Phase Ia Dose escalation： A maximum of 48 patients will be enrolled in this phase and are planned to be divided into eight dose groups: 0.3 mg/kg, 1mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
62640806|NCT03365661|EXPERIMENTAL|ALT-803|
62071726|NCT05051332|EXPERIMENTAL|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm\^3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
62276336|NCT03107793|EXPERIMENTAL|All Participants|At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (\>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
62454999|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
62455000|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
62455001|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
62640807|NCT01543568|OTHER|2.0 mg intravitreal Aflibercept|open label, Subjects seen monthly \& given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)
62640808|NCT04591639|OTHER|Patients with heart failure without type 2 diabetes|60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
62071727|NCT05051332|ACTIVE_COMPARATOR|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.
62071728|NCT00185510|EXPERIMENTAL|Arm 1|
62071729|NCT00185510|PLACEBO_COMPARATOR|Arm 2|
62071730|NCT05056064|EXPERIMENTAL|CA oral cavity|Standard Treatment+Oral exercise
62071731|NCT05056064|NO_INTERVENTION|control|Standard treatment
62071732|NCT00592046|EXPERIMENTAL|Single Arm|
62455002|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
62455003|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
62455004|NCT01418157|ACTIVE_COMPARATOR|Acetazolamide|
62071733|NCT01539174|EXPERIMENTAL|Treatment (monoclonal antibody, combination chemotherapy)|Patients receive rituximab IV on days 0, 1, 4, 8, and 15 of course 1; days 1, 8, and 15 of course 2; and day 1 of all subsequent courses. Patients also receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62071734|NCT05099913|EXPERIMENTAL|2-week group|Patients were treated with antidepressants for 10-14 days combined with first-class medication(anti-acid drugs, prokinetics), followed by on demand.
62071735|NCT05099913|EXPERIMENTAL|4-week group|Patients were treated with antidepressants for 4 weeks combined with first-class medication(anti-acid drugs, prokinetics).
62071736|NCT02207517|EXPERIMENTAL|Office-based verg/accomm therapy (OBVAT)|OBVAT requires a participant to undergo a specific vision therapy regimen with 16 weekly, 60-minute in-office treatment sessions. Vision Therapists (O.D., M.D., Orthoptists, or specially-trained technicians) administer the therapy in the office. OBVAT procedures are then supplemented with various home therapy procedures
62455005|NCT01418157|PLACEBO_COMPARATOR|Placebo|
62640809|NCT04591639|OTHER|Patients with heart failure with type 2 diabetes|60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
62640810|NCT03874832|EXPERIMENTAL|STS101 1.5 mg|STS101 (dihydroergotamine nasal powder), 1.5 mg
62276337|NCT03107793|EXPERIMENTAL|Routine Care Arm|In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
62276338|NCT03107793|EXPERIMENTAL|Treat to Target (T2T) Arm|UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with \<25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with \>=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.
62276339|NCT03107793|EXPERIMENTAL|Exploratory Extension period: From Week 48 to Week 104|At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score \<=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
62276340|NCT05122416|EXPERIMENTAL|Group 1a: SSD<15mm and with splenomegaly|Patients with a Spleen to Skin Distance less than 15mm and who present a splenomegaly.
62276341|NCT05122416|EXPERIMENTAL|Group 1b: SSD<15mm and without splenomegaly|Patients with a Spleen to Skin Distance less than 15mm and who does not present a splenomegaly.
62276342|NCT05122416|EXPERIMENTAL|Group 2a : 15<SSD<25mm and with splenomegaly|Patients with a Spleen to Skin Distance between 15 and 25 mm and who present a splenomegaly.
62276343|NCT05122416|EXPERIMENTAL|Group 2b : 15<SSD<25mm and without splenomegaly|Patients with a Spleen to Skin Distance between 15 and 25 mm and who does not present a splenomegaly.
62276344|NCT05122416|EXPERIMENTAL|Group 3a: SSD≥25mm and with splenomegaly|Patients with a Spleen to Skin Distance higher than 25 mm and who present a splenomegaly.
62276345|NCT05122416|EXPERIMENTAL|Group 3b: SSD≥25mm and without splenomegaly|Patients with a Spleen to Skin Distance higher than 25 mm and who does not present a splenomegaly.
62276346|NCT01251328|ACTIVE_COMPARATOR|General anaesthesia|General anaesthesia is performed under standardized conditions
62276347|NCT01251328|ACTIVE_COMPARATOR|Sedation|Sedation is performed under standardized conditions
62276348|NCT00613457|EXPERIMENTAL|I|o Arm I (closed to accrual as of 6/30/2006): Patients receive prednisone (PRED) on days 8-28.
62276349|NCT00613457|EXPERIMENTAL|II|o Arm II (closed to accrual as of 6/30/2006): Patients receive dexamethasone (DEXA) on days 8-28.
62276350|NCT00613457|EXPERIMENTAL|Reintensification Arm I|o Arm I (standard reinduction therapy, protocol II \[closed to accrual as of 6/30/2006\]): SR and IR patients receive DEXA on days 1-22; VCR and doxorubicin hydrochloride (DOX) in weeks 2-5; ASP on days 8, 11, 15, and 18; CPM on day 36; ARA-C and thioguanine (TG) on days 36-49; and MTX IT on days 38 and 45. Patients then proceed to maintenance therapy.
62276351|NCT00613457|EXPERIMENTAL|Reintensification Arm II|• Arm II (reduced-intensity reinduction therapy, protocol III \[closed to accrual as of 6/30/2006\]): SR patients receive DEXA on days 1-15; VCR and DOX on days 1 and 8; ASP on days 1, 4, 8, and 11; CPM on day 15; ARA-C and TG on days 15-28; and MTX IT on days 16 and 23. Patients then proceed to maintenance therapy.
62276352|NCT00613457|EXPERIMENTAL|Reintensification Arm III|• Arm III (reduced-intensity reinduction/second delayed reinduction therapy \[double reintensification therapy\] \[closed to accrual as of 6/30/2006\]): IR patients receive reduced-intensity reintensification therapy as in arm II. After a 10-week interim maintenance phase, treatment repeats once for a second delayed course of reintensification therapy. Patients then proceed to maintenance therapy.
62276353|NCT00613457|EXPERIMENTAL|Reintensification Arm IV|"• Arm IV (standard reintensification therapy \[closed to accrual as of 6/30/2006\]): HR patients receive one sequence of the following HR therapy elements, in this order: 1, 2, 3, following standard reinduction therapy protocol II repeated twice after a four weeks Interim Maintenance phase. Patients then proceed to maintenance therapy.~* Element HR-1: Patients receive DEXA on days 1-5; VCR on days 1 and 6; ARA-C twice on day 5; MTX and CPM every 12 hours on days 2-4 (5 doses); ASP on day 6 ; and MTX/ARA-C/PRED IT on day 1.~* Element HR-2: Patients receive DEXA on days 1-5; vindesine on days 1 and 6; DNR on day 5; MTX and ifosfamide every 12 hours on days 2-4 (5 doses); ASP on day 6; and MTX/ARA-C/PRED IT on day 1.~* Element HR-3: Patients receive DEXA on days 1-5; ARA-C every 12 hours on days 1-2 (4 doses); etoposide five times daily on days 3-5; ASP on day 5; and MTX/ARA-C/PRED IT on day 1."
62640811|NCT03874832|EXPERIMENTAL|STS101 3.0 mg|STS101 (dihydroergotamine nasal powder), 3.0 mg
62640812|NCT03874832|EXPERIMENTAL|STS101 6.0 mg|STS101 (dihydroergotamine nasal powder), 6.0 mg
62640813|NCT03874832|ACTIVE_COMPARATOR|DHE intramuscular injection|Dihydroergotamine mesylate
62640814|NCT03874832|ACTIVE_COMPARATOR|DHE nasal spray|Dihydroergotamine mesylate
62640815|NCT01341015|EXPERIMENTAL|ultrasound for fracture|All patients receive ultrasound for potential ankle fracture.
62640816|NCT02150928|EXPERIMENTAL|Erwinaze / Erwinase|
62640817|NCT01056692|ACTIVE_COMPARATOR|Active compound|OC000459 orally
62640818|NCT01056692|PLACEBO_COMPARATOR|Placebo|Placebo given orally
62276354|NCT00613457|EXPERIMENTAL|Reintensification Arm V|"• Arm V (extended reintensification therapy \[triple protocol III\] \[closed to accrual as of 6/30/2006\]): HR patients receive HR therapy elements 3, 2, and 1 following reintensification therapy repeated the therapy element three times with 4-week interim maintenance phases in between. Patients then proceed to maintenance therapy.~* Interim maintenance/maintenance therapy: Patients receive MTX once weekly and MP daily until week 104 plus IT MTX every eight weeks.~* Radiotherapy: HR patients or patients with T-cell acute lymphoblastic leukemia or CNS disease undergo CNS radiotherapy."
62276355|NCT02916355|EXPERIMENTAL|Normal BMI|Healthy young men, normal BMI (BMI \>18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
62276356|NCT02916355|EXPERIMENTAL|Overweight|Healthy young men (BMI \>30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
62640819|NCT04478058|EXPERIMENTAL|e-CBT|Weekly e-CBT sessions will occur through Online Psychotherapy Tool (OPTT) and consist of slides and interactive therapist videos. Content and format mirrors live CBT. Slides will highlight a different topic each week and include general information, overview of skills, and homework. Homework will be submitted through OPTT and reviewed by administrators with personalized feedback within three days. Weekly homework submission will be mandatory before beginning the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment. After each cycle of e-CBT, patients and healthcare providers involved in e-CBT will be recruited for focus groups once they have completed their 12-week program. Qualitative data will be gathered through 10 focus groups. The focus group prompts will pertain to experience and expectations of service. Patients will be contacted six months after treatment to complete DASS 21 and Q-LES-Q-SF questionnaires.
62640820|NCT04478058|ACTIVE_COMPARATOR|Live CBT|The content and format of live CBT will be mirrored by the e-CBT group over the course of 12 weeks. The sessions will highlight a different topic each week and include general information, an overview of skills, and homework on that topic. Live CBT homework will be reviewed by the CBT group organizer and provided at the beginning of the next CBT session. Weekly homework submission for feedback will be mandatory before being eligible for the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment for both live and e-CBT. All live and e-CBT patients will be contacted six months after the completion of their CBT to complete final DASS 21 and Q-LES-Q-SF questionnaires. This will allow for the examination of the longevity of e-CBT compared to live CBT.
62640821|NCT01288313|EXPERIMENTAL|rapeseed oil|
62071737|NCT02207517|PLACEBO_COMPARATOR|Office-based placebo therapy (OBPT)|"Office-based Placebo Therapy (OBPT) requires a participant to undergo a specific therapy regimen of 16 weekly, 60 minute, in-office treatment sessions. Vision therapists (optometrists, ophthalmologists, orthoptists, or specially-trained technicians) administer the therapy in the office. OBPT procedures are then supplemented with placebo home therapy procedures.~The procedures for OBPT are designed with the intent of not providing a beneficial training effect on vergence, accommodation, saccadic accuracy, or visual attention beyond normal activities. However, the procedures are designed to simulate real vision therapy in such a way that it will be difficult for participants and parents to know that they have been assigned to the control group and thus are not receiving bonafide OBVAT"
62276357|NCT01772615|EXPERIMENTAL|ciprofloxacin-EcN|
62276358|NCT01772615|EXPERIMENTAL|ciprofloxacin-placebo|
62640822|NCT01288313|EXPERIMENTAL|n-3 margarine and rapeseed oil|
62640823|NCT01288313|EXPERIMENTAL|n-3 margarine|
62640824|NCT01288313|ACTIVE_COMPARATOR|Olive oil|
62071738|NCT05000489||Minors 1|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
62071739|NCT05000489||Minor 2|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
62276359|NCT01772615|EXPERIMENTAL|placebo-EcN|
62276360|NCT01772615|PLACEBO_COMPARATOR|placebo-placebo|
62640825|NCT05718349||Non-cholestasis|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who do not have cholestasis preoperatively.
62276361|NCT01704352|ACTIVE_COMPARATOR|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment consisting of sleep restriction therapy, psychoeducation about sleep, stimulus control, stabilizing circadian rhythm and challenging beliefs and perception of sleep.
62276362|NCT01704352|NO_INTERVENTION|Treatment as usual|Treatment as usual (TAU) consists of pharmacological and supportive psychosocial treatment according to the needs of the patient.
62276363|NCT01331356|EXPERIMENTAL|Injection of botulinum toxin type A|
62276364|NCT01127724|EXPERIMENTAL|group 1- 1000 mcg|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
62276365|NCT01127724|EXPERIMENTAL|Group 2- 100 mcg|Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
62276366|NCT01127724|EXPERIMENTAL|group 3- 2000 mcg|Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
62276367|NCT02392182||healthy volunteers|no intervention to be administered in this observational study, although all participants will undergo fiberoptic bronchoscopy.
62276368|NCT03627845|EXPERIMENTAL|Experimental|PHP-303, single oral dose, up to 6 ascending dose cohorts
62640826|NCT05718349||Drained|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who had cholestasis and underwent ERCP (endoscopic retrograde choledochopancreatography) with stenting to normalize the enterohepatic circulation.
62071740|NCT05000489||Spina Bifida|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Spina Bifida clinic
62276369|NCT03627845|PLACEBO_COMPARATOR|Placebo|Placebo, single oral dose, up to 6 ascending dose cohorts
62276370|NCT03643380|EXPERIMENTAL|Investigational SNS device|
62455006|NCT04276038|ACTIVE_COMPARATOR|Active LLLT|"Patients will self-treat at home (active or sham), twice a day (excluding Weekends) for 1 month. The duration of each session will be 15-20 minutes and will include treatment over painful point on the knee and over regional lymph nodes (popliteal, inguinal). The treatment dose should be initiated gradually for the first week until reaching the maximum dose of 6-8 minutes per treatment point. This is the recommended dose for near infrared lasers for the indication of knee pain by the World Association for Laser Therapy (WALT). In the first days an increase in pain may be felt before the reduction in pain. If the increase in pain continues for more than a week under graded dosimetry, the treatment must be stopped.~Laser therapy will be administered to the patients in addition to standard of care therapy as customary in our institution."
62455007|NCT04276038|SHAM_COMPARATOR|Sham LLLT|Half of the LLT devices will be not activated at random before the application to the patients. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device.
62455008|NCT02658604||Home visit by pharmacist|Patients of participating pharmacies age 65 or older, who are on 5 or more chronic prescription medications, and who have a need for, and agree to, a home visit by a pharmacist for a medication review.
62455009|NCT05515952|OTHER|Active TBS-Sham TBS|Active TBS in block one, Sham TBS in block two
62455010|NCT05515952|OTHER|Sham TBS-Active TBS|Sham TBS in block one, Active TBS in block two
62455011|NCT03230851|EXPERIMENTAL|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
62640827|NCT05718349||Cholestasis|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who have cholestasis preoperatively and did not undergo drainage.
62640828|NCT03713684|PLACEBO_COMPARATOR|Placebo|Participants received placebo (matched to efpeglenatide) subcutaneous (SC) injection once weekly up to Week 56 on top of basal insulin alone or in combination with oral antidiabetic drugs (OADs).
62640829|NCT03713684|EXPERIMENTAL|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs.
62071741|NCT05000489||Pulmonology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the pulmonology clinic
62071742|NCT05000489||Endocrinology 1|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type I Diabetes
62276371|NCT00797732|ACTIVE_COMPARATOR|Active Acupuncture|The active intervention used a three-phase step-up protocol to gradually increase the body areas treated and needling intensity. Acupuncture needles (0.20x25mm) were inserted with a depth of 5-10 mm into predefined points based on a systematic literature review following the STRICTA guideline. Needles were stimulated to obtain the de qi sensation. An electroacupuncture (EA) device was connected at two acupoints. All needles remained in place for 30 minutes. The active acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. \[Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; MacPherson H, Altman DG et al. PLoS Med 2010;7:e1000261\]
62276372|NCT00797732|SHAM_COMPARATOR|Sham Acupuncture|The sham intervention was designed to be maximally inert and minimally invasive, while simulating most aspects of the active protocol. Sham needles (0.12x30mm) were inserted at 14 locations paralleling the same body regions needled in the active group; however, all sham point locations were off the pathways of traditional Chinese medicine acupuncture meridians and points. An identical but deactivated EA device was used following sham protocols previously used. The sham acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. \[Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; Wayne PA, Krebs DE et al. Arch Phys Med Rehabil 2005;86:2248-2255\]
62640830|NCT03713684|EXPERIMENTAL|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and maintained at the 4 mg dose through-out the treatment duration up to Week 56.
62640831|NCT03713684|EXPERIMENTAL|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 4 and later up-titrated to 6 mg and maintained at the 6 mg dose through-out the treatment duration up to Week 56.
62640832|NCT02626416|EXPERIMENTAL|telemedicine group|Congenital cataract patients use telemedicine to pursue and adjust the time of follow-up under non-clinical settings
62640833|NCT02626416|NO_INTERVENTION|non-telemedicine group|Congenital cataract patients pursue and adjust the time of follow-up through outpatient visit in the hospital
62640834|NCT02754232|ACTIVE_COMPARATOR|Telemedical training|Patients in the intervention group will receive telemedical training 21 times, three times weekly for seven weeks. During the first three weeks the regional physiotherapists will be responsible for the training. Municipal occupational -and physiotherapists will manage the last four weeks' training.
62640835|NCT02754232|NO_INTERVENTION|The usual training or no training|Patients in the control-group will receive no telemedical training. They will be discharged to the municipal sphere with a rehabilitation plan, where they have the possibility to receive training.
62640836|NCT02484144||patients receive usual information|Patients receive usual information before Scheduled Coronarography
62071743|NCT05000489||Endocrinology 2|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type II Diabetes
62071744|NCT05000489||Rheumatology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Rheumatology clinic
62071745|NCT05000489||Gastroenterology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Gastroenterology clinic
62640837|NCT02484144||patients receive modern information|Patients receive usual information and a information by video before Scheduled Coronarography
62071746|NCT05000489||Neurology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Neurology clinic
62071747|NCT05000489||Cardiology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Cardiology clinic
62455012|NCT03230851|EXPERIMENTAL|aspirin 100mg/2d therapy|Group2: aspirin ;
62640838|NCT03933163|OTHER|Resveratrol followed by placebo|1g micronised resveratrol twice daily for 24 weeks, a wash-out period of 4 weeks, followed by twice daily placebo for 24 weeks.
62640839|NCT03933163|OTHER|Placebo followed by Resveratrol|Twice daily placebo for 24 weeks, a wash-out period of 4 weeks, followed by 1g micronised resveratrol twice daily for 24 weeks
62640840|NCT05442060|ACTIVE_COMPARATOR|Erlotinib|Erlotinib (150 mg daily)
62640841|NCT05442060|EXPERIMENTAL|Erlotinib + OBI-833/OBI-821|Erlotinib (150 mg daily) + 30 μg OBI-833/100 μg OBI-821
62640842|NCT03150082|EXPERIMENTAL|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
62640843|NCT03150082|EXPERIMENTAL|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
62071748|NCT05000489||Hematology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Hematology clinic
62071749|NCT05000489||Nephrology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Nephrology clinic
62071750|NCT05000489||Oncology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Oncology clinic
62071751|NCT04362137|EXPERIMENTAL|Ruxolitinib 5 mg|Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
62071752|NCT04362137|PLACEBO_COMPARATOR|Placebo|Matching-image placebo for 14 days with possible extension of treatment to 28 days
62071753|NCT02977884|EXPERIMENTAL|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
62640844|NCT04630977|EXPERIMENTAL|Multi-Ingredient Pre-workout Supplement|"This group of participants will intake a multi-ingredient supplement around \~15 minutes before every workout.~The nutritional information of the supplement is: \~90 Kcal. for 25g of powder: carbohydrates -isomaltulose, fructose, maltodextrin- 15 g, essential amino-acids -Beta-alanine: 2.5g, L-arginine AKG: 2.5g, L-Leucine: 800mg, Taurine: 500mg, L-citrulline: 500mg- 6.8 g, Creatine monohydrate: 2.0g, Guarana Extract: 800mg, total caffeine: 160mg, and Magnesium: 112.5mg.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
62640845|NCT04630977|ACTIVE_COMPARATOR|Isocaloric Placebo|"This group of participants will intake an isocaloric (only carbohydrates: Maltodextrin) supplement comparator, around \~15 minutes before every workout.~The nutritional information of the supplement is: \~90 Kcal. for 23g of powder.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
62640846|NCT04630977|SHAM_COMPARATOR|Control|"These participants will drink a non-caloric admixture with the same taste, texture and flavour.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
62640847|NCT02433847|EXPERIMENTAL|mosapride|
62071754|NCT00552773|EXPERIMENTAL|Cyclamen Europaeum|
62276373|NCT05855447||Fibrosing Lung Disease Group|It will consist of 36 patients diagnosed with ILD. The patients whose demographic information such as age, height and weight will be questioned will then be evaluated with a desktop spirometer, peripheral muscle strength measurement with a digital myometer, and functional capacity with a 6MWT. The Moxy device, which is a NIRS, will be attached to the upper leg (the vastus lateralis of the quadriceps muscle) and the rib (intercostal muscles) with a silk patch, and the oxygenation of the muscles here will be measured during the 6MWT. In addition, fatigue status will be evaluated with the Modified Borg Scale.
62276374|NCT02847130||Observational (chart review, focus group, interviews)|"AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia \[FN\], chemotherapy induced nausea and vomiting \[CINV\], fertility preservation \[FP\]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs.~AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed.~AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing."
62276375|NCT03936504|ACTIVE_COMPARATOR|Control Group|Group received conventional exercise rehabilitation programs (CERP).
62276376|NCT03936504|EXPERIMENTAL|Experimental Group|Group received Tai Chi cardiac rehabilitation program(TCCRP).
62455013|NCT03230851|EXPERIMENTAL|aspirin 100mg/3d therapy|Groups3: aspirin ;
62071755|NCT00552773|PLACEBO_COMPARATOR|Placebo|
62088381|NCT04075981|PLACEBO_COMPARATOR|Placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo dissolved in 4 mL of 0.9% normal saline will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
62276377|NCT05882955|EXPERIMENTAL|Dietary app 1|Dietary app recommends high iron or iron focused recipes
62276378|NCT05882955|SHAM_COMPARATOR|Dietary app 2|Dietary app recommends standard iron recipes
62276379|NCT05882955|EXPERIMENTAL|Hydroponic unit 1|Growing vitamin B12 biofortified plants in a hydroponic unit
62455014|NCT03230851|EXPERIMENTAL|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
62455015|NCT03230851|EXPERIMENTAL|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
62455016|NCT03230851|EXPERIMENTAL|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
62455017|NCT03230851|EXPERIMENTAL|indobufen 100mg bid therapy|Group7: 100mg bid
62455018|NCT02270736|EXPERIMENTAL|Double-blind MP: Placebo (Age 6 to 17 Years)|Participants will receive placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.
62455019|NCT02270736|EXPERIMENTAL|Double-blind, MP: NT 201 (Age 6 to 17 Years)|Participants will receive NT 201 (up to 2.5 Units per kilogram \[U/kg\] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
62455020|NCT02270736|EXPERIMENTAL|Open-label, MP: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
62088382|NCT04267653|ACTIVE_COMPARATOR|lactoferrin|Oral bovine lactoferrin (bfl) 100 mg once daily on empty stomach
62088383|NCT04267653|ACTIVE_COMPARATOR|ferrous sulfate|Oral ferrous sulfate 3-6 mg/kg of elemental iron/day in divided doses
62088384|NCT04267653|ACTIVE_COMPARATOR|combined|combined therapy (both lactoferrin and ferrous sulfate)
62276380|NCT05882955|NO_INTERVENTION|Hydroponic unit 2|No hydroponic unit given to participants
62276381|NCT04092127||premature infants (<32 weeks of Gestation Age)|premature babies (\<32 weeks of Gestation Age) to be screened with RetCam for retinopathy of prematurity and who will be filmed during the screening procedure to evaluate pain with the PIPP score (Premature Infant Pain Profile)
62276382|NCT03511131|OTHER|QSE Resp (Only follow)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to no additional treatment, and then followed for the rest of the study.
62276383|NCT03511131|OTHER|QSE Resp (KIU at 6-month)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to receive Keep It Up (KIU), and then followed for the rest of the study.
62455021|NCT02270736|EXPERIMENTAL|OLEX: NT 201 (Age 6 to 17 Years)|"Participants will receive NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm will consist of participants who will participate in MP arms Double-blind, MP: placebo (age 6 to 17 years) and Double-blind, MP: NT 201 (age 6 to 17 years)."
62276384|NCT03511131|OTHER|QSE Non-Resp, KIU-Control Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), responded to KIU-Control at month-6, and then were followed for the rest of the study.
62276385|NCT03511131|OTHER|QSE Non-Resp, KIU-Control Non-Resp, KIU|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Keep It Up (KIU). After KIU, they were followed for the rest of the study.
62455022|NCT02270736|EXPERIMENTAL|OLEX: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).
62455023|NCT00894296||1|schizophrenia patients
62455024|NCT00894296||2|healthy control
62088385|NCT00002735|EXPERIMENTAL|Treatment arm|induction chemotherapy followed by chemoradiation
62276386|NCT03511131|OTHER|QSE Non-Resp, KIU Control Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Young Men's Health Project (YMHP). After YMHP, they were followed for the rest of the study.
62276387|NCT03511131|OTHER|QSE Non-Resp, KIU Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), responded to KIU at month-6, and then were followed for the rest of the study.
62276388|NCT03511131|OTHER|QSE Non-Resp, KIU Non-Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into no treatment/just follow for the rest of the study.
62455025|NCT01291303|EXPERIMENTAL|1- optimized ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
62640848|NCT06200935||Children with neurodevelopmental disorders|Boys and girls with neurodevelopmental disorders between 3 and 16 years of age, belonging to two educational centers in Madrid, attended by children with this type of disorders. Both centers have similar characteristics in terms of the type of feeding and management of the children attending them
62455026|NCT01291303|EXPERIMENTAL|2-standard setting of ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
62640849|NCT06177288|EXPERIMENTAL|DEBIRI|After dissolving 100 mg of irinotecan in water for injection or 4 ml of 5% glucose water, use 2 mL of 70 μm uniform particle size microspheres for loading and adsorption for 5 minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
62640850|NCT00507936|EXPERIMENTAL|A|ABT-894 1 mg BID
62276389|NCT03511131|OTHER|QSE Non-Resp, KIU Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into Young Men's Health Project. After YMHP, they were followed for the rest of the study.
62640851|NCT00507936|EXPERIMENTAL|B|ABT-894 2 mg BID
62640852|NCT00507936|EXPERIMENTAL|C|ABT-894 4 mg BID
62640853|NCT00507936|PLACEBO_COMPARATOR|D|
62640854|NCT00507936|ACTIVE_COMPARATOR|E|Duloxetine 60 mg QD
62640855|NCT03031340|PLACEBO_COMPARATOR|Placebo|
62640856|NCT03031340|EXPERIMENTAL|Pregabalin|
62640857|NCT02337491|EXPERIMENTAL|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
62640858|NCT02337491|EXPERIMENTAL|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
62088386|NCT06347471|ACTIVE_COMPARATOR|artemether-lumefantrine|artemether-lumefantrine according to manufacturer instructions
62088387|NCT06347471|EXPERIMENTAL|dihydroartemisinin-piperaquine|dihydroartemisinin-piperaquine according to manufacturer instructions
62088388|NCT01672983|EXPERIMENTAL|Arm 1|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
62088389|NCT01672983|EXPERIMENTAL|Arm 2|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
62088390|NCT01672983|EXPERIMENTAL|Arm 3|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
62088391|NCT01672983|EXPERIMENTAL|Arm 4|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
62088392|NCT01672983|EXPERIMENTAL|Arm 5|Participants with HCV GT2 received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
62088393|NCT01672983|EXPERIMENTAL|Arm 6|Participants with HCV GT2 received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
62088394|NCT05108727|ACTIVE_COMPARATOR|Active Diode Laser Therapy+ Modified Widman Flap|Diode laser with a wavelength of 810±5 nm and a power of 1 watt in continuous mode was applied to the Modified Widman Flap at the test sites
62088395|NCT05108727|SHAM_COMPARATOR|Sham Diode Laser Therapy+ Modified Widman Flap|Control sites were treated with MWF alone
62088396|NCT01289704|EXPERIMENTAL|TreSPE|Treatment with treadmill, proprioceptive and stretching exercises
62088397|NCT01289704|ACTIVE_COMPARATOR|SPE|Proprioceptive and stretching exercises
62088398|NCT03693820|ACTIVE_COMPARATOR|the infiltration group|a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline. We will administrate 5 ml lidocaine at each port site before incision, then immediately after the creation of the pneumoperitoneum, the surgeon will spray 50-75 ml of the total solution on the upper surface of the liver under the right sub-diaphragmatic space and another 50-75ml over the parietal peritoneum. The Trendelenburg position will be maintained for 2 minutes. Then 50 ml will be infiltrated in the bladder bed and pedicle after clamping of the cystic duct and artery. Infiltration will be through a laparoscopic suction needle, diameter 0.9 /330 mm (Zhejiang, China).
62088399|NCT03693820|PLACEBO_COMPARATOR|the control group|the same technique but the 50 ml for gallbladder infiltration will be replaced by saline.
62088400|NCT05504174||Ovarian cancer group|Patients pathologically diagnosed with ovarian cancer
62088401|NCT05504174||Control group|Patients with benign or borderline adnexal mass
62088402|NCT02887950|ACTIVE_COMPARATOR|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
62071756|NCT01987830|OTHER|TMZ-PET scans/ MRI-PET Scan|"The investigators plan to study patients with recurrent glioblastoma whose clinical care plan includes treatment with bevacizumab and temozolomide. Patients taking daily temozolomide 50 mg/m2/day will undergo a PET scan using radiolabeled temozolomide (TMZ-PET) at 3 time points: 7-13 days after initiation of temozolomide but before beginning bevacizumab (baseline- temozolomide steady-state scan), 1 day after initiation of bevacizumab (day 15) and 1 month after initiation of bevacizumab (day 45). Arterialized venous blood samples will be collected during the imaging in order to measure radioactivity, blood metabolites, and the relationship between radiotracer uptake and tumor features such as blood-brain barrier (BBB) breakdown and tumor blood flow.~In addition, we will explore the link between flow, permeability, and tumor temozolomide retention. These studies will be performed using our human simultaneous MRI-PET imaging camera."
62071757|NCT00432510|EXPERIMENTAL|Single Dose|1,000 Units (U) of C1INH-nf administered intravenously (IV).
62071758|NCT00432510|EXPERIMENTAL|First Dose Followed by Second Dose|1,000 U of C1INH-nf administered IV, followed by a second 1,000 U dose 60 minutes later.
62640859|NCT02337491|EXPERIMENTAL|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
62640860|NCT04611100|NO_INTERVENTION|Conventional|Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice
62640861|NCT04611100|EXPERIMENTAL|Radiofrequency ablation|Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice
62071759|NCT01738893|EXPERIMENTAL|A (test)/ B (reference)|initial administration of test and cross-over to reference
62276390|NCT05090839|ACTIVE_COMPARATOR|Spanish-Only Writing Group|Participants in this group will be required to write once weekly for 4 consecutive weeks. Participants will be instructed to write objectively about what they did the day prior and to avoid writing about their emotions or opinions. The participant will be required to write in their preferred language (English or Spanish).
62276391|NCT05090839|EXPERIMENTAL|English-Only Writing Group|Participants in this group will be asked to write about their most traumatic or upsetting experiences for a total of 4 sessions (one session a week for 4 consecutive weeks). The participant will be required to write in their preferred language (English or Spanish).
62276392|NCT01895127|ACTIVE_COMPARATOR|Standard of Care|"* Plasmapheresis (PP) x 3, at 40-60 cc/kg.~* Immunoglobulin (IVIg), to be administered after each PP"
62276393|NCT01895127|EXPERIMENTAL|Soliris (eculizumab)|"* 1200 mg first dose (Time: Screening/Week 0, after Biopsy Proven AMR)~* 900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)~* 1200 mg week 5~* Week 6: If donor specific antibody \< 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9"
62640862|NCT02256696|EXPERIMENTAL|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
62640863|NCT02256696|EXPERIMENTAL|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
62640864|NCT02256696|ACTIVE_COMPARATOR|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
62640865|NCT01644721|EXPERIMENTAL|Early measles vaccine|An additional measles vaccine at 4 months of age, at least 28 days after the third dose of pentavalent vaccine
62071760|NCT01738893|EXPERIMENTAL|B (reference/ A (test)|initial administration of reference and cross-over to test
62071761|NCT01082172|EXPERIMENTAL|Thoracic Stent Graft|Thoracic Stent Graft implanted device
62071762|NCT02608489|ACTIVE_COMPARATOR|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
62071763|NCT02608489|PLACEBO_COMPARATOR|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
62071764|NCT00624715|ACTIVE_COMPARATOR|THC|"* High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint~* Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~* Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint"
62071765|NCT00624715|PLACEBO_COMPARATOR|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
62276394|NCT00144898|EXPERIMENTAL|Sentinel Node Resection|Sentinel Node Resection
62640866|NCT01644721|NO_INTERVENTION|Control|Follows the normal vaccination schedule
62640867|NCT02308800|ACTIVE_COMPARATOR|Quantum™ Therapy/NPWT with Prontosan|Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
62640868|NCT02308800|ACTIVE_COMPARATOR|Quantum™ Therapy|Quantum™ Negative Pressure Wound Therapy without irrigant.
62276395|NCT00144898|OTHER|Conventional Axillary Dissection|Conventional Axillary Dissection
62071766|NCT02811016|EXPERIMENTAL|budesonide 200|inhaled budesonide 200 µg bid
62071767|NCT02811016|EXPERIMENTAL|budesonide 800|inhaled budesonide 800 µg bid
62455027|NCT02348268|ACTIVE_COMPARATOR|Manual Therapy + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally this group was treated with manual therapy (for 15 minutes).
62640869|NCT01139996|EXPERIMENTAL|Transdermal Clonidine/Oral Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
62071768|NCT02811016|PLACEBO_COMPARATOR|placebo|inhaled placebo bid
62276396|NCT03424759|EXPERIMENTAL|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
62276397|NCT02450578|EXPERIMENTAL|Cohort 1a: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0
62276398|NCT02450578|ACTIVE_COMPARATOR|Cohort 1b: Malarone, sporozoite inoculum|Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0
62071769|NCT05539521|EXPERIMENTAL|Remimazolam Besylate|Patients in the remimazolam group received remimazolam besylate at an initial infusion rate of 0.3 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
62071770|NCT05539521|ACTIVE_COMPARATOR|Propofol|Patients in the propofol group received propofol at an initial infusion rate of 3.0 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
62276399|NCT02450578|EXPERIMENTAL|Cohort 2: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0
62455028|NCT02348268|EXPERIMENTAL|Myofascial Release + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally, this group was treated with myofascial release therapy (for 15 minutes).
62455029|NCT02647983|EXPERIMENTAL|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection to be used a MRI contrast agent.
62640870|NCT01139996|PLACEBO_COMPARATOR|Comparator|Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet
62640871|NCT00313846|EXPERIMENTAL|BTDS|Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
62455030|NCT04901325|EXPERIMENTAL|Baricitinib for PG|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
62455031|NCT00577460|ACTIVE_COMPARATOR|Pramipexole|Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
62455032|NCT00577460|PLACEBO_COMPARATOR|Placebo|Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
62455033|NCT01755858|EXPERIMENTAL|Bendavia|Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.
62455034|NCT01755858|PLACEBO_COMPARATOR|Placebo|Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.
62071771|NCT05284019|EXPERIMENTAL|Eptinezumab|Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.
62455035|NCT04002388|EXPERIMENTAL|Activity Monitor Group|This arm will receive a FitBit and will be asked to wear this for one year
62455036|NCT04002388|ACTIVE_COMPARATOR|Usual Care Group|The usual care group will NOT receive a FitBit
62455037|NCT04787302|EXPERIMENTAL|CVL-231|
62455038|NCT04832230||Healthy individuals|This group is composed of healthy individuals without previous noise exposure.
62455039|NCT04832230||Acute acoustic trauma patients|This group is composed of patients suffering from acute acoustic trauma.
62640872|NCT00313846|PLACEBO_COMPARATOR|Placebo|Placebo to match BTDS 5, 10 or 20 mcg/h
62640873|NCT01586234|EXPERIMENTAL|DSAEK with graft shaping and smoothing|
62071772|NCT05284019|EXPERIMENTAL|Anti-CGRP injectables|Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
62640874|NCT01586234|ACTIVE_COMPARATOR|Standard DSAEK|
62640875|NCT06321822|EXPERIMENTAL|Epileptic Patients recruited for observational study|Patients with epilepsy recruited for observation study. When criteria for genetic epilepsy will be met, they will undergo testing for genetic investigation through exome NGS sequencing
62640876|NCT06434935|EXPERIMENTAL|True CABA|Patients will be implanted with a single TRUE CAB bypass (single proximal and distal anastomoses) to the second or third CA bypass target
62640877|NCT02062437||Total hip replacement using a ceramic friction pair|Patients treated with total hip replacement using a ceramic friction pair Biolox® Delta, with Meije Duo® stem associated with Dynacup® cup
62640878|NCT02200146|ACTIVE_COMPARATOR|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
62640879|NCT02200146|EXPERIMENTAL|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
62640880|NCT02212262||Multiple Myeloma Patients|Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only.
62640881|NCT02212262||Healthy subjects|Healthy subjects and multiple myeloma patients will undergo a blood draw
62640882|NCT02597309|ACTIVE_COMPARATOR|Intervention Group|Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
62640883|NCT02597309|PLACEBO_COMPARATOR|Control Group|Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
62276400|NCT02450578|EXPERIMENTAL|Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)|DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0
62276401|NCT05179317|EXPERIMENTAL|QL1706+chemotherapy±Bevacizumab|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1706 5mg/kg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m\^2 plus cisplatin 70 mg/m\^2 or paclitaxel 175 mg/m\^2 plus carboplatin Area Under the Curve (AUC) 6 withor without bevacizumab 15 mg/kg)
62276402|NCT02866825|ACTIVE_COMPARATOR|IFX-1|dose escalating single i.v. administration of IFX-1 (verum)
62640884|NCT05742334|EXPERIMENTAL|Robot Assisted Radical Prostatectomy with MLG-COMPLETE Allograft|Implantation of the MLG-COMPLETE allograft during your robot-assisted radical prostatectomy surgery.
62640885|NCT03781726|EXPERIMENTAL|Treatment with glecaprevir/pibrentasvir Fixed Dose Combination|8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
62640886|NCT04512963|EXPERIMENTAL|SAD Phase including Food Interaction|Single Ascending Dose (SAD) study with up to 6 cohorts + Food interaction phase on two cohorts
62640887|NCT04512963|EXPERIMENTAL|MAD Phase|Multiple Ascending Dose (MAD) study with up to 2 cohorts
62640888|NCT03814564||Circulatory failure / NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
62276403|NCT02866825|PLACEBO_COMPARATOR|Placebo|dose escalating mimicing single i.v. administration of placebo
62640889|NCT03814564||Circulatory Failure / no NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
62640890|NCT03814564||Gut dysbiosis, delirium and long term cognition|"ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.~Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission."
62640891|NCT03322293|ACTIVE_COMPARATOR|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
62276404|NCT05980715|EXPERIMENTAL|Arm 1（PD-1）|Radiotherapy free treatment: the experimental group took PD-1 inhibitor maintenance regimen.
62276405|NCT05980715|ACTIVE_COMPARATOR|Arm 2（radiotherapy）|conventional radiotherapy (chemoradiotherapy) regimen, and received comprehensive treatment according to the guidelines (radiotherapy or platinum-based concurrent chemoradiotherapy as stipulated in the guidelines).
62276406|NCT05231148|OTHER|infected non united fractures|patient of any age and any sex with infected non united fractures of long or short bones
62276407|NCT05201833||Telephone Assessment Battery|TRACK-TBI participants may complete up to three annual telephone calls to assess outcome status. These assessments will determine eligibility for the in-person study visit.
62455040|NCT05624931|EXPERIMENTAL|Treatment Condition: Brief CBT-Based Intervention|This group (n=30) will be guided through an adaptation of Life Steps, a single-session, cognitive behavioral therapy (CBT)-based medication adherence intervention that has been used to increase PrEP adherence. Participants will also receive four additional intervention sessions.
62455041|NCT05624931|ACTIVE_COMPARATOR|Control Condition: Enhanced Treatment as Usual|Participants randomized to the control condition (n= 30) will receive enhanced treated as usual.
62455042|NCT04085770|EXPERIMENTAL|Alfacalcidol|Patients allocated to the alfacalcidol group received 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay.
62455043|NCT04085770|NO_INTERVENTION|Control|Control group were exposed to the same conditions as the treatment group except they were not given one-alfacalcidol.
62455044|NCT06484218|EXPERIMENTAL|Group CET|The CET presented the conventional endodontic technique where one incisor was treated under microscope with an ultrasonic tip.
62455045|NCT06484218|ACTIVE_COMPARATOR|Group GET|The GET presented the guided endodontic technique where one incisor was treated with a surgical guide.
62455046|NCT01574248|EXPERIMENTAL|icatibant|30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
62455047|NCT01574248|PLACEBO_COMPARATOR|Placebo|Subcutaneous at time 0 and 6 hours
62455048|NCT02655237|EXPERIMENTAL|Relugolix 40 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by relugolix 40 mg, tablets, orally, once daily and leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 24 weeks in treatment period.
62455049|NCT02655237|ACTIVE_COMPARATOR|Leuprorelin 1.88 mg or 3.75 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by leuprorelin acetate 1.88 mg or 3.75 mg, injection, SC, once in 4 weeks and relugolix placebo matching tablets, orally, once daily for 24 weeks in treatment period.
62455050|NCT01581957|ACTIVE_COMPARATOR|Specific Enteral formulation|
62455051|NCT01581957|PLACEBO_COMPARATOR|Standard enteral formulation|
62455052|NCT02608502|EXPERIMENTAL|Treatment Group A|RSV-F Vaccine (0.5mL Injection)
62455053|NCT02608502|PLACEBO_COMPARATOR|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
62455054|NCT00414401|OTHER|Arm 1|
62455055|NCT00421005|EXPERIMENTAL|1|Fluvastatin 80mg
62455056|NCT00421005|ACTIVE_COMPARATOR|2|Fluvastatin 20, tapered up according to LDL concentration
62455057|NCT04854148||Experimental|Each participant will perform a Smartphone movement health assessment and a series of 12 gold standard tests under the supervision of a licensed physical therapist or other research study staff
62455058|NCT04550949|EXPERIMENTAL|QL1206|QL1206 injection(120mg)was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
62276408|NCT05201833||Comprehensive Assessment Battery (CAB)|Participants who demonstrate decision-making capacity will be asked to complete the Comprehensive Assessment Battery (CAB). The CAB in-person is comprised of measures of cognition (i.e. attention, memory, information processing speed, executive functions), mood (i.e., depression, anxiety), social participation, subjective well-being, post-traumatic stress, interviews, global functional status measures, and a COVID-19 questionnaire.
62640892|NCT03322293|EXPERIMENTAL|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
62640893|NCT03322293|EXPERIMENTAL|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
62455059|NCT04550949|ACTIVE_COMPARATOR|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
62455060|NCT04289545|PLACEBO_COMPARATOR|Control Bread|no added guar gum
62640894|NCT03834363|ACTIVE_COMPARATOR|Morphine capsules and Placebo patch|Morphine retard 10 mg twice daily Placebo patch, change every three days.
62640895|NCT03834363|EXPERIMENTAL|Placebo capsules and Fentanyl patch|Placebo capsules twice daily Fentanyl patch 12 mcg/hr, change every three days
62640896|NCT03834363|PLACEBO_COMPARATOR|Placebo capsules and Placebo patch|Placebo capsules twice daily Placebo patch, change every three days
62640897|NCT04391478|ACTIVE_COMPARATOR|milrinone|Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
62640898|NCT04391478|ACTIVE_COMPARATOR|sildenafil|Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.
62640899|NCT02987699|EXPERIMENTAL|Full Dosage|Full Dosage Chemotherapy regimen administered by HAI
62640900|NCT02987699|EXPERIMENTAL|Low Dosage of 5-Fu|Low Dose of 5-Fu Chemotherapy regimen administered by HAI
62455061|NCT04289545|ACTIVE_COMPARATOR|Functional Bread 1|10% guar gum, low molecular weight
62640901|NCT02987699|EXPERIMENTAL|Low Dosage of oxaliplatin|Low Dose of oxaliplatin Chemotherapy regimen administered by HAI
62640902|NCT03583658|ACTIVE_COMPARATOR|Ambroxol hydrochloride (BIH1526)|One lozenge 20 mg on as-needed basis, up to 6 times per day
62071773|NCT05284019|EXPERIMENTAL|Onabotulinumtoxin-A|Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.
62276409|NCT05201833||Abbreviated Assessment Battery (AAB)|Participants who do not have decision-making capacity will be asked to complete a modified assessment battery, called the Abbreviated Assessment Battery (AAB). The AAB in-person assessment will administer the Speech Intelligibility, GOAT, and CAP and/or CRS-R to study participants.
62455062|NCT04289545|ACTIVE_COMPARATOR|functional Bread 2|10% guar gum, high molecular weight
62455063|NCT04289545|ACTIVE_COMPARATOR|Functional Bread 3|15% guar gum, low molecular weight
62455064|NCT04289545|ACTIVE_COMPARATOR|Functional Bread 4|15% guar gum, high molecular weight
62640903|NCT03583658|PLACEBO_COMPARATOR|Placebo|One lozenge on as-needed basis, up to 6 times per day
62455065|NCT03076021|OTHER|Adolescents|dextromethorphan pre- and post isotretinoin
62640904|NCT05562752|EXPERIMENTAL|Active|Arm receiving investigational product (probiotic)
62640905|NCT05562752|PLACEBO_COMPARATOR|Placebo|Arm receiving placebo
62640906|NCT00243919|ACTIVE_COMPARATOR|Early Locomotor Training Program|body weight supported training program with treadmill
62640907|NCT00243919|ACTIVE_COMPARATOR|Late Locomotor Training Program|body weight supported training program with treadmill
62640908|NCT00243919|ACTIVE_COMPARATOR|Early Home Exercise Program|a non-specific low intensity exercise program
62640909|NCT02559037|EXPERIMENTAL|Acupuncture-moxibustion group|Receiving acupuncture and moxibustion treatment.
62640910|NCT02559037|SHAM_COMPARATOR|Sham acupuncture-moxibustion group|Receiving sham acupuncture and sham moxibustion.
62071774|NCT00782977|SHAM_COMPARATOR|1|Nasal cannulae with no oxygen flow
62071775|NCT00782977|ACTIVE_COMPARATOR|2|Nasal cannulae with oxygen flow at 5 L/minute
62640911|NCT02996916|ACTIVE_COMPARATOR|Olmesartan|Olmesartan 10-40mg daily
62640912|NCT02996916|ACTIVE_COMPARATOR|Amlodipine|Amlodipine 2.5-10mg daily
62640913|NCT03921736|NO_INTERVENTION|Control Group|Control group consisted of 40 postmenopausal women with normal blood pressure.
62640914|NCT03921736|EXPERIMENTAL|Hypertensive women group receiving hydrochlorothiazide|Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
62640915|NCT03921736|EXPERIMENTAL|Hypertensive women group receiving perindopril.|Patients received perindopril 4 mg/day p.o for 1 year.
62640916|NCT03921736|EXPERIMENTAL|Hypertensive women group receiving hydrochlorothiazide and EPT|Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
62640917|NCT03921736|EXPERIMENTAL|Hypertensive women group receiving perindopril and EPT.|Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
62640918|NCT03921736|EXPERIMENTAL|Hipotensive women group receiving EPT.|Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.
62640919|NCT00452374|EXPERIMENTAL|Oxaliplatin, Fludarabine, Cytarabine + Rituximab|Starting dose oxaliplatin 17.5mg/m\^2/day intravenous (IV) for 4 days; Fludarabine 30 mg/m\^2 IV and Cytarabine 1 g/m\^2 IV for two days, + Rituximab 375 mg/m\^2 IV on Day 3, Cycle 1 then Day 1 following cycles.
62640920|NCT01394536|SHAM_COMPARATOR|1|"Sham device - an EAS band placed over the P6 acupoint that will be turned off (inactive)."
62640921|NCT01394536|ACTIVE_COMPARATOR|2|The second arm will use the ReliefBand (Aeromedix, Jackson, WY), an FDA-approved, reusable, battery-operated electroacustimulation device.
62071776|NCT00782977|ACTIVE_COMPARATOR|3|Nasal cannulae with oxygen flow at 10 L/minute
62276410|NCT05928455|EXPERIMENTAL|LYB001|Participants receiving a boost with 30ug or 60ug LYB001 after a two-or three-dose primary series of inactivated COVID-19 vaccine.
62276411|NCT05928455|ACTIVE_COMPARATOR|CoronaVac|Participants receiving a boost with vaccine CoronaVac after a two-or three-dose primary series of inactivated COVID-19 vaccine.
62276412|NCT00493870|EXPERIMENTAL|TC|docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2
62276413|NCT00493870|ACTIVE_COMPARATOR|TAC|doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2
62455066|NCT04238156|EXPERIMENTAL|Hypopressive abdominal exercises|"Hypopressive abdominal exercises will be performed in basic postures (standing, sitting and supine position). In each posture, three slow cost-diaphragmatic respiration will be performed followed by an expiratory apnea and a rib cage opening, during 2 to 10 seconds, and an exhalation of 10 to 30 seconds. Each exercise will be repeated three times.~There will be 3 stages of application throughout the 12 intervention sessions, supervised by a physical therapist:~First stage: To explain the concept of hypopressive respiration and how to perform it.~Second stage: To explain and apply the hypopressive abdominal exercises: 1. Axial auto-elongation (reducing curvatures in the sagittal plane); 2. Cervical auto-elongation (chin toward the neck); 3. Moving forward of gravity axis; 4. Activation of the shoulder girdle (shoulder joint decoaptation); 5. Slight knee flexion; 6. Dorsal ankle flexion.~Third stage: To review and update all the exercises, increasing their intensity."
62455067|NCT00965653|EXPERIMENTAL|1|
62071777|NCT02161861|EXPERIMENTAL|group cFEE|"The group cFEE will be similarly inseminated with 100000/ml motile spermatozoa and will be supplemented with cFEE 100µM during 18 hours.~The cFEE will increase the fusiogenic capacities of a gamete,"
62071778|NCT02161861|NO_INTERVENTION|untreated group|control group
62071779|NCT02559609|ACTIVE_COMPARATOR|job activity contracting|Standard services plus job activity contracting and alcohol monitoring
62071780|NCT02559609|EXPERIMENTAL|reinforcement for negative alcohol samples|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
62071781|NCT02559609|EXPERIMENTAL|reinforcement for completing activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
62071782|NCT02559609|EXPERIMENTAL|reinforcement for negative alcohol samples & activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities
62276414|NCT04270929|EXPERIMENTAL|Oxaliplatin PEDD-PRVI|Two infusions of oxaliplatin (dose escalation: 20-40 mg) over the course of 4 weeks by Pancreatic Retrograde Venous Infusion (PRVI) utilizing Pressure Enabled Drug Delivery (PEDD) technology.
62276415|NCT02118688|PLACEBO_COMPARATOR|Placebo|"Drug: Placebo~* Placebo suspension administered PO/NG/FT q12h to mimic risperidone~* Placebo suspension administered PO/NG/FT q8h to mimic trazodone"
62276416|NCT02118688|ACTIVE_COMPARATOR|Risperidone alone|"Drug: Risperidone~* Initiate risperidone at 1 mg PO/NG/FT q12h~* Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~* Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
62276417|NCT02118688|ACTIVE_COMPARATOR|Trazodone alone|"Drug: Trazodone~* Initiate trazodone dosing at 50 mg PO/NG/FT q8h~* Trazodone dose can be titrated upwards every 24 hours by 25 mg per dose~* Maximum trazodone daily dose 600 mg per day (200 mg every 8 hours)"
62276418|NCT02118688|ACTIVE_COMPARATOR|Risperidone and Trazodone combination|"Drug: Risperidone~* Initiate risperidone at 1 mg PO/NG/FT q12h~* Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~* Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)~Drug: Trazodone~* Initiate risperidone at 1 mg PO/NG/FT q12h~* Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~* Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
62455068|NCT00965653|ACTIVE_COMPARATOR|2|
62640922|NCT03025321|EXPERIMENTAL|transcranial direct current stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for five consecutive days.
62071783|NCT03926065|EXPERIMENTAL|Standard Palatability and Standard Portion Size|Vegetables with Standard Palatability and Standard Portion Size
62640923|NCT03025321|SHAM_COMPARATOR|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
62071784|NCT03926065|EXPERIMENTAL|Standard Palatability and Larger Portion Size|Vegetables with Standard Palatability and Larger Portion Size
62071785|NCT03926065|EXPERIMENTAL|Enhanced Palatability and Standard Portion Size|Vegetables with Enhanced Palatability and Standard Portion Size
62071786|NCT03926065|EXPERIMENTAL|Enhanced Palatability and Larger Portion Size|Vegetables with Enhanced Palatability and Larger Portion Size
62071787|NCT01681498||Pregnancy|
62071788|NCT05228093|EXPERIMENTAL|Surgery group|Prior to surgery, a bacterial cultivation for purulent nasopharyngeal secretions and drug sensitivity assays were performed to identify sensitive antibiotics to be used postoperatively. Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. One side flap, typically the ipsilateral side, was harvested after complete radical endoscopic necrectomy.
62071789|NCT05228093|ACTIVE_COMPARATOR|Conservative group|"Patients receive debridement treatment of the necrotic tissues guided by endoscope and systematic antibiotic therapy partly under the guidance of nasopharyngeal secretion drug sensitivity test.~Patients could use a common nasopharyngeal irrigation pot to wash the nasopharynx three times a day with warm boiled water or light saltwater (500 ml). If possible, patients could also received direct irrigation with an electronic nasopharyngoscopy operated by a physician.~In addition, patients can receive hyperbaric oxygen therapy when conditions permit."
62640924|NCT02815306|EXPERIMENTAL|Brace goup|The infants who were brace group treated by braces which were designed and made by us.
62071790|NCT02119741||Affected Interdental Papillae Group|This is the only group in which the material will be used
62640925|NCT03261076|EXPERIMENTAL|SERIOUS Intervention|All youth will be juveniles in a residential facility for post-adjudicated youth. They will be recruited into the study as they are being placed in the facility post-adjudication, to ensure that they meet criteria and will be in the facility long enough to complete the program. All qualified youth will be invited to participate in the SERIOUS intervention; once a group of youth are recruited to complete the multiple baseline design and interventionists are free (from running interventions with other participants) to work with the youth, an intervention cycle will begin.
62640926|NCT04726735||Patients with histologically documented normal bladder|
62640927|NCT04726735||Patients with histologically documented Non Muscle Invasive Bladder Cancer|
62640928|NCT04726735||Patients with histologically documented Muscle Invasive Bladder Cancer|
62640929|NCT00249834|EXPERIMENTAL|Gonal-f 112.5 IU|
62640930|NCT00249834|EXPERIMENTAL|Gonal-f 37.5 IU|
62071791|NCT00603629||I|People with acute asthma in the Emergency department or inpatient settings
62071792|NCT02182219|EXPERIMENTAL|BIBF 1120|
62071793|NCT03316417||Patients under immunotherapy|All patients with Immune Checkpoints inhibitors treatment (Nivolumab, Pembrolizumab, ipilimumab, Atezolizumab), for dermatologic, pneumologic, or oncologic cancer treated on Centre Hospitalier Lyon Sud are included.
62640931|NCT00249834|EXPERIMENTAL|Gonal-f 75 IU|
62640932|NCT00249834|EXPERIMENTAL|Gonal-f 150 IU|
62640933|NCT00249834|EXPERIMENTAL|Gonal-f 187.5 IU|
62640934|NCT00249834|EXPERIMENTAL|Gonal-f 225 IU|
62640935|NCT00249834|EXPERIMENTAL|Gonal-f 262.5 IU|
62640936|NCT00249834|EXPERIMENTAL|Gonal-f 300 IU|
62640937|NCT03640169|EXPERIMENTAL|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
62640938|NCT03132545||PCOS|
62640939|NCT03132545||controls|
62640940|NCT03269201||Parkinson;s Disease|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
62640941|NCT03269201||Essential tremor|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
62640942|NCT03269201||Multiple system atrophy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
62640943|NCT03269201||Normal Pressure Hydrocephalus|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
62640944|NCT03269201||DYSTONIA-focal, generalized and others|"Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia~.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia"
62071794|NCT00941538|EXPERIMENTAL|intervention|"Residents aged 30-69 years in eight screening towns in the intervention group are invited to screening marker tests - IgA antibodies to EBV VCA/IgA and EBV nuclear antigen-1 (EBNA1/IgA) by ELISA.~The trial will use two minimally acceptable false-positive rates (i.e., 10% and 3%) as the cutoffs to define medium-risk (seropositive, 0.65 ≤ score \< 0.98) and high-risk participants (seropositive, score ≥ 0.98). After a blood test, participants whose EBV-based risk exceeds the predefined high-risk threshold (score ≥ 0.98) will be referred to endoscopy for clinical evaluation. Participants who are defined as medium-risk or high-risk (score ≥ 0.65) will be followed annually through blood testing and linkage to registers. The remaining participants (seronegative, score \< 0.65) will be asked to return for a follow-up visit after five years."
62071795|NCT00941538|NO_INTERVENTION|Control|The individuals aged 30-69 in the other eight towns will be included as controls, which is a comparable population that will not be screened for NPC.
62071796|NCT01486615|PLACEBO_COMPARATOR|Melatonin|Premedication with 3 mg melatonin (Meloset) tablet orally 1-2 hour prior to anesthesia
62071797|NCT01486615|PLACEBO_COMPARATOR|melatonin and alprazolam premedication|Premedication with 3 mg melatonin and 0.5 mg alprazolam (Stresnil) tablet orally 1-2 hrs prior to anesthesia
62071798|NCT01486615|PLACEBO_COMPARATOR|alprazolam premedication|Premedication with 0.5 mg alprazolam (Alprax) tablet orally 1-2 hr prior to anesthesia
62071799|NCT01486615|ACTIVE_COMPARATOR|placebo premedication|Premedication with a similar looking placebo tablet orally 1-2 hr prior to anesthesia
62071800|NCT01794117|EXPERIMENTAL|Arm A/Anakinra 100 mg/day|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg at week 8.
62071801|NCT02608762||pediatric/adolescent patients with brain tumors|A prospectively recruited of newly-diagnosed pediatric/adolescent patients with brain tumors or head/neck cancers
62071802|NCT03446105|EXPERIMENTAL|App-based behavioral intervention|Participants randomized to this study arm will take part in the Achieving Wellness After Kancer in Early life (AWAKE) behavioral intervention for 8 weeks.
62071803|NCT03446105|ACTIVE_COMPARATOR|Attention control group|Participants randomized to this study arm will take part in a behavioral intervention and coaching for 8 weeks.
62640945|NCT03269201||Cerebellar ataxia|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
62071804|NCT01149213|EXPERIMENTAL|Transcranial Direct Current Stimulation|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~The patient will receive tDCS every other week during the first three months, then once a month during the next three months."
62461672|NCT01520623|OTHER|Allografted patients|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
62461673|NCT02359305||IV Acetaminophen|Acetaminophen administered by intravenous infusion.
62071805|NCT01458990|EXPERIMENTAL|PPI inititation|Adding 40mg omeprazole QD for 14 days
62461674|NCT02359305||Rectal Acetaminophen|Acetaminophen administered by rectal suppository.
62071806|NCT01458990|ACTIVE_COMPARATOR|PPI withdrawal|The intervention here is systematically withdrawing chronic PPI for 14 days
62071807|NCT03497494|ACTIVE_COMPARATOR|Without hiatal suture|the different distance of pylorus without hiatal suture
62071808|NCT03497494|ACTIVE_COMPARATOR|With hiatal suture|the different distance of pylorus without hiatal suture
62071809|NCT06020664|EXPERIMENTAL|NOX1416+SOC|NOX1416 is a foam based gaseous nitric oxide (NO) product that will be topically applied directly onto the wound bed and left on the wound bed for a 5-minute period. Subjects randomized to the NOX1416 treatment group will receive once a day application, for a total of 12 weeks with a double treatment, 10 minutes apart, on the first day. Standard of care will include evaluation to document, off-loading adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment, and management of infection.
62071810|NCT06020664|PLACEBO_COMPARATOR|Placebo+SOC|Placebo is topically applied directly onto the wound bed and left on the wound bed for a 5-minute period. Subjects randomized to the control group will receive once a day application, for a total of 12 weeks with a double treatment, 10 minutes apart, on the first day. Standard of care will include evaluation to document, off-loading adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment, and management of infection.
62071811|NCT04370743||Group 1|
62071812|NCT04178512|ACTIVE_COMPARATOR|group Dexamethasone|Patients will receive 8 mg of dexamethasone(2ml) in addition to 2ml of hyperbaric bupivacaine 0.5% (total volume 4 ml) intrathecal injection.
62071813|NCT04178512|ACTIVE_COMPARATOR|group Fentanyl|patients will receive 20 microgram fentanyl(diluted in sterile normal saline0.9% to 2ml)in addition to 2ml of hyperbaric bupivacaine 0.5%(total volume 4 ml) intrathecal injection.
62071814|NCT04178512|ACTIVE_COMPARATOR|group Control|patients will receive 2ml of sterile normal saline0.9% in addition to 2ml of hyperbaric bupivacaine o.5% (total volume 4 ml) intrathecal injection.
62455069|NCT04132856|EXPERIMENTAL|Intervention Group|The Intervention group will receive the services of the Psychosocial Navigator (PSN) monthly for the full 12 months of the study. At baseline, the PSN will provide the health care providers (HCPs) and family with recommendations for mapping and triaging of resources to levels of psychosocial risk (PAT: Universal, Targeted, Clinical) and level of depression and anxiety (mild, moderate, and high mental health problems; as determined by the standardized norms for the measures). This information will be summarized in the Communication Summary Profile and shared with the treating team (oncologist, nurse, and Social Worker, core psychosocial staff involved in the child's care) and family within 48 hours of completion. The PSN will conduct follow-up psychosocial screenings on a monthly basis, using the Distress Thermometer for children and caregivers. Results of the monthly assessments and recommended resources will also be communicated to the caregiver/parent and treating team of the youth.
62640946|NCT03269201||Progressive supranuclear palsy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
62640947|NCT03269201||Corticobasal degeneration|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
62640948|NCT03269201||Dementia with Lewy Bodies|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
62640949|NCT00909064|EXPERIMENTAL|Arixtra|Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement
62640950|NCT00793689||total thyroidectomy|patients undergoing total thyroidectomy
62640951|NCT01891214||Ulcerative Colitis and Crohn's Disease|
62640952|NCT01663389|EXPERIMENTAL|GSK1322322 1000 mg IV|On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie \[μCi\] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.
62071815|NCT04694729|EXPERIMENTAL|study group|Videoconference-based
62455070|NCT04132856|NO_INTERVENTION|Treatment as Usual Group|Current psychosocial care services will be accessible to Treatment as Usual Group (e.g., social work, child life, psychology, art and music therapy, and psychiatry).
62640953|NCT01663389|EXPERIMENTAL|GSK1322322 1200 mg Oral Solution|On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).
62640954|NCT05545475||Anticoagulation group|1 mg/kg of nadroparin calcium or enoxaparin every 12 h, 5000 IU of low molecular weight heparin (LMWH) every 12 h, 20 mg of rivaroxaban once daily, or warfarin adjusted by an increase or decrease of 0.75 mg until the target international normalized ratio (INR) of 2-3 was reached.
62071816|NCT04694729|EXPERIMENTAL|control group|Video-based
62071817|NCT02418975|EXPERIMENTAL|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (\~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
62071818|NCT02418975|ACTIVE_COMPARATOR|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (\~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
62071819|NCT02083003|EXPERIMENTAL|Polyamine low-diet|Polyamines depleted diet during the week before surgery : 2 cans per day of Polydol (oral alimentation without polyamines), associated to predefined menus low in polyamines
62071820|NCT02083003|ACTIVE_COMPARATOR|Liberal alimentation|No specific alimentary diet
62071821|NCT00543400|ACTIVE_COMPARATOR|70 U/kg of unfractionated heparin given IV|Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
62071822|NCT00543400|EXPERIMENTAL|50 IU/KG of M118|Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
62640955|NCT05545475||Control group|No anticoagulation group.
62640956|NCT04918862|ACTIVE_COMPARATOR|Granisetron 1 mg|Granisetron 1 mg: 105 patients received 1mg granisetron
62640957|NCT04918862|ACTIVE_COMPARATOR|Granisetron 3 mg|Granisetron 3 mg: 105 patients received 3mg granisetron
62640958|NCT02889068||Intellectual disability|
62071823|NCT00543400|EXPERIMENTAL|75 IU/KG of M118|Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
62455071|NCT02863575|EXPERIMENTAL|Ibuprofen/Caffeine|Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
62640959|NCT03309553|ACTIVE_COMPARATOR|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
62276419|NCT02838407|OTHER|Total group|All enrolled subjects, male or female aged between 6 months included and less than 6 years at the time of enrollment, who visited the hospital with suspected chronic lower respiratory tract infections (LRTIs) and who had an indication for bronchoalveolar lavage (BAL).
62455072|NCT02863575|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 400 mg
62640960|NCT03309553|EXPERIMENTAL|Expedited Telemedicine Referral|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
62071824|NCT00543400|EXPERIMENTAL|100 IU/KG of M118|Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
62071825|NCT04017390|EXPERIMENTAL|Arm 1: Theraworx Foam alone|Theraworx foam only
62071826|NCT04017390|ACTIVE_COMPARATOR|Arm 2: Theraworx Foam and night splint|Theraworx foam with a night time splint
62071827|NCT04017390|PLACEBO_COMPARATOR|Arm 3: Placebo foam alone|Placebo foam alone
62071828|NCT04017390|OTHER|Arm 4: Placebo foam and night splint|Placebo foam with a night time splint
62071829|NCT06291675||Transgender women|Transgender women included in this study receive estrogen, either transdermally (Estrogel-Gel®, Estradot® or Estramon®) or orally (Estrofem®). If needed, the treatment can be supplemented by cyproterone acetate (Androcur®), and/or an alpha-5-reductase inhibitor (Finasterid Actavis/Arcana/Aurobindo®). The GAHT of our probands is prescribed and managed independently of the study, and the study has no effect on the treatment.
62455073|NCT02863575|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62455074|NCT05561400|ACTIVE_COMPARATOR|Real tDCS|the participant receives real tDCS to the right cerebellum during behavioral intervention (CILT)
62455075|NCT05561400|PLACEBO_COMPARATOR|Sham tDCS|the participant receives sham tDCS to the right cerebellum during behavioral intervention (CILT)
62455076|NCT05478226||control group|healthy people as control group
62455077|NCT05478226||IPAH group|patients with IPAH as IPAH group
62455078|NCT05478226||CTEPH group|patients with CTEPH as CTEPH group
62455079|NCT05478226||group D|Including CTEPH group and IPAH group
62455080|NCT02015000|EXPERIMENTAL|pterygium recurrence|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
62455081|NCT04590443|EXPERIMENTAL|NMP in Infrapiriformis level|Participants in this group received NMP of the sciatic nerve in the gluteus region
62071830|NCT06291675||Transgender men|The cohort of transgender men are persons who receive testosterone either intramuscularly (Nebido®) or transdermally (Testogel® or Testavan®). The GAHT of our probands is prescribed and managed independently of the study, and the study has no effect on the treatment.
62071831|NCT00047983|NO_INTERVENTION|Control|Controls and will receive no dietary supplements
62071832|NCT00047983|EXPERIMENTAL|Arginine and Canola Oil|Daily nutritional supplements of arginine and canola oil
62071833|NCT00047983|EXPERIMENTAL|Arginine and Coromega|Daily nutritional supplements of arginine and Coromega
62071834|NCT05842460|ACTIVE_COMPARATOR|Nutrient warnings|Individuals in this trial arm will see images of products carrying nutrient warnings that are currently included in Brazil's front-of-package labeling scheme.
62640961|NCT00683228|OTHER|Counseling|some caregivers will be provided counseling related to the hazards of secondhand smoke exposure
62640962|NCT05974254|EXPERIMENTAL|Electroauricular acupuncture|Immediately after Level 2 sedation is achieved, an enhanced auricular trauma protocol (ATP) will be administered on the ear ipsilateral to the operative side at 8 ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) as described by Cheng (2022). The original ATP was described by Helms (2011). Seirin L 0.2 x 30 mm needles will be placed at Hypothalamus and Shen Men points. Seirin J 0.18 x 15 mm needles will be placed at Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Vagus, and Insula points. Electrostimulation using an ITO ES 130 microstimulator at 30 HZ with Level 4 intensity, will be applied with the positive lead (red) on Hypothalamus and negative lead (black) at Shen Men for 60 minutes. All needles will be removed 1 hour after insertion.
62640963|NCT05974254|NO_INTERVENTION|No acupuncture|No acupuncture treatment given
62640964|NCT03272243|ACTIVE_COMPARATOR|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
62640965|NCT03272243|ACTIVE_COMPARATOR|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
62640966|NCT02283879|EXPERIMENTAL|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
62640967|NCT02914834|EXPERIMENTAL|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
62071835|NCT05842460|EXPERIMENTAL|Nutrient and ultraprocessed warnings|Individuals in this trial arm will see images of products carrying nutrient warnings that are currently included in Brazil's front-of-package labeling scheme and an experimental warning stating that the product is ultraprocessed.
62071836|NCT06016270|EXPERIMENTAL|hSTC810 400 mg + Paclitaxel|hSTC810 400 mg will be administered with a standard dose of paclitaxel
62071837|NCT06016270|EXPERIMENTAL|hSTC810 800 mg + Paclitaxel|hSTC810 800 mg will be administered with a standard dose of paclitaxel
62071838|NCT02104830|EXPERIMENTAL|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
62071839|NCT02104830|EXPERIMENTAL|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
62071840|NCT02104830|ACTIVE_COMPARATOR|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
62071841|NCT02931890|ACTIVE_COMPARATOR|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
62071842|NCT02931890|ACTIVE_COMPARATOR|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
62071843|NCT02931890|ACTIVE_COMPARATOR|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
62071844|NCT05622890|EXPERIMENTAL|treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
62640968|NCT02914834|ACTIVE_COMPARATOR|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
62455082|NCT04590443|EXPERIMENTAL|NMP in middle thigh level|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
62455083|NCT04590443|EXPERIMENTAL|NMP in middle distal level|Participants in this group received NMP of the sciatic nerve before popliteus region
62455084|NCT01830569|EXPERIMENTAL|EBMeDS group|The regular Evidence Linker and the EBMeDS system will be available in this group.
62455085|NCT01830569|OTHER|Control group|The regular Evidence Linker will be available in this group.
62455086|NCT01861366|EXPERIMENTAL|External facilitator|The external facilitation is a one year multifaceted intervention, including support, guidance, practice audit and feedback, training targeted to a team of practitioners involving the unit manager, the nurses and diet aides at the nursing home. The facilitator is a researcher and dietician.
62455087|NCT01861366|ACTIVE_COMPARATOR|Educational outreach visit|The outreach visit is a three hour lecture about the nutritional guidelines targeted to a team of practitioners including the unit manager, the nurses and diet aides at the nursing home. The trained person giving the lecture is a researcher and dietician.
62640969|NCT06245642|PLACEBO_COMPARATOR|Positive control group|Guipi Granule + compound Xiwujia granule simulator
62640970|NCT06245642|EXPERIMENTAL|Experimental group|Compound Xiwujia granule + Guipi granule simulator
62071845|NCT02191384|EXPERIMENTAL|Orcinoside 25mg per day|
62071846|NCT02191384|EXPERIMENTAL|Orcinoside 50mg per day|
62071847|NCT02191384|EXPERIMENTAL|Orcinoside 100mg per day|
62071848|NCT02191384|EXPERIMENTAL|Orcinoside 200mg per day|
62071849|NCT02191384|EXPERIMENTAL|Orcinoside 400mg per day|
62071850|NCT02191384|EXPERIMENTAL|Orcinoside 600mg per day|
62071851|NCT02191384|PLACEBO_COMPARATOR|placebo|
62071852|NCT03396432|ACTIVE_COMPARATOR|Video Laryngoscopy for endotracheal (ET) Placement|"Device:~Storz C-MAC Video Laryngoscope"
62071853|NCT03396432|ACTIVE_COMPARATOR|Direct Laryngoscopy for ET Placement|"Device:~Miller Laryngoscope"
62071854|NCT04140825||Group 1|Subjects\>=18 years old will measure as a minimum FOT and spirometry.
62071855|NCT03464604||Group 1 Control group|Patients randomized into this group will follow normal standard of care in Nova Scotia
62276420|NCT01025986||Noninfectious Uveitis|
62276421|NCT04908839||case: patient with otosclerosis|Diagnosis of otosclerosis with indication for primary stapedial surgery by the combination of arguments
62640971|NCT03131284|NO_INTERVENTION|Control|Families of newborns whose paediatrician is assigned to the control arm, receive usual education about nutrition and lifestyle, during their child's first two years of life.
62640972|NCT03131284|EXPERIMENTAL|Intensive education.|Families of newborns whose paediatrician is assigned to the intervention arm, receive standardized lifestyle counseling along with educational written material about their child's first two years of life, which corresponds to the experimental treatment.
62640973|NCT01861067|EXPERIMENTAL|LESS-TLH|laparoendoscopic single-site (LESS) total laparoscopic hysterectomy (TLH)
62640974|NCT01861067|ACTIVE_COMPARATOR|LESS-LAVH|laparoendoscopic single-site (LESS) laparoscopically-assisted vaginal hysterectomy (LAVH)
62640975|NCT01302405|EXPERIMENTAL|PRI-724|
62455088|NCT04842058||Orthostatic tolerant patients (OT)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilisation
62640976|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
62071856|NCT03464604||Group 2 Active group|"Patients randomized into this group will be part of the active arm of the study. They will be pre-screened and asked the following questions:~1. Sign an Information and Authorization form~2. Demographic data: gender, date of birth, ethnicity~3. Health history (duration of lesion, changes in lesion, specific changes, who identified the lesion, measurement in two greatest dimensions radially and color."
62455089|NCT04842058||Orthostatic intolerant patients (OI)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilisation
62455090|NCT05439824|EXPERIMENTAL|20 μg dose of SYS6006 (Aged 18~59 years or 60 years or more)|20μg dose of SYS6006 vaccine IM, on day 0 and day 21.
62455091|NCT05439824|EXPERIMENTAL|30 μg dose of SYS6006 (Aged 18~59 years or 60 years or more)|30 μg dose of SYS6006 vaccine IM, on day 0 and day 21.
62455092|NCT05439824|PLACEBO_COMPARATOR|Placebo(Aged 18~59 years or 60 years or more)|placebo IM, on day 0 and day 21 .
62455093|NCT00344552|EXPERIMENTAL|1|
62455094|NCT03342144||Participants Receiving Venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
62640977|NCT04041102||Infantile (Type 1) or Juvenile (Type 2) GM1 Gangliosidosis|This study observes one cohort: up to 40 Infantile GM1 (Type 1) or Juvenile GM1 (Type 2) subjects.
62276422|NCT04908839||case: otosclerosis patient with surgery|otosclerosis patient with surgery
62276423|NCT04908839||controle: Absence of known otological pathology|Absence of known otological pathology
62276424|NCT01688024|EXPERIMENTAL|Mitomycin C|Up to 10 mg administered during each standard of care endoscopic retrograde cholangiography. No more than five mitomycin C applications per every twelve months will be given.
62276425|NCT01688024|PLACEBO_COMPARATOR|Normal saline|Given during each standard of care endoscopic retrograde cholangiography. No more than five normal saline applications per every twelve months will be performed.
62276426|NCT06121414|EXPERIMENTAL|Laserpuncture|Laserpuncture using continous wave, 2 Joule in on condition
62276427|NCT06121414|SHAM_COMPARATOR|Sham Laserpuncture|Sham laser using laserpuncture in off condition
62276428|NCT05749614|EXPERIMENTAL|Group 1|
62276429|NCT05749614|EXPERIMENTAL|Group 2|
62276430|NCT05096988|EXPERIMENTAL|PKU sphere liquid|PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
62276431|NCT04812652|EXPERIMENTAL|Intervention group: Digitally distributed yoga|"Type of yoga: Physical yoga sequences that through scientific evaluation have proven to be effective and relevant for the target group. There will be 3 different programs during the 12-week-intervention Dose: twice weekly for 12 weeks; one yoga class live broadcasted and digitally distributed to the patient's computer or mobile device, and one class pre-recorded video for self-training.~Sequences: The yoga class will be 60 minutes including 10 minutes of final relaxation. Thereafter, a 5 minutes reflection will be offered.~Home Training: Instructions for yoga home practice will be standardized. The three yoga programs will be distributed in video-links for the participants to view at a time-point that suits them during the week. The recommendation will be to yoga at home once a week in addition to the digital yoga class in real time.~Participants are expected to use their own computer or mobile device."
62276432|NCT04812652|NO_INTERVENTION|Control group: Regulare care|Receive regular care, including written standardized information about the importance of physical activity by their contact nurse or physiotherapist, when discharged from the hospital accordingly to the routines at the clinic.
62276433|NCT01382732|EXPERIMENTAL|Carbetocin|"Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.~Ringer's Lactate 4mL applied to a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr"
62276434|NCT01382732|ACTIVE_COMPARATOR|Oxytocin|Protocol B (oxytocin + placebo) Ringer's Lactate 11mL directly into the vein in no less than two minutes. Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
62276435|NCT00282503|ACTIVE_COMPARATOR|methylprednisolone equivalent.|2mg/kg daily will be administered initially and may be tapered according to a tapering schedule provided in the protocol.
62276436|NCT00282503|EXPERIMENTAL|Uvadex+ECP|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~* Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~* Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days"
62640978|NCT05261165||NonManip|In the group of female patients operated without a uterine manipulator (NonManip), we included the female patients who were operated by abdominal approach without no need to use a manipulator. These female patients did not meet the predominantly anesthesiological requirements for the tolerance of the Trendelenburg position; respectively, the likelihood of adhesions in the abdominal cavity after previous laparotomy operations was there. Therefore, from a safety point of view, due to the risk of damage to the abdominal organs and the need for extensive adhesiolysis, the primary endoscopic surgery was not performed.
62455095|NCT03342144||Participants Receiving Venetoclax + Rituximab|Participants with CLL receiving venetoclax in combination with rituximab.
62071857|NCT06024629||Patients with equivocal BCC lesions|Patients with equivocal BCC lesions (18+ years) who will undergo biopsy conform regular care will undergo a cOCT and LC-OCT scan.
62071858|NCT05448586||Balanced anesthesia with opioids|Patients who had Major Surgery for gynecologic cancers (cervix, endometrium, ovarian and breast cancer) under balanced anesthesia including opioids between February 2019 and 2020 in Hospital La Paz.
62276437|NCT03707535|EXPERIMENTAL|CT-P13|
62276438|NCT03707535|ACTIVE_COMPARATOR|China-approved Remicade|
62276439|NCT03313674|EXPERIMENTAL|Seasonal Affective Disorder|The primary objective is to use neuroimaging paradigms to identify perturbations in neural circuits of SAD patients when they are clinically depressed in the winter, after bright light therapy treatment, and when they are healthy in the summer
62276440|NCT03313674|NO_INTERVENTION|Major Depressive Disorder|SAD patients will be compared to unipolar depressed patient cohort, who will be imaged in the winter and the summer.
62276441|NCT03313674|NO_INTERVENTION|Healthy Controls|SAD patients will be compared to healthy controls, who will be imaged in the winter and the summer.
62276442|NCT02661425||Standard of Care|
62276443|NCT02661425||EnteraGam|
62276444|NCT05461638|ACTIVE_COMPARATOR|Unrestricted Kinematic Alignment|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides
62276445|NCT05461638|ACTIVE_COMPARATOR|Restricted Kinematic Alignment|Mechanical Alignment and restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides
62071859|NCT05448586||Opioid Free Anesthesia (OFA)|Patients who had Major Surgery for gynecologic cancers (cervix, endometrium, ovarian and breast cancer) under Opioid Free anesthesia between February 2019 and 2020 in Hospital La Paz.
62455096|NCT03342144||Participants Receiving Venetoclax + Obinutuzumab|Participants with CLL receiving venetoclax in combination with obinutuzumab.
62455097|NCT00950807|PLACEBO_COMPARATOR|Placebo|Placebo
62455098|NCT00950807|ACTIVE_COMPARATOR|Tiotropium|Tiotropium
62455099|NCT00950807|EXPERIMENTAL|Arm 1|GSK573719 1000mcg once daily
62455100|NCT00950807|EXPERIMENTAL|Arm 2|GSK573719 500mcg once daily
62455101|NCT00950807|EXPERIMENTAL|Arm 3|GSK573719 250mcg once daily
62455102|NCT00950807|EXPERIMENTAL|Arm 4|GSK573719 125mcg once daily
62640979|NCT05261165||Manip|The female patients suitable for endoscopic performance to laparoscopic, respectively the robotic hysterectomies, in whom the use of a uterine manipulator (Manip) was planned, were assigned random into two groups.
62640980|NCT05261165||ManipHe|Subgroup of Manip group patients, in whome we used the Hegar's dilator as intrauterine manipulator.
62276446|NCT02638454|ACTIVE_COMPARATOR|HL-YNG|"Healthy young sedentary males and females 20-30 yrs old~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
62640981|NCT05261165||ManipKoRu|Subgroup of Manip group patients, in whome we used the Koh-Rumi device as intrauterine manipulator.
62640982|NCT00331565|EXPERIMENTAL|Surgery|Bariatric surgery
62276447|NCT02638454|EXPERIMENTAL|FL-OLD|"Functionally-limited older sedentary males and females without sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
62276448|NCT02638454|EXPERIMENTAL|SR-OLD|"Functionally-limited older sedentary males and females with clinically defined sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
62276449|NCT02326870|EXPERIMENTAL|The AutoLap system|Use of the AutoLap system for controlling the laparoscope during the procedure
62455103|NCT00950807|EXPERIMENTAL|Arm 5|GSK573719 62.5 mcg once daily
62455104|NCT00950807|EXPERIMENTAL|Arm 6|GSK573719 250mcg twice daily
62455105|NCT00950807|EXPERIMENTAL|Arm 7|GSK573719 125mcg twice daily
62455106|NCT00950807|EXPERIMENTAL|Arm 8|GSK573719 62.5mcg twice daily
62455107|NCT05084781|EXPERIMENTAL|Coblation Debridement|FLOW 90 / WEREWOLF debridement of rotator cuff footprint.
62455108|NCT05084781|ACTIVE_COMPARATOR|Mechanical Debridement|Standard mechanical debridement of rotator cuff footprint.
62640983|NCT03010826||40 Demyelinating Disease patients|
62276450|NCT01538485|EXPERIMENTAL|Cholecalciferol|
62455109|NCT00756288|EXPERIMENTAL|1|Topical retinoid and Light therapy with photosensitizing agent
62455110|NCT00756288|ACTIVE_COMPARATOR|2|Light therapy with photosensitizing agent
62455111|NCT01111110|EXPERIMENTAL|Anti-static then Static for Albuterol|albuterol anti-static first then static chamber second.
62640984|NCT03010826||40 Non-patient participants|
62640985|NCT03428100|EXPERIMENTAL|4 mg Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62640986|NCT03428100|EXPERIMENTAL|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276451|NCT01265459|EXPERIMENTAL|Durolane 3ml|Durolane 3 ml is an Intraarticular hyaluronic acid
62276452|NCT01265459|EXPERIMENTAL|Durolane 4.5|Durolane 4.5 is an Intraarticular hyaluronic acid
62276453|NCT01265459|EXPERIMENTAL|Durolane 6 ml|Durolane 6 ml is an Intraarticular hyaluronic acid
62276454|NCT05229107|ACTIVE_COMPARATOR|Cereset Research|Intervention arm using 6 CR sessions
62276455|NCT05229107|NO_INTERVENTION|Continued Current Care|Participants will continue their current care.
62640987|NCT03428100|EXPERIMENTAL|1 mg Baricitinib|1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62640988|NCT03428100|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once daily in combination with topical corticosteroids. Additional Placebo administered orally to maintain the blind.
62640989|NCT03428100|EXPERIMENTAL|Long Term Extension(LTE) Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)|4 mg Baricitinib administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62640990|NCT03428100|EXPERIMENTAL|LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)|4 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276456|NCT02697383|EXPERIMENTAL|Ixazomib (MLN9708) and Dexamethasone|Patients with high risk SMM will be enrolled on the pilot study and treated with 2 drug combination (Cycles 1-12 Ixazomib at 4 mg weekly on days 1, 8 and 15, and dexamethasone on days 1, 8, 15 and 22 of 28 day cycle); the dexamethasone dose will be 40 mg/week the first 4 cycles, thereafter 20 mg/week.
62640991|NCT03428100|EXPERIMENTAL|LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)|2 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276457|NCT01394445|ACTIVE_COMPARATOR|Physostigmine|
62276458|NCT01394445|PLACEBO_COMPARATOR|Placebo|
62276459|NCT00868881||1|Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
62276460|NCT00868881||2|Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
62276461|NCT00868881||3|Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
62276462|NCT00868881||4|Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
62276463|NCT00868881||5|Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
62276464|NCT00868881||6|Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
62276465|NCT05824754|EXPERIMENTAL|JITAI|"Experimental: Within-participant micro-randomization~Twice daily in the study, a participant is assigned to receive a message or no message. The micro-randomization will be performed by a reinforcement learning algorithm based on the participant's engagement with the intervention."
62640992|NCT03428100|EXPERIMENTAL|LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)|2 mg Baricitinib rerandomized to 1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62640993|NCT03428100|EXPERIMENTAL|LTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy|4 mg Baricitinib administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276466|NCT03592914||subjects with respiratory disease|This study is a comparative, single-center study. This is a minimal risk study using a non-significant risk device. A minimum of 60 and maximum of 70 subjects will be enrolled in the study. Subject participation will last approximately 1 hour(s).
62276467|NCT05250661|EXPERIMENTAL|Aqueous propolis extract|The individuals in the intervention group were asked to gargle with 5 ml aqueous propolis extract four times a day after meals (morning, noon, evening and night before bedtime) and wait average one minute in the mouth and then spit, in addition to the standard practice of the clinic. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. The patients were followed for 21 days. The 21-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
62071860|NCT03499379||Women initiating use of an intrauterine device|"Women obtaining a copper or hormonal intrauterine device for the purpose of contraception.~A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior vertex will be taken at the time of IUD insertion, 6 months post-insertion, and 12 months post-insertion."
62071861|NCT03341871||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.
62071862|NCT00581802||1|Intensively studied participants initiating potentially suppressive drug therapy. Group 1 participants may undergo optional leukapheresis. Group 1 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 1 participants will default to either Group 3 or Group 4.
62071863|NCT00581802||2|Intensively studied, well-suppressed participants on HAART. Participants in Group 2 may undergo optional leukapheresis. Group 2 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 2 participants will default to either Group 3 or Group 4.
62071864|NCT00581802||3|Nonintensively studied participants initiating potentially suppressive drug therapy
62071865|NCT00581802||4|Nonintensively studied well-suppressed participants on HAART
62276468|NCT05250661|NO_INTERVENTION|Control|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
62276469|NCT00835471|EXPERIMENTAL|1|Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
62640994|NCT03428100|EXPERIMENTAL|LTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy|2 mg Baricitinib administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276470|NCT00835471|ACTIVE_COMPARATOR|2|Erlotinib
62276471|NCT05462210|NO_INTERVENTION|Control group|The first mobilization of patients undergoing surgical treatment for lumbar disc herniation in the clinics where the study will be conducted is routinely performed within the first 24 hours after surgery. When the data collection process of the control group is completed, the data will be integrated with the mobilization protocol assisted with simulated clinical immersion videos created for the research.
62276472|NCT05462210|EXPERIMENTAL|Intervention group|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
62640995|NCT03428100|EXPERIMENTAL|LTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy|1 mg administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276473|NCT06355570|EXPERIMENTAL|Patient Arm|12 patients will be recruited pre-operatively and submitted to the study intervention
62276474|NCT01024998|EXPERIMENTAL|2 x 10^8 vector genomes (vg) AAV2-sFLT01|
62640996|NCT03428100|PLACEBO_COMPARATOR|LTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy|Placebo administered orally once daily (continued previous dose) in combination with topical corticosteroids. Additional placebo administered orally to maintain the blind.
62640997|NCT03428100|EXPERIMENTAL|LTE 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy|4 mg administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276475|NCT01024998|EXPERIMENTAL|2 x 10^9 vector genomes (vg) AAV2-sFLT01|
62276476|NCT01024998|EXPERIMENTAL|6 x 10^9 vector genomes (vg) AAV2-sFLT01|
62276477|NCT01024998|EXPERIMENTAL|2 x 10^10 vector genomes (vg) AAV2-sFLT01|
62071866|NCT00581802||5|Intensively studied participants who are currently participating in the Merck Expanded Access Program and receiving raltegravir. Participants in Group 5 may undergo optional leukapheresis. Group 5 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 5 participants will default to either Group 3 or Group 4.
62276478|NCT05720780|EXPERIMENTAL|Usual training with the support of music (MS)|This is the group performing training with the support of the music; it will be the intervention study group (MS)
62276479|NCT05720780|ACTIVE_COMPARATOR|Usual training without music (C)|This is the usual training group without the support of the music, it will be the control group (C)
62276480|NCT00531804|EXPERIMENTAL|1|
62455112|NCT01111110|EXPERIMENTAL|Static then Anti-static for Albuterol|static then antistatic albuterol
62640998|NCT03428100|EXPERIMENTAL|LTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy|2 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62640999|NCT03428100|EXPERIMENTAL|LTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy|2 mg Baricitinib rerandomized to 4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62641000|NCT03428100|EXPERIMENTAL|LTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy|1 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276481|NCT03280004||Moxifloxacin group|
62276482|NCT03280004||β-lactams group|
62276483|NCT02009644|EXPERIMENTAL|Treovance|Subjects who receive the Treovance stent-graft
62455113|NCT03836209|EXPERIMENTAL|Arm A|"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and gilteritinib."
62455114|NCT03836209|ACTIVE_COMPARATOR|Arm B|"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and midostaurin."
62455115|NCT01042366|EXPERIMENTAL|Vaccine co-cultured with melanoma cells|Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance
62455116|NCT01042366|EXPERIMENTAL|Vaccine pulsed with tumor cell lysates|Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance
62641001|NCT03428100|EXPERIMENTAL|LTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy|1 mg Baricitinib rerandomized to 4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62071867|NCT02483013|ACTIVE_COMPARATOR|Whitening dentifrices|Two groups used whitening dentifrices, three times per day during four weeks
62276484|NCT04792931|OTHER|Adult Autoimmune Myopathies|It is a description Autoimmune Myopathie cohort
62641002|NCT03428100|EXPERIMENTAL|LTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy|Placebo rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62276485|NCT01874691||acute myocardial infarction|acute myocardial infarction including ST-elevation and non ST-elevation myocardial infarction
62276486|NCT05930262|EXPERIMENTAL|the intervention group|TCM acupuncture therapy Conventional drug therapy Rehabilitation therapy Breathing training
62276487|NCT05930262|ACTIVE_COMPARATOR|the control group|Conventional drug therapy Rehabilitation therapy Breathing training
62276488|NCT01443533|EXPERIMENTAL|LARC script|Received routine postpartum counseling and LARC script.
62276489|NCT01443533|NO_INTERVENTION|No LARC script|Received only routine postpartum counseling
62276490|NCT06073392|EXPERIMENTAL|Intervention Group 1 (IG1)|Subjects in IG1 will be given a animation video screening in a specific room. IG1 intervention is on one topic cover only. The animation educational video covers on the topic of effective toothbrushing technique.
62455117|NCT01042366|EXPERIMENTAL|Vaccine fused with tumor cells|Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance
62276491|NCT06073392|EXPERIMENTAL|Intervention Group 2 (IG2)|Subjects in IG2 will be given a animation video screening in a specific room. IG2 intervention is on two topics cover only. The animation educational video covers on the topic of effective toothbrushing technique and effects of sugary diet.
62276492|NCT06073392|EXPERIMENTAL|Intervention Group 3 (IG3)|Subjects in IG3 will be given a animation video screening in a specific room. IG3 intervention is on two topics cover only. The animation educational video covers on the topic of effective toothbrushing technique, and dental caries.
62276493|NCT06073392|EXPERIMENTAL|Intervention Group 4 (IG4)|Subjects in IG4 will be given a animation video screening in a specific room. IG4 intervention is on three topics cover. The animation educational video covers on the topic of effective toothbrushing technique, effects of sugary diet, and dental caries.
62276494|NCT06460116|NO_INTERVENTION|Study Phase I: Stakeholder Interviews|Phase I interviews with stakeholders (Community Advisory Board members, CHWs, community members, students Grade 6-12, \& parent stakeholders) will be completed to inform the school-based community health worker and the enhanced usual care conditions in the Phase 2 feasibility pilot.
62276495|NCT06460116|EXPERIMENTAL|Study Phase II: School-based Community Health Worker Intervention|The School-Based Community Health Worker (SB-CHW) intervention is the active intervention in the Phase II feasibility trial.
62276496|NCT06460116|ACTIVE_COMPARATOR|Study Phase II: Enhanced Usual Care|Enhanced usual care (EUC) is the comparator in the Phase II feasibility trial.
62276497|NCT03262415||Study Cohort|30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
62276498|NCT02067039|EXPERIMENTAL|HIV self-testing|The intervention group of MSM (HIV negative or unaware of HIV status) will receive 4 rapid HIV test kits - 2 oral fluid tests (OraQuick), and 2 finger-stick blood tests (Sure Check). Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period, and men in the intervention arm will be allowed to order additional test kits to replenish the ones they use or give away. At month 12, all HIV-negative or those who are unaware of their HIV status participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a dried blood spot (DBS) specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
62276499|NCT02067039|NO_INTERVENTION|Information only|All comparison group of MSM (HIV negative or unaware of HIV status) will take a baseline survey. Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period. At month 12, all HIV-negative and unaware of their HIV status comparison arm participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a DBS specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
62276500|NCT00941876|EXPERIMENTAL|A. Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
62276501|NCT02108405||Sepsis|Sepsis Forty eight patients developed septic complication during ICU stay (sepsis group).
62276502|NCT02108405||SIRS group|SIRS group Forty seven patients were critically ill without evidence of infectious organism (SIRS group).
62276503|NCT05628714||Control group|Patients who did not use the PDA
62276504|NCT05628714||PDA-group|Patients who did use the PDA
62276505|NCT06269003|EXPERIMENTAL|Source|Participants in the source arm will receive e-cigarette education messages manipulated in one of two source types.
62276506|NCT06269003|EXPERIMENTAL|Sidedness|Participants in the sidedness arm will receive e-cigarette education messages manipulated in one of two sidedness types.
62276507|NCT06213727|EXPERIMENTAL|Trial drug group 1|lowe-dose ZKY001 eye drops
62276508|NCT06213727|EXPERIMENTAL|Trial drug group 2|Medium-dose ZKY001 eye drops
62276509|NCT06213727|PLACEBO_COMPARATOR|control group|ZKY001 simulated eye drops
62276510|NCT02237287|SHAM_COMPARATOR|wound dressing with VAC|After wound debridement wounds are treated for 2 weeks with VAC dressing alone
62276511|NCT02237287|OTHER|wound dressing with VAC and sNAG under Antiaggregation|In patients being under antiaggregation with Aspirin® 100mg daily, after wound debridement wounds are treated with VAC and sNAG
62276512|NCT02237287|EXPERIMENTAL|wound dressing with VAC and sNAG without antiaggregation|In patients NOT being under antiaggregation, after wound debridement wounds are treated with VAC and sNAG
62071868|NCT02483013|PLACEBO_COMPARATOR|Placebo|One group used conventional dentifrice, three times per day during four weeks
62276513|NCT06463067|OTHER|Play group|Before the examination process, the child was asked to select one of the five faces on the Facial Image Scale. The dentist evaluated and scored the patient's behaviors based on the categories in the Frankl Behavior Scale. Parents were asked to answer the questions in the Corah Dental Anxiety Scale on behalf of their children to assess their dental anxiety, and results were scored. Subsequently, the children's heart rate was measured and recorded with a pulse oximeter attached to the index finger of the left hand. Prior to the examination procedure, The patients in Play Group played a mobile game called 'Dentist' before the examination. After that patients were examined, and their anxiety levels were assessed using the same methods following the examination procedure
62641003|NCT03428100|EXPERIMENTAL|LTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy|Placebo rerandomized to 4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
62071869|NCT04660019|EXPERIMENTAL|Scalp and auricular acupuncture|Three scalp acupoints including GV 20, bilateral GB 15, stomach area and four ear acupoints (Shenmen, thalamus, cardia, stomach).
62071870|NCT04660019|PLACEBO_COMPARATOR|Seed acupressure|Three scalp acupoints including GV 20, bilateral GB 15, stomach area and four ear acupoints (Shenmen, thalamus, cardia, stomach).
62071871|NCT03621293|ACTIVE_COMPARATOR|Liberal Oxygenation (LO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
62071872|NCT03621293|EXPERIMENTAL|Conservative Oxygenation (CO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
62641004|NCT02899611|EXPERIMENTAL|ICV Valproate|Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
62071873|NCT03547284|ACTIVE_COMPARATOR|81 patients,group 1|81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery .
62071874|NCT03547284|NO_INTERVENTION|81 patients,group 2|81 patients will have traditional management(oral intake of clear fluids after hearing of first intestinal sounds or passage of flatus and regular diet after passage of stool)
62071875|NCT06207370|ACTIVE_COMPARATOR|Group 1|TQ: 2 x 100 mg TQ tablets orally on Days 1, 2, 3, and 4
62071876|NCT06207370|PLACEBO_COMPARATOR|Group 2|Placebo: 2 x 100 mg placebo tablets orally on Days 1, 2, 3, and 4
62071877|NCT05763992|PLACEBO_COMPARATOR|Arm A|12 consecutive cycles of weekly paclitaxel plus carboplatin (PCb) combined with 4 triweekly cycles of Pembrolizumab, followed by 4 consecutive cycles of triweekly anthracycline (doxorubicin or epirubicin)-cyclophosphamide (AC or EC) chemotherapy combined with 4 triweekly cycles of Pembrolizumab.
62071878|NCT05763992|EXPERIMENTAL|Arm B|Standard treatment (12 consecutive cycles of weekly paclitaxel plus carboplatin (PCb) combined with 4 triweekly cycles of Pembrolizumab, followed by 4 consecutive cycles of triweekly anthracycline (doxorubicin or epirubicin)-cyclophosphamide (AC or EC) chemotherapy combined with 4 triweekly cycles of Pembrolizumab) in combination with up to a maximum of 8 consecutive triweekly cycles of 5-day Fasting-Like Approach
62071879|NCT05430048|ACTIVE_COMPARATOR|Desmopressin group (Group D)|patients will received single puff (10 μg) of nasal desmopressin in the nasal cavity at the side of surgery 30 min preoperative.
62276514|NCT06463067|OTHER|Book group|"Before the examination, the child was asked to choose one of five faces from the Facial Image Scale. The dentist assessed and scored the patient's behaviour using the Frankl Behaviour Scale. Parents were asked to complete the Corah Dental Anxiety Scale on behalf of their children to assess their dental anxiety and the results were scored. The children's heart rate was then measured and recorded using a pulse oximeter attached to the index finger of the left hand. The researcher then read the storybook Elif Goes to the Dentist and showed the children pictures of dental instruments as described in the book. Behavioural techniques were used to examine the patients, and their anxiety levels were assessed after the examination using the same methods."
62276515|NCT06463067|OTHER|Video group|Before the examination, the child was asked to choose one of the five faces on the Facial Image Scale. The dentist assessed the patient's behaviour using the Frankl Behaviour Scale. Parents were asked to answer the questions on the Corah Dental Anxiety Scale on behalf of their children to assess their dental anxiety, and the results were scored. The children's heart rate was then measured and recorded using a pulse oximeter attached to the index finger of the left hand. Patients in the video group then watched an animated video entitled 'First meeting with the dentist' before the examination, and dental instruments were introduced using the terminology mentioned in the video. Using behavioural techniques, the patients were examined and their anxiety levels were assessed using the same methods after the examination.
62276516|NCT06463067|OTHER|Tell-show-do group|Before the examination, the child was asked to choose one of five faces on the Facial Image Scale (FIS). The dentist assessed and scored the patient's behaviour using the Frankl Behaviour Scale. Parents were asked to complete the Corah Dental Anxiety Scale on behalf of their children to assess their dental anxiety, and the results were scored. The children's heart rate was then measured and recorded using a pulse oximeter attached to the index finger of the left hand. Following the application of the behavioural techniques, the patients were examined and their anxiety levels were assessed using the same methods after the examination procedure.
62455118|NCT00724568|EXPERIMENTAL|Combination Drug Therapy|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.
62641005|NCT04600869|EXPERIMENTAL|Nursing Group|Nurses in the control group accepted the other non-fertility (standard) nursing training for the intervention, whereas those in the experimental group accepted the oncofertility training. Based on research ethics and design, a standard education course was held for the control group after completing data collection in the nursing experimental group. We began to recruit patients into the patient experimental group after all nurses completed their educational courses.
62641006|NCT04270461|EXPERIMENTAL|Arms|NKG2D-based CAR T-cells Injection; Dosage:1-10x10\^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
62071880|NCT05430048|ACTIVE_COMPARATOR|Bisoprolol group (group B)|patients will receive Oral bisoprolol 2.5 mg (Concor 2.5 mg; Merck/Amoun) 90 min preoperative.
62071881|NCT05091866|EXPERIMENTAL|Treatment (progesterone)|Patients receive progesterone SC QD for up to 24 weeks in the absence of disease progression or unacceptable toxicity.
62641007|NCT03556995||Bariatric surgery patients|All patients above 18 that underwent bariatric surgery
62641008|NCT02911649|EXPERIMENTAL|Wearable Device Only|Participants will be allowed to choose one of three wearable devices (FitBit, Garmi or Polar), for the wearable technology intervention. Once the participant has chosen their wearable device they will be oriented to their chosen device, platform to obtain information from the device, as well as a guide with ideas for reducing sedentary behaviour. Participants will be asked to wear the devices every day during waking hours.
62276517|NCT03666962||case group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
62276518|NCT03666962||control group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
62455119|NCT01451853|ACTIVE_COMPARATOR|SPI-1005 Low Dose|200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
62641009|NCT02911649|EXPERIMENTAL|Online Educational Workshop Only|The Online Educational Group will be asked to participate in 6 online workshops that will occur during the 12-week intervention. Adobe connect software will be used to implement these workshops which allows for interaction between participants and leader. Workshops will focus on specific aspects related to reducing sedentary behaviours and increasing PA time. Each workshop will be developed by study coordinator/author (MO) and constructed using Social Cognitive Theory (SCT), ensuring the themes such as self-efficacy, self-control and reinforcements are within each topic. EDU topics will include motivation, goal setting, and activities and ways to reduce sedentary behaviour.
62641010|NCT02911649|EXPERIMENTAL|Wearable Device+Online Edu Workshop|Both the wearable technology intervention and Online Educational Group intervention simultaneously.
62641011|NCT02911649|NO_INTERVENTION|Control Group|Participants in this group will receive usual care
62276519|NCT04418687|ACTIVE_COMPARATOR|Physiotherapy only|Standard treatment post Total Knee Arthroplasty
62276520|NCT04418687|EXPERIMENTAL|Physiotherapy + Orthoglide intervention|Standard treatment post TKA, with additional Orthoglide device provided.
62276521|NCT01157078|EXPERIMENTAL|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
62276522|NCT01157078|PLACEBO_COMPARATOR|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
62455120|NCT01451853|ACTIVE_COMPARATOR|SPI-1005 Middle Dose|400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
62455121|NCT01451853|ACTIVE_COMPARATOR|SPI-1005 High Dose|600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
62641012|NCT00511810|EXPERIMENTAL|Low Dose Fish Oil|Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
62641013|NCT00511810|EXPERIMENTAL|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
62641014|NCT06410664|EXPERIMENTAL|72-hour HME exchange interval group|Intervention group: daily care will be provided according to the local standards, with an HME exchange interval every 72 hours
62276523|NCT02011165||Tennis ball|Night with tennis ball fastened in the back of the night shirt. A positioning measuring device mounted.
62276524|NCT02011165||No tennis ball|Night without tennis ball fastened in the back of the night shirt. A positioning measure device mounted.
62276525|NCT04032210|EXPERIMENTAL|Regimen using dual Zinc plus Arginine based toothpaste|
62455122|NCT01451853|PLACEBO_COMPARATOR|Placebo|0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
62276526|NCT04032210|EXPERIMENTAL|Regimen using Zinc based toothpaste (Crest complete)|
62276527|NCT04032210|ACTIVE_COMPARATOR|Fluoride based toothpaste (Signal)|
62276528|NCT04393922|EXPERIMENTAL|Aim 1|"To accomplish this aim, we will conduct one experiment in two sessions separated by 2- 3 days using a crossover design. Participants will be assigned into one of three groups: spastic SCI, non-spastic SCI, and controls. We expect that people enrolled in Aim 1 will complete 2 visits within 1 week.~Visit 1 Measurements:~* MVCs~* MEP Recruitment Curves~* iMEPs~* StartReact~Visit 2 Measurements:~* Participant Reported Spasticity~* MAS~* PSAD~* KINARM~* MRI of brain and spinal cord"
62455123|NCT00526968|EXPERIMENTAL|1|EVT 101 8 mg capsule
62455124|NCT00526968|EXPERIMENTAL|2|EVT 101 15 mg capsule
62455125|NCT00526968|PLACEBO_COMPARATOR|3|Matching placebo capsule
62455126|NCT03703713||Hyponatremia|Patients treated for hyponatremia (\<125 mmol/L Sodium) in the intensive care department.
62641015|NCT06410664|ACTIVE_COMPARATOR|24-hour HME exchange interval group|Control group: daily care will be provided according to the local standards, with an HME exchange interval every 24 hours
62071882|NCT03769805|EXPERIMENTAL|Anlotinib Arm|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
62276529|NCT04393922|EXPERIMENTAL|Aim 2|"To accomplish this aim, we will use a randomized crossover design study with spastic SCI participants receiving a single intervention combining non-invasive acoustic stimuli (Startle) or sham-Startle with motor training to enhance cortico- and reticulo-spinal contribution, separated by \~2 weeks.~Visit 1 and Visit 2~Single intervention of:~Startle + exercise training OR sham-Startle + exercise training~Pre and post measurements:~* MVCs~* MEP recruitment curves~* iMEPs~* StartReact~* Participant reported spasticity~* MAS~* PSAD~* KINARM~* Neuromechanical hand and/or leg testing~* GRASSP~* TRI-HFT~* 10-meter walk test~* Pendulum Test"
62276530|NCT04852848|EXPERIMENTAL|Connect2Test Intervention|A brief MI intervention to motivate individuals to participate in COVID-19 testing after receiving syringe exchange services
62455127|NCT04360031||Tacrolimus / Mycophenolate Mofetil|All patients receive maintenance immunosuppressive treatment of tacrolimus in combination with Mycophenolate Mofetil.
62455128|NCT06486246|EXPERIMENTAL|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist prior the surgery, after inducction of general anesthesia.
62455129|NCT06486246|EXPERIMENTAL|Genicular nerve block|Injection of local anaesthetics under ultrasound guidance in the genicular nerves ( Superomedial genicular nerve, superolateral genicular nerve and inferomedial genicular nerve) by the anaesthesiologist prior the surgery, after inducction of general anesthesia.
62641016|NCT02728232|EXPERIMENTAL|Internal Iliac artery ligation group|in this group the patients will undergo bilateral internal iliac artery ligation prior to the hysterectomy procedure
62641017|NCT02728232|ACTIVE_COMPARATOR|Hysterectomy only|in this group patients will undergo cesarean hysterectomy only
62641018|NCT03499808|EXPERIMENTAL|Treatment (isatuximab)|Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
62641019|NCT00710931|EXPERIMENTAL|ReSTOR +3 Multifocal Lens|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL)
62641020|NCT01734447|EXPERIMENTAL|1.2, continuous treatment|
62641021|NCT01734447|EXPERIMENTAL|1.2, non-continuous treatment|
62641022|NCT01734447|EXPERIMENTAL|2.4, non-continuous treatment|
62276531|NCT04852848|NO_INTERVENTION|Control|Services as usual
62455130|NCT00067236|EXPERIMENTAL|PG-116800 tablet|PG-116800 tablet (200 mg) taken twice daily for 90 days
62455131|NCT00067236|PLACEBO_COMPARATOR|Placebo tablet|Placebo tablet taken twice daily for 90 days
62641023|NCT04500444|EXPERIMENTAL|Blood-Flow Restriction Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The blood flow restriction protocol will be applied to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. Before the first application, patients will be evaluated by a specialist physician using ultrasonography and it will be ensured that the arterial blood flow is not restricted as the blood flow restriction restricts only venous blood flow. The pressure threshold at this point is the level to be used in subsequent training sessions and the same person (physician) will be bandaging in the same way during all subsequent training sessions.
62641024|NCT04500444|SHAM_COMPARATOR|Control Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The sham blood flow restriction protocol will be applied which consists of loose bandaging to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. The same person (physician) will be bandaging in the same way during all subsequent training sessions. The pressure feeling of the patient must correspond to level 0 -not tight at all- before starting the exercise training.
62641025|NCT04579978||Subjects with advanced solid tumors starting immunotherapy|Subjects with advanced solid tumors planned to initiate standard of care immune checkpoint inhibitors
62641026|NCT04579978||Subjects with advanced solid tumors receiving ICIs|Subjects with advanced solid tumors already receiving standard of care immune checkpoint inhibitors
62641027|NCT02499107|EXPERIMENTAL|Rice treatment|Dietary Intervention: Ad libitum intake of white rice
62641028|NCT02499107|EXPERIMENTAL|Pasta treatment|Dietary Intervention: Ad libitum intake of pasta
62641029|NCT02499107|EXPERIMENTAL|boiled and mashed potato treatment|Dietary Intervention: Ad libitum intake of boiled and mashed potato
62641030|NCT02499107|EXPERIMENTAL|Baked french fries treatment|Dietary Intervention: Ad libitum intake of baked french fries
62641031|NCT02499107|EXPERIMENTAL|Fried french fries treatment|Dietary Intervention: Ad libitum intake of fried french fries
62641032|NCT03167242|EXPERIMENTAL|Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
62276532|NCT05808244|EXPERIMENTAL|tgCBFI|
62455132|NCT04668339|EXPERIMENTAL|Study Group 1, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
62455133|NCT04668339|EXPERIMENTAL|Study Group 2, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
62455134|NCT04668339|EXPERIMENTAL|Study Group 3, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
62071883|NCT06148675||Participants with emergent large vessel occlusion undegoing intracranial mechanical thromebctomy|Participants with emergent large vessel occlusion undergoing intracranial mechanical thrombectomy where the reperfusion catheter was delivered over a macrowire to perform thrombectomy.
62071884|NCT06029491|EXPERIMENTAL|Treatment Arm|Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove the thrombus in the neuro-vasculature using the RapidPulseTM Aspiration System.
62071885|NCT06335251||Radiotherapy to limbs|Collection of data of patients receiving RT to limbs
62071886|NCT02199821|ACTIVE_COMPARATOR|Soybean oil formula commonly used in the hospita|
62071887|NCT02199821|EXPERIMENTAL|Formula with soybean oil, medium-chain triglyce|
62071888|NCT05635318|PLACEBO_COMPARATOR|Group A|Group A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications
62071889|NCT05635318|ACTIVE_COMPARATOR|Group B|Group A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications plus Quantitative EEG Neurofeedback
62071890|NCT01850082|OTHER|Endoscopic Vein Harvest (EVH)|An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
62071891|NCT01850082|OTHER|Open Vein Harvest (OVH)|"Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as bridging technique) along the course of the vein."
62071892|NCT02780622|EXPERIMENTAL|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
62071893|NCT02780622|EXPERIMENTAL|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
62071894|NCT01265823|EXPERIMENTAL|Adalimumab|
62071895|NCT01756560|ACTIVE_COMPARATOR|control|in this group, plain bupivacaine will be used to block femoral and sciatic nerve
62071896|NCT01756560|EXPERIMENTAL|Dexamethasone|Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve
62071897|NCT02210819||Rivaroxaban|Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
62071898|NCT02210819||Standard of care|Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
62071899|NCT00853281|EXPERIMENTAL|Hammocks with LLIN|Locally-made hammocks covered with long-lasting insecticidal net (LLIN)- Olyset(R), used in addition to the standard vector control measures
62071900|NCT00853281|ACTIVE_COMPARATOR|ITN|Standard vector control measures (insectice-treated net or ITN)
62071901|NCT02133924|EXPERIMENTAL|Natalizumab with steroids|"For subjects whose GVHD assay is Ann Arbor score 2 or 3, the study treatment will consist of two drugs, prednisone (or methylprednisolone) and natalizumab.~Protocol treatment must start within 3 days of the subject's diagnosis of acute GVHD."
62071902|NCT04610762||(Ex) Drug users recognized at-risk population of infection with Hepatitis C virus|
62071903|NCT00363194|EXPERIMENTAL|Lead-In cohort|In Part 1 of Lead-In cohort, subjects will be dosed with a single dose of pazopanib with a high-fat breakfast to establish safety and tolerability.
62071904|NCT02526056|EXPERIMENTAL|Physiotherapists|The physiotherapist have to play the exergame once.
62071905|NCT02526056|EXPERIMENTAL|elderly people|The elderly people have play the exergame twice.
62071906|NCT03784092|NO_INTERVENTION|control|
62071907|NCT03784092|EXPERIMENTAL|feedback|
62071908|NCT05565235|ACTIVE_COMPARATOR|Group B|bupivacaine
62071909|NCT05565235|ACTIVE_COMPARATOR|Group BMG|bupivacaine/ magnesium.
62071910|NCT05565235|ACTIVE_COMPARATOR|Group BN|bupivacaine /nalbuphine.
62641033|NCT03167242|EXPERIMENTAL|Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 800 mg and LUM-SDF 960 mg
62641034|NCT03167242|EXPERIMENTAL|Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
62641035|NCT03167242|EXPERIMENTAL|Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 days|Participants received KAF156 200 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
62641036|NCT03167242|EXPERIMENTAL|Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
62071911|NCT04896125||Lumigan PF|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.03% bimatoprost (preservative-free) (Lumigan PF, Allergan Inc., CA, USA).
62641037|NCT03167242|EXPERIMENTAL|Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
62641038|NCT03167242|ACTIVE_COMPARATOR|Part A - Cohort 7: Coartem|Participants received Coartem twice daily via oral administration for 3 days
62641039|NCT03167242|EXPERIMENTAL|PK Run-in Cohort: KAF 200 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 200 mg and LUM-SDF 960 mg
62276533|NCT05808244|ACTIVE_COMPARATOR|Usual psychiatric care|
62641040|NCT03167242|EXPERIMENTAL|Part B - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
62641041|NCT03167242|EXPERIMENTAL|Part B - Cohort 2: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
62641042|NCT03167242|EXPERIMENTAL|Part B - Cohort 3: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
62641043|NCT03167242|ACTIVE_COMPARATOR|Part B - Cohort 4: Coartem|Participants received Coartem twice daily via oral administration for 3 days
62641044|NCT00743756|EXPERIMENTAL|1|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
62641045|NCT00743756|EXPERIMENTAL|2|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
62071912|NCT04896125||Xalatan|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.005% latanoprost (containing 0.02% BAK as a preservative) (Xalatan, Pfizer, NY, USA).
62071913|NCT04896125||Control|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were not diagnosed with glaucoma.
62641046|NCT00743756|OTHER|3|20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)
62641047|NCT04472221|EXPERIMENTAL|Vascular Access Venous Hypertension|Swollen upper limb with synthetic Arteriovenous graft
62641048|NCT03444844|EXPERIMENTAL|Biochemical recurrent prostate cancer|"IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by whole body PET/CT scanning (pelvis to shoulders) for \~ 60 min (\~150 min for first 10 patients/dosimetry) starting immediately after injection.~A contrast CT scan follows PET scan."
62071914|NCT06083675|EXPERIMENTAL|Semaglutide 25 mg|Participants will receive 25 mg oral semaglutide once daily in maintenance period after dose escalation period.
62071915|NCT06083675|EXPERIMENTAL|Semaglutide 50 mg|Participants will receive 50 mg oral semaglutide once daily in maintenance period after dose escalation period.
62455135|NCT04668339|PLACEBO_COMPARATOR|Study Group 4, Younger Adult Participants|Participants will receive one of Placebo (Saline) on Day 0, one dose of Placebo on Day 28, and one dose of Placebo on Day 208
62455136|NCT04668339|EXPERIMENTAL|Study Group 1, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
62641049|NCT03444844|EXPERIMENTAL|Intermediate/High Risk primary prostate cancer|IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by list mode PET/CT scanning using a fixed FOV including the pelvis area for \~ 50 min.
62641050|NCT00596219|EXPERIMENTAL|1|
62641051|NCT02964130|OTHER|Follow-up patient|Medical follow-up visit
62641052|NCT03994913|EXPERIMENTAL|CAR-CD19-T Cells|The subjects are enrolled into 3 dose levels cohorts in sequence.
62641053|NCT04348526|EXPERIMENTAL|Corticision|Patients will undergo a corticision procedure in order to accelerate tooth movement
62641054|NCT04348526|ACTIVE_COMPARATOR|Traditional treatment|Patients will undergo traditional orthodontic treatment without any surgical intervention.
62641055|NCT01656044|ACTIVE_COMPARATOR|Arm I (SSD)|Patients receive SSD over their closed laparotomy incision at the conclusion of their surgery.
62641056|NCT01656044|EXPERIMENTAL|Arm II (NPT)|Patients receive NPT dressing over their closed laparotomy incision at the conclusion of their surgery.
62455137|NCT04668339|EXPERIMENTAL|Study Group 2, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
62641057|NCT02592447|EXPERIMENTAL|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
62641058|NCT02592447|OTHER|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
62641059|NCT02661230|EXPERIMENTAL|COGNIPLUS|Exercise-Gaming
62641060|NCT05724303|EXPERIMENTAL|Training group|8-week neuromuscular training program
62641061|NCT05724303|NO_INTERVENTION|Control group|
62276534|NCT06348108|EXPERIMENTAL|Dose Escalation Cohort: Dose Level (DL) 1 (Talquetamab, Iberdomide, Dexamethasone)|Participants receive 0.8mg/kg of Talquetamab over 1-3 minutes on days 1, 4, 8, and 15 of cycle 1, days 1 and 15 of cycles 2-6, day 1 of cycle 7 and subsequent cycles, 0.75mg Iberdomide once a day on days -7 thru day 14 of cycle 1, days 1-21 of cycle 2 and subsequent cycles, and 20-40mg of Dexamethasone on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2-4, and may be continued at the discretion of the investigator. Treatment repeats every 35 days for cycle 1 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, imaging scans, tissue and blood sample collection throughout the study.
62276535|NCT06348108|EXPERIMENTAL|Dose Escalation Cohort: DL 2 (Talquetamab, Iberdomide, Dexamethasone)|Participants receive 0.8mg/kg of Talquetamab over 1-3 minutes on days 1, 4, 8, and 15 of cycle 1, days 1 and 15 of cycles 2-6, day 1 of cycle 7 and subsequent cycles, 1.0mg Iberdomide once a day on days -7 thru day 14 of cycle 1, days 1-21 of cycle 2 and subsequent cycles, and 20-40mg of Dexamethasone on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2-4, and may be continued at the discretion of the investigator. Treatment repeats every 35 days for cycle 1 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, imaging scans, tissue and blood sample collection throughout the study.
62276536|NCT06348108|EXPERIMENTAL|Dose Escalation Cohort: DL 3 (Talquetamab, Iberdomide, Dexamethasone)|Participants receive 0.8mg/kg of Talquetamab over 1-3 minutes on days 1, 4, 8, and 15 of cycle 1, days 1 and 15 of cycles 2-6, day 1 of cycle 7 and subsequent cycles, 1.3 mg Iberdomide once a day on days -7 thru day 14 of cycle 1, days 1-21 of cycle 2 and subsequent cycles, and 20-40mg of Dexamethasone on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2-4, and may be continued at the discretion of the investigator. Treatment repeats every 35 days for cycle 1 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, imaging scans, tissue and blood sample collection throughout the study.
62276537|NCT06348108|EXPERIMENTAL|Dose Expansion Cohort (Talquetamab, Iberdomide, Dexamethasone)|Participants receive the recommended phase 2 dose of Talquetamab and Iberdomide, and 20-40mg of Dexamethasone which may be continued at the discretion of the investigator. Treatment repeats every 35 days for cycle 1 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, imaging scans, tissue and blood sample collection throughout the study.
62276538|NCT06384885||Triathletes/Open water swimmers|Triathletes and open water swimmers in events at Boulder Ironman, St George Ironman and Without limits swim events
62276539|NCT00671255|EXPERIMENTAL|Ramelteon 4 mg QD|
62276540|NCT00671255|EXPERIMENTAL|Ramelteon 8 mg QD|
62276541|NCT00671255|PLACEBO_COMPARATOR|Placebo|
62276542|NCT01587079|EXPERIMENTAL|PT003 (Dose 1)|PT003 MDI Dose 1
62276543|NCT01587079|EXPERIMENTAL|PT003 (Dose 2)|PT003 MDI Dose 2
62071916|NCT06083675|EXPERIMENTAL|Empagliflozin 25 mg|Participants will 25 mg empagliflozin oral once daily in maintenance period after dose escalation period.
62071917|NCT06083675|EXPERIMENTAL|Metformin 2000 mg|Participants will receive metformin 1000 mg orally twice daily (total 2000 mg) in maintenance period after dose escalation period.
62455138|NCT04668339|EXPERIMENTAL|Study Group 3, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
62641062|NCT05619731|EXPERIMENTAL|Experimental arm with oncology tele-consultation and pharmaceutical tele-expertise|patients will benefit from geriatric oncology tele-consultation and pharmaceutical tele-expertise
62641063|NCT05619731|NO_INTERVENTION|Conventional care|patients will benefit from conventional care
62071918|NCT02519647|ACTIVE_COMPARATOR|tracheal intubation with Gliderite|Gliderite will be used for intubation
62071919|NCT02519647|EXPERIMENTAL|Tracheal intubation with S-Guide|S-Guide will be used for intubation
62071920|NCT05222438|EXPERIMENTAL|Loncastuximab tesirine|Patients will start loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles). Patients will receive IV infusion of loncastuximab tesirine 150 μg/kg at Q3W for the first 2 cycles followed by 75 μg/kg at Q3W for the remaining 6 cycles.
62071921|NCT03406702|EXPERIMENTAL|CX-8998|T-type calcium channel blocker
62276544|NCT01587079|EXPERIMENTAL|PT003 (Dose 3)|PT003 MDI Dose 3
62641064|NCT01015326||Expert Interviews|Expert cohort consists of providers with expertise in administering epidermal growth factor receptor inhibitors (EGFRI) or treating patients with EGFRI-associated skin toxicities. Experts will be asked open-ended questions about symptoms and issues as they relate to HRQL in patients with EFGRI skin toxicities. Experts will then be presented with a pool of potential items and will be asked through interview and questionnaire to relate items according to how common and how important they are when occurring in patients with this condition.
62276545|NCT01587079|EXPERIMENTAL|PT003 (Dose 4)|PT003 MDI Dose 4
62071922|NCT00754975|EXPERIMENTAL|I|JACTAX LD DES
62276546|NCT01587079|EXPERIMENTAL|PT003 (Dose 5)|PT003 MDI Dose 5
62276547|NCT01587079|EXPERIMENTAL|PT001|PT001 MDI
62276548|NCT01587079|EXPERIMENTAL|PT005|PT005 MDI
62276549|NCT01587079|ACTIVE_COMPARATOR|Spiriva® Handihaler®|Tiotropium Bromide
62455139|NCT04668339|PLACEBO_COMPARATOR|Study Group 4, Older Adult Participants|Participants will receive one dose of Placebo (saline) on Day 0, a second dose of Placebo on Day 28 and a third dose of Placebo on Day 208
62455140|NCT04858100|EXPERIMENTAL|Surgery|Each patient will receive the surgical excision of the lesion and subsequent follow-up
62455141|NCT04858100|ACTIVE_COMPARATOR|Wait and see|Each patient will receive clinical follow-up of the lesion with periodical incisional tissue biopsy.
62455142|NCT04189848|EXPERIMENTAL|Semaglutide followed by dulaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
62276550|NCT04338958|EXPERIMENTAL|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days
62276551|NCT00510627|EXPERIMENTAL|A|Radiofrequency ablation in conjunction with chemotherapy
62276552|NCT00510627|ACTIVE_COMPARATOR|B|Standard of care chemotherapy regimen
62641065|NCT01015326||Patient Interviews|Patient cohort will consist of those treated with an epidermal growth factor receptor inhibitor (EGFRI) and referred to a specialized dermatology clinic for skin rash management. Patients will be asked open-ended questions about symptoms and issues as they relate to their HRQL to elicit personal experiences about how EGFRI skin toxicities and its treatment affects patients. Patients will be asked through interview and questionnaire to rate items according to how often they are experienced and how important they are to the patient.
62641066|NCT05700734|EXPERIMENTAL|Panel A: MK-8510 at dose level 1|Single oral dose of MK-8510 administered at dose level 1 (≤1800 mg) following a 10-hour fast. Dose level 1 shall not exceed 1800 mg.
62071923|NCT00754975|ACTIVE_COMPARATOR|II|TAXUS™ Libertè™ DES
62071924|NCT00003048|EXPERIMENTAL|Amifostine|Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle)
62071925|NCT01950273|EXPERIMENTAL|BI695500|BI695500, once a week for 4 weeks (4 administrations in total)
62071926|NCT01950273|ACTIVE_COMPARATOR|MabThera|MabThera, once a week for 4 weeks (4 administration in total)
62071927|NCT00057187|OTHER|Arm 1|
62071928|NCT02104635|NO_INTERVENTION|Control group|The control group receives standard of care from Jacaranda clinic and does not receive any additional post-partum check-in from a community health worker.
62071929|NCT02104635|EXPERIMENTAL|CHW-Visit|The CHW-Visit group will receive a visit at their home from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
62071930|NCT02104635|EXPERIMENTAL|CHW-Phone|The CHW-Visit group will receive a phone call from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
62071931|NCT06429332|ACTIVE_COMPARATOR|Intervention group|A range of implementation methods will be used to introduce an active Care Bundle with time- and target-based metrics that involve the rapid correction of abnormal physiological variables over days or hospital discharge (or death, if sooner) and referral pathways
62071932|NCT06429332|PLACEBO_COMPARATOR|Usual care|For patients in the usual-care group, decisions about the location of care delivery, investigations, monitoring, and all treatments are made by the treating clinical team. Data will be collected regarding the management of patients, including insertion of invasive monitoring devices, intravenous fluid resuscitation, BP lowering, vasoactive support, glycemic control, mechanical ventilation, neurosurgery, and other supportive therapy.
62071933|NCT02524132|EXPERIMENTAL|Physical Activity|5 minute movement breaks
62071934|NCT01451736|EXPERIMENTAL|paliperidone palmitate (Invega Sustenna)|Participants will be provided paliperidone palmitate (Invega Sustenna), administered in injectible long-acting form, plus group skills training and case management
62071935|NCT01451736|ACTIVE_COMPARATOR|oral risperidone|Participants will be provided oral risperidone, plus group skills training and case management
62071936|NCT03636035|EXPERIMENTAL|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
62276553|NCT05150379||Dominant side shoulder surgery patients|
62641067|NCT05700734|EXPERIMENTAL|Panel B: MK-8510 at dose level 2|Single oral dose of MK-8510 administered at dose level 2 (≤2200 mg) following a 10-hour fast. Dose level 2 shall not exceed 2200 mg.
62641068|NCT05700734|EXPERIMENTAL|Panel C: MK-8510 at dose level 3|Single oral dose of MK-8510 administered at dose level 3 (≤2200 mg) following a 10-hour fast. Dose level 3 shall not exceed 2200 mg.
62071937|NCT01584492|EXPERIMENTAL|Treatment A|CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
62071938|NCT01584492|EXPERIMENTAL|Treatment B:|CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
62641069|NCT05700734|EXPERIMENTAL|Panel D: MK-8510 at dose level 4|Single oral dose of MK-8510 administered at dose level 4 (≤2200 mg) following a 10-hour fast. Dose level 4 shall not exceed 2200 mg.
62071939|NCT01584492|EXPERIMENTAL|Treatment C|CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
62276554|NCT05150379||Patients operated on the shoulder on the non-dominant side|
62276555|NCT05150379||Healthy volunteers|
62276556|NCT02280278|EXPERIMENTAL|CIK group|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.
62641070|NCT01251042|EXPERIMENTAL|Sangvia and retransfusion|
62071940|NCT01584492|ACTIVE_COMPARATOR|Treatment D|formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
62071941|NCT01584492|PLACEBO_COMPARATOR|Treatment E|placebo pMDI with spacer, 6 inhalations in the morning at the clinic
62071942|NCT05974579|EXPERIMENTAL|Healthy participants|Will receive 40MBq of 89Zr-DFO-AP-101, once, at Day 0.
62071943|NCT05974579|EXPERIMENTAL|Patients with ALS|Will receive 40MBq of 89Zr-DFO-AP-101, once, at Day 0.
62071944|NCT00744315|OTHER|1|Controlled
62276557|NCT02280278|ACTIVE_COMPARATOR|Control group|Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.
62276558|NCT04078698|EXPERIMENTAL|Treatment with the IgG immunoadsorber GLOBAFFIN®|Treatment with the IgG immunoadsorber GLOBAFFIN® in clinical routine according to their intended use.
62641071|NCT01251042|SHAM_COMPARATOR|Sangvia and no retransfusion|
62641072|NCT01447407|ACTIVE_COMPARATOR|NDV-3 vaccine with alum IM|300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM
62071945|NCT04239729|EXPERIMENTAL|ACT Website and Coaching Condition|Participants will be asked to complete 16 brief self-help website sessions, each taking around 15-20 minutes to finish, twice a week for eight weeks. Website exercises and examples primarily focus on hoarding, although some examples also discuss related mental health concerns such as anxiety, low mood, health behaviors, etc. The sessions use multimedia and are interactive. Participants assigned to the website condition will also receive coaching. The purpose of coaching will be to help participants engage with the website and adhere to the intervention. Coaching will consist of an initial phone call of 10-15 minutes followed by weekly email contact during the 8-week treatment period. Coaches will be graduate students trained in clinical psychology.
62641073|NCT01447407|ACTIVE_COMPARATOR|NDV-3 vaccine without alum IM|300 ug Als3 in PBS per dose, one dose administered IM
62641074|NCT01447407|PLACEBO_COMPARATOR|Placebo IM|0.5 mg Al as alum in PBS per dose, one dose administered IM
62071946|NCT04239729|NO_INTERVENTION|Waitlist Condition|Participants assigned to the waitlist will be asked to wait 12 weeks without intervention (access to the website or coaching). They will receive access to the website after 12 weeks, but supportive coaching will not be provided to waitlist participants.
62071947|NCT02783118|EXPERIMENTAL|Healthy sample, active intervention|Healthy participants will be testing a depression prevention app employing a self administered online CBT intervention, for 4 weeks.
62071948|NCT02783118|NO_INTERVENTION|Healthy sample, delayed intervention|Healthy participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
62071949|NCT02783118|EXPERIMENTAL|Mild depression, active intervention|Mildly depressed participants will be testing a depression prevention app, employing a self administered online CBT intervention, for 4 weeks.
62071950|NCT02783118|NO_INTERVENTION|Mild depression, delayed intervention|Mildly depressed participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
62071951|NCT03662360|NO_INTERVENTION|GROUP A - control group|16 patients who respect the inclusion criteria, treated with psychotropic drugs Pro Re Nata.
62071952|NCT03662360|EXPERIMENTAL|GROUP B - aromatherapy group|16 patients included in the inclusion criteria, treated with psychotropic drugs Pro Re Nata and, in a complementary way, with diffusion aromatherapy
62088403|NCT02887950|EXPERIMENTAL|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
62641075|NCT01447407|ACTIVE_COMPARATOR|NDV-3 vaccine without alum ID|30 ug Als3 in PBS per dose, one dose administered ID
62641076|NCT03321721|NO_INTERVENTION|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
62641077|NCT03321721|ACTIVE_COMPARATOR|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
62641078|NCT01687114|EXPERIMENTAL|cranberry juice|27% cranberry juice
62641079|NCT05259488||patients receiving immunonutrition supply|Dietary Supplement: Immunonutrition nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
62641080|NCT05259488||historical control group|standard dietary advice
62641081|NCT00004547|EXPERIMENTAL|Peritoneal mesothelioma|Patients with peritoneal mesothelioma suffer with intractable ascites but have a very surface oriented tumor which usually does not invade into organs and cause organ dysfunction. The main source of symptoms and cause of death is intractable ascites.
62641082|NCT00004547|EXPERIMENTAL|Low grade mucinous adenocarcinoma|Low grade mucinous adenocarcinoma also includes low grade mucinous neoplasms of borderline malignant potential. Patients with low grade mucinous adenocarcinoma can have prolonged survival with debulking surgery alone. The majority of patients with truly malignant disease will die of complications from intraperitoneal progression of tumor within 2 to 5 years. The tumors are often surface oriented within the peritoneal cavity without metastases to other distant sites. The most common origin for this type of tumor is the appendix and ovary.
62641083|NCT00004547|EXPERIMENTAL|Adenocarcinoma of gastrointestinal origin|Adenocarcinoma of gastrointestinal origin also includes other than low grade mucinous. Aggressive gastrointestinal adenocarcinomas such as gastric, small bowel, and colon cancer , tend to be more invasive into tissues and can more readily metastasize to distant sites. The cause of death is usually directly related to intraperitoneal progression of tumor. It is a more difficult group of patients to treat with intraperitoneal therapy because of the aggressive and invasive nature of the tumors.
62071953|NCT04759742|EXPERIMENTAL|group Ropivacaine|The recommended administration concentration of ropivacaine in the subarachnoid space was 0.5% and the dose was 2-3ml (practical clinical anesthesiology). Based on previous clinical experience, the starting dose of ropivacaine was set at 12.5mg (2.5ml) and Dixon's up-and down method was adopted (Dixon WJ, Massey FJ Jr. Introduction to Statistical Analysis. NY: McGraw-Hill;1969. P. 344.) The dose of ropivacaine in the next patient was adjusted to 0.5mg (0.1 mL) according to the results of the previous patient's trial.
62071954|NCT04496843||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings HWA09 Device and overnight PSG
62071955|NCT00664820|EXPERIMENTAL|Treatment group|Will receive two Urex-CAP-5 (probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14) capsules daily for 3 months.
62071956|NCT00707213|EXPERIMENTAL|All Participants|All Participants will be assessed by FDG-PET to identify possible sites of infection
62071957|NCT03545113|EXPERIMENTAL|Upper extremity arteriovenous graft (AVG) - first|Participants randomized to receive an AVG will undergo surgery to have an AVG placed.
62071958|NCT03545113|ACTIVE_COMPARATOR|Upper extremity arteriovenous fistula (AVF) - first|Participants randomized to receive an AVF will undergo surgery to have an AVF created.
62641084|NCT05469126|EXPERIMENTAL|LY3502970 alone (Period 1)|LY3502970 administered orally.
62641085|NCT05469126|EXPERIMENTAL|Clarithromycin + LY3502970 (Period 2)|Clarithromycin administered orally in combination with LY3502970 given orally.
62641086|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
62071959|NCT04107623|ACTIVE_COMPARATOR|Grupp 1|Patients will be allocated to preserving the right gastric artery during the resection of GEJ cancer.
62071960|NCT04107623|ACTIVE_COMPARATOR|Grupp 2|Patients will be allocated to an extensive lymphatic resection (ligating the right gastric artery) during the resection of GEJ cancer.
62071961|NCT05626972|ACTIVE_COMPARATOR|Tenecteplase (TNK)|Drug: Alteplase (tPA) Dose: 0.9 mg/kg Route: Intravenous (IV) infusion
62071962|NCT05626972|ACTIVE_COMPARATOR|Alteplase (tPA)|Drug: Tenecteplase (TNK) Dose: 0.25 mg/kg Route: Intravenous (IV) bolus injection
62071963|NCT02565004||1|Patients who were enrolled on protocol 09-C-0079, or family members of patients who were enrolled on protocol 09-C-0079
62071964|NCT02565004||2|Individuals found to harbor a germline APC promoter 1B variant not previously enrolled in Cohort l.
62071965|NCT04683523|EXPERIMENTAL|Anaerobic exercise training|
62071966|NCT04683523|ACTIVE_COMPARATOR|Aerobic exercise training|
62071967|NCT06442644|OTHER|Adult intensive care patients|Live music interventions
62071968|NCT01797341|EXPERIMENTAL|Prograf arm|"patients will self-administer tacrolimus in the form of Prograf (twice daily administration.~Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day."
62071969|NCT01797341|EXPERIMENTAL|Advagraf Arm|patients will self-administer tacrolimus in the form of Advagraf (once daily dosing) Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
62071970|NCT06393218|EXPERIMENTAL|Routine rehabilitation+Diaphragm Training|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding. Diaphragm Training will be given twice a day and 30min per time.
62071971|NCT06393218|ACTIVE_COMPARATOR|Routine rehabilitation|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
62641087|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
62641088|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"1. Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~2. In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.~3. Surveys conducted up to four times using validated survey tools."
62641089|NCT03212001||Informal caregiver (observations, interviews and surveys)|"1. Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~2. In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.~3. Surveys conducted up to four times using validated survey tools."
62641090|NCT03212001||Healthcare providers (observations, interviews and surveys)|"1. Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~2. In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
62641091|NCT03212001||Administrators and Decision Makers (observations, interviews)|"1. Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~2. In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
62641092|NCT03212001||Technician (observation, interviews)|"1. Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~2. In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
62641093|NCT01039467|ACTIVE_COMPARATOR|Managed Ventricular Pacing|Managed Ventricular Pacing group: programmed on
62071972|NCT01015807|PLACEBO_COMPARATOR|Placebo|Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
62071973|NCT01015807|ACTIVE_COMPARATOR|TAP (Bupi)|2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
62071974|NCT01015807|ACTIVE_COMPARATOR|Clo-TAP (Bupi + Clon)|2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
62641094|NCT01039467|ACTIVE_COMPARATOR|Search AV+|Search AV+: programmed on
62071975|NCT03577574|ACTIVE_COMPARATOR|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
62071976|NCT03577574|ACTIVE_COMPARATOR|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
62071977|NCT03577574|EXPERIMENTAL|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
62071978|NCT04602897|EXPERIMENTAL|cough group|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
62276559|NCT06386939||With Acanthosis Nigricans|T2DM with Acanthosis Nigricans
62641095|NCT00899834||Tumor Samples|fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.(peripheral blood is applicable only to patients with focal brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at diagnosis)
62641096|NCT00782197|EXPERIMENTAL|1|PRGF
62276560|NCT06386939||Without Acanthosis Nigricans|T2DM Without Acanthosis Nigricans
62276561|NCT03431987||Marijuana Users|
62276562|NCT01213212|EXPERIMENTAL|Caloric restriction|Caloric restriction
62276563|NCT01213212|SHAM_COMPARATOR|"Diet ad libitum"|"Diet ad libitum"
62641097|NCT00782197|ACTIVE_COMPARATOR|2|Hyaluronic Acid
62641098|NCT04566068|EXPERIMENTAL|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors. Interventionists will participate in weekly supervision. Approximately half of participants will be asked to wear sleep trackers for one-week prior to starting the intervention (T0) and one-week after completing the intervention (T1).
62641099|NCT04566068|PLACEBO_COMPARATOR|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
62071979|NCT04602897|NO_INTERVENTION|control|the control group received no pain management at all during different steps of IUD insertion
62071980|NCT01938105|EXPERIMENTAL|Nimotuzumab+chemoradiotherapy|
62071981|NCT04075799|EXPERIMENTAL|training|8 weeks using stair climbing with a frequency of thrice a week. For the first week of the stair training exercise program subjects will meet at UNM's Teaching Education Building (Stair Case 2). The following 7 weeks subjects can perform the exercise program at a staircase most convenient to them and approved by the research team. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will be comprised of 6-12 x 30-seconds bout of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. After the exercise session the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks.
62276564|NCT01788007|EXPERIMENTAL|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
62276565|NCT01788007|PLACEBO_COMPARATOR|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
62276566|NCT01788007|ACTIVE_COMPARATOR|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
62276567|NCT02740634|EXPERIMENTAL|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
62276568|NCT02740634|EXPERIMENTAL|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
62276569|NCT04625127|EXPERIMENTAL|Aim 2: Efficacy of the GaitBetter to improve motor-cognitive function of chronic stroke survivors|The investigators propose a single-arm, non-randomized study to test the hypothesis that the GaitBetter training is effective in improving gait and cognition in individuals with chronic stroke. This design was chosen given the expected stability of functional recovery in this population.
62276570|NCT04625127|EXPERIMENTAL|Aim 3: Efficacy of the GaitBetter to improve rehabilitation outcomes in sub-acute stroke survivors|The investigators propose a randomized, controlled study to evaluate the effects of using the GaitBetter system in patients with subacute stroke on recovery trajectory.
62276571|NCT05503381|EXPERIMENTAL|Natural Orifice Specimen Extraction Surgery Group|The patient underwent laparoscopic lower rectal cancer surgery with transanal specimen collection
62641100|NCT03991390|EXPERIMENTAL|Core stability and feedback visual laser exercises|"Two complementary protocols for the treatment of balance after stroke in patients with pusher syndrome were designed, including multidimensional physiotherapy exercises. Both protocols differentiate 3 levels of difficulty: Second level requires maintenance of balance sitting 5, if the patient does not succeed, stays in level 1. To move to L3 patients must stay seated 10''. Each exercise is repeated 5 times, always considering patients' levels of fatigue and safety.~Visual feedback with laser (Motion Guidance Clinical Kit, approved for therapeutic use): Through visual aid, patients' verticality is achieved by encouraging their active participation in correcting the imbalance while performing the exercises.~Core stability: The exercises have to be adapted for the pusher patient avoiding overuse of the less affected side of the body, and strengthening the muscles that stabilize the trunk."
62071982|NCT05764291|EXPERIMENTAL|FIT-TEENS|Participants in the intervention group will receive access to a digital behaviour change intervention (FIT-TEENS). Participants will need to complete 10 self-paced online modules and activities over a period of 10 weeks.
62641101|NCT03991390|ACTIVE_COMPARATOR|Control stroke|Rehabilitation program is based on a comprehensive approach, where the patient follows a personalized plan of exercises according to the deficits, the previous situation and personal concerns.
62641102|NCT00955500|ACTIVE_COMPARATOR|Normal-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).
62071983|NCT05764291|NO_INTERVENTION|Wait-list control|Participants in the waitlist-control group will be required to continue their usual physical activities. At the end of 10 weeks, they will also receive access to FIT-TEENS intervention.
62071984|NCT04845035|EXPERIMENTAL|BFM + Tyrosine Kinase Inhibitor|This study has 2 cohorts: participants aged 18 - 59 years and participants aged 60 or more years. Both cohorts receive the same study intervention with dosage adjusted for age. Participants receive the Berlin-Frankfurt-Münster (BFM) protocol plus dasatinib during a two-phase induction and a delayed re-induction. Participants receive the BFM protocol plus ponatinib during post-induction consolidations and maintenance.
62071985|NCT04711460||Younger participants|Participants were adults ages19 to 29 years who recieved CBT and 10 minutes of Mindfulness Training and practice in group therapy.
62071986|NCT04711460||Older participants|Participants were adults ages 30-54 years who received CBT and 10 minutes of Mindfulness Training and practice in group therapy.
62071987|NCT04711460||Treatment As Usual (TAU)|". Participants in the Treatment As Usual (TAU) group had Cognitive Behavioral Therapy and education about the mindfulness process, but no practice of the mindfulness technique as a group."
62276572|NCT05503381|NO_INTERVENTION|Traditional laparoscopic surgery|The patient underwent conventional laparoscopic lower rectal cancer surgery
62276573|NCT01819909|EXPERIMENTAL|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
62641103|NCT00955500|ACTIVE_COMPARATOR|Low-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine
62641104|NCT01619852|ACTIVE_COMPARATOR|Group L|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
62276574|NCT01819909|EXPERIMENTAL|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
62276575|NCT03674151|ACTIVE_COMPARATOR|Device: Silver Nylon dressing|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
62641105|NCT01619852|PLACEBO_COMPARATOR|.9% normal saline placebo|.9% normal saline administered as a bolus then as a maintenance infusion for the length of the surgical case.
62071988|NCT04711460||TAU plus mindfulness practice|Participants in the TAU plus Mindfulness Practice had Cognitive Behavioral Therapy (CBT) and 10 minutes of mindfulness practice in group therapy sessions.
62071989|NCT03519698|PLACEBO_COMPARATOR|Warm water|12 l footbath with warm water (40 °C)
62071990|NCT03519698|EXPERIMENTAL|Warm water & Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour
62071991|NCT03519698|EXPERIMENTAL|Warm water & Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour
62071992|NCT01512875||biopsy proven H. pylori|Patient must have lived in the districts of Lima, Peru listed in the protocol.
62071993|NCT06624332|NO_INTERVENTION|No intervention Routine HV Only|Routine home visiting only
62071994|NCT06624332|EXPERIMENTAL|e-SBI main session|e-SBI main session
62071995|NCT06624332|EXPERIMENTAL|e-SBI main session + booster|e-SBI main session and e-SBI booster session
62071996|NCT06624332|EXPERIMENTAL|Text messaging only|text messaging
62071997|NCT06624332|EXPERIMENTAL|e-SBI main session + text messaging|e-SBI main session Text messaging
62071998|NCT06624332|EXPERIMENTAL|e-SBI main + e-SBI booster + text messaging|e-SBI main session e-SBI booster session text messaging
62276576|NCT03674151|ACTIVE_COMPARATOR|Device: Manuka-Honey|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
62276577|NCT03674151|ACTIVE_COMPARATOR|Device: Povidone-Iod (PVP-Iod)|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
62276578|NCT03674151|ACTIVE_COMPARATOR|Device: Hydrogel|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
62276579|NCT05001347|EXPERIMENTAL|TJ004309 and Atezolizumab|TJ004309 20 mg/kg Q3W in combination with atezolizumab 1200 mg Q3W
62641106|NCT04126304||Common cold|A cold is a clinical diagnosis.Complaints may include a stuffy nose, sore throat, cough and headache.Objective signs are rare, but may include fever, enlarged anterior cervical lymph nodes, nasal mucosa and oropharyngeal erythema, and nasal mucus.
62641107|NCT04126304||acute bronchitis|In 2011, the European society of respiratory diseases (ERS) defined acute disease in patients with non-chronic lung disease. Symptoms include cough, with or without expectoration of phlegm, and other symptoms and signs may indicate lower respiratory tract infection and cannot be explained by other diseases (e.g., sinusitis, asthma).The main symptoms of acute bronchitis are cough, may be accompanied by fever, fatigue, asthma and dyspnea.
62641108|NCT04126304||Post-infection cough|The definition in the 2013 guidelines for diagnosis and treatment of chronic cough in Chinese children: cough refers to a recent history of respiratory tract infection;The cough lasted \> for 4 weeks, presenting an irritating dry cough or a little white phlegm.Chest x - ray examination showed no abnormality or only increased lung veins.The pulmonary ventilation function was normal, or presented transient high airway response.Coughs are usually self-limited, and other diagnoses should be considered if the cough is more than 8 weeks old.In addition to other causes of chronic cough.
62071999|NCT04394091||PET CT and ultrasensitive PET CT|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .
62072000|NCT01728805|EXPERIMENTAL|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
62276580|NCT05541614|EXPERIMENTAL|Subgingival debridement + Flapless Enamel Matrix Derivative|"Subgingival debridement following a minimally-invasive non-surgical treatment (MINST) approach with flapless application of EMD~Root instrumentation under local anesthesia using mini hand instruments (mini curettes) and ultrasonic instruments with fine tips in the furcation area of mandibular first or second molars with class II buccal furcation defects. EDTA gel will be applied for 2 minutes on the affected root surfaces, followed by rinsing with saline and drying prior to the application of Emdogain® FL. Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets."
62276581|NCT05541614|ACTIVE_COMPARATOR|Periodontal surgery + Enamel Matrix Derivative|"Periodontal surgery following a minimally-invasive surgical treatment (MIST) protocol with application of EMD~Following local anesthesia, minimal flap elevation on the buccal aspect of first or second molars associated with a grade II furcation defect will be performed.Removal of granulation tissues and root instrumentation with mini hand instruments (mini curettes) and ultrasonic instruments with fine tips in the furcation area will then be carried out. EDTA gel will be applied for 2 minutes on the affected root surfaces, followed by rinsing with saline and drying prior to the application of Emdogain®. Then, the surgical flaps will be positioned and sutured in order to completely cover the defects."
62276582|NCT00257439||CKD|Elevated se-creatinine + proteinuria
62276583|NCT00257439||Healthy controls|Healthy controls, normal se-creatinine, no proteinuria
62276584|NCT01049035|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein (MenACYW) Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.
62276585|NCT01049035|EXPERIMENTAL|Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
62072001|NCT01728805|ACTIVE_COMPARATOR|Vorinostat|vorinostat 400 mg once daily
62072002|NCT02023879|PLACEBO_COMPARATOR|Placebo Q2W|"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.~Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed."
62072003|NCT02023879|OTHER|Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)|"Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or \<30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
62072004|NCT02023879|EXPERIMENTAL|Alirocumab 150 mg Q4W/Up to 150 mg Q2W|"Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or \<30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
62276586|NCT01049035|EXPERIMENTAL|Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.
62641109|NCT04126304||community-acquired pneumonia|According to the 2019 guidelines for the diagnosis and treatment of community-acquired pneumonia in children, it is defined as infectious pneumonia developed outside the hospital (community), including pneumonia developed after admission due to infection of pathogens with a clear incubation period outside the hospital (community).
62641110|NCT06238427||Group 1|Group 1 participants underwent free gingival graft placement two months before implant placement.
62641111|NCT06238427||Group2|Group 2 in which the participants underwent the placement of the free gingival graft during the second stage of surgery, specifically at the time of healing abutment placement
62276587|NCT01049035|EXPERIMENTAL|Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months|Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.
62072005|NCT05197257|EXPERIMENTAL|Men with pathologically proven prostate adenocarcinoma|The intervention is a PET scan with the radiolabelled PSMA ligand, 68Ga-PSMA-11. The PET may be combined with a CT scan as a PET/CT or an MRI scan as PET/MRI. 68Ga-PSMA-11 PET/CT will be acquired using a modern digital GE PET/CT scanner or a modern digital PET / MRI scanner.
62072006|NCT03984019|OTHER|A|Radiotherapy; SBRT Additional cardiac diagnostics
62072007|NCT05719623|EXPERIMENTAL|CUEVAS MEDEK EXERCISES|Experimental group will get conventional treatment along with Cuevas Medak Exercises
62276588|NCT01049035|EXPERIMENTAL|Group 5: MenACYW Conjugate Vaccine: Month 12|Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.
62276589|NCT01049035|OTHER|Group 6: Control: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.
62276590|NCT01049035|OTHER|Group 7: Control: 2, 4, 6, 12, and 15 Months|Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
62072008|NCT05719623|OTHER|BALANCE AND POSTURAL|Controlled will get conventional treatment
62072009|NCT01380990|EXPERIMENTAL|Gene Therapy|Infusion of autologous EFS-ADA LV CD34+ cells
62072010|NCT01380990|OTHER|Historical Control Group|Historical data from ADA-SCID patients who were treated with Hematopoietic Stem Cell Transplantation (HSCT)
62072011|NCT02070120|EXPERIMENTAL|Chemoresection|4 once weekly outpatient intravesical instillations 40mg Mitomycin C
62072012|NCT02070120|OTHER|Surgical Management|Surgical management according to local practice
62072013|NCT02964715|EXPERIMENTAL|Interventional arm|Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months
62641112|NCT02427841|EXPERIMENTAL|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
62641113|NCT00421278|EXPERIMENTAL|1|Arm 1: Drug
62641114|NCT00026247|EXPERIMENTAL|RFA as pain therapy|Changes in the severity of pain as measured using using the Memorial Pain Assessment Cards (MPAC) before and after RadioFrequency Ablation (RFA) will be statistically analyzed
62641115|NCT00742794||1|Hymenoptera sting allergic patients under immunotherapy
62641116|NCT05623410|EXPERIMENTAL|Botulinum toxin type A(ATGC-110)|ATGC-110 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
62072014|NCT04310943|EXPERIMENTAL|Arm 1|Tislelizumab (200mg,Q3W )+Bevacizumab(15 mg/kg,Q3W)+Albumin paclitaxel(100mg/m2,d1,8,15) for 4 cycles, and if there is no disease progression, patients will receive Tislelizumab(200mg,Q3W) until progression or death.
62072015|NCT03759613|EXPERIMENTAL|Experimental Group|Thirty subjects with unilateral upper burn injury will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. Their evaluations will be made within 5 days following burn injury.
62072016|NCT03759613|ACTIVE_COMPARATOR|Control Group|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, they will be asked to walk their natural walking.
62072017|NCT03759613|SHAM_COMPARATOR|Control Grup (Restricted arm swing)|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, their arms will be fixed with a bandage on their bodies. Their arm swing will be restricted.
62072018|NCT01176604|EXPERIMENTAL|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0. Patients may receive additional treatments at 4-12 week intervals until all tumors in the liver have been treated in the absence of disease progression or unacceptable toxicity.
62276591|NCT03572556||Patients|Hereditary hemorrhagic telangiectasia patients
62641117|NCT05623410|ACTIVE_COMPARATOR|Incobotulinumtoxin A (Xeomin®)|Xeomin® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
62641118|NCT04488913|OTHER|Standard of Care Treatment|Exposure to traditional evaluation for suspected acute coronary syndrome (ACS) with ECG, 0- and 3-hour troponin testing using the 99th percentile as the upper reference limit, and application of the History, EKG, Age, Risk factors, and troponin (HEART) score.
62641119|NCT04488913|ACTIVE_COMPARATOR|RACE-IT pathway|Exposure to new protocol for suspected ACS, which includes the use of 0- and 1-hour ECG and high-sensitivity troponin testing and application of the HEAR score (a modification of the HEART score)
62641120|NCT06115174|OTHER|People not recieving the drug|(Control group; n=22) which will receive FOLFOX (leucovorin, fluorouracil, oxaliplatin) or XELOX (oxaliplatin + capecitabine) ± target therapy (Bevacizumab).
62641121|NCT06115174|ACTIVE_COMPARATOR|People recieving the drug|(Pentoxiphylline group; n=22) which will receive the same FOLFOX (leucovorin, fluorouracil, oxaliplatin) or XELOX regimen (oxaliplatin + capecitabine) ± target therapy (Bevacizumab) in addition to Pentoxiphylline 400 mg twice daily.
62641122|NCT03625726|EXPERIMENTAL|patients with cirrhosis|pathophysiology study, blood sample
62641123|NCT03625726|PLACEBO_COMPARATOR|healthy volunteers|pathophysiology study, blood sample
62641124|NCT03625726|PLACEBO_COMPARATOR|patients with hepatocellular carcinoma|pathophysiology study, blood sample
62072019|NCT06489574|EXPERIMENTAL|thoracic epidural with dexmedetomidine|Patients will receive 50 μg dexmedetomidine with 10 ml of 0.125% bupivacaine followed by a continuous infusion of (10 ml bupivacaine + 25 μg dexmedetomidine + 39 ml saline with rate of 5 ml per hour)
62276592|NCT03572556||Controls|Matched for age (+/- 5 ans) and sex.
62276593|NCT02239263|EXPERIMENTAL|N6 Input Processing Features|
62276594|NCT02316405|EXPERIMENTAL|Test Group|5 weeks of arm and leg cycling, 3 times per week for 30 minute of total exercise per session
62276595|NCT02507362|EXPERIMENTAL|experimental|Radiation: adjusted corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 7 minutes after 30 mitunes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
62641125|NCT02959502|EXPERIMENTAL|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
62072020|NCT06489574|EXPERIMENTAL|thoracic epidural with fentanyl|Patients will receive 50 μg fentanyl in addition to 10 ml 0.125% bupivacaine followed by a continuous infusion (10 ml bupivacaine + 100 μg fentanyl + 38 ml saline with rate of 5 ml per hour)
62072021|NCT02361060|EXPERIMENTAL|Sugammadex|sugammadex 4 mg/kg
62072022|NCT02361060|ACTIVE_COMPARATOR|Neostigmine + Atropine|Neostigmine 40µg/kg in combination with atropine 10µg/kg.
62072023|NCT05625919|EXPERIMENTAL|Sirolimus for Injection (Albumin-bound)|Sirolimus for injection (Albumin-bound) will be administered intravenously on day 1and day 8 every 21 days (a cycle).
62072024|NCT05991973|EXPERIMENTAL|low-dose chidamide maintenance therapy after allo-HSCT|
62276596|NCT02507362|ACTIVE_COMPARATOR|control|radiation: accelerated corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 10 minutes after 30 minutes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
62276597|NCT04838873|ACTIVE_COMPARATOR|Open Radical Cystectomy|Standard open radical cystectomy.
62276598|NCT04838873|EXPERIMENTAL|Laparoscopic-assisted radical cystectomy.|Laparoscopic-assisted radical cystectomy.
62276599|NCT04743180||LUMINOR© drug eluting balloon|
62276600|NCT01028625|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|
62276601|NCT01028625|OTHER|Usual Care|Participants who are randomly assigned to usual care will receive whatever treatment (if any) for depression their own physician may prescribe. In most cases, treatment (if any is provided) is likely to consist of a serotonin reuptake inhibitor (SSRI) antidepressant such as sertraline or citalopram.
62276602|NCT03312660|EXPERIMENTAL|Prebiotic group.|Group of 22 families consuming a fermented dairy product with prebiotic components, once a day for 4 months.
62276603|NCT03312660|PLACEBO_COMPARATOR|Placebo group|Group of 22 families consuming a dairy product with similar characteristics regarding color, flavor and nutritional composition, not containing the prebiotic components, once a day for 4 months.
62072025|NCT03758118|ACTIVE_COMPARATOR|NAION patients OS-Citicoline treated|In a group of patients with NAION, OS-Citicoline will be administered (500 mg/day) for 6 months followed by three months of suspension
62276604|NCT02441504|ACTIVE_COMPARATOR|Low intensity exercise|physical inactivity
62276605|NCT01065974|ACTIVE_COMPARATOR|Behavior Therapy|"Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~* Self monitoring~* Stimulus control~* Changing eating behaviors~* Goal setting~* Problem solving~* Social support~* Cognitive restructuring~* Relapse prevention"
62455143|NCT04189848|EXPERIMENTAL|Dulaglutide followed by semaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
62455144|NCT04276870|EXPERIMENTAL|Subjects with hypodiploid B-ALL|
62455145|NCT04276870|EXPERIMENTAL|Subjects with t(17;19) B-ALL|
62455146|NCT04276870|EXPERIMENTAL|Infant subjects with very high risk KMT2A B-ALL|
62455147|NCT04276870|EXPERIMENTAL|Subjects with central nervous system (CNS) relapse|who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT)
62276606|NCT01065974|EXPERIMENTAL|Behavior Therapy + Meal Replacements|The BT +MR condition will implement behavioral treatment strategies in a way that is nearly identical to that of the BT condition. However, participants in this condition also will use MRs during weight loss and weight loss maintenance.
62276607|NCT01065974|EXPERIMENTAL|Nutritrol|"Participants in this condition will be informed about the evidence indicating that the availability, structure and composition of foods they encounter or seek out in their daily lives will play a major role in determining their ability to maintain the weight they lose. We will present the treatment as an opportunity to make numerous changes to their personal food environment involving the variety, energy density, nutritional composition, and portion size of the foods they encounter in every day life.~The Nutritrol condition is comprised of several components:~* Food structure~* Energy density~* Reduce variety of foods high in energy density and increase variety of foods low in energy density~* Protein intake~* Controlling the personal food environment~* Individualized weight loss maintenance prescriptions"
62276608|NCT05836337|EXPERIMENTAL|Tattoo- Black Eye|to mark the biopsied axillary lymph node by tattooing
62276609|NCT05836337|ACTIVE_COMPARATOR|clip- HydroMARK|To mark the biopsied axillary lymph node by clip placement
62276610|NCT04634058|EXPERIMENTAL|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 antibody combined with CTLA-4 antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
62276611|NCT04506294|EXPERIMENTAL|eScreen Group|After randomization at baseline, use eScreen system (child screening component and parent information component) for 6 weeks.
62641126|NCT02959502|EXPERIMENTAL|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
62641127|NCT00430846|EXPERIMENTAL|A|
62641128|NCT00447772|EXPERIMENTAL|1|
62641129|NCT04309032|EXPERIMENTAL|Bladder fill|Retrograde bladder filling of 250cc of 0.9% normal saline for irrigation prior to removal of foley catheter
62641130|NCT04309032|NO_INTERVENTION|No bladder Fill|no filling prior to removal of foley catheter
62641131|NCT05848037|EXPERIMENTAL|cymactive catheter device arm|All participants will receive background local standard of care therapy according to participating institutions/hospitals regardless of the study group to which they belong. 60 participants will be recruited to this study. 30 patients in the CCD arm and 30 patients in the FTD.
62072026|NCT03758118|NO_INTERVENTION|NAION patients untreated|In one group of patients with NAION no type of treatment will be performed during 9 months of observation
62072027|NCT03813550|OTHER|PXE cohort 2019-2020|PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
62072028|NCT03135457|OTHER|Group A|Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min
62072029|NCT03135457|OTHER|Group B|Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min
62072030|NCT00743990|ACTIVE_COMPARATOR|A|
62072031|NCT00743990|PLACEBO_COMPARATOR|B|
62072032|NCT00743990|NO_INTERVENTION|3|no intervention
62072033|NCT04655079|EXPERIMENTAL|Real tDCS group|Participants receive anodal tDCS on the left dlPFC for 5 days/week for 2 weeks
62072034|NCT04655079|SHAM_COMPARATOR|Sham group|Participants receive sham stimulation on the left dlPFC for 5 days/week for 2 weeks
62072035|NCT03384953|EXPERIMENTAL|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
62072036|NCT03384953|EXPERIMENTAL|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
62072037|NCT01885273|EXPERIMENTAL|Pressurized irrigation method|Cleansing wound with pressurized irrigation technique using a pressurized irrigation device.
62072038|NCT01885273|ACTIVE_COMPARATOR|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack), and received the 'standardized usual care'. Frequency of dressing change depended on the amount of exudates.
62072039|NCT05619913|EXPERIMENTAL|Arm 1 - Single agent eribulin arm|"Eribulin until progression of disease (PD) as defined by RECIST v1.1, unacceptable toxicity or physician/patient discretion or choice to cease treatment.~Patients who progress on the single agent eribulin arm may receive combination eribulin and pembrolizumab."
62276612|NCT04506294|NO_INTERVENTION|Usual Care Group|Treatment as usual from baseline. Optional access to the game only (no screening, no parent information component) after completion of T3 assessment (\~12 weeks)
62072040|NCT05619913|EXPERIMENTAL|Arm 2 - Combination eribulin and pembrolizumab arm|Eribulin for a maximum of 6 cycles. Pembrolizumab until PD or a maximum of 35 cycles (including the 6 cycles where it is administered in combination with eribulin) or until unacceptable toxicity or physician/patient discretion or choice to cease treatment.
62072041|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
62072042|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
62072043|NCT00130793|EXPERIMENTAL|zoster vaccine live (Oka/Merck) refrigerated formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose-urea (PGSU) stabilizer (\~45,000 plaque-forming units \[PFU\]), 1 subcutaneous 0.65-mL injection
62072044|NCT00130793|ACTIVE_COMPARATOR|zoster vaccine live (Oka/Merck) frozen formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose (PGS) stabilizer (\~57,000 PFU), 1 subcutaneous 0.65-mL injection
62072045|NCT02444988|ACTIVE_COMPARATOR|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
62276613|NCT02059590|EXPERIMENTAL|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|single dose
62276614|NCT01128829|EXPERIMENTAL|water-sucralose|"Subjects in this group drank water 10 min before drinking a glucose load on their first oral glucose tolerance test (OGTT) and drank sucralose 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
62641132|NCT05848037|ACTIVE_COMPARATOR|Foley-type device arm|All participants will receive background local standard of care therapy according to participating institutions/hospitals regardless of the study group to which they belong. 60 participants will be recruited to this study. 30 patients in the CCD arm and 30 patients in the FTD.
62641133|NCT03175497|EXPERIMENTAL|Telatinib mesylate treatment arm|"Open label, single arm trial. For the 1st phase: three cohorts, and each with 3-6 solid tumor patients who will be treated with telatinib at predetermined dose: 600 mg bid, 900 mg bid, or 1200 mg bid, respectively.~For the 2nd phase, one cohort with 12 GC patients who will be treated with telatinib at 900 mg bid"
62641134|NCT04083560|EXPERIMENTAL|Intervention group|Group A Intervention: 360 pregnant women will receive 250 mcg of B-12 daily orally from 1st trimester to 6 months postpartum
62641135|NCT04083560|ACTIVE_COMPARATOR|Control group|Group B- Control: 360 pregnant women will receive 50 mcg of B-12 daily orally from 1st trimester to 6 months post partum
62641136|NCT05541939|EXPERIMENTAL|Treatment Arm A|Subjects will receive two separate single doses (Period 1 and Period 2) of encapsulated mizagliflozin
62641137|NCT05541939|EXPERIMENTAL|Treatment Arm B|Subjects will receive one dose of liquid formulation (Period 1), and one dose (optional) of encapsulated mizagliflozin (Period 2)
62072046|NCT02444988|ACTIVE_COMPARATOR|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
62072047|NCT01999062|EXPERIMENTAL|IMRT + CT + MR scan|
62072048|NCT06280287||Carotid stenosis|Patients with carotid stenosis and suitable for carotid endarterectomy
62072049|NCT06280287||Coronary artery disease|Patients with stable ischemic heart disease or acute coronary syndrome
62276615|NCT01128829|EXPERIMENTAL|sucralose-water|"Subjects in this group drank sucralose 10 min before drinking a glucose load on their first OGTT and drank water 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
62276616|NCT03032276|EXPERIMENTAL|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
62276617|NCT03032276|NO_INTERVENTION|Comparison|Another 15 union will be selected where no intervention will be implemented
62455148|NCT00098488|EXPERIMENTAL|Treatment (17-AGG and rituximab)|Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
62276618|NCT02934438|ACTIVE_COMPARATOR|Neo40 Supplement|Utilizing intellectual property developed out of the University of Texas Health Science Center in Houston, Neo40 is a GMP certified, over the counter, all natural formulation that provides a system for generating NO in an endothelium-dependent and independent manner. The NEO40™ Daily™ product ingredients list and packaging was submitted to FDA Office of Compliance by Neogenis Labs, Inc. for use as a dietary supplement. It is made up of Beet root extract, hawthorne berry, Vitamin C, L-citrulline and sodium nitrite. The lozenges utilize natural product chemistry activated by the saliva to generate authentic NO gas in the oral cavity through the one-electron reduction of nitrite. This product's formulation was designed to be a quick dissolve that melts in the mouth within four to five minutes.
62455149|NCT03659409|EXPERIMENTAL|Mindfulness Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
62455150|NCT03659409|OTHER|Treatment Waitlist Group|Participants will receive no intervention, except for a baseline follow-up at the start and again at the end of the first phase. 2 months after the end of the first intervention phase, participants in this group will receive the same mindfulness-based intervention for 4 weeks.
62641138|NCT06437925|EXPERIMENTAL|Probiotic ayran drink|The participants in this experimental group will use probiotic containing ayran for 42 days and then will be subjected to 5 days of experimental gingivitis.
62641139|NCT06437925|PLACEBO_COMPARATOR|Placebo ayran drink|The participants in this control group will use control ayran without probiotics for 42 days and then will be subjected to 5 days of experimental gingivitis.
62641140|NCT02016443|EXPERIMENTAL|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
62072050|NCT03545815|EXPERIMENTAL|anti-mesothelin CAR-T cells|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.~Patients receive anti-mesothelin-CAR T cells on day 0."
62461675|NCT04815083|PLACEBO_COMPARATOR|Standard of Care Arm|Patients in this arm will receive the placebo orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence-guided resection will not be performed in patients in this arm.
62072051|NCT04015791||Match Group|Surgery conducted at the disc level corresponding with the highest level of NOCISCORE value in the subject and that is classified as either NOCI + or NOCI mild
62072052|NCT04015791||Miss Group|Surgery conducted at a disc that: (a) corresponds with a low relative NOCISCORE value in the subject and that is classifies as NOCI - or (b) excludes the disc level with the highest NOCISCORE value in the subject and that is classifies as NOCI+ or NOCI mild
62072053|NCT01207050|EXPERIMENTAL|Rozerem (Ramelteon)|The primary drug of interest is a melatonin agonist for the treatment of insomnia.
62641141|NCT02016443|PLACEBO_COMPARATOR|Placebo|Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
62641142|NCT02250339||LAKU family program|Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
62072054|NCT01207050|PLACEBO_COMPARATOR|Sugar pill|Control condition.
62641143|NCT02250339||Etä-LAKU family program|Time-limited (18 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Etä-LAKU family program (18 months) includes 35 family-based meetings and two separate family weekends. A 24-month-program will include 10 additional family-based meetings.
62641144|NCT02250339||Family therapy|Time-limited (12 or 24 months) family therapeutic intervention for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Family therapy intervention includes 15 (1-year program) or 30 (2-year program) family meetings.
62641145|NCT02925858|EXPERIMENTAL|Intervention|Intraoperative infusion of ketamine
62641146|NCT02925858|PLACEBO_COMPARATOR|Control|Control group receiving a saline infusion
62641147|NCT02594319|ACTIVE_COMPARATOR|Control|Daily reporting of fruit and vegetable consumption
62641148|NCT02594319|EXPERIMENTAL|Daily reward|Incentives for fruit and vegetable consumption delivered daily
62641149|NCT02594319|EXPERIMENTAL|Delayed reward|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
62641150|NCT01837836|EXPERIMENTAL|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
62276619|NCT02934438|PLACEBO_COMPARATOR|Placebo|A placebo product has been manufactured that looks, tastes and feels like the Neo40 active lozenge without the active ingredients
62641151|NCT03257436|OTHER|Single Arm|General population who receive a Boston Scientific Resonate family of CRT-D device in accordance with its labeled indication for use.
62641152|NCT01365130|EXPERIMENTAL|real drug|patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity
62641153|NCT03588130|ACTIVE_COMPARATOR|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
62641154|NCT03588130|PLACEBO_COMPARATOR|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
62641155|NCT03588130|ACTIVE_COMPARATOR|Non-surgical standard of care (NSSOC)|Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved
62641156|NCT03765606|PLACEBO_COMPARATOR|Cocoa Flavanol beverage mix|Cocoa Flavanol beverage mix (flavanols, 566mg; caffeine, 11mg \& theobromine, 93mg)
62641157|NCT03765606|EXPERIMENTAL|De-xanthinated Cocoa Flavanol beverage mix|De-xanthinated Cocoa Flavanol beverage mix (flavanols, 583mg; caffeine, 0.6mg \& theobromine, 0.2mg)
62641158|NCT05865912|EXPERIMENTAL|[Mindfulness training + real tDCS]|
62641159|NCT05865912|PLACEBO_COMPARATOR|[Mindfulness training + sham tDCS]|
62641160|NCT05865912|NO_INTERVENTION|[Waiting list control group].|
62641161|NCT03416348|PLACEBO_COMPARATOR|Placebo Comparator AIM 1|Aim 1: Demonstration of a strong association of the Sweating Intensity Visual Scale (SIVS) score with the HDSS would provide validation for use of the SIVS in interpreting the iodine-starch test and would establish the value of the iodine-starch test in clinical practice guidelines for diagnosing hyperhidrosis in amputees, just as it is in dermatology practice.
62276620|NCT04831281|EXPERIMENTAL|40mg Dose|Daily subcutaneous injection of 40mg ATH-1017
62276621|NCT04831281|EXPERIMENTAL|70mg Dose|Daily subcutaneous injection of 70mg ATH-1017
62276622|NCT04831281|PLACEBO_COMPARATOR|Placebo|Daily subcutaneous injection of Placebo
62276623|NCT02925130|EXPERIMENTAL|Inhaled Salbutamol|Acute inhalation of 800 microgram Salbutamol
62276624|NCT02925130|EXPERIMENTAL|Oral Salbutamol|Acute oral intake of 4 mg Salbutamol
62276625|NCT02925130|PLACEBO_COMPARATOR|Placebo|Acute oral intake of a placebo
62276626|NCT05525117|EXPERIMENTAL|online intervention in addition to treatment-as-usual|online intervention: covivio in addition to treatment as usual
62641162|NCT03416348|ACTIVE_COMPARATOR|Aluminum Chloride vs Placebo in Amputees|Aim 2: The investigators will have completed the first clinical trial of Aluminum Chloride for residual limb hyperhidrosis. The investigators will then have a solid foundation of data that demonstrates the rates of adverse effects such as skin irritation, and rates and magnitudes of improvement in subjective and objective measures of sweating.
62641163|NCT02347046|EXPERIMENTAL|Moderately-decreased group|(eGFR: \>=30mL/min/1.73m\^2 and \< 60mL/min/1.73m\^2)
62641164|NCT02347046|EXPERIMENTAL|Slightly-decreased group|(eGFR: \>=60mL/min/1.73m\^2 and \< 90mL/min/1.73m\^2)
62641165|NCT02347046|EXPERIMENTAL|Normal group|(eGFR: \>=90mL/min/1.73m\^2)
62641166|NCT05387876|PLACEBO_COMPARATOR|Placebo intervention|A gummie candy the same consistency and nutrient value as the vitamin D gummie without any vitamin D will be taken as four gummies at the largest meal for 12 weeks once per day
62276627|NCT05525117|OTHER|treatment-as-usual|Other: treatment as usual
62276628|NCT01084187|ACTIVE_COMPARATOR|vardenafil on demand|four sexual attempts with 20 mg vardenafil during next four weeks
62276629|NCT01084187|PLACEBO_COMPARATOR|placebo|placebo of vardenafil during four weeks
62276630|NCT01084187|ACTIVE_COMPARATOR|daily vardenafil|10 mg of vardenafil each day during four weeks
62276631|NCT03828279||hereditary angioedema type I|Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
62641167|NCT05387876|EXPERIMENTAL|Vitamin D intervention|A vitamin D gummie the same consistency and nutrient value as the placebo gummie will be taken as four gummies at the largest meal for 12 weeks once per day providing 4000 IUs per day or 1000 IUs per gummie
62641168|NCT01087164|EXPERIMENTAL|Compliance|Parents will be randomized to receive high or no compliance condition where those in the experimental group will be asked about whether or not they will protect their daughter from cervical cancer or for males, their son from genital warts.
62641169|NCT01087164|EXPERIMENTAL|Message sidedness|Parents will be given either a one-sided verbal message or a two-sided verbal message about the HPV vaccine.
62641170|NCT02483884|EXPERIMENTAL|Low risk for recurrence|Diagnostic \[68Ga\]RM2 is administered to 10 primary prostate cancer patients with low risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
62641171|NCT02483884|EXPERIMENTAL|Intermediate risk for recurrence|Diagnostic \[68Ga\]RM2 is administered to 10 primary prostate cancer patients with intermediate risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
62641172|NCT02483884|EXPERIMENTAL|High risk for recurrence|Diagnostic \[68Ga\]RM2 is administered to 10 primary prostate cancer patients with high risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
62276632|NCT03828279||hereditary angioedema type II|Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was \>50% of normal
62276633|NCT05879783|EXPERIMENTAL|Probe-based confocal laser endomicroscopy biopsy|In this study , pCLE-based optical biopsy will be successively performed for peritoneal nodules in colorectal cancer patients during surgical operation.
62276634|NCT01384214|EXPERIMENTAL|1|botulinum toxin Type A
62276635|NCT01563887|EXPERIMENTAL|DD.com|Participants in this arm will receive the DiabetesDriving.com internet intervention intended to help reduce their risk of being in a future collision.
62276636|NCT01563887|EXPERIMENTAL|DD.com + MI|Participants will receive the DiabetesDriving Internet intervention and two 60 minute Motivational Interview (MI) sessions over the telephone. The MI sessions will take place once before and once following completion of the Internet intervention. This interview will focus on making explicit individual's ambivalence around changing behavior.
62276637|NCT00884104|EXPERIMENTAL|1.tamsulosin + solifenacin|
62276638|NCT03146533|EXPERIMENTAL|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
62276639|NCT02498626||venous saturations|venous saturations from the central venous line, venous side of the heart lung machine and from the pulmonary artery
62641173|NCT03283735|EXPERIMENTAL|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
62641174|NCT03283735|NO_INTERVENTION|Control|This will be the control group.
62641175|NCT00570401|EXPERIMENTAL|Dasatinib|"Beginning 1 week after completion of erlotinib hydrochloride or gefitinib therapy, patients receive oral dasatinib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.~Response is assessed by CT scan at 4 weeks, 8 weeks, and then every 8 weeks thereafter."
62641176|NCT04784234|ACTIVE_COMPARATOR|GlaucoCetin Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
62641177|NCT04784234|PLACEBO_COMPARATOR|Placebo Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
62641178|NCT04784234|ACTIVE_COMPARATOR|GlaucoCetin Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
62641179|NCT04784234|PLACEBO_COMPARATOR|Placebo Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
62641180|NCT00643760|PLACEBO_COMPARATOR|Placebo|Placebo
62641181|NCT00643760|OTHER|Pregabalin|Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks
62641182|NCT00643760|EXPERIMENTAL|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
62641183|NCT00643760|EXPERIMENTAL|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
62641184|NCT00643760|EXPERIMENTAL|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks
62641185|NCT05427435|EXPERIMENTAL|Marshall ethanolisation with specific catheter|Patients will undergo the destruction of Marshall bundles by ethanol infusion with the specific catheter
62641186|NCT02915146|ACTIVE_COMPARATOR|NB-UVB monotherapy|Narrowband ultraviolet B monotherapy will be used
62641187|NCT02915146|ACTIVE_COMPARATOR|NB-UVB + UVA1|Narrowband ultraviolet B combined with ultraviolet A1 phototherapy will be used
62641188|NCT02882334|EXPERIMENTAL|Finger individuation training|Finger Force Manipulandum
62641189|NCT02882334|ACTIVE_COMPARATOR|control|conventional physiotherapy
62641190|NCT00965133|NO_INTERVENTION|Normal daily activity|
62641191|NCT03732027|ACTIVE_COMPARATOR|Transversus Abdominis Block [TB] group|Patients will receive Surgical Transversus Abdominis Plane Block
62641192|NCT03732027|ACTIVE_COMPARATOR|Rectus Sheath Block [RB] group|Patients will receive Surgical Rectus Sheath Block
62641193|NCT00955799|EXPERIMENTAL|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
62641194|NCT00955799|PLACEBO_COMPARATOR|Placebo|Placebo: identical placebo tablets
62641195|NCT02028598|EXPERIMENTAL|Sequence A|Treatment 1 - Treatment 2 - Treatment 3
62072055|NCT03992885|EXPERIMENTAL|combination therapy with ectiecinib, pemetrexed and platinum|ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally;Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle, a total of 6 cycles.Maintenance therapy: ectinib: ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally, pemetrexed 500mg/m2,d intravenous infusion, day 1,21 days for a cycle
62641196|NCT02028598|EXPERIMENTAL|Sequence B|Treatment 1 - Treatment 3 - Treatment 2
62641197|NCT02028598|EXPERIMENTAL|Sequence C|Treatment 2 - Treatment 1 - Treatment 3
62641198|NCT02028598|EXPERIMENTAL|Sequence D|Treatment 2 - Treatment 3 - Treatment 1
62641199|NCT02028598|EXPERIMENTAL|Sequence E|Treatment 3 - Treatment 1 - Treatment 2
62641200|NCT02028598|EXPERIMENTAL|Sequence F|Treatment 3 - Treatment 2 - Treatment 1
62641201|NCT01905618|EXPERIMENTAL|Multi Modal Education (MME)|Medical students in the medical schools randomized to the MME will receive four interventions during the course of their medical education. The four interventions/components are: 1) web-based curriculum on tobacco dependence treatment; 2)tobacco counseling role play; 3) preceptor training and teaching medical students, preceptor modeling the 5As, student observation, and student feedback; and 4)booster session.
62641202|NCT01905618|NO_INTERVENTION|Traditional Education (TE)|Medical schools randomized to the Traditional Education (TE) will represent usual care and includes the current content and mode for tobacco teaching in the medical school.
62641203|NCT01187732|EXPERIMENTAL|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
62641204|NCT01187732|ACTIVE_COMPARATOR|Traditional soap and water bath|The control intervention is the traditional bathing assistance as performed in care dependent patients by using tap water, a bowl, towels, washcloths and soap.
62641205|NCT01026025|EXPERIMENTAL|Duet TRS|This is a single arm study.
62641206|NCT02493972|EXPERIMENTAL|manual exploration by GelPort|manual exploration in supplement of coelioscopy before laparotomy
62641207|NCT03199352||RYGB: Hand-sewn|This group would receive a Roux-en-y gastric bypass with the anastomosis hand-sewn using a minimally-invasive robotic surgical approach
62641208|NCT03199352||RYGB: linear-staple|This group would receive a Roux-en-y gastric bypass with the anastomosis sewn with a linear stapler using a laparoscopic surgical approach
62641209|NCT01620645||COPD, GOLD II severity or above|
62641210|NCT02172027||Lung Cancer, Pleural effusion|
62641211|NCT00509717|EXPERIMENTAL|experimental|
62641212|NCT00509717|ACTIVE_COMPARATOR|control|
62641213|NCT04744818|ACTIVE_COMPARATOR|Immediate iron treatment|Iron and multivitamin syrup
62641214|NCT04744818|PLACEBO_COMPARATOR|Delayed iron treatment|Multivitamin syrup
62641215|NCT01626846||NF1 teenagers|
62641216|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted \>72h at the Intensive Care Unit with the need of artificial Nutritional Support
62641217|NCT05289700|EXPERIMENTAL|HBOT intervention group (2 ATA, 95 min, FIO2=1)|Hyperbaric Oxygen Therapy (HBOT) is the administration of oxygen at a pressure higher than atmospheric pressure (2 ATA). By breathing pure oxygen at twice the atmospheric pressure, its concentration in the blood is multiplied by nearly ten times. This allows a greater oxygen concentration in poorly vascularised areas of the body.
62641218|NCT05289700|PLACEBO_COMPARATOR|placebo group (1.3 ATA, 95 min, FIO2=0.21)|Hyperbaric chamber is the same chamber used for HBOT, but with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers.
62641219|NCT01748968||Veterans with HIV/AIDS|Veterans with HIV/AIDS
62641220|NCT01065818|EXPERIMENTAL|Fluoro-L-Thymidine|Injection pre-Neoadjuvant Therapy (CRT, CT, or RT) and post-3 weeks Neoadjuvant Therapy (CRT, CT, RT)(3 weeks from the start of Neoadjuvant Therapy) prior to surgery.
62641221|NCT02351947|EXPERIMENTAL|persons with chronic stroke|upper limb rehabilitation for chronic stroke
62641222|NCT02351947|NO_INTERVENTION|Healthy, age matched control group|Healthy aged match control group undergoing MRI/EEG testing
62641223|NCT05104385||Hacettepe University Health Cohort- Students of Health Sciences|"Students of medical school (grades 4,5, and 6) in 2021 Spring Students of dental school (grades 4 and 5) in 2021 Spring New comers of grade 4 in both medical and dental school will be recruited early in October 2021.~There is no intervention. Vaccinations for COVID-19 have been provided by the Turkish Ministry of Health, in a pre-planned schedule. The study will follow students after vaccination, regardless of the type and dose administered."
62641224|NCT03830268|EXPERIMENTAL|MCT intake in young participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.~Interventions:~1. No MCT intake with breakfast, no lunch (i.e. CTL)~2. No MCT intake with lunch, no breakfast (i.e CTL inverted)~3. 10g of Betaquik with breakfast, no lunch (i.e BQ10)~4. 20g of Betaquik with breakfast, no lunch (i.e BQ20)~5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
62641225|NCT03830268|EXPERIMENTAL|MCT intake in older participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.~Interventions:~1. No MCT intake with breakfast, no lunch (i.e. CTL)~2. No MCT intake with lunch, no breakfast (i.e CTL inverted)~3. 10g of Betaquik with breakfast, no lunch (i.e BQ10)~4. 20g of Betaquik with breakfast, no lunch (i.e BQ20)~5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
62641226|NCT01164202|PLACEBO_COMPARATOR|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
62276640|NCT02025296|NO_INTERVENTION|Self-Monitoring of Blood Glucose|measurement of their blood glucose level using a glucometer at least eight times a week
62276641|NCT02025296|EXPERIMENTAL|U-healthcare|individualized multidisciplinary u-healthcare service combined with exercise monitoring and dietary feedback on glucose control
62276642|NCT01871961|EXPERIMENTAL|Methotrexate|
62276643|NCT06401161|EXPERIMENTAL|Experimental group|The recommended method for consuming 3T Pu-erh tea is as follows: according to individual preferences, once a day, 8 g/time, or twice a day, 4 g/time, using a 300 mL stew cup; Steep the tea in 200 mL of boiling water for 60-90 seconds and consume. The tea can be brewed multiple times, replacing regular water intake. Ensure that the entirety of the liquid in the cup is consumed during each session.
62276644|NCT06401161|PLACEBO_COMPARATOR|Control group|The recommended method for consuming traditional Pu-erh tea is as follows: according to individual preferences, once a day, 8 g/time, or twice a day, 4 g/time, using a 300 mL stew cup; Steep the tea in 200 mL of boiling water for 60-90 seconds and consume. The tea can be brewed multiple times, replacing regular water intake. Ensure that the entirety of the liquid in the cup is consumed during each session.
62641227|NCT01164202|EXPERIMENTAL|Sunitinib|sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year
62276645|NCT02170272|EXPERIMENTAL|Home-based Lymphedema Care Program|Home-based Lymphedema Care Program (HBLCP): Participants will undergo one training session with a lymphedema therapist, and then receive a self-care video and educational manual to review at home. After completion of training session, follow-up measures occur at 1, 2, and 3 months.
62276646|NCT02841410|OTHER|Healthy Volunteer|
62276647|NCT03244033|EXPERIMENTAL|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
62276648|NCT03244033|ACTIVE_COMPARATOR|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
62276649|NCT00676715|PLACEBO_COMPARATOR|Placebo|Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
62276650|NCT00676715|EXPERIMENTAL|Ocrelizumab 600 mg|Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
62276651|NCT00676715|EXPERIMENTAL|Ocrelizumab 1000 mg|Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
62276652|NCT00676715|ACTIVE_COMPARATOR|Avonex|Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
62276653|NCT05738239|EXPERIMENTAL|Active|Application of photo-biomodulation
62276654|NCT05738239|PLACEBO_COMPARATOR|Placebo|Inactive PBMT
62072056|NCT03115749|OTHER|Crohn's disease patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
62276655|NCT02205060|EXPERIMENTAL|virtual reality exposure therapy (VRET)|
62276656|NCT02205060|EXPERIMENTAL|cognitive and behavioral approaches therapy without VRET|
62276657|NCT03667703|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.
62276658|NCT03667703|ACTIVE_COMPARATOR|Study Drug|Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants \< 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
62276659|NCT00527605|EXPERIMENTAL|A|dutasteride 0.5mg once daily orally
62276660|NCT00527605|PLACEBO_COMPARATOR|B|Placebo matched once daily orally
62276661|NCT05388539|ACTIVE_COMPARATOR|Active Group - protocol of Theta Burst Stimulation|3 sessions of theta burst stimulation, 1200 pulses per session of 6 minutes duration, 30-minute interval between sessions. Stimulation directed to the left dorsolateral pre-frontal cortex. The protocol will be applied for 15 days, totalizing 45 sessions of stimulation.
62461676|NCT04815083|EXPERIMENTAL|PD G 506 A + Fluorescence-Guided Resection Arm|Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue.
62072057|NCT03115749|OTHER|Ulcerative colitis patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
62072058|NCT03115749|OTHER|Control group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
62072059|NCT01474616|OTHER|Sit-to-Stand Activity|
62072060|NCT00525603|EXPERIMENTAL|CFAR|CFAR = Cyclophosphamide 200 mg/m\^2/day 3-5 intravenous (IV) 5-30 minutes, Fludarabine 20 mg/m\^2/day 3-5 IV 5-30 minutes, Alemtuzumab 30 mg 1, 3,5 IV 2-4 hours, and Rituximab 375 mg/m\^2/day 2 IV 4-6 hours
62461677|NCT02904837|EXPERIMENTAL|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
62461678|NCT02904837|ACTIVE_COMPARATOR|Control Group|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
62072061|NCT06211062|ACTIVE_COMPARATOR|Individuals with ME/CFS with IBS on active medication|Individuals with ME/CFS with IBS take Floradapt Intensive GI (another name i3.1), one high dose capsule (\>3x10 to the ninth power) once daily for eight weeks.
62072062|NCT06211062|PLACEBO_COMPARATOR|Individuals with ME/CFS with IBS on placebo|Individuals with ME/CFS with IBS take a placebo, one capsule once daily for eight weeks.
62072063|NCT06211062|ACTIVE_COMPARATOR|Individuals with ME/CFS without IBS on active medication|Individuals with ME/CFS without IBS take Floradapt Intensive GI (another name i3.1), one high dose capsule (\>3x10 to the ninth power) once daily for eight weeks.
62276662|NCT05388539|PLACEBO_COMPARATOR|Placebo Group - Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS.
62276663|NCT00330473|EXPERIMENTAL|1|Treatment options available on the market plus the option of taking Human Insulin Inhalation Powder.
62072064|NCT06211062|PLACEBO_COMPARATOR|Individuals with ME/CFS without IBS on placebo|Individuals with ME/CFS without IBS take a placebo, one capsule once daily for eight weeks.
62072065|NCT00459303|ACTIVE_COMPARATOR|intraocular lens|patients with bilateral clinical significant cataract reisiceved cataract surgeries and recieved spherial intraocuar lens(SA60AT, Alcon) in one eye and aspherical intraocular lens(Tecnis Z9000, AMO)in the other respectively.
62276664|NCT00330473|ACTIVE_COMPARATOR|2|Treatment Options available on the market.
62276665|NCT02549768|ACTIVE_COMPARATOR|Dexmedetomidine|Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)
62276666|NCT02549768|PLACEBO_COMPARATOR|Placebo|"Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug Dexmedetomidine with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h."
62276667|NCT02596412|EXPERIMENTAL|augmented reality (Mini-Docs) on tablet|• Cerebral-palsied children using the module with augmented reality (Mini-Docs) on tablet during TB injections in addition to regular drug techniques (experimental group)
62276668|NCT02596412|NO_INTERVENTION|Control|Cerebral-palsied children with the usual pain care during TB injections, which combines drug techniques to distractibility techniques (control group)
62276669|NCT04477681||Patients in therapeutic failure or relapse|Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of an ATU or outside AMM, in one of the centers of the SFCE (Société Française Cancer Enfant)
62455151|NCT02240407|EXPERIMENTAL|rAAV9-DES-hGAA vector|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase injection.
62072066|NCT02327819|ACTIVE_COMPARATOR|BCAA supplement|Branched-chain amino acids supplement, 12 g/day
62455152|NCT02240407|SHAM_COMPARATOR|Excipient|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first saline injection.
62641228|NCT06204497|EXPERIMENTAL|Stent-based Diverting Technique|For Stent-based Diverting Technique, the small intestine measuring 15 cm from the ileocecal junction was pulled out through the median incision in the lower abdomen. After a length-wise incision was established in the mesenteric margin of the small intestine, the degradable stent was implanted, and the intestine was sutured. Then, the stent was held in place using an external tie around the bowel. Next, a mushroom-like tube (28 Fr) was placed into the intestine proximal (5-10 cm) to the aforementioned stent. The other side of the mushroom-like tube was inserted through the right lower abdominal wall and connected with a drainage bag. An abdominal drainage tube, or an anal tube, if necessary, was inserted in the proper location prior to the closure of the incision and the abdominal cavity. Abdominal X-ray was routinely performed every week to detect stent degradation, and the mushroom-like tube (28 Fr) was removed two days after stent degradation.
62072067|NCT02327819|SHAM_COMPARATOR|non-BCAA protein supplement|non-BCAA protein supplement
62072068|NCT00749385|EXPERIMENTAL|1|PN 400
62072069|NCT00749385|ACTIVE_COMPARATOR|2|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)
62072070|NCT00749385|ACTIVE_COMPARATOR|3|Enteric-coated naproxen tablet (500mg)
62072071|NCT00749385|ACTIVE_COMPARATOR|4|EC esomeprazole capsule (20mg)
62072072|NCT06495437|EXPERIMENTAL|single arm study|Subjects who met the inclusion criteria were intravenously infused with 100ml extracellular vesicles derived from umbilical cord mesenchymal stem cells, at a rate of 1-1.5 hours
62072073|NCT00936221|ACTIVE_COMPARATOR|1|AZD6244 in combination with dacarbazine
62072074|NCT00936221|PLACEBO_COMPARATOR|2|Placebo in combination with dacarbazine
62072075|NCT05106985|EXPERIMENTAL|ApplTree Reminder app|Following a randomised baseline period, each participant will use the ApplTree reminder app for 22 days to support adherence to goal-related tasks
62276670|NCT01083056||Epimacular Gliosis Without Macular Hole|
62276671|NCT01083056||Epimacular Gliosis With Macular Hole|
62276672|NCT00774345|EXPERIMENTAL|Experimental: 1|Lenalidomide po qd on days 1-28 of a 28 day cycle
62276673|NCT00774345|PLACEBO_COMPARATOR|Placebo Comparator: 2|Placebo capsules given orally on days 1-28 of a 28 day cycle
62276674|NCT05099640|EXPERIMENTAL|Part 1: PTC923|Participants will receive PTC923 7.5 milligrams (mg)/kilogram (kg) (participants 0 to \<6 months of age), 15 mg/kg (participants 6 to \<12 months of age), 30 mg/kg (participants 12 months to \<2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for 14 days.
62641229|NCT06204497|ACTIVE_COMPARATOR|Ileostomy|There will be an ileostomy for the control group. An incision with a diameter of 2 cm will be performed in the lower abdomen, and layers will be separated into the abdominal cavity. The intestine, 20cm to the ileocecal juction under laparoscopic vision, will be pulled out. The anterior sheath of the rectus abdominis and the serous layer of the intestine will be sutured with an absorbable line. Then, the middle point of the mesangial margin of the intestine will be transected, and the intestine will be fixed on the skin. No volvulus or angular formation of the intestine should be confirmed laparoscopically.
62276675|NCT05099640|EXPERIMENTAL|Part 2: PTC923|Participants will receive PTC923 20 mg/kg daily for Weeks 1 and 2, then PTC923 40 mg/kg daily for Weeks 3 and 4, then PTC923 60 mg/kg daily for Weeks 5 and 6.
62276676|NCT05099640|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive equivalent quantities of placebo to match the 20 to 40 to 60 mg/kg dose escalation of the PTC923 treatment arm.
62641230|NCT02515630|EXPERIMENTAL|Momelotinib|MMB for 24 weeks (± 7 days)
62641231|NCT00032591|ACTIVE_COMPARATOR|Arm 1|Patient Self-Testing (PST) of prothrombin time by international normalized ratio (PT-INR or INR) with weekly testing
62641232|NCT00032591|OTHER|Arm 2|High quality anticoagulation management (HQACM) with conventional monthly testing
62641233|NCT05179304|EXPERIMENTAL|Oncoplastic technique with a droplet-shaped glandular flap|
62641234|NCT03205150|EXPERIMENTAL|LIK066 30 mg|Film coated tablet of LIK066 30 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
62072076|NCT05243576||incomplete SCI|"1) Be motor incomplete; 2) Be AIS classified as C or D; 3) have a neurological level of injury from C6 - T6; 4) Have LEMS score \> 10; 5) Have Modified Ashworth Scale ≤ 3 for spasticity.~Additional - 1) Be able to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions; 3) Have been diagnosed with a spinal cord injury by a physician."
62072077|NCT05243576||complete SCI|"1) Be chronic (≥ 1-year post injury); 2) AIS classified as A or B motor-complete;~Additional - 1) Be able to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions; 3) Have been diagnosed with a spinal cord injury by a physician."
62276677|NCT01537211|EXPERIMENTAL|Microprocessor knee then Mechanical knee|
62276678|NCT01537211|EXPERIMENTAL|Mechanical Knee then Microprocessor knee|
62276679|NCT04848961|EXPERIMENTAL|Women who have had a mammogram|Participants will consist of eligible women who have had a mammogram
62455153|NCT05701683|EXPERIMENTAL|ERADICATION of H-PYLORI INFECTION with ADDITION of LACTOBACILLUS REUTERI|In experimental group, patients receiving clarithromycin based sequential therapy with LACTOBACILLUS REUTERI
62276680|NCT05019001|OTHER|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
62276681|NCT05019001|OTHER|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
62276682|NCT02275338|EXPERIMENTAL|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
62276683|NCT02689830|EXPERIMENTAL|Bead Block microspheres|Prostate embolization
62455154|NCT05701683|NO_INTERVENTION|ERADICATION of H-PYLORI INFECTION without LACTOBACILLUS REUTERI|control group included patients who received clarithromycin based sequential therapy alone
62641235|NCT03205150|EXPERIMENTAL|LIK066 150 mg|Film coated tablet of LIK066 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
62072078|NCT05243576||Able-bodied|1) Be able and willing to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions.
62276684|NCT03004378|NO_INTERVENTION|Control|Participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
62276685|NCT03004378|EXPERIMENTAL|Intervention|Fitbit (activity tracker) + participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
62276686|NCT00323557|EXPERIMENTAL|Pneumococcal Vaccine + GM-CSF|Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7.
62276687|NCT00323557|EXPERIMENTAL|Pneumococcal Vaccine Alone|First vaccine dose subcutaneously, Day 0.
62641236|NCT03205150|EXPERIMENTAL|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
62641237|NCT04102618|EXPERIMENTAL|Cohort 1 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole
62641238|NCT04102618|EXPERIMENTAL|Cohort 2 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
62641239|NCT04102618|EXPERIMENTAL|Cohort 3 (closed to enrollment)|TNBC patients who will receive pelareorep plus atezolizumab
62641240|NCT04102618|EXPERIMENTAL|Cohort 4 (closed to enrollment)|HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
62641241|NCT04102618|EXPERIMENTAL|Cohort 5 (closed to enrollment)|HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
62641242|NCT04102618|EXPERIMENTAL|Cohort 6|HER2+ (irrespective of HR status) (6 patients) who will receive pelareorep + trastuzumab
62641243|NCT01586052|EXPERIMENTAL|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
62641244|NCT02511301|EXPERIMENTAL|Cyrcadia CBR™ Device|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.There are no interventions after the CBR™ is removed from the Study Subject
62072079|NCT03856996|EXPERIMENTAL|Group 1: Stable CH505TF gp120 + GLA-SE|Participants in Group 1 will receive 100 mcg of Stable CH505TF gp120 admixed with 10 mcg of GLA-SE by intramuscular (IM) injection at Months 0, 2, and 6.
62072080|NCT03856996|EXPERIMENTAL|Group 2: Transient CH505TF gp120 + GLA-SE|Participants in Group 2 will receive 100 mcg of Transient CH505TF gp120 admixed with 10 mcg of GLA-SE by IM injection at Months 0, 2, and 6.
62641245|NCT06425796|ACTIVE_COMPARATOR|Iron 25|Iron 25 (total 25 mg/d of iron): 2 supplements of 12.5 mg of elemental iron + 1 multivitamin supplement;
62072081|NCT04878419|EXPERIMENTAL|Virtual Educational Intervention|Virtual Educational Intervention
62641246|NCT06425796|ACTIVE_COMPARATOR|IRON 50|Iron 50 (total 50 mg/d of iron): 2 supplements of 25 mg of elemental iron + 1 multivitamin supplement).
62641247|NCT01838538|EXPERIMENTAL|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
62072082|NCT05064553||Ultrasound Surveillance Group|Subjects will undergo standard of care ultrasound surveillance imaging. Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up with CT or MRI as well as other procedures as needed. Subjects with negative ultrasound will be sent for a study CT/MRI.
62641248|NCT01838538|ACTIVE_COMPARATOR|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
62641249|NCT03981471|OTHER|Elderly without fall history|Elderly people in the community who have no fall history
62641250|NCT03981471|OTHER|Elderly with fall history|Elderly people in the community who have fall history
62641251|NCT02271113|EXPERIMENTAL|GMI-1271|IV GMI-1271
62641252|NCT02271113|PLACEBO_COMPARATOR|Placebo|IV Placebo
62641253|NCT02271113|ACTIVE_COMPARATOR|Enoxaparin Sodium (Lovenox®)|SC Lovenox®
62641254|NCT01939314|ACTIVE_COMPARATOR|Bupivacaine|Bupivicaine .03ml to each nare
62641255|NCT01939314|PLACEBO_COMPARATOR|Normal Saline|normal saline .03 ml to each nare
62641256|NCT01502085|EXPERIMENTAL|Vorinostat, Lenalinomide, Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~\* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
62072083|NCT05064553||CT/MRI Surveillance Group|Subjects will undergo standard of care CT/MRI surveillance imaging.
62072084|NCT05714995||hypnosis|patients in the hypnosis group will perform self-hypnosis sessions
62641257|NCT05619666|OTHER|Severity of COVID-19 infection|Based on the severity of Covid-19 infection patients were divided into 2 groups: First group (MMG) mild to moderate group and second group (SSG) stable severe group.
62641258|NCT02573714|EXPERIMENTAL|Intranasal Ketamine|Patients allocated to receive intranasal ketamine (intervention) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
62641259|NCT02573714|PLACEBO_COMPARATOR|Normal Saline|Patients allocated to receive intranasal normal saline (placebo) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
62641260|NCT02990403|EXPERIMENTAL|aspirin+LMWH group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
62072085|NCT05714995||hypnosis with aromatherapy|patients in the hypnosis with aromatherapy group will perform self-hypnosis sessions with inhalation of an essential oil
62072086|NCT03656731|EXPERIMENTAL|Intervention group (n=50)|Patients in the intervention group will receive standard care and a 12-week exercise-based intervention.
62072087|NCT03656731|NO_INTERVENTION|Control group (n=50)|Patient in the control group will receive standard care.
62072088|NCT03863197|EXPERIMENTAL|Intervention group|During a 12-week period children receive 3-4 sessions of progressive strength training per week on top of the usual care. All children will be provided with an individualized training program and supporting equipment. One or 2 session per week will be performed under supervision of the physical therapist, whilst the remaining sessions will be performed at home. Progression is closely monitored by the principal investigator and training programs are adjusted if necessary.
62072089|NCT03863197|NO_INTERVENTION|Waitlist-control group|The waitlist-control group will continue their usual care without additional treatment for 12-weeks, followed by a 12-week period of progressive supervised home-based strength training.
62072090|NCT01590771|EXPERIMENTAL|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
62072091|NCT01590771|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.
62072092|NCT05844761|EXPERIMENTAL|Triggered Imaging with TrueBeam for prostate cancer|Patients will undergo radiotherapy using the Triggered Imaging technique with TrueBeam for prostate cancer. The technology on the TrueBeam allows for monitoring and gating of the radiation beam in relation to the target position.
62641261|NCT02990403|EXPERIMENTAL|aspirin+LMWH+immunoglobulin group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
62641262|NCT02990403|EXPERIMENTAL|aspirin+LMWH+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
62641263|NCT02990403|EXPERIMENTAL|aspirin+LMWH+IVIG+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
62641264|NCT02990403|OTHER|dydrogesterone group|dydrogesterone 20-30mg/day, po, tid
62641265|NCT05720416|EXPERIMENTAL|muscle strength training and protein supplementation|
62072093|NCT05844761|EXPERIMENTAL|Synchrony with Radixact for prostate cancer|Patients will undergo radiotherapy using the Synchrony technique with Radixact for prostate cancer. Multi-Leaf Collimator Adaptation (MLC) and kilovoltage (kV) Intrafraction Monitoring with the Synchrony technique on the Radixact radiotherapy machine.
62276688|NCT02680379|EXPERIMENTAL|Minocycline, then Minocycline/Lovastatin|Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.
62641266|NCT05720416|PLACEBO_COMPARATOR|usual care|
62641267|NCT05720416|EXPERIMENTAL|muscle strength training|
62641268|NCT01926028|EXPERIMENTAL|NDV-3A|Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
62072094|NCT05844761|EXPERIMENTAL|Synchrony with Radixact for lung cancer|Patients will undergo radiotherapy using the Synchrony technique with Radixact for lung cancer. MLC Adaptation, Respiratory Motion Tracking, and kV Intrafraction Monitoring with the adaptive Synchrony technique on the Radixact radiotherapy machine.
62072095|NCT00572624|EXPERIMENTAL|Diet|Participants who received counseling and instruction about weight loss through diet and exercise
62072096|NCT00572624|EXPERIMENTAL|Gastric bypass surgery|Participants who received gastric bypass surgery
62276689|NCT02680379|EXPERIMENTAL|Lovastatin, then Minocycline/Lovastatin|Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months
62276690|NCT02170662|ACTIVE_COMPARATOR|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
62641269|NCT01926028|EXPERIMENTAL|NDV-3|Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
62072097|NCT04903834||COVID-19 - no hyperinflammation|Confirmed Sars-CoV-2 infection Hospitalised case
62072098|NCT04903834||COVID-19 - hyperinflammation|Sars-CoV-2 infection Hospitalised case
62072099|NCT02992522|EXPERIMENTAL|Treatment (lenalidomide, venetoclax, obinutuzumab)|Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62072100|NCT03355105|EXPERIMENTAL|Objective adjustment of the MI/E exsuflation pressure|Objective adjustment of the MI/E exsuflation pressure based on the flow-volume curve generated during the cough.
62455155|NCT04558554|EXPERIMENTAL|Study 1a: Pharmacy-based PrEP delivery Pilot (13 months)|Participants in this study will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) at 4 retail pharmacies in Kenya.
62455156|NCT04558554|EXPERIMENTAL|Study 1b: Pharmacy-based PrEP delivery Refill (12 months)|Participants in this study (happening concurrently with Study 1a) will have the option to refill PrEP at 4 retail pharmacies in Kenya after having initiated PrEP at one of 2 public clinics.
62641270|NCT01926028|PLACEBO_COMPARATOR|Placebo|Placebo: aluminum hydroxide adjuvant
62641271|NCT02653365||Non-invasive ventilation|All patients eligible for inclusion in the study were treated with Non-invasive ventilation.
62072101|NCT03355105|ACTIVE_COMPARATOR|Subjective adjustment of the MI/E exsuflation pressure|Subjective adjustment of the MI/E exsuflation pressure based on the clinical judgment of the therapist and the patient.
62276691|NCT02170662|ACTIVE_COMPARATOR|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
62276692|NCT01956812|EXPERIMENTAL|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
62276693|NCT01956812|ACTIVE_COMPARATOR|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
62276694|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
62455157|NCT04558554|EXPERIMENTAL|Study 1a: Pharmacy-based PrEP delivery Pilot Extension (6 months)|Participants in this study will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) or initiate PEP at 12 retail pharmacies in Kenya. Additionally, at a subset of 4 pharmacies, participants will have the option to undergo STI testing.
62641272|NCT02151357|EXPERIMENTAL|DCBCI0901|DCBCI0901 7.5mg/m2, iv infusion for day 1-day 5 and day 15-day 20
62276695|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
62276696|NCT01476787|EXPERIMENTAL|Lenalidomide + Rituximab|"* Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles.~* Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
62276697|NCT01476787|ACTIVE_COMPARATOR|Control|• ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
62455158|NCT03734185|EXPERIMENTAL|Learning and Coping|A health pedagogical strategy that builds on inductive teaching with high involvement of the participants. Characteristics of Learning and Coping are that 'experienced patients' plan, teach and evaluate, in cooperation with health professionals.
62072102|NCT00636792|EXPERIMENTAL|1|This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
62276698|NCT02665286|PLACEBO_COMPARATOR|Placebo|Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
62276699|NCT02665286|ACTIVE_COMPARATOR|Orphenadrine|Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
62276700|NCT02665286|ACTIVE_COMPARATOR|Methocarbamol|Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
62276701|NCT06318533|EXPERIMENTAL|anti-CD19 CAR NK cells|
62455159|NCT03734185|ACTIVE_COMPARATOR|Usual Cardiac Rehabilitation|The theoretical frameworks used in some of these local healthcare services are empowerment, self-efficacy and self-management
62641273|NCT06435975|EXPERIMENTAL|Experimental|Participants in this arm will be asked to complete a series of surveys, participate in telehealth-based interventions, and engage in moderate physical activity.
62641274|NCT02539992|ACTIVE_COMPARATOR|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
62276702|NCT03800875|EXPERIMENTAL|Insulin-Pramlintide Closed-Loop Strategy|Fast-acting insulin will be delivered using two separate infusion pumps. The pumps' infusion rates will then be changed manually based on the computer-generated recommendation. The computer-generated recommendations are based on a dosing algorithm. With no-meal announcement or carbohydrate counting, the dual-hormone closed-loop system will be fully reactive, and insulin and pramlintide dosages will be based solely on sensor readings
62276703|NCT03800875|ACTIVE_COMPARATOR|Insulin-alone Closed Loop Strategy|"Fast-acting insulin will be delivered by a subcutaneous insulin infusion pump based on an algorithm that automatically adjusts insulin rates based on a dosing algorithm. The carbohydrate content for every ingested meal will be entered into the algorithm to calculate the insulin prandial bolus based on each participant's insulin-to-carbohydrate ratio. The carbohydrate content will be entered at the onset of the meal.~Drug(s): Insulin (FiAsp)"
62641275|NCT02539992|ACTIVE_COMPARATOR|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
62641276|NCT02539992|ACTIVE_COMPARATOR|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
62455160|NCT02109822||CF patients with pulmonary exacerbations|Patients with CF who are hospitalized with a pulmonary exacerbation treated with intravenous antibiotics.
62455161|NCT01517256|EXPERIMENTAL|Early Intervention Group|
62455162|NCT01517256|PLACEBO_COMPARATOR|Delayed Intervention Group|Initially wait-listed and served as control group. But later participants underwent the experimental intervention.
62455163|NCT00717457|ACTIVE_COMPARATOR|exenatide|
62641277|NCT04000178|OTHER|group A|patients who received polyurethane stents
62455164|NCT00717457|EXPERIMENTAL|taspoglutide 10mg|
62641278|NCT04000178|EXPERIMENTAL|group B|patients who received silicone stents
62455165|NCT00717457|EXPERIMENTAL|taspoglutide 10mg/20mg|
62641279|NCT00072384|EXPERIMENTAL|Treatment (chemotherapy, surgery)|Patients receive liposomal vincristine sulfate IV over 1 minute on day 1 and carboplatin IV over 1 hour and etoposide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 3 and continuing until blood counts recover. Patients receive subtenon carboplatin to each group C or D eye on day 0 or 1prior of courses 2-4 only. Treatment repeats every 28 days for 6 courses in the absence of occurrence of extraocular retinoblastoma or a second malignancy. Beginning with course 3 of systemic chemotherapy, patients undergo local ophthalmic therapy comprising local laser surgery and/or cryosurgery on day 1.
62641280|NCT05689359|EXPERIMENTAL|Addition of Hydroxychloroquine to paclitaxel|Hydroxychloroquine will be added to chemotherapy in patients with early stage (1-3) breast cancer and gynecological cancers.
62641281|NCT05757414|EXPERIMENTAL|Tailored Lighting intervention (TLI)|"The TLI will be performed for 2 hours each day over a 4-week period.~During the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days"
62641282|NCT05646368|EXPERIMENTAL|Formulation #1 of a multivitamin/mineral supplement|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
62641283|NCT05646368|ACTIVE_COMPARATOR|Formulation #2 of a multivitamin/mineral supplement|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
62455166|NCT00476606||Long-term pediatric cohort|Long-term follow-up cohort since 2003
62455167|NCT00763022|EXPERIMENTAL|TAK-559 16 mg QD|
62455168|NCT00763022|EXPERIMENTAL|TAK-559 32mg QD|
62455169|NCT00763022|PLACEBO_COMPARATOR|Placebo QD|
62455170|NCT01997541||plain tube|
62455171|NCT01997541||reinforced tube|
62455172|NCT03552757|EXPERIMENTAL|Semaglutide 1.0 mg|Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
62455173|NCT03552757|EXPERIMENTAL|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
62641284|NCT04650074|ACTIVE_COMPARATOR|LIDOCAINE 20 mg|4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).
62641285|NCT04650074|EXPERIMENTAL|LIDOCAINE 20 mg + KETAMINE 20 mg|4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).
62641286|NCT04650074|EXPERIMENTAL|LIDOCAINE 20 mg + KETAMINE 40 mg|4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).
62641287|NCT03069872|EXPERIMENTAL|Intervention|All GPs in Central Denmark Region, are planned to be enrolled in the study during the one year study period.
62641288|NCT02664077|EXPERIMENTAL|Group 1: Regorafenib|Patients receive regorafenib orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
62455174|NCT03552757|PLACEBO_COMPARATOR|Semaglutide placebo I/II|Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
62455175|NCT03500484|EXPERIMENTAL|obese subjects|Subjects will self-administer Liraglutide once daily for 12 weeks.
62455176|NCT03500484|NO_INTERVENTION|lean subjects|no intervention
62455177|NCT02317237|NO_INTERVENTION|General Anesthesia|The patients, who will receive general anesthesia during intervention
62455178|NCT02317237|EXPERIMENTAL|Local Anesthesia|The patients, who will receive local anesthesia/conscious sedation during intervention
62455179|NCT01282151|EXPERIMENTAL|Taxotere|Docetaxel plus Cisplatin
62455180|NCT01282151|ACTIVE_COMPARATOR|Pemetrexed|Pemetrexed plus Cisplatin
62455181|NCT05765565|EXPERIMENTAL|Octaray (intervention)|Octaray created 3D map quality
62455182|NCT05765565|ACTIVE_COMPARATOR|Pentaray (control)|Pentaray created 3D map quality
62641289|NCT02664077|PLACEBO_COMPARATOR|Group 2: Placebo|Patients receive placebo orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
62641290|NCT02037672|ACTIVE_COMPARATOR|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
62641291|NCT02037672|ACTIVE_COMPARATOR|metformin and roflumilast|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time roflumilast was initiated at a dose of 500 mg BID per os.
62641292|NCT00471497|EXPERIMENTAL|nilotinib 300mg bid (investigating arm)|
62641293|NCT00471497|EXPERIMENTAL|Nilotinb 400 mg bid (investigating arm)|
62641294|NCT00471497|EXPERIMENTAL|imatinib 400mg QD (control arm)|
62641295|NCT04463134||Treatment group|They will start pharmacological treatment according to guidelines and sensitivity
62641296|NCT04463134||Observation group|They will not start pharmacological treatment. They will be monitored on symptoms, sputum conversion and radiological progression
62641297|NCT04873089||RV3278A arm|RV3278A study product is applied twice a day (morning and evening) on the face during the whole study.
62641298|NCT04873089||Control Group|Subjects included in the control group did not receive the test product or other associated product
62641299|NCT01116921|ACTIVE_COMPARATOR|nCPAP Control Group|Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
62641300|NCT01116921|EXPERIMENTAL|LMA Group|Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
62641301|NCT05812950|EXPERIMENTAL|Group Schema Therapy for eating disorders (GST)|"GST starts with 5 individual sessions for introducing the ST model, placing the ED symptoms and behaviors in the context of coping modes, and organizing these in a mode map conceptualization. Thereafter there are 26 weekly group sessions of ST for EDs, supplemented with 8 optional individual ST sessions, and a psycho-education webinar for relatives. The sessions focus on recognizing and changing personal coping modes and underlying early maladaptive schemas, and developing and strengthening the healthy adult mode. GST combines interpersonal, experiential, cognitive and behavioral elements in a unified ST approach (Farrell et al., 2014). Although not at the core of GST, addressing the physiological aspects of the ED (weight care and (restrictive) eating) is necessary and therefore also incorporated in the protocol.~Note that the participants in this condition have followed phase 1 and 2 of CBT-E before starting the GST, as following these phases is required to be included in the RCT."
62641302|NCT05812950|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy-Enhanced (CBT-E) (TAU)|This transdiagnostic ED treatment (current standard of care/treatment of choice) consists of 20-40 individual therapy sessions, based on the transdiagnostic CBT model of EDs. CBT-E consists of four phases. In phase one, the patient creates a personal case formulation, and the focus is on psycho-education on maintaining factors and at starting well with monitoring eating behaviours and establishing a regular eating pattern. In phase two, the first phase is evaluated and a treatment plan is made. In phase three, the main mechanisms that are thought to maintain the patient's ED (over-evaluation of shape, weight, and eating, dietary restraint or restriction, being underweight, and event- or mood-triggered changes in eating behaviour), are targeted, and a relapse plan is created. Phase four focuses on evaluating the progress so far and maintaining the changes that have been obtained (Fairburn et al., 2009).
62276704|NCT02095743|EXPERIMENTAL|PICC line|Use of a PICC line for chemo administration (PowerPICC SOLO²)
62072103|NCT02572843|EXPERIMENTAL|MEDI4736|Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.
62072104|NCT04432064|EXPERIMENTAL|Phase 3 Active TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation. Participants will receive stimulation for 60 minutes on one day.
62072105|NCT04432064|SHAM_COMPARATOR|Phase 3 Sham TI-NDBS|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds.
62072106|NCT04432064|ACTIVE_COMPARATOR|Phase 4 Traditional tDCS|Participants assigned to this condition will receive traditional transcranial direct current stimulation for 60 minutes for 5 days.
62276705|NCT02095743|ACTIVE_COMPARATOR|Implanted Port|Use of an implanted port for chemo administration
62641303|NCT05669118||Autotransplantation|Patients who receive one tooth autotransplanted.
62641304|NCT05669118||Immediate implant|Patients who receive one inmediate dental implant.
62641305|NCT01487083|EXPERIMENTAL|Pomaglumetad methionil|Pomaglumetad methionil will be administered orally. Participants entering the study will be flexibly dosed between 20 mg, 40 mg, and 80 mg twice daily.
62641306|NCT01690182|EXPERIMENTAL|Study test meal 1|High volume, high energy density test meal. Volunteers will be given 490 mL of a high energy test meal once in the morning
62072107|NCT04432064|EXPERIMENTAL|Phase 4 TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation for 60 minutes for 5 days and will be compared to sham stimulation and tDCS.
62072108|NCT04432064|SHAM_COMPARATOR|Phase 4 Sham stimulation|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds. Participants will be in the scanner for 60 minutes for 5 days. This will be used as the control condition and compared with TI-NDBS and tDCS.
62072109|NCT04744181||cases|patients who fulfill the inclusion criteria
62072110|NCT04744181||controls|Patients who underwent cardiac surgery in 2019 and 2018
62072111|NCT05247827|NO_INTERVENTION|Control Group|Participants will receive usual and customary post-amputation treatment
62072112|NCT05247827|EXPERIMENTAL|Exercise Group|Participants will be trained for 3 consecutive weeks to perform the targeted exercise of their phantom limb in addition to receiving usual and customary post-amputation treatment.
62276706|NCT03347071||Prevention Course Group|The Prevention Course Group is composed of female student-athletes enrolled in the 7-week prevention course. The course occurs once a week (1 hour, 40 minute sessions) for a total of 7-weeks during the academic semester. Approximately 1 hour of each class session is lecture based, leaving 40 minutes for yoga practice administered by a certified yoga instructor. The course instructor is certified in Eat Breathe Thrive Program delivery. The course teaching assistant is certified in yoga instruction.
62641307|NCT01690182|EXPERIMENTAL|Study test meal 2|High volume, low energy density test meal. Volunteers will be given 490 mL of a high volume low energy density test meal once in the morning
62641308|NCT01690182|EXPERIMENTAL|Study test meal 3|A low volume, high energy test meal. Volunteers will be given 140 mL high energy density test meal once in the morning.
62072113|NCT04764929|EXPERIMENTAL|Helmet CPAP|Patients in the Pediatric Intensive Care Unit (PICU) already receiving CPAP through a facemask or nasal prongs or mask for at least four hours but no more than 48 hours will be transitioned to the Vyatil nonpowered oxygen tent system (Rochester, NY) by trained respiratory therapists per the manufacture's instructions: patient's neck circumference will be measured with a soft tape measure to ensure appropriate sizing. The helmet will be connected to at least 30 liters per minute of high flow medical air with an oxygen blender. The expiratory limb will be attached to the positive end expiratory pressure (PEEP) valve (initially set at 5 centimeters of water pressure) connected to a high-efficiency particulate air (HEPA) filter to prevent any viral particles from being released into the environment. A disposable manometer will be used to measure the pressure within the helmet. Once the flow to the helmet interface is on, the helmet will be sealed and secured with the system's arm straps.
62072114|NCT01484795|EXPERIMENTAL|Continuous positive airway pressure|
62072115|NCT01484795|EXPERIMENTAL|BILEVEL|
62072116|NCT01015313|EXPERIMENTAL|intensive sodium management|
62072117|NCT01015313|NO_INTERVENTION|standard care|
62072118|NCT05063305|EXPERIMENTAL|Male Probiotic|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
62276707|NCT03347071||Control Group|The Control Group is composed of female student-athletes not enrolled in the 7-week prevention course. Female student-athletes in this group will not be enrolled in the course during the period of data collection, nor will they have previously completed the course.
62641309|NCT02923700|EXPERIMENTAL|Leukocyte-rich PRP group|Three weekly knee intra-articular injections of leukocyte-rich PRP
62641310|NCT02923700|EXPERIMENTAL|Leukocyte-poor PRP group|Three weekly knee intra-articular injections of leukocyte-poor PRP
62641311|NCT03937115|EXPERIMENTAL|Group S1|High level jump practice : more 4000 hours of practice during the last five years
62641312|NCT03937115|EXPERIMENTAL|Group S2|Amateur jump practice : less 4000 hours of practice during the last five years
62641313|NCT03937115|EXPERIMENTAL|Group C1|High level cycling practice: more 4000 hours of practice during the last five years
62276708|NCT00714792||1|Subjects with urge incontinence due to overactive bladder
62276709|NCT00714792||2|women with no urge symptoms
62276710|NCT01604005|EXPERIMENTAL|PIT Arm|
62276711|NCT01604005|NO_INTERVENTION|No PIT Arm|
62276712|NCT02868346|EXPERIMENTAL|Patients admitted for sexually transmitted infection|
62276713|NCT00671385||Women 21-50 years old|Women without a diagnosis of cancer or a history of cancer.
62641314|NCT03937115|EXPERIMENTAL|Group C2|Amateur cycling practice: less 4000 hours of practice during the last five years
62072119|NCT05063305|PLACEBO_COMPARATOR|Male Placebo|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
62276714|NCT01760161|ACTIVE_COMPARATOR|Ropivacain|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
62641315|NCT03937115|EXPERIMENTAL|Group T|Sedentary : less two hours of recreationally practice of sport by week
62276715|NCT01760161|PLACEBO_COMPARATOR|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
62276716|NCT00946855||soccer players|players of the first two German soccer leagues
62276717|NCT04493801||with nasoseptal flap|patient who undergo a pituitary gland surgery with nasoseptal flap
62276718|NCT04493801||without nasoseptal flap|patient who undergo a pituitary gland surgery without nasoseptal flap
62641316|NCT02411240|OTHER|Air filtering in the living room|GENANO tubes, GENANO Benelux; Heusen-Zolder, Belgium
62641317|NCT00995839|EXPERIMENTAL|continuous terlipressin|
62641318|NCT00995839|EXPERIMENTAL|vasopressin|
62641319|NCT00995839|EXPERIMENTAL|terlipressin bolus dose|
62641320|NCT02390154|EXPERIMENTAL|Arm 1|Open label non-randomized non-controlled mass balance study in Cycle 1
62641321|NCT02390154|EXPERIMENTAL|Arm 2|Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles
62641322|NCT02728063|EXPERIMENTAL|Single arm|Supplementation with Lactibiane Tolerance
62641323|NCT06459713||Multiplex respiratory PCR test results of the groups|This single center retrospective observational study was conducted in Hisar Hospital Intercontinental between September 2021 and June 2023
62072120|NCT05063305|EXPERIMENTAL|Female Probiotic|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
62641324|NCT06459713||we evaluated the importance of respiratory PCR in CAP|Subjects who had an infection other than pneumonia, and had a diagnosis of malignancy, transferred to intensive care unit and pregnant women were excluded.
62641325|NCT00831220||1|Patients with a COPD exacerbation
62641326|NCT00831220||2|Patients with stable COPD
62641327|NCT00831220||3|Smokers or former smokers
62641328|NCT00831220||4|Never smokers
62641329|NCT03511768|EXPERIMENTAL|18F-AlF-NOTA-octreotide PET/CT|One injection of the radioligand 18F-AlF-NOTA-octreotide
62641330|NCT02938702||Active surveillance|Group with active surveillance of their PTC
62641331|NCT02938702||Surgery|Group who underwent surgery after diagnosis of PTC
62641332|NCT01046864|EXPERIMENTAL|Arm 1|
62641333|NCT01046864|EXPERIMENTAL|Arm 2|
62641334|NCT01046864|EXPERIMENTAL|Arm 3|Japanese Population
62641335|NCT05385146|EXPERIMENTAL|qigong group|The qigong group received Chan-Chuang qigong therapy with breathing meditation for 15 weeks.Qigong training program consisted of a warm-up, Chan-Chuang qigong, and breathing meditation. The whole process takes about 20 minutes.The qigong was monitored in terms of muscle elasticity and heart rate variability. After practicing the Chan-Chuang qigong, meditation with breathing was conducted for 10 minutes. In the meanwhile, sit down while relaxing with slow breathing and focus on the present feelings, with brain wave (NeuroSky's, Australia) to monitor and confirm that the eSense (attention and relaxation).
62072121|NCT05063305|PLACEBO_COMPARATOR|Female Placebo|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
62072122|NCT04161807|EXPERIMENTAL|Nerivio device treatment|participant will receive the Nerivio device for treating their migraine attacks. Treatment will be perform as soon as the participant feel that the migraine attack started
62276719|NCT03535623|EXPERIMENTAL|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
62641336|NCT05385146|NO_INTERVENTION|control group|those in the control group received usual care during the same study period.
62641337|NCT03598400|NO_INTERVENTION|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
62072123|NCT01639794||Male patients with non-neurogenic LUTS taking VESITRIM|Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
62641338|NCT03598400|ACTIVE_COMPARATOR|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
62072124|NCT05438225|EXPERIMENTAL|Automated Text Message Reminder|Participants will receive automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
62455183|NCT04057053|EXPERIMENTAL|Netarsudil use|Patient eye undergoes cataract surgery + DWEK, immediately after surgery Netarsudil 0.02% ophthalmic 1 drop daily is used in the operative eye until corneal clearance is documented.
62641339|NCT03598400|EXPERIMENTAL|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
62641340|NCT00729521|NO_INTERVENTION|Control|a control group receiving no special resources or guidance related to fall injury prevention or the community health improvement process;
62641341|NCT00729521|ACTIVE_COMPARATOR|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
62641342|NCT00729521|EXPERIMENTAL|Facilitative System|"a Facilitative System group receiving facilitative system support in addition to the resources provided the Standard Program group"
62072125|NCT05438225|NO_INTERVENTION|Control Group|
62072126|NCT02172456|EXPERIMENTAL|Tiotropium|
62455184|NCT04057053|ACTIVE_COMPARATOR|Standard of care + possible rescue drop|Patient eye undergoes cataract surgery + DWEK, no Netarsudil is used after surgery, if cornea is not cleared in time for first eye Netarsudil 0.02% ophthalmic 1 drop dailyadded daily as possible rescue drop and time to corneal clearance is documented
62455185|NCT03913000|EXPERIMENTAL|ID-085 single dose|Administration of the study treatment 200 mg to renally impaired subjects will be done by severity, starting with group A (mild), and followed by group B (moderate), C (severe) and D (healthy subjects).
62455186|NCT04449484|EXPERIMENTAL|MEDI1341|3 doses given at 4 week intervals
62641343|NCT01285661|EXPERIMENTAL|Proximal DVT|Patients whose veins have recanalized (either at the recruitment or later on during the follow-up) will receive the D-dimer determination before discontinuing sodium warfarin. Veins are defined as recanalized when the vein diameter under maximum compressibility is lower than 4 mm both at the common femoral and at the popliteal vein. In those with negative D-dimer sodium warfarin will be discontinued. These patients will have two further determinations of D-dimer (after 1 and 3 months, respectively). While patients with persistently negative D-dimer will no longer receive sodium warfarin, those in whom D-dimer is positive or reverts to positive values in the following determinations will have their sodium warfarin resumed and no longer discontinued.
62641344|NCT04331288|EXPERIMENTAL|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.
62641345|NCT02178904||Suspected Coronary Artery Disease|Subjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test
62641346|NCT05020041|EXPERIMENTAL|Intervention|"The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers, or manipulation of objects to maintain COVID-19 sanitary and safety protocols.~The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers."
62641347|NCT05020041|NO_INTERVENTION|Control|The schools participating in the control group will receive an online educational talk aimed at promoting healthy habits and the benefits of physical activity inside and outside the school environment.
62641348|NCT05762367|EXPERIMENTAL|Patients with IIH|Female patients with IIH between 20 and 40 years old
62072127|NCT05672303|NO_INTERVENTION|Control|Routine procedure will be applied
62641349|NCT05762367|ACTIVE_COMPARATOR|Healthy volunteers|Female healthy volunteers between 20 and 40 years old
62072128|NCT05672303|EXPERIMENTAL|Experimental|Palmar grasp reflex will be stimulated with routine procedure.
62072129|NCT05075343|EXPERIMENTAL|Custom foot orthoses (CFO)|Participants with a confirmed diagnosis of PsA and foot pain received and wore custom foot orthoses (CFO).
62072130|NCT02768415|EXPERIMENTAL|lapatinib+oral vinorelbine|"apatinib 425/500mg qd, 21days/cycle~oral vinorelbine 60mg/m2 d1, 8, 15 21days/cycle\*3cycles, after 3 cycles: 80mg/m2 d1, 8, 15 21days/cycle"
62072131|NCT01127217|EXPERIMENTAL|amlodipine/losartan|
62072132|NCT01127217|ACTIVE_COMPARATOR|amlodipine|
62072133|NCT05246072|ACTIVE_COMPARATOR|Ivermectin + colchicine + standard care|"In addition to the local standard of care for COVID 19 patients, the patient will receive:~Ivermectin + Colchicine"
62072134|NCT05246072|ACTIVE_COMPARATOR|Colchicine + standard care|"In addition to the local standard of care for COVID 19 patients, the patient will receive:~Colchicine"
62072135|NCT05246072|NO_INTERVENTION|standard care|Patients will receive Standard care
62072136|NCT01405755|EXPERIMENTAL|National Vaccine Program Plus Radio|Appropriate complementary feeding messages delivered using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio.
62641350|NCT05029908||TMD disorders|"75 patients with temporomandibular disorder (TMD) who will apply to the outpatient clinic of Istanbul Physical Therapy and Rehabilitation Training and Research Hospital will be included in our study. Ethics Committee approval was obtained from Bakırköy Sadi Konuk Training and Research Hospital before starting the study and a voluntary consent form will be signed by the patients before the evaluation.~In this cross-sectional study; 75 participants aged 18-65 years who has temporomandibular joint (TMJ) complaints for more than 3 months and has the cognitive ability to understand test instructions will be included. Patients with a history of previous TMJ operation, muscle, neurological or rheumatic disease that may affect TMJ, and a history of facial/cervical trauma or neoplasia will excluded from the study."
62641351|NCT05105074|ACTIVE_COMPARATOR|Intrathecal Morphine|One group will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and fentanyl 15 mcg for spinal anesthesia.
62641352|NCT05105074|PLACEBO_COMPARATOR|Placebo|One group will receive normal saline 100 mcg in addition to the standard dose of bupivacaine and fentanyl 15 mcg for spinal anesthesia
62641353|NCT03393182|EXPERIMENTAL|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
62641354|NCT03393182|EXPERIMENTAL|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
62276720|NCT03535623|SHAM_COMPARATOR|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
62276721|NCT01707693|EXPERIMENTAL|Lifestyle Physical Activity Intervention|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer \& LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
62276722|NCT01707693|ACTIVE_COMPARATOR|Information/Attention Comparison|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer \& LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
62276723|NCT03484468||femtosecond_laser|participants had there lasik corneal flap creation using femtosecond laser
62276724|NCT03484468||moria_microkeratome|participants had there lasik corneal flap creation using moria microkeratome
62276725|NCT00121212|ACTIVE_COMPARATOR|Surgery - Negative PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
62455187|NCT04449484|PLACEBO_COMPARATOR|Placebo|3 doses given at 4 week intervals
62072137|NCT01405755|NO_INTERVENTION|Comparison (no intervention)|No complementary feeding messages delivered.
62072138|NCT01574430|ACTIVE_COMPARATOR|50% dose PDT|patients in this group was given 50% verteporfin dose PDT
62455188|NCT01634906|EXPERIMENTAL|Discontinuation of statin therapy|
62455189|NCT05588856||Patients with Chronic Lung Disease|
62641355|NCT01870713||type 2 diabetes patients with gastric bypass surgery.|Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
62641356|NCT01870713||Weight matched non-operated controls|Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
62641357|NCT01088971|ACTIVE_COMPARATOR|Duolac 7S|
62641358|NCT01088971|PLACEBO_COMPARATOR|starch capsule|
62072139|NCT01574430|EXPERIMENTAL|30% dose PDT|patients in this group was given 30% verteporfin dose PDT
62072140|NCT05240274|ACTIVE_COMPARATOR|Metformin|metformin 500mg OD
62072141|NCT05240274|PLACEBO_COMPARATOR|Placebo|placebo 500mg OD
62072142|NCT01424436|EXPERIMENTAL|GSK933776 1mg/kg|single dose
62072143|NCT01424436|EXPERIMENTAL|GSK933776 0.1 or 3mg/kg|single dose
62072144|NCT01424436|EXPERIMENTAL|GSK933776 3 or 6mg/kg|single dose
62072145|NCT05053217|ACTIVE_COMPARATOR|Patients diagnosed with fibromyalgia|
62072146|NCT05053217|ACTIVE_COMPARATOR|Patients without a diagnosis of fibromyalgia|
62072147|NCT00566358|EXPERIMENTAL|1|Duodenal exclusion
62072148|NCT01026714|EXPERIMENTAL|flurbiprofen 50mg po|
62641359|NCT01885013|EXPERIMENTAL|Metformin + Myocet + Cyclophosphamide|"arm A : Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
62072149|NCT01026714|EXPERIMENTAL|flurbiprofen 50 mg po + CYP2C9 inducer|
62072150|NCT01026714|EXPERIMENTAL|flurbiprofen 50 mg po + CYP2C9 inhibitor|
62276726|NCT00121212|EXPERIMENTAL|Surgery - Positive PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
62641360|NCT01885013|ACTIVE_COMPARATOR|Myocet + Cyclophosphamide|arm B : Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days
62641361|NCT04710212||Induction Chemotherapy for Acute Leukemia|Receiving induction chemotherapy for acute leukemia, and receiving fluoroquinolone (FQ) prophylaxis.
62641362|NCT04710212||Hematopoietic stem cell transplantation (HCT)|Undergoing hematopoietic stem cell transplantation (HCT), and receiving fluoroquinolone (FQ) prophylaxis.
62641363|NCT06005363|EXPERIMENTAL|BIS group|Use BIS monitoring to adjust intraoperative anesthetics.
62072151|NCT01995019|PLACEBO_COMPARATOR|Physiologic saline|Sodium chloride 9 mg/ml liquid for parental use
62072152|NCT01995019|EXPERIMENTAL|Methylprednisolone|Depo-Medrol 40 mg/ml, single dose, injection, intra-articular
62072153|NCT05319561|EXPERIMENTAL|VAST+|Sites that implement the VAST augmented by quarterly facility-level Antibiotic Use Reports (VAST+).
62276727|NCT00121212|ACTIVE_COMPARATOR|Radiation therapy Negative or Positive PET scan|If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
62276728|NCT01948843|EXPERIMENTAL|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
62641364|NCT06005363|EXPERIMENTAL|DEX group|use BIS monitoring to adjust anesthetics and give dexmedetomidine infusion.
62641365|NCT06005363|NO_INTERVENTION|Usual group|usual care with 1 MAC sevoflurane maintainance.
62641366|NCT03388424||Control|Healthy people of both sex
62641367|NCT03388424||quantification of microbiota in Brain|Patients of both sex with neural disorders and diseases
62641368|NCT03388424||quantification of microbiota in GI|Patients of both sex with gastrointestinal diseases
62641369|NCT03388424||quantification of microbiota in Lung|Patients of both sex with Respiratory diseases
62641370|NCT03388424||quantification of microbiota Metabolic|Patients of both sex with Metabolic Diseases
62641371|NCT03388424||quantification of microbiota in UG|Patients of both sex with Uro-genital Diseases
62641372|NCT03323593|ACTIVE_COMPARATOR|iv|
62276729|NCT05572034|SHAM_COMPARATOR|Group A|A diagnostic electrophysiological study will be performed in patients of group A
62276730|NCT05572034|ACTIVE_COMPARATOR|Group B|A electrophysiological study with cardiac denervation, with right Ganglionated Plexi ablation exclusively will be performed in patients of group B
62072154|NCT05319561|NO_INTERVENTION|VAST -|to sites that implement the VAST and do NOT receive a quarterly facility-level Antibiotic Use Reports (VAST-).
62276731|NCT05572034|ACTIVE_COMPARATOR|Group C|A electrophysiological study with cardiac denervation, with right and left Ganglionated Plexi ablation will be performed in patients of group C.
62455190|NCT05588856||Healthcare professionals|
62641373|NCT03323593|ACTIVE_COMPARATOR|drip|
62641374|NCT03323593|ACTIVE_COMPARATOR|atomizer|
62641375|NCT05976789|EXPERIMENTAL|HAT-Online Counseling|In Aim 1, the investigators will provide remote counseling for four weeks to 60 participants and compare results to baseline. All participants will be in a wait list control for four weeks before the counseling begins.
62641376|NCT05976789|EXPERIMENTAL|Sound therapy|In Aim 2, the investigators will randomize the 60 participants to receive intervention using one of the two sound therapy approaches. Group 1: Listening to bothersome sounds or Group 2: Listening to low-level background noise.
62641377|NCT03451981|SHAM_COMPARATOR|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine.
62641378|NCT03451981|EXPERIMENTAL|Er:YAG laser|Er:YAG laser treatment will be provided on the implant surface.
62641379|NCT03451981|ACTIVE_COMPARATOR|Air Powder|an Air-Powder treatment will be provided on the implant surface.
62641380|NCT04378335|EXPERIMENTAL|one arm|oral disorder
62276732|NCT06448208||People With Neuroendocrine Tumors having a PET/CT or MRI|This is a non-interventional observational study of imaging.
62641381|NCT03003910|EXPERIMENTAL|Best Possible Self|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
62641382|NCT03003910|PLACEBO_COMPARATOR|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts occurred in the past 24 hours.
62276733|NCT04989582|EXPERIMENTAL|Nursing intervention|Nurses randomly assigned by applying a random selection method
62276734|NCT04989582|NO_INTERVENTION|No intervention|Nurses randomly assigned by applying a random selection method
62276735|NCT01070160||A|Women with PCOS initiating Metformin and exposure to vaginal progesterone for 6-8 days prior ro Endometrium Biopsy
62276736|NCT01070160||B|Women with PCOS not planning initiating Metformin and exposure to vaginal progesterone for 6-8 days prior to Endometrium Biopsy
62276737|NCT01070160||Women with PCOS who previously initiated metformin|Women with PCOS who initiated metformin at least 3 months prior to enrollment who have completed a 6-10 day course of progesterone
62276738|NCT02652897||Exposure to glioma resection surgery|Patients undergoing elective glioma resection
62276739|NCT02652897||Exposure to colon resection surgery|Patients undergoing elective colon cancer resection
62276740|NCT05718986||Bnai Zion Medical Center|Bnai Zion Medical Center
62641383|NCT01207947||Group 1|
62641384|NCT01662544|EXPERIMENTAL|HHFNC|Heated High Flow arm
62641385|NCT01662544|ACTIVE_COMPARATOR|Standard Nasal Cannula|Standard treatment
62641386|NCT04020367|OTHER|patients with biopsy|
62641387|NCT00036764|EXPERIMENTAL|Treatment|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62641388|NCT03363971|EXPERIMENTAL|Experimental group|Zhi Kang Capsule, 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery,treatment for 6 weeks.
62276741|NCT05718986||Tel Aviv Sourasky Medical Center - Ichilov Hospital|Tel Aviv Sourasky Medical Center - Ichilov Hospital
62276742|NCT05718986||Galil Medical Center|Galil Medical Center
62276743|NCT05718986||Ziv Medical Center|Ziv Medical Center
62276744|NCT05718986||Emek Medical Center|Emek Medical Center
62276745|NCT05718986||Beilinson Hospital|Beilinson Hospital
62276746|NCT05718986||Meir Medical Center|Meir Medical Center
62276747|NCT05718986||Kaplan Medical Center|Kaplan Medical Center
62276748|NCT05718986||Sheba Medical Center|Sheba Medical Center
62276749|NCT05718986||Rambam Medical Center|Rambam Medical Center
62276750|NCT05718986||Shaare Zdek Medical Center|Shaare Zdek Medical Center
62276751|NCT05718986||Hadassah Medical Center|Hadassah Medical Center
62276752|NCT05718986||Shamir Medical Center (Assaf Harofeh)|Shamir Medical Center (Assaf Harofeh)
62276753|NCT05718986||Soroka Medical Center|Soroka Medical Center
62072155|NCT04981522|EXPERIMENTAL|Active Treatment (AT): PM+ intervention|Active Treatment (AT) group will receive 05 sessions of indigenously adapted problem management plus (IA-PM+) intervention.
62276754|NCT05718986||Assuta Ashdod Hospital|Assuta Ashdod Hospital
62276755|NCT04786600|EXPERIMENTAL|ctDNA assay-guided intervention|Subjects on this arm will be tested with the Signatera ctDNA assay while receiving treatment on a pre-specified sequence of FDA-approved drugs and drug combinations. Subjects will move through this sequence based on the results of the ctDNA assay. Subjects will move to a new drug or drug combination in the sequence when the ctDNA assay indicates a significant increase in ctDNA level. Subjects will also have imaging scans every 12 weeks while on each drug or drug combination and subjects will move to a new drug or drug combination if these scans indicate disease progression.
62641389|NCT03363971|PLACEBO_COMPARATOR|Control group|Simulant agent for Zhi Kang Capsule,consistent with the appearance, color, odor, and usage of the Zhi Kang capsule, so that it can not be distinguished.oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery, treatment for 6 weeks.
62641390|NCT04071379|EXPERIMENTAL|HepB + Penta batch 1|Recombinant Hepatitis B + DTP-HB-Hib batch 1
62455191|NCT05328713||Prospective group with perinatally acquired HIV infection from Duke University Health System clinics|
62641391|NCT04071379|ACTIVE_COMPARATOR|Hep B + Pentabio (registered)|Recombinant Hepatitis B + Pentabio (registered)
62072156|NCT04981522|NO_INTERVENTION|Delayed Treatment Control (DTC): Treatment as usual|Delayed Treatment Control (DTC) group will receive routine treatment until the last follow-up.
62072157|NCT01410825|EXPERIMENTAL|Gene transfer|Open label single arm study
62072158|NCT01805882|EXPERIMENTAL|A: HCV GT-1, tx naïve, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment naïve patients
62276756|NCT04786600|ACTIVE_COMPARATOR|Scan-guided Intervention|Subjects on this arm will be treated with the same pre-specified sequence of FDA-approved drugs and drug combinations as those on the ctDNA assay- guided intervention arm. Subjects will move through the sequence based on the results of imaging scans, moving to a new drug or drug combination if imaging shows progressive disease.
62455192|NCT05328713||Control retrospective group|A retrospective age- and sex-matched HIV-uninfected comparator group from Duke University Health System (DUHS) electronic health record (EHR) and imaging database systems
62455193|NCT00442910|ACTIVE_COMPARATOR|3% SPL7013|Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
62455194|NCT00442910|PLACEBO_COMPARATOR|Placebo for SPL7013 Gel|Intravaginal application of 3.5 g placebo gel twice daily for 14 days
62641392|NCT01241279|EXPERIMENTAL|Crystalens AO|A silicone multi-piece accommodating intraocular lens
62641393|NCT01241279|ACTIVE_COMPARATOR|SoftPort LI61AO|A silicone multi-piece foldable aspheric intraocular lens
62641394|NCT02359461|EXPERIMENTAL|Stendo group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
62072159|NCT01805882|EXPERIMENTAL|B: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9669|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
62641395|NCT02359461|OTHER|control group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
62276757|NCT01532531|EXPERIMENTAL|Collateral Meridian Therapy|"The CMT group patients received, according to the CMT protocol described previously, CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
62276758|NCT01532531|NO_INTERVENTION|Control (CT) group|Patients in the CT group received electronic lead-patches applied on the treatment points, which was identical to what the CMT patients received, also for 6 minutes, though no electric stimulation was applied.
62641396|NCT04283786||General Practitioner|General Practitioners working within primary care in the UK
62641397|NCT04283786||Primary Care Patients|Patients cared for in primary care who started on oral bisphosphonates within the last 24 months for prevention of fragility fractures
62641398|NCT04283786||Secondary Care Clinicians|Clinicians working in secondary care as specialists (e.g. nurses, consultants) involved in the treatment of osteoporosis
62641399|NCT04283786||Secondary Care Patients|Patients cared for in secondary care receiving hospital based (intravenous) bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months
62641400|NCT04283786||Clinical Academics|Clinical academics involved in osteoporosis research
62641401|NCT04283786||Secondary Care Clinicians - Novel Care|Clinicians working in secondary care as specialists (e.g. nurses, consultants) from the osteoporosis service in Nottingham and Sheffield with insight into alternate bisphosphonate treatments
62072160|NCT01805882|EXPERIMENTAL|C: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9451 80mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
62641402|NCT04283786||Secondary Care Patients - Novel Care|Patients cared for in secondary care receiving alternative bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months at the osteoporosis service in Nottingham or Sheffield
62641403|NCT04283786||Commissioners|Commissioners involved in osteoporosis services
62276759|NCT05562154|ACTIVE_COMPARATOR|Lateral Approach|
62641404|NCT01883895|OTHER|exercise treatment|"Concentric exercise: subject will utilize a dumbbell with elbow flexion exercise.~Isometric exercise: Subjects will perform 5 sets of sustained muscle contraction.~Control: Subjects will undergo a control arm where they will rest for approximately 10 minutes.~Pain testing conducted by Forgionei-Barber pressure pain-stimulator for both the control and exercise treatments."
62641405|NCT00838071|EXPERIMENTAL|IGIV-HB Grifols|
62641406|NCT04601727||Rectal cancer patients|
62641407|NCT04100616||Obsese individuals|Patients with a BMI greater than or equal to 30
62641408|NCT01095835|EXPERIMENTAL|PEG-IFN48|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
62641409|NCT01095835|EXPERIMENTAL|PEG-IFN96|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
62641410|NCT01095835|EXPERIMENTAL|PEG-IFN+LAM96|Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).
62641411|NCT01051921|EXPERIMENTAL|CTS-1027, Peg IFN, Ribavirin|"Study drug (CTS-1027) plus Standard of Care treatment (pegylated interferon and ribavirin).~CTS-1027, 15 mg taken twice daily. Pegylated interferon, 180 μg injected once a week. Ribavirin, 1000 mg or 1200 mg daily (depending on patient weight), taken in two divided doses."
62641412|NCT06363643|EXPERIMENTAL|ELECTROSTIMULATION (ESM)|ESM will perform the Tele Prehab program based on indirect electrostimulation.
62641413|NCT06363643|ACTIVE_COMPARATOR|EXERCISE (C)|Group C will perform the Tele Prehab program based on supervised exercise.
62276760|NCT05562154|ACTIVE_COMPARATOR|Anterior Approach|
62276761|NCT03285243|SHAM_COMPARATOR|Blue light - non monochromatic|
62276762|NCT03285243|EXPERIMENTAL|Monochromatic blue light|
62641414|NCT03671070|ACTIVE_COMPARATOR|Low dose Epinephrine boluses|Patients suffering from acute hypo-tension will receive low dose IV epinephrine boluses ≤ 5 μg/kg/dose, 3 doses, within 3 hours
62641415|NCT03671070|PLACEBO_COMPARATOR|Traditional management of shock|Patients suffering from acute hypo-tension will be managed according to Traditional algorithm of Hypotension
62072161|NCT01805882|EXPERIMENTAL|D: HCV GT-1, tx-relapsed, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment-relapsed patients who previously received Sofosbuvir plus Ribavirin
62641416|NCT00735007|EXPERIMENTAL|1|
62072162|NCT01805882|EXPERIMENTAL|E: HCV GT-4, tx naïve/expd, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 4 treatment naïve subjects and interferon treament experienced subjects
62276763|NCT02346760|EXPERIMENTAL|UB-621|Intervention drug: UB-621
62276764|NCT06175858|OTHER|Population with echocardiographic or clinical red flags for cardiac amyloidosis|The study aims at including all population with the previously described red flags
62276765|NCT02930993|EXPERIMENTAL|anti-mesothelin CAR T cells|"Dose escalation study aimed to assess the safety and efficacy of anti-mesothelin CAR T cells.~CAR T dosage ranging from 5×10\^4 /kg to 1×10\^7 /kg will be tested ."
62072163|NCT01805882|EXPERIMENTAL|F: HCV GT-1, tx naïve/expd 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) and GS-9451 80mg, once daily, 6 weeks in HCV genotype 1 treatment naïve and treatment experienced subjects with advanced liver disease
62276766|NCT02187952|EXPERIMENTAL|Behavioral feeding intervention|Behavioral feeding intervention will be conducted as usual. The intervention will not be altered for purposes of the study.
62276767|NCT02187952|NO_INTERVENTION|Waitlist control|
62276768|NCT03767322|ACTIVE_COMPARATOR|Allopurinol group|The intervention group will receive 300 mg of allopurinol 12 hours before and 12 hours after the coronary intervention.
62276769|NCT03767322|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive 300 mg of placebo 12 hours before and 12 hours after the coronary intervention.
62276770|NCT03767322|ACTIVE_COMPARATOR|Febuxostat group|The intervention group will receive 80 mg of febuxostat 12 hours before and 12 hours after the coronary intervention
62276771|NCT01549769|EXPERIMENTAL|Bardoxolone Methyl 20 mg|
62276772|NCT02094144|OTHER|exercise group (brisk walking program)|The intervention is named brisk walking program. It consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
62276773|NCT02094144|OTHER|control group (physical activity habits)|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
62276774|NCT02635971|EXPERIMENTAL|TAI chemotherapy|Patients in this arm will receive transcatheter arterial infusion of chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
62641417|NCT01304797|EXPERIMENTAL|MM-302|
62641418|NCT01304797|EXPERIMENTAL|MM-302 in Combination with Trastuzumab|
62641419|NCT01304797|EXPERIMENTAL|MM-302 in Combination with Trastuzumab q3w|
23173378|NCT06578130||StypCel™ Neurosurgery Patients|This cohort includes patients undergoing neurosurgery where the StypCel™ Absorbable Hemostat is used to achieve hemostasis. The study will observe and document the effectiveness of the device in controlling bleeding during the surgery and track any subsequent complications, including infections and other adverse events, over a 6-month follow-up period.
62641420|NCT01304797|EXPERIMENTAL|MM-302 in Combination with Trastuzumab and Cyclophosphamide|
62641421|NCT01341496|EXPERIMENTAL|1|autologous tumor vaccine plus chemotherapy
62641422|NCT04064112|EXPERIMENTAL|S-BLR|For S-BLR, the lower horn of the LR is recessed based on near exodeviation and the upper horn is recessed based on distant exodeviation.
62641423|NCT04064112|ACTIVE_COMPARATOR|C-BLR|For C-BLR, the LR is recessed based on distant exodeviation.
62641424|NCT03786380|EXPERIMENTAL|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to approximately 22 months.
62641425|NCT02208544|EXPERIMENTAL|FDG-PET/CT-driven|"Following treatment based on FDG-PET/CT:~* negative: watchful waiting including confirmatory ultrasound~* positive: diagnostic thyroid surgery as planned"
62641426|NCT02208544|OTHER|Current Practice|diagnostic thyroid surgery despite results of FDG-PET/CT
62072164|NCT01805882|EXPERIMENTAL|G: HCV GT-1, tx naïve, 4 wks Sofosbuvir, Ledipasvir, GS-9451|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
62072165|NCT01805882|EXPERIMENTAL|H: HCV GT-1, tx naïve, 4 wks Sofos/Ledip/GS-9451/GS-9669|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, and GS-9669 250mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
62072166|NCT01805882|EXPERIMENTAL|D Retx: HCV GT-1, Re-Treatment, 12 wks Sofosbuvir, Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 1 subjects who failed HCV therapy in Arm B or Arm G or Arm H
62072167|NCT02452866|EXPERIMENTAL|SYM-1219|All pateints recieved single dose SYM-1219 Containing 2 Grams of Secnidazole
62072168|NCT02222519||Statin use group|patients taking statins for at least 3 months
62072169|NCT02222519||non statin use|no history of taking statin
62072170|NCT06019013|EXPERIMENTAL|Dose-Escalation Stage and PK-Expansion Stage|"Dose-Escalation Stage：Participants will be assigned sequentially to escalating doses of QLF3108, up to the maximum tolerated dose (MTD).~PK-Expansion Stage：1-4 recommended expansion dose will be proposed for the PK-expansion stage of the trial."
62072171|NCT03324399|EXPERIMENTAL|High Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
62276775|NCT02635971|ACTIVE_COMPARATOR|Chemotherapy|Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
62276776|NCT05964283||Anesthesia Specialists|
62276777|NCT05964283||Anesthesiologist residencies|
62276778|NCT06281483|ACTIVE_COMPARATOR|PRP / Group A|12 patient
62072172|NCT03324399|EXPERIMENTAL|Low Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
62072173|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
62072174|NCT01717183|EXPERIMENTAL|URGO 310 3113 dressing - new|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
62276779|NCT06281483|ACTIVE_COMPARATOR|PRF / Group B|12 patient
62276780|NCT06281483|ACTIVE_COMPARATOR|Group C (the control group)|12 patient
62072175|NCT01717183|PLACEBO_COMPARATOR|URGO 310 3113 dressing|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
62088404|NCT02887950|EXPERIMENTAL|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
62088405|NCT05651880|EXPERIMENTAL|Patient treated with baricitinib|Patient treated with baricitinib at a dose of 4 mg per day, taken orally in the morning, with one tablet per day for 6 months.
62088406|NCT02945774|EXPERIMENTAL|(18F)-FEPPA|
62088407|NCT03433092||Jing Huang et. al, 2017|
62088408|NCT03433092||Max Leenders et. al,2014|
62276781|NCT01863511|ACTIVE_COMPARATOR|usual care|IV loop diuretics
62276782|NCT01863511|ACTIVE_COMPARATOR|Usual care plus tolvaptan|IV loop diuretic plus Tolvaptan 30 mg orally once daily
62276783|NCT01863511|ACTIVE_COMPARATOR|ultrafiltration|Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein
62276784|NCT02263833||Overall Participants|Participants not previously on erythropoietin-stimulating agent (ESA) therapy and participants on ESA therapy who were switched to Mircera
62276785|NCT04887831|ACTIVE_COMPARATOR|Platinum-based chemotherapy followed by avelumab maintenance therapy|Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Avelumab (800 mg)
62455195|NCT00442910|PLACEBO_COMPARATOR|HEC Placebo Gel|Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
62088409|NCT03433092||Yusuke Okuyama et. al,2014|
62276786|NCT04887831|EXPERIMENTAL|Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy|Trilaciclib (240 mg/m2) + Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Trilaciclib (240 mg/m2) + Avelumab (800 mg)
62641427|NCT00449163|EXPERIMENTAL|Combination Chemotherapy and Bevacizumab|"Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:~* Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;~* Irinotecan: 110 mg/m\^2 via IV infusion on Days 1, 8, 22, 29;~* Leucovorin: 500 mg/m\^2 via IV infusion on Days 1, 8, 22 and 29;~* Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29."
62641428|NCT02182310|PLACEBO_COMPARATOR|BI 201335 placebo|crossover part
62641429|NCT02182310|EXPERIMENTAL|BI 201335 low dose|crossover part
62641430|NCT02182310|EXPERIMENTAL|BI 201335 high dose|crossover part
62641431|NCT02182310|ACTIVE_COMPARATOR|Moxifloxacin|crossover part
62641432|NCT02182310|EXPERIMENTAL|BI 201335 or Placebo|tolerability part in female subjects
62641433|NCT02564367|EXPERIMENTAL|Treatment|"First Cohort 1:~(n = 30 patients) 18 cycles S-1"
62455196|NCT05883410|EXPERIMENTAL|PNF Treatment Group|Hold-relax is a PNF technique will be applied to this group.
62455197|NCT05883410|ACTIVE_COMPARATOR|Mulligan Mobilization Treatment|The Mobilization with movement (MWM) technique will be applied to this group.
62455198|NCT03694990||Short-term|Patients will be scheduled for PO follow-up visits 2 weeks, and 8 weeks after surgery.
62455199|NCT03694990||Intermediate|Patients will be scheduled for PO follow-up visits 4 weeks, and 8 weeks after surgery.
62641434|NCT01954589|EXPERIMENTAL|ACT-462206 5 mg/Placebo|6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
62641435|NCT01954589|EXPERIMENTAL|ACT-462206 25 mg/Placebo|6 subjects received a single, 25 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
62641436|NCT01954589|EXPERIMENTAL|ACT-462206 100mg/Placebo|6 subjects received a single, 100 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
62088410|NCT03433092||GC Kabat et. al,2012|
62088411|NCT03433092||Christina Persson et. al,2008|
62088412|NCT03433092||M Jenab et. al,2006|
62088413|NCT03433092||Kenji Wakai et. al,2005|
62088414|NCT03433092||Christian C. Abnet et. al,2003|
62088415|NCT03433092||N Malila et. al,2002|
62455200|NCT03694990||Long-term|Patients will be scheduled for PO follow-up visits 8 weeks after surgery.
62455201|NCT02746952|EXPERIMENTAL|UCART19|
62641437|NCT01954589|EXPERIMENTAL|ACT-462206 200mg/Almorexant 400mg/Placebo|"Subjects were assigned to one of two possible treatment sequences: A/B or B/A with a washout period of 14 days between treatment periods.~Treatment A: Single oral dose of ACT-462206 200 mg or placebo. Treatment B: Single oral dose of almorexant 400 mg or placebo. In each sequence 6 subjects received ACT-462206 or almorexant \& 2 subjects received placebo"
62641438|NCT01954589|EXPERIMENTAL|Experimental: ACT-462206 400mg/Placebo|6 subjects received a single, 400 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
62641439|NCT01954589|EXPERIMENTAL|ACT-462206 1000 mg|6 subjects received a single, 1000 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
62641440|NCT01954589|EXPERIMENTAL|ACT-462206 1500mg/Placebo|6 subjects received a single, 1500 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
62641441|NCT05839717||PV and ET patients|The cohort will be composed of PV and ET patients, some with a history of thrombosis and some without any history of thrombosis. A comparison will also be performed between patients with different MPN (PV or ET) and the type of thrombosis (venous, arterial, splanchnic)
62641442|NCT02215850|EXPERIMENTAL|SLC-0111|
62641443|NCT01339871|EXPERIMENTAL|Pazopanib + Vorinostat|Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
62455202|NCT01856153|OTHER|Before meal|Strawberry-Placebo-Placebo
62455203|NCT01856153|OTHER|With Meal|Placebo-Strawberry-Placebo
62455204|NCT01856153|OTHER|After Meal|Placebo-Placebo-Strawberry
62641444|NCT04363060|EXPERIMENTAL|Azithromycin with amoxicillin/clavulanate|Combination of azithromycin during 4 days with amoxicillin/clavulanate during 7 days.
62641445|NCT04363060|ACTIVE_COMPARATOR|Amoxicillin/clavulanate|Amoxicillin/clavulanate every day during 7 days.
62641446|NCT04790695|EXPERIMENTAL|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
62072176|NCT04949139|ACTIVE_COMPARATOR|Rapid intermittent bolus group|"A : males \< 65 ; B : females \< 65 or males ≥ 65 ; C : females ≥ 65 yrs~\<During the first 3 h\>~Primary treatment over 1h A: 5DW 8 B: 5DW 7 C: 5DW 6 mL/kg~If undercorrected, Repeat the 5DW amount infused during primary treatment after 3 h~\<At 3-24 h\> Modify protocol based on sNa at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~* undercorrection \< 0.5: repeat the amount infused during primary treatment q 3 h~  ≥ 0.5: repeat the amount infused during primary treatment q 6 h~* target correction \< 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion~\<At 24-48 h\> Modify protocol based on sNa at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~* undercorrection \< 0.5: repeat the amount infused during primary treatment q 3 h~  ≥ 0.5: repeat the amount infused during primary treatment q 6 h~* target correction \< 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion"
62072177|NCT04949139|ACTIVE_COMPARATOR|Slow continuous infusion group|"Participants will be divided into three groups same as above~\<During the first 3 h\>~Primary treatment A: 5DW 1.8 B: 5DW 1.57 C: 5DW 1.35 mL/kg/h~Modify protocol as described below based on sNa measurement at 3 h~* undercorrection: maintain the infusion rate~* target correction: stop the infusion~\<At 3-24 h\> Modify protocol based on sNa measurement at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~• undercorrection~\< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~\< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion~\<At 24-48 h\> Modify protocol based on sNa measurement at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~• undercorrection~\< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~\< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion"
62072178|NCT05666544|ACTIVE_COMPARATOR|Written health education leaflets|Using written health education leaflets to conduct education.
62072179|NCT05666544|EXPERIMENTAL|Web-based patient decision aid|Using web-based patient decision aid of renal replacement therapy.
62072180|NCT02231437||chronic obstructive respiratory tract disease patients|
62072181|NCT01564745|OTHER|Cough Determinants|
62072182|NCT02359019|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
62072183|NCT04946955|EXPERIMENTAL|Application and website with promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
62072184|NCT04946955|OTHER|Application and website without promotion|
62072185|NCT04220671|EXPERIMENTAL|Intervention|Standard dose measles vaccine, 0.5 ml
62072186|NCT04220671|PLACEBO_COMPARATOR|Control|Saline injection, 0.5 ml
62072187|NCT06489093|EXPERIMENTAL|NSF (Gr-N)|The Gr-N will receive treatment with green synthesized Nano silver fluoride which is laboratory conducted
62072188|NCT06489093|ACTIVE_COMPARATOR|SDF+KI group (Gr-S)|The Gr-S will receive treatment with SDF + KI (Riva Star 38% , SDI) according to the manufacturer's instructions.
62072189|NCT06489093|PLACEBO_COMPARATOR|Control group (Gr-C)|The control group (Gr-C) receive no intervention except brushing twice daily with aminofluoride toothpaste and toothbrush provided by researcher.
62072190|NCT05880953|EXPERIMENTAL|Parent Coaching|"Participants will be involved for about 6 months or until they feel that they no longer need the parent-to-parent support.~Parents will participate in the following contact attempts:~* Introductions and rapport building which will include a demographic survey with a needs assessment, and the Family Empowerment Scale (FES)~* A series of coaching points which may include some or all of the following topics~  * Interviewing and selecting a home health agency~ * Expectation setting for home based nursing care~ * Tips for finding home health professionals from inpatient nursing~ * Tips for using personal and professional care networks to find and recruit home health team members~* An exit interview assessment including the FES and components of the demographic survey that may have changed"
62072191|NCT02224482|NO_INTERVENTION|Control|Print materials
62072192|NCT02224482|ACTIVE_COMPARATOR|Intervention Group|PROGRESS
62276787|NCT01937650|ACTIVE_COMPARATOR|Radiotherapy plus metronidazole|Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
62088416|NCT03433092||G Pappalardo et. al,1997|
62088417|NCT01719861|EXPERIMENTAL|Desipramine HCl|Desipramine is a tricyclic antidepressant (TCA).
62088418|NCT01536353|EXPERIMENTAL|AGSAV301|
62088419|NCT01536353|ACTIVE_COMPARATOR|Exforge 10/160|
62455205|NCT00421174|EXPERIMENTAL|Etanercept|Etanercept plus corticosteroids
62455206|NCT00421174|ACTIVE_COMPARATOR|Placebo|Placebo plus Corticosteroids
62455207|NCT01089699|ACTIVE_COMPARATOR|Professionally-led online support|Members assigned to 10-week online support group with a professional counsellor.
62455208|NCT01089699|ACTIVE_COMPARATOR|Peer-led online support|
62455209|NCT01089699|ACTIVE_COMPARATOR|self-study materials|
62455210|NCT06085677||Normal/mild gastritis|Patients enrolled with normal stomach epithelium or mild gastritis
62072193|NCT05623137|EXPERIMENTAL|Acu-TENS+SHP|The 120z Dual-Channel TENS Unit (ECS300A; Neurotrac, Verity Medical LTD, Ireland) will be used to stimulate the selected acupoints. The electrode will be placed over the acupoints and connected to the TENS stimulator. The stimulation frequency will be set at 100 Hz with a pulse width of 0.2 ms. Participants will also receive a set of instructions relating to SHP. SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. Participants will be instructed to read the guide after the baseline assessment (T0).
62072194|NCT05623137|SHAM_COMPARATOR|Sham Acu-TENS+SHP|Participants will receive similar treatment as Acu-TENS groups via identical-looking TENS devices with the electrical circuit disconnected.Participants will also receive a set of instructions relating to SHP. SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. Participants will be instructed to read the guide after the baseline assessment (T0).
62072195|NCT04109742|ACTIVE_COMPARATOR|Curcumin 500mg capsules|Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
62641447|NCT04609514|EXPERIMENTAL|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
62276788|NCT01937650|PLACEBO_COMPARATOR|Radiotherapy alone|Participants in the control arm received 500mg (two suppositories) of paracetamol as a placebo on similar days. This was in addition to the standard radiotherapy administration in two phases as described above.
62072196|NCT04109742|ACTIVE_COMPARATOR|Curcumin 1000mg capsules|Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
62072197|NCT04109742|PLACEBO_COMPARATOR|Placebo curcumin capsules|Dose will be matching placebo capsules daily, orally for 24 weeks
62072198|NCT00258440|ACTIVE_COMPARATOR|Weekly Procrit (epoetin alfa) dosing|Weekly dosing schedule subjects will get the study drug once every week until the end of the study.
62072199|NCT00258440|EXPERIMENTAL|Interval Dosing (epoetin alfa) PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who consented to pharmacokinetic testing
62072200|NCT00258440|EXPERIMENTAL|Interval Dosing (epoetin alfa) Non PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who did not consent to pharmacokinetic testing.
62276789|NCT04732754|PLACEBO_COMPARATOR|Control Group (CG)|This group will receive placebo capsules to be consumed for 8 weeks daily and will not exercise;
62072201|NCT06257719||Paediatric group|The investigators defined participants under 14 years old as the paediatric group.
62072202|NCT06257719||Adult group|The investigators defined participants over 14 years old as the adult group.
62072203|NCT05912114|EXPERIMENTAL|Mannitol|Use of oral 1L Mannitol for remediation of intestinal uncleanliness
62276790|NCT04732754|ACTIVE_COMPARATOR|Aerobic Exercise (AE)|This group will receive placebo capsules and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
62276791|NCT04732754|EXPERIMENTAL|Aerobic exercise + Theobroma cocoa (AETC)|This group will receive 500mg cocoa capsules to be consumed daily and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% VO2peak) for 8 weeks
62276792|NCT04732754|EXPERIMENTAL|Theobroma cocoa (TC)|This group will receive 500mg cocoa capsules to be consumed daily for 8 weeks.
62072204|NCT05912114|ACTIVE_COMPARATOR|Polyethylene glycol electrolyte|Use of oral 1L PEG for remediation of intestinal uncleanliness
62455211|NCT06085677||Chronic atrophic gastritis|Patients enrolled with chronic atrophic gastritis
62641448|NCT04609514|ACTIVE_COMPARATOR|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS (United States Department of Health and Human Services) Clinical Practice Guidelines. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
62641449|NCT01245101|EXPERIMENTAL|Raltegravir and then Observation|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
62641450|NCT01245101|ACTIVE_COMPARATOR|Observation and then Raltegravir|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
62641451|NCT05762237||Group|In the open source database (VitalDB, https://vitaldb.net), the patients who underwent general anesthesia with non-invasive monitoring including blood pressure, electrocardiography, pulse oximetry, bispectral index, capnography, and minimal alveolar concentration of inhalation agent.
62276793|NCT00958204|EXPERIMENTAL|1|Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
62276794|NCT00958204|EXPERIMENTAL|2|Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
62641452|NCT05252403|EXPERIMENTAL|CARCIK-CD19|
62641453|NCT04271124|ACTIVE_COMPARATOR|PR|
62641454|NCT04271124|EXPERIMENTAL|PR+ET|
62641455|NCT05645926||Patients with MI who underwent revascularization during study period|Patients newly diagnosed with MI and underwent revascularization (PCI or CABG) during study period
62641456|NCT05543538|PLACEBO_COMPARATOR|multimedia audio-visual program|
62276795|NCT00958204|ACTIVE_COMPARATOR|3|Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
62455212|NCT06085677||Intestinal metaplasia|Patients enrolled with intestinal metaplasia
62641457|NCT05543538|EXPERIMENTAL|multimedia audio-visual and experiential learning programmes|
62641458|NCT05543538|EXPERIMENTAL|multimedia audio-visual and teachers' personal demonstration and experiential learning|
62455213|NCT03914313|EXPERIMENTAL|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat Pro, in which the exoskeleton device is equipped with a VR screen. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Lokomat will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
62641459|NCT00920153|EXPERIMENTAL|Group 1 (favorable prognosis)|Patients receive ABVD and VABEM chemotherapy.
62641460|NCT00920153|EXPERIMENTAL|Group 2 (intermediate prognosis)|Patients receive ABVD and VABEM chemotherapy.
62641461|NCT00920153|EXPERIMENTAL|Group 3 (poor prognosis)|Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.
62641462|NCT02577536||1 All Subjects|No interventions
62072205|NCT05439577||Mucopolysaccharide Polysulfate Cream|Prescribed only for patients with Mucopolysaccharide Polysulfate Cream.
62276796|NCT00958204|PLACEBO_COMPARATOR|4|Negative ion generator (30 minutes daily) plus placebo pill every day
62276797|NCT05125250|EXPERIMENTAL|Motor Control Group|This group will receive treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day
62072206|NCT05439577||Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients whose prescriptions contain Mucopolysaccharide Polysulfate Cream and glucocorticoids (Combination therapy, but not always).
62072207|NCT04555512|ACTIVE_COMPARATOR|Standard-care interval-training group|Subjects will complete a standard interval-training program that remains constant for the entire 12 weeks of cardiac rehabilitation.
62276798|NCT05125250|ACTIVE_COMPARATOR|Vestibular Group|This Group will receive vestibular exercises which comprises of postural awareness training; Standing on a balance board, Foveal vision exercises.
62276799|NCT05731180|NO_INTERVENTION|Not trained group (CNT)|Control Group (CNT): 70 Students. The CNT group will only receive an introductory lecture about the SAITI-T study and how to use the website. The CNT subjects will not receive training on lung sounds.
62276800|NCT05731180|EXPERIMENTAL|Trained group for 3 days to identify pathological lung sounds (EXP)|Exposed group (EXP): 70 students. EXP group - subjects will be trained for 3 days to identify pathological lung sounds before assessment/assessments. The EXP subjects additionally have an introductory lecture about the SAITI-T study and how to use the website.
62276801|NCT05649293||major depressive disorder patients|patient diagnosed with major depression for first time
62276802|NCT05649293||depression free persons|healthy persons
62276803|NCT00876083||Group 1|
62276804|NCT01634438|EXPERIMENTAL|low dose heparin|30 units per kilogram of unfractionated heparin
62276805|NCT01634438|ACTIVE_COMPARATOR|High dose heparin|70 units per kilogram of unfractionated heparin (UFH) intravenously
62276806|NCT04623476|EXPERIMENTAL|Pathophysiological Excision for Chron's disease|Consecutive patients (\>18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD
62276807|NCT03418532|EXPERIMENTAL|single arm|MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
62461679|NCT00803803|EXPERIMENTAL|Pilocarpine Concentration|Varying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
62276808|NCT02235194|ACTIVE_COMPARATOR|Amino Acids, Chromium - Picolinate|Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
62276809|NCT02235194|PLACEBO_COMPARATOR|Placebo Drink|Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
62276810|NCT01882946|EXPERIMENTAL|DCVax-Direct|DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
62276811|NCT03371797||Treatment group|Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.
62287177|NCT02069002|EXPERIMENTAL|Applied relaxation group therapy|"There will be seven (7) manualized session, first 120 minutes and six (6) 90-minute group sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after treatment. Sessions include information about indoor air related symptoms, behavioral training and experiments focusing on applied relaxation technique and relapse prevention.~Intervention: Behavioral: group therapy (ART)~NB: The Applied Relaxation group Therapy won´t be carried out due to slow and prolonged recruiting process (A steering group agreement 4/2015 and the Ethics Committee approval 5/2015 for the change of the study plan)."
62641463|NCT03843372|EXPERIMENTAL|First night HFNC group|The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
62641464|NCT03843372|ACTIVE_COMPARATOR|First night CPAP group|In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.
62072208|NCT04555512|EXPERIMENTAL|Progressive interval-training group|Subjects will complete an interval-training program during which the number of intervals and the duration of each interval are changed across the 12-week cardiac rehabilitation program.
62072209|NCT02611310||Participants with HER2-positive unresectable LA/mBC|
62072210|NCT00996580|EXPERIMENTAL|DR-103|"Four 91-day cycles of the DR-103 regimen:~* 42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;~* 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by;~* 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by;~* 7 days of 10 mcg EE."
62072211|NCT01923428|EXPERIMENTAL|5 mg BID|AZD1722
62072212|NCT01923428|EXPERIMENTAL|20 mg BID|AZD1722
62072213|NCT01923428|EXPERIMENTAL|50 mg BID|AZD1722
62072214|NCT01923428|PLACEBO_COMPARATOR|Placebo|
62072215|NCT01170884|ACTIVE_COMPARATOR|Combigan® + Lumigan®|COMBIGAN® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution) adjunctive to LUMIGAN® (bimatoprost 0.03% ophthalmic solution)
62072216|NCT01170884|ACTIVE_COMPARATOR|Lumigan®|LUMIGAN® (bimatoprost 0.03% ophthalmic solution) plus Gen Teal® Mild (hypromellose 0.2% eye drops) used for masking purposes
62072217|NCT05216926|EXPERIMENTAL|Hypoglycemia predicition and preventive treatment|
62287178|NCT02069002|EXPERIMENTAL|Information session (psychoeducation)|"There will be one (1) manualized 90-minute individual session. The session includes information about indoor air related symptoms and factors affecting individual health behavior.~Intervention: Information session (psychoeducation)"
62455214|NCT03914313|ACTIVE_COMPARATOR|Robotic treatment without VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Nanos, in which the exoskeleton device is equipped with a screen with a visual feedback (but not virtual reality). The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Nanos will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
62641465|NCT06479382|EXPERIMENTAL|Investigational|Treatment with the ETX-4143 2.0 device
62641466|NCT06479382|SHAM_COMPARATOR|Control|Treatment with a sham ETX-4143 2.0 device
62072218|NCT05216926|OTHER|Corrective hypoglycemia treament (at hypogylcemia)|
62072219|NCT03497884|EXPERIMENTAL|Real rTMS (low frequency)|Real rTMS (low frequency) is 1Hz.
62072220|NCT03497884|SHAM_COMPARATOR|Sham rTMS|Sham rTMS session includes low frequency and high frequency stimulations.
62072221|NCT03497884|EXPERIMENTAL|Real rTMS (high frequency)|Real rTMS (high frequency) is 10Hz.
62072222|NCT00624663|ACTIVE_COMPARATOR|1|(1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule) X 2 per day, total of 5 intakes
62072223|NCT00624663|ACTIVE_COMPARATOR|2|(2 x 1.5 mg Exelon® Capsules) X 2 per day, total of 5 intakes
62072224|NCT00624663|PLACEBO_COMPARATOR|3|(2 x Placebo Capsules) X 2 per days, total of 5 intakes
62072225|NCT00903669||Peripheral Facial Paralysis (PFP)|Patients who are diagnosed with peripheral facial paralysis.
62072226|NCT04931459|EXPERIMENTAL|ACU193 Administration|Participants will receive 1 to 3 doses of ACU193 by intravenous (IV) infusion.
62072227|NCT04931459|PLACEBO_COMPARATOR|Placebo Administration|"Participants receive 1 to 3 doses of matching ACU193 placebo by intravenous (IV) infusion.~2 participants per cohort will receive placebo."
62072228|NCT04375982|OTHER|Blood collection|Venepuncture and fingerstick to obtain venous blood and capillary blood respectively
62088420|NCT03985852|ACTIVE_COMPARATOR|Patient Directed Standard of Care|Patients receive pre-test genetic counseling and, if relevant, post-test counseling for a negative result from an automated genetics education assistant.
62088421|NCT03985852|NO_INTERVENTION|Enhanced Standard of Care|Patients receive standard counseling from a genetic counselor.
62287179|NCT04764435||Patients receiving dialysis at a physician-owned dialysis facility|All adults with Medicare fee-for-service in 2017 who received dialysis at a physician-owned dialysis facility. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
62287180|NCT04764435||Patients receiving dialysis at a dialysis facility not owned by a physician|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility not owned by a physician. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
62287181|NCT04764435||Patients receiving dialysis at a facility owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
62287182|NCT04764435||Patients receiving dialysis at a facility NOT owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility NOT owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
62287183|NCT00802360|EXPERIMENTAL|Menopur/Endometrin|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62287184|NCT00802360|EXPERIMENTAL|Menopur/Progesterone in Oil|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62287185|NCT00802360|ACTIVE_COMPARATOR|Follistim/Endometrin|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62641467|NCT01224275|EXPERIMENTAL|Group antenatal care|The first arm is midwife which allocated to group based antenatal care. They have education in this model of care and follow up meeting to secure the intervention
62641468|NCT01224275|NO_INTERVENTION|Individual antenaal care|the second arm include midwife which allocated to traditional care as control group.
62641469|NCT06333730|EXPERIMENTAL|Inferior Alveolar Nerve Block (IANB)|48 patients will be randomly selected in inferior alveolar nerve block group
62641470|NCT06333730|EXPERIMENTAL|Mental Nerve Block (MNB)|48 patients will be randomly selected in mental nerve block group
62641471|NCT03728062|EXPERIMENTAL|Mindfulness meditation during lunch break|"Participants performed mindfulness meditation during lunch break at work place for a month, beginning with 15 minutes and ending with 30 minutes. They had available a quiet room and mp3 audios with guided meditations based on the MBSR program."
62072229|NCT02963051|EXPERIMENTAL|Neuroendocrine prostate cancer (NEPC)|"Subjects with neuroendocrine prostate cancer (NEPC)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
62072230|NCT02963051|EXPERIMENTAL|Adenocarcinoma CRPC with non-liver/peritoneal metastases|"Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
62455215|NCT03914313|ACTIVE_COMPARATOR|Conventional treatment|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a conventional gait rehabilitation. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Beside conventional overground training for gait, motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
62641472|NCT03728062|EXPERIMENTAL|Physical exercise during lunch break|Participants performed physical exercises during lunch break at a gym for a month, beginning with 15 minutes and ending with 30 minutes. They were instructed to do cardio exercise such as running through a park or going to the gym for running, rowing, cycling or elliptical exercise. 20-140 beats per minute must be reach.
62641473|NCT03728062|NO_INTERVENTION|Control group|Participants continue their normal lunch routine.
62641474|NCT02016989|OTHER|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
62641475|NCT02016989|EXPERIMENTAL|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
62088422|NCT03084952|EXPERIMENTAL|1 mg/day|
62088423|NCT03084952|EXPERIMENTAL|4 mg/day|
62455216|NCT04289636|EXPERIMENTAL|Weight loss and self-compassion|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week mindfulness-based self-compassion program which combines the skills of mindfulness and self-compassion as a means for improving emotional resilience, well-being, and weight control.
62455217|NCT04289636|ACTIVE_COMPARATOR|Weight loss and nutrition/cooking education|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week nutrition and cooking education program which will provide basic nutrition knowledge and cooking skills for healthy eating.
62641476|NCT04669431|EXPERIMENTAL|Xbox kinect Training|X Box Games include Tennis Playing, Joy riding, Rally ball.
62641477|NCT04669431|ACTIVE_COMPARATOR|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living
62641478|NCT03849534|ACTIVE_COMPARATOR|Soft occlusal appliance|Individually casted appliances
62641479|NCT03849534|ACTIVE_COMPARATOR|Jaw exercises|Resistance exercises to do twice a day
62641480|NCT03849534|ACTIVE_COMPARATOR|Counseling|Just information at the first visit
62088424|NCT03084952|EXPERIMENTAL|8 mg/day|
62455218|NCT00175019|EXPERIMENTAL|Febuxostat 80 mg QD|
62088425|NCT03084952|EXPERIMENTAL|12 mg/day|
62088426|NCT03084952|ACTIVE_COMPARATOR|Glucantime|
62088427|NCT03084952|EXPERIMENTAL|Best dose 18-MC|
62455219|NCT00175019|EXPERIMENTAL|Febuxostat 120 mg QD|
62455220|NCT00175019|ACTIVE_COMPARATOR|Allopurinol QD|
62455221|NCT05081440||patients diagnosed with hypertension or diabetes|Age ≥18 years; Patients with well-diagnosed hypertension (HTN) and/or type 2 diabetes (T2DM) and have been ill for ≥ 3 months; The patient underwent fasting lipid analysis in the past 1 month and the data was fully recorded
62641481|NCT02059837||Pterygium,recurrent|Consecutively recorded photographs of recurrent pterygium excision and following grafting were analyzed.
62641482|NCT04356937|EXPERIMENTAL|Tocilizumab|"Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.~Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures."
62072231|NCT02963051|EXPERIMENTAL|Adenocarcinoma CRPC with liver and/or peritoneal mets|"Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
62072232|NCT04066985|EXPERIMENTAL|Growth Mindset Intervention|"Includes one online, single-session program, the Growth Mindset Program. The 30-minute, self-administered youth program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
62641483|NCT04356937|PLACEBO_COMPARATOR|Standard of care plus placebo|Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.
62072233|NCT04066985|EXPERIMENTAL|Self-Kindness Intervention|Includes one online, single-session program, the Self-Kindness Program. The 30-minute, self-administered youth program includes: An introduction to the science behind why adolescents might think disliking themselves is necessary for success and thus fear self-compassion; Scientific evidence and testimonials from other teens that being self-compassionate actually predicts being more successful socially and academically; Evidence-based tips for overcoming common, fear of self-compassion based obstacles to self-compassion in day to day life; And an exercise in which youths write notes to younger students, using scientific information to explain the benefits of using self-kindness.
62088428|NCT03084952|EXPERIMENTAL|Minimum effective dose 18-MC|
62088429|NCT02492061|ACTIVE_COMPARATOR|Demand creation|In the intervention arm, demand creation for couples' HCT is done using small group (comprising about 20 people), couple-focused or men-only, interactive sessions. A senior counselor facilitates the sessions in which the advantages and fears associated with couples' HCT are discussed with invited couples or men. The sessions are reinforced by testimonies from couples or men who have ever tested as a couple. Attending couples or men receive couple invitation coupons inviting them to test for HIV together with their partners at a designated health facility in the community.
62276812|NCT01014117|PLACEBO_COMPARATOR|Placebo|"The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days.~A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days."
62276813|NCT01014117|ACTIVE_COMPARATOR|Placebo and 2.0g SRT2104|This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
62641484|NCT03538080|EXPERIMENTAL|ACCUVEIN plus ultrasound|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with Accuvein and ultrasound
62641485|NCT03538080|SHAM_COMPARATOR|Ultrasound only|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with ultrasound only.
62641486|NCT00652444|EXPERIMENTAL|1|Coadministration arm: simvastatin 20mg and ezetimibe 10mg
62641487|NCT00652444|EXPERIMENTAL|2|Monotherapy arm: simvastatin 20mg and ezetimibe placebo
62641488|NCT00659087|EXPERIMENTAL|Femoral Block|Those receiving femoral block in addition to usual pain management
62641489|NCT00659087|ACTIVE_COMPARATOR|Usual Care|Those receiving only usual pain management without a femoral block
62641490|NCT02419599|EXPERIMENTAL|Group A|The group who will receive high energy density, low volume oral nutritional supplement, to be taken for 4 weeks (28 days)
62641491|NCT02419599|ACTIVE_COMPARATOR|Group B|The group who will receive the standard energy density oral nutritional supplement, to be taken for 4 weeks (28 days)
62641492|NCT04343352|EXPERIMENTAL|In application group; Mobile Epilepsy Training Program Impleme|"* Mobile epilepsy training program will be introduced to the parents in the application group and pre-tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale).~* The participants will only use the mobile epilepsy training program application.~* Parents in the application group will be monitored for 3 months using the mobile epilepsy training program. The researcher will follow the participants' use of the mobile application with the interface of the mobile epilepsy training program.~During the monitoring phase, the Epilepsy Information Questions screen will be given once every 15 days, and the training module will be reopened automatically on missing or incorrect answers and the parent's information on this subject will be renewed.~- At the end of the 3rd month, posttests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale) will be applied face-to-face."
62276814|NCT01014117|ACTIVE_COMPARATOR|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
62276815|NCT03657043|EXPERIMENTAL|Safety Run-In (3Q4W Schedule)|28-day, 3 dose cycle
62276816|NCT03657043|EXPERIMENTAL|Part A: Tisotumab Vedotin|21-day, single dose cycle
62276817|NCT03657043|EXPERIMENTAL|Part A: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
62276818|NCT03657043|EXPERIMENTAL|Part B: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
62276819|NCT00755833||A|
62276820|NCT04929184|EXPERIMENTAL|Adults who stutter (AWS)|Participants will have 2 visits.
62276821|NCT04929184|OTHER|Healthy Adults|Participants will have 2 visits.
62276822|NCT04929184|EXPERIMENTAL|Children who Stutter|Participants will have 1 visit.
62641493|NCT04343352|NO_INTERVENTION|In the control group|"- The purpose of the project will be shared with the parents in the control group, and the pre-tests Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied.~There is no structured training program in the outpatient functioning. Routine practice of the hospital; is the education and information provided by the physician to the family during the outpatient clinic.~* At the end of the 3rd month, the final tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied face to face.~* After the work is completed, the mobile application will be installed on the phones of the control group, the application will be taught and applied."
62276823|NCT04929184|OTHER|Healthy Children|Participants will have 1 visit.
62641494|NCT03880747||Vagus nerve preserving group|Patients who underwent vagus nerve-preserving distal gastrectomy for early gastric cancer
62276824|NCT04690010|ACTIVE_COMPARATOR|Ambulatory tubeless PCNL|Patients will be discharged home on the same day as surgery. No nephrostomy tube will be placed (tubeless).
62276825|NCT04690010|ACTIVE_COMPARATOR|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days with a nephrostomy tube placed at the time of surgery that will then be removed prior to discharge.
62276826|NCT04001868|EXPERIMENTAL|Experimental Group|Application of the sub occipital inhibition technique.
62276827|NCT04001868|PLACEBO_COMPARATOR|Placebo Group|Hand contact in the sub occipital region without executing any technique.
62276828|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
62276829|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
62276830|NCT06501560|EXPERIMENTAL|Lifestyle counseling|
62276831|NCT06501560|EXPERIMENTAL|clinical examination|
62276832|NCT04588324|EXPERIMENTAL|Phase 1 Dose-Escalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
62276833|NCT04588324|EXPERIMENTAL|Phase 2 Dose-Expansion|SHR2150 RP2D will be combined with chemotherapy plus PD-1 or CD47 antibody in 3-week treatment cycles.
62276834|NCT03368183|EXPERIMENTAL|SCAMP arm|The SCAMP is a clinical decision support tool. See Mendu et al. CJASN 2017.
62276835|NCT03368183|ACTIVE_COMPARATOR|"Control arm SHAM SCAMP"|The control arm will be a form that asks questions about indications for renal replacement therapy but does not provide suggestions about when to initiate renal replacement therapy, as is being done in the active SCAMP arm. The goal of the control group is to test whether the SCAMP clinical decision support influences provider practice patterns and improves care.
62641495|NCT03669588|EXPERIMENTAL|ARGX-113|
62276836|NCT03907332|EXPERIMENTAL|Intervention Arm|"Study group 1 - Home visits by a team made up of a CHW and CHN in addition to all existing usual care practices (see below).~Standardized educational Messages will be given during these scheduled home visits by the CHW-CHN including:~* One visit during the second trimester of the pregnancy~* Two visits during the third trimester of pregnancy"
62455222|NCT02557607|OTHER|Monitoring a subarachnoid hemorrhage|Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic). An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
62455223|NCT03655106|ACTIVE_COMPARATOR|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
62641496|NCT03669588|PLACEBO_COMPARATOR|Placebo|
62641497|NCT00908765|ACTIVE_COMPARATOR|Aerobe Interval Training|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
62276837|NCT03907332|NO_INTERVENTION|Control Arm|Study group 2 (Control) - Existing usual care practices. Usual Care includes at least four antenatal visits and care package which includes education on pregnancy, labour and delivery given at the health facility or at community settings to individuals and/or groups of pregnant women.
62276838|NCT03591380|EXPERIMENTAL|Experimental: Belimumab|Belimumab 10mg/kg will be administered IV at the following intervals: at the time of transplant (Day 0), then post-transplant at 2, 4, 8, 12, 16, and 20 weeks.
62276839|NCT05359978|EXPERIMENTAL|cards|participants received 2 days at week during 30 minutes
62276840|NCT05359978|EXPERIMENTAL|significance activities|participants received 2 days a week during 30 minutes
62276841|NCT00954278|EXPERIMENTAL|sorafenib|
62276842|NCT00502190|EXPERIMENTAL|1|Silicon ring positioned in the vagina, around the cervix
62276843|NCT00502190|EXPERIMENTAL|2|Silicon ring positioned in the vagina, around the cervix
62276844|NCT01277133||Cohort|
62455224|NCT03655106|EXPERIMENTAL|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
62641498|NCT00908765|ACTIVE_COMPARATOR|Moderate Continous Training|Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
62641499|NCT02785393|PLACEBO_COMPARATOR|Sugar Pill|
62276845|NCT02148237|NO_INTERVENTION|Treatment as Usual|Participants in Treatment as Usual (TAU) will receive standard breastfeeding (BF) services from the WIC program and participate in research assessments. Standard services include an on-site and home-visiting lactation consultant, occasional one-on-one peer counseling, and an enhanced food package for BF women.
62276846|NCT02148237|EXPERIMENTAL|Contingency Management|These participants will receive usual WIC care. The frequency, duration, content, and size of the meetings and participation requirements will be the same as for the TAU group, except that this group will also receive contingency management (CM). Members will demonstrate breastfeeding and receive cash incentives weekly if they breastfeed.
62072234|NCT04066985|ACTIVE_COMPARATOR|Supportive Therapy Intervention|Includes one online, single-session active comparator program, the Supportive Therapy Intervention. The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. The 30-minute, self-administered control group program includes: vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family; the same number of reading and writing activities as the web-based growth mindset intervention. However, the only goals of the ST intervention are to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs.
62072235|NCT04789577|ACTIVE_COMPARATOR|FLU-Q-PAN H7N9 Formulation 1_B Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03B adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
62276847|NCT05751356|EXPERIMENTAL|TR128|
62276848|NCT04035317|EXPERIMENTAL|Aesculus hippocastanum|Patients will receive extract of Aesculus hippocastanum
62455225|NCT02384616|ACTIVE_COMPARATOR|Group High FiO2|Children will receive Fi02 100% during induction of anesthesia until end tidal oxygen concentration (Et 02) of 90% before intubation, anesthesia will be maintained with Fi02 of 80%. Then, shortly before the planned extubation, Fi02 will be increased to 100%.
62455226|NCT02384616|ACTIVE_COMPARATOR|Group Low FiO2|Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
62641500|NCT02785393|ACTIVE_COMPARATOR|Doxazosin|
62641501|NCT01325350|EXPERIMENTAL|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62641502|NCT01325350|EXPERIMENTAL|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62641503|NCT01325350|EXPERIMENTAL|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62641504|NCT01325350|PLACEBO_COMPARATOR|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
62641505|NCT01325350|ACTIVE_COMPARATOR|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
62641506|NCT03456466|EXPERIMENTAL|TQB2303|
62072236|NCT04789577|ACTIVE_COMPARATOR|FLU-Q-PAN H7N9 Formulation 1_A Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03A adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
62072237|NCT04789577|ACTIVE_COMPARATOR|FLU-Q-PAN H7N9 Formulation 2_B Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03B adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
62072238|NCT04789577|ACTIVE_COMPARATOR|FLU-Q-PAN H7N9 Formulation 2_A Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03A adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
62072239|NCT04789577|ACTIVE_COMPARATOR|FLU-Q-PAN H7N9 Formulation 3_B Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03B adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
62276849|NCT04035317|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo
62641507|NCT03456466|ACTIVE_COMPARATOR|Rituximab|
62276850|NCT05392348|PLACEBO_COMPARATOR|Normal Control group|Subjects with maltodextrin as intervention，5g/kg·bw/day.
62276851|NCT05392348|EXPERIMENTAL|Stachyose intervention group|Subjects with stachyose as intervention，5g/kg·bw/day.
62455227|NCT05524688|EXPERIMENTAL|Beta-glucan|500 mg/d of beta-glucan
62455228|NCT05524688|PLACEBO_COMPARATOR|Placebo|500 mg/d of cellulose
62641508|NCT03601169|EXPERIMENTAL|Low Dose MMFS-205-SR|Low dose, oral MMFS-205-SR twice daily (1,000 or 1,500 mg/day total, depending on lean body mass: \~22mg/kg LBM/day) for 6 weeks
62641509|NCT03601169|EXPERIMENTAL|High Dose MMFS-205-SR|High dose, oral MMFS-205-SR twice daily (1,500 or 2,000 mg/day total, depending on lean body mass: \~33mg/kg LBM/day) for 6 weeks
62641510|NCT03601169|PLACEBO_COMPARATOR|Placebo|Oral inactive placebo twice daily for 6 weeks
62641511|NCT02104661|EXPERIMENTAL|OxCarbazepine Treatment|Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs.
62641512|NCT02104661|PLACEBO_COMPARATOR|OxCarbazepine Placebo|Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs
62641513|NCT03918811|EXPERIMENTAL|Positive Pressure Extubation Technique|ETT is removed in PSV 15/10 mode and without endotracheal suction.
62641514|NCT03918811|ACTIVE_COMPARATOR|Traditional Extubation Technique|ETT is removed with continuous endotracheal suction
62641515|NCT02324751|EXPERIMENTAL|Vi-TCV|Single intramuscular injection
62641516|NCT02324751|ACTIVE_COMPARATOR|Vi-PS Vaccine|Single intramuscular injection
62641517|NCT02324751|OTHER|Control (Men ACWY)|Single intramuscular injection
62641518|NCT02145455|ACTIVE_COMPARATOR|Mechanical alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes mechanical alignment via measured resection to establish knee alignment.
62641519|NCT02145455|ACTIVE_COMPARATOR|Anatomic alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes anatomic alignment via ligament balancing with the tibial cut perpendicular to the tibial anatomic axis.
62641520|NCT00545025|EXPERIMENTAL|GSK1247446A Group|Subjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
62072240|NCT04789577|ACTIVE_COMPARATOR|FLU-Q-PAN H7N9 Formulation 3_A Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03A adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
62641521|NCT00545025|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
62641522|NCT06461169|EXPERIMENTAL|interventional|group applying the stress ball during the CPAP procedure
62072241|NCT04789577|PLACEBO_COMPARATOR|Placebo Group|Healthy male and female participants who received two doses of placebo, the first dose at Day 1 and the second dose at Day 22.
62072242|NCT04202744||Water Polo Group|"Participants were active water polo players who train regularly with ages in between 10-30 years.~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
62072243|NCT04202744||Non-Water Polo Group|"Participants who do not engage in overhead sports with ages in between 10-30 years.~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
62072244|NCT05942638||Concussion Group|
62072245|NCT05942638||Control Group|
62072246|NCT04083963|OTHER|Single arm|Low dose weekly carboplatin in combination with standard neoadjuvant chemotherapy
62072247|NCT04759521||Group 1|Inactive HBsAg carriers were patients with HBsAg positivity for more than 6 months
62072248|NCT04759521||Group 2|Patients diagnosed with chronic hepatitis B were patients with HBsAg positivity for more than 6 months
62072249|NCT04759521||Group 3|The control group was composed of healthy individuals who were not infected with hepatitis B virus and did not fit any exclusion criteria.
62072250|NCT04155437|EXPERIMENTAL|Intervention|A\&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities.
62072251|NCT04155437|NO_INTERVENTION|Control|Comparison areas: standard antenatal care services delivered at government health facilities.
62072252|NCT01500746|EXPERIMENTAL|Lavage arm|This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
62641523|NCT06461169|NO_INTERVENTION|control|The group in which no intervention was carried out and the routine care was provided by the nurses during the CPAP procedure
62641524|NCT02312960|OTHER|Arm 1|The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.
62641525|NCT05222880|EXPERIMENTAL|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
62072253|NCT01500746|ACTIVE_COMPARATOR|Moist dressings|This group will serve as the control group. They will undergo twice daily dressing changes with moist gauze dressings for a total of 4 days (8 dressing changes). Bacterial counts and gene expression analysis will be performed prior to the first dressing change and after the last dressing change.
62072254|NCT05808335|PLACEBO_COMPARATOR|Placebo to hzVSF-v13|Placebo to match hzVSF-v13 + oral antiviral agent
62641526|NCT05810701|ACTIVE_COMPARATOR|NACT and CGA+ physical training intervention|Elderly (≥70 years) ovarian cancer patients referred for Neo-adjuvant treatment randomized to comprehensive geriatric assessment and individualised physical training.
62072255|NCT05808335|EXPERIMENTAL|hzVSF-v13 50mg|hzVSF-v13 50 mg/dose + oral antiviral agent
62072256|NCT05808335|EXPERIMENTAL|hzVSF-v13 200mg|hzVSF-v13 200 mg/dose + oral antiviral agent
62072257|NCT05808335|EXPERIMENTAL|hzVSF-v13 800mg|hzVSF-v13 800 mg/dose + oral antiviral agent
62276852|NCT04116398|EXPERIMENTAL|Ozurdex®, 700µg dexamethasone intravitreal injection|Intravitreal injection of dexamethasone (Ozurdex®)
62276853|NCT02640417|EXPERIMENTAL|Nucleotides + B12|Nucleotides + Vitamin B12 Dose: two capsules, three times per day + placebo corresponding to Group B treatment
62276854|NCT02640417|ACTIVE_COMPARATOR|B vitamins|Vitamin B1 + Vitamin B6 + Vitamin B12 Dose: one tablet, three times daily + placebo corresponding to Group A treatment
62276855|NCT01123252|ACTIVE_COMPARATOR|Seasonal Affective Rhinitis Group 1|Active Comparator Group
62276856|NCT01123252|PLACEBO_COMPARATOR|Seasonal Affective Rhinitis Group 2|Placebo Group
62276857|NCT02507011|EXPERIMENTAL|Carvedilol First|Crossover Design: Participants receive Carvedilol first and placebo second
62276858|NCT02507011|PLACEBO_COMPARATOR|Placebo First|Crossover Design: Participants receive placebo first and Carvedilol second
62276859|NCT01164085|EXPERIMENTAL|Ketorolac|4mg intravitreal injection of ketorolac
62276860|NCT05331885|EXPERIMENTAL|AR-320 (Suvratoxumab)|Participants will receive a single intravenous (IV) dose of suvratoxumab on Day 0 of the study.
62276861|NCT05331885|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV dose of placebo to survatoxumab on Day 0 of the study.
62276862|NCT01276171|ACTIVE_COMPARATOR|Ultrasound|Participants will place arterial line using ultrasound technique
62276863|NCT01276171|ACTIVE_COMPARATOR|Doppler|Participants will place arterial line using doppler technique
62641527|NCT05810701|NO_INTERVENTION|NACT no intervention|Elderly (≥70 years) ovarian cancer patients referred for Neo-adjuvant treatment randomized to standard of care
62641528|NCT01684176|EXPERIMENTAL|Complex tailored intervention|"The intervention consists of 3 elements:~1. Medication review with recommendations focused on antithrombotics and adherence to guidelines and patient´s adherence to medications.~2. Discharge consultation with an pharmacist using motivational interviewing techniques.~3. Follow-up telephone calls one week, two months and six months after discharge."
62641529|NCT01684176|PLACEBO_COMPARATOR|Usual care|Usual care
62276864|NCT01276171|ACTIVE_COMPARATOR|Palpation|Participants will place arterial line using palpation technique
62276865|NCT04616469|ACTIVE_COMPARATOR|Root canal treatment using RaCe rotary system|Canal shaping using RaCe rotary system powered with endodontic motor with real time torque monitoring capacity
62276866|NCT04616469|EXPERIMENTAL|Root canal treatment using TruNatomy rotary system|Canal shaping using TruNatomy rotary system powered with endodontic motor with real time torque monitoring capacity
62455229|NCT06078163|EXPERIMENTAL|Treatment Group|Treatment Group was composed of patients who will undergo daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, Vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
62276867|NCT01614132|EXPERIMENTAL|Vincristin, CCNU, cis-platin|"radiotherapy and concomitant chemotherapy (7 cycles of 7 days):~* 2 mg/m2 vincristin i.v.~* 55,0 Gy Posterior cranial fossa (M0)~* 55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)~maintenance chemotherapy (8 cycles of 42 days):~* once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.~* once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v."
62276868|NCT06317480||bone resection|
62276869|NCT06317480||subperiosteal excision|
62276870|NCT02323698|ACTIVE_COMPARATOR|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine then AIH
62276871|NCT02323698|ACTIVE_COMPARATOR|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo then AIH
62455230|NCT06078163|PLACEBO_COMPARATOR|Control Group|Control Group was composed of patients who will only undergo a rehabilitation protocol lasting 20 sessions.
62455231|NCT00577668|EXPERIMENTAL|VDT and Melphalan|To find out if three drugs, bortezomib, thalidomide, and dexamethasone in addition to high doses of melphalan (M-VTD) and autologous transplant can be given safely and effectively to subjects who have failed previous regimens with transplant(s).
62455232|NCT00576381|EXPERIMENTAL|A|Neonates will be administered a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours post cardiac surgery.
62455233|NCT05145283|ACTIVE_COMPARATOR|Conestat alfa (Ruconest®) intervention group|The intervention group will receive conestat alfa (Ruconest®) as a 10-minute slow intravenous injection (up to 56 ml) once during the TAVI procedure followed by a second administration (up to 28 ml) again three hours later. The first administration will include a dosage of 100 U/kg (maximum 8400 U) conestat alfa. The dosing of the second administration will be 50 U/kg (maximum 4200 U).
62455234|NCT05145283|PLACEBO_COMPARATOR|saline injection placebo group|Subjects randomized into the placebo group will receive an intravenous normal saline injection with corresponding volume over 10 minutes during the TAVI procedure and three hours later after the first administration.
62276872|NCT02323698|ACTIVE_COMPARATOR|Caffeine/SHAM|Subjects with chronic, motor-incomplete SCI receive Caffeine then SHAM
62072258|NCT04854538|EXPERIMENTAL|T test|Test drug (Ekmasonid) 1 tablet contains 9 mg Budesonide
62072259|NCT04854538|EXPERIMENTAL|B reference (first dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
62072260|NCT04854538|EXPERIMENTAL|B reference (second dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
62072261|NCT04009005|NO_INTERVENTION|Usual care|Participants will receive usual care from their treating neurologist
62276873|NCT03778112|EXPERIMENTAL|Negative mpMRI Prostate Scan|SBRT to the whole prostate
62276874|NCT03778112|EXPERIMENTAL|Positive mpMRI Prostate Scan|IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions
62276875|NCT03324997|EXPERIMENTAL|Restylane|half the chest to be treated with Restylane Silk
62276876|NCT03324997|PLACEBO_COMPARATOR|Placebo|half-chest injections with saline as a placebo to Restylane Silk.
62276877|NCT04125355|PLACEBO_COMPARATOR|Placebo|Placebo control
62276878|NCT04125355|EXPERIMENTAL|Reflexology|foot reflexology
62276879|NCT02437162|PLACEBO_COMPARATOR|Group 1 (Placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape \[EE\]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100. Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
62276880|NCT02437162|EXPERIMENTAL|Group 2 (Ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (\<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
62072262|NCT04009005|EXPERIMENTAL|Therapeutic Lifestyle|Participants will be trained via videos from a three day in-person seminar that teaches the public about the use of a therapeutic diet and lifestyle to reduce multiple sclerosis related fatigue and improve quality of life.
62072263|NCT02600624||Participants|Women who are in active labor and their newborn infants.
62072264|NCT03183557|ACTIVE_COMPARATOR|ZA alone|
62072265|NCT03183557|ACTIVE_COMPARATOR|ZA plus VD|
62072266|NCT02329106|EXPERIMENTAL|NanoKnife LEDC System|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System, alao called Irreversible electroporation (IRE), 90 pulses of 70 microseconds each in duration will be administered per electrode pair.
62072267|NCT02329106|NO_INTERVENTION|Control|The patients without treatment
62072268|NCT06309030|EXPERIMENTAL|Intervention group|
62072269|NCT06309030|PLACEBO_COMPARATOR|Control group|
62455235|NCT02635100|EXPERIMENTAL|MNT Algorithm|All participants will be monitored using an existing (FDA approved) CPAP machine that has been modified to be externally controlled by a computer with the MNT algorithm, for titration.
62276881|NCT02437162|EXPERIMENTAL|Group 3 (Ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (\<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
62276882|NCT02249910|EXPERIMENTAL|Semaglutide|
62276883|NCT00609596|OTHER|Arm 1|
62276884|NCT06411795|EXPERIMENTAL|Group E (TEA)|Prior to pancreatoduodenectomy, patients undergo thoracic epidural placement and receive bupivacaine and hydromorphone continuous infusion via epidural for up to 72 hours postoperatively. Patients also receive iopamidol via epidural and undergo x-ray imaging on study.
62276885|NCT06411795|EXPERIMENTAL|Group RS (rectus sheath block)|Prior to pancreatoduodenectomy, patients undergo ultrasound and receive bupivacaine and liposomal bupivacaine injection into the rectus sheath.
62276886|NCT00956254|EXPERIMENTAL|Fentanyl sublingual spray 100 µg|Participants received a single administration of fentanyl sublingual spray 100 µg sublingually.
62641530|NCT01274533|EXPERIMENTAL|Lenalidomide|Oral lenalidomide is initiated on Day 1 of Cycle 1 and continues once daily days 1-21 of a 28 day cycle. Subjects may continue participation in the Treatment Phase of the study for 24 months unless disease progression or drug is discontinued for safety reasons.
62072270|NCT05142670|EXPERIMENTAL|task-oriented training individualized by the gravity perception|The training in the experimental group emphasizes the active use of intact or relatively preserved verticality perception to facilitate reestablishing vertical position of the participants. Additionally, a target such as an interesting person/object or an object with interesting music is used to direct the subject to accomplish a task in order to temporally desist from pathological pushing behavior.
62072271|NCT05142670|ACTIVE_COMPARATOR|visual feedback treatment|The training in the control group emphasizes the active use of visual feedback to facilitate reestablishing vertical position of the participants.
62072272|NCT02312674|EXPERIMENTAL|Intervention|Patient group which takes daily an adjusted amount of oral nutritional supplements through an intervention period of three months
62072273|NCT02312674|NO_INTERVENTION|Control|Patients group which takes no oral nutritional supplements
62276887|NCT00662792|EXPERIMENTAL|T+S_PE/ Tio18GEL / Salm50DPI / T18GEL+S_DPI|7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE)/ 18 µg Tiotropium (Tio18GEL) / 50 µg Salmeterol MDPI (Salm50DPI) / 18 µg Tiotropium (T18GEL) plus 50 µg Salmeterol MDPI (S_DPI) BID
62276888|NCT00662792|EXPERIMENTAL|Tio18GEL/ T18GEL+S_DPI/ T+S_PE/ Salm50DPI|18 µg Tiotropium (Tio18GEL) / 18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) / 50 µg Salmeterol MDPI (Salm50DPI)
62276889|NCT00662792|EXPERIMENTAL|Salm50DPI/ T+S_PE/ T18GEL+S_DPI/ Tio18GEL|50 µg Salmeterol MDPI (Salm50DPI) / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) / 18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 18 µg Tiotropium (Tio18GEL)
62641531|NCT05446961|ACTIVE_COMPARATOR|covid 19 LCLT supplement|LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g. Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
62641532|NCT05446961|PLACEBO_COMPARATOR|covid 19 placebo|The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
62072274|NCT05565274|EXPERIMENTAL|Tramadol plus Paracetamol|2ml of 100mg of intramuscular tramadol plus 2ml of 600mg of intramuscular paracetamol unlabeled
62641533|NCT05446961|ACTIVE_COMPARATOR|Healthy LCLT supplement|LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g. Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
62072275|NCT05565274|ACTIVE_COMPARATOR|Pentazocine plus placebo|2ml of 30mg of pentazocine plus 2 ml of water for injection will be administered intramuscularly during labour
62072276|NCT03978026|EXPERIMENTAL|nap in a bed|the participants take a nap of 30 min in a bed in a bedroom
62641534|NCT05446961|PLACEBO_COMPARATOR|Healthy Placebo|The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
62072277|NCT03978026|EXPERIMENTAL|nap in an armchair|the participants take a nap of 30 min in a car sit in a bedroom
62072278|NCT03978026|EXPERIMENTAL|nap in teh Sombox|the participants take a nap of 30 min in the micro-hotel Sombox
62072279|NCT03978026|SHAM_COMPARATOR|no nap in a bed|the participant stay awaked for 30 min in a bed in a bedroom
62072280|NCT05865457|EXPERIMENTAL|BUFY02|0.3% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.45 mL
62072281|NCT05865457|ACTIVE_COMPARATOR|TRB02|0.3% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.45 mL
62641535|NCT02164292||ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
62641536|NCT03352076|ACTIVE_COMPARATOR|Oral Danatrol|200 mg orally TDS (600 mg daily) for 5-7 days
62072282|NCT04583683|ACTIVE_COMPARATOR|Intensive lifestyle modification: Very low calorie diet|Patients will undergo a very low calorie diet
62072283|NCT04583683|ACTIVE_COMPARATOR|Metabolic Surgery|Patients will undergo metabolic surgery
62072284|NCT04093141|EXPERIMENTAL|Intervention|
62072285|NCT03816241|NO_INTERVENTION|Control|Vignette contains no extra information.
62072286|NCT03816241|EXPERIMENTAL|Frame|Vignette is framed in a particular manner
62072287|NCT03816241|EXPERIMENTAL|Norms|Vignette contains extra information about norms
62072288|NCT03816241|EXPERIMENTAL|All|Vignette contains extra information about norms and is framed in a particular manner.
62072289|NCT01719900|EXPERIMENTAL|Pulse Fibre|The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
62072290|NCT01719900|PLACEBO_COMPARATOR|Control|The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
62072291|NCT00968721||IBD patients|
62072292|NCT04563806|EXPERIMENTAL|Device feasibility (MRI-guided surgery)|Patients undergo standard of care spine surgery with MRI-based image guidance.
62072293|NCT04830605|EXPERIMENTAL|Intervention|Internet-delivered treatment for parents with health anxiety on behalf of their child. Eight weeks with therapist support.
62072294|NCT04581902|EXPERIMENTAL|Morning rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
62072295|NCT04581902|EXPERIMENTAL|Afternoon rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
62072296|NCT01763788|EXPERIMENTAL|Necitumumab + Gem and Cis|"Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m\^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m\^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.~Phase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m\^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m\^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
62072297|NCT01763788|ACTIVE_COMPARATOR|Gemcitabine + Cisplatin|Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m\^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles. Cisplatin 75 mg/m\^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles .
62072298|NCT01113619|EXPERIMENTAL|RP-G28|Study Drug RP-G28
62072299|NCT01113619|PLACEBO_COMPARATOR|Placebo|Study Drug Placebo
62072300|NCT06289790|ACTIVE_COMPARATOR|ESP block group|under general anaesthesia, preoperative ultrasound(USG) guided ESP blockade at Th5, single shot of 30 ml 0,3 % bupivacaine (not exceeding the maximum dose of 2 mg/kg of bupivacaine) with adrenaline 5 µg/ml and dexamethasone 0,15 mg/kg intravenously, post-operative infusion of 0,9% NaCl for 6 hours, infusion rate set as if it were lignocaine 1,5 mg/kg/h
62072301|NCT06289790|ACTIVE_COMPARATOR|Lignocaine infusion group|pre-induction lignocaine bolus of 1,5 mg/kg i.v. and dexamethasone 0,15 mg/kg intravenously, intraoperative infusion of lignocaine 2 mg/kg i.v., post-operative infusion of lignocaine 1,5 mg/kg i.v. for 6 hours
62072302|NCT01702818||HSDD group|Women with a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
62072303|NCT01702818||Control Group|Women without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
62072304|NCT03558958|EXPERIMENTAL|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
62276890|NCT00662792|EXPERIMENTAL|T18GEL+S_DPI/ Salm50DPI/ Tio18GEL/ T+S_PE|18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 50 µg Salmeterol MDPI (Salm50DPI) / 18 µg Tiotropium (Tio18GEL) / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE)
62072305|NCT01824914|EXPERIMENTAL|McGrath Videolaryngoscope|to compare the Cormack-Lehane grade in sedation and anesthesia by McGrath videolaryngoscope
62072306|NCT05429437|ACTIVE_COMPARATOR|Group I|will include 9 patients
62072307|NCT05429437|ACTIVE_COMPARATOR|Group II|will include 9 patients.
62072308|NCT02076867|EXPERIMENTAL|Intensive Short Term Dynamic Psychotherapy (ISTDP)|
62276891|NCT02584491|EXPERIMENTAL|Functional gait-related training|16 session, 6-week intensive functional gait-related training intervention based on motor learning principles that includes a motor imagery practice component.
62276892|NCT03572127|EXPERIMENTAL|Non-animal derived diet|High protein diet derived from non-animal sources.
62276893|NCT03572127|ACTIVE_COMPARATOR|Animal derived diet|High protein diet derived from animal sources.
62276894|NCT00493038|EXPERIMENTAL|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
62276895|NCT00493038|ACTIVE_COMPARATOR|Amoxicillin/Clavulanate|Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
62276896|NCT01490658|EXPERIMENTAL|Treatment period 1|
62072309|NCT02076867|ACTIVE_COMPARATOR|Medical Care As Usual (MCAU)|
62072310|NCT03436160|EXPERIMENTAL|WR826647|100 mcg Carbon-14 radio labeled WR826647 administered via IV
62276897|NCT01490658|EXPERIMENTAL|Treatment period 2|
62276898|NCT01490658|ACTIVE_COMPARATOR|Treatment period 3|
62276899|NCT02831673|EXPERIMENTAL|DTG + 3TC (50 mg+300 mg)|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the participant no longer derives clinical benefit, or (iv) the participant meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
62276900|NCT02831673|ACTIVE_COMPARATOR|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
62276901|NCT01422239|EXPERIMENTAL|Tailored behavioral counseling|"The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. The last 5 counseling sessions will be based on perceived risks of quitting."
62276902|NCT01422239|ACTIVE_COMPARATOR|Standard behavioral counseling|"The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual."
62276903|NCT03988907|EXPERIMENTAL|Part 1|Participants will receive a dose of 5 milligram (mg) risdiplam once daily (QD) for 14 consecutive days
62072311|NCT03436160|EXPERIMENTAL|WR909388|100 mcg Carbon-14 radio labeled WR909388 administered via IV
62072312|NCT03436160|EXPERIMENTAL|WR909390|100 mcg Carbon-14 radio labeled WR909390 administered via IV
62072313|NCT00863889|EXPERIMENTAL|1|1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
62072314|NCT00863889|PLACEBO_COMPARATOR|2|4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
62072315|NCT03396536||Group 1|Group 1 will be implants with keratinized mucosa (KM).
62072316|NCT03396536||Group 2|Group 2 implants without keratinized mucosa (KM). Alveolar mucosa (AM) directly present around the implant.
62072317|NCT04734535|EXPERIMENTAL|investigational|HEMOBLAST™ Bellows
62072318|NCT04734535|ACTIVE_COMPARATOR|control|absorbable gelatin sponge with thrombin
62072319|NCT00183456|EXPERIMENTAL|Intervention Condition: CHAT|Participants received the program over the course of five small group sessions and one individual session based on a harm reduction philosophy. Participants were trained as Peer Mentors and were encouraged to talk to their family, friends, and sex partners about a range of sex risk reduction options.
62072320|NCT00183456|ACTIVE_COMPARATOR|Comparison Condition: Standard of Care|The comparison condition consisted of one group session. The session focused on HIV and STIs transmission and risk reduction information.
62072321|NCT00183456|NO_INTERVENTION|Network Participants|Index participants generated a list of network members during their baseline visits and were asked to recruit eligible network members into the study. These network participants completed study interviews but did not participate in the intervention.
62072322|NCT00183456|NO_INTERVENTION|Non-randomized Baseline index participants|This arm includes those index participants that did not show up for randomization or did not recruit a network member were thus not eligible to be randomized into a study condition.
62072323|NCT03714022|EXPERIMENTAL|Treatment A|Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
62072324|NCT03714022|ACTIVE_COMPARATOR|Treatment B|Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
62072325|NCT01352702|EXPERIMENTAL|Arm 1|Dabigatran Therapy
62072326|NCT01352702|ACTIVE_COMPARATOR|Arm 2|Phenprocoumon Therapy
62072327|NCT04366219||2019|Data collection on patients with Lung cancer diagnosed between March 13, 2019 and August 28, 2019.
62072328|NCT04366219||2020|Data collection on patients with Lung cancer diagnosed between March 13, 2020 and August 28, 2020.
62072329|NCT02909023||Hepatitis B infected patients or cured|blood samples are performed to measure active T cellular immune response during a routine visit
62072330|NCT01435057|ACTIVE_COMPARATOR|endurance training|"Endurance training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min tread mill, rawing device or bicycle training.~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
62072331|NCT01435057|ACTIVE_COMPARATOR|strength training|"Strength training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min circle training~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of two to three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
62072332|NCT00237484|EXPERIMENTAL|Arm A|Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks
62276904|NCT03988907|EXPERIMENTAL|Part 2|All study participants will receive a single oral dose of 2 mg midazolam on Day 1. On Day 3, the 14-day QD treatment period with risdiplam will begin. The precise dose will be based on the results of Part 1, with single dose administration of 2 mg midazolam again on Day 15 (1 hour after the thirteenth dose of risdiplam)
62641537|NCT03352076|EXPERIMENTAL|Vaginal Danazol|100 mg of Danazol Cream to be applied vaginally for 5-7 days on a single daily dose
62072333|NCT00237484|ACTIVE_COMPARATOR|Arm B|PEGETRON treatment for up to 48 weeks
62072334|NCT04392232|EXPERIMENTAL|Convalescent Plasma|
62072335|NCT03694457|ACTIVE_COMPARATOR|deltopectoral approach|the patients are treated with deltopectoral approach surgery
62072336|NCT03694457|OTHER|lateral approach|the patients are treated with a lateral approach surgery
62072337|NCT02851160||Patients requiring lung cancer chemotherapy|30 major Patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment having a semi-structured interview conducted by a clinical psychologist
62072338|NCT02851160||Family of lung cancer patients receiving chemotherapy|30 Family of lung cancer patients receiving chemotherapy having a semi-structured interview conducted by a clinical psychologist
62072339|NCT02851160||doctors caring for lung cancer patients receiving chemotherapy|15 doctors caring for lung cancer patients receiving chemotherapy 15 have a semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
62641538|NCT06233786|EXPERIMENTAL|TENS in the bleeding phase|After completing the screening questionnaire and being evaluated, they receive TENS stimulation in the menstrual phase between days 25-28 (days before bleeding and where symptoms may begin) and 1-3 (first days of bleeding). They are evaluated again immediately after treatment and at the beginning of the next bleeding phase, being 28 days after the intervention.
62641539|NCT06233786|EXPERIMENTAL|TENS in the luteal phase|After completing the screening questionnaire and being evaluated, they receive TENS stimulation TENS stimulation in the luteal phase between days 17 to 24 of the menstrual cycle after the start of bleeding. They are evaluated again at the beginning of the next bleeding phase, being 7 days after the intervention, as well as 28 days after, being the next cycle.
62641540|NCT06233786|SHAM_COMPARATOR|Sham TENS in the bleeding phase|Same procedure as TENS in the bleeding phase, but without TENS stimulation.
62641541|NCT05412004|EXPERIMENTAL|Tirzepatide Maximum Tolerated Dose|"Participants will receive a low dose and then increase to a maximum tolerated dose 1 or dose 2 subcutaneously (SC).~GPI1: Participants are unwilling or unable to use PAP therapy.~GPI2: Participants are on PAP therapy."
62641542|NCT05412004|PLACEBO_COMPARATOR|Placebo|"Participants will receive placebo SC~GPI1: Participants are unwilling or unable to use PAP therapy.~GPI2: Participants are on PAP therapy."
62641543|NCT06204562|EXPERIMENTAL|one-month imitated laughter practice|The intervention is one-month imitated laughter practice. Each practice session lasts for 3 minutes once a day, giving a total of 21 minutes per week. A brief one-to-one training will be offered and a trained research assistant (RA1). Further in-person demonstration and return demonstration will be conducted until participant is able to demonstrate the Duchenne smile on their own. RA1 will be on-site for two days in the first week and one day in the second week to support the participants.
62072340|NCT04358341|ACTIVE_COMPARATOR|Irinotecan alone|150 mg/m2 iv drip d1; Repeat every 14 days.
62072341|NCT04358341|EXPERIMENTAL|Pegliposomal Doxorubicin and 5-FU|Pegliposomal Doxorubicin: 25mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h d1; Repeat every 14 days.
62072342|NCT05263076|EXPERIMENTAL|Uterine Transplant|uterus transplantation from living or deceased donor.
62072343|NCT03938064|ACTIVE_COMPARATOR|Group Early start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries from the day of ovum retrieval (OR).
62072344|NCT03938064|PLACEBO_COMPARATOR|Group Late start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries 2 days after OR.
62072345|NCT02601586|EXPERIMENTAL|PR oxycodone|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~* Oxycodone : 10 mg PR/day bid (5 mg PR/5 mg PR)~* Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~* Oxycodone : 20 mg PR/day tid (10 mg/0 mg/10 mg)~* Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~* Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)~* Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~  * A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~ * A withdrawal period:"
62072346|NCT02601586|ACTIVE_COMPARATOR|levodopa|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~* Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~* Levodopa 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~* Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~* Levodopa : 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~* Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~* Levodopa : 200 mg/day tid (100 mg/50 mg/50 mg)~  * A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~ * A withdrawal period:"
62088430|NCT02492061|NO_INTERVENTION|Standard of care|In the standard of care arm, participants receive general adult health talks to educate them about the importance of HIV testing (including couples' HCT) but no invitations are issued to invite couples to test for HIV together with their partners at a designated health facility. However, couples can seek HCT out of their own volition. The sessions are not stratified by marital status, and attendants include all those who are willing and are able to attend.
62641544|NCT06204562|EXPERIMENTAL|waitlist control|The waitlist control group will be under usual care for the first 8 weeks. Then, they will start intervention after the 8 week, and receive two additional outcome assessments.
62072347|NCT02601586|PLACEBO_COMPARATOR|Placebo|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~* Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~* Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~* Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~* Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~* Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~* Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~  * A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~ * A withdrawal period:"
62641545|NCT06006156|EXPERIMENTAL|dental implant with a convergent collar|One implant with a converging collar with micro threads will be installed in each patient according to the site randomization in the esthetic region of the upper jaw (between the second premolars).
62072348|NCT00937170|EXPERIMENTAL|Gender Specific LPS flex|Participants in this arm will receive the Zimmer LPS flex Gender Specific Implant design
62276905|NCT05728294|ACTIVE_COMPARATOR|Femoral nerve block|Femoral nerve block performed under ultrasound guidance with ropivacaine 0.5%, 20mL
62276906|NCT05728294|EXPERIMENTAL|Sciatic nerve block|Sciatic nerve block performed under ultrasound guidance with ropivacaine 0.5%, 20mL
62276907|NCT02273583|EXPERIMENTAL|Maintenance therapy|73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
62276908|NCT02273583|NO_INTERVENTION|Control|31 weeks of MAP.
62276909|NCT00488384|OTHER|a|single arm only. Only open label treatment anticipated
62276910|NCT01275482|EXPERIMENTAL|isolated contractions caused|The investigators do TFM causing isolated contractions in de muscle fibers containing de latent trigger point.
62455236|NCT02596503|EXPERIMENTAL|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
62641546|NCT06006156|ACTIVE_COMPARATOR|dental implant with a divergent collar|One implant with a diverging polished collar will be installed in each patient according to the site randomization in the esthetic region of the upper jaw ( between the second premolars).
62641547|NCT03546673|NO_INTERVENTION|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
62641548|NCT03546673|EXPERIMENTAL|Self-regulation Condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
62072349|NCT00937170|ACTIVE_COMPARATOR|LPS flex|Participants in this arm will receive the Zimmer High Flex LPS implant
62072350|NCT00937170|ACTIVE_COMPARATOR|Triathlon|Participants in this arm will receive the Stryker Triathlon Implant design
62072351|NCT03600038|EXPERIMENTAL|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
62072352|NCT03600038|ACTIVE_COMPARATOR|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
62072353|NCT01658709||Ankle Injured|Volunteers with an ankle injury
62072354|NCT01658709||Healthy|Healthy Volunteers
62072355|NCT00424853|EXPERIMENTAL|A|
62072356|NCT00424853|EXPERIMENTAL|B|
62276911|NCT01275482|ACTIVE_COMPARATOR|No isolated contraction caused|The investigators don´t cause contraction during the TFM
62276912|NCT01099072|ACTIVE_COMPARATOR|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Placebo
62276913|NCT01099072|EXPERIMENTAL|methylphenidate+carnitine|
62276914|NCT01844882||Chronic Kidney Disease|
62276915|NCT01142726|ACTIVE_COMPARATOR|Abatacept, 125 mg, plus methotrexate, 2.5 mg|Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
62276916|NCT01142726|ACTIVE_COMPARATOR|Methotrexate, 2.5 mg, plus abatacept placebo|Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
62276917|NCT01142726|ACTIVE_COMPARATOR|Abatacept, 125 mg, plus methotrexate placebo|Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
62276918|NCT01109030|ACTIVE_COMPARATOR|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
62276919|NCT01109030|PLACEBO_COMPARATOR|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks."
62287186|NCT00802360|ACTIVE_COMPARATOR|Follistim/Progesterone in Oil|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
62455237|NCT04641559|EXPERIMENTAL|Personalized nutrition group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue during four months.
62072357|NCT00594906|ACTIVE_COMPARATOR|Injection|30 participants will receive teriparatide (Forteo) injection pens.
62072358|NCT00594906|PLACEBO_COMPARATOR|Placebo|30 participants will receive placebo injection pens.
62072359|NCT02368002|EXPERIMENTAL|Behavioral weight loss therapy|Emphasizes 1) identifying behaviors in need of change, 2) setting goals for change, 3) monitoring progress, 4) modifying environmental cues to facilitate change, and 5) modifying consequences to motivate change.
62072360|NCT02368002|EXPERIMENTAL|Portion-controlled meals|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive portion-controlled meals in addition to standard behavioral weight loss therapy.
62072361|NCT02368002|EXPERIMENTAL|Acceptance-based treatment|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive an enhanced version of behavioral weight loss therapy teaching acceptance-based behavioral skills.
62072362|NCT05611905||11C-para-aminobenzoic acid PET/CT|
62072363|NCT04478084|EXPERIMENTAL|Group 1: pediatric participants; VRVg-2|VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
62072364|NCT04478084|ACTIVE_COMPARATOR|Group 2: pediatric participants; Verorab|Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
62072365|NCT04478084|EXPERIMENTAL|Group 3: adult participants; VRVG-2 + ERIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
62072366|NCT04478084|ACTIVE_COMPARATOR|Group 4: adult participants; Verorab + ERIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
62072367|NCT04478084|EXPERIMENTAL|Group 5: adult participants; VRVG-2 + HRIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
62072368|NCT04478084|ACTIVE_COMPARATOR|Group 6: adult participants; Verorab + HRIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
62072369|NCT01862458|ACTIVE_COMPARATOR|tPA alone|tPA alone used to treat empyema
62072370|NCT01862458|EXPERIMENTAL|tPA plus dornase|tPA plus dornase used to treat empyema
62641549|NCT03546673|EXPERIMENTAL|Emotional Disclosure condition|For the emotional disclosure condition, participants were asked to write about their deepest thoughts and feelings about their cancer experience for three weeks.
62072371|NCT02925260||Patients with normal ileal pouches|"Inclusion Criteria~* Ileal pouch reservoir in situ~* Greater than three years since closure of ileostomy~* Normal pouch function as defined by Orësland score of \<4~* Never had a diagnosis of pouchitis~* Never had treatment for pouchitis~* No evidence of pouchitis on rigid pouchoscopy~* CRP \<10"
62072372|NCT03915119|EXPERIMENTAL|VR Obstacle group|"Initial Visit: navigates a cluttered array of fixed and moving virtual obstacles to reach a way-point (goal) as fast and efficiently (avoiding obstacles) as possible. In each block, task difficulty (i.e., complexity) will increase linearly, regardless of success or failure (≥ 1 collision before reaching the goal).~Second (Training) Visit (randomized into two groups):"
62072373|NCT03915119|EXPERIMENTAL|Agility Group|"Initial Visit: Completes a soccer ball dribbling agility task in which they must dribble a soccer ball toward an artificial way-point, while avoiding artificial obstacles overlaid onto the real world via a Microsoft Hololens augmented reality display.~Second (Training) Visit"
62072374|NCT01197989|EXPERIMENTAL|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
62072375|NCT01197989|PLACEBO_COMPARATOR|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
62072376|NCT04177914|ACTIVE_COMPARATOR|ETV+CPC|Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus
62072377|NCT04177914|ACTIVE_COMPARATOR|Ventriculoperitoneal Shunt|Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus
62072378|NCT05766072|ACTIVE_COMPARATOR|Intervention arm|"Youth in this arm received the intervention over 10 weeks during one semester (recruiting children over 6 semesters in total), children meeting in groups of approx. seven children. The groups were led by school health nurses.~At the same time parents met for 7 group sessions, with the children participating in four of these"
62641550|NCT05892237|EXPERIMENTAL|central-type squamous NSCLC|"1. Phase I:~1. Chemo-Immulo-embolization via Tumor Arterial, CIETAI:~   DSA guided tumor artery infusion of nano-paclitaxel 200 mg+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~2. two cycles of chemotherapy combined with immune checkpoint inhibitors (q3w): Nano-paclitaxel 260 mg/m2, d1, ivgtt; Cisplatin 75mg/m2, d1, ivgtt; PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min 2. phase II: Chest radiotherapy: 60Gy/2Gy/30f 3. phase III: PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min Maintenance for 1 year"
62072379|NCT05766072|NO_INTERVENTION|Control arm|The youth in the control condition received treatment as usual, e.g. talks with school health nurses or no intervention
62072380|NCT03713372|EXPERIMENTAL|Anti-EGFR monoclonal antibody|6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
62072381|NCT00969345|SHAM_COMPARATOR|Control Group|Stretching exercises performed twice a day for 10 minutes (4 months)
62072382|NCT00969345|ACTIVE_COMPARATOR|Respiration Group|Respiratory Yoga exercises performed twice a day for 10 minutes (4 months)
62072383|NCT04876885|OTHER|General public|The individuals recruited to the study will include those who are age 16 and older. Due to recruitment feasibility we will focus efforts on individuals living in Ontario. We intend to recruit individuals from COVID-19 assessment centres that are partnering in our study as well as through social media posts (Facebook, Twitter, LinkedIn).
62072384|NCT04876885|OTHER|Healthcare professionals and public health professionals|The individuals recruited to the study will include healthcare professionals and public health professionals impacted by infectious disease outbreaks. Social media will be used to disseminate surveys to physicians, nurses, nurse practitioners, pharmacists, and healthcare workers. Public health units will disseminate surveys to their workforce.
62455238|NCT04641559|EXPERIMENTAL|Personalized Plan group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue and behavioural change program during four months.
62455239|NCT04641559|PLACEBO_COMPARATOR|Control group|General recommendations but not personalization nor behavioural change advice will be implemented during four months.
62641551|NCT02472730|EXPERIMENTAL|Cap Assisted Colonoscopy|The distal attachment cap is affixed to the colonoscope before every colonoscopy in this arm.
62641552|NCT02472730|NO_INTERVENTION|Standard Colonoscopy|Standard colonoscopy without the distal attachment cap is performed in this arm.
62641553|NCT01666483|ACTIVE_COMPARATOR|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
62072385|NCT03276663|OTHER|Formula fed group|Formula feeding regimen
62072386|NCT03276663|NO_INTERVENTION|Human milk-fed group|
62072387|NCT06489340|EXPERIMENTAL|2HPβCD|Study drug will be administered by IV infusion during the treatment period.
62072388|NCT02415920|EXPERIMENTAL|Experimental|These participants will receive 24 international units (IU) of oxytocin via a nasal spray.
62072389|NCT02415920|PLACEBO_COMPARATOR|Control - Placebo|These participants will receive 24 international units (IU) of a saline solution via a nasal spray.
62072390|NCT02110446|EXPERIMENTAL|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
62072391|NCT02110446|PLACEBO_COMPARATOR|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
62455240|NCT04574193|EXPERIMENTAL|Continuing Care App|Participants will receive the Continuing Care app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy).
62455241|NCT04574193|ACTIVE_COMPARATOR|Treatment As Usual|Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.
62455242|NCT04207879||weight loss group|Dynamic changes in body composition, biochemical metabolomics and gut microbiome will be reported among overweight and obese patients.
62455243|NCT00937066||1|Adult patients 18-65 years with moderate to severe uncontrolled asthma
62455244|NCT03709862||Syphilis|Patients with syphilis and detectable Treponema pallidum DNA in a routinely collected clinical sample
62072392|NCT06044220|EXPERIMENTAL|Intervention|The intervention group is given a 3-month reminder after the TSE training.
62072393|NCT06044220|OTHER|control|No training or reminders are given to the control group
62072394|NCT03963323|EXPERIMENTAL|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
62072395|NCT03963323|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
62072396|NCT06297681||newly diagnosed M-protein related cardiac disease group|M-protein related cardiac disease aged 18 and above (at least one of the following criteria is met): (1) Systemic amyloidosis of the affected heart; (2) Presence of M component and presence of arrhythmia, cardiac enzyme abnormalities, cardiac function abnormalities, and exclusion of other diagnosable cardiac diseases. It is expected to include 40 patients with M-protein related cardiac disease. The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
62072397|NCT02120885|EXPERIMENTAL|Exercise group|physical activity intervention
62072398|NCT02120885|NO_INTERVENTION|Control group|
62455245|NCT03958032||Participants with gastric cancer|All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
62072399|NCT04439006|EXPERIMENTAL|Arm A (ibrutinib)|Patients receive ibrutinib PO QD on days 1-7. Treatment repeats every 7 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who remain hospitalized or are re-admitted after 2 cycles may receive an additional 2 cycles per physician's discretion.
62072400|NCT04439006|ACTIVE_COMPARATOR|Arm B (usual care)|Patients receive usual care.
62072401|NCT01446263|ACTIVE_COMPARATOR|Radial access|
62072402|NCT01446263|ACTIVE_COMPARATOR|Femoral access|
62455246|NCT01315249|EXPERIMENTAL|QVA149|Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
62455247|NCT01315249|ACTIVE_COMPARATOR|fluticasone/salmeterol|Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).
62455248|NCT04751110|OTHER|block group|ultrasound guided rhomboid intercostal block will performed
62455249|NCT06485219|EXPERIMENTAL|Purinostat Mesylate group|
62641554|NCT01666483|ACTIVE_COMPARATOR|laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip.Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
62641555|NCT02204943|EXPERIMENTAL|Bone Biopsy and Circulating Tumor Cell Samples|
62641556|NCT03098680|EXPERIMENTAL|Group A (Placebo, Salbutamol, Nicardipine, Dobutamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)"
62641557|NCT03098680|EXPERIMENTAL|Group B (Placebo, Phenylephrine, Verapamil, Phentolamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)"
62641558|NCT00617357|EXPERIMENTAL|1|Strattice Reconstructive Tissue Matrix
62641559|NCT06154304|PLACEBO_COMPARATOR|Placebo Product|One actuation each from four different placebo inhalation aerosols.
62641560|NCT06154304|EXPERIMENTAL|Test Product|One actuation from the test inhalation aerosol and one actuation each from three different placebo inhalation aerosols
62641561|NCT06154304|ACTIVE_COMPARATOR|Reference 90mcg Product|One actuation from the reference inhalation aerosol and one actuation each from three different placebo inhalation aerosols.
62072403|NCT03853122|ACTIVE_COMPARATOR|Best current practice exercise programme|"Therapeutic physical exercise, best current practice:~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group)."
62072404|NCT03853122|EXPERIMENTAL|Experimental exercise programme|"Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages):~Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly"
62072405|NCT04912596|PLACEBO_COMPARATOR|Placebo group|Two different Reference Placebo inhalers and two different Test Placebo inhalers
62072406|NCT04912596|ACTIVE_COMPARATOR|Reference 1 group|One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers
62072407|NCT04912596|ACTIVE_COMPARATOR|Reference 2 group|Two different Reference inhalers and two different Test Placebo inhalers
62641562|NCT06154304|ACTIVE_COMPARATOR|Reference 180mcg Product|One actuation each from two different reference inhalation aerosols and one actuation each from two different placebo inhalation aerosols
62072408|NCT04912596|EXPERIMENTAL|Test group|One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers
62072409|NCT06316505|NO_INTERVENTION|Control group (CG)|Conventional oral hygiene education (COHE)
62072410|NCT06316505|EXPERIMENTAL|Intervention group (IG)|In addition to COHE, oral hygiene motivation with individual oral photographs
62641563|NCT00435617|EXPERIMENTAL|A|Hand Mentor
62641564|NCT02729337|EXPERIMENTAL|ITG (In This Together)|This will be a multi-week behavioral intervention delivered daily via text messaging. Content will be based upon the IMB model of HIV preventive behavior and informed by our formative work.
62641565|NCT02729337|NO_INTERVENTION|Control Group|Given the preliminary nature of the intervention development, the control group will be inactive but blinded. They will receive two messages per week encouraging them to make healthy sexual decisions to reduce their HIV risk. Messages will be didactic and not driven by the IMB model.
62641566|NCT03048045||Supportive Periodontal Treatment (SPT)|"* at least 18 years old.~* periodontal treatment (antiinfective therapy with subgingival debridement under local anesthesia and if required periodontal surgery) at the Dept. of Periodontology starting after April 2005 durchgeführt.~* complete periodontal charting (PPD and PAL-V at 6 sites per tooth, furcation involvement \[Hamp et al. 1975\] at all furcation sites of multi-rooted teeth) prior to treatment (baseline, T0) and after completion of active periodontal treatment (APT) (reevaluation 1 or 2/start of supportive periodontal therapy, T1)~* radiographs of all teeth (periapical radiographs or panoramic radiograph) from baseline~* written informed consent"
62072411|NCT05284292|EXPERIMENTAL|experimental arm|The Guardian platform consists of the robot Misty II, the Senior App and the Caregiver App will be tested by the elderly subjects together with their caregivers
62072412|NCT02401958|EXPERIMENTAL|Rheumatoid Arthritis Group|Resistance Training
62072413|NCT02401958|ACTIVE_COMPARATOR|Healthy control Group|Resistance Training
62072414|NCT00761917||1: Normal|Subjects without dry eye symptoms based on questionnaire.
62072415|NCT00761917||2: Dry Eye|Subjects with dry eye symptoms based on questionnaire.
62072416|NCT01563978|EXPERIMENTAL|Dosing Regimen A|Oral treatment
62072417|NCT01563978|PLACEBO_COMPARATOR|Dosing Regimen B|Oral treatment
62072418|NCT03151395|OTHER|Total Group|Moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) patients with at least 1 documented moderate or severe Acute exacerbation of COPD (AECOPD) in the year before enrolment and for whom sputum and blood samples are collected during specified visits
62088431|NCT02720887||pregnant woman|Patient to receive an amniocentesis for medical reasons other than study and who will have a measure of nanoparticles load
62088432|NCT01049750||type 2 diabetic patients|males; type 2 diabetic patients
62088433|NCT04710355||Chronic pain|Failed back surgery syndrome
62641567|NCT02184104|ACTIVE_COMPARATOR|Aeroshot|A single 100 mg caffeine dose administered using the Aeroshot device.
62641568|NCT02184104|ACTIVE_COMPARATOR|Energy Drink|A single 100 mg caffeine dose administered as an oral solution.
62641569|NCT01545388|EXPERIMENTAL|Metformin 500 mg q.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
62641570|NCT01545388|EXPERIMENTAL|Metformin 250 mg b.i.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
62641571|NCT01545388|PLACEBO_COMPARATOR|Placebo|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
62641572|NCT05660629|EXPERIMENTAL|Mulligan Mobilization|"Rehabilitation Program (Active wrist ROM exercises):~* Forearm pronation and supination~* Wrist flexion and extension~* Wrist flexion and extension (in the form of a fist)~* MCP Joint Flexion and Extension~* Thumb IC joint Flexion and Extension~* Abduction and Adduction of Fingers~These exercises will be performed by the physiotherapist in the form of 5 seconds of movement / 15 seconds of rest, 10 repetitions a day, 5 days a week for 6 weeks.~Mulligan Mobilization:~* Carpal Medio-lateral Glide (open kinetics, wrist flexion and extension movement)~* Carpal Rotation (open kinetics, wrist flexion and extension)~* Scaphoid Antero-posterior Glide (open kinetics)~* Metacarpal Antero-posterior Glide (When Clenching)~* Medio-lateral Glide to PIP-DIP joints (open kinetics, fingers flexed)"
62641573|NCT05660629|SHAM_COMPARATOR|Sham Mobilization|Participants will receive sham mobilization in addition to the ROM exercises given in the Mulligan group. Sham mobilization will be done in the same position as Mulligan but without any glide force.
62641574|NCT05660629|NO_INTERVENTION|Control|Participants will receive therapeutic patient training consisting of home exercise recommendations, basic disease information, physical activity advice, and joint protection methods.
62641575|NCT03918057|EXPERIMENTAL|Cognitive-Behavioural Therapy Group|Participants receive 5 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
62641576|NCT03918057|ACTIVE_COMPARATOR|Treatment as Usual Group|Participants receive usual obstetric care and are placed on a wait-list until six months postpartum. All activities or efforts participants make to treat or improve their sleep on their own is recorded and coded. After the final assessment six months postpartum, participants have the option of receiving 1.5-hour sessions (for a total of 5 session) of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
62641577|NCT02429050|ACTIVE_COMPARATOR|intervention|sustained release morphine
62641578|NCT02429050|PLACEBO_COMPARATOR|control|placebo
62641579|NCT03497871|EXPERIMENTAL|HeartMan intervention group|"80 patients are in the intervention group (40 in Belgium and 40 in Italy).~They use the HeartMan system in addition to receiving standard care."
62641580|NCT03497871|NO_INTERVENTION|Standard care (control) group|"40 patients are in the no-intervention group (20 in Belgium and 20 in Italy).~They receive standard care, which consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year."
62276920|NCT03569995|EXPERIMENTAL|Induction+Consolidation chemotherapy|"\[Induction phase\]~① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation~* Complete, partial response or stable disease-\> next step~* Progressive disease-\> eliminated~  ② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation~* Complete response -\> consolidation therapy(Rituximab-Cytarabine) progress~* Partial response or stable disease-\> Rituximab-Methotrexate 2 additional administrations~* Progressive disease-\> eliminated~  ③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation~* Complete, partial response or stable disease-\> consolidation therapy(Rituximab-Cytarabine)~* Progressive disease-\> eliminated"
62641581|NCT04383301|ACTIVE_COMPARATOR|Intra corneal ring segment|Intra corneal ring segment implantation for moderate keratoconus patients
62641582|NCT04383301|ACTIVE_COMPARATOR|Corneal Wavefront-guided TPRK and ACXL|Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking following intracorneal ring segment by at least three months
62641583|NCT04827277|ACTIVE_COMPARATOR|Reverse total shoulder replacement|Participants will receive a reverse total shoulder arthroplasty
62641584|NCT04827277|ACTIVE_COMPARATOR|Anatomic total shoulder replacement|Participants will receive an anatomic total shoulder arthroplasty
62641585|NCT01278342|ACTIVE_COMPARATOR|Sandostatin LAR high dose Alone|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with controlled GH and IGF-I after 3 months of Sandostatin LAR monotherapy continued to receive Sandostatin LAR 40 mg i.m. every 28 days for an additional 4 months.
62276921|NCT03704870|ACTIVE_COMPARATOR|Daily Chest Xray (standard)|
62276922|NCT03704870|EXPERIMENTAL|Chest Xray post chest tube removal only|
62072419|NCT01677780|EXPERIMENTAL|RO5045337|Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
62072420|NCT05428904|EXPERIMENTAL|Intervention Group|Nursing undergraduate students participating in a virtual reality simulation program
62072421|NCT05428904|NO_INTERVENTION|Control Group|Nursing undergraduate students receiving attention-matched training
62072422|NCT01984190||Lower Extremity Joint Arthroplasty|Postoperative venous thromboembolism incidence in lower extremity joint arthroplasty using only the mobile compression device with or without aspirin for venous thromboembolism prevention. Sub-analysis of Total Hip Arthroplasty and Total Knee Arthroplasty will be included.
62072423|NCT04287959|ACTIVE_COMPARATOR|A: wean to 30%|wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.
62641586|NCT01278342|EXPERIMENTAL|Sandostatin LAR high dose + Pegvisomat|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR40 mg every 28 days in combination with weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for a further 4 months
62641587|NCT01278342|EXPERIMENTAL|Sandostatin LAR high dose + Cabergoline|"All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR 40 mg every 28 days in combination with weekly cabergoline for a further 4 months, with cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
62641588|NCT04869592|EXPERIMENTAL|Phase 1 low-dose group|
62641589|NCT04869592|EXPERIMENTAL|Phase 1 high-dose group|
62641590|NCT04869592|PLACEBO_COMPARATOR|Phase 1 placebo group|
62641591|NCT04869592|EXPERIMENTAL|Phase 2 low-dose group A|
62641592|NCT04869592|EXPERIMENTAL|Phase 2 low-dose group B|
62641593|NCT04869592|EXPERIMENTAL|Phase 2 low-dose group C|
62641594|NCT04869592|EXPERIMENTAL|Phase 2 low-dose group D|
62641595|NCT04869592|EXPERIMENTAL|Phase 2 high-dose group A|
62641596|NCT04869592|EXPERIMENTAL|Phase 2 high-dose group B|
62641597|NCT04869592|EXPERIMENTAL|Phase 2 high-dose group C|
62641598|NCT04869592|EXPERIMENTAL|Phase 2 high-dose group D|
62455250|NCT02361047|EXPERIMENTAL|Phone Coaching Program|Participants will receive a nutrition and physical activity phone coaching program, in addition to standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
62455251|NCT02361047|NO_INTERVENTION|Standard Care Control|Participants will receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
62455252|NCT01089647|ACTIVE_COMPARATOR|budesonide and montelukast|treatment arm
62455253|NCT01089647|PLACEBO_COMPARATOR|placebo|sugar pill, salt water nasal spray
62455254|NCT00600925|EXPERIMENTAL|1|Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
62455255|NCT00600925|NO_INTERVENTION|2|Standard of care, ie, no gentamicin-collagen sponge.
62455256|NCT05903365||Patient with Fanconi disease|
62455257|NCT00592098|EXPERIMENTAL|1|2PX
62455258|NCT00592098|PLACEBO_COMPARATOR|2|Placebo
62455259|NCT01584921|PLACEBO_COMPARATOR|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
62455260|NCT01584921|ACTIVE_COMPARATOR|Low dose Erythropoietin|
62641599|NCT04869592|PLACEBO_COMPARATOR|Phase 2 placebo group A|
62641600|NCT04869592|PLACEBO_COMPARATOR|Phase 2 placebo group B|
62455261|NCT01584921|ACTIVE_COMPARATOR|High dose Eryhropoietin|
62072424|NCT04287959|ACTIVE_COMPARATOR|B: wean to 21%|wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.
62072425|NCT06108115|EXPERIMENTAL|Behavioral: CueToSleep (Full Intervention Package)|Individuals will be randomly allocated to receive the full Health Rhythms package (CueToSleep) program on their smartphones. The package includes 24/7 behavioral sensing from the participant's smartphone using the global positioning system, accelerometer, and screen on/off state, as well as a series of psychoeducational learning screens about the relationship among alcohol, mood disturbance and sleep, and personalized suggestions for behavior change to improve sleep that will be sent to the participant every 3 to 4 days. These suggestions will be based on behaviors indicated by the individual participant's sensor data over the previous 3 to 4 days.
62072426|NCT06108115|NO_INTERVENTION|Measure (Behavioral Sensing Only)|Individuals will only be monitored using the passive sensing capabilities of the Full Intervention Package on their smartphones. These participants will not receive psychoeducational learning screens or behavior change suggestions.
62276923|NCT00865020|EXPERIMENTAL|Aliskiren 300 mg|Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
62276924|NCT00865020|ACTIVE_COMPARATOR|Telmisartan 80 mg|Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
62276925|NCT03343275|EXPERIMENTAL|Experimental|"Dietary supplement : Lit-Control® pH Down~* Pharmaceutical form: capsules~* Administration : oral~* Dose: 3 capsules/day.~  • Sanitary product : Lit-Control® pH Meter~* In vitro diagnosis sanitary product~* Use:Urinary pH evaluation"
62276926|NCT03343275|PLACEBO_COMPARATOR|Placebo|"Placebo:~* Pharmaceutical form: capsules~* Administration : oral~* Dose: 3 capsules/day.~  • Sanitary product : Lit-Control® pH Meter~* In vitro diagnosis sanitary product~* Use:Urinary pH evaluation"
62276927|NCT05721508|EXPERIMENTAL|Individual practice at home|Participants will undergo a training program combining physical and cognitive activities in individual practice at home.
62455262|NCT01163760|OTHER|etafilcon A / ocufilcon D|etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable
62455263|NCT01163760|OTHER|oculfilcon D / etafilcon A|ocufilcon D contact lens worn first, etafilcon A contact lens worn second
62072427|NCT01465139|EXPERIMENTAL|CDX-301|CDX-301 (rhuFlt3L), administered to healthy patients.
62276928|NCT05721508|EXPERIMENTAL|Group practice in a traditional group environment (gymnasium)|Participants will undergo a training program combining physical and cognitive activities in group practice in a traditional group environment (gymnasium).
62276929|NCT05721508|EXPERIMENTAL|Group practice in an enriched environment fostering social relations|Participants will undergo a training program combining physical and cognitive activities in group practice in an enriched environment fostering social relations.
62276930|NCT02254031|EXPERIMENTAL|bivatuzumab mertansine|dose escalation
62455264|NCT01163760|OTHER|ocufilcon D / ocufilcon D|ocufilcon D contact lens worn first and second
62455265|NCT01163760|OTHER|etafilcon A / etafilcon A|etafilcon A contact lens worn first and second
62455266|NCT03744416|EXPERIMENTAL|Intervention group|Counseling based on Epstein's active decision making on birth plan
62455267|NCT03744416|NO_INTERVENTION|Control group|The standard midwife's advice on birth plan during prenatal care.
62455268|NCT06009913|EXPERIMENTAL|online teaching|Teaching was done completely online
62072428|NCT04691297|EXPERIMENTAL|Escape|The ESCAPE program provides 8 counseling sessions over the phone, provides nicotine replacement therapy at no cost, and education about lung screening
62455269|NCT06009913|ACTIVE_COMPARATOR|Conventional class room|Teaching was done completely offline in classroom
62455270|NCT03487055|EXPERIMENTAL|treatment group|The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.
62455271|NCT01716845||Development group 1|
62455272|NCT01716845||Development group 2|
62455273|NCT01716845||Development group 3|
62455274|NCT01716845||Validation group|
62641601|NCT04869592|PLACEBO_COMPARATOR|Phase 2 placebo group C|
62641602|NCT04869592|PLACEBO_COMPARATOR|Phase 2 placebo group D|
62641603|NCT05203640|EXPERIMENTAL|All participants|All participants will be in a single arm that undergoes two separate interventions. These interventions will include a high repetition, low resistance protocol, and a moderate repetition, moderate intensity protocol.
62641604|NCT05732376|EXPERIMENTAL|3D Printed Endoscopy Training Model Group|
62641605|NCT05732376|ACTIVE_COMPARATOR|Ready-Made Endoscopy Training Model Group|
62072429|NCT04691297|EXPERIMENTAL|Standard Care|The usual care program will include 1 counseling session, nicotine replacement therapy at no cost referral and enrollment in quitworks and an educational brochure about lung cancer screening
62072430|NCT05096676|EXPERIMENTAL|Adolescents diagnosed with Autism spectrum disorder|Participants in the ASD group received oxytocin and placebo in a randomized, double-blind placebo-controlled manner.
62276931|NCT05818657||Group-A CKD patients|Prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in PAI score, eGFR \& Systemic markers will be checked
62641606|NCT03928054|EXPERIMENTAL|"group 1 Kinesio Taping® KT"|Kinesio Taping® KT
62072431|NCT05096676|NO_INTERVENTION|Typically developing adolescents|Control participants were recruited using online ads. This group did not receive oxytocin or placebo due to ethical constraints in Israel.
62072432|NCT06124482|EXPERIMENTAL|Knee replacement|Implantation of FHK-CK prosthesis either for a complex primary arthroplasty or for revision intend
62072433|NCT01234766|EXPERIMENTAL|Single Arm|Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
62641607|NCT03928054|EXPERIMENTAL|" Kinesio Taping® with therapeutic alliance KT+AT"|Kinesio Taping® with therapeutic alliance
62641608|NCT01270035|EXPERIMENTAL|ADA 80 mg eow + MTX|
62072434|NCT00582491|EXPERIMENTAL|I|Modafinil 400mg orally everyday for 16 days
62072435|NCT00582491|PLACEBO_COMPARATOR|II|Placebo orally everyday for 16 days
62276932|NCT05818657||Group-B Healthy individuals|Prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in PAI score, eGFR \& Systemic markers will be checked
62276933|NCT00851071|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Three individual 45 minute cognitive behavioral therapy sessions over a 3 month period
62276934|NCT00851071|NO_INTERVENTION|Usual Care Arm|The Usual Care Arm will be the control arm. These patients will not be scheduled with any CBT sessions.
62276935|NCT06549205|EXPERIMENTAL|TUD group|an intraoral device will be administered in the TUD group in order to provide the stimulation of the dorsal surface of the tongue with dental TENS. The trial will last approximately 24 minutes, after the first 6 minutes, TENS activation will take place and how HRV values change will be evaluated. The Heart rate Variability parameters will be analysed with photopletismographic wave after 6 minutes of tongue stimulation
62276936|NCT06549205|ACTIVE_COMPARATOR|Tragus group|patients in this group will be administered traditional trigeminal stimulation with dental TENS at tragus level. Tens will be turned on for 6 minutes in which the HRV parameters will be analyzed with the photoplethysmograph and compared with the data obtained in the TUD group.
62641609|NCT05869370|EXPERIMENTAL|High intensity resistance training|
62072436|NCT01752595|NO_INTERVENTION|Standard|Subjects randomized to this group will receive standard, usual care with no intervention.
62072437|NCT01752595|ACTIVE_COMPARATOR|Preference Based Music Intervention|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods.
62641610|NCT05869370|EXPERIMENTAL|Low intensity resistance training combined with blood flow restriction|
62641611|NCT06021327|ACTIVE_COMPARATOR|Erector spinae plane block|will receive a US-guided ESPB
62641612|NCT06021327|ACTIVE_COMPARATOR|Retrolaminar block|will receive a US-guided RLB
62641613|NCT03044314|EXPERIMENTAL|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
62641614|NCT01851941|EXPERIMENTAL|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
62641615|NCT04322032|EXPERIMENTAL|Group 1|"1. Period 1: Reference drug~2. Period 2: Test drug"
62641616|NCT04322032|EXPERIMENTAL|Group 2|"1. Period 1: Test drug~2. Period 2: Reference drug"
62072438|NCT01752595|ACTIVE_COMPARATOR|Preference Based Rhythmic Auditory Stimulation Music|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods. Rhythmic Auditory Stimulation (accentuation of beats, frequencies) will be added to the music subliminally.
62641617|NCT01195350||stroke|
62276937|NCT01017952|EXPERIMENTAL|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62641618|NCT01251952|EXPERIMENTAL|Denileukin Diftitox (Ontak)|Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
62641619|NCT05266469||Ofatumumab|Patients prescribed with Ofatumumab
62072439|NCT04857112|EXPERIMENTAL|Low Dose|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
62276938|NCT01017952|EXPERIMENTAL|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62276939|NCT01017952|EXPERIMENTAL|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62276940|NCT01017952|EXPERIMENTAL|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
62276941|NCT05421910|EXPERIMENTAL|Early training group|The early group will receive robotic training combined with electrical stimulation as soon as possible after submission to the rehab center. With a frequency of three times a week for 3-5 weeks, dependent on the capabilities of the patients.
62276942|NCT05421910|ACTIVE_COMPARATOR|Late training group|The late training group will receive robotic training combined with electrical stimulation 3-5 weeks after submission to the rehab center. With a frequency of three times a week for 3-5 weeks, dependent on the capabilities of the patients.
62276943|NCT00983047|ACTIVE_COMPARATOR|Docetaxel|The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.
62276944|NCT00983047|EXPERIMENTAL|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2,efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD.No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment:Dose of 200mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxic."
62276945|NCT02377375|EXPERIMENTAL|Micro-assisted|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
62276946|NCT02377375|ACTIVE_COMPARATOR|Standard|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
62276947|NCT01660932|PLACEBO_COMPARATOR|placebo|placebo
62276948|NCT01660932|ACTIVE_COMPARATOR|omega 1|omega 1 gm
62276949|NCT01660932|ACTIVE_COMPARATOR|omega 2|omega 2 gm
62641620|NCT05266469||Ocrelizumab|Patients prescribed with Ocrelizumab
62641621|NCT01876524|EXPERIMENTAL|tRNS over Anterior Cingulate|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
62641622|NCT01876524|EXPERIMENTAL|tRNS applied over DLPFC|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
62641623|NCT01876524|SHAM_COMPARATOR|Sham Group|75 patients will be receive tRNS sham 35 sessions.
62641624|NCT01585883|EXPERIMENTAL|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session.
62072440|NCT04857112|EXPERIMENTAL|High Dose|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
62072441|NCT04857112|PLACEBO_COMPARATOR|Placebo|Matching placebo, QD (Day 1-85)
62072442|NCT05972733|EXPERIMENTAL|Open Arm Study|One dose given to all participants
62072443|NCT02826018|ACTIVE_COMPARATOR|ALN-HBV|
62276950|NCT01660932|ACTIVE_COMPARATOR|omega 4|omega 4 gm
62276951|NCT02872454|EXPERIMENTAL|Text Messaging|
62276952|NCT01750892|ACTIVE_COMPARATOR|Group 1: Control|Group 1 will be the control group. They will complete questionnaires but will otherwise receive usual care from their Primary Care Provider (PCP). At the end of the study period they will be given the Study Materials for participating.
62641625|NCT01585883|ACTIVE_COMPARATOR|Standard of care|Patients in this condition will receive usual care as decided by their oncology clinic team or physician.
62641626|NCT01518803|ACTIVE_COMPARATOR|Mediterranean-style breakfast|
62641627|NCT01518803|ACTIVE_COMPARATOR|Western-style breakfast|
62641628|NCT04319393|EXPERIMENTAL|CBT Nurses|Interventional group
62641629|NCT04319393|NO_INTERVENTION|Consultation Nurses|Control Group
62641630|NCT02889224|ACTIVE_COMPARATOR|Obese|Subjects with BMI between 30 - 40 kg/m2 and no alteration of corticotrope axis.
62641631|NCT02889224|EXPERIMENTAL|Hypercortisolism|Subject with BMI between 18 - 40 kg/m2 and presenting a hypercortisolism defined by HAS (Haute Autorité de Santé).
62641632|NCT02889224|EXPERIMENTAL|Hydrocortisone|Subject with BMI between 18 - 30 kg/m2 and with adrenal or corticotrope failure
62641633|NCT02889224|EXPERIMENTAL|Control|Subject with BMI between 18 - 30 kg/m2 and with a pituitary or adrenal tumor without effect on corticotrope axis.
62641634|NCT02072642|ACTIVE_COMPARATOR|Active light therapy (10,000 lux)|Light therapy: DayVia lamp 10000 lux
62641635|NCT02072642|PLACEBO_COMPARATOR|Placebo light therapy (70 lux)|Placebo light therapy
62641636|NCT05633433|EXPERIMENTAL|cohort A （Phase II）|Azvudine 5 mg, QD PO, D1-D7
62641637|NCT05633433|EXPERIMENTAL|cohort B （Phase II）|Azvudine 3 mg + placebo 2 mg, QD PO, D1-D7
62641638|NCT05633433|PLACEBO_COMPARATOR|cohort C （Phase II）|placebo 5 mg, QD PO, D1-D7
62641639|NCT05633433|EXPERIMENTAL|Arm 1 (Phase III)|Azvudine, dose to be determined according to phase II, QD PO, D1-D7
62641640|NCT05633433|PLACEBO_COMPARATOR|Arm 2 (Phase III)|Placebo, dose to be the same as Arm1, QD PO, D1-D7
62641641|NCT05720637|OTHER|Waiting list group|This group will include 40 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. At the end of this trial, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
62641642|NCT05720637|SHAM_COMPARATOR|SIA group|This group will include 40 patients with MDD who will be treated with sham intradermal acupuncture (SIA) combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
62641643|NCT05720637|EXPERIMENTAL|AIA group|This group will include 40 patients with MDD who will be treated with active intradermal acupuncture (AIA) combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
62641644|NCT03490955|SHAM_COMPARATOR|Salad|Subjects will consume a vegetable salad without dressing one time in the morning.
62641645|NCT03490955|ACTIVE_COMPARATOR|Salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
62276953|NCT01750892|EXPERIMENTAL|Group 3: Group Intervention|Group 3 (Group Intervention) will receive the Study Materials at the beginning of the study and will also be invited to attend two REACH for Independence group sessions.
62641646|NCT03490955|ACTIVE_COMPARATOR|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
62276954|NCT01750892|EXPERIMENTAL|Group 4: Full Intervention|Group 4 (Full Intervention) will receive the Study Materials at the beginning of the study, will be invited to attend the REACH for Independence group sessions, and will be invited to a Transition Consult with an MD and social worker.
62276955|NCT01750892|EXPERIMENTAL|Group 2: Basic Intervention|Group 2 (Basic Intervention) will receive the Study Materials at the beginning of the study but will otherwise continue with their usual PCP care.
62455275|NCT03614377||Patients with low burden of sleep-disordered breathing|
62455276|NCT03614377||Patients with high burden of sleep-disordered breathing|
62455277|NCT05707000|EXPERIMENTAL|group A, Concentric Muscle Training|leg press, knee flexion, knee extension, Quad drills with 1 RM
62455278|NCT05707000|EXPERIMENTAL|group B, Quadriceps Facilitatory Kinesiotaping|kinesiotaping on the quadriceps muscle in the faciliatory mode
62641647|NCT03490955|ACTIVE_COMPARATOR|Salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with dressing (canola oil) and with black pepper one time in the morning
62641648|NCT03490955|ACTIVE_COMPARATOR|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with dressing (olive oil) and with black pepper one time in the morning
62641649|NCT03490955|ACTIVE_COMPARATOR|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with dressing (corn oil) and with black pepper one time in the morning
62641650|NCT03490955|ACTIVE_COMPARATOR|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with dressing (sunflower oil) and with black pepper one time in the morning
62641651|NCT03490955|ACTIVE_COMPARATOR|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with dressing (flaxseed oil) and with black pepper one time in the morning
62641652|NCT00130507|ACTIVE_COMPARATOR|Arm A: VX|Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
62641653|NCT00130507|EXPERIMENTAL|Arm B: VXH|Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
62641654|NCT01711697|EXPERIMENTAL|Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)|Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
62072444|NCT02826018|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62072445|NCT01735357|PLACEBO_COMPARATOR|Olive oil (BP specification)|5g per day
62072446|NCT01735357|EXPERIMENTAL|DHA-rich oil|Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
62072447|NCT01735357|EXPERIMENTAL|EPA-rich oil|Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
62455279|NCT04982146|EXPERIMENTAL|Bromelain + N-Acetylcysteine|Patients with pseudomyxoma peritonei that are not candidates to surgical resection
62455280|NCT03118466|EXPERIMENTAL|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
62641655|NCT05253014|ACTIVE_COMPARATOR|lidocaine group|
62641656|NCT05253014|ACTIVE_COMPARATOR|bupivacaine group|
62641657|NCT05253014|ACTIVE_COMPARATOR|conservative group|
62641658|NCT05336266|EXPERIMENTAL|Ketorolac (open label)|Pancreatic patients receiving Ketorolac four times a day for up to five days
62641659|NCT02563899|EXPERIMENTAL|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
62641660|NCT02563899|PLACEBO_COMPARATOR|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
62641661|NCT04069715|EXPERIMENTAL|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng)|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
62641662|NCT04069715|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
62455281|NCT02606500|EXPERIMENTAL|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
62455282|NCT02606500|ACTIVE_COMPARATOR|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
62641663|NCT06286917|ACTIVE_COMPARATOR|NIV initiation in outpatient clinic in patients with ALS|Starting the NIV at the outpatient clinic
62641664|NCT06286917|ACTIVE_COMPARATOR|NIV initiation in pulmonary ward in patients with ALS|Starting the NIV in the pulmonary ward
62641665|NCT06220617||Case arm|Prospective enrollment of participants confirmed with colorectal adenocarcinoma or advanced adenoma
62641666|NCT06220617||Control arm|Prospective enrollment of healthy participants who have general risk or high risk of colorectal cancer
62641667|NCT01483638|EXPERIMENTAL|Experimental|axitinib
62641668|NCT01483638|PLACEBO_COMPARATOR|control|placebo
62276956|NCT01378286|EXPERIMENTAL|artesunate/amodiaquine|"artesunate (AS) / amodiaquine (AQ) as fixed dose combination~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment"
62641669|NCT02704312|EXPERIMENTAL|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
62641670|NCT04210297||Training cohort|Training cohort consists of the cirrhotic patients who collected from January 2018 to December 2019 of Qilu Hospital retrospectively.
62641671|NCT04210297||Internal validation cohort|Internal validation cohort consists of the cirrhotic patients who enrolled from January 2020 of Qilu Hospital prospectively.
62072448|NCT03760744|EXPERIMENTAL|CDT with Negative Pressure|CDT with LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
62455283|NCT01208519||Case Control Study 1|To define the impact of antibiotics on new acquisition of MRSA and ESBL-producing gram negative bacteria, a matched case-control study will be done (ratio 1:4). The control group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the corresponding case, with negative cultures at hospital admission. Matching criteria will include: age (±5 years), sex, and total length of hospitalization.
62276957|NCT01378286|ACTIVE_COMPARATOR|chloroquine|150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment
62641672|NCT04210297||External validation cohort|External validation cohort consists of the cirrhotic patients who enrolled from January 2020 in Jinan Central Hospital prospectively.
62641673|NCT02044042||HCV pregnant women|HCV chronically infected pregnant women, with a positive HCV RNA during pregnancy
62641674|NCT00488423|ACTIVE_COMPARATOR|Lap-band|Patient undergoing Lap-band Bariatric Surgery
62072449|NCT03760744|ACTIVE_COMPARATOR|CDT alone|CDT alone without LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
62072450|NCT03488524|EXPERIMENTAL|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
62072451|NCT00951509||Condition 1 (PC Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
62072452|NCT00951509||Condition 2 (PC Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
62072453|NCT00951509||Condition 3 (VR Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
62072454|NCT00951509||Condition 4 (VR Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
62072455|NCT00951509||Condntion 5 (Real-world driving)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
62072456|NCT05193084||Work Stream 1 (WS1)|"The general aim of this work stream is to assess the hypothesis can the volumes measured by the Heartfelt device be useful in titrating and optimising drug management for patients undergoing home-IV diuretics and after completion of IV-diuretic treatment.?~We will characterise the data collected by the Heartfelt device in the participants' home, correlating it to weight readings (either from the scales or paper weight diary) and medical observations recorded while patients are being treated with IV Diuretics.~Patients from WS1 will be invited to keep the device in their home for 3 months in total, which will therefore cover periods during which they do not receive IV diuretics, but are still at relatively high risk of decompensation. That data will be analysed in the same fashion as the data collected in WS2."
62072457|NCT05193084||Work Stream 2 (WS2)|"The general aim of WS2 is to assess the hypothesis can the Heartfelt device be used to monitor heart failure stability and detect fluid overload in patients recently discharged after an episode of decompensated heart failure?.~This work stream will also aim to examine whether the Heartfelt device gives an indication of the number of days prior to hospital admissions that the Heartfelt device can detect changes in foot volume. This will be achieved by comparing the data collected by the Heartfelt device in the participants' home, and correlating it to weight readings and medical observations. Hospital admissions will be a particularly useful correlation point as it would provide information on the detection of the forming oedema leading up to this event. In future, the information collected during this study will be used to design and power an interventional study to demonstrate the effectiveness of such data in providing a leading indicator of hospitalisation."
62072458|NCT00216320|EXPERIMENTAL|WalkAide|Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
62072459|NCT00216320|ACTIVE_COMPARATOR|Ankle Foot Orthosis|Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
62072460|NCT00216320|OTHER|No Crossover|Subjects wear AFO for entire 12 weeks with no crossover
62072461|NCT02066532|EXPERIMENTAL|Ruxolitinib/Trastuzumab|Jakafi (Ruxolitinib) and Trastuzumab (Herceptin) - 21 day cycle until disease progression
62276958|NCT03858959|EXPERIMENTAL|HYBENX® Oral Tissue decontaminantTM (HBX)|HYBENX® Oral Tissue decontaminantTM is a concentrated aqueous solution of sulfonated aromatics and free sulphates. Once placed onto susceptible organic material, the product instantly absorbs free and electrostatically bonded water, denaturing the molecular structure of the organic matter. Biofilm is expected to be especially sensitive to the disruptive action of HBX solution by virtue of its porous structure and high water content.
62455284|NCT01208519||Case control study 2|To define individual level of risk related to specific antibiotics, patients acquiring MRSA and ESBL-producing gram negative bacteria will be compared with patients not acquiring antibiotic-resistant strains after starting antibiotic therapy (ratio 1:4). Previously known risk factors or clinically relevant significant variables from the univariate analysis will be considered for inclusion in multivariate logistic regression analysis.
62641675|NCT00488423|ACTIVE_COMPARATOR|Gastric Bypass|Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
62641676|NCT04481139|EXPERIMENTAL|SHR0302 dose1|SHR0302 dose1 for 24 weeks
62072462|NCT01228344||Artemether-lumefantrine|
62072463|NCT03509792|EXPERIMENTAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
62072464|NCT03509792|PLACEBO_COMPARATOR|Attention placebo|Smartphone activity for same amount of time.
62072465|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF\<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
62072466|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF\>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
62072467|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
62072468|NCT04485650|EXPERIMENTAL|Music group|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group. The number of participants:30
62276959|NCT03858959|ACTIVE_COMPARATOR|Chlorhexidine Digluconate CorsodylTM (CHX)|Chlorhexidine Digluconate CorsodylTM Dental Gel 1% is an antiseptic gel with cationic nature, effective against a wide range of Gram positive and negative bacteria, favourable to the plaque control and oral inflammation prevention.
62276960|NCT00687284||A|
62276961|NCT02179229|PLACEBO_COMPARATOR|CONTROL|Patient in the CONTROL arm will receive a powder containing only tapioca-resistant starch comparable in colour, texture and taste to the synbiotic.
62641677|NCT04481139|EXPERIMENTAL|SHR0302 dose2|SHR0302 dose2 for 24 weeks
62072469|NCT04485650|ACTIVE_COMPARATOR|Sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
62072470|NCT04485650|OTHER|Non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
62072471|NCT02045433|EXPERIMENTAL|SABR Boost Therapy|
62072472|NCT01250119|EXPERIMENTAL|Single Arm|
62072473|NCT04529720||acellular pertussis vaccine|Antibody persistence at 5 years after a single dose vaccination of acellular pertussis vaccines (Pertagen;Boostagen;Adacel)
62072474|NCT01436123|EXPERIMENTAL|Stenting + Micro-infusion|Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
62072475|NCT01436123|ACTIVE_COMPARATOR|Stenting|Put in everolimus-eluting stent
62072476|NCT02030912|ACTIVE_COMPARATOR|3 doses of amoxicillin daily for 7 days|Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.
62072477|NCT02030912|ACTIVE_COMPARATOR|2 doses of minocycline daily for 5 days|Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.
62072478|NCT02030912|PLACEBO_COMPARATOR|2 doses of placebo daily for 5 days|Cohort C: 2 doses of placebo daily for five days (n=14). Follow up 12 months.
62072479|NCT04532021||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
62072480|NCT04532021||control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
62072481|NCT01114750|ACTIVE_COMPARATOR|Oral Insulin in Dextran Matrix|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
62072482|NCT01114750|PLACEBO_COMPARATOR|Placebo|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
62072483|NCT02211534|ACTIVE_COMPARATOR|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
62455285|NCT03328793|EXPERIMENTAL|Music Intervention (Intervention Group)|"The patients will assist to a live music session of 30 minutes which will be given by musicians (volunteers) and will undergo:~* mood assessment~* emotion assessment~* mobility assessment~* communication assessment"
62641678|NCT04481139|EXPERIMENTAL|SHR0302 dose3|SHR0302 dose3 for 24 weeks
62072484|NCT02211534|SHAM_COMPARATOR|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
62641679|NCT04481139|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62072485|NCT02951559|EXPERIMENTAL|Brushing|Patients will undergo nasal brushing as further described additionally to other gold standard practices according to the suspected aetiology (brain MRI, lumbar puncture, plasma tests, etc.)
62072486|NCT04975828||patients type 2 DM with coronary artery disease and diabetic retinopathy.|
62072487|NCT04975828||patients type 2 DM with coronary artery disease and diabetic neuropathy.|
62072488|NCT04975828||patients type 2 DM with coronary artery disease and diabetic nephropathy|
62072489|NCT04975828||patient type 2 DM with coronary artery disease and non microvascular complications.|
62072490|NCT05686525|EXPERIMENTAL|TUMT|In this arm, patients will undergo Transurethral Microwave Thermotherapy (TUMT) where microwave energy is used to destroy the prostate tissue. TUMT is performed under local anaesthesia. Usually, the patient can be discharged from the hospital on the same day. If the patient cannot be discharged on the same day, he will be admitted to the urological ward. After the treatment, a transurethral catheter is inserted. This will be removed at the physician's discretion when spontaneous voiding is achieved with an acceptable residual volume (in general \<100-150 ml), typically within four weeks.
62641680|NCT05938218|EXPERIMENTAL|intervention|In this intervention, VR glasses with an information module are utilized, lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures
62641681|NCT05938218|NO_INTERVENTION|Control Group|Usual Care
62641682|NCT03299101|EXPERIMENTAL|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
62641683|NCT01834547|EXPERIMENTAL|Methylphenidate|Methylphenidate
62072491|NCT05686525|EXPERIMENTAL|PAE|In this arm, patients will undergo prostate artery embolisation (PAE) where blocking the blood flow to the prostate causes it to shrink. PAE is performed under local anaesthesia. Usually, the patient can be discharged from the hospital on the same day. If the patient cannot be discharged on the same day, he will be admitted to the urological ward. Patients with a permanent catheter prior to PAE will keep the catheter up to four weeks after the procedure.
62072492|NCT04842864|EXPERIMENTAL|Young|10 healthy men and women 18-35 yo.
62072493|NCT04842864|ACTIVE_COMPARATOR|Older adults|10 healthy men and women 65-85 yo
62072494|NCT00277589|EXPERIMENTAL|1|
62072495|NCT00277589|ACTIVE_COMPARATOR|2|
62072496|NCT00277589|ACTIVE_COMPARATOR|3|
62072497|NCT00277589|PLACEBO_COMPARATOR|4|
62072498|NCT04415697||Responders|Those who present complete response, partial response, or stable disease, according to RECIST 1.1.
62072499|NCT04415697||Not responders|Those who present progression disease according to RECIST 1.1.
62072500|NCT02313818|EXPERIMENTAL|CPT-C|Cognitive Processing Therapy-Cognitive Only (CPT-C) conducted twice weekly for 4-24 sessions based on good end state functioning.
62072501|NCT04639518|EXPERIMENTAL|Sub-study 1|Pre-term formulas with HMO
62641684|NCT01834547|EXPERIMENTAL|modafinil|modafinil
62641685|NCT01834547|EXPERIMENTAL|caffeine|caffeine
62641686|NCT01834547|PLACEBO_COMPARATOR|placebo|placebo
62641687|NCT06555445|EXPERIMENTAL|BREATHING EXERCISE|The participants in group A will be engaging in structured breathing exercises, focusing on the following two techniques Diaphragmatic Breathing and Pursed Lip Breathing
62641688|NCT06555445|ACTIVE_COMPARATOR|BREATHING EXERCISE REGIMEN COUPLED WITH BREATHER DEVICE|Participants will use the BREATHER device daily, performing the routine 5-7 days per week
62641689|NCT01616043|EXPERIMENTAL|Glyaderm + STSG|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds of the patients are covered with Glyaderm®. After 6-8 days the wounds are finally covered with a thin STSG.
62072502|NCT04639518|EXPERIMENTAL|Sub-study 2|Pre-term formulas without HMO
62072503|NCT03312179||diabetics STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
62072504|NCT03312179||non diabetics STEMI|Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
62072505|NCT03312179||diabetics incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
62072506|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
62072507|NCT05890898|EXPERIMENTAL|Control: Nitrous Oxide, then Virtual Reality Goggles|Control group will receive the standard of care dental treatment with under nitrous sedation (N2O) and will have a second visit where Virtual Reality(VR) goggles will be used instead of N2O.
62072508|NCT05890898|EXPERIMENTAL|Treatment: Virtual Reality Goggles, then Nitrous Oxide|The treatment group will receive the standard of care dental treatment with VR googles first and will have a second visit under N2O will be used instead of VR.
62072509|NCT01864863|EXPERIMENTAL|Test→Reference|HGP1206 125 mg 1 tablet → Traclear 62.5 mg 2 tablets
62072510|NCT01864863|EXPERIMENTAL|Reference→Test|Traclear 62.5 mg 2 tablets → HGP1206 125 mg 1 tablet
62072511|NCT06028581|EXPERIMENTAL|Experimental Group|Breastfeeding support system will be applied to newborn babies in addition to breast milk.
62072512|NCT06028581|NO_INTERVENTION|Control Group|Newborn babies will receive breast milk.
62276962|NCT02179229|EXPERIMENTAL|SYNBIOTIC|Patients in this group will receive Probinul neutro® a synbiotic preparation containing (perpacket): lyophilised bacteria (5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subsp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarius and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus thermophilus), prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
62276963|NCT06123052||Patients unwilling to receive information|Interview
62276964|NCT06123052||Patients not interested in IBD-CE after receiving information|Interview
62276965|NCT06123052||Patients interested in IBD-CE after receiving information|Interview
62276966|NCT05549115|EXPERIMENTAL|clarithromycin-sensitive(first-line)|If H. pylori is sensitive to clarithromycin, we will administer clarithromycin triple therapy-esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily)-for 14 days
62276967|NCT05549115|EXPERIMENTAL|clarithromycin-resistant(first-line)|If H. pylori is clarithromycin resistance, we selected the High-dose dual therapy (HDDT) regimen as first-line treatment. HDDT-esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily)-will be used for 14 days.
62072513|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 500 subcutaneous|500 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
62072514|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 1000 subcutaneous|1000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
62072515|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 3000 subcutaneous|3000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
62072516|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 5000 subcutaneous|5000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
62072517|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 500 sublingual|500 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
62072518|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 1000 sublingual|1000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
62072519|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 3000 sublingual|3000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
62276968|NCT05549115|ACTIVE_COMPARATOR|empirical therapy group first-line|The empirical therapy group will receive Bismuth-containing quadruple therapy(BQT) as first-line treatment, The BQT regime is comprising of esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days.
62276969|NCT05549115|EXPERIMENTAL|levofloxacin-sensitive(rescue treatment)|If H. pylori was levofloxacin-sensitive, we will use the levofloxacin quadruple regimen as rescue treatment-esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily)-for 14 days.
62072520|NCT02654223|EXPERIMENTAL|MG56 Mannosylated 5000 sublingual|5000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
62072521|NCT02654223|PLACEBO_COMPARATOR|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
62072522|NCT01745315|ACTIVE_COMPARATOR|LigaSure (advanced bipolar device)|Laparoscopic hysterectomy will be done with LigaSure in 15 patients.
62072523|NCT01745315|ACTIVE_COMPARATOR|Halo PKSforceps(advanced bipolar device)|Laparoscopic hysterectomy will be done with Halo PKS cutting forceps in 15 patients.
62072524|NCT01745315|ACTIVE_COMPARATOR|EnSeal (advanced bipolar device)|Laparoscopic hysterectomy will be done with EnSeal in 15 patients.
62072525|NCT04013490|PLACEBO_COMPARATOR|Placebo capsule|Subject receive the Placebo product for 4 weeks.
62072526|NCT04013490|ACTIVE_COMPARATOR|Cassava dietary fiber capsule 1.5 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 1.5 g/day for 4 weeks.
62072527|NCT04013490|ACTIVE_COMPARATOR|Cassava dietary fiber capsule 3 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 3 g/day for 4 weeks.
62072528|NCT02795260|EXPERIMENTAL|ESAT6-CFP10 in the right arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of BCG immunization :ESAT6-CFP10 in the right arm and TB-PPD in the left arm concomitantly,according to a randomisation scheme.
62072529|NCT02795260|EXPERIMENTAL|ESAT6-CFP10 in the left arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of Bacillus Calmette - Guerin immunization :ESAT6-CFP10 in the left arm and TB-PPD in the right arm concomitantly,according to a randomisation scheme.
62276970|NCT05549115|EXPERIMENTAL|levofloxacin-resistant(rescue treatment)|If H. pylori was levofloxacin-resistant, we will use furazolidone quadruple regimen as rescue treatment-esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily)-for 14 days.
62276971|NCT05549115|ACTIVE_COMPARATOR|empirical therapy group rescue treatment|If BQT fails, HDDT-esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily)-will be used as a rescue treatment for 14 days.
62276972|NCT01082185|OTHER|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
62276973|NCT02217566|EXPERIMENTAL|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
62276974|NCT02317562|EXPERIMENTAL|I10E Arm|
62276975|NCT04510363||cardiac arrest survivors|cardiac arrest survivors
62276976|NCT04510363||age- and sex-matched controls|age- and sex-matched controls
62276977|NCT05786092|EXPERIMENTAL|treatment|
62276978|NCT05786092|NO_INTERVENTION|control|
62276979|NCT01254279|EXPERIMENTAL|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
62072530|NCT05232435|EXPERIMENTAL|pilate group|will receive pilate exercise(1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist) and standard treatment (stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) for 12 sessions(3 sessions/week) over a period of four weeks.
62072531|NCT05232435|EXPERIMENTAL|MET|will receiveMET treatment for hamstring and erector spinae and standard treatment(stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) for 12 sessions (3 sessions/week)over a period of four weeks.
62072532|NCT05232435|ACTIVE_COMPARATOR|control group|will receive standard treatment(stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) only for 12 sessions (3 sessions/week) over a period of four weeks.
62072533|NCT05285254|EXPERIMENTAL|Immunization Administration with Certified Child Life Specialist Support (CCLS)|Nursing will administer immunizations to children with the support of a CCLS
62072534|NCT05285254|NO_INTERVENTION|Current Standard of Care for Immunization Administration|Nursing will administer immunizations to children per their current standard of care.
62072535|NCT04213313||Control Group|health volunteers
62072536|NCT04213313||Infectious Keratitis Group|Infectious corneal patients
62276980|NCT01792908|EXPERIMENTAL|KT group|The KT group received ankle KT on the lateral ligament in the non-dominant leg and a recommendation guide. The Kinesio tape procedure was carried out by the same certified athletic therapist to ensure consistency throughout the study.
62276981|NCT01792908|NO_INTERVENTION|Control group|Any intervention has been applied. Using another kind of tape or a different KT application for control group may increase cutaneous information, undermining our goal.
62276982|NCT01582308|EXPERIMENTAL|Treatment Sequence 1|Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
62276983|NCT01582308|EXPERIMENTAL|Treatment Sequence 2|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
62072537|NCT04307498|OTHER|Intensive Outpatient Program - Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks plus seven augmentations designed to maximize treatment outcomes. If necessary, the treatment window may be extended for another week.
62072538|NCT01863043|ACTIVE_COMPARATOR|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
62072539|NCT01863043|EXPERIMENTAL|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
62072540|NCT00423852|EXPERIMENTAL|chemotherapy with Stem Cell Support|This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.
62072541|NCT04356339||BETASERON|Participants with Multiple Sclerosis treated with BETASERON using BETACONNECT autoinjector and myBETAapp will be enrolled
62276984|NCT01582308|EXPERIMENTAL|Treatment Sequence 3|Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
62276985|NCT01582308|EXPERIMENTAL|Treatment Sequence 4|Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
62276986|NCT01582308|EXPERIMENTAL|Treatment Sequence 5|Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
62276987|NCT01582308|EXPERIMENTAL|Treatment Sequence 6|Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
62276988|NCT01582308|EXPERIMENTAL|Treatment Sequence 7|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
62072542|NCT03695016|EXPERIMENTAL|Immediate Intervention|Participants will receive the ActiveGOALS 13 week, online self-directed intervention for increasing aerobic physical activity and decreasing time spent sitting. The intervention is based on social-cognitive theory models of behavior changes and utilizes barrier recognition, problem solving, and monitoring of behavior to initiate behavior change. They will also receive weekly feedback from a coach and be provided with online, paper, and wearable tracking devices. They will also be provided with links to tools that support physical activity.
62072543|NCT03695016|OTHER|Wait-listed Control|This group will receive a monthly newsletter with general health advice during the wait period (3 months). After the three month follow-up visit/ collection of outcomes they will be offered the ActiveGOALS intervention in its entirety.
62072544|NCT02096614|EXPERIMENTAL|Low dose TBI-1201 with pre-treatment 1|TBI-1201(5\*10\^8) single-dose administration with pre-treatment of cyclophosphamide alone.
62276989|NCT01582308|EXPERIMENTAL|Treatment Sequence 8|Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
62276990|NCT01582308|EXPERIMENTAL|Treatment Sequence 9|Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
62276991|NCT01582308|EXPERIMENTAL|Treatment Sequence 10|Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
62455286|NCT03328793|ACTIVE_COMPARATOR|Documentary watching (Control Group)|"The patients will watch a documentary for 30 minutes in the presence of a volunteer and will undergo:~* mood assessment~* emotion assessment~* mobility assessment~* communication assessment"
62455287|NCT01604044|ACTIVE_COMPARATOR|HP-hMG|
62455288|NCT01604044|ACTIVE_COMPARATOR|rFSH plus rLH|
62072545|NCT02096614|EXPERIMENTAL|High dose TBI-1201 with pre-treatment 1|TBI-1201(5\*10\^9) single-dose administration with pre-treatment of cyclophosphamide alone.
62072546|NCT02096614|EXPERIMENTAL|High dose TBI-1201 with pre-treatment 2|TBI-1201(5\*10\^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
62072547|NCT02096614|EXPERIMENTAL|TBI-1201 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
62072548|NCT01984424|OTHER|Part A: Atorvastatin 20 mg => Placebo|Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
62072549|NCT01984424|OTHER|Part A: Placebo => Atorvastatin 20 mg|Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
62072550|NCT01984424|ACTIVE_COMPARATOR|Part B: Ezetimibe|Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
62072551|NCT01984424|EXPERIMENTAL|Part B: Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
62072552|NCT01984424|EXPERIMENTAL|Part C: Open-label Evolocumab|Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
62641690|NCT01616043|OTHER|STSG alone|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds are immediately covered with a thin STSG.
62072553|NCT02494206|EXPERIMENTAL|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
62072554|NCT05689086||Program Participants|"Patients with HFrEF (LVEF\<40%) \& NYHA class II-III who are referred to and consent to participate in the Virtual Heart Failure Optimization Program"
62072555|NCT05521295||Conception positive|serum human chorionic gonadotropin ≥10 mIU/mL
62072556|NCT05521295||Conception negative|serum human chorionic gonadotropin \<10 mIU/mL
62072557|NCT04205929|PLACEBO_COMPARATOR|Placebo group|Placebo (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
62072558|NCT04205929|EXPERIMENTAL|Curcumin group|Curcumin 600 mg (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
62072559|NCT02150265|NO_INTERVENTION|Waiting list control group|6 week waiting list
62072560|NCT02150265|EXPERIMENTAL|Individual cognitive behavioral therapy with SMART|SMART manual cognitive behavioral therapy individual weekly sessions for 6 weeks
62072561|NCT06050291|EXPERIMENTAL|FDC Tablet Fed + Fast|Participants will receive a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Tablet in a fed condition on Day 1 of treatment followed by a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Table in a fasted condition after, at a minimum, a 56 day washout.
62072562|NCT06050291|EXPERIMENTAL|FDC Tablet Fast + Fed|Participants will receive a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Tablet in a fasted condition on Day 1 of treatment followed by a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Table in a fed condition after, at a minimum, a 56 day washout.
62072563|NCT04175353|EXPERIMENTAL|Dairy snack|Drink high in milk protein, 250 ml
62455289|NCT03682952|EXPERIMENTAL|Experimental group|Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.
62641691|NCT02696395|ACTIVE_COMPARATOR|DePuy Tri-Lock®|Total hip replacement with DePuy Tri-Lock® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
62072564|NCT04175353|ACTIVE_COMPARATOR|Orange juice|Regular orange juice, 250 ml
62072565|NCT04175353|EXPERIMENTAL|Berry snack 1|Bilberry-blackcurrant purée, 139 g
62072566|NCT04175353|EXPERIMENTAL|Berry snack 2|Lingonberry purée, 122 g
62072567|NCT04175353|ACTIVE_COMPARATOR|Berry soup|Bilberry soup, 250 ml
62455290|NCT03682952|NO_INTERVENTION|Anemia control group|Anemia patients
62455291|NCT03682952|NO_INTERVENTION|Control group|Healthy person
62641692|NCT02696395|ACTIVE_COMPARATOR|DePuy Corail®|Total hip replacement with DePuy Corail® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
62641693|NCT02236000|EXPERIMENTAL|Neratinib and T-DM1|
62072568|NCT00224523|EXPERIMENTAL|Arm 1|
62455292|NCT06440655|EXPERIMENTAL|PRF and PRP|"All patients were treated with both platelet rich fibrin and platelet rich plasma but each side of head (left or right) was split with~* one side of head was injected with platelet rich plasma at week 0,4 and 8 (total 3 times)~* another side of head was injected with platelet rich fibrin at week 0,4 and 8 (total 3 times)"
62641694|NCT04887649|PLACEBO_COMPARATOR|Placebo|Patients en treatment whit placebo, salIne solution in peridural cateter
62641695|NCT04887649|ACTIVE_COMPARATOR|Morphine|Epidural Catheter morphine 2mg
62641696|NCT04887649|ACTIVE_COMPARATOR|morphine|Epidurla cateter morphine 3 mg
62641697|NCT03469115|ACTIVE_COMPARATOR|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
62641698|NCT03469115|ACTIVE_COMPARATOR|BMI below 3%|Serum blood will be taken from slim youths
62641699|NCT04254510|EXPERIMENTAL|Study Group|Myofascial relaxation technique
62641700|NCT04254510|NO_INTERVENTION|Control group|
62641701|NCT04310722||Gram-negative bacilli and MRSA infections in ICU|Carbapenem-resistant Gram-negative bacilli \[Carbapenem-resistant Acinetobacter baumannii (CRAB), Carbapenem-resistant Klebsiella pneumoniae (CRKP), and Carbapenem-resistant Pseudomonas aeruginosa (CRPsA) \] and methicillin-resistant Staphylococcus aureus (MRSA) is prevalent around the world, and the isolation rate and resistance rate has increasing in China, especially in ICU. So, investigators aim to study transmission mechanism, resistance mechanism and horizontal transfer mechanism of these pathogens.
62641702|NCT02354287||Patients having outpatient Colonoscopy.|Patients with Polyps ≤7mm that are deemed appropriate to be removed by cold forceps polypectomy with pre lift
62641703|NCT01071174|PLACEBO_COMPARATOR|Placebo Ring|Vaginal Ring containing no drug substance
62641704|NCT01071174|EXPERIMENTAL|Dapivirine Ring|Dapivirine Vaginal Ring 25mg
62641705|NCT03826017|EXPERIMENTAL|Catechin high contain greentea extract|Catechin high contain greentea extract for 260 mg/day 12 weeks.
62641706|NCT03826017|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks.
62641707|NCT04345276|EXPERIMENTAL|Danoprevir+Ritonavir group|
62072569|NCT02204293|EXPERIMENTAL|Canakinumab|Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score \> 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score \> 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
62088434|NCT01023737|EXPERIMENTAL|Hydroxychloroquine and Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily and HCQ will be administered starting on Day 2 of Cycle 1 and both will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
62276992|NCT04621695|OTHER|Rubber band ligation|Rubber band ligation is performed by a suction device that allows a rubber band to be applied at the base of the haemorrhoid via a proctoscope. Maximal suction force used is 40 mmHg. A maximum of 3-4 bands are used per session. This rubber band constricts the blood supply causing it to become ischaemic before being sloughed approximately 1-2 weeks later. The resultant fibrosis reduces any element of haemorrhoidal prolapse that may have been present. No sedation is required for this day-care procedure. Patients are asked to administer an enema 2 hours prior to the procedure.
62276993|NCT04621695|OTHER|Hemorrhoidectomy|"There are two main excisional procedures currently carried out: open (Milligan and Morgan) and closed (Ferguson). Both have the intention of excising the haemorrhoidal cushions. The procedure is performed under either general or spinal anaesthesia in a day-care setting.~Patients were asked to administer an enema 2 hours prior to the procedure."
62455293|NCT02800798||High risk for OSA|High risk OSA defines as Stop-bang score ≥ 3
62641708|NCT05750758|EXPERIMENTAL|DAPT+rivaroxaban|Rivaroxaban 2.5 mg bid + aspirin 100 mg qd + ticagrelor 90 mg bid was used for 1 month after operation, and then aspirin 100 mg + ticagrelor 90 mg bid was used for 5 months.
62641709|NCT05750758|NO_INTERVENTION|DAPT|aspirin 100 mg qd + ticagrelor 90 mg bid for 6 months.
62641710|NCT01239797|ACTIVE_COMPARATOR|Lenalidomide + Dexamethasone|
62641711|NCT01239797|EXPERIMENTAL|Lenalidomide + Dexamethasone +Elotuzumab|
62641712|NCT04722029|NO_INTERVENTION|Donor|"Donors will be evaluated to determine suitability to undergo apheresis collection and their infectious disease status. Donor evaluation will include history and physical examination, laboratory tests, FDA- approved donor testing of communicable diseases (HIV, HVB, HCV, HTLV-I, II, WNV, T. pallidum, T. cruzi, and Zika virus), ABO and Rh typing, pregnancy tests, and donor serology for ADV.~Qualified donors will undergo leukapheresis. Collection will proceed for 2 hours or 2 blood volumes, whichever occurs first."
62641713|NCT04722029|EXPERIMENTAL|Recipient|"Recipient will undergo a screening period that will include history and physical examination, laboratory tests, performance status, HLA typing and pregnancy test (if needed).~Qualified patients will receive ADV-VSTS infusion from haploidentical donors up to a maximum of 5.0 x 104 interferon gamma-negative cells/kg. All patients will be followed for laboratory and clinical response, safety, efficacy and tolerance."
62088435|NCT04124822|NO_INTERVENTION|control|group 1 , is no intervention group in which root canal procedure will be done without drug as ideal protocol .
62641714|NCT02991365|ACTIVE_COMPARATOR|nasal insulin|daily administration of 160 U of human insulin as nasal spray
62641715|NCT02991365|PLACEBO_COMPARATOR|placebo spray|daily administration of placebo solution as nasal spray
62641716|NCT04824807|EXPERIMENTAL|Clinical Pilates Group|Individuals in the this group will receive 24 sessions of Clinical Pilates training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
62641717|NCT04824807|EXPERIMENTAL|Yoga Group|Individuals in the this group will be given 24 hours of yoga training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
62088436|NCT04124822|EXPERIMENTAL|Piroxicam|group 2 is given Piroxicam 20 mg half an hour before root canal treatment to manage post operative pain.
62455294|NCT02800798||Low risk for OSA|Low risk OSA defines as Stop-bang score \< 3
62276994|NCT02771132|EXPERIMENTAL|Intervention|"12-hour intervention IMPower empowerment self defense course for girls and 12-hour Source of Strength for boys+ 2 refresher sessions (at 2 hrs. per session)"
62641718|NCT04824807|OTHER|Control Group|Individuals in the this group will not receive any treatment. Individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
62641719|NCT02404545|NO_INTERVENTION|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
62641720|NCT02404545|ACTIVE_COMPARATOR|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
62641721|NCT00395993|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
62641722|NCT00395993|ACTIVE_COMPARATOR|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
62641723|NCT04946812|EXPERIMENTAL|Intervention group|The velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%. While the speed of the treadmill will not change throughout the study, the duration of the training will increase each week. In the first week, the SBTM training will take place for 10 minutes. There will be a 5-minute rest period, and the split-belt conditions will continue for another 10 minutes of training (total training time= 20 minutes).
62072570|NCT02204293|PLACEBO_COMPARATOR|Placebo|Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score \> 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score \> 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
62072571|NCT04264234|EXPERIMENTAL|Placenta Previa|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.
62072572|NCT03379064|EXPERIMENTAL|culturally adapted Cognitive Behavior Therapy|We will use The STreSS CBT manual developed by Schroder and his colleagues
62072573|NCT03379064|NO_INTERVENTION|Treatment As Usual|The Treatment As Usual (TAU) group will receive regular treatment they have been receiving already as prescribed by the physician.
62072574|NCT01133574|EXPERIMENTAL|A1|Part A, Parallel design Arm 1
62072575|NCT01133574|EXPERIMENTAL|A2|Part A, Parallel design Arm 2
62072576|NCT01133574|EXPERIMENTAL|A3|Part A, Parallel design Arm 3
62072577|NCT01133574|EXPERIMENTAL|A4|Part A, Parallel design Arm 4
62072578|NCT01133574|EXPERIMENTAL|A5|Part A, Parallel design Arm 5
62072579|NCT01133574|EXPERIMENTAL|A6|Part A, Parallel design Arm 6
62072580|NCT01133574|EXPERIMENTAL|A7|Part A, Parallel design Arm 7
62276995|NCT02771132|OTHER|Standard of Care|1-2 hour course based on Ministry of Education life skills course (no refresher sessions)
62276996|NCT00738478|EXPERIMENTAL|A|Arm A: with nasogastric tube
62072581|NCT01133574|EXPERIMENTAL|A8|Part A, Parallel design Arm 8
62072582|NCT01133574|PLACEBO_COMPARATOR|A9|Part A, Parallel design Arm 9
62276997|NCT00738478|ACTIVE_COMPARATOR|B|Arm B: without nasogastric tube
62072583|NCT01133574|EXPERIMENTAL|B1-1|Part B, Cross-over design, Arm 1
62276998|NCT03877172|NO_INTERVENTION|Face-mask oxygen therapy|Oxygen delivered through a conventional face mask to keep saturation above 92%.
62072584|NCT01133574|EXPERIMENTAL|B1-2|Part B, Cross-over design, Arm 2
62072585|NCT01133574|EXPERIMENTAL|B2-1|Part B, Cross-over design, Arm 3
62072586|NCT01133574|EXPERIMENTAL|B2-2|Part B, Cross-over design, Arm 4
62072587|NCT01133574|PLACEBO_COMPARATOR|B3|Part B, Cross-over design, Arm 5
62072588|NCT01018563|EXPERIMENTAL|MORAb-003|Maintenance infusions of MORAb-003 every 3 weeks
62072589|NCT01235130|ACTIVE_COMPARATOR|OMEGA-3|Long-Chain N-3 polyunsaturated fatty acids (OMEGA-3)
62072590|NCT01235130|PLACEBO_COMPARATOR|Placebo|Placebo soybean oil
62072591|NCT04376294|EXPERIMENTAL|Study group|This group received Extracorporeal Shockwave Therapy(ESWT) + conservative Physical Therapy Treatment (eccentric training + stretching exercise)
62072592|NCT04376294|ACTIVE_COMPARATOR|Control group|This group received conservative physical therapy treatment(eccentric training + stretching exercise) only.
62641724|NCT04946812|ACTIVE_COMPARATOR|Control group|"The subject will continue to walk under tied-belt conditions adjusted to the over-ground walking speed. In the first week, the treadmill training will be for 10 minutes. They will get a 5-minute break, similar to the intervention group, and continue for another 10 minutes under tied-belt conditions.~The duration of each session will increase by 8 minutes every week. For example, in week 1, the treadmill training will be for a total of 20 minutes; in week 2, for 28 minutes; in week 3, for 36 minutes, and so forth, until it gets to 60 minutes by week 6. The rest period will remain at 5 minutes each session, and will always take place at the halfway mark. All 3 sessions in the week will have the same duration of training.~If the subject cannot tolerate the velocity or duration of the session, the protocol will be adjusted to most recently tolerated session (and will be recorded for further interpretation and analysis)."
62641725|NCT04418362|EXPERIMENTAL|Neurofeedback training|Neurofeedback training: self-administered at home 4-6 times per week for 8 weeks. Each session consists of 6 blocks of 5 minute training with a one minute rest period between each block.
62072593|NCT02357680|EXPERIMENTAL|Intervention group|"Relatives randomized to the intervention group is provied with a diary. Nurses advice relatives on how to write and use the diary under and after the patients stay in the ICU. A written description on how to use the diary is also provided.~At least two photographs of the patient is taken by nurses. Photographs will first be included in the diary when full consent from the patient has been obtained.~Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU."
62072594|NCT02357680|NO_INTERVENTION|Control group|Standard Care. Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU.
62072595|NCT05171868|EXPERIMENTAL|EMDR receiving group|EMDR is a psychotherapeutic approach that emphasizes the role of the brain's information processing system in perfecting the psychological consequences of distressing events. EMDR is an eight-phase treatment protocol, including procedure that focuses on the memories underlying current problems and those that must be specifically addressed to bring the client to a robust state of psychological health. One of its distinguishing aspects is its use of bilateral physical stimulation, such as side-to-side eye movements, alternating hand taps, or alternating auditory tones while the person undergoing treatment is mentally focusing on aspects of various life experiences.
62641726|NCT06323759|NO_INTERVENTION|CONTROL GROUP|Pregnant women have taken a routine parenthood preparation courses and follow-up by independent midwives in antenatally
62641727|NCT06323759|OTHER|INTERVENTION GROUP|Pregnant women have taken a new parenthood preparation courses and follow-up by independent midwives in antenatality, postnatality short term, and postnatality long term)
62641728|NCT03266900|EXPERIMENTAL|re-TURBT|Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
62641729|NCT03266900|ACTIVE_COMPARATOR|6 BCG instillations|Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.
62641730|NCT02818855|EXPERIMENTAL|Collagen Matrix plus coronally advanced flap (CAF)|A new collagen matrix (Mucograft) associated to coronally advanced flap
62641731|NCT02818855|ACTIVE_COMPARATOR|Subepithelial connective tissue graft plus CAF|Subepithelial connective tissue graft associated to coronally advanced flap
62641732|NCT02071459|EXPERIMENTAL|L-Threo DOPS|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS
62641733|NCT02071459|PLACEBO_COMPARATOR|placebo|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo
62641734|NCT01651364|PLACEBO_COMPARATOR|Placebo|
62072596|NCT05171868|NO_INTERVENTION|Waiting list Control Group|The control group will receive their routine care as usual. Once the trial is completed they will be invited for EMDR sessions
62276999|NCT03877172|ACTIVE_COMPARATOR|High-flow nasal cannula|High-flow nasal cannula delivered at 50 L/min and FiO2 adjusted to keep saturation above 92%.
62072597|NCT02355522|ACTIVE_COMPARATOR|Lidocaine gel group|3ml of 2% lidocaine gel on the cervix and 5ml of intrauterine normal saline
62277000|NCT01999582|EXPERIMENTAL|Intravenous Dose Group 1, 2, and 3|Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
62641735|NCT01651364|ACTIVE_COMPARATOR|Cabergoline|
62641736|NCT01614470|EXPERIMENTAL|Part 1: Ivacaftor First, Then Placebo|Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
62641737|NCT01614470|EXPERIMENTAL|Part 1: Placebo First, Then Ivacaftor|Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
62641738|NCT01614470|EXPERIMENTAL|Part 2: Ivacaftor|Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
62641739|NCT02001571|EXPERIMENTAL|Cohort 1|Mild Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
62641740|NCT02001571|EXPERIMENTAL|Cohort 2|Moderate Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
62641741|NCT02001571|EXPERIMENTAL|Cohort 3|Normal Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
62641742|NCT01022203|EXPERIMENTAL|Structured Approach Therapy|Couple-Based Intervention called Structured Approach Therapy provides skills training to couple so they can reduce PTSD.
62641743|NCT01022203|ACTIVE_COMPARATOR|PTSD Family Education|Couple-Based Education called PTSD Family Education teaches couple about PTSD symptoms, related problems, and treatment.
62641744|NCT00600093|EXPERIMENTAL|A|
62641745|NCT00749398||Infliximab|Subjects with moderate-to-severe psoriasis who are treated with infliximab in daily clinics according to local country regulations and reimbursements.
62641746|NCT00225745||1|Pancreatic cancer patients
62641747|NCT00225745||2|Healthy controls
62641748|NCT00346957|EXPERIMENTAL|Anecortave Acetate 30|
62641749|NCT00346957|EXPERIMENTAL|Anecortave Acetate 15|
62641750|NCT00346957|EXPERIMENTAL|Anecortave Acetate 3|
62641751|NCT00346957|PLACEBO_COMPARATOR|Anecortave Acetate Vehicle|
62641752|NCT03351712|ACTIVE_COMPARATOR|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Gold Standard Intervention + Activity Tracker WITHOUT Feedback (Medical Rehabilitation, Motivational Support and Psycho-Education) During the in-patient phase, participants will participate in the intensive four-week hospital-based and medically-managed rehabilitation program for weight reduction. All patients will be placed on a hypocaloric nutritionally balanced diet tailored to the individual after consultation with a dietitian. Furthermore, they will receive nutritional counseling provided by dietitians, have physical activity training provided by physiotherapists and motivational support with elements of psycho-education provided by physicians trained and informed by psychologists-psychotherapists.
62072598|NCT02355522|ACTIVE_COMPARATOR|Intrauterine lidocaine group|3ml of KY jelly on the cervix and 5ml of 2% intrauterine lidocaine
62072599|NCT02355522|PLACEBO_COMPARATOR|Placebo group|3ml of KY jelly on the cervix and 5mL of intrauterine normal saline
62277001|NCT01999582|EXPERIMENTAL|Subcutaneous Dose Group 1, 2, and 3|Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
62277002|NCT05791279|EXPERIMENTAL|Interventional arm|"The participants in the intervention group will receive information about their ECG-based Heart-Age and the Heart Age. The estimated Heart Age and Heart Age Gap will be presented in writing to the participants in the experimental arm within 2 weeks after the baseline visit. The presentation will include a brief and easy-to-understand description on how the Heart Age has been estimated. In addition, patients will receive information about general advice on how to improve blood pressure levels and reduce the risk of future cardiovascular disease by adopting a healthy lifestyle and adhering to the prescribed medication. This information will be the same for participants in the two study arms, and is based on recommendations from the European Society of Cardiology.~For patients in the intervention group the ordinary primary care physicians will also be informed about the ECG-based Heart-Age."
62455295|NCT02603952|PLACEBO_COMPARATOR|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
62455296|NCT02603952|EXPERIMENTAL|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
62455297|NCT02603952|EXPERIMENTAL|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
62455298|NCT02603952|EXPERIMENTAL|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
62455299|NCT04809675|ACTIVE_COMPARATOR|HOS-HOS-FCM-FCM sequence|Use of a hard occlusal splint (HOS) for the first two weeks, followed by a week off, and a flexible customized mouthguard (FCM) for the fourth and fifth week.
62641753|NCT03351712|EXPERIMENTAL|Gold Standard Intervention and Activity Tracker WITH Feedback|In this experimental condition, will be provided the same rehabilitation program for the 4-weeks in-patient phase. In addition, for these subjects will be implemented a Stepped Protocol using wearable devices / activity trackers to collect information about daily physical activity and providing meaningful and informative feedbacks. The additional procedure starts during the in-patients phase, delivering and explaining the use of the wearable devices. In this meeting, longer than the one previously described for the control condition, experimenters provide information, set individualized goals and explain feedbacks which will be delivered after ending in-patients phase by the electronic wearable devices.
62072600|NCT03112200|ACTIVE_COMPARATOR|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
62088437|NCT04124822|EXPERIMENTAL|Prednisolone|group 3 is given Prednisolone 20mg half an hour before root canal treatment to manage post operative pain.
62088438|NCT06283082|EXPERIMENTAL|Asymptomatic subjects with an AGXT heterozygous mutation|
62088439|NCT06283082|ACTIVE_COMPARATOR|Symptomatic subjects with an AGXT heterozygous mutation|
62455300|NCT04809675|ACTIVE_COMPARATOR|FCM-FCM-HOS-HOS sequence|Use of a flexible customized mouthguard (FCM) for the first two weeks, followed by a week off, and a hard occlusal splint (HOS) for the fourth and fifth week.
62455301|NCT04375293|EXPERIMENTAL|AERD|Patients suffering from AERD
62072601|NCT03112200|SHAM_COMPARATOR|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:~* Partial meniscectomy~* Lavage~* Debridement~* Loose body removal~* Synovectomy~* Removal of osteophytes in the notch or locations other than those adjacent to BML(s)~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
62072602|NCT01673360||Elevate PC|Subjects implanted with Elevate PC
62072603|NCT01673360||Mini Arc Pro|Subjects implanted with Mini Arc Pro
62072604|NCT01673360||RetroArc|Subjects implanted with RetroArc
62072605|NCT01284140|EXPERIMENTAL|Sleep promotion protocol|Behavioral: 48 hours of sleep and circadian rhythm promotion including timed light exposure.
62072606|NCT01284140|ACTIVE_COMPARATOR|Usual care|Behavioral: 48 hours of usual care.
62072607|NCT04738890|EXPERIMENTAL|MBCT-PCCFA plus TAU|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing, plus treatment as usual.
62653035|NCT06351046|EXPERIMENTAL|VRPS program|VRPS is based on four evidence-based principles of cognitive-behavioral therapy and pain neuroscience education. For this project we have selected relaxation, mindful escapes, pain distraction games, and dynamic breathing modules.The eight consecutive weeks program period of intervention is composed of one initial physical meeting with 1h duration to explain the basis/principles of the virtual tools offered, how the virtual appliance works and should be used, including safety recommendations as calm environment at home, sitting or lying position during use. Groups of maximum 13 patients will be organized. Patients will be instructed to use the equipment at least once a day and it can be used as many times as they wish per day aiming to reduce pain intensity or to avoid pain. Patients will also be asked to keep a diary to register the equipment use during the study period to secure the data.
62072608|NCT04738890|OTHER|TAU control|Treatment as usual control group
62072609|NCT01340911|ACTIVE_COMPARATOR|Part 1A, Cohorts 1-6|"Approximately 48 healthy male subjects will be enrolled into 6 separate cohorts (8 subjects per cohort). Each Cohort of subjects will be dosed sequentially, approximately one week apart, at escalating doses. Within each cohort, 6 subjects will be randomized to receive a single dose of SRT3025, and 2 will be randomized to receive a single dose of placebo.~The following are the planned doses for Cohorts 1-6, with Cohort 1 being the lowest dose and Cohort 6 being the highest dose: 50, 150, 500, 1000, 2000, and 3000mg of SRT3025. Dose level may be altered as appropriate during the study based on real time analysis of the safety, tolerability, and /or PK data. Dose adjustment may involve an increase or decrease in dose or dividing the total daily dose allowing for twice-daily dosing. Total daily dosing will not exceed 3000mg."
62455302|NCT04375293|SHAM_COMPARATOR|Healthy|Healthy Controls
62455303|NCT04375293|ACTIVE_COMPARATOR|CRSwNP|Patients suffering from CRS with nasal polyps
62455304|NCT04375293|ACTIVE_COMPARATOR|CRSsNP|Patients suffering from CRS without nasal polyps
62641754|NCT03351712|EXPERIMENTAL|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|In this experimental condition, the subjects followed the normal medical rehabilitation program described above for the first experimental condition. For the out-patient phase the ACT intervention includes monthly 30 minutes skype-telephone sessions. The ACT-based interventions includes different processes: 1) Acceptance, that involves the active awareness of difficult private experiences without attempts to control or avoid unpleasant emotions. 2) Mindfulness, refers to engaging in present moment experience and adopting an open and curious attitude. 3) Defusion: Participants will be encouraged to defuse from thoughts and feelings by turning attention toward the 'noticing-self', instead of becoming attached to thoughts and 'run' through life on 'auto-pilot'. 4) Values and Commitment: encouraging participants to live in accordance with their values, participants can engage in meaningful activities despite experiencing unwanted emotions/ sensations.
62641755|NCT03351712|EXPERIMENTAL|ACT-Based Intervention and Activity Tracker WITH Feedback|ACT-Based Intervention and Activity Tracker WITH Feedback (Combining ACT and Behavioral Change) In the last experimental condition, obese individuals will follow the same rehabilitation program in the in-patients phase of the Behavioral Change condition, with the addition of the brief ACT intervention of 4 45-minutes sessions for a total amount of 3 hours one-to-one therapy sessions, exactly as in the ACT condition. In the out-patient phase of 16 weeks, each participant receive feedback from activity tracker following the same stepped protocol but message and feedbacks are informed by ACT therapist, including Value-based goal setting, prompt for including defusion from difficult thoughts, mindfulness cues and a set of ACT-consistent metaphors and messages.
62641756|NCT03251365|NO_INTERVENTION|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
62641757|NCT03251365|EXPERIMENTAL|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
62641758|NCT00264147|EXPERIMENTAL|Period I: 1|etoricoxib
62641759|NCT00264147|EXPERIMENTAL|Period I: 2|etoricoxib
62641760|NCT00264147|EXPERIMENTAL|Period I: 3|etoricoxib
62641761|NCT00264147|EXPERIMENTAL|Period I: 4|etoricoxib
62641762|NCT00264147|PLACEBO_COMPARATOR|Period I: 5|Placebo
62641763|NCT00264147|EXPERIMENTAL|Period II: 1|etoricoxib
62641764|NCT00264147|ACTIVE_COMPARATOR|Period II: 2|diclofenac
62641765|NCT02735031|ACTIVE_COMPARATOR|EXENATIDE|"Exenatide~* week 1-2: 5 µg twice daily~* week 3-6: 10 µg twice daily (if tolerated)"
62641766|NCT02735031|PLACEBO_COMPARATOR|PLACEBO|"Placebo matched to exenatide~* week 1-2: 5 µg twice daily~* week 3-6: 10 µg twice daily (if tolerated)"
62641767|NCT03667768|EXPERIMENTAL|Glass ionomer sealant|Two hand-mixed glass ionomer cements (GICs) available in the dental market were used, and they were mixed according to the manufacturer's instructions (powder/liquid ratio 1:1). The molars were cleaned with a toothbrush and wet cotton wool pellets. Isolation was performed with cotton wool rolls and the occlusal surface was conditioned with GIC liquid (20s), rinsed with wet cotton wool pellets and dried with dry cotton wool pellets. GIC was placed on the occlusal surface and pressed into the pits and fissures using the press-finger technique. The excess of material was removed and the occlusion checked and adjusted. Sealant was protected with a new layer of petroleum jelly and the children were instructed not to eat for at least one hour. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
62641768|NCT03667768|OTHER|Non-sealant (toothbrushing)|No sealant was performed. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
62641769|NCT02697214|ACTIVE_COMPARATOR|Apple Watch|Apple Watch heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device .
62641770|NCT02697214|ACTIVE_COMPARATOR|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
62641771|NCT02697214|ACTIVE_COMPARATOR|Mio Fuse|Mio Fuse heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
62641772|NCT02697214|ACTIVE_COMPARATOR|Basis Peak|Basis Peak heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
62641773|NCT05829499|EXPERIMENTAL|Eyedrops treatment arm|
62641774|NCT04804761|EXPERIMENTAL|Real EA group|
62072610|NCT01340911|ACTIVE_COMPARATOR|Part 1B, Cohorts 7-8|One to two of the doses administered in Part 1A may be selected for administration with food, based on expected changes in SRT3025 exposures with food, as well as safety, tolerability, and PK data from Part 1A. If initiated, the effect of a single dose of SRT3025 with a moderate fat/calorie meal may be initiated concurrently with a cohort in Part 2 of the study. Approximately 6 subjects would be enrolled into each cohort in Part 1B.
62277003|NCT05791279|NO_INTERVENTION|Control arm|The control group will receive standard care according to routine care at the individual primary health care center, and receive the same general advice, on how to improve blood pressure levels and/or to reduce risks of future cardiovascular disease, as the participants in the intervention group.
62277004|NCT05088278|ACTIVE_COMPARATOR|HS|Patients who underwent anatomical single-bundle ACL reconstruction with hamstrings
62641775|NCT04804761|SHAM_COMPARATOR|Sham EA group|
62641776|NCT03632564|EXPERIMENTAL|Stimulation Arm|REVIVIEW dichoptic audio-visual stimulation
62641777|NCT02048800||Treosulfan PK|Children with indication to HSCT receiving Treosulfan
62641778|NCT02198638|OTHER|Patients or healthcare workers|
62641779|NCT02590666|EXPERIMENTAL|Bipolar electrode|Polyps resection with bipolar electrode
62641780|NCT02590666|ACTIVE_COMPARATOR|Microscissors or graspers|Polyps resection with microscissors or graspers
62277005|NCT05088278|ACTIVE_COMPARATOR|BPT|Patients who underwent anatomical single-bundle ACL reconstruction with patellar tendon
62277006|NCT05088278|EXPERIMENTAL|Over-the-top plus lateral plasty|Patients who underwent ACL reconstruction with Over-the-top plus lateral plasty technique
62277007|NCT02175056|EXPERIMENTAL|HL2351|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
62277008|NCT02175056|PLACEBO_COMPARATOR|Placebo|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
62277009|NCT02175056|ACTIVE_COMPARATOR|Kineret(Anakinra)|100 mg (SC) / Single-Dose
62277010|NCT04913129|NO_INTERVENTION|Control Group|Standard physician-guided medical care after COVID-19
62277011|NCT04913129|EXPERIMENTAL|Interventional (exercise training) Group|8 week home-based exercise training
62277012|NCT02549755|OTHER|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
62277013|NCT02851914|ACTIVE_COMPARATOR|Arm 1 - TCA|"The Tricyclic Antidepressant (TCA) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
62277014|NCT02851914|ACTIVE_COMPARATOR|Arm 2 - SSRI|"The Selective Serotonin Reuptake Inhibitor (SSRI) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
62455305|NCT05237596||Prescription-grade Crystalline Glucosamine Sulfate Group (pCGS Group)|pCGS Group includes patients treated with pCGS (Dona®, VIATRIS), in sachets of powder for oral solution, at the dose of 1500 mg glucosamine sulfate once daily, for a total period of 6 consecutive months according to the approved indication for knee OA, in addition to conventional therapy for HOA.
62455306|NCT05237596||Control Group|Control Group includes patients treated with conventional therapy alone for at least 6 consecutive months.
62072611|NCT01340911|ACTIVE_COMPARATOR|Part 2A, Cohorts 9-11|Approximately 16-24 healthy subjects will be enrolled into 2 to 3 cohorts (8 subjects per cohort) in Part 2A. Within each cohort, 6 subjects will be randomized to receive multiple doses of SRT3025, and 2 will be randomized to receive multiple doses of placebo. The repeat dosing component of the study will be initiated, and doses selected, based on the evaluation of safety, tolerability, and PK data from Part 1A. Subjects in Part 2A will be randomized to receive 14 consecutive days of dosing with SRT3025 or matched-placebo. Subjects in these Cohorts will be dosed sequentially (in the fasted state) approximately two weeks apart.
62072612|NCT01340911|ACTIVE_COMPARATOR|Part 2B, Cohorts 12-13|If initiated, the effect of repeat doses of SRT3025 with moderate fat/calorie meals would occur in Part 2B (Cohorts 12 and 13). Each of these cohorts would enroll approximately 6 subjects.
62641781|NCT03308552|ACTIVE_COMPARATOR|SIB-IMRT combined chemotherapy followed by chemotherapy|"SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.~Concurrent chemotherapy: Paclitaxel and platinum based drug are administered once a week for at least 5 weeks during radiotherapy treatment days."
62641782|NCT03308552|PLACEBO_COMPARATOR|SIB-IMRT Alone followed by chemotherapy|SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
62641783|NCT02862301|OTHER|Control group|Healthy volunteers, free of any inflammatory disease. A blood sample is performed on the day of inclusion.
62641784|NCT02862301|EXPERIMENTAL|CIS group|patients with Clinically isolated syndrome. A blood sample is performed on the day of inclusion and after 3 months.
62641785|NCT00933725|EXPERIMENTAL|TCM intervention|Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone
62641786|NCT00933725|ACTIVE_COMPARATOR|Western intervention|Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs
62641787|NCT05726435|ACTIVE_COMPARATOR|Experimental group|Seven randomly selected active basketball players will be supplemented with defined prebiotic fibre (20 grams per day divided in two 10 gram doses - 85% total fiber content) for the total duration of 4 weeks, while being stationed in the training camp under constant coach and nutrition expert surveillance.
62072613|NCT04366570||The 1st group|(n=511; 36,45%) included patients with extra-articular injury of the proximal humerus (rotator cuff tear, anatomical and surgical neck fracture)
62072614|NCT04366570||The 2nd group|(n=309; 22,04%) included patients with intra-articular injury of the proximal humerus (contracture of the shoulder joint and shoulder instability, humeral head fracture, including Hill-Sachs lesion)
62072615|NCT04366570||The 3rd group|(n=582; 41,51%) - patients with injury of subacromial (suprahumeral) space (soft tissue injury, acromioclavicular and sternoclavicular joint injury, diaphyseal and distal end clavicle fracture)
62641788|NCT05726435|PLACEBO_COMPARATOR|Control group|Seven randomly selected active basketball players will be supplemented with placebo resembling prebiotic fibre in all visible and taste aspects (20 grams per day divided in two 10 gram doses) for the total duration of 4 weeks, while being stationed in the training camp under constant coach and nutrition expert surveillance.
62641789|NCT02460289|EXPERIMENTAL|Treatment|
62641790|NCT03729050|EXPERIMENTAL|Intervention with rehabilitation coordinator|
62641791|NCT03729050|NO_INTERVENTION|Control|
62641792|NCT06369558|EXPERIMENTAL|PYLOMETRIC|PLYOMETRIC TRAINING
62641793|NCT06369558|ACTIVE_COMPARATOR|CONTROL|CLASSIC PHYSIOTHERAPY PROGRAM
62072616|NCT05728593|ACTIVE_COMPARATOR|study group|Participants (n=15) were randomly selected by the researchers using the coin toss method, and thus the participants were divided into two groups as study (n=8) and control group (n=7) The study group received parent-based occupational therapy, while the control group received standard occupational therapy.
62455307|NCT00628160|EXPERIMENTAL|Terlipressin group|Terlipressin in continuous infusion plus alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
62641794|NCT02890316|EXPERIMENTAL|Radiation therapy with Homeopathy|Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.
62641795|NCT02890316|PLACEBO_COMPARATOR|Radiation therapy with placebo|Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.
62641796|NCT04705818|EXPERIMENTAL|Cohort A: pancreatic cancer|Patients with pancreatic cancer will be treated by durvalumab prescribed in association with tazemetostat
62455308|NCT00628160|ACTIVE_COMPARATOR|Control group|Alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
62455309|NCT00840905||1|HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
62641797|NCT04705818|EXPERIMENTAL|Cohort B: not MSI-H or MMR-deficient colorectal cancer|Patients with colorectal cancer will be treated bydurvalumab prescribed in association with tazemetostat
62641798|NCT04705818|EXPERIMENTAL|Cohort C: metastatic solid tumor|Patients with metastatic solid with positive interferon gamma signature and/or presence of tertiary lymphoid structurestumor will be treated bydurvalumab prescribed in association with tazemetostat
62641799|NCT04705818|EXPERIMENTAL|Cohort D: soft-tissue sarcoma|Patients with soft-tissue sarcoma will be treated by durvalumab prescribed in association with tazemetostat
62072617|NCT05728593|ACTIVE_COMPARATOR|control group|Participants (n=15) were randomly selected by the researchers using the coin toss method, and thus the participants were divided into two groups as study (n=8) and control group (n=7) The study group received parent-based occupational therapy, while the control group received standard occupational therapy.
62277015|NCT04507659|EXPERIMENTAL|Jaktinib 100mg|100 mg bid.po
62641800|NCT05971771|EXPERIMENTAL|Active: Sleep Supplement containing Magnesium and Saffron Extract|Powder that is to be mixed into 3oz. of water, 30-60 minutes before going to bed
62641801|NCT05971771|PLACEBO_COMPARATOR|Placebo|Placebo that is 2 softgels that will be taken with water, 30-60 minutes prior to going to bed.
62641802|NCT05606861|EXPERIMENTAL|Intervention group|Mindfulness Based Intervention in pediatric nurses components was applied to this group.
62641803|NCT05606861|NO_INTERVENTION|Control group|No procedure was conducted the control group.
62277016|NCT04507659|EXPERIMENTAL|Jaktinib 75mg|75 mg bid.po
62277017|NCT04507659|PLACEBO_COMPARATOR|Placebo|Placebo bid.po
62641804|NCT01172613||healthy subjects no symptoms|
62641805|NCT01172613||allergic rhinitis patient|
62641806|NCT05637034|EXPERIMENTAL|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
62641807|NCT04640922|ACTIVE_COMPARATOR|Gedea Pessary|pHyph, vaginal tablet, daily in Part 1 and once weekly in Part 2
62641808|NCT04640922|PLACEBO_COMPARATOR|Placebo|placebo, vaginal tablet, daily in Part 1 and once weekly in Part 2
62641809|NCT04361084|ACTIVE_COMPARATOR|traditional training|Participants will undertake the Community simulation using traditional methods, physical items to recreate the community environment. Training will be in pairs and will play the role of their own profession when undertaking simulated scenarios. Medium to low fidelity traditional simulation techniques involving scenarios played out using actors as (standardised patients) to participants. Following a briefing, the participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results and are anonymous. They will also complete their pre-questionnaire which will anonymous. Afterwards participants undertake a post-questionnaire and then asked if they wish to take part in a semi-structured interview.
62641810|NCT04361084|EXPERIMENTAL|mixed reality simulation training|Participants will undertake a mixed reality (MR) simulation training session set in two home situations; involving immersive virtual reality equipment. Participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results. The participants will then undertake the simulation watched via live camera by the simulation technician, simulation fellow and a community specialist. Participants will undertake a post simulation questionnaire and then asked if they wish to take part in a semi-structured interview (optional).
62641811|NCT03831776|EXPERIMENTAL|Bosutinib-Ropeginterferon combination|
62641812|NCT03831776|ACTIVE_COMPARATOR|Bosutinib monotherapy|
62277018|NCT02488395||de novo Parkinson's patients|"This group includes de novo Parkinson's patients who have just been diagnosed and not started their treatment at the inclusion.~This group will perform three fMRI sessions at different crucial steps of their normal follow up with a neurologist. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
62455310|NCT00840905||2|A cohort of HIV seropositive women from Gabarone Botswana
62455311|NCT00840905||3|A cohort of HIV seropositive women from Rio De Janeiro Brasil
62455312|NCT01506947|EXPERIMENTAL|Paricalcitol|"Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.~Participants may have also received routine darbepoetin alfa to treat anemia."
62455313|NCT03033420|EXPERIMENTAL|Intervention group|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
62641813|NCT01455623||Health Care Provider|A person working within the field of CMT.
62641814|NCT01455623||Patient with CMT|Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.
62641815|NCT00973583|ACTIVE_COMPARATOR|vitamin D|
62641816|NCT00973583|PLACEBO_COMPARATOR|placebo|
62641817|NCT04458519|EXPERIMENTAL|Probiorinse|Nasal irrigations with Probiorinse (2.4 Billion CFU (Colony-Forming Units) of Lactococcus Lactis W136, (NPN: 80085895)) twice-daily for a period of fourteen days
62072618|NCT02174874||Oral Ondansetron|Arm that receive oral solution .8 mgms per ml ondansetron - Apotex Brand DIN 02291967
62641818|NCT04458519|ACTIVE_COMPARATOR|Saline solution|Nasal irrigations with saline (NeilMed Sinus Rinse, (NPN: 80027142)) twice-daily for a period of fourteen days
62641819|NCT02815085|EXPERIMENTAL|RecoverLINK technology|RecoverLINK is a two-part mHealth technology designed to supplement traditional care transitional programs for heart failure (HF) patients.
62277019|NCT02488395||matching controls|"This group includes age-matching control participants to the first Parkinson group.~This group will perform one fMRI session. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
62455314|NCT03033420|NO_INTERVENTION|Control group|Treatment-as-usual
62455315|NCT02439398|EXPERIMENTAL|Allogeneic human cardiac stem cells|After randomization, subjects will received a suspension of allogeneic human cardiac stem cells (35 millions of CSCs - cell medicine) infused into the coronary artery responsible for the ischemic event.
62641820|NCT01927094|ACTIVE_COMPARATOR|Probiotic|"Saccharomyces boulardii 1 x 250 mg per day for 5 days, PO or Lactobacillus GG 1 x 10(9) CFU per day for 5 days or~Lactobacillus reuteri 1 x 10(8) CFU per day for 5 days"
62641821|NCT01927094|ACTIVE_COMPARATOR|Control|ORS-ad libitum
62641822|NCT05653232|EXPERIMENTAL|Prophylaxis (P2W)|Prophylaxis is one dose of sofosbuvir/velpatasvir (SOF/VEL) pre-HCV D+/R- kidney transplant (KT), continued for 2 weeks.
62277020|NCT00002827|EXPERIMENTAL|Treatment #1 (Without Zinecard)|"All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( \< 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days)."
62641823|NCT05653232|EXPERIMENTAL|Transmit and Treat (T&T)|T\&T is study-supplied SOF/VEL for 12 weeks starting on post-HCV D+/R- kidney transplant day participant's insurance approves standard of care DAAs, or post-KT day 14, whichever comes first.
62455316|NCT02439398|PLACEBO_COMPARATOR|Placebo: Human Serum Albumin-HSA 5%|After randomization, subjects will received placebo (which is also the cell medicine diluent). The placebo consists of a final administered volume of human serum albumin 5% in saline solution equivalent to the reconstituted cell medicine (18 mL). The placebo to be used is a marketed product (HSA 5%).
62455317|NCT03331042|EXPERIMENTAL|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
62072619|NCT02174874||Oral disintegrating tablets|Arm that receives the disintegrating tablets either 4mg or 8 mgs Glaxo Brand 4 mg DIN 02239372, 8 mg DIN 02239373
62072620|NCT03313115||No Sleep/Wake Protocol Implementation|No implementation of the sleep/wake protocol. A subset of participants in this group will have light and sound levels in the room recorded.
62455318|NCT03331042|EXPERIMENTAL|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
62641824|NCT04702464|EXPERIMENTAL|Treatment Administration|"* Day 1: Single dose of 100 mg fedratinib~* Days 10 to 23, inclusive: Single dose of 400 mg fluconazole on Day 10 and once daily (QD) doses of 200 mg fluconazole on Days 11 to 23, inclusive~* Day 18: Single dose of 100 mg fedratinib coadministered with the 200-mg fluconazole dose."
62072621|NCT03313115||Sleep/Wake Protocol Implementation|The sleep/wake protocol will be implemented. A subset of participants in this group will also have light and sound levels in the room recorded.
62641825|NCT04881812|EXPERIMENTAL|Drug-coated balloon|Patients will receive stenting of the actual CTO body with additional DCB treatment of the residual disease of the coronary artery.
62072622|NCT06274164||Patient group|"Subject enrollment: patients with RAI1-related disorders will be enrolled and will complete the following assessments:~* Clinical studies: vitals, history and physical examinations.~* Neurophysiological studies: sleep/EEG study (for a selected patient population).~* Molecular (biomarkers) studies: blood (required) and skin biopsy (optional)."
62072623|NCT06274164||Control group|"Subject enrollment: healthy family members of the patients with RAI1-related disorders who are willing to give a blood sample.~Molecular (biomarkers) studies: blood samples will be used as healthy control for biomarker studies."
62072624|NCT05924282||Sole PET group|Tumor recurrence was detected solely by PET; the surgery was performed and the extent of the resection was guided by the PET.
62072625|NCT05924282||Combined CT/MRI plus PET group|Tumor recurrence was detected by computed tomography (CT) / magnetic resonance imaging (MRI) and PET; the surgery was performed and the extent of the resection was guided by the CT/MRI+PET.
62072626|NCT05924282||Control group|Tumor recurrence was detected but no surgery was performed.
62072627|NCT00852137|EXPERIMENTAL|PEP005 (ingenol mebutate) Gel, 0.05%|
62072628|NCT00852137|PLACEBO_COMPARATOR|Vehicle Gel|
62072629|NCT05080673|EXPERIMENTAL|Arm 1|5-Year and 10-Year Surveillance Colonoscopy after Qualifying Colonoscopy
62072630|NCT05080673|EXPERIMENTAL|Arm 2|10-Year Surveillance Colonoscopy after Qualifying Colonoscopy
62455319|NCT03331042|EXPERIMENTAL|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
62455320|NCT03331042|EXPERIMENTAL|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
62641826|NCT04881812|ACTIVE_COMPARATOR|Drug-eluting stent|Patients will receive complete stenting of the CTO body and residual disease of the coronary artery.
62072631|NCT01108510|EXPERIMENTAL|ATV+COBI+FTC/TDF|COBI + RTV placebo + ATV + FTC/TDF once daily
62072632|NCT01108510|ACTIVE_COMPARATOR|ATV+RTV+FTC/TDF|RTV + COBI placebo + ATV + FTC/TDF once daily
62072633|NCT06004284|ACTIVE_COMPARATOR|control group|Only ergonomics training will be given to the control group.
62072634|NCT06004284|EXPERIMENTAL|exercise group|Participants will be given training including stretching and core exercises along with ergonomics training.
62653036|NCT06351046|NO_INTERVENTION|Control group|Participants in the control group will not receive any of the interventions. This study will not interfere with medical treatment plan and patients from the three groups can receive other pain treatment prescribed by physician.
62072635|NCT02109796|EXPERIMENTAL|hemiplegic patient|anodal transcranial direct current stimulation
62072636|NCT02109796|SHAM_COMPARATOR|patient control|Sham transcranial direct current stimulation
62072637|NCT04263090|EXPERIMENTAL|Rigosertib + Nivolumab|Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients
62072638|NCT02802319|EXPERIMENTAL|Test: Porcine Xenograft (Zcore)|Ridge preservation bone grafting surgery with porcine xenograft (Zcore)
62072639|NCT02802319|ACTIVE_COMPARATOR|Active Control: Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting surgery with bovine xenograft (Bio-Oss)
62072640|NCT01017653|EXPERIMENTAL|Panitumumab and irinotecan|
62641827|NCT01855958|EXPERIMENTAL|DIMST|The investigators used acupuncture needles with guide tubes (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd., 218, China) that were 40 mm in length and 0.25 mm in diameter. The needling in DIMST was applied using an electro acupuncture device (Cosmotron, São Paulo, Brazil) in the dermatomes corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). DIMST using was administered maintaining a distance from the spinous process line of 2 cm. The anatomic sites of peripheral DIMST were the muscles vastus medialis, rectus femoris, vastus lateralis, tibialis anterior; and the pes anserinus bursae. All subjects received one 30min session using a frequency of 2 Hz.
62072641|NCT05094193|EXPERIMENTAL|Trocar-site infiltration|Trocar-site infiltration with 20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 5 mm trocar site) associated with bilateral TAP block with 20 mL of normal saline in each side
62072642|NCT05094193|ACTIVE_COMPARATOR|TAP block|Trocar-site infiltration with 20 mL of normal saline associated with bilateral TAP block with 20 mL of ropivacaine 0.375% in each side
62641828|NCT01855958|SHAM_COMPARATOR|Placebo-sham|The investigators used the same electro acupuncture device (Cosmotron, Sao Paulo, Brazil), which was previously set to prevent the current to pass through the electrodes. Subjects were informed that it would be a stimulus of low intensity and high frequency that they probably would not have any sense of it. The electrodes were placed on the same points where the active stimulation was applied while the nerve stimulation unit was left in front of the subject, for 30 minutes. This positioning ensured that the intermittent diode simulating the electrical stimulus was visible and audible.
62641829|NCT02820077|EXPERIMENTAL|Hemospray|Patients treated with hemostatic powder
62641830|NCT02820077|NO_INTERVENTION|Clinical support|Patients treated with optimal clinical management, as it is been advised by the latest guidelines
62641831|NCT02174107|EXPERIMENTAL|Arm A|Percutaneous vertebroplasty
62641832|NCT02174107|EXPERIMENTAL|Arm B|External radiotherapy
62641833|NCT02831582|ACTIVE_COMPARATOR|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid supplementation PO QD for 6 months.
62641834|NCT02831582|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
62641835|NCT06465017|EXPERIMENTAL|68Ga-THP-Trop2 VHH|Each subject receives a single intravenous injection of 68Ga-THP-Trop2 VHH and undergoes PET/CT imaging within the specified time.
62641836|NCT01890655|EXPERIMENTAL|MT-1303-Low|MT-1303-Low Dose
62072643|NCT05559437|EXPERIMENTAL|Quadratus Lumborum Block group|Quadratus lumborum group (Q) (n=30): patients will receive Quadratus Lumborum Block using 20 mL of 0.25% Levo-bupivacaine
62072644|NCT05559437|EXPERIMENTAL|Ilioinguinal/Iliohypogastric Nerve Block group|Ilioinguinal/Iliohypogastric Nerve Block group (I) (n=30): patients will receive Ilioinguinal/Iliohypogastric Nerve Block using 5 mL of 0.25%Levo- bupivacaine
62072645|NCT00828906|EXPERIMENTAL|1|DuoTrav
62277021|NCT00002827|EXPERIMENTAL|Treatment #2 (with Zinecard)|Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15
62072646|NCT06038903||EFA group|This group for exploratory factor analysis (EFA)
62072647|NCT06038903||CFA group|This group for confirmatory factor analysis (CFA)
62072648|NCT02571621||Patients intubated with Combitube|Patients with Combitube intubation undergoing general anesthesia with ASA class I and II
62641837|NCT01890655|EXPERIMENTAL|MT-1303-Middle|MT-1303-Middle Dose
62641838|NCT01890655|EXPERIMENTAL|MT-1303-High|MT-1303-High Dose
62641839|NCT05879965||mpox patients|mpox cohort diagnosed and confirmed by PCR at the Institute of Tropical Medicine (ITM) in Antwerp during the recent mpox outbreak May-October 2022, 95 consented patients for follow-up
62072649|NCT01018641|EXPERIMENTAL|1|SA3Ag in both stage 1 and stage 2
62072650|NCT01018641|EXPERIMENTAL|2|SA3Ag in stage 1 followed by placebo in stage 2.
62072651|NCT01018641|PLACEBO_COMPARATOR|3|Placebo in both stage 1 and stage 2
62072652|NCT01018641|EXPERIMENTAL|4|SA3Ag in stage 1 and no vaccine in stage 2.
62072653|NCT01018641|PLACEBO_COMPARATOR|5|Placebo in stage 1 and no vaccine in stage 2.
62072654|NCT04911062|EXPERIMENTAL|Cohort 1: Bupivacaine HCl|Bupivacaine HCl without epinephrine, via injection into the surgical site.
62072655|NCT04911062|EXPERIMENTAL|Cohort 2: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
62072656|NCT04911062|EXPERIMENTAL|Cohort 3: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
62072657|NCT04867785|EXPERIMENTAL|0.5 milligrams (mg) LY3437943|Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
62072658|NCT04867785|EXPERIMENTAL|4 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
62072659|NCT04867785|EXPERIMENTAL|4 mg LY3437943 (4 mg)|Participants received 4 mg LY3437943 administered as SC injection QW.
62641840|NCT05879965||Smallpox vaccine recipients|sub-group 1: 100 participants routinely vaccinated with two subcutaneous 3rd generation smallpox vaccines sub-group 2: 100 participants routinely vaccinated with two intradermal 3rd generation smallpox vaccines
62641841|NCT05879965||Healthy controls|50 controls recruited during HIV-PrEP consultation (no former mpox infection, no smallpox vaccination)
62641842|NCT01405560|EXPERIMENTAL|Vaniprevir 24 Week Arm|Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment
62277022|NCT01815229|EXPERIMENTAL|tracheal lavages|"After the placement of the endotracheal tube (Hi-Lo™ Evac Mallinckrodt), tracheal lavages will be performed.~A simultaneous blood sample of approx 5cc, will be collected by venipuncture or by sampling from intravenous or arterial line if available. The same procedure for collection of tracheal sample and blood will be repeated at the end of the surgical procedure and immediately prior to removal of the ETT. A total of approx 10cc blood will be collected for research purposes."
62641843|NCT03851263|EXPERIMENTAL|Evolocumab|All subjects are treated with evolocumab 140mg every 2 weeks (q2w) starting on day 1 and ending on day 1071 (week 153).
62641844|NCT04754997|NO_INTERVENTION|Control group|This group will not take any exercise intervention.
62641845|NCT04754997|ACTIVE_COMPARATOR|Traditional exercise training group|This group will get traditional therapy that is include range of motion exercises and resistance exercise training.
62641846|NCT04754997|EXPERIMENTAL|Specific exercise training group|This group will get a specific programme that combinated with closed kinetic chain exercises and core exercises training
62641847|NCT04356157|OTHER|Special day|The special day takes place with an extraordinary opening of the clinical centre once a month on a pre-festive day (Saturday). During this day, access will be reserved exclusively for men, including those who are not on treatment for HIV. The centre will offer free health promotion services to all participants.
62641848|NCT04356157|OTHER|Male Champions|"The male champion is a figure present in a few settings which carries out home visits with men and couples and follows up with men who did not accompany their partners to Antenatal Care visits. Usually, this role is covered by the female Expert Clients, namely HIV+ patients working in the organization as volunteers after appropriate training. Some men among patients who are on treatment will be identified and trained to cover this role."
62641849|NCT04356157|OTHER|Nudge|The intervention based on the use of incentives (nudge) to men who follow the prevention and treatment program aims to evaluate whether this action is effective in guiding behaviour change towards the test, treatment, involvement and adherence to therapy approach.
62641850|NCT04356157|OTHER|No intervention|No intervention will be carried out in a center.
62641851|NCT03504215|EXPERIMENTAL|young adults|Both young adults born preterm (n=60) and term (n=30) will undergo the exercise intervention.
62641852|NCT03242941|EXPERIMENTAL|Persistent and Paroxtmal AF Patients|Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
62072660|NCT04867785|EXPERIMENTAL|8 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
62641853|NCT05859568|EXPERIMENTAL|Microphone Location versus Microphone Algorithm Comparison|Comparing performance and subjective feedback for pinna-located microphone versus a pinna-simulated microphone algorithm.
62641854|NCT02739217|EXPERIMENTAL|PBI-4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
62641855|NCT03819517|ACTIVE_COMPARATOR|Resveratrol|500 mg of time released micronized trans-Resveratrol
62641856|NCT03819517|PLACEBO_COMPARATOR|Placebo|Placebo will be used in the form of an empty white colored soft vegetarian capsule as resveratrol is presented
62641857|NCT03959007|ACTIVE_COMPARATOR|Control|Usual therapy and complete 3 questionnaire at 3 times during hospitalization : Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status
62641858|NCT03959007|EXPERIMENTAL|Experimental|9 consultations (3 x 3 sessions during hospitalization) of aesthetic care will be provided to patient include in experimental arm and 3 times questionnaires (Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status)
62641859|NCT02523430|EXPERIMENTAL|HepaSphere|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
62641860|NCT02523430|PLACEBO_COMPARATOR|control|nasopharyngeal carcinoma patients received traditional therapy
62072661|NCT04867785|EXPERIMENTAL|8 mg LY3437943 (4 mg)|Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
62072662|NCT04867785|EXPERIMENTAL|12 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.
62072663|NCT04867785|ACTIVE_COMPARATOR|1.5 mg Dulaglutide|Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.
62072664|NCT04867785|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered as SC injection QW.
62072665|NCT02861391|EXPERIMENTAL|CO2 AcuPulse Laser treatment|Subjects with USI as diagnosed by cough test intended to receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
62072666|NCT02861391|SHAM_COMPARATOR|Sham laser treatment|Subjects with USI as diagnosed by cough test intended to receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
62455321|NCT05143671||Hybrid coronary revascularization strategy (HCR)|Patients who undergo a combination of coronary artery bypass grafting and PCI.
62277023|NCT01815229|PLACEBO_COMPARATOR|Healthy Control|To replicate activation, neutrophils were isolated from 30mL blood of healthy volunteers and cocultured with TLF from subjects with or without sore throat pain.
62277024|NCT00954109|EXPERIMENTAL|Exercise|exercise - supervised exercise (treadmill walking or cycle ergometer use)
62455322|NCT05143671||Hybrid valve and coronary disease correction|Patients who undergo a combination of surgical valve replacement and PCI.
62455323|NCT05143671||Hybrid coronary and carotid artery disease treatment|Patients who undergo a combination of coronary artery bypass grafting and carotid stenting.
62641861|NCT01064479|EXPERIMENTAL|Arm A (combination chemotherapy and erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.
62641862|NCT01064479|ACTIVE_COMPARATOR|Arm B (combination chemotherapy and placebo)|Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.
62641863|NCT06515756|EXPERIMENTAL|All participates were divided into four experimantal groups according to the root canal sealers|Participates were divided into four experimantal groups.
62277025|NCT05999318|ACTIVE_COMPARATOR|active cTBS group|active cTBS combined with speech language therapy
62277026|NCT05999318|SHAM_COMPARATOR|sham cTBS group|sham cTBS combined with speech language therapy
62277027|NCT04997057|OTHER|Probiotics mixture|Daily supplementation with a mixture of probiotics for 12 weeks
62277028|NCT02547480|EXPERIMENTAL|TACE with irinotecan loaded LifePearl|10 patients receiving unilobar treatment: day 1=chemoembolization of first lobe of liver, day 14=chemoembolization of second lobe of liver, day 30=chemoembolization of first lobe of liver, day 44= chemoembolization of second lobe of liver; AND 10 patient receiving bilobar treatment: day 1=chemoembolization of both lobes of the liver, day 30=chemoembolization of both lobes of the liver
62277029|NCT06457581|OTHER|Dry Needling|
62277030|NCT06457581|EXPERIMENTAL|Trigger points injections|
62455324|NCT04085666|EXPERIMENTAL|1st Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
62072667|NCT01004250|EXPERIMENTAL|Study Treatment|
62641864|NCT06515756|EXPERIMENTAL|Groups were divided into two subgroups to be applied on teeth with pulpitis and apical periodontitis|Four different root canal sealer groups were divided into two subgroups to be applied on teeth with pulpitis and apical periodontitis. Although sealers were different, they was applied with the same technique.
62641865|NCT03446040|EXPERIMENTAL|Part A Dose Escalation: BMS-986258|
62641866|NCT03446040|EXPERIMENTAL|Part A1: BMS-986258 + Recombinant human hyaluronidase PH20 (rHuPH20)|
62641867|NCT03446040|EXPERIMENTAL|Part B Dose Escalation: BMS-986258 + nivolumab|
62641868|NCT03446040|EXPERIMENTAL|Part C Cohort Expansion: BMS-986258 + nivolumab|
62072668|NCT06122532|EXPERIMENTAL|Stem cell preparation combined with Reticular skin|
62072669|NCT06122532|EXPERIMENTAL|Stem cell preparation combined with MEEK skin|
62072670|NCT06122532|EXPERIMENTAL|Stem cell preparation combined with split-thickness skin|
62641869|NCT06197360|PLACEBO_COMPARATOR|General diabetes health education|Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
62641870|NCT06197360|EXPERIMENTAL|Based on BCW Theory of Health Education|A FOH intervention program based on BCW theory was implemented on top of the control group.
62641871|NCT02163161|EXPERIMENTAL|Treatment A|
62072671|NCT06122532|PLACEBO_COMPARATOR|autologous skin grafting|
62072672|NCT05716789|EXPERIMENTAL|CPR asseement|determine the success rate of CPR in Emergency room and factors predicting successful CPR
62641872|NCT02163161|EXPERIMENTAL|Treatment B|
62641873|NCT02163161|EXPERIMENTAL|Treatment C|
62641874|NCT04521595|EXPERIMENTAL|weigh smart intervention|open treatment arm to receive group based lifestyle intervention via telehealth.
62072673|NCT00599547|EXPERIMENTAL|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
62277031|NCT04494932|EXPERIMENTAL|Biceps Tenodesis|
62277032|NCT04494932|ACTIVE_COMPARATOR|SLAP Repair (Control)|
62277033|NCT00311467|ACTIVE_COMPARATOR|Capecitabine and Interferon|Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
62455325|NCT04085666|EXPERIMENTAL|2nd Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
62455326|NCT05792059||patients with HFpEF|
62641875|NCT01095497|EXPERIMENTAL|IV CINRYZE First, Then SC CINRYZE Dose 1|
62641876|NCT01095497|EXPERIMENTAL|IV CINRYZE First, Then SC CINRYZE Dose 2|
62641877|NCT06183034|OTHER|Very Low Calorie Diet|Very Low Calorie Diet - caloric intake restricted to approximately 800 kcal/day
62641878|NCT02499016|EXPERIMENTAL|suprapubic single-incision laparoscopic appendectomy|single incision laparoscopic surgery will be performed for patients in this group.
62641879|NCT02499016|ACTIVE_COMPARATOR|conventional multiport appendectomy|Conventional laparoscopic surgery will be performed for patients in this group.
62641880|NCT03451396|ACTIVE_COMPARATOR|Mild Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity \>308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
62641881|NCT03451396|ACTIVE_COMPARATOR|Moderate to Severe Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity \>320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
62641882|NCT03711435||Training set|The training set is composed of 30 IPF patients and 15 controls. The group is designed to identify differential metabolites between IPF and control groups.
62641883|NCT03711435||Validation set|The validation set is composed of 15 IPF patients and 15 controls. The group is designed to validate differential metabolites identified in the previous groups.
62641884|NCT03482050|EXPERIMENTAL|AstroRx|
62277034|NCT00311467|ACTIVE_COMPARATOR|Interferon|"Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
62455327|NCT05792059||patients without HFpEF|
62641885|NCT02770638|EXPERIMENTAL|Scoop Stretcher|Participant wearing light sports clothing will start with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
62277035|NCT05053295|EXPERIMENTAL|Immuncell-LC/Nivolumab group|Patients will receive nivolumab once a day at 4-week intervals and Immuncell-LC 12 times (3 treatments once a week, followed by 5 treatments every other week, and finally 4 treatments every 4 weeks).
62277036|NCT03243994|EXPERIMENTAL|COPD|Patients with COPD without Cor Pulmonale
62455328|NCT04091347|EXPERIMENTAL|Intervention Arm|The intervention group will receive the intervention for 12 weeks. The wait list control group will have outcomes measured but will not receive the intervention at this time.
62455329|NCT04091347|ACTIVE_COMPARATOR|Wait List Control Arm|Once the intervention group has completed the intervention the wait list control group will complete the intervention.
62455330|NCT04281992|EXPERIMENTAL|AUP1602-C|AUP1602-C will be administered topically once or repeatedly three times per week during the treatment period.
62455331|NCT03582332|ACTIVE_COMPARATOR|Group A in phase 1|Indomethacin 75 mg, extended release capsule twice daily
62455332|NCT03582332|ACTIVE_COMPARATOR|Group B in phase 1|Indomethacin 25 mg capsule, 2 capsule twice daily
62455333|NCT03582332|ACTIVE_COMPARATOR|Group A in phase 2|Etoricoxib 90 mg once daily
62455334|NCT03582332|ACTIVE_COMPARATOR|Group B in phase 2|Etoricoxib 60 mg once daily
62455335|NCT00597194|ACTIVE_COMPARATOR|OH|Inguinal hernia operated using a classic open herniotomy(OH)
62455336|NCT00597194|ACTIVE_COMPARATOR|LH|Laparoscopic herniorraphy (LH) for inguinal hernia
62455337|NCT03665103|EXPERIMENTAL|Laser-assisted ICSI|
62455338|NCT03665103|NO_INTERVENTION|conventional ICSI|
62455339|NCT01582607|ACTIVE_COMPARATOR|Group B|subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%
62277037|NCT03243994|EXPERIMENTAL|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
62277038|NCT01577485|EXPERIMENTAL|Probiotic pastille|Test group
62277039|NCT01577485|ACTIVE_COMPARATOR|Control pastille|Control group
62277040|NCT06335550|OTHER|Robotic mastectomy|All consecutive cases of robotic mastectomy over the study duration
62277041|NCT01358903|EXPERIMENTAL|A|
62277042|NCT01358903|EXPERIMENTAL|B|
62277043|NCT01317680|ACTIVE_COMPARATOR|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
62277044|NCT01317680|PLACEBO_COMPARATOR|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy.
62277045|NCT03697096|ACTIVE_COMPARATOR|Routine Care|Continued routine antibiotic stewardship strategies.
62277046|NCT03697096|ACTIVE_COMPARATOR|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for UTI in non-ICU patients in the first 3 days of hospitalization.
62277047|NCT03314545|OTHER|laminate veneers with coronal posts|anterior endodontically treated teeth restored with laminate veneers with coronal posts
62277048|NCT03314545|OTHER|post, core and crown|anterior endodontically treated teeth restored with post, core and crown
62277049|NCT01133171|EXPERIMENTAL|Dashboard Plus Nurse|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling plus a computerized dashboard intervention.
62277050|NCT01133171|EXPERIMENTAL|Nurse Alone|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling.
62072674|NCT01808976|ACTIVE_COMPARATOR|Evolution|This app is designed to be a cognitive training game that conditions the CCN. This is done by having participants play a multitasking game that targets their perceptual discrimination abilities, selective attention, and visuomotor tracking skills. At the first session, participants will be directed to an initial assessment of each of these cognitive control skills in a single task and dual-task setting (a total of 3 different diagnostics, described below). Each week, this diagnostic phase will reflect the training paradigm they will encounter for that week, as each week the perceptual and tracking challenges will increase.
62072675|NCT01808976|EXPERIMENTAL|Problem Solving Therapy|This app is based on the social problem solving protocol developed by Nezu and D'Zurilla . The app begins with explaining the PST steps. Participants are informed that they can learn each step one session at a time, or they can chose to learn all the steps at once. After each step completed, participants are asked if they want to continue onto the next step or save it for the next session, thus the app tailors itself to the users ability to absorb new information.
62641886|NCT02770638|ACTIVE_COMPARATOR|Long Back Spinal Board|Participant wearing light sports clothing will start with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
62072676|NCT01808976|ACTIVE_COMPARATOR|Basic health push app|This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
62072677|NCT04180839|EXPERIMENTAL|gaming-related retrieval-extinction|about 30 individuals with IGD will be randomly assigned to the R-E training group
62072678|NCT04180839|OTHER|nongaming-related retrieval-extinction|about another 30 individuals with IGD will be randomly assigned to the NR-E training group
62072679|NCT03548064|EXPERIMENTAL|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
62072680|NCT03548064|EXPERIMENTAL|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
62072681|NCT03548064|EXPERIMENTAL|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
62455340|NCT01582607|ACTIVE_COMPARATOR|Group R|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%
62072682|NCT03548064|EXPERIMENTAL|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
62072683|NCT03548064|EXPERIMENTAL|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
62072684|NCT03548064|EXPERIMENTAL|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
62072685|NCT03548064|EXPERIMENTAL|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
62072686|NCT03548064|EXPERIMENTAL|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
62072687|NCT03548064|EXPERIMENTAL|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
62072688|NCT04421937|EXPERIMENTAL|Neuromuscular Electrical Stimulation (NMES) with TDT|
62072689|NCT04421937|ACTIVE_COMPARATOR|Traditional Dysphagia Therapy (TDT)|
62072690|NCT03712540|EXPERIMENTAL|BMS-986278 + Rifampin|Treatment period A: BMS-986278 alone Treatment period B: Rifampin followed by BMS-986278
62072691|NCT03636945|EXPERIMENTAL|Medullary thyroid carcinoma|Patients with MTC who have serum calcitonin\> 150 pg / ml at initial diagnosis and have performed baseline imaging examinations within the last 3 months will be included in the study A PET at 18F-FDOPA will be performed according to a very powerful acquisition protocol
62072692|NCT03514407|EXPERIMENTAL|INCB059872|INCB059872
62072693|NCT04132570|EXPERIMENTAL|Budesonide 256 mcg per Day (Treatment A)|Participants will self-administer 2 nasal sprays of Budesonide (64 microgram \[mcg\]/spray) in each nostril once daily (every morning) up to 10 +\\- 3 Days.
62455341|NCT01582607|ACTIVE_COMPARATOR|Group LB|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%
62072694|NCT04132570|PLACEBO_COMPARATOR|Placebo (Treatment B)|Participants will self-administer 2 nasal sprays of matching placebo in each nostril once daily (in the morning) up to 10 +\\- 3 Days.
62641887|NCT01042470||control group|female patients without pelvic organ prolapse, stage 0 or I (POP-Q)
62641888|NCT01042470||pelvic organ prolapse|female patients with pelvic organ prolapse stage II or higher (POP-Q)
62641889|NCT00584584|EXPERIMENTAL|1|
62641890|NCT00584584|PLACEBO_COMPARATOR|2|
62641891|NCT05731310|EXPERIMENTAL|Angong Niuhuang Pill Group|Take half an Angong Niuhuang pill every day for 4 weeks
62641892|NCT05731310|EXPERIMENTAL|Angong Niuhuang pill combined with music electroacupuncture group|Take half an Angong Niuhuang pill every day for 4 weeks and Daily music scalp acupuncture treatment
62072695|NCT05896917|EXPERIMENTAL|Experimental|This group will receive 3D Printed Foot Orthoses
62455342|NCT01582607|ACTIVE_COMPARATOR|Group RF|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl
62455343|NCT01582607|ACTIVE_COMPARATOR|Group BF|subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
62455344|NCT01582607|ACTIVE_COMPARATOR|Group LBF|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
62455345|NCT03392298|EXPERIMENTAL|CCA group|Participants in CCA group will be treated with 15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd)， once daily for 4 weeks.
62641893|NCT05731310|NO_INTERVENTION|General control group|no intervention
62641894|NCT02039258|EXPERIMENTAL|Sequence AB|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B).
62641895|NCT02039258|EXPERIMENTAL|Sequence BA|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A).
62641896|NCT03610893|ACTIVE_COMPARATOR|Perineural dexamethasone|addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
62641897|NCT03610893|ACTIVE_COMPARATOR|Perineural dexmedetomidine|addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
62641898|NCT04284254|EXPERIMENTAL|Phase 1: Dose Escalation|
62641899|NCT04284254|EXPERIMENTAL|Phase 2 - Expansion at MTD|
62641900|NCT04354935|ACTIVE_COMPARATOR|Method 1 ( iTBS)|target region: Dorsolateral Prefrontal left Fréquence : 50 Hz Intensity of the stimulation : 120% SM duration : 3 minutes Number of pulses : 600
62641901|NCT04354935|ACTIVE_COMPARATOR|Method 2 (French touch)|target region : dorsolateral prefrontal cortex right Frequency:1HZ Intensity:120% SM duration : 8 Min 30 Sec Number of plulses : 360
62455346|NCT03392298|NO_INTERVENTION|Control group|Participants in Control group will be treated with nothing, but followed up for 4 weeks.
62072696|NCT05896917|ACTIVE_COMPARATOR|Control|This group will receive Prefabricated Foot Orthoses
62072697|NCT00479089|ACTIVE_COMPARATOR|Weekly Docetaxel|Docetaxel 25 mg/m\^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy.
62072698|NCT00479089|ACTIVE_COMPARATOR|Weekly Docetaxel + ZD1839|Docetaxel 25 mg/m\^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy. ZD1839 250 mg by mouth daily, without break.
62455347|NCT06196684||Patients with primary tricuspid valve insufficiency scheduled for tricuspid valve replacement|
62072699|NCT02600182|EXPERIMENTAL|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
62072700|NCT02600182|NO_INTERVENTION|Control|Routine physical therapy will be performed.
62072701|NCT01290536|EXPERIMENTAL|Yttrium-90 liver radioembolization|
62641902|NCT04354935|ACTIVE_COMPARATOR|Method 3 (FDA)|target region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM duration : 37 minutes Number of pulses : 3000
62641903|NCT04354935|ACTIVE_COMPARATOR|Method 4 (ITBS VIIT)|target region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
62641904|NCT04354935|ACTIVE_COMPARATOR|Method 5 (SNTm)|Target region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
62641905|NCT04354935|ACTIVE_COMPARATOR|Method 6 (SNT)|Target region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
62641906|NCT04354935|ACTIVE_COMPARATOR|Method 7 (DASH)|Target region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM Duration : 18.75 minutes Number of pulses : 3000
62641907|NCT04140409|EXPERIMENTAL|Treatment|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
62072702|NCT02004743|OTHER|Control|Treatment as Usual
62072703|NCT02004743|OTHER|Intervention|Psychological management guidelines + patient education
62455348|NCT00802451|ACTIVE_COMPARATOR|Test Drug|
62455349|NCT00802451|ACTIVE_COMPARATOR|Reference Drug|
62455350|NCT05449977||Patients with Schizophrenia|20 patients with schizophrenia will be conducted
62455351|NCT05140447|ACTIVE_COMPARATOR|Admira 50º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 50º C
62641908|NCT05414851|EXPERIMENTAL|Whole-Food, Plant-Based Start|This group starts with the whole-food, plant-based diet, then gets the low-carbohydrate diet after the washout period.
62641909|NCT05414851|EXPERIMENTAL|Low-Carbohydrate Start|This group starts with the low-carbohydrate diet, then gets the whole-food, plant-based diet after the washout period.
62641910|NCT05643391|EXPERIMENTAL|Single arm|"The treatment will include 1 preparatory angiography followed by treatment at a maximum 2 weeks interval. Dosimetry MRI will be performed just before and immediately after treatment. SPECT CT will be performed three days after treatment.~The activity of 166Ho that must be administered to a patient will depend on the tumor perfusion and absorbed dose linked to this activity.Q-SuiteTM 2.0 will be used, more precisely a dosimetry software to perform an optimal compartmental predictive dosimetry:~- minimum 150 Gy to the tumor, maximum 60 Gy to non-tumoral liver, maximum 30 Gy lung shunt fraction."
62277051|NCT01133171|NO_INTERVENTION|Control|Patients randomized to this group were followed retrospectively to collect data on their primary care visits and laboratory results and past medical history over the 12 month study period. They had no contact with study personnel and did not receive any type of intervention.
62277052|NCT05634863|EXPERIMENTAL|KIDNEY TRANSPLANT PATIENTS WITH THE IMPLANTABLE CONTINUOUS VASCULAR MONITORING DEVICE|The intervention that is intended to be investigated is the implantable vascular monitoring device manufactured by COOK Medical Company. Its principle intended use is continuous monitoring of the graft perfusion (i.e. transplanted kidney) for the first 72 hours postoperatively. The kidney transplant patients in the intervention group will receive implantable continuous vascular monitoring device surveillance for the first 72 hours in addition to the standard care clinical observation as part of their postoperative care. The intervention will be removed after 72 hours postoperatively.
62277053|NCT05634863|NO_INTERVENTION|KIDNEY TRANSPLANT PATIENTS WITH STANDARD CARE CLINICAL OBSERVATION|The kidney transplant patients in this group will receive the standard care clinical observation as part of their postoperative care. Their graft will be monitored postoperatively by the standard care clinical observation as per the NHS protocol.
62455352|NCT05140447|ACTIVE_COMPARATOR|Admira 70º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 70º C
62641911|NCT00572845|EXPERIMENTAL|1|Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.
62072704|NCT01770990|ACTIVE_COMPARATOR|Tel-PT without mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) without additional motivating letters.
62072705|NCT01770990|EXPERIMENTAL|Tel-PT including mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) with an additional motivating letter after every telephone session.
62277054|NCT00131846|ACTIVE_COMPARATOR|1|Diuretics use
62277055|NCT00131846|ACTIVE_COMPARATOR|2|No diuretics use
62277056|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
62277057|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
62277058|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
62455353|NCT05140447|ACTIVE_COMPARATOR|Viscalor 50º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 50º C
62455354|NCT05140447|ACTIVE_COMPARATOR|Viscalor 70º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 70º C
62455355|NCT05769530|EXPERIMENTAL|DEX and Nalbuphine group|In group B, DEX 0.5μg/kg was injected intravenously 30min before the end of the operation, 30min after the pump, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation.
62455356|NCT05769530|PLACEBO_COMPARATOR|placebo group|Group A was continuously injected with normal saline during the operation, and 5 mL of normal saline was injected intravenously 30min before the end of the operation
62641912|NCT03328481|EXPERIMENTAL|Loss-of-resistance|Patients in this group will receive Loss-of-resistance Quadratus lumborum block with 30 ml bupivacaine 0.25% in addition to general anesthesia.
62641913|NCT03328481|ACTIVE_COMPARATOR|Ultrasound-guided|Patients in this group will receive Ultrasound-guided Quadratus lumborum block type-II with 30 ml bupivacaine 0.25% in addition to general anesthesia.
62641914|NCT05426590|ACTIVE_COMPARATOR|Diabetic patient|Patient with diabetes will undergo cataract surgery
62641915|NCT05426590|ACTIVE_COMPARATOR|Non diabetic patients|Healthy non diabetic patients will undergo cataract surgery
62641916|NCT06252935|EXPERIMENTAL|FormaAid group|Patients with intrabony defects are randomly assigned to receive either FormaAid collagen membrane or Geistlich Bio-Gide (control)before the GTR. And then treated with GTR surgery, the surgical procedure involves a full-thickness flap, the affected area is cleaned, and the damaged or diseased tissue may be removed. The allograft will be then placed into the defect and the collagen membrane is then trimmed and adapted over the defect. After all the treatment is done, 5-0 nylon suture will be used for the flap closure.
62277059|NCT03238820|EXPERIMENTAL|The robot group|Patients undergo robotic gastric gastrointestinal stromal tumors resection.
62277060|NCT03240146|ACTIVE_COMPARATOR|Study Group|Subjects in this group will receive an active pulsed shortwave therapy device.
62277061|NCT03240146|PLACEBO_COMPARATOR|Control Group|Subjects in this group will receive a placebo pulsed shortwave device that it does not emit energy.
62277062|NCT05155501|ACTIVE_COMPARATOR|Robot-assisted radical prostatectomy (RP)|The conventional robotic-assisted radical prostatectomy is the gold standard approach to prostate cancer surgery.
62641917|NCT06252935|ACTIVE_COMPARATOR|Bio-Gide group|Patients with intrabony defects are randomly assigned to receive either FormaAid collagen membrane or Geistlich Bio-Gide (control)before the GTR. And then treated with GTR surgery, the surgical procedure involves a full-thickness flap, the affected area is cleaned, and the damaged or diseased tissue may be removed. The allograft will be then placed into the defect and the collagen membrane is then trimmed and adapted over the defect. After all the treatment is done, 5-0 nylon suture will be used for the flap closure.
62455357|NCT05769530|EXPERIMENTAL|nalbuphine group|Group C was continuously injected with normal saline 30 minutes before the end of the operation, and intravenous injection of nalbuphine 0.20 mg/kg (5 mL) 30 minutes before the end of the operation.
62072706|NCT01242176|EXPERIMENTAL|BI 10773 Final Formulation|one single film-coated tablet in the morning
62072707|NCT01242176|EXPERIMENTAL|BI 10773 XX Trial Formulation 2|one single dose tablet in the morning
62277063|NCT05155501|EXPERIMENTAL|Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)|A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate. These structures are disrupted and removed during conventional radical prostatectomy.
62277064|NCT00931216|EXPERIMENTAL|Integrated ANC, PMTCT and HIV Services|HIV care and treatment services are integrated into antenatal care (ANC) services for women testing positive within the ANC at this facility.
62277065|NCT00931216|NO_INTERVENTION|Non-Integrated Services|Women testing positive in the ANC department are referred for care at the HIV clinic. HIV care and treatment services are not provided within the ANC at facilities randomized to this arm.
62277066|NCT02300454|ACTIVE_COMPARATOR|Non-slip element balloon (NSE)|Lacrosse® NSE dilatation before use of SeQuent® Please drug coated balloon (DCB)
62277067|NCT02300454|PLACEBO_COMPARATOR|Balloon|Non-compliant balloon dilatation before use of SeQuent® Please drug coated balloon (DCB)
62277068|NCT05058508|EXPERIMENTAL|EXER|"Just Move exercises"
62277069|NCT05058508|EXPERIMENTAL|SOC EXER|Standard of Care Exercise
62277070|NCT04931004|EXPERIMENTAL|0.075% Cetylpyridinium Chloride|
62277071|NCT04931004|EXPERIMENTAL|1.5% Hydrogen peroxide|
62277072|NCT04931004|EXPERIMENTAL|Chlorhexidine gluconate|
62277073|NCT04931004|PLACEBO_COMPARATOR|Water rinse|Control for impact on viral load changes from mechanical rinsing
62277074|NCT03903510|EXPERIMENTAL|Virtual Reality|Participants will experience Virtual Reality during their cast removal
62277075|NCT03903510|NO_INTERVENTION|Standard of care|Participants will receive their usual standard of care treatment during cast removal
62277076|NCT02538068|EXPERIMENTAL|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
62277077|NCT02538068|ACTIVE_COMPARATOR|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
62455358|NCT01230580|EXPERIMENTAL|Protease Inhibitor Monotherapy|Ritonavir-boosted protease inhibitor
62455359|NCT01230580|ACTIVE_COMPARATOR|Control|Standard-of-care triple-therapy regimen
62455360|NCT02213471||Elevated risk for melanoma|Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.
62455361|NCT01933607|OTHER|TOPS System|Post Marketing Study
62277078|NCT04546685|OTHER|Usual Care (waitlist)|Participants will continue their usual clinical care.
62277079|NCT04546685|EXPERIMENTAL|1-Session pain relief skills class (online Spanish Empowered Relief)|Empowered Relief is a 2-hour one session pain relief skills intervention that is delivered to a group of patients by a Spanish-fluent certified instructor using a standardized treatment manual and electronic slide deck. Content includes completion of a pain survey, pain neuroscience education, information on pain and stress responses, experiential exercises, information on three core pain management skills, completion of a personalized plan for empowered relief, and receipt of a binaural app for daily use.
62277080|NCT01722500||10 year old children|500 children with mean age 10.5 years from each of 12 countries
62277081|NCT01150240||Primary Immunodeficiency Disease|Patients with primary Immunodeficiency disease (PID)
62277082|NCT03180775|SHAM_COMPARATOR|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
62277083|NCT03180775|EXPERIMENTAL|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
62277084|NCT03180775|EXPERIMENTAL|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
62277085|NCT03180775|EXPERIMENTAL|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
62277086|NCT03180775|EXPERIMENTAL|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
62277087|NCT03180775|EXPERIMENTAL|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
62277088|NCT03180775|EXPERIMENTAL|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
62455362|NCT01352325|EXPERIMENTAL|system constellations seminar (exp. group)|Study participants randomized to this group receive the intervention (system constellation seminar) 4 months prior to the control group
62455363|NCT01352325|EXPERIMENTAL|system constellations seminar (control group)|Study participants randomized to this group receive the intervention (system constellations seminar) 4 months after the experimental group.
62277089|NCT03180775|EXPERIMENTAL|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
62277090|NCT03180775|EXPERIMENTAL|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
62277091|NCT03180775|EXPERIMENTAL|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
62277092|NCT03180775|EXPERIMENTAL|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
62277093|NCT01138956|EXPERIMENTAL|Group 1|Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.
62277094|NCT01138956|ACTIVE_COMPARATOR|Group 2|Pentavalent antimonial, 20mg/kg/day, 28 days
62277095|NCT03504410|EXPERIMENTAL|CPI-613 + HD Cytarabine and Mitoxantrone|"CPI-613 + High Dose Cytarabine and Mitoxantrone~CPI-613 at 2,000 mg/m2/day from day 1 to 5.~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine."
62277096|NCT03504410|ACTIVE_COMPARATOR|Control (HAM) and control sub-groups (MEC and FLAG)|"High Dose Cytarabine and Mitoxantrone~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine.~Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6~Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
62277097|NCT03706287|EXPERIMENTAL|Anlotinib + AP/PC|
62277098|NCT06374017|PLACEBO_COMPARATOR|Group C|Group C: will receive 5ml of normal saline sprayed via long nostril syringe into oropharynx, the vocal cords and tracheobronchial tree 5 minutes before intubation
62277099|NCT06374017|ACTIVE_COMPARATOR|Group L|: : will receive 5ml of lidocaine 2% (100mg) sprayed via long nostril syringe into oropharynx , the vocal cords and tracheobronchial tree 5 minutes before intubation
62277100|NCT06374017|ACTIVE_COMPARATOR|Group D|will receive dexmedetomidine (1 μg/kg) diluted in 5ml normal saline sprayed via long nostril syringe into oropharynx , the vocal cords and tracheobronchial tree 5 minutes before intubation.
62277101|NCT06146725||Tumor resection|Tumor resection
62455364|NCT06012903||Parents|
62455365|NCT06012903||Children|
62455366|NCT06012903||Teachers|
62277102|NCT06146725||Tumor biopsy|Tumor biopsy
62455367|NCT05543148||normal hearing with subjective hearing difficulty|
62455368|NCT05543148||mild hearing loss (unaided)|
62455369|NCT05543148||moderate hearing loss (unaided)|
62277103|NCT06038331|EXPERIMENTAL|SclerFIX-IP|Treated, devitalised and sterile graft of umbilical cord amniotic membrane
62277104|NCT01990287|EXPERIMENTAL|SCS and PNfS|Eon or Eon Mini IPG with epidural leads in the spinal column and subcutaneous leads in the peripheral field
62277105|NCT01990287|ACTIVE_COMPARATOR|SCS Alone|Eon or Eon Mini IPG with epidural leads in the spinal column
62277106|NCT03013062||WITH PULMONARY HYPERTENSION|It is defined as MPAP \> 25 mm Hg at rest or \>30 mm Hg during exercise with PVR \> 3 wood units and PCWP \< 15 mm Hg.
62277107|NCT01385085||No natural sunlight|one group works in a basement with no natural sunlight
62277108|NCT01385085||Low level of Natural Sunlight|the second group work in offices with unopenable windows.
62277109|NCT01385085||High level of Natural Sunlight|The third group works outdoors.
62277110|NCT04563429|EXPERIMENTAL|Treatment Group|
62455370|NCT05543148||moderate hearing loss (aided)|
62455371|NCT01147952|EXPERIMENTAL|12 week exercise training|
62455372|NCT01147952|NO_INTERVENTION|Conventional Care|
62455373|NCT01400425|EXPERIMENTAL|Subjects with Progressive Cognitive Decline|Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
62455374|NCT03814343|ACTIVE_COMPARATOR|Active comparator|10 patients with NDMs onychomycosis treated with amphotericin B in 30% DMSO.
62455375|NCT03814343|PLACEBO_COMPARATOR|control comparator|10 patients with NDMs onychomycosis treated with 30% DMSO.
62455376|NCT03490721|EXPERIMENTAL|Intervention|Clustering care for 20 minutes.
62455377|NCT03490721|NO_INTERVENTION|Control|Standard care non clustered.
62455378|NCT01911195|ACTIVE_COMPARATOR|Control Group: Cognitive Testing|Control arm will receive cognitive testing only without undergoing general anesthesia
62455379|NCT01911195|EXPERIMENTAL|ISOFLURANE- Experimental Arm|Experimental arm will receive cognitive testing before and after general anesthesia
62455380|NCT04578743|EXPERIMENTAL|Graded Exercise|ClearPlay(TM): a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, will provide a telemetry-based graded exercise program for 20 minutes each day, identifying a heart rate target that will be advanced weekly for up to 8 weeks as symptoms resolve.
62455381|NCT04578743|EXPERIMENTAL|Passive Stretching|ClearPlay(TM): we have created a passive stretching program (placebo arm) downloadable to an Apple i-touch or i-phone device, that will provide a telemetry-based guided passive stretching program for 20 minutes each day for up to 8 weeks as symptoms resolve.
62641918|NCT00496340|EXPERIMENTAL|Conditioning Followed by HCT|"Pentostatin/Busulfan/Rituximab/Allogeneic Hematopoietic Cell Transplant (HCT).~Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m\^2 on day -28. Patients may receive additional doses on days -21 \& -14 depending on cell counts.~Conditioning:~1. Patients will receive anti-seizure prophylaxis with lorazepam 0.5 mg every 6 hours beginning day -6.~2. Intravenous Busulfan (1st dose) at a dose of 200mg/m\^2 on day -4.~3. Patient will then receive pentostatin at a dose of 4 mg/m\^2 by intravenous infusion over 1-2 hours on days -4, -3.~4. Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.~5. Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.~6. Rituximab: Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m\^2 according to prescribing and institutional guidelines."
62641919|NCT00706680|EXPERIMENTAL|1|All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.
62072708|NCT05646992|EXPERIMENTAL|Uterus Transplant Recipient|Uterus recipients, who are otherwise healthy, adult, genotypic females affected by uterine factor infertility, will undergo the surgically innovative uterus transplantation procedure combined with short-term use of conventional calcineurin inhibitor-based immunosuppression in to support a fetus to a viable delivery via Caesarian section.
62277111|NCT04563429|NO_INTERVENTION|Control Group|
62277112|NCT02761083|EXPERIMENTAL|Novosyn® Quick|Eye surgery using suture material
62277113|NCT02761083|ACTIVE_COMPARATOR|Vicryl® Rapid|Eye surgery using suture material
62277114|NCT04904458|EXPERIMENTAL|Experimental group|The experimental group receives the Enfacement Illusion toward a happy emotional face through a head mounted display.
62277115|NCT04904458|SHAM_COMPARATOR|Control Group|The control group receives the exposure to a pleasant virtual environment through a head mounted display
62641920|NCT04811157|EXPERIMENTAL|Test group|Healthy adults consuming test product
62072709|NCT02562963|EXPERIMENTAL|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment. Intervention: Biological: NKT cell
62277116|NCT00057473|EXPERIMENTAL|Arm A|
62277117|NCT00057473|ACTIVE_COMPARATOR|Arm B|
62641921|NCT04811157|PLACEBO_COMPARATOR|Control group|Healthy adults consuming control product
62641922|NCT04979481|EXPERIMENTAL|BRAVE Intervention Arm|The BRAVE campaign included 3-5 text messages per week, including 1 role model video per week and a related image.
62641923|NCT04979481|ACTIVE_COMPARATOR|STEM Control Arm|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image.
62641924|NCT04494646|EXPERIMENTAL|Bardoxolone Methyl|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
62641925|NCT04494646|PLACEBO_COMPARATOR|Placebo|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
62072710|NCT00385450|EXPERIMENTAL|Nelfinavir/placebo|
62072711|NCT01277536||hospitalization >24 hours|
62072712|NCT02158637||Cancer patients receiving treatment|Patients receiving active treatment for cancer or initiating treatment for cancer in the next 7 days
62072713|NCT02765490|EXPERIMENTAL|Group A|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
62277118|NCT01459705|ACTIVE_COMPARATOR|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
62277119|NCT01459705|EXPERIMENTAL|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
62277120|NCT01459705|PLACEBO_COMPARATOR|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
62277121|NCT00880893|EXPERIMENTAL|CYD Dengue Vaccine Group|Participant's received the CYD Dengue Vaccine at 0, 6, and 12 months as first, second, and third vaccinations, respectively.
62277122|NCT00880893|SHAM_COMPARATOR|Placebo Group|All participants received a placebo at first vaccination (Month 0). Participants \<12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants \>= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.
62641926|NCT01753349||Idiopathic cervical dystonia|Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia. BoNT-A injections, 3-4 times yearly.
62641927|NCT02615886|EXPERIMENTAL|Observational Control|Randomized participants will be observed for diarrhea incidences throughout the 6 month trial with no intervention.
62641928|NCT02615886|EXPERIMENTAL|Rice Bran|Randomized participants will consume a measured dose of rice bran daily throughout the 6 month trial.
62641929|NCT01413724||Surgical patients|PAtients who had surgery the previous day and are still hospitalized
62641930|NCT03884335|ACTIVE_COMPARATOR|epidural group|An epidural catheter was placed at L1-L2 level, and tested, prior to induction. Induction was performed intravenously with fentanyl (1.5mcg•Kg-1), propofol (1.5-2 mg•Kg-1), and rocuronium (0.6 mg•Kg-1). Orotracheal intubation was performed. Prior to skin incision 8 mL of 0.25% levo-bupivacaine were administered epidurally, and a continuous perfusion of 0.125% levo-bupivacaine at 5 mL was started.
62641931|NCT03884335|EXPERIMENTAL|TAP group|Bilateral Transversus abdominis plane blockade (TAP) was performed following induction of anaesthesia ( the same of epidural group) and prior to skin incision, the high-frequency lineal probe (Sonosite MicroMAXXTM) was placed midway between the costal margin and iliac crest, and transversus abdominis muscle located behind the rectus abdominis and below the IOM. 20 mL of LA (bupivacaine 0.375%) was administered via a 22 gauge Quincke spinal needle inserted in-plane on each side of the abdomen. A successful block was recorded if the plane was seen to expand with fluid under ultrasound vision.
62072714|NCT02765490|EXPERIMENTAL|Group B|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.
62072715|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
62072716|NCT05012215|EXPERIMENTAL|Paravertebral|Ultrasound-guided thoracic paravertebral block
62277123|NCT04986800|EXPERIMENTAL|Intervention Group|Participants in the Intervention Group will receive up to 10 sessions of the PROACTIVE Parent intervention.
62277124|NCT02597621||M/XDR|The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB
62277125|NCT02597621||Susceptible|The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
62277126|NCT02597621||Healthy Controls|Healthy controls.
62277127|NCT00762515|PLACEBO_COMPARATOR|A|commercially available Fluoride only toothpaste
62277128|NCT00762515|ACTIVE_COMPARATOR|B|Commercially available triclosan/copolymer/fluoride toothpaste
62277129|NCT03856255|EXPERIMENTAL|Micro-Tech Endoscopic Gauge|Use of the device during screening or surveillance colonoscopy
62072717|NCT05012215|ACTIVE_COMPARATOR|Caudal|Caudal block
62277130|NCT04711772||DOR group|Genomic DNA will be extracted from peripheral blood leukocytes to perform whole-genome sequencing in participates with diminished ovarian reserve.
62277131|NCT04711772||Control group|Participants with normal ovarian reserve will be recruited as control group and peripheral blood leukocytes genomic DNA will be extracted to perform whole-genome sequencing.
62277132|NCT00887757|EXPERIMENTAL|gemcitabine +ABT-263|
62277133|NCT03509519|EXPERIMENTAL|NMES-Millicurrent Group|NMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
62455382|NCT02305758|EXPERIMENTAL|Veliparib + modified FOLFIRI ± bevacizumab|Dosing of oral veliparib (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Modified FOLFIRI was administered as irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle.
62455383|NCT02305758|PLACEBO_COMPARATOR|Placebo + FOLFIRI ± bevacizumab|Dosing of oral placebo (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Standard FOLFIRI was administered as irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) on Day 1 of each 14-day cycle.
62455384|NCT05460065|EXPERIMENTAL|Cohort A|
62455385|NCT05460065|EXPERIMENTAL|Cohort B|
62455386|NCT05460065|EXPERIMENTAL|Cohort C|
62455387|NCT05460065|PLACEBO_COMPARATOR|Placebo|
62455388|NCT01531465|OTHER|HFNC to NCPAP|Infants who are currently on HFNC.
62455389|NCT01531465|OTHER|NCPAP to HFNC|Infants who are currently on NCPAP.
62455390|NCT02425579|EXPERIMENTAL|Cohort 1|Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
62455391|NCT02425579|PLACEBO_COMPARATOR|Cohort 1 (placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
62455392|NCT02425579|EXPERIMENTAL|Cohort 2|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
62455393|NCT02425579|PLACEBO_COMPARATOR|Cohort 2 (Placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
62455394|NCT05428722|EXPERIMENTAL|deep breathing group|The intervention group is the group in which the investigators applied deep breathing exercises with incentive spirometer starting from the preoperative period.
62455395|NCT05428722|NO_INTERVENTION|Control group|The control group is the group that receives standard clinical care.
62455396|NCT00593281|NO_INTERVENTION|1|IV Morphine
62455397|NCT00593281|EXPERIMENTAL|2|SC Morphine with Hylenex
62455398|NCT00593281|ACTIVE_COMPARATOR|3|SC Morphine with Saline
62641932|NCT04207905||Exempt for Evaluation Purposes|Individuals who would have been subject to the Healthy Michigan Plan (HMP) work requirements but have been randomly assigned to a control group that is exempt from reporting for evaluation purposes
62641933|NCT04207905||Work Requirement|Individuals who are subject to the Healthy Michigan Plan (HMP) work requirements
62641934|NCT06023966||with HMGC|patients with gastric cancer who developed hepatic metastasis after curative gastrectomy
62641935|NCT06023966||without HMGC|patients with gastric cancer who did not developed hepatic metastasis after curative gastrectomy
62641936|NCT05868135||Patients with moderate depression|
62641937|NCT05868135||Patients with social anxiety disorder|
62641938|NCT05868135||Patients with panic disorder|
62072718|NCT01586338|EXPERIMENTAL|Synvisc|Three intra-articular (IA) injections of Synvisc (2.25 ml glass syringe containing 16 mg hylan G-F 20) at intervals of one week. The total duration of observation was 26 weeks.
62641939|NCT02718872|EXPERIMENTAL|Tobacco cessation online training|Six hour smoking cessation online training addressed to health professionals from hospitals in 3 Latin American Countries. Participants are monitored by local coordinators that act as champions. They offer their assistance to log into the online platform, fill out the questionnaires, complete the evaluation, including other technical support. Participants' progress is monitored in real time onto the web platform. The project coordinator at ICO sends a report of the participants progress every other week to coordinators, and if necessary personal emails to motivate students to finish the course and complete the evaluations.
62641940|NCT05447273||Patients with penile squamous cell carcinoma.|Patients with penile squamous cell carcinoma.
62641941|NCT00764101|EXPERIMENTAL|1|9 sessions of attentional bias modification (computerized training program)
62641942|NCT00764101|PLACEBO_COMPARATOR|2|Attentional control condition (placebo training program)
62641943|NCT03606811|ACTIVE_COMPARATOR|fluroscopic guided block|
62455399|NCT05011500|EXPERIMENTAL|Starting with closed mask|Patient 1-8, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using a closed mask. For the next 5 fractions these patients will receive radiotherapy using an open mask. For the 5 fractions after that these patients will receive radiotherapy using no mask. This schedule repeats for the rest of their treatment.
62455400|NCT05011500|EXPERIMENTAL|Starting with open mask|Patient 9-16, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using an open mask. For the next 5 fractions these patients will receive radiotherapy using no mask. For the 5 fractions after that these patients will receive radiotherapy using a closed mask. This schedule repeats for the rest of their treatment.
62455401|NCT05011500|EXPERIMENTAL|Starting with no mask|Patient 17-24, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using no mask. For the next 5 fractions these patients will receive radiotherapy using a closed mask. For the 5 fractions after that these patients will receive radiotherapy using an open mask. This schedule repeats for the rest of their treatment.
62455402|NCT04126811|EXPERIMENTAL|Apatinib and Chemotherapy Test Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
62455403|NCT04126811|ACTIVE_COMPARATOR|Apatinib Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
62455404|NCT04126811|ACTIVE_COMPARATOR|Chemotherapy Group|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
62455405|NCT02171533|EXPERIMENTAL|Fixed sequence|Treatments will be given in a fixed sequence
62455406|NCT02171533|EXPERIMENTAL|Crossover|Treatments will be given in randomized sequences
62455407|NCT04648358|ACTIVE_COMPARATOR|Control group|The control group will receive scalp nerve blocks with 0.5% bupivacaine, plus normal saline with epinephrine at 1:200,000
62455408|NCT04648358|EXPERIMENTAL|DEX4mg group|DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine, plus 4 mg dexamethasone with epinephrine at 1:200,000.
62455409|NCT04696419|OTHER|ANIMAL CONTACT 1|Only one arm - within-subject design
62455410|NCT04123210|EXPERIMENTAL|Vitamin A supplement|Subjects receive a vitamin A supplement containing 175 or 525 micrograms of vitamin A as retinyl palmitate daily
62455411|NCT04123210|PLACEBO_COMPARATOR|Placebo|Subjects receive an oil placebo containing no vitamin A
62455412|NCT01479439|EXPERIMENTAL|Sickle cell disease|The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
62455413|NCT00765609||1|Using the information distributed with over-the-counter medication (The Patient Information Leaflet or PIL)
62641944|NCT03606811|EXPERIMENTAL|double modality guided block|
62641945|NCT02420535|EXPERIMENTAL|Immediately Receive Tool|Caregiver/Care Recipient Dyad will be randomly assigned to immediately receive the WeCareAdvisor Tool for 4 weeks.
62641946|NCT02420535|ACTIVE_COMPARATOR|One Month Delay|Caregiver/Care Recipient Dyad will be randomly assigned to a 4 week delay (usual care activities only) before receiving the WeCareAdvisor Tool for 4 weeks.
62072719|NCT04035655|EXPERIMENTAL|Clinical and electrophysiological evaluation of tDCS session|"In this prospective case-control study, the investigator's main goal was to evaluate the impact of a single standard-care tDCS session on brain activity (EEG).~The effect of a single 20 minutes 2 mA tDCS session with the anode placed over the left dorsolateral prefrontal cortex and the cathode over the right supraorbital cortex administered as routine care were evaluated by combined behavioral and electrophysiological assessments immediately before and after the stimulation.~The study consisted of the following interventions, administered immediately before and after the stimulation session:~* detailed behavioral assessment by the Coma Recovery Scale-Revised (CRS-R)~* 5 minutes resting state high-density EEG recordings and 6 minutes auditory oddball paradigm immediately.~Additionally, clinical anatomical MRI (T1) acquired as routine care were used to model the estimated tDCS-induced electric fields in the entire head of patients, based on available T1-weighted MRI."
62641947|NCT01918501|EXPERIMENTAL|Blood testing|Comparison of nutrition factors in MS patients and healthy volunteers as possibly source for the pathogenesis and for the remyelination process.
62641948|NCT05128838|EXPERIMENTAL|RISE Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management.
62641949|NCT00582465||Observation|Lupus
62072720|NCT00404534|EXPERIMENTAL|1|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
62072721|NCT00404534|PLACEBO_COMPARATOR|2|Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
62072722|NCT04596787||Non-Obese Patients (Group NO: body mass index (BMI) <30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
62641950|NCT06040814|EXPERIMENTAL|Rehabilitation Training|Rehabilitation Training is provided to patients with Liver Cirrhosis combined with sarcopenia.
62641951|NCT06040814|NO_INTERVENTION|No-Rehabilitation Training|No extra training is provided to patients with Liver Cirrhosis combined with sarcopenia.
62641952|NCT00646698||1|Premenopausal Upper Body Obese (UBO) women with waist-hip ratio \> 0.85 and BMI \> 28
62072723|NCT04596787||Obese Patients (Group O: body mass index (BMI) ≥30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
62072724|NCT01607385|ACTIVE_COMPARATOR|GSK2330672|
62641953|NCT00646698||2|Premenopausal Lower Body Obese (LBO) women with waist hip ratio \< 0.8 and BMI \> 28
62641954|NCT00646698||3|Premenopausal lean women with BMI \< 25
62641955|NCT03695146|EXPERIMENTAL|Paced breathing|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.
62072725|NCT01607385|PLACEBO_COMPARATOR|Placebo|
62072726|NCT05183737|ACTIVE_COMPARATOR|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis
62072727|NCT05183737|PLACEBO_COMPARATOR|Placebo Group|Participants will receive microcapsules containing arabic gum and cornstarch with the same weight and characteristics as the intersecting microcapsules
62072728|NCT05142410||Plasma from women with normal pregnancies|Plasma collected from women with normal pregnancies will be analyzed by mass spectrometry
62072729|NCT05142410||Plasma from women with placenta-mediated complications|Plasma collected from women who developed preeclampsia during pregnancy will be analyzed by mass spectrometry
62072730|NCT05857579|EXPERIMENTAL|MBE-IPL-MGX treatment and home-based therapy.|In this arm, participants received three sessions of MBE-IPL-MGX treatment and home-based therapy.
62072731|NCT05857579|ACTIVE_COMPARATOR|Home-based therapy|In this arm, participants received home-based therapy alone.
62072732|NCT02271750||Dementia|
62072733|NCT02271750||controls|
62072734|NCT02894320||Parkinson's disease|
62072735|NCT02894320||Healthy subjects|gender and age matched with Parkinson's disease patients, whose data will be extracted from an existing database
62641956|NCT03695146|ACTIVE_COMPARATOR|Relaxing music|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.
62641957|NCT03695146|NO_INTERVENTION|No intervention|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.
62641958|NCT01753882|EXPERIMENTAL|Gait Training with Lexapro|Gait training 2 weeks, gait training for 4 weeks (3X week) with Lexapro (10 mg SSRI), wash out period of 1 week, gait training for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
62641959|NCT01753882|ACTIVE_COMPARATOR|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
62641960|NCT04524689|EXPERIMENTAL|Tusamitamab ravtasine + Pembrolizumab|Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
62641961|NCT04524689|EXPERIMENTAL|Tusamitamab ravtansine + Pembrolizumab + carboplatin or cisplatin|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
62072736|NCT05364619|EXPERIMENTAL|QHD group|Qingre Huashi Granules 1 package twice daily, Rabeprazole 20mg triple daily, Amoxycillin 1g triple daily. The duration is 14 days.
62072737|NCT05364619|ACTIVE_COMPARATOR|Control group|Rabeprazole 20mg twice daily, bismuth potassium citrate 220mg twice daily, Amoxycillin 1g twice daily, clarithromycin 500mg twice daily. The duration is 14 days.
62072738|NCT03117517|EXPERIMENTAL|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
62641962|NCT04524689|EXPERIMENTAL|Tusamitamab ravtansine + Pembrolizumab + carboplatin or cisplatin + pemetrexed|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
62641963|NCT02228252|EXPERIMENTAL|20 g whey protein (-15 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
62641964|NCT02228252|EXPERIMENTAL|20 g whey protein (-30 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 30 min prior to the main meal.
62641965|NCT02228252|EXPERIMENTAL|20 g casein|20 g casein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
62641966|NCT02228252|EXPERIMENTAL|20 g gluten protein|21.5 g gluten protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
62641967|NCT02917174|EXPERIMENTAL|mobile management|use mobile management to improve asthma control
62641968|NCT02917174|OTHER|Traditional management|use Traditional management to improve asthma control
62072739|NCT03117517|ACTIVE_COMPARATOR|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
62455414|NCT00765609||2|Paediatric Analgesia Slide (the new device)
62641969|NCT02510937|EXPERIMENTAL|Low dose CC-90001|Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks
62641970|NCT02510937|EXPERIMENTAL|High dose CC-90001|High-dose (200 mg) CC-90001 administered orally Once Daily (QD) for 12 continuous weeks
62455415|NCT03311646|EXPERIMENTAL|Nicotine Content Manipulation|All participants receive normal nicotine content (NNC) cigarettes during Baseline and all participants receive very low nicotine content (VLNC) cigarettes during the very low nicotine content condition.
62072740|NCT04848662|EXPERIMENTAL|A/B - Treatment with BDA MDI (PT027) 160/180 μg followed by treatment with Pulmicort Respules 1mg|Subjects randomized to receive a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 2, and a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 3.
62072741|NCT04848662|EXPERIMENTAL|B/A - Treatment with Pulmicort Respules 1 mg followed by treatment with BDA MDI (PT027) 160/180 μg|Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 3.
62072742|NCT04396223|EXPERIMENTAL|Avelumab combined with methotrexate and folinic acid|Avelumab administration at 800 mg every 2 weeks and methotrexate administration at 1mg/kg/day during 4 months ½ (median)
62072743|NCT06528561|EXPERIMENTAL|Experimental group|Self-care program
62641971|NCT00945646|EXPERIMENTAL|FST-201 (dexamethasone 0.1%) Otic Suspension|
62072744|NCT06528561|ACTIVE_COMPARATOR|Control group|"EarlyRehabilitation in Cardiology-Heart Failure program (ERIC-HF)~Reference: Delgado B, Lopes I, Gomes B, Novo A. Early rehabilitation in cardiology - heart failure: The ERIC-HF protocol, a novel intervention to decompensated heart failure patients rehabilitation. Eur J Cardiovasc Nurs. 2020 Oct;19(7):592-599. doi: 10.1177/1474515120913806. Epub 2020 Apr 22."
62072745|NCT03711864|EXPERIMENTAL|IM21 CAR-T cells|IM21 CAR-T cells
62072746|NCT02677363|EXPERIMENTAL|Older adults|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
62072747|NCT05866250||critically ill patients|All newly admitted ICU patients
62072748|NCT02066350|EXPERIMENTAL|Single pancreas transplantation|This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation. Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft. A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
62072749|NCT03930914|OTHER|Active Treatment to Sham|Subjects randomized to the sequence Active Treatment/Sham Treatment arm will be instructed to first use the Parasym (TM) TENS device as active treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as sham treatment for the second phase of the study.
62072750|NCT03930914|OTHER|Sham to Active Treatment|Subjects randomized to the sequence Sham Treatment/Active Treatment arm will be instructed to use the Parasym (TM) TENS device as sham treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as active treatment for the second phase of the study.
62072751|NCT05571995|EXPERIMENTAL|Intervention|The intervention group will receive TRIMOSH
62641972|NCT00945646|PLACEBO_COMPARATOR|vehicle|
62455416|NCT05627427|EXPERIMENTAL|Surufatinib in combination of Sintilimab|Surufatinib Sintinlimab
62455417|NCT05814458|ACTIVE_COMPARATOR|tDCS group|The tDCS group will receive the active brain stimulation.
62455418|NCT05814458|SHAM_COMPARATOR|Placebo group|The placebo group will receive the sham brain stimulation.
62455419|NCT00389636|ACTIVE_COMPARATOR|1|TheraGauze alone
62455420|NCT00389636|ACTIVE_COMPARATOR|2|Theragauze + Regranex
62641973|NCT02201862||Euploid Subjects|Subject's with fetal euploidy confirmed by chromosome analysis
62641974|NCT02201862||Aneuploid Subjects|Subject's with fetal aneuploidy confirmed by chromosome analysis
62641975|NCT06216418|EXPERIMENTAL|BRFS-18G-S100WH|
62641976|NCT06216418|ACTIVE_COMPARATOR|MINT Lift FINE+|
62641977|NCT05437601|EXPERIMENTAL|Astaxanthin|Patients will receive three capsules of astaxanthin (4mg) daily for 8 weeks.
62641978|NCT05437601|PLACEBO_COMPARATOR|Control|Patients will receive three capsules of placebo daily for 8 weeks.
62641979|NCT03832283|OTHER|Usual Care Depression Screening|Patients randomized to this intervention arm will receive usual care annual depression screening when they come in for a clinic visit and are due for screening. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression screening. The CAD-MDD/CAT-DI screening during clinic visit will occur in a patient room, prior to their appointment with a primary care provider.
62641980|NCT03832283|EXPERIMENTAL|Population MyChart Depression Screening|Patients randomized to this intervention arm will continue to receive usual care annual depression screening when they come in for a clinic visit and are due for screening. In addition, they will receive email invitations to complete the CAD-MDD/CAT-DI screening via MyChart. Email invitations will be sent at preset intervals until depression screening is completed, or the end of the 1-year follow-up period, whichever comes first.
62641981|NCT03832283|OTHER|Usual Care Depression Monitoring|Patients who have depression and are randomized to this intervention arm will receive usual care PHQ-9 monitoring during clinic visits. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression assessment.
62641982|NCT03832283|EXPERIMENTAL|Population MyChart Depression Monitoring|Patients who have depression and are randomized to this intervention arm will continue to receive usual care depression monitoring when they come for clinic visits. In addition, they will receive email invitations at preset intervals to complete the CAT-DI monitoring via MyChart. Invitations will be sent until major depressive disorder (MDD) remission is achieved, or the 1-year follow-up period ends, whichever comes first.
62641983|NCT00703300|EXPERIMENTAL|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.
62641984|NCT03988361||Control group|Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
62641985|NCT03988361||Study group|"Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS.~The sperm used in this group is considered to be enriched in non apoptotic cells."
62641986|NCT01719380|EXPERIMENTAL|LGX818 + cetuximab|
62641987|NCT01719380|EXPERIMENTAL|LGX818 + BYL719 + cetuximab|
62072752|NCT05571995|NO_INTERVENTION|Control|The control group will receive no intervention.
62072753|NCT04453514|EXPERIMENTAL|Trauma-informed yoga video recording|Participants will complete a single trauma-informed yoga practice using a 45-minute guided video recording.
62072754|NCT02352662||Study Group|Three blood samples will be collected intra-operatively from each subject enrolled
62072755|NCT01137136||SMAC (SMc AI user Cohort)|All patients who took the AI (Aromatase inhibitor)will be enrolled
62072756|NCT03880318|OTHER|spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies in spasmodic flat foot
62072757|NCT05971134|EXPERIMENTAL|experimental group|Intervention group 1 consisted of patients with brescia-cimino fistula Intervention group 2 consisted of patients with snuff-box fistula Intervention group 3 consisted of patients with antecubital fistula.
62072758|NCT05971134|NO_INTERVENTION|Control Group|Control group 1 consisted of patients with brescia-cimino fistula Control group 2 consisted of patients with snuff-box fistula Control group 3 consisted of patients with antecubital fistula.
62072759|NCT03434613|ACTIVE_COMPARATOR|Rosuvastatin monotherapy|Rosuvastatin 5mg 1T daily for 6 months
62641988|NCT03398473|EXPERIMENTAL|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial (SDV)
62641989|NCT03398473|EXPERIMENTAL|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial (MDV)
62641990|NCT00723229|ACTIVE_COMPARATOR|1|
62641991|NCT00723229|NO_INTERVENTION|2|
62641992|NCT04270812|EXPERIMENTAL|Sleep Treatment|This arm consists of the sleep treatment that will be administered to all participants in the single-arm open trial.
62641993|NCT03675646|EXPERIMENTAL|Morphine group M|Experimental group M were administered preservative-free morphine 250 mcg in 2.5 ml NS intrathecal using 25 G needle in L1/2 - L5/S1 interspaces.
62641994|NCT03675646|NO_INTERVENTION|Control group C|No intervention
62072760|NCT03434613|EXPERIMENTAL|Rosuvastatin + ezetimibe combination therapy|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
62072761|NCT01703702|EXPERIMENTAL|Intervention|Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
62072762|NCT01703702|EXPERIMENTAL|Control|Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
62072763|NCT05756543||Cases|Individuals diagnosed with Parkinson's Disease consecutively recruited at the beginning of rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor or psychiatric disorders were exclusion criteria.
62072764|NCT05756543||Controls|Age-matched healthy individuals recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
62072765|NCT06208345|EXPERIMENTAL|Treatment as usual (TAU) with Life-Style app|Children in the intervention group receive treatment as usual (TAU) and the parents receive a smartphone app during the main intervention period of 20 weeks. The app (life-style app) aims to promote healthy behaviour through cognitive-behavioural impact factors.
62072766|NCT06208345|NO_INTERVENTION|Treatment as usual (TAU)|The children in the control group only receive treatment-as-usual (TAU) and the parents do not have an active app during the main intervention period of 20 weeks. TAU includes lifestyle behaviour counselling, dietary counselling by specialized dieticians, prescriptions for physiotherapy, as provided at the last clinical visit.
62641995|NCT06308471|EXPERIMENTAL|Group of baby massage|Being between 28-33 weeks of gestation, Not having a congenital disease, Meeting the readiness criteria for oral feeding, Must be in the weight range of 1000-2000 grams
62641996|NCT06308471|EXPERIMENTAL|Group of oral stimulation (Fucile Protocol)|Being between 28-33 weeks of gestation, Not having a congenital disease, Meeting the readiness criteria for oral feeding, Must be in the weight range of 1000-2000 grams
62641997|NCT05211934||The group with delirium|
62641998|NCT05211934||The group without delirium|
62641999|NCT01710020|EXPERIMENTAL|CP-690,550|
62072767|NCT05158439|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62455421|NCT03488342|OTHER|Rives technique|Rives technique for primary inguinal hernia
62642000|NCT05991310|EXPERIMENTAL|Telemedicine Assessment by Remote Neurologist|Following the initial assessment, the stroke nurse will activate the telemedicine video conference call and review the patient with the telemedicine neurologist. The telemedicine neurologist will perform a NIHSS with assistance from the stroke nurse, and this will be documented on the clinical records. Imaging will be evaluated remotely by the telemedicine neurologist. If there is a decision to administer thrombolysis, the stroke neurologist and nurse will discuss treatment with the patient or next of kin, where appropriate and able, to acquire assent in a timely manner.
62642001|NCT05991310|ACTIVE_COMPARATOR|In-Person Assessment by an Onboard Neurologist|Upon arrival on-scene, the MSU stroke nurse, neurologist, and paramedic will liaise with local ambulance services to obtain initial clinical details and perform an initial assessment. The NIHSS will be performed by the neurologist, and this will be documented on standardized clinical records. Imaging will be assessed at the console available within the ambulance. If there is a decision to administer thrombolysis, the stroke neurologist and nurse will discuss treatment with the patient or next of kin, where appropriate and able, to acquire assent in a timely manner.
62642002|NCT04995913|EXPERIMENTAL|Computer-based (PC) online CBT program (Web version of the EASE Online Program)|The Web version of the EASE Online Program delivers the online CBT program through the Program website. It includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy.
62642003|NCT04995913|EXPERIMENTAL|Smartphone-based (App) online CBT program (App version of the EASE Online Program)|The App version of the EASE Online Program delivers the online CBT program through a smartphone application. The program content and system functions are the same as those of the Web version.
62642004|NCT04995913|OTHER|Waitlist control group|The Waitlist control group will receive the service of the Web version of the EASE Online Program after the two experimental groups completed the service.
62072768|NCT05643963|EXPERIMENTAL|Focus on bladder protective diet|For 12 weeks, healthy volunteers will follow a bladder protective diet.
62455422|NCT03488342|OTHER|Lichtenstein repair|Lichtenstein repair for primary inguinal hernia
62455423|NCT00580138||Stroke or Head & Neck Cancer|Any subject who has suffered a stroke or has some form of head \& neck cancer (non-laryngectomee) may be enrolled.
62072769|NCT05643963|EXPERIMENTAL|No focus on bladder protective diet|For 12 weeks, healthy volunteers will not follow a specific diet.
62455424|NCT01179048|EXPERIMENTAL|Liraglutide|
62072770|NCT05285202|EXPERIMENTAL|Hotspot-focused ACF/TPT|ACF/TPT intervention will be delivered in a community setting, in geographic areas judged likely to have a high burden of undiagnosed TB
62072771|NCT05285202|EXPERIMENTAL|Facility-based ACF/TPT|ACF/TPT intervention will be delivered on the grounds of a health facility (hospital or large public health center)
62072772|NCT05285202|NO_INTERVENTION|No intervention|
62072773|NCT04315246|EXPERIMENTAL|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles.
62072774|NCT04718714|ACTIVE_COMPARATOR|midazolam|postoperative ventilation and sedation with continuous intravenous infusion of midazolam only for 24 hours
62072775|NCT04718714|ACTIVE_COMPARATOR|propofol|postoperative ventilation and sedation with continuous intravenous infusion of propofol only for 24 hours
62072776|NCT04718714|EXPERIMENTAL|dexmedetomidine|postoperative ventilation and sedation with continuous intravenous infusion of dexmedetomidine only for 24 hours
62455425|NCT01179048|PLACEBO_COMPARATOR|Placebo|
62455426|NCT01658943|EXPERIMENTAL|Arm I (mFOLFOX regimen)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and fluorouracil IV over 46-48 hours on days 1-2 and 15-16.
62455427|NCT01658943|EXPERIMENTAL|Arm II (Akt inhibitor MK2206 and selumetinib)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, and selumetinib PO daily on days 1-28.
62455428|NCT01292161|OTHER|Silymarin|Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
62642005|NCT02287038|ACTIVE_COMPARATOR|Atomoxetine 80mg|Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
62642006|NCT02287038|PLACEBO_COMPARATOR|Placebo|A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.
62642007|NCT03940833|EXPERIMENTAL|anti-tumor response of BCMA CAR-NK-92|Patients with relapsed and refractory MM of BCMA expression will be treated with BCMA CAR-NK 92 cells.
62642008|NCT05584995|EXPERIMENTAL|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
62642009|NCT05584995|EXPERIMENTAL|BUAL group|Cases will undergo Bilateral Uterine Artery Ligationafter Postpartum Hemorrhage after cesarean section resistant to medical treatment and did not need a hysterectomy.
62072777|NCT06012864|EXPERIMENTAL|modified supine PNL|patients doing FFMS PNL
62455429|NCT00723554|EXPERIMENTAL|Iloprost|"The study enrolled patients who were already using iloprost with PD-6 without any safety or tolerability concerns, thereby facilitating a direct comparison of the PD-15 to the PD-6.~The single-arm design allowed each patient to serve as his/her own control"
62642010|NCT02484014|EXPERIMENTAL|TSM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by teachers as SEHER Mitra)
62642011|NCT02484014|EXPERIMENTAL|SM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by SEHER Mitra)
62642012|NCT02484014|OTHER|Comparison Arm|Tarang Adolescence Education Programme
62642013|NCT05325996|EXPERIMENTAL|Moderate Glaucoma|"Subjects between ages 20-80 years with a diagnosis of mild and moderate Open Angle Glaucoma in at least one eye with 20/50 vision or better will be included in this study. All subjects will have the Olleyes Perimeter measure their own visual acuity and field once a week during a 2 year period and iCare home to measure their eye pressure 3 times a day for 7 days every 3 months during a 2 year period.~All patient will have their routine glaucoma assessment with the standard 24-2 Automatic Perimetry Humphrey Field Analyzer at baseline and every 6 months during a 2 year period; and Spectralis Optical Coherence Tomography thickness of peripapillary RNFL and macular ganglion cell at baseline and yearly during a 2 year period."
62642014|NCT03292510|EXPERIMENTAL|GO-OUT Group|Participants attend 1-day walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. The same activities are completed during both sessions within the same week. Each session includes a 10-minute warm-up, a distance walk, practice of a specific outdoor walking skill, a distance walk, and a 10-minute cool down. The warm up and cool down include stretching, functional strengthening exercises and balance exercises taught during the workshop. The program incorporates the principles of task-specific training by emphasizing repetitive practice of progressively more difficult outdoor walking tasks. The outdoor walking program is conducted in one or more large park settings given the mental health benefits of exercising in a natural environment.
62642015|NCT03292510|ACTIVE_COMPARATOR|Workshop Group|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
62072778|NCT06012864|EXPERIMENTAL|prone PNL|patients doing prone PNL
62072779|NCT05891418|EXPERIMENTAL|Control Group with a standard eligibility notice|Control group was assigned to receive no email outreach in June and July beyond an eligibility redetermination notice.
62072780|NCT05891418|EXPERIMENTAL|Treatment group with a standard eligibility notice and assigned two email nudges|Assigned to receive an eligibility redetermination notice along with two informational emails about the benefits of Cost-Sharing Reduction Silver plans.
62072781|NCT05882084|EXPERIMENTAL|Astaxanthin|6 mg daily
62072782|NCT05882084|PLACEBO_COMPARATOR|Placebo|
62072783|NCT04622137|NO_INTERVENTION|Arm sling only group (group S)|Participants used only arm sling for clavicula fracture
62072784|NCT04622137|ACTIVE_COMPARATOR|Arm sling with kinesiotaping therapy group (group K).|Participants used arm sling and the investigators applied kinesiotheraphy for clavicula fracture
62072785|NCT02351440|EXPERIMENTAL|Duloxetine|duloxetine 60mg PO
62072786|NCT02351440|PLACEBO_COMPARATOR|Placebo|placebo
62455430|NCT00802100|EXPERIMENTAL|Olanzapine|Participants will receive treatment with olanzapine and metformin, with the possible addition of simvastatin or benztropine, depending on side effects.
62642016|NCT06059040|ACTIVE_COMPARATOR|intervention groups|Patients in the intervention group will not be monitored for GRV (no GRV monitoring) and will be evaluated for the presence of feeding intolerance indicators such as vomiting, regurgitation, and abdominal distention.
62642017|NCT06059040|NO_INTERVENTION|control group|Patients in the control group will be subjected to GRV monitoring (with GRV monitoring).
62642018|NCT03220308|OTHER|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
62642019|NCT03220308|EXPERIMENTAL|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
62642020|NCT01668836|EXPERIMENTAL|men with resveratrol|12 men will receive a pill with 500mg of resveratrol daily for 30 days
62642021|NCT01668836|EXPERIMENTAL|women with resveratrol|12 women will receive a pill with 500mg of resveratrol daily for 30 days
62642022|NCT01668836|ACTIVE_COMPARATOR|men with caloric restriction|12 men will follow a 1000 calories per day diet for 30 days
62642023|NCT01668836|ACTIVE_COMPARATOR|women with caloric restriction|12 women will follow a 1000 calories per day diet for 30 days
62072787|NCT03126032||Patients with suspected sepsis|"Patients presenting in the Emergency Room (ER) with the clinical suspicion of infection/sepsis.~Evaluation of the glycocalyx damage with the use of GlycoCheck™-System, as well as blood sample at presentation, day 1 and day 7 of their hospital stay."
62455431|NCT00802100|EXPERIMENTAL|Perphenazine|Participants will receive treatment with perphenazine and benztropine, with the possible addition of simvastatin or metformin, depending on side effects.
62455432|NCT00802100|EXPERIMENTAL|Aripiprazole|Participants will receive treatment with aripiprazole, with the possible addition of simvastatin, metformin, or benztropine, depending on side effects.
62455433|NCT03931863|ACTIVE_COMPARATOR|Group A|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
62455434|NCT03931863|ACTIVE_COMPARATOR|Group B|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
62455435|NCT03931863|PLACEBO_COMPARATOR|Group C|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
62455436|NCT01837862|EXPERIMENTAL|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
62455437|NCT01837862|EXPERIMENTAL|High-grade Glioma/Pontine Glioma|"Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.~\*High grade arm enrollment complete, no additional spots"
62455438|NCT03172780|EXPERIMENTAL|Diclofenac Sodium Gel|Diclofenac Sodium Gel, 1%
62455439|NCT03172780|ACTIVE_COMPARATOR|Voltaren® Gel|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
62455440|NCT03172780|PLACEBO_COMPARATOR|Placebo gel|Placebo gel
62455441|NCT01110447|EXPERIMENTAL|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus.
62455442|NCT01110447|PLACEBO_COMPARATOR|Placebo|Placebo sachets contain corn starch
62455443|NCT05805553|EXPERIMENTAL|Group A|Propranolol will be given to this group
62455444|NCT05805553|EXPERIMENTAL|group b|steroid will be given
62455445|NCT05805553|EXPERIMENTAL|group c|both propranolol and steroids will be given
62455446|NCT03886090|EXPERIMENTAL|motor skill practice + aerobic exercise|acute bout of aerobic exercise following motor skill practice
62455447|NCT03886090|ACTIVE_COMPARATOR|motor skill practice + rest|seated rest following motor skill practice
62455448|NCT04666909||Hypertension Group|Participants will receive a free blood pressure screening and receive educational counseling about the importance of maintaining a healthy blood pressure. In addition, educational counseling will be administered in months 3 and 6.
62455449|NCT05921890|EXPERIMENTAL|GS3-007 oral liquid|36 subjects，12 subjects in each dose group. Two dose groups were planned: 0.8 mg/kg and 1.6 mg/kg once a day for 4 weeks. According to the research progress of 1.6mg/kg QD, it was decided whether to add 0.8 mg/kg twice a day for 4 weeks.
62455450|NCT04360993||Patients underwent PET/CT & PET/MRI|Patients with head and neck cancer were underwent PET/CT and PET/MRI for staging, assessment and follow up
62455451|NCT02315690|ACTIVE_COMPARATOR|Reactive case detection (RACD)|Individuals in RACD Target Areas will be tested by RDT (rapid diagnostic test) and if positive, taken to the nearest health facility for treatment with artemether-lumefantrine per national policy.
62455452|NCT02315690|EXPERIMENTAL|Reactive focal mass drug administration (fMDA)|In the fMDA arm, all individuals in the Target Area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
62455453|NCT02846948|NO_INTERVENTION|Non-echo group|Patients get the standard monitoring and treatment based on Good medical practice. Extended monitoring by focused echocardiography is not applied for this group.
62455454|NCT02846948|EXPERIMENTAL|Focussed echocardiography group|The extended cardiac monitoring by focused assessed transthoracic echocardiography is applied.
62455455|NCT04175951|ACTIVE_COMPARATOR|Tecnis Eyhance|Tecnis Eyhance hydrophobic IOL is a monofocal IOL with added advantage of slightly better unaided intermediate vision at 60 cms.
62455456|NCT04175951|ACTIVE_COMPARATOR|Rayner RayOne|Rayner Rayone is a monofocal hydrophilic IOL which is not intended to give better unaided or near vision.
62072788|NCT03126032||Non-Sepsis Patients|"Patients presenting in the Emergency Room with other conditions apart from infection/sepsis.~Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation."
62072789|NCT03126032||Healthy Individuals|Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation.
62072790|NCT01183702|ACTIVE_COMPARATOR|non-LASIK|These participants have NOT had LASIK surgery.
62461680|NCT00803803|EXPERIMENTAL|Pilocarpine Frequency|Varying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
62461681|NCT04901221|EXPERIMENTAL|Extrusion arch|"Hand made stainless steel extrusion arch wire (0.016x0.22)"
62072791|NCT01183702|ACTIVE_COMPARATOR|LASIK|These participants have had LASIK surgery.
62072792|NCT01333085|EXPERIMENTAL|RAD001-paclitaxel-carboplatin|RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles
62072793|NCT03452176|EXPERIMENTAL|Scrambler|This arm will receive the Scrambler intervention for 1 hour daily x10 days.
62072794|NCT03452176|SHAM_COMPARATOR|Sham-Control|This arm will receive the Sham-Control intervention for 1 hour daily x10 days.
62072795|NCT01627119||Gastric cancer patients|Gastric cancer patients who receive curative surgery at National Taiwan University Hospital
62072796|NCT03452020|OTHER|Tyto Thermometer, SoC Thermometer, Predicate IR Th|"All the study participants undergo temperature measurements with:~1. Tyto Thermometer~2. Standard of Care thermometer~3. Predicate IR thermometer"
62072797|NCT05046977|ACTIVE_COMPARATOR|Single tibial osteotomy|Single tibial osteotomy done to achieve correction
62072798|NCT05046977|ACTIVE_COMPARATOR|Double tibial osteotomy|Double tibial osteotomy done to achieve correction
62072799|NCT01520389|EXPERIMENTAL|MM-151 Dose Escalation|MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
62072800|NCT01520389|EXPERIMENTAL|MM-151 Expansion in KRAS wild type colorectal cancer|MM-151 given weekly
62072801|NCT01520389|EXPERIMENTAL|MM-151 + irinotecan|MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
62072802|NCT00773955|EXPERIMENTAL|Treatment (R-(-)-gossypol)|Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62072803|NCT06343337|EXPERIMENTAL|First trimester|
62642024|NCT02970955||Inoperable thoracic nodes metastases|Oligometastatic patients with inoperable thoracic nodes metastases from any primary
62642025|NCT02244684||Pregnant women|
62277134|NCT03509519|SHAM_COMPARATOR|NMES-Microcurrent Group|The NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
62277135|NCT00135122|PLACEBO_COMPARATOR|2|Placebo in six days
62277136|NCT01669954||Controls, females|Controls who are presumed HIV uninfected, females, aged 18 or above
62642026|NCT02708134||Pediatric Cardiac Arrests|Pediatric cardiac arrests requiring chest compressions for at least 1 minute managed at clinical centers identified as part of standard clinical operations.
62642027|NCT00903643||Healthy subjects|
62072804|NCT06343337|EXPERIMENTAL|Second trimester|
62277137|NCT01669954||Controls, males|Controls presumed HIV uninfected, males, aged 18 or above
62277138|NCT01669954||HIV infected patients, males|HIV patients, males, aged 18 or above
62277139|NCT01669954||HIV patients,|HIV patients, females, aged 18 or above
62277140|NCT05048719|EXPERIMENTAL|3 milligrams (mg) LY3502970|Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
62277141|NCT05048719|EXPERIMENTAL|12 mg LY3502970|Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
62277142|NCT05048719|EXPERIMENTAL|24 mg LY3502970|Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
62277143|NCT05048719|EXPERIMENTAL|36 mg LY3502970 - 1|Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
62277144|NCT05048719|EXPERIMENTAL|36 mg LY3502970 - 2|Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
62277145|NCT05048719|EXPERIMENTAL|45 mg LY3502970 - 1|Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
62461682|NCT04331665|EXPERIMENTAL|Ruxolitinib to prevent COVID-19 pneumonia|All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.
62642028|NCT00903643||PBS subjects|
62072805|NCT06343337|EXPERIMENTAL|Third Trimester|
62072806|NCT06343337|OTHER|Non-pregnant woman|Control group
62072807|NCT02527967||Group 1 (≤4 days)|Group 1 consisted of patients whose hospital stay was shorter or equal to the target LOS (≤ 4 days).
62072808|NCT02527967||Group 1 (>4 days)|In group 2 were patients whose hospital stay was longer than 4 days.
62277146|NCT05048719|EXPERIMENTAL|45 mg LY3502970 - 2|Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
62642029|NCT05022498|NO_INTERVENTION|Control 1|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
62642030|NCT05022498|NO_INTERVENTION|Control 2|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
62642031|NCT05022498|EXPERIMENTAL|Exercise 1|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
62642032|NCT05022498|EXPERIMENTAL|Exercise 2|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
62642033|NCT04541355|EXPERIMENTAL|Cisplatin, Radiotherapy, STS|Patients undergo standard of care radiation therapy daily in combination with cisplatin on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate over 1-2 hours on day 1. Treatment will continue on either a 1 week or 3 week cycle per physician discretion for up to 6-7 weeks in the absence of disease progression or unacceptable toxicity.
62072809|NCT04387539|ACTIVE_COMPARATOR|Non-Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian non-cirrhotic experienced HCV GT4 participants for 12 weeks
62455457|NCT02426957|EXPERIMENTAL|Motivational Enhancement Therapy|The 60-90 minute intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets. Personalized feedback for the intervention will be derived from the assessment battery and will be provided in both written and graphic formats. In addition to the 60-90 minute MI intervention delivered to the adolescent, a 30-45 minute intervention will be conducted with the adolescent and parent(s) the following day, in which the adolescent will review the goals, strategies, and change plan worksheets with the parent(s), facilitated by the therapist.
62642034|NCT03485443|ACTIVE_COMPARATOR|Group I (%0.9 NaCl 10ml/kg)|"The group (Group 1) received 10 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
62642035|NCT03485443|ACTIVE_COMPARATOR|Group II (%0.9 NaCl 20ml/kg)|"The group (Group 2) received 30 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
62642036|NCT03854578|EXPERIMENTAL|BI 1358894|
62642037|NCT03854578|EXPERIMENTAL|Citalopram|
62642038|NCT03854578|EXPERIMENTAL|Placebo matching BI 1358894|
62642039|NCT01455870|EXPERIMENTAL|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
62642040|NCT01455870|ACTIVE_COMPARATOR|sitagliptin|sitagliptin 100 mg/day
62642041|NCT03904823|EXPERIMENTAL|famitinib, HS-10296|
62642042|NCT02603198|ACTIVE_COMPARATOR|mepivacaine chloridrato epinephrine|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:100.000 epinephrine, maximum of 4 cartridges
62642043|NCT02603198|ACTIVE_COMPARATOR|mepivacaine chloridrato levonordefrin|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:20.000 levonordefrin, maximum of 4 cartridges
62642044|NCT01198652||Belfort-Dildy Obstetric Tamponade Tx|Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.
62642045|NCT06404437||Severe Aortic Stenosis|
62642046|NCT06404437||No Relevant Heart Valve Disease|
62642047|NCT02505958|OTHER|high caloric intake|Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain \~ 6,000 calories. Main meals will consist of \~ 1,500 calories and snacks will contain \~ 500 calories.
62072810|NCT04387539|ACTIVE_COMPARATOR|Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian cirrhotic experienced HCV GT4 participants for 12 weeks
62277147|NCT05048719|ACTIVE_COMPARATOR|1.5 mg Dulaglutide|Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
62277148|NCT05048719|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo.
62455458|NCT02426957|NO_INTERVENTION|Treatment As Usual|Treatment As Usual on inpatient psychiatric unit
62642048|NCT02505958|OTHER|reduced caloric intake|On days 5 and 6 subjects will receive 3 meals only and each meal will contain \~ 333 calories for a total of 1,000/ 24 hours.
62642049|NCT01798563||Tremor Dominant PD|Volunteers with predominantly tremor-related motor symptoms of PD
62642050|NCT01798563||Postural Instability & Gait Difficulty PD|Volunteers with primarily walking \& balance-related motor symptoms of PD.
62642051|NCT01798563||Healthy Controls|Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD.
62642052|NCT01739140|EXPERIMENTAL|Yoga|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
62642053|NCT05846750|EXPERIMENTAL|Obinutuzumab and lenalidomide|Patients will be treated with obinutuzumab and lenalidomide for 6 cycles as induction, and the patients who achieve at least a partial response after 6 cycles of induction therapy will be eligible to enter the maintenance phase for 2 years
62642054|NCT01836068|EXPERIMENTAL|Enfuvirtide monotherapy|Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.
62642055|NCT00918372||Extreme fitness|Female competitive long distance runners
62642056|NCT00918372||Control|Age and Risk matched controls
62642057|NCT01100502|EXPERIMENTAL|Brentuximab vedotin|brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
62642058|NCT01100502|PLACEBO_COMPARATOR|Placebo|placebo every 3 weeks by IV infusion
62642059|NCT01738100|EXPERIMENTAL|Ticagrelor + Intracoronary Morphine|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.
62642060|NCT01738100|EXPERIMENTAL|Ticagrelor + Intracoronary Saline|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.
62642061|NCT01738100|EXPERIMENTAL|Clopidogrel + Intracoronary Morphine|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.
62642062|NCT01738100|ACTIVE_COMPARATOR|Clopidogrel + Intracoronary Saline|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.
62642063|NCT04346953|EXPERIMENTAL|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
62642064|NCT04346953|NO_INTERVENTION|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
62642065|NCT03687983|EXPERIMENTAL|Intervention arm|Participants will be treated with GoldenFlow Peripheral Stent System.
62642066|NCT03042845|ACTIVE_COMPARATOR|Judkins L3.5/R4 cardiac catheters|
62642067|NCT03042845|EXPERIMENTAL|Tiger cardiac catheter|
62642068|NCT06138197||Robotic-assisted hysterectomy by da Vinci X surgical system, model IS4200 (INTUITIVE)|Women who undergo robotic-assisted hysterectomy by da Vinci X surgical system, model IS4200 (INTUITIVE)
62642069|NCT06138197||Robotic-assisted hysterectomy by VERSIUS ® surgical system (ROBOTIC SURGICAL SYSTEM)|Women who undergo robotic-assisted hysterectomy by VERSIUS ® surgical system (ROBOTIC SURGICAL SYSTEM)
62642070|NCT06138197||Robotic-assisted hysterectomy by HUGO ™ Robotic Assisted Surgery System (RAS) (MEDTRONIC)|Women who undergo robotic-assisted hysterectomy by HUGO ™ Robotic Assisted Surgery System (RAS) (MEDTRONIC)
62072811|NCT03324737|NO_INTERVENTION|Standard Care Arm|Subjects in the standard care arm will be informed of their increased risk of developing type 2 diabetes in the future, and given general lifestyle verbal advice to maintain a healthy weight, eat a well-balanced diet and do regular exercise during their 6 week postnatal visit. Women found to have impaired fasting glucose (6.1-6.9 mmol/L) or impaired glucose tolerance (2H post glucose of 7.8-11.0 mmol/L) will be issued a letter reinforcing lifestyle changes namely weight loss (if raised BMI), diet, exercise, and encouragement to consult a family physician to discuss the appropriateness of starting medications that can prevent the progression to type 2 diabetes, or restore the blood glucose to normal levels. Those with a normal OGTT result will just be informed that it is normal.
62072812|NCT03324737|ACTIVE_COMPARATOR|Interactive Smartphone App Arm|"Participants will download the INTERACTIVE SMARTPHONE APP and will be briefed on its use by our team of nutritionists/dieticians, exercise physiologists and life style coaches. Weight: Participants will be reminded that the goal is satisfactory weight loss.~NUH occupational therapist-trained lifestyle coaches, exercise physiotherapists, and clinical nutritionist/ dietician will interact with participants through real-time chats channels via the APP; all culturally appropriate and customized to the Singapore context."
62072813|NCT04517422|EXPERIMENTAL|Probiotics|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS)status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
62072814|NCT04517422|PLACEBO_COMPARATOR|Placebo|The control study product is identical in packaging and formulation except that Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483 (probiotic bacteria) are not present. The Control product only contains maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
62072815|NCT04756011||Group A (insulin pump)|30 patients who are on insulin pump.
62072816|NCT04756011||Group B (MDI)|30 patients who are on multiple daily injection.
62072817|NCT04521517|EXPERIMENTAL|Pamphlet with timing of family planning|"Pamphlet with timing of family planning and Routine service"
62072818|NCT04521517|NO_INTERVENTION|Only routine service|Receive only routine service
62072819|NCT05540743|OTHER|JIA associated uveitis|patients diagnosed with Juvenile idiopathic arthritis and uveitis taking immunosuppression including biologics 9of any type according to their rheumatologist recommendations) for control of their autoimmune uveitis.
62072820|NCT00203905|ACTIVE_COMPARATOR|A|Hydroxyurea at 500 mg PO q 12 hours x 6 days (11 total doses); Infusion of 5-FU (600 mg/m2/day x 5 days \[120 hours\]
62072821|NCT00203905|EXPERIMENTAL|B|Bevacizumab: 10 mg/kg will be given as a 90-minute infusion
62072822|NCT01421589|EXPERIMENTAL|Growth Hormone|
62277149|NCT05629325|EXPERIMENTAL|Buspirone => Washout => Placebo|Patients will take Buspirone hydrochloride 10mg oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will also report their perceived symptoms of dysphagia during the HRiM. A washout period of two weeks will take place. Afterwards, the second treatment period starts. Patients will take Placebo oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will also be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will again report their perceived symptoms of dysphagia during the HRiM.
62455459|NCT02236507|OTHER|children without anorectal disorders|All children will be investigated by 3D high resolution anorectal manometry procedure
62072823|NCT03885856||single row repair technique|patients surgically treated for rotator cuff lesion by single row repair technique
62072824|NCT03885856||double row repair technique|patients surgically treated for rotator cuff lesion by double row repair technique
62642071|NCT05181371|ACTIVE_COMPARATOR|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive programmed intermittent bolus of local anaesthetic: 20mls 0.125% levobupivacaine every two hours.
62072825|NCT03263234|ACTIVE_COMPARATOR|Group 1|Group 1 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 1 starts the 8 week control period and ends with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED).
62277150|NCT05629325|EXPERIMENTAL|Placebo => Washout => Buspirone|Patients will take Placebo oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will also report their perceived symptoms of dysphagia during the HRiM. A washout period of two weeks will take place. Afterwards, the second treatment period starts. Patients will take Buspirone hydrochloride oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will also be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will again report their perceived symptoms of dysphagia during the HRiM.
62642072|NCT05181371|ACTIVE_COMPARATOR|Ultrasound Guided ESP Block with Continuous Infusion (CI)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive a continuous infusion local anaesthetic: 0.125% levobupivacaine at an infusion rate of 10 ml/hr.
62277151|NCT04293679|EXPERIMENTAL|Cohort A: STP705 10 μg dose|Cohort A: STP705 10 μg dose, intradermal injection, given once a week for up to 6 weeks
62277152|NCT04293679|EXPERIMENTAL|Cohort B: STP705 20 μg dose|Cohort B: STP705 20 μg dose, intradermal injection, given once a week for up to 6 weeks
62277153|NCT04293679|EXPERIMENTAL|Cohort C: STP705 30 μg dose|Cohort C: STP705 30 μg dose, intradermal injection, given once a week for up to 6 weeks
62277154|NCT04293679|EXPERIMENTAL|Cohort D: STP705 60 μg dose|Cohort D: STP705 60 μg dose, intradermal injection, given once a week for up to 6 weeks
62277155|NCT04293679|EXPERIMENTAL|Cohort E: STP705 120 μg dose|Cohort E: STP705 120 μg dose, intradermal injection, given once a week for up to 6 weeks
62072826|NCT03263234|ACTIVE_COMPARATOR|Group 2|Group 2 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 2 starts with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED) and ends with the 8 week control period
62072827|NCT03263234|NO_INTERVENTION|Group 3. Control group|"Group 3 consists of elderly people with frailty living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are not having CALED installed.~This group serves as a control for:~* Physiological or mental decline in participants during the study period~* Seasonal variation"
62072828|NCT04880161|EXPERIMENTAL|Active|Ampion
62072829|NCT04880161|PLACEBO_COMPARATOR|Control|Placebo
62072830|NCT02757521|PLACEBO_COMPARATOR|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
62277156|NCT05331534|EXPERIMENTAL|patients with a PTSD receiving ACTo and prolonged exposure therapy.|
62277157|NCT05331534|SHAM_COMPARATOR|patients with PTSD receiving ACT and prolonged exposure therapy.|
62277158|NCT04267211|EXPERIMENTAL|Illustrated Consult|
62277159|NCT04267211|EXPERIMENTAL|Standard Consult|
62072831|NCT02757521|EXPERIMENTAL|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
62642073|NCT01418339|EXPERIMENTAL|Aripiprazole|Aripiprazole was administered orally once a week (QW) for 8 weeks in a double-blind manner. Participants randomized to aripiprazole received aripiprazole tablets at a starting dose of 52.5 milligrams (mg) QW on Day 0. At Week 1, according to the investigator's discretion based on efficacy and tolerability, the dose of aripiprazole could remain at 52.5 mg QW or could be increased to 77.5 mg QW. The dose could be increased to 110 mg QW as early as Week 2. For the remainder of the study (up to Week 8), the dose was to be adjusted up and down among these three dose levels, as determined by the investigator.
62072832|NCT04980716|EXPERIMENTAL|The early intervention group|"The early intervention group: evaluation and intervention based on impedance cardiography results at multiple timepoints. Specific intervention measures include:~1. cardiovascular drug treatment: based on the increase and decrease of the Golden Triangle~   1. ACEI, perindopril tert-butyrate 4mg qd~  2. β receptor antagonist, metoprolol succinate 47.5mg qd~  3. Spironolactone 20mg qd~  4. Drugs to improve myocardial metabolism: trimetazidine hydrochloride 35 mg bid~  5. Other therapeutic drugs include: loop diuretics, ARNI, sinus node If current selection specific inhibitors, statins, antiplatelet aggregation and nitrate drugs, etc.~2. Exercise intervention: exercise prescription based on the initial cardiopulmonary exercise test results."
62072833|NCT04980716|NO_INTERVENTION|The control group|This group will be under observation. When cardiovascular events (including ischemic cardiomyopathy, heart failure, arrhythmia requiring treatment, pericardial disease requiring treatment, valvular disease, etc.) happen, a cardiovascular specialist assessment and intervention will be given.
62072834|NCT04542226||Adult patients hospitalized with COVID-19|Patients eligible for enrollment into the study
62642074|NCT01418339|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo received aripiprazole-matching placebo, tablet, orally, QW for 8 weeks in a double-blind manner.
62642075|NCT06138210|EXPERIMENTAL|Exosomes group|Patients in this arm will be given exosomes derived from human induced pluripotent stem cell for injection once a day for 7 days.
62642076|NCT06138210|PLACEBO_COMPARATOR|Exosomes placebo group|Patients in this arm will be given a placebo of exosomes derived from human induced pluripotent stem cell for injection once a day for 7 days.
62642077|NCT01019161|EXPERIMENTAL|AZD1152|100 mg Lyophile 5 mL Diluent
62642078|NCT01019161|EXPERIMENTAL|C14 AZD1152|AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial.
62642079|NCT06282991||Lorlatinib|Patients received lorlatinib treatment under EAP
62642080|NCT03037515|ACTIVE_COMPARATOR|Intravenous Tranexamic Acid|The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
62642081|NCT03037515|ACTIVE_COMPARATOR|Oral Tranexamic Acid|The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
62642082|NCT04217291|EXPERIMENTAL|SY-004-1|a dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week
62642083|NCT04217291|EXPERIMENTAL|SY-004-2|a dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.
62642084|NCT04217291|EXPERIMENTAL|SY-004-3|a dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.
62072835|NCT02855164|EXPERIMENTAL|LJN452 10 μg|Tropifexor (LJN452) Part A
62072836|NCT02855164|EXPERIMENTAL|LJN452 30 μg|Tropifexor (LJN452) Part A
62277160|NCT02750462|EXPERIMENTAL|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
62642085|NCT04217291|PLACEBO_COMPARATOR|placebo|a dose of SY-004 matching placebo taken orally
62642086|NCT00125450|EXPERIMENTAL|A|Chest Physiotherapy with Forced Expiratory Technique
62642087|NCT00125450|ACTIVE_COMPARATOR|B|Aspiration
62642088|NCT02207062|EXPERIMENTAL|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
62642089|NCT03481452|EXPERIMENTAL|psychotherapy intervention group|NBO behavioral intervention would be used to improve mother-infant dyad interaction and infants' disorders of regulation of states.
62642090|NCT03481452|NO_INTERVENTION|control group|No behavioral intervention would be used.
62642091|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 1 dose of Formulation A1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
62642092|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 2 doses of Formulation A1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
62642093|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 1 dose of Formulation A2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
62642094|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 2 doses of Formulation A2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
62642095|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 1 dose of Formulation A3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
62642096|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 2 doses of Formulation A3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
62642097|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 1 dose of Formulation B1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
62642098|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 2 doses of Formulation B1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
62642099|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 1 dose of Formulation B2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
62642100|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 2 doses of Formulation B2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
62642101|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 1 dose of Formulation B3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
62642102|NCT01195779|EXPERIMENTAL|GSK2584786A vaccine 2 doses of Formulation B3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
62277161|NCT02750462|ACTIVE_COMPARATOR|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
62642103|NCT01195779|EXPERIMENTAL|GSK2321138A vaccine Group|Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
62642104|NCT01195779|ACTIVE_COMPARATOR|Fluarix Group|Subjects received 2 doses of Fluarix Vaccine.
62642105|NCT01256528|EXPERIMENTAL|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
62642106|NCT04125069||Patients aged from 18 to 85 years|Cardiac surgery patients aged from 18 to 85 years,programmed for Coronary artery bypass graft requiring ECC.
62072837|NCT02855164|EXPERIMENTAL|LJN452 60 μg|Tropifezor (LJN452) Parts A + B
62072838|NCT02855164|EXPERIMENTAL|LJN452 90 μg|Tropifexor (LJN452) Parts A + B
62642107|NCT01746719|EXPERIMENTAL|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
62072839|NCT02855164|PLACEBO_COMPARATOR|Placebo A+ B|Placebo Parts A + B
62072840|NCT02855164|EXPERIMENTAL|LJN452 140 μg|Tropifexor (LJN452) Part C
62072841|NCT02855164|EXPERIMENTAL|LJN452 200 μg|Tropifexor (LJN452) Part B
62072842|NCT02855164|PLACEBO_COMPARATOR|Placebo C|Placebo Part C
62277162|NCT00650754|EXPERIMENTAL|DHEA|Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
62277163|NCT00650754|PLACEBO_COMPARATOR|Placebo|Blinded placebo
62642108|NCT01746719|ACTIVE_COMPARATOR|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
62072843|NCT03072758|EXPERIMENTAL|Men's Club Intervention Group|Participants randomized to this group will receive interventions from the study team.
62072844|NCT03072758|NO_INTERVENTION|Men's Club Control Group|Male participants in the control group will receive only education pamphlets related to breastfeeding during the 3rd trimester of their female partner's pregnancy
62642109|NCT06424808|NO_INTERVENTION|Control Group|"1. The group assigned as the control group will receive information in the same manner as it is currently provided to patients.~2. A survey related to patient experience evaluation will be conducted before discharge. The survey will take about 10 minutes.~3. The control group will undergo two interviews, one during hospitalization and one before discharge. Each interview will last approximately 30 minutes. Interviews will be recorded or transcribed, and the recordings will be used until the research objectives are met, after which they will be disposed of."
62642110|NCT06424808|EXPERIMENTAL|Experimental Group|"1. The group assigned as the experimental group will receive information in the same manner as it is currently provided to patients, with the addition of a brochure provided once when moving to a general ward after surgery. The brochure can then be used freely.~2. A survey related to patient experience evaluation will be conducted before discharge. For the experimental group, an additional survey regarding the provided brochure will be included. The survey will take about 15 minutes.~3. The experimental group will undergo two interviews, one during hospitalization and one before discharge. Each interview will last approximately 30 minutes. Interviews will be recorded or transcribed, and the recordings will be used until the research objectives are met, after which they will be disposed of."
62642111|NCT02147171|ACTIVE_COMPARATOR|Active lutein group|44 participants taking VisionAce daily for a period of 1 year
62642112|NCT02147171|PLACEBO_COMPARATOR|Placebo group|44 participants taking placebo daily for a period of 1 year
62642113|NCT01320397|EXPERIMENTAL|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
62642114|NCT01320397|EXPERIMENTAL|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
62642115|NCT01320397|EXPERIMENTAL|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
62642116|NCT01320397|EXPERIMENTAL|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
62277164|NCT00993707|ACTIVE_COMPARATOR|0.01% CTX-100 (formerly ETX-100)|
62277165|NCT00993707|ACTIVE_COMPARATOR|0.03% CTX-100 (formerly ETX-100)|
62277166|NCT00993707|PLACEBO_COMPARATOR|Placebo|
62277167|NCT01466400||infants two to six months of age|
62455460|NCT00951288|ACTIVE_COMPARATOR|Saffron|Crocus Sativus extract
62455461|NCT00951288|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62642117|NCT05146752|EXPERIMENTAL|Extremely low frequency electromagnetic fields|After parental permission for participation was obtained, the preterm newborns were enrolled and divided into the experimental group, which received ELF-EMF therapy after a pretest in addition to regular medical care, and the control group, which received regular medical care only, using a random number table.
62277168|NCT02878980|EXPERIMENTAL|Arm I (exercise intervention)|Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum.
62277169|NCT04884555||post-stroke patient|patients with subacute stroke who have a stroke for the first time and admitted to the hospital for the first rehabilitation treatments
62277170|NCT04884555||Control|healthy volunteers who have not got any known disease and any sign in physical examination
62277171|NCT04677348|EXPERIMENTAL|PENG group|pericapsular nerve group (PENG) block before surgery
62277172|NCT04677348|ACTIVE_COMPARATOR|FICB group|suprainguinal fascia iliaca compartment block (FICB) before surgery
62277173|NCT00040755|EXPERIMENTAL|Arm I (rebimastat once daily)|Patients receive oral BMS-275291 once daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
62277174|NCT00040755|EXPERIMENTAL|Arm II (rebimastat twice daily)|Patients receive oral BMS-275291 twice daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
62277175|NCT05469971||NCWS patients|"The researchers will enrol NCWS, presenting with IBS and/or dyspepsia-like symptoms, according to the Rome IV criteria (20). These patients were diagnosed by DBPC wheat challenge between January 2010 and June 2022 in three tertiary centers for gluten-related disorders (Department of Internal Medicine, University Hospital of Palermo, Italy; Department of Internal Medicine, Cervello Hospital of Palermo, Italy, and Department of Internal Medicine, Hospital of Sciacca, Agrigento, Italy."
62277176|NCT05469971||Celiac disease|"The researchers will enrol CD patients diagnosed between January 2010 and June 2022 in three tertiary centers for gluten-related disorders (Department of Internal Medicine, University Hospital of Palermo, Italy; Department of Internal Medicine, Cervello Hospital of Palermo, Italy, and Department of Internal Medicine, Hospital of Sciacca, Agrigento, Italy."
62277177|NCT05469971||Blood donors|The researchers will enroll blood donors from the Transfusion Centre of the University Hospital of Palermo, Italy.
62277178|NCT05160935|EXPERIMENTAL|Coronary Angiography Training Manual|It is the form prepared by the researchers in line with the literature information and the opinion of the specialist physician was taken. It contains information about coronary artery disease, what to do before coronary angiography procedure and what kind of situations await individuals after the procedure.
62277179|NCT05866055|EXPERIMENTAL|Part A: Single Ascending Dose|Participants will be randomized to receive a single dose of VX-973 under fasted conditions.
62461683|NCT03884439||Infliximab [infliximab biosimilar 3]|Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
62461684|NCT03456570|ACTIVE_COMPARATOR|progesterone|these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
62461685|NCT03456570|PLACEBO_COMPARATOR|placebo|those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
62461686|NCT02865746|ACTIVE_COMPARATOR|Group betamethasone|Active Comparator: betamethasone disodium phosphate at a concentration of 4 mg / ml - dosage of 0.05 mg / kg
62461687|NCT02865746|PLACEBO_COMPARATOR|Group placebo|sterile saline solution (sodium chloride 0.9% - 1 ml ampoules) - dosage of 0.05 mg / kg
62461688|NCT02045927|ACTIVE_COMPARATOR|Intevention Group|sedation monitoring with RASS score plus sedation monitoring with BIS-Guided monitoring
62461689|NCT02045927|OTHER|Control Group|sedation monitoring with RASS score
62461690|NCT04920877|EXPERIMENTAL|Central catheter-related bloodstream infection rates in intensive care units|
62461691|NCT01767298|OTHER|Valsartan 320 mg alone|Valsartan alone
62461692|NCT01767298|OTHER|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide alone
62461693|NCT01767298|OTHER|Valsartan 320 mg + Hydrochlorothiazide 25 mg|Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg
62461694|NCT01767298|OTHER|Valsartan / Hydrochlorothiazide 320 mg/25mg|Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg
62461695|NCT03435705|EXPERIMENTAL|intervention arm|maintaining of occupational therapy for a 4 months period
62461696|NCT03435705|NO_INTERVENTION|control arm|usual care after the end of the recommended initial program
62461697|NCT04294108||Patients underwent VATS lobectomy|All consecutive patients scheduled for video-assisted thoracoscopic surgery lobectomy.
62461698|NCT05689463|EXPERIMENTAL|Patient with prurit|
62461699|NCT02187432||ADPKD|EuroCYST is and observational trail aiming to investigate disease progression across the different stages of disease and stage specific morbidity and mortality factors in a longitudinal observational multi center study and to evaluate the levels of and associations between the impacts of patients reported disease outcome (quality of life (QoL), pain, self-estimated health status, health burden).
62461700|NCT01616602|PLACEBO_COMPARATOR|Left-sided Position|
62461701|NCT01616602|EXPERIMENTAL|Prone Position|
62461702|NCT03085056|EXPERIMENTAL|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
62461703|NCT03659656|OTHER|Fitbit (FB)|The Fitbit only (FB) group will receive the Fitbit monitor to use for 3 months.
62461704|NCT03659656|EXPERIMENTAL|Fitbit + Health coaching (FB+)|The Fitbit + Health coaching (FB+) group will receive a Fitbit, weekly personalized physical activity report and health coaching by phone. The 3-month intervention will be delivered through health coaching (1-time per week for month 1, 1-time every other week for month 2 and 1 time for month 3) and use of a Fitbit activity monitor.
62461705|NCT01132963|EXPERIMENTAL|Outdoor Shoes|Patient will be asked to do balance tests while wearing outdoor shoes.
62072845|NCT00242203|EXPERIMENTAL|Zometa|"Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.~Neoadjuvant therapy~* Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~* Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~* Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~* Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~* All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
62277180|NCT05866055|EXPERIMENTAL|Part B: Multiple Ascending Dose|Participants will be randomized to receive multiple doses of VX-973 under fasted conditions. The dose and frequency will be determined based on Part A. Midazolam is planned to be administered as single oral doses of 2 mg first alone on Day -1 and then co-administered with study drug on Day 27.
62072846|NCT00242203|ACTIVE_COMPARATOR|No Zometa|"Neoadjuvant therapy~* Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~* Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~* Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~* Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~* All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
62642118|NCT05146752|OTHER|control group|routine care
62642119|NCT02101762||Silver Coated Catheters|Subjects that had previously received silver coated Foley catheters.
62642120|NCT02101762||ERASE CAUTI Non-Silver Coated Catheters|Subjects that received non-silver catheters from an ERASE CAUTI tray.
62642121|NCT06122350|EXPERIMENTAL|Experimental Group|The experimental group will be trained within the scope of the Earthquake Preparedness Guide.
62642122|NCT06122350|NO_INTERVENTION|Control Group|No intervention will be applied.
62642123|NCT03874793|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
62277181|NCT05866055|PLACEBO_COMPARATOR|Placebo Part A|Participants will be randomized to receive placebo matched to VX-973.
62642124|NCT03874793|ACTIVE_COMPARATOR|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
62642125|NCT06144515||Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome|
62642126|NCT01348126|ACTIVE_COMPARATOR|Single agent docetaxel|
62642127|NCT01348126|EXPERIMENTAL|Combination of ganetespib and docetaxel|
62642128|NCT04587817||Camrelizumab+Hypofractionated radiation therapy|"Camrelizumab: 200mg every 2 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Hypofractionated Radiotherapy(SABR): tumor center dose of 24-32Gy/8Gy/3-4f and surrounding important organs at risk ≤3.0Gy will be performed when one week following completion of the first immunotherapy. And the routine radiotherapy will be started with reaching a radical cure dose for the tumor margin. Generally, the radiotherapy will end before the fourth immunotherapy."
62642129|NCT06051877||suspPD|People referred to clinic with suspected PD
62642130|NCT06051877||confPD|People with confirmed PD
62642131|NCT06051877||HC|Healthy controls
62642132|NCT02280330|ACTIVE_COMPARATOR|MNP group|The MNP group will receive 60 sachets of MNP in a period of 6 months or 10 sachets per month equivalent to 3-4 sachets in a week.
62642133|NCT02280330|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive 60 sachets of placebo (with same characteristics) as the MNP or 10 sachets per month equivalent to 3-4 sachets in a week.
62642134|NCT06114680|OTHER|Session 1 - test group (self-reported hearing difficulties)|143 (130 + 10% potential drop-outs) subjects with self-reported hearing difficulties according to the HHIE-s questionnaire (score of \>4)
62642135|NCT06114680|OTHER|Session 1 - control goup (no self-reported hearing difficulties)|66 (60 + 10% potential drop-outs) subjects with no self-reported hearing difficulties according to HHIE-s questionnaire (score of ≤4)
62277182|NCT05866055|PLACEBO_COMPARATOR|Placebo Part B|Participants will be randomized to receive placebo matched to VX-973. Midazolam is planned to be administered as single oral doses of 2 mg first alone on Day -1 and then co-administered with placebo matched to VX-973 on Day 27.
62642136|NCT06114680|OTHER|Session 2 (self-reported hearing difficulties)|66 (60 + 10% potential drop-outs) subjects who participated in session 1 - test group
62642137|NCT06420531|EXPERIMENTAL|Intervention: 180-200 mL/kg/day of human milk|Study participants randomized to the intervention group will receive 180-200 mL/kg/day of human milk for 34 weeks corrected age.
62642138|NCT06420531|PLACEBO_COMPARATOR|Control:140-160 mL/kg/day of human milk|Study participants randomized to the control group will receive 140-160 mL/kg/day of human milk for 34 weeks corrected age.
62642139|NCT01611675|EXPERIMENTAL|Treatment Arm|Leflunomide + Vemurafenib
62642140|NCT04794257|ACTIVE_COMPARATOR|i-IONM|In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy.
62642141|NCT04794257|EXPERIMENTAL|NerveTrend|In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
62072847|NCT02489825|OTHER|Augmentation vertebroplasty|Single level fracture fixation with vertebroplasty
62277183|NCT01207557|ACTIVE_COMPARATOR|Standard education only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
62277184|NCT01207557|ACTIVE_COMPARATOR|Standard Education plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials plus the Ottawa Influenza Decision Aid and tested on their confidence with their immunization decision
62277185|NCT05698680|EXPERIMENTAL|Prednisolone 30mg (Day 0-4)|"As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the prednisolone arm will receive prednisolone plus a colchicine placebo. The prednisolone placebos contain a bittering agent due to the bitter taste of prednisolone to ensure a similar taste.~The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 150 mg for prednisolone."
62642142|NCT01285843|ACTIVE_COMPARATOR|Quadra Group|
62642143|NCT01285843|ACTIVE_COMPARATOR|AMIStem Group|
62642144|NCT05324306|EXPERIMENTAL|Application of Tourniquets on Lower Extremities|Participants will have their baseline blood pressure measured in their upper extremities followed by application of CAT tourniquets to both lower extremities. Blood pressure will be measured again in the upper extremities once the CAT tourniquets are deployed. This will be repeated 3 times.
62642145|NCT05560503||significant liver fibrosis|According to the Scheuer scoring system, the degree of fibrosis S2-S4 as significant liver fibrosis.
62642146|NCT05560503||non-significant liver fibrosis|According to the Scheuer scoring system, the degree of fibrosis S0-S1 was defined as non-significant liver fibrosis.
62642147|NCT01719250|EXPERIMENTAL|Treatment (buparlisib)|Patients receive buparlisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62072848|NCT02489825|OTHER|Augmentation and prophylactic vertebroplasty|Triple level augmentation with VP fixation of the fracture and additional prophylactic vertebroplasty in both the adjacent levels
62455462|NCT06001125|EXPERIMENTAL|Single Arm|"Methotrexate 20 mg PO weekly for 12 weeks.~Folic acid 1mg PO daily for as long as Methotrexate is given.~Prednisone starting at 20 mg PO daily for 8 weeks tapering dose."
62455463|NCT03061409|EXPERIMENTAL|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
62455464|NCT03061409|PLACEBO_COMPARATOR|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
62642148|NCT05558397|ACTIVE_COMPARATOR|Control Group (Oral Morphine)|The control group will be composed of 15 patients who will receive oral drug treatment according to the Clinical Protocol and Therapeutic Guidelines for Chronic Pain of the Brazilian Ministry of Health. The drugs included in the treatment plan are morphine (60 mg/day), pregabalin (150 mg/day) and duloxetine (60 mg/day), available free of charge to the participating patients. The treatment will be carried out orally in a home environment.
62642149|NCT05558397|EXPERIMENTAL|Interventional Group (Epidural morphine)|The intervention group will be composed of 15 patients who will undergo a surgical procedure for subcutaneous implantation of a catheter (Celsite ST304-19BBraun) that allows epidural administration of morphine and ropivacaine drugs. The treatment plan for such patients includes Patient Controlled Analgesia (PCA). Patients in this group will receive, via catheter, an anesthetic solution containing 2.0 mL of morphine (1.0 mg/mL), 3.0 mL of ropivacaine (7.5 mg/mL) and 5.0 mL of distilled water. For 24 hours after this application, if the patient continues to have pain, they may use a rescue dose of oral morphine of 10 mg.
62642150|NCT01143285|EXPERIMENTAL|I - Early and active nutritional support.|During the initial consultation, the dietician will answer the questions of the patient and their family. Patients will be seen regularly in follow-up for weight measurement, serum albumin assay, a 1 or 3 day food record and an evaluation of appetite level. Nutritional counselling is then adjusted accordingly and:Balanced meals are continued if weight is stable and appetite is undiminished.Protein and energy fortification is recommended if weight loss is observed or if food intake decreases between 2 consultations leading to total food intake of less than 50% of required food intake. When a patient presents with signs of malnutrition according to the criteria set out by the Authority for Health, oral nutritional support (ONS) is set up, in agreement with the department head. Two 200ml bottles of Fortimel Extra are to be taken every day. If this ONS strategy is insufficient to improve the patient's nutritional status, artificial nutrition should be discussed.
62642151|NCT01143285|NO_INTERVENTION|II - No nutritional support|Should malnutrition develop in a group II patient, ONS will be ordered. It will consist of two 200ml Fortimel Extra\* bottles per day in addition to regular meals. Ideally, the ONS should be taken as a snack outside of meal times so as to not spoil the appetite. If this ONS is insufficient to improve the nutritional status of the patient, artificial nutrition (either enteral or parenteral) will be discussed.
62642152|NCT04503317|EXPERIMENTAL|active acupuncture low level laser and aerobic exercise|active acupuncture, low level laser and aerobic exercise
62642153|NCT04503317|ACTIVE_COMPARATOR|aerobic exercise|aerobic exercise
62277186|NCT05698680|ACTIVE_COMPARATOR|Colchicine 1.5 mg (Day 0), 1.0 mg (Day 1-4)|"As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the colchicine arm will receive colchicine plus prednisolone placebo.~The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 5.5mg for colchicine."
62277187|NCT01580397|EXPERIMENTAL|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 8 consecutive cycles.
62455465|NCT01510886||1|
62455466|NCT02983708|EXPERIMENTAL|mPBMC group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. mPBMCs group would be included all patients who received mPBMCs at M1 or M7.
62455467|NCT02983708|PLACEBO_COMPARATOR|Placebo group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. Placebo group would be included all patients who received placebo at M1 or M7.
62455468|NCT02192346|EXPERIMENTAL|2.4 mg/kg α-TEA|Patients will receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
62642154|NCT04091165||Study Group|"Participants will be identified for inclusion by leaders of the GI Clinic after GI surgery has been scheduled. Upon consenting, participants will be instructed how to download and use the mobile phone application My Plate Calorie Counter."
62277188|NCT04114435||Neonatal profile|"Echocardiography at:~* 7 to 10 days of chronological age~* 35 to 37 weeks post-menstrual age (PMA = corrected age);~* 39 to 44 weeks PMA; Term equivalent"
62277189|NCT04114435||Infant profile ( between 4 months and 9 months)|"* Echocardiography~* Ages \& stages questionnaires CAT/CLAMS assessment"
62277190|NCT04114435||Pediatric profile (36 months and 5 years)|"* Echocardiography~* Ages \& stages questionnaires CAT/CLAMS assessment~* Results from 18 months PMA Bayley will be retrieved Figure 1: Premature population - Groups Recruited simultaneously"
62277191|NCT00458731|EXPERIMENTAL|Treatment (cediranib maleate and bevacizumab)|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bevacizumab and cediranib maleate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62455469|NCT02192346|EXPERIMENTAL|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
62455470|NCT02192346|EXPERIMENTAL|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
62455471|NCT02192346|EXPERIMENTAL|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
62455472|NCT02192346|EXPERIMENTAL|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
62277192|NCT01648231|OTHER|Treatment Period 1|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
62277193|NCT01648231|OTHER|Treatment Period 2|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
62277194|NCT01648231|OTHER|Treatment Period 3|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
62277195|NCT00824122||1|Children greater than 6 months receiving at least one dose of Vancomycin and Red Man Syndrome
62277196|NCT00824122||2|Children greater than 6 months receiving at least one dose of Vancomycin and has not had Red Man Syndrome
62455473|NCT02192346|EXPERIMENTAL|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
62455474|NCT02192346|EXPERIMENTAL|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
62455475|NCT02192346|EXPERIMENTAL|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
62455476|NCT02192346|EXPERIMENTAL|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
62642155|NCT05030844|EXPERIMENTAL|Intervention Group|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
62072849|NCT03029247|ACTIVE_COMPARATOR|Participants receiving Epoetin alfa|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
62072850|NCT03029247|EXPERIMENTAL|Participants receiving Daprodustat|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
62072851|NCT04226729||Healthy group|
62642156|NCT05030844|NO_INTERVENTION|Control Group|The control group received routine nursing care in the endocrine policlinic.
62642157|NCT00644761|OTHER|Treatment Arm 1|Adefovir dipivoxil 10 mg once daily with tacrolimus or cyclosporine for 14 days
62642158|NCT03092752||Patients with T2DM|
62642159|NCT04474340|EXPERIMENTAL|CCP patients|"1. Patient has to fulfil the inclusion/exclusion criteria of the ward or the ICU~2. Valid consent.~3. Request the CCP from the central blood bank (200-250 ml/dose - can be repeated again in 12 hours) this is through the local hospital blood bank.~How to transfuse CCP:~1. Dose required is 200-250 ml/hr (one dose, can be repeated in 12 hrs), max total 500ml.~2. Premedication prior to administration of CCP (Acetaminophen, diphenhydramine,steriods) or according to hospital guidelines."
62072852|NCT04226729||Mild visual impairment group|
62072853|NCT04226729||Moderate and severe visual impairment group|
62072854|NCT01763528|ACTIVE_COMPARATOR|nutrition intervention|high protein diet
62072855|NCT01763528|NO_INTERVENTION|control group|control diet
62072856|NCT00641186|EXPERIMENTAL|Xyrem in Parkinson disease|sodium oxybate 4.5 to 9.0 gms per night
62072857|NCT05286515|EXPERIMENTAL|Hybrid Preoperative Physical Therapy (PT)|
62072858|NCT05286515|ACTIVE_COMPARATOR|Control Standard Physical Therapy (PT)|
62277197|NCT04442841|EXPERIMENTAL|Single arm (vaccine)|No further description
62642160|NCT04474340|NO_INTERVENTION|Control|Standard COVID-19 treatment.
62642161|NCT02873767|PLACEBO_COMPARATOR|Placebo|Single dose placebo comparator for each active arm
62642162|NCT02873767|EXPERIMENTAL|UCB4019 Dose 1|Dose 1 calculated based on body weight
62642163|NCT02873767|EXPERIMENTAL|UCB4019 Dose 2|Dose 2 calculated based on body weight
62642164|NCT02873767|EXPERIMENTAL|UCB4019 Dose 3|Dose 3 calculated based on body weight
62642165|NCT02873767|EXPERIMENTAL|UCB4019 Dose 4|Dose 4 calculated based on body weight
62642166|NCT03472209||Group A|ETCO2=26-35 mmHg
62642167|NCT03472209||Group B|ETCO2=36-45 mmHg
62642168|NCT02976519|EXPERIMENTAL|BI 443651|
62642169|NCT02976519|PLACEBO_COMPARATOR|Placebo|
62072859|NCT04318756||Italian patients suffering from mucinous neoplasms|Italian patients suffering from mucinous neoplasms will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
62072860|NCT04318756||Italian patients with familiarity/genetic predisposition|Italian patients with familiarity/genetic predisposition will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
62072861|NCT02906085|EXPERIMENTAL|Endothelin-1|Intravenous infusion of pharmaceutical grade human endothelin-1
62072862|NCT02906085|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of placebo (isotonic saline)
62072863|NCT05225233|EXPERIMENTAL|Active tDCS with Cognitive Training|Participants will receive active tDCS stimulation with their cognitive training during a one-hour session each day which includes 20 minutes of stimulation at the beginning of a 46-minute task training session. Ten sessions will be completed over three weeks.
62455477|NCT02972398|EXPERIMENTAL|NAC group|"Participants of NAC group receive 1000 mg NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
62072864|NCT05225233|SHAM_COMPARATOR|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 seconds, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
62455478|NCT02972398|PLACEBO_COMPARATOR|Placebo group|"Participants of Placebo group receive placebo matched with NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
62072865|NCT05056090|EXPERIMENTAL|Patients will receive MV in PP|Patients assigned to the intervention group will be turned in PP within the two hours after randomization for at least 16 consecutive hours. Then, patients will be turned in SP. Then, PP sessions are repeated as long as stopping criteria for PP are not met
62072866|NCT05056090|NO_INTERVENTION|Patients will receive MV in SP|
62072867|NCT00899587|EXPERIMENTAL|Oxygen|
62072868|NCT00899587|EXPERIMENTAL|Enalapril|
62072869|NCT00899587|PLACEBO_COMPARATOR|Control|
62072870|NCT03897205|EXPERIMENTAL|Imlifidase|Subjects randomized to imlifidase treatment received one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
62072871|NCT03897205|ACTIVE_COMPARATOR|Plasma Exchange|Subjects randomized to plasma exchange (PE) treatment received 5-10 sessions of PE, as judged by the investigator. Immunoadsorption (IA) could replace PE, at the discretion of the investigator.
62277198|NCT05154292|EXPERIMENTAL|eHealth Emotion Regulation Skills|The intervention aims to develop competencies for emotional regulation through exposure and acceptance strategies for coping with circumstances that produce stress or emotional discomfort. The application has a series of mini-games that the user will overcome throughout a narrative, with different challenges and rewards
62277199|NCT05154292|NO_INTERVENTION|Waiting List|He or she will not be exposed to the intervention but will remain on the waiting list and will complete the pre and post-measures.
62277200|NCT02342405|PLACEBO_COMPARATOR|30% oxygen|Inhalation of 30% oxygen
62277201|NCT02342405|EXPERIMENTAL|80% oxygen|Inhalation of 80% oxygen
62277202|NCT01292057|ACTIVE_COMPARATOR|Aripiprazole|Medication
62277203|NCT01292057|PLACEBO_COMPARATOR|Sugar pill|
62455479|NCT01969357|PLACEBO_COMPARATOR|Placebo|
62455480|NCT01969357|EXPERIMENTAL|50 mg SP2086|
62455481|NCT01969357|EXPERIMENTAL|100 mg SP2086|
62455482|NCT01969357|EXPERIMENTAL|200 mg SP2086|
62277204|NCT03979157|EXPERIMENTAL|Healthy Volunteers|Multispectral Optoacoustic Tomography (MSOT) of proximal and distal leg muscles (total of 12 sites: left and right, 3 measurement points of Musculus quadriceps, and 3 measurement points of Musculus triceps surae) before and after the 6-Minute-Walk-Test by to independent investigators. Repetition of the same protocol after 14 days.
62277205|NCT05453643|EXPERIMENTAL|Sleep deprivation|healthy volunteers
62277206|NCT02655081|EXPERIMENTAL|Dietary supplement|Subjects will receive high arginine nutritional supplement (Nestle's Impact AR), prior to cystectomy
62455483|NCT01969357|ACTIVE_COMPARATOR|100 mg Sitagliptin|
62455484|NCT00938210|NO_INTERVENTION|Laparoscopic surgery|Patients undergoing laparoscopic colonic surgery are compared with a historical cohort of patients undergoing similar open colonic surgery (right hemicolectomy and sigmoid resections).
62455485|NCT04316312|EXPERIMENTAL|Inspiratory muscle training group|
62455486|NCT01718938|EXPERIMENTAL|Sequence 1|3-way crossover of velusetrag or placebo
62455487|NCT01718938|EXPERIMENTAL|Sequence 2|3-way crossover of velusetrag or placebo
62455488|NCT01718938|EXPERIMENTAL|Sequence 3|3-way crossover of velusetrag or placebo
62455489|NCT01718938|EXPERIMENTAL|Sequence 4|3-way crossover of velusetrag or placebo
62455490|NCT00331890|EXPERIMENTAL|Active|Receives active drug
62455491|NCT00331890|PLACEBO_COMPARATOR|Placebo|Receives a placebo
62455492|NCT06130735|EXPERIMENTAL|Computerized Cognitive Training|See section of intervention/treatment for additional information.
62455493|NCT05121233|ACTIVE_COMPARATOR|Diclofenac|Group A will receive a single dose 75 mg IV diclofenac by infusion prior to the procedure
62455494|NCT05121233|PLACEBO_COMPARATOR|Placebo|Group B who will receive placebo
62277207|NCT03195478|EXPERIMENTAL|Nivo/Ipi Combination Therapy A|
62277208|NCT03195478|EXPERIMENTAL|Nivo/Ipi Combination Therapy B|
62277209|NCT03195478|EXPERIMENTAL|Nivo/Ipi Combination Therapy C|
62277210|NCT03195478|EXPERIMENTAL|Nivo/Ipi Combination Arm D|
62277211|NCT05835479|EXPERIMENTAL|Rezafungin Acetate /Co-trimoxazole|"Rezafungin: Weekly intravenous infusion with a loading dose of 400 mg over 1 hour (±10 minutes) on Day 1 followed by maintenance doses of 200 mg over 1 hour (±10 minutes) on Day 8 and Day 15.~From Day 1 to Day 7, co-trimoxazole will also be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.~For participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day"
62277212|NCT05835479|ACTIVE_COMPARATOR|Co-trimoxazole|"From Day 1 to Day 21, co-trimoxazole will be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.~For participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day"
62455495|NCT02256085|SHAM_COMPARATOR|Sham rTMS|"Daily rTMS with Sham coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil"
62455496|NCT02256085|EXPERIMENTAL|Active rTMS|"Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
62455497|NCT02256085|EXPERIMENTAL|Open Active rTMS|"Open Label Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
62455498|NCT02457013|EXPERIMENTAL|HFNC treatment|HFNC : High flow nasal canula 24hours Patients will be treated by a High flow nasal canula (HFNC: 2l/kg/min) for the initial management of their bronchiolitis (24 hours)
62455499|NCT02457013|ACTIVE_COMPARATOR|nCPAP treatment|nCPAP : nasal NCPAP Patients will be treated by a nasal CPAP (n-CPAP: 7 cmH2O) for the initial management of their bronchiolitis (24 hours)
62455500|NCT04895111||Patients with suspected sarcoidosis|Consecutive patients with clinical and radiological (CT scan +/- PET) suspect of sarcoidosis
62455501|NCT04491149|EXPERIMENTAL|women using virtual glass during amniocentesis/foeticide|
62455502|NCT04491149|NO_INTERVENTION|women undergoing amniocentesis/foeticide|
62455503|NCT04035642|EXPERIMENTAL|IGRT 24 Gy Single dose|Patients will be treated using image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with a single fraction at a prescription dose of 24 Gy.
62455504|NCT03451669||Shunt suspected to be functioning|
62455505|NCT03451669||Shunt suspected to not be functioning|
62461706|NCT01132963|ACTIVE_COMPARATOR|Pillow Paws Slippers|Patient will be asked to complete balance tests while wearing standard hospital issue 'Pillow Paw' slippers on their feet
62461707|NCT01954264|OTHER|Overall Study Group|Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy.
62461708|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
62461709|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
62072872|NCT02858765|EXPERIMENTAL|white polychromatic light A|
62072873|NCT02858765|EXPERIMENTAL|white polychromatic light B|
62072874|NCT02858765|EXPERIMENTAL|white polychromatic light C|
62072875|NCT02858765|EXPERIMENTAL|white polychromatic light D|
62072876|NCT01563796||TCC positive|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology
62072877|NCT01563796||TCC negative|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.
62072878|NCT02817620|EXPERIMENTAL|Spirulysat®|Food supplement packaged in 10 ml vials called Spirulysat®. This product is a phycocyanin concentrated fresh spirulina water extract (Spirulina Platensis). 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
62072879|NCT02817620|PLACEBO_COMPARATOR|Placebo|Placebo with the same characteristics, appearance, packaging and composition as the active formula except for active ingredient (Spirulina) replaced by a classical blue food colorant used to colour desserts. 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
62072880|NCT01989598|EXPERIMENTAL|Treatment (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.
62072881|NCT06031168|EXPERIMENTAL|Test group|
62072882|NCT06031168|ACTIVE_COMPARATOR|Control group|
62277213|NCT01300182|EXPERIMENTAL|Whole body vibration therapy|Whole body vibration therapy on top of conventional physiotherapy treatment.
62277214|NCT01300182|ACTIVE_COMPARATOR|Control|Conventional post-operative physical therapy rehabilitation exercises.
62277215|NCT01828931|ACTIVE_COMPARATOR|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
62072883|NCT00439166|EXPERIMENTAL|1 AD combined doxycycline + rifampin|Doxycycline 100 mg b.i.d. plus rifampin 300 mg o.d. for 12 months.
62461710|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
62072884|NCT00439166|EXPERIMENTAL|2 AD Doxycycline only|Doxycycline 100 mg b.i.d. plus placebo matched to rifampin o.d. for 12 months.
62277216|NCT01828931|EXPERIMENTAL|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
62277217|NCT03249571|EXPERIMENTAL|Flavonoid|Flavonoid supplement
62277218|NCT03249571|PLACEBO_COMPARATOR|Placebo|Placebo
62277219|NCT02009527|EXPERIMENTAL|N-hydroxy-nor-arginine|N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
62277220|NCT02009527|PLACEBO_COMPARATOR|NaCl|NaCl 0.9%, 6 ml/min i.a. for 20 min
62461711|NCT05060315||De Novo Cohort|Patients new to parenteral prostacyclin-class therapy.
62072885|NCT00439166|EXPERIMENTAL|3 Rifampin only|Rifampin 300 mg o.d. plus placebo matched to doxycycline b.i.d. for 12 months.
62072886|NCT00439166|PLACEBO_COMPARATOR|4 Double Placebo|Placebo matched to Doxycycline b.i.d. plus placebo matched to rifampin o.d. for 12 months.
62072887|NCT06611098|EXPERIMENTAL|ABIO3419|Patients will be enrolled and randomised to receive ABIO3419 by intra-articular injection.
62072888|NCT06611098|ACTIVE_COMPARATOR|Synvisc|Patients will be enrolled and randomised to receive Synvisc(r) by intra-articular injection.
62072889|NCT01947296||"Group  coordinated care"|"Patient living in place covered by cancer network participating to the study is in the group coordinated care"
62072890|NCT01947296||"Group  usual care "|"Patient living in place covered by cancer network non participating to the study or without cancer network is in the group usual care"
62277221|NCT01405053|ACTIVE_COMPARATOR|Rufinamide|
62277222|NCT01405053|ACTIVE_COMPARATOR|Any other approved AED|
62277223|NCT00429585|OTHER|Randomized Treatment - Nail|Randomized Treatment - Nail
62277224|NCT00429585|OTHER|Randomized Treatment - Plate|Randomized Treatment - Plate
62277225|NCT03824860|EXPERIMENTAL|Yoga Program|Eight-weeks, therapist and self-guided yoga
62277226|NCT03824860|NO_INTERVENTION|Treatment as usual|Control group participants will continue to receive usual care and symptom management strategies from clinicians during the study.
62277227|NCT02981771|EXPERIMENTAL|experiment|A physical activity program that is based on balance and coordination exercises
62277228|NCT02981771|PLACEBO_COMPARATOR|control|A physical activity program that is based on strength exercises
62277229|NCT02542709|ACTIVE_COMPARATOR|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
62277230|NCT02542709|SHAM_COMPARATOR|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
62277231|NCT03993184|EXPERIMENTAL|90-minute Hot Yoga Classes|This group will complete 3, 90-minute hot yoga classes weekly for 12 weeks.
62277232|NCT03993184|EXPERIMENTAL|60-minute Hot Yoga Classes|This group will complete 3, 60-minute hot yoga classes weekly for 12 weeks.
62277233|NCT03993184|NO_INTERVENTION|Control|This group will maintain their current physical activity for 12 weeks.
62277234|NCT06023979|EXPERIMENTAL|Full weight bearing|After 2 weeks after surgery the arm will begin full weight bearing
62277235|NCT06023979|ACTIVE_COMPARATOR|Partial weight bearing|The arm will perform partial weight bearing for 6 weeks after surgery
62455506|NCT02116049|ACTIVE_COMPARATOR|Attention Control Case Management|"Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients. This project's case management will mimic the experimental condition with a meeting schedule reflective of the experimental arm plus a booster session at 3 months."
62455507|NCT02116049|EXPERIMENTAL|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
62455508|NCT01625026|ACTIVE_COMPARATOR|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
62455509|NCT01625026|PLACEBO_COMPARATOR|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
62642170|NCT02267941||case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. According to the Stanford classification system, type A aortic dissection was defined as any dissection that involves the ascending aorta and type B as any that does not. Acute stage was confined to initial 14 days after symptom onset. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
62642171|NCT02267941||control|As the control group, 2760 patients without AD were obtained from the hospitalized patients in the same period. Types of disease in the control group included congenital heart disease (632), coronary heart disease (467), adult valve disease (375), pulmonary artery hypertension (292), appendicitis (234), pneumonia (197), fracture (189), intestinal polyps (167), gallstone (156), esophagus cancer (51). Patients in the control group were derived from Department of Cardiovascular Surgery, Department of General Surgery, Department of Thoracic Surgery, and Department of Respiration, respectively.
62642172|NCT02464124|EXPERIMENTAL|lactulose plus nitazoxanide|"* Nitazoxanide dosing: 500 mg tablets twice daily~* Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day"
62455510|NCT01625026|ACTIVE_COMPARATOR|Gallstones OCA|Obeticholic acid 25 mg/day in three weeks
62455511|NCT01625026|PLACEBO_COMPARATOR|Gallstones Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
62455512|NCT02230397|OTHER|plantaricin a (active product)|Volunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
62642173|NCT02464124|ACTIVE_COMPARATOR|Lactulose alone|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
62642174|NCT02501824|EXPERIMENTAL|speech therapy first|11 sessions of speech therapy (anthroposophic therapeutic speech), then waiting phase
62642175|NCT02501824|EXPERIMENTAL|speech therapy second|10 weeks of waiting, then 11 sessions of speech therapy (anthroposophic therapeutic speech)
62642176|NCT03242369|EXPERIMENTAL|PEG group|100 patients undergoing colonoscopy.
62642177|NCT03242369|EXPERIMENTAL|SBS group|100 patients undergoing colonoscopy
62642178|NCT03242369|EXPERIMENTAL|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
62642179|NCT03242369|EXPERIMENTAL|PICO group|100 patients undergoing colonoscopy.
62642180|NCT02639871||healthy volunteers|31P-MR Spectroscopy and CEST for Validation of MRI/MRS methods
62642181|NCT02639871||HD presymptomatic individuals|General medical exam Clinical assessment with illness rating scales: Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS) and Total Functional Capacity (TFC), 31P-MR Spectroscopy and CEST
62642182|NCT02639871||early affected HD patients|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
62277236|NCT02668718|OTHER|Adjuvant radiotherapy|Patients who were randomized to adjuvant radiotherapy following radical prostatectomy
62277237|NCT02668718|NO_INTERVENTION|Watchful waiting|Patients who were randomized to watchful waiting following radical prostatectomy
62277238|NCT06549257|EXPERIMENTAL|Group 1|Vaccination with three doses of Pfs25-IMX313 10ug in 50ug Matrix M.
62642183|NCT02639871||Controls|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
62642184|NCT05116436||Patient with idiopathic scoliosis|
62642185|NCT05116436||Healthy related patients|
62642186|NCT04355364|EXPERIMENTAL|Experimental group|Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP \> 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure \< 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2\<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.
62642187|NCT04355364|ACTIVE_COMPARATOR|Control group|Patients will receive the usual care in accordance with good practice.
62642188|NCT05918536||Popolation|
62642189|NCT05676229|PLACEBO_COMPARATOR|Placebo|Volunteers supplemented with maltodextrin
62642190|NCT05676229|ACTIVE_COMPARATOR|Probiotic Blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858 - Final concentration: 1 x 10e10 UFC/ day
62642191|NCT03113045|EXPERIMENTAL|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
62642192|NCT03017092|EXPERIMENTAL|tablet-guided|Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer
62072891|NCT02164097|EXPERIMENTAL|ODSH and ICE Chemotherapy|"Patients will receive standard doses of ICE Chemotherapy:~* Ifosfamide 1800 mg/m2 mixed with Mesna 360 mg/m2 IV over 2 hours on days 1, 2, 3, 4, and 5~* Carboplatin 400 mg/m2 IV over 1 hour on days 1 and 2~* Etoposide 100 mg/m2 IV over 1 hour on days 1, 2, 3, 4, and 5~ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first ifosfamide dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for five consecutive days, on days 1-5, for a total of 120 hours of continuous ODSH infusion."
62072892|NCT00946179|EXPERIMENTAL|Group 1|Participants aged 18 to 60 years at enrollment
62642193|NCT01582113|EXPERIMENTAL|High Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
62642194|NCT01582113|EXPERIMENTAL|Low Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 250 mg of citicoline, of which they will be instructed to take 250 mg daily. This will be done in a double-blind, randomized fashion.
62642195|NCT01582113|PLACEBO_COMPARATOR|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
62642196|NCT04643132|PLACEBO_COMPARATOR|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
62642197|NCT04643132|ACTIVE_COMPARATOR|S-ketamine at low dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
62642198|NCT04643132|ACTIVE_COMPARATOR|S-ketamine at high dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
62642199|NCT04722107|EXPERIMENTAL|Single arm|All patients enrolled in the study will receive a single subretinal injection of ZVS101e in one eye
62642200|NCT05883696||Descriptive patient group|The research nurse will fill in the documents in Swedish Palliative care guide (S-PCG) together with the patient.
62642201|NCT01541709|EXPERIMENTAL|Imatinib|
62642202|NCT03663270|ACTIVE_COMPARATOR|Intervention arm|HPI monitoring to predict hypotension
62642203|NCT03663270|NO_INTERVENTION|Control arm|blinded HPI monitoring
62642204|NCT05554016||Group 1|Pediatric patients with obesity
62642205|NCT05554016||Group 2|Pediatric patients with obesity complicated by Metabolic Syndrome
62642206|NCT05554016||Group 3|Age- and sex-matched healthy controls
62642207|NCT05911217|EXPERIMENTAL|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Experimental: anti-claudin18.2 chimeric antigen receptor T-cell therapy Phase 1b: Evaluate the efficacy and safety of CT041
62642208|NCT06107114|EXPERIMENTAL|Experimental group|Patients with locally advanced operable head and neck squamous cell carcinoma
62642209|NCT00617552|PLACEBO_COMPARATOR|1|
62642210|NCT00617552|EXPERIMENTAL|2|
62642211|NCT00617552|EXPERIMENTAL|3|
62642212|NCT00617552|EXPERIMENTAL|4|
62642213|NCT00617552|EXPERIMENTAL|5|
62642214|NCT00617552|EXPERIMENTAL|6|
62642215|NCT00617552|EXPERIMENTAL|7|
62642216|NCT00617552|EXPERIMENTAL|8|
62642217|NCT03017807|EXPERIMENTAL|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance.
62642218|NCT04500808|EXPERIMENTAL|Part 1: Double Blind Phase|Participants will receive macitentan or matching placebo from Day 1 up to Day 13 under fed conditions and will be up-titrated starting with 2 once daily (QD) dosing of Dose 1 from Days 1 to 2 followed by 3 qd doses of Dose 2 of macitentan from Days 3 to 5, followed by qd doses of Dose 3 macitentan from Days 6 to 13.
62072893|NCT00946179|EXPERIMENTAL|Group 2|Participants aged 61 years or older at enrollment
62642219|NCT04500808|EXPERIMENTAL|Part 2: Open Label Phase: Treatment Sequence AB|Participants will receive Dose 3 of macitentan under fasted conditions (Treatment A) in period 1 followed by Dose 3 of macitentan under fed condition (Treatment B) in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
62642220|NCT04500808|EXPERIMENTAL|Part 2: Open Label Phase: Treatment Sequence BA|Participants will receive Treatment B in period 1 followed by Treatment A in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
62642221|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
62642222|NCT03939104|ACTIVE_COMPARATOR|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
62642223|NCT03939104|ACTIVE_COMPARATOR|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|Triple ACTs
62642224|NCT03939104|ACTIVE_COMPARATOR|artemether-lumefantrine+placebo (AL+PBO)|ACTs
62642225|NCT03939104|ACTIVE_COMPARATOR|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs.
62642226|NCT01284894|OTHER|Conventional manometry|
62642227|NCT01284894|EXPERIMENTAL|High resolution manometry|
62642228|NCT04654741|EXPERIMENTAL|Progestin Primed ovarian stimulation Group|progestin 10 mg daily during ovarian stimulation
62642229|NCT04654741|ACTIVE_COMPARATOR|GnRH antagonist|GnRH antagonist 0.25 mg daily during ovarian stimulation
62642230|NCT02062138|ACTIVE_COMPARATOR|continuous passive motion (CPM)|
62642231|NCT02062138|EXPERIMENTAL|controlled active motion (CAM I)|
62642232|NCT02062138|EXPERIMENTAL|controlled active motion (CAM II)|
62072894|NCT06469411|EXPERIMENTAL|Intervention group|Recipient of 6 doses secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) (It was produced through the cell culture from the placenta in the laboratory) 4 cc dissolved in albumin 20% every week for 6 weeks
62642233|NCT00738712|EXPERIMENTAL|New MRI techniques|New hardware or software technologies designed to improve MRI (Magnetic Resonance Imaging) exams.
62642234|NCT03856138||diarrhea with probiotics supplement|The children suffered from diarrhea, gastroenteritis oral probiotics during the clinical course
62642235|NCT03856138||diarrhea without probiotics supplement|The children suffered from diarrhea, gastroenteritis no oral probiotics during the clinical course
62642236|NCT03856138||healthy control|The children without diarrhea/ gastroenteritis
62642237|NCT02442596||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
62642238|NCT03619473|EXPERIMENTAL|intervention|"the group~1. assessed for proper helmet usage (type, chinstrap, standard helmet usage)~2. evaluated for the behavioral of helmet usage~3. underwent the educational session under helmet initiative program~4. received one standard motorcycle child safety helmet per family~5. assessed for proper helmet usage (type, chinstrap, standard helmet usage) 3 months after educational session and after received standard motorcycle child safety helmet~6. evaluated for the behavioral of helmet usage 3 months after educational session and after received standard motorcycle child safety helmet"
62072895|NCT06469411|PLACEBO_COMPARATOR|Control group|Recipient of 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
62642239|NCT03619473|NO_INTERVENTION|control|"the group~1. assessed for proper helmet usage (type, chinstrap, standard helmet usage)~2. evaluated for the behavioral of helmet usage~3. assessed for proper helmet usage after 3 months 4 evaluated for the behavioral of helmet usage after 3 months~do not receive any educational session or standard motorcycle child safety helmet"
62642240|NCT01618968|EXPERIMENTAL|10 mg Methotrexate (MTX)|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
62642241|NCT01618968|EXPERIMENTAL|15 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
62642242|NCT01618968|EXPERIMENTAL|20 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
62642243|NCT01618968|EXPERIMENTAL|25 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
62642244|NCT00828711|EXPERIMENTAL|MVI 100|MVI 100 mcg vaginal insert
62072896|NCT01354106|EXPERIMENTAL|3M Kind Removal Silicone Tape|"investigational medical Silicone tape, 1 x 1.5 sample, applied on time, worn for 24 hours."
62642245|NCT00828711|EXPERIMENTAL|MVI 150|MVI 150 mcg vaginal insert
62642246|NCT00828711|EXPERIMENTAL|MVI 200|MVI 200 mcg vaginal insert
62642247|NCT04264572|EXPERIMENTAL|Medically Tailored Meals (MTM)|Participants in this arm will receive MTM for 12 weeks. Meals will be prepared and delivered by MANNA, a non-profit organization that has provided MTM for patients with chronic illnesses in Philadelphia and Southern New Jersey since 1990. MANNA will deliver 21 complete meals to the patient's home each week, providing 45-60 grams of carbohydrates per meal for optimal glucose control based on ADA guidelines and 100% of overall nutritional requirements based on USDA guidelines. In addition, children and any senior dependents for whom the participant is the primary caregiver will receive meals for the entire 12 weeks for no additional cost, as this is standard of care of MANNA services. MANNA registered dieticians will cater the program to meet the specific needs (e.g., dietary restrictions, cultural preferences). Investigators will provide information on community resources in the area, including food resources, for all patients.
62277239|NCT06549257|EXPERIMENTAL|Group 2|Vaccination with three doses of Pfs48/45 10ug in 50ug Matrix M.
62642248|NCT04264572|EXPERIMENTAL|MTM + tele-Medical Nutrition Therapy (MNT)|Patients in this arm will receive MTM services as well as tele-MNT over 12 months. The tele-MNT intervention will be delivered by a registered dietician within the Jefferson endocrine clinic, with assistance by other endocrine dieticians and fellows. In the first months, video visits focus on supporting individuals who are not selecting, preparing or purchasing their own meals. As the end of MTM services approaches, the intervention shifts to focus on the transition from MTM to self-directed eating. Based on Academy of Nutrition and Dietetics recommendations, each participant's MNT will include the following core features: nutrition assessment, intervention, care coordination, monitoring and evaluation. The following will also be addressed: nutrition prescriptions, nutrient intake, energy intake, glycemic index and load, alcohol consumption and physical activity. The schedule includes individual visits in the first 6 months and monthly group session in months 7-12.
62072897|NCT01354106|OTHER|3M Micropore Medical Tape|"Commercially available Medical Paper Tape, 1 x 1.5 sample, applied on time, worn for 24 hours. Study Control."
62455513|NCT02230397|OTHER|placebo product|Volunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
62072898|NCT03559439|EXPERIMENTAL|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
62455514|NCT04714268||Procedures with EndoNaut|Endovascular interventions using the EndoNaut workstation. 3D image fusion is used for overlaying arterial information on top of fluoroscopic images
62455515|NCT04714268||Procedures without EndoNaut|Control group, endovascular interventions without 3D image fusion
62455516|NCT00520741|EXPERIMENTAL|Lacosamide 400 mg/day|Lacosamide 400 mg/day
62455517|NCT00520741|ACTIVE_COMPARATOR|Lacosamide 300 mg/day|Lacosamide 300 mg/day
62455518|NCT06076681|EXPERIMENTAL|Group A|TNP2198 capsules 200 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
62072899|NCT04522713|EXPERIMENTAL|Large-group transdiagnostic course|6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing
62072900|NCT00519896|EXPERIMENTAL|Treatment (enzyme inhibitor therapy, antiangiogenesis therapy)|Patients receive sunitinib malate PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
62072901|NCT03350113|EXPERIMENTAL|HemoSpec|Blood Sampling for analysis in the HemoSpec device
62072902|NCT00817804|EXPERIMENTAL|V60 then Conventional|Study device first
62455519|NCT06076681|EXPERIMENTAL|Group B|TNP2198 capsules 400 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
62072903|NCT00817804|EXPERIMENTAL|Conventional then V60|Conventional device first
62072904|NCT03263182||Nchelenge Facilities|Purposively selected health facilities based on criteria including: high demand for services, perceived need for support for quality improvement, and presence of a SBA to mentor.
62072905|NCT03603392|EXPERIMENTAL|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
62072906|NCT03918538|EXPERIMENTAL|The intervention group|"After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual.~The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers."
62277240|NCT06549257|EXPERIMENTAL|Group 3|Vaccination with three doses of Pfs25-IMX313 10ug in 50ug Matrix M and vaccination with three doses of Pfs48/45 10ug in 50ug Matrix M.
62277241|NCT00836433|ACTIVE_COMPARATOR|FALLS only|Traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
62455520|NCT06076681|EXPERIMENTAL|Group C|TNP2198 capsules 600 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
62455521|NCT06076681|EXPERIMENTAL|Group D|TNP2198 capsules 400 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID + amoxicillin capsules 1g BID
62455522|NCT02910609||Management at PN 3-7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
62455523|NCT02910609||Management after PN 7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
62455524|NCT05906810|EXPERIMENTAL|Peri-implantitis|Subjects diagnosed with peri-implantitis according to the most recent international guidelines and without cardiovascular diseases.
62642249|NCT04264572|NO_INTERVENTION|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with DM, which includes regular visits with a diabetes provider (primary care or endocrine), standard ADA information pamphlets and referral to 1) diabetes education classes and 2) nutrition counseling by dieticians and nurse practitioners. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and diabetes self-management (e.g., diabetes.org). The standard of care at Jefferson for patients with DM is to begin with a single group MNT visit lasting from 60-90 minutes. Each participant's need for additional sessions and general time-frame for follow-up is individually determined following the group session, based on patient preference. Historically, only about 2% of the Jefferson population engages in these services, thus minimizing dilution of the effect of the tele-MNT.
62642250|NCT03817606|EXPERIMENTAL|Tritanium Posterior Lumbar Cage|Surgical placement of the Tritanium Posterior Lumbar Cage
62642251|NCT03817606|ACTIVE_COMPARATOR|AVS PEEK UniLIF|Surgical placement of the AVS PEEK UniLIF Posterior Lumbar Cage
62642252|NCT05898035|EXPERIMENTAL|Piezo endodontic surgery|The osteotomy will be applied under magnification with a surgical operating microscope (at the apical third of the root .Osteotomy will be done with the Piezosurgery touch
62642253|NCT05898035|ACTIVE_COMPARATOR|Conventional endodontic surgery|The osteotomy will be applied under magnification with a surgical operating microscope at the apical third of the root .Osteotomy will be done with air motor high speed hand-piece and round bur with copious irrigation
62642254|NCT03961867|EXPERIMENTAL|DS|D2 resection -- S1 \* 1 cycle + DS \* 6 cycles + S1 \* 9 cycles
62642255|NCT03961867|ACTIVE_COMPARATOR|SOX|D2 resection -- SOX \* 8 cycles + S1 \* 8 cycles
62642256|NCT01856738|PLACEBO_COMPARATOR|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
62277242|NCT00836433|EXPERIMENTAL|CONNECT and FALLS|CONNECT educational intervention is designed to improve relationship-building and communication. The intervention includes 2 in-class session, group mapping exercise, individual relationship mapping exercises, Self-monitoring of interactions, individual staff coaching sessions. FALLS is a traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
62642257|NCT01856738|EXPERIMENTAL|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
62642258|NCT05015036||Minimally invasive surgery of the lumbar spine with ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
62642259|NCT05015036||Minimally invasive surgery of the lumbar spine|Minimally invasive surgery of the lumbar spine
62642260|NCT02630862|ACTIVE_COMPARATOR|aspirin|acetylsalcylic acid 100 mg per day give orally for six months, starting the day of carotid endoartherectomy
62642261|NCT02630862|ACTIVE_COMPARATOR|aspirin plus dipyridamole|acetylsalicylic acid 25 mg plus dipyridamole extended release 200 mg, combined in a capsule, per day starting the day of carotid endoartherectomy
62642262|NCT05294861|EXPERIMENTAL|YesMdiet|After one week baseline, the participants will be assigned to YesMdiet, consuming milk and dairy products for 14 days
62642263|NCT05294861|ACTIVE_COMPARATOR|NoMdiet|After one week baseline, the participants will be assigned to NoMdiet, consuming another source of protein and without milk or dairy products for 14 days
62642264|NCT03508778|EXPERIMENTAL|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
62642265|NCT03508778|ACTIVE_COMPARATOR|PanOptix|Commercially available trifocal IOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
62642266|NCT02097498|NO_INTERVENTION|Simulation only|One group will be randomized to receive simulation training similar to that required for certification. Paramedics in this group will then complete a second simulation scenario
62642267|NCT02097498|EXPERIMENTAL|Directed feedback|One group will review their baseline simulation scenario with a member of the research staff while providing specific feedback for errors made during the first simulation. Paramedics in this group will then complete a second simulation scenario.
62277243|NCT04870476|EXPERIMENTAL|"Internet-delivered treatment: One step at the time"|"Internet-delivered treatment: One step at the time. All participants receive the internet-delivered therapist-assisted 11-modules treatment program One step at the time."
62277244|NCT02559687|EXPERIMENTAL|Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62642268|NCT02097498|EXPERIMENTAL|Basic Videolaryngoscopy|One group will review a series of instructional videos related to common airway management errors. Paramedics in this group will then complete a second simulation scenario.
62642269|NCT03776448|EXPERIMENTAL|Sativa Nigra oil arm|A total of 15 subjects randomly allocated to the treatment arm will receive 2000mg a day of 'Sativa Nigra oil' softgels for 30 consecutive days. The total daily dose is divided in 4 doses taken 6 hourly (each softgel contains 500mg). This supplement is manufactured by \[Bioextract Ltd, Sri Lanka\] and is available commercially.
62072907|NCT03918538|NO_INTERVENTION|The control group|Participants in the control group received regular medication education.
62072908|NCT00841516|PLACEBO_COMPARATOR|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
62072909|NCT00841516|EXPERIMENTAL|80 µg rBet v1-FV Immunotherapy|All randomized patients were treated with either placebo or 80 µg rBet v1-FV (maintenance dose) for 2 years.
62072910|NCT04571463||HUCS A|Mothers visiting the prenatal care units within the Helsinki area.
62642270|NCT03776448|PLACEBO_COMPARATOR|The charcoal arm|Subject randomly allocated to the control arm will receive 1040mg a day of activated charcoal softgels for 30 consecutive days. The total daily dosage is divided in 4 doses taken 6 hourly (each softgel contains 260mg). This supplement is manufactured by \[Arkopharma Pharmaceutical Laboratories\] and is available commercially.
62072911|NCT04571463||HUCS HAL|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Helsinki area.
62072912|NCT04571463||PHHYKY A|Mothers visiting the prenatal care units within the Lahti area.
62072913|NCT04571463||PHHYKY HALSO|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Lahti area.
62072914|NCT05208385|OTHER|Standard umbilical trocar incision closure (UC)|standard umbilical trocar incision closure
62072915|NCT05208385|ACTIVE_COMPARATOR|Video-assisted umbilical trocar incision closure (UCVA))|video-assisted umbilical trocar incision closure
62072916|NCT00701337|EXPERIMENTAL|1 Oral|oestradiol by oral administration - Estrofem 2 mg
62072917|NCT00701337|EXPERIMENTAL|2 patch|oestradiol par patch - Estrapatch 60microg/24h
62072918|NCT03431090|EXPERIMENTAL|CliniMACS Isolation|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
62072919|NCT02349724|OTHER|Pancreatic cancer|Pancreatic cancer treated with Anti-CEA-CAR T.
62072920|NCT02349724|OTHER|Lung cancer|Lung cancer treated with T cells modified with Anti-CEA-CAR T.
62072921|NCT02349724|OTHER|Gastric cancer|Gastric cancer treated with T cells modified with Anti-CEA-CAR T.
62072922|NCT02349724|OTHER|Breast cancer|Breast cancer treated with T cells modified with Anti-CEA-CAR T.
62277245|NCT03512145|EXPERIMENTAL|VIPUN Balloon Catheter|Recording of gastric motility with the investigational medical device. Gastric emptying rate of a liquid meal is assessed with the 13C-octanoate breath test.
62277246|NCT03948178|EXPERIMENTAL|Levosimendan|Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.
62277247|NCT03515109|ACTIVE_COMPARATOR|group A|Altis tape surgical placement
62642271|NCT04892069||Ryzodeg®|Participants are patients with Type 2 Diabetes (T2D) treated with Ryzodeg® (Insulin Degludec/Insulin Aspart) in a real-world adult population in Lebanon
62642272|NCT00598728||1|Hodgkin lymphoma Survivors
62072923|NCT02349724|OTHER|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
62072924|NCT03304860|EXPERIMENTAL|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
62072925|NCT03459703|EXPERIMENTAL|Early Time-Restricted Feeding|
62072926|NCT03459703|ACTIVE_COMPARATOR|Control Schedule|
62072927|NCT02696330|ACTIVE_COMPARATOR|clopidogrel|50 patients undergoing ICSI
62072928|NCT02696330|ACTIVE_COMPARATOR|enoxaparin|50 patients undergoing ICSI
62072929|NCT02696330|PLACEBO_COMPARATOR|placebo|50 patients undergoing ICSI
62072930|NCT02105636|EXPERIMENTAL|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
62072931|NCT02105636|ACTIVE_COMPARATOR|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression~OR~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression~OR~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
62072932|NCT01473381|PLACEBO_COMPARATOR|Placebo|Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
62072933|NCT01473381|EXPERIMENTAL|Vilazodone 20 mg/day|Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
62072934|NCT01473381|EXPERIMENTAL|Vilazodone 40 mg/day|Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
62072935|NCT01473381|ACTIVE_COMPARATOR|Citalopram 40 mg/day|Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.
62072936|NCT00554333|EXPERIMENTAL|1|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
62072937|NCT00554333|ACTIVE_COMPARATOR|2|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
62277248|NCT03515109|PLACEBO_COMPARATOR|group B|TVT transobturator tape placement
62642273|NCT04849793|EXPERIMENTAL|Experimental|Before the intervention, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. After rubbing, each individual's pain threshold level will be taken as a basis in order not to cause tissue damage. The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes. In the study group, an average of 13 minutes will be applied to HT7, LI4 and EX-HN3 points (five points in total) for two minutes each. The nursing students participating in the research will be given a total of 12 acupressure intervention remotely, three days a week, for four weeks, at least two hours after dinner and when they are calmest.
62072938|NCT04813757|EXPERIMENTAL|intervention group|Participants in the intervention group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy. The exercise program will include 2 scapular and rotator cuff strengthening exercises emphasizing scapular upward rotation and posterior tilt and one additional flexibility exercise. These exercise will be repeated at home on the days in between the therapy sessions.
62455525|NCT05906810|ACTIVE_COMPARATOR|Peri-implant mucositis|Subjects diagnosed with peri-implant mucositis according to the most recent international guidelines and without cardiovascular diseases.
62455526|NCT05906810|NO_INTERVENTION|Healthy|Subjects without periodontitis and with good gingival health.
62455527|NCT00971893||Methylprednisolone Group|
62455528|NCT05197166||Nursing students|Nursing students exposed to standing environments (prolonged walking and prolonged standing) during acute clinical settings (e.g., hospitals).
62642274|NCT04849793|NO_INTERVENTION|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
62642275|NCT03638128|OTHER|Alternative Medications / Observational|"Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline.~Alternative osteoporosis medication(s) were determined at the investigator's discretion and per standard of care and local guidelines."
62642276|NCT03638128|EXPERIMENTAL|Denosumab 1 mg/kg Q6M|Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) by subcutaneous injection, but no Q3M denosumab during this study.
62455529|NCT01434836|ACTIVE_COMPARATOR|active tDCS and working memory training|
62642277|NCT03638128|EXPERIMENTAL|Denosumab 1 mg/kg Q3M|Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study.
62642278|NCT00524927|ACTIVE_COMPARATOR|A|
62642279|NCT00524927|PLACEBO_COMPARATOR|B|
62455530|NCT01434836|PLACEBO_COMPARATOR|sham tDCS and working memory training|
62455531|NCT01245166|ACTIVE_COMPARATOR|Acarbose|
62455532|NCT01245166|EXPERIMENTAL|Metformin/Acarbose|
62455533|NCT05389410|EXPERIMENTAL|Revision Hip surgery|Participants will be randomised to PICO 7 or PICO 14 intervention.
62455534|NCT05389410|ACTIVE_COMPARATOR|Revision knee surgery|Participants will be randomised to PICO 7 or PICO 14 intervention.
62455535|NCT05394168|EXPERIMENTAL|HLX53|an anti-TIGIT Fc fusion protein
62455536|NCT00861965|EXPERIMENTAL|Treatment|AlloStim-8
62455537|NCT02563756|EXPERIMENTAL|UKA, unicompartmental knee replacement|Procedure: Participants are operated with a mobile bearing medial unicompartmental knee arthroplasty (Oxford). They are followed with CT, functional tests and PROM, compared with those operated with TKA.
62455538|NCT02563756|EXPERIMENTAL|TKA, total knee replacement|Procedure: Participants are operated with a cruciate retaining conventional tricompartmental prosthesis (PFC). They are followed with CT, functional tests and PROM, compared with those operated with UKA.
62642280|NCT00308945|EXPERIMENTAL|2|cross-over comparison of two substances
62642281|NCT00308945|EXPERIMENTAL|1|
62277249|NCT04682405|EXPERIMENTAL|Uproleselan + Standard of Care Melphalan|"* On the evening of Day -3, patients will receive dose #1 of uproleselan~* On the following morning of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #2 of uproleselan~* On the evening of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #3 of uproleselan~* On Day -2 following completion of dose #3 of uproleselan, the patient will be administered the conditioning dose of melphalan (200mg/m\^2) as per institutional practice.~* On the following morning of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #4 of uproleselan~* On the evening of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #5 of uproleselan~* On the following morning of Day 0 (12 +/- 2 hours from prior dose) patients will receive dose #6 (final dose) of uproleselan~* On Day 0, 4 hours (+/- 2 hours) after the final dose of uproleselan, the patient will be infused with the HSC product. The patient will remain inpatient until engraftment"
62642282|NCT01959113|EXPERIMENTAL|Autologous Microbiome Transplant|Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
62642283|NCT01959113|PLACEBO_COMPARATOR|Placebo Arm|This arm will have a base moisturizer alone applied to it during the third visit.
62642284|NCT00967304|EXPERIMENTAL|1 Discontinue OAT or AAA|"Patients classified as being at low risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at low recurrence risk (\<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding."
62642285|NCT00967304|NO_INTERVENTION|2 Observation arm|"Men and patients classified as being at high risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding."
62277250|NCT04682405|PLACEBO_COMPARATOR|Placebo + Standard of Care Melphalan|"* On the evening of Day -3, patients will receive dose #1 of placebo~* On the following morning of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #2 of placebo On the evening of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #3 of placebo.~* On Day -2 following completion of dose #3 of placebo, the patient will be administered the conditioning dose of melphalan (200mg/m\^2) as per institutional practice.~* On the following morning of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #4 of placebo.~* On the evening of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #5 of placebo.~* On the following morning of Day 0 (12 +/- 2 hours from prior dose) patients will receive dose #6 (final dose) of placebo.~* On Day 0, 4 hours (+/- 2 hours) after the final dose of placebo, the patient will be infused with the HSC product. The patient will remain inpatient until engraftment"
62277251|NCT04264533|EXPERIMENTAL|VC|12g Vitamin C+sterile water for injection; total volume: 50ml. 12ml/h; infusion pump；q12h.
62277252|NCT04264533|PLACEBO_COMPARATOR|Sterile water for injection|50ml water for injection. 12ml/h; infusion pump; q12h.
62277253|NCT01667471|EXPERIMENTAL|RoActemra/Actemra|
62277254|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
62642286|NCT02344329|ACTIVE_COMPARATOR|Control|TCC-EZ and Standard Wound Care (Topical wound dressing) Two dressing and cast changes in week one followed by weekly applications until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
62642287|NCT02344329|EXPERIMENTAL|Intervention|TCC-EZ and Human Amnion Allograft One dressing and two cast changes in week one followed by dressing change every two to three weeks and weekly cast changes until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
62642288|NCT01307787|EXPERIMENTAL|fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
62642289|NCT01307787|OTHER|waiting list control group|The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.
62642290|NCT02324686|OTHER|Vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
62642291|NCT01980433|EXPERIMENTAL|Active rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
62642292|NCT01980433|SHAM_COMPARATOR|Sham rTMS|Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
62642293|NCT04835545|EXPERIMENTAL|Wet Perlite, 2L air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with 2L air pocket
62642294|NCT04835545|EXPERIMENTAL|Wet Perlite 2L air pocket with resistance compensation|Breathing in the simulated avalanche snow. Breathing into model of wet perlite 2L air pocket with resistance compensation
62642295|NCT04835545|EXPERIMENTAL|Wet Perlite, no air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with no air pocket
62642296|NCT04078464|EXPERIMENTAL|Acute Physical Activity + Mindfulness training|20 minutes of walking on a treadmill at a moderate pace while listening to a pre-recorded guided mindfulness meditation.
62642297|NCT04078464|EXPERIMENTAL|Mindfulness training|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 20 minutes.
62642298|NCT04078464|EXPERIMENTAL|Acute Physical Activity|20 minutes of walking on a treadmill at a moderate pace.
62642299|NCT04606693|NO_INTERVENTION|Patients with negative diagnosis of SAHS|Patients with low risk or negative diagnosis of SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit
62642300|NCT04606693|OTHER|Patients with positive diagnosis of SAHS|Patients with intermediate or high risk of SAHS and positive diagnosis
62642301|NCT04531865|EXPERIMENTAL|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
62277255|NCT01547325|EXPERIMENTAL|NanoDOX Hydrogel|
62277256|NCT01547325|PLACEBO_COMPARATOR|Placebo Hydrogel|
62277257|NCT01656863||Parents|Parents reporting to the emergency room with dehydrated children
62072939|NCT04813757|ACTIVE_COMPARATOR|control group|Participants in the control group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy, posterior shoulder stretching, and mobilization-with-movement into shoulder elevation. The exercise program will include 2 exercises focusing on scapular and rotator cuff strengthening without a special emphasis on scapular upward rotation as well as one additional flexibility exercise. These exercises will be performed at home on the days on between the therapy sessions.
62072940|NCT02629068|EXPERIMENTAL|PURPOSE|"Parents in the PURPOSE group will join a secret Facebook group for 2 months. Groups will be lead by 2 peer leaders and include 20 parent participants."
62072941|NCT02629068|NO_INTERVENTION|Treatment as Usual (TAU)|Treatment as Usual parents will be contacted after 8 weeks to complete follow-up interview. Will not receive PURPOSE intervention.
62277258|NCT02348515||Heart failure or coronary disease|This group will have small samples collected from the apex core (that would be routinely discarded at the time of the implantation procedure) by undergoing a left ventricular assist device implantation. In addition, a blood sample will be collected.
62277259|NCT02348515||Heart transplant patients|This group will have multiple samples collected including, excess myocardial biopsy samples that will not be utilized by pathology. In addition, a blood sample will be collected.
62277260|NCT02348515||Orthotopic Heart Transplant Patients|This group will have myocardial tissue samples collected from the diseased heart. In addition, a blood sample will be taken.
62642302|NCT04531865|PLACEBO_COMPARATOR|Rituximab Only|First course Course Rituximab at Randomization. Addition of Maintenance Placebo tablets matching Mycophenolate mofetil from 4 Month onwards.
62072942|NCT03022240|EXPERIMENTAL|Inhalational Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction. After inhalation induction of anesthesia with sevoflurane (in 100% O2), an IV will be obtained. Anesthesia will be maintained with sevoflurane (in a mixture of air:oxygen) with a minimum alveolar concentration of 1.0-1.3, titrated to effect. No long acting opioids or nitrous oxide will be used. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
62072943|NCT03022240|EXPERIMENTAL|Total Intravenous Anesthetic Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
62072944|NCT02274649|EXPERIMENTAL|Intervention|Intervention group receiving one-to-one peer mentoring
62277261|NCT02348515||Heart Surgery Patients|This groups will have samples collected from the left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. In addition, a blood sample will be taken.
62642303|NCT01179607|ACTIVE_COMPARATOR|M0002|"* Started at 0.3 mg/day and increased every 3 days (to 1, 3 and 6 mg/day)~* for hyponatraemic subjects: dose was increased until the evening serum level was between 132 mmol/l and 145 mmol/l;~* for normonatraemic subjects the dose was increased until a 500 ml increase in the 24-h urine volume compared with Day-1 was reached.~Once the required response or max dose was achieved, subjects entered a maintenance phase where they remained on the same dose of M0002 or placebo until 15 days."
62642304|NCT01179607|PLACEBO_COMPARATOR|Placebo|
62277262|NCT04490837||COVID-19 positive|Patients with clinical, radiological and/or PCR positive for COVID-19 infection
62277263|NCT04490837||Normal|Normal human serum from blood donnors before COVID-19 pandemia
62277264|NCT04490837||Pathological controls|Patients with other positive virological serologies
62642305|NCT01831869|ACTIVE_COMPARATOR|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
62642306|NCT01831869|NO_INTERVENTION|blank|no intervention
62642307|NCT02631447|EXPERIMENTAL|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
62072945|NCT02274649|ACTIVE_COMPARATOR|Control|Control group receiving general peer support
62072946|NCT05235763|PLACEBO_COMPARATOR|Control|A sham activity coach will be installed on the Optilogg system, slightly changing its appearance.
62642308|NCT02631447|EXPERIMENTAL|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
62072947|NCT05235763|EXPERIMENTAL|Intervention|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
62072948|NCT04282590|EXPERIMENTAL|Treatment Period 1: TRK-750, Treatment Period 2: placebo|
62072949|NCT04282590|EXPERIMENTAL|Treatment Period 1: placebo, Treatment Period 2: TRK-750|
62072950|NCT06305689|ACTIVE_COMPARATOR|Serial Casting|Repeated casts weekly until desired dorsiflexion range achieved
62072951|NCT06305689|ACTIVE_COMPARATOR|Surgery|Surgical procedure to the gastrocnemius and/or plantar fascia
62461712|NCT05060315||Transition Cohort|Patients who had been receiving SC treprostinil therapy via a previous generation infusion pump prior to transitioning to a next generation infusion pump.
62072952|NCT00661258|EXPERIMENTAL|Intervention|The intervention group patients were given their electronic drug monitoring feedback data at each monthly visit. The study coordinator would quickly calculate whether the patient's adherence was below 95% in the previous month. If so, that patient was flagged for enhanced counseling with a clinic doctor and this counseling was based on a printout containing the electronic drug monitoring data.
62072953|NCT00661258|NO_INTERVENTION|Comparison|"The comparison group patients were not given the data from the electronic data monitoring feedback data. Instead, they filled out a self report form that all patients fill out. If they indicated in this report that their adherence in the previous was less than 95%, then they were flagged for enhanced counseling with a doctor. This counseling was based on the patient's self report. Thus both groups received enhanced counseling if they indicated poor adherence, but only the intervention group were given their electronic data output."
62072954|NCT01790321|NO_INTERVENTION|Pump water|Untreated pump water (pump water recognised as improved water source by WHO)
62072955|NCT01790321|PLACEBO_COMPARATOR|Filtered water|Pump water purified by the LSF-filtering device
62072956|NCT01790321|EXPERIMENTAL|Zinc water|Pump water purified and zinc-fortified by the LSF-filtering device
62461713|NCT01959256|EXPERIMENTAL|Learning|Visual perceptual learning (VPL) group
62461714|NCT01959256|NO_INTERVENTION|Control|Control group
62461715|NCT04661397|EXPERIMENTAL|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide \[D/C/F/TAF\] as one fixed dose combination \[FDC\] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
62461716|NCT04661397|ACTIVE_COMPARATOR|Treatment B|Participants will receive Treatment B (a single dose of Darunavir \[DRV\], Emtricitabine/Tenofovir Alafenamide \[F/TAF\] and Cobicistat \[COBI\] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
62461717|NCT04545762|EXPERIMENTAL|Treatment Regimen|"Apheresis (1 day): Autologous lymphocytes/ mononuclear cell collection will be collected through standard apheresis procedures as per University of California, San Francisco (UCSF) institutional practices~CAR-T cell manufacturing (estimated \~13-14 days)~Lymphodepleting chemotherapy: 3 days of immunosuppressive chemotherapy. Cyclophosphamide given at a dose of 300 mg/m2/IV and fludarabine given at 30 mg/m2 /IV on days -5, -4, and -3.~CAR-T cell infusion (1 day): The infusion of CAR-T cells targeting CD19 will occur over 5-30 minutes."
62461718|NCT01112280|EXPERIMENTAL|cap-assisted chromoendoscopy|To the tip of the colonoscope, transparent cap is fitted and applied. In addition, panchromoendoscopy using indigocarmine solution is preformed in this group.
62461719|NCT01112280|NO_INTERVENTION|Standard colonoscopy|Neither transparent cap nor chromoendoscopy is applied in this group and standard colonoscopy is performed.
62461720|NCT04055337|EXPERIMENTAL|Flap Sliding|"noninvasive flap sliding technique for managing flap striae following laser in situ keratomileusis (LASIK)."
62461721|NCT02780570|ACTIVE_COMPARATOR|GBS patients|Small Volume Plasma Exchange
62461722|NCT02780570|NO_INTERVENTION|non-GBS|non-GBS patients with central venous catheter
62461723|NCT04185909|EXPERIMENTAL|All Subjects|Subjects will be treated with the Renuvion Dermal System.
62461724|NCT06404307|EXPERIMENTAL|Self-administration|Trained patients that will self-administer their antimicrobials in the outpatient setting
62461725|NCT04542603|EXPERIMENTAL|treatment naivete women with stage 1-4 newly diagnosed ovarian|
62642309|NCT02631447|EXPERIMENTAL|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
62642310|NCT00126594|EXPERIMENTAL|Sorafenib Tosylate|Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.
62642311|NCT00126594|EXPERIMENTAL|Sorafenib Tosylate, Recombinant interferon alfa-2b|Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
62072957|NCT01617005||Tocilizumab in Moderate to Severe Active RA|Moderate to severe active RA participants, receiving tocilizumab treatment according to effective official Summary of Product Characteristics (SPC), will be observed. The choice of therapy will be based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
62642312|NCT01842269|EXPERIMENTAL|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
62642313|NCT01842269|ACTIVE_COMPARATOR|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
62642314|NCT03909048|EXPERIMENTAL|Interactive Psycho-education|Interactive psycho-education using interactive dashboard.
62642315|NCT03909048|PLACEBO_COMPARATOR|Psycho-education|Non-interactive psycho-education not using interactive dashboard.
62642316|NCT01805895|EXPERIMENTAL|Minocycline|This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
62642317|NCT01805895|NO_INTERVENTION|Control|This arm will not receive any minocycline. This arm will receive standard of care treatment.
62642318|NCT03583957|EXPERIMENTAL|Entire Study|Each patient is eligible for all interventions in the study.
62642319|NCT01774591|ACTIVE_COMPARATOR|azilsartan medoximil.|Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
62072958|NCT03892369|EXPERIMENTAL|Alcohol|The participant receive 0.5 g ethanol per kg body weight over 10 minutes. Subsequently blood samples are taken frequently the next ten hours.
62072959|NCT04048759|OTHER|Remote Low|
62072960|NCT04048759|OTHER|Remote High|
62072961|NCT04048759|OTHER|Personal Coach|
62642320|NCT01774591|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
62642321|NCT03856697|EXPERIMENTAL|Abivertinib Maleate Capsules+ Placebo Gefitinib Tablets|Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Placebo Gefitinib Tablets (250 mg orally, once daily), in accordance with the randomization schedule.
62642322|NCT03856697|ACTIVE_COMPARATOR|Gefitinib Tablets+ Placebo Abivertinib Maleate Capsules|Placebo Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Gefitinib Tablets(250 mg orally, once daily), in accordance with the randomization schedule.
62642323|NCT03521557|EXPERIMENTAL|Gaze and Postural Stability|"The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
62642324|NCT03521557|ACTIVE_COMPARATOR|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength. The target duration of each in clinic visit will be 90 min (30 min of aerobic exercise, 30 min of lower extremity resistance exercises, and 30 min of rest interspersed throughout the exercise session.
62072962|NCT06479681|EXPERIMENTAL|Long-term peer recovery coaching intervention|bedside peer recovery coaching + 6-months long-term engagement
62072963|NCT06479681|ACTIVE_COMPARATOR|SBIRT Intervention|The control will receive a brief intervention, usual care (a referral list), contact information for the study team and hospital case management, and a follow-up contact at the end of the study period.
62072964|NCT03687450|EXPERIMENTAL|Intervention (Yoga) Arm|Received a weekly 60-minute yoga-based class over 6 weeks with direction for a 5-10 minute daily home practice.
62072965|NCT03687450|NO_INTERVENTION|No-treatment Control Arm|Waitlist control-- group received one session of yoga-based class at the completion of the study.
62072966|NCT04248465|EXPERIMENTAL|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
62072967|NCT04248465|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.
62277265|NCT01783678|EXPERIMENTAL|Genotype 2 treatment-naive|Treatment-naive (TN) participants with HIV-1 and genotype 2 HCV coinfection will receive sofosbuvir plus RBV for 12 weeks.
62277266|NCT01783678|EXPERIMENTAL|Genotype 2/3 treatment-experienced|Treatment-experienced (TE) participants with HIV-1 and genotype 2 or 3 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
62642325|NCT03509168|ACTIVE_COMPARATOR|Misoprostol Pfizer Brand arm|participants receive a single dose of 400mcg vaginal misoprostol preoperatively (60minutes before) during open myomectomy
62277267|NCT01783678|EXPERIMENTAL|Genotype 1/3/4 treatment-naive|Treatment naive (TN) participants with HIV-1 and genotype 1, 3, or 4 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
62642326|NCT03509168|OTHER|No misoprostol arm|standard of care
62642327|NCT05535608|EXPERIMENTAL|SRW Cel system|"Cel1, Cel2, Cel3~Patients will take all three supplements once daily. Patients will take 2 capsules of each supplement in the morning with food."
62642328|NCT03848559|EXPERIMENTAL|Airway device placement|airway device is placed during the dive
62642329|NCT01768780|EXPERIMENTAL|sensory nerve block level of spinal anesthesia|This test group and the control group. Because within the group in two ways to check the level after spinal anesthesia will be.
62642330|NCT05570552|EXPERIMENTAL|mHealth arm|mHealth arm will receive mobile phone based behavior change communication intervention to exclusively use clean fuel LPG for domestic cooking.
62642331|NCT05570552|NO_INTERVENTION|Control arm|Control arm will receive no mHealth based intervention.
62642332|NCT00169676||cohort|Registry and Database
62642333|NCT02778217|NO_INTERVENTION|Uninterrupted single embryo culture|The same single medium is used throughout the 5-6 days of culture with no replenishment on day 3.
62642334|NCT02778217|EXPERIMENTAL|Interrupted single medium culture|The single step medium is renewed on Day 3 of embryo culture.
62277268|NCT01571583|EXPERIMENTAL|Telaprevir+Peg-IFN-alfa-2a+Ribavirin|Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.
62642335|NCT02125890|EXPERIMENTAL|Tranexamic Acid|We will be administering Tranexamic Acid in patients with ruptured abdominal aortic aneurysms to determine if this has an effect on primary outcome measures as significant bleeding, blood transfusion requirements.
62642336|NCT01639352|EXPERIMENTAL|SOM230|60mg of SOM230 via injection intramuscularly every 28 days
62642337|NCT05316064|EXPERIMENTAL|probiotic 9 log CFU/day|Intervention consists of daily oral administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
62642338|NCT05316064|PLACEBO_COMPARATOR|placebo|placebo contains primarily carrier without probiotic and it is identical in taste and appearance and appear as light-yellow powder. It is also taken by the participants for 12 weeks.
62642339|NCT02187783|EXPERIMENTAL|LEE011|LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
62642340|NCT02142816|ACTIVE_COMPARATOR|Doppler|Fluid directed by oesophageal doppler
62277269|NCT06134154|PLACEBO_COMPARATOR|Air|
62461726|NCT02721264|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 5 month.
62461727|NCT02721264|ACTIVE_COMPARATOR|Standard Treatment Care|
62642341|NCT02142816|ACTIVE_COMPARATOR|PVI|Fluid therapy directed by Pleth Variability Index
62642342|NCT03893578|EXPERIMENTAL|Interventional Arm|Access, delivery, and retrieval of the Conveyor system with correct positioning of the valve delivery system to facilitate correct positioning of the implant at the mitral location in patients with a failing bioprosthetic valve.
62642343|NCT01030146|OTHER|NeilMed® Sinus Rinse™ System|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
62277270|NCT06134154|EXPERIMENTAL|Carbondioxide|
62277271|NCT01814163||Paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
62277272|NCT03434379|EXPERIMENTAL|Atezolizumab + Bevacizumab|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator
62461728|NCT06320977|NO_INTERVENTION|Control Condition|5-minute rest
62461729|NCT06320977|ACTIVE_COMPARATOR|Static Stretching of 30 seconds Condition|Static stretching of the gastrocnemius and tibialis anterior muscles for 30 seconds
62461730|NCT06320977|ACTIVE_COMPARATOR|Static Stretching of 90 seconds Condition|Static stretching of the gastrocnemius and tibialis anterior muscles for 90 seconds
62461731|NCT04343066|EXPERIMENTAL|External hex implant|External hexagone implant connection
62461732|NCT04343066|EXPERIMENTAL|Internal hex implant|Internal implant connection
62461733|NCT05416164|EXPERIMENTAL|Omission of radiotherapy|
62461734|NCT03318471|ACTIVE_COMPARATOR|Group M|received 50 mg/kg MgSo4 in 100 ml 0.9 NaCl 15 minutes prior to anesthesia induction over 15 minutes
62461735|NCT03318471|PLACEBO_COMPARATOR|Group S|received 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes.
62461736|NCT04190693|PLACEBO_COMPARATOR|Follow-up|No Investigational Medicinal Product (IMP) will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
62642344|NCT03159598|ACTIVE_COMPARATOR|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
62072968|NCT02591680|EXPERIMENTAL|Neuromuscular training|Neuromuscular, this arm will receive neuromuscular training and muscle strengthening.
62277273|NCT03434379|ACTIVE_COMPARATOR|Sorafenib|Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator
62455539|NCT04991779||The neonates with suspected seizures or high risk of seizures|The neonates with suspected seizures or high risk of seizures are monitored by continuous electroencephalogram (cEEG) at least 12 hours since admission. The cEEG will be interpreted by AI-assisted cEEG diagnostic tool at the end of cEEG monitoring. At the same time, the same cEEG will be manually reported according the reference standard.
62072969|NCT02591680|ACTIVE_COMPARATOR|Strength|Strength, this arm will receive only muscle strengthening.
62072970|NCT01539863|EXPERIMENTAL|Treatment at regular intervals|Participants will be scheduled to receive the intervention, maintenance care, i.e. care on a regular basis throughout the study period.Care may consist of manual treatment but also of e.g. advice concerning exercises, ergonomic adaptation and stress management
62455540|NCT05438797|EXPERIMENTAL|adoptive TIL-TCM transfer|TIL-TCM cells are isolated from the patients' Tumor tissue (or ascites) and peripheral blood obtained before standard chemotherapy and then cultured ex-vivo. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators.TIL-TCM cells are transfused to patients in a dosage escalated manner.The total dose was 1× 109-1 ×1010 cells.After cell infusion, IL-2 was administered at 720000 IU/kg (based on whole body weight) by intravenous (I.V.),every 8 hours for up to 4 days.
62455541|NCT05990478||Participants with Breast Cancer|Participants will have a diagnosis of breast cancer
62455542|NCT00747175|EXPERIMENTAL|1|3 (alt.4) gradually increasing repeated oral doses of AZD1656 given to 3 (alt.4) groups (6 on active and 2 on placebo in each group)
62455543|NCT00747175|EXPERIMENTAL|2|Oral dose of AZD1656 titrated during 3 days to a tolerable dose (15 on active and 5 on placebo)
62455544|NCT05975970|EXPERIMENTAL|MyoTrain AR System|Participants will undergo functional task training using the MyoTrain AR system, which includes the HoloLens 2 augmented reality head-mounted display, four HTC VIVE SteamVR kinematic trackers, eight surface EMG electrodes based on the Element hardware platform, and a desktop computer. Participants will be prompted to use a pattern recognition-based myoelectric controller to operate a virtual prosthesis and complete a simulation of the GaMA Cup Transfer Task.
62455545|NCT05975970|ACTIVE_COMPARATOR|Conventional Motor Imagery|Participants will be provided motor imagery exercises that involve brief attempts to move the missing limb in a similar manner to how they would control their pattern recognition system to strengthen their muscles. These exercises do not involve any real-time control feedback or functional assessment.
62455546|NCT04327258||All patients|Patients undergoing elective surgery with anesthesia
62455547|NCT03312257|EXPERIMENTAL|Multifocal D +2.50 add & 0.01% atropine|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power; the 0.01% atropine is a low-dose atropine."
62455548|NCT05300984|EXPERIMENTAL|Group 1|
62455549|NCT05300984|EXPERIMENTAL|Group 2|
62455550|NCT01638286||Eperisone|
62455551|NCT01638286||Aceclofenac|
62455552|NCT01638286||Eperisone hydrochloride, Aceclofenac|
62455553|NCT04099888|EXPERIMENTAL|PCI treatment in conjunction with Standard of Care (SoC)|Arm A: Fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by gemcitabine/cisplatin chemotherapy
62455554|NCT04099888|ACTIVE_COMPARATOR|Standard of Care (SoC)|Arm B: Gemcitabine/cisplatin chemotherapy
62455555|NCT00032162|EXPERIMENTAL|PLD|dose finding study of PLD in combination with Carboplatin
62455556|NCT05518435||Work package 1 (WP1) - survey|"WP1 aims to recruit a minimum of 252 survey respondents, providing a minimum of six responses for each of the 42 Integrated Care Systems (ICSs) in England. The aim will be to gather responses from as many respondents as possible, to provide as much information as possible on primary care provision across over \>1200 PCNs in England. This will provide the first national overview of prescribing practice and the availability of health care for young people with ADHD through primary care in England. The inclusion of three stakeholder groups (health professional, service users, and commissioners/providers) will ensure that the survey includes reports from a balance of perspectives and provide the opportunity to compare data between groups and locations.~The sampling frame for WP1 includes all stakeholders aged 16 or over with an interest in providing or receiving health care for young people with ADHD, as well as those involved in providing/commissioning local primary care provision."
62461737|NCT04190693|EXPERIMENTAL|IMCY_0098|No Investigational Medicinal Product (IMP) will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
62461738|NCT01941966|EXPERIMENTAL|Chemo-radiotherapy|Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy
62461739|NCT04456426||Patients treated with COVID-19|All populations of patients admitted with COVID-19 in healthcare institutions involved. No intervention but standard care designed by national guidelines will be provided.
62461740|NCT01698476|ACTIVE_COMPARATOR|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
62461741|NCT01698476|PLACEBO_COMPARATOR|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
62642345|NCT03159598|EXPERIMENTAL|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
62072971|NCT01539863|ACTIVE_COMPARATOR|Treatment as needed|Participants will receivethe intervention, i.e.care only when requested by them, i.e. when experiencing a relapse or deterioration
62277274|NCT01751971|ACTIVE_COMPARATOR|Inspired Oxygen First|Participants breathe air with additional inspired oxygen (40%) for 1 night during an overnight sleep study (15 L/min via venturi mask). 1 week later participants will crossover to Sham (sham comparator).
62277275|NCT01751971|SHAM_COMPARATOR|Sham First|Participants breathe air without additional inspired oxygen for 1 night during sleep (15 L/min via Venturi mask). 1 week later participants will crossover to Inspire Oxygen (active intervention).
62277276|NCT03376672|EXPERIMENTAL|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
62642346|NCT03159598|ACTIVE_COMPARATOR|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
62072972|NCT02245100||Predictive value of circulating DNA|Patients undergo blood sample collection within 1 month before surgery, radiation therapy, or chemotherapy; within 1 week after surgical resection (for patients having upfront surgery); within 1 month before beginning of post-operative radiation therapy (for patients having upfront surgery); during the second week of radiation therapy, during the last week of radiation therapy; and at 1 and 3 months after radiation therapy and then every 3 months for up to 18 months. Patients also undergo saliva sample collection within 1 month before surgery, radiation therapy, chemoradiation therapy, or system chemotherapy and tissue collection at the time of surgery (if upfront surgery is indicated). Blood, saliva, and tissue samples are analyzed for tumor mutations via next generation sequencing.
62277277|NCT03376672|EXPERIMENTAL|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
62277278|NCT03376672|EXPERIMENTAL|Standard and low risk maintenance arm|Lenalidomide
62277279|NCT01175044|ACTIVE_COMPARATOR|Betadine Lavage|dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000ml of sterile saline irrigation
62277280|NCT01175044|PLACEBO_COMPARATOR|Saline Lavage|2000 ml sterile saline lavage alone
62642347|NCT06028789||Study group|Patients undergoing elective thoracic aortic surgery.
62277281|NCT03002025|EXPERIMENTAL|Cohort 1: JNJ-64304500 50 milligram (mg) or placebo|Participants (Japanese) will receive single subcutaneous (SC) dose of JNJ-64304500 50 mg or placebo on Day 1.
62277282|NCT03002025|EXPERIMENTAL|Cohort 2: JNJ-64304500 150 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 150 mg or placebo on Day 1.
62277283|NCT03002025|EXPERIMENTAL|Cohort 3: JNJ-64304500 400 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 400 mg or placebo on Day 1.
62277284|NCT03002025|EXPERIMENTAL|Cohort 4: JNJ-64304500 150 mg or placebo|Participants (Caucasian) will receive single subcutaneous (SC) dose of JNJ-64304500 150 mg or placebo on Day 1.
62277285|NCT02254889|ACTIVE_COMPARATOR|pre-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) before ESD.
62277286|NCT02254889|PLACEBO_COMPARATOR|post-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) after ESD.
62277287|NCT01693315|EXPERIMENTAL|Cohort 1 - AMA0076 Dose A (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
62277288|NCT01693315|EXPERIMENTAL|Cohort 2: AMA0076 Dose B (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
62642348|NCT06028789||Control group|Patients admitted to our institution with active infectious endocarditis.
62642349|NCT01243918|EXPERIMENTAL|VNI/Optiflow, Immunodeficient patients|VNI = non invasive ventilation
62642350|NCT01243918|EXPERIMENTAL|Optiflow/VNI, Immunodeficient patients|VNI = non invasive ventilation
62642351|NCT01243918|EXPERIMENTAL|Ospal/Optiflow, Immunocompetent patients|
62642352|NCT01243918|EXPERIMENTAL|Optiflow/Ospal, Immunocompetent patients|
62277289|NCT01693315|EXPERIMENTAL|Cohort 3: AMA0076 Dose C (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
62277290|NCT01693315|EXPERIMENTAL|Cohort 4: AMA0076 Dose D (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
62072973|NCT03244241|ACTIVE_COMPARATOR|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
62072974|NCT03244241|NO_INTERVENTION|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
62072975|NCT05881135|EXPERIMENTAL|IV 1 mg/kg/day Citicoline|i.v. bolus of 10 ml normal saline containing citicoline 1 mg/kg, administered twice daily for 5 days.
62072976|NCT05881135|EXPERIMENTAL|IV 5 mg/kg/day Citicoline|i.v. bolus of 10 ml normal saline containing 5 mg/kg citicoline, administered twice daily for 5 days.
62072977|NCT05881135|EXPERIMENTAL|IV 10 mg/kg/day Citicoline|i.v. bolus of 10 ml normal saline containing 10 mg/kg citicoline, administered twice daily for 5 days.
62072978|NCT05881135|PLACEBO_COMPARATOR|IV 10 ml normal saline|i.v. bolus of 10 ml normal saline (without active ingredient) administered i.v., twice daily for 5 days.
62072979|NCT01643746|ACTIVE_COMPARATOR|Supera stent|The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
62072980|NCT01643746|ACTIVE_COMPARATOR|LifeStent|LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.
62072981|NCT00798486|OTHER|Subjects with and without Diabetes|Subjects participating in this study included 93 who had diabetes and 17 who did not have diabetes.
62277291|NCT05632679|EXPERIMENTAL|personalized music intervention|
62277292|NCT05632679|ACTIVE_COMPARATOR|selected audio book|
62277293|NCT05632679|NO_INTERVENTION|standard care|
62277294|NCT04536597|EXPERIMENTAL|Quince seed jelly group|
62461742|NCT02932696|EXPERIMENTAL|Exercise training|"Patients in this arm were encouraged to participate in an exercise training program, and they accepted to do so.~Intervention: Cardiac training program"
62072982|NCT05913856|EXPERIMENTAL|Chlorhexidine group|Applying 0.12% chlorhexidine mouthwash for oral care thrice daily.
62072983|NCT05913856|ACTIVE_COMPARATOR|Normal saline group|Applying normal saline for oral care thrice daily.
62072984|NCT02770092|EXPERIMENTAL|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
62072985|NCT02770092|EXPERIMENTAL|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
62072986|NCT02770092|EXPERIMENTAL|Congestive Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
62277295|NCT04536597|EXPERIMENTAL|Breast milk group|
62277296|NCT04536597|OTHER|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
62277297|NCT04995146||Retrospective 3 months cohort (admitted stroke patients)|
62277298|NCT04995146||"Prospective pre-implementation standard of core care quality measures cohort"|
62277299|NCT04995146||"Prospective post-implementation standard of core care quality measures cohort"|
62277300|NCT04067947|EXPERIMENTAL|XG005|XG005 in 4 dose levels
62277301|NCT04067947|PLACEBO_COMPARATOR|Placebo|Placebo in all cohort
62277302|NCT03843476||Surgical with Rod|The patient is being treated with the patient specific rod with a surgery date planned
62277303|NCT04547595|NO_INTERVENTION|CONTROL|Standard care
62277304|NCT04547595|ACTIVE_COMPARATOR|Hypnosis|Standard care + intervention
62277305|NCT05792735|EXPERIMENTAL|Cadonilimab group|Cadonilimab is administrated with 6mg/kg and repeated every 2 weeks.
62277306|NCT02403609|EXPERIMENTAL|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) on two consecutive days
62642353|NCT05511857|EXPERIMENTAL|The effect of a self-distanced view on pain perception.|The participant will exert self-distanced, third-person self-talk following a cue-card while induced with experimental pain.
62072987|NCT03662997|ACTIVE_COMPARATOR|Five-layer vs Hydropolymer|Bordered Five-layer Foam Dressing for 2 weeks, followed by Hydropolymer Foam Dressing for 2 weeks.
62072988|NCT03662997|ACTIVE_COMPARATOR|Hydropolymer vs Five-layer|Hydropolymer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
62072989|NCT03662997|ACTIVE_COMPARATOR|Five-layer vs Hydrocellular|Bordered Five-layer Foam Dressing for 2 weeks, followed by Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks.
62277307|NCT01534676|ACTIVE_COMPARATOR|Transfusion of Fresh blood|The recipient will receive one or two units of fresh blood \<14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
62277308|NCT01534676|EXPERIMENTAL|Transfusion of Stored blood|The recipient will receive one or two units of old blood \>28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
62277309|NCT01534676|ACTIVE_COMPARATOR|Transfusion of Cryopreserved Blood|The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
62277310|NCT01534676|ACTIVE_COMPARATOR|Transfusion of Washed Blood|The recipient will receive one or two units of washed (fresh/old) stored blood \>28 days old, as per their chronic transfusion schedule - off chelation therapy.
62277311|NCT00615615|EXPERIMENTAL|Levetiracetam (LEV)|LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
62072990|NCT03662997|ACTIVE_COMPARATOR|Hydrocellular vs Five-layer|Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
62072991|NCT05878223|EXPERIMENTAL|ESWT to gastrocnemius and soleus|ESWT to gastrocnemius and soleus muscles (2000 shots for each muscle, a total of 4000 shots per session)
62277312|NCT00615615|PLACEBO_COMPARATOR|Placebo|Subjects received Placebo matching to LEV treatment.
62277313|NCT03936374|EXPERIMENTAL|BMS-986205 + Omeprazole|
62277314|NCT01920711|EXPERIMENTAL|LCZ696|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
62277315|NCT01920711|ACTIVE_COMPARATOR|Valsartan|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
62277316|NCT01707407|EXPERIMENTAL|Pomalidomide|
62461743|NCT02932696|NO_INTERVENTION|No exercise training|Patients in this arm were encouraged to participate in an exercise training program, and they refused to do so.
62461744|NCT01246830||3D cephalometric analysis|
62072992|NCT05878223|ACTIVE_COMPARATOR|ESWT to gastrocnemius|ESWT to gastrocnemius muscle (2000 shots per session)
62072993|NCT01184001|EXPERIMENTAL|Sequence 1|
62072994|NCT01184001|EXPERIMENTAL|Sequence 2|
62072995|NCT02600858|EXPERIMENTAL|"Training off medication"|"Participants will train on the upper limb feeding task before taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while off dopamine replacement medication"
62072996|NCT02600858|OTHER|"Training on medication"|"Participants will train on the upper limb feeding task after taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while on dopamine replacement medication"
62072997|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Low Dose Intramuscular|Low Dose SC-Ad6-1, I.M., single-dose (Day 1)
62072998|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Medium Dose Intramuscular|Medium Dose SC-Ad6-1, I.M., single-dose (Day 1)
62277317|NCT01707407|EXPERIMENTAL|Pomalidomide plus Ketoconazole|
62277318|NCT01707407|EXPERIMENTAL|Pomalidomide plus Ketoconazole plus Fluvoxamine|
62277319|NCT01707407|EXPERIMENTAL|Pomalidomide plus Carbamazepine|
62461745|NCT01246830||2D cephalometric analysis|
62072999|NCT04839042|EXPERIMENTAL|SC-Ad6-1 High Dose #1 Intramuscular|High Dose #1 SC-Ad6-1, I.M., single-dose (Day 1)
62642354|NCT05511857|EXPERIMENTAL|The effect of a self-immersed view on pain perception.|The participant will exert self-immersed, first-person self-talk following a cue-card while induced with experimental pain.
62642355|NCT05511857|EXPERIMENTAL|The effect of non-view, self-talk on pain perception.|The participant will exert self-talk following a cue-card while induced with experimental pain.
62642356|NCT05511857|NO_INTERVENTION|Pain perception in induced, experimental pain.|Control group. This group will be induced with experimental pain, but will receive no specific task to exert.
62642357|NCT03318263|OTHER|experimental|
62073000|NCT04839042|EXPERIMENTAL|SC-Ad6-1 High Dose #2 Intramuscular|High Dose #2 SC-Ad6-1, I.M., single-dose (Day 1)
62073001|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Multiple Dose Intramuscular|Multiple Dose SC-Ad6-1, I.M., multiple-dose (Day 1 and Day 22)
62073002|NCT04839042|EXPERIMENTAL|SC-Ad6-1 High Dose #3 Intramuscular Booster|High Dose #3 SC-Ad6-1, I.M., single-dose booster (Day 1)
62073003|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Low Dose Intranasal|Low Dose SC-Ad6-1, I.N., single-dose (Day 1)
62073004|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Medium Dose Intranasal|Medium Dose SC-Ad6-1, I.N., single-dose (Day 1)
62073005|NCT04839042|EXPERIMENTAL|SC-Ad6-1 High Dose #1 Intranasal|High Dose #1 SC-Ad6-1, I.N., single-dose (Day 1)
62073006|NCT04839042|EXPERIMENTAL|SC-Ad6-1 High Dose #2 Intranasal|High Dose #2 SC-Ad6-1, I.N., single-dose (Day 1)
62642358|NCT02783170|OTHER|Simultaneous vaccination arm|In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
62642359|NCT02783170|OTHER|Sequential vaccination arm|In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
62642360|NCT04935203|NO_INTERVENTION|Control message group|Participants will not receive the priming manipulation.
62642361|NCT04935203|EXPERIMENTAL|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
62642362|NCT04935203|EXPERIMENTAL|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
62642363|NCT04935203|EXPERIMENTAL|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
62642364|NCT02179125|EXPERIMENTAL|Bronchoscopic LVR-coil treatment|Bronchoscopic lung volume reduction with coil treatment
62642365|NCT04670536||PASS LP implants|Patient suffering from a spinal degenerative disease and who is operated with PASS LP
62642366|NCT04670536||PASS Degen implants|Patient suffering from a spinal degenerative disease and who is operated with PASS DEGEN
62642367|NCT04670536||PASS Tulip PRIME implants|Patient suffering from a spinal degenerative disease and who is operated with PASS TULIP PRIME
62642368|NCT05337761|EXPERIMENTAL|Intervention|The peers will be trained to train their colleagues (fellow boaters) on proper lifejacket use. A training manual has been developed for this.
62642369|NCT05337761|PLACEBO_COMPARATOR|Control|The Marine Police will be encouraged to continue conducting their community policing on water safety and emphasize lifejacket wear.
62642370|NCT02624999|EXPERIMENTAL|Immunotherapy|Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
62461746|NCT01469767|EXPERIMENTAL|Fluocinonide cream|Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.
62642371|NCT02624999|ACTIVE_COMPARATOR|Standard chemotherapy|Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
62642372|NCT02358057|EXPERIMENTAL|Dexmedetomidine and Alfentanil|"Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.~At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.~Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.~Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine~Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.~A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN \> 50.~The maximum dose of alfentanil the patient can receive is 5 mcg / kg."
62642373|NCT02773498|ACTIVE_COMPARATOR|conventional TESE|Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
62642374|NCT02773498|EXPERIMENTAL|micro TESE|Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis
62642375|NCT01255215|EXPERIMENTAL|Inhaled Nitric Oxide|iNO, a gaseous molecule, will be administered by inhalational route over a maximum period of 72 hours.
62642376|NCT01255215|PLACEBO_COMPARATOR|Room air|Room air will be delivered by air compressor through an indistinguishable mask system.
62642377|NCT05570448|ACTIVE_COMPARATOR|Anti-reflux mucosal ablation (ARAT)|ablation in the gastric cardia using hybrid argon plasma coagulation
62642378|NCT05570448|SHAM_COMPARATOR|No treatment|no ablation
62642379|NCT00860275|ACTIVE_COMPARATOR|BMS-708163 / Ketoconazole|
62642380|NCT00860275|ACTIVE_COMPARATOR|BMS-708163 / Fluconazole|
62642381|NCT00528424|EXPERIMENTAL|AA4500 0.58 mg|
62642382|NCT03385213||Relapse|Patients who suffered colorectal cancer relapse after curative surgery
62642383|NCT03385213||Remission|Patients who get remission after curative surgery
62642384|NCT02935556||post partum pre-eclampsia|women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
62461747|NCT04626856|EXPERIMENTAL|Low dosage in adults|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
62642385|NCT02935556||controls|women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.
62642386|NCT00004244|EXPERIMENTAL|Arm I|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
62642387|NCT00004244|EXPERIMENTAL|Arm II|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
62642388|NCT00004244|EXPERIMENTAL|Arm III|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above."
62642389|NCT03472638|EXPERIMENTAL|Active -> Sham|15 days of active, followed by 15 days of sham rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
62642390|NCT03472638|EXPERIMENTAL|Sham -> Active|15 days of sham, followed by 15 days of active rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
62642391|NCT03594929|ACTIVE_COMPARATOR|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
62277320|NCT03721926|EXPERIMENTAL|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
62073007|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Multiple Dose Intranasal|Multiple Dose SC-Ad6-1, I.N., multiple-dose (Day 1 and Day 22)
62073008|NCT04839042|EXPERIMENTAL|SC-Ad6-1 High Dose #3 Intranasal Booster|High Dose #3 SC-Ad6-1, I.N., single-dose booster (Day 1)
62073009|NCT04839042|EXPERIMENTAL|SC-Ad6-1 High Dose #4 Intranasal Booster|High Dose #4 SC-Ad6-1, I.N., single-dose booster (Day 1)
62073010|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Low Dose Inhaled|Low Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
62073011|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Medium Dose Inhaled|Medium Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
62642392|NCT03594929|SHAM_COMPARATOR|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
62642393|NCT00103454|EXPERIMENTAL|Arm 1|
62642394|NCT01682980|EXPERIMENTAL|Strength training|The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
62642395|NCT01682980|EXPERIMENTAL|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 75% of maximal heart rate (calculated with formula for maximal heart rate reserve).
62073012|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Multiple High Dose Intranasal|Multiple High Dose SC-Ad6-1, I.N., multiple-dose (Day 1 and Day 29)
62073013|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Multiple High Dose Inhaled|Multiple High Dose SC-Ad6-1, I.H., multiple-dose (Day 1 and Day 29)
62073014|NCT04839042|EXPERIMENTAL|SC-Ad6-1 Multiple High Dose #2 Intranasal or Inhaled|Multiple High Dose #2 SC-Ad6-1, I.N. or I.H., multiple-dose (Day 1 and Day 29)
62073015|NCT05815732|EXPERIMENTAL|Physical exercise prescription|Prescription of a personalized exercise program, which will define modalities, intensity, duration, frequency and progression of the exercise. For each subject, at baseline and after 6 months, biological samples will be collected (blood, urine, saliva and nasal swab)
62073016|NCT02918929|EXPERIMENTAL|EDP 305 SAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
62073017|NCT02918929|EXPERIMENTAL|EDP 305 MAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days
62073018|NCT02918929|PLACEBO_COMPARATOR|EDP 305 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
62073019|NCT02918929|PLACEBO_COMPARATOR|EDP 305 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 14 days
62277321|NCT03721926|ACTIVE_COMPARATOR|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
62642396|NCT01682980|NO_INTERVENTION|Control group|The control group will do as usual.
62277322|NCT00430170|ACTIVE_COMPARATOR|1|dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg
62642397|NCT02938364|EXPERIMENTAL|Earplugs|The participant will be asked to put plastic earplugs in both ears for 10 minutes and then the impression will be made while they are still on.
62642398|NCT02938364|EXPERIMENTAL|Acupressure|The participant will be asked to wear sea bands on P6 points of both hand wrists for 10 minutes and then the impression will be made while they are still on.
62642399|NCT02938364|PLACEBO_COMPARATOR|Placebo|The participant will be asked to wear non pressure bands on both hand wrists for 10 minutes and then the impression will be made while they are still on.
62642400|NCT00802711|EXPERIMENTAL|Arm I|Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
62642401|NCT00802711|EXPERIMENTAL|Arm II|Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
62642402|NCT03735615|EXPERIMENTAL|chronic obstructive lung disease|
62073020|NCT01117753|EXPERIMENTAL|OPT-A|OPT-A is an outpatient family-based treatment for co-occurring substance use and internalizing disorders
62073021|NCT01117753|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual in a community based mental health center
62073022|NCT06345937|EXPERIMENTAL|Guidelines-based physical activity|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening
62277323|NCT00430170|PLACEBO_COMPARATOR|2|dipyridamol during 7 days and before ischemic exercise placebo
62277324|NCT04522674|EXPERIMENTAL|Autologous platelet rich plasma|0.5 mL of activated autologous PRP will be injected by fluoroscopic guidance into the affected lumbar facet joint (s) depending on the number of affected levels. A max of 4 joints will be injected per patient.
62277325|NCT00539695|EXPERIMENTAL|IL2 Administration|"SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.~Time will be measured as 'week beginning with first IL-2 injection.'~T cell Induction via IL-2 to reduce GVHD"
62277326|NCT04855994|ACTIVE_COMPARATOR|paravertebral group|The investigators performed Paravertebral block to that patient group for postoperative analgesia
62277327|NCT04855994|ACTIVE_COMPARATOR|pectoral group|The investigators performed pectoral block to that patient group for postoperative analgesia
62642403|NCT03735615|EXPERIMENTAL|healthy control|
62642404|NCT05471011||civilian|
62073023|NCT06345937|EXPERIMENTAL|Guidelines-based physical activity and healthy eating|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide
62073024|NCT06345937|PLACEBO_COMPARATOR|Stretching exercise|Whole-body stretching
62073025|NCT02011256|EXPERIMENTAL|Implantable loop-recorder|
62277328|NCT04282772||Ectopic Eruption|The ectopic eruption of PFMs were classified in two ways: impacted and self-corrected.
62277329|NCT03573453|EXPERIMENTAL|Intermittent|enteral nutrition will be administered via enteral feeding pump as 30-60minutes lasting bolus 6 times per day volume of initial bolus will be 80ml. The volume of bolus will be increased gradually according to tolerance, till the estimated target rate will be reached
62277330|NCT03573453|EXPERIMENTAL|Continuous|enteral nutrition will be administered via enteral feeding pump for at least 16 hours par day initial rate will be 25ml/hour. The rate will be increased gradually according to tolerance, till the estimated target rate will be reached
62277331|NCT03638505||patients|patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
62642405|NCT05471011||Veteran|
62642406|NCT06454474|EXPERIMENTAL|Closed-loop tACS stimulation based on addiction-induced states|In the initial phase of this study, participants will be subjected to individual closed-loop tACS interventions for ten-days intervals. Concurrently, they will be exposed to MA-related cue paradigms to induce brain addiction states, while scalp EEG signals are collected. Stimulation will be initiated only upon identifying specific neural signals associated with MA cues.
62642407|NCT02456727|ACTIVE_COMPARATOR|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
62642408|NCT02456727|ACTIVE_COMPARATOR|Group/Community Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
62642409|NCT02533700|EXPERIMENTAL|CEOP/IVE/GDP chemotherapy regimen|2 cycles of CEOP(cyclophosphamide,vincristine, epirubucin and prednisone),2 cycles of IVE(ifosfamide, epirubucin, etoposide)and 2 cycles of GDP(gemcitabine, cis-platinum, and dexamethasone)
62277332|NCT03638505||caregiver|the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
62277333|NCT00931489|ACTIVE_COMPARATOR|Wet AMD Patients Responders|Dilated eye exam once a month for 7 months; visual acuity and OCT once a month for 7 months; Lucentis(R)/ranibizumab injection once each month for the Baseline and Month 1-3 visits, then as needed at Month 4 and 5; 3 Tbls. blood draw at Baseline, Month 3 and Month 6 visits.
62277334|NCT00931489|NO_INTERVENTION|Normal Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
62277335|NCT00931489|ACTIVE_COMPARATOR|Wet AMD Patients Acute Non-responders|Participants in this Group will have not responded to 4 prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. Dilated eye exam at Month 4; visual acuity and OCT at Months 4-6; injection of anti-VEGF treatment as needed at Months 4 and 5; 3 Tbls. blood draw at Month 4
62277336|NCT00931489|NO_INTERVENTION|Dry AMD Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
62642410|NCT02533700|ACTIVE_COMPARATOR|CEOP chemotherapy regimen for 6 cycles|6 cycles of CEOP regimen(cyclophosphamide,vincristin,epirubucin and prednisone)
62642411|NCT04872088|NO_INTERVENTION|Control|The control group will receive preventive (BCC on child health and nutrition) and screening services from existing unsupervised Nutrition Activity Support Groups (NASGs) without additional support from the IRAM project. Children with wasting are eligible to be enrolled in the existing national Community Management of Acute Malnutrition (CMAM) program.
62277337|NCT00931489|ACTIVE_COMPARATOR|Wet AMD Patients Chronic Non-responderes|Participants in this Group will have not responded to 4 or more prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. One visit at Month 4: Dilated eye exam with visual acuity and OCT; injection of anti-VEGF as needed; 3 Tbls. blood drawn
62277338|NCT01570673|EXPERIMENTAL|Group Urotherapy|Children in this arm wil receive group urotherapy in small groups with other children.
62277339|NCT01570673|ACTIVE_COMPARATOR|Individual urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
62277340|NCT01211379|NO_INTERVENTION|FLU-Only Arm|In this arm, primary care patients who got flu shots were only provided with FOBT if the doctor decided to order it.
62277341|NCT01211379|EXPERIMENTAL|FLU-FOBT Arm|In this arm, patients who came in for primary care got a flu shot and were assessed by nurses for eligibility for colorectal cancer screening. Eligible patients were provided with home FOBT.
62277342|NCT04703894|EXPERIMENTAL|AYMES 'CARDIFF'|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'CARDIFF' for a period of 30 days.
62277343|NCT06057363||patients requiring vestibular soft tissue augmentation at implant sites|The present study was planned as prospective analysis with 12-month follow-up. It enrolled 12 partially edentulous patients (mean age 62; range 42-86) requiring vestibular soft tissue augmentation at implant sites in second-stage surgery because of mild horizontal ridge deficiency. As a whole, 16 implants were placed (8 single, 4 dual).
62277344|NCT03840538|EXPERIMENTAL|Probiotic group|Probiotic complex capsule taken twice daily for 5weeks
62642412|NCT04872088|EXPERIMENTAL|Intervention|"The intervention group will receive the integrated package of interventions that will be delivered by the NASGs.~The NASG platform will be strengthened by the IRAM project by increasing their number proportional to the size of the population of the catchment area they serve and by regular formative supervision by NGO and health center staff.~The package of interventions includes:~* Social and Behavioral Change Communication by NASGs during home visits and group sessions~* Monthly delivery of preventive SQ-LNS to children 6-17 months of age~* Screening and referral of children 6-59 months of age through the introduction of the MUAC family approach (distribution MUAC tapes to families and offering formative supervision by NASGs to enhance measurement quality)~* Cooking demonstrations for complementary foods using nutrientdense foods in the community."
62642413|NCT03080935|EXPERIMENTAL|Evolocumab|Single arm study administering Evolocumab.
62277345|NCT03840538|PLACEBO_COMPARATOR|Placebo group|Placebo capsule taken twice daily for 5 weeks
62277346|NCT01976923|ACTIVE_COMPARATOR|Study arm|Intravitreal bevacizumab Small-gauge pars plana vitrectomy
62277347|NCT01976923|SHAM_COMPARATOR|Control arm|Small-gauge pars plana vitrectomy
62277348|NCT02863809|EXPERIMENTAL|Active Treatment Arm|De-epithelialized corneas cross-linked with riboflavin 0.1% and dextran 20% solution AND ultraviolet A light (UVA Light Source).
62277349|NCT02863809|ACTIVE_COMPARATOR|Control Treatment Arm|De-epithelialized corneas will be exposed to only riboflavin 0.1% with dextran 20% solution (NO ultraviolet A light).
62642414|NCT04514900|ACTIVE_COMPARATOR|Video Chat +Personalized Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
62642415|NCT04514900|ACTIVE_COMPARATOR|Video Chat + Basic Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive basic feedback weekly on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
62277350|NCT03944239|EXPERIMENTAL|retinal pigment epitheliums transplantation|Transplant clinical-grade hESC derived retinal pigment epitheliums into subretinal of patients with retinitis pigmentosa.The dosage is 150000.
62277351|NCT01396343||Pediatric MS Case|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
62642416|NCT04514900|ACTIVE_COMPARATOR|Discussion Board for Social Support + Basic Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly basic feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
62642417|NCT04514900|ACTIVE_COMPARATOR|Discussion Board for Social Support+Personalized Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring from a trained interventionist. Participants will be asked to weigh daily on a digital scale, which will be provided.
62642418|NCT03846934||Ultrasonography thoracic|Ultrasonography thoracic
62642419|NCT01122498|EXPERIMENTAL|1|
62277352|NCT01396343||Pediatric Control|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
62642420|NCT01122498|EXPERIMENTAL|2|
62642421|NCT01122498|EXPERIMENTAL|3|
62642422|NCT05465902|EXPERIMENTAL|Inactivated COVID-19 vaccines cohort group 1|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
62642423|NCT05465902|ACTIVE_COMPARATOR|Inactivated COVID-19 vaccines cohort group 2|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
62277353|NCT05789017|EXPERIMENTAL|Group I|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months. Afterwards, patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.
62277354|NCT05789017|EXPERIMENTAL|Group II|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months. Afterwards, patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.
62277355|NCT00929071|EXPERIMENTAL|Pain assessment for Evolence/topical anesthetic|Assess injection pain severity for a one time 1.0 mL injection of Evolence with 0.2 ml of topical anesthetic, applied 30 minutes prior to injection, to the left nasolabial fold of each participant .
62277356|NCT00929071|EXPERIMENTAL|Pain assessment for Evolence/Lidocaine|Assess injection pain severity for a one time 1.0 mL injection of Evolence mixed with 0.18 mL of 2% lidocaine (0.3% final lidocaine-HCl) in the right nasolabial fold of each participant.
62642424|NCT05465902|EXPERIMENTAL|mRNA COVID-19 vaccines cohort group 1|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
62642425|NCT05465902|ACTIVE_COMPARATOR|mRNA COVID-19 vaccines cohort group 2|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: mRNA COVID-19 vaccine (Moderna)
62277357|NCT01531114|ACTIVE_COMPARATOR|Prasugrel loading dose|Patients will be randomized to this arm to receive loading dose of prasugrel
62277358|NCT01531114|NO_INTERVENTION|ticagrelor loading dose|Patients will be randomized to this arm to receive loading dose of ticagrelor
62277359|NCT00157612|OTHER|Intervention|use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, re-hydration and close monitoring by a research nurse
62277360|NCT00157612|NO_INTERVENTION|Comparator|usual care
62277361|NCT04991766|EXPERIMENTAL|[¹⁴C]-LY3484356 (Part 1)|Single dose of \[¹⁴C\]-LY3484356 administered orally.
62642426|NCT05465902|EXPERIMENTAL|Viral Vector COVID-19 vaccines cohort group 1|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
62642427|NCT05465902|ACTIVE_COMPARATOR|Viral Vector COVID-19 vaccines cohort group 2|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Viral Vector COVID-19 vaccine (AstraZeneca)
62642428|NCT02112942|EXPERIMENTAL|Group A|Healthy subjects, sequential dose escalation, IDX21459 capsules or Matching Placebo capsules, once daily, up to 7 days
62642429|NCT02112942|EXPERIMENTAL|Group B|HCV subjects genotype 1, IDX21459 capsules, once for 1 day
62642430|NCT02112942|EXPERIMENTAL|Group C|HCV subjects genotype 1, IDX21459 capsules or Matching Placebo capsules, once daily, for 7 days
62642431|NCT03552991|OTHER|Agio arm|It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.
62642432|NCT01463995||severe neurological diseases|Patients with severe neurological diseases treated on the neurological intensive care unit
62642433|NCT00671788|EXPERIMENTAL|Treatment (dasatinib)|Patients receive oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62642434|NCT05508373|EXPERIMENTAL|Dose Escalation: dose level：0.3mg/kg|Dose Escalation: 0.3mg/kg, IV infusion, every 3 weeks (q3w).
62642435|NCT05508373|EXPERIMENTAL|Dose Escalation: dose level：1 mg/kg|Dose Escalation: 1 mg/kg IV infusion, every 3 weeks (q3w).
62642436|NCT05508373|EXPERIMENTAL|Dose Escalation: dose level：3 mg/kg|Dose Escalation: 3 mg/kg IV infusion, every 3 weeks (q3w).
62642437|NCT05508373|EXPERIMENTAL|Dose Escalation: dose level：10 mg/kg|Dose Escalation: 10 mg/kg IV infusion, every 3 weeks (q3w).
62642438|NCT02755506|EXPERIMENTAL|patients with thoracic lesions|Patients with thoracic lesions is going to undergo endobronchial ultrasound elastography followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
62642439|NCT05900375|EXPERIMENTAL|Intervention Arm - Receipt of PtDA|Parents in the intervention arm will receive a paper decision aid prior to meeting with their health care professional about their child's treatment options for UPJO.
62642440|NCT05900375|NO_INTERVENTION|Control - Usual Care|Parents in the control arm will not receive a paper decision aid and instead will just receive usual care about their child's treatment options for UPJO.
62642441|NCT01061996|EXPERIMENTAL|1|
62642442|NCT04394598|EXPERIMENTAL|CRT with Dendrobium Huoshanense|"Dendrobium Huoshanense Granules: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
62642443|NCT04394598|PLACEBO_COMPARATOR|CRT with Placebo|"Placebo: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
62642444|NCT03466632|ACTIVE_COMPARATOR|• Propofol Group|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..
62642445|NCT03466632|ACTIVE_COMPARATOR|• Dexmedetomidine Group|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
62642446|NCT05797025|OTHER|Individuals with neck pain|To assess pressure pain threshold and pinch grip strengths.
62642447|NCT05797025|OTHER|Healthy group|To assess pressure pain threshold and pinch grip strengths.
62642448|NCT01505283|PLACEBO_COMPARATOR|Group Saline|Epidural administration of saline
62642449|NCT01505283|EXPERIMENTAL|Group Sufentanil|Epidural administration of sufentanil
62642450|NCT01505283|EXPERIMENTAL|Group Lidocaine|Epidural administration of lidocaine
62642451|NCT00421239||A|
62642452|NCT00421239||B|
62642453|NCT05502770||Natural cycle children|Children born from frozen embryo transfer with natural cycle protocol
62642454|NCT05502770||Modified natural cycle children|Children born from frozen embryo transfer with modified natural cycle protocol
62642455|NCT05502770||Artificial cycle children|Children born from frozen embryo transfer with artificial cycle protocol
62642456|NCT01085643|ACTIVE_COMPARATOR|Lubiprostone|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
62642457|NCT01085643|PLACEBO_COMPARATOR|Placebo|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
62642458|NCT01738945|OTHER|Amlodipine|Amlodipine 10 mg/day for 12 weeks
62642459|NCT01053741|EXPERIMENTAL|Seminal Fluid then Normosol|2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.
62642460|NCT01053741|EXPERIMENTAL|Normosol then Seminal Fluid|2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.
62642461|NCT05469945|NO_INTERVENTION|Control arm: no compressive garments|Patients detected with early stage LLL (0-1 ISL stadia) start with education and preventive measures.
62642462|NCT05469945|EXPERIMENTAL|Interventional arm: start of CC2 compressive garments|Patients in the experimental arm and detected with early stage LLL (0-1 ISL stadia) start with CC2 compressive garments in addition to education and preventive measures.
62642463|NCT03514550|EXPERIMENTAL|total intravenous anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia
62642464|NCT03514550|ACTIVE_COMPARATOR|Volatile anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia
62642465|NCT00534027|EXPERIMENTAL|Arm 2|Low Dose AMG 655 with paclitaxel/carboplatin
62642466|NCT00534027|PLACEBO_COMPARATOR|Arm 3|Placebo with paclitaxel/carboplatin
62642467|NCT00534027|EXPERIMENTAL|Arm 1|AMG 655 High doseplus paclitaxel/carboplatin
62642468|NCT00653393|EXPERIMENTAL|A|Subjects received Kali product under fasting conditions
62642469|NCT00653393|ACTIVE_COMPARATOR|B|Subjects received Parnate product under fasting conditions
62642470|NCT02238808|EXPERIMENTAL|Estradiol treatment|Estradiol 6 mg daily for 7-14 days
62642471|NCT05654571||significant weight loss+ breast cancer|The group that lost significant weight after laparoscopic sleeve gastrectomy and was diagnosed with breast cancer
62642472|NCT05654571||regain+breast cancer|The group who lost significant weight after laparoscopic sleeve gastrectomy and regained it afterwards, or who could not lose weight and were diagnosed with breast cancer
62642473|NCT04541563|EXPERIMENTAL|Immediate Treatment Arm|The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks.
62642474|NCT04541563|SHAM_COMPARATOR|Delayed Treatment Arm|In the delayed treatment arm, the participants will receive a sham device that looks exactly the same, but only provides treatment for 2 seconds. At week 4, sham arm participants will be unblinded and shipped an active device (limited to Level 2 output even if a participant raises the dial beyond that). The delayed arm participants will continue with active devices for the remaining 4 weeks of the trial.
62642475|NCT05157217||Group 1|COVID-19 carriers who were infected with SARS-CoV-2 and healed without suffering from any respiratory complications or the need for hospitalization
62642476|NCT05157217||Group 2|COVID-19 patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU
62642477|NCT02643875|SHAM_COMPARATOR|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
62461748|NCT04626856|EXPERIMENTAL|Medium dosage in adults|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
62461749|NCT04626856|EXPERIMENTAL|High dosage in adults|High dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
62461750|NCT04626856|EXPERIMENTAL|Low dosage in adolescents|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
62461751|NCT04626856|EXPERIMENTAL|Medium dosage in adolescents|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
62461752|NCT04626856|EXPERIMENTAL|High dosage in adolescents|High dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
62461753|NCT04626856|EXPERIMENTAL|Low dosage in infants (7-71 months old)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
62461754|NCT04626856|EXPERIMENTAL|Medium dosage in infants (7-71 months old)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
62461755|NCT04626856|EXPERIMENTAL|High dosage in infants (7-71 months old)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
62461756|NCT04626856|EXPERIMENTAL|Low dosage in infants (2-6 months old, two-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
62461757|NCT04626856|EXPERIMENTAL|Medium dosage in infants (2-6 months old, two-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
62461758|NCT04626856|EXPERIMENTAL|High dosage in infants (2-6 months old, two-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
62461759|NCT04626856|EXPERIMENTAL|Low dosage in infants (2-6 months old, three-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
62642478|NCT02643875|ACTIVE_COMPARATOR|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
62642479|NCT02110979|EXPERIMENTAL|PDA|Subjects receive an internet-based patient decision aid video. The PDA is viewed outside of the doctor's office via a personal computer in preparation for regularly scheduled face to face interaction between patients and clinicians.
62642480|NCT02110979|NO_INTERVENTION|Usual care|Patients receive usual care as determined by their clinician.
62642481|NCT05235438|EXPERIMENTAL|IMM27M|IMM27M 0.1, 0.3, 1.0, 2.0, 3.0 mg/kg
62642482|NCT01499810|EXPERIMENTAL|Renal denervation|All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.
62642483|NCT04080726|EXPERIMENTAL|HIP1601+HGP1705 Placebo|HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks
62642484|NCT04080726|EXPERIMENTAL|HGP1705+HIP1601 Placebo|HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks
62642485|NCT02541617|ACTIVE_COMPARATOR|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
62642486|NCT02541617|EXPERIMENTAL|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
62642487|NCT06182059|ACTIVE_COMPARATOR|fast track|continuous adductor canal block and ipack block
62642488|NCT06182059|EXPERIMENTAL|traditional|continuous femoral nerve block and continuous sciatic block
62642489|NCT02175121|PLACEBO_COMPARATOR|Treatment A- Placebo|
62642490|NCT02175121|EXPERIMENTAL|Treatment B- PF-06291874|
62642491|NCT02175121|EXPERIMENTAL|Treatment C- PF-06291874|
62642492|NCT02175121|EXPERIMENTAL|Treatment D- PF-06291874|
62642493|NCT02175121|EXPERIMENTAL|Treatment E- PF-06291874|
62642494|NCT05905432|EXPERIMENTAL|Dosage A1|n=2 will receive a dose of 20 mcg UF6b (A1), n=9 will receive 20 mcg AnAPN1: GLA-LSQ (5 mcg GLA/2 mcg LSQ) (A2)
62642495|NCT05905432|EXPERIMENTAL|Dosage B1|n=2 will receive 50 mcg UF6b (B1), n=9 will receive 50 mcg UF6b: GLA- LSQ (12.5 mcg GLA/5 mcg LSQ) (B2)
62642496|NCT05905432|EXPERIMENTAL|Dosage C1|n=2 will receive 100 mcg UF6b (C1); n=9 will receive 100 mcg UF6b: GLA- LSQ (25 mcg GLA/10 mcg LSQ) (C2)
62642497|NCT00823134|OTHER|AL + polysomnography|Participant wears an Apnea Link sleep apnoea screening device during the polysomnography to detect apnoeas (obstructive, central).
62642498|NCT05871307|EXPERIMENTAL|Experimental Arm A (Preoperativ SRS)|Preoperative stereotatic radiosurgery following resection of brain metastases after 1-7 days
62642499|NCT05871307|EXPERIMENTAL|Experimental Arm B (Intraoperativ SRS)|Intraoperative stereotactic radiotherapy after resection of brain metastases
62642500|NCT05871307|ACTIVE_COMPARATOR|Standard Treatment Arm C (Posoperativ SRS)|Resection of brain metastases following stereotactic radiotherapy after 2-6 weeks
62642501|NCT02373865|EXPERIMENTAL|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
62642502|NCT02373865|ACTIVE_COMPARATOR|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
62642503|NCT03217591|EXPERIMENTAL|IW-1973 Low Dose|Administered daily for 12 weeks
62642504|NCT03217591|EXPERIMENTAL|IW-1973 High Dose|Administered daily for 12 weeks
62642505|NCT03217591|PLACEBO_COMPARATOR|Placebo|Placebo to match experimental drug administered daily for 12 weeks
62642506|NCT03161301||Group 1|IL-37 genotype 1.1
62642507|NCT03161301||Group 2|IL-37 genotype 1.2
62642508|NCT03161301||Group 3|IL-37 genotype 2.2
62642509|NCT02163395|OTHER|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm
62642510|NCT01706367|EXPERIMENTAL|Low dose C diff vaccine|
62642511|NCT01706367|EXPERIMENTAL|Low dose C diff vaccine + adjuvant|
62642512|NCT01706367|EXPERIMENTAL|Mid dose C diff vaccine|
62642513|NCT01706367|EXPERIMENTAL|Mid dose C diff vaccine + adjuvant|
62642514|NCT01706367|EXPERIMENTAL|High dose C diff vaccine|
62642515|NCT01706367|EXPERIMENTAL|High dose C diff vaccine + adjuvant|
62642516|NCT06429865|EXPERIMENTAL|esophageal squamous cell carcinoma group|Participants were instructed to place the capsule near the root of the tongue and fold the string in their mouths, leaving approximately 20 cm of string outside, with a blue mark on the string right at the lips. The capsule was then swallowed with water, and the end of the string was held out of the mouth. Participants were then asked to slowly drink 150-200 mL of 50°C water in approximately 2 minutes to allow the capsule to dissolve so that the sponge mesh inside was released. The device was then slowly withdrawn up the esophagus by pulling the string. The retrieved and expanded cell collection material was put in preservative fluid (Froeasy Technology, Nanjing, China) and transferred to the cytology laboratory at room temperature.
62642517|NCT01952652|ACTIVE_COMPARATOR|Group Naproxen sodium (Group N)|Group N received naproxen sodium 550 mg 60 minutes before surgery.
62642518|NCT01952652|ACTIVE_COMPARATOR|Group Naproxen sodium codeine phosphate (Group NC)|Group NC received naproxen sodium 550 mg+30 mg codeine 60 minutes before surgery.
62642519|NCT01507350||Obesity Surgery|Patients having gastric band, sleeve gastrectomy, and gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
62642520|NCT04702152|EXPERIMENTAL|Experimental group|This is a within-subject study with a single group of participants
62073026|NCT04204772|EXPERIMENTAL|Solution A Dose 1, Then Solution B Dose 2|Participants initially assigned to Solution A Dose 1 will complete the three day course (days 1-3) and switch to the Solution B Dose 2 arm to complete the three day course (days 8-10). The dose level for Solution A Dose 1 is 12 grams of medical grade oral AC mixed with 4 ounces of tap water. Participants will report on a daily basis and consume the assigned combination of oral AC.
62642521|NCT01494818|EXPERIMENTAL|CLEAR CARE/AOSEPT Plus|Hydrogen peroxide-based contact lens care system used per manufacturer's instructions
62642522|NCT01494818|ACTIVE_COMPARATOR|ReNu MultiPlus|PHMB-containing contact lens solution used per manufacturer's instructions
62642523|NCT01460303|EXPERIMENTAL|OPTION-vf patient controlled catheter|"Patients who fail postop bladder challenge and are randomized to OPTION-vf arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
62642524|NCT01460303|ACTIVE_COMPARATOR|Transurethral catheter w/leg bag|"Patients who fail postop bladder challenge and are randomized to indwelling catheter with leg bag arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
62642525|NCT01033500|EXPERIMENTAL|SIK|Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
62642526|NCT01249911|EXPERIMENTAL|Lreuteri|Group of 130 infants allocated to receive L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
62642527|NCT01249911|PLACEBO_COMPARATOR|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
62642528|NCT02499055|EXPERIMENTAL|FearFighter|The experimental group will use the program FearFighter™.
62642529|NCT02499055|NO_INTERVENTION|Control group|The control group receive no intervention for nine weeks.
62642530|NCT05867381|EXPERIMENTAL|HEPA first and sham|This group of participants will be assigned to the intervention of HEPA filtration with the capacity to reduce indoor PM2.5 levels at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to sham filters (air purifier has the same appearance but HEPA filter is removed) for 9 months.
62642531|NCT05867381|EXPERIMENTAL|Sham first and HEPA|This group of participants will be assigned to the intervention of sham filtration with HEPA filter removed at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to the HEPA filtration for 9 months.
62642532|NCT02294279|EXPERIMENTAL|Active|4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
62642533|NCT02294279|NO_INTERVENTION|Placebo|Blinded placebo inhaler
62642534|NCT01198002|EXPERIMENTAL|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 100 weeks. Participants receive a 240 mg loading dose when initiating treatment. During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Weeks 16 and 52, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
62277362|NCT04991766|EXPERIMENTAL|LY3484356 + [¹⁴C]-LY3484356 (Part 2)|Single dose of LY3484356 administered orally followed by Single dose of \[¹⁴C\]-LY3484356 administered intravenously (IV).
62455557|NCT05518435||Work package 2 (WP2) - qualitative study|"WP2 aims to recruit between 20 and 30 participants, consisting of 10-15 young people (aged 16-25) with ADHD and their parent carers and 10-15 health professionals and commissioners/providers. Participants will be recruited from between three and six geographic locations (e.g., PCNs), dependent on findings from WP1. This sample size will enable qualitative data to be collected from approximately five participants per location.~The sampling frame for WP2 consists of a purposive selection of stakeholders."
62642535|NCT01198002|EXPERIMENTAL|90 mg LY2127399|"Given Q2W for 100 weeks. Participants receive a 180 mg loading dose when initiating treatment.~At Weeks 16 and 52, responders will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
62642536|NCT01198002|PLACEBO_COMPARATOR|Placebo|"Given Q2W for 52 weeks. At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 52 weeks.~At Week 52, responders are randomized to receive 1 of the 2 doses of LY2127399, with loading dose of 240 mg or 180 mg of LY2127399, followed by 120 mg of LY2127399 Q4W or 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.~At Week 16, NR will receive a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
62277363|NCT04740073||Patients|Persons undergoing total knee arthroplasty
62277364|NCT04740073||Controls|Persons not undergoing total knee arthroplasty who are age and sex-matched to the patient group.
62461760|NCT04626856|EXPERIMENTAL|Medium dosage in infants (2-6 months old, three-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
62461761|NCT04626856|EXPERIMENTAL|High dosage in infants (2-6 months old, three-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
62642537|NCT02171000|EXPERIMENTAL|BIBR 1048|BIBR 1048 MS
62642538|NCT05098080|ACTIVE_COMPARATOR|Hutrukin|At least six healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), will be administered Hutrukin.
62642539|NCT05098080|PLACEBO_COMPARATOR|Placebo|At least two healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), will be administered placebo.
62642540|NCT04746638|EXPERIMENTAL|Prostate cancer|At least five (5) evaluable subjects with prostate cancer.
62642541|NCT04746638|EXPERIMENTAL|Breast cancer|At least five (5) evaluable subjects breast cancer.
62642542|NCT04065490|EXPERIMENTAL|PBM Treatment|The Valeda™ Light Delivery System
62642543|NCT04065490|SHAM_COMPARATOR|Sham Treatment|The Valeda™ Light Delivery System non-effective treatment
62642544|NCT00904475|EXPERIMENTAL|1- Lidoderm®|Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
62277365|NCT06548893|EXPERIMENTAL|Group psychotherapy with ACT|16 sessions of group psychotherapy based on ACT + exposure with response prevention (EPR)
62461762|NCT04626856|PLACEBO_COMPARATOR|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
62461763|NCT04626856|PLACEBO_COMPARATOR|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
62277366|NCT06548893|NO_INTERVENTION|Treatment as usual|Patients will follow their usual treatment, without adding ACT-based group psychotherapy
62461764|NCT01762085|PLACEBO_COMPARATOR|healed DFU control arm|"clinic-specific usual best care"
62642545|NCT00904475|PLACEBO_COMPARATOR|2-Placebo|Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
62642546|NCT03518359|EXPERIMENTAL|Mental Training for Residents|The intervention will be the modified form of Mindfulness-Based Stress Reduction (MBSR). For this study investigator named the experimental arm Enhanced Stress Resilience Training (ESRT).
62642547|NCT03518359|ACTIVE_COMPARATOR|Active Control|"Active control that emphasizes externalized attention via the shared reading and listening model."
62642548|NCT01037426|OTHER|Study group|Falls before versus after pacemaker implant
62642549|NCT04737733|OTHER|The dementia friendly hospital program|The dementia-friendly hospital program comprised three parts; 1) Educational program for health practitioners to increase the staff's knowledge and awareness of patients with cognitive impairment and/or delirium; 2) Screening, for early identification of cognitive impairment and delirium, using the Four Assessment Test (4AT); 3) Delirium risk factor modification and management for patients defined with potential cognitive impairment and risk of delirium, implying that risk factor modifications should be implemented in the patient's care plan. For patients with suspected delirium, the program promoted an additional delirium management plan.
62073027|NCT04204772|EXPERIMENTAL|Solution A Dose 2, Then Solution B Dose 1|Participants initially assigned to Solution A Dose 2 will complete the three day course (days 1-3) and switch to the Solution B Dose 1 arm to complete the three day course (days 8-10). The dose level for Solution A Dose 2 is 25 grams of medical grade oral AC mixed with 4 ounces of tap water. Participants will report on a daily basis and consume the assigned combination of oral AC.
62277367|NCT06403085|EXPERIMENTAL|Study group|Rhythmic Stabilization, Limb Matching, Double and Single Arm Balance, Balance with Ball and Weight Transfer will be performed for 8 weeks.
62642550|NCT03657069|EXPERIMENTAL|Supportive care (Blossom Smart Expander Technology)|After mastectomy, participants undergo 2-staged IBR with the Blossom Smart Expander Technology comprising of the Blossom syringe assist device connected to the Mentor SPECTRUM adjustable saline breast implant.
62642551|NCT04237948|ACTIVE_COMPARATOR|physical therapy plus REAL tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.~Real Cerebellar tDCS will be applied for 10 days of time."
62642552|NCT04237948|PLACEBO_COMPARATOR|physical therapy plus SHAM tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.~Sham Cerebellar tDCS will be applied for 10 days of time."
62642553|NCT00477763|ACTIVE_COMPARATOR|1|
62642554|NCT00477763|PLACEBO_COMPARATOR|2|
62277368|NCT06403085|NO_INTERVENTION|Control group|No intervention will be applied to control group
62277369|NCT01298492|EXPERIMENTAL|Open-Label Treatment|Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008
62277370|NCT02116010|ACTIVE_COMPARATOR|E. coli, Standard of care : Silver Sulfadiazine|Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine
62277371|NCT02116010|EXPERIMENTAL|E. coli, Phages cocktail|Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail
62277372|NCT02116010|ACTIVE_COMPARATOR|P. aeruginosa, Standard of care : Silver Sulfadiazine|Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine
62277373|NCT02116010|EXPERIMENTAL|P. aeruginosa, Phages cocktail|Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail
62277374|NCT04017143|EXPERIMENTAL|HPV App group|Participants will be assigned to receive an HPV app.
62277375|NCT04017143|NO_INTERVENTION|Usual Care|This is a usual care group that receives a brochure that is usually distributed by a clinic.
62642555|NCT00018824|EXPERIMENTAL|1|Naltrexone
62642556|NCT00018824|PLACEBO_COMPARATOR|2|Placebo
62642557|NCT03089463||Observation group|The entire participants in this study will be included in this group.
62642558|NCT03401047|EXPERIMENTAL|Transdermal Estradiol|Subjects will undergo estradiol administration for up to 9 days. Transdermal estradiol patches will be applied each day by study staff during study days two through nine (patches deliver 0.1 mg/day for a total dose of up to 0.6 mg/day).
62642559|NCT04777981|EXPERIMENTAL|CBDRA60 supplement|Daily sublingual tablet containing 30mg Cannabidiol and 30mg Red Algae, a total of 60mg per dose. Participants will take 2 tablets per day, sublingually and with food, taken approximately and at least, 8 hours apart, daily for 28 days. Participants will be mailed a supply of pills by an overnight courier service.
62642560|NCT04777981|PLACEBO_COMPARATOR|Placebo|Control subjects will receive daily oral placebo tablets of identical appearance and taste containing no CBDRA60.
62642561|NCT01561937|EXPERIMENTAL|Pre-warfarin treatment (trial part A)|
62642562|NCT01561937|EXPERIMENTAL|Post-warfarin treatment (trial part B)|
62642563|NCT00119574|OTHER|Arm 1|
62642564|NCT03105037||Study group|CTM assessed with supraglottic airway in situ and without
62642565|NCT06446934|OTHER|CPAP|Interventional pre-post CPAP therapy
62073028|NCT04204772|EXPERIMENTAL|Solution B Dose 1, Then Solution A Dose 2|Participants initially assigned to Solution B Dose 1 will complete the three day course (days 1-3) and switch to the Solution A Dose 2 arm to complete the three day course (days 8-10). The dose level for Solution B Dose 1 is 12 grams of medical grade oral AC mixed with 4 ounces of apple juice. Participants will report on a daily basis and consume the assigned combination of oral AC.
62073029|NCT04204772|EXPERIMENTAL|Solution B Dose 2, Then Solution A Dose 1|Participants initially assigned to Solution B Dose 2 will complete the three day course (days 1-3) and switch to the Solution A Dose 1 arm to complete the three day course (days 8-10). The dose level for Solution B Dose 2 is 25 grams of medical grade oral AC mixed with 4 ounces of apple juice. Participants will report on a daily basis and consume the assigned combination of oral AC.
62642566|NCT04553666|EXPERIMENTAL|Intervention Group|Four 200mg EGCG pills and one 250mg Vitamin C pill taken one time each day
62073030|NCT04553263|EXPERIMENTAL|Contrave|Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg). The dose will be titrated: 8 mg/90 mg on Week 1, 16 mg/180 mg on Week 2, 24 mg/270 mg on Week 3 and 32 mg/360 mg on Week 4. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone.
62277376|NCT04676737|NO_INTERVENTION|Group 1 DWEK/DSO|Study subjects in Group 1 will undergo DWEK/ DSO and will not receive any TTHX1114
62277377|NCT04676737|EXPERIMENTAL|Group 2 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 2 will receive TTHX1114 (5 injections) and undergo DWEK/ DSO
62277378|NCT04676737|EXPERIMENTAL|Group 3 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 3 will receive TTHX1114 (1 injection) and undergo DWEK/ DSO
62642567|NCT04553666|NO_INTERVENTION|Usual Care Group|No study pills
62642568|NCT02706288|EXPERIMENTAL|Weight loss with diet with exercise|Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after \~7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until \~7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
62642569|NCT05524064|EXPERIMENTAL|FLASH radiotherapy for painful bone metastasis(-es)|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
62642570|NCT01897337|EXPERIMENTAL|Aprepitant group|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room (Before patient get in the operating room)
62642571|NCT01897337|PLACEBO_COMPARATOR|placebo group|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
62642572|NCT01181973|ACTIVE_COMPARATOR|Treatment sequence #1|One 1-mL subcutaneous injection at 30 mg/mL in Period 1 and two 1-mL subcutaneous injections at 15 mg/mL each in Period 2
62642573|NCT01181973|ACTIVE_COMPARATOR|Treatment sequence #2|Two 1-mL subcutaneous injections at 15 mg/mL each in Period 1 and one 1-mL SC injection at 30 mg/mL in Period 2
62642574|NCT03854942|OTHER|First Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
62642575|NCT03854942|OTHER|Second Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET
62642576|NCT03854942|OTHER|Third Arm|7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
62642577|NCT01064414|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
62642578|NCT01064414|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
62642579|NCT01064414|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo once daily for 52 weeks.
62642580|NCT00808223|EXPERIMENTAL|1. alefacept|
62642581|NCT02194972|EXPERIMENTAL|soluble dietary fiber|pectin, a kind of soluble dietary fiber
62642582|NCT02194972|NO_INTERVENTION|Placebo|Placebo
62642583|NCT05436990|EXPERIMENTAL|vactosertib in combination with pembrolizumab|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
62277379|NCT04676737|EXPERIMENTAL|Group 1a|Study subjects in Group 1a will consist of subjects in Group 1 if not recovered from DWEK/ DSO by Day 84 and will receive TTHX1114 (5 injections)
62277380|NCT04676737|EXPERIMENTAL|Group 3a|Study subjects in Group 3a will consist of subjects who had participated in in Group 3 if not recovered from DWEK/ DSO by the median time observed in Group 2 and will receive TTHX1114 (4 injections)
62277381|NCT03786367||CTEPH|Clinically stable patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) recruited from the Pulmonary Hypertension outpatient clinics at Hotel Dieu Hospital, Kingston, Ontario.
62642584|NCT05696067|EXPERIMENTAL|Group 0a|Single dose of 7.2 lg EID50 of H3N2 vaccine component
62642585|NCT05696067|EXPERIMENTAL|Group 0b|Single dose of 7.5 lg EID50 of H1N1pdm09 vaccine component
62642586|NCT05696067|EXPERIMENTAL|Group 0c|Single dose of 8.0 lg EID50 of H3N2 vaccine component
62642587|NCT05696067|EXPERIMENTAL|Group 0d|Single dose of 8.3 lg EID50 of H1N1pdm09 vaccine component
62642588|NCT05696067|EXPERIMENTAL|Group 1a|Low dose vaccine, two components received three weeks apart
62642589|NCT05696067|EXPERIMENTAL|Group 1b|High dose vaccine, two components received three weeks apart
62277382|NCT03786367||Control|Age and sex-matched healthy control data collected as part of previous studies will be used as historic controls for this study.
62277383|NCT01753908|EXPERIMENTAL|Arm I (broccoli sprout extract)|Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.
62277384|NCT01753908|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD on days 1-14 immediately prior to surgery.
62277385|NCT03561584|ACTIVE_COMPARATOR|Active Drug (Sulfasalazine)|
62277386|NCT03561584|PLACEBO_COMPARATOR|Placebo|
62277387|NCT02815839|EXPERIMENTAL|Cohort 1|2.5-mg SHR4640 or placebo
62277388|NCT02815839|EXPERIMENTAL|Cohort 2|5-mg SHR4640 or placebo
62277389|NCT02815839|EXPERIMENTAL|Cohort 3|7.5-mg SHR4640 or placebo
62277390|NCT02815839|EXPERIMENTAL|Cohort 4|10-mg SHR4640 or placebo
62642590|NCT05696067|PLACEBO_COMPARATOR|Group 1c|Placebo, two doses received three weeks apart
62277391|NCT02815839|EXPERIMENTAL|Cohort 5|20-mg SHR4640 or placebo
62642591|NCT05696067|EXPERIMENTAL|Group 2a|High dose vaccine, two components received three weeks apart
62642592|NCT05696067|PLACEBO_COMPARATOR|Group 2b|Placebo, two doses received three weeks apart
62642593|NCT01241474|EXPERIMENTAL|Fish oil|
62642594|NCT01241474|PLACEBO_COMPARATOR|Maize (corn) oil|
62642595|NCT02390271|EXPERIMENTAL|emotion focused therapy training CCT|The general training includes in an individual adjusted way the following techniques: biofeedback-assisted breathing classes that erase negative emotion involving the cardiac and limbic neural pathways, control one's own and other's emotions, mastering positive cognition and enhance self-concept, anchoring positive memories, learning how to recognize psychological reversal in others
62642596|NCT05801003|EXPERIMENTAL|Study group|Pre-dilation with cutting balloon followed by ASES implantation.
62642597|NCT05801003|ACTIVE_COMPARATOR|Control group|Pre-dilation with a standard balloon (semi-compliant or non-compliant) followed by ASES implantation.
62277392|NCT03170141|EXPERIMENTAL|Antigen-specific IgT cells|Patients will receive non-myeloablative chemotherapy consisting of fludarabine and/or cyclophosphamide, followed by intravenous infusion of autologous IgT cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of IgT cells. The tested IgT cell dosage ranges from 0.5×10\^5 /kg to 2.5×10\^7 /kg
62277393|NCT04323904||Hantavirus Group|Patients with cultural, serological, molecular evidence of hantavirus infection
62277394|NCT04323904||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
62277395|NCT04196660|EXPERIMENTAL|The Dance Practitioner Spouse/Partner Group|The Dance Practitioner Spouse/Partner Group (DPSG)
62277396|NCT04196660|EXPERIMENTAL|The Dance Practitioner Midwife Group|The Dance Practitioner Midwife Group (DPMG) included 40 pregnant women and midwives who had received labor dance training
62277397|NCT04196660|NO_INTERVENTION|The Control Group|The Control Group included 80 pregnant women who were subjected to routine treatment without dance
62277398|NCT02611635||VKA treatment of AF / Cohort 1|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
62277399|NCT02611635||NOAC treatment of AF / Cohort 2|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
62277400|NCT04834531|EXPERIMENTAL|Zhuli capsule|Base on the standard medical treatment, the patients in this group will be used Zhuli capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
62277401|NCT04834531|PLACEBO_COMPARATOR|Placebo|Base on the standard medical treatment, the patients in this group will be used placebo capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
62277402|NCT02643004|ACTIVE_COMPARATOR|Senofilcon A|Participants were randomized to wear senofilcon A lens pair for one week during the crossover study.
62642598|NCT03662126|EXPERIMENTAL|Part A Cohort 1|KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
62642599|NCT03662126|EXPERIMENTAL|Part A Cohort 2|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
62642600|NCT03662126|EXPERIMENTAL|Part A Cohort 3|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
62642601|NCT03662126|EXPERIMENTAL|Part A Cohort 4b|KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
62642602|NCT03662126|EXPERIMENTAL|Part B Arm 1 KRT-232|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
62642603|NCT03662126|ACTIVE_COMPARATOR|Part B Arm 2 Best Available Therapy|Best available therapy at the discretion of the investigator, on a 28-day cycle.
62642604|NCT04536363|ACTIVE_COMPARATOR|Standard therapeutic protocol|"1. Dexamethasone (4mg ampoule, intravenous)~2. Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe)~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)~6. Low molecular weight heparin (5000IU prefilled syringe)"
62642605|NCT04536363|EXPERIMENTAL|Standard Therapeutic Protocol + PGE1 Analog|"Analog of PGE1 + Standard therapeutic protocol~Standard medical treatment:~1. Dexamethasone (4mg ampoule, intravenous)~2. Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe)~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)~6. Low molecular weight heparin (5000IU prefilled syringe)"
62277403|NCT02643004|ACTIVE_COMPARATOR|Stenfilcon A|Participants were randomized to wear stenfilcon A lens pair for one week during the crossover study.
62073031|NCT04553263|EXPERIMENTAL|Bupropion|Participants will receive daily extended-release oral bupropion (Wellbutrin XL) at a dose of 450 mg. The dose will be titrated: 150 mg on Days 1 and 2, 300 mg on Days 3 and 4, and 450 mg on Day 5. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone. A reduction to 300 mg will permitted to alleviate medication-related adverse effects if they occur.
62073032|NCT04553263|NO_INTERVENTION|Treatment As Usual|Participants will complete inpatient treatment as usual and will not receive any medication. This arm serves as a TAU control to compare outcomes versus Bupropion and Contrave arms.
62073033|NCT05905887|EXPERIMENTAL|rivoceranib plus paclitaxel|
62073034|NCT00347100|EXPERIMENTAL|1|Administration of Insulin Glargine and Sulfonylurea or Metformin
62073035|NCT00347100|ACTIVE_COMPARATOR|2|Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
62073036|NCT04661072||Patients with Congenital Uterine Anomalies (CUA)|The rates of renal, breast, uterine, ovarian and vaginal cancers in women who have been diagnosed with a CUA will be studies
62642606|NCT01705041|EXPERIMENTAL|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
62073037|NCT01567943|EXPERIMENTAL|Contingency Management|Contingency Management plus treatment as usual
62642607|NCT05444699|EXPERIMENTAL|Prednisolone|"Prednisolone Sodium Phosphate (25 mg/5 mL) oral suspension administered 1 mg/kg\* (up to 20 mg = 4 mL) once a day for 3 days.~\*(0-5 kg: 5 mg; 5.01-7.5 kg: 7.5 mg; 7.51-10 kg: 10 mg; 10.01-12.5 kg: 12.5 mg; 12.51-15 kg: 15 mg; 15.01-17.5 kg: 17.5 mg; ≥ 17.51 kg: 20 mg)"
62642608|NCT05444699|PLACEBO_COMPARATOR|Placebo|Sugar syrup oral suspension containing saccharum 630-640 mg/g and aqua purificata 360-370 mg/g administered the same amount in milliliters as experimental product (up to 4 mL) once a day for 3 days.
62073038|NCT01567943|NO_INTERVENTION|Non-contingent control group|Treatment as usual plus reinforcement for attendance
62073039|NCT04914052||Study group|"Patients will be requested to sign an informed consent in which they will agree to have their face filmed in the post-anesthesia care unit.~The facial expressions will be filmed in 30 second segments. A pain assessment will be measured immediately following filming of each segment using two modalities:~* Pain score assessed by an attending anesthesiologist assigned to the study team.~* VAS assessment by the patient. Following data collection, the data will be forwarded in a coded manner, according to Clalit's data security regulations, to Third Eye systems a facial recognition software company.~Third Eye systems will analyze and process the data using AI and machine learning models and develop an algorithm that can predict pain level by watching facial expressions."
62642609|NCT00145886|EXPERIMENTAL|rhPTH|Subjects will be treated rhPTH for 12 months
62642610|NCT04284865|EXPERIMENTAL|Intervention group|The web platform includes three respiratory exercises: diaphragmatic breathing, thoracic expansion exercise and thoracic expansion exercise assisted upper limbs. It is suggested to do each of the three exercises once a day (AM and PM), four repetitions each. An electronic logbook is also available on the platform to record the duration and the type of others cardiorespiratory exercise of their choice (cycling, walking, using stairs, etc.) as well as strengthening (upper and lower body).
62073040|NCT03257293|ACTIVE_COMPARATOR|Routine Cystoscopy|
62073041|NCT03257293|EXPERIMENTAL|Modified Cystoscopy|
62642611|NCT02415543|ACTIVE_COMPARATOR|GROUP A|Group A will undergo SIL-TEP inguinal hernia repair with a single port LESS (12 to 15 mm paraumbilical)
62642612|NCT02415543|ACTIVE_COMPARATOR|GROUP B|Group B will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
62642613|NCT03846869|EXPERIMENTAL|major cations|bood sample
62642614|NCT04112576||HFrEF|Participants that are diagnosed with NYHA class II or III heart failure with reduced ejection fraction.
62642615|NCT04112576||HFpEF|Participants that are diagnosed with NYHA class II or III heart failure with preserved ejection fraction.
62642616|NCT04398680|EXPERIMENTAL|Part 1, Group 1: Participants with normal hepatic function|Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase \[AST\] less than or equal to \[\<=\] Upper limit of normal \[ULN\]) will be administered with Belantamab mafodotin
62073042|NCT00003143|EXPERIMENTAL|DHAP + amifostine|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
62073043|NCT00003143|OTHER|DHAP|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
62073044|NCT05351138|EXPERIMENTAL|TENS Group|Transcutaneus electric nerve stimulation intervention will be done for a total of 12 weeks, 2 sessions of 20 minutes per week.
62642617|NCT04398680|EXPERIMENTAL|Part 1, Group 2: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Serum bilirubin greater than \>1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin
62642618|NCT04398680|EXPERIMENTAL|Part 2,Group 3: Participants with severe hepatic impairment|Participants with severe hepatic impairment (Serum bilirubin \>3 times ULN and any AST) will be administered with Belantamab mafodotin
62642619|NCT02900742|EXPERIMENTAL|TCM granules plus Chemotherapy|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day until progression or unacceptable toxicity; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
62642620|NCT02900742|PLACEBO_COMPARATOR|Placebo granules plus Chemotherapy|Placebo granules: oral granules, oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
62642621|NCT06460259|EXPERIMENTAL|Experimental Group|Patients undergoing VATS or wedge resection procedures will be informed and their consent will be obtained prior to the procedure. Individuals who consent and meet the inclusion criteria will fill out a personal information form and then be randomly assigned to groups using simple randomization method. Breathing exercises will be taught individually to participants in the experimental group by the researcher. In the experimental group, breathing exercises will be performed approximately 10 minutes, four times a day, starting from the first day after oral intake.
62073045|NCT05351138|EXPERIMENTAL|Masaj Group|Massage intervention will be done in the form of massage practise to the abdominal region, 2 sessions of 20 minutes per week.
62073046|NCT02952911|EXPERIMENTAL|A: MS Participants|MS participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
62642622|NCT06460259|NO_INTERVENTION|Control Group|No intervention other than routine nursing care will be performed.
62073047|NCT02952911|OTHER|B: Healthy Controls|Healthy participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
62277404|NCT02750358|EXPERIMENTAL|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
62642623|NCT06165432|ACTIVE_COMPARATOR|Drug Arm :Topical benzocaine|since its a split mouth study one half of the hard palate will receive topical benzocaine i.e Group A
62642624|NCT06165432|ACTIVE_COMPARATOR|Topical ice|Other half of the palate will receive topical ice i.e Group B
62642625|NCT05366166|EXPERIMENTAL|Single Arm|The participants will receive neoadjuvant and adjuvant pembrolizumab and olaparib combination plus standard of care (chemoradiation therapy) as defined in the protocol.
62073048|NCT01424059||fear of labor|Parous women with fear of labor
62642626|NCT05081388|EXPERIMENTAL|REGN14256 + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1 Phase 3: (Open label) (≥12 and \<18 Years)
62277405|NCT02988765|EXPERIMENTAL|Invasive vulvar cancer (IVC)|"* Vulvar carcinoma (stromal infiltration \> 1 mm)~* Histotypes different from squamous cells carcinomas are included"
62277406|NCT06549387|ACTIVE_COMPARATOR|The topo-pachimetric customized accelerated epithelium-On (aCFXL group)|
62277407|NCT06549387|ACTIVE_COMPARATOR|The standard accelerated CXL (aCXL) protoco|
62277408|NCT06549387|ACTIVE_COMPARATOR|Progressive Fluence Epi-on accelerated crosslinking M nomogram|
62277409|NCT01935401||Women with Bulimia Nervosa|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
62277410|NCT01935401||Healthy Controls|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
62455558|NCT05518435||Work package 3 (WP3) - co-production of guidance|"WP3 aims to recruit between six and 16 participants, consisting of 2-6 young people (aged 16-25) with ADHD and/or their parents/carers, 2-6 health professional and/or commissioners/providers, and between 1 and 4 members of the research team. The sample will be sufficient to include perspectives from identified key stakeholders, while the relatively small group size will support close group work. The small sample size will also enable delivery of key features of co-production research such as building strong relationships and providing opportunities for growth and development of participants.~The sampling frame for WP3 consists of a purposive selection of key stakeholders. In addition to the key stakeholder groups outlined above, co-production activities will also involve MAP study researchers."
62642627|NCT05081388|EXPERIMENTAL|REGN14256|Phase 1, Phase 2: Randomized 1:1:1:1:1
62642628|NCT05081388|EXPERIMENTAL|Imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1
62642629|NCT05081388|EXPERIMENTAL|casirivimab + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
62642630|NCT05081388|EXPERIMENTAL|Placebo|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
62642631|NCT04576650|EXPERIMENTAL|Summit system|Implantation of Summit system, consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities.
62073049|NCT04505995|EXPERIMENTAL|Intervention group|
62073050|NCT01258660|EXPERIMENTAL|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
62277411|NCT01399580|PLACEBO_COMPARATOR|Group A - Placebo QD|
62642632|NCT01516723|EXPERIMENTAL|Hybrid sirolimus-eluting stents|ORSIRO, Biotronik Inc.
62642633|NCT01516723|ACTIVE_COMPARATOR|Everolimus-eluting stents|XIENCE PRIME, Abbott
62642634|NCT05625685|EXPERIMENTAL|Quitbuddy|Participants will be assigned to use a smartphone app (QuitBuddy) that will automatically guide NRT treatment delivery through the integration of ecological momentary assessments (EMA) and GPS into personalized relapse prevention algorithms.
62642635|NCT05625685|ACTIVE_COMPARATOR|Control|Control is intended to approximate the real-world experience where Participants will use The National Cancer Institute's smartphone app (QuitGuide) and will self-manage NRT treatment delivery based on written instructions.
62642636|NCT02614638|ACTIVE_COMPARATOR|1st observational period (before experimental intervention)|"Patients in this arm are included during a first month of observation before the intervention is implemented.~Intervention: One month of department-wide observation"
62277412|NCT01399580|ACTIVE_COMPARATOR|Group B - Low dose Atrasentan QD|
62277413|NCT01399580|ACTIVE_COMPARATOR|Group C - High dose Atrasentan QD|
62277414|NCT03542201|EXPERIMENTAL|PLS|Plain abstract about the Cochrane systematic review.
62277415|NCT03542201|EXPERIMENTAL|Blogshot|Blogshot presentation of the results of Cochrane systematic review.
62277416|NCT01448200|EXPERIMENTAL|Part I: single dose escalation in healthy volunteers|"There will be three sequential single dose cohorts:~Cohort A: PPI-668 dose D1 or placebo~Cohort B: PPI-668 dose D2 or placebo~Cohort C: PPI-668 dose D3 or placebo"
62642637|NCT02614638|EXPERIMENTAL|2nd obs. period (during experimental intervention)|"Following a one-month wash-out period, patients in this arm are included during a second month of observation during which the intervention is implemented.~Intervention: Pharm Tech participates in department"
62642638|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
62642639|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
62642640|NCT01951144|EXPERIMENTAL|Cohort 1:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
62642641|NCT01951144|EXPERIMENTAL|Cohort 2:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
62642642|NCT01951144|EXPERIMENTAL|Cohort 3:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
62642643|NCT01951144|EXPERIMENTAL|Cohort 4 (optional cohort):|Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.
62073051|NCT01258660|EXPERIMENTAL|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
62073052|NCT02869113|EXPERIMENTAL|Sunscreen agent A + control|Application of control and test product into one of the subjects two eyes.
62642644|NCT02158689|ACTIVE_COMPARATOR|human menopausal gonadotropin (hMG)|hMG at a dose of 300 IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
62073053|NCT02869113|EXPERIMENTAL|Sunscreen agent B + control|Application of control and test product into one of the subjects two eyes.
62073054|NCT02869113|EXPERIMENTAL|Sunscreen agent C + control|Application of control and test product into one of the subjects two eyes.
62073055|NCT02397460|EXPERIMENTAL|Gefapixant 50 mg|Gefapixant 50 mg (1 tablet) administered as a single dose
62073056|NCT02397460|EXPERIMENTAL|Gefapixant 300 mg|Gefapixant 300 mg (6 tablets) administered as a single dose
62073057|NCT02397460|PLACEBO_COMPARATOR|Placebo|Placebo-matching tablets administered as a single dose
62073058|NCT01088529|EXPERIMENTAL|AA+LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.
62073059|NCT01088529|EXPERIMENTAL|LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
62073060|NCT05653271|EXPERIMENTAL|Treatment Group A (ACE1831)|ACE1831 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE1831.
62073061|NCT05653271|EXPERIMENTAL|Treatment Group B (ACE1831 and obinutuzumab)|ACE1831 dose escalation, in combination with obinutuzumab. Lymphodepleting regimen followed by escalating doses of ACE1831, given in combination with obinutuzumab.
62073062|NCT03108963|EXPERIMENTAL|L-carnitine and Metformin|L-carnitine and Metformin in Obese PCOS Women trying induction of ovulation with clomiphene citrate.
62073063|NCT03108963|ACTIVE_COMPARATOR|placebo|placebo was given toObese PCOS Women trying induction of ovulation with clomiphene citrate.
62642645|NCT02158689|ACTIVE_COMPARATOR|Letrozole|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day will be initiated on the second or third day of spontaneous menstruation and continued for 5 days. Again on the second or third day of spontaneous menstruation, 150 IU of hMG will be started until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of hCG as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
62277417|NCT01448200|EXPERIMENTAL|Part I: multiple dose administration to healthy volunteers|"Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:~Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days"
62642646|NCT01248897||erbB2+/Her2 Breast Cancer Patients|erbB2+/Her2 Breast Cancer Patients Treated with Lapatinib and Other Anti-erbB2/Her2 Therapy
62073064|NCT02778191||Concomitant cisplatin|Patients treated with concomitant cisplatin
62073065|NCT02778191||Carboplatin plus 5-FU|Patients treated with carboplatin plus 5-FU
62073066|NCT02694484|OTHER|Healthy volunteers|For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit
62073067|NCT03957135|EXPERIMENTAL|Laparoscopic distal pancreatectomy|Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer
62642647|NCT05013411||Healthcare workers|Healthcare workers with patient care experience and are willing to share their experience of current practices of obtaining patient observations.
62073068|NCT03957135|ACTIVE_COMPARATOR|open distal pancreatectomy|Patients receiving open distal pancreatectomy for pancreatic tail and body cancer
62073069|NCT01143623|ACTIVE_COMPARATOR|Probiotic|
62073070|NCT01143623|ACTIVE_COMPARATOR|Probiotic-2|
62073071|NCT01143623|PLACEBO_COMPARATOR|Placebo|
62073072|NCT06061874|EXPERIMENTAL|FAPI PET/CT|"Patients with known or suspected peritoneal metastases from colorectal and ovarian cancers scheduled for complete cytoreductive surgery undergo FAPI PET/CT before the planned surgery.~In the target population, patients receiving neoadjuvant chemotherapy undergo FAPI PET/CT both before and after chemotherapy."
62073073|NCT04736550|EXPERIMENTAL|Assisted Exercise and I-STOP|Participant will receive Assisted Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
62073074|NCT04736550|EXPERIMENTAL|Voluntary Exercise and I-STOP|Participant will receive Voluntary Rate Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
62073075|NCT04736550|EXPERIMENTAL|No Exercise (TAU) and I-STOP|Participant will receive psychotherapy for pain (I-STOP). I-STOP will be offered 1 day/week.
62277418|NCT01448200|EXPERIMENTAL|Part II: multiple dose escalation in HCV subjects|"Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:~Cohort E (genotype-1): PPI-668 dose E1 or placebo~Cohort F (genotype-1): PPI-668 dose E2 or placebo~Cohort G (genotype-1): PPI-668 dose E3 or placebo~Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined~Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo"
62073076|NCT04736550|EXPERIMENTAL|Assisted Exercise and No I-STOP (TAU)|Participant will receive Assisted Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
62073077|NCT04736550|EXPERIMENTAL|Voluntary Exercise and No I-STOP (TAU)|Participant will receive Voluntary Rate Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
62073078|NCT04736550|NO_INTERVENTION|No Exercise (TAU) and No I-STOP (TAU)|Participant will receive their usual behavioral treatment offered at the residential drug treatment center and their medicated assisted treatment (MAT) as applicable.
62073079|NCT02018237|ACTIVE_COMPARATOR|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
62455559|NCT00920140|EXPERIMENTAL|Phase I|"The proposed treatment schedule of GSK1120212 is continuous daily dosing. At the initiation of dosing, a loading dose will be given prior to starting continuous dosing (maintenance dose).~Alterations to the dose and schedule will be based on emerging PK, PD, and tolerability data. The goal will be to define a regimen that is well tolerated and provides adequate PK and PD. This will be the recommended Phase II schedule."
62455560|NCT00920140|EXPERIMENTAL|Phase II|A dose determined by Phase I to further evaulate the safety profile, PK, PD, and clinical activity of GSK1120212.
62455561|NCT04986228|EXPERIMENTAL|Digital aftercare|The group with the new digital aftercare is compared with the active control group with regular aftercare.
62455562|NCT04986228|ACTIVE_COMPARATOR|Treatment-as-usual (TAU)|The group with regular aftercare (TAU) serves as an active control group.
62642648|NCT05720598|EXPERIMENTAL|Patients underdoing staging laparoscopy with indocyanine green (ICG)|"Patients will undergo upper GI endoscopy one day before SL will be dissolved in sterile water, resulting in a 0.125mg/ml concentration. 2 milliliters of the solution will be injected into the submucosa of 4 peritumoral sites - 0.5ml for each site. The following day patient will undergo SL~Intraoperative application of ICG-enhanced vision will be accomplished with dedicated optical devices. Alternate usage of white light and ICG fluorescence mode will allow precise location and cT stage determination of primary tumor, followed by identification of SN and its corresponding LN station, according to Japanese Gastric Cancer Association guidelines. Identified SN will be retrieved with a high-energy device, and the LN basin will be labeled with a magnetic clip."
62073080|NCT02018237|ACTIVE_COMPARATOR|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
62455563|NCT00117949|EXPERIMENTAL|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
62455564|NCT00117949|EXPERIMENTAL|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
62455565|NCT00117949|EXPERIMENTAL|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
62455566|NCT00117949|EXPERIMENTAL|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
62455567|NCT03929367|OTHER|Oxytocin (Pitocin®), 10 IU|Oxytocin 10 IU administered once per intravenous injection
62461765|NCT01762085|EXPERIMENTAL|healed DFU surgical intervention|"clinic-specific best care plus nerve decompression at 4 known sites of lower leg fibro-osseous entrapment"
62642649|NCT00101244|EXPERIMENTAL|Treatment (ispinesib)|"Patients receive SB-715992 IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the MTD."
62073081|NCT06449885||Newly diagnosed marginal zone lymphoma|Newly diagnosed marginal zone lymphoma，including Mucosa-associated lymphoid tissue (MALT) lymphoma, spleen MZL, and lymph node MZL, as well as primary cutaneous MZL, and pediatric NMZL.
62073082|NCT00586079|EXPERIMENTAL|A|Ten patients who have had deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
62277419|NCT05550155|SHAM_COMPARATOR|sham rTMS|"The sham treatment, following the group assignment, will be maintained during the two successive phases of the evaluated protocol. One initial sham rTMS phase will consist of four sham stimulation sessions (20 Hz sham) within two consecutive days. One sham rTMS maintenance phase will consist of two sham stimulation sessions on one day every week for one month and then every two weeks for three months.~Clinical data will be assessed by an investigator blind to group assignment until the end of the study. Patients will also be blind to stimulation. A questionnaire will assess the investigator physician and patient beliefs about what group the patient was involved in (placebo group or active group) at the end of the treatment initial phase and at the end of the treatment maintenance phase"
62277420|NCT05550155|EXPERIMENTAL|active rTMS|The active treatment, following the group assignment, will be maintained during the two successive phases of the evaluated protocol. One initial active rTMS phase will consist of four stimulation sessions (20 Hz) within two consecutive days. One active rTMS maintenance phase will consist of two active stimulation sessions on one day every week for one month and then every two weeks for three months.
62073083|NCT00586079|EXPERIMENTAL|B|Ten patients who are scheduled to have deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
62073084|NCT00089895|EXPERIMENTAL|Eptifibatide|Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
62073085|NCT00089895|PLACEBO_COMPARATOR|Placebo|Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
62277421|NCT02165384|EXPERIMENTAL|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
62277422|NCT04894929|EXPERIMENTAL|A. Multi-conponente exercise|"1. A 6-week therapeutic multi-component physical exercise program will be carried out. The ministerial guide will be followed by carrying out 5 weekly sessions (from Monday to Friday), offering the application through a web link of the weekly programming of the exercises for the patient (type of exercise, video of its execution, number of repetitions and description) having a approximate duration of 40 minutes.~2. Said sessions will be carried out daily and from the center a call was made at the end of the week to mark the follow-up and resolve any questions related to symptoms"
62461766|NCT06180512|EXPERIMENTAL|Beta Alanine high dose|Consumption for 1 day.
62461767|NCT06180512|EXPERIMENTAL|Beta Alanine low dose|Consumption for 1 day.
62073086|NCT04722861||Primary Glaucoma|Patients with primary glaucoma diagnosed by glaucoma professionals
62073087|NCT04722861||Glaucoma Suspect Controls|Glaucoma suspect controls had a diagnosis of glaucoma suspect or ocular hypertension, and also were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
62461768|NCT06180512|PLACEBO_COMPARATOR|Control group|Consumption for 1 day.
62277423|NCT04894929|EXPERIMENTAL|B. Vestibular exercise|"The vestibular exercises will be performed with the instructions of a physiotherapist, in sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec All participants will have a weekly follow-up from Monday to Friday to control attendance and compliance via telephone."
62277424|NCT01543087|OTHER|One group of subjects|
62277425|NCT03723629||pulmonary GGO|Patients with pulmonary GGO.
62277426|NCT02020486|EXPERIMENTAL|Group A|Experimental
62277427|NCT02020486|EXPERIMENTAL|Group B|Days 1-14: Multiple oral dose of 2 mg perampanel (one 2 mg tablet) Days 15-28: Multiple oral dose of 4 mg perampanel (two 2 mg tablets) Days 29-42: Multiple oral dose of 6 mg perampanel (three 2 mg tablets)
62277428|NCT05300191||Peritoneal dialysis patients|Patients undergoing peritoneal dialysis. Patients may be using either Continuous Ambulatory Peritoneal Dialysis (CAPD), Continuous Cycling Peritoneal Dialysis (CCPD) or Intermittent Peritoneal Dialysis (IPD).
62277429|NCT04269109||Control Cohort|A control cohort from September 1, 2018 - October 31, 2018
62277430|NCT04269109||Intervention Cohort|An intervention cohort from March 1, 2019 - April 30, 2019
62277431|NCT02450487|EXPERIMENTAL|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
62277432|NCT05509478|EXPERIMENTAL|Lenvatinib+PD-1 inhibitors|Participants received lenvatinib capsules 8 mg , orally, once daily (QD) PD-1 inhibitors in this study include, but not limited to, Pembrolizumab, nivolumab, sintilimab, toripalimab, etc. The usage and dosage refer to label information or other clinical study
62277433|NCT03971110|EXPERIMENTAL|Zoladex and Casodex|Subjects who are diagnosed with advanced prostate cancer at clinical stage of T3 and T4 (N0 or N1, M0 or M1 with five or fewer extra-pelvic lesions) are the target population of this study. The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
62277434|NCT05557058|EXPERIMENTAL|Gore GDI High Device Arm|Implantation of the GORE GDI High Device Configuration
62277435|NCT05557058|EXPERIMENTAL|Gore GDI Low Device Arm|Implantation of the GORE GDI Low Device Configuration
62277436|NCT01637545|ACTIVE_COMPARATOR|Preop. ramosetron 0.3mg i.v.|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery
62277437|NCT01637545|ACTIVE_COMPARATOR|Postop. ramosetron 0.3mg i.v.|G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
62277438|NCT01637545|ACTIVE_COMPARATOR|No Ramosetron|G3 - No medication but regular antiemetics injection if the patient wants
62277439|NCT05284682||Dilated cardiomyopathy|Patients with heart failure on the basis of dilated cardiomyopathy.
62277440|NCT05284682||Control group without heart failure|Control group from the ablation laboratory without heart failure
62642650|NCT05328427|ACTIVE_COMPARATOR|Stopping|Discontinuation of nucleoside analogue treatment
62642651|NCT05328427|NO_INTERVENTION|Continue|Treatment with nucleoside analogue continued
62073088|NCT02660762|EXPERIMENTAL|Modified MRCUKALLⅫ/ECOGE2993 Regimen|"All patients received phase 1 of induction therapy, which consisted of daunorubicin,vincristine,Pegaspargase,prednisone and methotrexate (intrathecally).Patients went on to phase 2 at the end of phase 1.Phase 2 therapy consisted of cyclophosphamide,cytarabine,6-Mercaptopurine and methotrexate intrathecally. After Induction therapy, all patients received intensification therapy with high-dose methotrexate followed by Pegaspargase. After intensification therapy,patients received consolidation(cytarabine, etoposide,Pegaspargase,dexamethasone,vincristine,cyclophosphamide,daunorubicin,thioguanine)and maintenance therapy(vincristine,6-mercaptopurine,methotrexate~,prednisone). Intrathecal methotrexate and intrathecal cytarabine were given as CNS prophylaxis."
62073089|NCT05410236|EXPERIMENTAL|Experimatal|Learning anatomy with 3D bronchial tree model.
62073090|NCT05410236|NO_INTERVENTION|Control group|Learning anatomy without 3D bronchial tree model.
62073091|NCT02207374|EXPERIMENTAL|Semaglutide 0.5 mg|
62073092|NCT02207374|EXPERIMENTAL|Semaglutide 1.0 mg|
62073093|NCT02207374|ACTIVE_COMPARATOR|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
62277441|NCT03987087|EXPERIMENTAL|Radiotherapy group|Thoracic intensity modulated radiation therapy (IMRT) concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.Cisplatin Thoracenteral infusion chemotherapy。 Thoracic intensity modulated radiation therapy (IMRT) concomitant with Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations.
62277442|NCT03987087|ACTIVE_COMPARATOR|Chemotherapy group|"EGFR-TKI on paticipants with known sensitive EGFR mutations,Cisplatin Thoracenteral infusion chemotherapy.~Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations."
62277443|NCT05361720|EXPERIMENTAL|Arm I (ipilimumab, nivolumab)|"INDUCTION: Patients receive ipilimumab and nivolumab IV on day 1. Cycles repeat every 21 days for 4 cycles.~MAINTENANCE: Patients receive nivolumab IV on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
62277444|NCT05361720|EXPERIMENTAL|Arm II (nivolumab, cabozantinib)|Patients receive nivolumab IV on day 1 and cabozantinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62277445|NCT01306734||Gradient cooling group|Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
62073094|NCT03249376|EXPERIMENTAL|Lumateperone|Lumateperone 42 mg (ITI-007 60 mg tosylate) administered once daily every evening for 6 weeks
62073095|NCT03249376|PLACEBO_COMPARATOR|Placebo|Placebo administered once daily every evening for 6 weeks
62277446|NCT01306734||Crash cooling group|Study group receiving rapid cooling using extracorporeal circulation. The protocol for rapid cooling is using routinely in the department and is not an experimental procedure. When cooling, the investigators aim for maximal difference in temperature between the heater-cooler unit of the ECC-machine.
62277447|NCT04961606||patients with coronary artery disease|
62277448|NCT04961606||medical professionals|
62642652|NCT00761228|ACTIVE_COMPARATOR|Apomorphine|Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
62642653|NCT00761228|PLACEBO_COMPARATOR|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
62642654|NCT02674139|ACTIVE_COMPARATOR|IUD insertion 6 Weeks after delivery|Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later
62073096|NCT03225521|EXPERIMENTAL|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
62073097|NCT05765097|EXPERIMENTAL|Artificial pancreas group|Using artificial pancreas system (composed of a CGM, a pump and AndroidAPS software) to treat adult patients with diabetes
62073098|NCT00057603|EXPERIMENTAL|Deep Brain Stimulation|Participants receive deep brain stimulation treatment for 30 months.
62277449|NCT00523991|PLACEBO_COMPARATOR|placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
62073099|NCT04948879||Vascular reconstruction|Patients who have undergone resection with or without reconstruction of a major blood vessel in the context of surgery for a locally advanced pelvic malignancy. This will mostly refer to patients who have had resection/reconstruction of their internal iliac vessels, or less likely common iliacs.
62073100|NCT05751538||Train dataset|This group is dedicated to developing an automated algorithm.
62073101|NCT05751538||Test dataset|This group is dedicated to testing the performance of an automated algorithm.
62073102|NCT05751538||Clinical Validation|This group is dedicated to assessing the clinical validity of the measurement in an independent validation cohort.
62073103|NCT02978989|PLACEBO_COMPARATOR|LC & nonsolo approach|The surgical intervention is nonsolo LC.
62073104|NCT02978989|ACTIVE_COMPARATOR|LC & solo approach|The surgical intervention is solo LC.
62073105|NCT02341144|ACTIVE_COMPARATOR|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
62073106|NCT02341144|ACTIVE_COMPARATOR|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
62073107|NCT04887181|ACTIVE_COMPARATOR|Teethmate Desensitizer|Tetracalcium phosphate and dicalcium phosphate containing desensitizer
62277450|NCT00523991|EXPERIMENTAL|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
62642655|NCT02674139|EXPERIMENTAL|Immediate Post-placental insertion|Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.
62073108|NCT04887181|ACTIVE_COMPARATOR|Gluma Desensitizer|%35 hydroxyethyl methacrylate and %5 glutaraldehyde containing desensitizer
62642656|NCT05497752|EXPERIMENTAL|cervical rehabilitation group|Positional release technique on trapezius muscle, suboccipital muscle release, pectoralis muscle stretching
62073109|NCT04887181|ACTIVE_COMPARATOR|Hybrid Bond|Self-etch adhesive resin
62073110|NCT04651270|EXPERIMENTAL|SurroundScope|For laparoscopic camera system, the SurroundScope. 270-degree angle videoscope (270Surgical, Israel) was used
62073111|NCT04804813||Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 26 weeks. Participants received interventions as part of routine medical care.
62073112|NCT00839774|EXPERIMENTAL|1|Whole yellow pea flour
62073113|NCT00839774|EXPERIMENTAL|2|Fractionated yellow pea flour
62073114|NCT00839774|EXPERIMENTAL|3|White wheat flour
62073115|NCT02952573|EXPERIMENTAL|FGFR3 wild-type|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
62073116|NCT02952573|EXPERIMENTAL|FGFR3 mutated|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
62073117|NCT04974814|PLACEBO_COMPARATOR|control group|in this group patients will not receive statin before primary PCI
62073118|NCT04974814|ACTIVE_COMPARATOR|atorvastatin group|in this group patients will receive 80 mg atorvastatin single dose before primary PCI
62073119|NCT04974814|ACTIVE_COMPARATOR|rosuvastatin group|in this group patients will receive 40 mg rosuvastatin single dose before primary PCI
62073120|NCT01037959|ACTIVE_COMPARATOR|Norfloxacin|Patients with severe cirrhosis treated with norfloxacin
62073121|NCT01037959|PLACEBO_COMPARATOR|Placebo|Patients with severe cirrhosis treated with placebo
62073122|NCT02546063|OTHER|GoCARB app|Smartphone app
62073123|NCT02546063|NO_INTERVENTION|Conventional carbohydrate estimating methods|Individual usual carbohydrate estimation methods (weighing, experience, carbohydrate exchange tables etc.).
62073124|NCT00859092|EXPERIMENTAL|Thickening of feeds|
62073125|NCT00859092|NO_INTERVENTION|Removal of thickener|
62277451|NCT01281410|NO_INTERVENTION|Standard physiotherapy|Standard Physiotherapy without Inspiratory Muscle Training
62277452|NCT01281410|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training with a device named Respifit in addition to the usual physiotherapy program
62277453|NCT03245450|EXPERIMENTAL|Eribulin mesilate plus irinotecan hydrochloride|In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m\^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m\^2 or 40 mg/m\^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m\^2 or 125 mg/m\^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
62277454|NCT05153057||Birdshot chorioretinopathy|Patients with a diagnosis of birdshot chorioretinopathy, with confirmed HLA-A29 positivity.
62073126|NCT02935868||Test group|Patients with Type 1 diabetes mellitus
62073127|NCT02935868||Control Group|Patients without systemic diseases
62073128|NCT05668364|EXPERIMENTAL|Exposition group|Outdoor cold air exposure (\<10°C or \<50°F) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
62073129|NCT05668364|NO_INTERVENTION|Control group|Indoor ambient air exposure (24-25°C or 75-77°C). Participants remained under observation at indoor ambient until 60 minutes from triage.
62642657|NCT05497752|ACTIVE_COMPARATOR|control group|shoulder and neck exercises
62642658|NCT01994213|EXPERIMENTAL|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
62073130|NCT01758861|EXPERIMENTAL|EPO group|EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.
62073131|NCT01758861|PLACEBO_COMPARATOR|Placebo group|Placebo group received normal saline via intravenous bolus administration after induction of anesthesia.
62073132|NCT06144944|EXPERIMENTAL|Neoadjuvant pyrotinib combined with chemotherapy|
62073133|NCT06144944|PLACEBO_COMPARATOR|Neoadjuvant chemotherapy|
62073134|NCT03161314|EXPERIMENTAL|(Sub-project 1)PHP / (Sub-project 3)Strengthening|
62073135|NCT03161314|ACTIVE_COMPARATOR|(Sub-project 1)Normal healthy / (Sub-project 3)Stretching|(Sub-project 3) Conservative physical therapy treatment with stretching exercise
62455568|NCT05360316|PLACEBO_COMPARATOR|ESWT|Patients assigned to the ESWT group received ESWT over the plantar fascia, three days/week, for six weeks. In addition patients participated additional in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
62455569|NCT05360316|NO_INTERVENTION|Placebo|Routine therapy Patients participated in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
62455570|NCT01562496|EXPERIMENTAL|Exercise|Twente patients will perform Aerobic exercise 3 times a week for at least 30 min
62455571|NCT01562496|NO_INTERVENTION|Control|Fifteen patients will be listed as a control group and will be instructed to continue their previous level of activity throughout the study
62073136|NCT03117465|EXPERIMENTAL|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
62073137|NCT03117465|OTHER|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
62073138|NCT06001281|OTHER|plasma collection|Plasma samples will be prospectively collected at relevant time points during patient treatment.
62073139|NCT03437928|EXPERIMENTAL|Directional Deep Brain Stimulation|
62073140|NCT03482817|EXPERIMENTAL|Probe drug cocktail / Ze 117|One-sequence, Probe drug cocktail alone and in combination with Ze 117.
62277455|NCT05110976|EXPERIMENTAL|Part A1: SAD (AZD8630)|Healthy participants will receive single inhaled doses 1 to 5 of AZD8630.
62277456|NCT05110976|EXPERIMENTAL|Part A1: IV (AZD8630)|Healthy participants will receive a single IV dose of AZD8630.
62455572|NCT03712553|ACTIVE_COMPARATOR|A1: Opt-In, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of an opt-in message encouraging participants to contact their primary care provider for Hepatitis C screening.
62455573|NCT03712553|EXPERIMENTAL|A2: Opt-Out, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of a message and a written laboratory order from primary care provider to complete Hepatitis C screening.
62277457|NCT05110976|PLACEBO_COMPARATOR|Part A1: IV (Placebo)|Healthy participants will receive single IV dose of Placebo.
62277458|NCT05110976|EXPERIMENTAL|Part A2: SAD (AZD8630)|Healthy participants of Chinese and Japanese ethnicity will receive single inhaled dose 5 of AZD8630.
62277459|NCT05110976|EXPERIMENTAL|Part A3: MAD (AZD8630)|Healthy participants will receive once daily inhaled doses 3, 4, and 5 of AZD8630.
62642659|NCT03559634|EXPERIMENTAL|Intervention group|Using an electronic application, participants answer survey questions about their sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception. Then, based on survey answers, they will be able to watch more in-depth educational videos on methods that they qualify for. Participants will only be offered methods that are considered low risk and without any contraindication based upon responses to survey screening. This may include, contraceptive implant, medroxyprogesterone acetate injection, microgestin pills, xulane patch, or intravaginal ring. Participants will then be given the opportunity to initiate contraception in the ED. All participants will be referred for follow up outpatient health services. Subjects who have medical contraindications to certain contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s) while in the ED.
62642660|NCT03559634|OTHER|Control Group|Using an electronic application, participants answer survey questions about their background, sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, based on participants medical history and contraceptive preferences they will be able to watch more in-depth counseling and educational videos on contraceptive methods that they qualify for. After these videos they will be given information on where they will be able to follow up to receive these contraceptive methods if they wish to start a method. Subjects who have medical contraindications to certain hormonal contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s), should this come up in future discussions with their providers.
62642661|NCT03539107|EXPERIMENTAL|Spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
62455574|NCT03712553|EXPERIMENTAL|B1: Active MPM User, UC Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
62455575|NCT03712553|EXPERIMENTAL|B2: Active MPM User, BE Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a letter with behavioral economic (BE) principles encouraging them to contact their primary care provider for Hepatitis C screening.
62642662|NCT03539107|ACTIVE_COMPARATOR|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
62455576|NCT03712553|ACTIVE_COMPARATOR|B3: Active MPM User, UC MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic usual care (UC) message on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
62642663|NCT00726609||Posaconazole (assigned by physician in normal practice)|"* Treatment of invasive fungal infection.~* Prophylaxis of invasive fungal infection."
62642664|NCT01791985|EXPERIMENTAL|Single arm study|"NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off."
62642665|NCT01477307||hypocaloric diet|The included patients are assigned to a hypocaloric standardized diet for 3 weeks.
62642666|NCT02389959|EXPERIMENTAL|Bevacizumab|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
62277460|NCT05110976|EXPERIMENTAL|Part A4: MAD (AZD8630)|Healthy participants of Chinese and Japanese ethnicity will receive once daily inhaled dose 5 of AZD8630.
62277461|NCT05110976|PLACEBO_COMPARATOR|Part A: SAD (Placebo)|Healthy participants and healthy participants of Chinese and Japanese ethnicity will receive single inhaled doses of placebo.
62277462|NCT05110976|PLACEBO_COMPARATOR|Part A: MAD (Placebo)|Healthy participants and healthy participants of Chinese and Japanese ethnicity will receive once daily inhaled dose of placebo.
62277463|NCT05110976|EXPERIMENTAL|Part B (AZD8630)|Participants with asthma will be randomized to one of 3 inhaled dose levels 3, 6, and 7 of AZD8630 once daily.
62073141|NCT03029260|EXPERIMENTAL|Neural mobilization - tension|It is anticipated that 30 participants will be in this group. They will receive tension type neural mobilization of the peroneal nerve in the dominant limb. This will consist of positioning the lower limb with inversion and plantar flexion of the ankle, extension of the knee and maximum flexion of the hip without pain. A physiotherapists will move the hip from this maximum position of flexion in direction to extension (for example if the participants reaches 80º of flexion the mobilization will be between 40º and 80º of flexion). Each participant will receive four series of 10 mobilizations with 1 minute rest between series.
62073142|NCT03029260|ACTIVE_COMPARATOR|Neural mobilization - sliding|It is anticipated that 30 participants will be in this group. They will receive sliding neural mobilization of the peroneal nerve in the dominant limb. Each participant will receive four series of 10 mobilizations with 1 minute rest between series of the following combination of movement: from ankle dorsiflexion, knee extension and hip extension to ankle plantarflexion, knee and hip flexion.
62073143|NCT02708589|ACTIVE_COMPARATOR|probiotic|the probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, and Lactobacillus bulgaricus) and prebiotic (fructooligosaccharide).
62277464|NCT05110976|PLACEBO_COMPARATOR|Part B (Placebo)|Participants with asthma will receive once daily inhaled dose of placebo.
62277465|NCT02074852||Immediate catheter removal|The catheter was removed immediately after the CS
62277466|NCT02074852||Delayed catheter removal|The catheter was removed 12 hours postoperatively
62277467|NCT04370327|ACTIVE_COMPARATOR|Pain Free Exercise (PF)|Patients will be randomised to twice weekly for 24 weeks of pain free exercise in a supervised exercise programme
62277468|NCT04370327|ACTIVE_COMPARATOR|Moderate Claudication Pain Exercise (MOD-P)|Patients will be randomised to twice weekly for 24 weeks of moderate claudication pain exercise in a supervised exercise programme
62277469|NCT04370327|ACTIVE_COMPARATOR|Maximal Claudication Pain Exercise (MAX-P)|Patients will be randomised to twice weekly for 24 weeks of maximal claudication pain exercise in a supervised exercise programme
62277470|NCT04013594|EXPERIMENTAL|carbohydrate group(CHO group)|
62073144|NCT02708589|PLACEBO_COMPARATOR|Placebo|Placebo capsules have identical appearance to probiotic capsules and contain Maltodextrin.
62073145|NCT02685371||Breathing effort type|Current known criteria for constrictive pericarditis will be test under: 1- spontaneous breathing 2- Breathing with a negative pressure of -15 to - 30 cm of water 3- Breathing with a negative pressure of more than - 30 cm of water.
62277471|NCT04013594|NO_INTERVENTION|control group|
62277472|NCT02288585|ACTIVE_COMPARATOR|Plant sterols|Plant sterols
62277473|NCT02288585|PLACEBO_COMPARATOR|Placebo product|Placebo product
62277474|NCT03642678|EXPERIMENTAL|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is \< 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
62277475|NCT03642678|NO_INTERVENTION|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
62277476|NCT01976598||Spinal Cord Stimulation: Sub-Sensory|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the treatment of chronic back and/or leg pain using Sub-Sensory Stimulation.
62277477|NCT02444273|NO_INTERVENTION|Control Group|Subjects will receive standard care both pre and post transplant.
62277478|NCT02444273|EXPERIMENTAL|Exercise Group|Subjects will receive a personalized home exercise program and regular phone calls from a therapist to monitor and promote activity.
62277479|NCT01868100|NO_INTERVENTION|self-completion questionnaire|
62277480|NCT04455555|EXPERIMENTAL|rotigotine treatment group|rotigotine sustained release microspheres therapy by injection
62277481|NCT04455555|PLACEBO_COMPARATOR|placebo comparator|placebo comparator/null microspheres
62461769|NCT04484545||Alive or Dead with COVID-19 diagnosis|Patients selected in phase 1 of study according to Health Protection Scotland criteria for diagnosis of COVID-19 infection Patients selected for phase 2 (validation phase) by PCR result
62461770|NCT05797558|ACTIVE_COMPARATOR|Surgically Treated Primary Aldosteronism|Standard therapy
62461771|NCT05797558|ACTIVE_COMPARATOR|Medically Treated Unilateral Primary Aldosteronism|Open label eplerenone treatment
62461772|NCT05137925|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in a group based, videoconference format with 90 minute sessions 1x/week.
62461773|NCT05137925|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU, or the control group, provides information about the benefits of mindfulness in pregnancy, offers referrals for psychotherapy in the community, and involves monthly phone or videoconference calls to maintain engagement.
62277482|NCT01243736|NO_INTERVENTION|Standard prep|One group will receive the standard bowel preparation, which consists of eating no solid foods after 7 p.m. the evening prior to the capsule endoscopy test and being able to consume clear liquids up to 4 hours prior to the capsule endoscopy test
62642667|NCT02389959|PLACEBO_COMPARATOR|Saline Control|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. The saline control placebo will be mixed by the Stanford Hospital Pharmacy to a total dose of 4mL in order to be identical in quantity and appearance to the mixed doses of bevacizumab, and 2mL will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
62277483|NCT01243736|ACTIVE_COMPARATOR|Combination Prep|"The other group will receive the combination bowel preparation, which consists of taking the standard bowel preparation plus:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
62277484|NCT00814229|ACTIVE_COMPARATOR|Vaccine 1|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
62277485|NCT00814229|ACTIVE_COMPARATOR|vaccine 2|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
62277486|NCT00814229|ACTIVE_COMPARATOR|Vaccine 3|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
62277487|NCT00814229|ACTIVE_COMPARATOR|Vaccine 4|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
62642668|NCT04088162|NO_INTERVENTION|Standard Dressing|In case of Control group. After Ileostomy closure skin will be closed by 6 to 8 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures, and sterile standard dressing will be placed.
62277488|NCT00814229|ACTIVE_COMPARATOR|Vaccine 5|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
62277489|NCT00814229|ACTIVE_COMPARATOR|Vaccine 6|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
62277490|NCT00814229|ACTIVE_COMPARATOR|Vaccine 7|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
62277491|NCT00814229|ACTIVE_COMPARATOR|Vaccine 8|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
62277492|NCT00814229|ACTIVE_COMPARATOR|Vaccine 9|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
62277493|NCT00814229|ACTIVE_COMPARATOR|Vaccine 10|influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection
62277494|NCT00814229|ACTIVE_COMPARATOR|Vaccine 11|influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection
62642669|NCT04088162|EXPERIMENTAL|Postoperative NPWT dressing|"In case of NPWT group. After Ileostomy closure skin will be closed by 3 or 4 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures. Between them small sponge tongues 1x 0,5x2 cm were placed and over whole incision an NANOVA (KCI USA) negative pressure dressing will be placed. In control group first dressing change was made in 48 hours after operation and then every day until suture removal at 7 postoperative day. In NPWT group NANOVA dressing was taken out at 72 hours. 3 steri-streps were placed between sutures and standard sterile dressing was placed. After it dressing was changed every 24 hours until suture removal at 7 postoperative day."
62642670|NCT03102762|EXPERIMENTAL|Botulinum Toxin Type A (BTX-A) Group|Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
62642671|NCT03102762|PLACEBO_COMPARATOR|Placebo Group|"Saline Group:~The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
62642672|NCT00863707|PLACEBO_COMPARATOR|Placebo|Matching intravenous (IV) bolus injection
62642673|NCT00863707|EXPERIMENTAL|Regadenoson|0.4 mg/5 mL intravenous bolus injection
62642674|NCT02051517||Vitrectomy|Subjects expected to have normal vitreous, undergoing vitrectomy surgery for medically indicated reasons.
62277495|NCT00814229|ACTIVE_COMPARATOR|Vaccine 12|influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection
62277496|NCT00814229|ACTIVE_COMPARATOR|Vaccine 13|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
62277497|NCT00814229|ACTIVE_COMPARATOR|Vaccine 14|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
62277498|NCT00940264||Given indication for cholecystectomy|
62277499|NCT01055535|EXPERIMENTAL|Microplasmin|
62642675|NCT02512887|EXPERIMENTAL|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
62642676|NCT02512887|ACTIVE_COMPARATOR|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
62642677|NCT04054830|EXPERIMENTAL|Topical, preservative-free NSAID|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
62642678|NCT04054830|ACTIVE_COMPARATOR|Topical, preservative-free steroid|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
62277500|NCT02777216|EXPERIMENTAL|ConfidenHT system|ConfidenHT system
62277501|NCT01309035|ACTIVE_COMPARATOR|With Tourniquet|Total Knee Arthroplasty. Surgery performed during use of a tourniquet.
62277502|NCT01309035|EXPERIMENTAL|Without Tourniquet|Total Knee Arthroplasty. Surgery performed without use of a tourniquet.
62277503|NCT06244238||Emergency Nurse|"1. Employed in an urgent care unit.~2. Holds a nursing or registered nurse license.~3. Currently engaged in nursing duties.~4. Has a minimum of three months of nursing service in this hospital."
62277504|NCT01995071|EXPERIMENTAL|Arm 1 Non-cirrhotic|ABT-493 Dose A (100 mg once daily \[QD\]) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62073146|NCT03250351|EXPERIMENTAL|Neural mobilization group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program (described in Torres Lacomba M) plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler and adapted by de la Rosa. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
62073147|NCT03250351|ACTIVE_COMPARATOR|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program (described in Torres Lacomba M). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
62277505|NCT01995071|EXPERIMENTAL|Arm 2 Non-cirrhotic|ABT-493 Dose B (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277506|NCT01995071|EXPERIMENTAL|Arm 3 Non-cirrhotic|ABT-493 Dose C (700 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277507|NCT01995071|EXPERIMENTAL|Arm 4 Non-cirrhotic|ABT-493 Dose D (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62073148|NCT01540396|ACTIVE_COMPARATOR|75 Gram OGTT|The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
62277508|NCT01995071|EXPERIMENTAL|Arm 5 Compensated cirrhotic|ABT-493 Dose E (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277509|NCT01995071|EXPERIMENTAL|Arm 6 Non-cirrhotic|ABT-530 Dose A (15 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277510|NCT01995071|EXPERIMENTAL|Arm 7 Non-cirrhotic|ABT-530 Dose B (120 mg QD) for 3 days,followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277511|NCT01995071|EXPERIMENTAL|Arm 8 Non-cirrhotic|ABT-530 Dose C (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277512|NCT01995071|EXPERIMENTAL|Arm 9 Non-cirrhotic|ABT-530 Dose D (40 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62642679|NCT04054830|EXPERIMENTAL|Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee
62642680|NCT05405985|EXPERIMENTAL|Nemolizumab With Auto-Injector (AI)|Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Auto-Injector (AI).
62461774|NCT03205254|ACTIVE_COMPARATOR|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
62461775|NCT03205254|ACTIVE_COMPARATOR|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
62073149|NCT01540396|ACTIVE_COMPARATOR|100 gram OGTT|A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
62073150|NCT06310603|EXPERIMENTAL|Low-Processed Food Group|
62073151|NCT06310603|NO_INTERVENTION|Typical Diet Group|
62073152|NCT05072522|EXPERIMENTAL|SKLB1028|"Dose-escalation stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles, in three doses beginning at 200 mg and rising to 400 mg.~Cohort-expansion stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles at selected dose as per the results of dose-escalation stage."
62277513|NCT01995071|EXPERIMENTAL|Arm 10 Compensated cirrhotic|ABT-530 Dose E (120 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277514|NCT01995071|EXPERIMENTAL|Arm 11 Non-cirrhotic|ABT-493 Dose F (300 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62073153|NCT00472186|EXPERIMENTAL|1|Post-operative administration of Lansoprazole
62073154|NCT00472186|PLACEBO_COMPARATOR|2|Placebo
62073155|NCT00071240|EXPERIMENTAL|Growth Hormone Arm|Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
62277515|NCT01995071|EXPERIMENTAL|Arm 12 Non-cirrhotic|ABT-530 Dose F (≤ 400 mg) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62277516|NCT03418012|EXPERIMENTAL|Cervical Pessary-Group|Cervical Pessary Group: placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37
62277517|NCT03418012|OTHER|Control-Group|Control-Group women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
62642681|NCT05405985|EXPERIMENTAL|Nemolizumab With Dual Chamber Syringe (DCS)|Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Dual Chamber Syringe (DCS).
62073156|NCT00071240|ACTIVE_COMPARATOR|2|Observation only in the 1st year, GH receipt in the second year
62073157|NCT05735457|EXPERIMENTAL|Intervention Arm|"Participants will be shown a short, animated storytelling (SAS) video on dietary sodium and thereafter be asked to complete a questionnaire to assess knowledge on dietary sodium and behavioral expectation.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
62073158|NCT05735457|NO_INTERVENTION|Exposed Control Arm|"Participants will be asked to complete a questionnaire to assess knowledge on dietary sodium and behavioral expectation (the same questionnaire as in arm 1, however, without being exposed to the SAS video on dietary sodium before.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
62073159|NCT05735457|PLACEBO_COMPARATOR|Attention Placebo Control Arm|"Participants will be shown a attention placebo control (APC) video, unrelated to the outcomes measured in this trial, before being asked to complete the knowledge and behavioral expectation questionnaire.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
62073160|NCT05735457|NO_INTERVENTION|Un-exposed Control Arm|"Participants will not view a video and will not be asked to complete the questionnaire.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
62073161|NCT03622385||Patients diagnosed with Serous Epithelial Ovarian Cancer|"Discovery Cohort: patients who were diagnosed with serous epithelial ovarian cancer whose tissue specimens were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to be cancerous."
62277518|NCT03413150||severely ill patients receiving amiodarone for ATs|cohort study was conducted from January 2007 to April 2012 in the 18-bed medical ICU of a tertiary teaching hospital.Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent atrial tachycardia during their hospitalization in the ICU.
62277519|NCT04336098|EXPERIMENTAL|Monotherapy Dose Escalation|The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of SRF617 as monotherapy in up to 36 patients with advanced solid tumors.
62277520|NCT04336098|EXPERIMENTAL|Monotherapy Tumor Biopsy Expansion|The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy in up to 20 patients at cleared and recommended phase 2 dose levels.
62277521|NCT04336098|EXPERIMENTAL|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel in patients with locally advanced or metastatic solid tumors.
62073162|NCT03622385||Normal patients|"Discovery Cohort: patients who were determined to have normal ovarian tissue specimens that were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to not be cancerous."
62073163|NCT06376643|EXPERIMENTAL|Arm A (Augmented Reality)|Participants that will use the augmented reality supportive tool during the simulation-based pediatric scenario.
62642682|NCT04188600|EXPERIMENTAL|treatment group|"The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations:~* Responding patients: this population, defined by FSFI score \> 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks).~* Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks)."
62073164|NCT06376643|ACTIVE_COMPARATOR|Arm B (Conventional methods)|Participants that will use conventional methods during the simulation-based pediatric scenario.
62073165|NCT02310893|ACTIVE_COMPARATOR|Contingency Management only|Participants assigned to this arm will receive payments for attending regular HIV medical appointments at the clinic and filling prescribed HIV medications at the pharmacy
62073166|NCT02310893|ACTIVE_COMPARATOR|Peer Navigation only|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care
62277522|NCT04336098|EXPERIMENTAL|Combination Therapy - SRF617 with Pembrolizumab Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with pembrolizumab (Keytruda®) in patients with locally advanced or metastatic solid tumors.
62277523|NCT04336098|EXPERIMENTAL|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Expansion|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with advanced pancreatic ductal adenocarcinoma (PDAC) to further evaluate safety with SRF617 and gemcitabine + albumin-bound paclitaxel combination therapy.
62277524|NCT04336098|EXPERIMENTAL|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion GC/GEJ|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 28 additional patients with 2 anti-PD-(L) 1 naive HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma to further evaluate safety with SRF617 and pembrolizumab combination therapy.
62073167|NCT02310893|EXPERIMENTAL|Combined Contingency Management and Peer Navigation|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care and will be eligible to receive incentives for attending HIV care visits/refilling prescriptions.
62277525|NCT04336098|EXPERIMENTAL|SRF617 + Pembrolizumab + Gemcitabine + Albumin-bound Paclitaxel Quadruplet Dose Expansion|Enrollment at the recommended phase 2 combination dose established in the combination dose escalation arms (if recommended phase 2 combination doses differ, the lower of the starting 2 doses will be used) may be expanded to include up to approximately 30 additional patients with advanced 1L PDAC.
62277526|NCT04336098|EXPERIMENTAL|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion anti-PD-L1 GC/GEJ, PD-L1+ NSCLC|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 29 additional patients with anti-PD-(L) 1 relapsed/refractory PD-L1+ HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma or advanced PD-L1+ NSCLC to further evaluate safety with SRF617 and pembrolizumab combination therapy.
62277527|NCT00391222|EXPERIMENTAL|001|Risperidone Long Acting Injectable (LAI) Intramuscular injections of risperidone LAI (25 37.5 or 50 mg) every 2 weeks and oral placebo daily
62073168|NCT02310893|NO_INTERVENTION|Usual care|Participants in this arm will receive the care that they would usually get in their clinic in the absence of this study.
62073169|NCT02655471|EXPERIMENTAL|HTLV-1 plus Tropical Spastic paraparesis|"Patients with recent onset of Tropical Spastic paraparesis due HTLV-1 will receive combination of Raltegravir and Zidovudine during 48 weeks"
62073170|NCT00385853|EXPERIMENTAL|PTK787|Single arm study of PTK787
62073171|NCT01269814||Go-home group|The patients with a Rockall score of 0 or 1 will be prescribed medical therapy, and will be scheduled for elective gastroscopy.
62073172|NCT04859530|EXPERIMENTAL|AVC test|
62073173|NCT04684641|EXPERIMENTAL|Phage therapy|Participants will be randomized to receive 3mL phage therapy, nebulized daily for 7 days.
62073174|NCT04684641|ACTIVE_COMPARATOR|Placebo|Participants will be randomized to receive the 3mL placebo, nebulized daily for 7 days.
62073175|NCT02910986|NO_INTERVENTION|Usual Care|Breast density notification using standard language reporting for dense and non-dense breasts within the mammogram results notification letter
62073176|NCT02910986|ACTIVE_COMPARATOR|Enhanced|Usual Care plus a written educational brochure
62073177|NCT02910986|ACTIVE_COMPARATOR|Interpersonal|Usual Care plus Enhanced plus interaction with a promotora (lay health educator)
62073178|NCT02406313|EXPERIMENTAL|CTS + ETP|Patients following a standardized thermal cure (CTS) follow an additional program called Fibr'eaux (ETP) that consists in discussion groups and physical activities allowing patients to learn how to manage their illness.
62277528|NCT00391222|PLACEBO_COMPARATOR|002|Placebo Intramuscular injections of placebo every 2 weeks and oral placebo daily
62277529|NCT00391222|ACTIVE_COMPARATOR|003|Olanzapine Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
62277530|NCT02055066|EXPERIMENTAL|Arm 1|ARGX-111 0.3 mg/kg
62277531|NCT02055066|EXPERIMENTAL|Arm 2|ARGX-111 1.0 mg/kg
62073179|NCT02406313|ACTIVE_COMPARATOR|CTS alone|Patients follow a standardized thermal cure that is a sedative, relaxing, antalgic and mobilizing treatment based on muds application, hydrotherapy and physiotherapy. The cure is made of 72 treatments selected among a list including muds application, massages, reeducation in thermal pool, baths and showers.
62073180|NCT01322438|EXPERIMENTAL|Arm 1|
62073181|NCT06384378|ACTIVE_COMPARATOR|IL-2 every 4 weeks|Aldesleukin every 4 weeks
62073182|NCT06384378|ACTIVE_COMPARATOR|IL-2 every 2 weeks|Aldesleukin every 2 weeks
62073183|NCT06384378|PLACEBO_COMPARATOR|Placebo|
62073184|NCT05344989|ACTIVE_COMPARATOR|APNmAb005 (5mg/kg) vs Placebo|Single Ascending Dose (SAD)
62073185|NCT05344989|ACTIVE_COMPARATOR|APNmAb005 (10 mg/kg) vs Placebo|Single Ascending Dose (SAD)
62073186|NCT05344989|ACTIVE_COMPARATOR|APNmAb005 (25 mg/kg) vs Placebo|Single Ascending Dose (SAD)
62277532|NCT02055066|EXPERIMENTAL|Arm 3|ARGX-111 3.0 mg/kg
62277533|NCT02055066|EXPERIMENTAL|Arm 4|ARGX-111 10 mg/kg
62277534|NCT01219231|EXPERIMENTAL|Exercise|
62277535|NCT01219231|PLACEBO_COMPARATOR|Placebo|
62277536|NCT03144466|EXPERIMENTAL|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
62073187|NCT05344989|ACTIVE_COMPARATOR|APNmAb005 (50 mg/kg) vs Placebo|Single Ascending Dose (SAD)
62073188|NCT05344989|ACTIVE_COMPARATOR|APNmAb005 (70 mg/kg) vs Placebo|Single Ascending Dose (SAD)
62073189|NCT03418935|EXPERIMENTAL|Remaxol 400 ml|Group I: treatment with Remaxol 400 ml IV + Ringer solution 400 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
62073190|NCT03418935|EXPERIMENTAL|Remaxol 800 ml|Group II: treatment with Remaxol 800 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
62073191|NCT03418935|PLACEBO_COMPARATOR|Control|Group III: Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
62277537|NCT03144466|EXPERIMENTAL|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
62277538|NCT03144466|EXPERIMENTAL|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
62277539|NCT05879042|EXPERIMENTAL|Group 1|Static Stretching
62073192|NCT04967625|EXPERIMENTAL|Sintilimab + Anlotinib|sintilimab 200mg, IV, d1, Q3W and anlotinib 12mg, PO, QD，d1-14, Q3W; treatment until disease progression, unacceptable toxicity, or death
62073193|NCT01486758|ACTIVE_COMPARATOR|Azithromycin|Oral azithromycin
62073194|NCT01486758|PLACEBO_COMPARATOR|Placebo|Oral Placebo
62073195|NCT03192540|EXPERIMENTAL|Exercise|These are participants who will be undergoing exercise intervention.
62073196|NCT02307747|EXPERIMENTAL|trauma patients|Blood samples will be collected every 4 hours during 24 h, between day 2 and day 4 after inclusion
62073197|NCT00505167|ACTIVE_COMPARATOR|1|Patients randomized to receive memantine
62073198|NCT00505167|ACTIVE_COMPARATOR|2|Patients randomized to receive donepezil
62073199|NCT04777929||healthy pregnant woman|pregnant woman without any disease of pregnancy
62073200|NCT04777929||pregnant woman with preeclampia|pregnant woman with preeclampia but without any other disease of pregnancy
62073201|NCT00649389|EXPERIMENTAL|OM40/AML10|olmesartan medoxomil 40mg and amlodipine 10mg
62073202|NCT00649389|ACTIVE_COMPARATOR|OM40/HCTZ25|olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
62073203|NCT00649389|ACTIVE_COMPARATOR|AML10/HCTZ25|amlodipine 10mg and hydrochlorothiazide 25mg
62073204|NCT00649389|ACTIVE_COMPARATOR|OM40/AML10/HCTZ25|olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg
62073205|NCT00836654|ACTIVE_COMPARATOR|1 Catumaxomab|Patient received Catumaxomab and paracentesis
62073206|NCT00836654|NO_INTERVENTION|2:|Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm
62073207|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
62277540|NCT05879042|EXPERIMENTAL|Group 2|Dynamic Stretching
62277541|NCT05879042|EXPERIMENTAL|Group 3|PNF Stretching
62277542|NCT05879042|SHAM_COMPARATOR|Group 4|Sham stretching
62277543|NCT01367795||palliative tumor disease|Patients in a known palliative setting with symptoms due to tumor growth.
62073208|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
62073209|NCT05389527|EXPERIMENTAL|experimental arm|Pembrolizumab+Lenvatinib
62073210|NCT02999711|EXPERIMENTAL|Cohort 1|REGN3500 low dose or placebo
62073211|NCT02999711|EXPERIMENTAL|Cohort 2|REGN3500 medium dose or placebo
62073212|NCT03940235|EXPERIMENTAL|Stereotactic body Radiotherapy (SBRT) only|ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously.
62073213|NCT03940235|ACTIVE_COMPARATOR|Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)|ARM 2: salvage SBRT (as described for ARM 1) + 6-month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within one week before the start of SBRT.
62073214|NCT04186650|EXPERIMENTAL|Autologous genetically modified tissue-engineered skin graft|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
62073215|NCT05085535|ACTIVE_COMPARATOR|Exercise|to which the treatment of therapeutic exercise and pain education will be applied,
62073216|NCT05085535|EXPERIMENTAL|Manual Therapy|to which the same treatment as the control group will be applied, adding manual therapy sessions based on musculoskeletal rhythmic mobilizations.
62073217|NCT00584805|EXPERIMENTAL|Vaccination|Inactivated, Dried, TSI-GSD 104, EEE
62073218|NCT00566943|ACTIVE_COMPARATOR|Control|"Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple lines including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine). intestine or mesentery.~Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without buttress at the GJ anastomosis. Linear buttress at the stomach/pouch staple line is required."
62277544|NCT05654831|PLACEBO_COMPARATOR|SAD Cohorts 1 to 2: Participants receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo.
62277545|NCT05654831|EXPERIMENTAL|SAD Cohorts 1 to 2: Participants receiving ECC5004|Participants in each SAD cohort will be randomized to receive up to 4 escalating doses of ECC5004 ranging from 1 mg to 300 mg.
62277546|NCT05654831|PLACEBO_COMPARATOR|MAD Cohorts 1 to 4: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 28 days.
62073219|NCT00566943|EXPERIMENTAL|PSD Veritas|"Linear Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas used as a staple line buttress at the stomach/pouch.~In addition to buttress of the stomach/pouch, patients may have PSD Veritas linear buttress at any of the following staple lines: intestine, mesentery, or anastomosis junction (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine).~Circular Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas circular buttress used as a staple line buttress at the GJ anastomosis. Linear buttress at the stomach/pouch is required."
62073220|NCT04950556|EXPERIMENTAL|Exercise group|Fast and slow contractions will be taught in PFMT. For fast contractions, they will be asked to contract and relax the pelvic floor muscles quickly. For slow contractions, they will be asked to contract the pelvic floor muscles slowly, keep them at maximum contraction and relax slowly. Ten slow contractions in addition to 10 fast contractions will be considered as 1 set of exercises. For the first week, they will be asked to do 5 sets of exercises per day, every day. Then, the number of sets will be increased by 5 each week and the number of sets will reach 30 in the 6th week. PFMT will be applied by the patients as a home program every day of the week for 6 weeks.
62073221|NCT04950556|OTHER|Control group|Waiting list will included in control group.
62073222|NCT06056986|EXPERIMENTAL|Patients|Chron's disease patients scheduled for ileo-colonic resection
62073223|NCT03664219|ACTIVE_COMPARATOR|isolation of IAN nerve with collagen membrane|
62073224|NCT03664219|EXPERIMENTAL|without isolation of the IAN with collagen|
62277547|NCT05654831|EXPERIMENTAL|MAD Cohorts 1 to 4: Participants receiving ECC5004|Participants will be randomized to receive a once-daily dose of 1 of 4 escalating doses of ECC5004 ranging from 10 mg to 150 mg for 28 days.
62642683|NCT04188600|ACTIVE_COMPARATOR|active control group|The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)
62073225|NCT00653263||Methamphetamine dependent|Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
62073226|NCT02938936|EXPERIMENTAL|Scheduling Intervention|Pre-natal visit scheduling
62073227|NCT02938936|NO_INTERVENTION|Control|
62277548|NCT01072370|ACTIVE_COMPARATOR|Treatment Group 1|
62277549|NCT01072370|SHAM_COMPARATOR|Treatment Group 2|
62277550|NCT01218607|PLACEBO_COMPARATOR|Placebo|
62277551|NCT01218607|ACTIVE_COMPARATOR|Active|
62277552|NCT05480813|OTHER|Prof. Dr. K. Corten|The one participant of the study is an orthopaedic surgeon. He will execute 48 THA procedures during 4 study days. 24 THA procedures will be executed using the automated KINCISE™ impaction system and 24 THA procedures will be executed using a standard mallet. He will undergo physical and cognitive test before and after the OR day and during lunch breaks. Next to that, operational efficiency and ergonomic impaction will be analysed
62073228|NCT02540395|ACTIVE_COMPARATOR|Group A: Standard of care|"Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines).~All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline"
62073229|NCT02540395|EXPERIMENTAL|"Group B: Low Immunosuppression regimen"|"(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant).~In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline."
62642684|NCT02888834||Adverse drug reaction|Patients aged over 65 years who presented a serious adverse drug reaction notified to the Regional Pharmacovigilance Center of Champagne-Ardenne between January and May 2013 were included in the study.
62642685|NCT05200169|EXPERIMENTAL|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
62073230|NCT05315830|EXPERIMENTAL|HER2 Vaccine alone|0.6 μg HER2 Vaccine
62073231|NCT05315830|EXPERIMENTAL|HER2 Vaccine plus Standard of Care Chemotherapy|0.6 μg HER2 Vaccine plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or other Standard of Care Chemotherapy
62073232|NCT00909103||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histological confirmation
62277553|NCT02135887||MB-6+FOLFOX chemotherapy|MB-6, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
62277554|NCT02135887||Placebo+FOLFOX chemotherapy|Placebo, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
62277555|NCT01272310|EXPERIMENTAL|Combination therapy|
62277556|NCT06342531|EXPERIMENTAL|eDASA+APP FI|Nurses in the study wards are using a CDSS 'eDASA+APP FI' in their daily clinical work to aid their short-term violence risk assessment and management, together with a patient if possible, to identify patients at elevated risk for violence in the coming 24 hours and to decrease (or maintain low) the risk with evidence-based, non-invasive nursing interventions.
62277557|NCT02245828|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62642686|NCT03369574||chronic rhinosinusitis and eosinophilic asthma|Adults over the age of 18, diagnosed with poorly controlled moderate to severe asthma with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment) who are initiating/undergoing reslizumab therapy and also carry a physician diagnosis of chronic rhinosinusitis with nasal polyposis
62642687|NCT01441141||Arm 1|Subjects with SCD
62277558|NCT02245828|EXPERIMENTAL|QCC374|Single and multiple ascending doses of QCC374
62277559|NCT01928160|EXPERIMENTAL|Arm I (chemotherapy, erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21, pemetrexed disodium IV and carboplatin IV or cisplatin IV on day 1. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance erlotinib hydrochloride PO QD on days 1-21 and pemetrexed disodium IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62642688|NCT01441141||Arm 2|Subjects without SCD
62277560|NCT01928160|EXPERIMENTAL|Arm II (chemotherapy)|Patients receive pemetrexed disodium and carboplatin or cisplatin as in Arm I. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance pemetrexed disodium as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62642689|NCT01198912|PLACEBO_COMPARATOR|placebo|
62642690|NCT01198912|EXPERIMENTAL|doxycycline 100 mg|
62642691|NCT05810896|EXPERIMENTAL|AF at Home|All recruited participants will participate in the AF at Home educational intervention.
62642692|NCT02532504|EXPERIMENTAL|CBT seven sheets|"8 sessions of CBT based intervention called change your life with seven sheets of paper"
62642693|NCT02532504|NO_INTERVENTION|Treatment As Usual|Treatment As Usual
62642694|NCT00004862|EXPERIMENTAL|Arm I|Patients receive augmerosen IV continuously on days 1-10 and filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover. Patients receive fludarabine IV over 30 minutes followed 3.5 hours later by cytarabine IV over 4 hours on days 6-10. Patients who achieve complete response (CR) receive a second course beginning 4 weeks after completion of the first course. Patients who achieve CR and have a matched sibling or unrelated bone marrow donor may undergo allogeneic bone marrow transplantation. Cohorts of 3-6 patients receive escalating doses of fludarabine and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
62642695|NCT05084976||Pediatric Technology Dependent Patients at Cohen Children's Medical Center|
62642696|NCT05084976||Pediatric Technology Dependent Patients at Ann & Robert H. Lurie Children's Hospital of Chicago|
62642697|NCT01021397|EXPERIMENTAL|1|Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
62073233|NCT00909103||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
62642698|NCT01021397|PLACEBO_COMPARATOR|2|Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
62642699|NCT03455517|EXPERIMENTAL|Veritas|"* Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.~* Step 2. All patients will receive 6 courses of the VR combination.~* Step 3. After 6 courses of VR combination:~  3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
62642700|NCT00541242|ACTIVE_COMPARATOR|1|bimatoprost 0.03% eye drops
62642701|NCT00541242|ACTIVE_COMPARATOR|2|latanoprost 0.005% eye drops
62642702|NCT01126099|EXPERIMENTAL|Prazosin|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
62642703|NCT01126099|PLACEBO_COMPARATOR|Placebo|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
62073234|NCT00710112||VLBW|infants less than 1500 grams at birth
62073235|NCT06420674|EXPERIMENTAL|RE-FER web|The study will be offered to all women receiving artificial inseminations in two Spanish public hospitals (Hospital Universitario General de Castellón and Hospital Universitario La Plana).
62642704|NCT06438211|ACTIVE_COMPARATOR|Group I (superficial serratus anterior plane block)|Single-shot ultrasound (Esaote Mylab30) guided Superficial SAP block with 30 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4- T5 ribs level (between the latissimus dorsi muscle and the serratus anterior muscle) was performed preoperatively to patients in the Superficial SAP group (Group I)
62642705|NCT06438211|ACTIVE_COMPARATOR|Group II (deep serratus anterior plane block)|Single- shot ultrasound (Esaote Mylab30) guided Deep SAP block with 30 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4- T5 ribs level ( between the serratus anterior muscle and the ribs) was performed preoperatively to patients in the Deep SAP group (Group I)
62642706|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
62642707|NCT04072029||Cataract - FECD|Eyes with FECD undergoing cataract surgery
62642708|NCT06316635||patient group|patient group has formed as operated patients because of OME A paracentesis and ventilation tube insertion will be performed them. After paracentesis, effusion otitis media will be trapped and sampled for microplastic analysis.
62642709|NCT03135314|ACTIVE_COMPARATOR|Hypoxia Cocoa flavanol|Exercise or cognitive test in (acute) hypoxic condition after 7 days of cocoa flavanol intake
62642710|NCT03135314|PLACEBO_COMPARATOR|Hypoxia Placebo|Exercise or cognitive test in (acute) hypoxic condition after 7 days of placebo intake
62642711|NCT03135314|ACTIVE_COMPARATOR|Normoxia Cocoa flavanol|Exercise or cognitive test in normoxic condition after 7 days of cocoa flavanol intake
62642712|NCT03135314|PLACEBO_COMPARATOR|normoxia placebo|Exercise or cognitive test in normoxic condition after 7 days of placebo intake
62642713|NCT00747916|EXPERIMENTAL|CryoSpray Ablation (TM) System|subjects will receive cryotherapy using the CryoSpray Ablation (TM) System DOSE: up to 3 cycles of 10-40 second sprays
62642714|NCT05306990|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin tablets Dosage and frequency: 40mg orally once daily
62642715|NCT05306990|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin tablets Dosage and frequency: 20mg orally once daily
62642716|NCT06521970||Female|Thoracic kyphosis (TK) angle of ≥ 50° The kyphosis angle, dynamic postural performance, forward head position
62642717|NCT06521970||Male|Thoracic kyphosis (TK) angle of ≥ 50° The kyphosis angle, dynamic postural performance, forward head position
62642718|NCT04610229|EXPERIMENTAL|Treated with hypofractionation|1
62642719|NCT02479750|EXPERIMENTAL|ColdZyme|ColdZyme® mouth spray liquid. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
62642720|NCT02479750|PLACEBO_COMPARATOR|Placebo|Sugar based mouth spray liquid manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
62642721|NCT02112695|EXPERIMENTAL|sportswomen|3 micrograms \[11C\]diprenorphine
62642722|NCT02112695|EXPERIMENTAL|control subjects|3 micrgrams \[11C\]diprenorphine
62642723|NCT00735709|EXPERIMENTAL|Vortioxetine 1 mg|Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.
62642724|NCT00735709|EXPERIMENTAL|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.
62642725|NCT00735709|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.
62642726|NCT00735709|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
62642727|NCT03834311|EXPERIMENTAL|isokinetic|
62642728|NCT03834311|ACTIVE_COMPARATOR|exercise band|
62642729|NCT02746835|EXPERIMENTAL|Exercise Protocol|Set of exercises for balance, endurance, muscle strength and flexibility
62642730|NCT02781324|EXPERIMENTAL|Ultrasonic Bone Scalpel Group|Surgeons will use the ultrasonic bone scalpel, to their discretion, along with standard of care manual devices when performing the posterior spinal fusion.
62642731|NCT02781324|ACTIVE_COMPARATOR|Standard of Care Group|Surgeons will use, to their discretion, only standard of care manual devices when performing the posterior spinal fusion.
62073236|NCT01987596|EXPERIMENTAL|Arm I (fixed filgrastim)|Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.
62073237|NCT01987596|EXPERIMENTAL|Arm II (flexible filgrastim)|Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.
62277561|NCT04476888|EXPERIMENTAL|Treatment arm/CP recipient|"Patients with severe/critical COVID 19 who will receive 500 ml of Convalescent plasma (CP), obtained from donors who have been recovered from SARS-CoV-2 infection.~These patients may or may not get other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
62277562|NCT04476888|OTHER|Control arm|"Patients with severe/critical COVID 19 who will not receive Convalescent plasma (CP). These will be those who were recruited during the period before CP becomes available or for whom no compatible CP is available.~These patients will receive one or more of the other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
62277563|NCT06538506|EXPERIMENTAL|RehUp BCI intervention|The BCI intervention will complete 24 one hour intervention sessions (3x/week for 8 weeks).
62073238|NCT03375125|EXPERIMENTAL|Probiotic|L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289), dose of 2x10\^8 Colony Forming Units (CFU). One lozenges will be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day
62642732|NCT06424522|EXPERIMENTAL|Group I (RRE, medical management)|Patients undergo a bowel management program comprising a medical management pathway (fiber, loperamide hydrochloride, pelvic floor physical therapy) in combination with RRE treatment for 1 year. Patients use the RRE system to self administer an individualized enema regimen via the rectum. Patients may undergo abdominal film x-rays throughout the trial.
62642733|NCT06424522|ACTIVE_COMPARATOR|Group II (medical management)|Patients receive medical management comprising fiber, loperamide hydrochloride, and pelvic floor therapy for 1 year. If medical management fails, patients may then be referred for surgery with sacral nerve stimulator placement.
62642734|NCT04221334|ACTIVE_COMPARATOR|Experimental Toothbrush 1|1. A connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
62642735|NCT04221334|ACTIVE_COMPARATOR|Experimental Toothbrush 2|2. A non-connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
62642736|NCT01321034|OTHER|Niacin/Laropiprant|Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study
62277564|NCT06538506|ACTIVE_COMPARATOR|Control Therapy|Participants randomly allocated to the control therapy arm will complete 24 one hour therapy sessions (3x/week for 8 weeks).
62642737|NCT00746551|ACTIVE_COMPARATOR|Ferrous fumarate, Ferri-6®, Oral tablet|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
62277565|NCT02646527|EXPERIMENTAL|DT+|Dignity Therapy is conducted with patients and partners
62073239|NCT03375125|PLACEBO_COMPARATOR|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
62073240|NCT00474929|EXPERIMENTAL|Multiple Myeloma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
62073241|NCT00474929|EXPERIMENTAL|Lymphoma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
62277566|NCT02646527|EXPERIMENTAL|DT|Dignity Therapy is conducted only with patients
62642738|NCT00746551|EXPERIMENTAL|iron sucrose, Venofer®, intravenous drug|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
62642739|NCT03548077|EXPERIMENTAL|Intervention group|Powerplay, a workplace wellness program designed for male-dominated work sites, is the intervention. The program focuses on physical activity, healthy eating, mental wellness, and smoking cessation as well as promoting changes in workplace environments to support employee health and wellness. Program delivery is supported with a detailed program manual and web-based resources. More information about the intervention is available here: http://www.powerplayatwork.com/
62073242|NCT00255658|EXPERIMENTAL|Treatment (sorafenib tosylate, temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. They also receive oral sorafenib\* twice daily starting on day 8 of course 1. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: \*On the days of the temsirolimus infusion, temsirolimus should be taken concurrently with the morning dose of sorafenib.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
62073243|NCT01232465||IVF|those individuals undergoing conventional IVF to inseminate their retrieved eggs
62073244|NCT01232465||ICSI|those individuals whose eggs were fertilized via intracytoplasmic sperm injection (ICSI)
62073245|NCT05222425|EXPERIMENTAL|Treatment group|Patients in the Treatment arm receive Xagrotin extract 2 grams three times a day in combination to the standard of care for sars-cov-2.
62073246|NCT05222425|NO_INTERVENTION|Control group|Patients in the Control arm received the standard of care for sars-cov-2.
62073247|NCT05222425|PLACEBO_COMPARATOR|Placebo group|Patients in the Treatment arm receive green tea 2 grams three times a day in combination to the standard of care for sars-cov-2.
62073248|NCT05389020|EXPERIMENTAL|Intervention group|70 minutes course using newly developed real-size infant's arm and leg manikin
62073249|NCT05389020|NO_INTERVENTION|Control group|70 minutes course using conventional manikin
62642740|NCT02988700|ACTIVE_COMPARATOR|Spinal group|"Intrathecal hyperbaric bupivacaine 0.25mg/kg will be give by lumber puncture that will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.~be given by ."
62073250|NCT03034213|ACTIVE_COMPARATOR|Treatment|Gentrix(TM) Surgical Matrix
62073251|NCT03034213|ACTIVE_COMPARATOR|Control|Standard of care mesh
62073252|NCT05089058|EXPERIMENTAL|Brief cognitive task (delivered digitally)|
62073253|NCT05089058|PLACEBO_COMPARATOR|Brief relaxation exercise task (delivered digitally)|
62073254|NCT04555590|NO_INTERVENTION|Pre H-HOPE Cohort|The Pre-H-HOPE Comparison Cohort will not receive the H-HOPE intervention, and represents the prior standard (non-HOPE).
62073255|NCT04555590|EXPERIMENTAL|H-HOPE Cohort|The H-HOPE Cohort will receive the H-HOPE intervention.
62073256|NCT02055573|EXPERIMENTAL|Ready To Learn|1) The Ready to Learn (RTL) arm will receive a DVD in both Spanish and English and a bilingual booklet (both produced by Parents' action for Children) addressing the benefits of reading, talking and playing with young children, as well as a new children's board book.
62642741|NCT02988700|ACTIVE_COMPARATOR|Caudal group|"caudal plain bupivacaine 2.5mg/kg 0.25% will be given caudally in The sacral hiatus between the sacral conru that will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
62642742|NCT01204671|EXPERIMENTAL|GSK2321138A Lot 1 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
62642743|NCT01204671|EXPERIMENTAL|GSK2321138A Lot 2 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
62642744|NCT01204671|EXPERIMENTAL|GSK2321138A Lot 3 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
62642745|NCT01204671|ACTIVE_COMPARATOR|Fluarix Group|Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
62073257|NCT02055573|EXPERIMENTAL|All Babies Cry|2) The All Babies Cry (ABC) arm will receive a DVD in both, Spanish and English and a bilingual booklet (both produced by VIDA Health Communications, INC) explaining crying as part of normal infant behavior, highlighting signs of parental distress and providing strategies to sooth parents and their children
62073258|NCT03039543|ACTIVE_COMPARATOR|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
62073259|NCT03039543|EXPERIMENTAL|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
62073260|NCT02071550||zero PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
62073261|NCT02071550||10 CM H2O PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
62642746|NCT01204671|ACTIVE_COMPARATOR|GSK2604409A Group|Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
62642747|NCT04245969|EXPERIMENTAL|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the shoulder
62642748|NCT04245969|EXPERIMENTAL|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the affected shoulder
62073262|NCT03650660||Patients with liver cirrhosis|
62073263|NCT05900219|EXPERIMENTAL|Assigned Interventions|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration
62073264|NCT00976482||Pacemaker|Patients currently implanted with permanent Pacemaker according to guidelines
62277567|NCT02646527|NO_INTERVENTION|SPC|standard palliative care
62277568|NCT05456477|EXPERIMENTAL|Beef|Subject will consume beef entrees each day of the study period, and will not consume any additional meat, poultry, seafood, and eggs, other than the study entrees.
62277569|NCT05456477|ACTIVE_COMPARATOR|Poultry|Subject will consume poultry entrees each day of the study period, and will not consume any additional meat, poultry, seafood, and eggs, other than the study entrees.
62277570|NCT01162421|EXPERIMENTAL|Early Adalimumab|Participants in the Early Adalimumab arm will receive adalimumab and methotrexate at Baseline and every other week for study duration.
62277571|NCT01162421|ACTIVE_COMPARATOR|Standard of Care|Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.
62277572|NCT01481311||Patients before dialysis treatment|
62277573|NCT01481311||Patients after dialysis treatment|
62277574|NCT03708055|EXPERIMENTAL|Prevention (weight bearing exercise program)|Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
62277575|NCT04761211|EXPERIMENTAL|smart bra|The patients who were going to take breast ultrasound in the breast surgery clinic were enrolled into the group. The patients were put on the device for about 3 minutes, and the breast was photographed at 5 sites. After that, the artificial intelligence learning was carried out on the photos of the training stage. For the photos of the verification stage, the algorithm obtained by the training stage was compared with the existing artificial intelligence algorithms of ultrasound and molybdenum target.
62277576|NCT01404299|EXPERIMENTAL|Supplementary Group|
62277577|NCT01404299|NO_INTERVENTION|Control Group|
62277578|NCT04173897|EXPERIMENTAL|Intervention arm|12 weeks access to LIBERATE online supportive intervention (dose not specified) including symptom monitoring questionnaire component, with questionnaire results integrated within electronic medical records for clinician review.
62277579|NCT04173897|NO_INTERVENTION|Waiting list control arm|Care and support as usual; no access to intervention. Placed on waiting list to receive intervention following study completion.
62277580|NCT05967663|EXPERIMENTAL|Intervention group|Immediate complete revascularisation
62277581|NCT05967663|ACTIVE_COMPARATOR|Control group|Staged complete revascularisation
62277582|NCT06149598|EXPERIMENTAL|Coughing at the time of first biopsy|Patients are asked to cough during the first biopsy. They should not cough during the second biopsy, and no additional interventions will be performed during the second biopsy.
62277583|NCT06149598|ACTIVE_COMPARATOR|Coughing at the time of second biopsy|Patients are asked to cough during the second biopsy. They should not cough during the first biopsy, and no additional interventions will be performed during the first biopsy.
62277584|NCT05217771|EXPERIMENTAL|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
62277585|NCT05217771|EXPERIMENTAL|control group|Patients in control group will receive high tone sham therapy 3 times per week and self-stretch for hand and shoulder.
62277586|NCT01991132|OTHER|MediView 2.0 software|
62277587|NCT03842020|EXPERIMENTAL|Amiodarone dosage|Blood pharmacokinetics samples
62277588|NCT03998358||High Fatigue|TBI patients with significant fatigue as calculated by a score of \>= 5.5 on the Fatigue Severity Scale
62073265|NCT03375632|EXPERIMENTAL|Uric acid-overproduction Type|
62073266|NCT03375632|EXPERIMENTAL|Uric acid-underexcretion Type|
62277589|NCT03998358||Low Fatigue|TBI patients without significant fatigue as calculated by a score of \< 5.5 on the Fatigue Severity Scale
62277590|NCT01355536||Preterm birth group|Women with prior preterm birth
62277591|NCT01355536||Term birth group|Women with prior term birth
62277592|NCT05824429|EXPERIMENTAL|Connective Tissue Manipulation Group|Urotheraphy Diaphragmatic Breathing Exercises Pelvic Floor Muscle Exercise Connective Tissue Manipülation
62277593|NCT05824429|ACTIVE_COMPARATOR|Control Group|Urotheraphy Diaphragmatic Breathing Exercises Pelvic Floor Muscle Exercise
62642749|NCT04245969|EXPERIMENTAL|No intervention group|To evaluate at the same time than the others groups but without being treated with 448 kilohertz Capacitive Resistive Monopolar Radiofrequency.
62642750|NCT03345641||dyads|dyads with babies and their mothers
62277594|NCT05079503|EXPERIMENTAL|TNT plus GEN-001|Total neoadjuvant therapy (TNT) includes short-course radiotherapy (25 Gy/5fx), followed by systemic chemotherapy with FOLFOX regimen for 3-6 months. GEN-001 is orally administered once daily during total TNT periods and surgery will be performed 1 month after systemic chemotherapy.
62277595|NCT04744337|OTHER|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliance for skeletal class II, Angle's class II division 2 malocclusion.
62277596|NCT03084640|EXPERIMENTAL|Part 1: Dose-Escalation - CMP-001 (SC) and Pembrolizumab|Participants will receive up to 7 escalating dose levels (5 milligrams \[mg\], 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, and 20 mg) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
62277597|NCT03084640|EXPERIMENTAL|Part 1: Dose-Expansion - CMP-001 (SC) and Pembrolizumab|Participants will receive RP2D (as determined in Part 1 dose-escalation phase) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
62073267|NCT03648203|EXPERIMENTAL|TEAMS|Routine asthma care, as provided in the University of Rochester Medical Center Medicine Clinic, will be augmented by three intervention components over a six-month pilot period : (1) Patient subject smartphone asthma monitoring; (2) Nursing telemedicine follow up (virtual home visits); (3) EMR custom programming to guide nursing assessment and management.
62073268|NCT06184490|NO_INTERVENTION|Usual prone position|Prone position with thoraco-abdominal support (cushions on the chest and hips, leaving the abdomen free)
62642751|NCT02113514||Normal Pap smear|Women with normal pap test.
62642752|NCT02113514||Abnormal Pap smear|Women with abnormal pap test.
62277598|NCT03084640|EXPERIMENTAL|Part 2: CMP-001 (SC and IT) and Pembrolizumab|Participants will receive CMP-001 via SC injection once weekly for 2 weeks, then IT injection once weekly for 4 weeks, and SC injection once weekly for every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule. CMP-001 planned IT dose level in Part 2 will be up to 10 mg and the SC dose will be the RP2D determined from Part 1 dose-escalation phase of the study.
62642753|NCT05246657||intervention|EUS-guided Entero-biliary Anastomosis
62642754|NCT05704816||Quincke (Q)-25 Gauge|
62642755|NCT05704816||Quincke (Q)-26Gauge|
62642756|NCT05704816||Quincke (Q)-27 Gauge|
62642757|NCT05704816||Pencil-point (P)-25Gauge|
62642758|NCT05704816||Pencil-point (P)-26Gauge|
62642759|NCT05704816||Pencil-point (P)-27Gauge|
62642760|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
62642761|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
62642762|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
62642763|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
62642764|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
62073269|NCT06184490|EXPERIMENTAL|Modified prone position|Prone position with lateral support (lateral cushions on the chest, hips and abdomen)
62073270|NCT00924560|EXPERIMENTAL|91-day Levonorgestrel Oral Contraceptive|Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
62073271|NCT00924560|ACTIVE_COMPARATOR|28-day Levonorgestrel Oral Contraceptive|Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).
62642765|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
62642766|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
62642767|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
62642768|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
62642769|NCT02572453|EXPERIMENTAL|ALK+ ALCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
62642770|NCT02572453|EXPERIMENTAL|Relapsed MCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
62073272|NCT00924560|NO_INTERVENTION|Untreated Control|Participants received no oral contraceptives during the study.
62073273|NCT06110741||Sampling and survey group|This group will complete questionnaires and participate in sample collection.
62073274|NCT06110741||Survey group|This group will only complete questionnaires
62277599|NCT03541005|EXPERIMENTAL|Obex|a nutritional supplement Obex® 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
62277600|NCT03541005|PLACEBO_COMPARATOR|Placebo|Placebo 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
62277601|NCT05957172||Active Treatment|Subjects assigned to wear the FDA-cleared AMS device for 30-60 days Sequential enrollment to avoid preferential selection Investigator blinded to the AMS data
62277602|NCT05853770|EXPERIMENTAL|TGfU volleyball intervention|"According to the national curriculum, children in Serbia must attend three regular physical education (PE) classes per week.~Besides attending two regular PE classes, participants in the experimental group also followed a 16-week TGfU volleyball intervention that was implemented during the third PE class. The total number of sessions: 32 regular PE + 16 TGfU volleyball intervention ."
62277603|NCT05853770|ACTIVE_COMPARATOR|Control group|Control group (CG) participants followed the national physical education curriculum. The CG participants conducted three regular PE classes per week or 48 regular PE classes in total.
62277604|NCT03188692|EXPERIMENTAL|BK1310|
62277605|NCT01392729||Cohort|
62277606|NCT05207878|EXPERIMENTAL|Movement task|"All participants perform the STEGA-MRI (standardized tracing evaluation \& grapheme assessment - MRI) precision drawing task during fMRI scanning.~Motor assessments outside the MRI do not qualify as interventions."
62277607|NCT04856514|EXPERIMENTAL|Treatment Group|Participation in 16 week telehealth administration of the PEERS protocol for teens (parallel teen and parent/caregiver groups)
62277608|NCT02250014|EXPERIMENTAL|Arm I (cryotherapy, sargramostim)|Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously on days 1, 3, 5, 8, 10, and 12.
62277609|NCT02250014|ACTIVE_COMPARATOR|Arm II (cryotherapy, standard of care)|Patients undergo cryotherapy on day 0.
62642771|NCT02572453|EXPERIMENTAL|BCL6+ DLBCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
62277610|NCT02969057|NO_INTERVENTION|Breakfast only|Control breakfast providing 50g carbohydrate
62277611|NCT02969057|ACTIVE_COMPARATOR|Breakfast with rice bran oil gel|Control breakfast, plus 25g rice bran oil gel (solid)
62277612|NCT02969057|ACTIVE_COMPARATOR|Breakfast with rice bran oil|Control breakfast, plus 25g rice bran oil (liquid)
62277613|NCT02969057|ACTIVE_COMPARATOR|Breakfast with palm oil gel|Control breakfast, plus 25g palm oil gel (solid)
62277614|NCT02969057|ACTIVE_COMPARATOR|Breakfast with palm oil|Control breakfast, plus 25g palm oil (liquid)
62277615|NCT01825031|EXPERIMENTAL|Antiretroviral Therapy|Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs
62277616|NCT01825031|EXPERIMENTAL|Opportunistic Infection (OI) Prophylaxis|Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.
62277617|NCT01825031|EXPERIMENTAL|Nutritional Support|Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.
62277618|NCT01363869|EXPERIMENTAL|Green tea extracts 2 gm/day|Green tea extracts 2 gm/day for 14 days
62277619|NCT01363869|EXPERIMENTAL|Green tea extracts 4 gm/day|Green tea extracts 4 gm/day for 14 days
62642772|NCT06485960||YONAS 1|ESDAM validation
62642773|NCT04925557|ACTIVE_COMPARATOR|Ocrevus|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Ocrevus by their neurologist.
62277620|NCT01363869|EXPERIMENTAL|Green tea extracts 6 gm/day|Green tea extracts 6 gm/day for 14 days
62277621|NCT04453579||116 patients completed a survey|116 patients were assessed during the Italian lockdown by means of a telephone interview performed by a trained researcher. The interview was composed of socio-demographic items (e.g. employed before and during the lockdown, own accommodation during lockdown etc.) and questions about physical and mental health in relation to the COVID-19 emergency
62642774|NCT04925557|ACTIVE_COMPARATOR|Mayzent|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Mayzent by their neurologist.
62073275|NCT01010477|EXPERIMENTAL|Nicotine Nasal Spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. . Nasal spray will be used from the TQD through the end of Week 20.
62277622|NCT00794209|EXPERIMENTAL|1|
62277623|NCT00742339|ACTIVE_COMPARATOR|1|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
62277624|NCT00742339|EXPERIMENTAL|2|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.
62073276|NCT01010477|PLACEBO_COMPARATOR|Placebo nasal spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Nasal spray will be used from the TQD through the end of Week 20.
62073277|NCT05762536|ACTIVE_COMPARATOR|Docetaxel or cabazitaxel (SOC)|
62073278|NCT05762536|EXPERIMENTAL|Docetaxel or cabazitaxel with darolutamide|
62642775|NCT04844216|EXPERIMENTAL|Nasolabial fold treated with experimental device|"STYLAGE® L Lidocaine is a hyalorunic acid injectable gel whose intended purpose is the filling of skin depressions on the face by dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
62642776|NCT04844216|ACTIVE_COMPARATOR|Nasolabial fold treated with comparator|"The active comparator is a hyalorunic acid injectable gel whose intended purpose is the filling of mid and/or deep depressions of the skin via mid and/or deep dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
62642777|NCT05356221||Ponto Users|Users that have been fitted with a Bone Anhcored Sound Processor, Ponto
62277625|NCT02766829|EXPERIMENTAL|CLSP Group|Those with cross leg sitting position: patients sit with both their knees flexed medially, hip flexed, resulting in pelvic leaning posteriorly and reducing lumbal lordosis.
62642778|NCT05986123|OTHER|Topical cream for PIH|The topical cream contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract.
62073279|NCT02780986|ACTIVE_COMPARATOR|Female entertainment worker intervention group|The intervention program for the female EE workers aims to increase STI/HIV prevention knowledge and develop their condom negotiation and application skills so as to increase condom use with both casual and paid partners. It consists of a total of 4 sessions: 2 on-site and 2 online sessions. For each on-site session, groups of 4 to 5 female EE workers will be gathered. The 2 on-site sessions would be delivered by peer educators. The 2 online sessions would be conducted via phone and other modes of network communication (e.g. SMS message or WhatsApp message) depending on the preference of each participant. In addition, all the intervention materials and video demonstrations will also be uploaded onto the web portal for the participant to access during their free time.
62073280|NCT02780986|NO_INTERVENTION|Female entertainment worker control group|"The female EE workers in the control group will receive the same number of 2 onsite and 2 online sessions but covering healthy eating and physical activity.~The following gives a summarised breakdown and content of each session:~Session 1 (on-site immediately after baseline survey, 10 minutes):~The peer educator will share information on healthy eating and physical activity using the educational pamphlets from the Health Promotion Board (HPB) with the participants.~Session 2 (online 1-2 weeks after baseline survey, 5 minutes):~The peer educator will share an app on healthy eating with the participants.~Session 3 (online 3-4 weeks after baseline survey, 5 minutes):~The peer educator will share an app on physical activity with the participants.~Session 4 (onsite during follow-up survey, 10 minutes):~The peer educator will reinforce information on healthy eating and physical activity based on the educational pamphlets from HPB with the participants."
62073281|NCT02780986|ACTIVE_COMPARATOR|Heterosexual men intervention group|The intervention program for heterosexual men patronising EEs will be a holistic non disease-centric, non-stigmatising and non-judgemental program addressing sexual well-being, avoidance of casual and paid sex if possible and safe sex such as condom use.
62642779|NCT02007902||Very preterm babies|Observational model: cohort
62073282|NCT02780986|NO_INTERVENTION|Heterosexual men control group|There will be a simultaneous programme on healthy eating and physical activity at the control site at Tanjong Pagar. Health promoters will go around Tanjong Pagar and distribute pamphlets and brochures developed by the HPB on healthy eating and physical activity to the heterosexual men who step into or out of the EEs there. These health promoters have been trained to give simple health advice on healthy eating and physical activity if the heterosexual men wish to find out more information.
62073283|NCT00450320|ACTIVE_COMPARATOR|Rapamycin|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen.
62277626|NCT02766829|ACTIVE_COMPARATOR|TSP Group|Those with traditional sitting position: patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion.
62277627|NCT01266486|EXPERIMENTAL|Metformin|
62277628|NCT02695511|EXPERIMENTAL|25% CR|25% caloric restriction
62277629|NCT02695511|NO_INTERVENTION|CO (control)|healthy lifestyle recommendation
62642780|NCT00552695|ACTIVE_COMPARATOR|1|Lidocaine 70 mg/tetracaine 70 mg skin patch
62642781|NCT00552695|PLACEBO_COMPARATOR|2|
62642782|NCT04564911|EXPERIMENTAL|Flash Glucose Monitoring and Education|Participants randomised to the experimental arm will receive an education package and wear the flash glucose monitoring system. They will use sensor glucose data for self-management.
62073284|NCT01317875|EXPERIMENTAL|Stratum -1|Participants with baseline Platelet counts of 75-99 x10\^9/L
62277630|NCT05976191|EXPERIMENTAL|experimental group|Patients whose blood glucose is measured intravenously and from the fingertip
62277631|NCT05976191|NO_INTERVENTION|control group|Patients with fingertip blood glucose measurement
62277632|NCT01747057|EXPERIMENTAL|Dynamic guide resuscitation|This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.
62277633|NCT01747057|ACTIVE_COMPARATOR|Standard resuscitation|This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.
62277634|NCT01963065||Moderately pre-term infants and their mothers|cohort of moderately pre-term infants and their mothers
62277635|NCT03567070|OTHER|qualitative study based on an individual clinical interview|
62277636|NCT00525759|ACTIVE_COMPARATOR|A|Neoadjuvant chemotherapy alone
62642783|NCT04564911|ACTIVE_COMPARATOR|Capillary Glucose Monitoring and Education|Participants randomised to the control arm will receive an education package and self-manage their glucose levels utilising a standard capillary blood glucose device, and keeping a glucose diary for the duration of the intervention period.
62642784|NCT01809756|ACTIVE_COMPARATOR|Caphosol|
62073285|NCT01317875|EXPERIMENTAL|Stratum -2|Participants with baseline Platelet counts of 50-74 x10\^9/L
62073286|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.~no intervention/Observational"
62277637|NCT00525759|EXPERIMENTAL|B|Neoadjuvant chemotherapy + zoledronic acid
62277638|NCT04368949|EXPERIMENTAL|Stepping-Up Group|Participants will attend one 2-hour virtual session (1-hour exercise and 1-hour SM) per week. Each class of 6-8 participants is supervised by a Physiotherapist (PT) and kinesiologist who will individually tailor the exercises for each participant.
62277639|NCT04368949|ACTIVE_COMPARATOR|TELE Group|The initial telephone session will be 20-30 minutes, with subsequent weekly calls will be approximately 10 minutes.
62642785|NCT01809756|NO_INTERVENTION|No intervention|
62277640|NCT04368949|PLACEBO_COMPARATOR|Chair-Based Yoga Group|Participants will attend two 1-hour virtual sessions per week to ensure this group is matched for attention to STEPPING-UP.
62642786|NCT02244983||EFAB 65|Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample
62073287|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.~no intervention/Observational"
62073288|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.~no intervention/Observational"
62277641|NCT03083028|ACTIVE_COMPARATOR|Non Operative|"Non-Operative~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
62277642|NCT03083028|ACTIVE_COMPARATOR|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
62277643|NCT01441570|ACTIVE_COMPARATOR|Nebivolol|
62277644|NCT01441570|ACTIVE_COMPARATOR|Metoprolol Succinate|
62277645|NCT02154087|EXPERIMENTAL|HP802-247|
62277646|NCT04275622|EXPERIMENTAL|Intervention|Intervention group receives lifestyle intervention for hypertriglyceridemia.
62277647|NCT04275622|NO_INTERVENTION|Control|Control group receives regular surveillance.
62277648|NCT03227705|ACTIVE_COMPARATOR|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
62277649|NCT03227705|EXPERIMENTAL|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
62277650|NCT02623738|PLACEBO_COMPARATOR|Placebo ophthalmic solution|Eyedrop
62642787|NCT01575080|EXPERIMENTAL|Intended Users of the Monitoring System|Untrained subjects with diabetes use Contour TS Blood Glucose Monitoring System.
62642788|NCT02124824|EXPERIMENTAL|Arm 1: Control|Control
62642789|NCT02124824|EXPERIMENTAL|Arm 2: Heart Failure|Heart Failure
62642790|NCT02247466|ACTIVE_COMPARATOR|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
62642791|NCT02247466|ACTIVE_COMPARATOR|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
62642792|NCT03528148|EXPERIMENTAL|active cycling group|effect of combine cycling and conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
62642793|NCT03528148|ACTIVE_COMPARATOR|control group|effect of combine conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
62073289|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).~no intervention/Observational"
62073290|NCT04772885|EXPERIMENTAL|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
62642794|NCT05799846|ACTIVE_COMPARATOR|STANDARD Behavioral|This is a 12-month Internet-delivered behavioral weight loss (iBWL) program that has been used in numerous studies and is currently considered our 'standard' treatment. Participants are asked to adhere to calorie and physical activity (PA) goals and are required to self-monitor weight, intake, and PA daily via a study website. Participants will have a training session prior to beginning iBWL to learn about the website and their specific weight-related goals. The iBWL includes 3 months of weekly video lessons teaching skills to modify eating and PA behaviors. These lessons and individualized feedback to participants incorporate key BWL strategies. Participants will then have a 'refresher' training session at 3 months to discuss standard behavioral weight loss strategies and help control for contact across arms. For the remainder of the program (months 4-12) participants will have monthly lessons, self-monitoring (tracking calories and PA 1 wk/month) and feedback.
62277651|NCT02623738|EXPERIMENTAL|DE-117 ophthalmic solution low|Eyedrop
62277652|NCT02623738|EXPERIMENTAL|DE-117 ophthalmic solution high|Eyedrop
62277653|NCT02623738|ACTIVE_COMPARATOR|Latanoprost ophthalmic solution 0.005%|Eyedrop
62642795|NCT05799846|EXPERIMENTAL|PREVENT|This is a 12-month Internet-delivered behavioral weight loss (iBWL) program in which participants are asked to adhere to calorie and physical activity (PA) goals and are required to self-monitor weight, intake, and PA daily via a study website. Additionally, PREVENT uses a future-oriented cognitive strategy featuring Episodic Future Thinking (EFT) to focus on long-term negative consequences of unhealthy choices. Participants will receive training in PREVENT strategies prior to beginning iBWL. The iBWL includes 3 months of weekly video lessons teaching skills to modify eating and PA behaviors. These lessons and individualized feedback to participants are framed according to PREVENT (i.e., focusing on avoiding long-term consequences of unhealthy choices) and include specific exercises and reminders to use the strategy. Participants will then have a 'refresher' training session at 3 months, followed by monthly lessons, self-monitoring (tracking calories and PA 1 wk/month) and feedback.
62277654|NCT02488863||Older Adults with Musculoskeletal Pain|Older adults (60+ years old) experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
62642796|NCT05799846|EXPERIMENTAL|PROMOTE|This is a 12-month Internet-delivered behavioral weight loss (iBWL) program in which participants are asked to adhere to calorie and physical activity (PA) goals and are required to self-monitor weight, intake, and activity daily via a study website. Additionally, PROMOTE uses a future-oriented cognitive strategy featuring Episodic Future Thinking (EFT) to focus on long-term benefits of healthy choices. Participants will receive cognitive training in PROMOTE prior to beginning iBWL. The iBWL includes 3 months of weekly video lessons teaching skills to modify eating and activity behaviors. These lessons and individualized feedback to participants are framed according to PROMOTE (i.e., focusing on achieving long-term benefits of healthy choices) and include specific exercises and reminders to use the strategy. Participants will then have a 'refresher' training at 3 months, followed by monthly lessons, self-monitoring (tracking calories and PA 1 wk/month), and feedback.
62277655|NCT02488863||Older Adults without Musculoskeletal Pain|Older adults (60+ years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
62073291|NCT04772885|EXPERIMENTAL|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
62277656|NCT02488863||Young Controls|Healthy young adults (18-25 years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
62277657|NCT04747171|ACTIVE_COMPARATOR|magnesium intrathecal|
62277658|NCT04747171|ACTIVE_COMPARATOR|dexamethasone intrathecal|
62642797|NCT04925102||GMFCS level I|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level I will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
62642798|NCT04925102||GMFCS level II|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level II will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
62277659|NCT04747171|ACTIVE_COMPARATOR|dexmedetomidine intrathecal|
62277660|NCT01046877|EXPERIMENTAL|Tympanostomy Tube placement|Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
62277661|NCT01702610|EXPERIMENTAL|Temozolomide, Accelerated Hypofractionated RT|Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
62642799|NCT04925102||GMFCS level III|Goal specific treatment protocol with respect to the problem enlisted in GMFCS level III will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
62277662|NCT03778164|EXPERIMENTAL|Fast Track Intervention|This arm refers to the new Partner Services-Sexual Health intervention offered to contacts by the Partner Services program
62642800|NCT04925102||GMFCS level IV|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level IV will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
62642801|NCT04925102||GMFCS level V|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level V will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
62642802|NCT01944657|ACTIVE_COMPARATOR|Standard Medication Monotherapy Group|A group of 15 patients will receive only standard antidepressant medication treatment.
62642803|NCT01944657|ACTIVE_COMPARATOR|Supplemental TMS plus Medication Group|A group of 15 patients will receive supplemental transcranial magnetic stimulation (TMS) plus standard antidepressant medication.
62277663|NCT03778164|ACTIVE_COMPARATOR|Standard of Care|This arm refers to the current standard practice for partners contacted by the Partner Services program
62277664|NCT01146678|EXPERIMENTAL|Lantus(insulin glargine)/lixisenatide on-site mix|Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions
62277665|NCT01146678|ACTIVE_COMPARATOR|lixisenatide + Lantus (insulin glargine)|Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions
62277666|NCT03061266|EXPERIMENTAL|E-health education group|E-health education group will be received the shared care program using e-health education.
62277667|NCT03061266|OTHER|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
62277668|NCT04803838||Patiens|Patients With symptomatic or asymptomatic carotid stenosis (\> 50%, NASCET criteria)
62277669|NCT04803838||Controls|For study 1: Healthy Controls, volunters (mostly blood donors) For study 2 and 3: Spouses/someone living in the same household as the patient.
62277670|NCT01847885|EXPERIMENTAL|Smartpatch Treatment Group|Subjects in the Treatment Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
62277671|NCT01847885|SHAM_COMPARATOR|Smartpatch Control Group|Subjects in the Control Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, but will not receive any electrical stimulation.
62277672|NCT06205108|EXPERIMENTAL|taVNS stimulation|taVNS is a non-invasive technique to stimulate the auricular branch of the vagus nerve. Transcutaneous electrodes are placed in the cymba concha of the ear and short bursts (20Hz, 1s, 400µs pulse widths) of stimulation are delivered either in parallel to the action or the feedback. Stimulation strength is individually calibrated. Stimulation lasts \~1h in the session.
62073292|NCT04772885|EXPERIMENTAL|Food Effect Cohort in healthy subjects|Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.
62277673|NCT06205108|SHAM_COMPARATOR|sham stimulation|Stimulation at the earlobe that is not innervated by the vagus nerve with the same parameters (short bursts, 20Hz, 1s, 400µs pulse widths, delivered in parallel to the action or the feedback). Stimulation strength is individually calibrated. Stimulation lasts \~1h throughout the study. Stimulation lasts \~1h in the session.
62642804|NCT05197816|EXPERIMENTAL|Deep brain stimulation|All patients will undergo adaptive deep brain stimulation with results compared before and after stimulation
62642805|NCT04693793|NO_INTERVENTION|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the Janssen test results.
62277674|NCT02396810|PLACEBO_COMPARATOR|No intra-operative MRI|Patients undergo transsphenoidal surgery without an intra-operative MRI.
62642806|NCT04693793|EXPERIMENTAL|Educational Materials and Janssen Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
62642807|NCT04693793|EXPERIMENTAL|Educational Materials and Janssen Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
62642808|NCT02988011|ACTIVE_COMPARATOR|Gastric by-pass surgery|Gastric by-pass surgery without prior low-caloric diet
62277675|NCT02396810|EXPERIMENTAL|intra-operative MRI|Patients undergo transspheonidal surgery followed by intra-operative MRI.
62277676|NCT01683201|EXPERIMENTAL|Functional exercise class|Functional exercise class 45 mins twice weekly from week 12 to week 18
62277677|NCT01683201|PLACEBO_COMPARATOR|Usual Care Group|Usual Care
62277678|NCT03731286|ACTIVE_COMPARATOR|Alpinia galanga|EnXtra: 2 capsules to be taken twice daily after breakfast and evening.
62277679|NCT03731286|ACTIVE_COMPARATOR|Composite (Alpinia galanga + Caffeine)|Composite: 2 capsules to be taken twice daily after breakfast and evening.
62277680|NCT03731286|PLACEBO_COMPARATOR|Placebo|Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.
62277681|NCT01629147|EXPERIMENTAL|Biogaia|5 drops containing Lactobacillus reuteri Protectis
62277682|NCT01629147|PLACEBO_COMPARATOR|Placebo|- 5 drops identical in appearance and taste
62277683|NCT02867995|NO_INTERVENTION|Control|No glaucoma drop aid control
62277684|NCT02867995|ACTIVE_COMPARATOR|Eye Drop Aids|Participants could be placed into one of the drop aid groups (Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, or the Simply Touch Eye Drop Applicator)
62277685|NCT03281980|EXPERIMENTAL|Intervention (UCT+HE+PS)|The participants of this arm will receive UCT and HE along with psychosocial stimulation (PS)
62277686|NCT03281980|SHAM_COMPARATOR|Government Intervention (UCT+HE)|The participants of this arm will receive only UCT and HE
62277687|NCT03281980|NO_INTERVENTION|Comparison|
62277688|NCT00720928|OTHER|single group|"Posterior uveitis patients having complete or incomplete type of Behcet's disease; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.~Selection of study eye : For patients with unilateral uveitis, the study eye will be the affected eye; for patients with bilateral uveitis, the study eye will be the more severely affected eye (i.e., the eye having suffered more recurrences in the previous year, or if equal, the eye having received more therapy in the previous year, or if equal, the eye having the worse VA, or if equal, the eye clinically judged to be the more severely affected eye)."
62277689|NCT04117776||Patients|Patient benefiting during the same hospitalization of the loss or the gain of a central venous catheter.
62277690|NCT04272931|EXPERIMENTAL|Portal and Hepatic Vein Embolization|3 patients per center over one year approximately 90 patients in total. Patients will undergo portal vein and hepatic vein embolization instead of only portal vein embolization.
62277691|NCT02526550|EXPERIMENTAL|Imojev|Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
62455577|NCT03712553|EXPERIMENTAL|B4: Active MPM User, BE MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic message with behavioral economic principles on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
62277692|NCT02532270|EXPERIMENTAL|Group C|Arterial pressure of the patients in Group C is measured by continuous non-invasive arterial pressure (CNAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
62277693|NCT02532270|EXPERIMENTAL|Group N|Arterial pressure of the patients in Group N is measured by intermittent oscillometric non-invasive arterial pressure (NIAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
62455578|NCT03712553|ACTIVE_COMPARATOR|B5: Non-MPM User, UC Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
62073293|NCT04772885|EXPERIMENTAL|Multiple dose cohort in HS and AD patients|A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.
62642809|NCT02988011|ACTIVE_COMPARATOR|Low-caloric diet|Low-caloric diet followed by gastric by-pass surgery
62642810|NCT03585270|EXPERIMENTAL|Clazosentan|Participants will receive clazosentan for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
62642811|NCT03585270|PLACEBO_COMPARATOR|Placebo|Participants will receive clazosentan matching-placebo for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
62642812|NCT03551795|EXPERIMENTAL|treatment|The eligible patient receive the experimental infusion of iNKT cells.
62642813|NCT01035749|EXPERIMENTAL|AREPANRIX-ADJUVANTED F1 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 1 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
62642814|NCT01035749|EXPERIMENTAL|AREPANRIX-ADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
62277694|NCT05558878|EXPERIMENTAL|Ambroxol (intervention arm)|40 patients will receive conventional therapy for diabetic neuropathy in addition to ambroxol 450 mg/day divided into 3 doses (each dose consists of 2 75mg capsules) daily for 3 months.
62277695|NCT05558878|NO_INTERVENTION|Control arm|40 patients will receive conventional therapy for diabetic neuropathy for 3 months.
62277696|NCT06165614|EXPERIMENTAL|Artesunate vaginal inserts/ pessaries|Artesunate vaginal inserts/pessaries are used as a treatment for cervical precancerous lesions.
62277697|NCT05429294|EXPERIMENTAL|Intervention|Pyrotinib combined with trastuzumab and albumin paclitaxel
62277698|NCT01888458|EXPERIMENTAL|Micafungine|
62455579|NCT03712553|EXPERIMENTAL|B6: Non-MPM User, BE Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a letter with behavioral economic principles (BE) encouraging them to contact their primary care provider for Hepatitis C screening.
62455580|NCT01532622|ACTIVE_COMPARATOR|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days.
62642815|NCT01035749|EXPERIMENTAL|AREPANRIX-ADJUVANTED F2 3D GROUP|Subjects received 3 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0, Day 21 and Day 182 (booster).
62642816|NCT01035749|EXPERIMENTAL|AREPANRIX-UNADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ unadjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
62642817|NCT00518570|EXPERIMENTAL|Open-Label treatment|Patients prospectively diagnosed with premenstrual dysphoric disorder.
62642818|NCT04184401|EXPERIMENTAL|Replacement with albumin|"1. Check drain amount every 4 hour after SICU admission~2. Replacement of 70% of drainage from previous 4 hours over next 4 hours~   * 30% of the drainage with 5% albumin~  * 40% of drainage with Hartmann's solution~  * If, serum K + level\> 5mEq/L, replace with 0.9% saline instead of Hartmann solution~  * If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
62642819|NCT04184401|ACTIVE_COMPARATOR|Replacement with Hartmann's solution|"1. Check drain amount every 4 hour after SICU admission~2. Replacement of 70% of drainage from previous 4 hours with Hartmann's solution over next 4 hours~   * If, serum K + level\> 5mEq/L, replace with 0.9% saline instead of Hartmann solution~  * If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
62642820|NCT06482164|OTHER|Dry Eye Disease|Patients who have signs of dry eye
62277699|NCT02525159|ACTIVE_COMPARATOR|DIM pills|75 mg of 3,3´-diindolylmethane (DIM) once a day for 30 days
62277700|NCT02525159|PLACEBO_COMPARATOR|Placebo pills|2 pills once a day for 30 days
62277701|NCT01949363|EXPERIMENTAL|Stage 2 (Cohorts C and D)|Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
62277702|NCT01949363|EXPERIMENTAL|Stage 1 (Cohorts A and B)|Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
62277703|NCT05090293|ACTIVE_COMPARATOR|Lifestyle Intervention (LI)|Participants will receive a standard, 12-week, group-delivered cognitive behavioral lifestyle intervention for weight loss.
62455581|NCT01532622|PLACEBO_COMPARATOR|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
62642821|NCT02084511|EXPERIMENTAL|BI 1026706 low dose|BI 1026706 low dose
62642822|NCT02084511|EXPERIMENTAL|BI 1026706 high dose|BI 1026706 high dose
62277704|NCT05090293|EXPERIMENTAL|Lifestyle Intervention with Body Image Treatment (LIBI)|Participants will receive a standard, 12-week, group-delivered cognitive behavioral lifestyle intervention for weight loss supplemented with a novel body image intervention designed to address body image issues in the context of weight loss.
62277705|NCT02007707|EXPERIMENTAL|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
62455582|NCT04330807|OTHER|Patient with chronic kidney disease|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
62642823|NCT02084511|EXPERIMENTAL|Placebo reference|Placebo reference
62642824|NCT02084511|EXPERIMENTAL|Celecoxib reference|Celecoxib capsule
62642825|NCT01187316|EXPERIMENTAL|TENS|
62642826|NCT01187316|ACTIVE_COMPARATOR|Massage therapy and muscle stretching|
62642827|NCT03297190|ACTIVE_COMPARATOR|SMS|Participants will receive SMS messages on nutrition and health related topics
62642828|NCT03297190|ACTIVE_COMPARATOR|Interpersonal|Participants will receive interpersonal counselling on nutrition and health related topics
62455583|NCT04330807|OTHER|CONTROL GROUP|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
62455584|NCT04058223||PPH/DST|Patients underwent hemorrhoidopexy by PPH or DST stapler.
62455585|NCT04219501|NO_INTERVENTION|Control Group|Subjects presenting for PVC/VT ablation will undergo ablation procedures using standard of care invasive electroanatomical mapping systems.
62455586|NCT04219501|EXPERIMENTAL|VIVO Arm|Subjects presenting for PVC/VT ablation, that have a previously acquired cardiac CT/MRI scan or are having a cardiac CT/MRI scan as per routine care, will undergo ablation procedures using VIVO, a novel, non-invasive mapping system.
62642829|NCT03297190|ACTIVE_COMPARATOR|SMS + Interpersonal|Participants will receive SMS messages on nutrition and health related topics as well as interpersonal counselling on nutrition and health related topics
62642830|NCT03297190|NO_INTERVENTION|Usual Care|
62642831|NCT03313739|EXPERIMENTAL|Intervention group|An Educational Program
62642832|NCT03313739|NO_INTERVENTION|Control group|This group(n=30) received no intervention.
62277706|NCT02007707|ACTIVE_COMPARATOR|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach.
62277707|NCT04731935|EXPERIMENTAL|tAN Therapy|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 120 hours (5 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness.
62073294|NCT04772885|EXPERIMENTAL|Multiple dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.
62073295|NCT00723333||Affected Group|Patients \> 60 years of age with Primary Myelofibrosis that have undergone an allogeneic transplant
62073296|NCT00042796|EXPERIMENTAL|Treatment (decitabine)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
62277708|NCT01531283|EXPERIMENTAL|decaylated ghrelin|UAG (4.0 µg/kg/hr)
62277709|NCT01531283|EXPERIMENTAL|acyl ghrelin|AG (1.0 µg/kg/hr)
62073297|NCT05731882|EXPERIMENTAL|Catheter ablation+E-SeaLATM|
62073298|NCT05099016|EXPERIMENTAL|Joint Effort (mobile application)|The Joint Effort mobile application aims to support young adults into taking action on their cannabis use. Based on the Theory of Planned Behaviour, the content focuses on intention, attitude and perceived behavioral control. Various intervention methods and strategies are used to address these determinants (e.g., personalized feedback, persuasive communication, self-observation and activation of intention). The objectives includes: to allow the individual to become aware (or more aware) of their cannabis use, to support the individual's decision-making process of taking action on their cannabis use, to guide and support the establishment and sustainability of an action plan. An optional logbook-type feature (weekly journal of cannabis use) allows personalized monitoring and data collection throughout the course of the intervention.
62277710|NCT01531283|EXPERIMENTAL|combined acyl and desacyl ghrelin|the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
62277711|NCT01531283|PLACEBO_COMPARATOR|saline|saline
62277712|NCT02313779|PLACEBO_COMPARATOR|Neutral|Reading passage about brain function which is masked as a news article.
62277713|NCT02313779|EXPERIMENTAL|Lovingkindness Meditation (LKM)|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
62277714|NCT02313779|PLACEBO_COMPARATOR|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
62277715|NCT02313779|EXPERIMENTAL|Positivity|Reading passage about prioritizing positive emotions which is masked as a news article.
62277716|NCT01465659|EXPERIMENTAL|Temozolomide 100 mg/m2 and Pazopanib 400 mg|Temozolomide 100 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
62277717|NCT01465659|EXPERIMENTAL|Temozolomide 75 mg/m2 and Pazopanib 400 mg|Temozolomide 75 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
62073299|NCT05099016|ACTIVE_COMPARATOR|Brief normative feedback and standard information|The comparator is composed of a a brief normative feedback regarding last month frequency of cannabis use and basic reliable non personalized information on lower-risk cannabis use (official public websites).
62073300|NCT03766893|EXPERIMENTAL|Pharmacy based opioid use disorder care|A single-arm pilot study to test the collaborative pharmacy practice agreement for MAT (using the medications buprenorphine or injectable naltrexone) care model with up to 12 patients with opioid use disorder, assessing feasibility of medication dispensing, administration, and monitoring in the pharmacy, and determining patient acceptability of this model.
62073301|NCT04186676||MINOCA patients|Prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in consecutive patients with Myocardial Infarction with Non-Obstructive Coronary Arteries admitted to study clinical sites
62277718|NCT01465659|EXPERIMENTAL|Temozolomide 150 mg/m2 and Pazopanib 400 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
62073302|NCT04017429|EXPERIMENTAL|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
62073303|NCT04017429|ACTIVE_COMPARATOR|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
62277719|NCT00684957|ACTIVE_COMPARATOR|Recombinant Human Growth Hormone first|Subjects will take rhGH for eight weeks followed by a two month wash out period and then will cross over to rhIGF1 for eight weeks.
62277720|NCT00684957|ACTIVE_COMPARATOR|Recombinant Human IGF-1|Subjects will take rhIGF1 for eight weeks followed by a two month wash out period and then will cross over to rhGH for eight weeks.
62277721|NCT04537689|EXPERIMENTAL|Ixekizumab|"Participants will be offered ixekizumab as first-line systemic treatment for moderate to severe PsO. The indication for ixekizumab will be equivalent to current registered indications. Standard dose of subcutaneous ixekizumab for moderate to severe PsO will be given at 160 mg at week 0, followed by ixekizumab 80mg at weeks 2, 4, 6, 8, 10 and 12, then 4 weekly thereafter, for a total duration of 6 months.~Ixekizumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO.~Relapses will be managed as per standard care."
62277722|NCT04537689|ACTIVE_COMPARATOR|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
62277723|NCT02154412|EXPERIMENTAL|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) \& an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
62277724|NCT02154412|NO_INTERVENTION|No respiratory training|Participants will not participate in the respiratory muscle training.
62455587|NCT00622609|EXPERIMENTAL|Subjects receiving GSK249320A|Eligible subjects will receive escalating doses of GSK249320A in cohort 1 to 6 with a starting dose of 0.04 milligrams/kilograms up to the maximum dose of 25 milligrams/kilograms, administered as a slow intravenous infusion over 1 hour on Day 1.
62455588|NCT00622609|PLACEBO_COMPARATOR|Subjects receiving placebo|Eligible subjects will receive single dose of sodium chloride in cohort 1 to 6, administered as a slow intravenous infusion over 1 hour on Day 1.
62455589|NCT01462565|EXPERIMENTAL|All subjects|Subjects enter the study already taking current marketed FLOLAN (epoprostenol sodium) and continue for 4 weeks (run-in). At baseline, they will be swopped to the new thermo stable formulation of epoprostenol sodium for 4 weeks (or longer if they continue in the extension phase of the study).
62073304|NCT03376802|EXPERIMENTAL|SAR425899|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 19 days
62073305|NCT03376802|PLACEBO_COMPARATOR|Placebo|Repeated once daily SC doses of placebo administered over 19 days
62073306|NCT02609659|EXPERIMENTAL|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) plus RBV (ribavirin \[600 mg once daily\]) for 12 weeks.
62277725|NCT03811509|ACTIVE_COMPARATOR|AI with osteoporosis|Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
62455590|NCT03670238|EXPERIMENTAL|Orogastric intubation|Orogastric intubation using a polyurethane enteral tube followed by fixation of the tube tip to a superior molar.
62455591|NCT03670238|ACTIVE_COMPARATOR|Nasogastric intubation|Nasogastric intubation using a polyurethane enteral tube followed by fixation of the tube to the patient face.
62073307|NCT05438030|EXPERIMENTAL|Paired cardiac MRI and echocardiographic measurements|
62073308|NCT04114136|EXPERIMENTAL|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Metformin|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)~Metformin - 500 mg by mouth twice daily"
62073309|NCT04114136|EXPERIMENTAL|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Rosiglitazone|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)~Rosiglitazone - 4 mg by mouth once daily"
62277726|NCT03811509|NO_INTERVENTION|AI without osteoporosis|All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
62277727|NCT06385015|EXPERIMENTAL|Diabetes Prevention Program (DPP) group|The DPP group will receive a tailored Diabetes Prevention Program.
62073310|NCT04114136|ACTIVE_COMPARATOR|Anti-PD-1 mAb (nivolumab or pembrozilumab)|nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
62277728|NCT06385015|NO_INTERVENTION|Control group|The control group will receive access to materials on study habits (fall), alcohol use (winter), and financial literacy (spring). The control group will receive the materials via e-mail for participants to review on their own time. A research assistant will meet with control participants via Zoom to explain the materials. The Zoom session will take approximately 1 hour.
62277729|NCT04638491|EXPERIMENTAL|single-arm|PM01183-Dose Escalation
62277730|NCT04682470||All patients|
62277731|NCT01583374|EXPERIMENTAL|Apremilast 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
62642833|NCT02115984|EXPERIMENTAL|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
62073311|NCT03124628|EXPERIMENTAL|Flywheel resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform flywheel leg press resistance exercise twice per week.
62277732|NCT01583374|EXPERIMENTAL|Apremilast 30 mg|Apremilast 30 mg was taken orally twice a day
62277733|NCT01583374|PLACEBO_COMPARATOR|Placebo|Identically matched placebo tablets were taken orally twice a day
62277734|NCT05688787|ACTIVE_COMPARATOR|Perineural injection arm|"30 patients will be received 4 sessions of perineural injection~1 week a part with optional additional sessions per the physician recommadation and the patient preference .injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest \&amp; T10 cross over iliac crest at a distance 8-10cm"
62277735|NCT05688787|NO_INTERVENTION|Standard treatment|will be received standard of care treatment of fibromyalgia
62642834|NCT02115984|PLACEBO_COMPARATOR|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
62642835|NCT05334667|PLACEBO_COMPARATOR|Control group|Patients will receive routine management only.
62642836|NCT05334667|ACTIVE_COMPARATOR|CRRT group|Patients will receive CRRT and routine management.
62642837|NCT05334667|ACTIVE_COMPARATOR|PPH group|Patients will receive plasmapheresis and routine management.
62642838|NCT00465530|EXPERIMENTAL|2|Saline plus Gentamycin
62642839|NCT00465530|PLACEBO_COMPARATOR|1|Saline
62642840|NCT02112253|EXPERIMENTAL|Deep brain stimulator ventral electrode up to 2 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
62642841|NCT02112253|EXPERIMENTAL|Deep brain stimulator ventral electrode up to 3 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
62642842|NCT02112253|EXPERIMENTAL|Deep brain stimulator dorsal electrode up to 2 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
62455592|NCT03784456|EXPERIMENTAL|25% protein group|This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
62642843|NCT02112253|EXPERIMENTAL|Deep brain stimulator dorsal electrode up to 3 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
62642844|NCT02112253|ACTIVE_COMPARATOR|Deep brain stimulator empirical programming|Any of the four electrode contacts on each of the two deep brain stimulation leads can be activated in any combination with any amplitude, frequency or pulse width settings to achieve optimized clinical control of motor tics whilst minimizing side effects. Both programmer and patient may be unblinded. The assessors are blinded to stimulation settings.
62642845|NCT03434483||Acute Coronary Syndrome|Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
62642846|NCT03434483||ACS-Angiographic substudy|"Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.~Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .~Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis"
62642847|NCT03434483||Chronic coronary atherosclerosis|Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
62642848|NCT04879017|EXPERIMENTAL|FHD-286 dose escalation and expansion|Up to approximately 125 patients will be enrolled in dose escalation and expansion
62642849|NCT01988467|EXPERIMENTAL|nasal breathing|"At the time that the exposure took place with nasal breathing, the study was as follows:~Before the exposure: rhinomanometry, IOS , FeNO , spirometry, plethysmography, P.100.~Exposure to second hand smoking:Each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: rhinomanometry, IOS , FeNO , spirometry,plethysmography , P.100."
62642850|NCT01988467|EXPERIMENTAL|oral breathing|"At the time that the exposure took place with oral breathing, the study was as follows:~Before the exposure: IOS, exhaled nitric oxide (FeNO), spirometry, plethysmography and P.100.~Exposure to second hand smoking: each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: IOS, FeNO, spirometry,plethysmography and P.100."
62642851|NCT04602286|EXPERIMENTAL|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce pain intensity and unpleasantness."
62642852|NCT04602286|SHAM_COMPARATOR|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
62642853|NCT04602286|SHAM_COMPARATOR|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
62642854|NCT04602286|NO_INTERVENTION|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
62642855|NCT06527690|EXPERIMENTAL|self-identified as from Black racial origin irrespective of ethnicity|Cohort A will include participants self-identified as from Black origin as defined as having origins in any of the Black racial groups of Africa, as per the FDA Guidance on Collection of Race and Ethnicity Data in Clinical Trials, and irrespective of ethnicity. This includes participants with more than one race, including pardos.
62642856|NCT06527690|EXPERIMENTAL|Racially self-identified as Native Indigenous American or self-identified Latino and racially White|"Cohort B will include participants of the following racial and ethnic backgrounds:~1. self-identified as from Native Indigenous American origins as per the FDA Guidance on Collection of Race and Ethnicity Data in Clinical Trials, irrespective of ethnicity (this includes participants with more than one race, including mestizos)~2. self-identified as from White origin as per the FDA Guidance on Collection of Race and Ethnicity Data in Clinical Trials, and ethnically self-identified as Latinos. This includes participants with mixed (or mestizo) races."
62642857|NCT06257732|NO_INTERVENTION|Control Group|This group will consist of individuals with liver fat accumulation under standard care and no exercise intervention will be implemented.
62642858|NCT06257732|EXPERIMENTAL|Fatmax Exercise Group|Individuals with liver fat accumulation under standard care will have their Fatmax values calculated and an exercise prescription will be designed accordingly.
62642859|NCT06257732|EXPERIMENTAL|Fatmax Exercise and Motivational Interviewing Group|In addition to the prescription of Fatmax exercise for individuals with liver fat accumulation under standard care, motivational interviewing principles will be applied.
62455593|NCT03784456|ACTIVE_COMPARATOR|15% protein group|This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
62642860|NCT06257732|EXPERIMENTAL|HIIT Group|Individuals with liver fat accumulation under standard care will be provided with a High-Intensity Interval Training (HIIT) exercise prescription.
62642861|NCT06257732|EXPERIMENTAL|HIIT and Motivational Interviewing Group|In addition to formulating a High-Intensity Interval Training (HIIT) exercise prescription for individuals with liver fat accumulation under standard care, motivational interviewing principles will be applied.
62642862|NCT06257732|EXPERIMENTAL|Resistance Exercise Group|Individuals with liver fat accumulation under standard care will be provided with a resistance exercise prescription.
62642863|NCT06257732|EXPERIMENTAL|Resistance Exercise and Motivational Interviewing Group|In addition to formulating a resistance exercise prescription for individuals under standard care with liver fat accumulation, motivational interviewing principles will be applied.
62642864|NCT05299866|EXPERIMENTAL|S-ketamine group|The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.
62642865|NCT05299866|PLACEBO_COMPARATOR|Control group|The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.
62642866|NCT02436824|EXPERIMENTAL|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
62455594|NCT05108038|EXPERIMENTAL|A|Period 1: CKD-382 Period 2: D860 Period 3: D027
62642867|NCT02436824|PLACEBO_COMPARATOR|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
62642868|NCT02943772|EXPERIMENTAL|Local hypothermia|Local application of a brick cooled to -20(celsius)
62642869|NCT02943772|SHAM_COMPARATOR|Control|Local application of a brick in room temperature
62073312|NCT03124628|ACTIVE_COMPARATOR|Weight-stack resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform conventional, weight-stack leg press resistance exercise twice per week.
62277736|NCT00794560|EXPERIMENTAL|clinical setting: intervention|"Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital.~Intervention: patient education"
62642870|NCT05453851|EXPERIMENTAL|Treatment (pancreatectomy, autologous islet cell transplant)|Patients undergo total pancreatectomy and autologous islet cell transplant IV over 15-60 minutes on day 1.
62073313|NCT00192140|ACTIVE_COMPARATOR|1|FluMist
62073314|NCT03634137|EXPERIMENTAL|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
62073315|NCT03634137|EXPERIMENTAL|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
62277737|NCT00794560|NO_INTERVENTION|clinical setting: standard care|Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
62277738|NCT00794560|EXPERIMENTAL|daily life setting: intervention|"Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists.~Intervention: patient education"
62277739|NCT00794560|NO_INTERVENTION|daily life setting: standard care|Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
62277740|NCT01767883|EXPERIMENTAL|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms~* On-going mentoring and practice facilitation"
62277741|NCT01767883|ACTIVE_COMPARATOR|Clinical Decision Support Only|"The primary care practices in this arm will receive:~* CKD decision support algorithms added to their Clinical Decision Support System~* Academic detailing concerning the rationale for the algorithms"
62455595|NCT05108038|EXPERIMENTAL|B|Period 1: CKD-382 Period 2: D027 Period 3: D860
62455596|NCT05108038|EXPERIMENTAL|C|Period 1: D860 Period 2: D027 Period 3: CKD-382
62642871|NCT00825123|EXPERIMENTAL|Ivabradine|
62642872|NCT00825123|ACTIVE_COMPARATOR|Metoprolol|
62642873|NCT00825123|PLACEBO_COMPARATOR|Placebo|
62642874|NCT04204005|ACTIVE_COMPARATOR|Probiotics|Composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams)
62642875|NCT04204005|PLACEBO_COMPARATOR|Placebo|Composition: maltodextrin (2 grams)
62642876|NCT02536937|EXPERIMENTAL|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
62642877|NCT02536937|EXPERIMENTAL|GZ385660 (subjects with mild renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
62642878|NCT02536937|EXPERIMENTAL|GZ385660 (subjects with moderate renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
62073316|NCT06123572|PLACEBO_COMPARATOR|Placebo|Mode of Usage: Twice a day on clean skin Route of Administration: Topical application.
62073317|NCT06123572|EXPERIMENTAL|Anti-Ageing and Skin Brightening Gel|Mode of Usage: Twice a day on clean skin Route of Administration: Topical application.
62073318|NCT01647308|ACTIVE_COMPARATOR|ISIS-APOCIIIRX|
62073319|NCT01647308|PLACEBO_COMPARATOR|Placebo|
62642879|NCT02536937|EXPERIMENTAL|GZ385660 (subjects with severe renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
62642880|NCT02087774|NO_INTERVENTION|Control School|Control School received no intervention.
62642881|NCT02087774|EXPERIMENTAL|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
62642882|NCT05861830|EXPERIMENTAL|Arm A|The combination of Dalpiciclib with physician-selected endocrine therapy
62642883|NCT05861830|ACTIVE_COMPARATOR|Arm B|Chemotherapy selected by the physician
62642884|NCT04630184|EXPERIMENTAL|Virtual reality and exercice|This group will receive the exposure intervention in virtual reality and physical activity during 12 weeks
62642885|NCT04630184|PLACEBO_COMPARATOR|Placebo and exercice|This group will receive the placebo intervention (relaxation) and physical activity during 12 weeks
62642886|NCT04630184|NO_INTERVENTION|waiting list|This group will receive no intervention during 12 weeks, then will be randomized in the experimental or placebo group
62642887|NCT03582384|EXPERIMENTAL|Treatment|
62642888|NCT05383378|EXPERIMENTAL|si-544|The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo.
62642889|NCT05383378|PLACEBO_COMPARATOR|Placebo|The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo.
62642890|NCT03440476|PLACEBO_COMPARATOR|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
62073320|NCT03826589|EXPERIMENTAL|Avelumab and Axitinib|"* Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)~* Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)"
62073321|NCT04752891|EXPERIMENTAL|AOM diagnosis with app|
62073322|NCT04752891|OTHER|AOM diagnosis without app|
62642891|NCT03440476|ACTIVE_COMPARATOR|Intervention plus feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-only booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The content is clearly automatically generated.
62642892|NCT03440476|ACTIVE_COMPARATOR|Intervention plus feedback and personal contact booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-plus-personal-contact booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The email is sent from a member of the research staff.
62642893|NCT00372138|EXPERIMENTAL|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
62642894|NCT05770713||Female patients with HR+/HER2- ABC/MBC who received a CDK4/6i based therapy for their ABC/MBC.|Female patients who received an oral treatment of CDK4/6i based therapy for their ABC/MBC.
62642895|NCT03208816|OTHER|single arm|symptom management program for chemotherapy patients
62642896|NCT04974073|NO_INTERVENTION|control group|with traditional western medicine treatment based on underlined disease
62642897|NCT04974073|EXPERIMENTAL|PHY606|PHY606 7.5gm BID for 3 months
62642898|NCT04974073|OTHER|Healthy group|PHY606 7.5gm BID for 2 days
62642899|NCT05098873||Group gifted teens|
62642900|NCT05098873||Group no gifted teens|
62642901|NCT05924165|ACTIVE_COMPARATOR|Opioid group|Patients will be prescribed 5mg Oxycodone, Q6 PRN postoperatively.
62642902|NCT05924165|ACTIVE_COMPARATOR|NSAID|Patients will be prescribed 10mg Ketorolac, Q6 PRN postoperatively.
62642903|NCT00566085|OTHER|Molecular Breast Imaging|
62277742|NCT05307315|EXPERIMENTAL|music|"The state/trait anxiety inventory and surgery-specific anxiety inventory will be administered to the experimental group before the surgery. Then they will listen to Turkish Classical Music for 30 minutes.~The scales will be applied again 15 minutes after the music ends."
62277743|NCT05307315|NO_INTERVENTION|control|The state/trait anxiety inventory and surgery-specific anxiety scale will be administered to the control group before surgery. The same scales will be applied again 45 minutes after the scales are applied.
62277744|NCT05547490||Moderate-to-severe Plaque PsO|Participants experiencing moderate-to-severe plaque PsO, who have had at least one clinical visit.
62642904|NCT01682252||musculoskeletal tumors|all patients undergoing surgery for musculoskeletal tumors
62642905|NCT00984412|EXPERIMENTAL|AATT|
62642906|NCT04655417|EXPERIMENTAL|INTERVENTION GROUP|SINGLE ARM OF PATIENTS WHO WILL RECEIVE SAME TREATMENT
62642907|NCT01200329|EXPERIMENTAL|Gemcitabine + Busulfan + Melphalan|Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.
62642908|NCT01088555|ACTIVE_COMPARATOR|Control group|Healthy subjects with no history of kidney stones, heart liver or kidney disease, not pregnant /lactating.
62642909|NCT01088555|ACTIVE_COMPARATOR|Stone formers|History of calcium containing kidney stones, hypercalciuria on previous urine tests, no heart /liver / kidney disease, not pregnant/lactating
62277745|NCT01402297|EXPERIMENTAL|COPD patients|Thirteen nonsmoking patients, suffering from GOLD II and GOLD III stage participated in the study (mean age 57 years (range 42-79), 9 men, 4 women). COPD was diagnosed based on GOLD 2009 criteria. All the participants were diagnosed at Department of Clinical Physiology, Medical university of Lodz.
62277746|NCT03333070|ACTIVE_COMPARATOR|Treatment Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of \~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: treated arm will receive probiotic containing Lactobacillus reuteri for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
62073323|NCT02125123|EXPERIMENTAL|Nutritional Supplement and Counseling|Two servings a day; ready-to-feed nutritional supplement plus dietary counseling
62073324|NCT02125123|ACTIVE_COMPARATOR|Counseling|Dietary Counseling
62073325|NCT02228473|EXPERIMENTAL|Glycopyrrolate|Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
62455597|NCT05108038|EXPERIMENTAL|D|Period 1: D860 Period 2: CKD-382 Period 3: D027
62642910|NCT01657396|ACTIVE_COMPARATOR|Standard Oral Hygiene|Oral hygiene provided by current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
62642911|NCT01657396|ACTIVE_COMPARATOR|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
62455598|NCT05108038|EXPERIMENTAL|E|Period 1: D027 Period 2: D860 Period 3: CKD-382
62455599|NCT05108038|EXPERIMENTAL|F|Period 1: D027 Period 2: CKD-382 Period 3: D860
62642912|NCT01657396|ACTIVE_COMPARATOR|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
62642913|NCT03368807||Blinded CGM (Continuous Glucose Monitoring)|Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
62642914|NCT03368807||Unblinded CGM|Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
62642915|NCT05604365|EXPERIMENTAL|Arm 1|Patients Only
62642916|NCT05604365|EXPERIMENTAL|Arm 2|Patients and Caregivers
62455600|NCT00243932|EXPERIMENTAL|2,700 mg CoQ10|
62073326|NCT02228473|ACTIVE_COMPARATOR|Atropine|Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
62073327|NCT04136652|PLACEBO_COMPARATOR|Sham|The women are randomized, by a computer program, to a sham laser-treatment with the laser not active.
62277747|NCT03333070|PLACEBO_COMPARATOR|Placebo Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of \~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: control arm will receive placebo for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
62073328|NCT04136652|ACTIVE_COMPARATOR|Laser|The women are randomized, by a computer program, to a vaginal CO2 laser-treatment with 30 w.
62642917|NCT05604365|EXPERIMENTAL|Arm 3|Caregivers Only
62073329|NCT04906109|EXPERIMENTAL|Reference-Test|
62073330|NCT04906109|EXPERIMENTAL|Test-Reference|
62073331|NCT06421753|EXPERIMENTAL|Spatially Distributed Sequential Functional Electrical Stimulation|Interventions: 3 FES cycling sessions separated by 48h of rest. Each session is comprised of 2 phases separated by 20 minutes of rest. Each phase is comprised of a 3 minutes passive cycling warm-up, followed by 3 minutes of electrically stimulated cycling.
62277748|NCT00159289|EXPERIMENTAL|1|Inhalation of LPS
62277749|NCT00159289|PLACEBO_COMPARATOR|2|PLacebo
62277750|NCT01251783|ACTIVE_COMPARATOR|Infant Formula|Infant Formula without lactobaillus or Metlin or Metlos
62277751|NCT01251783|ACTIVE_COMPARATOR|Fully breast milk|Group non randomized with fully breast milk
62277752|NCT01251783|EXPERIMENTAL|Metlin+Metlos+Lactobacillus GG|Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC
62642918|NCT04512989||Patients undergoing cardiac surgery|
62642919|NCT06037317|EXPERIMENTAL|Dose-escalation and Dose-expansion|"In dose-escalation phase, SY-3505 will be given orally in ascending doses (escalation cohort) until the DLT or RP2D is reached.~In dose-expansion phase, SY-3505 will be given at RP2D in 28-day cycle continuously."
62642920|NCT03600831|EXPERIMENTAL|concurrent chemoradiotherapy group|All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
62073332|NCT06421753|ACTIVE_COMPARATOR|Standard Electrical Stimulation During Functional Electrical Stimulation|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out. During the second session, the order of the stimulation phases is reversed.
62073333|NCT05271838|EXPERIMENTAL|High protein diet|High protein diet (2/g/kg/day)
62073334|NCT05271838|NO_INTERVENTION|Standard Nutritional care|Standard nutritional care.
62642921|NCT03600831|ACTIVE_COMPARATOR|radiotherapy group|All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).
62455601|NCT00243932|PLACEBO_COMPARATOR|placebo|
62642922|NCT01208272|EXPERIMENTAL|Binge Eating Disorder/Therapy|
62642923|NCT03384589|ACTIVE_COMPARATOR|Group 1: 3 doses of PCV13|PCV13, 0.5ml intramuscular at 2, 4 and 12 months of age
62642924|NCT03384589|EXPERIMENTAL|Group 2: 2 doses of PCV13|PCV13, 0.5ml intramuscular at 2 and 12 months of age
62642925|NCT05567081|EXPERIMENTAL|PRP group|3 cm of autologous platelet rich plasma injected once around the thickest part of ulnar nerve.
62642926|NCT05567081|EXPERIMENTAL|Corticosteroid group|Triamcinolone Acetonide 40mg/mL (1ml) mixed with 1ml lidocaine hydrochloride injected once around the thickest part of ulnar nerve.
62073335|NCT05271838|EXPERIMENTAL|Magnesium|Magnesium oral supplementation
62073336|NCT05271838|NO_INTERVENTION|Standard: No magnesium supplementation|No supplementation
62073337|NCT01160120|OTHER|1|Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.
62073338|NCT02327273|EXPERIMENTAL|Part A SAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
62455602|NCT00243932|EXPERIMENTAL|1,800 mg CoQ10|
62455603|NCT01249664|EXPERIMENTAL|Arm 1|
62455604|NCT01249664|SHAM_COMPARATOR|Arm 2|
62642927|NCT05133115|EXPERIMENTAL|Intervention Group|Schools with adolescents aged 12 to 15 in a context at risk. They will follow the intervention for 6 weeks (6 sessions, once a week).
62642928|NCT05133115|NO_INTERVENTION|Control Group|Schools in the control group will be all waitlisted to receive the intervention during the following academic year should it prove effectiveness. They will fill in the same research questionnaires as the Intervention group and at the same time period (January to December 2022).
62642929|NCT04332263|EXPERIMENTAL|Neuromuscular Electrical Stimulation - NMES|NMES will be applied bilaterally on the quadriceps femoris muscle of ICU patients. An electrical stimulation system and an ICU-designed dynamometer will be used with the patients lying in bed, with the hips and the knees flexed at 60 and 90 degrees, respectively. Supramaximal single-pulse's peak force will be used to determine the NMES intervention level. NMES (alternating biphasic current, stimulation frequency = 80 Hz, 1 ms pulse duration) will be used to evoke tetanic forces (EF) at 50% of the supra-maximal single-pulse EF (i.e., 10-12% of a maximal voluntary isometric contraction). NMES protocol will be performed five times a week, lasting 20 min. Muscle fatigue will be evaluated every 5 min of the intervention, and will be determined as a 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol. If and when a 10% reduction of the single-pulse EF is achieved, the intervention protocol will be terminated before the 20 min.
62642930|NCT04332263|NO_INTERVENTION|Control Group - CG|The control group (CG) will only perform conventional physiotherapy and will not receive any NMES training, but will be evaluated through the same evaluations and in the same moments of the two above mentioned intervention groups. Conventional physiotherapy will be given to all three groups.
62642931|NCT01307956|EXPERIMENTAL|Treatment (panitumumab, chemotherapy, radiation)|Patients receive panitumumab IV over 1 hour on day 1. Patients also receive oxaliplatin IV and leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1 (FOLFOX chemotherapy). Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Within 24 hours of the start of chemotherapy, patients undergo radiation therapy 5 days a week for 5.5 weeks. Patients then undergo surgery within 6-8 weeks after completion of radiation therapy. Patients with residual disease receive 4 additional courses of FOLFOX chemotherapy on days 1, 15, 29, and 42.
62642932|NCT04545801|ACTIVE_COMPARATOR|Ketamine Group|Patients recieving 0.25 mg/kg of ketamine 5 minutes after spinal anesthesia
62642933|NCT04545801|PLACEBO_COMPARATOR|Placebo Group|
62642934|NCT03398694|EXPERIMENTAL|Arm 1|This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-4 days prior to surgical resection.
62642935|NCT04102137||3|Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines
62642936|NCT02386852|EXPERIMENTAL|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (ginseng: group 1; ginkgo biloba: group 2).
62642937|NCT02386852|EXPERIMENTAL|Ginseng|Participants in the ginseng group received a medium, and higher dose of ginseng in addition to placebo capsules.
62642938|NCT02386852|EXPERIMENTAL|Ginkgo Biloba|Participants in the ginkgo biloba group received a medium, and higher dose of ginkgo in addition to placebo capsules.
62642939|NCT02812186|OTHER|Deep to Moderate NMB|This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
62642940|NCT02812186|OTHER|Moderate to Deep NMB|This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.
62642941|NCT00800358|EXPERIMENTAL|1|Oral Paricalcitol in varying doses
62642942|NCT00800358|ACTIVE_COMPARATOR|2|Calcitriol
62642943|NCT02654639|EXPERIMENTAL|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
62642944|NCT02203266|EXPERIMENTAL|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
62642945|NCT02203266|ACTIVE_COMPARATOR|Demonstration|Current best practice - inhaler technique education
62642946|NCT02203266|NO_INTERVENTION|Control|Usual care in the community pharmacy setting
62642947|NCT01689597|ACTIVE_COMPARATOR|Low dose epidural morphine|One dose of 1.25 mg epidural morphine
62642948|NCT01689597|ACTIVE_COMPARATOR|High dose epidural morphine|One dose of 2.5 mg epidural morphine
62642949|NCT01689597|PLACEBO_COMPARATOR|Saline|One dose of 10 ml saline administered through an epidural catheter
62642950|NCT05130437|EXPERIMENTAL|mRNA-3927|Participants will receive the applicable dose identified during Study mRNA-3927-P101 (NCT04159103) on Day 1. The dose can be adjusted based on Sponsor recommendation.
62642951|NCT01565213|ACTIVE_COMPARATOR|CBT cognitive behavioral therapy|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks
62642952|NCT01565213|ACTIVE_COMPARATOR|MMI Multimodal group intervention|group multimodal intervention
62642953|NCT01565213|OTHER|CAU|Care as usual given by the GPs
62642954|NCT00994305|ACTIVE_COMPARATOR|N-acetylcysteine|N-acetylcysteine 600 mg bid po 0-7 PO
62642955|NCT00994305|SHAM_COMPARATOR|control|No treatment: standard care provided. No N-acetylcysteine administration.
62642956|NCT02806713|PLACEBO_COMPARATOR|no phenazopyridine|Patients not receiving phenazopyridine (standard of care)
62642957|NCT02806713|EXPERIMENTAL|phenazopyridine|Patients receiving phenazopyridine
62642958|NCT03175185||Parents of children with ADHD|100 parents of 50 children who were diagnosed with ADHD and
62642959|NCT03175185||Parent of children without ADHD|100 parents of 50 children who are ADHD free as a control group
62642960|NCT04741438|EXPERIMENTAL|Arm A|"Arm A (Experimental arm).~* Nivolumab 3 mg/kg~* Ipilimumab 1 mg/kg"
62642961|NCT04741438|ACTIVE_COMPARATOR|Arm B|Arm B (Control arm). Pazopanib 800 mg/day
62642962|NCT06151808|SHAM_COMPARATOR|non-cognitive impairment|30 subjects with non-cognitive impairment
62642963|NCT06151808|EXPERIMENTAL|AD-derived MCI|30 subjects with AD-derived MCI
62642964|NCT06151808|EXPERIMENTAL|mild to moderate AD.|30 subjects with mild to moderate AD.
62642965|NCT05435547|EXPERIMENTAL|Steroids|Will be given pre-operative corticosteroid regimen
62642966|NCT05435547|PLACEBO_COMPARATOR|placebo|Will be given Placebo
62642967|NCT02280252|EXPERIMENTAL|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:~1. Paclitaxel, 30mg/m\^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule~2. Abraxane, 30mg/m\^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
62642968|NCT03035448|EXPERIMENTAL|Video 1: Counselor Alone|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
62642969|NCT03035448|EXPERIMENTAL|Video 2: Doctor + Counselor|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
62642970|NCT05322096|EXPERIMENTAL|RGH-706|Dose A once daily for 6 weeks
62642971|NCT05322096|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 6 weeks
62642972|NCT03043196|ACTIVE_COMPARATOR|Rosuvastatin Group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
62642973|NCT03043196|PLACEBO_COMPARATOR|Placebo Group|Oral prophylaxis followed by placebo gel placement in intrabony defects
62642974|NCT00468585|EXPERIMENTAL|1 Capecitabine and Bevacizumab|The Phase II trial has a Simon mini-max two-stage design. Twenty-seven patients will be enrolled to the first stage of the Phase II trial, with a target accrual of 40 patients. The treatment dose of capecitabine as determined in the Phase I portion of this trial will be administered orally in two divided doses daily on Days 1 through 7 and Days 15 through 21 in a 28 day cycle. Phase II patients will receive bevacizumab 10 mg/kg intravenously every 2 weeks concurrently with oral capecitabine. Patients will be evaluated for toxicity between Days 3 to 5 (complete blood count only), Day 8, Day 15, and Day 22 during cycle #1. Thereafter, toxicity will be assessed on Days 1 and 15. Efficacy will be assessed with every other week physical examination and radiographic scans of measurable disease every 12 weeks.
62073339|NCT02327273|EXPERIMENTAL|Part B MAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
62455605|NCT03778905||stroke patient with complete post-acute care hospitalization|This study aims on stroke patients with complete rehabilitative program in post acute care institution and we try to assess their functional improvements after rehabilitative training.
62455606|NCT04469153||SARS-COV 2 positive patient|57 SARS-COV-2 positive patients followed during the SARS-COV 2 epidemic in the internal medicine department of the Croix-Rousse hospital. For each patient ferritin and glycosylated ferritin was analysed one time (biological analysis) at the entry of the hospitalization.
62642975|NCT02979821|EXPERIMENTAL|Poziotinib|The study drug(poziotinib) will be administered orally as one 12 mg tablet once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug 12 mg daily can be reduced to 8 mg once daily according to dose reduction criteria.
62073340|NCT04743375|EXPERIMENTAL|Sericin dressing with collagen|Sericin dressing with collagen
62073341|NCT04743375|ACTIVE_COMPARATOR|Bactigras|Commercial dressing
62073342|NCT01432535|ACTIVE_COMPARATOR|Healthy Participants|Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m\^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
62277753|NCT01251783|ACTIVE_COMPARATOR|Metlin+Lactobacillus GG|Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC
62277754|NCT01251783|ACTIVE_COMPARATOR|Metlos+Lactobacillus GG|Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC
62277755|NCT01251783|ACTIVE_COMPARATOR|Lactobacillus GG|Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos
62277756|NCT01748344|EXPERIMENTAL|Experimental 1|High dose ONO-4053
62642976|NCT03177395|NO_INTERVENTION|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
62277757|NCT01748344|ACTIVE_COMPARATOR|Cetirizine|10mg Cetirizine
62277758|NCT01748344|EXPERIMENTAL|Experimental 2|Low dose ONO-4053
62642977|NCT03177395|EXPERIMENTAL|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~* Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~* Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~* Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes."
62642978|NCT04328337|EXPERIMENTAL|Non-diabetic, normal weight individuals receiving Intralipid|Non-diabetic, normal weight individuals receiving Intralipid. Participants will receive an infusion of Intralipid 20% for 12 hours through an IV (prior to and during scan #2)
62642979|NCT04328337|PLACEBO_COMPARATOR|Non-diabetic, normal weight individuals receiving saline|Non-diabetic, normal weight individuals receiving saline. Participants will receive an infusion of normal saline (1:1 randomization) at 30 ml/hr for 12 hours through an IV (prior to and during scan #2
62642980|NCT04621331|EXPERIMENTAL|Roxadustat|Starting doses of 20, 50, 70 or 100 mg based on weight.
62642981|NCT06108999|EXPERIMENTAL|Connettivia BIO Cream|All subjects will be treated with Connettivina BIO line (Cream or Gauze)
62642982|NCT06108999|EXPERIMENTAL|Connettivina BIO Gauze|All subjects will be treated with Connettivina BIO line (Cream or Gauze)
62642983|NCT00945841|OTHER|1|
62642984|NCT03641508|ACTIVE_COMPARATOR|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
62642985|NCT03641508|ACTIVE_COMPARATOR|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
62642986|NCT06265831|EXPERIMENTAL|Hand-fan application to the face|At the first meeting of the hand-fan application to the face group, the Patient Identification Form, Vital Signs Form, Modified Borg Scale, and Saint George Respiratory Questionnaire Form will be filled out. Afterward, training will be given (accompanied by an academic advisor) on how to apply cold air to the face with a hand fan (3 times a day for 5 minutes) for dyspnea management. Additionally, patients will be given a hand-fan application brochure. The researchers will monitor the patient every day for a week (7 days), fill out the vital signs form, and the final test will be administered by the researchers on the 8th day.
62642987|NCT06265831|NO_INTERVENTION|Standard care group|In the standard care group, the Patient Diagnosis Form, Vital Signs Form, Modified Borg Scale, and Saint George Respiratory Questionnaire Form will be filled in at the first interview. The clinic's routine care protocol will be applied to the patients in the control group, and the researchers will fill out a vital signs form every day for a week, and the patients will be followed up.
62642988|NCT02772666|EXPERIMENTAL|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
62642989|NCT02772666|ACTIVE_COMPARATOR|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
62642990|NCT01995669|EXPERIMENTAL|Treatment (lenalidomide, obinutuzumab)|Patients receive lenalidomide PO QD on days on days 2-22 and obinutuzumab IV over 4-5 hours on days 1, 2, 8, 15, and 22 of cycle 1 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients not experiencing progression and who in the opinion of treating physician are deriving benefit from combination treatment may continue lenalidomide for an additional 6 cycles (up to cycle 12) and obinutuzumab on day 1 every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
62277759|NCT01748344|PLACEBO_COMPARATOR|Placebo|Placebo
62455607|NCT02402166|EXPERIMENTAL|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
62455608|NCT01309945|ACTIVE_COMPARATOR|Arm 1: Duloxetine 30mg|
62455609|NCT01309945|PLACEBO_COMPARATOR|Arm 2: BMS-820836 placebo|
62642991|NCT06522750|EXPERIMENTAL|20 participants. Long covid patients.|All patients will undergo a caloric restriction diet for a week.This begins with the intake of a laxative fluid on the first fasting day. This fluid aids in bowel emptying, akin to preparations for a colonoscopy. Detailed instructions on how to use it will be provided along with the laxative, and the study physician or dietary team will discuss dosage and intake with you. The caloric restriction period will last for 7 days and then be broken with the consumption of an apple. Following the breaking of the fast, three build-up days will follow to gradually increase food intake.
62642992|NCT01443858|ACTIVE_COMPARATOR|Placebo + Nicotine Patch|Subjects in this group will take placebo meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Placebo meclizine will be administered in two doses each day.
62642993|NCT01443858|EXPERIMENTAL|25mg Meclizine + Nicotine Patch|Subjects in this group will take 25mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
62642994|NCT01443858|EXPERIMENTAL|50mg Meclizine + Nicotine Patch|Subjects in this group will take 50mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
62642995|NCT06144255|EXPERIMENTAL|Intranasal insulin and placebo|A total of 3 possible doses will be tested of insulin 0 units (u) (placebo (diluent), 500u, and 1000u. The order that participants will receive these doses will be in a random order.
62642996|NCT00863382|ACTIVE_COMPARATOR|1|Standard Event Monitor
62073343|NCT01432535|EXPERIMENTAL|Participants with Moderate Renal Impairment|Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m\^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
62642997|NCT00863382|ACTIVE_COMPARATOR|2|Sleuth recorder
62642998|NCT02642705|EXPERIMENTAL|High intensity interval training N|High intensity interval training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing ambient air (normoxia)
62642999|NCT02642705|EXPERIMENTAL|High intensity interval training H|High intensity interval training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing hypoxic air (about 3 500 m of altitude)
62643000|NCT02642705|ACTIVE_COMPARATOR|Constant load exercise training N|Constant load exercise training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing ambient air (normoxia)
62073344|NCT01432535|EXPERIMENTAL|Participants with Severe Renal Impairment|Participants with severe renal impairment defined as having a creatinine clearance test value of \<30 mL/min/1.73 m\^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
62073345|NCT06076473||Confirmed Primary Aldosteronism|Confirmed Primary Aldosteronism
62073346|NCT06076473||Non-Primary Aldosteronism|Other causes of hypertension
62277760|NCT05026788||Intra-COVID lockdown|Any patients treated for orthopaedic trauma within the mandatory lockdown due to the pandemic.
62455610|NCT01309945|EXPERIMENTAL|Arm 3: BMS-820836 0.5-2.0 mg/day|
62643001|NCT02642705|EXPERIMENTAL|Constant load exercise training H|Constant load exercise training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing hypoxic air (about 3 500 m of altitude)
62455611|NCT01309945|ACTIVE_COMPARATOR|Arm 4: Duloxetine 30mg|
62643002|NCT02642705|EXPERIMENTAL|Hypoxic conditioning at rest|Hypoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, hypoxic breathing for one hour (about 4500 m of altitude) while seating quietly
62455612|NCT01309945|PLACEBO_COMPARATOR|Arm 5: Duloxetine placebo|
62643003|NCT02642705|SHAM_COMPARATOR|Normoxic conditioning at rest|Normoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, normoxic breathing for one hour (ambient air) while seating quietly
62643004|NCT01283100|EXPERIMENTAL|Treatment A|GSK1349572 50mg q24h x 7 days
62643005|NCT01283100|EXPERIMENTAL|Treatment B|GSK2248761 200mg q24h x 7 days
62643006|NCT01283100|EXPERIMENTAL|Treatment C|GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
62643007|NCT06053385|EXPERIMENTAL|Melatonin sleep lotion Night 1; Placebo control lotion Night 2|"Participants in this arm received melatonin-containing sleep lotion to apply on the first night of saliva sampling. On the second night of saliva sampling, they received placebo control lotion."
62643008|NCT06053385|EXPERIMENTAL|Placebo control lotion Night 1; Melatonin sleep lotion Night 2|"Participants in this arm received placebo control lotion to apply on the first night of saliva sampling. On the second night of saliva sampling, they received melatonin-containing sleep lotion."
62643009|NCT00926250|EXPERIMENTAL|PS-IPC supplementation|
62643010|NCT00926250|PLACEBO_COMPARATOR|Placebo supplementation|
62643011|NCT02765737|ACTIVE_COMPARATOR|Group 1|Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
62073347|NCT03799679|EXPERIMENTAL|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1\* 12 cycles ( weekly), followed by epirubicin 90mg/m2, iv, d1 + cyclophosphamide 600mg/m2, iv, d1 \* 4 cycles (14 days per cycle)
62643012|NCT02765737|ACTIVE_COMPARATOR|Group 2|Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
62643013|NCT01755507|EXPERIMENTAL|B|norUDCA
62643014|NCT01755507|EXPERIMENTAL|C|norUDCA
62643015|NCT01755507|PLACEBO_COMPARATOR|placebo|Placebo
62643016|NCT01755507|EXPERIMENTAL|A|norUDCA
62643017|NCT03301389||Control group|
62643018|NCT03301389||Pretreatment group|Patients in pretreatment state
62643019|NCT03301389||Anthracycline-based chemotherapy (3 months)|Patients who received anthracycline-based chemotherapy 3 months ago
62643020|NCT03301389||Anthracycline-based chemotherapy (6 months)|Patients who received anthracycline-based chemotherapy 6 months ago
62643021|NCT03301389||Anthracycline-based chemotherapy (more than 1 year ago)|Patients who received anthracycline-based chemotherapy more than 1 year ago
62643022|NCT03301389||Other therapy group|Patients who have been treated with other therapies (other chemo-therapies, combined radiation therapy, target agent therapy, hormone therapy)
62643023|NCT04233853|EXPERIMENTAL|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
62643024|NCT04233853|ACTIVE_COMPARATOR|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
62643025|NCT00109863|EXPERIMENTAL|Hu14.18-IL2 Treatment|Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
62643026|NCT01596569|ACTIVE_COMPARATOR|Active TMS and Cognitive Intervention|"Active TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
62643027|NCT01596569|SHAM_COMPARATOR|Sham TMS and Cognitive Intervention:|"Sham TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
62643028|NCT01270477|EXPERIMENTAL|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment in an hyperbaric oxygen treatment chamber on an recognized treatment table.
62643029|NCT05033626|OTHER|Thyroidectomy|
62643030|NCT05033626|EXPERIMENTAL|Simultaneous thyroidectomy and hyoid suspension|
62643031|NCT03850717||Traditional Chinese Acupuncture|"Use traditional acupuncture, stronger, deeper, harder-acupuncture"
62643032|NCT03850717||Japanese Acupuncture|"Use traditional shallow, lighter acupuncture, softer-acupuncture"
62643033|NCT06336785|EXPERIMENTAL|Restylane Filler Line and Dysport Neuromodulator|"This study will consist of an open-label, prospective, cohort trial design. Twenty-four subjects will be recruited.~Subjects will be recruited based on their primary deficit, 8 subjects will have a primary deficit in lip volume, 8 subjects will have a primary deficit in lip framing and 8 subjects will have a primary deficit in expression. All subjects will receive active treatment with hyaluronic acid at Baseline, with an optional touch at week two. There will be no placebo or no-treatment control groups. Subjects will be followed for five months."
62643034|NCT05701709|EXPERIMENTAL|SHR-A2102|
62643035|NCT01726595||severe sepsis|Patients with severe sepsis or septic shock
62643036|NCT01726595||non-infected critically ill|Patients with severe non-infectious systemic inflammatory response syndrome
62643037|NCT01726595||healthy|healthy volunteers
62643038|NCT00434824|ACTIVE_COMPARATOR|Arm 1|Oral testosterone undecanoate (Andriol)
62643039|NCT00434824|PLACEBO_COMPARATOR|Arm 2|Placebo
62643040|NCT00843141|EXPERIMENTAL|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
62643041|NCT00843141|ACTIVE_COMPARATOR|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
62643042|NCT03245281|EXPERIMENTAL|Diuretic Suspension (DS)|
62643043|NCT03245281|EXPERIMENTAL|Diuretic Increase (DI)|
62643044|NCT03245281|EXPERIMENTAL|Diuretic and Medication Suspension (DMS)|
62643045|NCT02952651|EXPERIMENTAL|Children with hypovolemic state|Pulse oximeter plethysmography (POP) waveforms are obtained for 90 seconds in children with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Then, intravenous crystalloid fluid 10 mL/kg is infused for 15 min. Delta POP is calculated, and diagnostic power of delta POP for fluid responsiveness will be evaluated.
62643046|NCT03101306|EXPERIMENTAL|MR scans|As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment. These will take place in the 1st, 2nd and 5th weeks of treatment.
62643047|NCT05088772||Hyperbaric Oxygen Therapy - Experimental Group|Patients receiving hyperbaric oxygen therapy at the Hyperbaric Medicine Unit (University Health Network, Toronto, ON, Canada)
62073348|NCT03802162|EXPERIMENTAL|CKD-355A|
62073349|NCT03802162|EXPERIMENTAL|CKD-355B|
62073350|NCT03802162|ACTIVE_COMPARATOR|D797, D324|
62643048|NCT04023396|EXPERIMENTAL|ABX464 50mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
62643049|NCT03477578||FoG+|Parkinsonian patients with Freezing of Gait
62643050|NCT03477578||FoG-|Parkinsonian patients withou Freezing of Gait
62073351|NCT02314741|EXPERIMENTAL|POEM Treatment Arm|Patients treated with the POEM (per-oral endoscopic myotomy) procedure.
62643051|NCT06167408||Pemphigus patients in the First Affiliated Hospital of Chongqing Medical University|
62073352|NCT01272882|EXPERIMENTAL|Adults with ARDS or ALI|Adults with PaO2/FiO2 ratio less than 300. Consented patients will be placed on EIT monitor. The only intervention is the addition of Electrical Impedance Tomography monitoring using the Chest belt with 16 electrodes connected to the EIT device. No changes to standard patient care will occur other than collecting EIT monitor data.
62643052|NCT02824445|SHAM_COMPARATOR|Sham|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
62073353|NCT04654546|EXPERIMENTAL|Abdominal scans|Participants who performed an abdominal CT exam up to one month prior to the experimental ultrasound exam.
62277761|NCT05026788||Pre/post-COVID lockdown|Any patients treated for orthopaedic trauma either before or after the imposition of lockdown induced by the pandemic.
62073354|NCT01606956|EXPERIMENTAL|resting volume group|
62073355|NCT01606956|ACTIVE_COMPARATOR|half the maximum volume group|
62073356|NCT03358329|EXPERIMENTAL|S8 Sinus Implant|corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)
62073357|NCT06275659|EXPERIMENTAL|CT-100-004-A Psoriasis|
62073358|NCT06275659|SHAM_COMPARATOR|CT-100-004-B Psoriasis|
62073359|NCT06275659|EXPERIMENTAL|CT-100-004-A Atopic Dermatitis|
62073360|NCT06275659|SHAM_COMPARATOR|CT-100-004-B Atopic Dermatitis|
62643053|NCT02824445|EXPERIMENTAL|Treatment|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
62643054|NCT05913362|EXPERIMENTAL|IVUS based ultra-low contrast PCI|IVUS based ultra-low contrast PCI
62643055|NCT05913362|NO_INTERVENTION|Standard of care PCI|Guideline directed contrast induced nephropathy provention strategy with standard of care PCI procedure.
62643056|NCT05199246|EXPERIMENTAL|Lower-limb powered dermoskeleton|Patients and healthy subjects will use a lower-limb powered dermoskeleton to perform different standardised tasks
62073361|NCT02181972|EXPERIMENTAL|Gingko biloba|
62643057|NCT05199246|NO_INTERVENTION|No assistance device|Patients and healthy subjects will perform different standardised tasks without lower-limb powered dermoskeleton
62073362|NCT02181972|PLACEBO_COMPARATOR|Placebo|
62073363|NCT00722995|ACTIVE_COMPARATOR|1|Sleeve gastrectomy
62073364|NCT00722995|ACTIVE_COMPARATOR|2|Gastric Bypass
62073365|NCT02838628|EXPERIMENTAL|KX2-391 50 mg (Days 1 to 5)|Participants were applied 50 milligrams (mg) of KX2-391 Ointment 1% topically on face or scalp in 25 centimeter square (cm\^2) treatment area, once daily for 5 consecutive days.
62073366|NCT02838628|EXPERIMENTAL|KX2-391 50 mg (Days 1 to 3)|Participants were applied 50 mg of KX2-391 Ointment 1% topically on face or scalp in 25 cm\^2 treatment area, once daily for 3 consecutive days.
62073367|NCT02941393|ACTIVE_COMPARATOR|Intrauterine pressure catheter|Intrauterine pressure catheter is used during labor to follow up the contractions
62073368|NCT02941393|ACTIVE_COMPARATOR|External tocodynamometry|External tocodynamometry is used during labor to follow up the contractions
62643058|NCT01126216|EXPERIMENTAL|Reduced RT + Pacitaxel/Cisplatin|63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
62643059|NCT01126216|ACTIVE_COMPARATOR|Standard RT + 5-Fluorouracil/Cisplatin|70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor
62643060|NCT01062191|EXPERIMENTAL|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Nanoflex Powder Dressing applied to joint
62643061|NCT01062191|ACTIVE_COMPARATOR|Aquacel AG, typical carboxymethylcellulose dressing|Sodium CMC dressing control applied to joint
62643062|NCT00496769|EXPERIMENTAL|Apixaban|
62643063|NCT00496769|ACTIVE_COMPARATOR|Acetylasalicylic acid|
62643064|NCT05380245|EXPERIMENTAL|Treatment Voriconazole (alone), then Voriconazole + Clarithromycin.|On Day-1, Group-A participants first received Voriconazole (alone) (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral). After a washout period of two weeks. Then, on Day-16 they received Voriconazole (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral) along with Clarithromycin (Name of medication of Intervention Formulation: Tablet Klaricid, Dose: 500mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral).
62643065|NCT05380245|EXPERIMENTAL|Treatment Voriconazole + Clarithromycin, then Voriconazole (alone).|On Day-1, Group-B participants first received Voriconazole (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral) along with Clarithromycin (Name of medication of Intervention Formulation: Tablet Klaricid, Dose: 500mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral).After a washout period of two weeks. Then, on Day-16 they received Voriconazole (alone) (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral).
62643066|NCT04418947|NO_INTERVENTION|No intervention|
62643067|NCT04418947|ACTIVE_COMPARATOR|MPM control letter|
62643068|NCT04418947|EXPERIMENTAL|MPM intervention letter|
62643069|NCT04418947|ACTIVE_COMPARATOR|Mailed control letter|
62643070|NCT04418947|EXPERIMENTAL|Mailed intervention letter|
62643071|NCT03944616|ACTIVE_COMPARATOR|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
62643072|NCT03944616|EXPERIMENTAL|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
62643073|NCT01733277||With neuropathic pain (PainDETECT ≥ 13)|Magnetic Resonance Imaging (MRI)
62643074|NCT01733277||No neuropathic pain (PainDETECT<13)|Magnetic Resonance Imaging (MRI)
62643075|NCT01106131|EXPERIMENTAL|CKD-501 0.5mg|
62643076|NCT01106131|ACTIVE_COMPARATOR|Pioglitazone 15mg|
62073369|NCT02857660|EXPERIMENTAL|Whole-Body Electromyostimulation and Protein|16 weeks of whole-body intervention 1.5 x 20 min week with bipolar current up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
62073370|NCT02857660|ACTIVE_COMPARATOR|Protein supplementation|up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
62643077|NCT00702780|EXPERIMENTAL|Escitalopram|Escitalopram 20mg tablet by mouth once a day
62073371|NCT02857660|NO_INTERVENTION|sedentary Control Group|No protein supplementation or WB-EMS-application, but up to 800 IU/d Vitamin D-Supplementation
62643078|NCT00702780|PLACEBO_COMPARATOR|Placebo|Placebo 20mg tablet by mouth once a day
62643079|NCT02477592|EXPERIMENTAL|Individualized substrate modification|Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
62643080|NCT02477592|ACTIVE_COMPARATOR|Stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
62073372|NCT00735449|ACTIVE_COMPARATOR|Combigan ®|Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)
62073373|NCT00735449|ACTIVE_COMPARATOR|Timolol Maleate 0.5%|Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)
62643081|NCT04787848|EXPERIMENTAL|HIV negative without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-\<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
62643082|NCT04787848|EXPERIMENTAL|HIV negative with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-\<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
62643083|NCT04787848|EXPERIMENTAL|HIV positive without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-\<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
62073374|NCT03562260|EXPERIMENTAL|children who had bipolar release|children who had bipolar release are included
62277762|NCT06325488||Patients with Fabry Disease and impaired kidney function|"Participants included in this group~* 18 years of age or above~* Fabry Disease as verified by genetic analysis prior to inclusion~* Impaired kidney function according to the KDIGO classification (UACR ≥ 30 mg/g and eGFR \< 60 ml/min/1.73m2 \[≥ CKD G3a/A2\])"
62277763|NCT06325488||Patients with Fabry Disease and normal kidney function|"Participants included in this group~* 18 years of age or above~* Fabry Disease as verified by genetic analysis prior to inclusion~* Normal kidney function according to the KDIGO classification (UACR \< 30 mg/g and eGFR ≥ 60 will be included \[≤ CKD G2/A1\])"
62643084|NCT04787848|EXPERIMENTAL|HIV positive with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-\<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
62643085|NCT04027088|EXPERIMENTAL|Immunonutrition|Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
62643086|NCT04027088|PLACEBO_COMPARATOR|Standard|Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients
62643087|NCT03368664|EXPERIMENTAL|Alemtuzumab|- alemtuzumab - Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, prednisolone, H1 antagonist \[antihistamine\], H2 antagonist, paracetamol, acyclovir) will be administered prior alemtuzumab administration. - Type: Experimental
62073375|NCT05859802|EXPERIMENTAL|Drug Group|
62073376|NCT05859802|PLACEBO_COMPARATOR|Placebo Group|
62073377|NCT04845295|EXPERIMENTAL|Fast Tempo|Performed training intervention with a tempo of 1 second for eccentric and 1 second for concentric phase
62073378|NCT04845295|EXPERIMENTAL|Slow Tempo|Performed training intervention with a tempo of 4 seconds for eccentric and 1 second for concentric phase
62643088|NCT03654417|ACTIVE_COMPARATOR|EMLA|
62643089|NCT03654417|ACTIVE_COMPARATOR|Lidocaine|
62643090|NCT04339049|EXPERIMENTAL|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
62643091|NCT04339049|ACTIVE_COMPARATOR|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
62643092|NCT04339049|PLACEBO_COMPARATOR|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
62643093|NCT04686916|EXPERIMENTAL|IP2018_dose 1|IP2018_dose1
62643094|NCT04686916|EXPERIMENTAL|IP2018_dose 2|IP2018_dose2
62073379|NCT00886262|EXPERIMENTAL|Vasopressin|
62073380|NCT00886262|PLACEBO_COMPARATOR|Normal saline placebo|
62073381|NCT05334823|EXPERIMENTAL|pCAR-19B cells|Infusion of pCAR-19B cells by dose of 0.6-2 x106 cells/kg
62643095|NCT04686916|PLACEBO_COMPARATOR|Placebo|Placebo
62643096|NCT04627688|ACTIVE_COMPARATOR|Standard dietary advices|
62643097|NCT04627688|EXPERIMENTAL|Time restricted feeding|
62643098|NCT03894995|NO_INTERVENTION|Part 1. Focus group discussions on ventilation preferences|Participant's perceived benefits/detriments of having ventilation options in the household and their opinions on the behavior change material developed to encourage increased household ventilation will be explored using 6-9 focus group discussions with 10-12 participants each.
62643099|NCT03894995|NO_INTERVENTION|Part 2. PM 2.5 pilot|Indoor, outdoor, and personal particulate matter concentrations among ten mother-child pairs and their homes will be monitored.
62643100|NCT03894995|EXPERIMENTAL|Part 3. Intervention|Households will participate in a baseline survey and a Beck-DeGroot-Marshak auction to establish willingness-to-pay for ventilation. If the household wins, or if it is decided to install ventilation in all intervention households, the household will receive installation of a ventilating mechanism.
62643101|NCT03894995|NO_INTERVENTION|Part 3. Control|For 12 month after intervention, the air exchange rate will be measured in all control households.
62643102|NCT03894995|NO_INTERVENTION|Part 4. Spillover|Households that neighbor enrolled study households will be surveyed and asked whether they, on their own, chose to install a window. If they did install a window, they will be asked how much they paid.
62643103|NCT00368251|PLACEBO_COMPARATOR|Placebo|Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
62643104|NCT00368251|EXPERIMENTAL|Brivaracetam 5 mg/day|Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
62643105|NCT00368251|EXPERIMENTAL|Brivaracetam 150 mg/day|Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
62643106|NCT02794129|EXPERIMENTAL|Bipolar Disorder patients|
62277764|NCT06325488||Healthy controls|"Participants included in this group~* 18 years of age or above~* Normal kidney function according to the KDIGO classification (UACR \< 30 mg/g and eGFR ≥ 60 will be included \[≤ CKD G2/A1\])~Furthermore, healthy controls are excluded~* Suspected of Fabry Disease or verified by genetic analysis~* Related to a patient with Fabry Disease~* Have cancer with an expected influence on life expectancy~* Known apoplexia cerebri, heart failure or established kidney disease~* Recently initiated or have had recent changes in antihypertensive medication (within 3 months)"
62277765|NCT02963805|EXPERIMENTAL|High intensity physical activity (HIPA)|Participants attended high intensity vigorous activity after school clubs.
62277766|NCT02963805|EXPERIMENTAL|Fundamental movement skill (FMS)|Participants attended fundamental movement skill based after school clubs.
62277767|NCT02963805|EXPERIMENTAL|Physical activity signposting (PASS)|Participants attended educational physical activity signposting sessions during school hours.
62455613|NCT01179490|EXPERIMENTAL|SyB L-0501 + prednisolone|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
62277768|NCT02963805|NO_INTERVENTION|Control|Children in the control group received British Heart Foundation leaflets that included information on heart health (given to all groups). Children participated in their usual school curriculum including two hours of physical education and school sport per week, both within and beyond the curriculum.
62455614|NCT04611698|EXPERIMENTAL|Immediate loading group|Visit 1 Implant surgery + Device loading Baseline Visit 2 Followup examination 2 weeks (2/+ 5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
62643107|NCT02794129|EXPERIMENTAL|Healthy Controls|
62643108|NCT01776554|EXPERIMENTAL|aH5N1c-High dose|
62643109|NCT01776554|EXPERIMENTAL|aH5N1c-Low dose|
62643110|NCT06127277|EXPERIMENTAL|Next4You|Next4You is a web-based, self-paced program featuring 6 content modules, each containing 8-10 microlessons intended to reduce rates of unintended pregnancy and sexually transmitted infections (STI) and increase essential knowledge, attitudes, and skills among young people aged 16-19 currently in foster care in California. Each microlesson is 2-4 minutes with diverse content formats. Youth in the intervention condition will have unlimited access to the platform for an intensive 4-week period. During this period, engagement activities will be deployed twice weekly to draw users back into the platform for further engagement with the microlessons. Content will also be released on a schedule to encourage continued engagement. Following the intensive 4-week period, youth will retain unlimited access to the platform but will not receive reminders to engage with the content. Participants complete online surveys at baseline, as well as 3 months and 9 months after the intervention ends.
62643111|NCT06127277|ACTIVE_COMPARATOR|General Health Mobile Website|Youth randomized to the attention control condition will have access to a mobile-responsive website that contains digital resources focusing on nutrition, sleep, stress/anxiety, and exercise. Like the intervention group, participants in the attention control group will have unlimited access to the general health digital resources for an intensive 4-week period. Each topic area will have between 1-4 digital pamphlets (for a total of 12 pamphlets) that are downloadable and take between 2-4 minutes to read. Participants complete online surveys related to attitudes, knowledge, and behavior around romantic relationships and sexual behavior at baseline, as well as 3 months and 9 months after the intervention ends.
62643112|NCT02828865|EXPERIMENTAL|irreversible electroporation (IRE)|irreversible electroporation (IRE) (AngioDynamics, NY) To use 2 to 6 unipolar electrodes of IRE in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
62277769|NCT05702528|EXPERIMENTAL|Immediate treatment|The group will begin using the Apollo Neuro device immediately upon entering the study
62455615|NCT04611698|EXPERIMENTAL|2-week loading group|Visit 1 Implant surgery Baseline Visit 2 Device loading 2 weeks (2/+5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
62455616|NCT01335477|PLACEBO_COMPARATOR|placebo|patient receives capsules identical to those containing active drug
62455617|NCT01335477|EXPERIMENTAL|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
62455618|NCT02876913||Group Nasotracheal Intubation|Patients who are scheduled for nasotracheal intubation for general anesthesia
62455619|NCT02197468||Probiotics|"Preterm infants given probiotics: GA 24-27 weeks/Birth weight \< 1000 g~Preterm infants not given probiotics: GA 28-31 weeks/Birth weight 1000-1500 g~Full-term infants not given probiotics (control)"
62455620|NCT06346548||Group 1|This group will include patients with an age between 18 years old and 29 years old. The recruitment doesn't include a gender selection
62073382|NCT02240719|EXPERIMENTAL|Everolimus + Bendamustine|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62073383|NCT04797819||Serum sST2 level < 14.5 ng/mL|
62277770|NCT05702528|NO_INTERVENTION|Waitlist treatment|The group will be assigned to a waitlist and begin using the Apollo Neuro device twelve weeks after entering the study
62643113|NCT02455128|EXPERIMENTAL|Experimental Group|This group will receive the therapeutic listening.
62643114|NCT02455128|NO_INTERVENTION|Control Group|This group will receive usual care offered by the hospital where the study will be conducted.
62073384|NCT04797819||14.5 ng/mL ≤ Serum sST2 level < 20.5 ng/mL|
62073385|NCT04797819||20.5 ng/mL ≤ Serum sST2 level < 25.9 ng/mL|
62073386|NCT04797819||Serum sST2 level ≥ 25.9 ng/mL|
62073387|NCT04788030||Digital nerve reconstruction with muscle-in-vein conduits|
62073388|NCT01313611|EXPERIMENTAL|Rituximab + bendamustine|
62073389|NCT06226142|EXPERIMENTAL|Ultrasound guided percutaneous tracheostomy|The PDT will be performed by the attending physician exclusively with the aid of the ultrasound.
62073390|NCT06226142|ACTIVE_COMPARATOR|Bronchoscopy guided percutaneous tracheostomy|The PDT will be performed by the attending physician exclusively with the aid of the bronchoscope.
62073391|NCT06226142|ACTIVE_COMPARATOR|Ultrasound-bronchoscopy guided percutaneous tracheostomy|The PDT will be performed by the attending physician with the aid of the ultrasound and bronchoscope.
62073392|NCT02359591||text-based or multimedia|Subject fills in a questionnaire regarding whether the child meets developmental milestones for his/her developmental age, both the text-based and the multimedia version. A total score will be calculated and compared.
62277771|NCT02765360|EXPERIMENTAL|Treatment|Each patient will be assigned to Continuous Positive Airway Pressure (CPAP), Pressure Support Ventilation (PSV) and Pressure Control Ventilation (PCV) modes in a random order with a 10 minute washout period modes.
62277772|NCT02050269|EXPERIMENTAL|Iohexol|injection of 5 ml of iohexol
62455621|NCT06346548||Group 2|This group will include patients with an age between 30 years old and 59 years old. The recruitment doesn't include a gender selection
62455622|NCT06346548||Group 3|This group will include patients with an age over 60 years old. The recruitment doesn't include a gender selection
62643115|NCT02991274||T790M mutation test|genomic testing of T790M mutation
62643116|NCT02071485||No treatment|Subjects in this study will receive no treatment and rather will only be trained in using the motor imagination-based BCI system
62073393|NCT04041479|ACTIVE_COMPARATOR|Standard of Care|FDA-cleared, standard-of-care iTBS repetitive Transcranial Magnetic Stimulation targeting the left dorsolateral prefrontal cortex (DLPFC), regardless of the depression subtype (biotype) determined by a magnetic resonance imaging (MRI) scan.
62643117|NCT05985746|EXPERIMENTAL|Augmented Reality (AR) group.|- The experimental group will consist of approximately 20 undergraduate medical students. Participants will use the TEACHANATOMY learning application with the HoloLens 2.
62643118|NCT05985746|ACTIVE_COMPARATOR|Traditional learning (TL) group.|- The control group will consist of approximately 20 undergraduate medical students. Participants will use traditional learning methods with textbooks, atlases, videos, and online learning programs,
62643119|NCT06422728|EXPERIMENTAL|Transdiagnostic Unified Protocol|The intervention group will receive the transdiagnostic unified protocol (UP) for anxiety disorders that is developed in this study. The UP is based on CBT model and will last for 8 weeks and there will be a follow-up session after one month. Each session will last 1 and a half hours. The pre-, post- and follow-up tests will be given to them to test the effectiveness of the UP.
62643120|NCT06422728|ACTIVE_COMPARATOR|Client-Centered Supportive Therapy|The supportive therapy group will also last for 8 weeks and there will be a follow-up session after one month. Each session will last 1 and a half hours. The pre-, post- and follow-up tests will be given to them, too.
62643121|NCT00072449|EXPERIMENTAL|Rituximab monotherapy|Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
62277773|NCT05155254|EXPERIMENTAL|IO102-IO103 + pembrolizumab|"IO102-IO103 subcutaneous injections (85µg) every 3 weeks for a maximum 35 cycles (up to 2 years treatment). Additional dose given during the induction period on Day 8 of cycles 1 and 2. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years treatment).~Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles."
62277774|NCT05155254|ACTIVE_COMPARATOR|pembrolizumab|Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment).
62643122|NCT02306889|EXPERIMENTAL|Test|Fenofibrate Capsules, USP 130 mg
62643123|NCT02306889|ACTIVE_COMPARATOR|Reference|ANTARA® (fenofibrate) Capsules 130 mg
62643124|NCT01115452|EXPERIMENTAL|5% KNO3 solution|Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
62643125|NCT01115452|EXPERIMENTAL|2.5% KNO3 solution|Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
62643126|NCT01115452|PLACEBO_COMPARATOR|Sterile Water|Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period.
62643127|NCT03053882|ACTIVE_COMPARATOR|green tea and peppermint|
62277775|NCT04895761|EXPERIMENTAL|Arm A: DPX-Survivac, Letrozole|Letrozole 2.5 mg po daily, DPX-Survivac 0.25 mL SC week 2 and Week 5
62643128|NCT03053882|ACTIVE_COMPARATOR|peppermint and green tea|
62643129|NCT06514287|OTHER|Individualized intervention|It is a pragmatic intervention where three priorities were identified for physical activities in daily routines, considering the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. The therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. The intervention plan was implemented via online consultation using WhatsApp text, audio, and video messaging for asynchronous and synchronous communication. The focus of intervention was incorporating practice of goals into daily activity routines.
62073394|NCT04041479|EXPERIMENTAL|Targeted Side Arm|iTBS rTMS targeting the area of the brain (DLPFC or dorsomedial prefrontal cortex DMPFC)) that we hypothesize will be most effective for that subject's biotype (confirmation arm).
62277776|NCT04895761|EXPERIMENTAL|Arm B: DPX-Survivac, Letrozole, Radiation|Letrozole 2.5 mg po daily, XRT 10 Gy x 2, DPX-Survivac 0.25 mL SC week 2 and Week 5
62073395|NCT04041479|ACTIVE_COMPARATOR|Opposite Side Arm|iTBS rTMS targeting the opposite site (DLPFC or DMPFC) than the one we hypothesize will be most effective for that subject's biotype (disconfirmation arm).
62073396|NCT02807740|EXPERIMENTAL|Virtual Reality|Patients will be treated with a virtual reality rehabilitation program
62277777|NCT04895761|EXPERIMENTAL|Arm C: DPX-Survivac, Letrozole, cyclophosphamide|Letrozole 2.5 mg po daily, cyclophosphamide 50 mg po BID, DPX-Survivac 0.25 mL SC week 2 and Week 5
62277778|NCT00278681|EXPERIMENTAL|I|Zinc and ORS
62073397|NCT02807740|OTHER|Conventional Rehabilitation Program|Patients will be treated with a conventional rehabilitation program.
62643130|NCT04393649||Older patients / community dwellers|"The inclusion criteria are:~1. Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria~2. Living and staying at home because of physical and social distancing~3. Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.)~4. Agree to participate in the study~The exclusion criteria are:~1. A concomitant participation to another medical trial~2. Living in semi-autonomous residence or CHSLD"
62073398|NCT01428674|EXPERIMENTAL|10 minutes reading|
62277779|NCT04088344|PLACEBO_COMPARATOR|Isocaloric diet (7 days)|Protocole A
62277780|NCT04088344|EXPERIMENTAL|Hypercaloric diet enriched with carbohydrate food (7 days)|Protocole B
62643131|NCT01814007|EXPERIMENTAL|CoolSculpting Treatment Group|CoolSculpting treatments will be performed on all subjects with 1 cooling cycle on the lower abdomen, plus simultaneous treatment of both flanks, one cooling cycle each. Two control units will be utilized at protocol-defined temperatures and durations.
62277781|NCT00039988|EXPERIMENTAL|1|Participants will receive Copaxone and albuterol placebo
62455623|NCT02386033|PLACEBO_COMPARATOR|SRP plus placebo|SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
62277782|NCT00039988|EXPERIMENTAL|2|Participants will receive Copaxone and albuterol
62277783|NCT01145066|EXPERIMENTAL|borage and echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
62455624|NCT02386033|ACTIVE_COMPARATOR|SRP plus Atorvastatin|SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
62073399|NCT01428674|EXPERIMENTAL|20 minutes touch|
62073400|NCT01428674|EXPERIMENTAL|20 minutes reading|
62455625|NCT04686253||PFO patients with CS or/and TIA|PFO patients with CS or/and TIA (transcatheter closure of PFO was performed).
62455626|NCT04686253||PFO patients with migraine|PFO patients with migraine (transcatheter closure of PFO was performed).
62455627|NCT04686253||PFO patients without symptom|PFO patients without symptom (5-year follow-up).
62455628|NCT02541526|EXPERIMENTAL|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
62073401|NCT01428674|EXPERIMENTAL|10 minutes touch|
62073402|NCT04755439|OTHER|undergoing deep hypothermic cırculatory arrest patients|Difüsıon magnetic rezonans imaging , neuron spesific enolase enzym level , deep hypotermic cırculatory arrest
62277784|NCT01145066|ACTIVE_COMPARATOR|fish oil|Croda 18:12 fish oil
62277785|NCT01145066|PLACEBO_COMPARATOR|corn oil|
62277786|NCT06304454|EXPERIMENTAL|Cognitive and emotional board games|An experimental group that will carry out the cognitive and emotional game program in the classroom implemented by the teachers of the participating centers.
62277787|NCT06304454|ACTIVE_COMPARATOR|Motor/Luck board games|A control group that will be on board games that do not directly activate cognitive and emotional processes. These games are classified as motor or luck board games.
62277788|NCT03027752|ACTIVE_COMPARATOR|carotid endarterectomy patch angioplasty|Carotid endarterectomy with longitudinal incision carotid endarterectomy patch angioplasty
62643132|NCT00100906|ACTIVE_COMPARATOR|ATRA Followed by IL-2 - Dose Level A|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
62643133|NCT00100906|ACTIVE_COMPARATOR|ATRA Followed by IL-2 - Dose Level B|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
62277789|NCT03027752|EXPERIMENTAL|Carotid endarterectomy with autoarterial remodeling|Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery
62277790|NCT04192409|EXPERIMENTAL|Intervention-Smartphone Application|Patients will install a smartphone application that custom-developed for the study and learn to use it with the help of researchers. The application will have the following functions: 1) providing health education information about glycemic control, postoperative management and important of drug compliance; 2) providing alert \& record service on patients' DM and CAD medication treatment; 3) aiding patients to conduct self-evaluate by providing questionnaire about patients' recent basic health parameters on times. The information will be interpreted automatically by application and brief feedback will be provided to patients; 4) recording patients' fasting plasma glucose value that input by patients and generate a recent glycemic control report.
62277791|NCT04192409|NO_INTERVENTION|Control|Patients will receive no additional intervention from researchers except the usual care provided by hospital.
62643134|NCT00100906|ACTIVE_COMPARATOR|ATRA Followed by IL-2 - Level C|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
62073403|NCT05957757|EXPERIMENTAL|RC48+Tislelizumab|Approximately 20 subjects will be enrolled to evaluate the efficacy and safety of RC48 (RC48 2.0 mg/kg intravenously administered every two weeks) combined with Tislelizumab (Tislelizumab 200 mg intravenously administered every three weeks).
62277792|NCT06549491|EXPERIMENTAL|Sleep Wizard|These participants will be randomized to receive Sleep Wizard.
62073404|NCT02571439|EXPERIMENTAL|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
62073405|NCT02571439|ACTIVE_COMPARATOR|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
62643135|NCT02184819|ACTIVE_COMPARATOR|levosimendan|study drug
62643136|NCT02184819|PLACEBO_COMPARATOR|placebo|placebo group
62643137|NCT00583648|EXPERIMENTAL|1|Recieves urinalysis by nurse per set protocol based off of inclusion criteria
62643138|NCT00583648|NO_INTERVENTION|2|ordering of test will be up to the treating physician
62643139|NCT05883865||fenofibrate group|Women with TG level ≥10mM receive fenofibrate micronized capsule（200mg ，qd）or table（160mg ，qd）for at least 1 week during pregnancy.
62643140|NCT05883865||negative group|Pregnant women with TG level ≥10mM without fenofibrate treatment.
62643141|NCT04746469|NO_INTERVENTION|Control|This group will receive standard FIT mailer protocol (includes mailed FIT kit plus standardized messaging via EHR portal)
62643142|NCT04746469|EXPERIMENTAL|Intervention|This group will receive standard FIT mailer protocol (as above) PLUS delayed automated phone reminder
62643143|NCT05606601|EXPERIMENTAL|Intervention arm|Participants randomized into the intervention arm will be given immediate access to a fully functional version of the Minder app that includes baseline, interim and follow-up surveys and access to all app components and e-coaching.
62643144|NCT05606601|NO_INTERVENTION|Control arm|Participants randomized into the control arm will be given access to a restricted version of the app that only includes access to a generic study introduction video and baseline and follow up survey assessments delivered via the app.
62643145|NCT01298947|ACTIVE_COMPARATOR|Laser atherectomy and drug-coated balloon|Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries
62643146|NCT01298947|ACTIVE_COMPARATOR|Drug eluting Ballon PTA|Paclitaxel-coated balloon angioplasty
62643147|NCT02229591||EFL patients|Patients with Expiratory Flow Limitation undergoing surgery
62643148|NCT02229591||Control group|Patients withouth Expiratory Flow Limitation undergoing surgery
62643149|NCT03534661|PLACEBO_COMPARATOR|Teduglutide + Normal Saline|Teguglutide + (L-NMMA control)
62643150|NCT03534661|ACTIVE_COMPARATOR|Teduglutide + L-NMMA|Tedulgutide + L-NMMA
62643151|NCT03534661|PLACEBO_COMPARATOR|Placebo + L-NMMA|(Teduglutide control) + L-NMMA
62643152|NCT02785198|NO_INTERVENTION|Control group|A control group receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
62073406|NCT06529549||Organoid-Based Drug Sensitivity Screening|Organoid culture and drug sensitivity screening
62073407|NCT00798356|OTHER|1|Yoga training
62073408|NCT04142060|EXPERIMENTAL|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously
62073409|NCT05789862|EXPERIMENTAL|Virtual behavioral health|Participants will be assessed at 3 time points over the course the standard-of-care treatment before and after a scheduled craniotomy. At each time point, the participants will be asked to complete the questionnaires and engage in virtual counseling sessions.
62073410|NCT04041752|EXPERIMENTAL|Normal weight|30 healthy normal weight adults will be involved and will realize the three conditions
62277793|NCT06549491|OTHER|Waitlist control|These participants will be part of the waitlist control condition At the end of the 3-month follow-up visit, participants in the control group will be offered the intervention.
62277794|NCT01646632|EXPERIMENTAL|Physical exercise intervention|Progressive resistance training, balance training, functional training
62277795|NCT01646632|PLACEBO_COMPARATOR|Lifestyle counseling|Recreational sessions
62277796|NCT00911846||Buprenorphine|opioid-dependent patients with buprenorphine substitution
62277797|NCT00911846||methadone|opioid-dependent patients substituted with methadone
62277798|NCT00911846||no substitution|opioid-dependent patients without substitution
62643153|NCT02785198|EXPERIMENTAL|Passive training group|An Intervention group doing passive exercise for 8 weeks in knee extensor machine, and receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
62643154|NCT05564572|EXPERIMENTAL|Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
62643155|NCT05564572|NO_INTERVENTION|Usual Care|Patients will not complete a patient-reported health status measures.
62643156|NCT02134093|PLACEBO_COMPARATOR|Normal saline|Continuous pump infusion of normal saline with identical volume, compared with the low dose and high dose group,until the end of surgery
62643157|NCT02134093|EXPERIMENTAL|High dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 1μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.4μg/kg/h until the end of surgery
62277799|NCT00911846||therapists|therapists of the patients
62277800|NCT04381195||Aim 1|Item Drafting and Revising (Aim 1). Together with a stakeholder panel of autistic adults and adults with IDD and parents/caregivers, the study investigators will generate an item pool based on the conceptual model.
62277801|NCT04381195||Aim 2|Item Calibration (Aim 2). Measures will be completed online and therefore the sample will include those with self-reported IDD or autism diagnoses and their caregivers (total n of 1000 each)
62277802|NCT00002744|EXPERIMENTAL|Arm I|Therapy defined in description.
62277803|NCT00002744|EXPERIMENTAL|Arm 2|Therapy defined in description.
62277804|NCT00002744|EXPERIMENTAL|Arm 3|Therapy defined in description.
62643158|NCT02134093|EXPERIMENTAL|Low dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.2μg/kg/h until the end of surgery
62277805|NCT00002744|EXPERIMENTAL|Arm 4|Therapy defined in description.
62643159|NCT02585453|EXPERIMENTAL|Patients with dry eye syndrome 1|20 Patients with dry eye syndrome
62643160|NCT02585453|ACTIVE_COMPARATOR|Patients with dry eye syndrome 2|20 Patients with dry eye syndrome
62073411|NCT02218385||ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
62073412|NCT01225822|EXPERIMENTAL|BIBR 1048 50 mg bis in die(b.i.d)|BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
62277806|NCT02482584|ACTIVE_COMPARATOR|CPAP treatment|Continuous Positive Airway Pressure (CPAP) treatment during three month.
62277807|NCT02482584|OTHER|Control group|Control group
62277808|NCT02267590||MCL: 80-100 samples from 60- 70 patients|Mantle Cell lymphoma patients
62277809|NCT02267590||CLL: 15-20 samples from 10-15 patients|Chronic lymphocytic leukaemia patients
62277810|NCT02638701|EXPERIMENTAL|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
62643161|NCT02585453|ACTIVE_COMPARATOR|Patients with dry eye syndrome 3|20 Patients with dry eye syndrome
62643162|NCT00728494||Treatment and Patient Assistance Program|Patient assistance program was provided to the participants treated with PegIntron/Rebetol. The support program consisted of training by physicians or specialized nurses on the significance of treatment compliance, methods for managing adverse events, and correct drug administration, as well as informational materials and assistance in the management of adverse events.
62643163|NCT00728494||Treatment Alone|PegIntron/Rebetol treatment only.
62643164|NCT01876095|EXPERIMENTAL|Multidisciplinary medication review|"The multidisciplinary medication review consists of 5 steps:~Step #1: Assessing patients' experiences and preferences regarding medicine use en assessing their medical history, allergies and lab results Step #2: Drug reviewing to assess contra-indicated medication and duplicate medication using consensus criteria e.g. START STOPP Beers criteria Step #3: Reflecting on results of drug reviewing Step #4: Setting up a pharmacotherapeutical action plan Step #5: Execution of pharmacotherapeutical action plan"
62643165|NCT01876095|NO_INTERVENTION|usual care|Includes medication safety monitoring and ad hoc medication reviews on clinical indication that differ in quality and frequency, but no standardized multidisciplinary multistep medication reviews in the way as described for the intervention arm
62073413|NCT01225822|EXPERIMENTAL|BIBR 1048 150 mg b.i.d|BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
62643166|NCT00944918|EXPERIMENTAL|1|fulvestrant and anastrozole
62643167|NCT00944918|EXPERIMENTAL|2|fulvestrant and placebo
62643168|NCT00944918|ACTIVE_COMPARATOR|3|exemestane alone
62073414|NCT01225822|EXPERIMENTAL|BIBR 1048 225 mg b.i.d|BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
62073415|NCT01225822|EXPERIMENTAL|BIBR 1048 300 mg quaque die(q.d)|BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
62073416|NCT01225822|ACTIVE_COMPARATOR|Enoxaparin 40 mg subcutaneous(s.c)|placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
62073417|NCT03819777||Idiopathic PAH|
62073418|NCT03819777||CTD-PAH|
62073419|NCT03819777||CTD without PAH|
62277811|NCT03861637|ACTIVE_COMPARATOR|drug : ESA for p correction of PTA|ESA (Aranesp or mir-CERA) injection 1 mg per kg sc every week for 1 year to correct PTA to level between 12-13g/dl.
62277812|NCT03861637|ACTIVE_COMPARATOR|ara or cera|ESA (Aranesp) 1mg/ kg (or equivalent doses) of MIR-CERA injection for 1 year to correct PTA to level between 13-15g/dl.
62277813|NCT04631029|EXPERIMENTAL|Treatment (carboplatin, etoposide, atezolizumab, entinostat)|"INDUCTION THERAPY: Patients receive carboplatin IV over 30-60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, atezolizumab IV over 30-60 minutes on day 1, and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive atezolizumab IV over 30 minutes on day 1 and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity."
62643169|NCT02192671|EXPERIMENTAL|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and \>50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
62073420|NCT02611544|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy|6 weeks, the ACT group will meet weekly for 2 hours at one of three facilities.
62277814|NCT01315379||PTSD without TBI|"children and adolescents with a diagnosis of PTSD and without head injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
62277815|NCT01315379||PTSD with m-TBI|"children and adolescents with a diagnosis of PTSD and a diagnosis of mild traumatic brain injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
62277816|NCT03190200||MRI|Subjects with healthy knees
62277817|NCT03591445|EXPERIMENTAL|Experimental：Bronchoscopy|Patients with ground glass opacity featured lung cancer who are candidates for surgeyr received the bronchoscopy examination before surgery.
62643170|NCT02192671|ACTIVE_COMPARATOR|Radiofrequency ablation|RFA is performed in less than one week after clinical diagnosis.
62643171|NCT02109757|EXPERIMENTAL|Software intervention and education|This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.
62643172|NCT02109757|ACTIVE_COMPARATOR|Education only|This group will not receive software intervention prior to and after one-on-one education, only afterwards.
62643173|NCT05303116||Control|Patients with COVID who are NOT experiencing altered mental status
62643174|NCT05303116||COVID patients|COVID patients who are experiencing confusion,
62073421|NCT02611544|ACTIVE_COMPARATOR|Survivorship Education|6 weeks, SE group will meet weekly for 2 hours at one of three facilities.
62073422|NCT02611544|ACTIVE_COMPARATOR|Enhanced Usual Care|"Continue to meet with their health care team + receive a variety of readings at each data collection point on coping with common survivorship concerns, including a booklet from the National Cancer Institute entitled Facing Forward: Life After Cancer Treatment."
62073423|NCT03354637|ACTIVE_COMPARATOR|ATI-50002 high dose Topical Solution|High dose active
62073424|NCT03354637|ACTIVE_COMPARATOR|ATI-50002 low dose Topical Solution|low dose active
62073425|NCT03354637|PLACEBO_COMPARATOR|Vehicle Topical Solution|placebo
62643175|NCT00792285|EXPERIMENTAL|Automated Telephone Outreach|Automated Telephone Outreach with Speech Recognition
62643176|NCT00792285|NO_INTERVENTION|Usual Care|Usual Care
62455629|NCT02541526|PLACEBO_COMPARATOR|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
62643177|NCT05410678|EXPERIMENTAL|renal stent group|Acute coronary patients treatment with renal stent
62643178|NCT05410678|ACTIVE_COMPARATOR|BMCS group|Acute coronary patients treatment with bare-metal stent
62643179|NCT02617615|EXPERIMENTAL|MB-110|oral hard-gel capsule formulation. One dose strength, 25 mg of MB-110, will be filled into the #00 hard-gel capsule.
62643180|NCT02617615|PLACEBO_COMPARATOR|Placebo|in the same #00 hard-gel capsules.
62073426|NCT05085743||Training|Images and related clinical data along with the measured lip to carina length of the training group are fed into and used to fit out deep convolutional neural networks model.
62073427|NCT05085743||Validation|We evaluate the model accuracy and efficacy of predicting the lip to carina length with images and clinical data of those unforeseen cases in the validation group.
62073428|NCT02351882|ACTIVE_COMPARATOR|Nabilone|Participants randomized into the nabilone arm will be prescribed nabilone for 6 weeks. After one-week placebo washout, they will be taking placebo for an additional 6 weeks.
62073429|NCT02351882|PLACEBO_COMPARATOR|Placebo|Participants randomized into the placebo arm will be receiving placebo for 6 weeks. After one-week placebo washout, they will be prescribed nabilone for an additional 6 weeks.
62277818|NCT01592981|EXPERIMENTAL|bortezomib, cyclophosphamide, rituximab|"Bortezomib:1.6 mg/m2 s.c; days 1, 8, 15 of each cycle. Cyclophosphamide:250 mg/m2 oral; days 1, 8, 15 of each cycle. Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days. After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
62277819|NCT01592981|ACTIVE_COMPARATOR|fludarabine, cyclophosphamide, rituximab|"Fludarabine:40 mg/sq m, oral, days 1,2 and 3 of each cycle. Cyclophosphamide:250 mg/sq m; oral, days 1, 2 and 3 of each cycle. Rituximab: 375 mg/sq m i.v. infusion days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days.After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
62455630|NCT02896361|EXPERIMENTAL|Stimulation order 1|"Stimulations delivered in following order:~1. Standard burst~2. Burst Microdosing 1~3. Burst Microdosing 2"
62643181|NCT00716456|EXPERIMENTAL|1|In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
62643182|NCT02652169|EXPERIMENTAL|Study arm 1 - PRF plus amikacin and teicoplanin|PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
62643183|NCT02652169|EXPERIMENTAL|Study arm 2 - PRF plus normal saline|PRF mixed with normal saline is sprayed on the patients' ulcer
62643184|NCT02652169|EXPERIMENTAL|Study arm 3 - PRF mixed with PHMB plus Macrogolol|PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
62277820|NCT02618447|EXPERIMENTAL|Arm 1: 4D phase contrast MR scan|"* Each patient will undergo a total of 3 MRI/MRA scans (lasting 30-60 minutes):~  * Scan 1: Baseline (pre-portal vein embolization (PRE))~ * Scan 2: Early after PVE (within 48 hours)~ * Scan 3: Late after PVE (at 3-8 weeks).~* Scans 1 and 3: routine liver MR sequences with/without contrast (Gadoxetic acid, Eovist) and 4D phase contrast of the portal venous system. The 4D phase contrast sequence will be repeated twice at each time point, adding about 15-30 minutes to each scan.~* Scan 2: 4D phase contrast sequences and imaging for localization."
62277821|NCT05835869|EXPERIMENTAL|Study population|
62277822|NCT01158521|EXPERIMENTAL|Arm I|Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
62455631|NCT02896361|EXPERIMENTAL|Stimulation order 2|"Stimulations delivered in following order:~1. Burst Microdosing 1~2. Burst Microdosing 2~3. Standard burst"
62455632|NCT02896361|EXPERIMENTAL|Stimulation order 3|"Stimulations delivered in following order:~1. Burst Microdosing 2~2. Standard burst~3. Burst Microdosing 1"
62455633|NCT02472288|EXPERIMENTAL|Electroacupuncture (EA) group|"1. Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)~2. BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)~3. 20 minutes duration, middle frequency (30 Hz) of electrical stimulation~4. conventional treatments permitted"
62455634|NCT02472288|SHAM_COMPARATOR|Sham group|"1. Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)~2. BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)~3. 20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)~4. conventional treatments permitted"
62643185|NCT02652169|ACTIVE_COMPARATOR|Study arm 4 - Acticoat 7|A silver gauze (Acticoat 7®) is applied to the patients' ulcer
62643186|NCT01268163|ACTIVE_COMPARATOR|1|European Taxotere® (Taxotere EU) 60-100 mg/m\^2
62643187|NCT01268163|EXPERIMENTAL|3|Hospira Docetaxel Injection 60-100 mg/m\^2
62643188|NCT01268163|ACTIVE_COMPARATOR|2|American Taxotere® (Taxotere US) 60-100 mg/m\^2
62643189|NCT02076386||Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
62643190|NCT04805268|EXPERIMENTAL|One subject with possible Luft's disease|18F-FDG will be administered I.V., approximately 1 hour prior to PET/CT scan.
62643191|NCT03622762|EXPERIMENTAL|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
62643192|NCT03622762|PLACEBO_COMPARATOR|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
62277823|NCT00958139|EXPERIMENTAL|Permethrin treatment of clothing|0.5% permethrin sprayed one time on uniform shorts, pants, and socks
62643193|NCT01423825|EXPERIMENTAL|Sub C gp140/MF59C.1 Vaccine|Participants will receive Sub C gp140 vaccine (100 mcg) admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid at baseline and Month 3.
62643194|NCT01423825|PLACEBO_COMPARATOR|Sodium chloride for injection|Participants will receive placebo injection administered as 0.5 mL IM in either deltoid at baseline and Month 3.
62643195|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
62643196|NCT05021640|EXPERIMENTAL|Cohort 1: DCRAUD 80 mg|Participant received a single dose of DCR-AUD 80 mg, subcutaneous injection on Day 1.
62643197|NCT05021640|PLACEBO_COMPARATOR|Cohort 2: DCRAUD 240 mg|Participant received a single dose of DCR-AUD 240 mg, subcutaneous injection on Day 1.
62643198|NCT05021640|EXPERIMENTAL|Cohort 3: DCR-AUD 480 mg|Participant received a single dose of DCR-AUD 480 mg, subcutaneous injection on Day 1.
62643199|NCT05021640|PLACEBO_COMPARATOR|Cohort 4: DCR-AUD 960 mg|Participant received a single dose of DCR-AUD 960 mg, subcutaneous injection on Day 1.
62643200|NCT05021640|EXPERIMENTAL|Pooled Placebo|Participant received a single dose of DCR-AUD matching placebo, subcutaneous injection on Day 1.
62643201|NCT05021653||Men who have sex with men (MSM)|Chinese men who have sex with men living with HIV infection and attending the service of HIV specialist service in Hong Kong
62643202|NCT05021653||non-MSM|Chinese heterosexual men and women living with HIV infection and attending the service of HIV specialist service in Hong Kong
62643203|NCT01934465||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
62643204|NCT04347408||Healthy Children|Healthy children of healthcare workers between 2 and 15 years of age
62643205|NCT04347408||Paediatric Multisystem Inflammatory Syndrome|Children admitted to hospital with Paediatric Multisystem Inflammatory Syndrome
62277824|NCT00958139|SHAM_COMPARATOR|Placebo|Water sprayed on uniform shorts, pants, and socks
62277825|NCT01675986|EXPERIMENTAL|Pregabaline|Groups PREGABALINE : 150 mg de LYRICA®
62277826|NCT01675986|EXPERIMENTAL|Hydroxyzine|Groups HYDROXYZINE : 75 mg d'ATARAX®
62277827|NCT01675986|PLACEBO_COMPARATOR|Lactose|Groups placebo : 4 g de lactose
62277828|NCT02303626|EXPERIMENTAL|BCX4161 300 mg three times daily|Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth
62277829|NCT02303626|EXPERIMENTAL|BCX4161 500 mg three times daily|Five BCX4161 capsules (100 mg) to be taken three times daily by mouth
62277830|NCT02303626|PLACEBO_COMPARATOR|Placebo three times daily|Five placebo capsules to be taken three times daily by mouth
62643206|NCT04347408||Serious Infection|Children admitted to hospital with serious infections
62643207|NCT05784051|EXPERIMENTAL|Experimental group|Patients treated for PVCs with drug therapy and/or catheter ablation/ medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).
62643208|NCT05784051|ACTIVE_COMPARATOR|Control group|Patients with therapeutic abstention or no treatment modification such as drug therapy/ Therapeutic abstention or no modification of therapy
62643209|NCT01162733|ACTIVE_COMPARATOR|Study Drug 1|Vancomycin 15mg/kg
62643210|NCT01162733|ACTIVE_COMPARATOR|Study Drug 2|Vancomycin 30mg/kg
62643211|NCT03818152|OTHER|study group|Reliability study isokinetic strength assessment of the lower limbs.
62643212|NCT06521177|EXPERIMENTAL|Hand Serum Alone First|Participants will apply Hand Serum alone for the first period (6 weeks), followed by applying Hand Serum with Glove in the second period (6 weeks).
62643213|NCT06521177|EXPERIMENTAL|Hand Serum with Glove First|Participants will apply Hand Serum with Glove for the first period (6 weeks), followed by applying Hand Serum alone in the second period (6 weeks).
62643214|NCT01625468|NO_INTERVENTION|Control|Participant receives usual care
62643215|NCT01625468|EXPERIMENTAL|Intervention|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
62643216|NCT06269302||Patients with recurrent gastrointestinal bleeding|The data of all patients who applied to Samsun Training and Research Hospital for 12 months in 2022 and diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy were included in the study.Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of use of new generation oral anticoagulants in patients with rebleeding was determined, and data such as rebleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it.
62643217|NCT01183364|EXPERIMENTAL|STA-9090 and Docetaxel|STA-9090 (ganetespib) and Docetaxel
62643218|NCT01811732|EXPERIMENTAL|Delafloxacin plus placebo|Delafloxacin 300 mg IV every 12 hours for a minimum of 10 and up to a maximum of 28 doses
62643219|NCT01811732|ACTIVE_COMPARATOR|Vancomycin plus Aztreonam + placebo|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 and up to a maximum of 28 doses (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
62643220|NCT03347383|EXPERIMENTAL|Combination therapy DCB + stent|Patients treated with the Luminor DCB and the iVolution stent
62643221|NCT02074202|EXPERIMENTAL|FCH PET/CT scan results|PET/CT scan results with FCH intravenous injection
62643222|NCT02074202|ACTIVE_COMPARATOR|FDG PET/CT scan|PET/CT scan results with FDG intravenous injection
62643223|NCT01102023|EXPERIMENTAL|solar salt based-diet|
62643224|NCT03540264|ACTIVE_COMPARATOR|Composite resin|Restoration with composite resin has shown good clinical performance and limited occlusal wear. The Clearfil Majesty will be used in the present study.
62643225|NCT03540264|ACTIVE_COMPARATOR|Polymer-infiltrated-ceramic-network|This hybrid material seems to be a promising material that imitates natural tooth properties. The VITA-Enamic® will be used in this study.
62643226|NCT05802017|EXPERIMENTAL|Allergen-specific substitute diet|Participants follow a 4-month allergen-specific diet according to their immunology results.
62643227|NCT05802017|NO_INTERVENTION|Healthy diet|Participants follow a 4-month standard healthy diet.
62643228|NCT02832778|EXPERIMENTAL|Stage 1 London|"Stage 1, London:~* Phase 1 (2 weeks): tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily~* Phase 2 (12 weeks): tenofovir/emtricitabine or tenofovir /lamivudine or zidovudine/lamivudine) plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)"
62643229|NCT02832778|EXPERIMENTAL|Stage 2 Kampala|Tenofovir/emtricitabine or lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥ 50 kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg).
62643230|NCT01126892|EXPERIMENTAL|Nilotinib|
62277831|NCT03741166||Subject aged 45-49 with Average CRC Risk|Subjects will be men and women, 45-49 years of age, who enroll in Exact Sciences Protocol 2018-10. Subjects will provide a blood sample at time of enrollment.
62643231|NCT04870996|EXPERIMENTAL|Active transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent active tDCS and CT on five consecutive days. The participants received a ramp-up of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then a ramp-down of 30 seconds.
62643232|NCT04870996|SHAM_COMPARATOR|Sham transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent sham tDCS and CT on five consecutive days. The current was only delivered in the 30-second ramp-up and 30-second ramp-down periods.
62643233|NCT03905733||general anesthesia with rigid bronchoscopy|Patients 7 years or younger who undergo general anesthesia with rigid bronchoscopy
62643234|NCT05374447|ACTIVE_COMPARATOR|EBUS-TBNA|These will be the patient who undergo EBUS-TBNA only without EBUS-IFB
62277832|NCT03047070|ACTIVE_COMPARATOR|Lidocaine|IV Lidocaine infusion
62643235|NCT05374447|EXPERIMENTAL|EBUS-TBNA + EBUS-IFB|These will be the individuals who undergo EBUS-TBNA followed by EBUS-IFB in the same procedure
62643236|NCT02560285||Development / 2000 participants|"* Age \>18 years;~* Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score\>5 or EuroSCORE II\>5."
62643237|NCT02560285||Validation / 1000 participants|"* Age \>18 years;~* Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score\>5 or EuroSCORE II\>5."
62643238|NCT00305162|EXPERIMENTAL|Cangrelor|placebo capsules (to match) + cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
62643239|NCT00305162|ACTIVE_COMPARATOR|Clopidogrel|clopidogrel capsules (600 mg) + placebo bolus \& infusion (to match) + placebo capsules (to match) post infusion
62643240|NCT00025389|EXPERIMENTAL|Arm A|Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab
62643241|NCT02539069|EXPERIMENTAL|Chondron Implantation|Chondron Implantation for the suject with cartilage defect through arthroscopy
62643242|NCT05932888|EXPERIMENTAL|QLM3003|QLM3003 Single dose
62073430|NCT00953420|EXPERIMENTAL|Chemotherapy and Immunotherapy|"1. Docetaxel 60 mg/m2 IV on Day 1~2. Carboplatin with target AUC of 5 (mg/ml x min) on Day 1~3. Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1~4. After cycle 1, subsequent cycles of chemotherapy may start once ANC \> 1000 and platelets \> 100,000 post nadir~5. Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles"
62073431|NCT02967263||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
62073432|NCT05002374|EXPERIMENTAL|Experimental Group|
62277833|NCT03047070|PLACEBO_COMPARATOR|Control|IV normal saline infusion
62073433|NCT05002374|ACTIVE_COMPARATOR|Control Group|
62277834|NCT04683510|NO_INTERVENTION|Control Group|This group will receive no intervention before receiving the AMPLIFI Recruitment Call
62277835|NCT04683510|OTHER|Navigation|After receiving recruitment letter from AMPLIFI, participant randomized to this arm will receive a phone call from a Research Specialist who will discuss the importance of research participation for cancer survivors to increase research awareness and aid in recruitment. The information will focus on the importance of research and will be delivered from the perspective of either a researcher or a cancer survivor.
62643243|NCT05932888|PLACEBO_COMPARATOR|QLM3003 Placebo|QLM3003 vehicle Single dose
62643244|NCT01162616|OTHER|Iron absorption|
62073434|NCT05568836|ACTIVE_COMPARATOR|Intervention|single dose of 300000 IU vitamin D injection (IM)
62277836|NCT04683510|OTHER|Brochure|After receiving recruitment letter from AMPLIFI, participant randomized to this arm will receive a brochure which will focus on the importance of research participation for cancer survivors in order to increase research awareness and aid in recruitment.
62277837|NCT01077973|EXPERIMENTAL|Treatment A|
62643245|NCT05058989||Pregnant women who are aged between 18 to 47 years old (childbearing age).|These patients must be willing to be followed up for 1 year and agreeing to give the informed consent. Recruitment period will take up to three months. Follow up period will be conducted at the end of first, second and third trimester and three months after giving birth.
62277838|NCT01077973|ACTIVE_COMPARATOR|Treatment B|
62277839|NCT01077973|PLACEBO_COMPARATOR|Treatment C|
62073435|NCT05568836|OTHER|Control|No intervention
62073436|NCT01676025|EXPERIMENTAL|PRA|Persons who get PRA surgery.
62643246|NCT03949881|EXPERIMENTAL|FEMJA transplatation|"FEMJA epithelium is obtained by culturing oral mucosal epithelial cells without any need of support substrates, or carriers, and the transparent fabricated sheets show strong, rapid adhesion on corneal stroma in vivo, without any need for suturing.~The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation."
62643247|NCT06135181|EXPERIMENTAL|0.03 mmol Gd/kg BAY1747846 and matching placebo|12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo
62073437|NCT01676025|EXPERIMENTAL|LA|Persons who get LA surgery.
62073438|NCT01927731|EXPERIMENTAL|Arm I (cord blood transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.
62073439|NCT01927731|EXPERIMENTAL|Arm II (haploidentical donor stem cell transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.
62277840|NCT03712579|EXPERIMENTAL|SFA-Rich Meal|Participants will consume a SFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
62643248|NCT06135181|EXPERIMENTAL|0.1 mmol Gd/kg BAY1747846 and matching placebo|12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo
62643249|NCT05859217|EXPERIMENTAL|Cabozantinib and Atezolizumab|Cabozantinib 40mg po daily + Atezolizumab 1200mg iv on day 1; 1 cycle = 21 days
62643250|NCT01202500|OTHER|12 months|
62643251|NCT01202500|EXPERIMENTAL|3 months|
62643252|NCT03106688|ACTIVE_COMPARATOR|Low-risk group|Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
62073440|NCT02720289|EXPERIMENTAL|Video-based social learning|Video-based social learning class
62073441|NCT02720289|ACTIVE_COMPARATOR|Traditional didactic|Traditional didactic class
62073442|NCT01528644|EXPERIMENTAL|Iron in beads|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
62277841|NCT03712579|EXPERIMENTAL|MUFA-Rich Meal|Participants will consume a MUFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
62277842|NCT02482675|ACTIVE_COMPARATOR|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
62277843|NCT02482675|EXPERIMENTAL|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
62277844|NCT02482675|EXPERIMENTAL|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
62277845|NCT02482675|EXPERIMENTAL|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
62277846|NCT00804115|NO_INTERVENTION|1|Latanoprost in combination with Pilocarpine
62277847|NCT00804115|NO_INTERVENTION|2|Timolol or Cosopt
62277848|NCT02362503|EXPERIMENTAL|A1: BMS-663068|Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
62277849|NCT02362503|ACTIVE_COMPARATOR|B1: Placebo + BMS-663068|Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
62277850|NCT02362503|EXPERIMENTAL|BMS-663068|BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
62277851|NCT03005054|EXPERIMENTAL|StrataGraft skin tissue|
62277852|NCT04429061|NO_INTERVENTION|SOC Arm|Standard of care (SOC): the sexual reproductive curriculum which is implemented by the schools as part of mandatory SRH education.
62277853|NCT04429061|ACTIVE_COMPARATOR|Enhanced Arm|The SKILLZ-Girl Curriculum, plus the graduation event (including HIVST + access to family planning) and home based delivery of commodities with subsequent encouragement to be involved with SKILLZ-Clubs at their school
62277854|NCT03924986|EXPERIMENTAL|Tislelizumab combined with Gemcitabine Plus Cisplatin|"Tislelizumab will be administered once every 3 weeks (Q3W)~Gemcitabine on Day 1, Day 8 of each 3 week cycle, for 4 to 6 cycles~Cisplatin on Day 1 of each 3 week cycle, for 4 to 6 cycles"
62277855|NCT03924986|PLACEBO_COMPARATOR|Placebo combined with Gemcitabine Plus Cisplatin|"Placebo will be administered once every 3 weeks (Q3W)~Gemcitabine on Day 1, Day 8 of 3 week each cycle, for 4 to 6 cycles~Cisplatin on Day 1 of 3 week each cycle, for 4 to 6 cycles"
62277856|NCT01511770|EXPERIMENTAL|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
62277857|NCT01511770|ACTIVE_COMPARATOR|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
62277858|NCT04393610|ACTIVE_COMPARATOR|Group (L)|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group)
62277859|NCT04393610|ACTIVE_COMPARATOR|Group M|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
62643253|NCT03106688|ACTIVE_COMPARATOR|High-risk group|Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
62643254|NCT00909168|EXPERIMENTAL|Efficacy of FLAIMy|
62643255|NCT03885908|ACTIVE_COMPARATOR|In-person geriatric co-management group|"In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
62643256|NCT03885908|EXPERIMENTAL|Automated geriatric co-management program group|
62643257|NCT03143257||Subjects|Diagnosed with Conductive Hearing Loss (CHL), Single-Sided Deafness (SSD)and mixed Hearing Loss (HL) who currently have or have had the Sophono implant
62643258|NCT04621799|EXPERIMENTAL|Fibrin Group|Experimental: Non-Autologuos Fibrin (NAF) Subjects in the NAF arm received an injection of non-autologous fibrin
62643259|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
62643260|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
62643261|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
62643262|NCT00764790|EXPERIMENTAL|Fluarix Dose A Group|"Subjects were administered 1 or 2 doses\* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children \>12 months of age) or in the anterolateral thigh (children \<12 months of age).~\* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
62277860|NCT04393610|ACTIVE_COMPARATOR|Group F|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
62277861|NCT01305759||YoungTKA|Adults under 60 years who are having primary TKA
62277862|NCT01305759||YOUNGTHA|Adults under 60 years who are having primary THA
62277863|NCT01305759||PAOAarhus|Adults under 60 years who are having primary PAO
62277864|NCT02809287||study group|patients with left lateral position plus jackknife posture when perform laparoscopic hepatectomy
62455635|NCT02681965|EXPERIMENTAL|LEAN|Participants randomized to the weight loss program will initially receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity. Written instructions in the LEAN book will include recording daily diet and exercise in the logs. At the end of the study, participants will return, via a stamped addressed envelope, the logs to the study office so compliance can be assessed.
62643263|NCT00764790|EXPERIMENTAL|Fluarix Dose B Group|"Subjects were administered 1 or 2 doses\*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children \>12 months of age) or in the anterolateral thigh (children \<12 months of age).~\* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
62643264|NCT00764790|ACTIVE_COMPARATOR|Fluzone Group|"Subjects were administered 1 or 2 doses\* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children \>12 months of age) or in the anterolateral thigh (children \<12 months of age).~\* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
62643265|NCT02383524||Chronic Low Back Pain (Lumbar Facet Joints Mediated Pain)|
62277865|NCT01980797||Bicuspid aortic valve disease|"Group/Cohort Label - Bicuspid aortic valve~Group/Cohort Description -~* Patients diagnosed with bicuspid aortic valve~* All ages ≥8 years~* Able to provide fully informed consent"
62277866|NCT01980797||Tricuspid aortic valve control patients|"Group/Cohort Label - Tricuspid aortic valve control patients~Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched.~* Patients not diagnosed with bicuspid aortic valve~* All ages ≥8 years~* Able to provide fully informed consent"
62643266|NCT00512590|EXPERIMENTAL|Experimental|
62643267|NCT01012427|EXPERIMENTAL|Patients with 3.0 cm or smaller renal cancer|The interventions in this study are part of clinical care and include percutaneous image-guided biopsy, percutaneous renal tumor cryoablation, CT/MR imaging of the ablation bed, and repeat pathologic sampling of the tumor bed with percutaneous biopsy. The cryoablation is done as the therapeutic intervention in patients with small renal cancer. The CT/MR imaging is done to evaluate the treatment for residual disease after the ablation. The repeat biopsy (e.g. three cores) is done to confirm that the neoplasm has been eradicated. These patients have continued imaging, and if necessary, percutaneous biopsy to ensure no recurrent disease.
62643268|NCT04816916|EXPERIMENTAL|AXA1665 53.8 g per day|AXA1665 administered orally TID
62643269|NCT04816916|PLACEBO_COMPARATOR|Matching placebo|Placebo administered orally TID
62643270|NCT05108766|EXPERIMENTAL|Tildrakizumab|Subjects will receive 100 mg subcutaneous (SC) Tildrakizumab at Week 0 and Week 4, 100 mg subcutaneous placebo at Week 12. Subjects entered the extension study after completion of the base study and will receive 100 mg subcutaneous Tildrakizumab at Week 16, 28, 40, and 52.
62643271|NCT05108766|PLACEBO_COMPARATOR|Placebo|Subjects will receive 100 mg subcutaneous placebo at Week 0 and Week 4, and 100 mg subcutaneous Tildrakizumab at Week 12. Subjects entered the extension study after completion of the base study and will receive 100 mg subcutaneous Tildrakizumab at Week 16, 28, 40, and 52.
62643272|NCT00652847|EXPERIMENTAL|group 1|group 1: ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by an observational phase of 6 months.
62643273|NCT00652847|ACTIVE_COMPARATOR|Group 2|Group 2: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase.
62643274|NCT02169440|EXPERIMENTAL|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
62643275|NCT02169440|ACTIVE_COMPARATOR|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
62643276|NCT05337046||Tissue removal system|Endometrial polyp removed by hysteroscopic tissue removal system in a previous study.
62643277|NCT05337046||Bipolar resectoscopy|Endometrial polyp removed by hysteroscopic bipolar resectoscopy in a previous study.
62073443|NCT01528644|EXPERIMENTAL|Iron in capsule|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
62643278|NCT04126434|SHAM_COMPARATOR|no masking|not wearing facemask
62643279|NCT04126434|ACTIVE_COMPARATOR|masking|wearing facemask
62643280|NCT04771910|EXPERIMENTAL|Topical cream with live probiotic bacteria (YUN)|Patients with atopic dermatitis using topical cream with live probiotic bacteria
62643281|NCT04771910|PLACEBO_COMPARATOR|Placebo cream (YUN)|Patients with atopic dermatitis using placebo cream (same formulation as probiotic cream except live probiotic bacteria)
62643282|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
62643283|NCT02852421|ACTIVE_COMPARATOR|Multiple injection paravertebral blocks|"Patients in this group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
62643284|NCT02852421|EXPERIMENTAL|Single injection paravertebral block|"Patients in single injection group will receive single injection paravertebral blocks at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections."
62643285|NCT02427009|EXPERIMENTAL|The study population|"The study population consists of adult women requiring an epidural blood patch for the treatment of post-dural puncture headache following vaginal delivery. Women who delivered by cesarean section are not included due to the discomfort of the prone position while there is an abdominal scar.~Intervention: Prone position for 1 hour after blood patch"
62643286|NCT03954093|SHAM_COMPARATOR|Sham stimulation|
62643287|NCT03954093|ACTIVE_COMPARATOR|Motor cortex stimulation|
62643288|NCT03954093|EXPERIMENTAL|MEG-localized stimulation|
62643289|NCT02416661||Participants diagnosed with Gaucher disease|Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old
62455636|NCT02681965|NO_INTERVENTION|Waitlist Control|Participants randomized to the waitlist control study arm will be mailed the six-month questionnaires, which will include reporting of weight. On return of the 6-month questionnaires each woman will be provided with the entire weight loss program packet.
62643290|NCT01257347|OTHER|Concealment (control)|Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
62643291|NCT01257347|EXPERIMENTAL|Disclosure (intervention)|"Disclosure of adherence report to clinician:~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox)."
62643292|NCT05093582|ACTIVE_COMPARATOR|Levcromakalim|Intravenous infusion of levcromakalim (1 mg/20 ml). The infusion is administered at constant speed by an automatic pump, lasting 20 minutes.
62643293|NCT05093582|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of placebo (sterile saline, 20 ml). The infusion is administered at constant speed by an automatic pump, lasting 20 minutes.
62643294|NCT05321667||SMuRF-less|Patients presenting no standard modifiable risk factor of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension, and cigarette smoking).
62643295|NCT05321667||SMuRFs|Patients presenting at least one standard modifiable risk factor of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension, and cigarette smoking).
62643296|NCT03035162|EXPERIMENTAL|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20 minutes for the active conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
62643297|NCT03035162|ACTIVE_COMPARATOR|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow only 2 minutes for the sham conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
62455637|NCT03148574|EXPERIMENTAL|misoprostol|intrauterine 400 microgram
62455638|NCT03148574|ACTIVE_COMPARATOR|oxytocin|intravenous infusion 10 units
62455639|NCT01765530|EXPERIMENTAL|ETT cleaning manuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
62455640|NCT01765530|NO_INTERVENTION|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
62643298|NCT05387616|EXPERIMENTAL|Copanlisib + Obinutuzumab|
62643299|NCT03874442|NO_INTERVENTION|Controls|
62643300|NCT03874442|EXPERIMENTAL|CliniPup|
62643301|NCT03102502|EXPERIMENTAL|Enhanced External Counterpulsation|Patients receive a total of 35-36 hours of EECP treatment on top of guideline- driven standard medical therapy for coronary heart disease, 1-hour sessions every day over a 7-week period.
62643302|NCT03102502|ACTIVE_COMPARATOR|Control|Patients receive guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention.
62643303|NCT02100839|EXPERIMENTAL|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
62643304|NCT02100839|PLACEBO_COMPARATOR|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
62643305|NCT00830765|PLACEBO_COMPARATOR|1 Placebo|The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
62643306|NCT00830765|ACTIVE_COMPARATOR|Progesterone|The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
62643307|NCT01058447|EXPERIMENTAL|1|
62643308|NCT00228579||Bariatric Surgery|Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.
62643309|NCT03373214|EXPERIMENTAL|30 µg Na-GST-1 + CPG 10104|
62455641|NCT01079442|ACTIVE_COMPARATOR|Treatment arm: coffee|coffee administration
62455642|NCT01079442|PLACEBO_COMPARATOR|Water arm|The control drink consists of 100 ml warm water
62455643|NCT03541564|EXPERIMENTAL|BMS-986165 Dose 1 oral administration|BMS-986165 therapeutic single dose
62455644|NCT03541564|EXPERIMENTAL|BMS-986165 Dose 2 oral administration|BMS-986165 supratherapeutic single dose
62455645|NCT03541564|ACTIVE_COMPARATOR|Moxifloxacin Dose 3 oral administration|Moxifloxacin positive control single dose
62455646|NCT03541564|PLACEBO_COMPARATOR|Placebo Dose 4 oral administration|Placebo single dose
62455647|NCT03505853|EXPERIMENTAL|Givosiran with 5-probe cocktail|
62455648|NCT03544138|OTHER|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
62455649|NCT02878109||Post-treatment phase group|29 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before and after transarterial chemoembolisation (TACE).
62455650|NCT02878109||Pre-treatment phase group|11 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before treatment (if any).
62455651|NCT04518176|EXPERIMENTAL|study group|patients with twin pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
62455652|NCT04518176|ACTIVE_COMPARATOR|control group|patients with twin pregnancy undergoing cesarean section received oxytocin only.
62455653|NCT04132479|EXPERIMENTAL|Sequential therapy|Sequential Clarithromycin + Amoxycillin + Tinidazole + rabeprazole by mouth (Both amoxycillin 1000mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days, followed by clarithromycin 500 mg every 12 hours, tinidazole 500mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days)
62455654|NCT04132479|ACTIVE_COMPARATOR|Concomitant therapy|Concomitant clarithromycin 500mg every 12 hours + amoxycillin 1000mg every 12 hours + tinidazole 500mg every 12 hours + rabeprazole 20mg every 12 hours (all drugs by mouth for 14 days).
62455655|NCT03619252|EXPERIMENTAL|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
62455656|NCT03619252|ACTIVE_COMPARATOR|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
62455657|NCT05948748||Anxiety levels|pre-surgical anxiety levels in patients undergoing minimally invasive osteoarticular foot surgery
62455658|NCT03805464|EXPERIMENTAL|Knee Joint Effusion|Participants will receive a one-time injection of 60mL of sterile saline into the suprapatellar space of the dominant lower extremity. This injection will be conducted under ultrasound guidance by a board-certified orthopedic surgeon.
62455659|NCT06143865|EXPERIMENTAL|Closed aspiration group|Closed system aspiration is performed according to standard guidelines for patients.
62455660|NCT03287609|ACTIVE_COMPARATOR|Evolocumab|Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
62455661|NCT03287609|PLACEBO_COMPARATOR|Placebo|Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
62455662|NCT01060670|EXPERIMENTAL|Dermal Replacement Device|Device: INTEGRA® Dermal Regeneration Template
62455663|NCT01060670|ACTIVE_COMPARATOR|Moist Wound Therapy|0.9% Saline gel
62455664|NCT01881321|EXPERIMENTAL|Group 1: Counseling Intervention|Contraceptive counseling session based on the principles of motivational interviewing
62455665|NCT01881321|NO_INTERVENTION|Group 2: Usual Care|The standard clinic-based contraceptive counseling with no additional or theory-based contraceptive counseling session
62455666|NCT05712330|EXPERIMENTAL|non invasive ventilation|SMA patients with NIV
62643310|NCT03373214|EXPERIMENTAL|100 µg Na-GST-1 + CPG 10104|
62643311|NCT03373214|EXPERIMENTAL|100 µg Na-GST-1|
62643312|NCT04122261|EXPERIMENTAL|experimental group|MicroHand S robotic surgery group
62643313|NCT04122261|EXPERIMENTAL|control group|da Vinci robotic surgery group
62643314|NCT02459522||Dr.Tang's research group|This group included participants with completed both the short-term HRV test and Ewing's test.
62643315|NCT03225638|OTHER|Group 1|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (upper limit) strength thigh injection of 0.65ml of saline solution (0.9%)
62643316|NCT03225638|OTHER|Group 2|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (lower limit) strength thigh injection of 0.65ml of saline solution (0.9%)
62643317|NCT03278574|EXPERIMENTAL|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
62643318|NCT03278574|ACTIVE_COMPARATOR|Complete ring|Mitral valve repair with complete rigid ring
62643319|NCT05650203|EXPERIMENTAL|JS009 as a monotherapy and JS009 Combine with Toripalimab and JS006|"1. JS009 as Monotherapy in first cycle of dose escalation and the triple combination therapy will be administered in subsequent cycles：5 proposed dose levels（18mg, 60mg, 180mg, 600mg, 1200mg).~2. The triple combination therapy in dose expansion：1 or 2 proposed dose levels, to be determined.~3. The triple combination therapy in indication expansion：4 or more cohorts, to be determined."
62277867|NCT02466061|EXPERIMENTAL|Arm A: Telemedicine Group|"Telemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period.~All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 followup weight data also will be collected through medical record abstraction."
62455667|NCT01345019|ACTIVE_COMPARATOR|Zoledronic acid|Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
62455668|NCT01345019|EXPERIMENTAL|Denosumab|Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
62643320|NCT04227912|ACTIVE_COMPARATOR|Group TAP|Ultrasound-guided TAP Block
62643321|NCT04227912|ACTIVE_COMPARATOR|Group Local|Ultrasound-guided Local Infiltration
62643322|NCT04227912|ACTIVE_COMPARATOR|Group Dexketoprofen|Intravenous Dexketoprofen
62643323|NCT04829071|EXPERIMENTAL|Evaluating motor learning and brain structures post-stroke|We will use a single arm design to determine the impact of post-stroke cognitive impairment on two forms of motor learning (implicit and explicit) and evaluate the structural integrity of relevant brain structures in 65 individuals post stroke
62643324|NCT02577640|EXPERIMENTAL|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in \>33% of the participants or the daily target dose of 4 slices of bread \[132 mg soy isoflavone\] is reached.
62073444|NCT01528644|EXPERIMENTAL|Iron in beads in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
62455669|NCT04823299|ACTIVE_COMPARATOR|Cryoballoon ablation|Cryoballoon Pulmonary Vein Isolation-Wide area circumferential ablation (WACA)
62455670|NCT04823299|EXPERIMENTAL|RF based WACA ± EP testing guided ablation of non-PV triggers of AF and low voltage area ablation|Radiofrequency wide area circumferential ablation (WACA) ± electrophysiological testing guided ablation of non-pulmonary vein triggers of AF and low voltage area ablation
62643325|NCT02577640|EXPERIMENTAL|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
62643326|NCT02191488|EXPERIMENTAL|Experimental: 5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
62643327|NCT00176046|EXPERIMENTAL|viscum album pini|immediate start of treatment with Iscador P s.c.
62643328|NCT00176046|ACTIVE_COMPARATOR|waiting group|identical treatment with Iscador P s.c. after waiting period of 3 months
62643329|NCT03028181||1|Control group non-exposed to tobacco smoking
62643330|NCT03028181||2|Control group exposed to tobacco smoking
62643331|NCT03028181||3|Patients with acute pancreatitis non-exposed to tobacco smoking
62643332|NCT03028181||4|Patients with acute pancreatitis exposed to tobacco smoking
62455671|NCT01535326|PLACEBO_COMPARATOR|air insufflation|Use air insufflation during colonoscopy
62643333|NCT03524716|EXPERIMENTAL|Fitbit and Text Messages|Participants randomized to this arm receive print materials and a Fitbit Flex 2 at baseline and daily text messages for 12 weeks.
62643334|NCT03524716|NO_INTERVENTION|Usual Care|Participants randomized to usual care receive print materials at baseline.
62643335|NCT00897117||Resectable non-small cell lung cancer|Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
62643336|NCT02558049|EXPERIMENTAL|Decision aid|Patients will receive the patient decision aid during a 15 minute consultation with a clinical pharmacist.
62643337|NCT04745728|ACTIVE_COMPARATOR|cyclophosphamide and prednisone|"Prednisone will be given at 1mg/kg/d p.o. and will be tapered after 2 months and discontinued over a 6-12 month period.~Cyclophosphamide will be given at 1-2mg/kg/d p.o. with a target accumulated dose of 12g.~Azathioprine or mycophenolate mofetil are optional which could be given for a short period of time (\<6 months）after discontinuation of cyclophosphamide if patients do not remit at 6 month."
62643338|NCT04745728|ACTIVE_COMPARATOR|Rituximab|"Rituximab 1000mg I.V. on Day1 and at 6 month. After 6 months, in patients with response but without complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be given on the 15th day after each Rituximab infusion if CD19+ B cell count\>5/ul on the 15th day.~Calcineurin inhibitors (CNI) are optional but should be tapered after 6 months and discontinued after 9 months."
62643339|NCT01121471|PLACEBO_COMPARATOR|Safflower Oil|8.0 g/day safflower oil
62455672|NCT01535326|ACTIVE_COMPARATOR|water immersion|infuse water during insertion, remove water during withdrawal of colonoscopy
62643340|NCT01121471|EXPERIMENTAL|CLA 6.4g/day|Conjugated linoleic acid at a dose of 6.4g/day in a supplement with a total of 8.0g oil
62643341|NCT04682899|EXPERIMENTAL|PCT-guided antibiotic therapy (PCT group)|Participants in the PCT group will complete a PCT test within 2 hours after randomization and the results will be sent back to the clinician by laboratory through the internal network of the hospital. The prescribing clinician will use the results of the PCT to help guide their antibiotic prescription decision. The detailed recommendations are as follows: if PCT\<0.1ng/ml，strongly discouraged；if PCT (0.1-0.25ng/ml) and no sputum purulence, discouraged; if PCT (0.1-0.25ng/ml) and sputum purulence, Recommended; PCT\>0.25 ng/ml, Strongly recommended.
62643342|NCT04682899|ACTIVE_COMPARATOR|Guideline-guided antibiotic therapy (guideline group)|Participants in the guideline group will also need to complete a PCT test within 2 hours after randomization, however, the laboratory will save the results and do not sent back to the clinician. The clinician will make an antibiotic prescribing decision on the basis of the recommendations of GOLD guideline. The guideline recommend the following patients to receive antibiotic therapy. Patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).
62643343|NCT04140773|EXPERIMENTAL|D-serine group|Oral administration of 2g D-serine per day, for 6 weeks.
62643344|NCT04140773|PLACEBO_COMPARATOR|Placebo group|Oral administration of 2g Placebo (Mannitol) per day, for 6 weeks.
62643345|NCT02037893|EXPERIMENTAL|Antipyrine and Benzocaine Otic solution|antipyrine 54 mg and benzocaine 14 mg. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
62277868|NCT02466061|EXPERIMENTAL|Arm B: Text for Diet (Text4Diet) Group|"Text for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management.~All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
62455673|NCT01535326|ACTIVE_COMPARATOR|water exchange|infuse and remove water during insertion phase of colonoscopy
62455674|NCT04453748||COVID-19 convalescents|People who recovered from COVID-19: have no symptoms and no SARS-Cov2 RNA in PCR
62455675|NCT02351726|EXPERIMENTAL|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
62455676|NCT05048303|EXPERIMENTAL|Individualized Lutajet operative group|Arthroscopic modified individualized flexible Latarjet procedure with preservation of the coracoacromial arch. During the procedure, we perform coracoid osteotomy with preservation of coracoacromial arch, then split subscapular tendon, transfer the bone graft and fix it with double button under arthroscopy.
62455677|NCT01411332|ACTIVE_COMPARATOR|Arm I: SIMRT|'Participants in this group will receive the Standard Fractionated Intensity Modulated Radiotherapy (SIMRT) consisting 40 fractions over 8 weeks.
62455678|NCT01411332|ACTIVE_COMPARATOR|Arm II: HTIMRT|Participants in this group will receive the Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT) consisting of 38 fractions over 7.5 weeks.
62455679|NCT00004193|EXPERIMENTAL|ISIS 2503|patients who have metastatic and/or locally recurrent colorectal cancer
62455680|NCT02706236|ACTIVE_COMPARATOR|Intervention Arm|Pancreatic enzyme replacement (Pancrelipase) with meals and snacks daily, for 4 weeks.
62643346|NCT02037893|ACTIVE_COMPARATOR|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
62277869|NCT02466061|ACTIVE_COMPARATOR|Arm C: Enhanced Usual Care Group|"Enhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise.~All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
62455681|NCT02706236|PLACEBO_COMPARATOR|Placebo Arm|Lactose placebo tablets with meals and snacks, for 4 weeks.
62277870|NCT03286855|EXPERIMENTAL|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
62643347|NCT02037893|ACTIVE_COMPARATOR|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 ml. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
62643348|NCT02037893|PLACEBO_COMPARATOR|Placebo|Placebo otic solution will be glycerin that is dehydrated . Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
62643349|NCT06143397|EXPERIMENTAL|TTNS (Transcutaneous tibial nerve stimulation)|
62643350|NCT06143397|EXPERIMENTAL|PNS (Parasacral nerve stimulation)|
62643351|NCT06143397|SHAM_COMPARATOR|Sham stimulation|
62643352|NCT02004223|EXPERIMENTAL|Dose escalation using stereotactic boost|Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
62643353|NCT01331317|OTHER|Paricalcitol|Crossover study between paricalcitol and placebo
62643354|NCT04850651|EXPERIMENTAL|Pyrotinib/Fluconazole|Durg: Pyrotinib Durg: Pyrotinib/Fluconazole Participants received a single oral dose of pyrotinib 80 milligram (mg) on day1 and day9. Participants received a loading dose of fluconazole 400 mg on day6 followed by single dose of fluconazole 200 mg for oral administration from D7 to D18.
62643355|NCT02389660|EXPERIMENTAL|Blended CBT|Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 13 sessions (6 online and 7 face-to-face, session sequence - alternate, online platform - Moodbuster).
62643356|NCT02389660|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual (TAU) will be defined as the routine care CBT that subjects receive when they are diagnosed with depression in the setting of recruitment. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report (including TIC-P measurements).
62643357|NCT06134635||Statin-alone group|The participants in statin-alone group receive statins alone for lipid reduction.
62643358|NCT06134635||PCSK9-i group|The participants in PCSK9-i group receive statins and evolocumab for lipid reduction.
62643359|NCT00104052|EXPERIMENTAL|PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).
62643360|NCT05190796||women with history of recurrent pregnancy loss.|100 women who had history of recurrent pregnancy loss.
62643361|NCT05190796||women without history of recurrent pregnancy loss.|50 women who had given birth at term (\>37 weeks of gestation) to healthy infants (control group)
62643362|NCT03400449|ACTIVE_COMPARATOR|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
62643363|NCT03400449|ACTIVE_COMPARATOR|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
62277871|NCT03286855|ACTIVE_COMPARATOR|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
62277872|NCT03090594|OTHER|Biopsy|Transbronchial biopsies with cryoprobe.
62277873|NCT00453271|EXPERIMENTAL|NB-002 0.25% BID|
62277874|NCT00453271|EXPERIMENTAL|NB-002 0.5% QD|
62277875|NCT00453271|EXPERIMENTAL|NB-002 0.5% BID|
62277876|NCT00453271|SHAM_COMPARATOR|Vehicle control|
62455682|NCT04366336|EXPERIMENTAL|Blood Flow Restriction Training|"Blood flow restriction training (BFRT) uses a specialized tourniquet system to restrict arterial inflow and venous outflow to the limb during low-load resistance exercise.~BFRT involves placing the pressure cuff before the start of therapeutic exercises.~Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching"
62643364|NCT01190891|ACTIVE_COMPARATOR|Manual Physical Therapy|The orthopaedic manual physical therapy (OMPT) intervention approach used in this study will be based on an impairment model. The physical therapist providing the intervention will address the impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients will receive procedures tailored to their specific impairments. Procedures will include mobilizations and manipulations of the joint and soft-tissues.
62643365|NCT01190891|ACTIVE_COMPARATOR|Corticosteroid Injection (Subacromial)|Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL
62643366|NCT01041859|EXPERIMENTAL|Tapentadol Extended Release (ER)|
62643367|NCT01041859|PLACEBO_COMPARATOR|Placebo|
62643368|NCT02446691|EXPERIMENTAL|MenACWY Group|Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
62643369|NCT01838746||PCI|Patients undergoing PCI
62643370|NCT01838746||CABG|Patients undergoing CABG
62643371|NCT03115034|ACTIVE_COMPARATOR|CEA with melatonin|Patients under CEA with melatonin taken during perioperative period.
62643372|NCT03115034|PLACEBO_COMPARATOR|CEA with placebo|Patients under CEA with placebo taken during perioperative period.
62277877|NCT02789865|ACTIVE_COMPARATOR|Antibiotic therapy group|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
62277878|NCT02789865|EXPERIMENTAL|ERAT group|The patients will receive emergent endoscopic retrograde appendicitis therapy (ERAT).
62277879|NCT02789865|ACTIVE_COMPARATOR|Appendectomy group|The patients will receive laparoscopic appendectomy according to standard routines.
62277880|NCT03133845|ACTIVE_COMPARATOR|General anesthesia|In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values. Discretionary use of intrathecal morphine may be used.
62277881|NCT03133845|EXPERIMENTAL|Spinal anesthesia with light sedation|In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 10-15 mg of bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS\>60-70. Discretionary use of intrathecal morphine may be used.
62643373|NCT03115034|SHAM_COMPARATOR|CEA with blank control|Patients under CEA with nothing unnecessary taken during perioperative period.
62643374|NCT04288947|OTHER|Usual Care|Training of midwives on 4 respectful maternal care modules.
62643375|NCT03837717|EXPERIMENTAL|Holding First|Holding will occur on the second day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
62643376|NCT03837717|EXPERIMENTAL|No Holding First|Holding will occur on the third day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
62643377|NCT02870647|OTHER|Single arm study|only 1 arm - no comparison nor randomization in this study
62643378|NCT04331626|EXPERIMENTAL|Low-dose Gemcitabine Combined With nivolumab|Bristol-myers squibb (BMS) company's nivolumab injection liquid (trade name: odiwal). Recommended dosage: 3mg/kg, intravenously injected once every 2 weeks for 60 minutes. As long as clinical benefit is observed, continue treatment with this product for up to 6 courses. Gemcitabine hydrochloride injection from eli lilly. Use 50% of the recommended dose, i.e. 500mg/m2, intravenously for 30 minutes. Day 1 and day 8 administration. Depending on the patient's tolerance to gemcitabine, a reduced dose may be considered for each treatment cycle or one treatment cycle. Use for 1 year. If a Ⅲ magnitude of adverse reactions, it is necessary to permanently discontinued.
62643379|NCT02611882|EXPERIMENTAL|High-risk prostate cancer pre-prostatectomy (preRP) population|"Patients with high-risk prostate cancer pre-prostatectomy.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
62643380|NCT02611882|EXPERIMENTAL|Biochemical Recurrence (BCR)|"Patients with prostate cancer with biochemical recurrence~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
62643381|NCT02611882|EXPERIMENTAL|Castrate Resistant Prostate cancer (CRCP) population|"Patients with castrate resistant prostate cancer.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
62643382|NCT04405752||12-mm diameter metallic billiary stent|
62643383|NCT04405752||10-mm diameter metallic billiary stent|
62643384|NCT04451772|EXPERIMENTAL|Part 1: Elsubrutinib Dose A and Upadacitinib Dose A|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose A once daily (QD).
62643385|NCT04451772|EXPERIMENTAL|Part 2: Elsubrutinib Dose A and Upadacitinib Dose B|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose B QD.
62643386|NCT04451772|EXPERIMENTAL|Part 3: Elsubrutinib Dose A and Upadacitinib Placebo|Participants will receive Elsubrutinib Dose A and Upadacitinib placebo QD.
62643387|NCT04451772|EXPERIMENTAL|Part 4: Elsubrutinib Placebo and Upadacitinib Dose A|Participants will receive Elsubrutinib placebo and Upadacitinib Dose A QD.
62643388|NCT03943628|EXPERIMENTAL|Familias Unidas|Consists of eight parent group sessions and four family sessions with the adolescent.
62643389|NCT03943628|OTHER|Community Practice|Consists of community practice.
62643390|NCT05517629||All the time|Students who wore face masks all the time when outside
62643391|NCT05517629||Most of the time|Students who wore face masks most of the time when outside
62643392|NCT05517629||Only when told to|Students who wore face masks only when they were told to when outside
62643393|NCT05517629||Not At All|Students who did not wear face masks at all when outside
62643394|NCT02945436|ACTIVE_COMPARATOR|SOC + SOC|Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.
62073445|NCT01528644|EXPERIMENTAL|Iron in capsule in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
62073446|NCT01159223|EXPERIMENTAL|1|ATV/r 200 mg/100 mg OD
62073447|NCT01159223|EXPERIMENTAL|2|ATV/r 300 mg/100 mg OD
62073448|NCT00796536|EXPERIMENTAL|1|Participants will undergo 12 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
62277882|NCT00367042|NO_INTERVENTION|1|
62277883|NCT06500767||counselling A|receiving counselling prior to surgery in person
62455683|NCT04366336|ACTIVE_COMPARATOR|Standard Physical Therapy|Subjects will receive American College of Sports Medicine guided-strength training Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
62455684|NCT02891941||Mild Traumatic Brain Injury|This cohort will have sustained a closed head injury, defined as externally inflicted trauma without skull fracture within the last month.
62073449|NCT00796536|ACTIVE_COMPARATOR|2|Participants will received 12 weeks of pain education and a pre- and post-intervention MRI brain scan.
62073450|NCT06317350|EXPERIMENTAL|GNS-212-E1|
62073451|NCT06317350|EXPERIMENTAL|GNS-212-E2|
62277884|NCT06500767||counselling B|receiving counselling prior to surgery via telephone and with a video
62455685|NCT04878146|ACTIVE_COMPARATOR|Sacrocolpopexy|Used as the standard intervention for prolapse
62455686|NCT04878146|EXPERIMENTAL|Sacro-spinous fixation|To be demonstrated as non inferior
62455687|NCT01706926|PLACEBO_COMPARATOR|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram \[mg\] per week) through oral or parenteral route.
62073452|NCT06317350|ACTIVE_COMPARATOR|GNS-212-ER|
62073453|NCT02796287|EXPERIMENTAL|Patients with Ictus amnesic|Patients admitted in the hospital as part of their medical care with amnesic Ictus episode
62073454|NCT01535131|ACTIVE_COMPARATOR|Furlow palatoplasty|standard procedure
62073455|NCT01535131|EXPERIMENTAL|modified Furlow palatoplasty|standard procedure plus modification
62073456|NCT00180713|PLACEBO_COMPARATOR|Arm 1: Control|Placebo tablet once daily
62073457|NCT00180713|EXPERIMENTAL|Arm 2: Experimental|Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
62277885|NCT02535182||Control Arm|Patients who participate as controls on the main study will be controls on this ancillary study. The control arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
62277886|NCT02535182||Propranolol Arm|Patients who participate on the propranolol arm on the main study will be on the propranolol arm on this ancillary study. The propranolol arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
62277887|NCT01851850|EXPERIMENTAL|Drug|
62277888|NCT00713362|ACTIVE_COMPARATOR|1|Surgery: Video-assisted thoracoscopic surgery
62277889|NCT00713362|ACTIVE_COMPARATOR|2|Chest tube drainage
62277890|NCT04004598|EXPERIMENTAL|golf training|12-week golf training program
62277891|NCT02258360|ACTIVE_COMPARATOR|24 hours hypothermia|Therapeutic hypothermia for 24 hours after reaching target temperature
62277892|NCT02258360|EXPERIMENTAL|48 hours hypothermia|Therapeutic hypothermia for 48 hours after reaching target temperature
62277893|NCT04221880|ACTIVE_COMPARATOR|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine and Saline iv. bolus and infusion (same volume as Group Lidocaine)
62277894|NCT04221880|ACTIVE_COMPARATOR|Group Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion and, Ultrasound-guided erector spinae plane block with 20 ml saline
62455688|NCT01706926|EXPERIMENTAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
62643395|NCT02945436|EXPERIMENTAL|SOC + SUBI|Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.
62643396|NCT02945436|EXPERIMENTAL|SUBI + SUBI|Participants will receive the SUBI at both visit 1 and visit 2.
62643397|NCT02945436|EXPERIMENTAL|SUBI + SOC|Participants will receive the SUBI at visit 1 and SOC at visit 2.
62643398|NCT01116336|EXPERIMENTAL|Erlotinib and Green Tea Polyphenon E|Patients will receive erlotinib, at pre-defined dose level, with polyphenon E.
62643399|NCT04228484|PLACEBO_COMPARATOR|Placebo|Placebo infusion
62277895|NCT04221880|SHAM_COMPARATOR|Group Control|Ultrasound-guided erector spinae plane block with 20 ml saline and, Saline iv. bolus and infusion (same volume as Group Lidocaine)
62455689|NCT01706926|EXPERIMENTAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
62643400|NCT04228484|ACTIVE_COMPARATOR|GIP receptor antagonization|GIP(3-30)NH2 infusion
62277896|NCT03517631|EXPERIMENTAL|No busulfan preconditioning|shRNA-modified CD34+ cells without busulfan preconditioning.
62643401|NCT05696964|EXPERIMENTAL|Enhanced Motivational Interviewing Training|Participating medical residents will all receive two successive interventions, motivational interviewing (MI) booster training and the use of a dashboard that provides MI metrics. The booster training will make use of an artificial intelligence tool developed by our study team, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces metrics on important conversational skills (e.g., talking time, use of open-ended questions). The dashboard will produce these metrics during clinical encounters as a way to provide cuing for the MI approach.
62643402|NCT03093922|EXPERIMENTAL|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator. This cohort is NO LONGER ACCRUING patients since 5/22/2018.
62643403|NCT03093922|EXPERIMENTAL|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
62643404|NCT03093922|EXPERIMENTAL|Atezolizumab alone for 1 cycle prior to gemcitabine, cisplatin|"Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigators discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course."
62277897|NCT03517631|EXPERIMENTAL|Low dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
62277898|NCT03517631|EXPERIMENTAL|High dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
62277899|NCT00352105|EXPERIMENTAL|Concurrent Chemotherapy and ZD1839|
62643405|NCT04868669|EXPERIMENTAL|Intervention|In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
62643406|NCT04868669|NO_INTERVENTION|Control|Pregnant women in this arm will receive standard antenatal care.
62643407|NCT02338817||GSD 1|These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
62277900|NCT01114529|EXPERIMENTAL|Everolimus|Conversion from CNI to everolimus in combination with Myfortic and steroids
62277901|NCT01114529|ACTIVE_COMPARATOR|Calcineurin inhibitor, Prograf or Neoral|Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids
62277902|NCT03042936|EXPERIMENTAL|Arm 1|Insulin Superheroes Club Curriculum
62277903|NCT01821495|NO_INTERVENTION|B|After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
62277904|NCT01821495|EXPERIMENTAL|A|After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
62277905|NCT04642014|EXPERIMENTAL|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
62277906|NCT01022190|EXPERIMENTAL|Drug: Etoricoxib (Arcoxia, MSD), 90 mg.|Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.
62277907|NCT02114580|EXPERIMENTAL|Aerobic exercise|
62277908|NCT02114580|ACTIVE_COMPARATOR|stretching exercise|
62643408|NCT02338817||GSD 0, III, VI, or IX|These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
62643409|NCT05171322||All patients|All patients included were set up with the WARD monitoring devices.
62643410|NCT03567408|EXPERIMENTAL|Selective PCI with bivalirudin|Before PCI, bivalirudin is intravenously injected with 0.75 mg/kg, 1.75 mg/(kg.h) through continuous intravenous drip to finish surgery (no more than 4 hours), if necessary, after the surgery, with a low dose of 0.2 mg/(kg.h) intravenous drip less than 20 hours.
62643411|NCT03567408|PLACEBO_COMPARATOR|Unfractionated heparin|Before PCI, unfractionated heparin sodium is intravenously injected with 70-100 U/kg, and if the operation time exceeded 1h, an additional 1000 U/h would be added.
62643412|NCT03468842|PLACEBO_COMPARATOR|Placebo|Composition: excipients without probiotic: 2%w/v Guam guar and 6% w/v hydroxyethilcellulose Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
62643413|NCT03468842|ACTIVE_COMPARATOR|Probiotic|Composition: Streptococcus dentisani: 2,5E+09CFUs, 2% (p/v) Guam Guar and 6% (p/v) Hidroxietilcelulosa. Dose of 2.5E+09 cfu/vial considering one administration every 48 hours, it will be equivalent to a dose of 1.0E+10 cfu/week Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
62643414|NCT06551428||university students between age of 15 and 35|
62643415|NCT03586310|OTHER|4 nights with PSG|For all subjects: 4 nights with polysomnography and ear-EEG
62643416|NCT03586310|OTHER|12 nights with ear-EEG|"For a subset of the subjects in arm the '4 nights with PSG', a second phase follows in which each subject sleeps 12 nights with only ear-EEG.~If a night's recording is unsuccessful, for whatever reason, up to 6 additional nights may be attempted."
62643417|NCT01271647|EXPERIMENTAL|chinese herb|
62643418|NCT01271647|EXPERIMENTAL|placebo|
62643419|NCT03106116|EXPERIMENTAL|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
62643420|NCT03106116|ACTIVE_COMPARATOR|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
62643421|NCT00542893|EXPERIMENTAL|Group 1|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
62643422|NCT00542893|EXPERIMENTAL|Group 2|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
62643423|NCT03984708|OTHER|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
62643424|NCT03984708|OTHER|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
62643425|NCT04758806|EXPERIMENTAL|Fecal microbial transplantation from unrelated donor|Fecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days
62643426|NCT06496451||Friedreich ataxia|Adult patients with genetically proven Friedreich ataxia
62643427|NCT01309386|EXPERIMENTAL|Tapentadol ER|Tapentadol extended-release (ER) (JNS024ER) oral tablets 100 to 400 milligram (mg) daily for 8 weeks (maximum dose could be up to 500 mg daily), as per Investigator's discretion.
62643428|NCT01309386|ACTIVE_COMPARATOR|Morphine SR|Morphine sustained-release (SR) oral tablets 30 to 120 mg daily for 8 weeks (maximum dose could be up to 140 mg daily), as per Investigator's discretion.
62643429|NCT03387605|ACTIVE_COMPARATOR|Ivabradine|Initiation at dose 5 mg PO x 1 dose and further increased in 12 hours to 7.5 mg PO twice per day if patient is stable with mean BP≥ 60 mmHg, systolic blood pressure ≥ 90 mmHg and HR ≥100 bpm
62277909|NCT05896020|EXPERIMENTAL|Treatment group with SHR-A1811|
62643430|NCT03387605|PLACEBO_COMPARATOR|Placebo|Matching placebo given PO twice per day
62643431|NCT01163552|EXPERIMENTAL|Surgical Debulking and Intrathoracic Hyperthermic Chemotherapy|Patients in this trial will undergo surgical debulking followed by intrathoracic hyperthermic chemotherapy perfusion.
62643432|NCT01725685|EXPERIMENTAL|Treatment A - FF 400 microgram (mcg)|Subjects will be randomized to single dose of FF 400 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
62277910|NCT00328627|PLACEBO_COMPARATOR|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
62643433|NCT01725685|EXPERIMENTAL|Treatment B - UMEC 500 mcg|Subjects will be randomized to single dose of UMEC 125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
62643434|NCT01725685|EXPERIMENTAL|Treatment C - FF/UMEC 400/500 mcg|Subjects will be randomized to single dose of FF/UMEC 100/125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
62643435|NCT05683106|EXPERIMENTAL|Intervention Group|The participants will receive a custom silicone digital orthosis (CSDO) to realign the toes according to their needs. They will be instructed to use the CSDO throughout the day, remove it to sleep and reposition it on the foot the next day. Furthermore they will be assisted by a stomatherapy specialist, dermatology or clinical podiatry nurse and will receive foot care for thinning the calluses, referral (if necessary) to the Specialized Rehabilitation Center - CER, health equipment linked to SUS, for the purchase of insoles and/ or molded footwear (when indicated) and guidance on the use of therapeutic footwear.
62277911|NCT00328627|EXPERIMENTAL|Alogliptin 12.5 + Placebo|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
62277912|NCT00328627|EXPERIMENTAL|Alogliptin 25 + Placebo|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
62277913|NCT00328627|ACTIVE_COMPARATOR|Placebo + Pioglitazone 15|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
62277914|NCT00328627|EXPERIMENTAL|Alogliptin 12.5 + Pioglitazone 15|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
62277915|NCT00328627|EXPERIMENTAL|Alogliptin 25 + Pioglitazone 15|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
62277916|NCT00328627|ACTIVE_COMPARATOR|Placebo + Pioglitazone 30|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
62277917|NCT00328627|EXPERIMENTAL|Alogliptin 12.5 + Pioglitazone 30|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
62643436|NCT05683106|NO_INTERVENTION|Control Group|The participants will be assisted by the stomatherapy specialist, dermatology or clinical podiatry nurse and will receive foot care for thinning the calluses, referral (if necessary) to the Specialized Rehabilitation Center - CER, health equipment linked to SUS, for the purchase of insoles and/ or molded footwear (when indicated) and guidance on the use of therapeutic footwear.
62643437|NCT03257748|EXPERIMENTAL|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
62643438|NCT03257748|EXPERIMENTAL|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
62643439|NCT01228825||CABG without CPB|Patients undergoing coronary artery bypass graft (CABG) without Cardiopulmonary bypass ( CPB)
62643440|NCT01228825||CABG with CPB|Patients undergoing coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)
62643441|NCT00010257|EXPERIMENTAL|Paclitaxel plus Carboplatin|Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle
62643442|NCT01572402|EXPERIMENTAL|Patients with type 2 diabetes|Study group: 40 individuals with type 2 diabetes treated by diet and/or oral hypogylycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent
62643443|NCT01572402|ACTIVE_COMPARATOR|Healthy subjects|Mean and women, age 30-70 years, no diabetes, no metabolic syndrome
62277918|NCT00328627|EXPERIMENTAL|Alogliptin 25 + Pioglitazone 30|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
62277919|NCT00328627|ACTIVE_COMPARATOR|Placebo + Pioglitazone 45|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
62277920|NCT00328627|EXPERIMENTAL|Alogliptin 12.5 + Pioglitazone 45|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
62277921|NCT00328627|EXPERIMENTAL|Alogliptin 25 + Pioglitazone 45|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
62643444|NCT02627079|ACTIVE_COMPARATOR|Cohort 1|"Cohort 1 will include 15 sedentary participants who have completed all cancer therapy except adjuvant hormonal therapy.~All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity level for 12 weeks.."
62643445|NCT02627079|ACTIVE_COMPARATOR|Cohort 2|Cohort 2 will include 15 sedentary participants in active treatment. All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity levels for 12 weeks.
62643446|NCT00992862|EXPERIMENTAL|Moexipril HCl 15mg Tablets|
62643447|NCT00992862|ACTIVE_COMPARATOR|Univasc® 15mg Tablets|
62277922|NCT02792803|EXPERIMENTAL|Xalatan --> Apo-/Co-Latanoprost|Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
62643448|NCT03407313|EXPERIMENTAL|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
62643449|NCT05213299|EXPERIMENTAL|First auricular acupuncture, then sham acupuncture in left ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the left ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
62643450|NCT05213299|EXPERIMENTAL|First auricular acupuncture, then sham acupuncture in right ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the right ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
62643451|NCT03423043||Distal Radius Fracture Patients|Adult patients who have sustained a Distal Radius Fracture.
62643452|NCT03860636||Fresh Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at three different points during their treatments.~* The day they receive their HCG trigger,~* The day of transvaginal oocyte retrieval (TVOR) and~* The day of embryo transfer (ET)."
62643453|NCT03860636||Frozen Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at two different points during their treatments.~* The day we coordinate with embryologist (day of progesterone +/-1)~* The day of embryo transfer (ET)."
62643454|NCT04576013|EXPERIMENTAL|Active PNS during training|Individuals in this group will receive active PNS while participating in 2 hours of motor training of the affected arm.
62643455|NCT04576013|ACTIVE_COMPARATOR|Active PNS before training|Individuals in this group will receive 2 hours of active PNS before participating in 2 hours of motor training of the affected arm.
62643456|NCT04576013|SHAM_COMPARATOR|Sham PNS during training|Individuals in this group will receive 2 hours of sham PNS while participating in 2 hours of motor training of the affected arm.
62643457|NCT02524639|EXPERIMENTAL|Sirolimus|All enrolled subjects will receive Sirolimus 1 mg/m2/day twice a day for 6 weeks.
62643458|NCT06471439|ACTIVE_COMPARATOR|single leg resistance exercise intervantion in COPD|single leg resistance exercise intervantion in COPD will be perfomed at six weeks
62643459|NCT06471439|ACTIVE_COMPARATOR|single leg continous exercise intervantion in COPD|single leg continous exercise intervantion in COPD will be perfomed at six weeks
62643460|NCT06471439|ACTIVE_COMPARATOR|single leg high intensity exercise intervantion in COPD|single leg high intensity exercise intervantion in COPD will be perfomed at six weeks
62643461|NCT06212011|EXPERIMENTAL|Superimposed Neuromuscular Electrical Stimulation Group|Superimposed NMES involves stimulating the lumbar multifidus muscle while the individual performs a sit-to-stand activity.
62277923|NCT02792803|EXPERIMENTAL|Apo-/Co-Latanoprost --> Xalatan|Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
62277924|NCT00896610||Diabetes|Individuals who have been diagnosed with or are at risk for developing diabetes
62277925|NCT06201052||Junior|Junior soccer players 19 male, average training experience: 8 years
62277926|NCT06201052||Senior|Senior Soccer players 21 male, average training experience: 16 years
62277927|NCT01419431||Colon cancer patients|Laparoscopic resection
62277928|NCT05624008|EXPERIMENTAL|Bioceramic glass ionomer restoration|Calcium aluminate modified glass ionomer
62277929|NCT05624008|ACTIVE_COMPARATOR|Resin modified glass ionomer restoration|type II resin modified glass ionomer cement
62643462|NCT06212011|EXPERIMENTAL|Conventional Neuromuscular Electrical Stimulation Group|Conventional NMES intervention involves only stimulating the lumbar multifidus muscle while the individual is in the prone position, and the individual will not reveal any voluntary contraction during stimulation.
62073458|NCT02184663|ACTIVE_COMPARATOR|Standard care without APA program|"The control arm corresponds to usual care (without APA), including :~* Weekday hospital chemotherapy (every 7 or 14 days, depending on chemotherapy protocol)~* Evaluation by the oncologist at the usual rate~* Assessment every 8 weeks (TAP scan + CA-19.9)~* Nutritional, psychological and pain management as recommended, according to the usual schedule."
62643463|NCT02999789|ACTIVE_COMPARATOR|Intervention: Reminder System|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The intervention group will have SMS reminder and audiovisual reminder functions turned on. SMS reminders will be sent twice daily to child's caregiver's cell phone reminding them to administer daily asthma medication. SmartInhaler with reminder function turned on that is attached to Inhaler medication will remind child's caregiver twice daily to administer daily asthma medication.
62643464|NCT02999789|PLACEBO_COMPARATOR|Placebo: Delayed Reminder System|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The placebo group will have SMS reminder and audiovisual reminder functions turned off. The SmartInhaler will only function to measure daily adherence. Once intervention group has finished their 6 week period, this group will have intervention turned on.
62643465|NCT05719181|EXPERIMENTAL|control group|group consist of 16 patients with no protein application
62643466|NCT00869869|EXPERIMENTAL|melatonin|melatonin
62643467|NCT00869869|PLACEBO_COMPARATOR|placebo|placebo
62073459|NCT02184663|EXPERIMENTAL|Standard care with APA program|"The experimental arm corresponds to usual care, combined with a 16-week APA program.~The APA program consisted of personalized aerobic and resistance exercises, with a weekly remote supervision by an APA professional trainer, and unsupervised sessions with a family member or friend (APA partner)."
62277930|NCT05565469|EXPERIMENTAL|Neurostimulator group|Adjustment of neurostimulator settings to see whether or not abdominal stimulation can be provoked
62455690|NCT01706926|EXPERIMENTAL|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
62455691|NCT01371409|EXPERIMENTAL|active cTBS|
62455692|NCT01371409|SHAM_COMPARATOR|Sham cTBS|
62455693|NCT03565432||IBD in KHUH|Registered patients with Inflammatory bowel disease at Kyung Hee University Hospital
62277931|NCT01614093|ACTIVE_COMPARATOR|Oxytocin/Placebo|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
62277932|NCT01614093|ACTIVE_COMPARATOR|Placebo/Oxytocin|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
62277933|NCT04519645|EXPERIMENTAL|Lacosamide|Study participants randomized to this arm will receive lacosamide (LCM) as an intravenous infusion in the Treatment Period and may continue to receive lacosamide in the Extension Period. Participants should be switched to oral dosing of LCM as soon as medically possible during the Extension Period.
62455694|NCT02014181|EXPERIMENTAL|Flaxseed|40 grams finely ground flaxseed powder daily for one month in patient with cystic fibrosis
62455695|NCT04637438|ACTIVE_COMPARATOR|Fecal Microbiota Transplantation|
62455696|NCT04637438|PLACEBO_COMPARATOR|Plasebo|
62455697|NCT02179983|NO_INTERVENTION|Standard care|Standard care for exacerbation and follow-up without rehabilitation
62643468|NCT01449565|ACTIVE_COMPARATOR|Naltrexone|
62643469|NCT01449565|PLACEBO_COMPARATOR|Placebo|
62643470|NCT06043466|EXPERIMENTAL|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 2-10x10\^6 cells/kg
62643471|NCT06343116|EXPERIMENTAL|experimental group|Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A). Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
62455698|NCT02179983|EXPERIMENTAL|Pulmonary rehabilitation|6 weeks of exercise and patient education after exacerbation (pulmonary rehabilitation)
62455699|NCT03458871|EXPERIMENTAL|4-week TTNS home based protocol|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 4-week protocol.
62643472|NCT06343116|PLACEBO_COMPARATOR|control group|Placebo will be administered weekly (dose of placebo depends on part A). Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
62643473|NCT01564004|EXPERIMENTAL|Clinical hypnosis|20 minutes tape recorded clinical hypnosis intervention
62643474|NCT01564004|ACTIVE_COMPARATOR|Neuro-linguistic programming|20 minutes tape recording of nouro-linguistic programming intervention
62643475|NCT04887467|EXPERIMENTAL|Patients with Parkinson disease|Apomorphine 5mg/mL, solution for infusion, intraveinous use
62643476|NCT05560620|EXPERIMENTAL|Sleep Deprivation and Caffeine Intervention|Participants randomized into the sleep deprivation group and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
62643477|NCT05560620|SHAM_COMPARATOR|Sleep Deprivation and no Caffeine intervention|Participants randomized into the sleep deprivation group and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
62073460|NCT04005703||Pediatric Hodgkin's lymphoma|Children with newly diagnosed Hodgkin's lymphoma
62277934|NCT04519645|ACTIVE_COMPARATOR|Active Comparator|Study participants randomized to this arm will receive Active Comparator chosen based on standard of care (StOC) in the Clinical Practice in the Treatment Period and may continue to receive in the Extension Period.
62277935|NCT01184482|EXPERIMENTAL|Cetuximab and lapatinib|All patients will receive cetuximab by IB weekly and daily doses of lapatinib orally in 3 week cycles with response assessed every 2 cycles.
62277936|NCT02456428||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors \[sitagliptin, vildagliptin, and saxagliptin\] or GLP-1 analogs \[exenatide, liraglutide\]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
62643478|NCT05560620|ACTIVE_COMPARATOR|Control and Caffeine|Participants randomized into the control group, who will sleep regularly, and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
62643479|NCT05560620|SHAM_COMPARATOR|Control and No Caffeine|Participants randomized into the control group, who will sleep regularly, and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
62073461|NCT01939782|EXPERIMENTAL|Type 2 diabetic patients (T2D)|"In type 2 diabetic patients (T2D), the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~1. No Breakfast (NoB): fasting until lunch at 12:00~2. Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
62277937|NCT02456428||Treated with insulin|Current use of insulins between base cohort entry and the index or event day (alone or in combination with other anti-diabetic drugs) and no current use of incretin-based drugs.
62455700|NCT05749172|EXPERIMENTAL|Group A|This group was provided with Strength training along with parkour routine training.
62277938|NCT02456428||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
62455701|NCT05749172|ACTIVE_COMPARATOR|Group B|The control group was provided with parkour routine training
62073462|NCT01939782|ACTIVE_COMPARATOR|Healthy No Diabetics|"In healthy No Diabetics,: the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~1. No Breakfast (NoB): fasting until lunch at 12:00~2. Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
62073463|NCT01213043|ACTIVE_COMPARATOR|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
62455702|NCT05162404|EXPERIMENTAL|Video Intervention|The intervention in this study is a TED-talk style video series designed to provide patient education on cancer, care coordination, and self-advocacy. The content is designed to provide both a background about cancer disease and to address each of the specific domains in care coordination (CCI). The development of video contents was informed by our prior/current research in rural care coordination and components of evidence-based interventions including the patient navigator training by the George Washington University Cancer Institute, Imi Hale (the Native Hawaiian Cancer Network), and a supportive care intervention by Mokuau et al. As the target population of this intervention is rural patients, videos include some rural-specific considerations related to care coordination.
62643480|NCT06328972|EXPERIMENTAL|Intermittent Oro-Esophageal Tube Feeding+ systemic therapy|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
62643481|NCT06328972|ACTIVE_COMPARATOR|systemic therapy+Persistent Nasogastric Tube Feeding|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
62643482|NCT01168895|EXPERIMENTAL|Arm 1|
62643483|NCT01168895|EXPERIMENTAL|Arm 2|
62643484|NCT06047977|EXPERIMENTAL|TIL Therapy|TIL therapy with lymphodepleting chemotherapy and Interleukin 2
62643485|NCT02789501|ACTIVE_COMPARATOR|Control|Non-systemic intraluminal application of 4% citrate lock solution (CitraFlow™ 4%, MedXL, Montreal, Canada) 3 times per week after dialysis.
62643486|NCT02789501|EXPERIMENTAL|Test|"TauroLock™ based lock solution regimen:~Non-systemic intraluminal application of TauroLock™-Hep500, Tauropharm, Waldbüttelbrunn, Germany, 2x/week after dialysis (before short intervals) and TauroLock™-U25.000, Tauropharm, Waldbüttelbrunn, Germany, 1x/ week after dialysis (before long interval).~TauroLock™-Hep500 contains 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin.~TauroLock™-U25.000 contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase."
62643487|NCT03555149|ACTIVE_COMPARATOR|Regorafenib (Control)|Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
62643488|NCT03555149|EXPERIMENTAL|Atezolizumab + Imprime PGG + Bevacizumab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
62455703|NCT00968370|ACTIVE_COMPARATOR|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
62643489|NCT03555149|EXPERIMENTAL|Atezolizumab + Isatuximab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
62643490|NCT03555149|EXPERIMENTAL|Atezolizumab + Selicrelumab + Bevacizumab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
62643491|NCT03555149|EXPERIMENTAL|Atezolizumab + Idasanutlin|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
62643492|NCT03555149|EXPERIMENTAL|Atezolizumab + Regorafenib|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
62643493|NCT03555149|EXPERIMENTAL|Atezolizumab + Regorafenib + AB928|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
62643494|NCT03555149|EXPERIMENTAL|Atezolizumab + LOAd703|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
62643495|NCT00521365|EXPERIMENTAL|Quetapine 600 mg|
62455704|NCT00968370|OTHER|Hospital management|Hospital management: all children admitted at the hospital will be managed with injection Ceftriaxone and other micronutrients for the total duration of hospitalization as per approved protocol.
62455705|NCT00639990|ACTIVE_COMPARATOR|Control|Patients without lung injury and brain injury
62455706|NCT00639990|EXPERIMENTAL|Brain No ALI 1|Patients with brain injury and no lung injury within 72 hours from ICU entry
62073464|NCT01213043|EXPERIMENTAL|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
62643496|NCT02116868|EXPERIMENTAL|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
62643497|NCT02116868|NO_INTERVENTION|Standard practice (ST)|Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.
62643498|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
62643499|NCT03073928|ACTIVE_COMPARATOR|Interscalene Block|"Receives interscalene block with 15mL of ropivacaine 0.5% at the level of C6. A total of 15mL will be injected with repeated aspirations to rule out intravascular placement of the needle tip. Once this is done, the needle tip will be moved to the lateral edge of sternocleidomastoid muscle and additional 3mL of 0.5% ropivacaine will be injected between the deep fascia of the sternocleidomastoid and deep investing fascia of the neck (superficial cervical plexus block SCP).~We will administer injection of saline similar to experimental group to blind the patient"
62643500|NCT03073928|EXPERIMENTAL|Paracoracoid SPB|Receives paracoracoid subscapularis plane block with the ultrasound. Using a 50mm 22G block needle 15ml of 0.5% Ropivacaine will be deposited anterior to the fascia of subscapularis muscle after eliciting a motor response with 0.6mA current delivered through the needle. Following this, superficial cervical plexus block will be done using 3mL of 0.5% ropivacaine similar to group 1.
62643501|NCT01687634|EXPERIMENTAL|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
62643502|NCT01687634|EXPERIMENTAL|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
62643503|NCT04132037||patient with multiple sclerosis|At each visit, inclusion, 6 weeks, 6 months, 12 months, and 24 months, the clinical and urinary data will be recorded and the ISC frequency , ISC discontinuation and adherence scale will be evaluated
62643504|NCT05758896|EXPERIMENTAL|Isuzinaxib (APX-115)|4 x Isuzinaxib 88 mg calculated as free base (4 x 100mg APX-115(Isuzinaxib hydrocloride) capsules as salt form) administered QD, orally, for 5 consecutive days
62643505|NCT05758896|PLACEBO_COMPARATOR|Placebo|4 x Placebo capsules administered QD, orally, for 5 consecutive days
62643506|NCT03575702|EXPERIMENTAL|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
62073465|NCT03321513|ACTIVE_COMPARATOR|Aflibercept Group|2.0 mg intravitreous aflibercept
62073466|NCT03321513|EXPERIMENTAL|Bevacizumab + Deferred Aflibercept Group|1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
62455707|NCT00639990|EXPERIMENTAL|Brain No ALI 2|Patients with brain injury and no ALI after 72 hours from ICU entry
62455708|NCT00639990|EXPERIMENTAL|Brain ALI|Patients with brain injury and Acute Lung Injury (ALI)
62643507|NCT03575702|ACTIVE_COMPARATOR|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
62643508|NCT01486069||Dentofacial Deformity|Patients with dentofacial deformities candidate to orthognathic surgery
62643509|NCT04076241|EXPERIMENTAL|Combined intervention|Combined intervention group consisted of 16 pulmonary arterial hypertension (PAH) patients. Three different yoga breathing exercises were applied after osteopathic manipulative treatment (OMT). This combined intervention was applied 2 times a week for a period of 8 weeks with a total of 16 training sessions. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
62643510|NCT04076241|ACTIVE_COMPARATOR|Osteopathic manipulative treatment|OMT group consisted of 16 PAH patients. Six different OMT techniques were applied 2 times a week for a period of 8 weeks with a total of 16 sessions. The same osteopathic manipulative treatment techniques applied to combined intervention group were used for this study group. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
62073467|NCT02596022|EXPERIMENTAL|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
62073468|NCT02596022|ACTIVE_COMPARATOR|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
62073469|NCT01231685|ACTIVE_COMPARATOR|ritonavir-boosted protease inhibitor|
62073470|NCT01231685|EXPERIMENTAL|Raltegravir|
62073471|NCT06247332||Retrospective Long COVID cases|The target population will be as balanced as possible between subjects who needed specialized care due to long COVID-19 complications (either specialized care consultations or any non-planned hospital admission) at 1 month, 3 months, 6 months and 1 year from the long COVID-19 diagnose and those who did not require such specialized care.
62073472|NCT03929926|ACTIVE_COMPARATOR|Group 1 (usual care)|receive usual care
62455709|NCT00442936|EXPERIMENTAL|Telcagepant 150 mg|Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
62643511|NCT04076241|NO_INTERVENTION|Control|Control group also consisted of 16 PAH patients and serves as the controls. No interventions were applied for the patients in this group. Similar with the patients in other two groups, pharmacological treatment of the patients in this group continued and they were advised for using their medication properly, Patients in this group were also thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
62277939|NCT02456428||Treated with single oral agent|Current use of any single non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins.
62455710|NCT00442936|EXPERIMENTAL|Telcagepant 300 mg|Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
62643512|NCT02334163|EXPERIMENTAL|Nitazoxanide group|"12 patients will receive the following for 7 days:~* Oral lactulose~* 500 mg nitazoxanide tablets twice daily"
62643513|NCT02334163|ACTIVE_COMPARATOR|Metronidazole group|"12 patients will receive the following for 7 days:~* Oral lactulose~* 250 mg metronidazole tablets every 8 hours"
62643514|NCT02334163|ACTIVE_COMPARATOR|Rifaximine group|"12 patients will receive the following for 7 days:~* Oral lactulose~* Two 200 mg rifaximine tablets every 8 hours"
62643515|NCT05257317|EXPERIMENTAL|Intervention|It will consist of osteopathic manual therapy techniques applied to the occipital and temporal bones.
62277940|NCT02456428||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, insulins, ≥2 OHAs, or a single OHA.
62277941|NCT01436773||Recent Acute Coronary Event|Patients admitted to the hospital for recent STEMI or NSTEMI.
62643516|NCT05257317|PLACEBO_COMPARATOR|Placebo|It consists of a light contact applied to the cranial vault (frontal and parietal bones) where circular movements will be induced.
62073473|NCT03929926|EXPERIMENTAL|Group II (outreach contact)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Eligible and interested patients receive an office visit at the JLCSP for shared decision-making and possible lung cancer screening.
62277942|NCT01436773||Stable Coronary Artery Disease|Patients with known Coronary Artery Disease without recent acute coronary event.
62277943|NCT01436773||No Coronary Artery Disease|Patients with no evidence of coronary artery disease, assessed by coronary angiography.
62643517|NCT05294120|EXPERIMENTAL|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided RadIation Therapy|"If eligible, patients will undergo pretreatment RCM/OCT imaging, followed by RT.~Six weeks after the completion of RT, patients will undergo post-treatment assessment with RCM/OCT and biopsy. If residual carcinoma is detected on the biopsy, surgical excision of the BCC will be performed. If no residual carcinoma is detected on the biopsy, the patient will be monitored for clinical evidence of recurrence for up to 3 years."
62643518|NCT01799759|EXPERIMENTAL|Online intervention for parent and child|Children complete 8 online modules of Project FUN Parents complete 6 modules of Project FUN for Parents
62277944|NCT00002909|EXPERIMENTAL|Arm I|All patients receive oral phenylbutyrate three times daily. Groups of 4 or more patients receive escalating doses of phenylbutyrate until the maximum tolerated dose (MTD) is determined. Treatment continues until disease progression or unacceptable toxicity intervenes.
62277945|NCT01504282|ACTIVE_COMPARATOR|MMC group|One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
62277946|NCT01504282|PLACEBO_COMPARATOR|BSS group|One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
62277947|NCT04431830|EXPERIMENTAL|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery) for managing pain.
62643519|NCT01799759|OTHER|Instruments only|The waiting list control group only completes instruments and body composition, fitness measures
62643520|NCT02217748|EXPERIMENTAL|Survey questionnaire version 1|Name generator order: leisure, money, support
62277948|NCT04431830|NO_INTERVENTION|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
62643521|NCT02217748|EXPERIMENTAL|Survey questionnaire version 2|Name generator order: leisure, support, money
62643522|NCT02217748|EXPERIMENTAL|Survey questionnaire version 3|Name generator order: money, leisure, support
62643523|NCT02217748|EXPERIMENTAL|Survey questionnaire version 4|Name generator order: money, support, leisure
62643524|NCT02217748|EXPERIMENTAL|Survey questionnaire version 5|Name generator order: support, leisure, money
62277949|NCT05464355||Biomarker monitoring|
62277950|NCT02193958|EXPERIMENTAL|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
62277951|NCT02193958|EXPERIMENTAL|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
62643525|NCT02217748|EXPERIMENTAL|Survey questionnaire version 6|Name generator order: support, money, leisure
62643526|NCT02766647|EXPERIMENTAL|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
62643527|NCT02766647|EXPERIMENTAL|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
62643528|NCT00249704|EXPERIMENTAL|C|
62643529|NCT00249704|EXPERIMENTAL|B|
62643530|NCT00249704|EXPERIMENTAL|A|
62643531|NCT00249704|PLACEBO_COMPARATOR|D|
62277952|NCT02193958|EXPERIMENTAL|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
62277953|NCT02193958|EXPERIMENTAL|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
62277954|NCT02193958|EXPERIMENTAL|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
62277955|NCT02193958|EXPERIMENTAL|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
62643532|NCT06342947|EXPERIMENTAL|ALG-055009 softgel capsule 0.3mg|ALG-055009 softgel capsule 0.3mg Daily for 12 weeks
62643533|NCT06342947|EXPERIMENTAL|ALG-055009 softgel capsule 0.5mg|ALG-055009 softgel capsule 0.5mg Daily for 12 weeks
62073474|NCT03929926|EXPERIMENTAL|Group III (outreach + Decision Counseling Program)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Patients then undergo a decision counseling session through a semi-structured Decision Counseling Program that includes a review of the mailed educational materials and completion of an interactive exercise intended to clarify personal preference related to screening options (to have LDCT or not to have LDCT). Patients interested in screening schedule an office visit at JLCSP for possible screening or are referred to their primary care physician for consultation.
62277956|NCT02193958|EXPERIMENTAL|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
62277957|NCT02193958|EXPERIMENTAL|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
62277958|NCT02193958|EXPERIMENTAL|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
62073475|NCT02892487|EXPERIMENTAL|Early active swallowing therapy|
62073476|NCT02892487|NO_INTERVENTION|Usual care|
62073477|NCT04585490|EXPERIMENTAL|Cohort 1 minimal residual disease positive (MRD+)|Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy \[carboplatin/pemetrexed\], tremelimumab (75 mg IV every 21 days) and durvalumab (1500 mg IV every 21 days), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks. Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.
62277959|NCT03636139|EXPERIMENTAL|Anodal stimulation|transcranial DC stimulation : anodal
62277960|NCT03636139|SHAM_COMPARATOR|Sham stimulation|transcranial DC stimulation : sham
62277961|NCT01543516||Patients with Asthma|"Affected patients~-20 Patients suffering from asthma with an eNO over 30 bbp"
62277962|NCT01543516||Healthy Subjects|"Non-affected patients~-20 matched controls not suffering from asthma"
62643534|NCT06342947|EXPERIMENTAL|ALG-055009 softgel capsule 0.7mg|ALG-055009 softgel capsule 0.7mg Daily for 12 weeks
62277963|NCT04230174|EXPERIMENTAL|Multiple sclerosis patients|Multiple sclerosis patients will be evaluated with 11C-PBR28 MR-PET at baseline before and at 12 month follow up after Ocrelizumab therapy.
62277964|NCT04147351|EXPERIMENTAL|Atezolizumab+bevacizumab+pemetrexed+carboplatin or cisplatin|
62277965|NCT01447108|EXPERIMENTAL|TN patients|Patients suffering from Trigeminal neuralgia
62643535|NCT06342947|EXPERIMENTAL|ALG-055009 softgel capsule 0.9mg|ALG-055009 softgel capsule 0.9mg Daily for 12 weeks
62643536|NCT06342947|PLACEBO_COMPARATOR|Placebo|Placebo softgel capsule Daily for 12 weeks
62643537|NCT02623712|ACTIVE_COMPARATOR|More Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
62643538|NCT02623712|ACTIVE_COMPARATOR|Less Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
62643539|NCT05367245|EXPERIMENTAL|Cal-Mag-Butyrate|Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
62643540|NCT05367245|PLACEBO_COMPARATOR|Placebo for Cal-Mag-Butyrate|Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
62643541|NCT06523712|EXPERIMENTAL|intervention group|The participants assigned to Arm 1 will receive interactive oral care curriculum lessons designed to educate and engage them in oral hygiene practices. These lessons will cover various topics such as the importance of teeth, types of dentition, proper brushing techniques, prevention of dental caries, and the role of fluoride in maintaining oral health. The educational sessions will be delivered using interactive methods such as printed flashcards, games, and hands-on activities to enhance learning and retention. Participants will actively participate in the sessions, which will be tailored to their age group and comprehension level. The goal of Arm 1 is to assess the effectiveness of these interactive oral care lessons in improving oral hygiene knowledge, behavior, and plaque control among schoolchildren aged 5 to 12.
62643542|NCT06523712|NO_INTERVENTION|Control group|Participants assigned to Arm 2 will serve as the control group and will not receive any intervention ( interactive oral care lessons) during the study period except basic dental hygiene education as usually practiced by schools. The purpose of Arm 2 is to serve as a comparison group to evaluate the effectiveness of the interactive oral care lessons provided to participants in Arm 1.
62643543|NCT04350463|EXPERIMENTAL|Arm A: SCLC in ICI naïve subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
62643544|NCT04350463|EXPERIMENTAL|Cohort B: SCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
62643545|NCT04350463|EXPERIMENTAL|Cohort C: sqNSCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
62643546|NCT01172873|ACTIVE_COMPARATOR|DCS + Exposure and Response Prevention|Participants in this arm receive 10 twice-weekly 60-minute sessions of Exposure and Response Prevention (E/RP) therapy and 50mg of D-Cycloserine immediately after each therapy session. D-Cycloserine is only administered on days in which therapy sessions are held.
62643547|NCT01172873|ACTIVE_COMPARATOR|E/RP alone (no DCS administration)|Participants in this arm received twice-weekly 60 minute sessions of E/RP alone for a total of 10 sessions.
62455711|NCT00442936|ACTIVE_COMPARATOR|Zolmitriptan 5 mg|Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
62277966|NCT04121247|EXPERIMENTAL|Experimental: Parents in Chad will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
62073478|NCT04585490|EXPERIMENTAL|Cohort 2 minimal residual disease negative (MRD )|Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab (10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.
62643548|NCT02672241|EXPERIMENTAL|radio-chemotherapy plus nimotuzumab|Radiotherapy: The total radiation dose is 52.2Gy (1.8Gy fractions). Chemotherapy: Nimotuzumab, given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
62643549|NCT04802499||persons who using telehealth (patients)|patients who have received telehealth
62643550|NCT04802499||caregivers|family member of the patients who recieved telehealth
62643551|NCT04802499||health professions|persons who use the telehealth.
62643552|NCT04993573||Caregivers|Caregivers who work with older patients will be included. They will have a questionnaire
62643553|NCT04993573||Older|Older 65 people who live alone in their house will be included. They will have Individual interviews.
62643554|NCT03709251|EXPERIMENTAL|High Intensity Walking|HIW (70-80% Heart Rate max)
62073479|NCT04249336|EXPERIMENTAL|BioMin F Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
62643555|NCT03709251|EXPERIMENTAL|Casual Speed Walking|Self selected pace
62643556|NCT03288168||0-18 y/o Patients with Medulloblastoma|Patients treated with comprehensive treatments including surgery, chemo-therapy with / without (less than 3 y/o) radiation, during the period of Jan 2008 and Dec 2012, whose tumor samples will be tested by NanoString and Histochemistry methods, are enrolled in this cohort group.
62643557|NCT00413543|EXPERIMENTAL|interventional, rehabilitation|'early pulmonary lung rehabilitation'
62643558|NCT00413543|NO_INTERVENTION|control|"standard care"
62643559|NCT06277674|EXPERIMENTAL|cadonilimab plus pemetrexed and anlotinib|"Twenty elderly patients (age≥65 years) with advanced non-squamous NSCLC with T790M negative after EGFR-TKI resistance will be enrollrd in this study. Participants will receive 4 to 6 cycles of cardunnilumab in combination with pemetrexed and anlotinib every 3 weeks, followed by maintenance treatment with cadonilimab plus anlotinib until disease progression, intolerable toxicity, withdrawal of consent, death, or other protocol-specified causes, whichever occurs first.~Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule."
62643560|NCT05415306|EXPERIMENTAL|Attention Bias Modification Training|Participants randomized to the ABMT group will undergo active attention bias modification training. The emoji-based ABMT protocol will be adapted from the attention bias modification task from Browning et al., 2012. The stimuli used during the task are pictures of emoji displaying emotional expressions that have valences that are either positive, neutral, or negative. The positive, negative and neutral emojis will be chosen from the outcome of a preliminary rating questionnaire.
62073480|NCT04249336|ACTIVE_COMPARATOR|Colgate Sensitive Pro relief Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
62073481|NCT04249336|ACTIVE_COMPARATOR|Sensodyne Rapid Action Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
62073482|NCT04249336|PLACEBO_COMPARATOR|Colgate Total Trade Mark|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
62073483|NCT00720408|EXPERIMENTAL|Prograf-XL + MMF|
62073484|NCT00720408|ACTIVE_COMPARATOR|Prograf + MMF|
62073485|NCT04361513|ACTIVE_COMPARATOR|Nerve block group|3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.
62073486|NCT04361513|OTHER|intra-articular steroid injection|1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.
62073487|NCT00783471|EXPERIMENTAL|1|Erlotinib followed by Docetaxel
62073488|NCT00783471|EXPERIMENTAL|2|Docetaxel followed by Erlotinib
62073489|NCT03006198||Cohort 1: Rheumatoid Arthritis|Participants with Rheumatoid arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
62073490|NCT03006198||Cohort 2: Ankylosing Spondylitis|Participants with Ankylosing spondylitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
62073491|NCT03006198||Cohort 3: Psoriatic Arthritis|Participants with Psoriatic arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
62073492|NCT03006198||Cohort 4: Crohn's Disease|Participants with Crohn's disease as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
62073493|NCT03006198||Cohort 5: Ulcerative Colitis|Participants with Ulcerative colitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
62073494|NCT01806155||Craniotomy|Patient undergoing major craniotomy
62073495|NCT05414838|EXPERIMENTAL|Curcumin, Omega-3 and Vitamin-D (COD)|
62073496|NCT02649387|EXPERIMENTAL|Treatment (ibrutinib)|"Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 4 weeks\* for up to 36 courses in the absence of disease progression or unacceptable toxicity.~Note: \*The last course may last up to 56 days to accommodate the study drug discontinuation visit."
62073497|NCT00911105||Patients with multiple myeloma|Patients with multiple myeloma receiving second line therapy or higher.
62073498|NCT05843890|EXPERIMENTAL|Structured and tailored PainGuide|
62073499|NCT05843890|ACTIVE_COMPARATOR|Standard PainGuide|
62073500|NCT04029558|EXPERIMENTAL|Combination of plant extracts (BSL_EP024)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP024)
62073501|NCT04029558|PLACEBO_COMPARATOR|Placebo|The volunteers will take two capsules daily with maltodextrin.
62073502|NCT01494714|EXPERIMENTAL|Closed-patch test|
62073503|NCT01097395|ACTIVE_COMPARATOR|Standard Weight-Based Ribavirin Dosing|1000 mg daily in patients weighing \<75 kg and 1200 mg daily in patients weighing ≥ 75 kg
62073504|NCT01097395|EXPERIMENTAL|Concentration-Controlled Ribavirin Dosing|Dose adjusted based on first dose AUC0-12
62073505|NCT02917265|EXPERIMENTAL|TENS for vagus stimulation|A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
62073506|NCT02917265|SHAM_COMPARATOR|TENS for sham stimulation|A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
62073507|NCT03511872|EXPERIMENTAL|Peers' group|"36 Medical students are allocated randomly to Peers' group where they are trained on BLS skills by senior students.~Four students from the latest three years of study in medical schools in Syria (4th, 5th, and 6th) are randomly selected and enrolled to be instructors for basic life support training course to transfer the resuscitation skills to medical students from pre-clinical years."
62073508|NCT03511872|EXPERIMENTAL|Professionals' group|36 students are allocated randomly to professionals' group where they are trained on BLS skills by professional trainers in emergency. Four professionals (2 emergency doctors, cardiologist and anesthesiologist) are leading training to the control group to deliver the basic life support training course with the same duration and content as the intervention group.
62073509|NCT01381835|EXPERIMENTAL|001|TMC435 150 mg capsule once daily for 7 days
62073510|NCT00346996|ACTIVE_COMPARATOR|1|HUman Insulin
62073511|NCT00346996|EXPERIMENTAL|2|Analogue insulin
62073512|NCT00253279||1|16 healthy subjects will be studied. Each patient will undergo one PET Scan to measure muscle protein synthesis rate.
62073513|NCT00253279||2|48 burn patients will be studied. Each patient will have a maximum of 3 PET Scans, which will be done at different times during the first 24 months after injury. A maximum of 2 of these scans will be done while they are inpatient; one after discharge.
62073514|NCT03423875|NO_INTERVENTION|Control|Patients assigned to the control condition will be treated using the current standard of care, clinical assessments, to identify delirium.
62073515|NCT03423875|EXPERIMENTAL|Intervention|PrEDICTgame score (subject's relative risk of delirium) will be shared with ED physicians in the intervention arm. After viewing the tests results, ED physicians will be asked to reassess delirium risk, and indicate if they would change their management based on the PrEDICT app scores.
62073516|NCT01049061|EXPERIMENTAL|MORAb-003|
62643561|NCT05415306|SHAM_COMPARATOR|Sham Training|Participants in the sham control group will receive a sham version of the ABMT task. This condition is identical to the active ABM condition except for the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
62073517|NCT00745641||1|Sixty patients with abdominal illness and scheduled abdominal X-ray computed tomography examination will be included.
62643562|NCT05415306|ACTIVE_COMPARATOR|Deep-breathing training|The protocol for the deep breathing practice will be adapted from the procedure outlined in (Cheng et al., 2019). Participants randomized to the deep breathing group will undergo mindful deep breathing practice. Participants will be required to follow an instructional video and perform mindful deep breathing. The video guide will be sent to each participant in the deep breathing group, and they will be instructed to perform the exercise once a day at any time of their choice for the 14-day period.
62643563|NCT05415306|NO_INTERVENTION|No-intervention control|Participants in the no-intervention control group will not be required to undergo any intervention.
62643564|NCT00975936|EXPERIMENTAL|[14C]-GSK706769|Single dose of 50µg \[14C\]-GSK706769 containing 250 nCi
62643565|NCT00975936|EXPERIMENTAL|[14C]-GSK706769 + Ketoconazole|An oral, 5-day repeat dose of 200 mg Ketoconazole (Q12) with a concomitant single oral dose of 50 µg \[14C\]-GSK706769 containing 250 nCi on day 3.
62643566|NCT02002546||ED chest pain presenting patients|
62643567|NCT04712292||Study group|Patients undergoing surgery for confirmed or suspected colorectal cancer between January 2020 and December 2021
62643568|NCT04712292||Control group|Patients undergoing surgery for confirmed or suspected colorectal cancer between January 2018 and December 2019
62643569|NCT00254436|EXPERIMENTAL|Epoetin Alfa|
62643570|NCT05343325|EXPERIMENTAL|Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin|Neoadjuvant therapy will be performed for a total of 2 cycles, with 21 days as a cycle, which includes: ① Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles, and the total dose of radiation in the two cycles will be GTV 8 Gy/8 F and GTVnd 8 Gy/8 F; ② Teilizumab: 200 mg D1, Q3W for two cycles; ③ Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles; ④Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
62643571|NCT03433235|EXPERIMENTAL|Early edoxaban initiation group|Low dose of edoxaban (15 or 30 mg) once daily from Day 2, then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
62643572|NCT03433235|ACTIVE_COMPARATOR|Conventional edoxaban initiation group|No antithrombotic treatment† -- then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
62643573|NCT01443169|EXPERIMENTAL|Sequence 1|
62643574|NCT01443169|EXPERIMENTAL|Sequence 2|
62643575|NCT01443169|EXPERIMENTAL|Sequence 3|
62643576|NCT01443169|EXPERIMENTAL|Sequence 4|
62643577|NCT03593200|EXPERIMENTAL|Experimental: Cohort 1|270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364\*
62643578|NCT02854917||Memantine Alone|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine for a period of 28 weeks."
62643579|NCT02854917||Memantine plus Individualized Management of AD|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine plus individualized management of AD for a period of 28 weeks."
62643580|NCT01576575|EXPERIMENTAL|Healthy males and non-pregnant females|"Subjects will be studied during a maximum of seven occasions.~Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.~Sessions 1\&2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)~Sessions 3\&4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine~Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine~Sessions 6\&7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine"
62073518|NCT02381002|EXPERIMENTAL|Weight reduction|weight reduction program for 6 months
62643581|NCT04757155|EXPERIMENTAL|iCALM Intervention Group|iCALM is a brief, online psychotherapeutic intervention for patients with advanced and metastatic cancer. It consists of one introductory module and four therapeutic modules composed of written psychoeducational material, videos, and exercises. The intervention is designed to be completed in 9 weeks.
62643582|NCT04757155|NO_INTERVENTION|Care as usual|Participants in the usual care group (UC) will receive routine care. At Princess Margaret Cancer Centre, routine care includes a referral to Psychiatry, Psychology, or Social Work, based on patients' needs.
62073519|NCT03728114|EXPERIMENTAL|High Altitude RIC group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
62643583|NCT03564470|EXPERIMENTAL|Chidamide|Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).
62643584|NCT03564470|EXPERIMENTAL|Dasatinib|Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).
62643585|NCT00571623||1|All subjects act as their own contral
62643586|NCT05466721|EXPERIMENTAL|Hydrustoma C3|The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days.
62643587|NCT05466721|OTHER|Coloplast Alterna|The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days.
62643588|NCT02205372|EXPERIMENTAL|MT-3995|
62643589|NCT02205372|PLACEBO_COMPARATOR|Placebo|
62643590|NCT05827276|EXPERIMENTAL|Usage of Life Story Questionnaire|This group will receive 6 weeks of physical therapy treatment as usual with the usage of the Life story questionnaire.
62073520|NCT03728114|SHAM_COMPARATOR|High Altitude Sham group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
62073521|NCT03728114|EXPERIMENTAL|Low Altitude RIC group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
62073522|NCT03728114|SHAM_COMPARATOR|Low Altitude Sham group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
62073523|NCT02500212|EXPERIMENTAL|ENVARSUS tablets|"Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.~Envarsus® tablets will be administered orally once daily in the morning"
62073524|NCT02500212|ACTIVE_COMPARATOR|ADVAGRAF capsules|"Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.~Advagraf® capsules will be administered orally once daily in the morning"
62073525|NCT00305864|EXPERIMENTAL|Phase I: MGd 3 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62073526|NCT00305864|EXPERIMENTAL|Phase I: MGd 4 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40.Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62643591|NCT05827276|NO_INTERVENTION|No usage of Life Story Questionnaire|This group will receive 6 weeks of physical therapy treatment as usual with no usage of the Life Story Questionnaire.
62643592|NCT00244049|EXPERIMENTAL|Brief clinician advice|
62643593|NCT00801372||Pre-existing Fibroblast MCB|Pre-existing fibroblast donors for hESC derivation project
62643594|NCT02400801|ACTIVE_COMPARATOR|oral oestroprogestogen pre-treatment|preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle
62073527|NCT00305864|EXPERIMENTAL|Phase I: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62073528|NCT00305864|ACTIVE_COMPARATOR|Phase II: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62643595|NCT02400801|EXPERIMENTAL|gonadotropin-releasing hormone (GnRH) pre-treatment|preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle
62073529|NCT04666922|EXPERIMENTAL|1 mg BI 765080|BI 765080
62073530|NCT04666922|PLACEBO_COMPARATOR|Placebo group|Placebo group
62073531|NCT04666922|EXPERIMENTAL|10 mg BI 765080|BI 765080
62073532|NCT04666922|EXPERIMENTAL|25 mg BI 765080|BI 765080
62643596|NCT05983952|EXPERIMENTAL|Intervention（Anti-CD38 antibody）|10 enrolled subjects: once a week x 8 doses
62643597|NCT02728323|ACTIVE_COMPARATOR|Levobupivacaine 100 mg, USG TAP Block|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
62643598|NCT02728323|PLACEBO_COMPARATOR|Placebo|20 ml of Saline (for 100 mg Levobupivacaine) intramuscularly, at the end of surgery
62643599|NCT06319027|EXPERIMENTAL|Diagnostic (DSC-MRI, fluciclovine F18 PET, MR spectroscopy)|Patients receive a gadolinium-based contrast agent and undergo DSC-MRI scans at 4 and 8 weeks after completion of SOC radiation therapy. Patients with evidence of disease progression then undergo MR spectroscopy or receive fluciclovine F18 IV and undergo PET scan within 12 weeks of SOC radiation therapy completion.
62643600|NCT03457857|OTHER|Group 1 - Cleanser|Regimen with Baby Cleanser Only
62643601|NCT03457857|OTHER|Group 2 - Cleanser and Lotion|Regimen containing Baby Cleanser/Shampoo and Baby Lotion
62643602|NCT02432339|EXPERIMENTAL|mycophenolate mofetil (MMF)|Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.
62643603|NCT02432339|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill) in the same size capsule that the MMF is used in - twice a day for 7 1/2 days.
62643604|NCT02277483|ACTIVE_COMPARATOR|active treatment|LAIS® Mites Sublingual tablets + rescue medication
62073533|NCT04666922|EXPERIMENTAL|50 mg BI 765080|BI 765080
62073534|NCT04666922|EXPERIMENTAL|100 mg BI 765080|BI 765080
62073535|NCT04666922|EXPERIMENTAL|200 mg BI 765080|BI 765080
62455712|NCT00442936|PLACEBO_COMPARATOR|Placebo|Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
62073536|NCT03480139||Pregnant Women|Pregnant women aged 18 years and older
62643605|NCT02277483|NO_INTERVENTION|control|Rescue medication
62643606|NCT04195594|EXPERIMENTAL|Nic's Keto Diet|
62073537|NCT00744237|EXPERIMENTAL|1|"* Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration~* Open-label amlodipine may be given"
62073538|NCT00744237|ACTIVE_COMPARATOR|2|"* Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration~* Open-label amlodipine may be given"
62073539|NCT00744237|ACTIVE_COMPARATOR|3|"* HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration~* Open-label amlodipine may be given"
62643607|NCT01053156|PLACEBO_COMPARATOR|Placebo pill|All patients will be on placebo for 3 months in this crossover study.
62643608|NCT01053156|EXPERIMENTAL|Minocycline|All patients will be on minocycline for 3 months in this crossover trial.
62643609|NCT05276791|ACTIVE_COMPARATOR|Endoscopic submucosal dissection|
62643610|NCT05276791|ACTIVE_COMPARATOR|Endoscopic mucosal resection|
62073540|NCT04896944||ICU Centre Hospitalier de Saint Denis|
62073541|NCT04896944||ICU Hôpital Ambroise Paré Boulogne|
62455713|NCT02193438|ACTIVE_COMPARATOR|Spice 1|Red chili pepper extract
62455714|NCT02193438|ACTIVE_COMPARATOR|Spice 2|Cinnamon extract
62643611|NCT06123702|EXPERIMENTAL|Cannabidiol|600 mg oral cannabidiol
62643612|NCT06123702|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62643613|NCT00860639|ACTIVE_COMPARATOR|gemtuzumab ozogamycin|Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
62643614|NCT00860639|NO_INTERVENTION|without Mylotarg|
62073542|NCT05179044|EXPERIMENTAL|Guardian knee brace group|Patients undergoing elective Total knee arthroplasty (TKA) by surgeons from NYU Langone with the presence of a pre-operative knee flexion contracture greater than 5 degrees and willingness to participate in our institution's outpatient rehabilitation and physical therapy. Those randomized to this group will be fitted with a Guardian Rehabilitator Brace.
62073543|NCT05179044|NO_INTERVENTION|No Guardian brace used group|Patients undergoing elective Total knee arthroplasty (TKA) by surgeons from NYU Langone with the presence of a pre-operative knee flexion contracture greater than 5 degrees and willingness to participate in our institution's outpatient rehabilitation and physical therapy as part of standard of care.
62073544|NCT04367402||Symptomatic Patients|Patients who had symptoms related to COVID-19 infection
62073545|NCT04367402||Health people|Healthy people who never had syntomps related to COVID-19 infection
62073546|NCT04367402||Asyntomatic Individuals|Asyntomatic people to recruit after the restriction have ended
62073547|NCT04723160||Test Group|ophthalmologists read images applying the assistant software
62073548|NCT04723160||Control Group|ophthalmologists read images independently
62073549|NCT03939039||Dyslipidemia|Genotype/phenotype correlation in patients with dyslipidemia
62455715|NCT02193438|ACTIVE_COMPARATOR|Spice 3|Refreshing agent
62455716|NCT02193438|PLACEBO_COMPARATOR|Placebo|Tomato juice
62455717|NCT01189123|ACTIVE_COMPARATOR|Standard dose influenza vaccine|Fluzone (Sanofi Pasteur)
62455718|NCT01189123|ACTIVE_COMPARATOR|High Dose Vaccine|High Dose Fluzone by sanofi pasteur
62073550|NCT05522751|EXPERIMENTAL|AUD DBS|This is a single arm study. Participants will undergo baseline medical and psychiatric assessments, cognitive and behavioral testing, and positron emission tomography (PET) imaging. One to two weeks later, participants will undergo neurosurgical implantation of DBS electrodes in the limbic pallidum and a neurostimulator. Four weeks after DBS system implantation, the DBS system will be turned ON and the stimulation parameters optimized. Participants will be followed biweekly then monthly for repeat comprehensive assessments.
62073551|NCT04443387|ACTIVE_COMPARATOR|Asthmatic low vitamin D on treatment|asthmatic patient low vitamin D level received treatment for Vitamin D 50000IU weekly
62455719|NCT00048568|EXPERIMENTAL|Abatacept + Methotrexate|Short Term: Abatacept was dosed by weight with participants weighing \< 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants \> 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.
62643615|NCT04301856||CF children treated with CFTR modul|Cystic fibrosis patients under 18 years treated with CFTR modulators according to french health recommendations observational cohort study
62643616|NCT04387123|ACTIVE_COMPARATOR|Conventional vaginoscopy|Vaginoscopy without vulvar tightness
62643617|NCT04387123|ACTIVE_COMPARATOR|Tight vaginoscopy|Vaginoscopy via Darwish sheet
62643618|NCT01643330|EXPERIMENTAL|AAV1/SERCA2a (MYDICAR)|Intracoronary infusion
62643619|NCT01643330|PLACEBO_COMPARATOR|Placebo|Intracoronary infusion
62643620|NCT02276469|EXPERIMENTAL|peer support|peer support is delivered on individual basis for half a year, the frequency depends on the patients requirement, but at least 3 sessions has to occur
62643621|NCT02276469|NO_INTERVENTION|usual care|usual care was delivered to the patients
62643622|NCT05502627||Experimental group|scaling was done along with intervention (0.25% lemongrass mouthwash was given)
62643623|NCT05502627||control group|only scaling was done
62643624|NCT02415530|PLACEBO_COMPARATOR|Term infant control|term infant without intervention
62643625|NCT02415530|PLACEBO_COMPARATOR|VLBW infant control|very low birth weight infant without intervention
62643626|NCT02415530|EXPERIMENTAL|VLBW infant intervention|Combined home visiting and group intervention for very low birth weight infant
62643627|NCT01536210|EXPERIMENTAL|YY-162|"YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)~1T/Three times a day(Tid) for 8 weeks, PO medication"
62643628|NCT01536210|PLACEBO_COMPARATOR|Placebo|Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
62643629|NCT01851421||Double-Variant MC3R|Volunteers with homozygous polymorphisms causing protein changes to T6K and V81I.
62643630|NCT01851421||Wild Type MC3R|Volunteers with no polymorphisms in MC3R gene.
62643631|NCT00057135|OTHER|Arm 1|
62643632|NCT03569501|NO_INTERVENTION|nutritional guidance|routine care (all arms with nutritional guidance per routine care)
62455720|NCT00048568|ACTIVE_COMPARATOR|Placebo + Methotrexate|Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.
62455721|NCT00048568|EXPERIMENTAL|Abatacept + Methotrexate Open Label|Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing \< 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants \> 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.
62643633|NCT03569501|ACTIVE_COMPARATOR|oat grains|90 mg oat, per day.
62643634|NCT03569501|EXPERIMENTAL|oat grains and DHA tablets|90 mg oat and 500 mg DHA oral tablets, per day.
62643635|NCT03569501|ACTIVE_COMPARATOR|DHA tablets|500 mg DHA oral tablets, per day.
62643636|NCT04229043|ACTIVE_COMPARATOR|Early labor, no analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
62643637|NCT04229043|PLACEBO_COMPARATOR|Early Labor, no analgesia: Water|Subject will ingest 100 ml of water
62643638|NCT04229043|ACTIVE_COMPARATOR|Early labor, analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
62643639|NCT04229043|PLACEBO_COMPARATOR|Early labor, analgesia: Water|Subject will ingest 100 ml of water
62643640|NCT02343224|EXPERIMENTAL|Pegylated interferon alpha-2b|Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week
62643641|NCT05777421|ACTIVE_COMPARATOR|Conventional Physical Therapy Regime for Knee Osteoarthrithis|"Pt will receive conventional therapy targeting stretching and stretching of knee musculature in combination with electrotherapy for pain modulation.~Frequency : 2-3 times for a duration of 6 weeks Pt will be guided home plan based exercises."
62073552|NCT04443387|PLACEBO_COMPARATOR|Asthmatic low vitamin D on placepo|asthmatic patient low vitamin D level received placepo
62455722|NCT05434481|ACTIVE_COMPARATOR|Aneurysm group|Patients operated for aneurysm of the ascending aorta according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
62643642|NCT05777421|EXPERIMENTAL|Virtual reality Based Therapeutic Exercise Regimes|"VR-based therapeutic exercise regimes utilizing Xbox, that focus on different activities like Partial squatting, lunges, side lunge, calf raises, and hamstring curls.~Gaming exercises begin will an easy warm up round and get challenging with different rounds of each game as the patient progresses to week 6.~Frequency: 2-3 times for a duration for 6 weeks Pt will be guided home plan based exercises"
62643643|NCT02306876|EXPERIMENTAL|PF-06412562 3mg|PF-06412562 3mg BID
62643644|NCT02306876|PLACEBO_COMPARATOR|Placebo|Placebo BID
62643645|NCT02306876|EXPERIMENTAL|PF-06412562 15mg|PF-06412562 15mg BID
62643646|NCT01614301|EXPERIMENTAL|Experimental Arm|Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity
62643647|NCT01614301|OTHER|Controll Arm|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
62643648|NCT04605900|EXPERIMENTAL|Standard Footwear (SF)|Intervention: plantar orthoses, education on foot self-care and appropriate standard footwear.
62643649|NCT04605900|EXPERIMENTAL|Orthopedic Footwear (OF)|Intervention: plantar orthoses, education on foot self-care and orthopedic footwear.
62643650|NCT00073918|EXPERIMENTAL|Treatment (radio labeled monoclonal antibody, chemotherapy)|"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.~CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.~AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0."
62643651|NCT03537066|OTHER|CPAP treatment|All included OSA patients are going to be treated by CPAP
62643652|NCT01510405||40 Participants|Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
62643653|NCT04056208|ACTIVE_COMPARATOR|Evening Pistachio Consumption|Participants will consume two ounces per day (57 g) of pistachios as an evening snack (i.e., after dinner and before sleep).
62643654|NCT04056208|ACTIVE_COMPARATOR|Usual care|Advice to consume a snack that contains 1-2 exchanges (15-30 g of carbohydrate) as an evening snack - this is consistent with the current standard of care for people with impaired fasting glucose.
62643655|NCT00566488|EXPERIMENTAL|Thymus and Parathyroid transplantation|Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants
62643656|NCT03391752||Royal Alexandria|Administrative records
62643657|NCT03391752||Pasqua Regional hospital|Administrative records
62073553|NCT04560205|EXPERIMENTAL|Group intervene with Tocilizumab|"Review effect of Tocilizumab as clinical trial among hospitalized patients with COVID-19 infection.~Participants with severe disease will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory biomarkers."
62073554|NCT02487940|ACTIVE_COMPARATOR|Intralipid|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
62643658|NCT03391752||Concordia Hospital|Administrative records
62643659|NCT03391752||Niagara General Hospital|Administrative records
62643660|NCT03391752||Hospital 6|Administrative Records
62643661|NCT03391752||Hospital 7|Administrative Records
62643662|NCT03391752||Hospital 8|Administrative Records
62643663|NCT03391752||Hospital 9|Administrative Records
62643664|NCT03391752||Hospital 10|Administrative records
62073555|NCT02487940|PLACEBO_COMPARATOR|Placebo|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
62073556|NCT03691285|EXPERIMENTAL|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
62073557|NCT03691285|ACTIVE_COMPARATOR|Two-implant mandibular overdenture|Participants allocated to this group will have two implants placed in the inter-foraminal region after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
62073558|NCT03496818||Crohn's Disease|Participants age 18-80 years old, diagnosed with Crohn's disease with active disease based on MR enterography or CT enterography confirmed within the prior 90 days.
62277967|NCT04121247|EXPERIMENTAL|Experimental: Parents in Turkey will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
62277968|NCT00151671|EXPERIMENTAL|1|Perioperative Oral Nutritional Supplementation
62643665|NCT01471977|EXPERIMENTAL|education, counselling, default tracer|
62643666|NCT03541837|OTHER|peri operative analgesia|Post operative regional analgesia by Erector Spinae bilateral catheters with infusion of ropivacaine
62277969|NCT00151671|PLACEBO_COMPARATOR|2|Placebo of Perioperative Oral Nutritional Supplementation
62277970|NCT04902846||Control (no kidney injury)|Patients who receive ICI but no develop kidney injury
62277971|NCT04902846||Case (kidney injury)|Patients who receive ICI and develop kidney injury
62277972|NCT03496909|ACTIVE_COMPARATOR|Standard OT|
62643667|NCT03405727|NO_INTERVENTION|Standard treatment|
62643668|NCT03405727|EXPERIMENTAL|Oral dietary supplements|
62643669|NCT04970212||Study Arm|Subjects will receive your standard liver ablation procedure, including ultrasound images. Data will be collected from the standard liver ablation procedure, including imaging. Subjects will receive a CT scan within 24 hours after the liver ablation procedure. There will then be an analysis of ultrasound images and research CT scan.
62643670|NCT05807867|EXPERIMENTAL|WMM-based intersectional stigma intervention|"N=90 Women with SMI and HIV in arm 1 will receive WMM stigma intervention as clients transition from psychiatric hospitalization to outpatient care. The curriculum, co-led by a trained clinician and a peer woman with SMI and HIV, will comprise of 8 group sessions at \~60 minutes each. Following psychiatric stabilization, but while still an inpatient, women participants will receive 5 (delivered 2x weekly) of 8 session anti-stigma intervention. To facilitate community integration, the final 3 WMM-based intervention sessions will be delivered once every two weeks at a community-based setting in Gabarone.~Parallel Group Stigma intervention: N=90 Family members will receive an adapted 3-session WMM-based group intervention that uses the same intervention components. The first 2 sessions will be held weekly in a private room at Sbrana Hospital, while the final session will be held 2 weeks following client discharge in the same community-based setting as above."
62643671|NCT05807867|ACTIVE_COMPARATOR|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content. Control co-leaders will receive a 1-day training on the control manual and facilitation techniques. Sessions will focus on general health education (i.e., diet, exercise, avoiding alcohol, and healthy sleep habits) for women with SMI and HIV adapted from Ministry of Health materials. The investigators will offer in-person sessions including facilitated discussions to encourage interaction (per the WMM intervention). The investigators expect participation in the attention control arm (\~84% retention) to approximate that of women (and family members) attending the intervention arm. While intended to be salient to women participants and their family members, this program should not decrease stigma nor has it been shown to impact MH outcomes.
62643672|NCT01368419|EXPERIMENTAL|Treatment|
62643673|NCT04077892|EXPERIMENTAL|combination of budesonide and montelukast|receive treatment with either a combination of budesonide (Rhinorcort Astra Zeneca AB), 1 spray per nostril twice daily (total 256 μg/d) and 10mg oral montelukast tablet (Merck Sharp \& Dohme Australia Pty Ltd) in the evening for 14 days (BD+MNT treatment group)
62643674|NCT04077892|ACTIVE_COMPARATOR|only intranasal budesonide|treatment with only intranasal budesonide 1 spray per nostril twice daily for 14 days (BD treatment group)
62643675|NCT01989858|EXPERIMENTAL|peri-operative CHT (Arm A)|In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
62277973|NCT03496909|EXPERIMENTAL|PhysioTouch|
62643676|NCT01989858|ACTIVE_COMPARATOR|post-operative CHT (Arm B)|In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
62643677|NCT01989858|EXPERIMENTAL|peri-operative CHT + post-operative CHT-RTX (Arm C)|CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
62277974|NCT04947176|ACTIVE_COMPARATOR|Active|200mg of pentadecanoic acid (C15:0) supplementation in capsules form
62277975|NCT04947176|PLACEBO_COMPARATOR|Placebo|Matching placebo in capsules form
62643678|NCT01989858|ACTIVE_COMPARATOR|post-operative CHT + post-operative CHT-RTX (Arm D)|surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
62643679|NCT01746862|EXPERIMENTAL|Saizen Test Group|
62277976|NCT02704533|EXPERIMENTAL|Optimization Phase - Group A|"n=6; three times 9x10\^5 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group A will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If \>75% efficacious, the treatment will be simplified to two times 1.35x10\^6 PfSPZ Vaccine on Days 0 and 7 (Group B1).~If \<75% efficacious, the treatment will be increased to three times 1.35x10\^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group B2)"
62277977|NCT02704533|EXPERIMENTAL|Optimization Phase - Group B1|"n=6; two times 1.35x10\^6 PfSPZ Vaccine on Days 0 and 7 by DVI. Group B1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If \>75% efficacious, the treatment will be simplified to one injection 2.7x10\^6 PfSPZ Vaccine (Group C1).~If \<75% efficacious, the treatment will be increased to two times 2.7x10\^6 PfSPZ Vaccine on Days 0 and 7 (Group C2)."
62455723|NCT05434481|ACTIVE_COMPARATOR|Type A aortic dissection group|Patients operated for type A aortic dissection according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
62643680|NCT01746862|ACTIVE_COMPARATOR|Saizen Control Group|
62643681|NCT05595135|EXPERIMENTAL|Health services research (text messages, smart pill bottle)|Patients receive interactive text messages to help with adherence to medications and a smart pill bottle with medication reminders on study.
62643682|NCT00524433|EXPERIMENTAL|1|tezosentan
62643683|NCT00524433|PLACEBO_COMPARATOR|2|
62643684|NCT01563523|EXPERIMENTAL|Activated recombinant human factor VII|
62643685|NCT01563523|PLACEBO_COMPARATOR|Placebo|
62643686|NCT02869789|EXPERIMENTAL|Nivolumab in combination with Ipilimumab|Specified dose on specified days
62643687|NCT06017245|ACTIVE_COMPARATOR|Control|Healthy young-adult groups
62643688|NCT06017245|EXPERIMENTAL|Senile osteoporosis|Patients with senile osteoporosis
62643689|NCT06017245|EXPERIMENTAL|Postmenopausal osteoporosis|Patients with postmenopausal osteoporosis
62643690|NCT01290718|EXPERIMENTAL|Single Arm|
62643691|NCT02121210|EXPERIMENTAL|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
62643692|NCT02121210|EXPERIMENTAL|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
62643693|NCT04149418|EXPERIMENTAL|Yogurt-Control|Consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks, followed by a washout phase for 4 weeks, then consumption of 12 oz. control food (flavored soy pudding, 2 x 6 oz. servings) for 4 weeks.
62073559|NCT03496818||Healthy controls|Participants age 18-80 years old, with no diagnosis of inflammatory bowel disease.
62073560|NCT04894461|EXPERIMENTAL|Moxibustion|Moxibustion treatment sessions eight weeks from the baseline.
62277978|NCT02704533|EXPERIMENTAL|Optimization Phase - Group B2|"n=6; three times 1.35x10\^6 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group B2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If \>75% efficacious, the treatment will be simplified to two times 2.7x10\^6 PfSPZ Vaccine on Days 0 and 7 (Group C2).~If \<75% efficacious, the treatment will be increased to three times 2.7x10\^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group C3)."
62643694|NCT04149418|EXPERIMENTAL|Control-Yogurt|Consumption of control food (flavored soy pudding, 2 x 6 oz. servings), followed by a washout phase for 4 weeks, then consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks.
62643695|NCT06273761|EXPERIMENTAL|Intervention|Participants who join the trial will have have a control period (no intervention) of 3 to 12 months before receiving medication management service (MMS) at 8 NGO community pharmacies. Since there are 8 NGO community pharmacies, 2 NGO community pharmacies will start delivering MMS by phase at 3, 6, 9 and 12 month intervals. Therefore, all participants who join the trial will receive MMS by month 12 from recruitment date. During the MMS service, pharmacists will review the participants' medication history and conduct medication reconciliation, refer them to doctors for reviewing the prescribing decision if necessary, as well as provide education and lifestyle advice on medication management.
62643696|NCT06273761|NO_INTERVENTION|Control|Participants who join the trial will have have a control period of 3 to 12 months before receiving medication management service (MMS) at 8 NGO community pharmacies. Participants will have no MMS intervention during the control period. Since there are 8 NGO community pharmacies, two NGO community pharmacies will start delivering MMS by phase at 3, 6, 9 and 12 month intervals. Therefore, all participants who join the trial will receive MMS by month 12 from recruitment date.
62643697|NCT01595373|ACTIVE_COMPARATOR|Ghrelin|Ghrelin
62643698|NCT01595373|PLACEBO_COMPARATOR|Placebo|Ringer acetate is used for placebo.
62643699|NCT03305718|EXPERIMENTAL|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
62643700|NCT03305718|EXPERIMENTAL|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
62073561|NCT04894461|NO_INTERVENTION|Waiting|A waiting period of eight weeks by moxibustion treatment sessions in the same way with moxibustion group.
62643701|NCT03305718|EXPERIMENTAL|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
62073562|NCT02584855|EXPERIMENTAL|Ixekizumab Open Label|Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
62073563|NCT02584855|EXPERIMENTAL|Ixekizumab|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse)."
62073564|NCT02584855|PLACEBO_COMPARATOR|Placebo|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)"
62073565|NCT02584855|EXPERIMENTAL|IXE80Q2W Non-randomized|"Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period."
62073566|NCT04906369||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, 2 weeks after the start of treatment, and at the beginning of each new treatment cycle.
62277979|NCT02704533|EXPERIMENTAL|Optimization Phase - Group C1|"n=6; one time 2.7x10\^6 PfSPZ Vaccine by DVI. Group C1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C1 gets vaccinated, study will proceed to verification phase after completion."
62073567|NCT00678990|EXPERIMENTAL|Open, single arm|Transplantation of islets with heparin coating.
62073568|NCT05016011|EXPERIMENTAL|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Patients will receive 25 x 10\^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.
62073569|NCT05016011|ACTIVE_COMPARATOR|Marrow cellution (standard treatment)|Patients will undergo marrow cellution surgical procedure.
62643702|NCT03305718|EXPERIMENTAL|Meal sequence: 3B2C1D4A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3B2C1D4A."
62643703|NCT03305718|EXPERIMENTAL|Meal sequence: 4C2B1A3D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4C2B1A3D."
62643704|NCT03305718|EXPERIMENTAL|Meal sequence:1B4D3C2A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1B4D3C2A."
62643705|NCT03305718|EXPERIMENTAL|Meal sequence:4A1C2D3B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4A1C2D3B."
62643706|NCT03305718|EXPERIMENTAL|Meal sequence:1D3A4B2C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1D3A4B2C."
62073570|NCT02406885|ACTIVE_COMPARATOR|APB study: Apixaban Pharmacokinetics in VSG|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing vertical sleeve gastrectomy
62073571|NCT02406885|ACTIVE_COMPARATOR|APB study: Apixaban Pharmacokinetics in RYGB|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.
62073572|NCT06428838|OTHER|Standard of Care|SoC will be delivered at the discretion of the treating physician
62073573|NCT06428838|EXPERIMENTAL|Standard of Care + Eptinezumab|In addition to standard of care, participants randomized to the Standard of Care + Eptinezumab arm will receive a single infusion of eptinezumab (100mg/mL).
62073574|NCT05171140|EXPERIMENTAL|Hollow nails are arranged in a triangle|Hollow nails are arranged in a triangle
62073575|NCT05171140|EXPERIMENTAL|Hollow nail inverted triangle arrangement|Hollow nail inverted triangle arrangement
62073576|NCT02746757|NO_INTERVENTION|Ischemia-reperfusion no intervention|Ischemia-reperfusion without intervention
62073577|NCT02746757|EXPERIMENTAL|Ischemia-reperfusion with RIPC|Ischemia-reperfusion with intervention by RIPC
62073578|NCT02746757|EXPERIMENTAL|Ischemia-reperfusion with RIPC and Ex 9-39|Ischemia-reperfusion with RIPC and Ex 9-39
62073579|NCT02715895|EXPERIMENTAL|Friso|Friso formula feeding
62073580|NCT02715895|EXPERIMENTAL|Wyeth|Wyeth formula feeding
62073581|NCT02715895|ACTIVE_COMPARATOR|Breast milk|Breast milk feeding
62073582|NCT03535584|EXPERIMENTAL|Exercise Program|All participants will attend a 16-session exercise program based on pulmonary rehabilitation and will complete questionnaires and frailty testing.
62073583|NCT05624723|EXPERIMENTAL|Group 1: Normal Renal Function|Participants with normal levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
62073584|NCT05624723|EXPERIMENTAL|Group 2: Mild Renal Impairment|Participants with mild levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
62073585|NCT05624723|EXPERIMENTAL|Group 3: Moderate Renal Impairment|Participants with moderate levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
62277980|NCT02704533|EXPERIMENTAL|Optimization Phase - Group C2|"n=6; two times 2.7x10\^6 PfSPZ Vaccine by DVI. Group C2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C2 gets vaccinated, study will proceed to verification phase after completion."
62277981|NCT02704533|EXPERIMENTAL|Optimization Phase - Group C3|"n=6; three times 2.7x10\^6 PfSPZ Vaccine by DVI. Group C3 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~In case C3 shows \<75% efficacy, verification phase will not be done."
62277982|NCT02704533|EXPERIMENTAL|PfSPZ Challenge (7G8) dose finding - Group D1|"n=3, one dose of 800 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
62455724|NCT05434481|SHAM_COMPARATOR|Control group|Patients without aortic aneurysm or aortic dissection operated for aortic valve replacement (AVR) and/or coronary artery bypass with a saphenous vein graft for proximal aortic anastomosis to collect the aortic sample. For patients operated for AVR, an aortic sample will be collected before closing the aorta.
62455725|NCT04087395|EXPERIMENTAL|RHA®4 with new anesthetic agent|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
62643707|NCT03305718|EXPERIMENTAL|Meal sequence: 4D3B2C1A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4D3B2C1A."
62455726|NCT04087395|EXPERIMENTAL|RHA®4-Lidocaine|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
62455727|NCT02295878|ACTIVE_COMPARATOR|Treatment|400mg capsule containing seaweed extract (treatment)
62455728|NCT02295878|PLACEBO_COMPARATOR|Placebo|400mg capsule containing maltodextrin (placebo)
62455729|NCT02223000|ACTIVE_COMPARATOR|BIBV 308 SE solution|
62455730|NCT02223000|EXPERIMENTAL|BIBV 308 SE capsule 1|
62455731|NCT02223000|EXPERIMENTAL|BIBV 308 SE capsule 2|
62455732|NCT03958825|ACTIVE_COMPARATOR|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
62455733|NCT03958825|EXPERIMENTAL|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
62455734|NCT00854321||patients with active RA|drug, follow-up
62455735|NCT04440254|OTHER|ONE|One single group of patients
62455736|NCT02705053|ACTIVE_COMPARATOR|Sensor-Augmented Pump Open-Loop Care (Week 2)|The subjects' Sensor-Augmented Pump Open-Loop Care for the second week of the study before any adjustments to pump settings, using a CGM and Insulin Pump.
62643708|NCT03305718|EXPERIMENTAL|Meal sequence: 3A4C1B2D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3A4C1B2D."
62643709|NCT03305718|EXPERIMENTAL|Meal sequence: 1C2A3D4B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1C2A3D4B."
62643710|NCT03305718|EXPERIMENTAL|Meal sequence: 2B1D4A3C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2B1D4A3C."
62643711|NCT01952379||Melasma|Women affected by symmetric facial malar melasma.
62643712|NCT00888875|EXPERIMENTAL|1|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
62643713|NCT00888875|ACTIVE_COMPARATOR|2|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
62643714|NCT02668640||Participants with RA receiving adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks
62277983|NCT02704533|EXPERIMENTAL|PfSPZ Challenge (7G8) dose finding - Group D2|"n=3, one dose of 1,600 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
62277984|NCT02704533|EXPERIMENTAL|PfSPZ Challenge (7G8) dose finding - Group D3|"n=3, one dose of 3,200 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
62643715|NCT02351934|EXPERIMENTAL|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
62643716|NCT02351934|ACTIVE_COMPARATOR|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
62643717|NCT01219582||Group 1|
62643718|NCT03982524|EXPERIMENTAL|CBT complemented with emotion regulation training|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning nonjudgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
62643719|NCT03982524|ACTIVE_COMPARATOR|Cognitive behavior therapy (CBT)|"This arm is based on conventional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
62643720|NCT02051296|EXPERIMENTAL|minocycline|perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
62643721|NCT02051296|PLACEBO_COMPARATOR|Placebo|PLacebo
62643722|NCT01299558|OTHER|Treatment period 1|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
62643723|NCT01299558|OTHER|Treatment Period 2|Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
62643724|NCT01299558|OTHER|Treatment Period 3|Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
62643725|NCT00191243|EXPERIMENTAL|A|
62643726|NCT00191243|EXPERIMENTAL|B|
62643727|NCT03110107|EXPERIMENTAL|Part 1A: Monotherapy (BMS-986218)|
62073586|NCT05624723|EXPERIMENTAL|Group 4: Severe Renal Impairment|Participants with severe levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
62073587|NCT05624723|EXPERIMENTAL|Group 5: Kidney Failure|Group 5 participants with ESRD maintained on HD will receive a single dose of INCB054707 across 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB054707.
62073588|NCT03901469|EXPERIMENTAL|Part 1 and Part 2|ZEN003694 will be administered PO QD with Talazoparib PO QD in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
62073589|NCT03901469|EXPERIMENTAL|Expansion Cohort A - Combination Treatment in post-TROP2-ADC patients|ZEN003694 will be administered PO QD with Talazoparib PO QD at the RP2D in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
62073590|NCT03901469|EXPERIMENTAL|Expansion Cohort B - ZEN003694 Monotherapy|ZEN003694 will be administered PO QD as monotherapy at the RP2D in 28-day cycles with the option to cross-over to combination treatment of ZEN003694 PO QD with Talazoparib PO QD at the time of disease progression (but no sooner than after 6 weeks of monotherapy). Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
62073591|NCT03901469|EXPERIMENTAL|Expansion Cohort C - Combination Treatment in TROP2-ADC-naïve patients|ZEN003694 will be administered PO QD with Talazoparib PO QD at the RP2D in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in China only.
62073592|NCT03225846|EXPERIMENTAL|WVE-120102 (2 mg) or placebo|
62073593|NCT03225846|EXPERIMENTAL|WVE-120102 (4 mg) or placebo|
62073594|NCT03225846|EXPERIMENTAL|WVE-120102 (8 mg) or placebo|
62073595|NCT03225846|EXPERIMENTAL|WVE-120102 (16 mg) or placebo|
62073596|NCT03225846|EXPERIMENTAL|WVE-120102 (32 mg ) or placebo|
62073597|NCT03262090|NO_INTERVENTION|control group|Subjects were randomly assigned to receive saline before skin incision
62073598|NCT03262090|ACTIVE_COMPARATOR|0.2ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
62073599|NCT03262090|ACTIVE_COMPARATOR|0.4ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
62643728|NCT03110107|EXPERIMENTAL|Part 1B: Combination Therapy (BMS-986218 + Nivolumab)|
62073600|NCT03262090|ACTIVE_COMPARATOR|0.6ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
62073601|NCT03262090|ACTIVE_COMPARATOR|0.8ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
62073602|NCT03262090|ACTIVE_COMPARATOR|1.0ug/kg dexmedetomidine|Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
62073603|NCT02123537|EXPERIMENTAL|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System for walking daily during the 12 weeks of the study.
62073604|NCT02520180|EXPERIMENTAL|Firehawk™ stent system|MicroPort Firehawk™ stent system
62073605|NCT02520180|ACTIVE_COMPARATOR|Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
62073606|NCT04479241|EXPERIMENTAL|Lerapolturev|
62073607|NCT04808128|EXPERIMENTAL|Drink A + SC|In t0 the group will receive 250 ml XL energy drink + 20 gr sucrose.
62643729|NCT03110107|EXPERIMENTAL|Part 2A: Monotherapy (BMS-986218 OR Ipilimumab)|
62643730|NCT03110107|EXPERIMENTAL|Part 2B: Monotherapy (BMS-986218)|
62643731|NCT03110107|EXPERIMENTAL|Part 2C: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
62643732|NCT03110107|EXPERIMENTAL|Part 2D: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
62643733|NCT06221176|EXPERIMENTAL|Intervention Group|Being Brave
62643734|NCT03759925|EXPERIMENTAL|Nutritional Support|The intervention consists of home delivery of medically-appropriate food support (DASH and diabetic diet compliant) in the form of prepared meals and/or groceries and monthly individual nutritional counseling with a Registered Dietician.
62643735|NCT03759925|NO_INTERVENTION|Standard of Care|The control group will receive standard of care follow up care after their hospitalization for acute decompensated heart failure.
62643736|NCT05870852|EXPERIMENTAL|ESWT|All individuals who will participate in the study will be treated once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.
62643737|NCT05870852|EXPERIMENTAL|ESWT+PNF|PNF stretching techniques will be applied in addition to ESWT. PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
62643738|NCT00927875|EXPERIMENTAL|All Subjects|
62277985|NCT02704533|EXPERIMENTAL|Verification Phase - Group V1|"n=12; optimal regimen from phase 1 - shortest, well tolerated safe schedule that provides \>75% protection (5/6) against homologous CHMI (V1).~Optimal \& maximum regimens will be compared in this phase. The maximum regimen is a 3-dose regimen (Day 0, 7, 28) with highest well-tolerated PfSPZ Vaccine dose/injection (V2).~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered in one of 2 sequences (NF54-7G8 or 7G8-NF54). Allocation to the 2 sequences will be double blind, random, at a 1:1 ratio and nested within the intervention groups (V1 and V2 PfSPZ Vaccine and placebo (P1 and P2)). CHMI will be done at a dose of 3,200 PfSPZ unless the dose escalation study of PfSPZ Challenge (7G8) indicates that a different dose would be preferable for 7G8."
62643739|NCT03034369||Safety Net Clinic Patients|A Cohort of patients in 12 different primary care clinics will be studied to measure how changes in different integration factors impacts the following patient reported outcomes at baseline and 12 months: Access to Care, Patient-Provider Relationship, Patient-Clinic Interactions, Stigma, Provider Continuity, Symptom Severity, Diagnoses, and Social Support. Health care claims data will be accessed to analyze Depression Screening, Preventive Screening, Inpatient Hospitalization Utilization, Inpatient Readmissions, and Post-Admission follow-up at baseline and 12 months.
62073608|NCT04808128|ACTIVE_COMPARATOR|Drink B + SC|In t0 the group will receive 250 ml Fanta soft drink + 20 gr sucrose.
62073609|NCT04808128|ACTIVE_COMPARATOR|Drink C + SC|In t0 the group will receive 250 ml soda water + 47 gr sucrose.
62073610|NCT04808128|EXPERIMENTAL|Drink A + CC|In t0 the group will receive 250 ml XL energy drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
62073611|NCT04808128|ACTIVE_COMPARATOR|Drink B + CC|In t0 the group will receive 250 ml Fanta soft drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
62643740|NCT05507099|ACTIVE_COMPARATOR|Knee arm randomized to Lipoaspirate Concentrate and Bone Marrow Aspirate|The Subjects will be randomized to one of the treatment groups separately for the knee and hip arms of the study. Group A will receive a single intra-articular injection with lipoaspirate concentrate to the knee and Group B will receive a single intra-articular injection with bone marrow aspirate concentrate.
62073612|NCT04808128|ACTIVE_COMPARATOR|Drink C + CC|In t0 the group will receive 250 ml soda water + 27gr sucrose + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
62073613|NCT06106035|EXPERIMENTAL|Intervention Group: low-fat vegan diet|This arm of participants will be asked to attend weekly online classes in nutrition and health and to follow a low-fat, vegan diet for 16 weeks.
62073614|NCT02134119|EXPERIMENTAL|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
62073615|NCT02134119|PLACEBO_COMPARATOR|Sugar pill|Placebo given 8,000mg/day by mouth
62073616|NCT01416896|EXPERIMENTAL|"New venous needle, the BME needle"|"Hemodialysis using the new venous needle, the BME needle."
62073617|NCT01416896|ACTIVE_COMPARATOR|"Standard venous needle, the standard needle"|"One hemodialysis using the standard venous needle, the standard needle (device)."
62073618|NCT06130163||Intraoperative ERCP|Patients with cholecystocholedocholithiasis getting intraoperative ERCP
62643741|NCT05507099|ACTIVE_COMPARATOR|Hip Arm randomized to Lipoaspirate Concentrate and Bone Marrow Aspirate|The subjects will be randomized to one of the treatment groups separately for the knee and hip arms of the study. Groups C will receive a single intra-articular injection with lipoaspirate concentrate to the hip and Group D will receive a single intra-articular injection with bone marrow aspirate.
62643742|NCT02962427|EXPERIMENTAL|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
62643743|NCT02962427|ACTIVE_COMPARATOR|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
62643744|NCT01111565|EXPERIMENTAL|Phase B: Single-blind Prospective Treatment Phase|Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the Week 1 (end of Week 1) based upon tolerability profile, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
62643745|NCT01111565|EXPERIMENTAL|Phase B+: Single-blind Phase B Responders|Participants with response (≥50% reduction in depressive symptom severity in HAM-D17 Total Score; or a HAM-D17 Total Score of \<14 at Week 8 or a Clinical Global Impression of Improvement (CGI-I) Score of \<3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B, for an additional 6 weeks (Up to Week 14), in Phase B+.
62643746|NCT01111565|EXPERIMENTAL|Phase C: Aripiprazole/Escitalopram Combination|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
62073619|NCT06130163||Splitting|Patients with cholecystocholedocholithiasis getting therapeutic splitting
62073620|NCT02544269|EXPERIMENTAL|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
62073621|NCT02544269|ACTIVE_COMPARATOR|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
62073622|NCT03881033|PLACEBO_COMPARATOR|P12|
62073623|NCT03881033|ACTIVE_COMPARATOR|P7+5|
62073624|NCT06180941|ACTIVE_COMPARATOR|magnesium sulfate as adjuvant to bupivacaine.|Group M: 2mg/kg Magnesium sulfate will be added to 0.5 mL.kg-1 of 0.25% bupivacaine (max 2 mg/kg) with a total volume of 0.5 ml/kg, (according to the spread of local anesthetic surrounding the brachial plexus)
62643747|NCT01111565|EXPERIMENTAL|Phase C: Escitalopram Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
62073625|NCT06180941|ACTIVE_COMPARATOR|clonidine as adjuvant to bupivacaine.|Group C: 0.75 μg.kg-1 of clonidine will be added to 0.5 mL.kg-1 of 0.25% bupivacaine (max 2 mg/kg) with a total volume of 0.5 ml/kg, (according to the spread of local anesthetic surrounding the brachial plexus)
62277986|NCT02704533|EXPERIMENTAL|Verification Phase - Group V2|"n=12; maximum regimen from the phase 1 - 3-dose regimen (Day 0, 7 and 28) with highest well-tolerated PfSPZ Vaccine dose per injection (V2).~Optimal \& maximum regimens will be compared in this phase. The optimal regimen (shortest, well tolerated and safe schedule) that provides \>75% protection (5/6) against homologous CHMI (V1).~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10\^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
62455737|NCT02705053|EXPERIMENTAL|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on CGM glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device. Algorithmic adjustment of carbohydrate ratios prior to closed-loop initiation, and continued basal rate and carbohydrate ratio algorithmic optimization during closed-loop use will occur.
62455738|NCT04705142|EXPERIMENTAL|MgSO4|"MgSO4~1st dose within 6 hours of life @250mg/kg,2nd after 24 hours of life @250mg/kg, 3rd after 48 hours of life @250mg/kg.~Monitoring and Protective measures:~Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour."
62643748|NCT01111565|EXPERIMENTAL|Phase C: Aripiprazole Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily for 6 weeks (Up to Week 14), in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any visit, based upon tolerability.
62643749|NCT04554472||Study group|Patients with a distal radius fracture requiring surgery who meet the exclusion and inclusion criteria
62073626|NCT03753711|EXPERIMENTAL|LDH (lumbar disc hernia)|
62073627|NCT00128622|EXPERIMENTAL|Denileukin Diftitox plus vaccine|This is a single arm Phase I safety study.
62073628|NCT05950022|EXPERIMENTAL|Endoscopic tenotomy at the level of the lesser trochanter|Patients will benefit from endoscopic tenotomy surgery of the iliopsoas tendon at the level of the lesser trochanter.
62643750|NCT03111524|ACTIVE_COMPARATOR|Intervention school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
62643751|NCT03111524|ACTIVE_COMPARATOR|Intervention school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher.The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
62643752|NCT03111524|ACTIVE_COMPARATOR|Intervention school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
62643753|NCT03111524|ACTIVE_COMPARATOR|Intervention school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
62643754|NCT03111524|ACTIVE_COMPARATOR|Intervention school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
62643755|NCT03111524|PLACEBO_COMPARATOR|control school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
62643756|NCT03111524|PLACEBO_COMPARATOR|control school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
62643757|NCT03111524|PLACEBO_COMPARATOR|control school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
62643758|NCT03111524|PLACEBO_COMPARATOR|control school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
62643759|NCT03111524|PLACEBO_COMPARATOR|control school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
62643760|NCT00483652|PLACEBO_COMPARATOR|Placebo|Placebo control
62073629|NCT05950022|EXPERIMENTAL|Endoscopic tenotomy at the level of the acetabular notch|Patients will benefit from endoscopic tenotomy surgery of the iliopsoas tendon at the level of the acetabular notch.
62073630|NCT00289237|EXPERIMENTAL|High intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
62643761|NCT00483652|ACTIVE_COMPARATOR|Fampridine-SR|10 mg b.i.d.
62073631|NCT00289237|EXPERIMENTAL|Low intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
62073632|NCT00289237|NO_INTERVENTION|Control group|"Questionnaires regarding lifestyle and general health were sent to all participants in this group.~The importance of healthy lifestyle was not mentioned, and no intervention was offered."
62073633|NCT00324012|EXPERIMENTAL|treatment|taxotere and cisplatin day one every three weeks
62277987|NCT02704533|PLACEBO_COMPARATOR|Verification Phase - Group P1|"n=6; normal saline as placebo. This group will follow the regimen selected for Group V1.~Efficacy of the vaccination regimen will be determined by CHMI which will be done by repeat CHMI three and eight weeks after the last immunization. Inoculation of the two CHMIs will be done approximately 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
62277988|NCT02704533|PLACEBO_COMPARATOR|Verification Phase - Group P2|"n=6; NS as placebo. This group will follow the regimen selected for Group V2.~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10\^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after the last immunization. Inoculation of the 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
62643762|NCT04861142||Patients adherent to the anti-osteoporotic medication|
62643763|NCT04861142||Patients non-adherent to the anti-osteoporotic medication|
62643764|NCT06163118|EXPERIMENTAL|Patient aged 75 or over hospitalized in the Geriatric Short-Stay Unit|"Two caregivers from the Geriatric Short-Stay Unit will successively administer the Deglut'G tool to each patient, blind to each other, and blind to the SLP and ENT doctor examination. All patients will have a SLP examination and an ENT doctor examination aimed at detecting swallowing disorders."
62643765|NCT03425669|ACTIVE_COMPARATOR|Placebo medication and sham stimulation|Patients will be randomly chosen to the group who will get a combination of placebo and sham stimulation.
62643766|NCT03425669|ACTIVE_COMPARATOR|Active medication|Patients are randomly chosen to the group who will get active medication without stimulation.
62643767|NCT03425669|SHAM_COMPARATOR|Active stimulation|Patients are randomly chosen to the group who will get acitive stimulation without taking medicine.
62643768|NCT03425669|ACTIVE_COMPARATOR|Controls with sham stimulation|Controls without ADHD are randomly chosen to the group who will get sham stimulation.
62277989|NCT05789095||Case-group|13 adolescents, 9-16 years, with Osgood-Schlatter Disease.
62277990|NCT05789095||Control-group|13 healthy adolescents, 9-16 years, without any knee pain, matched on age, sex and type of sport on the group-level.
62277991|NCT01477385|ACTIVE_COMPARATOR|Resin Infiltration|Resin Infiltration 30% Silver Diammine Fluoride Placebo Dental Flossing
62277992|NCT01477385|EXPERIMENTAL|30% Silver Diammine Fluoride|30% Silver Diammine Fluoride Resin Infiltration Placebo Dental Flossing
62277993|NCT01477385|ACTIVE_COMPARATOR|Oral Hygiene|Dental Flossing 30% Silver Diammine Fluoride Placebo Resin Infiltration Placebo
62643769|NCT03425669|SHAM_COMPARATOR|Controls with active stimulation|Controls without ADHD are randomly chosen to the group who will get active stimulation.
62643770|NCT00643201|ACTIVE_COMPARATOR|Apixaban|apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
62643771|NCT00643201|EXPERIMENTAL|Enoxaparin + Warfarin|Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
62073634|NCT04363385|OTHER|Collection of blood sample|
62643772|NCT02851602|EXPERIMENTAL|Obese|
62643773|NCT02851602|PLACEBO_COMPARATOR|control|
62643774|NCT02398110|EXPERIMENTAL|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
62643775|NCT02398110|ACTIVE_COMPARATOR|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
62643776|NCT02425306|EXPERIMENTAL|Arm A:6MHP + Montanide ISA-51|Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
62643777|NCT02425306|EXPERIMENTAL|Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide|"Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~* Day -6 (Cycle 1)~* Day 8 (Cycle 2)~* Day 22 (Cycle 3)~* Day 36 (Cycle 4)~* Day 50 (Cycle 5)"
62073635|NCT05774496||Congenital toxoplasmosis women|Women older than 21 suffering from congenital toxoplasmosis, with or without children.
62073636|NCT01042899|EXPERIMENTAL|Teen Online Problem Solving (TOPS)|Web intervention
62277994|NCT03826927||AF and cerebrovascular event|patients with AF and recent (\< 3 month) stroke or transient ischaemic attack (TIA) or intracranial haemorrhage (ICH) with or without pre-existing oral anticoagulation, in whom treatment with NOACs or VKAs is initiated or continued for prevention of ischemic events
62277995|NCT00138736|EXPERIMENTAL|A|MBL until the patient's absolute neutrophil count (ANC) is above 500/microL blood.
62073637|NCT01042899|EXPERIMENTAL|Teen Online Problem Solving---Teen Only|Web Intervention
62073638|NCT01042899|ACTIVE_COMPARATOR|Internet Resources Comparison|Web Intervention
62073639|NCT01886638|EXPERIMENTAL|Abacavir|Abacavir 600mg (as two 300mg tablets) once daily for 15 days
62073640|NCT02821832|OTHER|Arm A - Expected high risk of relapse, standard of care TB treatment|Expected high risk of relapse, standard of care TB treatment
62073641|NCT02821832|ACTIVE_COMPARATOR|Arm B - Expected low risk of relapse, standard of care TB treatment|Expected low risk of relapse, standard of care TB treatment
62073642|NCT02821832|EXPERIMENTAL|Arm C - Expected low risk of relapse, shortened TB treatment|Expected low risk of relapse, shortened TB treatment
62073643|NCT02223065|EXPERIMENTAL|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
62277996|NCT00963274|EXPERIMENTAL|bortezomib + romidepsin|Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks. In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
62277997|NCT02471547|NO_INTERVENTION|TURBT ONLY|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
62277998|NCT02471547|EXPERIMENTAL|BWT with Mitomycin-C prior TURBT|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
62277999|NCT01457742|ACTIVE_COMPARATOR|Pulsed Radio Frequency (PRF)|
62073644|NCT02223065|EXPERIMENTAL|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
62073645|NCT05691348|EXPERIMENTAL|Ambulatory pathway|
62073646|NCT05691348|ACTIVE_COMPARATOR|Conventional hospitalisation|
62073647|NCT01717105||metastatic non-small cell lung cancer|Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
62073648|NCT05937009|EXPERIMENTAL|Experimental: Experimental Orienteering group program|The experimental group intervention will attend the orienteering program. The program integrates 3 sessions / week during 12 consecutive weeks.
62073649|NCT05937009|NO_INTERVENTION|The control group|"The control group will maintain the usually daily activities, not attending any exercise program.~After study end, the control group will have the opportunity to participate on an exercise program."
62073650|NCT04013958|ACTIVE_COMPARATOR|IV Ketamine|IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.
62073651|NCT04013958|EXPERIMENTAL|IM Ketamine|IM Ketamine group will receive IM Ketamine with IV morphine.
62073652|NCT01578096|NO_INTERVENTION|Diabetes education|Group-based diabetes education delivered to participants through community health workers
62073653|NCT01578096|EXPERIMENTAL|Diabetes education plus stress management|Group-based diabetes education plus stress management delivered to participants through community health workers
62073654|NCT05039177|EXPERIMENTAL|Dose Escalation (Parts A1a, A2a, or A3a): ERAS-007 in combination with encorafenib and cetuximab|ERAS-007 will be orally administered in combination with encorafenib and cetuximab to study participants with BRAFm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62073655|NCT05039177|EXPERIMENTAL|Dose Escalation (Parts B1a, B2a, B3a or B4a): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered in combination with palbociclib to study participants with KRASm or NRASm CRC and KRASm PDAC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62073656|NCT05039177|EXPERIMENTAL|Dose Expan (Parts A1b, A1c, A2b, A2c, A3b, or A3c): ERAS-007 in combo with encorafenib & cetuximab|ERAS-007 will be orally administered at the recommended dose (as determined from Parts A1a, A2a or A3a) in combination with encorafenib and cetuximab to study participants with BRAFm CRC.
62073657|NCT05039177|EXPERIMENTAL|Dose Expansion (Parts B1b, B2b, B3b, and B4b): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered at the recommended dose (as determined from Parts B1a, B2a, B3a or B4a) in combination with palbociclib to study participants with KRASm or NRASm CRC.
62278000|NCT01457742|SHAM_COMPARATOR|Sham|Use of Sham device for 15 minutes simulated treatment twice per day
62643778|NCT02425306|EXPERIMENTAL|Arm C:6MHP + polyICLC + Montanide ISA-51|Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
62643779|NCT02425306|EXPERIMENTAL|Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide|"Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~* Day -6 (Cycle 1)~* Day 8 (Cycle 2)~* Day 22 (Cycle 3)~* Day 36 (Cycle 4)~* Day 50 (Cycle 5)"
62643780|NCT00695123||Only 1 participant group (cohort)|The subject may have a blood disorder, may be a stem cell transplant donor, or may be a healthy volunteer.
62643781|NCT02980081||Plain abdominal x-ray|All patients admitted to 2 EDs and with a prescription of an abdominal plain x-ray.
62643782|NCT06147934||study group|All participants included will be in one study group.
62643783|NCT02964624|OTHER|Rehabilitation|The rehabilitation protocol will consist of three exercise session/week for eight weeks
62643784|NCT05858983|EXPERIMENTAL|FT-001 Dose 1|Intraocular administration of a single low dose of range FT-001
62278001|NCT01137383|EXPERIMENTAL|Treatment group|
62278002|NCT00278278|EXPERIMENTAL|Arm I|"Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
62278003|NCT00278278|ACTIVE_COMPARATOR|Arm II|"Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
62278004|NCT05407259|NO_INTERVENTION|Control condition|During the control condition, participants will be asked to read a book related to exercise for approximately 40 minutes.
62278005|NCT05407259|EXPERIMENTAL|Low-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 65% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: \~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
62643785|NCT05858983|EXPERIMENTAL|FT-001 Dose 2|Intraocular administration of a single Mid dose of range FT-001
62643786|NCT05858983|EXPERIMENTAL|FT-001 Dose 3|Intraocular administration of a single High dose of range FT-001
62643787|NCT02356120||Suspected Pulmonary Embolus|Patients with suspected pulmonary embolus who are getting a CTPA
62643788|NCT01099046|NO_INTERVENTION|medication only|medication = anti-diuretics
62643789|NCT01099046|ACTIVE_COMPARATOR|medication + water intake|anti-diuretics + water intake (at least 2.0 litters per day)
62643790|NCT01099046|ACTIVE_COMPARATOR|medication + tympanic tubing|anti-diuretics + tympanic tubing (under local anesthesia)
62643791|NCT01099046|ACTIVE_COMPARATOR|medication + regular sleep|anti-diuretics + regular sleep (regular sleep program under dark everynight)
62643792|NCT03142945|ACTIVE_COMPARATOR|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
62643793|NCT03142945|EXPERIMENTAL|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
62643794|NCT00529711|EXPERIMENTAL|Group 1|Hypertonic lactate
62643795|NCT00529711|ACTIVE_COMPARATOR|Group 2|Ringer's lactate
62643796|NCT02273401|EXPERIMENTAL|BI 11054 CL|
62643797|NCT02273401|PLACEBO_COMPARATOR|Placebo|
62643798|NCT04216147|EXPERIMENTAL|PNE group|Patients received 4 sessions, separated one week between them. The treatment consisted the application of a galvanic current through an acupuncture needle (0,30x30mm). The approach were performed with a transverse axis with a needle in plane, being superficial and deep interface of medium nerve the target tissue. The parameters will be 2 mA (milliamps), 10 seconds, 3 impacts (3: 3: 3).
62073658|NCT05253690|ACTIVE_COMPARATOR|speculum guided|view-guided approach using a speculum
62073659|NCT05253690|EXPERIMENTAL|manual guided|manual guided approach at cervical examination
62073660|NCT02176941||ATHEROMA group|"ATHEROMA group will include patients undergoing cardiovascular surgery or have pacemaker/defibrillator implantation and have a clinically significant atherosclerotic disease"
62643799|NCT04216147|EXPERIMENTAL|Surgery group|Patients received surgery for median nerve release.
62643800|NCT04070664||Central vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
62643801|NCT04070664||Peripheral vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
62073661|NCT02176941||Control Surgery group|"Control Surgery group will include patients undergoing other surgery or pacemaker/defibrillator implantation without evidence of clinical CV disease or history of previous CV disease."
62643802|NCT03060408||Open|Patients underwent open distal pancreatectomy
62643803|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
62073662|NCT01355419||obstructive sleep apnea, CPAP|moderate to severe obstructive sleep apnea requiring CPAP therapy
62073663|NCT06274580|EXPERIMENTAL|Embolization of the middle meningeal artery|Endovascular treatment of chronic subdural hematoma
62073664|NCT06274580|NO_INTERVENTION|standard of care|"control group will managed according to the current standard of care with wait and see approach and best medical treatment"
62643804|NCT04158869||Cases|Patients with pMDD, enrolled in the Investigator-initiated clinical trial IICT (ClinicalTrials.gov Identifier: NCT03167307)
62073665|NCT00107744|ACTIVE_COMPARATOR|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
62073666|NCT00107744|ACTIVE_COMPARATOR|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
62073667|NCT00107744|ACTIVE_COMPARATOR|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
62073668|NCT04674774|EXPERIMENTAL|tegoprazan based bismuth quadruple therapy group|tegoprazan based bismuth quadruple therapy group
62073669|NCT04674774|ACTIVE_COMPARATOR|PPI based bismuth quadruple therapy group|PPI based bismuth quadruple therapy group
62073670|NCT05295303|EXPERIMENTAL|Interventional group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review the physiological parameters of patients randomized to the Intervention group daily and treatment can be initiated or modified accordingly through instant communication (electronic communication and/or phone).
62073671|NCT05295303|PLACEBO_COMPARATOR|Control group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review individual patient physiological parameters and risk factors only during the clinic visits
62073672|NCT03251560|EXPERIMENTAL|Fuke Qianjin capsule|Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
62073673|NCT03251560|PLACEBO_COMPARATOR|Placebo oral capsule|placebo pills, 2 pills each time,three times a day, orally, for 2months
62073674|NCT05391022|EXPERIMENTAL|Run-In Food Effect Period|Unblinded, open label drug will be administered once in a fasted state and twice in a fed state with a minimum of 5 days between each dose prior to entering the continuous treatment phase.
62073675|NCT05391022|EXPERIMENTAL|Continuous Treatment Period|Unblinded, open label drug will be administered once daily for 14 consecutive days followed by a 7 day break, which is considered 1 cycle of treatment (1 cycle = 21 days).
62073676|NCT00518713|EXPERIMENTAL|Clobazam Low Dose|
62643805|NCT04158869||Controls|Controls matched to cases according to age, sex and school education
62073677|NCT00518713|EXPERIMENTAL|Clobazam Medium Dose|
62643806|NCT04222920|EXPERIMENTAL|Low serum drug concentration|Adalimumab dose reduction aiming a drug level of 2 mg/L
62073678|NCT00518713|EXPERIMENTAL|Clobazam High Dose|
62073679|NCT00518713|PLACEBO_COMPARATOR|Placebo|
62073680|NCT03687268|PLACEBO_COMPARATOR|Placebo|
62073681|NCT03687268|EXPERIMENTAL|Naloxone 24 mg|
62073682|NCT03687268|EXPERIMENTAL|Naloxone 48 mg|
62073683|NCT01422681|EXPERIMENTAL|DECOPD|patients with severe COPD exacerbation on NIV treated with the minimally invasive extracorporeal carbon dioxide removal device (Decap Smart)
62073684|NCT00373932|EXPERIMENTAL|MOBILE-A|Coached exercise persistence intervention
62073685|NCT00373932|ACTIVE_COMPARATOR|MOBILE-B|Self-monitored exercise persistence intervention
62073686|NCT00779558|ACTIVE_COMPARATOR|Study drug|Heparin sulfate infusion at 10 units/kg/hour
62643807|NCT04222920|ACTIVE_COMPARATOR|High serum drug concentration|Adalimumab dose reduction aiming a drug level of 5 mg/L
62073687|NCT00779558|PLACEBO_COMPARATOR|Placebo|Placebo - normal saline infusion
62073688|NCT04506996|EXPERIMENTAL|Intervention Group - Receiving Text Messages|"The 16-weeks text-messaging intervention centered around 8 goal topics: eating only when hungry, increasing PA, eating a lower fat diet, eating less sugar and reducing calories from beverages, exercising more, eating a balance diet, portion control, and making healthier food choices in social situations.~Messaging~Sun evening: asked to pick 1 of 3 goal topics~Mon morning: received a goal to focus on for the week~Mon evening: asked whether plans were made to reach the goal~Wed morning: received a tip to help reach goal~Wed evening: reminded that if having cravings, text tip to automatically receive a tip~Fri morning: received end of the week congratulations, encouragement to keep goals in mind over the weekend~Fri evening: asked for weight, congratulated if lost weight, or encouraged if no weight lost"
62073689|NCT04506996|ACTIVE_COMPARATOR|Control Group - Written Messages|"Participants in the control group, received a printed copy of the same messages that the intervention group received. However, the first eight-weeks' worth of messages and craving tips were given after the baseline assessment, and the rest were given after the first follow-up assessment (\~ 8 weeks post randomization).~The messages for each week were clearly laid out and labeled. Participants were given spaces to record their answers (i.e. to which goal they were selecting for each week). The study staff reviewed the first week's messages together with the study participants to get the participants comfortable with the format that the printed messages were presented in."
62073690|NCT06250543|OTHER|AbobotulinumtoxinA and lidocaine|"The bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 300 units of AbobotulinumtoxinA using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
62073691|NCT06250543|OTHER|AbobotulinumtoxinA and placebo|"The bladder was instilled with 40 ml of 0.9% NaCl solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 300 units of AbobotulinumtoxinA using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
62073692|NCT06250543|OTHER|IncobotulinumtoxinA and lidocaine|"The bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 100 units of IncobotulinumtoxinA using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
62073693|NCT06250543|OTHER|IncobotulinumtoxinA and placebo|"The bladder was instilled with 40 ml of 0.9% NaCl solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 100 units of IncobotulinumtoxinA. using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
62073694|NCT03049657|ACTIVE_COMPARATOR|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
62073695|NCT03049657|ACTIVE_COMPARATOR|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
62073696|NCT01219595|ACTIVE_COMPARATOR|Part 1|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
62073697|NCT01219595|OTHER|No treatment|20 non-UTI susceptible women will be enrolled to collect data on the types of E. coli flora present in non-UTI women.
62073698|NCT01219595|ACTIVE_COMPARATOR|Part 2A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
62073699|NCT01219595|PLACEBO_COMPARATOR|Part 2B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
62073700|NCT01219595|ACTIVE_COMPARATOR|Part 3A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
62643808|NCT03620513|PLACEBO_COMPARATOR|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
62643809|NCT03620513|EXPERIMENTAL|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
62643810|NCT03620513|EXPERIMENTAL|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
62643811|NCT03620513|EXPERIMENTAL|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
62073701|NCT01219595|PLACEBO_COMPARATOR|Part 3B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
62073702|NCT02709642|NO_INTERVENTION|Control|Control Participants will complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight.
62073703|NCT02709642|EXPERIMENTAL|Deposit Contract|The deposit contract group will also complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight. In addition, the deposit contract group will be asked to make a deposit of at least $100 each 10-week period over the course of one year (50 weeks). Each week, they will recoup 1/10 of their 10-week deposit if they are within two pounds of their baseline weight or lower. If they are more than two pounds above their baseline weight, they will forfeit 1/10 of their 10-week deposit. The money they forfeited for that week will go into a collective pool to be divided up at the end of each 10-week period by all deposit contract participants who successfully maintained their weight loss at the end of the 10-week period.
62073704|NCT01388192||Receiving pancreaticoduodenectomy|
62278006|NCT05407259|EXPERIMENTAL|Moderate-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 72% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: \~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
62278007|NCT05407259|EXPERIMENTAL|High-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 78% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: \~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
62278008|NCT02843620|PLACEBO_COMPARATOR|Placebo|The placebo arm will take a pill each day containing only excipients
62278009|NCT02843620|EXPERIMENTAL|b-2Cool|The b-2Cool arm will take a pill each day containing 40 mg of b-2Cool and excipients
62643812|NCT04144192|EXPERIMENTAL|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
62073705|NCT03571984|EXPERIMENTAL|Moving on ABC Plus|Moving on ABC Plus is combination of two interventions. The culturally adapted CBT and Moving on ABC. CBT will be integrated with The Moving on After Breast Cancer (ABC), which has been developed by Dr Anneela Saleem who suffered from breast cancer. The integrated intervention will consist of 12 sessions (60-90 minutes). The first 8 sessions will be delivered weekly and the last four sessions will be delivered fortnightly
62073706|NCT03571984|NO_INTERVENTION|Routine Care|This will consist of routine assessment and management as usually conducted by oncology clinics and general practice. GP's will be informed about the psychiatric diagnosis.
62278010|NCT05044052|EXPERIMENTAL|Intervention Group - Viral prescription pad + emphasis|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. As part of the intervention, these physicians will also receive additional emphasis on the viral prescription pad by 1) encouraging it in the dissemination email of the MyPractice feedback report, and (2) mailing a paper version of the viral prescription pad with instructions on embedding the viral prescription pad into the recipient's EMR.
62278011|NCT05044052|NO_INTERVENTION|Control group|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. This group will not receive any additional emphasis on the viral prescription pad and will not receive a paper copy in the mail.
62643813|NCT04144192|EXPERIMENTAL|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.
62643814|NCT03602105|ACTIVE_COMPARATOR|Intervention group|Exercise interventions for 6-12 weeks. Adherence is monitored with day journals
62643815|NCT03602105|NO_INTERVENTION|Control group|Care as usual
62643816|NCT00607243|EXPERIMENTAL|Conventional dose group|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
62073707|NCT05404867|OTHER|ALS patients|Patients with ALS
62073708|NCT05404867|OTHER|Healthy controls|Age-matched healthy controls
62643817|NCT00607243|EXPERIMENTAL|Low dose group|Diluted CJ-50300 2.5 x 10000pfu/dose vaccination
62643818|NCT04858152|EXPERIMENTAL|Experimental Arm: Transplantation of hair follicles to non-hair bearing areas affected by vitiligo|Punch biopsies will be used to extract hair follicles from area on participant's body that is not affected by vitiligo and has hair growth. The follicles will then be transplanted into an area of the body affected by vitiligo that is hairless.
62278012|NCT02282683|EXPERIMENTAL|Prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months.
62278013|NCT02282683|NO_INTERVENTION|Control|Maximum tolerated guideline-directed medical therapy
62278014|NCT05122637|EXPERIMENTAL|Treatment Arm|RapidPulseTM Aspiration System with commercially available Medtronic React 71 aspiration catheter and commercially available aspiration pump as frontline approach thrombectomy technique.
62278015|NCT05122637|OTHER|Control Arm|Treatment with commercially available aspiration catheter with commercially available aspiration pump as frontline approach thrombectomy technique.
62278016|NCT03604445|EXPERIMENTAL|BI 905677 0.05 mg/kg|0.05 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278017|NCT03604445|EXPERIMENTAL|BI 905677 0.1 mg/kg|0.1 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62643819|NCT03041441|EXPERIMENTAL|MRICP method|MRI sequences have been developed that may be able to estimate ICP in a non-invasive fashion.6-10 The MRI-based method for measurement of ICP (MRICP method) is based on basic principles of the cranio-spinal CSF physiology: The mono-exponential relationship between intracranial volume and pressure leads to a linear relationship between elastance (i.e., the derivative of pressure with respect to volume) and pressure.
62643820|NCT01748370|EXPERIMENTAL|Vitamin D hypogonadal|Vitamin D supplementation in hypogonadal men
62643821|NCT01748370|EXPERIMENTAL|Vitamin D eugonadal|Vitamin D supplementation in eugonadal men
62643822|NCT01748370|PLACEBO_COMPARATOR|Placebo hypogonadal|Vitamin D supplementation in hypogonadal men
62643823|NCT01748370|PLACEBO_COMPARATOR|Placebo eugonadal|Vitamin D supplementation in eugonadal men
62643824|NCT00983372|ACTIVE_COMPARATOR|Colchicine alone|-colchicine baseline pharmacokinetics
62643825|NCT00983372|EXPERIMENTAL|Colchicine with steady-state Diltiazem|-colchicine pharmacokinetics in presence of steady-state diltiazem
62278018|NCT03604445|EXPERIMENTAL|BI 905677 0.2 mg/kg|0.2 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278019|NCT03604445|EXPERIMENTAL|BI 905677 0.4 mg/kg|0.4 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278020|NCT03604445|EXPERIMENTAL|BI 905677 0.8 mg/kg|0.8 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278021|NCT03604445|EXPERIMENTAL|BI 905677 1.6 mg/kg|1.6 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278022|NCT03604445|EXPERIMENTAL|BI 905677 2.4 mg/kg|2.4 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278023|NCT03604445|EXPERIMENTAL|BI 905677 2.8 mg/kg|2.8 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278024|NCT03604445|EXPERIMENTAL|BI 905677 3.6 mg/kg|3.6 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
62278025|NCT06528275||Group 1 - control|Pregant women included in Nutri Pou Ti Moun 1 project who did not benefit from the health promotion intervention
62278026|NCT06528275||Group 2 - intervention|Pregant women included in Nutri Pou Ti Moun 1 project who benefited from the health promotion intervention
62278027|NCT04955561|EXPERIMENTAL|Randomised to begin with oxygen-supplementation at 10L/min during ESWT|Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
62278028|NCT04955561|EXPERIMENTAL|Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
62278029|NCT04955561|EXPERIMENTAL|Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
62278030|NCT02627495|EXPERIMENTAL|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
62278031|NCT06162208|NO_INTERVENTION|Home exercise group with information leaflet|These patients will be asked to do the exercises in the information leaflet themselves at home.
62278032|NCT06162208|ACTIVE_COMPARATOR|İnformation brochure+standard exercise program group based on telerehabilitation|Patients in this group will be followed up with telerehabilitation method accompanied by a physiotherapist for 30 minutes 3 times a week for 6 weeks after discharge.
62278033|NCT06162208|ACTIVE_COMPARATOR|İnformation brochure+standard exercise program+action observation therapy group.|Patients in this group will be followed up with telerehabilitation method accompanied by a physiotherapist for 30 minutes 3 times a week for 6 weeks after discharge. In addition, 15 minutes of movement observation therapy will be applied via video conferencing 3 days a week.
62278034|NCT02445586|EXPERIMENTAL|Pertuzumab in Combination with Trastuzumab and Docetaxel|Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62278035|NCT01459614|EXPERIMENTAL|GTX-C|"Each cycle is 21 days (2 weeks Tx + 1 week off). Xeloda given days 1-14, Gemcitabine, Taxotere, and Cisplatin given days 4 and 11.~For expansion cohort, each cycle is 28 days (2 weeks of Tx + 2 weeks off)"
62455739|NCT04955262|EXPERIMENTAL|Part 1 Initial Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214, 3 injections of 89Zr-Df-IAB22M2C, and 6 PET/CT scans. Starting with Cycle 2, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. Once the PET/CT imaging data from Part 1 have been reviewed, Part 2 will open for enrollment.
62643826|NCT03006562|EXPERIMENTAL|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
62643827|NCT03006562|NO_INTERVENTION|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
62278036|NCT04895150||Patients|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
62278037|NCT04895150||Healthy controls;|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
62278038|NCT05358379|EXPERIMENTAL|Phase 1 Dose Escalation|Phase 1 = CYC140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
62643828|NCT02662569|ACTIVE_COMPARATOR|Atorvastatin (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
62278039|NCT05358379|EXPERIMENTAL|Phase 2|Phase 2 = Recommended CYC140 phase 2 dose and schedule administered orally in 28-day cycles.
62278040|NCT05769179|EXPERIMENTAL|Massage group|Massage group will be applied classic massage+cervical stabilisation exercises
62278041|NCT05769179|EXPERIMENTAL|Connective tissue massage group|Connective tissue group will be applied connective tissue massage+cervical stabilisation exercises
62278042|NCT05769179|EXPERIMENTAL|Mobilization group|Mobilization group will be applied cervical mobilization techniques+cervical stabilisation exercises
62278043|NCT03166332|ACTIVE_COMPARATOR|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts.
62278044|NCT03166332|ACTIVE_COMPARATOR|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
62278045|NCT03166332|NO_INTERVENTION|No intervention|No intervention strategy
62278046|NCT01699087|EXPERIMENTAL|PRK ALLEGRETTO|Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
62278047|NCT05103345|OTHER|Cohort|"SGN1 will be injected into the target lesion intratumorally. According to the dose levels, the administered dose will be 0.5×108 CFU, 1×108 CFU, 2×108 CFU, 4×108 CFU, 6×108 CFU (optional). The patient will be administered once every week for 3 consecutive weeks followed by 1-week rest in 28-day treatment cycles. The duration of administration is until isease complete response/inability to continue intratumoral administration or disease progression, or intolerable toxicity or death or voluntary withdrawal or end of study, whichever came first.~The standard 3+3 dose escalation algorithm will be applied to explore dose limiting toxicity (DLTs) in at least 4 sequential cohorts with 3- 6 patients and identify the maximally tolerated dose (MTD).~When the cohort is completed in Part 1, the Part 2 study could be started according to the SMC evaluation. Enrollment of 2-4 dose level expansions will be opened to determine the safety and efficacy of SGN1 in specific tumor types"
62278048|NCT04080895|EXPERIMENTAL|group A|
62278049|NCT04080895|EXPERIMENTAL|group B|
62278050|NCT03759665|EXPERIMENTAL|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~* Patients aged 6-12 years weighing 15 to \<25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~* Patients aged 6-12 years weighing 25 to \<35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~* Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
62643829|NCT02662569|ACTIVE_COMPARATOR|Atorvastatin (QM)|Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
62278051|NCT03759665|NO_INTERVENTION|Post-Treatment Washout|After the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
62643830|NCT02662569|EXPERIMENTAL|Evolocumab Q2W + Atorvastatin|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
62643831|NCT02662569|EXPERIMENTAL|Evolocumab QM + Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.
62643832|NCT05749016|EXPERIMENTAL|Study group|Eligible patients received inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen every three weeks for a maximum of 6 cycles, followed by surgery.
62643833|NCT03072550|EXPERIMENTAL|Multi-center open label|Thirty Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
62643834|NCT00004246|EXPERIMENTAL|RT + Fludarabine|Radiotherapy (RT) on Days 1-5 for 7 weeks + Fludarabine IV, 3-4 hours prior to daily RT, Days 1-5 of weeks 6 and 7 of RT
62643835|NCT01317563|ACTIVE_COMPARATOR|Antioxidant arm|Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)
62643836|NCT01317563|PLACEBO_COMPARATOR|Placebo arm|two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)
62643837|NCT01339312|EXPERIMENTAL|VRVg Vaccine Group 1|Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
62278052|NCT02642094|EXPERIMENTAL|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
62278053|NCT02429362||Pregnant Women & their stillborn infants|All English speaking female patients who are seen in the Regional One Health perinatal clinics and/or deliver at Regional One Health are the group of study's focus. Likewise, when a delivery results in a stillbirth, the stillborn baby will also be an additional group of our study's focus.
62278054|NCT04136431|EXPERIMENTAL|Intervention group|
62643838|NCT01339312|EXPERIMENTAL|VRVg Vaccine Group 2|Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
62643839|NCT01339312|ACTIVE_COMPARATOR|Verorab Vaccine Group 1|Participants aged 18 years or older will receive Verorab Vaccine
62278055|NCT04136431|PLACEBO_COMPARATOR|Control group|
62278056|NCT05892809|OTHER|With incubator cover group and without incubator cover|The incubator cover was covered while the neonate was lying in the incubator. Vital signs were measured at 0th, 15th, and 30th minutes.
62278057|NCT06205849|EXPERIMENTAL|IRE + CD40 Antibody|
62278058|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
62278059|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
62278060|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
62643840|NCT01339312|ACTIVE_COMPARATOR|Verorab Vaccine Group 2|Participants aged 10 to 17 years will receive Verorab Vaccine
62073709|NCT03953729|EXPERIMENTAL|Group 1:Ibuprofeno|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
62073710|NCT03953729|PLACEBO_COMPARATOR|Group 2: Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
62073711|NCT02438150|EXPERIMENTAL|Intervention|Will receive hospital fire video training
62073712|NCT02438150|PLACEBO_COMPARATOR|Control|Will receive non-fire video training
62278061|NCT03299803|EXPERIMENTAL|Men's Healing Pathways|Men with physical disabilities will receive a 15 session weekly peer implemented program
62278062|NCT03299803|NO_INTERVENTION|Control group|Telephone contact only
62643841|NCT01317147||Gastric bypass patients|
62643842|NCT02089347|EXPERIMENTAL|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
62643843|NCT02089347|ACTIVE_COMPARATOR|DT Group|Participants randomized to receive DT vaccine subcutaneously
62643844|NCT05251584|EXPERIMENTAL|Mupirocin and Gentamicin|2% mupirocin ointments apply at exit-site once daily after wound cleaning before recruit in the study then use 0.1% gentamicin cream apply at exit-site once daily after wound cleaning after entry to the study.
62643845|NCT02598453|EXPERIMENTAL|Ibandronate IV|Participants will receive ibandronate 3 mg IV once every 3 months
62073713|NCT01304082|PLACEBO_COMPARATOR|normal saline|
62073714|NCT01304082|ACTIVE_COMPARATOR|lidocaine|
62073715|NCT01304082|EXPERIMENTAL|alkalinized lidocaine|
62073716|NCT01717443||Women, renal disease, transplantation|Women with end-stage renal disease, whose eligibility for renal transplantation is assessed
62278063|NCT04170595|EXPERIMENTAL|GB221,2mg/kg|Coprelotamab Injection, 2 mg/kg, Single dose,
62278064|NCT04170595|EXPERIMENTAL|GB221,6mg/kg|Coprelotamab Injection, 6 mg/kg, Single dose,
62278065|NCT04170595|ACTIVE_COMPARATOR|Herceptin,6mg/kg|Trastuzumab Injection, 6 mg/kg, Single dose,
62278066|NCT04170595|EXPERIMENTAL|GB221,8mg/kg|Coprelotamab Injection, 8 mg/kg, Single dose,
62278067|NCT04170595|EXPERIMENTAL|GB221+ Capecitabine|Multiple dose groups
62278068|NCT04170595|ACTIVE_COMPARATOR|Herceptin+Capecitabine|Multiple dose groups
62278069|NCT02633683|EXPERIMENTAL|HORIZANT 600 mg|HORIZANT 600 mg once daily
62643846|NCT02598453|EXPERIMENTAL|Ibandronate Oral|Participants will receive ibandronate 150 milligrams (mg) tablet once monthly
62643847|NCT06443294|EXPERIMENTAL|Video Group|Participants randomly assigned to this group will be provided access to the video intervention series.
62643848|NCT06443294|NO_INTERVENTION|No-Video Group|
62643849|NCT00889629|EXPERIMENTAL|Doxercalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Active group receives doxercalciferol (Hectorol) 1mcgwith active titration based on intact PTH plus 25-OH Vitamin D3 (cholecalciferol) 400 IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol if target PTH value is not achieved by the predetermined midpoint.
62643850|NCT00889629|PLACEBO_COMPARATOR|Cholecalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol) plus 25-OH Vitamin D3 (cholecalciferol) 400IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol placebo if target PTH value is not achieved by the predetermined midpoint.
62643851|NCT03860740||High intensity physical exercise|Supervised Exercise Group: Customized and supervised exercise high intensity training program during 2-3 weeks previous surgery.
62643852|NCT03860740||Control|Supervised Stretching Group: a stretching and body balance classes will be developed to control the possible confounders and to control the exercise level of participants.
62643853|NCT01178294|EXPERIMENTAL|OBI-1|Initial dose: 200 U/kg - additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours)
62643854|NCT00286182|EXPERIMENTAL|Erythropoietin alpha|Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
62643855|NCT00286182|PLACEBO_COMPARATOR|Placebo|Placebo consists of saline injections.
62643856|NCT03025373||Patients - prolonged ICU stay (> 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
62643857|NCT03025373||Heart surgery patients (< 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
62643858|NCT01784874|EXPERIMENTAL|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg) Serum Free
62643859|NCT01784874|EXPERIMENTAL|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies
62643860|NCT00086671|EXPERIMENTAL|ABT-874 200 mg weekly|
62643861|NCT00086671|PLACEBO_COMPARATOR|Placebo|
62643862|NCT00086671|EXPERIMENTAL|ABT 874 QOW|
62643863|NCT02683629|EXPERIMENTAL|NTCELL|NTCELL Implantation
62643864|NCT02683629|SHAM_COMPARATOR|Sham Surgery|Sham Surgery
62643865|NCT02687854||Apixaban|Non-valvular atrial fibrillation patients who were initiated on apixaban for stroke prevention
62643866|NCT02687854||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on Vitamin K antagonist for stroke prevention
62643867|NCT03212716|EXPERIMENTAL|diltiazem|oseltamivir + diltiazem
62643868|NCT03212716|PLACEBO_COMPARATOR|oseltamivir + placebo|oseltamivir + placebo of diltiazem
62643869|NCT00230035|EXPERIMENTAL|1|high dose immunosuppressie therapy (HDIT) followed by HSCT (hemopoietic stem cell transplantation).
62643870|NCT00230035|ACTIVE_COMPARATOR|2|Currently available immunosuppressive/immunomodulatory therapy
62643871|NCT02516072|NO_INTERVENTION|Control|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR.
62643872|NCT02516072|EXPERIMENTAL|Remote Ischaemic preconditioning (RIPC)|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR. Additionally, patients will receive RIPC; a blood pressure cuff will be placed around one arm of the patient, it will then be inflated to a pressure of 250mmHg for 5 minutes. The cuff will then be deflated and the arm allowed to reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles immediately prior to the procedure.
62643873|NCT04367298||Chronoprevention in hospital falls|Implementation of a hospital preventive measures program: adjusted to the identification of temporal patterns of falls and relative risk factors of falls.
62643874|NCT04478617|EXPERIMENTAL|Metronidazole|
62643875|NCT04478617|NO_INTERVENTION|Control|
62643876|NCT00950573||hemodialysis|patients treated with conventional hemodialysis
62643877|NCT00950573||peritoneal dialysis|patients treated with peritoneal dialysis
62643878|NCT00950573||nocturnal hemodialysis|patients treated with frequent nocturnal hemodialysis
62643879|NCT00950573||kidney transplantation|patients treated with renal transplantation
62643880|NCT04895917|EXPERIMENTAL|Pomalidomide and daratumumab|
62643881|NCT05493566|EXPERIMENTAL|Treatment (pembrolizumab, aldesleukin)|Patients will be treated with pembrolizumab 200 mg IV once every 3 weeks in combination with IL-2 given at 5 million IU subcutaneously twice daily for 3 weeks (5 days on, 2 days off each week, first dose in clinic and subsequent doses at home). IL-2 will be given only for the three weeks, after which pembrolizumab will be continued as monotherapy at either 200 mg every 3 weeks or 400 mg every 6 weeks.
62643882|NCT06003036|EXPERIMENTAL|iTBS, then Sham|
62643883|NCT06003036|EXPERIMENTAL|Sham, then iTBS|
62643884|NCT02816294|EXPERIMENTAL|Housing Prescription|Participants in the intervention group will be referred to the Care Coordinator at Project Hope, who will conduct case management with the family to stabilize their housing. The Care Coordinator will refer families all families to benefit maximization services and complete Problem Solving Education. The Care Coordinator will also refer families as necessary to Medical-Legal Partnership Boston for pro-bono legal services and/or the Boston Housing Authority for priority on a subsidized housing waitlist.
62643885|NCT02816294|NO_INTERVENTION|Resource List|At present, for families facing housing insecurity, Children's HealthWatch offers paper resources with contact information for local social service agencies that may assist with housing stability.
62643886|NCT04547855|EXPERIMENTAL|experimental group|anlotinib combined with dose-dense temozolomide
62643887|NCT00439972|ACTIVE_COMPARATOR|Group 1|Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R)
62643888|NCT00439972|ACTIVE_COMPARATOR|Group 2|Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
62278070|NCT05039359|ACTIVE_COMPARATOR|FlecIH-103 (flecainide acetate inhalation solution)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1. Dosing will continue until conversion of AF to SR is observed for ≥1 minute or the full dose (120 mg eTLD) is administered, whichever occurs first.
62278071|NCT05039359|PLACEBO_COMPARATOR|Vehicle-matched inhalation solution (placebo)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1.
62643889|NCT00439972|ACTIVE_COMPARATOR|Group 3|Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R)
62643890|NCT00439972|ACTIVE_COMPARATOR|Group 4|Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R)
62278072|NCT02609360|ACTIVE_COMPARATOR|0.9% NaCl|Circuit priming will be performed with 0.9% NaCl solution
62278073|NCT02609360|ACTIVE_COMPARATOR|Ringer Lactate|Circuit priming will be performed with Ringer Lactated
62643891|NCT00439972|ACTIVE_COMPARATOR|Group 5|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
62643892|NCT00439972|ACTIVE_COMPARATOR|Group 6|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R)
62643893|NCT06339775|EXPERIMENTAL|Blinatumomab followed by donor lymphocyte infusion|"Patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg)."
62643894|NCT02328612|EXPERIMENTAL|First arm|250,000 cells/kg will be administered via intravenous infusion.
62643895|NCT02328612|EXPERIMENTAL|Second arm|1,000,000 cells/kg will be administered via intravenous infusion.
62643896|NCT02328612|EXPERIMENTAL|Third arm|4,000,000 cells/kg will be administered via intravenous infusion.
62643897|NCT02328612|PLACEBO_COMPARATOR|Fourth arm|Placebo (Ringer's lactate solution) volume according to subject's weight.
62643898|NCT03226444|EXPERIMENTAL|0.005% Lacripep|0.005% Lacripep ophthalmic solution
62643899|NCT03226444|EXPERIMENTAL|0.01% Lacripep|0.01% Lacripep ophthalmic solution
62643900|NCT03226444|PLACEBO_COMPARATOR|placebo|placebo solution
62643901|NCT01930591|ACTIVE_COMPARATOR|Clopidogrel arm|Clopidogrel 300 mg before PCI followed by 75 mg po OD
62643902|NCT01930591|EXPERIMENTAL|Ticagrelor arm|Ticagrelor 180 mg before PCI followed by 90 mg po BID
62643903|NCT05190627|EXPERIMENTAL|Loratadine treatment on rapamycin|Loratadine (oral administration, daily dose 10mg) in LAM patients that are treated with rapamycin
62643904|NCT05190627|PLACEBO_COMPARATOR|Placebo treatment on rapamycin|Placebo (oral administration, daily dose 10 mg) in LAM patients that are treated with rapamycin
62643905|NCT02659943|EXPERIMENTAL|LEVEL 1 - Participants Who Received 0.66x10^6 CAR T Cells Only|LEVEL 1 - participants who received - 0.66x10\^6 Chimeric Antigen Receptor (CAR) T cells only
62643906|NCT02659943|EXPERIMENTAL|LEVEL 1 Foll/by LEVEL 2-Participants Who Received - 0.66x10^6 CAR T Cells Foll/by 2x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 2 - participants who received - 0.66x10\^6 Chimeric Antigen Receptor (CAR) T cells followed by 2x10\^6 CAR T cells
62643907|NCT02659943|EXPERIMENTAL|LEVEL 1 Foll/by LEVEL 3 - Participants Who Received 0.66x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 3 - participant who received - 0.66x10\^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10\^6 CAR T cells
62643908|NCT02659943|EXPERIMENTAL|LEVEL 2 - Participants Who Received 2x10^6 CAR T Cells Only|LEVEL 2 - participants who received - 2x10\^6 Chimeric Antigen Receptor (CAR) T cells only
62278074|NCT02609360|EXPERIMENTAL|Balanced Solution|Circuit priming will be performed with a Balanced Solution created by mixing 0.9% NaCl, Sodium bicarbonate (8.4%) and injectable sterile water, in order to obtain a solution with constant sodium concentration (140 mEq/l) and SID equal to patient's bicarbonate level.
62278075|NCT03714490|EXPERIMENTAL|Experimental group|The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.
62278076|NCT03714490|ACTIVE_COMPARATOR|Control group|The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.
62278077|NCT00553163|ACTIVE_COMPARATOR|Gut-focussed hypnotherapy (GFH).|Gut-focussed hypnotherapy (GFH).
62278078|NCT00553163|SHAM_COMPARATOR|Educational sessions|Regular sessions to learn about UC from research nurse
62278079|NCT06233526|EXPERIMENTAL|Individualized treatment group|Treating the R/R AML patients based on the transcriptomic profile and in vitro drug sensitivity Test
62278080|NCT06436885|EXPERIMENTAL|Treatment group|Iruplinaakib tablets should be administered orally at a roughly fixed time each day. Once daily, on an empty stomach or with food, 60mg per dose for days 1 to 7, 180 mg per dose from day 8 if tolerated. Swallow the tablet whole, do not crush, divide or chew the tablet
62278081|NCT05679635|OTHER|Study participants|"In intubated patients during CPAP ventilation, a conventional tube adapter (CTA, Ventinova Medical B.V., Eindhoven, The Netherlands) will be connected to the tracheal tube for tracheal pressure measurement. Tracheal pressure measurements will be recorded directly from the respirator Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) three times, as well as the corresponding airway pressure values from the Evita Infinity V500 respirator (Dräger Medical, Lübeck, Germany).~Study related time points:~T1: 10 minutes after insertion of the conventional tube adapter during CPAP without ventilator support T2: 10 minutes after T1 during CPAP with activated automatic tube compensation (ATC) T3: 10 minutes after T2 during CPAP with assisted spontaneous breathing (ASB) of 4 cmH2O"
62278082|NCT05987111|ACTIVE_COMPARATOR|Mat Pilates|Mat Pilates Exercises
62278083|NCT05987111|EXPERIMENTAL|Reformer Pilates|Reformer Pilates Exercises
62643909|NCT02659943|EXPERIMENTAL|LEVEL 2 Followed by LEVEL 3-Participants Who Received 2x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 2 followed by LEVEL 3 - participants who received - 2x10\^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10\^6 CAR T cells
62643910|NCT02659943|EXPERIMENTAL|LEVEL 3 - Participants Who Received 6x10^6 CAR T Cells Only|LEVEL 3 - participants who received - 6x10\^6 Chimeric Antigen Receptor (CAR) T cells only
62643911|NCT02850094|EXPERIMENTAL|Financial Bonuses|For two weeks following enrollment, subjects are monitored via their FitBit accelerometer to monitor their pre-intervention physical activity levels. For a twenty-four week period following the observational period, participants are eligible for financial bonuses based on their increased activity. Participants enroll as teams and are eligible for additional financial bonuses based on their team's performance.
62643912|NCT03353376|EXPERIMENTAL|group care with empowerment model|4 group visits a year according to empowerment model in a tertiary diabetes clinic
62643913|NCT03353376|ACTIVE_COMPARATOR|individual usual care|individual visits according to disponibility in the diabetes clinic and needs of the patients
62643914|NCT01976000||Group A|the surgeons were able to view 3D reconstructions before and during surgery
62643915|NCT01976000||Group B|the surgeons were only able to view 3D reconstructions after the surgery
62278084|NCT01564927|EXPERIMENTAL|Electroacupuncture to right LI4 and LI11|
62278085|NCT01564927|SHAM_COMPARATOR|Electroacupuncture to knee caps|Electroacupuncture to knee caps
62278086|NCT01564927|PLACEBO_COMPARATOR|Sham electroacupuncture to LI4 & LI11|
62278087|NCT00004156|EXPERIMENTAL|Vaccine: MUC1-KLH vaccine/QS21|Patients receive glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, and 19 for a total of 5 vaccinations. Patients are followed every 3 months.
62278088|NCT05991856||radiofrequency ablation|Patients with aldosterone-producing adenoma undergoing ultrasound-guided radiofrequency ablation
62278089|NCT05991856||laparoscopic adrenalectomy|Patients with aldosterone-producing adenoma undergoing laparoscopic adrenalectomy
62073717|NCT03178084|EXPERIMENTAL|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
62073718|NCT03178084|ACTIVE_COMPARATOR|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
62073719|NCT03178084|EXPERIMENTAL|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
62073720|NCT01157741|NO_INTERVENTION|Standard Practice (H-C)|1) Hospital control group (Group H-C): children assigned to this group received the standard hospital-based, outpatient treatment package, which consisted of fortnightly follow-up for growth monitoring, health and nutrition education, and micronutrient supplementation.
62278090|NCT01615848|EXPERIMENTAL|mediterranean diet restricted calorie|1500 k/calories 47-51% carbohydrate 14-17% protein 33-36% fat: 7-7.6% saturated fat 22-30% monounsaturated \& polyunsaturated fat
62278091|NCT01615848|EXPERIMENTAL|high protein diet, restricted calorie|1500 k/calories 40 % carbohydrate 30% protein 30% fat
62278092|NCT05519345|EXPERIMENTAL|Operant Conditioning|Motor evoked responses will be elicited along with operant conditioning training for about 2 weeks
62278093|NCT05519345|EXPERIMENTAL|Control|Motor evoked responses will be elicited without operant conditioning training for about 2 weeks
62278094|NCT04428931||PD patients|Patients with Asymmetric Parkinson's disease
62073721|NCT01157741|EXPERIMENTAL|C-C|Community-based follow-up (Group C-C): the standard community-based follow-up package was identical to the one provided to the hospital-based control group, except that the follow-up visits took place at the nearest CNFU rather than the HNFU.
62073722|NCT01157741|EXPERIMENTAL|C-SF|Community-based follow-up plus supplementary food (Group C-SF): children assigned to this group received the same treatment package as those in Group C-C, except that supplementary food (SF) packets and preparation instructions were also provided at the time of each follow-up clinic visit for consumption at home in addition to the children's usual meals.
62073723|NCT01157741|EXPERIMENTAL|C-PS|Community-based follow-up plus psychosocial stimulation (Group C-PS): children assigned to this group received the same treatment package as those in Group C-C, except that they were also provided with psychosocial stimulation (PS).
62278095|NCT02788214||Advanced intestinal metaplasia|"H. pylori strains from patients with:~* Complete-type intestinal metaplasia with extension to corpus, or~* Incomplete-type intestinal metaplasia of any extent"
62278096|NCT02788214||Non-atrophic gastritis|H. pylori strains from patients with non-atrophic gastritis
62278097|NCT02788214||Gastric cancer|H. pylori strains from patients with gastric cancer
62278098|NCT03473561|EXPERIMENTAL|Racecadotril plus standard treatment oral rehydration solution|Racecadotril Infants Granules for Oral Suspension 10 mg (in addition to standard treatment i.e. oral rehydration solution) Racecadotril Children Granules for Oral Suspension 30 mg (in addition to standard treatment i.e. oral rehydration solution)
62073724|NCT01157741|EXPERIMENTAL|C-SF+PS|Community-based follow-up plus SF and PS (Group C-SF+PS): children assigned to this group received the same treatment package as those in the Group C-C, except that they were also provided with both SF and PS, as described above.
62278099|NCT02341378|EXPERIMENTAL|TissueGene-C (Low dose)|Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10\^6 cells
62278100|NCT02341378|EXPERIMENTAL|TissueGene-C (High dose)|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10\^7 cells
62278101|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
62278102|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level \>2 mmol/L (18mg/dL) despite adequate volume resuscitation.
62073725|NCT03741244|EXPERIMENTAL|Temozolomide and apatinib|"Patients have treated with postoperative concurrent chemoradiation. Then Temozolomide (150mg/m2/d d1-5 in the first cycle, followed by 200mg/m2/d d1-5 q28d) + apatinib (500mg/d QD).~After 6 cycles,apatinib single drug maintained until progress."
62073726|NCT03741244|ACTIVE_COMPARATOR|Temozolomide|Patients were treated with postoperative concurrent chemoradiation.Then Temozolomide alone chemotherapy 6 cycles(first cycle 150mg/m2/d d1-5, later 200mg/m2/d d1-5 q28d).
62073727|NCT00962585|PLACEBO_COMPARATOR|Placebo|Placebo
62073728|NCT00962585|EXPERIMENTAL|S-equol 10 mg BID|S-equol 20 mg total daily dose
62073729|NCT00962585|EXPERIMENTAL|S-equol 50 mg BID|S-equol 100 mg total daily dose
62073730|NCT00962585|EXPERIMENTAL|S-equol 150 mg BID|S-equol 300 mg total daily dose
62073731|NCT01163903|EXPERIMENTAL|Pantoprazole and doxorubicin|
62073732|NCT02801474|EXPERIMENTAL|direct reduction|Intervention: The posterior and lateral malleoli were accessed via a posterolateral approach with the patients in prone position. The fibular fracture was exposed and reduced anatomically in the first place. The posterior malleolus was then exposed between the fiexor halluces longus and peroneus longus interval. The posterior malleolar fragment was then reduced with reference to the typical metaphyseal-diaphyseal spike of the posterior malleolus. One-third tubular plate, reconstruction plate, or distal radius plate were applied spanning the fracture in a buttress mode. Cannulated screws could also be used.
62643916|NCT05882929|EXPERIMENTAL|Experiment 1: Watching Cartoons|Watching Cartoon Movies will be performed after the child comes to the service after the operation and prepares for the postoperative period (taking vital signs, putting on clothes, controlling bleeding, telling the feeding time, etc.). Interventions will be implemented for a total of 15 minutes. Physiological Parameters Follow-up Form and Wong-Baker Faces Pain Scale will be filled in before the interventions are applied, 10 minutes during the intervention and 5 minutes after the intervention is completed.
62073733|NCT02801474|EXPERIMENTAL|indirect reduction|Intervention: After open reduction and internal fixation of lateral and medial malleolar fractures, the posterior malleolus was then reduced through ligamentotaxis with the ankle in dorsiflexion. One or two 4.0 mm cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
62455740|NCT04955262|EXPERIMENTAL|Part 2 Expansion Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214 or nivolumab, 2 injections of 89Zr-Df-IAB22M2C, and 3 PET/CT scans. In Cycle 2 and beyond, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. During Cycle 2, patients will receive 1 injection of 89Zr-Df-IAB22M2C and 1 PET/CT scan.
62643917|NCT05882929|EXPERIMENTAL|Experiment 1: ball spin|ball squeezing will be applied after the child comes to the service after the operation and the postoperative period preparation is made (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.). Interventions will be implemented for a total of 15 minutes. Physiological Parameters Follow-up Form and Wong-Baker Faces Pain Scale will be filled in before the interventions are applied, 10 minutes during the intervention and 5 minutes after the intervention is completed.
62455741|NCT02822248|EXPERIMENTAL|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62073734|NCT01782963|EXPERIMENTAL|Treatment Arm|"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)~Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15"
62643918|NCT05882929|NO_INTERVENTION|Control|In the control group, the 10th and 20th minute physiological parameters and Wong-Baker Faces Pain Scale will be evaluated after the child comes to the service after the operation and is prepared for the postoperative period (taking vital signs, putting on clothes, controlling bleeding, telling the feeding time, etc.).
62643919|NCT02891473|EXPERIMENTAL|Mézières Method group|Sessions of exercises for the recovery of midline symmetry, diaphragmatic breathing exercises, stretching of the latissimus dorsi respecting the global elongation according to the Mézières Method.
62073735|NCT06380660|EXPERIMENTAL|ACE-86225106 tablet|ACE-86225106 tablet monotherapy
62643920|NCT02891473|ACTIVE_COMPARATOR|Home based exercise program group|Sessions of home based exercises performed by the patients at their domicile after a training session about the exercise program made by a physiotherapy. The exercises aimed at promoting trunk control in static and dynamic position according to the specific guidelines for Parkinson's disease and proprioceptive exercises for the recovery of balance. An illustrated exercises booklet was given to the patient.
62073736|NCT04611113|EXPERIMENTAL|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
62073737|NCT04611113|ACTIVE_COMPARATOR|Control nutritional support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
62073738|NCT05170308|OTHER|Treatment (CO2 fractional laser) arm|CO2 fractional laser will be used to treat dyspigmentation in lichen planus pigmentosus in one half along sagittal midline section in each subject.
62073739|NCT05170308|NO_INTERVENTION|No treatment (Control) arm|One half along sagittal midline section in each subject will not receive the CO2 fractional laser treatment.
62643921|NCT02355678|EXPERIMENTAL|IV Dex|dexamethasone 0.5 mg/kg IV with placebo pre-incision infiltration
62073740|NCT05582213|OTHER|classic group (CL group)|20 patients will be enrolled to induction with sevofloran as inhalational anesthetics
62073741|NCT05582213|OTHER|Group ketamine:|This group includes (20) patients will receive ketamine 2 mg/kg intravenous for induction of sedation and unconsciousness
62073742|NCT03213496|EXPERIMENTAL|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
62073743|NCT03213496|OTHER|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
62073744|NCT02049060|EXPERIMENTAL|Tivantinib+carboplatino+pemetrexed|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
62073745|NCT05100836||Single arm all comers supported with Impella 5.5|
62073746|NCT01265095||VRE bacteremia|VRE bacteremia patients
62455742|NCT00534703|ACTIVE_COMPARATOR|AAV1/SERCA2A|SERCA gene therapy
62455743|NCT00534703|PLACEBO_COMPARATOR|Placebo|Placebo (saline solution)
62643922|NCT02355678|EXPERIMENTAL|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 1.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000, 3 ml of bupivacaine 0.5%, 0.5 ml fentanyl 50 µg ml-1, and 0.3 ml clonidine 150 µg ml-1
62643923|NCT04549194|EXPERIMENTAL|Tyrosine - External Operation|1-month L-Tyrosine treatment following 4-month external operation
62643924|NCT04549194|EXPERIMENTAL|Placebo - External Operation|1-month Placebo treatment following 4-month external operation
62643925|NCT04549194|EXPERIMENTAL|Tyrosine - Rear Base|1-month L-Tyrosine treatment following 4 months at rear base
62643926|NCT04549194|EXPERIMENTAL|Placebo - Rear Base|1-month Placebo treatment following 4 months at rear base
62643927|NCT02607813|EXPERIMENTAL|Dose escalation LXH254|
62643928|NCT02607813|EXPERIMENTAL|Dose expansion LXH254: Group 1|
62643929|NCT02607813|EXPERIMENTAL|Dose expansion LXH254: Group 2|
62643930|NCT02607813|EXPERIMENTAL|Dose expansion LXH254: Group 3|
62643931|NCT02607813|EXPERIMENTAL|Dose expansion: LXH254 + PDR001|
62643932|NCT02607813|EXPERIMENTAL|Dose escalation LXH254 + PDR001|
62643933|NCT00746005|EXPERIMENTAL|1|3 g EPA-DHA
62643934|NCT00746005|PLACEBO_COMPARATOR|2|Placebo: sunflower oil
62643935|NCT04624763|EXPERIMENTAL|LBBP group|In this arm, a left bundle branch pacing(LBBP) lead is attempted to be placed.
62455744|NCT01022619||Premature labor|Women at the third trimester of pregnancy with premature contractions and cervical dilation of effacement
62643936|NCT04624763|ACTIVE_COMPARATOR|RVP group|In this arm, a right ventricular pacing(RVP) lead are placed.
62643937|NCT01358474||PD Subjects|Subjects diagnosed with Parkinson's disease (PD)
62643938|NCT01358474||At-risk for PD|Subjects at-risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations)
62643939|NCT01358474||Healthy Controls|Healthy volunteers
62073747|NCT05849532|EXPERIMENTAL|Home-training with functional electrical stimulation|This study employs a single group pre-post design to determine the feasibility, safety and efficacy of a 12-week of home-based combined FES and task-specific training program. Also, this study will test the effect of the same intervention on gait, mobility and balance in adults with chronic stroke.
62073748|NCT04221061|OTHER|Non-surgical candidates|In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).
62455745|NCT01022619||Control|Women at the third trimester of pregnancy with uncomplicated pregnancy
62455746|NCT01022619||Pre-eclampsia|Women at the third trimester with pre-eclampsia
62455747|NCT01022619||Gestational diabets|Women at the third trimester of pregnancy with gestational diabetes requiring insulin
62455748|NCT06376786||iTTP patients|iTTP patients will be treated and followed-up as per standard clinical practice.
62455749|NCT01056796|EXPERIMENTAL|CAR™ 27|Any patient with a diagnosis of colorectal cancer that has been previously radiated to the pelvic area (6-8 weeks prior to surgery) and that is electively scheduled for an open or laparoscopic total mesorectal excision (TME) and low anterior resection surgery (\< 10cm from the anal verge) which requires the creation of an anastomosis, will be offered participation in this study.
62455750|NCT02524223|OTHER|Population of couples candidate for MAP program|MAP = medically assisted procreation
62455751|NCT02524990|EXPERIMENTAL|Home-based follow-up with SQPT|For the intervention, a semiquantitative pregnancy test (SQPT) will be performed at the health center before the participants take mifepristone, and again two weeks later by the participants, at home. Study staff will call the participants at two weeks to follow-up with the participants.
62455752|NCT05387902||ECMO|Patients receiving hemodynamic support with ECMO during high-risk PCI
62455753|NCT05387902||ECMO Standby|Patients with ECMO standby during high-risk PCI
62455754|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
62455755|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
62455756|NCT02518581|OTHER|Doubly labelled water|
62455757|NCT06396468|EXPERIMENTAL|sevoflurane group|Anesthesia was maintained with sevoflurane (1-1.2 MAC) with oxygen /air 1:1
62455758|NCT06396468|EXPERIMENTAL|Propofol group|Anesthesia was maintained continuous infusion of 100-400 mcg/kg /min of propofol and fentanyl 0.1 ug / kg/ min with oxygen /air 1:1
62455759|NCT00981357|EXPERIMENTAL|PF-04457845 followed by placebo|
62643940|NCT02139540|OTHER|N2O/Placebo|First session: Nitrous oxide Second session: placebo
62643941|NCT02139540|OTHER|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
62643942|NCT00354315|EXPERIMENTAL|1|Immediate Continuous medical education (CME)
62643943|NCT00354315|NO_INTERVENTION|2|control, 6 months delay CME intervention
62643944|NCT00902655|EXPERIMENTAL|Desmopressin|
62643945|NCT01692119|EXPERIMENTAL|regular, pharmacy-based intervention|providing medication in weekly dosing aids and regular contacts with the local pharmacy
62643946|NCT01692119|NO_INTERVENTION|usual care|usual care
62455760|NCT00981357|EXPERIMENTAL|Placebo followed by PF-04457845|
62455761|NCT00981357|ACTIVE_COMPARATOR|Naproxen followed by placebo|
62455762|NCT00981357|ACTIVE_COMPARATOR|Placebo followed by Naproxen|
62455763|NCT03372538||multidisciplinary team group|500 patients of placenta accreta managed by obstetricans and urologists
62455764|NCT03372538||obstetricians only group|500 patients of placenta accreta managed by obstetricans only
62455765|NCT01811043|EXPERIMENTAL|Guided Meditation|Guided meditation is played via headphones during biopsy
62455766|NCT01811043|ACTIVE_COMPARATOR|Music|Music is played via headphones during biopsy
62455767|NCT01811043|PLACEBO_COMPARATOR|Supportive Dialogue|Supportive dialogue is provided during biopsy by the radiologist performing the procedure
62455768|NCT05886426||Reference study|Healthy participants (bilateral scans so 60 wrists) will be needed for the volunteer study to determine the visibility of the wrist joints (DRUJ, CMC-1 and MCP-1); acquire normal values and investigate the left right differences between the wrists
62643947|NCT01165307|ACTIVE_COMPARATOR|Medical Therapy|Subjects will be prescribed monthly packets of Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills. Subjects who are unable to tolerate oral contraceptive pills or are unwilling to take oral contraceptive pills will be prescribed naproxen sodium pills. The latter will be administered as follows; 500mg with onset of menses, then 250mg three times daily for the duration of the menses (or maximum of five days).
62278103|NCT06501092|NO_INTERVENTION|Current/No Device|Baseline outcome measurements will be performed with subject's existing partial hand prosthetic treatment, as deemed standard-of-care by the patient's prosthetist. Device types include, but are not limited to, no prosthesis, passive prosthesis, passive positional prosthesis, body-powered prosthesis, myoelectric prosthesis, or other assistive device.
62278104|NCT06501092|EXPERIMENTAL|Point Mini|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, \~30 days post-fitting, and \~60 days post-fitting.
62278105|NCT02793232|EXPERIMENTAL|Single Ascending Dose Crossover|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
62278106|NCT02793232|EXPERIMENTAL|Multiple Ascending Dose|Multiple dose administration to Healthy Subjects in parallel cohorts (PF-06751979).
62278107|NCT02793232|EXPERIMENTAL|Multiple Dose Elderly|Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
62278108|NCT03906500|EXPERIMENTAL|Intervention|"The intervention consist of three main components.~School environmental component~The component targeting the high school environment consisted of two separate elements:~* Revision of school alcohol policy~* Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student components~The Student components consisted of three main elements:~* Web-based education for the student committees organizing events where alcohol is sold and the student introduction committee~* Pocket movie campaign~* Social norms campaign~Parent components~The parent component consisted of three separate elements:~* Parent Information Meeting~* Parent Information Folder~* Parent Information Website"
62455769|NCT05886426||Reliability study|Healthy participants (20 wrists) that underwent a 4DCT scan for the volunteer study will be needed to undergo a second unilateral scan to investigate the intra-patient test-retest reliability of the protocol
62073749|NCT04221061|OTHER|Surgical candidates|In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.
62278109|NCT03906500|NO_INTERVENTION|control group|Control high schools was asked to continue business as usual and promised to receive the intervention in the school year starting in 2020
62278110|NCT01407549|EXPERIMENTAL|Intervention group|The intervention group will participate in the Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention.
62455770|NCT05886426||DRUJ instability group|Patients with chronic unilateral wrist pain, in this study suspect for DRUJ instability, will be studied to evaluate the effect of TFCC injury on the wrist kinematics and evaluate the use of 4DCT for the diagnosis of TFCC injury
62455771|NCT00698399||1|Live Donor
62455772|NCT00698399||2|Cadaveric Donor
62455773|NCT01433666|EXPERIMENTAL|roflumilast 100ug|
62455774|NCT01433666|EXPERIMENTAL|roflumilast 300ug|
62455775|NCT01433666|EXPERIMENTAL|roflumilast1000ug|
62073750|NCT02089815|EXPERIMENTAL|Home based exercise|simple designed home based exercise program
62455776|NCT01433666|PLACEBO_COMPARATOR|placebo|
62455777|NCT06545201|EXPERIMENTAL|RE001T cell adoptive immunotherapy|3+3 dose increasing design was adopted, and the dose increasing scheme was as follows (deviation 30%): low dose group: 4×109, middle dose group: 8×109, and high dose group: 1.6×1010. If the subjects in the lower dose group continue to benefit clinically after the first T cell infusion treatment, the second T cell infusion treatment can be carried out after the researcher's suggestion and the sponsor's consent. The second infusion can be carried out within 6 months of the disease progression, and the interval between the last infusion and the last infusion is at least 8 weeks.
62455778|NCT01447563|EXPERIMENTAL|Clopidogrel tablets 75mg|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
62455779|NCT01447563|EXPERIMENTAL|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
62455780|NCT05150964|EXPERIMENTAL|Experimental|One group will be fit with commercially available hearing aids that will have different program settings
62455781|NCT01241968|ACTIVE_COMPARATOR|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
62643948|NCT01165307|ACTIVE_COMPARATOR|Radiofrequency Endometrial Ablation|Subjects will undergo NovaSure® radiofrequency endometrial ablation within 4 weeks of randomization. The procedure will occur at any time during the menstrual cycle, without endometrial pre-treatment. Endometrial thinning will be carried out using suction curettage in 50% of the cases included in the ablation group. Random assignment for this treatment will be included in the overall randomization plan.
62455782|NCT01241968|PLACEBO_COMPARATOR|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
62455783|NCT00788125|EXPERIMENTAL|Dasatinib with Ifosfamide, Carboplatin, Etoposide|
62455784|NCT03732170|EXPERIMENTAL|TotalFill® Bioceramic sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
62455785|NCT03732170|ACTIVE_COMPARATOR|AH plus® sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
62455786|NCT06195943|OTHER|Application Useage Arm|Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
62455787|NCT02426970||Lumbar spine pain inpatients|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and Montpellier University Hospitals.
62455788|NCT05258864|EXPERIMENTAL|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
62455789|NCT05258864|NO_INTERVENTION|Control|No Intervention Control
62455790|NCT04529109|EXPERIMENTAL|Test/Control|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Test/Control).
62455791|NCT04529109|EXPERIMENTAL|Control/Test|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Control/Test).
62455792|NCT00094302|PLACEBO_COMPARATOR|Placebo|Placebo of spironolactone
62455793|NCT00094302|EXPERIMENTAL|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
62455794|NCT03141203|EXPERIMENTAL|Dose Level 1|"8mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
62455795|NCT03141203|EXPERIMENTAL|Dose Level 2 (starting dose)|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
62455796|NCT03141203|EXPERIMENTAL|Dose Level 3|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
62455797|NCT03141203|EXPERIMENTAL|Dose Level 4|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
62455798|NCT03141203|EXPERIMENTAL|Dose Level 5|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
62455799|NCT03141203|EXPERIMENTAL|Dose Level 6|"14mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
62455800|NCT03247556|PLACEBO_COMPARATOR|Placebo|Placebo, qd, oral capsule
62455801|NCT03247556|EXPERIMENTAL|400mg SPN-812|400mg SPN-812, qd, oral capsule
62455802|NCT03247556|EXPERIMENTAL|600mg SPN-812|600mg SPN-812, qd, oral capsule
62455803|NCT05813028|EXPERIMENTAL|experimental group|"As an intervention, the mobile application called KRK-İnHED will be installed on the patients' phones. Patients in the experimental group will be interviewed the day before chemotherapy starts.~Personal Information Form, Multidimensional Perceived Social Support Scale, Quality of Life Scale, Beck Anxiety Scale will be filled in these patients.~Mobile application will be installed on the patient's phone by the researcher. The patient will be registered to the program by creating a user name.~The patient will be given 15-20 minutes of online training on the use of the mobile application.~The mobile application will be applied for a total of 12 weeks for 4 cycles (1 cycle/3 weeks) from the first day of chemotherapy treatment."
62455804|NCT05813028|NO_INTERVENTION|control group|Patients in the control group who will not have a mobile application installed on their phones will receive standard care.
62455805|NCT00796822|EXPERIMENTAL|1|Participants will receive pentoxifylline.
62455806|NCT00796822|PLACEBO_COMPARATOR|2|Participants will receive placebo.
62455807|NCT02397733|ACTIVE_COMPARATOR|Prophylactic cranial irradiation (PCI)|Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week
62455808|NCT02397733|EXPERIMENTAL|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week
62455809|NCT04260204|ACTIVE_COMPARATOR|Retrograde priming|retrograde autologous Blood Priming of Cardiopulmonary Bypass (RAP) in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
62455810|NCT04260204|ACTIVE_COMPARATOR|conventional priming|conventional cardiopulmonary priming in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
62455811|NCT00599209|EXPERIMENTAL|A - coded unit ID|Nursing home units provided the CDS intervention
62455812|NCT00599209|NO_INTERVENTION|B - coded unit ID|Nursing home units not provided the CDS intervention
62455813|NCT00584181||Lung transplant recipients|Lung transplant recpients enrolled as study subjects will undergo pulmonary function tests (spirometry and lung volume measurements) and initial HRCT of chest. These subjects will receive nebulized ipratropium followed by pulmonary function tests (spirometry and lung volume measurements) and repeat HRCT.
62643949|NCT03839134|EXPERIMENTAL|Pain of buccal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) buccal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
62278111|NCT01407549|NO_INTERVENTION|Control group|Participants in the control group will be assigned to a waiting list group. Participants will be told that they will be eligible for the intervention three months after the completion of a preliminary documentation of their symptoms and additional measures. Participants will complete the same battery of measures according to the same time table as participants in the intervention group.
62278112|NCT01997879|EXPERIMENTAL|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
62278113|NCT05894343|NO_INTERVENTION|Follow-up group|Participants who were randomized to immediate treatment in Study MGT-GAD-025 will transition directly to a long-term follow-up schedule to complete an additional 54 months of follow-up. All study participants are to be followed for a period of 60 months after vector administration.
62278114|NCT05894343|EXPERIMENTAL|Active treatment group|Participants who were randomized to sham surgery in Study MGT-GAD-025 will transition to an active treatment schedule including open-label bilateral treatment upon confirmation of continued eligibility. Upon completion of the treatment period, participants will enter the long-term follow-up schedule to complete a total of 60 months of follow-up.
62278115|NCT00005059|EXPERIMENTAL|carboplatin + paclitaxel|"Following completion of the Lubben Social Network Scale and Frailty Questionnaire, patients receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15.~Treatment repeats every 28 days for 2 courses. Patients with complete response receive 2 additional courses of therapy. Patients with partial response or stable disease may receive additional courses of therapy at investigator's discretion. Patients are followed every 3 months for 5 years or until disease progression."
62278116|NCT02743260|EXPERIMENTAL|pitavastatin (OATP1B1)|2 mg pitavastatin single dose
62278117|NCT02743260|EXPERIMENTAL|metformin (MATE1, MATE2K, OCT1, OCT2)|500 mg metformin single dose
62278118|NCT02743260|EXPERIMENTAL|digoxin (intestinal & renal P-glycoprotein)|0.5 mg digoxin single dose
62278119|NCT02743260|EXPERIMENTAL|adefovir dipivoxil (OAT1)|10 mg adefovir dipivoxil single dose
62278120|NCT02743260|EXPERIMENTAL|sitagliptin (OAT3)|100 mg sitagliptin single dose
62455814|NCT04607720|EXPERIMENTAL|the artificial-EUS-FNA group|the first two passes were made without the AI-assisted diagnosis system guidance during EUS-FNA, and then two passes were made under guidance from the AI-assisted diagnosis system
62455815|NCT04607720|EXPERIMENTAL|the AI-EUS-FNA group|the first two passes were made with the AI-assisted diagnosis system guidance and then another two manual passes without the AI-assisted diagnosis system guidance.
62455816|NCT04296903|EXPERIMENTAL|MID-C treatment|
62455817|NCT02422823|EXPERIMENTAL|injection of 1.8mL|injections of 1.8 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
62455818|NCT02422823|EXPERIMENTAL|injection of 3.6mL|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
62455819|NCT04611256|EXPERIMENTAL|MSC transfusion|
62455820|NCT04611256|ACTIVE_COMPARATOR|Control|
62455821|NCT01951846|EXPERIMENTAL|BIBF 1120|
62278121|NCT02743260|EXPERIMENTAL|cocktail (all substances)|combination of all individual drugs at respective single doses
62278122|NCT00971386|OTHER|Normal Healthy Subjects|Normal healthy subjects without history, signs-symptoms or diagnosis of heart failure
62278123|NCT00971386|OTHER|Chronic Ambulatory Heart Failure|Diagnosis of Chronic Heart Failure and currently on optimal medical therapy
62278124|NCT00971386|OTHER|Acute Heart Failure|Patients admitted to the hospital with acute congestive heart failure.
62455822|NCT05400876|EXPERIMENTAL|TQB2618 injction+penpulimab injection|TQB2618 injection with penpulimab injection, 21 days as a treatment cycle
62455823|NCT02162069|EXPERIMENTAL|transcatheter aortic valve replacement|Patients receive transcatheter aortic valve replacement.
62643950|NCT03839134|ACTIVE_COMPARATOR|Pain of buccal injection without DentalVibe®|Local anesthesia (LA) for buccal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
62643951|NCT03839134|EXPERIMENTAL|Pain of palatal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) palatal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
62643952|NCT03839134|ACTIVE_COMPARATOR|Pain of palatal injection without DentalVibe®|Local anesthesia (LA) for palatal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
62643953|NCT03839134|EXPERIMENTAL|Pain of block injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
62643954|NCT03839134|ACTIVE_COMPARATOR|Pain of block injection without DentalVibe®|Local anesthesia (LA) injection for inferior alveolar nerve (IAN) block using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
62643955|NCT00885118|EXPERIMENTAL|BI 10773 low dose quaque die (QD)|patient to receive a BI 10773 low dose tablet and a placebo tablet once daily
62073751|NCT02089815|ACTIVE_COMPARATOR|fall prevention education and counseling|fall prevention education \& counseling : home modification, vision screening, avoid sedative drugs use, proper shoes, report dizziness and fall to doctors
62073752|NCT04912141|PLACEBO_COMPARATOR|Conestat alfa 50 U/kg - Placebo|50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose
62073753|NCT04912141|ACTIVE_COMPARATOR|Conestat alfa 50 U/kg - Conestat alfa 50 U/kg|50 U/kg conestat alfa pre-angiography and 3 hours after the first dose
62073754|NCT04912141|ACTIVE_COMPARATOR|Conestat alfa 100 U/kg - Conestat alfa 50 U/kg|100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose
62073755|NCT04912141|PLACEBO_COMPARATOR|Placebo - Placebo|Placebo pre-angiography and 3 hours after the first dose
62073756|NCT04898842|EXPERIMENTAL|4 stage bowel obstruction diet|"All eligible participants will be assessed by a specialist dietitian and a diet history and symptoms will be recorded. Depending on the degree of sub-acute bowel obstruction, symptoms and type of diet being followed, patients will be given detailed instructions on which stage of the 4 stage diet to use. They will be followed up by telephone or face to face weekly for a 4 week period and shown how to alter their diet by moving up and down the stage of the diet if symptoms resolve or worsen. This is current standard of care.~Additional assessments will be carried out at the start and end of the study when participants will complete the Memorial Symptom Assessment Scale (MSAS) and EORTC QLQ-30 quality of life questionnaire. They will be asked to complete a daily diet diary, and an 'ease of use' questionnaire at the end of the 4 week period."
62073757|NCT05970835|ACTIVE_COMPARATOR|Control group|"Firstly, all patients will be evaluated using Physical Performance Test, Saint George's Respiratory Questionnaire , and Geriatric Pain Measure and the MiniMental Satet Exam to fulfill the eligibility criteria. After that participants will be randomly assigned using the software www.randomizer.org. to control or intervention group. Outcome assessors and data analysts will remain blinded to participant´s allocation group.~Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. They will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions."
62073758|NCT05970835|EXPERIMENTAL|Experimental group|Concerning patients from the intervention group will have an educational session given by one of the researchers, explaining how to use the HealthSmArt_ISAVE App. Then each patient will be given a unique code and password to log into the App and to start working with their smartphones. HealthSmArt_ISAVE App has three main components which are: evaluation (short, medium and long term); screening and intervention/rehabilitation.
62073759|NCT04343443|OTHER|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~* Clinical examination centered on congestion~* Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds~* Blood sample retrieved for biological assessment and biobanking~* Telephone interview"
62073760|NCT03402373|EXPERIMENTAL|Lycoderm|soft gel contains nutritional supplement
62073761|NCT03402373|PLACEBO_COMPARATOR|Placebo|Soft gel without active ingredients
62073762|NCT04175418|EXPERIMENTAL|Supervised Exercise Program Group|Participants in the supervised exercise group were included to a program that consisted of 16 individual physiotherapist supervised sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
62455824|NCT04817007|EXPERIMENTAL|Part 1A: BMS-986158 + Ruxolitinib|
62643956|NCT00885118|EXPERIMENTAL|BI 10773 mid-low dose QD|patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily
62455825|NCT04817007|EXPERIMENTAL|Part 1B: BMS-986158 + Fedratinib|
62455826|NCT04817007|EXPERIMENTAL|Part 2A1: BMS-986158 + Ruxolitinib|
62643957|NCT00885118|EXPERIMENTAL|BI 10773 mid-high dose QD|patient to receive two tablets of BI 10773 middle dose once daily
62643958|NCT00885118|EXPERIMENTAL|BI 10773 high dose QD|patient to receive a BI 10773 high dose tablet and a placebo tablet once daily
62643959|NCT00885118|PLACEBO_COMPARATOR|Placebo|patient to receive two tablets of placebo once daily
62643960|NCT04844320|ACTIVE_COMPARATOR|> 50 %EWL|Postoperative weight loss in first year \> 50 % EWL
62643961|NCT04844320|ACTIVE_COMPARATOR|50 - 25 % EWL|Postoperative weight loss in first year 25 - 50 % EWL
62643962|NCT04844320|ACTIVE_COMPARATOR|< 25 % EWL|Postoperative weight loss in first year \< 25 % EWL
62643963|NCT02866656|EXPERIMENTAL|control group|patients were given Conventional conservative treatment；
62643964|NCT02866656|EXPERIMENTAL|therapeutic ultrasound group|patients were given Conventional conservative treatment and low intensity ultrasonic treatment ；
62643965|NCT02675205|ACTIVE_COMPARATOR|clopidogrel-aspirin|clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.
62643966|NCT02675205|EXPERIMENTAL|ticagrelor-aspirin|Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery
62643967|NCT04133948|EXPERIMENTAL|A|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks)
62643968|NCT04133948|EXPERIMENTAL|B|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
62073763|NCT04175418|EXPERIMENTAL|Online Education Program Group|Participants in the online education group were included to a program that consisted of 16 online sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
62073764|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
62073765|NCT03109340|ACTIVE_COMPARATOR|Supervised treadmill group|a. Supervised treadmill group (Group I): The participants were instructed walking exercise at their target heart rate on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
62073766|NCT03109340|EXPERIMENTAL|ECE PEDO pedometer group|b. ECE PEDO® pedometer group (Group II): Participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from their target range of steps per minute.
62455827|NCT04817007|EXPERIMENTAL|Part 2B1: BMS-986158 + Fedratinib|
62643969|NCT04133948|EXPERIMENTAL|C|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
62073767|NCT03228017|OTHER|Psoriatic Disease Patients|Moderate to severe psoriatic disease
62073768|NCT03228017|NO_INTERVENTION|Healthy Control|
62455828|NCT04817007|EXPERIMENTAL|Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable|
62455829|NCT04817007|EXPERIMENTAL|Part 2A2 Add-On: BMS-986158 + Ruxolitinib|
62455830|NCT04817007|EXPERIMENTAL|Part 2A3: BMS-986158 + Ruxolitinib|
62073769|NCT00910637|EXPERIMENTAL|Arm 1|
62455831|NCT01890239|EXPERIMENTAL|Care Programme for the Last Days of Life|The Care Programme for the Last Days of Life will be implemented in the acute geriatric hospital wards randomized to the experimental group. Subsequently, older patients hospitalized in one of these experimental wards and for who the multidisciplinary team has decided that he or she has entered the dying phase, will benefit from this Care Programme.
62278125|NCT01548495||Responded to rHuEPO treatment|response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
62278126|NCT01548495||IR to rHuEPO treatment|No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
62278127|NCT01548495||Responded to high level rHuEPO|Responded to more than 80,000UI of rHuEPO treatment
62278128|NCT01548495||No rHuEPO treatment|
62278129|NCT03362775|OTHER|All subjects|EEG will be recorded in all subjects before (0.0 µL/mL) and during a target controlled infusion of propofol (0.5 µL/mL and 1.0 µL/mL).
62073770|NCT04484766||Patient after pre-eclampsia|Patients with pre-eclampsia who were treated at the University Hospital of Jena between 1999-2009.
62073771|NCT04484766||Patients after PETN treatment|Patients of the PETN pilot study, with PETN and patients who received PETN as an individual therapy trial
62073772|NCT03331029|OTHER|transesophageal echocardiography|Comparison of 3D Ultrasound with transesophageal echokardiography
62278130|NCT01227551|EXPERIMENTAL|Intratumoral injection|Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).
62278131|NCT06378086|EXPERIMENTAL|RHA® Redensity with new anesthetic agent|"Split-face injection of RHA® Redensity with new anesthetic agent in the perioral rhytids on one side of the mouth and RHA® Redensity with lidocaine in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
62278132|NCT06378086|EXPERIMENTAL|RHA® Redensity with lidocaine|"Split-face injection of RHA® Redensity with new anesthetic agent in the perioral rhytids on one side of the mouth and RHA® Redensity with lidocaine in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
62278133|NCT00477126|ACTIVE_COMPARATOR|1|start generic product cross over to reference product
62278134|NCT00477126|ACTIVE_COMPARATOR|2|start reference product cross over to generic product
62455832|NCT01890239|NO_INTERVENTION|Usual care|Care will be provided as usual, also for patients who have entered the dying phase.
62073773|NCT05230862|EXPERIMENTAL|Ladder Supplement|Ladder Supplement
62073774|NCT05230862|PLACEBO_COMPARATOR|Placebo|Placebo
62073775|NCT01130038||Children with DCD and Typical Development|
62073776|NCT01130038||Children with DCD|2 groups Children with DCD and Typical Development
62073777|NCT06421909|EXPERIMENTAL|mindfulness-based educational intervention group|
62278135|NCT01009476||001|
62278136|NCT01009476||002|
62278137|NCT03767608||Patients with type 2 diabetes mellitus|Patients diagnosed with T2DM according to the ADA
62278138|NCT03767608||Lean healthy controls|Lean healthy controls
62278139|NCT00091715|EXPERIMENTAL|1|62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
62278140|NCT00091715|PLACEBO_COMPARATOR|2|placebo for 6 months followed by an open label period
62278141|NCT03317769|EXPERIMENTAL|Experimental Treatment|Computerized cognitive training for 18 hours and structured social skills training for 9 hours over a 9 week period.
62073778|NCT06421909|NO_INTERVENTION|non-intervention group|
62278142|NCT03317769|ACTIVE_COMPARATOR|Active Comparator|Commercially-available computerized training for 18 hours and 9 hours of unstructured support group sessions over a 9 week period.
62643970|NCT04133948|EXPERIMENTAL|D|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + ipilimumab 80 mg (q3weeks) + domatinostat. Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200 mg, on days 1-14 (q3weeks). Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200 mg BID, days 1-14, q3weeks), a lower dosing scheme (100 mg OD, days 1-14, q3weeks), or the same dosing scheme (200 mg OD, days 1-14, q3weeks).
62643971|NCT00624793|EXPERIMENTAL|I. Standard|Standard - Formula Acup Protocol
62073779|NCT01175772|EXPERIMENTAL|Metronomic Chemoterapy|Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy
62073780|NCT02572817|EXPERIMENTAL|High-titer anti-influenza plasma|Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
62278143|NCT03331809|ACTIVE_COMPARATOR|Control|
62278144|NCT03331809|EXPERIMENTAL|Two-hand|
62278145|NCT05833672|EXPERIMENTAL|Locally Advanced Colon Cancers|Cycle 1 to Cycle 2 CapeOX + Terelizumab therapy(Day 1 through Day 21)
62278146|NCT04747925|ACTIVE_COMPARATOR|mulligan two leg rotation , core muscle strengthening exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
62278147|NCT04747925|EXPERIMENTAL|Mulligan bent leg raise technique core muscle strengthning exercises.|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
62455833|NCT01659307|ACTIVE_COMPARATOR|Aspirin 75mg|Aspirin 75mg once daily for 7 days. Administered by mouth.
62455834|NCT01659307|ACTIVE_COMPARATOR|Aspirin 1200mg|Asprin 600mg twice daily for 7 days. Administered by mouth.
62455835|NCT01659307|PLACEBO_COMPARATOR|Lactose powder|Placebo for 7 days. Administered by mouth.
62643972|NCT00624793|EXPERIMENTAL|2. Individualized|Individualized Acup protocol based on TCM diagnosis
62073781|NCT02572817|ACTIVE_COMPARATOR|Low-titer anti-influenza plasma|Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
62073782|NCT05498896|OTHER|Atezolizumab + Chemotherapy|Atezolizumab (1200mg IV Q3W x 1 cycle) followed by Paclitaxel (80 mg/m2 Q1W x 12) plus Atezolizumab 840 mg (Q2W x 6) followed by Doxorubicin (60 mg/m2) plus Cyclophosphamide (600 mg/m2 Q2W x 4) plus Atezolizumab (840 mg Q2W x 4)
62455836|NCT03384719|EXPERIMENTAL|35 g protein (30% milk + 70% rapeseed)|35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
62455837|NCT03384719|EXPERIMENTAL|35 g protein (54% milk + 46% rapeseed)|35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
62643973|NCT00624793|SHAM_COMPARATOR|3|(Control Group) Sham acupuncture
62643974|NCT06183138||Sick Neonatal Cohort|Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby\&#39;s medical history/physical exam, and the results of the genomic sequencing report.
62643975|NCT05002972|EXPERIMENTAL|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
62643976|NCT01884883|OTHER|Internal unicompartmental knee brace|
62643977|NCT03597737|EXPERIMENTAL|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
62643978|NCT00975416|PLACEBO_COMPARATOR|Methadone|Intranasal oxytocin administered in the context of cognitive behavioral therapy to methadone dependent outpatients
62643979|NCT00975416|PLACEBO_COMPARATOR|Outpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent outpatients
62643980|NCT00975416|PLACEBO_COMPARATOR|Inpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent inpatients
62643981|NCT01118052|EXPERIMENTAL|Treatment (EGEN-001)|Patients receive intraperitoneal EGEN-001 on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62643982|NCT04471961|EXPERIMENTAL|Children with cancer (Proband) with theirs parents|
62643983|NCT06427499|EXPERIMENTAL|Stannous Fluoride Toothpaste|
62643984|NCT06427499|ACTIVE_COMPARATOR|Colgate Cavity Protection Toothpaste|MFP Fluoride toothpaste
62073783|NCT05498896|EXPERIMENTAL|Atezolizumab + Chemotherapy + Ipatasertib|Atezolizumab (1200 mg, Q3W x 1 cycle), plus Ipatasertib (400 mg OD, days 1-14) followed by Paclitaxel (80 mg/m2 Q1W x 12) plus Atezolizumab (840 mg Q2W x 6), plus Ipatasertib, (400 mg OD, days 1-21 Q4W) followed by Doxorubicin (60 mg/m2) plus Cyclophosphamide (600 mg/m2 Q2W x 4) plus Atezolizumab (840 mg Q2W x 4).
62073784|NCT06475287|EXPERIMENTAL|HAIC combined with TQB2450 and Anlotinib|
62073785|NCT03122756|EXPERIMENTAL|Group (D)|will include 50 women who will receive intravenous dexamethasone.
62073786|NCT03122756|PLACEBO_COMPARATOR|Group (C)|will include 50 women who will receive intravenous normal saline (0.9 %).
62073787|NCT00910520|EXPERIMENTAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
62643985|NCT05589896|EXPERIMENTAL|Cohort 1|"Bone Marrow Transplant with Ossium HPC, Marrow~Pre-transplant myeloablative conditioning treatment with: Regimen A(MAC): Busulfan and Fludarabine \[OR\] Regimen B(MAC): Fludarabine and Total Body Irradiation~Post-Transplant treatment with Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, and Filgrastim"
62643986|NCT05589896|EXPERIMENTAL|Cohort 2|"\*Open to enrollment after DSMB review of Cohort 1 safety events through Day 56\*~Bone Marrow Transplant with Ossium HPC, Marrow~Pre-transplant conditioning treatment with:Regimen A(MAC): Busulfan and Fludarabine \[OR\] Regimen B(MAC): Fludarabine and Total Body Irradiation \[OR\] Regimen C(RIC): Fludarabine, Cyclophosphamide, and Total Body Irradiation~Post-Transplant treatment with Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, and Filgrastim"
62643987|NCT03464760|PLACEBO_COMPARATOR|Placebo|
62643988|NCT03464760|EXPERIMENTAL|Spirulina-Silicon supplementation|
62643989|NCT01340690|ACTIVE_COMPARATOR|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
62643990|NCT01340690|PLACEBO_COMPARATOR|placebo suspension|2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.
62643991|NCT04644029|EXPERIMENTAL|ISL QM|ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil) once daily. Following study-wide cessation of ISL administration, participants had the option to receive open-label FTC/TDF administered once daily.
62643992|NCT04644029|ACTIVE_COMPARATOR|FTC/TDF QD|FTC/TDF (TRUVADA™ or generic product emtricitabine/tenofovir disoproxil) administered once daily. Placebo to ISL (islatravir) administered once monthly. Following study-wide cessation of ISL administration, participants had the option to continue on open-label FTC/TDF. Placebo was no longer administered once open label treatment began.
62643993|NCT03566225|ACTIVE_COMPARATOR|Group A|Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction
62643994|NCT03566225|PLACEBO_COMPARATOR|Group B|Metformin in adose 1500 mg dialy will be administered + clomiphene citrate
62073788|NCT00910520|OTHER|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
62643995|NCT04897386|EXPERIMENTAL|Duvalizumab Combined With Neoadjuvant Chemotherapy|
62073789|NCT01584830|EXPERIMENTAL|Arm 1|
62073790|NCT01584830|PLACEBO_COMPARATOR|Arm 2|
62073791|NCT02342925|EXPERIMENTAL|RG1662 plus metformin|
62073792|NCT02342925|EXPERIMENTAL|metformin alone|
62073793|NCT04586777|EXPERIMENTAL|Anodal tvDCS|20 minutes of anodal tvDCS will be applied over the spine at 2.5mA.
62643996|NCT03290430|EXPERIMENTAL|Group Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 1-2 hours. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
62278148|NCT04647955|EXPERIMENTAL|Itopride|Oral dose of itopride 100 mg three times daily before the meal for 8 weeks
62073794|NCT04586777|EXPERIMENTAL|Cathodal tvDCS|20 minutes of cathodal tvDCS will be applied over the spine at 2.5mA.
62278149|NCT04647955|PLACEBO_COMPARATOR|Placebo|Oral dose of placebo three times daily before the meal for 8 weeks
62278150|NCT03413930|EXPERIMENTAL|TaTME|Patients with mid or low rectal cancer undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
62278151|NCT03413930|ACTIVE_COMPARATOR|LaTME|Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.
62643997|NCT03290430|EXPERIMENTAL|Individual Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 30-45 minutes. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
62073795|NCT04586777|SHAM_COMPARATOR|Sham tvDCS|20 minutes of sham tvDCS will be applied over the spine.
62073796|NCT04657523|EXPERIMENTAL|Investigational Ultrasound Imaging for Liver Fat Quantification|
62073797|NCT01383057|EXPERIMENTAL|Femtosecond Laser|
62278152|NCT02147483|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual as prescribed by clinician.
62278153|NCT02147483|EXPERIMENTAL|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention will be provided in eight in person sessions to prevent alcohol use.
62278154|NCT00105443|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
62455838|NCT03384719|ACTIVE_COMPARATOR|35 g protein (100% milk)|35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
62073798|NCT00904150||1 Menstrual migraine|Caucasian women with a current or past history of menstrual migraine (MM = pure menstrual migraine or menstrually-related migraine) attending the City of London Migraine Clinic
62073799|NCT00904150||2 No migraine|Caucasian women with no personal history of migraine
62073800|NCT01034579|OTHER|Rebif® Cohort|
62073801|NCT01034579|OTHER|Copaxone® Cohort|
62073802|NCT02813967|EXPERIMENTAL|chemoradiotherapy|Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
62073803|NCT02813967|ACTIVE_COMPARATOR|Radiotherapy 60 Gy|Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.
62073804|NCT00547911|EXPERIMENTAL|LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT|Each subject received 400 mg of droxidopa (LDOPS) with three separate interventions, i.e., LDOPS with 200 mg placebo, LDOPS with 200 mg carbidopa (CAR), and LDOPS with 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + CAR, followed by LDOPS + ENT.
62073805|NCT00547911|EXPERIMENTAL|LDOPS + Placebo; LDOPS + ENT; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.
62073806|NCT00547911|EXPERIMENTAL|LDOPS + CAR; LDOPS + Placebo; LDOPS + ENT|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + Placebo, and lastly LDOPS + ENT.
62073807|NCT00547911|EXPERIMENTAL|LDOPS + CAR; LDOPS + ENT; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + ENT, and lastly LDOPS + Placebo.
62073808|NCT00547911|EXPERIMENTAL|LDOPS + ENT; LDOPS + Placebo; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + Placebo, and lastly LDOPS + CAR.
62073809|NCT00547911|EXPERIMENTAL|LDOPS + ENT; LDOPS + CAR; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + CAR, and lastly LDOPS + Placebo.
62278155|NCT00105443|PLACEBO_COMPARATOR|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.
62278156|NCT05255328|EXPERIMENTAL|MELAS|Patients with MELAS syndrome will receive 12-18g/day of glutamine
62278157|NCT05452278|EXPERIMENTAL|Product sequence ABCD|Subjects use Product A on Day 1, Product B on Day 2, Product C on Day 3 and Product D on Day 4
62278158|NCT05452278|EXPERIMENTAL|Product sequence BCDA|Subjects use Product B on Day 1, Product C on Day 2, Product D on Day 3 and Product A on Day 4
62455839|NCT03400384|EXPERIMENTAL|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
62643998|NCT03290430|EXPERIMENTAL|Telephone Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 phone calls over 4 week, each lasting between 30-45 minutes. During these phone calls, participants will learn about how to quit smoking by changing habits. Sessions may be audio taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
62278159|NCT05452278|EXPERIMENTAL|Product sequence CDAB|Subjects use Product C on Day 1, Product D on Day 2, Product A on Day 3 and Product B on Day 4
62278160|NCT05452278|EXPERIMENTAL|Product sequence DABC|Subjects use Product D on Day 1, Product A on Day 2, Product B on Day 3 and Product C on Day 4
62455840|NCT03400384|NO_INTERVENTION|Control wait list|This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
62455841|NCT03348943|ACTIVE_COMPARATOR|Right hemiparesis, right upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
62455842|NCT03348943|EXPERIMENTAL|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
62278161|NCT06443905||PNS_ONLY|Only Xueshuantong injection(lyophilized) is used after surgery
62278162|NCT06443905||NON_INT|No thrombus prophylaxis after surgery
62278163|NCT06443905||LMWH_ONLY|Only low molecular weight heparin(LMWH) is used after surgery
62278164|NCT06443905||PNS+LMWH|Xueshuantong injection (lyophilized) and low molecular weight heparin are used simultaneously after surgery
62278165|NCT06443905||ICH_CTL|Conventional treatment
62455843|NCT03348943|ACTIVE_COMPARATOR|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
62278166|NCT06443905||ICH_PNS|Conventional treatment + Xueshuantong injection (lyophilized)
62278167|NCT06443905||AIS_CTL|Conventional treatment
62278168|NCT06443905||AIS_PNS|Conventional treatment + Xueshuantong injection(lyophilized)
62455844|NCT03348943|EXPERIMENTAL|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
62073810|NCT03338205|EXPERIMENTAL|Ketamine Treatment|"Everyone enrolled in study presenting in status asthmaticus to pediatric emergency department at Augusta University will receive a ketamine treatment, who include:~* Patients with a Clinical Asthma SCore (CAS) of greater than or equal to 10 on presentation and have received at least two (appropriately dosed based on weight) albuterol treatments prior to arrival~OR~* Patients with a CAS of ≥ greater than or equal to 10 that have not received treatment prior to arrival and after receiving 1 hour of treatment per the severe asthma pathway do not have a decrease in CAS of greater than 2~OR~* Patients with a CAS above \> 6 but less than \< 10 when as measured 1 hour after initiation of standard treatment per Augusta University's moderate asthma pathway"
62643999|NCT03290430|EXPERIMENTAL|Video Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 video calls over 4 week, each lasting between 30-45 minutes. During these video calls, participants will learn about how to quit smoking by changing habits. Sessions may be recorded.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
62644000|NCT03263455|EXPERIMENTAL|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
62644001|NCT03263455|SHAM_COMPARATOR|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
62073811|NCT04561011|EXPERIMENTAL|Persons with Mild Traumatic Brain Injury (mTBI)|
62073812|NCT01556815|ACTIVE_COMPARATOR|Group TACE|Patients who undergo TACE
62455845|NCT03003338|EXPERIMENTAL|OBV/PTV/r with DSV followed by placebo|OBV/PTV/r in combination with DSV for 12 weeks followed by 12 weeks matching placebo.
62644002|NCT05145985||Women over 60|Women aged over 60 years. Participants were allowed to participate in the study if they were able to walk independently and their health condition allowed them to perform the indicated fitness tests.
62455846|NCT03003338|EXPERIMENTAL|Placebo followed by OBV/PTV/r with DSV|Matching placebo for 12 weeks followed by 12 weeks OBV/PTV/r in combination with DSV.
62455847|NCT01972022|EXPERIMENTAL|EES SYNERGY™|coronary artery lesions treated with Bioabsorbable Polymer EES
62073813|NCT01556815|EXPERIMENTAL|Group Combination|Patients who are treated with sorafenib combined with TACE
62073814|NCT02550873|EXPERIMENTAL|PRM-151 10mg / kg|Dosing Every 4 Weeks
62073815|NCT02550873|PLACEBO_COMPARATOR|Placebo|Dosing Every 4 weeks
62073816|NCT01448421|EXPERIMENTAL|Keystone Heart Embolic Deflection Device|Protected Transcatheter Aortic Valve Replacement
62073817|NCT01133860|EXPERIMENTAL|eltrombopag|
62455848|NCT01972022|ACTIVE_COMPARATOR|ZES, RESOLUTE Integrity™|coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
62073818|NCT03229616|EXPERIMENTAL|BUCY+VP-16|For DLBCL patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/day on days -3 and -2.
62073819|NCT03229616|ACTIVE_COMPARATOR|BUCY|For DLBCL patients undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
62073820|NCT06390930|EXPERIMENTAL|AIH first|Participants in the first arm will undergo 2 sessions of AIH each separated by a 1-week washout period. 1 week later, participants will undergo 2 sessions of Sham AIH also separated by a 1-week washout period.
62073821|NCT06390930|EXPERIMENTAL|Sham First|Participants in the this arm will undergo 2 sessions of Sham AIH each separated by a 1-week washout period. 1 week later, participants will undergo 2 sessions of AIH also separated by a 1-week washout period.
62073822|NCT02783820|EXPERIMENTAL|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
62073823|NCT02783820|PLACEBO_COMPARATOR|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
62073824|NCT02783820|EXPERIMENTAL|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
62073825|NCT02783820|PLACEBO_COMPARATOR|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
62278169|NCT03650998|ACTIVE_COMPARATOR|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
62278170|NCT03650998|PLACEBO_COMPARATOR|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
62278171|NCT01612429|EXPERIMENTAL|Amino acid supplementation|Up to 500 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 6 weeks.
62278172|NCT00883246|OTHER|Atherectomy|All patients enrolled in this single-arm study were treated with directional atherectomy.
62278173|NCT04301141|EXPERIMENTAL|Virtual Reality Assisted Cognitive Behavioural Therapy|Between 8 to 20 individual in-person sessions of VR-assisted CBT will be delivered on a weekly basis by NHS therapists who are trained in delivering CBT to this patient group.
62278174|NCT02755272|EXPERIMENTAL|Pembrolizumab with Standard Chemotherapy|Pembrolizumab plus standard chemotherapy using carboplatin and gemcitabine.
62278175|NCT02755272|ACTIVE_COMPARATOR|Standard Chemotherapy Alone|Standard chemotherapy alone using carboplatin and gemcitabine.
62455849|NCT02385097|EXPERIMENTAL|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
62455850|NCT02385097|ACTIVE_COMPARATOR|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
62455851|NCT01824758|EXPERIMENTAL|brevibloc (esmolol)|Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
62455852|NCT01824758|ACTIVE_COMPARATOR|Aritmal (Lidocaine)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
62455853|NCT01824758|PLACEBO_COMPARATOR|Placebo (NaCl 0.9%, 5 ml)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
62455854|NCT03250533|EXPERIMENTAL|LED 620 nm group (G-LED 620)|The LED device in the red light spectrum, with a wavelength of 620 nm, will be applied over the full extent of the wound.
62455855|NCT03250533|EXPERIMENTAL|LED 940 nm group (G-LED 940)|The LED device in the infrared light spectrum, with a wavelength of 940 nm, will be applied over the full extent of the wound.
62073826|NCT02783820|EXPERIMENTAL|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
62278176|NCT05309863||Residential treatment|Patients administered for residential treatment of severe obesity will be included. Patients are treated according to standard of care in a multimodal program, focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support. Residential treatment is possible for a duration of maximum 1 year.
62278177|NCT05309863||Ambulatory treatment|Patients in specific pediatric obesity care pathways will be included. Patients are treated according to standard of care in a multimodal ambulatory program focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
62278178|NCT03302273|EXPERIMENTAL|Corneal Epithelial Stem Cell Transplant|The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.
62278179|NCT00983983|EXPERIMENTAL|High fat/high calorie|High fat/high calorie diet: Oxepa
62278180|NCT00983983|ACTIVE_COMPARATOR|High calorie|High calorie diet: Jevity 1.5
62455856|NCT03250533|EXPERIMENTAL|Fixed diphasic current group (G-DF)|The electrical stimulation will be carried out with the fixed diphasic current of the Dualpex 071 equipment, being applied throughout the extension of the wound.
62455857|NCT03250533|NO_INTERVENTION|Control group (G-C)|Volunteers from this group will not be submitted to treatment and will only be evaluated before, every 30 days, after the 12 week period and 30 days after the last evaluation. It is worth mentioning that, after the end of its participation, if the wound is not fully healed, the treatment will be offered with LED or diphasic current.
62455858|NCT01836419|EXPERIMENTAL|young adult group|young adult patients undergoing minor urologic surgery or lower extremity surgery
62455859|NCT01836419|ACTIVE_COMPARATOR|elderly group|elderly patients undergoing minor urologic surgery or lower extremity surgery
62073827|NCT02783820|PLACEBO_COMPARATOR|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
62073828|NCT03387514|EXPERIMENTAL|18F-DCFPyL whole body PET/CT scan|18F-DCFPyL whole body PET/CT scan at three time-points
62278181|NCT00983983|PLACEBO_COMPARATOR|Control|Control diet: Jevity 1.0
62278182|NCT00788346|EXPERIMENTAL|Computerized Alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
62278183|NCT00788346|EXPERIMENTAL|Alerts PLUS Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
62278184|NCT00788346|NO_INTERVENTION|Usual Care|Usual Care
62644003|NCT05696951|ACTIVE_COMPARATOR|The effectiveness of Tranexamic acid use of sleeve gastrectomy|In this study, it was determined which treatment package would be received by opening the closed envelopes of patients who had at least one point or more bleeding during the operation and had hemostasis with clips. In the intervention group, at the end of the surgery, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) saline.
62644004|NCT05696951|PLACEBO_COMPARATOR|Plasebo grup|The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
62644005|NCT05696951|ACTIVE_COMPARATOR|Sham grup|Patients with no bleeding to be treated were not enveloped and were excluded from the intervention or placebo group.
62644006|NCT03022006|OTHER|Dialysis patients with genotype 1 HCV infection|elbasvir/grazoprevir
62278185|NCT03333031|EXPERIMENTAL|HS-196|HS-196 will be administered intravenously as a single dose
62644007|NCT06241911|ACTIVE_COMPARATOR|tVNS|transcutaneous vagus nerve stimulation on the left auricle with 25-Hz frequency, with a 30-second on/off cycle.
62278186|NCT01396005|EXPERIMENTAL|Methadone + boceprevir|Participants receive standard methadone maintenance therapy (20-150 mg tablets, liquid, or disket, orally, once per day) on Days 1 through 8 + boceprevir (800 mg \[4 x 200 mg capsules\], orally, every 8 hours) on Days 2 through 7)
62644008|NCT06241911|SHAM_COMPARATOR|Sham tVNS|transcutaneous vagus nerve stimulation on the left earlobe with 25-Hz frequency, with the same stimulation parameters
62644009|NCT02672072||Control group|5-day specific training with dedicated scenario done by an ICU expert simulation team after the period of the study
62644010|NCT02672072||Simulation group|5-day specific training with dedicated scenario done by an ICU expert simulation team
62644011|NCT04773028||PATİENT GROUP(GROUP 1)|This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
62278187|NCT01396005|EXPERIMENTAL|Buprenorphine/naloxone + boceprevir|Participants receive standard buprenorphine/naloxone maintenance therapy (8/2-24/6 mg, tablets, sublingual, once per day) on Days 1 through 8 + boceprevir (800 mg \[4 x 200 mg capsules\], orally, every 8 hours) on Days 2 through 7
62278188|NCT02083380|EXPERIMENTAL|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
62644012|NCT04773028||CONTROL GROUP(GROUP 2)|This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
62644013|NCT01626066|EXPERIMENTAL|LUM015|Receive single dose of LUM015 through a vein in the arm the day prior to surgery
62073829|NCT04229680|EXPERIMENTAL|High Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 6,900 mg/d sodium.
62278189|NCT02083380|EXPERIMENTAL|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
62278190|NCT02083380|EXPERIMENTAL|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
62278191|NCT03143231|EXPERIMENTAL|Normal saline|Sodium Chloride 0.9% will be provided
62644014|NCT04795063|EXPERIMENTAL|Total Robotic Distal Gastrectomy|After exploration and randomization, patients received total robotic distal gastrectomy
62644015|NCT04795063|ACTIVE_COMPARATOR|Robotic-Assisted Distal Gastrectomy|After exploration and randomization, patients received robotic-assisted distal gastrectomy.
62278192|NCT03143231|EXPERIMENTAL|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
62278193|NCT03682172|EXPERIMENTAL|GLP-2 (10pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min
62278194|NCT03682172|EXPERIMENTAL|GLP-2 (1pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
62278195|NCT03682172|EXPERIMENTAL|Placebo|A single four hour intravenous infusion with saline water (placebo)
62455860|NCT04216069|EXPERIMENTAL|Total 12 regimen group|This group will use the following procedure: Colgate Ultrasoft toothbrush, Colgate Total 12 toothpaste and Plax Mouthwash.
62278196|NCT00876135|PLACEBO_COMPARATOR|Inhaled Bronchodilator|
62278197|NCT06537843|EXPERIMENTAL|VenCM|Venetoclax, Cytarabine, Metformin
62278198|NCT01623271|EXPERIMENTAL|CRPS I Pain Subjects|"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day"
62278199|NCT00693160|EXPERIMENTAL|Intrathecal Ketorolac|In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
62278200|NCT00693160|PLACEBO_COMPARATOR|Placebo intrathecal injection|In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
62073830|NCT04229680|PLACEBO_COMPARATOR|Recommended Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with placebo pills.
62278201|NCT05792085|ACTIVE_COMPARATOR|Telehealth Model|Patient enrolled in the GDMT Telehealth HF improvement program in which hone BP cuff is provided and medication is initiated and titrated over the phone
62278202|NCT05792085|NO_INTERVENTION|Control|Usual care, control group
62278203|NCT00119158|PLACEBO_COMPARATOR|placebo|Placebo cream
62278204|NCT00119158|ACTIVE_COMPARATOR|pimecrolimus cream|
62455861|NCT04216069|EXPERIMENTAL|Tooth brushing alone group|This group will use Colgate Ultrasoft toothbrush and Colgate Cavity Protection toothpaste.
62455862|NCT04953247||Methylprednisolone|"As there was no consensus on the use of steroids in the early stage of the COVID-19 pandemic, all steroid therapies were initiated at the time of admission at the discretion of attending physicians on the basis of clinical symptoms and CT images. According to our previous experience, intravenous methylprednisolone at a dose of 1.0-1.5 mg/kg every 12 h was initiated for 5 days or until oxygen saturation improved, followed by gradual tapering by 0.5 mg/kg every 3-5 days.~Standard care such as the use of antibiotics, ventilation, laboratory testing, and hemodynamic management were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China."
62455863|NCT04953247||Standard care|Standard care were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China.
62455864|NCT00438828|EXPERIMENTAL|Dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
62455865|NCT06093425|ACTIVE_COMPARATOR|TST001|TST001
62455866|NCT06093425|PLACEBO_COMPARATOR|Placebo|Placebo
62455867|NCT04325074|EXPERIMENTAL|Mental practice|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice group was n=12.
62455868|NCT04325074|EXPERIMENTAL|Mental practice + skill training|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice + skills training group was n=13.
62455869|NCT04325074|ACTIVE_COMPARATOR|Control group|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of control group was n=10.
62455870|NCT03238066|EXPERIMENTAL|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.~If HDR BT is chosen:~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT~If PDR BT is chosen:~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
62455871|NCT05249413||Endophthalmitis after primary cataract surgery.|Cases diagnosed as acute post-operative endophthalmitis after primary cataract surgery.
62644016|NCT04718922|EXPERIMENTAL|Experimental Arm|Mouthrinse with 100 ml 0.12% chlorhexidine for 1 min
62644017|NCT04718922|NO_INTERVENTION|Control Arm|No mouthrinse
62644018|NCT03835039||HIE|Infants with a diagnosis of HIE
62644019|NCT04168034|EXPERIMENTAL|Experimental: iParent2Parent Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 2 to 3 months
62644020|NCT04168034|ACTIVE_COMPARATOR|Waitlist Control Group|The control group will receive standard care but without the iParent2Parent program
62644021|NCT04768088|EXPERIMENTAL|One-week training of falling techniques on landing biomechanics associated with ACL loading|Participants will perform one-week training of single-leg falling techniques, a post-training assessment, a two-week break, and a retention assessment.
62644022|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
62644023|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
62073831|NCT02684903|NO_INTERVENTION|Services As Usual (SAU)|Participants receive all the usual services provided by Department of Human Services (DHS) Children's Services.
62455872|NCT03159156|NO_INTERVENTION|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
62455873|NCT03159156|EXPERIMENTAL|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
62455874|NCT03159156|EXPERIMENTAL|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
62644024|NCT01819714|EXPERIMENTAL|Study population|Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
62644025|NCT01100424|EXPERIMENTAL|Contact lens wearers|Contact lens wearers experienced three currently available contact lens/contact lens care combinations in randomized order: balafilcon A + Optifree RepleniSH, balafilcon A + ReNu MultiPlus, and balafilcon A + Unisol 4 saline.
62644026|NCT01100424|NO_INTERVENTION|Non-lens wearers|Non-lens wearers completed one study visit and served as the control group.
62644027|NCT04574089|EXPERIMENTAL|Baofukang Suppository 7 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days
62073832|NCT02684903|EXPERIMENTAL|Parent Child Interaction Therapy (PCIT)|"Participants receive Parent Child Interaction Therapy (PCIT). PCIT is designed to improve child functioning by interrupting patterns of harsh, coercive interaction and enhancing parents' warm, positive parenting, autonomy support, and competent child management skills.~."
62073833|NCT01941550|OTHER|Cabazitaxel chemotherapy|"Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.~For max. 6 times at all."
62644028|NCT04574089|EXPERIMENTAL|Baofukang Suppository 14 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days
62644029|NCT02816723|EXPERIMENTAL|Mindfulness|mindfulness/meditation/movement training
62644030|NCT02816723|ACTIVE_COMPARATOR|Brain Health|Brain Health education class
62644031|NCT01947348|EXPERIMENTAL|treatment with A3 SVF|These patients that have been treated. The control patients that have not been treated.
62644032|NCT04335435|EXPERIMENTAL|Oat Bran Consumption|Each subject consumed 120 g of oat bran (by dry weight) in a single dose, and samples (urine and fecal) were collected at different time points following the administration of oat bran.
62644033|NCT00766766|EXPERIMENTAL|1|Experimental Intervention Group
62644034|NCT00766766|NO_INTERVENTION|2|Standard Care Control
62073834|NCT01254565|EXPERIMENTAL|Etelcalcetide|Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
62278205|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
62278206|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
62455875|NCT03159156|EXPERIMENTAL|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
62455876|NCT06179238|OTHER|Patient with urinary catheter receiving patient education|The population of the study consisted of urinary catheterized patients treated in the clinics of a Training and Research Hospital. G\*Power power analysis was used to calculate the number of individuals constituting the sample. The effect size was set to 0.80, which is a high level according to Cohen for comparing the means of independent samples. To ensure that the statistical power of the study was above 95%, the sample size was set at a 5% significance level and the effect size was 0.5. (df = 68; t = 1.668) The sample size was calculated as 70 patients. The study is planned to be conducted with 35 patients for each of the two study groups.
62644035|NCT02649010|ACTIVE_COMPARATOR|Group A|Subjects will be randomly assigned to 2 groups (Group A \& Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
62644036|NCT02649010|ACTIVE_COMPARATOR|Group B|Subjects will be randomly assigned to 2 groups (Group A \& Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
62644037|NCT02414698|ACTIVE_COMPARATOR|Percutaneous Hydrodiscectomy|Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System
62073835|NCT01254565|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).
62073836|NCT04503538|OTHER|CAR-T cell therapy and Telemedicine|All outpatient CAR-T patients will require assessments for cytokine release syndrome and neurotoxicity three times daily (every 8 hours)
62278207|NCT06251232|ACTIVE_COMPARATOR|Active treatment|Oral prednisone
62278208|NCT06251232|PLACEBO_COMPARATOR|Placebo treatment|Placebo
62278209|NCT01411969||External nasal dilator, decongestion|
62644038|NCT02414698|ACTIVE_COMPARATOR|TESI|Transforaminal Epidural Steroid Injections
62644039|NCT06333639||orthopaedic surgery (goup 1 control)|30 individuals installed according to the usual procedures for an orthopaedic surgery
62073837|NCT04703803|EXPERIMENTAL|1% lidocaine injection|The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
62073838|NCT04703803|NO_INTERVENTION|Control Group|The control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors.
62278210|NCT04994106|EXPERIMENTAL|Cohort A1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
62278211|NCT04994106|EXPERIMENTAL|Cohort A2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
62278212|NCT04994106|EXPERIMENTAL|Cohort A3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
62644040|NCT06333639||orthopaedic surgery and fitted with a virtual reality headset (group 2 case)|30 individuals installed according to the usual procedures for an orthopaedic surgery and fitted with a virtual reality headset
62644041|NCT03342001|EXPERIMENTAL|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
62644042|NCT00998569|EXPERIMENTAL|Neurocognitive Enhancement|neurocongnitive enhancement
62278213|NCT04994106|EXPERIMENTAL|Cohort A4 Japanese descent: AZD5462 Dose 3|Randomized participants of Japanese descent will receive Dose 3 of AZD5462.
62278214|NCT04994106|EXPERIMENTAL|Cohort A5: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
62278215|NCT04994106|EXPERIMENTAL|Cohort A6 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
62644043|NCT00998569|OTHER|Wait List|no intervention
62644044|NCT06465472|EXPERIMENTAL|Stiripentol|Patients in this arms will receive 50 mg/kg/day oral stiripentol during the first 6 months double-blind placebo-controlled study period 1 (Day 1 through Month 6) then continue the same treatment for the following 6 months (period 2).
62073839|NCT05345288|EXPERIMENTAL|Intervention|Subjects randomized to the intervention group will complete prescribed cognitive training activities 3 times a week for 20-30 minutes each time for 6 weeks. Subjects randomized to the control group will complete computerized control activities that are not cognitive training on BrainHQ 3 times a week for 20-30 minutes each time for 6 weeks.
62278216|NCT04994106|EXPERIMENTAL|Cohort A7: AZD5462 Dose 5|Randomized healthy participants will receive Dose 5 of AZD5462.
62073840|NCT05345288|ACTIVE_COMPARATOR|Control|Subjects randomized to the control group will complete computerized control activities that are not cognitive training on BrainHQ 3 times a week for 20-30 minutes each time for 6 weeks.
62278217|NCT04994106|EXPERIMENTAL|Cohort A8 Japanese descent: AZD5462 Dose 5|Randomized participants of Japanese descent will receive Dose 5 of AZD5462.
62278218|NCT04994106|PLACEBO_COMPARATOR|Part A: Placebo (Healthy Participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
62278219|NCT04994106|PLACEBO_COMPARATOR|Part A: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
62278220|NCT04994106|EXPERIMENTAL|Cohort B1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
62278221|NCT04994106|EXPERIMENTAL|Cohort B2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
62278222|NCT04994106|EXPERIMENTAL|Cohort B3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
62278223|NCT04994106|EXPERIMENTAL|Cohort B4: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
62278224|NCT04994106|EXPERIMENTAL|Cohort B5 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
62278225|NCT04994106|PLACEBO_COMPARATOR|Part B: Placebo (Healthy participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
62278226|NCT04994106|PLACEBO_COMPARATOR|Part B: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
62278227|NCT01538238|EXPERIMENTAL|pazopanib|pazopanib 800mg qd
62278228|NCT06500091|EXPERIMENTAL|TQB2916 injection + doxorubicin hydrochloride for injection|TQB2916 injection + doxorubicin hydrochloride for injection, 21 days as a treatment cycle.
62278229|NCT06500091|EXPERIMENTAL|TQB2916 injection+penpulimab injection|TQB2916 injection+penpulimab injection , 21 days as a treatment cycle.
62278230|NCT01777581|EXPERIMENTAL|milnacipran|Milnacipran, flexibly dosed
62278231|NCT01777581|PLACEBO_COMPARATOR|Sugar pill (placebo)|Placebo
62278232|NCT02004873|EXPERIMENTAL|Micra Pacemaker Implant|
62278233|NCT00933049|ACTIVE_COMPARATOR|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo
62278234|NCT00933049|ACTIVE_COMPARATOR|Amoxicillin|Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo
62644045|NCT06465472|PLACEBO_COMPARATOR|Placebo|Patients in this arms will receive 50 mg/kg/day oral placebo during the first 6 months double-blind placebo-controlled study period 1 (Day 1 through Month 6) then patients receiving placebo will switch over the 6 to 12 month-period to stiripentol (period 2).
62644046|NCT02979964|EXPERIMENTAL|Arm 1, Positive Framing|All metrics in the audit and feedback practice reports presented with 'positive' framing, where the proportion of patients safe from risk (i.e., appropriate/desirable prescribing behaviours) is described.
62644047|NCT02979964|EXPERIMENTAL|Arm 2, Negative Framing|All metrics in the audit and feedback practice reports presented with 'negative' framing, where the proportion of patients at risk (i.e., due to inappropriate/undesirable prescribing behaviours) is described.
62073841|NCT01865123|EXPERIMENTAL|Transcendental Meditation|TM is a simple, natural, effortless mental technique practiced with eyes closed sitting for 20 minutes twice a day. This allows the practitioner to experience lesser excited levels of the mind and correspondingly greater degrees of physical relaxation. TM is a traditional meditation technique that has its origin in the ancient Vedic tradition of India.
62073842|NCT01865123|ACTIVE_COMPARATOR|Prolonged Exposure|Prolonged Exposure (PE) is a specialized type of Cognitive Behavorial Therapy employing a manualized, trauma-focused behavioral treatment for PTSD and is based on exposure principles and emotional processing theory.
62073843|NCT01865123|PLACEBO_COMPARATOR|Educational Control|Didactic based instructional classes will provide health education which will include the benefits of proper diet, exercise, and reducing smoking and alcohol. No stress management techniques will be taught.
62644048|NCT02979964|EXPERIMENTAL|Arm 3, Top Quartile Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the 75th percentile for performance by physicians working in nursing homes in the province for each metric.
62073844|NCT00873301|EXPERIMENTAL|vulvodynia|
62073845|NCT01609530|ACTIVE_COMPARATOR|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
62073846|NCT01609530|EXPERIMENTAL|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
62073847|NCT02669303|EXPERIMENTAL|platelet-rich plasma group|Autologous platelet-rich plasma subacromial injection
62073848|NCT02669303|ACTIVE_COMPARATOR|Methylprednisolone group|Methylprednisolone subacromial injection
62073849|NCT05666414|EXPERIMENTAL|computer guided sandwich interpositional bone grafting|patient specific cutting guide were fabricated to perform the osteotomies ( and another patient specific guide was then fabricated to start the fixation of the cut bony segment a full digital intervention for sandwich interpositional grafting in patients with vertically atrophied mandible (bilateral split mouth study)
62073850|NCT05666414|ACTIVE_COMPARATOR|conventional sandwich osteotomy interpositional bone grafting|conventional interpositional bone grafting was done for patients with vertically atrophied mandibles (bilateral split mouth study)
62073851|NCT04987190||all cleft patients divided into unilateral and bilateral groups|One group of cleft patients received the alveolar bone graft surgery
62073852|NCT00871351|EXPERIMENTAL|Ezetimibe + Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
62073853|NCT00871351|ACTIVE_COMPARATOR|Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
62073854|NCT00871351|ACTIVE_COMPARATOR|Rosuvastatin|Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
62073855|NCT03868241|EXPERIMENTAL|Bactiguard-coated Devices|Patients will receive endotracheal tube, central venous catheter and urinary cather coated with gold, silver and palladium (Bactiguard coating)
62073856|NCT03868241|PLACEBO_COMPARATOR|Control|Shelf endotracheal tube, central venous catheter and urinary cather available at each intensive care unit without any type of coating designed to prevent infection
62278235|NCT04110665|ACTIVE_COMPARATOR|Paracetamol+ ketoprofene and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was \> 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
62644049|NCT02979964|EXPERIMENTAL|Arm 4, Average Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the average performance by physicians working in nursing homes in the province for each metric.
62644050|NCT00807066|EXPERIMENTAL|A|Gefitinib
62644051|NCT00807066|ACTIVE_COMPARATOR|B|Platinum based chemotherapy
62644052|NCT01193946||Single-arm design|There is currently considerable debate regarding the accuracy of the estimated average requirement (EAR) and the recommended dietary allowance (RDA) for older people. Very limited data obtained from older individuals are available to support the assumption that age does not affect protein requirement. Existing method like nitrogen balance has inherent limitations that diminish it from being considered a reference method. Indicator amino acid oxidation technique is emerging as an alternative method to measure dietary protein requirement. It is more accurate and less demanding. The current study will be the first time this technique is used with elderly adults and will provide an important foundation for geriatric nutrition research
62073857|NCT06251258|EXPERIMENTAL|Insomnia|
62073858|NCT06251258|ACTIVE_COMPARATOR|Control|
62644053|NCT00914147|OTHER|Pulmonary Function Test (PFT)|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)
62073859|NCT00932646|EXPERIMENTAL|BI1744 (Olodaterol)|Medium Dose once Daily
62073860|NCT00932646|EXPERIMENTAL|BI 1744 (Olodaterol)|Low Dose once Daily
62073861|NCT00932646|PLACEBO_COMPARATOR|Placebo|Placebo once Daily
62073862|NCT00932646|ACTIVE_COMPARATOR|Foradil|12 mcg twice daily
62073863|NCT01257256||infertile patients|male infertile patients(ICD-9:606),female infertile patients(ICD-9:628)
62073864|NCT05694975|EXPERIMENTAL|Vitamin C|12 g Vitamin C will be infused within 6 hours by an infusion pump. This treatment will be repeated every 12 hours for 4 days.
62073865|NCT05694975|PLACEBO_COMPARATOR|Placebo|The control group is assigned a placebo (5% glucose).
62073866|NCT05764226|EXPERIMENTAL|35 kDa HA fragment HA35 injection|100 mg of the freshly made 35 kDa low molecular weight hyaluronan fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds
62644054|NCT00685516|ACTIVE_COMPARATOR|Arm I - Green Tea|Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
62644055|NCT00685516|PLACEBO_COMPARATOR|Arm II - Water|Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
62073867|NCT04232098|NO_INTERVENTION|Thermoneutral|thermoneutral condition
62073868|NCT04232098|EXPERIMENTAL|Feet heated|Hot water up to ankles
62073869|NCT04232098|EXPERIMENTAL|Calf heated|Hot water up to top of calves
62073870|NCT01476436|EXPERIMENTAL|LCHF diet|Advice of a diet low in carbohydrate
62073871|NCT01476436|ACTIVE_COMPARATOR|Usual diet|Subjects shall continue to eat their usual daily diet with no low carbohydrate intervention
62073872|NCT05860725|EXPERIMENTAL|PSA Development (Phase 1)|
62073873|NCT05860725|EXPERIMENTAL|Social Marketing Campaign (Phase 2)|
62073874|NCT05860725|NO_INTERVENTION|Organizational Stakeholders|Organizational stakeholders from organizations involved in Phase 1 and 2 will take part in a focus group after their respective phases have been completed to learn more about their experience.
62278236|NCT04110665|ACTIVE_COMPARATOR|Paracetamol+ ketoprofene+ Nefopam and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and Nefopam 120 mg intravenously were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was \> 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
62278237|NCT04110665|ACTIVE_COMPARATOR|Paracetamol+ ketoprofene and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was \> 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
62644056|NCT00685516|ACTIVE_COMPARATOR|Arm III - Decaffeinated black tea|Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
62644057|NCT04064268|EXPERIMENTAL|Healthy + Whey|Healthy conditions (overnight fast)
62644058|NCT04064268|EXPERIMENTAL|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
62073875|NCT00814515|ACTIVE_COMPARATOR|1|Ciclosporin 0.1%
62073876|NCT00814515|PLACEBO_COMPARATOR|2|Vehicle
62073877|NCT05643417|EXPERIMENTAL|Liver metastasis of gastric cancer|HAIC: refer to genetic test results，D1； Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073878|NCT05643417|EXPERIMENTAL|Liver metastasis of breast cancer|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073879|NCT05643417|EXPERIMENTAL|Liver metastasis of lung cancer|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073880|NCT05643417|EXPERIMENTAL|Liver metastasis of nasopharyngeal carcinoma|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073881|NCT05643417|EXPERIMENTAL|Liver metastasis of thyroid cancer|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073882|NCT05643417|EXPERIMENTAL|Liver metastasis of melanoma|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073883|NCT05643417|EXPERIMENTAL|Liver metastasis of stromal tumor|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073884|NCT05643417|EXPERIMENTAL|Liver metastasis of sarcoma|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073885|NCT05643417|EXPERIMENTAL|Liver metastasis of other solid tumor|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
62073886|NCT04095572|ACTIVE_COMPARATOR|intervention group A|50 ml of a sterile sodium HA (800 mg)- CS (1g) solution (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Via Martiri di Cefalonia 2, 26900 Lodi, Italy) weekly for four weeks, then every second week in the second month and four weeks later
62073887|NCT04095572|PLACEBO_COMPARATOR|control group B|50 ml sterile purified water weekly for four weeks, then every second week in the second month and four weeks later
62073888|NCT02491892|EXPERIMENTAL|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
62073889|NCT02491892|EXPERIMENTAL|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
62073890|NCT02773706|EXPERIMENTAL|Usual Subspecialty Care|"Once a subject is screened positive for anxiety or depression, the subspecialty provider is informed of the positive screen, and left to manage or refer the condition as per usual care by that provider.~Intervention: Depression / anxiety screen + clinician informed."
62073891|NCT02773706|ACTIVE_COMPARATOR|Integrated Psychology Care|"Once a subject is screened positive for anxiety or depression, an automated psychology referral occurs, in addition to any intervention determined by the subspecialty provider.~Intervention: Depression / anxiety screen + clinician informed + automated psychologist visit."
62073892|NCT03079505|ACTIVE_COMPARATOR|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
62073893|NCT03079505|EXPERIMENTAL|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
62073894|NCT02443025|EXPERIMENTAL|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
62278238|NCT04110665|ACTIVE_COMPARATOR|Paracetamol+ ketoprofene+Opioid delayed release and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and 20 mg of opioid delayed release (Oxycodone) were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was \> 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
62278239|NCT01392807|EXPERIMENTAL|Group 1|Normal hepatic function, 25 mg NKTR-118 administered orally
62278240|NCT01392807|EXPERIMENTAL|Group 2|Mild hepatic impairment, 25 mg NKTR-118 administered orally
62278241|NCT01392807|EXPERIMENTAL|Group 3|Moderate hepatic impairment, 25 mg NKTR-118 administered orally
62455877|NCT06179238|OTHER|Patient with urinary catheter without patient education|The population of the study consisted of urinary catheterized patients treated in the clinics of a Training and Research Hospital. G\*Power power analysis was used to calculate the number of individuals constituting the sample. The effect size was set to 0.80, which is a high level according to Cohen for comparing the means of independent samples. To ensure that the statistical power of the study was above 95%, the sample size was set at a 5% significance level and the effect size was 0.5. (df = 68; t = 1.668) The sample size was calculated as 70 patients. The study is planned to be conducted with 35 patients for each of the two study groups.
62455878|NCT03969953|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 2.5mg, twice daily.
62073895|NCT02443025|NO_INTERVENTION|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
62073896|NCT06131541|EXPERIMENTAL|Group I: autogenous bone graft group|11 subjects will be assigned to receive alveolar ridge splitting in combination with autogenous bone graft associated with immediate implant placement
62278242|NCT00533078|OTHER|1|
62278243|NCT05642910|EXPERIMENTAL|Azvudine group|Patients received Azvudine orally, for 7 consecutive days (7 doses in total) .
62455879|NCT03969953|PLACEBO_COMPARATOR|Placebo|Matched placebo, twice daily.
62644059|NCT04064268|EXPERIMENTAL|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
62073897|NCT06131541|EXPERIMENTAL|Group II: autogenous tooth graft group|11 subjects will be assigned to receive alveolar ridge splitting in combination with undemineralized autogenous tooth graft associated with immediate implant placement
62073898|NCT05690542||patients from intensive care units|patients with hemostasis disorders (coagulation and/or platelets), antiplatelet and/or anticoagulant treatment
62073899|NCT05690542||controls|healthy people
62073900|NCT02836327||Multiple sclerosis|Multiple sclerosis patients confirmed by neurologist according to the 2010 revised Mcdonald criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
62073901|NCT02836327||Neuromyelitis optica spectrum disorders|Neuromyelitis optica spectrum disorders confirmed by neurologist according to the 2015 revised diagnostic criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
62073902|NCT02836327||Health control|Health control is defined as no other nervous system diseases such as ischemic stroke, alzheimer disease and so on. The baseline data(age,education background etc.) is similar to multiple sclerosis and neuromyelitis optica spectrum disorders patients.All participants performed magnetic resonance imaging.
62073903|NCT02221323|EXPERIMENTAL|Insulin lispro|
62073904|NCT05891821|EXPERIMENTAL|Balstilimab|300 mg IV every 3 weeks for a maximum of 24 months
62073905|NCT02839122|EXPERIMENTAL|Dutasteride, Tadalafil|
62073906|NCT02839122|EXPERIMENTAL|Tadalafil, Dutasteride|
62278244|NCT05642910|ACTIVE_COMPARATOR|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
62278245|NCT00847327|EXPERIMENTAL|Parental Support|
62278246|NCT00847327|ACTIVE_COMPARATOR|Diabetes Education|
62278247|NCT04506983|EXPERIMENTAL|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).
62278248|NCT01650090|EXPERIMENTAL|ILC|Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
62278249|NCT03011658|PLACEBO_COMPARATOR|GROUP A|5 ml of venous blood will be obtained from this group who do not have oral lichen planus and suffering from anxiety and/or depression. They will be administered a HADS standard questionnaire and their stress related issues calculated accordingly. This group has 30 patients totally
62644060|NCT02530437|EXPERIMENTAL|Step I (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib PO for 7 days, followed by taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
62073907|NCT06192615|EXPERIMENTAL|Intravenous Dexmedetomidine|After admission to the ICU and discontinuation of mechanical ventilation, intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg) and a sublingual placebo (inert film) will be administered nightly for the first three nights while the patient is in the intensive care unit.
62278250|NCT03011658|OTHER|GROUP B|The group has 30 oral symptomatic lichen planus diagnosed patients also suffering with anxiety and/or depression. 5 ml of venous blood will be obtained from them for serum cortisol level analysis. HADS questionnaire will be administered for this group for evaluation of levels of anxiety and depression
62278251|NCT02160392||Endometrial biopsy|HIV + and HIV negative women underwent lower and upper genital tract sampling.
62278252|NCT02180893|EXPERIMENTAL|Paravertebral block|Patient receiving a PVB prior to robotic mitral valve surgery
62278253|NCT02180893|PLACEBO_COMPARATOR|No block|Patients who did not receive PVB
62278254|NCT06444672|EXPERIMENTAL|HBRP|The HBRP included whole-body training with various exercises for stretching, strength, endurance, and aerobic fitness. The treatment sessions were performed three times per week and had a 50-120-minute duration. The exercises were modified based on individual progress and included the use of a rubber ball for balance and strength as well as trunk flexibility, static balance, stability, and standing exercises.
62278255|NCT04598373||IDT patients|Allocated to an IDT program
62455880|NCT04989036|EXPERIMENTAL|CALCIUM HYDROXIDE™|Non-setting Calcium hydroxide Pulpotomy capping agent. Deepak. Promotion Industrial Park, Bari Brahmana, Jammu - 181133 India form : powder and liquid. application : Calcium hydroxide was mixed with saline to a thick consistency immediately before use. The paste was carefully placed on the pulp stump surface 2-3 mm thick over a small sterile wet cotton with a small condenser, and the excess material was scraped off.
62644061|NCT02530437|EXPERIMENTAL|Step II (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
62644062|NCT04531124||control group without an integrated management|
62644063|NCT04531124||observational group with an integrated management|
62644064|NCT00379834|ACTIVE_COMPARATOR|Cosopt|Cosopt twice daily in both eyes
62278256|NCT04598373||Non-IDT patients|Not allocated to an IDT program
62278257|NCT00110773|EXPERIMENTAL|S-Caine Peel|
62278258|NCT00110773|PLACEBO_COMPARATOR|Placebo Peel|
62644065|NCT03071211|EXPERIMENTAL|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
62644066|NCT03071211|ACTIVE_COMPARATOR|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
62073908|NCT06192615|EXPERIMENTAL|Sublingual Dexmedetomidine|After admission to the ICU and discontinuation of mechanical ventilation, sublingual dexmedetomidine (120 μg) and an intravenous placebo (0.9% saline over 40 minutes) will be administered nightly for the first three nights while the patient is in the intensive care unit.
62455881|NCT04989036|EXPERIMENTAL|Biodentine ™|Biodentine ™ Pulpotomy capping agent. Calcium Silicate-Based Material.Septodent®, Saint-Maurdes-Fosses, France form: capsule and liquid. application: According to the instructions of manufacture, Biodentine ™powder and liquid were mixed to achieve a creamy consistency, by mixing a single-unit powder part and 5 drops of a single-unit liquid part for 30 seconds by mixing device . Final mixing and adjustment were done manually to obtain the desired consistency for each case
62644067|NCT03071211|NO_INTERVENTION|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
62644068|NCT02358122|ACTIVE_COMPARATOR|Refined wheat|Refined wheat grain, a variety of cereal foods providing no wholegrain
62644069|NCT02358122|EXPERIMENTAL|Wholegrain wheat|Wholegrain wheat grain, a variety of cereal foods providing \>100g wheat wholegrain/day
62644070|NCT02358122|EXPERIMENTAL|Wholegrain rye|Wholegrain rye grain, a variety of cereal foods providing \>100g rye wholegrain/day
62644071|NCT05328960||Patients diagnosed before, during or after the pandemic|Patients with rectal cancer
62644072|NCT02791256|EXPERIMENTAL|Peginterferon Alfa-2a + Ribavirin|Participants will receive 360 microgram (mcg) of Peginterferon Alfa-2a subcutaneous (SC) once a week plus ribavirin (1000 - 1200 milligram per day \[mg/day\] orally as a split dose in the morning and the evening based on the participant's body weight) for 32 weeks.
62644073|NCT02736617|EXPERIMENTAL|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
62644074|NCT01229878|ACTIVE_COMPARATOR|Arm 1|Hemodialysis Patients randomized to take Vitamin D supplements
62644075|NCT01229878|PLACEBO_COMPARATOR|Arm 2|Hemodialysis Patients randomized to take placebo pills
62073909|NCT06192615|PLACEBO_COMPARATOR|Placebo|After admission to the ICU and discontinuation of mechanical ventilation, an intravenous placebo (0.9% saline over 40 minutes) and a sublingual placebo (inert film) will be administered nightly for the first three nights while the patient is in the intensive care unit.
62644076|NCT04258072|EXPERIMENTAL|open label,single arm|Vactosertib\* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours
62644077|NCT01015027|EXPERIMENTAL|Dose 1|(3:1, active:placebo)
62644078|NCT01015027|EXPERIMENTAL|Dose 2|(3:1, active:placebo)
62073910|NCT05987501|EXPERIMENTAL|Patients|patients with Crohn's disease or Ulcerative Colitis needing to begin biologic treatment
62278259|NCT02890550||30 Patients Alström syndrome|
62278260|NCT02890550||60 Related patients Alström syndrome|
62278261|NCT05791292|OTHER|Patients group|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
62278262|NCT05791292|OTHER|Healthy group|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
62455882|NCT02834000|NO_INTERVENTION|Standard Care|We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. The control group will compose of patients supervised in a standard way.
62644079|NCT01015027|EXPERIMENTAL|Dose 3|(3:1, active:placebo)
62644080|NCT01015027|EXPERIMENTAL|Dose 4|(3:1, active:placebo)
62644081|NCT04550078|ACTIVE_COMPARATOR|Calcium Carbonate|800 mg calcium as calcium carbonate in capsules consumed orally once with a standardized meal.
62644082|NCT04550078|EXPERIMENTAL|Calcium-enriched permeate|800 mg calcium as calcium permeate in capsules consumed orally once with a standardized meal.
62644083|NCT04550078|PLACEBO_COMPARATOR|Maltodextrin|0 mg calcium as placebo capsules with maltodextrin consumed orally once with a standardized meal.
62073911|NCT01985477|EXPERIMENTAL|Lenalidomide + Dexamethasone + All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21. Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22. ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment. Dexamethasone starting dose: Dose previously on when progressing prior to study entry. ATRA starting dose: MTD from Phase I.~Maintenance Therapy Group A: Lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days, with ATRA at dose determined in Phase I for 14/28 days, and Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22. After 3 months on therapy at MTD in Phase I study, patients must be switched to this dose schedule. Patients unable to tolerate either Dexamethasone during maintenance phase may dose reduce Dexamethasone as needed."
62073912|NCT01985477|EXPERIMENTAL|Lenalidomide + All-Trans Retinoic Acid (ATRA)|"Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent Lenalidomide prior to study enrollment. All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy: Maintenance therapy consists of lenalidomide at the dose level tolerated at the completion of cycle 3 for 21/28 days, with ATRA at the dose determined in the phase I portion of the trial for 14/28 days. Dexamethasone will not be administered. After 3 months on therapy at the MTD in the phase 1 study, patients must be switched to this dose schedule."
62073913|NCT02129816|ACTIVE_COMPARATOR|Bryophyllum|50% in 350mg Lactose, 2-2-2
62073914|NCT02129816|PLACEBO_COMPARATOR|Placebo|Lactose 350mg, 2-2-2
62073915|NCT02129816|EXPERIMENTAL|Solifenacin|10mg in 350mg Lactose, 2-2-2
62073916|NCT03165006||Screened women with breast cancer|
62073917|NCT05927376|EXPERIMENTAL|Mediterranean-style dietary pattern|A Mediterranean-style diet (as a whole diet, no supplements)
62073918|NCT05927376|ACTIVE_COMPARATOR|Western-style dietary pattern|A Western-style diet (as a whole diet, no supplements)
62073919|NCT04588896|EXPERIMENTAL|CGM+LMP|Continuous glucose monitoring (CGM) for 8 weeks in conjunction with lifestyle modification
62073920|NCT04588896|OTHER|LMP only|Lifestyle modification only
62278263|NCT01284166|EXPERIMENTAL|Triple Combination Therapy|Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
62073921|NCT06320496||Deconditioning to physical exertion|The children taking part in the return-to-physical-activity program are referred to the Flavigny-sur-Moselle CMPRE for medical consultation due to a state of deconditioning to physical exertion concomitant with a pathological situation. The pathology most frequently encountered during this stay is cerebral palsy. However, the Flavigny CMPRE is accredited in a number of fields (orthopedics, burns, neurology, oncology), and the pathologies of the children referred to this stay are representative of these. These include children with scoliosis, obesity, Guillain-Barré syndrome, cystic fibrosis, Charcot's disease and cancer.
62073922|NCT01410461||Patients with painful bladder syndrome|Patients with diagnosis of PBS Will be offered to take part in the following study.
62073923|NCT04639921|EXPERIMENTAL|active - placebo|intake of socalled gluten bars two daily for seven days, followed by one week wash-out, and then placebo bars for seven days
62073924|NCT04639921|PLACEBO_COMPARATOR|placebo - active|intake of placebo bars two daily, followoed by wash-out for one week, and gluten bars (experimental) for seven days.
62073925|NCT01342887|EXPERIMENTAL|Treatment (immunosuppression, enzyme inhibitor, and chemo)|Patients receive cyclosporine IV continuously on days 5-9. Patients also receive pravastatin sodium PO every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity.
62278264|NCT00731172|EXPERIMENTAL|1|20 mg copaxone(glatiramer acetate)subcutaneous injection(daily through week 12)
62278265|NCT00731172|PLACEBO_COMPARATOR|2|placebo subcutaneous injection(daily through week 12)
62644084|NCT02143817|NO_INTERVENTION|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
62073926|NCT01273532|EXPERIMENTAL|001|tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose
62278266|NCT04753398|EXPERIMENTAL|Telemonitoring group|Additional telemonitoring devices: Blood Pressure Monitor, medication dispenser, telemonitoring technology
62278267|NCT04753398|NO_INTERVENTION|Control group|usual care, without telemonitoring
62278268|NCT01395992|EXPERIMENTAL|Asenapine 5 mg|Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
62455883|NCT02834000|EXPERIMENTAL|LiDCO rapid™ CNAP monitoring|Young, healthy adult patients (ASA I and II) undergoing elective orthopaedic surgery under general anaesthesia will be included in to this study. We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. We will use in the LiDCO rapid™ CNAP monitoring group, the continuous real time haemodynamic monitoring through non-invasive arterial pressure waveform. The monitor LiDCO rapid™ CNAP permits, through analysis the arterial blood pressure trace, to acquire information about CO, SVR, HR variability, SV and BIS.
62455884|NCT02210403|ACTIVE_COMPARATOR|Upper limb motor function training + tDCS|Bi-hemispheric tDCS with motor function training
62455885|NCT02210403|SHAM_COMPARATOR|upper limb motor function training + sham tDCS|sham tDCS with motor function training
62455886|NCT01484405|OTHER|anterolateral approach|surgical intervention THA anterolateral approach
62455887|NCT01484405|OTHER|posterior approach|surgical intervention THA posterior approach
62644085|NCT02143817|EXPERIMENTAL|Whole body vibration training plus L-citrulline|Lower-body exercise training on a vibration platform combined with L-citrulline supplemetation (6 grams/day)
62073927|NCT01273532|EXPERIMENTAL|002|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
62278269|NCT01395992|EXPERIMENTAL|Asenapine 10 mg|Participants who were randomized to asenapine 10 mg BID during the P05691 study will be assigned to receive asenapine 10 mg BID on this extension study.
62278270|NCT06536400|EXPERIMENTAL|Phase Ia (Part A): HSK42360 as monotherapy|Phase 1a (Part A): dose escalation of HSK42360 as monotherapy at various dose levels
62278271|NCT06536400|EXPERIMENTAL|Phase Ia (Part B): HSK42360 as monotherapy|Phase 1a (Part B): dose extention of HSK42360 as monotherapy at certain dose levels
62278272|NCT06536400|EXPERIMENTAL|Phase Ib: HSK42360 as monotherapy|Phase 1b: dose expansion for HSK40118 as monotherapy at a dose determined during Phase 1a (Part B) in patients with BRAF V600 mutation locally advanced or metastatic solid tumors
62278273|NCT04933266|ACTIVE_COMPARATOR|Low dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 5ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 5ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 10ml will be given).
62644086|NCT02143817|EXPERIMENTAL|Whole body vibration training & placebo|Lower-body exercise training on a vibration platform combined with placebo supplementation (6 grams/day)
62644087|NCT02143817|EXPERIMENTAL|L-citrulline supplementation|(6g per day)containing L-citrulline
62644088|NCT06078215|NO_INTERVENTION|Thrombolysis and/or mechanical thrombectomy|patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - comparator
62644089|NCT06078215|EXPERIMENTAL|Cerebrolysin|patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy and treated with Cerebrolysin
62644090|NCT06078215|NO_INTERVENTION|No reperfusion therapy / no cerebrolysin|patients not referred to reperfusion therapy nor Cerebrolysin
62644091|NCT04443335|SHAM_COMPARATOR|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
62644092|NCT04443335|EXPERIMENTAL|sequential feeding|This feeding mode utilizes a combination of continuous feeding in the beginning, time-restricted feeding in the second stage and oral feeding in the last stage
62644093|NCT03010072|ACTIVE_COMPARATOR|low-dose sucroferric oxyhydroxide|Low dose 250 mg sucroferric oxyhydroxide (PA21) per day (1x 250mg tablets/day) for 14 days.
62644094|NCT03010072|ACTIVE_COMPARATOR|high-dose sucroferric oxyhydroxide|Uniform dose 2000 mg of sucroferric oxyhydroxide (PA21) per day (4x 500mg tablets/day) for 14 days
62644095|NCT00617279|ACTIVE_COMPARATOR|GORE PROPATEN Vascular Graft:|
62644096|NCT00617279|ACTIVE_COMPARATOR|Disadvantaged Autologous Vein Graft|
62644097|NCT05641571|EXPERIMENTAL|Exercise group|The 3\~6 months home-based extremity exercise program will be intervened between newly diagnosed with breast cancer to the completion of chemotherapy. Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time.
62073928|NCT00818909|EXPERIMENTAL|Systane|Systane ocular product
62644098|NCT05641571|NO_INTERVENTION|Observational group|The observational group will need to record the extra exercise performed and the exercise prescription will be distributed after the study.
62644099|NCT03884881|OTHER|metagenomic next generation sequencing|Adjust medication for patients with severe pneumonia based on mNGS results
62644100|NCT03884881|OTHER|Conventional pathogen detection|Blood, bronchoalveolar lavage fluid (BALF), bronchial secretions samples will be collected and microbiologically tested prior to initial empirical antibiotic use.
62644101|NCT03221114|EXPERIMENTAL|Positive Psychological Intervention|Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
62644102|NCT03221114|NO_INTERVENTION|Wait list control|Receipt after the active treatment group has completed the positive psychological intervention.
62073929|NCT04598737|EXPERIMENTAL|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
62073930|NCT04598737|EXPERIMENTAL|Lithium disilicate|Lithium disilicate laminate veneer treatment
62073931|NCT04139915|EXPERIMENTAL|10 mg daily RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 16 weeks
62073932|NCT04139915|PLACEBO_COMPARATOR|Placebo|Oral matching placebo once daily for 16 weeks
62644103|NCT04573660||Coronary and peripheral stents|Participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
62644104|NCT04573660||Pacing catheters|Participants in the Pacing catheters arm will receive Pacing catheters
62073933|NCT02512510|ACTIVE_COMPARATOR|TD-4208-1|88 mcg
62073934|NCT02512510|ACTIVE_COMPARATOR|TD-4208-2|175 mcg
62073935|NCT02512510|PLACEBO_COMPARATOR|Placebo|Placebo
62073936|NCT01982396|ACTIVE_COMPARATOR|Twice daily|
62073937|NCT01982396|EXPERIMENTAL|Once daily|
62073938|NCT04276662|EXPERIMENTAL|Cohort 1: Mild hepatic impairment|Participants who have mild hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
62644105|NCT04573660||Vascular plugs|Participants in the Vascular plugs arm will receive Vascular plugs
62644106|NCT04573660||Measurement and imaging (FFR and OCT)|Participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
62644107|NCT04573660||Peripheral dilatation catheters|Participants in the Peripheral dilatation catheters arm will receive Peripheral dilatation catheters
62644108|NCT04573660||Coronary dilatation catheters|Participants in the Coronary dilatation catheters arm will receive Coronary dilatation catheters
62073939|NCT04276662|EXPERIMENTAL|Cohort 2: Moderate hepatic impairment|Participants who have moderate hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
62073940|NCT04276662|EXPERIMENTAL|Cohort 3: Healthy participants|Healthy participants who have normal hepatic function with sex, age (±10 years \[y\]), and weight (±20%) matching with the mild and moderate hepatic impairment cohorts.
62073941|NCT03343860|ACTIVE_COMPARATOR|Conventional|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
62073942|NCT03343860|ACTIVE_COMPARATOR|Non inducibility|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT) .
62073943|NCT06098495||infertile women (unexplained, tubal, mild male factor)|women belonging to couples selected for homologous IVF due to an unexplained, tubal or mild male factor
62073944|NCT06098495||fertile women|women without any infertility history who are attempting to conceive naturally
62073945|NCT06098495||infertile women (ovarian factor)|women selected for homologous IVF for different reason og chohort 1
62073946|NCT06098495||recurrent pregnancy loss|women affected by idiopathic recurrent pregnancy loss
62278274|NCT04933266|ACTIVE_COMPARATOR|High dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 10ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 10ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 20ml will be given).
62073947|NCT02326116|EXPERIMENTAL|Group 1|Trachael Traction Exercises
62073948|NCT02326116|PLACEBO_COMPARATOR|Group 2|Trachael Massage
62073949|NCT05271682|EXPERIMENTAL|Part 1: 0.4 mg|FHND6091, 0.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62073950|NCT05271682|EXPERIMENTAL|Part 1: 0.8 mg|FHND6091, 0.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62455888|NCT01225146|ACTIVE_COMPARATOR|Treatment Experienced (Cohort 1|"Previously treated with 6 or more intravitreal ranibizumab with persistent edema followed in RAVE 1 (FVF3348s).~Cohort 1 patients will receive 1 dose of ranibizumab 2.0 mg, followed by PRN based on pre-defined retreatment criteria"
62073951|NCT05271682|EXPERIMENTAL|Part 1: 1.4 mg|FHND6091, 1.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62073952|NCT05271682|EXPERIMENTAL|Part 1: 2.0 mg|FHND6091, 2.0 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62073953|NCT05271682|EXPERIMENTAL|Part 1: 2.8 mg|FHND6091, 2.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62455889|NCT01225146|ACTIVE_COMPARATOR|Treatment Naive (Cohort 2)|Treatment naïve. Cohort 2 patients will receive 6 doses of ranibizumab 2.0 mg, followed by PRN based on pre-defined re-treatment criteria.
62644109|NCT04573660||Coronary and peripheral guidewires|Participants in the Coronary and peripheral guidewires arm will receive Coronary and peripheral guidewires
62073954|NCT05271682|EXPERIMENTAL|Part 1: 3.6 mg|FHND6091, 3.6 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62644110|NCT04573660||Vessel closure/compression devices|Participants in the Vessel closure/compression devices arm will receive Vessel closure/compression devices
62644111|NCT04573660||Vascular access introducers|Participants in the Vascular access introducers devices arm will receive Vascular access introducers
62073955|NCT05271682|EXPERIMENTAL|Part 2: lower dose expansion|FHND6091, a lower dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62073956|NCT05271682|EXPERIMENTAL|Part 2: MTD pr MTD-1 dose expansion|FHND6091, MTD or MTD-1 dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
62073957|NCT02854358|ACTIVE_COMPARATOR|control|In the control group, patients received Hypozalix (artificial saliva)spray three times per day for a period of four weeks.
62278275|NCT05070377|EXPERIMENTAL|Intervention|The ActTeens Program will include interventions in three different context: (1) structured physical activity sessions by physical education (school), (2) self-monitoring plus goal setting by pedometer (out-of-school), and (3) healthy lifestyle guidance (social support). The structured PA will be developed in PE lessons, twice a week, with twenty-minute each lesson (40 min·week) To promote active behavior out-of-school will be used a pedometer plus goals setting where each adolescent of the intervention group will receive their own goal (based on the number of steps measured in the baseline week) outlining the goals to achieve weekly. To improve healthy behavior will be sent by WhatsApp® messages about healthy eating and regular PA for the intervention and parents groups.
62278276|NCT05070377|NO_INTERVENTION|Control|The control group participated in usual practice (regularly scheduled PE and postcurricular school sport) for the duration of the study .
62278277|NCT01482910|EXPERIMENTAL|Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
62278278|NCT01482910|ACTIVE_COMPARATOR|PDT treatments|Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
62644112|NCT05073705|NO_INTERVENTION|Control Group|Control condition: The control condition will be standard of care. This will include regular review in the clinic for medical refills and adherence counseling that will be given in the clinic as required and determined by the attending clinicians and the counselors in the HIV clinic. The clinic visits will be guided by the clinical status, availability of school programs, distance from the clinic, and ability to afford transport fare to the clinic.
62073958|NCT02854358|EXPERIMENTAL|intervention|Patients in intervention group received sachets containing 4 grams of mixed powder of A. digitata and M. sylvestris (in a proportion of 1:1), three times per day for a period of four weeks
62073959|NCT03499626|EXPERIMENTAL|ASLAN001|A 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdrawal of consent.
62073960|NCT01950117|ACTIVE_COMPARATOR|Conventional polypectomy|Colorectal polyps from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was not performed for polypectomy. The snare used for polypectomy was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for conventional polypectomy. Prophylactic clipping after polyp removal was routinely performed.
62073961|NCT01950117|EXPERIMENTAL|Endoscopic mucosal resection|Colorectal polyp from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was performed for EMR. The snare used for EMR was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for EMR. Prophylactic clipping after polyp removal was routinely performed.
62073962|NCT02312180|EXPERIMENTAL|Cohort 1|low dose group of 2 mg/kg Plasminogen (Human) Intravenous
62644113|NCT05073705|EXPERIMENTAL|Empowerment and personal transformation intervention|Intervention/Treatment: The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
62073963|NCT02312180|EXPERIMENTAL|Cohort 2|mid-dose group of 6 mg/kg Plasminogen (Human) Intravenous
62073964|NCT00458679|EXPERIMENTAL|Vaccine|autologous B-CLL vaccine expressing CD40L and IL2
62644114|NCT06141252|EXPERIMENTAL|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
62073965|NCT03169270|EXPERIMENTAL|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
62073966|NCT03169270|ACTIVE_COMPARATOR|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
62073967|NCT04358419||PA proven/probable/possible|15 patients with proven, probable or possible PA
62073968|NCT04358419||PA suspected, not confirmed|15 patients as the PA patients, but where the diagnosis of PA is rejected.
62278279|NCT03462056|EXPERIMENTAL|CF Ready to Use Supplemental Food.|Participants will receive Cystic Fibrosis Ready to Use Supplemental Food sufficient to provide approximately 20% of estimated daily caloric needs up to 500kcal of total calories, 18.5 grams of protein and 28g of fat. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition
62644115|NCT06141252|NO_INTERVENTION|No hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated without hypothermia
62644116|NCT02069938||Healthy Subjects|Noninvasive Brain Computer Interface Control
62644117|NCT00646724|EXPERIMENTAL|1|cotransplantation of islet and mesenchymal stem cell
62644118|NCT02440269||A：day|the patients who receive surgery and anesthesia during 8:00 am to 6:00 pm
62278280|NCT05412680|ACTIVE_COMPARATOR|TOETVA|Patients submitted to transoral endoscopic thyroidectomy by vestibular approach
62278281|NCT05412680|ACTIVE_COMPARATOR|CONVENTIONAL THYROIDECTOMY|Patients submitted to conventional open thyroidectomy by cervical approach
62644119|NCT02440269||B：night|the patients who receive surgery and anesthesia during 10:00 pm to 5:00 am next day
62644120|NCT04500574|EXPERIMENTAL|Latanoprost contact lens|The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop.
62644121|NCT04500574|PLACEBO_COMPARATOR|Topical Latanoprost|The placebo arm will have a commercial contact lens with no drug with a nightly 0.005% latanoprost drop.
62644122|NCT00325741|EXPERIMENTAL|Hematopoietc Stem Cell Transplant|Hematopoietic Cell Transplantation. Total body irradiation and Stem cell infusion in life threating lupus patients
62644123|NCT00687934|EXPERIMENTAL|Ganetespib|Ganetespib once weekly infusion, dose escalation study, with treatment until progression
62073969|NCT04358419||Healthy controls (PA)|15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.
62073970|NCT04358419||Pneumocystis pneumonia positive|Four patients with confirmed pneumocystis pneumonia
62278282|NCT02387359|ACTIVE_COMPARATOR|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
62073971|NCT04358419||Pneumocystis pneumonia negative|If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.
62073972|NCT04358419||Healthy controls (pneumocystis pneumonia)|Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.
62073973|NCT03209401|EXPERIMENTAL|Niraparib and Carboplatin|"Niraparib will be administered orally, once daily for 21 days of each 21-day cycle in escalating doses depending on cohort patient is assigned to.~Carboplatin will be administered via an injection on Day 2 of a given 21-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
62073974|NCT00936520|EXPERIMENTAL|Dose 1|SAR 1118 dose 0.1%
62073975|NCT00936520|EXPERIMENTAL|Dose 2|SAR 1118 dose 1.0%
62455890|NCT02393040|EXPERIMENTAL|PRP/Saline|"PRP/Saline~Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride.~In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo).~This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6)."
62644124|NCT04025216|EXPERIMENTAL|Dose Escalation Arm1: Solid Tumors|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
62644125|NCT04025216|EXPERIMENTAL|Dose Escalation Arm 2: Multiple Myeloma|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
62644126|NCT06209632|EXPERIMENTAL|MT and CCFES group|mirror therapy combined with contralaterally controlled functional electrical stimulation to perform hand exercises
62644127|NCT06209632|SHAM_COMPARATOR|Sham MT and CCFES group|sham mirror therapy with contralaterally controlled functional electrical stimulation to perform hand exercises
62644128|NCT06209632|ACTIVE_COMPARATOR|Control group|conventional physiotherapy
62644129|NCT06416631|EXPERIMENTAL|artificial intelligence planning group|
62644130|NCT06416631|PLACEBO_COMPARATOR|manual planning group|
62644131|NCT04781712|EXPERIMENTAL|Self-management using mHealth|Self-management (physical activity, sleep, exercise, education, etc.) using mHealth
62644132|NCT04781712|NO_INTERVENTION|Exercise using brochure|Only exercise using brochure
62644133|NCT01210638|ACTIVE_COMPARATOR|Oxymorphone Hydrochloride|Tablet
62073976|NCT00936520|EXPERIMENTAL|Dose 3|SAR 1118 dose 5.0%
62073977|NCT05521594|EXPERIMENTAL|FNAC|
62073978|NCT05521594|EXPERIMENTAL|post operative hitopathology|
62073979|NCT01768754||COPD patients|Usual and Fast Walking Speeds
62073980|NCT00238420|EXPERIMENTAL|Group I (paclitaxel, trastuzumab, radiation therapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
62073981|NCT00238420|EXPERIMENTAL|Group II (paclitaxel, radiation therapy)|Patients receive paclitaxel and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50.
62073982|NCT01339988|EXPERIMENTAL|Busulfan/Cyclophosphamide|
62278283|NCT02387359|ACTIVE_COMPARATOR|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
62278284|NCT02387359|ACTIVE_COMPARATOR|Matching placebo|Placebo dosed daily for 12 weeks
62644134|NCT01210638|ACTIVE_COMPARATOR|Opana|Tablet
62644135|NCT05885932|EXPERIMENTAL|Drug-eluting stenting group|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus best medical treatment including Aspirin 100mg per day + Clopidogrel 75mg per day or Ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
62278285|NCT02257190|EXPERIMENTAL|Control (Con)|No exercise intervention.
62278286|NCT02257190|EXPERIMENTAL|Interval Walking - 3 min intervals (IW3)|One hour of classical interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking.
62278287|NCT02257190|EXPERIMENTAL|Interval Walking - 1 min intervals (IW1)|One hour of fast alternating interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking
62278288|NCT04178980|ACTIVE_COMPARATOR|case|
62278289|NCT04178980|PLACEBO_COMPARATOR|control|
62278290|NCT04046679|EXPERIMENTAL|Bleomycin|Bleomycin Infusion By Tattoo Machine
62278291|NCT04046679|PLACEBO_COMPARATOR|Saline Solution|Saline Infusion by Tattoo Machine
62278292|NCT05526027|OTHER|ETI|pwCF which are CFTR-modulator naive and pwCF previously treated with a CFTR-modulator (i.e. tezacaftor-ivacaftor or lumacaftor-ivacaftor) will undergo standard-of-care examinations as well as examinations in the context of this trial (i.e. CFQ-R, PHQ-9, GAD-7 and SNOT-22 questionnaires, fecal elastase measurement)
62644136|NCT05885932|ACTIVE_COMPARATOR|Medical group|All the participants in this group will be given medical therapy including Aspirin 100mg per day + Clopidogrel 75mg per day or Ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
62073983|NCT02265029|ACTIVE_COMPARATOR|Immediate spa treatment|Spa treatment during 18 days soon after randomization : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
62644137|NCT00745303||1|Subjects in this group received TCC training for 3 months
62073984|NCT02265029|SHAM_COMPARATOR|Late SPA treatment|Spa treatment during 18 days soon after 6 months visit : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
62073985|NCT04422366|EXPERIMENTAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
62073986|NCT04422366|ACTIVE_COMPARATOR|GARDASIL®|Participants in this arm would receive GARDASIL®
62278293|NCT00874250|EXPERIMENTAL|GORE CTAG Device|The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.
62278294|NCT01033409|EXPERIMENTAL|S. Typhi-vectored pneumo vaccine 10^7|Arm 1 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10\^7 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10\^7 CFU oral dosage through Day 28.
62278295|NCT01033409|EXPERIMENTAL|S. Typhi-vectored pneumo vaccine 10^8|Arm 2 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10\^8 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10\^8 CFU oral dosage through Day 28.
62278296|NCT01033409|EXPERIMENTAL|S. Typhi-vectored pneumo vaccine 10^9|Arm 3 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10\^9 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10\^9 CFU oral dosage through Day 28.
62278297|NCT01033409|EXPERIMENTAL|S. Typhi-vectored pneumo vaccine 10^10|Arm 4 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10\^10 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10\^10 CFU oral dosage through Day 28.
62278298|NCT04706039|EXPERIMENTAL|Outpatients without hospitalisation criteria|Symptomatic and asymptomatic outpatient without hospitalisation criteria presenting in a COVID-19 screening centre of the Hospices Civils de Lyon
62278299|NCT04607733|EXPERIMENTAL|Mirikizumab - Prefilled Syringe|2× 1mL (total 200 milligrams (mg) mirikizumab) administered by subcutaneous injection (SC) via a prefilled syringe (PFS)
62278300|NCT04607733|EXPERIMENTAL|Mirikizumab - Autoinjector|2× 1mL (total 200 milligrams (mg) mirikizumab) administered by subcutaneous injection (SC) via an autoinjector (AI)
62644138|NCT00745303||2|Subjects in this group received no TCC training within 3 months
62278301|NCT02508194|ACTIVE_COMPARATOR|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
62278302|NCT02508194|EXPERIMENTAL|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
62278303|NCT05664984|EXPERIMENTAL|1-face-to-face group|Cognitive rehabilitation intervention was given face-to-face.
62278304|NCT05664984|EXPERIMENTAL|2-tele rehabilitation group|Cognitive rehabilitation intervention was given tele-rehabilitation method.
62278305|NCT01354483|EXPERIMENTAL|Treatment Group A|Umbilical cord blood mononuclear cell, 1.6 million
62278306|NCT01354483|EXPERIMENTAL|Treatment Group B|Umbilical cord blood mononuclear cell, 3.2 million
62278307|NCT01354483|EXPERIMENTAL|Treatment Group C|Umbilical cord blood mononuclear cell, 6.4 million
62278308|NCT01354483|EXPERIMENTAL|Treatment Group D|Umbilical cord blood mononuclear cell, 6.4 million; mehtylprednisolone
62278309|NCT01354483|EXPERIMENTAL|Treatment Group E|Umbilical cord blood mononuclear cell, 6.4 million; methylprednisolone; 6 week course of lithium carbonate tablet
62278310|NCT03657615|ACTIVE_COMPARATOR|Control|Hearing Aid Fitting Patients with hearing loss but no tinnitus paired by age and hearing loss degree Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
62073987|NCT02037828||Stable COPD in STEP1|no intervention
62278311|NCT03657615|EXPERIMENTAL|Tinnitus|Hearing Aid Fitting Patients with tinnitus and hearing loss associated Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
62278312|NCT01163071|EXPERIMENTAL|ABI-011|
62278313|NCT03032952|EXPERIMENTAL|"Feel Stress Free"|"Access to the Feel Stress Free mobile application intervention for 12 weeks. Instructed to use it at least once per week for 15 minutes, for the first 6 weeks, then given free access thereafter."
62278314|NCT03032952|NO_INTERVENTION|Wait list control|Given access to the intervention at the end of the 12 weeks of the trial.
62278315|NCT06411275|EXPERIMENTAL|HTD1801 500 mg|Administered orally twice daily (BID)
62278316|NCT06411275|EXPERIMENTAL|HTD1801 1000 mg|Administered orally BID
62278317|NCT06411275|PLACEBO_COMPARATOR|Placebo|Administered orally BID
62278318|NCT03340844|EXPERIMENTAL|No Touch (NT)|Pancreatic and Periampullary Tumors resection by no-touch technique
62278319|NCT03340844|ACTIVE_COMPARATOR|Superior Mesenteric Artery First (SMA)|Pancreatic and Periampullary Tumors resection by superior Mesenteric Artery First technique
62278320|NCT01843855|EXPERIMENTAL|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
62073988|NCT02037828||Control in STEP 1|no intervention
62073989|NCT02037828||Case group in STEP 2|no intervention
62073990|NCT02037828||Control group in STEP2|no intervention
62073991|NCT01193543|EXPERIMENTAL|calanus oil|calanus oil 1 gram twice daily
62073992|NCT01193543|PLACEBO_COMPARATOR|olive oil|olive oil 1 gram twice daily
62073993|NCT05790226|EXPERIMENTAL|Raman Spectroscopy|Acquiring Raman spectroscopy data points ex vivo on recently excised lung tissue
62278321|NCT01843855|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
62278322|NCT06114979|ACTIVE_COMPARATOR|Silodosin|Patients will receive 8 mg of Silodosin tablet once daily.
62278323|NCT06114979|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pill once daily,
62073994|NCT01961596|EXPERIMENTAL|cooling ice|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
62073995|NCT01961596|PLACEBO_COMPARATOR|water|"A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
62073996|NCT06036563||Multicenter prospective cancer-screening cohort|The cohort, including cancer patients and non-cancer patients, will be prospectively enrolled in from different departments and centers. The focused cancers include lung cancer, gastric cancer, colorectal cancer, liver cancer, esophagus cancer, breast cancer and pancreas cancer.
62073997|NCT06172218|EXPERIMENTAL|Micronized Amniotic Membrane|Injection of micronized amniotic membrane reconstituted in 2.0 mL sterile, preservative free 0.9% NaCl
62073998|NCT06172218|PLACEBO_COMPARATOR|Preservative Free Normal Saline|2.0 mL sterile, preservative free 0.9% NaCl
62073999|NCT02707419|EXPERIMENTAL|Experimental group|Video of the exercises and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
62074000|NCT02707419|ACTIVE_COMPARATOR|Control group|Video of nature scenes and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
62074001|NCT06353659||Patients with acute kidney injury (AKI)|Patient diagnosed with AKI according to kidney disease improving global outcomes (KDIGO) 2012 criteria
62074002|NCT06353659||Patients without AKI|Patient diagnosed without AKI according to kidney disease improving global outcomes (KDIGO) 2012 criteria
62074003|NCT02710994|EXPERIMENTAL|CDFR0209, Then Losec|Subjects first received CDFR0209 each morning in a fasting state for 7 days. After a washout period of 14 days, they then received Losec 40 mg in a fasting state each morning for 7 days.
62644139|NCT05497323|EXPERIMENTAL|Combination Cream Group|Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning. Subjects were evaluated on day 28 and day 56.
62074004|NCT02710994|EXPERIMENTAL|Losec, Then CDFR0209|Subjects first received Losec 40 mg each morning in a fasting state for 7 days. After a washout period of 14 days, they then received CDFR0209 in a fasting state each morning for 7 days.
62074005|NCT06026527|EXPERIMENTAL|Group M|Magnesium group
62074006|NCT06026527|PLACEBO_COMPARATOR|Group C|Control group
62074007|NCT02737956||AMI patients with treatment of PCI|All the patiets treat with PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
62074008|NCT02737956||Medication|All the patiets treat with medication (standard secondary prevention) without PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
62074009|NCT04088474|EXPERIMENTAL|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.
62074010|NCT04088474|PLACEBO_COMPARATOR|placebo|Maltodextrin was used as a placebo.
62074011|NCT05512728|PLACEBO_COMPARATOR|midazolam group|
62074012|NCT05512728|ACTIVE_COMPARATOR|VR group|
62074013|NCT01156077|EXPERIMENTAL|oral TR-701 FA|Single oral dose of 200 mg TR-701
62074014|NCT01156077|EXPERIMENTAL|IV TR-701 FA|Single IV infusion of 200 mg TR-701 FA
62278324|NCT02164422|EXPERIMENTAL|Guanfacine 3mg/day|Guanfacine 3mg/day
62074015|NCT04343222|EXPERIMENTAL|Group A: Bromfenac then Artificial Tears|Participant receives 1 drop of topical Bromfenac 0.09% 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
62074016|NCT04343222|EXPERIMENTAL|Group B: Artificial Tears then Bromfenac|Participant receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of topical Bromfenac 0.09% immediately after the injection and wash.
62074017|NCT04343222|PLACEBO_COMPARATOR|Group C: Artificial Tears then Artificial Tears|Participants receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
62074018|NCT05907577||Disease cohort|Observational, no interventions
62074019|NCT05907577||Control cohort|Observational, no interventions
62455891|NCT00870870|EXPERIMENTAL|GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)|"Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~\*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
62074020|NCT05724914||Cardiac Arrest|Out-Of-Hospital Cardiac Arrest
62074021|NCT02088827|OTHER|Activity|During a 4 hour Meal Test subjects will cycle for 2 minutes every 20 minutes
62074022|NCT02088827|OTHER|Inactivity|During a 4 hour Meal Test study subjects will remain inactive (remain lying on a bed)
62074023|NCT04283344|EXPERIMENTAL|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula: (1) a fixed deduction, depending on county of residence, for transportation costs for six round trips to the grocery store per month; and (2) an earnings deduction equal to 10 percent of earned income for households with at least one employed household member.
62074024|NCT04283344|NO_INTERVENTION|Control Group|Households in the control group continued to receive their regular monthly SNAP benefit amounts.
62074025|NCT04672109|EXPERIMENTAL|Anodal-tDCS|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the supraorbital area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
62074026|NCT04672109|EXPERIMENTAL|Cathodal-tDCS|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) of non-dominant hemisphere and Anode on the supraorbital area of dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
62074027|NCT04672109|EXPERIMENTAL|Dual-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the primary motor area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
62644140|NCT05497323|OTHER|Adapalene 0,1% cream|The control group (Group 1) will use Adapalene 0.1% cream only every night. Subjects were evaluated on day 28 and day 56.
62074028|NCT04672109|SHAM_COMPARATOR|Sham-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins. Anode on dominant hemisphere, Cathode on non-dominant hemisphere. The scope of intervention is to investigate effect of tDCS on muscle strength.
62074029|NCT03876938|ACTIVE_COMPARATOR|aprepitant|aprepitant / dexamethasone/ ondansetron
62074030|NCT03876938|EXPERIMENTAL|olanzapine 10 mg|olanzapine 10 mg/dexamethasone/ ondansetron
62074031|NCT03876938|EXPERIMENTAL|olanzapine 5 mg|olanzapine 5 mg/dexamethasone/ ondansetron
62074032|NCT04657549|ACTIVE_COMPARATOR|Tonsillectomy|Patients will undergo tonsillectomy under general anesthesia within three weeks after enrollment.
62074033|NCT04657549|ACTIVE_COMPARATOR|Tonsillotomy|Patients will undergo tonsillotomy under general anesthesia within three weeks after enrollment.
62074034|NCT04657549|NO_INTERVENTION|Watchful waiting|Patients will be closely monitored for the 5-6 months monitoring period.
62074035|NCT03623880|EXPERIMENTAL|Unified Protocol|This is a type of CBT for emotional distress.
62074036|NCT03623880|ACTIVE_COMPARATOR|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
62074037|NCT05330130|ACTIVE_COMPARATOR|Daily 150 IU recFSH|Follitropin beta injection 150 IU daily
62074038|NCT05330130|ACTIVE_COMPARATOR|Daily 300 IU recFSH|Follitropin beta injection 300 IU daily
62074039|NCT02788006|EXPERIMENTAL|Regorafenib 160 mg|
62074040|NCT04188483|EXPERIMENTAL|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days. Thirty days after the start of the supplementation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
62074041|NCT04188483|OTHER|Non-Selenium Supplementation|The control group will not receive selenium supplementation. Thirty days after allocation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
62074042|NCT01161004|EXPERIMENTAL|Sugammadex - Nacl 9/00|"Sugammadex - Nacl 9/00:~Patients will first receive sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive Nacl 9/00 5 minutes after the first bolus of sugammadex.~The study is finished 5 minutes after this second injection and care is let to the choice of the anesthesiologist in charge."
62074043|NCT01161004|EXPERIMENTAL|Nacl 9/00 - sugammadex|"Nacl 9/00 - Sugammadex :~Patients wil first receive Nacl 9/00. In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive sugammadex 5 minutes after the first bolus of Nacl 9/00.~Sugammadex is given as: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~The study is finished 5 minutes after the injection of sugammadex and care is let to the choice of the anesthesiologist in charge."
62074044|NCT04516421|EXPERIMENTAL|Experimental group|The experimental group will receive a 12-weeks intervention, with each day a pack of supplementation containing 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
62074045|NCT04516421|PLACEBO_COMPARATOR|Control (Placebo) group|The control (placebo) group will receive a 12-week oat drink, with each day a pack of oat tea containing 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
62074046|NCT00000143|EXPERIMENTAL|Ganciclovir implant and oral ganciclovir|Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
62074047|NCT00000143|EXPERIMENTAL|Cidofovir IV (Intravenous)|cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
62074048|NCT05134714|EXPERIMENTAL|Group 1(study group): CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
62074049|NCT05134714|ACTIVE_COMPARATOR|Group 2(control): Conventional metal band and loop space maintainer|Stainless steel band and loop space maintainer will be made. Stainless steel appropriate band will be selected according to the size of the abutment teeth then design of the loop will be obtained, then will be send to the laboratory for soldering.
62278325|NCT02164422|EXPERIMENTAL|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
62278326|NCT02164422|PLACEBO_COMPARATOR|Placebo|Placebo
62278327|NCT00678145|EXPERIMENTAL|Healthy|Healthy individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
62278328|NCT00678145|EXPERIMENTAL|Type 1 Diabetes|T1D individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
62278329|NCT01401504|EXPERIMENTAL|ASP3026|
62278330|NCT02634580|ACTIVE_COMPARATOR|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
62278331|NCT02634580|ACTIVE_COMPARATOR|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
62278332|NCT02634580|EXPERIMENTAL|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
62455892|NCT00870870|ACTIVE_COMPARATOR|GCiC (Gemcitabine/Cisplatin/Cetuximab)|"Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~\*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
62644141|NCT03190824|EXPERIMENTAL|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
62455893|NCT05856045|EXPERIMENTAL|PNF intervention group|Proprioceptive neuromuscular facilitation (PNF) is a therapeutic approach that uses cutaneous, proprioceptive and auditory input to produce functional improvement in motor output.
62644142|NCT00125008|EXPERIMENTAL|1|Typhoid Vi vaccine
62644143|NCT00125008|ACTIVE_COMPARATOR|2|Hepatitis A vaccine
62074050|NCT02942680|EXPERIMENTAL|Experimental|acetylsalicylic acid started for 24 hours before surgery and determination of platelet function
62074051|NCT02942680|OTHER|Control|acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function
62074052|NCT01591460|EXPERIMENTAL|Dual Combination Therapy|
62074053|NCT01591460|EXPERIMENTAL|Triple Combination Therapy|
62074054|NCT06257901||Adults with Fabry disease|Focus groups and participatory workshops
62278333|NCT02634580|EXPERIMENTAL|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
62278334|NCT04224805|ACTIVE_COMPARATOR|Control|Interocclusal conventional splint is used to reposition the maxilla.
62278335|NCT04224805|EXPERIMENTAL|Study|Bone-borne splint is used to reposition the maxilla.
62278336|NCT05499065|EXPERIMENTAL|75mg cetuximab + 15mg cetuximab-800CW|To investigate if study drugs can assist in tumor-positive margin detection
62278337|NCT03796468|OTHER|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
62074055|NCT06257901||Lay specialist stakeholders|Focus groups
62074056|NCT06257901||Specialist stakeholders|Interviews
62278338|NCT03796468|OTHER|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best treatment medical
62074057|NCT03504735|PLACEBO_COMPARATOR|Therapeutic Lifestyle Change+Placebo|Therapeutic Life-style change intervention with Placebo pills.
62074058|NCT03504735|ACTIVE_COMPARATOR|Therapeutic Lifestyle Change+Caduet|Therapeutic Lifestyle Change intervention with Caduet pills.
62074059|NCT00763399|EXPERIMENTAL|97-0549B|
62074060|NCT03971812||Patient with high grade astrocytoma|Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study
62074061|NCT04694482||psychiatric patients|Psychometric scales
62074062|NCT04694482||healthy controls|Psychometric scales
62074063|NCT02268318|EXPERIMENTAL|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 1 bottle of dairy product/day with 1,6g of phytosterols
62074064|NCT02268318|PLACEBO_COMPARATOR|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 1 bottle of dairy product/day with no Phytosterols
62074065|NCT04328558|ACTIVE_COMPARATOR|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
62074066|NCT04328558|NO_INTERVENTION|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
62074067|NCT04882761|ACTIVE_COMPARATOR|Socket shield in direct contact with dental implant|eight partially extracted sockets where implant (Neobiotech) was placed in direct contact to socket shield
62074068|NCT04882761|ACTIVE_COMPARATOR|Socket shield with gap and xenograft with dental implant|eight partially extracted sockets where a gap was left between implant (Neobiotech) and socket shield
62074069|NCT00675506|EXPERIMENTAL|1|Participants will receive treatment with growth hormone releasing hormone 1-44 (TH9507).
62074070|NCT00675506|PLACEBO_COMPARATOR|2|Participants will receive treatment with placebo medication.
62074071|NCT00791921|EXPERIMENTAL|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
62074072|NCT00791921|PLACEBO_COMPARATOR|Placebo|Placebo of CDP870
62278339|NCT05196763|EXPERIMENTAL|Supplemental Nutrition Assistance Program-Education|"This group will receive the core content of the Supplemental Nutrition Assistance Program-Education over the 10-week intervention period."
62278340|NCT05196763|NO_INTERVENTION|Control|"This group will not receive the Supplemental Nutrition Assistance Program-Education during the intervention period nor throughout the study (1 year)."
62278341|NCT01842503|ACTIVE_COMPARATOR|GET 73|300 mg (3 capsules) tid for 3 days
62278342|NCT01842503|PLACEBO_COMPARATOR|inactive ingredients capsule|3 capsules tid for 3 days
62278343|NCT05167448|EXPERIMENTAL|Cohort 1 Phase 1|
62278344|NCT05167448|EXPERIMENTAL|Cohort 2 Phase 1|
62278345|NCT05167448|EXPERIMENTAL|RP2D Phase 2|
62278346|NCT04313907|EXPERIMENTAL|Acitve laser+topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus topical clonazepam 1 mg, 3 times at day, same 14 days both
62278347|NCT04313907|SHAM_COMPARATOR|Sham laser+topical clonazepam|Using sham laser (six sesions) plus topical clonazepam 1 mg, 3 times at day, same 14 days both
62278348|NCT04313907|PLACEBO_COMPARATOR|Active laser+placebo of topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus placebo of topical clonazepam (lactose), 3 times at day, same 14 days both
62278349|NCT00363038|EXPERIMENTAL|Bruising|Bruises at three time points: immediate after bruise creating, and at 1 and 2 weeks.
62278350|NCT04610528|EXPERIMENTAL|U3-1402|U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
62644144|NCT00000320|ACTIVE_COMPARATOR|1; liquid formulation|liquid formulation
62644145|NCT00000320|ACTIVE_COMPARATOR|2; tablet formulation|tablet formulation
62278351|NCT02666014|ACTIVE_COMPARATOR|Sugammadex group|"Sugammadex 2 mg/Kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation.~The drug is to be diluted with normal saline to make up to 5 ml volume to maintain blinding."
62644146|NCT05185063||Out of Hospital Cardiac Arrest|
62644147|NCT01338896|EXPERIMENTAL|Sequence A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)
62074073|NCT04445155|EXPERIMENTAL|Modified DECIDE-Provider Arm|2-4 hour workshop for providers to improve perspective-taking, reduce attributional errors, and increase receptivity to parent participation.
62074074|NCT04445155|EXPERIMENTAL|Modified DECIDE-Parent Arm|Up to three parent training sessions designed to help patients effectively ask questions and participate in decisions about care.
62278352|NCT02666014|ACTIVE_COMPARATOR|Neostigmine group|"Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg, diluted in normal saline to make up 5 ml total volume to maintain blinding.~Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation for reversal of neuromuscular blockade produced during surgery.~Atropine sulfate-diphenoxylate hydrochloride combination will be an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered."
62278353|NCT06103903||Children aged 6-13 years|Children aged 6-13 years with a chronic skin visible disease
62278354|NCT06103903||Adolescents aged 14-17 years|Adolescents aged 14-17 years years with a chronic skin visible disease
62278355|NCT06103903||Adult patients|Adult patients aged 18 years and more with a chronic skin visible disease
62278356|NCT06103903||Parents of children aged 6 years and more|Parents of children aged 6 years and more with a chronic skin visible disease
62278357|NCT03962985|OTHER|Intervention|The 41 participants will attend the guided tours at the Montreal Museum of Fine Arts.
62644148|NCT01338896|EXPERIMENTAL|Sequence B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)
62644149|NCT01382550||VTE subjects|"subjects with a recent (\<3 months) first VTE event undergoing long-lasting OAT or 12-month OAT~Exclusion criteria: missing data during the follow-up; contraindications to or lack of compliance to oral anticoagulation (OAT), lack of informed consent; history of previous VTE event; indication for continuous oral anticoagulation (e.g., an artificial heart valve or chronic atrial fibrillation); events occurring during pregnancy, malignancy, puerperium, oral contraceptive intake, hormone replacement therapy; deficiencies of Prot. C and Prot S or combined inhibitor deficiencies."
62278358|NCT02744157|OTHER|structured lifestyle program|The program consisted of an individual visit to a nurse for a health check-up and lifestyle counseling at baseline, six month and one year. The program also consisted of five group educations which included lectures on nicotine, alcohol, physical inactivity, eating habits, stress, sleeping habits and behavior changes
62455894|NCT05856045|EXPERIMENTAL|PBBT(pertubation based balance training) intervention group|Perturbation-based balance training (also referred to as reactive balance training or perturbation training) utilizes a task-specific approach to balance training, applying repeated exposure to unpredictable mechanical perturbations that mimic balance disturbances experienced in daily life.
62644150|NCT01764841|EXPERIMENTAL|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
62074075|NCT04445155|OTHER|Provider Subgroup Study|To boost provider recruitment, we sought recommendations from a subgroup of providers. We gave each provider access to the DECIDE online training and the pre- and post-survey.
62074076|NCT04445155|NO_INTERVENTION|Treatment as Usual|Control arm
62455895|NCT05856045|EXPERIMENTAL|PNF and PBBT intervention group|both techniques will be used
62278359|NCT00049088|EXPERIMENTAL|Treatment (docetaxel, bevacizumab)|For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
62278360|NCT06464146|ACTIVE_COMPARATOR|Morphine|Oral morphine (0.5mg/kg) and IN placebo
62455896|NCT01323764|ACTIVE_COMPARATOR|Radionuclide SPS|Radionuclide Shunt Patency Study
62455897|NCT02684682|OTHER|12h Group|Intervention 'Frequency of mechanical control of plaque (12h)'
62644151|NCT01764841|EXPERIMENTAL|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
62074077|NCT03702101||Orofacial pain group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
62074078|NCT03702101||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
62074079|NCT01572324|EXPERIMENTAL|Arterial infusion|
62278361|NCT06464146|EXPERIMENTAL|IN Fentanyl|placebo of oral morphine and IN fentanyl (1.5 µg/kg)
62278362|NCT06464146|EXPERIMENTAL|IN Ketamin|placebo of oral morphine and IN ketamine (1 mg/kg)
62278363|NCT01207622|ACTIVE_COMPARATOR|Atomoxetine|
62278364|NCT01207622|PLACEBO_COMPARATOR|Placebo|
62455898|NCT02684682|OTHER|24h Group|Intervention 'Frequency of mechanical control of plaque (24h)'
62455899|NCT02684682|OTHER|48h Group|Intervention 'Frequency of mechanical control of plaque (48h)'
62455900|NCT00483496|EXPERIMENTAL|V0096CR actives and vehicle|"Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window).~Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator."
62455901|NCT01223300||Osteoporosis|
62455902|NCT01932840||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is an online panel which answer surveys every 8-10 weeks about diet and health
62455903|NCT02154308|EXPERIMENTAL|IL-YANG influenza vaccine|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
62455904|NCT00784849|EXPERIMENTAL|1|One arm diagnostic
62455905|NCT05184049|EXPERIMENTAL|Epalrestat|oral epalrestat (50mg/ time, 3 times/day) + conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
62074080|NCT02899871||Control|patients treated with anti-TNF not presenting any joint symptoms.
62074081|NCT02899871||case|aetiology of joint symptoms
62074082|NCT03436134|ACTIVE_COMPARATOR|Plasma Exchange Group|Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
62074083|NCT03436134|EXPERIMENTAL|Double filtration PlasmaPheresis Group|Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
62074084|NCT00453310|EXPERIMENTAL|sunitinib malate|The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
62074085|NCT01061437|ACTIVE_COMPARATOR|Arm 1|Standard 14 day, 3-drug regimen
62074086|NCT01061437|EXPERIMENTAL|Arm 2|Concomitant Therapy - 5 day, 4-drug regimen
62074087|NCT01061437|EXPERIMENTAL|Arm 3|Sequential Therapy - 10 day, 4-drug regimen
62278365|NCT01797900|EXPERIMENTAL|Inductive + concurrent chemotherapy|Inductive chemotherapy :paclitaxel 175mg/m2 d1+ cisplatin 80mg/m2d1, every 21 days for two cycles concurrent chemotherapy:cisplatin 80mg/m2 on week 1, 4, 7 radiotherapy: IMRT
62455906|NCT05184049|EXPERIMENTAL|The control group|conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
62455907|NCT04140175||Women with suspected or confirmed endometriosis|Women with suspected or confirmed endometriosis undergoing standard of care treatments or interventions.
62455908|NCT02833038|EXPERIMENTAL|Magnesium group|Intravenous administration of Magnesium Sulfate
62644152|NCT01764841|PLACEBO_COMPARATOR|Placebo 28 Days on/off (Placebo 28)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
62074088|NCT05174104|EXPERIMENTAL|Early Vestibular Rehabilitation|This group will undergo a 4 weeks of vestibular rehabilitation in the first month and then it will be only followed up in the second month
62074089|NCT05174104|EXPERIMENTAL|Delayed Vestibular Rehabilitation|This group will be followed-up for the first month and the it will undergo 4 weeks of vestibular rehabilitation in the second month
62074090|NCT04297241|EXPERIMENTAL|Isosorbide Dinitrate|Each enrolled participant will be on a titrated dosage of isosorbide dinitrate to determine effectiveness on both primary and secondary outcome measures.
62278366|NCT01797900|ACTIVE_COMPARATOR|concurrent + adjuvant chemotherapy|concurrent chemotherapy: cisplatin 80 mg/m2, on week 1, 4, 7 adjuvant chemotherapy: paclitaxel 175mg/m2 + cisplatin 75mg/m2, every 21 days for 4 cycles radiotherapy: IMRT
62278367|NCT03029975|ACTIVE_COMPARATOR|RDA|Participants will be asked to consume the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein consumption will be emphasized and participants will consume a beef meal after each training session.
62278368|NCT03029975|EXPERIMENTAL|2x RDA|Participants will be asked to consume the twice the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein will be emphasized and participants will consume a beef meal after each training session.
62278369|NCT04203485|EXPERIMENTAL|Camrelizumab 200mg + Apatinib Mesylate 250mg|Camrelizumab 200mg q2w ivgtt+ Apatinib Mesylate 250mg once daily po qd
62278370|NCT04203485|EXPERIMENTAL|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
62278371|NCT04203485|ACTIVE_COMPARATOR|Pemetrexed/Paclitaxel injection+ Carboplatin|For non-squamous NSCLC: Pemetrexed disodium for injection + Carboplatin; For squamous NSCLC: Paclitaxel injection + Carboplatin
62278372|NCT01032551|EXPERIMENTAL|Vascular Access Patient Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
62278373|NCT01032551|NO_INTERVENTION|Usual Care|"The control group (those not randomized to the PtDA) will have usual care. Usual care involves a brief discussion, just prior to the CA procedure, with the treating physician, regarding the patient's eligibility for both vascular accesses, followed by the advantages and disadvantages of both. The details and duration of the discussion is left to the discretion of the treating physician as per their individual standard of care. There will be no access to a formal PtDA in this group."
62278374|NCT05010460|EXPERIMENTAL|Roxadustat|Roxadustat
62278375|NCT05010460|PLACEBO_COMPARATOR|placebo|Placebo has the same appearance with the experimental drug (Roxadustat).
62074091|NCT00504296|EXPERIMENTAL|SB939|
62074092|NCT02954900|OTHER|Decision aid|50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
62074093|NCT03882671|EXPERIMENTAL|Monitoring Device|Subjects will be asked to wear up to 3 different noninvasive seizure detection devices including EpiTel EpiLog, Empatica E4, GeneActiv
62455909|NCT02833038|PLACEBO_COMPARATOR|Control group|Intravenous administration of normal saline
62074094|NCT01232309|ACTIVE_COMPARATOR|High Dose Chitin-Glucan|Daily oral dose of 4.5 g of chitin-glucan
62074095|NCT01232309|ACTIVE_COMPARATOR|Low Dose Chitin-Glucan|Daily oral dose of 1.5 g chitin-glucan
62455910|NCT03852706|EXPERIMENTAL|LORETA|In the first session, Low Resolution Brain Electromagnetic Tomography (LORETA) will be used in combination with Z-scores to identify participants' resting state EEG differences relative to a database of norms of their demographic. EEG abnormalities which are consistent with the research literature on neural changes associated with AVH will then be targeted for normalization using neurofeedback training using LORETA in combination with Z-scores.
62455911|NCT03852706|OTHER|Treatment as usual|Maintenance use of an atypical antipsychotic (e.g., clozapine) with support, when needed, of a community nurse.
62074096|NCT01232309|EXPERIMENTAL|Low Dose Chitin-Glucan + Olive Extract|Daily oral dose of 1.5 g chitin-glucan + 135 mg olive extract
62074097|NCT01232309|PLACEBO_COMPARATOR|Placebo|Placebo (Rice Flour)
62074098|NCT01625624|PLACEBO_COMPARATOR|Control Food Product|
62074099|NCT01625624|EXPERIMENTAL|Experimental Food Product|
62074100|NCT00214032|EXPERIMENTAL|1|pycnogenol daily
62074101|NCT00214032|PLACEBO_COMPARATOR|2|placebo daily
62074102|NCT06139991|EXPERIMENTAL|Treatment sequence ABB|Participants will receive Treatment A, followed by Treatment B, followed by Treatment B, all treatments as a single dose, with a washout period of minimum 3 days, but no longer than 7 days, between each study dose administration.
62074103|NCT06139991|EXPERIMENTAL|Treatment sequence BBA|Participants will receive Treatment B, followed by Treatment B, followed by Treatment A, all treatments as a single dose, with a washout period of minimum 3 days, but no longer than 7 days, between each study dose administration.
62278376|NCT02658812|EXPERIMENTAL|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec IT on day 1. Cycles repeat every 3 weeks in cycle 1 and every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
62278377|NCT00428675||ACI Instrument|228 individuals completed the ACI instrument and other tools
62278378|NCT03164382|EXPERIMENTAL|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
62278379|NCT03164382|ACTIVE_COMPARATOR|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
62278380|NCT00577993|ACTIVE_COMPARATOR|1: FND + Rituximab Followed by Interferon|Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon
62278381|NCT00577993|ACTIVE_COMPARATOR|2: FND Followed by Interferon & Rituximab|Fludarabine/Novantrone/Decadron Followed by Interferon \& Rituximab
62278382|NCT00577993|ACTIVE_COMPARATOR|3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon|Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon
62644153|NCT01764841|PLACEBO_COMPARATOR|Placebo 14 Days on/off (Placebo 14)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
62644154|NCT03894358|ACTIVE_COMPARATOR|FeFum and 7.5 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture
62644155|NCT03894358|ACTIVE_COMPARATOR|FeFum and 3 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture
62644156|NCT03894358|ACTIVE_COMPARATOR|FeFum and no prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate
62074104|NCT06139991|EXPERIMENTAL|Treatment sequence BAB|Participants will receive Treatment B, followed by Treatment A, followed by Treatment B, all treatments as a single dose, with a washout period of minimum 3 days, but no longer than 7 days, between each study dose administration.
62278383|NCT06221982||Patients undergoing TIPS procedure|Patients undergoing TIPS procedure due to portal hypertension-related complications
62278384|NCT05893849||Older adults|Aged 60-74 years old, takes omeprazole or rabeprazole or pantoprazole or metoprolol or carvedilol or amlodipine or finasteride or simvastatin or rivaroxaban or meropenem or atorvastatin or rosuvastatin or metformin
62644157|NCT04142333|OTHER|GIA Access|All patients consented to this study will be given access to the GIA technology to share with their family members.
62644158|NCT04854239|EXPERIMENTAL|Machine-driven group|In the machine-driven group, after guided implant bed preparation, implant insertion was performed with contra-angled handpiece.
62644159|NCT04854239|EXPERIMENTAL|Manual group|In the manual group, after guided implant bed preparation, implant insertion was performed with torque-wrench.
62644160|NCT04149340|OTHER|Sufentanil sedation|3 microgram of Sufentanil IV
62644161|NCT04149340|PLACEBO_COMPARATOR|Placebo sedation|1 ml de NaCl 0,9%
62644162|NCT04149340|OTHER|Multimodal sedation|Clonidine, sufantil, midazolam, dihydrobenzperidol, ketamine
62644163|NCT02291978|EXPERIMENTAL|ExAblate 2100 Treatment|The ExAblate 2100 system will be used in the MRgHIFU treatment of lower back pain arising from facet joint arthritis.
62644164|NCT03225365|OTHER|Nivolumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab treatment.~30 patients will be included in the arm."
62644165|NCT03225365|OTHER|Nivolumab + Ipilimumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab + Ipilimumab treatment.~30 patients will be included in the arm."
62644166|NCT00603031|EXPERIMENTAL|GLP-1|time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
62074105|NCT02649322|EXPERIMENTAL|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
62074106|NCT02649322|ACTIVE_COMPARATOR|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
62074107|NCT01873547|ACTIVE_COMPARATOR|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
62074108|NCT01873547|EXPERIMENTAL|cell therapy|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
62074109|NCT01873547|NO_INTERVENTION|control|Patients receive no professional treatment in hospital or rehabilitation centre.
62074110|NCT03926585||Responders|Patients in combination therapy due to persistent symptoms on L-thyroxin mono-therapy who experience a longtime effect of triiodothyronine treatment.
62074111|NCT03926585||Non-responders|Patients who have tried combination therapy due to persistent symptoms on L-thyroxin mono-therapy, but did not experience a longtime effect.
62074112|NCT02222896|EXPERIMENTAL|Chlorhexidine Gluconate Cloth|2% CHG, single application
62074113|NCT02222896|PLACEBO_COMPARATOR|Vehicle Cloth|Excipients on cloth
62074114|NCT02222896|ACTIVE_COMPARATOR|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
62455912|NCT00727571||No CKD or Anemia|Chronic kidney disease (CKD) is based on estimated Glomerular Filtration Rate (GFR), calculated by the Modification of Diet in Renal Disease (MDRD) method, of \< 60 mL/min/1.73m\^2. Anemia is defined as Hemogloblin \<12 g/dL in women, \< 13 g/dL in men per World Health Organization (WHO) criteria. Participants completed the study after Week 1; data contributed to prevalence estimates.
62455913|NCT00727571||No CKD, but Anemia|CKD is based on estimated GFR calculated by the MDRD method of \< 60 mL/min/1.73m\^2. Anemia is defined as Hemogloblin \<12 g/dL in women, \< 13 g/dL in men per WHO criteria. Participants completed the study at Week 2 and completed an anemia work-up; data contributed to prevalence estimates.
62644167|NCT00603031|PLACEBO_COMPARATOR|NaCl|time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
62644168|NCT00603031|EXPERIMENTAL|GIP|time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
62074115|NCT04539119|EXPERIMENTAL|Entecavir and Tenofovir|
62074116|NCT04539119|ACTIVE_COMPARATOR|Entecavir|
62074117|NCT04266041|EXPERIMENTAL|High-density EEG localization in epilepsy|High-density EEG will be used for brain localization in epilepsy patients
62074118|NCT04266041|ACTIVE_COMPARATOR|High-density EEG localization in healthy controls|High-density EEG will be used for brain localization in healthy controls
62074119|NCT04266041|EXPERIMENTAL|High-density EEG localization in tumor patients|High-density EEG will be used for brain localization in tumor patients
62074120|NCT04266041|EXPERIMENTAL|High-density EEG localization in peripheral nerve patients|High-density EEG will be used for brain localization in patients with peripheral nerve dysfunction
62644169|NCT03530891|EXPERIMENTAL|Computer guided lag screw fixation|Patient specific surgical guided will be used for open reduction and internal fixation for anterior mandibular fracture by lag screws.
62644170|NCT03530891|ACTIVE_COMPARATOR|Conventional lag screw fixation|Open reduction and internal fixation for anterior mandibular fracture using lag screws.
62074121|NCT04266041|EXPERIMENTAL|High-density EEG localization in stroke patients|High-density EEG will be used for brain localization in patients who have recently experienced a stroke
62074122|NCT03498326|EXPERIMENTAL|gemcitabine|one group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection.
62074123|NCT03498326|EXPERIMENTAL|gemcitabine plus celecoxib|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection, and receive additional celecoxib every days during chemotherapy period.
62278385|NCT05893849||Old older adults|Aged \>75 years old, takes omeprazole or rabeprazole or pantoprazole or metoprolol or carvedilol or amlodipine or finasteride or simvastatin or rivaroxaban or meropenem or atorvastatin or rosuvastatin or metformin
62074124|NCT04420546|ACTIVE_COMPARATOR|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to be more physically active (We want you to plan to increase your level of physical activity). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted not to be physically active and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
62074125|NCT04420546|EXPERIMENTAL|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
62074126|NCT00512551||Cervical cancer tumor biopsy + radiation therapy|Cervical cancer tumor biopsy + radiation therapy.
62074127|NCT03591757|EXPERIMENTAL|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
62074128|NCT03073460|OTHER|Ultrasound examination|Participants will undergo an ultrasound examination at 40 weeks gestation to assess the fetal ductus arteriosis.
62074129|NCT05106153|EXPERIMENTAL|Qualification Phase: Treatment Sequence YXZ|Participants will receive a single oral dose of suvorexant (Treatment Y) in qualification period 1, followed by single oral dose of placebo (Treatment X) in qualification period 2 and then single oral dose of zolpidem (Treatment Z) in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
62074130|NCT05106153|EXPERIMENTAL|Qualification Phase: Treatment Sequence ZYX|Participants will receive Treatment Z in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
62074131|NCT05106153|EXPERIMENTAL|Qualification Phase: Treatment Sequence XZY|Participants will receive Treatment X in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
62644171|NCT01332825|NO_INTERVENTION|olfactory dysfunction|subjects diagnosed with olfactory dysfunction
62644172|NCT01332825|NO_INTERVENTION|normal olfaction, no saline|no smell dysfunction, not randomized to saline nasal irrigation for 7 days
62644173|NCT01332825|OTHER|normal olfaction|normal olfaction, randomized to saline nasal irrigation for 7 days
62644174|NCT01057836|EXPERIMENTAL|Neck strength training|
62644175|NCT01057836|EXPERIMENTAL|Neck endurance training|
62644176|NCT01057836|ACTIVE_COMPARATOR|Stretching|
62644177|NCT06088589|EXPERIMENTAL|Speech Sounds|Participants will hear repeated speech sounds while wearing a neuroimaging cap.
62644178|NCT01095172|EXPERIMENTAL|Rituximab|"Rituximab 375mg/m2~Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone"
62644179|NCT01095172|ACTIVE_COMPARATOR|Control group|Low dose tacrolimus with mycophenylate mofetil and continued prednisolone
62644180|NCT04680832|EXPERIMENTAL|ILD patients|Patients diagnosed with one of the most prevalent fibrotic ILDs: IPF, CHP, CTD-ILD, iNSIP, IPAF, and unclassifiable ILD (defined as unclassifiable disease at the time of the first MDT).
62644181|NCT00800046|EXPERIMENTAL|AccuCinch® Ventriculoplasty System|Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.
62644182|NCT01334086|EXPERIMENTAL|Aprepitant|
62644183|NCT04119934||Control - None|A retrospective chart review will assess physician/NP behaviour (rates of smoking cessation counselling and prescription of smoking cessation pharmacotherapy) in the one-year pre-intervention period.
62644184|NCT04119934||Intervention - Smoking cessation infographic|Throughout the intervention period, the personalized smoking cessation infographic will be provided to physicians/NPs (for eligible patients). Chart review will be conducted for the patient's physician/NP within a three-month window of receiving the infographic to assess outcomes.
62644185|NCT00176449|ACTIVE_COMPARATOR|Bupropion SR|
62644186|NCT00176449|PLACEBO_COMPARATOR|Placebo|
62644187|NCT02344823|ACTIVE_COMPARATOR|Vardenafil Phase A|HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7
62644188|NCT02344823|PLACEBO_COMPARATOR|Placebo Phase A|HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7
62644189|NCT02344823|ACTIVE_COMPARATOR|Vardenfil Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28
62644190|NCT02344823|PLACEBO_COMPARATOR|Placebo Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28
62644191|NCT03289338|EXPERIMENTAL|Zoledronic acid|Bisphosphonate Zoledronic acid
62644192|NCT03289338|ACTIVE_COMPARATOR|Methylprednisolone|Glucocorticoid Methylprednisolone
62644193|NCT03289338|PLACEBO_COMPARATOR|Placebos|Placebo normal saline
62074132|NCT05106153|EXPERIMENTAL|Qualification Phase: Treatment Sequence YZX|Participants will receive Treatment Y in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
62278386|NCT04858945|EXPERIMENTAL|Teach-back group|The first education session will be arranged at the day or the following day of admission before delivery, with a group meeting involving three women and one educator. The main purpose of the first session is to help women understand and prepare for the labor. On the day of discharge after delivery, women will receive the second group education session hosted by an educator. The main purpose of the second session is to help women understand postpartum health issues, get to know the practice of postpartum recovery and learn newborn care skills. At two-week postpartum, a short online meeting will be arranged. During the meeting, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
62278387|NCT04858945|ACTIVE_COMPARATOR|Control group|Teach-back group and control group share some education content and communication methods, e.g. power-point presentation, educational video clips, live demonstration, information booklet, group discussion, and Q\&A, expect that before the end of each education session.
62278388|NCT00117468|EXPERIMENTAL|1|
62278389|NCT00117468|ACTIVE_COMPARATOR|2|
62644194|NCT02697071|PLACEBO_COMPARATOR|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
62644195|NCT02697071|EXPERIMENTAL|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
62278390|NCT05760443|EXPERIMENTAL|Mindfulness-based intervention|6 week group mindfulness-based intervention
62644196|NCT01286129|ACTIVE_COMPARATOR|Allergic asthmatic|Subjects with allergic asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
62644197|NCT01286129|ACTIVE_COMPARATOR|Allergic rhinitic without asthma|Subjects with allergic rhinitis without asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
62644198|NCT01408706|ACTIVE_COMPARATOR|Miller enema air tip|The Miller enema air tip rectal balloon is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy.
62644199|NCT01408706|ACTIVE_COMPARATOR|Radiadyne Immobilizer|The Radiadyne Immobilizer Treatment Device is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy
62644200|NCT04135404||Pulmonary Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; pulmonary group are those who have reported any pulmonary diseases and they will be included in this study as pulmonary group.
62644201|NCT04135404||Control Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; The control group are subjects without pulmonary diseases and they will be included as (control group).
62644202|NCT04545073||Post-refractive trifocal IOL|
62644203|NCT00986414|EXPERIMENTAL|AFQ056-10mg|
62644204|NCT00986414|EXPERIMENTAL|AFQ056-25mg|
62644205|NCT00986414|EXPERIMENTAL|AFQ056-50mg|
62278391|NCT00250510|NO_INTERVENTION|1|
62644206|NCT00986414|EXPERIMENTAL|AFQ056-75mg|
62644207|NCT00986414|EXPERIMENTAL|AFQ056-100mg|
62644208|NCT00986414|PLACEBO_COMPARATOR|Placebo|
62278392|NCT00250510|EXPERIMENTAL|2|EatRight Program inquirers with BMI's of 30 kg/m2 or greater were told that they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if certain conditions were met.
62278393|NCT02881268||Patient with sepsis|Patient hospitalized in intensive care unit
62644209|NCT00975728|EXPERIMENTAL|Group 1 Product 825 (2-servings day)|30 subjects drinking 2 servings day of Product 825 for 8 weeks
62074133|NCT05106153|EXPERIMENTAL|Qualification Phase: Treatment Sequence ZXY|Participants will receive Treatment Z in qualification period 1, followed by Treatment X in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during qualification phase. Each treatment will be separated by washout of at least 3 days.
62278394|NCT02881268||Patient without sepsis|Patient hospitalized in intensive care unit
62278395|NCT01045980|EXPERIMENTAL|Bioimpedance and Vitamin D|
62278396|NCT01045980|EXPERIMENTAL|Usual care and Vitamin D|Vitamin D3
62278397|NCT01045980|EXPERIMENTAL|Bioimpedance and Placebo|
62278398|NCT01045980|PLACEBO_COMPARATOR|Usual Care and Placebo|
62644210|NCT00975728|EXPERIMENTAL|Group 1 Product 824 (2 servings-day)|30 subjects drinking 2 servings-day of Product 824 for 8 weeks
62278399|NCT05204043|EXPERIMENTAL|Peter Hess® sound massage|Peter Hess® sound massage using bowls dedicated to this technique.
62278400|NCT05204043|EXPERIMENTAL|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation.
62278401|NCT00000785||A|All eligible CPCRA subjects
62278402|NCT04461990||Luminal|"Luminal A：ER+ and/or PR+,HER2- Luminal B：ER+ and/or PR+,HER2+~\* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
62278403|NCT04461990||HER2 overexpression|"ER- PR-,HER2+~\* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
62278404|NCT04461990||Triple negative|"ER- PR-,HER2-~\* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
62644211|NCT00975728|EXPERIMENTAL|Group 2 Product 825 (1 serving-day)|30 subjects drinking 1 serving-day of Product 825 for 8 weeks
62644212|NCT00975728|EXPERIMENTAL|Gruop 2 Product 824 (1 serving-day)|30 subjects drinking 1 serving-day of Product 824 for 8 weeks
62644213|NCT00854997||1|AMI with OSA
62644214|NCT00854997||2|AMI without OSA
62644215|NCT02423226|ACTIVE_COMPARATOR|CT alone|Treated with systemic chemotherapy alone (FOLFIRI).
62644216|NCT02423226|EXPERIMENTAL|CT+BT|Treated with systemic chemotherapy (FOLFIRI) plus computed tomography guided radioactive seeds implant.
62644217|NCT00111761|EXPERIMENTAL|Part 1: Panitumumab + IFL|Panitumumab (2.5 mg/kg once weekly for up to 48 weeks or until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan, 5-fluorouracil (5-FU)and leucovorin (IFL chemotherapy regimen)
62074134|NCT05106153|EXPERIMENTAL|Qualification Phase: Treatment Sequence XYZ|Participants will receive Treatment X in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment Z in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
62074135|NCT05106153|EXPERIMENTAL|Treatment Phase: Treatment Sequence ABFCED|Participants will receive a single oral dose of placebo (Treatment A) in treatment period 1, followed by single oral dose of suvorexant (Treatment B) in treatment period 2, single oral Dose 3 of seltorexant (Treatment F) in treatment period 3, single oral dose of zolpidem (Treatment C) in treatment period 4, single oral Dose 2 of seltorexant (Treatment E) in treatment period 5 and then a single oral Dose 1 of seltorexant (Treatment D) in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
62074136|NCT05106153|EXPERIMENTAL|Treatment Phase: Treatment Sequence BCADFE|Participants will receive Treatment B in treatment period 1, followed by Treatment C in treatment period 2, Treatment A in treatment period 3, Treatment D in treatment period 4, Treatment F in treatment period 5 and then Treatment E in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
62074137|NCT05106153|EXPERIMENTAL|Treatment Phase: Treatment Sequence CDBEAF|Participants will receive Treatment C in treatment period 1, followed by Treatment D in treatment period 2, Treatment B in treatment period 3, Treatment E in treatment period 4, Treatment A in treatment period 5 and then Treatment F in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
62074138|NCT05106153|EXPERIMENTAL|Treatment Phase: Treatment Sequence DECFBA|Participants will receive Treatment D in treatment period 1, followed by Treatment E in treatment period 2, Treatment C in treatment period 3, Treatment F in treatment period 4, Treatment B in treatment period 5 and then Treatment A in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
62074139|NCT05106153|EXPERIMENTAL|Treatment Phase: Treatment Sequence: EFDACB|Participants will receive Treatment E in treatment period 1, followed by Treatment F in treatment period 2, Treatment D in treatment period 3, Treatment A in treatment period 4, Treatment C in treatment period 5 and then Treatment B in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
62074140|NCT05106153|EXPERIMENTAL|Treatment Phase: Treatment Sequence FAEBDC|Participants will receive Treatment F in treatment period 1, followed by Treatment A in treatment period 2, Treatment E in treatment period 3, Treatment B in treatment period 4, Treatment D in treatment period 5 and Treatment C in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
62074141|NCT01409421|EXPERIMENTAL|motivational interviewing|3 phone and 3 in person counseling support sessions with glaucoma educator
62074142|NCT01409421|ACTIVE_COMPARATOR|reminder calls|behavioral: three phone calls to remind patients to take their eye drops
62074143|NCT01409421|NO_INTERVENTION|standard care|standard care for glaucoma
62278405|NCT05529914|EXPERIMENTAL|Myofascial release + Neuromuscular exercises + Cold pack|
62278406|NCT05529914|ACTIVE_COMPARATOR|Neuromuscular exercises + Cold pack|
62278407|NCT04302532|ACTIVE_COMPARATOR|Clomiphene|clomiphene citrate 150 mg once a day for 5 days
62074144|NCT00063817|EXPERIMENTAL|Conditioning Regimen|"Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days."
62074145|NCT05686915||Revision Total Hip Arthroplasty|Patients who received a revision total hip surgery utilizing a ceramic femoral head with a titanium sleeve
62074146|NCT01627080||Cardiac Biomarkers|Patients with histologically proven esophageal cancer to be treated with radiation therapy with concurrent chemotherapy to a final dose of \>/=40 Gy included in this study at UT MD Anderson Cancer Center in Houston, Texas.
62278408|NCT04302532|EXPERIMENTAL|clomiphene and coenzyme q10|clomiphene citrate 150 mg once a day for 5 days and coenzyme q 10 120 mg each day
62278409|NCT02747030|EXPERIMENTAL|Ocriplasmin intravenously|All subjects included in this phase I study are in the experimental treatment arm and will undergo a vitrectomy augmented with retinal vein cannulation and intravenous Ocriplasmin infusion.
62278410|NCT06345456|EXPERIMENTAL|Capnography device|
62278411|NCT04186026|OTHER|Saline+Saline|
62278412|NCT04186026|OTHER|Neurotensin+Saline|
62278413|NCT04186026|OTHER|GLP-1+Saline|
62278414|NCT04186026|OTHER|Neurotensin + GLP-1|
62278415|NCT01020760|NO_INTERVENTION|No posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to avoid supine posturing for seven days after surgery, but will not be advised to posture in the face down or prone position.
62278416|NCT01020760|EXPERIMENTAL|Face down posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to posture in the face down or prone position for 50 minutes per hour for seven days.
62278417|NCT05346614|EXPERIMENTAL|Active lifestyle intervention|Individuals in the active intervention group will undergo diabetyping (diabetes type 2 phenotyping: glucose, and C-peptide responses to a glucose challenge). Based on the diabetype, individuals will receive recommendations to follow either a calorie-restricted (500kcal deficit minimum) low carbohydrate or a modified Mediterranean diet for a period of 18 weeks (total intervention is 24 weeks). Secondly, individuals will follow a personalized exercise program. Guidance and coaching (individual and small group) will be given via mobile app and digital platform. Individuals will receive real-time feedback based on their diet, exercise, and glucose levels (via continuous glucose monitoring for 4 weeks). Medications will be slowly withdrawn over the intervention period, with a focus on the first phase of the intervention.
62278418|NCT05346614|NO_INTERVENTION|Usual care group|Individuals in the usual care group will receive standard diabetes care.
62278419|NCT02727283|EXPERIMENTAL|Cohort 1|Subjects will receive 1 placebo and 3 escalating doses in one of the four treatment periods. The planned dose range is 10 mg to 200 mg. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
62455914|NCT00727571||CKD with Anemia|CKD is based on estimated GFR calculated by the MDRD method of \< 60 mL/min/1.73m\^2. Anemia is defined as Hemogloblin \<12 g/dL in women, \< 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.
62455915|NCT00727571||CKD with no Anemia|CKD is based on estimated GFR calculated by the MDRD method of \< 60 mL/min/1.73m\^2. Anemia is defined as Hemogloblin \<12 g/dL in women, \< 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed mobility and physical performance assessments.
62644218|NCT00111761|EXPERIMENTAL|Part 2: Panitumumab + FOLFIRI|Panitumumab (2.5 mg/kg once weekly until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan/5-FU/leucovorin chemotherapy (the FOLFIRI regimen)
62644219|NCT04599231|EXPERIMENTAL|Study group|"The investigators would perform the following tests preoperatively on the study subjects.~1. Hospital Anxiety and Depression Scale (HADS)~2. Amsterdam Preoperative Anxiety and Information Scale (APAIS)~3. Coping and Adaptation Processing Scale-Short Form (CAPS-SF)~4. Quality of Recovery -15 (QOR-15)"
62455916|NCT05742529|ACTIVE_COMPARATOR|TIP|
62455917|NCT05742529|ACTIVE_COMPARATOR|stitch by stitch|
62278420|NCT02727283|EXPERIMENTAL|Cohort 2|Cohort 2 will proceed after completion of the treatment periods in Cohort 1. Subjects assigned to Cohort 2 will participate in up to 4 dosing periods which include up to 2 escalating doses and placebo in Periods 1 and 2, and a pilot food effect in Periods 3 and 4. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
62644220|NCT03504800||Group A: Classification of Corneal Irregularities|This group will consist of participants \>14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
62074147|NCT02831309|SHAM_COMPARATOR|Sedentary Condition|Forty minutes of screen time. Standardized meals provided.
62074148|NCT02831309|ACTIVE_COMPARATOR|Light-Intensity Condition|Forty minutes of light-intensity activity. Standardized meals provided.
62074149|NCT02831309|ACTIVE_COMPARATOR|Moderate-Intensity Condition|Forty minutes of moderate-intensity activity. Standardized meals provided.
62074150|NCT02831309|ACTIVE_COMPARATOR|High-Intensity Condition|Forty minutes of high-intensity activity. Standardized meals provided.
62074151|NCT01882595|EXPERIMENTAL|Nebulization through the tracheostomy|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
62074152|NCT01882595|ACTIVE_COMPARATOR|Nebulization through the mouth|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
62278421|NCT01937455|EXPERIMENTAL|Group A|rAAV1-PG9DP or placebo (v:p = 3:1)
62278422|NCT01937455|EXPERIMENTAL|Group B|rAAV1-PG9DP or placebo (v:p = 3:1)
62278423|NCT01937455|EXPERIMENTAL|Group C/C1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
62278424|NCT01937455|EXPERIMENTAL|Group D/D1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
62278425|NCT00758472||Hip Resurfacing|
62278426|NCT04311086|EXPERIMENTAL|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
62278427|NCT02011009|EXPERIMENTAL|BLSE|The main objective of this study is to measure the carriage of antibiotic-resistant bacteria (enterobacteria ESBLs) in HIV seropositive patients looking for potential factors associated with sexual transmission. As a matter of fact, there is currently a worldwide community epidemic outbreak of enteric bacteria resistant to antibiotics for which the modes of transmission are still not fully known. There are many open questions about the possibility of sexual transmission and this study aims to find an answer.
62278428|NCT01770600|ACTIVE_COMPARATOR|Risperidone|Administer pill of risperidone 1 mg once a day by mouth for 5 days.
62074153|NCT02343588|EXPERIMENTAL|The Health Lifestyles Interventions|"1. Creating a supportive school, family and community environment;~2. Health lifestyles educational strategies;~3. Instruct and promote school physical education;~4. The monitoring and instruction of obesity related behaviors (focus group)"
62074154|NCT02343588|NO_INTERVENTION|Receive no intervention|Usual practice
62074155|NCT05994261|ACTIVE_COMPARATOR|Cereset Research Tune-Up Intervention Group|All study participants will receive 4 initial CR sessions. Afterwards, they will be randomized, and this group will receive an additional tune-up (maintenance) session every 6 weeks for one year. There will be a CR session at weeks 6, 12, 18, 24, 30, 36, 42, and 48.
62074156|NCT05994261|OTHER|Cereset Research Control Group|All study participants will receive 4 initial CR sessions. Afterwards, they will be randomized, and this group will continue their current care for 1 year with no additional CR sessions.
62074157|NCT06038812|OTHER|Group I|patients diagnosed with gingivitis
62074158|NCT06038812|OTHER|Group II|patients diagnosed with periodontitis
62074159|NCT06038812|OTHER|Group III|healthy control
62074160|NCT02881190|EXPERIMENTAL|RC48-ADC|The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.
62074161|NCT03164915|EXPERIMENTAL|LIV-GAMMA SN Inj.|
62278429|NCT01770600|PLACEBO_COMPARATOR|Placebo|Administer pill of placebo once a day by mouth for 5 days.
62278430|NCT01986062|EXPERIMENTAL|AR11 (amphetamine sulfate) (1 week) - double blind|AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
62644221|NCT03504800||Group B: Detection of Keratoconus Progression|Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.
62074162|NCT06429358|EXPERIMENTAL|Probiotic Group|The probiotic group received a daily oral supplement with Lactobacillus rhamnosus. The probiotic supplement was delivered as easy-to-swallow capsules.
62455918|NCT06298019|EXPERIMENTAL|Active Intervention with CAR T|All participants in the trial will receive an infusion of autologous, genetically modified CAR T cells specific for the CD19 antigen
62074163|NCT06429358|OTHER|Control Group|
62074164|NCT02216747|ACTIVE_COMPARATOR|prednisone 60 mg/meter square Body Surface Aera|A - 60 mg Prednisone/meter square Boby Surface Area( 30 twice)/day until there are 3 days of undetected protein in urine and tapering down to 40 mg ,30 mg, 20 mg ,10 mg and 5 mg and end.
62455919|NCT06121037|EXPERIMENTAL|Proximal group|proximal ultrasound-guided GON radiofrequency ablation
62644222|NCT03504800||Group C: OCT-and-Topography Guided PTK|Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.
62644223|NCT02337062|EXPERIMENTAL|APD421 + standard anti-emetic|Single dose of IV APD421
62644224|NCT02337062|PLACEBO_COMPARATOR|Placebo + standard anti-emetic|Single dose of IV placebo
62074165|NCT02216747|ACTIVE_COMPARATOR|prednisone 45 mg/meter square BSA|B- 45 mg prednisone / day until there are 3 days of undetected protein in urine and then 30 mg / day for two weeks and to 30,20,10,5 mg until treatment is ended.
62455920|NCT06121037|EXPERIMENTAL|Distal group|distal ultrasound-guided GON radiofrequency ablation
62455921|NCT00688064|EXPERIMENTAL|1|Adapalene-BPO + Doxycyline
62644225|NCT03636399|EXPERIMENTAL|Standard GIST|Standard Group Interactive Structured Treatment.
62644226|NCT03636399|OTHER|Waitlist control/Intensive GIST|After a wait list control period of nine months the participants receive Intensive Group Interactive Structured Treatment.
62644227|NCT05656196|EXPERIMENTAL|Dry eye syndrome (DES)|Dry eye syndrome (DES) will received Chinese herbal tea VGHTPE-DESJS-1 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62455922|NCT00688064|ACTIVE_COMPARATOR|2|Vehicle + Doxycycline
62644228|NCT05656196|EXPERIMENTAL|Sjögren's syndrome (SJS)|Sjögren's syndrome (SJS) will received Chinese herbal tea VGHTPE-DESJS-1 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62644229|NCT05656196|EXPERIMENTAL|Non DES SJS Healthy Controls (NHC)|Non DES SJS Healthy Controls (NHC) will received Chinese herbal tea VGHTPE-DESJS-1 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
62644230|NCT02402517|PLACEBO_COMPARATOR|Extruded snack control|100% corn flour
62644231|NCT02402517|EXPERIMENTAL|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
62644232|NCT02402517|EXPERIMENTAL|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
62644233|NCT02402517|EXPERIMENTAL|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
62644234|NCT02402517|EXPERIMENTAL|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
62644235|NCT02402517|EXPERIMENTAL|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
62074166|NCT02216747|ACTIVE_COMPARATOR|prednisone 30 mg/meter squer BSA|C- treatment of twice daily prednisone 30 mg per day until there are 3 days of undetectible protein in urine and then tapering down to 20 ,10 ,5 until treatment is ended.
62074167|NCT03030547|EXPERIMENTAL|Muscle Disease Group|Adult patients with muscle diseases diagnosed by neurologist, will wear SenseWear activity monitor for 5 days
62074168|NCT03030547|ACTIVE_COMPARATOR|Healthy Individuals Group|Healthy individuals with similar demographic characteristics as adult patients with muscle diseases, will wear SenseWear activity monitor for 5 days
62074169|NCT03859687|EXPERIMENTAL|Intervention group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) plus a liquid oral vitamin A supplementation
62074170|NCT03859687|EXPERIMENTAL|Control group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) only, 'No vitamin A supplementation'
62455923|NCT06196242|EXPERIMENTAL|DBS lead localization|Participates will receive a head MRI anc CT scan. The stimulation target and the related neural nuclei will be reconstructed using MRI images. The spatial position of the implanted lead will be identified with MRI and CT. Through comparing with the identified lead position by CT, the accuracy of lead localization by MRI will be evaluated.
62644236|NCT04976816|EXPERIMENTAL|A1 peri-levator betamethasone injection|patients with isolated thyroid-related upper lid retraction who will be given the Peri-levator injection of betamethasone suspension
62644237|NCT04976816|EXPERIMENTAL|A2 Peri-levator triamcinolone acetate injection|patients with isolated thyroid-related upper lid retraction who will be given Peri-levator injection of triamcinolone acetate
62644238|NCT04976816|EXPERIMENTAL|B1 Peri-levator and retrobulbar betamethasone injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of betamethasone suspension
62074171|NCT02632019|ACTIVE_COMPARATOR|gemcitabine|Gemcitabine treatments will be performed once a week with a total of six times
62455924|NCT01632709|ACTIVE_COMPARATOR|Sympathetic nerve block of bupivacaine|Sympathetic nerve block of bupivacaine
62455925|NCT01632709|PLACEBO_COMPARATOR|Dry needling at the sympathetic ganglion|Placebo/ Dry needling at the sympathetic ganglion
62644239|NCT04976816|EXPERIMENTAL|B2 Peri-levator and retrobulbar triamcinolone acetate injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of triamcinolone acetate
62278431|NCT01986062|PLACEBO_COMPARATOR|Placebo (1 week) - double blind|Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
62644240|NCT02172976|EXPERIMENTAL|FOLFIRINOX|Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery
62644241|NCT02172976|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery
62644242|NCT04522219|EXPERIMENTAL|Case group|Diagnosis of adnexal torsion confirmed by the surgical intervention: woman allocated to case group
62644243|NCT04522219|EXPERIMENTAL|Control group|Diagnosis of adnexal torsion not confirmed by the surgical intervention: woman allocated to control group
62644244|NCT03158207|EXPERIMENTAL|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
62644245|NCT03158207|ACTIVE_COMPARATOR|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
62644246|NCT02776566|ACTIVE_COMPARATOR|Anticoagulation Clinic|"Usual care through pharmacist managed anticoagulation clinic~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
62644247|NCT02776566|EXPERIMENTAL|Patient Self-Monitoring|"In home self-monitoring and pharmacist guided education~Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages."
62644248|NCT06435013||LenHAP|Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
62074172|NCT02632019|EXPERIMENTAL|Dendritic cell-precision T cell for neo-antigen|Dendritic cell-precision T cell for neo-antigen (DC-PNAT) combined with gemcitabine treatment: Gemcitabine: once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: once per 3 weeks with a total of three periods.
62644249|NCT06435013||BevHAP|Bevacizumab combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
62644250|NCT01213381|EXPERIMENTAL|SAR240550|"* single cohort: SAR240550~* combination cohort: SAR240550 in combination with Gemcitabine and Carboplatin"
62644251|NCT04593381|EXPERIMENTAL|SBRT treatment|Intervention: Radiation: SBRT
62278432|NCT04002310|EXPERIMENTAL|0.3 mg BI 754132 - SRD part|0.3 milligram (mg) BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. Single rising dose (SRD) part.
62074173|NCT00857441|EXPERIMENTAL|1|Use of Dior balloon and implant of Liberté Bare Metal Stent
62074174|NCT00857441|ACTIVE_COMPARATOR|2|Use of standard balloon and implant of Liberté Bare Metal Stent
62278433|NCT04002310|EXPERIMENTAL|1 mg BI 754132 - SRD part|1 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.
62455926|NCT01632709|ACTIVE_COMPARATOR|Neuroma injection of bupivacaine|Neuroma injection of bupivacaine
62455927|NCT01632709|PLACEBO_COMPARATOR|dry needling at the neuroma|Placebo/ dry needling at the neuroma
62455928|NCT04204577|NO_INTERVENTION|Thermal ablation|Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
62644252|NCT05938712|EXPERIMENTAL|Semaglutide|Semaglutide Subcutaneous 0.25mg once weekly for 4 weeks, then 0.5mg once weekly for 4 weeks, then 1mg once weekly for 4 weeks.
62074175|NCT00857441|ACTIVE_COMPARATOR|3|Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
62074176|NCT00030368|EXPERIMENTAL|Treatment (bortezomib, paclitaxel)|Patients receive bortezomib IV on days 2 and 9 and paclitaxel IV over 1 hour on days 1 and 8. For the first course only, patients do not receive paclitaxel on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62074177|NCT05359185|EXPERIMENTAL|Treatment-only|Participants in the this group will receive core Relationship Education programming, which consists of six weekly 2.5-hour Family Wellness Workshops.
62074178|NCT05359185|EXPERIMENTAL|Treatment-Plus|Participants in this group will receive an enhanced model that includes the core RE programming, and adds economic-focused services which include two 2.5-hour workshops (one on financial planning and one on career coaching), as well as individual financial planning and career coaching services ongoing for up to one year.
62074179|NCT04927039|PLACEBO_COMPARATOR|Control group|
62074180|NCT04927039|EXPERIMENTAL|Iloprost group|
62074181|NCT02391870|EXPERIMENTAL|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
62074182|NCT01714102|PLACEBO_COMPARATOR|Placebo|Placebo for 30 days
62074183|NCT01714102|ACTIVE_COMPARATOR|Resveratrol|1000 mg PO BID for 30 days
62074184|NCT05838274|ACTIVE_COMPARATOR|Alcohol|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
62074185|NCT05838274|PLACEBO_COMPARATOR|Placebo|placebo beverage condition
62074186|NCT00981825|PLACEBO_COMPARATOR|A|fluoride toothpaste control
62074187|NCT00981825|ACTIVE_COMPARATOR|B|triclosan/fluoride toothpaste
62074188|NCT06244121|EXPERIMENTAL|Standard treatment with pyridoxine|This group will receive standard treatment with pyridoxine 25 mg twice daily for 8 weeks
62074189|NCT06244121|PLACEBO_COMPARATOR|Standard treatment with placebo|This group will receive standard treatment with placebo 25 mg twice daily for 8 weeks
62074190|NCT06393686|EXPERIMENTAL|Yoga Group|The yoga intervention will be implemented every two weeks, with each session lasting 45 minutes and implemented for 10 weeks. Sessions will always be led by the same certified yoga instructor. Each session will include a variety of different yoga poses, as well as breathing techniques and deep relaxation methods.
62074191|NCT06393686|NO_INTERVENTION|Control Group|There will be no intervention in the control group.
62074192|NCT05138484|EXPERIMENTAL|M. sylvestris mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
62074193|NCT05138484|ACTIVE_COMPARATOR|CHX mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
62278434|NCT04002310|EXPERIMENTAL|3 mg BI 754132 - SRD part|3 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.
62644253|NCT05938712|EXPERIMENTAL|Dapagliflozin|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
62644254|NCT05194514|OTHER|SherpaPak™ Cardiac Transport System|When a matching donor heart from a non-local donor offer (from Northern California, Arizona, Nevada or farther geographies) becomes available the recipient will be assigned a subject identification number and randomized 1:1 to receive a heart transported using either standard of care cold storage or the SherpaPak™ Cardiac Transport System.
62074194|NCT05138484|PLACEBO_COMPARATOR|Placebo mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
62074195|NCT04524572|EXPERIMENTAL|Individual Challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure
62074196|NCT04524572|EXPERIMENTAL|friend challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure in comparison to the group average of all participants randomized to the friend challenge.
62074197|NCT04524572|EXPERIMENTAL|Team challenge|participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their teams' daily step counts and physical activity expenditure in comparison to the group average of other teams.
62074198|NCT03122262|ACTIVE_COMPARATOR|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
62278435|NCT04002310|EXPERIMENTAL|6 mg BI 754132 - SRD part|6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.
62074199|NCT03122262|ACTIVE_COMPARATOR|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
62074200|NCT03122262|ACTIVE_COMPARATOR|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
62278436|NCT04002310|EXPERIMENTAL|6 mg BI 754132 - MD part|6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as 3 injections, each separated by 4 weeks (that is, Day 1, Day 29 and Day 57). Multiple dose.
62278437|NCT04813185|NO_INTERVENTION|Treatment as usual|Adults who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
62644255|NCT05194514|OTHER|Cold Storage|When a matching donor heart from a non-local donor offer (from Northern California, Arizona, Nevada or farther geographies) becomes available the recipient will be assigned a subject identification number and randomized 1:1 to receive a heart transported using either standard of care cold storage or the SherpaPak™ Cardiac Transport System.
62644256|NCT05283434|PLACEBO_COMPARATOR|Double-Blind Clinical Trial- Placebo Group|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the placebo group will take the recommended doses of sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
62644257|NCT05283434|EXPERIMENTAL|Double-Blind Clinical Trial- Experimental Group|
62644258|NCT01542762|EXPERIMENTAL|LMWH|750 patients with lower leg cast immobilization will be randomized tot receive treatment with a LMWH.
62644259|NCT01542762|NO_INTERVENTION|No intervention|750 patients with lower leg cast immobilization will be randomized tot receive no treatment with LMWH.
62278438|NCT04813185|EXPERIMENTAL|In-hospital intervention|Adults randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 6-months of community case management and a firearm counseling program.
62644260|NCT05415293|ACTIVE_COMPARATOR|Expecta 200mg DHA supplement|"Women receive one daily softgel 200mg DHA algae-based DHA supplement sold as Expecta."
62278439|NCT03390738|EXPERIMENTAL|Intravenous nivolumab 240mg|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.
62278440|NCT05707780|EXPERIMENTAL|Resin-matrix ceramic|To assess the survival and clinical performance of resin-matrix posterior crows in a complete digital flow
62278441|NCT05707780|ACTIVE_COMPARATOR|Monolithic zirconia|To assess the survival and clinical performance of monolithic zirconia posterior crows in a complete digital flow
62644261|NCT05415293|ACTIVE_COMPARATOR|Promise 275mg DHA supplement|"Women receive one daily softgel 275mg DHA fish oil-based DHA supplement sold as Promise."
62644262|NCT05415293|NO_INTERVENTION|Control/ no supplement|Women received care as usual and did not take any DHA supplement.
62644263|NCT03294642|EXPERIMENTAL|Trial 1|Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
62278442|NCT05707780|ACTIVE_COMPARATOR|Metal-ceramic|To assess the survival and clinical performance of metal-ceramic posterior crows in a complete digital flow
62278443|NCT06447467||Diabetic patients|Diabetic patients
62644264|NCT03294642|EXPERIMENTAL|Trial 2|Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
62644265|NCT03294642|EXPERIMENTAL|Trial 3|Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
62278444|NCT06447467||Non Diabetic patients|Non Diabetic patients
62278445|NCT01017107|EXPERIMENTAL|Activated protein C|
62278446|NCT05087537|ACTIVE_COMPARATOR|Valve ablation|Valve ablation
62278447|NCT05087537|ACTIVE_COMPARATOR|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
62278448|NCT02793037|EXPERIMENTAL|A proof of concept of using zirconia bonded bridge|
62074201|NCT05108584|EXPERIMENTAL|Group 1 - Level 3 PPE and video laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
62074202|NCT05108584|EXPERIMENTAL|Group 2 - Level 3 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and direct laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
62074203|NCT05108584|EXPERIMENTAL|Group 3 - Level 2 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 2 PPE (surgical gown/apron, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
62074204|NCT06241196|ACTIVE_COMPARATOR|Group I|Ten sites will be treated by immediate implant and VST with Alloderm + allogenic bone membrane and xenograft.
62074205|NCT06241196|EXPERIMENTAL|Group II|Ten sites will be treated by immediate implant and VST with connective tissue graft + allogenic bone membrane and xenograft.
62278449|NCT05638048|ACTIVE_COMPARATOR|The control group|Patients were routinely implanted with PICC and received routine health education. The content of health education included face-to-face language explanation of the whole process of catheter knowledge, issuing catheter maintenance manual, issuing ordinary grip ball and telling how to use it, and follow-up.
62278450|NCT05638048|EXPERIMENTAL|Experiment 1 set|Patients were routinely implanted with PICC, and the optimal duration-relaxation time of grip strength training was adopted on the basis of health education in the control group.
62455929|NCT04204577|EXPERIMENTAL|Thermal ablation combined with apatinib|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take about half an hour after a meal (the daily dose should be as much as possible), and take it with warm water. Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib."
62644266|NCT05944835||Patient who has been treated for an aortoiliac aneurysm|Any patient who has been treated for an aortoiliac aneurysm with a standard Medtronic Endurant aortic stent, standard Gore Excluder or conformable Gore Excluder
62644267|NCT03019848|EXPERIMENTAL|Curcumin|Each patient of this group will receive 1.67 grams of curcumin ( 7 capsules of 231 mg) divided in 3 doses daily for 6 months.
62644268|NCT03019848|PLACEBO_COMPARATOR|Placebo|The control group will receive 7-capsules/ day identical in color and size, containing placebo for 6 months.
62644269|NCT00763217||stroke patient cohort|Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
62644270|NCT02941315|EXPERIMENTAL|with CMR confirmed etiology|Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
62644271|NCT02941315|PLACEBO_COMPARATOR|etiology unconfirmed without acute HF|Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
62644272|NCT02941315|PLACEBO_COMPARATOR|etiology unconfirmed with acute HF|Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
62644273|NCT02941315|EXPERIMENTAL|etiology confirmed with acute HF|Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.
62644274|NCT02079662|EXPERIMENTAL|Arm I (IO interventions)|Patients undergo up to 7 different IO intervention sessions per week during their 6-week course of radiotherapy for between 1 and 3 hours each session, in addition to, up to 6 aerobic training sessions per week and one grocery store trip during the course of the program. IO intervention programs consist of nutritional coaching, behavioral therapy, yoga and meditation practice, resistance training, and a weekly meal sharing and cooking class. Patients then have weekly meetings with the study psychologist on the computer for 6 months, followed by a monthly meeting on the computer from 6-12 months, and 2 hour meetings at all follow-up appointments during the first year after radiotherapy.
62644275|NCT02079662|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients undergo standard of care.
62074206|NCT04315623|EXPERIMENTAL|Reginal citrate anticoagulation|Patients accepted regional citrate anticoagulation for CRRT. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L. Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+. Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level.
62074207|NCT04315623|ACTIVE_COMPARATOR|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
62074208|NCT02597933|EXPERIMENTAL|Nintedanib|patient receives capsules containing nintedanib twice a day
62644276|NCT04549181|NO_INTERVENTION|Phase I: Qualitative|Rural HF dyads will participate in a one-time telephone-based semi-structured interview to explore the types of HF-related problems that rural HF dyads experience and how these problems are managed.
62074209|NCT02597933|PLACEBO_COMPARATOR|Placebo|patient receives capsules identical to those containing active drug
62074210|NCT02969980|EXPERIMENTAL|PTCy|Patients who receive post-transplantation cyclophosphamide
62644277|NCT04549181|EXPERIMENTAL|Phase II: Problem-Solving for Rural HF Dyads|The dyadic problem-solving intervention will be provided by a HF specialist nurse. The nurse will conduct the initial telehealth (virtual, telephone) session and provide dyads with an intervention booklet containing examples of common HF-related problems experienced by rural dyads and suggested management strategies tailored to the rural sociocultural context. The nurse will lead dyads in a card sorting task intended to help dyads prioritize current HF-related problems and will guide dyads in developing management strategies for the highest priority problem. Dyads will utilize these strategies until the next session at which time the nurse will guide dyads in evaluating the effectiveness of chosen strategies. The iterative process then begins again. Dyads will receive 7 follow-up telephone sessions with the nurse. In the intervention, the nurse will focus on problems related to self-care, including those specific to the rural population.
62644278|NCT04588974||Screening|Sixty-five cirrhotic patients with portal hypertensive symptoms (such as platelets count less than 100,000) will be enrolled to evaluate for the presence and stage of esophageal varices by using a magnetic-assisted capsule endoscope system with or without 3D image processing.
62074211|NCT01147211|EXPERIMENTAL|MK2206 in combination with Gefitinib|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
62074212|NCT05901415|EXPERIMENTAL|A Modified Semi-supine Position of Combined Anterior Lumbar and Lateral Sacral Plexus Block|Patients were placed in a supine position with a small pad put under the upper body at the surgical side, then they received a combined anterior lumbar and lateral sacral plexus block.
62074213|NCT05901415|SHAM_COMPARATOR|A classical Position of Combined Anterior Lumbar and Lateral Sacral Plexus Block|Patients received a combined anterior lumbar and lateral sacral plexus block in a lateral position.
62074214|NCT02641951|PLACEBO_COMPARATOR|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
62074215|NCT02641951|ACTIVE_COMPARATOR|Pecs II block|Ultrasound guided Pecs II block
62074216|NCT04913818|EXPERIMENTAL|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40 minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements in order to achieve a feeling of 'somewhat hard' at the Borg RPE rating of 12-14. The training session will end with a 10-minute cool down exercise session.
62074217|NCT04913818|ACTIVE_COMPARATOR|Usual Care|Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
62278451|NCT05638048|EXPERIMENTAL|Experiment 2 set|"On the basis of control group~1. Determine the best grip strength On the basis of the control group, color Doppler ultrasound and electronic grip force were used to record the optimal grip strength of patients to achieve effective blood flow velocity before and 24 hours after PICC insertion.~2. Design precise grip strength training guidance program On the basis of the control group, the patients were instructed to perform grip strength training according to the determined best grip strength and the best duration of clenching and relaxation time."
62278452|NCT00041093|EXPERIMENTAL|Treatment (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62278453|NCT03751865|EXPERIMENTAL|CBT group|This intervention aims for distress reduction, symptom coping, and life quality enhancement. It is a gender-specific CBT tailor-made for the at-risk population. The intervention is delivered by a registered clinical psychologist.
62278454|NCT03751865|ACTIVE_COMPARATOR|Psychoeducation group|The content of the psycho-education program will be related to healthy living content and mental health knowledge, such as food hygiene, psychological well-being, knowledge about psychosis and common mental disorder and food nutrition. In addition, a weekly call to remind the subject about healthy living will also be provided to the subjects. The intervention is delivered by a registered social worker.
62074218|NCT02476097|PLACEBO_COMPARATOR|Sudden discontinuation|placebo for 7 days
62074219|NCT02476097|ACTIVE_COMPARATOR|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
62074220|NCT01568827|EXPERIMENTAL|Blackraspberry slurry, washout, water|Blackraspberry slurry daily x 5 days, 2 day washout, 8 oz. water daily x 5 days
62074221|NCT01568827|EXPERIMENTAL|Water, washout, Blackraspberry slurry|8 oz. water daily x 5 days, 2 day washout, Blackraspberry slurry daily x 5 days
62074222|NCT04726475|EXPERIMENTAL|CBD-WR|"* 300 mg CBD-rich hemp extract oil administered within the reconsolidation window.~* The timing of CBD-rich oil administration is based on preclinical studies demonstrating that CBD's disruptive effects on reconsolidation procedurally depend on timing pharmacological administration to be within the memory reconsolidation window (\< 6 hrs. post-retrieval).~* Thus, immediately after the 35% CO2 interoceptive memory reactivation procedure and associated measures (see measures), participants will be asked to take a single 300mg CBD-rich oral dose of a hemp-derived oil formulation."
62074223|NCT04726475|PLACEBO_COMPARATOR|PBO-WR|"* Placebo administered within the reconsolidation window.~* Immediately after the 35% CO2 interoceptive memory reactivation procedure and associated measures (see measures), participants will be asked to take a single dose of an MCT coconut oil placebo solution."
62074224|NCT04726475|ACTIVE_COMPARATOR|CBD-OR|"* CBD-rich hemp extract oil administered outside of the reconsolidation window.~* Participants will be asked to take a single 300mg oral dose of CBD-rich oil approximately 24 hrs after the initial 35% CO2 interoceptive memory reactivation challenge.~* Thus, CBD will be administered well beyond the critical period for memory reconsolidation. The inclusion of this third arm provides a more robust test of the specific reconsolidation theory-based study hypotheses and aids in controlling for any nonspecific possible anxiolytic effects of CBD."
62074225|NCT06309095|EXPERIMENTAL|1 N (Newton) torque, 250 rpm(rotary per minute) speed|The values specified in the endomotor will be used during root canal treatment. 1 N torque, 250 rpm speed
62074226|NCT06309095|EXPERIMENTAL|1 N torque, 350 rpm speed|The values specified in the endomotor will be used during root canal treatment. 1 N torque, 350 rpm speed
62644279|NCT04588974||Follow-up|Thirty-five cirrhotic patients with a history of endoscopy-confirmed esophageal varices will be included for the follow-up examination by using the magnetic-assisted capsule endoscope system with or without 3D images.
62644280|NCT04588974||Control|Another 40 volunteers with GI symptoms but no known gastrointestinal disease will be enrolled as the control group.
62644281|NCT03490617|ACTIVE_COMPARATOR|Vaginal Misoprostol Group|Vaginal misoprostol (400 μg) 4 hours prior to IUD insertion
62644282|NCT03490617|PLACEBO_COMPARATOR|Placebo group|Vaginal placebo tablets 4 hours prior to IUD insertion
62644283|NCT04015739|EXPERIMENTAL|Bevacizumab, Olaparib and Durvalumab|Single arm study
62644284|NCT05866913|PLACEBO_COMPARATOR|Control group|Passive shoulder mobilizations for 90 seconds.
62644285|NCT05866913|EXPERIMENTAL|Experimental group 1|Sciatic nerve glide in a seated slump position for 90 seconds.
62644286|NCT05866913|EXPERIMENTAL|Experimental group 2|Passive stretching of the hamstring muscles with straight leg raising for 90 seconds.
62644287|NCT02481050|EXPERIMENTAL|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
62644288|NCT01583881|EXPERIMENTAL|Renal denervation|Renal denervation
62644289|NCT01583881|NO_INTERVENTION|control|No intervention
62074227|NCT06309095|EXPERIMENTAL|2 N torque, 250 rpm speed|The values specified in the endomotor will be used during root canal treatment. 2 N torque, 250 rpm speed
62074228|NCT06309095|EXPERIMENTAL|2 N torque, 350 rpm speed|The values specified in the endomotor will be used during root canal treatment. 2 N torque, 350 rpm speed
62074229|NCT01168674|PLACEBO_COMPARATOR|Sugar pill|Patients are randomized to a sugar pill (placebo), added to their current medications.
62644290|NCT00584389|EXPERIMENTAL|1|Rimonabant treatment (20mg/d) for 12 weeks
62074230|NCT01168674|ACTIVE_COMPARATOR|Ziprasidone|Patients are randomized to ziprasidone, added to their current medications.
62644291|NCT00584389|OTHER|2|Dietary intervention
62644292|NCT02658266|EXPERIMENTAL|Resistance training|Home based resistance training 12 weeks home based resistance training 3 times per week, 10-12 reps, 2 sets
62278455|NCT06282003|ACTIVE_COMPARATOR|Conventional ventilation procedure|
62644293|NCT02658266|NO_INTERVENTION|Control group|No instructed exercise training. Continue with habitual physical activity.
62644294|NCT03531866|EXPERIMENTAL|Intervention Version A|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version A will include an additional topic area.
62644295|NCT03531866|EXPERIMENTAL|Intervention Version B|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version B will include an additional topic area (different than in Version A).
62644296|NCT03531866|NO_INTERVENTION|Wait-List Control|Youth will not have access to DigiKnowIt News until after the post-test timepoint.
62644297|NCT03122171|EXPERIMENTAL|Prosthesis|
62644298|NCT04483414|EXPERIMENTAL|Patients with suspected BCR or metastatic prostate cancer|Patients with suspected BCR or metastatic prostate cancer
62644299|NCT05041400|OTHER|Healthy subjects|"Evaluation carried out on a BIODEX S4 Pro isokinetic dynamometer after a standardised 10-minute warm-up on this same dynamometer .~The measurement range will be from 0° (full extension) to 90° of flexion for each knee, providing 91 degrees of measurement."
62074231|NCT02864043|OTHER|EGD with NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe following standard of care endoscopy
62074232|NCT02054078|EXPERIMENTAL|Bevacizumab|Bevacizumab200mg by intrapleural administration
62074233|NCT02054078|ACTIVE_COMPARATOR|Pulvis talci|Pulvis talci 4g by intrapleural administration
62074234|NCT02435771|EXPERIMENTAL|BMI <25|Normal BMI
62074235|NCT02435771|EXPERIMENTAL|BMI 25-35|Overweight and obese by BMI
62074236|NCT02435771|EXPERIMENTAL|BMI >35|Obese by BMI
62074237|NCT02501759|EXPERIMENTAL|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
62074238|NCT01194882|EXPERIMENTAL|Insuman Implantable|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
62074239|NCT01194882|ACTIVE_COMPARATOR|Insuplant|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
62074240|NCT00651443|EXPERIMENTAL|1|
62074241|NCT03923218||Smoker patients with chronic periodontitis|Smoker patients with chronic periodontitis
62644300|NCT06514352|EXPERIMENTAL|skin-to-skin contact group immediately after birth|The newborn is placed face to face on the mother's abdomen or chest in the first minute after birth. If medically necessary, suctioning can be done while on the mother's abdomen or chest and the baby is dried thoroughly. To prevent heat loss, the baby's back is covered with a pre-warmed blanket and a hat is placed on his head. All other interventions with the newborn can be postponed until at least the end of the first hour after birth or the first successful breastfeeding.
62644301|NCT06514352|EXPERIMENTAL|very early skin contact group|In the first 30-40 minutes after birth, after the first and emergency intervention is given to the newborn in need of intervention, the newborn is placed face down on the mother's bare chest, naked with or without a hat. The newborn's back can be covered with a blanket.
62074242|NCT03923218||non-smoker patients with chronic periodontitis|non-smoker patients with chronic periodontitis
62074243|NCT03923218||periodontally healthy patients|periodontally healthy patients
62074244|NCT03435601|EXPERIMENTAL|Anifrolumab|Anifrolumab 300 mg IV administration Q4W, a total of 6 doses
62074245|NCT03435601|PLACEBO_COMPARATOR|Placebo|Placebo IV administration Q4W, a total of 6 doses
62074246|NCT03132623|ACTIVE_COMPARATOR|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
62074247|NCT03132623|PLACEBO_COMPARATOR|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
62074248|NCT03606941|EXPERIMENTAL|electroacupuncture treatment|"Participants in the treatment group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of operation."
62074249|NCT03606941|SHAM_COMPARATOR|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
62644302|NCT06514352|EXPERIMENTAL|early skin contact group|It can start any time between the first hour and 24 hours after birth. The baby is naked (with or without a diaper) and placed face down on the mother's bare chest between the breasts. The mother can wear a blouse or shirt that opens at the front, or a hospital gown that can be tied at the back. The baby is placed inside the apron so that only the head is exposed. What the mother wears, how the baby is kept warm, and what is placed on the baby's back may vary. The most important thing is that the mother and baby are in direct skin-to-skin contact and the baby is kept dry and warm.
62644303|NCT06514352|NO_INTERVENTION|control group|No treatment will be performed on the mothers and newborns in the control group, and the hospital's routine practices (birthing support, newborn and maternal care) will be carried out.
62074250|NCT05677737|EXPERIMENTAL|Experimental|In the study, the women in the experimental group will be trained every two weeks for 6 weeks.
62074251|NCT05677737|NO_INTERVENTION|Control|No intervention will be applied to the control group.
62074252|NCT03319186|EXPERIMENTAL|EDIT Management|
62074253|NCT03319186|ACTIVE_COMPARATOR|Standard Care|
62074254|NCT03204695|EXPERIMENTAL|WaveCrest®|Implant of WaveCrest® Left Atrial Appendage Occlusion System
62074255|NCT05540093|EXPERIMENTAL|high power pain threshold ultrasound|the patients will receive high power pain threshold ultrasound and traditional therapy twice a week for four weeks
62644304|NCT04321928|OTHER|Group A|General health education arm.
62644305|NCT04321928|OTHER|Group B|Personalized health education arm.
62644306|NCT05588531|ACTIVE_COMPARATOR|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g)|Four healthy subjects in group A1, two males and two females, without control, were administered the test drug
62644307|NCT05588531|ACTIVE_COMPARATOR|YK-1169 1.25 g (containing cefepime 1.0 g and avibactam 0.25 g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
62074256|NCT05540093|ACTIVE_COMPARATOR|traditional therapy|the patients will receive traditional therapy twice a week for four weeks
62644308|NCT05588531|ACTIVE_COMPARATOR|YK-1169 2.5g (containing cefepime 2.0g and avibactam 0.5g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
62074257|NCT04213586|EXPERIMENTAL|Whey Protein|Each participant will be supplemented with whey protein (7 d/wk) during 10 weeks.
62074258|NCT04213586|EXPERIMENTAL|Leucine-matched collagen|Each participant will be supplemented with collagen (7 d/wk) during 10 weeks.
62074259|NCT02171182||Qutenza patients w/ post-operative peripheral neuropathic pain|
62074260|NCT02055703|EXPERIMENTAL|E2609|Experimental drug for Parts A, B, and C
62074261|NCT02055703|ACTIVE_COMPARATOR|itraconazole|Comparator drug for Part A1
62074262|NCT02055703|ACTIVE_COMPARATOR|rifampin|Comparator drug for Part A2
62074263|NCT02055703|ACTIVE_COMPARATOR|digoxin|Comparator drug for Part B
62074264|NCT02055703|ACTIVE_COMPARATOR|donepezil|Comparator drug for Part C
62074265|NCT06117748|EXPERIMENTAL|Group (PCV-VG): Pressure controlled ventilation-volume guaranteed|Patients will receive pressure controlled ventilation-volume guaranteed
62074266|NCT06117748|OTHER|Group (VCV): Volume controlled ventilation|Patients will receive Volume controlled ventilation
62455930|NCT04204577|EXPERIMENTAL|Ablation combined with apatinib and PD-1 antibody SHR-1210|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take it with warm water about half an hour after a meal (the daily dose should be as much as possible). Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib.~SHR-1210, 200mg, intravenous infusion for 30 minutes (including the time of the tube,the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks; the first dose with the apatite Simultaneous administration of PD, PD-1 injection is not affected by thermal ablation."
62455931|NCT01715038|EXPERIMENTAL|Comprehensive|"Comprehensive LNS: LNS-PLW provided daily to mothers during pregnancy and postpartum lactation (a total of at least 11 months, starting by 20 weeks gestation and ending at 6 months post-partum) and LNS developed for infants and young children (LNS-child) provided daily to their infants (beginning at 6 months of age for a period of 18 months i.e., from 6-24 months of age)."
62455932|NCT01715038|EXPERIMENTAL|Child-only LNS|"Child-only LNS: Daily LNS-child supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
62074267|NCT00933842|EXPERIMENTAL|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Dermacyd PH_DESILSTY_FL (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
62074268|NCT03696277|EXPERIMENTAL|Stereotactic ablative body radiation (SABR)|SAbR will be used to treat all sites of measurable metastases. New sites of metastasis will be treated if deemed appropriate by both medical and radiation oncologists with SAbR.
62074269|NCT01474447|EXPERIMENTAL|Grinberg Method|
62074270|NCT05723848||CIDP patients|CIDP patients with ongoing standard of care IVIG treatment
62455933|NCT01715038|EXPERIMENTAL|Child-only MNP|"Child-only MNP: Daily MNP supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
62455934|NCT01715038|ACTIVE_COMPARATOR|Control: IFA|Control: No additional nutrient supplementation for the child will be provided through the study, but the regular nutrition education and visits provided by the program frontline staff will continue. Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum.
62455935|NCT00405678|EXPERIMENTAL|1|Subjects receiving chemo and exercise training
62455936|NCT00405678|EXPERIMENTAL|2|Subjects receiving chemo only
62455937|NCT00048048|EXPERIMENTAL|Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 (methoxy polyethylene glycol-epoetin beta \[Mircera\]) at a dose of 0.15 microgram per kilogram (mcg/kg) subcutaneously (SC) once every week to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62455938|NCT00048048|EXPERIMENTAL|Cohort 2 (RO0503821, 0.3 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every week to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62644309|NCT05588531|PLACEBO_COMPARATOR|YK-1169 3.75g (containing cefepime 3.0g and avibactam 0.75g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
62074271|NCT02493218|EXPERIMENTAL|Mindfulness Instruction|Instruction on mindfulness concepts and practices. Classes are 45-90 minutes each and held weekly for 12 weeks.
62074272|NCT02493218|ACTIVE_COMPARATOR|Health Education Instruction|Instruction on general health and wellness. Classes are 45-90 minutes each and held weekly for 12 weeks.
62074273|NCT02193802|OTHER|Endoscopy|"CHANCE is a single arm study: all patients will undergo one capsule endoscopy ( PillCam® COLON 2 capsule and PillCam Crohn's) of the whole intestine AND one ileocolonoscopy.~The patients will be then treated according to the preference of their physician and a second capsule endoscopy AND an ileoconoscopy will be performed 6 at 12 months later.~Both exams will be evaluated locally by two independent investigators and all the recorded films will be evaluated and compared by four central readers."
62074274|NCT01533714|EXPERIMENTAL|CDP6038 (olokizumab)|CDP6038 (olokizumab) 120 mg: subcutaneous injections at q2w (every two weeks). RA0089 is a single arm study, however, analysis will be presented according to the original treatment arms of the parent study NCT01463059 (RA0083).
62074275|NCT00313911|EXPERIMENTAL|Group 1: DTaP-IPV-Hep B-PRP-T|
62074276|NCT00313911|ACTIVE_COMPARATOR|Group 2: Tritanrix-Hep B/Hib™+OPV|
62074277|NCT04908124|EXPERIMENTAL|Lubricant A - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
62644310|NCT05588531|ACTIVE_COMPARATOR|YK-1169 5.0g (containing cefepime 4.0g and avibactam 1.0g)|8 healthy subjects, 6 of whom were administered the investigational product and 2 of whom were administered placebo, half males and half females
62074278|NCT04908124|EXPERIMENTAL|Lubricant B - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
62074279|NCT04908124|EXPERIMENTAL|Lubricant C - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
62074280|NCT04908124|EXPERIMENTAL|Lubricant D - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
62455939|NCT00048048|EXPERIMENTAL|Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62644311|NCT05588531|ACTIVE_COMPARATOR|Drug Interaction Studies|18 subjects (single gender not less than 1/3) were randomly divided into D1, D2 and D3 groups, 6 subjects for each group
62644312|NCT02696824|EXPERIMENTAL|CBT-AD|Those assigned to the CBT-AD \[cognitive behavioral therapy for adherence and depression) condition, will have up to 8 additional sessions delivered by the study clinic nurse. Additionally, those assigned to CBT-AD will have the procedures available to those assigned to ETAU.
62278456|NCT06282003|EXPERIMENTAL|The protective lung ventilation procedure|In the PV group, laung protective ventilation also included the procedure of opening the alveoli (recruitment maneuver, RM). RM was performed twice. The first instance occurred following the administration of anesthesia, with a FiO2 value of 50% (0.5). The second instance took place shortly before extubation. RM consisted of maintaining an airway pressure of 40-45 kPa for 40 s, which keeps the collapsed alveoli open and corresponds to maximum spontaneous inhalation. The specified pressure of PEEP during RM refers to conditions where hemodynamic stability. PEEP was set at 7 kPa, but just before the extubation and awakening, patients were switched to spontaneous breathing the PEEP was set to 10 kPa. There was no additive effect of positive pressure, just an addition of 3 kPa positive airway pressure was applied to keep current alveoli open continuously and possibly recruit some new ones in that short period, which corresponds to the stochastic model of respiration.
62278457|NCT01486199|EXPERIMENTAL|CF pediatric|In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
62278458|NCT01486199|EXPERIMENTAL|Controls adult|In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.
62644313|NCT02696824|NO_INTERVENTION|ETAU|"Participants in both conditions receive usual care plus the following procedures below.~All participant will have the benefit of the psychosocial assessment, and the clinic nurse will provide feedback to the participant and to their clinic doctor about their depression. Additionally, all participants will undergo standard of care second line treatment adherence counseling in the clinic . The clinic doctor will not be restricted in terms of referral or treatment of depression for their patient with respect to antidepressant medications or other interventions available."
62074281|NCT04908124|EXPERIMENTAL|Lubricant E - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
62644314|NCT04534751|EXPERIMENTAL|Intervention Group- Clotting Factor Concentrates|"Fibryga + Octaplex (Fibrinogen + PCC)~Fibrinogen Concentrate 4g (Fibryga) + Prothrombin Complex Concentrate 2000 IU (Octaplex) in the first and second massive hemorrhage protocol (MHP) packs."
62644315|NCT04534751|ACTIVE_COMPARATOR|Control Group: Standard FP transfusion|Frozen Plasma (FP)
62278459|NCT00384787|EXPERIMENTAL|1|Group 1 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intramuscularly at Month 6.
62074282|NCT04908124|EXPERIMENTAL|Lubricant A - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
62644316|NCT06227650||Group1|Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
62644317|NCT00371735|EXPERIMENTAL|Arm 1|
62644318|NCT03398096|EXPERIMENTAL|Cardiac shock wave therapy (CSWT) group|The CWST group were performed with a CSWT equipment (Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan with respect to the shockwave output and the number of shots implemented to each spot and the protocol developed by the University of Essen, Germany.
62074283|NCT04908124|EXPERIMENTAL|Lubricant B - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
62278460|NCT00384787|EXPERIMENTAL|2|Group 2 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intradermally at Month 6.
62644319|NCT03398096|NO_INTERVENTION|Control group|No CWST treatment.
62644320|NCT01802385|NO_INTERVENTION|Placebo|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day) + placebo
62074284|NCT04908124|EXPERIMENTAL|Lubricant C - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
62644321|NCT01802385|EXPERIMENTAL|Sertraline 400mg|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.
62644322|NCT04021966|EXPERIMENTAL|Laser|In this arm, participants will have 3 real laser treatments first, followed by 3 consecutive sham treatments.
62644323|NCT04021966|SHAM_COMPARATOR|Sham|In this arm, participants will have 3 sham treatments first, followed by 3 consecutive real laser treatments.
62278461|NCT00384787|EXPERIMENTAL|3|Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
62644324|NCT05556993||LGBTQIA+ Persons living with Parkinson's Disease|125 LGBTQIA+ persons living with Parkinson's Disease will be asked to do a 45-minute phone survey.
62074285|NCT04908124|EXPERIMENTAL|Lubricant D - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
62644325|NCT05556993||Non- LGBTQIA+ Persons living with Parkinson's Disease|125 Non- LGBTQIA+ persons living with Parkinson's Disease will be asked to do a 45- minute phone survey.
62644326|NCT05556993||LGBTQIA+ caregivers of people living with Parkinson's Disease|125 LGBTQIA+ caregivers of people living with Parkinson's Disease will do a 45-minute phone survey.
62644327|NCT05556993||Non- LGBTQIA+ caregivers of people living with Parkinson's Disease|125 non- LGBTQIA+ caregivers of people living with Parkinson's Disease will do a 45-minute phone survey.
62644328|NCT05556993||Health care providers of people living with Parkinson's Disease|100 health care providers of people living with Parkinson's Disease will complete a 45-minute online survey.
62644329|NCT03864081|OTHER|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
62644330|NCT03821129|OTHER|GORE® CARDIOFORM Septal Occluder|Single Arm Commercially available GORE® CARDIOFORM Septal Occluder
62644331|NCT01042340|EXPERIMENTAL|Intervention with energy dense formula|Patients were randomised to intervention with the energy dense formula Calogen.
62644332|NCT01042340|NO_INTERVENTION|Control group|The patients that were randomised to control group were assigned to ordinary treatment.
62074286|NCT04908124|EXPERIMENTAL|Lubricant E - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
62074287|NCT03069560|EXPERIMENTAL|SMS|The patients will receive from the caregiver a first SMS 48 hours after their discharge from the hospital then a total of 4 messages : 48 hours, S1, S2, and S4.
62074288|NCT02500875|EXPERIMENTAL|PTNiA|"Topical negative pressure therapy with instillation of saline solution (6 times daily).~During the instillation of saline solution, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
62074289|NCT02500875|EXPERIMENTAL|PTNiB|"Topical negative pressure therapy with instillation of Amukine Med 0,05% (6 times daily).~During the instillation of Amukine Med 0,05%, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
62278462|NCT04257994||patients with arrhythmic disorders|Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust as well as family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis.
62278463|NCT04023955||Intervention|Twitter messages delivered over 1 month period
62278464|NCT06032442|EXPERIMENTAL|ARTNEO|1 capsule 1 time per day for 6 months
62278465|NCT06032442|ACTIVE_COMPARATOR|Artra|1 tablet 2 times per day for 6 months
62278466|NCT00854828|ACTIVE_COMPARATOR|Surgical Intervention|
62278467|NCT00854828|ACTIVE_COMPARATOR|Non-Operative Intervention|
62644333|NCT05146778|ACTIVE_COMPARATOR|Opioid-free anesthesia group|OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.
62644334|NCT05146778|ACTIVE_COMPARATOR|Conventional anesthesia group with opioid|Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.
62074290|NCT02500875|ACTIVE_COMPARATOR|PTN|"Topical negative pressure therapy (without instillation). The device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
62074291|NCT01003184|EXPERIMENTAL|1|
62644335|NCT02127658|ACTIVE_COMPARATOR|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations from the Ryan White Center for Pediatric Infectious Disease, Riley Hospital.
62074292|NCT01003184|ACTIVE_COMPARATOR|2|
62074293|NCT06114563|EXPERIMENTAL|Spirulina yogurt|2 yogurts with spirulina each containing 2 g of spirulina
62074294|NCT06114563|ACTIVE_COMPARATOR|Conventional yogurt|2 conventional yogurts (without spirulina)
62074295|NCT05938725|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)|Dosing with KYV-101 CAR T cells
62278468|NCT05350462||Agboville, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
62278469|NCT05350462||Bangolo, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
62278470|NCT05350462||Man, Côte d'Ivoire|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
62278471|NCT05350462||Homa Bay, Kenya|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
62278472|NCT05350462||Kwale, Kenya|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
62278473|NCT05350462||Hoima, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
62278474|NCT05350462||Bugiri, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
62074296|NCT05938725|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)|Recommended Phase 2 Dose
62074297|NCT02875561|ACTIVE_COMPARATOR|Sonopet Ultrasonic Aspirator|Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
62644336|NCT02127658|ACTIVE_COMPARATOR|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
62644337|NCT00453375|EXPERIMENTAL|1|BHT-3021
62644338|NCT00453375|PLACEBO_COMPARATOR|2|BHT-Placebo
62644339|NCT05577416|EXPERIMENTAL|Safusidenib Erbumine (AB-218)|Part A: Peri-operative treatment (Phase 0); Part B: Post operative adjuvant therapy (phase 2)
62644340|NCT02842528|EXPERIMENTAL|Alcohol-dependent patients|
62644341|NCT02842528|ACTIVE_COMPARATOR|First-degree relatives of alcohol-dependent probands|
62644342|NCT02842528|ACTIVE_COMPARATOR|Healthy Controls|
62644343|NCT01166919|EXPERIMENTAL|Medical Tool|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
62644344|NCT05333211|EXPERIMENTAL|Investigational Arm with Ortho-R/PRP|Using a double row, Trans-osseous Equivalent Rotator Cuff Repair Technique (TOE) with Ortho-R/PRP combination
62644345|NCT05333211|NO_INTERVENTION|Control Arm Standard of Care without Ortho-R/PRP|Using the Trans-osseous Equivalent Rotator Cuff Repair Technique (TOE) without Ortho-R/PRP combination
62644346|NCT02118285|EXPERIMENTAL|Treatment|Haploidentical donor NK cells and IL-2 are infused intraperitoneally (IP) after a non-myeloablative preparative regimen of cyclophosphamide and fludarabine. INCB024360, at the assigned dose, begins 2 days before the NK cell infusion and continues twice daily for 90 days.
62644347|NCT00368108|EXPERIMENTAL|2 mg perampanel|The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
62644348|NCT00368108|EXPERIMENTAL|4 mg perampanel|The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
62644349|NCT00368108|PLACEBO_COMPARATOR|placebo|The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
62644350|NCT02376686|EXPERIMENTAL|Music intervention|Patient receives Music Intervention before going to sleep.
62644351|NCT02376686|NO_INTERVENTION|treatment as usual|Patient receives Treatment as usual.
62644352|NCT02114021|EXPERIMENTAL|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
62644353|NCT02114021|EXPERIMENTAL|lidocaine jelly|lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
62644354|NCT02114021|PLACEBO_COMPARATOR|distilled water|betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
62644355|NCT01963702|EXPERIMENTAL|Docetaxol ＆Capecitabine (TX)|Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
62074298|NCT02875561|EXPERIMENTAL|CO2 Laser Ablation|Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
62455940|NCT00048048|EXPERIMENTAL|Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every two week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62074299|NCT03655522|ACTIVE_COMPARATOR|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
62074300|NCT03655522|PLACEBO_COMPARATOR|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
62644356|NCT01963702|ACTIVE_COMPARATOR|Oxaliplatin ＆Capecitabine (XELOX)|Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
62644357|NCT03918265|EXPERIMENTAL|Efficiency of tacrolimus on autoimmune cytopenia|"A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
62074301|NCT05050214|EXPERIMENTAL|Experimental: GAZYVA, GAZYVARO(Obinutuzumab)|Participants will receive Obinutuzumab 1000 mg solution for infusion (total dose of 3000 mg in 30 days).
62074302|NCT01141335|EXPERIMENTAL|PTFE mesh|A Lichtenstein tension-free hernioplasty is performed using PTFE mesh
62455941|NCT00048048|EXPERIMENTAL|Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every two week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62644358|NCT05813756|EXPERIMENTAL|Experimental_Adults with Autism Spectrum Disorder|post diagnostic psychoeducational intervention and filling of scale and questionnaire
62278475|NCT00379795|EXPERIMENTAL|Ranibizumad 0.5 mg|Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
62278476|NCT02140671||Patients with an asthma diagnosis|
62278477|NCT02140671||Patients where there is diagnostic doubt|
62278478|NCT05066789|ACTIVE_COMPARATOR|Biodegradable Polymer DES|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use Orsiro Mission stent during the index procedure."
62278479|NCT05066789|ACTIVE_COMPARATOR|12-month DAPT|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive 12-month DAPT of aspirin (100mg once daily) plus prasugrel (10mg once daily)."
62455942|NCT00048048|EXPERIMENTAL|Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.2 mcg/kg SC once every two week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62074303|NCT01141335|ACTIVE_COMPARATOR|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using polypropylene mesh
62455943|NCT00048048|EXPERIMENTAL|Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.45 mcg/kg SC once every three week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62644359|NCT05813756|NO_INTERVENTION|Adults with Autism Spectrum Disorder|Filling of scale and questionnaire.
62644360|NCT05469646|EXPERIMENTAL|Dose Group 1: BI 1819479 (Low dose)|
62644361|NCT05469646|EXPERIMENTAL|Dose Group 2: BI 1819479 (Middle dose)|
62644362|NCT05469646|EXPERIMENTAL|Dose Group 3: BI 1819479 (High Dose)|
62644363|NCT05469646|PLACEBO_COMPARATOR|Placebo|
62278480|NCT05066789|EXPERIMENTAL|Polymer-free DCS|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use BioFreedom Ultra stent during the index procedure."
62278481|NCT05066789|EXPERIMENTAL|Prasugrel monotherapy|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive aspirin (100mg once daily) plus prasugrel (10mg once daily) for 1 month and thereafter prasugrel (10mg once daily) alone."
62278482|NCT01938365||Diabetes|
62644364|NCT05540704|EXPERIMENTAL|iACT Experimental Intervention|
62644365|NCT05540704|ACTIVE_COMPARATOR|Usual Care|
62074304|NCT05022602|EXPERIMENTAL|Imagio|Imagio Grayscale only probe and Imagio Duplex probe in ultrasound only and OA modes
62074305|NCT05314556|EXPERIMENTAL|Intervention|Group psychotherapy
62278483|NCT01938365||Normal glucose regulation|
62278484|NCT05654493|EXPERIMENTAL|240 Second Group|Receives 240 seconds total of MicroPulse Transscleral Laser Therapy with the revised P3 Delivery Device delivered in a total of 8 sweeps
62278485|NCT05654493|EXPERIMENTAL|300 Second Group|Receives 300 seconds total of MicroPulse Transscleral Laser Therapy with the revised P3 Delivery Device delivered in a total of 10 sweeps
62278486|NCT05654493|EXPERIMENTAL|200 Second Group|Receives 200 seconds total of MicroPulse Transscleral Laser Therapy with the revised P3 Delivery Device delivered in a total of 8 sweeps
62644366|NCT01041222|EXPERIMENTAL|Arm 1|0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
62644367|NCT01041222|EXPERIMENTAL|Arm 2|0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
62278487|NCT04409938|EXPERIMENTAL|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention.
62644368|NCT01041222|EXPERIMENTAL|Arm 3|1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
62644369|NCT01041222|EXPERIMENTAL|Arm 4|3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
62278488|NCT04409938|EXPERIMENTAL|Progressive Muscle Relaxation with Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds.
62644370|NCT01041222|PLACEBO_COMPARATOR|Placebo (phosphate buffered saline)|
62644371|NCT01339416||HIV infected cohort|HIV infected patients in the HIV cohorts at the three participating hospitals
62278489|NCT04409938|NO_INTERVENTION|Standard Practice|The standard practice of the lab was made.
62074306|NCT01582880|EXPERIMENTAL|Riboflavin Cross-linked donor cornea|the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
62644372|NCT04119648|EXPERIMENTAL|CAMS-4Kids|Participants will receive up to 10 sessions of CAMS-4Kids
62644373|NCT03915834||endovascular treatment group|
62644374|NCT01723072|EXPERIMENTAL|1 Omalizumab|omalizumab once a month via subcutaneous injection.
62644375|NCT01723072|PLACEBO_COMPARATOR|2 Placebo|placebo of omalizumab once a month via subcutaneous injection
62644376|NCT01065753|EXPERIMENTAL|Life-style modification|Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
62074307|NCT01373710|EXPERIMENTAL|Trastuzumab intrathecal|
62074308|NCT05225402||Septic Shock|Adult patients with septic shock, admitted to ICUs at Hvidovre and Bispebjerg Hospital, respectively. Sedated and mechanically ventilated adult patients (\>18 years).
62644377|NCT04440501|NO_INTERVENTION|Standard education (Control)|Standard education regarding the gluten free diet by the nutritionist will be provided.
62644378|NCT04440501|EXPERIMENTAL|Virtual Reality Program to teach gluten free diet|"Virtual Reality Goggles and education regarding the gluten free diet will be provided.~This group will receive VIRTUE, and watch a VR educational video, and play Chaos Café, which will be administered by a research team member. This group will be prescribed to take home the VIRTUE headset and play modules for 15 minutes per week until the 6-8 month follow up.~The VIRTUE technology will track frequency of game playing to control for adherence to the prescription."
62074309|NCT03758820|EXPERIMENTAL|BCT group|"Intervention : Behavorial Cognitive Therapy (BCT) will be delivered by two psychologists at six once-weekly sessions of 90 minutes (with homework activities between the sessions) + 4 booster sessions at week 6, 12, 18 and 36 after the end of the programme.~It was designed for groups of 8 to 10 people. The programme is standardised: PowerPoints presentations support each session and a detailed facilitator manual and companion patient workbook. accompany the programme."
62074310|NCT03758820|NO_INTERVENTION|Control group|Usual local practice
62074311|NCT02165904|EXPERIMENTAL|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
62074312|NCT05200936|PLACEBO_COMPARATOR|Arm 1- Placebo|A total of 26 patients will receive a placebo identical in appearance to the investigational medicinal product (IMP) administered orally twice weekly (e.g., Tuesday/Friday) for 6 weeks.
62074313|NCT05200936|EXPERIMENTAL|Arm 2- MM-120|A total of 26 patients will receive 20 μg of MM-120 administered orally twice weekly for 6 weeks.
62644379|NCT01735604|EXPERIMENTAL|anti-CD20-CAR T cell|Arm 1 Patients receive anti-CD20-CAR lentiviral vector-transduced autologous T cells with 41BB vector for 3-5 days in the absence of disease progression or unacceptable toxicity.
62644380|NCT00171249|EXPERIMENTAL|Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg|Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
62644381|NCT00171249|EXPERIMENTAL|Lymphoid Blast Crisis 400 mg|Participants with lymphoid blast crisis received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
62644382|NCT00171249|EXPERIMENTAL|Acute Lymphoblastic Leukemia 400 mg|Participants with acute lymphoblastic leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
62644383|NCT00171249|EXPERIMENTAL|Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg|Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
62644384|NCT00171249|EXPERIMENTAL|Lymphoid Blast Crisis 600 mg|Participants with lymphoid blast crisis received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
62644385|NCT00171249|EXPERIMENTAL|Acute Lymphoblastic Leukemia 600 mg|Participants with acute lymphoblastic leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
62644386|NCT00171249|EXPERIMENTAL|Acute Myeloid/Myelogenous Leukemia 600 mg|Participants with acute myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
62644387|NCT02797834||Patients Endometrial Fluid|"Endometrial fluid samples from healthy and fertile women in their natural cycles, with ages ranging from 18 to 35 years, normal karyotype, negative for HIV, HBV, HCV and RPR, BMI ranging from 18 to 30 Kg/m2 (both included) and regular menstrual cycle (3-4/28-30 days).~This unique assignment group will be divided into 5 subgroups attending to the moment of the menstrual cycle in which the patient could be classified: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (days 25-30)."
62644388|NCT02607631|EXPERIMENTAL|Single arm|Pembrolizumab 200mg IV every 3 weeks until tumor progression or unacceptable toxicity
62644389|NCT02414282||Experimental F 18 T807|
62278490|NCT06460571|EXPERIMENTAL|Standard Cardiac rehabilitation with Delorme technique|The intervention group will receive Delorme technique along with standard cardiac rehabilitation, involving 10 repetition max of aerobic exercises, resistance exercises of 10 minutes will be given in each training session
62278491|NCT06460571|ACTIVE_COMPARATOR|standard cardiac rehabilitation|The control group (Group B) will undergo standard cardiac rehabilitation (outpatient cardiac rehabilitation) which include walking, cycling and strength training which will have 5-10 minutes warm-up followed by training for 30-45 minutes, concluding with cool-down without the Delorme technique.
62278492|NCT03723187|EXPERIMENTAL|experimental group|use Normal saline
62278493|NCT03723187|ACTIVE_COMPARATOR|comparator group|use Heparin
62278494|NCT02902120|EXPERIMENTAL|Post-transplant|This arm will evaluate the treatment of patients with HCV and chronic kidney disease (GFR \<50) who have had a kidney transplant using grazoprevir and elbasvir.
62278495|NCT02653768|EXPERIMENTAL|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
62278496|NCT02653768|ACTIVE_COMPARATOR|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
62278497|NCT03269214|NO_INTERVENTION|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
62278498|NCT03269214|EXPERIMENTAL|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
62278499|NCT01681550|OTHER|Incretin theapy combined with insulin|
62278500|NCT00573794|EXPERIMENTAL|Adalimumab 40 mg EOW/EW|Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
62278501|NCT05156827|EXPERIMENTAL|TB006|Participants will receive intravenous (IV) 3 infusions of 4000 milligrams (mg) TB006, one every 28 days (Q28D).
62644390|NCT01053455||Starting on NCPAP|randomized to start on NCPAP
62278502|NCT05156827|PLACEBO_COMPARATOR|Placebo|Participants will receive an IV infusion of normal saline 500 milliliters (mL) Q28D.
62644391|NCT01053455||Starting on SiPAP|randomized to SiPAP
62644392|NCT01629550|ACTIVE_COMPARATOR|PVI paint|5% alcoholic povidone iodine paint
62278503|NCT03112174|EXPERIMENTAL|Safety Run-in Period|"Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.~Safety run-in phase for the study is closed to further enrollment as of 07-Nov-2018."
62278504|NCT03112174|EXPERIMENTAL|Phase 3: Ibrutinb + Venetoclax|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
62278505|NCT03112174|PLACEBO_COMPARATOR|Phase 3: Ibrutinib + Placebo|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
62278506|NCT03112174|EXPERIMENTAL|Treatment-naive|"This open-label arm is designed to explore the efficacy and safety of the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL.~Approximately 75 subjects (of which \~25 subjects with TP53 mutation) will be enrolled and treated with ibrutinib and venetoclax."
62278507|NCT05354323|EXPERIMENTAL|NECVAX-NEO1|Personalized patient-individual oral DNA vaccine
62278508|NCT04617158|ACTIVE_COMPARATOR|Early adjustable suture surgery|Suture adjustment after 2 hours of surgery
62644393|NCT01629550|ACTIVE_COMPARATOR|PVI scrub and paint|detersion with 4% povidone iodine scrub followed by 5% alcoholic povidone iodine paint
62644394|NCT01629550|ACTIVE_COMPARATOR|Chlorhexidine paint|2% alcoholic chlorhexidine paint
62644395|NCT01629550|ACTIVE_COMPARATOR|chlorhexidine scrub and paint|Detersion with 4% chlorhexidine scrub followed 2% alcoholic chlorhexidine paint
62644396|NCT00949442|EXPERIMENTAL|1|"Before randomization (common with arm 2):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose"
62644397|NCT00949442|ACTIVE_COMPARATOR|2|"Before randomization (common with arm 1):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: NPH + OAD(s) at stable dose"
62644398|NCT02227095|EXPERIMENTAL|After-school exercise program|40 min/day vigorous aerobic games after school
62644399|NCT02227095|ACTIVE_COMPARATOR|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
62644400|NCT02342626|NO_INTERVENTION|Control|No use of the decision aid dashboard before, during or after the treatment decision time period.
62644401|NCT02342626|EXPERIMENTAL|Dashboard|Use of the decision aid dashboard before, during and after the treatment decision time period.
62644402|NCT06552117|OTHER|immediately resectable patients.|10 immediately resectable patients receiving preoperative chemotherapy based on Folfox alone.
62644403|NCT06552117|OTHER|potentially resectable patients|30 potentially resectable patients (borderline) with two groups of patients representing the usual combinations of triplets: chemotherapy and targeted therapy: Folfox + bevacizumab (15 patients) and Folfox + Cetuximab (15 patients).
62644404|NCT06552117|OTHER|unresectable patients|10 unresectable patients with two groups of patients representing the usual combinations: pure cytotoxics vs cytotoxics + targeted therapy ( bevacizumab or Cetuximab).
62644405|NCT05380765|EXPERIMENTAL|Native PATHS Condition|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
62644406|NCT05380765|NO_INTERVENTION|Wait-List Control|Participants will receive the Native PATHS program once 6-month follow up surveys have been completed.
62644407|NCT04745117||Women with suspected breast cancer|"All women referred under the diagnosis suspected breast cancer will be asked to fill out the questionnaire READHY."
62644408|NCT05821049|ACTIVE_COMPARATOR|UPI65 (Low Dose)|One capsule to be taken 60 ± 10 mins before bed
62644409|NCT05821049|ACTIVE_COMPARATOR|UPI65 (High Dose)|One capsule to be taken 60 ± 10 mins before bed
62644410|NCT05821049|PLACEBO_COMPARATOR|Placebo|One capsule to be taken 60 ± 10 mins before bed
62644411|NCT04197271||Patients with acutely symptomatic abdominal wall hernia|Patients presenting to emergency surgical services with acutely symptomatic abdominal wall hernia (excluding parastomal).
62644412|NCT05107661||Telephone Prompt|Following consent, the Research Team will call participants three times in the first month (within the first week of signing consent at week 2 and repeated at week 3) and then one time per month for the following two months with scripted messaging reminding the participant to complete the screening activity (colonoscopy or fecal test). Interpreter services via phone will be utilized for non-English speaking participants.
62644413|NCT05107661||Digital Prompt|Following consent, scripted messaging will be sent three times in the first month (within the first week of signing consent at week 2 and repeated at week 3) and then once time per month for the following two months with scripted messaging reminding the participant to complete the screening activity (colonoscopy or fecal test). Digital prompts will be available in Spanish and English.
62644414|NCT00349336|EXPERIMENTAL|1|
62644415|NCT00349336|EXPERIMENTAL|2|
62644416|NCT01278758|EXPERIMENTAL|ASA404 + standard therpy|
62644417|NCT06148870|ACTIVE_COMPARATOR|MCL1|The MCL1 is a myopia control lens that will be worn in one eye for 6 months.
62644418|NCT06148870|EXPERIMENTAL|MCL2|The MCL2 is a myopia control lens that will be worn on the contralateral eye for 6 months.
62644419|NCT02517658|ACTIVE_COMPARATOR|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
62644420|NCT02517658|EXPERIMENTAL|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
62644421|NCT02517658|EXPERIMENTAL|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
62644422|NCT02880254|ACTIVE_COMPARATOR|Kurbo only|use of app plus standard of care
62644423|NCT02880254|ACTIVE_COMPARATOR|Kurbo plus PHC|use of app, personal health coach and standard of care
62644424|NCT01690663|PLACEBO_COMPARATOR|Bupivacaine 0.25% mixed with 1ml normal saline|Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)
62644425|NCT01690663|ACTIVE_COMPARATOR|Bupivacaine 0.25% with 1mg dexamethasone (1ml)|Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)
62074314|NCT02374593|EXPERIMENTAL|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
62278509|NCT04617158|ACTIVE_COMPARATOR|Late adjustable suture surgery|Suture adjustment after 24 hours of surgery
62278510|NCT02615990|EXPERIMENTAL|Erigo Pro plus standard Physical Therapy|The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
62278511|NCT02615990|ACTIVE_COMPARATOR|Standard Physical Therapy|Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
62278512|NCT04186455|ACTIVE_COMPARATOR|insertion time|lma pro seal and basks-mask in patients undergoing ups
62278513|NCT04186455|ACTIVE_COMPARATOR|oropharyngeal leak pressure|lma baska-mask undergoing urs
62278514|NCT02889458||Case|"Inclusion Criteria~* Female~* aged 18 or above~* Chinese~* Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)~* Able to speak Cantonese~* Newly diagnosed with breast cancer or DCIS in 24 weeks~Exclusion Criteria~- Undergoing treatment for any non-breast cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected."
62644426|NCT01690663|ACTIVE_COMPARATOR|Bupivacaine 0.25% mixed with 2mg dexamethasone|Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)
62644427|NCT01690663|ACTIVE_COMPARATOR|Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml|Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml
62644428|NCT02133157|EXPERIMENTAL|Sulfatinib capsule|cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.
62644429|NCT00598091|ACTIVE_COMPARATOR|A|
62644430|NCT00598091|ACTIVE_COMPARATOR|B|
62644431|NCT05265702|EXPERIMENTAL|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62644432|NCT02966834|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo
62644433|NCT02966834|EXPERIMENTAL|GSK2330672 20 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
62644434|NCT02966834|EXPERIMENTAL|GSK2330672 90 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
62074315|NCT05903690|EXPERIMENTAL|RAG-17|Doses of RAG-17 will range from a minimum of 60 mg to the maximum tolerated dose (MTD). Dosing once every two weeks, starting from 60 mg, with dose escalation. After reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months.
62074316|NCT00925782|OTHER|Melphalan-Alkeran|Subjects begin with treatment Melphalan and crossover to treatment Alkeran
62074317|NCT00925782|OTHER|Alkeran-Melphalan|Subjects begin with treatment Alkeran and crossover to treatment Melphalan.
62074318|NCT05392387||peg-IFN-alpha alone|Patients with chronic HBV infection only treated with peg-IFN-alpha
62644435|NCT02966834|EXPERIMENTAL|GSK2330672 180 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
62644436|NCT02966834|EXPERIMENTAL|GSK2330672 40 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
62644437|NCT02966834|EXPERIMENTAL|GSK2330672 90 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
62644438|NCT04630678|EXPERIMENTAL|Virtual Reality Group|"The first group was received conventional physiotherapy and virtual reality therapy for 60 minutes.~The conventional physiotherapy interventions, including joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles and special for the needs of the child, was applied to both groups. The virtual reality group received that simulate daily life and contain individual scenarios by using the USE-IT system for thirty minutes. USE-IT (Most Rehabilitation, Ankara, Turkey) is a 2D non-immersive virtual reality system that plays games on a 50-inches touchscreen. The children played the matching, plumber, plumber, math, and car wash games in accordance with their reaching map results. The treatment were given three times a week for eight weeks."
62074319|NCT05392387||nucleos(t)ide analogues alone|Patients with chronic HBV infection only treated with nucleos(t)ide analogues
62074320|NCT05392387||combination|Patients with chronic HBV infection treated with nucleos(t)ide analogues and peg-IFN-alpha
62074321|NCT00363896|EXPERIMENTAL|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
62074322|NCT00363896|PLACEBO_COMPARATOR|Placebo|Placebo once-daily via inhalation
62074323|NCT03623932|ACTIVE_COMPARATOR|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
62644439|NCT04630678|ACTIVE_COMPARATOR|Activity Training (Control) Group|The second group was received conventional physiotherapy and, activity training which the same movement patterns with virtual reality games for 60 minutes. The children in the activity training group received unilateral, bilateral, and bimanual activity training that supported manual skills for thirty minutes. Similar activity patterns were presented to the virtual reality group and activity training (control) group. The treatment were given three times a week for eight weeks.
62074324|NCT03623932|EXPERIMENTAL|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
62074325|NCT01842087|PLACEBO_COMPARATOR|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
62278515|NCT02889458||Control|"Inclusion Criteria~* Female~* aged 18 or above~* Chinese~* Usually residing in Hong Kong~* Able to speak Cantonese~Exclusion Criteria~- History of any cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected."
62074326|NCT01842087|EXPERIMENTAL|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
62074327|NCT04152785|EXPERIMENTAL|GHG|Information given regarding greenhouse gas emissions via a GHG score
62074328|NCT04152785|EXPERIMENTAL|Nutrition|Information given regarding nutrition via a nutrient profiling score
62074329|NCT04152785|EXPERIMENTAL|GHG+nutrition|Information given regarding GHG and nutrition via a combined score
62074330|NCT04152785|PLACEBO_COMPARATOR|No logo|No information given
62074331|NCT04055168|EXPERIMENTAL|Cohort 1 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
62074332|NCT04055168|EXPERIMENTAL|Cohort 2 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
62278516|NCT06036589|EXPERIMENTAL|CA application + BAM8-22|
62644440|NCT01146847|EXPERIMENTAL|1|Space TGC system with incorporated eMPC advised insulin titration to establish tight glycaemic control
62074333|NCT04055168|EXPERIMENTAL|Cohort 3 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 3 of AZD6615 (6 subjects) or matching placebo (2 subjects).
62074334|NCT04055168|EXPERIMENTAL|Cohort 1 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
62074335|NCT04055168|EXPERIMENTAL|Cohort 2 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
62074336|NCT01713790|EXPERIMENTAL|Training group|T0 - Intervention program 3x/ week over 10 weeks: Stochastic resonance whole-body vibration + Exergame + leg press - T1
62074337|NCT00861926|EXPERIMENTAL|Beclometasone/formoterol (100/6 µg)|Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
62074338|NCT00861926|ACTIVE_COMPARATOR|salbutamol|Ventolin : salbutamol sulphate 100 µg per metered dose
62074339|NCT00556374|EXPERIMENTAL|Denosumab|Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
62074340|NCT00556374|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
62074341|NCT00556374|EXPERIMENTAL|SubStudy: Zoledronic Acid|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
62074342|NCT00556374|OTHER|Substudy: Standard of Care|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
62278517|NCT06036589|EXPERIMENTAL|CA application and vehicle|
62644441|NCT00785356|EXPERIMENTAL|25 mg Proellex|Proellex 25 mg
62278518|NCT05075356|EXPERIMENTAL|Single participant arm|"The iToBoS intervention is a total body imaging device, to image the total skin surface in order to detect and monitor for signs of skin cancer.~The imaging process involves laying down on a bed that has a framework of cameras arched over it. The imaging process takes less then 10 minutes, and requires the participant to lay in two different positions (face-up and face-down).~The study visit also includes individual dermoscopic images taken of certain moles on the skin. This is done in combination with a clinical skin examination. Participants are given the option of providing a saliva sample for genetic research. Participants are then asked to complete a series of questionnaires.~There a three visits in total (month 0, 6 and 12), in which these procedures are repeated (except for saliva sample)."
62278519|NCT03463590|EXPERIMENTAL|DBS|All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.
62278520|NCT01350856|ACTIVE_COMPARATOR|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
62644442|NCT00785356|EXPERIMENTAL|Proellex 50 mg|Proellex 50 mg
62644443|NCT00785356|PLACEBO_COMPARATOR|Placebo|Placebo
62644444|NCT02920190|EXPERIMENTAL|Liraglutide Group|Participants in this group will receive the Liraglutide intervention for 12 months
62644445|NCT02528448|ACTIVE_COMPARATOR|plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
62278521|NCT01350856|EXPERIMENTAL|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
62644446|NCT02528448|ACTIVE_COMPARATOR|0,9% saline|Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
62278522|NCT04391959|EXPERIMENTAL|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to twice weekly.
62644447|NCT03627832|EXPERIMENTAL|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
62278523|NCT04391959|EXPERIMENTAL|AZR-MD-001 Active|AZR-MD-001 Active will be dosed up to twice weekly.
62278524|NCT03198494|EXPERIMENTAL|Acoustic 1Hz Stimulation|1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.
62278525|NCT03198494|SHAM_COMPARATOR|Sham Background Noise|Background noise applied via headphones and downloadable phone application during sleep every night.
62644448|NCT03627832|ACTIVE_COMPARATOR|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
62644449|NCT01133548|EXPERIMENTAL|1|Testosterone Gel 1.62%
62278526|NCT03198494|NO_INTERVENTION|Baseline Seizure Monitoring|No use of sound system; Patients record seizures in a diary.
62644450|NCT04556760|EXPERIMENTAL|Cohort 1|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (72 mg AZD9567 followed by 40 mg prednisolone \[AB sequence group\] or 40 mg prednisolone followed by 72 mg AZD9567 \[BA sequence group\]).
62644451|NCT04556760|EXPERIMENTAL|Cohort 2|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (40 mg AZD9567 followed by 20 mg prednisolone \[AB sequence group\] or 20 mg prednisolone followed by 40 mg AZD9567 \[BA sequence group\]).
62644452|NCT04556760|ACTIVE_COMPARATOR|Cohort 3|Participants will be randomised in a ratio of 1:1 to receive placebo and prednisolone over two 72 hour periods in a cross over design (placebo followed by 5 mg prednisolone \[AB sequence group\] or 5 mg prednisolone followed by placebo \[BA sequence group\]).
62644453|NCT00771368|EXPERIMENTAL|Nitric Oxide|gaseous nitric oxide delivered topically for 30 minutes
62644454|NCT02860936|EXPERIMENTAL|Lenvatinib|24 mg of lenvatinib will be administered daily to patients until progression of disease or intolerable toxicity or other criteria for discontinuation is met.
62644455|NCT05789966|NO_INTERVENTION|Control Group|The control group will receive a Fitbit device
62644456|NCT05789966|EXPERIMENTAL|Intervention Group - Genetic Risk Estimate+health coaching|Genetic: Genetic Risk Estimate The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated as well.
62278527|NCT05242250||Acute SOC Sites with Patients with paroxysmal or persistent atrial fibrillation|Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
62644457|NCT05789966|EXPERIMENTAL|Intervention Group - Genetic Risk Estimate + Fitbit Functions+health coaching|"Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well."
62074343|NCT03784352|EXPERIMENTAL|Virtual Reality (VR)|The intervention will consist of standard of care (SOC) in addition to the use of virtual reality. SOC consists of the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device) Patients assigned to the VR group will interact with VR through mobile-based VR googles.
62074344|NCT03784352|NO_INTERVENTION|No Virtual Reality (VR)|This arm will receive regular standard of care (SOC), the same that would be received if they were not enrolled in the study. SOC will include the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device)
62074345|NCT00631384|EXPERIMENTAL|1|Women to be asked to bring husbands for couple VCT
62455944|NCT00048048|EXPERIMENTAL|Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)|Eligible participants will be receiving RO0503821 at a dose of 0.9 mcg/kg SC once every three week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62644458|NCT05256823|EXPERIMENTAL|Experimental Group|Patients will be given a combination of Celecoxib and one nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
62644459|NCT05256823|OTHER|Control group|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
62644460|NCT05355558|EXPERIMENTAL|[18F]FLT-PET/MRI body scan|
62644461|NCT03259958|EXPERIMENTAL|Donepezil TDS|Corplex Donepezil TDS 5 mg/day followed by Donepezil TDS 10mg/day applied weekly for 5 consecutive weeks
62644462|NCT03259958|ACTIVE_COMPARATOR|Aricept|Aricept 5 mg/day followed by Aricept 10 mg/day once daily for 5 consecutive weeks
62644463|NCT00905996|ACTIVE_COMPARATOR|Endoscopic Cyanoacrylate injection|Endoscopic injection of cyanoacrylate in the gastric varix until obturation
62074346|NCT00631384|ACTIVE_COMPARATOR|2|Women to receive individual VCT
62074347|NCT04386590|SHAM_COMPARATOR|'Sham' manual therapy plus Pulmonary Rehabilitation (PR)|Treadmill walking, upper body exercise machine, light weight training and bicycle. These exercises are supervised. In addition to the standard exercise therapy, all participants will undergo a 20-minute session consisting of discussion with the patient and 11 minutes of detuned ultrasound, which has been used in previous studies to account for time and attention for the patient. The detuned ultrasound procedure is to apply the ultrasound gel and turn the machine on, but set the intensity at zero (0) W/cm2
62278528|NCT05242250||Symptomatic Monitoring SOC Sites with Patients with paroxysmal or persistent atrial fibrillation|Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
62455945|NCT00048048|EXPERIMENTAL|Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.8 mcg/kg SC once every three week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
62644464|NCT00905996|NO_INTERVENTION|No Intervention|No treatment offered for gastric varix
62278529|NCT05242250||Full Monitoring SOC Sites with Patients with paroxysmal or persistent atrial fibrillation|Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
62278530|NCT05246332|EXPERIMENTAL|Patient receive grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The grounding group use a grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
62074348|NCT04386590|EXPERIMENTAL|Manual therapy plus Pulmonary Rehabilitation (CMT+|Manual therapy is made up of gentle Effleurage and cross-fibre friction massage applied to the muscles of the posterior chest wall. Manual Therapy consists of two separate manipulations (Grade V mobilization). Each manipulation involves the delivery of a high-velocity low amplitude (HVLA) posterior to anterior force directed at the inter-vertebral, costo-vertebral and costo-transverse joints. The first manipulation is delivered at the level of the upper/middle thoracic spine while the second is at the level of the middle/lower thoracic spine. In addition to the MT, the participant will also undergo Pulmonary Rehab as previously described.
62644465|NCT00905996|OTHER|Beta-blocker (propranolol)|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
62278531|NCT05246332|SHAM_COMPARATOR|Patient receive sham-grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The sham-grounding group use a sham grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
62278532|NCT02899143|EXPERIMENTAL|Group 5-days|5-days targeted antibiotic therapy
62278533|NCT02899143|OTHER|Group 10-days|10-days targeted antibiotic therapy
62074349|NCT02840396|EXPERIMENTAL|rTMS|
62074350|NCT02840396|SHAM_COMPARATOR|Sham rTMS|
62278534|NCT03994510|OTHER|Patients with Borderline Personality Disorder|At each visit, these patients will have an interview that will allow for a clinical evaluation, as well as completing the hetero-questionnaires and self-questionnaires
62278535|NCT02606994|EXPERIMENTAL|Oral Defense Toothpaste|The experimental group will brush with Oral Defense Toothpaste three times per day during the study
62278536|NCT02606994|PLACEBO_COMPARATOR|Crest Toothpaste/Magic Mouth Rinse|The placebo group will brush with Crest Toothpaste three times per day during the study. Participants in the placebo comparator group who require additional management of their oral mucositis pain will be provided Magic Mouth Rinse.
62278537|NCT02458196|EXPERIMENTAL|Prednisone|Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
62278538|NCT02458196|EXPERIMENTAL|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
62278539|NCT05365165||sevoflurane|Standard anesthesia management will be applied in the induction and maintenance of anesthesia. In the induction of anesthesia 1mg/kg lidocaine , 1.5-2mg/kg propofol , 1 mcg /kg fentanyl citrate, 0.6 mg/kg rocuronium bromide will be administered. Sevoflurane for maintenance of anesthesia and propofol and fentanyl if needed bolus will be applied. BIS monitoring will be performed to control the depth of anesthesia.
62278540|NCT03412773|EXPERIMENTAL|Arm A: Tislelizumab & Safety Run-In Substudy [Japan Only]|
62278541|NCT03412773|ACTIVE_COMPARATOR|Arm B: Sorafenib|
62455946|NCT04669236|EXPERIMENTAL|Intervention group|Intervention promoting healthy sleep behaviour in adolescents based on a participatory health research approach. Based on participatory session, the pupils of the action group will develop the intervention. They will participate in every step of the development to maximize their input.
62278542|NCT02426177|ACTIVE_COMPARATOR|group A|tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
62278543|NCT02426177|ACTIVE_COMPARATOR|group B|tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
62278544|NCT01743482|EXPERIMENTAL|Pazopanib|Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.
62644466|NCT03523156|ACTIVE_COMPARATOR|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
62644467|NCT03523156|EXPERIMENTAL|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
62074351|NCT03820167||Fresh sample|"Morphologically good embryos will be cultured in a culture dish and the supernatants will be collected freshly from culture system at day 3 and stored at -20 ̊ c until being tested.~Quantification of mtDNA in fresh and frozen culture media using qPCR technique."
62278545|NCT01341327||Left Main disease|Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
62644468|NCT01811238|EXPERIMENTAL|Oxycodone/Naloxone|Single-arm study
62455947|NCT04669236|NO_INTERVENTION|Control group|Participants in the control group will receive no intervention.
62455948|NCT00795665|EXPERIMENTAL|Bevacizumab and Carmustine|
62455949|NCT05223556||Shaoguan Diabetic cohort|Patients with diabetes ages 30-80 were enrolled in Shaoguan Diabetic Eye Screening Programme, who will receive diabetic retinopathy screening both in a remote diagnostic imaging site and in a tertiary hospital
62644469|NCT00830128|EXPERIMENTAL|pregabalin (Lyrica)|
62644470|NCT04654013|EXPERIMENTAL|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
62074352|NCT03820167||Frozen embryos|Morphologically good embryos scheduled for freezing will be cryopreserved for less than one year and thawed, the supernatant will be collected and stored at -20 ̊ c until being tested. Quantification of mtDNA in fresh and frozen culture media using qPCR technique.
62074353|NCT03051490|EXPERIMENTAL|Liprotamase|Individually-optimized dose to be administered orally
62278546|NCT03170674|EXPERIMENTAL|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
62278547|NCT03170674|EXPERIMENTAL|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
62278548|NCT03170674|EXPERIMENTAL|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
62278549|NCT03170674|NO_INTERVENTION|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
62278550|NCT02500186|EXPERIMENTAL|High GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate white rice diet.
62278551|NCT02500186|EXPERIMENTAL|Low GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in low GI meal containing 55% carbohydrate group take 55% carbohydrate brown rice diet
62278552|NCT02500186|EXPERIMENTAL|High GI meal containing 40% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 40% carbohydrate group take 40% carbohydrate white rice diet.
62278553|NCT01964001|PLACEBO_COMPARATOR|Placebo|starch
62074354|NCT03051490|ACTIVE_COMPARATOR|porcine PERT|Individually-optimized dose to be administered orally
62074355|NCT01404611|ACTIVE_COMPARATOR|DF289|Ear drops
62074356|NCT01404611|ACTIVE_COMPARATOR|DF277|Ear drops
62074357|NCT01404611|EXPERIMENTAL|DF289 plus DF277|Ear drops
62074358|NCT05593211|EXPERIMENTAL|Patients undergoing a scheduled, elective, solid organ biopsy procedures on the liver or kidneys|
62278554|NCT01964001|EXPERIMENTAL|Dietary supplements|Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10
62278555|NCT05781828||Laboratory investigation|Complete blood count, liver function tests, prothrombin time(PT), prothrombin concentration(PC), international normalized ratio (INR), renal chemistry and electrolytes
62278556|NCT04109495|OTHER|Smart phone application(NOOM)|
62278557|NCT04109495|OTHER|Non-user|
62644471|NCT04654013|NO_INTERVENTION|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (18 months).
62074359|NCT04690374||Desmoplastic small round cell tumor (DSRCT)|Collect historical/longitudinal clinical, radiographic and molecular features of DSRCT patients as documented in medical records to improve knowledge about DSRCT
62074360|NCT05206864|EXPERIMENTAL|SBD111|
62074361|NCT05206864|PLACEBO_COMPARATOR|Placebo|
62074362|NCT01321398||Critically Ill patients receiving HFO|
62074363|NCT05990413||Hemiplegic Participants|Participants will be evaluated in terms of inclusion criteria, and fugl-meyer upper extremity performance assessment will be applied to eligible patients and it will be clarified whether they can be included. Participants who may be included in the study will fill in the patient demographic information form prepared by the researchers as a face-to-face interview. This form will take approximately 5 minutes, during which time the muscles will be rested. Then, the viscoelastic properties of the determined muscles of the participants will be evaluated. Finally, the participants will be evaluated in terms of the activation timing and percentages of the muscles determined during an open and closed kinetic chain activity. Half of the participants will do the open kinetic chain activity before the closed kinetic chain activity with a five-minute resting period between activities. The others will start with the closed kinetic chain activity first and then the open kinetic chain activity.
62074364|NCT05990413||Healthy Participants|Participants will be evaluated in terms of inclusion criteria. Eligable participants will fill in the patient demographic information form prepared by the researchers as a face-to-face interview. This form will take approximately 5 minutes, during which time the muscles will be rested. Then, the viscoelastic properties of the determined muscles of the participants will be evaluated. Finally, the participants will be evaluated in terms of the activation timing and percentages of the muscles determined during an open and closed kinetic chain activity. Half of the participants will do the open kinetic chain activity before the closed kinetic chain activity with a five-minute resting period between activities. The others will start with the closed kinetic chain activity first and then the open kinetic chain activity.
62074365|NCT04547426|ACTIVE_COMPARATOR|red wine and snuff|regular red wine and moist snuff
62074366|NCT04547426|ACTIVE_COMPARATOR|red wine and nicotine-free snuff|regular red wine and nicotine-free snuff
62074367|NCT04547426|ACTIVE_COMPARATOR|non alcoholic red wine and regular moist snuff|non alcoholic red wine and regular moist snuff with nicotine
62074368|NCT04547426|PLACEBO_COMPARATOR|non-alcoholic red wine and nicotine-free snuff|Non-alcoholic red wine and nicotine-free snuff
62278558|NCT02950233|EXPERIMENTAL|NMDA active + Steroid placebo|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
62644472|NCT06380062||Primary prostate cancer|"Men participants diagnosed with primary prostate cancer are cases"
62074369|NCT01426490|OTHER|Vitamin C|Vitamin C as control group.
62074370|NCT01426490|EXPERIMENTAL|Vitamin B6|
62074371|NCT01426490|EXPERIMENTAL|Folic acid|
62074372|NCT01426490|EXPERIMENTAL|Vitamin B6 plus folic acid|
62278559|NCT02950233|EXPERIMENTAL|Steroid active + NMDA placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID \[first week\]; one capsule BID \[following three weeks\]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
62074373|NCT01053637|EXPERIMENTAL|Hydrocodone/acetaminophen|Patients will receive 0.17 mg/kg hydrocodone component to a max of 10 mg hydrocodone.
62278560|NCT02950233|EXPERIMENTAL|NMDA active + Steroid active|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
62278561|NCT02950233|PLACEBO_COMPARATOR|NMDA placebo + Steroid placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID \[first week\]; one capsule BID \[following three weeks\]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
62278562|NCT05343065|EXPERIMENTAL|CGM insulin bolus calculator arm|Participants will use the CGM insulin bolus calculator arm
62278563|NCT04069052|EXPERIMENTAL|Inhaled Nitric Oxide|Inhaled nitric oxide administered throughout 4 min exercise protocol at 800 ppm.
62278564|NCT04069052|PLACEBO_COMPARATOR|Placebo|Inhaled room air administered throughout 4 min exercise protocol at FiO2 = 0.21.
62278565|NCT01500837|ACTIVE_COMPARATOR|RIFAMPIN|CLINDAMYCIN + RIFAMPIN
62644473|NCT06380062||Benign hyperplasia|"Men participants diagnosed with benign hyperplasia are the controls"
62644474|NCT03614104|ACTIVE_COMPARATOR|mobile health technology|Health education with mobile health technology
62644475|NCT03614104|SHAM_COMPARATOR|Without mobile health technology|Health education without mobile health technology
62278566|NCT01500837|ACTIVE_COMPARATOR|LEVOFLOXACIN|CLINDAMYCIN + LEVOFLOXACIN
62278567|NCT01409603|EXPERIMENTAL|Treatment arm A|darexaban, wash-out, naproxen, wash-out, combination therapy
62644476|NCT04388410|EXPERIMENTAL|convalescent plasma|Convalescent plasma obtained from volunteers who have recovered from COVID 19. Enclosed with a similar material as the control
62644477|NCT04388410|PLACEBO_COMPARATOR|Normal saline|Normal saline solution in 200 ml plasma bags enclosed with with a similar material as the plasma
62074374|NCT01053637|PLACEBO_COMPARATOR|Sugar water|Placebo
62278568|NCT01409603|EXPERIMENTAL|Treatment arm B|darexaban, wash-out, combination therapy, wash-out, naproxen
62278569|NCT01409603|EXPERIMENTAL|Treatment arm C|naproxen, wash-out, darexaban, wash-out, combination therapy
62074375|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
62074376|NCT01634958|EXPERIMENTAL|10.000 DPP/ml suspension for s.c. inj.|
62074377|NCT01634958|EXPERIMENTAL|5.000 DPP/ml suspension for s.c. inj.|
62074378|NCT01634958|EXPERIMENTAL|1.000 DPP/ml suspension for s.c. inj.|
62074379|NCT01634958|EXPERIMENTAL|100 DPP/ml suspension for s.c. inj.|
62074380|NCT05955521|EXPERIMENTAL|CtDNA/Exosome evaluation|
62074381|NCT05312437|EXPERIMENTAL|Interruptive Best Practice Advisory - CDS Intervention|"Adults at Elevated Predicted Risk (\>=2% predicted risk, based on our study, DOI: 10.1001/jamanetworkopen.2021.1428) at visit registration (aka check-in) will be randomized to either Interruptive Alert or Passive Prompt CDS interventions.~In the Interruptive Alert, the physician who next opens that patient's chart will be prompted to review a BPA describing the patient's risk and asking the physician to choose from the BPA options (see Interventions).~The BPA will need to be dismissed to the Epic Storyboard or completed as above to continue clinical workflow."
62074382|NCT05312437|ACTIVE_COMPARATOR|Passive Storyboard Prompt - CDS Intervention|"Adult patients in the highest predicted risk tier (\>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
62074383|NCT01971606|EXPERIMENTAL|Rosuvastatin group|Rosuvastatin group
62074384|NCT01971606|PLACEBO_COMPARATOR|Placebo group|Placebo group
62074385|NCT03162757|EXPERIMENTAL|Subclavian vein access|
62074386|NCT03162757|EXPERIMENTAL|Internal jugular vein access|
62278570|NCT01409603|EXPERIMENTAL|Treatment arm D|naproxen, wash-out, combination therapy, wash-out, darexaban
62278571|NCT01409603|EXPERIMENTAL|Treatment arm E|combination therapy, wash-out, naproxen, wash-out, darexaban
62278572|NCT01409603|EXPERIMENTAL|Treatment arm F|combination therapy, wash-out, darexaban, wash-out, naproxen
62278573|NCT00280995|EXPERIMENTAL|Cohort A|Loading doses followed by weekly maintenance doses
62278574|NCT00280995|EXPERIMENTAL|Cohort B|Loading doses followed by weekly maintenance doses
62644478|NCT06293742|EXPERIMENTAL|Digoxin, Rosuvastatin, ECC5004 (Part A)|Part A consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.
62074387|NCT05044975|EXPERIMENTAL|Sleep restriction, Stimulus control, and Systematic light exposure|
62074388|NCT05044975|EXPERIMENTAL|Sleep restriction and Stimulus control|
62074389|NCT05044975|EXPERIMENTAL|Sleep restriction and Systematic light exposure|
62074390|NCT05044975|EXPERIMENTAL|Stimulus control and Systematic light exposure|
62074391|NCT05044975|EXPERIMENTAL|Sleep Restriction|
62074392|NCT05044975|EXPERIMENTAL|Stimulus control|
62278575|NCT00280995|EXPERIMENTAL|Cohort C|Loading doses followed by weekly maintenance doses
62278576|NCT00280995|EXPERIMENTAL|Cohort D|Loading doses followed by extended weekly maintenance doses
62278577|NCT02496949|EXPERIMENTAL|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
62278578|NCT02427347|EXPERIMENTAL|Intervention group|Intervention including acupuncture treatment and healthy education.
62278579|NCT02427347|OTHER|Control group|Healthy education is given as a baseline treatment.
62455950|NCT00928083|EXPERIMENTAL|Part A - 50 mg Single Dose|OZ439 Single doses of 50mg (capsules)
62074393|NCT05044975|EXPERIMENTAL|Systematic light exposure|
62074394|NCT05044975|NO_INTERVENTION|Sleep tracking|
62278580|NCT06196866|ACTIVE_COMPARATOR|Control group|Participants carry out daily routine activities and/or receive standard physiotherapy for the whole 24 weeks of the trial, 1 session/week with a time of 45 minutes/session.
62455951|NCT00928083|EXPERIMENTAL|Part A - 100mg Single Dose|OZ439 Single doses of 100mg (capsules)
62455952|NCT00928083|EXPERIMENTAL|Part A - 200mg Single Dose|OZ439 Single doses of 200mg (capsules)
62455953|NCT00928083|EXPERIMENTAL|Part A - 400mg Single Dose|OZ439 Single doses of 400mg (capsules)
62455954|NCT00928083|EXPERIMENTAL|Part A - 400mg Single Dose + Food|OZ439 Single doses of 400mg (capsules) administered with food.
62455955|NCT00928083|EXPERIMENTAL|Part A - 400mg AD Single Dose|OZ439 Single doses of 400mg (aqueous dispersion)
62455956|NCT00928083|EXPERIMENTAL|Part A - 800mg Single Dose|OZ439 Single doses of 800mg (capsules)
62455957|NCT00928083|EXPERIMENTAL|Part A - 800mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
62455958|NCT00928083|EXPERIMENTAL|Part A - 1200mg Single Dose|OZ439 Single doses of 1200mg (capsules)
62455959|NCT00928083|EXPERIMENTAL|Part A - 1600mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
62074395|NCT06339125|EXPERIMENTAL|Unit 1|Usual care and live streaming electronic health record driven Algorithm alerts nurses to possible increase in fall risk for review of interventions in place.
62074396|NCT06339125|EXPERIMENTAL|Unit 2|Usual care and computer camera visualization detects and anticipates patient movement for patients at risk for falls and alerts nurses with fall risk potential.
62074397|NCT06339125|EXPERIMENTAL|Unit 3|Usual care and live streaming electronic health record driven Algorithm alerts nurses to possible increase in fall risk for review of interventions in place. AND Computer camera visualization detects and anticipates patient movement for patients at risk for falls and alerts nurses with fall risk potential.
62074398|NCT06339125|NO_INTERVENTION|Unit 4|Control group, no intervention and usual care.
62074399|NCT02111213|ACTIVE_COMPARATOR|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
62074400|NCT02111213|EXPERIMENTAL|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
62074401|NCT02319343|ACTIVE_COMPARATOR|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
62074402|NCT02319343|PLACEBO_COMPARATOR|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride.
62074403|NCT03656458|ACTIVE_COMPARATOR|Control Group A|Warm Up followed by Conventional Balance Training (Internal and External Perturbations)
62074404|NCT03656458|NO_INTERVENTION|Control Group B|Control group. No intervention given to participants.
62074405|NCT03656458|EXPERIMENTAL|Experimental Group|Warm Up followed by Biodex Balance Training
62074406|NCT01003639|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide given in escalating doses
62074407|NCT01003639|PLACEBO_COMPARATOR|Sugar pill|"Given in escalating dose (number of pill)"
62074408|NCT02530138|ACTIVE_COMPARATOR|Synbiotic|2 synbiotic capsules for 28 weeks
62074409|NCT02530138|PLACEBO_COMPARATOR|maltodexterin|two capsules per day for 28 weeks
62074410|NCT06476795|EXPERIMENTAL|Chardonnay Marc Intake Level 1|Daily intake of Chardonnay marc at 1.5 g
62074411|NCT06476795|EXPERIMENTAL|Chardonnay Marc Intake Level 2|Daily intake of Chardonnay marc at 4.5 g
62278581|NCT06196866|EXPERIMENTAL|Exergaming group 1|Participants receive Nintendo Ring Fit Adventure exergaming intervention for 12 weeks, 1 session/week with a time of 45 minutes/session + Control group intervention.
62278582|NCT06196866|EXPERIMENTAL|Exergaming group 2|Participants receive Nintendo Wii Fit exergaming intervention for 12 weeks, 1 session/week with a time of 45 minutes/session + Control group intervention.
62278583|NCT04746768|EXPERIMENTAL|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
62455960|NCT00928083|PLACEBO_COMPARATOR|Part A - Placebo|Placebo control for Single rising Part A
62455961|NCT00928083|EXPERIMENTAL|Part B - 800mg AD Single Dose Fed|Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
62455962|NCT00928083|EXPERIMENTAL|Part B - 800mg AD Single Dose Fast|Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
62644479|NCT06293742|EXPERIMENTAL|Midazolam, Atorvastatin, ECC5004 (Part B)|Part B consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.
62644480|NCT06293742|EXPERIMENTAL|Digoxin, Rosuvastatin, ECC5004 (optional Part C)|Optional Part C consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.
62278584|NCT04845412||Children of GDM parents|Children of mothers who have gestational diabetes mellitus
62278585|NCT04845412||Children of non-diabetic parents|Children of mothers without diabetes
62455963|NCT00928083|EXPERIMENTAL|Part C - 200mg AD Multiple Dose|200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
62455964|NCT00928083|EXPERIMENTAL|Part C - 400mg AD Multiple Dose|400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
62644481|NCT06293742|EXPERIMENTAL|Midazolam, Atorvastatin, ECC5004 (optional Part D)|Optional Part D consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.
62644482|NCT05861375||Non applicable (NA)|Patients with Anorexia Nervosa hospitalized for malnutrition
62644483|NCT04415346|EXPERIMENTAL|HU-014 Inj(Phase 1|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
62644484|NCT00568971|EXPERIMENTAL|weekly chemo|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
62644485|NCT03447548|EXPERIMENTAL|Processing speed training|Neurofeedback processing speed training
62644486|NCT03447548|ACTIVE_COMPARATOR|Active control|Computer games
62278586|NCT01935050|EXPERIMENTAL|Guided Cognitive-Behavioral Self-Help|All participants will receive the experimental intervention: Guided Cognitive-Behavioral Self-Help. The 10 patient treatment modules will incorporate exercise, behavioral activation, thought monitoring and restructuring, relaxation training, worry control, and sleep hygiene. The four caregiver educational modules will provide caregivers with the skills needed to facilitate patients' practice of treatment techniques learned in session. For example, caregivers will be taught to help patients identify negative thoughts and replace them with more balanced alternatives and will be given tools to assist patients complete therapy goals (i.e., exercise, socializing).
62644487|NCT02402374|EXPERIMENTAL|PRP gel|Autologous platelet rich plasma gel
62455965|NCT00928083|EXPERIMENTAL|Part C - 800mg AD Multiple Dose|800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
62455966|NCT00928083|PLACEBO_COMPARATOR|Part C - Placebo|Placebo control for Multiple rising Part C
62644488|NCT02402374|PLACEBO_COMPARATOR|Placebo|Saline gel
62644489|NCT03060473|EXPERIMENTAL|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
62455967|NCT03482882|EXPERIMENTAL|Drug - pimavanserin|
62455968|NCT04640103||adjuvant therapy|Patients who received immunotherapy in adjuvant treatment stage only
62455969|NCT04640103||neoadjuvant therapy|Patients who received immunotherapy in neoadjuvant treatment stage and achieved R0 resection
62455970|NCT00726960|EXPERIMENTAL|1|Aprepitant
62455971|NCT00726960|PLACEBO_COMPARATOR|2|Placebo
62455972|NCT02805322|EXPERIMENTAL|Temporal Temperature Measurement|Infrared Temporal Temperature Measurement using the ARC InstaTemp MD in three different age groups with a specified percentage reporting as febrile.
62455973|NCT02805322|ACTIVE_COMPARATOR|Tympanic and/or Sublingual Temperature|"Tympanic and/or Sublingual Temperature Measurement using one or both of two widely used reference clinical thermometers in three different age groups with a specified percentage reporting as febrile.~Choice between Tympanic and/or Sublingual is determined based on standard of care in study site~Reference Thermometer 1 - Covidien Genius 2 Tympanic Thermometer~Reference Thermometer 2 - Welch Allen SureTemp Plus Sublingual Thermometer"
62455974|NCT01739283|EXPERIMENTAL|hyperglycemia|Hyperglycemic clamping
62455975|NCT01739283|EXPERIMENTAL|hypoglycemia|Hypoglycemic clamping
62455976|NCT02802371|NO_INTERVENTION|control group|Patients and caregivers randomized in the control group will receive the current management in geriatric or memory consultation without multidisciplinary psychosocial intervention and pharmaceutical collaborative care.There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, but the recommendations will not be transmitted to the referring physicians of patients and caregivers.
62644490|NCT03060473|ACTIVE_COMPARATOR|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
62644491|NCT05224700|EXPERIMENTAL|Intervention group|The evaluator in charge will monitor the autonomous work of the participants during all 20 sessions of the program for stimulating cognitive and socioemotional skills while also answering questions, training the educators, and solving their doubts about the program and its implementation.
62074412|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:~1. Fever \>39~2. Lower respiratory tract infection~3. Acute otitis media~4. Serious extra-pulmonary manifestations (myositis, encephalitis)"
62644492|NCT05224700|SHAM_COMPARATOR|Painting group|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. They will play a tablet-based painting game that involves no cognitive, emotional, or social competence stimulation
62644493|NCT04175171|EXPERIMENTAL|GB221|Coprelotamab Injection, 8mg/kg, single dose
62644494|NCT04175171|ACTIVE_COMPARATOR|Herceptin|Trastuzumab Injection, 8mg/kg, single dose
62644495|NCT03644017|EXPERIMENTAL|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
62644496|NCT05405790||Patients receiving TEVAR|
62644497|NCT04044118|EXPERIMENTAL|Caloric Restriction|3-week low calorie diet
62644498|NCT00239720|EXPERIMENTAL|hOKT3gamma1 (Ala-Ala)|Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
62644499|NCT00239720|PLACEBO_COMPARATOR|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
62074413|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
62074414|NCT00827151|ACTIVE_COMPARATOR|Estrogen and lifestyle|
62074415|NCT00827151|NO_INTERVENTION|Lifestyle|
62074416|NCT02625194|EXPERIMENTAL|Oxygen|Oxygen is supplied through suction port in bronchoscope during bronchoscope-guided intubation.
62074417|NCT02625194|NO_INTERVENTION|Control|Bronchoscope-guided intubation is performed without oxygen supply.
62644500|NCT00481884|EXPERIMENTAL|RadiaPlexRx Gel|RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
62644501|NCT00481884|ACTIVE_COMPARATOR|Aquaphor Gel|Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
62644502|NCT02806440|ACTIVE_COMPARATOR|Low dose naltrexone|Low dose naltrexone 4.5 mg/tablet, 1 tablet a day for 21 days
62644503|NCT02806440|PLACEBO_COMPARATOR|Placebo|"Placebo tablet~1 tablet a day for 21 days"
62644504|NCT00405301|OTHER|Arm 1|Arm 1: will receive Isoniazide(5mg/kg/day), Rifampicin(10mg/kg/day) and Pyrazinamide(25mg/kg/day) in full doses on day 1 and continued further
62644505|NCT00405301|OTHER|Arm 2|Arm 2 : will receive Rifampicin(10mg/kg/day) in full dose on day 1 and continued, Isoniazide(5mg/kg/day)in full dose on day 8 and continued, Pyrazinamide(25mg/kg/day)on day 15 and continued
62644506|NCT00405301|OTHER|Arm 3|Arm 3 will receive 100 mg/day of Isoniazide on day 1 which is gradually increased to maximum dose (5mg/kg/day) by day 4 and continued. Rifampicin is introduced on day 8 in a dose of 150 mg/day which is gradually increased to maximum dose (10mg/kg/day) by day 11 and continued. Pyrazinamide is introduced on day 15 in a dose of 500mg/day which is gradually increased to maximum dose (25mg/kg/day) by day 18 and continued.
62644507|NCT05899530|ACTIVE_COMPARATOR|Conventional expander|Expansion using conventional orthodontic expander(hyrax)
62644508|NCT05899530|EXPERIMENTAL|Invisalign|Expansion with Invisalign appliance
62644509|NCT05549596|EXPERIMENTAL|Traction treatment|About 40 minutes spine traction including temperature application, Spine Scan, Pre-stroke, and Main Stroke
62644510|NCT05549596|ACTIVE_COMPARATOR|Physical Therapy|About 40 minutes standard physical therapy including temperature application and traction
62074418|NCT04831008|ACTIVE_COMPARATOR|Figure-of-eight|Using the figure-of-eight closure technique when closing access for structural heart therapies.
62074419|NCT04831008|ACTIVE_COMPARATOR|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
62074420|NCT02934360||Non-small cell Lung Cancer|Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
62074421|NCT02934360||Breast Cancer|Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
62074422|NCT03019120|EXPERIMENTAL|Active Comparator: Intervention group|Vitamin D supplementation for subjects with below normal levels of this vitamin.
62278587|NCT03473093|ACTIVE_COMPARATOR|morphine|This group will receive only morphine infusion (20microgram/kg/h)
62278588|NCT03473093|ACTIVE_COMPARATOR|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
62644511|NCT06011863||Group TEA (Thoracic Epidural Analgesia)|Group TEA (Thoracic Epidural Analgesia): Thoracic Epidural Application: The epidural area will be accessed from the 7th (T7)-8th (T8) level of the thoracic vertebral midline with an 18 gauge (G) epidural needle using the hanging drip technique. After 2 ml of 2% lidocaine is administered and no spinal effect is observed, a mixture of morphine and local anaesthetic 3-4 mg morphine hydrochloride + 5 ml 0.5% bupivacaine + 2 ml 0.9% saline will be administered through the epidural needle at once and the epidural needle will be withdrawn and sterile dressing will be applied.
62644512|NCT06011863||Grup ESP ( Erector spinae plane block)|Group ESP: Before induction of anaesthesia, the patient is placed on the operating table and placed in a forward tilted position. Asepsis and antisepsis conditions are provided. The linear USG probe is moved approximately 2-3 cm lateral to the spinous process T5 - T6 level on the side to be operated. The trapezius, rhomboid major and erector spinae muscles will be identified to find the correct probe position. A 22 gauge , 50 mm or 22 gauge 80 mm single shot nerve blocks needle will be inserted through the skin in a cranio-caudal direction. With the needle resting on the transverse process, the plane between the erector spinae muscle and the transverse process will be verified by hydrodissection with 5 ml saline solution. Then 20 ml of 0.25% bupivacaine will be injected. The ESP block will be considered successful if the local anaesthetic spreads linearly up to the T8 - T9 level. The patient will then be placed in the supine position and general anaesthesia will be administered.
62278589|NCT05776849|EXPERIMENTAL|Experimental group|The trainer shared the training presentation, visuals and videos (his own video explaining the episiotomy application and repair and other videos shared with the traditional group) prepared on the subject of episiotomy with the students through the course information system, one week before the episiotomy application. It was accepted that the students came to the episiotomy application with the theoretical training. Afterwards, episiotomy was applied.
62278590|NCT05776849|NO_INTERVENTION|No Intervention: Control group (Traditional education)|The students were given theoretical training. This training was implemented in two sessions, one lasting 50 minutes and the other 30 minutes. The content of the training; It included the definition of episiotomy, indications, risks, episiotomy application steps, materials used, episiotomy types, episiotomy repair and repair steps, suturing techniques and types, episiotomy care. Slide shows, related images and video presentations (3 videos showing episiotomy application and repair steps and suturing techniques) were used as teaching materials. A question-answer session was held at the end of the training. In addition, teaching materials were shared with the students after the application. Immediately after the training, episiotomy was applied.
62074423|NCT01636375||Direct Anterior Approach|
62074424|NCT01636375||Posterior Approach|
62074425|NCT03906513|ACTIVE_COMPARATOR|Active treatment|20 patients will be treated with active treatment (OMK2)
62074426|NCT03906513|PLACEBO_COMPARATOR|Placebo|10 patients will be treated with placebo (lubricant eye drops)
62074427|NCT01916499||"Switch trap-door re-implantation of the coronaries"|"Re-implantation of the coronary arteries into the neo-aortic sinuses through a trap-door as far distally as possible on the neo-aorta"
62074428|NCT01916499||"Switch non-trap-door re-implantation of the coronaries"|Re-implantation of the coronary arteries into the neo-aortic sinuses through small incisions or excision in the sinuses
62074429|NCT00974636|EXPERIMENTAL|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
62074430|NCT00974636|PLACEBO_COMPARATOR|Ususal Salt Diet|Usual salt intake (approximately \>180-200 mmol/day in the average American diet).
62074431|NCT06459791|OTHER|Line N in step 1|Step 1: follow-up of line N (standard care) when the tumorogram is established. Intervention is the biopsy performed before start of treatment in line N. Standard of Care treatment
62074432|NCT06459791|EXPERIMENTAL|Line N+1 in step 2|Step 2: in case of informative tumorogram: follow-up of experimental line N+1. If tumorogram is informative on organoid issued from biospy, a specific standard of Care treatment will be recommanded.
62074433|NCT03535051|EXPERIMENTAL|Treatment A|Combination treatment of fractional carbon dioxide laser monthly sessions and topical tacrolimus 0.03% daily application (Tacrolimus Oint 0.03%)
62074434|NCT03535051|ACTIVE_COMPARATOR|Treatment B|Monotherapy with only topical tacrolimus 0.03% daily intervention: Tacrolimus Oint 0.03%
62074435|NCT01805193||Suspected coronary heart disease|
62074436|NCT06386081|EXPERIMENTAL|Citrus pectin dietary intervention group|This group will orally take 10 g of citrus pectin with low DE (7,3%) + 5 g of maltodextrin twice a day during two months.
62074437|NCT06386081|EXPERIMENTAL|Apple pectin intervention group|This group will orally take 10 g of apple pectin with high DE (57%) + 5 g of maltodextrin twice a day during two months.
62278591|NCT01500057|ACTIVE_COMPARATOR|Greenlight XPS Laser|Greenlight XPS Laser of the prostate
62278592|NCT01500057|ACTIVE_COMPARATOR|BiVAP Saline Vaporization|BiVAP Saline Vaporization of the prostate
62278593|NCT04800731||Group 1|Group 1 will consist of 100 patients COVID-19 positive patients older than 70 years old hospitalized in UZ Brussel from February 2020 until September 2020 with a positive RT-PCR test for SARS-CoV-2.
62278594|NCT04800731||Group 2|Group 2 will consist of 100 patients older than 70 years old hospitalized in UZ Brussel for acute infections other than COVID-19.
62278595|NCT04800731||Group 3|Group 3 will consist of healthy aged people defined as in the modified SENIEUR protocol (12, 13). This group is recruited from a previously conducted study. These are community dwelling individuals above the age of 70 and considered as almost healthy with some conditions that are present in the majority of old people such as osteoporosis, osteoarthritis or atherosclerosis.
62278596|NCT06423079||IOL-Bag Dislocation patients|Patients affected by pseudoexfoliation syndrome, with inferior dislocation of the bag-IOL complex.
62278597|NCT00836134|EXPERIMENTAL|1|rectus sheath block
62278598|NCT00836134|ACTIVE_COMPARATOR|2|local anesthetic infiltration
62278599|NCT01526109|EXPERIMENTAL|strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
62278600|NCT01526109|PLACEBO_COMPARATOR|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
62278601|NCT01526109|EXPERIMENTAL|whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
62278602|NCT03664128||pregnant women positive for anxiety|"100 pregnant women who screen positive for anxiety symptoms (\>21 on the Perinatal Anxiety Screening Scale). Participants are matched for age, parity, and gestational age at enrollment.~Coping with Anxiety through Living Mindfully (CALM) Pregnancy: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants)"
62278603|NCT03664128||healthy pregnant controls|100 matched healthy pregnant women. Participants are matched for age, parity, and gestational age at enrollment.
62644513|NCT01658280|ACTIVE_COMPARATOR|Conventional TBNA + ROSE|"Patients allocated in this group will undergo conventional TBNA, performed in a bronchoscopy suite by the same operator under conscious sedation, using 19-G needle size. Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.~In case of samples obtained from conventional TBNA defined as non diagnostic, the operator will shift to the EBUS procedure.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs"
62278604|NCT02503904|ACTIVE_COMPARATOR|TAD+IVAD|
62278605|NCT02503904|ACTIVE_COMPARATOR|IVAD|
62278606|NCT02669472|EXPERIMENTAL|F&V Intervention|Housing complexes randomized to the intervention arm received a multicomponent intervention comprised of a year-round, discount, mobile fresh fruit and vegetable market ('Fresh To You') that was paired with nutrition education interventions including educational newsletters, recipe cards, campaigns, taste-testings and videos in both English and Spanish.
62278607|NCT02669472|EXPERIMENTAL|Control Intervention|Housing complexes randomized to the comparison arm received a year-long intervention on physical activity and stress reduction including educational campaigns and materials in both English and Spanish.and a YMCA membership for those who joined the campaigns.
62278608|NCT00000511|PLACEBO_COMPARATOR|Potassium, Magnesium, Calcium, The 3 together, Placebo|Parallel study design, 4 treatment groups
62278609|NCT01708980|EXPERIMENTAL|Six different strength training exercises|Six different strength training exercises are investigated. Four repetitions of each exercise are performed with a relative loading of 10 RM.
62278610|NCT01870739|EXPERIMENTAL|sacubitril/valsartan (LCZ696)|"Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
62074438|NCT06386081|PLACEBO_COMPARATOR|Placebo group|This group will orally take placebo (5 g of maltodextrin) twice a day during two months.
62074439|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
62074440|NCT00505726||Confocal Microscopy|
62074441|NCT01505751||cervical cancer|
62074442|NCT01654237|NO_INTERVENTION|Muskind|three questionnaires to be completed by the subjects
62455977|NCT02802371|ACTIVE_COMPARATOR|Psychosocial intervention|Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
62644514|NCT01658280|EXPERIMENTAL|EBUS-TBNA + ROSE|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
62074443|NCT03380832||Type 2 diabetes for at least 10 years|This is an observational study in which we will quantify vestibular thresholds in individuals who have had type 2 diabetes for at least 10 years. Normative data has recently been published and subjects with diabetes will be compared to a model that includes age effects.
62074444|NCT03388112|NO_INTERVENTION|antibiotics|the patients in this arm will not receive probiotics.
62074445|NCT03388112|EXPERIMENTAL|probiotics concurrent with antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks concurrent with antibiotic.
62074446|NCT03388112|EXPERIMENTAL|probiotics after antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks after antibiotic.
62074447|NCT06306950|EXPERIMENTAL|Near infrared spectroscopy neuromonitor|Patients were assigned into active treatment (intervention) with cerebral oximetry monitoring using Near infrared spectroscopy monitoring (NIRS) bilaterally (Root; Prime Medical Corporation, MASIMO, USA). After cleansing the adjacent skin area with alcohol, an adhesive optode pad was placed over each frontal to temporal area. Resting baseline rSO2 values were obtained after waiting at least 1 minute after the placement of the sensors. Once values had stabilized, the screen was electronically blinded, and the time monitoring and baseline parameters were recorded by taking the data frequency of 1 minute, 3 minutes after the start recording. For the intervention group, an alarm threshold at 55% of the resting baseline rSO2 value was established. Continuous rSO2 values were stored on a floppy disk with a 15-second update for the duration of the perioperative period.
62644515|NCT00416273|EXPERIMENTAL|Treatment group|Participants in the treatment group will receive Bortezomib at a dosage of 1.6 mg/m2.
62644516|NCT00416273|EXPERIMENTAL|Observation group|Participants in the observation group will not receive any consolidation therapy.
62644517|NCT02035540||Decellularized human valves|Pulmonary heart valve replacement
62074448|NCT06306950|NO_INTERVENTION|No neuromonitor|For usual care patients, the best clinical practices aim at maintaining hemoglobin (Hb) levels greater than 7 g/dl, blood glucose within the institutional normal range of 80-180 mg/dl, and mean arterial pressure (MAP) of 65 mmHg in the ICU and were monitored for invasive arterial blood pressure, peripheral O2 saturation (SpO2), and electrocardiograms. Sedative and paralysis agents were given; keep the Richmond Agitation Sedation Scale (RASS) less than -3 and the Bispectral Index (BIS) 40-60 monitoring based on bedside intensivist judgment, including fentanyl, propofol, midazolam, and cisatracurium. Patients were mechanically ventilated using a volume-control ventilation mode with a tidal volume of 8 ml/kg, a respiratory rate adjusted to maintain normocapnia, an inspired oxygen fraction adjusted to maintain SpO2 above 95%, and an inspiratory/expiratory ratio of 1:2.
62644518|NCT06458348|EXPERIMENTAL|Local opera appreciating|Received the local drama viewing .When the PSCI patient was hospitalized and discharged for 12 weeks. appreciating local drama for 30-45 minutes every day
62644519|NCT06458348|EXPERIMENTAL|Medical gymnastics training|Conducted medical gymnastics training .When the PSCI patient was hospitalized and discharged for 12 weeks. conduct medical gymnastics training for 30-45 minutes every day
62074449|NCT02116920||VIA Positive|Those patients having acetowhite lesion over cervix on visual inspection after application of acetic acid
62644520|NCT06458348|EXPERIMENTAL|Local opera appreciating and Medical gymnastics training|Received the drama viewing and conducted the medical gymnastics training .When the PSCI patient was hospitalized and discharged for 12 weeks. Appreciating local drama for 30-45 minutes and conduct medical gymnastics training for 30-45 minutes every day
62644521|NCT06458348|NO_INTERVENTION|Routine treatment|When the PSCI patient was hospitalized and discharged for 12 weeks, Received the routine treatment and care.
62074450|NCT04683302|ACTIVE_COMPARATOR|control|conventional 2D guided internal jugular vein catheterization
62074451|NCT04683302|EXPERIMENTAL|intervention|3D biplanar guided internal jugular vein catheterization
62074452|NCT00856934|NO_INTERVENTION|Control|Wounds covered with standard dressings: three layers of paraffin gauze, standard bandages, elastic bandage.
62644522|NCT00743210|EXPERIMENTAL|1|Oral L-citrulline, 3 grams once per day for 3 weeks.
62074453|NCT00856934|EXPERIMENTAL|PRP|PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
62074454|NCT00856934|EXPERIMENTAL|PRP+K|Keratinocytes suspended in PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
62074455|NCT04908683|EXPERIMENTAL|Group 1: Respiratory Syncytial Virus (RSV) vaccine|All participants in the active group will receive a single dose intramuscular (IM) injection of study vaccine on Day 1.
62644523|NCT00743210|PLACEBO_COMPARATOR|2|Placebo, 3 grams once per day for 3 weeks.
62074456|NCT04908683|PLACEBO_COMPARATOR|Group 2: Placebo|All participants in the placebo group will receive a single IM injection of matching placebo on Day 1.
62644524|NCT04773275|EXPERIMENTAL|Aliya PEF treatment|
62644525|NCT00259935|EXPERIMENTAL|All treated subjects|Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.
62644526|NCT02625701|EXPERIMENTAL|Goal-Directed-Therapy (GDT)|"Besides the basal infusion of crystalloids at 3-6 ml/kg/h, colloids (200 ml) or crystalloids (200 ml) are given over 10 min in the presence of signs of absolute/relative hypovolemia as detected by a fall in cardiac output/stroke volume (CO/SV) or if Pressure Pulse Variation (PVV) or Stroke Volume Variation (SVV) exceeds 10-12%, particularly in the presence. Fluid filling is interrupted when SV fail to increase \> 10% (or PVV/SVV =\< 10%) Otherwise, vasopressors can be used to achieve appropriate mean arterial pressure (MAP\>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1)."
62644527|NCT02625701|ACTIVE_COMPARATOR|Restrictive strategy|"Crystalloids are given at a fixed rate of 3-6 ml/kg/h. Otherwise, vasopressors can be used to achieve appropriate MAP (\>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1). Clinicians in charge of the patients are free to use hemodynamic parameters such as PVV or SVV, always attempting to limit the amount of fluid infusion and to maintain normovolemia"
62074457|NCT02137538|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg daily
62074458|NCT02137538|ACTIVE_COMPARATOR|Anastrozole|Anastrozole 1 mg daily
62074459|NCT02058420|NO_INTERVENTION|Placebo group|No active dose of tocotrienols
62074460|NCT02058420|ACTIVE_COMPARATOR|Low tocotrienols group|Low dose of tocotrienols
62074461|NCT02058420|ACTIVE_COMPARATOR|High tocotrienols group|High dose of tocotrienol
62074462|NCT03910348|EXPERIMENTAL|Whole body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting (2-4mm peak to peak) on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Each patient received the vibrations under supervision using five different static positions: squat, deep squat, widestep squat, lunge, and hands-front lunge. The exercise programs for each experimental groups consisted of 20 to 60-minute sessions on three days per week for 24 weeks, and they were performed under the supervision.
62074463|NCT03910348|EXPERIMENTAL|High-impact exercise|Depending on their individual calcium and vitamin D intakes, each patient advised to receive supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D.
62644528|NCT05117853|EXPERIMENTAL|Autofluorescent detection and injection of indocyanine green|"Drug: indocyanine green (ICG)~Autofluorescence detection of the parathyroid glands and injection of indocyanine green at two predefined timepoints will be performed to evaluate the vascularization of the parathyroid glands."
62644529|NCT05117853|PLACEBO_COMPARATOR|Control group|Gold standard of visual identification and evaluation of viability.
62644530|NCT06171893|EXPERIMENTAL|Control vs intervention|Each subject will take part in a four-week control period, followed by a four-week intervention period.
62278611|NCT01870739|ACTIVE_COMPARATOR|olmesartan|"Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
62074464|NCT03910348|NO_INTERVENTION|Control|Depending on their individual calcium and vitamin D intakes, each patient received supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D. The demographic characteristics of the participants were obtained at the baseline assessment.
62074465|NCT02415998||TEE|
62074466|NCT05280405|EXPERIMENTAL|Early-Proactive Therapeutic Drug Monitoring (E-pTDM)|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6. From week 6, the infusion interval will be adjusted based on pre-infusion IFX concentrations to target a trough level grater or equal to (\>=) 5 mcg/ml (\> 10 μg/ml in patients with perianal disease). For IFX concentrations below target, the infusion interval will be shortened (minimum interval 2 weeks). IFX dose increase will be performed as a second step.
62074467|NCT05280405|ACTIVE_COMPARATOR|Standard dosing|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6 followed by 5mg/kg infusions every 8 weeks.
62278612|NCT05845346|EXPERIMENTAL|Group TENS|Experimental group 1 will undergo a physiotherapy treatment based on TENS-type analgesic currents and application of massage therapy for neck pain.
62278613|NCT05845346|EXPERIMENTAL|Group STRECHING|Experimental group 2 will undergo a physiotherapy treatment based on stretching and the application of massage therapy therapy for neck pain.
62074468|NCT05775835|EXPERIMENTAL|Whole body vibration exercise group|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
62074469|NCT05775835|EXPERIMENTAL|Strength training group|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
62278614|NCT05845346|NO_INTERVENTION|Control Group|The control group will not undergo any physiotherapy treatment therapy for neck pain.
62278615|NCT05077488|EXPERIMENTAL|Juvéderm® VOLIFT™ with Lidocaine|Intradermal injection (deep dermis) in marionettes lines and/or forehead by a specialist injector
62278616|NCT03130790|EXPERIMENTAL|Varlititib+mFOLFOX6|
62278617|NCT03130790|PLACEBO_COMPARATOR|Placebo+mFOLFOX6|
62278618|NCT05455957|EXPERIMENTAL|Neuromuscular Training|The neuromuscular exercise training group includes single-leg stance, single leg hop and strength exercise.Each training session took approximately 60 minutes and 3 times a week for 4 weeks.The neuromuscular group included supervised, strength, balance and hop stabilization exercises on the different surfaces that focus on the restoring of static and dynamic balance. Both groups completed strength exercises in the same way. Strength exercises include ;4-way ankle theraband exercises,foot intrinsic strengthening (toe curl, doming),heel raises exercise,squat, lunge activities.Balance exercises include single-leg stance single leg hop and unticipated hop to stabilization activities.
62455978|NCT02802371|EXPERIMENTAL|Pharmaceutical care and psychosocial support|Pharmaceutical collaborative care integrated in a psychosocial program. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of caregivers; 2) collective session on medication management; and 3) optimization of drug prescribing. These collective and individual sessions of pharmaceutical care will allow an extended 18 month follow-up. Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
62455979|NCT02538445|EXPERIMENTAL|Patients group 1|Memorization of the verbs by miming the action
62455980|NCT02538445|EXPERIMENTAL|Patients group 2|Memorization of the verbs by imagining the action
62455981|NCT02538445|EXPERIMENTAL|Patients group 3|Memorization of the action verbs by means of another word
62074470|NCT05775835|EXPERIMENTAL|Whole body vibration and strengthening exercise group|"In the TVVE+KE group, the selected exercises will be performed with vibratory and dynamic strengthening exercises on the vibration platform. The application will be carried out on a whole body vibration device giving a constant vibration of 35 Hz. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. D For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
62074471|NCT05775835|NO_INTERVENTION|Control Group|No exercise recommendations or interventions will be made to the patients in the control group.
62074472|NCT02878070|EXPERIMENTAL|Peer Health Coaching|Calls from a Peer Health Coach for 6 months
62074473|NCT02878070|NO_INTERVENTION|Usual Care|
62074474|NCT00674635|PLACEBO_COMPARATOR|Placebo|matching placebo
62074475|NCT00674635|ACTIVE_COMPARATOR|GSK315234A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
62074476|NCT03051659|EXPERIMENTAL|Eribulin Mesylate|-Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle for 1.4mg/m\^2 intravenously.
62074477|NCT03051659|EXPERIMENTAL|Eribulin Mesylate Combine with Pembrolizumab|"* Pembrolizumab will be administered in clinic once per cycle, given 200mg/m\^2 intravenously prior to Eribulin Mesylate.~* Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle for 1.4 mg/m\^2 intravenously."
62074478|NCT05816148||Disabled persons|Members or users of APF France handicap
62074479|NCT02237339|ACTIVE_COMPARATOR|Allopurinol|Patients treated with Allopurinol 300mg daily for first month then 300mg twice daily for remainder trial.
62074480|NCT02237339|PLACEBO_COMPARATOR|Placebo tablet|Microcrystalline cellulose one tablet daily for first month then twice daily for remainder of trial.
62074481|NCT01980901||Ovation™/Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients.
62074482|NCT05620030|EXPERIMENTAL|Univentricular Heart|All patients with univentricular hearts
62074483|NCT05287230|EXPERIMENTAL|Intervention|
62074484|NCT05287230|OTHER|Control|
62074485|NCT04470219|EXPERIMENTAL|intervention group|Participants receive rehabilitation as usual and training how to use RemindMe by personnel from the research group and an occupational therapist working at the rehabilitation clinic. The participants will use RemindMe for two months. The participants choose activities that he/she wishes to remember to carry out with support by RemindMe. An individual follow-up session will be conducted once a week by the occupational therapist to evaluate if the chosen activities were performed and discuss strategies for the continued use of RemindMe. After two months the participants decide if he/she wants to continue to use RemindMe.
62644531|NCT02143232|EXPERIMENTAL|Remote patient monitoring (Telus RPM)|The remote monitoring device (Telus RPM) is used by every patient in the study post operatively at home.
62644532|NCT05010278||Latarjet|Patients followed up 6 months after a Latarjet procedure
62644533|NCT00781846|EXPERIMENTAL|1|30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
62644534|NCT00781846|EXPERIMENTAL|2|40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
62074486|NCT04470219|NO_INTERVENTION|control group|The control group receive treatment as usual by the rehabilitation personnel, for example, occupational therapists give interventions that provide support for memory, it could be a paper calendar or other memory devices or strategies.
62074487|NCT04924140|EXPERIMENTAL|Aducanumab Intravenous|Participants will receive aducanumab as body weight-based dose, via IV infusion for approximately 1 hour on Day 1.
62644535|NCT00781846|EXPERIMENTAL|3|40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks
62644536|NCT02686853|EXPERIMENTAL|Intrathecal administration group|
62644537|NCT03805594|EXPERIMENTAL|Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
62074488|NCT04924140|EXPERIMENTAL|Aducanumab Subcutaneous|Participants will receive aducanumab as fixed dose, via SC injection on Day 1.
62455982|NCT02538445|EXPERIMENTAL|Patients group 4|Simple memorization of the verbs
62455983|NCT02538445|ACTIVE_COMPARATOR|Healthy volonteers group 1|Memorization of the verbs by miming the action
62455984|NCT02538445|ACTIVE_COMPARATOR|Healthy volonteers group 2|Memorization of the verbs by imagining the action
62644538|NCT03805594|EXPERIMENTAL|Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
62074489|NCT02025920|EXPERIMENTAL|Salmon Group|Participants will eat 150g salmon for dinner, 3 times per week for 12 weeks
62074490|NCT02025920|EXPERIMENTAL|Cod Group|Participants will eat 150g cod for dinner, 3 times per week for 12 weeks
62074491|NCT02025920|ACTIVE_COMPARATOR|Meat Group|Participants will eat 150g mixed meat for dinner, 3 times per week for 12 weeks
62074492|NCT01760200||Drug eluting balloon angioplasty|Drug eluting balloon angioplasty
62074493|NCT01760200||Drug eluting stent group|Drug eluting stent intervention
62455985|NCT02538445|ACTIVE_COMPARATOR|Healthy volonteers group 3|Memorization of the action verbs by means of another word
62455986|NCT02538445|ACTIVE_COMPARATOR|Healthy volonteers group 4|Simple memorization of the verbs
62455987|NCT03056248|ACTIVE_COMPARATOR|Lithium|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
62074494|NCT01339364|ACTIVE_COMPARATOR|Didactic Lecture|
62074495|NCT01339364|EXPERIMENTAL|Lecture plus Case Disscussion|
62074496|NCT01339364|EXPERIMENTAL|Lecture plus Small Group Education|
62074497|NCT00306904|EXPERIMENTAL|1|3.0 mg/eye dose group
62074498|NCT00306904|EXPERIMENTAL|2|1.5 mg/eye dose group
62074499|NCT00306904|EXPERIMENTAL|3|0.2 mg/eye dose group
62074500|NCT03765762|EXPERIMENTAL|GRF6019|Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
62074501|NCT03765762|PLACEBO_COMPARATOR|Placebo|Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
62074502|NCT01849796|ACTIVE_COMPARATOR|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
62074503|NCT01849796|SHAM_COMPARATOR|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
62074504|NCT01933503|EXPERIMENTAL|OCA 5 mg|OCA 5 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 5 mg by mouth for 14 days.
62455988|NCT03056248|PLACEBO_COMPARATOR|Placebo|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
62455989|NCT05274711|ACTIVE_COMPARATOR|Conventional treatment|will receive conventional physical therapy prograM
62074505|NCT01933503|EXPERIMENTAL|OCA 10 mg|OCA 10 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 10 mg by mouth for 14 days.
62455990|NCT05274711|EXPERIMENTAL|Experimental treatment|will receive conventional physical therapy program and whole body vibration training
62074506|NCT01933503|EXPERIMENTAL|OCA 25 mg|OCA 25 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 25 mg by mouth for 14 days.
62455991|NCT03274310|EXPERIMENTAL|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
62278619|NCT05455957|EXPERIMENTAL|Vestibulo-Ocular Reflex Training|The vestibulo ocular reflex training group includes head and gaze stability exercises in addition to single le stance,single leg hop and strength exercise.Each training session took approximately 60 minutes and 3 times a week for 4 weeks.In the vestibulo- ocular exercise program, individuals tried to maintain their balance with head and eye movements in addition to balance and hop stabilization activities. Both groups completed strength exercises in the same way. Strength exercises include ;4-way ankle theraband exercises,foot intrinsic strengthening (toe curl, doming),heel raises exercise,squat, lunge activities.Balance exercises include single-leg stance single leg hop and unticipated hop to stabilization activities.
62278620|NCT01943565|ACTIVE_COMPARATOR|Hydromorphone 25mcg|The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
62278621|NCT01943565|ACTIVE_COMPARATOR|Hydromorphone 50mcg|The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
62278622|NCT01943565|ACTIVE_COMPARATOR|Hydromorphone 100mcg|The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
62278623|NCT02841059||Laparoscopic subtotal hysterectomy|women with benign gynecology disease and decided to receive laparoscopic subtotal hysterectomy (LSH) after discussion with her surgeon.
62074507|NCT06276127|EXPERIMENTAL|Oral Bisoprolol|A single oral dose of 5 mg Bisoprolol (maximum dose of 5 mg)
62278624|NCT02841059||Laparoscopic CLSH|women with benign gynecology disease and decided to receive laparoscopic cervical ligament sparing hysterectomy (CLSH) after discussion with her surgeon.
62278625|NCT02841059||Laparoscopic AVH|women with benign gynecology disease and decided to receive laparoscopic assisted vaginal hysterectomy (LAVH) after discussion with her surgeon.
62278626|NCT00584961||600 patients|Patients with diagnosis of Bipolar Disorder (DSM-IV TR)
62074508|NCT06276127|OTHER|Intravenous Diltiazem|single intravenous dose of Diltiazem at 0.25 mg/kg (to a maximum dose of 30 mg)
62644539|NCT03805594|EXPERIMENTAL|Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)|Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
62644540|NCT01288690|NO_INTERVENTION|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment.
62644541|NCT01288690|EXPERIMENTAL|Narrative Exposure Therapy|Patients in this condition receive 3 sessions of Narrative Exposure Therapy
62074509|NCT04761055|EXPERIMENTAL|Screening Visits for Breast Cancer|Consenting patients will receive their already scheduled standard CBE and mammogram and in addition will receive a breast exam utilizing the iBreast Exam (iBE).
62074510|NCT02115997|EXPERIMENTAL|Rituximab|Participants will receive IV infusion of rituximab once weekly from Week 1 to 4. Participants will also receive one pulse of methylprednisolone, followed by a tapering dose of oral prednisolone at the discretion of the investigator. Methylprednisolone may be repeated up to total of 3 pulses at the discretion of the investigator.
62074511|NCT05591469|EXPERIMENTAL|Noncontact Respiration monitoring group|
62074512|NCT05591469|EXPERIMENTAL|Contact Respiration monitoring group|
62074513|NCT01888913||Adult Women|Adult Women aged 18-50
62278627|NCT00494143|ACTIVE_COMPARATOR|Conventional Prosthetic foot|A conventional prosthetic foot that has limited energy storage and return capabilities. It is standardized and used by all subjects in the study.
62074514|NCT02273193||Pregnant Women|Pregnant Women in the first trimester (\<13 weeks) of pregnancy and the second trimester of pregnancy.
62074515|NCT06441058||Indirect post-endodontic restorations|Indirect post-endodontic restorations (e.g. crown, partial crown).
62074516|NCT04321993|EXPERIMENTAL|Baricitinib|Moderate and severe, not critical disease
62074517|NCT04321993|EXPERIMENTAL|Remdesivir|Moderate and severe, not critical disease
62074518|NCT04321993|EXPERIMENTAL|Remdesivir + baricitinib|Moderate and severe, not critical disease
62074519|NCT04321993|EXPERIMENTAL|Tocilizumab|Severe, critical disease
62074520|NCT04321993|NO_INTERVENTION|Clinical standard of care|Moderate and severe, not critical disease AND severe, critical disease as applicable
62074521|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
62455992|NCT03274310|NO_INTERVENTION|Surveillance-only arm|No intervention solely surveillance messages
62278628|NCT00494143|ACTIVE_COMPARATOR|Prescribed Prosthetic foot|the Prosthetic foot that the subject had prescribed for them by their clinical providers and was worn prior to study initiation
62278629|NCT00494143|EXPERIMENTAL|CESR foot|the experimental CESR, controlled energy storage prosthetic foot
62278630|NCT03104725|EXPERIMENTAL|Healthy Volunteers|HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
62074522|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
62278631|NCT03104725|EXPERIMENTAL|PD Patients|Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).
62644542|NCT03721757|OTHER|Nivolumab, Surgery, Radiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with low risk criteria following surgery will be assigned to radiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and commencement of radiotherapy (1-2 weeks prior).~Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks).~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals"
62074523|NCT02240589|EXPERIMENTAL|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
62074524|NCT02240589|PLACEBO_COMPARATOR|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
62278632|NCT03692858|ACTIVE_COMPARATOR|Group A|
62278633|NCT03692858|ACTIVE_COMPARATOR|Group B|
62278634|NCT03889561|EXPERIMENTAL|Improved Water Access, Promotion, and SSB taxes|Intervention parks will receive installation of water stations, multicultural water promotion campaign, and SSB taxes
62278635|NCT03889561|NO_INTERVENTION|Control|SSB taxes
62278636|NCT04435223||COVID-19 severe pneumonia|
62278637|NCT04435223||Severe pneumonia due to other pathogene|
62278638|NCT00460343|EXPERIMENTAL|max|
62278639|NCT00460343|ACTIVE_COMPARATOR|min|
62278640|NCT04702009|ACTIVE_COMPARATOR|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy
62278641|NCT04702009|EXPERIMENTAL|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy
62455993|NCT02175797|OTHER|Pacemaker + leads|all patients must have a MRI exam after pacemaker implantation
62074525|NCT04773886|SHAM_COMPARATOR|MTA GROUP|Vital Pulpotomy will be done using Mineral trioxide aggregate(MTA) as pulp capping agent.
62074526|NCT04773886|SHAM_COMPARATOR|BIODENTINE GROUP|Vital Pulpotomy will be done using Biodentine as pulp capping agent.
62074527|NCT04773886|ACTIVE_COMPARATOR|PRF + MTA GROUP|Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent
62644543|NCT03721757|OTHER|Nivolumab, Surgery, Chemoradiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria following surgery will be assigned to chemoradiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and chemoradiotherapy (1-2 weeks prior).~Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21.~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals."
62644544|NCT01329198|ACTIVE_COMPARATOR|Delayed Activation - Deep Brain Stimulation (DBS)|"Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.~* There will be a one month post-operative period during which stimulation is not turned on.~* One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~* By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~* Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
62644545|NCT01329198|ACTIVE_COMPARATOR|Immediate Activation - Deep Brain Stimulation (DBS)|"Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency \& severity, while limiting potential stimulation-induced side-effects.~* There will be a one month post-operative period during which stimulation is not turned on.~* One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~* By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~* Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
62644546|NCT02560168|EXPERIMENTAL|Coronary artery disease|Patients scheduled for computed tomographic coronary angiography (CTA)
62644547|NCT03087864|EXPERIMENTAL|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
62644548|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
62074528|NCT04773886|ACTIVE_COMPARATOR|PRF+ BIODENTINE GROUP|Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
62074529|NCT04833101|EXPERIMENTAL|"0-28 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 28, and a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
62074530|NCT04833101|PLACEBO_COMPARATOR|"0-28 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 28, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
62074531|NCT04833101|EXPERIMENTAL|"0-56 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
62074532|NCT04833101|PLACEBO_COMPARATOR|"0-56 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
62074533|NCT01784315||Chloroquine, primaquine and ACT|"Standard dose of Chloroquine( 10mg/kg on day 0 and 5mg/kg on day1 and day2) and Primaquine(0.25mg/kg for 14 days).~Artemisinin combination therapies (ACT) of 4 tablets on 0,8,24,36,48 and 60 hours will be used for Chloroquine resistant P.vivax infection"
62644549|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
62074534|NCT02678520|EXPERIMENTAL|3-D conformal radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using a 3-D conformal radiation technique (3-D CRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
62278642|NCT01390259|EXPERIMENTAL|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~* monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~* predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
62278643|NCT01390259|PLACEBO_COMPARATOR|Open Loop|The subject were in charge of their insulin treatment.
62278644|NCT03972722|EXPERIMENTAL|GLS-010|Full-human anti-pd-1 monoclonal antibodies
62278645|NCT05559723|EXPERIMENTAL|study group|electromagnetic field therapy
62644550|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
62278646|NCT05559723|EXPERIMENTAL|control group|the selected exercise program
62074535|NCT02678520|ACTIVE_COMPARATOR|Intensity modulated radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using intensity modulated radiation therapy (IMRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
62074536|NCT04915703|EXPERIMENTAL|Intervention|flushing of internal external PTBD catheter 3 times a day
62074537|NCT04915703|NO_INTERVENTION|Standard of Care|no flushing of PTBD catheter
62074538|NCT05257759|ACTIVE_COMPARATOR|Standard support|
62074539|NCT05257759|EXPERIMENTAL|Standard treatment coupled with electro-stimulation sessions|
62074540|NCT03220945|NO_INTERVENTION|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
62074541|NCT03220945|EXPERIMENTAL|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
62074542|NCT03481790|EXPERIMENTAL|Lactoferrin|100mg of bovine lactoferrin (Pravotin sachets, Hygint, Egypt) twice a day.
62278647|NCT04991298|ACTIVE_COMPARATOR|Group M|patients will be premedicated with the undiluted IV formulation of Midazolam
62278648|NCT04991298|ACTIVE_COMPARATOR|Group F|patients will be premedicated with the undiluted IV formulation of fentanyl citrate
62644551|NCT03073772|NO_INTERVENTION|Continued multimodal rehabilitation|No addition of extra training in this group. Only ordinary continued multimodal rehabilitation.
62074543|NCT03481790|EXPERIMENTAL|ferrous sulphate + folic acid (vitamin B9)|150mg of dried ferrous sulphate + folic acid (vitamin B9) 0.50mg (Ferrofol, E.I.P.I.C.O, Egypt) three capsules per day.
62074544|NCT03411889|EXPERIMENTAL|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
62074545|NCT05947773|EXPERIMENTAL|Robotically treated patient|They performed training with a robot 15 times over 3 weeks.
62074546|NCT05947773|EXPERIMENTAL|Walking training|Walking exercises were performed without a robot.
62074547|NCT05947773|EXPERIMENTAL|Control group|Physiotherapy treatment was carried out by the patients.
62074548|NCT01429506|ACTIVE_COMPARATOR|Sleeve gastrectomy|Will undergo laparoscopic sleeve gastrectomy
62074549|NCT01429506|ACTIVE_COMPARATOR|Intensive medical management|Will receive VLCD, exenatide, metformin, insulin detemir
62074550|NCT04012203||Healthy subjects|Participants free from any pain specific to the upper limb during the past 3 months, chronic pain or other disease.
62278649|NCT00715988|EXPERIMENTAL|Scheme 1|Patients who are feeding or not feeding and mechanically ventilated, \>/=3 d of age and 29 0/7wks-48 6/7 wks PMA, treated with i.v. bolus doses or infusion of fentanyl, morphine or methadone for clinical indications, with arterial/venous line in place \& expected treatment for at least 1-2 more days. Pk sampling = 0.5 ml blood samples x6/infant. ECG monitoring. Three patients will be enrolled in 5 PMA groups. Should apnea or hypotension occur, dosages for Treatment Scheme 2 will be reduced (50%); more patients will be studied in Treatment Scheme 1 to insure that the lower dose is well tolerated \& effective.
62278650|NCT00715988|EXPERIMENTAL|Scheme 2|Patients defined in Scheme 1, tolerating feeds for \>/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..
62278651|NCT04271098||Open-heart surgery|Patients undergoing open-heart surgery with cardiopulmonary bypass
62278652|NCT02721355|EXPERIMENTAL|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
62278653|NCT02721355|NO_INTERVENTION|Control|The subjects undergo the routine treatment regime without taking food supplement
62644552|NCT03073772|ACTIVE_COMPARATOR|Computer-based cognitive training|This arm also consisted of continued multimodal rehabilitation.
62074551|NCT00818064|EXPERIMENTAL|A, HV|Dose cohort 1 (3 subjects active, 1 placebo)
62074552|NCT00818064|EXPERIMENTAL|B, HV|Dose cohort 2 (3 subjects active, 1 placebo)
62074553|NCT00818064|EXPERIMENTAL|C, HV|Dose cohort 3 (3 subjects active, 1 placebo)
62074554|NCT00818064|EXPERIMENTAL|D, HV|Dose cohort 4 (3 subjects active, 1 placebo)
62644553|NCT03073772|ACTIVE_COMPARATOR|Physical fitness training|This arm also consisted of continued multimodal rehabilitation.
62644554|NCT00535613|EXPERIMENTAL|1|propofol
62074555|NCT00818064|EXPERIMENTAL|E, HV|Dose cohort 5 (3 subjects active, 1 placebo)
62644555|NCT00535613|SHAM_COMPARATOR|2|no propofol
62644556|NCT02513550|EXPERIMENTAL|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
62644557|NCT02513550|EXPERIMENTAL|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
62644558|NCT02513550|EXPERIMENTAL|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
62644559|NCT02513550|EXPERIMENTAL|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
62644560|NCT02513550|EXPERIMENTAL|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
62644561|NCT02513550|EXPERIMENTAL|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
62644562|NCT05590169|EXPERIMENTAL|Group I|They will be included in exercise training as a group (three or four participants) with telerehabilitation (via Zoom application) for eight weeks. Exercise program includes: (F) 3 times a week, (I) at 60-70% of the maximum heart rate, (T): breathing, stretching, aerobic, plyometric, balance exercises, (T) 30 minutes each session, a total of 8 week. During the exercise sessions, the heart rate will be monitored via a Polar Unite Fitness Watch, and the oxygen saturations will be monitored with a pulse oximeter.
62644563|NCT05590169|EXPERIMENTAL|Group 2|They will be individually included in exercise training with (via Zoom application) for eight weeks. Exercise program includes: (F) 3 times a week, (I) at 60-70% of the maximum heart rate, (T): breathing, stretching, aerobic, plyometric, balance exercises, (T) 30 minutes each session, a total of 8 week. During the exercise sessions, the heart rate will be monitored via a Polar Unite Fitness Watch, and the oxygen saturations will be monitored with a pulse oximeter.
62074556|NCT00818064|EXPERIMENTAL|A, RA|Dose cohort 1 (3 subjects active, 1 placebo)
62074557|NCT00818064|EXPERIMENTAL|B, RA|Dose cohort 2 (3 subjects active, 1 placebo)
62074558|NCT00818064|EXPERIMENTAL|C, RA|Dose cohort 3 (3 subjects active, 1 placebo)
62074559|NCT01757067|ACTIVE_COMPARATOR|ablation procedure vs medical therapy|PVC ablation vs medical therapy
62074560|NCT01757067|NO_INTERVENTION|Compare 2 arms for safety, symptoms|Compare control of PVC's between 2 groups.
62074561|NCT03688711|EXPERIMENTAL|Dasiglucagon|single fixed dose (subcutaneous injection) of dasiglucagon
62074562|NCT03688711|PLACEBO_COMPARATOR|Placebo|single fixed dose (subcutaneous injection) of placebo
62074563|NCT05834816|EXPERIMENTAL|Behavioral|Negative Affect Task
62074564|NCT03290690||All Subjects|"All subjects in this study will have their wounds imaged and assessed in the following manner:~Capture and save ST-image Capture and save FL-image Identify discrete locations of cyan (blue/green) fluorescent bacteria (FL_C) Acquire sample of tissue where cyan fluorescent bacteria are present (using curette method) Consent patient for inclusion in this study Note location of sample acquisition by annotating FL-image obtained in step 2 Send sample for microbiology analysis Note naming of microbiology sample on Case Report Form"
62074565|NCT05486234|EXPERIMENTAL|Group A: Treatment Group|
62074566|NCT05486234|SHAM_COMPARATOR|Group B: Control Group|
62074567|NCT03999905|EXPERIMENTAL|Intervention Arm|Online training on Oral anticoagulant counseling.
62074568|NCT03999905|NO_INTERVENTION|Control Arm|No counseling training
62074569|NCT03713814|EXPERIMENTAL|Experimental Group|8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.
62278654|NCT04393532|EXPERIMENTAL|Laparoscopic hernia repair using Su2ura Approximation Device|"Surgery will be performed under general anesthesia. Standard antibiotic prophylaxis will be administered at induction of anesthesia. A single surgeon, the PI, will perform the procedure. A surgical assistant will be selected by the PI from the surgical staff of the department.~The procedure will involve placement of laparoscopic ports, reduction of the hernia sac, closure of the defect with the Su2ura Approximation device and fixation of mesh with tacks over the closed defect.~Study follow up visits: at post operation discharge, 14 days, 3 months, 6 months."
62278655|NCT01271673||Women undertaking Breast Self Examination|Women attending Preventive Oncology Clinic during the month of November- December 2010,and undertaking BSE training whose Residential address mentioned as Mumbai and whose Contact number is available.
62455994|NCT01695070|EXPERIMENTAL|Melatonin|Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.
62455995|NCT01179880|EXPERIMENTAL|1|
62455996|NCT01179880|PLACEBO_COMPARATOR|2|
62455997|NCT02886078|EXPERIMENTAL|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
62644564|NCT05590169|NO_INTERVENTION|Group 3|They will continue their routine treatment (medical treatment, airway cleaning techniques, physical activity counseling).
62644565|NCT00086190|ACTIVE_COMPARATOR|paroxetine|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
62074570|NCT03713814|NO_INTERVENTION|Control group|After the 8 weeks of intervention, the pilots will receive explanation and handbook demonstration of the same exercises.
62455998|NCT02886078|ACTIVE_COMPARATOR|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
62074571|NCT02088775|EXPERIMENTAL|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
62455999|NCT03266237|EXPERIMENTAL|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
62456000|NCT03266237|EXPERIMENTAL|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
62456001|NCT03266237|EXPERIMENTAL|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
62456002|NCT03266237|EXPERIMENTAL|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
62644566|NCT00086190|ACTIVE_COMPARATOR|venlafaxine extended release|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
62644567|NCT00086190|PLACEBO_COMPARATOR|placebo|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
62644568|NCT02431689|ACTIVE_COMPARATOR|Antagonist|"Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
62644569|NCT02431689|ACTIVE_COMPARATOR|Short|"Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
62074572|NCT03160482||Papillary carcinoma, classical variant|
62074573|NCT03160482||Follicular carcinoma|
62074574|NCT03160482||Colloid nodule|
62074575|NCT03160482||Hyperplastic nodule|
62074576|NCT03160482||Adenomatoid nodule|
62074577|NCT03160482||Follicular adenoma|
62074578|NCT03160482||Papillary carcinoma, follicular variant|
62074579|NCT03160482||Medullary carcinoma|
62074580|NCT03160482||Lymphocytic thyroiditis|
62074581|NCT06091618|ACTIVE_COMPARATOR|new technique of ejaculatory preserving laser vaporization prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~1. Setting a mark cut 1 cm proximal of the verumontanum as orientation.~2. Complete resection of the middle lobe to the abovementioned mark.~3. Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~4. Circular resection of the internal bladder neck.~5. Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~6. Total removal of prostate cuts and final check to confirm that there are no obstructive components."
62074582|NCT06091618|ACTIVE_COMPARATOR|conventional technique laser vaporization prostatectomy|non ejaculatory preserving laser vaporization of the prostate
62074583|NCT04410887|EXPERIMENTAL|PISOXO|"1. st cycle of PIPAC during 1st laparoscopic exploration Three cycles of SOX~2. nd cycle of PIPAC during 2nd laparoscopic exploration Surgery Three cycles of SOX +/-OLAPARIB~PIPAC Intraperitoneal chemotherapy for PIPAC is Docetaxel Neoadjuvant Chemotherapy Patients will receive three cycles of a standard dose of Tegafur gimeracil oteracil potassium capsule (TGO) plus oxaliplatin (SOX) +Olaparib prior to curative gastrectomy.~Adjuvant chemotherapy Three cycles of SOX +/- OLAPARIB will be given as postoperative chemotherapy.~Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg oral twice a day"
62074584|NCT03935464|EXPERIMENTAL|Intervention Arm|POC adherence testing by a urine TFV assay with feedback
62074585|NCT03935464|NO_INTERVENTION|Standard of Care|Follow Kenya's PrEP guidelines on standard adherence counselling
62074586|NCT03898180|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue lenvatinib and participants who remain on treatment will receive open label pembrolizumab only, at the same dose and schedule (IV 200 mg on Day 1 of each 21-Day cycle for up to 35 cycles \[up to \~2 years\]).
62074587|NCT03898180|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years) PLUS placebo for lenvatinib via oral capsule QD until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue placebo and participants who remain on treatment will receive open label pembrolizumab only, at the same dose and schedule (IV 200 mg on Day 1 of each 21-Day cycle for up to 35 cycles \[up to \~2 years\]).
62074588|NCT02304328||No clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients without clinical signs of brain herniation syndrome
62074589|NCT02304328||Clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients with clinical signs of brain herniation syndrome
62074590|NCT03890536||Biliary atresia|Biliary atresia is an obstructive cholangiopathy of infancy. It is the most common cause of neonatal cholestasis and the most frequent indication for liver transplantation in children. Patients with biliary atresia have conjugated hyperbilirubinemia (serum direct bilirubin \> 1mg/dL) AND are scheduled for/undergo exploratory laparotomy for diagnosis and Kasai portoenterostomy for surgical treatment of BA.
62074591|NCT03890536||Non-BA=disease controls|All infants with other cholestatic syndromes (except biliary atresia) will be eligible for study enrollment in disease controls/non-biliary atresia. This involves the diagnosis of liver diseases caused by syndromes of intrahepatic cholestasis with or without hyperbilirubinemia.
62074592|NCT03890536||Normal|All healthy infants with no acute or chronic liver related illness.
62074593|NCT01099735||CPAP, Manometry|Patients undergoing Manometry before weight loss surgery
62074594|NCT01534455|EXPERIMENTAL|Lapatinib + 1,23 mg Eribulin|
62278656|NCT06257030||TARE group|(TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
62074595|NCT01534455|EXPERIMENTAL|Lapatinib + 1,76 mg Eribulin|
62074596|NCT03116503|EXPERIMENTAL|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
62074597|NCT04921514|EXPERIMENTAL|Patient and relatives|
62074598|NCT06488560|EXPERIMENTAL|commercial blenderized tube feed (CBTF)|
62074599|NCT06488560|ACTIVE_COMPARATOR|commercial formulas (CF)|
62074600|NCT02662803|EXPERIMENTAL|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
62644570|NCT03246464|PLACEBO_COMPARATOR|Single-vision spectacles|
62644571|NCT03246464|ACTIVE_COMPARATOR|Orthokeratology lenses|
62456003|NCT03145714|EXPERIMENTAL|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
62644572|NCT02112214|ACTIVE_COMPARATOR|Intervention group|10-day bismuth-based quadruple therapy for H. pylori positive subjects
62074601|NCT02662803|PLACEBO_COMPARATOR|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
62074602|NCT00128245|EXPERIMENTAL|Pimecrolimus 0.3%|ASM981 0.3%
62074603|NCT00128245|EXPERIMENTAL|Pimecrolimus 1%|ASM981 1%
62074604|NCT00128245|PLACEBO_COMPARATOR|Vehicle with carbopol|
62074605|NCT00128245|PLACEBO_COMPARATOR|Vehicle without carbopol|
62456004|NCT03145714|ACTIVE_COMPARATOR|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
62456005|NCT04183231|EXPERIMENTAL|Anti-caries varnish|topical dental varnish, 10% PVP-I, 2.5% NaF, topical application to teeth, 0.4 ml, single application
62074606|NCT03422458|NO_INTERVENTION|natural healing|no treatment and the coagulum within the socket is left open for spontaneous healing
62074607|NCT03422458|EXPERIMENTAL|Alveolar Ridge Preservation|A bone substitute material (BioOss Collagen) is placed within the bony envelope at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mucograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
62644573|NCT02112214|PLACEBO_COMPARATOR|Placebo group|Placebo for H. pylori positive subjects
62644574|NCT05734261|OTHER|Single Arm|
62074608|NCT03422458|EXPERIMENTAL|Immediate Implant + Alveolar Ridge Preservation|An immediate implant (Winsix) placement is performed. After implant insertion, a bone substitute material (BioOss Collagen) is placed in the gap occurred between the implant surface and the hard tissue walls of the extraction socket at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mugograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
62074609|NCT03754361|EXPERIMENTAL|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment
62074610|NCT03754361|ACTIVE_COMPARATOR|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent hemodialysis treatment 3-4 times per week,2-4 hours each time.
62074611|NCT03987568|EXPERIMENTAL|Diagnostic (MRI biospecimen collection)|Patients undergo MRI over 15 minutes before standard of care surgery. Patients also undergo collection of blood samples during MRI and at the time of surgery.
62074612|NCT02708602||β2AR Arg16Arg (AA group)|People with β2AR Arg16Arg genotype.
62074613|NCT02708602||β2AR Arg16Gly (AG group)|People with β2AR Arg16Gly genotype.
62074614|NCT02708602||β2AR Gly16Gly (GG group)|People with β2AR Gly16Gly genotype.
62074615|NCT02708602||β2AR Gln27Gln (CC group)|People with β2AR Gln16Gln genotype.
62074616|NCT02708602||β2AR Gln27Glu (CG group)|People with β2AR Gln27Glu genotype.
62074617|NCT02708602||β2AR Glu27Glu (GG group)|People with β2AR Glu27Glu genotype.
62456006|NCT05478148|EXPERIMENTAL|Gingival phenotype|A Periodontal probe was used to differentiate between thick and thin phenotypes and Color coded Biotype Probe was used to classified the phenotype as thin, moderate, thick and very thick phenotypes. Endodontic File and Florida probe were used to measure the gingival thickness.
62074618|NCT01663974||Bipolar disorder patients|
62074619|NCT04517370|ACTIVE_COMPARATOR|Laser treatment|Each patient will be treated once every 20-40 days, for a total of 3 laser treatments. In every visit during the study, patients will undergo gynecological examination and will complete questionnaires evaluating GSM symptoms, using a visual analogue scale (VAS) for each symptom (vaginal dryness, dyspareunia, discharge, itching and/or stinging, vaginal bleeding and dysuria) as well as treatment induced pain and side effects.
62074620|NCT04517370|SHAM_COMPARATOR|Sham treatment|"Each patient will be treated once every 20-40 days, for a total of 3 Sham treatments, in a similar procedure not using an active laser energy. Patients will be assessed in a similar manner.~Following 3 Sham-treatments patients in the placebo group will be offered the laser treatment in an open-label study ."
62074621|NCT00845871|EXPERIMENTAL|Deferasirox|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
62278657|NCT06399874|EXPERIMENTAL|Nightmare Deconstruction and Reprocessing|Psychotherapy that uses exposure to nightmare images for trauma activation with the goal of memory reconsolidation.
62456007|NCT00631033|PLACEBO_COMPARATOR|1|Placebo
62456008|NCT00631033|EXPERIMENTAL|2|Diazoxide
62074622|NCT02330419|PLACEBO_COMPARATOR|Placebo|Placebo 50mg, as needed
62278658|NCT06399874|EXPERIMENTAL|NightWare|Wristband device that detects physiologic signals during sleep that indicate a possible nightmare and gently vibrates to rouse the sleeper without fully waking them.
62278659|NCT02745561|EXPERIMENTAL|Chemoradiotherapy Arm|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy. Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
62278660|NCT04957134|EXPERIMENTAL|Electro-acupuncture|Participants will receive electro-acupuncture combined with lifestyle intervention. Participants will receive the treatment of electroacupuncture 3 times a week to fulfill a 8-session treatment course.
62278661|NCT04957134|PLACEBO_COMPARATOR|Sham electro-acupuncture|Participants will receive the treatment of sham electro-acupuncture 3 times a week to fulfill a 8-session treatment course, A superficial skin penetration (2-3 mm in depth) at nonacupoints will be performed in the sham acupuncture group, without needle manipulation for De qi. The internal output power cord of the electrical acupuncture stimulation instrument is interrupted.
62278662|NCT00022087|EXPERIMENTAL|Zoledronic acid initial tx|Zoledronic acid + calcium + Vit D for 2 years, followed by Calcium + vit D for 1 year
62278663|NCT00022087|EXPERIMENTAL|Calcium + Vit D initial Tx|Calcium + vitamin D for 1 year followed by zoledronic acid + calcium + vit D for 2 years
62456009|NCT00631033|EXPERIMENTAL|3|Metformin + Diazoxide
62456010|NCT01860976|EXPERIMENTAL|Abatacept|Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
62074623|NCT02330419|ACTIVE_COMPARATOR|Naltrexone|Naltrexone 50mg, as needed
62074624|NCT02244099|EXPERIMENTAL|Controlled Substance|Consenting physicians who care for patients who have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months in Martha Morehouse General Internal Medicine Resident Continuity Clinic.
62074625|NCT01099540|EXPERIMENTAL|Pazopanib|
62074626|NCT04572256|EXPERIMENTAL|Montelukast|Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
62456011|NCT01860976|PLACEBO_COMPARATOR|Placebo|Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
62456012|NCT05965609|OTHER|CBTI|Cognitive Behavioral Therapy for Insomnia
62644575|NCT05862935|EXPERIMENTAL|Supervised Physical Activity (Phase I: Strength training; Phase II: AMRAP training)|"These patients, in addition to receiving the usual treatment for their pathology, carry out supervised activity consisting of:~* Warm-up~* Strength circuit; At phase I it will be a standard strength training, while at Phase 2 it will be an AMRAP training)"
62456013|NCT05965609|OTHER|MRTI|Multicomponent Relaxation Therapy for Insomnia
62074627|NCT04572256|PLACEBO_COMPARATOR|Placebo|Patients will receive an oral placebo daily for 6 months after surgery.
62074628|NCT04562103|EXPERIMENTAL|Epinephrine QLB|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
62074629|NCT04562103|ACTIVE_COMPARATOR|Plane QLB|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
62074630|NCT01532180|EXPERIMENTAL|THN Therapy|
62074631|NCT00393744|EXPERIMENTAL|1|
62074632|NCT00393744|ACTIVE_COMPARATOR|2|
62074633|NCT01556763|PLACEBO_COMPARATOR|Placebo|Matching placebo was administered as one capsule per day for 21 days.
62074634|NCT01556763|EXPERIMENTAL|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
62456014|NCT00930423||cases|patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
62644576|NCT05862935|NO_INTERVENTION|Control|These patients only receive the usual treatment for their pathology.
62278664|NCT01034046|ACTIVE_COMPARATOR|Insulin Sensitive Study Participants|Insulin sensitive subjects stratified using fasting insulin levels.
62278665|NCT01034046|ACTIVE_COMPARATOR|Insulin Resistant Study Subjects|Insulin resistant subjects stratified using fasting insulin levels.
62278666|NCT00775580|EXPERIMENTAL|1|atenolol 100 mg Capsules of Ranbaxy
62278667|NCT00775580|ACTIVE_COMPARATOR|2|Tenormin 100mg capsules
62278668|NCT02373280|ACTIVE_COMPARATOR|10 day sequential group|After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.
62278669|NCT02373280|EXPERIMENTAL|7 days tailored PPI triple therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen \[PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)\] in this group.
62278670|NCT02373280|EXPERIMENTAL|7 days tailored MEA therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy \[Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)\] in this group.
62074635|NCT01556763|EXPERIMENTAL|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
62074636|NCT02857803|EXPERIMENTAL|Virtual Reality|The Virtual Reality group will perform personalised activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
62074637|NCT02857803|ACTIVE_COMPARATOR|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalised to their deficits and generated automatically through a Task Generator.
62074638|NCT02857803|ACTIVE_COMPARATOR|Conventional Therapy|The Conventional Therapy group will perform the activities offered by the public health system, which are motor-focused.
62074639|NCT04853901|EXPERIMENTAL|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone 1-2mg/kg for 5-7 days
62278671|NCT02373280|EXPERIMENTAL|7 or 14 days tailored EBMT therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy \[Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)\] in this group. If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
62456015|NCT00930423||controls|patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
62074640|NCT04853901|ACTIVE_COMPARATOR|Standard of care therapy|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days + Methylprednisolone 1-2mg/kg for 5-7 days
62456016|NCT01118936|NO_INTERVENTION|Washout|
62456017|NCT01118936|ACTIVE_COMPARATOR|Mablet|
62456018|NCT01118936|PLACEBO_COMPARATOR|Placebo|
62074641|NCT04758234|EXPERIMENTAL|LY3549492 (Part A)|LY3549492 administered orally as single ascending doses.
62074642|NCT04758234|EXPERIMENTAL|LY3549492 (Part B)|LY3549492 administered orally as multiple ascending doses.
62074643|NCT04758234|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62074644|NCT05817669|EXPERIMENTAL|Efgartigimod IV arm|patients receiving infusions of Efgartigimod IV
62278672|NCT01236430|ACTIVE_COMPARATOR|Ezetimibe 10mg and Atorvastatin 10mg|Ezetimibe 10mg tablet and Atorvastatin 10mg tablet coadministered
62278673|NCT01236430|EXPERIMENTAL|10mg Ezetimibe/10mg Atorvastatin|10mg Ezetimibe/10mg atorvastatin combination tablet
62278674|NCT01236430|ACTIVE_COMPARATOR|Ezetimibe 10mg and Atorvastatin 80mg|Ezetimibe 10mg tablet and Atorvastatin 80mg tablet coadministered
62278675|NCT01236430|EXPERIMENTAL|10mg Ezetimibe/80mg Atorvastatin|Ezetimibe/atorvastatin 10mg/80mg combination tablet
62278676|NCT03396380|ACTIVE_COMPARATOR|vitamin D|93 women who will receive clomiphene citrate for induction of ovulation with vitamin D and calcium supplement
62278677|NCT03396380|PLACEBO_COMPARATOR|placebo|93 women who will receive clomiphene citrate for induction of ovulation with placebo and calcium supplement
62278678|NCT04586985|EXPERIMENTAL|Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)|Subjects will be randomized to receive a single dose of FTX-6058 or placebo. Cohorts 1 and 2 will enroll 5 subjects per cohort randomized 3:2. Cohorts 3-8 will enroll 7 subjects per cohort randomized 5:2. Planned doses are 2 mg (Cohort 1), 4 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), 40 mg (Cohort 6), 60 mg (Cohort 7), and 90 mg (Cohort 8).
62278679|NCT04586985|EXPERIMENTAL|Multiple Ascending Dose (MAD) cohorts in Healthy Subjects (Part B)|Subjects will be randomized 3:1 to receive once daily FTX-6058 or placebo by mouth for 14 days. Up to 6 cohorts of 8 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 6 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), and 40 mg (Cohort 6).
62456019|NCT05587088|EXPERIMENTAL|Metastatic gastrointestinal tumors and acute leukemia patients|Patients with metastatic gastrointestinal tumors (colon, pancreas, stomach, and bile ducts) and newly diagnosed/relapse acute leukemias who meet the inclusion criteria will take the anamu extract with chemotherapy to evaluate the adverse drug-related side effects.
62644577|NCT00402831|EXPERIMENTAL|Intramuscular ProQuad®|Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
62644578|NCT00402831|ACTIVE_COMPARATOR|Subcutaneous ProQuad®|Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
62644579|NCT00626288|EXPERIMENTAL|A|Mesalazine cpr 800 mg t.i.d. for 12 weeks
62644580|NCT00626288|PLACEBO_COMPARATOR|B|Placebo cpr t.i.d. for 12 weeks
62074645|NCT05817669|PLACEBO_COMPARATOR|Placebo arm|patients receiving infusions of placebo IV
62074646|NCT03459313|EXPERIMENTAL|Active group|The active group will be provided the intervention program, i.e. access to a website.
62074647|NCT03459313|NO_INTERVENTION|Control group|The control group will continue to train according to their routines and will get access to the website after 4 months.
62074648|NCT02161601|EXPERIMENTAL|Correctly and incorrectly applied cricoid pressure|
62644581|NCT02065180|EXPERIMENTAL|commercially available nutrition supplement|this group receives a commercially available nutritional supplement for a period of 2 months
62644582|NCT02065180|PLACEBO_COMPARATOR|control group|this group receives a placebo for a period of 2 months
62644583|NCT01549145|EXPERIMENTAL|NIMBUS multifunctional stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
62278680|NCT04586985|EXPERIMENTAL|Pilot Food Effect Cohort in Healthy Subjects (Part C)|Ten subjects will be randomized to receive a single 20 mg dose of FTX-6058 with and without a high-fat meal with a washout period of 4 days.
62278681|NCT04586985|EXPERIMENTAL|Potential for CYP3A Induction in Healthy Subjects (Part D)|Sixteen subjects will receive 3 mg Midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 by mouth once daily. On Day 12, a second dose of 3 mg Midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.
62278682|NCT04586985|EXPERIMENTAL|Multiple Dose Cohort in Sickle Cell Disease Subjects (Part E)|Subjects will be randomized 3:1 to receive FTX-6058 or placebo once daily by mouth for 14 days. Up to 8 subjects will be enrolled. The planned dose is 6mg.
62278683|NCT06501625|EXPERIMENTAL|Safety Lead-In Phase|
62278684|NCT06501625|EXPERIMENTAL|Expansion Phase|
62278685|NCT05948280|EXPERIMENTAL|VR-supported mindfulness group|Participants in the intervention group will receive VR mindfulness intervention, consisting of four face-to-face sessions (twice a week for two weeks). During the first week, the interventionist will teach and guide the participant face-to-face. During the second week, participants will be required to practice VR on their own for self-help.
62278686|NCT05948280|ACTIVE_COMPARATOR|Mindfulness group|Participants in this group will receive a mindfulness exercise guided by the interventionist twice a week for two weeks.
62278687|NCT05948280|NO_INTERVENTION|Control group|Participants in the control group will not receive mindfulness or mindfulness plus VR.
62278688|NCT03257787|EXPERIMENTAL|Test of a new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation.
62278689|NCT03044860|EXPERIMENTAL|Type 2 diabetes|Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
62644584|NCT06325163|EXPERIMENTAL|A single arm consisting of 3 stages|"This study will include 3 stages:~1. CBCT examination stage: In this stage, CBCT scanning will be done and examined by by 2 blinded endodontists and the number of canals identified will be recorded~2. Clinical Stage: This is a clinical stage where patients will be randomly distributed upon 6 Practitioners using randomization software (Microsoft Office Excel). Practitioners will then proceed with the pretreatment procedures under dental operating microscope~3. Artificial intelligence stage: The carrying out of this stage will be solely undertaken by the principal investigator. The CBCT images will be uploaded to convolutional neural network software (CNN) that uses a deep learning algorithm and CBCT segmentation. The software will then record the number of canals it found"
62644585|NCT01376869|ACTIVE_COMPARATOR|102mg extract 1 hops|Equivalent to 0.5g dry weight
62644586|NCT01376869|ACTIVE_COMPARATOR|410mg extract 1 hops|Equivalent to 2g dry weight
62644587|NCT01376869|ACTIVE_COMPARATOR|79mg extract 2 hops|Equivalent to 0.5g dry weight
62278690|NCT03044860|EXPERIMENTAL|Healthy|Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
62278691|NCT02882295||writer's cramp|patients assessed without, then with Botulinum Neurotoxin injections
62644588|NCT01376869|ACTIVE_COMPARATOR|316mg extract 2 hops|Equivalent to 2g dry weight
62074649|NCT05122572|EXPERIMENTAL|Intravenous Injection|Intravenous with or without Intratumoral RT-01 in the treatment of patients with advanced solid tumors combined with or without Nivolumab in the treatment of patients with advanced solid tumors
62074650|NCT01740011|EXPERIMENTAL|Group A|Laparoscopic surgery with AirSeal CO2 pressure insufflation
62278692|NCT02882295||control|age and gender matched
62278693|NCT00956878||Cancer Pain Patients|
62278694|NCT01920360|EXPERIMENTAL|SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
62278695|NCT01920360|EXPERIMENTAL|NOT SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with not sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
62278696|NCT01920360|EXPERIMENTAL|CONTROL GROUP|This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
62644589|NCT01376869|PLACEBO_COMPARATOR|Placebo|
62644590|NCT00611585|OTHER|Hip Resurfacing|Birmingham Hip Resurfacing
62644591|NCT05426746|EXPERIMENTAL|ALT-100|"one of 4 ascending dose levels of ALT-100 administered as a single intravenous infusion with a staggered dose for sentinels followed by the rest of the cohort.~cohort 1: 0.1 mg/kg cohort 2: 0.4 mg/kg cohort 3: 1.0 mg/kg cohort 4: 4.0 mg/kg"
62644592|NCT05426746|PLACEBO_COMPARATOR|Saline|normal sterile saline (0.9% sodium chloride) administered as a single intravenous infusion at a constant infusion rate in a total volume and appearance matched to the active comparator, with a staggered dose for sentinels followed by the rest of the cohort
62644593|NCT03820401|EXPERIMENTAL|Solacea_postHDF_1/1anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro, Japan)~* choice of dialysis mode: post dilution hemodiafiltration~* choice of anticoagulation strategy: standard anticoagulation dose~measurements:~* blood \& dialysate sampling at 60min after dialysis start~* microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62074651|NCT01740011|ACTIVE_COMPARATOR|Group S|Laparoscopic surgery with standard CO2 pressure insufflation
62074652|NCT00613613||1|High drug metabolism genotype All receive fenofibrate
62074653|NCT00613613||2|Low drug metabolism genotype All receive fenofibrate
62074654|NCT01974466|ACTIVE_COMPARATOR|Goal A|"controled fluid therapy: 5\~10ml/kg/hr fulfillment of two or more of four criteria:~1. heart rate \<120 beats/min,~2. mean arterial blood pressure 65-85 mm Hg,~3. urine output ≥1 ml/kg /h~4. Hematocrit ≤35%."
62278697|NCT04459455|EXPERIMENTAL|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people from the US who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
62644594|NCT03820401|EXPERIMENTAL|Solacea_postHDF_1/2anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro Japan)~* choice of dialysis mode: post dilution hemodiafiltration~* choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~* blood \& dialysate sampling at 60min after dialysis start~* microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644595|NCT03820401|EXPERIMENTAL|FX800_postHDF_1/1anticoagulation|"intervention:~* choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~* choice of dialysis mode: post dilution hemodiafiltration~* choice of anticoagulation strategy: standard anticoagulation dose~measurements:~* blood \& dialysate sampling at 60min after dialysis start~* microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644596|NCT03820401|EXPERIMENTAL|FX800_postHDF_1/2anticoagulation|"intervention:~* choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~* choice of dialysis mode: post dilution hemodiafiltration~* choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~* blood \& dialysate sampling at 60min after dialysis start~* microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644597|NCT03820401|EXPERIMENTAL|Solacea_HD_1/1anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro, Japan)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: standard anticoagulation dose~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644598|NCT03820401|EXPERIMENTAL|Solacea_HD_1/2anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro, Japan)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644599|NCT03820401|EXPERIMENTAL|FX800_HD_1/1anticoagulation|"intervention:~* choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644600|NCT03820401|EXPERIMENTAL|FX800_HD_1/2anticoagulation|"intervention:~* choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62074655|NCT01974466|OTHER|Goal B|"controled fluid therapy: 5\~10ml/kg/hr fulfillment of all of the following criteria:~1 central venous pressure8-12 mmHg , 2.mean arterial pressure 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
62074656|NCT04020003|OTHER|Routine treatment|Routine treatment group: control infection, remove or control the primary disease; mechanical ventilation with low tidal volume and high PEEP mechanical ventilation strategy; strictly control volume, strengthen airway management, timely nutritional support and severe rehabilitation treatment.
62074657|NCT06317519||Physical Rehabilitation + GRAIL|Patients in this group receive Physical Rehabilitation and GRAIL treatment
62074658|NCT06317519||Physical Rehabilitation|Patients in this group receive Physical Rehabilitation not GRAIL treatment
62074659|NCT06392685|ACTIVE_COMPARATOR|Silane coupling agent(Comparator)|In the control group, Silane coupling agent (Porcelain primer) will be applied following the acid etch rinsing and drying step, for 30 seconds and then it will be thoroughly dried using air syringe then universal adhesive with regular silane will be actively applied for 20 seconds and then it will be light cured for 20 seconds and final restoration will be done.
62644601|NCT03820401|EXPERIMENTAL|FX800_HD_1/2anticoagulation_albuprime|"intervention:~* choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~* preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62074660|NCT06392685|ACTIVE_COMPARATOR|.Adhesive containing silane.(Intervention 1 )|Universal adhesive with regular silane will be applied for 20 seconds, air thinned for 10 seconds and then it will be light cured for 20 seconds and final restoration will be done using same resin composite material
62074661|NCT06392685|ACTIVE_COMPARATOR|Acid resistance silane containing adhesive.(Intervention 2)|Acid resistance silane containing adhesive will be applied for 20 seconds, dry with gentle air for 3 seconds, then with stronger air and light cured for 10 seconds and final restoration will be done
62074662|NCT01428804|ACTIVE_COMPARATOR|active tDCS|a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning and 1 afternoon) for 5 days with an electric current 2 mA
62074663|NCT01428804|SHAM_COMPARATOR|sham tDCS|a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and sham tDCS.
62074664|NCT05504213|EXPERIMENTAL|Cohort 1: Endocrine therapy-resistant (Stage 1)|Participants who are endocrine therapy pre-treated will be administrated at escalating doses orally of HS-10352 in combination with fulvestrant (500 mg, intramuscular).
62644602|NCT03820401|EXPERIMENTAL|Evodial_HD_no anticoagulation|"intervention:~* choice of dialyzer: Evodial 1.3 (Baxter, USA)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: no anticoagulation is administered~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644603|NCT03820401|EXPERIMENTAL|Evodial_HD_no anticoagulation_albuprime|"intervention:~* choice of dialyzer: Evodial 1.3 (Baxter, USA)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: no anticoagulation is administered~* preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62074665|NCT05504213|EXPERIMENTAL|Cohort 2: Endocrine therapy-resistant (Stage 2)|Participants who are endocrine therapy-resistant will be treated with HS-10352 orally at the MTD/MAD identified in Stage 1 or/and lower dose in combination with fulvestrant (500 mg, intramuscular)
62278698|NCT04459455|PLACEBO_COMPARATOR|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
62074666|NCT05504213|EXPERIMENTAL|Cohort 3: Endocrine therapy-sensitive or endocrine-naïve (Stage 2)|Participants who are endocrine therapy-sensitive or naïve will be treated with HS-10352 orally at MTD/MAD or/and lower dose identified in Stage 1 in combination with fulvestrant (500 mg, intramuscular)
62278699|NCT05402644||Non-CSPH|BCLC stage A patients who underwent hepatectomy in the group without clinically significant portal hypertension (Non-CSPH)
62278700|NCT05402644||CSPH|BCLC stage A patients who underwent hepatectomy in the group with clinically significant portal hypertension (CSPH)
62074667|NCT05092425||with CPPV|Group 1 is childrens with contralateral patent processus vaginalis.
62644604|NCT03820401|EXPERIMENTAL|Solacea_preHDF_1/4anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro Japan)~* choice of dialysis mode: pre dilution hemodiafiltration~* choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644605|NCT03820401|EXPERIMENTAL|Solacea_postHDF_1/4anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro Japan)~* choice of dialysis mode: post dilution hemodiafiltration~* choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62074668|NCT05092425||without CPPV|Group 2 is childrens without contralateral patent processus vaginalis.
62074669|NCT06238063|EXPERIMENTAL|Intervention|The ACP intervention, which was developed by the expert panel, will be delivered by trained nurses in each RCH during a mandatory annual individual care planning (ICP) meeting. Eligible residents and their family members will be invited to attend the ICP meeting with ACP discussion.
62074670|NCT06238063|NO_INTERVENTION|Control|Participants in the control arm will receive usual care with no ACP intervention.
62278701|NCT00772629|EXPERIMENTAL|Group 1|Subjects naïve to any meningococcal vaccination
62278702|NCT00772629|EXPERIMENTAL|Group 2|Subjects who previously received unconjugated polysaccharide vaccine (either bivalent A and C or tetravalent A, C, Y, and W 135)
62644606|NCT03820401|EXPERIMENTAL|Solacea_HD_1/4anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro Japan)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644607|NCT03820401|EXPERIMENTAL|Solacea_preHDF_no anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro Japan)~* choice of dialysis mode: pre dilution hemodiafiltration~* choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644608|NCT03820401|EXPERIMENTAL|Solacea_postHDF_no anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro Japan)~* choice of dialysis mode: post dilution hemodiafiltration~* choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644609|NCT03820401|EXPERIMENTAL|Solacea_HD_no anticoagulation|"intervention:~* choice of dialyzer: Solacea dialyzer (Nipro Japan)~* choice of dialysis mode: hemodialysis~* choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
62644610|NCT05956041|EXPERIMENTAL|Experimental|Pembrolizumab 400mg via IV over 30 minutes on Day 1 of each cycle (6 weeks) Mogamulizumab 1mg/kg via IV over a least 60 minutes Cycle 1: Days 1, 8, 15, and 22 Cycle 2+: Days 1, 15, and 29 Each cycle lasts 6 weeks with a maximum of 18 cycles If a subject achieves a complete response (CR) after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR they may discontinue study treatment and enter an observation period. Subjects who progress during the observation period may be eligible for up to an additional 12 cycles of pembrolizumab and mogamulizumab
62644611|NCT06405919||Patients with goitres 10 years or more|Patients with long standing multinodular goitres of 10years or more presenting to surgical unit in Khartoum Teaching Hospital -Sudan. Checking incidence of malignancy in this group.
62644612|NCT03319498|ACTIVE_COMPARATOR|Peppermint Oil Vapor|Exposure of the perineum to the vapor of the active comparator, 2 ml peppermint oil. The perineum will NOT come into contact with the oil directly.
62278703|NCT00477165|EXPERIMENTAL|Citalopram|One 20mg capsule per day for 4 weeks, then 2 capsules per day (40mg) for 4 weeks
62644613|NCT03319498|PLACEBO_COMPARATOR|Mineral Oil Vapor|Exposure of the perineum to the vapor of the placebo comparator, 2 ml mineral oil. The perineum will NOT come into contact with the oil directly.
62278704|NCT00477165|PLACEBO_COMPARATOR|Placebo|Identical to citalopram 20mg capsule. One capsule per day for 4 weeks, then 2 capsules per day for 4 weeks
62278705|NCT05008094||Genetic testing cohort (Phase 1)|Group of Croatian Parkinson's disease patients who will be tested with whole-exome sequencing in target Parkinson's genes.
62644614|NCT03156075|EXPERIMENTAL|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
62644615|NCT03156075|NO_INTERVENTION|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
62644616|NCT01525589|EXPERIMENTAL|PM01183|
62278706|NCT05008094||Drug-naive Parkinson's disease patients (Phase 2)|Drug-naive Parkinson's disease patients that will be prospectively followed in the two-year period for each patient.
62644617|NCT03256617|EXPERIMENTAL|Provider training|
62278707|NCT05008094||Control group (Phase 2)|Control patients who do not have neurodegenerative diseases. The control group will perform the same measurement as the drug-naive Parkinson's disease patients.
62278708|NCT06001944|ACTIVE_COMPARATOR|Control group|8 weeks, 2 days a week, a multi-model rehabilitation program is implemented.
62644618|NCT05287789|EXPERIMENTAL|Squatting position by footstool|"After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a footstool at the appropriate height on the water closet type toilet.~The patients used footstools in the hospital and throughout a week after discharge at home for defecation."
62644619|NCT05287789|NO_INTERVENTION|Control Group|The control group received the routine care provided to all the patients in the clinic with no additional interventions.
62644620|NCT04074265|ACTIVE_COMPARATOR|Pain injection|This group will be injected with a cocktail totaling 40mL (20mL on each side) that will be composed of ropivicaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), ketorolac 30mg/mL (0.5mg/kg).
62456020|NCT05587088|EXPERIMENTAL|Stage II Metastatic gastrointestinal tumors including pancreas|For solid metastatic tumors, 30 patients will be recruited, which can be from the colon, pancreas, stomach, and bile ducts, divided into two groups of 15 patients, an intervention group and a placebo group. The intervention group will receive the Esperanza extract at DMT for three continuous treatment cycles (approximately 12 weeks), and the other group will receive the placebo.
62644621|NCT04074265|PLACEBO_COMPARATOR|Normal saline|The control group will receive an injection of 40mL of 0.9% sodium chloride solution.
62644622|NCT04733924|ACTIVE_COMPARATOR|Withania somnifera 125 mg|One capsule before breakfast for 84 days
62644623|NCT04733924|ACTIVE_COMPARATOR|Withania somnifera 250 mg|One capsule before breakfast for 84 days
62644624|NCT04733924|PLACEBO_COMPARATOR|Microcrystalline Cellulose|One capsule before breakfast for 84 days
62644625|NCT04577066|EXPERIMENTAL|Group 1 (GA2)|Volunteers will be exposed to GA2-infected mosquito bites.
62644626|NCT04577066|ACTIVE_COMPARATOR|Group 2 (GA1)|Volunteers will be exposed to the GA1-infected mosquito bites.
62644627|NCT04577066|PLACEBO_COMPARATOR|Group 3 (Placebo)|Volunteers will be exposed to uninfected mosquito bites.
62644628|NCT05572203|ACTIVE_COMPARATOR|Healthy group (Control group )|This group will include healthy participants matching Crohn's group
62644629|NCT05572203|EXPERIMENTAL|Crohn's group or patients group|This group will include patients with Crohn's disease.
62644630|NCT03092427|EXPERIMENTAL|Probiotic VSL#3|
62644631|NCT03092427|PLACEBO_COMPARATOR|Placebo|
62644632|NCT02027025|ACTIVE_COMPARATOR|SPARC 1103 low dose|The subjects will receive SPARC 1103 low dose
62644633|NCT02027025|ACTIVE_COMPARATOR|SPARC1103 high dose|The subjects will receive SPARC1103 high dose
62644634|NCT02027025|PLACEBO_COMPARATOR|SPARC Placebo|The subjects will receive SPARC Placebo
62644635|NCT03802552|EXPERIMENTAL|Cefadroxil then Cephalexin|Receive cefadroxil first, then receive cephalexin after washout.
62644636|NCT03802552|EXPERIMENTAL|Cephalexin then Cefadroxil|Receive cephalexin first, then receive cefadroxil after washout.
62644637|NCT01763541|OTHER|Testosterone|"To determine the effect of testosterone on the NP responses to acute and chronic salt loading.~One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days.~Intervention: Leuprolide acetate and anastrozole"
62644638|NCT01763541|OTHER|Estradiol|"To determine the effect of estradiol on the NP responses to acute and chronic salt loading.~Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks.~Intervention: leuprolide acetate"
62644639|NCT01171378|OTHER|Ofatumumab|Single arm study
62644640|NCT03516565||Pregnancy group|Pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34)
62644641|NCT03516565||Postpartum group|Postpartum group included women, who were evaluated 6 months after giving birth
62644642|NCT03516565||Non-pregnant group|Women who were systemically healthy and non-pregnant.
62074671|NCT05871931|EXPERIMENTAL|Experimental|"Personal Information Form, Parents' Internalized Stigma in Mental Illnesses Scale and Psychological Well-Being Scale will be applied to the intervention group as part of the pre-test application. In order to provide individualized care in the research, face-to-face individual interviews will be conducted with each individual in the intervention group in line with the Tidal Model-based psychiatric nursing approach. The interview plan prepared in line with the Tidal Model-based psychiatric nursing approach to be applied to the mothers in the intervention group in the study consists of eight interviews. The average of the first and eighth interviews is 45-50 minutes; Other interviews are expected to last an average of 70-75 minutes."
62644643|NCT04895501|ACTIVE_COMPARATOR|running with stiff shoes|21 km of running with stiff shoes followed by a time-to-exhaustion run.
62644644|NCT04895501|EXPERIMENTAL|running flexible shoes|21 km of running flexible shoes followed by a time-to-exhaustion run.
62644645|NCT04789304|PLACEBO_COMPARATOR|Placebo / Placebo + Midazolam|Placebo matching BI 1595043. Patients included in the placebo arm corresponding to dose group 3, also received Midazolam.
62644646|NCT04789304|EXPERIMENTAL|15 mg BI 1595043|15 milligram (mg) BI 1595043. Dose group 1.
62644647|NCT04789304|EXPERIMENTAL|30 mg BI 1595043|30 mg BI 1595043. Dose group 2.
62644648|NCT04789304|EXPERIMENTAL|60 mg BI 1595043 + Midazolam|60 mg BI 1595043 + Midazolam. Dose group 3.
62644649|NCT06429904|EXPERIMENTAL|Nimotuzumab combined with NALIRIFOX|Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer
62644650|NCT03043456|ACTIVE_COMPARATOR|Thermoplastic Resin group|Thermoplastic complete denture placement is done (Thermoplastic Comfort Systems, inc.)
62644651|NCT03043456|PLACEBO_COMPARATOR|conventional acrylic resin group|Conventional acrylic resin complete denture placement is done. (Acrostone, inc.)
62644652|NCT02515435|EXPERIMENTAL|apatinib single agent|apatinib, single agent, 500mg or 750mg Qd po, continue until disease progression
62644653|NCT01305811|EXPERIMENTAL|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
62644654|NCT01305811|ACTIVE_COMPARATOR|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
62644655|NCT04261140|EXPERIMENTAL|High-viscosity glass ionomer|
62644656|NCT04261140|EXPERIMENTAL|flowable composite|
62644657|NCT04261140|EXPERIMENTAL|bulkfill composite|
62644658|NCT04261140|EXPERIMENTAL|nanohybrid composite|
62644659|NCT05446285||Treated|Patients initiating disease modifying treatment within the first year of diagnosis
62644660|NCT05446285||Untreated|Patients who do not initiate disease modifying treatment within the first year of diagnosis
62644661|NCT02092753|PLACEBO_COMPARATOR|Standard diet|Standard diet (SD): Nutrition following the standard recommendations of the German society for nutrition
62644662|NCT02092753|EXPERIMENTAL|Ketogenic diet|"Nutritional intervention: Ketogenic diet (KD).~Intervention: Nutritional support (hospital) + self support (outpatient phase) with KD"
62456021|NCT05587088|PLACEBO_COMPARATOR|Stage II Placebo Metastatic gastrointestinal tumors including pancreas|For solid metastatic tumors, 30 patients will be recruited, which can be from the colon, pancreas, stomach, and bile ducts, divided into two groups of 15 patients, an intervention group and a placebo group. The intervention group will receive the Esperanza extract at DMT for three continuous treatment cycles (approximately 12 weeks), and the other group will receive the placebo. Both groups will receive standard chemotherapy treatment for their underlying disease. The safety evaluation will be carried out in each treatment cycle, and the efficacy evaluation will be carried out at the end of the three cycles.
62644663|NCT02092753|EXPERIMENTAL|Logi diet|"Nutritional intervention: low glycämic and insulinemic diet (LOGI)~Intervention: Nutritional support (hospital) + self support (outpatient phase) with LOGI"
62644664|NCT02198534||ophthalomogically normal subjects|
62644665|NCT04535427|PLACEBO_COMPARATOR|Control|Participants in this arm will receive placebo per day.
62456022|NCT05587088|EXPERIMENTAL|Acute leukemia (Newly/Relapse)|"For newly diagnosed hematological tumors, 28 patients will be recruited and will receive the Esperanza extract at DMT. The intervention group will continuously receive the Esperanza extract at DMT for four weeks with the standard chemotherapy regimen for their underlying disease. The safety and efficacy evaluation will be carried out at the end of the treatment cycle.~Patients with relapsed or refractory acute leukemias will be admitted to receive the calculated DMT in phase Ib; A total of 6 patients will be recruited, and safety and efficacy evaluations will be performed during three treatment cycles or progression and death of the patient.~For the analysis of the response in patients with acute leukemia, a comparison will be made with a group followed historically. A propensity score matching will be performed for statistical analysis in case of differences in their baseline characteristics."
62456023|NCT05223582|EXPERIMENTAL|Fluzoparib and abiraterone treatment group|Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 150mg fluzoparib bid. Patients would be treated with 5mg prednisone bid. Patients would get medical castration.
62644666|NCT04535427|EXPERIMENTAL|Low dose L-arginine|Participants in this arm will receive 9g (3g tid) L-arginine per day.
62644667|NCT04535427|EXPERIMENTAL|High dose L-arginine|Participants in this arm will receive 15g (5g tid) L-arginine per day.
62074672|NCT05871931|NO_INTERVENTION|Control|"The mothers who met the inclusion criteria and agreed to participate in the study were informed about the research such as the subject, purpose and content of the research, their verbal and written consents were obtained, and the Personal Information Form, Parents' Internalized Stigma in Mental Illness Scale and '' An interview will be held with the aim of applying the Psychological Well-Being Scale pre-tests. A second interview will be held with the aim of applying the post-tests and conducting the interview on Self-Perception with the intervention group to the control group."
62074673|NCT04170296|EXPERIMENTAL|Cohort 1: Posterolateral Thigh|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
62278709|NCT06001944|EXPERIMENTAL|Experimental group|8 weeks, 2 days a week, blood flow restriction during exercise will be applied in addition to the multi-model rehabilitation program. The elbow will be placed near the elbow and the patient's systolic pressure will be used to restrict the blood flow with the recommended 40%-50% occlusion for the upper extremity, and the exercise intensity will be performed 75 times at 20-30% of 1 maximum repetition, 30-15-15-15 repetition and 30 seconds rest between sets.
62278710|NCT05403983|EXPERIMENTAL|In person movement intervention|In person yoga movement intervention (Les Mills BodyBalance: mixture of yoga, tai chi, pilates) two times per week
62278711|NCT05403983|ACTIVE_COMPARATOR|Online yoga movement intervention|Pre-recorded video of yoga movement intervention (Les Mills BodyBalance: mixture of yoga, tai chi, pilates) two times per week
62278712|NCT05403983|ACTIVE_COMPARATOR|Education|Education control group using a recently published postpartum physical activity guidebook through the Sport Information Resource Center
62278713|NCT05272865|ACTIVE_COMPARATOR|Dronabinol 5mg/mL|Drug: Dronabinol (SYNDROS) Oral solution of SYNDROS (5 mg/mL)
62278714|NCT05272865|EXPERIMENTAL|THC F1|Drug: THC Oral solution of THC (5 mg/mL)
62278715|NCT05272865|EXPERIMENTAL|THC F2|Drug: THC:CBG Oral solution of THC (5 mg/mL) \& CBG (5 mg/mL)
62278716|NCT05272865|EXPERIMENTAL|THC F3|Drug: THC:CBC Oral solution of THC (5 mg/mL) \& CBC (5 mg/mL)
62074674|NCT04170296|EXPERIMENTAL|Cohort 2: Buttocks|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
62074675|NCT04672889|PLACEBO_COMPARATOR|Placebo|consume 1 sachet per day for 1 months
62278717|NCT04476602||COVID-19 (SARS-CoV-2) patients|adults 18 or older, ambulatory , with COVID-19 (SARS-CoV-2)
62074676|NCT04672889|EXPERIMENTAL|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
62074677|NCT06360003|ACTIVE_COMPARATOR|Right Ventricular Outflow Tract (RVOT) Posterior Septum Pacing Group|
62074678|NCT06360003|ACTIVE_COMPARATOR|Convention Group|
62074679|NCT04976569|EXPERIMENTAL|DBS Regulation Group|All participants will receive STN-DBS sleep regulation.
62074680|NCT05274308||Patient blood sample collection|30 mL of whole blood collected from eligible patients in one sampling
62278718|NCT02486757|EXPERIMENTAL|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
62074681|NCT00791115|EXPERIMENTAL|prostatectomy after radiotherapy|
62074682|NCT00839917|EXPERIMENTAL|ProQuad™|
62074683|NCT00839917|ACTIVE_COMPARATOR|M-M-R™ II and Varivax™|
62644668|NCT02814071|NO_INTERVENTION|Fasting with intravenous fluids|The child will be kept fasted. Intravenous fluids will be at a rate and type as directed by the treating clinician. A low fat oral diet will be commenced once abdominal pain resolves and serum amylase/lipase levels decrease from the peak levels as per treating clinician. In the event that the patient is unable to tolerate oral feeding, tube feeding or parenteral nutrition may be commenced based on the clinical decision of the treating clinician(s). This will be recorded as an adverse event. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled as per treating clinician's discretion
62074684|NCT05904743|EXPERIMENTAL|Afrezza (Technosphere Insulin) + insulin degludec|The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase. Dexcom Continuous Glucose Monitoring (CGM) will be provided. The Afrezza-Degludec group will continue to use Afrezza and insulin degludec for an additional 13 weeks in the Extension Phase.
62074685|NCT05904743|ACTIVE_COMPARATOR|Usual Care: Insulin delivery with either MDI, a pump without automation, or an AID system and CGM|The Usual Care group will continue to receive insulin as they did before the study. This could be by multiple daily injections (MDI) or by using an insulin pump with or without automation for the 17 weeks of the randomized controlled trial (RCT) Phase. Participants will continue to use their personal continuous glucose monitor (CGM) as they did before the study. The Usual Care group will then use Afrezza and insulin degludec for 13 weeks in the Extension Phase. Dexcom CGM will be provided during the Extension Phase.
62074686|NCT00670696|EXPERIMENTAL|A|Rapydan medicated plaster administered 30 minutes prior to cannulation on Visit 1 and tetracaine gel administered 45 minutes prior to cannulation on Visit 2.
62074687|NCT00670696|ACTIVE_COMPARATOR|B|Tetracaine gel administered 45 prior to cannulation on Visit 1 and then Rapydan administered 30 minutes prior to cannulation on Visit 1
62074688|NCT05655104||Couplet Care group and their historical controls|"Postintervention group: All parents enrolled in 2022-23 are classified into this group. They receive the intervention Couplet Care.~Pre-intervention group: All parents enrolled in 2018-19 are treated as controls. They did not receive the intervention Couplet Care."
62074689|NCT04320615|EXPERIMENTAL|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
62074690|NCT04320615|PLACEBO_COMPARATOR|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
62074691|NCT03681483|EXPERIMENTAL|RO5126766 (CH5126766)|The study will begin with a standard 3+3 design. The study will enroll 3 patients at the previously identified MTD15 (4mg two times per week on days 1 and 4). The period of evaluation for dose limiting toxicity will be through completion of cycle 1. If ≤1 of the 3 initial patients at the proposed dose experience a DLT, then 3 additional patients will be enrolled for a total of 6 planned patients at that dose level. Otherwise, 3 patients will be enrolled at dose level -1. If ≤ 1 of these patients experience a DLT, then 3 additional patients will be enrolled at the same dose level. If more than 1 patient experiences a DLT in dose level -1, the study will be terminated.
62074692|NCT06365606|EXPERIMENTAL|Performance onsite|Capillary (fingerstick) blood samples collected from the participants will be tested with the iStatis Syphilis Ab Test in the hands of trained healthcare professionals at the point-of-care setting.
62074693|NCT06365606|EXPERIMENTAL|Performance in lab|Venous whole blood and plasma samples collected from the participants will be tested with the iStatis Syphilis Ab Test in the hands of trained healthcare professionals at the point-of-care setting. The results are compared with Abbott Architect Syphilis Tp (EDA) referent test, and in cases of positive results, further confirmatory testing (BD Macro-Vue Particle Agglutination (RPR) and Serodia Particle Agglutination (TPPA)) will be conducted.
62074694|NCT02587689|EXPERIMENTAL|anti-MUC1 CAR T Cells|The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the MUC1+ tumor cells.
62278719|NCT05273580||Patients|Eligible patients will be identified by the Nurse Practitioner Cancer \& Palliative Care.
62278720|NCT05273580||Carers|The respective carers who are identified by the Nurse Practitioner Cancer \& Palliative Care as eligible participants.
62644669|NCT02814071|EXPERIMENTAL|Early enteral feeding|Patients will commence on an unrestricted oral diet within 24 hours of presentation, meeting 50% of EER with a regular diet and no fat restriction for the first 24 hours of enteral feeding. A 75-100% EER is targeted ≥ 24 hours of enteral feeding.If the targeted EER is not met orally, a nasogastric tube will be inserted to provide bolus feeds of a standard formula with standard fat content. If the patient fails to tolerate both oral and bolus nasogastric tube feeding, continuous nasogastric tube feeding will be provided. If all fails, enteral nutrition by nasojejunal tube feeding or parenteral nutrition may be commenced based on the clinical decision. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled.
62644670|NCT02669706||IV pentamidine|Pentamidine 4mg/kg IV every month (maximum 300mg)
62278721|NCT06334094|EXPERIMENTAL|Ozanimod|Participants will receive Ozanimod and work up to .92 mg. They will then take one pill daily for a duration of 12 months.
62278722|NCT03675880|EXPERIMENTAL|1.25mg(0.05ml) single-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose
62278723|NCT03675880|EXPERIMENTAL|2.00mg(0.08ml) single-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose
62278724|NCT03675880|EXPERIMENTAL|2.50mg(0.10ml) single-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose
62644671|NCT05985863|PLACEBO_COMPARATOR|Group Control|standard medical treatment+Placebo(5% human serum albumin in 0.9% saline, at week0, week1 and week2)
62644672|NCT05985863|EXPERIMENTAL|Group MSC-1|Patients received standard medical treatment and infusions of hUC-MSC(1.5×10\^8) via peripheral veins once a week for 3 timess(at week0, week1, and week2).
62644673|NCT05985863|EXPERIMENTAL|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of hUC-MSC(1.5×10\^8) via peripheral veins once a week for another 2 timess(at week4 and week5).
62644674|NCT05847608|EXPERIMENTAL|Omega-3 Supplementation|This groups will supplement their regular diet with 1 tsp of fish oil containing 1.5 grams combined omega-3 fatty acid (EPA/DHA) supplement in liquid form on a daily basis until they are recovered or have been enrolled for 6 weeks.
62644675|NCT05847608|PLACEBO_COMPARATOR|Placebo|This group will supplement their regular diet with 1 tsp olive oil in liquid form on a daily basis until they are recovered or have been enrolled for 6 weeks.
62644676|NCT04420091|EXPERIMENTAL|Cartidyss|
62644677|NCT01521000|NO_INTERVENTION|Observation|Observation arm will continue to be followed with serial L-Dex and water volume displacement methods.
62644678|NCT01521000|OTHER|Intervention-garment sleeve|If the L-Dex is outside the normal range, or has increased 10 units from baseline, the patient will then be randomized to wear a compression sleeve (20 to 30 mm of Hg) daily for 4 weeks or observation (no sleeve). After 4 weeks, L-Dex measurements and water volume displacement will be reassessed in the treatment group.
62644679|NCT05880706|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 and BL-B01D1 in combination with Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62278725|NCT03675880|EXPERIMENTAL|1.25mg(0.05ml) multiple-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose
62278726|NCT03675880|EXPERIMENTAL|2.00mg(0.08ml) multiple-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose
62456024|NCT01202981||Group 1|Patients who had cataract surgery by the Investigators between July 1, 2007 and June 30, 2008.
62456025|NCT01202981||Group 2|Patients who had cataract surgery by the Investigators between July 1, 2008 and July 1, 2009.
62644680|NCT02976883|EXPERIMENTAL|[18F]HX4 diagnostic PET/CT scan|\[18F\]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.
62074695|NCT00846833|EXPERIMENTAL|Cyclophosphamide, high-dose interleukin-2, NK cell|
62278727|NCT03675880|EXPERIMENTAL|2.50mg(0.10ml) multiple-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose
62278728|NCT03190408||Shock|
62278729|NCT00559507|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62278730|NCT02810964|EXPERIMENTAL|Sulforaphane Nutraceutical|The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
62644681|NCT01206465|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62644682|NCT03292016|EXPERIMENTAL|APL-130277, sublingual thin film|APL-130277, sublingual thin film, once daily
62278731|NCT02810964|PLACEBO_COMPARATOR|Identical-appearing Placebo|The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
62278732|NCT05297968|ACTIVE_COMPARATOR|Oseltamivir Phosphate For Oral Suspension/Tamiflu|Tamiflu ,6mg/ml,batch no.3235821,manufactured by F.Hoffmann-La Roche Ltd.
62278733|NCT05297968|EXPERIMENTAL|Oseltamivir Phosphate For Oral Suspension|6mg/ml,batch no.GH1A0003,manufactured by Qilu Pharmaceutical(Hainan) Co., Ltd.
62644683|NCT03292016|ACTIVE_COMPARATOR|Subcutaneous APO-go|Subcutaneous APO-go, once daily
62644684|NCT03292016|ACTIVE_COMPARATOR|Subcutaneous APOKYN|Subcutaneous APOKYN, once daily
62644685|NCT02138565|EXPERIMENTAL|Bariatric surgery|
62644686|NCT06273488||Auriculotherapy intervention group|
62074696|NCT01227408|EXPERIMENTAL|Metronomic Chemotherapy|Doxorubicin will be administered as an intravenous bolus, careful intravenous injection. PPX will be administerd as an intravenous 10 mins. infusion. Capecitabine and methotrexate will be taken orally twice a day. Cyclophosphamide will be taken orally once a day.
62074697|NCT05270317|ACTIVE_COMPARATOR|Early-Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 6 weeks
62278734|NCT01243320|EXPERIMENTAL|10ppm Oral Silver|Oral Dose of 10ppm
62278735|NCT01243320|EXPERIMENTAL|32ppm Oral Silver|Oral Dose of 32ppm
62278736|NCT03174145|ACTIVE_COMPARATOR|Active group|
62278737|NCT03174145|SHAM_COMPARATOR|Control group|
62074698|NCT05270317|ACTIVE_COMPARATOR|Medium -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 8 weeks
62074699|NCT05270317|ACTIVE_COMPARATOR|Late -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 10 weeks
62074700|NCT01223222|PLACEBO_COMPARATOR|1% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
62278738|NCT03548441||Surgery|Exposed
62278739|NCT03548441||Non-surgical management|Non-exposed
62278740|NCT00466310|ACTIVE_COMPARATOR|Aripiprazole for 4 weeks|Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
62278741|NCT00466310|ACTIVE_COMPARATOR|Risperidone for 4 weeks|Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
62278742|NCT00466310|OTHER|Healthy volunteers|Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.
62278743|NCT05441774|SHAM_COMPARATOR|Sham stimulation plus sham imagery|Double sham group: Stimulator electrodes will be applied to earlobe (sham stimulation); imagery task will involve a 'draw-a-face-in-imagination' (sham imagery) task.
62644687|NCT06273488||Control group|
62644688|NCT04176224|EXPERIMENTAL|MT-1186|Patients receive the edaravone oral suspension.
62644689|NCT04166071|ACTIVE_COMPARATOR|Naltrexone|
62644690|NCT04166071|PLACEBO_COMPARATOR|Placebo|
62644691|NCT05036226|EXPERIMENTAL|Dose level 1|
62074701|NCT01223222|ACTIVE_COMPARATOR|2% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
62074702|NCT01223222|ACTIVE_COMPARATOR|5% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
62278744|NCT05441774|OTHER|Active stimulation plus sham imagery|Single (imagery) sham group: Stimulator electrodes will be applied to the tragus (active stimulation); 'draw-a-face-in-imagination' (sham imagery) task.
62278745|NCT05441774|OTHER|Sham stimulation plus active self-compassion imagery|Single (stimulation) sham group: earlobe (sham) stimulation; imagery task will involve directing compassion to the self (self-compassion, active imagery).
62278746|NCT05441774|ACTIVE_COMPARATOR|Active stimulation plus active self-compassion imagery|Double active group: tragus (active) stimulation; self-compassion (active imagery)
62456026|NCT05680350|ACTIVE_COMPARATOR|Study group|"Study group Patients with unexplained infertility had estimated their Plasma Expression level for GeneMicro RNA 203 \& 210 by qRT-PCR followed by laparoscopic exploration"
62644692|NCT05036226|EXPERIMENTAL|Dose level 2a|
62644693|NCT05036226|EXPERIMENTAL|Dose level 2b|
62644694|NCT05036226|EXPERIMENTAL|Dose level 3a|
62644695|NCT05036226|EXPERIMENTAL|Dose level 3b|
62644696|NCT05036226|EXPERIMENTAL|Dose level 4|
62644697|NCT03899727||Pregnant group|pregnant women in the third trimester of pregnancy
62644698|NCT03899727||Non-pregnant group|middle aged women
62644699|NCT02902835|ACTIVE_COMPARATOR|Referral to treatment (Control)|The control group will receive a referral to buprenorphine treatment by the research staff.
62644700|NCT02902835|EXPERIMENTAL|BUP-FAST Intervention|Thirty-six participants will each be paired with a trained peer mentor who will provide the BUP-FAST intervention.
62644701|NCT04724746|EXPERIMENTAL|Written Exposure and Cognitive Behavioral Therapy|Participants receive 5 to 6, 60 minute, sessions of written exposure therapy for posttraumatic stress disorder combined with cognitive behavioral therapy for substance use disorder.
62644702|NCT05768646||ALS patients|
62644703|NCT05768646||Healthy controls|
62456027|NCT05680350|ACTIVE_COMPARATOR|Control Group|Control group Patients with unexplained infertility underwent laparoscopy only
62456028|NCT00059371|ACTIVE_COMPARATOR|Circumcised immediately|
62456029|NCT00059371|PLACEBO_COMPARATOR|Delayed Circumcision|Men who were randomized to delayed circumcision were scheduled to be offered male circumcision 2 years after their randomization.
62456030|NCT05116930|EXPERIMENTAL|Postpartum dural puncture headache following dural puncture from Tuohy needle|Subjects identified as experienced a post dural puncture headache after a confirmed dural puncture from a Tuohy needle will receive an IV administration of the study medications neostigmine and glycopyrrolate.
62456031|NCT03976713|EXPERIMENTAL|Bufei Yishen granule plus Western medicine|Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
62456032|NCT03976713|PLACEBO_COMPARATOR|Placebo Bufei Yishen granule plus Western medicine|Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
62456033|NCT01941030|EXPERIMENTAL|Orbital Atherectomy System|Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
62456034|NCT01941030|ACTIVE_COMPARATOR|Balloon Angioplasty|Balloon Angioplasty (BA) alone
62644704|NCT01805661|ACTIVE_COMPARATOR|Femoral With Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa
62644705|NCT01805661|EXPERIMENTAL|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
62074703|NCT02746575|EXPERIMENTAL|treatment|Postsurgical: 5mg metoprolol, IV, prior to extubation, every 5 minutes to achieve target heart rate of 65/min, up to 15mg; then 25mg metoprolol, oral, every 8 hours for 72 hours.
62074704|NCT01977001||Primary Headache|Treatment with MigraineBoxTM
62074705|NCT06266702|EXPERIMENTAL|Group 1A - High Vitamin D, Experimental Oil|High dose Vitamin D mixed with Experimental Oil
62074706|NCT06266702|ACTIVE_COMPARATOR|Group 1B - High Vitamin D, Control Oil|High Dose Vitamin D mixed with Control Oil
62456035|NCT06306742|ACTIVE_COMPARATOR|OMT|"Participants will receive manual treatments. The treatment will include soft-tissue, joint mobilization techniques of the lumbar and sacral region. The treatment will also include the approach of the abdomen and lower limb with the same type of techniques.~Four treatments will be provided at 1, 2, 4 and 8 weeks."
62644706|NCT01833676|ACTIVE_COMPARATOR|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
62644707|NCT01833676|ACTIVE_COMPARATOR|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
62644708|NCT02858466|EXPERIMENTAL|peripheric nervous lesion|MRI scan
62074707|NCT06266702|EXPERIMENTAL|Group 2A - Low Vitamin D, Experimental Oil|Low dose Vitamin D mixed with Experimental Oil
62074708|NCT06266702|ACTIVE_COMPARATOR|Group 2B - Low Vitamin D, Control Oil|Low Dose Vitamin D mixed with Control Oil
62074709|NCT00309608|EXPERIMENTAL|Linagliptin low dose|Patients receive Linagliptin low dose tablets once daily
62456036|NCT06306742|EXPERIMENTAL|Open-label placebo|This group will receive an open-label placebo. The manual treatment will be performed in the same areas of the active comparator but using a very light pressure. Additionally, before the start of the treatment, Four treatments will be provided at 1, 2, 4 and 8 weeks.
62456037|NCT06306742|NO_INTERVENTION|Waiting list|Participants will receive no treatment.
62644709|NCT02858466|EXPERIMENTAL|medullar or encephalic lesion|MRI scan
62644710|NCT02858466|OTHER|control group|MRI scan
62644711|NCT03463083|ACTIVE_COMPARATOR|Bupivacaine dexmedetomidine group|Group 1 (bupivacaine + dexmedetomidine (BD) group); will Receive an epidural study solution of 18 ml of 0.25% of bupivacaine hydrochloride plus 1 ml of dexmedetomidine (1 mcg/kg) plus 1 ml normal saline keeping the total volume of 20 ml in a syringe pump .
62074710|NCT00309608|EXPERIMENTAL|Linagliptin medium dose|Patients receive Linagliptin medium dose tablets once daily
62074711|NCT00309608|EXPERIMENTAL|Linagliptin high dose|Patients receive Linagliptin high dose tablets once daily
62074712|NCT00309608|PLACEBO_COMPARATOR|Placebo|Patients receive tablets identical to those containing Linagliptin low, medium and high dose
62074713|NCT00309608|ACTIVE_COMPARATOR|Glimepiride|Patients receive Glimepiride tablets once daily
62074714|NCT02991235|EXPERIMENTAL|PRJ212|PRJ212 is a nutritional product with active food ingredients.
62074715|NCT02991235|PLACEBO_COMPARATOR|Placebo|Placebo is like PRJ212 without active food ingredients.
62074716|NCT03917160|EXPERIMENTAL|EMS treatment|Subjects will undergo treatment with EMS and measurements
62074717|NCT03917160|NO_INTERVENTION|Control|Subjects will undergo measurements only
62074718|NCT01700673|EXPERIMENTAL|Myeloablative BMT|Azacitidine and sargramostim after myeloablative stem cell transplant
62074719|NCT01700673|EXPERIMENTAL|Non-myeloablative BMT|Azacitidine and sargramostim after non-myeloablative stem cell transplant
62074720|NCT01700673|EXPERIMENTAL|Standard consolidation|Azacitidine and sargramostim after standard consolidation
62456038|NCT02659852|EXPERIMENTAL|Side by side group|
62644712|NCT03463083|ACTIVE_COMPARATOR|Bupivacaine fentanyl group|Group 2 (bupivacaine + fentanyl (BF) group) ; will Receive an epidural study solution of 18 ml of 0.25% bupivacaine plus 2 ml fentanyl (1 mcg/kg) keeping the total volume of 20 ml in a syringe pump .
62644713|NCT02707003||AZ PACU|Observation of standard of care with capnography blinded
62074721|NCT01221324||Patients after open resection of colorectal cancer|
62456039|NCT02659852|ACTIVE_COMPARATOR|Stent in stent group|
62456040|NCT04141033|OTHER|saliva neopterin levels|assessment of saliva neopterin levels in pre and post-menopausal women
62456041|NCT04141033|OTHER|GCF neopterin levels|assessment of GCF neopterin levels in pre and post-menopausal women
62074722|NCT04268953|EXPERIMENTAL|AC-SD-03|Study drug administered concurrently with a standard meal
62074723|NCT04739683|ACTIVE_COMPARATOR|Foley bulb|16F latex or silicone Foley catheter inflated with 30-40 cc of sterile water. The catheter will be taped to the inner thigh with gentle traction.
62456042|NCT04506242|EXPERIMENTAL|apatinib+ Neoadjuvant/Adjuvant camrelizumab|"Neoadjuvant: Prior to surgery, participants receive 3 cycles (cycle length: 2 weeks) of camrelizumab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with apatinib ,5 days on 2days off\].~Adjuvant: 4-8 weeks following surgery, participants receive up to 12 cycles (cycle length: 2 weeks) of camrelizumab \[200 mg, IV; given on cycle day 1\]. Participants who can not able to benefit from immunotherapy will not receive camrelizumab adjuvant therapy."
62456043|NCT00525590|EXPERIMENTAL|1|
62456044|NCT03843203|SHAM_COMPARATOR|s-tDCS|- Intervention: 'Transcranial Direct Current Stimulation - tDCS The patients will receive tDCS sham treatment. The patients will receive sham tDCS treatment over primary motor cortex. According to 10-20 EEG system, anode will be placed at left C3 and cathode at o contralateral F3. In sham stimulation the device only release flow current, in the first 30 s of session and in the remaining 30s in the end of the session, during 20 minutes.
62644714|NCT02707003||TWH PACU|Observation of standard of care with capnography blinded
62074724|NCT04739683|ACTIVE_COMPARATOR|DILAPAN-S®|Synthetic hydrogel cervical dilator consists of the dilating part, the polypropylene handle, and the marker string. The dilating part is manufactured from an anisotropic xerogel of AQUACRYL.
62074725|NCT05504382|EXPERIMENTAL|study group 1|receive especially electrical acupuncture on the knee joint
62074726|NCT05504382|EXPERIMENTAL|study group 2|receive naproxen phonophoresis on the knee joint
62074727|NCT05261932||The accuracy of expert with or with-out AI|
62278747|NCT06086847|EXPERIMENTAL|Warm up Exercise + stretching Exercise + progressive resistance exercises|"* Group A (Experimental Group):~* Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~  3. Progressive Resistance exercises:~ 1. Leg press :( dual leg press): Leg press target the~     Quadriceps or quads .but they also work your Hamstrings.~ 2. Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~1. Rectus femoris~2. Vastus lateralis~3. Vastus medialis~4. Vastus intermedius~4. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):"
62278748|NCT06086847|ACTIVE_COMPARATOR|warm up exercise + Stretching exercises|"Warm up exercise (for 5 min)~Stretching exercises (upper and lower extremity"
62456045|NCT03843203|ACTIVE_COMPARATOR|M1 a-tDCS|"* Intervention: 'Transcranial Direct Current Stimulation - tDCS~* The patients will receive tDCS active treatment over primary motor cortex.~* According to 10-20 EEG system, anode will be placed at left C3 and cathode at contralateral supraorbital Fp2.~* Active stimulation uses a 2 milliamperes current during 20 minutes."
62456046|NCT03843203|ACTIVE_COMPARATOR|DLPFC a-tDCS|"* Intervention: 'Transcranial Direct Current Stimulation - tDCS~* The patients will receive tDCS active treatment over dorsolateral prefrontal cortex.~* According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~* Active stimulation uses a 2 milliamperes current during 20 minutes."
62074728|NCT05261932||The accuracy non-expert with or with-out AI|
62074729|NCT06529354|EXPERIMENTAL|Moderate-intensity Group|Participants engaged in 45-minute water aerobics sessions twice a week for 24 weeks at moderate intensities.
62074730|NCT06529354|EXPERIMENTAL|High-intensity Group|Participants engaged in 45-minute water aerobics sessions twice a week for 24 weeks at high intensities.
62074731|NCT01421082|EXPERIMENTAL|LVRC Treatment|
62074732|NCT06414564|EXPERIMENTAL|AHCL system application|insulin infusion using AHCL system insulin pump (Medtronic 780G) with continous glucose monitoring (guardian G4)
62074733|NCT05393362|EXPERIMENTAL|Cardiac Rehabilitation Program (CR)|The CR program will consist of aerobic exercise sessions and strength exercise sessions. The exercises will be individualized after assessing short effort capacities (strength exercise) and long efforts (aerobic exercise). It will be done four days a week, with a minimum of 48 hours between sessions of the same type of exercise. To make progress will be taking a clinical criterion into account, determined by the absence of symptoms derived from HF at the current intensity, and a temporary criterion where provided that the clinical criterion is met, the intensity will be increased every two-three weeks.
62074734|NCT05393362|ACTIVE_COMPARATOR|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
62074735|NCT02910518|EXPERIMENTAL|Insulin glulisine (U300) - Test formulation|Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
62074736|NCT02910518|ACTIVE_COMPARATOR|Insulin glulisine - Reference formulation|Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
62074737|NCT03722719|EXPERIMENTAL|Group I (the Knack)|
62074738|NCT03722719|ACTIVE_COMPARATOR|Group II (PFMT)|
62074739|NCT03722719|ACTIVE_COMPARATOR|Group III (the Knack + PFMT)|
62278749|NCT00401063|OTHER|Single arm|Acupuncture treatment
62456047|NCT02853500|EXPERIMENTAL|TACE Procedure With TriNav|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via TriNav.~* Patients will undergo structural follow-up for a timeframe of one year post treatment~* Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
62074740|NCT04840888|EXPERIMENTAL|LY3484356 (Cohort 1)|LY3484356 administered as single doses orally with (fed) or without food (fasted).
62074741|NCT04840888|EXPERIMENTAL|LY3484356 + Omeprazole (Cohort 2)|LY3484356 administered as single dose orally on Day 1 and omeprazole administered orally as single dose on Days 5 to 8 followed by a single dose of LY3484356 co-administered with a single dose of omeprazole on Day 9 orally.
62074742|NCT04840888|EXPERIMENTAL|LY3484356 + Itraconazole (Cohort 3)|LY3484356 administered as single dose orally on Day 1 and itraconazole administered orally as single dose on Days 5 to 9. The single dose of LY3484356 co-administered with a single dose of itraconazole on Day 10 orally followed by single dose of itraconazole administered orally on Days 11 to 16.
62456048|NCT02853500|ACTIVE_COMPARATOR|TACE Procedure Traditional Delivery|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Traditional Delivery.~* Patients will undergo structural follow-up for a timeframe of one year post treatment~* Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
62074743|NCT04840888|EXPERIMENTAL|LY3484356 + Carbamazepine (Cohort 4)|LY3484356 administered as single dose orally on Day 1 and carbamazepine administered orally as single dose on Days 5 to 11. The single dose of LY3484356 co-administered with a single dose of carbamazepine on Day 12 orally followed by single dose of carbamazepine administered orally on Days 13 to 15.
62074744|NCT05159206|OTHER|CT group|CT-scan preoperatively, postoperatively and at 3 months, 1 and 2 years. Per-operative navigation based on the CT scan.
62074745|NCT00975572|EXPERIMENTAL|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|
62644715|NCT04282174|EXPERIMENTAL|Regimen A|Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: Hyperfractionated total body irradiation to dose of 1375cGy fractions at 4-6 hour intervals three times a day for a total of 11 or 12 doses depending on age and disease risk, followed by Thiotepa 5mg/kg/day x 2 (or 10mg/kg/day x 1) and cyclophosphamide 60mg/kg/day x 2 (or Fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
62074746|NCT00975572|EXPERIMENTAL|split-virion, adjuvanted H1N1 vaccine of 15 μg|
62644716|NCT04282174|EXPERIMENTAL|Regimen B|Regimen B: Busulfan/Melphalan/Fludarabine: Busulfan 0.8mg/kg/dose every six hours x 10-12 doses (depending on disease), Melphalan 70mg/m2/day x 2 and Fludarabine 25mg/m2/day x 5.
62644717|NCT02683109|EXPERIMENTAL|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
62074747|NCT00975572|EXPERIMENTAL|split-virion, adjuvanted H1N1 vaccine of 30 μg|
62074748|NCT00975572|EXPERIMENTAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|
62074749|NCT00975572|PLACEBO_COMPARATOR|Placebo control|
62074750|NCT00975572|EXPERIMENTAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|
62074751|NCT01738022|EXPERIMENTAL|Gas mixture administration|Subjects will breathe different gas mixtures with different densities and viscosity for brief periods in order to promote changes in peak inspiratory flow
62074752|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
62644718|NCT02683109|ACTIVE_COMPARATOR|Free combination tiotropium + olodaterol|
62644719|NCT03704064|EXPERIMENTAL|Stigma + BWL Intervention|Participants in this group will receive the standard behavioral weight loss (BWL) program, which will be combined with a stigma-reduction intervention (more details provided in the Intervention section). All group meetings will be 90 minutes. Beginning at week 5, the 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the monthly and every-other-month weight loss maintenance sessions from weeks 21-72, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically with physical activity.
62644720|NCT03704064|ACTIVE_COMPARATOR|Standard BWL Intervention|Participants in this group will be provided with 20 weekly behavioral weight loss (BWL) session (described in more detail in the Intervention section), followed by 6 monthly weight loss maintenance sessions and 3 every-other-month sessions (for a total of 29 visits over 72 weeks). All group meetings will be 90 minutes. Beginning at week 5, BWL content in these sessions will last 60 minutes, with an additional 30 minutes devoted to discussing recipes and food preparation.
62074753|NCT02140294|EXPERIMENTAL|Polymeric nutritional supplement|
62074754|NCT02140294|ACTIVE_COMPARATOR|Standard Nutritional Treatment|
62074755|NCT03045393|EXPERIMENTAL|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
62074756|NCT03306043|EXPERIMENTAL|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
62074757|NCT02843958|OTHER|Healthy volunteers and patients under Vitamin K antagonist|
62074758|NCT02976597|ACTIVE_COMPARATOR|Bupivacaine 0.25%|Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side on each side at end of the surgery.
62074759|NCT02976597|ACTIVE_COMPARATOR|Morphine 10mg|Morphine 10mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery.Patients will recieve 5mg morphine on each side
62074760|NCT02976597|ACTIVE_COMPARATOR|Morphine 15mg|Morphine 15mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery. Patients will recieve 7.5mg morphine on each side
62074761|NCT02341456|EXPERIMENTAL|AZD1775|AZD1775 will be administered orally as a single dose on Day 1 Cycle 0. Following a 5±2 days washout period, AZD1775 (5 doses BID over 2.5 days) will be taken in combination with paclitaxel and carboplatin in each 21-day cycle for 6 cycles. Following 6 cycles of combination treatment, patients may continue on AZD1775 monotherapy (5 doses BID Day 1 to Day 2.5 in each 21-day cycle) at the investigator's discretion.
62074762|NCT02341456|EXPERIMENTAL|Paclitaxel|Commercially available paclitaxel will be administered at a dosage of 175 mg/m2 as a 3-hour IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles.
62074763|NCT02341456|EXPERIMENTAL|Carboplatin|Following the paclitaxel infusion, carboplatin will be administered at a dose of AUC 5 as an IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles. According to the Cancer Therapy Evaluation Program Information Letter Regarding the AUC Based Dosing of Carboplatin, the maximum carboplatin dose should not exceed the target AUC (mg\*min/mL)\*150 mL/min, but it may be less (Ivy et al 2010). For this study, the maximum dose of carboplatin cannot exceed a total dose of 750 mg.
62074764|NCT06369025|EXPERIMENTAL|ICC-T & ICC-P|"ICC-T: 5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~ICC-P: 4 days with 8 hours of training for parents. Core training components include parents-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened children and implementation of the training materials into the daily home setting"
62074765|NCT06369025|NO_INTERVENTION|Monitoring condition|No intervention
62074766|NCT00429494|EXPERIMENTAL|Leuprolide Acetate|Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.
62074767|NCT02520999|ACTIVE_COMPARATOR|5days|5 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
62074768|NCT02520999|ACTIVE_COMPARATOR|35days|35 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
62074769|NCT05914831|ACTIVE_COMPARATOR|Partial Breast Irradiation|
62074770|NCT05914831|EXPERIMENTAL|Whole Breast Irradiation|
62074771|NCT00552786|EXPERIMENTAL|Acetin|
62074772|NCT00552786|PLACEBO_COMPARATOR|Glucose|
62074773|NCT01760746||PDR, Avastin/Lucentis, randomization, humour, inflamation|Patients will be randomized to receive pre-treatment with either bevacizumab or ranibizumab . Sample of aqueous humour will be taken before injection and before surgery.Both the patient and the treating physician will be masked to the identity of the study drug.
62074774|NCT06044363|EXPERIMENTAL|Satir group|Participants in the intervention group will receive a 10-session Satir model intervention.
62456049|NCT02924480|ACTIVE_COMPARATOR|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
62074775|NCT06044363|NO_INTERVENTION|Control group|Participants in the control group will receive care as usual.
62456050|NCT02924480|PLACEBO_COMPARATOR|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
62644721|NCT06473441|EXPERIMENTAL|12-Week Home Rehabilitation|Participants in this group will receive a 12-week home-based rehabilitation program. They will be provided with health education and an exercise prescription based on individual assessments by the research team. Rehabilitation equipment, including a home exercise bike, resistance bands, respiratory muscle training device, and a portable heart rate monitor, will be supplied. Participants will log their daily exercise intensity and duration in a rehabilitation diary. Regular follow-up calls will be made to monitor progress and address any issues.
62644722|NCT06473441|EXPERIMENTAL|6-Week Tele-Rehabilitation plus 6-Week Home Rehabilitation|Participants in this group will undergo a hybrid rehabilitation program. For the first 6 weeks, they will receive tele-rehabilitation therapy, involving twice-weekly sessions where therapists remotely supervise and guide exercises. This will be followed by 6 weeks of the same home rehabilitation program as Arm 1, with health education, exercise prescriptions, and regular follow-up calls.
62644723|NCT06473441|EXPERIMENTAL|12-Week Tele-Rehabilitation and Home Rehabilitation|Participants in this group will receive 12 weeks of combined tele-rehabilitation and home rehabilitation. They will have twice-weekly tele-rehabilitation sessions with remote supervision and guidance from therapists throughout the entire period. In addition, they will follow the same home rehabilitation protocol as described for Arm 1, with provided equipment, exercise logs, and regular follow-up calls to ensure adherence and address any difficulties.
62644724|NCT02321852|EXPERIMENTAL|Verum/Placebo|This group will start with triflusal and after washout will receive placebo
62074776|NCT05327335|EXPERIMENTAL|Intervention Group|Older adults without mobility and/or manipulability difficulties will be treated as reference group while older adults with mobility and/or manipulability difficulties will use the robotics system and integrated environment to perform daily self-care.
62074777|NCT02307110|OTHER|1 arm study|cross-sectional observation
62074778|NCT01216176|EXPERIMENTAL|Phase 1 - Cohort A|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer
62278750|NCT03909958|OTHER|Electroacupuncture+Routine rehabilitation training Group|42 patients will receive both electroacupuncture（HANS100A）therapy and routine rehabilitation training.
62644725|NCT02321852|EXPERIMENTAL|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
62644726|NCT05438563|EXPERIMENTAL|Treatment (MRI-guided TULSA)|Patients undergo MRI-guided TULSA. Patients may also undergo DRE, cystoscopy, biopsy, bone scan, PSMA PET, and/or mpMRI at screening.
62644727|NCT03609463|EXPERIMENTAL|Well-being and small change|Participants will be randomized to receive 4 individual 1-hour weekly sessions of the well-being intervention before starting the 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
62644728|NCT03609463|ACTIVE_COMPARATOR|Small change|Participants will be randomized to receive 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
62644729|NCT04971499|EXPERIMENTAL|Dose Selection|Dapansutrile starting at 500 mg PO BID plus Pembrolizumab 200 mg IV every three weeks. Dose escalation is planned to a maximum of 1000 mg BID of dapansutrile + pembrolizumab.
62644730|NCT04971499|EXPERIMENTAL|Dose Expansion|Dapansutrile at the RP2D plus Pembrolizumab 200 mg IV every three weeks
62644731|NCT04690465|EXPERIMENTAL|Resistance training|In the 16 week resistance training, there will be 3 sessions per week, the duration of each session will be 60 minutes, which include 10min of warm-up, 40min of main exercise, and 10min of cool-down. The intensity will be light to somewhat hard (Rating of Perceived Exertion (RPE) 11 to 13; using the Cantonese version of RPE). In resistance training, the weights (resistance) will be from participants' own bodies, dumbbells, and adjustable ankle weights.
61978732|NCT02812147|PLACEBO_COMPARATOR|Placebo|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.
62074779|NCT01216176|ACTIVE_COMPARATOR|Phase 2 - Cohort B [Anastrozole + AZD0530]|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression or 4-6 months of treatment completed.
62074780|NCT01216176|PLACEBO_COMPARATOR|Phase 2 - Cohort B [Anastrozole + Placebo]|Dual treatment with 1 mg anastrozole orally once daily together with Placebo orally once daily, or as specified per protocol, until disease progression or4-6 months of treatment completed.
62278751|NCT03909958|OTHER|Routine rehabilitation training Group|42 patients will receive simple routine rehabilitation training.
62278752|NCT02163434|EXPERIMENTAL|gabapentin|1800-2400mg/day divided tid or qid, orally.
62278753|NCT02163434|EXPERIMENTAL|metoclopramide|45-60mg/day divided tid or qid, orally
62278754|NCT05072847||ADAPT|The ADAPT system by Striker
62278755|NCT02574637|PLACEBO_COMPARATOR|Placebo|Placebo-matching brazikumab intravenous (IV) infusion and subcutaneous (SC) injection at Weeks 0 and 4 followed by placebo-matching brazikumab SC injection at Weeks 8 and 12 in the induction phase and at Weeks 16, 20 and 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection every 4 weeks up to Week 48 in the open-label period.
62074781|NCT05078528|EXPERIMENTAL|Experimental group - MMC|Imaging of study participants will be performed during the colposcopy examination. The mobile colposcope and the confocal imaging probe, together referred to as the Multimodal Mobile Colposcope (MMC), will be used to image and/or record videos the cervix. Cervical biopsies will be performed using biopsy forceps per standard protocols.
62644732|NCT04690465|ACTIVE_COMPARATOR|Eight-form Yang-style Tai Chi program|In Tai Chi, the 16-week program will be divided into cognitive, associated, and automatic stages. The coach will apply a group teaching with individual instruction on specific movements based on participant's needs in skills learning and acquisition. The same training principles of individuality and progression as well as training log-book used in resistance training will also be applied to Tai Chi training program.
62644733|NCT04690465|NO_INTERVENTION|Non-treatment Concurrent Control|Participants in this group will not participate in any specific intervention during the whole study (the 16-week intervention and 12-week follow-up periods), but they will be asked to keep a daily log on their physical activity, medicine used, illness, diet, sleep quality and other health and physical activity related information (e.g., attending healthy eating workshops).
62278756|NCT02574637|EXPERIMENTAL|Brazikumab High Dose|Brazikumab 700 mg, IV infusion and placebo-matching brazikumab, SC injection at Weeks 0 and 4 followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
62278757|NCT02574637|EXPERIMENTAL|Brazikumab High-Medium Dose|Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
62644734|NCT03049501|EXPERIMENTAL|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
62644735|NCT03049501|PLACEBO_COMPARATOR|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition.
62644736|NCT02704767|PLACEBO_COMPARATOR|TarceP|Tarceva with Placebo
62644737|NCT02704767|EXPERIMENTAL|TarceA|Tarceva with Apatinib
62644738|NCT03070873|EXPERIMENTAL|group A|accepted Perigee and Apogee mesh(PA)
62644739|NCT03070873|EXPERIMENTAL|group B|accepted Gynecare prolift mesh
62644740|NCT03070873|PLACEBO_COMPARATOR|group C|Traditional surgery without any mesh
62644741|NCT05480124|SHAM_COMPARATOR|Sham stimulation treatment|Sham stimulation during a computerized task and electroencephalogram (EEG) recording.
62644742|NCT05480124|EXPERIMENTAL|tACS brain stimulation treatment|tACS brain stimulation during a computerized task and EEG recording. Participants will receive tACS using individualized peak Phase-amplitude coupling (PAC) frequency pairs determined in Session 1.
62278758|NCT02574637|EXPERIMENTAL|Brazikumab Low-Medium Dose|Brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 105 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 105 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 105 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
62278759|NCT02574637|EXPERIMENTAL|Brazikumab Low Dose|Brazikumab 70 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 35 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 35 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 35 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
62644743|NCT00094445|EXPERIMENTAL|Curcumin|Oral curcumin daily for eight weeks, starting dose 8 gm per day.
62644744|NCT01208285|EXPERIMENTAL|Group A|approximately 12 male and female subjects with moderate hepatic impairment
62644745|NCT01208285|EXPERIMENTAL|Group B|approximately 12 healthy male and female subjects
61978733|NCT05392725||Normal renal function group|Observe survival time
61978734|NCT05392725||Renal dysfunction group|Observe survival time
61978735|NCT02011347|EXPERIMENTAL|Ketamine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)
62278760|NCT04127448|EXPERIMENTAL|Exergaming Training Group|Training was given using X-box 360 Kinect.
62278761|NCT04127448|ACTIVE_COMPARATOR|Aerobic Exercise Group|Session using treadmill (model no TMX58 220).
62278762|NCT05412914|EXPERIMENTAL|Remimazolam|remimazolam infusion
62278763|NCT05412914|ACTIVE_COMPARATOR|Propofol|propofol infusion
62456051|NCT01924858|EXPERIMENTAL|GSK2647544 oral and [18F]GSK2647544 IV bolus|All subjects will receive a single oral dose of GSK2647544 100 milligram (mg) approximately 2 hours before administration of \[18F\] GSK2647544 and a dynamic PET scan. \[18F\]-GSK2647544 will be administered to the subject as an IV bolus during the PET scan, which will be conducted for up to 120 minute post the injection of \[18F\]GSK2647544
62074782|NCT01857830|EXPERIMENTAL|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
62644746|NCT05661448|EXPERIMENTAL|Cognitive remediation|CR was developed by Dr. Bowie (PI). Approximately 60% of CR sessions are spent on cognitive training activities, 20% on developing, monitoring, and flexibly adjusting problem-solving strategies, and 20% on transfer activities. Transfer includes discussing and role-playing how cognitive skills and strategies are applied in everyday life and teaches potential compensatory strategies for overcoming cognitive challenges. Targeted cognitive domains are processing speed, attention, memory, and executive functions, which are all commonly impaired in psychosis. The manual includes 1.5-hour sessions and uses Brain Training Pro and will be offered over an 8-week period. Zoom Health will be used for group transfer activities.
62074783|NCT01857830|ACTIVE_COMPARATOR|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
62074784|NCT02971059|EXPERIMENTAL|Adult Males >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
61978736|NCT02011347|EXPERIMENTAL|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)
61978737|NCT01792674|EXPERIMENTAL|In situ simulation|'In situ simulation' which is training in the actual patient care unit, in this situation the labour suite and operation theatre
62074785|NCT02971059|EXPERIMENTAL|Adult Females >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
62074786|NCT02767635|EXPERIMENTAL|Botox-Epic group|20 units of Botox injection into lateral epicondyle in Botox-Epic group
61978738|NCT01792674|ACTIVE_COMPARATOR|Off site simulation|The control group will receive the same training 'off site simulation', i.e., in training rooms away from the actual patient care unit.
61978739|NCT00180414|EXPERIMENTAL|Ventricular Rate Regulation feature ON|
61978740|NCT00180414|ACTIVE_COMPARATOR|Ventricular Rate Regulation feature OFF|
62074787|NCT02767635|EXPERIMENTAL|Botox-Tend group|20 units of Botox injected into tender point of muscles in Botox-Tend group
62074788|NCT02767635|ACTIVE_COMPARATOR|Steroid group|40mg of triamcinolone acetonide but not Botox injected into lateral epicondyle in Steroid group
62074789|NCT00706784|EXPERIMENTAL|A|
62074790|NCT05262426|EXPERIMENTAL|Standard PrEP Counseling, MES-PrEP and Enhanced YaCool|Participants in this arm will receive standard PrEP counseling, followed by two mHealth interventions (MES-PrEP and Enhanced YaCool) to improve PrEP uptake and support PrEP adherence.
62644747|NCT05661448|EXPERIMENTAL|MetaCognitive Training|MCT, developed by Drs. Moritz (co-applicant) and Woodward (PI), is based in the theoretical foundations of CBT, but targets the biases underlying symptoms rather than symptoms directly. MCT includes eight modules targeting common cognitive errors and reasoning biases in schizophrenia that have, through decades of research, been shown to contribute to delusions (e.g., jumping to conclusions). MCT will be offered to groups of up to 8 participants over 12 sessions of 45-60 min each (two per week) through Zoom Health. Session aims include raising participants' awareness of distortions and prompting them to critically reflect on, expand upon, and change their current repertoire of problem-solving strategies.
62644748|NCT03011203|EXPERIMENTAL|Ketone-ester drink|Oral intake - physical exercise
62074791|NCT05262426|EXPERIMENTAL|Standard PrEP Counseling and MES-PrEP|Participants in this arm will receive standard PrEP counseling, followed by one mHealth intervention (MES-PrEP) to improve PrEP uptake and support PrEP adherence.
62074792|NCT05262426|EXPERIMENTAL|Standard PrEP Counseling and Enhanced YaCool|Participants in this arm will receive standard PrEP counseling, followed by one mHealth intervention (Enhanced YaCool) to improve PrEP uptake and support PrEP adherence.
62074793|NCT05262426|ACTIVE_COMPARATOR|Standard PrEP Counseling|Participants in this arm will receive the standard PrEP counseling.
62074794|NCT02521324|EXPERIMENTAL|Immediate treatment (IT)|Subjects from this group will perform 2 weeks of DGB with the DGB2 system immediately after 1 week of baseline monitoring. All subjects will answer questionnaires pertaining to their sleep quality.
62074795|NCT02521324|ACTIVE_COMPARATOR|Wait list control (WLC)|The subjects from the WLC group will do the same (answer questionnaires and perform 2 weeks of DGB with the DGB2 system) at a 1 week delay.
62074796|NCT05039034||Low-risk Group|Low-risk Group is defined as the population with \<3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but without chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
62644749|NCT03011203|ACTIVE_COMPARATOR|Carbohydrate drink|Oral intake - physical exercise
62074797|NCT05039034||Mediate-risk Group|Mediate-risk Group is defined as the population with \<3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but meanwhile suffer from chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
62074798|NCT05039034||High-risk Group|High-risk Group is defined as the population with ≥3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), or population with history of stroke or/and transient ischemic attack.
62074799|NCT03018743||dapoxetine treatment group|Consecutive patients who seek medical treatment for PE will be enrolled in the study.
62278764|NCT02653222|EXPERIMENTAL|Renal sympathicolysis|"The patient will have:~1. Ambulatory Blood Pressure Monitoring~2. Magnetic Resonance Angiography~3. Blood test~4. Renal sympathicolysis~5. Ambulatory Blood Pressure Monitoring~6. Magnetic Resonance Angiography"
61978741|NCT04758819|NO_INTERVENTION|Control group|Embryo selection according to Day 5/6 usual morphological criteria (Istanbul consensus)
62074800|NCT04166929|EXPERIMENTAL|Haplo-stem cell transplant followed by NK infusion|"Haplo stem cell transplant (from bone marrow or apheresis) is followed by a haplo-NK cell infusion (target dose ≥1\*106/kg b.w.) at day 7.~Unstimulated haplo-NK cells are collected through apheresis Mononuclear cells are then subjected to a preliminary negative selection of CD3+ cells and to a subsequent positive selection of CD56+ cells. CD3 negative/CD56 positive cells are infused"
62074801|NCT04166929|ACTIVE_COMPARATOR|Haplo-stem cell transplant|Patients in this arm receive standard haplo stem cell transplant (from bone marrow or apheresis) transplant without subsequent NK cell infusion.
62074802|NCT01288781|EXPERIMENTAL|Acetazolamide|Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
62074803|NCT01288781|PLACEBO_COMPARATOR|Placebo|Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
62074804|NCT02013973|EXPERIMENTAL|AMH-group|The patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
62074805|NCT02013973|NO_INTERVENTION|Non-AMH-group|The patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC
62278765|NCT04154501|PLACEBO_COMPARATOR|Cohort 1 Placebo|Oral Placebo Capsule
62278766|NCT04154501|EXPERIMENTAL|Cohort 1 Drug|25 mg Oral Capsule
62278767|NCT04154501|PLACEBO_COMPARATOR|Cohort 2 Placebo|Oral Placebo Capsule
62278768|NCT04154501|EXPERIMENTAL|Cohort 2 Drug|50 mg Oral Capsule
62278769|NCT04154501|PLACEBO_COMPARATOR|Cohort 3 Placebo|Oral Placebo Capsule
62278770|NCT04154501|EXPERIMENTAL|Cohort 3 Drug|100 mg Oral Capsule
62278771|NCT04154501|PLACEBO_COMPARATOR|Cohort 4 Placebo|Oral Placebo Capsule
62278772|NCT04154501|EXPERIMENTAL|Cohort 4 Drug|300 mg Oral Capsule
62278773|NCT04154501|PLACEBO_COMPARATOR|Cohort 5 Placebo|Oral Placebo Capsule
62278774|NCT04154501|EXPERIMENTAL|Cohort 5 Drug|450 mg Oral Capsule
62278775|NCT04154501|PLACEBO_COMPARATOR|Cohort 6 Placebo|Oral Placebo Capsule
62278776|NCT04154501|EXPERIMENTAL|Cohort 6 Drug|600 mg Oral Capsule
62278777|NCT04154501|PLACEBO_COMPARATOR|Cohort 7 Placebo|Oral Placebo Capsule
62278778|NCT04154501|EXPERIMENTAL|Cohort 7 Drug|800 mg Oral Capsule
62644750|NCT05765877|EXPERIMENTAL|WX-0593|The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 2 years. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
62644751|NCT06207409|EXPERIMENTAL|PARTS-SUD Arm|The Program for Alleviating and Reducing Trauma, Stress and Substance Use (PARTS-SUD) is a 12-week, Internal Family Systems-based, group intervention with 6 individual clinical sessions on a biweekly basis.
62644752|NCT02735564|EXPERIMENTAL|RYGB|Bariatric Surgery:Roux-en-y
62278779|NCT04154501|PLACEBO_COMPARATOR|Cohort 9 Placebo|Oral Placebo Capsule
62278780|NCT04154501|EXPERIMENTAL|Cohort 9 Drug|1000 mg Oral Capsule
62278781|NCT04154501|EXPERIMENTAL|Cohort 8 Fasted|Participant will take 300 mg Oral Capsule in a fasting state, and then fed state.
62278782|NCT04154501|EXPERIMENTAL|Cohort 8 Fed|Participant will take 300 mg Oral Capsule in a fed state, and then fasting state.
62278783|NCT04213859|EXPERIMENTAL|Virtual Reality Exposure Therapy (VRET)|"1. st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~2. nd stage: During the week prior to treatment, participants will complete a brief measure of emotion-related variables every evening at a fixed time (08:00 pm).~3. rd stage: Participants will receive therapy for fear of flying using a Virtual Reality (VR) simulator. Therapy sessions will be held once a week during 4 weeks. Participants will complete a brief measure of emotion-related variables at a random time during the 12 hours before the therapy session at a random time during the 12 hours after the therapy session. This will occur for every therapy session.~4. th stage: After treatment, participants will complete measures of fear of flying and emotional variables."
62644753|NCT02735564|EXPERIMENTAL|SG|Bariatric Surgery: Sleeve Gastrectomy
62644754|NCT02735564|PLACEBO_COMPARATOR|Control|BMI matched control
62644755|NCT03416439|EXPERIMENTAL|intervention arm|lifestyle intervention program carried out by trained professionals
62644756|NCT03416439|NO_INTERVENTION|control arm|standard, unstructured information given by the family physicians
62644757|NCT02646969|ACTIVE_COMPARATOR|Formula regimen 1|"Product Control from enrollment to transition phase 1 (blinded administration), followed by open label administration for 2 months.~Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old"
62644758|NCT02646969|ACTIVE_COMPARATOR|Formula regimen 2|Product Test 1 from enrollment to transition phase 1 (blinded administration) Product Control for 2 months(open label) Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old
62644759|NCT02646969|NO_INTERVENTION|Reference group|Infants fed HM exclusively through at least 4 months of age. Once breastfeeding is over and if wished Infant will receive Product test 2 until 1 year old followed by the commercial follow-up formula
62644760|NCT01458067|EXPERIMENTAL|Part 1|GSK2636771 single dose and then daily dosing after approximately 1 week
62644761|NCT01458067|EXPERIMENTAL|Part 2|GSK2636771 single dose and then daily dosing starting on Day 4
62278784|NCT04213859|NO_INTERVENTION|control|"1. st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~2. nd stage: During five weeks no therapy will be administered. Participants will fill questionnaires as follows: During the first week, participants will complete emotional measures every evening at a fixed time (08:00 pm)~3. rd stage: During each of the following 4 weeks, participants will complete two emotional measures during a 24 hour period.~4. th stage: Participants will complete measures of fear of flying and emotional variables."
62278785|NCT06240910|EXPERIMENTAL|Neurodynamics|Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per \~3-4 s. The participants rested for 60 s between each exercise. The total duration of the interventions was approximately 10 min.).The whole treatment session on a single day will be of 40-60 minutes of duration (involving both aerobic exercise + neurodynamics) 3. times a week for 6 weeks according to the American diabetes association, accumulating a minimum of 150 minutes/week.
62278786|NCT06240910|EXPERIMENTAL|Aerobic training|Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
62278787|NCT04363372|EXPERIMENTAL|MRx-4DP0004|Patients receiving standard of care will add MRx-4DP0004 to their treatment. MRx-4DP0004 is taken as 2 capsules, twice a day for 14 days. Daily dose is 4 x 10\^9 to 4 x10\^10 colony forming units.
62278788|NCT04363372|PLACEBO_COMPARATOR|Placebo|Patients receiving standard of care will also take 2 placebo capsules, twice a day for 14 days.
62644762|NCT01458067|EXPERIMENTAL|Part 3|GSK2636771 daily dosing
62644763|NCT04433104|EXPERIMENTAL|Treatment (UC-MSC trasnplatation)|1 x 10\^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure
62644764|NCT04433104|OTHER|control arm|drug therapy according to Vietnamese MOHS procedure
62644765|NCT04501250|EXPERIMENTAL|Rinsulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
62644766|NCT04501250|ACTIVE_COMPARATOR|Humulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
61978742|NCT04758819|EXPERIMENTAL|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts: CTTEB group|Trophectoderm cells will be analyzed by NGS. Culture media will also be stored for further non-invasive chromosomal testing. Embryo selection will be done according to international guidelines (www.pgdis.org; Newsletter May 27, 2019).
61978743|NCT06294964|EXPERIMENTAL|sleep education group|
61978744|NCT06294964|NO_INTERVENTION|routine management group|
62644767|NCT01917279|ACTIVE_COMPARATOR|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle.
62644768|NCT01917279|EXPERIMENTAL|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
62644769|NCT04277208||Arthroscopic Rotator Cuff Repair|
62278789|NCT02810028|EXPERIMENTAL|ACT + Standard Medical Care (SMC)|This consists of 4 self-guided psycho-education modules supported by weekly telephone contact with a health professional trained in Acceptance and Commitment Therapy (ACT). Standard medical care will be provided as usual.
62278790|NCT02810028|NO_INTERVENTION|Standard Medical Care (SMC)|All participants will receive SMC. As such, they will receive all the treatment and support they would otherwise receive outside of a research trial including a personalised assessment from the physiotherapist.
62278791|NCT04749069|EXPERIMENTAL|Continuous infusion of remifentanil|In continuous infusion group of patients, remifentanil was infused at a dose of 0.1 µg/kg/min and the additional bolus dose of 0.1 µg/kg was given if required. Before start of the operation, in both groups of patients, intravenous remifentanil at a bolus dose of 0.1 µg/kg was administered slowly in a duration of 60 seconds.
62644770|NCT02204917|EXPERIMENTAL|Comparative performance of ceVUS & VCUG|Contrast enhanced Voiding Urosonography (ceVUS) will be performed with the intravesical administration of 0.1%-0.5% OPTISON / normal saline solution. The exact OPTISON dose (ml) that will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. Voiding Cystourethrography (VCUG) exam will be subsequently performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
62644771|NCT02366416|EXPERIMENTAL|Exercise training|12 weeks of one hour exercise training twice weekly
62644772|NCT01741077||pregnant women|pregnant women taking 1 mg folic acid;
62644773|NCT01741077||non-pregnant women|non-pregnant women taking 0mg folic acid;
62644774|NCT01741077||non-pregnant women 2|non-pregnant women taking 1 mg folic acid
62644775|NCT01741077||non-pregnant women 3|non-pregnant women taking 5 mg folic acid
62644776|NCT03460678|OTHER|Pemetrexed Arm|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)
62644777|NCT03460678|OTHER|Erlotinib Arm|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)
62644778|NCT02221752|EXPERIMENTAL|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
62278792|NCT04749069|EXPERIMENTAL|Patient-controlled sedoanalgesia (PCSA) of remifentanil|In PCSA group of patients, remifentanil was given by bolus PCSA using a pump (Pain Management Provider, Abbott Laboratories and Eczacibasi-Baxter, Ireland). In PCSA group of patients, remifentanil infusion was at a dose of 0.05 µg/kg, a bolus dose of 0.1 μg/kg with a lock-out time of three minutes.
62644779|NCT02221752|EXPERIMENTAL|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate \[60 mg elemental iron\]) and the other with 0.40 mg folic acid from enrollment to delivery.
62644780|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
62644781|NCT05260814|NO_INTERVENTION|Control|Scaling and root planing and oral hygiene instructions with use of manual tools
62644782|NCT05260814|EXPERIMENTAL|Experimental|Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
62644783|NCT03052777|EXPERIMENTAL|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
62644784|NCT03052777|NO_INTERVENTION|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
62644785|NCT02915939|EXPERIMENTAL|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
62644786|NCT02915939|NO_INTERVENTION|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
62278793|NCT01980472|EXPERIMENTAL|bevacizumab, carboplatin and paclitaxel|bevacizumab, carboplatin and paclitaxel
61978745|NCT01770379|EXPERIMENTAL|Secukinumab 75 mg|Secukinumab 75 mg s.c.
62644787|NCT05702008|NO_INTERVENTION|Control Group|The participants in this study arm were administered no intervention.
62644788|NCT05702008|EXPERIMENTAL|Test Group|The participants in this arm were administered the following intervention: The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
62644789|NCT04595058|ACTIVE_COMPARATOR|EUSDB-LAMS|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent . Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.~EUSDB-LAMS (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent)"
62644790|NCT04595058|EXPERIMENTAL|EUSDB-LAMS-Pigtail|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stents without coaxial plastic stent. Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.~In this arm, a double pigtail through the lumen apposing metal stent will be inserted as an axis-orienting stent.~EUSDB-LAMS-Pigtial (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent through LAMS)"
62644791|NCT04646382|PLACEBO_COMPARATOR|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
62644792|NCT04646382|EXPERIMENTAL|Intervention|Garlic concentrated extract. Onion concentrated extract. Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
61978746|NCT01770379|EXPERIMENTAL|Secukinumab 150 mg|Secukinumab 150 mg s.c.
62074806|NCT03307915|EXPERIMENTAL|Group 1: Ad26.Mos4.HIV + MVA-Mosaic/Placebo|Participants will receive adenovirus serotype 26-Mosaic 4 -Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5\*10\^10 virus particles (vp) as intramuscular (IM) injection at Weeks 0 and 12 (1 injection) followed by modified Vaccinia Ankara-Mosaic (MVA-Mosaic) 10\^8 Plaque-forming unit (pfu) and placebo as IM injection at Weeks 24 and 36 (2 injections).
62644793|NCT03980548||CABG patients|
62644794|NCT03980548||PAD patients|
62644795|NCT03980548||Healthy volunteers|
62278794|NCT01131195|ACTIVE_COMPARATOR|Arm A: bevacizumab and paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle. Both medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug is given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion.
62644796|NCT03980548||Patients with CAD|
62644797|NCT03220841|ACTIVE_COMPARATOR|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
62644798|NCT03220841|EXPERIMENTAL|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
62644799|NCT02793986|EXPERIMENTAL|dexmedetomidine sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h.
62456052|NCT04104568|EXPERIMENTAL|iSupport for dementia - European-Portuguese version|Access, for 3 months, to an online self-help training and support program: iSupport for dementia - European-Portuguese version. The e-program offers information, skills training and support for informal caregivers of people with dementia. It comprises five modules, including twenty-three lessons on dementia and caregiver support. In line with good practices on digital engagement, the education plan can be personalized by the caregiver. This means that it can be adjusted to the person's availability and lessons can be selected according to particular needs. Each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques including psycho-education, behavioral activation, cognitive reframing, relaxation and antecedent-behavior-consequence (ABC) analysis.
62644800|NCT02793986|EXPERIMENTAL|propofol sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
62644801|NCT01577797|EXPERIMENTAL|CBT-based text messages - Week 1 or 3|One week CBT-based text messages followed by a 1-week washout period (Week 2)
62644802|NCT01577797|PLACEBO_COMPARATOR|Placebo text messages - Week 3 or 1|
62644803|NCT00569452|EXPERIMENTAL|A|
62644804|NCT00569452|EXPERIMENTAL|B|
62644805|NCT00717145|EXPERIMENTAL|1|One risedronate 20 mg DR tablet taken following an overnight fast, followed by a 4-hour fast.
62074807|NCT03307915|EXPERIMENTAL|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV, 5\*10\^10 vp as IM injection at Weeks 0 and 12 (1 injection) followed by both Ad26.Mos4.HIV 5\*10\^10 vp plus Clade C gp140 (125 microgram \[mcg\]) plus Mosaic gp140 (125 mcg) with aluminum phosphate adjuvant or an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36 (2 injections).
62074808|NCT03307915|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive 0.9 percent (%) saline as IM injection at Weeks 0, 12 (one injection) and at Week 24, 36 (two injections).
62074809|NCT03118544||Patients undergoing CTO PCI|Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.
62074810|NCT04328363|EXPERIMENTAL|Intervention|The intervention will be carried out by primary care nurses over eight visits: baseline visit and follow-up visits which take place 15 days, 1, 2, 4, 6, 9, and 12 months after baseline with a final visit evaluation at 18 months. The intervention will be based on the social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles in people with prediabetes. The content of the intervention proposed is based on the NHS and it will be carried out at three levels (individual, group and community) to facilitate the patient empowerment and promotion of healthy lifestyles with a positive orientation using the community resources.
62278795|NCT01131195|ACTIVE_COMPARATOR|Arm B: bevacizumab, cyclophosphamide and capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily. All three medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug(s) is (are) given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion
62278796|NCT00394849|EXPERIMENTAL|suture one tonsillar fossa|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
62278797|NCT00394849|NO_INTERVENTION|One side not sutured|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
62278798|NCT01472887|EXPERIMENTAL|SAR3419|All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation
62278799|NCT01116544|EXPERIMENTAL|AMES therapy with EMG biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of EMG activity the subject is able to generate in the hand. This study will examine whether AMES therapy combined with EMG biofeedback can restore hand opening to plegic stroke subjects.
62644806|NCT00717145|EXPERIMENTAL|2|One risedronate 20 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
62644807|NCT00717145|EXPERIMENTAL|3|One risedronate 35 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
62644808|NCT00717145|EXPERIMENTAL|4|One risedronate 35 mg IR tablet taken following an overnight fast, 30 minutes before ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
62644809|NCT01204034|OTHER|Inuvair|
62074811|NCT04328363|NO_INTERVENTION|Control|The Control group will receive routine standard care.
62074812|NCT05045911|EXPERIMENTAL|Endoscopic Barbed-clips Suturing|Patients will be closed the mucosal defect after colorectal ESD using Endoscopic Barbed-clips Suturing.
62074813|NCT01447849|ACTIVE_COMPARATOR|Lubiprostone 24 mcg Twice a day|Both controls and patients with chronic constipation will receive 1 week of therapy with lubiprostone and one week of placebo.
62074814|NCT01447849|PLACEBO_COMPARATOR|Placebo|Both controls and patients with chronic constipation will receive placebo pills twice daily for one week in cross over design
62074815|NCT03381508||The study population|"The study population corresponds to patients with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device.~Intervention: Brizzy continuous positive pressure device"
62074816|NCT02831179|EXPERIMENTAL|Treatment (capecitabine, temozolomide, veliparib)|Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
62644810|NCT02749409|ACTIVE_COMPARATOR|Control group|The control group will be given Morphine prn after admission
62278800|NCT01116544|EXPERIMENTAL|AMES therapy with Torque biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of torque (force) the subject is able to generate in the hand during the movement. This study will examine whether AMES therapy combined with Torque biofeedback can restore hand opening to plegic stroke subjects.
62644811|NCT02749409|EXPERIMENTAL|Experimental group|the experimental group will be given parecoxib after admission by intravenous method every 12 hours for 4 days. Then Morphine agent will be given prn usage
62644812|NCT03717597|EXPERIMENTAL|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
62644813|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
62074817|NCT03434236|PLACEBO_COMPARATOR|Placebo|Patients will be taking placebo twice daily for 5 days prior to surgery. The placebo has a similar taste and smell as the active supplement.
62074818|NCT03434236|EXPERIMENTAL|low dose Lipinova (30mL)|Patients will take 15 mL Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
62644814|NCT03226795|EXPERIMENTAL|interventional arm|
62644815|NCT05182944|EXPERIMENTAL|After 2 cycles of neoadjuvant therapy,non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel +Cisplatin and Camrelizumab maintenance treatment）
62074819|NCT03434236|EXPERIMENTAL|high dose Lipinova (60mL)|Patients will take 30mL of Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
62074820|NCT01706965|EXPERIMENTAL|Kuvan|Kuvan once-daily dosing initiated with 10mg/kg for the first week followed by 20mg/kg for the remaining weeks of the study
62074821|NCT01706965|ACTIVE_COMPARATOR|Multivitamin|Daily multivitamin tablet
62074822|NCT01406717|EXPERIMENTAL|SPIL1033|
62074823|NCT01406717|PLACEBO_COMPARATOR|Placebo|
62278801|NCT02475655|EXPERIMENTAL|Arm A: Ruxolitinib|Participants received ruxolitinib twice a day for 5 weeks. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
62074824|NCT05542732|EXPERIMENTAL|Single group|Each participant wore one CW2 sensor attached to the back of the wrist with a wrist band. Additionally, each participant wore a reference pulse oximeter (Nellcor PM10) attached to the middle finger of the ipsilateral hand. This enabled the comparison of the paired results of the CW2 sensor and reference pulse oximeter equipment for SpO2 measurements at different oxygen saturation levels. Twelve subjects of the 24 participants received an arterial catheter in the contralateral radial artery for exvivo SaO2 determination by CO-oximetry and in order to define the final accuracy of CW2 for SpO2 measurement.
62074825|NCT06488794|ACTIVE_COMPARATOR|colistin group|"Colistin group:~In the Nebulized Colistin (NC) group, 30 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base), (maximum 750000 IU) will be nebulized daily, divided into two doses. The lyophilisate of colistin will be reconstituted as follows: 1 million of IU is reconstituted in 3 mL of sterile 0.9% saline. The adequate volume is then withdrawn and administered immediately to mechanically ventilated patients via a nebulizer until the nebulized solution container becomes empty.~The nebulization is administered from day 3 of invasive mechanical ventilation, twice daily for 3 days or until extubation (whichever occurres first).~\*12500 International Units of colistimethate sodium = 1 mg colistimethate sodium = 0.4 mg of colistin base."
62074826|NCT06488794|PLACEBO_COMPARATOR|Control group|Nebulization of 3 ml of 0.9% saline twice a day for 3 days from day 3 of invasive mechanical ventilation will be administered via a nebulizer until the nebulized solution container becomes empty.
62644816|NCT05182944|ACTIVE_COMPARATOR|non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
62644817|NCT05182944|EXPERIMENTAL|pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
62644818|NCT05182944|ACTIVE_COMPARATOR|pCR patients adjuvant treatment(BSC)|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）
62644819|NCT04950400|EXPERIMENTAL|Carrelizumab + chemotherapy + apatinib|
62644820|NCT01669434|EXPERIMENTAL|ACEI continuation|Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
62644821|NCT01669434|EXPERIMENTAL|ACEI omission|Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.
62644822|NCT00697099|EXPERIMENTAL|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
62644823|NCT00697099|ACTIVE_COMPARATOR|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
62644824|NCT00869960|EXPERIMENTAL|Antiretroviral therapy|Healthy volunteers received two doses of Tenofovir, Emtricitabine, Atazanavir and Ritonavir administered twice (on day 6 - 10 and day 20 - 25 after day of Follicular phase); with pharmacokinetic measurements at 6 - 10 days after menses and then again at day 20 - 25 after menses.
62644825|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
62644826|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
62644827|NCT02801331|EXPERIMENTAL|Stochastic Vibrotactile Stimulation (SVS)|Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 48-hrs post birth. SVS will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed).
62644828|NCT02801331|NO_INTERVENTION|Treatment as Usual (TAU)|Infants randomized to this arm will be enrolled within 48-hours post birth and receive treatment as usual (TAU)- standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed). Infants will not receive any SVS.
62644829|NCT01762488|ACTIVE_COMPARATOR|Renal denervation by ablation of the renal arteries|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.
62644830|NCT01762488|SHAM_COMPARATOR|Control|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.
62644831|NCT04650737|ACTIVE_COMPARATOR|Group A (single shot,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine ;ultrasound guided ESPB
62644832|NCT04650737|ACTIVE_COMPARATOR|Group B (continous infusion,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs;ESPB
62644833|NCT02280434|ACTIVE_COMPARATOR|CBP-307|Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
62074827|NCT04243889|EXPERIMENTAL|NEOX Cord 1K applied fetoscopically|Patients intending to undergo open in-utero spina bifida repair, will be offered to be screened for an alternative minimally invasive approach. All eligible pregnant mothers' fetuses within the trial will receive NEOX Cord 1K® as a spinal cord cover to close the developmental defect. In some cases, at the discretion of the Neurosurgeon, NEOX Cord 1K® may be required to cover the skin. All eligible subjects meeting all inclusion criteria but none of the exclusion criteria may be enrolled.
62074828|NCT01427335|PLACEBO_COMPARATOR|saline|0.9% saline intravenous infusion
62074829|NCT01427335|EXPERIMENTAL|calcium|Calcium intravenous infusion
62074830|NCT02701751|OTHER|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
62074831|NCT01594177|EXPERIMENTAL|Treatment arm|Afatinib-Trastuzumab (6 weeks) followed by Afatinib\*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). \*only 11 weeks.
62074832|NCT03948425|EXPERIMENTAL|Stroke|Clinical suspicion of hyperacute stroke (6 hours after onset of symptoms):Intervention 'spectral CT'
62074833|NCT05172830||Group/Cohort|Ovation Alto™ Abdominal Stent Graft System Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
62074834|NCT03752762|NO_INTERVENTION|Standard Care|Participants will receive standard health care services provided by the Health Secretary
62074835|NCT03752762|EXPERIMENTAL|SPOON behavioral change strategy+SQ-LNS|Participants will receive SQ-LNS supplement from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits and group sessions. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
62074836|NCT01698658|EXPERIMENTAL|Diagnostic (SoftVue ultrasound tomography)|Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.
62644834|NCT02280434|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose or once daily dose of matching placebo for 28 days.
62074837|NCT02913521|EXPERIMENTAL|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
62074838|NCT02913521|ACTIVE_COMPARATOR|Voltaren Gel|Apply 4 g of gel to the knee four times a day
62074839|NCT02913521|PLACEBO_COMPARATOR|Placebo|Apply 4 g of gel to the knee four times a day
62644835|NCT01326871|EXPERIMENTAL|ALT-801 0.04 mg/kg with Cisplatin and Gemcitabine|
62074840|NCT04221750|EXPERIMENTAL|Lifestyle Therapy plus Metformin|Diet-induced weight loss and Exercise Training plus Metformin 1500 mg daily
62278802|NCT02475655|NO_INTERVENTION|Arm B: No Study Treatment|Participants did not receive any study treatment. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
62278803|NCT04545255|ACTIVE_COMPARATOR|active|A shockwave device with a probe that conveys shockwave energy
62278804|NCT04545255|SHAM_COMPARATOR|sham|A shockwave device with specially designed probe which has the shockwave energy blocked
62278805|NCT00982904|EXPERIMENTAL|Fexinidazole|
62278806|NCT00982904|PLACEBO_COMPARATOR|Placebo|
62278807|NCT02219139|OTHER|ESTA abutment Roxolid|"One study abutment per patient will be placed. After healing for 6 to 7 weeks, patients will be asked to stop oral hygiene at the study site for 2 weeks.~Sulcus fluid and plaque samples will be taken at the abutment site at several visits before and during abdication of oral hygiene.~The study finishes with biopsy visit. Afterwards a regular abutment will be placed and the patients will be treated according to the standard protocol of the clinic to obtain their final restoration."
62644836|NCT01326871|EXPERIMENTAL|ALT-801 0.06 mg/kg with Cisplatin and Gemcitabine|
62644837|NCT01326871|EXPERIMENTAL|ALT-801 0.06 mg/kg with Gemcitabine|
62278808|NCT05412771|EXPERIMENTAL|Main cohort|This is a single-arm study. Samples are collected from consenting donors undergoing surgery for medical purposes.
62278809|NCT00648167|EXPERIMENTAL|KRX-0502 (ferric citrate)|All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
62644838|NCT00546442|PLACEBO_COMPARATOR|2|Placebo of metformine 850-2550 mg/daily for 48 weeks
62644839|NCT00546442|EXPERIMENTAL|1|Metformine 850-2550 mg/daily for 48 weeks
62074841|NCT04221750|PLACEBO_COMPARATOR|Lifestyle Therapy plus Placebo|Diet-induced weight loss and Exercise Training plus Placebo
62074842|NCT04221750|ACTIVE_COMPARATOR|Healthy lifestyle plus Metformin|Healthy lifestyle and Metformin 1500 mg daily
62074843|NCT02710760|NO_INTERVENTION|Control|Households in the control group receive no special treatment.
62074844|NCT02710760|EXPERIMENTAL|Adoption Encouragement Treatment|"Households in the Adoption Encouragement Treatment group were visited between March and April 2015 and offered child nutrition focused adoption encouragement. Both the male household head and the primary female caregiver were invited to attend these meetings (though the household head is the primary target), where the nutritional benefits of Quality Protein Maize (QPM) adoption for children were emphasized along with the agronomic properties. In addition, the fact that only small amounts of QPM are necessary to nourish children was highlighted and small seed bag sizes were offered. During the adoption encouragement visit, we offered the option to order up to three 2 kg bags of QPM for free."
62074845|NCT02710760|EXPERIMENTAL|Consumption Encouragement Treatment|In addition to receiving the Adoption Encouragement Treatment, households in the Consumption Encouragement Treatment group received additional information, targeted to the caregiver, and tools for separating Quality Protein Maize and targeting it to young children in the household in August 2015. They will additionally receive further guidance in February 2016.
62074846|NCT04961736||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
62644840|NCT05423834||TAF-treated Chronic hepatitis B patients|Chronic hepatitis B patients that treated with Tenofovir alafenamide
62644841|NCT05423834||ETV-treated Chronic hepatitis B patients|Chronic hepatitis B patients that treated with Entecavir
62644842|NCT01364155|EXPERIMENTAL|600 mg LIM-0705 BID for 28 days|
62644843|NCT01364155|PLACEBO_COMPARATOR|Placebo LIM-0705 for 28 days|
62644844|NCT06202846|EXPERIMENTAL|Turner syndrome patients|Patients with a Turner syndrome confirmed by karyotype.
62074847|NCT04961736||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
62074848|NCT04757467|ACTIVE_COMPARATOR|Standard physiotherapy neuro-rehabilitation|Control Group: Patients included in the control group will receive standard physiotherapy neurorehabilitation protocols.
62074849|NCT04757467|EXPERIMENTAL|Repetition-CIMT|In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr
62074850|NCT04757467|EXPERIMENTAL|Hour-CIMT|The task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours.
62074851|NCT01705275|EXPERIMENTAL|ONO-8539 BID|ONO-8539
62074852|NCT01705275|PLACEBO_COMPARATOR|Placebo BID|0mg
62074853|NCT05471258|EXPERIMENTAL|Experimental: monopolar dielectric diathermy|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.
62074854|NCT05471258|PLACEBO_COMPARATOR|Placebo|"The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions."
62074855|NCT04513457||Liver resection and Neoadjuvant chemotherapy|Liver resection and Neoadjuvant chemotherapy
62456053|NCT04104568|ACTIVE_COMPARATOR|Education-only e-book|The control group will receive a minimal education-only intervention, consisting on an e-book. The manual contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
62074856|NCT04513457||Liver resection and Adjuvant chemotherapy|Liver resection and Adjuvant chemotherapy
62074857|NCT04513457||Liver resection, Neoadjuvant and Adjuvant chemotherapy|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy
62074858|NCT04513457||Liver resection|Liver resection
62074859|NCT03414697|OTHER|Control group|Routine rehabilitation treatments
62074860|NCT03414697|EXPERIMENTAL|Intravenous UC-MSCs group|Injection of UC-MSCs via the peripheral vein.
62074861|NCT03414697|EXPERIMENTAL|Intrathecal UC-MSCs group|Injection of UC-MSCs via the intrathecal route.
62074862|NCT03414697|EXPERIMENTAL|Intranasal UC-MSCs group|Injection of UC-MSCs via the nasal route.
62074863|NCT01807221|EXPERIMENTAL|Finerenone(BAY94-8862)[2.5mg] + Placebo|Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
62074864|NCT01807221|EXPERIMENTAL|Finerenone (BAY94-8862)[5mg] + Placebo|Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
62456054|NCT02559583||Participants with Chronic Lymphocytic Leukemia (CLL)|This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor.
62074865|NCT01807221|EXPERIMENTAL|Finerenone (BAY94-8862)[7.5mg] + Placebo|Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
62074866|NCT01807221|EXPERIMENTAL|Finerenone (BAY94-8862)[10mg] + Placebo|Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
62074867|NCT01807221|EXPERIMENTAL|Finerenone (BAY94-8862)[15mg] + Placebo|Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
62456055|NCT02559583||Participants with Multiple Myeloma (MM)|This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor.
62644845|NCT04862338|EXPERIMENTAL|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
62644846|NCT05100888|EXPERIMENTAL|Theta-burst rTMS|Theta-burst repetitive transcranial magnetic stimulation
62644847|NCT05100888|SHAM_COMPARATOR|Sham stimulation|Sham stimulation of the same location
62644848|NCT04836741|EXPERIMENTAL|Micro Hand S robot-assisted surgery|This group is consisted of 40 cases performed using the Micro Hand S robot by one single surgeon for rectal cancer
62644849|NCT04836741|ACTIVE_COMPARATOR|Laparoscopic surgery|This group is consisted of 65 cases performed using the laparoscope by one single surgeon for rectal cancer
62644850|NCT03474224||FloTrac patients|patients belong to this group will be managed with a stroke volume target hemodynamic protocol
62644851|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)|
62644852|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)|
62074868|NCT01807221|ACTIVE_COMPARATOR|Eplerenone [25 mg] + Placebo|Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
62278810|NCT04812626|EXPERIMENTAL|Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;|Group A: 1 ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline. 5 units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units,covering an area of 0.5X0.5 cm2 of scar. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs( maximum dose=2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
62456056|NCT02559583||Participants with Non-Hodgkin's lymphoma (NHL)|This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor.
62456057|NCT04270305|EXPERIMENTAL|orientation|Orientation training with GRAIL
62456058|NCT04270305|ACTIVE_COMPARATOR|walking|Walking training with GRAIL
62456059|NCT01310296|OTHER|Radiolabeled Lofexidine Oral Solution|Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.
62456060|NCT01310296|EXPERIMENTAL|Lofexidine Intravenous Solution|Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.
62456061|NCT03220919|EXPERIMENTAL|Weight-based|Weight-based insulin insulin titration regimen
62456062|NCT03220919|PLACEBO_COMPARATOR|Glucose level-based|Glucose level-based insulin titration regimen
62074869|NCT05693493|EXPERIMENTAL|Intervention group|Device: Proprioceptive knee brace Subjects will use proprioceptive knee brace for 6 weeks post-op, in addition to basic management such as physiotherapy.
62074870|NCT05693493|NO_INTERVENTION|Control group|No device. Subjects will receive basic management such as physiotherapy.
62074871|NCT01898520|ACTIVE_COMPARATOR|Sativex|Oromucosal spray containing delta-9-tetrahydrocannabinol (THC) (27 mg/mL):cannabidiol (CBD) (25 mg/mL). Each 100 μL spray to the sub-lingual or oral mucosa delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
62278811|NCT04812626|EXPERIMENTAL|Group B: Intralesional triamcinolone acetonide and 5-fluorouracil (5-FU) combination|"Group B: 1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU.~Injection Method: Five units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. (maximum dose 2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks), Post treatment follow up: at 12 weeks."
62456063|NCT03392909|EXPERIMENTAL|Intravenous Gentamicin|Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.
62456064|NCT03614520|EXPERIMENTAL|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
62456065|NCT03614520|EXPERIMENTAL|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
62456066|NCT03556566|EXPERIMENTAL|V3-OVA treatment arm|Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
62456067|NCT01568164|EXPERIMENTAL|Device Treatment|Treatment with the investigational device.
62456068|NCT02906709|EXPERIMENTAL|Omarigliptin 25 mg|Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
62644853|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)|
62644854|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)|
62644855|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)|
62644856|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)|
62456069|NCT02906709|EXPERIMENTAL|Placebo→Omarigliptin 25 mg|Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
62644857|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)|
62644858|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)|This cohort will enroll Northeast Asian participants.
62644859|NCT04126200|ACTIVE_COMPARATOR|Belantamab mafodotin monotherapy cohort expansion|
62644860|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)|
62644861|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)|
62644862|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3)|
62644863|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4)|
62644864|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5)|
62644865|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)|
62644866|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)|
62644867|NCT04126200|EXPERIMENTAL|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)|This cohort will enroll Northeast Asian participants.
62644868|NCT04267497|EXPERIMENTAL|Nebulized Amphotericin B|Amphotericin B.
62456070|NCT02820142||Bacteremia with Sepsis group|Patients aged 20 years or older with a diagnosis of bacteremia will be eligible for inclusion in the study.
62644869|NCT04267497|PLACEBO_COMPARATOR|Nebulized Placebo|Sterile water for injection.
62644870|NCT00733967|PLACEBO_COMPARATOR|Placebo|Matching oral placebo capsules as control.
62644871|NCT00733967|ACTIVE_COMPARATOR|Varenicline|See assigned interventions.
62644872|NCT05804812|NO_INTERVENTION|control group|"At the beginning of the study, data collection tools Personal Information Form and Psychological Well-Being Scale will be applied to the control group.~No intervention will be made in the control group. Measurement tools will be applied for the post-test."
62278812|NCT02600507|EXPERIMENTAL|Lumateperone 28 mg (ITI-007 40 mg tosylate)|Lumateperone 28 mg (ITI-007 40 mg tosylate) administered orally as capsules once daily for 6 weeks
62456071|NCT01819623|EXPERIMENTAL|Non-pharmacological therapy|This group will be supervised nonpharmacologic therapy
62644873|NCT05804812|EXPERIMENTAL|experimental group|Inclusion criteria for the research: Faculty of Health Sciences, to study in the 2022-2023 academic spring semester, to have been diagnosed with migraine, to be young and to volunteer to participate in the research. Exclusion criteria from the study; Not studying at the Faculty of Health Sciences and not volunteering to participate in the research. The application and control group will be determined on random.org among the group that constitutes the sample of the study. Laughter therapy sessions will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. At the end of two months, the Personal Information Form and Psychological Well-Being Scale will be administered again to both the application group and the control group.
62074872|NCT01898520|PLACEBO_COMPARATOR|Placebo|Oromucosal spray containing ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum number of daily sprays was 12.
62456072|NCT01819623|NO_INTERVENTION|Control|This group will receive the standard treatment for mild cognitive impairment
62456073|NCT00424203|EXPERIMENTAL|Myocet, Endoxan|
62644874|NCT06012136|EXPERIMENTAL|Participants Receiving VH4004280|
62644875|NCT06012136|PLACEBO_COMPARATOR|Participants Receiving Placebo|
62644876|NCT06012136|EXPERIMENTAL|Participants Receiving VH4011499|
62644877|NCT03639168|EXPERIMENTAL|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
62644878|NCT02631005|EXPERIMENTAL|Walk With Ease Participants|"Participants will receive a copy of the Walk With Ease workbook. This workbook provides guidance on walking safety and on how to start and maintain a regular walking program. It is designed to help participants increase their physical activity over a six-week period. Participants will complete self-reported outcomes questionnaires before and after completion of the program."
62644879|NCT06029764|EXPERIMENTAL|experimental group|The study will enroll patients with lumbar degeneration undergoing 1-2 level intervertebral fusion, and for patients with asymptomatic and non-instability intervertebral discs adjacent to the operative level with vacuum signs, extended one-level interbody fusion will be performed.
62644880|NCT06029764|NO_INTERVENTION|control group|The control group underwent intervertebral fusion only at the responsible segment.
62644881|NCT05828992||Person at risk|Survey personalised for people living at risk of developing Huntington's Disease, meaning they have a parent diagnosed with HD but the person themselves have not undertaken a genetic test.
62644882|NCT05828992||Person HD gene positive asymptomatic|Survey personalised for people that tested positive in their predictive genetic test but have not been yet diagnosed with clinical HD (manifest HD).
62644883|NCT05828992||Person HD gene positive symptomatic|Survey personalised for people that tested positive in their predictive genetic test and have been diagnosed with clinical HD (manifest HD).
62456074|NCT04041570|EXPERIMENTAL|Group 1: cAd3-EBO S vaccine (1x10^10 PU)|cAd3-EBO S vaccine (1x10\^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
62644884|NCT05828992||Informal caregiver|Survey personalised for people caring for another person diagnosed with HD.
62644885|NCT05828992||Former informal caregiver|Survey personalised for people that have cared for another person diagnosed with HD in the last 3 years.
62644886|NCT00721799|EXPERIMENTAL|FLT PET scan|"Subjects receive 2 18F-Fluorothymidine PET scans~* Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)~* Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)"
62644887|NCT02930785|EXPERIMENTAL|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62644888|NCT03925896|EXPERIMENTAL|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
62644889|NCT02551458|EXPERIMENTAL|Arm A: Systematic surgery|
61978747|NCT01770379|PLACEBO_COMPARATOR|Placebo|Placebo patients will be re-randomized 1:1 to secukinumab 75 or 150mg s.c. (non-responders at Week 16 will be re-assigned to new treatment at Week 16; responders at Week 16 will be re-assigned to new treatment at Week 24)
61978748|NCT05328882||ERAF after PFA|Patients with an early recurrence after pulsed field ablation of paroxysmal atrial fibrillation.
62644890|NCT02551458|EXPERIMENTAL|Arm B: Surveillance and rescue surgery in cases of resectable|
62644891|NCT03961399|ACTIVE_COMPARATOR|biventricular stimulation (BiV) group|patients with Abbott Medical® CRT implanted with only biventricular stimulation (BiV).
62644892|NCT03961399|EXPERIMENTAL|SyncAVTM stimulation group|patients with Abbott Medical® CRT implanted and SyncAVTM stimulation activated
62644893|NCT03037840||cancer patients|Low intensity amplitude-modulated RF EMFs
62644894|NCT03037840||healthy participators|Low intensity amplitude-modulated RF EMFs
62644895|NCT02381236|EXPERIMENTAL|G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
62644896|NCT01352078||Non Healing Ulcer|
62644897|NCT01352078||Hidradenitis suppurativa|
62278813|NCT02600507|EXPERIMENTAL|Lumateperone 42 mg (ITI-007 60 mg tosylate)|Lumateperone 42 mg (ITI-007 60 mg tosylate) administered orally as capsules once daily for 6 weeks
62644898|NCT01631448|NO_INTERVENTION|Control|Patients fron this group do not receive the fibrin sealant
62644899|NCT01631448|ACTIVE_COMPARATOR|Fibrin group|Patients from this group will receive the fibrin sealant
62644900|NCT01846858||CO2 Laser|
62644901|NCT01846858||Monopolar energy|
62644902|NCT05489575|EXPERIMENTAL|Active CPAP (Daytime Study)|CPAP at 8, 10, or 12 cm H2O is applied for up to 2 hours while supine and awake.
62644903|NCT05489575|SHAM_COMPARATOR|Sham CPAP (Daytime Study)|Sham CPAP is applied for up to 2 hours while supine and awake.
62278814|NCT02600507|PLACEBO_COMPARATOR|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
62278815|NCT03159312|EXPERIMENTAL|Assigned Interventions|20 individuals undergoing bariatric surgery and post surgery normal indications with moderate exercise program
62456075|NCT04041570|EXPERIMENTAL|Group 2: cAd3-EBO S vaccine (1x10^11 PU)|cAd3-EBO S vaccine (1x10\^11 PU) administered IM with needle and syringe in a volume of 1 mL
62644904|NCT05489575|EXPERIMENTAL|Active CPAP (Overnight Study)|CPAP at 8, 10, or 12 cm H2O is applied for up to 9 hours during the night.
62644905|NCT05489575|SHAM_COMPARATOR|Sham CPAP (Overnight Study)|Sham CPAP is applied for up to 9 hours during the night.
62644906|NCT05489575|ACTIVE_COMPARATOR|Sleeping in a head-up tilt position (Overnight Study)|Sleeping with the bed tilted head-up by 10 degrees for up to 9 hours during the night.
61978749|NCT05328882||no ERAF after PFA|Patients without an early recurrence after pulsed field ablation of paroxysmal atrial fibrillation.
62644907|NCT03471052|EXPERIMENTAL|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)
62644908|NCT03471052|NO_INTERVENTION|Sham procedure|Endoscopy will be performed under conscious sedation and all BarrX RFA equipment will be set up in room. A sound recording of the BarrxTM RFA device will be played (a distinct bell sound that is emitted from the generator) during the procedure.
62644909|NCT03684408|OTHER|RFID and Wire Localization|Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader.
62644910|NCT03684408|EXPERIMENTAL|RFID Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
62278816|NCT03159312|NO_INTERVENTION|Control group|Control group: 23 individuals undergoing bariatric surgery and post surgery normal indications without exercise program
62456076|NCT04913909|ACTIVE_COMPARATOR|Dentoblis™ group|In Probiotic group; Dentoblis™, as a test lozenge, contains 4 billion CFU/g S. salivarius M18 strain probiotic isolated from a healthy oral microbiota, has been utilized one lozenge a day for 30 days.
62456077|NCT04913909|PLACEBO_COMPARATOR|Placebo group|The placebo was indistinguishable in form, size, color, smell and taste from the probiotic lozenge, but contained no bacteria and utilized one lozenge a day for 30 days . Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code.
62456078|NCT02164786||Acute severe disease|
62644911|NCT03684408|ACTIVE_COMPARATOR|Wire Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
62644912|NCT05715619|PLACEBO_COMPARATOR|Placebo|Dose is 1mL of placebo given orally three times a day for 7 days (Phase 1) or 14 days (Phase 2a)
62644913|NCT05715619|ACTIVE_COMPARATOR|VRELysin™|Dose is 1mL of bacteriophage preparation given orally three times a day for 7 days (Phase 1) or 14 days (Phase 2a)
62644914|NCT02791269|EXPERIMENTAL|HBeAg Negative Participants|HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
62644915|NCT02791269|EXPERIMENTAL|HBeAg Positive Participants|HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
62278817|NCT04813029|EXPERIMENTAL|Straight Leg Raise|Patients perform straight leg raise maneuver at the end of High-resolution Manometry test
62278818|NCT04428177|EXPERIMENTAL|Intrvascular Lithotripsy|Calcified coronary lesions will be treated with intrvascular lithotripsy
62278819|NCT04428177|ACTIVE_COMPARATOR|Standard therapy|Standard treatment of calcified coronary lesions: cutting, scoring or non-compliant balloon predilatation or rotational atherectomy
62644916|NCT03736486||Type 2 Diabetes|Male and female adults of Hispanic and/or Latino heritage with an established diagnosis of Type 2 diabetes.
62644917|NCT00909844|EXPERIMENTAL|Triptorelin|
62644918|NCT01848171|ACTIVE_COMPARATOR|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
62644919|NCT01848171|NO_INTERVENTION|blank|No intervention
62644920|NCT00716612|PLACEBO_COMPARATOR|2|PO Placebo QD
62644921|NCT00716612|EXPERIMENTAL|1|PO Coenzyme Q 10 QD
62074873|NCT03121534|EXPERIMENTAL|Ibrutinib, Nivolumab and Blinatumomab|"2 (8week) cycles of ibrutinib, nivolumab and blinatumomab. 9 (4week) cycles ibrutinib and nivolumab. Maintenance with ibrutinib monotherapy until disease progression following completion of nivolumab.~Ibrutinib treatment will begin cycle 1, day 1 at 420mg/d. Nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.~blinatumomab continuous IV infusion, starting day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week blinatumomab treatment-free interval. Hospitalization in cycle 1 on day 15-31 (first 17 days of blinatumomab therapy). Blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28, followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days. Blinatumomab in cycle 2 will be administered at a dose of 112 mcg/day from day 1-28."
62074874|NCT01830881|PLACEBO_COMPARATOR|placebo-cherry syrup and ibuprofen|5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
62074875|NCT01830881|ACTIVE_COMPARATOR|Midazolam and ibuprofen|5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
62074876|NCT03748979|EXPERIMENTAL|Cohort A1; TAK-925 (Dose Level A1)|TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
62074877|NCT03748979|EXPERIMENTAL|Cohort A2; TAK-925 (Dose Level A2)|TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074878|NCT03748979|EXPERIMENTAL|Cohort A3; TAK-925 (Dose Level A3)|TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074879|NCT03748979|EXPERIMENTAL|Cohort A4; TAK-925 (Dose Level A4)|TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074880|NCT03748979|EXPERIMENTAL|Cohort A5; TAK-925 (Dose Level A5)|TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62278820|NCT00063401|EXPERIMENTAL|1|Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
62278821|NCT04852445||Stroke|We will include: 60 patients aged 18 years or older with clinical symptoms of hemispheric ischemic stroke due to occlusion of a large cerebral blood vessel, onset within 48 hours and NIHSS of 1 or more;
62456079|NCT00003313|EXPERIMENTAL|Arm 1|Radiation therapy and chemotherapy + Amifostine
62456080|NCT00003313|ACTIVE_COMPARATOR|Arm 2|Radiation therapy and chemotherapy alone
62456081|NCT01668888||Apparently Helathy Subjects|
62456082|NCT06266962|ACTIVE_COMPARATOR|1% Atropine drops|
62644922|NCT04785417|NO_INTERVENTION|CONTROL GROUP|received conventional occupational therapy program
62644923|NCT04785417|EXPERIMENTAL|STUDY GROUP|received conventional occupational therapy program in addition to using tablet
62644924|NCT05685121|EXPERIMENTAL|Apollo Neuro Group|The group will use the Apollo Neuro device daily for six weeks as an adjunct to their standard treatment plan.
62644925|NCT05685121|NO_INTERVENTION|Standard Treatment Group|The group will follow their standard treatment plan.
62074881|NCT03748979|EXPERIMENTAL|Cohort A6; TAK-925 (Dose Level A6)|TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62644926|NCT01386606|EXPERIMENTAL|Androxal 6.25 mg|Androxal 6.25 mg/day
62644927|NCT01386606|EXPERIMENTAL|Androxal 12.5 mg|Androxal 12.5 mg/day
62644928|NCT01386606|EXPERIMENTAL|Androxal 25 mg|Androxal 25 mg/day
62644929|NCT01386606|ACTIVE_COMPARATOR|AndroGel|AndroGel 5G topical testosterone
62644930|NCT04267978|EXPERIMENTAL|glioblastoma|
62644931|NCT04267978|EXPERIMENTAL|lower-grade glioma|
62644932|NCT02067858|OTHER|Stereotactic Radiosurgery|"3 fractions x 20 Gy 4 fractions x 12 Gy~Lesion dependent"
62644933|NCT03664843||The chemotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
62644934|NCT03664843||The radiotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
62278822|NCT04852445||Controls|30 healthy controls, age- and sex- matched with stroke study population
62644935|NCT03664843||The targeted therapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
62644936|NCT00850291||1|Electrosurgical vessel sealing device
62644937|NCT00850291||2|traditional surgical methods:stitches and ligations
62644938|NCT01911949|EXPERIMENTAL|Single shot femoral nerve block|Ultrasound guided Femoral Nerve Block-40ml of bupivacaine 0.5% with epinephrine
62644939|NCT01911949|PLACEBO_COMPARATOR|Placebo femoral nerve block|Sterile normal saline solution
62644940|NCT01899911|EXPERIMENTAL|Vital Signs Patch (VSP)|Infrared and Red absorbance measurement on chest
62278823|NCT04852445||Carotid arterectomy after stroke|10 patients undergoing carotid endarterectomy within 30 days after stroke
62456083|NCT06266962|ACTIVE_COMPARATOR|Epinephrine|
62644941|NCT05359471|ACTIVE_COMPARATOR|HIV with NAFLD|HIV Nonalcoholic fatty liver disease patients
62644942|NCT05359471|ACTIVE_COMPARATOR|HIV without NAFLD|HIV without Nonalcoholic fatty liver disease patients
62644943|NCT05619328|EXPERIMENTAL|Vitamin B combination tablet (B1, B6, B12)|
62644944|NCT05619328|PLACEBO_COMPARATOR|Placebo tablet|
62644945|NCT02960412|EXPERIMENTAL|furosemide|furosemide 10mg (1mL) IV push for one dose
62644946|NCT02960412|PLACEBO_COMPARATOR|placebo|normal saline 1mL IV push for one dose
62644947|NCT03242317|EXPERIMENTAL|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
62644948|NCT03599596|ACTIVE_COMPARATOR|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
62644949|NCT03599596|ACTIVE_COMPARATOR|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
62644950|NCT04968236|EXPERIMENTAL|Deep dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a deep dry needling technique to the latent trigger point and make 10-12 incisions.
62644951|NCT04968236|EXPERIMENTAL|Superficial dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a superficial dry needling technique to the latent trigger point. Once the needle is placed in the subcutaneous cellular tissue, we manipulate the needle by twisting it until an unpleasant response is provoked. We keep the needle for 5 minutes
62644952|NCT04968236|EXPERIMENTAL|Passive muscle stretching|With the patient positioned in the supine position, the pelvis stabilized with a strap and the lower extremity where we are going to apply the rectus femoris muscle stretch placed outside the table, we perform a passive stretching technique, increasing hip extension and knee flexion until the patient feels the tension. The position is held for 60 seconds.
62644953|NCT00758446|EXPERIMENTAL|A|BLX-028914 50 mg
62074882|NCT03748979|PLACEBO_COMPARATOR|Part A (Cohorts A1-A6); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in healthy participants.
62074883|NCT03748979|EXPERIMENTAL|Cohort B1; TAK-925 (Dose Level B1)|TAK-925, Dose Level B1, once daily for up to 7 days in participants with narcolepsy.
62074884|NCT03748979|EXPERIMENTAL|Cohort B2; TAK-925 (Dose Level B2)|TAK-925, Dose Level B2, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074885|NCT03748979|EXPERIMENTAL|Cohort B3; TAK-925 (Dose Level B3)|TAK-925, Dose Level B3, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074886|NCT03748979|EXPERIMENTAL|Cohort B4; TAK-925 (Dose Level B4)|TAK-925, Dose Level B4, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074887|NCT03748979|PLACEBO_COMPARATOR|Part B (Cohorts B1-B4); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
62644954|NCT00758446|EXPERIMENTAL|B|BLX-028914 15 mg
62644955|NCT00758446|PLACEBO_COMPARATOR|C|Placebo
62644956|NCT02739126|ACTIVE_COMPARATOR|Thick USS (1.7mm) with use of additional aspiration needle|
62644957|NCT02739126|ACTIVE_COMPARATOR|Thin USS (1.4mm)|
62644958|NCT02932436|EXPERIMENTAL|Empagliflozin|10 mg Empagliflozin daily per os for 12 weeks
62644959|NCT02932436|EXPERIMENTAL|Placebo|amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
62644960|NCT05540145||SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody|SOX: Oxaliplatin+S-1
62074888|NCT03748979|EXPERIMENTAL|Cohort C1; TAK-925 (Dose Level C1)|TAK-925, Dose Level C1, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62644961|NCT04735614|EXPERIMENTAL|ThoraxBelt|Received ThoraxBelt after the surgery. Standard care for pain management will be the same as the Standard Care Arm.
62644962|NCT04735614|NO_INTERVENTION|Standard care|Standard care with IV PCA and on-request oral painkiller.
62644963|NCT05601349|OTHER|Usual Implementation of the Clinical Practice Guideline|In this group, all participants (cluster) have access to the clinical practice guideline that has been sent to the office responsible for implementing the guideline in the hospital. Due to the characteristics of the intervention in the control group it does not work as a placebo or a sham intervention.
62644964|NCT05601349|ACTIVE_COMPARATOR|Tele-education strategy|Tele-educational program consisting of a virtual course with recommendations from the CPG of lower limb amputees, with three modules: Perioperative, rehabilitation and prostheses
62644965|NCT06472947||Patient with kidney transplant|Included are adult (\> 18 years) patients with kidney transplant where the indication for a kidney biopsy has been set during clinical routine
62644966|NCT02762032|ACTIVE_COMPARATOR|Arm 1|15 subjects will be randomized to receive PrimaVie Herbal Supplement 125 mg to take twice daily for 14 weeks.
62278824|NCT04852445||Carotid endarterectomy for asymptomatic stenosis|3 patients without stroke undergoing carotid endarterectomy for asymptomatic carotid stenosis.
62644967|NCT02762032|ACTIVE_COMPARATOR|Arm 2|15 subjects will be randomized to receive PrimaVie Herbal Supplement 250 mg to take twice daily for 14 weeks.
62644968|NCT02762032|PLACEBO_COMPARATOR|Arm 3|15 subjects will be randomized to receive placebo (control supplement) to take twice daily for 14 weeks.
62074889|NCT03748979|EXPERIMENTAL|Cohort C2; TAK-925 (Dose Level C2)|TAK-925, Dose Level C2, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074890|NCT03748979|PLACEBO_COMPARATOR|Part C (Cohorts C1-C2); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
62278825|NCT03631823||Radio/Chemotherapy group|The participants in this group receive the concurren radio/chemotrherapy
62278826|NCT03631823||Radio/ without chemotherapy group|The participants in this group receive the radiotherapy but without chemotrherapy
62074891|NCT03748979|EXPERIMENTAL|Cohort A'1; TAK-925 (Dose Level A'1)|TAK-925, Dose Level A'1, single dose in healthy participants.
62074892|NCT03748979|EXPERIMENTAL|Cohort A'2; TAK-925 (Dose Level A'2)|TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
62074893|NCT04772690|EXPERIMENTAL|BAL|A resource-orientered, individual and group-based intervention addressing balance in everyday life, activities and QoL among people with chronic or advanced cancer.
62278827|NCT03631823||Healthy volunteer group|The volunteers for control group
62278828|NCT02723825|PLACEBO_COMPARATOR|Less or equal to 2mm|the residual displacement is less than or equal to 2mm
62278829|NCT02723825|PLACEBO_COMPARATOR|Between 2-4mm|the residual shift is between 2-4mm, manual reset once again, as still between 2-4mm
62644969|NCT01268995|EXPERIMENTAL|Cyclosporine A|Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
62074894|NCT05438615|EXPERIMENTAL|Corneal Refractive Therapy - spherical|Subjects eyes shall be treated with two pair of the proximity control lenses in Paragon paflufocon D material by the qualified clinical investigator. The subjects shall be randomized for which of the two designs are applied first. The first pair shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure. The second design shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure.
62074895|NCT05438615|EXPERIMENTAL|Corneal Refractive Therapy - aspherical|Subjects eyes shall be treated with two pair of the proximity control lenses in Paragon paflufocon D material by the qualified clinical investigator. The subjects shall be randomized for which of the two designs are applied first. The first pair shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure. The second design shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure.
62278830|NCT02723825|ACTIVE_COMPARATOR|Greater than 4mm|the residual displacement is greater than 4mm
62278831|NCT03260569|ACTIVE_COMPARATOR|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
62278832|NCT03260569|PLACEBO_COMPARATOR|Placebo|Nitrogen only, administered once during first 36 hours following admission
62278833|NCT05872087|ACTIVE_COMPARATOR|Dexmedetomidine|will receive nebulized Dexmedetomidine 3 µg/kg
62278834|NCT05872087|ACTIVE_COMPARATOR|Midazolam|will receive nebulized Midazolam 0.3 mg/kg
62278835|NCT03349814||Appendicitis group|"Patients, who undergo a diagnostic laparoscopy, which because of the operative findings leads to an appendectomy, and the appendix is found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed."
62278836|NCT03349814||Normal appendix group|"Patients, who undergo a diagnostic laparoscopy, that either because of the operative findings (mesenteric lymphadenitis or normal diagnostic laparoscopy) does not lead to appendectomy, or leads to appendectomy, but the appendix is not found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.~OR~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed, but is not found to be inflamed in the pathology report."
62278837|NCT04010669|ACTIVE_COMPARATOR|Study group|The study group includes participants who will receive somatostatin postoperatively (after liver resection).
62278838|NCT04010669|PLACEBO_COMPARATOR|Control group|The control group includes participants who will receive placebo (a 24 hours infusion of 1000ml Normal Saline solution 0.9%) postoperatively (after liver resection).
62456084|NCT03304600|EXPERIMENTAL|Active stimulation|10 sessions (1 per day during 2 week) of active tDCS stimulation
62278839|NCT03915873||vWB patients|
62278840|NCT03915873||control|
62456085|NCT03304600|SHAM_COMPARATOR|Sham Stimulation|10 sessions (1 per day during 2 week) of sham stimulation
62644970|NCT01268995|ACTIVE_COMPARATOR|Tacrolimus|Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
62644971|NCT03712280|EXPERIMENTAL|Group A: MNK6106 2 grams (tid)|Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
62644972|NCT03712280|EXPERIMENTAL|Group B: MNK6106 4 grams (bid)|Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
62456086|NCT03493737||HaH (Hospital-at-Home)|Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
62456087|NCT03493737||OH (Outpatient Hospital)|Bortezomib is always injected at Outpatient hospital
62456088|NCT06413225||Prospective|All patients for whom the decision has been made to have the Synergy Disc system implanted and give informed consent will be enrolled in this study, following country-specific requirements.
62644973|NCT03712280|EXPERIMENTAL|Group C: MNK6106 4 grams (tid)|Participants receive 4 tablets of MNK6106 tid for 5 days
62644974|NCT03712280|ACTIVE_COMPARATOR|Group D: Rifaximin 550 mg (bid)|Participants receive 1 tablet of rifaximin bid for 5 days
62644975|NCT04447716|EXPERIMENTAL|Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)|Patient receive venetoclax PO QD on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) SC on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62278841|NCT03823612|EXPERIMENTAL|GC tooth mousse|Drug: GC tooth mousse it contains complex of Casein Phosphopeptide,Amorphous Calcium Phosphate ( CPP-ACP ) other name: Tooth Mousse (Bio-available calcium and phosphate, without fluoride)
62278842|NCT03823612|ACTIVE_COMPARATOR|clinpro tooth creme|"it contains 0.21% Sodium Fluoride, Anti-Cavity Paste is an advanced formula containing an innovative tri-calcium phosphate ingredient~other name:0.21% w/w Sodium Fluoride Anti-Cavity Paste with Tri-Calcium Phosphate"
62278843|NCT05442619|EXPERIMENTAL|Portable therapeutic baby nest group|Blood will be drawn from newborns using the portable therapeutic baby nest.
62278844|NCT05442619|ACTIVE_COMPARATOR|Control group|Blood collection from newborns will be done according to the clinical routine.
62278845|NCT03790280|EXPERIMENTAL|Standard of Care PLUS HFO|Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1).
62278846|NCT03790280|NO_INTERVENTION|Standard of Care|Surgery is tailored by standard ECoG alone (arm 2).
62278847|NCT01989000|ACTIVE_COMPARATOR|Neoadjuvant radiochemotherapy|Patients elected for neoadjuvant radiochemotherapy undergo DWI-MRI, DCE-MRI (Gadobutrol),T2\*-MRI and \[F-18\]HX4 PET/CT imaging within two weeks before start of the chemoradiation and again after radiochemotherapy (Gemcitabine/Radiotherapy), within two weeks before surgery (Pancreaticoduodenectomy).
62278848|NCT01989000|ACTIVE_COMPARATOR|Primary Surgery|Patients elected for primary surgery undergo DWI-MRI, DCE-MRI (Gadobutrol),T2\*-MRI and \[F-18\]HX4 PET/CT imaging within two weeks before surgery (Pancreaticoduodenectomy).
62278849|NCT00658242||I|Subjects having Craniofacial surgery
62278850|NCT01487915|ACTIVE_COMPARATOR|GCb|Gemcitabine plus Carboplatin
62278851|NCT01487915|EXPERIMENTAL|GemOx|Gemcitabine plus Oxaliplatin
62456089|NCT06413225||Retrospective|Patients who have previously received the Synergy Disc system in the last ten years are eligible for inclusion in the retrospective data collection; a waiver of consent, or an informed consent, for the retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations.
62074896|NCT03893864|EXPERIMENTAL|Intervention Group (CoQ10)|Runner athletes \> 50 years old, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions
62074897|NCT03893864|ACTIVE_COMPARATOR|Control Group|Runner athletes \> 50 years old with the same characteristics as the Experimental arm, served as control group, maintaining the training sessions Both groups were evaluated before and after the month of intervention or no intervention.
62278852|NCT05699174|ACTIVE_COMPARATOR|Standard of Care PO (oral) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to standard of care PO (oral) antibiotics for up to 6 weeks post hospitalization. No medications will be provided by the study. Study participants will be prescribed their oral antibiotics by their treating physician and the specific type will depend on their infection diagnosis. Medications will be obtained using health insurance and/or resources available at the treating facility therefore the mode of antibiotics utilized as standard of care will vary across participating sites. Sites will follow their standard of care delivery for antibiotics and the study will defer to this standard.
62074898|NCT04410328|EXPERIMENTAL|Participants receiving Dipyridamole and Aspirin|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally plus standard care. Participants will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), 2 times daily starting on the day of enrollment for a total of 2 weeks.
62074899|NCT04410328|OTHER|Participants receiving standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
62074900|NCT06381817|EXPERIMENTAL|Haplo-cord HCT|Patients enrolled in this arm will receive a coinfusion of cord blood unit in addition to a typical haploidentical hematopoietic cell transplantation
62074901|NCT06381817|ACTIVE_COMPARATOR|Haplo-HCT|Patients enrolled in this arm will receive a typical haploidentical hematopoietic cell transplantation
62074902|NCT03154840|EXPERIMENTAL|Eutropin 4IU|
62074903|NCT03154840|EXPERIMENTAL|Eutropin AQ 12IU|
62074904|NCT03154840|EXPERIMENTAL|Eutropin Pen 36IU|
62644976|NCT05263362||STARLINGS study population|The study population consists of breast cancer patients who were treated with breast conserving therapy (BCT) at one of the four participating hospitals (Erasmus MC, Albert Schweitzer hospital, Maasstad hospital and Franciscus hospital Gasthuis and Vlietland), for non-metastatic, histological proven invasive breast cancer or DCIS between 2016 and 2020 (at time of inclusion in 2022 respectively 6 to 2 years after treatment), and subsequently received adjuvant (whole breast) irradiation (WBI), with or without boost, at the Erasmus MC as part of their BCT.
62074905|NCT04713085|ACTIVE_COMPARATOR|Sacral Neuromodulation|"Sacral neuromodulation is surgically implanted within two surgeries:~1. Implantation of the final electrode (tined-lead electrode): This electrode is implanted to neuronal fibers of S3/4. Both sides are tested intraoperatively, the side with a sufficient response at lower intensity levels is finally implanted. Stimulation is conducted via an external pulse generator.~2. Implantation of the internal pacemaker system 4 weeks after the electrode's implantation.~Stimulation parameters: Single current, frequency 15Hz, duration 210μs. Stimulation intensity is individually determined beyond the pain threshold (adjustable amplitude between 0-10mA, depending on the intraoperative response).~Start point of clinical evaluation is time of implantation of tined lead electrode.~Medical and behavioral therapy is to be continued as started before intervention."
62456090|NCT05822232|ACTIVE_COMPARATOR|FreeStyle Libre 2|"Subjects randomized to Group 1: FreeStyle Libre 2 will wear two FreeStyle Libre CGM sensors for 12-14 days three times over a 12-week (3 month) period. They will have two sensors inserted under their skin:~FreeStyle Libre 2 sensor with display on, meaning they will be able to see their blood sugar values on the mobile application or a reader.~FreeStyle Libre Pro sensor is used without mobile application or reader. This sensor is place as a backup in case the information is missing from the Libre 2 sensor."
62278853|NCT05699174|ACTIVE_COMPARATOR|Standard of Care Intravenous (IV) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to intravenous (IV) antibiotics for up to 6 weeks post hospitalization. No medications will be provided by the study. Study participants will be prescribed their IV antibiotics by their treating physician and the specific type will depend on their infection diagnosis. Medications will be obtained using health insurance and/or resources available at the treating facility therefore the mode of antibiotics utilized as standard of care will vary across participating sites. Sites will follow their standard of care delivery for antibiotics and the study will defer to this standard.
62644977|NCT03581006||Intervention Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.~This intervention group will undergo technology based monitoring and behavioral participation in a dietary and exercise program with the intent of weight loss and compliance with a low-calorie Mediterranean diet."
62644978|NCT03581006||Control (Usual care) Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.~This group will receive no dietary or behavioral intervention. They will continue usual care with their home physicians."
62278854|NCT00035594|PLACEBO_COMPARATOR|Placebo|Breast cancer patients receiving docetaxel chemotherapy and placebo.
62278855|NCT00035594|EXPERIMENTAL|Pegfilgrastim|Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
62278856|NCT01676285|ACTIVE_COMPARATOR|Metoprolol succinate|Metoprolol succinate
62278857|NCT01676285|PLACEBO_COMPARATOR|Placebo|Placebo
62278858|NCT01676285|NO_INTERVENTION|Follow up|Group without cirrhotic cardiomyopathy, only follow up without randomization.
62278859|NCT05625776|EXPERIMENTAL|Pain Stimulus|Capsaicin combined with heat applied to intact skin
62278860|NCT05625776|ACTIVE_COMPARATOR|Distractor Somatosensory Stimulus|Sensory transcutaneous electrical nerve stimulation (TENS) applied to intact skin
62278861|NCT05625776|NO_INTERVENTION|No Stimulus|Nothing applied to skin
62278862|NCT06549959|EXPERIMENTAL|Telitacicept Pre-filled Injection 80mg|
62278863|NCT06549959|EXPERIMENTAL|Telitacicept Freeze-dried powder Injection 80mg|
62278864|NCT05422872||Croatia|Twenty to twenty-five professionals assigned to Croatian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62278865|NCT05422872||Estonia|Twenty to twenty-five professionals assigned to Estonian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62278866|NCT05422872||Finland|Twenty to twenty-five professionals assigned to Finnish healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62278867|NCT05422872||Germany|Twenty to twenty-five professionals assigned to German healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62278868|NCT05422872||Israel|Twenty to twenty-five professionals assigned to Israeli healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62278869|NCT05422872||Lithuania|Twenty to twenty-five professionals assigned to Lithuanian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62456091|NCT05822232|ACTIVE_COMPARATOR|Point of Care (POC) Self-Monitoring of Blood Glucose (SMBG) testing|Subjects randomized to Group 2: Point of Care (POC) Self-Monitoring of Blood Glucose (SMBG) testing will wear one FreeStyle Libre Pro CGM sensor without using the mobile application or reader (blinded). These subjects will have the one sensor inserted under their skin but you will not see sugar values on the CGM. Subjects will wear the CGM for 12-14 days three times over a 12-week (3 month) period but will not use the CGM to monitor and control their blood sugar. Instead, they will monitor their sugar values by the standard method of fingerstick before each meal and at bedtime.
62644979|NCT04176913|EXPERIMENTAL|Anti-CD20 Allogeneic CAR-T Cell Therapy|An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
62644980|NCT03122795|EXPERIMENTAL|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
62278870|NCT05422872||Malta|Twenty to twenty-five professionals assigned to Maltese healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62644981|NCT04161391|EXPERIMENTAL|TPX-0046|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0046.~The food-effect sub-study determines the effect of food on a dose of TPX-0046 at the RP2D dose level.~The Phase 2 part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.~Phase 2 Cohorts:~* Cohort I (NSCLC + RET fusion, RET TKI Therapy Naive)~* Cohort II (NSCLC + RET fusion, RET TKI Therapy Pre-treated)~* Cohort III (MTC + RET mutation, RET TKI Therapy Naive)~* Cohort IV (MTC + RET mutation, RET TKI Therapy Pre-treated)~* Cohort V (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Naive)~* Cohort VI (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Pre-Treated)"
62644982|NCT03821961|EXPERIMENTAL|Metabolic surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
62644983|NCT05034549|NO_INTERVENTION|Control|
62644984|NCT05034549|EXPERIMENTAL|Noninvasive ventilation|
62644985|NCT04082052|EXPERIMENTAL|Single Session Intervention for Self-Dislike|A 30-45 minute intervention delivered in a web browser that focuses on reducing self-dislike using facts about the brain, testimonials from peers, and writing exercises.
62074906|NCT04713085|ACTIVE_COMPARATOR|Non-invasive Sacral Neuromodulation|"Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field by single current with a 15 Hz frequency for a duration of 210μs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).~Start point of clinical evaluation is start of external stimulation.~Medical and behavioral therapy is to be continued as started before intervention."
62644986|NCT04082052|PLACEBO_COMPARATOR|Single Session Intervention for Feelings Disclosure|A 30-45 minute intervention delivered in a web browser that focuses on encouraging feelings disclosure using facts about the brain, testimonials from peers, and writing exercises.
62644987|NCT03348605|OTHER|First setting ON|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality ON. The second time the gait analysis is performed in the OFF modality.
62644988|NCT03348605|OTHER|First setting OFF|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality OFF. The second time the gait analysis is performed in the ON modality.
62074907|NCT04621136|EXPERIMENTAL|Ripasudil eye drops|Ripasudil eye drops
62278871|NCT05422872||Portugal|Twenty to twenty-five professionals assigned to Portuguese healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
61978750|NCT05422014|EXPERIMENTAL|LCS Intervention|With Opioid Risk Education, patients will receive opioid education after completing the validated Opioid Risk Tool (ORT), a detailed substance abuse survey and mental health screening, and Naloxone education. Therapeutic Intervention will include the Community Resiliency Model CRM), progressive muscle relaxation, sound therapy. Clinical Pain Coordination will include directed referrals for complex needs, including mental health and substance use disorders, as needed. In addition to above mentioned 3 intervention components, all patients in the LCS intervention arm will also receive the current standard-of-care.
62278872|NCT05422872||Slovakia|Twenty to twenty-five professionals assigned to Slovakian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62278873|NCT05422872||Spain|Twenty to twenty-five professionals assigned to Spanish healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
62456092|NCT05886543|EXPERIMENTAL|control group|"this group includes 30 patients who have post burn inhalation injury will receive conventional chest physiotherapy for(15-20) minutes 3times/week and medical treatment for 4 weeks as a total period of treatment.~• computerized spirometer assessment before treatment are ( The following variables were measured: forced vital capacity (PVC%) and forced ·expiratory volume in one second (FEVl %) and peak expiratory flow (PEF %)and after one month"
62456093|NCT05886543|EXPERIMENTAL|study group|this group includes 30 patients who have post burn inhalation injury will receive pilates exercise in addition to their conventional chest physiotherapy for(15-20) minutes 3times/week and medical treatment for 4 weeks as a total period of treatment.omputerized spirometer assessment before treatment are ( The following variables were measured: forced vital capacity (PVC%) and forced ·expiratory volume in one second (FEVl %) and peak expiratory flow (PEF %)and after one month
62644989|NCT00646828||without PHA1|patients without mineralocorticoid receptor mutation
62644990|NCT00646828||PHA 1|patients with a rare disease, pseudohypoaldosteronism type 1, due to heterozygous inactivating mutations of the mineralocorticoid receptor
61978751|NCT05422014|NO_INTERVENTION|No LCS Intervention|Patients will receive the current standard-of-care for pain management in the aftermath of trauma, which includes: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
61978752|NCT02631226||Pregnant women colonized by resistant enterobacteria|
62644991|NCT05626569|EXPERIMENTAL|PD-1 combined with SBRT for metastatic lesions|Participants will receive anti-PD1 and SBRT to the metastatic lesions which are amenable to the delivery of SBRT after 4\~6 cycles of systemic chemotherapy and anti-PD-1. SBRT for the metastatic lesions shall be conducted within two months after the completion of systemic therapy. The prescription of SBRT is determined by the investigator and the BED is required to over 50Gy.
62644992|NCT04189016|ACTIVE_COMPARATOR|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
62278874|NCT05422872||Serbia|Twenty to twenty-five professionals assigned to Serbian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
61978753|NCT02506140|EXPERIMENTAL|Ticagrelor/ASA|Drugs: Ticagrelor and Acetylsalicylic acid.
62074908|NCT04466423|EXPERIMENTAL|Small group intervention|Those randomized to the immediate intervention arm will be asked to meet approximately every other week for 6 months, covering 12 sessions. We will ask each group to meet in a relatively private setting (e.g., a restaurant near campus or a reserved meeting room), rather than more public spaces (e.g. river room, cafeteria) where interruptions are more likely.
62074909|NCT04466423|PLACEBO_COMPARATOR|Control|"Participants randomized to Arm 2 (delayed intervention) will be wait listed to begin sessions 6 months after the start of the study. This participation will be optional."
62074910|NCT01488864|EXPERIMENTAL|Applied Relaxation (AR)|
62074911|NCT01488864|NO_INTERVENTION|Untreated Control Group (CG)|The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
62074912|NCT05765188||< 25 years|42 patients younger than 25 years at the time of loop electrosurgical excision procedure
62074913|NCT05765188||> 25 years|73 patients 25 years or older at the time of loop electrosurgical excision procedure
62278875|NCT05250700||Adults (40-70yrs)|
62644993|NCT04189016|PLACEBO_COMPARATOR|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
62644994|NCT04391257|OTHER|Main|gekoTM neuromuscular electrostimulation device (NMES) briefly used on patients with cardiac pacemakers to check if pacemakers detect the gekoTM electrical pulses as interference.
62644995|NCT04882696|NO_INTERVENTION|usual care with bare feet|patients will be treated barefoot during their stay
62644996|NCT04882696|EXPERIMENTAL|specific care with anti-slip socks|Patients in this group will wear non-slip socks
62644997|NCT00492297|EXPERIMENTAL|Sorafenib + Dacarbazine|Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
62644998|NCT01483118|ACTIVE_COMPARATOR|Cinnamon Extract Arm|PCOS patients receiving abstract of cinnamon
61978754|NCT02506140|ACTIVE_COMPARATOR|Clopidogrel/ASA|Drugs: Clopidogrel and Acetylsalicylic acid.
62074914|NCT05727033|ACTIVE_COMPARATOR|Intervention Group|"The intervention of training-participatory activity will last between 45 and 60 minutes, divided into theoretical training of 15-30 minutes followed by discussion training of 30 minutes. Based on the projection of the posters, photographs and the short film, the pupils will be asked to participate and work on the problem of STIs as well as possible solutions. The group techniques of photo-talk and presentation with a discussion using the short film will be used. Finally, the training includes Kahoot®, a tool for learning and reviewing concepts in a fun, quiz-like way. Four multiple-choice questions have been included. They will learn in a participatory way about STIs, risk practices, barrier methods and health resources to consult or go to in case of suspicion of contracting an STI.~For the activity, a sequence of drawings and signs has been designed to put STIs, their causes and how to prevent infection into context."
62074915|NCT05727033|SHAM_COMPARATOR|Control Group|"Following the indications of the Department of Education and the Health and School Programme, non specific training intervention will be carried out in the control group out during the study period."
62074916|NCT03862703|EXPERIMENTAL|Experimental group|PTSD Help intervention combined with care as usual.
62074917|NCT03862703|NO_INTERVENTION|Control group|Care as usual.
62278876|NCT04816812|OTHER|Exercise|In the intervention arm, a 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level.
62278877|NCT04816812|OTHER|Comparison|Comparison
62644999|NCT01483118|PLACEBO_COMPARATOR|Placebo Arm|PCOS patients receiving placebo capsules
62074918|NCT00785538|EXPERIMENTAL|IMC-A12|All participants will receive intravenous (I.V.) infusions of IMC-A12, with the dose depending on which cohort they are enrolled into. A minimum of three participants will be enrolled in each cohort. When all participants complete a cohort, dose escalation to the next cohort will occur.
62074919|NCT05136911|EXPERIMENTAL|Intervention Group|The intervention group will receive the standard care in the form of HTN Canada Booklet, advice to see their health care provider, urgent care or walk-in clinic and the Salt Intervention (Salt Intervention Manual, five weekly online modules and five weekly telephone calls.
62074920|NCT05136911|NO_INTERVENTION|Usual Care Group|All participants in the usual care group will receive the standard care in the form of HTN Canada Booklet, advice to see their health care provider, urgent care of walk-in clinic.
62074921|NCT01248962|EXPERIMENTAL|Standard 30-minute infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatin containing chemotherapy regimen.
62074922|NCT01248962|EXPERIMENTAL|extended 3-hour infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatincontaining chemotherapy regimen.
62074923|NCT04139447||Healthy subjects|
62074924|NCT01741064||PTH below target iPTH in CKD|iPTH at one year post transplantation below target range of iPTH by stage of CKD (KDOQI-guidelines).
62074925|NCT01741064||iPTH within target range of iPTH in CKD|iPTH at one year post transplantation within target range of iPTH by stage of CKD (KDOQI-guidelines).
62074926|NCT01741064||iPTH above target range of iPTH in CKD|iPTH at one year post transplantation above target range of iPTH by stage of CKD (KDOQI-guidelines).
62074927|NCT00557622|EXPERIMENTAL|paroxetine|Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved \[i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)\] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
62074928|NCT00557622|PLACEBO_COMPARATOR|placebo|placebo
62074929|NCT01440582|EXPERIMENTAL|Panobinostat + Bortezomib + Lenalidomide + Dexamethasone|"Induction Starting Doses: Lenalidomide 25 mg orally daily on days 1-14; Bortezomib 1.3 mg/m\^2 intravenous (IV) daily on days 1, 4, 8 and 11; Dexamethasone 20 mg orally daily on days 1, 2, 4, 5, 8, 9, 11, 12 and Panobinostat orally 10 mg on days 1, 3, 5, 8, 10 and 12. Induction therapy consists of 21 day cycle in Part A and 28 day cycle in Part B.~Symptom Questionnaire completed on day 1 of each cycle."
62074930|NCT04570345|EXPERIMENTAL|Ticagrelor monotherapy|Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)
62074931|NCT04570345|ACTIVE_COMPARATOR|Aspirin with P2Y12 receptor inhibitor|Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)
62074932|NCT06218134|EXPERIMENTAL|human Wharton's jelly-derived mesenchymal stem cells (EN001)|"* human Wharton's jelly-derived mesenchymal stem cells (EN001) dose of administration: 2.5x106 cells/kg~* method of adminstration: one-time, intravenous administration"
62074933|NCT03492619|ACTIVE_COMPARATOR|Non-Intensive Intervention|Three short group sessions that promote healthy lifestyles
62278878|NCT00540579|EXPERIMENTAL|Intervention|All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
62278879|NCT02337088|ACTIVE_COMPARATOR|30 seconds|For subjects in the 30 second arm, the umbilical cord will be clamped at 30 seconds after delivery.
62645000|NCT02984982|ACTIVE_COMPARATOR|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level \<100 milligrams per deciliter (mg/dL).
62645001|NCT02984982|EXPERIMENTAL|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
62278880|NCT02337088|EXPERIMENTAL|60 seconds|For subjects in the 60 second arm, the umbilical cord will be clamped at 60 seconds after delivery.
62278881|NCT04525105||Study group|wıth URGE INCONTINANCE
62278882|NCT04525105||Control group|not urge incontinance
62645002|NCT02048423|EXPERIMENTAL|Ketamine|Drug
62645003|NCT04566107|NO_INTERVENTION|Enhanced Usual Care|The enhanced usual care group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, individuals in the enhanced usual care group will receive the mobile health platform to record medications taken and BlueTooth devices to record physiologic measurements.
62278883|NCT04279015|ACTIVE_COMPARATOR|Conventional rehabilitation treatment|Conventional physiotherapy program, consisting of standardised active (exercise) and passive (hotpack, ultrasound, conventional TENS) physical therapy methods, was applied by the same physiotherapist.
62278884|NCT04279015|ACTIVE_COMPARATOR|Kinesio tape procedure|In addition to the conventional physiotherapy program Kinesio tape was performed every day of conventional treatment immediately after the session ended by the same physiotherapist.
62278885|NCT06175897|EXPERIMENTAL|surgical group|Undergoing DBS
62278886|NCT06175897|SHAM_COMPARATOR|control group|Undergoing non-DBS
62278887|NCT04873479|EXPERIMENTAL|test group|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
62278888|NCT04873479|OTHER|control group|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.2-0.3ug/kg,Etomidate 0.2-0.3mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.1-0.3ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
62278889|NCT03077568|EXPERIMENTAL|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
62278890|NCT03077568|NO_INTERVENTION|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
62278891|NCT04730154|EXPERIMENTAL|Pain Neuroscience Education (PNE) + Motivational Interviewing (MI)|Breast cancer survivors assigned to the experimental intervention will participate in 1 online PNE session followed by 3 PNE + MI sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format, allowing to individually tailor content to the patient's maladaptive beliefs and perceived injustice. After the first live session, breast cancer survivors will receive a perceived injustice-targeted PNE information leaflet that they need to read carefully at home.
62645004|NCT04566107|EXPERIMENTAL|mHealth|The mHealth group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Subjects receive BlueTooth devices to record physiologic measurements.
62645005|NCT04566107|EXPERIMENTAL|mHealth Plus|The mHealth group plus will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth plus group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Participants receive BlueTooth devices to record physiologic measurements. The m-Health Plus group will receive real-time virtual visits with a nurse practitioner/community health worker team. Virtual visits are similar to an office follow-up visit with an health care provider using Zoom technology to allow for face-to-face interaction with the patient.
62456094|NCT03634709|EXPERIMENTAL|Memory Flexibility Training (MemFlex)|The MemFlex programme has been adapted from the initial format addressing depression-related memory distortions to facilitate completion with individuals experiencing posttraumatic stress. The workbook and associated materials have also been translated from English to Farsi. The programme consists of one researcher-facilitated session and eight self-guided workbook-based sessions that train memory retrieval skills and are completed over a one month period.
62645006|NCT01244074|EXPERIMENTAL|biofeedback|
62645007|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
62645008|NCT06516575|EXPERIMENTAL|Cochlear implant participants|Participants with cochlear implants. Speech recognition testing: Listening to and repeating speech in the free field in a sound-attenuated booth. We track percent-correct scores for whole sentences and words within each sentence. Changes in the participant's pupil size will be monitored by an Eyelink eye tracker placed 50 cm from the eyes. Phasic pupil dilations are linked with experiment timing landmarks interpreted as changes in listening effort.
62645009|NCT06516575|ACTIVE_COMPARATOR|Typical-hearing controls|Typical-hearing controls. Speech recognition testing: Listening to and repeating speech in the free field in a sound-attenuated booth. We track percent-correct scores for whole sentences and words within each sentence. Changes in the participant's pupil size will be monitored by an Eyelink eye tracker placed 50 cm from the eyes. Phasic pupil dilations are linked with experiment timing landmarks interpreted as changes in listening effort.
62645010|NCT04987047||Prescription with pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants based on the results of pharmacogenetics analyses.
62456095|NCT03634709|NO_INTERVENTION|Waitlist control|After randomisation, the waitlist control group will be informed that they have been placed on a waiting list for the intervention. The participants will complete the baseline assessment and receive no further contact from the researcher until the post assessment one month later, followed by the follow-up assessment three months later. After the three month assessment, wait listed participants will receive the intervention. No further assessments will be completed.
62456096|NCT03475784|EXPERIMENTAL|Restricted fluid therapy group|Restrictive fluid therapy: this group will not receive fluid pre-load, and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2mL/Kg/hour.
62645011|NCT04987047||Prescription without pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants left to the discretion of the clinician without pharmacogenetics assistance.
62645012|NCT01668420|EXPERIMENTAL|noxious thermal stimulation|Heat-pain:46-47°C and Cold-pain:2-3°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
62645013|NCT01668420|ACTIVE_COMPARATOR|thermal stimulation (innocuous)|Heat:40-41°C and Cold:23-24°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
62645014|NCT04587804|EXPERIMENTAL|Abdominal Toning and Reduction of Subcutaneous Fat|simultaneous treatment by repetitive pulse magnetic stimulation and radiofrequency energy for toning of abdomen and reduction of subcutaneous fat
62456097|NCT03475784|ACTIVE_COMPARATOR|Liberal fluid therapy group|Liberal fluid therapy: this group will receive fluid pre-load (5 mL/Kg), and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
62456098|NCT00248638|ACTIVE_COMPARATOR|Glutamine dipeptide|Glutamine dipeptide supplemented nutrition to be given to participants.
62456099|NCT00248638|PLACEBO_COMPARATOR|standard|Participants given standard nutrition without glutamine dipeptide
62645015|NCT01880827|ACTIVE_COMPARATOR|Royx-en-Y surgery|Mixed meal test (MMS) with flow studies before and 2 months after the operation
62645016|NCT01880827|ACTIVE_COMPARATOR|Control|Healthy volunteer group, GIP, GLP-1 and MMS studies
62645017|NCT01880827|EXPERIMENTAL|Sleeve gastrectomy|Mixed meal test (MMS) with flow studies before and 2 months after the operation
62645018|NCT06115018|ACTIVE_COMPARATOR|Palatal surgery group|In the palatal surgery group, the participants will receive palatal surgery.To evaluate the effect of treatments on the severity of OSA, tongue muscle strength and the space of the upper airway, the participants will receive polysomonogrphy test, tongue muscle strength test and computed tomography. The time of evaluation will include baseline, 3 and 6 months after treatment.
62645019|NCT06115018|ACTIVE_COMPARATOR|Oropharyngeal rehabilitation group|In the oropharyngeal rehabilitation (OPR) group, the participants will receive 12-week OPR. The OPR for the OPR group included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress. To evaluate the effect of treatments on the severity of OSA, tongue muscle strength and the space of the upper airway, the participants will receive polysomonogrphy test, tongue muscle strength test and computed tomography. The time of evaluation will include baseline, 3 and 6 months after treatment.
62645020|NCT06115018|EXPERIMENTAL|Palatal surgery combined OPR group|In the palatal surgery combined OPR group, the participants will receive palatal surgery, then 12-week OPR. The program of OPR for this group is as the same of OPR group.
62074934|NCT03492619|EXPERIMENTAL|Intensive Intervention|a) Individual level: a six-month intervention comprised of 12 two-hour sessions, three follow-up monthly sessions, two workshops with the participants' household members and community members and one final session that will be graduation day; b) Household level: 2 workshops about co-responsibility in the household, and self-care and nutrition, including a theater performance. Six assignments with household members' participation; c) Community level: Distribution of 2 different educational materials (one about co-responsibility and another about self-care, including healthy nutrition) and carry out the 2 workshops mentioned above, both with household and community members.
62074935|NCT02423590|ACTIVE_COMPARATOR|Gemcitabine/Carboplatin|"Gemcitabine/carboplatin will be administered as standard 21-day treatment cycles according to normal clinical practice.~* Gemcitabine will be given by 30 minute intravenous infusions on Day 1 and Day 8 of each 21-day Cycle.~* On Day 1, carboplatin (AUC5) will be given by infusion over 30-60 minutes."
62645021|NCT06270641|EXPERIMENTAL|Intervention ExerciseRx-MS|"Participants use the ExerciseRx app to meet personalized daily step targets and weekly goals. They will receive MS Exercise and Physical Activity Recommendations and complete in-app surveys about barriers to being active and physical activity level. The ExerciseRx app will adjust the personalized step count goals based on percentage met of the previous week goal and providers will send supportive messages based on participant activity. Participants will complete validated self-report assessments.~Providers may also provide participants with additional guidance, make referrals, or schedule telemedicine or in-person clinic follow ups if needed to support the participant's physical activity progression."
62645022|NCT06270641|NO_INTERVENTION|Usual care|"Participants receive MS Exercise and Physical Activity Recommendations, will continue typical physical activity, and complete validated self-report assessments.~At the end of 26 weeks, staff will offer the participants the ExerciseRx intervention protocol."
62278892|NCT04730154|ACTIVE_COMPARATOR|Biomedically-focused Education|Breast cancer survivors assigned to the experimental intervention will participate in 1 online biomedically-focused education session followed by 3 biomedically-focused education sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format in order to balance nonspecific treatment effects between treatment arms, the duration, format and number of sessions as well as the didactical approach will be identical in both treatment groups. After the first live session, breast cancer survivors will receive an information leaflet from 'Kom op tegen Kanker' regarding 'Pain in and after treatment' that they need to read carefully at home.
62645023|NCT01645436|EXPERIMENTAL|treatment (exercise)|combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
62645024|NCT01645436|NO_INTERVENTION|control (usual care)|Usual hospital care with no exercise
62278893|NCT00969215|EXPERIMENTAL|Laser treatment|Half of each subject's scar will be treated with a fractional CO2 laser.
61978755|NCT02227589|EXPERIMENTAL|MET/CBT-12 plus CBT-D|CBT-D is an integrated cognitive behavior therapy targeting depression, delivered by the same study therapist who delivers MET/CBT-12 to the adolescent. All adolescents receiving CBT-D remain in MET/CBT-12 with their study provider.
61978756|NCT02227589|ACTIVE_COMPARATOR|MET/CBT-12 plus D-TAU|D-TAU (Depression Treatment as Usual) consists of referral to a depression treatment provider in the community. In this study D-TAU will be enhanced by assistance from the study team in locating providers and, with consent, an assessment report about the adolescent from the study team to the provider. All adolescents receiving TAU for depression remain in MET/CBT-12 with their study provider.
62278894|NCT00969215|NO_INTERVENTION|No treatment|Half of each subject's scar will not be treated.
62278895|NCT02639780||healthy young female|
62278896|NCT02639780||healthy young male|
62645025|NCT02987010|EXPERIMENTAL|Cohort A|Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
62645026|NCT02987010|EXPERIMENTAL|Cohort B|Patients who have inoperable tumors but measurable 2HG pre-treatment will be treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG on MRS and disease is stable or improved, then the patient will continue on treatment for a maximum of 11 additional 28 day cycles.
62645027|NCT05609669|EXPERIMENTAL|CADENCE program pilot|
62645028|NCT01674725|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62645029|NCT01674725|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks
62456100|NCT01074710|EXPERIMENTAL|C13-URA|administered C13-URA 50, 100, 200mg in same subjects
62456101|NCT01074710|PLACEBO_COMPARATOR|Placebo|2 same subjects
62278897|NCT02639780||healthy older female|
62278898|NCT02639780||healthy older male|
62278899|NCT02639780||obese older female|
62278900|NCT02639780||obese older male|
62278901|NCT04479800|EXPERIMENTAL|Treatment A - Fasting|No food prior to dosing
62278902|NCT04479800|EXPERIMENTAL|Treatment B - Fed|High-fat/high-calorie meal prior to dosing
62278903|NCT04479800|EXPERIMENTAL|Treatment C - Fed|Low-fat/low-calorie meal prior to dosing
62456102|NCT03679000||The reproductive health of couples|The study is a prospective cohort study, and its participants are childbearing couples who are seeking assisted reproductive technologies for having a baby in the reproductive center in Tongji Hospital.The study is a observational study.
62456103|NCT03019965|ACTIVE_COMPARATOR|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.
62645030|NCT01867008|EXPERIMENTAL|Nucleus CI422 Cochlear Implant with Nucleus 6 (N6) Sound Processor|
62645031|NCT01328938|EXPERIMENTAL|Stage I - Arm I: GCPGC I (3.6mg)|GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
62645032|NCT01328938|EXPERIMENTAL|Stage I - Arm II: GCPGC II (6mg)|GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
62645033|NCT01328938|EXPERIMENTAL|Stage II - Arm I: GCPGC|"GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).~The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I."
62645034|NCT01328938|ACTIVE_COMPARATOR|Stage II - Arm II: Neulasta|Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)
62074936|NCT02423590|EXPERIMENTAL|Gemcitabine/carboplatin + Apatorsen|"* Apatorsen (OGX-427) will be administered as an intravenous infusion over 2 hours.~* Apatorsen (OGX-427) treatment will begin with a loading dose period prior to the initiation of chemotherapy. Patients will receive three loading doses of 400 mg within a 9-day period with at least 48 hours between infusions and between the last loading dose infusion and Day 1 of initiating chemotherapy. Chemotherapy must be initiated within 7 calendar days once the last loading dose infusion has been completed.~* Following the loading dose period, Apatorsen (OGX-427) will be given weekly at a dose of 400 mg by 2 hour intravenous infusions. On days when both chemotherapy and Apatorsen (OGX-427) are given, Apatorsen (OGX-427) should be given first followed by chemotherapy."
62074937|NCT01729897|EXPERIMENTAL|Etomidate & Fentanyl|"* 4 min before procedure: fentanyl 1 μg/kg (0.02 ml/kg), intravenous injection~* After injection of fentanyl, etomidate was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~* Additional dose of etomidate would be administrated separately when duration of procedure was prolonged."
62074938|NCT01729897|PLACEBO_COMPARATOR|Propofol & Fentanyl|"* 4 min before procedure: fentanyl 1 g/kg (0.02 ml/kg), intravenous injection~* After injection of fentanyl, propofol was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~* Additional dose of propofol would be administrated separately when duration of procedure was prolonged."
62278904|NCT05175807|EXPERIMENTAL|Mindfulness Group_1|The intervention will be characterized by be based on Mindfulness exercises (e.g. body scan, gentle yoga, sitting, grounding and walking meditation), relaxation techniques and cognitive rehabilitation exercises. walking), relaxation techniques and cognitive rehabilitation exercises. The objective is to provide specific practical skills to learn how to deal with difficult and/or stressful situations managing emotions and intercurrent thoughts. The intervention is proposed to last for a total of 5-6 sessions lasting 45 minutes each, two sessions per week, for a three-week commitment. In addition, between sessions, reflection materials, readings or exercises will be offered. The intervention will be conducted in telemedicine by a Psychologist, who has experience in conducting these interventions and who receives regular supervision. The sessions will be conducted through special platform and audio-recorded to ensure the reliability of the data collected, prior consent.
62645035|NCT05709665||Out-of-hospital cardiac arrest|Patient characteristics; Rescue time intervals; Time to eCPR Decision during high quality CPR;
62645036|NCT05709665||In-hospital cardiac arrest|Patient characteristics; Emergency team time intervals; Time to eCPR Decision during high quality CPR;
62456104|NCT03019965|EXPERIMENTAL|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.
62645037|NCT03778008|EXPERIMENTAL|Recombinant bovine basic fibroblast growth factor|
62645038|NCT03778008|ACTIVE_COMPARATOR|Quadruple mixture|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
62074939|NCT00664703|EXPERIMENTAL|Lobeline 7.5 mg|Sublingual tablet
62645039|NCT06151379||Pathologic complete response (pCR)|Patient with complete pathological response
62645040|NCT06151379||Pathologic incomplete response (non-pCR)|Patient with partial pathological response
62074940|NCT00664703|EXPERIMENTAL|Lobeline 15 mg|Sublingual tablet
62645041|NCT06184048|OTHER|Directly Address Two Concerns - Proper Reporting of PRP Composition and Greatly Decreasing Cost|As socioeconomic inequity directly relates to disability related to knee Osteoarthritis (OA), limiting the cost of treatment is of the utmost importance to ensure appropriate delivery of care to all patients. As PRP is currently not covered by the vast majority of public and private payors, patients are required to pay for the injections out of pocket, with an average cost of $714 per injection (as high as $2,092). Furthermore, research studies relating to PRP are often expensive due to the cost of the traditional method of extracting PRP, generally with commercial kits, and thus limited in scope. The investigators have developed and implemented a low-cost PRP (LC-PRP) preparation technique and have safely performed the injections on hundreds of patients with knee OA.
62645042|NCT03652818|EXPERIMENTAL|Group A|"Pre-op Placebo 1;~Post-op Placebo 1;~Post-op Placebo 2"
62645043|NCT03652818|EXPERIMENTAL|Group B|"Pre-op Placebo 1;~Post-op Placebo 2;~Post-op acetaminophen."
62645044|NCT03652818|EXPERIMENTAL|Group C|"Pre-op Placebo 1;~Post-op pregabalin;~Post-op Placebo 2."
62645045|NCT03652818|EXPERIMENTAL|Group D|"Pre-op Placebo 1;~Post-op pregabalin~Post-op acetaminophen."
62645046|NCT03652818|EXPERIMENTAL|Group E|"Pre-op pregabalin;~Post-op Placebo 1;~Post-op acetaminophen."
62645047|NCT04572373||SMOFlipid group|"TPN and SMOFlipid support were indicated for patients who received NPO for more than 3 days, such as those with repeated laparotomy, staged biliary reconstruction, massive nasogastric (NG) drainage (\>500 mL/day), ileus, diarrhoea, poor digestion (NG extraction \>50 mL/time), and chylous ascites.~Furthermore, SMOFlipid was discontinued when the platelet count decreased to 40,000/μL or less. In all cases, heparinisation was prescribed to maintain the aPTT level between 1.5 and 2 times the normal controlled level at least for 10-14 days, with daily blood examination conducted. Oral administration of dipyridamole (75 mg, QID) for 3 months was indicated for stimulation of antiplatelet activity when the platelet count increased to 40,000/μL or more."
62645048|NCT04572373||non SMOFlipid group|On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group and the SMOFlipid group , respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.
62645049|NCT00713076|EXPERIMENTAL|1|Polyquaternium-preserved Multi-purpose solution
62074941|NCT00664703|EXPERIMENTAL|Lobeline 30 mg|Sublingual tablet
62074942|NCT00664703|ACTIVE_COMPARATOR|Methylphenidate HCl 15 mg|Capsule
62456105|NCT03019965|ACTIVE_COMPARATOR|Intermittent Imipenem|Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.
62456106|NCT03019965|EXPERIMENTAL|Extended Imipenem|Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.
62645050|NCT00988702|EXPERIMENTAL|Dan Tian Breathing|subjects received one-month's training on the Dan Tian Breathing
62456107|NCT03019965|ACTIVE_COMPARATOR|Intermittent Meropenem|Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.
62645051|NCT00988702|ACTIVE_COMPARATOR|Progressive muscle relaxation training|Subjects received one-month's conventional progressive muscle relaxation training
62645052|NCT03343548|ACTIVE_COMPARATOR|Group I|magnesium group (Mg)
62645053|NCT03343548|PLACEBO_COMPARATOR|Group II|control group (C)
62645054|NCT05783934|EXPERIMENTAL|18F-Florbetaben PET/CT scan|All the partecipants will undergo PET/CT scan evaluation after 18F-florbetaben administration
62645055|NCT06193772|ACTIVE_COMPARATOR|"IPDT as usual for on track patients"|"IPDT as usual for patients who are identified as on track at week 3."
62645056|NCT06193772|EXPERIMENTAL|"IPDT adapted for at risk patients"|"Customized IPDT after therapist feedback for patients who are identified as at risk at week 3."
62645057|NCT06193772|ACTIVE_COMPARATOR|"IPDT as usual for at risk patients"|"IPDT as usual for patients who are identified as at risk at week 3."
62645058|NCT01928771|EXPERIMENTAL|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
62645059|NCT01928771|EXPERIMENTAL|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
62645060|NCT01928771|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62074943|NCT00664703|ACTIVE_COMPARATOR|Methylphenidate HCl 30 mg|Capsule
62645061|NCT04232631||patients with diabetic foot ulcers|"* Patient of the investigators~* Diagnosis of diabetes mellitus~* One or more moderate to severe diabetic foot ulcers/infections~* 18-89 years of age"
62074944|NCT00664703|PLACEBO_COMPARATOR|Lobeline 0 mg (placebo)|Sublingual tablet
62074945|NCT00664703|PLACEBO_COMPARATOR|Methylphenidate HCl 0 mg (placebo)|Capsule
62074946|NCT05245799|ACTIVE_COMPARATOR|Speech Language Therapy|Children who are deaf/hard of hearing will receive standard of care speech and language therapy with a speech language pathologist. Reading time is prescribed 20 min, 3x/week.
62074947|NCT05245799|EXPERIMENTAL|Speech Language Therapy + Digital Phase|Children who are deaf/hard of hearing will receive standard of care speech and language therapy with a speech language pathologist with the addition of the digital app named, Hear Me Read, that will be used to achieve reading, speech and language goals through interactive digital storybook reading. Reading time is prescribed 20 min, 3x/week.
62074948|NCT00464919|EXPERIMENTAL|A|
62074949|NCT05088967|EXPERIMENTAL|IBI110+sintilimab|IBI110 and sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. IBI110 and sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
62645062|NCT04232631||Normal healthy volunteers|over 18 years of age have a foot
62456108|NCT03019965|EXPERIMENTAL|Extended Meropenem|Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.
62456109|NCT01653665|ACTIVE_COMPARATOR|Leukine (Sargramostim, GM-CSF)|Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
62278905|NCT05175807|NO_INTERVENTION|Waiting List Group_2|"In both groups the usual care or usual treatment, will consist of the usual daily medical examinations of the department, respiratory and motor physiotherapy sessions. The Group 2, therefore, will not be submitted to other type of treatment outside of that previewed near O.U. for the course of the first three weeks, during which they will be placed on the waiting list. Once the Once the assessment is carried out after 3 weeks, we will proceed to implement the intervention proposed to the Group 1. If the participant has already been discharged from the structure, it will still be possible to proceed with the intervention, since it is online. If the participant has already been discharged from the structure, you can still proceed with the intervention, since this is in telemedicine, in order to promote the continuity hospital-territory."
62645063|NCT04882371||MRI RECIST|Radiological responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) and changes in contrast enhancement patterns on MRI
62645064|NCT04882371||PET-CT PERCIST|Radiological responses were evaluated according to the classification of PET Response Criteria in Solid Tumors (PERCIST) on PET-CT.
62645065|NCT01232283|EXPERIMENTAL|Apremilast|Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (\<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.
62456110|NCT01653665|PLACEBO_COMPARATOR|Placebo (normal saline)|Participants in the randomised controlled trial may be randomised to receive a daily subcutaneous injection of normal saline (placebo) for 4 or 7 days as decided following the results of the dose finding study
62456111|NCT02116803|EXPERIMENTAL|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
62645066|NCT01232283|PLACEBO_COMPARATOR|Placebo|Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( \< PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).
62074950|NCT05088967|ACTIVE_COMPARATOR|sintilimab|Sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. Sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
62074951|NCT05858320|EXPERIMENTAL|SmartHF application|The web application-based study intervention provides adaptive medication recommendations that can be shared with their HF provider.
62074952|NCT05858320|ACTIVE_COMPARATOR|Control - Patients Standard Medication(s)|No change to current medication(s)
62074953|NCT06059534|PLACEBO_COMPARATOR|Placebo|This group will be provided with placebo capsules for comparative purposes.
62074954|NCT06059534|EXPERIMENTAL|DracoBelleTM Nu|This group will be provided with DracoBelleTM Nu capsules, which will be compared to the placebo group.
62074955|NCT04018898||Observational|Each participant will be evaluated at Emergency Department based on ER2 screening tool (Emergency Room Evaluation and Recommendation Form). Six closed-ended format questions (i.e., yes versus no) composed ER2 assessment: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless its type, and temporal disorientation (inability to give the current month and/or year).
62456112|NCT02116803|EXPERIMENTAL|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
62074956|NCT02413684|OTHER|Asthma Patients|Patient engagement toolkit
62074957|NCT00127413|EXPERIMENTAL|Cognitive Behavioral Therapy - Pain|Cognitive Behavioral Therapy targeting chronic pain
62074958|NCT00127413|EXPERIMENTAL|Cognitive Behavioral Therapy-Integrated|Integrated treatment for comorbid chronic pain and PTSD
62074959|NCT00127413|EXPERIMENTAL|Cognitive Processing Therapy - PTSD|Cognitive Processing Therapy for PTSD
62278906|NCT02238457|ACTIVE_COMPARATOR|Low dose losartan|Low dose losartan
62278907|NCT02238457|ACTIVE_COMPARATOR|High dose losartan|High dose losartan
62456113|NCT05141864|ACTIVE_COMPARATOR|Acmella oleracea gel group|Formulation with Acmella oleracea will be used during the digital rectal examination.
62456114|NCT05141864|ACTIVE_COMPARATOR|Lidocaina gel group|The lidocaine gel will be used during the digital rectal examination.
62456115|NCT05141864|PLACEBO_COMPARATOR|Ultrasound gel group|The ultrasound gel will be used during the digital rectal examination.
62645067|NCT03201991|OTHER|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
62645068|NCT02202304|EXPERIMENTAL|Chlorhexidine/Thymol varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush by painting it over the surfaces of these teeth."
61978757|NCT02227589|ACTIVE_COMPARATOR|MET/CBT-12 alone|MET/CBT-12 consists of two sessions of motivation enhancement therapy and 10 sessions of cognitive behavior therapy, targeting alcohol or cannabis abuse. All adolescents in the study receive MET/CBT-12 over 12 to 14 weeks.
62278908|NCT03238105|EXPERIMENTAL|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
62456116|NCT04137211|EXPERIMENTAL|Prolonged sitting with social break|
62456117|NCT04137211|EXPERIMENTAL|Prolonged sitting with walk break|
62278909|NCT03238105|EXPERIMENTAL|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
62074960|NCT00127413|OTHER|Treat as Usual|Participants received care for pain and PTSD as usual from their Primary care provider
62278910|NCT01480297|EXPERIMENTAL|Salsalate|All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
62278911|NCT01583894||Chronic pain patients|
62456118|NCT04137211|EXPERIMENTAL|Prolonged sitting with simple resistance activities|
62456119|NCT05425667|EXPERIMENTAL|Experimental|sensory integration training exercise for improving balance and walking ability of patients with lumbar stenosis and neurological claudication.
62645069|NCT02202304|PLACEBO_COMPARATOR|Placebo varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush and painting it on all the surfaces of these teeth.."
62645070|NCT01797393|ACTIVE_COMPARATOR|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
61978758|NCT02968927|ACTIVE_COMPARATOR|2HRbEZ/4HRb|2HRbZE
61978759|NCT02968927|EXPERIMENTAL|Everolimus|Everolimus 0.5 MG
61978760|NCT02968927|EXPERIMENTAL|Auranofin|Auranofin 6 MG
61978761|NCT02968927|EXPERIMENTAL|Vitamin D|Vitamin D3
62456120|NCT02199392|EXPERIMENTAL|Lenvatinib 24 mg|The Pretreatment Phase will have two periods: Screening and Baseline 1. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
62074961|NCT05420324|EXPERIMENTAL|Intervention/treatment|YH003 in combination with pebolizumab and albumin paclitaxel in first-line treatment of patients with unresectable/metastatic mucosal melanoma
62074962|NCT05853757|EXPERIMENTAL|Zzowin Nutra Tablet|Zzowin Nutra Tablet contains Melatonin, Tagar, L-theanine, L-Tryptophan, vitamin B6, Iron, Zinc, and Magnesium. which is helpful to provide deep, calm, and restful sleep.
62074963|NCT02390063|EXPERIMENTAL|CHAMVA standard regime|ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
62074964|NCT02390063|EXPERIMENTAL|CHAMVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
62278912|NCT03221218|EXPERIMENTAL|Enhanced screening-informed letter|Family physicians will receive a letter that includes their patient's screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines for MTBI (2013).
62278913|NCT03221218|NO_INTERVENTION|Standard letter|Family physicians will receive a letter that includes generic recommendations for managing MTBI based on the Ontario Neurotrauma Foundation clinical practice guidelines (2013). Screening test results will not be provided.
62456121|NCT02973893|PLACEBO_COMPARATOR|Placebo plus Standard Care|Placebo plus Standard Care
62456122|NCT02973893|EXPERIMENTAL|VF001-DP LD plus Standard Care|VF001-DP (14 micrograms per treatment) and Standard Care (low dose \[LD\])
62456123|NCT02973893|EXPERIMENTAL|VF001-DP HD plus Standard Care|VF001-DP (140 micrograms per treatment) and Standard Care (high dose \[HD\])
62456124|NCT05685381||Black adults with persistent asthma in homes with gas kitchen appliances|Black adults with persistent asthma that reside in homes with kitchen appliances (i.e., cooktops, ovens, and ranges) fueled by combustible gas.
62074965|NCT02390063|ACTIVE_COMPARATOR|MVA standard regime|Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
62074966|NCT02390063|ACTIVE_COMPARATOR|MVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
62456125|NCT05685381||Black adults with persistent asthma in homes without gas kitchen appliances|Black adults with persistent asthma that reside in homes with kitchen appliances (i.e., cooktops, ovens, and ranges) not fueled by combustible gas.
61978762|NCT02968927|EXPERIMENTAL|CC-11050|CC-11050
62278914|NCT00700180|EXPERIMENTAL|1|
62645071|NCT01797393|EXPERIMENTAL|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .The mucosa was observed by inflating the bowel with air while withdrawing the colonoscope.All the patients were examined without sedation during the whole procedure.
62278915|NCT00700180|EXPERIMENTAL|2|
62278916|NCT00521521|ACTIVE_COMPARATOR|docetaxel and cisplatin|
62278917|NCT00521521|EXPERIMENTAL|docetaxel|
62278918|NCT03883880|EXPERIMENTAL|Epigallocatechin gallate|Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
62278919|NCT03883880|EXPERIMENTAL|Linoleic acid|Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
62456126|NCT00098371|EXPERIMENTAL|Treatment (alvocidib)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for \> 6 months after completion of treatment may receive 6 additional courses of flavopiridol.
62074967|NCT02390063|EXPERIMENTAL|CHAMVA accelerated regime|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
62074968|NCT02390063|EXPERIMENTAL|CHAMVA+CTX accelerated regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
62074969|NCT02390063|EXPERIMENTAL|CHAMVA accelerated regime AS|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
62074970|NCT02390063|EXPERIMENTAL|CHAMVA+CTX accelerated regime AS|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
62074971|NCT01749501|ACTIVE_COMPARATOR|Rocuronium|0.6 mg/kg once
62074972|NCT01749501|PLACEBO_COMPARATOR|Placebo|Placebo
62074973|NCT01952964|EXPERIMENTAL|JUC spray dressing|
62074974|NCT01863641|EXPERIMENTAL|treatment group|Patients will receive calcitriol at a fixed dose daily.
62074975|NCT01863641|ACTIVE_COMPARATOR|control group|Patients will receive placebo daily.
62278920|NCT03883880|EXPERIMENTAL|Capsaicin|Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
62278921|NCT00044512|EXPERIMENTAL|Sorafenib 400 mg b.i.d.|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
62278922|NCT02814149|ACTIVE_COMPARATOR|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
62074976|NCT01730014|EXPERIMENTAL|Trial part 1|
62074977|NCT01730014|EXPERIMENTAL|Trial part 2, treatment A|
62074978|NCT01730014|EXPERIMENTAL|Trial part 2, treatment B|
62074979|NCT02612896|EXPERIMENTAL|Elimination arm|"Both human and porcine interventions at four-monthly intervals in the first two study years, for a total of six iterations (only human interventions will be detailed here):~Human: Mass drug administration, praziquantel 10mg/kg, according to the list of WHO recommended anthelmintic drugs for use in preventive chemotherapy for taeniasis. And Health Education"
62074980|NCT02612896|EXPERIMENTAL|Control intervention arm|Human: yearly health education, for a total of five iterations. The intervention on the pig host will not be detailed here)
62074981|NCT06240858|EXPERIMENTAL|TAPP group|The TAPP group underwent laparoscopic transperitoneal preperitoneal hernia repair.
62074982|NCT06240858|EXPERIMENTAL|Lichtenstein group|The Lichtenstein group underwent Lichtenstein hernia repair.
62074983|NCT02127827|EXPERIMENTAL|investigational device off|
62074984|NCT02691351||non-Hodgkin T-cell Lymphoma|
62456127|NCT05019066|ACTIVE_COMPARATOR|Herbal Combination Group|"* Tablets of the herbal formulation will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/healthy-hair-tablets-10)~* Each 500 mg tablet contains a proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa~* Dose: subjects in this group will take 2 herbal formulation tablets twice per day for a total of 4 tablets per day"
62074985|NCT02827786|EXPERIMENTAL|Electromagnetic Acoustic Imaging|
62278923|NCT02814149|ACTIVE_COMPARATOR|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
62278924|NCT04347083|EXPERIMENTAL|Experiment|Reflex latency will be measured in this arm
62645072|NCT01797393|EXPERIMENTAL|" Air assisted water colonoscopy"|" Air assisted water injection colonoscopy: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.All the patients were examined without sedation during the whole procedure."
62278925|NCT01761266|ACTIVE_COMPARATOR|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62278926|NCT01761266|ACTIVE_COMPARATOR|Sorafenib|Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62074986|NCT00485056|PLACEBO_COMPARATOR|Placebo|Crossover arm
62074987|NCT00485056|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 45mgs daily
62074988|NCT00977405|NO_INTERVENTION|Control|Primary closure after standard washing of wound with chlorhexidine solution
62074989|NCT00977405|EXPERIMENTAL|Collatamp G|Primary closure of wound with collatamp G in subcutaneous layer
62074990|NCT04435392|EXPERIMENTAL|Part 1: Cohort 1, 0.5% Jaktinib Bid|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 0.5% Cream will be applied topically twice daily.
62074991|NCT04435392|EXPERIMENTAL|Part 1: Cohort 2,1.5% Jaktinib Bid|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 1.5% Cream will be applied topically twice daily.
62074992|NCT04435392|EXPERIMENTAL|Part 1: Cohort 3, 2.5% Jaktinib Qd|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically Once daily.
62074993|NCT04435392|EXPERIMENTAL|Part 1: Cohort 4, 2.5% Jaktinib Bid|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically twice daily.
62278927|NCT02752100|EXPERIMENTAL|Interventional Therapy|Percutaneous transluminal angioplasty.
62074994|NCT04435392|PLACEBO_COMPARATOR|Dose extension: Vehicle Control|the Vehicle Control cream will be applied topically twice daily
62074995|NCT04435392|EXPERIMENTAL|Dose extension: low-dose group, X%|X% based on results of part 1. The Jaktinib Hydrochloride X% Cream will be applied topically twice daily
62074996|NCT04435392|EXPERIMENTAL|Dose extension: high-dose group, Y%|Y% based on results of part 1. The Jaktinib Hydrochloride Y% Cream will be applied topically twice daily
62278928|NCT02752100|NO_INTERVENTION|Non-Interventional Therapy|
62074997|NCT01368211|ACTIVE_COMPARATOR|Mirasol first, then Reference|This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
62278929|NCT00171860|EXPERIMENTAL|STI571|
62074998|NCT01368211|ACTIVE_COMPARATOR|Reference first, then Mirasol|This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).
62074999|NCT00451841||1|Chronic cough caused by GERD
62075000|NCT00451841||2|Chronic cough without GERD
62075001|NCT04956263|EXPERIMENTAL|Treatment A|YG1699 10 mg
62075002|NCT04956263|EXPERIMENTAL|Treatment B|YG1699 25 mg
62075003|NCT04956263|ACTIVE_COMPARATOR|Treatment C|Dapagliflozin 10 mg
62278930|NCT01805947||Lifestyle Modification|"All patients with chronic pain conditions participate in a 8-weeks structured group program. Detailed information on the mindfulness based program can be found in the publication by Paul, A. et al. An Integrative Day Care Clinic for chronically ill patients: Concept and case presentation in the European Journal of Integrative Medicine, 2012, 4(4):e455-e459."
62278931|NCT01164722|EXPERIMENTAL|Arm I: Infrared coagulator treatment|Infrared photocoagulation therapy. The infrared coagulator (IRC) contact tip is placed in direct contact with lesion under high-resolution anoscopy (HRA) guidance. Patients then undergo IRC ablation for 1.5 second pulses. IRC ablation is reapplied until the level of submucosal vessels are reached.
62075004|NCT03567993|ACTIVE_COMPARATOR|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
62075005|NCT03567993|EXPERIMENTAL|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
62075006|NCT00341068||Cleft|children and adults with a cleft lip and/or cleft palate and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
62456128|NCT05019066|PLACEBO_COMPARATOR|Placebo Group|"* Supplement appearing similar to the herbal combination formulation.~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 2 placebo tablets twice per day for a total of 4 tablets per day"
62075007|NCT00341068||NTD|children and adults with an NTD (neural tube defects) and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
62075008|NCT00007475|EXPERIMENTAL|Plasma Exchange + Cyclophosphamide|"Procedure/Surgery: Plasma exchange A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.~Drug: Cyclophosphamide For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months."
62456129|NCT04056143||Dabigatran|Subjects who are receiving long-term Dabigatran for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
62456130|NCT04056143||Rivaroxaban|Subjects who are receiving long-term Rivaroxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
61978763|NCT04246294||Sleep apnea patients|"This group of patients will have been monitored over night with cardiorespiratory monitoring (CRM). CRM enables the physician to establish an Apnea-Hypopnea Index (AHI) which will be used for diagnosis. An AHI \> 15 is considered moderate-to-severe sleep apnea, and this is the focus group of patients in the current project.~These patients will be followed for 12 months during continuous positive airway pressure (CPAP) treatment. Adherence to the CPAP treatment will be closely monitored."
62456131|NCT04056143||Apixaban|Subjects who are receiving long-term Apixaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
62456132|NCT04056143||Edoxaban|Subjects who are receiving long-term Edoxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
62456133|NCT02126865|EXPERIMENTAL|BI 1060469 Healthy|Multiple rising dose qd for 15 days
62075009|NCT06265883||Len+DEB-TACE+HAIC|Patients were treated with Len+DEB-TACE+HAIC.
62075010|NCT06265883||Len+DEB-TACE|Patients were treated with Len+DEB-TACE.
62075011|NCT01190332|PLACEBO_COMPARATOR|conventional technique of ERCP|
62075012|NCT01190332|ACTIVE_COMPARATOR|Rendezvous technique|
62075013|NCT03781115|EXPERIMENTAL|Ziprasidone|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug ziprasidone (Geodon). The investigators will start with a single 20mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 40 and 60mg tablets). If Ziprasidone causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG) taken.
62456134|NCT02126865|PLACEBO_COMPARATOR|Placebo to BI 1060469|Matching placebo as tablet for 15 days
62075014|NCT03781115|EXPERIMENTAL|Olanzapine|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug olanzapine (Zyprexa). The investigators will start with a single 2.5 mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 5, 7.5, and 10 mg tablets).If olanzapine causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG).
62075015|NCT03781115|PLACEBO_COMPARATOR|Placebo Comparator|The investigators have prepared a placebo which duplicates the exact color and size of the study drug capsule to use as a non-drug control.
62075016|NCT05826522||asthmatics and asthmatics previously|
62278932|NCT01164722|ACTIVE_COMPARATOR|Arm II: Expectant management|Patients receive standard of care and undergo clinical observation. After 12 months, patients may receive IRC ablation to all anal intraepithelial neoplasia lesions despite of their size.
62278933|NCT01750515|EXPERIMENTAL|Intervention group - acupuncture treatment|
62278934|NCT01750515|NO_INTERVENTION|Control group|
62278935|NCT03995264|EXPERIMENTAL|Ultrasound group|Ultrasound-guided radial artery cannulation
62278936|NCT03995264|PLACEBO_COMPARATOR|Palpation group|Radial artery cannulation with palpation technique
62278937|NCT03863626|ACTIVE_COMPARATOR|Frusemide IV shots = group A|Frusemide as IV shots
62278938|NCT03863626|ACTIVE_COMPARATOR|Frusemide IV infusion = group B|Frusemide as continuous IV infusion
62278939|NCT03798886||Natural frozen embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. After spontaneous ovulation, embryo transfer will be planned. Luteal phase support will not be used.
62278940|NCT03798886||modified natural embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. When follicle diameter is 16-17 mm we will apply hCG (recombinant hCG). After ovulation, embryo transfer will be done. Luteal phase support will not be used.
62075017|NCT05826522||COPD (chronic obstructive pulmonary disease) patients|
62075018|NCT05826522||cystic fibrosis patients|
62278941|NCT01403337|PLACEBO_COMPARATOR|Control|Blood pressure cuff inflated in the right or left arm to 40-50 mmHg
62456135|NCT02126865|EXPERIMENTAL|BI 1060469 asthmatics|Multiple rising dose qd for 29 days
62456136|NCT02126865|PLACEBO_COMPARATOR|Placebo to BI 1060469 asthmatics|Matching placebo as tablet for 29 days
62278942|NCT01403337|ACTIVE_COMPARATOR|Preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP \> 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
62278943|NCT05692388||Aim 1|Qualitative Aim
62278944|NCT05692388||Aim 2|Quantitative Aim
62278945|NCT05692388||Aim 3|Integrative Aim
62456137|NCT03057899|EXPERIMENTAL|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
62456138|NCT03057899|PLACEBO_COMPARATOR|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
62456139|NCT05628636|EXPERIMENTAL|Arm 1|Days 1-3: 5 g BID 4-6: 10 g BID 7-9: 15 g BID 10-21: 20 g BID
62456140|NCT05628636|EXPERIMENTAL|Arm 2|Days 1-3: 10 g BID 4-6: 10 g BID 7-9: 10 g BID 10-21: 20 g BID
62075019|NCT05826522||patients with immunodeficiency with bronchial obstruction|
62075020|NCT05826522||lung transplant recipients with obstructive chronic lung allograft rejection (O-CLAD)|
62075021|NCT00358150|EXPERIMENTAL|Eliglustat tartrate|
62456141|NCT05628636|EXPERIMENTAL|Arm 3|Days 1-3: 15 g TID 4-6: 10 g TID 7-9: 10 g TID 10-21: 15 g TID
62456142|NCT04281706||Etomidate-Time-Frame|Patients that underwent cardiac surgery between October 1st, 2012 and September 30th, 2013
62075022|NCT03781232|EXPERIMENTAL|RSP-09-01|Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
62278946|NCT03664375|EXPERIMENTAL|Experimental Group|The experimental group received botulinum toxin type A. After one week of Botox administration, a specially made task specific training program was started for these patients. It was provided for a duration of one hour and for three times per week for a total of 12 weeks by a trained physiotherapist.
62278947|NCT03664375|PLACEBO_COMPARATOR|Control Group|The control group received only task specific training program with the same protocol as for the experimental group; for a duration of one hour and for three times per week up to a total of 12 weeks by a trained physiotherapist
62278948|NCT01625273|NO_INTERVENTION|IF (Infant formula)|
62278949|NCT01625273|EXPERIMENTAL|IF with L. paracasei strain F19|
62278950|NCT06314555||Women under 37 weeks of gestation age|A woman with suspected preeclampsia and with inclusion criteria receives a blood sample, according to the department's usual practices, to analyse the values of sFlt-1 and PlGF and the usual vascular-renal sample. The woman gave her verbal consent to participate in the study. The Roche Elecsys® immunoassay sFlt-1/PlGF ratio was used to measure the two markers in the patients' blood.
62278951|NCT06314555||Women above 37 weeks of gestation age|A woman with suspected preeclampsia and with inclusion criteria receives a blood sample, according to the department's usual practices, to analyse the values of sFlt-1 and PlGF and the usual vascular-renal sample. The woman gave her verbal consent to participate in the study. The Roche Elecsys® immunoassay sFlt-1/PlGF ratio was used to measure the two markers in the patients' blood.
62278952|NCT05314244|EXPERIMENTAL|pylorus resecting group|The patients who underwent pylorus resecting pancreaticoduodenectomy for periampullary tumors
62278953|NCT05314244|NO_INTERVENTION|pylorus preserving group|The patients who underwent pylorus preserving pancreaticoduodenectomy for periampullary tumors
62278954|NCT01851408|EXPERIMENTAL|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
62278955|NCT03056118|EXPERIMENTAL|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
62278956|NCT03056118|ACTIVE_COMPARATOR|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
62456143|NCT04281706||Propofol-Time-Frame|Patients that underwent cardiac surgery between February 1st, 2014 and January 31st, 2015
62645073|NCT01123655|EXPERIMENTAL|Arm 1|"The study will have 3 treatment arms each with 10-12 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 2 treatment arms (30 micrograms APL A12 or placebo). Each of the 2 treatments will be given for 16 weeks.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
62645074|NCT01123655|EXPERIMENTAL|Arm 2|"The next group will receive a higher dose (50 micrograms) and/or placebo (Block 2).~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
62645075|NCT01123655|EXPERIMENTAL|Arm 3|"Block 3 (Arm 3) will include placebo and both doses of APL/A12 to ensure 10-12 patients are enrolled in each arm ( total of approximately 32 subjects) so we will have 24 subjects who complete the 16 weeks of study treatment. Arms 2 and 3 will run simultaneously.~Intervention: Drug treatment will be stopped or interrupted if indicated."
62645076|NCT06149702|OTHER|Intervention|"Participants will attend a KOKU training session lasting for 60 minutes. A carer may also accompany if the participant feels that their support would be beneficial. An iPad will be provided to participants for the duration of the project and the app instruction booklet will also be provided for reference purposes. For participants who do not wish to attend the group training, ad hoc one-to-one training will be offered.~\* Participants will be advised to use the modified KOKU programme for 30 minutes, 3 times per week, for 6 weeks"
62645077|NCT06149702|OTHER|Control arm|Usual care
62645078|NCT02272530||Healthy|100 healthy volunteers in age of 20-75 years
62645079|NCT02272530||Patients|100 patients with stable coronary artery disease and accordingly endothelial dysfunction
62645080|NCT00956436|EXPERIMENTAL|Sorafenib Monotherapy|Sorafenib Monotherapy
62645081|NCT00956436|EXPERIMENTAL|Sorafenib with BIIB022|Sorafenib with BIIB022
62645082|NCT03817281||Accuryn Monitoring System|Observational only (no intervention). Study Cohort is patients using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
62645083|NCT03311867|ACTIVE_COMPARATOR|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
62645084|NCT03311867|ACTIVE_COMPARATOR|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
62278957|NCT03056118|ACTIVE_COMPARATOR|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
62278958|NCT03056118|ACTIVE_COMPARATOR|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
62278959|NCT05131061||unilateral primary aldosteronism(UPA)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI ≥ 4; If LI between 2 and 4, should be combined with contralateral inhibition index \< 1 or CT indicate typical adenomas on the dominant side.
62456144|NCT06487676||Toe transfer|Patients who have undergone toe to hand transfer
62456145|NCT06487676||Replantation|Patients who have undergone finger replantation
62456146|NCT02636816|EXPERIMENTAL|Infusion|carbetocin is given slowly
62456147|NCT02636816|ACTIVE_COMPARATOR|Bolus|carbetocin is given quickly
62456148|NCT03196947|EXPERIMENTAL|Single arm, APO010 Dose escalation|
62645085|NCT02510339||Observational|The Lysholm Knee score and the SF-36 questionnairs will be given to patients presenting to Orlando Regional Medical Center with open or closed fractures of the tibial shaft during their follow up visits post operativily.
62645086|NCT02821533|OTHER|TACE using a high dose of cisplatin|Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.
62645087|NCT01082029|EXPERIMENTAL|Lansoprazole|
62645088|NCT01082029|PLACEBO_COMPARATOR|Placebo|
61978764|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
61978765|NCT05286307|EXPERIMENTAL|Participants receiving IPACK block|Patients in this study group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%). And receive the additional IPACK block performed using 20 mL of Bupivacaine (0.25%) injected into the interspace between the popliteal artery and capsule of the knee.
62278960|NCT05131061||bilateral adrenal hyperplasia(BAH)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI \< 2; or LI between 2 and 4 but does not meet the UPA conditions
62278961|NCT05006014||Patient with non restorable teeth|Patient with non restorable teeth located in smile line needs extraction with immediate implantation and immediate provisionalization to improve psychiatric effect of tooth loss
62278962|NCT03423498|EXPERIMENTAL|groups with toe-spread-out exercise|This arm included individuals with hallux valgus (research group A) and without deformation (research group B), who were patients of Department of Rehabilitation, Poznan University of Medical Sciences. They performed the toe-spread-out exercises for 14 days and were examined twice: before and after exercises. The examination of participants included a surface electromyography, electroneurography and goniometer tests to measure the range of motion in the hallux joints.
62278963|NCT03423498|NO_INTERVENTION|control group|This arm included individuals with hallux valgus deformity from the control group which did not undergo any therapy of hallux. They were patients of Department of Rehabilitation as well. These participants were examined twice at an interval of 14 days in the same way as the patients from experimental arm.
62278964|NCT01006070||Patients with existing spinal fractures|Myeloma patients with documented x-ray evidence of spinal fractures.
62278965|NCT01006070||Patients without spinal fractures|Myeloma patients with bony disease in the spine without existing fractures.
62278966|NCT03940911|OTHER|Targeted therapy and severe fatigue (FSS)|"See bellow (section Interventions) the full description for~* Measurement of aerobic exercise on cycloergometer~* Measurement of muscle mass by two-photon absorptiometry: specific study~* Measurement of Isometric Muscle Strength~* Blood sampling for measurement of cytokine levels in the blood~* Measurement of sedentarity~* Psychological impact~* Fatigue measurement"
62645089|NCT04371016|EXPERIMENTAL|Verticalization group|"After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed :~* insertion of an esophageal balloon catheter (Nutrivent®, Sidam)~* installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger)~* insertion of a Swan-Ganz catheter~* continuous recording of digital and analogic data~After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected."
62645090|NCT03129932|ACTIVE_COMPARATOR|gluten phase|volunteers will receive 2 corn muffins containing12g of gluten/muffin to be consumed daily for 4 weeks
62278967|NCT03940911|OTHER|Targeted therapy and mild fatigue (FSS <4)|"See bellow (section Interventions) the full description for~* Measurement of aerobic exercise on cycloergometer~* Measurement of muscle mass by two-photon absorptiometry: specific study~* Measurement of Isometric Muscle Strength~* Blood sampling for measurement of cytokine levels in the blood~* Measurement of sedentarity~* Psychological impact~* Fatigue measurement"
62278968|NCT04592783|EXPERIMENTAL|Tight Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 140/90 mmHg
62645091|NCT03129932|PLACEBO_COMPARATOR|Placebo phase|volunteers will receive 2 corn muffins without gluten/muffin to be consumed daily for 4 weeks
62645092|NCT00001305|EXPERIMENTAL|Growth Hormone|Treatment of children with types III and IV osteogenesis imperfecta with Humatrope
62645093|NCT04411615|EXPERIMENTAL|Omega|Omega-3 re-esterified triglyceride form
62645094|NCT06313463|EXPERIMENTAL|Camrelizumab group|
62645095|NCT06313463|PLACEBO_COMPARATOR|Placebo group|
62645096|NCT05414214||Elderly|Elderly patients who are scheduled for elective surgeries under general anesthesia with endotracheal intubation accomplished using conventional laryngoscopy will be included.
62645097|NCT04550117|EXPERIMENTAL|Intraspinal Pressure Monitoring|A fiberoptic pressure monitoring device will be placed into the subarachnoid space at the site of traumatic spinal cord injury
62645098|NCT02047578|EXPERIMENTAL|Busulfan|Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
62645099|NCT06100952|EXPERIMENTAL|Active Treatment|Epithelium-on corneal cross-linking
62645100|NCT06100952|PLACEBO_COMPARATOR|Control Treatment|Placebo and sham for epithelium-on corneal cross-linking
62278969|NCT04592783|EXPERIMENTAL|Liberal Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 150/95 mmHg
62278970|NCT01559155||Bullous pemphigoid|Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
62278971|NCT01559155||Other bullous-like auto-immune|Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
62278972|NCT01559155||Control group|Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.
62278973|NCT02443064|EXPERIMENTAL|MRSA blood stream infection patient|"Intervention:Vancomycin~Dosing:~15-20mg/kg, IV,q 12\~8h (or 1 g, IV, q12\~8h) for adult patient with normal renal function; Dosage should be adjusted by blood creatinine clearance in patients with impaired renal function; Administration route： 1\~2 h/ dosing, IV~Drug combination:~Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can be combined in case of concurrent G- bacterial infections.~Duration:~Septicemia: 2\~4 weeks Endocarditis: 6\~8 weeks"
62075023|NCT03781232|EXPERIMENTAL|RSP-09-02|Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
62075024|NCT06138275|EXPERIMENTAL|Elranatamab|Elranatamab subcutaneous injections at pre-determined doses, administered at the following timepoints during each 28-day cycle: Cycle 1: Days 1, 4, 8, 15, and 22; Cycle 2: Days 1, 8, 15, and 22 ; Cycles 3-6: Days 1 and 15
62278974|NCT06427460|EXPERIMENTAL|stereotactic body radiation therapy|Central-boost ablative doses delivered by SBRT.
62645101|NCT01825824|EXPERIMENTAL|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization
62075025|NCT05214014|EXPERIMENTAL|Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells|Group 1: Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells
62075026|NCT05214014|ACTIVE_COMPARATOR|Patients with multiple sclerosis receiving standard treatment|Group 2: Patients with multiple sclerosis receiving standard treatment
62278975|NCT02599961|EXPERIMENTAL|UX007|UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.
62278976|NCT06517134||hypertensive subjects|
62278977|NCT06517134||non-hypertensive subjects|
62645102|NCT01700803|EXPERIMENTAL|Povidone Iodine 10%|Using Povidone Iodine 10% hand scrub before caesarian section
62645103|NCT01700803|EXPERIMENTAL|Povidone Iodine 7.5% hand scrub|Using Povidone Iodine 7.5% hand scrub before caesarian section
62075027|NCT01993823|EXPERIMENTAL|G238|Five drops into the ear canal twice daily for 14 days
62278978|NCT02950519|ACTIVE_COMPARATOR|As needed Cuff Pressure Checks|Cuff pressure checks upon intubation and after any manipulation of ET tube
62278979|NCT02950519|EXPERIMENTAL|Cuff Pressure checks every 8 hrs|Cuff pressure checks upon intubation, after manipulation of ET tube, and minimum of 8 hr interval
62645104|NCT01608165|OTHER|Partial nephrectomy|Patients randomised to this arm will undergo a partial nephrectomy
62278980|NCT05108987|EXPERIMENTAL|Exercise Morning|If subjects are randomly assigned to this group, they will participate in exercise training in the morning at a moderate to hard intensity. Subjects will be asked to regularly engage in morning exercise while supervised for about 2 weeks.
62278981|NCT05108987|ACTIVE_COMPARATOR|Exercise Afternoon|If subjects are assigned to this group, they will participate in the same exercise program but after in the afternoon.
62278982|NCT01557166|EXPERIMENTAL|Liraglutide 3.0 mg|
62278983|NCT01557166|PLACEBO_COMPARATOR|Placebo|
62278984|NCT04821804|EXPERIMENTAL|Experimental|local application of HYADENT BG on both donor and recipient sites
62645105|NCT01608165|OTHER|Radiofrequency ablation|Patients randomised to this arm will undergo radiofrequency ablation
62645106|NCT01608165|OTHER|cryoablation|Patients randomised to this arm will undergo cryoablation
62645107|NCT03217409|EXPERIMENTAL|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
62645108|NCT03217409|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
62278985|NCT04821804|PLACEBO_COMPARATOR|control|application of normal saline on both donor and recipient sites
62278986|NCT05788679|EXPERIMENTAL|Intervention in MRD positive patients|Azacitidine and / or Donor lymphocytes or tapering of immune suppression
62278987|NCT06303609|EXPERIMENTAL|Radiofrequency group|Once a week, for 8 weeks, patient will undergo monopolar non-ablative radiofrequency application by a trained researcher.
62278988|NCT06303609|ACTIVE_COMPARATOR|Sham group|Once a week, for 8 weeks, patient will undergo monopolar non-ablative radiofrequency application by a trained researcher, but the radiofrequency device will not emit the radiofrequency wave.
62278989|NCT05280977|EXPERIMENTAL|POST ISOMETRIC RELAXATION|
62278990|NCT05280977|EXPERIMENTAL|POST FACILITATION STRETCHING|
62278991|NCT04906135|EXPERIMENTAL|Usher Syndrome|Adult and pediatric cochlear implant users with Usher syndrome
62278992|NCT04906135|ACTIVE_COMPARATOR|Idiopathic Hearing Loss|Adult and pediatric cochlear implant users with idiopathic hearing loss
62645109|NCT03620448|EXPERIMENTAL|bCPAP Arm.|"Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components:~(i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya."
62645110|NCT03620448|OTHER|Oxygen Arm|Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
62278993|NCT04405401|ACTIVE_COMPARATOR|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
62278994|NCT04405401|EXPERIMENTAL|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
62278995|NCT06191250|EXPERIMENTAL|Neoadjuvant NORT-durvalumab|administration of non-ablative oligofractionated radiation therapy using 12 Gy in 3 fractions in combination with one dose of durvalumab (750 mg IV) prior to surgery.
62278996|NCT01872728|PLACEBO_COMPARATOR|Control|placebo for the realization of the facial block and morphine for intraoperative analgesia
62278997|NCT01872728|ACTIVE_COMPARATOR|Levobupivacaine|Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia
62278998|NCT04911582|ACTIVE_COMPARATOR|Cafestol 6 mg|6 mg cafestol
62075028|NCT01993823|ACTIVE_COMPARATOR|Clotrimazole|Five drops into the ear canal twice daily for 14 days
62075029|NCT04825821||Low transverse hysterotomy closed by double-layer unidirectional barbed suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by double-layer unidirectional barbed suture
62278999|NCT04911582|ACTIVE_COMPARATOR|Cafestol 12 mg|12 mg cafestol
62279000|NCT04911582|PLACEBO_COMPARATOR|Placebo|Placebo
62279001|NCT01150266|EXPERIMENTAL|Alteplase|Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
62279002|NCT03356184|EXPERIMENTAL|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
62279003|NCT03356184|ACTIVE_COMPARATOR|The Earlysense System Device Group|The reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
62279004|NCT04711200|EXPERIMENTAL|Adipose derived stromal cells intravenously injected|
62279005|NCT00684515|EXPERIMENTAL|Vorapaxar 2.5 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
62279006|NCT00684515|EXPERIMENTAL|Vorapaxar 1 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
62279007|NCT00684515|PLACEBO_COMPARATOR|Placebo + Aspirin|Placebo oral tablets; once daily for 60 days + Aspirin
62279008|NCT01827384|EXPERIMENTAL|Regimen I (veliparib, temozolomide)|Patients receive veliparib by mouth (PO) twice a day (BID) on days 1-7 and temozolomide PO every day (QD) on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62279009|NCT01827384|EXPERIMENTAL|Regimen II (adavosertib, carboplatin)|Patients receive adavosertib by mouth (PO) twice a day (BID) for 5 doses starting on day 1 and carboplatin intravenous (IV) over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62279010|NCT01827384|EXPERIMENTAL|Regimen III (everolimus)|Patients receive everolimus by mouth (PO) every day (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62075030|NCT04825821||Low transverse hysterotomy closed by conventional double-layer smooth suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by conventional double-layer smooth suture
62279011|NCT01827384|EXPERIMENTAL|Regimen IV (trametinib)|Patients receive trametinib by mouth (PO) every day (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62279012|NCT06548763|EXPERIMENTAL|Topotecanwith Terriptylimab|Oral administration of topotecan and intravenous infusion of trastuzumab until disease progression or toxicity intolerance occurs.
61978766|NCT05286307|NO_INTERVENTION|Standard of care group|Patients in the control group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%).
61978767|NCT02854735||Head and neck neoplasm|Patients with stage III-IV head and neck cancer (squamous cell carcinoma) patient undergoing CCRT
62279013|NCT03188445|EXPERIMENTAL|IV administration|Iron isomaltoside (Monofer) Administered iv
62645111|NCT03307174|ACTIVE_COMPARATOR|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
62645112|NCT03307174|EXPERIMENTAL|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
62645113|NCT04361656||Current standard of care preparation|Current Standard of Care for inpatient colonoscopy: The dose of PEG-ELS will be large-volume (4-Liter) administered as either single-dose if colonoscopy is scheduled BEFORE 11 a.m. (250 mL orally every 15 minutes between 6 p.m. and midnight the day prior to procedure), or split-dose if the colonoscopy is scheduled AT or AFTER 11 a.m. (First dose: 2-Liters; 250 mL orally every 15 minutes between 6-8 p.m. the day prior to procedure. Second dose: 2-Liters; 250 mL orally every 15 minutes to be completed 5 hours before the scheduled time of the procedure).
62645114|NCT04361656||Lubiprostone Intervention|"The study entails giving two doses of Lubiprostone in addition to the standard large-volume polythene glycol-electrolytes solution (PEG-ELS) according to the time of the procedure as follow: If the colonoscopy is scheduled BEFORE 11a.m. the patient will receive in addition to the PEG-ELS: Lubiprostone 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy.~If the colonoscopy is scheduled AT or AFTER 11a.m. the patient will receive in addition to PEG-ELS: Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS"
62645115|NCT04222543|ACTIVE_COMPARATOR|HPV Negative tumours|Patients will receive four scans.
62645116|NCT04222543|ACTIVE_COMPARATOR|HPV positive tumours|Patients will receive four scans.
62645117|NCT04493606|EXPERIMENTAL|Intervention Patients|SCI patients receiving the physical activity coaching (Objective 1)
62645118|NCT04493606|EXPERIMENTAL|Intervention- Interventionists|Interventionists receiving physical activity coaching training (Objective 2)
62645119|NCT02018133||Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
62645120|NCT01493713|EXPERIMENTAL|Bevacizumab, XELOX|Bevacizumab in combination with XELOX
62645121|NCT03353792|ACTIVE_COMPARATOR|CL/AP system|To improved glycemic control and strict avoidance of hypoglycemia via 8-week use of a CL/AP system (closed-loop/artificial pancreas) reverses brain metabolic adaptations in older adult T1DM patients.
62645122|NCT03353792|PLACEBO_COMPARATOR|usual care|Subjects in this control group will continue their usual diabetic care (insulin pump therapy) along with CGM recording.
62279014|NCT03188445|ACTIVE_COMPARATOR|Oral administration|Ferrous fumarate with ascorbic acid Administered oral
62645123|NCT01408069|EXPERIMENTAL|MIGRANE|1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg
62645124|NCT01408069|ACTIVE_COMPARATOR|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
62645125|NCT03628651||HCC Surveillance|Approximately 1400 HCC surveillance subjects (controls) will be enrolled.
62645126|NCT03628651||HCC|Approximately 700 subjects with untreated clinically diagnosed HCC will be enrolled.
62075031|NCT03915080|OTHER|Oktokog alpha (Advate)|Personalized treatment according to individual PK using intravenous injection of oktokog alpha with dose and dose interval according to MyPKFIT and phenotypic evaluation.
62279015|NCT01575210|EXPERIMENTAL|Group A_ washing procedure 1|This group will apply washing technique 1.
62456149|NCT06082258|NO_INTERVENTION|usual care|Patients followed by general practitioners with no specific education on long COVID or somatic symptom disorders
62645127|NCT01584713|EXPERIMENTAL|Adipose derived Stem Cells|
62645128|NCT04128917|EXPERIMENTAL|Tegoprazan 50 mg|Tegoprazan 50 mg Triple Therapy
62645129|NCT04128917|EXPERIMENTAL|Tegoprazan 100 mg|Tegoprazan 100 mg Triple Therapy
62645130|NCT04128917|ACTIVE_COMPARATOR|RAPAE01|RAPAE01 Triple Therapy
62645131|NCT02123381|EXPERIMENTAL|Arm A|All patients in the arm receive cetuximab combined with preoperative radiotherapy at first. 4-6 weeks after the rdiaotherapy，patients receive right thoracotomy with three incisions radical surgery.
62645132|NCT06080477|EXPERIMENTAL|Adapted ENHANCE Intervention|Nurse-delivered community-based treatment model for people living with psychosis in the community, coordinated with the usual outpatient care
62075032|NCT00322608|EXPERIMENTAL|Dose escalation|
62075033|NCT03768999||Study group|All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
62645133|NCT06080477|ACTIVE_COMPARATOR|Enhanced usual care|Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
62645134|NCT05428956|ACTIVE_COMPARATOR|Single breath technique|The technique of single maximal inhalation will be demonstrated to all the patients by a technician. In brief the patient will be asked to inhale slowly and maximally and hold the breath for at least 5 seconds. After the breath holding maneuver the patient will be asked to exhale. Salbutamol (100µg) be administered in a dose of 2 puffs, each after a one minute interval. The duration of the breath hold will be measured by a stop watch.
62645135|NCT05428956|EXPERIMENTAL|Tidal breath technique|The technique of 5 tidal breaths will be demonstrated to all the patients by a technician. In brief the patient will be asked to inhale 5 tidal breaths after administrating salbutamol in the spacer. After each breath patient will be asked to breathe out in the spacer. The spacer has a one way-valve and does not allow the exhaled air to enter in to the chamber, thus preventing rebreathing and dilution of the inhaled medicine. Salbutamol (100µg) be administered in a dose of 2 puffs, each after a one minute interval
62645136|NCT00461734|ACTIVE_COMPARATOR|RV Apex|
62075034|NCT02758574|ACTIVE_COMPARATOR|CDT without ultrasound acceleration|Standard Catheter-Directed Thrombolysis: Utilization of a standard infusion catheter, placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications to treat/dissolve pulmonary embolus
62075035|NCT02758574|EXPERIMENTAL|CDT ultrasound accelerated|Ultrasound Accelerated Catheter-Directed Thrombolysis: Utilization of an infusion catheter that incorporates an ultrasound emitting wire both placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications with the ultrasound emitting wire activated to treat/dissolve pulmonary embolus
62279016|NCT01575210|EXPERIMENTAL|Group B_washing procedure 2|This group will apply washing technique 2.
62279017|NCT01080885|EXPERIMENTAL|Busy Bodies/Better Bites|Healthy Eating/Physical Activity Intervention
62645137|NCT00461734|EXPERIMENTAL|RV High Septum|
62279018|NCT01080885|ACTIVE_COMPARATOR|Healthy Spots/Safe Tots|Injury Prevention and Safety Intervention
62456150|NCT06082258|EXPERIMENTAL|intervention|Patients followed by general practitioners who have received a training in long COVID and somatic symptom disorders diagnosis and treatment, with reimbursement of three long consultations
62456151|NCT05912322|EXPERIMENTAL|Black chokeberry juice|100ml black chokeberry juice/day
62456152|NCT05912322|NO_INTERVENTION|Control|Lifestyle changes. No juice
62456153|NCT06246032|EXPERIMENTAL|Modified feeding Protocol|Prospective
62645138|NCT01542008|EXPERIMENTAL|Customized Adherence Enhancement (CAE)|This arm will receive the CAE intervention.
62645139|NCT01542008|ACTIVE_COMPARATOR|broad non-individualized education (EDU)|This arm will receive the EDU intervention.
62645140|NCT06019572||Younger cohort (<80 years)|
62645141|NCT06019572||octogenarians (≥80 years)|
62645142|NCT05843409|NO_INTERVENTION|Control|Normal drug therapie or usual treatment
62645143|NCT05843409|EXPERIMENTAL|Intervention|Normal drug therapie or usual treatment with add Mindfulness-based stress reduction (MBSR)
62075036|NCT02790593|EXPERIMENTAL|Juxta-Cures™|Patients randomised to the Juxta-Cures™ device. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
62075037|NCT02790593|ACTIVE_COMPARATOR|Standard compression|Patients randomised to standard compression. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
62075038|NCT05024149|EXPERIMENTAL|Healthy group|Subjects in this group will not undergo acupuncture intervention. For participants in the healthy control group, the IRT examination of the measurement sites will last for 3 minutes, with one thermal image taken every 10s. In the Healthy group, there will be two visits, and the first visit will be considered as the screening stage (i.e., demographic data recording, medical history taking, physical examination report review and recording on the day of enrollment) and the second visit will be considered as the detection stage (i.e., the day of enrollment). At the second visit, the subjects received the Self-rating depression scale (SDS), HAMD, and then the infrared thermographic images to be acquired.
62075039|NCT05024149|EXPERIMENTAL|MDD electroacupuncture intervention group|
62279019|NCT02061254|EXPERIMENTAL|3 groups of subjects|"3 groups:~* group of 48 healthy volunteers (matched with venous insufficiency patients)~* group of 48 patients with venous insufficiency (16 with stage 1/2, 16 with stage 3/4, 16 with stage 5/6)~* group of 40 patients with unilateral lymphedema (20 on upper limb (10 early stage, 10 severe stage), and 20 on lower limb (10 early stage, 10 severe stage))~Each group have the same interventions: physical examination, measures by cutometer, high resolution ultrasonography, elastography 30 persons will have a skin biopsy (15 healthy volunteers and 15 patients with venous insufficiency) For patients with lymphedema, all measures will be performed on lymphedema limb and on controlateral healthy limb"
62645144|NCT03367000|EXPERIMENTAL|Ceprolac|Received supplementation which added 27.6g protein and 114kcal to daily nutritional intake as well as standard diet counselling for 6 months
62279020|NCT03873155|EXPERIMENTAL|Mindfulness-based cognitive therapy|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.
62279021|NCT01184937|EXPERIMENTAL|Patient education program|
62279022|NCT01184937|NO_INTERVENTION|Standard care|
62645145|NCT03367000|PLACEBO_COMPARATOR|Dietary counseling (DC)|Received standard diet counselling only for 6 months.
62645146|NCT02664675||Periimplantitis|"patients formerly treated with a non surgical procedure without antibiotics with at least one functional dental implant with at least on pocket deeper than 5 mm with bleeding on probing and radiographical alveolar bone loss.~These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis."
62645147|NCT02664675||Periodontitis|patients formerly treated with a non surgical procedure without antibiotics for a generalized severe chronic periodontitis (in accord to Armitage 2009) and needing a resective surgical procedure (periodontal pockets deeper than 5 mm with bleeding on probing) These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis.
62645148|NCT02664675||Healthy patient|healthy patients needing crown lengthening allowing collection of gingival explants
62645149|NCT01613443||Control|Healthy volunteers without medication
62645150|NCT01613443||Phenprocoumon|Patients receiving Marcumar having target INR 2-3
62645151|NCT01613443||Dabigatran|Patients receiving therapeutic dosis of Pradaxa
62645152|NCT01613443||Rivaroxaban|Patients receiving therapeutic dosis of Xarelto
62645153|NCT04724135||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
62075040|NCT05024149|EXPERIMENTAL|MDD waiting-list group|In this study, we used a waiting list control group. During the 4 weeks follow-up period, participants from the MDD waiting-list group had no contact with participants from the MDD EA intervention group and no access to the EA intervention. After the 4 weeks follow-up period, patients in the waiting list group received access to the EA intervention.
62075041|NCT04315415|OTHER|6 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 6 months.
62075042|NCT04315415|OTHER|12 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 12 months.
62075043|NCT04315415|OTHER|24 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 24 months.
62075044|NCT00114309|EXPERIMENTAL|1|3 Dose Regimen
62075045|NCT00114309|EXPERIMENTAL|2|6 Dose Regimen
62645154|NCT00846365|EXPERIMENTAL|Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
62075046|NCT06208072|ACTIVE_COMPARATOR|Irbesartan group|Randomized obese hypertensive patients will receive treatment with oral Irbesartan 150mg once daily for 8 weeks. Blood pressure response will be assessed at that time.
62075047|NCT06208072|ACTIVE_COMPARATOR|Eplerenone group|Randomized obese hypertensive patients will receive treatment with oral Eplerenone twice daily for 8 weeks. Blood pressure response will be assessed at that time.
62075048|NCT03050437|EXPERIMENTAL|Pem/Cis|Pem/Cis IV every 3 weeks
62075049|NCT03050437|ACTIVE_COMPARATOR|Pem alone|Pem IV alone every 3 weeks
62075050|NCT02905123|EXPERIMENTAL|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
62645155|NCT00846365|EXPERIMENTAL|Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
62645156|NCT00846365|ACTIVE_COMPARATOR|Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD|(dependant on blood pressure)
62645157|NCT01832766|ACTIVE_COMPARATOR|dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
62645158|NCT01832766|PLACEBO_COMPARATOR|sugar pill|one capsule given by mouth at 8:00 a.m.
62645159|NCT06473350|EXPERIMENTAL|Right lateral, supine, and prone position|In this study, the right lateral, supine, and prone positions were applied to each infant sequentially, consecutively, under identical conditions, and within the same time frame. Each position was maintained for three hours immediately after each infant's routine feeding time. Each position was applied immediately after feeding. Data on heart rate, oxygen saturation, respiratory rate, pain level, and comfort level were recorded immediately after positioning, one hour later, and three hours later. This procedure was repeated in the same manner, sequence, and time frame for three consecutive days.
62645160|NCT01850641|EXPERIMENTAL|PA21|
62645161|NCT01079780|ACTIVE_COMPARATOR|Arm A (IC)|Patients receive cetuximab (500 mg/m2) intravenously (IV) over 60-120 minutes and irinotecan hydrochloride (180 mg/m2) over 60-90 minutes on day 1. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
62645162|NCT01079780|EXPERIMENTAL|Arm B (ICR)|Patients receive ramucirumab (8 mg/kg) IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm A. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
62645163|NCT01079780|EXPERIMENTAL|Arm C (mICR)|Patients receive reduced dose of ramucirumab (6 mg/kg) IV over 60 minutes on day 1 and cetuximab (150 mg/m2) and irinotecan hydrochloride (400 mg/m2) as in arm B. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
62645164|NCT01042795|EXPERIMENTAL|Continuous Daily Dosing of Sunitinib|
62645165|NCT05959928||Hospital at Home patients|
62075051|NCT02905123|NO_INTERVENTION|Control|No Intervention Control
62075052|NCT03770013|ACTIVE_COMPARATOR|bupivacaine 0.25% and Dexmedetomidine|bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.)
62075053|NCT03770013|ACTIVE_COMPARATOR|bupivacaine and clonidine|20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP
62645166|NCT04811196|EXPERIMENTAL|Metronomic dosing|"This Arm is an open-label, non-randomized, phase 1 study of metronomic dosing of selinexor in patients with locally advanced or metastatic MPNST, ESS, LMS. Up to seven dose levels of Selinexor will be investigated.~Patients will undergo 3+3 based dose escalation to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Selinexor.~Escalating doses of selinexor will be given starting with 2.5 mg (taken orally 4 days in a row followed by 3 days break from treatment, repeating this weekly as part of a 28-day cycle). The first dose for the first 2 patients at each dose level will be staggered by 7 days. Minimum number of patients treated in this trial arm is 18 patients, and maximum 36 patients.~Schedule:~Selinexor flat dosing with dose levels (DLs) of 2.5mg (DL1), 5mg (DL2), 7.5mg (DL3), 10mg (DL4), 12.5mg (DL5), 15mg (DL6), 17.5mg (DL7). A DL-1 (1.25 mg) is also incorporated."
62645167|NCT04811196|EXPERIMENTAL|Split dosing|The second arm of the study is an open-label, non randomized, phase 1b study of selinexor in patients with any histological subtype of STS administered orally one day per week, 40mg in the morning, 20mg in the afternoon and 20mg at night as part of a 28 day cycle. Twenty patients will be accrued to this arm.
62075054|NCT03770013|PLACEBO_COMPARATOR|bupivacaine and placebo|bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP
62645168|NCT04632004|OTHER|Questionnaire survey|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
62075055|NCT02811094|OTHER|Adult patients with Systemic LupusErythematosus (SLE)|Adult patients with SLE, clinically quiescent and with no change in treatment in the past 3 months, will be included and followed-up for 12 months. Blood samples will be drawn every 3 months during 12 months in the absence of flare. Patients presenting a flare will be sampled at the time of the flare and 1 month later.
62075056|NCT01275196|EXPERIMENTAL|Nilotinib|
62075057|NCT01275196|ACTIVE_COMPARATOR|Imatinib|
62075058|NCT02339701|OTHER|IMRT|Patients will receive 38 fractions of radiation, each fraction size will be 2Gy. The total dose will be 78Gy to PTV 1. Whereas the total dose will be 70Gy over 38 fractions to PTV 2. The treatment will be delivered 5 fractions per week consecutively except public holiday, and the total duration of treatment will be 7.5 to 8 weeks.
62075059|NCT02339701|OTHER|SBRT|Patients will receive 5 fractions of radiation; each fraction size will be 7.25Gy. The total dose will be 36.25 Gy to PTV1. Whereas the total dose will be 32.5Gy over 5 fractions to PTV2. The 5 treatments will be scheduled to be delivered twice aweek over approximately 15-17 days. A minimum of 72 hours and a maximum of 96 hoursshould separate each treatment. No more than 2 fractions will be delivered per week. The total duration of treatment will be no shorter than 15 days and no longer than 17 days.
62645169|NCT00116688|EXPERIMENTAL|Romiplostim|Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.
62645170|NCT00315341|EXPERIMENTAL|Buprenorphine/Nx|For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
62645171|NCT00315341|ACTIVE_COMPARATOR|Methadone|For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
62645172|NCT06407817|EXPERIMENTAL|Spencer's technique|This group will receive the Spencer's technique.
62645173|NCT06407817|ACTIVE_COMPARATOR|reverse distraction technique|This group will recieve reverse distraction technique
62645174|NCT02051868|ACTIVE_COMPARATOR|Arm A|Cisplatin and 5-Fluorouracil
62645175|NCT02051868|EXPERIMENTAL|Arm B|Carboplatin plus Paclitaxel
62075060|NCT00994474|ACTIVE_COMPARATOR|Fractional carbon dioxide laser treatment|
62645176|NCT04264208|EXPERIMENTAL|68Ga-RM2 PET MRI then 68 Ga PMSA11 PET/MRI|Subjects will undergo either 68Ga RM2 PET/MRI followed within 2 weeks by 68Ga PMSA11 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
62645177|NCT04264208|EXPERIMENTAL|68Ga-PSMA-11 PET MRI then 68Ga-RM2 PET MRI|Subjects will undergo 68Ga PMSA11 PET/MRI followed within 2 weeks by 68Ga RM2 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
62645178|NCT00435071|ACTIVE_COMPARATOR|1|
62645179|NCT00435071|ACTIVE_COMPARATOR|2|
62645180|NCT01792739|EXPERIMENTAL|Kadit B|Probiotic Lactobacillus casei variety rhamnosus granules
62645181|NCT01792739|PLACEBO_COMPARATOR|Kadit A|Placebo
62645182|NCT04592016|EXPERIMENTAL|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
62075061|NCT00994474|ACTIVE_COMPARATOR|Fractional Er:YAG laser treatment|
62279023|NCT02504229|EXPERIMENTAL|Chemotherapy+DC-CIK|Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.
62279024|NCT02504229|ACTIVE_COMPARATOR|Chemotherapy alone|Chemotherapy: two groups were treated with SOX program,specific drugs:Venoclysis of oxaliplatin 130mg/㎡;Day 1; Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/㎡/d,two oral/d;Day 1 to 12; 21d as one cycle of treatment, evaluated the therapeutic effect after two cycles.
62645183|NCT04592016|EXPERIMENTAL|Pivotal Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 20 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
62645184|NCT02553174||Ketorolac|Patients who receive ketorolac perioperatively
62645185|NCT02553174||Caldolor|Patients who receive Caldolor perioperatively
62645186|NCT02553174||No NSAIDS|Patients who do not receive NSAIDS perioperatively
62645187|NCT06388772|EXPERIMENTAL|Part-A SAD in healthy subjects(Cohort 1-8)|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive QHRD106 by intramuscular-injection (im).
62645188|NCT06388772|EXPERIMENTAL|Part-B Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive placebo by intramuscular-injection (im).
62645189|NCT00087178|ACTIVE_COMPARATOR|Arm 1: adriamycin + cyclophosphamide|Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
62645190|NCT00087178|EXPERIMENTAL|Arm 2: fluorouracil + epirubicin + cyclophosphamide|Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
62645191|NCT04320498|ACTIVE_COMPARATOR|control group|The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)
62645192|NCT04320498|EXPERIMENTAL|PRP group|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
62645193|NCT02206347|OTHER|attention focus|
62645194|NCT00821535|OTHER|Active group|maraviroc dosing group
62645195|NCT03191799|EXPERIMENTAL|1.5 mg/kg Emicizumab QW|Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
62645196|NCT01107925|EXPERIMENTAL|5 mg prasugrel|
62279025|NCT05881187|ACTIVE_COMPARATOR|groupA (control group)|will include 20 eyes of 20 patients with infectious keratitis who will receive antimicrobial therapy.
62279026|NCT05881187|ACTIVE_COMPARATOR|group B|will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated cross-linking Protocol-1 (9 mW/cm2 for 10 minutes to achieve 5.4 J/cm2) followed by antimicrobial therapy
62279027|NCT05881187|ACTIVE_COMPARATOR|group C|will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated crosslinking Protocol-2 (18 mW/cm2 for 7 minutes to achieve 7.2 J/cm2) followed by antimicrobial therapy
62279028|NCT01584037||Observational|This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
62279029|NCT05792878||Interferon treatment group|Patients with chronic hepatitis B who received antiviral treatment with Interferon at the Second Department of Hepatology, Beijing Ditan Hospital Affiliated to Capital Medical University from February 2022 to December 2023 were enrolled.
62645197|NCT01107925|ACTIVE_COMPARATOR|10 mg prasugrel|
62456154|NCT06246032|NO_INTERVENTION|Current feeding Protocol|"Retrospective data will be collected from medical record of patients undergo the current feeding protocol as follow~Initiation of feeding (average):~8.7cc/kg (6-12cc/kg)~Advancement based on birthweight (average):~\<750g: 20cc/kg/d (17-24cc/kg/d) 750-999g: 29cc/kg/d (25-34cc/kg/d) 1000-1249g: 22cc/kg/d (20-24cc/kg/d) 1250-1499g: 24cc/kg/d (21-25cc/kg/d) 1500-1749g: 20cc/kg/d (18-21cc/kg/d) 1750-2000g: 34cc/kg/d (32-36cc/kg/d)~Starting Human milk fortification when feed reach at 120cc/kg/d"
62645198|NCT01107925|ACTIVE_COMPARATOR|75 mg clopidogrel|
62645199|NCT04478838|EXPERIMENTAL|Extended Dosing Group|Participants taking olanzapine or risperidone will be switched to an alternate day dosing schedule.
62456155|NCT04870190|EXPERIMENTAL|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
62456156|NCT04870190|ACTIVE_COMPARATOR|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
62645200|NCT04478838|NO_INTERVENTION|Treatment as Usual group|Participants will continue to take their olanzapine or risperidone following the same prescribed daily schedule.
62645201|NCT03289078|EXPERIMENTAL|Thermal care|Spa Treatment realised daily 6 days a week during 18 days
62645202|NCT03289078|NO_INTERVENTION|Standard Care|Usual care
62456157|NCT02323490|EXPERIMENTAL|with microfractures|Standardized meniscal repair with bone marrow stimulation techniques (microfractures)
62279030|NCT05792878||nucleoside analogues treatment group|Patients with chronic hepatitis B who received antiviral treatment with nucleoside analogues at the Second Department of Hepatology, Beijing Ditan Hospital Affiliated to Capital Medical University from February 2022 to December 2023 were enrolled
62279031|NCT00751673||TESS prosthesis|Consecutive series of patients with a TESS prosthesis.
62279032|NCT03472560|EXPERIMENTAL|Avelumab in combination with axitinib|Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
62456158|NCT02323490|PLACEBO_COMPARATOR|without microfractures|Standardized meniscal repair without augmentation
62456159|NCT04346706|EXPERIMENTAL|Immediate implantation|Tooth extraction, immediate insertion of an implant with immediate temporization
62456160|NCT04346706|EXPERIMENTAL|Delayed implantation|Implant inserted in a healed socket with immediate temporization
62645203|NCT02732639|EXPERIMENTAL|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
62645204|NCT05110508|EXPERIMENTAL|Physical Activity Self-Regulation|Participants will receive multiple weekly text messages. Texts will contain wear reminders, encouragements, congratulatory content, and behavior change messages based on the Garmin data. Some text message content asks for a response from the participant to help tailor later messages for behavior change support.
62645205|NCT05342896|EXPERIMENTAL|MIND diet intervention|3-month intervention of dietary counseling to adhere to the MIND diet
62645206|NCT05342896|EXPERIMENTAL|MIND-plus-FB intervention|3-month intervention of dietary counseling to adhere to the MIND diet plus Forest Bathing intervention
62645207|NCT05342896|NO_INTERVENTION|Control group|For the control group, the participants will be received routine care.
62645208|NCT05228067|ACTIVE_COMPARATOR|Anodal stimulation|Anodal tDCS of the hypothalamus network
62279033|NCT00985400|EXPERIMENTAL|Exercise Program|Arm I (exercise program): Oncologist advice; Resistance bands \& pedometer with written/DVD instructions for resistance exercise twice a week for 16 weeks. Brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day. Monthly newsletters; Telephone counseling weekly for 4 weeks then monthly for 12 weeks; and tailored message telephone prompts once every 2 weeks during last 12 weeks of the study intervention.
62279034|NCT00985400|EXPERIMENTAL|Relaxation Intervention|Arm II (relaxation program): Oncologist advice; Written/CD audio instructions on diaphragmatic breathing and guided imagery. Practice relaxation techniques for 15 minutes/day, 5-7 days/week, for 16 weeks. Monthly newsletters, telephone counseling, and tailored-message telephone prompts as in arm I.
62456161|NCT01353495|EXPERIMENTAL|APM Graft (BIOTAPE XMTM|graft applied to wound q 3 weeks for 12 weeks
62279035|NCT00845988|ACTIVE_COMPARATOR|treatment as usual|patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine
62279036|NCT00845988|EXPERIMENTAL|switch to aripiprazole|aripiprazole
62279037|NCT01407926||Nurse-Led Mental Health Promotion Group|Interprofessional nurse-led strategy involving regular home visits over 6 months by an RN and PSW. The RN will conduct a comprehensive health assessment and screen clients for risk factors for depression and other chronic conditions, implement health promotion strategies to address this risk factors and enhance health, review their medications, conduct in-home exercise , refer clients to other health services
62279038|NCT02306460||left atrial catheter ablation|
62279039|NCT02306460||left atrial appendix closure|
62279040|NCT02306460||paroxysmal atrial fibrillation control group|
62456162|NCT01353495|ACTIVE_COMPARATOR|standard wound care|Wound debridement and gels and foams applied to wound weekly for 12 weeks.
62456163|NCT03189706|EXPERIMENTAL|Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS)|Each cycle consists of four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.
62456164|NCT04558307||Observational Intervention|Rapid SARS-CoV-2 testing strategy
62456165|NCT04558307||Behavioral Intervention|Community-driven messages to promote COVID-19 testing
62456166|NCT01092351|EXPERIMENTAL|Nitrofurantoin|Adult patients with a microbiologically confirmed uncomplicated urinary tract infection
62456167|NCT05251103|EXPERIMENTAL|time-restricted feeding trial|The participants were divided into the time-restricted feeding trial for 5 days
62456168|NCT05251103|EXPERIMENTAL|control trial|The participants in the control trial did not practice intermittent fasting methods
62456169|NCT01406678|ACTIVE_COMPARATOR|RIPC|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
62456170|NCT01406678|PLACEBO_COMPARATOR|Control|Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol
62456171|NCT06069297|EXPERIMENTAL|Multimodal Prehabilitation|A 4-week long preoperative intervention including exercise training, nutritional therapy and anxiety reduction techniques
62456172|NCT06069297|NO_INTERVENTION|Usual care|Usual preoperative care
62456173|NCT00818337|ACTIVE_COMPARATOR|Aspirin 81mg|Resistant
62456174|NCT01471366|ACTIVE_COMPARATOR|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products
62456175|NCT01471366|ACTIVE_COMPARATOR|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
62456176|NCT01471366|ACTIVE_COMPARATOR|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
62456177|NCT01471366|ACTIVE_COMPARATOR|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
62456178|NCT02268500|ACTIVE_COMPARATOR|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
62456179|NCT02268500|ACTIVE_COMPARATOR|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
62456180|NCT01939197|EXPERIMENTAL|ARM A|ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
62456181|NCT01939197|EXPERIMENTAL|ARM B|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
62456182|NCT01939197|EXPERIMENTAL|ARM C|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir once-daily
62456183|NCT01939197|EXPERIMENTAL|ARM D|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir twice-daily
62456184|NCT01939197|EXPERIMENTAL|ARM E|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for noncirrhotic (at screening) GT1b-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
62456185|NCT01939197|EXPERIMENTAL|ARM F|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
62456186|NCT01939197|EXPERIMENTAL|ARM G|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
62456187|NCT01939197|EXPERIMENTAL|ARM H|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-experienced participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
62279041|NCT02306460||persistent atrial fibrillation control group|
62456188|NCT01939197|EXPERIMENTAL|ARM I|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for noncirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
62645209|NCT05228067|ACTIVE_COMPARATOR|Cathodal stimulation|Cathodal tDCS of the hypothalamus network
62075062|NCT02338518|EXPERIMENTAL|SEEOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80～120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
62279042|NCT01014585|PLACEBO_COMPARATOR|1|Placebo tablets administered orally twice daily
62645210|NCT05228067|SHAM_COMPARATOR|Sham stimulation|Sham tDCS of the hypothalamus network
62279043|NCT01014585|EXPERIMENTAL|2|Milnacipran tablets administered orally twice daily
62279044|NCT01363986|EXPERIMENTAL|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.
62456189|NCT01939197|EXPERIMENTAL|ARM J|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for cirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
62456190|NCT01939197|EXPERIMENTAL|ARM K|ABT-450/r/ABT-267 coadministered with RBV for 12 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
62645211|NCT02644018|EXPERIMENTAL|Ingavirin|Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
62645212|NCT02644018|PLACEBO_COMPARATOR|Placebo|Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
62645213|NCT04268693||Study cohort|urinary bisphenol and phthalate levels
62645214|NCT02783638|EXPERIMENTAL|YHD1119 (Pregabalin 300mg)|YHD1119 (Pregabalin 300mg)
62456191|NCT01939197|EXPERIMENTAL|ARM L|ABT-450/r/ABT-267 coadministered with RBV for 24 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
62456192|NCT00395226|EXPERIMENTAL|Zinc sulfate|220 mg of zinc sulfate
62645215|NCT02783638|ACTIVE_COMPARATOR|Lyrica (Pregabalin 150mg)|Lyrica (Pregabalin 150mg)
62645216|NCT02938468|ACTIVE_COMPARATOR|Surgery|Patients in this arm will receive any form if surgical intervention (i.e. bedside burrhole craniostomy, 2 burrhole washout, craniotomy, endoscopy etc.) for treatment of their chronic subdural hematoma
62645217|NCT02938468|EXPERIMENTAL|Dexamethasone|Patients in this arm will receive Dexamethasone over a 21day period for treatment of their chronic subdural hematoma
62645218|NCT01298206||H1N1 not exposed controls|For every enrolled H1N1 case, the study will enroll 2 sex matched controls. On the date of enrollment of a case, 2 sex-matched controls will be located from the same clinic from which the case was enrolled. Enrolled controls will then be verified to be free from influenza infection at the time of enrollment by RT-PCR.
62645219|NCT01298206||H1N1 exposed Cases|A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
62645220|NCT02035566|EXPERIMENTAL|Telehome Care Monitoring + Usual Care|
61978768|NCT00869206|EXPERIMENTAL|Arm I (zoledronic acid every 4 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62075063|NCT02338518|ACTIVE_COMPARATOR|SOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80\~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
62075064|NCT05943418|EXPERIMENTAL|Active Intervention|
62075065|NCT05943418|ACTIVE_COMPARATOR|Control arm|
62279045|NCT01882283|EXPERIMENTAL|Tea Treatment Group|5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
62456193|NCT00395226|PLACEBO_COMPARATOR|Lactose|270 mg lactose
62456194|NCT03110315|EXPERIMENTAL|Suvorexant|Suvorexant - 10 mg (one tablet) taken by mouth once daily at bedtime with option to up-titrate to 20 mg (two tablets) taken by mouth once daily at bedtime.
62645221|NCT02035566|NO_INTERVENTION|Usual Care|
62645222|NCT04437758|EXPERIMENTAL|Hydrolyzed collagen and Vitamin C powder mix|20 g hydrolyzed collagen + 50 mg vitamin C (ascorbic acid) pre-packed powder diluted in 250 ml (8 oz) of water
62645223|NCT04437758|PLACEBO_COMPARATOR|Maltodextrin powder|20 g maltodextrin pre-packed powder diluted in 250 ml (8 oz) of water
62645224|NCT00942916||Patients with confirmed diagnosis of NTM pulmonary disease|Those with sputum mycobacterial culture yielded the same NTM species for at least two sets within one year.
62645225|NCT00942916||Patients with not definite NTM pulmonary disease|Those who had sputum culture yielded NTM but did not satisfy the criteria for diagnosis with NTM pulmonary disease.
62645226|NCT01981616|EXPERIMENTAL|Vedolizumab 750 mg|Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
62645227|NCT01981616|PLACEBO_COMPARATOR|Placebo|Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
62645228|NCT06207955|ACTIVE_COMPARATOR|TMJ arthrocentesis + (I-PRF) injection & injection of Botox to lateral pterygoid muscle|
62645229|NCT06207955|ACTIVE_COMPARATOR|TMJ arthrocentesis followed by intra-articular injection of liquid platelet rich fibrin ( I-PRF )|
62645230|NCT06207955|ACTIVE_COMPARATOR|TMJ arthrocentesis|
62645231|NCT03012269|EXPERIMENTAL|Working Memory Training|The subjects of experimental group received a series of working memory training, 30 min for 5 days per week during 6 weeks.
62645232|NCT03012269|NO_INTERVENTION|Non-Working Memory Training|The subjects of control group performed traditional cognitive rehabilitation without working memory training, 30 min for 5 days per week during 6 weeks.
62645233|NCT02349555|EXPERIMENTAL|Nutritional Supplement Blend|The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.
62456195|NCT03110315|PLACEBO_COMPARATOR|Placebo|Placebo - one tablet taken by mouth once daily at bedtime and two tablets taken by mouth daily at bedtime if subject up-titrates.
62456196|NCT00413556|ACTIVE_COMPARATOR|1|
62645234|NCT01429090|EXPERIMENTAL|Test|Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
62645235|NCT01429090|ACTIVE_COMPARATOR|Reference|Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
62645236|NCT01482546||Water Colonoscopy Method|As first described by Dr. Felix W. Leung, the maneuvers can be summarized as warm water infusion in lieu of air insufflation combined with suction removal of all residual colonic air and residual feces by water exchange. The air pump will be turned off before insertion of the colonoscope into the rectum to avoid accidental insufflation of air. Warm water (at 36-37ºC) maintained using a water bath and heat saver envelop will be infused intermittently. The minimum amount of water needed to distend the colon and open the lumen will be used during scope insertion. Cecal intubation will be suggested by appropriate movement of the endoscopic image on the monitor screen when the right lower quadrant is palpated or the appendiceal orifice visualized under water. The cecum will then be distended by air to confirm visualization of the ileocecal valve and appendiceal orifice. No specific limit will be set for the volume of water to be used.
62645237|NCT01482546||Air Colonoscopy Method|The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
62645238|NCT01474395|EXPERIMENTAL|D-serine 60 mg/kg|double blind dose of d-serine
62645239|NCT01474395|PLACEBO_COMPARATOR|Placebo D-serine|
62645240|NCT03011996|EXPERIMENTAL|CJ-12420 100mg|CJ-12420 100mg BID for 5 days
62645241|NCT03011996|EXPERIMENTAL|CJ-12420 50mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days
62645242|NCT03011996|ACTIVE_COMPARATOR|Pantoprazole 40mg + CLR 500mg + AMX 1g|coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days
62456197|NCT00413556|PLACEBO_COMPARATOR|2|
62075066|NCT05071274|EXPERIMENTAL|SkinPen Precision System|"After a 15-minute acclimation to ambient temperature and humidity conditions, subjects will participate in bio instrumentation to assess for erythema and will participate in standard photography.~The Investigator will treat each subject's face from hairline to jawline with the SkinPen Precision System following instructions in the SKINPEN PRECISION SYSTEM INSTRUCTIONS with the following treatment of the face at depths of up to 1.5mm. Treatment depth will be recorded for each subject at every visit. Subjects will be dispensed a study provided diary and trained on compliance."
62075067|NCT03084939|EXPERIMENTAL|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
62075068|NCT03084939|ACTIVE_COMPARATOR|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
62279046|NCT01882283|PLACEBO_COMPARATOR|Placebo Group|5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
62645243|NCT03011996|EXPERIMENTAL|CJ-12420 100mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days
62645244|NCT03011996|EXPERIMENTAL|CLR 500mg/AMX 1g|CLR 500mg/AMX 1g BID for 5 days
62645245|NCT03011996|EXPERIMENTAL|CJ-12420 100mg + CLR 500mg/AMX 1g|coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days
62645246|NCT03499795|EXPERIMENTAL|VGX-3100|Adult participants who were HIV negative with histologically confirmed anal or anal/peri-anal HSIL associated with HPV-16 and/or 18, received four 6 mg doses of VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 40 followed immediately by EP using the CELLECTRA™ 5PSP device.
62075069|NCT04771858||Study Group|No intervention
62075070|NCT06241261|EXPERIMENTAL|Silver diamine fluoride gel|38% silver diamine fluoride gel
62075071|NCT06241261|ACTIVE_COMPARATOR|Silver diamine fluoride solution|38% silver diamine fluoride solution
62645247|NCT02522117|ACTIVE_COMPARATOR|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
62645248|NCT02522117|PLACEBO_COMPARATOR|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
62645249|NCT05596071|EXPERIMENTAL|Sufentanyl+Epidural analgesia|Combined use of sufentanil and ropivacaine for intraoperative and postoperative analgesia
62645250|NCT05596071|SHAM_COMPARATOR|Epidural analgesia|Only use of ropivacaine for intraoperative and postoperative analgesia
62645251|NCT04624113|EXPERIMENTAL|Phase I: Tazemetostat + Pembrolizumab|"* Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~* Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend on dose level assigned~* Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
62075072|NCT04156152|ACTIVE_COMPARATOR|Grupo I|16 patients
62075073|NCT04156152|ACTIVE_COMPARATOR|Grupo II|16 patients
62279047|NCT03607331|EXPERIMENTAL|Auricular vagus nerve stimulation|Auricular Concha Electro-acupuncture: twice a day at home as required, once in the morning and once in the evening, with 5 consecutive days per week for two months
62279048|NCT03607331|ACTIVE_COMPARATOR|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
62279049|NCT06237894|EXPERIMENTAL|Multisensory Stimulation|
62279050|NCT01365663|EXPERIMENTAL|Cohort 1|0.25 mg/kg in Healthy Subjects
62456198|NCT03207581|EXPERIMENTAL|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
62645252|NCT04624113|EXPERIMENTAL|Phase 2: Tazemetostat + Pembrolizumab|"* Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~* Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend of recommended phase 2 determined in Phase I portion of study.~* Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
62645253|NCT02611947||Healthy Volunteers|"Inclusion criteria:~1. Aged 18 or more.~2. Never smoked.~3. No respiratory infection in the 4 weeks before the begin of the study.~4. No history of pulmonary resection.~5. No active malignancy or malignancy of any organ system within the past 5 years."
62279051|NCT01365663|EXPERIMENTAL|Cohort 2|0.5 mg/kg in Healthy Subjects
62279052|NCT01365663|EXPERIMENTAL|Cohort 3|1.0 mg/kg in Healthy Subjects
62279053|NCT01365663|EXPERIMENTAL|Cohort 4|1.5 mg/kg in Healthy Subjects
62279054|NCT01365663|EXPERIMENTAL|Cohort 5|2.0 mg/kg in Healthy Subjects
62279055|NCT01365663|PLACEBO_COMPARATOR|Saline 0.9%|
62279056|NCT01042080|ACTIVE_COMPARATOR|PSV-ET 25|Pressure support ventilation with expiratory trigger set at 25 %.
62279057|NCT01042080|ACTIVE_COMPARATOR|PSV-ET 50|Pressure support ventilation with expiratory cycling set at 50 %.
62645254|NCT04165122|EXPERIMENTAL|HDIT101 + Valaciclovir placebo|"Group A:~Patients treated with a single i.v. infusion of 2 g HDIT101 for 60 min at the randomization visit and with an episodic Valaciclovir placebo bid for 3 days."
62645255|NCT04165122|ACTIVE_COMPARATOR|HDIT101 placebo + Valaciclovir|"Group B:~Patients treated with a single i.v. infusion of HDIT101 placebo for 60 min at the randomization visit and with episodic Valaciclovir 500 mg twice daily for 3 days."
62645256|NCT02830568||couples kidney living donor - receiver|"Three groups for each technique of taking of kidney :~1. open donor nephrectomy~2. standard and hand-assisted laparoscopic donor nephrectomy~3. laparoscopic robotic-assisted nephrectomy"
62645257|NCT00972621|EXPERIMENTAL|Vitrax II|Investigational dispersive viscoelastic
62645258|NCT00972621|ACTIVE_COMPARATOR|Viscoat|Marketed control dispersive viscoelastic
62645259|NCT04191746||Participants with critical limb disease|This registry will collect data from participants with critical limb disease from Duke University and approximately 40 sites in North America.
62645260|NCT03732378|EXPERIMENTAL|Omega-3|one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time)
62645261|NCT03732378|PLACEBO_COMPARATOR|Placebo|one capsule of 500 mg corn oil, along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time) were given to placebo group
61978769|NCT00869206|EXPERIMENTAL|Arm II (zoledronic acid every 12 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62279058|NCT01042080|EXPERIMENTAL|NAVA|NAVA level is adjusted to achieve similar peak inspiratory pressure levels than during PSV.
62645262|NCT02756702||All-Poly|All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components
62645263|NCT06235671|EXPERIMENTAL|Chiropractic intervention|Upper cervical chiropractic care
62645264|NCT03335345|OTHER|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
62645265|NCT03335345|OTHER|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
62456199|NCT03207581|ACTIVE_COMPARATOR|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
62645266|NCT03520452|PLACEBO_COMPARATOR|Placebo|Placebo
62645267|NCT03520452|EXPERIMENTAL|302 mg green coffee extract|Green coffee extract
62456200|NCT00928954|ACTIVE_COMPARATOR|Gabapentin|Increasing dose to 300 mg four times per day (total of 1200 mg/day)
62456201|NCT00928954|ACTIVE_COMPARATOR|Memantine|Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
62279059|NCT06501274|OTHER|all eligible patients with non stenotic eosinophilic oesophagitis|single arm observational study
62279060|NCT00838019|EXPERIMENTAL|Cord blood|
62456202|NCT01303978|EXPERIMENTAL|APD421 starting dose|
62456203|NCT02403700||All study participants|One group observation study
62456204|NCT01625637|EXPERIMENTAL|AAT-avoid cigarette condition|Adolescent smokers are trained to avoid tobacco in a training AAT
62645268|NCT03520452|EXPERIMENTAL|604 mg green coffee extract|Green coffee extract
62279061|NCT03607279||NGAL - retropubic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
62456205|NCT01625637|PLACEBO_COMPARATOR|AAT-no contingency continued assessment|
62456206|NCT04784000|EXPERIMENTAL|AT-527 550 mg + carbamezepine|
62645269|NCT03520452|EXPERIMENTAL|906 mg green coffee extract|Green coffee extract
62075074|NCT00823732|ACTIVE_COMPARATOR|Phase 2 Intervention|GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
62075075|NCT00823732|NO_INTERVENTION|Phase I Usual Care|GROUP I (usual care): Patients receive standard care.
62075076|NCT01468922|EXPERIMENTAL|A/Combination pazopanib plus ARQ 197 (Tivantinib)|Combination pazopanib plus ARQ197 at doses established during escalation phase
62075077|NCT00787592||Silver Sulfadiazide (SSD)|Patients that receive SSD as the topical debriding agent
62075078|NCT00787592||Collagenase|Patients that receive collagenase as the debriding agent
62075079|NCT03077373|EXPERIMENTAL|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
62075080|NCT03077373|NO_INTERVENTION|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
62075081|NCT01495182|EXPERIMENTAL|Dietary Fiber - Dose 1|Dietary fiber will be added to study foods
62075082|NCT01495182|EXPERIMENTAL|Dietary Fiber - Dose 2|Dietary fiber will be added to study foods
62075083|NCT01495182|ACTIVE_COMPARATOR|Control|Study foods with no added fiber will be given
62075084|NCT01479686|ACTIVE_COMPARATOR|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
62075085|NCT01479686|EXPERIMENTAL|intraoperative MRI|iMRI guided resection in adults with glioma
62075086|NCT01397565|ACTIVE_COMPARATOR|Laparoscopic cholecystectomy|Patients in this arm will undergo conventional laparoscopic cholecystectomy
62075087|NCT01397565|EXPERIMENTAL|Minilaparoscopic cholecystectomy|Patients in this arm will undergo laparoscopic cholecystectomy using minilaparoscopic instruments
62075088|NCT02583568|EXPERIMENTAL|Part 1|In part 1 a dose escalation will be performed for the tracer bevacizumab-800CW in four different dose groups (4,5mg 10mg 25mg 50mg)
62075089|NCT02583568|EXPERIMENTAL|Part 2|In part 2, the two best performing dose groups of bevacizumab-800CW of part 1 will be expanded to a total of 10 patients per group.
62075090|NCT06255093|OTHER|Pre-Surveys Only|Pre-surveys only (did not meet referral criteria based on screening assessment) and receive online wellness education and anxiety treatment options information
62075091|NCT06255093|OTHER|Pre-Surveys, Recreational Program Referral, Post Surveys|Pre-surveys, meet referral criteria, referred to a program, post-surveys. Post-surveys will occur at the end of the out-of-school program, or 4 months after joining the program (whichever comes first).
61978770|NCT02985164|EXPERIMENTAL|PDSa (Pocket radiation dosimeter a)|"A co-researcher reset and prepared 4 pocket dosimeters (PDS) and labelled as PDSa1, PDSa2, PDSb1 and PDSb2.~The PDSa1 and PDSa2 were placed on the outside and inside of a lead shirt respectively. The shirt-covered box was close to an anesthetic machine. This box would represent anesthetic personnel on duty and marked as position A. Position A was 160 cm. above the floor"
62075092|NCT03988010|EXPERIMENTAL|Amantadine Sulphate|200 mg ıv Amantadine Sulphate in 500 cc solution
62075093|NCT03988010|PLACEBO_COMPARATOR|Placebo group|iv 500 cc %0.9 sodium chloride
62075094|NCT02189096||No change from current practice|"Phase 1 (4 months)~No change from current practice. Each Paramedic crew routinely documents patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be electronically captured. The data will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria \[signs of systemic inflammation\] and suspicion of infection) by the study investigators. An estimate will be made of the time of completion of the ePRF in relation to patient transport."
62279062|NCT03607279||NGAL - robotic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
62279063|NCT02371265|EXPERIMENTAL|Adherence and retention intervention|Implementation of adherence and retention package
62279064|NCT02371265|NO_INTERVENTION|Control|Clusters continue without intervention package
62279065|NCT01744288|EXPERIMENTAL|1|Ticagrelor with Platelet transfusion
62075095|NCT02189096||NEWS and Sepsis Screening|"Phase 2 (4 months)~The ten crews will undertake implementation of NEWS and Sepsis Screening. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, the patients transfer will be as per normal protocol but receiving ED staff will receive the information about NEWS score and Sepsis screening as part of a structured handover."
62075096|NCT02189096||Point of care lactate measurement|"Phase 3 ( 4 months)~The ten crews will undertake Point of Care Lactate measurement when NEWS ≥ 4 or when the patient screens positive for Sepsis. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection).~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge. The lactate level, along with the NEWS score and sepsis screening, will be given to the receiving ED staff as part of a structured handover."
62075097|NCT05287568|EXPERIMENTAL|Cohort 1 CC-486 200 mg|CC-486 200 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
62075098|NCT05287568|EXPERIMENTAL|Cohort 2 CC-486 300 mg|CC-486 300 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
62075099|NCT05287568|EXPERIMENTAL|Dose Expansion Cohort|CC-486 MTD will be determine following the completion of Cohort 1 and Cohort 2 with venetoclax at 400 mg/day PI regimen for 28 days.
62075100|NCT02258464|EXPERIMENTAL|Radium 223 dichloride|Participants treated with a single hormonal agent as background therapy received 50 kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update) of Radium 223 dichloride intravenously for a maximum of 6 cycles at intervals of 4 weeks
62075101|NCT02258464|PLACEBO_COMPARATOR|Placebo|Participants treated with a single hormonal agent as background therapy received isotonic saline (0.9% sodium chloride solution for injection) intravenously for a maximum of 6 cycles at intervals of 4 weeks
62075102|NCT01991249|EXPERIMENTAL|blood sample|
62279066|NCT01744288|EXPERIMENTAL|2|Ticagrelor without Platelet transfusion
62456207|NCT04784000|EXPERIMENTAL|AT-527 1100 mg + carbamezepine|
62075103|NCT01046461|EXPERIMENTAL|Ramosetron, Aprepitant, Dexamethasone|
62279067|NCT01744288|ACTIVE_COMPARATOR|3|Clopidogrel with Platelet transfusion
62279068|NCT01744288|ACTIVE_COMPARATOR|4|Clopidogrel without Platelet transfusion
62279069|NCT03836300|EXPERIMENTAL|Infants with a rare neurogenetic condition and their parent/primary caregiver(s)|PIXI
62279070|NCT04911946||R1|Resident of the first year of orthopedics and traumatology at IOT-HC-FMUSP.
62279071|NCT04911946||R2|Resident of the second year of orthopedics and traumatology at IOT-HC-FMUSP.
62279072|NCT04911946||R3|Resident of the third year of orthopedics and traumatology at IOT-HC-FMUSP.
62279073|NCT01820325|EXPERIMENTAL|Buparlisib + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib for up to 6 cycles, followed by blinded buparlisib maintenance
62279074|NCT01820325|PLACEBO_COMPARATOR|Placebo + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib-matching placebo for up to 6 cycles, followed by blinded placebo maintenance
62279075|NCT04090541|NO_INTERVENTION|Control|Tests were applied with any taping.
62456208|NCT02456948|EXPERIMENTAL|Minocycline|Minocycline and standard antidepressant treatment
62456209|NCT02456948|PLACEBO_COMPARATOR|Placebo|Placebo and standard antidepressant treatment
62075104|NCT03394261|EXPERIMENTAL|Patient Decision Aid|Patients in this arm will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
62075105|NCT03394261|NO_INTERVENTION|Record-only control group|Treatment records of patients receiving treatment in the same clinic in the prior 3 months will be abstracted for comparison purposes.
62456210|NCT04896164|EXPERIMENTAL|Investigational arm|Patients in the investigational arm will receive curcumin lozenges (4 gm BD containing 400 mg curcumin BD) as prophylaxis from two days prior to receiving high dose chemotherapy .
62456211|NCT04896164|PLACEBO_COMPARATOR|Control arm|patients in the control arm will receive matching placebo lozenges from two days prior to receiving high dose chemotherapy
62456212|NCT00269048|EXPERIMENTAL|Arm 1|SB-480848
62456213|NCT00269048|PLACEBO_COMPARATOR|Arm 2|placebo
62075106|NCT00850044|ACTIVE_COMPARATOR|1|ABT-450
62075107|NCT00850044|PLACEBO_COMPARATOR|2|Placebo for ABT-450
62075108|NCT00850044|ACTIVE_COMPARATOR|3|ABT-450/ritonavir
62075109|NCT00850044|PLACEBO_COMPARATOR|4|Placebo for ABT-450/placebo for ritonavir
62279076|NCT04090541|SHAM_COMPARATOR|Sham Taping|In ST stage; medical purpose, hypoallergenic OctaCare® Rigid Transparent Plaster was applied as a rigid tape. This tape is also used under rigid tapes for protecting the skin. In this study investigators didn't prefer extra rigid tape on the plaster because that was very light and less sensitive material to our knowledge so it suited our aim of placebo control.
62456214|NCT02373332||Healthy subjects|Healthy subjects for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
62456215|NCT02373332||Type 2 diabetes mellitus (T2DM) patients|T2DM patients for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
62075110|NCT04571632|ACTIVE_COMPARATOR|Immediate treatment arm:|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1, approximately 2 hours after the last SBRT fraction, intratumoral injection of ipilimumab (Yervoy®, 50mg/10mL solution) at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) and avelumab (Bavencio®, 200mg/10mL solution) at maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) will be performed. Subject will also receive a standard 200mg (fixed dose) intravenous infusion of pembrolizumab (Keytruda®, 100 mg/4mL solution).~On day 2, autologous, non-substantially manipulated CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be intratumorally administered. Previously cryopreserved CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be thawed before administration.~On day 21 and every 21 days thereafter, IT injection of ipilimumab and avelumab and IV pembrolizumab at the same dose as on day 1 will be performed. Treatment will be discontinued upon disease progression"
62279077|NCT04090541|EXPERIMENTAL|Kinesiology Taping|In KT stage; the original Kinesio Tex® Tape Classic was applied as a kinesiology tape. In this study, investigators applied the tape with muscle activation technique and paper of tension (it was declared %10) according to Kenzo Kase's Kinesio Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
62645270|NCT00193375|EXPERIMENTAL|Intervention|Patients received carboplatin \[area under the concentration-versus-time curve of 5 intravenously (IV) day 1 every 3 weeks x 4), irinotecan (50mg/m2 IV days 1 and 8 every 3 weeks x 4\], and radiation (1.8 Gy daily to a total of 61.2 Gy beginning with the 3rd cycle). Cycles 3 and 4 were 28 days each; with restaging after 4 cycles. Patients without progressive disease received bevacizumab (10 mg/kg IV every 14 days x 10).
62645271|NCT06519916||Patients with CD|Patients with CD, who have been diagnosed according to the Guidelines for diagnosing CD of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition and stick strictly to a gluten-free diet (transglutaminase negative, at least for a year)
62645272|NCT06519916||Healthy control group|Age-and-sex-matched healthy control. Exclusion criteria for healthy controls were chronic diseases, regular medication intake, food allergies or specific diets.
62645273|NCT03768713|EXPERIMENTAL|Drug (Suvorexant)|20 mg of Suvorexant daily (taken orally \~1 hour before bedtime)
62645274|NCT03768713|PLACEBO_COMPARATOR|Placebo|20 mg of Placebo daily (taken orally \~1 hour before bedtime)
62645275|NCT02023489|OTHER|Type 2 Diabetes Mellitus|
62645276|NCT02023489|OTHER|Insulin sensitive volunteers|
62645277|NCT02023489|OTHER|prediabetic subjects|
62645278|NCT02023489|OTHER|familiar hypocalciuric hypercalcemic patients|
62645279|NCT02023489|OTHER|Type 1 diabetes mellitus|
62645280|NCT06258850|EXPERIMENTAL|Calcifediol|Calcifediol (25-OH vitamin D3) in oral soft capsules (Hidroferol® 0,266 mg, equivalent to 15960 IU vitamin D).
62645281|NCT06258850|PLACEBO_COMPARATOR|Placebo|Placebo in oral soft capsules (externally indistinguishable from Hidroferol®).
61978771|NCT02985164|EXPERIMENTAL|PDSb (Pocket radiation dosimeter b)|"The PDSb1 and PDSb2 were placed on the outside and inside of the glass shield of control room respectively. This glass shield would represent all personnel working in the operating theatre and marked as position B.~Position B was 160 cm. above the floor."
61978772|NCT03741179|EXPERIMENTAL|ASA-withdrawn group|ASA treatment will be withdrawn if patients present an sFlt/PlGF \< 38 at 24+0-27+6 weeks of gestation.
62645282|NCT02125552|EXPERIMENTAL|Ultrasound guided intravenous access|This group will have their IV placed by ultrasound guidance.
62645283|NCT02125552|PLACEBO_COMPARATOR|Traditional intravenous access|The patients randomized to traditional IV access will have their IVs placed by standard technique.
62645284|NCT06333691|ACTIVE_COMPARATOR|Group A:(Calcium gluconate Group)|About 60 women patients,in which took IV infusion of calcium gluconate (Calcionate 10ml of 10% calcium gluconate, Memphis) in 200ml saline within 30 minutes of ovum pickup and contained for the next 3 days in addition to diosmin 2 tablets (500mg) t.d.s for 2 weeks.
62456216|NCT05080751|NO_INTERVENTION|Control|In this modality of intervention, the focus will be on the development of skills through educational actions in health, using the pedagogy of transmission. The focus will be based on content related to food, nutrition and quality of life. Materials like videos, áudios (podcasts), booklets and short films will be available weekly, following a schedule of sessions.
62456217|NCT05080751|EXPERIMENTAL|Eating Behaviors|In the intervention group, the focus will be the development of skills through educational health actions that provide the development of autonomy and empowerment for behavior change, based on cognitive behavioral interventions, which involve eating behavior and impact on quality of life. Cognitive behavioral therapy (CBT) is based on ten principles that influence and / or determine treatment attitude and approach. Intervention group sessions will be based on principles.
62645285|NCT06333691|ACTIVE_COMPARATOR|Group B:(Cabergoline Group)|About 60 women patients,in which took cabergoline (Dostinex 0.5 mg, Pfizer, Montreal, Canada) orally daily for 8 days after hCG triggering.
62645286|NCT06333691|ACTIVE_COMPARATOR|Group C:(Diosmin Group)|About 60 women patients,in which took diosmin , 2 tablets (500mg) t.d.s for 2 weeks in addition to cabergoline 1 tablet 0.5 mg/day orally for 8 days starting at the day of hCG injection.
62645287|NCT03195439|EXPERIMENTAL|patients in ICU|
62645288|NCT01836952||Infants|Infant born via vaginal delivery
62645289|NCT03844659|EXPERIMENTAL|Intervention Group|"The song Weightless by Marconi Union will be playing during subjects labor epidural placement."
62645290|NCT03844659|OTHER|Non Intervention Group|No song will be played during subjects labor epidural placement.
62645291|NCT03844906|EXPERIMENTAL|SAGE-718|
62645292|NCT03844906|PLACEBO_COMPARATOR|Placebo|
62645293|NCT02449434||Severe Tooth Wear|"Severe tooth wear with a BEWE score of 12 and at least one score of 3 in three quadrants Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
62645294|NCT02449434||Without Tooth Wear|"BEWE score of 10 or lower and no score of 3 on any surface of any tooth (clinically classified as no or mild erosive tooth wear) Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
62645295|NCT04108078|EXPERIMENTAL|Intervention|This arm consists of 1) MSM who receive the intervention (not wait listed) and healthcare facility staff who work at health facilities that have been chosen for the intervention.
62645296|NCT04108078|NO_INTERVENTION|Wait listed|Participants in this arm (MSM and staff at health facilities that were wait listed) will complete assessments, but will receive the intervention after the experimental arm of the study.
62645297|NCT03155711|EXPERIMENTAL|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
61978773|NCT03741179|NO_INTERVENTION|ASA group|ASA treatment will continue until 36 weeks of gestation if patients present an sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks of gestation.
61978774|NCT04859881||Barotrauma/cases|Cases were defined as patients with barotrauma consulted with the Surgery Department
62075111|NCT04571632|ACTIVE_COMPARATOR|Contemporary control arm|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1 and every + 21 days thereafter, subjects will receive a standard 200mg (fixed dose) IV pembrolizumab (Keytruda®, 100 mg/4mL solution) dose.~On disease progression, intratumoral administration as in the immediate-treatment arm will be conducted. Thus, intratumoral injection of ipilimumab at a maximum total dose of 10 mg and avelumab at maximum total dose of 40 mg will be performed. Administration of pembrolizumab at a dose of 200 mg will be continued.~Tumor response assessments by whole body PET/CT will be scheduled in week 12 and every 12 weeks thereafter during the treatment phase; . Baseline scan will be performed during screening period Procurement of tumor tissue by fine needle aspirates will be performed at the time of every intra-tumoral study drug administration"
62456218|NCT00192608|EXPERIMENTAL|saquinavir at baseline|patients receiving NRTIs + saquinavir + ritonavir 1000/100 mg BID at entry switch from 200 mg SQV capsules to 500 mg SQV tablets following PK at day 0. After PK at day 8 NRTIs ceased and regimen changed to ATV/SQV/RTV 300/1500/100 QD using 500 mg SQV formulation and continued to week 48
62075112|NCT04799860|EXPERIMENTAL|health promotive work-way|Six primary care units that voluntarily enrolls as experimental units. The units will receive implementation support based on previous research and tailored to the specific prerequisits and context for each unit. Strategies includes involvement of target groups; informationa and interactive education;use of external and internal facilitators tarined for the purpose; systematic feedback and learning dialogs during the project. The implementation support will take approximately 12 months.
62279078|NCT04090541|EXPERIMENTAL|Biomechanical Taping|In BT stage; Dynamic Tape® was applied as a biomechanical tape. In this study, investigators applied the tape with offload technique and paper of tension according to Ryan Kendrick's Biomechanical Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
62279079|NCT03686566||13C-glucose infusion|Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
62456219|NCT00192608|EXPERIMENTAL|other boosted PI at baseline|Patients receiving NRTIs + PI/RTV randomised at baseline to receive ATV/SQVRTV 300/1500/100 QD using 500 mg SQV formulation or ATV/SQV/RTV 300/1600/100 QD using 200 mg formulation. Following PK at day 7, SQV formulation switched with second PK assessment at day 15. Patients then receive ATV/SQV/RTV 300/1500/100 QD to week 48.
62279080|NCT03686566||No 13C-glucose infusion|Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
62279081|NCT04613726|PLACEBO_COMPARATOR|IV 10 ml normal saline|Control group consisted of patients receiving IV 10 ml normal saline.
62456220|NCT03044548|EXPERIMENTAL|Experimental|Supportive supervision
62456221|NCT03044548|NO_INTERVENTION|Control|No intervention
62456222|NCT01505530|EXPERIMENTAL|300 mg LY2495655 + chemotherapy|300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
62456223|NCT01505530|EXPERIMENTAL|100 mg LY2495655 + chemotherapy|100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
62456224|NCT01505530|PLACEBO_COMPARATOR|Placebo + chemotherapy|Placebo in combination with standard of care chemotherapy (investigator's choice)
61978775|NCT04859881||No braotruma/Controls|Controls were selected from a random sample of the COVID-19-ARDS cohort.
62279082|NCT04613726|ACTIVE_COMPARATOR|IV 8 mg ondansetron in 10 ml of normal saline|This group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline,
62279083|NCT04613726|ACTIVE_COMPARATOR|IV 3 mg granisetron in 10 ml of normal saline|This group consisted of receiving IV 3 mg granisetron diluted in 10 ml of normal saline.
62075113|NCT04799860|NO_INTERVENTION|Control|Six primary care centers of similar size and socioeconomic background in the population listed to each center.
62075114|NCT05561348|EXPERIMENTAL|active transcutaneous auricular vagus nerve stimulation|For Experimental Arm, active transcutaneous auricular vagus nerve stimulation, Patients underwent seven consecutive daily sessions of taVNS.
62075115|NCT05561348|SHAM_COMPARATOR|sham transcutaneous auricular vagus nerve stimulation|For sham transcutaneous auricular vagus nerve stimulation arm, Sham Comparator, patients underwent seven consecutive daily sessions of sham-taVNS (the electrodes were fixed at the same position without releasing current).
62075116|NCT05989165|EXPERIMENTAL|Minoxidil 5% solution|Patients will receive minoxidil 5%, twice a day, for a total duration of 12 weeks.
62279084|NCT04448990|EXPERIMENTAL|tVNS|Stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) bilaterally at the cymba conchae of the auricles for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
62075117|NCT05989165|EXPERIMENTAL|Combination therapy of microneedling and minoxidil 5% solution|Patients will receive a combination therapy of microneedling and minoxidil 5%. Minoxidil 5%, will be given twice a day for a total duration of 12 weeks. The microneedling treatment will be given every 4 weeks (week 0, week 4, week 8)for a total duration of 12 weeks.
62075118|NCT06071520||PTI patients treated with fostamatinib|Patient with criteria of PTI who has been treated with fostamatinib in the time described
62075119|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
62075120|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
62075121|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin \> 8µg/ml)
62075122|NCT06198296|EXPERIMENTAL|21.15.GPC3-CAR T cells|GPC3-CAR and the IL15 plus IL21 will be administered to patients with GPC3-positive solid tumors.
62075123|NCT03549234|EXPERIMENTAL|Erector Spinae (single injection)|
62075124|NCT03549234|ACTIVE_COMPARATOR|Paravertebral (single injection)|
62075125|NCT05223842|EXPERIMENTAL|Family Promoting Positive Emotions Group|Each dyad (mother and their child) will receive 8 sessions of promoting positive emotions intervention with a clinician for 8 weeks.
62075126|NCT05223842|ACTIVE_COMPARATOR|Written Information Group|Mothers will be sent written information and resources on depression for 8 weeks over email.
62075127|NCT00111254|EXPERIMENTAL|1|In group I, acute effect group, each subject will undergo microdermabrasion of the hip/buttock. Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device). 4mm punch biopsies will be performed in the treated area at 4hrs, 8hrs, and 24hrs post-treatment. In addition, one 4mm punch biopsy will be obtained from adjacent untreated skin.
62075128|NCT00111254|EXPERIMENTAL|2|In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
62075129|NCT00715741|ACTIVE_COMPARATOR|1|Group 1 will receive 30% oxygen plus PEEP + 3 to 5 cm Water duration of anesthesia and surgery
62075130|NCT00715741|ACTIVE_COMPARATOR|2|Group 2 will receive 30% oxygen without PEEP for the duration of anesthesia and surgery
62645298|NCT03155711|ACTIVE_COMPARATOR|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
62075131|NCT00715741|ACTIVE_COMPARATOR|3|Group 3 will receive \> 90% oxygen plus PEEP + 3 to 5 cm of water for the duration of anesthesia and surgery
62075132|NCT00715741|ACTIVE_COMPARATOR|4|Group 4 will receive \> 90% oxygen and no PEEP for the duration of anesthesia and surgery
62075133|NCT00406471|ACTIVE_COMPARATOR|1|500 micrograms of ranibizumab
62075134|NCT00406471|ACTIVE_COMPARATOR|2|300 microgram ranibizumab
62279085|NCT04448990|SHAM_COMPARATOR|Sham|Same stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) to bilaterally to the earlobes for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
62075135|NCT00917267|EXPERIMENTAL|1|
62075136|NCT00917267|ACTIVE_COMPARATOR|2|
62075137|NCT04193748|ACTIVE_COMPARATOR|Control group|Topical triamcinolone acetonide 0.1% available commercially (Kenacort- in orabase) has been used. Topical corticosteroid treatment has be repeated four times per day for four weeks.
62075138|NCT04193748|EXPERIMENTAL|Group S|Topical pomegranate seeds extract treatment has been repeated four times per day for four weeks.
62075139|NCT04193748|EXPERIMENTAL|Group P|Topical pomegranate peel extract treatment has been repeated four times per day for four weeks.
62075140|NCT01666054|ACTIVE_COMPARATOR|Proportional Assist Ventilation (PAV)|Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
62075141|NCT01666054|ACTIVE_COMPARATOR|Pressure Support Ventilation (PSV)|Pressure Support Ventilation on the PV840 ventilator will be used according to a weaning algorithm. If patients develop distress despite maximal level of support on PSV, they will be temporarily switched to assist-control mode.
62075142|NCT06489054|EXPERIMENTAL|Peer education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the experimental group (peer-based education). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
62075143|NCT06489054|ACTIVE_COMPARATOR|Conventional education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the control group (dentist lecture). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
62075144|NCT01042990|ACTIVE_COMPARATOR|Home Exercise Only|Participants receive education and instruction on a home exercise program which they do on their own, with intermittent encouragement from study personnel.
62075145|NCT01042990|EXPERIMENTAL|APA|Participants exercise in a gym setting 3x/week for six months, performing gait and balance exercises along with a progressive walking program.
62279086|NCT02356562|EXPERIMENTAL|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily \[QD\] and dasabuvir twice daily \[BID\]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
62456225|NCT04332978|EXPERIMENTAL|Group I|"Drug names: Fluticasone Propionate - PLURAIR® brand Pharmaceutical form: Nasal spray (50mcg / dose) Administration: Topical nasal route Posology 02 jets in each nostril 1 time a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~Manufacturer: Libbs Farmacêutica Ltda. Presentation: Deliver 1 bottle of 120 doses in original packaging"
62075146|NCT01042990|EXPERIMENTAL|APA+TM|Participants exercise in a gym setting 3x/week for six months, performing a combined program of adaptive physical activity (gait and balance training) and progressive treadmill walking.
62279087|NCT02049047|EXPERIMENTAL|Everolimus|oral everolimus
62279088|NCT01113970|EXPERIMENTAL|Single Arm|open label, single arm, unblinded
62279089|NCT03353727|EXPERIMENTAL|Orthoptic rehabilitation|
62075147|NCT04981132|EXPERIMENTAL|Education+Exercise Group|Group 1: Patients will have 15 minutes of pain neuroscience education (PNE) and 30 minutes of progressive therapeutic exercise training (PTE) with the telerehabilitation method.
62075148|NCT04981132|EXPERIMENTAL|Exercise group|Group 2: Patients will have 45 minutes of progressive therapeutic exercise training (PTE) with the telerehabilitation method.
62075149|NCT04981132|NO_INTERVENTION|Control Group|Group 3: Participants will be taken for the waiting list after evaluation with the telerehabilitation method.
62075150|NCT04788069|ACTIVE_COMPARATOR|Wholemeal bread|Treatment with wholemeal bread
62075151|NCT04788069|ACTIVE_COMPARATOR|Sourdough bread|Treatment with sourdough bread
62075152|NCT04788069|ACTIVE_COMPARATOR|Bread with sourdough|Treatment with bread with sourdough
62075153|NCT04114851|EXPERIMENTAL|Active|Patients who get active monitor NoL
62075154|NCT04114851|NO_INTERVENTION|control|control no NoL
62075155|NCT03651232|EXPERIMENTAL|yoga|weekly prenatal yoga group class
62075156|NCT03651232|ACTIVE_COMPARATOR|support|weekly group support class
62075157|NCT02769065|PLACEBO_COMPARATOR|SRD: Placebo Cohorts 1-6, 18 and 19|TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.
62075158|NCT02769065|EXPERIMENTAL|SRD: Cohort 1: TAK-071 1 mg|TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.
62075159|NCT02769065|EXPERIMENTAL|SRD: Cohort 2: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
62075160|NCT02769065|EXPERIMENTAL|SRD: Cohort 3: TAK-071 9 mg|TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
62075161|NCT02769065|EXPERIMENTAL|SRD: Cohort 4: TAK-071 20 mg|TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.
62075162|NCT02769065|EXPERIMENTAL|SRD: Cohort 5: TAK-071 40 mg|TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.
62075163|NCT02769065|EXPERIMENTAL|SRD: Cohort 6: TAK-071 80 mg|TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5
62075164|NCT02769065|PLACEBO_COMPARATOR|MRD: Placebo Cohorts 7-9|TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.
62075165|NCT02769065|EXPERIMENTAL|MRD: Cohort 7: TAK-071 3 mg|TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
62075166|NCT02769065|EXPERIMENTAL|MRD: Cohort 8: TAK-071 9 mg|TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
62075167|NCT02769065|EXPERIMENTAL|MRD: Cohort 9: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
62075168|NCT02769065|PLACEBO_COMPARATOR|MRD: TAK-071 Placebo Cohorts 10-12+Donepezil|TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
62645299|NCT05598970|NO_INTERVENTION|Control|This group will serve as the Control group (81 HDs, 81 communities, 810 households) to identify the effects of a Parenting only, Unconditional Cash Transfer (UCT) only, and Parenting+UCT interventions. Caregivers will continue benefiting from a traditional government CHW home visit program, focusing on maternal and child health and nutrition, which is currently in practice in Tanzania.
62075169|NCT02769065|EXPERIMENTAL|MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg|TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
62075170|NCT02769065|EXPERIMENTAL|MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg|TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
62075171|NCT02769065|EXPERIMENTAL|MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg|TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
62075172|NCT02769065|EXPERIMENTAL|MRD: Placebo Cohorts 13-15|TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.
62279090|NCT06025266|EXPERIMENTAL|Unilateral Heel Raise|Muscle fatigue was created by exercise consisting of a combination of repetitive plantar flexion and dorsiflexion movements performed during the entire range of motion of the ankle at the frequency of movement determined by the metronome on one step.
62279091|NCT06025266|EXPERIMENTAL|Closed Chain Resisted Foot Adduction|The exercise was performed on the designed wooden assembly. The device was used to maintain the neutral position of the subtalar joint, stabilize the lateral and medial malleoli, and prevent compensation with the knee and hip joints. Individuals were seated with the knee flexed approximately 80 degrees and separated from the other extremity by the length of the forearm, and the contralateral knee was stabilized with the ipsilateral hand. The foot was brought from the abduction position to the adduction position and the heel was not lifted from the ground throughout the movement. The exercise was performed using a green elastic band.The movement was performed in sets of 50 concentric/eccentric contractions. A rest period of 10 seconds was added between each set.
62075173|NCT02769065|EXPERIMENTAL|MRD: Cohort 13: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
62075174|NCT02769065|EXPERIMENTAL|MRD: Cohort 14: TAK-071 9 mg|TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
62075175|NCT02769065|EXPERIMENTAL|MRD: Cohort 15: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
62075176|NCT02769065|EXPERIMENTAL|Cohort 16|
62075177|NCT02769065|EXPERIMENTAL|Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC|A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
62075178|NCT02769065|EXPERIMENTAL|BA/Food Effect: Cohort 17 Sequence BCA|B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
62075179|NCT02769065|EXPERIMENTAL|BA/Food Effect: Cohort 17 Sequence CAB|C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
62279092|NCT06025266|EXPERIMENTAL|Combined Exercise|Unilateral Heel Raise and Closed Chain Resisted Foot Adduction exercises were performed sequentially.
62456226|NCT04332978|ACTIVE_COMPARATOR|Group II|"Fluticasone Propionate - FLIXONASE® brand Nasal spray (50mcg / dose) Topical nasal route 02 jets in each nostril once a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~GlaxoSmithKline. Deliver 1 bottle of 120 doses in original packaging"
62653037|NCT06422533|EXPERIMENTAL|Ceftolozane/tazobactam|Ceftozolane/tazobactam (C/T) is a combination antibiotic with a new cephalosporin, structurally similar to ceftazidime, plus tazobactam. The FDA approved This known beta-lactamase inhibitor in 2018 to treat intra-abdominal and complicated urinary infections. In 2019, its indication was expanded to nosocomial pneumonia and those associated with mechanical ventilation. In Mexico, it was approved for marketing in June 2019. C/T has broad-spectrum activity since it has action against ESBL-producing Enterobacteria and MDR P. aeruginosa. Studies carried out in the real world using this antibiotic in patients with hematological malignancies have demonstrated clinical success in reports and case series, considered a therapeutic option in patients with Enterobacteriaceae and P. aeruginosa infections, particularly in MDR pathogens.
62456227|NCT06257290||Venous ThromboEmbolic (VTE) patients|a diagnosis of Venous ThromboEmbolic (VTE) less than 72 hours old at inclusion, with a follow-up of 3 to 6 months
62075180|NCT02769065|EXPERIMENTAL|SRD: Cohort 18: TAK-071 120 mg|TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
62075181|NCT02769065|EXPERIMENTAL|SRD: Cohort 19: TAK-071 160 mg|TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
62645300|NCT05598970|EXPERIMENTAL|Parenting only|88 HDs, 77 communities, 770 households. Existing CHWs will be trained to use an innovative digital application for the delivery of integrated ECD services to mothers who are at least 20 weeks pregnant and less than 32 weeks pregnant for a period of 15 months. CHWs will provide tailored ECD services (e.g., prompting messages tailored to child age and triggering follow-up visits conditional on changing conditions), covering all aspects of the Nurturing Care Framework (Health, Nutrition, Responsive Caregiving, Early Learning, Safety and Security (WHO, UNICEF, World Bank Group, 2018)). Real time data will be recorded by the CHWs in each visit using the application. Data will include information on visit attendance, activities conducted, home environment, caregiver practices, and CHW observations. From when the target child is 6 months old, group sessions will be organised by CHWs, focusing on caregiver-child interaction and stimulation activities.
62279093|NCT04121442|EXPERIMENTAL|Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor|Patients will receive specified dose of Isunakinra as monotherapy for three weeks, followed by combination with a PD-(L)1 inhibitor
62075182|NCT02769065|PLACEBO_COMPARATOR|SRD: TAK-071 Placebo+Donepezil Placebo|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.
62075183|NCT02769065|PLACEBO_COMPARATOR|SRD: TAK-071 Placebo+Donepezil|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.
62075184|NCT02769065|EXPERIMENTAL|SRD: Cohort 20: TAK-071 40 mg+Donepezil|TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
62279094|NCT00355394|PLACEBO_COMPARATOR|Placebo|Standard care including intravenous fluid, but no metoclopramide.
62645301|NCT05598970|EXPERIMENTAL|Parenting+Unconditional Cash Transfer|88 HDs, 77 communities, 770 households. In addition to the Parenting Intervention, pregnant women in the study sample will receive a bi-monthly unconditional mobile money transfer of 77,000 TZS (33 USD) from 5-7 months pregnancy over a period of 15 months (7 transfers in total).
62075185|NCT02769065|EXPERIMENTAL|SRD: Cohort 21: TAK-071 60 mg+Donepezil|TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.
62075186|NCT02769065|EXPERIMENTAL|SRD: Cohort 22: TAK-071 80 mg+Donepizil|TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.
62279095|NCT00355394|ACTIVE_COMPARATOR|Metoclopramide|Standard care including intravenous fluid PLUS metoclopramide.
62279096|NCT04465682|EXPERIMENTAL|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm. Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user
62075187|NCT03653663|PLACEBO_COMPARATOR|Placebo|8 weeks treatment with placebo (or until muscle symptoms appear for at least 1 week or are unbearable)
62075188|NCT03653663|ACTIVE_COMPARATOR|20 mg simvastatin|8 weeks treatment with 20 mg simvastatin daily (or until muscle symptoms appear for at least 1 week or are unbearable)
62279097|NCT01526083|OTHER|Single dose of Warfarin on day 3|Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID
62279098|NCT01526083|OTHER|Single dose of Warfarin|
62279099|NCT01241214|EXPERIMENTAL|Investigational drug - Dose 1|
62279100|NCT01241214|EXPERIMENTAL|Investigational drug - Dose 2|
62279101|NCT01241214|EXPERIMENTAL|Investigational drug - Dose 3|
62279102|NCT01241214|EXPERIMENTAL|Investigational Drug - Dose 4|
62075189|NCT03698760|EXPERIMENTAL|Mild stage Alzheimer group|Participants with mild stage Alzheimer's disease
62279103|NCT01241214|OTHER|Active Matching Reference|
62279104|NCT01241214|PLACEBO_COMPARATOR|Matching Placebo|
62279105|NCT03498274|EXPERIMENTAL|Fitting System|a self-directed hearing screening based on a known algorithm from Audiology Inc. sold in an automated audiogram by Grason Stadler, GSI and a simplified version of the software. The flow of the new software is driven by the end user, but a trained professional should always assist with the fitting. The new software will first perform a hearing screening on the end user and then recommend a hearing aid and prescribe amplification to the hearing aid based on the hearing screening results.
62279106|NCT03498274|ACTIVE_COMPARATOR|Traditional Fitting System|A traditional fitting method will be used as a control. This system is controlled by a trained professional, who performs the entire fitting without much interaction from the end user. The hearing instruments will be fit with the same settings as the experimental arm.
62279107|NCT02710357|ACTIVE_COMPARATOR|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
62279108|NCT02710357|EXPERIMENTAL|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 4 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
62279109|NCT02623335|EXPERIMENTAL|QPL (question prompt list) brochure|Patients were mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
62075190|NCT03698760|EXPERIMENTAL|Control Group|Participants without cognitive disorders
62279110|NCT02623335|NO_INTERVENTION|Usual care|The investigators observed that usual care included informed consent and a surgeon-directed deliberative phase in which surgeons presented their own evaluation of the trade-offs and goals of the proposed intervention.
62279111|NCT03796767|EXPERIMENTAL|Arm A (radiation therapy)|Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.
62279112|NCT03796767|EXPERIMENTAL|Arm B (salvage oligometastasectomy)|Patients with nodal metastases undergo salvage oligometastasectomy.
62279113|NCT03796767|EXPERIMENTAL|Arm C (salvage oligometastasectomy, radiation therapy)|Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
62279114|NCT01135589|EXPERIMENTAL|HSCT|
62075191|NCT01865617|EXPERIMENTAL|ALL (high tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg"
62279115|NCT00486278|EXPERIMENTAL|vatreptacog alfa 5 mcg/kg|
62279116|NCT00486278|EXPERIMENTAL|vatreptacog alfa 10 mcg/kg|
62279117|NCT00486278|EXPERIMENTAL|vatreptacog alfa 20 mcg/kg|
62279118|NCT00486278|EXPERIMENTAL|vatreptacog alfa 40 mcg/kg|
62279119|NCT00486278|EXPERIMENTAL|vatreptacog alfa 80 mcg/kg|
62279120|NCT00486278|EXPERIMENTAL|rFVIIa 90 mcg/kg|
62279121|NCT02833246|EXPERIMENTAL|SMS/MMS text messaging|Patients will be able to tailor their SMS/MMS reminders with respect to when (i.e., what time of day) they wish to receive the reminders, as well as how often the messages are sent (e.g., morning and evening).
62279122|NCT02833246|ACTIVE_COMPARATOR|usual care|This includes physician and nursing assessment and intervention for any identified AEs. Of note, there is not currently standard follow-up that patients receive from nursing or physician staff while on an OAM treatment. Patients are encouraged to call their physician's office with any questions or changes in their medical status but are not called routinely by MSK staff.
62279123|NCT02361164||Mother/child pair|Mother/child pair.
62653038|NCT06422533|ACTIVE_COMPARATOR|Piperacillin/tazobactam|At our hospital, Piperacillin/tazobactam is the primary drug used as an empirical treatment in patients with severe neutropenia and fever, according to Clinical Practice Guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
62075192|NCT01865617|EXPERIMENTAL|ALL (high tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
62653039|NCT04519424|EXPERIMENTAL|CSL324|CSL324 administered intravenously
62653040|NCT04519424|PLACEBO_COMPARATOR|Placebo|Normal saline administered intravenously
62075193|NCT01865617|EXPERIMENTAL|ALL (high tumor burden) dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg"
62075194|NCT01865617|EXPERIMENTAL|ALL (low tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg"
62075195|NCT01865617|EXPERIMENTAL|ALL (low tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
62075196|NCT01865617|EXPERIMENTAL|CLL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg"
62075197|NCT01865617|EXPERIMENTAL|CLL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg"
62075198|NCT01865617|EXPERIMENTAL|CLL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg"
62279124|NCT00197054|EXPERIMENTAL|VACC 1 (RTS, S/AS01B)|RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
62075199|NCT01865617|EXPERIMENTAL|CLL (ibrutinib) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg"
62075200|NCT01865617|EXPERIMENTAL|NHL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg"
62075201|NCT01865617|EXPERIMENTAL|NHL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
62075202|NCT01865617|EXPERIMENTAL|NHL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg"
62279125|NCT00197054|EXPERIMENTAL|VACC 2 (RTS, S/AS02A)|RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
62075203|NCT01865617|EXPERIMENTAL|NHL (dose dense) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
62075204|NCT05429359|ACTIVE_COMPARATOR|CSII users|Patients using Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps)
62279126|NCT00197054|ACTIVE_COMPARATOR|Rabipur (Rabies) Vaccine|Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
62645302|NCT05598970|EXPERIMENTAL|Unconditional Cash Transfer only fixed amount|89 HDs, 80 communities, 800 households. Households, in addition to the CHWs delivering health and nutrition services as usual, will receive a fixed bi-monthly unconditional mobile money transfer each of 109,000 TZS (47USD) from 5-7 months pregnancy over a period of 15 months (7 transfers in total). The transfer will be randomly assigned between mothers and fathers/spouses within each community, where in half of the eligible households, mothers will receive the transfer and in the other half, fathers/spouses (or household head where the father/spouse is not available) will receive the transfer.
62279127|NCT00343512|EXPERIMENTAL|Therapeutic Intervention|
62279128|NCT02602223|EXPERIMENTAL|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
62279129|NCT02602223|ACTIVE_COMPARATOR|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
62279130|NCT00500682|PLACEBO_COMPARATOR|Placebo|
62645303|NCT05598970|EXPERIMENTAL|Unconditional Cash Transfer only vary amount|89 HDs, 75 communities, 375 households. In addition to the previous four main treatment arms, there is another UCT only treatment study group where the level of the cash amount varies across communities. Communities, in addition to the CHWs delivering health and nutrition services as usual, in this group will be randomised to receive one of the bi-monthly unconditional mobile money transfer amounts: 32,000 TZS (14USD), 77,000 TZS (33USD), 109,000 TZS (47USD) from 5-7 months pregnancy over a period of 15 months (7 transfers in total). The transfers will be randomly assigned between mothers and fathers/spouses within each community, where in half of the eligible households, mothers will receive the transfer and in the other half, fathers/spouses (or household head where the father/spouse is not available) will receive the transfer.
62279131|NCT00500682|EXPERIMENTAL|AST-120|
62075205|NCT05429359|ACTIVE_COMPARATOR|MDI users|Patients using Multiple Daily Injections (only Tresiba and Toujeo as basal insulin)
62279132|NCT03880201||patient undergoing upper limb orthopaedic surgery|The study will be performed on patient undergoing upper limb orthopaedic surgery which will be performed under ultrasound guided supraclavicular block.
62279133|NCT03875950|EXPERIMENTAL|Training intervention|In this cluster randomized control trial design, the experimental arm refers to the 12 study sites that are randomly assigned to receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
62279134|NCT03875950|NO_INTERVENTION|Standard of care control|In this randomized cluster randomized control trial design, the no intervention arm refers to the 12 study sites that are randomly assigned not to receive the clinician training intervention. Instead, these study sites will receive the standard of care, which is no standardized patient actor training, for health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
62279135|NCT01817816|EXPERIMENTAL|Botox_A|receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)
62279136|NCT01817816|PLACEBO_COMPARATOR|placebo_A|receiving placebo injection at both aLE \& aUE ; receiving Botox-A at both aLE \& aUE at 6-month.
62456228|NCT03548168||Healthy Adults|Eligible healthy young adults, aged 18-30 years, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
62456229|NCT03548168||Low Back Pain|Eligible young adults, aged 18-30 years, with chronic low back pain will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
62645304|NCT03641976|EXPERIMENTAL|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
62645305|NCT03641976|ACTIVE_COMPARATOR|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
62645306|NCT02150941|EXPERIMENTAL|BioVac Direct Suction Device|Experimental arm
62645307|NCT02150941|ACTIVE_COMPARATOR|Standard Endoscopy Suction|Control arm
62645308|NCT02938780|PLACEBO_COMPARATOR|Control|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
62645309|NCT02938780|EXPERIMENTAL|Intervention|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message.
62645310|NCT01687153||Traumatic Brain Injury (TBI)|65-100 Vietnam Veterans with Traumatic Brain Injury (TBI), but without PTSD, mild cognitive impairment (MCI)/dementia
62645311|NCT01687153||Post Traumatic Stress Disorder (PTSD)|65-100 Vietnam Veterans with PTSD, but without TBI, MCI/dementia
62456230|NCT03548168||Older Adults|Eligible healthy middle aged and older adults, aged 55 years and older, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
62456231|NCT03548168||Trunk Experts|Eligible healthy middle aged and older adults, aged 55 years and older, with high levels of trunk muscle control (ie. individuals with expertise in the Pilates Method of exercise) will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
62645312|NCT01687153||Controls|65-100 Vietnam Veteran Controls without TBI or PTSD and comparable in age, gender, and education to the other cohorts
62645313|NCT01687153||TBI w/ MCI|65-100 Vietnam Veterans with TBI but without PTSD who meet the criteria for MCI but not dementia
62279137|NCT01817816|EXPERIMENTAL|Botox_B|receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.
62279138|NCT01817816|PLACEBO_COMPARATOR|placebo_B|receiving placebo injection at both aLE \& aUE ; receiving Botox-A only at aLE at 6-month.
62279139|NCT06057779|OTHER|Slow and heavy exercise therapy|Participants perform eccentric heel drop exercises into maximal dorsiflexion at slow speed.
62645314|NCT01687153||PTSD w/ MCI|65-100 Vietnam Veterans with PTSD but without TBI who meet the criteria for MCI but not dementia
62075206|NCT05011916|NO_INTERVENTION|Control group|Patients in the control group received 0.1% fluorometholone eye drops (0.1% fluorometholone + 0.05% tacrolimus eye drops for patients after corneal transplantation). The patients applied 0.1% fluorometholone eye drops 4 times daily for 10 weeks. Patients were instructed to continue with their usual ophthalmic medication regimens, such as topical antibacterial and antiviral drugs.
62645315|NCT01687153||Controls w/ MCI|65-100 Vietnam Veteran Controls without TBI or PTSD who meet the criteria for MCI but not dementia, and are comparable in age, gender, and education to the other cohorts
62645316|NCT01336725||Morbid obesity|All attending learning and mastery courses for persons with morbid obesity
62645317|NCT03229187||neoadjuvant chemotherapy|
62645318|NCT03277937|EXPERIMENTAL|Patients with gastric varices|Patients above 18 years old with gastric varices (GV) on the initial standard diagnostic upper endoscopy will be enrolled and treated using angiography in EUS-injection of coils + CYA. GV will be classified according to Sarin and Kumar classification. Only gastro-esophageal varices type II (GOV II) (fundal varices communicating with esophageal varices) and isolated gastric varices type I (IGV I) (fundal varices within a few centimeters of the gastric cardia) will be included. Gastro-esophageal varices type I (GOV I) will be excluded. Patients with active bleeding and history of previous bleeding due to GV (secondary prophylaxis) will be included as well as patients with high-risk GV suitable for primary prophylaxis according to Baveno VI consensus. T
62645319|NCT00875316|EXPERIMENTAL|Cohort A|
62645320|NCT00875316|EXPERIMENTAL|Cohort B|
62645321|NCT00875316|EXPERIMENTAL|Cohort C|
62645322|NCT00875316|EXPERIMENTAL|Cohort D (Optional)|
62075207|NCT05011916|EXPERIMENTAL|Low-concentration group|Patients in the low-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
62075208|NCT05011916|EXPERIMENTAL|Medium-concentration group|Patients in the medium-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
62075209|NCT05011916|EXPERIMENTAL|High-concentration group|Patients in the High-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
62075210|NCT04191070|EXPERIMENTAL|Class II correction using infrazygomatic crest miniscrews|class II correction by distalization using infrazygomatic crest miniscrews (G1)
62279140|NCT06057779|OTHER|Slow and light exercise therapy|Participants perform eccentric heel drop exercises into neutral ankle position at slow speed.
62279141|NCT06057779|OTHER|Fast and heavy exercise therapy|Participants perform eccentric heel drop exercises into maximal dorsiflexion at fast speed.
62075211|NCT04191070|EXPERIMENTAL|Class II correction using zygomatic miniplates|class II correction by distalization using zygomatic miniplates (G2)
62075212|NCT04014478|EXPERIMENTAL|Endovascular Denervation|
62075213|NCT05936203|EXPERIMENTAL|Target|Setting a higher glucose target starting from 1 hour before until the end of walk.
62075214|NCT05936203|EXPERIMENTAL|Snack|Consumption of 15 g of complex carbohydrates as whole grain crackers every 30 minutes, during the 4 hours of walk.
62075215|NCT05936203|EXPERIMENTAL|Target + Snack|Combination of both Target and Snack interventions.
62075216|NCT01554943|ACTIVE_COMPARATOR|CMF|adjuvant standard CMF given from 1988 to 1996
62075217|NCT01554943|EXPERIMENTAL|EC|Adjuvant EC chemotherapy given from 1988 to 1996
62075218|NCT01554943|EXPERIMENTAL|HEC|High dose epirubicin (HEC) given from 1988 to 1996
62456232|NCT04005664|NO_INTERVENTION|Bolus group|Hypotension occurring under spinal anaesthesia (SBP \< 90mmHg) requires pharmacological treatment. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. The dose within this range will be decided by the attending anaesthetist. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
62075219|NCT03612518|EXPERIMENTAL|Text and Voice Messages|Participants will receive text messages and voice messages
62075220|NCT03612518|EXPERIMENTAL|Interactive Phone Call|Participants will receive interactive phone calls
62075221|NCT03612518|NO_INTERVENTION|Control|Participants in this arm will not be exposed to any intervention.
62075222|NCT03909802|EXPERIMENTAL|Experimental group|This arm will receive interventions consisting of self-management combined with family management programs.
62075223|NCT03909802|PLACEBO_COMPARATOR|Control group|Usual care refers to incorporating wound assessment, wound irrigation using NaCl, debridement, wound dressing, evaluation, and health education unmet with the self-and-family management of DFU program criteria in this study. All of the usual care will be performed and evaluated by the wound care nurses working at the selected clinics for this study.
62075224|NCT02258932||Continuous subcutaneous insulin infusion|This group will consist of patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
62279142|NCT06439368|EXPERIMENTAL|Test group|At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
62279143|NCT06439368|OTHER|Control group|At the end of the operation, sufentanil injection 3.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was immediately administered after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
62075225|NCT02922985|PLACEBO_COMPARATOR|Placebo Control Group|Patients will receive a placebo dose of all three study medications: Patients will receive the pre-operative dose of IV normal saline placebo within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of 20 mL of subcutaneous normal saline placebo after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive an IM dose of normal saline placebo.
62075226|NCT02922985|ACTIVE_COMPARATOR|Multimodal Pain Regimen Group|Patients will receive the actual study medication for all three study medications: Patients will receive the pre-operative dose of IV acetaminophen 1 g within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of either 20 mL of bupivacaine 0.25% after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive 60 mg of IM ketorolac.
62075227|NCT03217734|PLACEBO_COMPARATOR|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
62075228|NCT03217734|ACTIVE_COMPARATOR|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
62075229|NCT04623411|EXPERIMENTAL|Intervention Group|Neonatal resuscitation training with classical method and serious game simulation method
62075230|NCT04623411|EXPERIMENTAL|Control Group|Neonatal resuscitation training with classical method.
62075231|NCT05867264|PLACEBO_COMPARATOR|EOF 1 group：Early drinking water group|After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.
62075232|NCT05867264|EXPERIMENTAL|EOF 2 group: Early oral carbohydrate group|After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).
62075233|NCT05867264|PLACEBO_COMPARATOR|Control group: Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
62075234|NCT01565005||Microcephaly|Microcephaly Intellectual abilities Cranial MRI
62075235|NCT01565005||FANCONI ANEMIA|
62075236|NCT00976703|ACTIVE_COMPARATOR|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
62075237|NCT00976703|ACTIVE_COMPARATOR|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
62075238|NCT00820820|ACTIVE_COMPARATOR|Rouvax|
62075239|NCT00820820|PLACEBO_COMPARATOR|Placebo|Sub cutaneous injection of vehicle
62075240|NCT01297530|EXPERIMENTAL|Arm 1|
62075241|NCT01674933|ACTIVE_COMPARATOR|treatment as usual|any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing
62075242|NCT01674933|EXPERIMENTAL|Duraphat® Fluoride Varnish|treatment as usual (ie any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing) plus up to 4 six-monthly applications of Duraphat Fluoride Varnish in the nursery school setting.
62075243|NCT01812005|EXPERIMENTAL|Cohort A (alisertib, rituximab)|Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62075244|NCT01812005|EXPERIMENTAL|Cohort B (alisertib, rituximab)|Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62075245|NCT04676711|EXPERIMENTAL|GFH312|
62075246|NCT04676711|PLACEBO_COMPARATOR|Placebo|
62279144|NCT01625520|EXPERIMENTAL|SOM230 alone or in combination with RAD001|Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
62279145|NCT00910156|ACTIVE_COMPARATOR|Airtraq|
62075247|NCT00451568|ACTIVE_COMPARATOR|1|metformin
62075248|NCT00451568|ACTIVE_COMPARATOR|2|desorelle
62075249|NCT00451568|ACTIVE_COMPARATOR|3|desorelle + metformin
62075250|NCT01967264|EXPERIMENTAL|Udenafil 150 mg + Udenafil 150 mg|Udenafil 150 mg, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
62279146|NCT00910156|ACTIVE_COMPARATOR|Glidescope|
62279147|NCT00910156|ACTIVE_COMPARATOR|Macintosh|
62279148|NCT02569060|EXPERIMENTAL|Immediate Intervention|"Participants randomized to the Intervention Arm will immediately begin a four-component intervention.~1. Testing and monitoring of blood glucose levels~2. Referral to and/or coordination with primary care provider~3. Diabetes-appropriate food packages~4. Diabetes self-management education and support"
62075251|NCT01967264|EXPERIMENTAL|Udenafil 150 mg + Placebo|Udenafil 150 mg, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
62075252|NCT01967264|EXPERIMENTAL|Placebo + Udenafil 150 mg|Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
62075253|NCT01967264|PLACEBO_COMPARATOR|Placebo + Placebo|Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
62075254|NCT03607903|ACTIVE_COMPARATOR|Subcutaneous adalimumab and placebo|adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)
62075255|NCT03607903|ACTIVE_COMPARATOR|PLacebo and subcutaneous adalimumab|saline ID (0.9%, 0.4 mL) and adalimumab SC (40 mg in 0.4 mL)
62075256|NCT03607903|EXPERIMENTAL|Placebo and intradermal adalimumab|saline SC (0.9%, 0.4 mL) and adalimumab ID (40 mg in 0.4 mL)
62279149|NCT02569060|ACTIVE_COMPARATOR|Waitlist Control|"Participants randomized to the Waitlist Control arm will receive no intervention for six months, after which time they will begin a modified, four-component intervention.~1. Testing and monitoring of blood glucose levels~2. Referral to and/or coordination with primary care provider~3. Diabetes-appropriate food packages~4. Limited diabetes self-management education and support"
62075257|NCT03607903|EXPERIMENTAL|Intradermal adalimumab and placebo|adalimumab ID (40 mg in 0.4 mL) and saline SC (0.9%, 0.4 mL)
62279150|NCT04312698|EXPERIMENTAL|Experimental Group 1|
62075258|NCT05921071|ACTIVE_COMPARATOR|Tranexamic acid arm|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery.
62075259|NCT05921071|PLACEBO_COMPARATOR|Placebo arm|patients will receive 10 ml of normal saline 0.9% intravenously.
62075260|NCT06048757|EXPERIMENTAL|Experimental app intervention group|The intervention in the experimental group will center around the use of a mobile application (i.e., device), namely the Diactive-1 app.
62645323|NCT01894906|PLACEBO_COMPARATOR|Control|Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
62075261|NCT06048757|NO_INTERVENTION|Waiting-list control group|This arm will not complete an intervention. Participants will be instructed to continue to follow their normal daily diabetes care plan (i.e., standard care). This group will be granted access to the app following the intervention.
62075262|NCT02582164|EXPERIMENTAL|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
62075263|NCT02582164|EXPERIMENTAL|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
62075264|NCT02582164|EXPERIMENTAL|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
62075265|NCT02582164|EXPERIMENTAL|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
62279151|NCT04312698|PLACEBO_COMPARATOR|Comparator Group 1|
62279152|NCT04312698|PLACEBO_COMPARATOR|Comparator Group 2|
62075266|NCT00822003|ACTIVE_COMPARATOR|1|Human GLP-1
62075267|NCT00822003|PLACEBO_COMPARATOR|2|Placebo tablet
62075268|NCT01556074|EXPERIMENTAL|Yoga treatment|
62279153|NCT04313829|ACTIVE_COMPARATOR|Intervention group|The intervention group received Pharmacist counseling for 15 minutes include giving standard medicine information service and explaining the validated pharmacist counseling module which contained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed dose.
62279154|NCT04313829|NO_INTERVENTION|Control group|The control group received standard medicine information services by Pharmacists.
62645324|NCT01894906|EXPERIMENTAL|Soluble Ferric Pyrophosphate|Group/ cohort designation: Cellulose dialysis membrane (CT-190)/ Polyamide membrane. Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
62075269|NCT00284089|EXPERIMENTAL|Group A: Ranibizumab 0.3 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.
62075270|NCT00284089|EXPERIMENTAL|Group A: Ranibizumab 0.5 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.
62279155|NCT01043757|EXPERIMENTAL|Control|1) Control Group. Receives daily step goals via emails and has access to the study website to allow them to track their progress. Eligible for check-in incentives.
62645325|NCT03406520|EXPERIMENTAL|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week
62075271|NCT00284089|EXPERIMENTAL|Group B: Ranibizumab 0.3 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.
62075272|NCT00284089|EXPERIMENTAL|Group B: Ranibizumab 0.5 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.
62075273|NCT00001626|EXPERIMENTAL|A|D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months
62075274|NCT00001626|EXPERIMENTAL|B|ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months
62075275|NCT01812538|PLACEBO_COMPARATOR|Placebo|Placebo
62075276|NCT01812538|EXPERIMENTAL|Experimental 1|DIC075V 37.5 mg
62075277|NCT01812538|EXPERIMENTAL|Experimental 2|DIC075V 75 mg
62645326|NCT03945513|EXPERIMENTAL|LPRI424|Dienogest 2 mg / ethinyl estradiol 0.02 mg tablet orally once daily for 24 days followed by 4 placebo tablets for a 28 day cycle, for 13 cycles
62075278|NCT01812538|ACTIVE_COMPARATOR|Active control|Moxifloxacin hydrochloride 400 mg
62645327|NCT00808158||1|Children ages 9 to 10 years old, with a body mass index (BMI) in the 50th to 98th percentile range
62075279|NCT05047562|ACTIVE_COMPARATOR|Pilates Group|Participants will undergo 16 sessions, twice a week on alternate days through the following Pilates Method exercises: Pelvic Curl, Leg lift Supine, One leg circle modified and Hundred modified. There will be 4 sets of 5 repetitions in the first week, 6 repetitions in the second week, 7 repetitions in the third week, 8 repetitions in the fourth week, 9 repetitions in the fifth week, 10 repetitions in the sixth to eighth week.
62645328|NCT00048152|EXPERIMENTAL|1|
62645329|NCT00048152|EXPERIMENTAL|2|
62645330|NCT00048152|EXPERIMENTAL|3|
62645331|NCT03095807|EXPERIMENTAL|NNC9204-1706 A|
62645332|NCT03095807|PLACEBO_COMPARATOR|Placebo|
62075280|NCT05047562|ACTIVE_COMPARATOR|Segmental Stabilization Group|Participants will undergo 16 consultations, twice a week on alternate days through the following Segmental Stabilization exercises: multifidus in prone position, transverse abdomen in four supports, transverse abdomen in dorsal decubitus and transverse abdomen associated with multifidus in position orthostatic. There will be 4 sets of 10 repetitions of 10 seconds in all appointments.
62075281|NCT04676009|EXPERIMENTAL|Exercise arm :|"Patient randomized to the Exercise arm will receive physical activity recommendations at inclusion and nutritional assessment will be carried out during the first and last treatment cure. Patients will receive an acute physical exercise just before immunotherapy and chemotherapy infusion.They will have a home walking program and will have to wear an activity tracker during the 3 months of intervention.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3)."
62279156|NCT01043757|EXPERIMENTAL|Fixed|"Receives control intervention plus are incentivized to attain their daily step goals through daily lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot. Participants who meet their step goal for the day and who upload their data will be entered into the same lottery each day, where the small jackpot is $10 and the large jackpot is $100."
62456233|NCT04005664|ACTIVE_COMPARATOR|Phenylephrine coload group|Phenylephrine 500ug will be added to the first litre of ringer's lactate infused on initiation of spinal anaesthesia. If the phenylephrine infusion protocol is being used, and the mean arterial pressure (MAP) rises to greater than 20% of the initial MAP, and where this rise in MAP is not due to a recent bolus of either phenylephrine or ephedrine (within 2 minutes), the Ringers Lactate infusion will be switched off. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
62456234|NCT05068622||patients with nasogastric tube before surgery|
62456235|NCT05068622||patients without nasogastric tube before surgery|
62456236|NCT03022071|EXPERIMENTAL|Cognitive behavior therapy|The included patients will receive cognitive therapy for depression for 16 weeks and monthly booster sessions up to 28 weeks.
62456237|NCT03022071|ACTIVE_COMPARATOR|Psychodynamic psychotherapy|The included patients will receive time-limited psychodynamic psychotherapy for 28 weeks.
62456238|NCT00626548|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62456239|NCT00626548|EXPERIMENTAL|ZD4054|ZD4054 (Zibotentan)
62456240|NCT04799600||Acute Renal Failure in ICU|COVID-19 Patients with Acute Renal Failure in ICU
62645333|NCT02453607||CD Monotherapy|Crohn's disease treated with infliximab (monotherapy)
62645334|NCT02453607||CD Combo therapy|Crohn's disease treated with infliximab in combination with thiopurine (a 6MP metabolite) (combo therapy)
62075282|NCT04676009|NO_INTERVENTION|Control arm|"Patients will receive physical activity recommendations at inclusion and a nutritional assessment will be carried out during the first and last treatment cure. They will receive the usual care and standard treatment protocol (immunotherapy and chemotherapy).~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place 40 min before the administration of treatments (1), just before the administration of treatments (2) and 12 hours after the start of treatment (3)."
62075283|NCT02282319|EXPERIMENTAL|A chloro|spinal chloroprocaine 40 mg
62075284|NCT02282319|EXPERIMENTAL|B chloro+ spin dexdor|Spinal chloroprocaine 40 mg spinal dexmedetomidine 0.5 mcg
62075285|NCT02282319|EXPERIMENTAL|C chloro + IV dexdor|Spinal chloroprocaine 40 mg IV dexmedetomidine 0.5 mcg/kg
62456241|NCT02161913|ACTIVE_COMPARATOR|SCI Education Control Group|The SCIEC condition is a 16-session, highly structured educational intervention that provides information on how SCI affects the body; methods for maximizing function, coping, and living with SCI; and staying healthy with SCI. It also includes general guidelines for improving health behavior. Each SCIEC session follows the same structure, beginning with a presentation of the objectives for the current session and a brief review of material from the previous session before introducing the session's topic and presenting information on one or two key problem areas. SCIEC utilizes a traditional didactic model with information delivered by an expert SCI educator in a classroom or lecture setting.
62456242|NCT02161913|EXPERIMENTAL|Multi-family Group Treatment|The MFG Program uses a structured problem-solving and skills training program to provide participants with SCI and their caregivers with tools and information to improve coping and help family members to connect through positive behavioral exchanges. MFG educators are health professionals with experience in management of SCI, such as physical therapists, recreational therapists, occupational therapists, and psychologists. MFG will last for 16 sessions across 9 months.
62075286|NCT00895843|ACTIVE_COMPARATOR|Conventional ibuprofen|
62075287|NCT00895843|EXPERIMENTAL|Brufen retard|
62075288|NCT00593320|ACTIVE_COMPARATOR|1|Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
62075289|NCT00593320|ACTIVE_COMPARATOR|2|High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy
62456243|NCT04903262|EXPERIMENTAL|ECCO2R|"Patients will be initially treated with standardized ventilation: volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45.~ECCO2R initiated during standardized ventilation with blood flow between 1000 and 1500 mL/min. Anticoagulation with unfractionated heparin to a target aPTT of 1.5-2.0x baseline. Target: maintain PaCO2 at baseline ± 20%.~VT initially reduced to 5 mL/kg. Sweep gas initiated and VT decreased to 4.5 then 4 mL/kg; PEEP adjusted to maintain same mean airway pressure as during standardized ventilation, provided that Pplat ≤ 25 cmH2O.~Respiratory rate decreased to 8 bpm. If PaCO2 \> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.~Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center)."
62645335|NCT01392599|EXPERIMENTAL|Surgery|Patients with CRPS Type II
62075290|NCT03810313|EXPERIMENTAL|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
62075291|NCT03810313|ACTIVE_COMPARATOR|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
62075292|NCT01775930|EXPERIMENTAL|Carfilzomib|Patients receive Carfilzomib at dose of 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
62075293|NCT03729011|ACTIVE_COMPARATOR|Volatile anesthesia group|
62075294|NCT03729011|ACTIVE_COMPARATOR|TIVA group|
62279157|NCT01043757|EXPERIMENTAL|Ascending|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot.~Participants can increase their daily jackpots by meeting their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $4 and the large jackpot is $40; if they successfully meet their step goal on the first day of the week, the jackpots for the second day increase to $6/$60, and so on such that if they reach their goals each day, the jackpots on day seven will reach $16/$160."
62075295|NCT05239416|EXPERIMENTAL|Fat grafting combined with compression therapy|"Fat grafting + compression bandages/stockings~Fat grafting:~For the purposes of this study, the standard technique will be used for all patients~* General or local anaesthesia.~* Performed under the supervision of a plastic surgeon.~* Harvest site will be either abdomen or lower limb.~* After harvesting fat by liposuction, the lipoaspirate (which contains the ASCs) will be injected at the base of the healed venous ulcer within the same aseptic operative setting.~Compression therapy:~compression bandages / stockings as per routine practice"
62075296|NCT05239416|NO_INTERVENTION|Compression therapy only|"Compression therapy:~compression bandages / stockings as per routine practice"
62075297|NCT02690636|ACTIVE_COMPARATOR|Conventional|The patients will receive adjuvant radiotherapy conventionally fractionated 5000 cgy fractionated by 200cgy daily fractions, five fractions per week over 5 weeks with an additional 200cgy daily for five days as boost for patients with breast conservative surgery.
62075298|NCT02690636|EXPERIMENTAL|Hypofractionated|The patients will receive adjuvant radiotherapy hypofractionated 266cgy daily fractions, five fractions per week for total 16 fractions and an additional five daily fractions will be added as boost for patients with breast conservative surgery.
62075299|NCT06345222|EXPERIMENTAL|Prolotherapy|Patients to whom prolotherapy treatment applied (n=32).
62279158|NCT01043757|EXPERIMENTAL|Decreasing|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Daily drawing procedure same as Ascending condition; structure of incentives is different: Participants can decrease their daily jackpots by failing to meet their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $16 and the large jackpot is $160; if they successfully meet their step goal on the first day of the week, the jackpots will remain at $16/$160; if they do not meet their goal the jackpots will decrease to $14/$140, and so on such that if they fail to reach their goals each day, the jackpots on day seven will decrease to $4/$40."
62279159|NCT04003688|PLACEBO_COMPARATOR|Placebo group|Patient will be administered saline solution followed by venous general anesthesia.
62279160|NCT04003688|EXPERIMENTAL|Magnesium sulfate through real weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's actual weight followed by venous general anesthesia.
62279161|NCT04003688|EXPERIMENTAL|Magnesium sulfate through ideal corrected weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's ideal corrected weight followed by venous general anesthesia.
62075300|NCT06345222|OTHER|Control|Patients to whom no prolotherapy applied. No intervention with their treatment (n=33).
62075301|NCT03570125|EXPERIMENTAL|Dietary intervention arm|"group will follow an ad libitum diet but, every two months, will follow a 5 day of fasting mimicking diet (PROLON). The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS).~Prolon will be provided for free by L-nutra or in case of unforeseeable budget constraint at one fifth of its commercial value."
62075302|NCT03570125|NO_INTERVENTION|no intervention|Control/Placebo with multivitamin supplementation
62279162|NCT02910245|ACTIVE_COMPARATOR|Mercaptopurine (Purinethol)|Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks \& Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks \& Mesalamine, 2 g/day oral, 52 weeks.
62279163|NCT02910245|PLACEBO_COMPARATOR|Placebo|Placebo, 1-1.5 mg/kg/day, 52 weeks \& Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks \& Mesalamine, 2 g/day oral, 52 weeks.
62279164|NCT06071858|NO_INTERVENTION|Coordinated Specialty Care (CSC; standard of care)|Care as usual; no intervention.
62645336|NCT02460016|EXPERIMENTAL|AK0529|AK0529 pellets
62279165|NCT06071858|EXPERIMENTAL|Enhanced Coordinated Speciality Care (CSC 2.0)|CSC 2.0 arm will be offered 1:1 peer support, digital outreach, care coordination, multi-family group therapy, and cognitive remediation (if applicable).
62279166|NCT02449642||group 1|group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up
62279167|NCT02449642||group 2|group 2 include 10 women in which blood tests will be taken on the day of embryo transfer
62645337|NCT03511703|EXPERIMENTAL|Apatinib|
62645338|NCT03511703|OTHER|TACE|
62645339|NCT00601055|EXPERIMENTAL|Problem Solving-Rx Adherence (PSA)|Participants will receive problem-solving therapy integrated with adherence-enhanced procedures (PSA).
62075303|NCT01226979|EXPERIMENTAL|HDRBT (High Dose Rectal Brachytherapy)|Radiation: High-dose endorectal brachytherapy The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer. A daily dose of 6.5 Gy over four consecutive days
62645340|NCT00601055|ACTIVE_COMPARATOR|PID-C|Participants will receive adherence-enhanced (PID-C) procedures, a treatment mobilizing patients to participate in their care.
62075304|NCT01755520|EXPERIMENTAL|Ticagrelor|Intervention: Drug: Ticagrelor verum + Aspirin placebo
62075305|NCT01755520|ACTIVE_COMPARATOR|Aspirin|Intervention: Drug: Aspirin verum + Ticagrelor placebo
62645341|NCT02091700||Normals|Subjects with normal visual and retinal function will be enrolled
62645342|NCT01226329|EXPERIMENTAL|RQP-MH|Participants in the intervention arm will receive three Patient Activation and Self-Management education sessions, plus a fourth booster session if they show difficulty mastering the content of the first three trainings.
62075306|NCT06261463|EXPERIMENTAL|CAFES2 family and social strengthening intervention|Families randomized into CAFES2 receive a home visit and participate in six multiple family group sessions in addition to any outside services or programs they are participating in.
62075307|NCT06261463|NO_INTERVENTION|Enhanced Control|Families randomized to the enhanced control arm will not receive the CAFES2 intervention Instead, they will continue with their usual care, and also receive healthy lifestyle materials.
62075308|NCT05197790|OTHER|Assess device prototype functionality|Everyone will be in the same arm
62279168|NCT01180933|EXPERIMENTAL|fish oil|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA and 150 eicosapentaenoic acid per day from gestational week 22 until delivery
62279169|NCT01180933|EXPERIMENTAL|folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 400 µg folate (methyltetrahydrofolate)per day from gestational week 22 until delivery
62279170|NCT01180933|EXPERIMENTAL|fish oil + folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA, 150 mg eicosapentaenoic acid and 400 µg MTHF per day from gestational week 22 until delivery
62279171|NCT01180933|PLACEBO_COMPARATOR|placebo|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women from gestational week 22 until delivery
62279172|NCT04031079|EXPERIMENTAL|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program).
62279173|NCT04031079|ACTIVE_COMPARATOR|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
62279174|NCT02456350|EXPERIMENTAL|Anti-CD19-CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
62279175|NCT04688294|EXPERIMENTAL|Sacubitril/valsartan|Group 30 patients will undergo treatment with sacubitril/valsartan combination according to guideline-directed medical therapy.
62279176|NCT04688294|ACTIVE_COMPARATOR|Valsartan|Group 30 patients will undergo treatment with valsartan according to guideline-directed medical therapy.
62279177|NCT04233749|EXPERIMENTAL|Treatment|All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.
62279178|NCT00482014|EXPERIMENTAL|A: Pemetrexed + Carboplatin|Pemetrexed + Carboplatin
62279179|NCT00482014|EXPERIMENTAL|B: Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
62279180|NCT02587338|EXPERIMENTAL|Verum tDCS|Left frontal anodal stimulation, supraorbital right cathodal stimulation
62645343|NCT01226329|ACTIVE_COMPARATOR|Comparison Group|"Participants in this arm will receive a pamphlet in either Spanish or English called Managing Your Mental Health Care."
62279181|NCT02587338|EXPERIMENTAL|Sham tDCS|sham stimulation, same electrode positions
62279182|NCT00214123|EXPERIMENTAL|Bin 1|bin assignment based on tumor volume
62279183|NCT00214123|EXPERIMENTAL|Bin 2|Bin assignment based on tumor volume
62279184|NCT00214123|EXPERIMENTAL|Bin 3|Bin assignment based on tumor volume
62279185|NCT00214123|EXPERIMENTAL|Bin 4|Bin assignment based on tumor volume
62279186|NCT00214123|EXPERIMENTAL|Bin 5|Bin assignment based on tumor volume
62279187|NCT01076257|EXPERIMENTAL|Constraint-induced Movement Therapy|
62645344|NCT01404910|EXPERIMENTAL|Apheresis|Apheresis using Liposorber LA-15 System
62645345|NCT06290986|ACTIVE_COMPARATOR|Pyrocardan® implant|
62645346|NCT06290986|ACTIVE_COMPARATOR|Ligament reconstruction and tendon interposition (LRTI)|
62075309|NCT05467917||Index Case|a) minor testing positive for SARS-CoV-2; b) symptomatic health workers or any individual with a history of exposure to SARS-CoV-2 confirmed positive patients; c) health workers or any individual who tests positive regardless of symptoms. Index case must be living in a multi-person household that includes at least one child with a history of exposure to SARS-CoV-2 positive patients
62075310|NCT05467917||Household Contact|Anyone residing in the house for at least 24 hours at the time of the index case diagnosis or study enrollment.
62075311|NCT02443103|EXPERIMENTAL|Guanabenz|
62075312|NCT02762383|EXPERIMENTAL|Peginterferon Alfa-2a|Participants will receive a low dose of peginterferon alfa-2a for 18 months.
62075313|NCT01743690|ACTIVE_COMPARATOR|fluocinolone, placebo|fluocinolone, placebo
62075314|NCT01743690|EXPERIMENTAL|fluocinolone, probiotic|fluocinolone, Probiotic lactobacilli reuteri
62075315|NCT01743690|ACTIVE_COMPARATOR|Nystatin, placebo|Nystatin, placebo
62279188|NCT01076257|OTHER|Transditional rehabilitation|
62456244|NCT04903262|ACTIVE_COMPARATOR|Standard of care|"Patients will be treated with standardized ventilation: volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45.~Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center)."
62075316|NCT01743690|EXPERIMENTAL|nystatin, probiotic|nystatin, Probiotic lactobacilli reuteri
62075317|NCT05140811|EXPERIMENTAL|Relapse/Refractory AML|"IMM01 and Azacitidine in Relapse/Refractory AML~Interventions:~Drug: IMM01 Drug: Azacitidine"
62075318|NCT05140811|EXPERIMENTAL|Relapsed or Refractory MDS|"IMM01 and Azacitidine in Relapse/Refractory MDS~Interventions:~Drug: IMM01 Drug: Azacitidine"
62075319|NCT05140811|EXPERIMENTAL|Treatment naive AML|"IMM01 and Azacitidine in treatment naive AML~Interventions:~Drug: IMM01 Drug: Azacitidine"
62075320|NCT05140811|EXPERIMENTAL|Treatment naive MDS and naive CMML|"IMM01 and Azacitidine in treatment naive MDS and naive CMML~Interventions:~Drug: IMM01 Drug: Azacitidine"
62075321|NCT05689814|EXPERIMENTAL|Paraffin based Denture Fixative|Participants will use the paraffin-based denture fixative to secure their denture for 4 days and an additional 21-35 days during the observational (safety) period in accordance with the randomization schedule.
62075322|NCT05689814|ACTIVE_COMPARATOR|Polydecene based Denture Fixative|Participants will use the polydecene based denture fixative to secure their denture for 4 days and an additional 21-35 days during the observational (safety) period in accordance with the randomization schedule.
62075323|NCT05689814|NO_INTERVENTION|No Denture Fixative Control|Participants will continue to wear their dentures for 4 days and will not use any denture fixative as part of this study arm.
62075324|NCT00960102|ACTIVE_COMPARATOR|bilateral cochlear implant|
62075325|NCT00960102|ACTIVE_COMPARATOR|cochlear implant and hearing aid|
62075326|NCT00960102|ACTIVE_COMPARATOR|bilateral hearing aid|
62075327|NCT01435044|EXPERIMENTAL|SOF+RBV 12 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 12 weeks.
62075328|NCT01435044|EXPERIMENTAL|SOF+RBV 24 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 24 weeks.
62075329|NCT01435044|EXPERIMENTAL|GS-0938 Alone|Participants were randomized to receive GS-0938 plus placebo to match sofosbuvir for up to 24 weeks.
62075330|NCT01435044|EXPERIMENTAL|GS-0938+SOF|Participants were randomized to receive GS-0938 plus sofosbuvir for up to 24 weeks.
62075331|NCT01435044|EXPERIMENTAL|GS-0938+SOF+RBV|Participants were randomized to receive GS-0938 plus sofosbuvir plus RBV for up to 24 weeks.
62075332|NCT01435044|EXPERIMENTAL|Placebo|Deferred start group: Participants were randomized to receive placebo to match GS-0938 plus placebo to match sofosbuvir for 24 Weeks.
62279189|NCT06050538|ACTIVE_COMPARATOR|Transabdominal preperitoneal (TAPP)|patients with recurrent inguinal hernia who had Transabdominal preperitoneal (TAPP) approach
62279190|NCT06050538|ACTIVE_COMPARATOR|Total extraperitoneal (TEP) approach|patients with recurrent inguinal hernia who had Total extraperitoneal (TEP) approach
62279191|NCT05466461|EXPERIMENTAL|Beautifil Flow Plus X.|Giomers is a hybrid material category which contains Surface Pre-Reacted Glass-ionomer filler or S-PRG filler is produced from fluoroboro-alumino-silicate glass and polyacrylic acid through an acid-base reaction to form a stable glass ionomer phase on glass filler particle surfaces. S-PRG fillers can release and recharge fluoride. Also, the S-PRG filler-containing resinous materials are able to release various ions, such as aluminum (Al3+), boron (BO3 3-), fluoride (F- ), sodium (Na+), silicon (SiO3 2-), and strontium (Sr2+), in neutral and acidic conditions.
62456245|NCT01874158||TV postive women|All women who are TV positive by wet prep or in-pouch and meet the inclusion exclusion requirements.
62645347|NCT03458377|EXPERIMENTAL|Telephone call group|The patient receives the colonoscopy information from the primary care center on the day of the request for the test and a 20 minute educational telephone call 7 days before de procedure.
62645348|NCT03458377|NO_INTERVENTION|Non-telephone call group|The patient only receives the colonoscopy information from the primary care center on the day of the request for the test.
62075333|NCT01435044|EXPERIMENTAL|Retreatment Group - SOF+RBV 24 Weeks|After discontinuing a regimen containing GS-0938, participants received sofosbuvir plus RBV for up to 24 weeks.
62075334|NCT01342029|EXPERIMENTAL|Ranolazine|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
62075335|NCT01342029|PLACEBO_COMPARATOR|Placebo|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
62075336|NCT06413550|EXPERIMENTAL|Intervention group|patients in test group will topically apply 20 mL of Hibiscus Sabdariffa L. to the oral mucosa as oral rinse 3 times per day. Patients were advised to rinse 20 mL of Hibiscus Sabdariffa L. from the fourth week of radiotherapy to three months after radiotherapy.
62075337|NCT06413550|PLACEBO_COMPARATOR|Control group|Patients in the control arm will topically apply 20 mL of 0.9% of normal saline rinses 3 times per day. Patients were advised to rinse with 20 mL normal saline from the fourth week of radiotherapy to three months after radiotherapy.
62075338|NCT05401370|ACTIVE_COMPARATOR|MB group|Mb group will undergo surgeries with methylene blue staining
62075339|NCT05401370|NO_INTERVENTION|Control group|Control group will undergo surgeries without methylene blue staining
62075340|NCT03585114|EXPERIMENTAL|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive \[F-18\] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
62075341|NCT03200301|EXPERIMENTAL|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
62075342|NCT03200301|NO_INTERVENTION|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
62279192|NCT05466461|ACTIVE_COMPARATOR|Activa bioactive restorative|Activa BioACTIVE Restorative (Activa), developed by Pulpdent (Watertown, MA, USA), is a new bioactive restorative material that combines the advantages of an RMGIC (resin modified glass ionomer cement) and RBC (resin based composite), representing a new category of restorative materials that are ion releasing. It contains methacrylate- based monomers, a modified polyacrylic acid, modified Diurethane Dimethacrylate (rubberized resin), and fillers
62279193|NCT01175941|EXPERIMENTAL|NRL001|10 mg NRL001 in a 2 g suppository
62456246|NCT06116409||M-TAPA GROUP|Group 1 patients will receive a modified thoracoabdominal nerve block (M-TAPA) with a perichondrial approach using 40 ml of 0.25% bupivacaine guided by ultrasound (US).
62645349|NCT02995993|EXPERIMENTAL|Moss-aGal|Single administration of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion
62456247|NCT06116409||CONTROL GROUP|Patients in Group 2 (the control group) will receive routine multimodal analgesia, which includes tramadol at a dose of 1 mg/kg and paracetamol at a dose of 15 mg/kg.
62456248|NCT00582088|EXPERIMENTAL|Vaccine|VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205
62645350|NCT02425137|EXPERIMENTAL|S-1/Gemcitabine|single-arm
62645351|NCT05556655|EXPERIMENTAL|Active TMS|Repetitive TMS for the brain
62645352|NCT05556655|PLACEBO_COMPARATOR|Sham TMS|Scalp stimulation that does not affect the brain.
62645353|NCT03687632|EXPERIMENTAL|Single arm - active|ST266 eye drops given to the study eye for 28 days (112 doses total will be administered).
62075343|NCT03171558|EXPERIMENTAL|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
62075344|NCT03171558|ACTIVE_COMPARATOR|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
62279194|NCT01175941|PLACEBO_COMPARATOR|Placebo|Matched placebo control
62279195|NCT03793387|EXPERIMENTAL|Pre-op|
62279196|NCT03793387|ACTIVE_COMPARATOR|Intra-op|
62279197|NCT04378803|EXPERIMENTAL|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session. Then, 4 weeks of no-training interval followed by a testing session.
62279198|NCT04378803|EXPERIMENTAL|Wait-list control (WLC) group|Receives 4 weeks of no-training interval followed by a testing session. Then, 4 weeks of mindfulness training followed by a testing session.
62279199|NCT03553186|EXPERIMENTAL|ivTXA + topical TXA|"TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
62645354|NCT01929889|EXPERIMENTAL|Iloperidone|Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
62645355|NCT05567536||Clopidogrel group|This group are those who received clopidogrel 75mg qd as a single antiplatelet agent therapy after PCI.
62075345|NCT02337478|EXPERIMENTAL|Treatment (vincristine sulfate liposome)|Patients receive vincristine sulfate liposome via injection on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62075346|NCT01791452||NAFLD|
62075347|NCT04047381||Atrial Fibrillation|Turkish patients diagnosed with atrial fibrillation
62075348|NCT05366049|EXPERIMENTAL|using a medicine pacifier to give acetaminophen|
62075349|NCT05366049|ACTIVE_COMPARATOR|using an enjector to give acetaminophen|
62075350|NCT04291235|ACTIVE_COMPARATOR|Airway Management Pathway|An airway management pathway consisting of daily assessments and removal of the breathing tube as soon as patients can breathe on their own and appear able to protect their airway
62075351|NCT04291235|ACTIVE_COMPARATOR|Usual Care|The usual clinical practice is often to keep the patient on artificial respiration for longer in the hope that the patient will wake up before removing the tube, or performing a tracheostomy if the patient doesn't wake up
62075352|NCT04911257||Degenerate Disc Disease|Subjects who will undergo spinal fusion surgery utilizing Stryker Interbody Systems.
62075353|NCT01764373|EXPERIMENTAL|16-Week Exercise Program|Subjects to participate in 16-week3 supervised aerobic exercise 3 times per week. Exercise sessions to last between 30 and 60 minutes.
62075354|NCT01425164|ACTIVE_COMPARATOR|Carvedilol|
62075355|NCT01425164|EXPERIMENTAL|Ivabradine|
62075356|NCT03863743|OTHER|Control|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. Patient will undergo treating physician's standard of care for total hip or knee replacement. Patient will receive bladder scans in PACU, upon admission to the nursing unit, and prior to discharge (post-void).
62075357|NCT03863743|EXPERIMENTAL|Experimental|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. If considered high risk (determined by IPSS), then patient Patient will undergo integrated care pathway that avoids narcotics. Bladder volume will be measured in PACU, after admission to the nursing unit, and prior to discharge from the hospital (post-void).
62075358|NCT05794282||Group rTHA (robotic total hip arthroplasty)|the robot assisted total hip arthroplasty
62075359|NCT05794282||Group cTHA (conventional total hip arthroplasty)|the conventional total hip arthroplasty
62279200|NCT03553186|PLACEBO_COMPARATOR|IV TXA + topical placebo|"Placebo solution (200 cc sterile normal saline + placebo TXA ampule (normal saline) (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
62645356|NCT05567536||Aspirin group|This group are those who received aspirin 100mg qd as a single antiplatelet agent therapy after PCI.
62645357|NCT04710121|EXPERIMENTAL|Intervention Arm|"The experimental group will be asked about their anxiety states with the State and Trait Anxiety Inventory, their pain conditions with the Analog Scale (VAS), and their first life findings will be measured, and the first measurement values will be recorded in the Vital Signs Follow-up Form. Virtual reality glasses will be placed on the patient's head during colonoscopy. The duration of the colonoscopy will vary between 3-10 minutes, videos with music background, park, nature and seaside walks, underwater videos, which the patient chooses, will be watched and the Vital Signs Tracking Form Second measurement values will be recorded by making measurements. Immediately after the colonoscopy procedure is completed, Visual Analogue Scale (VAS), Vital Signs Follow-up Form (measurement will be made and 3rd measurement values will be recorded. The State Anxiety Inventory will be read and the answers will be recorded."
62075360|NCT03969082|EXPERIMENTAL|Bibliotherapy|"Students will read to patients receiving active treatment using the read aloud method. This will be performed in a 1: 1 relationship for half an hour for 8-10 times during a period of six months."
62075361|NCT01715623||Children with HSP|children with Purpura of Henoch-Schönlein with or without renal complication
62075362|NCT01715623||healthy volunteers|healthy volunteers without allergy
62075363|NCT01715623||subjects with allergy|subjects with peanut allergy or hymenoptera venom allergy
62075364|NCT01715623||lymphoma|lymphoma-proliferation with chromosome 14 translocation
62075365|NCT06077916|PLACEBO_COMPARATOR|Control|iv perfusion of 250 mL of 0.9% saline solution
62075366|NCT06077916|EXPERIMENTAL|Azithromycin|iv perfusion of 500 mg azithromycin in 250 mL of 0.9% saline solution
62075367|NCT02792985|EXPERIMENTAL|Multisensory stimulation protocol|The Experimental group will follow an intervention protocol.
62075368|NCT02792985|ACTIVE_COMPARATOR|Control protocol|The Control group will follow the current protocol for patients in PTA at the Institut Guttmann.
62075369|NCT02349568||High risk group|High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
62075370|NCT02349568||Intermediate risk group|Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
62075371|NCT02155959||one group|one group receiving a toric intraocular lens during cataract surgery.
62279201|NCT03940066|OTHER|Monitoring group|
62279202|NCT03940066|OTHER|Standard Care|
62279203|NCT05524545|EXPERIMENTAL|Evorpacept (ALX148) + Enfortumab Vedotin|"Phase 1a Dose Escalation: Evorpacept (ALX148) infusions will be administered every two weeks.~Enfortumab vedotin will be administered at 1.25 mg/kg IV on Days 1, 8, and 15 of each 28-day cycle."
62279204|NCT01793415|ACTIVE_COMPARATOR|IodoCarb (r)|3 g iodinated activated charcoal, IodoCarb(r), daily for 28 +-2 days.
62075372|NCT04730921|EXPERIMENTAL|LBBAP group|AV block patients randomized to left bundle branch area pacing
62075373|NCT04730921|ACTIVE_COMPARATOR|RVP group|AV block patients randomized to right ventricular pacing group
62279205|NCT01793415|PLACEBO_COMPARATOR|Placebo|3 g of non-iodinated activated charcoal daily for 28+-2 days.
62279206|NCT06205186|OTHER|Program Users|
62279207|NCT03282760|EXPERIMENTAL|Human Neural Stem Cells Suspension|Intraventricular injections of Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10,16 or 24 millions)
62645358|NCT04710121|NO_INTERVENTION|Control Arm|No application will be made in the control group. during and after colonoscopy and routine treatment and care will be applied.
62645359|NCT00447408|ACTIVE_COMPARATOR|A|Education in the hemodialysis diet.
62645360|NCT00447408|EXPERIMENTAL|B|Education in the hemodialysis diet. Behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
62645361|NCT05988372|EXPERIMENTAL|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|enrolled, eligible patients receive Surufatinib, Serplulimab, Gemcitabine and Albumin-paclitaxel
62645362|NCT05988372|EXPERIMENTAL|Albumin-paclitaxel + Gemcitabine|enrolled, eligible patients receive Gemcitabine and Albumin-paclitaxel
62645363|NCT03728569|OTHER|Subjects over the age of 70 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
62645364|NCT03728569|OTHER|Subjects between 18 and 30 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
62645365|NCT00597259|EXPERIMENTAL|A|
62645366|NCT00597259|ACTIVE_COMPARATOR|B|Entecavir Alone
62075374|NCT00431639|ACTIVE_COMPARATOR|Comparison|For the comparison condition, subjects will be asked to choose one of four topics that will be determined thatday with a recreational therapist for 20 minutes.
62075375|NCT00431639|ACTIVE_COMPARATOR|Treatment|The treatment condition will consist of a 20-minute visit by a therapy dog and its owner. Therapy dogowners will be instructed to limit conversation with the patient to topics of the therapy dog, thepatients pets, and pets in general.
62075376|NCT02383511|OTHER|Sequence 1|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
62279208|NCT03529292|EXPERIMENTAL|Matrix and Cells obtained by the AmeaCell® device|
62279209|NCT03254966|EXPERIMENTAL|SHR0302 dose level 1|
62279210|NCT03254966|EXPERIMENTAL|SHR0302 dose level 2|
62279211|NCT03254966|EXPERIMENTAL|SHR0302 dose level 3|
62279212|NCT03254966|EXPERIMENTAL|SHR0302 dose level 4|
62279213|NCT03254966|PLACEBO_COMPARATOR|Placebo|
62279214|NCT06084130|EXPERIMENTAL|Zolpidem|The participants in Zolpidem group will receive 10 milligrams zolpidem contained in white-color opaque medicine capsule prepared by the pharmacist. The participants will be advised to take the medication 30 minutes prior to the bedtime until the 1-week follow up visit.
62279215|NCT06084130|PLACEBO_COMPARATOR|Placebo|The participants in Placebo group will receive placebo which is corn-starch contained in identical white-color opaque medicine capsule. The participants will be advised to take the medication 30 minutes prior to the bedtime until the 1-week follow up visit.
62279216|NCT00217087|OTHER|Endoscopic Mucosal Resection|Patients will undergo endoscopic mucosal resection at time of endoscopy if indicated.
62279217|NCT00217087|OTHER|Photodynamic Therapy|Patients will have endoscopic mucosal resection with photodynamic therapy.
62645367|NCT00161213|EXPERIMENTAL|Gemcitabine and Imatinib|
62645368|NCT03560908|EXPERIMENTAL|Dasatinib plus chemotherapy|Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation
62075377|NCT02383511|OTHER|Sequence 2|Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
62075378|NCT02383511|OTHER|Sequence 3|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
62279218|NCT02412293|EXPERIMENTAL|Intervention|"Health Education \& Promotion: LHWs and CHWs will delivered the package via community awareness sessions and two one-to-one counselling sessions to pregnant women during third trimester and five newborn assessment visits in the neonatal period in intervention areas.~Training of Health Workers: The LHWs and CHWs will receive trainings on IMNCI-based training package.~Community Mobilization: For community mobilization and education, two types of tools will be used one group session by use of flip charts and group session by use of video."
62279219|NCT02412293|NO_INTERVENTION|Control|Control areas will continue to receive the routine standard health services of governmental and non-governmental organizations in the area.
62279220|NCT03913156|OTHER|Part 1|Part 1 of the study will recruit subjects who are about to be introduced to a concentrated phe-free protein substitute (i.e. second stage protein substitute) for the first time.
62279221|NCT03913156|OTHER|Part 2|Part 2 of the study will recruit subjects who have already been introduced to a concentrated phe-free protein substitute (i.e. have already transferred from phe-free infant formula onto a second stage protein substitute). This group will be included to evaluate the acceptability of the study product in patients who have already moved onto a second stage protein substitute.
62279222|NCT03869580||Stent infection|Patients diagnosed with urinary tract infection associated with double J stent
62279223|NCT03869580||No stent infection|Patients with double J stent without infection during the study period
62279224|NCT05506397|EXPERIMENTAL|Acupressure (intervention group)|Acupressure was applied to individuals in the acupressure group every day for 12 days.
62279225|NCT05506397|PLACEBO_COMPARATOR|control group|Placebo acupressure was applied to the individuals in the placebo acupressure group in accordance with the same protocol.
62279226|NCT02784938|EXPERIMENTAL|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
62279227|NCT02784938|NO_INTERVENTION|Wait-list Control|Services as usual
62279228|NCT01988090|EXPERIMENTAL|High Dose Vitamin D ARM|50,000 IU Vitamin D supplement
62279229|NCT01988090|ACTIVE_COMPARATOR|800 IU Vitamin D Supplement|800 IU Vitamin D Supplement
62279230|NCT05983289|EXPERIMENTAL|HSK7653|Single dose, oral
62279231|NCT05983289|PLACEBO_COMPARATOR|Placebo|Single dose, oral
62279232|NCT03817372|ACTIVE_COMPARATOR|Anterior-posterior electrode position|The anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
62279233|NCT03817372|ACTIVE_COMPARATOR|Anterior-lateral electrode position|The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
62279234|NCT00625092|EXPERIMENTAL|Hyperthermic Treatment|Patients receiving combination of hyperthermic intraperitoneal chemotherapy (HIPC) with oxaliplatin plus intraperitoneal 5-Fu and intraperitoneal leucovorin with peritoneal metastases.
62279235|NCT02458508||GBM patients|patients with diagnosis of glioblastoma treated with concomitant radio-chemotherapy with temozolomide as Stupp protocol will be evaluated for pharmacogenetic evaluation
62075379|NCT03765463|EXPERIMENTAL|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 4 two-hour sessions in an intensive format.
62075380|NCT02377713|EXPERIMENTAL|KHK6640|KHK6640
62075381|NCT02377713|PLACEBO_COMPARATOR|Placebo|Placebo
62075382|NCT04974541|EXPERIMENTAL|Cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga
62279236|NCT01629641||Normals|Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
62279237|NCT00626093|OTHER|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.
62279238|NCT05613530|EXPERIMENTAL|"digital MAX néonat (intervention group or  MAX + group)"|"Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes."
62279239|NCT05613530|ACTIVE_COMPARATOR|"MAX néonat on poster/paper (control group or  MAX - group)"|Participants have no cognitive aid
62279240|NCT06102733||Adult chronic pain patients|Adult chronic pain patients with pelvic, inguinal or sacroiliac pain
62645369|NCT06106750|EXPERIMENTAL|Nasobiliary duct cutting|Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then, extracting the severed nasobiliary duct and retaining the portion inside it.
62279241|NCT01055002|ACTIVE_COMPARATOR|Artemether/lumefantrine tablets|Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
62279242|NCT01055002|ACTIVE_COMPARATOR|Atovaquone/Proguanil HCl tablets|Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
62279243|NCT01595815|ACTIVE_COMPARATOR|Conventional ICSI|The couple showed complete fertilization failure after ICSI.
62279244|NCT01595815|ACTIVE_COMPARATOR|Convention ICSI|The couple showed a low fertilization rates after ICSI.
62075383|NCT04974541|ACTIVE_COMPARATOR|Cardiac rehabilitation with standard psychosocial care|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial education component
62075384|NCT02663375||ACURATE TA™ Transapical Aortic Biorposthesis|Patients implanted with ACURATE TA™ Transapical Aortic Biorposthesis and Delivery System
62075385|NCT01821443|EXPERIMENTAL|Stereotactic Radiosurgery (SRS)|Stereotactic radiosurgery technique via Gamma Knife® Perfexion™ radiosurgical system
62075386|NCT02513992|EXPERIMENTAL|intra-arterial injection of tracer|The perfusion tracer 99m-Technetium Ethyl Cysteinate Dimer will be injected via an intra-arterial catheter by a pressure injector to obtain a subtracted ictal SPECT co-registered with MRI (SISCOM)
62075387|NCT01886963|ACTIVE_COMPARATOR|Control - Blinded use of SPY Elite|Group A will consist of intraoperative abdominal wall imaging prior to incision, followed by ventral hernia repair with subcutaneous advancement flaps without viewing the imaging contained within the Spy Elite system. A digital photograph will be taken before and immediately after initial incision, as well as immediately prior to and after closure. The patient will have digital photographs of the surgical wound taken by the surgical team daily until discharge, and on follow-up visits at one week, two weeks, four weeks and twelve weeks. After twenty patients have completed phase I, the surgical team will be unblinded to Spy Elite imaging. The Spy Elite imaging and all digital photographs of all patients will be reviewed.
62075388|NCT01886963|EXPERIMENTAL|SPY - Unblinded Use of SPY Elite|Group B will have incision and advancement flap performed based on assessment of blood supply using the Spy Elite system, as well as potential flap revision if portions of the flap appear under-perfused in the pre-closure imaging. Patients will be blinded to whether or not their intraoperative Spy Elite imaging was used for operative planning. All patients will have digital photographs of the surgical wound taken by a blinded member of the surgical team daily until discharge, and on follow-up visits at one to two weeks, four weeks, and 12 weeks post-operatively. Digital photographs will be reviewed by a blinded surgeon, who will assess the wound for complications.
62075389|NCT02500485|EXPERIMENTAL|SHR3824 20mg/SP2086 100mg|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
62075390|NCT05509543|ACTIVE_COMPARATOR|A group|"Period 1 : Ilaprazole 10mg 2Tab, one a day~Period 2 : Ilaprazole 20mg 1Tab, one a day"
62075391|NCT05509543|ACTIVE_COMPARATOR|B group|"Period 1 : Ilaprazole 20mg 1Tab, one a day~Period 2 : Ilaprazole 10mg 2Tab, one a day"
62279245|NCT05358847|EXPERIMENTAL|Cellulite|
62279246|NCT03489798|EXPERIMENTAL|6 Misoprostol|Up to six doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
62645370|NCT06106750|ACTIVE_COMPARATOR|Bilateral plastic stent|Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
62075392|NCT01077362|EXPERIMENTAL|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 40. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
62075393|NCT01077362|EXPERIMENTAL|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 40. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
62075394|NCT01077362|EXPERIMENTAL|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
62075395|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
62279247|NCT03489798|ACTIVE_COMPARATOR|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
62075396|NCT05764239|EXPERIMENTAL|DEP (Part 1, SYNB1934v1)|"Participants received SYNB1934v1 orally immediately after meals on the following dose-ramp regimen:~Dose level 1 (Days 1-9): 3 × 10\^11 live cells partial dose up to 3 times daily (TID); Dose level 2 (Weeks 4-6): 6 × 10\^11 live cells up to TID; Dose level 3 (Weeks 7-9): 1 × 10\^12 live cells up to TID."
62075397|NCT05764239|EXPERIMENTAL|RWP (Part 2, SYNB1934v1)|Participants who completed the DEP were randomized 1:1 to receive SYNB1934v1 at their iTD established in the DEP orally immediately after meals. Participants remained on this dose of SYNB1934v1 for the duration of the RWP; doses of SYNB1934v1 were not permitted to be modified during the RWP.
62279248|NCT02368327|ACTIVE_COMPARATOR|Fluad|Participants receive one dose of Fluad vaccine
62279249|NCT02368327|ACTIVE_COMPARATOR|Fendrix|Participants receive one dose of Fendrix vaccine
62075398|NCT05764239|PLACEBO_COMPARATOR|RWP (Part 2, Placebo)|Participants who completed the DEP were randomized 1:1 to receive placebo orally immediately after meals. Participants remained on the same dose of placebo for the duration of the RWP; doses of placebo were not permitted to be modified during the RWP.
62075399|NCT05764239|EXPERIMENTAL|OLE (Part 3, SYNB1934v1)|Participants completed a dose ramp to their iTD guided by tolerability, as described for the DEP, including the full dose-ramp schedule. The iTD in the OLE may have been different from the iTD in the DEP or RWP. The investigator may have escalated the dose of SYNB1934v1 up to 1 × 10\^12 live cells based on tolerability; multiple attempts to escalate to a higher dose level were permitted per investigator discretion.
62075400|NCT03395210|EXPERIMENTAL|Rilzabrutinib (PRN1008) Daily|"Part A approximately 60 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension.~Part B approximately 25 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension"
62075401|NCT00829361|OTHER|Telemedicine|
62279250|NCT02368327|PLACEBO_COMPARATOR|Placebo|Participants receive one dose of saline placebo
62279251|NCT06471764||FX+ and 12-Lead ECG Monitor Recording|
62279252|NCT05949229|EXPERIMENTAL|Duloxetine group (Group D)|patients received oral duloxetine 60 mg 2 hours just before operation.
62279253|NCT05949229|PLACEBO_COMPARATOR|Control group (Group C)|patients received an identical placebo pill 2 hours just before operation.
62645371|NCT06450769|EXPERIMENTAL|Mediterranean diet group|An individually planned nutrition program suitable for the energy-restricted Mediterranean diet will be created for individuals in this group.
62075402|NCT04533776|EXPERIMENTAL|PEER-INTERACTION GROUP SUPPORT|"All the sessions of the research took place in a classroom in the hospital. The sessions lasted an average of 90 minutes with two 45-minute sections. During the break, which lasted about 20 minutes, gluten-free products were offered. During the break, adolescents were given the opportunity to chat and interact with each other.~Peer interactive group support was implemented for 3 months with an interval of one week. A total of 6 sessions were held with the study group. Adolescents in the study group were contacted by phone before each session. The day before the session, a text message was sent to all participants informing the location and time of the meeting. The contents of the first and second sessions in relation to the study were created beforehand. However, contents of the third, fourth, fifth and sixth sessions were prepared after the first two sessions."
62075403|NCT04533776|EXPERIMENTAL|routine health care- control group|Peer interactive group support was not provided to the control group.
62075404|NCT05597800|EXPERIMENTAL|Cohort A: HBV and HCV patients|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections, such as HBV and HCV in cohort A.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
62075405|NCT05597800|EXPERIMENTAL|Cohort B: HIV patients|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections such as HIV in cohort B.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
62075406|NCT05597800|EXPERIMENTAL|Cohort C: Long COVID syndrome|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections such as Long Covid syndrome in Cohort C.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
62075407|NCT02806284|ACTIVE_COMPARATOR|Neurotrauma|Patients with basilar skull fracture with or without known cerebrospinal fluid leakage were enrolled in the neurotrauma (NT) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from trauma.
62645372|NCT06450769|EXPERIMENTAL|Mediterranean diet supplemented with aronia group|An individually planned nutrition program suitable for the energy-restricted Mediterranean diet will be created for individuals in this group. Also 100 mL/day of 100% aronia juice will be given.
62645373|NCT06450769|EXPERIMENTAL|Low-fat diet group|An individually planned nutrition program suitable for the energy-restricted low-fat diet will be created for individuals in this group.
62075408|NCT02806284|ACTIVE_COMPARATOR|Neurosurgery|Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
62075409|NCT02806284|ACTIVE_COMPARATOR|Control|All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b. They were vaccinated at least three weeks after trauma or surgery. The vaccines were administered by subcutaneous injections.
62075410|NCT05733819|ACTIVE_COMPARATOR|Walking without personalized rhythmic auditory stimulation|Subjects will complete a 6MWT without any auditory cues
62075411|NCT05733819|EXPERIMENTAL|Walking with personalized rhythmic auditory stimulation|Subjects will complete a 6MWT with personalized rhythmic auditory cues
62075412|NCT02951910|EXPERIMENTAL|Intervention|Patients receiving zinc-hyaluronate eye drop
62279254|NCT03438045|EXPERIMENTAL|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
62279255|NCT03388463|ACTIVE_COMPARATOR|Omeprazole group|Patients received intravenous bolus of 80 mg omeprazole followed by 8mg/h infusion for the whole period of ICU stay.
62279256|NCT03388463|PLACEBO_COMPARATOR|Placebo group|Patients received intravenous omeprazole 40mg bolus dose once daily followed by normal saline infusion.
62645374|NCT06450769|EXPERIMENTAL|Low-fat diet supplemented with aronia group|An individually planned nutrition program suitable for the energy-restricted low-fat diet will be created for individuals in this group. Also 100 mL/day of 100% aronia juice will be given.
62653041|NCT06192316|EXPERIMENTAL|Nicotine Concentration: None Displayed; Nicotine Source Claim 1|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62279257|NCT03833830||longterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) \>20 injections
62279258|NCT03833830||shortterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) \< 5 injections
62279259|NCT00883532|EXPERIMENTAL|budesonide|The treatment group will receive surfactant and budesonide.
62279260|NCT00883532|PLACEBO_COMPARATOR|surfactant and air|The placebo group will receive surfactant and air as control.
62279261|NCT00820755|ACTIVE_COMPARATOR|Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy|
62279262|NCT00820755|ACTIVE_COMPARATOR|Cetuximab 500 mg/m^2 every 2 weeks|
62279263|NCT00820755|ACTIVE_COMPARATOR|Cetuximab 250 mg/m^2 weekly|
62279264|NCT05213988|EXPERIMENTAL|Low-Carbohydrate/High-Protein Diet|
62279265|NCT05213988|EXPERIMENTAL|Fibrate|
62279266|NCT05213988|EXPERIMENTAL|Intermittent Fasting|
62645375|NCT04720443|EXPERIMENTAL|SAD Part 1 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 10 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
62645376|NCT04720443|EXPERIMENTAL|SAD Part 1 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 30 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
62279267|NCT05213988|NO_INTERVENTION|Control|
62645377|NCT04720443|EXPERIMENTAL|SAD Part 1 Cohort 3|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 100mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
62645378|NCT04720443|EXPERIMENTAL|SAD Part 1 Cohort 4|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 300 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
62653042|NCT06192316|EXPERIMENTAL|Nicotine Concentration: None Displayed; Nicotine Source Claim 2|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62075413|NCT02076685|EXPERIMENTAL|isoniazid rechalleng|When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.
62279268|NCT05276661|EXPERIMENTAL|"A gel (TAC/Collagen gel)"|"The A gel (TAC/Collagen gel) was applied on subjects' right face"
62279269|NCT05276661|PLACEBO_COMPARATOR|"B gel (placebo lotion)"|"the B gel (placebo lotion) on their left face"
62279270|NCT00930215|EXPERIMENTAL|D961H 40 mg gelatin capsule|2 way crossover
62279271|NCT00930215|EXPERIMENTAL|D961H 40 mg HPMC capsule|2 way crossover
62279272|NCT00532480|OTHER|Duolxetine|Open-label duloxetine 30 - 60 mg oral administration
62279273|NCT02800655|EXPERIMENTAL|DHFS with IS-ARV|Digital Health Feedback System (DHFS) with either IS- Odefsey®, IS- Genvoya®, IS-Biktarvy®, IS- Tivicay® and Truvada® or IS- Tivicay® and Descovy ® (IS-co-encapsulated with ingestion sensor) -1 or 2 capsules daily (QD), depending on the treatment regimen, administered orally for 16 weeks.
62279274|NCT00317460|ACTIVE_COMPARATOR|1|Physician Management
62279275|NCT00317460|EXPERIMENTAL|2|Physician Management and counseling (drug counseling and medication adherence)
62075414|NCT04545294|EXPERIMENTAL|Active theta (6Hz) in-phase tACS|θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany), via 10 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), at 6 Hz frequency, 2 mA current intensity without DC offset, with 100 cycles ramp-up/ramp-down and a 0° relative phase, for 20 min, twice-daily on 5 consecutive weekdays.
62075415|NCT04545294|SHAM_COMPARATOR|Sham tACS|During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.
62075416|NCT03009890|EXPERIMENTAL|Open reduction internal fixation|Surgical open reduction internal fixation (ORIF)
62075417|NCT03009890|ACTIVE_COMPARATOR|Plaster immobilization|Standard local hospital protocol for cast treatment
62075418|NCT00432835|ACTIVE_COMPARATOR|Gastric Stimulation Days1-4/Sham5-8|The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days
62075419|NCT00432835|ACTIVE_COMPARATOR|Sham1-4/Gastric Stimulation Days5-8|The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.
62279276|NCT04771533|EXPERIMENTAL|Passive stabilization of the trunk and the upper extremity|The intervention (passive stabilization of the trunk and the upper arm) was tested in post-stroke patients (study group) and in patients with back pain, but without neurological deficits (control group)
62279277|NCT00168831|OTHER|Tiotropium Respimat 5mcg (Tio R5)|
62279278|NCT00168831|OTHER|Tiotropium Respimat 10mcg (Tio R10)|
62279279|NCT00168831|OTHER|Placebo|
62279280|NCT04257760|NO_INTERVENTION|Standard care|These ALS patients and their caregivers will receive standard care.
62645379|NCT04720443|EXPERIMENTAL|SAD Part 1 Cohort 5|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 500 mg)or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
62645380|NCT04720443|EXPERIMENTAL|MAD Part 2 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage 1) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Two dose levels (dose 1 and dose 2) proposed for MAD part will be determined based on the doses evaluated in SAD part.
62075420|NCT01282320|EXPERIMENTAL|Increased Physical Activity|Individually tailored training one hour, 2-3 sessions per week.
62075421|NCT01282320|NO_INTERVENTION|"Activity as usual (Buisness as usual)"|
62279281|NCT04257760|EXPERIMENTAL|Early palliative care|These patients will receive a palliative care consultation that would not be requested by their care team as standard of care.
62653043|NCT06192316|EXPERIMENTAL|Nicotine Concentration: None Displayed; Nicotine Source Claim 3|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62075422|NCT02334527|OTHER|Palbociclib Single Arm trial|Palbociclib
62075423|NCT03906981||Caries free|6-9 year old caries free children
62075424|NCT03906981||Caries active|6-9 year-old caries active (\>5 dmft/DMFT) children
62075425|NCT05476991|EXPERIMENTAL|Colchicine + Ticagrelor|
62075426|NCT05476991|EXPERIMENTAL|Colchine + Aspirine|
62075427|NCT05476991|EXPERIMENTAL|SOC + Ticagrelor|
62075428|NCT05476991|ACTIVE_COMPARATOR|SOC + Aspirine|
62075429|NCT01682564|EXPERIMENTAL|Candemore tablet|"Candemore tablet~* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
62075430|NCT01682564|ACTIVE_COMPARATOR|Atacand tablet|"Atacand tablet~* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
62075431|NCT03989635|EXPERIMENTAL|QAW039|QAW039 450mg
62075432|NCT03989635|PLACEBO_COMPARATOR|Placebo|Placebo to QAW039
62075433|NCT05592080||pcos|
62075434|NCT05592080||non-pcos|
62075435|NCT03337880||Cases|newborns who were delivered with an extractor
62075436|NCT03337880||Controls|newborns who were not delivered with an extractor
62075437|NCT04081298|EXPERIMENTAL|Health services research (eHealth program)|Patients attend 6 online nutrition and PA education classes, cooking sessions, and participate in physical activities over 120 minutes each. Patients also receive text messages, electronic newsletters and have access to an interactive nutrition website.
62456249|NCT05417425|EXPERIMENTAL|Omeza combination therapy and SOC with total contact cast|"Omeza's products were developed to utilize the benefits of essential omega fatty acids to reduce chronic inflammation and disrupt biofilm colonization commonly found in chronic wounds. The Omeza combination treatment under investigation in this study includes two over the counter (OTC) drugs, Omeza® Lidocaine Lavage and Omeza® Skin Protectant, and a 510(K) medical device, Omeza® Collagen Matrix.~In combination with standard of care and total contact cast, the products will be applied on a weekly basis. There will be a 14-day screening period to assess chronicity from standard of care alone. At that time treatment will be applied weekly for 4 weeks. Further treatment will be at the discretion of the PI to continue for 8 more weeks or until wound closure."
62653044|NCT06192316|EXPERIMENTAL|Nicotine Concentration: Low; Nicotine Source Claim 1|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62075438|NCT01644474|ACTIVE_COMPARATOR|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
62075439|NCT01644474|EXPERIMENTAL|Alirocumab 75/Up to 150 mg Q2W|SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
62075440|NCT05690789||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
62075441|NCT05690789||Health Care Professionals (HCPs)|HCPs treating people who have obesity
62075442|NCT05690789||Employers|Single-selection response from defined list
62075443|NCT04905732|EXPERIMENTAL|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
62075444|NCT04905732|ACTIVE_COMPARATOR|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
62075445|NCT02290366|EXPERIMENTAL|Focal Therapy|
62645381|NCT04720443|EXPERIMENTAL|MAD Part 2 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage 2) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Two dose levels (dose 1 and dose 2) proposed for MAD part will be determined based on the doses evaluated in SAD part.
62075446|NCT03180216|EXPERIMENTAL|Prophylactic and treatment|"Virus Specific T cells (VSTs) for prophylactic and treatment of active viral infection(s) after HSCT.~3 different dose levels starting with 1 x 10E7 /m2 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 2 x 10E7/m2 and a final dose 5 x 10E7 VSTs/m2"
62075447|NCT03859375||2 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint two of a predefined area of the skin.
62075448|NCT03859375||3 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint three of a predefined area of the skin.
62075449|NCT04140890|EXPERIMENTAL|Treatment|Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
62075450|NCT04140890|PLACEBO_COMPARATOR|Control|Participants in the control group will receive newsletters focused on general healthy aging topics over 12 weeks. With the exception of two, 1-page handouts covering PA and dietary recommendations, the weekly content will not overlap with the treatment content. Within 4 days of mailing the newsletter, a trained research assistant (RA) will call the participant, verify receipt of the newsletter, and ask them if they have any questions about the materials. The phone call will last \~15 minutes. Control condition participants receive no further intervention.
62075451|NCT03525574|EXPERIMENTAL|ELX/TEZ/IVA|"Treatment Period: Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks.~Extension Period: Participants from certain countries participated in extension period and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the extension period for 48 weeks."
62075452|NCT04398784|OTHER|1-Blueberry First/Placebo First|Participants will be randomly assigned into either blueberry-first treatment or placebo-first group.
62075453|NCT04398784|OTHER|2-Crossover|Participants who received blueberry treatment will switch to placebo and vice versa.
62279282|NCT05254028|ACTIVE_COMPARATOR|Auricular points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.20mm x 13mm are inserted at the auricular acupuncture points shenmen (TF4), thalamus (AT4), and occiput (AT3) bilateral."
62279283|NCT05254028|ACTIVE_COMPARATOR|Body points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.25mm x 25mm are inserted at the acupuncture points LI4 Hegu, LR3 Taichong, dan GB20 Fengchi bilateral."
62456250|NCT01075581|ACTIVE_COMPARATOR|Topical administration|An an intranasal injection of saline will be used as control, and thereafter cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
62645382|NCT04232839|EXPERIMENTAL|T3-R1-T1-T4-T2-T5 (sequence I+T5)|"Sequence I+T5, with treatments in the following order: T3-R1-T1-T4-T2-T5 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62653045|NCT06192316|EXPERIMENTAL|Nicotine Concentration: Low; Nicotine Source Claim 2|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62456251|NCT01075581|EXPERIMENTAL|Intranasal injection|An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
62645383|NCT04232839|EXPERIMENTAL|T3-R1-T1-T4-T2-T6 (sequence I+T6)|"Sequence I+T6, with treatments in the following order: T3-R1-T1-T4-T2-T6 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62645384|NCT04232839|EXPERIMENTAL|T2-T1-T3-R1-T4-T5 (sequence II+T5)|"Sequence II+T5, with treatments in the following order: T2-T1-T3-R1-T4-T5with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62645385|NCT04232839|EXPERIMENTAL|T2-T1-T3-R1-T4-T6 (sequence II+T6)|"Sequence II+T6, with treatments in the following order: T2-T1-T3-R1-T4-T6 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62645386|NCT04232839|EXPERIMENTAL|T4-T3-R1-T2-T1-T5 (sequence III+T5)|"Sequence III+T5, with treatments in the following order: T4-T3-R1-T2-T1-T5 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62645387|NCT04232839|EXPERIMENTAL|T4-T3-R1-T2-T1-T6 (sequence III+T6)|"Sequence III+T6, with treatments in the following order: T4-T3-R1-T2-T1-T6 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62653046|NCT06192316|EXPERIMENTAL|Nicotine Concentration: Low; Nicotine Source Claim 3|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62075454|NCT00079443|EXPERIMENTAL|Treatment|"PHASE II: Patients receive FR901228 IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients who achieve a complete or partial remission receive 2 additional courses (for a total of 6 courses). Patients with stable disease after 4 courses or progressive disease at any time after 2 courses proceed to the phase I portion of the study.~PHASE I: Patients receive rituximab IV over approximately 4-8 hours on day 1; fludarabine IV over 10-30 minutes on days 2-4; and FR901228 IV over 4 hours on days 2, 9, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
62279284|NCT02340663|EXPERIMENTAL|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
62279285|NCT02340663|ACTIVE_COMPARATOR|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
62075455|NCT04329858|ACTIVE_COMPARATOR|conventional glass ionomer|
62456252|NCT05423808|EXPERIMENTAL|Intervention group|Patients in the intervention group will be part of a renewed care pathway supported by digital tools.
62456253|NCT05423808|NO_INTERVENTION|Control group|Patients in the control group will receive standard of care, specific to the hospital where the patient is being treated.
62645388|NCT04232839|EXPERIMENTAL|T1-T4-T2-T3-R1-T5 (sequence IV+T5)|"Sequence IV+T5, with treatments in the following order: T1-T4-T2-T3-R1-T5 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62279286|NCT03683394|ACTIVE_COMPARATOR|SMARRT Intervention|The SMARRT intervention team will use a standardized procedure to develop an individualized Alzheimer's risk profile for each participant randomized to the SMARRT intervention arm. Participants will then meet in-person with an interventionist to review their risk profile and develop an initial personalized risk reduction action plan. For the few participants enrolled during COVID, initial interventionist visits were conducted by phone. Targeted areas will include: increasing physical, mental and social activities; quitting smoking; healthy diet; controlling cardiovascular risk factors (diabetes, hypertension), including avoiding hypoglycemia in people with diabetes; reducing depressive symptoms; improving sleep; and decreasing use of potentially harmful medications.
62279287|NCT03683394|ACTIVE_COMPARATOR|Health Education Intervention|Participants in the Health Education arm will be mailed general information that will address factors that will be targeted in the SMARRT intervention, including physical, mental and social engagement; management of cardiovascular risk factors; quitting smoking, healthy diet; depression; sleep; and contraindicated medications. HE participants will not be provided with personalized information about their risk of Alzheimer's and dementia.
62645389|NCT04232839|EXPERIMENTAL|T1-T4-T2-T3-R1-T6 (sequence IV+T6)|"Sequence IV+T6, with treatments in the following order: T1-T4-T2-T3-R1-T6 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62645390|NCT04232839|EXPERIMENTAL|R1-T2-T4-T1-T3-T5 (sequence V+T5)|"Sequence V+T5, with treatments in the following order: R1-T2-T4-T1-T3-T5 with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62653047|NCT06192316|EXPERIMENTAL|Nicotine Concentration: High; Nicotine Source Claim 1|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62279288|NCT01507376|EXPERIMENTAL|A: recombinant hCG(250 µg Ovitrell)|1- Group A consisted of 60 infertile women who received recombinant hCG(250 µg Ovitrelle)
62075456|NCT04329858|EXPERIMENTAL|zinc modified glass ionomer|
62075457|NCT04329858|EXPERIMENTAL|silver modified glass ionomer|
62653048|NCT06192316|EXPERIMENTAL|Nicotine Concentration: High; Nicotine Source Claim 2|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62075458|NCT05164731|EXPERIMENTAL|3 months after two doses|the third does was given 3 months after two doses
62075459|NCT05164731|EXPERIMENTAL|4 months after two doses|the third does was given 4 months after two doses
62075460|NCT05164731|EXPERIMENTAL|5 months after two doses|the third does was given 5 months after two doses
62075461|NCT05164731|EXPERIMENTAL|6 months after two doses|the third does was given 6 months after two doses
62075462|NCT04288674||Leptospirosis group|Patients with cultural, serological, molecular or histological evidence and clinical evidence of invasive leptospirosis disease.
62075463|NCT04288674||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
62279289|NCT01507376|EXPERIMENTAL|B: recombinant hCG(500 µg Ovitrell)|2- Group B consisted of 60 infertile women who received recombinant hCG(500 µg Ovitrelle)
62279290|NCT01507376|EXPERIMENTAL|C: urinary hCG|3- Group C consisted of 60 infertile patients received 10,000 IU urinary hCG
62279291|NCT02304198|EXPERIMENTAL|Udenafil|Udenafil 50mg tablet by mouth, every 12 hours for 1-year(48-weeks)
62279292|NCT00535925|ACTIVE_COMPARATOR|Standard of Care (SoC) therapy|Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
62653049|NCT06192316|EXPERIMENTAL|Nicotine Concentration: High; Nicotine Source Claim 3|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
62075464|NCT03232320|EXPERIMENTAL|MEDITOXIN|
62456254|NCT00637299|ACTIVE_COMPARATOR|Active osteopathic treatment (OMT+PR)|The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
62456255|NCT00637299|SHAM_COMPARATOR|SOT + PR|Sham osteopathic treatment (manipulation)
62075465|NCT03232320|PLACEBO_COMPARATOR|Placebo|
62456256|NCT05706077|EXPERIMENTAL|active tDCS + real Physical Therapy|"Active Transcranial Direct Current Stimulation will be applied associated with real physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites.~To stimulate the primary motor cortex the active electrode will be positioned on the C3 point and the reference electrode on the contralateral supraorbital region."
62456257|NCT05706077|PLACEBO_COMPARATOR|active tDCS + placebo Physical Therapy|"Active Transcranial Direct Current Stimulation will be applied associated with placebo physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites.~To stimulate the primary motor cortex the active electrode will be positioned on the C3 point and the reference electrode on the contralateral supraorbital region."
62456258|NCT05706077|SHAM_COMPARATOR|sham tDCS + real Physical Therapy|Sham Transcranial Direct Current Stimulation will be applied associated with real physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites. The anode electrode will be positioned on the C3 point (primary motor cortex) and the reference electrode on the contralateral supraorbital region.
62456259|NCT05706077|OTHER|sham tDCS + placebo Physical Therapy|Sham Transcranial Direct Current Stimulation will be applied associated with placebo physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites. The anode electrode will be positioned on the C3 point (primary motor cortex) and the reference electrode on the contralateral supraorbital region.
62456260|NCT02330068||Controls|Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
62456261|NCT02330068||Cases|Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
62075466|NCT02429921|EXPERIMENTAL|low-Se lentils|50 mg of low-selenium lentils per person consumed as soups
62075467|NCT02429921|EXPERIMENTAL|high-Se lentils|50 mg of high-selenium lentils per person consumed as soup
62456262|NCT01048437|NO_INTERVENTION|Standard transplant education|Missouri Kidney Program's standard Patient Education Program (PEP) transplant module.
62645391|NCT04232839|EXPERIMENTAL|R1-T2-T4-T1-T3-T6 (sequence V+T6)|"Sequence V+T6, with treatments in the following order: R1-T2-T4-T1-T3-T6with a washout period of at least 4 days between treatments. All test treatments (T1-T6) were one single dose of 62.5 milligram. R1 and T1-T4: taken orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours. T5-T6: taken orally with 240 mL of water following a high-fat high-calorie breakfast.~Reference (R1): 60 milligram (mg) (6 x 10 mg tablets) BI 894416 Reference Formulation, immediate release (IR) tablets.~Test 1 (T1): 1 tablet BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR).~Test 2 (T2): 1 tablet BI 894416 Formulation C2, ER tablet (slow release rate, SRR).~Test 3 (T3): 1 capsule BI 894416 Formulation D2, ER capsule (FRR). Test 4 (T4): 1 capsule BI 894416 Formulation F2, ER capsule (SRR). Test 5 (T5): 1 tablet BI 894416 Formulation C2, ER tablet (SRR). Test 6 (T6): 1 capsule BI 894416 Formulation F2, ER capsule (SRR)."
62645392|NCT06194916|EXPERIMENTAL|education group|A 4-week web-based self-management training will be administered to epilepsy patients in the experimental group.
62645393|NCT06194916|ACTIVE_COMPARATOR|Control Group|routine interventions
62645394|NCT03106077|EXPERIMENTAL|Cohort A (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unaccepted toxicity.
62645395|NCT03106077|EXPERIMENTAL|Cohort B (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
62456263|NCT01048437|EXPERIMENTAL|Transplant education with video|Explore Transplant transplant module featuring video
62645396|NCT02647138|EXPERIMENTAL|White Noise|Subject will have white noise machine placed in room.
62645397|NCT05178017|EXPERIMENTAL|Participants|Individuals with Irritable Bowel Syndrome (IBS)
62645398|NCT00967122|NO_INTERVENTION|No Arm|
62645399|NCT04368169|EXPERIMENTAL|Aromatic Extract|Participants receive the aromatic botanical extract orally every 4-6 waking hours for 3 days.
62645400|NCT04368169|PLACEBO_COMPARATOR|Placebo|Participants receive the placebo matching the botanical extract orally every 4-6 waking hours for 3 days.
62075468|NCT06294015|EXPERIMENTAL|20% Autologous serum eye drops + Artificial tear drops|
62075469|NCT06294015|PLACEBO_COMPARATOR|0.9% NS eye drops + Artificial tear drops|
62075470|NCT01026675||Pregnant women 6-13 weeks|
62075471|NCT00948883||Patient-Case|Transplanted patient with cancer
62456264|NCT01048437|EXPERIMENTAL|Transplant education with speakers|Explore Transplant transplant module featuring live guest speakers.
62456265|NCT02753842|EXPERIMENTAL|Fitted, Then Thin, Then Standard Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
62075472|NCT00948883||Patient-Control|Transplanted patient without cancer
62645401|NCT01195649||Group 1|
62645402|NCT00499811|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|"Vorinostat (SAHA) will be administered as a single oral dose on day -6 for all patients. Blood samples are obtained periodically on day -6 for pharmacokinetic studies.~One week later (day 1), the first course of oral vorinostat will be initiated on a continuous daily oral regimen. Each treatment course will consist of 21 days of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
62075473|NCT03849716||Participants with atopic dermatitis (AD)|Participants included in observational study OBS15333 (atopic dermatitis pediatric registry) who consent to enter this companion study LPS15496. Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enter either protocol, and neither protocol OBS15333 nor LPS15496 specifies assignment of any drug intervention
62075474|NCT03665883|ACTIVE_COMPARATOR|Diathermy preferred|Monopolar energy is the preferred dissection approach in this group of patients undergo TEP. Total time of activation of monopolar machine will recorded by specially designed device
62075475|NCT03665883|ACTIVE_COMPARATOR|Blunt dissection preferred|Blunt dissection is the preferred dissection approach in this group of patients undergo TEP. Use of monopolar energy for haemostasis is still allowed upon surgeons' decision. Total time of activation of monopolar machine will recorded by specially designed device
62075476|NCT03550430|EXPERIMENTAL|ADR neurofeedback|Ten ADR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions consists of five training blocks each. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
62075477|NCT03550430|ACTIVE_COMPARATOR|BTR neurofeedback|Ten BTR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions each consists of five training blocks. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
62075478|NCT03550430|ACTIVE_COMPARATOR|Diary Control Group|Daily diary completion for two weeks in the period between baseline and end-point assessments (total period baseline to end-point = four weeks).
62075479|NCT05892835|OTHER|educative intervention|A 2-hour training workshop was carried out where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Mannequin for CPR practices Little Anne QCPR. Laerdal) and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
62075480|NCT02936622|EXPERIMENTAL|Stent 1|Zilver® PTX Stent
62075481|NCT02936622|EXPERIMENTAL|Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
62075482|NCT02936622|EXPERIMENTAL|Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
62075483|NCT05799300||Hip fracture cohort|"Gender, Age, Racial and Ethnic Origin of Subjects Male and female adults over the age of 18 years; all origins, all races will be included.~Inclusion/exclusion criteria as below"
62075484|NCT05242575|NO_INTERVENTION|Book condition|Participants in the control condition will be receive a pre-recorded audio-visual book presentation. The purpose of pre-reading is to provide consistency in the examiner's affect and presentation, thereby controlling for potential examiner effects on study outcomes. Participants in the control group will receive three interventions each lasting 15-minutes. The number of sessions and intervention time is equal for both the control and experimental groups. The information provided in the control book and experimental iVFT parallel one another.
62456266|NCT02753842|EXPERIMENTAL|Fitted, Then Standard, Then Thin Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
62456267|NCT02753842|EXPERIMENTAL|Thin, Then Fitted, Then Standard Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
62075485|NCT05242575|EXPERIMENTAL|Immersive virtual field trip (iVFT)|The study intervention is a multisensory immersive virtual reality trip to the moon. Participants will use 3D cardboard goggles and a smart phone. No additional interventions will occur. Participants in the iVFT experimental group will receive three interventions each lasting 15-minutes. The number of sessions and intervention time is equal for both the control and experimental groups. Participants will explore the moon through a virtual reality scene by moving their body and head, which creates a 360º view. When hovering over items, participants are presented with several key elements related to word learning (e.g., written and spoken words/narrative). Multiple items are given extra emphasis through hotspots that provide audiovisual content in the form of brief videos and spoken scripts. The information provided in the iVFT and control book parallel one another.
62075486|NCT01340313||Group 1|4 times evaluation according to doses in 1 group
62456268|NCT02753842|EXPERIMENTAL|Thin, Then Standard, Then Fitted Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
62645403|NCT03609047|EXPERIMENTAL|experimental palbociclib arm|Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.
62075487|NCT06187350||Screened women in Region Östergötland, Sweden|All screened women in Region Östergötland, Sweden.
62075488|NCT02008968|ACTIVE_COMPARATOR|Uric acid ≥7 mg/dL|This arm will receive allopurinol treatment. 50 subjects will be recruited.
62075489|NCT02008968|ACTIVE_COMPARATOR|Uric acid ≥6 and <7|This arm will not receive allopurinol. 50 subjects will be recruited.
62075490|NCT02008968|PLACEBO_COMPARATOR|Normouricemic|This arm is healthy controls. 30 subjects will be recruited.
62075491|NCT01405794|EXPERIMENTAL|32ppm Oral Silver|14 Days Active Silver Solution
62075492|NCT01405794|PLACEBO_COMPARATOR|Sterile Water|No Silver Nanoparticles
62075493|NCT01570543||orthopedic implants, no treatment|
62456269|NCT02753842|EXPERIMENTAL|Standard, Then Fitted, Then Thin Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
62075494|NCT03746977|ACTIVE_COMPARATOR|energy restriction and protein supplementation|Energy restriction of 500 kcal/d and total Protein Uptake (including Supplementation) of 1.2 g/kg body mass/d
62075495|NCT03746977|ACTIVE_COMPARATOR|Energy restriction, walking and protein|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d) and total protein uptake (including supplementation) of 1.5 g/kg body mass/d
62075496|NCT03746977|ACTIVE_COMPARATOR|Energy restriction, walking, protein and WB-EMS|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d), total protein uptake (including supplementation) of 1.5 g/kg body mass/d and WB-EMS application 1,5x 20 min/week
62075497|NCT02357043|EXPERIMENTAL|Dario Blood Glucose Monitoring System|Subject will be requested to follow the device instructions and perform his/her own finger-stick test using the Dario Glucose Monitoring System (BGMS).
62075498|NCT04324255||Low ratio|Liver recipient with low preoperative von Willbrand factor-to-protein C ratio
62075499|NCT04324255||High ratio|Liver recipient with high preoperative von Willbrand factor-to-protein C ratio
62075500|NCT03524456|EXPERIMENTAL|Home blood pressure monitoring|
62456270|NCT02753842|EXPERIMENTAL|Standard, Then Thin, Then Fitted Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
62456271|NCT00307190||Binge Eating Disorder|Women with Binge Eating Disorder
62075501|NCT03524456|NO_INTERVENTION|Usual monitoring|
62075502|NCT02424552|EXPERIMENTAL|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
62075503|NCT02424552|PLACEBO_COMPARATOR|Placebo|Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks
62279293|NCT00535925|EXPERIMENTAL|Multifactorial Intensified therapy|"An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.~In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (\<130/80 mmHg)."
62456272|NCT00307190||Controls|Weight, age, and gender-matched control subjects
62456273|NCT01802697|EXPERIMENTAL|IdeS|Intravenous infusion
62075504|NCT04980768|OTHER|Root canal treatment|Root canal treatment will be provided to all the participants with the diagnosis of apical periodontitis.
62075505|NCT03410914|EXPERIMENTAL|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery
62075506|NCT05768516|EXPERIMENTAL|Multi-level intervention|General practioners in this arm will receive the multi-level intervention composed of Stratified care, Healthcare professional education, Patient education and Interprofessional collaboration.
62075507|NCT05768516|NO_INTERVENTION|Usual care|GPs in the control group will have no specific training or intervention. They will treat patients according to their usual practice.
62075508|NCT03093519|EXPERIMENTAL|KHK6640|Intravenous administration
62075509|NCT03093519|PLACEBO_COMPARATOR|Placebo|Intravenous administration
62075510|NCT05874271|EXPERIMENTAL|Revised case management package|
62075511|NCT03655873|EXPERIMENTAL|HEC30654AcOH capsule|"single ascending-dose study: Including 7 dose groups(5-、10、15-、30-、60-、90-、120mg)，Day1 ante meridiem(AM) 8:00 (±1h) with 240ml warm water to taking the experiment drug，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 Post Meridiem(PM) (±1h), with 240ml warm water to take the experiment drug On an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the experiment drug，On an empty stomach."
62075512|NCT03655873|PLACEBO_COMPARATOR|placebo capsule|"single ascending-dose study: Including 6 dose groups(10、15-、30-、60-、90-、120mg)，Day1 morning 8:00 (±1h) with 240ml warm water to taking the placebo capsule，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 PM (±1h), with 240ml warm water to take the placebo capsule on an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the placebo capsule，on an empty stomach."
62279294|NCT02635620||e-cigarette group|Probands are smokers who intend to start vaping for the first time. The probands are recruited in e-cigarette shops. It is aimed to include 60 persons who start vaping. A baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking/vaping behaviour and health status at the beginning and after 1, 2 and 3 months.
62645404|NCT03609047|ACTIVE_COMPARATOR|control chemotherapy arm|"Adjuvant chemotherapy:~4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w~Followed by standard adjuvant endocrine therapy for a duration of at least 5 years."
62645405|NCT03290742||Patients without documented infection.|Patients without infection during 30 day follow-up after radical cystectomy.
62645406|NCT03290742||Patients with documented infection.|Patients with documented any kind of infection (urinary tract infection, blood infection/septic shock, surgical site infection) during 30 day follow-up after radical cystectomy.
62645407|NCT03783637|OTHER|Whole Grain Oat|Volunteers will consume a breakfast meal containing whole grain oats after 7 days of a whole grain free diet.
62075513|NCT04877574|EXPERIMENTAL|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI index.
62279295|NCT02635620||smoking cessation group|Probands are smokers who intend to quit smoking within a clinical conducted smoking cessation program. It is aimed to include 20 persons who stop smoking. Like in the e-cigarette group, a baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking behaviour and health status at the beginning and after 1, 2 and 3 months.
62645408|NCT03783637|OTHER|Whole Grain Wheat|Volunteers will consume a breakfast meal containing whole grain wheat after 7 days of a whole grain free diet.
62645409|NCT03484169|NO_INTERVENTION|Control group|No intervention
62645410|NCT03484169|EXPERIMENTAL|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
62075514|NCT04877574|ACTIVE_COMPARATOR|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
62075515|NCT01708889|EXPERIMENTAL|Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2
62075516|NCT01708889|EXPERIMENTAL|Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2
62075517|NCT01708889|EXPERIMENTAL|Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2
62075518|NCT01708889|EXPERIMENTAL|Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2
62075519|NCT01708889|EXPERIMENTAL|Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR \< 15 mL/min/1.73 m2 (on hemodialysis \[HD\] or non-HD)
62075520|NCT02406118|EXPERIMENTAL|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
62075521|NCT01443975||All patients|Measurement with x-pander in acetabulum prior to inserting the artificial hip socket.
62075522|NCT00579540|ACTIVE_COMPARATOR|1|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
62075523|NCT00579540|ACTIVE_COMPARATOR|2|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
62075524|NCT00579540|ACTIVE_COMPARATOR|3|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
62075525|NCT00469781|ACTIVE_COMPARATOR|1|
62075526|NCT00469781|OTHER|2|
62075527|NCT01899274|EXPERIMENTAL|bant Group|Subjects in the bant Group will receive care as usual, as well as an iPhone loaded with the bant iPhone application and a bluetooth enabled glucometer. Participants will have their A1C levels measured every 3 months (for 1 year), and also complete questionnaires/interviews relating to their diabetes management and lifestyle.
62279296|NCT01492998|EXPERIMENTAL|Guggulsterone|One arm of 15 chronically HCV genotype one infected patients
62456274|NCT01802697|PLACEBO_COMPARATOR|PBS Buffer|Intravenous infusion
62456275|NCT02227251|EXPERIMENTAL|Part 1: Selinexor 60 mg|Participants received fixed dose of 60 mg selinexor orally, twice weekly (BIW) on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1-4 of each four week (each cycle of 28 days) cycle (total of 8 doses per cycle).
62456276|NCT02227251|EXPERIMENTAL|Part 2: Arm A-Selinexor 40 mg|Participants received selinexor 40 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles (28 days) until disease progression (total of 8 doses per cycle).
62075528|NCT01899274|NO_INTERVENTION|Control Group|Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.
62075529|NCT03518528||transdermal|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
62075530|NCT03518528||vaginal|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
62075531|NCT05399992||Inclisiran cohort|Participants prescribed inclisiran in combination with Standard of Care (SoC)
62279297|NCT04226404|EXPERIMENTAL|CSD1905-11|Subjects will be assigned to flavor variant CSD1905-11 of 4.8% ENDS products based on their preferred flavor.
62279298|NCT04226404|EXPERIMENTAL|CSD1905-12|Subjects will be assigned to flavor variant CSD1905-12 of 4.8% ENDS products based on their preferred flavor.
62456277|NCT02227251|EXPERIMENTAL|Part 2: Arm B-Selinexor 60 mg|Participants received selinexor 60 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles) for 2 cycles (each cycle of 28 days) followed by 60 mg once weekly (QW) in the subsequent cycles until disease progression (total of 8 doses per cycle).
62456278|NCT04480788|EXPERIMENTAL|T cell injection targeting CD7 chimeric antigen receptor|
62075532|NCT05399992||SoC cohort|Participants prescribed standard of Care (SoC) only. Patients can be treated with maximum tolerated dose of statins and/or with add-on therapy with ezetimibe, PCSK9 inhibitors (alirocumab or evolocumab), fibrates, bempedoic acid or bile acid sequestrants, but not inclisiran.
62075533|NCT05297617|EXPERIMENTAL|Aromatase inhibitor|Patient will receive standard endocrine therapy (single agent aromatase inhibitors) for a maximum of 2 years.
62075534|NCT05769699|EXPERIMENTAL|Biomarkers|
62075535|NCT04181424|ACTIVE_COMPARATOR|Group 1- Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
62075536|NCT04181424|EXPERIMENTAL|Group 2 - Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
62075537|NCT04181424|EXPERIMENTAL|Group 3 - Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
62075538|NCT04181424|EXPERIMENTAL|Group 4 -- Diabetes Education Plus Combination of Monthly Food|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
62075539|NCT05330741|EXPERIMENTAL|Designed Physical Therapy Program|Designed Physical Therapy Program Down syndrome children will receive the designed physical therapy program for 1 hour. The duration of treatment will be 3 times/week for 12 weeks.
62075540|NCT05330741|EXPERIMENTAL|Whole-Body Vibration|Designed physical therapy program in addition to whole-body vibration. Down syndrome children will receive the designed physical therapy program for 1 hour in addition to whole-body vibration with an amplitude of 2 mm, vibration frequency ranged from 25 to 30 Hz and, vibration time ranged from 5 to10 minutes. The duration of treatment will be 3 times/week for 12 weeks.
62075541|NCT05330741|EXPERIMENTAL|Gravity Force Stimulation|Designed physical therapy program in addition to gravity force stimulation. Down syndrome children will receive the designed physical therapy program for 1 hour in addition to gravity force stimulation with 10 repetitions for each position. The duration of treatment will be 3 times/week for 12 weeks.
62075542|NCT04284761|EXPERIMENTAL|Biolen|Biolen bicalutamide implant. Single implantation. In situ until prostatectomy
62075543|NCT05388994|EXPERIMENTAL|Exercise|The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
62075544|NCT05036889|EXPERIMENTAL|MND|Subject's physician in this group will be using the Mind.Px report as a treatment reference for prescribing the subject's biologic.
62075545|NCT05036889|NO_INTERVENTION|TAU|Treatment as usual. This group will have the biologic prescribed with results given to the physician at the end of the subject's participation and will not be used as a reference for the subject's treatment.
62645411|NCT03316586|EXPERIMENTAL|Nivolumab + Cabozantinib|"* Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter~* Cabozantinib was administered orally, once daily for 28 days at a dose of 40 mg."
62075546|NCT05774405|EXPERIMENTAL|Experimental|All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Estradiol patch (Climara 7.8 mg patch/week, Bayer, Germany) for 14 days.
62075547|NCT05774405|PLACEBO_COMPARATOR|Placebo|All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Hydrogel patch (Adhesive Hydrogel patch/week, Rebul Pharmacy, Turkey) for 14 days.
62075548|NCT02762981|EXPERIMENTAL|Relacorilant with nab-paclitaxel|Participants will be treated with relacorilant in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.
62075549|NCT01448720|EXPERIMENTAL|Paliperidone palmitate|
62075550|NCT02265224|EXPERIMENTAL|Test - Reference|N-acetylcysteine (NAC) 600 mg uncoated tablet (single dose) followed by NAC 600 mg film-coated tablet (single dose)
62075551|NCT02265224|ACTIVE_COMPARATOR|Reference - Test|N-acetylcysteine (NAC) 600 mg film-coated tablet (single dose) followed by NAC 600 mg uncoated tablet (single dose)
62075552|NCT04440644||Patients|patients with amyotrophic lateral sclerosis
62645412|NCT03928457|EXPERIMENTAL|preterm neonate|
62645413|NCT03234465|EXPERIMENTAL|AG013: three mouth rinses/day|Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
62645414|NCT03234465|PLACEBO_COMPARATOR|Placebo: three mouth rinses/day|Subjects will rinse three times per day with placebo mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
62075553|NCT04440644||Healthy control|healthy control participants
62075554|NCT03601104|ACTIVE_COMPARATOR|HIET (n = 15)|High intensity eccentric training: A high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
62075555|NCT03601104|EXPERIMENTAL|HIET-BFR (n= 15)|High intensity eccentric training with blood flow restriction (BFR): A high intensity eccentric (80% isometric peak) training of the knee extensors in isokinetic will be performed, associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) for 6 weeks, 3 times a week.
62075556|NCT03601104|EXPERIMENTAL|LIET-BFR (n = 15)|Low intensity eccentric training with blood flow restriction (BFR): A low intensity eccentric (40% isometric peak) training of the knee extensors in isokinetic will be performed associated with a pressure cuff placed in the proximal thigh (40% absolute occlusion pressure) for 6 weeks, 3 times a week.
62075557|NCT03601104|ACTIVE_COMPARATOR|LIET (n= 15)|Low intensity eccentric training: A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
62075558|NCT01159535|ACTIVE_COMPARATOR|MBRP|The Mindfulness Based Relapse Prevention (MBRP) intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include mindfulness practices targeting craving, Negative affect, and reactivity, as well as discussion about how to implement practice into high-risk situations and in daily life.
62075559|NCT01159535|ACTIVE_COMPARATOR|Relapse Prevention (RP)|The RP intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include discussions of personal high-risk situations, coping skills assessment, and exercises to evaluate expectancies, self-efficacy, and craving.
62075560|NCT01159535|ACTIVE_COMPARATOR|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
62653050|NCT02757196|EXPERIMENTAL|Rituximab plus methylprednisolone|Combination therapy with rituximab （1000mg IV day1, week 3, week 17 , and week 19）plus short-term methylprednisolone (1mg/kg, oral or IV; reduce to 50% of base dose at week 4, then reduce 8mg every 1 week until stopped).
62075561|NCT03632434|EXPERIMENTAL|Active tDCS|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
62075562|NCT03775408||FAST Patients|Patients at Sunnybrook Health Sciences Centre with femur fractures that will undergo a femoral antegrade intramedullary nailing procedure.
62075563|NCT02867969|OTHER|Motor training|The motor training comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
62075564|NCT01266993|EXPERIMENTAL|Nimenrix Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Nimenrix vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Nimenrix vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
62075565|NCT01266993|EXPERIMENTAL|Menjugate Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Menjugate vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Menjugate vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
62075566|NCT03343405|EXPERIMENTAL|Intervention: Online Mind/Body|Participants randomized to the intervention group (i.e., Online Mind/Body Program for Fertility) were provided the 10 online modules provided weekly (one module per week), intended to be completed over 10 weeks. Additionally, participants received weekly therapeutic feedback.
62075567|NCT03343405|NO_INTERVENTION|Wait-List|After 10-weeks being in the wait-list group, participants had the potential to participate in the intervention protocol if they desire.
62653051|NCT02757196|ACTIVE_COMPARATOR|Methylprednisolone|standard dose methylprednisolone alone (1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks).
62653052|NCT00058591|EXPERIMENTAL|Treatment|Treatment dose levels 1, 2 and 3
62075568|NCT03743363|EXPERIMENTAL|Exergame 3/week|The group does active training for 8 weeks after not training.
62075569|NCT03743363|EXPERIMENTAL|Exergame 2/week|The group does active training for 8 weeks after not training.
62075570|NCT03743363|EXPERIMENTAL|Healthy control / Exergame 1/week|In the first 8 week-long only control group, The group will do 1 training/week for the next 8 weeks.
62075571|NCT02718534|EXPERIMENTAL|ERTAS-1|first limb rehabilitation therapy took place within 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
62075572|NCT02718534|ACTIVE_COMPARATOR|ERTAS-2|first limb rehabilitation therapy took place after 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
62075573|NCT01954524|EXPERIMENTAL|IV bolus injection of Sildenafil|CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
62075574|NCT00982982|ACTIVE_COMPARATOR|THC and Iomazenil|"* Iomazenil: 3.7 μg/kg intravenously over 10 minutes~* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes"
62075575|NCT00982982|PLACEBO_COMPARATOR|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
62075576|NCT03393403|EXPERIMENTAL|Dexmedetomidine_iv group|Dexmedetomidine 0.5mcg/kg (diluted in normal saline) intravenously infusion for 30min
62075577|NCT03393403|EXPERIMENTAL|Dexmedetomidine_adj group|Dexmedetomidine 0.5mcg/kg (adding to local anesthetic) perineural single bolus for subcostal TAP block 0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min
62075578|NCT03393403|ACTIVE_COMPARATOR|Control group|0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min No dexmedetomidine use
62075579|NCT01419860|EXPERIMENTAL|Pixel intensity|Pixel intensity of fluorescence signal describing pixel microcirculation of colon
62075580|NCT06141304|EXPERIMENTAL|Plerixafor plus DLI|DLI will be given to the participants three days after chemotherapy, and plerixafor will be administrated ten days post DLI.
62645415|NCT02981979|ACTIVE_COMPARATOR|Leflunomide group|Use Leflunomide 20mg qd po. for 24 weeks for induced remission therapy combine with the basic prednisone therapy(start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. If the subject has not achieve clinical remission,do not change prednisone dose）. Subjects who have achieved clinical remission, with the prednisone dose reduced to 10mg within 20 weeks and maintained to the end of 24 weeks enter the maintenance therapy.The next 32 weeks for maintenance therapy use leflunomide combine with prednisone 10mg per day.
62645416|NCT02981979|PLACEBO_COMPARATOR|Control Group|Use Placebo for 24 weeks for induced remission therapy(24 weeks) and use leflunomide 20mg qd po. for maintenance therapy in the next 32 weeks. Prednisone is used as basic therapy during the whole trial (start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. Then maintain 10mg per day until the end of the study). All subjects in control group enter maintenance therapy.
62075581|NCT00110513|EXPERIMENTAL|Recombinant Human Antithrombin (rhAT) Infusion|Intravenous infusion of rhAT.
62279299|NCT04226404|EXPERIMENTAL|CSD1905-13|Subjects will be assigned to flavor variant CSD1905-13 of 4.8% ENDS products based on their preferred flavor.
62279300|NCT04226404|EXPERIMENTAL|CSD1905-14|Subjects will be assigned to flavor variant CSD1905-14 of 4.8% ENDS products based on their preferred flavor.
62653053|NCT02525068|EXPERIMENTAL|Phase ISafety Run-In|18 patients will receive the combination of enzalutamide and AZD5363 (on an intermittent schedule 4 days on 3 days off) to determine the AZD5363 dose to be used for the randomised phase II and single stage phase II expansion cohort. Approximately three dose-levels of AZD5363 in combination with enzalutamide are planned although other dose levels may be required.
62653054|NCT02525068|PLACEBO_COMPARATOR|Randomised phase II|100 patients will be randomised in a 1:1 ratio to receive 160mg enzalutamide od + AZD5363 bid 4 days on 3 days off (recommended dose from Phase I) vs 160mg enzalutamide od + matching placebo bid 4 days on 3 days off.
62075582|NCT06531148|EXPERIMENTAL|Chemo-mechanical caries removal|A Chemo-mechanical caries removal agent for one side of the bilateral carious teeth (selected randomly). Application of the material will be done according to the manufacturer's instructions
62279301|NCT04226404|EXPERIMENTAL|CSD1905-15|Subjects will be assigned to flavor variant CSD1905-15 of 4.8% ENDS products based on their preferred flavor.
62279302|NCT04226404|EXPERIMENTAL|CSD1905-16|Subjects will be assigned to flavor variant CSD1905-16 of 4.8% ENDS products based on their preferred flavor.
62279303|NCT04226404|EXPERIMENTAL|CSD1905-17|Subjects will be assigned to flavor variant CSD1905-17 of 4.8% ENDS products based on their preferred flavor.
62279304|NCT01516515|PLACEBO_COMPARATOR|placebo, gel|placebo comparator
62279305|NCT01516515|ACTIVE_COMPARATOR|SR-T100 with 2.3% of SM, gel|2.3% of SM in Solanum undatum plant extract
62279306|NCT00874211||Observation|Patients will be observed and will undergo assessment of therapy complications.
62075583|NCT06531148|OTHER|Conventional drilling method|"* In this group, caries removal was performed using a low-speed handpiece with a carbon steel round bur.~* The cavities were then examined using the same criteria that had been used with Group I to assess for any remaining caries.~* After caries removal, a dentin sample was taken from the cavity floor in both groups using a sterile sharp spoon excavator.~* The dentin sample was transported to a sterile screw-cap vial for bacterial count examination."
62279307|NCT04160390||Arm I (biospecimen collection)|Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
62279308|NCT00573001|EXPERIMENTAL|1|
62279309|NCT00573001|EXPERIMENTAL|2|
62279310|NCT00573001|EXPERIMENTAL|3|
62279311|NCT00573001|ACTIVE_COMPARATOR|4|
62279312|NCT00852293||study group|Patients with liver disease followed at the liver unit at Hadassah Medical Center.
62279313|NCT02441790|EXPERIMENTAL|Early Active Range of Motion|Early Active Range of Motion (EAROM) 3-9 days following hand fracture
62279314|NCT02441790|ACTIVE_COMPARATOR|Standard Immoblization|Standard immobilization with plaster splint for 21-27 following hand fracture
62075584|NCT01193582|EXPERIMENTAL|Group 1|
62075585|NCT01193582|EXPERIMENTAL|Group 2|
62279315|NCT04358783|EXPERIMENTAL|Plasma|Convalescent plasma from cured COVID-19 patients y Supportive management depending on individual needs
62279316|NCT04358783|EXPERIMENTAL|Best Available Therapy|Will receive supportive management depending on individual needs including.
62279317|NCT04492436|EXPERIMENTAL|Low Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
62279318|NCT04492436|EXPERIMENTAL|High Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
62279319|NCT04492436|PLACEBO_COMPARATOR|Placebo|Reconstituted lyophilized placebo with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
62279320|NCT04410419|NO_INTERVENTION|Standard Care|Standard care for patients with diabetes pre-operatively .
62279321|NCT04410419|EXPERIMENTAL|Carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
62279322|NCT05467722|EXPERIMENTAL|CTP-543 Treatment - Mild Hepatic Impairment|
62279323|NCT05467722|EXPERIMENTAL|CTP-543 Treatment - Moderate Hepatic Impairment|
62279324|NCT00358787|ACTIVE_COMPARATOR|1|Crossed K wire orientation for surgical management of a type III Supracondylar fracture.
62279325|NCT00358787|ACTIVE_COMPARATOR|2|Lateral K wire orientation for surgical management of a type III Supracondylar fracture.
62279326|NCT00485888|ACTIVE_COMPARATOR|1|
62279327|NCT00485888|PLACEBO_COMPARATOR|2|
62279328|NCT00841763|EXPERIMENTAL|TIV + aH5N1|First dose of the non-adjuvanted trivalent influenza virus vaccine (TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1).
62456279|NCT00208286|OTHER|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
62075586|NCT01193582|EXPERIMENTAL|Group 3|
62075587|NCT01193582|EXPERIMENTAL|Group 4|
62279329|NCT00841763|ACTIVE_COMPARATOR|PL + aTIV|First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV).
62645417|NCT02799927|EXPERIMENTAL|Biodentine|"Biodentine (Septodont, Saint-Maur-des-Fosses, France) has been recently introduced and marketed as a bioactive dentin substitute. The Biodentine powder contains tricalcium silicate, dicalcium silicate and calcium oxide, while its liquid consists of calcium chloride and a carboxylate-based hydrosoluble polymer (water-reducing agent).~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the preparation of Biodentine liner (a mix of powder and liquid), following the manufacturers' instructions, and its placement over the remanent carious dentin layer."
62645418|NCT02799927|ACTIVE_COMPARATOR|Ultra-Blend plus (Calcium hydroxide)|"Ultra-Blend plus® (Ultradent Products Inc., South Jordan, UT, USA). This material is a light-activated calcium hydroxide based-liner. Calcium hydroxide has demonstrated to reduce and promote immediate deactivation of the residual microorganisms after IPT.~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the placement of Ultra-Blend plus liner over the remanent carious dentin layer, using a dycal metallic applicator. Finally, the liner is cured through light exposure during 20 seconds ."
62075588|NCT04415385|EXPERIMENTAL|Camrelizumab + Apatinib|Participants receive Camrelizumab 200mg intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
62075589|NCT04504318|EXPERIMENTAL|Apixaban|Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.
62279330|NCT05223361|ACTIVE_COMPARATOR|Hydroxy ethyl starch (HES)|Six percent hydroxy ethyl starch 130/0.4 additive to ringer lactate as priming solution during CPB
62456280|NCT00208286|ACTIVE_COMPARATOR|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
62456281|NCT04098536|EXPERIMENTAL|Diesel Exposure|
62075590|NCT04504318|ACTIVE_COMPARATOR|Enoxaparin|Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.
62075591|NCT01217489||Attendees to symptomatic breast clinic|
62075592|NCT05199909|EXPERIMENTAL|Intervention ( zanubrutinib)|10 enrolled patients are picked up to take zanubrutinib at the indicated dose.
62075593|NCT00354133|ACTIVE_COMPARATOR|DBS treatment|Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment
62075594|NCT00354133|ACTIVE_COMPARATOR|BMT treatment|Patients in this arm get best medical treatment only.
62075595|NCT03743662|EXPERIMENTAL|Recurrent Glioblastoma, No Surgery|One cohort is for patients with recurrent GBM who are not undergoing surgical debulking as part of their treatment plan
62075596|NCT03743662|EXPERIMENTAL|Recurrent Glioblastoma, Surgery|The second cohort is for patients with recurrent GBM who are undergoing surgery as part of their treatment.
62075597|NCT01737060|ACTIVE_COMPARATOR|Angular stable plate Philos|Open Reduction and Osteofixation with Philos plate and TiCron cerclages
62075598|NCT01737060|EXPERIMENTAL|Reverse Total Shoulder Artroplasty|Intervention group
62075599|NCT02538679|PLACEBO_COMPARATOR|PLACEBO|No TAP block performed
62075600|NCT02538679|EXPERIMENTAL|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
62075601|NCT02538679|EXPERIMENTAL|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
62279331|NCT05223361|ACTIVE_COMPARATOR|Ringer lactate (RL)|Ringer lactate as priming solution during CPB
62279332|NCT01968460|EXPERIMENTAL|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
62279333|NCT01968460|EXPERIMENTAL|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
62456282|NCT04098536|PLACEBO_COMPARATOR|Filtered Air Exposure|
62456283|NCT06139003|EXPERIMENTAL|3d Printed implant overdenture|patients will receive maxillary CD and mandibular 2-implant retained overdenture over locator attachment constructed by digital technique.
62456284|NCT06139003|EXPERIMENTAL|Conventionally constructed implant overdenture|patients will receive maxillary CD and mandibular 2-implant retained overdenture over locator attachment constructed by conventional technique.
62645419|NCT01266616|EXPERIMENTAL|Cohort 1: Vaccine alone IM/EP|HIV MAG pDNA alone IM/EP
62645420|NCT01266616|PLACEBO_COMPARATOR|Cohort 1: Placebo|Placebo given as an injection in each upper arm
62075602|NCT05461014|EXPERIMENTAL|Digital Cognitive Behavioral Intervention (DCBI)|The dCBI, RxWell, is a trans cognitive behavioral therapy (CBT) mobile app product addressing depression and anxiety that was developed based on standard CBT techniques.
62075603|NCT01026909|EXPERIMENTAL|Injection|Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
62075604|NCT01026909|NO_INTERVENTION|Control|Patients will be enrolled in physical therapy
62075605|NCT01824563||study population|Subjects will need to be standard CI patients acording to national implant criteria and the study criteria.
62075606|NCT00802828|ACTIVE_COMPARATOR|Test Product|
62075607|NCT00802828|ACTIVE_COMPARATOR|Reference Product|
62075608|NCT00902889|EXPERIMENTAL|1|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation with GPE (upper cranial two contacts).
62645421|NCT01266616|EXPERIMENTAL|Cohort 2: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 50 mcg of IL-12 pDNA IM/EP
62645422|NCT01266616|PLACEBO_COMPARATOR|Cohort 2: Placebo|Placebo given as an injection in each upper arm
62075609|NCT00902889|EXPERIMENTAL|2|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
62075610|NCT02038764|PLACEBO_COMPARATOR|Placebo|Placebo
62075611|NCT02038764|EXPERIMENTAL|PF-06342674|
62075612|NCT05501171|EXPERIMENTAL|DREAMLAND|"Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.~* Participants will use DREAMLAND and during hospitalization for treatment of AML to learn how to cope most effectively with the diagnosis of AML using an iPad provided by the study team or participant's own iPad.~* Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days."
62075613|NCT05501171|ACTIVE_COMPARATOR|CERENA|"Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.~* Participants will use the mobile app CERENA during hospitalization for treatment of AML to learn how to best care for themselves using an iPad provided by the study team or participant's own iPad.~* Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days."
62645423|NCT01266616|EXPERIMENTAL|Cohort 3: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 250 mcg of IL-12 pDNA IM/EP
62645424|NCT01266616|PLACEBO_COMPARATOR|Cohort 3: Placebo|Placebo given as an injection in each upper arm
62075614|NCT03005093||CAREGIVERS|Caregivers of pediatric patients with swallowing disorders will be recruited.
62645425|NCT01266616|EXPERIMENTAL|Cohort 4: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 1,000 mcg of IL-12 pDNA IM/EP
62645426|NCT01266616|PLACEBO_COMPARATOR|Cohort 4: Placebo|Placebo given as an injection in each upper arm
62075615|NCT03005093||CHILDREN OF CAREGIVERS|Pediatric patients with swallowing disorders will be recruited.
62645427|NCT01266616|EXPERIMENTAL|Cohort 5: Vaccine plus IL-12 IM|HIV MAG pDNA plus 1,000 mcg (or highest dose reached) IL-12 pDNA IM
62645428|NCT01266616|PLACEBO_COMPARATOR|Cohort 5: Placebo|Placebo given as an injection in each upper arm
62075616|NCT01504451|ACTIVE_COMPARATOR|Biosense Webster ablation|Biosense Webster irrigated multi-electrode phased radiofrequency AF ablation
62075617|NCT01504451|ACTIVE_COMPARATOR|Surgical ablation|Minimally invasive thoracoscopic surgical AF ablation
62075618|NCT01504451|ACTIVE_COMPARATOR|Medtronic ablation|Medtronic multi-electrode phased radiofrequency AF ablation
62075619|NCT00721643|EXPERIMENTAL|1|Healthy control, 5g dry power of angel's plant (Angelica keiskei)
62645429|NCT00971217|EXPERIMENTAL|Exercise|"Participants will engage in 2 exercise sessions each week for 10 weeks. Each session will last 50 minutes and will commence with a 5 minute warm up on the bike or treadmill and conclude with a 5 minute cool down. The participants will be required to exercise on their own without interference from others. Participants will wear heart rate monitors to ensure that they are exercising to moderate intensity (70-80% of age predicted maximum heart rate).~Exercise: Aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines."
62645430|NCT00971217|EXPERIMENTAL|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a web-site specifically aimed at young men once per week and complete the set cognitive-behavioural tasks.
62645431|NCT00971217|EXPERIMENTAL|Combined Exercise/Online CBT|Participants will simultaneously par-take in both the exercise and the online CBT conditions already outlined.
62645432|NCT00971217|NO_INTERVENTION|Control|Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
62075620|NCT00721643|EXPERIMENTAL|2|Metabolic syndrome, 5g dry powder of angel's plant (Angelica keiskei)
62645433|NCT03832556|EXPERIMENTAL|Preoperative evaluation: CT + MRI|"Preoperative evaluation by 2 examinations: CT scan and MRI.~* CT scan with biphasic injection of contrast product;~* MRI with injection of contrast."
62645434|NCT01550133|EXPERIMENTAL|Not Learned: Non-nutritive bev to Nutritive bev|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid and act as a control for the learned effects.
62075621|NCT02631811|EXPERIMENTAL|Supportive /palliative care intervention|patients will be supported by a multidisciplinary palliative specialist team
62075622|NCT02631811|NO_INTERVENTION|usual medical follow up|patients will be supported by the support care team if asked by the oncologist
62075623|NCT04864041||Patients hospitalised in ICU for vaso-occlusive crisis|
62075624|NCT02327624|ACTIVE_COMPARATOR|Clopidogrel|The standard antiplatelet treatment for patients is pretreatment with aspirin and clopidogrel. In this trial patients will be randomised in clopidogrel orTicagrelor of two doses
62075625|NCT02327624|EXPERIMENTAL|Ticagrelor 60|Ticagrelor 60 is a new dosage to be tried in this trial.
62075626|NCT02327624|EXPERIMENTAL|Ticagrelor 90|Ticagrelor 90 is used following clopidogrel as maintenance therapy with aspirin 75 mg daily and clopidogrel 75 mg daily following PCI for at least 1 month.
62075627|NCT05627401||Single Group Assignment|patients with sight-threatening Graves orbitopathy (GO) who underwent customized/individual multiple orbital wall decompression plus fat removal
62075628|NCT01777243|EXPERIMENTAL|Part A Arm|Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) \[approximately equivalent to 0.1 mg/kilogram (kg)\]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
62279334|NCT01968460|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 12 weeks.
62279335|NCT01656434|EXPERIMENTAL|NOMAC-E2|Participants received a NOMAC-E2 tablet (2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NOMAC-E2 tablets on Days 1 to 24 and placebo tablets on Days 25 to 28.
62645435|NCT01550133|EXPERIMENTAL|Not Learned: Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid and act as a control for the learned effects.
62645436|NCT01550133|EXPERIMENTAL|Not Learned: Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage and act as a control for the learned effects.
62645437|NCT01550133|EXPERIMENTAL|Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
62653055|NCT02525068|EXPERIMENTAL|Single stage phase II expansion cohort|Following progression on enzalutamide alone, 18 patients will receive enzalutamide 160mg od and AZD5363 bid (recommended dose from phase I) 4 days on 3 days off
62075629|NCT01777243|EXPERIMENTAL|Part B Arm|The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
62075630|NCT00482222|ACTIVE_COMPARATOR|OxMdG / IrMdG chemotherapy|OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
62279336|NCT01656434|ACTIVE_COMPARATOR|NETA-EE|Participants received a NETA-EE tablet (1 mg norethisterone acetate and 10 μg ethinylestradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NETA-EE tablets on Days 1 to 24; EE 10 μg tablets on Days 25 and 26; and ferrous fumarate 75 mg tablets on Days 27 and 28.
62075631|NCT00482222|EXPERIMENTAL|OxMdG / IrMdG chemotherapy with cetuximab|OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
62075632|NCT04399187|EXPERIMENTAL|scaling and root planing, Sodium hypochlorite gel application|Periodontal pockets \> 5 mm in patients of test group were treated by scaling and root planing and Sodium hypochlorite gel application
62075633|NCT04399187|PLACEBO_COMPARATOR|scaling and root planing alone|scaling and root planing alone was performed
62279337|NCT02240043|OTHER|growth hormone secretion|The elderly had common morbidities peculiar to their age, such as systemic arterial hypertension, diabetes mellitus, Parkinson's disease, initial stages of senile dementia, and osteoporosis.
62279338|NCT02126085|ACTIVE_COMPARATOR|Intubation|Intubation and invasive mechanical ventilation + endovascular recanalisation
62279339|NCT02126085|EXPERIMENTAL|No Intubation|Conscious sedation and non-invasive ventilatory support + endovascular recanalisation
62279340|NCT01733030||250 mg Seromycin|Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
62279341|NCT01733030||500 mg Seromycin|Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
62075634|NCT02701946|EXPERIMENTAL|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US).
62075635|NCT02701946|PLACEBO_COMPARATOR|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
62075636|NCT04325464|EXPERIMENTAL|PEAR-003A|Digital Therapeutic
62075637|NCT03257423|ACTIVE_COMPARATOR|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
62075638|NCT03257423|ACTIVE_COMPARATOR|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
62075639|NCT03257423|PLACEBO_COMPARATOR|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
62075640|NCT03257423|OTHER|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
62075641|NCT03257423|OTHER|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
62279342|NCT01733030||Placebo|Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
62456285|NCT00948519|EXPERIMENTAL|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
62645438|NCT01550133|EXPERIMENTAL|Learned: Non-Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of non-nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage to determine if cephalic phase response changes with learning.
62645439|NCT01550133|EXPERIMENTAL|Learned: Nutritive solid to Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid to determine if cephalic phase response changes with learning.
62645440|NCT01550133|EXPERIMENTAL|Learned: Nutritive beverage to Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive beverage to determine if cephalic phase response changes with learning.
62456286|NCT00948519|ACTIVE_COMPARATOR|Laser only|same as above, without ICG
62645441|NCT01550133|EXPERIMENTAL|Not Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
62645442|NCT03656341|EXPERIMENTAL|2 Feet 4 Life|Intervention group will receive one hour intervention weekly for four consecutive weeks. Outcomes will be measured at baseline (before the intervention), immediately after the intervention (1 month), three months post-intervention, and six months post-intervention
62645443|NCT03656341|NO_INTERVENTION|True control group|Will complete the same four assessment visits as the intervention group.
62645444|NCT03656341|NO_INTERVENTION|Bias control group|Will complete outcome assessments at baseline and the final assessment.
62645445|NCT01370421||Knee OA patients undergoing Total Knee Arthroplasty (TKA)|Participants will be 45 years or older, diagnosed with Osteoarthritis of the knee and be scheduled for a unilateral total knee replacement surgery.
62075642|NCT03257423|ACTIVE_COMPARATOR|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
62075643|NCT00393900||1|Children with tympanostomy tubes for chronic OME
62075644|NCT04412252|EXPERIMENTAL|Tofacitinib|Participants will receive tofacitinib 10 mg twice per day for 14 days and standard of care therapy.
62075645|NCT04412252|PLACEBO_COMPARATOR|Placebo|Participants will receive tofacitinib-matching placebo twice per day for 14 days and standard of care therapy.
62075646|NCT00339703||Control|Subjects between the ages of 18 and 65 without a diagnosis of asthma or other inflammatory disease were enrolled from the patient population at Wilford Hall Medical Center. Subjects underwent a single blood draw and spirometer.
62279343|NCT04497025|EXPERIMENTAL|Immersive virtual reality-based vestibular training.|"Subjects in this group will receive the same intervention than the other group of study, but they will wear a 3D head mounted display (Oculus Quest glasses) and will receive real-time gaming feedback in terms of visual and audio output while using the training system.~Participants will receive a total of 20 sessions (3 sessions of 50 minutes per week, 7 weeks). These sessions will be divided in 10 initial sessions (based on the three first blocks of Cawthorne-Cooksey protocol) and 10 advanced sessions in which vestibular exercises are gradually get more complicated by modifiying the following exercise parameters: base of support width, standing on unstable surface, alternatives single leg support, tandem position, increased velocity of head movements, higher head range motion and coordinated movements with arms and trunk.~Same location, tailoring parameters and physical therapist supervision than conventional vestibular training."
62456287|NCT05829148|ACTIVE_COMPARATOR|Dexmedetomidine Group|This Group about 30 patients will receive dexmedetomidine loading dose 1 µg/kg over a period of 15 minutes and maintenance 0.2µg/kg/h throughout the surgery .
62075647|NCT00339703||Mild to Moderate Asthma|Subjects between the ages of 18 and 65, who were previously diagnosed with moderate to severe persistent asthma as defined by the National Asthma Education and Prevention Program (NAEPP), were enrolled from the Allergy and Immunology clinic at Wilford Hall Medical Center. Subjects on inhaled corticosteroids or other controller medications were allowed in the study, but subjects on oral corticosteroids were excluded. Subjects underwent a single blood draw and spirometer.
62075648|NCT04663568|OTHER|Levonorgestrel-releasing intrauterine system|
62075649|NCT01611818|OTHER|Low intensity Internet-delivered psychotherapy|Low intensity Internet-delivered psychotherapy + improved treatment as usual by GP.
62075650|NCT01611818|OTHER|Self-guided Internet-delivered psychotherapy|Self-guided Internet-delivered psychotherapy + improved treatment as usual
62075651|NCT01611818|OTHER|Improved treatment as usual by GP|
62075652|NCT06013332|EXPERIMENTAL|Group 1|right face will be injected with PBF PLLA microsphere, and left face with Sculptra®
62456288|NCT05829148|ACTIVE_COMPARATOR|Melatonin Group|This Group about 30 patients will receive 10 mg melatonin (2 tablets) one hour before starting of the operation.
62456289|NCT05829148|ACTIVE_COMPARATOR|Pregabalin Group|This Group about 30 patients will receive oral pregabalin 150 mg one hour before starting of the operation..
62456290|NCT05829148|PLACEBO_COMPARATOR|Control Group|This Group about 30 patients will receive oral starch tablet as a control. Heart rate (HR) and blood pressure values will be recorded at various intervals.
62645446|NCT02739893|EXPERIMENTAL|Scope Guide Assisted|Scope Guide Assist to be utilized during colonoscopy
62645447|NCT02739893|PLACEBO_COMPARATOR|Standard|Colonoscopy completed using current SOC without scopeguide assist.
62075653|NCT06013332|EXPERIMENTAL|Group 2|right face will be injected with Sculptra® and left face with PBF PLLA microsphere
62075654|NCT02293525|ACTIVE_COMPARATOR|Ropivacaine|Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)
62075655|NCT02293525|PLACEBO_COMPARATOR|Saline|Continuous saline infusion until catheter removal (typically 36 hours)
62075656|NCT03133949||Patients with idiopathic inflammatory aortitis|
62075657|NCT03133949||a group of witnesses|
62075658|NCT00859508|EXPERIMENTAL|SyntheCel|
62645448|NCT02193841|ACTIVE_COMPARATOR|C & P|Curettage with puncture (C \& P) will be performed alone
62645449|NCT02193841|ACTIVE_COMPARATOR|C & P with Vitoss|A predetermined amount of Vitoss morsels will be injected following the curettage and puncture (C \& P)
62645450|NCT02908139||Patients before kidney transplantation|The study included who had been admitted to the TransplantClinic before kidney transplantation
62075659|NCT00859508|ACTIVE_COMPARATOR|other FDA cleared dura replacements|
62075660|NCT03063970|EXPERIMENTAL|Experimental Group|Wear of the tailor made Dynamic Lycra Orthosis for up to eight hours every day for eight weeks Usual rehabilitation
62075661|NCT03063970|ACTIVE_COMPARATOR|Comparison Group|Usual rehabilitation
62075662|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
62075663|NCT06177301|EXPERIMENTAL|Tislelizumab combined with GX|"Patients will receive tislelizumab combined with GX regimen： Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."
62075664|NCT06177301|EXPERIMENTAL|Tislelizumab combined with GP|"Patients will receive tislelizumab combined with GX regimen： Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles."
62075665|NCT00206388|EXPERIMENTAL|Zolendric acid with Cyclophosphamide|Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
62075666|NCT05119413|EXPERIMENTAL|New traitement|Thiamidol, retinoid, topical steroid preparation
62075667|NCT05119413|OTHER|Kligman's trio|Application once a day for 12 weeks
62279344|NCT04497025|ACTIVE_COMPARATOR|Conventional vestibular training.|"Subjects in the control group will receive a total of 20 sessions of 50 minutes (3 sessions per week, 7 weeks). They will receive traditional Cawthorne-Cooksey vestibular rehabilitation exercises. This program improves vestibular compensation through a mechanism of neuroplasticity known as adaptation, habituation and substitution. Just like the virtual reality intervention it will be divided in 10 initial sessions and 10 advanced sessions. For the advanced phase of intervention exercises parameters were the same described for the virtual vestibular rehabilitation intervention.~A physical therapy with at least two years of expertise in vestibular rehabilitation will adjust the difficulty level. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain)."
62279345|NCT02513329|ACTIVE_COMPARATOR|Bupivicaine|Stellate Ganglion Block injection with 10 mL .5 % bupivacaine.
62279346|NCT02513329|SHAM_COMPARATOR|Saline|Saline injection (.9 normal saline) 5 ml.
62279347|NCT02580331|PLACEBO_COMPARATOR|SRP and placebo|Oral prophylaxis followed by placement of placebo gel
62279348|NCT02580331|ACTIVE_COMPARATOR|SRP and 1% metformin|Oral prophylaxis followed by placement of 1% metformin gel
62279349|NCT05352581||BD Veritor|"Each subject will:~Self collect a nasal swab for testing on the BD Veritor At-home test (test device) Have a clinician collected nasal swab for testing on the BD Veritor Professional Test (test device) Have a clinical collected nasal swab for testing on an FDA cleared/approved RT-PCR assay (control device)"
62279350|NCT00744900|EXPERIMENTAL|A|
62279351|NCT01739751|NO_INTERVENTION|Control Group|Patients without feedback of a pedometers, followed for 3 months
62645451|NCT01494636|EXPERIMENTAL|GSK2339345 (solution) (part A)|Part A
62279352|NCT01739751|EXPERIMENTAL|Pedometers|With a program of physical activity enhancement using pedometers as a feedback
62279353|NCT04086251|EXPERIMENTAL|Gaido Intervention|All patients enrolled in the study will participate in the Gaido Intervention, which entails wearing the Biovotion Everion continuously and take blood pressure and oral temperature spot checks per clinician orders. Patients will also be responsible for filling out PRO surveys and any surveys that trigger as a result of their vital signs falling outside of tailored thresholds.
62456291|NCT01215890|ACTIVE_COMPARATOR|risedronate plus calcium and viamin D|
62456292|NCT01215890|PLACEBO_COMPARATOR|placebo plus clacium and vitamin D|
62456293|NCT01799681|EXPERIMENTAL|EXPERIMENTAL|a 4-week indoor and 4-week outdoor balance training with stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
62075668|NCT00445263|EXPERIMENTAL|Early Invasive strategy|Tirofiban and coronarography within 6 hours
62075669|NCT00445263|ACTIVE_COMPARATOR|Delayed invasive strategy|Coronarography after 6 hours
62075670|NCT02323035|EXPERIMENTAL|Headgear|Investigative Headgear with CPAP Mask.
62075671|NCT04003662||inpatients|Vital signs measurement - standard of care and prototype
62075672|NCT04003662||outpatients|Vital signs measurement - standard of care and prototype
62456294|NCT01799681|ACTIVE_COMPARATOR|CONTROL|an eight-week training on upper limb stretching and strengthening, hand agility exercise, knot tying and Chinese calligraphy
62456295|NCT05751382|EXPERIMENTAL|Group A - Restoration with Surefil one hybrid composite|Restoration will be performed with Surefil one hybrid composite applied according to manufacturer's instruction and cured for 20 secunds with a LED lamp (Smartlamp Pro).
62645452|NCT01494636|EXPERIMENTAL|GSK2339345/ Placebo/ Lidocaine (nebulised) (part B)|Part B
62075673|NCT04003662||Healthy controls|Vital signs measurement - standard of care and prototype
62645453|NCT03228030|EXPERIMENTAL|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
62645454|NCT03228030|PLACEBO_COMPARATOR|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
62075674|NCT00536068|EXPERIMENTAL|1, 2, 3, 4|"1. acetylsalicylic acid 100 mg/po,acetaminophen 3x1g/po~2. acetylsalicylic acid 100 mg/po,diclofenac 3x50mg/po~3. acetylsalicylic acid 100 mg/po,naproxen 3x250mg/po~4. acetylsalicylic acid 100 mg/po,placebo 3x1/po"
62279354|NCT03020862|EXPERIMENTAL|Placebo ---> Dietary beetroot|"Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial.~The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.~Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days."
62075675|NCT04672356|EXPERIMENTAL|Phase Ia: IBI939 in combination with Sintilimab|IBI939 10mg/kg combination with Sintilimab
62075676|NCT04672356|EXPERIMENTAL|Phase Ia:IBI939 in combination with Sintilimab|IBI939 20mg/kg combination with Sintilimab
62075677|NCT04280718|EXPERIMENTAL|efgartigimod PH20 SC|Patients treated with efgartigimod PH20 SC
62075678|NCT02934516|EXPERIMENTAL|Disimpaction with lower uterine support|Cesarean section with support of the lower uterine segment
62075679|NCT02934516|ACTIVE_COMPARATOR|Classic push method|Cesarean section with push method
62075680|NCT01778062|EXPERIMENTAL|Indacaterol|Indacaterol 150 µg once daily
62279355|NCT03020862|EXPERIMENTAL|Dietary beetroot juice --> Placebo|The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
62456296|NCT05751382|ACTIVE_COMPARATOR|Group B - Restoration with Venus Pearl composite|After the application of the adhesive system (iBond universal), the Venus Pearl composite will be layered on the cavity and cured for 20 seconds with a LED lamp Smartlamp Pro).
62456297|NCT00898079||Observational|Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
62645455|NCT01447888|EXPERIMENTAL|150% Oral Morphine Equivalent (OME)|Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients
62456298|NCT01453075|EXPERIMENTAL|Arm 1: valacyclovir|Assigned patients will take 1.5 mg po valacyclovir twice daily
62456299|NCT01453075|PLACEBO_COMPARATOR|Arm 2: placebo|Assigned patients will receiving matching placebo twice daily
62456300|NCT05055349|ACTIVE_COMPARATOR|corneal collagen cross linking and intrastromal corneal keraring segments.|20 eyes will undergo corneal collagen cross linking (epithelium off) 1 month after Femtosecond laser assisted intrastromal corneal keraring segments
62075681|NCT01778062|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62075682|NCT05390138|EXPERIMENTAL|Smart Sleep Apnea Self-management Support Programme (4S)|Patients will receive Smart Sleep Apnea Self-management Support Programme (4S) in addition to usual care
62075683|NCT05390138|PLACEBO_COMPARATOR|General Hygiene Information (GH)|Patients will receive general hygiene information (GH) in addition to usual care
62645456|NCT01447888|ACTIVE_COMPARATOR|Control|Standard perioperative dosing, which does not currently account for patients' baseline opiate use.
62645457|NCT00896493|EXPERIMENTAL|Total lymphoid irradiation & anti-thymocyte immunoglobulin|TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.
62075684|NCT05424445|EXPERIMENTAL|Cytotec®|IOL with misoprostol oral solution (Cytotec®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
62075685|NCT05424445|ACTIVE_COMPARATOR|Angusta®|IOL with misoprostol oral tablets (Angusta®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
62279356|NCT05325775|EXPERIMENTAL|ACER-801 50 mg BID|ACER-801 (osanetant) 50 mg BID (1 x 50 mg and 3 x placebo, twice daily)
62075686|NCT00880321|EXPERIMENTAL|Part 1|Part 1 will identify the recommended Part 2 dose using a dose-escalation procedure. Escalation may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached. Subjects may dose up to three times a day.
62075687|NCT00880321|EXPERIMENTAL|Part 2|Part 2 will explore further the safety, tolerability, and clinical activity of GSK2118436 in subjects with BRAF mutation-positive tumors using the recommended part 2 dose identified during Part 1. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
62279357|NCT05325775|EXPERIMENTAL|ACER-801 100 mg BID|ACER-801 (osanetant) 100 mg BID (2 x 50 mg and 2 x placebo, twice daily)
62279358|NCT05325775|EXPERIMENTAL|ACER-801 200 mg BID|ACER-801 (osanetant) 200 mg BID (4 x 50 mg and 0 x placebo, twice daily)
62279359|NCT05325775|PLACEBO_COMPARATOR|Placebo|Placebo (4 x Placebo of ACER-801 twice daily)
62279360|NCT05598255|ACTIVE_COMPARATOR|Caudal blockade (with levobupivacaine) and dexamethasone IV|Administration of levobupivacaine 0,25% 0,5 ml/kg through the hiatus sacralis lege artis. IV administration of dexamethasone 0,5mg/kg (max. 5mg) during standard anaesthetic management.
62279361|NCT05598255|ACTIVE_COMPARATOR|Dorsal penile nerve block (with levobupivacaine) and dexamethasone IV|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia. IV administration of dexamethasone 0,5mg/kg (max. 5mg) during standard anaesthetic management.
62279362|NCT05598255|ACTIVE_COMPARATOR|Dorsal penile nerve block (with levobupivacaine)|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia.
62279363|NCT05162066|EXPERIMENTAL|C3G cohort|Approximately 14 eligible participants with C3G will be enrolled.
62456301|NCT05055349|ACTIVE_COMPARATOR|toric phakic posterior IOL implantation and corneal collagen cross linking|20 eyes will undergo toric phakic posterior IOL implantation 1 year after corneal collagen cross linking (epithelium off).
62645458|NCT04072874|ACTIVE_COMPARATOR|Régimen 1|"* Regimen 1: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 4 weeks.~* For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
62645459|NCT04072874|ACTIVE_COMPARATOR|Régimen 2|"* Regimen 2: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 6 weeks.~* For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
62645460|NCT02627560|EXPERIMENTAL|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
62645461|NCT02627560|PLACEBO_COMPARATOR|placebo control|saline to be smeared on surgical wounds before closure
62279364|NCT05162066|EXPERIMENTAL|IgAN cohort|Approximately 14 eligible participants with IgAN will be enrolled.
62279365|NCT05162066|EXPERIMENTAL|PMN cohort|Approximately 14 eligible participants with PMN will be enrolled.
62279366|NCT01711827|EXPERIMENTAL|Isavuconazole and Prednisone|Single dose of prednisone on Days 1 and 9, isavuconazole 3 times a day (TID) on Days 5-6, isavuconazole once a day (QD) on Days 7-10
62279367|NCT01231997|EXPERIMENTAL|Healthy Volunteers|
62279368|NCT01231997|EXPERIMENTAL|Patients with mild renal impairment|
62279369|NCT01231997|EXPERIMENTAL|Patients with moderate renal impairment|
62279370|NCT01231997|EXPERIMENTAL|Patients with severe renal impairment|
62645462|NCT05849077|EXPERIMENTAL|Sat75|FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth.
62645463|NCT05849077|ACTIVE_COMPARATOR|Sat50|FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve NRP recommended target SpO2 which approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth.
62645464|NCT01317940|EXPERIMENTAL|Group A (Newly Diagnosed Subjects)|
62645465|NCT01317940|NO_INTERVENTION|Standard of Care Group A|
62645466|NCT01317940|EXPERIMENTAL|Group B (Early Survivors)|
62645467|NCT01317940|NO_INTERVENTION|Observation Only - Group B|
62645468|NCT01317940|NO_INTERVENTION|Group C (Siblings of Group A)|
62645469|NCT04827862|EXPERIMENTAL|Pembrolizumab and Radiation Therapy|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
62645470|NCT00900939|EXPERIMENTAL|Low-fat, vegan diet|
62645471|NCT00900939|PLACEBO_COMPARATOR|Control|
62645472|NCT05706324|EXPERIMENTAL|Low dose|21\~65 year old healthy subjects, received low dose of RCVi
62075688|NCT05666375|ACTIVE_COMPARATOR|Percutaneous translumbar permcath|"* Local anesthesia in adults and general anesthesia in pediatrics.~* The patient under fasting condition is placed prone on angiography table.~* Skin preparation and a sterile draping of the operating field.~* Puncture site is chosen 1.5 cm above right iliac crest 10 cm lateral to the posterior median line.~* Puncture into inferior vena cava is made using 21 gauge 15 cm long needle, inserted at 45 degree angle from the horizontal and advanced medially and superiorly under us then fluoroscopic guidance.~* Entry into the IVC is made below the level of the renal veins, immediately anterior to the 3rd lumber vertebra.~* Intravascular position of the needle is confirmed by free aspiration of blood and injection of contrast media under fluoroscopy.~* A guide wire is introduced through the needle and advanced well into the IVC.~* The needle is replaced with a dilator. A catheter of appropriate length is tunneled subcutaneously from the right flank and advanced to the IVC"
62075689|NCT05666375|ACTIVE_COMPARATOR|Percutaneous transhepatic permcath|"* The patient lies in supine position.~* The procedure is done under local anesthesia.~* Under ultrasound guidance; access by a 21 gauge angiocatheter (15cm) to right or middle hepatic vein through intercostal or subcostal approach.~* Entrance of the hepatic veins is confirmed by injection of diluted contrast media (iopromide) under fluoroscopy.~* A 0.018-inch guidewire is advanced through the needle and into the right atrium.~Intravascular catheter length is measured and selected in standard fashion.~* The initial access needle is exchanged over the guidewire for a coaxial transitional sheath, which permits replacement of the 0.018-inch guidewire with a 0.035-inch guidewire.~* The tunneled catheter is inserted over the wire through a peel-away sheath"
62075690|NCT01349413|PLACEBO_COMPARATOR|Placebo|Identical looking placebo (once daily)
62075691|NCT01349413|EXPERIMENTAL|Esomeprazole 20mg daily|Esomeprazole 20mg daily Oral for 8 weeks
62075692|NCT02165085||Vascular-Ehlers Danlos syndrome|N=50 patients with vascular Ehlers-Danlos syndrome
62075693|NCT02165085||Spontaneous arterial dissection(s)|N=50 patients
62075694|NCT02165085||Healthy volunteers|n=100 Healthy volunteers
62279371|NCT03213366|EXPERIMENTAL|E-PrEP- Peer-Led Intervention about PrEP|8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm. Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms. PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues. All contents will be formatted to be both mobile device accessible.
62279372|NCT03213366|ACTIVE_COMPARATOR|BxNow - General Health Campaign|BxNow is an attention-matched control. Eight of the 16 PLs will be randomly assigned to the BxNow arm. The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm. Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups. General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
62279373|NCT00963898|EXPERIMENTAL|Mental Retardation|
62279374|NCT05296577|EXPERIMENTAL|anlotinib and vinorelbine|anlotinib combined with vinorelbine
62456302|NCT06300957|EXPERIMENTAL|Intervention|"Participants will be randomly assigned 2:1 to Experimental or Waitlist Control conditions. Experimental group will immediately access Help Wanted, a secondary prevention program for adults who self-identify as having sexual attraction to children. Help Wanted is an online self-help curriculum to prevent Child Sexual Abuse (CSA) and reduce the psychosocial stressors of help-seekers. Content is designed to increase knowledge about CSA, counter distorted attitudes and cognitions, cope with sexual thoughts and urges about children, support development of a healthy sexuality, counter stigma and shame, build a positive self-image, and encourage safe disclosure practices. Harm and risks are clearly identified within an overall positive messaging framework. Help Wanted incorporates testimonials from survivors and from positive role models, avoids the collection of personal identifiers or reportable information, and adheres to other best practices of prevention programming."
62456303|NCT06300957|OTHER|Waitlist Control|Participants randomized to the Waitlist Control group will be barred from accessing the Help Wanted program for a period of one month.
62456304|NCT02242201|ACTIVE_COMPARATOR|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
62645473|NCT05706324|EXPERIMENTAL|Medium dose|21\~65 year old healthy subjects, received medium dose of RCVi
62075695|NCT01903408|OTHER|Arm 1: Boost to prostate|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate (76.5 Gy) in 34 fractions Arm finished recruitment and follow-up
62075696|NCT01903408|OTHER|Arm 2: Boost to prostate and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate (76.5 Gy) \& pelvic lymph node mets (61.2 Gy) in 34 Fx
62075697|NCT01903408|OTHER|Arm 3: Boost to prostate bed|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate bed (68 Gy) in 34 fractions Arm finished recruitment and follow-up and is published
62075698|NCT01903408|OTHER|Arm 4: Boost to prostate bed and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate bed 68 Gy) \& lymph node metastases (61.2 Gy) in 34 Fx
62075699|NCT01903408|OTHER|Arm 5: Boost to lymph node metastases|Patients with previous irradiation of the prostate bed: IMRT of the pelvic lymphatic drainage (46.8 Gy) above the previous treatment fields, SIB to lymph node metastases (63.2 Gy) in 26 Fx
62279375|NCT05296577|PLACEBO_COMPARATOR|vinorelbine|placebo and vinorelbine
62279376|NCT01064167|EXPERIMENTAL|Tranexamic Acid group|
62645474|NCT05706324|EXPERIMENTAL|High dose|21\~65 year old healthy subjects, received high dose of RCVi
62075700|NCT02557906|EXPERIMENTAL|Implant and Surgimend|Breast reconstruction surgery with an implant and an ADM (Surgimend)
62075701|NCT02557906|ACTIVE_COMPARATOR|Autologous tissue|Breast reconstruction surgery with autologous tissue
62075702|NCT02557906|ACTIVE_COMPARATOR|Implant + dermal sling/LD flap|Breast reconstruction surgery using a dermal sling or a latissimus dorsi (LD)flap
62075703|NCT01664936||pts receiving a PET/CT scan with Metastatic LNs|This study seeks to optically image the Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I in a cohort of patients with primary tumor sites and from pathologic lymph nodes after routine 18F-FDG PET 31I radiotherapy and/or investigational study scans. We will include a subset of patients with normal lymph nodes during screening. This subset of patients will be imaged as a negative control for this study.
62075704|NCT01395043|OTHER|TAP-catheter|Each patient receives bilateral TAP-catheters preoperatively.
62279377|NCT01064167|PLACEBO_COMPARATOR|Control group|
62279378|NCT02693314|EXPERIMENTAL|Jarro-Dophilus EPS® Group|Jarro-Dophilus EPS® (5 billion CFU/capsule) probiotic formulation capsule for 28 days
62279379|NCT02693314|EXPERIMENTAL|Jarro-Dophilus EPS® High Potency Group|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule) probiotic formulation capsule for 28 days
62279380|NCT02693314|PLACEBO_COMPARATOR|Placebo Group|Placebo capsule for 28 days
62279381|NCT04280354||patients with severe community acquired pneumonia (cases)|Cases: Patients with severe community acquired pneumonia with required ICU admission.
62279382|NCT04280354||patients without pneumonia or sepsis (controls)|Controls: Clinical phenotype of inflammation not due to suspected sepsis; patients with fever \>38°C, C reactive Protein (CRP) \>100mg/L, no infection focus expected in ≥ 24h.
62279383|NCT01499017|EXPERIMENTAL|Cohort A|Each subjects in Cohort A will receive 3 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-4.
62279384|NCT01499017|EXPERIMENTAL|Cohort B|Each subjects in Cohort B will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
62645475|NCT04309331|EXPERIMENTAL|PKU Motion|amino acid based protein substitute
62645476|NCT04831710|EXPERIMENTAL|Sintilimab+Chidamide|Participants will receive Sintilimab,200mg, ivd, d1; Chidamide,30mg,po,biw,d1-21; repeated every 3 weeks(up to 1 year) until disease progression, intolerable toxicity, death, or termination of the study for any reason.
62645477|NCT05074875||Cohort 1|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 1 subjects will undergo Visit 0 after informed consent is obtained. Eligible subjects will return for follow-up at Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks"
62075705|NCT00953095|EXPERIMENTAL|Caregiver Mediated Model (CMM)|focuses on joint attention/engagement intervention using an established evidence based treatment (Kasari et al., 2006). It involves meeting the parent and child in their home for one hour, twice a week for 12 weeks. In this intervention, the parent-child pair meet with the interventionist (as opposed to the group training in the CEM condition). Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input and coaching from the interventionist) as they implement these techniques with their child.
62279385|NCT04747015|ACTIVE_COMPARATOR|Cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus
62279386|NCT04747015|ACTIVE_COMPARATOR|Active management|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
62075706|NCT00953095|EXPERIMENTAL|Caregiver Education Model (CEM)|focuses on teaching parents information about autism, behavior modification, and community services using a manualized approach (Brereton \& Tonge, 2005). Parents will receive information on child development each week, and will be able to ask questions and discuss the information vis-à-vis their own child. This intervention is manualized (Brereton \& Tonge 2005). In the CEM condition, parents meet in a group (without their children) in a community-based setting to receive the intervention. Intervention sessions occur once a week for 2 hours.
62075707|NCT01476917|EXPERIMENTAL|Treatment|Subjects that completed the ATLAST Study
62075708|NCT01226628|EXPERIMENTAL|Cohort A|Phase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC)
62075709|NCT01226628|EXPERIMENTAL|Cohort B|Phase 1: 3 patients will receive 120,000 hUTC
62075710|NCT01226628|EXPERIMENTAL|Cohort C|Phase 1: 3 patients will receive 300,000 hUTC
62279387|NCT01009957|EXPERIMENTAL|Everolimus|Everolimus + standard therapy for CKD
62279388|NCT01009957|NO_INTERVENTION|Control|Standard therapy for CKD
62279389|NCT01155115|EXPERIMENTAL|Primary Ciliary Dyskinesia (PCD) Patients|
62279390|NCT01155115|EXPERIMENTAL|Cystic Fibrosis (CF) Patients|
62456305|NCT02242201|ACTIVE_COMPARATOR|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
62456306|NCT02242201|ACTIVE_COMPARATOR|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
62456307|NCT04813809|EXPERIMENTAL|BARRIER EasyWarm|This is an open, non randomised, single arm study
62456308|NCT03920007|EXPERIMENTAL|ATSN-101|ATSN-101 single dose according to an ascending dose design (dose escalation phase) or ATSN-101 single dose (dose expansion phase)
62456309|NCT04996238|OTHER|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid will be collected just before the first vaccination (T1: pre-vaccination), between 14 and 30 days after the second vaccination (T2: post-vaccination), 6 months after the second vaccination (T3: 6 months post-vaccination), between 14 and 30 days after the third/booster vaccination (T4: post-booster-vaccination) and 6 months after the third/booster vaccination (T5: 6 months post-booster-vaccination)
62645478|NCT05074875||Cohort 2|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 2 subjects will undergo Visit 1, within 4 (+/- 2) weeks of hospital discharge or outpatient infection, after informed consent is obtained. Eligible subjects will return for follow-up Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks."
62645479|NCT05074875||Cohort 3a|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled within ≤ 12 weeks of hospital discharge or outpatient COVID- 19 infection will undergo their first study visit at Visit 1 (Weeks 6-12)."
62075711|NCT01226628|EXPERIMENTAL|Cohort D|Phase 1: 3 patients will receive 560,000 hUTC
62075712|NCT01226628|EXPERIMENTAL|Cohort E|Phase 1: 6 patients will receive 300,000 hUTC
62075713|NCT01226628|EXPERIMENTAL|Cohort F|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
62075714|NCT01226628|EXPERIMENTAL|Cohort G|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
62653056|NCT01351636|EXPERIMENTAL|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride
62075715|NCT01226628|EXPERIMENTAL|Phase 2a|Up to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study
62075716|NCT05348343|OTHER|Autocontrolled Arm|The subject will be treated with both the experimental treatment and the active comparator.
62075717|NCT01551303|PLACEBO_COMPARATOR|Placebo|Matched nasal spray placebo.
62279391|NCT05197231|EXPERIMENTAL|IV amino acids + standardized physiotherapy with lower limb resistance exercise.|Research subjects randomized to the intervention group will receive an infusion of IV amino acids during a session of protocolized physiotherapy that includes a knee extension resistance exercise targeting the thigh muscles. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
62279392|NCT05197231|ACTIVE_COMPARATOR|IV amino acids + standardized physiotherapy.|Research subjects randomized to the control group will receive an infusion of IV amino acids during a session of protocolized physiotherapy NOT including lower limb resistance exercise. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
62279393|NCT02266680|EXPERIMENTAL|Yoga Treatment Group|BFY will be taught by a trained yoga instructor. Group sessions will be offered twice a week for 60 minutes each (i.e., a total of 2 hours per week), for 8 weeks.
62075718|NCT01551303|EXPERIMENTAL|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
62075719|NCT05273086|EXPERIMENTAL|Sleep intervention program|The Sleep Intervention program Group will be subdivided into two groups of 10 participants to receive the sleep quality improvement program. The program consists of 2 sessions of 90 minutes during one week.
62075720|NCT05273086|NO_INTERVENTION|Control Group|The control group will continue with their usual routine.
62075721|NCT04963972|EXPERIMENTAL|Arm I (Lucid Lane)|Patients participate in the Lucid Lane therapy program including working with a mental health therapist on mindfulness, CBT, group therapy, and mind-body therapies for 3-9 months or until the tapering off period is complete.
62075722|NCT04963972|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard of care post-surgical opioid education.
62279394|NCT02266680|NO_INTERVENTION|Waitlist Group|Waitlisted participants will receive BFY at the next available group after their waitlist period is completed
62279395|NCT03437551||no intervention|Cross-sectional Observation study
62279396|NCT03036527|EXPERIMENTAL|Activity-based locomotor training|To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
62279397|NCT03036527|EXPERIMENTAL|Activity-based stand training|To understand the effects of weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based stand training interventions include stand training with a harness and body-weight support or stand training over ground, 5 days a week for a total of 80, 1-hour sessions.
62456310|NCT03319056|ACTIVE_COMPARATOR|Real purification|Air purifier turned on
62653057|NCT01351636|PLACEBO_COMPARATOR|Non arotinolol group|Antihypertensive medications without arotinolol hydrochloride
62645480|NCT05074875||Cohort 3b|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled ≥ 12 weeks from hospital discharge or outpatient COVID- 19 infection will undergo their first visit within 4 weeks before week 24. Subjects that are enrolled into Cohort 3 will be followed until Week 72."
62645481|NCT02966704|EXPERIMENTAL|meal 1|mixed meal with high level of intrinsically labeled milk protein
62645482|NCT02966704|EXPERIMENTAL|meal 2|mixed meal with low level of intrinsically labeled milk protein
62645483|NCT01001429|ACTIVE_COMPARATOR|Propofol|propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
62645484|NCT01001429|EXPERIMENTAL|dexmedetomidine infusion|Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.
62456311|NCT03319056|SHAM_COMPARATOR|Sham purification|Air purifier turned off
62645485|NCT00663650|ACTIVE_COMPARATOR|1|Permanent Section Control
62645486|NCT00663650|ACTIVE_COMPARATOR|2|Frozen Section Control
62645487|NCT04890808|EXPERIMENTAL|Over-the-Counter Dietary Supplement Inosine|capsules containing 500 mg of inosine Two capsules Twice Daily Other Name: hypoxanthine 9-β-D-ribofuranoside 9-\[(2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl) oxolan-2-yl\]-1H-purin-6-one
62645488|NCT04890808|EXPERIMENTAL|Over-the-Counter Dietary Supplement IP6|"capsules containing 500mg of IP6 Two capsules Twice Daily Other Name: Inositol hexaphosphate~(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexakis\[dihydrogen (phosphate)\]"
62645489|NCT01103323|EXPERIMENTAL|Regorafenib (Stivarga, BAY73-4506)+BSC|Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
62645490|NCT01103323|PLACEBO_COMPARATOR|Placebo+BSC|Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).
62645491|NCT01884597|ACTIVE_COMPARATOR|Cohort 1|12 monthly, intravitreal injections of 2.0mg ranibizumab followed by 12 monthly, intravitreal injections of 1.0mg ranibizumab
62645492|NCT01884597|ACTIVE_COMPARATOR|Cohort 2|6-months of monthly, intravitreal injections of ranibizumab 2.0mg followed by 18 months of monthly, intravitreal injections of ranibizumab 1.0mg
62645493|NCT01884597|ACTIVE_COMPARATOR|Cohort 3|24 months of monthly, intravitreal injections of ranibizumab 1.0mg
62645494|NCT01978457|EXPERIMENTAL|cocaine hydrochloride|cocaine hydrochloride
62645495|NCT01978457|EXPERIMENTAL|propranolol|propranolol
62645496|NCT01978457|PLACEBO_COMPARATOR|placebo|placebo
62645497|NCT02771275|EXPERIMENTAL|Harpoon Medical Device TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
62645498|NCT04458896|EXPERIMENTAL|Stand When You Can|The intervention is grounded in Social Cognitive Theory and the Social Ecological Model (SEM). Multiple levels of the SEM will be targeted (individual, environmental, and organizational) over 6 weeks.
62645499|NCT04012528||"the before group"|75 teenagers after scoliosis surgery before ERAS program implementation
62645500|NCT04012528||"the after group"|75 teenagers after scoliosis surgery after ERAS program implementation
62279398|NCT03036527|EXPERIMENTAL|Activity-based upper arm ergometry|To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
62653058|NCT00719901|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62653059|NCT01641536|EXPERIMENTAL|1mg of HB-110|The subjects in this group will be administered 1 mg of HB-110 according to the protocol.
62279399|NCT03036527|EXPERIMENTAL|Activity based training + spinal epidural stimulation|combination effect of both locomotor training and/or stand training with epidural stimulation targeting locomotion and/or stand.
62456312|NCT03532321||Caregivers|Caregivers in the participating hospital departments : medical (doctors, midwives) and paramedical (nurses' aides, registered nurses, specialized nurses and head nurses) staff, working in hospital departments drawn at random among five volunteer hospital centers in Paris, and who will be present at the time of investigator's passage, at a date drawn at random during the inclusion phase.
62456313|NCT04791553|EXPERIMENTAL|Normal Hepatic Function|Group 1 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to Matching healthy subjects with normal hepatic function
62456314|NCT04791553|EXPERIMENTAL|Hepatic Impairment|Group 2 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to subjects with severe hepatic impairment
62456315|NCT02067364|OTHER|Fit & function test|CRT ShuntCheck sensors will be applied over the shunts of asymptomatic hydrocephalus patients. The device will be activated, cooling the skin under the sensor. Patients will change positions during the one hour procedure and data will be recorded. Data will be analyzed offline to identify product performance issues due to motion.
62653060|NCT01641536|EXPERIMENTAL|2mg of HB-110|The subjects in this group will be administered 2 mg of HB-110 according to the protocol.
62653061|NCT01641536|EXPERIMENTAL|4mg of HB-110|The subjects in this group will be administered 4 mg of HB-110 according to the protocol.
62075723|NCT05745480||Pre-Intervention Period: Usual Care with Ad-Hoc Addiction Consults|UW Hospital launched an Addiction Medicine inpatient consult service in 1991 to address the high prevalence of substance use disorders in hospitalized adults. Currently, a single screening item queries 'marijuana or other recreational drug use,' but no formal screening process was in place specifically targeting opioid misuse. For patients at risk of an opioid use disorder, the practice was ad-hoc consultations at the discretion of the primary provider.
62075724|NCT05745480||Post-Intervention Period: Artificial intelligence-driven clinical decision support|The technical architecture that enabled the real-time, NLP CDS tool incorporated industry-leading and emerging technological capabilities. The NLP CDS infrastructure exports the notes from the EHR, organizes them and feeds them into an NLP pipeline, inputed the processed text features into the opioid screener deep learning model, and delivered the resultant scores back to the bedside electronic health record as a best practice alert.
62075725|NCT06144268|ACTIVE_COMPARATOR|Density Gradient Centrifugation (DGC)|During this procedure, raw semen sample is placed on 2 gradients: a lower phase (80%) and an upper phase (40%) followed by centrifugation. The composition of the gradients include a colloidal suspension of silica particles. At the end of centrifugation, each spermatozoa is situated at the gradient level that matches its density. The highly motile, morphologically normal, viable spermatozoa form a pellet at the bottom of the tube.
62075726|NCT06144268|EXPERIMENTAL|ZyMōt Multi (850µL)|ZyMōt Multi (850µL) is a flow-free dual chambered single-use device. The first chamber contains a sample inlet and a fluid channel separated from the second collection chamber by an 8-μm microporous membrane. Channel dimension and membrane porosity are designed to optimize the sorting and collection of the most motile sperm. Sorting is accomplished by the passage of sperm through the micropores of the membrane. This procedure does not require any preliminary semen processing, all centrifugation steps being eliminated.
62279400|NCT04357106|EXPERIMENTAL|Convalescent Plasma|200 ml of convalescent plasma, single dose.
62279401|NCT03851783|EXPERIMENTAL|Solar-powered oxygen|Solar panels used to drive an oxygen concentrator will deliver medical grade oxygen at a rate of 1-5L/min, for the treatment of children with hypoxemia.
62279402|NCT03851783|NO_INTERVENTION|Standard of care|Patients presenting with hypoxemia and pneumonia will be treated by standard of care prior to the implementation of solar-powered oxygen at a chosen site. This may include some allocation of oxygen via cylinders, but will likely be minimal or not available.
62279403|NCT05481372|EXPERIMENTAL|Standard radiotherapy with research image acquisition|Radiotherapy delivered as per standard of care Additional trans-perineal ultrasound (TPUS) imaging at three timepoints (1 x pre-treatment and 2 x treatment). Additional magnetic resonance imaging (MRI) pre-treatment.
62279404|NCT03094195|EXPERIMENTAL|EMA401 25mg BID|Ema401 25 mg was administered orally twice a day
62279405|NCT03094195|EXPERIMENTAL|EMA401 100mg BID|Ema401 100 mg was administered orally twice a day
62279406|NCT03094195|PLACEBO_COMPARATOR|Placebo BID|Matching placebo capsules administered orally twice a day
62456316|NCT00919464|OTHER|Needle Insertion into Femur|Data gathering with monitoring of pressures in the thigh via via needle in femur.
62456317|NCT01879280|EXPERIMENTAL|osteoplastic craniotomy|Half of the study population will be randomized to traditional pterional craniotomy as the method of exposure. The other half will be randomized to osteoplastic craniotomy as the method of exposure. All other aspects of medical care will remain the same.
62653062|NCT01963234|EXPERIMENTAL|Seva|Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
62279407|NCT01436344||1|"Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the cases group."
62075727|NCT05391360|EXPERIMENTAL|Freethiadine tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 5 dose cohorts: 5 mg、10 mg、200 mg(food effect)、400 mg、600 mg; multiple-dose study: 100 mg、200 mg、300 mg、150 mg
62075728|NCT05391360|PLACEBO_COMPARATOR|Freethiadine placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 5 dose cohorts: 5 mg、10 mg、200 mg(food effect)、400 mg、600 mg; multiple-dose study: 100 mg、200 mg、300 mg、150 mg
62075729|NCT05391360|EXPERIMENTAL|Freethiadine tablet|part 2(Patients with chronic hepatitis B): There will be a total of 4 dose cohorts:100 mg、200 mg(BID or QD)、300 mg
62075730|NCT05391360|ACTIVE_COMPARATOR|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
62645501|NCT04621721|EXPERIMENTAL|Intervention Group|The intervention will consist of a 16-week, home-based gait/balance training and progressive resistance exercises for lower extremities using resistance power bands. Participants will be given the home-based gait/balance training and progressive resistance exercise training access via a link or by DVD, and the resistance training band, and wide, firm foam surface. The intervention group will begin with light warm-up and stretching activity then a 10 minute each of gait/balance and 10 minutes of resistive (strength) training components. The program begins with light stretching to address any range of motion limitations that may affect ability to maintain balance and postural stability, and consisted of hamstring quadricep, gastroc, and soleus stretches. During stretching exercises, participants held each stretch for 10-15 seconds, repeating each stretch 2-3 times for each lower extremity. Stretching exercises do not change during the intervention.
62075731|NCT03551808|ACTIVE_COMPARATOR|installation of Ketorolac Tromethamine Eye Drop|
62075732|NCT03551808|NO_INTERVENTION|not receiving placebo|
62075733|NCT03017235|EXPERIMENTAL|NaP/MC Oral Solution|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
62075734|NCT03017235|ACTIVE_COMPARATOR|PREPOPIK®|
62645502|NCT04621721|ACTIVE_COMPARATOR|Attention Control Group|The Attention Control group will receive an educational intervention via a journal in which to record their clinic appointments, and standardized American Cancer Society pamphlets which have been adjusted to fit within the journal binding for easy reference. At each data collection encounter, the intervention research assistant will discuss the information in each pamphlet, allowing time for questions related to the material. The educational materials consist of 1) Emotions and Breast Cancer; 2) Body Image and Sexuality After Breast Cancer; 3) Follow up Care After Breast Cancer Treatment; 4) Nutrition and Cancer. Sessions last approximately 45-60 minutes and occur at the same intervals as the intervention group and will precede data collection. Attention Control group participants will receive telephone calls every other week which will entail a social visit and reminder of data collection/attention intervention appointments to further equalize contact.
62279408|NCT01436344||2|Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
62075735|NCT02123290|EXPERIMENTAL|Plasmodium falciparum|Patients with Plasmodium falciparum malaria
62075736|NCT02123290|EXPERIMENTAL|Plasmodium vivax|Patients with Plasmodium vivax malaria
62279409|NCT05883189||Group1: non-pregancy health women.|
62279410|NCT05883189||Group 2:Pregancy health women.|
62279411|NCT05883189||Group 3: Diagnosed Antiphospholipid syndrome patients|
62279412|NCT05031026|ACTIVE_COMPARATOR|donor group|where donors only will receive dexmedetomidine
62279413|NCT05031026|ACTIVE_COMPARATOR|recpient group|where recepients only will receive dexmedetomidine
62075737|NCT00004203|EXPERIMENTAL|Arm A|On Day 1 of each 21-day treatment cycle, patients receive 130 mg/m2 oxaliplatin diluted in 250 to 500 mL Dextrose 5% in Water infused intravenously over 2 hours through a peripheral or central vein
62075738|NCT05216224|EXPERIMENTAL|ATI-450|ATI-450 50mg oral tablet BID
62075739|NCT05216224|EXPERIMENTAL|Placebo|Placebo oral tablet BID
62075740|NCT05266651|ACTIVE_COMPARATOR|tadalafil group|5 mg of Tadalafil on daily bases for one month duration
62075741|NCT05266651|PLACEBO_COMPARATOR|placebo group|the patients will receive oral tablets without any active substance for one month
62075742|NCT01119339|EXPERIMENTAL|LAS 41004 dosage 1|
62075743|NCT01119339|EXPERIMENTAL|LAS 41004 dosage 2|
62075744|NCT01119339|EXPERIMENTAL|LAS 41004 dosage 3|
62075745|NCT01119339|EXPERIMENTAL|LAS 41004 dosage 4|
62075746|NCT01119339|EXPERIMENTAL|LAS 41004 dosage 5|
62075747|NCT01119339|EXPERIMENTAL|LAS 41004 dosage 6|
62075748|NCT01119339|PLACEBO_COMPARATOR|Placebo|
62075749|NCT01119339|ACTIVE_COMPARATOR|Reference|
62075750|NCT00854295|EXPERIMENTAL|Post-Approval Study Group (Group 2)|Subjects enrolled in a short-term study (5 years) consisted of cases eligible to receive the LPS-Flex Mobile Bearing Knee implanted by orthopedic surgeons experienced in primary total knee replacement. All Group 2 subjects, both unilateral and bilateral subjects, are in the same arm of the study. As part of the PAS study, these subjects were followed from Pre-operative to 5 years.
62075751|NCT00854295|EXPERIMENTAL|Investigational Device Exemption Group (Group 1)|Subjects who were implanted with either the LPS Flex Fixed Bearing Knee (control population) or the LPS Flex Mobile Bearing Knee device during the previous Investigational Device Exemption study. As part of the PAS study, these subjects were followed from 4 years to 10 years.
62279414|NCT05031026|PLACEBO_COMPARATOR|control group|both donors and recipients will receive a placebo
62279415|NCT05241327|ACTIVE_COMPARATOR|Active|Beetroot Juice (Nitrate, 400 mg)
62279416|NCT05241327|PLACEBO_COMPARATOR|Placebo|Beetroot Juice (Nitrate, 0 mg)
62279417|NCT03644433|PLACEBO_COMPARATOR|Single layer|Single layer closure
62075752|NCT03119337|EXPERIMENTAL|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
62075753|NCT03119337|NO_INTERVENTION|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
62075754|NCT02067637||Exposed|Individuals with one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer.
62075755|NCT02067637||Unexposed|Healthy controls
62075756|NCT03912220|EXPERIMENTAL|Nicotinamide Riboside|Experimental group of participants will receive Nicotinamide riboside at a dose of 900 mg twice a day orally.
62075757|NCT03912220|PLACEBO_COMPARATOR|Placebo|Study participants in the placebo arm will receive placebo pills that are similar in size and shape to the experimental group drug.
62075758|NCT06031909||Stroke patients|Stroke patients admitted to the certified stroke-unit of the Department of Neurology, University Hospital Giessen, Germany.
62075759|NCT01868074|NO_INTERVENTION|Usual|Participants who are not randomized to the fitted insole intervention
62075760|NCT01868074|EXPERIMENTAL|Insole|Participants randomized to use of a custom-molded insole during pregnancy
62075761|NCT00900575|EXPERIMENTAL|Colposcope|Patients referred for GYN procedures. Specifically, patients will be referred for Pap smear, colposcope or LEEP. The intervention for this arm is the use of the bench-top, miniature optical spectrometer or trans-vaginal colposcope
62075762|NCT04702100|EXPERIMENTAL|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization+conventional therapy three times per week for four week
62075763|NCT04702100|EXPERIMENTAL|integrated neuromuscular inhibition technique|the patients will receive integrated neuromuscular inhibition technique+ conventional therapy. three times a week for four week
62075764|NCT04702100|ACTIVE_COMPARATOR|conventional therapy|the patients will receive conventional therapy three times a week for four week
62279418|NCT03644433|ACTIVE_COMPARATOR|Double layer with resection|Double layer closure after resection uterine scar
62075765|NCT03352063|ACTIVE_COMPARATOR|Sitting with Exercise|Subjects will complete a short term training protocol while sitting \>11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
62075766|NCT03352063|ACTIVE_COMPARATOR|Walking with exercise|Subjects will complete a short term training protocol while sitting \<5 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
62075767|NCT06229184|EXPERIMENTAL|Control group|Fecal calprotectin samples taken for comparison from healthy adolescents
62075768|NCT06229184|EXPERIMENTAL|Obese group|Fecal calprotectin samples taken from obese adolescents
62075769|NCT06229184|EXPERIMENTAL|Obese + NAFLD group|Fecal calprotectin samples taken from obese adolescents that have NAFLD
62075770|NCT04160611|EXPERIMENTAL|Premedication with Midazolam|Patients will be randomly divided into two groups, control and midazolam. The midazolam group will receive midazolam premedication in such a way that 7.5mg midazolam will be taken orally 30 minutes before the aspiration procedure. Because midazolam causes sedation, the woman will be monitored by midazolam after medical premedication to avoid possible complications and will not be allowed to get out of bed on her own for 30 minutes. After 30 min, all women, both test and control group, will begin aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
62075771|NCT04160611|NO_INTERVENTION|No Premedication with Midazolam|Women in the control group will undergo aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
62075772|NCT03288389|PLACEBO_COMPARATOR|Placebo|Participants will take 4 placebo wafers per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
62075773|NCT03288389|ACTIVE_COMPARATOR|NTFactor Lipids®|Participants will take 4 NTFactor Lipid® wafers (4 g) per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
62075774|NCT03764358|ACTIVE_COMPARATOR|Arteriovenous fistula|
62075775|NCT03764358|EXPERIMENTAL|Tunneled Cuffed Catheter|
62075776|NCT03165162|EXPERIMENTAL|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
62075777|NCT05989321||PVI alone group|Patients who undergo PVI alone using ThermoCool SmartTouch catheter.
62075778|NCT05989321||PVI + SPs ablation group|Patients who undergo PVI + SPs ablation using ThermoCool SmartTouch catheter.
62075779|NCT03698864|EXPERIMENTAL|PCS499 900mg twice a day|
62075780|NCT04559490||Standard formula|Participants receiving intact protein lactose-based formula, exclusively for at least 3 months.
62075781|NCT04559490||Sensitive|Participants receiving intact protein glucose/sucrose- based formula, exclusively for at least 3 months.
62279419|NCT03056573|EXPERIMENTAL|Subclavian/axillary|Subclavian/axillary access route
62075782|NCT04883593|EXPERIMENTAL|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
62075783|NCT04883593|PLACEBO_COMPARATOR|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
62075784|NCT01614574|EXPERIMENTAL|Investigational|velaglucerase alfa
62075785|NCT03477786|ACTIVE_COMPARATOR|tight BP|"Interventions: anti-hypertension drug prescription by physician and case management by health educator.~Blood pressure is targeted at 120/80 mmHg in the tight BP control group."
62279420|NCT03056573|EXPERIMENTAL|Transaortic|Transaortic access route
62279421|NCT05997355|EXPERIMENTAL|Treatment|Patient will be treated with preoperative gabapentin
62075786|NCT03477786|PLACEBO_COMPARATOR|usual BP|"Interventions: The physicians follow their usual care patterns to prescribe anti-HT drugs.~Blood pressure is targeted at \< 140/90 mmHg in the usual BP control group."
62075787|NCT04360122|ACTIVE_COMPARATOR|Levamisole|Oral Levamisole 150 mg/day for two days per week for two months
62075788|NCT04360122|ACTIVE_COMPARATOR|Isoprinosine|Oral Isoprinosine 1 g 3 times per day daily for two months
62279422|NCT05997355|NO_INTERVENTION|No treatment|Patient will not be treated with preoperative gabapentin
62279423|NCT04787965||ONGENTYS|Opicapone 50 mg capsule once daily for 6 months
62279424|NCT05730595|EXPERIMENTAL|D2 lymph node dissection|The D2 lymph node region are dissected. And 1-3 lymph nodes of the D2 region will be selected for intraoperative frozen section. If no lymph node metastasis is found in freezing, the D3 region lymph nodes in the root of the submesenteric artery were preserved.
62075789|NCT04360122|ACTIVE_COMPARATOR|Levamisole and Isoprinosine|Oral Levamisole 150 mg/day for two days per week and Oral Isoprinosine 1 g 3 times per day daily for two months
62075790|NCT04360122|NO_INTERVENTION|Non-interventional group|No-intervention
62279425|NCT05730595|ACTIVE_COMPARATOR|D3 lymph node dissection|Thorough dissection of lymph nodes in the D3 region.
62456318|NCT01879280|ACTIVE_COMPARATOR|traditional pterional craniotomy|traditional pterional craniotomy
62075791|NCT03509376|EXPERIMENTAL|Suture repair|Diastasis recti is repaired using nylon suture for the plication
62075792|NCT03509376|EXPERIMENTAL|Rolled mesh repair|Diastasis recti is repaired with self gripping mesh to reinforce the suture line
62075793|NCT02446093|EXPERIMENTAL|Test Arm|CAN-2409 + prodrug (valacylovir or acyclovir) in combination with neoadjuvant chemoradiation or SBRT + Surgery
62075794|NCT02446093|ACTIVE_COMPARATOR|Control Arm|Neoadjuvant chemoradiation or SBRT + Surgery
62075795|NCT00453102|EXPERIMENTAL|Zevalin + Rituximab|Ibritumomab Tiuxetan (Zevalin) + Rituximab
62279426|NCT02218918|ACTIVE_COMPARATOR|Supervised Treadmill Walk Training|Based on 6 minute walk distance, treadmill speed initiated and progression on basis new 6 minute walk distance every 2 weeks
62279427|NCT02218918|EXPERIMENTAL|Supervised Ground walk training|Ground walk training progressed on the basis of 6 minute walk distance (70 - 90%), Weekly 3 days and for 6 weeks
62456319|NCT01520857|ACTIVE_COMPARATOR|Spinal anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. spinal anesthesia
62075796|NCT00759772|ACTIVE_COMPARATOR|Teriparatide|
62075797|NCT00759772|PLACEBO_COMPARATOR|Placebo|
62075798|NCT02589041|EXPERIMENTAL|Intraneural|Using an Up-and-down methodology, the first patient receives 15 ml ropivacaine 1% intraneural injection. If unsuccessful, following patient will receive an increased dose of LA (2 ml). If successful, following patient will be randomized to have either the same LA dose (9 out of 10 probability) or 2 ml reduction of LA dose (1 out of 10 probability)
62075799|NCT04724356|EXPERIMENTAL|Virtual Reality Group|The Kinect based rehabilitation group received virtual reality therapy using Xbox Kinect-based games, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
62279428|NCT00654498|OTHER|Pramipexole|4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
62279429|NCT00654498|OTHER|Placebo|4 weeks of individual dose titration as for the investigational product, once daily
62279430|NCT03220672|EXPERIMENTAL|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
62279431|NCT04622176||Patients with rectal cancer|Patients with rectal cancer will be included and asked to participate in the study where a MMUS will be used after resection to test diagnostic accuracy.
62279432|NCT05054725|EXPERIMENTAL|RMC-4630 and sotorasib, Safety Run-in|"Safety Run-In:~RMC-4630 and sotorasib"
62279433|NCT05054725|EXPERIMENTAL|RMC-4630 and sotorasib, Expansion|"Dose Expansion:~RMC-4630 and sotorasib"
62456320|NCT01520857|ACTIVE_COMPARATOR|General Anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. general anesthesia
62456321|NCT00556049|EXPERIMENTAL|1|Sunitinib and gemcitabine
62075800|NCT04724356|EXPERIMENTAL|Resistance exercise Group|The resistance exercise group received resistance training, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
62279434|NCT03581851|EXPERIMENTAL|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62279435|NCT03581851|EXPERIMENTAL|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
62456322|NCT00650000|EXPERIMENTAL|1|Modafinil Tablets 200 mg
62456323|NCT00650000|ACTIVE_COMPARATOR|2|Provigil® Tablets 200 mg
62456324|NCT00728026||1|Cyclic Vomiting Syndrome
62456325|NCT00728026||2|Irritable Bowel Syndrome
62456326|NCT00728026||3|Postural Orthostatic Tachycardia Syndrome
62456327|NCT00728026||4|Functional Abdominal Pain
62075801|NCT02392884|ACTIVE_COMPARATOR|EON-MEM|Intervention: Cognitive Rehabilitation and compensatory strategies will be taught to subjects to help them remember routes, viral load count, CD4 count, faces of providers and managing their schedules. Over the course of 5 visits, subjects will receive this intervention.
62075802|NCT02392884|ACTIVE_COMPARATOR|Compensatory Cognitive Training|Cognitive Rehabilitation and physical reminders, such as calendars, smart phones, self-notes and other methods to help subjects remember to attend all medical appointments and take their HIV medication. Subject will be exposed to 5 sessions of this particular training.
62075803|NCT02392884|NO_INTERVENTION|Psychoeducation|The psychoeducation group, which aims to teach subjects the importance of taking medications and attending all doctor's appointment for HIV treatment. If you subjects are assigned to this group, they will be followed and receive the care generally followed for individuals with this condition.
62075804|NCT00334867|ACTIVE_COMPARATOR|Arm I|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-15; doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 1, 7, and 13; cyclophosphamide IV over 1 hour on day 1 in weeks 1, 7, and 13; and ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4, 10, and 16. Patients undergo local therapy comprising conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19.
62645503|NCT01201642|EXPERIMENTAL|Prednisolone|Prednisolone as 5 mg tablets will be given within 72 h after onset of Bell's palsy as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
62075805|NCT00334867|EXPERIMENTAL|Arm II|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-16; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 13; cyclophosphamide IV over 30 minutes on days 1-5 in weeks 1 and 13 and IV over 1 hour on day 1 in weeks 7 and 16; ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4 and 10; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 7 and 16. Patients also undergo local therapy comprising of conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19. Patients then proceed to combination chemotherapy.
62075806|NCT02450773|EXPERIMENTAL|Furosemide/Potassium chloride|40 mg furosemide; 20 meq potassium chloride
62279436|NCT04525716||COVID-19|Patients with confirmed COVID-19 infection
62279437|NCT04525716||Non-COVID-19|Patients without confirmed COVID-19 infection
62279438|NCT01238692|EXPERIMENTAL|LBH589|
62279439|NCT01238692|EXPERIMENTAL|LBH589 plus Rituximab|
62279440|NCT05156294|EXPERIMENTAL|Test|Mucoperiosteal flaps will be raised and the conventional drilling sequence for implants will be implemented (Camlog Conelog Screw-Line Promote Plus implants). Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
62075807|NCT02450773|PLACEBO_COMPARATOR|Placebo|Placebo #1, Placebo #2
62075808|NCT03629990|EXPERIMENTAL|Active ABM + CBT/MET|"Participants in the Active ABM condition will receive approach bias modification (ABM) training sessions aimed at reducing cognitive bias for cannabis cues.~All participants will receive MET/CBT therapy."
62075809|NCT03629990|SHAM_COMPARATOR|Sham ABM + CBT/MET|"Participants in the Sham ABM condition will undergo similar computerized tasks without the manipulation of response contingencies that target modification of approach bias.~All participants will receive MET/CBT therapy."
62279441|NCT05156294|OTHER|Control|Mucoperiosteal flaps will be raised and the conventional drilling sequence for implants will be implemented (Camlog Conelog Screw-Line Promote Plus implants). Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
62279442|NCT03664245||experimental group|Critically ill patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
62279443|NCT01207271|EXPERIMENTAL|Cognitive Therapy|
62279444|NCT01207271|EXPERIMENTAL|Dynamic Therapy|
62279445|NCT04058327||MHE group|Patients whose MHE test are positive
62279446|NCT04058327||no HE group|Patients whose MHE test are negative
62456328|NCT00728026||5|Chronic Nausea
62279447|NCT04820400|EXPERIMENTAL|VR-360 group (VR-group)|Patients will watch a VR-360 distraction video during dressing change. The patient will be asked or helped to wear the HMD write in full at the onset of a procedure and watch the VR-360 video during the dressing change procedure. When experiencing pain, the patient may indicate the need for further analgesic medication during the procedure, the patient will be asked to push a button in their hand that will trigger a light-based signal for the nurse to provide further analgesic medication. Should their hands both be involved in the burn injury, the patient will indicate the same verbally.
62075810|NCT02930564|EXPERIMENTAL|a milk fat or gluten challenge|patients will regress to the first stage diet with either a milk fat /emulsifier or a gluten/emulsifier challenge over 7 days.
62456329|NCT03238677|EXPERIMENTAL|Biofeedback, Massed->Distributed|Sequenced biofeedback Mass Practice--\> Distributed Scheduling
62645504|NCT01201642|EXPERIMENTAL|Acute stage acupuncture|Accept acupuncture therapy within 10days after onset of Bell's palsy, do not accept prednisolone therapy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints within 72 h after onset of Bell's palsy. Yifeng (TE17), Hegu (LI4) are punctured 0.5-1.0 cun, the others are punctured 0.1-0.3 cun. and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
62645505|NCT01201642|EXPERIMENTAL|Prednisolone + acute stage acupuncture|Accept prednisolone and acupuncture therapy within 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
62645506|NCT01201642|EXPERIMENTAL|Resting stage acupuncture|Accepted acupuncture therapy after 10 days of the onset of Bell's palsy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. Penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints 7 d after enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
62645507|NCT01201642|EXPERIMENTAL|Prednisolone + resting stage acupuncture|Accept prednisolone and acupuncture therapy more than 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Resting stage acupuncture.
62279448|NCT04820400|NO_INTERVENTION|Control Group (standard treatment)|The patients will receive standard treatment and will be instructed to use the same button to indicate their pain.
62279449|NCT02396732|EXPERIMENTAL|Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)|Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
62279450|NCT02396732|ACTIVE_COMPARATOR|Low Molecular Weight Heparin (LMWH) Alone|Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.
62645508|NCT01201642|OTHER|Other treatment|Do not accept neither prednisolone nor acupuncture therapy. The therapy accepted is different from the five Arms Previously.
62279451|NCT05535881|EXPERIMENTAL|Experimental Group|
62279452|NCT05535881|NO_INTERVENTION|Waitlist Control Group|
62279453|NCT04126382|ACTIVE_COMPARATOR|INSURE|Intubate-Surfactant-Extubate(INSURE) technique is a Important treatment in premature infants with RDS.
62279454|NCT04126382|EXPERIMENTAL|LISA|Less invasive surfactant administration(LISA) technique is a Important treatment in premature infants with RDS.
62279455|NCT02711280|EXPERIMENTAL|Sevoflurane General anesthesia|Anesthesia was induced with 8% sevoflurane with 8L/min oxygen. Anesthesia was maintained with 1-3% sevoflurane in oxygen/air mixture.
62456330|NCT03238677|ACTIVE_COMPARATOR|No Biofeedback, Distributed|Speech Motor Chaining with no biofeedback. 2 sessions/wk for 10 weeks
62075811|NCT03115008|EXPERIMENTAL|Video-based terminal feedback|
62075812|NCT03115008|NO_INTERVENTION|Conventional concurrent feedback|
62456331|NCT03238677|EXPERIMENTAL|Biofeedback, Distributed|Sequenced biofeedback, 2 sessions/wk for 10 weeks
62456332|NCT03238677|EXPERIMENTAL|No Biofeedback, Massed-> Distributed|Speech Motor Chaining with no biofeedback. Mass Practice--\> Distributed Scheduling
62456333|NCT06096103|PLACEBO_COMPARATOR|Placebo|Take the test treatment once a day with food
62279456|NCT02711280|EXPERIMENTAL|Propofol General anesthesia|Anesthesia was induced with propofol 4mg/kg. Anesthesia was maintained with propofol 7-12mg/kg/h.
62645509|NCT02548936|EXPERIMENTAL|Lipid-lowering treatment|The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
62075813|NCT03198793|EXPERIMENTAL|QGC001|Capsules of QGC001 250 mg
62075814|NCT02085837|EXPERIMENTAL|Healthy Transitions Group|"* Additional nursing services will be provided to this group in addition to a usual care by Nephrologist.~* Daily weight measurement and monitoring~* Medication review~* Universal dietary education~* Focused advanced directive program~* Countdown to fistula program"
62075815|NCT02085837|NO_INTERVENTION|Usual Care Group|Usual care by nephrologist. No additional nursing support services will be provide to this group.
62075816|NCT02479035|ACTIVE_COMPARATOR|Red raspberry meal 1|\~125 g fresh weight (1 cup equivalent)
62075817|NCT02479035|ACTIVE_COMPARATOR|Red raspberry meal 2|\~250 g fresh weight (2 cup equivalent)
62075818|NCT02479035|PLACEBO_COMPARATOR|Control meal|0 g red raspberry
62075819|NCT01874093|EXPERIMENTAL|Active Stimulation|INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
62075820|NCT01874093|SHAM_COMPARATOR|Sham Stimulation|Sham implantation, 5 Days of Sham Stimulation + Standard of Care
62075821|NCT04263792|OTHER|Biodistribution cohort|The Biodistribution cohort will include up to 5 patients who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution \[18F\]fluoropropyl-trimethoprim PET/CT scans over a period of approximately 4 hours.
62075822|NCT04263792|OTHER|The Dynamic cohort|The Dynamic cohort will include up to 15 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans post injection of \[18F\]fluoropropyl-trimethoprim.
62279457|NCT06542315|NO_INTERVENTION|No IOPTH monitoring arm|Surgery for patients randomized to this arm will not require guidance with any IOPTH monitoring. These will be allowed to use frozen section analysis, if deemed appropriate by the surgeon.
62279458|NCT06542315|EXPERIMENTAL|10 minute arm|Surgery for patients randomized to this arm will need to use IOPTH monitoring. Surgeons in this arm will decide to end surgery or perform surgical re-exploration if the IOPTH level at 10 minutes following ligation of all hyperfunctioning parathyroid tissue is \>=50% from the highest pre-incision or pre-excision baseline IOPTH level.
62456334|NCT06096103|EXPERIMENTAL|Botanical Extract Standardised for Iron + Vitamin C|The botanical extract standardised for iron and vitamin c is specially formulated for iron deficiency anaemia or anaemia. Vitamin C can promote the Iron absorption
62456335|NCT06096103|EXPERIMENTAL|Botanical Extract Standardised for Iron|The botanical extract standardised for iron is formulated for iron deficiency anaemia or anaemia
62456336|NCT06196060|EXPERIMENTAL|Visual perspective taking training|Participants will receive visual perspective taking training in this arm.
62075823|NCT01248520|PLACEBO_COMPARATOR|General health information|Pregnant women receiving text messages containing general health messages without including information regarding the importance of the influenza vaccination
62075824|NCT01248520|ACTIVE_COMPARATOR|Influenza and general health information|Pregnant women receiving text messages with influenza facts and the importance of the influenza vaccination, as well as general health messages Intervention: Text messages with influenza facts
62075825|NCT01917305|EXPERIMENTAL|platform-switched implant|platform-switched implant
62279459|NCT06542315|EXPERIMENTAL|15 minute arm|Surgery for patients randomized to this arm will need to use IOPTH monitoring. Surgeons in this arm will decide to end surgery or perform surgical re-exploration if the IOPTH level at 15 minutes following ligation of all hyperfunctioning parathyroid tissue is \>=50% from the highest pre-incision or pre-excision baseline IOPTH level.
62279460|NCT06542315|EXPERIMENTAL|20 minute arm|Surgery for patients randomized to this arm will need to use IOPTH monitoring. Surgeons in this arm will decide to end surgery or perform surgical re-exploration if the IOPTH level at 20 minutes following ligation of all hyperfunctioning parathyroid tissue is \>=50% from the highest pre-incision or pre-excision baseline IOPTH level.
62279461|NCT06542315|EXPERIMENTAL|25 minute arm|Surgery for patients randomized to this arm will need to use IOPTH monitoring. Surgeons in this arm will decide to end surgery or perform surgical re-exploration if the IOPTH level at 25 minutes following ligation of all hyperfunctioning parathyroid tissue is \>=50% from the highest pre-incision or pre-excision baseline IOPTH level.
62279462|NCT03669809||male, non-obese|male with BMI\<28
62456337|NCT06196060|EXPERIMENTAL|Block building training|Participants will receive block building training in this arm.
62456338|NCT06196060|ACTIVE_COMPARATOR|Thought-bubble training|Participants will receive thought-bubble training in this arm.
62075826|NCT01917305|ACTIVE_COMPARATOR|platform-matched implant|platform-matched implant
62075827|NCT05473091||Experimental group|
62075828|NCT05473091||Control group|
62075829|NCT02144519|EXPERIMENTAL|Immediate Intervention|Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
62645510|NCT02548936|NO_INTERVENTION|No lipid-lowering treatment|Without any Lipid-lowering treatment for 12 month.
62645511|NCT01506180||Patients admitted to Geriatric Department|The patients receive comprehensive geriatric assessment
62645512|NCT01506180||Patients admitted to general medical departments|This group do not receive comprehensive geriatric assessment
62645513|NCT04315441||Soldiers|any soldier who attended the Military Medical Center of Sector N°5 for the annual re-engagement medical visit during the period from January 1, 2017 to November 13, 2018.
62075830|NCT02144519|EXPERIMENTAL|Delayed Intervention|Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.
62645514|NCT04315441||Civilians|The civilian populations were recruited from two free cardiovascular risk factors screening campaigns carried out from January 04, 2017 to January 10, 2017 and from November 12, 2018 to November 18, 2018
62645515|NCT02737722|EXPERIMENTAL|Bisphosphocin Nu-3|Dosage Form: Topical Antimicrobial, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
62645516|NCT02737722|PLACEBO_COMPARATOR|Placebo|Dosage Form: Diluent, Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
62645517|NCT00594776||1|Patients who have received a structrual allograft or vascularized fibular autograft surgery to reconstruct their tibia, femur, ulna/radius or humerus for treatment of a bone tumor.
62645518|NCT02679664|EXPERIMENTAL|Treatment group|20 mg tablet of rosuvastatin PO once-a-day starting at the time of randomization until the completion of follow-up at 6 months.
62645519|NCT02679664|NO_INTERVENTION|Control group|Standard medical care only. No rosuvastatin group.
62075831|NCT01829893|ACTIVE_COMPARATOR|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
62075832|NCT01829893|EXPERIMENTAL|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
62075833|NCT05433896|EXPERIMENTAL|Dasatinib ASD alone|At the clinic, participants were administered a single oral dose of 90 mg Dasatinib (Amorphous Solid Dispersion Film-Coated Tablet) on Day 1 after an overnight fast of at least 9 hours. Dasatinib was given with approximately 240 mL of room temperature water. Fasting continued for at least 4 hours following drug administration, after which a standardized lunch was served.
62075834|NCT05433896|OTHER|Dasatinib ASD + Omeprazole|"At the clinic, on Day 2 to Day 6, participants were administered a single oral dose of Omeprazole 40 mg × 1 Delayed Release Capsule once before meals in the evening with approximately 150 mL of room temperature water. No food was allowed two hours before and one hour after administration of Omeprazole.~In addition, participants were administered a single oral dose of 90 mg Dasatinib (Amorphous Solid Dispersion Film-Coated Tablet) on Day 6 after an overnight fast of at least 9 hours. Dasatinib was given with approximately 240 mL of room temperature water. Fasting continued for at least 4 hours following drug administration, after which a standardized lunch was served."
62075835|NCT01501916|EXPERIMENTAL|vitamin d|
62279463|NCT03669809||male, obese|male with BMI≥28
62279464|NCT03669809||female, non-obese|female with BMI\<28
62279465|NCT03669809||female, obese|female with BMI≥28
62645520|NCT05025930|EXPERIMENTAL|endoscopic surgical instrument control system (SP1000: single- port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (SP1000)
62645521|NCT05025930|ACTIVE_COMPARATOR|Comparator: endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (IS3000)
62645522|NCT03880474|EXPERIMENTAL|MVA-NP+M1|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\^8 pfu.)
62645523|NCT03880474|PLACEBO_COMPARATOR|Saline Placebo|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)
62645524|NCT01192321|EXPERIMENTAL|Toric T3 - T9|Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
62645525|NCT01192321|ACTIVE_COMPARATOR|Monofocal|Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.
62645526|NCT01854814|EXPERIMENTAL|mycophenolate mofetil|mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
62645527|NCT01854814|ACTIVE_COMPARATOR|losartan|maximus tolerated labeled dose of losartan
62645528|NCT02585869|EXPERIMENTAL|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
62456339|NCT06196060|PLACEBO_COMPARATOR|Treatment as usual|Participants will continue to receive routine therapy in this arm.
62456340|NCT00861809|EXPERIMENTAL|Cohort 1 Period 1|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
62645529|NCT02585869|EXPERIMENTAL|Gemcabene 300 mg|Gemcabene 300 mg once daily (QD)
62075836|NCT01501916|PLACEBO_COMPARATOR|Placebo|
62075837|NCT03625505|EXPERIMENTAL|Dose Escalation Venetoclax + Gilteritinib|Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
62456341|NCT00861809|EXPERIMENTAL|Cohort 1 Period 2|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
62456342|NCT00861809|EXPERIMENTAL|Cohort 1 Period 3|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
62456343|NCT00925769|EXPERIMENTAL|1|
62456344|NCT03858712|OTHER|Passive Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.~* Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice~* ePRO Home: -- ePRO oral between visits at home.~* Passive care team alert -- EHR inBasket notification"
62456345|NCT03858712|OTHER|Active Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.~* Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice~* ePRO Home: -- ePRO oral between visits at home.~* Active care team alert -- practice nurse monitoring of ePRO home responses score = 3 indicating a moderate-severe toxicity (grade 3 or higher"
62456346|NCT00649870|EXPERIMENTAL|1|Valacyclovir Hydrochloride Tablets 1000 mg
62456347|NCT00649870|ACTIVE_COMPARATOR|2|Valtrex® Tablets 1000 mg
62075838|NCT03625505|EXPERIMENTAL|Dose Expansion Venetoclax + Gilteritinib|Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.
62075839|NCT04448236|EXPERIMENTAL|BFR-RE intervention group|"The participants will have the standardised 2 week resistance training with BFR-device with details as follows:~* Cuff size: medium~* Restriction time: 5- 10 mins (stop after finishing 4 sets of training or terminating by Physiotherapists)~* Applied location: alternate quadriceps in consecutive day~* Applied pressure: 80% limb occlusion pressure (LOP)"
62075840|NCT04448236|NO_INTERVENTION|Control group|"Same standardized 2-week in-patient rehabilitation and same amount of the above-mentioned resistance training without the BFR device."
62456348|NCT06371248|EXPERIMENTAL|Intervention|Three-month, twice weekly, exercise intervention and usual care for fall prevention.
62456349|NCT06371248|ACTIVE_COMPARATOR|Control|Usual care for fall prevention.
62456350|NCT03089112|EXPERIMENTAL|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
62456351|NCT03089112|EXPERIMENTAL|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
62456352|NCT03089112|EXPERIMENTAL|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
62456353|NCT03089112|EXPERIMENTAL|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
62456354|NCT03089112|EXPERIMENTAL|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
62645530|NCT02585869|EXPERIMENTAL|Gemcabene 600 mg|Gemcabene 600 mg once daily (QD)
62645531|NCT02585869|EXPERIMENTAL|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
62645532|NCT02585869|PLACEBO_COMPARATOR|Placebo|Placebo once daily (QD)
62645533|NCT00547144|EXPERIMENTAL|Gemcitabine|
62645534|NCT04044105|NO_INTERVENTION|No Education|Patients in this arm receive no education regarding how to dispose of their opiate medication
62645535|NCT04044105|EXPERIMENTAL|Pamphlet education|Patients receive an educational pamphlet only, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment.
62645536|NCT04044105|EXPERIMENTAL|Pamphlet education + texts|Patients receive an educational pamphlet, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment. In addition, 3 automated text messages sent at those same time points.
62645537|NCT02271451|EXPERIMENTAL|Q collar|subjects wearing the q collar
62645538|NCT02271451|NO_INTERVENTION|Control|subjects not wearing the Q collar
62075841|NCT03621982|EXPERIMENTAL|ADCT-301 Monotherapy|"In Part 1 (dose escalation) participants received escalating doses of ADCT-301 as monotherapy.~Camidanlumab tesirine is administered as a 30-minute intravenous (IV) infusion on Day 1 of each cycle. Participants treated with camidanlumab tesirine as monotherapy, in the initial dose cohort will receive 20 μg/kg Q3W and the highest dose was 150 μg/kg Q3W."
62075842|NCT03621982|EXPERIMENTAL|ADCT-301 Combination Therapy|"In Part 1 (dose escalation) participants received escalating doses of ADCT-301 in combination with pembrolizamab as combination therapy.~In Part 2 (dose expansion), participants received ADCT-301 in combination with pembrolizamab as combination therapy at the dose identified in Part 1 (dose escalation).~Participants treated with camidanlumab tesirine in combination with pembrolizumab, in the initial dose cohort received 30 μg/kg Q3W of camidanlumab tesirine.~Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the camidanlumab tesirine infusion)."
62075843|NCT02096133|EXPERIMENTAL|Cholecalciferol|Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
62075844|NCT02096133|PLACEBO_COMPARATOR|Placebo comparator|placebo drops during 16 weeks
62075845|NCT00822315|ACTIVE_COMPARATOR|1|efavirenz
62075846|NCT00822315|EXPERIMENTAL|2|raltegravir 400 mg
62075847|NCT00822315|EXPERIMENTAL|3|raltegravir 800 mg
62279466|NCT03429946|ACTIVE_COMPARATOR|Hypoglycemia and Spironolactone|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of 100 mg of spironolactone - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
62456355|NCT03089112|EXPERIMENTAL|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
62456356|NCT04060368|EXPERIMENTAL|ESG Stitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
62456357|NCT04060368|ACTIVE_COMPARATOR|LSG + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
62456358|NCT01264224|EXPERIMENTAL|PAC-14028|
62456359|NCT01521195|EXPERIMENTAL|Patients on veno-arterial (VA) ECMO|
62456360|NCT03621748|ACTIVE_COMPARATOR|Non-Awake Cohort|Cohort undergoing craniotomy utilizing general anesthesia protocol
62456361|NCT03621748|EXPERIMENTAL|Awake Cohort|Cohort undergoing craniotomy utilizing awake anesthesia protocol
62456362|NCT04090892||Persons with spasticity 4.0-20.11 years|Study personnel are not carrying out the surgical intervention but are assessing the outcomes of the surgery on gait and motor function.
62456363|NCT00957047|EXPERIMENTAL|ESL 400 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I
62456364|NCT00957047|EXPERIMENTAL|ESL 800 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I
62456365|NCT00957047|EXPERIMENTAL|ESL 1200 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I
62456366|NCT00957047|PLACEBO_COMPARATOR|placebo|Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied
62456367|NCT00957047|EXPERIMENTAL|ESL - Part II|All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.
62456368|NCT06291948|ACTIVE_COMPARATOR|Humira® (adalimumab) AC Pen [Reference Product]|A single subcutaneous dose of 40 mg of the Reference Product- Humira® AC Pen \[Reference Product\]
62456369|NCT06291948|ACTIVE_COMPARATOR|Adalimumab Richmond [Test Product]|A single subcutaneous dose of 40 mg of the Test Product- Adalimumab Richmond \[Test Product\]
62645539|NCT01292408|EXPERIMENTAL|Daily HCQ|Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
62645540|NCT04341935|EXPERIMENTAL|DPP4 group|Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
62645541|NCT04341935|ACTIVE_COMPARATOR|Control group|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
62645542|NCT02963480||Sepsis|Patients, who developed postoperative sepsis
62645543|NCT02963480||SIRS|Patients, who developed postoperative SIRS
62645544|NCT03608826|EXPERIMENTAL|Single Arm Study|Invesigational RAMware will be downloaded onto the LINQ device.
62645545|NCT03290625|EXPERIMENTAL|DexKet|Intranasal DEXMEDETOMIDINE (2.0 mcg/kg, maximum 100 mcg) + KETAMINE (1.0 mg/kg, maximum 100 mg)
62075848|NCT00204308|EXPERIMENTAL|combination tenofovir-emtricitabine|
62075849|NCT00204308|NO_INTERVENTION|control arm|
62075850|NCT04998695|EXPERIMENTAL|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
62075851|NCT04998695|ACTIVE_COMPARATOR|Sunflower oil|Intake of 45 g/d of sunflower oil as the only source of oil in the diet
62075852|NCT05200637|ACTIVE_COMPARATOR|Orsiro|Two-stent DK-crush technique with Orsiro
62075853|NCT05200637|ACTIVE_COMPARATOR|Xience|Two-stent DK-crush technique with Xience
62075854|NCT05200637|OTHER|Single stent|Provisional one-stent strategy with any drug-eluting stent
62075855|NCT01990820|ACTIVE_COMPARATOR|Adenoidectomy without balloon dilation|Subjects will have Adenoidectomy + maxillary sinus irrigation, without balloon dilation.
62075856|NCT01990820|EXPERIMENTAL|Adenoidectomy with balloon dilation|Adenoidectomy + balloon dilation of maxillary sinus ostia using Acclarent Relieva Balloon Sinuplasty + irrigation
62075857|NCT02930642|EXPERIMENTAL|Mindful Eating|Participants in this arm will receive a 50 min mindful eating training with four pieces of food. They will practice mindful eating at home with two meals for a one-week duration.
62075858|NCT02930642|ACTIVE_COMPARATOR|Nutrition Digital Video Disc (DVD)|Participants will watch a 50 min DVD on nutrition and receive four pieces of food. They will receive prompts twice a week to give one-word answers to questions about food.
62075859|NCT02930642|NO_INTERVENTION|Control|Participants will receive four pieces of food. They will not receive any prompts during the one week.
62645546|NCT03290625|ACTIVE_COMPARATOR|Dex|DEXMEDETOMIDINE (2.5 mcg/kg, maximum 100 mcg)
62645547|NCT01622556|EXPERIMENTAL|Reduced Intensity Conditioning with UCB Transplant|
62075860|NCT02444234|EXPERIMENTAL|Tedizolid PO|Tedizolid phophate 200mg tablet
62075861|NCT02444234|EXPERIMENTAL|Tedizolid IV|Tedizolid phophate 200mg IV
62075862|NCT02818660|EXPERIMENTAL|Synacthen|The patient get Synacthen to stimulate the adrenals to produce cortisol
62075863|NCT06526702|EXPERIMENTAL|High-flux hemodialysis then post-dilution hemodiafiltration|Participants will first receive high-flux hemodialysis. Following a washout period of 1-3 weeks, they will receive post-dilution hemodiafiltration.
62075864|NCT06526702|EXPERIMENTAL|Post-dilution hemodiafiltration then high-flux hemodialysis|Participants will first receive post-dilution hemodiafiltration. Following a washout period of 1-3 weeks, they will receive high-flux hemodialysis.
62075865|NCT01598974|EXPERIMENTAL|Traditional Acupuncture|Participants will receive acupuncture over 6 30-minute sessions.
62075866|NCT01598974|EXPERIMENTAL|Laser Acupuncture|Participants will receive laser acupuncture over 6 30-minute sessions.
62075867|NCT01598974|NO_INTERVENTION|Wait-List|Subjects will be put on a 6 week wait-list and receive vouchers for acupuncture at a local clinic.
62075868|NCT04136535|EXPERIMENTAL|Pemetrexed and Carboplatin with Anlotinib|Pemetrexed and Carboplatin with Anlotinib
62075869|NCT04136535|ACTIVE_COMPARATOR|Pemetrexed and Carboplatin without Anlotinib|Pemetrexed and Carboplatin without Anlotinib
62075870|NCT03900143|EXPERIMENTAL|Treatment - Tightra|Treatment group with the Tightra device
62075871|NCT01898143|OTHER|Whole body vibration in COPD|Patients with COPD GOLD III or IV
62075872|NCT01898143|OTHER|Whole body vibration in ILD|PAtients with interstitial lung disease
62075873|NCT01054872|EXPERIMENTAL|Monozygotic (MZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
62456370|NCT05944354||Low Back Pain|Subjects with Low Back Pain
62645548|NCT02631395|OTHER|Training group|Six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition season; the training Group (intervention Group) and the Control Group.The intervention group completed strength training exercises Three times a week the Whole competition season.
62075874|NCT01054872|EXPERIMENTAL|Dizygotic (DZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
62075875|NCT00955734|EXPERIMENTAL|Early motion|This group of patients will begin wrist motion 1 week after surgery.
62279467|NCT03429946|ACTIVE_COMPARATOR|Hypoglycemia and Placebo|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
62279468|NCT03429946|PLACEBO_COMPARATOR|Euglycemia and Placebo|Participants undergo two 120-minute euglycemic hyperinsulinemic clamp procedures (90 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
62279469|NCT02301923||CPAP compliant (C)|Patients confirmed with obstructive sleep apnea and succeeded to pursue treatment with CPAP
62279470|NCT02301923||CPAP noncompliant (NC)|Patients confirmed with obstructive sleep apnea but did not succeed to pursue treatment with CPAP
62456371|NCT05944354||Neck Pain|Subjects with Neck Pain
62075876|NCT00955734|ACTIVE_COMPARATOR|Immobilization|This group will be casted for 6 weeks after surgery
62075877|NCT04027205|EXPERIMENTAL|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
62075878|NCT04027205|ACTIVE_COMPARATOR|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation.
62075879|NCT03781713|ACTIVE_COMPARATOR|STUDY GROUP|patients who triggered triggers and had interventions. Kdigo: interventions to prevent renal replacement therapy Delta SOFA: interventions to improve SOFA score Hypoglycemia: Interventions to prevent new episodes of hypoglycemia in the next 24 hours Drug interaction risk D or X - Intervention in the therapeutic plan in order to avoid adverse drug reactions. Antimicrobial stewardship: optimization of antimicrobial therapy based on Gram stain, MALDI TOF, MIC, antimicrobial susceptibility
62075880|NCT03781713|NO_INTERVENTION|CONTROL GROUP|patients who did not triggered triggers
62075881|NCT04704401||Patients PWV follow-up|"Patients included in the meta-analysis sleep apnea syndrome and arterial stiffness and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire."
62075882|NCT04939311|EXPERIMENTAL|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
62075883|NCT04939311|PLACEBO_COMPARATOR|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
62075884|NCT01674257||Carotid Endarterectomy|Patients due to undergo carotid endarterectomy for symptomatic carotid artery stenosis will undergo an 18F-Fluoride PET/CT, an 18F-Flurodeoxyglucose PET/CT and a USPIO (ferumoxytol)-enhanced MRI scan (2 MRI scans).
62075885|NCT05700006||Age 65+, AI therapy|Postmenopausal women age 65 and older who are starting treatment with standard of care aromatase inhibitor therapy
62075886|NCT05700006||Age 65+, no endocrine therapy|Postmenopausal women age 65 and older who are not starting treatment with any endocrine therapy
62075887|NCT05700006||Age under 65, AI therapy|Postmenopausal women age less than 65 who are starting treatment with standard of care aromatase inhibitor therapy
62075888|NCT03417882|EXPERIMENTAL|Cohort 1|All subjects will have newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
62075889|NCT03817346|ACTIVE_COMPARATOR|Experimental GT-002 SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
62075890|NCT03817346|PLACEBO_COMPARATOR|Experimental Placebo oral capsule SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
62279471|NCT04143269|ACTIVE_COMPARATOR|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the GammaCore device (ElectroCore LLC)
62279472|NCT04143269|SHAM_COMPARATOR|Sham Treatment|Inactive sham vagus nerve stimulation applied by the GammaCore sham device (ElectroCore LLC)
62075891|NCT00450515|EXPERIMENTAL|vinflunine + capecitabine|"Patients receive vinflunine IV over 20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed periodically for up to 5 years."
62075892|NCT06102031|EXPERIMENTAL|Randomized Arm-Treatment Group|"Management of subjects based on lung fluid content derived from the ReDS™ system.~All subjects will receive ReDS™ test during hospitalization, at discharge, several home visits and 3 times outpatient follow-up.~For home visits frequency, ReDS™ tests will be performed every 7 days within 1 month of discharge; at the 2nd to 3rd month, ReDS™ test wil be performed every 15 days. Then ReDS™ test will be performed every 30 days from 4th to 12th months.~Patients will be followed up in outpatient at 3 months, 6 months, and 12 months after discharge."
62279473|NCT02748460||Patients treated with Esmya|Any patient who was confirmed as receiving one dose of Esmya
62456372|NCT05944354||Control|Subjects with healthy spines, who have no neck or low back pain
62075893|NCT06102031|SHAM_COMPARATOR|Randomized Arm-Control Group|"Management of subjects based on standard of care(signs, symptoms, weight, biomarkers, etc.) without lung fluid content information.~All subjects will receive ReDS™ test during hospitalization, at discharge, several home visits and 3 times outpatient follow-up.~For home visits frequency, ReDS™ tests will be performed every 7 days within 1 month of discharge; at the 2nd to 3rd month, ReDS™ test wil be performed every 15 days. Then ReDS™ test will be performed every 30 days from 4th to 12th months.~Patients will be followed up in outpatient at 3 months, 6 months, and 12 months after discharge."
62075894|NCT05887284|EXPERIMENTAL|Low dose Radiation Therapy|In the test group, patients receive radiotherapy with six fractions of 0.5 Gy each over a period of 3 weeks, with 2 doses applied per week (total dose 3.0 Gy). After the 1st follow-up (3 months after radiotherapy), patients receive the patients in both arms have the option to receive a 2nd series of radiotherapy in consultation with the study physician if no improvement in symptoms has occurred or patients are still not sufficiently satisfied with the outcome (this decision is still made by the physician and patient in a blinded manner). The patients from the test group receive another irradiation series with six fractions of 0.5 Gy each according to the same schedule as before (total dose 3.0 Gy and in sum with the first series 6.0 Gy).
62075895|NCT05887284|PLACEBO_COMPARATOR|Mock Radiation Therapy|In the control group, patients receive sham irradiation with six fractions of 0.0 Gy each over a period of 3 weeks, with 2 treatments per week. After the 1st follow-up (3 months after radiotherapy), patients receive the patients in both arms have the option to receive a 2nd series of radiotherapy in consultation with the study physician if no improvement in symptoms has occurred or patients are still not sufficiently satisfied with the outcome (this decision is still made by the physician and patient in a blinded manner). The patients in the control group, on the other hand, now also receive a radiotherapy with six fractions of 1.0 Gy each over a period of 3 weeks with 2 fractions per week (total dose 6.0 Gy).
62075896|NCT03732586|EXPERIMENTAL|Omega 5 fatty acid supplement|20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid
62075897|NCT03732586|PLACEBO_COMPARATOR|PLACEBO|20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo
62075898|NCT01315275|EXPERIMENTAL|Ranibizumab|
62075899|NCT02353832|OTHER|No Arm|Study did not have Arm(s)
62075900|NCT01948362|ACTIVE_COMPARATOR|Sulforadex|Active compound
62075901|NCT01948362|EXPERIMENTAL|alpha Cyclodextrin|Placebo control arm
62075902|NCT00245336|EXPERIMENTAL|1|rThrombin
62075903|NCT00245336|ACTIVE_COMPARATOR|2|bThrombin
62075904|NCT06030453|EXPERIMENTAL|SMART HOME Care Gruop|"Experimental Group:SMART HOME refers to a set of interventions aimed at preventing delirium. Sleep hygiene.Multidisciplinary collaboration.Assessment of pain/anxiety/agitation.Release of tracheal tubes and restraints.Time and schedule.Home-like environment and Hearing.Orientation support.Medication review and adjustment.Early mobilization and nutrition."
62075905|NCT06030453|ACTIVE_COMPARATOR|Control Group|Control Group: The control group will receive traditional comprehensive care in the ICU based on the PADIS (pain, agitation, delirium, immobility, sleep disruption) assessment. This care will be administered by ICU nurses and will include pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions.
62075906|NCT02208882|EXPERIMENTAL|Panel 1: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
62456373|NCT05944354||Operational Air Crew|Subjects that are in training aircrew program
62279474|NCT01110395|EXPERIMENTAL|MR Spectroscopy Post-Heart Transplant|Patients post heart transplant getting heart biopsy
62075907|NCT02208882|EXPERIMENTAL|Panel 2: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
62075908|NCT02208882|EXPERIMENTAL|Panel 3: BMS-986120 or Placebo + Midazolam|BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified
62279475|NCT02595190|EXPERIMENTAL|surgery group|sacral canal cyst microscopic tamponade treatment; resting state functional magnetic resonance imaging (rfMRI)
62279476|NCT02595190|EXPERIMENTAL|drug group|gabapentin + tramadol tablets; resting state functional magnetic resonance imaging (rfMRI)
62279477|NCT02595190|PLACEBO_COMPARATOR|control group|resting state functional magnetic resonance imaging (rfMRI)
62279478|NCT02971878|NO_INTERVENTION|Control|Culture media without addition of antioxidants
62456374|NCT02827409|ACTIVE_COMPARATOR|Short Delay Cord Clamping|Subject will have umbilical cord clamped and cut by 1 minute of life.
62456375|NCT02827409|ACTIVE_COMPARATOR|Extended Delay Cord Clamping|Subject will have umbilical cord clamped and cut after at least 5 minutes of delayed cord clamping. Duration of cord clamping after 5 minutes will depend on if the subject is breathing and/or if the cord has stopped pulsating
62456376|NCT05396430|EXPERIMENTAL|Urinary catheter 8 hours|The urinary cathter is to be removed at 8 hours after the end of surgery
62456377|NCT05396430|EXPERIMENTAL|Urinary catheter 10 hours|The urinary cathter is to be removed at 10 hours after the end of surgery
62456378|NCT05396430|ACTIVE_COMPARATOR|Urinary catheter 12 hours|The urinary cathter is to be removed at 12 hours after the end of surgery
62075909|NCT02208882|EXPERIMENTAL|Panel 4: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
62279479|NCT02971878|ACTIVE_COMPARATOR|Treatment|Culture media with the addition of antioxidants
62279480|NCT02067754||metastatic Cancer|metastatic gastrointestinal cancer, genitourinary cancer , rare cancer with treated any anti-cancer therapy
62279481|NCT01769092|EXPERIMENTAL|Fish Oil|Each capsule contains 625 mg of fish oil (100 mg EPA \& 250 mg DHA). Participants will take 12 capsules per day over 6 months.
62279482|NCT01769092|PLACEBO_COMPARATOR|Safflower Oil|Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
62279483|NCT04429126|EXPERIMENTAL|4-point acupressure group|"The 5-point acupressure group will be instructed on the following acupressure points: sanyinjiao (SP6), Zu San Li (ST36), shenmen (TF4), Yongquan (KI-1), and He Gu (LI4).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
62279484|NCT04429126|ACTIVE_COMPARATOR|4 -point acupressure group|"The 2-point acupressure group will be instructed on the following acupressure points: He Gu (LI4) and Tai Chong (LV3).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
62279485|NCT04429126|NO_INTERVENTION|Usual care|The usual care group will be required to maintain their daily activities. Weekly telephone follow-up will be conducted by principle investigator.
62456379|NCT02003183||Suspected CTE|A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, \[F-18\]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).
62456380|NCT06278142|EXPERIMENTAL|Guided Web-Based Intervention|Participants in this group will use the web-based intervention with guidance support.
62456381|NCT06278142|EXPERIMENTAL|Without Guidance Web-Based Intervention|Participants in this group will use the web-based intervention without guidance support.
62279486|NCT03739073|EXPERIMENTAL|Patient with coronary arterial indication|A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).
62456382|NCT06278142|NO_INTERVENTION|Waitlist|Participants will have no contact with the study team during the waiting period.
62279487|NCT05408520|EXPERIMENTAL|Amputation with TMR|Amputation will follow standard procedure, but with the addition of the TMR procedure, which involves rerouting severed or injured nerves to new muscle targets using microsurgical techniques to provide the nerve endings with a new muscle to innervate.
62456383|NCT03955770|EXPERIMENTAL|HFOT first then LFOT|
62279488|NCT05408520|NO_INTERVENTION|Amputation without TMR (SOC)|A traditional amputation follows the normal standard of care, with transection of peripheral nerves.
62279489|NCT03657901|EXPERIMENTAL|Breathing|Guided slow breathing for 30 minutes before sleep onset
62279490|NCT03657901|ACTIVE_COMPARATOR|Music listening|Guided music listening for 30 minutes before sleep onset
62279491|NCT05271513|ACTIVE_COMPARATOR|real transcranial magnetic stimulation plus real transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds over the hand area plus 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-cervical vertebrae for consecuative 10 days (5 days/week)
62456384|NCT03955770|EXPERIMENTAL|LFOT first then HFOT|
62456385|NCT01825993|EXPERIMENTAL|PCA endovenous|1mg/10 min Morphine
62456386|NCT01825993|ACTIVE_COMPARATOR|PERIDURAL CATHETER|Peridural L-bupivacaine 0.25%
62456387|NCT01825993|ACTIVE_COMPARATOR|TANSABDOMINAL BLOCK (TAP)|L-BUPIVACAINE im
62075910|NCT02999620|ACTIVE_COMPARATOR|Alpha-cycoldextrin|All subjects randomized to receive Alpha-cycoldextrin will orally ingest two tablets containing Alpha-cyclodextrin, with their standardized liquid breakfast (100 micro Ci of \[3H\]triolein and 20 micro Ci of \[14C\]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
62279492|NCT05271513|ACTIVE_COMPARATOR|real transcranial magnetic stimulation with sham transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds plus sham stimulation 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-dorsal vertebrae for 10 consecutive days (5 sessions/week)
62279493|NCT05031741|EXPERIMENTAL|Telemedicine|Teens who are randomly assigned a telemedicine card will have exposure to a pretend telemedicine visit equipped with an iPad and telehealth provider on the other end. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care through telemedicine from their own home or private space.
62456388|NCT04303988|EXPERIMENTAL|Cohort HR-/HER2-|Hormone receptor negative, HER2 negative participants will receive SHR1316 in combination with bevacizumab plus cisplatin or carboplatin until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62075911|NCT02999620|PLACEBO_COMPARATOR|Placebo|All subjects randomized to receive placebo will orally ingest two placebo tablets with their standardized liquid breakfast (100 micro Ci of \[3H\]triolein and 20 micro Ci of \[14C\]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
62075912|NCT05287334|EXPERIMENTAL|Voluntary blood donors|Voluntary blood donors undergoing standard blood donation while measuring electrical impedance of the chest .
62645549|NCT02631395|OTHER|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
62279494|NCT05031741|EXPERIMENTAL|In-person Mobile Unit|Teens who are randomly assigned a in-person mobile unit card will have exposure to a pretend mobile unit visit equipped with a healthcare provider. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care on the mobile unit.
62075913|NCT01622348|PLACEBO_COMPARATOR|Placebo|Saline for Injection
62075914|NCT01622348|ACTIVE_COMPARATOR|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection
62075915|NCT01622348|ACTIVE_COMPARATOR|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection
62279495|NCT01412970|OTHER|study group|comparison of ability to predict volume responsiveness and precision of measurement of stroke volume variation assessed by electrical impedance tomography in comparison to clinically established invasive hemodynamic monitoring devices, i.e. arterial pulse contour analysis during volume loading procedures
62075916|NCT05445024|EXPERIMENTAL|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
62075917|NCT05445024|PLACEBO_COMPARATOR|sufentanil group|sufentanil (1/1000\* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
62075918|NCT00950937||HIV Group|HIV infected persons
62075919|NCT00950937||Control Group|Non HIV-infected persons
62075920|NCT02556515|ACTIVE_COMPARATOR|Trapeziektomi and ligament interposition|Interpositional arthroplasty Interpositional arthroplasty (Burton-Pellegrini procedure)
62279496|NCT01491256|ACTIVE_COMPARATOR|High dose Atorvastatin|Arm of pre-procedural high dose atorvastatin loading
62279497|NCT01491256|PLACEBO_COMPARATOR|Control|No pre-procedural high dose atorvastatin loading
62279498|NCT02995304|ACTIVE_COMPARATOR|Morphine and Midazolam premedication|30 children will receive 0.025 mg/kg midazolam IV followed by 0.1 mg/kg morphine 20 to 30 min before surgical incision.
62279499|NCT02995304|ACTIVE_COMPARATOR|Midazolam only premedication|30 children who will receive 0.025 mg/kg midazolam IV followed by saline 20 to 30 min before surgical incision.
62279500|NCT03664414|PLACEBO_COMPARATOR|Placebo group|Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
62279501|NCT03664414|ACTIVE_COMPARATOR|Pentoxifylline group|Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
62075921|NCT02556515|EXPERIMENTAL|Total joint replacement|Elektra CMC1 uncemented prosthesis Elektra prosthesis
62075922|NCT00762684|EXPERIMENTAL|TAK-559 32 mg QD|
62075923|NCT00762684|PLACEBO_COMPARATOR|Placebo QD|
62075924|NCT04162990|EXPERIMENTAL|Lifestyle remodeling|
62075925|NCT04162990|ACTIVE_COMPARATOR|Does Comparator: regular treatment|
62075926|NCT00387166||1|Mexican-American women, aged 40-65
62279502|NCT00880256|EXPERIMENTAL|MBSR|Patients who undergo mindfulness-based stress reduction will fill out measures of IBS severity before and after the mindfulness course.
62279503|NCT02935400||Asymptomatic|Group 1 will have had no symptoms of porphyria in the past year.
62075927|NCT02092038|EXPERIMENTAL|Preoperative chemoradiation|Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide
62075928|NCT05345457|EXPERIMENTAL|Antibiotics|Patients randomized into the treatment (i.e., antibiotics) arm of the study will be treated with a seven-day course of oral azithromycin and amoxicillin. Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days). Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
62075929|NCT05345457|NO_INTERVENTION|No antibiotics|Patients randomized into the control (i.e., no antibiotics arm) will be managed according to standard of care practices for previable PPROM desiring of expectant management.
62075930|NCT04436796|EXPERIMENTAL|Artificial Pancreas|Subjects will be provided the Interoperable Artificial Pancreas System (iAPS) which includes the iAPS phone platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This iAPS is designed to help control blood sugar in people living with type 1 diabetes.
62075931|NCT04436796|ACTIVE_COMPARATOR|Sensor Augmented Pump/Predictive Low Glucose Suspend|Subjects will continue use of home insulin pump with a study continuous glucose monitor (CGM) and study glucometer. Subject may use home pump in PLGS mode if this is supported and compatible with the study sensor.
62279504|NCT02935400||Symptomatic and treated with hemin|Group 2 will have a history of symptoms within the past year.
62456389|NCT02974075|EXPERIMENTAL|Salvage lymph node dissection|Patients will undergo extended pelvic salvage lymph node dissection
62075932|NCT03102658|EXPERIMENTAL|Obese subjects 100mg|8 subjects with a BMI\>40kg/m2 will receive 100mg Micafungin
62075933|NCT03102658|ACTIVE_COMPARATOR|Obese subjects 200mg|8 subjects with a BMI\>40kg/m2 will receive 200mg Micafungin
62075934|NCT03102658|ACTIVE_COMPARATOR|non-obese subjects|8 non obese subjects with a BMI \>18.5 and \<25 kg/m2 will receive 100mg Micafungin
62075935|NCT02636894|OTHER|Restylane Silk|Restylane Silk
62075936|NCT01493661||Group 1|Men with Total Sleep Time ≤ 6h that will undergo 25 percent of chronic sleep restriction of their TST
62456390|NCT02325271||Control group|Subjects with normal glucose tolerance
62075937|NCT01493661||Group 2|Men with Total Sleep Time (range 7-8h)that will undergo 25 percent of chronic sleep restriction of their TST
62075938|NCT01493661||Group 3|Men with Total Sleep Time ≥ 9h that will undergo 25 percent of chronic sleep restriction of their TST
62075939|NCT06116214|ACTIVE_COMPARATOR|Control group|in this group the teeth will be irrigated with 2.5% Sodium Hypochlorite (gold standard)
62456391|NCT02325271||Diabetes group|Patients with type 2 diabetes
62456392|NCT04457843||COPD patients|
62279505|NCT05164445|ACTIVE_COMPARATOR|Transbronchial forceps biopsy|Patients, whose transbronchial forceps biopsy was performed
62279506|NCT05164445|ACTIVE_COMPARATOR|Transbronchial forceps biopsy+Transbronchial cryobiopsy|Patients, whose transbronchial forceps biopsy and transbronchial cryobiopsy were performed as well
62456393|NCT01432795|EXPERIMENTAL|Test series of 6 types of gliding aids|"Each study subjects tests a series of gliding aids or stocking butlers:~* 4 gliding aids~* 2 stocking butlers, one with and without handle~* 3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~* 3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~* 2 superimposed stockings with closed tip, compression class 1 (18-21 mmHg)"
62456394|NCT00584311|EXPERIMENTAL|1|All patients (with no structural damage on the plain x-ray) will receive a MRI and Ultrasound (US) of their most involved joint and an asymptomatic joint.
62075940|NCT06116214|EXPERIMENTAL|Experimental group|in this group the teeth will be irrigated with 10% V. Nelotica (Herbal irrigant)
62279507|NCT00248703|EXPERIMENTAL|Docetaxel|Patients with presence of disseminated tumor cells in bone marrow after (no-taxane) epirubicin-containing adjuvant treatment receive 6 cycles of docetaxel (100 mg/m2) 3 qw.
62075941|NCT03757806|EXPERIMENTAL|Experimental group|The experimental group will receive the LiFE4D in addition to usual care (e.g., pharmacologic treatment).
62075942|NCT03757806|NO_INTERVENTION|Control group|The control group will receive usual care only.
62075943|NCT03022838|ACTIVE_COMPARATOR|Caffeine|Caffeine tablets (Recip) 100 mg, 300-800 mg
62075944|NCT03022838|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62075945|NCT02391935|EXPERIMENTAL|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
62456395|NCT00881621|EXPERIMENTAL|Lapatinib and Capecitabine|Treatment
62075946|NCT02391935|PLACEBO_COMPARATOR|Placebo|cryomedium
62075947|NCT00494936||HIV/HCV|HIV and HCV coinfected
62075948|NCT00494936||HIV infected|HIV monoinfected
62075949|NCT00494936||HIV/HCV nonviremnic|HIV and HCV coinfected with HCV RNA less than 600 copies
62075950|NCT00494936||HCV infected|HCV monoinfected with HCV viremia
62279508|NCT04765280||Patients with chronic musculoskeletal pain|Patients with any musculoskeletal pain for at least 3 months
62456396|NCT02063295|PLACEBO_COMPARATOR|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
62645550|NCT01369381|EXPERIMENTAL|Airtraq laryngoscope|The Airtraq is an alternative indirect laryngoscope that appears to cause less cervical spine motion during intubation that conventional direct laryngoscopy (Macintosh blade)
62456397|NCT02063295|EXPERIMENTAL|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
62645551|NCT01369381|ACTIVE_COMPARATOR|Macintosh laryngoscope|This arm constitutes intubation with a conventional direct laryngoscopy with a Macintosh blade which has been shown to result in cervical spine extension, particularly in the upper cervical segments.
62645552|NCT05633511|EXPERIMENTAL|All Participants|Participants will receive the CTG procedure on one side and the PRF procedure on the other. Both are standard of care soft tissue grafting methods and a split mouth design is standard of care.
62075951|NCT02213055|EXPERIMENTAL|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
62075952|NCT02213055|ACTIVE_COMPARATOR|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
62075953|NCT00266474||Cross sectional CF study|Multicentric study, including 187 CF patients of all age groupr in 5 CF centres.
62456398|NCT00596388||1|Subjects diagnosed as intermediate AMD
62456399|NCT03878095|EXPERIMENTAL|Treatment (olaparib, ceralasertib)|Patients receive olaparib PO BID on days 1-28 of each cycle and ceralasertib PO QD on days 1-7 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies during screening and on study, collection of blood samples throughout the trial, and undergo CT and/or MRI scans throughout the trial. Patients may also undergo bone marrow aspiration and biopsy as clinically indicated on study.
62456400|NCT00357448|EXPERIMENTAL|Arm I|Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62645553|NCT00945217||Postmenopausal women|women with natural menopause
62645554|NCT05430906|EXPERIMENTAL|AK104+chemotherapy|Participants received 3-4 neo-adjuvant cycles of AK104 10mg/kg Q3W then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] Q3W; followed by surgery
62075954|NCT05851924|EXPERIMENTAL|NALIRIFOX + AD-XRT and capecitabine|Patients will receive neoadjuvant chemotherapy for 4 months. Patients will undergo a CT scan at 8 weeks and 16 weeks after the start of neoadjuvant chemotherapy to assess treatment response. Patients without disease progression will then undergo AD-XRT for 15 to 25 fractions (3 to 5 weeks). Patient's whose disease is deemed resectable based on their re-evaluating imaging, will be recommended surgical intervention with consideration for laparotomy or laparoscopy if deemed appropriate at multidiscplinary cancer conference review.
62075955|NCT03514264|EXPERIMENTAL|GUTTA PERCHA and AHPLUS cement (group A)|43 patients will undergo endodontic treatment with obturation with AHPlus cement and Gutta-Percha cones. This treatment will be performed in 2 sessions. First intervention: endodontic instrumentation and introduction of intra-canal medication that will remain in the tooth for 4 weeks. Second intervention: removal of intracanal medication and filling with cement and gutta percha AHPlus.
62645555|NCT01190917|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy Group|
62075956|NCT03514264|EXPERIMENTAL|PBS CIMMO cement (group B)|43 patients will undergo endodontic treatment with PBS CIMMO® cement (single material).This treatment will be performed in 1 session.Single intervention: endodontic instrumentation and cement filling PBS CIMMO.
62075957|NCT06328166|EXPERIMENTAL|recombinant human fibroblast growth factor 1 (ES135)|Ultrasound-guided injection with recombinant human fibroblast growth factor 1 (ES135) between carpal tunnel and median nerve.
62075958|NCT06328166|PLACEBO_COMPARATOR|normal saline|Ultrasound-guided injection with normal saline between carpal tunnel and median nerve.
62075959|NCT02604836|EXPERIMENTAL|Ibandronate|Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
62279509|NCT05368610||Very high power-short duration ablation|PVI performed by point-by-point very high power-short duration radiofrequency ablation (QDOT-micro catheter, Biosense Webster; Qmode+; 90 W; 4 sec; target intertag distances: posterior wall 4 mm, proximity of the esophagus 5 mm, all other 3 mm)
62645556|NCT01190917|ACTIVE_COMPARATOR|Social Play Group|
62645557|NCT05837195||Control group|"Standard care:~Doppler velocimetry: UA \& MCA PI, DV PIV, CPR; Indirect cardiotocography (CTG) Biophysical profile (BPP)"
62645558|NCT05837195||DDA Doppler group|Standard care plus DDA Doppler monitoring
62645559|NCT05493826||Group 1|Patients treated with cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation
62645560|NCT02633722|EXPERIMENTAL|TRF-b|Participants are instructed to eat between 8am-5pm
62645561|NCT02633722|EXPERIMENTAL|TRF-d|Participants are instructed to eat only between 12-9pm
62645562|NCT02633722|NO_INTERVENTION|Baseline|No lifestyle instruction given
62645563|NCT02502370|ACTIVE_COMPARATOR|Group1 Arm A Observation|
62645564|NCT02502370|EXPERIMENTAL|Group 1 Arm B LV5FU2|
62645565|NCT02502370|ACTIVE_COMPARATOR|Group 2 Arm C LV5FU2|
62645566|NCT02502370|EXPERIMENTAL|Group 2 ARM D FOLFOX|
62645567|NCT00560963|EXPERIMENTAL|1 RAD001|
62075960|NCT01087723|EXPERIMENTAL|Bivalirudin|Given immediately upon enrollment as an intravenous (IV) bolus of 0.75 mg/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continuously until completion of PCI, at which time the infusion was reduced to 0.25 mg/kg/h for at least 4 hours. An optional PCI-dose infusion of 1.75 mg/kg/h was also permitted for up to 4 hours at the discretion of the operator.
62075961|NCT01087723|ACTIVE_COMPARATOR|Standard of Care: Heparins with Optional GPI|"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of STE-ACS, not including bivalirudin: UFH (100 international units/kg \[IU/kg\] without GPI and 60 IU/kg with GPI). Any of the following approved GPIs were used either as a routine strategy or as a bail out: eptifibatide (two 180-micrograms/kilogram \[μg/kg\] IV boluses with a 10-minute \[min\] interval followed by an infusion of 2.0 μg/kg/min for 72-96 hours); tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18-24 hours); or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours \[maximum dose of 10 μg/min\]).~For this study, the control consisted of treatment with UFH or low molecular weight heparin (LMWH) with or without GPI and is referred to as heparins with optional GPI."
62456401|NCT05090657|OTHER|Open label presurgical nasal decolonization|All patients presenting for surgery will be offered nasal decolonization with the combination product. After informed consent a nasal culture will be obtained followed by a 4-minute nasal decolonization treatment and a post-treatment culture. The intervention consists of swabbing the nose with a methylene blue/chlorhexidine gluconate solution followed by non-thermal nasal illumination with red light. There will only be a single treatment.
62456402|NCT04891081||Patients with cyanotic Congenital Heart Disease|
62456403|NCT04891081||Patients with acyanotic Congenital Heart Disease|
62456404|NCT04366232|EXPERIMENTAL|Anakinra +/- Ruxolitinib|"According to clinical stage (gradual strategy):~* Stage 2b or 3 : Anakinra 300 mg IV~* Overcome stage 3 : Anakinra 300 mg IV and Ruxolitinib 5 mg x 2"
62456405|NCT04366232|ACTIVE_COMPARATOR|Standard of care|Treatment with drugs or procedures in routine clinical practice
62645568|NCT02302274||flecainide infusion test|Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.
62456406|NCT03536338|ACTIVE_COMPARATOR|Control|Sit-to-stand training alone
62456407|NCT03536338|EXPERIMENTAL|Treatment|Sit-to-stand training combined with Spinal Stimulation
62456408|NCT02735746||High fidelity functional lung imaging|High fidelity functional lung imaging (HFFLI) is an improved method of measuring pulmonary function by analyzing 3-Dimensional (3D) motion. Using this technique, we are able to detect and localize pathological changes in the lung with sub-segmental resolution. The approach uses a unique cross-correlation analysis and non-linear optimization to reconstruct lung tissue motion from a small number of standard projections. All participants will undergo standard 4D Computed Tomography (CT), standard Cone Beam CT, research Low-dose Cinefluorography, and additional research Pulmonary Function Tests.
62645569|NCT01003106|EXPERIMENTAL|BRVO- Ranibizumab 0.5mg alone|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation.
62645570|NCT01003106|EXPERIMENTAL|BRVO- Pro re nata (prn) ranibizumab with laser|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
62645571|NCT01003106|EXPERIMENTAL|BRVO- Ranibizumab 2.0mg alone|Branch retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
62645572|NCT01003106|EXPERIMENTAL|BRVO- Pro re nata (prn) ranibizumab|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
62075962|NCT04206137|EXPERIMENTAL|Group A (PNF rhythmic initiation group )|PNF rhythmic initiation with bilateral asymmetrical upper and lower limb pattern will administered on both sides, there will be 10 repetition and 3 sets for each side, 20 second rest between two sets.
62075963|NCT04206137|ACTIVE_COMPARATOR|Group B (Swiss ball exercise group)|Swiss ball exercises will be administered. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
62075964|NCT02351596|ACTIVE_COMPARATOR|Intervention Group 7-12 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
62075965|NCT02351596|ACTIVE_COMPARATOR|Control Group 7-12 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
62075966|NCT02351596|ACTIVE_COMPARATOR|Clontarf Intervention Group 13-17 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
62279510|NCT05368610||Matched control group conventional ablation|PVI performed by conventional point-by-point radiofrequency ablation (40 W; ablation index-guided: posterior wall 350, other 450; target intertag distance 3.0 - 5.0 mm)
62279511|NCT01657578|EXPERIMENTAL|neonates of less than 32 weeks gestational age|omeprazole
62075967|NCT02351596|ACTIVE_COMPARATOR|Clontarf Control Group 13-17 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
62075968|NCT05103813|EXPERIMENTAL|Beraprost Sodium Tablets|
62279512|NCT01657578|EXPERIMENTAL|neonates born between 32 and 35 weeks of GA|omeprazole
62279513|NCT01657578|EXPERIMENTAL|neonates of more than 36 weeks of GA|omeprazole
62645573|NCT01003106|EXPERIMENTAL|CRVO- Ranibizumab 0.5mg alone|Central retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation
62645574|NCT01003106|EXPERIMENTAL|CRVO- Pro re nata (prn) ranibizumab with laser|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
62645575|NCT01003106|EXPERIMENTAL|CRVO- Ranibizumab 2.0mg alone|Central retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
62645576|NCT01003106|EXPERIMENTAL|CRVO- Pro re nata (prn) ranibizumab|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
62645577|NCT03163446|EXPERIMENTAL|CF-301|Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
62075969|NCT04039074|EXPERIMENTAL|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
62075970|NCT04039074|ACTIVE_COMPARATOR|Iyengar yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
62075971|NCT04039074|ACTIVE_COMPARATOR|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
62075972|NCT01801553|ACTIVE_COMPARATOR|spinal manipulation intervention group|Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
62075973|NCT01801553|SHAM_COMPARATOR|Spinal manipulation control group|Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation
62075974|NCT04681677|EXPERIMENTAL|Experimental: Intra-operative Radiation Therapy - IORT|Radiation: Intra-operative Radiation Therapy - IORT
62075975|NCT00179348|EXPERIMENTAL|Group I (yoga-based rehabilitation program)|Participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks.
62075976|NCT00179348|ACTIVE_COMPARATOR|Group II (standard care/control)|After a 3 month wait period, participants undergo a yoga-based rehabilitation program as in Group I.
62075977|NCT05502224|OTHER|Specific fatigue management program|
62075978|NCT00991614||EVOLUTION® Duodenal Stent|
62075979|NCT00415974|OTHER|Enhanced Usual Care|"Enhanced Usual Care Arm: This group will receive 2 face-to-face sessions with a health educator for dietary and health counseling in addition to an initial physician-patient visit. Educational materials that a patient might receive at his/her physician's office will also be provided at the initial health educator visit and monthly thereafter. This condition is called Enhanced Standard Care because it is, in fact, more than most obese adolescents currently receive in primary care offices in San Diego."
62645578|NCT03163446|PLACEBO_COMPARATOR|Placebo|Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
62456409|NCT00302952|EXPERIMENTAL|Lovastatin|Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D\&C Yellow #10, FD\&C Blue #1, and Yellow #6 were added as dyes.
62645579|NCT06213987|EXPERIMENTAL|Tretinoin|Apply 1 gram of tretinoin cream to the axillary region before bedtime once every other day during the first two weeks, and then once daily after that, total duration of 8 weeks.
62645580|NCT06213987|PLACEBO_COMPARATOR|Cream based|Apply 1 gram of cream based to the axillary region on the opposing side before bedtime once every other day during the first two weeks, and then once daily after that, total duration of 8 weeks.
62645581|NCT00805259|ACTIVE_COMPARATOR|1. Atomistic|payment for own work
62645582|NCT00805259|ACTIVE_COMPARATOR|2. Altruistic|payment for partner's work
62645583|NCT00805259|ACTIVE_COMPARATOR|3. Team-based|payment for relative performance of combined effort of each team
62645584|NCT00805259|NO_INTERVENTION|4. Control|access to software but no financial incentives
62279514|NCT02544412|EXPERIMENTAL|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, \& Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
62645585|NCT03908411|ACTIVE_COMPARATOR|Paratracheal pressure|Left Paratracheal pressure is applied by ultrasound transducer after confirmation of the location of the esophagus.
62645586|NCT03908411|ACTIVE_COMPARATOR|Sellick's maneuver|Conventional Sellick's maneuver is applied.
62645587|NCT01701245|NO_INTERVENTION|Standard of care|No intervention, standard of care
62645588|NCT01701245|ACTIVE_COMPARATOR|GammaCore|Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
62645589|NCT04137198|NO_INTERVENTION|control|classic analgetic protocol
62645590|NCT04137198|EXPERIMENTAL|intervention|intranasal Sufentanil
62645591|NCT00914368|ACTIVE_COMPARATOR|1|Patients with previously experienced stent thrombosis while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
62645592|NCT00914368|ACTIVE_COMPARATOR|2|Patients with previously experienced myocardial infarction while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
62456410|NCT00302952|PLACEBO_COMPARATOR|Placebo|Participants are randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188.
62456411|NCT00820625|ACTIVE_COMPARATOR|1|ablation: pulmonary vein isolation
62075980|NCT00415974|EXPERIMENTAL|Stepped Care|"PACE-PC is a 1-year stepped-care intervention (subdivided into three 4-month blocks) utilizing multiple modalities including clinician and tailored health educator counseling, phone counseling, mailed content for overweight adolescents and their family to promote improved diet and physical activity behaviors aimed at weight loss and weight loss maintenance.~PACE-PC is designed to be based in the primary care setting and promotes involvement, management, and decision-making by the primary care provider about the level of PACE-PC step for each enrolled patient~Participants randomized to the PACE-PC condition will be enrolled in Step 1 (the most intensive) for the first 4 months. Depending upon response at the end of Step 1, for the next 4 months adolescents will be triaged to Step 2 (less intensive) or will repeat Step 1. At 8 months, again based upon treatment response, triage will occur to either Step 3 (least intensive) or repetition of the previous step."
62075981|NCT02006420||ARFI-SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
62456412|NCT00820625|ACTIVE_COMPARATOR|2|ablation: pulmonary vein isolation with additional ablation of fragmented potentials
62075982|NCT02006420||Healthy Volunteers: ARFI/SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
62075983|NCT03399149||"Before phase"|Retrospective study of ICU admissions of hematology patients for respiratory and hemodynamic reasons Time period: January 2012 to March 2017
62456413|NCT01936948|ACTIVE_COMPARATOR|Clip closure + EndoCut|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the EndoCut electrocautery mode.
62456414|NCT01936948|ACTIVE_COMPARATOR|Clip closure + Coagulation|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the Coagulation electrocautery mode.
62075984|NCT03399149||"After Phase: Systematic evaluation by an intensivist"|"Corresponding to the period after the implementation of a systematic intensivist evaluation Daily screening of systolic blood pressure, oxygen saturation and oxygen requirements of all patients hospitalized in hematology wards. Systematic evaluation of any patient presenting the inclusion criteria by an intensivist and collegial care planning.~Time period: From March 2017 to end of study"
62279515|NCT02544412|NO_INTERVENTION|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
62456415|NCT01936948|NO_INTERVENTION|No clip closure + EndoCut|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the EndoCut electrocautery mode.
62456416|NCT01936948|NO_INTERVENTION|No clip closure + Coagulation|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the Coagulation electrocautery mode.
62456417|NCT03735602|EXPERIMENTAL|perceptual training|Orientation discrimination task, which is a cognitive task. Patients were trained for 1 hour per day, 15 days in total.
62456418|NCT04298164|EXPERIMENTAL|Intervention group|Group that receives the intervention
62456419|NCT04298164|ACTIVE_COMPARATOR|Control group|Group that receives treatment as usual
62645593|NCT00914368|ACTIVE_COMPARATOR|3|Patients without previously experienced myocardial infarction or stent thrombosis 6 within months after coronary stenting for coronary artery disease(matched controls for group 1 and 2)
62456420|NCT05941221|EXPERIMENTAL|study group|patients will receive pericapsular nerve group (PENG )block through ultrasound at the end of the surgery.
62456421|NCT03432013|ACTIVE_COMPARATOR|SUD-CBT|Standard cognitive behavioral therapy for substance use disorder
62456422|NCT03432013|EXPERIMENTAL|CUD-AMT|Experimental affective management training for cannabis use disorder specifically
62645594|NCT01548404|PLACEBO_COMPARATOR|Placebo|Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
62645595|NCT01548404|EXPERIMENTAL|Dupilumab 300 mg|Dupilumab 300 mg once weekly for 12 weeks by SC injection.
62645596|NCT03030521||experimental group|In this group, the specimen of aortic wall is bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
62645597|NCT03030521||control group|In this group, the specimen of aortic wall is not bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
62645598|NCT03879031||Outpatients with low back pain|"All outpatients with non-specific subacute or chronic low back pain will be submitted to a physical therapy program including:~* information on pain mechanisms and the favorable nature of non-specific low back pain;~* advice on positions, movements and activities recommended or advised against in people with low back pain, both at work and during leisure time;~* active postural correction exercises, overactive muscles lengthening and weak musculature strengthening;~* passive manual techniques, aimed at muscle relaxation and recovery of lumbar joint mobility.~A cluster of Clinical tests to measure lumbar stability will be administrated before the starting of the first session and at the ending of the last session of the physical therapy program."
62279516|NCT02294513||AD_HI|This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
62456423|NCT04844840|EXPERIMENTAL|Cohort 1: STP705 10 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
62456424|NCT04844840|EXPERIMENTAL|Cohort 2: STP705 20 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
62456425|NCT04844840|EXPERIMENTAL|Cohort 3: STP705 30 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
62645599|NCT00044291|EXPERIMENTAL|Atamestane + toremifene|
62456426|NCT04844840|EXPERIMENTAL|Cohort 4: STP705 40 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
62456427|NCT04844840|PLACEBO_COMPARATOR|Cohort 5: Placebo control|Placebo (saline) will be injected intradermal into the excised keloid site
62456428|NCT04844840|NO_INTERVENTION|Cohort 6: SOC alone|SOC (no injection)
62645600|NCT00044291|ACTIVE_COMPARATOR|Letrozole + placebo|
62279517|NCT02294513||NC_HI|This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
62279518|NCT02582957|EXPERIMENTAL|Sigh breaths|Sigh breaths consisting of a Tidal volume (VT) that produces a plateau pressure (Pplat) of 35 cmH2O (or 40 cmH2O in patients with BMIs \> 35 or in patients with moderate or severe abdominal distension from ascites, blood and/or ileum, or prone patients). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
62279519|NCT02582957|NO_INTERVENTION|Usual Care|Usual care, meaning that the treating physician will be free to treat the patient in any way he or she sees fit, including utilizing invasive mechanical ventilation as they wish.
62279520|NCT02801214||Recreational Cannabis Use|ages 18-40
62279521|NCT02801214||Healthy control subjects|socio-demographically matched
62279522|NCT04189679||First line|20 patients in first line of treatment
62456429|NCT05425147||Post-induction hypotension group|Post-induction hypotension is defined as systolic blood pressure (SBP) \<90 mmHg, mean arterial pressure (MAP) \<65 mmHg, or a decrease of more than 30% of baseline within 20 minutes after induction or before incision.
62456430|NCT05425147||Stable blood pressure group|All enrolled elderly patients will undergo surgery under general anesthesia after preoperative monitoring. Those patients whose blood pressure is relatively stable after induction and does not meet the PIH criteria is classified as the stable blood pressure group.
62645601|NCT02934971||Supervised cohort of 200 chemo-treated patients|cohort of 200 patients undergoing a chemo therapy accordingly to the inclusion criteria patients
62645602|NCT02934971||Age matched control group of 200 normal subjects|200 age matched control group of subjects from the outpatient clinic who are not chemo-treated and who fit the inclusion and exclusion criteria
62075985|NCT02726399|EXPERIMENTAL|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
62279523|NCT04189679||Second or third line|40 patients in second and third line of treatment
62279524|NCT01078766|EXPERIMENTAL|CIMT+HABIT|"Form of summer camp, for six hours per day for 10 consecutive work days."
62279525|NCT06300853|OTHER|Cancer patients|Adult patients with a solid tumor diagnosis \[I, II, III, IV stage,\] and active anti-cancer treatment or treatment discontinued for less than 6 months, followed at IRCCS Sacro Cuore - Don Calabria, Negrar (Verona), Italy will be prospectively recruited at the moment of the future booster doses administration of SARS-CoV-2 vaccine.
62279526|NCT06300853|OTHER|Elderly subjects|Subjects over 70 years of age who live in the nursing home in the social area at the IRCCS Sacro Cuore - Don Calabria Hospital will be prospectively recruited at the moment of the future booster doses administration of SARS-CoV-2 vaccine.
62279527|NCT00262431|ACTIVE_COMPARATOR|Early (A)|Patients of the EARLY group (A) will be submitted to tracheostomy on day 3-5 from oro/nasotracheal intubation.
62075986|NCT06294691|ACTIVE_COMPARATOR|the early infused group|infused stem cell within 11:30 am and 12:30 am
62075987|NCT06294691|SHAM_COMPARATOR|the late infused group|infused stem cell within 5:30 pm and 6:30 pm
62075988|NCT03901599||Children between 5-10Kg|Children with a body weight between 5-10Kg
62279528|NCT00262431|ACTIVE_COMPARATOR|Late (B)|Patients of the LATE group (B) will undergo tracheostomy on day 10-12 from oro/nasotracheal intubation.
62075989|NCT03901599||Children between 10-20Kg|Children with a body weight between 10-20Kg
62075990|NCT03901599||Children between 20-40Kg|Children with a body weight between 20-40Kg
62075991|NCT02947464|ACTIVE_COMPARATOR|Control|Standard clinical practice
62075992|NCT02947464|EXPERIMENTAL|Intervention|Standard clinical practice + Rapid Maxillary Expansion
62075993|NCT03904342|ACTIVE_COMPARATOR|Sophie CBT|The Sophie Cognitive Behavioral Therapy (CBT) intervention is a tablet-based computerized CBT and self-management education intervention that consists of an evidence-based cognitive behavioral therapy self-management curriculum divided into 6 discrete modules. Patients will have up to 8 weeks to work through the modules on the tablet.
62075994|NCT03904342|ACTIVE_COMPARATOR|iHope CBT|iHope CBT is a telemedically-delivered CBT package. The iHope system comprises a HIPAA-compliant platform on which real, live, licensed clinicians provide cognitive behavioral therapy via video conferencing, phone calls, and text messaging. iHope will be delivered on subjects' preferred electronic device (mobile phone, laptop, tablet).
62075995|NCT06449014|EXPERIMENTAL|CRAP|Continuous Rapid Activation Protocol: 1 activation of the expansion screw per day which is equal to 0,17 mm expansion of the maxilla per day till reaching the clinical goal
62075996|NCT06449014|EXPERIMENTAL|SCAP|Continuous Slow Activation Protocol: 2 activations of the expansion screw which is equal to 0,33 mm expansion of the maxilla per day during the first 7 days. After that first week, then each third day 1 activation (0,17 mm / 3 days).
62456431|NCT02968485|EXPERIMENTAL|SHR7390|60 subjects with advanced solid tumors were received single and then multiple oral doses of SHR7390(2 cycles,each cycle 28days).
62075997|NCT06449014|EXPERIMENTAL|FCPC|force-controlled polycyclic protocol: 2 activations of the expansion screw which is equal to 0,33 mm expansion of the maxilla per day during the first 7 days. Then the expansion screw will be turned 6 sides backward, and after 15 min, the expansion screw will be turned forward 6 sides again. And every third day, the device will be additionally activated by 0.17mm (0,17 mm / 3 days)
62075998|NCT03289481|ACTIVE_COMPARATOR|Active lozenge first|Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
62075999|NCT03289481|ACTIVE_COMPARATOR|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.
62076000|NCT01196221||Patients with 30 to 70% carotid artery stenosis|
62076001|NCT01992549|EXPERIMENTAL|Human-cl rhFVIII|
62076002|NCT05292196|EXPERIMENTAL|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation, four weeks as a treatment cycle.
62076003|NCT05292196|PLACEBO_COMPARATOR|TQC3721 suspension placebo for inhalation|TQC3721 suspension placebo for inhalation, four weeks as a treatment cycle.
62279529|NCT06548204|EXPERIMENTAL|Fexofenadine hydrochloride 60mg bid|Fexofenadine hydrochloride 60mg bid was added to the standard treatment 3 days after the completion of primary PCI and CMR examination for 6 months.
62076004|NCT02037867||Patients|"Patients identified with one of the below chronic liver disease risk factors and undergoing community liver disease stratification using fibrosis biomarkers:~* Hazardous alcohol use (\>14 units per week in females, \>21 units per week in males, alcohol AUDIT score \>=8 or read code relevant to alcohol abuse on GP system)~* Type 2 Diabetes~* Obesity~* Persistently raised serum ALT level, negative liver serology, and absence of above 2 risk factors"
62076005|NCT01638468|EXPERIMENTAL|AngioJet Ultra PE Thrombectomy System|Patients are treated with the AngioJet Ultra PE Thrombectomy System
62279530|NCT06548204|PLACEBO_COMPARATOR|Placebo|Participants will receive a matched 60mg placebo tablet orally twice a day for 6 months, which was added to the standard treatment.
62279531|NCT06548204|EXPERIMENTAL|Fexofenadine hydrochloride 120mg bid|Fexofenadine hydrochloride 120mg bid was added to the standard treatment 3 days after the completion of primary PCI and CMR examination for 6 months.
62279532|NCT04857099||Macular edema|
62645603|NCT02934971||A:machine learning approach (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
62076006|NCT03796013|EXPERIMENTAL|Form A to Form C Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
62076007|NCT03796013|EXPERIMENTAL|Form C to Form A Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
62076008|NCT04705220|EXPERIMENTAL|Nutritional Supplementation with Test Product|Subjects will receive 1 tablet of MERIVA® in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months. This treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
62076009|NCT04705220|PLACEBO_COMPARATOR|Control Group without Nutritional Supplementation|Subjects will receive 1 tablet of placebo in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months.
62076010|NCT01962025|ACTIVE_COMPARATOR|Buttonhole needling technique|the intervention is the Buttonhole needling technique for home hemodialysis
62076011|NCT01962025|NO_INTERVENTION|Step Ladder Group|Patients will use step ladder needling technique
62076012|NCT01848834|EXPERIMENTAL|Cohort A: Triple Negative Breast Cancer|Participants receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
62076013|NCT01848834|EXPERIMENTAL|Cohort B: Head & Neck Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
62076014|NCT01848834|EXPERIMENTAL|Cohort C: Urothelial Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
62076015|NCT01848834|EXPERIMENTAL|Cohort D: Gastric Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
62076016|NCT01848834|EXPERIMENTAL|Cohort B2: Head & Neck Cancer Expansion|Participants receive pembrolizumab, 200 mg, IV once every 3 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
62076017|NCT05585190|OTHER|Control|Subjects will not receive a sit/stand desk for the duration of the study and will be asked to follow their normal work day routine.
62076018|NCT05585190|ACTIVE_COMPARATOR|2-Hour Group|Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 2 hours each work day.
62076019|NCT05585190|ACTIVE_COMPARATOR|3-Hour Group|Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 3 hours each work day.
62076020|NCT04126096|EXPERIMENTAL|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive beta lactam containing antibiotics during surgery (other than penicillin) in order to determine Negative Predictive Values and Non-Irritant Concentrations.
62076021|NCT01936129|ACTIVE_COMPARATOR|Copaxone|COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
62076022|NCT01936129|PLACEBO_COMPARATOR|Placebo|Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
62076023|NCT03731130||neoadjuvant short term radiation|Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.
62279533|NCT01627860|ACTIVE_COMPARATOR|Topiramate add-on therapy|
62645604|NCT02934971||B: conventional echocardiographic parameters (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
62076024|NCT03731130||neoadjuvant long-term chemoradiation|Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire
62076025|NCT01910727|EXPERIMENTAL|Together on Diabetes-Hopkins|
62076026|NCT05269537||Study Group|Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.
62076027|NCT06109415|EXPERIMENTAL|Treatment Group 1 Cohort 1|HTX-011 + multimodal analgesic (MMA) regimen
62076028|NCT06109415|ACTIVE_COMPARATOR|Treatment Group 2 Cohort 1|Bupivacaine HCl + MMA regimen
62076029|NCT05922163|EXPERIMENTAL|Intervention Group|Receive the usual blood transfusion education (i.e. Zoom lecture) with the developed VR (Virtual Reality) video education.
62076030|NCT05922163|NO_INTERVENTION|Control Group|Receive the usual blood transfusion education (i.e. Zoom lecture) only.
62076031|NCT04758221|EXPERIMENTAL|Single arm : Composite coronal build up strip crown|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
62076032|NCT04548531|NO_INTERVENTION|Usual Care Arm|This arm will be a usual care arm. Patients may call to schedule a colonoscopy or other tests as desired.
62076033|NCT04548531|EXPERIMENTAL|Shared Decision Making Arm|This is the intervention arm. Patients will receive a shared decision making information sheet in the mail and will be able to receive decision coaching from study staff to support selection of an option if desired.
62456432|NCT00270959|EXPERIMENTAL|1|Stepped collaborative care (combination of behavioral therapy and drug therapy)
62076034|NCT02640976|ACTIVE_COMPARATOR|Poor responders|"This group will include women who underwent IVF/ICSI cycle and produced 4 oocytes or less.~intervention:~1. fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (300 IU).~2. On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~3. Finally, when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
62076035|NCT02640976|ACTIVE_COMPARATOR|Good responders|"This group will include women who produced (5 or more oocytes) after COH.~Intervention:~1. fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (225 IU) for participants with AMH levels \> 1.5 ng/ml and/or FSH levels ≤ 8 mIU/ml~2. On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~3. When at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
62076036|NCT03806946||group1|ADHD with normal EEG
62076037|NCT03806946||group 2|ADHD with abnormal EEG
62279534|NCT01627860|EXPERIMENTAL|Topiramate monotherapy|
62279535|NCT02103868|NO_INTERVENTION|Control|No active intervention will be given for tobacco cessation.
62456433|NCT00270959|ACTIVE_COMPARATOR|2|Standard care provided to injured trauma survivors
62076038|NCT03806946||group 3|Epilepsy
62076039|NCT03806946||group 4|Healthy control group
62076040|NCT03806946||group 5|ADHD and epilepsy
62076041|NCT05112341||group 1 standared hypofractonation|
62076042|NCT05112341||group 2 fast forward group|
62279536|NCT02103868|EXPERIMENTAL|Medium Intervention|Tobacco Cessation Counseling : Medium intervention in the form of 3 contact sessions will be given for tobacco cessation.
62279537|NCT02103868|EXPERIMENTAL|Low intensity intervention|Tobacco Cessation Counseling: Only a single contact session will be done for tobacco cessation.
62279538|NCT03842930|OTHER|Platinum-fibered Microcoils (FPC)|Embolization using platinum fibred Coils (Cook Incorporated, Bloomington, IN, USA)
62456434|NCT01900509|EXPERIMENTAL|Treatment|"All participants who meet eligibility for this study will follow the same treatment regimen.~INTERVENTIONS: bendamustine, clofarabine, etoposide (or etoposide phosphate), dexamethasone."
62456435|NCT04090086|EXPERIMENTAL|Treatment Sequence 1: Treatment ABC|Participants will receive Treatment A (JNJ-53718678 once daily for 7 days) in Treatment Period 1, followed by Treatment B (JNJ-64417184 once daily for 7 days) in Treatment Period 2, followed by Treatment C (JNJ-53718678 once daily + JNJ-64417184 once daily for 7 days) in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
62279539|NCT03842930|OTHER|MVP® Vascular Plug|Embolization using MVP®-Plug (Medtronic Inc., Minneapolis, MI, USA).
62456436|NCT04090086|EXPERIMENTAL|Treatment Sequence 2: Treatment BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
62456437|NCT04090086|EXPERIMENTAL|Treatment Sequence 3: Treatment CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
62645605|NCT02755753|EXPERIMENTAL|Study Group|"1. Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~2. Mucosta® (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
62076043|NCT03116243||MSHS children and families|"Cohort includes:~* children (1272)~* parents (1272)~* teachers (159)~* teaching assistants (159)~* program and center directors (253)"
62076044|NCT02225821|ACTIVE_COMPARATOR|antibiotic prophylaxis|a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)
62076045|NCT02225821|PLACEBO_COMPARATOR|No antibiotic prophylaxis|a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).
62076046|NCT03125941|ACTIVE_COMPARATOR|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
62076047|NCT03125941|ACTIVE_COMPARATOR|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
62076048|NCT05450445|EXPERIMENTAL|Intervention: myHealthHub|
62076049|NCT05450445|ACTIVE_COMPARATOR|Active control: TV-only|
62076050|NCT04380818|ACTIVE_COMPARATOR|Control group|a control group only receive pharmacological treatment
62076051|NCT04380818|EXPERIMENTAL|Experimental group|an experimental group will receive low-dose lung irradiation
62076052|NCT06012565|EXPERIMENTAL|KAND567|
62076053|NCT06012565|PLACEBO_COMPARATOR|Placebo|
62279540|NCT06550037||Pediatric patients affected by MDD|14-17 years (70 pediatric patients)
62279541|NCT06550037||Group 1 of adult patients affected by MDD|18-30 years (100 adult patients)
62279542|NCT06550037||Group 2 of adult patients affected by MDD|31-39 years (90 adult patients)
62279543|NCT06550037||Group 3 of adult patients affected by MDD|40-50 years (90 adult patients)
62279544|NCT03516344|NO_INTERVENTION|Control|Subjects will remain at rest in supine position for one minute.
62645606|NCT02755753|PLACEBO_COMPARATOR|Control Group|"1. Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~2. Mucosta®-placebo (rebamipide-placebo), 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
62076054|NCT05583851|EXPERIMENTAL|Digi-ACT Intervention group|22 day long interactive mobile app intervention with daily activities. The intervention will include 5 total modules: psychoeducation on depression/anxiety and the cancer journey; acceptance; cognitive fusion; mindfulness; and committed valued living. There will be different games and reward components for the Through out the course of the intervention, participants will also do video journals to reflect on the different modules and activities they do.
62076055|NCT05583851|ACTIVE_COMPARATOR|Psychoeducational Video Control group|22 day long mobile app where participants will be given a 15 minute long psychoeducational clip from a publicly available online seminar (from the Hong Kong College of Psychiatrists) on a bi-daily basis. Through out the course of the intervention, participants will also do video journals to reflect on the content of the different video clips.
62076056|NCT04256590||Study|Patients aged 16 years or younger who were to undergo adenoidectomy surgery were eligible for inclusion in this group. Tongue surface areas were measured twice by submental USG.The first measurements (TSA2) were done immediately after endotracheal intubation but before insertion and placement of the tongue depressor. The second measurements (TSA1) were done after adenoidectomy surgery and after removal of the tongue depressor but just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue swelling.
62456438|NCT04090086|EXPERIMENTAL|Treatment Sequence 4: Treatment ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
62076057|NCT04256590||Control|This group included patients aged 16 years or younger who did not need adenoidectomy surgery and any head and neck procedures. Tongue surface areas of the patients were measured twice by submental USG as in the study group. TSA1s were done immediately after endotracheal intubation, and TSA2s were done at the end of the surgical procedure just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue edema.
62076058|NCT01936610|EXPERIMENTAL|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section .
62076059|NCT01936610|EXPERIMENTAL|lecture|describe the advantages and disadvantages of normal delivery and cesarian section
62076060|NCT02223117|EXPERIMENTAL|Intervention|Thrombosomes
62279545|NCT03516344|EXPERIMENTAL|Iliac psoas muscle|In supine position with a high-density foam cushion under the subject's feet, they will be asked to make a push in the caudal direction, against the cushion, alternating between both feet with their knees stretched out, for one minute
62456439|NCT04090086|EXPERIMENTAL|Treatment Sequence 5: Treatment BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
62456440|NCT04090086|EXPERIMENTAL|Treatment Sequence 6: Treatment CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
62456441|NCT01954680|EXPERIMENTAL|COGFLEX-skill building levels|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
62456442|NCT01954680|EXPERIMENTAL|COGFLEX-control condition|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or the control condition--which is just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
62456443|NCT03561142|EXPERIMENTAL|Radiochemotherapy -> chemotherapy.|Radiochemotherapy followed by consolidation chemotherapy. Deep regional hyperthermia can additionally be performed at the centers in Tübingen and Erlangen.
62456444|NCT02041871|EXPERIMENTAL|Impact control|ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
62456445|NCT02041871|PLACEBO_COMPARATOR|Placebo|Placebo
62456446|NCT01164813|EXPERIMENTAL|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
62076061|NCT02223117|PLACEBO_COMPARATOR|Placebo|Buffer/placebo Control
62076062|NCT06364592|EXPERIMENTAL|Electroacupuncture, Then Sham Electroacupuncture|Fifteen participants will first receive electroacupuncture for two consecutive menstrual cycles. After a washout period of one menstrual cycle, they then will receive sham electroacupuncture for another two consecutive menstrual cycles.
62076063|NCT06364592|SHAM_COMPARATOR|Sham Electroacupuncture, Then Electroacupuncture|Fifteen participants will receive sham electroacupuncture for two consecutive menstrual cycles. After a washout period of one menstrual cycle, they then will receive electroacupuncture for another two consecutive menstrual cycles.
62076064|NCT00663962|EXPERIMENTAL|Perioperative pregabalin|Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).
62076065|NCT00663962|PLACEBO_COMPARATOR|Placebo control|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)
62076066|NCT03663777|EXPERIMENTAL|Isometric Handgrip Training|Experimental group will perform home-based bilaterall handgrip exercise and will be recommended to increase daily physical activity levels.
62076067|NCT03663777|OTHER|Control group|Control gorup will be recommended to increase daily physical activity level
62076068|NCT00871819|OTHER|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
62076069|NCT03993899|ACTIVE_COMPARATOR|Cochlear implant (CI) with FineHearing Strategy then HDCIS|cochlear implant with FineHearing strategy first during 15 days then with HDCIS strategy during 15 days
62456447|NCT01164813|ACTIVE_COMPARATOR|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
62456448|NCT04113239||Diagnosed Type 2 Diabetes Mellitus|Patients with incident type 2 diabetes mellitus
62456449|NCT04113239||Control|Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria
62076070|NCT03993899|ACTIVE_COMPARATOR|CI with HDCIS Strategy then FS4|cochlear implant with HDCIS strategy first during 15 days then with FS4 strategy during 15 days
62076071|NCT00832338|EXPERIMENTAL|Docetaxel with Cytoxan|Patients will be treated with docetaxel at 75 mg/m² concomitantly with cytoxan 600 mg/m² (TC) IV D1 every 3 weeks for 6 cycles. Due to known toxicity of docetaxel, all patients require dexamethasone 4 mg twice daily (BID) PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel to minimize hypersensitivity reactions and fluid retention.
62076072|NCT05082896||Conscious Sedation|
62279546|NCT03516344|EXPERIMENTAL|Diaphragmatic Breathing|Subjects perform five cycles of diaphragmatic breathing in the supine position.
62456450|NCT05067361|EXPERIMENTAL|Experimental Group|
62076073|NCT05082896||General Anesthesia|
62076074|NCT01254175|EXPERIMENTAL|rHPIV3cp45 Vaccine|Participants will receive one dose of the rHPIV3cp45 vaccine at baseline and a second dose at Month 6.
62279547|NCT03516344|EXPERIMENTAL|Liver pumping|A technique of hepatic supine pumping is performed by simultaneous compression in the right hypochondrium and epigastrium, in the opposite direction, during the inspiratory phase, stopping during the expiratory phase and repeating the maneuver for five respiratory cycles.
62456451|NCT05067361|ACTIVE_COMPARATOR|Active control Group|
62076075|NCT01254175|PLACEBO_COMPARATOR|Placebo Vaccine|Participants will receive one dose of the placebo vaccine at baseline and a second dose at Month 6.
62076076|NCT04259775|ACTIVE_COMPARATOR|Automated Insulin Dose Adjustment (AIDA)|Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
62076077|NCT04259775|ACTIVE_COMPARATOR|Control|Standard Care - change in therapy settings effected a regularly scheduled patients visits
62076078|NCT00991822|ACTIVE_COMPARATOR|1|Patients with open angle glaucoma
62076079|NCT00991822|ACTIVE_COMPARATOR|2|Patients with open angle glaucoma
62456452|NCT01621022|ACTIVE_COMPARATOR|Active bupropion-Active gum|150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
62279548|NCT03516344|EXPERIMENTAL|Spinal manipulation|A semi-direct vertebral manipulation, type Dog Technique in extension, will be performed on level D8
62456453|NCT01621022|ACTIVE_COMPARATOR|Active bupropion-Placebo gum|150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
62456454|NCT01621022|ACTIVE_COMPARATOR|Placebo medication-Placebo gum|Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)
62456455|NCT05341232|EXPERIMENTAL|Problem-Solving Training|Participants will learn to program LEGO robots and will be encouraged to actively solve problems.
62456456|NCT05341232|ACTIVE_COMPARATOR|Step-By-Step Training|Participants will learn to program LEGO robots and will be instructed step by step.
62456457|NCT05341232|PLACEBO_COMPARATOR|Board Games|Participants will play boards games under a schedule matching the Experimental and Active Comparator arms.
62279549|NCT05184647||Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie
62279550|NCT05184647||Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie
62279551|NCT01481675||BPDLL group|Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
62279552|NCT01481675||LSG group|Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively
62279553|NCT03768947|EXPERIMENTAL|Heat Therapy Arm|Participants in this open-label pilot study will undergo heat therapy via hot water immersion (hot-tub).
62279554|NCT05630287|EXPERIMENTAL|[14C] Selpercatinib - Part 1|\[14C\] Selpercatinib administered as an oral solution
62279555|NCT05630287|EXPERIMENTAL|Selpercatinib and [14C] Selpercatinib - Part 2|Single oral dose of Selpercatinib followed 2 hours later by single dose of \[14C\] Selpercatinib administered as an intravenous (IV) push.
62279556|NCT04418765|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to eptinezumab by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
62456458|NCT01652079|EXPERIMENTAL|Treatment Arm|CRLX101
62456459|NCT00583258|EXPERIMENTAL|A|
62279557|NCT04418765|EXPERIMENTAL|Eptinezumab 100 mg|Participants will receive eptinezumab 100 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
62279558|NCT04418765|EXPERIMENTAL|Eptinezumab 300 mg|Participants will receive eptinezumab 300 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
62456460|NCT00583258|PLACEBO_COMPARATOR|B|
62456461|NCT02367638|EXPERIMENTAL|MG1111|
62456462|NCT02367638|ACTIVE_COMPARATOR|VARIVAX|
62456463|NCT06139237|EXPERIMENTAL|High-protein supplement|The high-protein supplements contains 47.3% protein, 39.4% carbohydrates, 13.3% lipids. A dose containing 20.8 g protein and diluted to a volume of 200 mL will be administered (187 Kcal).
62456464|NCT06139237|ACTIVE_COMPARATOR|Balanced supplement|The high-protein supplements 22.2% protein, 67.85% carbohydrates, 9.95% lipids. A dose containing 20.8 g protein and diluted to a volume of 200 mL will be administered (399.3 Kcal)
62456465|NCT06248450|OTHER|Physical setting|Medical yoga at a yoga local led by a yoga-instructor for 75 minutes once a week and individual yoga for a minimum of 10 minutes daily using a yoga-application for 12 weeks.
62456466|NCT06248450|OTHER|Digital setting|Medical yoga online using videoconference system led by a yoga-instructor for 75 minutes once a week and individual yoga for a minimum of 10 minutes daily using a yoga-application for 12 weeks.
62456467|NCT03881826|EXPERIMENTAL|Haematological patients|
62456468|NCT03881826|ACTIVE_COMPARATOR|Healthy volunteers|
62456469|NCT04603092|EXPERIMENTAL|Disadvantaged women in primary setting receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This group will receive the digital health literacy intervention.
62279559|NCT04102969|EXPERIMENTAL|Intervention group|"Intervention group will be instructed by an interventionist who is qualified in stress management and relaxation will perform the Benson relaxation technique to the intervention group to perform the Benson relaxation technique two times a day for 10 minutes during the study period ( two months).~Training session of the technique will be repeated if necessary over one or two sessions until the interventionist confirm that the participants acquired sufficient skills. A total of two hours will be scheduled for each session and will be coordinated with the nursing manager of the hemodialysis department."
62279560|NCT04102969|OTHER|Control Group|A qualified nutritionist will run out a nutrition package session for hemodialysis patients in the control group. This nutrition package session will be for one session for one hour.
62279561|NCT06502093||Observational Study Group|"* Aged 18-65,~* Volunteers at the Isparta City Hospital~* Patients who were hospitalized in neurology, internal medicine, general surgery, cardiovascular surgery, and chest disease clinics for at least seven days"
62279562|NCT05928975|EXPERIMENTAL|MT+ PNE with MI|Participants allocated to this group will receive 10 sessions of MT, along with 4 sessions of PNE with MI, over a period of four weeks.
62279563|NCT05928975|EXPERIMENTAL|MT|Participants allocated to this group will receive 10 sessions of MT (without PNE with MI), over a period of four weeks.
62279564|NCT05928975|ACTIVE_COMPARATOR|Control|Participants allocated to this group will engage in a home-based general exercise program.
62279565|NCT02836015|EXPERIMENTAL|Shared Medical Visit Groups|All patients will be enrolled in the experimental group and will be involved in shared medical visits.
62279566|NCT05649995|EXPERIMENTAL|Pain science education group|the program integrated with pain science education (exercise, walking program and recommendations for reducing sedentary behaviors)
62076080|NCT06249620|EXPERIMENTAL|Active group|The product (with the active ingredients) is randomly given to 20 participants for ingestion for two months.The dosage regimen is two capsules per day in a single dose.
62076081|NCT06249620|PLACEBO_COMPARATOR|Placebo|The other 20 participants will receive a similar looking product but with inert substances (placebo group).The dosage regimen is two capsules per day in a single dose.
62076082|NCT04524728||Cohort A|Patients that received palbociclib combined with letrozole 2.5 mg
62076083|NCT04524728||Cohort B|Patients that received palbociclib combined with fulvestrant 500 mg
62076084|NCT00245011|EXPERIMENTAL|Samarium-153|Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.
62076085|NCT04854850|EXPERIMENTAL|Apollo|Participants will all receive Apollo devices.
62076086|NCT04432402|EXPERIMENTAL|Lenalidomide in Combination With R-GemOx|Lenalidomide 10mg、15mg、20mg、25mg qd PO d1-7 Rituximab 375mg/m2 ivd d0 Gemcitabine 1g/m2 ivd d1 Oxaliplatin 100mg/m2 ivd d1 every14 days as a cycle
62279567|NCT05649995|EXPERIMENTAL|Biomedical education group|the program integrated with biomedical education (exercise, walking program and recommendations for reducing sedentary behaviors)
62279568|NCT01450423|EXPERIMENTAL|Physical activity|
62279569|NCT01450423|NO_INTERVENTION|Control|
62279570|NCT01051141|ACTIVE_COMPARATOR|CBI in ED with AMET at 3 months|computer brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
62076087|NCT03219450|EXPERIMENTAL|NeoVax|"* NeoVax will be administered in a priming and booster phase.~* The priming shots will comprise days 1, 4, 8, 15, and 22.~* Booster shots will be given on days 78 and 134."
62076088|NCT03219450|EXPERIMENTAL|Neovax + Low-dose cyclophosphamide|"* NeoVax will be administered in a priming and booster phase.~* The priming shots will comprise days 1, 4, 8, 15, and 22.~* Booster shots will be given on days 78 and 134.~* Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
62076089|NCT03219450|EXPERIMENTAL|Neovax + Low-dose cyclophosphamide + Pembrolizumab|"* NeoVax will be administered in a priming and booster phase.~* The priming shots will comprise days 1, 4, 8, 15, and 22.~* Booster shots will be given on days 78 and 134.~* Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5~* Pembrolizumab will be administered starting on Week 12 Day 78 and for up to 17 cycles (approximately 1 year)."
62076090|NCT03729596|EXPERIMENTAL|Cohort 1|0.5 mg/kg IV every 3 weeks
62076091|NCT03729596|EXPERIMENTAL|Cohort 2|1.0 mg/kg IV every 3 weeks
62076092|NCT03729596|EXPERIMENTAL|Cohort 3|2.0 mg/kg IV every 3 weeks
62076093|NCT03729596|EXPERIMENTAL|Cohort 4|3.0 mg/kg IV every 3 weeks
62076094|NCT03729596|EXPERIMENTAL|Cohort 5|4.0 mg/kg IV every 3 weeks
62279571|NCT01051141|ACTIVE_COMPARATOR|CBI in ED with EUC at 3 months|
62279572|NCT01051141|ACTIVE_COMPARATOR|IBI in ED with AMET at 3 months|
62279573|NCT01051141|ACTIVE_COMPARATOR|IBI in ED with EUC at 3 months|
62279574|NCT01051141|ACTIVE_COMPARATOR|EUC in ED with AMET at 3 months|
62279575|NCT01051141|NO_INTERVENTION|EUC in ED with EUC at 3 months|
62279576|NCT01207973|EXPERIMENTAL|BI 113823|5 dose-groups of multiple oral doses of BI 113823
62279577|NCT05220605|EXPERIMENTAL|Bromac (100ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (100micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
62279578|NCT05220605|EXPERIMENTAL|Bromac (150ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (150micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
62456470|NCT04603092|NO_INTERVENTION|Disadvantaged women in primary setting not receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This control group will not receive the digital health literacy intervention.
62076095|NCT03729596|EXPERIMENTAL|mCRPC expansion|3.0 mg/kg IV every 3 weeks
62076096|NCT03729596|EXPERIMENTAL|NSCLC expansion|3.0 mg/kg IV every 3 weeks
62076097|NCT03729596|EXPERIMENTAL|TNBC expansion|3.0 mg/kg IV every 3 weeks
62076098|NCT03729596|EXPERIMENTAL|Melanoma expansion|3.0 mg/kg IV every 3 weeks
62076099|NCT03729596|EXPERIMENTAL|SCCHN expansion|3.0 mg/kg IV every 3 weeks
62076100|NCT03428568|EXPERIMENTAL|Herbal Melanin|Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)
62076101|NCT03428568|ACTIVE_COMPARATOR|Nexium|omeprazole 40 mg once per day for one month.
62076102|NCT03428568|EXPERIMENTAL|H-Pylori infected : Herbal Melanin|Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)
62456471|NCT01642511|ACTIVE_COMPARATOR|Control Group|conventional technique: 99mTc-labeled Sulfur Colloid was injected into the tumor quadrant 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
62456472|NCT01642511|EXPERIMENTAL|Study Group|modified technique: 99mTc-labeled Sulfur Colloid was injected into 2 quadrants of the breast 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
62456473|NCT05649475||Patients receiving neoadjuvant therapy|
62456474|NCT06486116|EXPERIMENTAL|Individualized Task Specific Physical Therapy Home Exercise Program|Physical Therapy Home Exercise program based on specific outcome measure findings.
62456475|NCT06486116|ACTIVE_COMPARATOR|Generic physical therapy home exercise program|Generalized fitness-based exercise program
62456476|NCT05902143||Experimental Group|children with Specific Learning Disorder
62456477|NCT05902143||Control Group|children with typically developing children
62456478|NCT01072110||Group 1: Patients with diarrhea undergoing endoscopy|Standard video colonoscope.
62456479|NCT01072110||Group 2: Patients with diarrhea undergoing endoscopy.|Confocal laser endomicroscopy (CLE).
62456480|NCT03392610||Bronchial endoscopy|Compare quality procedures performed with reusable versus disposable bronchoscopes in respiratory endoscopy unit
62456481|NCT03392610||Critical care unit|Compare quality procedures performed with reusable versus disposable bronchoscopes in critical care unit
62456482|NCT03392610||Anesthesia department|Compare quality procedures performed with reusable versus disposable bronchoscopes in anesthesia department
62076103|NCT03428568|ACTIVE_COMPARATOR|nexium+ amoxil+clarithromycin|"omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.~Omeprazole+Amoxil+clarithromycin is the standard triple therapy given"
62456483|NCT02187978|EXPERIMENTAL|Early total enteral feeding (ETEF)|"Feeding will be initiated on D1 with 80ml/kg/day of expressed breast milk or LBW formula milk.~No intravenous fluid will be provided. Feeds will be advanced till 150ml/kg/day is attained."
62456484|NCT02187978|ACTIVE_COMPARATOR|Conventional enteral feeding (CEF)|"Feeding will be initiated on D1of life with 20ml/kg of expressed breast milk or LBW formula milk.~Remaining requirement as intravenous fluids. Feeds advanced by 20ml/kg/day for next 2 days and then 30ml/kg/day for the next three days until 150ml/kg/day is reached."
62456485|NCT01601197|EXPERIMENTAL|Tactile stimulation|Ipsilateral limb will be rubbed immediately before, during and after immunization injection(s)
62456486|NCT01601197|NO_INTERVENTION|No tactile stimulation|There will be no tactile stimulation of ipsilateral limb before, during and after immunization injection(s)
62456487|NCT01297049|EXPERIMENTAL|Lifestyle counseling|
62456488|NCT04078477|EXPERIMENTAL|Lateral tilt bed|Special lateral tilt bed.
62456489|NCT04078477|NO_INTERVENTION|Body positioning|Standard NICU preventive strategy
62456490|NCT04149964|ACTIVE_COMPARATOR|Standard of Care arm|Standard of Care Post-operative pain medication, Acetaminophen 325 mg every 6 hours as needed for pain plus acetaminophen/hydrocodone 7.5 mg/325 mg 1 tab every 4 hours as needed for pain.
62456491|NCT04149964|EXPERIMENTAL|Study Arm|Acetaminophen 650 mg 1 tab every 6 hours round the clock plus Oxycodone 5 mg 1 tab every 6 hours as needed for breakthrough pain,.
62076104|NCT03428568|EXPERIMENTAL|nexium +Herbal melanin|omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested
62076105|NCT03428568|EXPERIMENTAL|Herbal melanin+amoxil+ clarithromycin|Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested
62076106|NCT05793710|EXPERIMENTAL|the principle of laughter plus Qigong|"The basic method of  LQP  is the principle of laughter plus Qigong, combined with the sound of laughter, stretching the body, thereby activating the parasympathetic nerve, so that the body can automatically relax, and at the same time guide the individual to face their own emotions when facing pressure, and transform emotions into positive energy or relieve negative emotions through practice, so as to achieve the energy balance of body, mind and spirit."
62279579|NCT05220605|EXPERIMENTAL|Bromac (200ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (200 micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
62279580|NCT03099707|NO_INTERVENTION|Standard of Care|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200 Rand to complete all three surveys) only. This group will not receive any additional engagement to care intervention. Investigators intend to follow their clinical outcomes through medical registries, pharmacy data, and the National Health Laboratory Service (a national database for all individuals living with HIV in South Africa regarding engagement in care).
62279581|NCT03099707|ACTIVE_COMPARATOR|Treatment Ambassador Intervention|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200R to complete all three surveys). For participants randomized to the intervention arm, they will immediately meet with a Treatment Ambassador to begin the 8 session intervention, which has components of motivational interviewing, peer-support, and peer navigation. The protocol is detailed in a study manual that has been reviewed and undergone multiple iterative revisions to ensure cultural acceptability.
62279582|NCT02586792|EXPERIMENTAL|Group 2|N up to 10 in prior receipt of a placebo in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
62279583|NCT02586792|EXPERIMENTAL|Group 1|N up to 40 in prior receipt of a monovalent inactivated influenza A/H7N7 virus vaccine in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
62456492|NCT02366780|EXPERIMENTAL|Manual expression followed by electric pump|Mothers will be assigned to first express breast milk manually followed by electric pump
62076107|NCT05793710|NO_INTERVENTION|their current lifestyle for a 12-week|After baseline testing, participants in the waitlist control group (CON) were asked to maintain their current lifestyle for a 12-week. Participants in the CON group will then undergo a 12-week fully supervised intervention.
62076108|NCT02291224|OTHER|Control|The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
62279584|NCT05230888||Cohort|The effect of immunotherapy treatment will be assessed using the comprehensive geriatric assessment (CGA) and vulnerable elders survey (VES-13) in 100 non-small cell lung cancer patients, aged ≥70 years old, receiving immune checkpoint inhibitor (ICI) treatment.
62456493|NCT02366780|EXPERIMENTAL|Electric pump followed by manual expression|Mothers will be assigned to first express breast milk by electric pump followed by manual expression
62279585|NCT04979754||RENAL TRANSPLANT RECIPIENTS|All patients with previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
62279586|NCT04979754||NON RENAL TRANSPLANT RECIPIENTS|All patients without previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
62279587|NCT03370159|EXPERIMENTAL|Treatment (CPI-613, docetaxel)|Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62279588|NCT01791907|EXPERIMENTAL|Structured education in carbohydrate counting|A structured education in carbohydrate counting, a course inspired by the DAFNE program (Dose Adjustment For Normal Eating)
62279589|NCT01791907|EXPERIMENTAL|Structured education in healthy food choices and low GI|"A new, structured education for heart healthy food choices and low glycemic index in type 1 diabetes. The education is called My Wellness-LADDER (Lifelong Adult Diet \& Diabetes Education Resource) and it is specifically designed to provide high long-term adherence through improved empowerment and transformative life style change."
62279590|NCT01791907|NO_INTERVENTION|Regular routine|
62279591|NCT02769728|EXPERIMENTAL|EndoBarrier|EndoBarrier will be implemented for 9 months.
62456494|NCT06223451|ACTIVE_COMPARATOR|Active repetitive transcranial magnetic stimulation in stroke patients with unilateral neglect.|Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation. Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
62456495|NCT06223451|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation in stroke patients with unilateral neglect.|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
62456496|NCT01008657|EXPERIMENTAL|"extranodular no touch multipolar RFA"|
62279592|NCT01871584|EXPERIMENTAL|Hydrocolonic cleansing|Subjects undergo colon cleansing by hydrotherapy with the study device
62279593|NCT01871584|ACTIVE_COMPARATOR|Standard preparation solution|Subjects undergo colon cleansing by standard preparation solution
62279594|NCT02112500|EXPERIMENTAL|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
62279595|NCT06492044|EXPERIMENTAL|o Patient with septic shock for less than 48 hours|
62279596|NCT00682266|EXPERIMENTAL|Aerobic interval training|intensity-controlled interval training
62279597|NCT00682266|EXPERIMENTAL|MTG|multidisciplinary approach
62279598|NCT02013843|OTHER|Community-based treatment|"Overweight and obese children are seen on a regular basis by health care professionals in the 8 communities included in the project. The care providers are all trained thoroughly in using the Holbaek-method for treatment of pediatric obesity."
62279599|NCT03167073|EXPERIMENTAL|BreastFeeding Friend (BFF)|BFF is a novel android app initially created in Microsoft PowerPoint with the results of a well-validated questionnaire administered to the target patient population, in which participants identified barriers preventing them from starting or continuing breastfeeding. The app was then modified by a multidisciplinary team of neonatologists, perinatologists, and certified lactation consultants. The finalized prototype was presented to three focus groups of test users sociodemographically similar to the target population. This approach allowed BFF to be adjusted to maximize the users' experience per their opinions. Once the focus groups' feedback was consistent, the app prototype was provided to a freelance coding team at Washington University of St. Louis, which built a native android app.
62279600|NCT03167073|PLACEBO_COMPARATOR|dummy app|The dummy app looks identical to BFF but is limited to a few pages of information on breastfeeding that is provided in hand-out form during routine prenatal care.
62645607|NCT03054428|EXPERIMENTAL|Placebo|Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling the amount of placebo on day 1 to match the loading dose). In order to maintain blinding for the study, participants in the \<60 kilogram (kg) weight stratum received, in a 1:1 ratio, either placebo matching 200 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose) or placebo matching 300 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose). In the ≥60 kg weight stratum, the participants randomized to the placebo group received placebo matching 300 mg dupilumab (including doubling the amount of placebo on day 1 to match the loading dose).
62645608|NCT03054428|EXPERIMENTAL|Dupilumab 300 mg Q4W|Participants received once every 4 weeks (Q4W) subcutaneous (SC) injections of 300 milligrams (mg) dupilumab following a loading dose of 600 mg on day 1. In order to maintain blinding, all participants received an injection once every 2 weeks (Q2W) from day 1 to week 14. Participants received placebo 2 milliliter (mL) injection at the weeks dupilumab was not given.
62645609|NCT03054428|EXPERIMENTAL|Dupilumab 200 mg or 300 mg Q2W|Participants with baseline weight \<60 kg received once every 2 weeks (Q2W) subcutaneous (SC) injections of 200 milligrams (mg) dupilumab following a loading dose of 400 mg on day 1. Participants with baseline weight ≥60 kg received Q2W SC injections of 300 mg dupilumab following a loading dose of 600 mg on day 1.
62645610|NCT03794895|EXPERIMENTAL|Single arm clinical trial|
62645611|NCT00513929|EXPERIMENTAL|X: Zinc sulphate|
62645612|NCT00381628||Stable subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro.
62645613|NCT00381628||Exacerbating subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) at the beginning and end of treatment for a pulmonary exacerbation. These cells will be studied in vitro.
62645614|NCT00381628||Stable subjects with asthma|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the disease control group.
62279601|NCT04405375|EXPERIMENTAL|treatment arm|gemcitabine 1.25g/㎡ d1, pegaspargase 2500IU/㎡ d1 (max dose =\<3750IU) etoposide 75mg/㎡ d1-3 dexamethasone 20mg d1-4 repeated every 21 days, up to 6 cycles.
62279602|NCT00610142|ACTIVE_COMPARATOR|1|
62279603|NCT00610142|ACTIVE_COMPARATOR|2|
62279604|NCT03439709|EXPERIMENTAL|intervention|Gamma knife radiosurgery (Leksell Gamma Knife, Elekta AB, Stockholm, Sweden) is used for intervention. Administration of standard medical therapy using Lanreotide 60 mg concurrently starts with radiosurgery
62279605|NCT03439709|ACTIVE_COMPARATOR|control|Without radiosurgery, standard medical therapy (Lanreotide 60Mg Solution for Injection) same with interventional group is applied
62279606|NCT01910675|EXPERIMENTAL|PCC group|Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
62456497|NCT01008657|ACTIVE_COMPARATOR|intranodular multipolar RFA|
62456498|NCT03237819|PLACEBO_COMPARATOR|Placebo|Glucose serum (3 ampoules)
62456499|NCT03237819|EXPERIMENTAL|Magnesium Sulfate|20/5000 magnesium sulfate (4 ampoules, 1,5g each)
62456500|NCT03677232||Hong Kong Chinese adolescents with CHD|Hong Kong Chinese adolescents with CHD aged 12-18 who are able to read and write chinese
62456501|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
62645615|NCT00381628||Healthy volunteers|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the control group
62279607|NCT01910675|ACTIVE_COMPARATOR|FFP group|Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
62279608|NCT03588377|ACTIVE_COMPARATOR|Intervention Cluster|Signs and symptoms of severe pneumonia Pulse Oximetry
62279609|NCT03588377|NO_INTERVENTION|Non-Intervention Cluster|Signs and symptoms of severe pneumonia
62456502|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
62456503|NCT02210715|EXPERIMENTAL|switch to Isentress|28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.
62456504|NCT02210715|ACTIVE_COMPARATOR|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
62456505|NCT00662025|EXPERIMENTAL|1|
62456506|NCT02310165|OTHER|Z-tract Insertion Technique|For this technique, the skin is pulled 2 cm downward before the paracentesis needle is inserted and advanced.
62456507|NCT02310165|OTHER|Coaxial Insertion Technique|For this technique, the needle is directly inserted to minimize the distance between he cutaneous tissue and ascites
62645616|NCT06166563|ACTIVE_COMPARATOR|AF-FM|Patients with Fibromyalgia
62645617|NCT06166563|ACTIVE_COMPARATOR|AF-IBS|Patients with irritable bowel syndrome
62645618|NCT06166563|ACTIVE_COMPARATOR|AF-FM-IBS|Patients with fibromyalgia and irritable bowel syndrome
62076109|NCT02291224|EXPERIMENTAL|Intervention|"1. Enrollment~   * Interactive multimedia platform focused on DP strategies.~  * Intervention arm counseling by a health care provider to select DP strategy.~  * Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.~2. Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.~3. 6 month visit~   * Abbreviated version of the interactive multimedia platform on DP strategies and adherence.~  * Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.~4. Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care."
62076110|NCT00865891|EXPERIMENTAL|A|Nifedipine Extended Release tablets 60 mg, single dose
62076111|NCT00865891|ACTIVE_COMPARATOR|B|ADALAT® CC Extended Release Tablets 60 mg
62076112|NCT01479491||Case Group|Children aged \< 12 months presenting with IS and covered by the Japan Medical Data Centre Company Limited (JMDC), Tokyo referred to as the JMDC Medical Data Bank (JMDC-MDB).
62076113|NCT04942912||French patients with juvenile Pompe disease|We aim to include all French patients with juvenile Pompe disease (maltase acid deficiency without cardiomyopathy)
62076114|NCT00389090|EXPERIMENTAL|Temozolomide + O6BG|
62456508|NCT02115906||Acromegalic patients|Acromegalic patients before and after initiation of individual therapy will be investigated by 1H/31P magnetic resonance spectroscopy, thyroid sonography and oral glucose tolerance testing
62076115|NCT00883103|ACTIVE_COMPARATOR|Lidocaine|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
62076116|NCT00883103|PLACEBO_COMPARATOR|Aqueous gel|Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
62076117|NCT02333734|EXPERIMENTAL|Type 2 diabetic subjects|Type 2 diabetic subjects physical training (interval training 3 times at week) in a period of 8 weeks.
62076118|NCT02333734|EXPERIMENTAL|Healthy subjects|Healthy subjects physical training (interval training 3 times at week) in a period of 8 weeks.
62279610|NCT04072757|ACTIVE_COMPARATOR|Intervention Group|The cooking skill building/nutrition education workshops will be led by a multidisciplinary team comprised of: a chef/instructor, a nutritionist and/or registered dietitian, MD and/or Preventive Medicine Resident, and Yale-Griffin Prevention Research Center staff. The cooking/nutrition education workshop sessions will be approximately 45 minutes and will: include a plant forward approach to healthy eating; integrate nutrition and health-related information and cooking instruction (i.e. knife skills, equipment use); show participants how to prepare meals that are simple, nutritious, affordable, and delicious; provide recipes and nutrition information aimed at improving dietary intake and health status; and provide an enjoyable program that participants will look forward to attending. Fruit and vegetable prescription vouchers will be redeemed at ShopRite grocery stores (Ansonia and Shelton locations) and Griffin Hospital's farmers market, where redemption will be tracked.
62279611|NCT04072757|PLACEBO_COMPARATOR|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
62279612|NCT02337790||Cohort 1|Subjects will have a pacemaker, implanted cardioverter-defibrillator, or ventricular assist device.
62456509|NCT02115906||Healthy control subjects|Age and Body mass index matched control subjects will be investigated by 1H/31P magnetic resonance spectroscopy and oral glucose tolerance testing
62456510|NCT01544790|EXPERIMENTAL|Robot-assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
62456511|NCT01544790|ACTIVE_COMPARATOR|Open transthoracic esophagectomy|traditional open transthoracic esophagectomy with gastric conduit formation.
62456512|NCT00489203|EXPERIMENTAL|Arm I|Patients receive oral beclomethasone dipropionate 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
62456513|NCT00489203|ACTIVE_COMPARATOR|Arm II|Patients receive oral placebo 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
62456514|NCT02754401|OTHER|group 1|non-periodontitis persons (PSI 0-2)
62076119|NCT02136498|ACTIVE_COMPARATOR|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
62456515|NCT02754401|OTHER|group 2|periodontitis persons (PSI 3-4)
62456516|NCT04338867|ACTIVE_COMPARATOR|Therapeutic arm|Patients who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN) with the release of 10 mg in 24 hours, for 24 hours with a 12-hour rest interval (to avoid saturation of receptors)
62456517|NCT04338867|ACTIVE_COMPARATOR|Control arm|Patients who received whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions, in 10 days of treatment)
62279613|NCT05664165|EXPERIMENTAL|Dry needling|It was performed using a deep dry needling technique using 0.25x25 mm disposable sterile steel acupuncture needles (HuaLong, China) while patient was in prone position. The needle inserted in the trigger point and stimulation was performed by manipulating it up and down several times. The needle was kept in the trigger point for 1-3 minutes and removed after the muscle spasm regressed . One session per week, a total of 3 sessions were applied.
62645619|NCT05295381|EXPERIMENTAL|abdominal weight training with cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily. Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
62279614|NCT05664165|EXPERIMENTAL|Cold spray and stretching|The patient was placed on the chair with the head and body upright in the most comfortable position possible and voluntary relaxation was achieved. One end of the muscle was fixed in order to apply passive stretching. The cooler spray (in its content; 0.06% menthol, 2.06% isopropyl alcohol, 2% isopropyl alcohol) was sprayed to the surface at an angle of 30° from a distance of approximately 30-50 cm, while passive stretching was applied. One session per week, a total of 3 sessions were applied
62279615|NCT05139225|EXPERIMENTAL|TTI-622 dosing will occur over 8 weeks + Daratumumab Hyaluronidase-fihj|TTI-622 will be administered weekly at the assigned dose levels per the ramp-up schedule. Daratumumab hyaluronidase-fihj 1800 mg will administered on a standard schedule consisting of weekly administration for 8 weeks, every other week administration for 16 weeks, followed by every 4-week administration thereafter.
62279616|NCT05139225|EXPERIMENTAL|TTI-622 dosing will occur over 4 weeks + Daratumumab Hyaluronidase-fihj|TTI-622 will be administered weekly at the assigned dose levels per the ramp-up schedule. Daratumumab hyaluronidase-fihj 1800 mg will administered on a standard schedule consisting of weekly administration for 8 weeks, every other week administration for 16 weeks, followed by every 4-week administration thereafter.
62456518|NCT02752126|ACTIVE_COMPARATOR|Standard Palliative Radiation|Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
62645620|NCT05295381|EXPERIMENTAL|abdominal weight training (AWT) without cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
62645621|NCT05295381|NO_INTERVENTION|control|no abdominal weight training and no cough machine
62456519|NCT02752126|EXPERIMENTAL|Esophageal Sparing IMRT|Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.
62456520|NCT02925442|EXPERIMENTAL|Standard Thermal radiofrequency ablation|Patients randomized to t-RFA will receive standard genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
62456521|NCT02925442|EXPERIMENTAL|Cooled radiofrequency ablation|Patients randomized to C-RFA will receive cooled genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
62645622|NCT05026502||Participants Being Treated With Elagolix + E2/NETA|Participants will receive Elagolix with Estradiol/Norethindrone Acetate per Standard of Care, as prescribed by their physicians.
62076120|NCT02136498|EXPERIMENTAL|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects \& secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
62076121|NCT02809508|EXPERIMENTAL|Oily fish|
62076122|NCT02809508|EXPERIMENTAL|Poultry (control)|
62076123|NCT05966376|EXPERIMENTAL|Modified Terumo Radial Band|"A standard hemostatic device used for proximal radial approach. The hard plastic component is removed to achieve better attachment in the distal radial approach.~* Clean and dry the puncture site.~* The introducer is withdrawn 2 cm.~* Place the device on the patient's hand depending on the approach side.~* Terumo logo is positioned toward the little finger side.~* The green mark is positioned 1 cm proximal to the puncture site.~* The bands are adjusted and fixed around the wrist.~* The Terumo syringe is filled with 15 ml of air.~* The balloon of the device is slowly inflated through the valve while the introducer is slowly withdrawn simultaneously.~* Once the introducer is completely withdrawn, the balloon continues to be inflated until the absence of bleeding is verified.~* Once hemostasis is achieved, the patient must be able to move his fingers and wrist without bleeding. If bleeding is observed, the balloon is inflated to achieve adequate hemostasis."
62645623|NCT00572689|EXPERIMENTAL|A|Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
62076124|NCT05966376|ACTIVE_COMPARATOR|PreludeSYNC distal|"A specific hemostatic device, designed for distal radial approach.~* Clean and dry the puncture site.~* Selection and preparation of the PreludeSYNC distal device according to the approach side.~* The introducer is withdrawn 2cm.~* The hemostasis device is placed on the patient's hand.~* Bands position: 1) little finger side; 2) thumb side; 3) between the thumb and the index finger.~* The circular mark of the balloon is positioned 1cm proximal to the puncture site.~* Bands are adjusted and fixed.~* The syringe is filled with 10 ml of air.~* The balloon of the device is slowly inflated while the introducer is slowly withdrawn simultaneously.~* Once the introducer is completely withdrawn, the balloon continues to be inflated until the absence of bleeding is verified.~* Once hemostasis is achieved, the patient must be able to move his fingers and wrist without bleeding. If bleeding is observed, the balloon should be inflated to achieve adequate hemostasis."
62076125|NCT01001780|EXPERIMENTAL|Pentostatin, Cyclophosphamide, Rituximab|
62076126|NCT04961320|EXPERIMENTAL|Supportive care (OT, questionnaires)|Patients participate in OT sessions weekly for 3 weeks over 30 minutes each. Patients also complete questionnaires to assess anxiety, depression, fatigue and pain at baseline, 5 and 12 weeks.
62076127|NCT03871049|PLACEBO_COMPARATOR|group 1|intathecal bupivacaine
62076128|NCT03871049|ACTIVE_COMPARATOR|group 2|intrathecal bupivacaine with dexamethasone
62076129|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
62076130|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
62076131|NCT05261750|EXPERIMENTAL|Auto-Dendritic Adjuvant Therapy|Patients will be given standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
62279617|NCT06399497|EXPERIMENTAL|Intervention Group|A physical therapist, with more than 10 years of experience, performs a high-velocity low-amplitude spinal manipulation at the L5 level by means of the lumbar roll technique, performed with the subject in right lateral decubitus.
61978776|NCT03486132|OTHER|interrupted repair of mediolateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut"
62076132|NCT05261750|EXPERIMENTAL|Allo-Dendritic-secretome and Auto-Dendritic Adjuvant Therapy|Patients will be given standrad medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
62076133|NCT02372123|OTHER|control|lifestyle advice
62076134|NCT02372123|ACTIVE_COMPARATOR|intervention|connective tissue manipulation
62076135|NCT02753725|ACTIVE_COMPARATOR|Fentanyl group|Fentanyl given at a dose of one micro gram per kilogram body weight
62279618|NCT06399497|PLACEBO_COMPARATOR|Control Group|A physical therapist performance a simulated manipulation intervention, for which the same position as in the Intervention Group will be used, in right lateral decubitus with the left leg flexed and the left foot resting on the right popliteal fossa. Without stretching the paravertebral tissues, the participant will remain for approximately 20 seconds without receiving manual impulse.
62279619|NCT01663948||Patients with Plastic bronchitis|
62456522|NCT02925442|SHAM_COMPARATOR|Control:Placebo Sham|Patients randomized to control will receive simulated genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty and receive the industry standard of care for unilateral knee arthroplasty pain management.
62456523|NCT02759289||Group A|Prediabetes glycohemoglobin test A1c 5.7-6.4%
62456524|NCT02759289||Group B|"T2D glycohemoglobin test= A1c 6.5-7.9% without T2D medications~T2D glycohemoglobin test=A1c ≥ 8.0% with/without T2D medications"
62456525|NCT02759289||Group C|Control
62645624|NCT00572689|NO_INTERVENTION|B|Patients given mixed meal test and blood samples drawn for laboratory testing
62645625|NCT02667652|ACTIVE_COMPARATOR|short biliarypancreatic limb|short biliarypancreatic limb
62076136|NCT02753725|PLACEBO_COMPARATOR|normal saline group|placebo arm will be given normal saline at a volume equivalent to Fentanyl dose as per body weight.
62076137|NCT04345198|EXPERIMENTAL|Intervension|Adrenal artery ablation is performed in PA patients with resistant hypertension.
62076138|NCT02591420|EXPERIMENTAL|Group 1: immediate ART and placebo infusion|Participants will start ART and will receive a single infusion of placebo at Day 0.
62076139|NCT02591420|EXPERIMENTAL|Group 2: immediate ART and VRC01 infusion|Participants will start ART and receive a single infusion of VRC01 at Day 0.
62645626|NCT02667652|ACTIVE_COMPARATOR|long biliarypancreatic limb|long biliarypancreatic limb
62076140|NCT02591420|EXPERIMENTAL|Group 3: immediate VRC01 infusion and subsequent ART|Participants will receive a single infusion of VRC01 on Day 0 followed by ART initiation on Day 7.
62076141|NCT03508804|EXPERIMENTAL|Lidocaine-prilocaine cream|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the lidocaine-prilocaine cream vaginally using a syringe
62076142|NCT03508804|PLACEBO_COMPARATOR|Placebo cream (pain lucubrating gel)|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the placebo cream vaginally using a syringe
62076143|NCT03146858|EXPERIMENTAL|Enoxaparin|The patients will receive a 3-6 hour infusion of enoxaparin. The effects of the infusion will be assess when used on patients will acute heart attacks and undergoing emergency treatment with PPCI.
62076144|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
62076145|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
62076146|NCT02475291||Significant coronary lesions|Significant lesions with more than 70% diameter stenosis at proximal major coronary arteri(es).
62076147|NCT01464255|EXPERIMENTAL|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
62076148|NCT01464255|ACTIVE_COMPARATOR|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
62076149|NCT00252590|EXPERIMENTAL|Health Motivational Feedback|Personalized health-related feedback
62076150|NCT00252590|ACTIVE_COMPARATOR|Health Education|Non-personalized didactic health-related education
62076151|NCT00252590|ACTIVE_COMPARATOR|Control - treatment as usual|No added treatment control
62279620|NCT01647607|EXPERIMENTAL|Young Women's Intervention (YWI)|This arm involves administration of an educational intervention that focuses on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
62645627|NCT03055871|NO_INTERVENTION|Standard education control group|The control group package will consist of Canada's PA guidelines recommending 180 min per week for young children, transitioning to 60 minutes of activity a day for children at five and a breakdown of ways for the parent to help their child achieve this PA (unstructured, endurance, strength, activities) commensurate with this guide. The guide also contains arguments and information about the benefits of PA.
62645628|NCT03055871|OTHER|Physical activity planning intervention|The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercise for children where they list physical activities that they have found fun in the past, as well as activities that they would find enjoyable to do as a family.
62645629|NCT03055871|OTHER|Habit formation intervention|The habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines, or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
62076152|NCT04022889|EXPERIMENTAL|Stage 1|The study will be performed in two stages. Stage 1 is a randomized, 2-period crossover design. Test platelets stored for 7 days will be radiolabeled based on either the BEST or Variant 1 methods (depending on the period and randomization scheme for the Test platelets) for 12 healthy subjects. The recovery and survival for Test platelets prepared with the BEST and Variant 1 methods will be compared with each other and against the fresh platelet Control. With agreement from the FDA (BQ200481, July 8, 2020), completion of Stage 1 is not required.
62076153|NCT04022889|EXPERIMENTAL|Stage 2|Stage 2 is a single arm design. Test platelets from 24 healthy subjects, stored for 7 days, will be prepared for radiolabeling following the Variant 1 methodology. The recovery and survival for Test platelets will be compared against the fresh platelet Control. Stage 1 subjects with evaluable Variant 1 method data will contribute to the requirement of the 24 subjects for Stage 2.
62076154|NCT05294874|ACTIVE_COMPARATOR|classical gait training|physical therapy exercises including classical gait training
62076155|NCT05294874|ACTIVE_COMPARATOR|classical gait training using ankle weight|physical therapy exercises including classical gait training while using ankle weight
62279621|NCT01647607|ACTIVE_COMPARATOR|Physical Activity Intervention (PAI)|This arm involves administration of an educational intervention that focuses on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
62279622|NCT05443204|EXPERIMENTAL|Standard Formula (Fortimel)|Fats 35% total caloric volume (VCT) Carbohydrates: 49% del VCT Proteins: 16% del VCT Density: 1.5 kcal/ ml
62456526|NCT04888910||asthma with nasal polyps|severe asthma with involvement of the upper airways (chronic rhinosinusitis with nasal polyps)
62076156|NCT05294874|EXPERIMENTAL|gait training using ankle weight after botulinum toxin injection|physical therapy exercises including classical gait training while using ankle weight and with BOTOX injection
62076157|NCT03488290|EXPERIMENTAL|LTP Plus TF CBT|LTP Plus TF CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
62076158|NCT03488290|OTHER|Treatment as Usual|TAU group will receive routine care consisting of routine follow ups
62279623|NCT05443204|EXPERIMENTAL|Specific formula for diabetes (Nutrision Advanced)|Fats: 46% del VCT (60% monounsaturated fatty acids) Carbohydrates: 31% del VCT Proteins: 21% del VFiber: 2% VCT (80% soluble y 20% insoluble) Density: 1.5kcal/ml
62076159|NCT01023880|EXPERIMENTAL|1|CEP-18770
62076160|NCT01972334|EXPERIMENTAL|FMT or fecal microbial transplant|intervention is fecal microbial transplant done through endoscopy, subjects will be randomized 1:1 to receive either FMT or placebo
62076161|NCT01972334|PLACEBO_COMPARATOR|placebo|1:1 randomization to FMT versus placebo (which is saline or salt water)
62076162|NCT01466296|EXPERIMENTAL|Re-Step|"Mechatronic shoe with a sole made to change slopes in the swing phase of walking.~This unpredictable change will introduce a situation of necessary adaptation to keep balance"
62076163|NCT01466296|EXPERIMENTAL|Dummy shoes|The shoes are in the same shape and weight of the Re-Step without the perturbations.
62076164|NCT01466296|ACTIVE_COMPARATOR|treadmill|A treadmill with safety adaptation and all the usual characteristics of speed and slopes of fitness treadmills.
62279624|NCT02584192|EXPERIMENTAL|the rehabilitation group|entailing an early home-based CR program
62279625|NCT02584192|OTHER|the control group|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
62076165|NCT06339294|EXPERIMENTAL|Group A (clotrimazole ointment group)|"Clotrimzole ointment~1ml dose Frequency one time application Duration one time application with aural toilet after 7 days"
62076166|NCT06339294|EXPERIMENTAL|Group B(Povidone Iodine group)|"Povidone iodine solution~1ml dose Frequency one time application Duration one time application with aural toilet after 7 days"
62279626|NCT03036293|EXPERIMENTAL|Tenoten, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
62279627|NCT03036293|PLACEBO_COMPARATOR|Placebo, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
62279628|NCT03036293|EXPERIMENTAL|Tenoten, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
62279629|NCT03036293|PLACEBO_COMPARATOR|Placebo, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
62279630|NCT06207266|EXPERIMENTAL|Participants with opioid use disorder group with emotion intelligence program (n=20)|Participants with opioid use disorder group who had emotion intelligence program to increase aware about definition, component, how to deal with EI to reduce relapse rate.
62076167|NCT06255847|EXPERIMENTAL|Reduced-dose pomalidomide/cyclophosphamide/dexamethasone (PCd) regimen group|
62076168|NCT05266664||preterm|preterm infants gestational age less than 32 weeks
62076169|NCT05266664||healthy controls|healthy term infants
62076170|NCT05744024|EXPERIMENTAL|Virtual Reality Therapy (Intervention group 1)|In addition to the standard wound care procedure, the Virtual Reality Therapy group (intervention group 1) will receive the VR system during the wound care. The VR system consists of Virtual Reality glasses, a controller and a headphone. The application SyncVR Relax \& Distract will be used, which will contain various videos for the patient those from to relax and be distracted. This group wears the VR system 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
62076171|NCT05744024|EXPERIMENTAL|Music Therapy (Intervention group 2)|In addition to the standard wound care procedure, the Music Therapy group (intervention group 2) will be hearing their preferred audio, chosen by patient to be relaxing and to offer distraction, through headphones during wound care. This group wears the headphone with music 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
62456527|NCT04888910||severe asthma without nasal polyps|severe asthma without involvement of the upper airways
62076172|NCT05744024|NO_INTERVENTION|Care as usual (control group/group 3)|The care as usual group (control group) will receive the care as usual. This group receives neither VRT nor MT during wound care.
62076173|NCT00627068||1|High cardiovascular risk age over 61 years.
62076174|NCT00627068||2|Low Cardiovascular risk age over 61.
62076175|NCT00627068||3|High cardiovascular risk age over 25 but under 61.
62076176|NCT00627068||4|Low cardiovascular risk age over 25 under 61.
62076177|NCT03507543|EXPERIMENTAL|IMP4297|
62279631|NCT06207266|NO_INTERVENTION|Participants with opioid use disorder group without intelligence program (n=20).|Participants with opioid use disorder group who had traditional medical treatment only
62279632|NCT06207266|NO_INTERVENTION|A healthy group (n=20) served as a control group.|A healthy group who did not have history of psychiatric illness or substance use.
62279633|NCT02604940|EXPERIMENTAL|dexmedetomidine|Experimental group will receive 1mcg/kg IV dexmedetomidine over 10 minutes intraoperatively at the beginning of surgical closure
62645630|NCT02524119|EXPERIMENTAL|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
62645631|NCT04665908|OTHER|PT-led triage|Patients are assessed by PT
62645632|NCT04665908|OTHER|Standard care|The patiens are assessed by a orthopedic surgeon
62645633|NCT00514085|EXPERIMENTAL|Recombinant human interleukin-21|
62645634|NCT05524142||Atrial fibrillation|Patients with atrial fibrillation underwent radiofrequency ablation.
62645635|NCT05524142||Control|Patients underwent electrophysiological examination alone and were confirmed no arrhythmia.
62645636|NCT05500586|EXPERIMENTAL|Healthy Adults|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
62645637|NCT05500586|EXPERIMENTAL|Obese Adults|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
62645638|NCT05500586|EXPERIMENTAL|Adults with Type 2 Diabetes|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
62645639|NCT02217956|EXPERIMENTAL|HCIP + bevacizumab|"4 dose level of cisplatin are planned: Level 1 : 50 mg/m2 (start level) Level 2 : 60 mg/m2 Level 3 : 70 mg/m2 Level 4 : 80 mg/m2 Level -1: 40 mg/m2 (in case of DLT at level 1)~bevacizumab: Treatment starts between week 10 and 14 after HCIP. Dosage: 15 mg/kg for a total of 22 injections every 3 weeks for 15 months"
62645640|NCT05925192||Chronic musculoskeletal pain patients|Chronic musculoskeletal pain patients
62279634|NCT02604940|ACTIVE_COMPARATOR|Normal Saline|Control group will receive Normal saline over 15 minutes at the beginning of surgical closure
62645641|NCT00469131|ACTIVE_COMPARATOR|1 Drug:|tacrolimus + steroid
62645642|NCT00469131|ACTIVE_COMPARATOR|2 Drug:|tacrolimus + mycophenolate mofetil
62645643|NCT00427934|PLACEBO_COMPARATOR|2|
62645644|NCT00427934|EXPERIMENTAL|1|This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
62279635|NCT04044833||intervention|(n=63)
62279636|NCT04044833||control|(n=65)
62645645|NCT00217490|EXPERIMENTAL|Computer Only|Dietary Counseling delivered by interactive computer program, without the addition of individual counseling provided by a health counselor. This arm tested a completely automated counseling program that did not include personalized behavioral counseling provided by a study staff member.
62645646|NCT00217490|EXPERIMENTAL|Counseling only|In this arm, dietary counseling was delivered by nutritionist, and this counseling did not include use of an automated, computer program.
62076178|NCT01346761|EXPERIMENTAL|Telephone genetic counseling|Participants randomly assigned to telephone counseling are mailed packets that included a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer (HBOC) genetic counseling with visual aids. At the time of their session, participants open their envelope and counselors use the visual aids to explain breast-ovarian cancer genetics and administer BRCA1/BRCA2 genetic counseling. Women receiving in-person counseling are given these same materials during their session at the community clinic. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
62456528|NCT01333527|EXPERIMENTAL|Group A (early ROM)|Group A (early ROM) will use the sling for comfort only
62456529|NCT01333527|ACTIVE_COMPARATOR|Group B (usual care)|Group B (usual care) will be immobilized in a sling for 6 weeks.
62456530|NCT05395858||Hemophilia A patients|Patients will be identified via standard medical charts or electronic medical records (EMRs).
62456531|NCT05602519|ACTIVE_COMPARATOR|Group fentanyl|Patients will receive 50 ug of fentanyl 20 min before the end of surgery.
62456532|NCT05602519|ACTIVE_COMPARATOR|Group oxycodone|Patients will receive 4 mg of oxycodone 20 min before the end of surgery.
62645647|NCT00217490|EXPERIMENTAL|Combined|In this arm, participants received dietary counseling delivered using both the automated computer program and additional counseling by a study nutritionist. That is, this arm combined the intervention programs delivered in the other two active intervention arms.
62645648|NCT00217490|ACTIVE_COMPARATOR|Physical Activity-computer|Participants assigned to this arm did not receive nutrition counseling, but they were provided physical activity counseling delivered by computer only.
62645649|NCT05004090||children with ND|children with neurodevelopmental disabilities (ND) age between 3 and 24 months (chronologically or corrected in the case of children born preterm).
62645650|NCT05004090||Typical developed children (TD)|children with typical development age between 3 and 24 months (chronological).
62645651|NCT05496023||Pre PCI state|The current study will analyze the angio-FFR and generate the virtual pullback. The pullback will be co-registered by overlaying the pullback onto coronary angiogram.
62645652|NCT05496023||Post-PCI state|The post-PCI FFR and angio-FFR will be meaured.
62645653|NCT05470452|EXPERIMENTAL|Physician AI-assisted diagnosis group|
62645654|NCT05470452|SHAM_COMPARATOR|Physician Independent Diagnostic Group|
62645655|NCT01236924|EXPERIMENTAL|Lifestyle counseling|
62645656|NCT01311219|ACTIVE_COMPARATOR|No surgery|Non-operative Treatment
62645657|NCT01311219|ACTIVE_COMPARATOR|Plate fixation|Operative Treatment-Plate fixation
62645658|NCT01311219|ACTIVE_COMPARATOR|Intramedullary pinning|Operative Treatment-Intramedullary Pinning
62456533|NCT00440557|EXPERIMENTAL|TIW: Epoetin alfa 3 injections Weekly/Once Weekly|Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
62456534|NCT00440557|EXPERIMENTAL|QW: Epoetin alfa once weekly|Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
62456535|NCT00440557|EXPERIMENTAL|Q2W: Epoetin alfa once every two weeks|Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
62645659|NCT00963534|EXPERIMENTAL|lenalidomide, bendamustine, rituximab|
62645660|NCT04236843|ACTIVE_COMPARATOR|Smal intestine once|90-g fecal transplant given into the small intestine once.
62456536|NCT05287594|EXPERIMENTAL|TRAINER|The TRAINER group will receive an integrated exercise program, led by a peer-trainer, including a neuromuscular warm-up and high intensity interval training at their respective fire stations 2 times per week for 6 weeks.
62279637|NCT02903537|EXPERIMENTAL|5 * 10 ^6 tolDC-VitD3|5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
62279638|NCT02903537|EXPERIMENTAL|10 * 10 ^6 tolDC-VitD3|10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
62279639|NCT02903537|EXPERIMENTAL|15 * 10 ^6 tolDC-VitD3|15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
62279640|NCT02903537|EXPERIMENTAL|Interferon-beta|Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied
62279641|NCT04580290||JewelACL + Autograft (Hybrid)|JewelACL + Autograft (Hybrid)
62279642|NCT04580290||JewelACL only|JewelACL only
62279643|NCT04498845|ACTIVE_COMPARATOR|Basic intervention group|Participants in the basic intervention group will have a 1-hour in-home assessment plan and family educational session.
62279644|NCT04498845|EXPERIMENTAL|Intermediate intervention group|Participants in the intermediate intervention group will have a 1-hour in-home assessment plan and educational session and refer worker to a 1-hr worker take home prevention educational session.
62279645|NCT04498845|EXPERIMENTAL|Advanced intervention group|Participants in the advanced intervention group will have a 1-hour in-home assessment plan and educational session, refer worker to a 1-hr worker take home prevention educational session, and provision of D-LEAD all-purpose cleaner and laundry detergent.
62279646|NCT05644366|EXPERIMENTAL|Balance Assessment Children with Autism|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
62279647|NCT01548001|EXPERIMENTAL|Iguratimod monotherapy|
62076179|NCT01346761|ACTIVE_COMPARATOR|In-person genetic counseling|In-person BRCA1/BRCA2 genetic counseling is delivered by board-certified genetic counselors using a guide-line-concordant semistructured protocol that allows for personalization of counseling and is similar to that used by others. All sessions are audiotaped for treatment fidelity assessments. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
62279648|NCT01548001|EXPERIMENTAL|Iguratimod and MTX combination|
62645661|NCT04236843|ACTIVE_COMPARATOR|Small intestine twice|90-g fecal transplant given into the small intestine twice with 1 week interval.
62645662|NCT04236843|ACTIVE_COMPARATOR|Large intestine once|90-g fecal transplant given into the large intestine once.
62279649|NCT01548001|ACTIVE_COMPARATOR|MTX monotherapy|
62279650|NCT03993366|EXPERIMENTAL|Simple Meal Announcement|Before every meal, the meal will be simply announced to the algorithm by a member of the study team. Meal bolus computation will be independent of the carbohydrate content of the meal.
62279651|NCT03993366|ACTIVE_COMPARATOR|Full Carbohydrate counting|The carbohydrate content of the meal selected by the participant will be entered into the dosing algorithm by a member of the study team at the onset of the meal to compute the insulin prandial bolus.
62279652|NCT05599997|EXPERIMENTAL|Healthy|Age-, weight- and gender- matched control group of healthy volunteers received a single oral dose of 30 mg BAY1753011 tablet.
62279653|NCT05599997|EXPERIMENTAL|Mild renal impairment|Subjects with mild renal impairment received a single oral dose of 30 mg BAY1753011 tablet.
62279654|NCT05599997|EXPERIMENTAL|Moderate renal impairment|Subjects with moderate renal impairment received a single oral dose of 30 mg BAY1753011 tablet.
62279655|NCT05599997|EXPERIMENTAL|Severe renal impairment|Subjects with severe renal impairment received a single oral dose of 15 mg BAY1753011 tablet.
62456537|NCT05287594|NO_INTERVENTION|Waitlist Control|The waitlist control group will not receive training during the course of the study, but will be offered the opportunity to receive the integrated exercise program after the study ends.
62456538|NCT00804661||1|Children and adults with cystic fibrosis
62456539|NCT00883090|EXPERIMENTAL|FXIII|All subjects treated with Factor XIII Concentrate (Human) (FXIII)
62645663|NCT06542367|EXPERIMENTAL|"Transcanal tympanoplasty under local anasthesia with fat graft and Tachosil"|"eligibale participatns with chronic tympanic membrane perforation will be offered to participate.~Under local anesthesia, subcutaneous fat from the neck will be harvested. After that trimming of the perforation edges, planting the fat graft medial to the tympanic membrane and placement of the Tachosil on top of the fat graft.~gelfoam is placed lateral to the tympanic membrane fo fill the ear canal. follow-up will be held at 2, 4-6 and 12 month following the procedure, with audiometric and otological evaluation"
62645664|NCT04224246|EXPERIMENTAL|One arm with Gamma-OH® treatment|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours between 10 p.m. to 4 a.m.
62645665|NCT05465395|EXPERIMENTAL|Upper Cervical Adjustment|Upper cervical adjustemnt
62645666|NCT05465395|ACTIVE_COMPARATOR|Thoracic Adjustment|Thoracic adjustment
62645667|NCT04390165||Malaysian COVID-19 Cohort|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
62645668|NCT03054142||AKI|
62645669|NCT03054142||non-AKI|
62645670|NCT03175796|EXPERIMENTAL|IMH-HV Treatment Group|Infant Mental Health-Home Visiting. Weekly home visits for up to one year by a trained IMH-HV treatment provider. Treatment delivery consistent with the IMH-HV manual.
62645671|NCT03175796|NO_INTERVENTION|Treatment as Usual Control Group|No intervention provided as part of participation in this study; families are free to access community resources including any available treatment(s) in the community.
62645672|NCT06332222|ACTIVE_COMPARATOR|Vistula Tart Cherry|Supplemented with tart cherries.
62076180|NCT05419882||colorectal surgery patients|In patients undergoing colorectal surgery, blood samples will be collected at 5 times: preoperatively, and at 2, 6, 24 and 48 hours after finishing surgery, respectively.
62645673|NCT06332222|PLACEBO_COMPARATOR|Placebo|Supplemented with a calorie matched placebo.
62645674|NCT00746369|NO_INTERVENTION|2|
62645675|NCT00746369|EXPERIMENTAL|Intervention|IMARA HIV Prevention Intervention. Three individual sessions for incarcerated female teens.
62645676|NCT05553405|NO_INTERVENTION|Baseline [11C]PBR28 PET Scan|Subjects will complete a 120-minute baseline \[11C\]PBR28 PET scan.
62076181|NCT02670538|EXPERIMENTAL|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
62076182|NCT02670538|EXPERIMENTAL|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
62076183|NCT02670538|PLACEBO_COMPARATOR|Placebo|Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
62076184|NCT00714350||Simulator Group - With Display|ICU nurses who viewed the new ICU display visualization
62076185|NCT00714350||Simulator Group - Without Display|"ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional spreadsheet style presentation of ICU trends of data"
62076186|NCT01554982|OTHER|Ferric Citrate|Open label extension of those completing study KRX-0304
62645677|NCT05553405|EXPERIMENTAL|Post-Intralipid Infusion [11C]PBR28 PET Scan|Subjects will complete a second 120-minute \[11C\]PBR28 PET scan 4 hours after Intralipid Infusion
62645678|NCT05671081|ACTIVE_COMPARATOR|General anethesia +Dexmedetomidine plus Bupivacaine for Erector spinae plane block|
62645679|NCT05671081|ACTIVE_COMPARATOR|General anethesia +Magnesium sulfate plus Bupivacaine for Erector spinae plane block|
62076187|NCT03467438|EXPERIMENTAL|A|Zinc-l-carnosine, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
62076188|NCT03467438|PLACEBO_COMPARATOR|B|Placebo, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
62076189|NCT02142920|EXPERIMENTAL|[14C] PF 05212384|Receive PF-05212384 89 mg Dose
62076190|NCT01482650|EXPERIMENTAL|Baska mask|
62076191|NCT01482650|ACTIVE_COMPARATOR|single use laryngeal mask airway (LMA)|
62076192|NCT00612404||1|patients with gastrointestinal disorders who need an endoscopy.
62645680|NCT05671081|ACTIVE_COMPARATOR|general anesthesia+conventional postoperative narcotic analgesia|
62645681|NCT03642990|EXPERIMENTAL|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
62645682|NCT01670370|EXPERIMENTAL|Rituximab+Gemcitabine+oxaliplatin (R-GemOx)|Rituximab: 375 mg/m2 IV day1, Gemcitabine 1g/m2 IV day 2, oxaliplatin 100mg/m2 IV day2(every 14 days)
62076193|NCT00366860|EXPERIMENTAL|Soy bread|Soy bread (75-100 mg isoflavone/day) for 12 weeks
62076194|NCT00366860|ACTIVE_COMPARATOR|Wheat bread|Wheat bread for 12 weeks
62076195|NCT01903343||Healthy Volunteers|Single group of healthy male medical students at Ninewells Hospital \& Medical School, Dundee.
62076196|NCT04406337|EXPERIMENTAL|Low intensity pulsed ultrasound|Participants in this arm will receive low intensity pulsed ultrasound therapy on the affected knees for 20 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
62076197|NCT04406337|ACTIVE_COMPARATOR|High intensity continuous ultrasound|Participants in this arm will receive high intensity continuous ultrasound therapy on the affected knees for 10 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
62076198|NCT04169581||Experimental Group|The experimental group received 18F-FDG PET examination
62076199|NCT04169581||Control Group|The control group received 18F-FDG PET examination
62076200|NCT00003095||bone marrow transplant|bone marrow transplant
62076201|NCT00003095||standard chemotherapy|standard chemotherapy
62456540|NCT05127577|EXPERIMENTAL|Abdominal massage group|Abdominal massage will be applied to the experimental group 2 times a day, morning and evening, until defecation, starting in the evening of the first day after the surgical intervention.
62279656|NCT03382574|EXPERIMENTAL|Arm I (denosumab, risk-reducing salpingo-oophorectomy)|Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.
62076202|NCT04842994|EXPERIMENTAL|IONM arm|Intra operative nerve monitoring (IONM) is a technique of monitoring the RLN during surgery, to help identification and safe guarding of the nerve during total thyroidectomy as well as central compartment clearance (CCC). This is a well established technique with many centers in the world routinely using monitoring during surgery.
62076203|NCT04842994|NO_INTERVENTION|Visual Identification arm|Patients randomized to this arm will undergo total thyroidectomy as per standard procedures with visual identification of the RLNs
62076204|NCT06230302|EXPERIMENTAL|Kefir Postbiotics Group|"* 30 healthy adult participants~* Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~* Period of use: 12 months~* Storage method: Store at room temperature~* Manufacturing method: The whey postbiotics derived from kefir lactic acid bacteria used in the test food are produced in the laboratory at Hanyang University, and additional ingredients are purchased from finished products. Laboratory collects the ingredients and delivers them to the manufacturer, Neo Natural, to manufacture them so that there are no differences in properties and formulations."
62076205|NCT06230302|PLACEBO_COMPARATOR|Control Group|"* 30 healthy adult participants~* Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~* Period of use: 12 months~* Storage method: Store at room temperature~* Manufacturing method: The same product without whey postbiotics."
62645683|NCT05810402|EXPERIMENTAL|BCLC B and C HCC patients|"For each participant, 30mL of blood will be collected at inclusion/before treatment initiation (baseline) and during standard of care follow-up.~The blood sample will be taken, in consultation or in outpatient clinic during a blood test for health purposes."
62645684|NCT05571111|EXPERIMENTAL|Dose 1 of FE 999302|Subcutaneous injection of Dose 1 of FE 999302 as a single dose.
62645685|NCT05571111|EXPERIMENTAL|Dose 2 of FE 999302|Subcutaneous injection of Dose 2 of FE 999302 as a single dose.
62279657|NCT03382574|ACTIVE_COMPARATOR|Arm II (risk-reducing salpingo-oophorectomy)|Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.
62279658|NCT04541004|EXPERIMENTAL|HDM SLIT Tablet|House dust mite (HDM) Sublingual allergy immunotherapy tablet
62279659|NCT06000358|ACTIVE_COMPARATOR|Cryotherapy and Pembrolizumab monotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab monotherapy (PD-L1 expression equal to or greater than 50%, no EGFR mutations or ALK translocations). Bronchoscopic cryotherapy procedure is performed before the start of systemic treatment.
62456541|NCT05127577|NO_INTERVENTION|Control group|The control group will be received routine treatment and care in the unit.
62645686|NCT05571111|EXPERIMENTAL|Dose 3 of FE 999302|Subcutaneous injection of Dose 3 of FE 999302 as a single dose.
62645687|NCT05571111|ACTIVE_COMPARATOR|250 μg OVITRELLE|Subcutaneous injection of 250 μg of OVITRELLE. 0.5 mL as a single dose.
62645688|NCT05571111|ACTIVE_COMPARATOR|10,000 IU NOVAREL|"Subcutaneous injection of 10,000 IU NOVAREL.~1 mL as a single dose."
62645689|NCT05717998||Ancillary-correlative (CMR, PET/CT, biospecimen collection)|Within 2 weeks of starting RT, patients undergo CMR, cardiac PET/CT and blood sample collection at baseline, then between fractions 12-17 of RT and at 6 months after completion of RT.
62645690|NCT00621790|EXPERIMENTAL|Fenoldopam|Fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min) for up to 4 days
62645691|NCT00621790|PLACEBO_COMPARATOR|Placebo|Placebo (normosaline), continuous perfusion
62645692|NCT05247762|SHAM_COMPARATOR|Sham acupuncture group|Use Wangbuliu Xingzi Paste on the skin, once a week, once for 20 minutes, for 24 weeks.
62645693|NCT05247762|EXPERIMENTAL|Acupuncture group|Use stainless steel needles on the skin, once a week, once for 20 minutes, for 24 consecutive weeks.
62645694|NCT02552927|EXPERIMENTAL|CALF|Chest shield with aluminum foil
62645695|NCT02552927|SHAM_COMPARATOR|SHIELD|Chest shield without aluminum foil
62076206|NCT05595421|EXPERIMENTAL|The right cerebellum (anode) and the left OFC (cathode) tDCS|Stimulation sessions will be carried out using a neuroConn DC stimulator (Ilmeneau, GmbH) with two rubber electrodes placed inside two 5 × 7 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). Electrodes will be placed on the basis of the international 10-20 electrodes placement system. The cathode will be placed over the left OFC on the FP1 point according to the EEG international reference. The anode will be placed over the right cerebellum 3 cm below the inion and 1 cm right from the midline. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
62645696|NCT05890079|ACTIVE_COMPARATOR|Subcostal transversus abdominis plane block group|The patients in subcostal transversus abdominis plane block group will be received subcostal transversus abdominis plane block and patient controlled analgesia with morphine for postoperative analgesia
62645697|NCT05890079|ACTIVE_COMPARATOR|External oblique intercostal plane block group|The patients in External oblique intercostal plane block group will be received external oblique intercostal plane block and patient controlled analgesia with morphine for postoperative analgesia
62645698|NCT04510272|EXPERIMENTAL|High risk critically ill patients|Critically ill patients requiring vasopressor support or mechanical ventilation will receive aloud real time ICU diary reading intervention
62645699|NCT04539977|EXPERIMENTAL|LS-SCLC Surgery|"Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles.~Surgery (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3 + Carboplatin,AUC5 (ivgtt, q3w,Two cycles) + TQB24501200mg, d1 (ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen \[except radiotherapy\], withdrawal of informed consent or death)."
62645700|NCT04539977|EXPERIMENTAL|LS-SCLC Radiotherapy|"Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles.~Radiotherapy (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3+Carboplatin,AUC5 (ivgtt, q3w,Two cycles)+TQB24501200mg, d1(ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen \[except radiotherapy\], withdrawal of informed consent or death)."
62645701|NCT02392780|EXPERIMENTAL|Cannabidiol|
62645702|NCT04579809|ACTIVE_COMPARATOR|children below six years|children below sex years both genders
62645703|NCT04579809|ACTIVE_COMPARATOR|cooperative children|repair of the tendos by modified kessler
62645704|NCT01403662|EXPERIMENTAL|Minocycline|
62645705|NCT00623532|EXPERIMENTAL|CA|"Cognition and action are an inseparable whole while functioning, a new intervention based approach using familiarity based movements and non judgmental approach was labeled cognition-action."
62645706|NCT00623532|ACTIVE_COMPARATOR|AT|Adapted Tai Chi is based on Tai Chi like movements
62645707|NCT00623532|NO_INTERVENTION|C|Control
62456542|NCT01806922|EXPERIMENTAL|Yoga training, Tradiational physiotherapy|Experimental Group(20 people) receive tradiational physiotherapy(4 times in a week, every time 1 hour), and 8-weeks yoga training(2 time in a week, every time 1 hour)
62456543|NCT01806922|NO_INTERVENTION|Tradiational physiotherapy|Control Group(20 people)only receive tradiational rehabiliation( 4 times in a week, every time 1 hour ) for 8 weeks.
62456544|NCT01242865|OTHER|Attention and Interpretation Therapy|
62076207|NCT05595421|EXPERIMENTAL|The bilateral pre-SMA (cathode) and right deltoid (reference) tDCS|Stimulation sessions will be carried out using a neuroConn DC stimulator (Ilmeneau, GmbH). The stimulator is connected to two rubber electrodes which are placed inside two sponge electrodes soaked in a saline solution (0.9% NaCl), respectively. The active electrode (cathode) is 5×5 cm and placed on the sagittal midline at 15% of the distance between inion and nasion anterior to Cz (vertex), using the International 10-20 EEG System, to target the bilateral presupplementary motor area (pre-SMA). The reference electrode is 5×7 cm and placed on the lateral surface of the patient's right deltoid. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
62076208|NCT05595421|EXPERIMENTAL|The left OFC (cathode 1), bilateral pre-SMA (cathode 2), and right deltoid (reference) tDCS|Stimulation sessions are carried out using a neuroConn DC stimulator (Ilmeneau, GmbH). The stimulator is connected to a 2 × 1 wire adaptor (Equalizer Box, NeuroConn) that links three rubber electrodes placed inside sponge electrodes soaked in a saline solution (0.9% NaCl) will be applied. One active electrode (the 1st cathode) is 5×5 cm and placed on the sagittal midline at 15% of the distance between inion and nasion anterior to Cz (vertex), using the International 10-20 EEG System, to target the bilateral presupplementary motor area (pre-SMA). The other active electrode (the 2nd cathode) is 5×7 cm and placed over the left OFC on the FP1 point according to the EEG international system. The reference electrode is 5×7 cm and placed on the lateral surface of the patient's right deltoid. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
62456545|NCT04646109|NO_INTERVENTION|Control Group|"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with PCR positivity in respiratory tract samples were included into the study. They were randomized to the control and study group, respectively. Hydroxychloroquine, favipiravir and azithromycin (HFA) standard treatment protocol were given to the control group as recommended in the COVID-19 (SARS-CoV-2 Infection) Guide prepared by the Republic of Turkey Ministry of Health."
62456546|NCT04646109|EXPERIMENTAL|Study Group|In addition to HFA treatment, ivermectin 200 micrograms/kg/day (9mg between 36-50 kg, 12mg between 51-65 kg, 15mg between 66-79 kg and 200 micrograms/kg in \> 80 kg) in the form of a solution prepared for enteral use was added (HFA+I) to the treatment protocol of the study group's for five days. Blood sample was taken with the first dose of ivermectin and haplotype analysis was performed in ABCB1 and CYP3A4 genes in the whole study group.
62456547|NCT05780541|EXPERIMENTAL|PF-07304814 plus SOC|"* PF-07304814 250 mg per day for 5 days; administered as a constant rate IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62456548|NCT05780541|PLACEBO_COMPARATOR|Placebo plus SOC|"* Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62456549|NCT01189669|ACTIVE_COMPARATOR|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
62456550|NCT01189669|PLACEBO_COMPARATOR|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
62456551|NCT01189669|NO_INTERVENTION|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
62456552|NCT03602326|EXPERIMENTAL|Neurodevelopmental Therapy-Bobath group|Bobath Approach Principles and exercises will be performed 5 days a week with physical therapists and everyday with caregivers. Physiotherapy will be initiated as early as possible according to the principles of the method by experienced NDT-B therapists. Exercises will be implemented according to the patients' status and will be used to maintain and improve muscle strength and endurance. Both the unaffected and affected side will be included in rehabilitation. The exercises given are designed to be simple, understandable, task-oriented and repetitive, in accordance with the Bobath approach and the functional state of the patient at that time. In order to prevent motor amnesia and neglect of the affected side, correct positioning and sensory input will be provided since the first session.
62456553|NCT03602326|ACTIVE_COMPARATOR|Standart Rehabilitation Group (SR group)|Patients will be included in standard rehabilitation sessions, 5 days per week. The rehabilitation sessions will be performed by standard clinical physiotherapists according to the hospital routine. The rehabilitation program will consist of in-bed joint range of motion exercises and bedside mobilization applications. The patients will be included in the rehabilitation program as early as possible and the program will continue until the patients are discharged
62456554|NCT03030066|EXPERIMENTAL|Experimental Drug DS-1001b|Oral administration
62456555|NCT05960526|ACTIVE_COMPARATOR|nasal irrigation with Saline group|The patient uses nasal irrigation with saline only and then mixed with 300 ml of water. The treatment was done by tilting the head 45 degrees, then spraying 150 ml of liquid on one side and repeating it on the other. The treatment was done twice daily (morning and evening) for 14 days.
62279660|NCT06000358|ACTIVE_COMPARATOR|Cryotherapy and Pembrolizumab with platinum-based chemotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab and platinum-based chemotherapy (PD-L1 expression less than 50%, no EGFR mutations or ALK translocations). Bronchoscopic cryotherapy procedure is performed before the start of systemic treatment.
62279661|NCT06000358|ACTIVE_COMPARATOR|Pembrolizumab monotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab monotherapy (PD-L1 expression equal to or greater than 50%, no EGFR mutations or ALK translocations).
62456556|NCT05960526|EXPERIMENTAL|nasal irrigation with Saline combination with binahong extract|The patient uses nasal irrigation with saline and combination with Binahong Extract 2,5% and then mixed with 300 ml of water. The treatment was done by tilting the head 45 degrees, then spraying 150 ml of liquid on one side and repeating it on the other. The treatment was done twice daily (morning and evening) for 14 days.
62456557|NCT01822600|EXPERIMENTAL|Normal albumin group|"Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L.~Patients in this group receive intravenous omeprazole treatment."
62456558|NCT01822600|EXPERIMENTAL|Intervention group|"Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin \< 30 g/L.~Patients in this group receive both Human albumin and intravenous omeprazole."
62456559|NCT01822600|EXPERIMENTAL|Cohort control group|"The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level \< 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group.~Patients in this group receive intravenous omeprazole treatment."
62456560|NCT01739790|PLACEBO_COMPARATOR|Sugar Pill|Identical placebo pills twice daily for 8 weeks Placebo pills manufactured to mimic appearance of intervention drug n-acetylcysteine and prescribed with identical frequency and duration.
62456561|NCT01739790|ACTIVE_COMPARATOR|N-Acetylcysteine|1800 mg twice daily for 8 weeks
62456562|NCT03815838|EXPERIMENTAL|PET imaging|18F-FDOPA and 18F-Fallypride PET imaging
62456563|NCT02485808||Surgical|"Men and women presenting for clinical care for whom surgical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
62456564|NCT02485808||Medical|"Men and women presenting for clinical care for whom medical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
62645708|NCT04997304|EXPERIMENTAL|AirDuo and ProAir|This trial includes using the inhaler (AirDuo®) Digihaler™ and rescue inhalers (ProAir®) Digihaler™.
62645709|NCT05926609|ACTIVE_COMPARATOR|EB-PA|One capsule to be taken after breakfast once a day for 30 days
62645710|NCT05926609|PLACEBO_COMPARATOR|Placebo|One capsule to be taken after breakfast once a day for 30 days
62645711|NCT02948816|EXPERIMENTAL|Facebook|Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
62279662|NCT06000358|ACTIVE_COMPARATOR|Pembrolizumab with platinum-based chemotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab and platinum-based chemotherapy (PD-L1 expression less than 50%, no EGFR mutations or ALK translocations).
62279663|NCT01061450|PLACEBO_COMPARATOR|Placebo|Placebo
62279664|NCT01061450|EXPERIMENTAL|Simvastatin|Simvastatin 80 mg/day
62456565|NCT02485808||Controls|"Men and women who are not experiencing lower urinary tract symptoms.~This group will undergo MRI, pain and auditory sensitivity testing."
62456566|NCT02485808||Neuroimaging & Sensory Testing|"Subjects from the Medical and Surgical Cohorts who agree to additional testing in the form of neuroimaging (via fMRI) and multimodal sensory testing.~This group will undergo MRI, pain and auditory sensitivity testing."
62456567|NCT02920996|EXPERIMENTAL|NSCLC (Met Exon 14 Mutation)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
62456568|NCT02920996|EXPERIMENTAL|Solid Tumor (NTRK1,2,3 Rearrangement)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
62645712|NCT02948816|EXPERIMENTAL|Facebook + Food|Participants will spend 30 minutes interacting with a Facebook page that is made up of 70% food-related posts, and 30% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
62076209|NCT01929330|EXPERIMENTAL|Sequence AB|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A), in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subject will receive or 5 x 0.1mg oral dose of dutasteride (Sequence B) in similar fashion as that of Sequence A. The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
62076210|NCT01929330|EXPERIMENTAL|Sequence BA|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 5 x 0.1mg oral dose of dutasteride (Sequence B) in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A) in similar fashion as that of Sequence B, The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
62076211|NCT00262288|EXPERIMENTAL|Recombinant Human C1INH|
62456569|NCT00339768|EXPERIMENTAL|Amox/omepr|2 weeks; placebo controlled
62456570|NCT00339768|EXPERIMENTAL|Garlic|Supplement for 7 years; placebo controlled
62645713|NCT02948816|ACTIVE_COMPARATOR|Colouring|Participants will spend 30 minutes colouring. They will be provided with bowls of snacks, which will be weighed before and after their session.
62456571|NCT00339768|EXPERIMENTAL|Vitamins|Supplement for 7 years; placebo controlled
62645714|NCT03120611|EXPERIMENTAL|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
62076212|NCT04466618|PLACEBO_COMPARATOR|Saline|Saline infusion
62076213|NCT04466618|ACTIVE_COMPARATOR|Exendin-9,39|Exendin-9,39 infusion
62076214|NCT04466618|ACTIVE_COMPARATOR|Saline + Intralipid/Heparin|Induction of acute insulin resistance during Saline infusion
62076215|NCT04466618|ACTIVE_COMPARATOR|Exendin-9,39 + Intralipid/Heparin|Induction of acute insulin resistance during Exendin-9,39 infusion
62076216|NCT03555578||Leuprorelin Acetate 11.25 mg|Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
62076217|NCT02361593|EXPERIMENTAL|Cap group|Patients will receive endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices with assistance of a transparent cap in front of gastroscopy.
62076218|NCT02361593|ACTIVE_COMPARATOR|Control group|Patients will receive routine endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices(no transparent cap involved).
62076219|NCT02835443|EXPERIMENTAL|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
62076220|NCT02036515|EXPERIMENTAL|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily for 52 weeks
62076221|NCT02036515|EXPERIMENTAL|Ertugliflozin 15 mg|Ertugliflozin, 15 mg, oral, once daily for 52 weeks
62076222|NCT02036515|PLACEBO_COMPARATOR|Placebo|Matching placebo to ertuglifozin, oral, once daily for 52 weeks
62076223|NCT03681262|EXPERIMENTAL|High frequency spinal cord stimulation|Implant of the device that can deliver high frequency waveform to spinal cord
62076224|NCT03681262|EXPERIMENTAL|Burst spinal cord stimulation|Implant of the device that can deliver burst waveform to spinal cord
62076225|NCT06286579|EXPERIMENTAL|Immediately implant placement|Atraumatic tooth extraction and immediately placement of implant with a new surface
62076226|NCT06286579|ACTIVE_COMPARATOR|Delayed implant placement|Atraumatic tooth extraction, after the site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place
62645715|NCT03120611|ACTIVE_COMPARATOR|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
62076227|NCT00003534|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62076228|NCT05921721|EXPERIMENTAL|EOS imaging system|Participants will undergo CT and EOS imaging pre- and post- operatively. The EOS is being compared to the reference method CT scan.
62076229|NCT03948867|EXPERIMENTAL|Elevated Initial Screening TCD|Those who have an elevated initial screening TCD (either conditional or abnormal TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule.
62645716|NCT03620799|EXPERIMENTAL|Intervention group|10 participants will be assigned to the intervention group in order to the inclusion criteria for the study. Experimental group. Manual therapy intervention
62456572|NCT03272139|EXPERIMENTAL|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
62645717|NCT03620799|NO_INTERVENTION|Control group|10 participants will be assigned to the control group in order to the inclusion criteria for the study. Control group
62076230|NCT03948867|EXPERIMENTAL|Normal Initial Screening TCD|Those who are found to have a normal TCD at enrolment are a part of the observation/control cohort and will undergo repeat TCD every 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the study participant will be reassigned to the elevated initial screening TCD arm and can begin study treatment (hydroxyurea), but will not be included in the primary endpoint analysis.
62076231|NCT06174974|EXPERIMENTAL|Experimental group|The patients in the experimental group will be informed by the researcher in the training room in the ward 1 day before the operation (verbal permission was obtained) with an educational presentation on intensive care unit stressors.
62076232|NCT06174974|NO_INTERVENTION|Control group|Patients in the control group will not be given preoperative training on intensive care unit stressors by the researcher. Patients in the control group will receive standard care\*.
62076233|NCT03050398|EXPERIMENTAL|ribociclib + letrozole|ribociclib with letrozole per the core study
62279665|NCT04475692|EXPERIMENTAL|Intervention|"Conventional care will continue.~Participants (and proxy, where relevant) will be trained to use the intervention platform (GripAble). Participants will be loaned a GripAble device and advised to continue a self-selected training dose throughout the intervention period.~Weekly follow-up phone calls will be conducted, remote tech support will be available. Adherence with the intervention will be remotely monitored via an inbuilt data capture system.~At 3months post stroke, the intervention period will conclude, outcome measures will be implemented. Participants will be invited to complete a post intervention survey and interview. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.~At 6months post stroke, follow-up outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
62279666|NCT04475692|ACTIVE_COMPARATOR|Control|"Baseline data collection and outcome measures will be completed.~Conventional care will continue, no restrictions/specifications will be placed on this.~At 3months post stroke, UL outcome measures will be implemented. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.~At 6months post stroke, follow-up UL outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
62645718|NCT05785962|EXPERIMENTAL|Intervention group for people with brain damage|"Other: Vojta The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
62645719|NCT05785962|EXPERIMENTAL|Intervention group for people without brain damage|"Other: Vojta The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
62645720|NCT04713072|EXPERIMENTAL|ABY-035 40 mg|40 mg ABY-035 SC
62645721|NCT04713072|EXPERIMENTAL|ABY-035 80 mg|80 mg ABY-035 SC
62645722|NCT04713072|PLACEBO_COMPARATOR|Placebo|Placebo, switching to 80 mg ABY-035 after 16 weeks
62645723|NCT01294423|EXPERIMENTAL|1|Dapagliflozin 5 mg
62645724|NCT01294423|EXPERIMENTAL|2|Dapagliflozin 10 mg
62645725|NCT01294423|PLACEBO_COMPARATOR|3|
62645726|NCT01575132||Parkinson's Disease, DBS, 10-14 years|
62645727|NCT06054386|ACTIVE_COMPARATOR|Integrated ABM (I-ABM)|The I-ABM will include four progressively difficult levels of training blocks, each containing 72 trials. Participants will be required to tap or swipe the probe in the correct direction during the first and second levels of training. The inhibitory control components will be included in the third and fourth levels, where participants should not respond to the probe under certain conditions. Each training will take 10-15 minutes, and participants will complete the sessions three times a week for three weeks.
62076234|NCT03619941|PLACEBO_COMPARATOR|Placebo|
62076235|NCT03619941|EXPERIMENTAL|Montmorency Tart Cherry Juice|
62076236|NCT01454830|EXPERIMENTAL|Tailored|Tailored, or individualized, intervention addressing patient education, skills training, and cognitive perceptions
62645728|NCT06054386|PLACEBO_COMPARATOR|Placebo Training (PLT)|The PLT has four training blocks that follow the same basic design as the I-ABM training. However, the PLT will not aim to change social anxiety-related attention bias. Participants will simply swipe or tap the probe regardless of the stimuli condition, which is expected to exert a minimum level of effect on changing the attention bias linked to social anxiety. Participants will complete the training three times per week for three weeks.
62076237|NCT01454830|ACTIVE_COMPARATOR|Usual care|The comparison group, usual care, includes the standard of care delivered to all newly-diagnosed OSA persons proceeding to CPAP treatment
62076238|NCT06285617|EXPERIMENTAL|Experimental group|Participants in the experimental group received 20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib on Day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
62076239|NCT06285617|ACTIVE_COMPARATOR|Control group|Participants in the control group received 20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
62076240|NCT05334121|EXPERIMENTAL|Product - Beta Alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
62076241|NCT05334121|PLACEBO_COMPARATOR|Control group - Placebo|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
62076242|NCT03139838|ACTIVE_COMPARATOR|EHR-Based Intervention A|Intervention A (Prognostication) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
62076243|NCT03139838|ACTIVE_COMPARATOR|EHR-Based Intervention B|Intervention B (Accountable Justification) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
62076244|NCT03139838|ACTIVE_COMPARATOR|Combined EHR-Based Intervention (A+B)|Intervention A and B prompts will be combined and triggered for eligible patients simultaneously. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
62076245|NCT03139838|NO_INTERVENTION|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 5 months of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the hospital. The length of the control phase will differ at each hospital, dependent on the sequence in which hospitals are assigned to switch to the intervention phase.
62076246|NCT05272423||Cohort 1A|Patients who are currently progressing on a KRAS G12C inhibitor. Plasma for ctDNA analysis will be collected.
62076247|NCT05272423||Cohort 1B|Patients who have already had a sequencing assay performed to determine the resistance mechanism to a KRAS G12C inhibitor. These patients will be invited to share their data and medical history. Plasma for ctDNA analysis will be optional.
62076248|NCT05950503||mCRC patients|Patients with mCRC with liver-only metastases
62076249|NCT01722318|ACTIVE_COMPARATOR|Plecanatide 0.3mg|Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
62076250|NCT01722318|ACTIVE_COMPARATOR|Plecanatide 1.0mg|Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
62076251|NCT01722318|ACTIVE_COMPARATOR|Plecanatide 3.0mg|Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
62279667|NCT05922865|EXPERIMENTAL|KNEESUP smart knee assistive device + KNEESUP care APP|The participants with KNEESUP smart knee assistive device and KNEESUP care APP do exercise training at home.
62456573|NCT03272139|EXPERIMENTAL|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
62456574|NCT05984420|EXPERIMENTAL|Treatment group LimpiAD|LimpiAD 2,5% plus cream to be applied twice a day (morning and evening) for 8 weeks
62645729|NCT03194477|EXPERIMENTAL|Mobile-enhanced Engagement Intervention|Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.
62076252|NCT01722318|ACTIVE_COMPARATOR|Plecanatide 9.0mg|Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
62076253|NCT01722318|PLACEBO_COMPARATOR|Placebo|Placebo, one tablet by mouth daily for 12 weeks
62076254|NCT01487304||Low dose HRT|
62076255|NCT04094701|PLACEBO_COMPARATOR|Control Group|"Control Group will receive the following pain medication regimen:~- Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
62076256|NCT04094701|EXPERIMENTAL|Experimental Group - Opioid Reduced|"Experimental - opioid reduced: 50% less oxycodone relative to control group~* Tylenol extra strength (1000 mg, three times daily for 10 days following surgery)~* Gabapentin (300 mg at night for 10 days following surgery)~* Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
62076257|NCT05408923|PLACEBO_COMPARATOR|Placebo Group|Patients in this group will be given the placebo (sterile saline).
62076258|NCT05408923|ACTIVE_COMPARATOR|Irrisept|Patients in this group will be given the study drug (Irrisept).
62076259|NCT00840996|PLACEBO_COMPARATOR|Placebo|Perioperative placebo IV infusion besides the standard anesthesia care, including general anesthesia and postoperative patient controlled analgesia.
62076260|NCT00840996|ACTIVE_COMPARATOR|Lidocaine|Perioperative intravenous lidocaine infusion besides the standard anesthesia care, including general anesthesia plus and post operative patient controlled analgesia.
62076261|NCT01219803|EXPERIMENTAL|High dose GGQL Decoction|
62456575|NCT05984420|ACTIVE_COMPARATOR|Control group Vehicle of LimpiAD|Vehicle of LimpiAD 2,5% plus cream to be applied twice a day (morning and evening) for 8 weeks.
62645730|NCT03194477|NO_INTERVENTION|Control - SOC Case Management|Standard of care (SOC) case management.
62645731|NCT01603680|OTHER|Circumferential (C)|"Circumferential(C) spread group will be defined as mepivacaine injectate visualized by ultrasonography all around the median and ulnar nerves imaged in short axis."
62076262|NCT01219803|EXPERIMENTAL|Mild dose GGQL Decoction|
62076263|NCT01219803|EXPERIMENTAL|Low dose GGQL Decoction|
62076264|NCT01219803|PLACEBO_COMPARATOR|Placebo|
62456576|NCT05984420|ACTIVE_COMPARATOR|Control group Emollient|Emollient standard cream to be applied twice a day (morning and evening) for 8 weeks.
62076265|NCT03219203|EXPERIMENTAL|Arm A: Single dose hepatitis B vaccine|Single dose of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at entry
62076266|NCT03219203|ACTIVE_COMPARATOR|Arm B: 3-dose series of hepatitis B vaccine|3-dose series of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at month 0, 1, and 6
62279668|NCT05922865|ACTIVE_COMPARATOR|KNEESUP care APP|The participants with KNEESUP care APP do exercise training at home.
62456577|NCT03203915|EXPERIMENTAL|Group 1|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo"
62456578|NCT03203915|EXPERIMENTAL|Group 2|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose"
62456579|NCT03203915|EXPERIMENTAL|Group 3|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose"
62456580|NCT03203915|EXPERIMENTAL|Group 4|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo"
62645732|NCT01603680|OTHER|Non circumferential (NC)|Local anesthetic spread will be asymmetrical around the median and ulnar nerves, the mepivacaine will be partially in contact with the nerve
62645733|NCT05509361|EXPERIMENTAL|AK101 135mg|"Subjects who have completed AK101-302 receive AK101 135mg injection subcutaneously every 12 weeks.~Subjects newly enrolled receive AK101 135mg injection subcutaneously at Week 0, 4 and then every 12 weeks."
62076267|NCT00153946|ACTIVE_COMPARATOR|A|The patients who are allocated to Argatroban monotherapy
62456581|NCT03203915|EXPERIMENTAL|Group 5|"Order of treatments:~C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose"
62456582|NCT03203915|EXPERIMENTAL|Group 6|"Order of treatments:~C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose"
62456583|NCT05679648||Rheumatoid arthritis patients|
62456584|NCT05679648||control|
62645734|NCT04761003|ACTIVE_COMPARATOR|Group I (Cryobiopsy group):|patients where patients will be subjected to thoracoscopic cryobiopsy.
62076268|NCT00153946|ACTIVE_COMPARATOR|B|The patients who are allocated to Edaravone-Argatroban combination therapy
62076269|NCT01254305|EXPERIMENTAL|1|40 -120 mg/day Levomilnacipran ER capsules, oral administration
62076270|NCT01254305|ACTIVE_COMPARATOR|2|Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
62076271|NCT01254305|PLACEBO_COMPARATOR|3|Matching placebo capsules, oral administration
62076272|NCT03752619|EXPERIMENTAL|Contraction Producing Peripheral Nerve Stimulation|This group will receive: 1) muscle contraction producing peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
62279669|NCT05922865|PLACEBO_COMPARATOR|Health consultation|The participants with healthy consultation do aerobic training at home.
62456585|NCT04296149|EXPERIMENTAL|Y-90-DOTATOC|Patients affected by Small Intestine neuroendocrine tumors
62456586|NCT04097600|EXPERIMENTAL|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
62456587|NCT04097600|EXPERIMENTAL|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
62456588|NCT04097600|EXPERIMENTAL|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
62456589|NCT04097600|EXPERIMENTAL|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
62456590|NCT04097600|EXPERIMENTAL|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
62456591|NCT04097600|EXPERIMENTAL|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
62076273|NCT03752619|ACTIVE_COMPARATOR|Non Contracting Producing Peripheral Nerve Stimulation|This group will receive: 1) non contraction producing peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
62076274|NCT00229619|EXPERIMENTAL|Rituximab (Rituxan)|This is a non-randomized, off label, pilot study of humanized anti CD20 rituximab (Rituxan®) in patients with moderate aplastic anemia, pure red cell aplasia or Diamond-Blackfan anemia who have either failed to respond to at least one prior course of immunosuppressive therapy (PRCA/DBA patients only)or who have relapsed disease after prior immunosuppressive therapy (PRCA/DBA patients only).
62076275|NCT05672004|ACTIVE_COMPARATOR|Implementation as usual|Healthcare professionals will be instructed to implement ProMuscle in their practice as usual
62279670|NCT05616702|EXPERIMENTAL|Pressure Biofeedback Therapy + Progressive Muscle Relaxation Technique + Thermotherapy.|"This study ARM will receive following therapies~1. Pressure Biofeedback Therapy~2. Progressive Muscles Relaxation Technique~3. Thermotherapy"
62076276|NCT05672004|EXPERIMENTAL|PUMP-fit strategy: Implementation toolbox|Healthcare professionals receive a personal implementation toolbox, tailored to their contexts' barriers for implementation
62076277|NCT01079624|EXPERIMENTAL|GIP two doses and GLP-1 one dose|Intervention with infusion of GIP or GLP-1 intravenously
62076278|NCT01079624|PLACEBO_COMPARATOR|Saline infusion|Control
62076279|NCT02791555||Pradaxa|20 men and 20 women on Pradaxa for non valvular atrial fibrillation
62076280|NCT02791555||Warfarin|20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort
62076281|NCT04461925|EXPERIMENTAL|Experimental group|"On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day 1, Day 4, Day 7."
62076282|NCT04461925|ACTIVE_COMPARATOR|Control Group|Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies
62456592|NCT06056869|ACTIVE_COMPARATOR|buscopan group|will receive 2 ml (40 mg) of hyoscine butylbromide
62076283|NCT06387589|EXPERIMENTAL|Static Stretching Group|Core stabilization exercises along with Static Stretching of Iliopsoas (Hold for 7-8s x 10 reps) Week 1 Lifting the leg while lying in a prone position with the knee bent Week 2 Lifting the leg in a prone position with a straight knee Week 3 Stretch in the modified Thomas test position Week 4 Modified launch stretch
62076284|NCT06387589|EXPERIMENTAL|PFS Group|"Core stabilization exercises along with Post Facilitation Stretch of Iliopsoas (5-10s x 10 reps) Patient's position supine at the edge of the table, non-effected hip and knee in flexion, experimental thigh and leg hang on the edge of table. Extend the hip of the opposite thigh up to the barrier. After that, the patient flexes the hip against maximal resistance (isometric) and breathes in for 5-10 seconds. Tell the patient Relax, whereas the therapist applies a rapid stretch to a new barrier and is held for 10 seconds."
62076285|NCT02738671||Type 1 Diabetes Mellitus|These T1DM patients have late diabetes onset.(latent autoimmune diabetes in adult, LADA)
62279671|NCT05616702|ACTIVE_COMPARATOR|Progressive Muscle Relaxation Technique + Thermotherapy|"This study ARM will receive following therapies~1. Progressive Muscles Relaxation Technique~2. Thermotherapy"
62456593|NCT06056869|PLACEBO_COMPARATOR|control group|will receive 2 ml of normal saline
62076286|NCT02738671||Type 2 Diabetes Mellitus|A subgroup of these T2DM patients are obesity patients who will have the bariatric surgery. These obese T2DM subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain MRI at baseline and 6 months after their surgery.
62645735|NCT04761003|ACTIVE_COMPARATOR|Group II (Forceps group)|patients where patients will be subjected to thoracoscopic forceps biopsy.
62645736|NCT04361058|EXPERIMENTAL|Arm A - HLA-matched unrelated donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with an HLA-matched unrelated donor will be separated into Arm A and treated with Nivolumab post-SCT
62645737|NCT04361058|EXPERIMENTAL|Arm B - HLA-haploidentical donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with a HLA-haploidentical donor will be separated into Arm B and treated with Nivolumab post-SCT
62645738|NCT03526042|EXPERIMENTAL|Losartan|AT1R-ab effect can be blocked with the use of angiotensin-II receptor blockers. The participants will receive losartan.
62076287|NCT02738671||Control|A subgroup of these non-diabetic people are obesity patients who will have the bariatric surgery. These obese subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain fMRI at baseline and 6 months after their surgery.
62076288|NCT01812382|EXPERIMENTAL|Microdialysis arm|Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
62279672|NCT02181166|EXPERIMENTAL|kinesiotherapy + High voltage electrical stimulation|Same protocol group kinesiotherapy + high voltage electrial stimulation with two rectangular electrodes (3x5 cm) active silicon-carbon and an electrode rectangular dispersive (10x18cm) aluminum wrapped with a damp felt in water. The active electrodes are positioned in central myofascial trigger point of the upper trapezius muscle after application of water soluble gel. The dispersive electrode was placed in the lumbar region. The following parameters will be use: frequency of 10 Hz, twin pulses of 20μs to 100ms between pulses and the maximum voltage tolerated by voluntary until the motor threshold (visible muscle contraction) to increase every five minutes, totaling 30 minutes of stimulation. The negative polarity will be use.
62279673|NCT02181166|EXPERIMENTAL|Kinesiotherapy group|The volunteer will be subjected to the following protocol: These exercises involve stretching of the cervical, anterior and posterior chain of the upper trunk and active mobilization of the cervical, shoulder movements of flexion, extension, abduction and adduction of the shoulder and upper limb. The exercises lasted 50 minutes, with 10 minutes of walking, and stretching was performed with two repetitions of 20 seconds, and active mobilization exercises of three sets of eight repetitions and final relaxation of 10 minutes were performed.
62279674|NCT02181166|EXPERIMENTAL|kineshioterapy + isquemic compression|The same protocol group kinesiotherapy + ischemic compression in central myofascial trigger point of the upper trapezius muscle. This procedure was performed for 90 seconds.
62279675|NCT03665051|OTHER|Young adults|Obtain muscle biopsy specimens from young adults (ages 20-40) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
62279676|NCT03665051|OTHER|Older adults|Obtain muscle biopsy specimens from older adults (ages 60-80) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
62279677|NCT00331409|EXPERIMENTAL|Everolimus and Imatinib Mesylate|Everolimus: 2.5 mg daily by mouth Imatinib Mesylate: 600 mg daily by mouth
62279678|NCT02153567|PLACEBO_COMPARATOR|Control (Placebo) group|"Identical looking placebo (once daily)~Double blinding of study medication is achieved by repacking Escitalopram 5mg and 10mg as blue and green capsules respectively.. Identical appearing placebos packed in blue and green capsules will be used for the control group."
62279679|NCT02153567|EXPERIMENTAL|Escitalopram|Escitalopram 5mg \& 10mg daily
62456594|NCT01064128|ACTIVE_COMPARATOR|conventional laparoscopic hysterectomy|Three or four ports conventional laparoscopic hysterectomy
62456595|NCT01064128|ACTIVE_COMPARATOR|SPA laparoscopic hysterectomy|Single umbilical incision laparoscopic hysterectomy
62456596|NCT04982848||Talzenna treated group|Talzenna treated gBRCA Breast cancer patients in the real world setting in Korea
62456597|NCT02511405|EXPERIMENTAL|Arm 1|VB-111 + Bevacizumab
62645739|NCT03526042|ACTIVE_COMPARATOR|Enalapril|Angiotensin converting enzyme inhibitors are indicated in the management of active lupus nephritis but do not block the effect of AT1R-Ab.
62645740|NCT06041204|ACTIVE_COMPARATOR|Letrozole Group|Participants randomized to letrozole group will take 5mg tablets orally daily for 5 days starting on day 3 of cycle. Dose can be adjusted up to 7.5mg based on ovulation response, maintained for subsequent cycles. Treatment continues for up to 6 ovulatory cycles or until pregnancy occurs. Ovulation assessed by follicular monitoring and progesterone. Compliance monitored by pill counts and diary. Routine antenatal care if pregnant. Adverse effects monitored per guidelines. Participants followed for multiple pregnancies. Tablets taken at same time each day. Maximum treatment period is 6 months.
62456598|NCT02511405|ACTIVE_COMPARATOR|Arm 2|Bevacizumab
62456599|NCT01356849|PLACEBO_COMPARATOR|Group A - Placebo QD|
62456600|NCT01356849|ACTIVE_COMPARATOR|Group B - Low dose Atrasentan QD|
62456601|NCT01356849|ACTIVE_COMPARATOR|Group C - High dose Atrasentan QD|
62456602|NCT01272752|EXPERIMENTAL|Study Group|Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
62456603|NCT01272752|PLACEBO_COMPARATOR|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
62456604|NCT03682900|EXPERIMENTAL|Intervention: Click City Tobacco Prevention Program|Participation consisted of a baseline assessment one-week prior to starting the program, and a follow-up assessment one-week following completion of the program. The expectation was that students complete two lessons a week of the computer-based program over a four-week period.
62645741|NCT06041204|EXPERIMENTAL|Letrozole plus levothyroxine|Participants randomized to this group will take letrozole tablets at same dose and schedule as letrozole only group. In addition, they will take levothyroxine tablets orally once daily. Levothyroxine dose will start at 25mcg and be titrated based on TSH level, with a target TSH in the normal range. Participants will take levothyroxine at approximately same time each day. Letrozole dosing and schedule as described for other group. Treatment continues for up to 6 ovulatory cycles or until pregnancy occurs. Ovulation assessed by follicular monitoring and progesterone. Compliance monitored by pill counts, TSH levels and diary. Routine antenatal care if pregnant. Adverse effects monitored per guidelines. Participants followed for multiple pregnancies. Maximum treatment period is 6 months.
62645742|NCT04480528|EXPERIMENTAL|BFRT Group|This group will receive physical therapy plus active BFRT.
62645743|NCT04480528|SHAM_COMPARATOR|Standard of Care Group|This group will receive physical therapy plus sham BFRT.
62645744|NCT05951634|EXPERIMENTAL|Investigational Device Arm (PerQseal Elite)|Large hole percutaneous arterial closure device - PerQseal Elite
62645745|NCT02271321|NO_INTERVENTION|control group|The control group will receive usual care
62645746|NCT02271321|EXPERIMENTAL|experimental group|The experimental group will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
62279680|NCT05239520||People affected by FSHD|Participants with a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound.
62279681|NCT05239520||Age matched control group|Participants without a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound
62279682|NCT01833884|OTHER|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
62279683|NCT05854901|EXPERIMENTAL|PCT-guided treatment|Patients randomized to this arm will only receive antibiotic treatment when the procalcitonin concentration is \> 0.25ug/L.
62279684|NCT05854901|ACTIVE_COMPARATOR|Usual care|Patients randomized to this arm will receive antibiotic treatment based on the physician's decision.
62456605|NCT03682900|EXPERIMENTAL|Control: Usual Tobacco Prevention Curriculum|Students in control schools completed the baseline and follow-up assessments during the same week as students in their yoked intervention school. The expectation was that students would participate in the standard tobacco curriculum over this period.
62456606|NCT02042846|EXPERIMENTAL|SportWelding Fiji Anchor|
62645747|NCT01494207|EXPERIMENTAL|Lifestyle intervention|Participants will receive the intervention (counseling) or usual care (control group)
62279685|NCT00374738|EXPERIMENTAL|GIFT Intervention|Guided Imagery for Trauma (GIFT)
62279686|NCT00374738|NO_INTERVENTION|Music Control|Relaxing Music Audio control; same music used in guided imagery, with no narrative voice.
62279687|NCT01636466|EXPERIMENTAL|Everolimus conversion|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to take everolimus 0.75 mg twice daily after discontinuing current calcineurin inhibitor. Subjects will be weaned off of all other immunosuppression medicines when dialysis starts.
62279688|NCT01636466|NO_INTERVENTION|Control|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to continue on current immunosuppressive regimen. Subjects will be weaned off of all immunosuppression medicines when dialysis starts.
62279689|NCT04429815||Active smokers.|Active smokers since October 2019.
62279690|NCT04429815||Smokers undergoing smoking cessation|Smokers undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019.
62279691|NCT04429815||Non-smoking.|Person who's never smoked before.
62279692|NCT01370395||Left ventricular function|According to the result of the echocardiographic exam, the patients will be divided into subgroups with (LV-EF\>=55%) and without preserved ejection fraction (LV-EF\<55%).
62279693|NCT06481761|ACTIVE_COMPARATOR|Single-slot brackets|"Bonding of the upper arch up to second molars with Roth prescription 0.022x.028 single slot brackets (MINI MS-American orthodontics)"
62279694|NCT06481761|EXPERIMENTAL|Double-slot brackets|"Double slot brackets (SORTECH-South Orthodontic Technology) will be Bonded on the upper arch up to the second molars. The brackets are of Roth prescription \& have two slots, cervical 0.018x.025 slot and incisal/occlusal 0.022x.028 slot"
62456607|NCT00720096|EXPERIMENTAL|Liposomal Doxorubicin|Liposomal Doxorubicin - Chemotherapy single agent systemic.
62456608|NCT00720096|EXPERIMENTAL|Topotecan|Topotecan - Chemotherapy single agent systemic.
62456609|NCT05806710|EXPERIMENTAL|dysphagic subjects|elderly patients with dysphagia
62456610|NCT02227121|EXPERIMENTAL|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
62279695|NCT01899170|SHAM_COMPARATOR|Sham-DBS|Only patients. Inactive deep brain stimulation for the initial three months following implantation.
62645748|NCT02536911|EXPERIMENTAL|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
62645749|NCT02536911|EXPERIMENTAL|GZ385660 (subjects with mild hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
62279696|NCT01899170|ACTIVE_COMPARATOR|Active DBS|Only patients. Active deep brain stimulation for the initial three months following surgery.
62456611|NCT04785456|EXPERIMENTAL|Active TBS|"Daily, 4-week, 5-days per week treatment sessions, each consisting of:~First, intermittent TBS (iTBS) over the L-DLPFC: triplet 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, (600 pulses per session, total duration of 3 min 9 s), then continuous TBS (cTBS) over the R-DLPFC as 40 s uninterrupted bursts (600 pulses). Intensity at 120% resting motor threshold (RMT)."
62279697|NCT01899170|EXPERIMENTAL|TMS and PET imaging|This experiment includes all participants (cases and controls). Each subject will undergo both active and sham stimulation (cross-over) with Cervel Neurotech Multi-coil TMS and related test/re-test PET imaging with 11C-Carfentanil. Only patients will proceed into deep brain stimulation experiments.
62456612|NCT04785456|SHAM_COMPARATOR|Sham TBS|Daily, 4-week, 5-days per week treatment sessions. The sham coil will generate auditory and somatosensory (vibratory) stimuli identical to the active stimulation.
62645750|NCT02536911|EXPERIMENTAL|GZ385660 (subjects with moderate hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
62645751|NCT01873014|EXPERIMENTAL|high Iodine intake|
62645752|NCT01873014|ACTIVE_COMPARATOR|low Iodine intake|
62645753|NCT01700491|ACTIVE_COMPARATOR|Epidural Catheter 0.2% ropivacaine|Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
62645754|NCT01700491|ACTIVE_COMPARATOR|Paravertebral Catheter 0.4% ropivacaine|Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.
62279698|NCT05299385|ACTIVE_COMPARATOR|Comparator|"The investigator provide conventional-treatment to subjects when distributing respiratory rehabilitation education leaflets, Investigators explain the leaflets and self-practice until the subjects fully understand them. Compactor conducts respiratory rehabilitation treatment for 12 weeks according to the following procedures at home~☞ The investigator shall contact the subject every two weeks during the respiratory rehabilitation period and encourage them to perform respiratory rehabilitation treatment according to the assigned group. Subjects perform respiratory rehabilitation exercises at home.~They have to visit hospital at 8 weeks (visit 3) and 12 weeks (visit 4) and then examine the factor of the outcome measure following the clinical protocol"
62279699|NCT05299385|EXPERIMENTAL|Experimental treatment|"Subjects install software as a medical device for clinical trials on smart-phones, so that the subject can perform respiratory rehabilitation treatment at home.~Respiratory rehabilitation treatment for 12 weeks~☞ Respiratory rehabilitation treatment using a mobile-based software, consists of aerobic exercise and anaerobic exercise, and the subject performs themselves~They have to visit hospital at 8 weeks (visit 3) and 12 weeks (visit 4) and then examine the factor of the outcome measure following the clinical protocol"
62279700|NCT02944448|ACTIVE_COMPARATOR|CR845 tablet 1 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
62279701|NCT02944448|ACTIVE_COMPARATOR|CR845 tablet 2.5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
62456613|NCT00411866|EXPERIMENTAL|Subjects receiving ketoconazole for 8 days|In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
62456614|NCT00411866|EXPERIMENTAL|Subjects receiving ketoconazole for 14 days|In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
62645755|NCT02595658|EXPERIMENTAL|1|Carbohydrate only meal: Participants will consume a standardised carbohydrate meal (80 g of carbohydrates, 25 g protein, 0 g fat: meal composition, white rice, chicken, curry sauce; 420 kcal) and will self-administer (into the subcutaneous tissue of the abdomen, as per their regular routine) a rapid-acting insulin dose calculated as per the carbohydrate-counting ratio (e.g. 1 IU of insulin per 10 g of carbohydrates).
62645756|NCT02595658|EXPERIMENTAL|2|Participants will replicate Trial 1, but on this occasion the meal consumed will have an additional 50 g of fat (via addition of Ghee). This fat will be added to the sauce within the meal (80 g of carbohydrates, 25 g of protein, 50 g of fat; 735 Kcal). Participants will administer their rapid-acting insulin as per the carbohydrate counting method (i.e. the same IU of insulin as per Trial 1).
62645757|NCT02595658|EXPERIMENTAL|3|Trial 3) Participants will replicate Trial 2, but will administer a rapid-acting insulin dose that has been increased by 30%.
62645758|NCT02595658|EXPERIMENTAL|4|Participants will replicate Trial 2, but will administer an additional rapid-acting insulin dose of 30% 3 hrs post-meal.
62645759|NCT03217292|EXPERIMENTAL|Group S|"IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.~20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB."
62279702|NCT02944448|ACTIVE_COMPARATOR|CR845 tablet 5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
62279703|NCT02944448|PLACEBO_COMPARATOR|Placebo tablet|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
62279704|NCT02381431|EXPERIMENTAL|Thermal Imaging|imaging using a thermal camera
62279705|NCT01014845|EXPERIMENTAL|Hepatitis E vaccine|Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
62279706|NCT01014845|PLACEBO_COMPARATOR|HBV vaccine|Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
62645760|NCT03217292|ACTIVE_COMPARATOR|Group T|IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
62076289|NCT05601921|EXPERIMENTAL|Active stimulation group|Patients in the real stimulation group will receive rTMS treatment to the motor cortex (M1) of the affected hemisphere at a frequency of 5 Hz, once a day for 3 weeks and a total of 15 sessions. The application will be performed with Neurosoft-Neuro MS / D device. Before each session, the patient's resting motor threshold (RMT) value will be determined. RMT will be detected by obtaining a motor evoked potential of \>50 μV amplitude on electromyography recording of the contralateral first dorsal interosseous muscle in at least five out of 10 stimulations to the primary motor cortex.The stimulus intensity to be used in the treatment will be set as 90% of the motor threshold for the affected motor cortex and 100% of the motor threshold for the unaffected motor cortex.One session of stimulation will last for a total of 20 minutes and a total of 1000 pulses in the form of 5 Hz stimulation.
62279707|NCT03024775|ACTIVE_COMPARATOR|Active Comparator 1|Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
62279708|NCT03024775|ACTIVE_COMPARATOR|Active Comparator 2|Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
62279709|NCT03024775|PLACEBO_COMPARATOR|Placebo 1|Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
62076290|NCT05601921|SHAM_COMPARATOR|Sham stimulation group|Fifteen sessions of sham repetitive transcranial magnetic stimulation (rTMS) treatment will be applied to the lesional primary motor cortex. The application will be performed with Neurosoft-Neuro MS / D device. The probe of the device will be held perpendicular to the motor cortex and operated from the lowest operating power of 1, so that the device makes the same sounds as the active application.
62076291|NCT03106519|EXPERIMENTAL|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
62076292|NCT03106519|ACTIVE_COMPARATOR|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
62076293|NCT05102591|OTHER|Standard-of-Care IV Group|Patients randomised to the standard of care IV group will receive a single, 45-minute stimulation from a sham remote electrical neuromodulation (REN) device, which will not administer the typical electrical stimulation (modulated frequency of \~ 0.083 Hz and a modulated pulse width of 40-550 µs), and will be given a single dose IV ketorolac and IV metoclopramide, at a dose of 0.5 mg/kg (for a maximum 30 mg) and 0.15 mg/kg (for a maximum 10mg), respectively. Metoclopramide will be infused over 15-30 minutes and ketorolac will be administered as a direct IV push over 1-5 minutes.
62076294|NCT05102591|OTHER|REN Group|Patients randomised to the REN group will receive a single 45-minutes stimulation from the REN device (modulated frequency of 100-120 Hz and a pulse width of 400 µs) and will also receive two doses of normal saline though an IV. Two doses of saline will be used to match the dosage, route of administration, and duration to ketorolac and metoclopramide, as described above in the standard-of-care IV group.
62076295|NCT01614847|EXPERIMENTAL|Isotonic hyaluronate artificial tear|At random, subjects will receive isotonic hyaluronate artificial tear or a control (normal saline).
62076296|NCT01614847|PLACEBO_COMPARATOR|Normal saline|
62076297|NCT02766998|EXPERIMENTAL|Preserved umbilical vein|Preserved umbilical vein as shunt/conduit
62076298|NCT03937323||Group 1: Pancreatitis group|Patients with biliary pancreatitis
62456615|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
62456616|NCT02840409|ACTIVE_COMPARATOR|Arm A|68 weeks of single agent Vinblastine administered once weekly IV
62456617|NCT02840409|EXPERIMENTAL|Arm B|68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
62456618|NCT05836805|EXPERIMENTAL|[14C]XZP-3621|Eligible healthy 6 volunteers will receive a single oral dose of 400 mg/200 µCi \[14C\]XZP-3621 administered by mouth, as a suspension solution.
62456619|NCT02094820||Single Group Study|Questionnaires
62456620|NCT06369948|EXPERIMENTAL|Pericapsular Nerve Group (PENG) Block (P group)|Patients who will undergo elective hip hemiarthroplasty and receive the Pericapsular Nerve Group (PENG) block postoperatively.
62076299|NCT03937323||Group 2: Control group,|Healthy volunteers
62076300|NCT01900054|EXPERIMENTAL|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
62076301|NCT03864926|ACTIVE_COMPARATOR|Standard of Care|Standard of Care Tacrolimus
62076302|NCT03864926|EXPERIMENTAL|Experimental|Envarsus XR
62076303|NCT01264029|EXPERIMENTAL|Group A|Movement meditation for 2 hours
62076304|NCT01264029|ACTIVE_COMPARATOR|Group B|Non-moving sitting meditation for 2 hours
62456621|NCT06369948|ACTIVE_COMPARATOR|Control group (C group)|Patients who will undergo elective hip hemiarthroplasty without receiving a PENG block.
62279710|NCT03024775|PLACEBO_COMPARATOR|Placebo 2|Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.
62456622|NCT03622658|PLACEBO_COMPARATOR|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeks
62645761|NCT05398107|EXPERIMENTAL|Experimental: The BEAM program|The BEAM Program is delivered through a mobile application, weekly group telehealth sessions, and an online community forum. BEAM includes \~ 20 minutes of weekly video modules on parenting and mental health. Mental health videos provide content and emotion-regulation strategies drawn from the Unified Protocol, an evidence-based treatment for depression and anxiety disorders. Self-compassion and effective communication are also central focuses of the mental health content. Supportive parenting videos will provide mothers with emotion-focused parenting strategies and help mothers understand and respond to their children's challenging emotions and behaviours. The weekly group telehealth sessions will allow mothers to discuss content and ask questions, with the purpose of developing a sense of community and social support. The online community forum will provide a space for mothers to reflect on their learned skills and connect with other mothers taking part in the program.
62645762|NCT05398107|ACTIVE_COMPARATOR|Standard of Care: MoodMission|MoodMission is an evidence-based app which was developed based on cognitive behavioural therapy (CBT). The MoodMission app will provide mothers with missions. Missions are mental health strategies based on scientific evidence which are easily achievable (e.g., relaxation tips, exercise and fitness activities, yoga, mindfulness meditations, affirmations and coping statements). MoodMission will tailor missions based on the mothers current mood.
62645763|NCT04523012||HIV patients|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
62645764|NCT04486664|EXPERIMENTAL|Mediterranean diet|Mediterranean diet twice per day for four weeks
62645765|NCT04486664|PLACEBO_COMPARATOR|Conventional diet|Conventional diet for four weeks
62645766|NCT06201312|EXPERIMENTAL|Early Postmenopausal Exercise Group (EE)|
62645767|NCT06201312|EXPERIMENTAL|Late Postmenopausal Exercise Group (LE)|
62279711|NCT02734251|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo
62456623|NCT03622658|EXPERIMENTAL|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeks
62645768|NCT06201312|NO_INTERVENTION|Early Postmenopausal Control Group (EC)|
62645769|NCT06201312|NO_INTERVENTION|Late Postmenopausal Control Group (LC)|
62645770|NCT03955172|EXPERIMENTAL|Everolimus|
62645771|NCT05301439|EXPERIMENTAL|Restoration Group|Participants in this group will receive the universal adhesive restorative procedure combined with condensable bulk fill resin, for the restoration of the cavited teeth.
62645772|NCT05301439|EXPERIMENTAL|Hall Technique Group|Participants in this group will receive the Hall Technique with steel crowns for the restoration of the cavited teeth.
62645773|NCT05301439|EXPERIMENTAL|Steel Crown with Conventional Technique Group|Participants in this group will receive steel crowns with conventional technique for the restoration of the cavited teeth.
62645774|NCT00373503|EXPERIMENTAL|lofexidine, dronabinol, marijuana|lofexidine (.6 mg qid), dronabinol (20 mg tid)
62645775|NCT03843996|EXPERIMENTAL|Treatment left|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
62279712|NCT02734251|EXPERIMENTAL|Relora|Dietary Supplement: Relora, 750 mg/day
62279713|NCT06348342|NO_INTERVENTION|Control|
62279714|NCT06348342|EXPERIMENTAL|Kegel|Kegel exercises
62279715|NCT06348342|EXPERIMENTAL|Core|Core exercises
62456624|NCT02464566|EXPERIMENTAL|L Group|"Weekly individual session in obesity clinic (15 to 20 min.) for the first 4 weeks then one individual session in obesity clinic (10 to 20 min.) every two weeks (week 5 to week 12).~Total sessions in 12 weeks: 8 (including the final data collection visit). The components of the program:~1) Low carbohydrate (aim to achieve spontaneous reduction in calorie intake) 2) increased physical activity; 3) behavioural strategies to facilitate adherence to diet and activity prescriptions."
62456625|NCT02464566|ACTIVE_COMPARATOR|C Group|One session regarding diet restriction and physical activity with printed health education papers.
62279716|NCT06348342|EXPERIMENTAL|Kegel+core|Kegel and core exercises
62279717|NCT01092845|EXPERIMENTAL|PF-04457845 followed by placebo|
62076305|NCT01264029|ACTIVE_COMPARATOR|Group C|Mall Walking for 2 hours
62645776|NCT03843996|EXPERIMENTAL|Treatment right|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
62076306|NCT01264029|ACTIVE_COMPARATOR|Group D|Weekly Discussion
62279718|NCT01092845|EXPERIMENTAL|Placebo followed by PF-04457845|
62645777|NCT00245804||Adult dyslexia|Adult dyslexia
62645778|NCT00245804||Minor-Dyslexia|Minor-Dyslexia
62645779|NCT00245804||Adult-Control|Adult-Control
62645780|NCT00245804||Minor-Control|Minor-Control
62645781|NCT02081729||high VZV ELISPOT results|high spot counts in ELISPOT
62645782|NCT02081729||low VZV ELISPOT results|low spot counts in ELISPOT
62645783|NCT03017859|EXPERIMENTAL|High flow nasal cannula treatment|Airvo 2 device will be used to administer high flow air during the night
62645784|NCT01604785|EXPERIMENTAL|Experimental Treatment Group|Propofol at subanesthetic dose via IV push
62645785|NCT01604785|ACTIVE_COMPARATOR|Standard Treatment Group|Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
62645786|NCT00058253|EXPERIMENTAL|Group I|Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62645787|NCT00058253|EXPERIMENTAL|Group II|Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62076307|NCT01898975||500ml fluid loading|All enrolled patients
62279719|NCT01238939|EXPERIMENTAL|Treatment|
62645788|NCT02617537|EXPERIMENTAL|BAY86-5300|Patients suffering from dysmenorrhea, treated with Yaz
62645789|NCT02617537|PLACEBO_COMPARATOR|Placebo|Patients suffering from dysmenorrhea,treated with placebo
62645790|NCT04159467|ACTIVE_COMPARATOR|Group 1- diet therapy (control)|Control group undergoing a low calorie diet will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and after 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
62645791|NCT04159467|EXPERIMENTAL|Grupo 2 - low calorie diet + PFMT (experimental)|"The experimental group will receive supervised pelvic floor muscle training in addition to a hypocaloric diet. Women will be instructed to perform daily pelvic floor muscle training at home. 4 sets of 10 maximal voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary contractions of the pelvic floor muscles. The 4 sets will be performed in 2 different positions (sitting and standing). Once a month, they will receive a supervised in-person session using the same protocol described above, in the other weeks of the month will receive a session supervised by telephysiotherapy once a week. In addition to supervised sessions, women will be encouraged to perform the protocol three more days a week. In addition, they will be instructed to perform the knack maneuver."
62645792|NCT01531400|EXPERIMENTAL|music|Investigators played self-selected background music in the music group
62076308|NCT06453018|EXPERIMENTAL|Intervention|Positional therapy
62645793|NCT01531400|NO_INTERVENTION|no music (control)|Investigators played no music in the music group
62279720|NCT04880187|EXPERIMENTAL|AXA1125 22.6g|22.6 g AXA1125 administered orally BID with or without food
62645794|NCT05036681|EXPERIMENTAL|futibatini|
62076309|NCT02214823|EXPERIMENTAL|FES-Cycling|"Timeframe: Within 72 hours of ICU admission. Program: Standard care physiotherapy AND up to one hour of supine cycling daily using a cycle ergometer (RT300 supine model Restorative Therapies, Ltd or Letto 300.) attached to a six channel stimulator (SAGE) and 2 additional RT50 wireless stimulator channels.~One leg will undergo cycling alone without the electrodes turned on (sham) and the other leg will undergo cycling and muscle stimulation. Electrodes will be placed on all major lower limb muscles. Intervention will be provided individually and supervised by a physiotherapist in ICU only. Duration /Intensity: Up to 1 hour at least 5 times a week for 28 days or ICU discharge, if 20 sessions have not occurred at this time, intervention will continue until this is achieved. Intensity of muscle stimulation will be delivered at a level able to cause visible muscle contractions, confirmed by palpation.~A subgroup of 10 individuals will be involved in biomarker analyses."
62645795|NCT05036681|EXPERIMENTAL|pembrolizumab|
62645796|NCT03091153|NO_INTERVENTION|Control|Standard care. Annual medication review
62645797|NCT03091153|EXPERIMENTAL|Intervention|In depth medication review with a focus on deprescribing
62645798|NCT02587208|ACTIVE_COMPARATOR|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
62645799|NCT02587208|ACTIVE_COMPARATOR|plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
62645800|NCT00563290|EXPERIMENTAL|Arm I (dasatinib 100 mg PO BID)|Patients receive 100 mg dasatinib PO BID on days 1-28
62645801|NCT00563290|EXPERIMENTAL|Arm II (dasatinib 70 mg PO BID)|Patients receive 70 mg dasatinib PO BID on days 1-28
62645802|NCT02578017|EXPERIMENTAL|Mobile DOT|All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
62279721|NCT04880187|EXPERIMENTAL|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
62279722|NCT04880187|PLACEBO_COMPARATOR|Placebo|Matching Placebo administered orally BID with or without food
62279723|NCT00837785|EXPERIMENTAL|1|240 mg (two 120 mg capsules) twice a day
62279724|NCT00837785|EXPERIMENTAL|2|240 mg (two 120 mg capsules) three times a day
62645803|NCT02578017|NO_INTERVENTION|Post-intervention observation|All participants will not receive any additional adherenece intervention after completing the Mobile DOT arm. Participants will be observed for 6 months.
62645804|NCT00624988|EXPERIMENTAL|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
62645805|NCT04960215|ACTIVE_COMPARATOR|Coenzyme Q10|
62645806|NCT04960215|PLACEBO_COMPARATOR|Placebo|
62645807|NCT06391424||Spontaneous Breathing Trial|Patients who will undergo a spontaneous breathing trial
62645808|NCT01953016||immunodeficiency|Individuals of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.
62645809|NCT00850694||1|Obese female adolescents
62645810|NCT02634255|ACTIVE_COMPARATOR|Rocuronium elective surgery|patients undergoing inguinal herniorrhaphy
62645811|NCT02634255|EXPERIMENTAL|Rocuronium emergency surgery|patients undergoing appendectomy
62076310|NCT02214823|ACTIVE_COMPARATOR|Standard Care|"Both groups will receive usual medical and nursing care in the ICU and ward. Both groups (control and intervention) will receive standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.~A subgroup of 10 individuals will be involved in biomarker analyses. This will involve collection of muscle biopsy, blood and urine analyses at baseline and ICU discharge."
62076311|NCT06348537|EXPERIMENTAL|Group 1|Group 1: consisting of 20 patients diagnosed with FM, who received a daily dose of 3 capsules (2 in the morning and 1 in the evening) of Mygrium® during 60 days.
62645812|NCT00192114|EXPERIMENTAL|Enzastaurin HCl|
62645813|NCT01524315|EXPERIMENTAL|Supplementation|6 ml Vitamin-B1-ratiopharm in 100 ml normal saline, intravenous, preoperative
62645814|NCT01524315|PLACEBO_COMPARATOR|Placebo|100 ml normal saline, intravenous, preoperative
62645815|NCT03720886|EXPERIMENTAL|rhPTH（1-34） 28.2μg|Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
62645816|NCT03720886|EXPERIMENTAL|rhPTH（1-34） 56.5μg|Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
62645817|NCT03720886|ACTIVE_COMPARATOR|teriparatide acetate(Teribone™)|Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.
62645818|NCT02227641|EXPERIMENTAL|Adoptive transfer of CMV/EBV specific T-cells|Repetitive adoptive T-cell transfer starting at day 30 after allogeneic stem cell transplantation.
62645819|NCT02227641|NO_INTERVENTION|Control|Observation only.
62645820|NCT01682096|ACTIVE_COMPARATOR|Computed coronary angiography (CTA)|Patients will undergo a MDCT as the initial diagnostic test to rule out Acute Coronary Syndrome
62645821|NCT01682096|ACTIVE_COMPARATOR|Exercise stress echocardiography|Patients will undergo exercise stress echocardiography as the initial diagnostic test to rule out acute coronary syndrome.
62645822|NCT06077539|ACTIVE_COMPARATOR|Dexmedetomidine group|25 patients will receive Dexmedetomidine 1 μg/kg bolus over 10 min followed by 0.5 μg/kg/h as maintenance volume-matched 0.9% saline.
62645823|NCT06077539|ACTIVE_COMPARATOR|Magnesium group|25 patients will receive IV magnesium as a loading dose 15 mg/kg diluted in 0.9% NaCl given over 10 min followed by 10mg/kg/h IV infusion( for Concentration of solution will not exceed 1gm/25 mL (40 mg/ml).
62645824|NCT06077539|ACTIVE_COMPARATOR|Ketamine group|25 patients will receive intravenous (IV) ketamine 1mg/kg diluted in 0.9% NaCl as a loading dose over 10min then 1mg/kg/h IV infusion
62076312|NCT06348537|PLACEBO_COMPARATOR|Group 2|Group 2: 20 patients diagnosed with FM, who received a daily dose of 3 capsules (2 in the morning and 1 in the evening) of a placebo (maltodextrins) during 60 days. This intervention group served as a control.
62076313|NCT01830192|OTHER|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
62076314|NCT01830192|OTHER|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
62645825|NCT06077539|PLACEBO_COMPARATOR|Control group|in 25 patients saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups.
62645826|NCT03613493|OTHER|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
62645827|NCT03613493|EXPERIMENTAL|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
62645828|NCT03613493|EXPERIMENTAL|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
62279725|NCT03308864|EXPERIMENTAL|Interpersonal Psychotherapy for Adolescents (IPT-A)|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
62279726|NCT03308864|ACTIVE_COMPARATOR|Treatment as Usual|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
62279727|NCT05666531||Healthy people|The physical examination ruled out the disease
62456626|NCT04192500|EXPERIMENTAL|OVX836 - 90µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 90µg dose on Day 1.
62645829|NCT03613493|ACTIVE_COMPARATOR|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
62076315|NCT02654795|PLACEBO_COMPARATOR|Patients without stroke|This group will consists of patients scheduled for atrial fibrillation ablation without history of stroke.
62279728|NCT05666531||Chronic gastritis|The endoscopic diagnosis is consistent with chronic gastritis or self-reported stomachache
62279729|NCT05666531||Insomnia|The Pittsburgh Sleep Quality Index Scale was measured and assessed as meeting a diagnosis of insomnia disorder or self-reported insomnia for more than three months
62279730|NCT04142983|EXPERIMENTAL|Study Group|Participants will receive a single dose of Tdap vaccine (Adacel) every 3 months for a total of 5 immunizations over a period of 12 months.
62645830|NCT01511926||1|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid arthritis (RA) or ankylosing spondylitis
62645831|NCT02352857|PLACEBO_COMPARATOR|Sugar|Control group consuming sponge cakes containing in total 24g of dextrose.
62076316|NCT02654795|EXPERIMENTAL|Patients with history of stroke|This group will consists of patients after ischemic stroke and history of atrial fibrillation.
62076317|NCT01700348|EXPERIMENTAL|Airflosser|Use of Airflosser
62456627|NCT04192500|EXPERIMENTAL|OVX836 - 180µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180µg dose on Day 1.
62279731|NCT06214260||Endometriosis|Women suggested endometriosis by clinical presentations \& imaging and scheduled for surgical treatment (laparotomy/laparoscopy) at the age of 18-45 years having regular menstrual cycles will be recruited. Finally laparoscopy and histology confirmed endometriosis cases will be eligible for the final analysis.
62456628|NCT04192500|ACTIVE_COMPARATOR|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|Licensed quadrivalent seasonal influenza subunit vaccine for season 2019-2020. One full dose to be administered at Day 1
62456629|NCT03827109|EXPERIMENTAL|Mentoring program|The Mentoring Program consists of year-long, 1:1 mentee-mentor relationships with group educational activities, online educational information, and a parent support component. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month. Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. They also provide opportunities to socialize with other mentors and mentees: lunch and games are provided before or after the educational event. Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing. Parents join the mentees and mentors for the educational topics. Due to the COVID-19 pandemic, these activities can be conducted virtually.
62456630|NCT03827109|ACTIVE_COMPARATOR|Educational activity program|The Educational Activity comparison group consists of separate educational group events on the same topics (with no social time), educational information posted online, and monthly encouragement to engage in activities in the community. Due to the COVID-19 pandemic, participants are encouraged to interact socially in safe ways, e.g., outdoors or virtually.
62279732|NCT06214260||Healthy groups|Control subjects at the age of 18-45 years, who have regular menstrual cycles and self-reported no history suggestive of a diagnosis of endometriosis will be recruited.
62279733|NCT02007603|EXPERIMENTAL|Ampicillin / sulbactam|Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
62279734|NCT02007603|EXPERIMENTAL|Amoxicillin / clavulanic acid|Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
62279735|NCT01465308|EXPERIMENTAL|receiving Honey|The patients will receive honey mouthwash rinses
62456631|NCT04522609|NO_INTERVENTION|Control group|Guideline recommended pharmacologic therapy
62456632|NCT04522609|EXPERIMENTAL|NMES group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
62456633|NCT01282606|EXPERIMENTAL|Drug I: SI-6603 (Low)|
62456634|NCT01282606|EXPERIMENTAL|Drug II: SI-6603 (Middle)|
62076318|NCT01700348|ACTIVE_COMPARATOR|Manual Floss|Normal Routine
62279736|NCT01465308|ACTIVE_COMPARATOR|Saline mouthwash|The patients in this group will receive saline rinses
62279737|NCT03344666|EXPERIMENTAL|First Treatment|Participants will be randomized to first treatment to compare Brief Intervention + Health Coach (Step 1 Treatment BI+HC) to Brief Intervention + Text Messages (Step 1 Treatment BI+TM). Participants in the BI+HC will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks. Participants in the BI+TM will receive a BI in the ED, followed by daily TMs for 4 weeks.
62456635|NCT01282606|EXPERIMENTAL|Drug III: SI-6603 (High)|
62645832|NCT02352857|EXPERIMENTAL|FOS|Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
62076319|NCT00064272|EXPERIMENTAL|Arm I|Patients receive lower-dose oral ginger twice daily.
62076320|NCT00064272|EXPERIMENTAL|Arm II|Patients receive higher-dose oral ginger twice daily.
62076321|NCT00064272|PLACEBO_COMPARATOR|Arm III|Patients receive oral placebo twice daily.
62076322|NCT00650494|EXPERIMENTAL|1|Valacyclovir Hydrochloride Tablets 1000mg
62456636|NCT06545253||USH2A-RP|Patients affected by genetically-confirmed USH2A-RP.
62645833|NCT01228006|EXPERIMENTAL|Treatment|NatusGerin
62076323|NCT00650494|ACTIVE_COMPARATOR|2|Valtrex® Tablets 1000 mg
62076324|NCT04658732|EXPERIMENTAL|Alprazolam (A group)|patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer.
62076325|NCT04658732|EXPERIMENTAL|Gabapentin (G group)|patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer.
62076326|NCT04658732|EXPERIMENTAL|Dexmedetomidine (D group)|Dexmedetomidine 0.25 µg/kg loading dose will be infused intravenously over 10 minutes through syringe pump before surgery in the control group (Prepared using Precedex vial 200mcg/2ml manufactured by Hospira Inc, Highway 301,Rocky Mount,NC 278001 USA)
62076327|NCT01729728|EXPERIMENTAL|Tapentadol|
62456637|NCT06545253||controls|Healthy control subjects
62456638|NCT03417544|EXPERIMENTAL|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:~* Atezolizumab (IV) every 3 weeks (q3w)\]~* Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)~* High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
62456639|NCT01964742|EXPERIMENTAL|HIV-HCV co-infected patients|
62645834|NCT01228006|PLACEBO_COMPARATOR|Control|Gelatin capsules identical to drug test
62645835|NCT04249479|EXPERIMENTAL|CM temperature 20° C|CM is administered to the patient at a temperature of 20° C.
62645836|NCT04249479|ACTIVE_COMPARATOR|CM temperature 37° C|CM is administered to the patient at a temperature of 37° C.
62076328|NCT00307099|EXPERIMENTAL|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
62076329|NCT00307099|ACTIVE_COMPARATOR|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
62076330|NCT05453981|EXPERIMENTAL|TranS-C group|The TranS-C group will receive weekly 2 hour TranS-C group intervention delivered by 2 clinical psychology trainees for 6 weeks, contents being core modules from Harvey et al. (2016)'s protocol.
62645837|NCT03277131|EXPERIMENTAL|1|Antimicrobial Dressing
62645838|NCT06230263|EXPERIMENTAL|DAILIES TOTAL1® for Astigmatism|DAILIES TOTAL1® for Astigmatism
62645839|NCT06230263|ACTIVE_COMPARATOR|Spherical Contact Lenses|DAILIES TOTAL1® Spherical Contact Lenses
62645840|NCT02656030|EXPERIMENTAL|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise 2 times/week, 6 weeks duration
62645841|NCT02656030|EXPERIMENTAL|cranio-cervical flexion exercise|cranio-cervical flexion exercise 2 times/week, 6 weeks duration
62645842|NCT02656030|ACTIVE_COMPARATOR|usual care|Usual care 2 times/week, 6 weeks duration
62076331|NCT05453981|NO_INTERVENTION|CAU group|The CAU group will receive care as usual.
62076332|NCT02087150|NO_INTERVENTION|Medical management (MM)|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
62076333|NCT02087150|EXPERIMENTAL|Eustachian tube balloon catheter (ETBC) plus MM|Eustachian tube dilation with the ETBC plus medical management
62076334|NCT03905590|EXPERIMENTAL|periapical surgery with amniotic membrane|periapical surgery will be done and amniotic membrane will be placed over the defect before closure of flap
62456640|NCT05090332|EXPERIMENTAL|Facial Gun|Vibrations through Facial gun along with conventional Therapy
62456641|NCT05090332|EXPERIMENTAL|Dry needling|Dry needling along with conventional treatment.
62456642|NCT04172363|NO_INTERVENTION|Standard Care|Octenisept will be used as standard care antiseptic for dressing change
62456643|NCT04172363|EXPERIMENTAL|Resistance testing|Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results
62456644|NCT04103177|EXPERIMENTAL|Intervention group|20 participants to receive physical activity educational booklet with instructions on chair based exercises, Instructor-led training on how to perform the chair based exercises, two times a week, over a 6 week period, and motivational interviewing and prompts.
62456645|NCT05314400|ACTIVE_COMPARATOR|Full Protocol|Routine Primovist MRI
62456646|NCT05314400|EXPERIMENTAL|Abbreviated Protocol|Shortened Primovist MRI
62645843|NCT01192165|EXPERIMENTAL|Treatment Group 1|Trametinib plus Docetaxel
62645844|NCT01192165|EXPERIMENTAL|Treatment Group 2|Trametinib plus Erlotinib
62645845|NCT01192165|EXPERIMENTAL|Treatment Group 3|Trametinib plus Pemetrexed
62645846|NCT01192165|EXPERIMENTAL|Treatment Group 4|Trametinib plus Pemetrexed and Carboplatin
62645847|NCT01192165|EXPERIMENTAL|Treatment Group 5|Trametinib plus nab-Paclitaxel
62645848|NCT01192165|EXPERIMENTAL|Treatment Group 6|Trametinib plus Pemetrexed and Cisplatin
62645849|NCT02666976|EXPERIMENTAL|ilaprazole group|ilaprazole 20mg once daily for 4 weeks.
62645850|NCT04384900|EXPERIMENTAL|Accelerated prone position|Prone position ventilation initiated as soon as possible following intubation. The patients are maintained in a prone position for 12-16 hrs daily for 5 days, unless one of the following criteria are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption. Following the five day intervention period, prone position ventilation will be continued according to the intervention in the control group
62076335|NCT03905590|ACTIVE_COMPARATOR|periapical surgery without amniotic membrane|periapical surgery will be done without the placement of amniotic membrane over the defect before closure of flap
62076336|NCT06146309|EXPERIMENTAL|Patients with unilateral BRVO|
62076337|NCT06146309|NO_INTERVENTION|Healthy individuals|
62456647|NCT02126306|PLACEBO_COMPARATOR|Placebo|Normal saline administered orally daily as a placebo
62456648|NCT02126306|ACTIVE_COMPARATOR|Beta Glucosylceramide|Beta glucosylceramide administered orally daily
62456649|NCT01950208||knee pain|patients suffering from knee injury
62456650|NCT06458439|EXPERIMENTAL|Epcoritamab|Study participants will bridging epcoritamab on Cycles 1-3, Days 1, 8, 15, and 22 (once weekly).
62456651|NCT04505033|EXPERIMENTAL|50 mg s.c|
62456652|NCT04505033|PLACEBO_COMPARATOR|50 mg placebo|
62456653|NCT04505033|EXPERIMENTAL|150 mg s.c.|
62456654|NCT04505033|PLACEBO_COMPARATOR|150 mg placebo|
62456655|NCT04505033|EXPERIMENTAL|300 mg s.c.|
62456656|NCT04505033|PLACEBO_COMPARATOR|300 mg placebo|
62456657|NCT04505033|EXPERIMENTAL|450 mg s.c.|
62456658|NCT04505033|PLACEBO_COMPARATOR|450 mg placebo|
62456659|NCT00532636|ACTIVE_COMPARATOR|1|Children 1-5 years of age
62456660|NCT00532636|ACTIVE_COMPARATOR|2|Children 6-10 years of age
62456661|NCT00385684|EXPERIMENTAL|A1: hydrocodone/APAP w placebo PRN|This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
62456662|NCT00385684|PLACEBO_COMPARATOR|A2: placebo w hydrocodone/APAP PRN|This is a fully crossed study, each participant serves as his own control. Phase A: Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
62456663|NCT00385684|ACTIVE_COMPARATOR|B: Open label hydrocodone/acetaminophen|Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
62456664|NCT00369590|EXPERIMENTAL|All Study Patients|"Patients receive VEGF Trap (ziv-aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis."
62456665|NCT01256684|PLACEBO_COMPARATOR|Placebo|
62456666|NCT01256684|EXPERIMENTAL|0.25% DHEA|
62456667|NCT01256684|EXPERIMENTAL|0.5% DHEA|
62456668|NCT02152878|ACTIVE_COMPARATOR|Active stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 10 days and two extra sessions every other week (total of 12 sessions).
62456669|NCT02152878|PLACEBO_COMPARATOR|Sham stimulation|For Sham Transcranial Direct Current Stimulation, the device is automatically turned off after 30 seconds of stimulation and remains turned off.
62456670|NCT03765632|EXPERIMENTAL|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
62456671|NCT04598984||Low levels of serum adipokines|
62456672|NCT04598984||High levels of serum adipokines|
62279738|NCT03344666|EXPERIMENTAL|Second Treatment for Responders and Non-Responders|"Beginning in week 5, all participants will be classified as Responders or Non-Responders (based on weekly assessments) and re-randomized.~Step 2 Treatment Responders: Responders will be randomized to either stay the course or be stepped down. Specifically, participants in the BI+HC will either continue to receive the HC or stepped down to receive a control brochure; participants in the BI+TM will either continue to receive the TM or stepped down to receive a control brochure.~Step 2 Treatment Non-Responders: Non-Responders will be randomized to either stay the course or be stepped up. Specifically, participants in the BI+HC will either continue to receive the HC or stepped up to receive a HC+; participants in the BI+TM will either continue to receive the TM or stepped up to receive HC."
62279739|NCT01554930|ACTIVE_COMPARATOR|Western therapy|
62279740|NCT01554930|EXPERIMENTAL|Xiyanping injection plus western therapy|
62279741|NCT02900703||PATIENT|
62279742|NCT00330187|EXPERIMENTAL|Bupropion SR + Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
62279743|NCT00330187|ACTIVE_COMPARATOR|Placebo + Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
62279744|NCT00330187|ACTIVE_COMPARATOR|Bupropion SR + No Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management is not provided in this arm.
62279745|NCT00330187|PLACEBO_COMPARATOR|Placebo + No Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management is not provided in this arm.
62279746|NCT01925209|EXPERIMENTAL|BYM338/bimagrumab 10 mg/kg|Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
62279747|NCT01925209|EXPERIMENTAL|BYM338/bimagrumab 3 mg/kg|Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
62279748|NCT01925209|EXPERIMENTAL|BYM338/bimagrumab 1 mg/kg|Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
62279749|NCT01925209|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
62279750|NCT03885271|EXPERIMENTAL|Group A (Experimental group) Hall Technique|Clinical examination to assess the clinical inclusion criteria. Radiographic examination.The child will be positioned upright in the dental chair . The correct size of PMC for the tooth will be selected. The tooth will be rinsed and dried, and the PMC dried. The PMC will be filled with glass ionomer luting cement. The PMC will be placed evenly over the tooth and the child instructed to bite down firmly until the crown was pushed down over the tooth;If the child was unable or unwilling to bite down on the PMC, finger pressure will be used to seat the crown Extruded cement will be removed, and the child will be asked to keep biting on the Hall PMC until the cement sets and once cement sets, excess cement is removed, floss will be used to clear the aproximal contacts, and post-fitting instructions will be given (Innes et al. 2007).
62456673|NCT03093506|ACTIVE_COMPARATOR|Low-dose rhEpo|RhEpo 60IU/kg/week
62456674|NCT03093506|ACTIVE_COMPARATOR|Micro-dose rhEpo|RhEpo 20IU/kg/week
62456675|NCT03093506|PLACEBO_COMPARATOR|Placebo Control|Saline
62456676|NCT02128152|EXPERIMENTAL|Ekso Training Safety and Efficacy|
62456677|NCT00914667|EXPERIMENTAL|Warfarin Alone|Reference treatment
62456678|NCT00914667|EXPERIMENTAL|Warfarin Concomitantly With Fesoterodine|Test treatment
62456679|NCT03839706|EXPERIMENTAL|PET MRI Arm|Patient enrolled in the study will have a PET MRI exam scheduled before transplant
62456680|NCT01365429|EXPERIMENTAL|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the XPS™ with Steen Solution™ and undergone ex-vivo lung perfusion before being transplanted.
62456681|NCT01365429|NO_INTERVENTION|Control Group|Control Group are those recipient lung transplant patients that receive donor lungs via conventional transplant.
62456682|NCT01234103|EXPERIMENTAL|Preventing sexual health risks|The over goal is to prevent STIs, unintended pregnancies, and related behaviors including sexual risk, alcohol and other substance misuse
62076338|NCT01566786|EXPERIMENTAL|activated recombinant human factor VII|
62076339|NCT01566786|PLACEBO_COMPARATOR|Placebo|
62456683|NCT01234103|OTHER|Improving nutrition, fitness and injury prevention|The goals are: (1) maintain and improve nutrition and physical fitness through healthier lifestyle and food choices; (2) reduce the risk of sports or physical training injuries and learning how to treat injuries; and (3) Learn to recognize stress and the steps you can take to reduce stress
62645851|NCT04384900|ACTIVE_COMPARATOR|Standard prone position|Standard of care: Prone position applied according to standard indications (severe ARDS not improving with 12-24 hours of mechanical ventilation with PaO2-to-FiO2 ratio (PAF) \< 150 mmHg with FiO2 of ≥0.6, a positive end-expiratory pressure (PEEP) of ≥5 cm of water, and a tidal volume of about 6 ml per kilogram of predicted body weight). Until one of the following are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption.
62645852|NCT03413592|OTHER|Driving test|
62076340|NCT00569361|OTHER|A|Collection of nasal epithelial cells by brushing
62076341|NCT02890914|NO_INTERVENTION|Standard Education|These residents received their standard residency education and experience.
62076342|NCT02890914|EXPERIMENTAL|DVD Intervention|These residents received a one-hour long DVD lecture in addition to standard residency education and experience.
62456684|NCT01563757||Fontan Patients with PLE and PB|Fontan Patients with Protein Losing Enteropathy and Plastic Bronchitis
62076343|NCT06488391|EXPERIMENTAL|Visualized Self-Training|
62076344|NCT06488391|NO_INTERVENTION|No-Visualized Self-Training|
62076345|NCT02101099||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
62076346|NCT00850720||Cardiac Surgery|Infants with congenital defects.
62076347|NCT04443933||Cerebral Small Vessel Disease|In this group, patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI.
62076348|NCT04443933||non-Cerebral Small Vessel Disease|In this group, cerebral small vessel disease is ruled out by preoperative multimodal MRI.
62456685|NCT01563757||Fontan Patients w/out PLE & PB|Protein Losing Enteropathy and Plastic Bronchitis
62279751|NCT03885271|ACTIVE_COMPARATOR|Group B (control group) Formecresol Pulpotomy|Clinical examination to assess the clinical inclusion criteria. Radiographic examination. The teeth anesthetized, rubber dam isolation, Complete caries removal achieved with a sterile round steel bur in a slow- speed handpiece. Access to the pulp chamber performed using a sterile slow-speed round steel bur. The pulp amputation with a sterile diamond bur in a high-speed handpiece and pulpal debris removed with a sterile saline solution on a sterile cotton pledget. After pulp amputation haemostasis achieved using a sterile cotton pledget. Formocresol (FC) applied using a sterile cotton pledget for 5 minutes. After removal of the formocresol soaked cotton pledget, the pulp chamber rinsed with water using an air-water syringe. The pulp chamber dried with a sterile cotton pledget, followed by application of Zinc Oxide \& Eugenol and zinc phosphate. Tooth preparation done to receive stainless steel crown.
62456686|NCT01563757||Glenn Physiology Patients|
62456687|NCT01563757||2 ventricle heart with ASD|2 ventricle heart with Atrial Septal Defect
62279752|NCT01660217|EXPERIMENTAL|Initial Verbal Instruction Group|"The group who initially received only verbal instruction, and then later (in the crossover portion) received a written Eczema Action Plan (EAP)"
62279753|NCT01660217|EXPERIMENTAL|Written Eczema Action Plan (EAP)|The group given a written EAP after verbal instruction
62279754|NCT02887131|EXPERIMENTAL|Healthy volunteers|
62279755|NCT02887131|EXPERIMENTAL|Arthritis|
62279756|NCT02887131|EXPERIMENTAL|Instability|
62279757|NCT02491294|EXPERIMENTAL|School Only|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components
62279758|NCT02491294|EXPERIMENTAL|School + Family|Students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs)
62279759|NCT02491294|EXPERIMENTAL|School + About Eating|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components and their parents are invited to participate in the online 6 lesson About Eating program.
62279760|NCT02491294|EXPERIMENTAL|School + Family + About Eating|students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs) and their parents are invited to participate in the online 6 lesson About Eating program.
62456688|NCT02101346|EXPERIMENTAL|Healthy, Round 1|For feeding of 5 different fatty acid meals in order to assess the monocyte response ex vivo Mixed high fat diet Low fat diet Saturated fat diet Monounsaturated fat diet Polyunsaturated fat diet
62456689|NCT02101346|EXPERIMENTAL|Healthy, Round 2|"For feeding of 2 different fatty meals, in order to assess the molecular monocyte response and track the fate of fats.~Saturated fat Triolein 13C"
62456690|NCT01617668|EXPERIMENTAL|Paclitaxel with LCL161|Patients randomized to the experimental arm received paclitaxel 80 mg/m2 weekly + LECL161 1800 mg once weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
62456691|NCT01617668|ACTIVE_COMPARATOR|Paclitaxel without LCL161|Patients randomized to the control arm received paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
62456692|NCT04457999|EXPERIMENTAL|Lipiflow treatment|Lipiflow thermal pulsation prior to cataract surgery
62645853|NCT02461693|EXPERIMENTAL|Caffeine|One-time treatment with 200mg caffeine pill
62645854|NCT02461693|PLACEBO_COMPARATOR|Placebo|One-time treatment with lactose-based placebo pill
62279761|NCT02491294|NO_INTERVENTION|Control|students and their parents in all schools during cohort 1 and 4 (and Ponderosa students in cohort 3) are tested but provided no intervention
62279762|NCT00272987|EXPERIMENTAL|Cohort 1|Participants received: paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily
62279763|NCT00272987|EXPERIMENTAL|Cohort 2|Participants received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily.
62456693|NCT01309607|EXPERIMENTAL|Pre-operative Therapy|Neoadjuvant paclitaxel/carboplatin/lapatinib x 12 weeks
62645855|NCT04000113|EXPERIMENTAL|laser acupuncture treatment|Subjects accept low-dose near-infrared laser acupuncture (10mWx10) treatment for 5 minutes in each trial.
62076349|NCT04934774|EXPERIMENTAL|anti-CD7 CAR T cells|anti-CD7 CAR T cells Dose escalation phase: anti-CD7 CAR T cells transduced with a lentiviral vector to express CD7 chimeric receptor domain on T cells with an escalation approach, 1 e6 to 5 e6 CAR-T cells/kg.
62279764|NCT00272987|EXPERIMENTAL|Cohort 3|Participants in this arm received 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 750 mg PO
62279765|NCT01450982|EXPERIMENTAL|001|JNJ-38518168 / MTX Day 1: MTX: Route=oral use single dose of participant's weekly MTX dose Days 2-15: MTX: Route=oral use single dose of participant's weekly MTX dose and of JNJ-38518168 Type=exact unit=mg number=100 form=capsule route=oral use administered daily.
62076350|NCT01672450|EXPERIMENTAL|All patients|All participants in this study will receive the same treatment.
62076351|NCT05923593|EXPERIMENTAL|Oral nutritional supplement|Oral nutritional supplement that contains MAG oil
62279766|NCT04437212|EXPERIMENTAL|Toripalimab Group|All patients will receive radiation therapy scheme: 41.4Gy in 23 fractions over 5 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 45mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22,29 and 2 cycles of toripalimab 240 mg every 3 weeks after chemoradiotherapy. Esophagectomy is performed 6-8 weeks after CRT completion and after operation patients received 4 cycles of toripalimab 240 mg every 3 weeks for adjuvant treatment.
62279767|NCT04660643|EXPERIMENTAL|Tirzepatide (lead-in)|Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
62279768|NCT04660643|EXPERIMENTAL|Tirzepatide MTD|Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.
62279769|NCT04660643|PLACEBO_COMPARATOR|Placebo|Participants received weekly doses of placebo SC for 52 weeks.
62279770|NCT06128655|NO_INTERVENTION|CONTROL GROUP: survey and Standard Care (SC) or no NURSE-TECH-Family during PFCC-IR participation|15 family members
62279771|NCT06128655|EXPERIMENTAL|EXPERIMENTAL GROUP: participation in NURSE-TECH-Family during PFCC-IR|15 family members
62279772|NCT02280213|EXPERIMENTAL|Intubation without chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) during resuscitation without chest compressions.
62076352|NCT04388930||Kidney transplant live-donor|Participants that will be a planned live renal transplant donor
62076353|NCT04388930||Kidney transplant recipient|Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant
62076354|NCT05353543|EXPERIMENTAL|Acupuncture (strong reaction acupoints) group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Strong reaction acupoints selected in the first part of the study will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
62279773|NCT02280213|EXPERIMENTAL|Intubation with chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) with uninterrupted chest compressions. Chest compressions with the two thumb-encircling hands technique were performed by the same Basic Life Support (BLS) instructor at a rate of 100 compressions per minute and at a depth of about 1.5 inches according to the European Resuscitation Council guidelines of 2010 year.
62279774|NCT01717131|ACTIVE_COMPARATOR|Surgery for standard axillary node dissection|Standard axillary dissection
62279775|NCT01717131|EXPERIMENTAL|No axillary lymph node dissection|No surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial)
62279776|NCT06488261||Subjects who received AVR-RD-02|Subjects who received AVR-RD-02 in a separate parent trial
62279777|NCT04840472|EXPERIMENTAL|111-In panitumumab|The study drug (111In panitumumab) 5 mCi, allowable range 4.5 to 5.5 will be administered on Day 0, and subjects will undergo one 111In panitumumab SPECT/CT imaging anytime between Day 1 and Day of Surgery. Subjects will undergo surgical resection after infusion of 111In panitumumab.
62279778|NCT01924208|ACTIVE_COMPARATOR|Timothy|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
62279779|NCT01924208|ACTIVE_COMPARATOR|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
62645856|NCT04000113|SHAM_COMPARATOR|Sham laser acupuncture treatment|Subjects accept the sham (blank) laser acupuncture treatment for 5 minutes in each trial.
62279780|NCT01924208|ACTIVE_COMPARATOR|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
62279781|NCT01924208|NO_INTERVENTION|No intervention|No intervention (n=60, 50:50 atopic:non-atopic).
62645857|NCT01953029||non obstructive coronary disease|non obstructive coronary disease
62645858|NCT02991001|EXPERIMENTAL|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
62645859|NCT02991001|PLACEBO_COMPARATOR|Normal saline|Ultrasound-guided injection with normal saline at subcutaneous layer beyond the carpal tunnel region
62279782|NCT04702932||Patient with Monoclonal gammopathies of inflammatory significance|This group of patient will present a monoclonal gammopathy associated with inflammatory symptoms without known origin.
62279783|NCT04702932||Control group|The Control group will be healthy subject and patients with monoclonal gammopathies without inflammatory symptoms.
62279784|NCT01964235|EXPERIMENTAL|INC280 plus best supportive care|Approximately 46 patients will be treated with INC280 600 mg twice a day plus best supportive care.
62279785|NCT01964235|PLACEBO_COMPARATOR|Placebo plus best supportive care|Approximately 23 patients will be treated with matching placebo twice a day plus best supportive care.
62645860|NCT00687908|EXPERIMENTAL|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel once daily
62645861|NCT00687908|PLACEBO_COMPARATOR|2|Vehicle Gel once daily
62645862|NCT00618293|ACTIVE_COMPARATOR|1|intravenous infusion of Haemate (dosage dependent on body weight)
62645863|NCT00618293|PLACEBO_COMPARATOR|2|intravenous infusion of 0.9% NaCl solution
62645864|NCT04268160||Patients with severe aortic stenosis undergoing TAVR|GPx activity levels will be measured on the day of TAVR procedure, the day of discharge, 1 month, and 6 months after the procedure
62645865|NCT04268160||Patients without aortic stenosis|GPx activity levels will be measured on day of recruitment
62645866|NCT00848497|ACTIVE_COMPARATOR|Testim® + Viagra®|Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night
62645867|NCT00848497|PLACEBO_COMPARATOR|Placebo Testim® + Viagra®|Placebo Testim® gel once daily + Viagra® 25 mg tablet every night
62645868|NCT01347463||Traditional|
62645869|NCT02063672|EXPERIMENTAL|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
62645870|NCT02063672|ACTIVE_COMPARATOR|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
62645871|NCT03717571||Control group|age and sex matched healthy control persons
62076355|NCT05353543|EXPERIMENTAL|Acupuncture (weak reaction acupoints) group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Weak reaction acupoints selected in the first part of the study will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
62076356|NCT05353543|EXPERIMENTAL|Sham acupuncture group|This group will include 40 patients with MDD who will be treated with sham acupuncture and SSRIs antidepressants. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
62645872|NCT03717571||isolated tear|patients with isolated complete supraspinatus muscle tear
62076357|NCT03708419|EXPERIMENTAL|Optimal diet|Participants will follow a diet for a total duration of 12 weeks, optimal for their metabolic phenotype. For participants with muscle insulin resistance (MIR) this will be a diet high in monounsaturated fatty acids, for participants with liver insulin resistance (LIR) this will be a diet high in protein and fiber and low in fat.
62076358|NCT03708419|EXPERIMENTAL|Suboptimal diet|Participants will follow a diet for a total duration of 12 weeks, suboptimal for their metabolic phenotype. For participants with liver insulin resistance (LIR) this will be a diet high in monounsaturated fatty acids, for participants with muscle insulin resistance (MIR) this will be a diet high in protein and fiber and low in fat.
62076359|NCT03326089|ACTIVE_COMPARATOR|High flow oxygen supplementation|Pulmonary rehabilitation with constant high flow supplementary oxygen supply FiO2 50% for 2 months (Group A).
62645873|NCT03717571||combined tear|patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
62645874|NCT02936973|EXPERIMENTAL|Real catgut implantation|Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
62645875|NCT02936973|SHAM_COMPARATOR|sham catgut implantation|Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
62645876|NCT05634655||invasive PAs|
62645877|NCT05634655||non-invasive PAs|
62076360|NCT03326089|PLACEBO_COMPARATOR|Oxygen supplementation upon hypoxemia|Pulmonary rehabilitation without oxygen supply unless upon resting or exercise induced hypoxemia for 2 months (Group B).
62076361|NCT03173443|EXPERIMENTAL|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
62645878|NCT01302899|EXPERIMENTAL|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
62076362|NCT03173443|EXPERIMENTAL|double lumen tube|fiberoptic intubation with double lumen tube.
62645879|NCT01302899|EXPERIMENTAL|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule placebo to HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
62076363|NCT05418777|EXPERIMENTAL|TMP-SMX|Suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
62076364|NCT05418777|PLACEBO_COMPARATOR|Placebo|Suspension with placebo by mouth every 12 hours for 10 days
62076365|NCT00931450|ACTIVE_COMPARATOR|Group 1|Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
62076366|NCT00931450|EXPERIMENTAL|Group 2|Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
62076367|NCT01734850|EXPERIMENTAL|No busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning
62279786|NCT06451432|ACTIVE_COMPARATOR|Intervention group|Percutaneous Inguinal Ring Suturing (PIRS) technique
62279787|NCT06451432|NO_INTERVENTION|Control group|Open inguinal hernia repair
62279788|NCT01882907|EXPERIMENTAL|vildagliptin|vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
62076368|NCT01734850|EXPERIMENTAL|1 x 4mg/kg busulfan preconditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant
62076369|NCT01734850|EXPERIMENTAL|2 x 4mg/kg busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant
62076370|NCT04985734|EXPERIMENTAL|Patients under diagnostic work-up|
62076371|NCT01933386|OTHER|SoundBite|SoundBite will be used for the first 30 days
62076372|NCT01933386|OTHER|Surgically Implanted BCD|The subject's own surgically implanted bone conduction device will be used for the first 30 days.
62076373|NCT04374500|EXPERIMENTAL|Leptin infusion|This applies to protocol 1 when 10 healthy men got leptin infused locally in the forearm and forearm blood flow (FBF) was measured. The other forearm was used as the control.
62076374|NCT04374500|EXPERIMENTAL|Leptin infusion plus vasodilator infusion|This applies to protocol 2 when 10 healthy men got either a background infusion of leptin or saline locally in the forearm when measuring vasoresponse (FBF) to four vasodilatators. Each participant had two examinations with either leptin or saline and the order was randomised. The other forearm was used as the control.
62076375|NCT04374500|EXPERIMENTAL|Vasodilator infusion in CAD patients|This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse (FBF). The other forearm was used as the control.
62076376|NCT03194074|EXPERIMENTAL|propofol group|Propofol/remifentanil-based general anesthesia.
62076377|NCT03194074|EXPERIMENTAL|desflurane group|Desflurane/remifentanil-based general anesthesia.
62076378|NCT00742105|EXPERIMENTAL|BGT226|
62279789|NCT01882907|ACTIVE_COMPARATOR|pioglitazone|Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
62279790|NCT02613728|ACTIVE_COMPARATOR|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
62279791|NCT02613728|EXPERIMENTAL|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
62279792|NCT04041895||Alzheimer's Disease|Those individuals who possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
62279793|NCT04041895||Control|Those individuals who do not possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
62279794|NCT00801866|EXPERIMENTAL|Group 1|Panretinal Photocoagulation + Bevacizumab
62279795|NCT00801866|EXPERIMENTAL|Group 2|Panretinal Photocoagulation
62279796|NCT03341169|EXPERIMENTAL|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
62279797|NCT03341169|PLACEBO_COMPARATOR|Placebo|
62645880|NCT05449899|EXPERIMENTAL|G-CSF+DAC+BF|For patients with sAML undergoing allo-HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
62076379|NCT05027737|EXPERIMENTAL|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
62279798|NCT03373565|ACTIVE_COMPARATOR|Radial|Coronary angiography using radial approach
62456694|NCT05897398||Patients already receiving WEGOVY® treatment included in the ATUc/AP2|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
62076380|NCT05027737|NO_INTERVENTION|Traditional closure (control)|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo a standardized reversal of their diverting loop ileostomy. The latter will be performed with a stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia and will be performed no earlier than 12 weeks following their index surgery.
62279799|NCT03373565|EXPERIMENTAL|palmar|Coronary angiography using palmar approach
62279800|NCT06358222||Blood ctDNA + methylation + PET-CT vs Postoperative pathology|
62279801|NCT06358222||MRD+ methylation (or combined with PET-CT) vs Invasive mediastinoscopy /EBUS-TBNA|
62279802|NCT06358222||Lymph Node dissection vs no lymph node dissection|
62456695|NCT05897398||New WEGOVY® patients included in the AP2,|"At initiation, 6 months and 12 months of WEGOVY® treatment, the following procedures will be performed (in addition to the data collection already provided for in the ATU/AP2):~* Blood sampling for routine care (max 15mL) and constitution of a plasma bank (28 mL)~* Completion of questionnaires for the entire cohort:~  * To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire~ * To assess physical activity: short IPAQ~ * To assess sleep behaviour: MCTQ~ * To assess quality of life: EQ5D5L~ * To assess digestive system disorders: GIQLI~ * To assess anxiety and depression: HAD~* Collection of clinical and biological data from the WEGOVY® ATU/AP eCRF"
62456696|NCT04217408|EXPERIMENTAL|ON stimulation followed by OFF stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of ON (active) stimulation, followed by 2 weeks of OFF (sham) stimulation
62456697|NCT04217408|EXPERIMENTAL|OFF stimulation followed by ON stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of OFF (sham) stimulation, followed by 2 weeks of ON (active) stimulation
62456698|NCT01840371|EXPERIMENTAL|Propofol based group|
62456699|NCT01840371|ACTIVE_COMPARATOR|Fentanyl based group|
62456700|NCT05344872|ACTIVE_COMPARATOR|Group A|Weaning trial will be done for 17 patients using PSV 0 cmH2O with 100% automatic tube compensation (ATC).
62456701|NCT05344872|ACTIVE_COMPARATOR|Group B|Weaning trial will be done for 17 patients using PSV 8 cmH2O without ATC.
62456702|NCT05866497||diabetes and periodontitis group (group 1)|"35 subjects with type 2 diabetes and severe periodontitis were recruited in group 1.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
62076381|NCT02183428|EXPERIMENTAL|BI 1356|"Treatment sequence AB_C or C_AB~* Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~* Treatment B: 1 day of combined treatment of BI1356 and glyburide~* Treatment C: 1 day of treatment with glyburide alone"
62279803|NCT00703664|EXPERIMENTAL|Treatment (vorinostat, bortezomib)|"Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.~Treatment arm consists of 3 cohorts, all receiving the same treatment:~A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib."
62279804|NCT01323205|EXPERIMENTAL|JNJ-40411813 (Part A)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
62279805|NCT01323205|EXPERIMENTAL|JNJ-40411813 (Part B)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks.
62456703|NCT05866497||diabetes and periodontally healthy (group 2)|"34 subjects with type 2 diabetes and periodontally healthy were recruited in group 2.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
62076382|NCT02183428|ACTIVE_COMPARATOR|Glyburide|"Treatment sequence AB_C or C_AB~* Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~* Treatment B: 1 day of combined treatment of BI1356 and glyburide~* Treatment C: 1 day of treatment with glyburide alone"
62456704|NCT05866497||systemically healthy and periodontitis (group 3)|"32 systemically healthy subjects with severe periodontitis were recruited in group 3.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
62076383|NCT01418040||High risk prostate cancer|Histologically confirmed patients with high risk prostate cancer seen at Calvary Mater Newcastle.
62076384|NCT01706224||Group A|Subjects in this group will be all physicians actively working at hospital centres in Spain.
62076385|NCT01706224||Group B|Subjects in this group will be all nurses actively working at hospital centres in Spain.
62076386|NCT01706224||Group C|Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.
62279806|NCT01323205|EXPERIMENTAL|Placebo and JNJ-40411813 (Part B)|Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks.
62279807|NCT04291755||Checkpoint inhibitor therapy|Patients will be administered a checkpoint inhibitor therapy, including but not limited to pembrolizumab, nivolumab, ipilimumab, and atlizumab, at the standard dosing regimen prescribed by their physician. Stool, blood, and urine samples will be collected from patients prior to start of treatment, and at 4 more timepoints over the next 12 months.
62279808|NCT05152082||patients with colorectal advanced adenomas|
62279809|NCT05152082||patients without colorectal advanced adenomas|
62279810|NCT05364411|EXPERIMENTAL|HYDRA-protons|group 1, n=25, run at HollandPTC
62279811|NCT05364411|ACTIVE_COMPARATOR|Conventional fractionated proton therapy|group 2, n=25, run at HollandPTC
62279812|NCT05364411|EXPERIMENTAL|HYDRA-photons|group 3, n=25 run at Erasmus MC
62456705|NCT05866497||systemically healthy and periodontally healthy (group 4)|"35 systemically and periodontally healthy subjects were recruited in group 4.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
62456706|NCT03091946|PLACEBO_COMPARATOR|Cooked cream of rice|Cream of rice with additional dried fruits, nuts and seeds cooked just prior to its consumption and served with skim milk as a beverage
62456707|NCT03091946|EXPERIMENTAL|Overnight oats|Oats with additional dried fruits, nuts and seeds soaked overnight in skim milk
62456708|NCT00637390|EXPERIMENTAL|one|
62456709|NCT01184560|EXPERIMENTAL|Sibutramine + Orlistat|"A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence"
62456710|NCT01184560|PLACEBO_COMPARATOR|Sibutramine + Orlistat(Placebo)|"1. Sibutramine : one of components included into Diet Pills. This reduces appetite, normalizes amount of cholesterol in blood, and reduces abdominal fat.~2. Orlistat : A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence."
62456711|NCT06324149||older volunteers|"1250 individuals of the FRASNET study (original promoter of the study Ospedale San Raffaele, Principal Investigator Professor Paolo Manunta): older volunteers who were either robust or frail at the evaluations performed in 2016-2017)~* completion of scales and questionnaires~* venous blood sampling~* muscle ultrasound~* cardiac ultrasound~* electrocardiogram~* bioelectrical impedance analysis"
62456712|NCT06324149||neurology patients|"720 patients suffering from cognitive impairment and clinically followed at the Neurology Department of the San Raffaele Hospital (UniSR Prof Agosta)~* completion of scales and questionnaires~* venous blood sampling~* muscle ultrasound~* cardiac ultrasound~* electrocardiogram~* bioelectrical impedance analysis"
62456713|NCT05904808|ACTIVE_COMPARATOR|Diuretic comparison|each participant will be followed for 4 consecutive weeks. during which 3 different diuretic regimens will be given (random sequence). Last week follow up without protocol regimen.
62279813|NCT05364411|ACTIVE_COMPARATOR|Conventional fractionated photon therapy|group 4, n=25 run at Erasmus MC
62279814|NCT00524537||Adalimumab (Humira) Treatment|Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.
62279815|NCT01775631|EXPERIMENTAL|Arm -1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
62279816|NCT01775631|EXPERIMENTAL|Arm 1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
62279817|NCT02160405|EXPERIMENTAL|Normal diet|
62279818|NCT04672161|EXPERIMENTAL|Vaccine Education|Patients randomized to the Experimental arm will receive a baseline educational intervention on vaccination following a vaccination history survey. Patients will be followed 6-months after the intervention to record prospective clinical data. Evidence of vaccination-status will be documented. Besides standard of care visits and testing, no additional procedures will be carried out for the purpose of this study.
62279819|NCT04672161|NO_INTERVENTION|No Vaccine Education|Patients randomized to the No Intervention arm will not receive the Vaccine Education. They will only complete the survey on their vaccination history.
62279820|NCT04755946|EXPERIMENTAL|roflumilast arm|
62279821|NCT04755946|PLACEBO_COMPARATOR|placebo arm|
62279822|NCT01963481|EXPERIMENTAL|Exemestane and cyclophosphamide|"A treatment cycle is defined as 4 weeks:~One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
62279823|NCT02499029|EXPERIMENTAL|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
62076387|NCT01706224||Group D|Subjects in this group will be all midwives actively working at hospital centres in Spain.
62456714|NCT05874466||Pediatric patients, 16-37 months of age, recruited through pediatric medical clinics|Consecutive pediatric participants will be recruited and enrolled via \> 6 participating sites comprised of pediatric medical clinics (e.g., primary care and family medicine clinics) that are part of the broader Duke University Health System (DUHS) located in North Carolina. Enrollment will proceed until the targets of N = 150 participants diagnosed with autism spectrum disorder and N = 200 without autism are reached.
62456715|NCT05432011|EXPERIMENTAL|PENG block plus Femoral Cutaneous Nerve Block|Participants receiving PENG block combined to Lateral Femoral Cutaneous Nerve Block
62456716|NCT05432011|ACTIVE_COMPARATOR|PENG block plus Wound Infiltration|Participants receiving PENG block combined to wound infiltration
62076388|NCT05642546|EXPERIMENTAL|NM8074|6 subjects per each of the 5 cohorts will receive a single dose of NM8074 administered via IV (intravenous) infusion at 0.3, 1.0, 3.0, 10, or 20 mg/kg
62076389|NCT05642546|PLACEBO_COMPARATOR|Placebo|2 subjects per each of the 5 cohorts will receive saline placebo administered via IV infusion.
62456717|NCT05881096|EXPERIMENTAL|START (Startle Adjuvant Rehabilitation Therapy)|Participants in this group practice a functional reaching task with the START condition (startling acoustic stimuli applied during 33% of trials).
62076390|NCT06420102||Grade 1 pressure ulcer cohort|Individuals who are in hospital that present with a confirm grade 1 pressure ulcer. These include a range of sex, age and ethnicities.
62076391|NCT00759824|EXPERIMENTAL|1|Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
62076392|NCT02479997|ACTIVE_COMPARATOR|Radioisotope (RI)|"Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected only RI~* fill the Primay Case Report Form during surgery~  * PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- ."
62456718|NCT05881096|SHAM_COMPARATOR|Control|Participants in this group will practice a functional reaching task without the START (Startle Adjuvant Rehabilitation Therapy) intervention
62279824|NCT02499029|PLACEBO_COMPARATOR|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
62645881|NCT05449899|ACTIVE_COMPARATOR|G-CSF+DAC+BUCY|For patients with sAML undergoing allo-HSCT, Granulocyte Colony -Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3, -2.
62645882|NCT00787826|EXPERIMENTAL|Vaccination|Live Francisella Tularensis Vaccine
62645883|NCT06422039|EXPERIMENTAL|Treatment group A|
62645884|NCT06422039|EXPERIMENTAL|Treatment group B|
62645885|NCT06422039|EXPERIMENTAL|Treatment group C|
62645886|NCT01348841|NO_INTERVENTION|Control Arm|Usual care is care as currently delivered to clients with chronic wounds in the community.
62645887|NCT01348841|EXPERIMENTAL|Intervention Arm|"Systematic referral to MDWCT and comprehensive primary care:~Intervention consists of systematic referral to MDWCT in conjunction with comprehensive primary care.Systematic referral to, and follow up, by MDWCTs, co-ordinated by the CM, will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4."
62645888|NCT03271138|ACTIVE_COMPARATOR|Bifidobacterium Infantis NLS Super Strain|Participants in the probiotic period will take two capsules of Bifidobacterium infantis NLS super strain (Natren LIFE START®2) three times per day for three weeks. Each capsule contains 2 x 10\^9 colony-forming units (CFU) of Bifidobacterium infantis NLS super strain, for a total daily dose of 12 X 10\^9 CFU. The probiotic will be kept refrigerated during transportation and throughout the study period.
62645889|NCT03271138|PLACEBO_COMPARATOR|Placebo|Participants in the placebo period will take two capsules of placebo three times per day for three weeks. The placebo capsules contain rice flour, hydroxypropyl and methylcellulose. The placebo will be kept refrigerated during transportation and throughout the study period.
62645890|NCT02069795|EXPERIMENTAL|Voice recording|Subjects voices were recorded as they spoke specific words
62645891|NCT01449253|ACTIVE_COMPARATOR|Monotherapy|Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months
62076393|NCT02479997|ACTIVE_COMPARATOR|Indocyanine green (ICG) +RI|"Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected RI +ICG~* prepare fluorescence camera when the surgery begin~* surgeon uses the camera to decect fluorescence flow on SLN~* fill the Primay Case Report Form during surgery~  * PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-"
62076394|NCT03580356|EXPERIMENTAL|Ligelizumab 120 mg|Ligelizumab 120 mg arm: 1 injection of 1.0 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
62076395|NCT03580356|EXPERIMENTAL|Ligelizumab 72 mg|Ligelizumab 72 mg arm: 1 injection of 0.6 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
62076396|NCT03580356|ACTIVE_COMPARATOR|Omalizumab 300 mg|Omalizumab 300 mg arm: 2 injections of 1.2 mL omalizumab q4w
62076397|NCT03580356|PLACEBO_COMPARATOR|Placebo|Placebo-ligelizumab arm: 2 injections of 1.0mL of ligelizumab placebo from Week 0 through Week 20; 1 injection of 1.0mL of ligelizumab 120 mg + 1 injection of 1.0 mL ligelizumab placebo from Week 24 through Week 48
62279825|NCT00292500|NO_INTERVENTION|C-Port|Automated distal anastomotic device
62076398|NCT05642273|EXPERIMENTAL|Intervention|Oxiris for 24 h
62076399|NCT05642273|ACTIVE_COMPARATOR|Control|Usual care
62076400|NCT01358448|NO_INTERVENTION|Newsletter|
62645892|NCT01449253|ACTIVE_COMPARATOR|Sequential Therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started be added after 3 months. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. Bosentan and sildenafil will be in combination in the last 3 months. No fixed dose combination will be used.
62645893|NCT01449253|ACTIVE_COMPARATOR|Combination therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. No fixed dose combination will be used.
62645894|NCT02281708|NO_INTERVENTION|low risk|low risk; observation
62645895|NCT02281708|NO_INTERVENTION|high risk; observation group|high risk: observation
62645896|NCT02281708|EXPERIMENTAL|high risk; adjuvant chemotherapy group|high risk. vinorelbine plus cisplatin
62645897|NCT01916200|EXPERIMENTAL|Paroxetine CR group|Paroxetine CR plus IBS regular treatment group
62645898|NCT01916200|NO_INTERVENTION|Blank group|IBS regular treatment group
62076401|NCT01358448|EXPERIMENTAL|Growth Monitoring|
62076402|NCT01358448|EXPERIMENTAL|Growth Monitoring plus Family-based Behavioral Counseling|
62076403|NCT04336423||Healthy smoker|Healthy smokers with smoking history at least 10 pack-years and normal spirometry value
62076404|NCT04336423||COPD patient|Patients with smoking history at least 10 pack-years and persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \<0.7)
62076405|NCT04683289|EXPERIMENTAL|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy
62076406|NCT04683289|ACTIVE_COMPARATOR|viscotrabeculotomy|Viscotrabeculotomy
62279826|NCT02738658|EXPERIMENTAL|Bioresorbable vascular scaffold (BVS)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.
62456719|NCT03236181|OTHER|Saturated Fat/SFA|30 grams saturated fat (SFA) in the form of heavy whipping cream will be provided to subject in a mixed meal shake
62456720|NCT03236181|OTHER|Monounsaturated Fat/MUFA|30 grams monounsaturated fat (MUFA) in the form of olive oil will be provided to subject in a mixed meal shake
62456721|NCT03236181|OTHER|Polyunsaturated Fat Linoleic/PUFA|30 grams high linoleic polyunsaturated fat (PUFA) in the form of high linoleic sunflower oil will be provided to subject in a mixed meal shake
62456722|NCT03236181|OTHER|Polyunsaturated Fat Omega-3/LCn3|30 grams high omega-3 polyunsaturated fat (LCn3) in the form of fish oil will be provided to subject in a mixed meal shake
62456723|NCT02954757|EXPERIMENTAL|Treatment arm|HIFU treatment
62279827|NCT02738658|ACTIVE_COMPARATOR|Everolimus-eluting stent (EES)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .
62279828|NCT02816957|ACTIVE_COMPARATOR|patients receiving Nigella|40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.
62456724|NCT03735758|EXPERIMENTAL|Pazopanib|Pazopanib; 800 mg; daily; oral
62456725|NCT03735758|ACTIVE_COMPARATOR|Chemotherapy|Guideline-conform chemotherapy
62456726|NCT01667783|ACTIVE_COMPARATOR|Gastric Banding|Laparoscopic Adjustable Gastric Banding
62456727|NCT01667783|ACTIVE_COMPARATOR|Medical Weight Loss|Medical Weight Loss using a comprehensive lifestyle intervention consisting of diet (meal replacements), physical activity and behavioral techniques
62456728|NCT01667783|ACTIVE_COMPARATOR|Gastric Bypass|Roux-en-Y Gastric Bypass
62076407|NCT06355713|EXPERIMENTAL|Essure Group|Patients requiring removal of the Essure® contraceptive implant
62456729|NCT05586009|ACTIVE_COMPARATOR|Group 1|(n=25): receive cisplatin with hydration 1000mg magnesium (8 Meq) intravenous infusion ( IVI ).
62456730|NCT05586009|ACTIVE_COMPARATOR|Group 2|(n=25): receive cisplatin with hydration 2000mg magnesium (16 Meq) ( IVI ).
62456731|NCT05586009|ACTIVE_COMPARATOR|Group 3|(n=25): receive cisplatin with hydration 3000 mg magnesium (32 Meq) ( IVI ).
62076408|NCT06355713|ACTIVE_COMPARATOR|Control Group|Control patients who should benefit from a salpingectomy with or without hysterectomy for a benign indication
62076409|NCT04934137|ACTIVE_COMPARATOR|Sensoria first intervention|Group 1 participants will receive the Sensoria intervention during the first intervention phase for 4 weeks, and then the AW-Shift intervention during the second intervention phase for 4 weeks.
62279829|NCT02816957|NO_INTERVENTION|patients not received nigella as controls|40 patients in the control group will not receive nigella sativa and continued on the usual chelators
62279830|NCT01121380|EXPERIMENTAL|Cohort A - 10 mg|
62456732|NCT04277910|ACTIVE_COMPARATOR|MT2004|MT2004 oral capsules treated group
62279831|NCT01121380|EXPERIMENTAL|Cohort B - 20 mg|
62076410|NCT04934137|ACTIVE_COMPARATOR|AW-Shift first intervention|Group 2 participants will receive the AW-Shift intervention during the first intervention phase for 4 weeks, and then the Sensoria intervention during the second intervention phase for 4 weeks.
62076411|NCT01427621|EXPERIMENTAL|RIPCcom group|
62076412|NCT01427621|NO_INTERVENTION|Control group|
62076413|NCT03745794|ACTIVE_COMPARATOR|Arm I (QL block, standard of care)|Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery.
62279832|NCT01121380|EXPERIMENTAL|Cohort C - 40 mg|
62279833|NCT01121380|EXPERIMENTAL|Cohort D - 80 mg|
62279834|NCT01121380|EXPERIMENTAL|Cohort E - X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
62279835|NCT01121380|EXPERIMENTAL|Cohort F - 2X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
62279836|NCT01121380|EXPERIMENTAL|Cohort G - 4X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
62456733|NCT04277910|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules treated group
62456734|NCT03270293|EXPERIMENTAL|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:~1. zygomatic protuberance~2. nostril's angle~3. inferior margin of tragus~4. lip marionette lines~5. mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
62456735|NCT04525248|ACTIVE_COMPARATOR|High resection|Laparoscopic total colectomy + High resection of rectum
62456736|NCT04525248|EXPERIMENTAL|Low resection|Laparoscopic total colectomy + Low resection of rectum
62456737|NCT02512666|EXPERIMENTAL|Non-Invasive Imaging|"Commercial portable optical microscope (AM4113-N5UT Dino-Lite ) which will be employed during the study for a pre determined time of non-invasive imaging of the nailfold capillaries in ASCT patients.~For Autologous Stem Cell Transplant (ASCT) participants, the imaging will be performed once prior to ASCT upon admission to the hospital, and then daily after ASCT (starting on day +7) until count recovery"
62456738|NCT01114464||young women with breast cancer|
62279837|NCT01121380|PLACEBO_COMPARATOR|Placebo|In each cohort there is a placebo arm
62279838|NCT01997463|NO_INTERVENTION|Regular Therapy|Regular Asthma Therapy
62279839|NCT01997463|EXPERIMENTAL|Supervised Therapy|Supervised asthma therapy in schools
62279840|NCT02082678|ACTIVE_COMPARATOR|Ondansetron|Ondansetron will be given 0.5 mg twice a day (BID). The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
62076414|NCT03745794|EXPERIMENTAL|Arm II (second QL block)|Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care.
62645899|NCT03964207|EXPERIMENTAL|(T1): 5μg tiotropium Respimat®, then (T2): 18μg tiotropium Handihaler®|"From Day 1 of Period 1 participants received Test treatment (T1): tiotropium Respimat® (Spiriva® Respimat®) 5 microgram (μg) once daily for a duration of 4 weeks, given as 2.5μg per puff, two puffs (2.5μg per puff) inhalation solution of tiotropium, orally via Respimat®.~From Day 1 of Period 2 participants received comparator treatment(T2): tiotropium Handihaler® (Spiriva®) 18μg once daily for a duration of 4 weeks, inhalation powder tiotropium with 1 Handihaler® device."
62645900|NCT03964207|EXPERIMENTAL|(T2): 18μg tiotropium Handihaler®, then (T1): 5μg tiotropium Respimat®|"From Day 1 of Period 1 participants received comparator treatment (T2): tiotropium Handihaler® (Spiriva®) 18 microgram (μg) once daily for a duration of 4 weeks, inhalation powder tiotropium with 1 Handihaler® device.~From Day 1 of Period 2 participants received Test treatment (T1): tiotropium Respimat® (Spiriva® Respimat®) 5 microgram (μg) once daily for a duration of 4 weeks, given as 2.5μg per puff, two puffs (2.5μg per puff) inhalation solution of tiotropium, orally via Respimat®."
62279841|NCT02082678|PLACEBO_COMPARATOR|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
62645901|NCT01378208|EXPERIMENTAL|Normal weight|Body Mass Index between 18-25 kg/m2 Age between 18-35 years male
62279842|NCT06253039|EXPERIMENTAL|Normobaric hypoxia (RSH)|The RSH group will perform training sessions in a normobaric hypoxic chamber at a simulated altitude of 3000 meters (FiO2 14.5%)
62279843|NCT06253039|EXPERIMENTAL|Hypoventilation (RSH-VHL)|RSH-VHL group will be asked to exhale down to functional residual capacity just before each repetition and then hold their breath until the end of the sprint
62279844|NCT06253039|ACTIVE_COMPARATOR|Normoxia (RSN)|The control group will perform the training sessions in normoxia (FIO2, 20.9%)
62279845|NCT06425809||Observational group|"Data collection will take place between May and June 2024. This will be done through a self-questionnaire format with closed questions where no data will be collected that allow the identification of the subject (name, surname, or national identity document).~The coding of the data collected and its analysis will be carried out under the supervision of the principal investigator, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the patients whose data are collected."
62279846|NCT03050580|EXPERIMENTAL|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
62279847|NCT03050580|ACTIVE_COMPARATOR|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
62456739|NCT04588753|ACTIVE_COMPARATOR|Active Isolated Stretch|active isolated stretching, strengthening exercises
62076415|NCT04002180||Vedolizumab 300 mg|Vedolizumab (Genetical Recombination) 300 mg, IV infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
62076416|NCT03498014|ACTIVE_COMPARATOR|Prescription as standard|
62076417|NCT03498014|EXPERIMENTAL|Pharmacogenetic-guided prescription|
62076418|NCT03936296|ACTIVE_COMPARATOR|fusion arm|Patients in this arm will be undertaken standard transrectal prostate biopsy and MR guided MR-US fusion prostate biopsy
62076419|NCT03936296|OTHER|Standard arm|Patients in this arm will be undertaken only standard transrectal prostate biopsy
62076420|NCT01257139|NO_INTERVENTION|dual-agent therapy or docetaxel alone|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, according to PS or age
62076421|NCT01257139|EXPERIMENTAL|dual-agent therapy or docetaxel or best supportive care|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, or best supportive care, allocated on the basis of a simplified geriatric scale, plus a more thorough geriatric evaluation if necessary
62076422|NCT02693886||A group|Experience of endoscopist: \>2000 cases
62279848|NCT05719480||Liver Cancer patients|Patients who meet the diagnostic criteria of the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (Version 2019) of the Chinese Medical Association
62456740|NCT04588753|ACTIVE_COMPARATOR|Post Facilitation Stretch|Post Facilitation Stretching, strengthening exercises
62456741|NCT02475915|EXPERIMENTAL|ART + VHM|"Group 1: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.~Plus: 3 X 14-day cycles of vorinostat administered at weeks 0, 4 and 8; hydroxychloroquine and maraviroc prescribed at week 0 for a period of 10 weeks."
62076423|NCT02693886||B group|Experience of endoscopist:between 1000 and 2000 cases
62076424|NCT02693886||C group|Experience of endoscopist:between 500 and 1000 cases
62076425|NCT02693886||D group|Experience of endoscopist:\<500 cases
62645902|NCT03971331|NO_INTERVENTION|control group|Patients in control group received usual care that was decided by attending.
62645903|NCT03971331|EXPERIMENTAL|study group|Patients in study group who had been placed the PAC were performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately.
62076426|NCT03693716|EXPERIMENTAL|Dynamic Anterior Stabilization|Arthroscopic Dynamic Anterior Capsular Stabilization with Trans subscapular Long Head of the Biceps Tenodesis
62076427|NCT03008122|EXPERIMENTAL|Group 1|5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29 , n=45 (2 sentinels, 43 non-sentinels) or placebo, n=5
62076428|NCT03008122|EXPERIMENTAL|Group 2|2.5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29, n=35 or placebo, n=5
62076429|NCT00991159|EXPERIMENTAL|RN316|
62076430|NCT02868580|EXPERIMENTAL|Single arm open label|All subjects will receive open label Triumeq following a lead-in phase. Triumeq is abacavir 600mg, lamivudine 300mg, dolutegravir 50mg
62076431|NCT00061620|EXPERIMENTAL|Tezacitabine|Tezacitabine as a bolus infusion daily x 5
62279849|NCT05719480||Liver Cirrhosis patients|Patients who meet the diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Liver Cirrhosis (2019) issued by the Hepatology Branch of the Chinese Medical Association
62076432|NCT03936413|EXPERIMENTAL|Bay Labs EchoGPS group|In this arm, medical residents will use the Bay Labs EchoGPS system to perform an echocardiogram.
62076433|NCT03936413|ACTIVE_COMPARATOR|Native Terason group|In this arm, medical residents will use the native Terason machine to perform an echocardiogram.
62076434|NCT03253770|EXPERIMENTAL|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
62076435|NCT03253770|EXPERIMENTAL|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
62645904|NCT01868659|EXPERIMENTAL|Diagnostic checklist|Diagnostic checklist used before patient discharged
62076436|NCT03253770|EXPERIMENTAL|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.~Intervention : paper cognitive aid in the hand of the leader during crises management."
62076437|NCT00654329|EXPERIMENTAL|Dexmedetomidine 1microgram/kilogram|Dexmedetomidine 1microgram/kilogram intranasal
62076438|NCT00654329|EXPERIMENTAL|Dexmedetomidine 2 micrograms/kilogram|Dexmedetomidine 2 micrograms/kilogram intranasal
62076439|NCT00654329|ACTIVE_COMPARATOR|Fentanyl 2 micrograms/kilogram|Fentanyl 2 micrograms/kilogram intranasal
62076440|NCT00654329|PLACEBO_COMPARATOR|Normal saline placebo|Normal saline placebo intranasal
62645905|NCT01868659|PLACEBO_COMPARATOR|Usual care|No diagnostic checklist used during patient encounter
62076441|NCT05297721||Nurse|Nurses who (1) were employed as a nurse for at least 1 year, (2) cared for patients aged 65 and over and (3) agreed to participate in the study were included in the study.
62076442|NCT01165840|EXPERIMENTAL|Dapsone|Dapsone 100 mg PO x 1 dose
62076443|NCT01622712|EXPERIMENTAL|Unilateral inguinal hernia|A Nitinol containing large pore polypropylene mesh will be placed in patients with unilateral inguinal hernia.
62279850|NCT05719480||Fatty Liver patients|Patients whose liver imaging findings meet the imaging diagnostic criteria for diffuse fatty liver disease or whose liver biopsy histology changes meet the pathological diagnostic criteria for fatty liver disease
62645906|NCT00578903|EXPERIMENTAL|Patients|"Patients with a diagnosis of severe aplastic anemia who require an allogeneic stem cell transplant but lack an Human Leukocyte Antigen (HLA) identical family member.~Cytoxan, Campath, TBI-Total Body Irradiation, FK-506, Methotrexate, Stem Cell Infusion"
62076444|NCT02632786|EXPERIMENTAL|NEOD001|Study Drug given IV every 28 days at 24mg/kg
62076445|NCT02632786|PLACEBO_COMPARATOR|Placebo|Placebo
62076446|NCT05741970|ACTIVE_COMPARATOR|IL-6 and CRP levels of the hypertensive and periodontitis group|All patients with periodontitis received phase I periodontal therapy including oral hygiene instruction (OHI) and scaling/root planning (SRP) without any antimicrobial therapy. GCF and saliva samples were obtained and clinical measurements were performed at baseline (before treatment (BT) and four weeks (4 weeks 3 days) after the phase I periodontal therapy (AT).
62076447|NCT05741970|NO_INTERVENTION|IL-6 and CRP levels of the hypertensive and healthy group|GCF and saliva samples were obtained and clinical measurements were performed at baseline
62076448|NCT05741970|ACTIVE_COMPARATOR|IL-6 and CRP levels of the periodontitis and healthy group|All patients with periodontitis received phase I periodontal therapy including oral hygiene instruction (OHI) and scaling/root planning (SRP) without any antimicrobial therapy. GCF and saliva samples were obtained and clinical measurements were performed at baseline (before treatment (BT) and four weeks (4 weeks 3 days) after the phase I periodontal therapy (AT).
62279851|NCT05719480||Hepatitis patients|Patients who meet the diagnostic criteria for hepatitis B (ws 299-2008) and are diagnosed as hepatitis B;
62279852|NCT05719480||healthy people|Healthy people without liver related medical history or other diseases known to affect blood lipid/protein metabolism
62279853|NCT00763321|EXPERIMENTAL|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
62279854|NCT00763321|EXPERIMENTAL|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
62279855|NCT00763321|PLACEBO_COMPARATOR|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
62076449|NCT05741970|NO_INTERVENTION|IL-6 and CRP levels of the systemically and periodontally healthy group|GCF and saliva samples were obtained and clinical measurements were performed at baseline
62076450|NCT06475560|ACTIVE_COMPARATOR|CCE arm|Symptomatic patients referred by their GP for a 2 week diagnostic lower gastrointestinal procedure will be randomized in clusters determined by the GP clinic provider number. At the start of the project, odd provider numbers will be referred to OC, and even provider numbers will be referred to CCE. After the inclusion of the first 200 consecutive CCE patients, the two arms will be swapped, i.e., patients from clinics with even provider numbers are referred for OC, and odd provider numbers are referred for CCE.
62279856|NCT06500832||All participants|
62076451|NCT06475560|PLACEBO_COMPARATOR|OC arm|Symptomatic patients referred by their GP for a 2 week diagnostic lower gastrointestinal procedure will be randomized in clusters determined by the GP clinic provider number. At the start of the project, odd provider numbers will be referred to OC, and even provider numbers will be referred to CCE. After the inclusion of the first 200 consecutive CCE patients, the two arms will be swapped, i.e., patients from clinics with even provider numbers are referred for OC, and odd provider numbers are referred for CCE.
62076452|NCT05387486|ACTIVE_COMPARATOR|ALT|
62076453|NCT05387486|ACTIVE_COMPARATOR|USG-Pre|
62076454|NCT05387486|ACTIVE_COMPARATOR|USG -RT|
62076455|NCT06488768|EXPERIMENTAL|Opioid tolerant|Daily use of opioid of 60 mg or more
62279857|NCT00328146||Observation of Sternal Re-entry|All subjects.
62645907|NCT03673891|NO_INTERVENTION|Control|After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
62645908|NCT03673891|EXPERIMENTAL|LifeFlow group|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
62645909|NCT05120076|ACTIVE_COMPARATOR|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
62645910|NCT05120076|PLACEBO_COMPARATOR|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. 3ml of a 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
62076456|NCT06488768|EXPERIMENTAL|Opioid naive|No use of opioids within the last 30 days
62076457|NCT00684268|EXPERIMENTAL|on treatment nonresponders|naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
62076458|NCT00684268|EXPERIMENTAL|Nonresponders to previous antiviral combination therapy|Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy
62076459|NCT03953404||septic shock|
62076460|NCT03953404||severe sepsis|
62076461|NCT03953404||sepsis|
62076462|NCT03953404||sirs positive, not septic|
62456742|NCT02475915|ACTIVE_COMPARATOR|ART alone|Group 2: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and either an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
62076463|NCT04929366|EXPERIMENTAL|End-stage kidney patients treated in the dialysis unit group 1|
62076464|NCT04929366|EXPERIMENTAL|End-stage kidney patients treated in the dialysis unit group 2|
62076465|NCT05480332||EndoPAT Measured|Study participants who will undergo EndoPAT testing to obtain a non-invasive measurement of their endothelial function
62076466|NCT04864821|OTHER|T cell injection targeting CD276 chimeric antigen receptor|
62076467|NCT01831414|EXPERIMENTAL|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
62076468|NCT01831414|EXPERIMENTAL|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
62076469|NCT03669094|ACTIVE_COMPARATOR|L. salivarius V4II-90|Lactobacillus salivarius V4II-90; approximately 1\*10E9 colony forming unit (CFU) of L. salivarius V4II-90 in 1 oral capsule per day for 12 weeks.
62076470|NCT03669094|PLACEBO_COMPARATOR|Control group|Placebo supplement in 1 oral capsule per day for 12 weeks.
62279858|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
62279859|NCT00624520|ACTIVE_COMPARATOR|Cognitive Behavioral Stress Management|10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
62279860|NCT00624520|ACTIVE_COMPARATOR|Patient Education|10 week program of once weekly Patient Education group sessions
62456743|NCT00118053|EXPERIMENTAL|Docetaxel, Carboplatin and Trastuzumab|"A total of six cycles of TCH \[(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)\] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.~* Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.~* If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
62456744|NCT04347291|EXPERIMENTAL|FAMS 2.0|"Patient participants will receive FAMS 2.0 components (monthly phone coaching and text message support for goals and medication adherence) for nine months. Linked support persons will receive text message support tailored to the goal set by the patient participant.~All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes."
62076471|NCT05995613||MABOS|Participants will have one FDA-approved pulse oximeter (Nonin PureSat) along with our novel pulse oximeter placed to acquire 90 minutes of biometric data
62279861|NCT06528470|EXPERIMENTAL|Posterior Tibial Nerve Stimulation (PTNS)|Patients in the PTNS arm will undergo 30-minute sessions of PTNS after their first four pelvic floor biofeedback therapy sessions.
62279862|NCT06528470|SHAM_COMPARATOR|Sham Stimulation|Patients in the PTNS arm will undergo 30-minute sessions of sham stimulation after their first four pelvic floor biofeedback therapy sessions.
62279863|NCT04307238|OTHER|Propofol group|General anesthesia will be maintained by continually intravenous administered propofol.
62279864|NCT04307238|OTHER|Sevoflurane Group|General anesthesia will be maintained by inhalative administered sevoflurane.
62456745|NCT04347291|PLACEBO_COMPARATOR|Print Materials|All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes.
62456746|NCT04849884|EXPERIMENTAL|CORI TENSIONER|Subjects having a robotic TKA procedure with the CORI Surgical System, including the use of the CORI™ KNEE TENSIONER accessory.
62076472|NCT05569824||Prospective Study Pathway|Child or young person undergoing a Broncho-alveolar Lavage (BAL) for suspected pulmonary Invasive Fungal Disease (IFD) and consent obtained.
62076473|NCT04364321|EXPERIMENTAL|Single dose Clonazepam|Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)
62076474|NCT04364321|ACTIVE_COMPARATOR|Intermittent oral diazepam|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.
62279865|NCT04774965|EXPERIMENTAL|Slumber Curve Group|Patients receiving Slumber Curve sleep aid for management of pain and sleep quality following rotator cuff repair.
62076475|NCT05724901||Adults with MS|Participants will complete an in-clinic visit (self-reported outcome of MS disability, a standard walking clinical evaluation, and a sensor-based gait evaluation) and 3 remote supervised self-administered gait assessments using the MS-GRCA system.
62279866|NCT04774965|NO_INTERVENTION|Normal Sleep Routine Group|Patients not receiving sleep aid.
62279867|NCT02397850|EXPERIMENTAL|30 min or 50 min|Patients receive either seven 30 minutes or 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
62279868|NCT03174210|EXPERIMENTAL|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
62645911|NCT00313235|EXPERIMENTAL|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10\^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
62645912|NCT03008044|EXPERIMENTAL|Device: FiberSense system|10 subjects will wear 2 FiberSense system in abdomen and upper arm respectively and Dexcom G4 Platinum CGM sensor for 1 day.
62076476|NCT00849680|PLACEBO_COMPARATOR|Placebo|Participants receiving 1.0 ml of placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine or the placebo to the MRKAd5 HIV-1 gag vaccine injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26 or a 2-dose regimen at Day 1 and Week 26 or Day 1 and Week 4.
62279869|NCT03174210|EXPERIMENTAL|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
62279870|NCT00006295||Pedigree 1|
62645913|NCT03008044|EXPERIMENTAL|Extension Phase|2 subjects will extend the wearing of the sensors up to 14 days (2 FiberSense systems to Day 14 and Dexcom sensor to Day 7±1) after the glucose clamp study.
62645914|NCT01895985|EXPERIMENTAL|Latanoprostene Bunod|Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
62279871|NCT00006295||Pedigree 2|
62279872|NCT00006295||Pedigree 3|
62456747|NCT04761731|EXPERIMENTAL|ADVAGRAF®|One arm: Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
62456748|NCT01282047|EXPERIMENTAL|Lenalidomide|
62279873|NCT00006295||Pedigree 4|
62279874|NCT00006295||Pedigree 5|
62279875|NCT00006295||Pedigree 6|
62279876|NCT00006295||Pedigree 7|
62279877|NCT00006295||Pedigree 8|
62279878|NCT00006295||Pedigree 9|
62279879|NCT00006295||Pedigree 10|
62279880|NCT00006295||Pedigree 11|
62279881|NCT00006295||Pedigree 12|
62279882|NCT04733547||Donor hepatectomy|Live donors undergoing hepatectomy
62279883|NCT05573971|EXPERIMENTAL|with verbal encouragement|
62279884|NCT05573971|NO_INTERVENTION|without verbal encouragement|
62279885|NCT06229951|EXPERIMENTAL|Collagen supplement group|Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) 2 tabs a day
62076477|NCT00849680|EXPERIMENTAL|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Participants receiving 1.0 ml of the Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
62076478|NCT00849680|EXPERIMENTAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
62076479|NCT00849680|EXPERIMENTAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
62076480|NCT00849680|EXPERIMENTAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
62456749|NCT03209882|EXPERIMENTAL|One TILS, one sham, and then five TILS interventions|Participants first received a TILS intervention, followed by a sham session one week later. Then, participants received another five weekly TILS interventions.
62456750|NCT03209882|EXPERIMENTAL|One sham, then six TILS interventions|Participants first received a sham session, followed by six weekly TILS sessions.
62645915|NCT01715831|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
62645916|NCT05652127|EXPERIMENTAL|Intervention: Child play of Mightier|Ad lib child biofeedback video game play in home
62076481|NCT00849680|EXPERIMENTAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
62076482|NCT00849680|EXPERIMENTAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26, or in a 2-dose regimen at Day 1 and Week 4 (with no vaccine administered at Week 26) or Day 1 and Week 26 (with placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine administered at Week 4)
62076483|NCT00849680|EXPERIMENTAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
62076484|NCT01054196|EXPERIMENTAL|all patients|subjects will receive daily doses of lenalidomide starting on Day -5 of transplant and melphalan on Days -2 and -1.
62076485|NCT04888481|EXPERIMENTAL|68Ga-HA-DOTATATE PET/CT scan|2.64 MBq/kg (minimum 37 MBq, maximum 250 MBq) 68Ga-HA-DOTATATE intravenous single-dose administration for PET/CT imaging
62076486|NCT00674271||Diabetics|100 patients with newly diagnosed (\<5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.
62076487|NCT00674271||Controls|100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender
62076488|NCT01792362|EXPERIMENTAL|AMH|obese PCOS patients who underwent weight loss diet
62076489|NCT02067351|EXPERIMENTAL|Mindfulness Intervention|Mindfulness intervention
62279886|NCT06229951|PLACEBO_COMPARATOR|Control group|Control patients will take placebo 2 tabs a day
62456751|NCT01217086|ACTIVE_COMPARATOR|CT-P13|
62456752|NCT01217086|ACTIVE_COMPARATOR|Remicade|
62456753|NCT05289713|ACTIVE_COMPARATOR|Surgery|In the surgery group, patients undergo laparoscopic appendectomy within 18 hours after randomization.
62279887|NCT04438031|EXPERIMENTAL|Navigation Intervention Prenatal 1.0 (arm closed and modified to 2.0 design. Data will not be used)|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits (using prenatal navigation version 1.0), establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
62645917|NCT02309021|OTHER|Sport Group|Participants randomised to the exercise condition will receive 12 weeks of physical exercise training. Once they have been assigned to this group, they will be informed about the training programme and its content. Training will be carried out in groups (two groups of ten or four groups of five, depending on scheduling, sport preferences, available materials) to ensure that individual attention can be paid to each participant.
62456754|NCT05289713|ACTIVE_COMPARATOR|Symptomatic treatment|Symptomatically treated patients are hospitalized for at least 24 hours, and receive intravenous fluids and analgesics according to standard clinical practice.
62645918|NCT02309021|OTHER|Control Group|The control group will not receive any exercise training. In order to control, as far as possible, for the potentially therapeutic effects of extra contact time with investigators, and the potentially motivational elements of participation in an intervention, the C group will have equal contact time with an investigator and participate in a leisure program without physical activity component. This time will be filled with group mealtimes, games, films, painting, handcrafts, stretching or relaxation exercises.
62076490|NCT05048368|EXPERIMENTAL|Cohort A-Larotinib|Cohort A:Healthy participants with normal hepatic function （match to subjects with mild hepatic impairment_cohort B）
62076491|NCT05048368|EXPERIMENTAL|Cohort B-Larotinib|Subjects with mild hepatic impairment
62076492|NCT05048368|EXPERIMENTAL|Cohort C-Larotinib|Healthy participants with normal hepatic function （match to subjects with moderate hepatic impairment_cohort D）
62076493|NCT05048368|EXPERIMENTAL|Cohort D-Larotinib|Subjects with moderate hepatic impairment.
62076494|NCT02456337|EXPERIMENTAL|CAF+MC+EMD|Coronally Advanced Flap with Mucograft and Emdogain
62076495|NCT02456337|ACTIVE_COMPARATOR|CAF+MC|Coronally Advanced Flap with Mucograft
62076496|NCT02456337|ACTIVE_COMPARATOR|CAF+EMD|Coronally Advanced Flap with Emdogain
62076497|NCT02456337|ACTIVE_COMPARATOR|CAF|Coronally Advanced Flap alone
62076498|NCT05929261||Study Group|Study group will be examined for outcome measurements.
62076499|NCT05929261||Control Group|Control group will be examined for outcome measurements.
62076500|NCT01521325|EXPERIMENTAL|Amatuximab infusion|Subjects will receive one infusion of radiolabeled amatuximab.
62076501|NCT03413410|EXPERIMENTAL|Metoprolol interventional group|"This is a multi-center, prospective, open label, single-arm interventional study.~Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study."
62076502|NCT03664037|ACTIVE_COMPARATOR|D group, (n=55)|
62076503|NCT03664037|PLACEBO_COMPARATOR|C group, (n=55)|
62456755|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
62076504|NCT02754414|EXPERIMENTAL|Healthy Volunteers|Autologous, cold stored, PAS/plasma suspended platelets stored for various periods (3 to 20 days).
62076505|NCT05752422|EXPERIMENTAL|Active transcranial Photobiomodulation (t-PBM)|Active t-PBM will be delivered to the forehead using the Niraxx Smart Headband (gen 1). Daily treatments of 40 min
62076506|NCT05752422|SHAM_COMPARATOR|Sham t-PBM|To the subjects belonging to the sham arm the sham treatment sessions will be performed using the same device, during the same time but the device will not be turned on.
62076507|NCT00249496|ACTIVE_COMPARATOR|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
62076508|NCT00249496|EXPERIMENTAL|Contingency Management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
62076509|NCT05515029|EXPERIMENTAL|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab,calcineurin inhibitor|
62076510|NCT06077435|ACTIVE_COMPARATOR|CAD-EYE|AI system 1. Sealed envelopes in blocks of four were used for randomisation.
62076511|NCT06077435|ACTIVE_COMPARATOR|GI-GENIUS|AI system 2. Sealed envelopes in blocks of four were used for randomisation
62076512|NCT06077435|ACTIVE_COMPARATOR|Endo-AID|AI system 3. Sealed envelopes in blocks of four were used for randomisation
62076513|NCT06077435|NO_INTERVENTION|No AI|No AI. conventional examination. Sealed envelopes in blocks of four were used for randomisation
62076514|NCT01209338|ACTIVE_COMPARATOR|sensitized group|One arm will be a sensitized group which would have received cancer health awareness sessions and / or screening earlier at least once in the past.
62645919|NCT02385786|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
62645920|NCT00495053|EXPERIMENTAL|hMaxi-K 5000 µg/mL|5000 micrograms (µg)/90 milliliter (mL) intravesical instillation
62645921|NCT00495053|EXPERIMENTAL|hMaxi-K 10000 µg/mL|10000 µg/90 mL intravesical instillation
62645922|NCT00495053|PLACEBO_COMPARATOR|Placebo|Matching placebo (PBS-20% sucrose)
62645923|NCT01140971|ACTIVE_COMPARATOR|Misoprostol|Use 25 micrograms vaginal every 6 hours (max dosis 200 micrograms in 48 hours)
62645924|NCT01140971|ACTIVE_COMPARATOR|Foley|Foley catheter number 14 or 16 was installed intracervical for no more than 48 hours.
62645925|NCT06519331|EXPERIMENTAL|Adult patient (age >= 18 y.o) followed for a liver disease, all etiologies combined|Adult patients followed in the Hepatology or Endocrinology department for a liver disease, suspected chronic liver disease or consequences of chronic liver disease, all etiologies combined.
62645926|NCT01105052|ACTIVE_COMPARATOR|Bibliotherapy|A group receiving a self-help book to work on for six weeks with no therapist support.
62645927|NCT01105052|EXPERIMENTAL|Bibliotherapy with support|A group receiving a self-help book to work on for six weeks, together with brief weekly telephone calls (\<15 minutes) from a therapist.
62645928|NCT01105052|NO_INTERVENTION|Wait-list control group|This group receives no intervention until about five months after the two treatment groups, when participants in this group receive the self-help book without therapist support.
62645929|NCT02937597|ACTIVE_COMPARATOR|National e-learning programme only (HSE)|Active Comparator: National e-learning programme only (HSE) National e-learning programme only Recent successful completion of the National e-learning programme by certificate will be displayed. Students then undergo performance assessment via low fidelity simulation and complete a questionnaire.
62645930|NCT02937597|ACTIVE_COMPARATOR|eS: eScenarios|Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to an online learning course with 4 scenarios to work through but no requirement to meet a proficiency benchmark. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
62645931|NCT02937597|EXPERIMENTAL|ePBP: eProficiency Based Progression|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to a PBP e-learning course using the same series of cases as S. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks for the cases within the e-learning course to allow progression through the cases. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
62645932|NCT01571388|EXPERIMENTAL|Group 1|Healthy Subjects to receive dacomitinib
62645933|NCT01571388|EXPERIMENTAL|Group 2|Subjects with mildly impaired hepatic function to receive dacomitinib
62645934|NCT01571388|EXPERIMENTAL|Group 3|Subjects with moderately impaired hepatic function to receive dacomitinib
62645935|NCT04763720||Dyadic Developmental Psychotherapy|Families being treated with DDP at either of the centres
62645936|NCT05984719||New daily persistent headache (NDPH) group|Participants with NDPH will be administered an online survey.
62645937|NCT02100332||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
62645938|NCT03074500|EXPERIMENTAL|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
62076515|NCT01209338|NO_INTERVENTION|non-sensitized group|The second arm will belong to an area which has never been exposed to any form of cancer awareness or screening activities thus this group is a completely non-sensitized group.
62645939|NCT03074500|SHAM_COMPARATOR|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
62645940|NCT03074500|OTHER|Control|Stretching and strengthening exercises of wrist
62645941|NCT01863771|EXPERIMENTAL|Golimumab|
62076516|NCT03657927|ACTIVE_COMPARATOR|C-MAC Videolaryngoscope|Morbidly obese patients intubated with C-MAC Videolaryngoscope
62645942|NCT01863771|PLACEBO_COMPARATOR|Placebo|
62645943|NCT05573243|EXPERIMENTAL|Etch-and-rinse|G2 Bond Universal bonded to NCCL using etch-and-rinse technique
62645944|NCT05573243|EXPERIMENTAL|Selective enamel etching|G2 Bond Universal bonded to NCCL using selective enamel etching technique
62645945|NCT05573243|EXPERIMENTAL|self-etch|G2 Bond Universal bonded to NCCL using self-etch technique
62645946|NCT02173782|EXPERIMENTAL|Berodual® Respimat ® high dose|
62645947|NCT02173782|ACTIVE_COMPARATOR|Berodual® MDI|
62645948|NCT02173782|EXPERIMENTAL|Berodual® Respimat® low dose|
62645949|NCT02173782|PLACEBO_COMPARATOR|Placebo|
62645950|NCT01213238|EXPERIMENTAL|Oxaliplatin + Capecitabine + Bevacizumab|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle. Bevacizumab 10 mg/kg by vein on day 1 of a 21 day cycle.
62645951|NCT01213238|EXPERIMENTAL|Oxaliplatin + Capecitabine|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 -14 of a 21 day cycle.
62076517|NCT03657927|ACTIVE_COMPARATOR|McGrath MAC Videolaryngoscope|Morbidly obese patients intubated with McGrath MAC Videolaryngoscope
62076518|NCT01364727|EXPERIMENTAL|Amrubicin|Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
62456756|NCT06144671|EXPERIMENTAL|GT201 treatment group|GT201 5E9（5×10\^9）;GT201 1E10（1×10\^10）;GT201 5E10（5×10\^10）.
62645952|NCT00039403|EXPERIMENTAL|Treatment (UCN-01, gemcitabine hydrochloride)|"Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose."
62645953|NCT03778671|EXPERIMENTAL|Group B|Patients will receive Levobupivacaine 5%
62645954|NCT03778671|ACTIVE_COMPARATOR|Group D|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine .
62076519|NCT00154063|PLACEBO_COMPARATOR|Placebo|During the Titration Phase, placebo was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
62279888|NCT04438031|OTHER|Control Intervention|Brief educational information will be provided about pregnancy (provided prenatally) and child development at 12, 24, and 36 months.
62456757|NCT00751465|ACTIVE_COMPARATOR|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997)
62076520|NCT00154063|EXPERIMENTAL|E2007|During the Titration Phase, perampanel was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
62456758|NCT00751465|ACTIVE_COMPARATOR|Standard CBT|standard Cognitive Behavior Therapy, standard CBT following the model of Clark and Wells (1995).
62645955|NCT03778671|ACTIVE_COMPARATOR|Group F|Patients will receive Levobupivacaine 5% + 1µg/kg fentanyl
62645956|NCT00289211|EXPERIMENTAL|C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV). If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
62645957|NCT00289211|PLACEBO_COMPARATOR|Placebo|Matching placebo (saline) administered IV. If there was no response to treatment 60 minutes after the first dose, a second placebo (saline) dose could be administered.
62076521|NCT02385617|EXPERIMENTAL|Esophagectomy|Double blind single dose placebo-octreotide crossover
62279889|NCT04438031|EXPERIMENTAL|Navigation Intervention Prenatal 2.0|This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
62645958|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
62076522|NCT02385617|EXPERIMENTAL|Total gastrectomy|Double blind single dose placebo-octreotide crossover
62279890|NCT05953792||thoracic kyphosis|patients with their kyphotic apex located at T10 or above
62279891|NCT05953792||thoracolumbar kyphosis|patients with their kyphotic apex located below T10
62076523|NCT02385617|ACTIVE_COMPARATOR|Control - no surgery|Double blind single dose placebo-octreotide crossover
62279892|NCT02171975|ACTIVE_COMPARATOR|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthetic.
62279893|NCT02171975|EXPERIMENTAL|Group P|This group had their spinal anaesthetic done based on pre-procedure ultrasound guided paramedian spinal
62279894|NCT01382459||type 1 DM children- intervention group|will have home visits and trainings at school
62645959|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
62645960|NCT00919880|EXPERIMENTAL|Experimental|
62076524|NCT02385617|EXPERIMENTAL|Pancreaticoduodenectomy|Double blind single dose placebo-octreotide crossover
62076525|NCT02155556||Healthy volunteers|
62076526|NCT02464930||No-GERD Controls|"NERD controls will be enrolled from subjects presenting to the endoscopy unit who are being evaluated for reasons other than GERD or BE surveillance. These are patients who are referred to the endoscopy unit for: evaluation of anemia, dysphagia, occult blood positivity, gastrointestinal blood loss etc.~* No history of GERD~* Response no to presence of symptoms on a standardized GERD questionnaire~* No prescriptions for acid suppressive medication over the past 2 years as documented in electronic pharmacy records.~* Normal endoscopy that does not find Barrett's esophagus, hiatus hernia or erosive esophagitis."
62076527|NCT02464930||GERD Controls|"* Respond yes to the presence of symptoms on a standardized GERD questionnaire~* Prescriptions for acid suppressive medication as documented in electronic pharmacy records."
62076528|NCT02464930||BE Cases|• Patients who present for evaluation of reflux symptoms and are found to have at least 1 cm of columnar lined esophagus on endoscopy with intestinal metaplasia on biopsies. This will include patients with esophageal adenocarcinoma
62279895|NCT01382459||type 1 DM children- control group|will receive the standard care at the clinic
62645961|NCT00919880|ACTIVE_COMPARATOR|Active Comparator|
62279896|NCT03686501|EXPERIMENTAL|PF-06412562|To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of PF-06412562.
62456759|NCT00751465|NO_INTERVENTION|Wait list control|Wait list control group
62645962|NCT04942262|EXPERIMENTAL|denture adhesive use|Participants were instructed to use a cream-type denture adhesive (Polident®, GlaxoSmithKline, Ireland) once a day in the morning and use it throughout the day. They applied denture adhesive onto the tissue surface of their maxillary and mandibular dentures using a spot method. The participants had to remove the DA and clean the denture every day after the last meal by soaking and brushing the CD with liquid soap and a soft toothbrush under running tap water. Two gauze pads were used to remove DA from the denture and oral mucosa. After the 1-month trial period of DA use. The outcomes were evaluated with all participants using DA, and they had to choose whether they wanted to continue or discontinue using DA for another 1 month. At 1-month after continuing or discontinuing DA use. At this time, some participants used DA during the outcome evaluations, while some did not, depending on the patient's decision on DA use.
62645963|NCT04041622|OTHER|Endoscopy and biopsy|Participants of the HUNT study with a positive serological assay for celiac disease are invited to attain a diagnostic endoscopy with duodenal biopsies
62645964|NCT06207474|OTHER|Video + Chatbot|
62076529|NCT03598218|EXPERIMENTAL|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
62076530|NCT03598218|EXPERIMENTAL|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
62076531|NCT03016117|EXPERIMENTAL|Pecs II block and parasternal block|Pecs II block and parasternal block performed to provide anesthesia of breast, before of quadrantectomy with or without axillary dissection. Pecs II block performed at the 4th rib level and 20 ml of 0.5% Levobupivacaine injected, and parasternal block performed at the level of the 2nd and 4th intercostal space level, and 4 ml of 0.375% Levobupivacaine injected
62076532|NCT01061918|ACTIVE_COMPARATOR|Tecnis MF|
62076533|NCT01061918|ACTIVE_COMPARATOR|ReSTOR|
62076534|NCT00786474|PLACEBO_COMPARATOR|Placebo|
62076535|NCT00786474|EXPERIMENTAL|Dalteparin|
62076536|NCT04456582|EXPERIMENTAL|Amyloidosis transthyretin with cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
62076537|NCT04456582|EXPERIMENTAL|Amyloidosis transthyretin without cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
62076538|NCT04456582|PLACEBO_COMPARATOR|Healthy subjects|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
62645965|NCT06207474|OTHER|Video + Paper|
62645966|NCT06207474|OTHER|Paper + Chatbot|
62076539|NCT00878475||Group with obstructive causes of dyspnea|Criteria for clinical assessment of severe asthma (diffuse polyphonic bilateral and particular expiratory wheezes, chest tightness, shortness of breath, using accessory muscles of breathing, signs of hyperinflation, atopic condition, personal or family history of asthma, tachypnea, previous asthma and asthma medications, and the value of modified Boston criteria for HF ≤ 5) and criteria for chronic obstructive pulmonary disease (COPD) exacerbation (history of COPD, COPD medications, cough, worsening dyspnea, increased sputum production and volume, increased sputum purulence, rhonchi and rales, modified Boston criteria for HF ≤ 5)
62076540|NCT00878475||Heart failure group|The investigators protocol for clinical assessment of HF-related acute dyspnea (the prehospital clinical assessment for HF) was designed based on Boston (13) and Framingham criteria for HF (14) (Table 1). The investigators did not use certain criteria from the original protocols, which were not available in the prehospital setting (e.g., chest radiography).
62279897|NCT05350059|EXPERIMENTAL|High Intensity Focused Ultrasound (HIFU) treatment to breast cancer|High-Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer prior to surgical resection
62279898|NCT02416557|EXPERIMENTAL|Group P|Patients using positive end-expiratory pressure (PEEP) of 10 cmH2O (centimeter of water) intraoperatively
62456760|NCT05718778|EXPERIMENTAL|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
62645967|NCT06207474|OTHER|Paper + Paper|
62645968|NCT00480844|EXPERIMENTAL|Sertindole|
62645969|NCT00480844|ACTIVE_COMPARATOR|Risperidone|
62645970|NCT00966095||men scheduled for prostate biopsy|
62076541|NCT04906590|EXPERIMENTAL|Study Drug|All participants will receive PI-2620.
62645971|NCT05555498|EXPERIMENTAL|Intervention group: VR-glasses added to standard care of conscious sedation|For the intervention group, Virtual Reality glasses will be administered on top of standard pain and anxiety management. Standard pain and management consists of conscious sedation, where benzodiazepines and opioids are administrered. In addition, participants are asked to complete 4 questionnaires on different times : immediately before, immediately after and three days after oocyte retrieval. In case of ongoing pregnancy, women are asked to complete a questionnaire approximately a month after their expected date of delivery.
62279899|NCT02416557|NO_INTERVENTION|Group C|Patients using no positive end-expiratory pressure (zero PEEP) intraoperatively
62076542|NCT02951650|EXPERIMENTAL|Cyberonics VNS|Cyberonics VNS
62279900|NCT01791855|EXPERIMENTAL|Healthy Volunteers|
62279901|NCT01791855|EXPERIMENTAL|Mild Renal Impairment|
62279902|NCT01791855|EXPERIMENTAL|Moderate renal impairment|
62279903|NCT01791855|EXPERIMENTAL|Severe renal impairment|
62456761|NCT05978427|ACTIVE_COMPARATOR|interscalene block group|participants undergoing shoulder surgeries will receive ultrasound guided interscalene block
62456762|NCT05978427|ACTIVE_COMPARATOR|superior trunk block group|participants undergoing shoulder surgeries will receive ultrasound guided superior trunk block
62279904|NCT05999825|EXPERIMENTAL|Vaccine group|The vaccine group will be immunised three times with 30 μg Sm-p80 + 5 μg GLA-SE i.m. at weeks 0,4, and 8. Participants will be exposed to 20 male Schistosoma mansoni cercariae at week 12.
62456763|NCT02912897|EXPERIMENTAL|Cellular therapy with EBV specific autologous CTL infusion|
62456764|NCT03450564|EXPERIMENTAL|Women Education|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
62076543|NCT04334785|EXPERIMENTAL|cryo-ablation group|In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery. In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.
62645972|NCT05555498|NO_INTERVENTION|standard care consisting of conscious sedation|The control group will receive standard pain- and anxiety management during oocyte retrieval in IVF/ICSI treatment, consisting of opioids combined with benzodiazepines. This will result in a conscious sedated state. In addition, participants are asked to complete 4 questionnaires on different times : immediately before, immediately after and three days after oocyte retrieval. In case of ongoing pregnancy, women are asked to complete a questionnaire approximately a month after their expected date of delivery.
62645973|NCT00666237|EXPERIMENTAL|Tube shunt surgery group|Participants in this group will receive a tube shunt surgery (Baerveldt Glaucoma implant).
62645974|NCT00666237|EXPERIMENTAL|Trabeculectomy with Mitomycin C|Participants in this group will receive a Trabeculectomy surgery with Mitomycin C
62279905|NCT05999825|PLACEBO_COMPARATOR|Placebo control group|The placebo control group will be immunised three times with saline i.m. at weeks 0,4, and 8. Participants will be exposed to 20 male Schistosoma mansoni cercariae at week 12.
62279906|NCT04527198|EXPERIMENTAL|group 1|Major patients, admitted in intensive care for a SARS-CoV-2 infection and requiring mechanical ventilation and deep sedation (with or without neuromuscular blockade)
62456765|NCT03450564|EXPERIMENTAL|Male Involvement|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, model who allows his wife to use FP, religious leader, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
62645975|NCT01882569||Back surgery|
62645976|NCT04405336|ACTIVE_COMPARATOR|giving tab block|giving patients tab block
62645977|NCT04405336|ACTIVE_COMPARATOR|giving PCA|Giving PCA to patients
62645978|NCT04405336|NO_INTERVENTION|Patients who will not receive PCA or tab block|No tab block or PCA
62645979|NCT06090838|EXPERIMENTAL|Intervention, BPA|Will receive questionnaires, exercise testing and BPA at baseline, follow up with questionnaires and exercise testing will be done at 6,12 and 24 months.
62279907|NCT05730400|ACTIVE_COMPARATOR|BMAC/bovine graft|Bone marrow aspirate concentrate loaded on bovine graft (Tutogen Medical GmbH, Neunkirchen am Brand, Germany, 1- 2mm particle size) utilization for sinus floor augmentation with residual alveolar bone height less than 5 mm, 1st arm
62645980|NCT06090838|NO_INTERVENTION|Control, no BPA|Will receive questionnaires, exercise testing at baseline. Due to the crossover design, they will receive BPA at 6 months. Follow up with questionnaires and exercise testing will be done at 6,12 and 24 months.
62645981|NCT03248037|EXPERIMENTAL|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
62645982|NCT03248037|PLACEBO_COMPARATOR|Placebo|Placebo eye drop, dosed topically once a day for 9 months
62645983|NCT03074695|EXPERIMENTAL|Dural Puncture Epidural (DPE)|Women who have analgesia initiated with a DPE technique
62645984|NCT03074695|EXPERIMENTAL|Standard Epidural (EPL)|Women who have analgesia initiated with an epidural technique
62279908|NCT05730400|ACTIVE_COMPARATOR|Bovine graft group|bovine graft utilization for sinus floor augmentation with residual alveolar bone height less than 5 mm, 2nd arm
62279909|NCT02049398||Oral microbiome cohort|a cohort of 40 adults willing to provide oral samples approximately every two months forone year
62076544|NCT01927718|EXPERIMENTAL|Thalidomide + Lenalidomide|"Thalidomide 100 mg by mouth daily for 28 days in a 28 day cycle started after the clinical documentation of biochemical progression.~Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle."
62645985|NCT02394769|PLACEBO_COMPARATOR|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
62076545|NCT04198740||Control group|Healthy, normal ocular surface
62076546|NCT04198740||Dry eye syndrome|"Patients suffering from either:~* Lacrimal insufficiency~* Anterior blepharitis~* Posterior blepharitis~* Sjögren syndrome"
62279910|NCT05227339|EXPERIMENTAL|Interventional (RAE + Usual Care)|Subjects will receive usual care through an outpatient substance use disorder treatment facility, will be provided with a wearable sensor and the RAE mobile application. Participants will be instructed to use the RAE app for a minimum of 30 days.
62456766|NCT03450564|OTHER|Control group|The third arm in this community-based intervention was following the community without provision of male and married women education. In this arm, there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
62645986|NCT02394769|ACTIVE_COMPARATOR|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
62456767|NCT06254248|EXPERIMENTAL|Atezo-Beva combination|first-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of acute cellular rejection
62456768|NCT00128453|PLACEBO_COMPARATOR|Placebo|Conventional therapy plus placebo
62456769|NCT00128453|ACTIVE_COMPARATOR|Colchicine|Conventional therapy plus colchicine
62645987|NCT02394769|ACTIVE_COMPARATOR|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
62645988|NCT06472752||Neoadjuvant radiotherapy+radical surgery|Patients with high-risk UTUC without distant metastases (which can be accompanied by regional lymph node metastases) were selected to receive short-course neoadjuvant stereotactic radiotherapy (neoadjuvant SBRT, naSBRT) after completion of biopsy and definitive pathological diagnosis, and to undergo radical surgery within 3 months from completion of the last radiotherapy session
62076547|NCT04198740||Allergic conjunctivitis|Patients suffering from allergic conjunctivitis
62076548|NCT04198740||Mucous membrane pemphigoid|Patients suffering from mucous membrane pemphigoid
62076549|NCT04198740||Infectious keratoconjunctivitis|"Patients suffering from keratitis and/or conjunctivitis of various etiology:~* Viral~* Bacterial~* Fungal~* Acanthamoeba"
62076550|NCT03479749|EXPERIMENTAL|RegenoGel-OSP - RegenoGel-OSP|First injection- the patients will receive RegenoGel-OSP; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP also
62076551|NCT03479749|EXPERIMENTAL|RegenoGel - RegenoGel|First injection- the patients will receive RegenoGel; Second injection (after 3 months interval)- the patients will receive RegenoGel also
62279911|NCT05227339|NO_INTERVENTION|Control (Usual care)|Subjects will receive usual care through an outpatient substance use disorder treatment facility and will be provided with a wearable sensor (fitness tracker). They will not be given access to the RAE mobile app.
62645989|NCT06472752||Neoadjuvant radiotherapy and drug therapy+radical surgery|Patients with high-risk UTUC without distant metastases (which may be accompanied by regional lymph node metastases) were selected to receive a short course of neoadjuvant stereotactic radiotherapy (neoadjuvant SBRT, naSBRT) + drug therapy after completing a biopsy and making a definitive pathological diagnosis, and to undergo a radical surgical procedure within 3 months from the end of the last radiotherapy session (full-length radical nephroureteral resection + cystocele sleeve resection ) treatment. Pharmacological treatment can be chemotherapy/immunotherapy/ADC treatment etc.
62645990|NCT01968421|EXPERIMENTAL|OM-85|The subjects will be randomly received two courses of 7mg of OM-85 to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
62645991|NCT01968421|PLACEBO_COMPARATOR|Placebo|The subjects will be randomly received two courses of 7mg of matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
62645992|NCT03188575|EXPERIMENTAL|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
62645993|NCT03188575|ACTIVE_COMPARATOR|Waiting List|Waiting list control
62076552|NCT03479749|PLACEBO_COMPARATOR|Placebo - RegenoGel-OSP|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP
62456770|NCT01991470|EXPERIMENTAL|Enlite sensors|Each subject will first wear enlite sensors and will come for clinic visit for YSI (Yellow Spring Instruments). Then each subject will wear enlite 3 sensors and will come for clinic visit for YSI (Yellow Spring Instruments) or SMBG (Self-Monitoring of Blood Glucose) testing. SMBG testings are for subjects 2-6 years of age and cannot tolerate YSI. In addition. In addition, subjects aged 2-6 years old will not participate in Enlite phase. They only participate in Enlite 3 phase.
62456771|NCT03489759|EXPERIMENTAL|ViE15-A|The patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using ViE15-A hemofilter
62645994|NCT04246463||Thoracic - TEVAR|
62645995|NCT04246463||Abdominal - EVAR|
62645996|NCT04246463||Custom Device|
62645997|NCT04246463||Other indications|Isolated Iliac Artery Aneurysm (IIAA)
62645998|NCT05413798|OTHER|Single Arm|This is a single arm study. All participants will receive same interventions.
62645999|NCT02715908|EXPERIMENTAL|LBEC0101|Etanercept 50mg
62646000|NCT00586560|EXPERIMENTAL|1|Stratum 1 (\~ 25 patients) will include patients with known bone marrow metastases or those who have had prior intensive myelosuppression therapy (including autologous or allogeneic stem cell rescue \[SCR\], total body irradiation \[TBI\], craniospinal irradiation \[CSI\], or hemipelvic radiation).
62646001|NCT00586560|EXPERIMENTAL|2|Stratum 2 (\~ 25 patients) will include patients without previous intensive myelosuppressive therapy and bone marrow metastases.
62646002|NCT05197439|ACTIVE_COMPARATOR|DEX group|Dexmedetomidine will be given at the beginning of the second step of DBS and last for 48 hours by electronic pump.
62646003|NCT05197439|PLACEBO_COMPARATOR|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively and postoperatively the same duration just like the DEX group would do.
62646004|NCT03850626||Immunotherapy Trees|Patients allergic to tree pollen
62646005|NCT03850626||Immunotherapy Grass|Patients allergic to grass pollen
62646006|NCT03850626||Immunotherapy Mites|Patients allergic to HDM
62646007|NCT01339065|ACTIVE_COMPARATOR|Ketamine|will be given low sub-anesthetic doses of Ketamine 0.5mg/kg.
62646008|NCT01339065|PLACEBO_COMPARATOR|Placebo|will get placebo treatment
62076553|NCT03479749|PLACEBO_COMPARATOR|Placebo - RegenoGel|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel
62076554|NCT01355874|EXPERIMENTAL|Iferanserin|
62646009|NCT00809796|EXPERIMENTAL|single arm|Use of pentamidine in second and/or third line metastatic colon cancer
62646010|NCT04886414|EXPERIMENTAL|Phone-based monitoring without blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer (ABHS).
62076555|NCT01355874|EXPERIMENTAL|Placebo|
62076556|NCT01355874|EXPERIMENTAL|Iferanserin + Placebo|
62076557|NCT04765293|EXPERIMENTAL|Gravity group|"GRAVITY® system exercise is conducted on a machine. The tasks were non-weight bearing, and the only external load was the body mass of the trainee. The degree of unloading (the level of exercise) was chosen depending on the patient's body mass, their current health and the difficulty of the exercise. The machine allowed for exercising any chosen muscle group at chosen setting of the bench, platform and ropes. GRAVITY® system exercise aimed at general posture improvement and at strengthening the desired movement path, along with strengthening the deep spinal and abdominal muscles.~GRAVITY therapy group had therapy twice a week for 4 weeks for 40 minutes that made 2x40 minx 4 weeks=320 minutes."
62076558|NCT04765293|ACTIVE_COMPARATOR|Control group|Control group had standard, two weeks ambulant every day physical therapy sessions ( laser therapy, cryotherapy, magnetotherpy, TENS and interference currents), 5 times a week 30 min, that is 10 sessions 30 min x10=300 min.
62076559|NCT00649493|EXPERIMENTAL|1|Rabeprazole Sodium Tablets 20 mg
62076560|NCT00649493|ACTIVE_COMPARATOR|2|Aciphex® Tablets 20 mg
62076561|NCT04957732|ACTIVE_COMPARATOR|Standard of Care (SoC)|For subjects randomized to the control group, Standard of Care (SoC), which was normal saline, was used.
62076562|NCT04957732|ACTIVE_COMPARATOR|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
62076563|NCT04725630|EXPERIMENTAL|Subsidized Healthy Food Prescription Incentive|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider and a weekly incentive of $10.50/household member to purchase healthy foods in supermarkets for 12 months. The list of incentive-eligible foods includes whole, minimally processed foods with little to no added fat, sugar or salt from all food groups.
62076564|NCT04725630|ACTIVE_COMPARATOR|Healthy Food Prescription Comparison|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider. The pamphlet closely mimics current standard of care for patients with diabetes in Alberta (i.e., nutrition counselling).
62456772|NCT03489759|ACTIVE_COMPARATOR|REXEED-15A|TThe patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using REXEED-15A
62076565|NCT02950935|EXPERIMENTAL|Progesterone|25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
62076566|NCT02950935|PLACEBO_COMPARATOR|Placebo|placebo will be administered twice à day until the 12th week of gestation.
62076567|NCT02834572|EXPERIMENTAL|All About Me|assessment and algorithm to provide participants with a tailored recommendation of their optimal HIV testing approach
62076568|NCT02834572|ACTIVE_COMPARATOR|Control|HIV testing information
62076569|NCT01474837|EXPERIMENTAL|Exercise with motivational interviewing|Young people with depression exposed to exercise with motivational interviewing
62076570|NCT01474837|NO_INTERVENTION|Treatment as usual|Young people with depression receiving treatment as usual
62076571|NCT05663983||AIEOP|This is a National Association for the treatment of pediatric patients with hematological or oncological disease
62076572|NCT05663983||FIL|This is a National Association that brings together many centers with particular attention to the treatment of adult lymphomas
62076573|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
62456773|NCT04883801||COVID-19 case group|Newborns born to pregnant women diagnosed with COVID-19 during hospitalization for delivery
62456774|NCT04883801||Control group|Newborns born to pregnant women who were not diagnosed with COVID-19 in their medical history and hospitalization for delivery
62456775|NCT03677648|ACTIVE_COMPARATOR|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 24.
62076574|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
62076575|NCT05976113||Patients with multiple classifier endometrial cancer|Endometrial cancer patients who have two or more molecular features
62076576|NCT03587350|ACTIVE_COMPARATOR|Interventional Treatment|
62076577|NCT03587350|NO_INTERVENTION|Usual care|
62076578|NCT00312858|ACTIVE_COMPARATOR|1|Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
62076579|NCT00312858|ACTIVE_COMPARATOR|2|Arm 2: ProQuad™ 0.5 mL injection (2 doses \~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.
62076580|NCT01165710||001|Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
62076581|NCT03001401|ACTIVE_COMPARATOR|iDesign|Eyes will under LASIK using iDesign platform for treatment of sphere and cylinder power
62456776|NCT03677648|EXPERIMENTAL|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 24.
62456777|NCT03677648|EXPERIMENTAL|SHR0302 dose C|Participants randomized in this arm will receive dose C of SHR0302 until end of study at week 24.
62456778|NCT03677648|PLACEBO_COMPARATOR|Placebo|Participants randomized in this arm will receive placebo until week 12, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 24.
62456779|NCT04355455|ACTIVE_COMPARATOR|Citalopram|Administration of citalopram to assess the esophageal sensitivity in HV
62076582|NCT03001401|ACTIVE_COMPARATOR|SMILE|Eyes will under SMILE using Visumax platform for treatment of sphere and cylinder power
62279912|NCT03440827|OTHER|Child with slow-flow malformation|"Phase 1: Collect of experiences, perceptions, difficulties, needs and expectations of patients with slow-flow vascular malformation (for the age group of 11 to 15 years-old) using the focus group method.~Phase 2 : Administration of the scale of life's quality for validation."
62456780|NCT04355455|PLACEBO_COMPARATOR|Placebo|Administration of placebo to assess the esophageal sensitivity in HV
62456781|NCT05163951|ACTIVE_COMPARATOR|Trabeculectomy|Forty-four patients with advanced primary angle closure glaucoma will receive trabeculectomy.
62456782|NCT05163951|EXPERIMENTAL|SPI+GSL+GT|Forty-four patients with advanced primary angle closure glaucoma will receive surgical peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT).
62456783|NCT00093925|EXPERIMENTAL|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
62456784|NCT00093925|ACTIVE_COMPARATOR|nicardipine|Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
62279913|NCT00679952|ACTIVE_COMPARATOR|1|closed suction drainage group (CD group)
62456785|NCT04433910|EXPERIMENTAL|Convalescent plasma|Convalescent plasma transfusion on day 1, 3 and 5.
62456786|NCT04433910|NO_INTERVENTION|Best supportive care|Best supportive care, cross over for patients with progressive disease on day 14 with convalescent plasma transfusion on day 15, 17 and 19.
62456787|NCT00638599|EXPERIMENTAL|1|LMA® is placed after anesthesia induction till the end of operation
62456788|NCT00638599|ACTIVE_COMPARATOR|2|Standard tracheal tube is inserted after anesthesia induction till the end of operation
62076583|NCT02053428|ACTIVE_COMPARATOR|Gastrostomy - pull technique|Percutaneous image-guided gastrostomy using large-bore mushroom-retained catheters via the pull technique
62279914|NCT00679952|ACTIVE_COMPARATOR|2|natural drainage group (ND group)
62279915|NCT00067704|EXPERIMENTAL|Trauma writing|Four sessions of writing about traumatic experiences.
62279916|NCT00067704|SHAM_COMPARATOR|Writing about daily events|Four sessions of writing about their daily experiences.
62076584|NCT02053428|ACTIVE_COMPARATOR|Gastrostomy - push technique|Percutaneous image-guided gastrostomy using small-bore cope loop catheters via the push technique
62076585|NCT04037241|EXPERIMENTAL|2nd Line: Anti-CEA CAR-T Cells + gemcitabine/nab paclitaxel|"Patients in the anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
62076586|NCT04037241|EXPERIMENTAL|2nd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|"Patients in the anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will have achieved at least stable disease during the Bridging Therapy Period with NLIR + FU/FA, and will receive the CAR-T cells in Cycles 1 and 3 and the NLIR/FU/FA regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
62279917|NCT05116800|EXPERIMENTAL|Stratum A: Soft Tissue Sarcoma|Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62646011|NCT04886414|EXPERIMENTAL|Phone-based monitoring without blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
62646012|NCT04886414|EXPERIMENTAL|Phone-based monitoring with blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer.
62076587|NCT04037241|ACTIVE_COMPARATOR|2nd Line: Gemcitabine /nab paclitaxel Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving gemcitabine plus nab paclitaxel will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
62076588|NCT04037241|ACTIVE_COMPARATOR|2nd Line: NLIR + FU/FA Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
62076589|NCT04037241|EXPERIMENTAL|3rd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab paclitaxel plus gemcitabine during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
62076590|NCT04037241|EXPERIMENTAL|3rd Line: Anti-CEA CAR-T Cells Plus Capecitabine|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Capecitabine chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nanoliposomal irinotecan fluorouracil/leucovorin during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
62279918|NCT05116800|EXPERIMENTAL|Stratum B: Bone Sarcoma|Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62279919|NCT01929304||Video|Patients in this group will be shown an informational video, narrated in English.
62456789|NCT06217653|EXPERIMENTAL|İntervention|"Intervention Group: A mother-baby yoga video prepared by the researchers was sent to the mothers in the intervention group. Before the mothers yoga practice, a 10-minute training was given about mother-baby yoga. Mothers were asked to do yoga at least 3 times a week for 4 weeks. Counseling and follow-up of the process were carried out by a researcher by calling the mothers once a week.~Mothers were asked to choose the most suitable time of the day for the baby and herself, to have the baby fed at least 45 minutes before yoga, and to practice in a calm and dim environment, listening to music or white noise of her choice. Approximately one yoga session is 20 minutes.~It was monitored once a week for 4 weeks, a total of 4 times. Postnatal Breastfeeding Self-Efficacy Scale-Short Form, Mother-Infant Attachment Scale, and Sleep Diary were administered to mothers at each follow-up."
62076591|NCT04037241|ACTIVE_COMPARATOR|3rd Line: NLIR+FU/FA Alone|Patients randomized to the chemotherapy alone treatment arm who developed disease progression during the Bridging Therapy Period while receiving nab paclitaxel plus gemcitabine will be treated with nanoliposomal irinotecan plus fluorouracil/leucovorin during the Treatment Period.
62456790|NCT06217653|NO_INTERVENTION|Control|Data Collection Form, Postnatal Breastfeeding Self-Efficacy Scale-Short Form, Mother-Infant Attachment Scale, and Sleep Diary were administered to mothers.It was monitored once a week for 4 weeks, a total of 4 times. Postnatal Breastfeeding Self-Efficacy Scale-Short Form, Mother-Infant Attachment Scale, and Sleep Diary were administered to mothers at each follow-up.
62456791|NCT04265365|EXPERIMENTAL|rTMS+rPMS_iTBS_R|In this group, they received intermittent theta burst stimulation(iTBS) on affected hemisphere after following iTBS at radial nerve on affected hand.
62456792|NCT04265365|EXPERIMENTAL|rTMS+rPMS_cTBS_R|In this group, they received intermittent theta burst stimulation on affected hemisphere after following continuous theta burst stimulation(cTBS) at radial nerve on affected hand.
62456793|NCT04265365|SHAM_COMPARATOR|rTMS +sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at radial nerve on affected hand.
62456794|NCT04265365|EXPERIMENTAL|rTMS+rPMS_iTBS_M/U|In this group, they received iTBS on affected hemisphere after following iTBS at median/ulnar nerve on affected hand.
62456795|NCT04265365|EXPERIMENTAL|rTMS+rPMS_cTBS_M/U|In this group, they received iTBS on affected hemisphere after following cTBS at median/ulnar nerve on affected hand.
62456796|NCT04265365|SHAM_COMPARATOR|sham-rTMS+sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median/ulnar nerve on affected hand.
62456797|NCT04265365|EXPERIMENTAL|rTMS + optimal-rPMS|In this group, patient received iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation(rPMS) on affected hand.
62279920|NCT01929304||Text|Patients in this group will read a single-page printed information sheet in English.
62279921|NCT06483880|ACTIVE_COMPARATOR|Albendazole arm|The administration of albendazole therapy is recommended at a dosage of 15 mg/kg/day, given in two equally split doses per day. This is within two 15-day cycles following surgery.
62279922|NCT06483880|PLACEBO_COMPARATOR|Placebo arm|Patients will receive the placebo, which will be in two equally split doses per day. This is within two 15-day cycles following surgery.
62456798|NCT04265365|EXPERIMENTAL|rTMS+ sham-rPMS|In this group, patient received iTBS on affected hemisphere after following sham repetitive peripheral magnetic stimulation on affected hand.
62456799|NCT04265365|SHAM_COMPARATOR|sham-rTMS+optimal-rPMS|In this group, patient received sham iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation on affected hand.
62076592|NCT04037241|ACTIVE_COMPARATOR|3rd Line: Capecitabine Alone|Patients that developed disease progression during the Bridging Therapy Period while receiving nanoliposomal irinotecan plus 5-FU/leucovorin will be treated with capecitabine during the Treatment Period.
62076593|NCT04039178|ACTIVE_COMPARATOR|Treatment group|Real BQ treatment, 40 treatments including 20 minutes of device guided functional motor tasks.
62076594|NCT04039178|SHAM_COMPARATOR|Control group|Sham BQ treatment, (zero intensity) 40 treatments including 20 minutes of device guided functional motor tasks.
62279923|NCT02605642||CT-P13|biosimilar infliximab
62279924|NCT05982262|EXPERIMENTAL|Patients with hematological conditions|Patients will be referred by the medical or nursing staff of the Hematology Unit at the Bnai Zion Medical Center according to inclusion criteria
62279925|NCT01700192|EXPERIMENTAL|MK-8237|MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).
62279926|NCT01700192|PLACEBO_COMPARATOR|Placebo|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
62279927|NCT02913157|EXPERIMENTAL|Hydroxychloroquine|Oral Hydroxychloroquine, 200mg BID
62279928|NCT01331304|OTHER|Li + APT|Study participants will take lithium in addition to any other medications recommended by the study physician.
62279929|NCT01331304|OTHER|QTP + APT|Study participants will take quetiapine in addition to any other medications recommended by the study physician.
62456800|NCT00257712|EXPERIMENTAL|1|
62456801|NCT00257712|PLACEBO_COMPARATOR|2|
62456802|NCT04551638||Online Videogame Players|One cohort of healthy young adults players of online video games.
62456803|NCT05258942||Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery|Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery
62279930|NCT01310335|EXPERIMENTAL|Training|The whole-body vibration (WBV) training
62456804|NCT05258942||Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)|Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)
62456805|NCT05258942||Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery|Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery
62456806|NCT05258942||Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery|Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery
62456807|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)|Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)
62456808|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Mitra Clip|Heart Failure Patients Scheduled for Transcatheter Mitra Clip
62456809|NCT05258942||Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation|Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation
62279931|NCT02401737|EXPERIMENTAL|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 28 days
62279932|NCT02401737|PLACEBO_COMPARATOR|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
62279933|NCT02401737|EXPERIMENTAL|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
62456810|NCT05258942||Heart Failure Patients Scheduled for Stellate Gangliectomy|Heart Failure Patients Scheduled for Stellate Gangliectomy
62456811|NCT05258942||Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery|Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery
62456812|NCT05258942||Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery|Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery
62456813|NCT05364957|OTHER|control (PEC dietary hygiene)|Diet and exercise alone (control)
62646013|NCT04886414|EXPERIMENTAL|Phone-based monitoring with blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
62279934|NCT02401737|ACTIVE_COMPARATOR|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
62279935|NCT05680987|OTHER|Retrograde Femoral Nail-Advanced|
62279936|NCT02532855|EXPERIMENTAL|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
62279937|NCT02532855|ACTIVE_COMPARATOR|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
62279938|NCT03027583|EXPERIMENTAL|Probiotic|63 subjects will be randomized to the experimental arm. The experimental product is a vegetable capsule containing a probiotic strain. Subjects will consume 1-2 capsules daily together with breakfast, equivalent to a dose of 50 bill CFU for 6 weeks.
62456814|NCT05364957|EXPERIMENTAL|Experimental (BIG + PEC dietary hygiene)|Intragastric balloon combined with diet and exercise (active)
62646014|NCT03504917|EXPERIMENTAL|Balovaptan|
62456815|NCT05473052|EXPERIMENTAL|Preoperative home-based exercise training|Patients received usual care plus a preoperative home-based exercise program consisting of aerobic and resistance exercise. In addition, a physical therapist carried out weekly telephone supervision with all participants
62076595|NCT03522987|EXPERIMENTAL|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
62076596|NCT00188318|EXPERIMENTAL|Hyperfractionated Accelerated Radiotherapy|Hypofractionated Accelerated Radiotherapy with integrated neck surgery
62076597|NCT03862651|EXPERIMENTAL|Cangrelor|Cangrelor, 0.75 μg/Kg/min, a cangrelor infusion will be started in addition to SOC when the P2Y12 inhibitor has been discontinued after the need for surgery has been determined. The infusions (cangrelor or matching placebo) will continue throughout the pre-operative period
62076598|NCT03862651|NO_INTERVENTION|placebo|patients will receive only standard of care, in which the P2Y12 inhibitor is discontinued after the need for surgery has been determined and a placebo infusion is administered
62076599|NCT03040687|EXPERIMENTAL|Anti-CS6 group|Anti-CS6 BSIgG and challenge strain CS6-expressing ETEC (B7A)
62076600|NCT03040687|EXPERIMENTAL|Anti-whole cell B7A|Anti- whole cell B7A (killed) BSIgG and challenge strain CS6-expressing ETEC (B7A)
62076601|NCT03040687|EXPERIMENTAL|control Immunoglobulin group|Negative Control (Nonhyperimmune BSIgG placebo) and challenge strain CS6-expressing ETEC (B7A)
62076602|NCT00214903||1|New users of oral continuous combined HRT containing drospirenone
62076603|NCT00214903||2|New users of oral continuous combined HRT containing other progestagens
62076604|NCT00794820|EXPERIMENTAL|FCR-Multiple Dose Rituximab|Fludarabine phosphate + Cyclophosphamide + Rituximab
62076605|NCT00278785|NO_INTERVENTION|1|Control group to receive informational pamphlet on alcohol use and list of self referral agencies
62076606|NCT00278785|EXPERIMENTAL|2|Intervention group receives pamphlet on alcohol and self referral information in addition to brief motivational interview
62076607|NCT01159639|NO_INTERVENTION|aspirin low responders monotherapy|patients with inappropriate response to aspirin assessed by multiple electrode aggregometry
62076608|NCT01159639|ACTIVE_COMPARATOR|aspirin low responders dual antiplatelet therapy|patients with inappropriate response to aspirin 300 mg therapy after CABG, randomized to receive clopidogrel 75 mg in addition to aspirin
62076609|NCT04930458|EXPERIMENTAL|Nanosilver fluoride group|Nanosilver fluoride will be applied on carious lesion
62076610|NCT04930458|ACTIVE_COMPARATOR|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate group|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate will be applied on carios lesion
62076611|NCT04930458|ACTIVE_COMPARATOR|Sodium fluoride varnish group|Sodium fluoride varnish will be applied on carios lesion
62076612|NCT04239456|EXPERIMENTAL|Group A|Receive intervention 2 weeks after group assignment.
62076613|NCT04239456|OTHER|Group B|Wait List - Receive intervention 3 months after initial testing.
62279939|NCT03027583|PLACEBO_COMPARATOR|Placebo|63 subjects will be randomized to the placebo arm.The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics. Subjects will consume 1-2 capsules daily with breakfast for 6 weeks.
62279940|NCT02916654|ACTIVE_COMPARATOR|sulphate iron|patients administered with sulphate iron
62076614|NCT03694015|ACTIVE_COMPARATOR|SUPR (Arm 1)|"Planning according to local protocols. No more than 2 fields; no beam modifying devices, other than multileaf collimators (MLCs). Alternate weighting of beams allowed (ie. 1:2 AP:PA). Review of dosimetry not required, if performed as per institutional standard.~Minimum of kV image matching on unit daily."
62076615|NCT03694015|ACTIVE_COMPARATOR|VMAT rapid (Arm 2)|"Contouring: GTV based on available imaging (CT sim scan alone-no special imaging), expect to be between 1.5cm and 20cm clinically or from imaging. CTV-optional in all scenarios. If using CTV=GTV +0.5 to 0.7cm adjust to anatomy as follows:~* If only bone involved: recommend not to expand past bone; but a 0.5-0.7cm CTV expansion outside of bone into muscle or soft tissue is allowed at RO discretion~* If bone and soft tissue involved: 0.5 to 0.7cm CTV expansion is optional, allowed at RO discretion~* If spinal metastases: CTV is optional. If used can include whole vertebral body at RO discretion PTV=CTV or GTV+(1 to 1.5)cm at RO discretion. PTV_eval=PTV cropped 0.5cm below skin. OARs: max 2 OARs permitted for VMAT arm. OAR constraints are at RO discretion. If lung/kidneys are within 5cm of PTV, absence of constraints for contours should be noted in treatment plans or dose constraint sheet prior to planning. PTV can be compromised for OAR at RO's discretion. Kidneys considered 1 organ"
62279941|NCT02916654|EXPERIMENTAL|sucrosomial iron|patients administered with sucrosomial iron
62279942|NCT00769119|EXPERIMENTAL|AZD9668 active treatment|
62279943|NCT00769119|PLACEBO_COMPARATOR|AZD9668 placebo treatment|
62456816|NCT04981899|EXPERIMENTAL|Main arm|"Patients will receive 6 cycles of nivolumab at the fixed dose of 40 mg, with subsequent assessment of response by PET-CT. Patients with CR will proceed to ASCT.~Patients with \<CR after nivolumab monotherapy will be treated with 2 cycles of a combination of nivolumab at the fixed dose 40 mg, ifosfamide, carboplatin and etoposide (NICE-40), with subsequent PET-CT assessment."
62646015|NCT03504917|PLACEBO_COMPARATOR|Placebo|
62076616|NCT04641195|PLACEBO_COMPARATOR|Placebo- Placebo|Participants in the PLACEBO-PLACEBO group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
62279944|NCT03514927|EXPERIMENTAL|Treatment (HIFU, radical prostatectomy)|"HIFU PHASE: Participants undergo mpMRI and CEUS pre-HIFU treatment and then CEUS post-HIFU treatment. Participants then undergo HIFU treatment over 2-2.5 hours.~PROSTATECTOMY PHASE: Within 2-4 weeks post-HIFU treatment, participants undergo mpMRI 1-2 days prior to radical prostatectomy. On the day of surgery, participants undergo CEUS prior to radical prostatectomy."
62279945|NCT01820442|ACTIVE_COMPARATOR|Lofexidine Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
62279946|NCT01820442|PLACEBO_COMPARATOR|Placebo Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g., Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) to mimic titration for subjects randomized to lofexidine.
62279947|NCT03345472|EXPERIMENTAL|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
62279948|NCT05211557|EXPERIMENTAL|fhB7H3.CAR-T cells|In phase I study, 9 enrolled patients diagnosed with advanced ovarian cancer will receive one-time infusion of fhB7H3.CAR-Ts at the doses of 1×10\^6/kg, 3×10\^6/kg and 5×10\^6/kg, 3 patients for each dose. To further confirm the therapeutic efficacy, in phase II study, 6 enrolled patients will receive an optimal dose (balancing effectiveness and toxicity) of fhB7H3.CAR-Ts. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
62279949|NCT06176937|ACTIVE_COMPARATOR|hyaluronic acid gel|Hyaluronic acid considers as a high molecular weight glycosaminoglycan (GAG) consists of multiple disaccharide non-sulfated units of D-glucuronic acid and N-acetylglucosamine
62279950|NCT06176937|OTHER|empty socket|extraction socket without application any drug
62456817|NCT01127022|ACTIVE_COMPARATOR|480 mg/d choline intake|480 mg/d choline derived from the diet \[380 mg choline/d\] plus supplemental choline chloride \[100 mg choline/d\]
62456818|NCT01127022|EXPERIMENTAL|930 mg/d choline intake|930 mg/d choline derived from the diet \[380 mg choline/d\] plus supplemental choline chloride \[550 mg choline/d\]
62456819|NCT02451605|ACTIVE_COMPARATOR|Femoral nerve blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
62456820|NCT02451605|ACTIVE_COMPARATOR|Adductor canal blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.
62646016|NCT01155570||Humira|Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.
62076617|NCT04641195|EXPERIMENTAL|Vitamin D- Placebo|Participants in the VITAMIN D-PLACEBO group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and daily placebo zinc supplements.
62076618|NCT04641195|EXPERIMENTAL|Placebo-Zinc|Participants in the PLACEBO-ZINC group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and actual daily zinc supplements.
62076619|NCT04641195|EXPERIMENTAL|Vitamin D- Zinc|Participants in the VITAMIN D-ZINC group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and actual daily zinc supplements.
62076620|NCT04142814|EXPERIMENTAL|T-PEP|"Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound.~T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation."
62076621|NCT04142814|ACTIVE_COMPARATOR|IPV|"Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound.~IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation."
62279951|NCT02787850|EXPERIMENTAL|CoolSculpting Treatment Cohort A|"Cohort A will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 60 minutes using the CoolMax applicator without the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with the Crown Cooling Insert at a second protocol-defined temperature for 45 minutes.~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
62646017|NCT05030116|EXPERIMENTAL|Experimental group|
62646018|NCT05030116|ACTIVE_COMPARATOR|Control Group|
62646019|NCT05983536||Cancer patients|Cancer patints that confirmed by pathological examination
62646020|NCT05983536||Patients with blood diseases|Bone marrow aspiration and biopsy confirmed the blood disease
62646021|NCT05925439|EXPERIMENTAL|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
62076622|NCT05685771|OTHER|Auditory stimulation first|This study group receives auditory stimulation in the first intervention week (second week of trial) and sham stimulation in the second intervention week (fourth week of trial).
62076623|NCT05685771|OTHER|Sham stimulation first|This study group receives sham stimulation in the first intervention week (second week of trial) and auditory stimulation in the second intervention week (fourth week of trial).
62456821|NCT02451605|ACTIVE_COMPARATOR|Subgluteal sciatic nerve blockade|In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
62646022|NCT05925439|ACTIVE_COMPARATOR|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
62646023|NCT01506856|ACTIVE_COMPARATOR|Standard treatment: dd-TCiv therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
62646024|NCT01506856|EXPERIMENTAL|Study treatment: dd-TCip therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
62076624|NCT03604263|EXPERIMENTAL|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
62076625|NCT06142435||Controls|Participants should not be part of the Intended Use Population. Subjects that present to the hospital, clinic, or emergency department, either as a patient or non-patient, with no history of head trauma and, are 18-45 years of age.
62076626|NCT06142435||TBI-Suspected Patients|TBI participants 18-45 years of age, recruited from patients at a clinical research facility who present with head trauma. Clinical evaluation for the patient can be positive (target condition present) or negative (target condition absent) for mTBI. Testing will occur on Day-0, Day-14, and Day-30.
62076627|NCT02161328||ICU patients undergoing a dilatative tracheotomy.|
62456822|NCT04942756|EXPERIMENTAL|Continuous Glucose Monitoring|"The FreeStyle Libre 2 Flash Glucose Monitoring System (FSL2) is a CGM device with real time alarms capability indicated for the management of diabetes in persons aged 4 and older. The Sensor holds eight (8) hours of data at a time. In order to have a daily diary of the Glucose level the patients or family or HCP must read the sensor (with reader or app) at least every height (8) hours. Every day at least three (3) scans of the sensor should be performed using the reader or the Smartphone App, generally at wake up in the morning, in the afternoon and at the time to go to sleep.~The alarm system will be activated, so that the Glucose level is over the cut off limit of 180 mmol/L or when it is lower than the cut-off limit of 80 mmol/L, the patient and/or the family members and/or the caregiver will check the Glucose level by scanning the reader/smartphone over the sensor."
62279952|NCT02787850|ACTIVE_COMPARATOR|CoolSculpting Treatment Cohort B|"Cohort B will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 45 minutes using the CoolMax applicator with the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with a second protocol-defined temperature for 60 minutes with the Crown Cooling Insert.~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
62279953|NCT04663945|EXPERIMENTAL|Intervention|"This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions.~Other: remote controlled exercise plus home exercise~Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise"
62456823|NCT04942756|ACTIVE_COMPARATOR|Standard Care|"This arm will perform the usual standard routine for blood glucose monitoring in patients with insulin therapy, that is represented by at least three finger pricks/die according to the usual standards routine of each center.~Different frequency of finger pricks glucose measurements could be performed on the basis of health care professional patient assessment of each patient's needs."
62456824|NCT05875337|EXPERIMENTAL|Acupressure Group (experimental)|In the acupressure groups the points are LI4, LI11 and HT7.
62456825|NCT05875337|PLACEBO_COMPARATOR|Placebo Acupressure Group (control)|In the placebo acupressure group the points are 1.5 cm away from LI4, LI11 and HT7 points.
62456826|NCT00154180|ACTIVE_COMPARATOR|Arm 1|CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg
62456827|NCT00154180|PLACEBO_COMPARATOR|Arm 2|Placebo patch, placebo CEE, placebo Prometrium
62646025|NCT02814526|EXPERIMENTAL|Aerobic|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
62646026|NCT02814526|ACTIVE_COMPARATOR|Stretching/balance/range of motion|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
62646027|NCT03994380|EXPERIMENTAL|Intervention|rhDNAse 2.5 mg nebulizer daily for 4 weeks
62076628|NCT02125032|ACTIVE_COMPARATOR|Transcranial pulsed electromagnetic fields (T-PEMF)|One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.
62456828|NCT03221374|EXPERIMENTAL|Mindfulness Based Stress Reduction|Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
62456829|NCT03221374|NO_INTERVENTION|Waitlist|Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.
62646028|NCT05878236||Acute Pancreatitis|Patients meeting Revised Atlanta Criteria for diagnosis of acute pancreatitis
62646029|NCT05590338|EXPERIMENTAL|Part A: GSK1070806|Participants in Part A will receive single dose of GSK1070806 intravenous (IV) infusion
62456830|NCT01440283|EXPERIMENTAL|Treatment|"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen will be eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients will begin the planning process for abdominal irradiation.~Interventions: Intensity Modulated Radiation Therapy (IMRT)"
62456831|NCT03156764||Qp/Qs ratio monitoring|Qp/Qs ratio monitoring
62076629|NCT02125032|PLACEBO_COMPARATOR|Trancranial electromagnetic pulsed fields (T-PEMF)|8 weeks of T-PEMF treatment placebo.
62076630|NCT02473887|EXPERIMENTAL|gastroenteritis with persistent vomiting.|patients with gastroenteritis with persistent vomiting received single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
62456832|NCT01775319|ACTIVE_COMPARATOR|Biofortified wheat|Biofortified wheat
62456833|NCT01775319|PLACEBO_COMPARATOR|Control wheat|Control wheat with low level of Zn
62456834|NCT01775319|ACTIVE_COMPARATOR|Fortified wheat|Wheat fortified before consumption
62646030|NCT05590338|EXPERIMENTAL|Part B: GSK1070806|Participants in Part B will receive single dose of GSK1070806 IV bolus
62646031|NCT05590338|PLACEBO_COMPARATOR|Part A: Placebo|Participants in Part A will receive single dose of placebo
62076631|NCT06524505|EXPERIMENTAL|dTMS group|Participants receive active stimulation with H1 coil, consisting of 55 18 Hz, 2 s trains at 120% MT intensity, with a between-train interval of 20 s ,1980 pulses per day. The subjects were stimulated every day for 4 weeks (except weekends).
62076632|NCT06524505|SHAM_COMPARATOR|sham group|The sham stimulation was performed using the same procedures, with the sham coil.
62076633|NCT05518422|EXPERIMENTAL|Oral Bosentan|
62076634|NCT00211237|EXPERIMENTAL|Balloon Kyphoplasty (BKP)|The subjects assigned to this group will undergo the treatment with Balloon kyphoplasty for their painful VCFs.
62076635|NCT00211237|ACTIVE_COMPARATOR|Non Surgical Management|The subjects in this group will undergo the non-operative treatments aimed at alleviation of back pain and restoration of decreased function associated with VCFs.
62076636|NCT04453501||Azithromycin or non-azithromycin group|Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
62646032|NCT00997334|EXPERIMENTAL|Erlotinib|Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.
62646033|NCT01542827|PLACEBO_COMPARATOR|Placebo|Topical gel containing a menthol scent, but no active menthol
62646034|NCT01542827|EXPERIMENTAL|Biofreeze|Biofreeze topical gel containing 3.5% menthol
62646035|NCT00776880||1|Patients assessed with ASA physical status scale
62646036|NCT00776880||2|Patients assessed with PPS scale
62456835|NCT01734291|ACTIVE_COMPARATOR|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the patients.
62456836|NCT01734291|PLACEBO_COMPARATOR|Treatment as usual(TAU)|Treatment as usual administered by physician and counseling administered by nurse.
62456837|NCT04266210|EXPERIMENTAL|Fuji Bulk|Glass ionomer (Fuji Bulk, GC, Tokyo Japan)
62456838|NCT04266210|EXPERIMENTAL|G-ænial Posterior|Posterior composite resin(G-ænial Posterior, GC, Tokyo Japan)
62456839|NCT05291871|EXPERIMENTAL|IM Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered intramuscularly
62646037|NCT03780582|EXPERIMENTAL|Probabilistic Classification|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan."
62646038|NCT03780582|EXPERIMENTAL|Classification Plus Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. They also see ROIs identified by the AI that represent lung nodules."
62456840|NCT05291871|EXPERIMENTAL|ID Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
62456841|NCT05291871|EXPERIMENTAL|IM Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered intramuscularly
62456842|NCT05291871|EXPERIMENTAL|ID Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
62456843|NCT00262600|ACTIVE_COMPARATOR|Dabigatran dose 2|twice a day
62456844|NCT00262600|ACTIVE_COMPARATOR|Warfarin|once a day
62456845|NCT00262600|ACTIVE_COMPARATOR|Dabigatran dose 1|twice a day
62456846|NCT05666583|EXPERIMENTAL|Intervention Group|Within the scope of the research, the art of marbling was made by the art expert, accompanied by a total of 5 sessions ney concerts for 10 weeks, with two-week intervals. The art application was made to last 20-30 minutes before the patients received chemotherapy. The scales were administered to the individuals in the intervention groups three times in total.
62456847|NCT05666583|EXPERIMENTAL|Control Group|No treatment was applied to the control group. The scales were administered to the individuals in the control groups three times in total.
62456848|NCT01616732|ACTIVE_COMPARATOR|testosterone|against placebo
62456849|NCT01616732|PLACEBO_COMPARATOR|placebo|
62456850|NCT05071937|EXPERIMENTAL|ZEN003694 + Talazoparib|"ZEN003694: 48.0 mg daily (oral) in 28-day cycles~Talazoparib: 0.75 mg daily (oral) at the same time as ZEN003694"
62646039|NCT03780582|EXPERIMENTAL|Classification With Delayed Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions."
62456851|NCT04604704|EXPERIMENTAL|Treatment with LDN and NAD+|LDN will be used at a dosage of 4.5 mg/day, which will be taken orally in the form of tablets. NAD+ will be administered using the IontoPatch iontophoresis patch containing 400 mg of NAD+ solution which is worn on the skin for 4-6 hours once per week.
62456852|NCT02429271|ACTIVE_COMPARATOR|Ticagrelor|1st day 270 mg \& from then onwards 180 mg per day
62456853|NCT02429271|ACTIVE_COMPARATOR|Clopidogrel|1st day 300 mg \& from then onwards 75 mg per day
62456854|NCT03344081||Meditators|Meditators will have practiced meditation for at least the 5 years, at least 90 minutes weekly. They will have completed at least 14 days of retreat practice in the past 5 years. At least half of their meditation practice will include attention to the breath and body. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
62456855|NCT03344081||Controls|Control participants will be age- and gender-matched to each meditators. They will have little to no previous meditation experience. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
62646040|NCT03836586|EXPERIMENTAL|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
62646041|NCT03836586|ACTIVE_COMPARATOR|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
62456856|NCT05188937|EXPERIMENTAL|validity and reliability of Dual-task Questionnaire|"This study was conducted as test-retest design and the psychometric properties of Dual-task Questionnaire were examined in patients with MS."
62456857|NCT04066361|EXPERIMENTAL|Chatbot|"* Participant is given a pamphlet introducing genetic testing~* Participant is given information utilized for clinical, standard of care testing.~* Will receive genetic information with a virtual interactive Chatbot prior to genetic testing. After the Chatbot education, participant is asked if they would like to proceed with genetic testing.~* Participant is asked to complete an electronic family history tool"
62076637|NCT03562351|EXPERIMENTAL|Verbal Instructions on use of RM|Caregivers will undergo an educational intervention with typical training with verbal instructions and use of a rectal diazepam trainer.
62646042|NCT04159714|EXPERIMENTAL|Bandage Contact Lens (BCL) group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have a bandage contact lens soaked in antibiotic solution placed in the affected eye
62646043|NCT04159714|NO_INTERVENTION|Usual Care Group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have usual care provided in the Emergency Department
62646044|NCT04929015|EXPERIMENTAL|Diagnostic (biospecimen collection)|"Patients will receive standard treatment with surgery, HIPEC, and chemotherapy as appropriate to the patient situation, extent of disease and multi-disciplinary evaluation.~Patients undergo blood sample collection for ctDNA analysis at baseline, pre-surgery, post-surgery and every 3 months up to 2 years.~Patients undergo tissue collection before or during surgery and their medical records are reviewed."
62646045|NCT03534024|ACTIVE_COMPARATOR|nanomicielle curcumin|
62646046|NCT03534024|PLACEBO_COMPARATOR|plecebo|
62646047|NCT04104971||with complications|children who did liver transplantation and develop complications
62076638|NCT03562351|EXPERIMENTAL|Video on use of RM|Caregivers will undergo an educational intervention with training by watching an instructional video regarding rescue medication administration
62076639|NCT03562351|EXPERIMENTAL|Mannequin on use of RM|Caregivers will undergo an educational intervention with training by use of a mannequin to practice administering the rescue medication
62076640|NCT05998772||PD patients with craving for sweets|
62076641|NCT05998772||PD patients without craving for sweets|
62646048|NCT04104971||without complications|children who did liver transplantation and do not develop complications
62279954|NCT04663945|NO_INTERVENTION|Control|"This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training.~Other: basic education"
62279955|NCT05797428|EXPERIMENTAL|Logotherapy|3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy.
62279956|NCT05797428|NO_INTERVENTION|Routine psychiatric outpatient treatment|Will not provide any logotherapy. Just routine psychiatric outpatient treatment.
62279957|NCT00526344||1|Subjects with complete remission of asthma
62646049|NCT04477135|OTHER|perinatologists|perinatologists working actively and performing ultrasonography every day
62646050|NCT00000948|EXPERIMENTAL|1|Participants will be broken into 3 groups. Each group will receive ART and escalating doses of aldesleukin. All participants will then receive that maximum tolerated dose of aldesleukin.
62076642|NCT04262102|ACTIVE_COMPARATOR|Group 1 (SD_SF)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
62279958|NCT00526344||2|Subjects with symptomatic remission of asthma
62076643|NCT04262102|EXPERIMENTAL|Group 2 (SD_BLW)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
62076644|NCT04262102|EXPERIMENTAL|Group 3 (HFV_SF)|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
62646051|NCT00000948|ACTIVE_COMPARATOR|2|All participants will receive ART
62076645|NCT04262102|EXPERIMENTAL|Group 4 (HFV_BLW)|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
62279959|NCT00526344||3|Subjects with asthma
62279960|NCT00526344||4|Healthy controls
62279961|NCT03598855|EXPERIMENTAL|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
62279962|NCT03598855|NO_INTERVENTION|Control|
62279963|NCT03908619|ACTIVE_COMPARATOR|TTP (Group A)|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
62279964|NCT03908619|ACTIVE_COMPARATOR|TTP (Group B)|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
62279965|NCT03908619|ACTIVE_COMPARATOR|TTP (Group C)|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
62279966|NCT03908619|EXPERIMENTAL|TTP (Group D)|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
62279967|NCT03473132|EXPERIMENTAL|Treatment|Based on starting international normalized ratio (INR) and target INR, the dose of four factor prothrombin complex concentrate will be calculated and infused. Coagulation factor levels will be assessed over 48-72 hours.
62279968|NCT04538391|ACTIVE_COMPARATOR|bupivacaine group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.
62646052|NCT00648180|EXPERIMENTAL|1|Doxycycline Monohydrate Tablets 100 mg
62646053|NCT00648180|ACTIVE_COMPARATOR|2|Adoxa Tablets 100 mg
62646054|NCT00785083|EXPERIMENTAL|1|
62076646|NCT01366651|EXPERIMENTAL|Doripenem|Doripenem Type=exact number unit=mg/kg number=10 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients \<12 weeks of age.Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.,Doripenem Type=exact number unit=mg/kg number=30 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to \<1 year of age. Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.
62076647|NCT00253786|EXPERIMENTAL|Intensive multifactorial therapy (Protocol A)|Protocol A: serum creatinine \<1.2 mg/dl in male and \<1.0 mg/dl in female.
62279969|NCT04538391|ACTIVE_COMPARATOR|meloxicam group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.
62279970|NCT04538391|ACTIVE_COMPARATOR|placebo group|included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline.
62646055|NCT00785083|PLACEBO_COMPARATOR|2|
62279971|NCT02580500|ACTIVE_COMPARATOR|group 1|Pilonidal dermoid cyst surgery in Spinal anaesthesia
62279972|NCT02580500|ACTIVE_COMPARATOR|group 2|Pilonidal dermoid cyst surgery in Epidural anaesthesia
62279973|NCT01461174|EXPERIMENTAL|Modafinil|200 mg tablet, single dose
62279974|NCT01461174|EXPERIMENTAL|Donepezil|5 mg tablet one per day, 15 days
62456858|NCT04066361|EXPERIMENTAL|Video Education|"* Participant is given a pamphlet introducing genetic testing~* Participant is given information utilized for clinical, standard of care testing.~* Participant will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing. After the video education, participant is asked if they would like to proceed with genetic testing.~* Participant is asked to complete an electronic family history tool"
62456859|NCT03799666|EXPERIMENTAL|Pulmonary Rehabilitation Group|Patients will participate in a 12-week community-based pulmonary rehabilitation programme.
62456860|NCT03799666|ACTIVE_COMPARATOR|Standard Care Group|Patients will continue to receive the standard care, which means the daily medication prescribed by the pshysician from the primary care centre team.
62456861|NCT01654107|EXPERIMENTAL|Persistence Targeted Smoking Cessation|Persistence Targeted Smoking Cessation - 8 weeks counseling + 12 weeks nicotine lozenge
62646056|NCT06303817|OTHER|Double knots group|The edge of the fascia was determined with a Kocher clamp. The fascia was closed starting from the opposite side with a synthetic absorbable multifilament suture in a continuous fashion up to the Kocher clamp and tied the knots with the same single suture.
62646057|NCT06303817|OTHER|Triple knots group|The edge of the fascia was fixed with the same suture material instead of the Kocher clamp, and the fascia was closed similarly, starting from the opposite corner via the second loop. Then the loops from the first suture were tied to the second suture.
62646058|NCT00889304||A|HTO cohort
62456862|NCT01654107|ACTIVE_COMPARATOR|Clearing The Air|Clearing the Air Smoking Cessation intervention - 8 weeks counseling + 12 weeks nicotine lozenge
62456863|NCT04875065|EXPERIMENTAL|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
62456864|NCT00714103|EXPERIMENTAL|8-Chloro-Adenosine|Starting dose for first cohort of patients 45 mg/m2 intravenous over 1 hr daily for 5 days every 4 weeks (± 3 days).
62456865|NCT04458649||No increased risk of hypoglycemia|Infants born with no obvious risk factors for hypoglycemia in the neonatal period.
62456866|NCT04458649||Increased risk of hypoglycemia|"Infants considered at increased risk for hypoglycemia after birth including the following criteria:~* Infant born to a diabetic mother~* Very large for gestational age (VLGA) infant with weight \>97%"
62076648|NCT00253786|ACTIVE_COMPARATOR|Standard therapy (Protocol A)|Protocol A: serum creatinine \<1.2 mg/dl in male and \<1.0 mg/dl in female.
62279975|NCT01461174|EXPERIMENTAL|Memantine|10 mg tablet one per day, 15 days
62646059|NCT01959100|EXPERIMENTAL|Azithromycine|250 mg x 3/week during a meal for a period of 2 years
62456867|NCT05473169||Patients|Patients with Vocal fold immobility
62456868|NCT05473169||Control|Normal volunteer don't have dysphagia , neurological diseases , heart burn and acid regurgitation
62456869|NCT01720082|ACTIVE_COMPARATOR|Single incision laparoscopic appendectomy|Acute appendicitis with surgical indication
62646060|NCT01959100|PLACEBO_COMPARATOR|Placebo|250 mg x 3/week during a meal for a period of 2 years.
62646061|NCT06095908||'rectus sheath block'|Patients in Group I underwent postoperative USG-guided bilateral rectus sheath block at the T9-10 level with 20 ml of 0.25% bupivacaine (40 ml in total).
62646062|NCT06095908||'wound infiltration'|Group II (control group), 20 ml of 0.25% bupivacaine was applied subcutaneously to each wound lip (40 ml in total).
62646063|NCT02068937|ACTIVE_COMPARATOR|Control Group|In the control group, patients just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline. The patients do not receive phone calls neither advising on non-pharmacological treatment; The medication is adjusted by the doctor during the initial evaluation of study baseline.
62646064|NCT02068937|EXPERIMENTAL|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.
62456870|NCT01720082|ACTIVE_COMPARATOR|Multiport Laparoscopic appendectomy|Acute appendicitis with surgical indication
62456871|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
62646065|NCT02879318|ACTIVE_COMPARATOR|Gemcitabine plus Nab-Paclitaxel|Gemcitabine 1000 mg/m2 IV \& Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Days 1, 8, 15 Q28 days.
62646066|NCT02879318|EXPERIMENTAL|Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab|"Gemcitabine 1000 mg/m2 IV \& Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 8, 15 Q28 days.~plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity."
62646067|NCT01578772|EXPERIMENTAL|Telmisartan|Open label
62076649|NCT00253786|EXPERIMENTAL|Intensive multifactorial therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
62076650|NCT00253786|ACTIVE_COMPARATOR|Standard therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
62646068|NCT03651141|EXPERIMENTAL|Neurodynamic Sliding|neurodynamic sliding consists of 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets.
62076651|NCT05993286|OTHER|Psychoeducation|This was an active control group and included information on the proposed mechanism of the development of misophonia, how symptoms are reinforced, and basic coping skills.
62076652|NCT05993286|EXPERIMENTAL|Exposure Therapy and Psychoeducation|Exposure has been successfully used in the treatment of anxiety disorders, phobias, and obsessions. There are also case reports showing its effectiveness in the treatment of misophonia. The proposed procedure is to expose the misophonic person to the triggering sound in a controlled and gradual manner until habituation/desensitization to the trigger occurs. In the current research setting, each participant was asked to choose the two misophonic sounds that are most disturbing.
62456872|NCT04908748|EXPERIMENTAL|Active Arm|Esflurbiprofen Hydrogel Patch containing 165 mg Esflurbiprofen
62456873|NCT04908748|PLACEBO_COMPARATOR|Control Drug|Placebo patch that does not contain the active ingredient but is otherwise indistinguishable from the investigational drug Esflurbiprofen Hydrogel Patch
62076653|NCT05993286|ACTIVE_COMPARATOR|Sound Therapy and Psychoeducation|The music used in the current study was adapted from the protocol used by Jastreboff and Jastreboff (2013) for the treatment of misophonia. It includes noises such as white (noise with equal volume in all octaves) or pink noise (noise that decreases by 3 dB per octave towards high frequencies) or relaxing instrumental music
62076654|NCT02229643||Traumatic brain injury|Patients delivered within 4 h whose highest abbreviated injury score (AIS) was 3 or less (other than head injury) were considered to be isolated traumatic brain injury cases and were included in this study.
62076655|NCT03003546|EXPERIMENTAL|Treatment (AR160)|Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62076656|NCT05908890|EXPERIMENTAL|Experimental Denture Adhesive|
62076657|NCT05908890|ACTIVE_COMPARATOR|Marketed Denture Adhesive|
62456874|NCT03194464|EXPERIMENTAL|Task-failure, Extended Session|Repeated sub-maximal gripping exercise with the less affected hand to task-failure - followed by repeated measurements (5) during recovery period
62456875|NCT03165565|EXPERIMENTAL|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
62456876|NCT03165565|ACTIVE_COMPARATOR|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
62279976|NCT04232735|EXPERIMENTAL|Intervention|"The Source tool is used by care givers for informing patients about the outcomes of treatment. Prediction models are developed and built in the website in order to generate a personalized prediction of the outcomes: survival, toxicity and/or complications and HRQL. These predictions are visualized in clear and comprehensible graphs with a broad variation of options available for tailoring of the visualizations.~In order for care givers to be able to use this tool effectively, we designed the Source training. This communication skills training is comprised of an e-learning, two face-to-face group sessions and an individual booster session. Aside from an instruction video on the navigation within the Source tool, the e-learning consists of theory and tips and tricks on how to inform patients and communicate risks. The face-to-face components of the training are focused on getting the skilled use of the source tool into practice, by receiving personal feedback on the performance."
62279977|NCT03380910|EXPERIMENTAL|Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
62279978|NCT03380910|OTHER|Not Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are not ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
62279979|NCT04458844|EXPERIMENTAL|Fundamental Movement Skill (FMS) Training|Exercise 2 x per week focusing on Fundamental Movement Skill Development
62456877|NCT02946762|OTHER|Universal Test and Treat|All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
62646069|NCT03651141|EXPERIMENTAL|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
62646070|NCT03651141|SHAM_COMPARATOR|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
62279980|NCT04458844|EXPERIMENTAL|FMS and strength|Replacement of 50% FMS training with integrated strength training.
62279981|NCT04458844|NO_INTERVENTION|Control|No intervention.
62279982|NCT02262494|OTHER|Suspected first episode of DVT|"The study population consists of patients presenting with suspected first episode of DVT at the Nîmes University Hospital.~Intervention: portable venous compression ultrasonography Intervention: venous compress ultrasonography Intervention: Doppler ultrasound of the lower limbs"
62279983|NCT00720460||Experimental|Healthy Volunteers
62279984|NCT00926692||Healthy Subjects|All subjects are considered healthy
62279985|NCT05167019|ACTIVE_COMPARATOR|Usual care|Usual care
62279986|NCT05167019|EXPERIMENTAL|The CODE intervention|The CODE intervention consists of 4 items, of which individual coaching sessions of 1 hour. In total each doctor taking care of hospitalized patients will be able to receive maximum 16 individual coaching sessions during the 4 months intervention period (one weekly). Every doctor will be invited to participate to at least 8 coaching sessions, to be extended on request, during the intervention period.
62456878|NCT03501875|EXPERIMENTAL|CAC Score|CAC Score evaluated by the Agatston method
62456879|NCT02576249|ACTIVE_COMPARATOR|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
62646071|NCT03904654|EXPERIMENTAL|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 60-minute consecutive weekly MBCT group sessions.
62646072|NCT00851487|EXPERIMENTAL|Amoxicillin|Oral amoxicillin in the dose of 15 mg/kg/dose 8 hourly was given as an active drug
62646073|NCT00851487|PLACEBO_COMPARATOR|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
62279987|NCT06308770|ACTIVE_COMPARATOR|Standard care|Participants will be provided with access to Versus Arthritis and Lupus UK fatigue booklets.
62076658|NCT04219254|EXPERIMENTAL|BI-1206 + Pembrolizumab 25mg/mL (MK-3475)|BI-1206 administrated either IV or SC + Pembrolizumab 200mg administered IV every third week as a fixed dose will be used.
62279988|NCT06308770|ACTIVE_COMPARATOR|Standard care and 4 week Fatigue Management Programme (FMP)|Participants will be provided with access to Versus Arthritis and Lupus UK fatigue booklets and be randomised to a 4 week virtual FMP. They will attend live online group weekly sessions for 3 consecutive weeks followed by a review session at week 11.
62279989|NCT06308770|ACTIVE_COMPARATOR|Standard care and 7 week Fatigue Management Programme (FMP)|Participants will be provided with access to Versus Arthritis and Lupus UK fatigue booklets and be randomised to a 7 week virtual FMP. They will attend live online group weekly sessions for 6 consecutive weeks followed by a review session at week 14.
62456880|NCT02576249|EXPERIMENTAL|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
62076659|NCT02663414|EXPERIMENTAL|Atlas device|Each patient in this arm will receive the Atlas Knee System device on the medial side of the symptomatic knee.
62279990|NCT02161562|EXPERIMENTAL|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
62279991|NCT02161562|EXPERIMENTAL|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
62279992|NCT04508660|EXPERIMENTAL|Subjects with facial redness|Topical application twice daily for 4 weeks
62279993|NCT01277094|EXPERIMENTAL|1|
62456881|NCT05048992|ACTIVE_COMPARATOR|ELDOA method|Twenty (20) patients will be treated with ELDOA method
62076660|NCT01115491|EXPERIMENTAL|A|
62076661|NCT01213862|EXPERIMENTAL|intervention and control|"* Group I - Intervention: Routine follow-up in a reference health institution with four home visits and four telephone contacts with specialist nurses.~* Group II - Control: Routine follow-up with the health team in the reference institution."
62076662|NCT00065468|ACTIVE_COMPARATOR|A|
62076663|NCT00065468|EXPERIMENTAL|B|
62076664|NCT00065468|EXPERIMENTAL|C|
62279994|NCT01277094|PLACEBO_COMPARATOR|2|
62279995|NCT00356031|EXPERIMENTAL|Bevacizumab, Radiation, and Surgery|Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)
62456882|NCT05048992|ACTIVE_COMPARATOR|Post-facilitation stretching|Twenty (20) patients will be treated with Post-facilitation stretching technique.
62646074|NCT04539990|EXPERIMENTAL|Behavioral Sleep Treatment|"Parents of children with autism will come to two group meetings (up to 5 families in each group) where they will be receive information regarding sleep hygiene and behavioral techniques for reducing sleep onset delays and night awakenings. The program will last 8 weeks. Meetings will be held on week 1 and week 3. In addition parents will receive a weekly phone call where they will be asked about their ability to implement the behavioral techniques.~Sleep of the children will be measured using questionnaires, sleep diaries and with a Fitbit sensor before and after the program."
62279996|NCT06221020||Patients with ERAS|"In the experimental group (Patients with ERAS), participants will undergo an assessment of the Enhanced Recovery After Surgery (ERAS) consensus items.~The experimental group will complete all the items on the ERAS forms as far as possible. All groups will undergo our routine preoperative evaluation for pituitary tumor surgery, such as cardiopulmonary function, hormone testing, vision and visual field examination, etc. The care during hospitalization and surgery will be the same as previously for patients with pituitary tumors, and the post-discharge outpatient follow-up will also be the same as for patients who have undergone pituitary tumor surgery."
62279997|NCT06221020||Patients with Regular|"In the control group (Patients with Regular), participants will only complete the routine items as before.~All groups will undergo our routine preoperative evaluation for pituitary tumor surgery, such as cardiopulmonary function, hormone testing, vision and visual field examination, etc. The care during hospitalization and surgery will be the same as previously for patients with pituitary tumors, and the post-discharge outpatient follow-up will also be the same as for patients who have undergone pituitary tumor surgery."
62279998|NCT01625780|EXPERIMENTAL|Study group: 3-layer block|Patients in this group will receive the 3-layer ilioinguinal nerve block.
62279999|NCT01625780|ACTIVE_COMPARATOR|Control: single-shot block|Patients in this group will receive a standard, single-shot ilioinguinal nerve block.
62076665|NCT01492179|ACTIVE_COMPARATOR|Intravenous Lidocaine|Intravenous lidocaine would be administered as an infusion for pain management both intra- and post-operatively.
62280000|NCT02397928|EXPERIMENTAL|TTFields concomitant to pemetrexed plus cisplatin/carboplatin|Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
62280001|NCT03461133||Reference|All patients admitted to the participating surgical wards from 2015-01-01 to 2015-12-31
62076666|NCT01492179|ACTIVE_COMPARATOR|Intra-abdominal Lidocaine|Lidocaine would be administered intermittently, once each hour intra-abdominally for postoperative pain management.
62280002|NCT03461133||Intervention|All patients admitted to the participating surgical wards from 2016-07-01 to 2017-06-30
62280003|NCT01469000|EXPERIMENTAL|250 mg Gefitinib/500 mg Pemetrexed|250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.
62280004|NCT01469000|ACTIVE_COMPARATOR|250 mg Gefitinib|250 milligrams (mg) Gefitinib taken orally QD
62456883|NCT01103505|OTHER|ForeseeHome AMD Monitoring Device|Participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device in addition to standard care
62456884|NCT01103505|NO_INTERVENTION|Standard care alone (control) arm|Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD and routine eye exams
62456885|NCT05962554|EXPERIMENTAL|Intervention group|The group that will be first randomly allocated to iJobs.
62456886|NCT05962554|EXPERIMENTAL|Waiting list control group|This group will receive the intervention 2-weeks after the intervention group finishes it.
62456887|NCT02651441|EXPERIMENTAL|D-CIK|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines,patients will receive 3 cycles of D-CIK treatment.
62456888|NCT02651441|ACTIVE_COMPARATOR|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
62076667|NCT01492179|PLACEBO_COMPARATOR|Normal saline|Normal saline would be administered intra-abdominally and intravenously in the same patient. Rescue analgesia in the form of morphine (PCA) would be used for pain management.
62280005|NCT05261204||Transcatheter Aortic Valve Implantation|Patients with aortic-valve stenosis at risk to severe valve obstruction who received TAVI with or without CABG or PCI. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, aortic valve stenosis, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.
62280006|NCT05261204||Bioprosthesis|Patients with aortic-valve stenosis at risk to severe valve obstruction who undervent SAVR with the use of bioprosthesis with or without CABG or PCI. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, aortic valve stenosis, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.
62280007|NCT05261204||Sutureless|Patients with aortic-valve stenosis at risk to severe valve obstruction who were managed by mean of SAVR with the use of sutureless with or without CABG or PCI. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, aortic valve stenosis, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.
62076668|NCT03181126|EXPERIMENTAL|Venetoclax + Navitoclax + Chemotherapy|Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase \[or any other forms of asparaginase\], vincristine, dexamethasone) and tyrosine kinase inhibitor \[TKI, if applicable\]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.
62076669|NCT02304250|ACTIVE_COMPARATOR|Group D|Group D: dexamethasone group
62076670|NCT02304250|PLACEBO_COMPARATOR|Group S|Group S: saline group
62076671|NCT01272713|OTHER|Oxygen therapy|"* Standard acute coronary syndrome treatment as per hospital protocol~* Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~* In-hospital oxygen as per hospital protocol"
62076672|NCT01272713|OTHER|No oxygen therapy|"* Standard acute coronary syndrome treatment as per hospital protocol~* No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%."
62076673|NCT03424720|EXPERIMENTAL|Comparison of PLE and BIS|Investigators assess PLE and BIS values as indicators of the depth of anesthesia during induction and emergence of anesthesia and facial nerve integrity monitoring
62076674|NCT02597205|EXPERIMENTAL|Mobile app|Multi-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages
62280008|NCT06350383|EXPERIMENTAL|WINGS+PM+|WINGS+PM+ is a safety, harm reduction, and brief psychological intervention that involves seven 90-minute weekly sessions focused on exploring types and mechanisms of IPV; building motivation to address IPV; safety planning and revision; enhancing social support to address IPV; goal setting and revision; identifying IPV-related services and needs; linkage and referral to services; self-care planning; learning and practicing a stress management technique; identifying, defining, and managing problems through goal setting and review; increasing engagement in positive activities; strengthening social supports; and developing plans to stay healthy and well beyond the intervention.
62076675|NCT05771584|EXPERIMENTAL|Total 300 μg of AST-301|AST-301/rhuGM-CSF (3-week interval, 3 cycles in total)
62076676|NCT05771584|EXPERIMENTAL|Total 600 μg of AST-301|AST-301/rhuGM-CSF (3-week interval, 6 cycles in total)
62076677|NCT05926128|OTHER|CML patient TKI discontinuation study|Treatment free remission in patients with chronic myeloid leukemia in chronic phase who achieved deep molecular response with tyrosine kinase inhibitors
62076678|NCT01565200|OTHER|T-DM1|After an imaging phase, the patient will receive T-DM1 iv every 3 weeks until progression or toxicity
62280009|NCT06350383|ACTIVE_COMPARATOR|PM+-Only|PM+: is a brief psychological intervention also designed to be facilitated by non-specialists (e.g. CHVs) and focused on problem management and evidence-based behavioral strategies to enhance one's capacity to adaptively manage psychological distress. It has been shown to be effective at reducing psychological distress among women who have experienced gender-based violence in informal settlements in Nairobi, Kenya. PM+ involves five 90-minute, weekly individual sessions focused on learning and practicing a stress management technique; identifying, defining, and managing problems through goal setting and review; increasing engagement in positive activities; strengthening social supports; and developing plans to stay healthy and well beyond the intervention.
62076679|NCT01714973|EXPERIMENTAL|ST266 intact|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The first cohort will receive ST266 and saline placebo applied to intact skin beginning immediately following the first radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
62076680|NCT01714973|EXPERIMENTAL|ST266 inflamed|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The second cohort will receive ST266 and saline placebo applied to inflamed skin (after inflammation is first noted) beginning immediately following the radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
62456889|NCT05641909|EXPERIMENTAL|Remifentanil|"Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml)~+ 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase). Only when the opioid infusion rate had reached the 'propofol trigger dose' (12ml/h; 12ug/ kg per hour) was propofol to be administered as an initial bolus dose of up to 0.5 mg/kg and an infusion of 0.5mg/kg per hour, and titrated in 25% increments (0.25mg/kg bolus dose + 0.125mg/kg per hour rate increase to treat agitation."
62076681|NCT04670926|EXPERIMENTAL|TruGraf - Group 1:|Patients randomized to Group 1 will receive serial TruGraf testing at months 3, 4, 5, 6, 7, 8, 9, and 12. Results will be available in real-time and used by the physician to guide management of immunosuppression.
62076682|NCT04670926|ACTIVE_COMPARATOR|CPMC Standard of Care - Group 2:|Patients randomized to Group 2 or CPMC Standard of Care Group patients will have current standard of care laboratory assessments.
62076683|NCT04192214|ACTIVE_COMPARATOR|BC 007|The treatment arm will comprise 20 randomly allocated β1-AAb positive dilative cardiomyopathy (DCM) patients. Participants will receive a continuous 75 minute infusion of 1350 mg BC 007 at day 1. The β1-AAb status will be monitored 10 days after treatment and every month. Treatment is repeated once up to month 11 if the participant's β1-AAbs were not neutralized after 1st dosing on day 1 or reoccur.
62076684|NCT04192214|NO_INTERVENTION|Control|The control arm will comprise 10 randomly allocated β1-AAb positive DCM patients. Participants will receive standard therapy but no intervention. The β1- AAb status will be monitored every month.
62076685|NCT02406261|EXPERIMENTAL|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;~20 mg simvastatin, single oral dose on Days 2 and 36;~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;~50 mg lanabecestat, single oral dose on Day 4;~50 mg lanabecestat, single oral dose, Days 10 to 37"
62076686|NCT02406261|EXPERIMENTAL|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;~5 mg donepezil, single oral dose on Day 28, Period 2"
62076687|NCT02141659|EXPERIMENTAL|Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
62076688|NCT02141659|EXPERIMENTAL|Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
62280010|NCT05834010|EXPERIMENTAL|FMT|rectal or oral route FMT
62280011|NCT02668367|ACTIVE_COMPARATOR|BTA-C585 oral capsules|100 mg capsules; Multiple ascending doses (MAD) from 100 mg to 600 mg
62280012|NCT02668367|PLACEBO_COMPARATOR|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
62280013|NCT04235686|ACTIVE_COMPARATOR|Mydayis - Active|"MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
62280014|NCT04235686|PLACEBO_COMPARATOR|Placebo|"Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
62280015|NCT03031600|ACTIVE_COMPARATOR|Radiodilution via Daxor BVA-100|In study arm 1, actual blood volume will be measured using the Daxor Blood Volume Analyzer-100 (BVA-100). In this technique, the subject is injected with 1 ml of human serum albumin labeled with iodine131 (25 microcuries). A small amount of blood is collected from the subject just before injection and at 12, 18, 24, 30, and 36 min after injection.
62280016|NCT03031600|EXPERIMENTAL|Hemodilution via hematocrit measurement|In study arm 2, estimated blood volume will measured via hemodilution. . A blood sample (5 ml) will be drawn for baseline determination of hematocrit via iSTAT and lab measurement from the non-dominant arm. After the baseline hematocrit blood sample is drawn, a volume of normal saline equivalent to 10% of the subject's ideal blood volume will be administered over a 12-minute period through the dominant arm IV catheter. Twelve minutes after the infusion is complete, a second blood sample (5 ml) will be drawn from the non-dominant arm for determination of post-bolus hematocrit via iSTAT and lab. Subjects will then be asked to void into a urinal, and urine output will be measured in ml.
62280017|NCT03723681|EXPERIMENTAL|Quizartinib 20 mg|Participants receive 20 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
62280018|NCT03723681|EXPERIMENTAL|Quizartinib 40 mg|Participants receive 40 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
62076689|NCT02141659|EXPERIMENTAL|Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
62076690|NCT02141659|EXPERIMENTAL|Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg|TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
62076691|NCT02141659|EXPERIMENTAL|Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
62076692|NCT02141659|EXPERIMENTAL|Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
62280019|NCT01649947|EXPERIMENTAL|Cohort 2: Bevacizumab ineligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Hydroxychloroquine 200 mg PO BID
62280020|NCT01649947|EXPERIMENTAL|Cohort 1: Bevacizumab eligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for Hydroxychloroquine 200 mg PO BID
62280021|NCT01535365|ACTIVE_COMPARATOR|Heat|Application of Heat pad to site of muscle sprain.
62280022|NCT01535365|ACTIVE_COMPARATOR|Cold|Application of ice pack to muscle sprain.
62076693|NCT02807246|ACTIVE_COMPARATOR|Probiotic|Experimental: Breast milk+ Probiotics(Maflor®, Mamsel Pharmaceuticals, Turkey) The study group will be fed with probiotics at a dose of 1x109 CFU/day (Lactobacillus rhamnosus GG 109colony ). Probiotic is in a liquid drop form at a dose of 5 drops a day and is used orally for 10 days.
62076694|NCT02807246|ACTIVE_COMPARATOR|Saline|Active Comparator: Breast milk+five drops of saline The control group will be given Breast milk without the addition of probiotics
62076695|NCT00323713|EXPERIMENTAL|VLPD diet|Adavnced CKD patients (stage 4-5) on a very low protein diet
62076696|NCT00323713|ACTIVE_COMPARATOR|LPD diet|Adavnced CKD patients (stage 4-5) on a low protein diet
62076697|NCT03016793|EXPERIMENTAL|puerarin and β- tricalcium phosphate|"purabone (puerarin) is an osteoinductive bone grafts used to augment bone healing.~β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing"
62076698|NCT03016793|ACTIVE_COMPARATOR|β- tricalcium phosphate alone|β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing
62076699|NCT02459080|ACTIVE_COMPARATOR|TD-4208-1|88 mcg
62076700|NCT02459080|ACTIVE_COMPARATOR|TD-4208-2|175 mcg
62076701|NCT02459080|PLACEBO_COMPARATOR|Placebo|Placebo
62076702|NCT03627611|ACTIVE_COMPARATOR|T4|
62076703|NCT03627611|EXPERIMENTAL|T3|
62076704|NCT00660920|EXPERIMENTAL|ponatnib|Comparison of different dosages of ponatinib given orally once per day.
62076705|NCT06460415|EXPERIMENTAL|Photobiomodulation group (GPBM)|The volunteers in the GFBM group will undergo 8 sessions of a combined red and infrared laser protocol with 4J of infrared power and 4J of red power. Being applied at 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) points in the intravaginal pelvic floor region.
62076706|NCT06460415|PLACEBO_COMPARATOR|Shan group (GS)|"The placebo control will be administered using the same device as the GFBM, but without any therapeutic dose delivery. Furthermore, the irradiated sites and irradiation time will be the same as PBMT. Volunteers will receive a total dose of 0 J in placebo mode. This treatment was also carried out in 8 sessions.~For volunteers in the control group. There will be the possibility of them receiving treatment later if it proves effective in reducing pain."
62076707|NCT01706211|EXPERIMENTAL|BRL 49653C|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
62076708|NCT01706211|PLACEBO_COMPARATOR|placebo|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
62076709|NCT04425993|EXPERIMENTAL|Rectal indomethacin and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
62076710|NCT04425993|ACTIVE_COMPARATOR|Rectal indomethacin and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
62076711|NCT04425993|ACTIVE_COMPARATOR|Rectal placebo and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
62076712|NCT04425993|PLACEBO_COMPARATOR|Rectal placebo and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
62076713|NCT04287192|NO_INTERVENTION|Control|Control: Control participants will complete surveys at 4 time points (baseline, 1-2 weeks, 3 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, and assess their quality of life. Aside from completion of these surveys, no changes to their usual care will occur.
62076714|NCT04287192|EXPERIMENTAL|(Digital Bridge intervention)|"Experimental (Digital Bridge intervention) participants will complete surveys at 4 time points (baseline, 1-2 weeks, 3 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, assess their quality of life, and goal attainment.~One to two days before discharge, patients will work with their team to develop the PODS in Care Connector. Once the PODS is created, the patient and hospital provider will be prompted to set transition goals using the ePRO tool."
62076715|NCT06488703||Participants with underlying condition (UC)|Participants with UCs (Bronchial Asthma, coronary obstructive pulmonary disorder \[COPD\], Chronic Arthritis und Rheumatism, Systemic lupus erythematosus, Vasculitis, Eosinophilic granulomatosis with polyangiitis \[EGPA\], Chronic rhinosinusitis \[CRS\], Crohn's disease, and Ulcerative colitis) with Systemic (cortico)steroids/systemic glucocorticoids (SCS) exposure will be evaluated.
62076716|NCT06488703||Matching control group|Participants with the same UC but without SCS treatment will be evaluated.
62076717|NCT01377415|ACTIVE_COMPARATOR|bupivacaine|a continuous flow of 5 mg/ml bupivacaine 2 ml/h 48 h
62646075|NCT01411852|EXPERIMENTAL|0.9% Sodium Chloride 250 mL bolus|0.9% Sodium Chloride 250 mL bolus - A large bore IV will be placed and a 250cc bag of normal saline (NS) will be hung. If IV placement is difficult, NS can be given through an intraosseous line. Using small bags versus large bags will physically limit the amount of fluid given to patients in the experimental group. The requirement to change the smaller bags of fluid and recheck the pulse or blood pressure will limit the amount of fluid given. The procedure will continue until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
62646076|NCT01411852|ACTIVE_COMPARATOR|0.9% Sodium Chloride 2000 mL bolus|0.9% Sodium Chloride 2000 mL bolus - The treatment of the control group will be consistent with traditional Prehospital Trauma Life Support and Advanced Trauma Life Support guidelines which recommend early aggressive fluid resuscitation. An intravenous line (IV) will be placed and a 1000cc bag of normal saline will be hung. If IV placement is difficult, fluid can be given through an intraosseous line. This procedure will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
62076718|NCT01377415|PLACEBO_COMPARATOR|saline|saline 9 mg/ml infusion 2 ml/h 48 h
62076719|NCT04396353||Physically active|Those who receive regular amounts of physical activity. Those who participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen as recommended by the health organizations. Additionally, a person who spend less time sitting (i.e. watching television, surfing the web, playing video games).
62076720|NCT04396353||Sedentary|Those who do not receive regular amounts of physical activity. Where physical inactivity is considered the failure to meet the recommendations of the health organizations, stating that an individual should participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen. Sitting about 70-85% of the time (i.e. watching television, surfing the web, playing video games) is also considered a person living a sedentary lifestyle.
62076721|NCT05148832|EXPERIMENTAL|Cortocosteroid|ageusia and anosmia were recruited (that their covid infection was confirmed by using PCR). 10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery. All data were recorded and then analyzed.
62280023|NCT05323435|EXPERIMENTAL|Recombinant Two-Component COVID-19 Vaccine (CHO cell), 20μg|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate (ReCOV for short, 20μg)
62646077|NCT00454298|ACTIVE_COMPARATOR|A|AGG-523 1800 mg QD PO (12 capsules) for 28 days
62646078|NCT00454298|ACTIVE_COMPARATOR|B|AGG-523 900 mg BID PO (12 capsules) for 28 days
62646079|NCT00454298|PLACEBO_COMPARATOR|C|Placebo QD PO (12 capsules) for 28 days
62646080|NCT00454298|PLACEBO_COMPARATOR|D|Placebo BID PO (12 capsules) for 28 days
62076722|NCT06243848|ACTIVE_COMPARATOR|Minimal Incision Surgery for median nerve decompression|Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
62076723|NCT06243848|EXPERIMENTAL|Ultrasound-guided perineural injection with 5 cc 5% Dextrose|The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
62076724|NCT02980796|EXPERIMENTAL|Exercise + practice|Individuals will complete 20 minutes of exercise on a recumbent bicycle before practicing a novel motor task.
62076725|NCT02980796|ACTIVE_COMPARATOR|Rest + practice|Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
62076726|NCT01321762||1|Pregnant Women with singleton pregnancy
62646081|NCT05975489|EXPERIMENTAL|Caffeine 3mg/kg intake|A dose of 3 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.
62646082|NCT05975489|EXPERIMENTAL|Caffeine 6mg/kg intake|A dose of 6 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.
62076727|NCT04403802|EXPERIMENTAL|Arm A: Voxx socks followed by placebo socks|Continuous wear of Voxx Human Performance Technology Socks for 2 weeks, followed by continuous wear of placebo socks for 2 weeks (separated by a 2-week washout period)
62076728|NCT04403802|EXPERIMENTAL|Arm B: Placebo socks followed by Voxx socks|Continuous wear of placebo socks for 2 weeks, followed by continuous wear of Voxx Human Performance Technology Socks for 2 weeks (separated by a 2-week washout period)
62076729|NCT02400359|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to either placebo or Lorcaserin HCl.
62076730|NCT02400359|ACTIVE_COMPARATOR|Active|Subjects will be randomized to either placebo or Lorcaserin HCl.
62646083|NCT05975489|PLACEBO_COMPARATOR|Placebo intake|A dose of 3 mg/kg of placebo (Cellulose, Guinama, Valencia, Spain) was ingested before the beginning of each test.
62646084|NCT05164978|EXPERIMENTAL|DEP combine with PD-1 antibody|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 1.5mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; sintilimab injection 200mg day 4. This regimen was repeated after 2 weeks.
62646085|NCT05095519|EXPERIMENTAL|18F-DCFPyL|Patients will undergo PET/CT imaging following intravenous administration of 18F-DCFPyL
62646086|NCT03311555|EXPERIMENTAL|Recurrent PSA-only non-metastatic prostate cancer|Subjects with recurrent PSA-only prostate cancer within 4 years of prostatectomy, and a PSA of greater than 0.2 ng/mL and less than 4 ng/mL in the absence of metastatic disease on CT and bone scans.
62646087|NCT03599570|EXPERIMENTAL|Intervention|Arm 1 will receive the STOP-HPV performance feedback intervention
62646088|NCT03599570|NO_INTERVENTION|Control|Arm 2 will receive standard of care
62076731|NCT05276843|EXPERIMENTAL|group A|receive Qigong exercise in addition to traditional physical therapy program
62076732|NCT05276843|NO_INTERVENTION|group B|receive traditional physical therapy program only
62076733|NCT01129336|EXPERIMENTAL|Patients without bone metastases|Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.
62456890|NCT05641909|ACTIVE_COMPARATOR|Fentanyl|"Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score~≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase). Only when the opioid infusion rate had reached the 'propofol trigger dose' (12ml/h; 2ug/kg per hour) was propofol to be administered as an initial bolus dose of up to 0.5 mg/kg and an infusion of 0.5mg/kg per hour, and titrated in 25% increments (0.25mg/kg bolus dose + 0.125mg/kg per hour rate increase to treat agitation."
62646089|NCT01787552|EXPERIMENTAL|LDE225 + INC424|LDE225 and INC424 in combination
62646090|NCT04499703||Group 1|Subjects with normal macular thickness in one or both eyes.
62646091|NCT04499703||Group 2|Subjects with center-involving macular edema due to wAMD in one or both eyes
62646092|NCT04499703||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes
62280024|NCT05323435|EXPERIMENTAL|Recombinant Two-Component COVID-19 Vaccine (CHO cell), 40μg|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate (ReCOV for short, 40μg)
62280025|NCT05323435|ACTIVE_COMPARATOR|COVID-19 Vaccine (Vero Cell), Inactivated|Antigen: inactivated SARS-CoV-2 Virus (19nCoV-CDC-Tan-HB02 strain) Adjuvant: aluminum hydroxide Excipients: disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride
62280026|NCT02065739|EXPERIMENTAL|Period 1|Participants will receive a single 30-mg dose of JNJ-42165279 on Day 1.
62280027|NCT02065739|EXPERIMENTAL|Period 2|Participants will receive itraconazole 200 mg once a day from Day 4 to Day 10. A single oral 30-mg dose of JNJ-42165279 will be administered on Day 8 along with the dose of 200 mg itraconazole.
62646093|NCT03908346|OTHER|Decision Aid for Surrogate Decision Makers|In this pilot trial all participants will be presented with the decision aid and queried as to the feasibility, acceptability and knowledge translation that is gained by exposure to the decision aid
62280028|NCT02264587|EXPERIMENTAL|mosapride|mosapride 5mg by mouth, 30 minutes before meals, every times one day for 14days
62280029|NCT02264587|ACTIVE_COMPARATOR|domperidone|domperidone 10mg by mouth, 30 minutes before meals, every times one day for 14days
62280030|NCT02436603|OTHER|Nutrition/Mind-Body Coaching|The intervention will consist of weekly group sessions lasting 75-90 minutes during which participants will receive training in the FODMAP diet and mind-body skills.
62456891|NCT03909516|NO_INTERVENTION|Standard of Care|"Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded."
62456892|NCT03909516|ACTIVE_COMPARATOR|Standard of Care + iovera° Treatment|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded.~Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events.~Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
62646094|NCT03707496||DeWinterCohort|Patients with de Winter syndrome pattern ECG
62646095|NCT03805334|EXPERIMENTAL|Touchpoints|Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn \~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
62646096|NCT03830021|EXPERIMENTAL|Salt reduction program|Salt reduction program.
62646097|NCT03830021|ACTIVE_COMPARATOR|Healthy lifestyle program|Healthy lifestyle program.
62646098|NCT02785939|EXPERIMENTAL|Arm I - Palbociclib|"Participants receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
62280031|NCT02436603|NO_INTERVENTION|Waitlist Control Group|Waitlist subjects. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention.
62280032|NCT00141765|EXPERIMENTAL|Myeloablative Chemotherapy with Stem Cell Rescue|Myeloablative Chemotherapy, followed by stem cell rescue
62280033|NCT01004302|SHAM_COMPARATOR|Sham surgery|
62280034|NCT01004302|ACTIVE_COMPARATOR|Active radiosurgery|
62280035|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of \>16 weeks.
62646099|NCT02785939|EXPERIMENTAL|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~Closed to accrual 12/18/2015"
62076734|NCT01129336|EXPERIMENTAL|Patients with bone metastases|Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy)
62076735|NCT01693003|EXPERIMENTAL|Indacaterol first|"Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
62076736|NCT01693003|EXPERIMENTAL|Tiotropium first|"Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
62076737|NCT00801424|EXPERIMENTAL|standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
62076738|NCT04720963|PLACEBO_COMPARATOR|group P (Placebo group)|intranasal placebo about 30min before anesthesia induction
62076739|NCT04720963|EXPERIMENTAL|group R (remimazolam group)|intranasal remimazolam about 30min before anesthesia induction
62076740|NCT04720963|ACTIVE_COMPARATOR|group D (Dexmedetomine group)|intranasal dexmedetomidine about 30min before anesthesia induction
62076741|NCT00878358|ACTIVE_COMPARATOR|Physiotherapy|
62646100|NCT02785939|EXPERIMENTAL|Arm III - Palbociclib re-reg|"Participants in Arm II eligible for re-registration receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
62646101|NCT05281406|EXPERIMENTAL|Osimertinib in combination with platinum-based chemotherapy|all patients received a platinum-based chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed) for a maximum of 4 cycles (q3w) in combination with 80 mg Osimertinib daily
62646102|NCT06551038|EXPERIMENTAL|Primary suicide prevention intervention|The framework of the primary suicide prevention intervention is psychoeducation. The intervention lasts for 90 minutes and is conducted in groups of 5 to 15 (on average 10) participants. It provides general information on suicidal behaviors, information about facts and myths about suicide, identification of risk factors and warning signs of suicidal behaviors, and information on ways to seek for help and get support for themselves and others in the canton. The intervention includes a lecture, group discussions based on case examples, and a quiz on facts and myths about suicide. It is conducted by a trained staff member with the support of a psychologist trained in suicide prevention for children and adolescents. It follows a standardized format.
62076742|NCT00878358|EXPERIMENTAL|Hydrotherapy|
62076743|NCT05179941|EXPERIMENTAL|patients requiring a shoulder arthroplasty|Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an FDA approved imaging system.
62076744|NCT02246829|OTHER|Aflibercept 2mg Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
62076745|NCT04081519|ACTIVE_COMPARATOR|DLPFC-DLPFC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over DLPFC
62076746|NCT04081519|EXPERIMENTAL|DLPFC-LPC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over LPC
62076747|NCT04081519|SHAM_COMPARATOR|DLPFC-SHAM|15 sessions of active rTMS over DLPFC + 15 sessions of sham rTMS over DLPFC or LPC
62076748|NCT04691882|EXPERIMENTAL|Diaphragmatic contraction|
62076749|NCT04691882|ACTIVE_COMPARATOR|Diaphragmatic relaxation|
62076750|NCT06344611||Decompensated Cirrhosis|
62076751|NCT02691104|EXPERIMENTAL|Intervention|"Use of the app and Fitbit alongside 5-7 week pulmonary rehabilitation programme (plus goal-setting help from physiotherapist), and then app and Fitbit plus intermittent contact with physiotherapist for 8 weeks after pulmonary rehabilitation~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
62456893|NCT02745899|ACTIVE_COMPARATOR|Soy milk substitute Healthy|Healthy children aged 6-18 will drink 240 ml of soy milk substitute.
62076752|NCT02691104|OTHER|Control|"Attend 5-7 week pulmonary rehabilitation programme (usual care) and wear blinded Fitbit during pulmonary rehabilitation and for 8 weeks afterwards~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
62076753|NCT03382600|EXPERIMENTAL|Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)|Participants receive pembrolizumab 200 mg every 3 weeks (Q3W) plus oxaliplatin 130 mg/m\^2 Q3W by intravenous (IV) infusion plus TS-1 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course, and will continue for up to \~3 years.
62076754|NCT03382600|EXPERIMENTAL|Pembrolizumab + Cisplatin +TS-1 (Cohort 2)|Participants receive pembrolizumab 200 mg Q3W plus cisplatin 60 mg/m\^2 Q3W by IV infusion plus TS-1 BID by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course, and will continue for up to \~3 years.
62076755|NCT06278116|ACTIVE_COMPARATOR|Water|
62076756|NCT06278116|ACTIVE_COMPARATOR|Dish soap|
62076757|NCT06278116|ACTIVE_COMPARATOR|Polident Antibacterial Denture Cleaner®|
62076758|NCT06278116|ACTIVE_COMPARATOR|Invisalign Cleaning Crystals®|
62076759|NCT06278116|ACTIVE_COMPARATOR|Geldis®|
62076760|NCT05854329|EXPERIMENTAL|Immersive Virtual Reality Exposure|Immersive Virtual Reality Dental Game for 15 minutes. Participants will be actively involved with the game, in placing restorations, scaling virtually playing the role of the dentist.
62456894|NCT02745899|ACTIVE_COMPARATOR|Soy milk substitute Asthma|Asthmatic children aged 6-18 will drink 240 ml of soy milk substitute.
62076761|NCT05854329|ACTIVE_COMPARATOR|Non Immersive Virtual Reality Exposure|Participants will be made to watch dental related cartoon passively while sitting using the Virtual Reality device for 15 minutes.
62076762|NCT05854329|NO_INTERVENTION|Control Group|Participants will be waiting for 15 minutes as usual prior to their treatment.
62076763|NCT01865864||1|Compliant with CPAP
62456895|NCT02745899|EXPERIMENTAL|Cow milk Healthy|Healthy children aged 6-18 will drink 240 ml of cow milk.
62076764|NCT01865864||2|noncompliant with CPAP
62076765|NCT00990301|EXPERIMENTAL|Moexipril HCl/ Hydrochlorothiazide 15mg/25mg Tablets|
62076766|NCT00990301|ACTIVE_COMPARATOR|Uniretic® 15mg/25mg Tablets|
62076767|NCT04786470|ACTIVE_COMPARATOR|Local Anaesthetic Infusion|
62076768|NCT04786470|SHAM_COMPARATOR|Saline Infusion|
62076769|NCT00975455||Subjects with hematuria|
62076770|NCT00492934|ACTIVE_COMPARATOR|1|Daily injections with a small dose of gonadotrophins from day 2 of the cycle
62076771|NCT00492934|NO_INTERVENTION|2|No daily injections with hormones
62456896|NCT02745899|EXPERIMENTAL|Cow milk Asthma|Asthmatic children aged 6-18 will drink 240 ml of cow milk.
62076772|NCT03552705|EXPERIMENTAL|Tranexamic Acid|5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
62456897|NCT03059862|EXPERIMENTAL|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
62456898|NCT03059862|PLACEBO_COMPARATOR|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
62646103|NCT06551038|ACTIVE_COMPARATOR|Art-based control intervention|The control intervention will be an art-based activity, a workshop on slam poetry. At the end of the study, participants will get a flyer containing information on suicide prevention with the participants of the control group. Therefore, they will have a low-threshold intervention.
62076773|NCT03552705|PLACEBO_COMPARATOR|Placebo|5-day course of placebo and intravenous saline during ACL reconstruction surgery
62076774|NCT03747289|EXPERIMENTAL|weight bearing group|performing exercises in a weight bearing posture
62076775|NCT03747289|ACTIVE_COMPARATOR|non-weight bearing group|performing exercises in a non- weight bearing posture
62076776|NCT00268931|NO_INTERVENTION|True Control|This group is being enrolled as a true control group. This group will not participate in the movement training or social training however, they will be evaluated in the same way.
62076777|NCT00268931|EXPERIMENTAL|Social Training|This group underwent specific social interactions two times each day with their parents.
62076778|NCT00268931|EXPERIMENTAL|Movement Training|This group of preterm infants underwent movement training two times per day with their parents.
62076779|NCT02999893|EXPERIMENTAL|APR-246|"The trial regimen consists of the investigational agent APR-246, along with standard chemotherapy, Cisplatin and 5-FU. A maximum of 8 cycles of treatment will be given.~APR-246 and 5-FU must both commence on Day 1 and given on days 1 to 4 via intravenous infusion over 6 hours, whilst 5-FU must be given as a continuous infusion over 96 hours.~On Days 2-4, APR-246 must be given first via intravenous infusion over 6 hours, then commence cisplatin via intravenous infusion over one hour.~This is a dose-escalation study to determine the maximum tolerated dose (MTD) of the combination therapy. The 3 dose levels are described as follows:~Dose Level 1:~APR-246 Dose: 75mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level 2:~APR-246 Dose: 100mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level -1:~APR-246 Dose: 50mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI"
62456899|NCT02494765|ACTIVE_COMPARATOR|I-gelTM|I-gel is a supraglottic device made of gel like material. It is used for administration of anesthesia in selected patients.
62076780|NCT04384458|ACTIVE_COMPARATOR|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with with 20 milligrams twice on day of active zinc for 45 consecutive days
62456900|NCT02494765|ACTIVE_COMPARATOR|Ambu® AuraOnceTM|Ambu AuraOnce (AO) is a supraglottic device having different material and its shaft has greater curvature than I-gel. It is also used for administration of anesthesia in selected patients.
62646104|NCT01420159|EXPERIMENTAL|Methoxyflurane|
62646105|NCT01420159|PLACEBO_COMPARATOR|Normal Saline|
62646106|NCT05374096|EXPERIMENTAL|Music Via Headphones|Headphones will be placed with patient-selected music playing for the duration of the surgical procedure.
62646107|NCT05374096|PLACEBO_COMPARATOR|Silence Via Headphones (Control)|Headphones will be placed with silence for the duration of the surgical procedure.
62646108|NCT02047916||Normal Neonates > 33 weeks gestation|"* Neonates \>33 weeks gestational age~* Postnatal age \<72 hours;~* Parental informed consent;~* Inpatient at the Royal Sussex County Hospital (RCSH): either receiving special care on the Trevor Mann Baby Unit (TMBU) or normal care on the postnatal ward"
62646109|NCT01132508||Treatment|
62076781|NCT04384458|ACTIVE_COMPARATOR|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
62076782|NCT04217993|EXPERIMENTAL|Jaktinib Hydrochloride Tablets 100mg twice a day.|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets）dose group for twice a day.
62456901|NCT02923947|EXPERIMENTAL|Normal renal function|For inclusion in the study as a patient with normal renal function, patients must have creatinine clearance ≥90 mL/min.
62646110|NCT00580476||1|150 patients will be women with breast cancer (75 early stage and 75 late stage)
62646111|NCT00580476||2|150 will be men with prostate cancer (75 early stage and 75 late stage)
62646112|NCT02391337|ACTIVE_COMPARATOR|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
62076783|NCT04217993|EXPERIMENTAL|Jaktinib Hydrochloride Tablets 150mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 150mg （3 tablets）dose group for once a day.
62076784|NCT04217993|EXPERIMENTAL|Jaktinib Hydrochloride Tablets 100mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets） dose group for once a day
62456902|NCT02923947|EXPERIMENTAL|Severe renal impairment|For inclusion in the study as a patient with severe renal impairment, patients must have stable severe renal impairment (creatinine clearance \<30 mL/min), as defined by the Cockcroft Gault equation, for at least 2 months prior to Day 1.
62646113|NCT02391337|ACTIVE_COMPARATOR|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
62646114|NCT00060411|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive oral elotinib alone once daily for 1 week before the beginning of course 1. Patients then receive oral erlotinib once daily on days 1-28; oxaliplatin IV over 2 hours on day 1; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Patients also receive bevacizumab IV over 30-90 minutes on day 15 of course 1 and on days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62076785|NCT04217993|EXPERIMENTAL|Jaktinib Hydrochloride Tablets 200mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 200mg （4 tablets）dose group for once a day.
62076786|NCT01912222|EXPERIMENTAL|IXAZOMIB Arm 1|"Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 4 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
62076787|NCT01912222|EXPERIMENTAL|IXAZOMIB Arm 2|"Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 2.3 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
62076788|NCT01912222|EXPERIMENTAL|IXAZOMIB Arm 3|"Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 1.5 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
62076789|NCT05203575|NO_INTERVENTION|Control|Control condition
62076790|NCT05203575|EXPERIMENTAL|Weekly nudge in Cycle 2|Weekly nudge intervention in Cycle 2
62076791|NCT05203575|EXPERIMENTAL|Fast-forwarding|Fast-forwarding interventions in both Cycles
62076792|NCT05203575|EXPERIMENTAL|Fast-forwarding with weekly nudge in Cycle 2|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 2
62456903|NCT03564548|EXPERIMENTAL|PPP001|Inhaled cannabinoids (PPP001)
62456904|NCT03564548|ACTIVE_COMPARATOR|Morphine sulfate or Hydromorphone or Oxycodone|Oral morphine sulfate or hydromorphone or oxycodone at the previous stabilized dosage
62456905|NCT02696681|EXPERIMENTAL|Cognitive Behavioral Therapy|Integrating CBT for any substance use or mental health problems with CBT for adherence/self-care
62646115|NCT03292302|PLACEBO_COMPARATOR|Placebo Comparator Arm|Placebo
62646116|NCT03292302|ACTIVE_COMPARATOR|Active treatment|ELX-02
62646117|NCT03768193|EXPERIMENTAL|Deep serratus anterior plane block|Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
62076793|NCT05203575|EXPERIMENTAL|Weekly nudge in Cycle 1|Weekly nudge intervention in Cycle 1
62076794|NCT05203575|EXPERIMENTAL|Weekly nudge|Weekly nudge interventions in both Cycles
62076795|NCT05203575|EXPERIMENTAL|Fast-forwarding with weekly nudge in Cycle 1|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 1
62076796|NCT05203575|EXPERIMENTAL|Full intervention|All interventions applied in all Cycles
62076797|NCT05203575|EXPERIMENTAL|Fast-forwarding in Cycle 1|Fast-forwarding intervention in Cycle 1
62076798|NCT05203575|EXPERIMENTAL|Full in Cycle 1|Fast-forwarding and weekly nudge interventions in Cycle 1
62076799|NCT01079143|EXPERIMENTAL|Certican EMT+|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
62076800|NCT01079143|EXPERIMENTAL|Certican EMT-|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
62076801|NCT01079143|ACTIVE_COMPARATOR|Neoral EMT+|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
62076802|NCT01079143|ACTIVE_COMPARATOR|Neoral EMT-|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
62076803|NCT03143335|ACTIVE_COMPARATOR|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
62076804|NCT03143335|ACTIVE_COMPARATOR|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
62076805|NCT03389685|EXPERIMENTAL|Platelet Rich Plasma|Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.
62076806|NCT03389685|PLACEBO_COMPARATOR|Saline Placebo|Unmarked syringe with 5 ml of saline
62076807|NCT00462644|ACTIVE_COMPARATOR|Etomidate|Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications
62076808|NCT00462644|ACTIVE_COMPARATOR|Fentanyl-Midazolam|Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.
62076809|NCT06168591||ELDERLY|MIDDLE-AGED and OLD individuals of both sexes will be recruited. The stratification into ACTIVE and SEDENTARY will be done according to current public health guidelines
62076810|NCT01097460|EXPERIMENTAL|MM-111 + Herceptin|MM-111 will be combined with Herceptin
62076811|NCT02124876||Transtibial amputees|
62456906|NCT01074554|EXPERIMENTAL|Antibiotic Regimen|"The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.~All four drugs are given concomitantly."
62076812|NCT05634122|EXPERIMENTAL|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
62076813|NCT05634122|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Standard care. The standard treatment would generally be pharmacological to address chronic pain, adjusted to the symptomatic profile of each patient.
62076814|NCT03317379|EXPERIMENTAL|Peer mentorship|Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
62076815|NCT03317379|ACTIVE_COMPARATOR|Social support mentorship|Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
62076816|NCT03317379|NO_INTERVENTION|Wait list|Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later
62076817|NCT04994041|EXPERIMENTAL|Pelvic floor muscle plus adductor strengthening|pelvic floor muscle plus adductor strengthening
62076818|NCT04994041|ACTIVE_COMPARATOR|Pelvic floor muscle exercises|pelvic floor muscle exercises
62076819|NCT06080230|ACTIVE_COMPARATOR|Psychoeducation Program Group|Participants in the 8-week Program
62076820|NCT06080230|NO_INTERVENTION|Control Group|Those who do not participate in the 8-week Program
62076821|NCT05239871||Women with surgical diagnosis of parametrial endometriosis|This cohort will include patients with surgical diagnosis of parametrial endometriosis
62076822|NCT05239871||Women without surgical diagnosis of parametrial endometriosis|This cohort will include patients without surgical diagnosis of parametrial endometriosis
62076823|NCT01253122|EXPERIMENTAL|TRx0037|
62456907|NCT01074554|PLACEBO_COMPARATOR|Placebo Regimen|The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
62646118|NCT03768193|ACTIVE_COMPARATOR|Surgically-placed paravertebral block|Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
62646119|NCT00744939||Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Participants received Magnevist in accordance with its labeling
62646120|NCT04145063|NO_INTERVENTION|uncomplicated ureteroscopic lithotripsy with DJ-US|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent will be placed (usually the standard of care)
62076824|NCT01253122|ACTIVE_COMPARATOR|TRx0014|
62076825|NCT02276378|EXPERIMENTAL|Telmisartan low / HCTZ fixed-dose combination, fed|
62076826|NCT02276378|EXPERIMENTAL|Telmisartan high / HCTZ fixed-dose combination, fed|
62076827|NCT02276378|ACTIVE_COMPARATOR|Telmisartan low /HCTZ fixed-dose combination, fasted|
62076828|NCT02276378|ACTIVE_COMPARATOR|Telmisartan high /HCTZ fixed-dose combination, fasted|
62076829|NCT02492646|EXPERIMENTAL|Saline group|In the saline group, disposable endotracheal tube was immersed in the 1 liter of sterile 0.9% sodium chloride irrigation solution before anesthetic induction.
62076830|NCT02492646|EXPERIMENTAL|Dry group|In the dry group, endotracheal tube was peeled off from sterile packing just before orotracheal intubation.
62076831|NCT01158430|EXPERIMENTAL|ACT group therapy|"Third generation cognitive behavioral therapy~Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions \& 1 booster session 1 month after 9th session, a total of 35.5 hours"
62076832|NCT01158430|NO_INTERVENTION|Control|Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
62076833|NCT06381440|EXPERIMENTAL|Low-intensity RAGT at progressively increasing intensity|Participants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, subjects allocated to this group will receive gait rehabilitation on the Lokomat device (Hocoma). The device in use will be set at 60% robotic assistance, 50% of load suspension, and a speed initially set at 1.0 km/h, with progressive increments of 0.1 km/h at each training session. The working time consists of bouts of 3 minutes of work alternated by 1 minute of recovery, to be repeated 8 times.
62646121|NCT04145063|ACTIVE_COMPARATOR|uncomplicated ureteroscopic lithotripsy without US|Following uncomplicated uretroscopic lithotripsy no uretric stent will be placed
62646122|NCT04145063|NO_INTERVENTION|uncomplicated ureteroscopic lithotripsy with DJ-US-string|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent with an extraxtion string will be placed
62456908|NCT03377400|EXPERIMENTAL|study arm|Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
62456909|NCT02208726|PLACEBO_COMPARATOR|Sucrose pillules|Unmedicated sucrose pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
62456910|NCT02208726|EXPERIMENTAL|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH. Pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
62456911|NCT04284488|EXPERIMENTAL|APG-1387 in combination with Toripalimab|
62646123|NCT01990326|EXPERIMENTAL|XAF5 Gel|The patient will apply XAF5 Gel to the skin of the submental area once a night.
62646124|NCT01990326|PLACEBO_COMPARATOR|Placebo Gel|The patient will apply a Placebo Gel to the skin of the submental area once a night.
62646125|NCT05067478||Cohort A Vibegron|Participants with previous anticholinergic therapy experience will receive vibegron as per the United States (U.S.) label.
62076834|NCT06381440|ACTIVE_COMPARATOR|Conventional RAGT|Participants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, subjects allocated to this group will receive gait rehabilitation on the Lokomat device (Hocoma). . In this case the parameters for setting the machine will be determined by the physiotherapist in charge for treatment administration in relation to the specific characteristics of the patient.
62076835|NCT06381440|ACTIVE_COMPARATOR|Over ground training (OGT)|Participants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, the subject will perform a 40-minute walk on a flat surface, preceded by a warm-up phase and followed by a 10 minute warm-down phase each. Subjects will walk back and forth over a distance of approximately 30 metres using their walking aid.
62646126|NCT05067478||Cohort B Vibegron|Participants with previous mirabegron monotherapy or mirabegron plus solifenacin or combination therapy experience will receive vibegron as per the U.S. label.
62076836|NCT05033743|EXPERIMENTAL|Treatment Group|Secnidazole treatment
62646127|NCT01965327|EXPERIMENTAL|Interferon Gamma-1b (ACTIMMUNE)|All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.
62076837|NCT06095232||Pregnant women|Primiparous women will participate in the study during the 1st - 3rd trimester of pregnancy and during the postpartum period.
62076838|NCT06095232||Control group|Nulliparous women with a regular natural menstrual cycle will undergo the same study procedure as pregnant women.
62076839|NCT02290717|EXPERIMENTAL|Laser+fluticason+UVB|The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
62076840|NCT02290717|EXPERIMENTAL|Laser+UVB|In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).
62076841|NCT02290717|ACTIVE_COMPARATOR|UVB|As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.
62076842|NCT03753217|EXPERIMENTAL|qCON Monitor|Simultaneous measurement of BIS and qCON
62076843|NCT02293174||Normal Healthy Eyes|Willing and able subjects with normal and healthy eyes
62076844|NCT02668237|EXPERIMENTAL|Experimental group|The intervention for this group will be the use of a OptiPAC. A molecular technique and urinary tests will be performed to test a panel of infectious agents : the results will allow the children to benefit from an adapted treatment.
62646128|NCT02485665|NO_INTERVENTION|Kegel exercise education|Prostate cancer patients of control group will received Kegel exercise education for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
62076845|NCT02668237|ACTIVE_COMPARATOR|Control Group|The children will benefit from the usual care : an antibiotic prevention treatment.
62646129|NCT02485665|EXPERIMENTAL|Extracorporeal biofeedback device|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
62076846|NCT02372058|OTHER|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
62076847|NCT03423160||Autism|Right-handed children, ages 8.0-12.9, diagnosed with high-functioning ASD (and no co-morbid conditions, excluding anxiety disorders)
62076848|NCT03423160||Control|Right-handed children, ages 8.0-12.9, with no neurological or psychiatric diagnoses, currently or by history
62076849|NCT02666963|EXPERIMENTAL|RTA 901 10 mg or 40 mg or Placebo|RTA 901 capsules (10 mg or 40 mg) or placebo taken orally in a single dose. Group 1: RTA 901 10 mg or matching placebo Group 2: RTA 901 20 mg or matching placebo Group 3: RTA 901 ≤ 40 mg or matching placebo Group 4: RTA 901 ≤ 80 mg or matching placebo Group 5: RTA 901 ≤ 160 mg or matching placebo Group 6: RTA 901 ≤ 320 mg or matching placebo Group 7: RTA 901 ≤ 640 mg or matching placebo Dose selection will be based on the safety, tolerability and available pharmacokinetics observed in prior study groups.
62076850|NCT02666963|EXPERIMENTAL|RTA 901 Dose TBD or Placebo|RTA 901 capsules, Dose TBD mg or placebo taken orally once daily for 14 days. Group 8: RTA 901 X mg or matching placebo Group 9: RTA 901 ≤Y mg or matching placebo Group 10: RTA 901 ≤Z mg or matching placebo The actual doses for Arm 2 will be selected based on the safety and available pharmacokinetic data obtained from Arm 1.
62076851|NCT00992160|EXPERIMENTAL|Active|Vestipitant 15mg once daily
62076852|NCT00992160|PLACEBO_COMPARATOR|Placebo|Placebo
62076853|NCT03375684|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
62076854|NCT03375684|EXPERIMENTAL|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
62076855|NCT04376697|EXPERIMENTAL|Active rTMS|Treatment will be delivered daily (weekdays) rTMS treatments, for up to 10 daily sessions and up to 75 sessions in total.
62076856|NCT03335891|EXPERIMENTAL|Training Group|Asthma Education Program Breathing Exercises Core Stabilization Exercises
62076857|NCT03335891|ACTIVE_COMPARATOR|Control Group|Asthma Education Program Breathing Exercises
62076858|NCT00436176|EXPERIMENTAL|1|Intervention clinicians receive monthly performance reports, cultural competency training, and health navigation training
62076859|NCT00436176|NO_INTERVENTION|2|Control clinicians function within the context of the generic chronic care model.
62076860|NCT04532242|EXPERIMENTAL|fMRI Participants|Participants will be scanned in an fMRI session lasting approximately 45-50 minutes and will be shown negative images for which they will have to take on a cognitive reappraisal tactic. All participants will be taken through the scanner with the same reappraisal protocol for each participant.
62076861|NCT03043222|EXPERIMENTAL|PAE-Prostate Arterial Embolization|PAE-Prostate Arterial Embolization
62076862|NCT03043222|ACTIVE_COMPARATOR|PUL- Prostatic urethral lift|PUL- Prostatic urethral lift
62076863|NCT06048796|EXPERIMENTAL|Early cessation of sedation and TTM|Early cessation of sedation and targeted temperature management (TTM), with subsequent weaning from mechanical ventilation if appropriate (intervention group).
62076864|NCT06048796|NO_INTERVENTION|Standard Care|Standard care, including sedation and targeted temperature management (TTM) for at least 24-48 hours (control group).
62646130|NCT06120725|ACTIVE_COMPARATOR|ticagrelor arm|The ticagrelor arm will receive (180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day)
62646131|NCT06120725|ACTIVE_COMPARATOR|clopidogrel arm|The clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset followed by 75 mg once daily from the 2nd day to the 90th day)
62646132|NCT04584632|EXPERIMENTAL|EVSS|Efemoral Vascular Scaffold System (EVSS)
62646133|NCT00069264|EXPERIMENTAL|E7389|
62076865|NCT01805765|ACTIVE_COMPARATOR|Qing'E pills|9 g pills,twice a day for 12 weeks
62076866|NCT01805765|PLACEBO_COMPARATOR|Placebo|9 g pills,twice a day for 12 weeks
62076867|NCT05447793||Fitostimoline Plus|Formulation in gauzes and cream based on a particular Triticum Vulgare Extract (Rigenase®) and polyhexanide, an antiseptic which does not give any bacterial resistance.
62646134|NCT05453136|EXPERIMENTAL|5 mg|Period in which participants received repeated doses of 5 mg TS-142 prior to bedtime
62076868|NCT05447793||Connettivina Bio Plus|Formulation in gauzes and cream based on hyaluronic acid and silver sulphadiazine.
62076869|NCT05774028|EXPERIMENTAL|P-GEMD group|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
62076870|NCT03299062|ACTIVE_COMPARATOR|Parkinson's Disease with Voice Dysfunction Patients|• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor
62076871|NCT03299062|ACTIVE_COMPARATOR|Other Neurodegenerative Disorders with Voice Dysfunction|• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.
62076872|NCT03299062|PLACEBO_COMPARATOR|Voice Dysfunction|Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.
62076873|NCT02814110|OTHER|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy
62076874|NCT01101139|EXPERIMENTAL|Experimental|Single injection of Sugammadex 0.25 mg/kg
62456912|NCT04607239|EXPERIMENTAL|Telemonitoring|"In addition to the usual care, this group benefits from a weekly telephone call by the Clinical Research Associate (CRA) for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~This group will also benefit from a monthly call by the attending physician for treatment titration and side effects check."
62076875|NCT01101139|PLACEBO_COMPARATOR|Placebo comparator|Single injection of Saline 0.9%
62646135|NCT05453136|EXPERIMENTAL|10 mg|Period in which participants received repeated doses of 10 mg TS-142 prior to bedtime
62456913|NCT04607239|OTHER|Conventional|"This group will benefit form the usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.~The usual care includes attending the follow up visits after inclusion at Day 90 (D-90) \& Day 180 (D-180) for face to face consultation with the attending physician."
62456914|NCT02799797|ACTIVE_COMPARATOR|short axis (SAX) placement of adductor canal catheters|Procedure: Ultrasound guided short axis (SAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a PAJUNK Contiplex S catheter along the short axis of the middle part of adductor canal
62076876|NCT06315764|EXPERIMENTAL|Aerobic training|Each patient in this study did 20 minutes of peddler aerobic training, with the first 5 minutes serving as a warm-up with intensity set at 60 - 65 percent of maximal heart rate, followed by another 10 minutes of peddler training with intensity gradually increased up to 70 - 75 percent, and the last 5 minutes serving as a cooling down with intensity set at 60 - 65 percent of maximal heart rate. After the warm-up and at the end of each training phase, the participants' heart rates were monitored. Finally, if the individual experienced pain, fainting, or shortness of breath, the training was promptly terminated
62076877|NCT06315764|EXPERIMENTAL|Reflexology|"This group consisted of twenty female patients suffering from hypertension who received the same drugs as group (A) as well as reflexology three times per week for eight weeks .~Following four weeks of treatment (post-1) and additional four weeks of treatment (post-2) the post evaluation was used (post-2).Before and after the foot reflexology, blood pressure was checked twice. Around 20 minutes is spent on foot reflexology ."
62076878|NCT01497405|ACTIVE_COMPARATOR|Test, Treat, Retain(TTR) only|Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
62076879|NCT01497405|EXPERIMENTAL|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
62076880|NCT03836898|EXPERIMENTAL|Implantation phakic intraocular lens|Presbyopic posterior chamber phakic intraocular lens IPCL implanted to the participants eye
62076881|NCT06313996|ACTIVE_COMPARATOR|Arm A|"Active Comparators:~R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)~B-R (bendamustine and rituximab)~R2 (rituximab and lenalidomide)"
62076882|NCT06313996|EXPERIMENTAL|Arm B|Lisocabtagene Maraleucel
62456915|NCT02799797|EXPERIMENTAL|long axis (LAX) placement of adductor canal catheters|Procedure: Ultrasound guided long axis (LAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a catheter along the long axis of the middle part of adductor canal
62456916|NCT04602507|EXPERIMENTAL|Intervention|50 patients with the routine care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
62076883|NCT02590068|EXPERIMENTAL|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
62076884|NCT02590068|ACTIVE_COMPARATOR|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
62076885|NCT03895437|EXPERIMENTAL|TOL-3021|TOL-3021 2 mg/mL
62076886|NCT03895437|PLACEBO_COMPARATOR|TOL-3021 Placebo|TOL-3021 Placebo
62076887|NCT01236703||ICU patients|ICU patients (post-operative and none operative patients) will be enrolled in the study. They are followed up until the end of ICU stay or, for a maximum of 60 days.
62076888|NCT03972774|OTHER|Cardiac PET stress testing and test-dependent management|Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not).
62076889|NCT03972774|OTHER|Management without stress-imaging|Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up.
62076890|NCT04039503|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62456917|NCT04602507|PLACEBO_COMPARATOR|Control|50 patients with routine care offered in the hospital plus placebo orally (2 drops per kg) in a single dose.
62646136|NCT05453136|PLACEBO_COMPARATOR|Placebo|Period in which participants received repeated doses of placebo prior to bedtime
62456918|NCT05757011|PLACEBO_COMPARATOR|Placebo|Before the removal of uterus and the closure of vaginal cuff, insertion of 6inch 22G needle 2 to 3 cm below the umbilicus, 30 ml normal saline (sodium chloride solution 0.9%, FIPCO, Egypt)will be administered , then the uterus will be removed, and the operation will be terminated
62646137|NCT00962286|EXPERIMENTAL|Furosemide, obesity, glomerular hyperfiltration|
62646138|NCT04606758|ACTIVE_COMPARATOR|PCNL under fluoroscopic control|
62646139|NCT04606758|ACTIVE_COMPARATOR|PCNL under ultrasound control|
62456919|NCT05757011|EXPERIMENTAL|pre-sacral nerve block|"Uterosacral nerve block will be performed before the removal of uterus and the closure of vaginal cuff, and before the removal of trocars from abdominal cavity, insertion of 6-inch 22G needle 2 to 3 cm below the umbilicus, injection of the SHP area which situated anterior to L5-S1 vertebral bodies, Caudal to the bifurcation of the abdominal aorta with 30 ml 0.25% bupivacaine (Marcaine®0.25% , Astra Zeneca, Egypt) will be administered. Following the injection of local anesthetic, patient will be placed from Trendelenburg position to horizontal position. The we will remove the uterus and trocars , and the operation will be terminated.~Data will be recorded in a case report form (CRF) and statistical analysis will be done."
62456920|NCT02276196|EXPERIMENTAL|Lixisenatide|Lixisenatide will be administered subcutaneously, once daily for 8 weeks
62076891|NCT04039503|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62456921|NCT02276196|ACTIVE_COMPARATOR|Insulin glulisine|Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
62456922|NCT05627609|EXPERIMENTAL|Participants with high Vitamin D genotype risk score|
62456923|NCT05627609|EXPERIMENTAL|PArticipants with low Vitamin D genotype risk score|
62076892|NCT04039503|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62076893|NCT04039503|PLACEBO_COMPARATOR|Placebo|Placebo administered SC once a week.
62076894|NCT04558203||Confirmed COVID19|Confirmed COVID19
62456924|NCT02003053|EXPERIMENTAL|IMT|In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
62456925|NCT02003053|SHAM_COMPARATOR|Sham|In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
62456926|NCT05146596|EXPERIMENTAL|LLLT group|use low level light therapy,The Dr.Tai's energy cap
62456927|NCT05146596|NO_INTERVENTION|control group|routine care.
62456928|NCT02125266|EXPERIMENTAL|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
62456929|NCT02125266|EXPERIMENTAL|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
62646140|NCT02453464|EXPERIMENTAL|Sevacizumab+FOLFIRI|Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
62646141|NCT02903446|ACTIVE_COMPARATOR|Intervention|Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
62646142|NCT02903446|NO_INTERVENTION|Control|Standard urate lowering therapy
62076895|NCT04558203||Not COVID19|Not COVID19
62076896|NCT02965118|EXPERIMENTAL|PAC-14028 cream 1.0%|PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.
62076897|NCT02965118|PLACEBO_COMPARATOR|PAC-14028 cream Vehicle|PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.
62076898|NCT03210688|ACTIVE_COMPARATOR|High dose prednisolone|Prednisolone 1 mg/kg/day
62076899|NCT03210688|EXPERIMENTAL|Alfacalcidol and low dose prednisolone|Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
62076900|NCT03871270||Participants|Those with severe chronic illnesses, which included but were not limited to various forms of advanced cancer, blood dyscrasias, graft vs. host disease, and rare genetic conditions.
62076901|NCT04763083|EXPERIMENTAL|Group A: Haematological malignancies|
62076902|NCT04763083|EXPERIMENTAL|Group B: Solid tumours|
62076903|NCT05911490|ACTIVE_COMPARATOR|Prolonged sitting|Participants sat on a chair during the trial in the laboratory.
62076904|NCT05911490|EXPERIMENTAL|Breaking prolonged sitting|Participants walked regularly during the trial in the laboratory.
62076905|NCT04924764|ACTIVE_COMPARATOR|Follow-up on daily basis|Patient receiving treatments on daily basis (5 days a week)
62076906|NCT04924764|ACTIVE_COMPARATOR|Follow-up on alternate days|Patients receiving treatment on alternate days (3 days a week)
62076907|NCT03646903|EXPERIMENTAL|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using mental health services (e.g., Seeking help for my problems means I am weak). Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced (e.g., That's right! You are correct!). Participants in this condition will complete three separate 15-minute CBM-HS sessions."
62076908|NCT03646903|PLACEBO_COMPARATOR|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a similar CBM task with neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
62076909|NCT03646903|ACTIVE_COMPARATOR|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration of self-directed psychoeducation will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
62076910|NCT05148624|EXPERIMENTAL|Immediate ambulation|Sub-infertile women will immediately ambulate and empty her bladder after embryo transfer.
62076911|NCT05148624|ACTIVE_COMPARATOR|short time bed rest|Sub-infertile women will stay in the bed (same bed where embryo transfer was performed) after embryo transfer for a period of 5 minutes without emptying her bladder.
62076912|NCT00975221|EXPERIMENTAL|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally BID and were eligible for a dose titration once every 3 weeks during the 12-week dose-titration phase based on corrected total serum calcium concentration and safety assessments. Participants continued to receive cinacalcet for another 16 weeks during the efficacy assessment phase and then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
62076913|NCT00975221|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally twice a day (BID) for 12 weeks during the dose titration phase and for another 16 weeks during the efficacy assessment phase. Participants then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
62456930|NCT00416481||Patient assessment|"Patients undergo assessments of cognition and performance status using the healthcare professional-rated Karnofsky performance scale. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed.~Patients also complete self-administered questionnaires that measure level of functioning and need for services. It also includes questionnaires that measure higher levels of physical functioning, performance related to survival and clinically significant illness and measures of comorbidity and the impact on daily activities. Lastly, questionnaires are administered to measure the impact of cancer on patients' social functioning and perceived availability of social support.~Patients then begin planned treatment."
62076914|NCT04475848|EXPERIMENTAL|Part 1: SAD/FE|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of RO6953958 while fasted. Participants in the fed (FE) cohort will return to receive the same single oral dose of RO6953958 repeated in the fed state.
62456931|NCT00623207|PLACEBO_COMPARATOR|1|Pateints who achieve target haert rate or conclusive test will not be given Atropine
62076915|NCT04475848|PLACEBO_COMPARATOR|Part 1: SAD placebo|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of a placebo while fasted/fed.
62076916|NCT04475848|EXPERIMENTAL|Part 2: MAD|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 once daily (QD) for 10 days.
62456932|NCT00623207|ACTIVE_COMPARATOR|2|Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine
62456933|NCT01117610|ACTIVE_COMPARATOR|epidural injection (group I)|patients in Group I will receive epidural injection of 0.1% ropivacaine 10 ml before skin incision.
62456934|NCT01117610|PLACEBO_COMPARATOR|epidural injection group (group C)|control group will receive no medication preoperatively and during operation
62646143|NCT03995563|ACTIVE_COMPARATOR|D group|0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
62646144|NCT03995563|PLACEBO_COMPARATOR|N group|0.19% Ropivacaine 8mL only every other day injection during 10 days
62076917|NCT04475848|PLACEBO_COMPARATOR|Part 2: MAD placebo|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of palcebo QD for 10 days.
62076918|NCT04475848|EXPERIMENTAL|Part 3: DDI|"RO6953958 will be administered at the maximum dose QD that was tested in the ongoing Part 2 (MAD).~Participants will also be administered midazolam."
62076919|NCT00391014|EXPERIMENTAL|1|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
62646145|NCT05402059||Cohort A|Study Cohort A will include patients with unresectable and/or metastatic melanoma, regardless of BRAF mutation in the tumor, who were started on any of the drug regimens in accordance with current clinical guidelines, except for patients assigned to the vemurafenib + cobimetinib + atezolizumab, which should be included in the A1 cohort. The initiation of therapy on the regimen that will be used at the time of signing the informed consent will be considered an index event.
62456935|NCT04217447|ACTIVE_COMPARATOR|Experimental group|Patients intaking full-dose OAC + ASA 100mg od
62456936|NCT04217447|PLACEBO_COMPARATOR|Control group|Patients intaking full-dose OAC + Placebo of ASA 100mg od
62456937|NCT04820803|EXPERIMENTAL|Cetylpyridinium Chloride (CPC) 0,07%|patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds
62456938|NCT04820803|PLACEBO_COMPARATOR|Placebo: Distilled water with the same flavor and coloring as the product to be evaluated|patients who rinse with distilled water mouthwash for 60 seconds
62456939|NCT03155984||Anti-CD20 antibody|Patients with hematological malignancies receiving anti-CD20 antibody therapy
62456940|NCT02931318|EXPERIMENTAL|Nevsehir|People Living in the City Center of Nevşehir
62456941|NCT05399264|EXPERIMENTAL|Auditory-working memory training group|"The auditory-working memory training (AT-WMT) program is home-delivered, non-clinician-administered, and computer-based. That is, training will be self-paced and administered by the participants themselves at home using a computer. A software program has been created to facilitate the administration. Participants will spend one hour per day and five days per week for 4 weeks on training.~During the training, the following two adaptive tasks will be administered simultaneously: repeating the sentences masked by noise (i.e., AT component) and recalling the first or the final two words of all sentences in a given sentence set (i.e., WMT component)."
62076920|NCT01630343|EXPERIMENTAL|Regular oral Panadol and Tramadol|Geriatric (age \>65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
62646146|NCT05402059||Cohort A1|Study Cohort A1 will include patients with unresectable and/or metastatic melanoma and an activating BRAF mutation in the tumor who were treated with vemurafenib + cobimetinib + atezolizumab, either newly diagnosed or progressing during previous lines of therapy. Initiation of vemurafenib + cobimetinib + atezolizumab would be considered an index event.
62076921|NCT01630343|EXPERIMENTAL|Panadol and tramadol oral in prn basis|Control group is that patient having geriatric hip fracture will have oral analgesics ( Panadol 500mg Q4H and tramadol 50mg Q4H ) in prn basis.
62076922|NCT03263143|NO_INTERVENTION|Standard of Care|
62076923|NCT03263143|OTHER|Early Palliative Care Consultation|
62456942|NCT05399264|ACTIVE_COMPARATOR|Adaptive Auditory training group|The sentences used in the AT program are the same as those in the AT-WMT program. However, only the AT component (i.e., adaptive sentence perception in noise) of the AT-WMT program is required in the AT program. Participants do not need to recall the first or the final two words of the sentences. The same software in the experimental group will be used. Participants will spend one hour per day and five days per week for 4 weeks on training.
62456943|NCT05399264|PLACEBO_COMPARATOR|Mindfulness training group|Participants in this group will participate in a mindfulness training program using newlife.330 (Psychiatric Rehabilitation Association, 2018) which is a Cantonese online platform for self-guided mindfulness training. The time and computer use of the active-control group will match to those of the above two groups.
62646147|NCT05402059||Cohort B|Study Cohort B will include patients with stage III equivalent skin melanoma (i.e., regional lymph node involvement), regardless of tumor BRAF mutation, who have undergone surgery (lymphadenectomy, SLNB, or metastasectomy) and/or initiated or planned treatment according to any of the drug therapy regimens or only dynamic observation, in accordance with current clinical guidelines. Surgery for stage III melanoma will be considered an index event.
62076924|NCT04238403|EXPERIMENTAL|Behavioral Parent Training|Parent training intervention based on social learning and operant conditioning theory, generally referred to as Behavioral Parent Training.
62076925|NCT02904109|EXPERIMENTAL|Verum/Placebo|This group will start with triflusal and after washout will receive placebo.
62076926|NCT02904109|EXPERIMENTAL|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
62076927|NCT02905019|ACTIVE_COMPARATOR|Standard Dose x3 (Group 1)|R21 with Matrix-M1. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0, 28 and 56.
62076928|NCT02905019|ACTIVE_COMPARATOR|High Dose (Group 2)|R21 with Matrix-M1. Two vaccinations with 50µg R21/50µg Matrix-M1 on days 0 and 28 and one vaccination with 10 µg R21/ 50 µg Matrix M1 on day 56.
62456944|NCT03682562||Oral Cancer|Patients diagnosed clinically and histopathologically as having oral cancer.
62456945|NCT03682562||Premalignant Oral Lesions|Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
62456946|NCT03682562||Normal Subjects|"Patients who give a history of:~* No smoking~* No alcohol~* No systemic disease; and who on conventional oral examination have:~* No visible oral lesions on conventional oral examination .~* Good oral hygiene."
62076929|NCT02905019|ACTIVE_COMPARATOR|Combination (Group 3)|R21 with Matrix-M1, ChAd63 ME-TRAP and MVA ME-TRAP. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 , 28 and 56. Plus one vaccination with ChAd63 ME-TRAP on day 7 and one vaccination with MVA ME-TRAP on day 63.
62076930|NCT02905019|NO_INTERVENTION|Control Group 4a|These volunteers will not be vaccinated and will serve as infectivity controls when groups 1-3 undergo challenge.
62076931|NCT02905019|NO_INTERVENTION|Control Group 4b|These volunteers will not be vaccinated and will serve as infectivity controls when group 5-7 and sterilely protected volunteers from groups 1-3 undergo challenge.
62076932|NCT02905019|NO_INTERVENTION|Control Group 4c|These volunteers will not be vaccinated and will serve as infectivity controls if any volunteers from groups 5 and 7 are rechallenged.
62646148|NCT05402059||Cohort C|Study cohort C will include patients with stage 0-II equivalent skin melanoma (i.e., no regional lymph node involvement), regardless of BRAF mutation in the tumor, who have undergone surgery (excision of the primary tumor +/- SLNB) and/ or initiated or planned treatment for any of the drug regimens or only dynamic observation, in accordance with current clinical guidelines. Surgical treatment (operation) for stage 0-II melanoma will be considered an index event.
62646149|NCT05402059||Cohort D|Study cohort D will include patients with stage 0-IV non-cutaneous melanoma, regardless of the BRAF mutation in the tumor, who underwent morphological verification of the diagnosis, surgery (any volume) and / or treatment initiated or planned for any of the drug therapy regimens or only dynamic observation, in accordance with current clinical guidelines. Initiation of therapy according to the regimen that will be used at the time of signing of informed consent or surgical treatment will be considered an index event.
62646150|NCT05902065|EXPERIMENTAL|AVR Treadmill training with C-Mill|"Participants (N=30) will undergo the AVR Treadmill training intervention with 5 AVR applications named Nature Island, stepping stones, walking area: obstacles avoidance, and track."
62646151|NCT05902065|ACTIVE_COMPARATOR|Conventional Treadmill training with C-Mill|"Participants (N=30) will undergo the Traditional Treadmill intervention."
62646152|NCT03567681|EXPERIMENTAL|Extended release oxcarbazepine|Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
62646153|NCT03567681|EXPERIMENTAL|Immediate release oxcarbazepine|Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
62646154|NCT01529606|ACTIVE_COMPARATOR|Standard care|Fifty patients will be recruited into standard treatment group and they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline.
62646155|NCT01529606|EXPERIMENTAL|Plasma treatment|Fifty patients will be recruited into plasma treatment group and they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth.
62076933|NCT02905019|ACTIVE_COMPARATOR|Fractional Dose (Group 5)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28 and one vaccination with 2µg R21/ 50 µg Matrix-M1 on day 56.
62076934|NCT02905019|NO_INTERVENTION|Long-term Efficacy (Group 6)|Volunteers in this group have received vaccinations in a different malaria vaccine trial. These volunteers will not receive any vaccinations in this trial, but will undergo controlled human malaria infection as part of this study.
62076935|NCT02905019|ACTIVE_COMPARATOR|Standard Dose x2 (Group 7)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
62076936|NCT04084782||Onychomycosis group|Subjects in this group suffer from onychomycosis of the toenail, who chose to self treat by purchasing the product from an online platform.
62076937|NCT06281262||Pregnant women|Singletone pregnancy, gestational age 9+0 - 12+0, history of preeclampsia (PE) or spontaneous preterm birth (PTL = preterm labour) or pPROM (preterm premature rupture of membranes).
62076938|NCT04454905|EXPERIMENTAL|Camrelizumab combination with Apatinib|Camrelizumab 200mg, every 3 weeks, intravenous infused. Apatinib 250mg, once a day, orally. Until progression or unacceptable toxicity events develop.
62646156|NCT00004233|EXPERIMENTAL|5-FU, Leucovorin and PN-401|PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
62646157|NCT03089476|OTHER|High Risk Atopic Infants|Infants, who are at high risk of atopy, which will be determined by a validated questionnaire, will be enrolled. Infants will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), bacterial swabs, and parental questionnaires at each visit (3 visits total). At the latter 2 visits, infants will also undergo skin prick testing to evaluate for food sensitization.
62646158|NCT03089476|OTHER|Atopic Adults|Parents of infants enrolled in the study will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), and complete questionnaires at the first visit.
62076939|NCT03990363|EXPERIMENTAL|High Dose|High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300
62076940|NCT03990363|EXPERIMENTAL|Intermediate Dose|Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300
62076941|NCT03990363|EXPERIMENTAL|Low Dose|Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at Visit 9.
62076942|NCT03990363|EXPERIMENTAL|Allopurinol alone (0/300 mg)|Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300
62076943|NCT03990363|PLACEBO_COMPARATOR|Placebo (0/0 mg)|Placebo (mg) in 3 steps_0/0
62076944|NCT03729895|EXPERIMENTAL|patients with OSAS in different degrees|OSAS patients will be treated with an adjustable oral appliance and evaluated with cone-beam computed tomography and polysomnography.
62076945|NCT03820531|EXPERIMENTAL|Suspected mucinous pancreas cyst|In all pancreas cysts \> 15mm and/or pancreas duct dilatation \> 5mm in patients who are fit for surgery EUS-guided pancreas cyst fluid aspiration is conducted. In cyst fluid CEA and lipase examination, cytology and Next Generation Sequencing is performed. After that, the pancreas cyst will be resected and histopathologically analysed.
62076946|NCT04822935|NO_INTERVENTION|Posterior Spinal Instrumentation|
62076947|NCT04822935|EXPERIMENTAL|Vertebral Body Tethering|
62076948|NCT04679103|EXPERIMENTAL|Eculisumab (JSC GENERIUM, Russia)|Eculizumab
62456947|NCT05834283|EXPERIMENTAL|aerobic exercises|"This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint."
62646159|NCT01724827|ACTIVE_COMPARATOR|ceramic|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
62646160|NCT01724827|ACTIVE_COMPARATOR|composite|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
62646161|NCT03435055|EXPERIMENTAL|Nitrous Oxide - inhaled|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.
62646162|NCT05027854|EXPERIMENTAL|Stimulation|TMS or tES, depending on experiment
62646163|NCT05027854|SHAM_COMPARATOR|Sham|Corresponding sham TMS or tES
62076949|NCT02019602|EXPERIMENTAL|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.~Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
62076950|NCT00719303|EXPERIMENTAL|Group I (lifestyle intervention)|Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
62076951|NCT00719303|ACTIVE_COMPARATOR|Group II (observation)|Participants receive a study notebook containing general study-related information. Participants are not asked to record diet or physical activity but are provided a single sample diary in their study notebook. Participants receive telephone contact on a sliding scale similar to the intervention group, but at less frequent intervals (22 versus 33 calls over the course of the intervention).
62076952|NCT03010579|EXPERIMENTAL|erythropoietin group|For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
62646164|NCT02745470|EXPERIMENTAL|Lixisenatide injection|intervention : Lyxumia® pen injection 10 microgram (Lixisenatide) subcutaneous injection 30 minutes before functional MRI
62646165|NCT02745470|PLACEBO_COMPARATOR|Normal saline|control : normal saline 0.3 cc subcutaneous injection before functional MRI
62646166|NCT05113082||Participants with SBS-IF|Participants with SBS-IF who as part of standard or routine clinical practice, that underwent intestinal transplantation over the last 10 years (both dead and alive at the time of study enrollment) will be observed in this retrospective observational study for 10 months.
62076953|NCT03010579|ACTIVE_COMPARATOR|iron supplementation|If necessary，oral ferrous succinate, vitamins B12 and folic acid will be administered.
62076954|NCT04958928||Persistent AF Group|
62646167|NCT05251597|EXPERIMENTAL|green exercise group-1 (aerobic)|Forty participants who meet the inclusion criteria will first be given warm-up exercises for 10 minutes, then walking at a moderate intensity (65% of heart rate) for 40 minutes and then stretching exercises for 5 minutes
62646168|NCT05251597|EXPERIMENTAL|green exercise group-2 (aerobic+resistance)|For 40 participants who met the inclusion criteria, first 10 minutes of warm-up exercises, then 20 minutes of moderate-intensity (65% of heart rate) walking, followed by 10 minutes of low-intensity (50% of the maximum repetitions) and 10 minutes of high-intensity (80% of the maximum repetitions) resistance exercises will be applied in the presence of a physiotherapist. resistance exercises; shoulder flexors and abductors, elbow flexors and extensors, hip flexors and extensors, knee flexors and extensors, hip abductor muscle group will be performed. At the end of each session, 5 minutes of stretching exercises will also be applied.
62646169|NCT05251597|NO_INTERVENTION|Control group|The exercise program will not be implemented. Evaluations will be made at the beginning and end of the study.
62646170|NCT04905043|EXPERIMENTAL|SmartPill® + Acalabrutinib|Participants will receive 1 SmartPill® capsule followed immediately by a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). There will be 72 hours of washout between acalabrutinib dosing of each period.
62646171|NCT02847325|EXPERIMENTAL|AC0058TA|Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA
62646172|NCT02847325|PLACEBO_COMPARATOR|Placebo capsules|Drug: Placebo capsules
62646173|NCT02190955||NEPTUNE contact registry patients|Patients and caregivers will be recruited from the Nephrotic Syndrome Study Network (NEPTUNE) Patient Contact Registry. Over 1000 patients and caregivers are members of the registry and have already provided permission to be contacted for future research studies. Analysis of the one-time online questionnaire will be done in collaboration with investigators from the NEPTUNE Consortium.
62076955|NCT01033773|OTHER|Diabetes education and medication management|All enrolled patients received the intervention. There was no comparative arm. The analysis was done as pre and post.
62646174|NCT06114212|EXPERIMENTAL|H4 dTMS|The participants will receive 18 H4 dTMS sessions over 4-6 weeks as an adjunct to evidence-based standard care for CUD (i.e., motivational interviewing and contingency management).
62646175|NCT03630848|EXPERIMENTAL|10 mg/ml protein concentration in Embryo Culture Media|
62646176|NCT03630848|NO_INTERVENTION|5 mg/ml protein concentration in Embryo Culture Media|
62646177|NCT01551667||Cases / bacteraemia|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
62646178|NCT01551667||Controls|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients does not have bacteraemia.
62646179|NCT06492083|NO_INTERVENTION|control group|All chemotherapies were strictly followed by drug-use routine. The paclitaxel and platinum administration rate were set as 180ml/h. Health guidance should provide before and after chemotherapies, including precautions for chemotherapy, dietary guidance, life guidance, etc. For patients with peripheral neuropathy that gradually worsen and affect muscle and joint functions, environmental management and self-management should be guided to prevent from falls, bumps, scalds, frostbite, sharps and other accidents.
62646180|NCT06492083|EXPERIMENTAL|observation group|In addition to the usual nursing measures of the control group, traditional Chinese medicine was used for acupoint treatment and home care：Patients are consulted by TCM specialist nurses and join the WeChat group to complete the hot package home care health education. Heat herbal packets and keep the temperature at 40-50 °C, fix the hot bag on the corresponding acupuncture points of each limb for 30 minutes. Chemotherapy should not be used on the same day and the next day, and the rest of the time should be treated with hot package every day.
62646181|NCT01107548|EXPERIMENTAL|Evidence-based treatment, lifestyle counseling|
62076956|NCT05989867||CP|patients with chronic pancreatitis but not combined with diabetes
62456948|NCT05834283|EXPERIMENTAL|core stability exercises|"This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat."
62646182|NCT00266708|EXPERIMENTAL|Risedronate|subjects received Risedronate for one year
62646183|NCT00266708|PLACEBO_COMPARATOR|subjects received placebo|subjects received placebo for 1 year
62646184|NCT03377465|EXPERIMENTAL|Experimental Group|Patients with stroke of undetermined cause age 18-65
62646185|NCT03377465|ACTIVE_COMPARATOR|Comparative group|Healthy patients age 18-65
62646186|NCT06130995|EXPERIMENTAL|Prostate Cancer Combo Therapy Trial|A single-arm Phase Ib study explores the effectiveness and safety of neoadjuvant and adjuvant hormonal therapy combining relugolix and enzalutamide in high-risk locally advanced prostate cancer patients eligible for ADT followed by radiation therapy or surgery.
62646187|NCT02402400|ACTIVE_COMPARATOR|Oral Ticagrelor|
62646188|NCT02402400|EXPERIMENTAL|Sub Lingual Ticagrelor|
62646189|NCT04796727||OHCA|300 OHCA admitted directly to the cathlab and alive at discharge during a 2 years period of enrolement.
62456949|NCT00220337|EXPERIMENTAL|Lacosamide (LCM)|Open label active treatment
62646190|NCT02507570|EXPERIMENTAL|Open label|Single arm study to evaluate safety and tolerability of Enzalutamide with concurrent administration of Radium ra 223 dichloride in subjects with symptomatic metastatic prostate cancer.
62646191|NCT02219256|EXPERIMENTAL|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
62646192|NCT02219256|EXPERIMENTAL|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
62646193|NCT02219256|PLACEBO_COMPARATOR|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
62646194|NCT02757157|EXPERIMENTAL|COPD (normal weight)|People with COPD (BMI 21 kg/m2 to 29 kg/m2)
62646195|NCT02757157|EXPERIMENTAL|COPD (obese)|People with COPD (BMI \>/= 30 kg/m2)
62646196|NCT06011811||Patients with episodic or chronic cluster headache|Patients with a diagnosis of episodic or chronic cluster headache, as diagnosed by a health care professional and to be confirmed by questions on the study survey.
62646197|NCT03107429|ACTIVE_COMPARATOR|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
62646198|NCT03107429|EXPERIMENTAL|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
62646199|NCT05285748|EXPERIMENTAL|Self-Paced Intensity Physical Activity|
62646200|NCT05285748|ACTIVE_COMPARATOR|Prescribed Moderate Intensity Physical Activity|
62646201|NCT02233530|EXPERIMENTAL|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
62076957|NCT05989867||PPDM-C|patients with post-chronic pancreatitis diabetes mellitus
62076958|NCT05989867||CP+IGT|patients with chronic pancreatitis combined with impaired glucose tolerance
62076959|NCT05989867||CP+T2DM|patients with chronic pancreatitis combined with type 2 diabetes mellitus
62076960|NCT05451381|EXPERIMENTAL|Propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group (PR):~continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h"
62076961|NCT05451381|EXPERIMENTAL|Dexmedetomidine group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group Dexmedetomidine (DEX):~continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h"
62646202|NCT04127617|EXPERIMENTAL|Osteopathic Manipulative Treatment|the treatment group will receive 5 osteopathic manipulative treatment. The treatment will last 45 - 60 minutes with the following frequency: the subjects will receive 3 OMT on a weekly basis, the two following twice weekly. The osteopathic treatment protocol will therefore last 7 weeks. Each individual patient will be taken in charge by two operators during the entire duration of the study.
62646203|NCT04127617|ACTIVE_COMPARATOR|Nursing Care|The conventional treatment consists in educational nursing care.
62646204|NCT06251804|EXPERIMENTAL|Water exercise program|The treatment program includes in-water exercise program. Participants will be exercised twice a week for six weeks.
62456950|NCT04700826|EXPERIMENTAL|Direct Oral anticoagulants (DOAC)|Commence DOAC even with low or intermediate risk of stroke or thromboembolism, which could include currently licensed drugs apixaban, dabigatran, edoxaban or rivaroxaban; choice of drug and dose according to local practice guidelines
62076962|NCT05451381|EXPERIMENTAL|Dexmedetomidine and propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DEX+PR:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\\kg\\h"
62076963|NCT05078684|ACTIVE_COMPARATOR|Actual LGSB|"The patients will receive an actual LGSB procedure:~Using ultrasound navigation and an echo-contrast needle, 8ml of bupivacain (5%) will be applied to the site of the left ganglion stellate through an anterolateral approach in the neck region."
62076964|NCT05078684|SHAM_COMPARATOR|Sham procedure|The procedure will be performed using the same instruments and anesthetic drug as the actual LGSB. However, the operator will apply only 0.5-1ml of the anesthetic drug and only subcutaneously to the site where an actual LGSB would be performed.
62646205|NCT06251804|ACTIVE_COMPARATOR|Land-based-program|The treatment program includes land-based exercise program. Participants will be exercised twice a week for six weeks.
62076965|NCT01276249||Fortevo Endograft|All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who meet the inclusion/exclusion criteria for the registry, are eligible for enrollment if treated with the Fortevo Endograft.
62076966|NCT03978390|EXPERIMENTAL|Superhero images, Reward at the beginning,|Also, Showing superhero images for 5 minutes before starting the dental procedure. Also, providing the children with reward before begging the dental procedure and telling them that they can only keep it if they cooperate during the treatment procedure.
62076967|NCT03978390|EXPERIMENTAL|Superhero images, Reward at the end|Universally-accepted positive reinforcement to increase children cooperation in dental settings
62076968|NCT03978390|EXPERIMENTAL|No Superhero Images, Reward at the beginning|Showing superhero images for 5 minutes before starting the dental procedure
62456951|NCT04700826|NO_INTERVENTION|No anticoagulant therapy (usual care)|Continuation of usual anticoagulant prescribing practice in patients with AF; e.g. according to National Institute for Health and Care Excellence (NICE), patients with AF should commence oral anticoagulation with a CHA2DS2-VASc score of 2 or above.
62646206|NCT01287936|EXPERIMENTAL|SB623 Implant (2.5M)|2.5 million SB623 cells
62646207|NCT01287936|EXPERIMENTAL|SB623 Implant (5.0M)|5 million SB623 cells
62076969|NCT03978390|ACTIVE_COMPARATOR|No Superhero Images, Reward at the end|Showing no picture before starting the dental procedure
62076970|NCT00618462|EXPERIMENTAL|1|Participants will receive psychoeducation therapy plus case management and a referral to Gamblers Anonymous.
62076971|NCT00618462|EXPERIMENTAL|2|Participants will receive cognitive behavioral therapy plus contingency management and a referral to Gamblers Anonymous.
62076972|NCT00618462|EXPERIMENTAL|3|Participants will receive cognitive behavioral therapy and a referral to Gamblers Anonymous.
62456952|NCT04105881||Full term labor|Measured by flow cytometry and ELUSA
62456953|NCT04105881||Preterm labor|Measured by flow cytometry and ELISA
62456954|NCT04105881||Control|For comparison
62456955|NCT01587222|EXPERIMENTAL|Albumin, Midodrine, Octreotide|
62456956|NCT03772483|ACTIVE_COMPARATOR|Control group|Local anesthesia with conventional syringe
62076973|NCT00159601||outpatients in Child and Adolescent Mental Health Service|
62076974|NCT00159601||youth from general population|
62076975|NCT02861677|NO_INTERVENTION|Control group|The control group will receive the usual medical care by physicians and nurses
62456957|NCT03772483|ACTIVE_COMPARATOR|Virtual reality group|Local anesthesia with conventional syringe + VR device
62456958|NCT03711409|EXPERIMENTAL|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of the muscles around the shoulder. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
62456959|NCT03711409|EXPERIMENTAL|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
62456960|NCT01485965|EXPERIMENTAL|Fasted condition|Subjects in the Fasted group will take study drug after an overnight fast (since at least midnight). Additionally, on PK assessment days, no food will be allowed for at least 4 hours after study drug administration.
62646208|NCT01287936|EXPERIMENTAL|SB623 Implant (10.0M)|10 million SB623 cells
62076976|NCT02861677|EXPERIMENTAL|Intervention group|the intervention group will receive clinical pharmacy services
62646209|NCT04014777|EXPERIMENTAL|NGM621 Cohort 1 Single Ascending Dose|NGM621 single IVT injection Cohort-Dose 1
62646210|NCT04014777|EXPERIMENTAL|NGM621 Cohort 2 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 2
62646211|NCT04014777|EXPERIMENTAL|NGM621 Cohort 3 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 3
62646212|NCT04014777|EXPERIMENTAL|NGM621 Cohort 4 Multiple Dose|NGM621 multiple IVT injection Cohort--Dose 4
62646213|NCT05346796|NO_INTERVENTION|Control|Group that will receive written survivorship care information.
62646214|NCT05346796|EXPERIMENTAL|Intervention|Group that will be provided access to the survivorship care plan-personal health record tool.
62646215|NCT06550492|EXPERIMENTAL|experimental group using smoke filtering electrocautery device|experimental group using smoke filtering electrocautery device
62646216|NCT06550492|EXPERIMENTAL|experimental group using double mask|experimental group using double mask
62076977|NCT01840319||1|Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)
62076978|NCT02328976|EXPERIMENTAL|chronic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
62076979|NCT02328976|EXPERIMENTAL|Episodic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
62076980|NCT03012789|OTHER|Post Surgery|
62076981|NCT03070184|EXPERIMENTAL|Black Participants|Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
62076982|NCT03070184|ACTIVE_COMPARATOR|White Participants|Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
62076983|NCT03558464|EXPERIMENTAL|Intervention|"Intervention (agriculture-focused package~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
62076984|NCT03558464|ACTIVE_COMPARATOR|Control|(agriculture-focused package)
62076985|NCT00267111|EXPERIMENTAL|Amethocaine gel 4% Group|1 g of topical amethocaine gel 4%
62076986|NCT00267111|PLACEBO_COMPARATOR|Placebo Group|
62076987|NCT00231998|EXPERIMENTAL|1|
62076988|NCT01118130||Case|MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
62076989|NCT01118130||Control|MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
62076990|NCT02484560|EXPERIMENTAL|Ambulatory Patients|Ambulatory patients receiving stem cell therapy
62076991|NCT02484560|EXPERIMENTAL|Non-Ambulatory Patients|non-ambulatory patients receiving stem cell therapy
62456961|NCT01485965|EXPERIMENTAL|Fed condition|Subjects in the Fed group will take study drug within 30 minutes after starting breakfast; these subjects will otherwise maintain their normal eating schedule.
62456962|NCT01610466|EXPERIMENTAL|Curriculum training group|Surgical residents in the curriculum training group will complete the entire curriculum. They will participate in a cognitive component, which will consist of self-directed readings and a faculty-led seminar. Participants will also train to proficiency in laparoscopic jejunojejunostomy and gastrojejunostomy using a laparoscopic box trainer with cadaveric porcine bowels. Finally, for the non-technical skills component participants will participate in an introductory lecture on non-technical skills in surgery, as well as a practice crisis scenario with a debriefing session.
62076992|NCT00627042|EXPERIMENTAL|Ramucirumab (IMC-1121B)|
62076993|NCT01654822|PLACEBO_COMPARATOR|olive oil with 10% d-limonene|Topical spray one-time administration 2 puffs of 100µl
62076994|NCT01654822|EXPERIMENTAL|AV2-DM antiviral spray|Topical spray one-time application 2 puffs of 100µl
62076995|NCT02450019|OTHER|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP. Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to protective.
62076996|NCT02450019|OTHER|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2). Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to traditional.
62076997|NCT05092048||CML patient|≥18 years old CML patiente
62076998|NCT02029040|EXPERIMENTAL|3% hypertonic saline group|Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
62076999|NCT02029040|PLACEBO_COMPARATOR|0.9% normal saline group|Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
62456963|NCT01610466|NO_INTERVENTION|Conventional training group|Participants in the conventional training group will proceed through surgical residency training in the usual fashion.
62077000|NCT02043730|EXPERIMENTAL|nab-paclitaxel and gemcitabine|ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
62077001|NCT02043730|ACTIVE_COMPARATOR|Gemcitabine|ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
62077002|NCT00447044|EXPERIMENTAL|2|Subjects drink essential amino acid supplement 3x day for 2 days.
62077003|NCT00447044|PLACEBO_COMPARATOR|1|Subjects receive inert substance versus protein supplement.
62077004|NCT00447044|EXPERIMENTAL|3|Resistance exercise.
62077005|NCT06333990|EXPERIMENTAL|Quetiapine|Quetiapine will be cross-tapered up to a maximum dose of 200 mg (as tolerated) as other standard of care medications are discontinued.
62077006|NCT06333990|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants in the TAU group will have doses adjusted over the same period as indicated by usual care criteria.
62077007|NCT02398058|EXPERIMENTAL|Trabectedin plus olaparib|"All patients will be treated with trabectedin and olaparib in an open-label fashion.~The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment."
62077008|NCT00874289||Acute heart failure patients|
62077009|NCT00874289||Chronic heart failure patients|
62077010|NCT05133466||Northern pattern|Mothers recruited from Beijing
62077011|NCT05133466||East coastal pattern|Mothers recruited from Wuxi
62077012|NCT05133466||South-western pattern|Mothers recruited from Chengdu
62077013|NCT06477367|EXPERIMENTAL|The group receiving video-based training|Researchers will present a 5-7 minute instructional video aimed at helping participants recall the technique for performing the exercises. These instructional videos will be sent to the researchers' mobile phones via WhatsApp. Participants will be instructed to perform the exercises three times a day for 15 minutes each, for a period of 30 days. To encourage regular exercise, participants will be provided with an exercise diary, and researchers will send reminder SMS messages at the same time every day.
62077014|NCT06477367|NO_INTERVENTION|The group not receiving video-based training|The control group will receive the clinic's routine dyspnea care protocol. After thirty days, final tests will be administered to both groups, and the research will be concluded.
62077015|NCT04399239|EXPERIMENTAL|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
62077016|NCT00988351|ACTIVE_COMPARATOR|PSG CPAP titration then CPAP treatment|Patients diagnosed with sleep apnea will have a continuous positive airway pressure (CPAP) titration with polysomnography (PSG) followed by continuous positive airway pressure (CPAP) Treatment
62077017|NCT00988351|ACTIVE_COMPARATOR|Auto-Adjusting Positive Airway Pressure|Following diagnosis of obstructive sleep apnea patients will be have auto-adjusting positive airway pressure treatment without a titration.
62077018|NCT02528435||JIA patients|observationational study including children diagnosed with JIA. Patients aged 9 years and above, whom are treated with low-dose MTX may be included.
62077019|NCT02528435||ALL patients|observationational study including children diagnosed with ALL. Patients aged 9 years and above, whom are in maintenance treatment with low-dose MTX may be included.
62077020|NCT06106074|EXPERIMENTAL|Part 1a|3 single ascending doses of SAR442168 or placebo in fasted and fed (high-fat breakfast) conditions
62077021|NCT06106074|EXPERIMENTAL|Part 1b|2 single doses of SAR442168 under fed conditions (moderate-fat breakfast).
62077022|NCT06106074|EXPERIMENTAL|Part 1c|1 single dose of SAR442168 under fasting and fed conditions (high-fat breakfast).
62077023|NCT06106074|EXPERIMENTAL|Part 1d|1 single dose of SAR442168 under fasting and fed conditions (Standardized high-fat breakfast).
62077024|NCT06106074|EXPERIMENTAL|Part 2|3 ascending once-daily repeated single doses of SAR442168 or placebo for 14 days under fed conditions (moderate-fat breakfast)
62077025|NCT06050356|EXPERIMENTAL|Arm 1 (phase 1a)|H107e
62077026|NCT06050356|EXPERIMENTAL|Arm 2 (phase 1a)|CAF®10b
62077027|NCT06050356|EXPERIMENTAL|Arm 3 (phase 1a)|H107e/CAF®10b - low adjuvant dose
62077028|NCT06050356|EXPERIMENTAL|Arm 4a (phase 1a)|H107e/CAF®10b - full adjuvant dose - low dose intranasal H107e
62077029|NCT06050356|EXPERIMENTAL|Arm 4b (phase 1a)|H107e/CAF®10b - full adjuvant dose - full dose intranasal H107e
62077030|NCT06050356|EXPERIMENTAL|Arm 1 (phase 1b)|H107e/CAF®10b
62077031|NCT06050356|EXPERIMENTAL|Arm 2 (phase 1b)|H107e/CAF®10b + BCG
62077032|NCT06050356|ACTIVE_COMPARATOR|Arm 3 (phase 1b)|BCG
62077033|NCT06050356|PLACEBO_COMPARATOR|Arm 4 (phase 1b)|Placebo
62456964|NCT04362397|EXPERIMENTAL|A (first group to receive the intervention)|This arm will receive the attention, care, and self-care training first.
62077034|NCT06529900|EXPERIMENTAL|Oral Mastication Training and Texture and Diet Education|Participants in this arm will receive oral mastication training combined with texture and diet education.
62077035|NCT06529900|ACTIVE_COMPARATOR|Texture and Diet Education|Participants in this arm will receive texture and diet education without the oral mastication training component.
62077036|NCT05552274|PLACEBO_COMPARATOR|SAD Cohorts 1 to 2: Participants receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo
62077037|NCT05552274|EXPERIMENTAL|SAD Cohorts 1 to 2: Participants receiving ECC4703|Participants in each SAD cohort will be randomized to receive up to 4 escalating doses (1 mg, 4 mg, 12 mg, 32 mg, 80 mg, 160 mg, 320 mg or 400 mg).
62077038|NCT05552274|PLACEBO_COMPARATOR|MAD Cohorts 1 to 4: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
62646217|NCT06550492|NO_INTERVENTION|control group|group using standard methods
62646218|NCT05287815||1|experimental(30 people) groups health education will be given by making a home visit
62646219|NCT05287815||2|control(30 people) no intervention
62077039|NCT05552274|EXPERIMENTAL|MAD Cohorts 1 to 4: Participants receiving ECC4703|Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (40 mg, 80 mg, or 160 mg) for 14 days.
62077040|NCT00515398||1|Group 1 (all subjects)
62077041|NCT03432949|NO_INTERVENTION|Standard of Care Radium-223|Radium-223 treatment will be administered as per standard of care.
62456965|NCT04362397|EXPERIMENTAL|B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive it after this period.
62646220|NCT00049816|NO_INTERVENTION|1|Participants will receive no intervention and will act as the control group.
62646221|NCT00049816|EXPERIMENTAL|2|Participants will partake in a walking exercise program.
62077042|NCT03432949|EXPERIMENTAL|Radium-223 with oral Dexamethasone 0.5 mg|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
62077043|NCT01820533||smokers|
62077044|NCT01702389|EXPERIMENTAL|Remifentanil|The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.
62077045|NCT00833222||Full Term Infants|Infants born between 37 4/7 weeks and 42 3/7 weeks gestation.
62077046|NCT00833222||Preterm Infants|Infants born between 32 4/7 weeks and 35 3/7 weeks gestation.
62077047|NCT03751163|ACTIVE_COMPARATOR|Study|Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
62077048|NCT03751163|PLACEBO_COMPARATOR|Control|Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
62646222|NCT00049816|EXPERIMENTAL|3|Participants will partake in a cycling exercise program.
62646223|NCT04703413|EXPERIMENTAL|LoFric® OrigoTM or LoFric® SenseTM|Hydrophilic male (LoFric Origo) and female (LoFric Sense) urinary catheters for single use. Target subject population are subjects suffering from bladder voiding dysfunction and are experienced in intermittent catheterization (IC).
62646224|NCT06305663|EXPERIMENTAL|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)|
62646225|NCT06305663|ACTIVE_COMPARATOR|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens|
62077049|NCT02865057||3rd year Residents|3rd year Ob, Gyn Residents
62077050|NCT02865057||4th Year Residents|4th year Ob, Gyn Residents
62077051|NCT04712474|EXPERIMENTAL|In-home decluttering|Study participants receive weekly sessions of in-home decluttering for 10 weeks.
62077052|NCT04712474|NO_INTERVENTION|Delayed treatment|Study participants receive weekly session of in-home decluttering after a 10 week delay.
62077053|NCT05706792|EXPERIMENTAL|Nordic Sensi Chair|Participants received three times a week one session per day of 20 minutes in the Relax for deep relaxation program of the Nordic Sensi Chair.
62646226|NCT05728476|EXPERIMENTAL|Vitrectomy group|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
62077054|NCT05706792|NO_INTERVENTION|Standard of care|Participants did not participate in the Nordic Sensi Chair sessions, but received, at the same time and duration, the care and activities that were part of the daily routines of the center, including group sessions of cognitive stimulation, training in activities of daily living or communication training.
62646227|NCT05728476|ACTIVE_COMPARATOR|Anti-VEGF group|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
62646228|NCT03350386|EXPERIMENTAL|Single dose|Single administration of FYU-981
62646229|NCT03350386|EXPERIMENTAL|Concomitant administration|Concomitant administration of FYU-981 with oxaprozin at steady state
62646230|NCT02643693|EXPERIMENTAL|P3L Product use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
62077055|NCT06206980|EXPERIMENTAL|Physical Activity Promotion Group|"The rehabilitation program has the purpose of motivating patients to be more physically active. The treatment protocol had a total duration of 12 weeks.~During hospitalization, an education of patients is conducted and physical activity is initiated. A diary is provided to patients to record the activities that they perform during each week until completing the 12 weeks.~Additionally, phone calls are performed at 15 days, 1 and 2 months to motivate patients and answer any questions they may have."
62077056|NCT06206980|ACTIVE_COMPARATOR|Control group|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
62077057|NCT04131283|EXPERIMENTAL|Epinephrine effect throught keratinized ginigva|1 mg/ml epniephrine vs physiologocal saline
62077058|NCT04131283|EXPERIMENTAL|Epinephrine effect throught gingival sulcular epithelium|1 mg/ml epniephrine vs physiologocal saline
62646231|NCT02643693|EXPERIMENTAL|VUSE Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
62646232|NCT02643693|EXPERIMENTAL|CC Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
62646233|NCT04872283|ACTIVE_COMPARATOR|Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive 30 mg of IV ketorolac during surgery as well as 20 mg ketorolac pills to take after surgery for pain
62077059|NCT02508766|EXPERIMENTAL|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
62077060|NCT02508766|NO_INTERVENTION|Control group|Volunteers received no intervention. They just sat there for 20 minutes before being evaluated.
62077061|NCT06017687|OTHER|Principal Arm|Each participant will use the OptiBP Study app on their smartphone
62077062|NCT00872430|ACTIVE_COMPARATOR|Placebo/Laxative tea crossover|This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
62077063|NCT00872430|ACTIVE_COMPARATOR|Laxative tea/Placebo crossover|This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).
62646234|NCT04872283|ACTIVE_COMPARATOR|No Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive the standard treatment of 30 tablets of oxycodone-acetaminophen to take as needed for pain
62646235|NCT05760599|EXPERIMENTAL|Candonilimab Plus Bevacizumab|Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week
62077064|NCT02803320|EXPERIMENTAL|SPF 50 Y65 110|All subjects received baseline skin evaluation and 1 day of sun exposure.
62077065|NCT06401759|EXPERIMENTAL|Podcast|
62077066|NCT06401759|NO_INTERVENTION|Control|
62077067|NCT04059393|EXPERIMENTAL|Group I (web-based legacy intervention)|Patients participate in a web-based legacy intervention by answering questions about themselves and uploading videos, photographs, and music to create a digital story within 2 weeks.
62456966|NCT02305966|ACTIVE_COMPARATOR|pressfit humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is -pressfit humerus \& non-lateralized glenoid.
62077068|NCT04059393|ACTIVE_COMPARATOR|Group II (standard of care)|Patients receive standard of care. Patients have the option to participate in the web-based legacy intervention after 2 months.
62646236|NCT02982707|EXPERIMENTAL|Mild Hepatic Subjects|Subjects are given a single dose of BMS-986177
62646237|NCT02982707|EXPERIMENTAL|Moderate Hepatic Subjects|Subjects are given a single dose of BMS-986177
62646238|NCT02982707|EXPERIMENTAL|Healthy Match Subjects|Subjects are given a single dose of BMS-986177
62646239|NCT05573230|EXPERIMENTAL|Midazolam + LY3502970|Midazolam administered orally followed by LY3502970 given orally.
62646240|NCT05573230|EXPERIMENTAL|Cyclosporine + Midazolam + LY3502970|Cyclosporine administered in combination with midazolam and LY3502970 given orally.
62646241|NCT02064556|EXPERIMENTAL|A(Amlodipine 10mg)|Amlodipine 10mg 1T, PO, QD for 9days
62646242|NCT02064556|EXPERIMENTAL|B(Amlodipine 10mg/Candesartan 32mg)|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
62646243|NCT01066572|EXPERIMENTAL|Lisinopril|Experimental
62646244|NCT01066572|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62646245|NCT00023231|EXPERIMENTAL|1|Participants will receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus prior to transplantation. Bactrim and ganciclovir will be taken for infection prophylaxis. If the participant has consistent high levels of fasting cholesterol, treatment with lipitor may be given.
62646246|NCT03753035||epileptic children|Completion of questionnaire, during medical consultation, on compliance and quality of life
62077069|NCT02664779|EXPERIMENTAL|Arrhythmia diagnosis with the 10 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias.
62077070|NCT02664779|ACTIVE_COMPARATOR|Arrhythmia diagnosis with the 6 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
62077071|NCT02664779|ACTIVE_COMPARATOR|Arrhythmia diagnosis with the 4 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
62646247|NCT05334394|EXPERIMENTAL|Mulligan Group|
62646248|NCT05334394|EXPERIMENTAL|Control Group|
62646249|NCT00003537|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62646250|NCT00449839|OTHER|A, CSII without bolus|Period A: A constant subcutaneous infusion rate of insulin aspart (0.5 U/hr) is given for 8 hours. Following 3 hours of blood sampling.
62646251|NCT00449839|OTHER|B; CSII with bolus|Period B: A constant subcutaneous infusion of insulin aspart (0.5 U/hr) is given for 8 hours and upon start a s.c.bolus (1.4 U)of insulin aspart is given. Hereafter follows 3 hours of blood sampling.
62646252|NCT00449839|OTHER|C; CSII with bolus, optional|A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
62077072|NCT03636360|EXPERIMENTAL|LED - Sunlike|LED lighting with spectral pattern similar to that of sunlight
62646253|NCT00677898|EXPERIMENTAL|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
62646254|NCT00677898|ACTIVE_COMPARATOR|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
62077073|NCT03636360|ACTIVE_COMPARATOR|Fluorescent|Fluorescent light at same illuminance (lux) as LED light
62077074|NCT03636360|PLACEBO_COMPARATOR|Dim|"Dim fluorescent light with same spectrum as Fluorescent condition"
62077075|NCT03636360|ACTIVE_COMPARATOR|LED|Standard LED lighting
62077076|NCT01881269||No treatment|No treatment, prospective observational
62077077|NCT03309163|ACTIVE_COMPARATOR|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
62077078|NCT03309163|PLACEBO_COMPARATOR|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
62077079|NCT03309163|PLACEBO_COMPARATOR|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
62077080|NCT03685032|EXPERIMENTAL|The study group (Gr. D)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. D was administered 4 mg of dexamethasone in 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. D received ondansetron 4 mg in 2 ml iv."
62077081|NCT03685032|PLACEBO_COMPARATOR|the control group (Gr. N)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. N received normal saline 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. N received normal saline 2 ml iv."
62077082|NCT01013974|EXPERIMENTAL|GSK573719 250 microgram (μg) arm|Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
62077083|NCT01013974|EXPERIMENTAL|GSK573719 500 μg arm|Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
62077084|NCT01013974|EXPERIMENTAL|GSK573719 1000 μg arm|Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
62077085|NCT01013974|PLACEBO_COMPARATOR|Placebo|Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
62646255|NCT00956202|EXPERIMENTAL|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
62646256|NCT00956202|EXPERIMENTAL|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
62077086|NCT05408000|ACTIVE_COMPARATOR|ketofol|patient given titrated dose of ketofol
62077087|NCT05408000|ACTIVE_COMPARATOR|propofol|patient given titrated dose of propofol
62077088|NCT02811289|EXPERIMENTAL|Mirabegron|Mirbetriq (Mirabegron) (50mg) will be administered orally at time 0 to activate brown adipose tissue.
62077089|NCT02811289|ACTIVE_COMPARATOR|Cold exposure|Cold exposure protocol using a water-conditioned cooling suit will be applied
62077090|NCT04781647|ACTIVE_COMPARATOR|ABI-H0731 + ETV|Participants with cHBV will receive ABI-H0731 with ETV for 48 weeks, followed by ETV alone for 12 weeks
62077091|NCT04781647|EXPERIMENTAL|ABI-H0731 + ETV + Peg-IFNα|Participants with cHBV will receive ABI-H0731 with ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
62077092|NCT04781647|ACTIVE_COMPARATOR|ETV + Peg-IFNα|Participants with cHBV will receive ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
62077093|NCT05488938|EXPERIMENTAL|Immediate intervention (Group 1)|Group 1 will start the rehabilitative intervention immediately after the first evaluation (T1) and carry it out for 10 months with remote supervision until the second evaluation meeting (T2). Then they will be invited to continue the intervention for the next 10 months (between T2 and T3) until the third evaluation meeting but without remote supervision.
62077094|NCT05488938|EXPERIMENTAL|Delayed intervention (Group 2)|Group 2 will not conduct the rehabilitative intervetion between T1 and T2. They will start the rehabilitative intervention immediately after the second evaluation (T2) and carry it out for 10 months with remote supervision until the third evaluation meeting (T2).
62646257|NCT00956202|EXPERIMENTAL|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
62646258|NCT03810183|EXPERIMENTAL|QAW039 450 mg|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet.
62646259|NCT03810183|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 6 weeks administered orally as a tablet.
62646260|NCT04763993|ACTIVE_COMPARATOR|RYGBP|RYGBP: Roun-en-Y Gastric Bypass
62646261|NCT04763993|EXPERIMENTAL|SG|SG: Sleeve Gastrectomy
62646262|NCT03469544||Group 1 (30)|"Patient with cancer thyroid proved by cytological analysis Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood ,Enzyme linked Immunosorbent Assay for serum midkine level"
62077095|NCT04565756|EXPERIMENTAL|Dose Escalation Cohort 1|Each subject will receive a low-dose 0.5 mg/mL (0.05%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
62077096|NCT04565756|EXPERIMENTAL|Dose Escalation Cohort 2|Each subject will receive a mid-dose 1 mg/mL (0.1%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
62646263|NCT03469544||Group 2 (30)|"Patient with benign thyroid nodule Interventions;complete blood picture ,serum urea and creatinine,liver function test ,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
62646264|NCT03469544||Group 3 (30)|"Normal healthy subjects as control group Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
62077097|NCT04565756|EXPERIMENTAL|Dose Escalation Cohort 3|Each subject will receive a high-dose 1.5 mg/mL (0.15%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
62077098|NCT04565756|EXPERIMENTAL|Dose Expansion Cohort|The highest well-tolerated dose of EXN407 will be evaluated where subjects will receive EXN407 at the selected dose or placebo twice a day for up to 84 days resulting in a total of 168 doses
62077099|NCT01313923|EXPERIMENTAL|Sirolimus (formerly known as Rapamycin)|Subjects with stable pemphigus vulgaris already on treatment with prednisone will be enrolled. Subjects will start taking oral sirolimus and have it up-titrated while decreasing the prednisone dosage. Their disease state will be monitored during this time.
62077100|NCT03803020||single coronary chronic total occlusion|"symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI.~fractional flow reserve and SPECT detection before and after intervention."
62077101|NCT04095104|EXPERIMENTAL|Phentermine & Topiramate|"Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration:~4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
62077102|NCT04095104|PLACEBO_COMPARATOR|Placebo Drugs|"Placebo Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration: 4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Placebo Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
62646265|NCT01207193|EXPERIMENTAL|bone cyst|Patients with bone cyst defect are injected with mesenchymal cells.
62646266|NCT04582656|EXPERIMENTAL|Targeted microwave ablation|Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion
62646267|NCT05433610|EXPERIMENTAL|Constant Treadmill Load Test (CTLT) using non-invasive ventilation (NIV)|Exercise capacity testing using PS in HF patients
62077103|NCT02250521|EXPERIMENTAL|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The liquid crystal display (LCD) monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
62077104|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
62077105|NCT03489005|OTHER|Treatment Period 1|"Interventions to be administered:~Schema 1:~1. 400 mg BIA 5-1058~2. 1200 mg BIA 5-1058~3. Placebo~4. Moxifloxacin~Schema 2:~1. 1200 mg BIA 5-1058~2. Placebo~3. 400 mg BIA 5-1058~4. Moxifloxacin"
62077106|NCT03489005|OTHER|Treatment Period 2|"Interventions to be administered:~Schema 1~1. 1200 mg BIA 5-1058~2. Moxifloxacin~3. 400 mg BIA 5-1058~4. Placebo~Schema 2:~1. Placebo~2. Moxifloxacin~3. 1200 mg BIA 5-1058~4. 400 mg BIA 5-1058"
62456967|NCT02305966|ACTIVE_COMPARATOR|pressfit humerus & lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is - pressfit humerus \& lateralized glenoid.
62646268|NCT05433610|EXPERIMENTAL|Constant Treadmill Load Test (CTLT) using NIV|Exercise capacity testing using CPAP in HF patients
62646269|NCT05433610|ACTIVE_COMPARATOR|Constant Treadmill Load Test (CTLT) without NIV|Exercise capacity testing without NIV in HF patients
62646270|NCT01035138|EXPERIMENTAL|Drug: semagacestat|
62646271|NCT04040686|EXPERIMENTAL|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99m-Tc-NM-02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection
62077107|NCT03489005|OTHER|Treatment Period 3|"Interventions to be administered:~Schema 1~1. Placebo~2. 400 mg BIA 5-1058~3. Moxifloxacin~4. 1200 mg BIA 5-1058~Schema 2~1. 400 mg BIA 5-1058~2. 1200 mg BIA 5-1058~3. Moxifloxacin~4. Placebo"
62077108|NCT03489005|OTHER|Treatment Period 4|"Interventions to be administered:~Schema 1~1. Moxifloxacin~2. Placebo~3. 1200 mg BIA 5-1058~4. 400 mg BIA 5-1058 Schema 2~1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058"
62077109|NCT05586854|EXPERIMENTAL|end-stage renal disease patients with heparin-induced thrombocytopenia|The research procedure consists of dialysing patients on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol. This protocol of decrease is done over a period of about 6 months divided into 4 periods.
62077110|NCT04503382|EXPERIMENTAL|Kindness media|Short videos of kindness media. As part of a program entitled EnSpire®, this media consists of short videos that display acts of kindness and compassion that are edited together into a single reel.
62077111|NCT04503382|ACTIVE_COMPARATOR|Standard television|Children's commercial programming--as the control condition, participants watched commercial children's programming such as Disney, Nickelodeon, etc.
62077112|NCT04265443||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured invasive physiologic indices after PCI
62646272|NCT00968461|EXPERIMENTAL|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
62646273|NCT02288676||Case Group|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
62646274|NCT02288676||Control Group|Participants must not be under investigation for any pre-cancerous or cancerous lesions of the genital tract, and must be scheduled for a hysterectomy, bilateral salpingectomy with/without bilateral oopherectomy for presumed benign condition.
62646275|NCT00333528|EXPERIMENTAL|1|Administration of one dose of the active drug (6 volunteers)
62646276|NCT00333528|PLACEBO_COMPARATOR|2|Administration of placebo (2 volunteers)
62646277|NCT03305562||Retrospective cohort|The cohort of patients seen prior to the implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected retrospectively.
62646278|NCT03305562||Prospective cohort|The cohort of patients seen initially seen after implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected prospectively.
62077113|NCT01015222|EXPERIMENTAL|Dasatinib, Bevacizumab + Paclitaxel|"Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15~Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation."
62646279|NCT04795635|EXPERIMENTAL|CMM + Axon Therapy|"Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days). Participants randomized to the CMM plus Axon Therapy group will return to the clinic for Axon Therapy treatments as follows:~* Month 1: 6 treatments~  * WEEK 1: 3 treatments (consecutive treatments are best)~ * WEEK 2-4: Weekly treatments~* Month 2: Bi-monthly treatment~* Months 3-12: Treatments every 2-4 weeks~In addition to in-clinic assessments and treatments, all participants will a receive weekly phone follow-up to assess pain intensity and occurrence of adverse events after treatment starts. Weekly phone follow-ups will only occur during weeks when the participant is not in clinic for treatment."
62646280|NCT04795635|NO_INTERVENTION|CMM Only|Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days)
62077114|NCT02773264||UltraSound Patients|All patients will undergo next to the clinical indicated conventional US-examination, US Elastography after informed consent. After completion of these three examinations, the participation in the study is completed.
62077115|NCT02809586|ACTIVE_COMPARATOR|SMI + Incentives|A Social Media + Incentives (SMI + I) condition
62077116|NCT02809586|ACTIVE_COMPARATOR|SMI|A Social Media Intervention (SMI) condition
62077117|NCT02809586|NO_INTERVENTION|Control|An Attention-Control E-News (CONTROL) condition
62077118|NCT02619227|EXPERIMENTAL|Immediate treatment|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
62077119|NCT02619227|NO_INTERVENTION|Delayed treatment|Participants will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
62077120|NCT05699902|ACTIVE_COMPARATOR|PECs block group|Female undergone mastectomy and received pectoral nerve block
62077121|NCT05699902|SHAM_COMPARATOR|Non PECs block group|Female undergone mastectomy and not received pectoral nerve block but have received conventional analgesic methods
62280036|NCT06220656|EXPERIMENTAL|Immediate biopsy (usual care)|"The aim of biopsy is to sample the thyroid nodule so that it can be tested for cancer. A biopsy is done with a small needle in an office. If the biopsy result shows the nodule is unlikely to be cancer, the next step is check-ups every 6 months to a year for two years followed by additional checkups that occur less frequently.~If the biopsy result shows the nodule may be cancerous, usual treatment is surgery to remove part or all of the thyroid gland. Afterwards, regular check-ups and ultrasounds follow. Surgery may be outpatient or overnight stay. Recovery takes a couple weeks or more. Time in the hospital and recovering depends on the type of operation and any side-effects."
62646281|NCT04005040|ACTIVE_COMPARATOR|Mobile X-ray|Intervention: X-ray examination in the patients own home
62646282|NCT04005040|PLACEBO_COMPARATOR|X-ray at the Hospital|Control: X-ray at the hospital
62646283|NCT00597272|EXPERIMENTAL|1|Vaccine- KLH conjugates with GD2L and GD3L
62646284|NCT06294288|EXPERIMENTAL|Cohort 1: LP-003 Dose 1 (Single)|
62646285|NCT06294288|EXPERIMENTAL|Cohort 2: LP-003 Dose 2 (Single)|
62646286|NCT06294288|EXPERIMENTAL|Cohort 3: LP-003 Dose 3 (Single)|
62077122|NCT02456974||amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care.
62077123|NCT02456974||piperacilline-tazobactam|Patients receiving piperacilline-tazobactam as part of routine clinical care.
62646287|NCT06294288|EXPERIMENTAL|Cohort 4: LP-003 Dose 4 (Single)|
62646288|NCT06294288|EXPERIMENTAL|Cohort 5: LP-003 Dose 5 (Single)|
62077124|NCT02456974||vancomycin|Patients receiving vancomycin as part of routine clinical care.
62280037|NCT06220656|EXPERIMENTAL|Active monitoring, proceeding to biopsy if needed|"The aim of Active Monitoring is to monitor the thyroid nodule closely. An ultrasound and a check-up with a clinician are done every six months for two years, then less often after that.~If no changes in the nodule or new abnormal lymph nodes are seen, Active Monitoring continues and surgery and its side-effects are avoided. If changes in the nodule are seen on ultrasound, they are explained at the visit. The doctor may recommend that continued Active Monitoring or recommend a biopsy to investigate the changes. The biopsy result may suggest Active Monitoring can be continued, or may indicate surgery should be done, as described above."
62646289|NCT06294288|PLACEBO_COMPARATOR|Cohort 6: Placebo (Single)|
62646290|NCT06294288|EXPERIMENTAL|Cohort 7: LP-003 Dose 6 (Multiple)|
62646291|NCT06294288|EXPERIMENTAL|Cohort 8: LP-003 Dose 7 (Multiple)|
62646292|NCT06294288|EXPERIMENTAL|Cohort 9: LP-003 Dose 8 (Multiple)|
62646293|NCT06294288|PLACEBO_COMPARATOR|Cohort 10: Placebo (Multiple)|
62646294|NCT06508255|EXPERIMENTAL|Early Time-Restricted Eating|
62646295|NCT06508255|EXPERIMENTAL|Late Time-Restricted Eating|
62646296|NCT05089214|EXPERIMENTAL|Intra oral clinical examination|
62646297|NCT04324229|ACTIVE_COMPARATOR|liraglutide|
62646298|NCT04324229|PLACEBO_COMPARATOR|placebo|
62646299|NCT06520956|EXPERIMENTAL|Video-based exercise group|In each session, 2 videos will be applied and each will be repeated 2-3 times, with a 3-minute rest break between each video. The total session will last an average of 20-30 minutes and 16 sessions of physical activity will be performed twice a week for a total of 8 weeks. A total of at least 140 GCH Brain Breaks® videos, each 3-4 minutes long, include aerobic exercises that include large joint movements, yoga and movements specific to different sports branches such as volleyball, basketball, football, tennis, karate, judo, warm-up and cool-down movements. includes national dances of different cultures
62646300|NCT06520956|NO_INTERVENTION|Control group|Any intervention will not be performed. After the initial evaluation, patients in this group will be given a single session of training on balance and posture exercises.
62646301|NCT02390232||NAFLD with simple steatosis|Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy
62646302|NCT02390232||NAFLD with steatohepatitis|Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy
62646303|NCT05605353||Colorectal|Patients with rectal or colon cancer
62646304|NCT05605353||Gynaecological|Patients with uterine, ovarian or cervical cancers
62646305|NCT05605353||Urological|Patients with bladder or prostate cancers
62646306|NCT04469439||Surgical group|Individuals with cystic fibrosis and chronic rhinosinusitis who undergo endoscopic sinus surgery
62646307|NCT04469439||Medical group|Individuals with cystic fibrosis and chronic rhinosinusitis who do not undergo endoscopic sinus surgery
62646308|NCT06011642||Clinical sample|Participants will be recruited from families in Bochum who receive treatment or wait for the treatment to begin at the Forschungs- und Behandlungszentrum (FBZ; outpatient treatment center).
62077125|NCT02456974||teicoplanin|Patients receiving teicoplanin as part of routine clinical care.
62077126|NCT02456974||meropenem|Patients receiving meropenem as part of routine clinical care.
62646309|NCT06011642||Nonclinical sample|Participants will be recruited from families in Bochum who take part in experiments and studies at the Department of Clinical Child and Adolescent Psychology at the Ruhr-University. The Department of Clinical Child and Adolescent Psychology maintains a database of families interested in participating in research.
62077127|NCT02456974||ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care.
62077128|NCT02456974||amikacin|Patients receiving amikcain as part of routine clinical care.
62077129|NCT03758638|EXPERIMENTAL|Healthy Eating & Active Living Taught at Home|"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).~Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits."
62077130|NCT03758638|ACTIVE_COMPARATOR|Usual Care|Participants at usual care PAT sites will receive PAT as usual
62077131|NCT01777594|EXPERIMENTAL|G-202 (Mipsagargin)|G-202 (mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
62077132|NCT00548041|OTHER|Rapid HIV Tested|Subjects have HIV testing by oral swab performed.
62077133|NCT01267825|EXPERIMENTAL|CT-guided intervention|CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
62646310|NCT03733808|ACTIVE_COMPARATOR|Active rTMS treatment|Active High frequency rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. The stimulation protocol parameters will be set as follow: frequency of 15 Hz, of 100% of resting motor threshold (rMT), 40 trains, 60 pulses per train, 15 s intertrain-interval, 2400 pulses per session.
62077134|NCT01267825|ACTIVE_COMPARATOR|Standard medical care|
62077135|NCT02926547||CCIS|
62077136|NCT02926547||invasive breast cancer|
62077137|NCT03461250||HCV serology negative in HD|Risk factors
62077138|NCT03461250||HCV serology positive in HD|Risk factors HCV viral load HCV genotype Liver elastography by Fibroscan
62077139|NCT01731587|EXPERIMENTAL|L-BLP25 plus Cyclophosphamide (CPA)|
62077140|NCT04519541|EXPERIMENTAL|Neurolyser XR treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
62077141|NCT06336499||Malignant orbital tumors|Patients with malignant orbital tumors (lymphoma, melanoma, ...) diagnosed by pathological confirmation.
62077142|NCT06336499||Benign orbital tumors|Patients with benign orbital tumors (cavernous hemangioma, inflammatory pseudotumor, ...) diagnosed by pathological confirmation.
62280038|NCT01652287|ACTIVE_COMPARATOR|BB-12 supplemented yogurt|Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
62280039|NCT01652287|PLACEBO_COMPARATOR|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
62646311|NCT03733808|SHAM_COMPARATOR|Sham rTMS treatment|Sham rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same procedures of active High frequency rTMS will be used.
62646312|NCT00614835|EXPERIMENTAL|1 patients with completely resected uterine leiomyosarcoma|Docetaxel plus Gemcitabine
62646313|NCT04927910|EXPERIMENTAL|True self-acupressure|1) two individual/group acupressure training sessions over 2 weeks and (2) self-acupressure for 6 weeks.
62646314|NCT04927910|SHAM_COMPARATOR|Sham self-acupressure|Same protocol to the true self-acupressure group but on the sham acupoints
62646315|NCT04927910|OTHER|Usual care|General advise on managing symptoms provided by healthcare providers
62646316|NCT01751282|PLACEBO_COMPARATOR|Standard therapy and control saline spray|Conventional standard therapy and control saline spray
62646317|NCT01751282|SHAM_COMPARATOR|standard therapy and fibrin spray|Conventional standard therapy and fibrin spray
62077143|NCT02532322|EXPERIMENTAL|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
62077144|NCT02532322|PLACEBO_COMPARATOR|normal saline|normal saline (placebo control) 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
62077145|NCT02535559|EXPERIMENTAL|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
62077146|NCT02535559|NO_INTERVENTION|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
62077147|NCT01818141|ACTIVE_COMPARATOR|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
62077148|NCT01818141|ACTIVE_COMPARATOR|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
62077149|NCT01169181|ACTIVE_COMPARATOR|AMES therapy with rTMS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+rTMS, followed by an EMG test. During the hand-opening phase of the AMES therapy, the subjects assigned to the AMES+rTMS treatment group will be subjected to trains of TMS pulses.
62077150|NCT01169181|ACTIVE_COMPARATOR|AMES therapy with tDCS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+tDCS, followed by an EMG test. A constant current will be applied throughout the entire 20-minute therapy session with the AMES device.
62077151|NCT00393094|EXPERIMENTAL|Bevacizumab & Irinotecan Patients|Bevacizumab - 10 mg/kg intravenous injection Irinotecan - 125 mg/m\^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m\^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
62077152|NCT03958630|EXPERIMENTAL|Healthy volunteers|Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PIB followed by brain magnetic resonance imaging (MRI)
62077153|NCT03958630|EXPERIMENTAL|Subjects with chromosome 9 open reading frame 72 (C9ORF72)|Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PIB followed by brain magnetic resonance imaging (MRI)
62077154|NCT03958630|EXPERIMENTAL|Subjects with Frontotemporal dementia (FTD)|Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PiB followed by brain magnetic resonance imaging (MRI)
62077155|NCT05368506|EXPERIMENTAL|Treatment (wee1 inhibitor ZN-c3)|Patients receive Wee1 inhibitor ZN-c3 PO QD on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62077156|NCT03514862|EXPERIMENTAL|Intervention|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then will be invited to continue to participate in 4 additional Mindfulness Booster Training.
62077157|NCT03514862|ACTIVE_COMPARATOR|Control|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then continue to Self-Practice for 4 weeks.
62077158|NCT05517720|EXPERIMENTAL|Aria Trio complete Facial System|Skincare system targetting wrinkles, pore size, sun spots, and overall skin quality.
62077159|NCT05969522|OTHER|Control group-Low and medium risk group|"The children with AAGN admitted to all cooperating units during 2017.01.01 to 2022.12.31 were followed up for more than 6 months, and the case data were complete.~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
62077160|NCT05969522|OTHER|Control group-High risk group|"The children with AAGN admitted to all cooperating units during 2017.01.01 to 2022.12.31 were followed up for more than 6 months, and the case data were complete.~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
62280040|NCT02399033|NO_INTERVENTION|the control group|Patients in Control group were not received Xihuang Capsules.
62280041|NCT02399033|EXPERIMENTAL|Xihuang Capsules group|Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
62280042|NCT01002092|ACTIVE_COMPARATOR|Chemotherapy|
62280043|NCT01002092|EXPERIMENTAL|Endostar plus Chemotherapy|
62646318|NCT01751282|EXPERIMENTAL|Conventional standard therapy and MSCs|Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
62646319|NCT06213116|EXPERIMENTAL|MADgic Atomizer|"Group M(MADgic) acting as Intervention Group:~Patients receiving Lignocaine 30mg (3 alliquotes) given via MADgic Laryngotracheal Atomization Device prior to endotracheal intubation."
62646320|NCT06213116|ACTIVE_COMPARATOR|Lignocaine Spray|"Group S (Spray) acting as Control Group:~Patients receiving Lignocaine 30 mg (3 puffs) given via 10mg Lignocain Pump Spray prior to endotracheal intubation."
62646321|NCT05401175|EXPERIMENTAL|Autologous blood transfusion support therapy group|Bone aspiration and bone marrow examination before concurrent chemoradiotherapy.Peripheral blood stem cells were mobilized, frozen and stored before treatment. Resuscitate and reinfusion autologous peripheral blood 24 hours after completion of concurrent chemoradiotherapy.
62646322|NCT05401175|NO_INTERVENTION|Conventional treatment group|Bone aspiration and bone marrow examination before concurrent chemoradiotherapy.Undergo standard radiotherapy for cervical cancer.
62646323|NCT00053625|ACTIVE_COMPARATOR|SA #1 Arm 1: Unilateral DBS in GPi|
62646324|NCT00053625|ACTIVE_COMPARATOR|SA #1 Arm 2: Unilateral DBS in STN|
62646325|NCT00053625|ACTIVE_COMPARATOR|SA #2 Arm 1: Bilateral DBS in GPi|Patients with GPi bilateral DBS (previously had unilateral DBS in the GPi, now have bilateral DBS in GPi)
62646326|NCT00053625|ACTIVE_COMPARATOR|SA #2 Arm 2: Bilateral DBS in STN|Patients with STN bilateral DBS (previously had unilateral DBS in the STN, now have bilateral DBS in STN)
62646327|NCT00906126|EXPERIMENTAL|Oral Misoprostol 1|Oral misoprostol 25 micrograms every 4 hours for up to two doses.
62646328|NCT00906126|EXPERIMENTAL|Oral Misoprostol 2|Oral misoprostol 50 micrograms every 4 hours for up to two doses.
62646329|NCT00906126|EXPERIMENTAL|Oral Misoprostol 3|Oral misoprostol 100 micrograms every 4 hours for up to two doses.
62646330|NCT00906126|EXPERIMENTAL|Oral Misoprostol 4|Oral Misoprostol 50 micrograms every 2 hours for up to two doses.
62280044|NCT03174483|EXPERIMENTAL|hypertonic saline|nasal spray will be used twice daily
62280045|NCT03174483|ACTIVE_COMPARATOR|fluticasone|nasal spray will be used once daily
62280046|NCT00915200|PLACEBO_COMPARATOR|Placebo|N-acetylcysteine placebo + silibin placebo
62280047|NCT00915200|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine active + silibin placebo
62280048|NCT00915200|EXPERIMENTAL|silibin|N-acetylcysteine placebo + silibin active
62646331|NCT00906126|EXPERIMENTAL|Oral Misoprostol 5|Oral Misoprostol 75 micrograms every 4 hours for up to two doses.
62646332|NCT02190188|NO_INTERVENTION|No specific treatment|No specific treatment after partial meniscectomy
62646333|NCT02190188|OTHER|Wedge Insole with 5mm wedge angel|Participants wear a wedge insole after partial meniscectomy
62646334|NCT02190188|OTHER|Knee Brace|Participants wear a knee brace after partial meniscectomy
62646335|NCT01530269|EXPERIMENTAL|PET/CT imaging with C11-Sodium Acetate|
62077161|NCT05969522|EXPERIMENTAL|Experimental group-Low and medium risk group|"Newly diagnosed children with AAGN admitted to our partners during the period of 2023.01.01 to 2023.12.31.~All children with AAGN were PARRG risk graded before treatment with RTX and CTX:~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
62077162|NCT05969522|EXPERIMENTAL|Experimental group-High risk group|"Newly diagnosed children with AAGN admitted to our partners during the period of 2023.01.01 to 2023.12.31.~All children with AAGN were PARRG risk graded before treatment with RTX and CTX:~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
62077163|NCT01597661||Malformed and population-based sample of non-malformed infants|Infants with any of a wide range of malformations are identified at tertiary care and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using approaches that include reviewing lists of discharge diagnoses available in medical records; contacting newborn nursery and/or labor and delivery rooms; reviewing admission/discharge lists; and reviewing clinic and surgical logs. A population-based random sample of non-malformed newborns in Massachusetts is also included. Information gathered on each subject includes name, address, telephone number, diagnostic information, and date of birth.
62077164|NCT03289390||Acetaminophen to close PDA|Infants with PDA treated with acetaminophen beyond 14 days of life or in whom acetaminophen is used due to contraindication to ibuprofen
62077165|NCT02610218||histo-HER2+ gastric cancer patients|Histologically HER2 positive gastric cancer patients treated with HER2 targeted therapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
62077166|NCT02610218||histo-HER2- gastric cancer patients|Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
62077167|NCT01887314|EXPERIMENTAL|Standardized Ginger extract soft gel capsules|Patients receive 2 soft gel capsules of Ginger extract, twice a day
62077168|NCT01887314|PLACEBO_COMPARATOR|Placebo soft gel capsules|Patients receive 2 soft gel capsules of Placebo, twice a day
62077169|NCT06119906|EXPERIMENTAL|Standard + Experimental Endoscopy|The endoscopist will intubate the patient with a high resolution white light endoscope (Olympus GIFH290Z or GIF-EZ1500) and thoroughly inspect the mucosal surface of the oesophagus. A careful note will be made of any visible lesion with their location, and the surrounding mucosa will be marked with cautery to localize the lesion for further hyperspectral imaging and biopsy. We will aim to identify at least two areas of interest per patient with the possibility to select more if the length of the Barrett's oesophagus allows. The endoscopist will remove the standard of care endoscope and then reintubate the patient with the experimental device and perform unbiased imaging first followed by targeted imaging of the endoscopic areas previously marked
62077170|NCT02916004|OTHER|Measurement of NFR and PDR|Diagnostic intervention: excite NFR and PDR in comparison to behavior pain scale (BPS)
62077171|NCT02500979|EXPERIMENTAL|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
62646336|NCT01768663|EXPERIMENTAL|Treatment Group (Cohort 1)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21.
62646337|NCT01768663|EXPERIMENTAL|Treatment Group (Cohort 2)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21.
62646338|NCT01768663|EXPERIMENTAL|Treatment Group (Cohort 3)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24.
62646339|NCT01768663|EXPERIMENTAL|Treatment Group (Cohort 4)|Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days.
62077172|NCT02500979|PLACEBO_COMPARATOR|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
62077173|NCT00993317|PLACEBO_COMPARATOR|Placebo of CDP870+MTX|
62077174|NCT00993317|EXPERIMENTAL|CDP870 200mg+MTX|
62646340|NCT00843492|ACTIVE_COMPARATOR|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
62646341|NCT00843492|EXPERIMENTAL|Fondaparinux|After randomization (Day 1), subjects will receive subcutaneously, once daily, fondaparinux 2.5 mg (1.5 mg in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
62646342|NCT00925717||2500 patients|Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.
62646343|NCT05273762|EXPERIMENTAL|FlowTriever|
62077175|NCT02569320|EXPERIMENTAL|Treatment (pomalidomide, dexamethasone, HDAC inhibitor AR-42)|Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO BIW or TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW for weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62077176|NCT03296618|EXPERIMENTAL|NSI-566 neural stem cell implantation|
62077177|NCT01419145|EXPERIMENTAL|Multimodal intervention|
62077178|NCT01419145|ACTIVE_COMPARATOR|Standard Care|
62077179|NCT05555862|EXPERIMENTAL|Artesunate suppositories|Four 5-day cycles of artesunate suppositories
62077180|NCT05555862|PLACEBO_COMPARATOR|Placebo suppositories|Four 5-day cycles of placebo suppositories
62077181|NCT03831828||Lymph node metastasis Positive|good prognosis; without Lymph node metastasis.
62077182|NCT03831828||Lymph node metastasis Negative|poor prognosis; with Lymph node metastasis.
62077183|NCT02091869|EXPERIMENTAL|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
62077184|NCT02091869|EXPERIMENTAL|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
62077185|NCT04797169|EXPERIMENTAL|Noom Health|
62077186|NCT04797169|ACTIVE_COMPARATOR|Noom Digital Health|
62077187|NCT02509351|EXPERIMENTAL|misoprostol|women receiving pre-operative rectally administered 400 microgram misoprostol
62077188|NCT02509351|ACTIVE_COMPARATOR|placeboo|women receiving placebo
62077189|NCT02774408|OTHER|CPAP|"Infants on CPAP will receive backup breafs whenever the SpO2 \<88 % along with~automated FiO2 controller. In the control period they will receive automated FiO2~alone"
62077190|NCT02774408|OTHER|NIMV/NIPPV|"Infants on NIMV NIPPV will receive an increase in the backup rate to 2 times the rate~of the backup triggered by apnoe (apnoe time 5s), whenever the SpO2 under 88%~( max rate 100/min) in the reference period as compared to baseline (automated FiO2~- control + unchanged SIPPV settings)"
62077191|NCT02210962|EXPERIMENTAL|essential fatty acids|The experimental treatment is a food supplement containing fish oil. The daily dose of 4 capsules provides 1320 mg of eicosapentaenoic acid and 880 mg of docosahexaenoic acid, 26 weeks intervention
62646344|NCT05588258|ACTIVE_COMPARATOR|Pharmacy cream 10% urea|Use of pharmacy cream in prevention
62646345|NCT05588258|ACTIVE_COMPARATOR|Supermarket cream 10% urea|Use of supermarket cream in prevention
62646346|NCT04500951|EXPERIMENTAL|Optimized resting environment|"The optimized resting environment will consist of the following complex intervention.~* Technically assisted noise control in regards of alarms in the patient room~* Visual signing reminding staff that the patient is not to be disturbed during rest~* Individual optimization of room environment according to information received from relatives~* Individual optimization of room environment and positioning according to systematized knowledge on best practice in the intervention ward including auditory and visual stimuli"
62646347|NCT04500951|OTHER|Standard resting environment|Standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward.
62077192|NCT02210962|PLACEBO_COMPARATOR|olive oil|Placebo capsules contain olive oil and trace amount of fish oil to assure comparable taste, 26 weeks intervention
62077193|NCT02488382|EXPERIMENTAL|Lonquek|treatment with Lonquek for autologous stem cell collection
62077194|NCT04276090|EXPERIMENTAL|Colorectal liver metastases|Patients with unresectable colorectal liver metastases will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (FOLFOX, FOLRIRI, or oxaliplatin/irinotecan, or panitumumab if KRAS/NRAS wild type)
62077195|NCT04276090|EXPERIMENTAL|Intrahepatic cholangiocarcinoma|Patients with unresectable intrahepatic cholangiocarcinoma will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (gemcitabine/oxaliplatin or gemcitabine alone)
62077196|NCT03472092|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
62077197|NCT03472092|PLACEBO_COMPARATOR|Placebo|The placebo pill will be administered once a day at home, to be taken by mouth.
62077198|NCT03472092|ACTIVE_COMPARATOR|Amitriptyline|Amitriptyline will be administered once a day at home, to be taken by mouth. Dosage will be weight-based.
62077199|NCT03472092|ACTIVE_COMPARATOR|Biofeedback-Assisted Relaxation Training (BART)|Biofeedback-Assisted Relaxation Training (BART) is a mind and body based intervention that focuses specifically on mind and body techniques such as deep breathing, muscle relaxation, and guided imagery skills to manage pain.
62280049|NCT00915200|EXPERIMENTAL|N-acetycysteine + silibin|N-acetylcysteine active + silibin active
62280050|NCT00915200|EXPERIMENTAL|N-acetylcysteine + high-dose silibin|N-acetylcysteine active + high-dose silibin active
62646348|NCT05319548|ACTIVE_COMPARATOR|Starting with Purple-Red Carrot Juice|Participants are randomized to consume purple-red carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple carrot juice.
62077200|NCT03472092|ACTIVE_COMPARATOR|Cognitive Retraining (CR)|Cognitive Retraining (CR) is a mind and body based intervention that focuses on the use of tests of evidence and other cognitive strategies such as positive coping statements and pleasant activities and mindfulness to manage pain.
62077201|NCT02221895|EXPERIMENTAL|Early Follow-up|Postpartum follow up appointment 2-3 weeks after delivery
62077202|NCT02221895|ACTIVE_COMPARATOR|Traditional Follow-up|Postpartum follow up 6-8wk after delivery (current clinical standard)
62077203|NCT06306560|EXPERIMENTAL|Immuno-cherapy for extensive small cell lung cancer|Adebrelimab in combination with famitinib and chemotherapy
62077204|NCT04762329|EXPERIMENTAL|Patient group using Manage My Pain (MMP) digital application for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits, on the Manage My Pain (MMP) digital application
62077205|NCT04762329|NO_INTERVENTION|Patient group using paper format for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits on paper format or phone interviews.
62077206|NCT02053194|EXPERIMENTAL|Pharmacist-led educational intervention|Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists. Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.
62077207|NCT02053194|NO_INTERVENTION|Control|Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.
62077208|NCT01244139|EXPERIMENTAL|Active study drug|Treatment
62077209|NCT01244139|EXPERIMENTAL|Comparator|Dummy drug
62077210|NCT01219621|ACTIVE_COMPARATOR|DDD Long AVD|
62077211|NCT01219621|EXPERIMENTAL|safeR|
62077212|NCT04732715|EXPERIMENTAL|CaRE Course|Black American caregivers of PLWD will participate in the CaRE Course.
62077213|NCT06245265|EXPERIMENTAL|Clinical Healthy|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the clinically healthy group.
62077214|NCT06245265|EXPERIMENTAL|Periodontitis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. ANGPTL-4 analysis will be performed by ELISA in saliva and serum of individuals. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
62077215|NCT06245265|EXPERIMENTAL|Periodontitis with rheumatoid arthritis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. ANGPTL-4 analysis will be performed by ELISA in saliva and serum of individuals. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontitis with rheumatoid arthritis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
62077216|NCT06245265|EXPERIMENTAL|Healthy individuals with RA|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum fluid will be taken from all individuals at the beginning of the study. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the healthy individuals with RA group.
62077217|NCT03989791|ACTIVE_COMPARATOR|Absolute diet|
62077218|NCT03989791|EXPERIMENTAL|Normal diet|
62077219|NCT05435235|EXPERIMENTAL|Dapagliflozin arm|Patients who received Dapagliflozin 10 mg daily starting 48h prior to PCI and continuing for 48h post-PCI.
62077220|NCT05435235|NO_INTERVENTION|Standard of care|Patients who received the standard of care.
62077221|NCT05652855|EXPERIMENTAL|MHB088C administered|MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W).
62077222|NCT05973084||Natural infection cohort|Up to 200 symptomatic subjects (index cases) will be enrolled when they seek diagnosis for their symptoms of COVID-19 and have their SARS-CoV-2 infection confirmed. All their household contacts (anticipated 700) aged 5-75 years who provide consent (participants) will be examined for infection through two consecutive SARS-CoV-2 RT-PCR. Blood will be drawn from all participants who provide consent. Venous Blood will be drawn at the first visit (so called W0). A second collection is planned for 15 days after the first visit, a third collection at three months after the first visit, and subsequent collections are planned at six, nine, and 15 months after the first visit. At the visits one month, nine months and 15 months after the first visit, capillary blood will be collected. A stool sample will be collected for diagnosis of intestinal parasites.
62077223|NCT05973084||Vaccine cohort|Up to 600 subjects 18-75 years will be recruited when they attend a vaccination clinic at one of the study health centers in Blantyre to receive their 1st dose of the AstraZeneca (AZ) or the Johnson and Johnson (JJ) COVID-19 vaccines. Venous blood will be collected at that time. For AZ vaccinees, at their 2nd vaccine dose, about 90 days after the 1st dose, they will be given a stool sample container. JJ vaccinees will receive the stool sample container when they receive the first vaccine dose. Two weeks after completion of the primary regimen (2nd dose of the AZ \[M3.5\] and 1st dose of the JJ vaccines \[M0.5\]), venous blood draws will be repeated and stool containers will be collected. Subsequent visits/procedures will happen at one month thereafter (M4.5 for AZ and M1.5 for JJ), and 3, 6, 9, and 12 months after the primary regimen. Venous blood will be collected at the visit 1.5, 3, 6, and 12 months after the primary regimen and capillary blood will be collected at the other visits.
62077224|NCT02310126|ACTIVE_COMPARATOR|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
62280051|NCT02864472|OTHER|combination Tx|combination Tx(vPDT +ranibizumab) (M0) + ranibizumab PRN (M3-6)
62077225|NCT02310126|ACTIVE_COMPARATOR|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
62077226|NCT01872780|ACTIVE_COMPARATOR|rosiglitazone|avandia
62077227|NCT01872780|ACTIVE_COMPARATOR|genetic polymorphism|avandia CYP2C8 genotype
62077228|NCT00287469|EXPERIMENTAL|20mcg Recombinant HEV|20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
62077229|NCT00287469|PLACEBO_COMPARATOR|Placebo|PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
62077230|NCT01779011||A cohort post amputation|Those patients undergoing either traumatic amputation or surgical amputation of limb
62077231|NCT01779011||A cohort post limb conserving surgery|Patients whose surgical management involved conservation of their injured limb
62077232|NCT00574990||VA Physicians|VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
62077233|NCT00574990||VA Nurses|VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
62077234|NCT00574990||VA Pharmacists|VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
62077235|NCT01173640|EXPERIMENTAL|Midazolam Alone|Baseline pharmacokinetics. On Study Visit Day 1, subjects will receive a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
62077236|NCT01173640|EXPERIMENTAL|Single dose resveratrol|On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
62077237|NCT01173640|EXPERIMENTAL|Multiple dose resveratrol|Between Study Visit Days 8 and 15, subjects will take a 1 g dose of resveratrol daily. On Study Visit Day 15, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
62646349|NCT05319548|ACTIVE_COMPARATOR|Starting with Purple Carrot Juice|Participants are randomized to consume purple carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple-red carrot juice.
62646350|NCT05319548|ACTIVE_COMPARATOR|Starting with Red Carrot Juice|Participants are randomized to consume red carrot juice first (250 mL) in under 2 minutes. They will crossover to purple-red carrot juice and to purple carrot juice.
62646351|NCT06132971|ACTIVE_COMPARATOR|NBP2|Participants were assigned to the 2-session New Beginnings Program intervention
62077238|NCT02456389|ACTIVE_COMPARATOR|Standard perioperative management|Standard postoperative care
62077239|NCT02456389|EXPERIMENTAL|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
62646352|NCT06132971|EXPERIMENTAL|NBP10|Participants were assigned to the 10-session New Beginnings Program
62646353|NCT02097732|ACTIVE_COMPARATOR|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
62077240|NCT05701722|NO_INTERVENTION|Routine Care|Women with recurrent BV who are randomly assigned to the Routine Care (control) arm will undergo assessments at baseline, 12 weeks, and 24 weeks. They will be treated with appropriate antibiotics or antifungals in case of BV or yeast infection, respectively, but otherwise will not receive any treatment. They may engage in any vulvovaginal hygiene of their choosing except for using products made by Good Clean Love.
62077241|NCT05701722|EXPERIMENTAL|Flourish HEC|Women with recurrent BV who are randomly assigned to the Flourish HEC (intervention) arm will undergo assessments at baseline, 12 weeks, and 24 weeks. They will receive routine care as needed (see Routine Care arm). In addition, they will use the Flourish HEC Vaginal Care System regularly for the 24-week duration of the study. Briefly, they will use Balance intimate wash daily with regular bathing; BioNourish vaginal moisturizing gel every other day; and BiopHresh homeopathic vaginal suppository with probiotics every 3rd day. They will use no other products (except menstrual hygiene products) in the vulvovaginal area during the study.
62077242|NCT02498730|ACTIVE_COMPARATOR|Interval Training|6 stimulous (30 s) at 100% VO2Max/ 1 min 30 s to rest, 19 minutes (total exercise), 3 times/ week, 12 weeks
62077243|NCT02498730|ACTIVE_COMPARATOR|Continuous Training|Running at 60% VO2Max, 25 minutes (total exercise), 3 times/week, 12 weeks
62077244|NCT02498730|SHAM_COMPARATOR|Control|Only Dependent Variables Measures
62077245|NCT01759680|EXPERIMENTAL|Whole Body Vibration Group|The whole body vibration group received 3 training sessions every week composed of 5 series of 15 seconds of vibrations at 30 Hz intensity.
62077246|NCT01759680|NO_INTERVENTION|Control Group|The control group had a normal daily life for the whole study period
62077247|NCT05231564|EXPERIMENTAL|Hybrid training|15 women for hybrid training.
62077248|NCT05231564|NO_INTERVENTION|Healthy lifestyle counseling|15 women for healthy lifestyle counseling
62077249|NCT05047796|EXPERIMENTAL|Intervention Protocol|Visceral osteopathic techniques
62077250|NCT05047796|SHAM_COMPARATOR|Sham Protocol|Simulated visceral osteopathic techniques
62280052|NCT02864472|OTHER|mono Tx|Ranibizumab (at 4 weeks interval) \*3 (M0-2) + ranibizumab PRN (M3-6)
62280053|NCT03737773|ACTIVE_COMPARATOR|group prisms|Patients that receive active prismatic lenses
62646354|NCT02097732|EXPERIMENTAL|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
62646355|NCT02343861|ACTIVE_COMPARATOR|Tailored leaflet group|Participants (parents of children with atopic dermatitis) receive a tailored leaflet about the detailed amount of emollients as well as general information about use of emollients.
62646356|NCT02343861|PLACEBO_COMPARATOR|Control group|Participants (parents of children with atopic dermatitis) receive general information about use of emollients only.
62280054|NCT03737773|PLACEBO_COMPARATOR|group placebo lenses|Patients that receive non-active prismatic lenses
62077251|NCT03753282||Population 1|Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
62077252|NCT03753282||Population 2|Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
62077253|NCT02465021|EXPERIMENTAL|Snack bar 1|Dietary intervention: 190 Kcal, 12g fat, 14g carbohydrate, 5g fibre, 6g sugar, 10g protein
62077254|NCT02465021|EXPERIMENTAL|Snack bar 2|Dietary intervention: 200 Kcal, 15g fat, 12g carbohydrate, 5g fibre, 4g sugar, 8g protein
62077255|NCT02465021|EXPERIMENTAL|Snack bar 3|Dietary intervention: 210 Kcal, 16g fat, 12g carbohydrate, 2g fibre, 6g sugar, 6g protein
62077256|NCT02465021|EXPERIMENTAL|Control 1|Dietary intervention: Water (500 g)
62077257|NCT02465021|EXPERIMENTAL|Control 2|Dietary intervention: White bread (190 Kcal, 2g fat, 37g carbohydrate, 2g fibre, 3g sugar, 6g protein)
62077258|NCT02465021|EXPERIMENTAL|Control 3|Dietary intervention: Soft baked pretzel (190 Kcal, 2g fat, 38g carbohydrate, 2g fibre, 6g sugar, 4g protein)
62077259|NCT03877705|EXPERIMENTAL|Dissolving xylitol chewable tablets|Listerine ready tabs 3 times/day
62077260|NCT03877705|ACTIVE_COMPARATOR|Xylitol chewing gum|Trident original 3 times/day
62077261|NCT03410238|EXPERIMENTAL|Treatment|Participants receive Saferteens Brief Intervention and a brochure containing psycho-education and resources.
62077262|NCT03410238|NO_INTERVENTION|Control|Participants receive a brochure containing psycho-education and resources only.
62077263|NCT00493337|NO_INTERVENTION|Control group|
62077264|NCT00493337|EXPERIMENTAL|Advanced counseling|
62077265|NCT00493337|ACTIVE_COMPARATOR|Compliance Card only|
62077266|NCT02320786|EXPERIMENTAL|CoPILOT|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (one hour, four times per week for three weeks).
62077267|NCT02320786|NO_INTERVENTION|Standard of Care|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair, consisting of 12 hour protocols in a standard power wheelchair (one hour, four times per week for three weeks).
62077268|NCT05104918|EXPERIMENTAL|Vorscot Arm|Vortioxetine 10 mg
62077269|NCT05104918|ACTIVE_COMPARATOR|Vanlafexine Arm|Venlafaxine 75 mg
62646357|NCT04830735|EXPERIMENTAL|Arm I (dasatinib anhydrous)|Patients receive dasatinib anhydrous PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
62646358|NCT04830735|PLACEBO_COMPARATOR|Arm II (placebo administration)|Patients receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
62077270|NCT03668730|EXPERIMENTAL|Reduced dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome, Cisplatin and 5-Fluorouracil, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive cisplatin once per three week for 3 cycles.
62077271|NCT03668730|EXPERIMENTAL|Standard dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome,Cisplatin and 5-Fluorouracil, patients undergo standard-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cisplatin once per three week for 3 cycles.
62646359|NCT00318695|EXPERIMENTAL|Probiotics|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
62646360|NCT00318695|PLACEBO_COMPARATOR|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
62077272|NCT04199715|EXPERIMENTAL|Heplisav-B Vaccine Recipient|There will be a single group of 18 immune compromised patients who will receive the Heplisav-B vaccine.
62077273|NCT05683522|EXPERIMENTAL|Sub-omohyoidal Plane Block|Patients randomized to receive sub-omohyoid plane block.
62077274|NCT05683522|EXPERIMENTAL|Costoclavicular Block plus Cervical Plexus Block|Patients randomized to receive costoclavicular brachial and cervical plexus block.
62077275|NCT02044419|EXPERIMENTAL|lomitapide sprinkled in applesauce|Contents of single 20 mg capsule of lomitapide sprinkled in applesauce
62077276|NCT02044419|EXPERIMENTAL|lomitapide sprinkled in mashed banana|Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana
62077277|NCT02044419|EXPERIMENTAL|lomitapide (intact)|Intact capsule of 20 mg lomitapide
62077278|NCT06100380||patients with Thromboembolic event and Hemorrhage group|patients who present a hemorrhage or a thromboembolic event
62077279|NCT06100380||patients without Thromboembolic event and Hemorrhage|patients who don't present a hemorrhage or a thromboembolic event
62077280|NCT04625647|EXPERIMENTAL|Treatment (AMG 510)|Patients receive AMG 510 PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62077281|NCT05706181|EXPERIMENTAL|Home-based heat therapy and functional capacity in older adults|The investigators will determine the extent to which home-based leg heat therapy improves functional capacity in older adults. Functional capacity will be assessed before and after heat therapy or sham intervention via the 6-min walk test and the Short Physical Performance Battery.
62077282|NCT05706181|EXPERIMENTAL|Home-based heat therapy and vascular function and exercise hyperemia in older adults|The investigators will determine if home-based leg heat therapy improves vascular function and exercise hyperemia in the older adults of Aim 1. Using state-of-the-art techniques of skeletal muscle microdialysis and high-resolution duplex ultrasound, the investigators will pharmacodissect mechanisms of vascular function and exercise hyperemia before and after each intervention. The outcomes of Aim 2, while providing insight into the mechanisms whereby heat therapy improves functional capacity, should be considered independent of the outcomes of Aim 1 given that vascular health is a key independent, yet modifiable risk factor for cardiovascular morbidity and mortality.
62646361|NCT00937534|ACTIVE_COMPARATOR|Part A|Young male healthy volunteer
62646362|NCT00937534|ACTIVE_COMPARATOR|Part B|Elderly male healthy volunteer
62646363|NCT01201330||ONJ sufferers|history of jaw osteonecrosis
62646364|NCT01201330||Bisphosphonate exposure|patients with exposure to bisphosphonates
62646365|NCT03694379|EXPERIMENTAL|Apneic Oxygenation|Participants receiving apneic oxygenation
62646366|NCT03694379|NO_INTERVENTION|No Apneic Oxygenation|Participants not receiving apneic oxygenation
62077283|NCT05342116|NO_INTERVENTION|Fasting Arm|Patient will fast at least 6 hours prior to endoscopy
62077284|NCT05342116|ACTIVE_COMPARATOR|Water Arm|Patient will drink 400 ml of water 2 to 4 hours prior to endoscopy
62077285|NCT05342116|EXPERIMENTAL|CHO Arm|Patient will drink 400 ml of Preload 2 to 4 hours prior to endoscopy
62077286|NCT02441920||Patients with rheumatoid arthritis|The inception cohort of 400 patients will be followed up for 20 years following recruitment.
62077287|NCT01467258|EXPERIMENTAL|Amantadine|Single dose
62077288|NCT00719602|ACTIVE_COMPARATOR|1|Previously received single-dose nevirapine (SD NVP); assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
62077289|NCT00719602|ACTIVE_COMPARATOR|2|Have not previously received SD NVP; assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
62077290|NCT02220335|EXPERIMENTAL|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
62077291|NCT02220335|ACTIVE_COMPARATOR|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.
62077292|NCT04610151|EXPERIMENTAL|Guided Imagery|Guided Imagery Intervention:The pretest data of the patients with a pain score of 4 or higher according to VAS were collected. Afterwards, the experiment group patients were applied guided imagery.
62077293|NCT04610151|NO_INTERVENTION|No-Reflexology Application , control group.|No intervention was applied on the control group patients.
62077294|NCT05859711|EXPERIMENTAL|thyme honey|oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
62077295|NCT05859711|ACTIVE_COMPARATOR|Saline|oral rinses with saline 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy.
62077296|NCT03318211|ACTIVE_COMPARATOR|MgSO4 discontinuation|after delivery , no Extradoses of MgSO4 were given
62077297|NCT03318211|ACTIVE_COMPARATOR|MgSO4 continuation|After delivery , Mg Sop4 was given at a rate of 1 gram /hour for 24 hours after delivery
62077298|NCT02241720|EXPERIMENTAL|Regorafenib treatment|
62077299|NCT03615209|ACTIVE_COMPARATOR|Transauricular vagus nerve stimulation|Non invasive vagus nerve stimulation will be conducted with Cerbomed NEMOS via the left ear.
62077300|NCT03615209|SHAM_COMPARATOR|Transauricular sham stimulation|Non invasive sham stimulation will be conducted with Cerbomed NEMOS via the left ear lobe.
62077301|NCT05372679|EXPERIMENTAL|Renal denervation|Denervating the sympathetic nerves surrounding the renal vasculature using unfocused ultrasound
62077302|NCT02705040||Normal|bone mineral density T\>=-1.0
62077303|NCT02705040||Osteopenia|bone mineral density -1.0\>T\>=-2.5
62077304|NCT02705040||Osteoporosis|bone mineral density T\<-2.5
62077305|NCT02774265|ACTIVE_COMPARATOR|VTE prophylaxis with Enoxaparin 30mg BID|The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
62077306|NCT02774265|ACTIVE_COMPARATOR|VTE prophylaxis with Aspirin 81mg BID|The group receiving VTE prophylaxis with ASA 81mg PO BID
62077307|NCT04543370|EXPERIMENTAL|Treatment A|2 mg midazolam on Day 1 and 36 mg deflazacort on Day 2.
62077308|NCT04543370|EXPERIMENTAL|Treatment B|2000 mg edasalonexent TID on Day 1 to Day 11 with 2 mg midazolam on Day 10 and with 36 mg deflazacort on Day 11.
62077309|NCT00861796|EXPERIMENTAL|1|
62646367|NCT02988661|ACTIVE_COMPARATOR|Chronic Disease Self-management Program (CDSMP)|A random sample of African American women with SLE selected from the Georgians Organized Against Lupus (GOAL) parent cohort will be used to recruit participants into the CDSMP. This group will be identified as the WELL Cohort.
62646368|NCT02988661|NO_INTERVENTION|Usual Care|African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.
62077310|NCT00861796|PLACEBO_COMPARATOR|2|
62077311|NCT06189430|EXPERIMENTAL|Yoga Group|Individuals in the yoga group of the study had 10 minutes of meditation, 10 minutes of warm-up, and 40 minutes of vinyasa yoga practice, 2 days a week face-to-face and 1 day online, for a total of 12 weeks.Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation.
62077312|NCT06189430|ACTIVE_COMPARATOR|Control Group|In order to better understand the effectiveness of Vinyasa yoga, individuals in the control group will perform moderate-intensity standard exercise (50-70% MHR: maximum pulse rate) for the same duration and at the same hours.
62077313|NCT02874664|EXPERIMENTAL|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine intravenously on Day 1 of every 6-week treatment cycle for 2 cycles omitting every third cycle
62077314|NCT05276323|EXPERIMENTAL|Medihoney Derma Cream|Intervention group: Medihoney Derma Cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
62646369|NCT04976127|EXPERIMENTAL|Talineuren dose escalation|14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).
62077315|NCT05276323|ACTIVE_COMPARATOR|Hydrocortisone 1% cream|control group: Hydrocortisone 1% cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
62077316|NCT05189509|EXPERIMENTAL|TNK group|intravenous thrombolysis with 0.25 mg/kg TNK, with the biggest dose of 25 mg
62077317|NCT05189509|PLACEBO_COMPARATOR|control group|
62077318|NCT04800757|EXPERIMENTAL|individual (Brief Motivational Intervention)|
62077319|NCT04800757|EXPERIMENTAL|Group (Group Problem Solving)|
62077320|NCT04800757|PLACEBO_COMPARATOR|Standard of Care|
62077321|NCT03137602|OTHER|ATOMIC mobile app|The proposed ATOMIC intervention consists of four primary components: (a) one-on-one chats with a PA coach, (b) informational posts, (c) PA self-monitoring through an activity tracker and (d) educational modules regarding different aspects of becoming PA delivered through our MS specific PA app.
62077322|NCT00573950|EXPERIMENTAL|Cilostazol|cilostazol group
62077323|NCT00573950|PLACEBO_COMPARATOR|Placebo|placebo group
62646370|NCT04976127|EXPERIMENTAL|Talineuren repeated dose|8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose). Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).
62646371|NCT04976127|EXPERIMENTAL|Talineuren dose consolidation with intrapatient dosing|8 months repeated doses of 720mg GM1 Ganglioside (Amendment 3).
62646372|NCT05363202|EXPERIMENTAL|Fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd.)|
62646373|NCT05363202|ACTIVE_COMPARATOR|FLOVENT HFA|
62077324|NCT03881059|PLACEBO_COMPARATOR|Part A: Placebo|
62077325|NCT03881059|EXPERIMENTAL|Part A: BMS-986165 Dose A|
62077326|NCT03881059|EXPERIMENTAL|Part A: BMS-986165 Dose B|
62646374|NCT05363202|PLACEBO_COMPARATOR|Placebo of Fluticasone propionate inhalation aerosol 44 mcg|
62077327|NCT03881059|EXPERIMENTAL|Part B: Ustekinumab + BMS-986165 Placebo|
62077328|NCT03881059|EXPERIMENTAL|Part B: BMS-986165 Dose A + Ustekinumab Placebo|
62077329|NCT03881059|EXPERIMENTAL|Part B: BMS-986165 Dose B + Ustekinumab Placebo|
62077330|NCT00451217|EXPERIMENTAL|Rocuronium + Sugammadex|After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
62077331|NCT00451217|ACTIVE_COMPARATOR|Rocuronium + Neostigmine|After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
62077332|NCT00451217|EXPERIMENTAL|Vecuronium + Sugammadex|After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
62077333|NCT00451217|ACTIVE_COMPARATOR|Vecuronium + Neostigmine|After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
62077334|NCT05299879||Symptomatic patients with HFrEF corresponding to NYHA II-III|
62077335|NCT01845948|PLACEBO_COMPARATOR|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
62077336|NCT01845948|EXPERIMENTAL|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
62077337|NCT05716737|EXPERIMENTAL|TMJ RT|Patients receiving irradiation to the TMJ
62077338|NCT00664664|EXPERIMENTAL|1|APD125 20 mg
62077339|NCT00664664|EXPERIMENTAL|2|APD125 40 mg
62077340|NCT00664664|PLACEBO_COMPARATOR|3|Matching Placebo
62077341|NCT04827290|EXPERIMENTAL|Normal-protein and low-AGE through raw or rare proteins diet|Normal-protein (0,8g/kg/day) and low-AGE through raw or rare proteins diet during 24 months
62077342|NCT04827290|ACTIVE_COMPARATOR|Normal-protein and AGE-rich diet|Normal-protein (0,8g/kg/day) and high-AGE through overcooked proteins diet during 24 months
62280055|NCT02417389|EXPERIMENTAL|cinacalcet|Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate
62280056|NCT05604599|ACTIVE_COMPARATOR|Intranasal dexmedetomidine group|30 patients will receive 1µg/kg dexmedetomidine diluted in 10ml 0.9% saline intranasally preoperative administered to each naris as drops 45 -60 min before the operation +infusion saline.
62646375|NCT01474486|EXPERIMENTAL|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
62646376|NCT06399601|EXPERIMENTAL|Intervention group|wo identical didactic courses on drug allergy will be delivered. Changes in knowledge and clinical practice will be measured by serial practice questionnaires and knowledge quizzes conducted before and after the course. Group 1 will undergo the course first.
62646377|NCT06399601|ACTIVE_COMPARATOR|Control group|Group 2 will undergo an identical course one month later. By comparing any changes in knowledge or practice between groups, this ensures that any changes in knowledge or practice were solely due to the course and not other external factors.
62646378|NCT04775030|EXPERIMENTAL|CBD occlusal appliance|CBD occlusal appliance
62077343|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:~* An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;~* No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and~* Normal and stable allograft function at screening visit defined as-~  * For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)~ * For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) \> 45 ml/min/1.73 m\^2."
62646379|NCT04775030|PLACEBO_COMPARATOR|occlusal appliance|Traditional material occlusal appliance
62077344|NCT02755454|OTHER|open label|Perfusion CT Imaging
62077345|NCT04025203|EXPERIMENTAL|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
62077346|NCT04025203|ACTIVE_COMPARATOR|Ibuprofen arginine|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
62646380|NCT04722562|EXPERIMENTAL|Child Pugh A|Participants with mild hepatic impairment
62646381|NCT04722562|EXPERIMENTAL|Child Pugh B|Participants with moderate hepatic impairment
62646382|NCT04722562|EXPERIMENTAL|Healthy participants|Participants with normal hepatic function
62646383|NCT00686972|EXPERIMENTAL|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
62646384|NCT01387269|EXPERIMENTAL|100 mg QD|Anamorelin HCL 100 mg will be administered daily
62646385|NCT01387269|PLACEBO_COMPARATOR|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
62077347|NCT04025203|ACTIVE_COMPARATOR|Gabapentin|Oral capsule pharmaceutical treatment. Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
62646386|NCT05139342|ACTIVE_COMPARATOR|PD patients|patients diagnosed with PD will be allocated to this arm
62646387|NCT05139342|ACTIVE_COMPARATOR|MSA patients|patients diagnosed with MSAwill be allocated to this arm
62646388|NCT05139342|ACTIVE_COMPARATOR|4RT patients|patients diagnosed with 4RT will be allocated to this arm
62646389|NCT04350593|ACTIVE_COMPARATOR|Dapagliflozin 10mg|Dapagliflozin 10 mg daily
62646390|NCT04350593|PLACEBO_COMPARATOR|Placebo|Dapagliflozin matching placebo 10 mg daily
62646391|NCT02618746|EXPERIMENTAL|Group A, Telerehabilitation|The 12-month home care/rehabilitative program will include the following components: a) individualized action plan; b) educational session on self management; c) physical exercise sessions to remote monitoring; d) access to the call centre; e) professional weekly calls by physiotherapists, dietician and physician with remote connection as a response to possible incidents; f) remote monitoring selectively and temporarily.
62077348|NCT04025203|NO_INTERVENTION|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
62646392|NCT02618746|ACTIVE_COMPARATOR|Group B, Hospital based Rehabilitation|Patients assigned to the hospital based program will visit the hospital twice weekly for 12 months in order to participate in a multidisciplinary rehabilitation program including exercise, physiotherapy dietary and psychological advice by the staff of the rehabilitation centre based at the University clinic.
62077349|NCT06092541|EXPERIMENTAL|Intervention group: pericervical anesthesia|Intervention group: pericervical anesthesia
62077350|NCT06092541|ACTIVE_COMPARATOR|Control group: nitrous oxide anesthesia|Control group: nitrous oxide anesthesia
62077351|NCT03922802|EXPERIMENTAL|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|"May receive up to 45 minutes of AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.~Intervention: Device: AIH prior to Noninvasive spinal stimulation during gait training"
62077352|NCT03922802|SHAM_COMPARATOR|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
62077353|NCT03922802|SHAM_COMPARATOR|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with sham transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
62077354|NCT02926508|EXPERIMENTAL|Prebiotic (Bimuno)|Bimuno (B-GOS, Galacto-oligosaccharides, produced and provided by Clasado BioSciences Ltd)
62077355|NCT02926508|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62077356|NCT01515345|ACTIVE_COMPARATOR|standard therapy|standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
62077357|NCT01515345|EXPERIMENTAL|individualized therapy|dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer
62077358|NCT06321250|EXPERIMENTAL|Dose Escalation|Subjects will be assigned to pre-specified dose level to determine MTD/MAD of JMKX003948. Each treatment cycle will be 21 days.
62077359|NCT06321250|EXPERIMENTAL|Dose Expansion|Subjects will be assigned to the recommended dose level determined in dose escalation Phase. Each treatment cycle will be 21 days.
62077360|NCT03147066|EXPERIMENTAL|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
62077361|NCT03147066|ACTIVE_COMPARATOR|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
62077362|NCT01839357|EXPERIMENTAL|Rivaroxaban|
62077363|NCT03241264|EXPERIMENTAL|Module A|Lyophilized Formulation
62077364|NCT03241264|EXPERIMENTAL|Module B|Frozen Formulation
62077365|NCT03953144|EXPERIMENTAL|Synapse 3D Lung Modelling + IC-GREEN Segmentectomy|Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Synapse 3D to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus
62646393|NCT02618746|NO_INTERVENTION|Group C, Usual care Group|The control group will follow the usual care not involving the initial 8-week rehabilitation program neither maintenance hospital rehabilitation sessions or home telemonitoring of vital signs.
62077366|NCT04221815|ACTIVE_COMPARATOR|IVUS guided PCI|Patients will receive a pre-PCI IVUS, IVUS guided stent sizing and optimization per study protocol, post-PCI IVUS
62077367|NCT04221815|PLACEBO_COMPARATOR|Angiographic-guided PCI|Patients will receive angiography guided PCI and angiographic optimization per local standard practice, as well as a post-PCI IVUS blinded to the investigator
62646394|NCT06550726|EXPERIMENTAL|Study subjects|Study subjects will be recruited for scanning in a 3T MRI scanner with dedicated high-resolution MRI sequences as stated in our research protocol.
62646395|NCT02766543|EXPERIMENTAL|MRI-guided Transurethral Ultrasound Ablation Device|Magnetic resonance imaging-guided transurethral ultrasound ablation of whole-gland prostate tissue.
62646396|NCT02078817|EXPERIMENTAL|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
62646397|NCT01919931||Candida Infection|Patients infected with Candida albicans
62646398|NCT01919931||No infection|Patients with no Candida albicans infection
62280057|NCT05604599|ACTIVE_COMPARATOR|Intravenous dexmedetomidine group|30 patients will receive a dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia + intranasal saline.
62646399|NCT03180710|EXPERIMENTAL|BioChaperone® Combo 75/25 at 0.6 U/kg|Single subcutaneous injection of 0.6 U/kg
62646400|NCT03180710|EXPERIMENTAL|BioChaperone® Combo 75/25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
62646401|NCT03180710|EXPERIMENTAL|BioChaperone® Combo 75/25 at 1.0 U/kg|Single subcutaneous dose of 1.0 U/kg
62646402|NCT03180710|ACTIVE_COMPARATOR|Humalog® Mix25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
62646403|NCT01685879|EXPERIMENTAL|High Amylose Rice 1|Test rice with high dietary fiber content
62646404|NCT01685879|EXPERIMENTAL|High Amylose Rice 2|Test rice with high dietary fiber content
62646405|NCT01685879|PLACEBO_COMPARATOR|Control Rice|Rice portion that contains 50 g carbohydrate.
62646406|NCT01685879|PLACEBO_COMPARATOR|Glucose beverage|Glucose beverage with 50 g carbohydrate
62646407|NCT05578339|OTHER|Capsular bag size|"Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).~We will perform a multiple linear regression analysis (that allows determination of the overall fit (variance explained) of the model and the relative contribution of each of the predictors to the total variance explaine) between the independent and the dependent variable."
62646408|NCT03186313|EXPERIMENTAL|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
62646409|NCT03186313|ACTIVE_COMPARATOR|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
62077368|NCT06022718|EXPERIMENTAL|Kinesio-taping Group|Kinesio® Tex GoldFP (USA) was applied on both feet in the prone position with the knee extended, and the feet in a slightly plantar flexed position and hanging off the bed. The first Kinesio-taping was cut as an I shape and prepared for the transverse arch ligament correction technique. The non-stretched starting anchor was attached to the dorsum of the 5th metatars on the lateral side of the foot, passed from the plantar surface to the medial side with 75-100% tension. The non-stretched end was attached to the medial side of the ankle over the navicular region. The non-stretched initial anchor of the second Kinesio-taping strip starting from the proximal dorsal of the 5th. metatarsal on the lateral side of the foot.
62646410|NCT03186313|EXPERIMENTAL|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
62646411|NCT03186313|ACTIVE_COMPARATOR|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks.
62646412|NCT05525260|ACTIVE_COMPARATOR|Limonene capsules(marketed product in China)|Limonene capsules(marketed product in China) donate by pharmaceutical company.
62646413|NCT05525260|PLACEBO_COMPARATOR|Limonene capsules(Placebo)|Same smell, color and shape as limonene capsules(marketed product in China), without limonene in capsules.
62280058|NCT04314960|EXPERIMENTAL|CAI subjects|Subjects in this group will receive eight 20-minutes gait training sessions with functional electrical stimulation.
62646414|NCT00695227|EXPERIMENTAL|Screening for Barrett's Esophagus|
62646415|NCT05678361|EXPERIMENTAL|Sleep after exposure|Participants take a nap during 90 min following three exposure (WET) sessions.
62646416|NCT05678361|NO_INTERVENTION|Wake after exposure|Participants watch a 90 min documentary following three exposure (WET) sessions.
62077369|NCT06022718|EXPERIMENTAL|Rigid-taping Group|Low dye bandage technique was used with a 3.8 cm wide rigid band (Leuko® Sportstape Premium, Germany) for rigid taping. Rigid taping was performed on both feet in the subtalar neutral position while participants in the prone position with their heels and feet out of the bed. The taping protocol described elsewhere was followed. 21 To optimise rigid tape adhesion, feet were washed and dried before taping. To increase consistency, the same researcher (MU) applied all taping.
62077370|NCT05324501|EXPERIMENTAL|Cohort A: MTX-110|Weekly dosing of MTX110 via CED until progression/ unacceptable toxicity.
62077371|NCT05324501|EXPERIMENTAL|Cohort B: MTX-110 with optional catheter repositioning|Weekly dosing of MTX110 via CED until progression. At progression, optional catheter repositioning may occur, followed by continued weekly dosing of MTX110 until next progression/ unacceptable toxicity.
62646417|NCT06098989|ACTIVE_COMPARATOR|Normal voltage in LA posterior wall - PVI alone|Patients with normal LA posterior wall will be assigned directly to arm 1, receiving PVI alone.
62646418|NCT06098989|ACTIVE_COMPARATOR|Low voltage in LA posterior wall - PVI alone|Patients with low voltage/scar on the LA posterior wall will be randomized to arm 2, receiving PVI alone.
62646419|NCT06098989|ACTIVE_COMPARATOR|Low voltage in LA posterior wall - PVI + PWI|Patients with low voltage/scar on the LA posterior wall will be randomized to arm 3, receiving PVI + PWI.
62456968|NCT02305966|ACTIVE_COMPARATOR|cemented humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component. Therefore, 4 randomization groups will be created and one of them is cemented humerus \& non-lateralized glenoid
62456969|NCT02305966|ACTIVE_COMPARATOR|cemented humerus & lateralized glenoid.|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is cemented humerus \& lateralized glenoid.
62077372|NCT01945567|EXPERIMENTAL|Dorsal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
62077373|NCT01945567|EXPERIMENTAL|Caudal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
62077374|NCT01945567|EXPERIMENTAL|Empirical deep brain stimulation|Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.
62077375|NCT03047174|EXPERIMENTAL|Arm A: Treatment with Mepitel® Film|"Arm A:~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
62077376|NCT03047174|ACTIVE_COMPARATOR|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
62077377|NCT04444375||obese, non-obese|obese and non-obese diabetic patients
62077378|NCT01055093||Diabetes Cohort|Prospectively followed cohort of newly diagnosed patients with diabetes mellitus, aged 18-69 years at inclusion into the study
62077379|NCT01055093||Control Cohort|Prospectively followed cohort of glucose tolerant humans, aged 18-69 years at inclusion into the study
62077380|NCT01776684|EXPERIMENTAL|EGFR positive arm|Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
62077381|NCT02796781|EXPERIMENTAL|lung stem cells|Patients will receive 0.5-5x10\^6 (0.5-5 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
62077382|NCT05909319||ACLF|
62077383|NCT03760822|EXPERIMENTAL|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
62077384|NCT03760822|ACTIVE_COMPARATOR|Ramucirumab + Paclitaxel|IV ramucirumab at 8 mg/kg on D1 and D15 IV paclitaxel at 80 mg/m² on D1, D8 and D15
62077385|NCT05895058|EXPERIMENTAL|2D 4K laparoscopic imaging system|Performing gastric bypass surgery intervention using a 2D 4K laparoscopic imaging system.
62077386|NCT05895058|ACTIVE_COMPARATOR|3D HD laparoscopic imaging system|Performing gastric bypass surgery intervention using a 3D HD laparoscopic imaging system.
62077387|NCT03100565|PLACEBO_COMPARATOR|colposcopic biopsy under local anesthetic sp|
62077388|NCT03100565|PLACEBO_COMPARATOR|Patients underwent colposcopic biopsy under forced coughing|
62077389|NCT03657381|EXPERIMENTAL|F520 0.2mg/kg single-dose|F520 0.2mg/kg single-dose
62077390|NCT03657381|EXPERIMENTAL|F520 1.0mg/kg single-dose|F520 1.0mg/kg single-dose
62077391|NCT03657381|EXPERIMENTAL|F520 3.0mg/kg single-dose|F520 3.0mg/kg single-dose
62077392|NCT03657381|EXPERIMENTAL|F520 200mg/times single-dose|F520 200mg/times single-dose
62077393|NCT03657381|EXPERIMENTAL|F520 10mg/kg single-dose|F520 10mg/kg single-dose
62077394|NCT03657381|EXPERIMENTAL|F520 1mg/kg multiple dosing, every 2 weeks|F520 1mg/kg every 2 weeks
62077395|NCT03657381|EXPERIMENTAL|F520 3mg/kg multiple dosing, every 2 weeks|F520 3mg/kg every 2 weeks
62077396|NCT03657381|EXPERIMENTAL|F520 200mg/times multiple dosing, every 2 weeks|F520 200mg/times every 2 weeks
62077397|NCT03657381|EXPERIMENTAL|F520 10mg/kg multiple dosing, every 2 weeks|F520 10mg/kg every 2 weeks
62077398|NCT03657381|EXPERIMENTAL|F520 3mg/kg multiple dosing, every 3 weeks|F520 3mg/kg every 3 weeks
62077399|NCT03657381|EXPERIMENTAL|F520 200mg/times multiple dosing, every 3 weeks|F520 200mg/times every 3 weeks
62077400|NCT04537897|EXPERIMENTAL|BI 474121 2.5mg (Part A)|"Young participants administered 1 tablet of 2.5 milligrams (mg) BI 474121 orally once daily over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily."
62077401|NCT04537897|EXPERIMENTAL|BI 474121 5mg (Part A)|Young participants administered 2 tablets of 2.5 mg BI 474121 orally once daily (daily dose: 5 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.
62077402|NCT04537897|EXPERIMENTAL|BI 474121 10mg (Part A)|"Young participants administered 1 tablet of 10 milligrams (mg) BI 474121 orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h)."
62077403|NCT04537897|EXPERIMENTAL|BI 474121 20mg (Part A)|"Young participants administered 2 tablets of 10 milligrams (mg) BI 474121 orally once daily (daily dose: 20 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h)."
62280059|NCT02721537|ACTIVE_COMPARATOR|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
62280060|NCT02721537|PLACEBO_COMPARATOR|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
62077404|NCT04537897|EXPERIMENTAL|BI 474121 30mg (Part A)|"Young participants administered 3 tablets of 10 milligrams (mg) BI 474121 orally once daily (daily dose: 30 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h)."
62077405|NCT04537897|PLACEBO_COMPARATOR|Placebo (Part A)|"Young participants administered matching placebo to part A once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) for placebo participants matched to 2.5mg BI, 10mg BI, 20mg BI, and 30mg BI groups."
62077406|NCT04537897|PLACEBO_COMPARATOR|Placebo (Part B)|Elderly participants administered matching placebo to part B once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days
62077407|NCT04537897|EXPERIMENTAL|BI 474121 5mg (Part B)|Elderly participants administered 2 tablets of 2.5 mg BI 474121 orally once daily (daily dose: 5 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.
62077408|NCT04537897|EXPERIMENTAL|BI 474121 10mg (Part B)|Elderly participants administered 1 tablet of 10 milligrams (mg) BI 474121 orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.
62077409|NCT02843880||Septic shock patients|Septic shock patients staying over 3 days mechanically ventilated in the ICU
62077410|NCT03406793|EXPERIMENTAL|1. Standard MNP|
62077411|NCT03406793|EXPERIMENTAL|2. High zinc, low iron MNP|
62077412|NCT03406793|EXPERIMENTAL|3. High zinc, low/no iron|
62077413|NCT03406793|ACTIVE_COMPARATOR|4. Dispersible zinc supplement|
62077414|NCT03406793|EXPERIMENTAL|5. Intermittent zinc supplement|
62077415|NCT03406793|PLACEBO_COMPARATOR|6. Placebo powder|
62077416|NCT05155592|EXPERIMENTAL|Patients with inactive uveitis|Patients with non-infectious uveitis whose inflammation reached remission for at least six months after treatment with Adalimumab
62077417|NCT03826134|EXPERIMENTAL|[11C]-PXT012253|
62077418|NCT06524245||CRC Patients - Curative Surgery|This cohort includes patients diagnosed with stage I-IV colorectal cancer (CRC) who have undergone curative surgery. Inclusion criteria: patients aged 18 years or older, histologically confirmed CRC, no prior history of malignancy, availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood), and primary tumor tissue samples. Patients must not have received neoadjuvant therapy before surgery and must have complete follow-up data. Exclusion criteria: prior history of other malignancies, incomplete clinical information or pathology reports, and incomplete follow-up records. The study aims to identify specific biomarkers associated with CRC recurrence and metastasis through comprehensive multi-omics sequencing and develop predictive models for CRC recurrence and metastasis.
62077419|NCT04210193|ACTIVE_COMPARATOR|Active booster|After three basic open label grass allergen ILIT injections the patient is randomized to an active ILIT booster 1 year after the first treatment.
62077420|NCT04210193|PLACEBO_COMPARATOR|Placebo booster|After three basic open label grass allergen ILIT injections the patient is randomized to a placebo ILIT booster 1 year after the first treatment.
62077421|NCT02032173|EXPERIMENTAL|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
62456970|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
62456971|NCT04010799|EXPERIMENTAL|CHF6333|"CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).~CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days."
62077422|NCT03820791|EXPERIMENTAL|Poster|A poster with pictorial information about dysphagia-specific food procedures placed in patients' rooms for one month
62077423|NCT03820791|NO_INTERVENTION|No poster|No poster is placed in patients' room.
62077424|NCT03656484|ACTIVE_COMPARATOR|Tetracycline-Metronidazole (TM) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.
62077425|NCT03656484|EXPERIMENTAL|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.
62077426|NCT04418414|EXPERIMENTAL|Autologous HSCT CD68-ET3-LV gene therapy|G-CSF/Plerixafor mobilization and apheresis will be used for collection of hematopoietic stem cells and subjects will receive transplantation of autologous CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector encoding the human factor VIII gene.
62077427|NCT01680458||fluconazole|Infant Subjects who are treated with fluconazole
62077428|NCT00896129||Study population|
62077429|NCT05532020|EXPERIMENTAL|Open-label DCCR|75 - 525 mg DCCR
62077430|NCT05778331||Group A : POSEIDON group 3|"1. Age : \< 35~2. AFC: \< 5~3. AMH : \< 1.2~4. Planning for IVF"
62077431|NCT05778331||Group B: POSEIDON group 4|"1. Age : ≥ 35 years old~2. AFC : \< 5~3. AMH : \< 1.2~4. Planning for IVF"
62077432|NCT00183443|PLACEBO_COMPARATOR|DVP + placebo|Participants will receive divalproex ER at a therapeutic dose, plus placebo
62646420|NCT04511325|OTHER|Potato Regimen Arm|All participants will be randomly assigned to receive the potato regimen daily for the 12-week treatment period, separated by a 2-week washout.The potato regimen (75 grams of baked white russet potato with the skin) and refined grain (100 grams of long grain white rice) regimen will be matched for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day.
62077433|NCT00183443|ACTIVE_COMPARATOR|DVP + Quetiapine|Participants will receive divalproex ER at a therapeutic dose, plus quetiapine up to 800 mg
62077434|NCT00183443|ACTIVE_COMPARATOR|DVP + Lithium|Participants will receive divalproex ER at a therapeutic dose, plus lithium at a therapeutic blood level
62077435|NCT03246425|ACTIVE_COMPARATOR|1. Volume control- Pressure control- APRV- VPA group|
62077436|NCT03246425|ACTIVE_COMPARATOR|2. Pressure control- APRV- Volume control- PAV group|
62077437|NCT03246425|ACTIVE_COMPARATOR|3. APRV- Volume control- pressure control- AVP group|
62077438|NCT04455334|OTHER|healthy|year 1 study
62077439|NCT04455334|OTHER|stroke|year 1 study
62077440|NCT04455334|ACTIVE_COMPARATOR|active control group|year 2 study
62456972|NCT04010799|PLACEBO_COMPARATOR|CHF6333 Placebo|"Part I (SAD): Single dose of placebo matching CHF6333 at each period~Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days"
62077441|NCT04455334|EXPERIMENTAL|Error-augmented treadmill training|year 2 study
62077442|NCT04455334|EXPERIMENTAL|Error-augmented concept combined physical therapy group|year 3 study
62077443|NCT04455334|ACTIVE_COMPARATOR|conventional physical therapy group|year 3 study
62077444|NCT02646306||Shoulder Impingement Syndrome|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
62077445|NCT02646306||Healthy Subjects|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
62077446|NCT04086979|EXPERIMENTAL|Parental Friendship Coaching (PFC)|
62077447|NCT04086979|ACTIVE_COMPARATOR|Coping with ADHD through Relationships and Education (CARE)|
62077448|NCT00547105|EXPERIMENTAL|erlotinib in combination with SBRT|Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib
62077449|NCT00649740|EXPERIMENTAL|1|Topiramate Sprinkle Capsules 25 mg
62077450|NCT00649740|ACTIVE_COMPARATOR|2|Topamax® Sprinkle Capsule 25 mg
62077451|NCT06441825||Myasthenic Syndromes Observational Cohort|Cohort to be characterized via clinical, serological and digital observations
62280061|NCT04001855|EXPERIMENTAL|Dilute vinegar vs. dilute bleach bath|Subjects will complete a total of 5 study visits over 11 days. At visits 1-4, subjects will soak their forearms in either dilute bleach or dilute vinegar for 10 minutes. At all visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected.
62077452|NCT01049074|EXPERIMENTAL|Verus acupuncture|
62077453|NCT01049074|SHAM_COMPARATOR|Sham acupuncture|
62077454|NCT00158522|EXPERIMENTAL|1|
62077455|NCT03780595|EXPERIMENTAL|Passiflora|
62077456|NCT03780595|PLACEBO_COMPARATOR|Control|
62077457|NCT04827563||Participants with Normal Baseline Endothelial Function|
62077458|NCT04827563||Participants with Abnormal Baseline Endothelial Function|
62077459|NCT01428921|EXPERIMENTAL|Extended Education|"* Standard education programme as described above,~* Plus~  1. Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~ 2. Follow-up phone call would be arranged within 1 week after using CPAP.~ 3. Video, slides and booklets would be used as education media."
62646421|NCT04511325|OTHER|Refined Grain Regimen Arm|All participants will be randomly assigned to the calorie-matched refined grain daily for the 12-week treatment period, separated by a 2-week washout.The refined grain (100 grams of long grain white rice) regimen will be matched to the potato regimen for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day. Long-grain boiled white rice also has a similar glycemic index to that of a baked white potato.
62077460|NCT01428921|NO_INTERVENTION|Standard education|- Each subject will receive advice from Sleep Lab staff on the need for CPAP treatment, and the care of CPAP device and mask.
62646422|NCT00688441|EXPERIMENTAL|Active|CO2 Gas
62646423|NCT00688441|PLACEBO_COMPARATOR|Placebo|Inactive Placebo Gas
62077461|NCT03675841|EXPERIMENTAL|0.1% single-dose pre|Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
62077462|NCT03675841|EXPERIMENTAL|0.1% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
62077463|NCT03675841|EXPERIMENTAL|0.3% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose
62077464|NCT03675841|EXPERIMENTAL|0.5% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose
62646424|NCT04349644|EXPERIMENTAL|SENSE Theatre|A peer-mediated, theatre-based intervention designed to improve social cognition and behavior.
62646425|NCT04349644|NO_INTERVENTION|Waitlist Control Group|This group will not receive the intervention during the testing phase of the intervention but will eventually receive the theatre intervention.
62646426|NCT04256343|EXPERIMENTAL|D2O Dose 1|Lower dose of D2O for MPS
62646427|NCT04256343|EXPERIMENTAL|D2O Dose 2|Moderate dose of D2O MPS
62077465|NCT00609141|EXPERIMENTAL|Treatment (monoclonal antibody therapy)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.
62077466|NCT02248961|EXPERIMENTAL|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
62077467|NCT02248961|ACTIVE_COMPARATOR|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
62077468|NCT03954496|EXPERIMENTAL|Active tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2.5mA, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
62077469|NCT03954496|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
62077470|NCT05139641|PLACEBO_COMPARATOR|control group|
62077471|NCT05139641|EXPERIMENTAL|counseling theraphy|
62077472|NCT05139641|NO_INTERVENTION|Retrospective data|
62646428|NCT04256343|EXPERIMENTAL|D2O Dose 3|Higher dose of D2O for MPS
62077473|NCT04675112|EXPERIMENTAL|group A genetically informed intervention|Group A patients are offered a genetically based approach to tinnitus management that includes a genetic test and at least three office based treatment sessions. A rationally-designed personalized management plan based on the genetic results is based on four single nucleotide polymorphisms (SNPs) of the dopamine and serotonin pathways, namely COMT rs4680, HTR2A rs7997012, HTR2A rs6311, and TPH2 rs4570625, that have been associated with behavioral or cognitive responses
62077474|NCT04675112|OTHER|group B control|In Group B, treatments are offered randomly taking care to offer CBT to equal number of patients as in Group A. In both groups, during the first visit, patients are offered a simple, few-minute tinnitus update and advice, relevant to their educational level and are being suggested that an average of 4 sessions are required over a period of approx. 4 months for making tinnitus noise less or not bothersome
62077475|NCT06231290|ACTIVE_COMPARATOR|Postgraduate operator with magnification|
62077476|NCT06231290|EXPERIMENTAL|Postgraduate operator without magnification|
62077477|NCT06231290|EXPERIMENTAL|Undergraduate operator with magnification|
62077478|NCT06231290|EXPERIMENTAL|Undergraduate operator without magnification|
62077479|NCT03067103|ACTIVE_COMPARATOR|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
62077480|NCT03067103|ACTIVE_COMPARATOR|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
62077481|NCT03067103|PLACEBO_COMPARATOR|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
62077482|NCT01785628|EXPERIMENTAL|Sarcosine capsule|Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.
62077483|NCT01785628|PLACEBO_COMPARATOR|Placebo capsule|Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.
62646429|NCT03238417|EXPERIMENTAL|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
62077484|NCT05275751|PLACEBO_COMPARATOR|Hot injection without TRP-channel inhibition|Pain induced by an increasingly hot intradermal injection up to 52°C over 2 minutes.
62077485|NCT05275751|EXPERIMENTAL|Hot injection with TRPA1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62646430|NCT03238417|NO_INTERVENTION|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
62646431|NCT02674516|EXPERIMENTAL|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
62077486|NCT05275751|EXPERIMENTAL|Hot injection with TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077487|NCT05275751|EXPERIMENTAL|Hot injection with TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077488|NCT05275751|EXPERIMENTAL|Hot injection with TRPA1- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077489|NCT05275751|EXPERIMENTAL|Hot injection with TRPA1- and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62646432|NCT02674516|SHAM_COMPARATOR|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
62077490|NCT05275751|EXPERIMENTAL|Hot injection with TRPM3- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62646433|NCT00818935|EXPERIMENTAL|Low-Intermediate-Glycemic Index diets|
62646434|NCT00818935|ACTIVE_COMPARATOR|High GI diet|
62646435|NCT05402956|EXPERIMENTAL|Aerobic exercise|
62646436|NCT05402956|NO_INTERVENTION|Control|
62646437|NCT04014530|EXPERIMENTAL|Phase I dMMR and pMMR|2-4 groups of 3 patients treatment with 200mg i.v. Pembrolizumab q3w and dose escalation of Ataluren in order to determine the Ataluren MTD. These patients can either be pMMR/dMMR CRC and dMMR EC patients.
62646438|NCT04014530|EXPERIMENTAL|Phase II dMMR|Mismatch repair deficient CRC or EC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
62646439|NCT04014530|EXPERIMENTAL|Phase II pMMR|Mismatch repair proficient CRC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
62646440|NCT05475522|EXPERIMENTAL|Ultrasound|Intraoperative extent of tumor resection will be assessed using sonography
62077491|NCT05275751|EXPERIMENTAL|Hot injection with TRPA1-, TRPV1 and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPV1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077492|NCT05275751|EXPERIMENTAL|Hot injection with TRPA1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077493|NCT05275751|EXPERIMENTAL|Hot injection with TRPV1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077494|NCT05275751|EXPERIMENTAL|Hot injection with TRPA1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077495|NCT05275751|EXPERIMENTAL|Hot injection with TRPV1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077496|NCT05275751|EXPERIMENTAL|Hot injection with TRPV1-, TRPA1, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077497|NCT05275751|EXPERIMENTAL|Hot injection with TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62646441|NCT05475522|ACTIVE_COMPARATOR|Fluorescence|Intraoperative extent of tumor resection will be assessed using fluorescence with 5-aminolevulinic acid
62646442|NCT05836480||Suboptimal repair|Patients discharged with a residual mitral regurgitation of at least moderate (2+)degree
62646443|NCT05836480||Optimal repair|Patients discharged with a residual mitral regurgitation of mild (1+) or less degree (trace or 0)
62646444|NCT05207865|EXPERIMENTAL|Rimegepant|rimegepant 75 mg ODT daily
62646445|NCT04343183|ACTIVE_COMPARATOR|HBOT treatment group|Patients will receive hyperbaric oxygen therapy
62646446|NCT04343183|NO_INTERVENTION|Standard of Care group|Patients will not receive hyperbaric oxygen therapy and will receive the current standardized treatment protocol
62646447|NCT03519009|EXPERIMENTAL|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
62646448|NCT03519009|NO_INTERVENTION|Usual Care Control|Counseling and referrals to employment and treatment programs.
62646449|NCT05444816|EXPERIMENTAL|Personalised Neurofeedback training at home|All patients will perform personalised neurofeedback training at home with the device Brainhero 2019, type 201
62646450|NCT03622567|OTHER|Push Notifications|Push notification number (0, 1, 3, 5) will be counter balanced within-subjects.
62646451|NCT04951141|EXPERIMENTAL|anti-GPC3 CAR-T|
62646452|NCT00383799|ACTIVE_COMPARATOR|Group 1|IV procainamide (single dose: 10 mg/kg over 20 min)
62646453|NCT00383799|ACTIVE_COMPARATOR|Group 2|IV Amiodarone (single dose: 5 mg/kg over 20 min)
62646454|NCT04174066||SNLGM|70 patients with an SNLGM
62646455|NCT04174066||primary FSH|74 with a primary FSH
62646456|NCT01313754|OTHER|Vicryl|These patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive the vicryl material on the left.
62646457|NCT01313754|EXPERIMENTAL|Dermabond|The patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive dermabond skin glue on the left
62646458|NCT04030312|ACTIVE_COMPARATOR|Standard Infant Formula|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of standard 20 calorie-per-ounce infant formula up to two times during the duration of the study to treat hypoglycemia.
62646459|NCT04030312|EXPERIMENTAL|Commercially-Sterilized Donor Human Milk|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of 20 calorie-per-ounce commercially-sterilized donor human milk up to two times during the duration of the study to treat hypoglycemia.
62646460|NCT05854641|EXPERIMENTAL|Stempeucel®|Stempeucel® (Ex-vivo cultured MSCs) supplied in 15 ml cryo bags consisting of 200 million or 150 million MSCs, 85% PlasmaLyte-A, 5% HSA and 10% DMSO in a total volume of 15 ml. Following thawing, 35 ml of PlasmaLyte A will be added to the Stempeucel® to make a total volume of 50 ml (Refer section 6.6 IMP Preparation and Designation). The final concentration of components will be 1.5% HSA and 3% DMSO.
62646461|NCT04768140|EXPERIMENTAL|Bobath group|A conventional physiotherapy program was applied to this group. Additionally, Bobath treatment approach was applied for 10 repetitions during a 30-min session in the experimental group, in addition to the conventional physiotherapy program.
62077498|NCT05275751|EXPERIMENTAL|Hot injection with TRPV1-, TRPA1, and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62646462|NCT04768140|ACTIVE_COMPARATOR|Conventional physiotherapy group|Only conventional physiotherapy program was applied to this group.
62646463|NCT05891548|EXPERIMENTAL|1.0 mg CLS-AX|Suprachoroidal injection of 10 mg/mL (1.0 mg in 0.1 mL) of CLS-AX
62646464|NCT05891548|ACTIVE_COMPARATOR|Aflibercept|Intravitreal injection of aflibercept (2 mg in 0.05 mL)
62646465|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
62077499|NCT05275751|EXPERIMENTAL|Hot injection with chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while a chloride channel is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
62077500|NCT00743587|PLACEBO_COMPARATOR|A|
62077501|NCT00743587|ACTIVE_COMPARATOR|B|
62077502|NCT00743587|ACTIVE_COMPARATOR|C|
62077503|NCT00743587|ACTIVE_COMPARATOR|D|
62077504|NCT03159650|EXPERIMENTAL|intravascular ultrasonography guided|
62077505|NCT03159650|ACTIVE_COMPARATOR|Angiography guided|
62077506|NCT03816891|EXPERIMENTAL|Phase 2a - Vixarelimab 360 mg SC QW|Vixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
62077507|NCT03816891|PLACEBO_COMPARATOR|Phase 2a - Placebo SC QW|Placebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
62077508|NCT03816891|EXPERIMENTAL|Phase 2b - Vixarelimab 540 mg SC Q4W (DBL)|Vixarelimab 540 mg SC, every 4 weeks for 16 weeks during Double Blind Period
62646466|NCT02940301|EXPERIMENTAL|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.
62646467|NCT02809365|OTHER|Libre|FreeStyle Libre users: FreeStyle Libre Flash Glucose Monitoring System is an interstitial glucose monitoring system intended to be replacement for the capillary blood glucose measurement. The system contains several features that distinguish it from exiting sensor technology including no user calibration during 14 days of wear. The sensor is applied to the upper arm of the patient and the hand-held reader is used to scan the sensor to receive glucose result along with historic results with a 15 min frequency for up to 8 hours.
62646468|NCT02809365|OTHER|SMBG|Self monitoring blood glucose: patients in this arm will measure blood glucose with personal glucometer
62077509|NCT03816891|EXPERIMENTAL|Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL)|Vixarelimab 360 mg SC, every 4 weeks for 16 weeks during Double Blind Period
62077510|NCT03816891|EXPERIMENTAL|Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL)|Vixarelimab 120 mg SC, every 4 weeks for 16 weeks during Double Blind Period
62077511|NCT03816891|PLACEBO_COMPARATOR|Phase 2b - Placebo SC, Q4W (DBL)|Placebo SC, every 4 weeks for 16 weeks during Double Blind Period
62077512|NCT03816891|EXPERIMENTAL|Phase 2b - Vixarelimab 360 mg SC, Q2W (OLE)|Vixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension
62077513|NCT00345787|PLACEBO_COMPARATOR|0|
62077514|NCT00345787|EXPERIMENTAL|1|
62077515|NCT01356901||Treatment naïve and pre-treated CHB patients|subanalysis with migrant and non-migrant patients
62077516|NCT00821132||ALS families|Patients with either inherited or sporadic ALS or PLS and selected family members
62077517|NCT04446910|EXPERIMENTAL|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to encourage attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
62077518|NCT04446910|ACTIVE_COMPARATOR|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
62077519|NCT03789643|EXPERIMENTAL|JTT-251 Dose 1|One dose of study drug by mouth daily for 24 weeks
62077520|NCT03789643|EXPERIMENTAL|JTT-251 Dose 2|One dose of study drug by mouth daily for 24 weeks
62077521|NCT03789643|EXPERIMENTAL|JTT-251 Dose 3|One dose of study drug by mouth daily for 24 weeks
62077522|NCT03789643|PLACEBO_COMPARATOR|Placebo|One dose of study drug by mouth daily for 24 weeks
62077523|NCT03354520|ACTIVE_COMPARATOR|Tailored Videos|
62077524|NCT03354520|ACTIVE_COMPARATOR|Standard Videos|
62077525|NCT03354520|ACTIVE_COMPARATOR|OSA Treatment|
62077526|NCT05754138||study population|The study population will consist of patients with an implanted S-ICD as their first implanted device, who continue to exercise regularly and actively participate in competitive or recreational sports with a sport-intensity above a predefined level
62077527|NCT03938948|EXPERIMENTAL|Treatment Arm|62 participants shall be enrolled
62077528|NCT05913375|EXPERIMENTAL|Cardiac radioablation|Patients with ventricular tachycardia will undergo cardiac radiosurgery with one fraction of 20 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
62077529|NCT00005973|EXPERIMENTAL|Treatment|Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62077530|NCT03134378|EXPERIMENTAL|14 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
62077531|NCT03134378|PLACEBO_COMPARATOR|10 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
62077532|NCT05886686||Hospitalised inpatients|Ten patients admitted into the Acute Care of the Elderly (ACE) ward will be approached for inclusion in the study. Patients will be given written information about the trial. Nursing staff looking after these patients will be asked to utilise the device after vital sign measurements obtained from standard hospital equipment when conducting routine vital sign measurements. Nurses will do this for the duration of the admission of 7days, thus generating 28 paired data points for comparison.
62077533|NCT05886686||Inpatients at home|"Fifteen patients admitted into the home-based ward would be approached for inclusion in the study. Participants will undergo a 20 minute education session then be supplied with the device, companion app (user interface) on a mobile tablet, and written information about the trial.~Participants will be asked to measure their vital signs four times a day, with one of those measurements occurring immediately after the clinical nurse' home review using standard hospital equipment for vital sign measurements (this matched pair of vital signs measurements will be taken as reference). Participants will do this for at least 7 days, thus generating 7 matched data points for comparison against reference, and 21 data points where participants independently conducted vital signs measurements with the Norbert sensor."
62077534|NCT01222611|NO_INTERVENTION|Standard HAART|ART with 3 drugs including 2 NRTIs plus a ritonavir boosted PI (different to FPV) or a NNRTI
62077535|NCT01222611|EXPERIMENTAL|HAART inlcuding Fos APV/r|ART with 3 drugs including 2 NRTIs plus ritonavir boosted fosamprenavir
62077536|NCT04181541|ACTIVE_COMPARATOR|Women receiving abortion care by physicians|Patients who receive second trimester medical abortion care from a physician.
62077537|NCT04181541|EXPERIMENTAL|Women receiving abortion care from midlevel providers|Patients who receive second trimester medical abortion care from a midlevel provider.
62456973|NCT05617703|EXPERIMENTAL|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|"Glass Hybrid restorative systems in the clinical point of view are self-cure bulk fill materials laminated with a nano-filled, self-adhesive resin coat.~Nowadays, a new glass hybrid innovation called Advanced Glass Hybrid technology was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using prefractive indexes."
62456974|NCT05617703|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer (Fugi II LC, GC, Japan).|
62077538|NCT06526377|EXPERIMENTAL|Natrunix 400 mg Natrunix in Combination with Standard of Care|This arm will have 40 subjects receiving Natrunix in Combination with Standard of Care in HLA-B27 Positive Patients with Axial Spondyloarthritis
62456975|NCT02195778||Young, 18 to 30|
62077539|NCT06526377|EXPERIMENTAL|Placebo in combination with Standard of Care|This arm will have 20 subjects receiving Placebo in Combination with Standard of Care in HLA-B27 Positive Patients with Axial Spondyloarthritis
62077540|NCT01993537|NO_INTERVENTION|Sufficeint|In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.
62077541|NCT01993537|NO_INTERVENTION|Mild Insufficiency|In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.
62077542|NCT01993537|NO_INTERVENTION|Severe Deficiency no treatment|In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.
62077543|NCT01993537|EXPERIMENTAL|Severe Deficiency - Treatment|In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
62077544|NCT01718236|EXPERIMENTAL|Rocuronium + sugammadex|Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
62077545|NCT01718236|EXPERIMENTAL|Succinylcholine + Neostigmine|Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
62077546|NCT02397486|EXPERIMENTAL|Intervention Group|"Platinum based concurrent chemoradiotherapy \[cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks\] .~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks."
62077547|NCT02397486|ACTIVE_COMPARATOR|Control Group|Platinum based concurrent chemoradiotherapy \[cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks\] .
62077548|NCT05172882|EXPERIMENTAL|Wound Infiltration|Wound infiltration will be applied to the surgical incision site for patients in this group. Infiltration fluid will contain 20 ml 0.25% bupivakain.
62077549|NCT05172882|EXPERIMENTAL|Transversalis Fascia Plane Block|Transversalis fascia plane block will be performed on only one periinguinal side for patients in this group. Block fluid will contain 20 ml 0.25% bupivakain.
62077550|NCT03786094|ACTIVE_COMPARATOR|Eribulin|
62077551|NCT03786094|EXPERIMENTAL|Balixafortide + Eribulin|
62077552|NCT03450213|ACTIVE_COMPARATOR|Patients with keratoconus|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
62077553|NCT03450213|PLACEBO_COMPARATOR|Normal people at the same age and sex|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
62077554|NCT02550132|EXPERIMENTAL|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
62077555|NCT02870946|EXPERIMENTAL|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced.
62646469|NCT00226252|EXPERIMENTAL|Instruction Only (IO)|IO participants will train on the dynamometer for the same length of time as the Feedback Group. They will only be instructed to follow what they learned from the video presented at the beginning of the training session.
62077556|NCT02870946|EXPERIMENTAL|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
62077557|NCT02068534||survivors from charcoal-burning suicide|survivors from charcoal-burning suicide and at least above 20 years old.
62077558|NCT02640599|EXPERIMENTAL|Vestibular Rehabilitation + Areobic Exercise|
62077559|NCT02640599|ACTIVE_COMPARATOR|Vestibular Rehabilitation|
62077560|NCT04285437|EXPERIMENTAL|massage|neonates are massaged by their mother during the first 2 months after birth.
62077561|NCT04285437|NO_INTERVENTION|control|neonates are not massaged.
62077562|NCT01112605||otherwise healthy persons|healthy persons, no major trauma or surgery of ankle or calves, no bone or muscle disease, age 18-60
62077563|NCT02464111|EXPERIMENTAL|Group 1|Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses
62077564|NCT02464111|EXPERIMENTAL|Group 2|Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose
62077565|NCT02464111|EXPERIMENTAL|Group 3|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses
62646470|NCT00226252|EXPERIMENTAL|Instruction and Feedback Group (FB)|The FB group will receive video training, and real time feedback from the SMART Wheel as they push their wheelchair. A monitor displaying a random combination and amount of biomechanical feedback variables will be placed in front of subjects. Subjects will be instructed to adjust their stroke to optimize their biomechanics with feedback from the screen.
62077566|NCT02464111|EXPERIMENTAL|Group 4|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given
62077567|NCT02464111|EXPERIMENTAL|Group 5|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given
62077568|NCT02464111|EXPERIMENTAL|Group 6|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose
62077569|NCT02912156|EXPERIMENTAL|Vaway FC Tablets|Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
62077570|NCT02912156|ACTIVE_COMPARATOR|VFEND FC Tablets|VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
62077571|NCT05140187|EXPERIMENTAL|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive one to three infusions of donor-derived CMV-TCR-T cells, with the escalated dose ranging from 1×10\^3/kg to 5×10\^5/kg CMV-TCR-T cells per dose.
62077572|NCT03329313|ACTIVE_COMPARATOR|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
62646471|NCT00226252|NO_INTERVENTION|Control Group|Wheelchair characteristics will be noted; however, no wheelchair manipulation or changes in equipment will be performed or recommended.
62646472|NCT00794664|PLACEBO_COMPARATOR|Placebo|Weekly subcutaneous injections for 26 weeks
62077573|NCT03329313|SHAM_COMPARATOR|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
62077574|NCT03952455|EXPERIMENTAL|DBS|All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
62077575|NCT04515563|PLACEBO_COMPARATOR|Control Group|Subjects in the care control group will perform once-a-week stretching exercise intervention. Each session lasts for 75 minutes and covers the major muscle groups.
62077576|NCT04515563|EXPERIMENTAL|Low-frequency, moderate-intensity walking group|A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 150-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 150 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting \[23\]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable \[24\].
62077577|NCT04515563|EXPERIMENTAL|High-frequency, moderate-intensity walking group|Intervention of high-frequency, moderate-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 50-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 50 minutes of exercise time. If needed, there will be one 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting \[23\]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable \[24\].
62077578|NCT04515563|EXPERIMENTAL|Low-frequency, vigorous-intensity walking group|Intervention of low-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 75-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 75 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting \[23\]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable \[24\].
62456976|NCT02195778||Middle, 31 to 50|
62456977|NCT02195778||Older, 51 to 70|
62456978|NCT01636570|ACTIVE_COMPARATOR|Vitamin D3 (cholecalciferol)|10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
62456979|NCT01636570|PLACEBO_COMPARATOR|Sugar Pill|Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
62456980|NCT04071444|EXPERIMENTAL|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
62456981|NCT04071444|NO_INTERVENTION|Control group|The control group (CG) received routine care.
62456982|NCT01492361|EXPERIMENTAL|AMR101|AMR101 (icosapent ethyl) + statin therapy, daily
62456983|NCT01492361|PLACEBO_COMPARATOR|Placebo|Placebo + statin therapy, daily
62456984|NCT01491581|EXPERIMENTAL|micronutrient enriched bar|bar enriched with micronutrients
62456985|NCT01491581|PLACEBO_COMPARATOR|control arm|normal bar
62456986|NCT04590378||Covid-19 Patients with Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
62456987|NCT04590378||Covid-19 Patients without Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.
62456988|NCT03273322|EXPERIMENTAL|1: Rivaroxaban 10 mg qd|Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
62456989|NCT03273322|EXPERIMENTAL|2: Rivaroxaban 15 mg qd|"Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90~should be taken between 8 and 10 AM"
62456990|NCT03273322|ACTIVE_COMPARATOR|3: DAPT|Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
62456991|NCT00918567|EXPERIMENTAL|Combined therapy|atomoxetine plus behavior therapy
62456992|NCT00918567|ACTIVE_COMPARATOR|Drug therapy|atomoxetine alone
62456993|NCT02917902|EXPERIMENTAL|Immediate intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
62646473|NCT00794664|EXPERIMENTAL|Mipomersen|200 mg weekly subcutaneous injections for 26 weeks
62646474|NCT05075278|ACTIVE_COMPARATOR|Attending physician for direct 1:1 supervision|Participants will be assigned to an attending physician for direct 1:1 supervision. The participants will fill out a survey at the end of the day for 16 consecutive days.
62646475|NCT05075278|EXPERIMENTAL|Senior resident for direct 1:1 supervision|Participants will be assigned to an senior resident as a direct supervisor with oversight from an attending physician (in accordance with CMS/ACGME staffing criteria). The participants will fill out a survey at the end of the day for 16 consecutive days.
62646476|NCT01284868|EXPERIMENTAL|Mirabegron|
62077579|NCT04515563|EXPERIMENTAL|High-frequency, vigorous-intensity walking group|Intervention of high-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 25-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 25 minutes of exercise time. If needed, there will be a 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting \[23\]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable \[24\].
62077580|NCT01154049|EXPERIMENTAL|single arm|3 doses of the vaccine, on days 0, 30 and 60.
62077581|NCT02167152|EXPERIMENTAL|Ischemic Preconditioning Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
62077582|NCT02167152|ACTIVE_COMPARATOR|Control Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
62077583|NCT02953093|OTHER|Acarbose first|Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
62077584|NCT02953093|OTHER|Placebo first|Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
62077585|NCT00999973|ACTIVE_COMPARATOR|Mitomycin c 0.02%|
62646477|NCT04003909|EXPERIMENTAL|ESP group|patients will have ultrasound guided ESP block before spinal anesthesia.
62646478|NCT04003909|EXPERIMENTAL|Control group|patients will have spinal Anesthesia without ESP block
62646479|NCT03792646|EXPERIMENTAL|Experimental|The experimental group will inject 20 grams of whey protein diluted in water after the exercise training.
62077586|NCT00999973|PLACEBO_COMPARATOR|Placebo|
62646480|NCT03792646|PLACEBO_COMPARATOR|Placebo|The placebo group will inject 20 grams of maltodextrin diluted in water after the exercise training.
62646481|NCT02119299|EXPERIMENTAL|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
62077587|NCT02392767|ACTIVE_COMPARATOR|Verum|2 times 2 tablets a day for 4 weeks.
62077588|NCT02392767|PLACEBO_COMPARATOR|Placebo|2 times 2 tablets a day which cornstarch. Tablets look identical like verum tablets.
62077589|NCT02908854|EXPERIMENTAL|School Lunch Participants|School lunch participants will be given vegetables with and without additional spices and herbs to determine if intake will increase with the addition of spices and herbs.
62077590|NCT01372358|EXPERIMENTAL|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
62646482|NCT06019871||Decided for conservative kidney management|Patient with advanced kidney disease and decided for conservative kidney management
62077591|NCT01372358|ACTIVE_COMPARATOR|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
62077592|NCT00655551|EXPERIMENTAL|Lacosamide 200 mg cohort|Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
62077593|NCT00655551|EXPERIMENTAL|Lacosamide 300 mg combined cohorts|Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
62077594|NCT00655551|EXPERIMENTAL|Lacosamide 400 mg cohort|Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily
62077595|NCT02637050||CTEPH Patients|Patients with confirmed diagnosis of CTEPH
62646483|NCT06019871||Decided for dialysis|Patient with advanced kidney disease and decided for dialysis
62646484|NCT04398836|ACTIVE_COMPARATOR|Malnourished patients - EEN|patiens will receive EEN for 4 week prior surgery
62646485|NCT04398836|OTHER|Malnourished patients - enriched diet|patiens will receive an enriched high energy and protein diet.
62646486|NCT04398836|OTHER|Well nourished patients|Patient will receive a standard nutrition
62646487|NCT06379243|EXPERIMENTAL|non-operative vertebra refracture|observe non-operative vertebra refracture after PVP/PKP surgery.
62646488|NCT02659501|ACTIVE_COMPARATOR|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
62646489|NCT02659501|EXPERIMENTAL|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
62646490|NCT01255163|EXPERIMENTAL|Exendin-4|Exenatide 5 mcg or 10 mcg SC twice daily
62646491|NCT01255163|PLACEBO_COMPARATOR|Placebo|Placebo SC twice daily
62646492|NCT05201092|EXPERIMENTAL|[14C]-Lu AG06466|Participants will receive a single oral dose of \[14C\]-Lu AG06466 on Day 1 in the fed state.
62646493|NCT04644172|EXPERIMENTAL|Immediate Treatment|The treatment will have 3 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is training following shaping principles on simulated instrumental activities of daily living (IADL), such as making a telephone call or generating a shopping list, in the treatment setting. Shaping involves progressively increasingly the complexity of a task in incremental steps as a participant gains mastery. Frequent, positive feedback is another important aspect of shaping. The third component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily
62646494|NCT04644172|OTHER|Delayed Treatment|Participants in this arm will receive testing on the same schedule as the Immediate Treatment up to six-month followup. Delayed Treatment participants will not receive any treatment from the study during this period but will permitted to receive any healthcare that is available on a clinical basis. After six-month followup, participants in this arm will be crossed over to receive the experimental treatment.
62646495|NCT02295644|EXPERIMENTAL|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
62646496|NCT02295644|EXPERIMENTAL|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
62646497|NCT02295644|EXPERIMENTAL|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
62646498|NCT02295644|EXPERIMENTAL|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
62646499|NCT02501408|EXPERIMENTAL|Propriofoot prosthesis|New propriofoot prosthesis is worn instead of usual prosthesis foer 1 month
62646500|NCT02501408|NO_INTERVENTION|Control|Usual prosthesis is worn for 1 month
62646501|NCT00546403|PLACEBO_COMPARATOR|Placebo|Adjunctive treatment with placebo
62646502|NCT00546403|EXPERIMENTAL|Modafinil|Treatment with titrated dose of study drug, modafinil.
62646503|NCT00450957|EXPERIMENTAL|Arm I (high-dose lycopene)|Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
62646504|NCT00450957|EXPERIMENTAL|Arm II (low-dose lycopene)|Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days
62077596|NCT06106841|EXPERIMENTAL|400mg of TQB3909 tablets|tablet, 28 days as a treatment cycle.
62456994|NCT02917902|OTHER|Delayed intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
62077597|NCT06106841|EXPERIMENTAL|600mg of TQB3909 tablets|tablet, 28 days as a treatment cycle.
62077598|NCT05918315|ACTIVE_COMPARATOR|Dorsolateral approach urethroplasty|Use of dorsolateral(Kulkarni technique) urethroplasty.
62456995|NCT01591174||Functional Dyspepsia with PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
62646505|NCT04051541|OTHER|Simulation arm|All patients were entered into the Simulation arm and received 3 pushes of agitated saline via 3 different methods of delivery. All patients received all methods. The order of the methods for each patient was randomized.
62077599|NCT05918315|ACTIVE_COMPARATOR|Dorsal approach urethroplasty|Use of dorsal (Barbagli technique) urethroplasty
62077600|NCT01978275|EXPERIMENTAL|stimulating catheters group|Lumbar plexus block performed through stimulating catheter
62646506|NCT00915590|EXPERIMENTAL|Placebo first, then IL-1RA|It is our intent that 10 patients will complete a course of treatment with placebo, followed by a course of treatment with 5% custom made topical IL-1Ra.
62646507|NCT00915590|EXPERIMENTAL|IL-1RA first, then Placebo|It is our intent that 10 patients will complete a course of treatment with 5% custom made topical IL-1Ra, followed by a course of treatment with placebo
62077601|NCT01978275|ACTIVE_COMPARATOR|nonstimulating catheters|lumbar plexus block through nonstimulating catheters
62077602|NCT02698280|EXPERIMENTAL|Treatment|Patients are treated with bevacizumab and nimustine. Every 6 weeks is defined as one therapeutic cycle. Adverse effect is evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Hematologic toxicity is evaluated every 2 weeks. Liver function, renal function, and electrolytes are assessed every 4-6 weeks. Platelet should be no less than 100\*10\^9/L and neutrophil count should be no less than 1.5\*10\^9/L.
62077603|NCT04724720|ACTIVE_COMPARATOR|Famotidine|Participants in this study arm will receive standard of care and prescribed famotidine at 80mg TID for a maximum of 14 days, or until hospital admission.
62077604|NCT04724720|PLACEBO_COMPARATOR|Placebo|Participants in this study arm will receive standard of care and placebo for a maximum of 14 days.
62646508|NCT02965651|EXPERIMENTAL|ECA System|Access to website and virtual patient advocate
62646509|NCT02965651|NO_INTERVENTION|Standard of Care|Patient information sheets and meditation CD
62646510|NCT03985683|ACTIVE_COMPARATOR|Control group|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
62646511|NCT03985683|EXPERIMENTAL|Experimental (Nutritional Interventional)|In experimental group athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively. Average carbohydrates required for athletes are 6 to 10 gram per kilogram per day. T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test will use as baseline assessment and after 6 days of intervention.
62077605|NCT02726776|EXPERIMENTAL|Suspension without prior climbing|Free Suspension in a harness after baseline measurements and without prior climbing
62077606|NCT02726776|EXPERIMENTAL|Suspension with prior climbing|Free Suspension in a harness after baseline measurements and after climbing in moderate intensity for 10 minutes
62077607|NCT00936494|NO_INTERVENTION|Control|No inferior turbinate surgery.
62077608|NCT00936494|OTHER|Intervention|Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).
62646512|NCT04525521||Non-Atopic Individuals|Individuals with no history of atopic dermatitis, food allergy, asthma, or allergic rhinitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
62646513|NCT04525521||Individuals with Atopic Dermatitis|Individuals with history of atopic dermatitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
62646514|NCT03356652|EXPERIMENTAL|Tailor-made CRT delivery|Patient undergoes acute noninvasive electrical dyssynchrony study with various CRT configurations. CRT device is then implanted with optimal configuration.
62646515|NCT01298830|EXPERIMENTAL|GLP-1 CellBeads|
62456996|NCT01591174||Functional Dyspepsia without PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
62456997|NCT01591174||Control Group|Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
62456998|NCT04034576|EXPERIMENTAL|TAU + mindfulness intervention|The mindfulness-based intervention consists of three five to ten minutes session-introducing interventions (mindful walking, body scan, breathing space). At the beginning of each of the 24 therapy sessions patients receive one of the three mindfulness interventions. Each intervention is instructed for four sessions consecutively and eight sessions in total. After completion of the mindfulness intervention, the regular therapy session begins.
62456999|NCT04034576|ACTIVE_COMPARATOR|TAU + relaxation intervention|The relaxation interventions (progressive muscle relaxation (PMR), imagery journey, walking relaxation) are parallelized to the three mindfulness-based interventions. At the beginning of each of the 24 therapy sessions, patients receive one of the three relaxation interventions. Each intervention is instructed for four sessions consecutively and eight sessions in total. After completion of the relaxation intervention, the regular therapy session begins.
62457000|NCT04034576|OTHER|Treatment as usual|Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions. No particular session-introductions are applied.
62457001|NCT03062566||Severe TBI patients|GCS 3-8
62457002|NCT05976399|ACTIVE_COMPARATOR|Manual lymph drainage group|The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
62457003|NCT05976399|ACTIVE_COMPARATOR|Connective tissue massage group|"In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed."
62457004|NCT06148090|EXPERIMENTAL|Treated with clobetasol propionate|
62457005|NCT02946125|EXPERIMENTAL|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
62457006|NCT02946125|ACTIVE_COMPARATOR|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
62077609|NCT05853874|EXPERIMENTAL|Nutritional intervention|"Nutritional intervention consist in a macro- and micronutrients balanced nutritional protocol with a focus on sustainability and personalized according to the individual malnutrition severity. In particular, an adequate coverage of energy, protein and water requirements will be guaranteed according to Italian reference values (LARN) and European (ESPEN) guidelines.~In light of the scientific literature and the principal issues founding in malnourished older people, the proposed nutritional protocol will provide an adequate and sustainable consumption of animal and vegetable proteins and an appropriate water intake.~The nutritional intervention will be carried out by a qualified staff."
62077610|NCT05853874|OTHER|Control|The control group receive the standard of care provided for malnutrition treatment by hospitals
62077611|NCT03414788|EXPERIMENTAL|Treatment Arm - PF 06687234 and [124I]IB PF 06687234|PF 06687234 and \[124I\]IB PF 06687234
62077612|NCT03868293|EXPERIMENTAL|Drug-Resistant Epilepsy (temporal lobe)|Pulsed low intensity focused ultrasound
62077613|NCT00374972||combined contraceptives|combined contraceptives
62077614|NCT00374972||pregesterone only contraceptives|pregesterone only contraceptives
62077615|NCT02314221|EXPERIMENTAL|Exoskeletal-Assisted Walking (WALK)|WALK first for 12 weeks (36 sessions)
62457007|NCT02946125|ACTIVE_COMPARATOR|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
62457008|NCT03652077|EXPERIMENTAL|INCAGN02390|
62457009|NCT06317246|EXPERIMENTAL|Investigation of BRAF mosaicism|The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
62457010|NCT04287426|ACTIVE_COMPARATOR|Group receiving rocuronium at induction|Rocuronium 0,6 mg/kg at induction
62457011|NCT04287426|ACTIVE_COMPARATOR|Group receiving remifentanil at induction|Remifentanil 2 μg/kg at induction
62077616|NCT02314221|NO_INTERVENTION|Usual Activities (UA)|Usual activities first for 12 weeks
62077617|NCT00781742|EXPERIMENTAL|1|100 mg iv once per dosing day
62077618|NCT00781742|EXPERIMENTAL|2|150 mg iv once per dosing day
62077619|NCT00781742|PLACEBO_COMPARATOR|3|
62077620|NCT04213989|ACTIVE_COMPARATOR|Conservative Care|Conservative care (may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT)
62077621|NCT04213989|EXPERIMENTAL|Flexitouch Plus and Conservative Care|Flexitouch Plus with conservative care
62646516|NCT02507791|EXPERIMENTAL|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
62077622|NCT05828225|EXPERIMENTAL|Treatment Group|Myasthenia Gravis
62077623|NCT01622101|EXPERIMENTAL|zantrex|The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
62077624|NCT01622101|PLACEBO_COMPARATOR|Control|The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or appearance.
62077625|NCT04024787|EXPERIMENTAL|Immediate intervention|
62077626|NCT04024787|NO_INTERVENTION|Waitlist|
62077627|NCT02810691|ACTIVE_COMPARATOR|Soluble fiber, dose #1|Soluble fiber supplementation with dose #1 (smaller dose) of psyllium fiber.
62077628|NCT02810691|ACTIVE_COMPARATOR|Soluble fiber, dose #2|Soluble fiber supplementation with dose #2 (bigger dose) of psyllium fiber.
62457012|NCT01475838|EXPERIMENTAL|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
62457013|NCT01475838|ACTIVE_COMPARATOR|PI+RTV+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of a PI boosted with RTV plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
62077629|NCT02810691|PLACEBO_COMPARATOR|Placebo|A 250 ml placebo solution of orange-flavored water will be drink at breakfast.
62077630|NCT00077350|EXPERIMENTAL|Treatment (triapine and gemcitabine hydrochloride)|Patients receive 3-AP (Triapine\^®) IV over 2 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62077631|NCT00507741|EXPERIMENTAL|Ertafolide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg ertafolide labeled with 20 to 25 mCi of technetium-99m Part A: Induction phase of treatment: Two 4-week cycles; if stable disease or better at week 8 computed tomography (CT), participant may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit. Part B: 4-week cycles with CT every 8 weeks. Participants continue until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
62077632|NCT06247670|EXPERIMENTAL|Single Ascending Dose Part|Adult healthy volunteers in 4 cohorts of 12 will receive CMP-CPS-001 or placebo. Four dose levels will be evaluated.
62077633|NCT06247670|EXPERIMENTAL|Multiple Ascending Dose Part|Adult healthy volunteers in 4 cohorts of 12 will receive 3 monthly doses of either CMP-CPS-001 or placebo. Four dose levels will be evaluated.
62077634|NCT01933347|EXPERIMENTAL|Gefitinib 250mg/d|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period.
62077635|NCT05721573|ACTIVE_COMPARATOR|0.5 mg/kg ABC008|"Part A - ABC008 N=12~Part B - ABC008 N= 67"
62077636|NCT05721573|ACTIVE_COMPARATOR|2.0 mg/kg ABC008|"Part A - ABC008 N=12~Part B - ABC008 N= 67"
62077637|NCT05721573|PLACEBO_COMPARATOR|Placebo|"Part A - Placebo N= 6~Part B - Placebo N= 67"
62077638|NCT00287248|EXPERIMENTAL|Assess [123I] IMPY & SPECT Imaging|To assess \[123I\] IMPY \& SPECT Imaging
62077639|NCT00736073|ACTIVE_COMPARATOR|1|aprepitant
62077640|NCT00736073|PLACEBO_COMPARATOR|2|Placebo
62077641|NCT05955456||Participants in primary care with risk factors for heart failure|
62077642|NCT06359600|EXPERIMENTAL|Cohort 1|Single dose of HS-10501 administered orally under fasted conditions
62077643|NCT06359600|EXPERIMENTAL|Cohort 2|Single dose of HS-10501 administered orally under fasted conditions
62077644|NCT06359600|EXPERIMENTAL|Cohort 3|Single dose of HS-10501 administered orally under fed and fasted conditions
62077645|NCT06359600|EXPERIMENTAL|Cohort 4|Single dose of HS-10501 administered orally under fasted conditions
62457014|NCT01502943|EXPERIMENTAL|Phlegm and blood stasis Syndrome G|
62646517|NCT02507791|ACTIVE_COMPARATOR|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
62646518|NCT03052894|EXPERIMENTAL|Hydraulic Monitoring Device|Monitoring device to be compared to electromyographic (EMG) device in the same patient; measures depth of neuromuscular blockade during general anesthesia based on the pressure exerted by the muscles of the thumb.
62646519|NCT03052894|ACTIVE_COMPARATOR|Standard EMG Monitoring Device|Currently used standard monitoring device; measures depth of neuromuscular blockade during general anesthesia based on the action potential of the muscles of the thumb.
62646520|NCT05247164|EXPERIMENTAL|PDAC Patients|Patients undergoing EUS for characterization of a PDAC lesion will receive EUS-guided portal blood sampling.
62077646|NCT06359600|EXPERIMENTAL|Cohort 5|Single dose of HS-10501 administered orally under fasted conditions
62077647|NCT06359600|EXPERIMENTAL|Cohort 6|Single dose of HS-10501 administered orally under fasted conditions
62646521|NCT04961359|EXPERIMENTAL|Population Ⅰ|Population Ⅰ has 20 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅠis intramuscular injection of deltoid muscle of upper arm with vaccine.
62646522|NCT04961359|PLACEBO_COMPARATOR|Population Ⅱ|Population Ⅱ has 5 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅱ is a placebo intramuscular injection of deltoid muscle of the upper arm.
62077648|NCT06359600|EXPERIMENTAL|Cohort 7|Drugs are given twice a day (BID) for 27 days, and only one morning dose is given on the 28th day.
62077649|NCT06359600|EXPERIMENTAL|Cohort 8|Drugs are given once a day (QD) for 28 days.
62077650|NCT06359600|EXPERIMENTAL|Cohort 9|Drugs are given twice a day (BID) for 27 days, and only one morning dose is given on the 28th day.
62077651|NCT01620736|EXPERIMENTAL|Raltegravir|Treatment with raltegravir for 8 wks
62077652|NCT02384005|OTHER|Self-anal exam arm|Study only has one arm.
62077653|NCT03108287|ACTIVE_COMPARATOR|RAK therapy|rabeprazole+amoxicillin+clarithromycin
62077654|NCT03108287|ACTIVE_COMPARATOR|RBAK therapy|rabeprazole+amoxicillin+clarithromycin+bismuth subcitrate
62077655|NCT04430296|ACTIVE_COMPARATOR|High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU)|
62077656|NCT04430296|ACTIVE_COMPARATOR|MicroPulse cyclophotocoagulation (MP-CPC)|
62457015|NCT01502943|PLACEBO_COMPARATOR|Phlegm and blood stasis control G|
62457016|NCT01502943|EXPERIMENTAL|Qi deficiency and blood stasis G|
62457017|NCT01502943|PLACEBO_COMPARATOR|Qi deficiency and blood stasis control G|
62457018|NCT04909164||Immunotherapy group|Patients receiving reimbursed immunotherapy as a second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy)
62457019|NCT04909164||Cytotoxic chemotherapy group|Patients receiving reimbursed cytotoxic chemotherapy as second-line therapy after failure of platinum-based chemotherapy
62457020|NCT01718639|ACTIVE_COMPARATOR|IQP-LH-101 tablet|4 chewable tablets to be chewed thoroughly before swallowing
62457021|NCT01718639|ACTIVE_COMPARATOR|IQP-LH-101 liquid|2 liquid sachets to be emptied into the mouth and consumed.
62646523|NCT04961359|EXPERIMENTAL|Population Ⅲ|Population Ⅲ has 20 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is intramuscular injection of deltoid muscle of upper arm with vaccine.
62646524|NCT04961359|PLACEBO_COMPARATOR|Population Ⅳ|Population Ⅳ has 5 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅳ is a placebo intramuscular injection of deltoid muscle of the upper arm.
62646525|NCT04961359|EXPERIMENTAL|Population Ⅴ|Population Ⅴ has 20 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅤ is intramuscular injection of deltoid muscle of upper arm with vaccine.
62646526|NCT04961359|PLACEBO_COMPARATOR|Population Ⅵ|Population Ⅵ has 5 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅵ is a placebo intramuscular injection of deltoid muscle of the upper arm.
62646527|NCT03588273|OTHER|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
62646528|NCT04752930|EXPERIMENTAL|ctDNA monitoring|ctDNA monitoring will be performed at protocol-specified intervals and requirement
62646529|NCT04752930|ACTIVE_COMPARATOR|Imageology (SOC)|Imaging examination will be performed at protocol-specified intervals and requirement
62646530|NCT03365180|EXPERIMENTAL|The Starter Kit Algorithm|Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.
62077657|NCT04430296|ACTIVE_COMPARATOR|Continuous Wave cyclophotocoagulation (CW-CPC)|
62077658|NCT03069820|EXPERIMENTAL|Study Population|Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
62077659|NCT04768933|EXPERIMENTAL|Toddler Milk Group|All enrolled subjects with be provided a new toddler milk for 28 days. Aligned with clinical and label recommendations, they will be required to intake at least 3 servings of 130 ml per day.
62077660|NCT05980429|EXPERIMENTAL|Music Therapy, Prescribed|During weeks 2-5, participants in the prescribed music group underwent a minimum of 15 minutes (mandatory) of nightly self-administered music intervention immediately before bedtime.
62457022|NCT01718639|PLACEBO_COMPARATOR|Placebo|1 tablet to be swallowed with water.
62457023|NCT04797403|EXPERIMENTAL|Intervention|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
62457024|NCT04797403|NO_INTERVENTION|Enhanced Usual Care|Enhanced usual care will include an education session on the ACC/AHA hypertension guideline to providers and proper BP measurement to providers and staff at enhanced usual care clinics.Otherwise, no active intervention will take place, and all usual care clinics will follow their routine clinic practice.
62457025|NCT02079532|EXPERIMENTAL|MabThera (Rituximab)|
62457026|NCT05842538|EXPERIMENTAL|MAKO TKA|
62457027|NCT05842538|ACTIVE_COMPARATOR|Conventional|
62457028|NCT06170866|EXPERIMENTAL|Social support for physical activity|Socially supported (peer, family and group) physical activity group.
62646531|NCT02266823|ACTIVE_COMPARATOR|Intervention: Lifestyle A.|"Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
62077661|NCT05980429|EXPERIMENTAL|Music Therapy, Self-selected|During weeks 2-5, participants in the self-selected music group underwent a minimum of 15 minutes (mandatory) of nightly self-administered music intervention immediately before bedtime.
62646532|NCT02266823|OTHER|Intervention: Lifestyle B.|"Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
62077662|NCT05980429|NO_INTERVENTION|No Music Therapy Control|During weeks 2-5, participants in the no-music group continued as usual.
62077663|NCT05406037||Patients with MM|"Age : from 3 to 75 years old ;~- Specific medical conditions : patient hospitalized in one of the departments of the University Hospital of Lille or Amiens, in whom the diagnosis of mucormycosis will have been made on the criteria below, with compatible clinical and radiological evolution :~* conventional mycology data and/or~* positive q-PCR and/or~* pathology data confirmed by PCR;"
62457029|NCT00970697|EXPERIMENTAL|becaplermin gel|application of a continuous thin layer of becaplermin gel (Regranex Gel®) during 8 weeks. The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment.
62457030|NCT00970697|ACTIVE_COMPARATOR|Duoderm Hydrogel™|application of a continuous thin layer of hydrogel dressing (Duoderm Hydrogel®), during 8 weeks. Duoderm Hydrogel™ is a sodium carboxymethylcellulose aqueous-based gel, similar in composition to becaplermin excipient.
62457031|NCT01975805|EXPERIMENTAL|Chlorhexidine Gluconate|Use of Chlorhexidine Gluconate as skin disinfectant for cesarean section.
62457032|NCT01975805|EXPERIMENTAL|Povidone Iodine|Use of Povidone Iodine as skin disinfectant for cesarean section.
62457033|NCT03757364||19 patients with Ps|19 patients with Ps with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
62457034|NCT03757364||13 patients with PsA|13 patients with PsA with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
62457035|NCT03055949|NO_INTERVENTION|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
62457036|NCT03055949|EXPERIMENTAL|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
62457037|NCT02924948|NO_INTERVENTION|Conventional insertion|EUS will be inserted with conventional method.
62457038|NCT02924948|EXPERIMENTAL|Balloon inflated insertion|EUS will be inserted with balloon inflated method
62457039|NCT02829268|EXPERIMENTAL|Pediatric|Pediatric patients treated with dantrolene sodium
62077664|NCT05406037||High-risk patients without MM (control group 1)|"Age : from 18 to 75 ;~- Specific medical conditions : patients hospitalized at the University Hospital of Lille or Amiens for whom a diagnosis of candidiasis or invasive aspergillosis has been made according to specific classifications (EORTC/MSG criteria, AspICU criteria)"
62077665|NCT05406037||Patients with another IFI (control group 2)|"* Age : from 18 to 75 ;~* Specific medical conditions : patients undergoing assessment for haematopoietic stem cell transplantation, considered at risk of invasive fungal infection but for whom the pre-transplant assessment will have excluded an ongoing infection."
62457040|NCT02829268|EXPERIMENTAL|Adult|Adult patients treated with dantrolene sodium
62457041|NCT03239522|EXPERIMENTAL|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of \[14C\]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg \[14C\]-GSK1278863 as an oral solution.
62077666|NCT03172741|PLACEBO_COMPARATOR|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
62077667|NCT03172741|EXPERIMENTAL|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (\<1%) / CBD (\>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
62077668|NCT03172741|EXPERIMENTAL|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (\>10%) / CBD (\<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
62077669|NCT03172741|EXPERIMENTAL|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
62077670|NCT06195124|EXPERIMENTAL|RGL-193（low-dose）Treatment group|Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.
62077671|NCT06195124|EXPERIMENTAL|RGL-193（high-dose）Treatment group|Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.
62077672|NCT05437042||Individuals with pronated foot|
62077673|NCT04308538|ACTIVE_COMPARATOR|Standard Recession|Bilateral lateral rectus muscle recession using standard tables stated by Parks.
62077674|NCT04308538|EXPERIMENTAL|Reduced Recession|Bilateral lateral rectus muscle recession using reduced numbers by one millimeter than the standard tables.
62077675|NCT01603420|ACTIVE_COMPARATOR|Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)|Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
62457042|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
62457043|NCT01921920|ACTIVE_COMPARATOR|Omeprazole 20mg aqueous|Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)
62457044|NCT01921920|ACTIVE_COMPARATOR|Omeprazole 20mg organic|Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)
62457045|NCT01921920|ACTIVE_COMPARATOR|Omeprazole 40mg aqueous|Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)
62077676|NCT01603420|EXPERIMENTAL|Radiation + Chemo + 6mo luteinizing hormone-releasing hormone|Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
62077677|NCT02166918||patients with schizophrenia|320 patients with a diagnosis of schizophrenia according to Diagnostic and Statistical Manual IV edition (DSM-IV) criteria, confirmed by the Structured Clinical Interview for DSM-IV - Patient Version (SCID -IP), will be included in the study.
62457046|NCT01921920|ACTIVE_COMPARATOR|Omeprazole 40mg organic|Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)
62457047|NCT02820090||Success with SBT|The patient have a success in SBT.
62457048|NCT02820090||Success with mechanical ventilation|Weaning from mechanical ventilation is successful
62457049|NCT02820090||failure with SBT|The patient have a failure in SBT.
62457050|NCT02820090||failure with mechanical ventilation|Weaning from mechanical ventilation is failed
62457051|NCT02016170|EXPERIMENTAL|Ticagrelor 180mg|Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
62457052|NCT02016170|EXPERIMENTAL|Ticagrelor 90mg|Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
62457053|NCT02016170|ACTIVE_COMPARATOR|Prasugrel 10mg|Patients already on prasugrel, will maintain prasugrel
62457054|NCT04230226|ACTIVE_COMPARATOR|Pre-workout and Post-workout Product|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
62457055|NCT04230226|PLACEBO_COMPARATOR|Study Placebo|non-caloric powder mixed with water consumed within 30 minutes prior to exercise and within 15 minutes post exercise
62457056|NCT03980483|EXPERIMENTAL|GSK3196165 90mg + MTX|Participants received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with methotrexate (MTX).
62457057|NCT03980483|EXPERIMENTAL|GSK3196165 150mg + MTX|Participants received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with MTX.
62457058|NCT03980483|ACTIVE_COMPARATOR|Tofacitinib 5mg + MTX|Participants received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with MTX plus placebo injection weekly to maintain the blind for 52 weeks.
62457059|NCT03980483|PLACEBO_COMPARATOR|Placebo + MTX and GSK3196165 90mg + MTX|Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with MTX until Week 52.
62457060|NCT03980483|PLACEBO_COMPARATOR|Placebo + MTX and GSK3196165 150mg + MTX|Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with MTX until Week 52.
62077678|NCT02166918||unaffected first-degree relatives|240 unaffected first-degree relatives of the recruited patients (120 unaffected parents and 120 unaffected siblings)
62077679|NCT02166918||healthy control|320 healthy control subjects.
62077680|NCT03300375|ACTIVE_COMPARATOR|Home-Based Resistance Exercise Intervention Group|Participants in the HBRX group will be coached through six phases of the intervention with two weeks per phase. Exercise will use body weight and resistance exercise bands. A set of commercial elastic resistive bands and a stability pad (TheraBand, Inc.) will be provided to each participant to keep for personal use after their participation in the study. The use of elastic bands for resistance training can induce similar results in neuromuscular adaptations as well as strength to those achieved by weight machines and free-weights.
62077681|NCT03300375|EXPERIMENTAL|Wait-List Control Condition Group|Participants who are assigned to the CON group will wait to participate in the resistance training after a three month wait period. Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time. The participants will be contacted by phone on a monthly basis during the study period to determine if any changes in LBP symptoms have occurred. At month three, these participants will also receive the elastic resistive bands and a stability pad.
62077682|NCT06270420|EXPERIMENTAL|HosmartAI training|HosmartAI training will consist of motor training provided by technological devices (i.e. OAK, VRRS, AMADEO, PABLO) in the HoSmartAI room.
62077683|NCT06545396|ACTIVE_COMPARATOR|Conventional photodynamic therapy with red light and methyl aminolevulinate|PDT exposing the area to a red light source for 8 minutes with a spectrum of 630 nm and 37J/cm2, with the illumination intensity being less than 200 mW/cm2.
62077684|NCT06545396|EXPERIMENTAL|Half-dose illumination protocol photodynamic therapy with red light and methyl aminolevulinate|PDT exposing the area to a red light source for 8 minutes with a spectrum of 630 nm and 18,5J/cm2, with the illumination intensity being less than 200 mW/cm2.
62077685|NCT01711138||Intervention|Intervention group is geographically located near a built environment intervention (neighbourhood redevelopment).
62077686|NCT01711138||Comparison|Comparison group is not exposed to the built environment intervention according to their geographic location.
62077687|NCT01450787||diabetics|diabetics
62077688|NCT01450787||non diabetics|non diabetics
62077689|NCT01095705|ACTIVE_COMPARATOR|Conventional procedure|Local anaesthesia (Lidocaïne)
62077690|NCT01095705|EXPERIMENTAL|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) and Hypnosis
62077691|NCT05293288|EXPERIMENTAL|EEG-guided general anesthesia|EEG-guided general anesthesia group (i.e., intervention group): For pEEG monitoring we will use the SEDLine monitor (Masimo, Irvine, CA) which provides the patient state index (PSi; a processed EEG parameter with values from 1 to 100), density spectral array (DSA; a display that represents the frequencies and amplitudes of brain waves through time), spectral edge frequency (SEF), and the raw EEG signal.
62457061|NCT03980483|PLACEBO_COMPARATOR|Placebo + MTX and Tofacitinib 5mg + MTX|Participants received Placebo capsule weekly in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with MTX plus placebo injection to maintain the blind for 52 weeks.
62077692|NCT05293288|NO_INTERVENTION|Routine care|Routine care group (i.e., control group): Adjustment of depth of general anesthesia will be at the discretion of the treating anesthesiologist.
62457062|NCT01023074|NO_INTERVENTION|Non-MS Control|Non-MS control group
62457063|NCT01023074|ACTIVE_COMPARATOR|MS: Auditory Training|MS group receiving auditory training
62457064|NCT01023074|PLACEBO_COMPARATOR|MS: Control Activity|MS group not receiving auditory training, doing control activity
62457065|NCT02722590||All Participants|Participants who are prescribed Fycompa (Perampanel) film-coated tablets and oral suspension per approved prescribing information in a normal clinical practice setting will be enrolled and observed prospectively for up to 24 Weeks.
62457066|NCT02997800|EXPERIMENTAL|Esmolol|Esmolol infusion and 1 ml saline infusion
62457067|NCT02997800|EXPERIMENTAL|Labetalol|Labetalol Bolus and saline infusion
62457068|NCT02997800|ACTIVE_COMPARATOR|Fentanyl|Fentanyl Bolus and saline infusion
62646533|NCT01107145|EXPERIMENTAL|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
62077693|NCT03741205|EXPERIMENTAL|Treatment Group|SPEAC System
62077694|NCT03741205|NO_INTERVENTION|Standard of Care|Standard of Care
62457069|NCT04323202|EXPERIMENTAL|Permbrolizumab|Participants will undergo fine cut CT imaging (head and neck) followed by at least 4 doses of pembrolizumab q 3 weeks. After the 4th dose of pembrolizumab as appropriate, patients will undergo standard surgical resection, with all non-marginal tissue as well as the pre-op biopsy to be stored for collateral research. 2 weeks after initial flap or graft insert (which would be equivalent to stage 1 of a forehead flap) patients would continue for a total of approximately 1 year of pembrolizumab q 3 weeks (another 13 doses, thus 17 doses total).
62077695|NCT01551251||Advanced NSCLC with high TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
62457070|NCT05845996|EXPERIMENTAL|SAR441344|Single or multiple Ascending dose of SAR441344 Dose 1 administered intravenously and/or subcutaneously
62457071|NCT05845996|PLACEBO_COMPARATOR|placebo|matching placebo
62457072|NCT04941248||Healthy controls|All healthy subjects will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
62077696|NCT01551251||Advanced NSCLC with low TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
62457073|NCT04941248||Patients with decreased cardiac function|All patients will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
62457074|NCT01643707||Phase I|Control
62457075|NCT01643707||Phase II|Treatment
62457076|NCT04630938|ACTIVE_COMPARATOR|G-M|Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative.
62457077|NCT04630938|ACTIVE_COMPARATOR|G-ML|Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative.
62457078|NCT04630938|PLACEBO_COMPARATOR|G-0|Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups.
62457079|NCT06256536|EXPERIMENTAL|GZR18|GZR18 injection s.c.
62457080|NCT06256536|PLACEBO_COMPARATOR|Placebo|Placebo injection s.c.
62457081|NCT03308019|EXPERIMENTAL|Adjunctive photodynamic therapy|This arm will be given scaling and root planing (SRP) with adjunctive photodynamic therapy (aPDT)
62457082|NCT03308019|ACTIVE_COMPARATOR|Dental scaling|This arm will be given scaling and root planing (SRP) only
62457083|NCT01545076|EXPERIMENTAL|IgPro20 low dose|
62457084|NCT01545076|EXPERIMENTAL|IgPro20 high dose|
62457085|NCT01545076|PLACEBO_COMPARATOR|Placebo|
62457086|NCT06093997|EXPERIMENTAL|Experimental Group|Cupping and bloodletting therapy
62077697|NCT02247414|EXPERIMENTAL|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
62457087|NCT06093997|EXPERIMENTAL|Control Group|Massage treatment
62457088|NCT03436680|EXPERIMENTAL|Group I (neurofeedback)|Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.
62457089|NCT03436680|ACTIVE_COMPARATOR|Group II (standard of care)|Participants receive standard of care.
62457090|NCT00097695|EXPERIMENTAL|Icatibant- Randomized|Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.
62457091|NCT00097695|PLACEBO_COMPARATOR|Placebo-Randomized|Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.
62457092|NCT00097695|EXPERIMENTAL|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
62457093|NCT00097695|EXPERIMENTAL|Untreated Patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )
62457094|NCT04833998|PLACEBO_COMPARATOR|Placebo|Placebo will be cream without the active ingredient. It will be matched in appearance, smell, consistency, and color to Extremecare topical cream. Patients will be instructed to apply the placebo cream to the hand and feet.
62457095|NCT04833998|EXPERIMENTAL|Extremecare|Extremecare is a moisturizing cream based on Thoitaine, Aloe Vera and Calendula for topical use. Patients will be instructed to apply the moisturizing cream to the hand and feet.
62457096|NCT01439165|EXPERIMENTAL|Adacel® Vaccine Group|Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)
62457097|NCT01439165|ACTIVE_COMPARATOR|Td Adsorbed Vaccine Group|Participants randomized to receive Subjects randomized to receive a Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine.
62457098|NCT04217720|EXPERIMENTAL|SNS-301|SNS-301
62457099|NCT06367829||Primary hip replacement patients|Patients who have received primary hip replacement therapy with an indication of osteoarhritis, osteonecrosis or fracture.
62457100|NCT02146430|EXPERIMENTAL|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
62457101|NCT02146430|EXPERIMENTAL|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
62077698|NCT02247414|ACTIVE_COMPARATOR|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
62077699|NCT06112613|EXPERIMENTAL|ARM A (Enhanced usual care)|Patients use the WiseBag medication dispenser and receive access to educational materials every 4 weeks over 12 months.
62646534|NCT01107145|EXPERIMENTAL|Artemether-Lumefantrine|Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
62077700|NCT06112613|EXPERIMENTAL|ARM B (CONCURxP program)|Patients use the WiseBag medication dispenser and receive personalized text message reminders, medication tracking and healthcare provider follow ups as part of the CONCURxP platform over 12 months. Patients may complete an interview over 20-30 minutes within 6 months of study completion.
62077701|NCT06112613|EXPERIMENTAL|ARM C (Non-patient interview)|Participants complete an interview over 20-30 minutes 15-39 months post-first patient enrollment.
62077702|NCT04672512|EXPERIMENTAL|SAD Cohort A CORT125329|Participants will receive a single dose of CORT125329 30 mg lipid capsule formulation 1 in the fasted state on Day 1
62077703|NCT04672512|EXPERIMENTAL|SAD Cohort B CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 in the fasted state on Day 1. The dose will be determined after review of safety, tolerability, and PK data from SAD Cohort A.
62077704|NCT04672512|EXPERIMENTAL|SAD Cohorts C through H CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
62646535|NCT01107145|ACTIVE_COMPARATOR|Chloroquine|Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
62646536|NCT04101292|EXPERIMENTAL|Fluorescence characterization|
62077705|NCT04672512|PLACEBO_COMPARATOR|SAD Cohorts A through H Placebo|Participants will receive a single dose of placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each placebo cohort will match that used in the corresponding CORT125329 cohort.
62077706|NCT04672512|EXPERIMENTAL|MAD Cohorts A through D CORT125329|Participants will receive CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency (once- or twice-daily), formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
62077707|NCT04672512|PLACEBO_COMPARATOR|MAD Cohorts A through D Placebo|Participants will receive placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency, formulation, and prandial state for each cohort will match that used in the corresponding CORT125329 cohort.
62077708|NCT04672512|EXPERIMENTAL|Pharmacodynamic (PD) Effect Cohort|Participants will receive a single dose of prednisone 25 mg in the fasted or fed state on Day 1 of Period 1. The prandial state for the Period 1 treatment will be determined after review of safety and tolerability data from the SAD Cohorts. After a 7-day washout period, participants will receive a single dose of prednisone 25 mg and a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 of Period 2. The formulation and dose level of CORT125329 treatment in Period 2 will be determined after review of safety, tolerability, and PK data from the SAD cohorts. The prandial state for treatment in Period 2 will be the same used in Period 1.
62646537|NCT01973881||T1 weighted MRI (magnetic resonance imaging)|For the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters.
62077709|NCT01815814|EXPERIMENTAL|Rolfing After 3-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 3 months after they start the study.
62646538|NCT02965924|EXPERIMENTAL|Phenylephrine|Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
62646539|NCT04509271||Normal aged|
62646540|NCT04509271||MCI due to AD|
62646541|NCT04509271||Mild AD|
62646542|NCT04509271||Moderate AD|
62646543|NCT04509271||Severe AD|
62077710|NCT01815814|OTHER|Rolfing After 6-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 6 months after they start the study.
62077711|NCT00955006|EXPERIMENTAL|Group 1|Participants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
62077712|NCT01369056|EXPERIMENTAL|Advanced Adherence Counseling (AdvAdh)|Please see the Intervention Description section
62077713|NCT01369056|NO_INTERVENTION|Control|Standard of care (including counseling regarding antiretroviral treatment adherence) received by HIV/AIDS patients at the study clinic
62077714|NCT01652820|EXPERIMENTAL|Docetaxel +Carboplatin +concomitant chemoradiation|Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
62077715|NCT01652820|EXPERIMENTAL|C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom|Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
62077716|NCT03227484|ACTIVE_COMPARATOR|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
62077717|NCT03227484|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet once daily over 8 weeks
62646544|NCT04509271||Dementia with Lewy body|
62646545|NCT04509271||Frontotemporal dementia|
62646546|NCT02130869|EXPERIMENTAL|Group A: Neuroblastoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group A participants receive busulfan, melphalan, CD133+ selected autologous stem cell infusion, hu14.18K322A, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
62646547|NCT02130869|EXPERIMENTAL|Group B: Lymphoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group B participants receive bendamustine, etoposide (or etoposide phosphate), cytarabine, melphalan, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
62077718|NCT01130883||Respiratory Infections|Czech patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid®SR treatment 6 weeks prior to the next Klacid®SR dose or in intervals: 7-week - 3- month, 4- month - 12- month, 13- month - 24- month prior to the next Klacid®SR dose (next Klacid®SR dose = dose administered within this PMOS).
62077719|NCT06197243|EXPERIMENTAL|Feasibility, Adherence and Acceptability Measure|Assay of feasibility of study enrollment and feasibility of study treatments, the latter of which is measured via fidelity, adherence, and acceptability of/to treatments and interventions. Interventions administered for 12 weeks. Fidelity, adherence, and acceptability will be measured via patient survey and engagement.
62077720|NCT01997320|EXPERIMENTAL|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks combined with nutrient supplementation twice daily each containing 20g of milk protein.
62077721|NCT01997320|ACTIVE_COMPARATOR|Nutrition supplement|Nutrient supplementation twice daily for 12 weeks. Each supplement contains 20g of milk protein.
62646548|NCT02130869|EXPERIMENTAL|Group C: High-Risk Tumors|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group C participants receive melphalan, etoposide (or etoposide phosphate), carboplatin, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
62077722|NCT01448044|EXPERIMENTAL|BMS-790052 + PegIFNα-2a + Ribavirin|"* BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~* PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~* Ribavirin 400 mg (2 tablets for participants \< 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response"
62457102|NCT02146430|ACTIVE_COMPARATOR|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
62457103|NCT02146430|PLACEBO_COMPARATOR|Placebo|Participants take one each of placebo tablet and capsule BID
62646549|NCT01725672|ACTIVE_COMPARATOR|Part A and B:Arm 1: 500 mg metformin XR / 1 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 500 mg metformin XR and 1 mg glimepiride IR on Day 1 of the respective period per randomized sequence
62646550|NCT01725672|ACTIVE_COMPARATOR|Part A and B:Arm 2: 1000 mg metformin XR / 2 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 1000 mg metformin XR and 2 mg glimepiride IR on Day 1 of the respective period per randomized sequence
62646551|NCT01725672|EXPERIMENTAL|Part A:Arm 3: 500 mg metformin XR and 1 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
62646552|NCT01725672|EXPERIMENTAL|Part A:Arm 4: 1000 mg metformin XR and 2 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
62646553|NCT01725672|EXPERIMENTAL|Part B:Arm 5: 500 mg metformin XR and 1 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC3) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
62646554|NCT01725672|EXPERIMENTAL|Part B:Arm 6: 1000 mg metformin XR and 2 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC4) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
62077723|NCT01448044|PLACEBO_COMPARATOR|Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin|"* Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~* PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~* Ribavirin 400 mg (2 tablets for participants \< 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks"
62077724|NCT03864289|EXPERIMENTAL|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours.
62077725|NCT03546361|EXPERIMENTAL|Treatment (Ad-CCL21-DC vaccine, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by autologous dendritic cell-adenovirus CCL21 vaccine by CT-guided or bronchoscopic IT injection on days 0, 21, and 42. Patients then receive pembrolizumab every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
62457104|NCT05508100|EXPERIMENTAL|Part A: IO-108 monotherapy dose confirmation|Patients with advanced or metastatic solid tumors will be enrolled and treated with IO-108, intravenously, every 21 days.
62457105|NCT05508100|EXPERIMENTAL|Part B: IO-108 + anti-PD-1 dose confirmation.|Patients will receive IO-108 in combination with with a fixed dose of pembrolizumab, intravenously, every 21 days; Patients will receive IO-108 in combination with with a fixed dose of tislelizumab, intravenously, every 21 days.
62646555|NCT03118050|EXPERIMENTAL|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.
62646556|NCT03118050|EXPERIMENTAL|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
62457106|NCT05508100|EXPERIMENTAL|Part C: Dose expansion|Patients with advanced or metastatic solid tumors who meet the specific criteria will be enrolled into one of the cohorts.
62646557|NCT03118050|EXPERIMENTAL|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
62077726|NCT00321334|ACTIVE_COMPARATOR|Docetexel|Chemotherapy+Surgery
62457107|NCT01880034||Regional Anesthesia Section Heads|This group will consist of Regional Anesthesia Section Heads at anesthesia residency training programs.
62646558|NCT03118050|EXPERIMENTAL|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
62646559|NCT03118050|EXPERIMENTAL|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
62457108|NCT03131180|EXPERIMENTAL|RLHS dashboard|Patients randomized to RLHS website access are given instructions on how the RLHS dashboard works both by phone and by email and are given open access to the RLHS dashboard website immediately after enrollment and before meeting with the CCPR clinical team for their consultation. Each user has an access code, which allows them to track their access. They maintain access to the website throughout their care in the CCPR. Patients in the RLHS access group complete the System Usability Scale (SUS; a 10 item questionnaire to evaluate software, websites, and applications) after use of the RLHS at consultation. Those in the RLHS access group also complete a 7-item exit interview either via phone or on REDCap.
62457109|NCT03131180|NO_INTERVENTION|Standard consultation alone|Those not randomized to RLHS access undergo standard consultation only.
62457110|NCT05543356|ACTIVE_COMPARATOR|Monovalent Pfizer-BioNTech(BNT162b2): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Tozinameran - Monovalent Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
62077727|NCT00967018|EXPERIMENTAL|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. For patients treated with goserelin in the previous trials (CS28, CS30 and CS31),a starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to the end of the trial. For patients treated with degarelix in the previous trials, maintenance doses of 80 mg (20 mg/mL) degarelix were continued and were administered as single 4 mL s.c. injections at 28 day intervals to the end of the trial.
62077728|NCT03653416|EXPERIMENTAL|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
62077729|NCT03653416|ACTIVE_COMPARATOR|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
62077730|NCT02218489|PLACEBO_COMPARATOR|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
62077731|NCT02218489|ACTIVE_COMPARATOR|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
62077732|NCT03529422|OTHER|Open-label, single-arm|Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments
62077733|NCT00118144|EXPERIMENTAL|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1 and 8.
62077734|NCT04241575|EXPERIMENTAL|Intervention group|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
62457111|NCT05543356|ACTIVE_COMPARATOR|Monovalent Moderna(mRNA-1273, Spikevax®): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Elasomeran - Monovalent Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)."
62457112|NCT05543356|ACTIVE_COMPARATOR|Monovalent Pfizer-BioNTech(BNT162b2): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Tozinameran - Monovalent Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
62457113|NCT05543356|ACTIVE_COMPARATOR|Monovalent Moderna(mRNA-1273, Spikevax®):AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Elasomeran - Monovalent Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)."
62646560|NCT03118050|EXPERIMENTAL|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
62646561|NCT03118050|EXPERIMENTAL|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
62646562|NCT02273167|EXPERIMENTAL|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
62646563|NCT02273167|EXPERIMENTAL|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
62077735|NCT04241575|NO_INTERVENTION|Control group|Patients in the control group will undergo the same assessments as patients in the intervention group. Although physicians will have access to the raw liver biochemistry results and platelet count, the fibrosis score results will not be specifically shown, and there will be no electronic reminder messages regardless of the fibrosis scores. This is to mimic usual care when there is no dedicated care model for case identification.
62077736|NCT01649596|ACTIVE_COMPARATOR|Warming Gown|Comparison of two types of warming processes prior to, during, and after the surgery procedure.
62077737|NCT01649596|OTHER|Standard of Care Warming|Standard of care warming with hospital-issued blankets.
62457114|NCT05543356|ACTIVE_COMPARATOR|Bivalent Pfizer-BioNTech (BNT162b2 OMI): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Pfizer-BioNTech, BNT162b2 OMI - bivalent Pfizer-BioNTech bivalent COVID-19 vaccine contains ancestral BNT162b2 and Omicron variant BNT162b2 Omi (BA.1). The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
62457115|NCT05543356|ACTIVE_COMPARATOR|Bivalent Moderna (mRNA-1273.214): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\])."
62457116|NCT05543356|ACTIVE_COMPARATOR|Bivalent Pfizer-BioNTech (BNT162b2): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1-S, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Pfizer-BioNTech, BNT162b2 OMI - bivalent Pfizer-BioNTech bivalent COVID-19 vaccine contains ancestral BNT162b2 and Omicron variant BNT162b2 Omi (BA.1). The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA."
62457117|NCT05543356|ACTIVE_COMPARATOR|Bivalent Moderna (mRNA-1273.214): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1-S, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\])."
62457118|NCT00852436|ACTIVE_COMPARATOR|1|Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
62077738|NCT01060020|EXPERIMENTAL|Sildenafil 40mg or 80mg|A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (\<50%) EF.
62457119|NCT00852436|PLACEBO_COMPARATOR|2|Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
62457120|NCT01949428||HDM-Induced Rhinoconjunctivitis Subjects|
62457121|NCT02037997|EXPERIMENTAL|combination with Erlotinib|Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2
62457122|NCT02037997|ACTIVE_COMPARATOR|sequential chemotherapy for Erlotinib|docetaxel 75mg/m2 or pemetrexed 500mg/m2，after PD，Erlotinib 150mg qd
62457123|NCT00843271||MESA Lung|MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
62077739|NCT04555915||Intervention group|Intervention Group of the SafeboosC Phase III Trial
62457124|NCT05522907||Neoadjuvant|From the beginning of the project for the past five years to the next three years, underwent prostate cancer biopsies at the First Affiliated Hospital of Xi'an Jiaotong University before neoadjuvant therapy, and underwent radical prostatectomy after 3-6 months of neoadjuvant therapy.
62457125|NCT05522907||CRPC|Patients with CRPC-diagnosed prostate cancer after initial continuous ADT therapy, with serum testosterone reaching castration levels (\<50ng/dl or \<1.7nmol/L) but with progressive disease, and who were diagnosed with CRPC at Xi'an Jiaotong University The First Affiliated Hospital did a prostate cancer biopsy.
62457126|NCT02395003||High VAT/SAT high Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming high Palmatite oil diet for 12 weeks
62457127|NCT02395003||Low VAT/SAT|Subjects with a low ratio of visceral to subcutaneous fat
62457128|NCT02395003||Lean Controls|Lean control
62077740|NCT04555915||Control group|Control Group of the SafeboosC Phase III Trial
62077741|NCT04443439||No related neurological symptoms and transient ischemic attack|Mild stenosis group: CTA suggested carotid stenosis \< 30%; Moderate stenosis group: CTA suggested carotid stenosis of 30-69%; Severe stenosis group: CTA indicated carotid stenosis ≥70%;
62077742|NCT01225835|EXPERIMENTAL|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
62077743|NCT01225835|ACTIVE_COMPARATOR|Follitrophin Alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
62077744|NCT00199030|EXPERIMENTAL|Arm A|In Arm A, patients with refractory relapse receive a 2 week treatment with MabCampath followed by remission evaluation. In case of insufficient response, treatment with cladribine is added.
62077745|NCT00199030|EXPERIMENTAL|Arm B|In Arm B, patients with molecular relapse (minimal residual disease) receive a 4 week treatment with MabCampath followed by remission evaluation.
62077746|NCT01574547||Cat Scratch Colon|Patients with mucosal tears during colonoscopy
62077747|NCT01574547||Control group|Patients without mucosal tears during the colonoscopy
62077748|NCT02653014|EXPERIMENTAL|Cohort 1|Healthy Volunteers will receive 2.5mg of KBP-5074, QD, 14 days
62077749|NCT02653014|EXPERIMENTAL|Cohort 2|Healthy Volunteers will receive 5.0mg of KBP-5074, QD, 14 days
62077750|NCT02653014|EXPERIMENTAL|Cohort 3|Subjects with mild to moderate renal impairment will receive 0.5mg of KBP-5074, QD, 56 days
62077751|NCT02653014|EXPERIMENTAL|Cohort 4|Subjects with mild to moderate renal impairment will receive 2.5mg of KBP-5074, QD, 56 days
62077752|NCT02605161||Parkinson's disease group|"* patients diagnosed with Parkinson's disease by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~* to undergo pre-operative MRI with contrast"
62077753|NCT02605161||Control group|"* patients diagnosed with either essential tremor or cervical dystonia by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~* to undergo pre-operative MRI with contrast"
62077754|NCT00747058|EXPERIMENTAL|healthy volunteers|
62077755|NCT00747058|PLACEBO_COMPARATOR|Placebo|
62077756|NCT03896451|OTHER|GMK Sphere|"Patients receiving total knee replacement surgery with the device Medacta GMK Sphere"
62646564|NCT02273167|ACTIVE_COMPARATOR|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
62077757|NCT03896451|OTHER|GMK PS|"Patients receiving total knee replacement surgery with the device Medacta GMK PS"
62077758|NCT02342184|EXPERIMENTAL|GB-0998|
62077759|NCT01402258|EXPERIMENTAL|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
62077760|NCT06078930||Patients with gastric cancer|
62077761|NCT06078930||Healthy participants|
62077762|NCT05385328||Healthy people|Undiagnosed persons will be evaluated by the EYEFUL system performing activities of daily living. Patterns of action will be recorded, to establish outcome measures in healthy population.
62077763|NCT05385328||people with physical or psychological diagnoses|People with various clinical diagnoses will be evaluated by the EYEFUL system performing activities of daily living. Patterns of action will be recorded, in order to establish outcome measures in comparison with healthy population and with other diagnoses.
62077764|NCT01542541|EXPERIMENTAL|Rifaximin|
62077765|NCT01542541|NO_INTERVENTION|Control|Randomly-selected matched PET-CT scans performed on same day as intervention group.
62077766|NCT01761786|NO_INTERVENTION|Control group|CYP2C19 genotyping will be performed after end of study. Patients will be treated with prasugrel or ticagrelor, according to local protocol.
62077767|NCT01761786|ACTIVE_COMPARATOR|Intervention group|CYP2C19 genotyping will be performed \<48h after PCI and antiplatelet treatment will be chosen based on genotyping results.
62077768|NCT01235975|EXPERIMENTAL|Group A|
62077769|NCT01235975|ACTIVE_COMPARATOR|Group B|
62077770|NCT02100540|PLACEBO_COMPARATOR|I placebo capsule|I placebo capsule
62077771|NCT02100540|EXPERIMENTAL|II RDC 0.3mg capsule|II RDC 0.3mg capsule
62077772|NCT02100540|EXPERIMENTAL|III RDC 0.6mg capsule|III RDC 0.6mg capsule
62077773|NCT00488215|ACTIVE_COMPARATOR|1|Prucalopride
62077774|NCT00488215|PLACEBO_COMPARATOR|2|Placebo
62077775|NCT02311322||Children with growth disorders|Children with growth disorders
62077776|NCT02311322||Family members of subjects with growth disorders|Family members of subjects with growth disorders
62077777|NCT03786484|EXPERIMENTAL|PBF-999 20 mg|
62077778|NCT03786484|EXPERIMENTAL|PBF-999 40 mg|
62077779|NCT03786484|EXPERIMENTAL|PBF-999 80 mg|
62077780|NCT03786484|EXPERIMENTAL|PBF-999 120 mg|
62077781|NCT03786484|EXPERIMENTAL|recommended phase 2 dose (RP2D)|
62077782|NCT01287793|EXPERIMENTAL|high dose tigecycline|
62646565|NCT06481787|EXPERIMENTAL|Vonorasan fumarate|Vonorasan fumarate, 20 mg twice daily orally before meals for 8 weeks of treatment.
62077783|NCT01287793|EXPERIMENTAL|regular dose tigecycline|
62077784|NCT01287793|ACTIVE_COMPARATOR|moxifloxacin|
62077785|NCT01287793|PLACEBO_COMPARATOR|placebo|
62077786|NCT01471158|ACTIVE_COMPARATOR|Azarga/Cosopt|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Azarga will be instilled one drop in each eye on Day One, after which Cosopt will be administered one drop in each eye on Day Two.
62077787|NCT01471158|ACTIVE_COMPARATOR|Cosopt/Azarga|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Cosopt will be administered one drop in each eye on Day One, after which Azarga will be administered one drop in each eye on Day Two.
62077788|NCT04091906|EXPERIMENTAL|Healthy donor|
62077789|NCT02404493|ACTIVE_COMPARATOR|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
62077790|NCT02404493|EXPERIMENTAL|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
62077791|NCT02951299|EXPERIMENTAL|pentoxifylline group|Received oral pentoxifylline (400 mg) three times a day for 14 days.
62077792|NCT02951299|NO_INTERVENTION|no treatment group|No intervention.
62077793|NCT01224808|EXPERIMENTAL|Experimental|
62077794|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
62077795|NCT05743192||Before group|Group of patients with a positive urine culture for Enterococcus faecalis before the procedure consisting of systematically performing an antibiotic susceptibility test.
62077796|NCT05743192||After group|Group of patients with a positive urine culture for Enterococcus faecalis after the procedure consisting of systematically performing an antibiotic susceptibility test.
62077797|NCT00859131|ACTIVE_COMPARATOR|Thymoglobulin|Subjects receiving Thymoglobulin as induction agent in renal transplantation
62077798|NCT00859131|ACTIVE_COMPARATOR|Zenapax|subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
62457129|NCT02395003||High VAT/SAT- low Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming low Palmatite oil diet for 12 weeks
62077799|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA \<26
62077800|NCT03403257||Caregivers|Primary caregivers of subjects
62077801|NCT01958762|OTHER|Screening for cancers in the oral cavity|
62457130|NCT03724149|EXPERIMENTAL|Direct-acting antiviral treatment for HCV|
62457131|NCT04315857||diabetics|diabetics receiving chemotherapy for cancer
62077802|NCT06424379||Follicular lymphomas with BCL6 gene rearrangement|Diagnoses of follicular lymphomas based on the last World Health Organization (WHO) classification of haematolymphoid tumours at the time of occurrence of the disease. Fluorescence in situ hybridization (FISH) utilizes Vysis' Dual-Color Break-Apart Rearrangement Probes to detect BCL6 gene alterations. FISH patterns have been interpreted following established protocols.
62457132|NCT03249064||Vitiligo untreated patients|
62457133|NCT03249064||Control. Patients without vitiligo|
62457134|NCT05703308|EXPERIMENTAL|MenSCs group|Study group, treated with autologous intra-ovarian MenSCs injection and monitored for spontaneous pregnancy for 3 months after intervention. ICSI was used in cases where the pregnancy did not occur naturally.
62457135|NCT05703308|NO_INTERVENTION|ICSI group|Control group, monitored for spontaneous pregnancy for 3 months after their last ovarian stimulation for ICSI or IVF. ICSI was used in cases where the pregnancy did not occur naturally.
62077803|NCT06424379||Marginal zone lymphomas with BCL6 gene rearrangement|Diagnoses of marginal zone lymphomas based on the last WHO classification of haematolymphoid tumours at the time of occurrence of the disease. FISH utilizes Vysis' Dual-Color Break-Apart Rearrangement Probes to detect BCL6 gene alterations. FISH patterns have been interpreted following established protocols.
62457136|NCT00515203|PLACEBO_COMPARATOR|II.|5 thrombocytopenic (as defined per protocol) subjects
62457137|NCT00515203|EXPERIMENTAL|I.|15 thrombocytopenic (as defined per protocol) subjects
62646566|NCT06481787|EXPERIMENTAL|Zuojin Pills combined with Vonorasan Fumarate|Add Zuojin Pills, 3g each time, twice daily, on top of Vonorasan Fumarate treatment for 8 weeks.
62077804|NCT06424379||Diffuse large B-cells lymphomas with BCL6 gene rearrangement|Diagnoses of diffuse large B-cells lymphomas based on the last WHO classification of haematolymphoid tumours at the time of occurrence of the disease. FISH utilizes Vysis' Dual-Color Break-Apart Rearrangement Probes to detect BCL6 gene alterations. FISH patterns have been interpreted following established protocols.
62457138|NCT05189184|EXPERIMENTAL|Study group|Inductive therapy with Camrelizumab and Apatinib Plus Albumin-bound paclitaxel and cisplatin
62457139|NCT04894747|EXPERIMENTAL|Mycoprotein|Bolus ingestion of mycoprotein providing 25g of protein.
62457140|NCT04894747|EXPERIMENTAL|Pea protein|Bolus ingestion of pea protein providing 25g of protein.
62457141|NCT04894747|EXPERIMENTAL|Mycoprotein/pea protein dry blend|Bolus ingestion of mycoprotein/pea protein dry blend providing 25g of protein.
62457142|NCT01159548|NO_INTERVENTION|Saline|
62457143|NCT01159548|OTHER|Promethazine 6.25 mg|
62457144|NCT01159548|OTHER|Promethazine 3 mg|
62457145|NCT01056770|EXPERIMENTAL|Vaccinia-naive group|2.5 \* 10\^5 pfu/dose
62457146|NCT00733616|EXPERIMENTAL|1|
62457147|NCT04339465|EXPERIMENTAL|CARE-FAM|The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).
62646567|NCT04236037|ACTIVE_COMPARATOR|Ultrasound-guided thoracentesis|Ultrasound guided thoracentesis
62646568|NCT04236037|EXPERIMENTAL|Ultrasound-guided pleural biopsy and thoracentesis|Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis
62646569|NCT03686592|EXPERIMENTAL|pancreatectomized patients|Patients with pancreatic cancer who underwent a pancreatectomy at Institut Paoli Calmettes
62646570|NCT03686592|ACTIVE_COMPARATOR|Volunteers|
62646571|NCT01433159|EXPERIMENTAL|HP011-101|
62646572|NCT01433159|ACTIVE_COMPARATOR|Various|Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
62077805|NCT04198532|EXPERIMENTAL|Complex Regional Pain Syndrome(CRPS) group|Stroke patients with complex regional pain syndrome
62077806|NCT04198532|OTHER|Control Group|Stroke patients without complex regional pain syndrome
62077807|NCT03584893||Epidemiologic observational study cohort|All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.
62077808|NCT04001140|ACTIVE_COMPARATOR|Intervention group|The intervention group will take part in the sessions of the intervention, in which they learn different skills for the purpose of emotion regulation. All participants will complete the questionnaires and take part in the experiment again. This group prevention program, which is short-term, entailing 7 sessions, synthesizes techniques from three therapeutic models: Cognitive-Behavioral Therapy, Dialectical-Behavioral Therapy and Acceptance and Commitment Therapy.
62646573|NCT01694693||RA patients treated by Orencia|RA patients treated by Orencia according to usual practice from June 1st 2007
62646574|NCT01892332|OTHER|lidocaine with fentanyl 75ug|
62646575|NCT05463965|EXPERIMENTAL|Treatment Group|Single injection with QM1114-DP in glabellar lines
62646576|NCT05463965|ACTIVE_COMPARATOR|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
62646577|NCT05463965|PLACEBO_COMPARATOR|Placebo-Controlled Group|Single injection with placebo in glabellar lines
62646578|NCT03059667|ACTIVE_COMPARATOR|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:~* topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)~* or re-induction by carboplatin - etoposide chemotherapy."
62646579|NCT03059667|EXPERIMENTAL|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
62646580|NCT04042831|EXPERIMENTAL|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial, and collection of blood and tissue samples on study.
62646581|NCT06376968|EXPERIMENTAL|BioLogic Fusion followed by standard dialysis|Patients will be dialysed first with the BioLogic Fusion feature activated and then switched to standard dialysis with the BioLogic Fusion feature de-activated
62646582|NCT06376968|EXPERIMENTAL|Standard dialysis followed by BioLogic Fusion|Patients will be dialysed first with standard dialysis with the BioLogic Fusion feature de-activated and then switched to the BioLogic Fusion feature activated
62646583|NCT00466817|EXPERIMENTAL|Valganciclovir|Six months of oral Valganciclovir.
62646584|NCT00466817|PLACEBO_COMPARATOR|Placebo|Six weeks of oral Valganciclovir followed by placebo to complete the six month time period.
62646585|NCT02080416|EXPERIMENTAL|Nelfinavir|Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles
62646586|NCT02126280||Subclinical atherosclerosis|In vitro estimation of individual reactivity of monocytes in study participants with asymptomatic atherosclerotic plaques found in carotid arteries by ultrasound examination
62646587|NCT02126280||Healthy subjects|In vitro estimation of individual reactivity of monocytes in study participants without ultrasound signs of subclinical carotid atherosclerosis
62646588|NCT02126280||Diffuse intimal thickening|In vitro estimation of individual reactivity of monocytes in study participants with diffuse intima-media thickening of carotid arteries found at ultrasound examination
62646589|NCT03538041|EXPERIMENTAL|Parsaclisib 1 mg QD|Parsaclisib at 1 milligram (mg) once daily (QD) for 12 weeks followed by extension period, with a dose-increase option (to 2.5 mg QD) at Week 6 for participants who fulfill dose increase criteria.
62646590|NCT03538041|EXPERIMENTAL|Parsaclisib 2.5 mg QD|Parsaclisib at 2.5 mg QD for 12 weeks followed by extension period.
62646591|NCT02420639|EXPERIMENTAL|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
62646592|NCT03404245|ACTIVE_COMPARATOR|Immediate Intervention Group|Education, Fitbit/self-management web app, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered physical therapist (PT), and an orientation to the Fitbit device and the web app. Participants will be provided access to a Fitbit and an app account. The PT will review physical activity goals with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using Fitbit and the app and have access to a PT via email as needed, but no phone call. In Months 7-12, participants may keep their Fitbit and app account, but will not have access to a PT.
62646593|NCT03404245|PLACEBO_COMPARATOR|Delayed Intervention Group|Same intervention with a 6 month delay: The full intervention will be initiated in Month 7 and 8 with a brief education session, use of a Fitbit paired with the self-management web app, and counseling by a physical therapist (PT). In Month 9-12, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
62646594|NCT03473405|SHAM_COMPARATOR|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
62646595|NCT03473405|EXPERIMENTAL|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
62077809|NCT04001140|NO_INTERVENTION|Waiting-list group|The waiting-list group will receive the intervention 7 weeks after the intervention group finishes. The intervention group will finish the research in week 7, while the waiting-list group will start to attend the intervention. They will complete the questionnaires and the experiment.
62077810|NCT04507360|EXPERIMENTAL|Study 1, Generic Response + Generic Resources|"The Generic Response + Generic Resources will feature the response-as-usual on Mental Health America (MHA)'s website and the four generic resource pages on MHA's website.~Participants will be randomized into this condition, and participants who do not respond to the demographics survey or the Next Steps survey items will be placed in this condition."
62646596|NCT05074966|EXPERIMENTAL|mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
62077811|NCT04507360|EXPERIMENTAL|Study 1, Generic Response + Tailored Resources by Demographics|This condition will feature the response-as-usual on Mental Health America (MHA)'s website and resources tailored to two demographics. People who endorse being Lesbian, Gay, Bisexual, Transgender, or Queer (LGBTQ) will receive 4 resources associated with LGBTQ issues. People who endorse being 8-17, 18-24, 25-44, or 45+ years of age will receive 4 resources used by people in those age groups. If someone enters both age and LGBTQ status, they will be provided with 2 resources tailored to age and 2 resources tailored to LGBTQ status, randomly chosen.
62077812|NCT04507360|EXPERIMENTAL|Study 1, Generic Response + Tailored Resources by Desired Resources|"This condition will feature the response-as-usual on Mental Health America (MHA)'s website and 4 resources tailored to a survey question that asks participants what they would like to do next on the website after screening is complete (e.g., Learn more about depression, Take another mental health screening)"
62077813|NCT04507360|EXPERIMENTAL|Study 1, Tailored Response + Generic Resources|"This condition will feature a response tailored to screening status (above or below criteria for depression) and expressed need for mental health support (e.g., We're so glad to hear you're open to exploring how to improve your mental health. People who score with minimum or mild depression often notice that symptoms can get worse in the weeks after taking a Depression test.) They will also receive the 4 generic resources."
62077814|NCT04507360|EXPERIMENTAL|Study 1, Tailored Response + Tailored Resources by Desired Resources|"This condition will feature a response tailored to screening status (above or below criteria for depression) and expressed need for mental health support, and will receive resources tailored to a survey question that asks participants what they would like to do next on the website after screening is complete (e.g., Learn more about depression, Take another mental health screening)."
62646597|NCT05074966|ACTIVE_COMPARATOR|FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab：500 mg/m2, IV, d1, q2w Oxaliplatin： 85 mg/m2, IV d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
62646598|NCT05246254||Prefrailty group|According to the frailty index(FI) and FI =0.12\~0.25
62646599|NCT05246254||Frailty group|According to the frailty index(FI) and FI≥ 0.25
62077815|NCT04507360|EXPERIMENTAL|Study 1, Embedded single-question DIY|Participants who visit content pages on the Mental Health America (MHA) website after completing screening will receive stage 2 randomization into one of three content page conditions. In the embedded single-question Do-It-Yourself (DIY) condition, a single DIY question will be embedded within the content page.
62646600|NCT05246254||Nonfrailty group|According to the frailty index(FI) and FI\<0.12
62646601|NCT03207399|OTHER|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
62646602|NCT00927199|EXPERIMENTAL|High-Oleic Canola Oil|
62077816|NCT04507360|EXPERIMENTAL|Study 1, Embedded full DIY within content page|Participants will be randomized into one of three content page conditions. In the embedded full Do-It-Yourself (DIY) condition, the full DIY tool will be embedded within the content page.
62077817|NCT04507360|EXPERIMENTAL|Study 1, Single question plus full DIY|Participants will be randomized into one of three content page conditions. In the single question plus full Do-It-Yourself (DIY) condition, a single question plus the full DIY tool will be embedded within the content page.
62077818|NCT04507360|EXPERIMENTAL|Study 1, Content-as-usual|The content page will not include any embedded Do-It-Yourself (DIY) tool.
62077819|NCT04507360|EXPERIMENTAL|Study 2, Control|Participants in the Do-It-Yourself (DIY) control group will receive psychoeducation materials in W0. They will view content as usual (no DIY) and will receive surveys from W1 to W4 and follow-up surveys in W5 and at the end of W8.
62077820|NCT04507360|EXPERIMENTAL|Study 2, DIY tool without AI|Participants in the Do-It-Yourself (DIY) tool without Artificial Intelligence (AI) group will be instructed to use the DIY tool 3 times a week. They will receive surveys from W1 to W4 and follow-up surveys in W5 and at the end of W8.
62077821|NCT04507360|EXPERIMENTAL|Study 2, DIY tool with AI|Participants in the Do-It-Yourself (DIY) tool with Artificial Intelligence (AI) group will be instructed to use the DIY tool with AI 3 times a week. They will receive surveys from W1 to W4 and follow-up surveys in W5 and at the end of W8.
62077822|NCT04250961|EXPERIMENTAL|Shower Group|Patients who had a shower in 48-72 hours after Median Sternotomy
62646603|NCT00927199|EXPERIMENTAL|High-Oleic Canola/Flaxseed Oil Blend|
62646604|NCT00927199|ACTIVE_COMPARATOR|Western Diet|
62646605|NCT02669849|PLACEBO_COMPARATOR|Placebo|
62077823|NCT04250961|ACTIVE_COMPARATOR|Control Group|Patients whose sternal incision site was not connected water until remove sutures
62077824|NCT00422799|EXPERIMENTAL|bortezomib and rituximab|bortezomib and rituximab
62646606|NCT02669849|EXPERIMENTAL|VX-210|
62077825|NCT01915199|EXPERIMENTAL|Intervention|Patients in this arm received a comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance.
62077826|NCT01915199|NO_INTERVENTION|Control|Patients randomized in this group did not receive any intervention and treatment continued according to conventional practice.
62077827|NCT03589729|EXPERIMENTAL|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
62077828|NCT01914978|EXPERIMENTAL|Handbook|Food allergy handbook for parents
62457148|NCT04339465|EXPERIMENTAL|WEP-CARE|The online intervention WEP-CARE addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform. The 12 writing tasks will be conducted with a weekly frequency and participants will receive personalized feedback. WEP-CARE aims at enhancing mental health problems and the coping strategies of the family.
62457149|NCT04339465|EXPERIMENTAL|CARE-FAM + WEP-CARE|The families will receive both the face-to-face intervention CARE-FAM and the online intervention WEP-CARE.
62077829|NCT01914978|PLACEBO_COMPARATOR|Treatment as usual|Food allergy treatment as usual
62077830|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
62077831|NCT06443203|EXPERIMENTAL|Trimodal prehabilitation|physical exercise, psychological support and nutritional optimization 4-weeks before surgery
62646607|NCT00113607|EXPERIMENTAL|DOXIL + trabectedin|Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
62077832|NCT06443203|NO_INTERVENTION|control group without preoperative prehabilitation|Patients no receiveing prehabilitation and undergoing standard rehabilitation alone after surgery
62646608|NCT00113607|ACTIVE_COMPARATOR|DOXIL|Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.
62077833|NCT05244590|EXPERIMENTAL|Intervention|"GPs' eligibility criteria~* Working in the centre health care region in Portugal.~* Authorisation of the coordinator of each GP health care unit to integrate the study.~Patients' eligibility criteria~Inclusion criteria~* Belonging to the list of patients of the recruited GPs.~* 18 years or older.~* Diagnosis of advanced stage neoplasm (ASN), Chronic Obstructive Pulmonary Disease (COPD) Gold III/IV, Congestive Heart Failure (CHF) NYHA III/IV, Chronic Kidney Disease (CKD) stage IV/V.~Exclusion Criteria~* Refusal, at any time, to participate in the study.~* Level of understanding or execution that compromises taking part in the study and answering the IPOS patient version (evaluated using Mini Mental State Examination score).~* Level of disease severity requiring urgent intervention (GP clinical judgement)."
62077834|NCT05332951||Adult patients followed for multiple sclerosis|
62457150|NCT04339465|NO_INTERVENTION|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
62646609|NCT02752139||patients with sleep disorders|
62646610|NCT02752139||normal individuals without sleep disorders|
62646611|NCT01477801|EXPERIMENTAL|CHOLECALCIFEROL|
62646612|NCT01477801|PLACEBO_COMPARATOR|PLACEBO|
62646613|NCT05393596|EXPERIMENTAL|Experimental Group (Incluyete VR Software)|Through virtual reality headsets, the software Inclúyete VR will be used, in which situations related to stigma in Severe Mental Disorder are recreated. Specifically, its purpose is to put the participant in a virtual world that shows how the stigma towards people with severe mental health problems is and also to experience situations of rehabilitation and social inclusion, thus giving a more real and closer image of what can be the current treatment in mental health. The approximate duration is 15 minutes.
62646614|NCT05393596|ACTIVE_COMPARATOR|Control Group (Welcome Oculus Software)|Participants will use the default virtual reality headset welcome game, unrelated to mental health. It presents an interactive virtual environment, with various playful interfaces and instructions for use. The duration is approximately 15 minutes.
62646615|NCT01937988|EXPERIMENTAL|Doula Arm|Women in the doula arm will have standard procedure protocol with addition of doula support at the time of the procedure.
62077835|NCT06118775|EXPERIMENTAL|EaDyn weaning arm|In the EaDyn weaning arm of the study, dynamic arterial elastance (EaDyn) will be utilized as a specialized hemodynamic tool to guide the gradual reduction of vasopressor support in patients diagnosed with septic shock. EaDyn, a measure of the relationship between arterial pressure and stroke volume variation over the cardiac cycle, provides valuable insights into vascular tone and cardiac performance
62457151|NCT02365207|EXPERIMENTAL|BCG treatment of invasive bladder cancer|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
62457152|NCT02069626|ACTIVE_COMPARATOR|No wait|Usage of linear stapler without waiting of compression time
62457153|NCT02069626|ACTIVE_COMPARATOR|20 second wait|Usage of linear stapler with 20 second compression time
62646616|NCT01937988|NO_INTERVENTION|Control Group|Women in the control arm will have standard procedure protocol at the time of the procedure.
62646617|NCT04533178|ACTIVE_COMPARATOR|Restriction of sports activities|No sports during the 6 week treatment period
62646618|NCT04533178|EXPERIMENTAL|Restriction of sports activities and soft spinal brace|No sports and use of a soft spinal brace 16 hours per day during the 6 week treatment period
62646619|NCT05550168|EXPERIMENTAL|Intervention (Laser group)|The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
62646620|NCT05550168|NO_INTERVENTION|Contralateral (Non-laser group)|Laser was not applied to the contralateral side of the intervention group (n=10) and the individuals in the control group (n=10); thus, no application was made to accelerate tooth movement
62646621|NCT05550168|NO_INTERVENTION|Control (Non-laser group)|Laser was not applied to the contralateral side of the intervention group (n=10) and the individuals in the control group (n=10); thus, no application was made to accelerate tooth movement
62646622|NCT01007799|PLACEBO_COMPARATOR|Placebo|Placebo pills to take for 12 weeks
62646623|NCT01007799|ACTIVE_COMPARATOR|Vitamin D|Vitamin D supplement for 12 weeks
62646624|NCT00707837|EXPERIMENTAL|Infant Formula|Preterm infant formulas containing lipid soluble compounds
62646625|NCT00707837|ACTIVE_COMPARATOR|Preterm formulas|Standard preterm infant formula and discharge formulas
62646626|NCT00843466|ACTIVE_COMPARATOR|Mild moisturizing Hand Cleanser|The test group will be provided with a mild moisturizing hand cleanser for all hand cleansing needs during the duration of the study.
62646627|NCT00843466|NO_INTERVENTION|Current Hand Cleanser|The control group will continue to use their current cleanser for all hand washing.
62646628|NCT02523352|EXPERIMENTAL|Treatment|Volunteers with a BMI \> 35 Kg/m2 and central fat distribution, without any past medical history
62646629|NCT01830517|EXPERIMENTAL|amlodipine camsylate|amlodipine camsylate 5mg
62646630|NCT01830517|ACTIVE_COMPARATOR|losartan potassium|losartan potassium 50mg
62646631|NCT00157339|EXPERIMENTAL|1|
62646632|NCT00157339|ACTIVE_COMPARATOR|2|
62646633|NCT01087060||cysts surgically removed|
62646634|NCT01087060||cysts under surveillance|
62077836|NCT06118775|ACTIVE_COMPARATOR|PAM weaning arm|In the PAM (Mean Arterial Pressure) weaning arm of the study, mean arterial pressure (MAP) will be used as the primary parameter to guide the gradual reduction of vasopressor support in patients diagnosed with septic shock. Mean arterial pressure represents the average pressure in the arteries during one cardiac cycle and is a crucial indicator of perfusion to vital organs. Participants in this group will be monitored continuously for their MAP values, allowing real-time assessment of their hemodynamic status.
62077837|NCT06740799|EXPERIMENTAL|Severe HI|Participants will receive a single oral dose of 30 mg quizartinib
62646635|NCT03439137|EXPERIMENTAL|MT-6548|
62646636|NCT03439137|ACTIVE_COMPARATOR|Darbepoetin alfa|
62077838|NCT06740799|EXPERIMENTAL|Control Group|Healthy participants will receive a single oral dose of 30 mg quizartinib
62077839|NCT05752643|NO_INTERVENTION|Control|Participants will have 4 face-to-face quarterly follow up visits per year
62077840|NCT05752643|EXPERIMENTAL|Experimental|Participants will alternate face-to-face visits with online screening every three months. They will have two face-to-face and two online screenings per year
62457154|NCT02069626|ACTIVE_COMPARATOR|60 second wait|Usage of linear stapler with 60 second compression time
62457155|NCT01659203|EXPERIMENTAL|Treatment Arm IMPT|IG-IMPT with SIB to the high risk margin
62457156|NCT01659203|EXPERIMENTAL|Treatment Arm IMRT|IG IMRT with SIB to the high risk margin
62646637|NCT03347643|ACTIVE_COMPARATOR|tDCS with real stimulation|A total of 25 patients will be allocated into active comparator with real stimulation with tDCS.
62646638|NCT03347643|SHAM_COMPARATOR|tDCS with sham stimulation|A total of 25 patients will be allocated into sham comparator with sham stimulation with tDCS.
62646639|NCT01112319|EXPERIMENTAL|Elf_care|The trial group will receive with Elf_Care unit (Hot-Cold \& Electrotherapy) during physiotherapy treatment ( 28 minutes twice a week)
62646640|NCT01112319|ACTIVE_COMPARATOR|control group|The control group will receive before physiotherapy COLD HOT or Electrotherapy treatment depends on the patient and physiotherapy prefer.
62646641|NCT04526002|EXPERIMENTAL|Concurrent TBS/fNIRS with iTBS and followed by cTBS after 1h|self-explanatory, see Arm Title
62646642|NCT02222662|EXPERIMENTAL|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
62646643|NCT02222662|EXPERIMENTAL|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
62646644|NCT04688632|ACTIVE_COMPARATOR|Group 1a|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin \<Dose A\>
62646645|NCT04688632|ACTIVE_COMPARATOR|Group 1b|Day 1: Single dose of Moxifloxacin \<Dose A\>; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin Placebo
62646646|NCT04688632|EXPERIMENTAL|Group 2 - Treatment|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 7: Single daily dose of Ampreloxetine \<Dose A\>; Day 8 - Day 14: Single daily dose of Ampreloxetine \<Dose B\>; Day 15: Single dose of Moxifloxacin Placebo; Day 15: Single dose of Ampreloxetine Placebo;
62646647|NCT03055884|EXPERIMENTAL|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
62646648|NCT03055884|EXPERIMENTAL|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
62077841|NCT01449721|NO_INTERVENTION|Control|Standard medical care by the primary treatment team.
62077842|NCT01449721|EXPERIMENTAL|Interventional arm|Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization
62646649|NCT03055884|SHAM_COMPARATOR|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
62646650|NCT03055884|SHAM_COMPARATOR|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
62646651|NCT02262780|EXPERIMENTAL|Single low dose Telmisartan with HCTZ|
62646652|NCT02262780|EXPERIMENTAL|Single high dose Telmisartan with HCTZ|
62077843|NCT01438671|EXPERIMENTAL|All participants|Nintendo Wii Fit Balance training followed by traditional balance training
62077844|NCT02635087||high risk group|"the miRNA tool predict this group of patients as high risk"
62077845|NCT00675324|ACTIVE_COMPARATOR|A|Traditional bowel preparation with Laxabon
62077846|NCT00675324|ACTIVE_COMPARATOR|B|Bowel preparation with nutritional drinks
62077847|NCT05086822|EXPERIMENTAL|Treatment group A|Treatment group : Irinotecan liposome
62077848|NCT05515718|ACTIVE_COMPARATOR|Standard pain management|"Patients receive a standard analgesic treatment, in accordance with the latest international guidelines :~* if pain EN is ≥ 3: Paracetamol 1g every 6 hours (age \<75 years) or every 8 hours (# 75 years) and/or Tramadol 50 mg every 8 hours ;~* and/or if verbal EN for pain is ≥ 7: intravenous morphine titration according to local protocol: 3 mg bolus if weight \> 60 kg and age ≤ 80 years; Bolus of 2 mg if weight ≤ 60 kg and age ≤ 80 years ; Bolus of 1 mg if age\>80 years, regardless of weight ; This bolus is repeated every 5 minutes until an EN≤ 3 is obtained."
62646653|NCT02262780|EXPERIMENTAL|Multiple high dose Telmisartan with HCTZ|
62646654|NCT00259103|EXPERIMENTAL|7.5 µg/kg/d|Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.
62646655|NCT00259103|EXPERIMENTAL|25 µg/kg/d|Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.
62646656|NCT00259103|EXPERIMENTAL|75 µg/kg/d|Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.
62646657|NCT00259103|EXPERIMENTAL|Placebo|Participants who received IV infusion of placebo, some during part A and others during part B.
62646658|NCT00208364|OTHER|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
62646659|NCT04927637||Orthopedic Infection|Subjects who have undergone previous orthopaedic trauma surgery and have developed and infection will be assessed for protocol inclusion criteria. Patients who meet all inclusion criteria and no exclusion criteria will be administered a single dose 2.5-5 mg/kg ICG dose intravenously ideally 24h prior to surgical debridement. Fluorescent images will be obtained pre and post irrigation and debridement
62646660|NCT00892021|EXPERIMENTAL|NSA-789|Active study drug
62646661|NCT00892021|PLACEBO_COMPARATOR|Placebo|Inactive study drug
62646662|NCT05009355|EXPERIMENTAL|experimental|A Group: Consisted of 20 patients who were treated with scaling and root planing in conjunction with 2g antioxidant Vit (C)
62077849|NCT05515718|EXPERIMENTAL|Femoral nerve block|"Patients receive a standard analgesic treatment, in accordance with the latest international guidelines 5,13,45: - if pain EN is ≥ 3:~Paracetamol 1g every 6 hours (age \<75 years) or every 8 hours (# 75 years) and/or Tramadol 50 mg every 8 hours; - and/or if verbal EN for pain is ≥ 7: intravenous morphine titration according to local protocol: 3 mg bolus if weight \> 60 kg and age ≤ 80 years; Bolus of 2 mg if weight ≤ 60 kg and age ≤ 80 years ; Bolus of 1 mg if age\>80 years, regardless of weight ; This bolus is repeated every 5 minutes until an EN≤ 3 is obtained."
62077850|NCT04447820|EXPERIMENTAL|K-877-ER Dose A|K-877-ER dose A administered once daily
62077851|NCT04447820|EXPERIMENTAL|K-877-ER Dose B|K-877-ER dose B administered once daily
62077852|NCT04447820|EXPERIMENTAL|K-877-IR|K-877-IR administered twice daily.
62646663|NCT05009355|NO_INTERVENTION|Control|A Group: consisted of 20 patients who were treated with scaling and root planing.
62646664|NCT03735290|EXPERIMENTAL|Phase 1b: Cohort 1, ilixadencel + pembrolizumab|3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab I.V. q3w
62646665|NCT03735290|EXPERIMENTAL|Phase 1b: Cohort 2, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w
62646666|NCT03735290|EXPERIMENTAL|Phase 1b: Cohort 3, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w
62646667|NCT03735290|EXPERIMENTAL|Phase 1b: Cohort 4, ilixadencel + pembrolizumab|Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w
62646668|NCT03735290|EXPERIMENTAL|Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.
62077853|NCT05545969|EXPERIMENTAL|Neoadjuvant and Adjuvant Therapy|Neoadjuvant pembrolizumab \& lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks
62077854|NCT03186326|ACTIVE_COMPARATOR|Arm A Chemotherapy (standard treatment)|FOLFOX or FOLFIRI +/- targeted therapy
62077855|NCT03186326|EXPERIMENTAL|Arm B - Immunotherapy (experimental arm)|Avelumab
62077856|NCT00794625|EXPERIMENTAL|1|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
62077857|NCT00794625|EXPERIMENTAL|2|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
62077858|NCT00794625|PLACEBO_COMPARATOR|3|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
62077859|NCT04485676||Dalbavancin|"Patients to be included in this study have been treated with Dalbavancin according to clinician's judgement and clinical practice according national or international guidelines.~Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Information about dosing treatment will be collected."
62077860|NCT04814875|EXPERIMENTAL|Part 1 - ACD (Safety)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
62077861|NCT04814875|EXPERIMENTAL|Part 2 - ACD (Efficacy)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
62077862|NCT03990714|EXPERIMENTAL|Intracorporeal anastomosis|The specimen was preferentially extracted via a small Pfannenstiel-type incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). The incision for the extraction of the right colon is sutured in two layers by absorbable suture. The ileum was held by the assistant to prevent rotation of its mesentery. A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon, respectively, and then held by the assistant. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed. Drains were not used routinely.
62077863|NCT03990714|EXPERIMENTAL|Extracorporeal anastomosis|The mobilized colon was externalized preferentially via a transverse or midline incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed.The incision for the extraction of the right colon and the realization of the anastomosis is sutured in two layers by absorbable suture. Drains were not used routinely.
62457157|NCT03746353|EXPERIMENTAL|Early closure of ileostomy|Early clousure of ileostomy before 30 days
62646669|NCT03735290|ACTIVE_COMPARATOR|Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.
62077864|NCT01751113|ACTIVE_COMPARATOR|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
62077865|NCT01751113|ACTIVE_COMPARATOR|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
62077866|NCT01751113|ACTIVE_COMPARATOR|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
62077867|NCT05985993|ACTIVE_COMPARATOR|single-target group (left DLPFC)|34 eligible patients will be treated with active TUS for 4 weeks on the left DLPFC
62077868|NCT05985993|ACTIVE_COMPARATOR|both-target group (both left DLPFC and right STG)|34 eligible patients will be treated with active TUS for 4 weeks on the both left DLPFC and right STG
62077869|NCT05985993|SHAM_COMPARATOR|sham group|34 eligible patients will be treated with sham TUS for 4 weeks on the left DLPFC
62077870|NCT04625478||Patients having had an osteo-articular infection with Stahylococcus|Patients having had an osteo-articular infection with Stahylococcus managed at the Croix Rousse hospital
62077871|NCT01896115|EXPERIMENTAL|Short PW|Patients with a Vercise DBS system programmed to 30 microseconds pulse width
62077872|NCT01896115|EXPERIMENTAL|Conventional PW|Patients with a Vercise DBS system programmed to 60 microseconds pulse width
62077873|NCT01896115|EXPERIMENTAL|Ventral current steering|Patients with a Vercise DBS system programmed to steer current ventrally
62077874|NCT01896115|EXPERIMENTAL|Dorsal current steering|Patients with a Vercise DBS system programmed to steer current dorsally.
62077875|NCT01394250|EXPERIMENTAL|Buzzy|If randomized to Buzzy®, the nurse will demonstrate the cold pack and the device just prior to the IV cannulation procedure. The device will be applied with a Velcro strap 5 centimeters proximal to the site of IV cannulation; it will remain in place until the IV cannula is inserted and secured. All nurses that work during the study hours will be trained on the device prior to beginning the study. Training includes direct one-one training with the device including return demonstration.
62077876|NCT01394250|ACTIVE_COMPARATOR|Topical Lidocaine 4% Cream|If randomized to topical lidocaine cream, subjects will have the cream placed on two or more potential IV sites as soon as possible after the consent procedure is complete. These subjects will undergo IV placement no less than 30 minutes after the cream is applied.
62646670|NCT02374983||Research group|The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
62077877|NCT03947359|OTHER|Participants with a thoracic diameter < 75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
62077878|NCT03947359|OTHER|Participants with a thoracic diameter >75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
62457158|NCT03746353|ACTIVE_COMPARATOR|Conventional closure of ileostomy|Conventional closure of ileostomy after 30 days
62457159|NCT04652453|EXPERIMENTAL|Post-Intervention Group (Geriatrics Bundle)|Enrolled participants in the intervention arm will receive all 3 components of the geriatrics bundle: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
62457160|NCT04652453|NO_INTERVENTION|Pre-Intervention Group (Control)|Participants in the control arm will be enrolled prior to implementation of the geriatrics bundle to gather preliminary data about the secondary outcomes.
62646671|NCT01033838|ACTIVE_COMPARATOR|laparoscopic-assisted rectosigmoid resection|
62646672|NCT01033838|EXPERIMENTAL|laparoscopic rectosigmoid resection and transrectal retrieval|
62077879|NCT04815486|EXPERIMENTAL|Bilateral rTMS combined with MI through a BCI training platform in VR with NeuRow|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks, and Motor Imagery (MI) treatment through the BCI training paradigm in VR (NeuRow) for 12 sessions in four weeks (3 sessions a week).The first 6 MI-neurofeedback sessions will carry out after bilateral stimulation with rTMS (i.e., rTMS as a priming method during the first two weeks), and the last 6 sessions, without rTMS as prior priming during the last two weeks
62457161|NCT05865600|OTHER|Cohort study|All patients with symptomatic chronic coronary syndrome undergoing clinically referred \[15O\]H2O cardiac PET/CT will be included in a prospective cohort with repeated symptom questionnaires and outcomes registered in national registries. A total of 570 patients are expected to be included in order to have 200 randomized patients reaching the 3-month assessment
62077880|NCT04815486|ACTIVE_COMPARATOR|Repetitive TMS in bilateral cortical primary motor area|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks.
62077881|NCT05466903|NO_INTERVENTION|Control arm|patients were given a liquid diet 6 hours after the operation
62077882|NCT05466903|EXPERIMENTAL|Experimental arm|patients were given a liquid diet 2 hours after the operation
62646673|NCT02541344|ACTIVE_COMPARATOR|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
62077883|NCT00767104|EXPERIMENTAL|Silk-Like Pillowcase|Silk- Like pillowcase-One-half of subjects will be assigned to sleep on the study product, which is a standard size pillowcase made of a silk-like fabric every night for 12 weeks. The study pillowcases are fabricated from a light-weight plain-weave fabric woven of 100 percent synthetic yarns. The fabric is comprised of approximately 50% polyester and 50% nylon. The yarns in the fabric are formed from continuous-filament fibers, with no fibers projecting beyond the planar surface of the fabric. The antimicrobial technology used in the fabric is incorporated into the fibers during the finishing process and does not migrate out of the fabric or cause adverse reactions with skin contact.
62077884|NCT00767104|PLACEBO_COMPARATOR|Cotton Pillowcase|Placebo Comparator-One-half of subjects will be assigned to sleep on the placebo pillow case every night for 12 weeks. Placebo pillowcase is made of 100% cotton
62077885|NCT06184360||Treatment-Experienced|
62077886|NCT06184360||Treatment-Naive|
62646674|NCT02541344|ACTIVE_COMPARATOR|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
62646675|NCT02541344|PLACEBO_COMPARATOR|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
62646676|NCT04352348|OTHER|COVID-19 negative|Patients with exclusion diagnosis for COVID-19 infection
62646677|NCT04352348|OTHER|COVID-19 positive, not severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and not requiring hospitalization
62646678|NCT04352348|OTHER|COVID-19 positive, severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and requiring hospitalization
62646679|NCT04352348|OTHER|Follow-up after COVID-19 hospitalization|"Patients previously hospitalized for COVID-19 infection but not recruited for the study can be recruited during a follow-up visit in hospital scheduled in standard care at 3 to 6 months after the hospitalization.~For this arm, T0 = 3 to 6 months post-COVID-19 follow-up visit"
62646680|NCT02933853|EXPERIMENTAL|Faster Aspart|
62646681|NCT02933853|ACTIVE_COMPARATOR|Insulin Aspart|
62646682|NCT04268355|EXPERIMENTAL|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers
62077887|NCT04977947|EXPERIMENTAL|Healthy Eating for My Infant Intervention|Participants and their parents will participate in a 6 session intervention targeting healthy introduction of complementary foods, and responsive feeding and mealtime behaviors. Intervention sessions will occur when the infant is 3, 4, 5, 6, 7, and 8 months of age.
62077888|NCT04977947|NO_INTERVENTION|Control|Participants and their parents will complete baseline and post-treatment study visits to assess study outcomes. They will receive no intervention.
62077889|NCT05601713|ACTIVE_COMPARATOR|No cooling intervention (control)|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
62077890|NCT05601713|EXPERIMENTAL|Lower limb immersion|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
62077891|NCT05601713|EXPERIMENTAL|Lower limb immersion + neck cooling|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
62077892|NCT05364918|EXPERIMENTAL|Jeksung|
62077893|NCT05364918|NO_INTERVENTION|Control|
62077894|NCT05551481|EXPERIMENTAL|In Group A,(Variolink II, Ivoclar Vivadent).|In Group A, the onlays and overlays were luted adhesively with etch and rinse, dual cure resin cement (Variolink II, Ivoclar Vivadent).
62077895|NCT05551481|ACTIVE_COMPARATOR|In Group B, (Relyx U200, 3M ESPE).|In Group B the onlays and overlays were luted using a self-adhesive resin cement (Relyx U200, 3M ESPE).
62077896|NCT01645371||Subjects with opioid induced constipation|
62077897|NCT06375135|EXPERIMENTAL|Arm 1 (starts on TXTXT only)|Arm 1 will begin with TXTXT only. ART adherence will be assessed at 3 months. If they are 90% adherent or above, they will continue with TXTXT only for an additional 3 months. If they are less than 90% adherent, they will be re-randomized (1:1) into staying only with TXTXT, or into receiving TXTXT plus e-Navigation for an additional 3 months. At 6 months, all interventions will end. Participants in this arm will be followed for 6 months after interventions cease.
62077898|NCT06375135|EXPERIMENTAL|Arm 2 (starts with TXTXT and e-Navigation)|Arm 2 will begin with TXTXT and e-Navigation. ART adherence will be assessed at 3 months. If they are 90% adherent or above, they will continue with TXTXT and e-Navigation only for an additional 3 months. If they are less than 90% adherent, they will be re-randomized into staying only with TXTXT and e-Navigation, or into receiving TXTXT, e-Navigation plus EMA support for an additional 3 months. At 6 months, all interventions will end. Participants in this arm will be followed for 6 months after interventions cease.
62077899|NCT06161103|EXPERIMENTAL|Experimental: 3D Printed Prefabricated Composite Resin Crown group|(Custom Composite Resin (Custom Resin Solutions, CRSCAM TEKNOLOJİ AŞ., ANTALYA, TURKEY)
62077900|NCT06161103|EXPERIMENTAL|Active Comparator: Prefabricated stainless steel crown group|Stainless Steel Crown (SSC, Kids Crown, Shinghung, Seoul, Korea)
62077901|NCT04387838||Anti-SARS-CoV2 serological status|"At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.~For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60.~For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped."
62077902|NCT02947607||Healthy control|Patients undergoing lower GI endoscopy without any colorectal adenoma or carcinoma.
62077903|NCT02947607||Adenoma|Patients undergoing lower GI endoscopy with presence of colorectal adenoma detected.
62077904|NCT02947607||Colorectal cancer|Patients diagnosed with colorectal cancer and referred to surgical carcinoma resection.
62077905|NCT05811429|EXPERIMENTAL|Aerobic exercises|Group A will receive aerobic exercises 2 sessions per week for 8 weeks total 16 sessions will be held.
62646683|NCT03371914|EXPERIMENTAL|Treatment: Management + data training|"The treatment group in the study will receive a 5-day training. The first two days of the training will consist of introducing the data collection tools and collecting baseline data. Days three through five of the training will consist of a variety of management topics.~On a monthly basis, the treatment group will receive data visualizations that will compare their site's performance that month to pervious performance and to other sites in the study. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis."
62077906|NCT05811429|ACTIVE_COMPARATOR|Pilates exercises|Group B will receive pilates exercises 2 sessions per week for 8 weeks total 16 sessions will be held.
62077907|NCT06330636|EXPERIMENTAL|D-Allulose|15g D-Allulose added to a high glycaemic index oat porridge
62077908|NCT06330636|PLACEBO_COMPARATOR|Saccharin|Sodium saccharin (1x 'Sweetex' tablet) added to a high glycaemic index oat porridge
62077909|NCT03017989|EXPERIMENTAL|NIRF imaging|After the white light (WL) imaging, NIRF imaging will be performed. 2.5 mg of ICG will be administered i.v. up to 5 times if needed. The lesions identified in WL, are inspected in NIRF mode. The surgeon indicated whether the lesions are more easily identified in WL or the NIRF mode and scores the visibility on a 1-10 scale. Next, inspection will take place for lesions that are seen in NIRF mode but not in WL. Biopsies will be taken from the lesions and from normal tissue for reference and sent for histology. Evaluation will take place whether the lesions differ in histological characteristics
62077910|NCT06233123|EXPERIMENTAL|Application|intervention group that will download the Medisafe android application (https://www.medisafe.com). This mobile application uses simple English language and figures to remind the patient about the dose
62077911|NCT06233123|NO_INTERVENTION|control|control group with Standard Care and Medication Monitoring
62077912|NCT03188900||preeclampsia|pregnancy with preeclampsia
62077913|NCT03188900||control|pregnancy without preeclampsia
62077914|NCT01150578||Lexi-Echo pilot|Appropriate patients at University of Arizona Medical Center stress imaging laboratory who have a routine regadenoson SPECT nuclear scan will have simultaneous cardiac echo images obtained.
62077915|NCT02264496|NO_INTERVENTION|Control|Standard pre-operative care
62077916|NCT02264496|EXPERIMENTAL|Exercise|A 2-4 week low volume, moderate intensity, supervised, one to one, individualised exercise programme. '
62077917|NCT03053674|EXPERIMENTAL|Explanation|Explanation to parents on importance of post-partum influenza vaccination on health of their newborn infant with a follow-up questionnaire to determine rate of vaccination
62077918|NCT03053674|ACTIVE_COMPARATOR|No explanation|No explanation will be given to parents but they will be followed-up with a questionnaire to determine rate of vaccination
62077919|NCT03650595|EXPERIMENTAL|Single arm prospective clinical trial|This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time
62077920|NCT00259376|EXPERIMENTAL|Dronedarone 400mg bid|dronedarone 400mg tablets
62077921|NCT00259376|EXPERIMENTAL|Placebo|matching placebo tablets
62077922|NCT00671996|ACTIVE_COMPARATOR|A|Mangafodipir treatment
62457162|NCT05865600|EXPERIMENTAL|Immediate referral to invasive coronary angiography|Patients with abnormal perfusion on \[15O\]H2O cardiac PET/CT and clinical indication for invasive coronary angiography randomized to immediate referral for invasive coronary angiography with concomitant optimization of guideline-directed medical therapy. Enrollment will continue until a total of 200 randomized patients reach the 3-month assessment.
62646684|NCT03371914|NO_INTERVENTION|Control: data training only|The control group will receive only a 2-day training which will focus on data collection alone. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.
62077923|NCT00671996|PLACEBO_COMPARATOR|B|
62077924|NCT05409274||Pregnant women|Pregnant women enrolled across 5 country study sites at any point during pregnancy, up to and including the day of delivery.
62077925|NCT03398915||Robot-Guided Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
62646685|NCT01009593|EXPERIMENTAL|ABT-869|
62646686|NCT01009593|ACTIVE_COMPARATOR|Sorafenib|
62646687|NCT04610775|OTHER|Small Cuff (0, +1, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Small
62646688|NCT04610775|OTHER|Small Cuff (0, +2, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Small
62646689|NCT04610775|OTHER|Small Cuff ( +1, 0, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Small
62646690|NCT04610775|OTHER|Small Cuff ( +1, +2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Small
62646691|NCT04610775|OTHER|Small Cuff ( +2, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Small
62077926|NCT03398915||Navigated Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
62457163|NCT05865600|EXPERIMENTAL|Delayed referral to invasive coronary angiography|Patients with abnormal perfusion on \[15O\]H2O cardiac PET/CT and clinical indication for invasive coronary angiography randomized to 3-months delayed referral for invasive coronary angiography with concomitant optimization of guideline-directed medical therapy. Enrollment will continue until a total of 200 randomized patients reach the 3-month assessment.
62457164|NCT05896956||Patients with benign or malignant tumors of the biliary system|Patients enrolled should be clinically diagnosed with benign or malignant tumors of the biliary system, including unoperated patients with preliminary diagnosis of benign or malignant tumors of the biliary tract based on imaging examinations and laboratory test results, or pathological examination of patients treated with surgery confirmed as benign and malignant tumors of the gallbladder; The primary tumor is located in the extrahepatic bile ducts, intrahepatic bile ducts, gallbladder floor, gallbladder body, gallbladder neck, or gallbladder duct.
62646692|NCT04610775|OTHER|Small Cuff ( +2, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Small
62646693|NCT04610775|OTHER|Regular Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Regular
62646694|NCT04610775|OTHER|Regular Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Regular
62646695|NCT04610775|OTHER|Regular Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Regular
62646696|NCT04610775|OTHER|Regular Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Regular
62077927|NCT03398915||Freehand Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
62077928|NCT01189890|EXPERIMENTAL|Sitagliptin|Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
62077929|NCT01189890|ACTIVE_COMPARATOR|Glimepiride|Glimepiride 1-6 mg QD
62646697|NCT04610775|OTHER|Regular Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Regular
62646698|NCT04610775|OTHER|Regular Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Regular
62077930|NCT03086824|EXPERIMENTAL|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
62077931|NCT05372887|EXPERIMENTAL|TNX-102 SL, 5.6 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
62077932|NCT05372887|PLACEBO_COMPARATOR|Placebo|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
62646699|NCT04610775|OTHER|Large Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Large
62646700|NCT04610775|OTHER|Large Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Large
62646701|NCT04610775|OTHER|Large Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Large
62646702|NCT04610775|OTHER|Large Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Large
62646703|NCT04610775|OTHER|Large Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Large
62646704|NCT04610775|OTHER|Large Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Large
62646705|NCT04610775|OTHER|Extra Large Cuff (0, -2, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Extra Large
62077933|NCT01219530||Gestational Carriers|
62077934|NCT01219530||Intended Parents|
62077935|NCT04089774|EXPERIMENTAL|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
62077936|NCT04089774|NO_INTERVENTION|Kiné|Standard physiotherapy treatment, at least 20 sessions, renewed at least once, spread over 12 months
62077937|NCT04138030|ACTIVE_COMPARATOR|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
62077938|NCT04138030|ACTIVE_COMPARATOR|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
62077939|NCT01478815|PLACEBO_COMPARATOR|Standard Care|
62077940|NCT01478815|EXPERIMENTAL|Contingency management for abstinence from drugs|
62077941|NCT01799720|EXPERIMENTAL|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet. Follow-up 30 days
62646706|NCT04610775|OTHER|Extra Large Cuff (0, -1, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Extra Large
62646707|NCT04610775|OTHER|Extra Large Cuff (-1, 0, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Extra Large
62646708|NCT04610775|OTHER|Extra Large Cuff (-1, -2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Extra Large
62646709|NCT04610775|OTHER|Extra Large Cuff (-2, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Extra Large
62646710|NCT04610775|OTHER|Extra Large Cuff (-2, 0, -1 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Extra Large
62077942|NCT01799720|EXPERIMENTAL|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 2 took 2 capsules/day of one of the most oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
62077943|NCT01799720|EXPERIMENTAL|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 3 only took diet and no capsules. Follow-up 30 days
62077944|NCT03555604||Scheduled cesarean section|Gastric ultrasound in term pregnant patients to correlate with NPO time in relation to body mass index
62646711|NCT00664586|EXPERIMENTAL|Terameprocol (EM-1421)|Terameprocol (EM-1421) will be administered as an intravenous infusion over 24 hours, weekly. Dose will commence in the first cohort with 100 mg per hour (2400 mg in a 24 hour period)with escalation in the 5 cohorts of 3 to 6 patients with increments of 25 mg per hour to a maximum of 200 mg/hr (4800 mg/24 hour period) or until MTD is defined. When the MTD has been declared, then 11 additional subjects will be enrolled at the MTD dose level (to total 14 subjects treated in dosage cohort).
62646712|NCT05064254|ACTIVE_COMPARATOR|Treatment as usual|All participants allocated to the control group will have access to standard care.
62077945|NCT03511079|EXPERIMENTAL|Music|This group will be given a subscription to Pandora Plus for the duration of the study. Beginning two nights before surgery, they will listen to a music playlist they created for 30 minutes prior to going to sleep. This will continue each night with the final time being 6 nights after surgery.
62077946|NCT03511079|NO_INTERVENTION|Control|This group will not listen to music each night for the duration of the study.
62077947|NCT04103554|EXPERIMENTAL|sacubitril/valsartan|
62077948|NCT04103554|ACTIVE_COMPARATOR|Standard of care|Standard of care for treating blood pressure per center protocols
62457165|NCT05228522|EXPERIMENTAL|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
62646713|NCT05064254|EXPERIMENTAL|Mindful Adaptive Practice in Pregnancy Therapy|"Participants allocated to the intervention group will have access to treatment as usual in addition to synchronous virtual MAPP.~MAPP draws upon existing integrative principles of structured psychotherapies (mindfulness-based, cognitive, behavioural and relational psychotherapy)"
62646714|NCT03174444|EXPERIMENTAL|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
62646715|NCT03174444|NO_INTERVENTION|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
62077949|NCT03171168|ACTIVE_COMPARATOR|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
62077950|NCT03171168|EXPERIMENTAL|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
62077951|NCT03993405|ACTIVE_COMPARATOR|Control group:young|Sixty older subjects will be evaluated in this study.
62077952|NCT03993405|ACTIVE_COMPARATOR|Control Group:Middle-aged|Sixty middle-aged subjects will be evaluated in this study.
62077953|NCT03993405|EXPERIMENTAL|Experimental group:older|Sixty older subjects will be evaluated in this study.
62077954|NCT01918293|EXPERIMENTAL|SMART arm|Using smartphone application for control of asthma
62077955|NCT01918293|NO_INTERVENTION|conventional arm|non-using smartphone application for control asthma
62077956|NCT06450587|EXPERIMENTAL|Measurement of IOP Values|Measurement of IOP pressure with four different tonometers.
62077957|NCT01875861|EXPERIMENTAL|Intervention|Evidence-Based Quality Improvement plus external facilitation to promote uptake of quality improvement tools and improvement strategies available as part of a national initiative (the MIAMI Project) to disseminate recommendations, tools, and improvement strategies relevant to metabolic monitoring and management.
62077958|NCT01875861|NO_INTERVENTION|Comparison|"Usual care, in the context of the MIAMI Project."
62077959|NCT00912821|ACTIVE_COMPARATOR|8 L dialysate|8 L peritoneal dialysis solution
62077960|NCT00912821|EXPERIMENTAL|6 L dialysate|6 L peritoneal dialysis solution
62077961|NCT00818415|EXPERIMENTAL|Arm 1|
62457166|NCT05228522|NO_INTERVENTION|Comparison control|Comparison control families meet with the Study Physician and a Registered Dietitian as a family to review laboratory results and receive lifestyle counseling. Control families will be contacted on a monthly basis for a total of 12 months.
62646716|NCT04919707|EXPERIMENTAL|Older Adolescent Soccer Players|10 male, 10 female soccer players, grades 11-12, age 16-18 Neurocognitive measures, physical measures, header session, MRI
62077962|NCT00818415|ACTIVE_COMPARATOR|Arm 2|
62077963|NCT04842396|EXPERIMENTAL|Experimental: Motorized cycle ergometer|"The exercise group cycles 20 minutes per session on the MOTOmed Muvi 3 days per week for 6 weeks at an intensity guided by the perception of effort.~A cycling cadence is fixed between 25 and 30 rpm for all sessions since that cadence is comfortable for every participant. Researchers adjust resistance on the motorized cycle to increase the external load until it reached the level required to reach the intensity of effort programmed by the OMNI-RPE. The six weeks are programmed in the form of two intensity-differentiated training phases of three weeks. In the first training phase (i.e., the first three weeks), participants are requested to cycle simultaneously with the upper and lower limbs at an intensity equivalent to a perception of 3 (i.e., easy to somewhat moderate) on the OMNI-RPE (0-10)."
62457167|NCT04165538|EXPERIMENTAL|TEG group|
62457168|NCT04165538|NO_INTERVENTION|Non-TEG group|
62457169|NCT01764438||very early or early staged patients|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT
62646717|NCT04919707|EXPERIMENTAL|Younger Adolescent Soccer Players|10 male, 10 female soccer players, grades 6-7, age 12-13 Neurocognitive measures, physical measures, header session, MRI
62077964|NCT04842396|NO_INTERVENTION|Control group|Participants are evaluated the week before and the week after the experimental group finishes the training period (pre- vs. postintervention) to facilitate an examination of the changes in body composition, functional performance, and resting cardiovascular state.
62077965|NCT03587805|EXPERIMENTAL|Tralokinumab, all subjects|"Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~From Week 2 up to Week 266\*: SC injection of tralokinumab maintenance dose.~\*The length of treatment for each subject will depend on when they enter the trial, and on which parent trial and country they come from."
62077966|NCT04402593|EXPERIMENTAL|Modified Heidelberg Model of Neuro-Music Therapy (mHNMT)|The mHNMT for Tinnitus program was modified based on participant feedback of the original HNMT. This study will include 6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
62077967|NCT00367393|EXPERIMENTAL|1|Pimecrolimus cream 1%
62077968|NCT05316168|ACTIVE_COMPARATOR|isolated adductor canal block (ACB)|Adductor Canal Block with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone.
62457170|NCT05825495|ACTIVE_COMPARATOR|Experimental group|Subjects will intragluteally injected with a dose of 150 mg dinalbuphine sebacate at least 12 hours before surgery. During intra- and post-operative period, the pain management will execute following our routine practice.
62457171|NCT05825495|SHAM_COMPARATOR|Control group|The pain management will peri-operatively execute following our routine practice without dinalbuphine sebacate administration.
62077969|NCT05316168|ACTIVE_COMPARATOR|isolated adductor canal block (ACB) + IPACK|ACB with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone, and iPACK with 20cc 0.5% bupivacaine + 2mg dexamethasone.
62646718|NCT05079971|ACTIVE_COMPARATOR|Group A is a control group with aEEG monitoring only, and with retrospective cEEG review|
62646719|NCT05079971|EXPERIMENTAL|Group B is undergoing aEEG monitoring with concurrent full EEG review|
62646720|NCT00933595|EXPERIMENTAL|Smoking Cessation|The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
62077970|NCT02733042|EXPERIMENTAL|Arm A: Durvalumab + Lenalidomide ± Rituximab|"Participants assigned to Arm A will receive:~* Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and~* Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of:~  * Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or~ * All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL~* Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5.~All treatment cycles were 28 days."
62077971|NCT02733042|EXPERIMENTAL|Arm B: Durvalumab + Ibrutinib|"Participants assigned to Arm B will receive:~* Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~* Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason.~All treatment cycles were 28 days."
62077972|NCT02733042|EXPERIMENTAL|Arm C: Durvalumab + Rituximab ± Bendamustine|"Participants assigned to Arm C will receive:~* Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~* Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose)~* Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6.~All treatment cycles were 28 days."
62457172|NCT05133609|EXPERIMENTAL|Group 1|Health professionals who will receive vaccine in the vaccination campaign against SARS-CoV-2.
62646721|NCT01776086|OTHER|Normal patients|for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task
62077973|NCT02733042|EXPERIMENTAL|Arm D: Durvalumab Monotherapy|Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.
62077974|NCT03518736|NO_INTERVENTION|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
62077975|NCT03518736|EXPERIMENTAL|SPEEDI_Early|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting in the hospital and lasting for 4 months. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
62077976|NCT03518736|EXPERIMENTAL|SPEEDI_Late|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting at 4 months post baseline or approximately 3 months after discharge from the hospital. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
62077977|NCT04767360|OTHER|Open labele BIONESS-Training|Four-week therapeutic treatment of foot drop with the electrical stimulation device Bioness L300. This treatment will be performed five times a week for at least 30 minutes
62646722|NCT05523726|EXPERIMENTAL|Preventative Cognitive Behavioral Therapy for Insomnia|Participants in this group will complete daily sleep diary entries for one week, and then have a telehealth pCBT-I session with a nurse coach, where they will receive personalized sleep recommendations to improve sleep quality.
62077978|NCT01414218|EXPERIMENTAL|Humor as Way of Life Seminar|See description of study in previous section for further details.
62077979|NCT03074110|ACTIVE_COMPARATOR|Isocapnic hyperventilation|After end of surgery, hyperventilation and administration of a small, precalculated amount of CO2 into the breathing circuit will be performed.
62077980|NCT03074110|NO_INTERVENTION|Standard procedure|After end of surgery, patients will be subdued to a standard weaning procedure.
62077981|NCT01625195|PLACEBO_COMPARATOR|Omega-3 fatty acid supplement|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with eachthe breackfast and two capsules with dinner. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
62457173|NCT05133609|EXPERIMENTAL|Group 2|Patients with immune-mediated inflammatory diseases who will receive vaccine in the vaccination campaign against SARS-CoV-2.
62457174|NCT01832701|EXPERIMENTAL|coffee|4 cups of soluble coffee per day (2.5g per cup)
62457175|NCT01832701|PLACEBO_COMPARATOR|Maltodextrine with caffeine|4 cups per day containing 2.5 g of product each
62077982|NCT01625195|ACTIVE_COMPARATOR|Placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 50:50% corn/soybean oil as used in other randomized placebo-controlled trials.
62646723|NCT05523726|NO_INTERVENTION|Digital Sleep Education Control|Participants in this group will receive digital sleep education, including tips on how to improve your sleep via interactive email. These materials are selected to help prevent chronic insomnia.
62077983|NCT06410846|EXPERIMENTAL|TopSpin device|TopSpin360 device/neck strengthening exercises.
62077984|NCT06410846|ACTIVE_COMPARATOR|Control group|Neck Strengthening exercises.
62077985|NCT03428815|EXPERIMENTAL|PCM liner|Willowwood Smart Temp Liner
62077986|NCT03428815|ACTIVE_COMPARATOR|regular liner|User's regular prescribed liner
62077987|NCT03197103|EXPERIMENTAL|N-Acetylcysteine (NAC)|Breast enlargement with autologous fat graft obtained by liposuction with Pietruski solution (tumescent solution with NAC).
62077988|NCT03197103|NO_INTERVENTION|Control|Contralateral breast enlargement with autologous fat graft obtained by liposuction with standard tumescent solution.
62077989|NCT00963989|EXPERIMENTAL|Penumbra Device Arm|
62077990|NCT06007079|EXPERIMENTAL|Device Use|Patients will be given the CPM device to take home and use once daily
62077991|NCT01471067|EXPERIMENTAL|Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|Myeloablative Regimen: Rituxan 375 mg/m\^2 (B cell malignancy) by vein (IV) on Day -10; Busulfan AUC 4,000 IV either as an outpatient prior to admission or as an inpatient on Day -9; Clofarabine 30 mg/m\^2 IV Day -7 to Day -4; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; Fludarabine 10 mg/m\^2 IV on Days -7 to -4; Total Body Irradiation (TBI) 2 Gy on Day -3; with Cord Blood infusions on Day 0.
62077992|NCT01471067|EXPERIMENTAL|Fludarabine + Melphalan|Reduced Intensity: Fludarabine 40 mg/m\^2 IV on Days -5 to -2; Melphalan 140 mg/m\^2 IV on Day -2; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; with Cord Blood infusions on Day 0.
62077993|NCT04447443|EXPERIMENTAL|Prebiotic Fiber|
62077994|NCT04447443|PLACEBO_COMPARATOR|Maltodextrin|
62077995|NCT04912622|EXPERIMENTAL|Control|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
62077996|NCT04912622|EXPERIMENTAL|Patient|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
62077997|NCT00886470|EXPERIMENTAL|ST266 1|Topical treatment every other day
62077998|NCT00886470|EXPERIMENTAL|ST266 2|Topical treatment every 4th day
62077999|NCT00886470|EXPERIMENTAL|ST266 3|Topical treatment every 7th day
62078000|NCT01633086|ACTIVE_COMPARATOR|nitric oxide gel|"1. st gel: sodium nitrites~2. nd gel: maleic/ascorbic acids"
62078001|NCT01633086|PLACEBO_COMPARATOR|Placebo gel|"1. st gel: phosphate-buffered saline~2. nd gel: maleic/ascorbic acids"
62078002|NCT01152541|ACTIVE_COMPARATOR|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
62078003|NCT01152541|ACTIVE_COMPARATOR|Riboflavin/dextran|Administration of Riboflavin/dextran every 2 minutes for the duration of UV exposure.
62078004|NCT02565355|OTHER|Lifestyle Modification/Dietary Exclusion|In the lifestyle modification group, where specific IgG antibodies to foods are identified, the intervention is appropriate dietary elimination. The IgG antibody results will be disclosed and specific dietary elimination advice will be provided by an experienced dietician; provide diet alternatives to prevent nutritional deficiencies and improve adherence to diet. To improve compliance, a maximum of 2 high IgG positive foods will be eliminated at any one time in each 4 week period. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
62078005|NCT02565355|OTHER|The Standard Treatment Group|The standard therapy group will not receive results of IgG antibody testing. The patients will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relief as appropriate. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
62646724|NCT02048436||male female 18-45 years range of body types|18 male female subject mix that are 18-45 years of age and selected to represent a range of body types of varying physiques and body mass indexes
62646725|NCT03758729|EXPERIMENTAL|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
62646726|NCT01931384|EXPERIMENTAL|Intervention group|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
62078006|NCT05480033|EXPERIMENTAL|Intervention group|The imagery technique was applied to the students in this group on the day of the laboratory practice, before the lesson, once a week for 4 weeks. The laboratory practice consisted of 6 weeks. Pre-test was performed on the first week, followed by 4 weeks of imagery technique, and the pre-test was performed on the final week. In each application of the imagery technique, four scenarios that could be encountered in clinical practice that required skill practice were used for 30 minutes. The imagery technique was applied by the second author who had expertise and training in nursing and imagery technique. The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
62078007|NCT05480033|NO_INTERVENTION|Control group|No intervention was performed on the students in this group.
62078008|NCT00436579|EXPERIMENTAL|Arm I (higher-dose enzyme inhibitor therapy)|Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
62078009|NCT00436579|ACTIVE_COMPARATOR|Arm II (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate three times daily on days 15-36.
62078010|NCT00436579|ACTIVE_COMPARATOR|Arm III (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate twice daily on days 15-36. (closed to accrual as of 4/29/2009)
62078011|NCT01544621||Successful quitters Sustained smokers|Successful quitters
62078012|NCT04600297|EXPERIMENTAL|3D printed resin composite posterior FDP|Three units posterior fixed dental prosthesis made with 3D printed resin composite material
62078013|NCT06134934|EXPERIMENTAL|Telemonitoring design 1|"* Self-Monitoring of Blood Glucose (SMBG)~* Sleep~* Mental health~* Blood pressure~* Activity"
62078014|NCT06134934|EXPERIMENTAL|Telemonitoring design 2|"* Self-Monitoring of Blood Glucose (SMBG)~* Sleep~* Mental health"
62078015|NCT02881177|EXPERIMENTAL|Oxytocin|Oxytocin 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
62078016|NCT02881177|PLACEBO_COMPARATOR|Placebo|Placebo 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
62078017|NCT06291532|EXPERIMENTAL|Experimental Group (EG)|The group consists of patients diagnosed with autism spectrum disorder and intellectual disability who underwent treatment with VRRS
62078018|NCT00687661|ACTIVE_COMPARATOR|1|Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
62078019|NCT00687661|PLACEBO_COMPARATOR|2|Arm #2 will include patients randomized to receive placebo therapy for 24 months
62078020|NCT01750593|EXPERIMENTAL|radiofrequency ablation of thyroid nodule|Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation
62078021|NCT03549611|EXPERIMENTAL|Multimodel Drug Regimen|"The patients randomized to this arm will receive the following multimodal oral drug regimen administered shortly before induction of general anesthesia~1. Tylenol, 975mg (3 tabs)~2. 800mg Gabapentin~3. 400mg Celecoxib~4. 10mg Oxycodone"
62078022|NCT03549611|ACTIVE_COMPARATOR|Acetaminophen Only|"The patients randomized to this arm will receive oral acetaminophen only administered shortly before induction of general anesthesia~1. Tylenol, 975mg (3 tabs)"
62078023|NCT03929419|ACTIVE_COMPARATOR|Insulin nasal spray|160 Units of human insulin as nasal spray
62078024|NCT03929419|PLACEBO_COMPARATOR|Placebo nasal spray|Nasal spray containing placebo solution
62078025|NCT02827214||Surgical treatment|"Several surgical treatments exist to treat the fractures included in the study. The following section describes the different surgical treatment modalities in more detail~Approaches:~* Open short segment surgical fixation (1 level above and below the fracture level) with or without posterior decompression~* Open long segment posterior fixation (2 or more levels above, 2 or more levels below) with or without posterior decompression~* Posterior short or long fixation with posterolateral corpectomy and reconstruction~* Anterior alone instrumentation~* Combined Anterior Posterior (AP) instrumentation~* Percutaneous posterior fixation combined with anterior instrumentation~* Percutaneous posterior fixation with or without vertebroplasty"
62078026|NCT02827214||Non-surgical treatment|"Non-surgical treatment is defined as bed rest followed by immobilization with:~* Custom-molded or prefabricated total body contact thoracolumbosacral orthosis (TLSO)~* Thermoplastic removable brace~* Jewett hyperextension braces~* Anterior hyperextension brace (ASH)~* Taylor-Knight brace~* Plaster of Paris (POP)"
62078027|NCT02796547|EXPERIMENTAL|Levobupivacaine|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with Levobupivacaine. This is the only intervention specific to the study, as compared to the standard of care.
62078028|NCT02796547|PLACEBO_COMPARATOR|Placebo|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with physiological serum.This is the only intervention specific to the study, as compared to the standard of care.
62078029|NCT05457816||family members|family members of those with rheumatoid arthritis
62078030|NCT05457816||rheumatoid arthritis|persons with rheumatoid arthritis
62078031|NCT05823337|ACTIVE_COMPARATOR|only given diet therapy|only diet theraphy
62078032|NCT05823337|EXPERIMENTAL|given diet therapy and selenium|diet theraphy and 200 mcg selenium
62078033|NCT04685733||Group 1|Comparison of blood pressure, LVET and CO/SV measures with respective Gold Standards
62646727|NCT01931384|PLACEBO_COMPARATOR|control group|normal saline (placebo) intramuscular injection will be given on the day of FET and 6 days later
62078034|NCT04685733||Group 2|Comparison of blood pressure and HRV measures with respective Gold Standards
62646728|NCT04700969|EXPERIMENTAL|A support program to facilitate implementation of EBP for postoperative urinary retention|12- month support program. Multi-professional facilitator-teams will be supported by a 12-month support program including seminars and monthly supervision (e-discussion forum and group teleconferences) to develop an awareness of, and skills in facilitating implementation of evidence/EBP in clinical everyday care.
62078035|NCT04685733||Group 3|Comparison of blood pressure and CO/SV measures with respective Gold Standards
62078036|NCT02323893|EXPERIMENTAL|18F-FAraG|A single dose intravenous injection of 18F-FAraG followed by PET scanning.
62078037|NCT04161417|OTHER|Biopsy Material Required for Registration|The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer
62078038|NCT01822353|EXPERIMENTAL|Milk allergy|Dietary supplement, milk in increasing dosages, delivered daily and orally.
62078039|NCT01822353|EXPERIMENTAL|Egg allergy|Dietary supplement, egg protein given in increasing dosages, delivered daily and orally.
62078040|NCT01822353|EXPERIMENTAL|Nut allergy|Dietary supplement, nut cream including nut allergens, delivered in increasing dosages, daily and orally.
62646729|NCT04700969|NO_INTERVENTION|Control-No support program|No support program
62078041|NCT06531135|EXPERIMENTAL|stress management|10 weeks of group intervention of Taiwanese version stress management intervention.
62646730|NCT04071041|EXPERIMENTAL|Standard care plus albumin|"Patients will receive human albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.~Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team."
62078042|NCT06531135|ACTIVE_COMPARATOR|Support group|5 weeks of supportive group intervention.
62078043|NCT03380884|NO_INTERVENTION|Control|Control group will remain in their habitual life style and no vibration used
62078044|NCT03380884|EXPERIMENTAL|Vibration Group|The intervention group will undergo Low-magnitude high-frequency vibration (LMHFV) at 35Hz, 0.3g (peak to peak magnitude), displacement of \<0.1mm, 20 min/day, at least 3 times per week, for 6 months in community centres
62078045|NCT01081353|EXPERIMENTAL|Arm 1|
62078046|NCT01081353|ACTIVE_COMPARATOR|Arm 2|
62078047|NCT01081353|ACTIVE_COMPARATOR|Arm 3|
62078048|NCT01081353|ACTIVE_COMPARATOR|Arm 4|
62078049|NCT03011515||LRTI patients|Patients with suspicion of LRTI, excluding episodes of COPD exacerbations
62078050|NCT03011515||Non-infectious patients|Afebrile patients with no apparent infectious disease
62078051|NCT03011515||LRTI patients with COPD|Patients with suspicion of LRTI in a sub-group of patients with COPD
62078052|NCT04493918|EXPERIMENTAL|MSC Group|Mesenchymal Stem Cell + NaCl 0,9% 2ml
62078053|NCT02100111||Participants with advanced or metastatic BCC|Participants with BCC who received any treatment including surgeries, radiation, photodynamic therapy, chemotherapy, supportive/palliative care, or other therapies, will be included as a part of study.
62078054|NCT06370338||Delphi Panel|Experts in the field of cardiothoracic critical care with administrative, educational, and research roles.
62078055|NCT00209274|EXPERIMENTAL|1|Percutaneous mitral valve repair using MitraClip implant. The calculated sample size was 186 patients in the device arm
62078056|NCT00209274|ACTIVE_COMPARATOR|2|Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.
62078057|NCT03783481|EXPERIMENTAL|Mobile community group|join the mobile community via the smartphone application
62078058|NCT03783481|ACTIVE_COMPARATOR|No community group|
62078059|NCT02260089|EXPERIMENTAL|Low dose of telmisartan|4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
62078060|NCT02260089|EXPERIMENTAL|High dose of telmisartan|After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
62078061|NCT05280847|EXPERIMENTAL|10 ml ESP group|ESP group using 10 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
62078062|NCT05280847|EXPERIMENTAL|20 ml ESP group|ESP group using 20 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
62078063|NCT04366206||Patients exposed to the study variable|Depending on the studied variable (treatment or risk factor)
62078064|NCT04366206||Patients not exposed to the study variable|Depending on the studied variable (treatment or risk factor)
62078065|NCT01397929|EXPERIMENTAL|Drug: BAL101553 at MTD|
62646731|NCT04071041|NO_INTERVENTION|Standard care alone|Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team.
62078066|NCT01397929|EXPERIMENTAL|Drug: BAL101553 at 50% of MTD|
62078067|NCT03454217|ACTIVE_COMPARATOR|Oxycodone|Postoperative pain treatment with oxycodone
62078068|NCT03454217|ACTIVE_COMPARATOR|Tramadol|Postoperative pain treatment with tramadol
62078069|NCT01429519|EXPERIMENTAL|Treatment|
62078070|NCT02092818||Group 1|Patients who have been prescribed Adempas for a medically appropriate use
62078071|NCT06208722|EXPERIMENTAL|Experimental|Children in the experimental arm will receive the same health education module as in the control arm. They will also receive a brief tutorial on additional app components in the form of a digital social story, which is an effective way to convey information to children with autism. Participants will be completing 26-item Behavioral Survey at 2 weeks, 1 month, 2 month, and 3 month. Participants will be using the app during toothbrushing 2x a day for 3 months under direct supervision of the caregiver.
62078072|NCT06208722|OTHER|Control|The control arm will consist of a 20-second health education module delivered through the control app that consists of a digital selfie mirror and a timer that matches the length of brushing time in the experimental app. Participants will be completing all the survey activities similar to that of the participants in the experimental arm.
62078073|NCT03859336|EXPERIMENTAL|Transdermal Neuromodulation Stimulation|"Day 1 of Transdermal Neuromodulation Stimulation (TENS) is a one-day sham stimulation, consisting of: 30 seconds of sensation in which amplitude is increased up to the threshold of salient sensation, followed by 19 minutes of no stimulation (device is turned off), followed by 30 more seconds of salient stimulation. Day 1 is used to exclude those who cannot tolerate study procedures and placebo responders; it will also serve as baseline for anxiety measures. TENS treatment begins one day after sham, and lasts 3 days with 20 minutes of stimulation per day. One day following open label treatment all participants will once again receive sham stimulation following the same procedures utilized at Day 1.~Treatment amplitude is adjusted for each participant, in which the stimulation will be administered just below the participant's sensation threshold. Amplitude from the TENS device does not exceed 20mA. Frequency will be at 300hz."
62078074|NCT03857581|EXPERIMENTAL|Clozapine Arm|
62078075|NCT03857581|ACTIVE_COMPARATOR|Olanzapine Arm|
62078076|NCT03315819|EXPERIMENTAL|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique. The procedure must be performed within 15 days of dislocation.
62646732|NCT03702660|EXPERIMENTAL|GIP(3-30)NH2|GIP receptor antagonist
62078077|NCT03315819|ACTIVE_COMPARATOR|Immobilization interne rotation|Immobilization of the shoulder during 3 weeks
62646733|NCT03702660|PLACEBO_COMPARATOR|Placebo|Placebo (saline infusions)
62646734|NCT03702660|ACTIVE_COMPARATOR|GLP-1|
62078078|NCT01558076||Subjects with sickle cell anemia|60 subjects with sickle cell anemia will be enrolled on the study.
62078079|NCT01558076||30 healthy controls|30 controls without sickle cell anemia or sickle cell trait will be enrolled on the study.
62078080|NCT04668287|OTHER|Increasing Self-Esteem|All participants will be included in working groups.
62078081|NCT06510491|EXPERIMENTAL|Safety Lead-In Epcoritamab|"Participants will be enrolled using a modified 3+3 dose-escalation design to establish the Recommended Phase 2 Dose of Epcoritamab and will complete study procedures as follows:~* Baseline visit with CT scan and bone marrow biopsy.~* Bone marrow biopsy before cycle 6.~* Cycles 1 - 3:~  --Days 1, 8, 15, and 22 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily.~* Cycles 4 - 9:~  --Days 1 and 15 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily.~* Cycles 10 - 12:~  --Day 1 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily.~* End of Treatment visit with CT scan and bone marrow biopsy.~* Follow up visits: every 3 months for 2 years~* Off study visit~* If there are 0 out of 3 dose-limiting toxicities (DLTs), the study will proceed to phase II. If 1/3 participants experience a DLT, up to 3 additional participants will be treated at the same dose level. If more than 1/6 total participants experience a DLT, then the study will not proceed to phase 2."
62078082|NCT06510491|EXPERIMENTAL|Phase II Epcoritamab|"Participants will be enrolled and will complete study procedures as follows:~* Baseline visit with CT scan and bone marrow biopsy.~* Bone marrow biopsy before cycle 6.~* Cycles 1 - 3:~  --Days 1, 8, 15, and 22 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily.~* Cycles 4 - 9:~  --Days 1 and 15 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily.~* Cycles 10 - 12:~  --Day 1 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily.~* End of Treatment visit with CT scan and bone marrow biopsy.~* Follow up visits: every 3 months for 2 years~* Off study visit"
62078083|NCT05000528|EXPERIMENTAL|Therapeutic education|
62078084|NCT05000528|ACTIVE_COMPARATOR|Individualized consultation|
62457176|NCT03328780||Hemoglobin determination|In this study classical laboratory determination, determination with HemoCue® and Rad-67™ will be performed to compare precision of those three methods as well as their correlation.
62646735|NCT03702660|EXPERIMENTAL|GLP-1 + GIP(3-30)NH2|
62646736|NCT01166256|EXPERIMENTAL|High-flow nasal cannula|In this arm,patients with acute hypoxemic respiratory failure were treated with high-flow nasal cannula system(Optiflow, Fisher \& Paykel, Auckland, New Zealand) to achieve SpO2 \>92% or PaO2 \>65 mmHg.
62646737|NCT01166256|ACTIVE_COMPARATOR|Non-invasive ventilation|In this arm, patients with acute hypoxemic respiratory failure is treated with the bi-level positive airways pressure mode (BiPAP Vision, Respironics Inc., Murrysville, PA) S/T mode to achieve SpO2 \>92% or PaO2 \>65 mmHg.
62078085|NCT01185054|EXPERIMENTAL|Fluids as Tolerated (FAT) Group|The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
62078086|NCT01185054|ACTIVE_COMPARATOR|Electrolyte Maintenance Solution (EMS)|The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
62646738|NCT01123330|EXPERIMENTAL|Motivational Interviewing plus DVD|Caregivers watched a 15-minute educational video designed for the project emphasizing the importance of good oral health in children, and how the caregiver can keep children free from tooth decay. The MI interviewer engaged the parent in a discussion of their thoughts and concerns regarding their child's oral health and what changes they wished to make regarding monitoring their child's oral health. Feedback from the child's dental exam was also reviewed. MI+DVD caregivers received a brochure displaying a photo of their child and for those who chose to set specific goals for their child's oral health, those goals were listed on the brochure. Caregivers choosing not to set specific goals were offered a list of 10 project recommendations regarding dietary intake, oral hygiene, and dental check-ups. The session ended with a dialogue regarding possible barriers to implementing the personal plan and how the caregiver planned to overcome those barriers.
62646739|NCT01123330|ACTIVE_COMPARATOR|DVD only|Caregivers watched the same educational video. At the end of the video, caregivers were given a glossy-printed brochure displaying the project developed recommendations as well as the child's photograph. The brochure was not re-mailed, as it was for the MI+DVD group and caregivers in this condition did not receive any feedback from the dental examination regarding their child's oral health status.
62078087|NCT04619342|EXPERIMENTAL|GSMs-TACE+ Surgical Resection Group|After TACE using epirubicin and GSMs (150-350μm or 350-560μm), patients that meet certain criteria will receive surgical resection of PVTT, as specified per protocol.
62078088|NCT04619342|ACTIVE_COMPARATOR|GSMs-TACE Group|Patients will receive TACE using epirubicin and GSMs (150-350μm or 350-560μm), as specified per protocol.
62078089|NCT00976079|EXPERIMENTAL|Active TENS|Active TENS therapy for 4 weeks plus standard physical therapy for same time period.
62078090|NCT00976079|PLACEBO_COMPARATOR|Placebo TENS|Placebo TENS for 4 weeks plus standard physical therapy for same time period.
62078091|NCT00976079|NO_INTERVENTION|Control Group|No TENS, standard physical therapy for 4 weeks.
62078092|NCT04089371||Arm A Total Shoulder Arthroplasty / Hemiarthroplasty|Total Shoulder Arthroplasty (TSA) Humeral \& Glenoid components as a Hemiarthroplasty or Total Shoulder Replacement.
62078093|NCT04089371||Arm B Reverse Shoulder Arthroplasty|Reverse Shoulder Arthroplasty (RSA) Humeral \& Glenoid Components as a primary, fracture or revision total shoulder replacement
62078094|NCT01804816|EXPERIMENTAL|Acupuncture|10 standardized verum acupuncture (VA) sessions twice a week, over 5 weeks. The 5 weeks of acupuncture were scheduled after the period of no acupuncture for each subject.
62078095|NCT01804816|PLACEBO_COMPARATOR|No Acupuncture|"No acupuncture treatment or other study intervention over 5 weeks. All subjects had a 5 week period of no acupuncture prior to the 5 weeks of acupuncture sessions."
62078096|NCT04815213|EXPERIMENTAL|Arm 1|Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
62078097|NCT05153759|ACTIVE_COMPARATOR|High protein|Consuming a meal composed of 2:1 grams of protein to carbohydrate during the night shift between 7pm-7am
62078098|NCT05153759|PLACEBO_COMPARATOR|Moderate protein|Consuming a meal composed of 1:1 grams of protein to carbohydrate during the night shift between 7pm-7am
62078099|NCT03973138|EXPERIMENTAL|Treatment group|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab under the pro re nata (PRN) treatment regimen.
62078100|NCT04869683|OTHER|MDS follow up|it is a description MDS patients study
62078101|NCT01364402|EXPERIMENTAL|Erythropoietin|
62078102|NCT01364402|PLACEBO_COMPARATOR|Placebo|
62078103|NCT04215185|EXPERIMENTAL|Blood pressure monitor|The CS6BP device will be placed on non-anesthetized subjects in the ICU (Intensive Care Unit) with arterial line placement in the radial artery. The first measurement will be for up to 24h; subsequent measures will be up to 5h.
62280062|NCT04001855|EXPERIMENTAL|Dilute vinegar vs. dilute bleach gauze soaks|Subjects will complete a total of two study visits over 21 days, and will be instructed to apply gauze soaks daily at home over the 21-day study period. At baseline and 21-day follow-up visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected. Subjects will also be provided with a non-invasive skin barrier measurement device to take daily recordings at home.
62646740|NCT00856180|EXPERIMENTAL|Bevacizumab then Cyclophosphamide with Bevacizumab|Patients were given a regimen of sequential antiangiogenic blockade and disease assessed serologically and radiologically every 2 cycles/6 weeks. Patients started with bevacizumab 15 mg/kg IV every 3 weeks until they experienced progressive disease (PD) \[RECIST 1.0 or Rustin criteria\] or significant toxicity. If clinically stable as assessed by their treating physician, patients then received cyclophosphamide 50 mg orally (PO) daily continuously with bevacizumab treatment. If second PD occurred, patients discontinued the combination treatment.
62646741|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
62646742|NCT03040232|EXPERIMENTAL|MPFl Reconstruction|subjects that have had MPFL reconstruction surgery
62646743|NCT03040232|ACTIVE_COMPARATOR|Active Controls|subjects that have not had MPFL reconstruction surgery
62646744|NCT03468088|EXPERIMENTAL|Hand grip strengthening|This group will receive handgrip strengthening exercises.
62646745|NCT03468088|ACTIVE_COMPARATOR|Conventional treatment|This group will receive conventional exercises.
62078104|NCT05363137|EXPERIMENTAL|Experimental|
62078105|NCT05363137|ACTIVE_COMPARATOR|Control|
62078106|NCT03062098|EXPERIMENTAL|IVF patients|IVF patients before embryo transfer. Before performing embryo transfer in the routine manner, ten patients will be asked to participate in the study. After signing informed consent, participants will undergo the experimental procedure: Speculum will be placed to visualize the cervix. The thin ultrasound probe will be places posterior to the cervix. While viewing the image on the ultrasound screen, the probe will be moved manually to obtain the best imaging of the cervical canal. An empty embryo transfer catheter will be introduced to the cervical canal and will be advanced under ultrasound imaging up to the internal os. The catheter will be withdrawn, and routine embryo transfer will follow.
62078107|NCT02444585|EXPERIMENTAL|Denosumab|Drug for prevention of bone loss
62078108|NCT02444585|PLACEBO_COMPARATOR|Control|Hip Replacement Patient without Drug
62078109|NCT02790216||Brachytherapy|men eligible for monotherapy seed implant brachytherapy
62078110|NCT01359618|EXPERIMENTAL|Part A 1|TC-5214
62078111|NCT01359618|EXPERIMENTAL|Part A 2|TC-5214 placebo
62078112|NCT01359618|EXPERIMENTAL|Part B 1|TC-5214 8 mg + moxifloxacin placebo
62078113|NCT01359618|EXPERIMENTAL|Part B 2|TC-5214 supratherapeutic dose + moxifloxacin placebo
62078114|NCT01359618|ACTIVE_COMPARATOR|Part B 3|TC-5214 placebo + moxifloxacin 400 mg
62078115|NCT01359618|PLACEBO_COMPARATOR|Part B 4|TC-5214 placebo + moxifloxacin placebo
62078116|NCT03734159|EXPERIMENTAL|parasternal block|preoperative parasternal block by ropivacaine injection
62078117|NCT03734159|PLACEBO_COMPARATOR|physiological serum|sodium chloride injection
62280063|NCT02734069||Sarcopenic|Patients with sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
62646746|NCT02493959|EXPERIMENTAL|PYY infusion|IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
62280064|NCT02734069||Non Sarcopenic|Patients without sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
62646747|NCT03346239|EXPERIMENTAL|Gaze Contingent Music Reward Therapy|Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
62078118|NCT03722264|EXPERIMENTAL|OpalSeal|"OpalSeal will be applied~1. to the buccal surfaces of to-be-extracted teeth on one side of the mouth which will be determined randomly for each participant during bonding of orthodontic brackets, or~2. to the proximal surfaces following IPR in accordance to manufacturer instructions. Since OpalSeal has fluoride releasing capability, this would be experimental arm"
62078119|NCT03722264|PLACEBO_COMPARATOR|Transbond XT|"TransbondXT will be applied~1. to the buccal surfaces of to-be-extracted teeth on the other side of the mouth which will be determined based on which side received OpalSeal for each participant during bonding of orthodontic brackets, or~2. to the proximal surfaces following IPR in accordance to manufacturer instructions. Transbond XT does not have fluoride and hence would be considered as a placebo."
62078120|NCT03854240|ACTIVE_COMPARATOR|Classic block (Group C)|In group C, classic technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and multifidus muscles. Between these muscles, block needle will be inserted within in plane technique in a lateral-to-medial direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
62078121|NCT03854240|ACTIVE_COMPARATOR|Modified block (Group M)|In group M, modified technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
62078122|NCT03393143||Oregon patients|Adult Medicaid patients with back pain who get their care in community health clinics in Oregon
62078123|NCT03393143||California patients|Adult Medicaid patients with back pain who get their care in community health clinics in California
62078124|NCT02961855|EXPERIMENTAL|Clife1 gel (lidocaine plus diclofenac)|Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
62078125|NCT02961855|ACTIVE_COMPARATOR|Clife2 gel (lidocaine)|Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
62646748|NCT03346239|ACTIVE_COMPARATOR|Selective Serotonin Reuptake Inhibitors|Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
62078126|NCT04814927|ACTIVE_COMPARATOR|Copper IUD|The copper IUD contains approximately 176 mg of copper wire wrapped around a vertical stem. It is FDA approved for pregnancy prevention for 10 years.
62646749|NCT03346239|PLACEBO_COMPARATOR|Waitlist Control|Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
62078127|NCT04814927|ACTIVE_COMPARATOR|Etonogestrel Implant|The ETG implant is a single, radiopaque, rod shaped implant containing 68 mg of etonogestrel. It is FDA approved for pregnancy prevention for 3 years.
62078128|NCT04814927|ACTIVE_COMPARATOR|Levonorgestrel IUS|The LNG IUS contains approximately 52 mg. of LNG. It is FDA approved for pregnancy prevention for 5 - 6 years.
62078129|NCT04814927|ACTIVE_COMPARATOR|DMPA Sub-cutaneous|DMPA contains 104 mg of medroxyprogesterone acetate in 0.65 mL of fluid, administered by subcutaneous injection in the abdominal fat, thigh or skin over the deltoid muscle. It is FDA approved for pregnancy prevention for 14 weeks.
62078130|NCT00556348|EXPERIMENTAL|1|
62078131|NCT03441113|OTHER|Cohort 1: Study GS-US-352-0101|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
62078132|NCT03441113|OTHER|Cohort 2: Study GS-US-352-1214|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
62078133|NCT03441113|OTHER|Cohort 3: Study GS-US-352-1154|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases..
62078134|NCT03441113|OTHER|Cohort 4: Study SRA-MMB-301|Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
62078135|NCT01009047|EXPERIMENTAL|Paliperidone extended-release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
62078136|NCT01009047|ACTIVE_COMPARATOR|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
62078137|NCT06196580|EXPERIMENTAL|SHR4640 group A|
62078138|NCT06196580|EXPERIMENTAL|SHR4640 group B|
62078139|NCT06196580|PLACEBO_COMPARATOR|SHR4640 Placebo|
62078140|NCT01047475|ACTIVE_COMPARATOR|MB-6+FOLFOX4|MB-6 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
62078141|NCT01047475|PLACEBO_COMPARATOR|Placebo+FOLFOX4|Placebo, 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
62078142|NCT06145022|EXPERIMENTAL|intervention group|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
62078143|NCT06145022|ACTIVE_COMPARATOR|waitlist control group|A unique education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.
62078144|NCT04227860|ACTIVE_COMPARATOR|Group 1: G I primary KOA|Exercise and balance training
62078145|NCT04227860|ACTIVE_COMPARATOR|Group 2: G II primary KOA|Exercise and balance training
62078146|NCT04227860|ACTIVE_COMPARATOR|Group 3: G III primary KOA|Exercise and balance training
62078147|NCT04227860|ACTIVE_COMPARATOR|Group 4: G IV primary KOA|Exercise and balance training
62078148|NCT04539379|ACTIVE_COMPARATOR|magnesium sulfate|intravenous infusion of magnesium sulfate at a dose of 4 gm intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..
62646750|NCT05388799|EXPERIMENTAL|application group|Before the operation, training will be given in line with the training brochure prepared by the researcher in the outpatient clinic and the printed version of the training brochure will be given to the patient. The training will be repeated by calling the patients the day before the surgery.
62646751|NCT05388799|NO_INTERVENTION|control group|Standard care will be applied.
62078149|NCT04539379|ACTIVE_COMPARATOR|labetolol|The patients will be given intravenous infusion of labetolol (Trandate™, 5mg/ml) available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with 20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the infusion as required every 15 - 30min to a maximum dose of 160mg/hr.
62078150|NCT01978340||sleeplab|Sleep Lab examined, usualy with some obesity or sleeping disorders.
62078151|NCT04751175|EXPERIMENTAL|Ketamina bolus plus Dexamethasone bolus plus infusion ketamine|Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)
62078152|NCT04751175|EXPERIMENTAL|Ketamine bolus plus ketamine infusion|Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.
62078153|NCT04751175|ACTIVE_COMPARATOR|Dexametasone arm|Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA
62078154|NCT04751175|PLACEBO_COMPARATOR|Saline bolus|Saline bolus + saline bolus + saline infusion up to three hours after admission to the URPA
62078155|NCT01028521|EXPERIMENTAL|CM3.1-AC100|
62078156|NCT01028521|PLACEBO_COMPARATOR|Placebo|
62078157|NCT00715507||1|For the phase of the study in which the utility of the graphical medication monitor is assessed, the monitor will not be shown to anesthesiologists placed in the control condition.
62078158|NCT00715507||2|In the experimental condition, anesthesiologists will be shown the medication monitor to aid their expertise and decision-making.
62078159|NCT03815279|EXPERIMENTAL|High-risk SMM and MM|"Twelve cycles of Carfilzomib-Lenalidomide-Dexamethason. Each cycle is 28 days. Carfilzomib intravenous, days 1, 8 and 15 (starting dose, 20 mg/m2 on day 1 of cycle 1; target dose, 56 mg/m2 thereafter) during cycles 1 through 12.~Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks then 20 mg weekly for 16 weeks and thereafter 10 mg weekly for 16 weeks.~Maintenance (1 year):~Carfilzomib intravenous days 1 and 15 (56 mg/m2) during cycles 13 through 24. Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks Dexamethasone 10 mg weekly for 52 weeks."
62078160|NCT03815279|EXPERIMENTAL|Intermediate-risk SMM|"Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks, then 20 mg weekly for 16 weeks.~Maintenance (1 year):~Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks."
62078161|NCT04866511|EXPERIMENTAL|NET intervention|This study will follow a single case design and will involve delivering and evaluating the child-friendly protocol of NET. Therefore, there will only be one arm (NET intervention) and no comparators.
62078162|NCT02169947|ACTIVE_COMPARATOR|Weight loss core|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program.
62078163|NCT02169947|EXPERIMENTAL|Weight loss core plus maintenance|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program PLUS 12 maintenance sessions.
62078164|NCT04788290||Single group(No interventional)|Other Name: Observational Rabone D®, Once daily administered per the locally approved product information
62078165|NCT06174935|EXPERIMENTAL|Atropine 0.01%|Patients will apply 1 drop daily of atropine 0.01%
62078166|NCT05303038|EXPERIMENTAL|cryoablation combined with tirelizumab + Bevacizumab|
62078167|NCT03647839|EXPERIMENTAL|Arm 1|Nivolumab and BNC105
62646752|NCT04405258|ACTIVE_COMPARATOR|PVI alone|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
62646753|NCT04405258|ACTIVE_COMPARATOR|PVI and PWI|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
62078168|NCT03647839|EXPERIMENTAL|Arm 2|Nivolumab and BBI-608
62078169|NCT05251441|EXPERIMENTAL|F50|Patients in the group in which fortification was started when enteral nutrition reached 50 cc/kg
62078170|NCT05251441|ACTIVE_COMPARATOR|F100|Patients in the group in which fortification was started when enteral nutrition reached 100 cc/kg
62078171|NCT01263184||sportive wheelchair users|
62078172|NCT01263184||sportive non disabled|
62078173|NCT01263184||non sportive wheelchair users|
62078174|NCT03195920|EXPERIMENTAL|Enhanced Lithotripsy System|Treatment for urinary stones with the Enhanced Lithotripsy System
62078175|NCT05377086|EXPERIMENTAL|schroth group|This arm was planned as the exercise group which includes Schroth 3-Dimensional scoliosis exercise.
62078176|NCT05377086|EXPERIMENTAL|conventional group|This arm was planned as the exercise group which includes conventional scoliosis exercise.
62078177|NCT01449214|EXPERIMENTAL|Ultrasound|Use of ultrasound to identify interlaminar spaces for needle insertion. Intervention/Procedure: ultrasound-guided technique.
62646754|NCT03337516|EXPERIMENTAL|Patients treated with Cytarabine|
62646755|NCT01004939||fondaparinux prescribed subjects|fondaparinux prescribed subjets
62078178|NCT01449214|ACTIVE_COMPARATOR|Landmarking|Use of manual palpation to identify anatomic landmarks for needle insertion. Procedure/Intervention: landmark-guided technique.
62078179|NCT01752413|EXPERIMENTAL|Ferrous gluconate 325mg|Those found iron depleted by ferritin measure will receive 325 mg Ferrous gluconate twice a day for 100 days. They will be deferred as a whole blood donor for 120 days until completion of iron therapy. They will receive standard dietary counseling.
62078180|NCT01752413|ACTIVE_COMPARATOR|Nutrition counseling|For those consenting to this study but who demonstrate adequate ferritin levels (\>20 micrograms/L female, \>30 micrograms/L males), they will not receive oral iron or additional deferral period but will be allowed to donate after the standard 56 days. They will receive standard counseling about iron rich foods. Rate and frequency of subsequent donations will be tracked and compared to those receiving iron supplementation.
62078181|NCT05681403|EXPERIMENTAL|Improved BEAM regimen|The enrolled subjects will received mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine as conditioning regimen for ASCT.
62078182|NCT01388374|NO_INTERVENTION|General Practitioners Care|Usual medical care provided by a general practitioner at the Primary Out of Hours Emergency Service.
62457177|NCT04835922|EXPERIMENTAL|Intercostal Nerve Block|• In Group I (ICBN group): Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine at the termination of PCNL under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each).
62457178|NCT04835922|ACTIVE_COMPARATOR|Peritract infiltration|In Group P (PTI): Single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given on completion of PCNL by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position). Then the surgical wound and intervention site will be covered with an occlusive dressing.
62457179|NCT06131281|EXPERIMENTAL|E-TORe|Participants in this arm received the E-TORe procedure
62457180|NCT06131281|ACTIVE_COMPARATOR|c-TORe|"Participants in this arm received the classical or c-TORe procedure"
62457181|NCT03805438|EXPERIMENTAL|Chloroprocaine dose|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
62646756|NCT01288300|ACTIVE_COMPARATOR|Comprehensive diabetes self-management intervention|Diabetes education, self-empowerment training, exercise, patient navigator
62646757|NCT01288300|OTHER|Control|Diabetes self-management lecture
62078183|NCT01388374|EXPERIMENTAL|Nurse Practitioners Care|Medical care provided by the Nurse Practitioner at the Primary Out of Hours Emergency Service.
62078184|NCT02624206|ACTIVE_COMPARATOR|Juice A|Half of the group to receive Juice A, a novel juice flavor.
62078185|NCT02624206|ACTIVE_COMPARATOR|Juice B|Half of the group to receive Juice B, a novel juice flavor different from Juice A.
62078186|NCT01628211|EXPERIMENTAL|Second look laparoscopy|Second look laparoscopy to evaluate for and treat peritoneal carcinosis
62078187|NCT01628211|NO_INTERVENTION|standard follow up|
62078188|NCT06362239||High-access home-based hospice and palliative care (HBHPC)|Patients with high-access to home-based hospice and palliative care (HBHPC) enrolled from three sites: Nationwide Children's Hospital, Columbus, OH (NCH); Akron Children's Hospital, Akron, OH (ACH); and Medical University of South Carolina, Charleston, SC (MUSC).
62078189|NCT06362239||Low-access home-based hospice and palliative care (HBHPC)|Patients with low-access to home-based hospice and palliative care (HBHPC) (i.e., primarily or exclusively hospital-based services) enrolled from two sites: Nemours Children's Hospital, Wilmington, DE (Nemours); and Texas Children's Hospital, Houston, TX (TCH).
62078190|NCT03614884|EXPERIMENTAL|Gambling and Smoking Treatment|Participants in this arm will be given access to the online integrated treatment for gambling and smoking.
62078191|NCT03614884|ACTIVE_COMPARATOR|Gambling Only Treatment|Participants in this arm will be given access to the online gambling only treatment.
62078192|NCT05008159|EXPERIMENTAL|The EMBOLDEN program|3 month community-based mobility and healthy aging intervention
62646758|NCT03912389|EXPERIMENTAL|BCD-100|BCD-100 3 mg/kg Q3W
62646759|NCT03912389|PLACEBO_COMPARATOR|Placebo|
62646760|NCT00228163|EXPERIMENTAL|Teriflunomide 7 mg|
62457182|NCT04927533|EXPERIMENTAL|Older adults with psychiatric problems|The target group is a group of older adults with psychiatric problems (≥60 years old) admitted to a residential psychogeriatric department of the Psychiatric Clinic of the Alexians Care Group Tienen. The following exclusion criteria apply: a score of less than 21 on the MMSE (excluding dementia or other moderate to severe cognitive disorders), a mother tongue other than Dutch and having undergone surgery and/or chemotherapy in the last 3 months.
62457183|NCT01464866|ACTIVE_COMPARATOR|Hospital Feed|Standard hospital food
62457184|NCT01464866|EXPERIMENTAL|Hospital Feed plus nutritional supplement|Standard hospital food plus nutritional supplement
62457185|NCT01976130|EXPERIMENTAL|bronchoscopy|Procedure
62078193|NCT05008159|NO_INTERVENTION|Usual care|
62078194|NCT00871793|ACTIVE_COMPARATOR|1|Occupational therapy
62078195|NCT00871793|NO_INTERVENTION|2|watchful waiting
62457186|NCT01442402||2 APOL1 genotypes|African American transplant recipients with homozygous APOL1 gene variants
62457187|NCT01442402||0 or 1 APOL1 genotypes|African American transplant recipients without homozygous APOL1 gene variants
62457188|NCT02980978|EXPERIMENTAL|Intervention|Individuals assigned to the intervention group will have supplemental care provided by a registered dietitian/certified diabetes educator which includes counseling on lifestyle to improve diabetes and overall health. Additionally, individuals in this group may be started on medications (or adjustments to current medications) for blood pressure, cholesterol or blood glucose to meet diabetes care goals
62646761|NCT00228163|EXPERIMENTAL|Teriflunomide 14 mg|
62646762|NCT04143659|EXPERIMENTAL|LB injection 40mg intramuscular (IM) with 20 mg/ml concentration|27 subjects (18 with BMI \<30mg\^2; 9 with BMI \>=30kg/m\^2 and \<40kg/m\^2) were administered a single dose of levonorgestrel butanoate (LB) injection 40mg intramuscular (IM) using 20 mg/ml concentration
62646763|NCT04143659|EXPERIMENTAL|LB injection 40 mg subcutaneous (SC) with 20 mg/ml concentration|32 subjects (25 with BMI \<30mg\^2; 7 with BMI \>=30kg/m\^2 and \<40kg/m\^2) were administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 20 mg/ml concentration
62646764|NCT04143659|EXPERIMENTAL|LB injection 50mg subcutaneous (SQ) with 70 mg/ml concentration|8 subjects (8 with BMI \<40 kg/m2) will be administered a single dose of levonorgestrel butanoate (LB) injection 50mg intramuscular (IM) using 70 mg/ml concentration
62078196|NCT05718648|EXPERIMENTAL|BI 1015550 Severe renal impairment|Participants with severe renal impairment and not requiring dialysis.
62078197|NCT05718648|EXPERIMENTAL|BI 1015550 Moderate renal impairment|Participants with moderate renal impairment.
62078198|NCT05718648|EXPERIMENTAL|BI 1015550 Normal renal function|Participants with normal renal function.
62078199|NCT02169895|EXPERIMENTAL|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~Every period with concomitant single oral administration of Prolopa® 100-25"
62078200|NCT02169895|EXPERIMENTAL|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
62078201|NCT02169895|EXPERIMENTAL|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
62078202|NCT02169895|ACTIVE_COMPARATOR|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
62078203|NCT02793635|EXPERIMENTAL|SCI Patients|"* 10 subjects with complete or incomplete SCI (\> 1 year post-injury) with preserved LE function will be recruited.~* No control group"
62078204|NCT03543722|EXPERIMENTAL|National Career Coach Program|This program has four main components: a 4-day in-person introductory seminar held in Alpharetta, GA, up to 18 months of job coaching provided by telephone and Skype, a human capital fund to pay for expenses of securing a job (e.g., travel, clothing, computers, professional organization fees), and an opportunity for two years to earn a bonus for employment earnings above a certain level.
62078205|NCT03543722|ACTIVE_COMPARATOR|Local Community Resources Program|Consists of referral to three local face-to-face service providers offering veterans training, financial assistance, and paid work experiences: The Department of Veterans Affairs Compensated Work Therapy Program, the state Vocational Rehabilitation program, and the Department of Labor America's Job Center.
62078206|NCT02846558|EXPERIMENTAL|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
62457189|NCT02980978|NO_INTERVENTION|Standard of Care|Individuals will be followed by their Primary Care Provider as standard of care and per usual clinical need
62078207|NCT02846558|EXPERIMENTAL|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
62078208|NCT02846558|PLACEBO_COMPARATOR|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
62078209|NCT02846558|NO_INTERVENTION|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index \< 25 kg/m\^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
62078210|NCT03179631|EXPERIMENTAL|Ataluren|10, 20 milligrams per kilogram (mg/kg)
62078211|NCT03179631|PLACEBO_COMPARATOR|Placebo|10, 20 mg/kg
62078212|NCT02237378|EXPERIMENTAL|FDG PET scan|A PET scan using F-18 FDG, N-13 Ammonia will be performed
62646765|NCT04143659|EXPERIMENTAL|LB injection 60mg Subcutaneous (SQ) with 70 mg/ml concentration|32 subjects (16 with BMI \<30mg\^2; 16 with BMI \>=30kg/m\^2 and \<40kg/m\^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 60mg subcutaneous (SC) using 70 mg/ml concentration
62078213|NCT03146481|EXPERIMENTAL|Aceclofenac|Aceclofenac 100 mg tablet
62078214|NCT03146481|PLACEBO_COMPARATOR|placebo|Placebo
62078215|NCT01605734|ACTIVE_COMPARATOR|Group TACE|TACE will be carried out with chemotherapeutic agents and lipiodol; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated if clinically indicated
62078216|NCT01605734|EXPERIMENTAL|Group Combination|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
62078217|NCT04478227|EXPERIMENTAL|Arm A|"Arm A will include acquired bone marrow failure (BMF) disorders including aplastic anemia, refractory cytopenia of childhood/Myelodysplastic Syndrome(MDS) without monosomy 7 and 5q deletion abnormalities, toxin induced myelosuppression due to infection and inherited cytopenia with or without involvement of other cell lines who are transfusion dependent and or showing progression to bone marrow failure.~Arm A: Start at 5 microgram/kg/dose per week along with standard of care and escalate with 2.5 microgram/kg/dose increments (per week at physician's discretion depending on the clinical and laboratory response) (Maximum: 20 microgram/kg/dose) based on response for at least 24 weeks or until hematopoietic response is seen, whichever comes first. If patient shows response, therapy will be continued for a total of 52 weeks."
62457190|NCT01887626|EXPERIMENTAL|A|Ticagrelor 90 mg as a whole tablet
62457191|NCT01887626|EXPERIMENTAL|B|Ticagrelor 90 mg tablet crushed and suspended in water
62457192|NCT01887626|EXPERIMENTAL|C|Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach
62457193|NCT04946877||case group|100 ADHD patients; will be taken from outpatient clinic of child and adolescence psychiatry of Assiut university hospitals.
62646766|NCT04143659|EXPERIMENTAL|LB injection 40 mg subcutaneous (SQ) with 70 mg/ml concentration|32 subjects (21 with BMI \<30mg\^2; 11 with BMI \>=30kg/m\^2 and \<40kg/m\^2) were administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 70 mg/ml concentration
62646767|NCT06374303|NO_INTERVENTION|Nutritional Education (NE) control condition|Nutritional Education (NE) participants received brief education, a list of FI-related resources in their community, and assistance with contacting those resources.
62078218|NCT04478227|EXPERIMENTAL|Arm B|"Arm B will include children with chemo and or radiotherapy induced thrombocytopenia/cytopenia and children undergoing stem cell transplantation (SCT).~Arm B: Starting dose 2 microgram/kg/dose per week with increments at 1 microgram/kg/dose (Maximum: 10 micrograms/kg/dose) depending on the laboratory response."
62078219|NCT00050089|ACTIVE_COMPARATOR|No ARDFP+Standard-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Standard-ART
62078220|NCT00050089|ACTIVE_COMPARATOR|No ARDFP+Mega-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Mega-ART
62078221|NCT00050089|ACTIVE_COMPARATOR|ARDFP+Standard-ART|Antiretroviral Drug-Free Period (ARDFP) and Standard-ART
62078222|NCT00050089|ACTIVE_COMPARATOR|ARDFP+Mega-ART|Antiretroviral Drug-Free Period (ARDFP) and Mega-ART
62078223|NCT05576805||Cohort 1: Resistant, Refractory, or Intolerant (RRI) to Anti-CMV Treatment|Participants who had an SOT after January 1, 2016 and must have developed post-transplant CMV infection and were subsequently characterized as RRI to currently available anti-CMV treatment at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.
62078224|NCT05576805||Cohort 2: Pre-emptive CMV Treatment|Participants who had an SOT after January 1, 2019, and who were preemptively treated for CMV at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.
62078225|NCT03749460|EXPERIMENTAL|Treatment (nivolumab, ipilimumab, SBRT)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.
62078226|NCT00164853|ACTIVE_COMPARATOR|Standard sphincterotomy (ES)|After deep cannulation, a pull-type sphincterotomy will be performed with a 25mm sphincterotome (eg clever cut, Olympus, Tokyo, Japan) with division of sphincter up to the duodenal wall. A complete sphincterotomy is defined by the free passage of a fully bowed sphincterotome with a 25m wire and spontaneous bile drainage.
62457194|NCT04946877||control group|100 normal children; they will be selected from neurology clinic complaining from minor neurological complaint e.g : headache, will match with the case group for age, sex and educational level.
62457195|NCT02607319|EXPERIMENTAL|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
62457196|NCT02607319|NO_INTERVENTION|No intervention group|Control group receiving standard care.
62457197|NCT05616247|EXPERIMENTAL|ECALC|Cognitive Behavioral Program to Change Expectancy Processes
62457198|NCT05616247|EXPERIMENTAL|ECALC Plus Weekly Boosters|Cognitive Behavioral Program to Change Expectancy Processes with Weekly Booster Content Delivered by Mobile Device
62078227|NCT00164853|ACTIVE_COMPARATOR|Sphincterotomy plus balloon dilation (ESBD)|After complete sphincterotomy, a 3-cm long 15mm diameter CRE balloon is passed over a guidewire across the lower end of common bile duct. The contrast filled balloon is inflated to the size of the bile duct for around 30 seconds until waisting is abolished.
62078228|NCT01800149|ACTIVE_COMPARATOR|BBM+collagen|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with BioOss Collagen and covered with Bio-Gide
62078229|NCT01800149|ACTIVE_COMPARATOR|BBM granules|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with Bio-Oss Granules, 0-25-1 mm, and covered with Bio-Gide
62078230|NCT04642469|EXPERIMENTAL|Durvalumab|Intravenous administration of Durvalumab
62078231|NCT04642469|PLACEBO_COMPARATOR|Placebo|Intravenous administration of placebo
62078232|NCT02480686|EXPERIMENTAL|SOF+PEG+RBV|Participants with HCV genotype 1b infection will receive Sofosbuvir (SOF) 400 mg +PEG+RBV for 12 weeks.
62078233|NCT05640076||2018-19 - Oncologic patients under home palliative care|Oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2018 and 31/12/2019
62457199|NCT05616247|NO_INTERVENTION|Control|Control Group Presentation on Body Image
62646768|NCT06374303|EXPERIMENTAL|Nutritional Eduction + Meal Delivery (NE+MD) experimental condition|NE + Meal Delivery (NE+MD) participants received the same educational platform plus weekly meal deliveries using a commercial service that delivers premade, refrigerated meals directly to the participant's home.
62646769|NCT05767983|EXPERIMENTAL|Fat-free milk|Treatment
62646770|NCT05767983|EXPERIMENTAL|Fat-free yogurt|Treatment
62457200|NCT03080090|EXPERIMENTAL|High Intensity Exercise|Individuals in this condition will engage in aerobic exercise 3 times a week for 25 minutes each at 60% to 85% of age-predicted HRmax and smoking cessation intervention through a national quitline while using nicotine replacement patches.
62457201|NCT03080090|ACTIVE_COMPARATOR|Low Intensity Exercise|The intervention procedures for this group are identical to the Experimental Group group except that the target training intensity will be low intensity exercise, self-selected at 20% to 40% of age-predicted HRmax.
62457202|NCT04856449|EXPERIMENTAL|DBT Skills Training|This intervention will consist of a 6-month-group DBT-skills training continuation, in which participants will be trained in mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.
62457203|NCT04856449|ACTIVE_COMPARATOR|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR will consist of individual therapy sessions that will be focused on processing traumatic memories. Participants will receive up to 16 individual EMDR sessions, of 60 min each.
62646771|NCT05767983|EXPERIMENTAL|Low-fat cheese|Treatment
62646772|NCT05767983|EXPERIMENTAL|Fruit juice|Treatment
62646773|NCT05767983|EXPERIMENTAL|Snack skipping|Treatment
62078234|NCT05640076||2018-19 - Non-oncologic patients under home palliative care|Non-oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2018 and 31/12/2019
62078235|NCT05640076||2021-2022 - Oncologic patients under home palliative care|Oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2021 and 31/12/2022
62646774|NCT01109407||patients with MGUS or SMM|patients with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM)
62078236|NCT05640076||2021-2022 - Non-Oncologic patients under home palliative care|Non-oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2021 and 31/12/2022
62078237|NCT02036190||Control group|Former or current smokers without emphysema
62078238|NCT02036190||Emphysema|Current or former smokers with emphysema
62078239|NCT03800966|EXPERIMENTAL|Intervention|The intervention leaflets will contain information on the TI's tactics to get young people to smoke.
62646775|NCT04072861|EXPERIMENTAL|Cohort 1|9 mg RBT-9, single dose
62646776|NCT04072861|EXPERIMENTAL|Cohort 2, Healthy Volunteers|27 mg RBT-9, single dose
62078240|NCT03800966|PLACEBO_COMPARATOR|Control|The control leaflets will contain information on the tobacco control in Hong Kong.
62078241|NCT04157686|EXPERIMENTAL|Placebo/MT10109L Dose 1|The participant pool in this arm are from the MT10109L-001 lead-in study (NCT03795922), who received Placebo in period 1 and MT10109L Dose 1 in period 2. Eligible participants from this study continue receiving Dose 1 in the open-label MT10109L-004 study
62078242|NCT04157686|EXPERIMENTAL|Placebo/MT10109L Dose 2|The participant pool in this arm are from the MT10109L-002 lead-in study (NCT03785145), who received Placebo in period 1 and MT10109L Dose 2 in period 2. Eligible participants from this study continue receiving Dose 2 in the open-label MT10109L-004 study.
62078243|NCT04157686|EXPERIMENTAL|Placebo/MT10109L Dose 1 + Dose 2|The participant pool in this arm are from the MT10109L-005 (NCT03721016) and MT10109L-006 (NCT03732833) lead-in studies, who received Placebo in periods 1 \& 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
62078244|NCT04157686|EXPERIMENTAL|MT10109L Dose 1/Dose 1|The participant pool in this arm are from the MT10109L-001 lead-in study (NCT03795922), who received MT10109L Dose 1 each in period 1 and period 2. Eligible participants from this study continue receiving Dose 1 in the open-label MT10109L-004 study.
62078245|NCT04157686|EXPERIMENTAL|MT10109L Dose 2/Dose 2|The participant pool in this arm are from the MT10109L-002 lead-in study (NCT03785145), who received MT10109L Dose 2 each in period 1 and period 2. Eligible participants from this study continue receiving Dose 2 in the open-label MT10109L-004 study.
62078246|NCT04157686|EXPERIMENTAL|MT10109L Dose 1/Dose 1+2|The participant pool in this arm are from the from MT10109L-005 lead-in study (NCT03721016), who received MT10109L Dose 1 in periods 1 and 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
62646777|NCT04072861|EXPERIMENTAL|Cohort 3, Healthy Volunteers|90 mg RBT-9, single dose
62646778|NCT04072861|EXPERIMENTAL|Cohort 4, Subjects with CKD Stage 3|27 mg RBT-9, single dose
62646779|NCT04072861|EXPERIMENTAL|Cohort 5, Subjects with CKD Stage 3|90 mg RBT-9, single dose
62646780|NCT04072861|EXPERIMENTAL|Cohort 6, Subjects with CKD Stage 4|27 mg RBT-9, single dose
62646781|NCT04072861|EXPERIMENTAL|Cohort 7, Subjects with CKD Stage 4|90 mg RBT-9, single dose
62646782|NCT00000575|ACTIVE_COMPARATOR|1 Budesonide|Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
62646783|NCT00000575|ACTIVE_COMPARATOR|2 Nedocromil|Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
62646784|NCT00000575|PLACEBO_COMPARATOR|3 Placebo|Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.
62646785|NCT05029661||No intervention|No intervention
62646786|NCT03222908|NO_INTERVENTION|Control: Prescriptive Advice|Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
62646787|NCT03222908|EXPERIMENTAL|Intervention1: Contract Agreement|Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
62646788|NCT03222908|EXPERIMENTAL|Intervention2: Implementation Intentions|Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.
62646789|NCT01092013|ACTIVE_COMPARATOR|Operating room training|
62646790|NCT01092013|ACTIVE_COMPARATOR|Skills lab training|
62646791|NCT01851993|EXPERIMENTAL|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
62646792|NCT01851993|PLACEBO_COMPARATOR|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
62646793|NCT01430377|EXPERIMENTAL|SB predilatation|
62078247|NCT04157686|EXPERIMENTAL|MT10109L Dose 2/Dose 1+2|The participant pool in this arm are from the MT10109L-006 lead-in study (NCT03732833), who received MT10109L Dose 2 in periods 1 and 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
62078248|NCT04157686|EXPERIMENTAL|MT10109L Dose 1+2/Dose 1+2|The participant pool in this arm are from the MT10109L-005 (NCT03721016) and MT10109L-006 (NCT03732833) lead-in studies, who received MT10109L Dose 1 into GL and Dose 2 into LCL in periods 1 \& 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
62078249|NCT02324023|EXPERIMENTAL|Endoscopic ultrasound and pathology|Endoscopic ultrasound and contrast enhanced endoscopic ultrasound for staging and perfusion (preoperatively) compared to pathological stage and vessel density in the pathological specimen (postoperatively).
62078250|NCT05733806||Gynecologic rare tumors|The study will include patients with rare gynecologic malignancies
62078251|NCT01216982|ACTIVE_COMPARATOR|Lovaza, omega-3 fatty acid ethyl ester|
62078252|NCT01216982|PLACEBO_COMPARATOR|Placebo|one gram corn oil in a soft gelatin capsule
62078253|NCT01576055|EXPERIMENTAL|TIGRIS Vascular Stent|GORE TIGRIS Vascular Stent
62078254|NCT01576055|ACTIVE_COMPARATOR|BARD LifeStent|BARD LifeStent
62078255|NCT00641849|ACTIVE_COMPARATOR|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
62078256|NCT00641849|ACTIVE_COMPARATOR|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
62078257|NCT02300389|EXPERIMENTAL|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
62078258|NCT02300389|ACTIVE_COMPARATOR|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
62078259|NCT03449537|EXPERIMENTAL|EHCF+LGG|extensively hydrolyzed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG
62646794|NCT04352673||Healthy individuals|Healthy students 18 years and older
62078260|NCT03449537|ACTIVE_COMPARATOR|AAF|hypoallergenic formula based on amino acid-based formula
62078261|NCT05611970|EXPERIMENTAL|Intervention|Each study participant serves as her own control.
62078262|NCT05501769|EXPERIMENTAL|ARV-471 and Everolimus|ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
62078263|NCT06458829|EXPERIMENTAL|Intervention group|The intervention group will receive SEARCH-AF intervention which includes opportunistic screening and screening promoting strategies.
62078264|NCT06458829|ACTIVE_COMPARATOR|Control group|All the control groups will finally receive the SEARCH-AF intervention.
62078265|NCT00517426|EXPERIMENTAL|Active Acetazolamide|
62078266|NCT01448525|ACTIVE_COMPARATOR|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
62078267|NCT01448525|PLACEBO_COMPARATOR|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
62646795|NCT03710512||hydroset|patients receiving hydroset at osteotomy site
62646796|NCT03710512||Control|patients not receiving hydroset at osteotomy site
62646797|NCT04294277|EXPERIMENTAL|Treatment arm|Treatment with Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule until 12 months.
62646798|NCT04753866|EXPERIMENTAL|Rehabilitated|Initial lip support condition of the patient when presents himself/herself at the office with indication for full arch implant rehabilitation. Then, the patient is facially scanned before and after the implant surgery.
62646799|NCT00972270|EXPERIMENTAL|IMPELLA LP 2.5|
62646800|NCT00972270|ACTIVE_COMPARATOR|Intra-Aortic Balloon Pump|
62646801|NCT05267665|EXPERIMENTAL|BFI|Family members in this arm receive the 2-session BFI intervention.
62646802|NCT05267665|NO_INTERVENTION|No BFI|Family members in this arm do not receive the BFI sessions
62646803|NCT00153426|EXPERIMENTAL|lifestyle counseling|Women assigned to lifestyle change intervention arm for nutrition and physical activity with print-based tailored health communications and a computer-based interactive nutrition program targeting health behaviors of diet and physical activity. Women in a control group did not receive the intervention.
62646804|NCT05143424|ACTIVE_COMPARATOR|CBD (350 mg)|CBD 350 mg twice per day for 3 days
62646805|NCT05143424|ACTIVE_COMPARATOR|CBD (700 mg)|CBD 700 mg twice per day for 3 days
62646806|NCT02970084|EXPERIMENTAL|Group with K2|"The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months.~All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)"
62646807|NCT02970084|NO_INTERVENTION|Control group (no vitamin K2)|The control group did not take the supplement of Vitamin K2. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
62078268|NCT05386186|EXPERIMENTAL|Glimepiride|All participants have background therapy of metformin 1500mg-2000mg, glimepiride1-4mg were added in the patients randomised to this arm considering the baseline HbA1c of the participants.
62078269|NCT05386186|ACTIVE_COMPARATOR|Sitagliptin|All participants have background therapy of metformin 1500mg-2000mg, Sitagliptin 100mg were added in the patients randomised to this arm regardless of the baseline HbA1c level in this arm.
62457204|NCT05702567|EXPERIMENTAL|RF + PFMT|The participants recieve 18 sessions of radiofrequency (RF) and pelvic floor muscle training (PFMT), divided into three sessions per week for a total of six weeks, with a net treatment time of 40 minutes, each one.
62078270|NCT02693912||acute lung injury|Patients with a diagnosis of acute lung injury (ALI) under mechanical ventilation.Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
62646808|NCT02064036|EXPERIMENTAL|Single|Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
62078271|NCT02693912||control|Patient under mechanical ventilation without any lung diseases. Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
62457205|NCT05702567|PLACEBO_COMPARATOR|PFMT|The participants recieve 18 sessions of no radiofrequency (RF) and pelvic floor muscle training (PFMT), divided into three sessions per week for a total of six weeks, with a net treatment time of 40 minutes, each one. The RF device is started, but in this case, the program does not work or apply radiofrequency to the patients.
62646809|NCT01652690||Denosumab|Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
62646810|NCT00427908|EXPERIMENTAL|Group A|All subjects received GSK Biolgicals' meningococcal vaccine 134612.
62646811|NCT00427908|ACTIVE_COMPARATOR|Group B|Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.
62078272|NCT03059693|EXPERIMENTAL|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
62457206|NCT04211818|EXPERIMENTAL|Patients|
62457207|NCT05167357|EXPERIMENTAL|COVID+ group|As the performance of the Richalet test is done by both arms, the intervention rather is the having undergone COVID19.
62646812|NCT06249581|EXPERIMENTAL|Arm A: fasting|AUX-001 40mg QD
62646813|NCT06249581|EXPERIMENTAL|Arm B: fed|AUX-001 40mg QD
62646814|NCT06107452|EXPERIMENTAL|Experimental group|Patient with acute coronary syndrome will be included. According to their initial strength-speed profile, coronary patients will benefit from an individualized cardiac rehabilitation program, with strength or speed training adapted to the autonomic nervous system (ANS).
62646815|NCT06107452|ACTIVE_COMPARATOR|Control group|Patient with acute coronary syndrome will be included. According to their initial force-velocity profile, coronary patients will have an individualized cardiac rehabilitation program, either with a training in force or in velocity.
62646816|NCT02461212|EXPERIMENTAL|Liver MRI|Liver MRI imaging will be performed on subjects undergoing a liver biopsy
62457208|NCT05167357|NO_INTERVENTION|Control group / COVID- group|Performance of the Richalet test is done by both arms, the control in this study here is the having stayed clear of COVID19.
62646817|NCT02461212|EXPERIMENTAL|Liver MRI repositioned|Liver MRI imaging will be performed on subjects undergoing a liver biopsy and then they will be repositioned and will repeat the MRI
62646818|NCT02073786|ACTIVE_COMPARATOR|Lightwand|Conventional lightwand intubation will performe for intubation
62280065|NCT04752995|OTHER|high tibial osteotomy|Under general anesthesia, a one-cm vertical skin incision was done at the medial subcutaneous border of the tibia, one fingerbreadth below the tibial tuberosity. This was confirmed by intra-operative C-arm images. Longitudinal periosteal incision was done with minimal dissection. Incomplete medial transverse osteotomy including both anterior and posterior cortex was performed using drill bit or small thin osteotome.Osteotomy was completed manually by osteoclasis of the lateral cortex to provide postoperative stability by the preserved lateral periosteum. No fibular osteotomy was needed in the present study.
62280066|NCT05381129|OTHER|Chronic migraine|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3).
62457209|NCT02502253|EXPERIMENTAL|Low dose|
62457210|NCT02502253|EXPERIMENTAL|moderate dose|
62457211|NCT02502253|EXPERIMENTAL|High dose|
62646819|NCT02073786|EXPERIMENTAL|Optiscope|Rigid video stylet, manufactural named Optiscope, will perform for intubation
62646820|NCT02431013|EXPERIMENTAL|Simvastatin+Cilostazol|Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.
62078273|NCT03059693|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
62457212|NCT02519322|EXPERIMENTAL|Arm A (nivolumab, surgery)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
62646821|NCT02431013|ACTIVE_COMPARATOR|Pravastatin+Cilostazol|Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.
62646822|NCT05637502|EXPERIMENTAL|Graded Motor Imagery|Participants receiving a tailored Graded Motor Imagery program for pelvic pain.
62078274|NCT03428282|EXPERIMENTAL|VR Box|Inferior alveolar nerve block will be performed with the aid of VR box as a means of distracting patients' attention.
62078275|NCT03428282|EXPERIMENTAL|Tablet device|Inferior alveolar nerve block will be performed with the aid of a tablet device as a means of distracting patients' attention.
62646823|NCT05637502|NO_INTERVENTION|Control|Participants initially receiving no intervention at all.
62646824|NCT00038766|EXPERIMENTAL|Semapimod 60 mg|Semapimod 60 mg IV x 5 days
62646825|NCT00038766|EXPERIMENTAL|Semapimod IV 30 mg|Semapimod IV 30 mg x 5 days
62078276|NCT03428282|ACTIVE_COMPARATOR|Anesthesia|Inferior alveolar nerve block will be performed in the normal manner without any specific intervention to distract patients' attention. Classic anesthesia will be applied.
62078277|NCT04876560|ACTIVE_COMPARATOR|CDSS (intervention) group|Personalised nutritional advice: daily dietary programme with specific meals, products, recipes, food portions (in grams) based on the Meditteranean diet together with physical activity guidelines, all generated by a food database clinical decision support system (CDSS). Scheduled phone interviews every 15 days with the appointed dieticians assisted nutritional and lifestyle consultation.
62078278|NCT04876560|OTHER|Control group|"General lifestyle advice: based on the updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention via scheduled phone interviews every 15 days."
62078279|NCT02329600|NO_INTERVENTION|control subjects|10 systemically healthy control subjects taking no medication.
62078280|NCT02329600|ACTIVE_COMPARATOR|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
62078281|NCT02329600|EXPERIMENTAL|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
62646826|NCT00038766|PLACEBO_COMPARATOR|Placebo|Placebo IV x 3 or 5 days
62078282|NCT05377840|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Participants in this arm will participate in CBT to assess the impact it will have on anxiety or depression among patients with Crohn's disease
62078283|NCT05377840|EXPERIMENTAL|Sudarshan Kriya Yoga|Participants in this arm will participate in SKY to assess the impact it will have on anxiety or depression among patients with Crohn's disease
62078284|NCT02112058|EXPERIMENTAL|Program|A series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program. Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula. The third component was family support services.
62078285|NCT02112058|NO_INTERVENTION|Control|Business as usual
62078286|NCT04045639||Intervention arm|The AF risk prediction algorithm will be run on patient records within the Egton Medical Information Systems (EMIS) data base, in order to identify patients at risk of developing AF
62078287|NCT04045639||Control arm|Patients may be diagnosed with AF through routine clinical practice only
62646827|NCT06069804|EXPERIMENTAL|The TR group|The respective drugs to be used for incision-site infiltration were prepared by an independent study investigator in the two groups: Participates will receive peri-incisional scalp infiltration with10 mg triamcinolone acetonide, 150 mg ropivacaine diluted to a total volume of 30 mL in 0.9% saline . The concentration of ropivacaine was 0.5% in both groups. The anesthesia protocol and monitoring were standardized for all patients. Monitoring, including blood pressure (BP), heart rate (HR), 5-lead electrocardiography (ECG), peripheral oxygen saturation (SpO2) and bispectral index (BIS) were continuously performed.
62078288|NCT01562847||Nilotinib|
62078289|NCT04305899|EXPERIMENTAL|Treatment Group 1|
62078290|NCT04305899|EXPERIMENTAL|Treatment Group 2|
62078291|NCT04305899|EXPERIMENTAL|Treatment Group 3|
62078292|NCT04305899|EXPERIMENTAL|Treatment Group 4|
62078293|NCT04305899|EXPERIMENTAL|Treatment Group 5|
62078294|NCT04305899|EXPERIMENTAL|Treatment Group 6|
62078295|NCT04305899|EXPERIMENTAL|Treatment Group 7|
62078296|NCT04305899|EXPERIMENTAL|Treatment Group 8|
62078297|NCT04305899|EXPERIMENTAL|Treatment Group 9|
62078298|NCT04305899|EXPERIMENTAL|Treatment Group 10|
62078299|NCT04273503|EXPERIMENTAL|Intervention|All participants will receive education on maintaining a healthy diet and improving physical activity.
62078300|NCT04825860|EXPERIMENTAL|SEP-363856 50 mg/day|Subjects randomized to the SEP-363856 50 mg/day group will receive the assigned dose of SEP-363856 50 mg/day throughout the double-blind phase.
62078301|NCT04825860|EXPERIMENTAL|SEP-363856 75 mg/day|Subjects randomized to the SEP-363856 75 mg/day group will receive SEP-363856 50 mg/day on Day 1 through Day 3 and then the assigned dose of SEP-363856 75 mg/day thereafter.
62078302|NCT04825860|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo group will receive placebo throughout the double-blind phase.
62078303|NCT03897101||MILD NE|"gestational age \> 35 weeks and weight \> 1800 gr~* Apgar score \< 5 at 10 minutes o need for cardiopulmonary resuscitation at 10 minutes or evidence of base excess \> 12 mmol/L or pH \< 7,0 at initial blood gas analyses~* evidence of mild encephalopathy graded according to Sarnat\&Sarnat neurological evaluation~* normal amplitude integrated electroencephalography~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
62078304|NCT03897101||ISOLATED METABOLIC ACIDOSIS|"gestational age \> 35 weeks and weight \> 1800 gr~* evidence of base excess \> 12 mmol/L or pH \< 7,0 at initial blood gas analyses~* Normal Sarnat\&Sarnat neurological evaluation~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
62078305|NCT03897101||HEALTY CONTROLS|"gestational age \> 35 weeks and weight \> 1800 gr Normal blood pH or base excess~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokiness will be evaluated"
62078306|NCT06204328|ACTIVE_COMPARATOR|Benson relaxation technique and mHealth psychoeducation|Intervention Group will receive 6 months mHealth psychoeducation \& Benson Relaxation Technique
62078307|NCT06204328|NO_INTERVENTION|Usual care|The usual care group will follow established and common practices by healthcare providers in these settings.
62078308|NCT03603015|OTHER|Pilot group: urodynamics and cuff test|Single-arm study with all participants undergoing cystometrogram, then cystometrogram with simultaneous penile cuff test, then penile cuff test alone
62078309|NCT05140213||Group 1 : Before|"Before phase including 186 patients patients included before the implementation of the prescription support tool"
62078310|NCT05140213||Group 2 : After|"After phase including 185 patients patients included after the implementation of the prescription support tool"
62078311|NCT05706987|EXPERIMENTAL|lidocaine infusion|intravenous lidocaine infusion 1.5mg/kg/hr (ideal body weight) during labiaplasty
62078312|NCT05706987|PLACEBO_COMPARATOR|normal saline infusion|equal volume of normal saline infusion during labiaplasty
62646828|NCT06069804|ACTIVE_COMPARATOR|The R group|The respective drugs to be used for incision-site infiltration were prepared by an independent study investigator in the two groups: Participates will receive peri-incisional scalp infiltration with 150 mg ropivacaine diluted to a total volume of 30 mL in 0.9% saline in the control group. The concentration of ropivacaine was 0.5% in both groups. The anesthesia protocol and monitoring were standardized for all patients. Monitoring, including blood pressure (BP), heart rate (HR), 5-lead electrocardiography (ECG), peripheral oxygen saturation (SpO2) and bispectral index (BIS) were continuously performed.
62646829|NCT05552196|EXPERIMENTAL|Treatment A: Ponesimod|Participants will receive up-titrated Ponesimod orally once daily from Day 1 to Day 15.
62646830|NCT05552196|EXPERIMENTAL|Treatment B: Ponesimod + Carbamazepine|Participants will receive up-titrated Carbamazepine from Day 1 to Day 7 and from Day 23 to Day 26. Participants will also receive up-titrated Ponesimod and Carbamazepine from Day 8 to Day 22.
62646831|NCT03456245||Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
62078313|NCT01816763|EXPERIMENTAL|tablet based NRS pain one week, followed by nurse pain screen|tablet-based patient self-report of the 'NRS pain one week'
62078314|NCT01816763|EXPERIMENTAL|tablet based PEG, followed by nurse pain screen|tablet-based enhanced pain screening with the PEG (pain intensity, emotional, and functional pain interference)
62078315|NCT01816763|EXPERIMENTAL|DVPRS, followed by nurse pain screen|Defense Veterans Pain Rating Scale on tablet followed by usual nursing staff documented pain screening with NRS pain now
62078316|NCT02593539|EXPERIMENTAL|Participants recieving nemiralisib|
62078317|NCT05165875|OTHER|Randomized: Steroid injection|1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.
62078318|NCT05165875|OTHER|Randomized: Splint|a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks
62078319|NCT05856240|EXPERIMENTAL|Group-Based Psychological Intervention|Single-arm feasibility trial, so all participants will receive the intervention.
62078320|NCT00881010||Telephone Intervention|
62078321|NCT00881010||Usual Care|
62646832|NCT04809116|EXPERIMENTAL|open-label pimavanserin 34mg at bedtime for 6 weeks|Subjects enrolled into treatment with open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
62646833|NCT04695288||Fibromyalgia Syndrome|100 participants with a diagnosis of Fibromyalgia Syndrome according to the 2016 revised American College of Rheumatology diagnostic criteria.
62646834|NCT04695288||Control subjects|60 healthy participants do not meet the exclusion criteria of the study.
62646835|NCT01774981|PLACEBO_COMPARATOR|Placebo (Part A)|Part A: Placebo administered by 60 minute Intravenous (IV) infusion at Week 1 and Week 4.
62646836|NCT01774981|EXPERIMENTAL|10 mg LY3016859 (Part A)|Part A: 10 milligram (mg) LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
62646837|NCT01774981|EXPERIMENTAL|100 mg LY3016859 (Part A)|Part A: 100 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
62078322|NCT04375696|EXPERIMENTAL|Product|75 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in \> 75 kg
62078323|NCT04375696|PLACEBO_COMPARATOR|Placebo|75 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in \> 75 kg
62078324|NCT04441424|EXPERIMENTAL|Convalescent plasma group|21 critically-ill COVID-19 patients were given convalescent plasma: 400 ml of convalescent plasma from COVID-19 recovered subjects. The plasma infusion lasts for one hour.
62646838|NCT01774981|EXPERIMENTAL|750 mg LY3016859 (Part A)|Part A: 750 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
62646839|NCT01774981|PLACEBO_COMPARATOR|Placebo (Part B)|Part B: Placebo administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
62646840|NCT01774981|EXPERIMENTAL|50 mg LY3016859 (Part B)|Part B: 50 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
62078325|NCT04441424|OTHER|Control group|"This group is 28 critically-ill COVID-19 patients who are at the same disease stage to those of experimental group that were treated with conventional therapy without taking convalescent plasma.~The conventional therapy: 400 mg once PO Hydroxychloroquine/day with 250mg once PO Azithromycin."
62646841|NCT01774981|EXPERIMENTAL|250 mg LY3016859 (Part B)|Part B: 250 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
62078326|NCT00864838|NO_INTERVENTION|1|Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
62078327|NCT00864838|EXPERIMENTAL|2|Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
62078328|NCT00864838|EXPERIMENTAL|3|topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
62078329|NCT00864838|EXPERIMENTAL|4|anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
62646842|NCT01774981|EXPERIMENTAL|750 mg LY3016859 (Part B)|Part B: 750 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
62646843|NCT03575260||Fulvestrant|Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter
62646844|NCT03575260||Exemestane|Exemestane 25mg per day
62646845|NCT03236597|NO_INTERVENTION|Usual Desk|participants will work at their usual desk for four weeks.
62646846|NCT03236597|EXPERIMENTAL|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of 30 minutes per day for four weeks (Participants will sign up for a total of 30 minutes each day). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to up to 10 people over the four week period).
62646847|NCT06001879|EXPERIMENTAL|SBLST Group|Treatment (B): Simulation in basic life support training The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020, a simplified two-part; PowerPoint presentation and clinical simulation training.
62078330|NCT02411591|EXPERIMENTAL|Necitumumab + Abemaciclib|"Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.~Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met."
62078331|NCT02622633|EXPERIMENTAL|Stimulation|One week after implantation of the device, participants randomized in this arm will receive continuous magnetic stimulation of high frequency (50Hz) with epidural electrode for 12 weeks. And then, the epidural electrode will be turned off for more 12 weeks in a crossover fashion.
62078332|NCT02622633|SHAM_COMPARATOR|Sham Stimulation|One week after implantation of the device, participants randomized in this arm will receive sham stimulation for 12 weeks and then continuous magnetic stimulation with epidural electrode of high frequency (50Hz) stimulation for more 12 weeks.
62078333|NCT00734513|EXPERIMENTAL|1|Partner-assisted Emotional Disclosure
62078334|NCT00734513|ACTIVE_COMPARATOR|2|Cancer Education
62078335|NCT05601492|ACTIVE_COMPARATOR|Arm 1 - Standard of Care|Participant will be given the medication with an electronic monitoring cap attached and a return appointment for a standard of care regular visit
62280067|NCT05381129|OTHER|Temporomandibular dysfunction|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3), and patients with temporomandibular dysfunction.
62457213|NCT02519322|EXPERIMENTAL|Arm B (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV over 1 hour and ipilimumab IV over 90 minutes on days 1, 22, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
62646848|NCT06001879|ACTIVE_COMPARATOR|Standard Group|The investigator will give the participants in the control group; the standard treatment by using an AHA-BLS 2020 brochure. The participants will read and understand this brochure over 30 minutes, including a brief guideline about basic life support guidelines, and after these 30 minutes, the participants will move to the post-test.
62646849|NCT02834975|EXPERIMENTAL|Pembrolizumab, Paclitaxel + Carboplatin|"The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:~* Pembrolizumab 200mg intravenously (IV);~* Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);~* Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);~* Carboplatin IV area under the curve (AUC) of 6."
62646850|NCT00496418|EXPERIMENTAL|Prophylactic stoma mesh|Mesh
62646851|NCT00496418|ACTIVE_COMPARATOR|No mesh prophylaxis|No mesh
62646852|NCT04265677|EXPERIMENTAL|Telemedicine FCR|These patients will be eligible to use telemedicine for Family Centered Rounds
62646853|NCT04265677|PLACEBO_COMPARATOR|Control|These patients will not be eligible to use telemedicine for Family Centered Rounds (standard of care)
62646854|NCT01518101|EXPERIMENTAL|Vildagliptin/Metformin followed by Liraglutide+Metformin|In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
62646855|NCT01518101|EXPERIMENTAL|Liraglutide + Metformin followed by Vildagliptin/Metformin|In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
62280068|NCT04075929|OTHER|4x8 min|4x8-min intervals with 2-min recovery periods. The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x8-min = 32 min
62078336|NCT05601492|EXPERIMENTAL|Arm 2 - Reminder text|Participant will be given the medication with an electronic monitoring cap attached and receive weekly electronic text/email-based reporting intervention that is designed to promote better adherence to treatment (to help assure that the study have subjects who have excellent adherence. Having patients report their progress on a regular basis promotes better treatment adherence, perhaps by creating the same sense of accountability promoted by regular office visits
62078337|NCT05601492|EXPERIMENTAL|Arm 3 - Initial patient consult|Participant will be given the medication with an electronic monitoring cap attached and will receive an initial patient consultation intervention, which will focus on the prescribed medication education and setting expectations of what to anticipate with usage of the medication
62078338|NCT04410679|EXPERIMENTAL|injectabl PRF for treatment of internal root resorption|
62078339|NCT01349660|EXPERIMENTAL|BKM120/Bevacizumab|"Phase I:~BKM 120 orally (PO) once daily (dose is 60mg or 80mg). Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks~Phase II:~BKM 120 orally (PO) once daily - dose is optimal dose determined in Phase I. Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks"
62078340|NCT02531295|EXPERIMENTAL|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
62078341|NCT02531295|EXPERIMENTAL|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
62078342|NCT02531295|EXPERIMENTAL|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
62078343|NCT04594551|EXPERIMENTAL|Group 1: VRVg-2 + HRIG|"VRVg-2 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21~+ HRIG at D0"
62457214|NCT02519322|EXPERIMENTAL|Arm C (nivolumab, relatlimab, surgery)|Patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour on days 1 and 29. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour every 4 weeks for 10 doses in the absence of disease progression or unacceptable toxicity.
62457215|NCT01166542|ACTIVE_COMPARATOR|REOLYSIN, paclitaxel, carboplatin|
62457216|NCT01166542|PLACEBO_COMPARATOR|placebo, paclitaxel, carboplatin|
62646856|NCT00447083|EXPERIMENTAL|UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with UV. The dose of UV (time of exposure) will be progressively increased from 3 minutes to 9 minutes over the 6 visits to acclimate subjects to UV light. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive UVB tanning bed treatment first, then switch to the non-UVB treatment.
62646857|NCT00447083|PLACEBO_COMPARATOR|Non-UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with non-UV bulbs. The time of exposure will be progressively increased from 3 minutes to 9 minutes over the 6 visits to mirror UVB treatment. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive non-UVB tanning bed treatment first, then switch to the UVB treatment.
62078344|NCT04594551|ACTIVE_COMPARATOR|Group 2: Verorab + HRIG|"Verorab 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21~+ HRIG at D0"
62078345|NCT01121718|EXPERIMENTAL|ICG Intervention|Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)
62078346|NCT04893070||COVID+|Questionnaires on COVID-19 symptomatology and quality of life
62078347|NCT04893070||COVID-|Questionnaires on quality of life
62457217|NCT05539820|EXPERIMENTAL|Reiki group|PIF-I and STAS were administered to the Reiki group through an online questionnaire. After the pretests of the students were completed, between 14-17 June 2022, the distant reiki application was made under the guidance of a researcher with a Usui Reiki Master \&Teacher degree and by the researchers with Reiki -II or Reiki-III degrees. The application was carried out for 20 minutes on four consecutive days. Before the final exams (19 June 2022), the posttests (PIF-II and STAS) were applied to the students through an online questionnaire.
62457218|NCT05539820|NO_INTERVENTION|Control Group|PIF-I and STAS were administered to the control group through an online questionnaire. Then before the final exams on 19 June 2022, the posttests (PIF-II and STAS) were applied to the students through an online questionnaire.
62457219|NCT01185496||CGM|Blinded/Unblinded CGM wear in adjunct with SMBG meter diabetes management
62078348|NCT02325713|EXPERIMENTAL|Sequence A-B-C1-D1|
62078349|NCT02325713|EXPERIMENTAL|Sequence A-B-C1-D2|
62078350|NCT02325713|EXPERIMENTAL|Sequence A-B-C2-D1|
62078351|NCT02325713|EXPERIMENTAL|Sequence A-B-C2-D2|
62078352|NCT02325713|EXPERIMENTAL|Sequence A-B-D1-C1|
62078353|NCT02325713|EXPERIMENTAL|Sequence A-B-D2-C1|
62078354|NCT02325713|EXPERIMENTAL|Sequence A-B-D1-C2|
62078355|NCT02325713|EXPERIMENTAL|Sequence A-B-D2-C2|
62078356|NCT02325713|EXPERIMENTAL|Sequence B-A-C1-D1|
62078357|NCT02325713|EXPERIMENTAL|Sequence B-A-C1-D2|
62078358|NCT02325713|EXPERIMENTAL|Sequence B-A-C2-D1|
62078359|NCT02325713|EXPERIMENTAL|Sequence B-A-C2-D2|
62078360|NCT02325713|EXPERIMENTAL|Sequence B-A-D1-C1|
62078361|NCT02325713|EXPERIMENTAL|Sequence B-A-D2-C1|
62078362|NCT02325713|EXPERIMENTAL|Sequence B-A-D1-C2|
62078363|NCT02325713|EXPERIMENTAL|Sequence B-A-D2-C2|
62078364|NCT05769270|EXPERIMENTAL|Peer Navigation and Coping Skills|Participants will receive peer navigation and coping skills to increase PrEP use.
62078365|NCT05769270|SHAM_COMPARATOR|Treatment as usual|Participants will receive referrals to PrEP and services.
62078366|NCT01628302|NO_INTERVENTION|Normal salt diet|The group had normal salt diet (250mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had low salt diet (50mmol) at the last 3 weeks of the study.
62078367|NCT01628302|EXPERIMENTAL|Low salt diet|The group had low salt diet (50mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had normal salt diet at the last 3 weeks of the study.
62457220|NCT00146523|EXPERIMENTAL|mifepristone 600 mg|
62457221|NCT00146523|PLACEBO_COMPARATOR|matching placebo|
62078368|NCT04972981|EXPERIMENTAL|Part 1: Dose Escalation|In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of ADCT-901 as monotherapy. Participants can receive ADCT-901 until disease progression, adverse event (AE), or other discontinuation criteria, whichever occurs first.
62078369|NCT04972981|EXPERIMENTAL|Part 2: Dose Expansion|"In Part 2 (dose expansion), participants will receive ADCT-901 monotherapy at the dose identified as the RP2D/MTD in Part 1 (dose escalation).~Participants will be split into two groups:~Group 1: An indication for which ADCT-901 showed in Part 1 to have preliminary activity.~Group 2: A group of participants with Part 1 indications, except for the one selected in Group 1 of Part 2. No more than 30% of participants with the same indication are allowed in this basket group.~Participants can receive ADCT-901 until disease progression, AE, or other discontinuation criteria, whichever occurs first."
62078370|NCT00247624|EXPERIMENTAL|A|Participants will receive treatment with eszopiclone and fluoxetine
62646858|NCT00447083|EXPERIMENTAL|UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of UVB.
62078371|NCT00247624|ACTIVE_COMPARATOR|B|Participants will receive treatment with placebo and fluoxetine
62078372|NCT04888637||All Subjects|MEG baseline session Receptive Language Task Memory Task
62078373|NCT03179800|EXPERIMENTAL|MobiusHD Implantation|MobiusHD Implantation
62078374|NCT03179800|SHAM_COMPARATOR|Sham Implantation|Sham Implantation
62078375|NCT04866914|EXPERIMENTAL|ACT for Insomnia|
62078376|NCT04866914|ACTIVE_COMPARATOR|CBT for Insomnia|
62078377|NCT04866914|NO_INTERVENTION|Wait List|
62078378|NCT00862953|ACTIVE_COMPARATOR|Normal protein normal carbohydrate|Normal protein normal carbohydrate calory restricted nutrition
62078379|NCT00862953|EXPERIMENTAL|Normal protein low carbohydrates|Normal protein low carbohydrate energy-restricted diet
62457222|NCT03527745|EXPERIMENTAL|200 mg albendazole|against T. trichiura in preschool-aged children or against hookworm infections in preschool-aged children, school-aged children and adults
62457223|NCT03527745|EXPERIMENTAL|400 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or against hookworm infections in preschool-aged children, school-aged children and adults
62457224|NCT03527745|EXPERIMENTAL|600 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
62457225|NCT03527745|EXPERIMENTAL|800 mg albendazole|against T. trichiura in school-aged children and adults or against hookworm infections in school-aged children and adults
62457226|NCT03527745|PLACEBO_COMPARATOR|Placebo|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
62646859|NCT00447083|PLACEBO_COMPARATOR|Non-UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of non-UVB exposure
62646860|NCT03710330|PLACEBO_COMPARATOR|normal saline|the patients receives 110 ml normal saline IV just before skin incision
62646861|NCT03710330|ACTIVE_COMPARATOR|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
62646862|NCT03710330|ACTIVE_COMPARATOR|0.5 gm tranexamic acid|0.5 gm tranexamic acid (1 ampoule of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
62646863|NCT00262119|ACTIVE_COMPARATOR|Control Group|PM programming according to actual clinical practice
62646864|NCT00262119|ACTIVE_COMPARATOR|MVP Only|PM programming according to actual clinical practice + MVP algorithm ON
62646865|NCT00262119|ACTIVE_COMPARATOR|DDDRP|PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
62646866|NCT01924533|EXPERIMENTAL|Olaparib+ paclitaxel|olaparib + paclitaxel
62646867|NCT01924533|PLACEBO_COMPARATOR|Placebo+paclitaxel|placebo+ paclitaxel
62078380|NCT00862953|EXPERIMENTAL|High protein normal carbohydrates|High protein normal carbohydrates
62078381|NCT00862953|EXPERIMENTAL|High protein low carbohydrate|High protein low carbohydrate nutrition
62078382|NCT01450280|EXPERIMENTAL|Group 1A|AdCh63 CS 5x10\^9 vp
62457227|NCT05739045|EXPERIMENTAL|nivolumab combined with SOX|Medication regimen: nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles); Surgery is performed 2 - 6 weeks after the last dose of neoadjuvant therapy, and postoperative adjuvant therapy is initiated at least 4 weeks after surgery.
62457228|NCT06257745||ERACS group|Any patient admitted to our post-anesthesia care unit following cardiac surgery and planned for overnight stay.
62457229|NCT04486196|EXPERIMENTAL|Control (No Laser) Group|The final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water.
62457230|NCT04486196|EXPERIMENTAL|Laser Disinfection (LD) Group|After final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water, root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle. This cycle was applied 4 times for each root canal. The optical fiber (Medency) was inserted 1 mm short of the apex and the root canals were slowly (at a speed of 2mm/s) irradiated from apical to coronal in continuous circling movements to treat all dentinal tubules in one cycle for each power.
62646868|NCT03241693|OTHER|control group|Physiotherapy students
62646869|NCT03241693|EXPERIMENTAL|experimental group|Physiotherapy students
62078383|NCT01450280|EXPERIMENTAL|Group 1B|ChAd63 CS 5x10\^9 vp Day 0; MVA CS 2x10\^8 pfu Day 56
62646870|NCT04999241|EXPERIMENTAL|EEN combined therapy group|in the induction of remission phase, EEN will be used combine with corticosteroids or infliximab
62646871|NCT04999241|ACTIVE_COMPARATOR|Non EEN combination group|in the induction of remission phase, corticosteroids or infliximab will be used without EEN
62646872|NCT05316558|EXPERIMENTAL|Body Confident Coaching|Participants in the intervention condition will take part in an online program consisting of five modules over two weeks.
62646873|NCT05316558|NO_INTERVENTION|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
62646874|NCT01436734|EXPERIMENTAL|GIP|
62646875|NCT06247150|OTHER|Patients with cGVHD|
62646876|NCT06247150|OTHER|Patients without cGVHD|
62646877|NCT03844841|ACTIVE_COMPARATOR|Propofol|Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous
62646878|NCT03844841|ACTIVE_COMPARATOR|Dexmedetomidine|Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous
62078384|NCT01450280|EXPERIMENTAL|Group 2A|AdCh63 CS 5 x 10\^10 vp
62078385|NCT01450280|EXPERIMENTAL|Group 2B|ChAd63 CS 5x10\^10 vp Day 0; MVA CS 2x10\^8 pfu Day 56
62078386|NCT03413358|EXPERIMENTAL|Treatment group|Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid.
62078387|NCT03413358|EXPERIMENTAL|Control group|Blank control and Platinum-based two medicine (carboplatin / cisplatin) .
62078388|NCT02892942|ACTIVE_COMPARATOR|Control Group|"Background therapy which is the usual COH treatment:~* Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~* GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®."
62280069|NCT04075929|OTHER|4x(8x40/20s)|4x(12x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group:4x(12x40/20-sec) = 32 min if the 20-sec recovery is not included in the total time of HIT
62646879|NCT05697913|EXPERIMENTAL|MRDI-driven treatment|Patients continue treatment until complete remission with negative MRD and Image is achieved, changing the therapeutic line if this is not achieved with the prescribed treatment. In this group of patients, treatment is suspended only when this degree of profound response is reached, in any phase of treatment.
62078389|NCT02892942|EXPERIMENTAL|NATOS Group|"Background therapy which is the usual COH treatment:~* Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~* GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®.~GnRH antagonist treatment (Cetrotide®, MerckSerono Pharmaceuticals) will be reinforced and patients will receive 1.5 mg/day (6 ampoules of 0.25 mg), S.C., starting on day 1 (S1) of Gonal-F® treatment until dhCG"
62646880|NCT05697913|NO_INTERVENTION|Conventional treatment|The patients of the conventional treatment group (control group) received six cycles of the induction traetment, bone marrow auto-transplantation, and consolidation treatment after transplantation if complete remission had not been achieved.
62646881|NCT03337126|ACTIVE_COMPARATOR|Fasting Condition|Single dose of ATI-1501(oral suspension) administered under fasting conditions; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
62078390|NCT01463917|ACTIVE_COMPARATOR|Hypertonic|Use of Hypertonic solution during left marginal branch CABG surgery.
62078391|NCT01463917|PLACEBO_COMPARATOR|Isotonic|Use of Isotonic solution during left marginal branch CABG surgery.
62646882|NCT03337126|ACTIVE_COMPARATOR|Fed Condition|Single dose of ATI-1501(oral suspension) administered under fed condition; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
62457231|NCT05676866|EXPERIMENTAL|Breast cancer patients with positive axillary nodes|Female with invasive breast cancer with axillary metastasis , who recieve neo adjuvant therapy with complete axillary response
62457232|NCT00368953|EXPERIMENTAL|1|
62646883|NCT04991714|EXPERIMENTAL|Sucrose|10% solution in water
62646884|NCT04991714|EXPERIMENTAL|Sucrose + Reb M|10% sucrose + 60 mg/L Rebaudioside M
62457233|NCT00368953|ACTIVE_COMPARATOR|2|
62457234|NCT02849652|EXPERIMENTAL|ATTOC|Addressing Tobacco Through Organizational Change is a multi-phase organizational intervention to promote the treatment of tobacco dependence
62457235|NCT02849652|OTHER|Usual Care|Usual Care is the typical guideline based smoking cessation intervention
62646885|NCT04991714|EXPERIMENTAL|Sucrose + Lactisole|10% sucrose + 30 mg/ L Lactisole
62646886|NCT04991714|EXPERIMENTAL|Sucrose + Reb M + Lactisole|10% sucrose + 60 mg/L Rebaudioside M + 30 mg/ L Lactisole
62646887|NCT01450488|EXPERIMENTAL|masitinib 3 mg/kg/day|
62646888|NCT01450488|EXPERIMENTAL|masitinib 6 mg/kg/day|
62646889|NCT01060462||001|Pts. w/ neutropenic fever associated w/ hematologic malignancy Itraconazole 200 mg twice daily for 2 days for a total of 4 doses then 200 mg once daily for 12 days. After 14 days of IV administration itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
62646890|NCT02266485|EXPERIMENTAL|BIBB 515 BS|
62646891|NCT02266485|ACTIVE_COMPARATOR|Pravastatin|
62078392|NCT03841981||I- Hypothalamic amenorrhea|10 women with exercise-associated hypothalamic amenorrhea
62078393|NCT03841981||II- Hyperandrogenic polycystic ovary syndrome|5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.
62078394|NCT03841981||III- Non-hyperandrogenic polycystic ovary syndrome|5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome
62078395|NCT03841981||IV- Trained women without ovulatory dysfunction|10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.
62078396|NCT03841981||V- Non-hyperandrogenic healthy women|10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis
62078397|NCT04228549|NO_INTERVENTION|Control|Usual care
62457236|NCT03765502|EXPERIMENTAL|Nasal Glucagon Device (NG)|Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
62646892|NCT02266485|PLACEBO_COMPARATOR|Placebo|
62646893|NCT04010279|ACTIVE_COMPARATOR|spontaneous breathing|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the spontaneous position.
62078398|NCT04228549|EXPERIMENTAL|MyPADMGT|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed.
62078399|NCT04228549|EXPERIMENTAL|MyPADMGT + Nudging|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed. In addition, nudging support available to help patients make better choices and decisions.
62646894|NCT04010279|ACTIVE_COMPARATOR|spontaneous breathing with APL 5 cmH2O|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the 5 cmH2O position.
62078400|NCT05581238||TRACK|External validation of TRACK prediction model with 5 variables: age, weight, sex, pre-op HCT, Type of surgery.
62078401|NCT05581238||TRACK-TCT|New model development with 6 variables. 5 From the TRACK model: age, weight, sex, pre-op HCT, Type of surgery. A sixth variable will be added i.e.: pre-operative P2Y12 drug use
62646895|NCT04010279|ACTIVE_COMPARATOR|CPAP 5cmH2O PEEP|volunteers will breath via an anesthesia face mask spontaneously on the CPAP mode of the anesthesia workstation with 5 cmH2O PEEP.
62646896|NCT05181150|EXPERIMENTAL|Meal test|
62646897|NCT05181150|EXPERIMENTAL|GIP, Glucose-dependent insulinotropic polypeptide|
62078402|NCT02471404|ACTIVE_COMPARATOR|Dapagliflozin+metformin|Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
62078403|NCT02471404|ACTIVE_COMPARATOR|Dapagliflozin+saxagliptin+metformin|Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
62078404|NCT02471404|ACTIVE_COMPARATOR|Glimepiride+metformin|Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
62078405|NCT02050022||Exacerbation|Patients experiencing acute exacerbation of COPD.
62078406|NCT02050022||Non-Exacerbation|COPD patients not experiencing acute exacerbation of COPD.
62078407|NCT04747275|OTHER|Liquid Stable Levothyroxine (l-T4) TirosintSOL first, then Oral Tablet Levothyroxine (L-T4)|Participants start on Liquid Tirosint®-SOL for 8 weeks using continued same daily dose of LT4. Dose adjustments are allowed as needed, based on laboratory results and clinical response. Then Participants will crossover to conventional therapy of LT4 tablets for 8 weeks. Participants total participation will be 16 weeks total.
62078408|NCT04747275|OTHER|Oral Tablet Levothyroxine (L-T4) first, then Liquid Stable Levothyroxine (L-T4) Tirosint-SOL|Participants continue conventional therapy of LT4 tablets for 8 weeks at current dose, after 8 weeks will crossover to receive Liquid Stable Levothyroxine (L-T4) Tirosint-SOL for 8 weeks. Participants total participation will be 16 weeks total.
62078409|NCT01163747|ACTIVE_COMPARATOR|Methotrexate|Participants continued to receive their standard dose of methotrexate up to Week 8. From Week 8 participants also received 8 mg/kg tocilizumab intravenously every 4 weeks until Week 20. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
62078410|NCT01163747|EXPERIMENTAL|Tocilizumab + Methotrexate|Participants received 8 mg/kg tocilizumab intravenously at Baseline (Day 1) and every 4 weeks up to Week 20, in addition to their standard dose of methotrexate. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
62078411|NCT02868437|ACTIVE_COMPARATOR|Group 1|The patients who are having curettage for retained product after second trimester abortion will also receive an intervention of intrauterine self-cross-linked hyaluronic acid gel after the procedure
62078412|NCT02868437|NO_INTERVENTION|Group 2|The patients who are having curettage for retained product after second trimester abortion will receive no intervention
62646898|NCT05181150|EXPERIMENTAL|GLP-2, Glucagon-like-peptide-2|
62078413|NCT05015673|EXPERIMENTAL|SEP-363856 25mg|SEP-363856 25 mg given orally
62078414|NCT05015673|EXPERIMENTAL|SEP-363856 50mg|SEP-363856 50mg given orally
62078415|NCT05015673|PLACEBO_COMPARATOR|Placebo|Placebo given orally
62078416|NCT04151693|EXPERIMENTAL|Research group ME/CFS|"Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)~8 sessions in 4 months. n=35-40 patients~ME/CFS -Current knowledge Smart goals Stress management in every day life Pacing Psychological effects of illness and adaptation Coping strategies Emotional support Focus on autonomic nervous system (hyperarousal, cognitive disabilities) Focus on health"
62457237|NCT03765502|ACTIVE_COMPARATOR|Glucagon Emergency Kit (GEK)|Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
62646899|NCT05181150|EXPERIMENTAL|GIP + GLP-2|
62078417|NCT04151693|EXPERIMENTAL|Control group ME/CFS|"Control group~6 sessions in 3 months n=35-40 patients~Health, lifestyle and wellbeing counselling (sleep, nutrition, activities in daily life)"
62646900|NCT05181150|PLACEBO_COMPARATOR|Placebo (saline)|
62646901|NCT06073288||Crohn's Disease (CD)|"15 CD patients (5 patients/stage: (B1 (more inflammatory, non-structuring), B2 (structuring, non-penetrating) and B3 (structuring and penetrating).~Patient stratification is based on previous classifications done in accordance with the standard of care through TC, RMI or Ecography. For this reason, patients classification is known before surgery."
62646902|NCT06073288||non-Intestinal Bowel Disease patients (no-IBD)|5 patients without IBD-related diseases (ex. diverticulitis)
62078418|NCT00518141|EXPERIMENTAL|1|FER
62078419|NCT00518141|NO_INTERVENTION|2|FER
62078420|NCT00518141|EXPERIMENTAL|3|SET
62078421|NCT00518141|NO_INTERVENTION|4|SET
62078422|NCT00518141|EXPERIMENTAL|5|DET
62078423|NCT00518141|NO_INTERVENTION|6|DET
62646903|NCT05883514|EXPERIMENTAL|Intervention group|Group one (study group, 35 patients): received the Motivational interviewing intervention.
62078424|NCT05611697|EXPERIMENTAL|Single anastomosis sleeve ileal bypass|A Single anastomosis sleeve ileal bypass procedure is performed.
62078425|NCT05611697|ACTIVE_COMPARATOR|Sleeve gastrectomy|A sleeve gastrectomy procedure is performed.
62078426|NCT04499417|EXPERIMENTAL|Experimental-Condition|"8 weeks x weekly 20 minutes whole-body-workouts with simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
62078427|NCT04499417|SHAM_COMPARATOR|Sham-Condition|"8 weeks x weekly 20 minutes whole-body-workouts without simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are not actually stimulated by EMS."
62078428|NCT06415786||Healthy Volunteers|
62078429|NCT04404621|EXPERIMENTAL|Cross-Over Sequence A|Participants in this arm will be randomized to receive the 18 week program first and be in treatment as usual comparison condition in the following 18 weeks.
62078430|NCT04404621|EXPERIMENTAL|Cross-Over Sequence B|Participants in this arm will be randomized to remain in treatment as usual during the first 18 week period and then receive the 18 week program during the following 18 weeks.
62078431|NCT02023138|ACTIVE_COMPARATOR|Focus group|
62078432|NCT02023138|EXPERIMENTAL|Wiki|
62078433|NCT04645524|EXPERIMENTAL|AD182|Oral capsule administered before bed
62457238|NCT02450981|EXPERIMENTAL|BCD-021 group|BCD-021 (bevacizumab) at a dose of 1.25 mg, administered as single intravitreal injection every 28 days up to 12 months.
62646904|NCT05883514|NO_INTERVENTION|Control group|Group two(the control group, 35 patients): will receive routine hospital care such as medication administration, assessment of vital signs, and hygienic care.
62646905|NCT04273815|EXPERIMENTAL|TQ-A3334 tablets|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle.
62646906|NCT04273815|EXPERIMENTAL|TQ-A3334 tablets + anlotinib capsules|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62646907|NCT04670601|EXPERIMENTAL|Flurbiprofen 8.75 mg|Flurbiprofen 8.75 mg lemon and honey flavour lozenge
62078434|NCT04645524|EXPERIMENTAL|AD504|Oral capsule administered before bed
62078435|NCT04645524|PLACEBO_COMPARATOR|Placebo|Oral capsule administered before bed
62078436|NCT04888702|EXPERIMENTAL|SMA patients|Patients with type 2 or 3 spinal muscular atrophy undergoing Spinraza° or risdiplam treatment.
62078437|NCT05542381|EXPERIMENTAL|Loteprednol|1 drop of Loteprednol is administered immediately after the intravitreal injection in this treatment arm.
62078438|NCT05542381|PLACEBO_COMPARATOR|Artificial tears|1 drop of artificial tears is administered immediately after the intravitreal injection in this treatment arm. This arm acts as a negative control.
62078439|NCT03435458|EXPERIMENTAL|Balloon catheter + oral misoprostol|
62078440|NCT03435458|ACTIVE_COMPARATOR|Oral misoprostol alone|
62078441|NCT02164162|EXPERIMENTAL|Experimental group|"Participants received 12 sessions of robotic assisted body weight-supported treadmill training on the Lokomat. Training occurred approximately 3 days/ week for 4 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support.~Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session."
62646908|NCT04670601|ACTIVE_COMPARATOR|Strepfen 8.75 mg|Strepfen 8.75 mg lemon and honey lozenge
62646909|NCT00129337|EXPERIMENTAL|1|0.1 mg/kg
62646910|NCT00129337|EXPERIMENTAL|2|0.3 mg/kg
62646911|NCT00129337|EXPERIMENTAL|3|1 mg/kg
62646912|NCT00129337|EXPERIMENTAL|4|3 mg/kg
62646913|NCT05944939|EXPERIMENTAL|Case group|After third molar extraction concentrated growth factor is palced in socket and closure with silk3.0 compare bone density with control group
62646914|NCT05944939|EXPERIMENTAL|Control group|After extraction closure with silk 3.0 compare bone density with cases
62646915|NCT06253377||Study cohort|Patients with Acute Kidney Injury and Renal Replacement Therapy indication, following local clinical patterns, who were treated with Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™
62280070|NCT04075929|OTHER|4x(12x40/20s)|4x(8x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x(8x40/20-sec) = 32 min if the 20-sec recovery is included in the total time of HIT
62457239|NCT06433375|EXPERIMENTAL|Non surgical debulking group|Teeth undergo non-surgical debulking of periapical tissues.
62457240|NCT06433375|EXPERIMENTAL|Growth hormone group|Teeth undergoes Growth Hormone application.
62457241|NCT06433375|EXPERIMENTAL|Non surgical Debulking & Growth hormone group|Teeth undergo non-surgical debulking of periapical tissues with Growth Hormone application.
62457242|NCT06433375|EXPERIMENTAL|Control group|Teeth undergo conventional root canal treatment without any additional intervention
62457243|NCT03699644||Healthy Control|Healthy controls will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all healthy controls will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
62457244|NCT03699644||Alzheimer's Dementia|Subjects with Alzheimer's Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all subjects with Alzheimer's Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
62457245|NCT03699644||Frontotemporal Dementia|Subjects with Frontotemporal Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, subjects with Frontotemporal Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
62457246|NCT02787278|EXPERIMENTAL|SP-8203 High dose group|SP-8203 160mg (80mg/dose twice a day for three days)
62457247|NCT02787278|EXPERIMENTAL|SP-8203 Low dose group|SP-8203 80mg (40mg/dose twice a day for three days)
62457248|NCT02787278|PLACEBO_COMPARATOR|Placebo group|Placebo group: twice a day for three days
62457249|NCT02850770|OTHER|Control|Pedometers and walking logs
62457250|NCT02850770|EXPERIMENTAL|Phone Messaging|Phone Messaging
62457251|NCT02850770|EXPERIMENTAL|Phone Messaging + Family/Friend Support|Phone Messaging + Family/Friend Support
62457252|NCT04084483|EXPERIMENTAL|Group 1|K-161 Ophthalmic Solution Dose A.
62457253|NCT04084483|EXPERIMENTAL|Group 2|K-161 Ophthalmic Solution Dose B.
62457254|NCT04084483|EXPERIMENTAL|Group 3|K-161 Ophthalmic Solution Dose C.
62457255|NCT04084483|PLACEBO_COMPARATOR|Group 4|Vehicle Solution Dose.
62457256|NCT06109103|EXPERIMENTAL|Group 1|Telerehabilitation-based physiotherapy program + telerehabilitation-based motor imagery training Telerehabilitation-based physiotherapy program; Eight (8) weeks, three (3) sessions per week, 40 minutes, using an image-based rehabilitation system, by connecting volunteers with a physiotherapist online in their home environment. Telerehabilitation-based motor imagery training will only be applied to the treatment group by the same physiotherapist for 15-20 minutes in addition to the physiotherapy training, three (3) sessions per week for eight (8) weeks.
62457257|NCT06109103|ACTIVE_COMPARATOR|Group 2|"Telerehabilitation-based physiotherapy program~Telerehabilitation-based physiotherapy program; Eight (8) weeks, three (3) sessions per week, 40 minutes, using an image-based rehabilitation system, by connecting volunteers with a physiotherapist online in their home environment."
62457258|NCT06109103|NO_INTERVENTION|Healthy children group|No intervention will be applied.
62457259|NCT04008784||Crisaborole 2% Topical Application Ointment [EUCRISA]|Crisaborole 2% Topical Application Ointment \[EUCRISA\] applied twice a day for 8 weeks
62457260|NCT04008784||Crisaborole 2% plus Triamcinolone Acetonide 0.1%Ointment|Crisaborole 2% plus Triamcinolone Acetonide 0.1% Ointment applied twice a day for the first 2 weeks, followed by Crisaborole 2% alone applied twice a day for the following 6 weeks
62457261|NCT01658384||cognitive evolution, observational,MS|multiple sclerosis tysabri treated patients
62646916|NCT02346734|ACTIVE_COMPARATOR|MSHAT|The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and the intervention group will receive access to the MSHAT system via a website in which they will utilize each day. The study participants in the intervention group will login to the MSHAT system, go through a pre-exercise symptom diary to determine their eligibility to exercise, perform exercise while watching a video demonstration and report results real-time. The intervention group will also be able to send and receive messages via the MSHAT system. The time to complete the daily exercises will vary from patient to patient ranging for 10-30 minutes.
62078442|NCT02164162|ACTIVE_COMPARATOR|Control group|Participants received 20 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 4 weeks, and each training session lasted 1 hour .Patients allocated to the Control Group performed a general exercise program and a conventional gait training with a 5-minute rest between them. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long.
62078443|NCT02878213|EXPERIMENTAL|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
62078444|NCT02982720|EXPERIMENTAL|Pembrolizumab and Sylatron|Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
62457262|NCT03225196||Samples|We seek to measure a 665 exRNAs spanning a variety of classes in plasma from 4095 young to middle-aged adult participants in the Third Generation cohort of the FHS
62457263|NCT01362998|ACTIVE_COMPARATOR|Preservative free morphine|This group will receive 3mg of preservative free morphine epidurally during the procedure.
62457264|NCT01362998|ACTIVE_COMPARATOR|Fentanyl infusion|This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days.
62457265|NCT02220868|OTHER|Sofossbuvir, Riabvirin, Stribild|Open-Label SIngle Arm of Sofosbuvir, Ribavirin and Stribild
62078445|NCT02228525|EXPERIMENTAL|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
62078446|NCT05601635|ACTIVE_COMPARATOR|High dose|Dietary supplement containing 200 mg of active ingredient tributyrin
62078447|NCT05601635|ACTIVE_COMPARATOR|Low dose|Dietary supplement containing 100 mg of active ingredient tributyrin
62078448|NCT02030275|EXPERIMENTAL|RXI-109|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
62457266|NCT02550223|EXPERIMENTAL|Oblique|Ultrasound guided radial artery catheterization using oblique view obtained by tilting the US probe 30-45 degrees over the course of the artery
62457267|NCT02550223|ACTIVE_COMPARATOR|Transverse group|Ultrasound guided radial artery catheterization using transverse view
62457268|NCT02550223|ACTIVE_COMPARATOR|Longitudinal group|Ultrasound guided radial artery catheterization using longitudinal view
62078449|NCT02030275|PLACEBO_COMPARATOR|Placebo|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
62078450|NCT03410290||Group 1|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
62078451|NCT03902938|EXPERIMENTAL|Biodesign Otologic Graft|Graft following canal wall down mastoidectomy.
62078452|NCT03902938|ACTIVE_COMPARATOR|Autograft temporalis fascia|Graft following canal wall down mastoidectomy.
62078453|NCT00358215|EXPERIMENTAL|Darbepoetin alfa|Starting dose of 0.75 µg/kg subcutaneously every 2 weeks until hemoglobin concentrations reach 13.0 g/dL on 2 consecutive visits, then monthly dosing, titrated to achieve hemoglobin target of 13.0 g/dL, not to exceed 14.5 g/dL.
62078454|NCT00358215|PLACEBO_COMPARATOR|Placebo|Participants received dose and administration schedule (every 2 weeks or once a month) changes that simulated the changes for participants receiving darbepoetin alfa.
62078455|NCT02265380|EXPERIMENTAL|Treatment with OptiVein|The patient will have an IV catheter placed with the use of OptiVein device.
62078456|NCT02265380|ACTIVE_COMPARATOR|Treatment with Vasofix Certo|The patient will have an IV catheter placed with the use of Vasofix Certo device.
62078457|NCT02791490|EXPERIMENTAL|Sitagliptin|Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day \[b.i.d.\]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
62457269|NCT03465566||Children with BECTS|"Children with active BECTS according to state-of-the-art diagnostic criteria of ILAE (International League Against Epilepsy). Eligible subjects will be recruited at their first clinical observation in the epilepsy centers involved in the study.~All subjects will perform five diagnostic evaluations named:~IDS (Intelligence and Development Scale) MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
62457270|NCT03465566||Healthy children|"Healthy controls matched for sex, age range, and education with no family history for epilepsy or other neuropsychiatric disorders.~All subjects will perform the following tests:~MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
62457271|NCT01232634||All Subjects|
62457272|NCT06014437|EXPERIMENTAL|PLCL/Fg|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
62457273|NCT06014437|ACTIVE_COMPARATOR|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds.
62646917|NCT02346734|NO_INTERVENTION|Control|The study participants randomized to group 2 will serve as the control. The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and will be given a paper diary to report their exercise completion. The control group will bring their paper diary showing their exercise completion results to their 3 month and 6 month follow-up visits.
62646918|NCT06506123||Artificial Intelligence Detection and Classification of Patient-Ventilator Dyssynchronies|This is a single arm study, since all subjects included will be exposed to both diagnostic methods (artificial intelligence and experts). The proposed diagnostic method is a machine learning algorithm integrated in the mechanical ventilator FlexiMag Max 700 (Magnamed, Brazil), which will continuously record data from mechanical ventilation of included subjects for a time period of up to 72 hours. The gold-standard involves esophageal pressure waveform recording and offline analysis by experts.
62457274|NCT04997343|EXPERIMENTAL|MS patients|All MS patients will undergo clinical and neurophysiological evaluation at baseline (T0). The baseline will consider the radiological data of disease activity obtained from the most recently performed MRI according to clinical practice. These evaluations will be repeated according to clinical practice in patients taking DMT or every 6 months, in a stable condition or according to the indication of the treating neurologist in case of disease reactivation. A one-year neurophysiological, clinical and radiological observation is foreseen. Healthy subjects will undergo only the neurophysiological evaluation at baseline.
62457275|NCT04997343|OTHER|Healthy controls|Healthy subjects will undergo only the neurophysiological evaluation at baseline.
62457276|NCT02621775|EXPERIMENTAL|Computer-based stress management program|Immediate e-learning condition with minimal contact (n =40),
62646919|NCT06550778|EXPERIMENTAL|Intervention group|
62646920|NCT06550778|NO_INTERVENTION|Control group|
62646921|NCT03098316||POAG|Primary open angle glaucoma patients
62078458|NCT02791490|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
62457277|NCT02621775|EXPERIMENTAL|Stress management in face-to-face|Immediate treatment in face - to- face (n = 40)
62457278|NCT02621775|OTHER|Waiting list|Waiting list (n=40)
62646922|NCT03098316||NTG|Normal/Low tension glaucoma patients
62646923|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
62646924|NCT06445933|EXPERIMENTAL|Experimental arm|After recruitment during 24-28 weeks of gestation, women would be given Vitamin B6 tablets (25mg/tablet, 75mg/day) until delivery. After delivery of the baby, the participants would be asked to take tablets(25mg/tablet, 50mg/day) up to six weeks postpartum.
62646925|NCT06445933|PLACEBO_COMPARATOR|Placebo arm|After recruitment during 24-28 weeks of gestation, women would be given three placebo tablets per day until delivery. After delivery of the baby, the participants would be asked to take two placebo tablets per day up to six weeks postpartum.
62646926|NCT01653275|EXPERIMENTAL|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
62646927|NCT04824001||STEMI|ST-segment elevation myocardial infarction (STEMI) is defined by symptoms of myocardial ischemia accompanied by a persistent elevation of the ST segment on the electrocardiogram (ECG) and the subsequent release of biomarkers of myocardial necrosis.
62646928|NCT04824001||NSTEMI|If there is elevation of the blood markers suggesting heart damage, but no ST elevation seen on the EKG tracing, this is known as a non ST-elevation myocardial infarction (NSTEMI).
62646929|NCT04289909|OTHER|MS patients|RRMS Patients with optic neuritis, RRMS patients without optic neuritis or Progressive MS patients
62646930|NCT04289909|OTHER|Control group|Healthy volunteers
62078459|NCT00910806|EXPERIMENTAL|TMC207, nevirapine|
62078460|NCT00867490|EXPERIMENTAL|Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine|
62078461|NCT04293809|EXPERIMENTAL|Cohort 1 - EXPAREL|A total of 15 subjects will be enrolled in this cohort. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of saline
62078462|NCT04293809|EXPERIMENTAL|Cohort 2 - EXPAREL|A total of 15 subjects will be enrolled. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of 0.5% bupivacaine HCl (150mg)
62078463|NCT06403839||No preoperative dental screening|No preoperative dental screening in patients undergoing surgical valve replacement.
62457279|NCT05375409||Postoperative Delirium (+)|
62457280|NCT05375409||Postoperative Delirium (-)|
62457281|NCT05375409||Healthy Control|
62646931|NCT04782284|EXPERIMENTAL|Comprehensive swallowing rehabilitation|
62457282|NCT04745026|EXPERIMENTAL|GWP42003-P 10 mg/kg/day|Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive 5 milligrams per kilogram per day (mg/kg/day) GWP42003-P for 1 week and then 10 mg/kg/day GWP42003-P for 11 weeks.
62457283|NCT04745026|PLACEBO_COMPARATOR|Placebo|Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive matching placebo for 12 weeks.
62457284|NCT01076972||Lopinavir/ritonavir group|All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
62457285|NCT01421706|ACTIVE_COMPARATOR|sibutramine-clopidogrel|sibutramine-clopidogrel
62646932|NCT04782284|ACTIVE_COMPARATOR|Swallowing education|
62646933|NCT04420507||GDM group|pregnant women who are diagnosed after 75g OGTT test between 24\~27+6 gestational weeks
62457286|NCT01421706|ACTIVE_COMPARATOR|sibutramine-clarithromycin|sibutramine-clarithromycin
62457287|NCT01341366|EXPERIMENTAL|Fast-track perioperative program|
62646934|NCT04420507||health group|pregnant women who pass the 75g OGTT test and aren't diagnosed as GDM, and also don't have any other conditions, like hypertensive disorders, IBD, gastrointestinal ulcer, and so on.
62646935|NCT03377439||Group A|Participants with platelet counts \<32×10\^9/L.
62457288|NCT01341366|ACTIVE_COMPARATOR|Traditional perioperative program|
62457289|NCT06359808||Ulcerative colitis group|Ulcerative colitis patients aged 18-65 years will be recruited from The First Affiliated Hospital of the Air Forth Medical University from April 2024 to December 2024.
62457290|NCT06359808||Healthy subjects|Age-, gender-, and education level-matched healthy controls will be recruited from The First Affiliated Hospital of the Air Forth Medical University from April 2024 to December 2024.
62457291|NCT03113006|ACTIVE_COMPARATOR|Standard Panretinal Photocoagulation|Localized to all four retinal quadrants.
62457292|NCT03113006|EXPERIMENTAL|Individ. Panretinal Photocoagulation|Localized to only the affected quadrants.
62646936|NCT03377439||Group B|Participants with platelet counts between 32×10\^9/L and 132×10\^9/L.
62646937|NCT03377439||Group C|Participants with platelet counts \>132×10\^9/L.
62646938|NCT02208908||Patient with cancer hospitalize inpalliative situation|"An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.~An assessment of the traceability of clinical assessment and appropriate treatment prescribed or will be conducted on day 3 and repeated the day of the release of hospitalization (or day 15) from information recorded in the patient record"
62646939|NCT01566110|EXPERIMENTAL|Diet Intervention Group|
62646940|NCT01566110|NO_INTERVENTION|Control Group|Subjects assigned to the control group will continue their usual diet. They will receive dietary teaching at each study visit as part of their diabetes management.
62457293|NCT02687048|ACTIVE_COMPARATOR|EX protocol|Participants will receive a revised version of the Otago exercise program (OEP) - an individualized home-based exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week. The exercises are for strength and balance and are gradually progressed over the course of the study to meet the individual's abilities.
62646941|NCT02873975|EXPERIMENTAL|Homologous Repair (HR) Deficiency Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with homologous repair (HR) deficiency on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
62646942|NCT02873975|EXPERIMENTAL|Replicative Stress Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with advanced solid tumors exhibiting replicative stress on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
62646943|NCT02873975|EXPERIMENTAL|CCNE1 Amplification Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with CCNE1 amplification on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
62646944|NCT02841124|OTHER|Qualitative research|Semi-structured interviews
62646945|NCT04626323|EXPERIMENTAL|RYGB (intervention arm)|Thirty (30) obese patients with DKD will undergo gastric bypass. Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA. The surgical procedure will consist of a laparoscopic surgery performed by an experienced surgeon (approximately 6000 bariatric surgeries), who is accredited as surgeon of excellence by the Brazilian Society of Bariatric and Metabolic Surgery and Surgical Review and Surgical Review Corporation program since 2009.
62646946|NCT04626323|ACTIVE_COMPARATOR|BMT (control arm).|Thirty (30) obese patients with DKD will undergo best medical treatment for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA.
62646947|NCT04753034|EXPERIMENTAL|TER-101|BID (twice daily) application
62646948|NCT04753034|PLACEBO_COMPARATOR|Vehicle|Vehicle ointment, BID (twice daily) application
62646949|NCT01135342|EXPERIMENTAL|Diet & Exercise plus Sleep Intervention|Diet and exercise instruction to promote weight loss plus cognitive behavioral therapy for insomnia.
62646950|NCT01135342|SHAM_COMPARATOR|Diet & Exercise plus Passion and Balance|Diet and exercise instruction to promote weight loss plus sessions that are of general interest, but unrelated to diet, exercise, or sleep.
62646951|NCT01186770|EXPERIMENTAL|MNTX 150 mg|Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).
62646952|NCT01186770|EXPERIMENTAL|MNTX 300 mg|Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
62646953|NCT01186770|EXPERIMENTAL|MNTX 450 mg|Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
62646954|NCT01186770|PLACEBO_COMPARATOR|Placebo|Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).
62646955|NCT03233074||Acute Myeloid Leukemia patients|For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.
62646956|NCT03233074||Healthy donors|Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.
62646957|NCT04316117|EXPERIMENTAL|Diagnostic (FDG-PET/CT)|Patients receive FDG IV and undergo PET/CT scan over 15-30 minutes at baseline (within 21 days before start of standard systemic treatment) and at 12 weeks after start of standard systemic treatment in the absence of unacceptable toxicity.
62646958|NCT03515746|ACTIVE_COMPARATOR|Exergaming2D|The participants will practise grab and grasp through exergaming in virtual environment (VE) on a laptop computer. During the task, they will sit in a comfortable chair in front of the screen.
62646959|NCT03515746|ACTIVE_COMPARATOR|Exergaming3D|The participants will practise grab and grasp through exergaming in virtual environment (VE) in 3D VE using Oculus Rift CV1 3D goggles. During the task, they will sit in a comfortable chair with head-mounted 3D display.
62646960|NCT01420536|EXPERIMENTAL|Canine Guidance|"Complete dentures adjusted with mutually protected articulation in which the vertical and horizontal overlap of the canine teeth disengage the posterior teeth in the excursive movements of the mandible (The Glossary of Prosthodontic Terms. J. Prosthet. Dent., 94(1): 10-92)"
62646961|NCT01420536|SHAM_COMPARATOR|Bilateral Balanced Occlusion|Complete dentures as conventionally adjusted: anterior and posterior teeth presented bilateral contact in excentric positions
62078464|NCT06403839||Mandatory preoperative dental screening|Mandatory preoperative dental screening in patients undergoing surgical valve replacement
62078465|NCT03706157|ACTIVE_COMPARATOR|Iodinate contrast|Doxorubicin solution reconstituted in 5 mL iso-osmolar ionic iodinated contrast media
62078466|NCT03706157|ACTIVE_COMPARATOR|Normal saline|Doxorubicin solution reconstituted in 5 mL normal saline
62078467|NCT02040090|EXPERIMENTAL|KamRAB|KamRAB 20 IU/kg body weight via IM injection, once on Day 0
62078468|NCT02040090|ACTIVE_COMPARATOR|FDA approved HRIG product|Comparator product: Intramuscular (IM) injection once on Day 0 in the same manner and at the same dosage as KamRAB.
62078469|NCT05640167|OTHER|EMPOWER PD Clinic Participation|All participants will be assigned to the same interdisciplinary clinic and educational intervention
62646962|NCT02696889|EXPERIMENTAL|ROSE-1 Protocol|Patients with POF, POI or Low Ovarian Reserve choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1). They will undergo diagnosis and screening confirming diagnosis including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy and subsequent injection of the bone marrow derived stem cells into the right ovary.
62646963|NCT01477281|EXPERIMENTAL|Venafon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
62646964|NCT01477281|ACTIVE_COMPARATOR|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
62078470|NCT00259324|EXPERIMENTAL|1|Diet and Activity
62646965|NCT02024061|EXPERIMENTAL|Peer support|"The intervention will be similar with the exception that in the experimental group during the interventions (Interactive Sessions, Physical activity sessions and holiday camps), the presence of peers is predominant, indispensable and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
62646966|NCT02024061|ACTIVE_COMPARATOR|Regular treatment|"The intervention will be similar with the exception that in the experimental group during the interventions (IS, PA sessions and holiday camps), the presence of peers is predominant, indispensible and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
62646967|NCT02574585|EXPERIMENTAL|Treated group|Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
62646968|NCT02574585|NO_INTERVENTION|Control group|Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.
62078471|NCT00259324|EXPERIMENTAL|2|Diet and Activity
62078472|NCT00259324|PLACEBO_COMPARATOR|3|Education
62078473|NCT05784662|EXPERIMENTAL|Social Workers Addressing Firearm Risk|The Social workers Addressing Firearm Risk (SAFR) intervention is fully-online intervention that contains four modules. Each module includes interviews with experts, didactic content, handouts, and brief quizzes to check learning (required by New York State for continuing education credit).
62078474|NCT05784662|NO_INTERVENTION|Control|Wait list control. Will receive access to SAFR intervention at conclusion of the study.
62078475|NCT04333173||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
62078476|NCT03202030|EXPERIMENTAL|IDR|Immediate dentoalveolar restoration conducted with bone removed from the tuber
62078477|NCT03202030|ACTIVE_COMPARATOR|Bio-oss|Bovine demineralized bone (Bio-oss Collagen) applied on the buccal resorption of the immediate implant
62078478|NCT05298462|OTHER|Patients|
62078479|NCT05298462|OTHER|Hospital staff|
62078480|NCT06039228|EXPERIMENTAL|Intervention group|
62078481|NCT00662493|EXPERIMENTAL|1|Motor control retraining program
62078482|NCT02552433||Body Contouring Surgery|All patients who undergo BCS after bariatric surgery.
62078483|NCT00502996|EXPERIMENTAL|Rituximab|Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
62078484|NCT06210763|EXPERIMENTAL|group A|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
62646969|NCT05126316|EXPERIMENTAL|Lu AG09222 Low Dose|Participants will receive Lu AG09222 injection at a low dose level 3 times with 4 weeks between each administration.
62078485|NCT06210763|ACTIVE_COMPARATOR|group B|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). The study duration will be 1 month.
62646970|NCT05126316|EXPERIMENTAL|Lu AG09222 High Dose|Participants will receive Lu AG09222 injection at a high dose level 3 times with 4 weeks between each administration.
62078486|NCT02836613|ACTIVE_COMPARATOR|Galcanezumab Reference|Single dose of 240 milligrams (mg) galcanezumab (LY2951742) administered subcutaneously (SC) by manual prefilled syringe (PFS).
62078487|NCT02836613|EXPERIMENTAL|Galcanezumab Test|Single dose of 240 mg galcanezumab (LY2951742) administered SC by autoinjector.
62078488|NCT02044237|EXPERIMENTAL|Decoupling|specific technic to reduce hair pulling
62078489|NCT02044237|ACTIVE_COMPARATOR|progressive muscle relaxation|Progressive relaxation relaxation technic
62078490|NCT03499574|EXPERIMENTAL|Biofeedback group|Dysphagia therapy using surface EMG as biofeedback - 10 x 45 minute sessions of swallow strength and skill training using surface electromyography as biofeedback tool. This group will also receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education.
62646971|NCT05126316|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to Lu AG09222 injection 3 times with 4 weeks between each administration.
62078491|NCT03499574|OTHER|Control group|This group will receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education
62078492|NCT00787722|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
62078493|NCT01995357|EXPERIMENTAL|First Coloplast Teast A; then Coloplast Test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Coloplast Test B; Standard product; Training + Coloplast Test A; Training + Coloplast Test B"
62078494|NCT01995357|EXPERIMENTAL|First Coloplast Test A; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Standard product; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
62078495|NCT01995357|EXPERIMENTAL|First Coloplast Test B; Then Colopast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test B; Coloplast Test A; Standard product; Training + Coloplast Test B; Training + Coloplast Test A"
62646972|NCT01869400||Yondelis-Pegylated liposomal Doxorubicin|30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks
62646973|NCT05621161|ACTIVE_COMPARATOR|GroupFICB= fascia iliaca compartment block|ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and then for correction of the needle 2 ml saline will be injected deep into the erector spinae muscle fascia. Following confirmation of the correct position of the needle 30 ml 0.25% bupivacaine will be administered for the block.
62078496|NCT01995357|EXPERIMENTAL|First Coloplast Test B; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test b; Standard product; Coloplast Test A; Training + Coloplast Test B; Training + Coloplast Test A"
62078497|NCT01995357|EXPERIMENTAL|First Standard product; Then Coloplast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test A; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
62078498|NCT01995357|EXPERIMENTAL|First Standard Product, Then Coloplast test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test B; Coloplast Test A; ; Training + Coloplast Test B; Training + Coloplast Test A"
62078499|NCT03851913|EXPERIMENTAL|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
62078500|NCT03851913|NO_INTERVENTION|control group|no neo-adjuvant treatment before operation
62078501|NCT02337205|EXPERIMENTAL|KX2-391 Ointment|
62078502|NCT02218021|EXPERIMENTAL|Samidorphan Dose 1|
62078503|NCT02218021|EXPERIMENTAL|Samidorphan Dose 2|
62078504|NCT02218021|EXPERIMENTAL|Samidorphan Dose 3|
62078505|NCT02218021|PLACEBO_COMPARATOR|Placebo|
62078506|NCT02218021|ACTIVE_COMPARATOR|Oxycodone Dose 1|
62078507|NCT02218021|ACTIVE_COMPARATOR|Oxycodone Dose 2|
62078508|NCT05184738|EXPERIMENTAL|Oligomeric nutritional formula arm (Bi1 peptidic)|Individuals will receive a Oligomeric nutritional formula.
62078509|NCT05184738|OTHER|Standard arm|Individuals will receive a Standard nutritional formula.
62078510|NCT01651936|EXPERIMENTAL|Base Study: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
62078511|NCT01651936|PLACEBO_COMPARATOR|Base Study: Placebo|Participants received placebo BID orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
62078512|NCT01651936|EXPERIMENTAL|Safety Extension: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Safety Extension was to last up to 76 weeks.
62078513|NCT02242240|EXPERIMENTAL|Tiotropium with single dose of formoterol|
62078514|NCT02242240|EXPERIMENTAL|Tiotropium with double dose of formoterol|
62078515|NCT02242240|EXPERIMENTAL|Tiotropium with Placebo|
62078516|NCT05197686|EXPERIMENTAL|HFNC|
62078517|NCT05197686|ACTIVE_COMPARATOR|COT|
62078518|NCT05312515|EXPERIMENTAL|Warm Application to Feet and Follow-up After Cesarean Section|Warm application will be applied to the feet of women who come to the surgical service after cesarean delivery, 3 hours after they are admitted to the service. For hot application, a hot water bag will be used, the temperature of the water to be placed in the hot water bag is max. It will be set by the researcher to be 44°C. Since the temperature of the water (max. 44°C) does not create a risk of burns, no additional precautions were required. A stopwatch clock will be used to track the duration of the application. After the application will be done for 30 minutes, a hot water bag will be taken. Hot application will be done once. During the application, the researcher will be with the women, will check whether any complications have developed, and if complications or discomfort develop, the application will be terminated.
62078519|NCT05312515|NO_INTERVENTION|Control|The control group will be given routine post-operative care without any intervention and data collection tools will be applied at the same time as the intervention group. In addition, the patient and his family will be informed to write it down with the watch if there is gas after the procedure when the researcher is not with them.
62078520|NCT02102464|EXPERIMENTAL|LipiFlow|Single 12-minute LipiFlow treatment
62457294|NCT02687048|EXPERIMENTAL|EX Plus protocol|"These participants will receive mindful meditation coaching via 6 one-hour small group sessions with an experienced meditation instructor. They will also be expected to practice mindful meditation at home following online audio recordings (free of charge from University of California, Los Angeles; http://marc.ucla.edu/body.cfm?id=22) and written instructions a minimum of five times per week for 30 minutes. Participants will complete a meditation log to record their practice.~These participants will also receive the same revised version of the Otago exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week."
62646974|NCT05621161|ACTIVE_COMPARATOR|Group ESPB = erector spina plan block|FIC block will be performed in the supine position. The linear probe is placed transversely to identify the femoral artery, iliopsoas muscle, and fascia iliaca at the inguinal crease. The probe will be tilted cranially and caudally until optimal images of the fascia iliaca are obtained. Block needle (50 mm, 22G) will be passed through the iliac fascia via the in-plane method. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected.
62078521|NCT02102464|NO_INTERVENTION|Untreated Control|Untreated Control (No Intervention)
62078522|NCT02102464|EXPERIMENTAL|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
62646975|NCT05137236|EXPERIMENTAL|Part A: mRNA-1283 Dose Level 1|Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.
62078523|NCT01951092|EXPERIMENTAL|Single Arm intervention study|All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
62078524|NCT06159296|OTHER|Treatment-Placebo arm|The participants in this arm are given a machine that produces hydroxy gas in the first three weeks. In the final three weeks of the study, they will use a machine that produces a placebo gas.
62078525|NCT06159296|OTHER|Placebo-treatment arm|The participants in this arm are given a machine that produces a placebo gas in the first three weeks. In the final three weeks of the study, they will use a machine that produces hydroxy gas.
62078526|NCT05592535||FFR below 0.80|Patients with significant coronary hyperemic gradient
62457295|NCT05666752|EXPERIMENTAL|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
62457296|NCT05666752|PLACEBO_COMPARATOR|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
62457297|NCT02975466|EXPERIMENTAL|AirQ Blocker supra-glottic airway device|Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
62646976|NCT05137236|EXPERIMENTAL|Part A: mRNA-1283 Dose Level 2|Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.
62646977|NCT05137236|EXPERIMENTAL|Part A: mRNA-1283 Dose Level 3|Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.
62078527|NCT05592535||FFR above 0.80|Patients without significant coronary hyperemic gradient
62078528|NCT03638635|ACTIVE_COMPARATOR|Standard Bupivacaine|Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
62078529|NCT03638635|EXPERIMENTAL|Bupivacaine Liposome|Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
62078530|NCT05851911||Control group 1|Mother not vaccinated with COVID-19 vaccine
62078531|NCT05851911||Control group 2|The mother was vaccinated with COVID-19 vaccine before pregnancy, and was not infected during pregnancy
62078532|NCT05851911||Control group 3|The mother was vaccinated with COVID-19 vaccine before pregnancy, and was infected during pregnancy
62078533|NCT05851911||Experimental group|The mother was not vaccinated with COVID-19 vaccine before pregnancy, so she was infected during pregnancy
62078534|NCT02922673|EXPERIMENTAL|Treatment group|7 day treatment with placebo - first LPS challenge - 7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - second LPS challenge
62078535|NCT02922673|ACTIVE_COMPARATOR|Prophylaxis group|7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - first LPS challenge - 7 day treatment with ASA (no loading dose on first day) - second LPS challenge
62646978|NCT05137236|EXPERIMENTAL|Part A: mRNA-1283.211 Dose Level 1|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.
62646979|NCT05137236|EXPERIMENTAL|Part A: mRNA-1283.211 Dose Level 2|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.
62646980|NCT05137236|ACTIVE_COMPARATOR|Part A: mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1.
62646981|NCT05137236|EXPERIMENTAL|Part B: mRNA-1283.529 Dose Level 1|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.
62646982|NCT05137236|EXPERIMENTAL|Part B: mRNA-1283.529 Dose Level 2|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 2 on Day 1.
62646983|NCT05691101|EXPERIMENTAL|Continuous interscalene brachial plexus block(CISB) with IV PCA group|Patients in this group received continuous interscalene brachial plexus block(CISB) and intravenous PCA
62078536|NCT02922673|PLACEBO_COMPARATOR|Placebo group|7 day treatment with placebo - first LPS challenge - 7 day treatment with placebo - second LPS challenge
62078537|NCT03407261|EXPERIMENTAL|Micro-osteoperforations|Minimally invasive micro-osteoperforations procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice
62078538|NCT03407261|NO_INTERVENTION|Control|Anterior retraction after premolars extraction will be done conventionally (sliding mechanics)
62078539|NCT01518660|EXPERIMENTAL|Training|
62646984|NCT05691101|ACTIVE_COMPARATOR|Continuous interscalene brachial plexus block (CISB) group|Patients in this group received continuous interscalene brachial plexus block (CISB)
62646985|NCT01464268|ACTIVE_COMPARATOR|Riboflavin drops every minute|Administration of riboflavin every 2 minutes for the duration of UV exposure.
62646986|NCT01464268|ACTIVE_COMPARATOR|Riboflavin drops every 2 minutes|Administration of riboflavin every 1 minute for the duration of UV exposure.
62646987|NCT01660568||relapsed or refractory NK/T cell lymphoma with gemcitabine|
62646988|NCT01407016|EXPERIMENTAL|1.0|
62646989|NCT06202859|EXPERIMENTAL|MIE group|"* Manual techniques of secretion drainage~* Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips."
62078540|NCT01518660|NO_INTERVENTION|Control|
62078541|NCT00652262|EXPERIMENTAL|Arm 1|
62078542|NCT00275496|ACTIVE_COMPARATOR|WEX only|
62078543|NCT00275496|ACTIVE_COMPARATOR|WEX + SLND|
62078544|NCT00275496|ACTIVE_COMPARATOR|WEX+SLND+CLND|
62078545|NCT02169219|EXPERIMENTAL|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
62078546|NCT04183673|EXPERIMENTAL|Laser-cryo-usual care|Sessions 5 days a week for 3 weeks. Each session includes laser therapy+ cryo-thermal followed by standard rehabilitation program
62646990|NCT06202859|ACTIVE_COMPARATOR|Control group|Maintained following national guidelines.
62646991|NCT02039934|EXPERIMENTAL|high intensity interval training|30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week
62646992|NCT00855218|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) + TACE|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Patients were then also treated with Transarterial Chemoembolization (TACE) performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of sorafenib, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
62457298|NCT02975466|EXPERIMENTAL|AuraGain supra-glottic airway device|Group of patients in which the AuraGain will be used and measured as an intubation conduit.
62078547|NCT04183673|ACTIVE_COMPARATOR|usual care|Sessions 5 days a week for 3 weeks. Each session includes only standard rehabilitation program
62078548|NCT00305682|ACTIVE_COMPARATOR|Arm 1-Previous Autologous Transplant|Arm 1 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
62078549|NCT00305682|ACTIVE_COMPARATOR|Arm 2 - No Prior Autologous Transplant|Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
62078550|NCT00305682|ACTIVE_COMPARATOR|Arm 3 - Refractory Leukemia/Lymphoma|Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
62078551|NCT00305682|ACTIVE_COMPARATOR|Arm 4: MT2006-01 coenrolling patients|Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
62078552|NCT00305682|ACTIVE_COMPARATOR|Arm 5 - Previous Autologous Transplant|Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
62078553|NCT00305682|ACTIVE_COMPARATOR|Arm 6 - No prior autologous transplant|Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
62078554|NCT02981485|EXPERIMENTAL|Experimental|Treatment of breast cancer related lymphedema by fat grafting
62078555|NCT04176133|EXPERIMENTAL|Entolimod 1 mcg|Subjects will receive entolimod as a single dose administered intramuscularly (1mcg)
62078556|NCT04176133|EXPERIMENTAL|Entolimod 3 mcg|Subjects will receive entolimod as a single dose administered intramuscularly (3mcg)
62078557|NCT04176133|EXPERIMENTAL|Entolimod 10 mcg|Subjects will receive entolimod as a single dose administered intramuscularly (10mcg)
62457299|NCT02975466|EXPERIMENTAL|I-Gel supra-glottic airway device|Group of patients in which the I-Gel will be used and measured as an intubation conduit.
62646993|NCT00855218|PLACEBO_COMPARATOR|Placebo + TACE|Placebo was to be orally administered as 2 tablets bid (twice daily). Patients were then also treated with TACE performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of placebo, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
62646994|NCT02076100|EXPERIMENTAL|Part I GT3 Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
62646995|NCT02076100|EXPERIMENTAL|Part II GT1a Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
62457300|NCT03818802|ACTIVE_COMPARATOR|Nicotinamide Riboside|NR is a single chemical moiety containing nicotinamide and ribose. The investigational product is a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels.
62457301|NCT03818802|PLACEBO_COMPARATOR|Placebo|Correspondent placebo, a pill not containing the active component.
62457302|NCT06127498|EXPERIMENTAL|A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|Specifications: 5 mg/mL, 6 mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
62457303|NCT06127498|PLACEBO_COMPARATOR|A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient|Specification: 0 mg/mL, 6 mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
62078558|NCT04176133|PLACEBO_COMPARATOR|Placebo|Subjects will receive a placebo as a single dose administered intramuscularly (no study drug); placebo that looks exactly like the study drug, but contains no active ingredient.
62078559|NCT03935217|EXPERIMENTAL|Solosec (containing 2 grams of secnidazole)|Orally administered as a single dose with applesauce.
62078560|NCT03935217|PLACEBO_COMPARATOR|Placebo|Orally administered as a single dose with applesauce.
62078561|NCT05554146|OTHER|Coupon for a Discounted Placebo Product|We will observe participants who were previously randomized to a coupon for discounted placebo soft-gel capsules by our collaborators, Vireo.
62078562|NCT05554146|OTHER|Coupon for a Discounted High THC Product|We will observe participants who were previously randomized to a coupon for discounted 4.3 mg THC/0.7 mg CBD soft-gel capsules by our collaborators, Vireo.
62078563|NCT05554146|OTHER|Coupon for a Discounted Equal THC and CBD Product|We will observe participants who were previously randomized to a coupon for discounted 2.5 mg THC/2.5 mg CBD soft-gel capsules by our collaborators, Vireo.
62078564|NCT05554146|OTHER|Coupon for a Discounted High CBD Product|We will observe participants who were previously randomized to a coupon for discounted 0.2 mg THC/4.8 mg CBD soft-gel capsules by our collaborators, Vireo.
62078565|NCT02560740|EXPERIMENTAL|PerOx Arm|PerOx Quench arm 4g/sachet each time by water, q6h
62078566|NCT02560740|PLACEBO_COMPARATOR|Comparative Arm|PerOx Quench placebo 4g/sachet each time by water, q6h
62078567|NCT05975866|EXPERIMENTAL|The group receiving anti-inflammatory diet with curcumin supplement|Implementation of an anti-inflammatory diet along with the daily consumption of three 500 mg curcumin capsules along with the main meals of breakfast, lunch, and dinner.
62078568|NCT05975866|PLACEBO_COMPARATOR|Group receiving anti-inflammatory regimen with curcumin placebo|Implementation of an anti-inflammatory diet along with the daily consumption of three 500 mg placebo capsules of curcumin (microcrystalline cellulose) and the main meals of breakfast, lunch, and dinner.
62078569|NCT04246203||Group A|Patients are allocated to group A according to preoperative presence of detectable ctDNA.
62646996|NCT02076100|EXPERIMENTAL|Part III GT2b Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
62646997|NCT04421417|ACTIVE_COMPARATOR|Standard Arthroscopic Rotator Cuff Repair|
62078570|NCT04246203||Group B|Patients are allocated to group B according to preoperative absence of detectable ctDNA.
62078571|NCT02605382|EXPERIMENTAL|chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
62078572|NCT02605382|PLACEBO_COMPARATOR|placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
62646998|NCT04421417|EXPERIMENTAL|Microfracture and Arthroscopic Rotator Cuff Repair|
62646999|NCT06238414|EXPERIMENTAL|Intervention/case participant|The case group will receive an 8-session early psychological intervention
62647000|NCT06238414|NO_INTERVENTION|Control case/participant|The control group will be treated as usual (TAU)
62647001|NCT03258255|ACTIVE_COMPARATOR|Pudendal block group in circumcision|Nerve stimulated pudendal nerve block performed under general anesthesia
62647002|NCT03258255|ACTIVE_COMPARATOR|Penil block group in circumcision|Penil block performed by surgeon under general anesthesia
62647003|NCT02351921|EXPERIMENTAL|iTBS to primary motor cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
62647004|NCT02351921|EXPERIMENTAL|iTBS to primary somatosensory cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the primary somatosensory cortex located 2cm posterior to the motor hotspot for the representation of the flexor carpi radialis muscle.
62647005|NCT02351921|SHAM_COMPARATOR|Sham iTBS to primary motor cortex|Sham iTBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS sham coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
62078573|NCT03701009|OTHER|Stone removal (Saline 50ml each time)|After CBD stone removal via lithotripsy, and the cholangiogram showed normal, residual CBD stones were detected by SpyGlass in the first round, if CBD not clean, sterile saline 50ml were intermittently irrigated into the CBD. After that, if bile duct clearance was not achieved, another 50ml saline will be irrigated into CBD again until the clear bile duct determined by SpyGlass.
62078574|NCT02547571|ACTIVE_COMPARATOR|1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
62647006|NCT03665337|EXPERIMENTAL|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
62647007|NCT03665337|ACTIVE_COMPARATOR|Control|Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.
62647008|NCT02102555|ACTIVE_COMPARATOR|IV acetaminophen|Patients in the IV acetaminophen arm will receive a one gram dose of IV acetaminophen in the pre-operative area prior to their surgery.
62647009|NCT02102555|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive normal saline in the pre-operative area.
62647010|NCT02711462|OTHER|Cohort 1|Subjects will receive 2mg of PF 06687234 or placebo via the SC route
62647011|NCT02711462|OTHER|Cohort 2|Subjects will receive 20mg PF 06687234 or placebo via the SC route
62647012|NCT02711462|OTHER|Cohort 3|This is an optional cohort that may be added anytime during the study. In this cohort, subjects will receive PF 06687234 or placebo via the SC route
62647013|NCT02711462|OTHER|Cohort 4|Subjects will receive 40mg of PF 06687234 or placebo via the SC route
62647014|NCT02711462|OTHER|Cohort 5|Subjects will receive 80mg of PF 06687234 or placebo via the SC route
62078575|NCT02547571|ACTIVE_COMPARATOR|1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue|
62647015|NCT02711462|OTHER|Cohort 6|Subjects receive a single dose of PF 06687234 or placebo via the IV route
62647016|NCT02711462|OTHER|Cohort 7|This is an optional cohort where Japanese subjects will receive PF 06687234 or placebo via the SC route
62647017|NCT02711462|OTHER|Cohort 8|Subjects in this cohort may receive 20 mg of PF 06687234 or placebo via the SC route every week with a total of 5 doses
62647018|NCT02711462|OTHER|Cohort 9|Subjects in this cohort may receive 40 mg of PF 06687234 or placebo via the SC route every two weeks with a total of 3 doses
62647019|NCT02711462|OTHER|Cohort 10|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
62647020|NCT02711462|OTHER|Cohort 11|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
62647021|NCT00587093|OTHER|1|CT scan and CA-125
62078576|NCT02547571|ACTIVE_COMPARATOR|1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
62078577|NCT02547571|ACTIVE_COMPARATOR|1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue|
62078578|NCT02547571|ACTIVE_COMPARATOR|1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid|
62078579|NCT02547571|ACTIVE_COMPARATOR|1) Early colonoscopy; 2) High-dose, day before; 3)Low residue|
62078580|NCT02547571|ACTIVE_COMPARATOR|1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
62647022|NCT02087098||Patients with residual OAB symptoms|Urge urinary incontinence, urgency, and frequency after treatment with other antimuscarinics
62647023|NCT02936947|EXPERIMENTAL|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
62078581|NCT02547571|ACTIVE_COMPARATOR|1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue|
62078582|NCT02547571|ACTIVE_COMPARATOR|1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
62078583|NCT02547571|ACTIVE_COMPARATOR|1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue|
62078584|NCT02547571|ACTIVE_COMPARATOR|1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid|
62078585|NCT02547571|ACTIVE_COMPARATOR|1) Later colonoscopy; 2) Low volume day before; 3)Low residue|
62647024|NCT02936947|EXPERIMENTAL|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
62647025|NCT02008526|EXPERIMENTAL|TXT-PHE|"Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)~This condition is interactive and tailored to the needs of the individual participant. PHEs initiate (i.e., push) text messages to participants and also respond to participant-initiated queries and participant responses to the PHE messages (i.e., pull).~Participants receive five pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
62457304|NCT02786238|ACTIVE_COMPARATOR|Standard Behavioral Treatment (SBT)|For the Standard Behavioral Treatment (SBT) condition, participants will participate in the standard behavioral weight loss programming, which utilizes strategies from existing obesity treatments (e.g., the Diabetes Prevention Program). These features include the following: 1) nutritional education, 2) diet and physical activity, 3) expectations for daily self-monitoring of calorie intake and activity, 4) stimulus control, behavior shaping, behavior analysis, and relapse prevention strategies, and 5) social support.
62647026|NCT02008526|EXPERIMENTAL|TXT-Auto|"Group 2: Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)~Participants assigned to this group receive automatic text-messages.~Following the initial welcome message, participants receive five pre-written messages per day sent on a predetermined schedule.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
62647027|NCT02008526|NO_INTERVENTION|Assessment Only (AO)|During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
62647028|NCT02121977|ACTIVE_COMPARATOR|Elevate Anterior and Apical|Prolapse repair with mesh
62647029|NCT02121977|ACTIVE_COMPARATOR|Native Tissue Repair|Prolapse repair with sutures
62457305|NCT02786238|EXPERIMENTAL|Acceptance-Based Treatment (ABT)|"The Acceptance-Based Treatment (ABT) group will receive most features listed in the SBT arm as well as unique ABT training designed to help individuals increase awareness of their cognitive and affective experiences, and the following exercises: 1) identifying weight-related goals from personal life values (e.g., health) and connecting these values to day-to-day eating, 2) increasing awareness of moment-by-moment behavior choices, 3) tolerating aversive internal states that include eating-related states as well as affective states such as stress, sadness, and anxiety (i.e., urge-surfing). These strategies that have been empirically tested and found to be effective in the NIH-funded Mind Your Health RCT (R21DK080430)."
62647030|NCT06047405|ACTIVE_COMPARATOR|Average Volume-Assured Pressure Support (AVAPS)|Average Volume-Assured Pressure Support (AVAPS) setting on the noninvasive ventilator. The exact AVAPS setting will be titrated by the clinical team involved directly in the patient's care based on patient comfort and clinical response.
62647031|NCT06047405|ACTIVE_COMPARATOR|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T) setting on the noninvasive ventilator. The exact BIPAP S/T setting will be titrated by the clinical team involved directly in the patient's care based on patient comfort and clinical response.
62647032|NCT04386447|EXPERIMENTAL|Oxytocin 40 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
62457306|NCT00847548|EXPERIMENTAL|combined treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
62457307|NCT00847548|ACTIVE_COMPARATOR|control condition|Cognitive behavioral therapy addressing partner violence
62457308|NCT05475353|ACTIVE_COMPARATOR|Asyncronized Exercise Group|- Ergonomics awareness education and exercise suggestions
62457309|NCT05475353|EXPERIMENTAL|Syncronized Exercise Group|- Ergonomics awareness education and than 6 weeks online supervised exercise training
62457310|NCT01611389|EXPERIMENTAL|Long AV delay.|
62457311|NCT01611389|ACTIVE_COMPARATOR|Short AV delay.|
62457312|NCT04465409|EXPERIMENTAL|Presbyopic adults|"Presbyopic adults, male or female between 40-65 years of age who need from +1.25 D to +3.50 D of reading addition in the non-dominant eye to improve near visual acuity by at least one line or more.~In this investigation, CorVision® will be implanted in the non-dominant eye to improve near vision and the dominant eye is left intact or corrected by a standard refractive surgery to emmetropia. In brief, subjects will undergo laser corneal surgery on their non-dominant eye to create an anterior stromal pocket into which the investigational device will be implanted."
62457313|NCT01701726|EXPERIMENTAL|Acupuncture|Two types of acupuncture are given, one is acupuncture at affected meridian points, the other is at non-affected. For the first type, We select the acupoints from the affected meridians.Patients in this group are divided into two subgroups according meridian syndrome differentiation(jue-yin style,yang-ming style).Patients pertaining to Jue-yin-style are treated with taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6) .Patients pertaining to Yang-ming-style: taichong(LR3), renying(ST9), zusanli(ST36), quchi(LI11). For the second,We select the acupoints from the non-affected meridians.Patients assigned into the non-affected meridian acupuncture group will be treated with Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), xuehai (SP10).
62457314|NCT01701726|SHAM_COMPARATOR|Sham acupuncture|"we use sham acupoints:~1. The edge of the tibia (1-2cm lateral and horizontal to the zusanli (ST36))~2. Half way between the tip of the elbow and the axilla~3. On the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.~4. 2cm superior to fu tu(LI18)"
62457315|NCT01701726|NO_INTERVENTION|Waiting list|Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
62457316|NCT01229852|EXPERIMENTAL|Active DSF-rTMS|Active rTMS treatment.
62457317|NCT03535168|EXPERIMENTAL|Dose 1 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.
62457318|NCT03535168|EXPERIMENTAL|Dose 2 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.
62457319|NCT03535168|EXPERIMENTAL|Dose 3 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.
62078586|NCT03490903|EXPERIMENTAL|VR with or without Moderate Sedation|"Patients randomized to receive a Virtual Reality Intervention will be fitted with a VR headset and headphones and undergo a continuous immersive meditation experience. This will begin immediately prior to the start of the procedure, and continue until the procedure is completed.~Patient pain and anxiety levels will be frequently assessed by procedure operator and circulating nurse, and pain medication or anxiolytic medications will be administered in the absence of contraindications. Baseline amounts of sedation pre-procedurally will not be used in either arm. Pain and Anxiety Scores will be assessed pre, intra, and post-procedurally. If no contraindications, the operator will decide upon how much sedation medication to administer if indicated or requested. This is the usual manner in which pain and anxiety is treated in the cath lab."
62457320|NCT03535168|EXPERIMENTAL|Matching placebo|Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.
62078587|NCT03490903|ACTIVE_COMPARATOR|Moderate Sedation without VR|Subjects randomized to the comparison arm will not undergo the Virtual Reality Intervention. Baseline amounts of sedation pre-procedurally will not be used in either arm. Subjects will be assessed periodically by physicians and/or circulating nurses for their pain and anxiety levels. The patient may also prompt the staff that they are anxious or in pain, and if no contraindications, the operator will decide upon how much medication to administer. This is the usual manner in which pain and anxiety is treated in the cath lab.
62078588|NCT02065570|EXPERIMENTAL|Induction: Standard Induction Dose|Participants randomized to receive received blinded adalimumab 160 mg at Baseline and matching placebo at Week 1, adalimumab 80 mg and matching placebo at Week 2, matching placebo at Week 3, and then adalimumab 40 mg every other week (eow) starting at Week 4 through Week 12.
62457321|NCT03535168|EXPERIMENTAL|BAY1902607+Matching Placebo|"Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo"
62457322|NCT03535168|EXPERIMENTAL|Matching Placebo+BAY1902607|"Part 2:~Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607"
62457323|NCT03072680|EXPERIMENTAL|BPS PAST + BPS FUT|Participants practice BPS PAST the first week, then they switch fot BPS FUT.
62457324|NCT03072680|EXPERIMENTAL|BPS FUT|Participants practice BPS FUT during the two weeks.
62457325|NCT03072680|ACTIVE_COMPARATOR|CONTROL|Participants practice DAILY ACTIVITIES for the two weeks.
62457326|NCT03834805|EXPERIMENTAL|Pregnant women with a normal pregnancy|Assesment of fetal lung and liver stiffness with 2D Ultrasounds Shear Wave Elastography
62457327|NCT06058728||Part 1 - Oriahnn Exposure Cohort|Participants prescribed Oriahnn for management of heavy menstrual bleeding (HMB) due to uterine fibroids (UF).
62457328|NCT06058728||Part 2 - Nested Hair Loss Cohort|Participants prescribed Oriahnn for management of HMB due to UF, with meaningful hair loss.
62457329|NCT02456493||increased carotid IMT group|Patients who have increased carotid IMT (intima media thickness)
62457330|NCT02456493||normal carotid IMT group|Patients who have normal carotid IMT
62078589|NCT02065570|EXPERIMENTAL|Induction: Higher Induction Dose|Participants randomized to receive blinded adalimumab 160 mg at Baseline, Week 1, Week 2, and Week 3. At Week 4, participants receive adalimumab 40 mg eow through Week 12.
62457331|NCT04352361|EXPERIMENTAL|TVB-2640 tablets|
62457332|NCT04352361|PLACEBO_COMPARATOR|placebo|
62457333|NCT05229757|EXPERIMENTAL|Study Group|Children with cerebral palsy in the patient group received treatment in a special education and rehabilitation center two days a week for 8 weeks.
62457334|NCT05229757|ACTIVE_COMPARATOR|Control Group|Individuals in the control group were followed with a home program for 8 weeks.
62457335|NCT06497153||sickle cell anaemia patients with acute chest syndrome|
62457336|NCT03204526|EXPERIMENTAL|low frequency stimulation (LFS)|Low-frequency deep brain stimulation of the subthalamic nucleus
62457337|NCT03184441|EXPERIMENTAL|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
62457338|NCT04460105|EXPERIMENTAL|Lanadelumab|Participants receive 300 milligram (mg) of lanadelumab intravenous (IV) infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
62457339|NCT04460105|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching IV infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
62457340|NCT02368405|ACTIVE_COMPARATOR|Control|Control group will receive standard of care
62457341|NCT02368405|EXPERIMENTAL|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
62457342|NCT01513083|EXPERIMENTAL|Mild hepatic dysfunction|
62457343|NCT01513083|EXPERIMENTAL|Moderate hepatic dysfunction|
62457344|NCT01513083|EXPERIMENTAL|Normal hepatic function|
62457345|NCT02720510|ACTIVE_COMPARATOR|Arm 1 - RVD + Pan|Revlimid, Velcade, dexamethasone and Farydak
62457346|NCT02720510|ACTIVE_COMPARATOR|Arm 2 - RVD|Revlimid, Velcade and Dexamethasone
62078590|NCT02065570|EXPERIMENTAL|Maintenance: Clinically Adjusted (CA) Regimen|Participants randomized to the CA regimen receive adalimumab 40 mg eow beginning at Week 12. The adalimumab dose will be escalated to every week (ew) starting as early as Week 14 and up to Week 54 based on Crohn's Disease Activity Index (CDAI) or high-sensitivity C-reactive protein (hs-CRP) values, using results from the prior or current study visit. Once participants in the CA regimen are escalated, they remain on adalimumab 40 mg ew dosing.
62078591|NCT02065570|EXPERIMENTAL|Maintenance: Therapeutic Drug Monitoring (TDM) Regimen|At Weeks 14, 28 and 42, the adalimumab dose for participants randomized to the TDM will be determined by protocol-established dose adjustment criteria. Doses will be determined using blinded serum concentrations at the prior visit (Weeks 12, 26 and 40, respectively) as well as the CDAI or hs-CRP values from the current or prior study visit. Participants who meet criteria for dose escalation at Weeks 14, 28 or 42 will receive 40 mg ew.
62078592|NCT04453670||COVID-19 non-survivors|ICU adults who died from severe COVID-19 and in whom autopsy could be performed
62078593|NCT04113330||Study Group|Participant vaccinated with CYD Dengue Vaccine and classified as seronegative or undetermined at baseline in previous dengue studies in Colombia
62078594|NCT01439087|EXPERIMENTAL|OFDI imaging|OFDI imaging
62078595|NCT06264934||Part A|Twenty healthy participants will be recruited to examine the ability of the Z-scanner to identify healthy breast tissue and assess repeatability and reproducibility of the device.
62078596|NCT06264934||Part B|70 participants (35 benign and 35 malignant) will be recruited to investigate the ability of the Z-scanner to correctly identify and differentiate malignant and/or benign lesions from healthy breast tissue.
62078597|NCT04392440|EXPERIMENTAL|intervention|
62457347|NCT00755326|ACTIVE_COMPARATOR|Huo-Luo-Xiao-Ling|Active herb Huo-Luo-Xiao-Ling (HLXL) The subjects in the HLXL group received the medium dose of HLXL (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/day) for the subsequent 6 weeks.
62457348|NCT00755326|PLACEBO_COMPARATOR|Placebo|Placebo Huo-Luo-Xiao-Ling (HLXL): Subjects in the placebo group received an equal number of placebo capsule.
62457349|NCT02010762|ACTIVE_COMPARATOR|Vitamin D|Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection
62078598|NCT04392440|OTHER|control|Usual care
62078599|NCT02329990|ACTIVE_COMPARATOR|phosphorus|phosphorus ingestion (375mg) with each main meal ( breakfast, lunch, dinner)
62078600|NCT02329990|PLACEBO_COMPARATOR|placebo|ingestion of placebo tablets with each meal ( breakfast, lunch, dinner)
62078601|NCT05495061|EXPERIMENTAL|STN1012600 0.002%|
62078602|NCT05495061|ACTIVE_COMPARATOR|Latanoprost 0.005%|
62078603|NCT00865111|EXPERIMENTAL|A|Bupropion 150 mg Extended-Released Tablet, single dose
62078604|NCT00865111|ACTIVE_COMPARATOR|B|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
62078605|NCT02604732|ACTIVE_COMPARATOR|Patients who stop Aspirin perioperatively|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
62078606|NCT02604732|EXPERIMENTAL|Patients who continue Aspirin perioperatively|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
62078607|NCT06089421|ACTIVE_COMPARATOR|Standard of care telegenetics with a UVA genetic counselor (GC) for pre-test counseling|Pre-genetic test counselling with a genetic counselor from the University of Virginia
62457350|NCT02010762|PLACEBO_COMPARATOR|Placebo|Weekly placebo drops for 6 months following ileocoecal resection
62457351|NCT04788238|EXPERIMENTAL|Intervention group|Participants in the intervention arm will participate in the dual-task Zumba Gold (DTZ) program. They will be grouped into 10 participants per class.
62457352|NCT04788238|NO_INTERVENTION|Control group|Participants in the control group will receive health education about dementia risk reduction provided by community health nurses.
62457353|NCT06224725||The Cohort of 60-year-olds (60YO): case-cohort study design|"The project is an observational study and will employ a case-cohort design using two cohorts Swedish cohorts- The Cohort of 60-year-olds (60YO) and the Swedish Mammography Cohort (SMC).~A sub-cohorts will be randomly selected from the full cohorts (aprox n = 450 around 5 %-of the baseline population in 1997-1999, for 60YO, and 2003-2009, for SMC). All the cases of each of the diseases under investigation occurring outside the sub-cohorts will be included. The cases will include participants free of any diagnosis of each of the diseases investigated at the time of sampling. Incident cases of the diseases under investigation will be identified through linkage to the Swedish National Cancer Register, National Patient Register, Cause of Death Register and Swedish registry for cognitive/dementia disorders till the end of follow-up (2022 for both cohorts)."
62457354|NCT06224725||The Swedish Mammography Cohort (SMC)|"A case-cohort design will be employed as for 60YO cohort (see cohort label 60YO)"
62078608|NCT06089421|EXPERIMENTAL|Novel interventional arm of pre-test counseling via GIA|Pre-genetic test counselling through novel chat bot Genetic Information Assistant (GIA)
62078609|NCT03085550|NO_INTERVENTION|Control|Conventional dressings management
62078610|NCT03085550|EXPERIMENTAL|Fat grafting only|Patients will undergo conventional fat harvesting as per Coleman technique and infiltration of fat into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
62647033|NCT04386447|EXPERIMENTAL|Oxytocin 25 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
62647034|NCT04386447|OTHER|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients."
62647035|NCT05379920|EXPERIMENTAL|Concussed Participants Group 1|High Volume Group
62647036|NCT05379920|EXPERIMENTAL|Concussed Participants Group 2|Low Volume Group
62647037|NCT05379920|ACTIVE_COMPARATOR|Healthy controls Group 1|High Volume Group
62647038|NCT05379920|ACTIVE_COMPARATOR|Healthy Controls Group 2|Low Volume Group
62647039|NCT04960267|EXPERIMENTAL|Use of pre-peritoneal drainage after rTAPP|"Use of pre-peritoneal drainage after rTAPP~Outcomes will be compared with retrospective cohort from our previous experiments"
62078611|NCT03085550|EXPERIMENTAL|Fat grafting + Platelet rich plasma|Patients will undergo conventional fat harvesting as per Coleman technique. Fat will be mixed with autologous PRP and infiltrated into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
62078612|NCT05285826|EXPERIMENTAL|V503|Participants will receive a single 0.5 mL intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
62078613|NCT05285826|PLACEBO_COMPARATOR|Placebo|Participants will receive a single 0.5 mL IM injection of placebo at Day 1, Month 2, and Month 6.
62078614|NCT04723251|EXPERIMENTAL|Taking Photographs|Participants will be asked to take photos with their cell phone.
62078615|NCT00253539|EXPERIMENTAL|Arm I|Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
62078616|NCT00253539|EXPERIMENTAL|Arm II|Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
62078617|NCT00253539|PLACEBO_COMPARATOR|Arm III|Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
62078618|NCT00875849|EXPERIMENTAL|Cetuximab|
62078619|NCT05758155|EXPERIMENTAL|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
62078620|NCT05758155|EXPERIMENTAL|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
62647040|NCT02117258|EXPERIMENTAL|Z-360 60mg+Gemcitabine|Z-360 60 mg will be taken orally, twice daily (BID) after a meal.
62647041|NCT02117258|EXPERIMENTAL|Z-360 120mg+Gemcitabine|Z-360 120 mg will be taken orally, twice daily (BID) after a meal.
62647042|NCT02117258|EXPERIMENTAL|Z-360 240mg+Gemcitabine|Z-360 240 mg will be taken orally, twice daily (BID) after a meal.
62647043|NCT02117258|PLACEBO_COMPARATOR|Placebo+Gemcitabine|Placebo will be taken orally, twice daily (BID) after a meal.
62647044|NCT01020123|EXPERIMENTAL|1|AZD1656
62647045|NCT01020123|EXPERIMENTAL|2|AZD1656
62078621|NCT02753530|EXPERIMENTAL|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
62078622|NCT02753530|PLACEBO_COMPARATOR|Placebo|248 mg matching placebo 3 times daily
62457355|NCT01052090|EXPERIMENTAL|Lifestyle counseling|
62078623|NCT01721395|PLACEBO_COMPARATOR|Colored, Flavored water|The placebo will be colored to approximate the reddish amber color of the agave syrup. The placebo will use the same flavoring used in the agave syrup. The placebo will be created in a GMP facility
62078624|NCT01721395|EXPERIMENTAL|Agave Syrup|The formulation of pasteurized agave syrup consists of pasteurized agave syrup and natural flavoring.
62078625|NCT01721395|SHAM_COMPARATOR|Air-filled oral syringe|Air-filled oral syringe to match experimental and placebo arm
62078626|NCT00206960|ACTIVE_COMPARATOR|1|
62078627|NCT00206960|ACTIVE_COMPARATOR|2|
62078628|NCT00972387|ACTIVE_COMPARATOR|Order 1|Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
62078629|NCT00972387|ACTIVE_COMPARATOR|Order 2|Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
62078630|NCT00972387|ACTIVE_COMPARATOR|Order 3|Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
62078631|NCT00972387|ACTIVE_COMPARATOR|Order 4|Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
62078632|NCT06548685|OTHER|Participant 1|"Bone grafting at one site and Vegetable Ivory Bone grafting at a parallel site in a tooth socket bone preservation intervention where the drug' is the vegetable ivory bone replacement material in one site and human allograft bone graft on the other."
62647046|NCT01020123|EXPERIMENTAL|3|AZD1656
62457356|NCT03189888|OTHER|apheresis|leukapheresis in ulcerative colitis
62647047|NCT01020123|EXPERIMENTAL|4|AZD1656
62647048|NCT01020123|EXPERIMENTAL|5|AZD1656
62457357|NCT03451201|EXPERIMENTAL|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer 3 times a week for 8 weeks
62457358|NCT03451201|ACTIVE_COMPARATOR|Moderate Continuous Exercise Training|Moderate Continuous Interval Training
62457359|NCT03451201|OTHER|Non-exercise|Sedentary Type 1 Diabetes Controls.
62647049|NCT01020123|PLACEBO_COMPARATOR|6|
62647050|NCT01020123|ACTIVE_COMPARATOR|7|Glipizide administered to 1 group of patients
62647051|NCT01612663|ACTIVE_COMPARATOR|deep needle non-site specific|
62647052|NCT01612663|ACTIVE_COMPARATOR|contralateral elbow to the knee pain|
62647053|NCT01612663|ACTIVE_COMPARATOR|Energy of Living Systems Needling|
62647054|NCT01612663|PLACEBO_COMPARATOR|Sham acupuncture|
62647055|NCT03087058|EXPERIMENTAL|Cohort 1|Patiromer for age 12 to \< 18 years
62647056|NCT03087058|EXPERIMENTAL|Cohort 2|Patiromer for age 6 to \< 12 years
62647057|NCT03087058|EXPERIMENTAL|Cohort 3|Patiromer for age 2 to \< 6 years
62647058|NCT03359434|EXPERIMENTAL|Two measuring methods of blood pressure|
62078633|NCT06548685|OTHER|Participant 2|"Bone grafting at one site and Vegetable Ivory Bone grafting at a parallel site in a tooth socket bone preservation intervention where the drug' is the vegetable ivory bone replacement material in one site and human allograft bone graft on the other."
62078634|NCT06548685|OTHER|Participant 3|"Bone grafting at one site and Vegetable Ivory Bone grafting at a parallel site in a tooth socket bone preservation intervention where the drug' is the vegetable ivory bone replacement material in one site and human allograft bone graft on the other."
62647059|NCT04818944|EXPERIMENTAL|Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))|Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
62647060|NCT04818944|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
62457360|NCT05266248|EXPERIMENTAL|Fed state|Standardized high fat breakfast before dosing
62457361|NCT05266248|EXPERIMENTAL|Fasted state|Remain fasted for 4 hours post-dose
62457362|NCT02626949|EXPERIMENTAL|MBSR Course|Mindfulness-Based Stress Reduction Course (MBSR) consisting of 8 weekly sessions, 2.5 hours each, and a 5 hour silent retreat during the 6th week of the program.
62457363|NCT02626949|EXPERIMENTAL|HEP Course|Health Enhancement Program (HEP) consisting of 8 weekly sessions, 2.5 hours each, and 1.5 hour monthly educational sessions after the 8 week intervention.
62457364|NCT00379756|ACTIVE_COMPARATOR|Levitra|10mg x 4 weeks, with option to increase to 20mg aat that time if desired
62457365|NCT00379756|PLACEBO_COMPARATOR|placebo|
62457366|NCT03678636|EXPERIMENTAL|Intervention|The wound will be treated with a silver antimicrobial dressing appropriate for the exudate level as per manufacturer instructions for use for 2 weeks +/- 3 days, in addition to any necessary standard care (e.g. compression for a venous leg wound).
62457367|NCT03678636|ACTIVE_COMPARATOR|Control|The wound will be treated as per usual care.
62647061|NCT01717222|ACTIVE_COMPARATOR|Intraperitoneal (IP) group|Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
62647062|NCT01717222|ACTIVE_COMPARATOR|Intravenous (IV) group|Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.
62647063|NCT02737267|EXPERIMENTAL|Moderately high protein diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 40% of the energy derived from carbohydrates, 30% of the energy derived from protein and 30% of the energy derived from fat
62647064|NCT02737267|PLACEBO_COMPARATOR|Low fat diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 60% of the energy derived from carbohydrates, 18% of the energy derived from protein and 22% of the energy derived from fat
62647065|NCT01665742|ACTIVE_COMPARATOR|Anti-inflammatory supplement|"8-weeks of daily supplementation with:~1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene~in conjunction with a weight management programme"
62647066|NCT01665742|PLACEBO_COMPARATOR|Placebo supplement|"8 weeks of daily supplementation with:~1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets~in conjunction with a weight management programme"
62647067|NCT03084237|EXPERIMENTAL|HLX02+Docetaxel|HLX02+Docetaxel
62647068|NCT03084237|ACTIVE_COMPARATOR|Herceptin®+Docetaxel|Herceptin®+Docetaxel
62647069|NCT02443623|EXPERIMENTAL|Single Arm Vaccinated with ACAM2000|"* To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).~* To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data."
62647070|NCT02160938||3 year follow-up cohort|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At as close to the age of 3 as possible, the following exams will be performed and are described below:~* The Vineland-II Adaptive Behavior Scale (VABS)~* Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~* Children will also be photographed (for review by the study dysmorphologist)"
62647071|NCT02160938||Limited follow-up cohort|Women with children who will not reach the age of 2 years 6 months by the end of our study but have a prenatally diagnosed CNV will be recruited into the limited follow-up study. Each center will describe the study to eligible women and will verbally obtain their permission to be contacted by the Study Follow-up Specialist. The Study Follow-Up Specialist will contact the patient, explain the study, and obtain full written informed consent.
62457368|NCT00449878|EXPERIMENTAL|Liprotamase|"Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units).~Open Label Period: Liprotamase administered orally with each of three meals and two snacks daily for 21 days.~Double Blind Treatment Period: Administered orally with each of three meals and two snacks daily for 6 days.~Second Open Label Period: Administered orally with each of three meals and two snacks daily for 7 days."
62647072|NCT05514366|EXPERIMENTAL|End inspiratory pause under tOLA|"Application of four different end inspiratory pauses (EIP) corresponding to 10, 20, 30 and 40% of inspiratory time.~Phase 1) before the application of pneumoperitoneum and forced trendelenburg. Phase 2) during the application of pneumoperitoneum and forced trendelenburg. During both phases, all patients will be ventilated under a tOLA strategy (see Study Description section)."
62647073|NCT02111200|ACTIVE_COMPARATOR|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
62647074|NCT02111200|ACTIVE_COMPARATOR|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
62647075|NCT02111200|ACTIVE_COMPARATOR|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
62647076|NCT06472739|EXPERIMENTAL|GM-CSF group|Patients use GM-CSF mouthwash four times per day during radiotherpay.
62647077|NCT06472739|NO_INTERVENTION|Convertional care group|Patients receive convertional care during radiotherapy.
62078635|NCT06548685|OTHER|Participant 4|"Bone grafting at one site and Vegetable Ivory Bone grafting at a parallel site in a tooth socket bone preservation intervention where the drug' is the vegetable ivory bone replacement material in one site and human allograft bone graft on the other."
62457369|NCT00449878|PLACEBO_COMPARATOR|Placebo|Double Blind Treatment Period: Placebo (microcrystalline cellulose) administered orally with each of three meals and two snacks daily for 6 days.
62078636|NCT06548685|OTHER|Participant 5|"Bone grafting at one site and Vegetable Ivory Bone grafting at a parallel site in a tooth socket bone preservation intervention where the drug' is the vegetable ivory bone replacement material in one site and human allograft bone graft on the other."
62457370|NCT06137677|EXPERIMENTAL|Sweet Snack|A sweet food will be served as the snack
62457371|NCT06137677|EXPERIMENTAL|Savory Snack|A savory food will be served as the snack
62647078|NCT03916588||Memory Care Unit Residents|Residents on a locked memory care unit in southeastern Louisiana will be enrolled. Engaged family members and staff will also consent to provide qualitative information on the resident.
62647079|NCT05716334||Rituximab originator recipients|Patients aged ≥18 with a diagnosis of GPA or MPA treated with rituximab (RTX) originator for induction and/or maintenance.
62647080|NCT05716334||Rituximab biosimilar recipients|Patients aged ≥18 with a diagnosis of GPA or MPA treated with RTX biosimilars (e.g. Ruxience, Truxima, Riximyo, etc) for induction and/or maintenance.
62647081|NCT04668690|EXPERIMENTAL|Experimental: Mitoxantrone Hydrochloride Liposome Injection|Patients with relapsed/refractory PTCL will receive Mitoxantrone Hydrochloride Liposome Injection every 28 days (a cycle) for a maximum of 8 cycles. The dose of Mitoxantrone Hydrochloride Liposome Injection is 20 mg/m2.
62647082|NCT04668690|ACTIVE_COMPARATOR|Active Comparator: Chidamide|Patients with relapsed/refractory PTCL will receive Chidamide 30 mg p.o., twice per week until disease progression.
62457372|NCT05770726|ACTIVE_COMPARATOR|probiotics-spray (PS) group|In the PS group, the colonoscopic prescription of 10 grams of probiotics powder is performed once on one of the first three days (D0-D3).
62457373|NCT05770726|ACTIVE_COMPARATOR|probiotics-oral (PO) group|In the PO group, we will prescribe oral probiotics 2 capsules once per day for 5 days (a total of 10 grams) as adjunctive treatment during the first five days (D0-D4).
62647083|NCT03362944|EXPERIMENTAL|Active Music Therapy|
62647084|NCT03362944|EXPERIMENTAL|Passive Music Therapy|
62078637|NCT05595330|EXPERIMENTAL|intervention group|Patients in the intervention group were managed with an upper extremity lymphedema prevention program.
62078638|NCT05595330|NO_INTERVENTION|control group|The control group received normal perioperative and chemotherapy nursing measures
62647085|NCT03082508|EXPERIMENTAL|Algisyl|Algisyl device (implants) administered during a surgical procedure.
62647086|NCT03082508|ACTIVE_COMPARATOR|Standard Medical Therapy|as per protocol
62647087|NCT05333497|EXPERIMENTAL|Programmed acupiont stimulation group|"On the basis of routine treatment in the Department of Acupuncture, the fourth generation of low-frequency acupoint electric stimulation therapy instrument (patent No. : ZL201610793646.9) jointly developed by our research group and the Robotics Institute of Harbin Institute of Technology is used to improve the program. The output of the improved instrument program is: the patient should complete the program of reaching and retrieving, namely shoulder joint forward flexion - elbow extension - wrist dorsal extension - finger extension ( reaching for objects ), then grasping - wrist flexion - elbow flexion - shoulder joint backward extension ( retrieve objects ). All patients were in a sitting position, the wrist of the affected limb is suspended, and the other parts do not touch any plane."
62647088|NCT05333497|ACTIVE_COMPARATOR|Conventional acupiont stimulation group|On the basis of the basic treatment in the Department of Acupuncture, the output mode of the fourth generation of low-frequency acupoint electric stimulation instrument of the original program is adopted to synchronously stimulate the flexor and extensor acupoints respectively. The selection of acupoints, treatment time and course of treatment were the same as those of the programmed acupoint electric stimulation group.
62078639|NCT04883983|ACTIVE_COMPARATOR|Pain Medication as Standardly Prescribed|Patients will receive pain medication as standardly prescribed. Refills at the 2 week followup will be provided as per the standard treatment protocol.
62078640|NCT04883983|EXPERIMENTAL|Open Label Placebo|Initial post-op pain medication will be prescribed. On 2 week followup, refill request will be filled with an open label placebo.
62078641|NCT01863602||Subjects prescribed lamotrigine tablets|Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
62457374|NCT02204969|SHAM_COMPARATOR|Transcranial magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
62078642|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples, stool samples, and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 6 weeks duration but not more than 52 weeks.
62078643|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples, stool samples and intestinal biopsies from standard of care colonoscopy.
62647089|NCT05333497|NO_INTERVENTION|Healthy controls|"No treatment. Ask them to do the reaching and retrieving gross motor and record the resting brain electrical and motion state of electrical parameters. Brain electric power spectrum analysis and electromyography synergy - coherence analysis are made to evaluate the brain energy state and degree of muscle coordination, for better interpreting the movement of the central nervous system control strategy and providing a reference for the prognosis of patients and the curative effect evaluation."
62647090|NCT00869414|ACTIVE_COMPARATOR|insulin glargine only in morning|Morning only administration of insulin glargine
62078644|NCT05643482|EXPERIMENTAL|HBOT Arm|Pressurized at 2.0 atmospheres absolute of pressure (ATA) Breathe 100% oxygen 90 minute session, 5 days per week, for 20 sessions
62078645|NCT05643482|SHAM_COMPARATOR|Control Arm|Placebo Gas Pressurized at 2.0 ATA Breathe placebo gas system of 10.5% oxygen and 89.5% nitrogen to mimic the partial pressure of oxygen breathed in regular air at sea level pressure 90 minute session, 5 days per week, for 20 sessions
62078646|NCT00581113|ACTIVE_COMPARATOR|1|Standard Whole Brain Radiotherapy
62078647|NCT00581113|EXPERIMENTAL|2|Neural Stem Cell-Preserving Whole Brain Radiotherapy
62078648|NCT01425632|EXPERIMENTAL|TAU-284 Low|
62078649|NCT01425632|EXPERIMENTAL|TAU-284 High|
62078650|NCT01425632|PLACEBO_COMPARATOR|Placebo|
62078651|NCT02126787|EXPERIMENTAL|Intensive Group Analytic Psychotherapy|Intensive Group Analytic Psychotherapy in a day clinic setting
62078652|NCT02126787|EXPERIMENTAL|Intensive GCBT|Intensive transdiagnostic cognitive-behavioral group therapy in a day clinic setting
62078653|NCT02126787|NO_INTERVENTION|Wait-list control group|
62457375|NCT02204969|PLACEBO_COMPARATOR|lithia water|"* Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~* Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
62078654|NCT02231372||chronic obstructive airways disease patients|
62457376|NCT02979353|EXPERIMENTAL|Shed-Meds: A Patient-Centered Deprescribing Intervention|Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
62647091|NCT00869414|ACTIVE_COMPARATOR|insulin glargine only at evening|Evening only administration of insulin glargine
62647092|NCT00869414|ACTIVE_COMPARATOR|split dose insulin glargine|Split dose administration of insulin glargine, half dose in morning, half dose in evening
62647093|NCT00634517|EXPERIMENTAL|T|Armstrong Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
62647094|NCT00634517|ACTIVE_COMPARATOR|R|Proventil-HFA, Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
62647095|NCT02528474|EXPERIMENTAL|Pantera Lux|
62647096|NCT02528474|ACTIVE_COMPARATOR|SeQuent Please|
62647097|NCT03194334|NO_INTERVENTION|Control|continued their omnivorous diet throughout the entire study
62078655|NCT04161599|EXPERIMENTAL|Oral + Parenteral prophylaxis + Mechanical Bowel Preparation|"Drug: Extra dosage - cefuroxime (750mg) I.V~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Sodium picosulfate, magnesium oxide, citric acid anhydrous 15.08 g oral An oral laxative for bowel cleansing (2 doses) the day before surgery.~Drug: Metronidazole 1 g Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
62457377|NCT02979353|NO_INTERVENTION|Control Group|Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.
62457378|NCT02377336|EXPERIMENTAL|GS-6615|GS-6615 30 mg (5 x 6 mg) on Day 1, followed by 6 mg twice daily
62647098|NCT03194334|EXPERIMENTAL|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
62078656|NCT04161599|ACTIVE_COMPARATOR|Oral + Parenteral prophylaxis|"Drug: Extra dosage - cefuroxime (750mg) I.V In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Metronidazole 1 gr Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
62078657|NCT02258685||Cohort A1|ART-treated HIV-infected individuals with lipodystrophy
62078658|NCT02258685||Cohort A2|ART-treated HIV-infected individuals without lipodystrophy
62078659|NCT02258685||Cohort A3|HIV-1 infected individuals naïve to ART
62078660|NCT02258685||Cohort A4|HIV-1 seronegative individuals who are at a high risk for infection
62078661|NCT02258685||Cohort B1|A subset of subjects from Cohort A: ART-treated HIV-infected individuals with HIV-associated dysbiosis
62078662|NCT02258685||Cohort B2|A subset of subjects from Cohort A: ART-treated HIV-infected individuals without HIV-associated dysbiosis
62078663|NCT01013935|ACTIVE_COMPARATOR|Full CARE+ Spanish computer-counseling group|
62078664|NCT01013935|ACTIVE_COMPARATOR|Brief risk assessment study group only (control)|
62078665|NCT03941314|EXPERIMENTAL|Supera® Peripheral Stent System|Femoro-popliteal arterial stenting with Supera® Peripheral Stent System as CE-marked by the manufacturer Abbott
62078666|NCT03941314|ACTIVE_COMPARATOR|EverFlex™ Self-Expanding Peripheral Stent System|Femoro-popliteal arterial stenting with EverFlex™ Self-Expanding Peripheral Stent System with Entrust™ Delivery System or as Protégé™ EverFlex™
62457379|NCT02377336|PLACEBO_COMPARATOR|Placebo|Placebo to match GS-6615 (5 tablets) on Day 1, followed by placebo to match GS-6615 twice daily
62457380|NCT00682305|OTHER|Single-Arm|Single-Arm
62457381|NCT04366141|EXPERIMENTAL|COVID-19 barrier box intervention group|Attending anesthesiologists will use a COVID-19 barrier box for intubating the patient participants of this group.
62647099|NCT03194334|EXPERIMENTAL|Veg+ creatine and beta-alanine|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
62078667|NCT04716413|EXPERIMENTAL|Treatment|Subjects will receive dose of Dsuvia 30mcg SL (1st dose) after induction but before first incision. Post-operatively, if subject rates pain higher than 4 out of 10, subject will receive a second dose of Dsuvia 30mcg SL (sublingual). If 30 minutes after second dose, subject rates pain higher than 4 out of 10, subject will receive ibuprofen 800mg IV. If 60 minutes after second dose, subject rates pain higher than 7 out of 10, subject will receive hydromorphone 0.4 mg IV.
62647100|NCT00569985|EXPERIMENTAL|Treatment (autologous HCT)|CONDITIONING: Patients receive carmustine IV over 1-2 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANTATION: Patients undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells IV on day 0.
62078668|NCT04716413|NO_INTERVENTION|Control|Subjects will be receive routine standard of care.
62078669|NCT06355908|EXPERIMENTAL|IL13Rα2 CAR-T|Biological: IL13Rα2 CAR-T
62078670|NCT00645216|EXPERIMENTAL|CP-945,598 with Grapefruit Juice|CP-945,598 with Grapefruit Juice
62078671|NCT00645216|EXPERIMENTAL|CP-945,598 alone|CP-945,598 alone
62647101|NCT04844463|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Participants will receive a single ascending oral dose of JNJ-68179280 or placebo capsules under fasted condition (Cohort 1, 2 and 5) and under fasted-fed condition (either Cohort 3 or 4) on Day 1. In 1 of the study cohorts 3 or 4, participants will also receive study intervention on Day 8 under fed condition. One additional optional Cohort 6 may be dosed to assess the safety and pharmacokinetics (PK) of an alternate dose of formulation A under fasted condition.
62078672|NCT05409196|EXPERIMENTAL|ShigETEC vaccine|"In Stage 1 subjects will be allocated randomly to one of four study cohorts to receive a single oral dose of one of four escalating dose levels of ShigETEC vaccine (ShigETEC 1x10\^9 CFU, ShigETEC 1x10\^10 CFU, ShigETEC 5x10\^10 CFU, ShigETEC 2x10\^11 CFU). 8 subjects per dose group will be administered.~Subjects in Stage 2 will be enrolled sequentially by group and allocated randomly to one of three study cohorts determined from Stage 1 to receive either two, three or four doses of the 5x10\^10 ShigETEC vaccine at 3-day interval. 8 subjects per dose group will be administered."
62078673|NCT05409196|PLACEBO_COMPARATOR|Placebo|"In Stage 1: 4 subjects in each dose group will receive a single oral dose of placebo~In Stage 2: 4 subjects in each cohort will either receive 2, 3 or 4 doses of placebo at 3-day intervals."
62078674|NCT00746317|EXPERIMENTAL|1|
62078675|NCT02075190|EXPERIMENTAL|Treatment Group|Participants randomized to receive remediation training intervention delivered online (60 days of online training)
62078676|NCT02075190|ACTIVE_COMPARATOR|Control Group|Participants randomized to receive online gaming intervention (60 days of online play)
62078677|NCT01961713||Prostatectomy|Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
62078678|NCT02916992|ACTIVE_COMPARATOR|Spontaneous pneumothorax patients 1|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: visit to out-patient clinic,CT scan of pulmones."
62078679|NCT02916992|ACTIVE_COMPARATOR|Spontaneous pneumothorax patients 2|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: withdrawal of blood sample for DNA analyses,"
62457382|NCT04366141|NO_INTERVENTION|Control group|Attending anesthesiologists will use standard intubation procedures.
62647102|NCT04844463|EXPERIMENTAL|Part 2: Multiple Ascending Dose (MAD)|Participants will receive multiple ascending oral doses of JNJ-68179280 or placebo capsules once daily in Cohort 1 through 4 or twice daily in Cohort 5 (optional) on Days 1 through 14 under fasted or fed condition.
62647103|NCT04844463|EXPERIMENTAL|Part 3: Multiple Dose Alternative Formulation (Optional)|Participants will receive multiple oral doses of an alternative JNJ-68179280 formulation once daily in Cohort 1 and Cohort 2 (optional) on Days 1 through 14 under fasted or fed condition. Doses in Part 3 will depend on the safety, tolerability, PK and pharmacodynamics data from Part 1 and Part 2.
62078680|NCT05217823|EXPERIMENTAL|Er:YAG laser|Teeth treated with Er:YAG laser
62078681|NCT05217823|ACTIVE_COMPARATOR|Hand instruments|Teeth treated with Gracey curettes
62457383|NCT03219398|ACTIVE_COMPARATOR|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
62078682|NCT05773131|EXPERIMENTAL|VR collaborative visualization group|In this intervention system, the stimulation materials, communication interface, collaboration tasks, and immersive 360-degree scenario will be played inside a commercially available head-mounted display on the patient side, as well as these materials will be played in the smartphone on the family members' side.
62078683|NCT05773131|NO_INTERVENTION|Standard ICU Care|Patients will be treated with standard ICU care and not receive VR stimulation.
62647104|NCT05802888|EXPERIMENTAL|Tid group|Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
62647105|NCT05802888|ACTIVE_COMPARATOR|Qid group|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid
62647106|NCT04041817|EXPERIMENTAL|Trigger increasing steps|"Trigger variations will be performed following increasing steps of 2 L/min every 15 minutes. End expiratory lung volume and lung aeration will be conducted using elecrical impedance tomography. Diaphragmatic motion and thickening will be analyzed by ultrasonography. Work of breathing will be evaluated using gastric and oesophageal pressure measurements.~Measurements will be conducted during the last minute of each step."
62647107|NCT03326440|OTHER|Study Arm|Patients with a histological diagnosis of prostate cancer are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system prior to the start of Radiotherapy.
62647108|NCT03326440|OTHER|Control Arm|Patients with a histological diagnosis of prostate cancer who are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system following completion of Radiotherapy.
62078684|NCT04550273|EXPERIMENTAL|study group|The study group (n=20) will receive three sessions of aerobic walking exercise per week for 3 months in addition to the traditional medical treatment
62078685|NCT04550273|NO_INTERVENTION|control group|The control group (n=20) will receive no training
62078686|NCT01490203||Group 1: HCC resection/RFA|Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
62078687|NCT01490203||Group 2: Potential liver donor|Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
62457384|NCT03219398|ACTIVE_COMPARATOR|12-14 mmHg|Patients receive higher pneumoperitoneum pressure
62457385|NCT00101582|EXPERIMENTAL|Palifermin|Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course.
62647109|NCT02911454|EXPERIMENTAL|Healthy infants: fully or partly formula fed|
62647110|NCT02022358|ACTIVE_COMPARATOR|M|"Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy ."
62647111|NCT02022358|EXPERIMENTAL|GluM|"Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy"
62647112|NCT04147156|ACTIVE_COMPARATOR|Epley's Maneuver|Treatment of posterior canal BPPV with Epley's maneuver in the ROTUNDUM-chair.
62647113|NCT04147156|EXPERIMENTAL|Semont Maneuver|Treatment of posterior canal BPPV with the Semont maneuver in the ROTUNDUM-chair.
62647114|NCT04147156|ACTIVE_COMPARATOR|360 degree vertical rotation|Treatment of posterior canal BPPV with a 360 degree vertical rotation in the ROTUNDUM-chair.
62078688|NCT00788255||All participants|"For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows:~Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL~After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation."
62647115|NCT01921400||HCV-infected mothers|in situ hybridization
62647116|NCT01921400||Uninfected mothers|in situ hybridization
62647117|NCT02081989|EXPERIMENTAL|Denervation|Renal denervation
62647118|NCT02081989|NO_INTERVENTION|No intervention|Control group - no intervention
62647119|NCT03779269|EXPERIMENTAL|color meditation|only color meditation
62647120|NCT03779269|EXPERIMENTAL|Sound meditation|Only sound mediation
62647121|NCT03779269|EXPERIMENTAL|Color and sound combined meditation|Combined group
62078689|NCT02226172|EXPERIMENTAL|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
62078690|NCT02226172|PLACEBO_COMPARATOR|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
62078691|NCT02915575|OTHER|Control Arm (usual care)|Participants will be discharged as per usual ward discharge protocols.
62078692|NCT02915575|OTHER|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (\<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
62457386|NCT00101582|PLACEBO_COMPARATOR|Placebo|Participants received a single IV dose of placebo three days before the start of radiotherapy, and then 7 once weekly placebo doses during a 7-week radiotherapy/chemotherapy course.
62647122|NCT03779269|NO_INTERVENTION|Control group|Only control group
62647123|NCT05931263|EXPERIMENTAL|C-BEAM|Chidemide，carmustine, etoposide, cytarabine, and melphalan plus autologous stem cell transplantation
62647124|NCT05931263|SHAM_COMPARATOR|BEAM|carmustine, etoposide, cytarabine, and melphalan plus autologous stem cell transplantation
62647125|NCT05579639|EXPERIMENTAL|Xylitol|Xylitol, a naturally occurring sugar alcohol found in plums, strawberries, and various vegetables such as cauliflower, has been approved for use in food by the US FDA since 1963. Spiffies Xylitol Wipes will be used.
62647126|NCT05579639|PLACEBO_COMPARATOR|Grape-flavored Wipes|Grape-flavored wipes will be used with 2 drops of PCCA colorless grape flavoring. The grape-flavored wipes each contain a solution of 0.9% Sodium Chloride, purified water, and Benzalkonium chloride. PCCA artificial colorless grape flavoring will be used. The PCCA grape flavoring contains propylene glycol, ethyl alcohol, and artificial flavoring.
62647127|NCT00463736|ACTIVE_COMPARATOR|Magnesium sulfate|x 48 hours IV
62647128|NCT00463736|PLACEBO_COMPARATOR|Normal saline|x 48 hours IV
62078693|NCT04196374|EXPERIMENTAL|FHS & JHS participants with an actionable genomic finding|Framingham and Jackson Heart Study participants who have had their genomes sequenced as part of TOPMed will be notified if an actionable genetic result in an ACMG v2.0 gene is identified and will be offered the opportunity to have their research result clinically confirmed by the study.
62078694|NCT05297916|ACTIVE_COMPARATOR|delayed enteral feeding|delayed enteral feeding
62078695|NCT05297916|ACTIVE_COMPARATOR|early enteral feeding|early enteral feeding
62647129|NCT04074811|SHAM_COMPARATOR|Sham rTMS|Sham rTMS will be applied over the left dorsolateral prefrontal cortex using a sham figure of 8 coil (within-subject crossover). Sham rTMS will consist of the same auditory and tactile stimuli as the active condition, but does not induce an electromagnetic field and does not affect cortical excitability.
62647130|NCT04074811|ACTIVE_COMPARATOR|Active rTMS|Active rTMS will be applied over the left dorsolateral prefrontal cortex using an active figure of 8 coil (within-subject crossover). In the active rTMS condition, the investigators will use high-frequency (10Hz) dorsolateral prefrontal cortex (dlPFC) stimulation with intensity of 110% of resting motor threshold. rTMS will consist of 120 trains with 50 stimuli per train (i.e. 5-sec long at 10 Hz) and 10-sec intertrain interval for a total of 6000 pulses. The entire protocol will last 30 min (120 trains with 5-sec on/10-sec off).
62647131|NCT02774317|ACTIVE_COMPARATOR|FFP|Patients receive FFP as clinically indicated (INR 1.5 or more)
62647132|NCT02774317|EXPERIMENTAL|FP24|Patients receive FP24 as clinically indicated (INR 1.5 or more)
62078696|NCT05470413|ACTIVE_COMPARATOR|SHR0302 4 mg|Drug：SHR0302
62078697|NCT05470413|ACTIVE_COMPARATOR|SHR0302 8 mg|Drug：SHR0302
62647133|NCT01503554|EXPERIMENTAL|Social Worker + Pharmacist Intervention|Intervention arm offering enhanced services from a social worker and a pharmacist post-discharge
62647134|NCT01503554|EXPERIMENTAL|Usual Care|Patients receiving usual care will have a medication reconciliation performed by a physician or nurse during their hospital stay. No further support or interventions are provided post discharge.
62647135|NCT02776293|ACTIVE_COMPARATOR|Relaxation Group|The relaxation group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to sit undisturbed for 20 minutes.
62647136|NCT02776293|EXPERIMENTAL|Music Group|The music group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to listen to pre-recorded songs specifically composed for pregnancy.
62078698|NCT05470413|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62078699|NCT04684927|EXPERIMENTAL|MID-C treatment|Follow-up measurements during 5 years post MIC-C system implantationin order to evaluate safety and efficacy parameters.
62078700|NCT03580460|NO_INTERVENTION|Waitlist control|After 8 weeks, individuals randomized to this arm receives the computer-delivered smoking cessation counseling intervention
62078701|NCT03580460|EXPERIMENTAL|Computer Delivered Intervention|Individuals receive a 15-20 minute computer delivered smoking cessation counseling intervention
62078702|NCT01529190|ACTIVE_COMPARATOR|pregabalin 300mg|Group 1 patients will receive a single dose of 300 mg pregabalin, 1 hour before the surgical incision; group 2 patients will receive a placebo dose. Pain intensity will be assessed with the numeric rating scale. The consumption of tramadol in 24 hours after surgery and the time for the first complementation dose will be registered. Blood samples will be collected by 6 hours and 24 hours after surgical incision, for IL-6 dosage, and maintained at -70 celsus degree
62078703|NCT01529190|PLACEBO_COMPARATOR|sugar pill|group 2 will receive a placebo dose, 1 hour before tue surgical icnision
62457387|NCT00536900|EXPERIMENTAL|1|Advisor-Teller Money Manager
62457388|NCT00536900|ACTIVE_COMPARATOR|2|FIT (finance instruction therapy)
62457389|NCT03208543|EXPERIMENTAL|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
62457390|NCT00048646|PLACEBO_COMPARATOR|placebo|placebo
62457391|NCT00048646|EXPERIMENTAL|IV progesterone|IV progesterone
62457392|NCT05028842||Non Cirrhotic|Non Cirrhotic
62457393|NCT05028842||Compensated Cirrhotics|Compensated Cirrhotics
62457394|NCT05028842||Decompensated Cirrhotics|Decompensated Cirrhotics
62078704|NCT06100601|EXPERIMENTAL|Autonomic nervous system (ANS) regulation therapy|HRV biofeedback is a non-invasive intervention that focuses on increasing heart rate oscillations through real-time feedback and slow-paced breathing training (Lehrer et al., 2020; Laborde et al., 2022; Pizzoli et al., 2021). Participants will practice 20 min a day (2 sessions of 10 min) for 1 month. One weekly session will be organized in the clinic under the guidance of the therapist (individual sessions), the other sessions will be organized at home, and tracked by a chest strap heart rate monitor (Polar H10) and the Elite HRV app (elitehrv.com). First, the resonance frequency (RF) (i.e. respiration rate with the highest HRV) will be personalized for each participant. Biofeedback slow-paced breathing exercises in the app will then be customized based on this RF (40% inhale, 60% exhale: e.g. 6 bpm: 4s inhale, 6s exhale). Participants will be asked to breathe in through the nose and breathe out through pursed lips, following the breath pacer with visual feedback.
62457395|NCT05020847|ACTIVE_COMPARATOR|Standard F75|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
62457396|NCT05020847|EXPERIMENTAL|Alternative F75 with CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
62457397|NCT05020847|EXPERIMENTAL|Alternative F75 without CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
62457398|NCT01504737|EXPERIMENTAL|Supervised Exercise Training|12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
62647137|NCT02787980|OTHER|Patients = premature newborns|"Patients will consist of all premature babies (\<37 weeks of amenorrhea), managed in the first 24 hours of life at the Reims university hospital for whom parents accepted to participate in the research Additional taking blood"
62457399|NCT01504737|ACTIVE_COMPARATOR|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
62457400|NCT00571428|EXPERIMENTAL|15 mcg BID / 30 mcg QD|Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
62078705|NCT06100601|ACTIVE_COMPARATOR|conventional voice therapy (CVT)|The CVT will be based on Meerschman et al. (2019). This therapeutic program has been proven effective in voice therapy and is the standard clinical care for FD patients. The program is a combination of education, vocal hygiene, posture, local relaxation, costo-abdominal breathing, resonant voice, voice placing, forward focus, voice onset, semi-occluded vocal tract exercises and laryngeal manipulation. Identical to the ANS regulation therapy, participants will practice 20 min a day for 1 month. One weekly session will be organized in the clinic under the guidance of the therapist (individual sessions), the other sessions will be organized at home and tracked by the RedCap app.
62078706|NCT06100601|ACTIVE_COMPARATOR|ANS regulation therapy + CVT|The third group will receive a combination of both therapies. The same frequency and duration of practice (20 min a day for 1 month) will apply. They will also receive one weekly session in the clinic under the guidance of the therapist (individual sessions) and the other sessions will be completed at home, tracked by the Elite HRV app and the RedCap app.
62078707|NCT04070053|EXPERIMENTAL|TheraPPP Pathway|"We will perform a before and after study to evaluate the feasibility and acceptability of the HRF and ARDS Pathway during its pilot implementation.~All mechanically ventilated patients will enter the pathway during the one month implementation and one year post-implementation periods.~To assess Pathway feasibility we will collect patient data for approximately two years and one month: one year immediately prior to implementation, one month during, and one year following implementation.~To assess acceptability of the pathway we will conduct a survey to clinicians who used the Pathway."
62647138|NCT02787980|OTHER|"Controls = children born full term"|"For controls the participation to research would be proposed to parents of children born full term, just after each patient child included.~Additional taking blood"
62647139|NCT02360046|OTHER|Higher hydrocortisone dose|Established hydrocortisone replacement therapy plus 10mg of hydrocortisone
62647140|NCT02360046|OTHER|Lower hydrocortisone dose|Established hydrocortisone replacement therapy plus placebo
62078708|NCT00936338|ACTIVE_COMPARATOR|splint|
62078709|NCT00936338|ACTIVE_COMPARATOR|joint mobilization self exercise|
62078710|NCT02635282|ACTIVE_COMPARATOR|IN fentanyl and midazolam|group of patients who are randomized to receive intranasal fentanyl and midazolam
62078711|NCT02635282|EXPERIMENTAL|IN ketamine|group of patients who are randomized to receive intranasal ketamine
62647141|NCT00167700|EXPERIMENTAL|Probiotics|
62647142|NCT00167700|EXPERIMENTAL|Probiotics + Dietary counseling|
62647143|NCT00167700|EXPERIMENTAL|Dietary counseling + placebo|
62647144|NCT00167700|EXPERIMENTAL|Prebiotics|
62647145|NCT00167700|PLACEBO_COMPARATOR|Placebo|
62647146|NCT00167700|NO_INTERVENTION|Control|
62647147|NCT01898403|EXPERIMENTAL|Sentinel Lymph Node (SLN) Detection|All patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution for detection of melanoma in lymph nodes. In addition, lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) will be conducted for all participants with the same objective.
62647148|NCT04584814|EXPERIMENTAL|Babies born Preterm|Preterm babies, healthy at the time of the study, free of neonatal diseases and/or sequelae or malformations or genetic diseases. They were random assigned to two-hours blocks of basal, and dorsal stimulation protocol at 20 or 40 times per minute, each.
62647149|NCT01911247|EXPERIMENTAL|Arm 1|
62647150|NCT02959801|EXPERIMENTAL|Percutaneous Mechanical Thrombectomy|Percutaneous mechanical thrombectomy（PMT）uses a number of catheter-based mechanical devices to deliver the thrombolytic agent as well as to produce some combination of thrombus fragmentation, distribution of thrombolytic drugs throughout the thrombus, and/or thrombus aspiration.
62078712|NCT04448431|EXPERIMENTAL|Vortioxetine|8 weeks treatment
62078713|NCT04448431|ACTIVE_COMPARATOR|Desvenlafaxine|8 weeks treatment
62078714|NCT05538481||Focus Group|A total of 16 participants, including patients and caregivers, will be enrolled for 2 focus groups (group of 8 patients with cancer and group of 8 caregivers).
62078715|NCT05538481||Cognitive Interviews Group|A total of up to 30 participants will be enrolled in this cohort, and up to 3 rounds of cognitive interviews will be conducted. This cohort of participants will be enrolled after survey development based on the themes identified from the focus group analyses.
62647151|NCT01819675|EXPERIMENTAL|High frequency (10Hz) rTMS|\<high frequency rTMS parameters\> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
62078716|NCT03262701|EXPERIMENTAL|Hydrogen Peroxide gel for 13weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 13 weeks.
62078717|NCT03262701|EXPERIMENTAL|Hydrogen Peroxide gel for 26weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 26 weeks.
62457401|NCT00571428|EXPERIMENTAL|30 mcg QD / 15 mcg BID|Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.
62457402|NCT01345149|EXPERIMENTAL|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
62647152|NCT01819675|EXPERIMENTAL|Low frequency (1Hz) rTMS|\<low frequency rTMS parameters\> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
62647153|NCT01819675|SHAM_COMPARATOR|Sham rTMS|\<Sham rTMS parameters\> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp
62647154|NCT01717495||Implantation Procedures|Patients submitted to initial pacemaker or ICD implantation
62647155|NCT01717495||Reoperation Procedures|Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
62647156|NCT06200532|EXPERIMENTAL|Single cohort of people using home footwear self-assessment kit|"FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. This feasibility study aims to determine whether people with diabetes and their footwear buddies can use FOOTSAK with sufficient (1) accuracy, (2) reliability and (3) ease of use to identify incorrectly fitting footwear (IFF).~We will recruit ten people with type 1 or 2 diabetes without any minor or major toe or foot amputation to use the FOOTSAK. Given that foot measurements have to be made whilst standing (to ensure full blood flow to feet during measurements), we will also recruit ten 'Footwear buddies' - people with or without diabetes willing to measure the feet of participating people with diabetes (for example, a spouse, partner, carer, friend, neighbour, or housemate)."
62647157|NCT02861313|EXPERIMENTAL|CM LOC attachment|CM LOC attachment other names: resin matrix attachment
62647158|NCT02861313|ACTIVE_COMPARATOR|ball attachment|ball attachment other names metallic ball attachment
62647159|NCT05498389|EXPERIMENTAL|Part 1 Dose Escalation (Phase Ib), Part 2 Dose Expansion (Phase II)|"In Part 1 dose escalation, patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached, or all planned doses are administered.~In Part 2 dose expansion, patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28 at the recommended phase II dose (RP2D) regimen. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity."
62647160|NCT01535118||Adults and Children with Allergic Rhinoconjunctivitis (ARC)|Adults and children with ARC who complete the survey
62647161|NCT06101238|EXPERIMENTAL|Iron Supplementation|
62647162|NCT06101238|NO_INTERVENTION|Standard of Care|
62647163|NCT03795506|EXPERIMENTAL|Active TLA Device|12 week overnight treatment with the active Temperature Controlled Laminar Airflow device.
62078718|NCT03262701|OTHER|Scaling and Root Planing|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without any interventional hydrogen peroxide application in one or two visits.
62078719|NCT01503138|EXPERIMENTAL|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
62078720|NCT01503138|NO_INTERVENTION|Standard community health education program|The community health education programme consists of two group sessions with one on the topic of osteoporosis and one on dietary therapy based on the concepts of Chinese medicine.
62647164|NCT03795506|PLACEBO_COMPARATOR|Placebo TLA Device|12 week overnight treatment with the placebo Temperature Controlled Laminar Airflow device.
62647165|NCT03766035||Consented, enrolled PSC patients undergoing ERCP + SpyGlass|Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.
62647166|NCT03384199|EXPERIMENTAL|Dose escaltion|insertion of 3 fiducial markers, prostate will receive 78 Gy with dose escalation to prostate focal lesion up to 87 Gy
62078721|NCT02864511|EXPERIMENTAL|Intervention group|
62078722|NCT04472780|EXPERIMENTAL|HBOT Group|will benefit from HBOT
62078723|NCT04472780|NO_INTERVENTION|Control group|will benefit from the conventional treatment
62078724|NCT03923361|EXPERIMENTAL|Propofol|
62078725|NCT05255484|EXPERIMENTAL|LM-108 Dose Escalation|Drug: LM-108 Administered intravenously
62078726|NCT05255484|EXPERIMENTAL|LM-108 Dose Expansion|Drug: LM-108 Administered intravenously
62078727|NCT05255484|EXPERIMENTAL|LM-108 Combination Dose Escalation|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
62078728|NCT05255484|EXPERIMENTAL|LM-108 Combination Dose Expansion|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
62457403|NCT01345149|EXPERIMENTAL|Exercise|Exercise: Individual counselling
62647167|NCT01896063|EXPERIMENTAL|Electroacupuncture preconditioning|
62647168|NCT03670992||Pancreatic Metastases|Patients with only pancreatic metastases from RCC
62647169|NCT03670992||extra-pancreatic metastases|patients with extra pancreatic metastases from RCC
62647170|NCT01338688||Td ,Td and TIG|
62647171|NCT03711890|EXPERIMENTAL|Diagnostic (resection, OCT)|Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
62647172|NCT05233735|OTHER|topical treatment|Topical Betamethasone for the Treatment of Vitiligo Disease
62647173|NCT05233735|EXPERIMENTAL|Enhanced Transcutaneous Delivery|Enhanced Transcutaneous Delivery of Topical Betamethasone after a treatment with Tixel device for the Treatment of Vitiligo Disease
62647174|NCT02687802||Mechanical ventilation|Patients under mechanical ventilation for more than 24h
62647175|NCT03962400|ACTIVE_COMPARATOR|Control|Subjects will have warfarin dose determined in the usual fashion by a health care provider.
62078729|NCT04181398|EXPERIMENTAL|Baseline high hs-CRP|"Anthropometry:~* Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio.~Blood pressure (mean of 3 measurements)~Peripheral arterial tonometry~Questionnaire~Blood sample (hsCRP)"
62078730|NCT04181398|EXPERIMENTAL|Baseline low hs-CRP|"Anthropometry:~* Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio.~Blood pressure (mean of 3 measurements)~Peripheral arterial tonometry~Questionnaire~Blood sample (hsCRP)"
62078731|NCT01346670|EXPERIMENTAL|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor Tablet after single oral administration in healthy subjects using a 2x2 crossover design
62078732|NCT05221749|ACTIVE_COMPARATOR|Silver diamine fluoride|These active caries lesions will receive silver diamine fluoride treatment
62078733|NCT05221749|EXPERIMENTAL|Nanosilver fluoride|These active caries lesions will receive nanosilver fluoride treatment
62078734|NCT03364439|EXPERIMENTAL|One arm for all patients|Patients eligible for the study will receive 6 courses of R-CHOP14 or R-CHOP21.
62078735|NCT05709691|EXPERIMENTAL|Experimental|Oculomotor therapy and adapted yoga.
62078736|NCT05709691|ACTIVE_COMPARATOR|Active Comparator|Adapted yoga.
62078737|NCT02676986|ACTIVE_COMPARATOR|Cohort I (ER positive cohort)|Approximately 180 patients with ER positive breast cancer will be randomised 2:1 in favour of enzalutamide to receive enzalutamide plus exemestane or exemestane alone.
62647176|NCT03962400|EXPERIMENTAL|Treatment|Subjects will have warfarin dose determined using a reinforcement learning computer model.
62647177|NCT04539275|EXPERIMENTAL|Convalescent Plasma|The study intervention consists of intravenous administration of 200-500 mL of convalescent plasma administered in two equally divided doses, less than 12 hours apart.
62647178|NCT04539275|PLACEBO_COMPARATOR|Masked Saline Placebo|The study intervention consists of intravenous administration of 200-500 mL of 0.9% saline administered in two equally divided doses, less than 12 hours apart.
62647179|NCT04182919|EXPERIMENTAL|Arm 1|Phlai 2 capsules (compound D 8 mg) od evening after meal x 4 weeks
62647180|NCT04182919|EXPERIMENTAL|Arm 2|Phlai 1 capsules (compound D 4 mg) and placebo 1 capsule od evening after meal x 4 weeks
62647181|NCT04182919|PLACEBO_COMPARATOR|Arm 3|Placebo 2 capsules od evening after meal x 4 weeks
62647182|NCT05239572|EXPERIMENTAL|Screening and early detection of diabetes and cardiovascular diseases|"Screening for NCDs based on questionnaire concerning vital information, lifestyle, simple measures of length, bodyweight, BMI, blood pressure, application of FinRisk score and WHO risk score.~Health promotion and lifestyle counselling and referral to PHC facilities for further diagnosis and treatment."
62647183|NCT06026436|EXPERIMENTAL|CKD patients|
62647184|NCT02951312|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
62647185|NCT02951312|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
62647186|NCT02951312|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
62647187|NCT02951312|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
62647188|NCT02951312|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
62647189|NCT02951312|EXPERIMENTAL|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
62647190|NCT02951312|PLACEBO_COMPARATOR|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
62647191|NCT02917746|EXPERIMENTAL|Imiquimod treatment arm|Treatment by vaginal imiquimod cream during 16 weeks.
62647192|NCT02917746|ACTIVE_COMPARATOR|Standard treatment arm|Treatment by large loop excision of the transformation zone.
62647193|NCT00921323|PLACEBO_COMPARATOR|Control|The control group will be advised to continue to be physically active and record daily steps
62647194|NCT00921323|ACTIVE_COMPARATOR|Goal-setting group|This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months.
62647195|NCT01254500||patients with brain lesions|
62647196|NCT01254500||young normal controls|
62078738|NCT02676986|ACTIVE_COMPARATOR|Cohort II (AR positive, TNBC cohort)|55 patients with AR positive, TNBC will receive single agent treatment with enzalutamide.
62457404|NCT01345149|NO_INTERVENTION|Control|Standard treatment without intervention.
62078739|NCT05034224|SHAM_COMPARATOR|Sham|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is kept deflated.
62457405|NCT03673488||TephaFlex™ mid-urethral sling for SUI|P4HB material ( TephaFlex ™) will be implanted in 25 women with confirmed Stress Urinary Incontinence (SUI).
62078740|NCT05034224|ACTIVE_COMPARATOR|Coronary sinus occlusion|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is inflated.
62647197|NCT01254500||old normal controls|
62647198|NCT02554396|EXPERIMENTAL|PRX-100|PRX-100 ophthalmic solution
62647199|NCT02554396|PLACEBO_COMPARATOR|Placebo|saline solution
62647200|NCT01075048|EXPERIMENTAL|Phase 2: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
62647201|NCT01075048|PLACEBO_COMPARATOR|Phase 2: Placebo, cetuximab, irinotecan|Placebo in combination with irinotecan and cetuximab
62647202|NCT01075048|EXPERIMENTAL|Phase 1: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
62647203|NCT04919317|PLACEBO_COMPARATOR|Control|Control group patients received 29mL bupivacaine plus 1mL 0.9% saline. Like the experimental group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
62647204|NCT04919317|EXPERIMENTAL|Experimental|Experimental group patients received 29mL bupivacaine plus 1mL of 4mg/mL dexamethasone. Like the control group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
62647205|NCT01531426||NIRS continuous monitoring|
62647206|NCT06174285|EXPERIMENTAL|Psyrreal|Psychedelic virtual reality experience.
62647207|NCT06174285|SHAM_COMPARATOR|Routine Realms|A non-psychedelic virtual reality experience that is largely analogous to Psyrreal.
62647208|NCT06174285|NO_INTERVENTION|No intervention|A conditional waiting list condition. This condition may be included, dependent on the availability of sufficient participants and resources.
62078741|NCT00398398|EXPERIMENTAL|Capecitbine, oxaliplatin, cetuximab|Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
62647209|NCT02953730|EXPERIMENTAL|PEG-rhG-CSF|
62647210|NCT03531749|EXPERIMENTAL|HIV+ MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
62647211|NCT03531749|EXPERIMENTAL|HIV+ ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90 days
62647212|NCT03531749|EXPERIMENTAL|HIV- MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
62647213|NCT03531749|EXPERIMENTAL|HIV- ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90
62078742|NCT06078592|EXPERIMENTAL|BRIDIN-plus Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
62647214|NCT03531749|NO_INTERVENTION|HIV- Control|Unsupplemented
62647215|NCT03531749|NO_INTERVENTION|HIV+ Control|Unsupplemented
62647216|NCT04006145|EXPERIMENTAL|Elobixibat|Elobixibat 5 mg once daily
62647217|NCT04006145|PLACEBO_COMPARATOR|Placebo|Placebo
62647218|NCT00580320|EXPERIMENTAL|A|dacarbazine + bortezomib
62647219|NCT06120608|EXPERIMENTAL|Restriction high bioavailability potassium sources|Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
62078743|NCT06078592|ACTIVE_COMPARATOR|Combigan Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
62078744|NCT03000673|ACTIVE_COMPARATOR|Dose Sequence 1|UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
62647220|NCT06120608|ACTIVE_COMPARATOR|Control|Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
62647221|NCT04215367|EXPERIMENTAL|High phenolic EVOO intake|Patients with CLL consumed before their meals, 40 ml/day of EVOO rich in oleocanthal and oleacin for 6 months,
62647222|NCT04215367|EXPERIMENTAL|No High phenolic EVOO intake|Patient's history were recorded for third and sixth month before dietary the intervention, taking into consideration that the patients did'nt consume high phenolic EVOO.
62647223|NCT03879070|EXPERIMENTAL|Intervention group|
62647224|NCT03879070|NO_INTERVENTION|Control group|
62647225|NCT04237363|EXPERIMENTAL|Exercise|Walk training
62647226|NCT03650153|ACTIVE_COMPARATOR|Trans-rectal MRI targeted Biopsy|Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
62647227|NCT03650153|ACTIVE_COMPARATOR|Trans-perineal MRI targeted Biopsy|Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
62647228|NCT04415801|EXPERIMENTAL|Implant abutments|implant abutments
62078745|NCT03000673|ACTIVE_COMPARATOR|Dose Sequence 2|BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
62647229|NCT04381065|EXPERIMENTAL|PKG+ Group|For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is in the target range or out of the target range based on scores provided by the PKG.
62647230|NCT04381065|PLACEBO_COMPARATOR|PKG- Group|For subjects in the PKG- Group, participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
62078746|NCT03000673|ACTIVE_COMPARATOR|Dose Sequence 3|BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
62078747|NCT03000673|ACTIVE_COMPARATOR|Dose Sequence 4|Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
62078748|NCT04005729|EXPERIMENTAL|Cangrelor + Ticagrelor|Bolus of cangrelor (30 mcg/kg) and immediately afterwards a continuous intravenous infusion of 4 mcg/kg/min at the start of the primary percutaneous coronary intervention. Crushed and dissolved ticagrelor tablets (180 mg) will be given via inserted enteral tube.
62078749|NCT04005729|NO_INTERVENTION|Ticagrelor|Crushed and dissolved ticagrelor tablets (180 mg) will be given via enteral tube (standard care).
62078750|NCT00492843|EXPERIMENTAL|A|Intravenous infusion of either 6mg Bondronat on three consecutive days
62078751|NCT00492843|ACTIVE_COMPARATOR|B|Intravenous infusion of 6mg Bondronat on one day
62647231|NCT00001566|EXPERIMENTAL|Peptide vaccine/autologous T cell transplant/indinavir therapy|Patients receive oral indinavir sulfate 350 mg/m\^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10\^6 injection; harvested autologous T cells (minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
62647232|NCT03598426|ACTIVE_COMPARATOR|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
62078752|NCT02126436|ACTIVE_COMPARATOR|Acupuncture|"Eight treatments of acupuncture will be given to participants twice weekly over four weeks. A combination of body and auricular acupuncture will be given and treatment will be pragmatic.~In addition the group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff)."
62078753|NCT02126436|OTHER|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
62647233|NCT03598426|ACTIVE_COMPARATOR|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
62647234|NCT03598426|ACTIVE_COMPARATOR|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
62647235|NCT02905162||HIV positive individuals incarcerated at Lusaka Central Prison|Cohort of individuals scheduled for release within 30 days will be followed for 6 months post release
62647236|NCT04460053|EXPERIMENTAL|Neurofilament light protein measurement|Neurofilament light protein measurements in peripheral blood pre- peri- and postoperatively.
62078754|NCT05825664|EXPERIMENTAL|Underwater endoscopic mucosal resection|Intervention: Non-pedunculated polyps will be removed by underwater endoscopic mucosal resection. The UEMR procedure included the following: (1) complete deflation of the colorectal lumen; (2) total immersion of the lesion in normal saline using a mechanical water pump; (3) snaring the lesion and the surrounding mucosa; and (4) resection using electrocautery.
62078755|NCT05825664|ACTIVE_COMPARATOR|Conventional endoscopic mucosal resection|Intervention: Non-pedunculated polyps will be removed by conventional endoscopic mucosal resection. The CEMR procedure included the following: (1) needle injection of normal saline into the submucosa; (2) entrapment of the mucosal protrusion with a snare; and (3) resection applying the same electrocautery setting as was used for UEMR.
62078756|NCT02723279|EXPERIMENTAL|EPNS group|
62078757|NCT02723279|ACTIVE_COMPARATOR|TT group|
62078758|NCT01815736|EXPERIMENTAL|E/C/F/TAF|"Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
62647237|NCT01925443|EXPERIMENTAL|low level laser therapy|individuals will be subject to the application of low level laser therapy, but this group will have three subdivisions related to dose in joules that will be administered to the individual, and J 4, J 6, 8 J. To be administered in the quadriceps muscle.
62647238|NCT01925443|NO_INTERVENTION|Control Group|will consist of individuals diagnosed with diabetes mellitus non-insulin-dependent, however, will not perform low level laser therapy, participate only in the evaluations
62647239|NCT01925443|EXPERIMENTAL|Placebo group|individuals will be subject to the application of low level laser therapy but with a dose of 0 Joules.
62647240|NCT00190268|EXPERIMENTAL|3,4-diaminopyridine|3,4-diaminopyridine
62647241|NCT01979562||100 runners|Male runners between 18-60 years.
62647242|NCT05370170|NO_INTERVENTION|Routine antenatal care|the control group will receive routine antenatal care and will not receive the guidelines group included 30 cases
62647243|NCT05370170|EXPERIMENTAL|Ottawa guidelines|study group will receive routine antenatal care in addition to the Ottawa nutritional guidelines group included 30 cases
62647244|NCT03022409|EXPERIMENTAL|AZD6738|AZD6738 (160 mg) tablet twice daily continuous dosing for a minimum of 9 days and a maximum of 21 days.
62647245|NCT03022409|EXPERIMENTAL|Olaparib|Olaparib (300 mg) tablets administered orally twice daily continuously for a minimum of 9 days and a maximum of 21 days.
62647246|NCT06349876||lap chole|patients presented by cholecystitis with silent CBD stones
62647247|NCT06360861|EXPERIMENTAL|Placenta derived mesenchymal cells|Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection
62647248|NCT04400266|EXPERIMENTAL|Buspirone and Melatonin|Buspirone 15mg and Melatonin 3mg
62647249|NCT06403657|EXPERIMENTAL|Implementation of the enhanced model|"The enhanced model of hepatitis testing and linkage to care includes three implementation interventions: 1) continued medical education (CME) for primary health providers, 2) electronic health records-based best practice alerts (BPA) for chronic hepatitis B testing, 3) point-of-care HBsAg testing (POC). These implementation interventions will be introduced sequentially and cumulatively every four months for 12 months. For example, during the first 4-month period, only CME is implemented. In the next 4 months, BPA will be introduced, coupled with the ongoing CME. In the last 4 months, POC will be introduced, together with the ongoing CME and BPA.~Since this implementation study is single-sited, the period before the implementation will be used as a control arm."
62647250|NCT02605330||Fibrinogen plasma level in CABG|In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level
62647251|NCT02605330||Fibrinogen plasma level in AVR|In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level
62457406|NCT06496061|EXPERIMENTAL|Leg wrapping and norepinephrine infusion|Leg wrapping and norepinephrine infusion. using a crepe bandage (CB) to wrap both legs of the patient from the ankle up to mid-thigh. This CB will be applied tightly enough that the patient feels the tightness but is still comfortable with intact capillary pulsation in the toes and applying norepinephrine infusion 0.5 mg norepinephrine added to 50 ml Normal Saline and set it to run with 0.05 mg/kg/min.
62457407|NCT06496061|ACTIVE_COMPARATOR|Norepinephrine infusion|Norepinephrine infusion . applying norepinephrine infusion 0.5 mg norepinephrine added to 50 ml Normal Saline and set it to run with 0.05 mg/kg/min.
62647252|NCT02605330||Fibrinogen plasma level in AAR|In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level
62647253|NCT02444026|EXPERIMENTAL|iCBT for Insomnia|The Internet intervention offered is the SHUT-i program (Sleep Healthy Using The Internet), which is based on the existing consensus concerning non-pharmacological treatment of insomnia and builds on previous validated CBT's for insomnia (CBT -I)
62647254|NCT02444026|NO_INTERVENTION|Control|The control group will be offered the intervention AFTER the study
62647255|NCT05869799|EXPERIMENTAL|Vigiis 101 Lactobacillus Capsules|Vigiis 101 Lactic Acid Bacteria Capsules is a commercially available product for Lactobacillus paracasei subspecies paracasei NTU 101 (NTU 101) is a strain of Lactobacillus isolated from the intestinal tract of newborns in Taiwan. 10 billion CFU/cap of NTU 101 freeze-dried powder (production research and development: Chenhui Biotechnology Co., Ltd. Biotechnology Co., Ltd., Taipei, Taiwan), corn starch, crystalline cellulose and excipients in vegetable capsules were prepared.
62647256|NCT05869799|PLACEBO_COMPARATOR|Placebo Capsules|Maltodextrin was used as a placebo.
62647257|NCT00773617|EXPERIMENTAL|1|Integrative cognitive affective therapy (ICAT)
62647258|NCT00773617|ACTIVE_COMPARATOR|2|Cognitive behavioral therapy (CBT)
62647259|NCT02857868|EXPERIMENTAL|ABL001|
62647260|NCT00297167|EXPERIMENTAL|EUR-1008 (APT-1008) First, Then Placebo|
62647261|NCT00297167|EXPERIMENTAL|Placebo First, Then EUR-1008 (APT-1008)|
62647262|NCT05519865|EXPERIMENTAL|Tucidinostat Combined with Tislelizumab|Subjects receive Tucidinostat 30mg orally biw and Tislelizumab 200 mg intravenously (IV) Q3W.
62647263|NCT05519865|ACTIVE_COMPARATOR|Tislelizumab|Subjects receive Tislelizumab 200 mg intravenously (IV) Q3W.
62647264|NCT05508958|EXPERIMENTAL|Anterior approach|Cup revision surgery through the anterior approach
62647265|NCT05508958|ACTIVE_COMPARATOR|Posterolateral approach|Cup revision surgery through the posterolateral approach
62647266|NCT02378662|EXPERIMENTAL|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
62647267|NCT02378662|EXPERIMENTAL|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
62647268|NCT03757416||Flexor tenosynovectomy surgery|Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.
62647269|NCT03720925|EXPERIMENTAL|TDI treatment|"The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and from between 3 to 6 months after the TDI treatment ."
62647270|NCT02551016||Primary care only|Patients with heart failure recorded in primary care and never hospitalized for heart failure
62647271|NCT02551016||Primary care and secondary care|Patients with heart failure recorded in primary care with at least one record of a heart failure related hospitalization.
62647272|NCT02551016||Secondary care only|Patients with heart failure recorded in at least one heart failure related hospitalization without a concurrent primary care record.
62647273|NCT05997277|EXPERIMENTAL|Deucravacitinib - Study Drug|Deucravacitinib group: 6 mg po bid x 16 weeks
62647274|NCT05997277|PLACEBO_COMPARATOR|Placebo|Placebo group: 1 tablet po bid x 16 weeks
62647275|NCT01589315|EXPERIMENTAL|FEAST|Active right unilateral focal ECT
62647276|NCT03744832|EXPERIMENTAL|Point of Care Testing|"Point of care testing using the Alere i™ Strep A assay for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. If test is positive, patients will be started on antibiotics prior to discharge from the ED. If test is negative, patients will not be started on antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
62078759|NCT01815736|ACTIVE_COMPARATOR|Stay on Baseline Treatment Regimen (SBR)|"Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
62078760|NCT01973894||Midazolam|"Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.~Blood and urine sampling will follow this schedule:~* 24h: blood (3ml)~* 48h: blood (3ml) and urine~* End of infusion: blood (3ml)~* 6h after end of infusion: blood (3ml) and urine.~Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
62078761|NCT02948348|EXPERIMENTAL|Nivolumab & Ipilimumab(Only Cohort D)|chemoradiotherapy with capecitabine+ Nivolumab + Ipilimumab(Only Cohort D) + surgical therapy
62078762|NCT03660033|EXPERIMENTAL|With ECG|These teams will have access to ECG monitoring (intervention) during the scenario
62457408|NCT01134523|ACTIVE_COMPARATOR|Group A: EC-T regimen|
62457409|NCT01134523|EXPERIMENTAL|Group B: ET regimen|
62457410|NCT03503448|OTHER|space between 11/21|Osteotomy between the maxillary central incisors
62457411|NCT03503448|OTHER|space between 12/13 and 22/23|Osteotomy between the maxillary lateral incisors and canines
62457412|NCT04418726|EXPERIMENTAL|Intensive Monitoring and Preemptive Intervention|In this group patients receive intensive monitoring and preemptive intervention. AVF surveillance refers to using non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa every month. Clinical assessment refers to monitoring for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V. Preemptive intervention is performed as long as problems are recognized, including health education and timely surgery.
62457413|NCT04418726|NO_INTERVENTION|Traditional Monitoring and Intervention|In this group patient receive traditional AVF monitoring, includes clinical assessment for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V.
62457414|NCT03987009|EXPERIMENTAL|Without RAMP and without video|Sniffing position and a standard Macintosh laryngoscope
62457415|NCT03987009|EXPERIMENTAL|With RAMP and with video|Ramped position and a McGrath Mac videolaryngoscope
62457416|NCT03987009|EXPERIMENTAL|Without RAMP and with video|Sniffing position and a McGrath Mac videolaryngoscope
62457417|NCT03987009|EXPERIMENTAL|With RAMP and without video|Ramped position and a standard Macintosh laryngoscope
62647277|NCT03744832|ACTIVE_COMPARATOR|Standard Care|"Conventional testing using a standard bacterial throat culture for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. Patients will be discharged with a post-dated prescription and will be contacted in approximately 3 days if their culture results are positive to fill/take the antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
62078763|NCT03660033|NO_INTERVENTION|Without ECG|These teams will NOT have access to ECG monitoring during the scenario
62078764|NCT05081375|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin dose will not be held for surgical procedure.
62078765|NCT05081375|PLACEBO_COMPARATOR|Placebo dose given and Enoxaparin dose held|Enoxaparin dose will be held and replaced by placebo and not given prior to surgical procedure.
62078766|NCT00549419|EXPERIMENTAL|1|In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
62078767|NCT00549419|ACTIVE_COMPARATOR|2|
62078768|NCT04430335|OTHER|Telephone-Based Cognitive Behavioral Therapy|Participants with moderate or severe anxiety and/or depressive symptoms will participate in the telephone-based intervention that consists of the CBT workbook (15 minutes daily to complete exercises), plus psychotherapy delivered by telephone with a licensed bilingual mental health provider (45-50 minute sessions weekly).
62078769|NCT03983902|ACTIVE_COMPARATOR|Delayed cord clamping|Delayed cord clamping
62078770|NCT03983902|ACTIVE_COMPARATOR|Umbilical cord milking|Umbilical cord clamping
62078771|NCT03983902|ACTIVE_COMPARATOR|Immediate cord clamping|Immediate cord clamping
62078772|NCT05967104|EXPERIMENTAL|Experimental group|"Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.~Questionnaires (Introductory individual form, Gynecological cancer awareness scale and Sexual Attitudes and Beliefs Scale) were completed by students included in the intervention and control groups at the beginning and one month after the completion of the 3 training sessions."
62078773|NCT05967104|NO_INTERVENTION|Control group|The students in the control group were not given any training within the scope of the study, and they only had knowledge about gynecological cancers and sexuality, which are included in the course content of gynecological diseases. However, in order to comply with ethical principles, training information was provided online to the control group after the study data collection process was completed.
62078774|NCT03237962|EXPERIMENTAL|High Flow Nasal Cannula|Patients are randomly assigned into High flow nasal cannula group for the exercise training
62078775|NCT03237962|EXPERIMENTAL|Nasal Cannula|Patients are randomly assigned into nasal cannula group for the exercise training.
62078776|NCT03006627|ACTIVE_COMPARATOR|Male group|All male patients scheduled for upper abdominal surgeries
62078777|NCT03006627|ACTIVE_COMPARATOR|Female group|All female patients scheduled for upper abdominal surgeries
62078778|NCT03941743|EXPERIMENTAL|Prevention (fingolimod hydrochloride)|Patients receive fingolimod hydrochloride PO QD starting the day before chemotherapy, the day of chemotherapy, and 1 day after chemotherapy for 12 weeks.
62647278|NCT00573664|ACTIVE_COMPARATOR|1|Gabapentin
62078779|NCT02589392|EXPERIMENTAL|Moisturizer + Body wash|Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)
62078780|NCT02589392|ACTIVE_COMPARATOR|Body wash|Cetaphil® Restoraderm® body wash (1/day)
62457418|NCT02457429|OTHER|Routine oesophageal pH monitoring|Routine oesophageal pH investigation involves the trans-nasal placement of a microelectrode into the distal oesophagus as per hospital protocol. Examining the oropharynx and confirming visualisation of the red LED at the catheter tip in the correct position just below the soft palate will confirm its position in the oropharynx. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
62647279|NCT00573664|PLACEBO_COMPARATOR|2|Placebo
62647280|NCT01865357|EXPERIMENTAL|Patient|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
62078781|NCT00312975|EXPERIMENTAL|Arm A|
62078782|NCT00312975|ACTIVE_COMPARATOR|Arm B|
62078783|NCT01054690|EXPERIMENTAL|Silver alloyed urinary catheter|
62078784|NCT01054690|PLACEBO_COMPARATOR|Silicone urinary catheter|
62078785|NCT02032667|EXPERIMENTAL|Multi-player condition|The multi-player condition examines the aspect of online gaming and social interaction with adherence to the exergame.
62078786|NCT02032667|NO_INTERVENTION|Single-player condition|This arm will look at whether those who play an exergame by themselves or with a computer generated player have the same adherence and use when compared to a multi-player condition.
62078787|NCT05909228||Children with intestinal failure|Children with intestinal failure on parenteral nutrition
62078788|NCT05909228||Healthy controls|Healthy controls without parenteral nutrition
62078789|NCT01736358|EXPERIMENTAL|Intranasal Ketoralac|A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
62078790|NCT01736358|PLACEBO_COMPARATOR|Placebo|A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
62078791|NCT06737315|EXPERIMENTAL|Test. Increased treatment frequency|Submucosal instrumentation will be performed at baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 16 weeks, 24 weeks and 36 weeks
62078792|NCT06737315|ACTIVE_COMPARATOR|Control. Conventional frequency|Submucosal instrumentation will be performed at baseline, 12 weeks, 24 weeks and 36 weeks
62078793|NCT06268041|ACTIVE_COMPARATOR|Moderate-Intensity Aerobic Training|
62078794|NCT06268041|EXPERIMENTAL|High-Intensity Interval Training|
62647281|NCT01865357|EXPERIMENTAL|Control|healthy subject
62647282|NCT02758782|ACTIVE_COMPARATOR|Golimumab monotherapy|Treatment with 50 mg Golimumab subcutaneous once monthly
62647283|NCT02758782|ACTIVE_COMPARATOR|Golimumab combined with Celecoxib|Treatment with Golimumab 50 mg subcutaneous once monthly in combination with Celecoxib 400 mg orally every day
62078795|NCT06463028|EXPERIMENTAL|sapanisertib and serabelisib (PIKTOR) with paclitaxel|Subjects will receive doses of sapanisertib and serabelisib (PIKTOR) administered orally and paclitaxel administered intravenously.
62078796|NCT04240756|EXPERIMENTAL|Parent Stimulant Medication + Child Treatment Strategy|Parent stimulant medication first followed by a child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
62078797|NCT04240756|ACTIVE_COMPARATOR|Child Treatment Strategy|Child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired. In this arm, parents do not receive stimulant medication before behavioral parent training.
62078798|NCT06738368|EXPERIMENTAL|Treatment (DA-EPOCH, rituximab, JZP458)|Patients receive etoposide IV, doxorubicin IV and vincristine IV over 96 hours on days 1-4, cyclophosphamide IV over 1 hour on day 5, prednisone PO BID on days 1-5 of each cycle. In addition, CD20 positive patients receive rituximab IV on day 1 or 5 of each cycle. Patients also receive JZP458 IM every 2-3 days on days 7-21 for up to 7 doses. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 6, 7, or 8, patients also receive pegfilgrastim SC once or filgrastim SC QD until ANC \> 2000/uL past nadir. Patients also undergo blood sample collection and bone marrow collection throughout the study. Additionally, patients with extramedullary disease may undergo CT or PET/CT throughout the study.
62078799|NCT03806465||Feasibility survey|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age. For the midline household survey, this would be restricted to children aged 12-23 months of age.
62078800|NCT03806465||Sentinel hospital surveillance|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age who are hospitalized in the 18 sentinel hospitals.
62078801|NCT03806465||Community mortality surveillance|These will be children whose deaths are reported in the vaccinating and in non-vaccinating areas aged less than 5 years of age .
62078802|NCT00001309|OTHER|Pharmacokinetics and Biodistribution of Ascorbic Acid|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
62078803|NCT00197028|EXPERIMENTAL|RTS,S/AS02D Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of RTS,S/AS02D at days 14, 44 and 74 and a 3-dose vaccination course of TETRActHib™ vaccine at days 0, 30 and 60. The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
62078804|NCT00197028|ACTIVE_COMPARATOR|Engerix-B Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine at days 14, 44 and 74 and a 3-dose of TETRActHib™ vaccine at days 0, 30 and 60. The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
62078805|NCT05093751||Meningioma patients|
62078806|NCT05264493|EXPERIMENTAL|naloxone 5 mg IM autoinjector|participants will receive in random order, a single naloxone 5 mg IM autoinjector injection into the lateral thigh
62078807|NCT05264493|ACTIVE_COMPARATOR|naloxone 2 mg IM|participants will receive in random order, a single naloxone 2 mg IM injection into the gluteus muscle
62078808|NCT05264493|ACTIVE_COMPARATOR|naloxone 2mg bolus IV|participants will receive in random order, a single naloxone 2 mg bolus IV injection
62078809|NCT03677063|NO_INTERVENTION|Dressing|"It is the historical cohort which is composed of patients over 18 years of age treated by peritoneal dialysis in the nephrology department of Universty Hospital of Caen Normandie. Patients with the same non-inclusion criteria as the experimental group will not be included. The data will be extracted from the Registry of Peritoneal Dialysis of French Language. The number of patients included from the register can not be fixed in advance; this number will correspond to the 4-year follow-up at the start date of the study to ensure at least two years of patient follow-up~Usually care~First dressing 5 or 10 days after the pose of the catheter :~* Cleaning emergence with antiseptic soap~* Rinsing with saline~* Drying~* Application of a hazelnut mupirocin on the exit-site~* Application of an occlusive dressing on the exit-site Then, care is the same. Exit-site care is performed daily if the patient takes a shower or twice a week."
62078810|NCT03677063|EXPERIMENTAL|No dressing|No application of sterile dressing at the exit-site of periotoneal dialysis catheter for all patients (30 days after the placement of the peritoneal dialysis catheter)
62078811|NCT03684005|OTHER|Single-Arm Smartphone App Use|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
62078812|NCT02765555|EXPERIMENTAL|RBP-7000|All subjects that meet initial study entry criteria will receive a test dose of 0.25mg of oral risperidone. Subjects who continue to be eligible will return to the clinical unit in one week and receive a single dose of 60mg RBP-7000 after a 2 hour fast. Subjects will remain in the clinical unit for 14 days, then return for 10 additional weeks after discharge.
62078813|NCT01817634|EXPERIMENTAL|Food supplement Intervention - Capsule Intervention|Omega 3 food supplement + Omega 3 capsule.
62078814|NCT01817634|EXPERIMENTAL|Food Supplement Intervention - Capsule Control|Omega 3 food supplement + Control Capsule.
62078815|NCT01817634|EXPERIMENTAL|Food Supplement Control - Capusle Intervention|Food supplement control + Omega 3 Capsule.
62078816|NCT01817634|ACTIVE_COMPARATOR|Food Supplement Control - Capsule Control|Food supplement control + Control Capsule.
62647284|NCT04212429|ACTIVE_COMPARATOR|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62647285|NCT04212429|ACTIVE_COMPARATOR|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62078817|NCT01155388|EXPERIMENTAL|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~* Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3\* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). \*Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~* Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
62078818|NCT01155388|ACTIVE_COMPARATOR|Oral Iron|Participants will receive oral iron: 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
62078819|NCT02917044|ACTIVE_COMPARATOR|Group A - Standard Care|The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
62078820|NCT02917044|EXPERIMENTAL|Group B - Rhythmia mapping|The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
62078821|NCT04203927|ACTIVE_COMPARATOR|Empagliflozin + insulin infusion|vascular measurements in overnight fasted state and during insulin infusion
62078822|NCT04203927|ACTIVE_COMPARATOR|Empagliflozin + mixed meal|vascular measurements in overnight fasted state and 2 hours after mixed meal 10kcal/kg body weight ( 55% Cho, 30%Fat, 20% Pro)
62078823|NCT02769611|EXPERIMENTAL|Ruboxistaurin 64 mg|ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration
62078824|NCT02769611|EXPERIMENTAL|Ruboxistaurin 128 mg|ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration
62078825|NCT02769611|EXPERIMENTAL|Ruboxistaurin 256 mg|ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration
62078826|NCT01369173|ACTIVE_COMPARATOR|Mexican Menu|24 days, all foods and drinks provided, menu consists of traditional mexican meals
62078827|NCT01369173|ACTIVE_COMPARATOR|US diet|24 days, all foods and drinks provided, menu consists of foods commonly eaten in contemporary United States
62457419|NCT04048148|OTHER|Novel myopia control lenses|This group will be randomized to wear test lenses for 6 months followed by control lenses for 6 months and then test lenses for another 6 months
62647286|NCT04212429|ACTIVE_COMPARATOR|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62647287|NCT04212429|ACTIVE_COMPARATOR|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62647288|NCT04212429|ACTIVE_COMPARATOR|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62647289|NCT04212429|ACTIVE_COMPARATOR|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62647290|NCT04212429|ACTIVE_COMPARATOR|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62647291|NCT04212429|ACTIVE_COMPARATOR|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 8-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
62457420|NCT04048148|OTHER|Single vision lenses|This group will be randomized to wear control lenses for 6 months followed by test lenses for 12 months
62647292|NCT03885947|EXPERIMENTAL|VPA expanded cord blood stem cells|"CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.~VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation"
62647293|NCT04813523|EXPERIMENTAL|Experimental: Pembrolizumab+Cisplatin+5-FU|Participants receive preoperative pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m\^2 IV Q3W, and 5-FU 600 mg/m\^2/day IV infusion on Days 1 to 5. There are 3 cycels of preoprative therapy and 3 cycles of postoperative therapy.
62647294|NCT05966298|EXPERIMENTAL|Core stabilization group|Individuals included in this group will receive 20 minutes of core stabilization training in addition to 40 minutes of standard rehabilitation. Patients will be trained 5 days a week for first 3 weeks(standart rehabilitation + core stabilization training) then will be trained 3 days a week on 4-6 week (only core stabilization training). The next 6 weeks will be given a home exercise program including shoulder exercises and core stabilization training.
62078828|NCT02672163|EXPERIMENTAL|AACD-Therapy group|6 patients are recruited to the AADC-therapy group. Autologous atrial appendage derived cells (AADCs) are harvested from the appendage tissue removed during the venal cannulation of bypass. The cells and their extracellular matrix are placed with tissue clue to Cormatrix-sheet and further on top of the myocardium in the area of infarction scar. The procedure is done simultaneously with CABG surgery. The patients will be carefully monitored after the operations and cardiac MRI and echocardiogram will be performed previously to surgery as well as during the follow ups.
62078829|NCT02672163|ACTIVE_COMPARATOR|Control group|20 patients are recruited to form the control group. They are patients scheduled for elective CABG surgery and they meet the same inclusion and exclusion criteria as the therapy group. There patients are followed as the hospital protocol with out any additional imagination or blood tests.
62457421|NCT00825708|ACTIVE_COMPARATOR|rTMS|rTMS session
62457422|NCT00825708|SHAM_COMPARATOR|SHAM|sham session
62457423|NCT02296775|EXPERIMENTAL|DRL_RI|
62457424|NCT02296775|ACTIVE_COMPARATOR|Rituxan|
62457425|NCT02296775|ACTIVE_COMPARATOR|MabThera|
62457426|NCT01643837|NO_INTERVENTION|Standard|Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.
62457427|NCT01643837|SHAM_COMPARATOR|Light Touch (LT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~Light touch protocol."
62457428|NCT01643837|EXPERIMENTAL|Osteopathic Manipulative Treatment (OMT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~OMT Protocol."
62457429|NCT00805558|EXPERIMENTAL|Moxifloxacin|Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
62078830|NCT05318846|EXPERIMENTAL|Treatment group A|
62078831|NCT05318846|PLACEBO_COMPARATOR|Treatment group B|
62078832|NCT01187290|NO_INTERVENTION|neoadjuvant chemotherapy|Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
62078833|NCT01187290|EXPERIMENTAL|neoadjuvant chemoradiotherapy|Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
62078834|NCT00919893|ACTIVE_COMPARATOR|Cernilton|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
62078835|NCT00919893|PLACEBO_COMPARATOR|Placebo|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
62078836|NCT05974553|EXPERIMENTAL|Dialectical Behavior Therapy for Justice-Involved Veterans|16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans
62078837|NCT05974553|ACTIVE_COMPARATOR|Supportive Group Psychotherapy|16 weeks of supportive group psychotherapy for justice-involved Veterans
62078838|NCT01797796|EXPERIMENTAL|PF-06305591|
62078839|NCT01797796|PLACEBO_COMPARATOR|Placebo|
62647295|NCT05966298|OTHER|Control group|Individuals included in this group will receive only 40 minutes of standard rehabilitation. Patients will be trained 5 days a week for first 3 weeks(only standart rehabilitation). The next 9 weeks will be given a home exercise program including shoulder exercises.
62078840|NCT03509922|EXPERIMENTAL|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
62078841|NCT03509922|EXPERIMENTAL|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
62078842|NCT01402167|EXPERIMENTAL|Kyphoplasty|Patients randomized to this arm will be treated via balloon kyphoplasty.
62078843|NCT01402167|ACTIVE_COMPARATOR|Vertebroplasty|Patients randomized to this arm will be treated via vertebroplasty.
62078844|NCT02552680|EXPERIMENTAL|Exercise + guideline|Participants will participate in eight meetings consisting of exercise and guidelines on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
62078845|NCT02552680|ACTIVE_COMPARATOR|brochure|Participants will receive a manual-brochure - containing information about general health.
62078846|NCT02254850|EXPERIMENTAL|Mesoglycan|"The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml and inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg and Inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
62078847|NCT02254850|PLACEBO_COMPARATOR|Placebo|"The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
62078848|NCT05291884|EXPERIMENTAL|Subjects receiving the Impella BTR|
62647296|NCT05620524||Patients treated with FLOT regimen|Exposure to 5-FU in patients treated with FLOT
62647297|NCT02479841|EXPERIMENTAL|self management program|Participation in an 11 week self-management program
62457430|NCT00805558|ACTIVE_COMPARATOR|Ciprofloxacin plus metronidazole|Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
62647298|NCT02479841|NO_INTERVENTION|Control group|
62647299|NCT03886272|EXPERIMENTAL|BI 730357 (Test)|
62647300|NCT03886272|EXPERIMENTAL|BI 730357 (Reference)|
62647301|NCT06523127||Patients with severe acute brain injury and with withholding of life-sustaining treatment|Assessment of quality of life in patients with severe acute brain injury based on the audio recording during post-ICU follow-up.
62647302|NCT06523127||Patients with severe acute brain injury and without withholding of life-sustaining treatment|Assessment of quality of life in patients with severe acute brain injury based on the audio recording during post-ICU follow-up.
62647303|NCT03286764|PLACEBO_COMPARATOR|Placebo|Distilled water spray as a placebo during Colonoscopy
62457431|NCT01893957|EXPERIMENTAL|Healthy|Healthy women undergoing high voltage electrical stimulation
62457432|NCT01893957|EXPERIMENTAL|Axillary lymphadenectomy|Axillary lymphadenectomy volunteers undergoing to high voltage electrical stimulation
62647304|NCT03286764|EXPERIMENTAL|Peppermint Oil|Peppermint Oil spray during Colonoscopy
62647305|NCT02824107|EXPERIMENTAL|patients with myocardial infarction|
62647306|NCT02824107|EXPERIMENTAL|patients with stroke|
62647307|NCT05686577||learning database group|The results of blood cultures and the clinical elements of the patients in the first sample (1600 patients) will constitute the learning database. A supervised learning will be performed on these data in order to select a set of clinical elements allowing to define a predictive score of positive blood cultures
62647308|NCT05686577||validation database group|The score will be validated on the remaining sample (800 patients), independent of the first sample. Both samples will be constituted by randomization.
62647309|NCT06104917|EXPERIMENTAL|High Dose Maolactin|Maolactin 500mg per day - 2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day
62647310|NCT06104917|EXPERIMENTAL|Low Dose Maolactin|Maolactin 250mg per day - 1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day
62647311|NCT06104917|PLACEBO_COMPARATOR|Maltodextrin|Placebo capsule - 2 capsules containing Maltodextrin per day
62647312|NCT02278653||Study group|The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
62647313|NCT00957281||Asthma|Asthma patients on inhaled corticosteroids
62647314|NCT04421755|EXPERIMENTAL|Produce Only|Receives weekly home delivery of fresh fruits and vegetables
62647315|NCT04421755|EXPERIMENTAL|Produce + Cooking Classes|Receives weekly home delivery of fresh fruits and vegetables plus invitation to participate in a series of three small group culinary medicine cooking classes
62078849|NCT01818934|ACTIVE_COMPARATOR|expert clinical exam only|all babies assigned to this group had expert clinical examination only, no hip ultrasound
62078850|NCT01818934|ACTIVE_COMPARATOR|selective hip ultrasound screening|all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
62078851|NCT01818934|ACTIVE_COMPARATOR|universal hip ultrasound screening|All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination
62078852|NCT05796960||Surgical operations for advanced thyroid cancer|All adult (18 years old and older) patients registered in EUROCRINE® database with stage IV thyroid cancer, M1, N1b, or T3b and above will be included
62078853|NCT00326690|EXPERIMENTAL|treatment|
62078854|NCT00326690|NO_INTERVENTION|Control|
62647316|NCT04421755|NO_INTERVENTION|Control|Control group with no cooking classes or groceries
62647317|NCT02644044|EXPERIMENTAL|Treatment|Treatment with IT methotrexate
62647318|NCT00296244|OTHER|Steroid -free immunosuppression|Study group - Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
62647319|NCT00296244|OTHER|Steroid containing immunosuppression|Control group- Basiliximab, Tacrolimus, EC-MPA, steroids
62647320|NCT05944640||Patients with DR|Adult patients with T1DM or T2DM with any form of diabetic retinopathy and diabetic macular edema, indicated for ocular surgical procedure as standard of care. Blood samples and samples of intraocular fluids will bee taken during the ocular surgery.
62647321|NCT05944640||Patients without DR|Adult patients with T1DM or T2DM without any signs of diabetic retinopathy, indicated for ocular surgical procedure from other reasons as standard of care. Blood samples and samples of intraocular fluids will bee taken during the ocular surgery.
62078855|NCT01409746||twins|twin pairs
62078856|NCT01932138|EXPERIMENTAL|Enhanced CHW intervention|CHWs will 1) identify pregnant women through home visits and refer them to ANC; 2) inform pregnant women on antenatal care ANC and PMTCT; 3) visit women at home to ascertain ANC attendance; and 4) follow up women who have missed ANC or PMTCT appointments.
62078857|NCT01932138|OTHER|Standard of care|Clinic-based health workers follow-up patients who have missed scheduled PMTCT appointments (through telephone calls and/or in-person visits). The standard of care does not include any specific interventions to improve ANC attendance.
62078858|NCT01034241|EXPERIMENTAL|Control|Diet consists of 15% dairy protein and low Glycemic Index (GI \< 40), 55 En% carbohydrates and 30 En% fat
62078859|NCT01034241|EXPERIMENTAL|High dairy protein|Diet consists of 25% dairy protein and low GI (GI \< 40), 45 En% carbohydrates and 30 En% fat
62078860|NCT01034241|EXPERIMENTAL|vegetable protein|Diet consists of 15 En% vegetable protein and low GI (GI \< 40), 55 En% carbohydrates and 30 En% fat
62078861|NCT01034241|EXPERIMENTAL|High GI|Diet consists of 15 En% dairy protein and high GI(GI \> 60, 55 En% carbohydrates and 30 En% fat
62647322|NCT05944640||Control group|Subjects without diabetes mellitus indicated for ocular surgery from other reasons (cataract, retinal detachment, macular hole, idiopathic epiretinal membrane) as standard of care. Blood samples and samples of intraocular fluids will bee taken during the ocular surgery.
62647323|NCT04217759|EXPERIMENTAL|Intervention group|Intervention group went through a healthy lifestyle intervention using evidence-based SCT strategies emphasising on PA and diet for 12 weeks via face-to-face sessions and social media tools (Facebook and WhatsApp)
62647324|NCT04217759|NO_INTERVENTION|Control group|Control group only received leaflets on healthy lifestyle with no further guidance.
62647325|NCT03366246|ACTIVE_COMPARATOR|lidocaine / prilocaine cream|according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy.
62647326|NCT03366246|PLACEBO_COMPARATOR|placebo|according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy.
62647327|NCT04559113|EXPERIMENTAL|Group intervene with Methylprednisolone|"Review effect of Methylprednisolone as clinical trial among hospitalized patients with COVID-19 infection.~Anyone of the following Corticosteroids dose will be given to moderate disease patients of COVID-19~1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day. \*Note: in Diabetic patients' dose of methyl prednisolone should be divided in doses preferably 40mg BD."
62647328|NCT01005667|EXPERIMENTAL|BirthTrack Monitor|
62457433|NCT05586022||Patients with lower extremity arterial occlusion undergoing endovascular revascularization|We will enroll the patients with lower extremity arterial occlusive disease admitted to the Department of Vascular Surgery of The First Affiliated Hospital of Xi 'an Jiaotong University. These patients undergo successful endovascular revascularization of the diseased vessel.
62647329|NCT01005667|NO_INTERVENTION|Control - no BirthTrack Monitor|
62647330|NCT04821063|EXPERIMENTAL|Therapeutic dose: ITF2357 100 mg|Participants will receive a single dose of ITF2357 100 mg administered as 10 milliliters (mL) of ITF2357 10 milligrams per milliliter (mg/mL) oral suspension and 20 mL of placebo matched to ITF2357 oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
62647331|NCT04821063|EXPERIMENTAL|Supratherapeutic dose: ITF2357 300 mg|Participants will receive a single dose of ITF2357 300 mg administered as 30 mL of ITF2357 10 mg/mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
62647332|NCT04821063|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo matched to ITF2357 administered as 30 mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
62647333|NCT04821063|ACTIVE_COMPARATOR|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg tablet under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
62647334|NCT05512117|EXPERIMENTAL|Midline Catheter|Midline catheter insertion
62078862|NCT04275180|NO_INTERVENTION|control|Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
62647335|NCT05512117|NO_INTERVENTION|Peripheral intravenous cannulation (PIVC)|Peripheral intravenous cannulation (PIVC)
62647336|NCT05074329|ACTIVE_COMPARATOR|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
62647337|NCT05074329|PLACEBO_COMPARATOR|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
62078863|NCT04275180|EXPERIMENTAL|Argatroban group|Argatraban is used on the basis of standard medical treatment.
62647338|NCT03027947|EXPERIMENTAL|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial and trans-femoral amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
62647339|NCT02744716|EXPERIMENTAL|non-balloon group|with aspirin
62647340|NCT02744716|EXPERIMENTAL|balloon group|with aspirin and intrauterine balloon
62647341|NCT02744716|NO_INTERVENTION|control group|without aspirin and intrauterine balloon
62647342|NCT02433769|ACTIVE_COMPARATOR|TOf-Watch-SX|Train-of-four (TOF) ratios will be measured with the TOF-Watch-SX and compared to TOF ratios measured simultaneously with the TOFscan
62647343|NCT02433769|EXPERIMENTAL|TOFscan|Train-of-four (TOF) ratios obtained from the TOFscan will be compared to TOF ratios measured simultaneously with the TOF-Watch-SX
62647344|NCT04023201||Parkinson's disease patients|Parkinson's disease patients with or without nocturnal symptoms
62078864|NCT04719936|EXPERIMENTAL|inferior capsulotomy group|inferior capsulotomy will be conducted during posterior approach.
62078865|NCT04719936|ACTIVE_COMPARATOR|superior capsulotomy group|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
62647345|NCT00879658|EXPERIMENTAL|BAF312 10mg (period 1)|
62647346|NCT00879658|EXPERIMENTAL|BAF312 2 mg (period 1)|
62647347|NCT00879658|EXPERIMENTAL|BAF312 0.5 mg (period 1)|
62647348|NCT00879658|EXPERIMENTAL|BAF312 dose between 0.1 to 8 mg period 2|
62647349|NCT00879658|EXPERIMENTAL|BAF312 dose between 0.1 - 8 mg period 2|
62647350|NCT00879658|PLACEBO_COMPARATOR|Placebo (period 1, 2)|
62647351|NCT05461040|EXPERIMENTAL|Optic capture of Intraocular lens without anterior vitrectomy (Group 1)|
62647352|NCT05461040|EXPERIMENTAL|in-the-bag implantation of Intraocular lens with anterior vitrectomy (Group 2).|
62647353|NCT03618901|EXPERIMENTAL|Rock Steady Boxing|Non-contact boxing program.
62647354|NCT03618901|ACTIVE_COMPARATOR|PD SAFEx|Sensory attention focused exercise.
62078866|NCT00356486|EXPERIMENTAL|A|Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks
62647355|NCT01005238|ACTIVE_COMPARATOR|telbivudine|patients in this arm will continue to take telbivudine
62647356|NCT01005238|EXPERIMENTAL|lamivudine|patients in this arm will take lamivudine
62647357|NCT05158621||Advanced/Metastatic Colorectal Cancer|Eligible patients include those with newly-diagnosed or recurrent advanced/metastatic CRC who are initiating fluoropyrimidine and oxaliplatin (FOLFOX or CAPEOX) in combination with bevacizumab. Patients will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE(TM), to warrant manufacturing of an individualized vaccine. Patients with sufficient neoantigens will have vaccine manufactured while receiving FOLFOX or CAPEOX/bevacizumab.
62078867|NCT00356486|EXPERIMENTAL|B|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
62078868|NCT05506865|EXPERIMENTAL|Indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once daily, with dry powder inhaler device.
62078869|NCT05506865|ACTIVE_COMPARATOR|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once daily, with dry powder inhaler device
62078870|NCT00474175|PLACEBO_COMPARATOR|1|Placebo control
62647358|NCT05158621||Localized Colon Cancer|Eligible patients include those with high-risk Stage II or Stage III colon cancer who have MRD based on the presence of ctDNA following surgical resection. Patients with MRD will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE(TM), to warrant manufacturing of an individualized vaccine.
62647359|NCT04896216|EXPERIMENTAL|Stigma Reduction Intervention|"A Stigma Reduction Intervention curriculum developed using data generated from Stage 1 of the study.~For stage 2/intervention stage, participants who are providers and randomized to the Stigma Reduction Intervention arm through clinic-level randomization"
62647360|NCT04896216|NO_INTERVENTION|Control|"For stage 2/intervention stage, participants who are providers and randomized to the Control arm through clinic-level randomization"
62078871|NCT00474175|ACTIVE_COMPARATOR|2|10% benzocaine gel formulation
62078872|NCT00474175|ACTIVE_COMPARATOR|3|20% benzocaine gel formulation
62078873|NCT03816592||Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
62078874|NCT03816592||Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
62078875|NCT01182727|EXPERIMENTAL|salsalate|Salsalate will be administered in two divided doses of 2grams in the morning and 2 grams in the evening. Salsalate will be administered for 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until a tolerated dose or a minimum dose of 2 grams per day is reached.
62078876|NCT01306721|ACTIVE_COMPARATOR|FEX 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)"
62078877|NCT01306721|EXPERIMENTAL|FEX 60 mg/PSE 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination~Double-blind treatment period:~1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)"
62078878|NCT01306721|EXPERIMENTAL|FEX 60 mg/PSE 120 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg"
62647361|NCT01316614|EXPERIMENTAL|With Stylet & Without Stylet|There will only be one arm in this study. This arm will undergo EUS-guided FNA with the use of a stylet for half of their FNA passes and without a stylet for the other half. Patients will be exposed to an equal number of passes with and without a stylet. Each pass will be individually assessed by a skilled cytopathologist who is blinded to the technique used. We will compare the adequacy of both techniques to determine whether or not a stylet leads to a higher diagnostic accuracy rate in patients with solid lesions.
62647362|NCT02845674|EXPERIMENTAL|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
62078879|NCT04837521|EXPERIMENTAL|Therapist Delivered Unified Protocol|This is a five session psychotherapy designed to help people with problems such as anxiety and depression.
62647363|NCT01156519|OTHER|Salivary cortisol|
62647364|NCT04517682||Positive for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a positive result.
62647365|NCT04517682||Negative for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a negative result.
62647366|NCT06466343|OTHER|symptomatic non pregnant women|Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.
62647367|NCT06077175|EXPERIMENTAL|intervention group|
62647368|NCT06077175|NO_INTERVENTION|Control group|
62647369|NCT02100124|EXPERIMENTAL|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
62647370|NCT02100124|EXPERIMENTAL|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
62647371|NCT02100124|ACTIVE_COMPARATOR|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
62647372|NCT01710462|EXPERIMENTAL|Pantoprazole + Domperidone|The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma. For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
62647373|NCT01710462|ACTIVE_COMPARATOR|Pantozol® (Takeda)|The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg. For this study will be used 20 mg tablets.
62647374|NCT03897816||"PERINATAL"|Pregnant women consecutively referred and admitted to the Perinatal Psychiatric Outpatient Department
62647375|NCT03897816||"OUTPTS"|Pregnant women belonging to the Outpatients Psychiatric Department who did not have psychiatric issues linked to their pregnancy or in the relationship with their children
62078880|NCT04837521|EXPERIMENTAL|Self-Guided Unified Protocol|This is a five session treatment that patients can complete independently.
62078881|NCT03620682|EXPERIMENTAL|Mobile mental health intervention|Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
62078882|NCT01389063|ACTIVE_COMPARATOR|Arm A|HAART of subjects in arm A will be intensified with maraviroc during week 1-8.
62457434|NCT04834037|EXPERIMENTAL|Experimental|"Patients in the experimental group were provided with information in addition to routine nursing care and supportive care interventions were made. The information leaflet was explained to the patients in the experimental group face to face by the researchers and the information was repeated according to the patient's needs.~As a pre-test measure, blood gases were taken from the patients in the experimental and control groups, their vital signs were measured, their state of consciousness was evaluated, and DASS-21 (anxiety and stress sub-dimension) and RASS (agitation dimension) were practiced by face-to-face interviews with the patients. As the last test, the same measurements were made 5 days after the first measurement and before the patients were transferred to the normal service. An information pamphlet consisting of textual material about NIV treatment was developed."
62647376|NCT03897816||Healthy controls|Pregnant women the general population, with no history of mental health issues
62078883|NCT01389063|ACTIVE_COMPARATOR|Arm B|HAART of subjects enrolled in arm B will be intensified with maraviroc during week 9-16
62647377|NCT06083129|ACTIVE_COMPARATOR|Anti-T lymphocyte globulin (ATLG)|
62647378|NCT06083129|ACTIVE_COMPARATOR|Anti Thymocyte Globulins (ATG)|
62647379|NCT04036604|EXPERIMENTAL|Group of pelvic floor exercise|Group of pelvic floor exercise include 47 elderly people which contains contraction and repetition of pelvic floor muscle exercises during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.
62078884|NCT00255229|ACTIVE_COMPARATOR|1|Irinotecan, 5FU, Glutamine
62078885|NCT00255229|PLACEBO_COMPARATOR|2|Irinotecan, 5FU, Placebo
62078886|NCT02869269||Early stage|patients who diagnosed as TNM stage 1 and 2
62078887|NCT02869269||Late stage|patients who diagnosed as TNM stage 3 and 4
62078888|NCT06358872|ACTIVE_COMPARATOR|Continuous Distribution|Azithromycin distribution to children 1-59 months of age for four years using a door-to-door delivery approach via existing community health workers
62647380|NCT04036604|NO_INTERVENTION|Group of pelvic floor education|Group of pelvic floor education include 47 elderly people which contains anatomy of pelvic floor and dysfunction during once a week for 8 weeks performed by an expert pelvic health physiotherapist.
62647381|NCT02472899||Alzheimer's Disease|Blood sample from subjects older than 60 years with a clinical diagnosis of Alzheimer's Disease
62647382|NCT02472899||Older controls|Blood sample from subjects older than 60 years who are cognitively normal
62647383|NCT02472899||Younger controls|Blood sample from healthy subjects aged 20 to 30 years who are cognitively normal
62078889|NCT06358872|ACTIVE_COMPARATOR|Delayed Distribution|Delayed, by two years, azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
62078890|NCT06358872|ACTIVE_COMPARATOR|Stop Distribution|Stopping azithromycin distribution after two years to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
62078891|NCT04099381|EXPERIMENTAL|Group 1 Low HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or less HLA compatibility degree in A, B, DRB1 loci will be used.
62078892|NCT04099381|EXPERIMENTAL|Group 2 High HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or more HLA compatibility degree in A, B, DRB1 loci will be used.
62078893|NCT04099381|OTHER|Group 3 Control|Patients with standard therapy as a control group.
62078894|NCT04315714|EXPERIMENTAL|IBS Yoga Intervention (delivered online/virtually via Zoom)|Ten participants with IBS will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
62078895|NCT04315714|EXPERIMENTAL|IBS Waitlist Control Condition|Ten participants with IBS will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
62647384|NCT06105606|EXPERIMENTAL|AvuCure Microwave Ablation|"Participants will undergo study procedures as follows:~* Baseline assessments~* Hospital admission for bronchoscopy under general anesthesia and microwave ablation via standard of care.~* Participants will be followed at 1, 3, and 6 months post-procedure."
62078896|NCT04315714|EXPERIMENTAL|HC Yoga Intervention (delivered online/virtually via Zoom)|Ten participants serving as HC will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
62078897|NCT04315714|EXPERIMENTAL|HC Waitlist Control Condition|Ten participants serving as HC will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
62647385|NCT05335616|EXPERIMENTAL|"Intervention Guideline"|Participants are given written information (a hypothetical new guideline).
62647386|NCT05335616|EXPERIMENTAL|"Intervention Treatment fee item"|Participants are given written information about a hypothetical new treatment fee item.
62078898|NCT05759312|EXPERIMENTAL|zimberelimab plus metformin|Patients will start metformin at 1,000mg by mouth once daily during a 7-day induction period prior to starting zimberelimab. The dose will be increased by 500mg every 7 days until reaching the target dose of 2000mg. Zimberelimab will be administered at a fixed dose of 240 mg IV every 14 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity, or withdrawal of consent.
62078899|NCT03242603|EXPERIMENTAL|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
62078900|NCT02025452|ACTIVE_COMPARATOR|Rapid diagnostics and probiotic|
62078901|NCT02025452|PLACEBO_COMPARATOR|Rapid diagnostics and placebo|
62078902|NCT02025452|EXPERIMENTAL|Delayed diagnostics and probiotic|
62078903|NCT02025452|PLACEBO_COMPARATOR|Delayed diagnostics and placebo|
62078904|NCT01454180|ACTIVE_COMPARATOR|Arm A|Control treatment arm will be treated with any of the schemes used in the study according to the discretion of the physician responsible
62078905|NCT01454180|EXPERIMENTAL|Arm B|treatment guided by the therapeutic targets
62078906|NCT05969938||Treatment group|A total of 50 patients with stage II-III rectal cancer who plan to receive neoadjuvant chemoradiotherapy between the ages of 18-75 years old, and these patients have no distant metastasis, normal main organ function, and can receive long-term follow-up. simultaneously, these patients are required to provide sufficient ' colonoscopy collection ' tumor tissue samples for MRD customization, and sufficient whole blood samples are required for baseline MRD detection.
62078907|NCT02359383|ACTIVE_COMPARATOR|Chest Physiotherapy group|Conventional medical treatment plus Chest Physiotherapy
62078908|NCT02359383|NO_INTERVENTION|Control grup|Conventional medical treatment
62078909|NCT01501422|EXPERIMENTAL|Estrogen|Use estrogen patch for 8 weeks
62078910|NCT01501422|EXPERIMENTAL|Placebo|Use placebo patch for 8 weeks
62647387|NCT02930694|EXPERIMENTAL|Group 1: Treatment Sequence AB|Participants will receive Treatment A \[JNJ-54175446, 50 milligram (mg) capsule\] on Day 1 of period 1 followed by Treatment B \[JNJ-54175446, 50 mg suspension\] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
62647388|NCT02930694|EXPERIMENTAL|Group 1: Treatment Sequence BA|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
62078911|NCT02551744|ACTIVE_COMPARATOR|proton pump inhibitor group|Pantoprazole Tab 40mg qd for 6 monthrs.
62078912|NCT02551744|EXPERIMENTAL|histamine-2 receptor antagonist group|famotidine Tab 40 mg qd for 6 months.
62078913|NCT02255630|EXPERIMENTAL|Salbutamol inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
62078914|NCT02255630|EXPERIMENTAL|Placebo inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
62078915|NCT04394741|EXPERIMENTAL|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
62457435|NCT04834037|NO_INTERVENTION|No intervention|Routine nursing care was practiced to the control group in the intensive care clinic where the patients were located.
62078916|NCT04394741|SHAM_COMPARATOR|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
62457436|NCT00175357|ACTIVE_COMPARATOR|1|Oral methadone
62457437|NCT00175357|EXPERIMENTAL|2|Injected diacetylmorphine
62078917|NCT04376229||Cancer patients receiving proton radiation therapy|Registry of cancer patients who receive proton radiation therapy to track disease and toxicity outcomes.
62078918|NCT03298607|PLACEBO_COMPARATOR|Placebo|2 capsules daily for 2 months containing inactive substances
62457438|NCT02384174|EXPERIMENTAL|Resistant starch (RS)|Resistant starch (RS3)
62457439|NCT02384174|EXPERIMENTAL|Dietary fibre|Dietary fibre (Arabinogalactan, gum guar, pectin)
62457440|NCT01004211|ACTIVE_COMPARATOR|Standard transurethral resection|Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
62078919|NCT03298607|ACTIVE_COMPARATOR|Serelys PMS|2 capsules daily for 2 months containing pollen extract
62078920|NCT04401553|EXPERIMENTAL|First Tier Antibiotic|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
62078921|NCT04401553|ACTIVE_COMPARATOR|Second Tier Antibiotic|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam
62078922|NCT03250026|EXPERIMENTAL|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
62078923|NCT03250026|ACTIVE_COMPARATOR|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
62078924|NCT06275048|EXPERIMENTAL|Wrist/hand immobilization|Participants will have their wrist and hand immobilized using a rigid splint continuously for 7 days. The splint will restrict all wrist and hand movement and must be worn at all times for the full 7 day period, and may only be removed under supervision of the research participants.
62078925|NCT04861662|NO_INTERVENTION|Keratinized Mucosa Sufficient (KMS)|Implants exhibiting the width of keratinized mucosa (KM) ≥2 mm at the midbuccal aspect
62078926|NCT04861662|NO_INTERVENTION|Keratinized Mucosa Deficient (KMD)|Implants exhibiting KM\<2 mm at the midbuccal aspect
62078927|NCT04861662|EXPERIMENTAL|Free Gingival Graft (FGG)|Implants with KM\<2 mm initially and having surgically increased keratinized mucosa with free gingival graft after prothesis delivery
62647389|NCT02930694|EXPERIMENTAL|Group 2: Treatment Sequence CD|Participants will receive Treatment C \[JNJ-54175446, 100 mg capsule\] on Day 1 of period 1 followed by Treatment D \[JNJ-54175446, 100 mg suspension\] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
62647390|NCT02930694|EXPERIMENTAL|Group 2: Treatment Sequence DC|Participants will receive Treatment D on Day 1 of period 1 followed by Treatment C on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
62647391|NCT05889975|ACTIVE_COMPARATOR|interdental tooth brush|the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily,then the brush will be used after completion of manual tooth brushing it will be gently inserted between the teeth and orthodontic appliance, the patient will be instructed to use appropriate size brush and a smaller brush size if it feels too tight.
62647392|NCT05889975|ACTIVE_COMPARATOR|single tufted brush|the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily,then the brush will be used after completion of manual tooth brushing it will be gently inserted between the teeth and orthodontic appliance.
62078928|NCT03048032||Acute heart failure patients|Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
62078929|NCT03048032||Control group|Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.
62647393|NCT05889975|ACTIVE_COMPARATOR|water irrigator|the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily,thenThe patients will be instructed to use water irrigator after manual tooth brushing with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation.
62647394|NCT03597802|NO_INTERVENTION|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
62647395|NCT03597802|ACTIVE_COMPARATOR|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
62647396|NCT03597802|ACTIVE_COMPARATOR|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
62647397|NCT06321523||ATTR-CM patients in Korea|transthyretin amyloid cardiomyopathy (ATTR-CM) patients in Korea
62647398|NCT04312100||Mild cases with conventional oxygen therapy|COVID-19 patients who were considered mild cases will receive conventional oxygen therapy in addition to standard treatment
62078930|NCT01245868|EXPERIMENTAL|Bupivacaine|Bupivacaine as used routinely
62647399|NCT04312100||Moderate/Severe cases with nasal high flow oxygen inhalation|COVID-19 patients who were considered Moderate/Severe cases will receive nasal high flow oxygen inhalation in addition to standard treatment
62647400|NCT04312100||Moderate/Severe cases with non-invasive ventilation|COVID-19 patients who were considered Moderate/Severe cases will receive non-invasive positive pressure ventilation in addition to standard treatment
62078931|NCT01245868|PLACEBO_COMPARATOR|Lidocaine added to bupivacaine|lidocaine is added to bupivacaine
62078932|NCT00230321|EXPERIMENTAL|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
62078933|NCT01162941|EXPERIMENTAL|Steroid dependant ITP|more than 10 mg of prednisolone per day is required to maintain a platelet count above 20X109/L (minimum follow up duration: 3 months after diagnosis)
62078934|NCT05606315|EXPERIMENTAL|Remimazolam besylate|Remimazolam besylate is a new ultra-short-acting benzodiazepine drug, which is a benzodiazepine central nervous system inhibitor. It can bind to central GABAA receptors and produce sedative effects in animal experiments. Currently, it is used in painless diagnosis and treatment sedation, colonoscopy sedation, general anesthesia, ICU sedation and local anesthesia sedation.
62078935|NCT05606315|ACTIVE_COMPARATOR|propofol|Propofol, known chemically as 2, 6-diisopropyl phenol, is an organic compound with the chemical formula C12H18O and is a short-acting intravenous anesthetic used for the induction and maintenance of general anesthesia. It is often used in conjunction with epidural or spinal anesthesia, as well as with analgesics, muscle relaxants, and inhalation anesthetics.
62078936|NCT05606315|ACTIVE_COMPARATOR|midazolam|Midazolam, an organic compound with the chemical formula C18H13ClFN3, is used clinically to treat insomnia and can also be used to induce sleep during surgery or diagnostic tests.
62078937|NCT05073744|EXPERIMENTAL|Tumor ablation using nalbuphine for pain control and anaesthesia|Nalbuphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
62078938|NCT05073744|ACTIVE_COMPARATOR|Tumor ablation using morphine for pain control and anaesthesia|Morphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
62078939|NCT01215708|ACTIVE_COMPARATOR|Nifedipine|nifedipine retard 20mg daily
62078940|NCT01215708|ACTIVE_COMPARATOR|tamsulosin|tamsulosin 0,4mg
62078941|NCT01215708|PLACEBO_COMPARATOR|placebo|placebo capsule
62078942|NCT01952301|ACTIVE_COMPARATOR|xenogeneic collagen matrix|Xenogeneic collagen matrix device placed on treatment wound bed site
62078943|NCT01952301|ACTIVE_COMPARATOR|Free Gingival Graft|Traditional free gingival graft (autogenous graft device harvested from patient's palate) placed on treatment site wound bed
62457441|NCT01004211|EXPERIMENTAL|Narrow band imaging transurethral resection|The system will be switched to narrow band imaging by simply pushing a button. Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
62457442|NCT06356675|EXPERIMENTAL|treatment group|Tislelizumab 200mg iv D1+anlotinib(12mg D1-12)
62457443|NCT03689790|ACTIVE_COMPARATOR|liver function|liver function
62457444|NCT03103100|ACTIVE_COMPARATOR|1% Lidocaine|Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine
62457445|NCT03103100|ACTIVE_COMPARATOR|0.25% Bupivacaine|Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine
62457446|NCT03103100|ACTIVE_COMPARATOR|Bupivacaine plus Lidocaine|Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.
62647401|NCT05452265||endoscopic resection (ER)|ER with backup surgery was indicated for patients with endoscopic intent, and a small tumor size tolerated endoscopic retrieval.
62078944|NCT01905579|EXPERIMENTAL|patients with uveitis|Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery
62457447|NCT02689908|OTHER|The patients underwent thorax CT|The patients refered to radiology service underwent thorax computed tomography without contrast material for the evaluation of various complaints such as dyspnea, hemoptysis and pulmonary infections.
62457448|NCT02679001||RA participants treated with a TNF inhibitor or TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling will be observed.
62647402|NCT05452265||laparoscopic resection (LR)|LR was indicated for patients with surgical intent, and those with the following conditions, which were not suitable for ER: (1) large tumor size with difficult endoscopic retrieval ; (2) symptoms of gastrointestinal tract bleeding with difficulty in endoscopic visualization; (3) suspicion of tumor rupture that required intra-abdominal exploration; and (4) histologic diagnosis of GIST with initial treatment of target therapy.
62647403|NCT03689517|EXPERIMENTAL|placebo arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. Participants took placebos (pills made by starch) that were told to be an effective analgesic
62647404|NCT03689517|SHAM_COMPARATOR|sham arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. But participants do not take placebos
62647405|NCT02669875|ACTIVE_COMPARATOR|Serelaxin|IV infusion of serelaxin (RLX030) for 2 hours
62647406|NCT02669875|PLACEBO_COMPARATOR|Placebo|IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours
62647407|NCT05948085|EXPERIMENTAL|Zavegepant 10 mg Intranasal (IN)|All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
62078945|NCT01905579|EXPERIMENTAL|patients without uveitis|Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery
62078946|NCT05802160|EXPERIMENTAL|Good Start Matters Parenting intervention|The intervention group will receive immediate access to the app where the Good Start Matters - Parenting intervention will be delivered over a 2-months period.
62078947|NCT05802160|NO_INTERVENTION|Control|The control group will not receive access to the intervention until they complete the follow-up measures (after 10 weeks).
62078948|NCT00838643||Allogeneic pts|Adult allogeneic HSCT recipients
62078949|NCT01454492||Allergy rhinitis|Allergy rhinitis patients group
62078950|NCT01454492||Non- Allergy rhinitis|Non- Allergy rhinitis patients group
62078951|NCT00570661|EXPERIMENTAL|ITF2357|"ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength (dose strengths of 7.5, 10, 12.5, 15, 20 mg and 50 mg).~Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity"
62078952|NCT01423864|SHAM_COMPARATOR|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
62078953|NCT01423864|EXPERIMENTAL|Drug: intrapleural steroid instillation|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
62078954|NCT03541642|EXPERIMENTAL|Enhanced Intervention|Women who are eligible and randomized to the Enhanced Intervention will receive targeted PrEP counseling; targeted written/visual materials, follow up supportive text messages, and distribution of PrEP at the syringe exchange
62078955|NCT03541642|ACTIVE_COMPARATOR|Basic Intervention|"Women who are eligible and randomized to the Basic Intervention will receive usual care with general messaging from medical personnel, reminder text messages, and distribution of PrEP at the syringe exchange"
62078956|NCT01387503|EXPERIMENTAL|Group 1 - Transplant strategy|Patients randomized to Group 1 will be enlisted for liver transplantation and will undergo liver transplantation within 8 months unless oncological (i.e. extrahepatic disease) or medical (i.e. cardiac insufficiency) will occur
62647408|NCT03826251||systematic nasogastric tube|NGT was left systematically after surgery and removed after the first flattus
62078957|NCT01387503|NO_INTERVENTION|Group 2 - Non-transplant strategy|Patients randomized to Group 2 will continue to receive treatments according to their stage of disease, or will undergo only strict follow-up should a complete response after downstaging treatments have been achieved
62078958|NCT05310032|EXPERIMENTAL|HSG4112 800 mg Single Dose|Single oral dosing of HSG4112 800 mg
62078959|NCT05310032|EXPERIMENTAL|HSG4112 1200 mg Single Dose|Single oral dosing of HSG4112 1200 mg with a high-fat meal or fasting condition, with a washout period of 21 days in between each dosing
62078960|NCT05310032|EXPERIMENTAL|HSG4112 800 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
62647409|NCT03826251||Non systematic nasogastric tube|Nasogastric tube was removed immediately after surgery and was replaced in case of vomiting
62078961|NCT05310032|PLACEBO_COMPARATOR|Placebo 800 mg Multiple Dose|Multiple oral dosing of placebo 800 mg for 14 days
62647410|NCT00830219|EXPERIMENTAL|1|
62647411|NCT00830219|ACTIVE_COMPARATOR|2|
62647412|NCT04507152|EXPERIMENTAL|Blood flow restriction resistance training|
62647413|NCT04507152|ACTIVE_COMPARATOR|Resistance training|
62647414|NCT04722406||Low TGR group|Patients with low level of TGR determined by X-tile program
62078962|NCT05310032|EXPERIMENTAL|HSG4112 1200 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
62078963|NCT05310032|PLACEBO_COMPARATOR|Placebo 1200mg Multiple Dose|Multiple oral dosing of placebo 1200 mg for 14 days
62078964|NCT04681430|EXPERIMENTAL|convalescent plasma (CP)|Administration of 2 units of CP (neutralizing anti-SARS-CoV-2 antibody titer of at least 1:160) on day 1
62078965|NCT04681430|OTHER|Standard of Care|Standard of care allowed
62078966|NCT04681430|EXPERIMENTAL|Camostat Mesilate|Tablets 600 mg per day in 3 doses over 7 days
62647415|NCT04722406||High TGR group|Patients with high level of TGR determined by X-tile program
62647416|NCT04578665|EXPERIMENTAL|Healthy Participants Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
62647417|NCT04578665|EXPERIMENTAL|Healthy Participants Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
62647418|NCT04578665|EXPERIMENTAL|Clinical Populations Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
62647419|NCT04578665|EXPERIMENTAL|Clinical Populations Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
62078967|NCT04681430|PLACEBO_COMPARATOR|Placebo camostat|Placebo Tablets in 3 doses over 7 days (blinded)
62078968|NCT02810119|EXPERIMENTAL|LO2A|Sodium Hyaluronate
62647420|NCT03228901|EXPERIMENTAL|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
62647421|NCT03228901|PLACEBO_COMPARATOR|Placebo|Matched nasal spray
62647422|NCT01737606|EXPERIMENTAL|echography|Fast Cerebral Pulsatility Imaging
62647423|NCT02532036|EXPERIMENTAL|Starter Group|Receive 1x10\^7 pfu aerosol inhaled MVA85A at day 0.
62647424|NCT02532036|EXPERIMENTAL|Group A|Receive 5x10\^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
62647425|NCT02532036|EXPERIMENTAL|Group B|Receive 5x10\^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
62647426|NCT01470716|EXPERIMENTAL|Study arm|Neo-adjuvant Erlotinib treatment arm.
62457449|NCT02620345|EXPERIMENTAL|Dydrogesterone M/ Women Pregnancy|"* Reducing the size of fibroids with medication~* Drug: Dydrogesterone M 15mg/Fibroids/Women Pregnancy~* Dosage:~* 1tablet/24 hours/day/ (when seeing fibroids to 4 weeks after postpartum). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~  * The lost in size of fibroids throughout pregnancy after 48 weeks."
62647427|NCT04346316|ACTIVE_COMPARATOR|SHR0302 Dose#1|
62647428|NCT04346316|ACTIVE_COMPARATOR|SHR0302 Dose#2|
62647429|NCT04346316|ACTIVE_COMPARATOR|SHR0302 Dose#3|
62647430|NCT04346316|PLACEBO_COMPARATOR|Placebo|
62647431|NCT02135952|ACTIVE_COMPARATOR|SRP+MTZ+AMX|Scaling and root planing (SRP) + metronidazole (MTZ; 400 mg thrice a day \[TID\] for 14 days) + amoxicillin (AMX; 500 mg TID for 14 days)
62078969|NCT02810119|PLACEBO_COMPARATOR|Placebo-Controlled Saline|Placebo
62078970|NCT05192980|OTHER|Peripheral neuroblastic tumors (ganglioneuroma, ganglioneuroblastoma and neuroblastoma)|
62078971|NCT01915147|EXPERIMENTAL|OXN PR followed by OxyPR tablets|OXN PR followed by OxyPR tablets
62647432|NCT02135952|PLACEBO_COMPARATOR|SRP+placebo|Scaling and root planing + placebo
62647433|NCT06464627|EXPERIMENTAL|Physical activity|The project lasts 16 weeks and focuses on: improving skills and capacities of refugee and host community youth to support their psychosocial wellbeing and mental health through improved access to safe sport; developing a new/strengthened social and support network through safe sport, including those from diverse backgrounds among refugee and host community youth; working with and ensuring District Level officials appreciate and advocate for Sport for Protection activities.
62078972|NCT01915147|EXPERIMENTAL|OxyPR followed by OXN PR tablets|OxyPR followed by OXN PR tablets
62078973|NCT06475469|OTHER|Patients with untreated Chronic Lymphocytic Leukemia (CLL)|
62078974|NCT05217069|OTHER|RAS wild-type Avelumab|"Induction therapy:~FOLFIRI 5-FU: 400 mg/m2 (i.v. bolus) Folinic acid: 400mg/m2 Irinotecan: 180 mg/m2 5-FU: 2.400 mg/m2 (i.v. 46h)~Cetuximab 400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w~Maintenance therapy:~Avelumab 10mg/kg IV (day 1 q2w)"
62647434|NCT06464627|NO_INTERVENTION|Wait list|Wait list
62647435|NCT04559984|EXPERIMENTAL|JUVÉDERM VOLUX®|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional touch-up treatment at week 4 if agreed upon by both the participant and Treating Investigator.
62647436|NCT04559984|OTHER|Control- No treatment|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
62647437|NCT05143463|EXPERIMENTAL|Sequential SAD - NS101|A staggered dosing schedule will be used for each dose level administered under fasting conditions.
62647438|NCT05143463|PLACEBO_COMPARATOR|Sequential SAD - NS101 Placebo|Volume of matching placebo will be determined based on subject weight and NS101 concentration per cohort.
62647439|NCT03052205|EXPERIMENTAL|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
62647440|NCT03523286|EXPERIMENTAL|RAPID-VT Software guided ablation|The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation
62647441|NCT01217593|EXPERIMENTAL|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
62647442|NCT01217593|ACTIVE_COMPARATOR|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
62647443|NCT00235807|OTHER|1|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
62647444|NCT00235807|OTHER|2|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
62647445|NCT00235807|OTHER|3|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
62647446|NCT03273855|ACTIVE_COMPARATOR|Intervention|Active Comparator. Transplant from Donor A or Donor B, or Donor C or Donore D, one transplant consist of 50-80g of feacal matter.
62647447|NCT03273855|PLACEBO_COMPARATOR|Placebo|Placebo. Patient will recieve an autologous fecal microbiota transplantation.
62647448|NCT01173172|EXPERIMENTAL|BNCT, recurrent head and neck cancer|Single arm treated by BNCT only
62078975|NCT01466764|ACTIVE_COMPARATOR|Anakinra|Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
62647449|NCT02377596||Perceived Feeding Difficulties|To complete the study we will recruit at least 40 of the children perceived by their parents or guardian to have feeding difficulties.
62647450|NCT05137665||Amyotrophic Lateral Sclerosis ALS|Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
62647451|NCT05137665||Healthy|Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
62647452|NCT03568201|EXPERIMENTAL|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
62647453|NCT03568201|SHAM_COMPARATOR|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
62078976|NCT01466764|PLACEBO_COMPARATOR|Saline injection|Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
62457450|NCT02620345|EXPERIMENTAL|Dydrogesterone M/ Reproductive Age|"* Reducing the size of fibroids with medication~* Drug: Dydrogesterone M 15mg/Fibroids/Reproductive Age~* Dosage:~* 1tablet/24 hours/day/24 weeks ( from discovered fibroids through 24 weeks). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~  * The lost in size of fibroids after 24 weeks."
62078977|NCT05649488|EXPERIMENTAL|Experimental group|184 patients were enrolled in the experimental group
62457451|NCT04605107|EXPERIMENTAL|A test|Epifasi 5000 I.U. Ampoules
62647454|NCT04031716|NO_INTERVENTION|Control|Participants in the control group will receive present standard of care, which includes an assessment of participant/family needs by integrative care after surgery, as well as standard holistic health care by a licensed/certified holistic health specialist. They will not receive the MUSETM focused-attention meditation training or intervention protocol.
62078978|NCT05649488|OTHER|Optical Coherence Tomography Subgroup|70 patients in the test group were enrolled in the OCT subgroup.
62078979|NCT04017702||Pregnant women with gestational age between 32-40 weeks.|100 patients scheduled for cesarean section under neuraxial anesthesia with 150 mcg intrathecal or 3-mg epidural morphine.
62078980|NCT04017702||Patients post anesthesia care units (PACU) and surgical floor.|100 patients scheduled to receive General Anesthesia (GA) and planned to receive opioid intravenously (boluses/patient controlled analgesia (PCA).
62078981|NCT04017702||Patients in step down/ICU.|50 patients suffered from rib fracture and 50 patients after weaning from mechanical ventilation and extubation.The Expiron will provide continuous information about the respiratory status (tidal volume, respiratory rate and minute ventilation) of non-intubated patients specifically: sleeping or awake; with the use of incentive spirometry; the response to medications and other interventions (such as paravertebral/epidural block); the need for endotracheal re-intubation.
62078982|NCT02963688||KGOG 3019|Korean women with HG serous and/or endometrioid epithelial ovarian cancer
62078983|NCT01957696||Pancreas-Tx recipients; single cohort|This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients \> 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.
62457452|NCT04605107|ACTIVE_COMPARATOR|B reference|Pregnyl 5000 I.U. Ampoules
62457453|NCT03127137|ACTIVE_COMPARATOR|Experimental Group 1|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
62457454|NCT03127137|PLACEBO_COMPARATOR|Experimental Group 2|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
62647455|NCT04031716|EXPERIMENTAL|Meditation|Participants randomized to receive focused-attention meditation training will attend a preoperative training session, provided by a licensed/certified Holistic Health Specialist. The content will include an age appropriate explanation of focused-attention meditation, using breath as the focus; set-up and utilization of the MUSETM headband; and experiential practices. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions, and thoughts), provide self-regulation strategies, and promote healthy and adaptive responses to stress.
62647456|NCT05181267|EXPERIMENTAL|Intermittent fasting|Three weeks of alternate-day fasting.
62647457|NCT05181267|NO_INTERVENTION|Western diet|Three weeks of normal Western diet (no restrictions).
62647458|NCT05190614||thick-gingiva group|After the insertion of the probe into the facial aspect of the sulcus through the gingival margin, the simple visual method is based on the transparency of the periodontal probe through the gingival margin while probing the buccal sulcus at the midfacial aspect of the tooth. When the outline of the underlying periodontal probe can't be seen through the gingival, the gingival phenotype is considered thick.
62647459|NCT05190614||thin-gingiva group|After the insertion of the probe into the facial aspect of the sulcus through the gingival margin, the simple visual method is based on the transparency of the periodontal probe through the gingival margin while probing the buccal sulcus at the midfacial aspect of the tooth. When the outline of the underlying periodontal probe can be seen through the gingival, the gingival phenotype is considered thin.
62647460|NCT02075125|EXPERIMENTAL|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
62647461|NCT02075125|EXPERIMENTAL|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
62647462|NCT03071601|EXPERIMENTAL|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
62647463|NCT03071601|EXPERIMENTAL|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
62647464|NCT02059707|EXPERIMENTAL|LAA exclusion procedure|LAA exclusion with the LARIAT RS Suture Delivery Device
62078984|NCT02506959|EXPERIMENTAL|Treatment (panobinostat, Gem/Bu/Mel, ASCT)|Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.
62078985|NCT00549822|EXPERIMENTAL|Intermittent letrozole therapy|Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
62457455|NCT01196052|EXPERIMENTAL|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.
62457456|NCT03832400|EXPERIMENTAL|MET-2 20 g|Subjects will be given a once-daily loading dose of 5 grams (g) of MET-2 in the form of 10 MET-2 capsules orally for the first 4 days. For the following 10 days, patients will take 1.5 g MET-2 in the form of three MET-2 capsules taken once-daily
62078986|NCT06413641|ACTIVE_COMPARATOR|Usual care|Usual care follow up in general practice
62078987|NCT06413641|EXPERIMENTAL|Low intensity intervention|Individualized video-based or ambulatory consultation by a special trained nurse within 2 weeks from the index CTA test
62078988|NCT06413641|EXPERIMENTAL|High intensity intervention|Individualized video-based or ambulatory consultation by a special trained nurse within 2 weeks from the index CTA test combined with visualization of the individual CTA images with focus on the atherosclerotic findings and the effect of statin treatment on the disease
62457457|NCT03832400|EXPERIMENTAL|MET-2 40 g|Subjects will be given a once-daily loading dose of 10 g of MET-2 in the form of 20 MET-2 capsules orally for the first 4 days. For the following 10 days, subjects will take 1.5 g MET-2 in the form of three MET-2 capsules taken once daily
62457458|NCT03832400|PLACEBO_COMPARATOR|Placebo oral capsule|Subjects receive 10 placebo capsules that are identical in appearance to the MET-2 capsules
62457459|NCT03006016|EXPERIMENTAL|Omega 3|The patient will take Omega 3 before intervention 4-week course of 1.500 Mg/ day without caloric restriction
62457460|NCT03006016|PLACEBO_COMPARATOR|Placebo|The patient will take placebo before intervention 4-week course of 1.500 Mg/ day without caloric restriction
62457461|NCT03180866|NO_INTERVENTION|Non-treatment Control|Control arm will not have any intervention
62457462|NCT03180866|EXPERIMENTAL|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
62457463|NCT03160352|EXPERIMENTAL|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
62647465|NCT06389617|ACTIVE_COMPARATOR|GROUP DF|supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous dexamethasone 4mg
62647466|NCT06389617|ACTIVE_COMPARATOR|GROUP DE|supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous dexamethasone 8mg
62078989|NCT04695158||COVID-19 group (Group I)|Patients diagnosed with COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatment according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020.
62647467|NCT01545336|EXPERIMENTAL|Anastrozole|1 mg tablet by mouth once daily for 3 months
62647468|NCT01545336|PLACEBO_COMPARATOR|Placebo|Placebo tablet by mouth once daily for 3 months
62647469|NCT01544036|EXPERIMENTAL|Contrast Enhanced Ultrasound|Renal blood flow before and after exposure to iodinated contrast agent (perflutren) also known as Definity will be measured using contrast enhanced ultrasound (CEUS).
62647470|NCT05265117||HIPEC|HIPEC is given after primary debulking surgery or interval debulking.
62647471|NCT05265117||CONTROL|No HIPEC
62078990|NCT04695158||Type II Diabetes Mellitus and COVID-19 group (Group II)|Patients diagnosed with both Type II Diabetes Mellitus and COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatments according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020 and routine treatment for Type II Diabetes Mellitus.
62078991|NCT04695158||Control group (Group III)|Healthy volunteers will be in this group. No intervention will be applied in this group.
62078992|NCT05193721|EXPERIMENTAL|Treatment group|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
62647472|NCT02123641|ACTIVE_COMPARATOR|Heavy resistance training|Heavy resistance training of the lower and upper extremities three times weekly for 52 weeks.
62647473|NCT02123641|EXPERIMENTAL|Moderate intensity training|Home-based moderate intensity training of the lower and upper extremities three times weekly for 52 weeks.
62647474|NCT02123641|EXPERIMENTAL|Control|No training
62647475|NCT06178692||Arm 1|IDH1 mutated
62647476|NCT06178692||Arm 2|IDH1 wt
62647477|NCT02709746|EXPERIMENTAL|Vortioxetine 10 mg/day|
62647478|NCT02709746|EXPERIMENTAL|Vortioxetine 20 mg/day|
62647479|NCT02709746|ACTIVE_COMPARATOR|Fluoxetine 20 mg/day,|
62647480|NCT02709746|PLACEBO_COMPARATOR|Placebo|
62078993|NCT01927692||MG subjects|MG subjects will have serum acetylcholine receptor (AChR) antibodies
62078994|NCT02398162||STP|Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
62078995|NCT02398162||STE|Scrub Typhus Exposed (STE, n=80) Cohort. Single blood sample collection.
62647481|NCT04333004|EXPERIMENTAL|Pembrolizumab Combined With Chemotherapy|
62647482|NCT04956211|EXPERIMENTAL|Non-surgical periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments .
62647483|NCT04956211|ACTIVE_COMPARATOR|Conventional periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Supragingival cleaning and polishing of all dentition will be delivered to individuals in this group.
62647484|NCT00997945|EXPERIMENTAL|1|ZD4054 (Zibotentan) 10mg
62647485|NCT01535885|EXPERIMENTAL|Multi-Virus CTLs|The treatment plan delivers a single dose of Multi-Virus CTL to all patients enrolled on study.
62647486|NCT01923519|EXPERIMENTAL|allergic rhinitis|
62647487|NCT01923519|EXPERIMENTAL|allergic rhinitis and asthma|
62647488|NCT01923519|EXPERIMENTAL|witnesses|
62647489|NCT05469594||Termination of pregnancy between 12-14 weeks of gestation|
62647490|NCT05469594||Termination of pregnancy between 14-16 weeks of gestation|
62647491|NCT06312917|EXPERIMENTAL|Physical activity group|Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China
62457464|NCT05327699|EXPERIMENTAL|Major depressive disorder (MDD) Ketamine|Participants randomized to the ketamine arm will receive a single intravenous (IV) infusion of ketamine at 0.5mg/kg through an indwelling catheter over a 40-100min period.
62078996|NCT02398162||STH|Scrub Typhus Healthy (STH, n=30) Cohort. Single blood sample collection
62457465|NCT05327699|PLACEBO_COMPARATOR|Major depressive disorder (MDD) Placebo|Participants randomized to the placebo arm will receive a single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
62647492|NCT06312917|NO_INTERVENTION|control group|Maintain the current state of physical activity, do not do physical activity intervention.
62647493|NCT01932489|OTHER|Sequencing of a metastatic lesion.|Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
62647494|NCT05024279|EXPERIMENTAL|Intervention Arm|Patients are randomized to receive left bundle branch are pacing due to higher degree AV block
62647495|NCT05024279|ACTIVE_COMPARATOR|Control Arm|Patients are randomized to receive standard right ventricular pacing due to higher degree AV block.
62647496|NCT01108939|EXPERIMENTAL|Antimalarial treatment|
62647497|NCT01108939|SHAM_COMPARATOR|Observation|
62457466|NCT05327699|NO_INTERVENTION|Healthy Controls|The subjects in this group will not receive any intervention.
62457467|NCT06440564|EXPERIMENTAL|Er:YAG Laser intervention|In addition to the standard DAIR procedure, laser light is used to disrupt the biofilm from implant surfaced.
62457468|NCT06080061|EXPERIMENTAL|Hypofractionated accelerated radiation therapy (HART)|Patients will either be treated with 60-66 Gy in 30, 25, or 20 fractions based on ability to meet constraints to key organs at risk
62457469|NCT03399526|EXPERIMENTAL|Mapracorat|10 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
62647498|NCT01565863|EXPERIMENTAL|Progressive Goal Attainment Program|
62647499|NCT01565863|NO_INTERVENTION|VA employment services|
62647500|NCT02592824|ACTIVE_COMPARATOR|Intravenous glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
62457470|NCT03399526|ACTIVE_COMPARATOR|Prednicarbate|10 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
62457471|NCT03399526|ACTIVE_COMPARATOR|Clobetasol|10 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
62647501|NCT02592824|PLACEBO_COMPARATOR|Intravenous saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
62647502|NCT03558516|EXPERIMENTAL|Magnesium group|The patient will receive magnesium sulfate injection 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed
62647503|NCT03558516|PLACEBO_COMPARATOR|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed
62078997|NCT03157024|EXPERIMENTAL|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
62078998|NCT03157024|ACTIVE_COMPARATOR|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
62078999|NCT03157024|SHAM_COMPARATOR|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
62647504|NCT05786859|EXPERIMENTAL|Rifaximin Treatment Group|
62457472|NCT03399526|ACTIVE_COMPARATOR|Calcipotriene|10 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
62647505|NCT05786859|SHAM_COMPARATOR|Standard Treatment Group (control group)|
62647506|NCT04351620|EXPERIMENTAL|Hydroxychloroquine|"Hydroxychloroquine 1200 mg daily administered as 600 mg BID for five days or until fevers abate (maximum ten days of treatment allowed).~If patients report gastrointestinal discomfort, the dose will be administered as 400 mg TID."
62647507|NCT01330888||Group 1|ARNG Chaplains
62647508|NCT06054841|EXPERIMENTAL|Follow up cards|Subjects will receive a personalized postpartum health card with recommendations for follow up based on their comorbid conditions in pregnancy. They will receive education about these comorbid conditions when they receive their cards.
62647509|NCT06054841|PLACEBO_COMPARATOR|Standard education|Subjects will receive standard postpartum education as it is routinely performed by nurses prior to discharge.
62647510|NCT06284499||Group 1|"Group 1 (n = 31), which contained patients fitted with 0.038 × 0.016 stainless steel wire (Ortho FlexTech® chain, Reliance Orthodontic Products, Itasca, IL, USA)"
62647511|NCT06284499||Group 2|"Group 2 (n = 23), which contained patients fitted with 0.010 × 0.026 8-braided dead soft wire (Bond-A-Braid,Reliance Orthodontic Products, Itasca, IL, USA)"
62079000|NCT04956861|NO_INTERVENTION|Phase 1|Phase 1 is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 7 hours/night (short sleep).
62647512|NCT06284499||Group 3|"Group 3 (n = 28), which contained patients fitted with 0.0215 5-stranded stainless steel wire (Penta-One®, Masel Orthodontics, Carlsbad, CA, USA)"
62647513|NCT06284499||Control group|Control group (n = 20), which contained individuals who had not received any orthodontic treatment
62647514|NCT03318185|EXPERIMENTAL|gasless single-port laparoscopic surgery|radical resection of rectal carcinoma is performed by gasless single-port laparoscopic-assisted surgery.
62647515|NCT03318185|SHAM_COMPARATOR|conventional laparoscopic surgery|radical resection of rectal carcinoma is performed by conventional laparoscopic surgery.
62079001|NCT04956861|EXPERIMENTAL|Phase 2|Phase 2 is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep less than 7 hours/night.
62079002|NCT02618057|EXPERIMENTAL|Steroid|Prednisolone, 1.0 mg/kg/day, PO, for 5 days Levofloxacin, 10mg/kg/day, IV, for 5days
62079003|NCT02618057|ACTIVE_COMPARATOR|Control|Levofloxacin, 10mg/kg/day, IV, for 5days
62647516|NCT02700399|OTHER|Erigo® First|"Erigo® 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Traditional Tilt table 0 - 60 degrees~Step frequency on Erigo® = 48"
62647517|NCT02700399|OTHER|Traditional first|"Traditional Tilt table 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Erigo® 0 - 60 degrees~Step frequency on Erigo® = 48"
62647518|NCT03385733|EXPERIMENTAL|Inspiratory muscle training group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with %30 MIP at home.
62647519|NCT03385733|NO_INTERVENTION|control group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with 9 cmH2O pressure at home.
62647520|NCT04590118|EXPERIMENTAL|Experimental: it-hMSC|Single intravenous infusion of 0.5×10\^6, 1×10\^6, 2×10\^6 it-hMSC/kg
62647521|NCT04590118|PLACEBO_COMPARATOR|Placebo-controlled: Placebo|Single intravenous infusion of 1 ml/kg placebo
62647522|NCT05348304|NO_INTERVENTION|Control|Hypocaloric diet
62647523|NCT05348304|EXPERIMENTAL|EUDIAMET|Hypocaloric diet plus a supplementation with myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
62647524|NCT05159934|ACTIVE_COMPARATOR|Nicotine|Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
62647525|NCT05159934|PLACEBO_COMPARATOR|saline|Saline will compared to different nicotine doses. Nicotine doses: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
62079004|NCT01604811|EXPERIMENTAL|Tested product|
62079005|NCT01604811|ACTIVE_COMPARATOR|Comparator|
62280071|NCT05673941|EXPERIMENTAL|Creative movement|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
62647526|NCT02860988|EXPERIMENTAL|MCCC Treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
62647527|NCT02860988|NO_INTERVENTION|MCCC Comparison|Participants in this condition did not receive reentry services related to responsible parenting, economic stability and mobility, or healthy marriage and relationships.
62647528|NCT01980953|EXPERIMENTAL|Part 1: Food Effect|GDC-0032 will be administered orally over 3-Treatment Period (TP) in 6-sequence as one 3 milligrams (mg) capsule in TP-A after 10 hour fasting from food, one 3 mg Phase III tablet in TP-B after 10 hour fasting from food and one 3 mg Phase III tablet in TP-C following the start of standard Food and Drug Administration (FDA) high-fat breakfast. Washout period o 14 to 20 days will be given between each TP.
62647529|NCT01980953|EXPERIMENTAL|Part 2: Tablet Formulation Comparison|Different formulations of tablets (Tablet A and Tablet B) of GDC-0032 will be administered orally over 2-TP having 10 hour fasting from food. Participants will receive one 3 mg Tablet A in TP-A and one 3 mg Tablet B in TP-B after 14 to 20 days washout period.
62647530|NCT01980953|EXPERIMENTAL|Part 3: Capsule API Lot Comparison|Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
62280072|NCT05673941|NO_INTERVENTION|Control group|The control group receives standard medical care and gets access to the intervention in digital form after the study has ended.
62457473|NCT03399526|ACTIVE_COMPARATOR|Calcipotriene/Betamethasone dipropionate|10 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total \[diameter 2 cm, distance to next test field at least 2 cm\]). 200 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total \[diameter 1.8 cm, distance to next test field at least 1.5 cm\]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
62647531|NCT01980953|EXPERIMENTAL|Part 4: Tablet Relative Bioavailibity|GDC-0032 will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 2 mg Phase III tablet in TP-B after 14 to 20 days washout period.
62647532|NCT00193908|EXPERIMENTAL|1|
62647533|NCT00193908|EXPERIMENTAL|2|
62647534|NCT05310877|EXPERIMENTAL|Values-affirmation|
62647535|NCT01922934|EXPERIMENTAL|Intervention|"350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability."
62647536|NCT01922934|NO_INTERVENTION|Control|Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.
62647537|NCT06003361|EXPERIMENTAL|Digital CBT|digitally-delivered CBT for depression accessed via mobile app
62280073|NCT04123158||WHITE|If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
62647538|NCT06003361|OTHER|Waitlist|Participants will wait for 5 weeks prior to receiving the intervention
62647539|NCT05252637|EXPERIMENTAL|Duplication plus LSC|Laparoscopic duplication of posterior vagina plus mesh placement
62457474|NCT00741663|ACTIVE_COMPARATOR|A|
62457475|NCT00741663|EXPERIMENTAL|B|
62647540|NCT05252637|NO_INTERVENTION|LSC|Laparoscopic Sacral Colpopexy with mesh placement on posterior vagina
62647541|NCT02125240|EXPERIMENTAL|Icotinib|125 mg three times daily (375 mg per day) by mouth
62647542|NCT02125240|ACTIVE_COMPARATOR|Placebo|1 tablet three times daily by mouth
62647543|NCT03659344|ACTIVE_COMPARATOR|Vicryl plus|In this group, vicryl plus(Triclosan coated) sutures were used to close flaps
62647544|NCT03659344|NO_INTERVENTION|vicryl|In this group, vicryl sutures were used to close flaps
62647545|NCT06441409|EXPERIMENTAL|lifestyle intervention|"Patients were intervened with lifestyle only and returned to clinic for tests in 6 months.~Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day."
62647546|NCT03203785|EXPERIMENTAL|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
62647547|NCT03203785|PLACEBO_COMPARATOR|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
62647548|NCT05831800|OTHER|Wearable bioimpedance sensor|
62079006|NCT02710058||Arab American Women with Breast Cancer|We conducted a study using an evaluation assessment survey to assess the impact of the AMBER support groups on quality of life parameters, compliance with treatment appointments, and patient/family support. After reviewing preliminary results, we identified several recurrent themes, such as the need for health information, discrepancies around the extent of family support and disease disclosure, and an overall satisfaction with the support groups. To further examine these themes, we are initiating a qualitative research study using an in-depth interview guide. A trained interviewer bilingual in Arabic and English will conduct 10-15 in-depth interviews, to saturation, with AMBER's support group participants over a 6 month period.
62079007|NCT00729690|EXPERIMENTAL|1 Multi-Dose Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
62647549|NCT06032637|ACTIVE_COMPARATOR|Pfannenstiel incision|Patients randomized to the Pfannenstiel incision arm will undergo a transverse skin incision 2-3cm above the symphysis pubis. Subcutaneous tissue will be dissected until anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the inferior epigastric arteries. Rectus muscles will be separated manually along midline using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally with uterine traction to deliver fetus. The visceral peritoneum will not be closed. Rectus muscles will not be re-approximated. Subcutaneous tissue will not be irrigated. Subcutaneous tissue will be closed if over 2cm depth. Skin will be closed with non-absorbable suture subcuticularly.
62079008|NCT00729690|EXPERIMENTAL|2 single-dose pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
62079009|NCT00729690|PLACEBO_COMPARATOR|3 Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
62079010|NCT05636137||High School Students|The sample of the study consists of high school students who do not have mental disabilities that will prevent them from understanding and answering the questions, aged 15-18 and volunteer to participate in the study, have internet at home and have an individual device that provides internet access.
62079011|NCT01928225|EXPERIMENTAL|Human Papillomavirus vaccine|Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
62079012|NCT01928225|PLACEBO_COMPARATOR|Saline placebo|The participants receive saline placebo at entry, week 4 and week 26.
62079013|NCT04131959|EXPERIMENTAL|Pharmacodynamic population|Single arm
62647550|NCT06032637|EXPERIMENTAL|Supra-Umbilical|Patients randomized to the supra-umbilical transverse incision arm will undergo a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. Subcutaneous tissue will be bluntly dissected until anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. Rectus muscles will be split manually along midline using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally with uterine traction to deliver fetus. The visceral peritoneum will not be closed. Rectus muscles will not be re-approximated. Subcutaneous tissue will not be irrigated. Subcutaneous tissue will be closed if over 2cm depth. Skin will be closed with non-absorbable suture subcuticularly.
62647551|NCT03933488|EXPERIMENTAL|TAK-994: Part A|TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 \[fasted and fed dosing conditions\]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.
62647552|NCT03933488|EXPERIMENTAL|TAK-994: Part B|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
62079014|NCT05221203|EXPERIMENTAL|Training|Participants in this arm will perform seven bodyweight training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
62079015|NCT05221203|NO_INTERVENTION|Control|Participants in this arm will receive no intervention.
62079016|NCT00798174|EXPERIMENTAL|Standard configuration vs. azygos coil|"The DFT with the standard Superior Vena Cava (SVC) coil vs. DFT with the azygos coil.~In this crossover study, each patient serves and own control, with defibrillation testing performed with and with the azygos coil"
62079017|NCT01272986|PLACEBO_COMPARATOR|Healthy patients|
62079018|NCT01272986|ACTIVE_COMPARATOR|Asymptomatic myocardial Ischemic patients|
62079019|NCT01272986|ACTIVE_COMPARATOR|Acute Coronary Syndrome Patients|
62647553|NCT03933488|EXPERIMENTAL|TAK-994: Part C|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
62079020|NCT03230864|EXPERIMENTAL|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
62079021|NCT03230864|EXPERIMENTAL|Double-blind treatment (DBT) period, Lu AF35700 10 mg|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks
62079022|NCT03230864|EXPERIMENTAL|DBT Period, Continued treatment from PC Period|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks. Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period
62647554|NCT03933488|EXPERIMENTAL|TAK-994: Part D|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
62079023|NCT02685592|EXPERIMENTAL|Lentigo maligna patients|All the participants with histologically confirmed lentigo maligna will receive photodynamic therapy three times with 2 weeks' intervals. The borderline of treatment area is delineated with Wood's lamp and hyperspectral imaging system using 5 millimeter margins. Before applying the 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) light sensitizing gel the skin of treatment area is prepared with fractional ablative CO2-laser to enhance absorption. Ameluz® is spread as a 1 millimeter thick layer on the skin. After light sensitizer absorption the treatment area is illuminated with artificial red light (Aktilite CL128 lamp) using a light dose of 90 J/cm2. Finally 4 weeks after the last PDT treatment LM is excised surgically using 5 mm margins.
62079024|NCT05602337||Immunocompetent BCC Subjects|BCC-predominant group
62079025|NCT05602337||Immunocompetent SCC Subjects|SCC-predominant group
62079026|NCT05602337||Immunocompetent MM Subjects|Melanoma group
62647555|NCT03933488|EXPERIMENTAL|TAK-994: Part E|TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
62647556|NCT03320356||shoulder pain|Patients presenting inflammatory, degenerative, or post-traumatic shoulder pain and consulting at Orthopaedic Department, Reims Teaching Hospital.
62647557|NCT04407546||Families with Children|Families containing an immunocompromised individual that have children in the family setting.
62079027|NCT05602337||Control|age, sex and Fitzpatrick phototype match
62079028|NCT05602337||Solid Organ Transplantation Recipient - SC|At least 5 skin cancers and at least 5 years post-transplant
62079029|NCT05602337||Solid Organ Transplantation Recipient|No more than 1 skin cancer and at least 5 years post-transplant
62079030|NCT02328157|EXPERIMENTAL|Cataract with ERM and astigmatism|Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter.
62079031|NCT00914537||1|Human immunodeficiency virus (HIV) positive adult men who have sex with men that are members of KPNC (Kaiser Permanente Northern California) and do not have a current anal cancer diagnosis.
62457476|NCT01641445|ACTIVE_COMPARATOR|Topiramate|Topiramate (200 mg) taken orally daily
62457477|NCT01641445|PLACEBO_COMPARATOR|Sugar pill|"Placebo (sugar pill) taken orally daily"
62647558|NCT04407546||Famlies without children|Families containing an immunocompromised individual that do not have children in the family setting.
62647559|NCT05286892|ACTIVE_COMPARATOR|Control|Participants randomized to the control group will receive enhanced pre-release diabetes education with registered or licensed practical nurse-delivered diabetes education about medications and insulin administration supplemented with the literacy tailored diabetes education packets used in the principal investigator's prior research.
62079032|NCT00003384|EXPERIMENTAL|Diagnostic|"Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression.~Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks."
62647560|NCT05286892|EXPERIMENTAL|Intervention|Because eight avatars plus the educator avatar are allowed in the VE classroom at one time, we will cap enrollment for the feasibility study to allow for CHW and CDE training and the opportunity to work together during LIVE JustICE sessions. The DSMES will consist of six synchronous 1-hour education sessions and an hour support session for participants living in supervised community housing in the experimental group. We will run the six-week series sequentially a total of eleven times over 18 months. LIVE JustICE sessions will be held conveniently for participants, and days/times rotated if needed.
62647561|NCT05026554||CHE|Adults with moderate to severe chronic hand eczema
62647562|NCT05026554||Healthy Volunteers|Healthy adults
62457478|NCT05436756|OTHER|sampling and clinical data collection|"* Biological sampling and collection:~  * whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~ * urine: 1 bottle of 30ml~* Freezing of serum after centrifugation~* Storage at Biological Ressources Center~* Collection of clinico-biological data on a dedicated eCRF"
62079033|NCT02269943|EXPERIMENTAL|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
62079034|NCT06362343||Patients with pulmonary embolism and using direct oral anticoagulants|Patients with pulmonary embolism and using direct oral anticoagulants
62079035|NCT01378520|EXPERIMENTAL|ketoconazole|600 mg ketoconazole
62457479|NCT04012697|EXPERIMENTAL|Peer Support|Peer support services from a peer support worker in the emergency department.
62457480|NCT04012697|NO_INTERVENTION|Usual care|Usual care in the emergency department.
62457481|NCT05939674|PLACEBO_COMPARATOR|Normal saline group|Participants are administered 3mL of 0.9% normal saline at the end of anesthesia
62457482|NCT05939674|ACTIVE_COMPARATOR|Flumazenil group|Participants are administered 0.3mg(3mL) of flumazenil at the end of anesthesia
62457483|NCT00732290|ACTIVE_COMPARATOR|1|Clopidogrel then fluoxetine+clopidogrel
62647563|NCT05026554||Atopic Dermatitis|subjects with moderate to severe AD
62647564|NCT02142842|EXPERIMENTAL|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be injected into joints of 16 patients with grade 2, 3 radiographic OA severity with 16 patients as control.
62647565|NCT00787878||A|
62647566|NCT00787878||B|
62079036|NCT01378520|PLACEBO_COMPARATOR|inert powder|inert powder in capsule
62079037|NCT00487786|EXPERIMENTAL|A|Each patient receives OGX-427
62079038|NCT04001764|ACTIVE_COMPARATOR|The first group|The radial artery catheterization with ultrasound-guided short axis out of plane intervention will be performed over 2 cm of the wrist for this group.
62079039|NCT04001764|EXPERIMENTAL|The second group|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
62647567|NCT00787878||C|
62457484|NCT00732290|ACTIVE_COMPARATOR|2|Fluoxetine+clopidogrel then clopidogrel
62457485|NCT05194358|EXPERIMENTAL|Cohort 1 SIAN|SIAN dose of 0.28 mg/kg (20 μL) will be administered from a single syringe-based spray device into left nostril.
62647568|NCT05730426|ACTIVE_COMPARATOR|Group A|In addition to Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors), patients received deep dry needling on active trigger points in selected muscles (upper trapezius, levator scapulae, and sternocleidomastoid ), 3 sessions/week, for 4 weeks period.
62079040|NCT04001764|EXPERIMENTAL|The third group|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
62079041|NCT04829435|EXPERIMENTAL|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
62079042|NCT04829435|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
62079043|NCT06002061|EXPERIMENTAL|Muscle Activation|Participants in this arm will receive intervention via application of brief air pressure maneuvers.
62079044|NCT03945110|EXPERIMENTAL|Arm A|Patients in this Arm will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later.
62457486|NCT05194358|EXPERIMENTAL|Cohort 2 SIAN|SIAN dose of 0.73 mg/kg (50 μL) will be administered from a single syringe-based spray device into left nostril.
62647569|NCT05730426|ACTIVE_COMPARATOR|Group B|In addition to Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors), patients received muscle energy technique (post isometric relaxation) in selected muscles (upper trapezius, levator scapulae, and sternocleidomastoid ), 3 sessions/week, for 4 weeks period.
62647570|NCT05730426|PLACEBO_COMPARATOR|Group C|Patients receive Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors) , 3 sessions/week, for 4 weeks period.
62647571|NCT02074514|EXPERIMENTAL|Sofosbuvir+RBV 16 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
62647572|NCT02074514|EXPERIMENTAL|Sofosbuvir+RBV 24 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.
62647573|NCT04577872|EXPERIMENTAL|Supine group (n=22)|The 22 participants with lower muscle strength (under 60 microvolt) comprised the supine group.
62079045|NCT03945110|NO_INTERVENTION|Arm B|Patients in this Arm will receive usual bladder care only.
62457487|NCT05194358|EXPERIMENTAL|Cohort 3 SIAN|SIAN dose of 1.45 mg/kg (100 μL) will be administered from a single syringe-based spray device into left nostril.
62457488|NCT05194358|EXPERIMENTAL|Cohort 4 SIAN|SIAN dose of 2.18 mg/kg (150 μL) will be administered from a single syringe-based spray device into left nostril.
62647574|NCT04577872|EXPERIMENTAL|Sitting group (n=19)|The 19 participants with higher muscle strength (over 60 microvolt) formed the sitting group.
62647575|NCT04577872|NO_INTERVENTION|Control group (n=14)|The control group comprised 7 individuals with lower muscle strength (under 60 microvolt) and 7 with higher muscle strength (over 60 microvolt)
62647576|NCT05344469||Ofatumumab|Patients treated with ofatumumab
62647577|NCT05344469||Standard of Care (SoC)|Patients treated with either interferon β1 (IFN-β1) or glatiramer acetate (GA)
62647578|NCT00914121|EXPERIMENTAL|1|SKI-606 alone
62647579|NCT00914121|PLACEBO_COMPARATOR|2|Placebo
62647580|NCT00914121|ACTIVE_COMPARATOR|3|Moxifloxacin
62079046|NCT03945110|EXPERIMENTAL|Arm C|Patients in this Arm will be Spinal Urology Outpatients or Inpatients who are eligible for inclusion and experiencing significant urinary tract infection recurrence and/or complications. Patients will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later. Patients will be encouraged and supervised to self-administer iAluRil® intravesical instillations.
62079047|NCT01330264||Dyad|
62079048|NCT00289770|EXPERIMENTAL|Group A|Was vaccinated with Lot A in the primary study.
62079049|NCT00289770|EXPERIMENTAL|Group B|Was vaccinated with Lot B in the primary study.
62079050|NCT00289770|EXPERIMENTAL|Group C|Was vaccinated with Lot C in the primary study.
62647581|NCT00914121|EXPERIMENTAL|4|SKI-606 plus ketoconazole
62647582|NCT00914121|PLACEBO_COMPARATOR|5|Placebo plus ketoconazole
62647583|NCT01670292|OTHER|Experimental: HVLA-SM|Experimental High Velocity Low Amplitude Spinal Manipulation
62647584|NCT01047449|ACTIVE_COMPARATOR|SVG harvest - conventional, placebo|
62647585|NCT01047449|EXPERIMENTAL|SVG harvest - no-touch, fish oils|
62647586|NCT01047449|PLACEBO_COMPARATOR|SVG harvest - no-touch, placebo|
62079051|NCT03874780|EXPERIMENTAL|Treatment|Subjects treated with Botox (TM) with the Vibe investigational delivery system
62079052|NCT01644396|OTHER|Adalimumab|Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
62079053|NCT02382237|OTHER|PET/TDM|Evaluation by PET/TDM at 2 times
62079054|NCT05073068|EXPERIMENTAL|AM exercise|
62079055|NCT05073068|EXPERIMENTAL|PM exercise|
62079056|NCT05073068|ACTIVE_COMPARATOR|Control|
62079057|NCT05693467|EXPERIMENTAL|The dexamethasone palmitate emulsion(DXP) plus ropivacaine group|The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of dexamethasone palmitate emulsion(DXP) and ropivacaine.
62079058|NCT05693467|ACTIVE_COMPARATOR|The ropivacaine alone group|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone.
62079059|NCT03649269|EXPERIMENTAL|PC-300 tea|Patients that received the Eryngium heterophyllum + Amphipterygium adstringens tea, one cup half an hour before eating.
62647587|NCT01047449|ACTIVE_COMPARATOR|SVG harvest - conventional, fish oils|
62647588|NCT06550479|EXPERIMENTAL|SBAVF|Patients enrolled for snuffbox fistula creation.
62647589|NCT06550479|EXPERIMENTAL|RCAVF|Patients enrolled for RCAVF
62079060|NCT03649269|ACTIVE_COMPARATOR|Bezafibrate|Patients that received fibrate (bezafibrate) 200 mg/day.
62079061|NCT03059160|EXPERIMENTAL|open label|
62079062|NCT06349122|EXPERIMENTAL|Group A: Screen-and-Treat Strategy|Patients are systematically screened for BV before 18 weeks' gestation by means of a vaginal swab analyzed by the innovative technique, whose result will be disclosed. If positive, appropriate treatment will be prescribed.
62647590|NCT06550479|EXPERIMENTAL|RCAVF with venous branch patch|Patients enrolled for RCAVF with venous branch patch
62647591|NCT05136599|EXPERIMENTAL|Study 1 (Dose-identification study), Cohort 1, Dose #3|Challenge dose of 10\^4 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
62647592|NCT05136599|EXPERIMENTAL|Study 1 (Dose-identification study), Cohort 2, Dose #5|Challenge dose of 10\^5 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647593|NCT05136599|EXPERIMENTAL|Study 1 (Dose-identification study), Cohort 3, Dose #6|Challenge dose of 5 x 10\^5 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647594|NCT05136599|EXPERIMENTAL|Study 1 (Dose-identification study), Cohort 4, Dose #7|Challenge dose of 10\^6 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647595|NCT05136599|EXPERIMENTAL|Study 1 (Dose-identification study), Cohort 5, Dose #8|Challenge dose of 5 x 10\^6 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647596|NCT05136599|EXPERIMENTAL|Study 1 (Dose-identification study), Cohort 6, Dose #9|Challenge dose of 10\^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647597|NCT05136599|EXPERIMENTAL|Study 1 (Dose-identification study), Cohort 7, Dose #9 Repeat|Challenge dose of 10\^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647598|NCT05136599|EXPERIMENTAL|Study 2 (Dose confirmation study), Cohort 8, Dose #9|Challenge dose of 10\^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62079063|NCT06349122|ACTIVE_COMPARATOR|Group B: Control Group/Usual Care or Standard Strategy|Patients are not systematically screened for BV /usual care group.
62079064|NCT00679484|EXPERIMENTAL|1|
62079065|NCT00679484|EXPERIMENTAL|2|
62079066|NCT01157143|EXPERIMENTAL|NV1FGF 500 μg|8 intramuscular injections for a total of 500 μg administered in one single administration 3 to 8 days before major amputation
62079067|NCT01157143|EXPERIMENTAL|NV1FGF 2000 μg|8 intramuscular injections for a total of 2000 μg administered in one single administration 3 to 8 days before major amputation
62647599|NCT05136599|EXPERIMENTAL|Study 2 (Dose confirmation study), Cohort 8, Dose #10|Challenge dose of 5 x 10\^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647600|NCT05136599|EXPERIMENTAL|Study 2 (Dose confirmation study), Cohort 9, Dose #9|Challenge dose of 10\^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647601|NCT05136599|EXPERIMENTAL|Study 2 (Dose confirmation study), Cohort 9, Dose #10|Challenge dose of 5 x 10\^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647602|NCT05136599|EXPERIMENTAL|Study 2 (Dose confirmation study), Cohort 10, Dose #8|Challenge dose of 5 x 10\^6 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62079068|NCT01157143|EXPERIMENTAL|NV1FGF 4000 μg|8 intramuscular injections for a total of 4000 μg administered in one single administration 3 to 8 days before major amputation
62457489|NCT05194358|EXPERIMENTAL|Cohort 5 SIAN|"SIAN dose of 2.90 mg/kg (200 μL) will be administered in two syringe-based spray devices, each containing 100 μL, with dose administered in left then right nostril, one device per nostril.~For doses of 2.90 milligram/kilogram (200 microliter) and higher, the dose will be split equally between the two nostrils to avoid drug overflow from the nose (using two syringe-based spray devices one immediately followed by the other). Lower doses will be administered by a single device to one nostril."
62457490|NCT05194358|EXPERIMENTAL|Cohort 6 SIAN|SIAN dose of 3.63 mg/kg (250 μL) will be administered in two syringe-based spray devices, each containing 125 μL, with dose administered in left then right nostril, one device per nostril.
62647603|NCT05136599|EXPERIMENTAL|Study 2 (Dose confirmation study), Cohort 11, Dose #10|Challenge dose of 5 x 10\^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62079069|NCT03656393|EXPERIMENTAL|Gefitinib therapy group|Patients are treated with Gefitinib (250 mg, orally, every day) for 56 days and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
62079070|NCT03656393|ACTIVE_COMPARATOR|Vinorelbine combination therapy group|Patients are treated with vinorelbine (60 mg/m2, orally, Once every three weeks) plus carboplatin (AUC5, intravenously drip, once a week) for 6 weeks and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
62647604|NCT05136599|EXPERIMENTAL|Sub-Study (Dose confirmation study), Cohort 11, Dose #11|Challenge dose of 10\^8 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
62647605|NCT03641027|EXPERIMENTAL|Increased physical activity|Increased physical activity daily before surgery. Standard care during hospital stay and continued training after discharge.
62647606|NCT03641027|OTHER|Standard care|Standard care
62647607|NCT04644263||Validity and reliability|
62647608|NCT05916222|ACTIVE_COMPARATOR|Indirect Training (DTTC + Home Practice)|Children in the Indirect Training Arm will receive DTTC treatment 2x/week administered by an SLP for 8 weeks. Parent/caregivers in this Arm will complete an online, self-paced educational module on CAS prior to the start of treatment, observe all treatment sessions, and review home practice guidelines with the clinician at the end of each therapy session. Parent/caregivers will engage their children in home practice during the treatment phase and follow-up phase. Home practice will consist of 30-minute practice sessions 3x/week during the 8-week treatment phase and 6x/week during the 4-week follow-up phase.
62079071|NCT03664739|EXPERIMENTAL|IDP-120 Gel|IDP-120 Gel, once-daily application
62079072|NCT03664739|PLACEBO_COMPARATOR|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
62079073|NCT02398682|EXPERIMENTAL|After study Intervention arm Heartlands|"The trial has 4 arms in a Before and After design:~Arm 3. After/Heartlands area patients receiving the experimental intervention~Patients who have AKI and are either inpatients in the Intervention hospital or living within the surrounding catchment area are eligible. The intervention will be in the form of a telephone call to the primary clinician or visit to the patient. The intervention will include:~Rapid diagnosis of AKI cause; Rapid treatment of AKI cause; Stopping 'nephrotoxic' drugs; Early nephrology followup for stage 3 AKI survivors; and preventing recurrent AKI."
62079074|NCT02398682|ACTIVE_COMPARATOR|After study Control arm Good Hope|"The trial has 4 arms in a Before and After design:~Arm 4. After/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
62079075|NCT02398682|ACTIVE_COMPARATOR|Before study Heartlands area|"The trial has 4 arms in a Before and After design:~Arm 1. Before/Heartlands area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Heartlands Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
62079076|NCT02398682|ACTIVE_COMPARATOR|Before study Good Hope area|"The trial has 4 arms in a Before and After design:~Arm 2. Before/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
62079077|NCT04792606||"Natural History or watchful waiting"|
62079078|NCT04792606||Serial botulinum toxin injections|
62647609|NCT05916222|EXPERIMENTAL|Direct Training (DTTC + Coaching + Home Practice)|Children in the Direct Training Arm will receive DTTC treatment 2x/week for 8 weeks with half of each session administered only by the SLP. In the other half of the session, DTTC will be administered by the parent/caregiver with online coaching by the SLP. During the coaching portion of treatment sessions, the SLP will provide direct training to guide the parent/caregiver in the administration of DTTC to support home practice sessions. Parent/caregivers in this Arm will also complete an online, self-paced educational module on CAS prior to the start of treatment and review home practice guidelines with the clinician at the end of each therapy session. Parent/caregivers will engage their children in home practice during the treatment phase and follow-up phase. Home practice will consist of 30-minute practice sessions 3x/week during the 8-week treatment phase and 6x/week during the 4-week follow-up phase.
62647610|NCT02771756|EXPERIMENTAL|test group|Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g, Bid), a total of 150 people, are used for 42 days continuously.
62647611|NCT02771756|PLACEBO_COMPARATOR|placebo group|Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang placebo (50g,Bid), a total of 150 people, are used for 42 days continuously.
62647612|NCT03727165|ACTIVE_COMPARATOR|Continuous infusion|Patients with continuous infusion enteral nutrition in the intensive care unit at San Ignacio University Hospital
62647613|NCT03727165|EXPERIMENTAL|Cyclic infusion|Patients formulated with cyclic enteral nutrition infusion, administrated at night hours, from 4pm until 7am.
62647614|NCT01603277|EXPERIMENTAL|Anti-GM-CSF Monoclonal Antibody 400mg|
62079079|NCT04792606||Adductor (+/- psoas) muscle releases alone|
62079080|NCT04792606||Hip reconstructive surgery|
62079081|NCT04792606||Salvage hip surgery|
62647615|NCT01603277|PLACEBO_COMPARATOR|Normal Saline|
62647616|NCT01276977|EXPERIMENTAL|Zolmitriptan 5 mg nasal spray|
62647617|NCT01276977|ACTIVE_COMPARATOR|Eletriptan 40 mg Tablet|
62079082|NCT06445855|EXPERIMENTAL|Experimental group|Women in the experimental group will receive an 8-week online intervention program based on interpersonal relationships. An internet-based intervention application will be developed for this intervention. All interventions will be implemented from this intervention.
62079083|NCT06445855|OTHER|Waiting group|After the interventions in the experimental group are completed, the intervention program will be applied to the women in the waiting group.
62079084|NCT00696163||A|
62079085|NCT02667444|EXPERIMENTAL|SB204 4%|SB204 4% topically once daily
62079086|NCT02667444|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel topically once daily
62079087|NCT05744882|PLACEBO_COMPARATOR|Control Group|no further treatment provided after coronectomy
62079088|NCT05744882|ACTIVE_COMPARATOR|Experimental Group|root canal treatment provided after the coronectomy procedure
62079089|NCT03486899|EXPERIMENTAL|BMS-986036 Dose Level 1|Administered by subcutaneous injection.
62079090|NCT03486899|EXPERIMENTAL|BMS-986036 Dose Level 2|Administered by subcutaneous injection.
62079091|NCT03486899|EXPERIMENTAL|BMS-986036 Dose Level 3|Administered by subcutaneous injection.
62079092|NCT03486899|PLACEBO_COMPARATOR|Placebo|Administered by subcutaneous injection.
62079093|NCT05744050|EXPERIMENTAL|Low energy density|The meal served at lunch time to participants will have a low energy density of \~1.1kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
62079094|NCT05744050|EXPERIMENTAL|Medium energy density|The meal served at lunch time to participants will have a low energy density of \~1.7kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
62079095|NCT05744050|EXPERIMENTAL|High energy density|The meal served at lunch time to participants will have a low energy density of \~3kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
62079096|NCT01154023|EXPERIMENTAL|stimulus control therapy|Focuses on strengthening the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, and developing a consistent sleep-wake pattern
62079097|NCT01154023|EXPERIMENTAL|sleep restriction therapy|Sleep restriction therapy consolidates sleep by restricting the amount of time spent in bed and limiting sleep to a specific time period .
62079098|NCT01154023|EXPERIMENTAL|multi-component intervention|Combines stimulus control and sleep restriction: strengthen the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, develop a consistent sleep-wake pattern, consolidate sleep by restricting the amount of time spent in bed and limit sleep to a specific time period
62079099|NCT06494319|EXPERIMENTAL|SIT NAVIGATOR plus Stress NAVIGATOR group|
62079100|NCT06494319|ACTIVE_COMPARATOR|SIT NAVIGATOR only group|
62079101|NCT02441205|EXPERIMENTAL|HIIT Aging|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
62079102|NCT04773574|EXPERIMENTAL|Normal pregnant women with high myopia|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA) were performed in each trimesters and at 6 weeks after childbirth.
62647618|NCT01350219|EXPERIMENTAL|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations.
62647619|NCT00392106|ACTIVE_COMPARATOR|Control|Class I or III anti-arrhythmic drug for the treatment of AF
62647620|NCT00392106|EXPERIMENTAL|Treatment|Pulmonary vein ablation with HIFU
62647621|NCT02000921|EXPERIMENTAL|CN + combusted & non-combusted products|Subjects will be asked to smoke the assigned conventional nicotine content (CN) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
62647622|NCT02000921|EXPERIMENTAL|VLNC + combusted & non-combusted products|Subjects will be asked to smoke the assigned very low nicotine content (VLNC) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
62079103|NCT01899118|EXPERIMENTAL|Nimotuzumab plus chemoradiotherapy|
62079104|NCT05715450|OTHER|Falciformopexy for Treatment Perforated Peptic Ulcer|Use falciform ligament flap for repair perforated peptic ulcer
62079105|NCT06132672|EXPERIMENTAL|Navigators (peer navigator) training|Training is designed to increase knowledge and skills. Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4
62079106|NCT06132672|EXPERIMENTAL|delayed-intervention group|Training is designed to increase knowledge and skills. The delayed-intervention group will be trained in year 5
62079107|NCT06529601|EXPERIMENTAL|CAD/CAM mandibular fixed retainer|
62079108|NCT06529601|ACTIVE_COMPARATOR|Conventional mandibular fixed retainer|
62079109|NCT00550173|EXPERIMENTAL|Pemetrexed + Erlotinib|Pemetrexed 500 milligrams per meter squared (mg/m\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
62079110|NCT00550173|ACTIVE_COMPARATOR|Erlotinib|Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
62079111|NCT00550173|ACTIVE_COMPARATOR|Pemetrexed|Pemetrexed 500 mg/m\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.
62079112|NCT02585037|EXPERIMENTAL|Kinesio Taping for facilitation|To provide the facilitation of muscle activity (G1 group) a Kinesio Taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. Bandage in group G1 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
62457491|NCT05194358|EXPERIMENTAL|Cohort 7 SIAN|SIAN dose of 4.35 mg/kg (300 μL) will be administered in two syringe-based spray devices, each containing 150 μL, with dose administered in left then right nostril, one device per nostril.
62457492|NCT03413046||ALL|30 children with a recent diagnosis of PreB ALL
62457493|NCT03413046||Control|30 healthy children
62457494|NCT05701371||Centenarian cohort|
62079113|NCT02585037|EXPERIMENTAL|Kinesio Taping for inhibition|For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
62079114|NCT02585037|PLACEBO_COMPARATOR|Kinesio Taping and Placebo|For the control group (G3 group) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis. Bandages in the G3 group will be applied laterally to produce a similar visual effect, which control for the placebo effect, but without tension so that a muscle stimulus will be not generated. With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
62647623|NCT02000921|EXPERIMENTAL|VLNC with non-combusted products|Subjects will be asked to smoke very low nicotine content (VLNC) cigarettes instead of their usual cigarettes for an 8 week period and will be given the opportunity to use non-combusted types of tobacco and medicinal tobacco products.
62079115|NCT03044353|EXPERIMENTAL|Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants|Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy \[ATTR-CM\]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR will be included. Participants will receive 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.
62457495|NCT01985802|OTHER|Pacing - Cross-over|Pacing will be conducted in 3 different ways (atrial, dual chamber and His-bundle pacing) at 2 different rates (basal and 100 bpm).
62647624|NCT02726347|ACTIVE_COMPARATOR|Smokers between the ages of 19-80|current smokers between the ages of 19 and 80
62647625|NCT02726347|ACTIVE_COMPARATOR|elderly individuals (over age 50)|elderly individuals, defined as subjects age 50 years or older, without a history of frequent infections, COPD, or asthma
62647626|NCT02726347|ACTIVE_COMPARATOR|COPD subjects|COPD subjects between the age of 19 and 80, without history of recurrent bacterial infections.
62647627|NCT02726347|ACTIVE_COMPARATOR|Asthmatics subjects|Asthmatics between the ages of 19 and 80
62647628|NCT02726347|ACTIVE_COMPARATOR|Subjects with recurrent bacterial infections|Individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency
62647629|NCT04907123|EXPERIMENTAL|UNa+ Driven Intensive Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 6 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: Spot Urinary Sodium \> 70 mEq/L AND mean diuresis \> 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
62647630|NCT04907123|ACTIVE_COMPARATOR|Standard Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 12 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: mean diuresis \> 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
62647631|NCT01297686|EXPERIMENTAL|Exercise|Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
62647632|NCT01297686|ACTIVE_COMPARATOR|Standard of Care|This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
62647633|NCT01285518|EXPERIMENTAL|Treatment|
62647634|NCT01285518|PLACEBO_COMPARATOR|Placebo|0.9% w/v sodium chloride injection, USP
62647635|NCT03167918|EXPERIMENTAL|Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO
62647636|NCT03167918|EXPERIMENTAL|Xuefuzhuyu Decoction|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po
62647637|NCT03167918|EXPERIMENTAL|Xuefuzhuyu Decoction &Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)\& Xuefuzhuyu Decoction（100 ml bid，po)
62647638|NCT05937880|EXPERIMENTAL|Administration of Leflunomide in refractory skin Henoch-Schonlein purpura|Rashes are dense and large in area, often treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rash does not subside or new rash still appears, and it frequently repeats more than 3 times during hospitalization.
62647639|NCT04212117|OTHER|Arm 1 - Educational Platform, PALS|The Patient Activated Learning System is a free, health education platform written bu trusted MDs.
62647640|NCT04212117|OTHER|Arm 2 - WebMD|WebMD is a widely used educational platform for health information.
62647641|NCT02887703|EXPERIMENTAL|Sensory Augmentation Group 1|Each subject in Group 1 will undergo 6 weeks of balance training with sensory augmentation followed by 6 weeks of balance training without sensory augmentation.
62647642|NCT02887703|EXPERIMENTAL|Sensory Augmentation Group 2|Each subject in Group 2 will undergo 6 weeks of balance training without sensory augmentation followed by 6 weeks of balance training with sensory augmentation.
62647643|NCT04345003|EXPERIMENTAL|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
62647644|NCT00526617|EXPERIMENTAL|Open Label|Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
62647645|NCT01558934|EXPERIMENTAL|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume. If the therapeutic dose is not reached under 50% methadone reduction conditions, the methadone dose will be further reduced to 0 mg for 2 days followed by reintroduction of 25% of the starting dose on the 3rd day, and on such 3rd day lofexidine titration will resume again.
62647646|NCT00553774|EXPERIMENTAL|Flavanol|Cocoa Flavanol
62647647|NCT00553774|PLACEBO_COMPARATOR|Placebo|
62647648|NCT03613298|EXPERIMENTAL|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:~* Evaluate its ability to locate and assess the volume of the endometriosic lesion~* Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
62457496|NCT05710978|EXPERIMENTAL|Work Heat Stress|Each participant will complete three consecutive days of heavy intensity aerobic work in a hot environment.
62457497|NCT02857270|EXPERIMENTAL|LY3214996 Dose Escalation|LY3214996 given orally once a day (or twice a day) for 21 days.
62457498|NCT02857270|EXPERIMENTAL|LY3214996 + Midazolam|"(Preliminary Drug-Drug Interactions \[DDI\])~LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days)."
62457499|NCT02857270|EXPERIMENTAL|LY3214996 Dose Expansion|LY3214996 given orally (once a day) during each 21 day cycle.
62647649|NCT05314309||mtFIT|Individuals who consent to participate in the study, will be asked to take two stool samples from the same bowel movement. In a central laboratory these two samples then will be analyzed. One with the standard of care faecal immunochemical test (FIT) and the other with the multi-target faecal immunochemical test (mtFIT). If either one of these two tests is positive, individuals will be referred to undergo a colonoscopy procedure. The performance of mtFIT, in comparison to FIT, will be evaluated against the colonoscopy findings.
62079116|NCT03044353|EXPERIMENTAL|Group 2: Post-chemotherapy AL Amyloidosis participants|Immunoglobin light chain amyloidosis (AL) participants who attain either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.
62647650|NCT04331106||Population in Germany|Reasonably large and representative sample of the general population in Germany
62079117|NCT03044353|EXPERIMENTAL|Group 3: Newly diagnosed Mayo stage II/IIIa AL participants|Newly diagnosed Mayo stage II/IIIa AL participants who attain a free light chain CR during the first 3 cycles of first-line chemotherapy where the first cycle was cyclophosphamide, bortezomib, dexamethasone (CyBorD) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.
62079118|NCT05267314|NO_INTERVENTION|standard therapy|standard therapy
62079119|NCT05267314|EXPERIMENTAL|exerciser and standard therapy|exerciser and standard therapy
62079120|NCT00931138|ACTIVE_COMPARATOR|Arm1 = Aracytine + Daunorubicin|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
62457500|NCT02857270|EXPERIMENTAL|LY3214996 + Abemaciclib|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.
62079121|NCT00931138|ACTIVE_COMPARATOR|Arm 3 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
62079122|NCT00931138|ACTIVE_COMPARATOR|Arm 2 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
62079123|NCT03837613||Group 1 (TT<4mm)|Patients with a preoperative tumor thickness less than 4 mm. Intervention: tumor resection and neck dissection
62079124|NCT03837613||Group 2 (TT >= 4mm)|Patients with a preoperative tumor thickness equal to or more than 4 mm Intervention: tumor resection and neck dissection
62457501|NCT02857270|EXPERIMENTAL|LY3214996 + Nab-Paclitaxel + Gemcitabine|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.
62079125|NCT01971580|OTHER|Ambrisentan first, Placebo second|These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
62079126|NCT01971580|OTHER|Placebo first, Ambrisentan second|These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
62079127|NCT03376503|EXPERIMENTAL|Pegcyte (Nanogen pegfilgrastim)|pegcyte 6 mg in the first cycle
62457502|NCT02857270|EXPERIMENTAL|LY3214996 + Encorafenib + Cetuximab|Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.
62079128|NCT03376503|ACTIVE_COMPARATOR|Neulastim (Roche pegfilgrastim)|Neulastim 6 mg in the first cycle
62079129|NCT00438867|EXPERIMENTAL|1|
62079130|NCT00438867|EXPERIMENTAL|2|
62079131|NCT00438867|PLACEBO_COMPARATOR|3|
62079132|NCT02610712|EXPERIMENTAL|TRD patients|Treatment-Resistant (TRD) patients to receive intravenous ketamine at 0.5 mg/kg dose.
62079133|NCT03203668|OTHER|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
62079134|NCT06121518|EXPERIMENTAL|Experimental Group|D064 and D702 Combination Therapy
62079135|NCT06121518|ACTIVE_COMPARATOR|Comparator Group 1|D064 Monotherapy
62079136|NCT06121518|ACTIVE_COMPARATOR|Comparator Group 2|D702 Monotherapy
62079137|NCT03319030||Duchenne Muscular Dystrophy (DMD)|Enrolls boys with a genetically confirmed diagnosis of DMD.
62079138|NCT01941004|EXPERIMENTAL|double blinded Fingolimod 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
62079139|NCT01941004|PLACEBO_COMPARATOR|Placebo 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
62079140|NCT01132638|ACTIVE_COMPARATOR|Magnesium Pantoprazole|
62079141|NCT01132638|ACTIVE_COMPARATOR|Magnesium Esomeprazole|
62079142|NCT06410378|ACTIVE_COMPARATOR|Erector Spinae Plane Block|"patient place in sitting position. Type of needle Using 22-gauge spinal needle 10 cm Linear ultrasound probe is placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process.~The erector spinae muscle is identified superficial to the tip of The T5 transverse process.~Needle insertion The needle is inserted in- plane superior to inferior approach. The tip of the needle is placed into the fascial plane on the deep aspect of erector spinae muscle.~The location of the needle tip is confirmed by visible normal saline fluid spread separating erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging .~Local anesthetic and volume Injection of 20 ml of bupivacaine 0.25 %."
62079143|NCT06410378|ACTIVE_COMPARATOR|Serratus Anterior Plane Block:|"The patient lies supine with placing the ipsi-lateral upper limb in abduction at 90° positio Using 22-gauge spinal needle 10 cm length. After skin sterilization, Ultrasound device with high frequency \[9-12\] and superficial linear probe that is first placed inferior to the middle of the clavicle and moved laterally and downward to locate the 1st rib where pectoralis major and pectoralis minor muscles are identified at this US window.~The US probe is moved toward axilla till serratus anterior muscle is identified above 2nd, 3rd and 4th ribs. The transducer is held at a slightly oblique angle at the level of the 4th and 5th rib, with the upper edge supero-anterior and the lower edge infero-anterior.~Needle insertion After infiltration of the skin at puncture site with 3 ml of lidocaine 1%, the needle is inserted inplane between the anterior serratus and the latissimus dorsi muscle on the mid-axillary line.~Injection of 20 mL of 0.25% bupivacaine."
62079144|NCT06410378|ACTIVE_COMPARATOR|control group|patients will receive only general anesthesia for Modified Radical Mastectomy.
62079145|NCT04057820|ACTIVE_COMPARATOR|Usual care, Finnegan Neonatal Abstinence Scoring Tool|Usual institutional care for infants with NOWS with the Finnegan Neonatal Abstinence Scoring Tool (FNAST)
62079146|NCT04057820|ACTIVE_COMPARATOR|Eat, Sleep, Console care tool|New treatment implemented at the site for infants with NOWS using the Eat, Sleep, Console (ESC) care tool
62079147|NCT04088318|EXPERIMENTAL|OQL011 Dose I|OQL011, Dose I, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
62079148|NCT04088318|EXPERIMENTAL|OQL011 Dose II|OQL011, Dose II, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
62079149|NCT04088318|EXPERIMENTAL|OQL011 Dose III|OQL011, Dose III, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
62079150|NCT04088318|OTHER|Vehicle Ointment|Vehicle ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
62079151|NCT06171906|EXPERIMENTAL|MSCs treatment group|
62079152|NCT02377830|EXPERIMENTAL|Early Cycling and routine physiotherapy|Patients will receive 30 minutes of in-bed cycling in addition to routine physiotherapy, 5 days per week, for the duration of their ICU stay
62079153|NCT02377830|ACTIVE_COMPARATOR|Routine physiotherapy|Patients will receive routine physiotherapy per current institutional practice
62457503|NCT02857270|EXPERIMENTAL|Japan Part 1|LY3214996 given orally.
62079154|NCT05107245||COVID-19 patients|Hospitalised COVID-19 patients
62079155|NCT05107245||Controls|Exposed medical staff
62079156|NCT06352268||Lesioning group|Participants who undergo pallidal, subthalamic or thalamic lesioning for the management of Dystonia, Parkinson's disease or essential tremors
62079157|NCT06352268||Control group|Participants who were considered for pallidal, subthalamic or thalamic lesioning for the management of Dystonia, Parkinson's disease or essential tremors but went on to continue best medical management
62079158|NCT06381037|EXPERIMENTAL|Experimental group|"The experimental group is given the workshop How to improve your strengths and quality of life."
62647651|NCT06328140||Lurasidone Treatment|"Patients with bipolar disorder or psychotic disorders for whom lurasidone is a US Food and Drug Administration (FDA)-approved treatment.~Patients will be treated with a daily dose of 40-80 mg./day for schizophrenia and 30-60 mg./day for bipolar disorder."
62457504|NCT02857270|EXPERIMENTAL|Japan Part 2|LY3214996 given orally and abemaciclib given orally.
62079159|NCT06381037|NO_INTERVENTION|Control group|"The control group is not given the workshop How to improve your strengths and quality of life."
62079160|NCT03444220|ACTIVE_COMPARATOR|ACHIM|Anaerobically Cultivated Human Intestinal Microbiota
62079161|NCT03444220|PLACEBO_COMPARATOR|Placebo|Anaerobically Cultivated medium
62079162|NCT06077669|EXPERIMENTAL|Methylphenidate - low dose|5 mg of methylphenidate
62079163|NCT06077669|EXPERIMENTAL|Methylphenidate - high dose|10 mg of methylphenidate
62079164|NCT06077669|PLACEBO_COMPARATOR|Placebo|placebo
62079165|NCT04098640|OTHER|FMI|FoundationOne CDx will be performed using archival tumor tissue
62079166|NCT02702349|OTHER|1|penicillin test and challenge
62079167|NCT00625235|OTHER|1|High Carbohydrate diet
62457505|NCT05924529||Samoans in American Samoa|Cognitive assessments will be administered to all participants to assess cognitive status. Gold standard evaluations will be administered to cross-validate the results of the cognitive assessments. Blood will be extracted from all participants to cross-validate results from the prior cognitive assessments and Gold Standard evaluations and conduct plasma and genetic analysis.
62457506|NCT01124396||30 ug|30 ug
62079168|NCT00625235|OTHER|2|High Protein diet
62457507|NCT01124396||60 ug|60 ug
62457508|NCT01124396||Placebo|Placebo
62647652|NCT06328140||Treatment as usual for major depression|Patients with major depression will received treatment with antidepressant treatments that are approved by the US FDA for treatment of major depression. All dosing will be required to be consistent with the FDA approved package insert.
62457509|NCT00001849|EXPERIMENTAL|Patients with Cushing Syndrome|Patients receive various types of radiologic or nuclear medicine scans to identify tumor
62457510|NCT04912349|EXPERIMENTAL|Test Group|Patients received the transurethral split of the prostate(TUSP) treatment.
62457511|NCT04912349|ACTIVE_COMPARATOR|Control Group|Patients received the transurethral resection of the prostate(TURP) treatment.
62457512|NCT04957108||All cardiac implantable devices|Assessed separately by Pacemaker ID app and cardia-x algorithm
62457513|NCT02064595|OTHER|Intramedullary nail|Fractures treated with intramedullary reamed nail
62457514|NCT02064595|ACTIVE_COMPARATOR|External fixator|Tibial fractures treated with biplanar external fixation
62457515|NCT01357603|EXPERIMENTAL|Glaritus arm|Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
62457516|NCT01357603|ACTIVE_COMPARATOR|Lantus arm|Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
62457517|NCT00678366|EXPERIMENTAL|1|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
62457518|NCT00678366|ACTIVE_COMPARATOR|2|pure carbon dioxide pneumoperitoneum
62457519|NCT05524103|EXPERIMENTAL|ALMB-0166|Two-thirds of patients will be randomized to receive a single dose of ALMB-0166 within 72 hours after spinal cord injury.
62457520|NCT05524103|PLACEBO_COMPARATOR|Placebo|One-third of patients will be randomized to receive a single dose of placebo within 72 hours after spinal cord injury.
62457521|NCT05883176|EXPERIMENTAL|B-TACE|TACE Combined With Bevacizumab Biosimilar
62457522|NCT05052164|EXPERIMENTAL|Gluten-free nutrition plan + exercise group|Celiac women who perform a physical exercise program 3/4 times per week and a gluten-free isocaloric dietary plan.
62457523|NCT05052164|EXPERIMENTAL|Gluten-free nutrition plan group|Women with celiac disease following a gluten-free isocaloric dietary plan.
62457524|NCT05052164|ACTIVE_COMPARATOR|Celiac controls group|Women with celiac disease in whom all variables are measured but no intervention is performed.
62457525|NCT05052164|NO_INTERVENTION|Non-celiac controls group|Non celiac menopausal or post-menopausal in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
62457526|NCT05075603|EXPERIMENTAL|NT-I7 after CAR-T (Kymriah, Yescarta, or Breyanzi) infusion|CAR-T infusion administered per standard of care at Day 0 followed by NT-I7 on Day 21.
62457527|NCT01850420|EXPERIMENTAL|IMC-1|Experimental intervention
62457528|NCT01850420|PLACEBO_COMPARATOR|Matching placebo|
62647653|NCT02695069|EXPERIMENTAL|All Participants|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
62079169|NCT05475938|EXPERIMENTAL|Analysis of painting|Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
62647654|NCT01100385|PLACEBO_COMPARATOR|Healthy (placebo)|
62647655|NCT01100385|ACTIVE_COMPARATOR|Healthy (Ateronon)|
62647656|NCT01100385|PLACEBO_COMPARATOR|Cardiovascular Group (placebo)|
62647657|NCT01100385|ACTIVE_COMPARATOR|Cardiovascular Group (Ateronon)|
62647658|NCT01249131|EXPERIMENTAL|Treatment A first, then Treatment B, followed by Treatment C|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
62647659|NCT01249131|EXPERIMENTAL|Treatment A first, then Treatment C, followed by Treatment B|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
62647660|NCT01249131|EXPERIMENTAL|Treatment B first, then Treatment A, followed by Treatment C|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
62647661|NCT01249131|EXPERIMENTAL|Treatment B first, then Treatment C, followed by Treatment A|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
62079170|NCT05475938|EXPERIMENTAL|Psychological treatment|After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
62079171|NCT03963882|EXPERIMENTAL|Group A|Patients in group A don't receive neoadjuvant chemotherapy
62079172|NCT03963882|EXPERIMENTAL|Group B|Patients in group B receive neoadjuvant chemotherapy and achieve imaging response
62079173|NCT03963882|EXPERIMENTAL|Group C|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy
62647662|NCT01249131|EXPERIMENTAL|Treatment C first, then Treatment A, followed by Treatment B|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
62647663|NCT01249131|EXPERIMENTAL|Treatment C first, then Treatment B, followed by Treatment A|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
62647664|NCT00873158|NO_INTERVENTION|Physical Therapy Group|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
62647665|NCT00873158|EXPERIMENTAL|Dynasplint Group|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
62079174|NCT03963882|EXPERIMENTAL|Group D|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy
62079175|NCT00588718||Cases|Infants who meet the entry criteria
62079176|NCT00588718||Controls|Banked blood samples from newborns who do not meet inclusion criteria for this study will be held at Stanford University Core Laboratory and will constitute controls. Proteomic and genomic profiles in blood samples of cases will be compared with blood samples of controls.
62079177|NCT01280240|ACTIVE_COMPARATOR|Monofer 500 mg|
62079178|NCT01280240|ACTIVE_COMPARATOR|Monofer 250 mg|
62079179|NCT05779839|EXPERIMENTAL|Algorithmically Matched|Individuals that identify as a current and/or former caregiver for a person with dementia will be matched to other caregivers using an algorithm that matches a caregiver to another caregiver based on specific preferences each caregiver identifies in a questionnaire.
62647666|NCT03903172|EXPERIMENTAL|Binder Arm|Abdominal binder + standard of care postpartum pain management
62647667|NCT03903172|NO_INTERVENTION|Standard of Care|Standard of care postpartum pain managment
62079180|NCT05779839|ACTIVE_COMPARATOR|Randomly Matched|Individuals that identify as a current and/or former caregiver for a person with dementia will be randomly matched to other caregivers not based on the preferences they identified in a questionnaire.
62079181|NCT03111758|ACTIVE_COMPARATOR|Geko Device|Neuromuscular Stimulator
62079182|NCT03111758|ACTIVE_COMPARATOR|IPCS|Intermittent Pneumotic Compression Stocking
62079183|NCT02595177|EXPERIMENTAL|Multifocal IOL|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, multifocal intraocular lens implantation in both eyes planning for emmetropia complete the intervention.
62647668|NCT03444207|EXPERIMENTAL|Group A|Endurance training
62647669|NCT03444207|EXPERIMENTAL|Group B|Endurance-strength training
62647670|NCT00909467||myeloproliferative, -dysplastic disease|
62647671|NCT02071537|EXPERIMENTAL|Chloroquine with Carboplatin/Gemcitabine|Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2). Chloroquine dose is escalating.
62647672|NCT03175211|EXPERIMENTAL|BI 456906|
62079184|NCT02595177|EXPERIMENTAL|Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
62079185|NCT02595177|EXPERIMENTAL|Hybrid Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation in the dominant eye and a multifocal IOL in the non-dominant eye complete the intervention.
62079186|NCT00656916|EXPERIMENTAL|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
62079187|NCT00656916|NO_INTERVENTION|Observational Group|Comparator group, no intervention.
62647673|NCT03175211|PLACEBO_COMPARATOR|Placebo|
62647674|NCT01268267|EXPERIMENTAL|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using an investigational blood glucose monitoring system (development name Ninja 2).
62079188|NCT03904537|EXPERIMENTAL|PD1-TIL combined with chemotherapy|Participants would received anti-PD-1 antibody-activated TILs after the final adjuvant chemotherapy.
62647675|NCT01591148|EXPERIMENTAL|Morbidly obese subjects|Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
62647676|NCT01591148|ACTIVE_COMPARATOR|Control subjects (body mass index 20-25)|Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
62647677|NCT03053739|ACTIVE_COMPARATOR|Combination arm A-Sildenafil and Bosentan|"Combination Arm A -Intervention- Drug~* Tab Sildenafil 20 mg - three times a day for 6 months,and~* Tab Bosentan 62.5mg - twice a day for 6 months"
62647678|NCT03053739|PLACEBO_COMPARATOR|Monotherapy arm-Sildenafil and Placebo|Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
62647679|NCT01081197||Out-day patients' clinic|Alcohol abusers referred to out-day patients' clinic which consent to participate in the study
62647680|NCT01081197||Control|Control group for the cardiac arm of the study will be matched controls from the Nord-Trøndelag Health Study (HUNT)
62079189|NCT05279430|NO_INTERVENTION|Control arm|Patients allocated to the control arm will not receive inspiratory muscle training. They will be checked each week by a physiotherapist responsible for training intervention who will measure their maximal inspiratory pressure
62079190|NCT05279430|ACTIVE_COMPARATOR|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
62079191|NCT02060292||COPD|Stable, Non hypoxaemic, without history of vascular disease
62079192|NCT02060292||Healthy smokers|Age matched, smokers without COPD
62079193|NCT03376841|EXPERIMENTAL|Severe hepatic impairment|Cenicriviroc tablet; single-dose oral administration
62079194|NCT03376841|EXPERIMENTAL|Normal Hepatic function|Cenicriviroc tablet; single-dose oral administration
62079195|NCT01282476|EXPERIMENTAL|Panobinostat/Rituximab|single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
62079196|NCT02117882||minimally invasive approach test|minimally invasive lateral approach
62079197|NCT02117882||control lateral traditional approach|standard surgical approach
62079198|NCT02220686|EXPERIMENTAL|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
62079199|NCT02220686|NO_INTERVENTION|Usual Care|Physician will follow their institution's standard of care for smoking cessation.
62079200|NCT03782896||mastectomy group|All patients who received the mastectomy (breast conserving surgery and sentinel lymph node dissection)
62079201|NCT04022642|EXPERIMENTAL|HIIT Group|Two HIIT sessions delivered at the beginning of Physical education classes
62079202|NCT04022642|NO_INTERVENTION|Control Group|Usual programmed Physical education classes
62079203|NCT04683471|EXPERIMENTAL|Neuromodulation|Neuromodulation
62647681|NCT00977197|ACTIVE_COMPARATOR|Pregabalin|"Subjects randomized to this arm will receive the following dosage:~75 mg (one tablet) twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study."
62647682|NCT00977197|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo matching the study drug.
62647683|NCT04079504|ACTIVE_COMPARATOR|Ligation|Ligation of indirect inguinal hernia sac in inguinal hernioplasty patients
62647684|NCT04079504|EXPERIMENTAL|Non-ligation|Non-Ligation of Indirect inguinal hernia sac/ simple inversion/reduction of indirect inguinal hernia sac in inguinal hernioplasty patients
62647685|NCT06411652|EXPERIMENTAL|Reflexology Group|The researcher has received a practitioner reflexology certificate. The researcher will begin the massage during the second hour of dialysis, as the patient's condition is more stable and the unit is less crowded due to routine care. Before the intervention, the patient's privacy will be protected in the reflexology group; The researcher will sit in a chair at the foot of the patient's bed and perform a reflexology massage.
62647686|NCT06411652|EXPERIMENTAL|Therapeutic Touch Group|In order to perform Therapeutic Touch application, the researcher attended the first level training prepared by the International Therapeutic Touch Association and received a certificate. For therapeutic touch application, the researcher will start the application in the second hour of dialysis, as the patient's condition is more stable and the unit is less crowded due to routine care. Therapeutic touch application will be applied to women in the hemodialysis care unit, twice a week for four weeks, for a total of 8 sessions, each lasting 15 minutes.
62647687|NCT06411652|NO_INTERVENTION|Control group|No intervention will be made.
62647688|NCT04630743|OTHER|Cognitive and Behavioral Intervention|Non-pharmacological strategies for the Management of episodic breathlessness
62647689|NCT00120471|EXPERIMENTAL|1|Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.
62079204|NCT04683471|SHAM_COMPARATOR|Sham|Sham
62647690|NCT00120471|EXPERIMENTAL|2|Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
62079205|NCT01482949|EXPERIMENTAL|AGS-003 in combination with sunitinib|Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.
62079206|NCT01060995||SmartConsent|Subjects receiving SmartConsent informed consent
62079207|NCT01060995||Standard consent|Subjects receiving standard consent
62079208|NCT04235868|ACTIVE_COMPARATOR|control group|
62079209|NCT04235868|EXPERIMENTAL|experimental group|
62079210|NCT04635501|EXPERIMENTAL|ABS 5.6.7|Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device
62079211|NCT02430922|EXPERIMENTAL|iVolution stent|Patient's treated with the iVolution stent from iVascular for the treatment of femoropopliteal lesions.
62079212|NCT02977065|ACTIVE_COMPARATOR|Atorvastatin 20 mg|To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks
62079213|NCT02977065|EXPERIMENTAL|Atorvastatin 20 mg + CKD-519 50 mg|To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks
62079214|NCT02977065|EXPERIMENTAL|Atorvastatin 20 mg + CKD-519 100 mg|To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
62079215|NCT02977065|EXPERIMENTAL|Atorvastatin 20 mg + CKD-519 200 mg|To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks
62079216|NCT02977065|ACTIVE_COMPARATOR|Rosuvastatin 10 mg|To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks
62647691|NCT00120471|EXPERIMENTAL|3|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
62647692|NCT00120471|EXPERIMENTAL|4|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
62079217|NCT02977065|EXPERIMENTAL|Rosuvastatin 10 mg + CKD-519 100 mg|To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
62079218|NCT00658736|EXPERIMENTAL|1|EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
62079219|NCT00658736|PLACEBO_COMPARATOR|2|EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
62647693|NCT06284161|OTHER|Quadriceps Combined Test|
62647694|NCT00943436|ACTIVE_COMPARATOR|Active males|Males who participate in at least 30 minutes of physical activity on 5 or more days per week for the last month.
62647695|NCT00943436|ACTIVE_COMPARATOR|Inactive males|Males who participate in less than 1 hour of physical activity per week for the last month.
62647696|NCT04303351||0-9 missing teeth|participants with 0-9 missing teeth
62647697|NCT04303351||10-19 missing teeth|participants with 10-19 missing teeth
62647698|NCT04303351||23-31 missing teeth|participants with 23-31 missing teeth
62647699|NCT04303351||Edentulous|participants with no teeth
62079220|NCT05359835|EXPERIMENTAL|Chelation with open-label Ca-DTPA and Zn-DTPA|Six chelation treatments utilizing Ca-DTPA on day 1 and Zn-DTPA on day 2. Paired, 2-chelation day treatments will take place at intervals of one week or more.
62079221|NCT02698436|EXPERIMENTAL|Acne Mask|"The light therapy acne device is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.~Other Names: Cleanser is marketed while the device is not marketed"
62079222|NCT02698436|ACTIVE_COMPARATOR|2.5% Benzoyl Peroxide Treatment|"Cleanser and 2.5% Benzoyl Peroxide Treatment Both the cleanser and the 2.5% Benzoyl Peroxide Treatment are applied twice daily, once in the morning and once in the evening.~Other names: Both products are marketed"
62079223|NCT03666910||children of rheumatic diseased mothers not on treatment|
62079224|NCT03666910||children of rheumatic diseased mothers on antimalarial drugs|
62079225|NCT03666910||children of normal mothers|
62079226|NCT01890902|EXPERIMENTAL|Impracor (Ketoprofen 10% Cream)|Topical Cream over a period of 14 days
62079227|NCT01890902|PLACEBO_COMPARATOR|Placebo Cream:|Topical Cream over a period of 14 days
62079228|NCT04690296|EXPERIMENTAL|US group|a group underwent real time USG-SCV catheterization
62079229|NCT04690296|EXPERIMENTAL|LM group|a group in whom anatomical LM method was used
62079230|NCT02631083|EXPERIMENTAL|Breakfast, lunch, snack and dinner (high GI)|Subjects will consume meals which are high glycemic index for breakfast (Honey stars cereal), lunch (glutinous rice meal) and snack (white bread and jam) in the whole body calorimeter. A take-away high glycemic index dinner will be provided.
62079231|NCT02631083|EXPERIMENTAL|Breakfast, lunch, snack and dinner (low GI)|Subjects will consume meals which are low glycemic index for breakfast (All bran cereal), lunch (basmati rice meal) and snack (multigrain bread and sugar-free jam) in the whole body calorimeter. A take-away low glycemic index dinner will be provided.
62647700|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
62647701|NCT04699539|EXPERIMENTAL|Arm A|GTV uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel or S-1.
62647702|NCT04699539|EXPERIMENTAL|Arm B|GTV non-uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel or S-1.
62457529|NCT04122430||GCT treated with first line chemotherapy|"Men with disseminated Germ Cell Tumours-GCT (AJCC Stage IS, 2, or 3) and have received first line chemotherapy with curative intent for disseminated GCT~."
62457530|NCT03312530|EXPERIMENTAL|A: Cobimetinib|Participants will receive the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants will be allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
62079232|NCT02701322|EXPERIMENTAL|Medical Clown|the study group will be accompanied by a medical clown from the arrival to the premise, through the actual examination and after exiting the exam room. The medical clown will explain about the upcoming examination and will induce a less stressed atmosphere. After the examination the clown will close the session for the patient.
62079233|NCT02701322|NO_INTERVENTION|Control|The control group will do the same videofluoroscopic procedure but without a medical clown.
62079234|NCT02989363|EXPERIMENTAL|O-Arm in deep brain stimulation surgeries (DBS)|Use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
62079235|NCT02989363|EXPERIMENTAL|Control group Not O-Arm in deep brain stimulation surgeries|Not use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
62079236|NCT02989363|EXPERIMENTAL|O-Arm in complex back surgeries (RAQUIS)|Use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
62079237|NCT02989363|EXPERIMENTAL|Control group Not O-Arm in complex back surgeries (RAQUIS)|Not use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
62079238|NCT06451575||Cases with Behcet's disease|Behcet's disease
62079239|NCT06451575||healthy individuals|Healthy control group
62079240|NCT02646111|EXPERIMENTAL|Genotype 1b without cirrhosis|12 weeks without Ribavirin
62079241|NCT02646111|EXPERIMENTAL|Genotype 1b with cirrhosis|12 weeks with Ribavirin
62079242|NCT02646111|EXPERIMENTAL|Genotype 1a without cirrhosis|12 weeks with Ribavirin
62647703|NCT04366245|EXPERIMENTAL|Experimental|
62647704|NCT04366245|ACTIVE_COMPARATOR|Comparator|
62079243|NCT02646111|EXPERIMENTAL|Genotype 1a with cirrhosis|24 weeks with Ribavirin
62079244|NCT03844321|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
62079245|NCT03844321|EXPERIMENTAL|Brief Mindfulness|3 sessions of online mindfulness therapy
62079246|NCT05050474|EXPERIMENTAL|V-01 COVID-19 Vaccine|One dose administrated by intramuscular injection
62079247|NCT04736589|EXPERIMENTAL|Inetetamab plus Rapamycin plus Chemotherapy|"Drug: Inetetamab Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks, until disease progression (PD) or other termination criteria are met;~Drug: Rapamycin Oral 2mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
62079248|NCT04736589|ACTIVE_COMPARATOR|Pyrotinib plus chemotherapy|"Drug:Pyrotinib Oral 400mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
62079249|NCT01013532|EXPERIMENTAL|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
62079250|NCT01013532|ACTIVE_COMPARATOR|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
62079251|NCT01013532|EXPERIMENTAL|Cilostazol|cilostazol plus placebo of aspirin
62079252|NCT01013532|ACTIVE_COMPARATOR|Aspirin|aspirin plus placebo of cilostazol
62079253|NCT02339389||ventilation during labor analgesia|We are simply measuring ventilation changes that occur following labor analgesia.
62079254|NCT04800523|EXPERIMENTAL|Arm 1 - Non-functional Device|a non-functional UroMonitor will be inserted by urologist.
62079255|NCT04607473|EXPERIMENTAL|ABUS|ABUS is performed by experienced technicians using a GE inveniaTM. Each breast is imaged in three views with an automated 15.4-cm 14-6-MHz linear- array transducer, which acquires up to 1000 two-dimensional images in the transverse plane, imaging the breast in three parts: the central (anteroposterior), lateral, and medial portions of the breast. To ensure inclusion of all breast tissue, particularly in participants with very large breasts, additional views are obtained as deemed necessary by the technician to cover the entirety of the breast.
62079256|NCT00893568|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers without treatment
62079257|NCT00893568|EXPERIMENTAL|CBT|Psychotraumatized patients treated by Cognitive and Behavioral Therapies (CBT)
62079258|NCT00893568|EXPERIMENTAL|EMDR|Psychotraumatized patients treated by Eye Movement Desensitization and Reprocessing (EMDR)
62079259|NCT00589550|EXPERIMENTAL|Peginterferon alfa-2b|Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
62079260|NCT04110873|EXPERIMENTAL|Antroquinonol capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
62079261|NCT04110873|EXPERIMENTAL|Antroquinonol capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
62079262|NCT04110873|PLACEBO_COMPARATOR|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
62079263|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
62079264|NCT01102179||Chronic kidney disease|"All patients with stage 2-5 (pre-dialysis) chronic kidney disease~One-time blood draw (10 ml)"
62079265|NCT02694640|EXPERIMENTAL|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
62079266|NCT02694640|EXPERIMENTAL|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
62079267|NCT02694640|EXPERIMENTAL|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
62079268|NCT00698321|EXPERIMENTAL|1|Participating schools will deliver HIV/STD prevention modules.
62079269|NCT00698321|ACTIVE_COMPARATOR|2|Participating schools will deliver general health promotion modules.
62079270|NCT00873093|EXPERIMENTAL|Pre-B ALL Relapse<18 mths from diagnosis (chemo) age<=21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
62079271|NCT00873093|EXPERIMENTAL|Pre-B ALL Relapse 18-36 mths from diagnosis (chemo) age<=21 yr|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
62079272|NCT00873093|EXPERIMENTAL|Pre-B ALL Relapse<36 mths from diagnosis (chemo) age>21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
62079273|NCT00873093|EXPERIMENTAL|T-cell ALL (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
62079274|NCT00873093|EXPERIMENTAL|T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
62079275|NCT04122560|EXPERIMENTAL|Obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
62079276|NCT04122560|ACTIVE_COMPARATOR|Non-obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
62079277|NCT05379140|EXPERIMENTAL|The Therapeutic Chinese Massage Group|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
62079278|NCT05379140|PLACEBO_COMPARATOR|The Placebo Massage Group|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
62079279|NCT03379714||Patients with ruptured or unruptured intracranial aneurysms|
62079280|NCT02145793|ACTIVE_COMPARATOR|ADHD Group Curriculum|Participants assigned to the group visit intervention agree to participate in 5 group visits every 3 months rather than individual ADHD follow-up visits to the clinic. Parents and children participate in separate but simultaneously run groups. Group portion is 60 minutes and then parent-child dyads complete individual visits for medication titration and physical exam.
62079281|NCT02145793|NO_INTERVENTION|Control|Participants continue to go to the clinic for 5 routine ADHD follow-up visits to the clinic every 3 months as usual clinical protocol.
62647705|NCT05485753|EXPERIMENTAL|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62647706|NCT00605683|ACTIVE_COMPARATOR|1|50 mg/day Safinamide
62647707|NCT00605683|ACTIVE_COMPARATOR|2|Safinamide 100mg/day
62647708|NCT00605683|PLACEBO_COMPARATOR|3|Placebo 0mg/Safinamide
62647709|NCT05635903|EXPERIMENTAL|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (50mls/24h continuous infusion using a syringe pump)
62647710|NCT05635903|EXPERIMENTAL|Intermittent nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Intermittent nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (5mls 0.9% normal saline nebulised every 6 hours)
62647711|NCT05635903|ACTIVE_COMPARATOR|Intermittent standard nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|Intermittent standard nebulization of 0.9% normal saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser ((5mls 0.9% normal saline nebulised every 6 hours)
62647712|NCT01417169|EXPERIMENTAL|Micafungin|
62647713|NCT01125098||PRO-CT group: Experimental|COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.
62079282|NCT06115902|EXPERIMENTAL|TQB2102 for injection|Dose: 6.0 mg/kg or 7.5 mg/kg of TQB2102 for injection. Administration: Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle.
62079283|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
62647714|NCT01125098||Standard group: No intervention|COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
62647715|NCT01948245|ACTIVE_COMPARATOR|TaurolockTMHep100|"2-4 ml of TaurolockTMHep100 will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of TaurolockTMHep100 administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
62647716|NCT01948245|PLACEBO_COMPARATOR|Heparin 100 IE/ml|"2-4 ml of Heparin 100 IE/mk will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of Heparin 100 IE/ml administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
62647717|NCT00855348||Adults > 50 Years Scheduled for Colonscopy|Average to increased risk adults older than 50 years without symptoms indicative of CRC and designated for colonoscopy.
62647718|NCT03057886||Compare the Spot On with others consecrated thermometers|This study intends to compare the accuracy of the new device(SPOT ON thermometer) with the oral and esophageal in participants submitted to general and spinal anesthesia, in different types of population (pediatric and adult)
62647719|NCT03381872|ACTIVE_COMPARATOR|Intravascular imaging arm|The choice of intravascular imaging devices such as IVUS or OCT during PCI will be left to the operator's discretion. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended. Use of intravascular imaging devices will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but intravascular imaging evaluation after stent implantation will be mandatory.
62647720|NCT03381872|ACTIVE_COMPARATOR|Angiography arm|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
62647721|NCT06399042|EXPERIMENTAL|SP5M002 inj|SP5M002 inj 3 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients
62647722|NCT06399042|ACTIVE_COMPARATOR|Synovian inj|Synovian inj 3 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients
62647723|NCT02873234||Traditional Chinese Medicine|Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.
62647724|NCT02873234||TCM plus antidepressants|This is a integrative therapy that refers to a new treating system including TCM and antidepressants.
62647725|NCT02873234||Antidepressants|Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.
62647726|NCT02811770||children with HSN|
62079284|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
62079285|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
62079286|NCT01804894||athletes with lower extremity injury|athletes who were injured during one season of play
62079287|NCT05993195||Conduit Interbody device|The Conduit Titanium Interbody Graft will be compared to the Concorde Bullet Device group for PLIF and TLIF.
62079288|NCT05993195||Concorde Bullet Device|The control group is patients with degenerative spondylotic disease undergoing either one level or two level fusions with Concorde Bullet Device interbody device.
62079289|NCT04873622|EXPERIMENTAL|RESTORE intervention|Participants who screen eligible and consent will receive RESTORE with guidance.
62457531|NCT03312530|EXPERIMENTAL|B: Cobimetinib + Venetoclax|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
62079290|NCT05536674|NO_INTERVENTION|No SMS reminder|This group will receive no reminder
62457532|NCT03312530|EXPERIMENTAL|C: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
62457533|NCT03312530|EXPERIMENTAL|Safety Run-In: Cobimetinib + Venetoclax|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.
62457534|NCT03312530|EXPERIMENTAL|Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.
62457535|NCT00775177|EXPERIMENTAL|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
62457536|NCT00775177|ACTIVE_COMPARATOR|2|Adoxa ® 100mg tablets of Bradley Pharmaceuticals, Inc
62457537|NCT00922909|ACTIVE_COMPARATOR|2|Day 1 : morning : Medication on ; Stimulation : off afternoon : Medication : on ; Stimulation : on Day 2 : morning : Medication : off ; Stimulation : off afternoon : medication : off ; stimulation : on
62457538|NCT00922909|ACTIVE_COMPARATOR|3|Day 1 : morning : Medication off ; Stimulation : on afternoon : Medication : off ; Stimulation : off Day 2 : morning : Medication : on ; Stimulation : on afternoon : medication : on ; stimulation : off
62079291|NCT05536674|EXPERIMENTAL|Short SMS with no additional information|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. Contact your family doctor today to arrange an appointment."
62079292|NCT05536674|EXPERIMENTAL|Short SMS + NCDC link|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. Contact your family doctor today to arrange an appointment. More information on the official NCDC website"
62079293|NCT05536674|EXPERIMENTAL|"SMS with reserved for her framing + NCDC link"|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. Her vaccine is reserved at the policlinic. Contact your family doctor today to arrange an appointment. More information on the official NCDC website"
62079294|NCT05536674|EXPERIMENTAL|SMS with safety information + NCDC link|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. The vaccine has been given safely to more than 118 million girls worldwide. Contact your family doctor today to arrange an appointment. More information on the official NCDC website"
62079295|NCT05462652|EXPERIMENTAL|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
62079296|NCT05462652|NO_INTERVENTION|Usual Care|UC is based on a stepped care model for treatment for symptoms of depression. It can include any of the following: active monitoring of depressive symptoms and suicidality, supportive counseling by a healthcare provider, psychosocial support interventions, collaborative care (e.g. facilitation of parental and patient self-management, referral for peer support or other community or school-based behavioral health programs), psychoeducation, complementary and alternative medicine approaches, psychotherapy (e.g. behavioral treatment, interpersonal therapy, cognitive behavioral therapy), pharmacotherapy for mood problems, visit to a primary care provider, behavioral or mental health specialist or therapist, counselor or coach for mood disorder. For purposes of this study, UC will be enhanced by prompting participants to complete a weekly PHQ-8 assessment in a mobile app.
62079297|NCT02708238|EXPERIMENTAL|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
62079298|NCT02708238|ACTIVE_COMPARATOR|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
62079299|NCT02708238|ACTIVE_COMPARATOR|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
62079300|NCT01088308|EXPERIMENTAL|Single Arm|All Patients underwent Intervention.
62079301|NCT05401630|EXPERIMENTAL|Symptomatic women with no obstructive CAD who have CMD|Symptomatic women with chest pain and no obstructive CAD who have an abnormal myocardial flow reserve (MFR \< 2.5)
62079302|NCT05401630|EXPERIMENTAL|Symptomatic women with chronic obstructive CAD (oCAD)|This group will serve as one comparison group since these women represent the prevailing paradigm of ischemia from obstructive stenosis while sharing common cardiovascular risk factors with the CMD group.
62079303|NCT05401630|ACTIVE_COMPARATOR|Asymptomatic control women with no prior history of CAD or angina|Asymptomatic control women with no prior history of CAD or angina, who are age-matched to the CMD women; not on any cardiac medications, who will also have to pass a maximal Bruce protocol exercise treadmill test.
62079304|NCT01352234|EXPERIMENTAL|Group A|Acetylsalicylic Acid 160mg administered at bedtime
62079305|NCT01352234|ACTIVE_COMPARATOR|Group B|Acetylsalicylic Acid 80mg administered at bedtime
62079306|NCT05758363|EXPERIMENTAL|Experimental Group|Consumption of dietary supplement capsules for 6 months.
62079307|NCT05758363|PLACEBO_COMPARATOR|Control Group|Identically appearing placebo capsules consumed for 6 months.
62079308|NCT04349410|EXPERIMENTAL|Treatment 1|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Azithromycin 500 mg IV on day 1, followed by 250 mg IV on days 2-5 (to prevent bacterial superinfection ).
62647727|NCT05232227|ACTIVE_COMPARATOR|Standard regimen Primaquine single dose over 14 days|The standard regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 3.5 mg/kg divided over 14 days (0.25mg/kg/day)
62079309|NCT04349410|EXPERIMENTAL|Treatment 2|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Doxycycline 100mg IV q 12 hrs with each dose given over 1 to 4-hours (to prevent bacterial superinfection ).
62079310|NCT04349410|EXPERIMENTAL|Treatment 3|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
62079311|NCT04349410|EXPERIMENTAL|Treatment 4|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
62079312|NCT04349410|EXPERIMENTAL|Treatment 5|Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days. This treatment arm is not available for intubated patients due to the absence of an IV form of Primaquine.
62079313|NCT04349410|EXPERIMENTAL|Treatment 6|Remdesivir 200 mg IV on day 1, followed by 100 mg IV qD for a total of 10-days.
62079314|NCT04349410|EXPERIMENTAL|Treatment 7|"Tocilizumab 8mg/kg IV (not to exceed 800 mg) over 60-minutes. If clinical improvement is not noted, three additional doses may be administered at q 8-hour intervals from the initial infusion for a total of 4-doses maximum.~ANY PATIENT DEMONSTRATING CYTOKINE RELEASE SYNDROME WILL HAVE THIS TREATMENT ARM AUTOMATICALLY ADDED."
62079315|NCT04349410|EXPERIMENTAL|Treatment 8|Methylprednisolone 125 mg IV every 6-hours for 3 days; then 125 mg IV every 12-hours for 2 days; then 125 mg IV daily for 2 days; then 60 mg IV daily for 2 days \[with each infusion given over 30-minutes\]; then Solumedrol dose pack to taper off steroids.
62079316|NCT04349410|EXPERIMENTAL|Treatment 9|Interferon alpha-2b 5 million units per nebulizer BID.
62079317|NCT04349410|EXPERIMENTAL|Treatment 10|Losartan 25 mg po qD. IRB held due to questions about benefit.
62647728|NCT05232227|EXPERIMENTAL|Treatment regimen Primaquine double dose over 14 days|The treatment regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 7 mg/kg divided over 14 days
62079318|NCT04349410|EXPERIMENTAL|Treatment 11|Convalescent Plasma 2-units ABO-compatible with antibody titer of 1:320 dilution. Each unit intravenously infused over 4-hours.
62079319|NCT04261738|NO_INTERVENTION|Control|The first 2-hour session will be a control where participants will sit quietly (as they would in the hyperbaric chamber) and will not be allowed to consume carbohydrates unless directed to by the hyperbaric department hypoglycemia protocol.
62079320|NCT04261738|EXPERIMENTAL|Hyperbaric Oxygen|"The following day for the HBO2 session, subjects will be fitted for an oxygen hood and given a standard HBO2 treatment. In the chamber the pressure will increase to approximately 2-1/2 times normal atmospheric pressure (2.4 atmospheres absolute \[ATA\]). Once they reach the treatment pressure, subjects will breathe oxygen by placing the hood over their head and securing it in place. They will breathe oxygen for a 30-minute period, and then take the hood off for 5 minutes for an air break. They will have a total of three 30-minute oxygen periods and two 5-minute air breaks. A subject will be in the hyperbaric chamber for approximately 2 hours."
62079321|NCT00915902|EXPERIMENTAL|Omega-3-acid ethyl esters (Lovaza)|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. GlaxoSmithKline supplied the study drug and the placebo. The study drug, Omega-3-acid ethyl esters (Lovaza) was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week treatment period. The study drug contained minimally 1.5 g DHA (docosahexaenoic acid) and 1.86 g EPA (eicosapentaenoic acid).
62079322|NCT00915902|PLACEBO_COMPARATOR|Placebo|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. The corn oil placebo was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week non-treatment (placebo) period.
62079323|NCT06043063|EXPERIMENTAL|Topical anesthesia alone|2.5% EMLA cream + intraurethral 2% lidocaine gel for 15 min
62079324|NCT06043063|ACTIVE_COMPARATOR|Topical anesthesia with periurethral block|"2.5% EMLA cream + intraurethral 2% lidocaine gel for 15 min~+ periurethral block (5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock to depth of 1.5 cm using 25G needle)~Block sits for 5 min if lidocaine, 10 min if bupivacaine"
62079325|NCT02118714|EXPERIMENTAL|Atrasentan|Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
62079326|NCT04384679|EXPERIMENTAL|Hydrophilic polymer and potassium ferrate powder|Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved
62079327|NCT04384679|NO_INTERVENTION|Direct pressure with sterile gauze|Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved
62079328|NCT03751540||OSTAP|Data of patients (performed oblique subcostal transversus abdominis plane-OSTAP- block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
62079329|NCT03751540||SIPB plus rectus sheath block|Data of patients (performed serratus intercostal plane block-SIPB- plus rectus sheath block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
62079330|NCT01580098|NO_INTERVENTION|Control group|treatment as usual
62079331|NCT01580098|EXPERIMENTAL|Self-monitoring for patients with Diabetes mellitus type 2|Patients are self-monitoring and submitting their vital parameters.
62079332|NCT01580098|EXPERIMENTAL|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are measuring and entering the vital parameters of the patients.
62079333|NCT03575689|EXPERIMENTAL|Splint|A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
62647729|NCT05423977|EXPERIMENTAL|Experimental:ZV0203|
62079334|NCT03575689|NO_INTERVENTION|No Splint|B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same.
62079335|NCT00802659|EXPERIMENTAL|Group -1|1000 cGY radiation
62079336|NCT00802659|EXPERIMENTAL|Group 1|1200 cGY radiation
62079337|NCT00802659|EXPERIMENTAL|Group 2|1400 cGY radiation
62079338|NCT00802659|EXPERIMENTAL|Group 3|1600 cGY radiation
62079339|NCT05211375|ACTIVE_COMPARATOR|SG group|Patients undergoing sleeve gastrectomy
62079340|NCT05211375|EXPERIMENTAL|DJB group|Patients undergoing duodenojejunal bypass with sleeve gastrectomy
62079341|NCT03318952|EXPERIMENTAL|lidocaine then articaine|For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
62079342|NCT03318952|EXPERIMENTAL|articaine then lidocaine|For the first dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered. For the second dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed.
62079343|NCT06398340|EXPERIMENTAL|High Calorie, Then Low Calorie|Subjects will receive an unhealthy meal that against the healthy eating guidelines. After a washout period of at least 24hours, subjects will receive a balanced diet that meets healthy eating guidelines.
62079344|NCT06398340|EXPERIMENTAL|Low Calorie, Then High Calorie|Subjects will receive a balanced diet that meets healthy eating guidelines. After a washout period of at least 24hours, subjects will receive an unhealthy meal that against the healthy eating guidelines
62079345|NCT00823550|EXPERIMENTAL|A|entecavir 0.5 mg QD
62079346|NCT00823550|ACTIVE_COMPARATOR|B|lamivudine 100 mg QD
62079347|NCT00088205|EXPERIMENTAL|A|
62079348|NCT02166151|EXPERIMENTAL|Omalizumab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
62079349|NCT02584764|EXPERIMENTAL|CBT with Internet support|16 sessions of Cognitive behavior therapy in group with Internet support between group sessions
62079350|NCT01085929|ACTIVE_COMPARATOR|Incision and Drainage|Abscess underwent incision and drainage
62079351|NCT01085929|ACTIVE_COMPARATOR|Ultrasound guided needle aspiration|Ultrasound was used to identify the abscess location. A needle was introduced into the abscess cavity and aspiration of the contents were attempted.
62079352|NCT05939817|EXPERIMENTAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|"UC-MSC was collected in 50 mL of transport medium, which contained alpha minimal essential medium (αMEM \[GIBCO 12000-0221\]), penicillin/streptomycin (final concentration 300u/mL \[GIBCO 15140-122\]) and amphotericin B (final concentration 7500ng /mL \[JR Scientific 50701\]), and processed in less than 8 hours after collection.~Group 1 was given UC-MSC 2 million cells/mL/cm3"
62079353|NCT05939817|EXPERIMENTAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|group 2 was given UC-CM 1 mL/cm3
62079354|NCT05939817|ACTIVE_COMPARATOR|triamcinolone acetonide|group 3 was given TA 40 mg/mL/cm3
62079355|NCT03124030||Direct Oral Anticoagulants|assuming Pradaxa or Apixaban or Eliquis; undergo simple dental extraction
62079356|NCT03124030||Oral Anticoagulant therapy|assuming Coumadin or Sintrom; undergo simple dental extraction
62079357|NCT03188614|PLACEBO_COMPARATOR|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
62079358|NCT03188614|EXPERIMENTAL|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
62079359|NCT01710774|NO_INTERVENTION|Traditional follow-up|Traditional follow-up with standard consultations at the Section of Endocrinology. For some patients, this will include follow-up from nurses in the home care or general practice office related to wound care. However, this is not the standard procedure and will not take place in combination with telemedicine follow-up.
62079360|NCT01710774|ACTIVE_COMPARATOR|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
62079361|NCT05827666|ACTIVE_COMPARATOR|Children|Participants will undergo four metabolic trials in a randomized crossover design, where they will be provided with an isoenergetic (i.e., equal calories) amount of one of the following beverages upon completing a standardized bout of variably intensity exercise: 2% milk, almond 'milk,' soy 'milk,' or rice 'milk.'
62079362|NCT05827666|ACTIVE_COMPARATOR|Adolescent females|Participants will undergo four metabolic trials in a randomized crossover design, where they will be provided with an isoenergetic (i.e., equal calories) amount of one of the following beverages upon completing a standardized bout of variably intensity exercise: 2% milk, almond 'milk,' soy 'milk,' or rice 'milk.'
62079363|NCT05827666|ACTIVE_COMPARATOR|Adolescent males|Participants will undergo four metabolic trials in a randomized crossover design, where they will be provided with an isoenergetic (i.e., equal calories) amount of one of the following beverages upon completing a standardized bout of variably intensity exercise: 2% milk, almond 'milk,' soy 'milk,' or rice 'milk.'
62079364|NCT02313896|NO_INTERVENTION|Standard of Care|Patients recieve standard care. On discharge they receive an information packet about cirrhosis and hepatic encephalopathy. They will continue to follow with their doctor as usual.
62457539|NCT00922909|ACTIVE_COMPARATOR|4|Day 1 : morning : Medication off ; Stimulation : off afternoon : Medication : off ; Stimulation : on Day 2 : morning : Medication : on ; Stimulation : off afternoon : medication : on ; stimulation : on
62079365|NCT02313896|EXPERIMENTAL|Phone calls|On discharge, patients will receive an information package about cirrhosis and hepatic encephalopathy. In addition to regular visits with the doctor, they will receive phone calls from one of our research providers who will be a nurse practitioner, doctor, or physician assistant. In the first 2 weeks after discharge, they will receive phone calls every other day. For the following 10 weeks, they will receive phone calls once a week.
62079366|NCT05814757|EXPERIMENTAL|OTX-DED 0.3mg|
62079367|NCT05814757|EXPERIMENTAL|Controlled Insertion utilizing Collagen Punctal Plug|
62079368|NCT05814757|PLACEBO_COMPARATOR|Collagen Punctal Plug (Full Insertion)|
62079369|NCT02711176|EXPERIMENTAL|Tavanex & Nexium & Tinafas|"Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days"
62079370|NCT02711176|ACTIVE_COMPARATOR|Lanzol & Klacid &Iramox|Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days
62079371|NCT03542448||Study group|"97 eye of 49 normal Egyptian volunteers were divided into groups according to age, AL, SE of refractive error, minimum corneal thickness (MCT) and mean corneal power as follow:~Age into 3 groups:~Group A: from 18 to 30 years old Group B: from 31 to 40 years old Group C: \> 40 years old~Axial length into 3 groups:~Group A: from 22 to less than 24 mm Group B: from 24 to 26 mm Group C: \> 26 mm~Spherical equivalent of refractive error into :~Group A : from zero to - 2 D Group B : from - 2 to \> - 4 D Group C : from - 4 to \> - 6 D Group D: from - 6 to - 8 D~Minimum corneal thickness (MCT) into 3 groups:~Group i: \< 500 um Group ii: from 500 to 540 um Group iii: \> 540 um~Refractive power of cornea (Mean K) into 3 groups:~Group 1: 41 to less than 44 D Group 2: 44 to 46 D Group 3: \> 46 D"
62079372|NCT01496508|EXPERIMENTAL|HFOV|A SLE5000 infant ventilator was used as the high-frequency ventilator.HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg.Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 \<0.3 and respiratory rate \<25/min.
62079373|NCT01496508|EXPERIMENTAL|CV|A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to \<60/min. The weaning process was initiated when the following parameters were achieved: PIP \<18 cmH2O, PEEP \<4 cmH2O, and FIO2 \<0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 \<0.3 and respiratory rate \<25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
62079374|NCT05291013|EXPERIMENTAL|Gastric bypass with T2DM|
62079375|NCT05291013|EXPERIMENTAL|Gastric bypass without T2DM|
62079376|NCT05291013|NO_INTERVENTION|Control group|
62079377|NCT06237374|EXPERIMENTAL|Treatment|Community health workers (CHWs) will receive the intervention training videos, job aids and chatbot tool to share with patients via WhatsApp in addition to standard CHW training provided by Lwala Community Health Alliance.
62079378|NCT06237374|ACTIVE_COMPARATOR|Control|Participants in the control group will receive standard community health worker (CHW) training provided by Lwala Community Health Alliance.
62079379|NCT05185128|NO_INTERVENTION|Control arm|Typically developing control participants will undergo cognitive assessments and MRI imaging 16 weeks apart with no intervention in between.
62079380|NCT05185128|EXPERIMENTAL|Patient arm|Both ASD and SSD participants will undergo cognitive assessments and MRI imaging pre- and post- the 16-week PEERS social skills intervention.
62079381|NCT04100200|ACTIVE_COMPARATOR|Mixed Berries|Strawberry and red raspberry composite served as a frozen drink
62079382|NCT04100200|ACTIVE_COMPARATOR|FOS|Non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic served as a frozen drink
62079383|NCT04100200|ACTIVE_COMPARATOR|Combination|Mixed berry composite + FOS served as a frozen drink
62079384|NCT04100200|PLACEBO_COMPARATOR|Control|Placebo similar in color to mixed berry supplement without any polyphenols served as a frozen drink
62079385|NCT02019563|EXPERIMENTAL|MTA/FS pulpotomy Group|Children randomized to this arm will undergo a mineral trioxide aggregate (MTA) pulpotomy after hemostasis is achieved using ferric sulfate (FS).
62079386|NCT02019563|ACTIVE_COMPARATOR|RCT Group|Children randomized to this group will undergo the root canal therapy (RCT) technique.
62079387|NCT03657264|EXPERIMENTAL|Sequence 1|"The sequence of administration is: P/ScD/PC/CD~Where:~* P = Placebo (Nacl 0.9%)~* CD = P03277 tested at 0.1 mmol/kg~* ScD = P03277 tested at 0.3 mmol/kg~* PC = Positive control (moxifloxacin 400 mg - per os)."
62079388|NCT03657264|EXPERIMENTAL|Sequence 2|"The sequence of administration is: CD/PC/ScD/P~Where:~* P = Placebo (Nacl 0.9%)~* CD = P03277 tested at 0.1 mmol/kg~* ScD = P03277 tested at 0.3 mmol/kg~* PC = Positive control (moxifloxacin 400 mg - per os)."
62079389|NCT03657264|EXPERIMENTAL|Sequence 3|"The sequence of administration is: ScD/CD/P/PC~Where:~* P = Placebo (Nacl 0.9%)~* CD = P03277 tested at 0.1 mmol/kg~* ScD = P03277 tested at 0.3 mmol/kg~* PC = Positive control (moxifloxacin 400 mg - per os)."
62079390|NCT03657264|EXPERIMENTAL|Sequence 4|"The sequence of administration is: PC/P/CD/ScD~Where:~* P = Placebo (Nacl 0.9%)~* CD = P03277 tested at 0.1 mmol/kg~* ScD = P03277 tested at 0.3 mmol/kg~* PC = Positive control (moxifloxacin 400 mg - per os)."
62079391|NCT00634322|EXPERIMENTAL|A|HDMTX-LV with glucarpidase
62079392|NCT00634322|ACTIVE_COMPARATOR|B|HDMTX-LV with placebo
62079393|NCT00634322|EXPERIMENTAL|C|compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment
62079394|NCT06301659|EXPERIMENTAL|modified mirror therapy+routine rehabilitation therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy.
62079395|NCT06301659|ACTIVE_COMPARATOR|routine rehabilitation therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
62079396|NCT01091428|EXPERIMENTAL|Alisertib (Phase 1 - Ovarian cancer)|Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
62079397|NCT01091428|EXPERIMENTAL|Alisertib (Phase 1 - Breast cancer)|Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
62079398|NCT01091428|EXPERIMENTAL|Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2)|Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
62079399|NCT01091428|EXPERIMENTAL|Paclitaxel 80 mg/m^2 (Phase 2)|Paclitaxel 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
62079400|NCT01558674|EXPERIMENTAL|MK-7145 8 mg (Part I:Period 1)|Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
62079401|NCT01558674|ACTIVE_COMPARATOR|Furosemide 40 mg (Part I:Period 2)|Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
62079402|NCT01558674|EXPERIMENTAL|MK-7145 16 mg (Part I:Period 3)|Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
62079403|NCT01558674|ACTIVE_COMPARATOR|Furosemide/Torsemide Run-in (Part II:Period1)|Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
62079404|NCT01558674|EXPERIMENTAL|MK-7145 10 mg (Part II:Period 2)|Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
62079405|NCT01558674|EXPERIMENTAL|MK-7145 16 mg (Part II:Period 3)|Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
62079406|NCT01558674|EXPERIMENTAL|MK-7145 24 mg (Part II:Period 4)|Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state
62079407|NCT01265030|EXPERIMENTAL|Sirolimus|"Preoperative sirolimus:~* loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligram)~* starting 24 hours after the initial loading dose, subjects will receive a dose of 4 milligram/meters2 daily; Per Os (PO), by mouth days 2 through 28"
62079408|NCT03529786||Retrospective|An observational medical records review study (data collected retrospectively) in subjects with the severe form of MPS II.
62079409|NCT05233722|PLACEBO_COMPARATOR|Post-exercise insulin sensitivity following placebo administration|Young healthy males will ingest placebo (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
62079410|NCT05233722|EXPERIMENTAL|Post-exercise insulin sensitivity following Rapamycin administration|Young healthy males will ingest Rapamycin (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
62079411|NCT01695122|EXPERIMENTAL|valproic acid|
62079412|NCT02812212|EXPERIMENTAL|Open-label|"Device: ultrasonography and diuretic renography Bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.~Diuretic renography to measure the cortical transit time"
62079413|NCT00972179|EXPERIMENTAL|Tezepelumab|Tezepelumab will be administered subcutaneously (SC) at doses from 35 mg once every 28 days (Q28D) (cohort 1) up to 210 mg once every 7 days (Q7D) (cohort 5) and an intravenous (IV) dose cohort of 700 mg Q28D (cohort 6).
62079414|NCT00972179|PLACEBO_COMPARATOR|Placebo|Two participants in each cohort (cohorts 1 to 6) will receive matching placebo administered subcutaneously (cohorts 1-5) or intravenously (cohort 6), matching the treatment regiment of tezepelumab.
62079415|NCT03537261|EXPERIMENTAL|CPI-Parent Training|Will receive one-day (6-hour) training in P-CPI including the use of nonverbal, paraverbal, verbal, and physical intervention techniques.
62079416|NCT03537261|NO_INTERVENTION|Waitlist Control|"Will not receive active P-CPI training during the experimental treatment interval.~NOTE: The waitlist group will be offered the P-CPI training session after the treatment group completes their follow-up measures."
62079417|NCT05392075||COVID-19 diagnosis|The study will enroll all subjects who received care at Methodist Dallas Medical Center between August 1, 2021 and February 28, 2022, and were diagnosed with COVID-19. COVID-19 diagnosis for the purpose of this study is either a positive COVID-19 antigen or a positive COVID-19 PCR test.
62079418|NCT02488694|EXPERIMENTAL|Arm A: Afatinib|105 patients to be treated with afatinib
62079419|NCT02488694|ACTIVE_COMPARATOR|Arm B: Pemetrexed|105 patients to be treated with pemetrexed
62079420|NCT02724787|OTHER|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
62079421|NCT06043596|EXPERIMENTAL|SafeSpace Sexual Health|The proposed intervention is a 10-week app-based program, SafeSpace Sexual Health. SafeSpace Sexual Health will be implemented using a secure, anonymous mobile app that uses authentic stories to engage young people with sexual health information and resources. The program addresses healthy relationships, anatomy and physiology, identity, adolescent development, STIs/HIV, pregnancy and reproduction, decision-making, personal safety, communication, and accessing healthcare. Each lesson includes a story written by youth with lived experience, two to three key facts developed by sexual health experts, a reflection prompt, and two to three reputable resources.
62079422|NCT06043596|ACTIVE_COMPARATOR|SafeSpace General Health|Participants in the control condition will participate in a 10-week app-based general health program, SafeSpace General Health. Lessons address general health topics including self-care, stress, sleep, nutrition, physical activity, substance use, driving and seatbelt use, and social media. Each lesson contains 2-3 key facts created by public health experts and reputable resources. Similar to SafeSpace Sexual Health, youth will receive SafeSpace General Health over 10 weeks, although SafeSpace General Health includes one lesson per week and does not contain youth stories or reflection prompts.
62079423|NCT04299802|ACTIVE_COMPARATOR|Leukocyte-Rich Platelet-Rich Plasma (LR-PRP)|LR-PRP will be administered via usual protocol with venous blood draw and concentration via centrifugation. The LR-PRP will be injected under ultrasound guidance into the gluteus minimus and gluteus medius tendons, enthesis and surrounding bursae.
62079424|NCT04299802|ACTIVE_COMPARATOR|Percutaneous Ultrasonic Tenotomy|Percutaneous Ultrasonic Tenotomy will be administered via usual protocol within an outpatient surgical setting or in-office procedure. Patient will be anesthetized with local anesthetic and a \<5mm incision will be made along the lateral hip with an #11 scalpel. A 14-G angiocath will be introduced through the defective area of the tendon down to the enthesis. Multiple passes will be made and then the percutaneous ultrasonic tenotomy device will be introduced to the defective area. No more than 5 minutes of energy cutting time will be used to address the defective area down to the enthesis, which will debride abnormal tissue but leave normal healthy tissue intact.
62079425|NCT06739928|EXPERIMENTAL|Irinotecan liposome (II)+adebrelimab+carboplatin|The patient received treatment with Irinotecan liposome (II), adebrelimab, and carboplatin.
62079426|NCT06739928|OTHER|etoposide+adebrelimab+carboplatin|The patient received treatment with etoposide, adebrelimab, and carboplatin.
62079427|NCT03575637|EXPERIMENTAL|Olanzapine intervention group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
62079428|NCT03575637|NO_INTERVENTION|Control group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen.
62079429|NCT01301768|EXPERIMENTAL|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
62079430|NCT01301768|NO_INTERVENTION|Usual care|Women in the control group receive the usual care during the pregnancy
62079431|NCT04026282|EXPERIMENTAL|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
62079432|NCT04026282|ACTIVE_COMPARATOR|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about 14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
62079433|NCT06624072|EXPERIMENTAL|Treatment sequence R-T1-T2|
62079434|NCT06624072|EXPERIMENTAL|Treatment sequence T1-T2-R|
62079435|NCT06624072|EXPERIMENTAL|Treatment sequence T2-R-T1|
62079436|NCT06080737||standard oxygen group|telephone interview comprising a quality of life questionnaire
62079437|NCT06080737||awake prone group|telephone interview comprising a quality of life questionnaire
62079438|NCT06739213|EXPERIMENTAL|Experimental group|SYHA1813
62079439|NCT06739213|ACTIVE_COMPARATOR|Control group|Investigator's Choice Treatment
62079440|NCT06739798|EXPERIMENTAL|Exp Group|
62079441|NCT06739798|ACTIVE_COMPARATOR|Control Group|
62079442|NCT03918239|EXPERIMENTAL|SHP643 Prefilled Syringe (PFS)|Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
62079443|NCT03918239|EXPERIMENTAL|SHP643 Autoinjector (AI)|Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
62079444|NCT04817917|EXPERIMENTAL|3JEV-I (Group 1)|"Retrospective: 3 doses of JE vaccines. 2 doses of Inactivated JE Vaccine (JEV-I, 7-10 days apart) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
62079445|NCT04817917|EXPERIMENTAL|JEV-L+JEV-I (Group 2)|"Retrospective: 2 doses of JE vaccines.~1 dose of JE attenuated live vaccine (JEV-L) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
62079446|NCT04817917|EXPERIMENTAL|JEV-L+2JEV-I (Group 3)|"Retrospective: 3 doses of JE vaccines.~1 dose of JEV-L at 8 months of age and 2 dose (7-10 days apart) of JEV-I at 2 years old."
62079447|NCT04817917|EXPERIMENTAL|2JEV-I+JEV-L (Group 4)|Retrospective: 3 doses of JE vaccines. 2 doses of JEV-I (7-10 days apart) at 8 months of age and 1 dose of JEV-L at 2 years old.
62647730|NCT06467695|EXPERIMENTAL|Electrical Stimulation (experimental)|Transcranial Direct Current Stimulation will be administered in a high definition anodal montage at 2 milliamps with anode over T3 (adjusted for each participant) and cathode in an equidistance ring around it with 4 return electrodes. There will be 13 minutes of active stimulation followed by a twenty minute delay, followed by 13 minutes of stimulation. Participants in the pilot study will be administered 2 mA of current at a steady state with a 30 second ramp-up and ramp-down period at the beginning and end of each 13 minute stimulation interval.
62647731|NCT06467695|SHAM_COMPARATOR|Sham Stimulation|For the sham TDCS condition, 10 participants will receive receive sham tDCS consisting of 30 seconds of ramp-up and then the amperage will be reduced to 0 for the remainder of the session.
62647732|NCT03019484|EXPERIMENTAL|Intervention|The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
62647733|NCT03019484|NO_INTERVENTION|Control: Standard Care|"This group received standard antenatal and postnatal care by midwives and nurses caring for them during their regular antenatal visits and after delivery.~The professionals delivering the intervention were the same than those providing the standard care. That was the reason to first collect the data from the control group and after that organising the training of health professionals to deliver de intervention."
62647734|NCT04534309|OTHER|Self-Directed Weight Loss with year-long weight tracking|Written Weight Loss Material.
62647735|NCT04534309|OTHER|App-Directed Weight Loss with year-long weight tracking|Smart phone Weight Loss App.
62647736|NCT04534309|OTHER|Coach-Directed Weight Loss with year-long weight tracking|Behavioral Lifestyle Weight Loss Intervention with Smart phone Weight Loss App.
62647737|NCT06326736|EXPERIMENTAL|Pancreatic Cancer|Resectable primary pancreatic tumor
62079448|NCT04817917|EXPERIMENTAL|2JEV-L (Group 5)|Retrospective: 2 doses of JE vaccines. 2 doses of JEV-L respectively administered at 8 months of age and 2 years old.
62079449|NCT06392061|EXPERIMENTAL|Probiotic|Contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule.
62457540|NCT00922909|ACTIVE_COMPARATOR|1|Day 1 : morning : Medication on ; Stimulation on afternoon : Medication on ; Stimulation off Day 2 : morning : Medication off ; Stimulation on afternoon : Medication off ; Stimulation off
62457541|NCT05783284||Readers|5 trained GI surgeons within liver surgery (the readers) will identify pre-defined anatomical landmarks in liver CT images that have been processed by HS2
62457542|NCT00841100|EXPERIMENTAL|Acute 24 Hour Component|Participants will receive one dose of Kuvan 20 mg/kg on Day 1 and assessed for Acute 24 hour Kuvan response.
62457543|NCT00841100|EXPERIMENTAL|Phase 1 Group|After completion of acute 24 hour component, participants can enroll in Phase 1 and will receive Kuvan 20 mg/kg by mouth once daily for 28 consecutive days
62079450|NCT06392061|NO_INTERVENTION|Control|The patients will be asked to continue their usual lifestyle without change in their usual medication and nutritional intake.
62079451|NCT05781490|EXPERIMENTAL|Lumentin® 44|Lumentin® 44 Powder for oral foam
62457544|NCT00841100|EXPERIMENTAL|Phase 2 Group|Participants in Phase 1 that was not responsive will continue on to the Phase 2 of the study. Positive response is defined as a decrease of blood phenylalanine of 30% or greater from baseline taken from morning blood serum. The Phase 2 component of the study will be a 2 week period of dietary restriction.
62457545|NCT00841100|EXPERIMENTAL|Phase 3 Group|Participants in Phase 2 that achieves a fasting blood phenylalanine of less than 600 umol/l after 2 week dietary restriction will be retreated with Kuvan 20 mg/kg by mouth once daily for a period of 28 consecutive days.
62647738|NCT00526474|PLACEBO_COMPARATOR|Placebo|1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
62647739|NCT00526474|EXPERIMENTAL|Vorapaxar|one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
62647740|NCT03876925|EXPERIMENTAL|CT053PTSA|60-100mg
62647741|NCT04597567|ACTIVE_COMPARATOR|Metal removal|
62647742|NCT04597567|NO_INTERVENTION|Metal retention|
62647743|NCT00839124|ACTIVE_COMPARATOR|Allergic asthma|subjects with allergic asthma will undergo challenge with 20,000 EU CCRE
62647744|NCT00839124|ACTIVE_COMPARATOR|healthy control|Healthy volunteers will undergo challenge with 20,000 EU CCRE
62457546|NCT04088214|EXPERIMENTAL|ArtDSTP|Arthroscopic lateral soft tissue release
62647745|NCT02868515|EXPERIMENTAL|Oatmeal containing beta-glucan|43 g cereal containing 3g fiber per serving
62079452|NCT04295746|EXPERIMENTAL|Serious Game ShopAut|Each participant played 10 game sessions, one per week, for no more than 30 minutes.
62079453|NCT04267575|EXPERIMENTAL|Primary Arm|After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
62079454|NCT02300480|EXPERIMENTAL|CTB group|Participants in this group will receive a single injection for calot's triangle block combined with PCIA post-operatively. CTB will be conducted by bile duct needle and 1.0% 10 ml ropivacaine will be injection in calot's triangle when before surgical dissection.Participants in this group will also receive PCIA after surgery,the regimens of PCIA are included tramadol 800 mg, flurbiprofenaxetil 100 mg with normal saline added up to a volume of 80 ml in total.
62079455|NCT02300480|ACTIVE_COMPARATOR|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with normal saline added up to a volume of 80ml in total ) .The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
62079456|NCT06275672|ACTIVE_COMPARATOR|Cohort 1|An Ugandan adapted version of the mhGAP-IG child and adolescent mental health module will be used for identification, assessment, and management of common mental disorders in children and adolescents at primary schools.
62079457|NCT06275672|ACTIVE_COMPARATOR|Cohort 2|Same as arm 1
62079458|NCT06275672|ACTIVE_COMPARATOR|Cohort 3|Same as arms 1-2
62079459|NCT06275672|ACTIVE_COMPARATOR|Cohort 4|Same as arms 1-3
62079460|NCT06275672|ACTIVE_COMPARATOR|Cohort 5|Same as arms 1-4
62079461|NCT06275672|ACTIVE_COMPARATOR|Cohort 6|Same as arms 1-5
62079462|NCT04438096|EXPERIMENTAL|100 mg|
62079463|NCT04438096|EXPERIMENTAL|200 mg|
62079464|NCT04438096|EXPERIMENTAL|300 mg|
62079465|NCT04438096|PLACEBO_COMPARATOR|Placebo|
62647746|NCT06312709|EXPERIMENTAL|teleABLE|Participants meet with a study therapist 2x/week for 6 weeks (12 sessions) to complete behavioral activation focused on adding personally meaningful non-sedentary activities during times when they typically spend sitting. All sessions are delivered remotely using Zoom videoconferencing.
62647747|NCT06312709|ACTIVE_COMPARATOR|Health Education|Participants meet with a study therapist 1x/week for 6 weeks (6 sessions) to review fact sheets focused on healthy lifestyles after stroke. All sessions are delivered remotely using Zoom videoconferencing.
62079466|NCT06465121|EXPERIMENTAL|Ultrasound guidance|peripheral intravenous catheterization performed with ultrasound guidance by a trained nurse
62079467|NCT06465121|NO_INTERVENTION|Standard of care|Peripheral intravenous catheterization by visualization and palpation of the vein alone
62079468|NCT04130711|OTHER|TEST 1: Visual virtual Conditions|"* 50 subjects (30 healthy volunteers and 20 patients after stroke)~* 3 different situations of vibration applications, without EGG neurofeedback session"
62079469|NCT04130711|OTHER|TEST 2: Standard EEG|"* 20 subjects (healthy volunteers)~* 3 separate electroencephalographic recording conditions without Neurofeedback"
62079470|NCT04130711|OTHER|TEST 3: Neurofeedback Training Stroke Patients|"* 26 patients after stroke~* 12 neurofeedback sessions spread over 6 weeks according to the feedback modality that will be drawn (visual or visuo-vibratory)"
62079471|NCT01714596|ACTIVE_COMPARATOR|Oral Antibiotic|Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.
62079472|NCT01714596|ACTIVE_COMPARATOR|IV Antibiotic|Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.
62079473|NCT02341911|EXPERIMENTAL|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
62079474|NCT02341911|ACTIVE_COMPARATOR|Gemcitabine,carboplatin|GC (gemcitabine and carboplatin combination)
62079475|NCT03979261||sex ratio evaluation|Valvular surgery is performed in 30-40% of cases. The Cardiology and Cardiac Surgery De la Timone services 1000 patients as part of their valvulopathy and 450 benefit from cardiac surgery. On the other hand, transcriptomic analysis by microarray will only be done on 40 patients because the analysis costs 150 € / patients.
62079476|NCT02360839|NO_INTERVENTION|Early|Study subjects (patients) undergoing endoscopic ultrasound (with or without FNA/TCB) for clinical reasons during 2005-2011.
62079477|NCT02360839|OTHER|Late|"Study subjects (patients) undergoing endoscopic ultrasound with EUS-guided sampling of various lesions for clinical reasons during 20012-2015.~Subjects sampled with both EUS-FNA and EUS-FNB on the same lesion. Randomization on first needle order."
62079478|NCT06418958|ACTIVE_COMPARATOR|Blue Light|Light-curing procedure performed using blue light emission.
62457547|NCT06387147|EXPERIMENTAL|Gentamicin + Metronidazole|Gentamicin 80 mg Metronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
62457548|NCT06387147|PLACEBO_COMPARATOR|Placebo|Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
62079479|NCT06418958|EXPERIMENTAL|Red Light|Light-curing procedure performed using red light emission.
62079480|NCT00552474|PLACEBO_COMPARATOR|Group B|Implanted but no active stimulation
62079481|NCT00552474|EXPERIMENTAL|Group A|Active Stimulation
62079482|NCT04063579|EXPERIMENTAL|Patients with heart failure with preserved ejection fraction|
62079483|NCT04063579|EXPERIMENTAL|Non-heart failure patients|
62079484|NCT04063579|EXPERIMENTAL|Normal Volunteers|
62457549|NCT01624376|ACTIVE_COMPARATOR|DLX105|DLX105 local injection into the identified fistula(s)
62457550|NCT01624376|PLACEBO_COMPARATOR|Placebo Injection|
62079485|NCT06223477|EXPERIMENTAL|Platelet-rich Fibrin|A 20 ml blood sample will be drawn from the median cubital vein into a PRF tube. Centrifugation will be done at 700 rpm for 3 minutes and the liquid of PRF will be suctioned out using a separate syringe. PRF will be injected distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
62079486|NCT06223477|EXPERIMENTAL|Vitamin D3|Subjects will receive vitamin Dꝫ injection distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
62079487|NCT06691282|EXPERIMENTAL|Self-compassion group|Participants in the intervention group will receive 4 weeks self-compassion training.
62079488|NCT01813032||Firefighters|20 firefighters will attend for vascular assessments following a minimum of 48 hours off-duty.
62079489|NCT01813032||Police Officers|20 police officers will attend for vascular assessments following a minimum of 48 hours off-duty.
62079490|NCT00075569|ACTIVE_COMPARATOR|1 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
62079491|NCT00075569|ACTIVE_COMPARATOR|2 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy
62079492|NCT02427555|EXPERIMENTAL|Barley kernel bread|
62079493|NCT02427555|SHAM_COMPARATOR|Whit wheat flour bread|
62079494|NCT06053177||Type 2 Diabetes|Participants with type 2 diabetes
62079495|NCT06053177||Pre Diabetes|Participants who's most recent HbA1c is in the prediabetes range.
62079496|NCT04902170|EXPERIMENTAL|study group|Highly myopic patients with vitreoretinal disease requiring pars plana vitrectomy. The 30mm (shaft length) vitrectomy probe (25 gauge) would be used in the surgery.
62079497|NCT04902170|ACTIVE_COMPARATOR|control group|Highly myopic patients with vitreoretinal disease requiring pars plana vitrectomy. The 27mm (shaft length) vitrectomy probe (25 gauge) would be used in the surgery.
62079498|NCT02369315|EXPERIMENTAL|Treatment (Invited entry 2012)|Children offered entry to music program in September 2012
62079499|NCT02369315|EXPERIMENTAL|Control (Invited entry 2013)|Children offered entry to music program delayed until September 2013
62079500|NCT06712121|EXPERIMENTAL|decitabine and venetoclax arm|arm treated with venetoclax plus decitabine
62079501|NCT02826148|OTHER|Patients with autism disorder|The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician
62079502|NCT02743000||Women ages 18-35|Women ages 18-35 who do and do not engage in binge eating will be included in the study
62079503|NCT02933190|OTHER|CSP；transvaginal surgery；UAE and D&C|Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar
62079504|NCT00101569|EXPERIMENTAL|A1|
62079505|NCT00101569|EXPERIMENTAL|A2|
62079506|NCT03821701|EXPERIMENTAL|Newly diagnosed HFrEF ARNI|Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
62079507|NCT03821701|ACTIVE_COMPARATOR|Newly diagnosed HFrEF ACEI/ARB|Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
62079508|NCT03821701|EXPERIMENTAL|Prior diagnosed HFrEF ARNI|Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
62079509|NCT03821701|ACTIVE_COMPARATOR|Prior diagnosed HFrEF ACEI/ARB|Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
62079510|NCT01907074|EXPERIMENTAL|Cholates Compound|
62079511|NCT06066489|EXPERIMENTAL|Nurses|Nurses will be assessed first about their knowledge about VAP then they will receive an educational program about VAP and will be assessed immediately and 3 months after the program
62079512|NCT06066489|EXPERIMENTAL|newborns|the prevalence of VAP will be assessed among all ventilated newborns who will meet inclusion criteria in the study before implementing the program, immediately and 3 months after the program using PNU1
62079513|NCT01495221|OTHER|Intravitreal aflibercept|All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.
62457551|NCT03680898|EXPERIMENTAL|revogene Testing|The swab will be used for the testing on the revogene using the GenePOC Carba assay.
62457552|NCT03680898|ACTIVE_COMPARATOR|Reference Method|The other swab will be used in the Reference Method.
62647748|NCT00492492|OTHER|trans-styloid and intrafocal pinning on the one side|trans-styloid and intrafocal pinning on the one side
62079514|NCT06374069||Cases - Enriched for familial longevity|Siblings of dutch Caucasian descent ages 75 and older
62079515|NCT06374069||Controls - Non-enriched for familial longevity|Individuals of dutch Caucasian descent ages 75 and older solely in their family.
62079516|NCT03004664||Support Empowerment Model|"The Center for Diabetes Education at the University of New Mexico Hospital (CDE) uses the Diabetes Self-Management Support Empowerment Model (DSMS). The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions. Patients attend a six-week group instructional session with 9 hours of class plus an individual follow-up with a certified diabetes educator. The group sessions have discussion supported by didactic conversation maps where the facilitator guides but does not control the conversation based on session thematic goals."
62647749|NCT00492492|OTHER|volar fixed-angle plating on the other side|volar fixed-angle plating on the other side
62079517|NCT03004664||The Chronic Care Model|One Hope Centro de Vida Diabetes Program is based on the Chronic Care Model (CCM). The CCM involves 6 synergistic domains: 1.) Improved access to care, 2.) Patient self-management support, 3.) Patient decision support, 4.) Care coordination, 5.) Integrated health information systems, and 6.) Access to community resources. To create a holistic care regime, the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design.
62079518|NCT06738147|EXPERIMENTAL|Experimental Group (A)|It will consist of (15) postmenopausal females are complaining of urinary incontinence and balance disturbances who will be treated by pelvic floor muscle training (PFMT) for 30 min., 3 sessions/ week in addition to traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
62079519|NCT06738147|OTHER|Control Group (B)|It will consist of (15) postmenopausal females are complaining of urinary incontinence and balance disturbances who will be treated by traditional physical and balance training program only (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
62079520|NCT02120846|EXPERIMENTAL|Flywheel leg-press resistance exercise|Participants from the resistance exercise group will perform a 12-wk unilateral flywheel resistance training program with the paretic limb. Four sets of seven coupled concentric and eccentric actions will be completed in the leg press device using flywheel technology twice weekly. Power in each set and repetition will be measured. During all training sessions, subjects will receive visual real-time feedback of power and force produced during each concentric-eccentric action.
62079521|NCT02120846|NO_INTERVENTION|Control|Daily routines
62079522|NCT06527651|OTHER|Genicular blocks|Genicular blocks were applied bilaterally by another physiatrist who was experienced in ultrasonographic (US) interventional procedures more than 5 years. Total of 6mL solution consisting of 0.5 mg/2mL dexamethazone and 4mL %1 lidocaine for three branches of genicular nerves (superomedial, superolateral and inferomedial branches) was divided into three branches for each knee. Total of 12 mL solution was applied for each patient. Antiseptic precautions were taken, sterile environment was prepared. A 5-12 MHz linear probe (Loqiq P5, GE Medical systems) was used for all US evaluations. The probe was positioned in line with the femur shaft. Firstly to find the superomedial genicular nerve, probe was moved to the junction of femur shaft and medial femoral condyle. Color doppler was used to clarify superomedial genicular artery and 2mL injection solution was applied around the pulsatile artery region.
62079523|NCT05332574|EXPERIMENTAL|GB263T|Experimental: GB263T
62079524|NCT05043311|EXPERIMENTAL|Experimental: 20 µg dose, 18-59 years of age (phase 1/2)|
62079525|NCT05043311|EXPERIMENTAL|Experimental: 20 µg dose, ≥60 years of age (phase 1/2)|
62079526|NCT05043311|EXPERIMENTAL|Experimental: 40 µg dose, 18-59 years of age (phase 1/2)|
62079527|NCT05043311|EXPERIMENTAL|Experimental: 40 µg dose, ≥60 years of age (phase 1/2)|
62079528|NCT05043311|PLACEBO_COMPARATOR|Placebo Comparator: Placebo, 18-59 years of age (phase 1/2)|
62079529|NCT05043311|PLACEBO_COMPARATOR|Placebo Comparator: Placebo, ≥60 years of age (phase 1/2)|
62079530|NCT05013996|EXPERIMENTAL|Intervention|Patients randomized to the experimental (MIDSA groupe) will be treated according to the usual methods of each of the centers (CMP / CRIAVS / private practitioners, etc.) completed with the Multidimensional Inventory of Development, Sex, and Aggression-MIDSA groupe Multidimensional Inventory of Development, Sex, and Aggression-inventory tool.
62079531|NCT05013996|ACTIVE_COMPARATOR|Control|Patients randomized to the control group will be treated according to the usual methods of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
62079532|NCT05266040|EXPERIMENTAL|valacyclovir group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
62079533|NCT05266040|PLACEBO_COMPARATOR|Control group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
62079534|NCT02746081|EXPERIMENTAL|BAY1436032|"Dose escalation: Patients with any type of IDH1-R132X-mutant solid tumor may be eligible for enrollment. A minimum of 3 patients per cohort will be treated. If dose limiting toxicities (DLTs) occur, Bayesian dose-DLT modeling will be performed to help guide dosing decisions and to identify the maximum tolerated dose (MTD). If the MTD is not reached, a recommended phase II dose (RP2D) will be chosen based on available safety, tolerability, PK, PD and clinical efficacy data.~Dose expansion: The dose and schedule that was determined to be most appropriate in the dose escalation part of the study, which may be the MTD and / or the RP2D, will be used. Cohorts will consist of patients with the following IDH-R132X-mutant tumor types: (1) anaplastic glioma; (2) glioblastoma; (3) intrahepatic cholangiocarcinoma; (4) tumor types other than those in Cohorts 1-3."
62079535|NCT05421520|EXPERIMENTAL|A novice with ai-assisted assistance|When patients are randomly assigned to the experimental group, the visiting physician will perform endoscopic ultrasound with the assistance of the ai-assisted system
62079536|NCT05421520|NO_INTERVENTION|A novice without ai-assisted assistance|When the patients were randomly assigned to the control group, the visiting physician would not perform endoscopic ultrasonography with the assistance of the AI-assisted system
62079537|NCT01674595|EXPERIMENTAL|Immunotherapy|AVANZ
62079538|NCT04678869|EXPERIMENTAL|Cirprofloxacin prophylaxis|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
62079539|NCT04678869|ACTIVE_COMPARATOR|Standard of care|standard of care
62079540|NCT06082622|EXPERIMENTAL|NEW PROTOCOL|Using the triple therapy protocol for management of FC
62079541|NCT06082622|EXPERIMENTAL|CONVENTIONAL|Using the conventional laxative therapy with rehabilitation (two axis) only
62079542|NCT02826564|EXPERIMENTAL|Sequential|Stereotactic body radiotherapy prior to pembrolizumab treatment
62079543|NCT02826564|EXPERIMENTAL|Concurrent|Stereotactic body radiotherapy concurrent with pembrolizumab treatment
62079544|NCT05853978|EXPERIMENTAL|BSS Plus|
62079545|NCT05853978|ACTIVE_COMPARATOR|BSS|
62079546|NCT01948271|EXPERIMENTAL|TSO 7500|Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
62079547|NCT00941278|EXPERIMENTAL|PH-10 Treatment|
62079548|NCT04267614||Patients with Rheumatoid Arthritis (RA)|Patients receiving etanercept from Baghdad teaching hospital registry(Rheumatology center) from 2012 till 2017. Patients were identified as receiving early versus delayed etanercept treatment.
62079549|NCT00437125|EXPERIMENTAL|Duloxetine|Participants received duloxetine 30 milligram (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg orally QD for 11 weeks
62079550|NCT03209713|ACTIVE_COMPARATOR|Parental Education|Participants will receive parental education on HPV vaccine and the vaccine's benefits.
62079551|NCT03209713|EXPERIMENTAL|Parental Education + Text Messaging|Participants will receive parental education on HPV vaccine and the vaccine's benefits plus text messaging reminder.
62079552|NCT02572336|ACTIVE_COMPARATOR|THR-18|Single administration of intravenous THR-18 solution
62079553|NCT02572336|PLACEBO_COMPARATOR|Placebo|Single administration of intravenous THR-18 lookalike solution
62079554|NCT05629442||EVALUATION OF CTDNA|"This prospective observational, non-therapeutic study will enroll patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy/ All procedures involved with this trial will be done as per standard of care~- Except for the initial research biopsy, quality of life assessments and ctDNA collection"
62079555|NCT02291289|OTHER|Cohort 1: Induction Phase (IP)|Includes participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
62079556|NCT02291289|OTHER|Cohort 2 (IP)|Includes participants with BRAFwt. All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
62079557|NCT02291289|OTHER|Cohort 3 (IP)|Includes participants with human epidermal growth factor receptor 2 positive (HER2+). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
62079558|NCT02291289|OTHER|Cohort 4 (IP)|Includes participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
62079559|NCT02291289|EXPERIMENTAL|Cohort 1 (Maintenance Phase[MP]):5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m\^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m\^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
62079560|NCT02291289|ACTIVE_COMPARATOR|Cohort 1 Control (MP): 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
62457553|NCT03190577|EXPERIMENTAL|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
62457554|NCT05491083|EXPERIMENTAL|Phase 1b Pembrolizumab & ADG106|Intravenous Pembrolizumab + ADG106 on day 1 of each 3-weekly cycle
62079561|NCT02291289|EXPERIMENTAL|Cohort 2 (MP):5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m\^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
62079562|NCT02291289|ACTIVE_COMPARATOR|Cohort 2 Control (MP): 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
62647750|NCT03386526|EXPERIMENTAL|APG-1387 for Injection|APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
62079563|NCT02291289|EXPERIMENTAL|Cohort 3 (MP): capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m\^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
62079564|NCT02291289|ACTIVE_COMPARATOR|Cohort 3 Control (MP): 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
62079565|NCT02291289|EXPERIMENTAL|Cohort 4 (MP): Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
62079566|NCT02291289|ACTIVE_COMPARATOR|Cohort 4 Control (MP): 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
62079567|NCT02291289|OTHER|Early Progressing BRAFmut Cohort|BRAFmut participants experiencing early disease progression during induction treatment will have the option of proceeding immediately to receive second-line treatment with 5-FU/LV, cetuximab and vemurafenib if their primary tumor is MSS, or with a fluoropyrimidine (5-FU/LV or capecitabine), bevacizumab, and atezolizumab if their primary tumor is MSI-H. This cohort will be followed for adverse events during the study, but is not part of the Maintenance Phase study objectives.
62079568|NCT01982162||Cohort A|severe school aged asthma cohort
62079569|NCT01982162||Cohort B|mild to moderate school aged asthma cohort
62079570|NCT01982162||Cohort C|Severe pre school wheeze cohort
62079571|NCT01982162||Cohort D|Mild to moderate pre school wheeze cohort
62079572|NCT04779164|EXPERIMENTAL|Patients with type 2 diabetes|Patients with diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
62079573|NCT04779164|OTHER|Patients without type 2 diabetes|Patients without diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
62079574|NCT00697554|EXPERIMENTAL|Group A|
62079575|NCT00697554|ACTIVE_COMPARATOR|Group B|
62079576|NCT02712112|EXPERIMENTAL|Intermittent dosing arm|one-week on and one-week off schedule(Imatinib Mesylate, 400 mg once daily, oral)
62079577|NCT02712112|SHAM_COMPARATOR|Continuous dosing arm|continuous dosing without off-treatment schedule(Imatinib Mesylate, 400 mg once daily, oral)
62079578|NCT04299282|ACTIVE_COMPARATOR|CanGaroo|The treatment group will receive a CanGaroo envelope with implantation of a CIED
62079579|NCT04299282|NO_INTERVENTION|No CanGaroo|The control group will not receive a CanGaroo envelope with implantation of a CIED
62079580|NCT00440180|PLACEBO_COMPARATOR|Group B|Placebo
62079581|NCT00440180|EXPERIMENTAL|Group A|Anastrozole
62079582|NCT03552718|EXPERIMENTAL|Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)|
62079583|NCT06740175|EXPERIMENTAL|Experimental MSOT measurement|imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo).
62079584|NCT06736600|EXPERIMENTAL|Goal Encouragement|Eligible participants will be identified using electronic health record
62079585|NCT06736600|EXPERIMENTAL|No Goal Encouragement|Eligible participants will be identified using electronic health record
62079586|NCT01836458|EXPERIMENTAL|Dose 1: 30 mg|Single dose of KAE609 30 mg
62079587|NCT01836458|EXPERIMENTAL|Dose 2: 20 mg|Single dose of KAE609 20 mg
62079588|NCT01836458|EXPERIMENTAL|Dose 3: 10 mg|Single dose of KAE609 10 mg
62079589|NCT01836458|EXPERIMENTAL|Dose 4: 15 mg|Single dose of KAE609 15 mg
62079590|NCT04843865|EXPERIMENTAL|Chinese Herbs|Participants received standardized Chinese Herbs treatment orally twice daily for 1 week.
62079591|NCT06739252|EXPERIMENTAL|Neobrave|Perioperative treatment
62079592|NCT06739967||Speech and Language Tailored Interventions|Patients will receive three days a week for 5 weeks of 45 minute sessions of a tailored speech and language intervention
62647751|NCT00442624||1|Patients with chronic insomnia
62647752|NCT00442624||2|age, sex, bmi matched healthy controls
62647753|NCT03964948|OTHER|Healthy Volunteers|20 healthy volunteers will be recruited and will receive a kidney MRI and the same blood and urine labs that are collected for the other arms. Results will be compared to the disease groups.
62647754|NCT03964948|OTHER|Kidney Transplant|20 subjects that have received a kidney transplant that have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
62079593|NCT05838521|EXPERIMENTAL|Sacituzumab Govitecan|Sacituzumab govitecan, 10 mg/kg for the first 2 weeks of 21-day cycle until progression or adverse effects prohibit further treatment.
62079594|NCT06052566|EXPERIMENTAL|Efinopegdutide in Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment receive a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection.
62079595|NCT06052566|EXPERIMENTAL|Efinopegdutide in Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment receive a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.
62079596|NCT06052566|EXPERIMENTAL|Efinopegdutide in Healthy-Matched Control Group|Healthy matched participants receive a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.
62079597|NCT06198426|EXPERIMENTAL|IBI3004|
62079598|NCT06559475|EXPERIMENTAL|Super-Bore Thrombosis Aspiration Catheter treatment group|For the subjects randomized to the Super-Bore Thrombosis Aspiration Catheter treatment group, mechanical thrombectomy will be performed using a Super-Bore 8/7F Thrombosis Aspiration Catheter.
62079599|NCT06559475|ACTIVE_COMPARATOR|Conventional thrombectomy device treatment group|For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8/7F Thrombosis Aspiration Catheter.
62079600|NCT05645003|EXPERIMENTAL|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily at a frequency of 10 HZ at 110% intensity of the motor threshold for 15 sessions.
62079601|NCT05645003|SHAM_COMPARATOR|Sham rTMS Protocol|It was planned to apply daily sham rTMS to the dorsolateral prefrontal cortex for 15 sessions.
62079602|NCT04277741|EXPERIMENTAL|Resistant starch bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.
62457555|NCT05491083|EXPERIMENTAL|Phase 2 Pembrolizumab & ADG106|Intravenous Pembrolizumab + ADG106 each 3-weekly cycle
62079603|NCT04277741|ACTIVE_COMPARATOR|Native wheat bar|The control group will consume one native wheat starch bar per day.
62457556|NCT00406913|EXPERIMENTAL|Mupirocin ointment|
62457557|NCT00406913|ACTIVE_COMPARATOR|Standard of Care sterilization|
62457558|NCT04183881|EXPERIMENTAL|Brodalumab 210mg SC|Brodalumab 210mg subcutaneous injection
62457559|NCT01751347|ACTIVE_COMPARATOR|Lidocaine|Subjects randomized to this treatment arm will receive lidocaine during their elective hand surgery.
62457560|NCT01751347|EXPERIMENTAL|Bupivacaine|Subjects randomized to this treatment arm will receive bupivacaine during their elective hand surgery.
62457561|NCT01390363|NO_INTERVENTION|control|This study arm will receive usual clinical care, but no specific intervention will be made to inform the parent or adolescent that the adolescents is overdue for a routine vaccine.
62457562|NCT01390363|EXPERIMENTAL|Parent Only Group|Parent Only Phone Call
62457563|NCT01390363|EXPERIMENTAL|Parent and Adolescent Group|Parent and Adolescent Phone Call
62457564|NCT00116922|ACTIVE_COMPARATOR|A|Avandamet \[ Rosuglitazone 2 and Metformin 500\]
62457565|NCT03064022||Size < the 3rd or 10th percentiles|Infant size smaller than the 3rd or 10th percentiles relative to the Fenton growth chart for weight or head circumference at discharge from neonatal intensive care
62457566|NCT03064022||Rapid early growth|Rapid early growth will be defined as exceeding birthweight in the first week of life
62457567|NCT03064022||Growth velocity calculation methods|We will compare a variety of growth velocity calculation methods used in clinical care and research to compare and assess growth velocity calculation methods
62457568|NCT03064022||Size for gestational age|Small size for gestational age
62457569|NCT04917978||beta thalassemia patients|
62647755|NCT03964948|OTHER|Stage 2-5 CKD|20 subjects that have been diagnosed with stage 2-5 CKD and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
62079604|NCT06737081|EXPERIMENTAL|SAL-0951 tablets 4mg|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
62079605|NCT06737081|EXPERIMENTAL|SAL-0951 tablets 5mg|initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
62079606|NCT06124690|ACTIVE_COMPARATOR|Pulmonary vein isolation (no low voltage)|Patients without the presence of low voltage areas receive pulmonary vein isolation only.
62079607|NCT06124690|ACTIVE_COMPARATOR|Pulmonary vein isolation only (evidence of low voltage areas)|Patients with the evidence of low voltage areas are randomized to either pulmonary vein isolation only or PVI plus ablation of low voltage areas.
62079608|NCT06124690|ACTIVE_COMPARATOR|Pulmonary vein isolation plus ablation of low voltage areas|Patients with the evidence of low voltage areas are randomized to either pulmonary vein isolation only or PVI plus ablation of low voltage areas.
62079609|NCT06508021|EXPERIMENTAL|Part 1a: PET/CT Study|a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) Study to assess the impact of two dose levels of andecaliximab administered subcutaneously (SC), once-a-week (QW) in participants age ≥ 15 years, with FOP on a number of outcomes including Safety, Pharmacokinetic (PK) and pharmacodynamic (PD) and the change from baseline of Na18F uptake in HO lesions by PET/CT scan, and Patient Reported Outcomes (PROs).
62079610|NCT06508021|EXPERIMENTAL|Part 1b: Flare-up Study|a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) study to assess the impact of two dose levels of andecaliximab administered SC QW in participants ≥12 years of age with a recent history of frequent flare-up episodes on a number of outcomes including safety, PK/PD, and flare-up incidence and symptoms and PROs.
62457570|NCT02138279||Male and female adults 18+ years of age|
62457571|NCT03344445|NO_INTERVENTION|traditional vist|Patients receive traditional anesthesiologist visit
62647756|NCT03964948|OTHER|Lupus nephritis|"20 subjects that have that have active lupus nephritis and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.~Subjects that are post-lupus treatment will receive an additional MRI at the time of the next biopsy."
62647757|NCT03951519|EXPERIMENTAL|Water|
62647758|NCT03951519|ACTIVE_COMPARATOR|Physiological serum|
62647759|NCT05639517|EXPERIMENTAL|Group 1|Patients in this group will receive spinal stabilization training through augmented reality based telerehabilitation application.
62457572|NCT03344445|EXPERIMENTAL|video-assisted|Patients watch the video, then an anesthesiologist visit
62457573|NCT01882140|EXPERIMENTAL|Study Group|Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
62457574|NCT01882140|PLACEBO_COMPARATOR|Control Group (Sham devices)|Patients in the control group (Sham group) will receive the same treatment but the device remains off. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP.
62457575|NCT01864330|EXPERIMENTAL|Dry Eye Syndrome I|20 patients with moderate dry eye syndrome
62457576|NCT01864330|ACTIVE_COMPARATOR|Dry Eye Syndrome II|20 patients with moderate dry eye syndrome
62457577|NCT01864330|ACTIVE_COMPARATOR|Dry Eye Syndrome III|20 patients with moderate dry eye syndrome
62457578|NCT05123690|EXPERIMENTAL|Neurofeedback|24 sessions of ca 45 minutes neurofeedback using alpha-theta protocol.
62457579|NCT05123690|NO_INTERVENTION|Waiting list|Those assigned to waiting list will be able to pick one of the two interventions at the end of the study.
62457580|NCT03633890|EXPERIMENTAL|DaZhu Rhodiola Rosea Capsule|
62457581|NCT03633890|PLACEBO_COMPARATOR|DaZhu Rhodiola Rosea Simulation Capsule|
62457582|NCT03943056|EXPERIMENTAL|Single Ascending Dose (SAD): Cohort 1A|Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1.
62457583|NCT03943056|EXPERIMENTAL|(SAD): Cohort 2A|Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1.
62457584|NCT03943056|EXPERIMENTAL|(SAD): Cohort 3A|Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal.
62457585|NCT03943056|EXPERIMENTAL|(SAD): Cohort 4A|Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1.
62647760|NCT05639517|ACTIVE_COMPARATOR|Group 2|Patients in this group will receive spinal stabilization training face-to-face.
62079611|NCT06508021|PLACEBO_COMPARATOR|Part 2: Main Study|1-year (52-week) double-blind (Investigator, participant, and sponsor all blinded), placebo-controlled study of andecaliximab Dose level A or B (or age adjusted) SC QW or placebo in pediatric and adult patients with FOP. The Main Study will enroll approximately 80 participants, randomized in a 1:1:1 ratio to andecaliximab Dose level A or B (or age adjusted) SC QW or placebo.
62079612|NCT02689791|NO_INTERVENTION|Control (SWF)|Standard Wheat Flour (SWF) Muffins
62079613|NCT02689791|EXPERIMENTAL|Resistant Starch Type 4|Resistant Wheat Starch Muffins
62079614|NCT04701593|NO_INTERVENTION|Control|No additional drug given
62079615|NCT04701593|EXPERIMENTAL|Experimental (Triamcinolone Acetonide)|receives a sub-tenon irrigation of 1 cc 40mg/mL triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation
62079616|NCT06103669|EXPERIMENTAL|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
62079617|NCT03809637|EXPERIMENTAL|pemetrexed+cisplatin|Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.
62079618|NCT06740227|ACTIVE_COMPARATOR|Control Group|"Conventional Balance Training one minute of rest for every five minutes of exercise~Conventional Balance workout session will be for about 30-40 minutes Warm-up for 5 minutes For Static Balance, Static Balance, Single Leg Standing, Stork Standing will be used For Dynamic Balance, Weight Shifts, Tandem Walk, Single Leg Balance with Arm Movements 5 minutes will be given for cool down"
62079619|NCT06740227|EXPERIMENTAL|Experimental group|"Virtual Reality based balance training~Virtual reality workout session will be for about 30-40 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For Static Balance, Lotus Focus, Tree pose, Warrior Pose games will be used For Dynamic Balance, Soccer Heading, Ski Jump, Tight Rope Walk, Table Tilt, Ski Slalom games will be used 5 minutes will be given for cool down."
62079620|NCT05744921|EXPERIMENTAL|PNH Transition Patients|Patients with PNH who completed treatment/ protocol requirements (as applicable) in the parent study (R3918-PNH-2021 \[NCT05133531\])
62647761|NCT02233127||Birth Cohort|The cohort will comprise approximately 3000 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02130856).
62647762|NCT02819713|PLACEBO_COMPARATOR|ultrasound gel|
62079621|NCT05744921|EXPERIMENTAL|C5 Polymorphism Patients|Patients who have not been treated in either parent study but who have a documented complement component 5 (C5) variation rendering them refractory to eculizumab/ravulizumab. Note: Loading dose of pozelimab administered IV on Day 1.
62647763|NCT02819713|ACTIVE_COMPARATOR|Instillagel|
62647764|NCT00676117|EXPERIMENTAL|1|
62079622|NCT05617547||Pulse Oximetry Observational Cohort|
62079623|NCT02460081|EXPERIMENTAL|PDA-002 -3x10^6 cells|Subjects will be treated with Investigational Product (IP) administered intramuscular (IM) on Study Days 1, 29 and 57.
62647765|NCT00676117|ACTIVE_COMPARATOR|2|
62647766|NCT04273321|EXPERIMENTAL|MP group|
62647767|NCT04273321|NO_INTERVENTION|Con group|
62647768|NCT02090296|PLACEBO_COMPARATOR|Sugar water|Placebo arm
62647769|NCT02090296|ACTIVE_COMPARATOR|Hydroxyurea|Treatment Arm
62647770|NCT01164761|EXPERIMENTAL|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
62647771|NCT01164761|ACTIVE_COMPARATOR|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
62079624|NCT02460081|EXPERIMENTAL|PDA-002 - 30X10^6 cells|Subjects will be treated with IP administered IM on Study Days 1, 29 and 57.
62079625|NCT02460081|PLACEBO_COMPARATOR|Placebo|Subjects will be treated with Placebo administered IM on Study Days 1, 29 and 57.
62079626|NCT02270073|EXPERIMENTAL|TAU + mindfulness intervention|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together the brief intervention with mindfulness elements. Participants sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The text is standardized and spoken by Dr. Thomas Heidenreich. During the exercise, participants are instructed to observe their breathing and body sensations. After completion of the mindfulness intervention, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
62079627|NCT02270073|ACTIVE_COMPARATOR|TAU + progressive muscle relaxation|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together a short version of progressive muscle relaxation (PMR). Both patient and therapist sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The PMR text is standardized and spoken by Dr. Thomas Heidenreich. Wording is as similar as possible to the mindfulness interventions.During the exercise, participants are instructed to tense and relax arms, face, body and legs. After completion of PMR, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
62079628|NCT02270073|OTHER|Treatment as usual|"No specific intervention is conducted at the beginning of therapy sessions. Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions.~Intervention: Cognitive behavior therapy of trainee therapists"
62079629|NCT05903911|EXPERIMENTAL|Trans Care Intervention|
62079630|NCT05903911|NO_INTERVENTION|Waitlist Control|
62079631|NCT06741345|EXPERIMENTAL|Multiple Ascending Dose|The multiple ascending dose study has a single arm. Three cohorts are enrolled sequentially and given ascending doses of study intervention.
62079632|NCT06741345|EXPERIMENTAL|Food Effect: Fed-Fasted Arm|Food effect study arm that is administered the study intervention first under fed conditions and then under fasted conditions following crossover.
62079633|NCT06741345|EXPERIMENTAL|Food Effect: Fasted-Fed|Food effect study arm that is administered the study intervention first under fasted conditions and then under fed conditions following crossover.
62079634|NCT06738693|EXPERIMENTAL|External Fixation|Patients in this arm will undergo external fixation for unstable intra-articular distal radius fractures. The procedure involves the placement of an external fixator to stabilize the fracture, followed by postoperative care including pin tract cleaning and removal of the fixator after radiological confirmation of bone healing (6-8 weeks). Functional outcomes, fracture union, and complications will be assessed at regular intervals.
62079635|NCT06738693|EXPERIMENTAL|Volar Locking Plate|Patients in this arm will undergo open reduction and internal fixation (ORIF) using a volar locking plate for unstable intra-articular distal radius fractures. This method provides stable fixation, allowing early mobilization. Postoperative outcomes, including functional scores, union rates, and complications, will be evaluated at follow-up visits.
62079636|NCT06739265|EXPERIMENTAL|G-CHOP arm|
62079637|NCT01285193|EXPERIMENTAL|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
62079638|NCT01770249|OTHER|POEM procedure|An endoscopic surgical procedure for achalasia; Per-oral Endoscopic Esophagomyotomy (POEM)will be performed. The POEM procedure will be performed in the operating room under general anesthesia and a scope will then be inserted into your mouth and down your throat and measurements will be taken. With the use of this lighted flexible scope the surgeon will make a small incision in the inner lining of your esophagus (throat), create a tunnel and then cut the muscle between the esophagus (throat) and the stomach. The initial little opening will be closed with a small clip. This procedure will allow easier passage of food into the stomach.
62079639|NCT06195046|SHAM_COMPARATOR|control (BAT off)|Baroreflex activation therapy turned off for three months
62079640|NCT06195046|EXPERIMENTAL|treatment (BAT on)|Baroreflex activation therapy turned on for three months
62079641|NCT02178436|EXPERIMENTAL|Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)|Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62457586|NCT03943056|EXPERIMENTAL|(SAD): Cohort 5A|Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1.
62079642|NCT02178436|EXPERIMENTAL|Group II: Phase II Group I (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
62079643|NCT02178436|EXPERIMENTAL|GroupIII: Phase II Group II (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62079644|NCT03673371||Women Veterans with Lower Limb Amputations|Questionnaire
62079645|NCT06740500|EXPERIMENTAL|Probiotic Bi66|Bi66 group adminster a sachet of probiotic powder (1 g), including Bifidobacterium animalis subsp. lactis Bi66 6.0 × 1010 CFU and a maltodextrin carrier once daily for 8 weeks.
62079646|NCT06740500|PLACEBO_COMPARATOR|Placebo|Placebo group adminster a sachet of placebo powder (1 g) containing maltodextrin once daily for 8 weeks.
62079647|NCT05655195|ACTIVE_COMPARATOR|Alzheimer's Active Arm|Exposure to active sensory stimulation (40Hz) for 60 minutes daily for the length of the trial (6 months).
62079648|NCT05655195|SHAM_COMPARATOR|Alzheimer's Control Arm|Exposure to control stimulation (sham) for 60 minutes daily for the length of the trial (6 months).
62457587|NCT03943056|EXPERIMENTAL|Multiple Ascending Dose (MAD): Cohort 1B|Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14.
62457588|NCT03943056|EXPERIMENTAL|(MAD): Cohort 2B|Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
62457589|NCT03943056|EXPERIMENTAL|(MAD): Cohort 3B|Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
62457590|NCT00169533|EXPERIMENTAL|Arm 1|Lapatinib either 750, 1000, 1250 or 1500 mgs
62457591|NCT04182737|EXPERIMENTAL|IgM titer-based treatment|The treatment with IgM preparation will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The calculation of the dose is based on IgM single compartment distribution. The first dose of IgM preparation will be calculated on IgM serum concentration obtained within 24 hours after shock appearance to achieve serum titers above 100mg/dl. In the next days, the daily IgM preparation dose will be assessed individually on the basis of IgM serum titers assessment performed in the morning with the purpose of maintaining IgM serum titers above 100 mg/dl, up to discontinuation of vasoactive drugs or day 7 after enrolment. Daily, the calculated dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg per hour (20mg/kg per hour). IgM preparation will be administered up to the withdrawal of vasoactive drugs with a maximum allowed of 7 days of therapy and a maximum dose of 350mg/Kg/day.
62457592|NCT04182737|ACTIVE_COMPARATOR|IgM Flat treatment|The IgM treatment will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The dose of IgM preparation will be 250mg/kg for 3 days, the dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg (20mg/kg per hour) until reaching 250mg/kg.
62457593|NCT00991445|ACTIVE_COMPARATOR|Group MIS|Minimal Invasive Surgery
62079649|NCT06056999||A. pure ground-glass nodule|Patients with pure ground-glass nodules (GGNs).
62079650|NCT06056999||B. part-solid nodule|Patients with part-solid nodules (PSNs).
62079651|NCT06056999||C. solid nodule|Patients with solid nodules (SNs).
62079652|NCT03103932|NO_INTERVENTION|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
62079653|NCT03103932|EXPERIMENTAL|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
62079654|NCT05176080|EXPERIMENTAL|Treatment group|Famitinib Plus SHR6390 and Endocrine therapy
62457594|NCT00991445|ACTIVE_COMPARATOR|Conventional Exposure|
62457595|NCT02695732|EXPERIMENTAL|Carvedilol|Carvedilol，6.25mg-12.5mg/d,oral,6-36 months
62079655|NCT05015660|EXPERIMENTAL|left bundle branch pacing|
62079656|NCT05015660|ACTIVE_COMPARATOR|Right ventricular pacing|
62079657|NCT06736652|EXPERIMENTAL|Main study arm|All subjects perform the same activities (described in the protocol), but in different orders for counterbalancing purposes.
62079658|NCT02284919|EXPERIMENTAL|ISO-1 PET/CT|All subjects will receive an \[18F\]ISO-1 PET/CT scan
62079659|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
62079660|NCT06738030|EXPERIMENTAL|Active transcranial stimulation|This group will receive active transcranial alternating current stimulation that matches the envelope of the target speech.
62079661|NCT06738030|SHAM_COMPARATOR|Sham stimulation|This group will receive transcranial stimulation that ramps on and off before the speech is presented.
62457596|NCT02695732|ACTIVE_COMPARATOR|endoscopy|endoscopy，every 4 weeks until eradication of varices
62457597|NCT04314869|EXPERIMENTAL|Recipient|Patient with absolut uterine factor will undergo uterus transplantation.
62079662|NCT05115474||Participants with TNBC (triple negative breast cancer)|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
62457598|NCT02328690|EXPERIMENTAL|Music with BBT|Music embedded with special tones.
62457599|NCT02328690|PLACEBO_COMPARATOR|Music without BBT|Music not embedded with special tones.
62457600|NCT01717976|EXPERIMENTAL|Intervention|primary care based nurse telephone support
62457601|NCT01717976|NO_INTERVENTION|Control|usual care
62647772|NCT06293833|EXPERIMENTAL|High-risk (ex-) smokers|Prevention and early detection of lung cancer are considered the cornerstones to increase the chances of successful treatment and improved outcomes. There is strong scientific evidence that screening for lung cancer through an annual low-dose CT scan (LDCT) in a high-risk population of (ex-)smokers significantly reduces lung cancer mortality and is cost-effective. This implementation study will investigate the participation rate of eligible high risk (ex-)smokers in the First Line Zone (ELZ) South East Region of Antwerp (ZORA) in a LDCT screening program, combined with smoking cessation.
62079663|NCT05115474||Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
62647773|NCT03149536|ACTIVE_COMPARATOR|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
62647774|NCT03149536|ACTIVE_COMPARATOR|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
62079664|NCT05115474||Participants with Hormone Receptor (HR) +Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
62647775|NCT03149536|ACTIVE_COMPARATOR|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
62079665|NCT02825953|ACTIVE_COMPARATOR|Nebulized surfactant|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV), and than premature babies with RDS breathing spontaneously will be administered surfactant by nebulizer.
62079666|NCT02825953|ACTIVE_COMPARATOR|Endotracheal bolus application|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The investigators will administer surfactant via fundamental method.
62079667|NCT02825953|ACTIVE_COMPARATOR|Minimally invasive surfactant therapy|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). After randomisation, the investigators will administer surfactant via minimally invasive surfactant therapy (MIST) method which is recently very popular method
62647776|NCT03149536|ACTIVE_COMPARATOR|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
62647777|NCT03149536|ACTIVE_COMPARATOR|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
62079668|NCT06117995||Infertile couples have indication of IUI|Infertile couples have an indication of IUI
62079669|NCT05785611|EXPERIMENTAL|Radiographic Part (Study A) Filgotinib|Participants will receive filgotinib 200 mg or placebo to match filgotinib. Participants will receive blinded treatment until Week 16. After that participants with an age under 65 and without certain health risks will enter open label period and will receive filgotinib 200 mg until Week 52. Participants reaching an Ankylosing Spondylitis Disease Activity Score (ASDAS) \<2.1 at weeks 40 and 52, will enter dose de-escalation phase and will be randomized to filgotinib 200 or 100 mg until Week 104. Participants, with an age of 65 or above or with certain health risks, will enter open label period until Week 104 and will receive 100 or 200 mg filgotinib a day, depending on their axSpA symptoms. The maximum duration of treatment period will be up to Week 104.
62079670|NCT05785611|EXPERIMENTAL|Non-radiographic Part (Study B) Filgotinib|Participants will receive filgotinib 200 mg or placebo to match filgotinib. Participants will receive blinded treatment until Week 16. After that participants with an age under 65 and without certain health risks will enter open label period and will receive filgotinib 200 mg until Week 52. Participants reaching an ASDAS \<2.1 at weeks 40 and 52, will enter dose de-escalation phase and will be randomized to filgotinib 200 or 100 mg until Week 104. Participants, with an age of 65 or above or with certain health risks, will enter open label period until Week 104 and will receive 100 or 200 mg filgotinib a day, depending on their axSpA symptoms. The maximum duration of treatment period will be up to Week 104.
62079671|NCT02071563|ACTIVE_COMPARATOR|CSB14|Isocaloric amount and cost-effectiveness of CSB14 (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO).
62079672|NCT02071563|ACTIVE_COMPARATOR|RUSF1|Isocaloric amount and cost-effectiveness of Ready-to Use Supplementary Food 1(RUSF1), USAID's Lipid-Based Nutrient Supplement (LNS) product
62647778|NCT03149536|ACTIVE_COMPARATOR|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
62079673|NCT02071563|ACTIVE_COMPARATOR|SC+|Isocaloric amount and cost-effectiveness of Supercereal Plus (SC+), the FBF used by WFP, which has an enhanced nutrient profile, dairy ingredient (non-fat dry milk), and oil already embedded into the flour
62079674|NCT02071563|NO_INTERVENTION|CSB+|Isocaloric amount and cost-effectiveness of Supercereal/CSB+ prepared with FVO.
62079675|NCT04489589|EXPERIMENTAL|Midodrine|Midodrine 10mg PO/NG q8h
62647779|NCT04151264|NO_INTERVENTION|Control Arm|blinded HPI monitoring
62079676|NCT04489589|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose PO/NG q8h
62079677|NCT00344188||1|This population of patients are referred from their physicians both regionally and nationally.
62079678|NCT06736847||Radical gastrectomy with membrane dissection|
62079679|NCT04340843|EXPERIMENTAL|Treatment (belinostat, guadecitabine, ASTX727)|Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood during screening, tumor biopsy during screening and on study, and MRI or CT throughout the trial.
62079680|NCT06428383|EXPERIMENTAL|Vericiguat|Vericiguat administered orally in either tablet or suspension once daily until end of treatment
62079681|NCT06740019|EXPERIMENTAL|Arm A|JMKX000197 Dose 1
62079682|NCT06740019|EXPERIMENTAL|Arm B|JMKX000197 Dose 2
62079683|NCT06740019|OTHER|Arm C|Tube thoracostomy drainage
62079684|NCT05559658||Group 1|"A: Current chemsex users Men who have sex with men, Aged 16-35 years, Able to communicate in Thai fluently, Current chemsex users.~B: Former chemsex users (discontinued ≥90 days) Men who have sex with men, Aged 16-35 years, Able to communicate in Thai fluently, Former chemsex users (discontinued ≥90 days)."
62079685|NCT01634711|EXPERIMENTAL|The L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an interventional device intended for ACL reconstruction surgery within 13 weeks of acute rupture of the ACL and no previous treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
62079686|NCT02212938|EXPERIMENTAL|BI 14332 CL fasted|
62079687|NCT02212938|EXPERIMENTAL|BI 14332 CL fed|
62079688|NCT06738615||Mitral Regurgitation|Patients with mitral regurgitation undergoing a left heart catheterization prior to mitral valve surgery or mitral valve clip.
62079689|NCT04381767||Concussion Evaluation|Adult athletes receiving a clinical evaluation for a suspected concussion after head injury
62079690|NCT05290597|EXPERIMENTAL|IBI363|Single arm
62079691|NCT05827822|EXPERIMENTAL|Punch-in Intervention Group|4 weeks of alcohol-related daily tracking + brief assessment and intervention
62457602|NCT04003779|OTHER|Participant stability with various room configurations|Single-arm. Ergonomically exploring patient stability moving around various configurations of a hospital room.
62457603|NCT01240005|EXPERIMENTAL|DCIK|
62079692|NCT05827822|NO_INTERVENTION|Control Group|waiting list group
62079693|NCT04350476|OTHER|Vital Connect Patch Arm|"This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system:~VitalConnect Vital Sign Patch (FDA approved for this indication)"
62457604|NCT00113347|EXPERIMENTAL|Erlotinib + Docetaxel|Erlotinib 100, 125, or 150 mg orally daily except days receive Docetaxel 15 mg/m\^2 or 20 mg/m\^2 intravenously with Concomitant Boost Radiation to Head/Neck
62647780|NCT04151264|ACTIVE_COMPARATOR|Intervention Arm|HPI monitoring to predict hypotension
62079694|NCT06740136|EXPERIMENTAL|Exercise|exercise group
62079695|NCT06558110||Students|Students of the Faculty of Health Sciences in Istanbul
62079696|NCT06129760|EXPERIMENTAL|Wearing the Apple watch and the associated logging of health data|As part of the monitoring needed for this study, participants will be enrolled for at least 6 months, as this will give enough data to understand how the participant's health changes associate with what is measured by the Apple watch. After this 6 month period, participants may choose to end their participation on the study, or continue if they wish.
62079697|NCT03760471|EXPERIMENTAL|Collaborative palliative and oncology care|
62079698|NCT02800824|EXPERIMENTAL|Budesonide rectal foam|
62079699|NCT02800824|ACTIVE_COMPARATOR|Uceris rectal foam|
62079700|NCT06741358|EXPERIMENTAL|Glialia|Participants in the PPPD-Glialia group must be between the ages of 18 and 65 years and have a confirmed diagnosis of Persistent Perceptual Postural Dizziness (PPPD). They must also either have recovered from a COVID-19 infection or have no history of such an infection. Individuals with concurrent neurological or otological disorders, as well as pregnant women, will be excluded from this group.
62079701|NCT06741358|PLACEBO_COMPARATOR|Placebo|Participants in the PPPD-Glialia group must be between the ages of 18 and 65 years and have a confirmed diagnosis of Persistent Perceptual Postural Dizziness (PPPD). They must also either have recovered from a COVID-19 infection or have no history of such an infection. Individuals with concurrent neurological or otological disorders, as well as pregnant women, will be excluded from this group.
62457605|NCT00864864|EXPERIMENTAL|Sunitinib|
62079702|NCT06741358|OTHER|Control group|The Control Group will consist of individuals aged between 18 and 65 years who have a previous history of COVID-19 infection, matched for timing with the PPPD-Glialia group. Exclusion criteria for this group will also include the presence of any neurological or otological disorders and pregnancy, ensuring that the results are focused on the impact of the Glialia supplement in the context of PPPD and recovery from COVID-19.
62079703|NCT02606747||Diabetes mellitus with DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes with DPN.
62079704|NCT02606747||Diabetes mellitus without DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes without DPN.
62079705|NCT03997162||Observational (ERAS protocol)|Participants complete standard of care early recovery after surgery protocol beginning the day before surgery to day 6 after surgery.
62079706|NCT01628380|ACTIVE_COMPARATOR|CRS + HIPEC|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel
62457606|NCT04137679|EXPERIMENTAL|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
62079707|NCT01628380|ACTIVE_COMPARATOR|CRS alone|Cytoreductive Surgery alone
62079708|NCT06738238|EXPERIMENTAL|Eldova|Elongation Longitudinaux Avec Decoaption Osteo Articulaire
62079709|NCT06738238|EXPERIMENTAL|Corrective exercises|corrective exercises
62079710|NCT02311374|SHAM_COMPARATOR|Phase 2|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM-12 PM).
62079711|NCT02311374|SHAM_COMPARATOR|Phase I|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9 AM-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM 12 PM).
62079712|NCT02312505|OTHER|COPFX|cardiac output by PulsioFlex® Monitoring system (COPFX)
62079713|NCT06424288|EXPERIMENTAL|BI 690517 + empagliflozin|
62079714|NCT06424288|PLACEBO_COMPARATOR|Placebo + empagliflozin|
62079715|NCT00776100|OTHER|Arm I|Patients undergo observation for 6 weeks.
62079716|NCT00776100|EXPERIMENTAL|Arm II|Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.
62079717|NCT06736834|EXPERIMENTAL|College students participating in sensory evaluation|Youtiao and porridge with different processing time and temperature
62079718|NCT01310868|EXPERIMENTAL|5-ALA and Gliadel wafers|This is a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Gliadel wafers) in the surgical management of patients with GBM.
62079719|NCT06739018||keratoconic group|patients with keratoconus
62079720|NCT06739018||high myopic astigmatim group|patients with high myopic astigmatism
62079721|NCT06738173||Groups/Cohorts|"Study cohort consists of patients enrolled in the national colorectal cancer (CRC) screening program.Participants will be selected among those enrolled in the nationalcolorectal cancer (CRC) screening program and among who refer to all centers involved in this study for screening colonoscopy. Patients with all inclusion criteria and none of the exclusion criteria will be considered for this study. N=1202 patients will be enrolled, based on sample size calculation and including a validation group.~N=911 patients will be needed, and we will add 91 patients to cover a 10% potential drop-out and 200 patients as a validation group (20% of the study cohort)."
62079722|NCT02190760|ACTIVE_COMPARATOR|Group I (ISB-P)|Interscalene block with perineural injection of dexamethasone 0.1 mg/kg
62079723|NCT02190760|ACTIVE_COMPARATOR|Group II (ISB-S)|Interscalene block with systemically injection of dexamethasone 0.1 mg/kg.
62079724|NCT02190760|ACTIVE_COMPARATOR|Group III - ISB-C|Interscalene block without adjuvant.
62457607|NCT04137679|ACTIVE_COMPARATOR|Neoadjuvant Radiochemotherapy followed by surgery|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
62079725|NCT06740903|EXPERIMENTAL|Dexmedetomidine infusion|inj dexmedetomidine infusion @ 0.2-0.4 μg/kg/h
62079726|NCT06740903|EXPERIMENTAL|Lignocaine infusion|inj.lignocaine infusion @1-2 mg/kg/h
62079727|NCT04989530|ACTIVE_COMPARATOR|Low energy level of ESWT|
62079728|NCT04989530|ACTIVE_COMPARATOR|medium energy level of ESWT|
62079729|NCT04989530|ACTIVE_COMPARATOR|high energy level of ESWT|
62457608|NCT00825227|ACTIVE_COMPARATOR|Patient responses to 150 mg/day armodafinil|"* 150 mg/day armodafinil~* taxane chemotherapy treatment alone or in combination with other agents"
62457609|NCT00825227|PLACEBO_COMPARATOR|Patient responses to placebo|"* placebo~* taxane chemotherapy treatment alone or in combination with other agents"
62647781|NCT04326257|EXPERIMENTAL|Nivolumab+Relatlimab|"Nivolumab will be dosed 480mg IV q 4 weeks and Relatlimab 160mg IV q 4 weeks~One cycle is defined as 4 weeks of treatment and both drugs are given on the same day.~Patients will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
62079730|NCT06737965||Extremely low gestational age foetuses|Material (cord blood/myocardial tissu/ vascular segment) from foetuses resulting from medical abortion before 28 weeks of gestation (and after 22 weeks of gestation)
62079731|NCT06737965||Control group : foetuses ≥ 34 weeks of gestation|Material (cord blood/myocardial tissu/ vascular segment) from foetuses resulting from medical abortion after or during 34 weeks of gestation
62079732|NCT03309124|EXPERIMENTAL|White bread|Matched for energy content and available carbohydrate content of potato treatments
62079733|NCT03309124|EXPERIMENTAL|Baked potato with skin|Baked russet potato
62079734|NCT03309124|EXPERIMENTAL|Mashed potatoes|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
62079735|NCT03309124|EXPERIMENTAL|Fried French fries|Matched for available carbohydrate content of baked potato
62079736|NCT03309124|EXPERIMENTAL|Meal skipping|No food given
62079737|NCT05048394|EXPERIMENTAL|Standard-of-care then Semi-autonomous myoelectric control|"The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand~The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand."
62079738|NCT05048394|EXPERIMENTAL|Semi-autonomous then Standard-of-care myoelectric control|"The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.~The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand"
62079739|NCT06034197|EXPERIMENTAL|VGT-309|Subjects will receive an IV infusion of 0.32 mg/kg VGT-309 12 to 36 hours before a standard of care endoscopy procedure.
62079740|NCT00673634|ACTIVE_COMPARATOR|1|Standard preoxygenation
62079741|NCT00673634|ACTIVE_COMPARATOR|2|BiPAP assisted preoxygenation
62079742|NCT00344370|EXPERIMENTAL|Pitavastatin|Pitavastatin 4 mg QD
62079743|NCT00344370|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 40 mg
62079744|NCT00432679|EXPERIMENTAL|arm 1|study drug
62079745|NCT01165346|EXPERIMENTAL|Stereotaxic radiation by CyberKnife|Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days
62079746|NCT05057832||Cases|Patients treated with Ustekinumab.
62079747|NCT06737211|EXPERIMENTAL|Intervention|2000 mL of peripheral parenteral nutrition with electrolytes (20 mL 7.45% KCl, 10 mL 20% MgSO4 and 20 mL 8.7% Na3PO4) will be administered via a peripheral venous catheter with a rhythm of 80cc/h from the time they will leave the operation room and will be transferred to the ward or the critical care unit (CCU) until the 5th postoperative day
62079748|NCT06737211|NO_INTERVENTION|Control|1000 mL of 10% glucose saline with electrolytes (20 mL 7.45% KCl, 10 mL 20% MgSO4 and 20 mL 8.7% Na3PO4) will be administered via a central or peripheral venous catheter with a rhythm of 80cc/h until the 5th postoperative day
62079749|NCT02035215|EXPERIMENTAL|Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g|Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d
62079750|NCT02035215|PLACEBO_COMPARATOR|Atorvastatin 20mg, Placebo|Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d
62079751|NCT06206746|EXPERIMENTAL|Device arm|May Health procedure performed with the use of the May Health system intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to Polycystic Ovary Syndrome.
62079752|NCT06206746|NO_INTERVENTION|Control arm|No fertility medication. Crossover participants who choose to crossover after the 3 month follow up visit will restart follow up as per the Device arm.
62079753|NCT06738940|EXPERIMENTAL|Use of CPAP device|CPAP 48 weeks
62079754|NCT06738940|NO_INTERVENTION|Usual care|Usual care 48 weeks
62079755|NCT00670462|ACTIVE_COMPARATOR|Standard Behavioral Treatment (SBT)|"Standard Behavioral Treatment (SBT) for weight loss intervention introduces a core set of instructions on diet and exercise at the beginning of the intervention and then embellishes these instructions with suggested refinements of behavioral choices over time (e.g., different menus and amounts or types of physical activity)."
62079756|NCT00670462|EXPERIMENTAL|Maintenance-Tailored Treatment (MTT)|"Maintenance-Tailored Treatment (MTT) for weight loss intervention treats diet and exercise strategy embellishments as separate interventions with discrete and independent status. MTT differs from SBT in its emphasis on skills for long-term weight control, namely, the strategy of initiating varied weight-control strategies as a response to the demands of changing environmental challenges and to sustain effective cues and reinforcements needed to motivate weight-loss behaviors."
62079757|NCT02456818||Centers using contact isolation|"* Isolation triggered by the detection of ESBL-EC at hospital admission in surveillance screening or during the hospitalization by weekly screening or clinical cultures~* Contact isolation terminated, after at least two negative consecutive fecal screening cultures~* Contact isolation resumed, if subsequent ESBL-EC positive cultures are identified for the same patient including readmissions~Contact isolation must include:~* Patient placement in single rooms~* Cohorting only possible, when no single rooms available and corresponding ESBL-EC strains are phenotypically identical~* Staff and visitors wearing gloves and gowns as contact precautions when entering the room, patient when leaving the room"
62079758|NCT02456818||Centers using no contact isolation|"* not regularly isolating for ESBL-EC~* ESBL-EC colonized or infected patients with urinary or fecal incontinence or diarrhea (\>3 loose bowel movements/day) isolated in single rooms with above described contact precautions"
62079759|NCT05668858|EXPERIMENTAL|Study treatment|Participants will receive treatment during the first cycle. Participants with clinical benefits received more cycles of additional therapy. Administration will be discontinued due to disease progression or occurrence of intolerable toxicity or other reasons.
62079760|NCT03358979||Severe eye dryness|
62079761|NCT03358979||absence of eye dryness|
62079762|NCT06574425|EXPERIMENTAL|Patients undergoing maintenance hemodialysis with once-weekly hemoadsorption|The blood flow rate is based on the actual blood flow speed displayed by the dialysis machine; the dialysis fluid flow rate is 500 ml/min; the total ultrafiltration volume in 4 hours does not exceed 4500 ml.All subjects undergo a self-controlled before-and-after comparison, with continuous 3 weeks of HA+HD treatment, once a week. The HA+HD treatment is implemented at a short interval of 1 day after the previous dialysis treatment. Group 1 is the routine treatment group, Group 2 is the extended time group, and Group 3 is the extended time and increased blood flow group, also known as the modified HA+HD group. The treatment modes of the three groups are implemented sequentially in order.
62079763|NCT06741137|EXPERIMENTAL|inhaled nitric oxide combined with prone position ventilation|
62079764|NCT05586737|EXPERIMENTAL|rituximab|Controlled ovarian hyperstimulation will be performed before and four months after two infusions of 1-gram rituximab (Mabthera®).
62079765|NCT05865418|EXPERIMENTAL|Loaded high intensity circuit training|These participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 2-5 of the intervention, the participants will perform the exercises with an adjustable weight vest starting with 2.5% to finally reaching 10% of their body weight.
62079766|NCT05865418|ACTIVE_COMPARATOR|High Intensity Training|These participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
62079767|NCT05865418|NO_INTERVENTION|Control|They will continue their standard-of-care plan and will not involve in any new structured exercise program for 6 weeks.
62457610|NCT04033952|EXPERIMENTAL|Assigned Interventions|The OPASS program will be delivered to the intervention group. The intervention protocols of the OPASS program were developed based on the strategy training guidelines developed by Skidmore et al. and based on the findings identified from the feasibility study. Trained research therapists will take the responsibility for delivering the intervention to participants. The program consists of four critical ingredients: self-selected goals, self-evaluation of performance, strategy development, and implementation, and therapeutic guided discovery.
62457611|NCT04033952|NO_INTERVENTION|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
62457612|NCT03061734|EXPERIMENTAL|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
62457613|NCT03061734|EXPERIMENTAL|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
62457614|NCT03061734|ACTIVE_COMPARATOR|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
62457615|NCT03061734|ACTIVE_COMPARATOR|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
62457616|NCT03061734|PLACEBO_COMPARATOR|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
62457617|NCT00537147|EXPERIMENTAL|1|1 vaccination of a 10\^4 plaque-forming units (PFU) dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
62457618|NCT00537147|EXPERIMENTAL|2|1 vaccination of a 10\^5 PFU dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
62457619|NCT00537147|PLACEBO_COMPARATOR|3|1 vaccination of a placebo administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
62647782|NCT04326257|EXPERIMENTAL|Nivolumab+Ipilimumab|"Nivolumab will be dosed at 3mg/kg IV q 2 weeks and Ipilimumab 1mg/kg IV q 6 weeks.~Patients will receive four doses of Ipilimumab and the last dosage of Nivolumab 3mg/kg IV q 2 weeks will be given at the time of the 4th dose of Ipilimumab, followed 2 weeks later by Nivolumab 480 mg IV q 4 weeks. A cycle of therapy will be defined as 4 weeks of treatment. The patient will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
62457620|NCT06441578||Recombinant ADAMTS13|Participants will receive recombinant ADAMTS13 intravenous injection.
62457621|NCT02166138|EXPERIMENTAL|Laser treated Group|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits. Thus, patients in this group will be getting the Non-Abilative laser treatment.
62079768|NCT05055648|ACTIVE_COMPARATOR|Photon Arm|Standard arm with neoadjuvant chemoradiotherapy (nCXT) with photons
62079769|NCT05055648|EXPERIMENTAL|Proton Arm|Experimental arm with neoadjuvant chemoradiotherapy (nCPT) with protons
62079770|NCT06737718||Patients|Children with Angelman syndrome followed at Necker-Enfants Malades hospital, Assistance Publique-Hôpitaux de Paris in the Centre Expert Angelman.
62647783|NCT03821038|EXPERIMENTAL|CYT107|Intravenous (IV) administration of CYT107 at 10 μg/kg twice a week for 3 weeks
62647784|NCT03821038|PLACEBO_COMPARATOR|Placebo|Intravenous (IV) administration of the same volume of NaCl 0.9% twice a week for 3 weeks
62079771|NCT06737718||Controls|Healthy volunteer children from the patients' entourage, without known neurological, genetic or psychiatric pathology.
62647785|NCT02060357|ACTIVE_COMPARATOR|Resolute Integrity Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
62079772|NCT06739642|EXPERIMENTAL|Intervention|caregivers in the intervention group (n=45) received an individualized educational program intervention
62079773|NCT06739642|NO_INTERVENTION|Control|Caregivers in the control group (n=44) continued to receive routine care.
62079774|NCT00658671|EXPERIMENTAL|1|Dose-escalation
62079775|NCT00658671|EXPERIMENTAL|2|Advanced cancer, excluding patients with colorectal or ovarian cancers
62079776|NCT00658671|EXPERIMENTAL|3|Recurrent or resistant epithelial ovarian cancer
62079777|NCT00658671|EXPERIMENTAL|4|Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
62079778|NCT06027775||Chemotherapy plus Targeted therapy (CT)|The treatment decisions and evaluation of treatment outcomes, such as the assessment of metastases resectability and tumor response, were carried out by the multi-disciplinary team (MDT) comprising experts from each medical centers. In this cohort, initially unresectable colorectal cancer liver metastasis (CRLM) patients who were successfully converted and achieved no evidence of disease status were treated with chemotherapy plus targeted therapy, as adjuvant therapy.
62079779|NCT06027775||Chemotherapy Alone (CA)|In this cohort, initially unresectable colorectal cancer liver metastasis (CRLM) patients who were successfully converted and achieved no evidence of disease status were treated with chemotherapy, as adjuvant therapy.
62079780|NCT04765592|EXPERIMENTAL|WeFlow-Arch Modeler Embedded Branch Stent Graft System|Participants will be treated with WeFlow-Arch Modeler Embedded Branch Stent Graft System
62079781|NCT02918890|EXPERIMENTAL|Constraint Induced Movement Therapy|Procedure: Constraint-Induced Movement Therapy 90 hours Other Name: CIT, CI Therapy, restraint therapy, PT, OT, rehab
62079782|NCT02918890|EXPERIMENTAL|Hand-Arm Bimanual Intensive Therapy|Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) 90 hours Other Name: HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
62079783|NCT00982150|EXPERIMENTAL|Talampanel|Talampanel 50mg tid
62079784|NCT02978313|EXPERIMENTAL|Cet maintenance|Cetuximab maintenance treatment following induction treatment
62079785|NCT02978313|ACTIVE_COMPARATOR|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
62079786|NCT00806624|EXPERIMENTAL|2|DU-176b tablets: high-dose
62079787|NCT00806624|ACTIVE_COMPARATOR|3|Warfarin tablets
62079788|NCT00806624|EXPERIMENTAL|1|DU-176b tablets: low-dose
62647786|NCT02060357|ACTIVE_COMPARATOR|Promus Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
62647787|NCT00609817|EXPERIMENTAL|GCS-100|
62079789|NCT06738186|EXPERIMENTAL|Video-based exericse program|"Video-based exercise program Bliib fit - mach mit!"
62647788|NCT03279042|EXPERIMENTAL|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
62079790|NCT06738186|ACTIVE_COMPARATOR|Caregiver-led activation program|An activation (exercise) program that is instructed and carried out by care professionals as optimized standard care.
62079791|NCT03223272|EXPERIMENTAL|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
62079792|NCT04439487||Obese patients requiring general anesthesia|Group consists of consecutive, adult, obese patients undergoing elective surgical procedures requiring general anaesthesia, direct laryngoscopy and intubation. All patients undergo general anesthesia according to a standardised protocol. They are preoxygenated with 100% oxygen breathed through a face mask for 3-5 minutes. Induction of general anaesthesia is achieved with propofol 1,5-2 mg·kg-1 (of Ideal Body Weight) and 0,1mg fentanyl or sufentanil 10µg. Muscle relaxation is accomplished with rocuronium 0.6 mg ·kg-1 (of Ideal Body Weight). Depth of muscular blockade is monitored using Train of Four (TOF) method. The first laryngoscopy attempt is performed at TOF 0. The patient is placed in an optimal, sniffing or ramped position as appropriate and a #3 or #4 Macintosh blade is used. Successful intubation is confirmed with bilateral auscultation and capnography.
62079793|NCT06736795|EXPERIMENTAL|Single-visit, Physical Therapist Initiated and Self-Pace Rehabilitation|"Participants will complete 7 online modules, which will take 30 minutes each. The modules can be completed at their own pace over 8 weeks and include:~1. Exercise participation: Participants will receive instruction on how to progress a home exercise program. Participants will also need to complete a home exercise log.~2. Education: Participants will be given homework to do at home in between online module sessions. Online quizzes will help review the educational material."
62647789|NCT03279042|ACTIVE_COMPARATOR|Traditional corticotomy|Traditional corticotomy will be performed in this group.
62647790|NCT03779646|EXPERIMENTAL|bisoprolol fumarate|In this arm, the participants will receive different dose of bisoprolol fumarate.
62647791|NCT03779646|NO_INTERVENTION|Control|In the control (no beta blocker) group, the patients not taking beta blocker will receive outpatient clinic or video visit every 8 weeks and provide their cardiac symptoms, heart rate, blood pressure and ECG. After 12 months , the patients will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG,BNP and echocardiography records.
62647792|NCT05885217||group 1|mild form of acne vulgaris
62647793|NCT05885217||group2|moderate form of acne vulgaris
62647794|NCT05885217||group 3|severe form of acne vulgaris
62647795|NCT05885217||group 4|control group
62647796|NCT04617821|EXPERIMENTAL|albumin bound paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine were given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles.
62079794|NCT06736795|ACTIVE_COMPARATOR|Multi-visit, Physical Therapist Guided Rehabilitation|"Participants will attend 7 telehealth sessions over 8 weeks, which will last 30 minutes each and include:~1. Exercise participation: Instruction from a physical therapist will be provided on how to complete a home exercise program between treatment sessions. Participants will also need to complete a home exercise log.~2. Education: Participants will be given homework and online quizzes to do at home in between treatment sessions. The physical therapist will review the educational material at each visit."
62079795|NCT06741085|EXPERIMENTAL|osimertinib and stereotactic radiosurgery (SRS)|
62647797|NCT04617821|ACTIVE_COMPARATOR|mFOFLIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
62079796|NCT06741085|ACTIVE_COMPARATOR|osimertinib alone (standard systemic therapy)|
62079797|NCT01662622|EXPERIMENTAL|Sevoflurane|Anaesthesia was induced by 8% sevoflurane. Cisatracurium 0.15mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow 2L min-1. Gas concentrations were analysed using a gas analyser.The end-tidal concentration of carbon dioxide was maintained at 4.7kPa; an esophageal temperature probe was inserted and a warming unit was used if necessary to maintain normothermia (35.5°-38.5°). The surgical incision was performed at least 30min after tracheal intubation. When arterial blood pressure (MAP) decrease exceeding 20% of baseline values. Phenylephrine 0.1mg was administered intravenously if necessary to maintained MAP and recorded.
62079798|NCT06737237|ACTIVE_COMPARATOR|ultrasound guided cervical plexus block|u/s guided cervical plexus block will be performed with active local anesthetic, while the surgeon-administered local infiltration analgesia will be performed with placebo (0.9% sodium chloride)
62457622|NCT02166138|PLACEBO_COMPARATOR|Not Laser treated Group|Patients in this group will be given the laser treatment with the 1540 non-abilative laser device, but the device will not be set to provide treatment. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
62457623|NCT02171052|EXPERIMENTAL|Dabigatran etexilate plus digoxin|
62647798|NCT06270108|EXPERIMENTAL|Treatment-resistant schizophrenia patients receiving riluzole|
62079799|NCT06737237|ACTIVE_COMPARATOR|local infiltration analgesia|surgeon-administered local infiltration analgesia will be performed with active local anesthetic, while the u/s guided cervical plexus block will be performed with placebo (0.9% sodium chloride)
62457624|NCT02171052|ACTIVE_COMPARATOR|Dabigatran etexilate|
62457625|NCT02171052|ACTIVE_COMPARATOR|Digoxin|
62457626|NCT03965858|EXPERIMENTAL|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62457627|NCT03965858|EXPERIMENTAL|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62457628|NCT03965858|EXPERIMENTAL|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62457629|NCT03965858|PLACEBO_COMPARATOR|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62647799|NCT06270108|NO_INTERVENTION|Treatment-responsive schizophrenia patients|
62647800|NCT06270108|NO_INTERVENTION|Healthy controls|
62647801|NCT01621009|ACTIVE_COMPARATOR|Active bupropion + counseling|Active bupropion SR plus eight 10-minute individual counseling sessions.
62647802|NCT01621009|ACTIVE_COMPARATOR|Active bupropion , No counseling|Active bupropion, No counseling, only medication checks
62647803|NCT01621009|PLACEBO_COMPARATOR|Placebo medication + counseling|Placebo bupropion plus eight 10-minute individual counseling sessions
62647804|NCT01621009|PLACEBO_COMPARATOR|Placebo medication, No counseling|Placebo bupropion, No counseling, just medication checks
62647805|NCT00003686|ACTIVE_COMPARATOR|Pilocarpine|
62647806|NCT00003686|PLACEBO_COMPARATOR|Placebo|
62647807|NCT05218694|EXPERIMENTAL|CT-guided algorithm (CTGA)|In the CTGA group only the artery suspected of having obstructive coronary disease is examined. Anatomy of the vessel, optimal viewing projections and choice of catheter is determined. A guiding catheter is used as first choice based on the artery involved and the aortic anatomy. Time is recorded according to the ST group, with timepoint 1 after conclusion of the angiogram, timepoint 2 after FFR.
62647808|NCT05218694|NO_INTERVENTION|Standard treatment (ST)|"ST includes the use of two diagnostic cathers and examination of both coronary arteries by at least 6 different standard projections best optimizing the view of the coronary lesions.~Additional projections may be included if deemed necessary for optimal angiographic evaluation"
62457630|NCT05063409|ACTIVE_COMPARATOR|1:1 Ratio of FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:1 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
62647809|NCT00313872|EXPERIMENTAL|FOLFIRI|
62647810|NCT00313872|EXPERIMENTAL|DP|"D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr~D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan"
62647811|NCT03312816|PLACEBO_COMPARATOR|Placebo|0 mg/d added POP
62647812|NCT03312816|ACTIVE_COMPARATOR|low dosage|low added POP
62647813|NCT03312816|ACTIVE_COMPARATOR|Medium dose|medium added POP
62647814|NCT03312816|ACTIVE_COMPARATOR|Hige dose|high added POP
62457631|NCT05063409|ACTIVE_COMPARATOR|1:4 Ratio FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
62457632|NCT01255878|EXPERIMENTAL|stabilization splint|
62647815|NCT04175717|EXPERIMENTAL|physiotherapy-led follow-up programme|
62647816|NCT00505297||A|Subjects with potentiall rapidl progressing OA
62647817|NCT00505297||B|Age-matched healthy subjects with no knee pain
62647818|NCT04625036||Group 1: COVID-19 patients|Patients, from acute care hospitals, diagnosed with COVID-19 pneumonia, with documented positive throat swab, within one month from discharge.
62647819|NCT00550199|EXPERIMENTAL|LBH589 and Gemcitabine|Phase I dose escalation study
62647820|NCT03713463||Oral Nutritional Supplement (ONS)|2 servings per day ONS
62647821|NCT05115799|EXPERIMENTAL|Patients with Axilliary Web Syndrome and manual therapy and scar massage.|"These users will come from the first moment of the diagnosis of the thrombus in our unit, to receive manual therapy by the physical therapist. They will receive 15 sessions of manual therapy by the physiotherapist, 5 days a week, each session being approximately 40 minutes long. The session will begin with pendulum exercises of the shoulder to warm up the joint and give proprioceptive stimulation to the joint capsule. The physiotherapist will perform passive stretches looking to put tension on the cord lymphatic, never exceeding grade 6 VAS pain. Mainly the shoulder will be worked affected, and if the cord reaches the crease of the elbow or thumb, the extension-supination of the elbow, and ulnar deviation of the wrist.~Scar massage will be done in the area where the lymphatic cord originates at the proximal level while maintaining the tolerable tension of the lymphatic cord (during the massage also pain grade 6 VAS will be exceeded)."
62647822|NCT05115799|OTHER|Patients with Axilliary Web Syndrome and health education and kinesiotherapy.|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
62457633|NCT01255878|EXPERIMENTAL|Gabapentine|
62457634|NCT05717036||TS Meter-DSP Measurement and Refractix DSP Measurement|The study will involve blood serum samples from (36) participants. Participants will be those presenting at a plasma collection center for routine plasma donation. Ordinary pre-screening for plasma donation includes a fingerstick and the collection of one small capillary tube (\<0.085ml) of blood. Participants will be asked to provide a second capillary tube (\<0.085ml) of blood from this fingerstick.
62647823|NCT05376501|EXPERIMENTAL|Astaxanthin|"Active Ingredient:~Astaxanthin~Inactive ingredients:~Modified food starch, sucrose, water, sodium ascorbate, DL- alpha tocopherols"
62647824|NCT05376501|PLACEBO_COMPARATOR|Placebo|Modified food starch, sucrose, hylocereus polyrhizus (pitaya) concentration
62647825|NCT02171403||Lactose intolerance|Patients with a positive lactose-breath test and complaints during the test
62647826|NCT02171403||Lactose malabsorption|Patients with a positive lactose-breath test and no complaints during the test
62647827|NCT02171403||Healthy controls|Subjects with a negative lactose-breath test
62647828|NCT01068236|EXPERIMENTAL|Healthy lifestyle intervention|lifestyle/weight-loss intervention for overweight (95th - 99th percentile) female adolescents (13-15 years of age at study entry) to a usual-care control condition. The intervention will be 20-sessions and combines group visits, individual telephone coaching calls, and tailored pediatric primary care providers (PCP) visits.
62647829|NCT01068236|NO_INTERVENTION|Usual care|In the usual care control condition adolescents and their family will receive individualized feedback from the assessments as well as handouts outlining healthy means of maintaining / reducing weight for adolescents through improving nutrition and physical activity. In addition, these participants will be encouraged to seek any appropriate health care/education services available through Kaiser Permanente or in the community.
62647830|NCT03501251|EXPERIMENTAL|Moxidectin 8 mg|A single tablet of 8 mg of moxidectin
62647831|NCT03501251|EXPERIMENTAL|Moxidectin 8 mg + Albendazole|A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
62647832|NCT03501251|EXPERIMENTAL|Moxidectin 16 mg|Two tablets of 8 mg of moxidectin ( = 16 mg)
62647833|NCT03501251|EXPERIMENTAL|Moxidectin 16 mg + Albendazole|Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
62647834|NCT03501251|EXPERIMENTAL|Moxidectin 24 mg|Three tablets of 8 mg of moxidectin ( = 24 mg)
62457635|NCT01677078|EXPERIMENTAL|Neuronavigation system|"10 sessions of rTMS coupled with a neuronavigation system~Description of 1 session of the rTMS protocol :~* Frequency: 20Hz~* Intensity: 110% of motor threshold~* 80 train of 2 seconds duration~* 10 seconds between two trains~* 3200 pulses~Devices :~* rTMS: System Mag Pro (Magventure, Denmark)~* Neuronavigation system: Syneika One (Syneika, France)"
62457636|NCT01677078|SHAM_COMPARATOR|Standard localisation method|"10 sessions of rTMS with manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')~Description of 1 session of the rTMS protocol :~* Frequency: 20Hz~* Intensity: 110% of motor threshold~* 80 train of 2 seconds duration~* 10 seconds between two trains~* 3200 pulses~Devices :~- rTMS: System Mag Pro (Magventure, Denmark)"
62457637|NCT04642950|EXPERIMENTAL|NPC-26|Sargramostim (125 μg) will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
62647835|NCT03501251|EXPERIMENTAL|Moxidectin 24 mg + Albendazole|Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
62079800|NCT06736639||Anchor + titanium cable cerclage (ISB-LP)|This group includes patients with inferior pole patellar fractures (IPPF) treated using anchor suture fixation combined with titanium cable cerclage. The intervention involves securing fracture fragments with anchors to provide stable fixation, reinforced by a titanium cable cerclage for additional stability. This method is intended to reduce hardware-related complications while maintaining biomechanical stability and supporting functional recovery. The outcomes for this group include operative time, postoperative knee range of motion, incidence of complications, need for secondary surgery, and functional scores such as the Bostman score.
62457638|NCT04642950|PLACEBO_COMPARATOR|NP-26 Placebo|Physiological saline will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
62457639|NCT00241917|EXPERIMENTAL|Video|
62457640|NCT00241917|NO_INTERVENTION|Control|
62457641|NCT00352690|OTHER|Cohort 1 (first 12 eligible patients)|"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
62647836|NCT03501251|PLACEBO_COMPARATOR|Placebo|A single tablet of placebo
62647837|NCT04328987||Clopidogrel user|"\* Uninterrupted (continuous) use of clopidogrel: cessation of clopidogrel less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of clopidogrel is sum of before and after the CSP~1. patient who stopped clopidogrel only on the day of colonoscopy and resumed the day after colonoscopy -\> cessation of clopidogrel was 1 day.~2. patient who stopped clopidogrel from 3 days before colonoscopy and resumed the day after colonoscopy -\> cessation of clopidogrel was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -\> interruption of clopidogrel -\> excluded from study.~3. patient who stopped clopidogrel from 2 days before colonoscopy and resumed 2 days after colonoscopy -\> cessation of clopidogrel was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -\> interruption of clopidogrel -\> excluded from study."
62079801|NCT06736639||TBW-LP fixed (TBW-LP group)|This group includes patients with inferior pole patellar fractures (IPPF) treated using Kirschner-wire tension band combined with patellar cerclage (TBW-LP group). This intervention involves the placement of Kirschner wires to create a tension band construct across the fracture site, stabilizing the fragments, with additional support provided by a cerclage wire. This method is widely used in clinical practice due to its simplicity and cost-effectiveness. The study evaluates key outcomes for this group, including operative time, knee range of motion, incidence of postoperative complications such as hardware irritation or infection, and functional recovery based on Bostman scores. This group serves as a comparison to newer techniques like anchor suture with titanium cable cerclage.
62079802|NCT03888508|EXPERIMENTAL|SIT plus standard therapy|Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses such as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home Sensory integration kit will be prepared which consists of varying textures from soft to hard items (wool, jute, sand paper, velvet), picture cards, sensory brush, elastic band(Thera tube) and also usage of other home based items such as swings, sofa/bed, textured board, black board, wet chalks and paint. Each session would take approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 d Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving as a standard therapy
62079803|NCT03888508|NO_INTERVENTION|Standard therapy alone|Standard therapy -Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving
62079804|NCT04451135|EXPERIMENTAL|Patients with Treatment-Resistant Depression|
62079805|NCT06737432|NO_INTERVENTION|Control|We will monitor without clinician use of the software.
62079806|NCT06737432|ACTIVE_COMPARATOR|Use of RKP|Use of RKP alerts to the standard of care.
62079807|NCT01388530|EXPERIMENTAL|trigeminal nerve stimulation|Open label treatment with trigeminal nerve stimulation in an 8-week trial.
62079808|NCT03604913|ACTIVE_COMPARATOR|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
62079809|NCT03604913|ACTIVE_COMPARATOR|B(Bentall operation)|Undergo Bentall operation
62079810|NCT04944225|NO_INTERVENTION|Control group: Pain management during the standard of care phase|In the standard of care phase, anesthetic and surgical care will be as per standard practice (according to local hospital protocol) for both the control and the intervention group. Generally, this means patients will be maintained on a more liberal opioid regime than in the opioid reduction strategy phase and will receive opioid and other medications for the acute postoperative pain. The choice of opioids will be at the discretion of the managing team. There will be a minimum 2-month baseline period before entry of the first randomized cluster to the intervention arm.
62079811|NCT04944225|EXPERIMENTAL|Intervention group: Pain management in the opioid reduction strategy phase|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
62647838|NCT04328987||Aspirin user|"\* Uninterrupted (continuous) use of aspirin: cessation of aspirin less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of aspirin is sum of before and after the CSP~1. patient who stopped aspirin only on the day of colonoscopy and resumed the day after colonoscopy -\> cessation of aspirin was 1 day.~2. patient who stopped aspirin from 3 days before colonoscopy and resumed the day after colonoscopy -\> cessation of aspirin was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -\> interruption of aspirin -\> excluded from study.~3. patient who stopped aspirin from 2 days before colonoscopy and resumed 2 days after colonoscopy -\> cessation of aspirin was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -\> interruption of aspirin -\> excluded from study."
62647839|NCT01614652|EXPERIMENTAL|Parachute Implant and All Appropriate Medical Therapy (AAMT)|
62079812|NCT05256381|EXPERIMENTAL|Nanrilkefusp Alfa and Pembrolizumab|Participants will be treated with 12 μg/kg of nanrilkefusp alfa on Day 1, Day 2, Day 8, and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.
62079813|NCT06442072|ACTIVE_COMPARATOR|CBT Group Standard Guidance|"* 9 group sessions, at week 0-6, 8, 12, 18~* groups of 4-6 peers and a trained facilitator~* participants work through the tailored Third Wave CBT workbook by Rethink Wellbeing, one chapter each week~* in between sessions, people practice the new skills learned in the workbook and are supported in an online community, guided by a trained psychologist and psychotherapist"
62457642|NCT00352690|EXPERIMENTAL|Cohort 2 (remaining patients)|"Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
62457643|NCT03131037|EXPERIMENTAL|Study Arm|CAN-2409 + valacyclovir
62079814|NCT06442072|ACTIVE_COMPARATOR|CBT Buddy Standard Guidance|"* 9 1:1 sessions after buddies get training in supporting each other - at week 0-6, 8, 12, 18~* groups of up to 30 peers and a trained facilitator~* participants work through the tailored Third Wave CBT workbook by Rethink Wellbeing, one chapter each week~* in between buddy-sessions, people practice the new skills learned in the workbook and are supported in an online community, guided by a trained psychologist and psychotherapist"
62079815|NCT06442072|ACTIVE_COMPARATOR|CBT Group Minimum Guidance|"* 3 instead of 9 sessions, in week 1, 8 and 16.~* groups of up to 30 peers and a trained facilitator~* participants work through the tailored Third Wave CBT workbook by Rethink Wellbeing, one chapter each week~* in between, people practice the new skills learned in the workbook and are supported in an online community, guided by a trained psychologist and psychotherapist"
62079816|NCT06442072|ACTIVE_COMPARATOR|IFS Group Standard Guidance|"* 9 group sessions, at week 0-6, 8, 12, 18~* groups of 4-6 peers and a trained facilitator~* Internal Family Systems methods taught instead of CBT methods as in every other group~* participants work through the book Self-Therapy: A Step-By-Step Guide to Creating Wholeness and Healing Your Inner Child Using IFS, A New, Cutting-Edge Psychotherapy by Jay Earley, a few chapters each week~* in between, people practice the new skills learned in the workbook and are supported in an online community, guided by a trained psychologist and psychotherapist"
62079817|NCT06737757|EXPERIMENTAL|Experimental group(PoliaValve)|Using artificial polymer heart valves(PoliaValve, Hearthill Medical) for aortic valve replacement
62079818|NCT06737757|ACTIVE_COMPARATOR|Control Group|Using bovine pericardium aortic valve for aortic valve replacement
62079819|NCT06122181|EXPERIMENTAL|HS-10384|Multiple ascending doses of HS-10384 orally
62079820|NCT06122181|PLACEBO_COMPARATOR|Placebo|Multiple ascending doses of HS-10384 placebo orally
62079821|NCT06741124||Channel Esophagogastrostomy (CE)|Patients who underwent Channel Esophagogastrostomy reconstruction
62079822|NCT06741124||Double Tract Reconstruction (DTR)|Patients who underwent DTR reconstruction during LAPG
62079823|NCT04855487|EXPERIMENTAL|Intervention group|Adolescents/young adults with cancer will participate in a 5-week online expressive storytelling intervention. They will independently create digital stories about themselves while their target audiences are their primary nurses. They will then participate in weekly online meetings with nursing research staff, during which they introduce their stories and discuss their reflections. In the final session, they will create a one-page or five-slide story to share with their primary nurses, if they want.
62079824|NCT06168851|EXPERIMENTAL|Experimental: Intervention (Anti-CD38 antibody)|20 enrolled subjects : once a week x 8 doses
62079825|NCT06273579|NO_INTERVENTION|Tutored by AI|31 participants allocated. During their second, third, fourth, and fifth repetition of the practice subpial brain tumor resection scenario, participants will receive verbal ICEMS feedback when the system detects an error on their performance.
62079826|NCT06273579|EXPERIMENTAL|Tutored by human instructor using AI's words|29 participants allocated. During their second, third, fourth, and fifth repetition of the practice subpial brain tumor resection scenario, participants will receive verbal feedback from an expert instructor. The expert instructor will deliver this feedback using the same words as the ICEMS.
62457644|NCT03563105|EXPERIMENTAL|Desaturation|Vascular Occlusion Test
62457645|NCT02228382|EXPERIMENTAL|Bosutinib|
62457646|NCT06309706||cross-sectional|To analyze the maxillary sinus anatomy over edentulous ridges in the bilateral posterior maxillary area in Chinese patients using cone-beam computed tomography (CBCT).
62457647|NCT04835493|EXPERIMENTAL|Intervention|Intervention individuals will receive the 12-month diabetes program
62457648|NCT04835493|OTHER|Usual Care (UC)|We will define UC as usual clinical care, which consists of diabetes management provider encounters (mean quarterly) plus monthly individual appointments with a pharm-Ds or nutritionists as clinically indicated. In addition, clinics offer multiple other individual and group opportunities.
62457649|NCT04259229|EXPERIMENTAL|Mushroom intervention|Subjects will be randomized and assigned to consume the Mediterranean Diet with mushrooms for eight weeks.
62647840|NCT01614652|NO_INTERVENTION|All Appropriate Medical Therapy (AAMT)|
62079827|NCT06273579|EXPERIMENTAL|Tutored by human instructor using wording of choice|28 participants allocated. During their second, third, fourth, and fifth repetition of the practice subpial brain tumor resection scenario, participants will receive verbal feedback from an expert instructor. The expert instructor will use their expertise to deliver personalized feedback to the participant.
62079828|NCT04251702||Healthy Low-Risk Individuals in Labor|Healthy laboring individuals with a Singleton Term fetus in the Vertex position. Patients requiring medical management of diabetes or hypertension will be excluded.
62079829|NCT03957915|EXPERIMENTAL|INA03|INA03 administration
62079830|NCT06740045|EXPERIMENTAL|Tezepelumab|Tezepelumab 210 mg subcutaneous injection every 4 weeks to all 10 participants
62079831|NCT02862275|EXPERIMENTAL|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30- 60 minutes on day 1. Cycles repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and biopsy on study. Patients also undergo blood sample collection on study.
62079832|NCT06293482|EXPERIMENTAL|Cochlear™ Nucleus® System|Participants will be implanted with a commercially approved Cochlear™ Nucleus® implant.
62079833|NCT06364358|ACTIVE_COMPARATOR|Usual Care|The research assistant (RA) will use tablet to give participants baseline General Health Knowledge and Intent survey and leave printed patient education materials about general health maintenance. In the initial consent, pre-intervention survey and education materials, investigators will not provide CKD specific knowledge or inform participants about their CKD.
62079834|NCT06364358|EXPERIMENTAL|Computerized Patient Education|The RA will assist participants in starting the computer program and encourage review of the advanced CKD education module. The computer-adaptive education module will alter the content of education topics based on some preliminary participant information.
62079835|NCT06369961||Group A|Those who used TDF
62079836|NCT05028010|EXPERIMENTAL|Training|There will be one arm, intervention group.
62079837|NCT03360279|ACTIVE_COMPARATOR|Regular balloon|Use the regular balloon to perform standard balloon angioplasty.
62079838|NCT03360279|ACTIVE_COMPARATOR|DCB (paclitaxel-coated balloon)|Use DCB (paclitaxel-coated balloon) to perform additional balloon angioplasty.
62079839|NCT01335308|ACTIVE_COMPARATOR|Standard Care with Education Materials|Measure height and weight only. usual care
62079840|NCT01335308|EXPERIMENTAL|Moderate Dose Motivational Interviewing|MI delivered by PCP, 4 sessions
62079841|NCT01335308|EXPERIMENTAL|Higher Dose Motivational Interviewing|MI delivered by PCP, 4 sessions plus MI delivered by RD, 6 sessions
62647841|NCT02431598|ACTIVE_COMPARATOR|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
62079842|NCT05071066|EXPERIMENTAL|Group-based ADHD+ Treatment|"This randomized controlled trial (RCT) will run in multi-sites including 5 non-governmental organizations (NGOs) in Hong Kong. Core treatment components are developed by an expert group comprised of psychiatrists and clinical psychologists including internet use/addiction intervention, cognitive training, etc.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months."
62079843|NCT05071066|OTHER|wait-list control group|For participants in the waiting list control group, they will receive 1-3 hours psychoeducation during the 3 months wait period. Appropriate intervention will be offered after the treatment group.
62647842|NCT02431598|ACTIVE_COMPARATOR|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
62079844|NCT06740812|EXPERIMENTAL|Investigational Intervention|Fosaprepitant
62079845|NCT06740812|ACTIVE_COMPARATOR|Standard-of-Care Intervention|Metoclopramide
62079846|NCT05176704||CDR = 0.5|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Questionable/very mild dementia (CDR = 0.5)
62079847|NCT05176704||CDR = 1|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Mild dementia/MCI (CDR = 1)
62079848|NCT05176704||CDR = 2|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Moderate dementia (CDR = 2)
62079849|NCT05176704||CDR = 3|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Severe dementia (CDR = 3)
62079850|NCT05176704||Healthy Control|50 Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
62079851|NCT06633016|EXPERIMENTAL|ABX-002 + SSRI/SNRI|Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to ABX-002.
62647843|NCT02431598|ACTIVE_COMPARATOR|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
62079852|NCT06633016|PLACEBO_COMPARATOR|Placebo + SSRI/SNRI|Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to the Placebo.
62647844|NCT02327234|EXPERIMENTAL|Ibuprofen|400mg (2X200mg) ibuprofen single dose once
62647845|NCT02327234|PLACEBO_COMPARATOR|Placebo|identical appearing lactose capsules single dose 2 capsules once
62079853|NCT06349200|EXPERIMENTAL|432 Hz Music|Group A will listen to music tuned to 432 Hz (Summer by Stefano Crespan Shantam on Spotify) using wireless headphones for 10 minutes.
62079854|NCT06349200|EXPERIMENTAL|Binaural Beats|Group B will listen to binaural beats (220 Hz for the right ear and 210 Hz for the left ear) using wireless headphones for 10 minutes. The frequencies will be generated by the mobile application BrainWaves Binaural Beats, MynioTech Apps, Chanpeco, Santa Catarina, Brazil.
62079855|NCT06349200|ACTIVE_COMPARATOR|Control|Group C will be the active control group. The patients will listen to white noise for 10 minutes using wireless headphones.
62457650|NCT04259229|ACTIVE_COMPARATOR|Control|Subjects will be randomized and assigned to consume the Mediterranean Diet without mushrooms for eight weeks.
62647846|NCT02284100|EXPERIMENTAL|animal assisted therapy group|the dog was present during post-operative awakening (2 hours after surgery)
62647847|NCT02284100|NO_INTERVENTION|standard group|children had standard post-operative medical care
62647848|NCT02118623|ACTIVE_COMPARATOR|Level 1|Moderated discussion board only
62647849|NCT02118623|ACTIVE_COMPARATOR|Level 2|Moderated discussion board plus psychoeducation
62079856|NCT03502733|EXPERIMENTAL|Cohort I (Doublet) (copanlisib, nivolumab)|Patients receive copanlisib IV over 1 hour on days 1 and 15 or days 1, 8, and 15 of each cycle and nivolumab IV over 30 minutes on day 1 or days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up, as well as tumor biopsy on study. Patients also undergo an ECHO during screening and as clinically indicated on study.
62079857|NCT03502733|EXPERIMENTAL|Cohort II (Triplet Safety) (copanlisib, nivolumab, ipilimumab)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle, nivolumab IV over 30 minutes on day 1 of each cycle, and ipilimumab IV over 90 minutes on day 1 for cycles 1-4. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo an ECHO during screening and as clinically indicated on study.
62079858|NCT03502733|EXPERIMENTAL|Cohort III (Triplet) (copanlisib, nivolumab, ipilmumab)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle, nivolumab IV over 30 minutes on day 15 of cycle 1 and then day 1 of each subsequent cycles, and ipilimumab IV over 90 minutes on day 1 for cycles 2-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up, as well as tumor biopsy on study. Patients also undergo an ECHO during screening and as clinically indicated on study.
62079859|NCT06741111||Cohort|People who underwent health check-up in Meinian check-up centres between the period January 1st, 2023, to December 31st, 2023
62079860|NCT04266795|ACTIVE_COMPARATOR|Venetoclax 100/200/400 mg + Azacitidine 75 mg/m^2|Venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m\^2 intravenous (IV) or subcutaneous (SC) dosing on Days 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle up to primary completion date: 06 September 2022.
62079861|NCT04266795|EXPERIMENTAL|Pevonedistat 20 mg/m^2 + Venetoclax 100/200/400 mg + Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m\^2 as a 60-minute IV infusion on Days 1, 3, and 5 in each 28-day cycle plus venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m\^2 IV or SC dosing on Day 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle up to primary completion date: 06 September 2022.
62079862|NCT03813095|EXPERIMENTAL|APH-1501 400mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 400mg BID( twice daily) for 28 days.
62079863|NCT03813095|EXPERIMENTAL|APH-1501 600mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 600mg BID ( twice daily) for 28 days.
62079864|NCT03813095|EXPERIMENTAL|APH-1501 800mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 800mg BID ( twice daily) for 28 days.
62079865|NCT03813095|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Nano-encapsulated for oral delivery. The study is planned for patients to receive a placebo dose BID ( twice daily) for 28 days.
62079866|NCT03941574|EXPERIMENTAL|HLX10|
62079867|NCT02954575|EXPERIMENTAL|All patients|All patients will receive Wilate for prophylactic treatment
62079868|NCT00433576|EXPERIMENTAL|Treatment (resveratrol, colorectomy)|"STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm colorectal adenocarcinoma histology and require surgical resection continue on study stage 2.~STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day 9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes."
62647850|NCT02118623|ACTIVE_COMPARATOR|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools.
62647851|NCT05218278||Patients with favorable neurlogical outcome|CPC 1/2
62647852|NCT05218278||Patients with non-favorable neurological outcome|CPC3-5
62647853|NCT05898516|EXPERIMENTAL|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, which involve regular phone calls to check in and assess functioning, and will receive access to the JoyPop app for 4 weeks.
62079869|NCT05219799|OTHER|Hypoxia Exposure|Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
62079870|NCT06739915|NO_INTERVENTION|No Intervention: Standard of care study arm|In the standard TUTT implementation arm, ART clients who initiated or re-initiated ART will be referred to the PHRU study nurse for eligibility screening, enrolment, and a clinical evaluation after the consultation has been completed. All laboratory investigations and ART and TPT prescribing will occur as per routine care in the facility prior to referral to the PHRU study nurse who will obtain written informed consent for study participation.
62079871|NCT06739915|EXPERIMENTAL|TUTT-PT Intervention|In the TUTT-PT arm, newly initiating or re-initiating ART clients will be referred by clinic staff after ART initiation to the PHRU study nurse for eligibility screening and enrolment. All TUTT-PT arm participants who provide written informed consent will have sputum collected for TB testing (if sputum was not already collected by the clinic staff) and will receive a clinical evaluation for the presence of TB symptoms (cough, fever, weight loss, night sweats) and serious contraindications for TPT initiation (known liver disease, high alcohol intake (men: \>5 drinks/day or \>15 drinks/week; women: \>4 drinks/day or \>8 drinks/week), or strong clinical suspicion of TB disease as evidenced by severity of symptoms, including haemoptysis, or Karnofsky score ≤50. PLHIV for whom the study nurse does not have a strong clinical suspicion of TB nor evidence of serious TPT contraindications will be referred to clinic staff for TPT initiation, irrespective of the presence or absence of TB symptoms.
62079872|NCT05113264|EXPERIMENTAL|Penny, a SMS Text-based chatbot intervention|This is a single arm study. All recruited patients will be entered on the Penny SMS Text-based chatbot intervention.
62079873|NCT06716528||Former BioCog patients|Former BioCog patients from the Berlin study center who have undergone baseline cognitive testing and from whom plasma samples are available
62079874|NCT06716528||Former BioCog subjects in the non-surgical comparison cohort|Former BioCog subjects in the non-surgical comparison cohort from the Berlin study center who have undergone baseline cognitive testing
62079875|NCT05562960|OTHER|ALS patients receiving plasmapheresis|Plasmapheresis in ALS patients with different titers of autoantibody against NRIP
62079876|NCT06736977|EXPERIMENTAL|The Onsite Nurse-Led Education Programme on IPC|The researcher will conduct the Nurse-Led Education Programme on IPC for one experimental group through face-to-face/onsite delivery.
62079877|NCT06736977|EXPERIMENTAL|The Online Nurse-Led Education Programme on IPC|The researcher will conduct the Nurse-Led Education Programme on IPC for another experimental group through online platform delivery.
62079878|NCT06736977|NO_INTERVENTION|The Control Group|Participants in the control group will continue their usual practice without receiving any intervention and materials until the post-intervention assessment at six months. After that, the researcher will provide the online or onsite programmes and distribute all materials.
62079879|NCT06738069||Pregnant female with CKD|Pregnant female Newly discovered as chronic kidney disease by our study.inclusion criteria including age 18 or above who accept to precipitate this study.. exclusion criteria including female actually known as CKD and female refusing to precipitate in our study... this female confirmed as CKD by positive Alb/Cr ratio in 2 occasions with 3 months duration in between
62079880|NCT06738069||Healthy pregnant female|Pregnant female without ckd and Alb /Cr ratio was negative
62079881|NCT06739395|OTHER|Monotherapy|In the OncoKB(Precision Oncology Knowledge Base) database, the gene alteration has a variant of clinical evidence in this tumor or other tumor types and is considered to be an interventional variant. Cohort-1may include different observation subgroups（dMMR/MSI-H,TMB-H,NTRK fusion,RET-fusion,BRAF(p.V600E),KRAS(p.G12C),HER2(IHC,3+)）. For example, substudy-1: monotherapy/combination therapy for patients with A1-relative. Substudy-x: monotherapy/combination therapy for patients with Ax-relative.
62079882|NCT06739395|EXPERIMENTAL|Combination therapy-cohort1|The characteristics of enrolled patients are the presence of two or more interventional or potential actionable targets(only TP53 alteration,MAP2K1 alteration,PMA pathway alteration,11q13 amplification,MET alteration).
62647854|NCT05898516|NO_INTERVENTION|Usual Practice|Participants will be monitored through existing wait-list practices which involve regular phone calls to check in and assess functioning. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
62079883|NCT06739395|EXPERIMENTAL|Combination therapy-cohort2|The characteristics of enrolled patients are primary or secondary drug resistance during treatment.
62079884|NCT06739395|EXPERIMENTAL|Olaparib+Anlotinib/Temozolomide|The gene TP53 alteration that MTB combines with clinical practice and literature reports that can match targeted therapy is considered to be potential actionable targets.
62079885|NCT06739395|EXPERIMENTAL|Trametinib±Vebreltinib|The gene MAP2K1 alteration that MTB combines with clinical practice and literature reports that can match targeted therapy is considered to be potential actionable targets.
62079886|NCT06739395|EXPERIMENTAL|Alpelisib|The PMA(PI3K/mTOR/AKT ) pathway active alteration that MTB combines with clinical practice and literature reports that can match targeted therapy is considered to be potential actionable targets.This subgroup is not included in breast cancer patients.
62079887|NCT06739395|EXPERIMENTAL|Palbociclib+Pazopanib|The gene alteration(Chromosome 11q13 amplification (CCND1, FGF3, FGF4, and FGF19)) that MTB combines with clinical practice and literature reports that can match targeted therapy is considered to be potential actionable targets.
62079888|NCT06739395|EXPERIMENTAL|Vebreltinib|MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 (METex14)-skipping/MET-amplification.
62457651|NCT06114732|EXPERIMENTAL|Walking exercise behaviour change intervention + TENS|Participants in the Intervention groups will be asked to attend four telehealth appointments with a physiotherapist. They will also be provided with a TENS machine and training at the baseline appointment on how to use it. They will be instructed to use it daily as their symptoms require for 12 weeks. The device will be set at High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
62079889|NCT06739395|EXPERIMENTAL|Combination therapy group based on PD-1/L1 immune checkpoint inhibitors|MTB combined with clinical practice and literature reports can not match the gene alteration of targeted therapy, which is considered as an irreversible gene alteration.This subgroup may use functional models (including but not limited to PDX(Patient-Derived Tumor Xenograft Model), organoids, etc.) for intervention therapy.
62079890|NCT06739226|EXPERIMENTAL|CAR T/CTL/DCvac cells to treat melanoma|Antigen-specific CAR T, CTL and DCvac to treat melanoma.
62079891|NCT06097377||ToF|
62079892|NCT06097377||Controls|
62079893|NCT02576834|EXPERIMENTAL|CTSP + SAU|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with optional 9 booster sessions + SAU
62079894|NCT02576834|OTHER|Services as Usual (SAU)|client receives services they would normally receive within the community
62079895|NCT05697939||Adolescent Idiopathic Scoliosis|Reproducibility group
62647855|NCT04625283|EXPERIMENTAL|Ketamine|Participants in this arm will receive intraoperative ketamine bolus (0.5mg/kg) followed by continuous infusion 5 mcg/kg/min and also will receive postoperative ketamine infusion (2.5 mcg/kg/min, up to 100kg max) for 48 hours.
62079896|NCT05678673|EXPERIMENTAL|XL092 + Nivolumab|Subjects with advanced or metastatic nccRCC will receive XL092 + nivolumab
62079897|NCT05678673|ACTIVE_COMPARATOR|Sunitinib Malate|Subjects with advanced or metastatic nccRCC will receive an active comparator of sunitinib
62079898|NCT01824472|ACTIVE_COMPARATOR|CPAP+CC|Continuous Positive Airway Pressure (CPAP) therapy for sleep apnea and contact control (CC) (placebo/sham for cognitive-behavioral therapy for insomnia)
62079899|NCT01824472|SHAM_COMPARATOR|sham CPAP+CC|sham CPAP (ineffective CPAP--placebo/sham for sleep apnea) and contact control (placebo/sham for cognitive-behavioral therapy for insomnia)
62457652|NCT06114732|NO_INTERVENTION|Usual Care control|Usual Care at NHS Lanarkshire Vascular Services and/or Intermittent Claudication service.
62457653|NCT05944107|ACTIVE_COMPARATOR|Activated Clotting Time (ACT)|"In this group, only ACT measurements and fixed doses of heparin and protamine are administered.~ACT is measured using the ACT Plus device (Medtronic, MN, USA). Heparin formulation administered is HEPARIN/LEO INJ.SOL 25000IU/5ML. Protamine formulation administered is PROTAMINE SULPHATE/LEO PHARMA 10mg/ml"
62079900|NCT01824472|ACTIVE_COMPARATOR|CPAP+CBT|CPAP therapy for sleep apnea and cognitive-behavioral therapy (CBT) for insomnia
62079901|NCT05921630|PLACEBO_COMPARATOR|Control group|Control group The control group was given standard routine information by the technician before spirometry.
62079902|NCT05921630|EXPERIMENTAL|Leaflet group|Information via leaflets: The subjects were given a leaflet prepared by the researchers based on literature review . The leaflet contained written and visual information about the steps of spirometry. The patients then underwent routine spirometry.
62079903|NCT05921630|EXPERIMENTAL|Video|Video-assisted education: Using a mobile phone, patients were shown a two-minute video prepared by the researchers in accordance with the guidelines that demonstrated how spirometry is performed.
62079904|NCT05921630|EXPERIMENTAL|Leaflet + Video|Education via leaflets + video: Subjects in this group were first given a leaflet and shown the video. They later underwent routine spirometry.
62079905|NCT06741150|EXPERIMENTAL|Cohort A Cohort A( HPV-16 related Cervical, vaginal, and vulvar intraepithelial neoplasia patients )|Patients in Cohort A will be assigned to three dose groups. Each patient will be administered NWRD09 by intramuscular injection. The Maximum Tolerated Dose of NWRD09 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
62079906|NCT06741150|EXPERIMENTAL|Cohort B(HPV-16 related cervical cancer patients)|Patients in Cohort B will be assigned to three dose groups. Each patient will be administered NWRD09 by intramuscular injection. The Maximum Tolerated Dose of NWRD09 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
62079907|NCT04667468|EXPERIMENTAL|Cold-stored Platelet (CSP)|early infusion of one apheresis unit urgent release cold stored platelets (CSP)
62079908|NCT04667468|ACTIVE_COMPARATOR|Standard Care|resuscitation, blood and blood component transfusion per site standard care
62079909|NCT04048070|EXPERIMENTAL|ERAS with postoperative intravenous Flubiprofen Axetil|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
62079910|NCT04048070|EXPERIMENTAL|ERAS with analgesia pump|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
62079911|NCT04048070|EXPERIMENTAL|Traditional care with Flubiprofen Axetil|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
62079912|NCT04048070|EXPERIMENTAL|Traditional care with analgesia pump|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
62079913|NCT04048070|PLACEBO_COMPARATOR|traditional care without postoperative intravenous analgesia.|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Intravenous saline with necessary oral analgesic for postoperative pain management.
62079914|NCT05874492|ACTIVE_COMPARATOR|Immediate spa treatment|The spa treatment must be carried out within a maximum of 6 weeks after the inclusion visit.
62079915|NCT05874492|SHAM_COMPARATOR|Late spa treatment|The spa treatment must be carried out after the 6-month visit.
62079916|NCT04361474|EXPERIMENTAL|Experimental group|Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
62079917|NCT04361474|PLACEBO_COMPARATOR|Control group|Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory re-education twice a day.
62079918|NCT04426006|OTHER|PRO-SERO-COV|Blood sample and self-administered questionnaire
62079919|NCT04345874|EXPERIMENTAL|Nutrition technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
62079920|NCT04345874|EXPERIMENTAL|Children's environmental health technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
62647856|NCT04625283|PLACEBO_COMPARATOR|Saline|Participants in this arm will receive an equivalent volume of intraoperative saline bolus followed by continuous saline infusion and also will receive postoperative saline infusion for 48 hours.
62079921|NCT06737341|EXPERIMENTAL|bupivacaine liposomes(BL)|20ml of bupivacaine liposomes + 10ml 0.75% bupivacaine hydrochloride + 20ml normal saline for ultrasound-guided bilateral costal margin block. Block method: First, the high-frequency ultrasound probe is placed in the direction of the parasternal line parallel to the costal edge, and find the image of the costal cartilage and rectus abdominis space 。The needle was inserted along the medial side of the rectus to the lateral plane, and 15 ml of local anesthetic was injected between the costal cartilage and rectus abdominis space 。The ultrasound probe was then moved along the costal margin to the axillary front, flush with the tenth rib, and 10 ml of local anesthetic was injected in the plane between the tenth rib and the extraabdominal oblique muscle 。Similarly, perform ultrasound-guide costal rim block on the other side.
62079922|NCT06737341|ACTIVE_COMPARATOR|bupivacaine(B)|10 ml of 0.75% bupivacaine hydrochloride + 40ml normal saline for ultrasound-guided bilateral costal margin block in the same method as the experimental group
62079923|NCT03316612|EXPERIMENTAL|Intervention group|"Ingredients: Vaccinium Myrtillus L. extracts, and excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet, 650mg per tablet with 150mg Vaccinium Myrtillus L. extracts, twice a day, 2 tablets each time.~The intervention period is about 3 months."
62647857|NCT02465450|EXPERIMENTAL|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
62647858|NCT02465450|EXPERIMENTAL|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
62647859|NCT02465450|PLACEBO_COMPARATOR|Placebo|Placebo once a day on Days 1-28.
62079924|NCT03316612|PLACEBO_COMPARATOR|Placebo group|"Ingredients: excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet without Vaccinium Myrtillus L. extracts, 650mg per tablet, twice a day, 2 tablets each time.~The intervention period is about 3 months."
62457654|NCT05944107|ACTIVE_COMPARATOR|Heparin Concentration (HC)|"In this group, the Hepcon HMS Plus (Medtronic, MN, USA) is used to perform heparin concentration calculations and test each patient's individual response to heparin. Specifically tests performed were:~* Heparin Dose Response test~* Heparin Assay test"
62457655|NCT01229020||COPD patients|Patients diagnosed with COPD, by the pulmonologist at the institute,who are referred to undergo ventilation/perfusion scans.
62457656|NCT04193566|ACTIVE_COMPARATOR|Dapagliflozin|"Patients in the active arm will be treated with dapagliflozin 50 mg once on site for visit 2 and once at home on the evening before visit 3.~Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf."
62457657|NCT04193566|PLACEBO_COMPARATOR|Placebo|"Patients in the placebo arm will be treated with placebo once on site for visit 2 and once at home on the evening before visit 3.~Placebo drug:~The composition equals the composition of Forxiga® - just with the active ingredient omitted. Active drug and placebo are similar in appearance and smell."
62457658|NCT03332693|ACTIVE_COMPARATOR|No exercise|Volunteers will not participate in exercise
62457659|NCT03332693|ACTIVE_COMPARATOR|Light exercise|Volunteers will participate in one short exercise
62647860|NCT02465450|EXPERIMENTAL|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
62647861|NCT02465450|EXPERIMENTAL|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
62647862|NCT02465450|PLACEBO_COMPARATOR|Placebo BID|Placebo twice daily on Days 29-84.
62079925|NCT06728332||Group 1|Females experiencing sleep disturbances associated with menopause
62079926|NCT06688786|EXPERIMENTAL|Combinational treatment group|neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy
62079927|NCT04574154|EXPERIMENTAL|FIB|ultrasound guided Fascia Iliaca Block
62079928|NCT04574154|EXPERIMENTAL|ESPB|ultrasound guided Erector Spinae Plane Block
62079929|NCT06527079||Usual Care|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
62079930|NCT06527079||CDS Notification|Providers will see a clinical decision support tool within the electronic health record when treating a patient who may benefit from or is currently tapering opioid medications to encourage the provider to use a clinical care pathway that provides resources and decision support in tapering.
62079931|NCT04345913|ACTIVE_COMPARATOR|Group I (eribulin)|Patients receive eribulin IV over 2 to 5 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI at screening, cycle 3 day 1, and every 9 weeks thereafter. Patients also undergo a biopsy at baseline, cycle 2 day 1, and at time of disease progression and blood sample collection at baseline, cycle 2 day 1, every 9 weeks and at time of disease progression.
62079932|NCT04345913|EXPERIMENTAL|Group II (eribulin, copanlisib)|Patients receive copanlisib IV over 1 hour and eribulin IV over 2 to 5 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI at screening, cycle 3 day 1, and every 9 weeks thereafter. Patients also undergo a biopsy at baseline, cycle 2 day 1, and at time of disease progression and blood sample collection at baseline, cycle 2 day 1, every 9 weeks and at time of disease progression.
62079933|NCT05958407|EXPERIMENTAL|Tralokinumab|Tralokinumab is administered for 32 weeks (16 weeks double-blinded period + 16 weeks open-label period)
62079934|NCT05958407|PLACEBO_COMPARATOR|Placebo + tralokinumab|Placebo is administered for 16 weeks (double-blinded period) prior to roll-over to a 16 weeks open-label period where tralokinumab is administered
62457660|NCT03332693|ACTIVE_COMPARATOR|Heavy exercise|Volunteers will participate in heavy exercise
62457661|NCT03395106|EXPERIMENTAL|Parent source + intuitive story content|
62457662|NCT03395106|EXPERIMENTAL|Doctor source + intuitive story content|
62457663|NCT03395106|EXPERIMENTAL|Parent source + deliberative content|
62457664|NCT03395106|EXPERIMENTAL|Doctor source + deliberative content|
62457665|NCT03977051||Focus group|Focus group to explore immunosuppressant medication adherence in kidney transplant patients
62457666|NCT03361228|EXPERIMENTAL|INCB001158 + Epacadostat + Pembrolizumab|
62457667|NCT03361228|EXPERIMENTAL|INCB001158 + Epacadostat|
62457668|NCT00686049||Study Group|Participants will complete two audio computer assisted self interviews on laptop computers. This study will also involve the abstraction of participants' viral load and CD4 counts from their medical charts.
62457669|NCT02219165|EXPERIMENTAL|IVIG 2 g/kg|Intravenous human immunoglobulin Day 1: As soon as there is suspicion of TSS, randomisation will be performed in order for the study treatment to be administered within the 12h following PICU admission (or following the manifestation of the first signs of shock). Concurrently, the TSS antibiotherapy following Surviving Sepsis Campaign recommendations is given
62647863|NCT04198935|EXPERIMENTAL|Intervention|Participants will be enrolled on to a 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
62647864|NCT01178788|ACTIVE_COMPARATOR|17 alfa hydroxy Progesterone caproate|Women treated with i.m. 17P injection/weekly (Lentogest, IBSA, Italy)
62647865|NCT01178788|ACTIVE_COMPARATOR|Micronized Progesterone|micronized P 200 mg per vagina /day (Utrogestan, Besins Healthcare, Belgium)
62647866|NCT01178788|ACTIVE_COMPARATOR|Control|Routine clinical controls
62647867|NCT05327452|EXPERIMENTAL|Supervised aerobic and resistance exercise (SUP)|"Participants will be randomly assigned to receive 3x weekly at home, virtually supervised aerobic and resistance exercise sessions with a certified exercise trainer for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
62079935|NCT06738862||PD group|
62079936|NCT06738862||MSA group|
62079937|NCT06738862||RBD group|
62079938|NCT06738862||HC group|
62079939|NCT06104124|EXPERIMENTAL|Dazodalibep Dose 1|Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.
62079940|NCT06104124|EXPERIMENTAL|Dazodalibep Dose 2|Participants will be administered dose 2 of dazodalibep by IV infusion.
62079941|NCT06104124|PLACEBO_COMPARATOR|Placebo|Participants will be administered placebo by IV infusion.
62079942|NCT05143957|EXPERIMENTAL|Sapablursen Dose Level 1|Sapablursen will be administered by SC injection every 4 weeks.
62079943|NCT05143957|EXPERIMENTAL|Sapablursen Dose Level 2|Sapablursen will be administered by SC injection every 4 weeks
62079944|NCT02014792||Chronic kidney disease, stage 5|Patients with stage 5 chronic kidney disease who have recently commenced haemodialysis treatment (within 6-10 weeks of starting treatment)
62079945|NCT05987618|EXPERIMENTAL|Oral appliance with elastic bands|Oral appliance therapy with elastic bands.
62079946|NCT05987618|ACTIVE_COMPARATOR|Oral appliance without elastic bands|Oral appliance therapy without elastic bands.
62079947|NCT01347853|EXPERIMENTAL|Ketorolac tromethamine|
62079948|NCT01347853|PLACEBO_COMPARATOR|Placebo|
62079949|NCT01564719|EXPERIMENTAL|Immediate-intervention arm|This is a holistic health intervention. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
62079950|NCT01564719|EXPERIMENTAL|One-year waitlist arm|This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
62079951|NCT01564719|EXPERIMENTAL|Two-year waitlist arm|This holistic health intervention arm for Cohort 3 was the same as Cohort 2's, only Cohort 3 waited for two years and received the stress management program meQuilibrium rather than Williams LifeSkills.
62079952|NCT05548959|EXPERIMENTAL|Microshunt patients|Pneumatonometry of the intraocular pressure was performed on patients who have undergone previous microshunt implantation.
62079953|NCT05548959|EXPERIMENTAL|Ab interno trabeculectomy patientes|Pneumatonometry of the intraocular pressure was performed on patients who have undergone previous ab interno trabeculectomy.
62079954|NCT01398436|EXPERIMENTAL|Catheter tip in right atrium|In this group a central venous catheter will be advanced for its entire length unless arrhythmias develop.Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography.
62457670|NCT02219165|PLACEBO_COMPARATOR|Albumin 4%|Same study scheduling as the first arm. Only the study treatment given is different (albumin instead of IGIV)
62647868|NCT05327452|EXPERIMENTAL|Unsupervised aerobic and resistance exercise (UNSUP)|"Participants will be randomly assigned to receive 3x weekly at home, unsupervised aerobic and resistance exercise sessions with a 1x weekly telehealth call with a certified exercise trainer for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
62647869|NCT05327452|ACTIVE_COMPARATOR|Attention Control (AC)|"Participants will be randomly assigned to receive 3x weekly at home stretching exercise for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
62647870|NCT05553834|EXPERIMENTAL|Alirocumab and Cemiplimab|Combination of anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab
62647871|NCT03922685|ACTIVE_COMPARATOR|Morning sedentary arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 11:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
62079955|NCT01398436|NO_INTERVENTION|Catheter tip in superior vena cava|In this group a central venous catheter will be inserted for 15 cm in accordance with standard practice. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
62457671|NCT05493176|EXPERIMENTAL|Dry immersion|5 days of dry-immersion
62647872|NCT03922685|ACTIVE_COMPARATOR|Morning exercise arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 7:20 and 11:20, 3-ml blood samples were collected at 10-min intervals.After the 11:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
62079956|NCT06738264||seronegative RA|Rheumatoid arthritis patients with negative rheumatoid factor and negative anti citrullinated proteins
62079957|NCT06738264||seropositive RA|Rheumatoid arthritis patients with positive rheumatoid factor and positive anti citrullinated proteins
62079958|NCT06479720|ACTIVE_COMPARATOR|Solifenacin and mirabegron|Solifenacin 5mg and Mirabegron 25mg
62457672|NCT03348670|EXPERIMENTAL|Abiraterone - Usual|"* ZYTIGA - Abiraterone~* Combined Chemotherapy (high dose)~* ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated~* Usual Approach Group (high dose)"
62457673|NCT03348670|EXPERIMENTAL|Abiraterone - Study|"* ZYTIGA - Abiraterone~* Combined Chemotherapy (low dose)~* ZYTIGA - abiraterone acetate tablet~* ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated~* Usual Approach Group (low dose)"
62457674|NCT03393650|ACTIVE_COMPARATOR|Exercise + Placebo group|50 subjects will receive a placebo supplementation with an exercise intervention (EX group)
62457675|NCT03393650|ACTIVE_COMPARATOR|Exercise + Protein group|50 subjects will receive a protein supplementation combined with an exercise intervention (PROTEX group)
62647873|NCT03922685|ACTIVE_COMPARATOR|Evening sedentary arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 23:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
62079959|NCT06479720|EXPERIMENTAL|Solifenacin with vaginal estrogen cream|Solifenacin 5mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.
62079960|NCT06479720|EXPERIMENTAL|Mirabegron with vaginal estrogen cream|Mirabegron 25mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.
62079961|NCT04063111|ACTIVE_COMPARATOR|group A|Group A will be treated with vacuum assistant closure
62079962|NCT04063111|ACTIVE_COMPARATOR|group B|Group B will be treated with conventional dressing
62079963|NCT05509712||Focus Groups to Refine MobileMen App Content|Focus groups are conducted virtually to refine content in the mobile app for African American men. African American men are recruited in Louisiana and Washington, DC and surrounding areas, using via listservs, ResearchMatch, social media, community events, local networking, and word of mouth.
62079964|NCT05509712||Beta testing of MobileMen App Prototype|The prototype MobileMen app is evaluated for feasibility, acceptability, and usability in semi-structured interviews with African American men recruited in Louisiana who meet eligibility criteria similar to those used for the focus groups
62457676|NCT00925626|EXPERIMENTAL|Sub - Vastus arthrotomy|Sub-vastus arthrotomy
62079965|NCT00652925|EXPERIMENTAL|High Dose|
62079966|NCT00652925|EXPERIMENTAL|Low Dose|
62079967|NCT00652925|ACTIVE_COMPARATOR|Naproxen|Control comparator, 15 mg/kg/dy target dose
62079968|NCT01430312|EXPERIMENTAL|Verum|Topical application of verum (azelaic acid pre-foam formulation) on the skin
62079969|NCT01430312|PLACEBO_COMPARATOR|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
62079970|NCT01430312|PLACEBO_COMPARATOR|Negative control|Topical application of distilled water (negative control) on the skin
62457677|NCT00925626|ACTIVE_COMPARATOR|Mid-Vastus arthrotomy|Mid-vastus arthrotomy
62647874|NCT03922685|ACTIVE_COMPARATOR|Evening exercise arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 19:20 and 23:20, 3-ml blood samples were collected at 10-min intervals.After the 23:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
62647875|NCT03261206|NO_INTERVENTION|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
62079971|NCT01430312|ACTIVE_COMPARATOR|Positive control|Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin
62079972|NCT06272019|EXPERIMENTAL|Gargle method|the participant will use 0.2% iodine gargle with gargle method by hold in mouth 30 second and gargle 30 seconds after that spit out
62647876|NCT03261206|EXPERIMENTAL|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
62079973|NCT06272019|EXPERIMENTAL|Swab method|the participant will use 0.2 iodine gargle with swab method by the researcher apply on mouth 1 minute without spit out
62079974|NCT03312465||AS Domelock System Subjects|Subjects that receive the Anatomical Shoulder Domelock System
62079975|NCT03903796|EXPERIMENTAL|HS-10234 25mg|HS-10234 + TDF placebo for up to 96 weeks
62647877|NCT00641563|ACTIVE_COMPARATOR|Dex/Remi followed by Mida/Remi|Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week
62647878|NCT00641563|ACTIVE_COMPARATOR|Mida/Remi followed by Dexa/Remi|Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week
62079976|NCT03903796|ACTIVE_COMPARATOR|TDF 300mg|TDF + HS-10234 placebo for up to 96 weeks
62079977|NCT03903796|EXPERIMENTAL|Open-label HS-10234|All participants who complete the double-blind period (96 weeks) will be eligible to receive open-label HS-10234 until week 144 of the study.
62079978|NCT06170957|EXPERIMENTAL|Experimental group|For the experimental group; A modified pacifier will be given to the newborn during the heel blood collection procedure.
62079979|NCT06170957|NO_INTERVENTION|Control group|For the control group; The newborn will not be given a modified pacifier during the heel blood collection procedure.
62079980|NCT06731452|EXPERIMENTAL|Online Strategic Memory Advanced Reasoning Training & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance Stress Solutions provides individuals with opportunities to extend the SMART principles to domains of stress and resilience.
62079981|NCT05249296|EXPERIMENTAL|Group 1: intervention/control group|"Phase 1: Two weeks of green space intervention~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
62079982|NCT05249296|EXPERIMENTAL|Group 2: control/intervention group|"Phase 1: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of green space intervention~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
62079983|NCT06097637|EXPERIMENTAL|underwater endoscopic mucosal resection|underwater endoscopic mucosal resection for resection of big pedunculated colorectal polyps
62079984|NCT06097637|ACTIVE_COMPARATOR|hot snare polypectomy|hot snare polypectomy for resection of big pedunculated colorectal polyps
62079985|NCT06737458|ACTIVE_COMPARATOR|Serratus anterior plane block group|Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
62079986|NCT06737458|EXPERIMENTAL|Erector spinae plane block group|Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
62079987|NCT06714552|EXPERIMENTAL|Beta-galacto-oligosaccharide|
62079988|NCT06714552|OTHER|Glucose|Control
62079989|NCT05818189|EXPERIMENTAL|Personalized cueing|Personalized, step-synchronized tactile cueing, enhancing proprioceptive inputs, in the form of real-time, closed-loop tactile feedback signaling left and right stance times while walking
62079990|NCT05818189|ACTIVE_COMPARATOR|Fixed cueing|Tactile cueing at fixed intervals, enhancing proprioceptive inputs, in the form of open-loop tactile feedback (fixed rhythm) signaling left and right stance times while walking
62079991|NCT06671093|EXPERIMENTAL|Tune-401 SAD 1|Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
62079992|NCT06671093|EXPERIMENTAL|Tune-401 SAD 2|Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
62079993|NCT06671093|EXPERIMENTAL|Tune-401 SAD 3|Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
62079994|NCT06671093|EXPERIMENTAL|Tune-401 Expansion Dose|Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
62079995|NCT06294678|ACTIVE_COMPARATOR|the early infused group|infused stem cell within 11:30 am and 12:30 am
62079996|NCT06294678|SHAM_COMPARATOR|the late infused group|infused stem cell within 5:30 pm and 6:30 pm
62079997|NCT06677203|EXPERIMENTAL|ASN51: Low Dose|Participants will receive low dose of ASN51 once daily (QD).
62079998|NCT06677203|EXPERIMENTAL|ASN51: High Dose|Participants will receive high dose of ASN51 QD.
62457678|NCT06354803|EXPERIMENTAL|intervention group|23 women below 28 week gestation were received kinaesthetic exercises on the Pezzi ball and standard antenatal care
62457679|NCT06354803|NO_INTERVENTION|control group|22 women belowe 28 week gestation were received just standard antenatal care
62457680|NCT02401126|ACTIVE_COMPARATOR|Nitrate supplementation|Concentrated nitrate-rich beetroot juice
62457681|NCT02401126|PLACEBO_COMPARATOR|Placebo|Nitrate-depleted beetroot juice
62647879|NCT06492629|EXPERIMENTAL|Toripalimab Combined With Chidamide group|Toripalimab:Intravenous infusion, 240mg, administered once every 3 weeks. Chidamide:Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses
62647880|NCT00745888||1|age \> 18 y/o Patients admitted to surgical ICU
62079999|NCT06677203|PLACEBO_COMPARATOR|Placebo|Participants will receive ASN51 matching placebo QD.
62080000|NCT03226457|ACTIVE_COMPARATOR|Empagliflozin/Placebo|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
62080001|NCT03226457|ACTIVE_COMPARATOR|Placebo/Empagliflozin|Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
62080002|NCT00445601|EXPERIMENTAL|Arm I|Patients receive intravesical gemcitabine hydrochloride over 1 hour.
62080003|NCT00445601|PLACEBO_COMPARATOR|Arm II|Patients receive intravesical placebo over 1 hour.
62080004|NCT00927043||1|
62080005|NCT04857190|ACTIVE_COMPARATOR|Group DS (n=40)|Parker Flex-it Directional Stylet group
62080006|NCT04857190|ACTIVE_COMPARATOR|Group MS (n=40)|Conventional Malleable Stylet group
62080007|NCT00674882||Participants|Data Collection
62457682|NCT02329756|ACTIVE_COMPARATOR|Treatment|Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
62647881|NCT02049216|SHAM_COMPARATOR|Sham tape|"* Fixomull tape only~* Single piece of 10cm wide, 32cm long applied from inferior to tibial tuberosity, over patella and onto quadriceps muscle. Corners rounded. Tape to be applied with the knee in 90 degrees flexion.~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
62647882|NCT02049216|EXPERIMENTAL|Flexible tape|"Flexible tape (rocktape brand) applied as follows:~First piece of tape 10 cm wide and 32cm long (length of a standard goniometer). Split down centre 18cm from 1 end. Second piece of tape 5cm wide and 14cm long.~Tape applied in 90 degrees knee flexion Applied with no tension in proximal and distal ends. 30% tension to un-split portion placed over quads. 50% tension to split portion placed either side of patella and crossing over at tibial tuberosity Additional piece of 5cm wide flexible tape applied with 80% tension over patella tendon, with no tension in 3cm from ends All tape corners rounded~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
62647883|NCT05739916|EXPERIMENTAL|Sequence A(Before→ After)|
62080008|NCT04938167|NO_INTERVENTION|Standard arm|target preductal SpO2 - 91 to 95%
62080009|NCT04938167|EXPERIMENTAL|Intervention arm|target preductal SpO2 - 95 to 99%
62080010|NCT04431687|EXPERIMENTAL|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
62080011|NCT04431687|EXPERIMENTAL|Sequence 2|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days"
62080012|NCT04431687|EXPERIMENTAL|Sequence 3|"Period 1: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
62080013|NCT04431687|EXPERIMENTAL|Sequence 4|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets)."
62080014|NCT03396731|NO_INTERVENTION|Standard care alone (control)|Multilayer/multi component compression bandaging treatment
62080015|NCT03396731|ACTIVE_COMPARATOR|6 hours geko™ (no longer recruiting)|geko™ device 6 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
62080016|NCT03396731|ACTIVE_COMPARATOR|12 hours geko™|geko™ device 12 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
62080017|NCT04069221|EXPERIMENTAL|Part 1, single arm|"This was an open-label study in 8 healthy subjects to determine the absolute bioavailability of OZ439 following a single oral dose of OZ439 and co-administration of a single iv infusion of a \[14C\]-OZ439 radiolabeled microdose at the anticipated Tmax of the oral dose. Subjects received the following treatment:~Treatment A: A single oral dose of 800 mg OZ439 simple granules administered as a 100-mL dispersion followed by a 15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439 (47 kBq \[1.27 μCi\]) beginning 3 hours after the oral dose administration."
62080018|NCT04069221|EXPERIMENTAL|Part 2, Treatment B: single oral dose of 800 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
62080019|NCT04069221|EXPERIMENTAL|Part 2, Treatment C: single oral dose of 400 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
62457683|NCT02329756|PLACEBO_COMPARATOR|Control|Matching placebo (sodium chloride 0.9%) will be compared with treatment group
62457684|NCT02354742|ACTIVE_COMPARATOR|Early Goal Directed Therapy (EGDT)|EGDT is currently standard of care in management of septic shock, so assignment to this treatment arm will confer no additional risk above that of standard of care. EGDT utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications. EGDT uses central venous catheter to assess central venous pressure and ScVO2.
62647884|NCT05739916|EXPERIMENTAL|Sequence B(After→ Before)|
62080020|NCT04069221|EXPERIMENTAL|Part 2, Treatment D:single oral dose 400 mg OZ439+cobicistat|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
62080021|NCT01557972||1. Morning HP and NT|Subjects based on HBP were divided into MH and MN patients
62080022|NCT01557972||2. Clinic HP and NT|Subjects based on CBP were divided into CH and CN patients
62457685|NCT02354742|EXPERIMENTAL|Echo Guided Fluid Resuscitation|The echo arm also utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications, all of which are interventions found in standard care. The central venous pressure will not be monitored in this arm. Instead, decisions for giving fluids will be directed by the results of Echocardiography. Echocardiography poses no known risk to the patient, and it is non-invasive. The only risk of echocardiography is that of misdiagnosis.
62647885|NCT06386406|EXPERIMENTAL|TAP insole|
62647886|NCT02317653||Overweight/Obese|Archive blood, archive breast milk, and clinical assessment data from 15 participants who were considered overweight or obese at enrollment in the Expecting Success study conducted at Pennington Biomedical Research Center (NCT01610752) will be used to represent the overweight and obese sample for study investigations.
62080023|NCT01854294|EXPERIMENTAL|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
62080024|NCT01854294|PLACEBO_COMPARATOR|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
62080025|NCT03355365|EXPERIMENTAL|Intrathecal MSC-NP injection|Patients will receive six autologous stem cell injections through spinal taps every 2 months over a year.
62080026|NCT03355365|PLACEBO_COMPARATOR|Intrathecal saline injection|Patients will receive six placebo injections through spinal taps every 2 months over a year.
62080027|NCT03285113|EXPERIMENTAL|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
62080028|NCT02688374|OTHER|Treatment A:Treatment B:Treatment C|Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
62080029|NCT02688374|OTHER|Treatment B:Treatment C:Treatment A|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
62080030|NCT02688374|OTHER|Treatment C:Treatment A:Treatment B|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
62080031|NCT02688374|OTHER|Treatment A: Treatment C:Treatment B|Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
62080032|NCT02688374|OTHER|Treatment B:Treatment A: Treatment C|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
62080033|NCT02688374|OTHER|Treatment C:Treatment B:Treatment A|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
62080034|NCT01945762||1. patient cohorts (40 patients/cohort)|RET positive patient cohorts
62080035|NCT01945762||2. patient cohorts (40 patients/cohort)|RET negative patient cohorts
62457686|NCT04494659|EXPERIMENTAL|Single arm|single dose of Famitinib on Day 1, and co-administered with Rifampicin on Day 16
62457687|NCT03093324|EXPERIMENTAL|ALKS 8700|Oral capsules, administered orally twice daily.
62457688|NCT03093324|ACTIVE_COMPARATOR|Dimethyl Fumarate|Oral capsules, administered orally twice daily.
62457689|NCT00496444|EXPERIMENTAL|Azacitidine + Valproic Acid|
62457690|NCT01979081||People with chronic disease|Participants greater than or equal to 44 years of age with a chronic disease (diabetes, heart disease, stroke, hypertension, osteoporosis, osteoarthritis, rheumatoid arthritis, chronic obstructive pulmonary disease, back pain, Multiple Sclerosis, Parkinson's Disease).
62457691|NCT01979081||People without chronic disease|Participants greater than or equal to 65 years of age without a chronic disease.
62647887|NCT02317653||Normal Weight|Up to 20 pregnant women who were considered normal weight (18.5 ≤ BMI ≤ 24.9 kg/m2) prior to pregnancy will be enrolled in the study.
62647888|NCT06375382|EXPERIMENTAL|acupuncture group|Receiving acupuncture and moxibustion
62647889|NCT06375382|SHAM_COMPARATOR|sham acupuncture group|Receiving sham acupuncture and sham moxibustion
62647890|NCT05049005|ACTIVE_COMPARATOR|RED FOOD Intervention Group|Participants in the RED FOOD group will be taught a simplified way of identifying high-calorie foods (red foods) and reducing them using the Traffic Light Diet. Limiting the number of red foods consumed is a simple way to reduce calories without having to track calories. Participants in this group will use the study website to track their red foods and will be given a daily red food limit base on their baseline weight and will track their red foods on the study website daily. Participants will be recommended to enter their red foods at least once per day (at which time they would enter all red foods for the day), but ideally multiple times per day to reduce errors associated with recall.
62647891|NCT05049005|EXPERIMENTAL|GREEN FOOD Intervention Group|Participants in the GREEN FOOD group will be taught a simplified way of identifying low-calorie foods (green foods) and maximizing them using the Traffic Light Diet. Maximizing the number of green foods consumed is a simple way to reduce dietary energy density while allowing for consumption of a satisfying amount (i.e. weight and volume) of food. Maximizing green food consumption may simultaneously reduce red food consumption, thereby reducing calorie intake and promoting greater diet quality than red food reduction alone. Participants in this group will also use the study website to track their green foods and will be given a daily green food goal based on their baseline weight and will track their green foods on the study website daily. Participants will be recommended to enter their green foods at least once per day (at which time they would enter all green foods for the day), but ideally multiple times per day to reduce errors associated with recall.
62647892|NCT00183339|PLACEBO_COMPARATOR|Placebo|Placebo, liquid solution flexible dose 0.5 to 5ml every morning (AM)
62647893|NCT00183339|EXPERIMENTAL|fluoxetine|Fluoxetine, 20mg/5ml solution, flexible dose 0.5 to 5ml every AM
62647894|NCT00682877||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
62647895|NCT00682877||Gastroparesis|Subjects with documented gastroparesis
62647896|NCT04891172|NO_INTERVENTION|Control|The Control group will be receive Standard of care only
62647897|NCT04891172|EXPERIMENTAL|C-IVIG|The intervention group will receive the single dose of C-IVIG (0.15g/kg) with Standard of Care
62647898|NCT02597608|EXPERIMENTAL|UPPR: Control|No interventions are provided.
62647899|NCT02597608|EXPERIMENTAL|UPPR: Livelihoods only|Livelihoods programmes offered by UPPR.
62647900|NCT02597608|EXPERIMENTAL|UPPR: Livelihoods plus nutrition|Livelihoods programmes offered by UPPR, plus nutrition programmes offered by UPPR.
62647901|NCT02597608|EXPERIMENTAL|CLP: Livelihoods only|Livelihoods programmes offered by CLP.
62647902|NCT02597608|EXPERIMENTAL|CLP: Livelihoods plus nutrition|Livelihoods programmes offered by CLP, plus nutrition programmes offered by CLP.
62080036|NCT06417190|EXPERIMENTAL|Single Arm|Neoadjuvant chemotherapy followed by trimodal therapy consisting of TURBT followed by concurrent chemotherapy with radiation therapy
62647903|NCT02597608|EXPERIMENTAL|Shiree: Livelihoods only|Livelihoods programmes offered by Shiree.
62080037|NCT01000376|EXPERIMENTAL|Group 1|
62080038|NCT01000376|EXPERIMENTAL|Group 2|
62647904|NCT02597608|EXPERIMENTAL|Shiree: Livelihoods plus nutrition|Livelihoods programmes offered by Shiree, plus nutrition programmes offered by Shiree.
62647905|NCT05261906|EXPERIMENTAL|LIBERATE Intervention|
62647906|NCT03581214|ACTIVE_COMPARATOR|Room air|Room air (no mask)
62647907|NCT03581214|PLACEBO_COMPARATOR|Oxygen|10L/min Oxygen by facemask
62647908|NCT02089477|EXPERIMENTAL|Support|"The participants in the intervention group receives the intervention and support consisting of:~1. Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~2. SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
62647909|NCT02089477|NO_INTERVENTION|Control group|Patient's in the control group receives the intervention with interval Walking and no other support.
62647910|NCT01940822|EXPERIMENTAL|Energy drink first, then placebo drink|Participants will receive an energy drink at the first study visit, and a placebo drink at the second study visit.
62647911|NCT01940822|EXPERIMENTAL|Placebo drink first, then energy drink|Participants will receive a placebo drink at the first study visit and an Energy Drink at the second study visit.
62647912|NCT05278468||case group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University who had positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
62647913|NCT05278468||control group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University with negative positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
62647914|NCT01699750|EXPERIMENTAL|Air Optix Aqua|Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
62647915|NCT01699750|ACTIVE_COMPARATOR|Acuvue Oasys|Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
62647916|NCT00910949||Painfree|Thoracotomy patients without chronic pain
62647917|NCT00910949||With Pain|Thoracotomy patients with chronic pain
62647918|NCT00611806|ACTIVE_COMPARATOR|Folate with B12|Participants will take folic acid plus B12 for 18 weeks.
62647919|NCT00611806|PLACEBO_COMPARATOR|Placebo|Participants will take placebo for 18 weeks.
62647920|NCT06054997||lower dose UFH/kg group|UFH below or equal to 60 IU/kg/surgery
62647921|NCT06054997||higher dose UFH/kg group|UFH above 60 IU/kg/surgery
62647922|NCT05637983|EXPERIMENTAL|US-guided femoral puncture|US-guided femoral puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
62647923|NCT05637983|ACTIVE_COMPARATOR|Fluoroscopy-guided puncture|Fluoroscopy-guided puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
62647924|NCT03991871|PLACEBO_COMPARATOR|Control Group|35 hours ECP treatment, initial treatment pressure is 75 mmHg
62647925|NCT03991871|EXPERIMENTAL|Intervention Group|35 hours ECP treatment, initial treatment pressure is 300 mmHg
62647926|NCT05615077|EXPERIMENTAL|Combined exercise-education intervention group|Combined exercise-education intervention by fall risk state for 12 months during intervention period.
62647927|NCT05615077|NO_INTERVENTION|Control group|No intervention for 12 months during intervention period.
62647928|NCT01235988||Eltrombopag & standard of care|
62647929|NCT01235988||Standard of care|
62647930|NCT02484677|EXPERIMENTAL|Head and neck cancer patient|Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation
62647931|NCT02678468||high-risk group|children with birth history of pre-term, low birth weight children with develop delay
62647932|NCT02678468||normal group|children with normal birth history and normal development
62647933|NCT04584788|EXPERIMENTAL|Healthy Adult Volunteers|Controlled hypoxia will be induced and Masimo O3 regional oximeter-derived tissue oxygen saturation (rSO2) readings of somatic tissue will be measured. The readings will be compared with blood reference oxygen saturation values.
62647934|NCT04208893|EXPERIMENTAL|Aerobic training only|The aerobic training intervention will include 60 minutes/session, 3 times/week for 12 weeks at an intensity of 65% - 85% of participants' heart rate reserve (HRR), as determined by the CPET. Patients will be asked to wear a fitness-tracking device to monitor their heart rate response and in order to comply with the prescribed training intensity. All training sessions will start with a 10-minute warm up, 40-minute aerobic interventions, and ends with 10-minute of cool down. One study doctor will be on call during in-hospital training. Onsite supervised aerobic interventions will include play-based activities, whereas home-based aerobic activities will include stationary bikes and exercise activities that would target desired heart rate ranges. Home exercise equipment will be provided.
62647935|NCT04208893|EXPERIMENTAL|Combined aerobic and strength training|Participants in this group will perform a combination of aerobic and strength training activities for 60 minutes/session, 3 times/week for 12 weeks. Aerobic activities for this group will be similar to Arm 1. Strength training will be based on participant's individual assessment findings and developmental status. Resistance level will be set at approximately 50% of the patient maximal load and increased by 3 pounds (or the next level of resistance band) once the patient is able to perform 30 repetitions. Closed kinetic chain exercises such as pushups, squats, and lunges will be made more challenging by the addition of weight or change in body position. Training sessions will include a 10-minute warm up, 40-minute aerobic and strength exercises, and a 10-minute cooldown.
62647936|NCT04583982||Prospective Study Arm SARS-CoV-2 negative and positive samples|
62647937|NCT03085303|EXPERIMENTAL|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
62647938|NCT03085303|EXPERIMENTAL|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
62080039|NCT06737848|EXPERIMENTAL|Single Catheter Adrenal Vein Sampling|Patients in the Intervention group will utilize a multifunctional catheter for bilateral adrenal vein sampling.
62080040|NCT06737848|ACTIVE_COMPARATOR|Double Catheter Adrenal Vein Sampling|Patients in this group will utilize two catheters for bilateral adrenal vein sampling.
62080041|NCT03982888|EXPERIMENTAL|DBS Treatment|Deep brain stimulation of both limbic and dysfunctional reward processing circuits for treatment of repetitive self injurious behaviours in children with ASD
62080042|NCT02074540||Diabetes Type II Patients|
62080043|NCT00601718|EXPERIMENTAL|Treatment (enzyme inhibitor, monoclonal antibody, chemotherapy|Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
62080044|NCT06720389|ACTIVE_COMPARATOR|milled mandibular overdenture opposed by maxillary complete denture|A denture base milled from a pre-polymerized block of polymethylmethacrylate (Ivobase CAD) along with milled denture teeth from a block of tooth coloured material PMMA (SR Vivodent CAD).
62080045|NCT06720389|ACTIVE_COMPARATOR|3D-Printed mandibular overdenture|The printer (Rasdent 3d printer) was loaded with material of 3D-printed denture base and 3D- printed denture teeth (Dentca denture teeth shade A2). The mandibular denture teeth were printed as one unit then bonded to the lower printed denture base.
62080046|NCT05209074|EXPERIMENTAL|Ivosidenib+mFOLFIRINOX|
62080047|NCT02829710||group 1 : pre implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between January 2013 and December 2013.~Prior to implementation of the protocol, analgesia and sedation were managed by the attending physician's order."
62080048|NCT02829710||group 2 : post implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between May 2014 and March 2015.~Nurses managed analgesia and sedation following an algorithm, including COMFORT-B scale."
62080049|NCT06737224|EXPERIMENTAL|Fasting + Exercise (FAST+EX): fasting + exercise condition|48-hour fast with 60 minutes of cycling on the first and second day of the fast.
62080050|NCT06737224|EXPERIMENTAL|Fasting only (FAST): Non-exercise fasting condition|48-hour fast with no structured exercise on fasting days.
62080051|NCT02971384|EXPERIMENTAL|Echinaforce Junior Tablets|Hydroalcoholic extract of Echinacea purpurea herb and radix
62647939|NCT03085303|PLACEBO_COMPARATOR|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
62080052|NCT02971384|ACTIVE_COMPARATOR|Vitamin C Tablets|synthetically produced ascorbic acid
62080053|NCT06737471||Extensive rehabilitation treatment|A 3-hour weekly rehabilitation treatment is delivered to each patient in an outpatient setting for 15 weeks.
62647940|NCT05800678||nulliparous|"inclusion: reproductive age~exclusion: history of gynecological surgery or disorder with possible impact on pelvic floor"
62080054|NCT06737471||Intensive rehabilitation treatment|A 3-hour daily rehabilitation treatment is delivered to each patient in the care units of the Hospital for 5 weeks.
62080055|NCT04266093||Cohort 1|Subjects who have received treatment on an NCI CIO or CIO gene therapy protocol.
62080056|NCT05672849|EXPERIMENTAL|Modified Devices in fetoscopic NTD repair|Single arm study. All patients will undergo fetoscopic NTD repair with the use of the modified devices.
62080057|NCT05583448||ExploR Radial Head|Subjects who have received the ExploR Radial Head Device.
62080058|NCT00001813||1|Subjects with clinical and/or laboratory documentation of typical features or suggestiveclinical features of XP, CS, TTD, or overlap syndromes
62080059|NCT00001813||2|Family members of patients with XP, CS, TTD, or overlap syndromes
62080060|NCT00001813||3|Healthy volunteers
62080061|NCT05870787||Swede score colposcopy|Swede score colposcopy: includes application with acetic acid, supplemented with a systematic scoring system (the Swede score) including Lugols iodine, and collection of cervical biopsies.
62080062|NCT05870787||Conventional colposcopy|Conventional colposcopy: includes application with acetic acid and collection of cervical biopsies.
62080063|NCT02548559|EXPERIMENTAL|Full-Spectrum Cannabidiol|1 ml of full-spectrum sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
62080064|NCT02548559|EXPERIMENTAL|Single-Compound Cannabidiol|1 ml of single-compound sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
62647941|NCT05800678||primiparous|"Inclusion: reproductive age, vaginal birth~exclusion:~* history of gynecological surgery or disorder with possible impact on pelvic floor~* assisted vaginal delivery (forceps, vaccumextraction)~* labour induction~* pregnancy-related disorders~* perineal tear grade III-IV (women with episiotomy were included)~* suspicion of LAM avulsion by ultrasound or palpation~* Oxford score 4 or 5 after delivery"
62647942|NCT06545305||Patients with Homocystinuria|Homocystinuria patients with Ocular complications
62647943|NCT06071416|ACTIVE_COMPARATOR|Group 1 BCP alone|Lateral bone augmentation with biphasic calcium phosphate BCP bone substitute application
62647944|NCT06071416|ACTIVE_COMPARATOR|Group 2 BCP with I-PRF|Lateral bone augmentation with biphasic calcium phosphate BCP bone substitute application with addition of injectable platlet rich fibrin I-PRF
62647945|NCT00792181|EXPERIMENTAL|1|Medical intervention - with benzodiazepines (Midazolam).
62647946|NCT00792181|EXPERIMENTAL|2|Course intervention - a professional development course for caregivers.
62647947|NCT00792181|EXPERIMENTAL|3|Combination of both medical interventions and a professional development course for caregivers.
62647948|NCT00792181|NO_INTERVENTION|4|No intervention at all = a control group
62647949|NCT05782517|EXPERIMENTAL|I-gel|
62457692|NCT02802436|EXPERIMENTAL|Extraction with socket graft and GEM21|"Intervention - Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Test site (active arm) will be injected with Bioactive Agent (PDGF - Platelet derived growth factor). At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd.~Bioactive agent - GEM21S (Growth factor enhanced matrix) Dosage - one cup containing 0.5 cc of ß-TCP particles (0.25 to 1.0 mm); and one syringe containing a solution of 0.5 mL rhPDGF-BB (0.3 mg/mL)"
62647950|NCT05782517|ACTIVE_COMPARATOR|Endotracheal Tube|
62647951|NCT00183079|ACTIVE_COMPARATOR|1|Brief, motivationally-focused alcohol intervention
62647952|NCT02215902|EXPERIMENTAL|Hemopurifier|Affinity plasmapheresis
62647953|NCT00096213|OTHER|surgery|intralesional resection
62647954|NCT02452047|EXPERIMENTAL|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations \>21 days may be approved by the Sponsor for participants requiring longer treatment duration.
62647955|NCT02452047|ACTIVE_COMPARATOR|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations \>21 days may be approved by the Sponsor for participants requiring longer treatment duration.
62647956|NCT02452047|EXPERIMENTAL|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations \>21 days may be approved by the Sponsor for participants requiring longer treatment duration.
62080065|NCT02548559|PLACEBO_COMPARATOR|Placebo|1 ml of placebo solution administered three times per day (TID) for four weeks.
62080066|NCT06738706|EXPERIMENTAL|Intermittent Hypoxia-Hyperoxia Training|Participants will receive 14 times intermittent hypoxia-hyperoxia training interventions within 2 to 3 weeks.
62457693|NCT02802436|OTHER|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Normal saline will be used and no growth factor to maintain the volume in control sites
62457694|NCT01967108|EXPERIMENTAL|chest physiotherapy|chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more.
62080067|NCT01295346||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
62080068|NCT00656461|EXPERIMENTAL|1|
62080069|NCT02348437|EXPERIMENTAL|Repair|Repair of the pronator quadratus muscle
62457695|NCT01967108|NO_INTERVENTION|control group|This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration
62457696|NCT01402908|EXPERIMENTAL|PI-88|Arm 1
62457697|NCT01402908|PLACEBO_COMPARATOR|Placebo|Arm 2
62457698|NCT03160677|EXPERIMENTAL|Intensive blood pressure management|
62457699|NCT03160677|ACTIVE_COMPARATOR|Standard blood pressure management|
62457700|NCT03622866|ACTIVE_COMPARATOR|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
62457701|NCT03622866|ACTIVE_COMPARATOR|Traditional pulse width|Traditional pulse width stimulation using the Algovita System
62457702|NCT02232100|EXPERIMENTAL|10AMG|Attentional bias modification group - 10 training sessions
62457703|NCT02232100|PLACEBO_COMPARATOR|10ACG|Attentional control group - 10 placebo sessions
62457704|NCT02232100|EXPERIMENTAL|18AMG|Attentional bias modification group - 18 training sessions
62080070|NCT02348437|ACTIVE_COMPARATOR|Non-repair|Non-repair of the pronator quadratus muscle
62080071|NCT06739564|EXPERIMENTAL|Dry needling|Dry needling on lower limbs
62080072|NCT06739564|EXPERIMENTAL|Ice packing|ice packing on lower limbs
62080073|NCT06739564|NO_INTERVENTION|controls|control group
62647957|NCT04960787|ACTIVE_COMPARATOR|Group I (usual care)|"Patients receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.~If participating, spouse/partner caregivers will receive the same intervention, and will complete questionnaires and have credit reports assessed at baseline and 3, 6, and 12 months."
62647958|NCT04960787|EXPERIMENTAL|Group II (financial navigation intervention)|"Patients receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients also meet with CENTS counselor and PAF case manager over approximately 1 hour every month for 6 months (with each group). Patients also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.~If participating, spouse/partner caregivers will receive the same intervention, and will complete questionnaires and have credit reports assessed at baseline and 3, 6, and 12 months."
62647959|NCT04758455|EXPERIMENTAL|P53 IHC|P53 staining density and intensity will be calculated. To assess P53 density in a semiquantitative way, a score of 0 will be given assigned if less than 5% of tumour cells expressed p53, 1 if 5% to 50% expressed p53 and 2 if more than 50% stained positive for p53. To evaluate P53 intensity, a score of 0 means weak or absent staining, 1 refers to the intermediate intensity and 2 stands for strong intensity.
62647960|NCT04758455|EXPERIMENTAL|Ki67 IHC|Ki67 proliferation index will be used to detect rapidly proliferating cells which means the percentage of positive Ki67 cells over 5 high power fields. It will be semiquantitatively graded as low, moderate, or high and correlated with histological staging.
62647961|NCT04758455|EXPERIMENTAL|Cyclin A IHC|Regarding Cyclin A, a standard peroxidase-conjugated streptavidin-biotin labelling was used for visualization, with 3,3 diaminobenzidine as chromogen. Level of cyclin A expression will be classified as absent (-), focal (+), moderate (++) diffuse (+++).
62647962|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
62080074|NCT04769713|EXPERIMENTAL|Hepatic hilar nerve block in ablation patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
62080075|NCT04769713|PLACEBO_COMPARATOR|Placebo procedure in ablation patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
62080076|NCT04769713|EXPERIMENTAL|Hepatic hilar nerve block in chemoembolization patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
62080077|NCT04769713|PLACEBO_COMPARATOR|Placebo procedure in chemoembolization patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
62080078|NCT06393127|EXPERIMENTAL|BI 1015550 Formulation C2 (T) then BI 1015550 Formulation C1 (R)|
62080079|NCT06393127|EXPERIMENTAL|BI 1015550 Formulation C1 (R) then BI 1015550 Formulation C2 (T)|
62080080|NCT06237309|EXPERIMENTAL|Part A1 High Dose|Single ascending dose cohort
62080081|NCT06237309|EXPERIMENTAL|Part A1 Low Dose|Single ascending dose cohort
62080082|NCT06237309|EXPERIMENTAL|Part A1 Optional|Single ascending dose cohort
62080083|NCT06237309|EXPERIMENTAL|Part A2 High Dose, sacubitril-valsartan group|Single ascending dose cohort
62080084|NCT06237309|EXPERIMENTAL|Part A2 Low Dose, sacubitril-valsartan group|Single ascending dose cohort
62080085|NCT06237309|PLACEBO_COMPARATOR|Placebo for Part A2, sacubitril-valsartan group|
62080086|NCT06237309|EXPERIMENTAL|Part A2 High Dose, Low estimated glomerular filtration rate (eGFR) group|Single ascending dose cohort
62080087|NCT06237309|EXPERIMENTAL|Part A2 Low Dose, Low eGFR group|Single ascending dose cohort
62080088|NCT06237309|PLACEBO_COMPARATOR|Placebo for Part A2, Low eGFR group|
62080089|NCT06237309|EXPERIMENTAL|Part B High Dose|
62080090|NCT06237309|EXPERIMENTAL|Part B Low Dose|
62080091|NCT06237309|PLACEBO_COMPARATOR|Part A1 and Part B Placebo Only|
62080092|NCT03989089|EXPERIMENTAL|Pembrolizumab single agent|Pembrolizumab 200 mg will be given intravenously every 3 weeks , on Day 1 on each 3 week cycle. Pembrolizumab can be given up to 35 adminstration (2 years).
62080093|NCT00967174|EXPERIMENTAL|Three Treatments Applied to Lower Back|Treatments were applied on the lower back, according to treatment sequence, daily for 21 days.
62457705|NCT02232100|PLACEBO_COMPARATOR|18ACG|Attentional control group - 18 placebo sessions
62080094|NCT06527430|ACTIVE_COMPARATOR|Spinal anesthesia with 4 mg bupivacaine|After the patients are monitored, they will be placed in the lateral decubitus position. After appropriate field sterilization, patients will undergo unilateral spinal anesthesia with 4 mg bupivacaine. At the fifth minute after spinal anesthesia, patients will be placed in the supine position.
62647963|NCT02896348|EXPERIMENTAL|SynPhNe therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system."
62080095|NCT06527430|ACTIVE_COMPARATOR|Spinal anesthesia with 6 mg bupivacaine|After the patients are monitored, they will be placed in the lateral decubitus position. After appropriate field sterilization, patients will undergo unilateral spinal anesthesia with 6 mg bupivacaine. At the fifth minute after spinal anesthesia, patients will be placed in the supine position.
62080096|NCT02490696|EXPERIMENTAL|Miso|In this arm two PET scans wiil be realized. The first one will be made with F-Miso tracer. 24 hours later the FAZA PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
62647964|NCT02896348|ACTIVE_COMPARATOR|Conventional therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage."
62647965|NCT01525797||Control|
62647966|NCT01525797||Rejection|
62647967|NCT03555552|EXPERIMENTAL|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
62647968|NCT03555552|ACTIVE_COMPARATOR|Duke Central Automated Laboratory (DCAL)|
62647969|NCT06390098|EXPERIMENTAL|ASN51|
62647970|NCT06502548|OTHER|Patient with endometriosis|Endometriosis patients will be operated on as part of their pathology.
62647971|NCT06502548|OTHER|Healthy control patient|Healthy patients will be operated for tubal ligation or hysterectomies.
62080097|NCT02490696|EXPERIMENTAL|FAZA|In this arm two PET scans wiil be realized. The first one will be made with FAZA tracer. 24 hours later the F-Miso PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
62080098|NCT00904228|EXPERIMENTAL|Plastic Cap|Plastic lined stockinet cap (polyethylene bag)
62457706|NCT00771537|NO_INTERVENTION|Arm 1. Control PLUS Control|
62080099|NCT00904228|ACTIVE_COMPARATOR|Stockinet Cap|Usual practice
62457707|NCT00771537|EXPERIMENTAL|Arm 2. Control PLUS 1-Sided|No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
62080100|NCT06738758||Intensive treatment group|patients were treated with PCSK9 inhibitors (with or without statins)
62080101|NCT06738758||Conventional combination therapy group|patients were treated with statin ＋ ezetimibe
62080102|NCT06738758||control group|patients were treated with statin only
62457708|NCT00771537|EXPERIMENTAL|Arm 3. Control PLUS 2-Sided Trivial|No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
62080103|NCT03873246|ACTIVE_COMPARATOR|OC-01 0.1%, 0.6 mg/ml|OC-01 (varenicline) nasal spray, 0.6 mg/mL
62080104|NCT03873246|ACTIVE_COMPARATOR|OC-01 0.2%, 1.2 mg/ml|OC-01 (varenicline) nasal spray, 1.2 mg/mL
62080105|NCT03873246|PLACEBO_COMPARATOR|Placebo|vehicle control
62080106|NCT01038674|EXPERIMENTAL|Anti-IL-20|
62080107|NCT01038674|PLACEBO_COMPARATOR|Placebo|
62080108|NCT06740526|EXPERIMENTAL|Sibeprenlimab|
62080109|NCT06738160|EXPERIMENTAL|Nalusobasumab + SBRT + chemotherapy + immunotherapy|
62080110|NCT06738199|EXPERIMENTAL|glycoprotein matrix iron|Acute glycoprotein matrix iron was ingested to assess blood appearance levels from pre and at 30-, 60-, 90-, 120-, 180-, 240-, 300-, 360-, 420-, and 480-minutes post-ingestion.
62080111|NCT06738199|EXPERIMENTAL|ferrous bisglycinate chelate iron|Acute ferrous bisglycinate chelate iron was ingested to assess blood appearance levels from pre and at 30-, 60-, 90-, 120-, 180-, 240-, 300-, 360-, 420-, and 480-minutes post-ingestion.
62080112|NCT06738199|EXPERIMENTAL|ferrous fumarate iron|Acute ferrous fumarate iron was ingested to assess blood appearance levels from pre and at 30-, 60-, 90-, 120-, 180-, 240-, 300-, 360-, 420-, and 480-minutes post-ingestion.
62080113|NCT04860843|EXPERIMENTAL|Local anesthetic TPVB + Local anesthetic Pecs block|Patients will receive a thoracic paravertebral with pecs block, both with local anesthetic infiltrate.
62080114|NCT04860843|SHAM_COMPARATOR|Local anesthetic TPVB + Sham Pecs block|Patients will receive a thoracic paravertebral with local anesthetic infiltrate and a pecs block with saline infiltrate.
62080115|NCT06739070|EXPERIMENTAL|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.
62080116|NCT06739070|EXPERIMENTAL|Plyometric|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
62080117|NCT06739070|OTHER|Control|compare with other groups
62080118|NCT01115023|EXPERIMENTAL|iron group|This group received an iron cooking pot for daily household cooking as an intervention
62080119|NCT01115023|NO_INTERVENTION|Aluminium group|the subjects in this group were asked to continue cooking in the aluminium pot and not to cook in the iron pot if they possessed one.
62080120|NCT02651285|EXPERIMENTAL|G-CSF|The embryos obtained with IVF in patients included iin this arm will be incubated after fertilization with medium supplemented with G-CSF
62080121|NCT02651285|PLACEBO_COMPARATOR|CONTROL|The embryos obtained by women undergoing IVF included in this arm will be incubated with a standard medium for IVF, and utilized as control group.
62457709|NCT00771537|EXPERIMENTAL|Arm 4. Control PLUS 2-Sided Major|No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
62457710|NCT00771537|EXPERIMENTAL|Arm 5. 1-Sided PLUS Control|1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
62080122|NCT06139263|ACTIVE_COMPARATOR|Control Group|All individuals participating in the study will receive a conventional treatment program 4 days a week. In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
62080123|NCT06139263|EXPERIMENTAL|Vibration Group|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
62080124|NCT06676540|ACTIVE_COMPARATOR|Neurodevelopmental Therapy (NDT)|The Neurodevelopmental Therapy (NDT) treatment program, which was determined by the physiotherapist to be individual and suitable for the needs of the cases in both groups participating in the study, will continue throughout the study, with 2 sessions per week and 40 minutes each session. The orthoses and assistive devices used by the cases will continue to be used without any changes and no changes will be made to the treatment program.
62457711|NCT00771537|EXPERIMENTAL|Arm 6. 1-Sided PLUS 1-Sided|1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
62647972|NCT01244867|EXPERIMENTAL|20 microgram H5 VLP vaccine + Alhydrogel|
62647973|NCT01244867|EXPERIMENTAL|30 micrograms H5 VLP vaccine + Alhydrogel|
62080125|NCT06676540|EXPERIMENTAL|Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)|The subjects in the study group will be applied NDT 20 minutes twice a week, each session lasting 40 minutes, and in addition, an eccentric exercise program of 20 minutes will be applied in each session. For eccentric exercise training, a functional eccentric exercise program will be applied especially for the hip flexor (m. iliopsoas, m. rectus femoris) muscle group, which is the most common and intense spasticity seen in the lower extremities, hip adductors (m. adductor magnus and minimus, m. adductor longus and brevia, m. pectineus, m. gracillis), knee flexors (m. semitendinosus, m. semimembranouzsu, m. biceps femoris) and plantar flexors (m. gastrocnemius, m. soleus and m. tibialis posterior). If the orthosis used by the individual is applied during the eccentric exercise program, it will be removed.
62080126|NCT06740487|ACTIVE_COMPARATOR|Traditional ET Treatment|The active comparator group receives traditional prolonged exposure therapy alone, delivered in 90 minute sessions over 10 days across 5-10 weeks (sessions to occur 1-2x/week, with weekends off). Participants in both groups will be advised to continue in vivo exposure to real life situations (grocery shopping, going out, going to gatherings, etc.) in-between the sessions.
62080127|NCT06740487|EXPERIMENTAL|ARET + Traditional ET Treatment|The experimental group receives prolonged exposure therapy delivered in 90 minute sessions over 10 days across 5-10 weeks (sessions to occur 1-2x/week, with weekends off). Participants receive ARET for 30 minutes of each 90-minute session, and wear AR goggles during exposure therapy to AR scenarios. Participants in both groups will be advised to continue in vivo exposure to real life situations (grocery shopping, going out, going to gatherings, etc.) in-between the sessions.
62457712|NCT00771537|EXPERIMENTAL|Arm 7. 1-Sided PLUS 2-Sided Trivial|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
62457713|NCT00771537|EXPERIMENTAL|Aim 8. 1-Sided PLUS 2-Sided Major|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
62080128|NCT06290102|EXPERIMENTAL|Sequence 1|
62080129|NCT06290102|EXPERIMENTAL|Sequence 2|
62080130|NCT06290102|EXPERIMENTAL|Sequence 3|
62457714|NCT00771537|EXPERIMENTAL|Arm 9. 2-Sided Trivial PLUS Control|2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
62080131|NCT06290102|EXPERIMENTAL|Sequence 4|
62080132|NCT06290102|EXPERIMENTAL|Sequence 5|
62080133|NCT06290102|EXPERIMENTAL|Sequence 6|
62080134|NCT05239793|OTHER|NJOY e-cigarette|NJOY e-cigarette containing 5% nicotine strength pods
62457715|NCT00771537|EXPERIMENTAL|Arm 10. 2-Sided Trivial PLUS 1-Sided|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
62457716|NCT00771537|EXPERIMENTAL|Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
62080135|NCT06731049|ACTIVE_COMPARATOR|Treadmill Based Training Group|In the study, for 8 weeks, the Treadmill-based Training Group will undergo walking training on a treadmill two days a week.
62080136|NCT06731049|EXPERIMENTAL|Dual-Task Treadmill Based Training Group|Dual-Task Treadmill-based Training Group will receive dual-task walking training involving both motor and cognitive tasks on the treadmill for 8 week, two days in a week.
62457717|NCT00771537|EXPERIMENTAL|Arm 12. 2-Sided Trivial PLUS 2-Sided Major|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
62457718|NCT00771537|EXPERIMENTAL|Arm 13. 2-Sided Major PLUS Control|2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
62457719|NCT00771537|EXPERIMENTAL|Arm 14. 2-Sided Major PLUS 1-Sided|2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
62457720|NCT00771537|EXPERIMENTAL|Arm 15. 2-Sided Major PLUS 2-Sided Trivial|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
62457721|NCT00771537|EXPERIMENTAL|Arm 16. 2-Sided Major PLUS 2-Sided Major|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
62457722|NCT05194748||camptocormia group|Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
62647974|NCT01244867|EXPERIMENTAL|45 micrograms H5 VLP vaccine + Alhydrogel|
62647975|NCT01244867|EXPERIMENTAL|45 micrograms H5 VLP vaccine|
62080137|NCT04674969||Clinical Cohort|All enrolled patients are included in the Clinical Cohort. Patients will complete assessments per standard of care through 2-year follow-up in Australia, Austria, Canada, France, Germany, Poland, Spain, Taiwan, Thailand, and the United States. Patients will complete assessments per standard of care through 5-year follow-up in China.
62080138|NCT04674969||Outcomes Cohort|Patients at select sites will complete the Clinical Cohort standard of care assessments and additional assessments as part of the Outcomes Cohort, including Quality of Life questionnaires, six-minute walk test (6MWT), and Healthcare Utilization data collection.
62080139|NCT05746429|EXPERIMENTAL|Arm I (mobile CBT + active tDCS)|Participants receive mobile CBT and undergo active tDCS to the dorsolateral prefrontal cortex (DLPFC) over 20 minutes twice a week for 6 weeks.
62080140|NCT05746429|SHAM_COMPARATOR|Arm II (mobile CBT + sham tDCS)|Participants receive mobile CBT and undergo sham tDCS to the DLPFC over 20 minutes twice a week for 6 weeks.
62080141|NCT05746429|EXPERIMENTAL|Interview|Participants attend virtual meetings and virtual focus groups during the cultural adaptation phase. Feedback is collected and analyzed to develop the finalized adaptation.
62080142|NCT06697197|EXPERIMENTAL|Part 1A|
62457723|NCT05194748||no camptocormia group|Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
62457724|NCT02356471|EXPERIMENTAL|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
62457725|NCT02445664|EXPERIMENTAL|Video intervention|A tablet-administered educational video (10 minutes duration).
62647976|NCT01244867|PLACEBO_COMPARATOR|Placebo|
62080143|NCT06697197|EXPERIMENTAL|Part 1B1|
62080144|NCT06697197|EXPERIMENTAL|Part 1B2|
62080145|NCT06697197|EXPERIMENTAL|Part 1B3|
62080146|NCT06697197|EXPERIMENTAL|Part 1C|
62080147|NCT06697197|EXPERIMENTAL|Part 2A|
62080148|NCT06697197|EXPERIMENTAL|Part 2B1|
62080149|NCT06697197|EXPERIMENTAL|Part 2B2|
62080150|NCT06697197|EXPERIMENTAL|Part 2B3|
62080151|NCT05511740|NO_INTERVENTION|Morning Radiation|
62457726|NCT02445664|NO_INTERVENTION|Control|No intervention (no video)
62457727|NCT02583503||Hindfoot alignment view x ray|Patients undergoing TKR for osteoarthritis will have an additional x ray (hindfoot alignment view) as well as the standard hip knee ankle x ray extended to include the heel.
62457728|NCT05083299||Anpl-one SR Tablet|Patients who prescribed Anpl-one SR Tablet
62647977|NCT01880606||patients with PSC-IBD|Only patients, colonoscopy with endomicroscopy
62647978|NCT05673395|EXPERIMENTAL|EARW group|This group drink electrolyzed alkaline reduced water (EARW, pH 9.5) 10 mL/kg body weight in 10 min after exercise.
62080152|NCT05511740|ACTIVE_COMPARATOR|Afternoon Radiation|
62080153|NCT02991690|EXPERIMENTAL|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
62080154|NCT02991690|NO_INTERVENTION|Control|Standard of care medical treatment, specific to each individual.
62080155|NCT06741293||Control group|Healthy participants with a negative colonoscopy result
62080156|NCT06741293||Colorectal cancer|Participants with colorectal cancer diagnosis confirmed by colonoscopy
62080157|NCT06741293||Low-risk polyps|Participants with positive colonoscopy and detection of low-risk adenomas
62080158|NCT06741293||High-risk polyps|Participants with positive colonoscopy and detection of high-risk adenomas
62080159|NCT06738420|EXPERIMENTAL|ABB S3 - active|Postbiotic ABB S3 for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
62080160|NCT06738420|PLACEBO_COMPARATOR|ABB S3 - Placebo|Placebo for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
62080161|NCT06738420|EXPERIMENTAL|ABB C22 - active|Oral Rehydration Solution containing postbiotics ABB C22 for the management of diarrhoea signs of dehydration
62080162|NCT06738420|PLACEBO_COMPARATOR|ABB C22 - placebo|Oral Rehydration Solution containing placebo for the management of diarrhoea signs of dehydration
62080163|NCT02262260|EXPERIMENTAL|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
62457729|NCT01259869|EXPERIMENTAL|PX-866|
62457730|NCT05925595|EXPERIMENTAL|Experimental Arm|Arm: Medical Device Iniettabile Ginocchio
62457731|NCT05925595|ACTIVE_COMPARATOR|Comparator Arm|Arm: Medical Device Jonexa (active comparator medical device from the market )
62457732|NCT01975064|ACTIVE_COMPARATOR|Propofol|Propofol for maintenance of anesthesia
62457733|NCT01975064|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane for maintenance of anesthesia
62457734|NCT01586247|EXPERIMENTAL|Synbiotic|8g/day gluco-oligosaccharide + 109 CFU/day B. lactis BI07
62457735|NCT01586247|EXPERIMENTAL|Placebo|8g/day maltodextrin
62457736|NCT01586247|EXPERIMENTAL|Prebiotic|8g/day galacto-oligosaccharides (GOS)
62457737|NCT01586247|EXPERIMENTAL|Probiotic|109 CFU/day B. lactis BI07
62647979|NCT05673395|SHAM_COMPARATOR|PW group|PW is purified water generated from sham device, and PW group drink 10 mL/kg body weight in 10 min after exercise.
62080164|NCT02262260|EXPERIMENTAL|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
62080165|NCT06241703|EXPERIMENTAL|ICCAUT Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will undergo bladder training. The bladder training include intermittent catheter clamping and active urination to facilitate complete bladder emptying each time the catheter is released, which we called ICCAUT strategy. The training will commence at 9:00 am on the first postoperative day, and the catheter will be removed at 9:00 am on the second postoperative day after the bladder is empty.
62080166|NCT06241703|OTHER|Free Drainage Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will have their urinary catheter kept open postoperatively, and the catheter will be removed at 9:00 am on the second postoperative day.
62080167|NCT06737926|EXPERIMENTAL|Group A: Experimental Group receiving Sensorimotor Training Exercise.|Participants will undergo sensorimotor training exercises targeting balance, pain reduction, and functional exercise capacity.
62647980|NCT04163874|EXPERIMENTAL|Fiasp-plus-Placebo with Full Carbohydrate Counting|Fiasp insulin and placebo insulin infusion in two insulin pumps with full carbohydrate counting.
62647981|NCT04163874|PLACEBO_COMPARATOR|Fiasp-plus-placebo with Simple Meal Announcement|Fiasp insulin and placebo (saline) insulin infusion in two insulin pumps using the simple meal announcement system.
62080168|NCT06737926|ACTIVE_COMPARATOR|Group B: Control Group receiving Conventional Exercise Therapy.|Participants will receive conventional exercise therapy as per standard guidelines.
62080169|NCT06740253|EXPERIMENTAL|Placebo IVR|Participants will use a placebo IVR for 14 days.
62080170|NCT05646979|EXPERIMENTAL|Experimental group|EFT application will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
62080171|NCT05646979|NO_INTERVENTION|Control group|Women in the control group who will have a cesarean section at 32-38 weeks of gestation will not be interfered with.
62080172|NCT06690424|EXPERIMENTAL|group R|This group is the experimental group with remimazolam for anesthesia induction and maintenance
62080173|NCT06690424|ACTIVE_COMPARATOR|group P|This group is the control group with propofol for anesthesia induction and maintenance
62080174|NCT06740370|EXPERIMENTAL|TACE plus Lenvatinib and PD-1 inhibitor|TACE was first performed, then Lenvatinib and PD-1 inhibitor were administered within seven days.
62080175|NCT00615433|EXPERIMENTAL|Lurasdione 40mg tablets|
62080176|NCT00615433|EXPERIMENTAL|120mg|
62080177|NCT00615433|ACTIVE_COMPARATOR|15mg Olz|
62080178|NCT00615433|PLACEBO_COMPARATOR|Sugar pill|
62080179|NCT06737679|EXPERIMENTAL|Experimental group|"The experimental group will receive a body scan intervention. Body scan is a guided meditation technique that allows people to detect signs and signals from their body (for instance, heart rate).~The intervention will last 20 minutes and will be performed 21 consecutives days. The first and last days it will be performed in presence, while the other ones online."
62457738|NCT01469364|EXPERIMENTAL|Aztreonam Lysine for Inhalation (AZLI)|Patients to received Aztreonam Lysine(AZLI)
62647982|NCT04163874|ACTIVE_COMPARATOR|Fiasp-plus-Pramlintide with Simple Meal Announcement|Fiasp insulin and pramlintide insulin infusion in two insulin pumps using the simple meal announcement system.
62647983|NCT05406323|EXPERIMENTAL|Web-Based Fall Prevention Program Intervention|Participants in this group will receive a 6-week Web-Based Fall Prevention Program intervention, comprising of health education, exercise and safe home environment. Web-Based Fall Prevention Program will be conducted on web based (Web - Based Fall Prevention Program website)
62457739|NCT02294812|ACTIVE_COMPARATOR|Control, cognitive training|Participants in the control arm will receive cognitive training for cognitive abilities not affected by age-related hearing loss.
62647984|NCT05406323|NO_INTERVENTION|Control Group|The control group will not receive any intervention during the study. Participants in the control group will take the same program after the study is complete.
62647985|NCT05670444|ACTIVE_COMPARATOR|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
62080180|NCT06737679|NO_INTERVENTION|Control group|The control group will not receive the intervention, but only standard care
62080181|NCT06737250|EXPERIMENTAL|NB02 (Poseltinib) combined Rituximab and Lenalidomide|
62457740|NCT02294812|EXPERIMENTAL|Experimental, cognitive training|Participants in the experimental arm will receive cognitive training for cognitive abilities affected by age-related hearing loss.
62080182|NCT06738524|EXPERIMENTAL|Education|"The intervention group was given Fighting with Digital Addiction training."
62647986|NCT05670444|PLACEBO_COMPARATOR|placebo|Patients from the placebo group received three similar pills
62080183|NCT06293911|EXPERIMENTAL|Postbiotic group|
62080184|NCT06293911|ACTIVE_COMPARATOR|Placebo group|
62080185|NCT01689740|EXPERIMENTAL|Lead in: 125 mg MDMA (Open Label)|Participants receive open-label MDMA with an initial dose of 125 mg, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
62080186|NCT01689740|PLACEBO_COMPARATOR|Active placebo dose MDMA (25 mg)|Participants receive initial dose of 25 mg MDMA, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
62080187|NCT01689740|EXPERIMENTAL|Full dose MDMA (125 mg)|Participants receive initial dose of 125 mg MDMA, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
62080188|NCT04678336|EXPERIMENTAL|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
62080189|NCT02671721|NO_INTERVENTION|Conventional Strategy|Patients will receive usual and prudent PEEP and tidal volume settings.
62647987|NCT01764412||Healthy women|Non interventional
62647988|NCT04344717|EXPERIMENTAL|Anticoagulation and teduglutide naive short bowel syndrome|Apixaban-, vitamin K antagonist- and teduglutide naive patients with short bowel syndrome requiring long term parenteral support
62647989|NCT04344717|EXPERIMENTAL|Healthy volunteers|Apixaban- and vitamin K antagonist naive healty volunteers
62647990|NCT04344717|OTHER|Short bowel syndrome on apixaban|Patients with short bowel syndrome requiring long term parenteral support and taking apixaban 2.5 mg twice daily or 5 mg twice daily
62647991|NCT04344717|OTHER|Patients with a normal gastrointestinal tract on apixaban|Patients with a normal gastrointestinal tract taking apixaban 2.5 mg twice daily or 5 mg twice daily
62647992|NCT04344717|EXPERIMENTAL|Anticoagulation naive short bowel syndrome on teduglutide|Apixaban- and vitamin K antagonist naive patients with short bowel syndrome requiring long term parenteral support and initiated on teduglutide
62080190|NCT02671721|EXPERIMENTAL|Maximal Compliance Strategy|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
62647993|NCT06227169|EXPERIMENTAL|Community mental health clinician training cohort 1|In this stepped wedge design, cohorts of community-based clinicians receive a training in how to conduct an evidence-based cognitive behavioral intervention in suicide prevention for justice-involved youth. There are 15 clinicians in each training cohort.
62647994|NCT06227169|EXPERIMENTAL|Community mental health clinician training cohort 2|In this stepped wedge design, cohorts of community-based clinicians receive a training in how to conduct an evidence-based cognitive behavioral intervention in suicide prevention for justice-involved youth. There are 15 clinicians in each training cohort.
62647995|NCT06227169|EXPERIMENTAL|Community mental health clinician training cohort 3|In this stepped wedge design, cohorts of community-based clinicians receive a training in how to conduct an evidence-based cognitive behavioral intervention in suicide prevention for justice-involved youth. There are 15 clinicians in each training cohort.
62647996|NCT02404571|EXPERIMENTAL|GDP chemotherapy|GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
62647997|NCT05771467||Trauma Group|Non-Trauma Eye After Open-Globe Injury
62647998|NCT05771467||Control Group|Age-, sex-matched healthy volunteers
62647999|NCT03980067|EXPERIMENTAL|Virtual Reality Group|The children in the experimental group will receive the standard of care (access to in room activity including television (TV) distraction if desired, parent support and distraction at bedside, and quiet time) in addition to our intervention, an interactive virtual reality game, played for a minimum of 5 minutes prior to procedural sedation.
62648000|NCT03980067|NO_INTERVENTION|Standard of Care|The children in the control group receiving standard of care will have access to in room activity including TV distraction if desired, parent support and distraction at bedside, and quiet time.
62648001|NCT01917643||Symbicort|BFC patients new to ICS/LABA and LAMA therapies
62648002|NCT01917643||Spiriva|Tiotropium bromide patients new to ICS/LABA and LAMA therapies
62648003|NCT04873726|NO_INTERVENTION|Pre: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
62648004|NCT04873726|NO_INTERVENTION|Pre: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
62648005|NCT04873726|NO_INTERVENTION|Pre: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
62648006|NCT04873726|EXPERIMENTAL|Post Exp: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
62648007|NCT04873726|EXPERIMENTAL|Post Exp: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
62648008|NCT04873726|EXPERIMENTAL|Post Exp: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
62080191|NCT02671721|EXPERIMENTAL|Transpulmonary Pressure Strategy|Personal PEEP titration using transpulmonary pressures obtained from a naso/orogastric tube containing an esophageal balloon port
62648009|NCT04873726|PLACEBO_COMPARATOR|Post Pla: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
62648010|NCT04873726|PLACEBO_COMPARATOR|Post Pla: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
62648011|NCT04873726|PLACEBO_COMPARATOR|Post Pla: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
62080192|NCT06185946||ultrasonography group|
62080193|NCT06185946||mammoragraphy group|patient with ultrasoundy only
62080194|NCT06185946||CT group|pateint with postive node undergo further staging
62080195|NCT06185946||MRI group|patient whit postive node with staging
62648012|NCT00834041|EXPERIMENTAL|Aliskiren 2 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
62648013|NCT00834041|EXPERIMENTAL|Aliskiren 6 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning
62648014|NCT04306523||Observational Cohort|One group of 100 sets of twin infants, observed from 4 months of age until 2years of age.
62648015|NCT01465672||neurosurgical patients|Patients undergoing transphenoidal pituitary adenoma resection and patients with transcranial surgery of tumors close to the pituitary gland and hypothalamus.
62648016|NCT04032132|EXPERIMENTAL|curcumin paste in conjunction with open flap debridement surge|curcumin paste (2% circumin) in conjunction with open flap debridement surgery
62648017|NCT04032132|PLACEBO_COMPARATOR|open flap debridement surgery only|surgical treatment for periodontal pocket
62648018|NCT00288912|ACTIVE_COMPARATOR|Health Education Intervention|Health Education Intervention
62648019|NCT00288912|NO_INTERVENTION|Usual Medical Care|Usual Medical Care
62648020|NCT00288912|EXPERIMENTAL|Osteoarthritis Self-Management|Osteoarthritis Self-Management
62648021|NCT04574518|EXPERIMENTAL|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
62648022|NCT04574518|OTHER|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
62648023|NCT03587233|ACTIVE_COMPARATOR|Women with higher professional status|"Women with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
62648024|NCT03587233|ACTIVE_COMPARATOR|Women with lower professional status|"Women with lower professional status in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
62648025|NCT03587233|ACTIVE_COMPARATOR|Men with higher professional status|"Men with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
62648026|NCT03587233|ACTIVE_COMPARATOR|Men with lower professional status|"Men with lower professional status working in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form' and the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
62080196|NCT06740630|EXPERIMENTAL|VNS_Lot 1 Group|Participants receive 1 dose of the investigational VNS vaccine of Lot 1, 1 dose of measles, mumps, and rubella (MMR) vaccine, 1 dose of hepatitis A vaccine (HAV), and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
62080197|NCT06740630|EXPERIMENTAL|VNS_Lot 2 Group|Participants receive 1 dose of the investigational VNS vaccine of Lot 2, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
62080198|NCT06740630|EXPERIMENTAL|VNS_Lot 3 Group|Participants receive 1 dose of the investigational VNS vaccine of Lot 3, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
62080199|NCT06740630|ACTIVE_COMPARATOR|VV_Lot 1 Group|Participants receive 1 dose of a marketed varicella vaccine (VV) of Lot 1, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
62080200|NCT06740630|ACTIVE_COMPARATOR|VV_Lot 2 Group|Participants receive 1 dose of a marketed VV of Lot 2, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
62080201|NCT05792839|ACTIVE_COMPARATOR|Concomitant abdominoplasty with ventral hernia repair .|We do abdominoplasty with concomitant repair of the hernial defect and abdominal wall muscles in the same setting.
62457741|NCT02294812|ACTIVE_COMPARATOR|Active Control, crossword training|Participants in this group will undergo crossword puzzle training. The purpose of this group is control for any effects that may be due to engaging in cognitive training.
62457742|NCT05198050|ACTIVE_COMPARATOR|single dose letrozole tablets|starting from the first of January, patients will receive a single dose of letrozole (20 mg) two days, before starting misoprostol administration. Placebo tables with a similar appearance to letrozole will be administered the day before misoprostol administration and on the day of misoprostol administration.
62080202|NCT05792839|ACTIVE_COMPARATOR|Ventral Hernioplasty|We do hernioplasty with mesh placement for a surgical treatment for ventral hernia.
62080203|NCT02988206|OTHER|Personalized Objects|"The item Functional Object Use was assessed by using personalized objects (e.g., cigarette, paper) and non-personalized objects, which presented in a random order.."
62457743|NCT05198050|ACTIVE_COMPARATOR|multiple dose letrozole tablets|starting from the first of January, patients will receive 10 mg letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
62457744|NCT05198050|ACTIVE_COMPARATOR|misoprostol tablets|starting from the first of January, patients will receive placebo tablets with a similar appearance to letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
62457745|NCT02423902|EXPERIMENTAL|Ad-RTS-hIL-12 + Veledimex|Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
62457746|NCT06346210||Not tracheostomised|Invasively mechanically ventilated COVID-19 patients who did not receive a tracheostomy within 60 days from tracheal intubation.
62080204|NCT02988206|OTHER|non-personalized objects|"The item Functional Object Use was assessed by using non-personalized objects"
62080205|NCT06741332||Historical cohort|Control group selected retrospectively from each participating center
62080206|NCT06741332||Prospective cohort|Patients included prospectively after the integration of the Methinks Stroke Suit into the usual stroke care workflow of the participating centers
62080207|NCT03733093||1|HIV Positive
62080208|NCT03726021|EXPERIMENTAL|experimental arm|Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.
62080209|NCT06737705|NO_INTERVENTION|Control|Standardized treatment for respiratory protection and/or ALI after ICH according to the related guidelines.
62080210|NCT06737705|EXPERIMENTAL|Intervention Arm|Besides standardized treatment (background therapy) for respiratory protection and/or ALI after ICH according to the related guidelines, participants will receive additional baritinib administration.
62080211|NCT06739824|EXPERIMENTAL|Control Group|
62080212|NCT06739824|ACTIVE_COMPARATOR|EXP group|
62080213|NCT02850328|OTHER|high-load resistance training for long term space flights|"Short duration electrical will be delivered and the resulting EMG will be recorded. Intensity of electrical stimulation will be progressively increased until we observed a maximal EMG response.~Finally an ultrasound probe (similar to that used for prenatal diagnostic imaging) will be fixed behind your calf in order to visualize muscle."
62080214|NCT03481738||PKD Diagnosed|Participants diagnosed with PK deficiency by the presence of 2 or more PKLR gene mutations as well as clinical features.
62080215|NCT06737406|EXPERIMENTAL|A|5% fluorouracil cream + 0.005% calcipotriol ointment
62080216|NCT06737406|EXPERIMENTAL|B|5% fluorouracil cream + Placebo
62080217|NCT06737406|EXPERIMENTAL|C|0.005% calcipotriol ointment + Placebo
62080218|NCT04047004|EXPERIMENTAL|High-risk gastric cancer patients|The study population of high-risk gastric cancer patients will be offered one session of PIPAC immediately after laparoscopic removal of the stomach.
62080219|NCT06739551|ACTIVE_COMPARATOR|Oral methotrexate group (Group A)|Patients with generalized lichen planus will be given 10 mg per week
62080220|NCT06739551|ACTIVE_COMPARATOR|Oral Acitretin group (Group B)|Patients with generalized lichen planus will be given oral acitretin 50 mg once daily
62080221|NCT06738095|EXPERIMENTAL|red-light|Children with ultra-high myopia were treated with daily low-level red-light, which was used twice a day, with four hours interval. Three minutes for each session of treatment
62080222|NCT01621958|EXPERIMENTAL|Motor training|
62080223|NCT01621958|PLACEBO_COMPARATOR|Intensity control|
62080224|NCT06350097|EXPERIMENTAL|Arm 1: Osimertinib in combination with Datopotamab Deruxtecan|Participants in this group will receive osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion q3w of Day 1 of every 21-day cycle.
62648027|NCT03946423|EXPERIMENTAL|Sleeve Gastrectomy & Lifestyle Intervention|
62648028|NCT03946423|ACTIVE_COMPARATOR|Lifestyle Intervention|
62648029|NCT03496389|EXPERIMENTAL|Gabapentin + panadol|
62648030|NCT03496389|ACTIVE_COMPARATOR|Tramadol + panadol|
62080225|NCT06350097|ACTIVE_COMPARATOR|Arm 2: Osimertinib monotherapy|Participants in this group will receive osimertinib 80 mg QD as oral tablet.
62080226|NCT06187038|ACTIVE_COMPARATOR|Therapeutic exercise group|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. The therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
62080227|NCT06187038|EXPERIMENTAL|Therapeutic exercise group and pain neuroscience education program|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. The therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets. The chronic pain neuroscience education program will be based on three domains. Making sense of pain, exposure with control, and lifestyle changes.
62080228|NCT05479994|EXPERIMENTAL|Treatment Arm|Participants will receive BGB-11417 orally until disease progression, intolerable toxicity, or other scenarios specified in the protocol
62080229|NCT01851395||1/Thoracic|Patients with histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma
62080230|NCT01851395||2/Genitourinary|Patients with genitourinary malignancies
62080231|NCT01851395||3/ACT|Patients treated with an adoptive cellular therapy
62080232|NCT01851395||4/Ovarian|Patients with ovarian cancer
62080233|NCT01851395||5/Epithelial|Patients with breast, colorectal, pancreatic, stomach or biliary cancer.
62080234|NCT04416581|EXPERIMENTAL|P-CAB 50mg group|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
62080235|NCT04416581|ACTIVE_COMPARATOR|PPI group|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
62080236|NCT06696326|EXPERIMENTAL|68Ga-MY6349|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
62080237|NCT06657183|EXPERIMENTAL|Remote Monitoring with Smartpatch|Participants will be continuously monitored through the device, providing crucial physiological data. The Smartpatch will allow for early detection of chemotherapy-related toxicities.
62080238|NCT06739187|ACTIVE_COMPARATOR|Virtual reality|Participants will use the virtual reality during the standard dialysis session for 30 minutes, three times a week for 12 weeks.
62080239|NCT06739187|NO_INTERVENTION|Standard care|Participants will perform the standard dialysis session three times a week for 12 weeks without virtual reality training sessions.
62457747|NCT06346210||Tracheostomised|Invasively mechanically ventilated COVID-19 patients who did receive a tracheostomy within 60 days from tracheal intubation.
62648031|NCT02865161||NISELAT|Amtolmetin guacil should be taken in fasting conditions. The recommended dose is 600 mg b.i.d. Maximum daily dose - 1800 mg
62648032|NCT04692987|EXPERIMENTAL|Intervention|Participants will receive decision-aid video
62648033|NCT04692987|NO_INTERVENTION|Usual care|Participants will receive usual care
62080240|NCT05580640|EXPERIMENTAL|6 months + post knee surgery|: For study participation subjects need a history of unilateral knee arthroscopy or arthroplasty performed \> 6 months ago with completion of post-operative rehabilitation. Subjects will be between the ages of 21 and 90 years old and the ability to walk for 5-10 minutes on level ground.
62648034|NCT00549393|EXPERIMENTAL|1|Daily bathing with 2% chlorhexidine gluconate
62080241|NCT00471250||1|Healthy Volunteers
62080242|NCT00471250||2|NIH patients with known or suspected susceptibility to infection.
62080243|NCT00675545|EXPERIMENTAL|docetaxel and prednisolone|"Patients in study will receive both chemotherapeutic agents on day 1 and day 8 of every 21-day cycle as described below:~* Docetaxel 30 mg/m2 over 1 hour IV infusion, followed by~* Carboplatin (AUC 2) over 1 hour IV infusion~* Additonal medication required: IV Dexamethasone 10 mg followed by PO dexamethasone 4 mg 8 hourly x 4 doses, starting 12 hours after starting iv docetaxel."
62080244|NCT04134845|EXPERIMENTAL|Dantrolene/Ryanodex|Dantrolene/Ryanodex; intravenous administration of dantrolene; 1 mg/ kg IV over 3 minute, one time dose
62080245|NCT04134845|PLACEBO_COMPARATOR|Placebo|controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
62080246|NCT02438774|ACTIVE_COMPARATOR|Routine agriculture extension services|Routine agriculture extension services alone
62080247|NCT02438774|EXPERIMENTAL|Post-harvest intervention package|Post-harvest intervention package and routine agriculture extension services
62080248|NCT06292533|EXPERIMENTAL|Intervention Group|Ultrapulse treatment will be delivered by trained beautician for 6 sessions with 2 weeks interval. After the last session, participants will then follow up every 2 weeks for 1 month.
62648035|NCT00549393|NO_INTERVENTION|2|Standard bathing with soap and water basin or disposable cloth
62080249|NCT06292533|NO_INTERVENTION|Control-waitlist Group|Participants in control-waitlist group will receive homecare treatment that does not interfere with hair growth for 6 sessions with 2 weeks interval, follow up every 2 weeks for 1 month after last session and receive Ultrapulse treatment after the research end.
62080250|NCT00027690|EXPERIMENTAL|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62080251|NCT06741098|EXPERIMENTAL|NCR100 injection|Subjects will receive four injections of NCR100
62080252|NCT06741098|PLACEBO_COMPARATOR|0.9% Normal saline|Subjects will receive four injections of 0.9% Normal saline
62080253|NCT06741098|EXPERIMENTAL|NCR100 injection and 0.9% Normal saline|Subjects will receive two injections of 0.9% Normal saline and two injections of NCR100
62080254|NCT03537053|EXPERIMENTAL|A plan to Move a Little and Often|"The intervention will consist of 3 components: a short video will raise awareness about the impact of sedentary behaviours, a booklet, and an online forum on Facebook to encourage participants to support each other.~At the end of the baseline data collection, participants will be asked to watch the video. They will then be given the booklet and invited to join the Facebook group. A minimum of 5 participants must be recruited prior to running the Facebook group."
62080255|NCT06736353||Type 2 myocardial infarction|All patients reported as type 2 myocardial infarction (first reporting) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)
62648036|NCT00572832|ACTIVE_COMPARATOR|6 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
62648037|NCT00572832|ACTIVE_COMPARATOR|12 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.
62648038|NCT05185804|EXPERIMENTAL|Group DD217|Study drug Dimolegin - DD217, 60 mg orally, 1 time per day
62648039|NCT05185804|ACTIVE_COMPARATOR|Group Clexane|Reference drug Clexane, 40 mg subcutaneously, 1 time per day
62648040|NCT00656526|PLACEBO_COMPARATOR|A01L|
62648041|NCT00656526|NO_INTERVENTION|B01C|
62080256|NCT03626038|EXPERIMENTAL|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
62080257|NCT06741215||Group 1: High kinesiophobia group|Tampa kinesiophobia score greater than 37
62648042|NCT00597818|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo capsules for 20 months
62080258|NCT06741215||Group 2: Low kinesiophobia group|Tampa kinesiophobia score less than 37
62648043|NCT00597818|EXPERIMENTAL|Cobiprostone QD|Participants receive 18 mcg cobiprostone once daily (QD) for 20 months
62080259|NCT06117774|EXPERIMENTAL|Tarlatamab|Participants will receive tarlatamab on Cycle 1 Day 1, 8 and 15, and once every 2 weeks (Q2W) thereafter (cycle is 28 days).
62080260|NCT06117774|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo on Cycle 1 Day 1, 8 and 15, and Q2W thereafter (cycle is 28 days).
62648044|NCT00597818|EXPERIMENTAL|Cobiprostone BID|Participants receive 18 mcg cobiprostone twice daily (BID) for 20 months
62080261|NCT05843448|EXPERIMENTAL|Treatment (IO102-IO103, pembrolizumab)|Patients receive PD-L1/IDO peptide vaccine SC and pembrolizumab IV on study. Patients also undergo CT and/or CT/PET and collection of blood samples throughout the trial.
62080262|NCT04704661|EXPERIMENTAL|Treatment (trastuzumab deruxtecan, ceralasertib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and ceralasertib PO BID on days 1-7. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: During the dose-expansion phase, the first 6 patients in each disease cohort (gastroesophageal cancer \[cohort A\] and colorectal cancer \[cohort B\]) receive only trastuzumab deruxtecan for the first cycle, followed by trastuzumab deruxtecan and ceralasertib together in subsequent cycles. Additionally, patients undergo tissue biopsy on study and blood sample collection, CT or PET/CT and ECHO or MUGA throughout the study.
62080263|NCT03448393|EXPERIMENTAL|Dose escalation|CD19/CD22-CAR-transduced T cells at escalating doses
62080264|NCT03448393|EXPERIMENTAL|Dose expansion|CD19/CD22-CAR-transduced T cells at MTD or highest dose administered
62080265|NCT06280963|EXPERIMENTAL|muscle energy technique arm|this arm will receive muscle energy technique
62080266|NCT06280963|EXPERIMENTAL|posterior innominate mobilization arm|this arm will receive posterior innominate mobilization
62648045|NCT00597818|EXPERIMENTAL|Cobiprostone TID|Participants receive 18 mcg cobiprostone three times daily (TID) for 20 months
62648046|NCT00853294|ACTIVE_COMPARATOR|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
62648047|NCT00853294|EXPERIMENTAL|A|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
62648048|NCT03265795|EXPERIMENTAL|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
62648049|NCT03738930|NO_INTERVENTION|normal follow-up group|normal follow-up in ACS patients after PCI
62648050|NCT03738930|EXPERIMENTAL|AI based mHealth system follow-up group|AI based mHealth system follow-up in ACS patients after PCI. ACS patients in this group will receive message to take more notice to bleeding events.
62648051|NCT00595361|ACTIVE_COMPARATOR|Arg/Arg|Arg/Arg subjects on 2 week salmeterol treatment
62648052|NCT00595361|ACTIVE_COMPARATOR|Gly/Gly|Gly/Gly subjects on 2 week salmeterol treatment
62648053|NCT02507076|EXPERIMENTAL|Treatment (ILP with melphalan)|Patients undergo ILP with melphalan IV over 60 minutes.
62080267|NCT06280963|PLACEBO_COMPARATOR|control arm|this arm will receive conventional treatment
62080268|NCT05968885|ACTIVE_COMPARATOR|Intradetrusor onabotulinumtoxinA injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
62080269|NCT05968885|EXPERIMENTAL|Combination pharmacotherapy|Combine Mirabegron and Solifenacin.
62080270|NCT03959774|EXPERIMENTAL|breast or colorectal or lung cancer, age 70 or older|breast or colorectal or lung cancer, age 70 or older
62080271|NCT06467175|EXPERIMENTAL|cax index with 1 to 2 relatives|
62648054|NCT00571675|EXPERIMENTAL|1|AT-101, prednisone and docetaxel
62648055|NCT00571675|PLACEBO_COMPARATOR|2|Placebo, prednisone and docetaxel
62080272|NCT06737861|EXPERIMENTAL|Group A (Buerger Exercises + Whole Body Vibration Therapy)|Participants in this arm will perform both Buerger exercises daily and receive Whole Body Vibration (WBV) therapy three times per week.
62080273|NCT06737861|EXPERIMENTAL|Group B (Buerger Exercises only)|Participants in this arm will perform only Buerger exercises daily, without the addition of WBV therapy.
62080274|NCT06739135|EXPERIMENTAL|DPN intervention group|Drivers with DPN receive visual feedback training in a driving simulator over 6 visits a month apart
62080275|NCT06739135|NO_INTERVENTION|DPN control group|Drivers with DPN receive no visual feedback training in a driving simulator over 3 visits (timed to match visits 1, 3 and 6 of the intervention group)
62080276|NCT06739135|NO_INTERVENTION|No/Low DPN group|Drivers with diabetes but no diagnosed neuropathy receive no intervention at a single visit
62080277|NCT05690776||Patients who received the Quattro X BroadBand|No specific interventions will be administered.
62080278|NCT06739655|ACTIVE_COMPARATOR|Standard treatment arm|"Treatment in this arm consists of:~1. Skin/Nipple-Sparing Mastectomy (SSM/NSM)~2. Immediate or delayed breast reconstruction.~3. Postoperative radiation therapy, according to the SoC as indicated by international guidelines.~\[Systemic treatments are not considered as study treatments and will be implemented at the discretion of the treating physician.\]"
62080279|NCT06739655|EXPERIMENTAL|Experimental treatment arm|"Treatment in this arm consists of:~1. Preoperative radiotherapy. Since preoperative radiotherapy is not SoC and the experimental intervention of this study, the SoC principles for 'postoperative' radiotherapy, as indicated by international guidelines and applied by the treating radiotherapist, will be applied to preoperative radiotherapy.~2. Skin/Nipple-Sparing Mastectomy (SSM/NSM) combined with immediate breast reconstruction~\[Systemic treatments are not considered as study treatments and will be implemented at the discretion of the treating physician.\]"
62080280|NCT05345184|EXPERIMENTAL|Cognitive Behavioral Suicide Prevention for psychosis (treatment group)|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions in addition to standard/current services.
62648056|NCT06432387||Patients undergoing complex thoraco-abdominal aortic aneurysm repair|"Perioperative laboratory examinations will follow institutional guidelines. These will include, but will not be limited to full blood count, conventional coagulation tests, liver function, and kidney function tests. Moreover, for the purpose of this study, the following parameters will also be obtained; vWF, factors VIII and XI, D-dimers, fibrinogen, platelets activation (multiplate), adams-13, anti-Xa and high sensitivity troponin. All samples will be obtained via puncture from a peripheral vein. Blood samples will obtained at three time points; preoperatively before induction to GA (01), postoperative day 1 (02) and postoperative day 3rd-4th (03). During hospitalization any myocardial injury after non cardiac surgery, acute kidney injure and post-implantation syndrome will be recorded.~Of note, at 30 days, 3, 6 and 12 months our patients will undergo an evaluation for any major cardiovascular event, implant failure or death of any cause."
62080281|NCT05345184|ACTIVE_COMPARATOR|Services as Usual (SAU; comparison group)|Services as usual involve standard and current services that clients are eligible for receiving.
62080282|NCT02322177||1|Participants are women with inborn errors of metabolism who have been pregnant
62080283|NCT01309490|EXPERIMENTAL|Ribavirin, nucleoside analog|
62080284|NCT05365113|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP) then extended sigh|"Patients assigned to this group will receive a CPAP ARM (40cmH2O during 50 seconds), followed by a 10-minute pause corresponding to a period of return to basal state.~Then an ARM by extended sigh (e-sigh) also 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure).~Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
62080285|NCT05365113|ACTIVE_COMPARATOR|extended sigh then continuous positive airway pressure (CPAP)|"Patients assigned to this group will receive an ARM by extended sigh (e-sigh) during 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure), followed by a 10-minute pause corresponding to a period of return to basal state.~Then they receive a CPAP ARM (40cmH2O during 50 seconds). Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
62648057|NCT03139500|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
62648058|NCT03139500|EXPERIMENTAL|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
62648059|NCT03139500|EXPERIMENTAL|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
62080286|NCT04715087|OTHER|Atopic dermatitis patients|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be re-applied (via patchtest) to AD patient. After reading the patch test results, skin biopsies will be performed
62080287|NCT04715087|OTHER|Healthy controls|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. After reading the patch test results, skin biopsies will be performed.
62080288|NCT06192355|EXPERIMENTAL|Single-use gastroscope|A disposable endoscope designed for a one-time use during a Gastroscopy, eliminating the need for reprocessing or sterilization. After a single procedure, the entire gastroscope is discarded, reducing the risk of cross-contamination and ensuring a fresh, sterile instrument for each patient intervention
62080289|NCT06192355|ACTIVE_COMPARATOR|reusable gastroscope|A durable endoscope designed for multiple uses after thorough reprocessing and sterilization
62080290|NCT06379750|NO_INTERVENTION|Enhanced Usual Care (EUC)|Enhanced usual care provided by facility MD or equivalent (control group)
62648060|NCT01958905|EXPERIMENTAL|Artemether-Lumefantrine|All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children
62648061|NCT01627548|ACTIVE_COMPARATOR|Waitlisted Intervention|Couple will be consented, assessed and randomized to a waitlist of 4 months. The couple will be reassessed at 8 weeks and prior to initiating intervention.
62648062|NCT01627548|ACTIVE_COMPARATOR|Immediate Intervention|Eligible couples who are randomized to immediate intervention will begin sessions with a trained interventionist within weeks of consent and initial assessments
62648063|NCT06023693|EXPERIMENTAL|Guided online self-help intervention|The intervention will be a guided e-health intervention based on CBTi principles (i-Sleep \& BioClock). It consists of 5 modules, to be completed in about 5 weeks, and is aimed at improving sleep in university students. The intervention will be entirely held online and will be supported by e-coaches. The topics covered will be sleep hygiene, psychoeducation on sleep and the biological clock, sleep restriction, stimulus control, worrying and relaxation, dysfunctional thoughts, and relapse prevention.
62648064|NCT06023693|ACTIVE_COMPARATOR|Online psychoeducation|The control group will receive access to the platform and to the sleep diary. Their intervention will consist of brief, unstructured online PE for insomnia based on recognized sleep hygiene advice, for example, recommendations about evening routines, and use of alcohol and caffeine. Students will be advised to monitor their sleep in the diary. In contrast to the intervention group, the control group will not receive support of an e-coach. Key differences to the CBTi group are that the online PE (1) does not provide individualized support by an e-coach; (2) includes less content, and (3) is not delivered in a step-by-step manner, but will be provided all at once.
62648065|NCT05619133|NO_INTERVENTION|placebo|No PBM will be emitted from the device; dose: 0 J.cm-2
62648066|NCT05619133|EXPERIMENTAL|PBM High standard|A PBM high standard dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%
62648067|NCT05619133|EXPERIMENTAL|PBM High wavelength|A PBM high dose of 6.5 J.cm-2 with a wavelength of 940 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%
62648068|NCT05619133|EXPERIMENTAL|PBM High pulse|A PBM high dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 100 Hz and 1.2 ms and duty factor of 12%
62080291|NCT06379750|ACTIVE_COMPARATOR|EUC + community support|Enhanced usual care AND community-based peer-support model using WelTel check-ins and BCC SMS and facilitated group self monitoring
62080292|NCT06379750|ACTIVE_COMPARATOR|EUC + nurse-delivered check ins|Enhanced usual care AND nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management using WelTel check-ins and BCC SMS
62457748|NCT01575522|EXPERIMENTAL|Treatment (tivantinib)|Patients receive tivantinib 360 mg PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.
62080293|NCT06379750|ACTIVE_COMPARATOR|EUC + community support + nurse-delivered check ins|Enhanced usual care AND nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management using WelTel check-ins and BCC SMS AND community-based peer-support model using WelTel check-ins and BCC SMS and facilitated group self monitoring
62648069|NCT05619133|EXPERIMENTAL|PBM High skin only|A PBM high standard dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%, but in this case the participants will wear filtering googles which will not allow PBM from entering the eyes
62648070|NCT06160271|EXPERIMENTAL|TEP 68Ga-FAPI|Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
62648071|NCT03183908|ACTIVE_COMPARATOR|Adjuvanted influenza vaccine (FLUAD®)|In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.
62080294|NCT06737809|EXPERIMENTAL|IP coated hip arthroplasty implants|Participants receive an infection prevention (IP) coated hip implant
62080295|NCT06737809|ACTIVE_COMPARATOR|Standard hip arthroplasty implants|Participants receive a standard (uncoated) hip implant
62080296|NCT06566313|EXPERIMENTAL|tDCS group|a course of tDCS treatment is performed for 10 days
62080297|NCT00555789|ACTIVE_COMPARATOR|1|mycophenolic and tacrolimus
62080298|NCT00555789|EXPERIMENTAL|2|mycophenolic and tacrolimus
62080299|NCT06740032|ACTIVE_COMPARATOR|autonomic function|
62080300|NCT06740032|ACTIVE_COMPARATOR|somatic function|
62080301|NCT06053814|EXPERIMENTAL|Part 1: NS-050/NCNP-03|Participants will be randomized and receive NS-050/NCNP-03 intravenous (IV) infusions once weekly for 2 weeks at each of MAD levels (1.95, 5, 10, 20, 40, and 80 mg/kg).
62080302|NCT06053814|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will be randomized and receive NS-050/NCNP-03 placebo-matching IV infusions once weekly for 2 weeks at each of MAD levels.
62080303|NCT06053814|EXPERIMENTAL|Part 2: NS-050/NCNP-03|Participants will receive NS-050/NCNP-03 IV infusions once weekly for 24 weeks at the dosage selected by the Data and Safety Monitoring Board (DSMB) at the conclusion of Part 1.
62080304|NCT06739811|EXPERIMENTAL|MIIPS 2020|Subjects implanted with the MIIPS 2020 and treated with intraperitoneal insulin infusion.
62457749|NCT00552331|ACTIVE_COMPARATOR|LISS|Treatment of distal femur fracture with less invasive stabilization system
62457750|NCT00552331|ACTIVE_COMPARATOR|Standard Treatment|Treatment of distal femoral fractures using locking condylar plates or dynamic condylar screws
62457751|NCT01106326|EXPERIMENTAL|Intervention|"Teens participating in this study will have:~1. directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~2. three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
62648072|NCT03183908|ACTIVE_COMPARATOR|High-dose influenza vaccine (Fluzone® HD)|In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.
62457752|NCT02512978|EXPERIMENTAL|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
62080305|NCT03368924|OTHER|SCA patients (SS genotype)|"* To compare the level of anti band 3 antibodies in steady state and during vaso-occlusive crises in SCA patients.~* To assess the relationship between level of biomarkers of oxidation of SS RBCs, altered hemorheological parameters, biomarkers of cellular activation (microparticles) and anti band 3 antibodies rate, taking into account the alpha-globin genes status.~* To study the relationship between level of anti band 3 antibodies and severity of these VOC using an index of clinical severity (IS2) calculated at the end of SCA patients hospitalization for VOC.~* To study early clinical (including the activity of the autonomic nervous system activity) and biological items to evaluate the relationship between these items and severity of VOC."
62080306|NCT06015880|EXPERIMENTAL|Treatment (mosunetuzumab, polatuzumab vedotin, lenalidomide)|Patients receive mosunetuzumab IV over 2-4 hours on days 1, 8, and 15 of cycle 1 and then day 1 of each subsequent cycle. Treatment repeats every 28 days for 8 cycles in patients who achieve a CR or up to 17 cycles for patients with a PR or SD in the absence of disease progression or unacceptable toxicity. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 for 6 cycles and lenalidomide PO on days 1-21 for 8 cycles in patients who achieve CR or up to 17 cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT and blood sample collection throughout the study.
62648073|NCT01663623|PLACEBO_COMPARATOR|Placebo plus azathioprine|Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.
62648074|NCT01663623|EXPERIMENTAL|Belimumab 10 mg/kg plus azathioprine|Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.
62648075|NCT00002551|EXPERIMENTAL|Bolus 5-FU, Pelvic XRT + PVI 5-FU, Bolus 5-FU|Bolus 5-FU (fluorouracil) (500mg/m2/day on days 1-5, 29-33), Pelvic XRT + PVI 5-FU, Bolus 5-FU (450mg/m2/day for 5 days beginning 28 days after RT, for 2 cycles on days 1-5 of a 28 days cycle).
62648076|NCT00002551|EXPERIMENTAL|PVI 5-FU+Pelvic XRT+PVI 5-FU+PVI 5-FU|5-FU (fluorouracil) 300mg/m2/day for 42 days followed by 2 week interruption, Day 57 through XRT will receive 225mg/m2/day of 5-FU followed by 1 month interruption, 4 weeks after completion of XRT 1 8wk cycle of 5-FU 300mg/m2/day.
62080307|NCT06737796|EXPERIMENTAL|experimental 1|Preterm babies in the finger feeding group, which constituted the study group, were finger fed by the neonatal intensive care nurse responsible for the baby's care, three times a day for no more than 20 minutes. If babies had breast milk during feedings, breast milk was given first. Formula milk was used when breast milk was not available. The amount of milk that the preterm baby should receive, determined by the neonatal specialist physician, was completed after the planned 20 minutes of feeding time and at other feeding meals during the day, according to the clinic's feeding protocol. In addition, preterm babies have three meals a day; Heart rate, respiration and saturation before and after feeding, and evaluation of feeding duration, amount of feeding and vomiting at the end of feeding were recorded in PBIF. The Preterm Baby Monitoring Form, which was planned to be used at this stage, was filled out by the neonatal intensive care nurse or the researcher.
62080308|NCT06737796|EXPERIMENTAL|experimental 2|Preterm babies in the syringe feeding group, which constituted the other study group, were fed with a syringe three times a day for no more than 20 minutes by the neonatal intensive care nurse responsible for the baby's care. If babies had breast milk during feedings, breast milk was given first. Formula milk was used when breast milk was not available. The amount of milk that the preterm baby should receive, determined by the neonatal specialist physician, was completed after the planned 20 minutes of feeding time and at other feeding meals during the day, according to the clinic's feeding protocol. In addition, preterm babies have three meals a day; Heart rate, respiration and saturation before and after feeding, and evaluation of feeding duration, amount of feeding and vomiting at the end of feeding were recorded in PBIF. The Preterm Baby Monitoring Form, which was planned to be used at this stage, was filled out by the neonatal intensive care nurse or the researcher.
62080309|NCT05753748|NO_INTERVENTION|Endoscopic Surveillance|Subjects in the randomized control trial and observational cohort study, undergoing surveillance endoscopy will undergo surveillance biopsies in a 4-quadrant fashion every 1 cm throughout the extent of the Barrett's esophagus using the Seattle biopsy protocol, along with targeted biopsies from any visible lesions. For incident low grade dysplasia (newly diagnosed low grade dysplasia - within 12 months of enrollment), surveillance endoscopies will be performed every 6 months for the first year and then annually until the end of the study period. For prevalent low grade dysplasia (diagnosed \>1 year prior to enrollment), surveillance endoscopies will be performed annually until the end of the study period. The number of evaluations will depend on a subject's enrollment time.
62080310|NCT05753748|EXPERIMENTAL|Endoscopic Eradication Therapy|Subjects undergoing endoscopic eradication therapy will undergo radiofrequency ablation every 2-3 months until complete eradication of intestinal metaplasia (CE-IM) is achieved or 5 treatments have been delivered, whichever is first. After achieving CE-IM, surveillance endoscopy will performed every 6 months for the first year and annually thereafter until the end of the study period. Surveillance biopsies will be obtained using a standardized protocol.
62080311|NCT06350084|EXPERIMENTAL|Mother's Touch Group|Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
62080312|NCT06350084|EXPERIMENTAL|Nurse's Therapeutic Touch Group|Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
62080313|NCT06350084|NO_INTERVENTION|Control Group|In this group, infants received routine heel blood collection procedure.
62080314|NCT00439179|EXPERIMENTAL|Cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
62080315|NCT00439179|EXPERIMENTAL|Cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
62080316|NCT00439179|EXPERIMENTAL|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
62457753|NCT02512978|NO_INTERVENTION|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
62457754|NCT05818696|EXPERIMENTAL|LMC - CUE|In this arm, participants will receive Lethal Means Counseling before receiving CBT for Uncertainty-Enhanced (CUE).
62080317|NCT00439179|EXPERIMENTAL|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
62080318|NCT06740123|EXPERIMENTAL|Periodontal pocket (Test group)|To be treated with non-surgical periodontal treatment and intra-pocket H42 hydrogel application.
62080319|NCT06740123|EXPERIMENTAL|Periodontal pocket (Control group)|To be treated with non-surgical periodontal treatment only
62080320|NCT06740123|EXPERIMENTAL|Peri-implant pocket (Test group)|Will be treated with non-surgical periodontal treatment and intra-pocket H42 hydrogel application.
62080321|NCT06740123|EXPERIMENTAL|Peri-implant pocket (Control group)|will be treated with non-surgical periodontal treatment only
62080322|NCT05830266|EXPERIMENTAL|"Mindful with your Baby group-based therapist-guided intervention (Intervention group)"|"Group-based Mindful with your Baby therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
62457755|NCT05818696|EXPERIMENTAL|CUE - LMC|In this arm, participants will receive CBT for Uncertainty-Enhanced (CUE) before receiving Lethal Means Counseling.
62457756|NCT03095222|ACTIVE_COMPARATOR|Group 1: Daily|Daily ketamine infusions of 5 hours in length. Duration of participation will last 4 days.
62080323|NCT05830266|OTHER|"Mindful with your baby self-guided online intervention (Waitlist control group)"|"The waitlist control group receives an individual self-guided online Mindful with your baby intervention after a 10-week waiting period."
62648077|NCT00002551|EXPERIMENTAL|Bol 5-FU+LV+LEV+Pel XRT+Bol 5-FU+LV Bol 5-FU + LV + LEV|5-FU (fluorouracil) 425/mg/m2/day Days 1-5,29-33; LV (leucovorin calcium) 20mg/m2/day Days 1-5,29-33; LEV (levamisole hydrochloride) 150mg/day (50mg TID) for 3 days every 14 days starting after each course of 5-FU. During RT: 5-FU and LV 4 days on wk 1 and wk 5 of RT. LV 20 mg/m2/day IV bolus within 2hrs after completion of that day's radiation therapy, for four days in each cycle. Followed immediately by 5- FU 400 mg/m2/day IV bolus. Treatment will be given on days 57 - 60 and 85 - 88.Treatment post-RT-chemotherapy 28 days after completion of RT consist of 5 days of chemotherapy in 28 day cycles. 5-FU, 380 mg/m2/day on days 1 - 5 and LV given at a dose of 20 mg/m2/day on days 1 - 5 with the 5-FU given immediately after the LV. For 2 post-radiation cycles on days 1 - 5 of a 28 day cycle. Levamisole will be given orally at a dose of 150 mg/day (50 mg tid) for 3 days every 14 days during the 1st 3 days of each cycle of 5-FU, and again 14 days after starting each course of 5-FU.
62080324|NCT03528928|EXPERIMENTAL|Surface electrical stimulation|Each subject did a Kegel pelvic floor contraction, had the surface electrical stimulation turned on at highest comfortable intensity, did a Kegel contraction with surface electrical stimulation on, and had second electrical stimulation turned on.
62080325|NCT01784913|EXPERIMENTAL|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.
62080326|NCT05832229|EXPERIMENTAL|Active|Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry or on a protease inhibitor) rosuvastatin by mouth once daily, followed by a period of 96 weeks rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor).
62080327|NCT05832229|PLACEBO_COMPARATOR|Placebo|Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry or on a protease inhibitor) rosuvastatin by mouth once daily, followed by a period of 96 weeks placebo.
62080328|NCT03713255|ACTIVE_COMPARATOR|PVB group|paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
62080329|NCT03713255|EXPERIMENTAL|MTP block group|MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
62080330|NCT03713255|SHAM_COMPARATOR|control group|local anesthetic infiltration subcutaneous 1% lidocaine
62080331|NCT03875911|ACTIVE_COMPARATOR|Preoperative Subconjunctival injection of MMC|Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).
62080332|NCT03875911|ACTIVE_COMPARATOR|Intraoperative subconjunctival injection of MMC|Intraoperative subjconjunctival injection of 0.1 mL of Mitomycin-C 0.01% (0.1mg/mL) to the site of trabeculectomy
62080333|NCT03875911|ACTIVE_COMPARATOR|Intraoperative topical application of MMC|Topical application of Mitomycin-C intraoperatively by applying a sponge soaked in 1mL of Mitomycin-C 0.02 mg/mL for 1 minute to the site of trabeculectomy
62080334|NCT05539690|EXPERIMENTAL|Balance training group|A single training group
62080335|NCT04687631|EXPERIMENTAL|mFOLFOXIRI plus Cetuximab|
62080336|NCT04687631|EXPERIMENTAL|mFOLFOXIRI plus Bevacizumab|
62080337|NCT06255236|EXPERIMENTAL|BIS|The patients will receive both standard frontal and nasal BIS monitoring during general anesthesia.
62080338|NCT06608966|EXPERIMENTAL|Epilepsy Journey web-based modules alone|Participants assigned to Epilepsy Journey modules will independently review web-based EJ modules. Participants will be targeted to complete 10 EJ modules (\~15-30 minutes each session) within 14 weeks.
62080339|NCT06608966|EXPERIMENTAL|Epilepsy Journey web-based modules + telehealth with a therapist|Participants will receive both the Epilepsy Journey web-based modules and telehealth sessions with a therapist weekly. Participants will review 10 modules independently (\~15-30 minutes) and complete 10 telehealth sessions (\~30-45 minutes each session) within a 14-week time frame.
62080340|NCT06608966|EXPERIMENTAL|Telehealth with a therapist alone|Participants will meet with a therapist for 10 telehealth sessions (30-45 minutes each session) within a 14-week time frame.
62080341|NCT06608966|NO_INTERVENTION|Treatment as Usual|Participants will receive no active behavioral health treatment components and will be followed in usual epilepsy care for 14 weeks.
62080342|NCT03133663|ACTIVE_COMPARATOR|Control group|Pulse oximeter and auscultation to determine heart rate during neonatal resuscitation. Pulse oximeter will be used to determine oxygen saturation.
62080343|NCT03133663|EXPERIMENTAL|Electrocardiogram group|Electrocardiogram to determine heart rate during neonatal resuscitation. Pulse oximeter will still be used per Neonatal Resuscitation Program guidelines for oxygen saturation.
62648078|NCT04889040|PLACEBO_COMPARATOR|Placebo|The dose and regimen of the placebo will match that of AT-527.
62648079|NCT04889040|EXPERIMENTAL|RO7496998 (AT-527)|Orally administered, 550 mg twice daily (BID) for 5 days
62080344|NCT01969162||All Participants|Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
62080345|NCT06739044|EXPERIMENTAL|Experimental group|
62080346|NCT06739044|ACTIVE_COMPARATOR|Active Comparator|
62080347|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
62080348|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
62648080|NCT00948545||No treatment|Observing individuals pre and post bariatric surgery
62648081|NCT03056521|EXPERIMENTAL|Info|"In this arm the patients are counseled preoperatively about post operative pain.~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
62080349|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
62080350|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
62648082|NCT03056521|NO_INTERVENTION|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
62080351|NCT06259162|EXPERIMENTAL|LAG-3 expression/immune checkpoint protein expression evaluation|
62080352|NCT06739707|EXPERIMENTAL|A dose of 74 mg of MD-18 or placebo three times per week for 4 consecutive weeks|Cohort 1: Four subjects will be administered a dose of 74 mg of MD-18 and two will receive placebo subcutaneously three times per week for 4 consecutive weeks
62080353|NCT06739707|EXPERIMENTAL|A dose of 114 mg of MD-18 or placebo three times per week for 4 consecutive weeks|Cohort 2: Four subjects will be administered a dose of 114 mg of MD-18 and two will receive placebo subcutaneously three times per week for 4 consecutive weeks.
62648083|NCT05063253|EXPERIMENTAL|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once weekly.
62080354|NCT06739707|EXPERIMENTAL|A dose of 227 mg of MD-18 or placebo three times per week for 4 consecutive weeks|Cohort 3: Four subjects will be administered a dose of 227 mg of MD-18 and two will receive placebo subcutaneously three times per week for 4 consecutive weeks.
62080355|NCT06739707|EXPERIMENTAL|A weekly dose of 302 mg of MD-18 or placebo for 4 consecutive weeks|Cohort 4: Four subjects will be administered a weekly dose of 302 MD-18 and two will receive placebo subcutaneously for 4 consecutive weeks.
62080356|NCT06739707|EXPERIMENTAL|A dose of 302 mg of MD-18 or placebo three times per week for 4 consecutive weeks|Cohort 5: Four subjects will be administered a dose of 302 mg of MD-18 and two will receive placebo subcutaneously three times per week for 4 consecutive weeks.
62080357|NCT06739707|EXPERIMENTAL|A daily dose of 302 mg of MD-18 or placebo for 4 consecutive weeks|Cohort 6: Four subjects will be administered a daily dose of 302 mg of MD-18 and two will receive placebo subcutaneously for 4 consecutive weeks.
62080358|NCT06739707|EXPERIMENTAL|The highest tolerated dose/dose-frequency identified in the first six cohorts|Cohort 7: Twelve non-diabetic obese subjects will be treated with the highest tolerated dose/dose-frequency identified in the first six cohorts and six subjects will be administered placebo.
62648084|NCT05063253|EXPERIMENTAL|TG103, 22.5 mg|TG103 (22.5 mg) will be administered via subcutaneous injection once weekly.
62648085|NCT05063253|EXPERIMENTAL|TG103, 30 mg|TG103 (30 mg) will be administered via subcutaneous injection once weekly.
62648086|NCT05063253|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via subcutaneous injection once weekly.
62648087|NCT01227369||Bisphosphonates|Korean postmenopausal osteoporosis patients with bisphosphonate treatment
62080359|NCT03927768||200 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
62080360|NCT03927768||50 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
62080361|NCT00925340|EXPERIMENTAL|1 - Family Check Up|Brief family intervention that employs Motivational Interviewing.
62080362|NCT00925340|ACTIVE_COMPARATOR|2 - Psychoeducation|
62080363|NCT04052022||1|Patients with TB who have already initiated treatment and are suspected to have paradoxical reactions, as well as patients taking TB treatment without signs of paradoxical reactions.
62080364|NCT05616871||Upadacitinib Alone or In Combination with Methotrexate|Participants will receive upadacitinib alone or in combination with methotrexate as prescribed by their physician according to local label in real- world practice.
62080365|NCT06740617||calcaneal spur group|twenty six patients with calcaneal spur will participate in this group
62080366|NCT06740617||healthy group|twenty six healthy subjects will participate in this group
62080367|NCT06740357|EXPERIMENTAL|Experimental: Tumor response monitoring program with shared decision-making|
62080368|NCT06740357|ACTIVE_COMPARATOR|Control: Standard assessment of tumor response (validated in the GRECCAR 2 trial - Lancet 2017)|
62080369|NCT01544114|EXPERIMENTAL|VIMOVO|"Three VIMOVO strengths will be used in this study: 250 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 250/20), 375 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 375/20), and 500 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 500/20). The VIMOVO strength allocated to each participant will be determined by the participant's weight at baseline and based on investigator's discretion.~The target dose of the naproxen component will be within the range of 10-20 mg/kg/day divided twice daily (BID) with a maximum daily dose of 1000 mg."
62080370|NCT02862847||gastroenteritis|
62080371|NCT02862847||control|
62080372|NCT06292546|EXPERIMENTAL|Group A|vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days.
62080373|NCT06292546|EXPERIMENTAL|Group B|vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days.
62080374|NCT06292546|EXPERIMENTAL|Group C|2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
62080375|NCT06292546|ACTIVE_COMPARATOR|Group D|vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
62080376|NCT06739694|EXPERIMENTAL|Experimental group|Participants will receive 4 sessions of PNE and 5 sessions of manual therapy and exercises.
62648088|NCT04112732|EXPERIMENTAL|Multivitamin|1 multivitamin tablet administered by mouth daily for 12 weeks, to be taken with main meal.
62080377|NCT06739694|ACTIVE_COMPARATOR|Control group|Participants will receive 5 sessions of manual therapy and exercises.
62080378|NCT04821141|EXPERIMENTAL|Bazedoxifene plus conjugated estrogens immediately|BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing immediately.
62080379|NCT04821141|OTHER|Bazedoxifene plus conjugated estrogens wait list|No intervention for initial 6 months (wait list), then BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing 6 months after enrollment. Optional on the part of subject.
62080380|NCT06739668|EXPERIMENTAL|Active device|The active device will generate a low amplitude magnetic field. 20 participants will be randomized to this arm.
62080381|NCT06739668|SHAM_COMPARATOR|Sham device|The sham device will not generate a low amplitude magnetic field. 10 participants will be randomized to this arm.
62080382|NCT00604786|EXPERIMENTAL|Omalizumab subcutaneous|"This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks"
62080383|NCT00604786|PLACEBO_COMPARATOR|Placebo Subcutaneous|"This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks."
62080384|NCT01281553|EXPERIMENTAL|001|Cisapride 0.2 mg/kg suspension q.i.d.for 8 weeks.
62080385|NCT01281553|PLACEBO_COMPARATOR|002|Placebo Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
62080386|NCT03869060|EXPERIMENTAL|Inoculated Group|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) given as a single dose \[0.5 mL of 6.5 x 10\^3 plaque forming units/milliliter (PFU/mL)\] inoculated subcutaneously.
62080387|NCT06134362|EXPERIMENTAL|CAB LA 600 mg (Q8W)|All enrolled participants have previously received CAB LA as part of the HPTN 083 and HPTN 084 parent studies or their sub-studies. Participants will continue receiving CAB LA 600 mg via gluteal intramuscular (IM) injection.
62080388|NCT06029530|ACTIVE_COMPARATOR|0.01% Atropine|0.01% atropine eye drops
62080389|NCT06029530|ACTIVE_COMPARATOR|0.03% Atropine|0.03% atropine eye drops
62648089|NCT04112732|PLACEBO_COMPARATOR|Placebo|1 placebo tablet administered by mouth daily for 12 weeks, to be taken with main meal.
62648090|NCT01912976|EXPERIMENTAL|Er:YAG AFL-PDT|Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
62648091|NCT01912976|ACTIVE_COMPARATOR|MAL-PDT|Left leg on each patient was selected to receive 2 sessions of MAL-PDT
62080390|NCT06029530|ACTIVE_COMPARATOR|0.05% atropine|0.05% atropine eye drops
62080391|NCT03981536|EXPERIMENTAL|AP-101: Dose Level 1|Single dose of AP-101
62080392|NCT03981536|EXPERIMENTAL|AP-101: Dose Level 2|Single dose of AP-101
62457757|NCT03095222|ACTIVE_COMPARATOR|Group 2: Continuous|Continuous ketamine infusions (24 hours/day). Duration of participation will last 4 days.
62457758|NCT02958709|EXPERIMENTAL|high dose RIF, INH, PZA, EMB|Arm 1 participants will receive high-dose rifampicin for 8 weeks plus ethambutol at standard doses, in addition to standard doze pyrazinamide (PZA) and isoniazid.
62457759|NCT02958709|EXPERIMENTAL|high dose RIF, INH, PZA, LEVO|Arm 2 participants will receive high-dose rifampicin plus levofloxacin for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
62457760|NCT02958709|ACTIVE_COMPARATOR|standard dose RIF, INH, PZA, EMB|Arm 3 participants will receive standard of care dose rifampicin plus ethambutol for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
62457761|NCT02976207||OSA diagnosed patients|patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.
62457762|NCT01124149|EXPERIMENTAL|MMX mesalamine/ mesalazine|
62457763|NCT01684553|EXPERIMENTAL|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
62457764|NCT01684553|ACTIVE_COMPARATOR|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
62080393|NCT03981536|EXPERIMENTAL|AP-101: Dose Level 3|Single dose of AP-101
62080394|NCT06737666|EXPERIMENTAL|Tong-Xie-Yao-Fang intervention group|
62080395|NCT06737666|NO_INTERVENTION|healthy people|
62080396|NCT03728192|EXPERIMENTAL|Mangosteen treated group|"HeLa and H357 cell lines were procured and were further subdivided into 2 subdivisions and were assigned interventions:~Mangosteen group- cells treated with mangosteen extract and Camptothecin group - cells treated with standard anticancer drug camptothecin(25 micro mole)"
62080397|NCT03728192|NO_INTERVENTION|Untreated group|H357 and HeLa cell line without any drug intervention.
62080398|NCT02250495|EXPERIMENTAL|Sympara Therapeutic System|All subjects will wear for the Sympara device for 30 days
62080399|NCT01727518||Reference Population|No Intervention
62080400|NCT01843075|EXPERIMENTAL|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
62080401|NCT01843075|PLACEBO_COMPARATOR|Placebo|Daily administration of matched placebo by subcutaneous injection
62080402|NCT06422793|EXPERIMENTAL|No NG Gastric Decompression|No NG tube gastric decompression for orthognathic surgery. This group will not have a NG tube inserted. The remainder of their surgical care will be identical to the other group. PONV will be evaluated by nursing and surgical team at two time points in the 24 hour postoperative period (early \[0-2 hours\] and delayed \[2-24 hours\]).
62457765|NCT00118105|EXPERIMENTAL|Chemotherapy + Surgery + Chemotherapy|"Preoperative Neoadjuvant Chemotherapy~* Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3~* Oxaliplatin, 130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4~* Capecitabine, 1,700 mg/m\^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4~Conventional surgery: After 4 cycles of chemotherapy~Postoperative Neoadjuvant Chemotherapy~* Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4~* Oxaliplatin, 130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4~* Capecitabine, 1,700 mg/m\^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4"
62457766|NCT05233280||Group A|Early feeding group
62457767|NCT05233280||Group B|Delayed feeding group
62457768|NCT05054868|ACTIVE_COMPARATOR|Group 1 (Control group) - Oxycodone only|Subjects randomized to this group will receive oxycodone for postop pain management (standard of care).
62457769|NCT05054868|EXPERIMENTAL|Group 2 (Treatment group) - Oxycodone and Ketorolac|Subjects randomized to this group will receive oxycodone and ketorolac for postop pain management.
62457770|NCT01678547|EXPERIMENTAL|Robot G-EO|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling.
62457771|NCT01678547|ACTIVE_COMPARATOR|Treadmill Training|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the treadmill system device, according to individually tailored exercise scheduling.
62457772|NCT01678547|ACTIVE_COMPARATOR|Ground treatment|Ground Control Group (cCG): Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) of traditional lower limb physiotherapy treatment.
62457773|NCT02909140|EXPERIMENTAL|Topical Mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
62457774|NCT02909140|EXPERIMENTAL|Intracameral Mydriasis|Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
62457775|NCT02909140|EXPERIMENTAL|Topical + Intracameral mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
62457776|NCT02226458|EXPERIMENTAL|EPI-743|15 mg/kg oral solution three times per day, maximum of 200 mg per dose
62457777|NCT01279356||Patients with liver diseases of various etiologies|"* viral hepatitis~* cholestatic liver diseases~* auto-immune hepatitis~* NAFLD~* ALD~* sarcoidosis of the liver"
62457778|NCT06457945|EXPERIMENTAL|Narcolepsy type 1|"Patients with narcolepsy type 1 according to International Classification of Sleep Disorders (ICSD3-TR) criteria; they will have to fill study questionnaires and perform the ASRT.~A subset of patients will undergo polysomnography recording (EEG, EOG, EMG, ECG) during the ASRT."
62457779|NCT06457945|EXPERIMENTAL|Idiopathic hypersomnia|"Patients with Idiopathic hypersomnia according to ICSD3-TR and with mean sleep latency ≤8min at the multiple sleep latency test (MSLT) (whatever total sleep time/24h bedrest); they will have to fill study questionnaires and perform the ASRT.~A subset of patients will undergo polysomnography recording (EEG, EOG, EMG, ECG) during the ASRT."
62648092|NCT05325359||Multiple sclerosis|. Inclusion criteria for volunteers; Individuals with relapsing-remitting type MS, who are between 18-65, EDSS scores between 1 ≤ and ≤ 5.5, individuals who score 24 and above in Mini Mental State Examination and who can walk a minimum of 20 m independently will be included. In addition, exclusion criteria for volunteers; Severe spasticity of the lower extremities (Ashworth score 3 or 4), having an acute MS attack or a history of an attack in the last 1 month, having an orthopedic or systemic problem that would prevent participation in the tests, having another neuromuscular disorder other than MS, visual involvement or diplopia, and is that he has a cardio-pulmonary problem that will prevent him from participating in the tests.
62080403|NCT06422793|NO_INTERVENTION|NG Gastric Decompression|Participants will undergo NG tube gastric decompression according to our institution's typical gastric decompression regimen. Once patients are anesthetized and intubated, and a #14 French NG tube will be inserted in the naris opposite the nasotracheal tube and hooked up to low suction to confirm placement. If in the correct position, gastric contents will be seen in suction tubing. If no gastric contents are seen, the NG tube will be adjusted accordingly. The NG tube will be connected to suction until all stomach contents are effectively removed, as demonstrated by no new secretions in the suction tubing. It will then be disconnected from suction, secured with tape throughout surgery and temporarily hooked back up to suction at the end of surgery to reconfirm position and suction stomach contents present. The NG tube will then be secured to the participant's nose and left in place during extubation and transfer to PACU.
62648093|NCT04134039|EXPERIMENTAL|Polyurethane (PU) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
62080404|NCT06391229|EXPERIMENTAL|Project Support|All caregivers will receive the Project Support intervention over the course of 4-6 weeks.
62080405|NCT06606886|ACTIVE_COMPARATOR|(Group A) Tablet Metformin|Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
62080406|NCT06606886|ACTIVE_COMPARATOR|(Group B) Tablet Hydroxyurea|Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
62080407|NCT06740721|EXPERIMENTAL|Experimental: Intervention|Device: False Lumen Embolization System Device: IMPEDE-FX RapidFill
62080408|NCT05740475|EXPERIMENTAL|9MW3811 injection|single dose escalation for experimental drug
62080409|NCT05740475|PLACEBO_COMPARATOR|placebo|matching placebo administration for control
62080410|NCT03679013|OTHER|Opioid based standard of care regimen.|Inova Heart and Vascular Institute (IHVI) opioid based standard of care regimen given for post operative cardiac surgery pain.
62080411|NCT03679013|EXPERIMENTAL|Opioid sparing pain regimen.|Multimodal pain regimen consisting of PO Gabapentin paired with intravenous Acetaminophen given for post operative cardiac surgery pain.
62080412|NCT06543914||Atogepant|Participants will receive atogepant as prescribed by their physician in routine clinical practice.
62080413|NCT06741202|EXPERIMENTAL|Men's MST Group (MMG)|This is a 12-week long group that meets for 90 minutes weekly. This group will draw on interventions, developed in our pilot study, and also based on the PI's previous clinical experience designing and delivering a men's MST Group oriented to reduce psychiatric distress including identity-based shame by promoting group discussion among Veteran men about masculinity, sexuality, belongingness, and emotion regulation. The group is oriented around building core drivers of recovery: 1) agency through exposure- and mindfulness-based interventions to improve distress management; 2) social belongingness through group discussions on gender-specific themes; and 3) hope through coping skill training and treatment experienced as relevant. The protocol will be further revised based on research activity during Aims 1 and 2.
62080414|NCT06741202|ACTIVE_COMPARATOR|Present-Centered Group Therapy (PCGT)|"PCGT is a time-limited treatment for PTSD that focuses on increasing adaptive responses to current life stressors and difficulties that are directly or indirectly related to trauma or PTSD symptoms. PCGT was initially developed as a nonspecific comparison condition to test the effectiveness of trauma-focused cognitive behavioral therapy. The number of PCGT sessions has ranged from 12 to 32 for the group format, and is thus appropriate to utilize for the nature of this study. To minimize possible confounds, PCGT will be delivered for a 12-week period. The basis of PCGT is to provide common factors of psychotherapy, demonstrating the effects of what is unique in therapies. In this instance, PCGT may help articulate whether the effect of MMG is due to being gender-specific (bringing men together in the same group therapy setting) or being gender-tailored (delivering treatment that is specifically oriented to men, such as MMG group discussions)."
62080415|NCT01274130|EXPERIMENTAL|Ranitidine|
62080416|NCT01274130|EXPERIMENTAL|Verapamil|
62080417|NCT05694715|EXPERIMENTAL|Cohort 1 (Niraparib, Irinotecan)|Participants will receive a starting dose of 100 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
62080418|NCT05694715|EXPERIMENTAL|Cohort 2 (Niraparib, Irinotecan)|Participants will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
62080419|NCT05694715|EXPERIMENTAL|Cohort 3a (Niraparib, Irinotecan)|Participants weighing \< 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
62648094|NCT04134039|EXPERIMENTAL|Natural Rubber Latex (NRL) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
62648095|NCT06281561|PLACEBO_COMPARATOR|Control|Nasal spray with nomal saline before anesthesia
62080420|NCT05694715|EXPERIMENTAL|Cohort 3b (Niraparib, Irinotecan)|Participants weighing \>= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
62648096|NCT06281561|EXPERIMENTAL|Dexmedetomidine|Nasal spray with dexmedetomidine before anesthesia
62648097|NCT05731115|EXPERIMENTAL|Experimental Vaccine-lot 1|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 1.
62648098|NCT05731115|EXPERIMENTAL|Experimental Vaccine-lot 2|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 2.
62648099|NCT05731115|EXPERIMENTAL|Experimental Vaccine-lot 3|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 3.
62648100|NCT04744298|EXPERIMENTAL|TheraPPP Pathway|"The investigators will perform an effectiveness-implementation hybrid study design (type 1) to evaluate the effectiveness and implementation of the TheraPPP pathway.~All mechanically ventilated patients admitted to the ICU will enter the pathway. To evaluate effectiveness the investigators will collect patient data for approximately 29 months. To assess acceptability of the pathway the investigators will conduct a survey and focus groups to clinicians who used the Pathway."
62648101|NCT05618223|EXPERIMENTAL|Dapagliflozin group|Dapagliflozin 10 mg once a day and standard treatment
62648102|NCT05618223|NO_INTERVENTION|Control group|Standard treatment only.
62648103|NCT02292576|EXPERIMENTAL|Acute dose/Chronic dose|Acute dose/Chronic dose.
62648104|NCT02292576|EXPERIMENTAL|Chronic dose/Acute dose|Chronic dose/Acute dose.
62648105|NCT01780766||Indolent myeloma patient|
62648106|NCT01780766||Symptomatic Myeloma patient|
62648107|NCT01607164|EXPERIMENTAL|Online self-help mood management|"Healthy Mood Project Website~Online self-help automated mood management course available in Spanish and English via a website.~Intervention consisted of 8 cognitive-behavioral mood management lessons."
62648108|NCT04275336|EXPERIMENTAL|EMLA group|The specialist nurse who is to perform IV cannulation determine the puncture site. A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse performed IV cannulation for them.
62648109|NCT04275336|EXPERIMENTAL|Distraction group|The multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They are also taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
62080421|NCT05694715|EXPERIMENTAL|Cohort 4a (Niraparib, Irinotecan)|Participants weighing \< 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
62080422|NCT05694715|EXPERIMENTAL|Cohort 4b (Niraparib, Irinotecan)|Participants weighing \>= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
62080423|NCT05638880|EXPERIMENTAL|Control Group|30 patients will receive Valsartan 80 mg once daily titrated till blood pressure ≤ 130/80 plus Empagliflozin 10 mg once daily for 3 months
62080424|NCT05638880|ACTIVE_COMPARATOR|Levocetirizine group|30 patients will receive Valsartan 80 mg once daily titrated till blood pressure ≤ 130/80 plus Empagliflozin 10 mg once daily plus Levocetirizine 5 mg once daily in the evening titrated according to creatinine clearance for 3 months.
62080425|NCT01191684|EXPERIMENTAL|Treatment (vaccine therapy)|Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.
62080426|NCT01722916|EXPERIMENTAL|Dose of Hyaluronidase|
62080427|NCT02787720|EXPERIMENTAL|Family centered empowerment model|The Family-Centered Empowerment Model (FCEM)
62080428|NCT02787720|EXPERIMENTAL|Continuous care model|The Continuous Care Model
62080429|NCT03241043|EXPERIMENTAL|Envarsus - Advagraf|
62080430|NCT03241043|ACTIVE_COMPARATOR|Advagraf - Envarsus|
62080431|NCT04765865||Wave 1|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, blood sample collection for fatty acid estimation, and four (4) 24-hour dietary recalls (n=450).
62080432|NCT04765865||Wave 2|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey and 24-hour and spot urine assessments (n=450).
62080433|NCT04765865||Wave 3|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, and four (4) 24-hour dietary recalls (n=450).
62080434|NCT05967130|EXPERIMENTAL|UC Positives|Stable Transplanted Patients with Positive UC
62080435|NCT02826304|ACTIVE_COMPARATOR|VH|Vaginal Hysterectomy for uteri larger than 280gm
62080436|NCT02826304|ACTIVE_COMPARATOR|LAVH|Laparoscopic assisted vaginal hysterectomy for uteri larger than 280gm
62080437|NCT02818075|EXPERIMENTAL|Mobile Phone Based Peer Support|Mobile phone-based peer support (MPPS)
62080438|NCT02818075|ACTIVE_COMPARATOR|Usual Care|Standard community prenatal and postpartum support services
62080439|NCT02640651|EXPERIMENTAL|DC-Stimulator (PLUS version)|For tDCS stimulation, anodal stimulation of the right dorsolateral prefrontal cortex will be performed for twenty minutes at 2mA. The current will be applied by a battery-driven tDCS stimulator via a pair of saline-soaked sponge electrodes (25 cm2 surface). The anodal electrode will be placed on the scalp at the F4 position according to the international 10-20 EEG coordinate system. 20 minute tDCS sessions will be conducted ten times over a two week period
62080440|NCT06738303|EXPERIMENTAL|Arm 1: Cabazitaxel and carboplatin|"Cabazitaxel: Participants will receive cabazitaxel 20 mg/m2 as a one-hour intravenous infusion every three weeks for a total of 10 cycles or until disease progression, unacceptable toxicity.~Carboplatin: Participants will receive carboplatin AUC 4 mg/mL/min every three weeks for a total of 10 cycles or until disease progression, unacceptable toxicity"
62080441|NCT06738303|EXPERIMENTAL|Arm 2: Lu-PSMA-617|Participants will receive 177Lu-PSMA-617 7.4 GBq IV on Day 1 (+/-1 week) of each 6-week cycle for up to 6 cycles or until disease progression, unacceptable toxicity
62080442|NCT02895490|EXPERIMENTAL|Arm I (DVD)|Patients receive a DVD containing educational information about patients' legal rights in the workplace and communication skills demonstrated through four scenarios depicting a variety of employer-employee communication challenges for patients, provided by LINC group.
62080443|NCT02895490|ACTIVE_COMPARATOR|Arm II (control)|Patients receive information about the LINC group.
62080444|NCT06740734|NO_INTERVENTION|Control Group|The group will be given routine care
62080445|NCT06740734|ACTIVE_COMPARATOR|Stress ball|Sterile Stress ball applied to pregnant women during mediolateral episiotomy repair. Participants in the stress ball group will be asked to squeeze and loosen the stress ball in their hands
62080446|NCT06740734|ACTIVE_COMPARATOR|Expressive touch applications|During the mediolateral episiotomy repair, expressive touch will be applied to one hand of the mother by the researcher, lasting approximately 15-20 minutes.
62080447|NCT01635361|EXPERIMENTAL|NMS|Patients in this arm will receive the full NMS service
62080448|NCT01635361|NO_INTERVENTION|Current Practice|Patients in this arm will receive the normal advice with their new medicine as dictated by current professional practice
62080449|NCT06736717|EXPERIMENTAL|Treatment|"Study Drug: Onvansertib:~Orally daily on D1 - 5 of each 14-day cycle~NALIRIFOX Intravenous D1 of each 14-day cycle"
62080450|NCT02499328|EXPERIMENTAL|Part A1: AZD9150 / MEDI4736|Patients allocated in cohort of arm A1 (AZD9150/MEDI4736 will be evaluated for DLT until an MTD is achieved.
62080451|NCT02499328|EXPERIMENTAL|Part A2: AZD5069 / MEDI4736|Patients allocated in cohort of arm A2 (AZD5069/MEDI4736 will be evaluated for DLT until an MTD is achieved.
62080452|NCT02499328|EXPERIMENTAL|Part B1:AZD9150+MEDI4736:PDL1 pretreated|Patients in arm B1 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
62648110|NCT04275336|EXPERIMENTAL|Combined group|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
62080453|NCT02499328|EXPERIMENTAL|Part B2:AZD5069+MEDI4736:PDL1 pretreated|Patients in arm B2 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
62080454|NCT02499328|EXPERIMENTAL|Part B3: AZD9150+MED4736:naiive 2L|Patients in arm B3 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
62080455|NCT02499328|EXPERIMENTAL|Part B4:AZD5069+MEDI4736:naiive patients|Patients in arm B4 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
62457780|NCT06457945|ACTIVE_COMPARATOR|Subjective hypersomnolence|"Patient with subjective hypersomnolence without underlying cause (negative extensive work-up including actigraphy, polysomnography (PSG), MSLT, 24h bedrest, biological tests, MRI, psychiatric consultation; this allows to rule out sleep deprivation, irregular sleep/wake schedule, sleep apnea or other sleep disorders associated with sleep fragmentation, somatic/psychiatric causes of hypersomnolence, sedative substance intake).~A subset of patients will undergo polysomnography recording (EEG, EOG, EMG, ECG) during the ASRT.~They will have to fill study questionnaires and perform the ASRT."
62457781|NCT02388763|OTHER|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
62457782|NCT02388763|OTHER|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
62648111|NCT01518816||preterm labor cases|Group A: 35 pregnant women diagnosed with preterm labor(Preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation \< 2cm and effacement\< 50%) which will deliver within one week maximum after hospitalization.
62648112|NCT01518816||control group|Group B: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit.
62648113|NCT02417025|EXPERIMENTAL|PE-HBT|Prolonged Exposure via home-based telehealth (i.e., completed using videoconferencing technology)
62648114|NCT02417025|ACTIVE_COMPARATOR|PE-SD|Prolonged Exposure via standard delivery (i.e., completed in person at the therapist's office)
62080456|NCT02499328|EXPERIMENTAL|Part B5: AZD9150 in naiive patients|Patients in arm B5 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
62080457|NCT02499328|EXPERIMENTAL|Part B6:AZD5069 in naiive patients|Patients in arm B6 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
62080458|NCT02499328|EXPERIMENTAL|Part A3: AZD5069/MEDI4736|Patients allocated in cohort of arm A3 (AZD5069/MEDI4736) will be evaluated for DLT and viability as alternate dosing option for Phase 2 studies
62080459|NCT02499328|EXPERIMENTAL|Part A4: AZD9150/Treme/MEDI4736|Patients allocated in cohort of arm A4 (AZD9150/treme/MEDI4736) will be evaluated for DLT and MTD
62080460|NCT02499328|EXPERIMENTAL|Part A5: AZD5069/Treme/MEDI4736|Patients allocated in cohort of arm A5 (AZD5069/treme/MEDI4736) will be evaluated for DLT and MTD.
62080461|NCT02499328|EXPERIMENTAL|Part A6: AZD9150/MEDI4736|Patients allocated in cohort of arm A6 (AZD9150/MEDI4736) will be evaluated for safety, PK and PD.
62080462|NCT02499328|EXPERIMENTAL|Part A7: AZD5069/MEDI4736|Patients allocated in cohort of arm A7 (AZD5069/MEDI4736) will be evaluated for safety, PK and PD.
62080463|NCT02499328|EXPERIMENTAL|Part B7: AZD9150+MEDI4736: naiive 1L|Patients in Arm B7 will be evaluated for efficacy until disease progression and then followed up for safety and survival
62080464|NCT02499328|EXPERIMENTAL|Part B8: AZD9150 (every other week)+MEDI4736: naive 1L|Patients in Arm B8 will be evaluated for efficacy until disease progression and then followed up for safety and survival
62080465|NCT06740097|EXPERIMENTAL|Aspirate tissue monitoring|In total fifty (n=50) patients referred for resection surgery for suspected high-grade glioma or its recurrence at the Kuopio University Hospital, Tampere University Hospital and Oslo University Hospital, and potential other trial sites, will be recruited to the study. The patients are prescribed oral 5-ALA preoperatively according to the institution's practices. The cases are operated with the help of aspirate tissue monitoring and the controls without. Other preferred adjunct techniques are used in both groups.
62457783|NCT01756937|ACTIVE_COMPARATOR|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
62457784|NCT01756937|PLACEBO_COMPARATOR|Placebo|1 capsule once daily for 24 weeks
62648115|NCT03541993|EXPERIMENTAL|Resveratrol Hypoxia|500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
62648116|NCT03541993|PLACEBO_COMPARATOR|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
62648117|NCT03541993|EXPERIMENTAL|Resveratrol Normoxia|500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
62648118|NCT03541993|PLACEBO_COMPARATOR|Placebo Normoxia|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
62648119|NCT02193100||13C-glucose|experimental (13C-glucose)
62648120|NCT02193100||No glucose|control (no glucose)
62080466|NCT06740097|ACTIVE_COMPARATOR|Fluorescence-guided surgery|The cases are compared with controls (n=50) from applicable local clinical site registers (matched controls).
62080467|NCT06129409|EXPERIMENTAL|NT-0796|BID
62648121|NCT05827848|EXPERIMENTAL|Treatment group|Turn on the machine for continuous nerve stimulation
62648122|NCT05827848|NO_INTERVENTION|control group|Turn off the machine
62648123|NCT02719977|EXPERIMENTAL|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
62648124|NCT00709085||1|HCC patients without liver cirrhosis
62648125|NCT00709085||2|HCC patients with liver cirrhosis
62648126|NCT04435496|OTHER|GYN-CS insertion|GYN-CS device will be inserted in women during their c-section. The study patient can chose between a lifespan of 3 years (GYN-CS 3) and a lifespan of 10 years (GYN-CS 10) of the device.
62648127|NCT00251758|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62648128|NCT00251758|EXPERIMENTAL|Dexlansoprazole MR 90 mg QD|
62080468|NCT06129409|PLACEBO_COMPARATOR|Placebo|BID
62080469|NCT06740461||Aortic coarctation patient|
62080470|NCT04570735||patients with type 2 diabetes and diabetic kidney disease|
62080471|NCT04570735||patients with type 2 diabetes and no diabetic kidney disease|
62080472|NCT04570735||patients with obesity, no diabetes and no kidney disease|
62648129|NCT00251758|PLACEBO_COMPARATOR|Placebo|
62648130|NCT02944175|EXPERIMENTAL|Sugammadex|Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
62648131|NCT02944175|ACTIVE_COMPARATOR|Neostigmine|Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
62648132|NCT01670864|EXPERIMENTAL|Counseling group|Study participants in the counseling group will receive a brief on-site face-to-face smoking cessation counseling from our trained smoking cessation counselor on the study site after signing the consent form. They will receive advice on quitting smoking and specific warning about the hazardous effects of smoking on health. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week \& 1-month will be made to the participants in this group.
62648133|NCT01670864|EXPERIMENTAL|SMS intervention group|Study participants in the SMS group will receive SMS text messages on smoking cessation advice and warning on the hazardous effects of smoking on health. The participants will receive a total of 16 tailored SMS messages after recruitment.
62648134|NCT01670864|NO_INTERVENTION|Control group|Study participants in the control group will not receive any quitting assistance other than the self-help materials from the recruitment sites.
62648135|NCT06188117|EXPERIMENTAL|Experimental Group|The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.
62648136|NCT06188117|NO_INTERVENTION|Control Group|The digital Game Addiction Awareness Training program will not be applied to parents in the control group.
62648137|NCT01501240||liver cirrhosis, liver transplantation|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1 month will be eligible population in the study
62648138|NCT00853762|EXPERIMENTAL|Atacicept 25 mg (With Loading)|
62648139|NCT00853762|EXPERIMENTAL|Atacicept 75 mg (With Loading)|
62080473|NCT03685708|EXPERIMENTAL|Chronic Lymphocytic Leukemia Patients That Are Treatment Naïve|Treatment naïve Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL) patients will receive HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
62080474|NCT03685708|EXPERIMENTAL|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
62080475|NCT03685708|EXPERIMENTAL|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
62080476|NCT00974103|EXPERIMENTAL|Chiropractic treatment, exercise|Chiropractic treatment and exercise
62457785|NCT05814848|EXPERIMENTAL|single arm|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
62648140|NCT00853762|EXPERIMENTAL|Atacicept 150 mg (With Loading)|
62457786|NCT02719249||Men with ESRD on dialysis or transplant|
62080477|NCT00974103|EXPERIMENTAL|Exercises|Exercise advise
62457787|NCT04043871||Patients with renal insufficiency|
62648141|NCT00853762|EXPERIMENTAL|Atacicept 150 mg (Without Loading)|
62080478|NCT05914649|EXPERIMENTAL|999 mL normal Saline|999 mL of normal saline infused intravenously.
62080479|NCT05914649|PLACEBO_COMPARATOR|50 mL normal Saline|50 mL of normal saline infused intravenously.
62080480|NCT06011876|EXPERIMENTAL|Single-session testing days|Participants will complete three separate single-session testing days. Baseline testing will be performed, then on each day, participants will receive AIH, AIHH, and sham AIH in random order. Post-testing will occur after each intervention.
62080481|NCT06011876|EXPERIMENTAL|Respiratory strength training blocks|Participants will complete three separate respiratory strength training blocks. In each block, participants will receive 5 days of AIH, 5 days of AIHH, and 5 days of sham AIH in random order, followed by respiratory strength training. Each block will include 5 days of intervention and training, and post-testing 1, 3, and 7 days after intervention and training has concluded.
62080482|NCT06046443|EXPERIMENTAL|LB54640 Low dose|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
62080483|NCT06046443|EXPERIMENTAL|LB54640 Middle dose|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
62457788|NCT00220701|EXPERIMENTAL|escitalopram|Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
62457789|NCT00220701|PLACEBO_COMPARATOR|Placebo|inactive comparator
62457790|NCT01274364|EXPERIMENTAL|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
62457791|NCT01274364|ACTIVE_COMPARATOR|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
62648142|NCT04801095|EXPERIMENTAL|WM-S1-030|Dose escalation (part 1) and Dose expansion (part 2)
62648143|NCT06330415|EXPERIMENTAL|Intervention group|Unlimited access to the SME tool.
62648144|NCT06330415|NO_INTERVENTION|Control group|Care as usual by the occupational health service.
62648145|NCT03532737|EXPERIMENTAL|Investigational Arm|"All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor CHEMOTHERAPY: Cisplatin: 100 mg/m2 Q21d D1, D22, D43. OR Cetuximab Loading dose 400 mg/m², one week before radiation then maintenance dose 250 mg/m² weekly, D8, D15, D22, D29, D36, D43.~PD-1 inhibitor: Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks 21 days prior to radiation, then Day 1 of radiation and then every 21 days for total 6 doses~Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66-70 Gy/ 30-35 Fr over 6-7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB)."
62648146|NCT01547481||Parkinson's Disease Cohort|Individuals Diagnosed with Parkinson's Disease
62648147|NCT01547481||Essential Tremor cohort|Individuals Diagnosed with Essential Tremor
62648148|NCT01547481||Rapid Eye Movement Disorder Cohort|Individuals Diagnosed with Rapid-Eye Movement Behavior Disorder (RBD). Eligible individuals will have been diagnosed with RBD based on a sleep study prior to entering the study. This study does not pay for or support a sleep study.
62648149|NCT01547481||Healthy Control group|Individuals are healthy, without a known neurologic disease.
62648150|NCT01547481||Progressive Supranuclear Palsy Cohort|Individuals diagnosed with Progressive Supranuclear Palsy (PSP).
62648151|NCT01547481||Parkinsonism - Undifferentiated|Individuals with any form of Parkinsonism, not meeting any of the above cohorts.
62648152|NCT01149941|EXPERIMENTAL|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
62648153|NCT01149941|ACTIVE_COMPARATOR|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
62648154|NCT02955875|EXPERIMENTAL|Pharmaceutical care|Participants received systematically organized pharmaceutical care services, which were provided by pharmacists, in addition to the usual care. The usual care includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
62080484|NCT06046443|EXPERIMENTAL|LB54640 High dose|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
62080485|NCT06046443|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
62080486|NCT06046443|EXPERIMENTAL|Open-label LB54640|Eligible participants who provide consent to continue into the open-label portion of the study will receive open-label LB54640.
62080487|NCT05468775|EXPERIMENTAL|intervention group|
62080488|NCT05468775|NO_INTERVENTION|control group|
62080489|NCT05714085|EXPERIMENTAL|Base Period: Vericiguat|Participants in the Base Period receive 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form for 52 weeks; or 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form for 52 weeks.
62080490|NCT05714085|PLACEBO_COMPARATOR|Base Period: Placebo|Participants in the Base Period receive placebo for vericiguat administered orally once daily in tablet form for 52 weeks, or administered orally once daily in suspension form for 52 weeks.
62648155|NCT02955875|NO_INTERVENTION|Usual care|Participants received the usual care, which includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
62080491|NCT05714085|EXPERIMENTAL|Extension Period: Vericiguat|Participants in the Extension Period receive either 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form; or 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form; following completion of the Base Period.
62080492|NCT06740344|EXPERIMENTAL|Intervention: Two-handed facemask hold|Two-handed mask hold technique while giving facemask ventilation, with another operator designated to deliver positive inspiratory pressure (PIP) via the T-piece. The operators may be any member of the neonatal team, who have undergone Neonatal Resusctiation Programme (NRP) certification. Standardised mask size and shape for gestation and weight, as per local policy, will be used.
62080493|NCT06740344|PLACEBO_COMPARATOR|Control: One-handed facemask hold|One-handed mask hold technique while giving facemask ventilation, with the same operator holding the mask and delivering positive pressure ventilation (PPV) via the T-piece.
62080494|NCT01374594||Healthy adults|
62080495|NCT01374594||Type 2 diabetes|
62080496|NCT01233167|EXPERIMENTAL|clopidogrel|
62080497|NCT01233167|PLACEBO_COMPARATOR|placebo|
62080498|NCT01233167|EXPERIMENTAL|steply discontinued clopidogrel|
62457792|NCT04839367|EXPERIMENTAL|Cohort 1 - 100 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 100 MBq 64Cu-SAR-bisPSMA.
62457793|NCT04839367|EXPERIMENTAL|Cohort 2 - 150 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 150 MBq 64Cu-SAR-bisPSMA.
62457794|NCT04839367|EXPERIMENTAL|Cohort 3 - 200 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 200 MBq 64Cu-SAR-bisPSMA.
62080499|NCT04898894|EXPERIMENTAL|Treatment|"Dose Escalation Phase:~Venetoclax plus selinexor will initially be given at dose level 1 in combination with intravenous (IV) cytarabine and fludarabine. Dosing of venetoclax and selinexor will be based on tolerability.~Intrathecal (IT) chemotherapy (IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are all acceptable) will be given.~G-CSF SC may be given.~Part 1 has been completed and RP2D has been determined to be Dose Level 2. All participants will be treated at Dose Level 2.~Dose Expansion Phase:~Two expansion cohorts will be treated at the recommended phase 2 dose (RP2D). Cohort A will include venetoclax-naïve patients, whereas Cohort B will include patients with prior exposure to venetoclax."
62080500|NCT06526754|EXPERIMENTAL|3D Printed Model Group (3DP)|Participants in this group will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. The surgical procedures will be guided by these 3D-printed models.
62080501|NCT06526754|EXPERIMENTAL|3D Virtual Model Group (3DV)|Participants in this group will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. The surgical procedures will be guided by these digital simulations.
62080502|NCT00654693||monitored|patients hospitalized for longer than 24 hours and are located on the 4th, 5th, and 6th floors of the Vanderbilt University Medical Center Round Wing
62648156|NCT02924935|EXPERIMENTAL|Treatment|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
62648157|NCT00829270||mitochondrial diseases diagnosis|
62648158|NCT01505920|EXPERIMENTAL|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
62648159|NCT01505920|ACTIVE_COMPARATOR|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally to the four quadrant of the cervix, 3 minutes before starting cervical excision
62457795|NCT02835482|EXPERIMENTAL|Patient with glaucoma|Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.
62648160|NCT06551896|EXPERIMENTAL|Pemigatinib combined with immune checkpoint inhibitor|Pemigatinib 13.5mg，two weeks on and one week off, and with immune checkpoint inhibitor selected by investigator.
62457796|NCT02835482|OTHER|Patient without glaucoma|Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.
62457797|NCT00290147|EXPERIMENTAL|1.0 mg of D1ME100 vaccine|1.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
62457798|NCT00290147|EXPERIMENTAL|5.0 mg of D1ME100 vaccine|5.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
62457799|NCT02129348|ACTIVE_COMPARATOR|Lithium Treatment Group|"The patient will be started on lithium 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on lithium blood level. Blood will be drawn at each study visit. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
62457800|NCT02129348|PLACEBO_COMPARATOR|Placebo Group|"The patient will be started on placebo 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on sham lithium blood level. Blood will be drawn for sham lithium levels at weeks 2, 4, 6, 8, and 12. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
62457801|NCT00494975|EXPERIMENTAL|NB-UVB|Narrow band-Ultraviolet B phototherapy
62648161|NCT02377453||Control|Control: Healthy adult
62648162|NCT02377453||Experimental|Experimental: patients with stroke
62648163|NCT01244464|EXPERIMENTAL|Study Group|
62457802|NCT00494975|PLACEBO_COMPARATOR|UVA|Ultraviolet A Phototherapy
62648164|NCT02247622||Healthy control|
62648165|NCT02247622||IBD|patients with inflammatory bowel disease, study group
62648166|NCT02247622||PSC|patients with primary sclerosing cholangitis, study group
62648167|NCT02989974|EXPERIMENTAL|KY LEADS Survivorship Care - Survivor|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to individuals diagnosed with lung cancer (survivor).
62457803|NCT00507897||A|Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
62457804|NCT00507897||A1|Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
62457805|NCT00507897||B|Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
62457806|NCT00507897||B1|Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1
62457807|NCT05589311|EXPERIMENTAL|Intervention group|One-time 2.5-hour virtual lecture on musculoskeletal pain conducted following Transformative Learning principles
62080503|NCT05203510|EXPERIMENTAL|Treprostinil|"Participants will receive parenteral treprostinil at initial dose of 1.25 nanograms/kilogram/minute (at minimum) either intravenously or subcutaneously. Based on mPAP assessments and after a minimum dose of parenteral treprostinil is reached, at Investigator's (PI's) discretion, participants may transition to oral treprostinil and continue dose uptitration for further reduction of mPAP. Based on Month 12 mPAP assessment, participants may transition from parenteral to oral treprostinil at PI's discretion after completion of Month 12 assessment and continue uptitration for further reduction of mPAP. If minimum dose of parenteral treprostinil is not reached at Month 6/12 at PI's discretion, uptitration of parenteral treprostinil or oral treprostinil transition may occur to maintain normal mPAP.~Treprostinil therapy (parenteral or oral) may continue as tolerated toward goal of further reduction of mPAP until Month 36."
62648168|NCT02989974|EXPERIMENTAL|KY LEADS Survivorship Care - Caregiver|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to caregivers of individuals diagnosed with lung cancer (caregiver)
62080504|NCT06637436|EXPERIMENTAL|Contingency Management|Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
62080505|NCT06637436|EXPERIMENTAL|Motivational Interviewing (MI)|Two-session counseling intervention focusing on PrEP use (Session 1) as well as co-occurring substance use and HIV risk (Session 2)
62080506|NCT06637436|EXPERIMENTAL|MI+CM|Both the CM and MI interventions described above.
62080507|NCT05883631|EXPERIMENTAL|De Novo Arm: Electrographic Flow (EGF) mapping|Subjects with persistent or long-standing persistent atrial fibrillation (AF), coming in for a De Novo pulmonary vein isolation procedure.
62080508|NCT05883631|EXPERIMENTAL|Redo Arm: Electrographic Flow (EGF) mapping and guided ablation of EGF-identified sources|Subjects with paroxysmal, persistent or long-standing persistent atrial fibrillation (AF) coming in for a redo AF procedure.
62648169|NCT01078038|ACTIVE_COMPARATOR|Cypher|Sirolimus-eluting stent
62648170|NCT01078038|ACTIVE_COMPARATOR|Xience V|Everolimus-eluting stent
62648171|NCT02430558|EXPERIMENTAL|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
62080509|NCT05883631|EXPERIMENTAL|Recurrence: Electrographic Flow (EGF) mapping and guided ablation of EGF-identified sources|"Subjects from the De Novo or Redo Arm in which symptomatic atrial fibrillation (AF) recurrence occurs at any time after the 90-day blanking period are eligible for a recurrence procedure. This procedure follows the same workflow as the Redo arm."
62080510|NCT03351998|PLACEBO_COMPARATOR|Placebo|Participants receiving matching placebo oral tablet.
62080511|NCT03351998|ACTIVE_COMPARATOR|Low dose statin|Participants will receive Lipitor 20Mg Tablet to take daily.
62648172|NCT05482802|ACTIVE_COMPARATOR|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short-lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
62648173|NCT05482802|PLACEBO_COMPARATOR|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
62648174|NCT01718483|EXPERIMENTAL|SPD489 (Lisdexamfetamine dimesylate)|
62648175|NCT01718483|PLACEBO_COMPARATOR|Placebo|
62648176|NCT03261999|EXPERIMENTAL|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
62080512|NCT03351998|ACTIVE_COMPARATOR|High dose statin|Participants will receive Lipitor 80Mg Tablet to take daily.
62648177|NCT04818099|EXPERIMENTAL|routine supportive psychotherapy and votioxetine|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given votioxetine 10mg/tablet, one tablet each time, once a day, for 2 months.
62648178|NCT04818099|PLACEBO_COMPARATOR|routine supportive psychotherapy and control|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given placebo, one tablet each time, once a day, for 2 months.
62648179|NCT06200012|ACTIVE_COMPARATOR|Control arm: educational training only|This arm received only an educational training for mental health professionals about substance use-related stigma
62648180|NCT06200012|EXPERIMENTAL|Experimental arm: educational training plus a policy change for controlled substance agreements|"This arm received both 1) an educational training for mental health professionals about substance use-related stigma; and 2) a policy change that replaced the standard LifeStance Health system's controlled substance agreement (CSA) with a new agreement integrating principles of shared decision-making and offering prescribers a communication tool with suggestions for how to implement principles of shared decision-making and patient centered care in their use of the new CSA"
62648181|NCT06515288|EXPERIMENTAL|Intervention schools|The intervention group will receive baseline educational intervention (Nutrition Education Capacity Building for Teachers and Management) and all components of the Nutrition Goes to School (NGTS) program.
62648182|NCT06515288|NO_INTERVENTION|Control schools|The control group receive no specific intervention other than current school health program conducted by the local public health centers (puskesmas).
62648183|NCT01840397||Spine surgery|Patients undergoing spine surgery
62648184|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
62648185|NCT00622765|EXPERIMENTAL|001|R256918 5 mg capsule twice daily
62648186|NCT00622765|EXPERIMENTAL|002|R256918 10 mg capsule twice daily
62648187|NCT00622765|EXPERIMENTAL|003|R256918 15 mg capsule twice daily
62648188|NCT00622765|PLACEBO_COMPARATOR|004|placebo Placebo capsule twice daily
62080513|NCT05389332|EXPERIMENTAL|Mobile skin cancer intervention|Conduct a pilot of the refined intervention among Hispanics to evaluate the preliminary efficacy of the user-centered mobile skin cancer intervention program.
62080514|NCT05389332|ACTIVE_COMPARATOR|Control group: physical activity and nutrition information|Participants will complete a baseline survey first; and then they will be randomly assigned into either the intervention group or the control group. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. The participants will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
62080515|NCT03257995|EXPERIMENTAL|Sequence 1|A-B-C
62080516|NCT03257995|EXPERIMENTAL|Sequence 2|B-C-A
62080517|NCT03257995|EXPERIMENTAL|Sequence 3|C-A-B
62080518|NCT03257995|EXPERIMENTAL|Sequence 4|A-C-B
62080519|NCT03257995|EXPERIMENTAL|Sequence 5|B-A-C
62080520|NCT03257995|EXPERIMENTAL|Sequence 6|C-B-A
62080521|NCT01990300||Alogliptin/Pioglitazone combination tablets|Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
62080522|NCT01991197|EXPERIMENTAL|Sitagliptin|"Double blind phase (week 0-16):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
62080523|NCT01991197|ACTIVE_COMPARATOR|Gliclazide|"Double-blind phase (week 0-16):~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
62080524|NCT02701582|EXPERIMENTAL|Goal Directed Therapy|Flotrack monitor is connected and based on what anesthesiologist sees and following study algorithm, anesthesiologist chooses: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
62080525|NCT02701582|ACTIVE_COMPARATOR|Control Group|FloTrac monitor is connected, but he anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be given a study algorithm to follow for the duration of the surgery, and based on it will choose: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
62457808|NCT05589311|ACTIVE_COMPARATOR|Control group|One-time 2.5-hour virtual lecture on musculoskeletal pain conducted using conventional didactic approach
62457809|NCT04304963||T1DM and intact awareness of hypoglycaemia|200 participants with T1DM and intact awareness of hypoglycaemia
62648189|NCT06000644|EXPERIMENTAL|combined group|The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing.
62457810|NCT04304963||T1Dm and impaired awareness of hypoglycaemia|50 participants with T1Dm and impaired awareness of hypoglycaemia
62457811|NCT04304963||insulin treated T2DM|350 participants with insulin treated T2DM ( \> 1 injections / day)
62457812|NCT01648842||Pregnant women|
62457813|NCT00940368|EXPERIMENTAL|Ginger arm|"The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day"
62648190|NCT06000644|ACTIVE_COMPARATOR|cognitive group|The cognitive group will receive cognitive training while walking on the treadmill.
62648191|NCT06000644|ACTIVE_COMPARATOR|rhythmic group|The rhythmic group will hear rhythmic auditory stimulation while treadmill walking.
62648192|NCT06000644|ACTIVE_COMPARATOR|treadmill group|The treadmill group will train only in progressive treadmill walking.
62648193|NCT04291040|EXPERIMENTAL|Decision Aid|
62648194|NCT04291040|ACTIVE_COMPARATOR|Routine Care|
62648195|NCT01499485|EXPERIMENTAL|Acetazolamide|
62648196|NCT01499485|PLACEBO_COMPARATOR|placebo|
62648197|NCT05573152|EXPERIMENTAL|Nursing|Nursing Group (Nurse): the nursing team will use of the warming device air flow device from the moment the patients enter the operating room until anesthesia induction. The warming device will be set up connected to the patient and to the motor with the activation of the system at 43°C by the nursing team. The monitoring of the times since the entrance of the patient in the operating room until the induction of the anesthesia will be controlled by a member of the anesthesia team (regardless of the room process);
62648198|NCT05945095|EXPERIMENTAL|Experimental group|Gum chewing group
62648199|NCT05945095|NO_INTERVENTION|Control group|Routine care
62080526|NCT01592695|EXPERIMENTAL|Tailored Intervention Group|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
62080527|NCT01592695|ACTIVE_COMPARATOR|Enhanced Standard of Care Group|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
62080528|NCT06738576|EXPERIMENTAL|single dose of 40 million HC016|They will receive 1 single dose 1 dose of 40 million cells of HC016 at a concentration of 10 million cells/mL. N=40
62080529|NCT06738576|PLACEBO_COMPARATOR|Saline solution|They will receive a single dose of the saline solution in which the HC016 cells are conditioned, which consists of lactated ringer's, glucosaline, sodium bicarbonate and human albumin. N=20
62648200|NCT03109483|OTHER|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
62080530|NCT06738394|EXPERIMENTAL|High-Velocity Resistance Training (HVRT)|Those assigned to HVRT will attend three small-group (two to five people) exercise sessions lasting 60-75 minutes per week consisting of upper- and lower-body movements performed with weighted vests, medicine balls, and resistance bands. For all exercises, the concentric phase (muscle-shortening portion) will be performed as quickly as possible while maintaining good form, followed by a 1-second pause and then the eccentric phase (lengthening portion) completed in a slow and controlled fashion. Following completion of the 12-week intervention, all participants will be asked to complete the same baseline tests to assess changes in physical function, body composition, quality of life, and cognitive function outcomes.
62080531|NCT06738394|ACTIVE_COMPARATOR|Control Group|Participants randomized to the attention control group will receive dedicated contact, information, and motivation throughout the course of the intervention via weekly group sessions and informational handouts. Each in-person group meeting will last approximately one hour. These group sessions will take place in a classroom/conference room setting and include information on such topics as blood pressure, reading food labels, healthy eating, and memory. The class will be a PowerPoint presentation with incorporated question/answer, lively discussion, and group-bonding activities. Following completion of the 12-week intervention, all participants will be asked to complete the same baseline tests to assess changes in physical function, body composition, quality of life, and cognitive function outcomes.
62080532|NCT05886777|EXPERIMENTAL|Group 1|Combination \[RSVpreF+BNT162b2\] + Quadrivalent influenza vaccine (QIV)
62080533|NCT05886777|EXPERIMENTAL|Group 2|Combination \[RSVpreF+BNT162b2\] + placebo
62080534|NCT05886777|ACTIVE_COMPARATOR|Group 3|BNT162b2 + placebo
62080535|NCT05886777|ACTIVE_COMPARATOR|Group 4|RSVpreF + placebo
62080536|NCT05886777|ACTIVE_COMPARATOR|Group 5|QIV + placebo
62080537|NCT05886777|EXPERIMENTAL|Group 6|Coadministration RSVpreF + bivalent BNT162b2 + placebo
62080538|NCT05886777|EXPERIMENTAL|Group 7|Coadministration RSVpreF + bivalent BNT162b2 + QIV
62080539|NCT02822170|EXPERIMENTAL|IV amino acids and in-bed cycle ergometry|"Beginning within 96 hours of ICU admission, participants will receive the following combined intervention:~1. IV amino acids (15% solution) delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day.~2. In-bed cycle ergometry exercise delivered in 45-minute sessions 5 days per week according to a detailed specific protocol that includes a safety check and gradual increases in resistance if the participant is actively cycling."
62080540|NCT06739200|EXPERIMENTAL|PRF Membrane Group|Participants in this group will undergo periapical surgery in which a platelet-rich fibrin (PRF) membrane will be placed at the surgical site. The PRF membrane is designed to promote healing and reduce postoperative swelling and pain. Outcomes, including swelling, pain levels, and healing progress, will be evaluated.
62648201|NCT00320086||diabetes group|6 to 18 years old males and females, with confirmed diagnosis of Type I or Type II Diabetes with no history of: kidney disease, documented urinary tract infection, cardiovascular disease, liver disease, nocturnal enuresis, metabolic disease other that diabetes, abnormal body temperature at start of study visit, no strenuous exercise 24 hours prior to start of study visit.
62457814|NCT00940368|PLACEBO_COMPARATOR|Placebo arm|"Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day"
62648202|NCT00320086||control group|6 to 18 years old males and females, with no history of: Type I or Type II Diabetes and/or other metabolic disease, kidney disease, documented urinary tract infection, cardiovascular disease, liver disease, nocturnal enuresis, abnormal body temperature at start of study visit, no strenuous exercise 24 hours prior to start of study visit.
62648203|NCT03492203|EXPERIMENTAL|Active Cognitive Remediation -Long-term|Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
62648204|NCT03492203|ACTIVE_COMPARATOR|Active Cognitive Remediation -Short-term|Participants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
62648205|NCT03492203|PLACEBO_COMPARATOR|Cognitive Remediation Control|Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
62648206|NCT03665870|EXPERIMENTAL|Intervention Arm|Hypoglycemia Education: Participants will receive educational support to prevent repeat episodes of hypoglycemia.
62648207|NCT04194164|EXPERIMENTAL|Fluid intake app|Participants in this arm will use the fluid intake app to help them decrease interdialytic fluid intake. Participants will take a survey to assess the efficacy of the fluid app..
62648208|NCT01244477|EXPERIMENTAL|CPT-C|Participants in group CPT-C
62648209|NCT01244477|NO_INTERVENTION|Treatment-as-Usual|Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).
62648210|NCT05677399|EXPERIMENTAL|Treatment Group|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
62648211|NCT05677399|NO_INTERVENTION|Control Group|Control group continued to use their usual medical treatment.
62648212|NCT00906243|EXPERIMENTAL|CV9103|CV9103 will be applied intradermally on three (3) or five (5) time points. Treatment with CV9103 is administered over a period of either seven (7) or twenty-three (23) weeks.
62648213|NCT05068843|ACTIVE_COMPARATOR|Arthroscopic partial meniscectomy|"In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy (APM) within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.~Other Names:~APM meniscal surgery surgery"
62648214|NCT05068843|OTHER|Physical therapy|The physical therapy program consisted of a physical therapist-led incremental exercise program containing of coordination/balance, closed kinetic chain strengths and cardiovascular exercises (see Appendix 1). The program was designed for 8 weeks with a total of 16 treatment sessions, each with a duration of 30 minutes. All 16 sessions were reimbursed. If knee symptoms persisted following the physical therapy program (e.g., knee pain, limitations in daily activities or mechanical dysfunction ), the patient could attend additional physical therapy sessions (not reimbursed by the study) or have meniscal surgery, depending on a shared decision after consultation with their orthopaedic surgeon.
62648215|NCT05046808|EXPERIMENTAL|Famitinib Malate Capsules 10mg|
62648216|NCT05046808|EXPERIMENTAL|Famitinib Malate Capsules 15mg|
62648217|NCT05046808|EXPERIMENTAL|Famitinib Malate Capsules 20mg|
62080541|NCT06739200|NO_INTERVENTION|Control Group|Participants in this group will undergo periapical surgery without the use of a PRF membrane. This group will serve as a comparison to evaluate the effectiveness of the PRF membrane in promoting healing and reducing postoperative swelling and pain. Outcomes, including swelling, pain levels, and healing progress, will be evaluated.
62080542|NCT01084590|EXPERIMENTAL|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
62457815|NCT04028453||Mother|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation questionnaire.
62457816|NCT03394209|EXPERIMENTAL|Favipiravir+oseltamivir|Favipiravir+oseltamivir will be given twice daily for a 10-day period.
62648218|NCT05046808|EXPERIMENTAL|Famitinib Malate Capsules 10mg*2|
62648219|NCT05046808|EXPERIMENTAL|Famitinib Malate Capsules 25mg|
62457817|NCT05597345|EXPERIMENTAL|Experimental: Treatment|Selinexor 40mg weekly for up to 12 cycles. Each cycle will be 28 days in length.
62457818|NCT04055402|EXPERIMENTAL|EMA group|Participate in the baseline survey, 2-week ecological momentary assessments and a 1-month follow-up survey
62457819|NCT04055402|ACTIVE_COMPARATOR|Control group|Participate in the baseline survey,and a 1-month follow-up survey
62648220|NCT02144909|EXPERIMENTAL|Partners in Care with Semi-Structured Support Group|Partners in Care with Semi-Structured Support Group: participants will receive the Partners in Care intervention followed by 6 semi-structured support groups, conducted every other week for 3 months. Half of the support groups will be conducted by professionals with diabetes specific knowledge, e.g., pharmacists, physicians, nutritionists. While the other half will be conducted by the trained diabetes self-management facilitator.
62080543|NCT01084590|ACTIVE_COMPARATOR|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
62080544|NCT06326463|EXPERIMENTAL|CD70- CAR T cell Therapy|Patients will receive autologous (their own) cells.
62457820|NCT03248063|ACTIVE_COMPARATOR|Cloxacillin|Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion.
62648221|NCT02144909|NO_INTERVENTION|Partners in Care Standard Follow-up|Participants will receive the Partners in Care intervention followed by monthly healthy lifestyle tips related to diabetes self-management
62457821|NCT03248063|EXPERIMENTAL|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion.
62457822|NCT02566824|EXPERIMENTAL|Cognitive Behavioural & Skills Training|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of group cognitive behavioral and skills training therapy.
62648222|NCT06401291|OTHER|Open label|See intervention: all patients included in the study will receive TENS treatment for a period of 1 month
62648223|NCT05691543||study group|patients with symptomatic Stage II , III and Stage IV Apical Prolapse (diagnosed by pop Q test)
62648224|NCT04893161|OTHER|belimumab|All patients with SLE receive belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48. The patients who had SRI-4 response at week 48 were divided into response group and the patients without SRI-4 response at week 48 were divided into no response group.
62648225|NCT05457699|EXPERIMENTAL|SABR consolidation|
62648226|NCT05457699|ACTIVE_COMPARATOR|Control - no SABR consolidation|
62648227|NCT03405311|ACTIVE_COMPARATOR|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
62648228|NCT03405311|EXPERIMENTAL|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
62080545|NCT04627727|EXPERIMENTAL|low FODMAP diet|
62080546|NCT03292042|EXPERIMENTAL|Experimental Group|"This group will carry out the lifestyle intervention (Physical health promotion program) during 6 months.~The group will attend a session per week."
62080547|NCT03292042|NO_INTERVENTION|Control group|usual care
62648229|NCT00323063|ACTIVE_COMPARATOR|Arm I (Gemcitabine Hydrochloride)|Patients receive gemcitabine hydrochloride IV on days 3 and 10.
62648230|NCT00323063|EXPERIMENTAL|Arm II (Gemcitabine Hydrochloride + Imatinib)|Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.
62648231|NCT02397746||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® Gladiator femoral stem, MicroPort acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
62648232|NCT02580656|EXPERIMENTAL|Metacognitive Therapy|Metacognitive Therapy (MCT) is a brief psychological intervention which will be delivered over a course of six, one hour weekly sessions. Treatment will follow a manualised protocol.
62080548|NCT06740188|EXPERIMENTAL|Intervention group|The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone.
62280074|NCT04123158||GREEN|"Patients will be assessed by a Green Card to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics.~* If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form will be fulfilled in order to check the presence of the criteria described in the Orange Card~* In case of negative Orange Criteria (no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of positive Orange Criteria the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately."
62080549|NCT06740188|ACTIVE_COMPARATOR|Control group|The control group was given citalopram hydrobromide combined with zolpidem.
62280075|NCT04123158||ORANGE|- If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 30 days and triaged to surgery (to be performed within 60 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled Histology of the target myometrial lesion will be considered as the gold standard parameter.
62648233|NCT05507138|EXPERIMENTAL|AKL-T01|Participants in the intervention group will complete 25 minutes of AKL-T01 per day, 5 days/week, for 6 weeks. AKL-T01 trains rapid multitasking on an iPad in an immersive videogame-like environment. Participants complete go/no-go + navigation exercises by moving the iPad to navigate a character on a path while tapping when a certain stimulus is presented and ignoring other stimuli. Participants will also receive weekly 45-minute metacognitive strategy coaching sessions delivered by a clinician. Sessions use guided questions and worksheets (shared virtually) to help participants reflect on their experience with AKL-T01 and link it to daily functioning, generate strategies for daily activities, and explore any emotional responses that arise during gameplay.
62080550|NCT04575935|EXPERIMENTAL|Arm A (MIS, standard of care chemotherapy)|Patients undergo MIS within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. If during MIS the surgeon thinks complete gross resection can only be accomplished by performing an open procedure, patients may undergo laparotomy instead. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
62280076|NCT00511680|EXPERIMENTAL|Behavioral based In-home Intervention|This group will recieve up to 10 1-hour sessions over a 4 month period.
62080551|NCT04575935|ACTIVE_COMPARATOR|Arm B (laparotomy, standard of care chemotherapy)|Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
62080552|NCT00954018||Cystic Fibrosis patient during outpatient clinic visit|
62080553|NCT00954018||Cystic Fibrosis patients during hospitalization|
62080554|NCT00954018||CF patients about to have sinus surgery and bronchoscopy|
62280077|NCT04337411||Cohort 1|Non-ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≤ 2)
62280078|NCT04337411||Cohort 2|Ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≥ 3)
62280079|NCT01893398|EXPERIMENTAL|rehabilitation (MST) program|The Multidimensional Stimulation group therapy (MST) involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
62080555|NCT05776979|EXPERIMENTAL|isatuximab plus lenalidomide after an autologous stem cell transplantation (ASCT)|Both isatuximab and lenalidomide are FDA approved and commercially available for the treatment of relapsed or refractory MM (MM that has come back or stopped responding to treatment). Participants will begin taking the study drugs about 60-180 days after your ASCT. Participants may receive the study drugs for about 3 years. After that, participants will have follow-up visits 1 time a year for the 3 years after your last dose of study drugs
62080556|NCT04920149|EXPERIMENTAL|Mesalamine|Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
62080557|NCT04920149|PLACEBO_COMPARATOR|Placebo|Placebo for Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
62080558|NCT06435273|EXPERIMENTAL|AZD4604|AZD4604
62080559|NCT06435273|PLACEBO_COMPARATOR|Placebo to AZD4604|Placebo to AZD4604
62080560|NCT05235295|EXPERIMENTAL|Fluoroscopic-guided sacroiliac joint injection|
62080561|NCT05235295|ACTIVE_COMPARATOR|Ultrasound-guided sacroiliac joint injection|
62648234|NCT05507138|PLACEBO_COMPARATOR|Enhanced Metacognitive Strategy Training|"In the control group, participants will complete-at the same frequency and duration as the intervention group-iPad-based games designed to provide general cognitive stimulation (word searches, checkers, and spot the differences between two pictures). Concurrently with these cognitive stimulation games, participants will receive weekly metacognitive strategy coaching sessions akin to that described above."
62648235|NCT02517840||Nonagenarian CLI|Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization
62648236|NCT04211584|ACTIVE_COMPARATOR|forearm radial artery access|traditional access (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
62080562|NCT04241874|EXPERIMENTAL|Low PEEP and full inspiratory synchronization|PEEP = 5 cmH2O + clinically selected pressure support (PSVclin)
62080563|NCT04241874|EXPERIMENTAL|High PEEP and full inspiratory synchronization|PEEP = 15 cmH2O + clinically selected pressure support (PSVclin)
62080564|NCT04241874|EXPERIMENTAL|Low PEEP and inspiratory desynchronization|PEEP = 5 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
62280080|NCT01893398|NO_INTERVENTION|Usual care program|Usual care PWA program
62280081|NCT01469910|EXPERIMENTAL|Simotinib|
62280082|NCT01469910|PLACEBO_COMPARATOR|Placebo|
62280083|NCT04677439|EXPERIMENTAL|Flumatinib|
62280084|NCT05004545|EXPERIMENTAL|group 1 Profol Infusion to CABG patients to check lactate level|Propofol infusion according to bodyweight will be given to check lactate level on CPB
62280085|NCT05004545|ACTIVE_COMPARATOR|sevoflurane will be given to group 2 to check lacate level|Sevoflurane MAC % will be given to CABG patients to check lactate level
62648237|NCT04211584|ACTIVE_COMPARATOR|anatomic snuffbox access|access in the snuffbox area of the wrist (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
62080565|NCT04241874|EXPERIMENTAL|High PEEP and inspiratory desynchronization|PEEP = 15 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
62280086|NCT05462509|EXPERIMENTAL|bCPAP and blenders|"all patients admitted to the newborn care unit with respiratory failure will be evaluated for treatment with bCPAP per unit standards. All patients that meet treatment criteria will receive bCPAP. Patients for whom consent is available will be enrolled and start bCPAP therapy with the PATH kit. Patients for whom consent is not given or not available will start Kiwoko bCPAP. Patients who began bCPAP therapy with the Kiwoko kit and obtain consent within 24 hours of starting their bCPAP therapy may switch from Kiwoko to PATH bCPAP. Patients with \>24 hours of Kiwoko bCPAP therapy are no longer eligible for enrolment. , oxygen blending for patients treated with PATH bCPAP will occur by the following two methods- and will be used in this order of preference:~1. blending via air compressor (standard of care in unit and used when available)~2. blending via PATH blender (when no compressor available)"
62280087|NCT03126760|EXPERIMENTAL|Acthar Gel|Participants receive Acthar Gel under the skin once a day for 14 consecutive days
62648238|NCT01317641|EXPERIMENTAL|ODM-201 Phase I|
62648239|NCT01317641|EXPERIMENTAL|ODM-201 Phase II Dose 1|
62080566|NCT06738121|ACTIVE_COMPARATOR|Traditional Infra-umbilical incision|Patients randomized to this arm with have the traditional curvilinear infra-umbilical incision
62080567|NCT06738121|ACTIVE_COMPARATOR|Vertical Trans-umbilical Incision|Patients in this arm will have the cranio-caudal vertical incision right through the umbilicus for the repair of the umbilical hernia
62080568|NCT06498713|ACTIVE_COMPARATOR|Nurse Administered Acetaminophen|Participants will receive acetaminophen pills 650 mg every 4 hours as needed (PRN) administered by nurse per standard of care
62280088|NCT03126760|PLACEBO_COMPARATOR|Placebo|Participants receive Placebo under the skin once a day for 14 consecutive days
62457823|NCT02566824|ACTIVE_COMPARATOR|Supportive Group Therapy|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of supportive group therapy.
62457824|NCT02566824|ACTIVE_COMPARATOR|Treatment as Usual - community resources|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they are referred to their treating physicians and are free to use any resources that are available to them in their communities.
62648240|NCT01317641|EXPERIMENTAL|ODM-201 Phase II Dose 2|
62648241|NCT01317641|EXPERIMENTAL|ODM-201 Phase II Dose 3|
62648242|NCT00325637|ACTIVE_COMPARATOR|A,1,III|To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke
62648243|NCT01586195|EXPERIMENTAL|Vemurafenib|Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.
62648244|NCT04325880|PLACEBO_COMPARATOR|Placebo arm|Patients in this arm will receive a placebo formula
62648245|NCT04325880|ACTIVE_COMPARATOR|Mirabegron arm|Patients in this arm will receive Mirabegrone 50 mg once daily
62648246|NCT04325880|ACTIVE_COMPARATOR|Tamsulosin arm|Patients in this arm will receive tamsulosin o.4 mg once daily
62648247|NCT04325880|ACTIVE_COMPARATOR|Solifenacin arm|Patients in this arm will receive solifenacin 10 mg once daily
62080569|NCT06498713|EXPERIMENTAL|CADD pump Administered Acetaminophen (Participant Controlled)|Participants will receive a CADD pump primed and programmed to deliver 650 mg liquid acetaminophen into a medication cup every 4 hours as needed (PRN).
62457825|NCT02339766|SHAM_COMPARATOR|Group 1|Group 1 will receive intrathecal morphine co-administered with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Sham Block be done with 25 mL of saline per side.
62648248|NCT03042546|ACTIVE_COMPARATOR|Calcium Sulphate|
62648249|NCT03042546|ACTIVE_COMPARATOR|PMMA|
62648250|NCT03042546|ACTIVE_COMPARATOR|Nothing|
62648251|NCT04245774|EXPERIMENTAL|Group L (Hyperbaric Levobupivacaine)|"7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.~In order to obtain hyperbaric levobupivacaine, 1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) was added to 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water."
62648252|NCT04245774|ACTIVE_COMPARATOR|Group B (Hyperbaric Bupivacaine)|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (Marcaine® Spinal Heavy, 0.5%, 4 mL ampoule, AstraZeneca/England, Eczacıbaşı/Turkey, dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.
62648253|NCT05363228|EXPERIMENTAL|Therapy by Dance and Movement|Participants assigned to this part take part in Dance Movement Therapy twice a week (90 minutes each) for the duration of three months.
62648254|NCT05363228|NO_INTERVENTION|Control to Dance Movement Therapy|Participants assigned to this arm take part in no particular activity for the three months.
62648255|NCT05363228|EXPERIMENTAL|Movement Therapy by Tai Chi|Participants assigned to this part take part inTai Chi class twice a week (90 minutes each) for the duration of three months.
62648256|NCT05363228|NO_INTERVENTION|Control to Tai Chi|Participants assigned to this arm take part in no particular activity for the three months.
62080570|NCT06643377|EXPERIMENTAL|Panel A: Severe Renal Impairment|Participants with severe renal impairment receive enlicitide once daily (QD) for 28 days.
62080571|NCT06643377|EXPERIMENTAL|Panel B: Healthy|Healthy participants receive enlicitide QD for 28 days.
62457826|NCT02339766|ACTIVE_COMPARATOR|Group 2|Group 2 will receive an equivalent volume of intrathecal saline co-administered with the spinal anesthetic. After surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
62648257|NCT03713918|EXPERIMENTAL|Reinforced lithium silicate endocrown|Device: Endocrown restoration
62648258|NCT03713918|ACTIVE_COMPARATOR|Reinforced lithi silicate crn e post|Device: Post retained reinforced lithium silicate crowns
62648259|NCT00748202|ACTIVE_COMPARATOR|1|intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
62648260|NCT00748202|ACTIVE_COMPARATOR|2|subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.
62648261|NCT02147301|EXPERIMENTAL|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
62648262|NCT02462265|EXPERIMENTAL|'Oshadi D & Oshadi R; salvage therapy'|Oshadi D (180mg/tid) \& Oshadi R (180mg/tid) will be administrated orally; Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days) will be administrated
62648263|NCT00947544|EXPERIMENTAL|HPN-100 and NaPBA|1 week of NaPBA treatment followed by 1 week of HPN-100 treatment.
62648264|NCT06238739|PLACEBO_COMPARATOR|Group 1|Standard measures administered to patients
62648265|NCT06238739|EXPERIMENTAL|Group 2|Passive measures
62648266|NCT06238739|EXPERIMENTAL|Group 3|Active measures (Blanketrol)
62648267|NCT06238739|EXPERIMENTAL|Group 4|Active measures (HotDog)
62648268|NCT03297632|EXPERIMENTAL|Intervention Group|Receives instructor-based functional resistance exercise. 45 minutes per session. 3 times per week, during 10 weeks in total.
62648269|NCT03297632|NO_INTERVENTION|Control group|Asked to normally active according to their current lifestyle
62648270|NCT03297632|ACTIVE_COMPARATOR|Home-based group|Receives home-based exercises with written instructions and digital video support. 45 minutes per session. 3 times per week, during 10 weeks in total.
62648271|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
62648272|NCT02265965|EXPERIMENTAL|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
62648273|NCT02265965|NO_INTERVENTION|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
62648274|NCT03277040|EXPERIMENTAL|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
62648275|NCT03277040|NO_INTERVENTION|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
62648276|NCT01640977||Open PLIF|The PLIF procedure achieves access to the degenerated disc from the back of the spine, and is performed through a single midline posterior incision that is typically expanded bilaterally past the facet joints to expose bony landmarks for pedicle screw fixation, which are traditionally placed in a trajectory from lateral to medial, requiring a more lateral starting point.
62648277|NCT01640977||MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach, avoiding the far lateral exposure typical of the traditional PLIF.
62648278|NCT02158897|NO_INTERVENTION|Control|Participants will consume their normal diet. Body weight and physiological change at two time points (approximately 2-3 months apart) will be examined. The participants will be crossed over to the diet group.
62648279|NCT02158897|EXPERIMENTAL|Prolon Diet|Participants will be provided with a 5-day supply of fasting-mimicking diet, including energy bars, soups, drink packets and dietary supplements. Participants will diet for 3 cycles. Each one-month cycle consists of 5 days of dieting with a calorie intake estimated at 600-1200 calories per day. The rest of the month participants will eat normally. After 3 cycles, participants will be examined again after consuming their normal diet after 2-3 months.
62648280|NCT04805333|EXPERIMENTAL|Dose 1 - 450mg Artemisia annua|Participants in this group will consume 1 cup of decaffeinated coffee (450 mg Artemisia annua).
62280089|NCT05201755|OTHER|A|"Investigators will evaluate the diameter of the basilica vein and venous flow-velocity after 5 minutes of breathing at room air. Investigators will collect basic vital parameters (heart rate, blood pressure, pulsoximetry).~Afterwards, the investigators will administer CPAP through a helmet, with the straps placed under the armpits. After 5 minutes, the investigators will collect again ultrasound data (venous diameter of basilica vein, flow-velocity) and basic vital parameters (heart rate, blood pressure, pulsoximetry).~Then the CPAP helmet will be tied to the bed and the armpit straps removed. After 5 minutes the investigators will collect ultrasound data and basic vital parameters as in the steps before (venous diameter, flow-velocity, heart rate, blood pressure, pulsoximetry). After this three steps, the protocol ends."
62648281|NCT04805333|EXPERIMENTAL|Dose 2 - 900mg Artemisia annua|Participants in this group will consume 2 cups of decaffeinated coffee (900 mg Artemisia annua).
62648282|NCT04805333|EXPERIMENTAL|Dose 3 - 1350mg Artemisia annua|Participants in this group will consume 3 cups of decaffeinated coffee (1350 mg Artemisia annua).
62648283|NCT04805333|EXPERIMENTAL|Dose 5 - 1800mg Artemisia annua|Participants in this group will consume 4 cups of decaffeinated coffee (1800 mg Artemisia annua).
62648284|NCT04805333|EXPERIMENTAL|Dose Expansion - Recommended Phase II Dose|This cohort will be an expansion of 6 patients for further tolerability and secondary endpoints analysis. They will consume the recommended phase II dose (dependent on prior analysis).
62648285|NCT03953742|EXPERIMENTAL|CPI-200|"Dose Escalation Group: CPI-200 will be administered via intravenous infusion once every 3 weeks for up to 7 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
62648286|NCT03618875|ACTIVE_COMPARATOR|ice|Patients were randomly assigned to receive an ice 5 minutes prior the IViT
62648287|NCT03618875|PLACEBO_COMPARATOR|placebo|Patients were randomly assigned to a room temperature patch (placebo) 5 minutes prior the IViT
62648288|NCT02017002|ACTIVE_COMPARATOR|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
62648289|NCT02017002|PLACEBO_COMPARATOR|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
62648290|NCT04135547|EXPERIMENTAL|intra-osseous access, IO at the humeral site|the OHCA patients receiving IO at the humeral site by paramedics in the field
62280090|NCT05201755|OTHER|B|Same interventions and measurements as A, in different order (breathing room air, then with a CPAP helmet tied to the bed, then with a CPAP helmet fastened with armpit straps).
62648291|NCT04135547|ACTIVE_COMPARATOR|intravenous access; IV at the upper limb|the OHCA patients receiving IV at the upper limb by paramedics in the field
62648292|NCT00296517|PLACEBO_COMPARATOR|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
62080572|NCT06741020|EXPERIMENTAL|HAICI group|"Day 1: Adebrelimab 1200mg, administer over 1 hour. Day 1: Oxaliplatin 85mg/m², administer over 1-3 hours; Day 1: Leucovorin calcium 400mg/m², administer over 3-4 hours; Day 1: Fluorouracil 400mg/m², administer as a bolus infusion (50ml/min) at the 4th hour; Fluorouracil 2400mg/m², continue infusion for more than 46 hours; If the patient has two or more supplying arteries, consider placing a perfusion catheter in the main artery for infusion, and use iodinated oil, doxorubicin or idarubicin, oxaliplatin, and other drugs for chemoembolization in other arteries.~The above treatment regimen is repeated every 3 weeks for a treatment cycle."
62080573|NCT06308081|EXPERIMENTAL|Tailored|Participants in the tailored arm will receive SGM-tailored anti-vaping health messages delivered via text message
62080574|NCT06308081|NO_INTERVENTION|Non-Tailored|Participants in the non-tailored arm will receive non-tailored anti-vaping health messages delivered via text message
62080575|NCT05781386|EXPERIMENTAL|SIM1811-03 monotherapy or SIM1811-03 in combination with Sintilimab injection|All participants receive SIM1811-03 or SIM1811-03 in combination with Sintilimab injection
62080576|NCT05560646|EXPERIMENTAL|Group A: OG-6219 Dose 1|Group A: OG-6219 Dose 1 BID
62080577|NCT05560646|EXPERIMENTAL|Group B: OG-6219 Dose 2|Group B: OG-6219 Dose 2 BID
62080578|NCT05560646|EXPERIMENTAL|Group C: OG-6219 Dose 3|Group C: OG-6219 Dose 3 BID
62280091|NCT05201755|OTHER|C|Same interventions and measurements as A, in different order (breathing with a CPAP fastened with armpit straps, breathing with a CPAP helmet tied to the bed and breathing at room air).
62280092|NCT05201755|OTHER|D|Same interventions and measurements as A, in different order (breathing with a CPAP helmet tied to the bed, breathing with a CPAP helmet fastened with armpit straps and breathing at room air).
62280093|NCT05634759|EXPERIMENTAL|Routine Community-wide MDA followed by Two Additional Rounds of Treatment for Children|The enhanced MDA Strategy 1 consists of a routine community-wide MDA followed by two additional rounds targeted to children age 6 months to 9 years. The additional rounds of treatment will occur 2 weeks apart and will begin 1 week after the community-wide MDA.
62280094|NCT05634759|EXPERIMENTAL|Routine Community-wide MDA followed by a Second Community-wide MDA|The enhanced MDA Strategy 2 consist of a routine community-wide MDA followed by a second community-wide MDA approximately 6-8 months later. The timing of the second MDA will depend on local conditions and logistical concerns.
62080579|NCT05560646|PLACEBO_COMPARATOR|Group D: Placebo|Group D: Placebo BID
62080580|NCT06396377|NO_INTERVENTION|Control|If the resident is randomized to the control group, the resident will not receive a reborn®doll. The investigating team will observe the resident's behavior as if he or she were receiving a doll.
62280095|NCT05634759|ACTIVE_COMPARATOR|Standard-of-Care Annual MDA|Programmatic Control Comparator data for the standard-of-care annual MDA will come from the MDA conducted in 2022 in a random selection of 15 non-study villages.
62280096|NCT04468217||Subjects with positive test to SARS-COV2|Employees of critical services companies and healthcare workers with a positive test to SARS-COV2.
62080581|NCT06396377|EXPERIMENTAL|Reborn doll|The investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
62280097|NCT04468217||Subjects with negative test to SARS-COV2|Employees of critical services companies and healthcare workers with a negative test to SARS-COV2.
62280098|NCT06067880||Lower Limb Lymphedema|This was a retrospective cohort propensity score-matched study. Patients with cancer-related unilateral lower limb lymphedema were enrolled.
62280099|NCT05376085|EXPERIMENTAL|RT|"T: DA-5215 R: DA-5215-R"
62648293|NCT00296517|EXPERIMENTAL|Bupropion SR|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
62280100|NCT05376085|EXPERIMENTAL|TR|"T: DA-5215 R: DA-5215-R"
62280101|NCT01780610|OTHER|group OI-A|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited , who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the Letrozole and human chorionic gonadotrophin ovulation induced cycles.
62457827|NCT02339766|ACTIVE_COMPARATOR|Group 3|Group 3 will receive will receive intrathecal morphine with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
62457828|NCT05527756||Totally endoscopic aortic/mitral valve replacement|Study procedures include the Scar Cosmesis Assessment and Rating (SCAR) scale and numerical rating scale (NRS) questionnaire at one, 14 and 30 days after totally endoscopic aortic/mitral valve replacement. Additionally, a photo of the incisions will be taken at these time points.
62648294|NCT05220423|OTHER|Reminders Group|This group will receive 6 reminders (sms/emails) on top of the National annual communication campaign organized by the French Health System authorities
62457829|NCT05527756||Totally endoscopic coronary artery bypass grafting|Study procedures include the Scar Cosmesis Assessment and Rating (SCAR) scale and numerical rating scale (NRS) questionnaire at one, 14 and 30 days after totally endoscopic coronary artery bypass grafting. Additionally, a photo of the incisions will be taken at these time points.
62457830|NCT02256007|ACTIVE_COMPARATOR|Standardized Assessments|"Standardized Assessments (paper and pencil tests) to be given to each participant. The standardized assessments will be completed in paper and pencil format. These tests include:~* Line Bisection Test~* Patient Reported Outcomes~* Trial Making A and B~* Usability Questionnaire"
62457831|NCT02256007|EXPERIMENTAL|Videogame Assessments|"Videogame assessments will be performed by each participant using videogames. The videogame assessments will be performed using videogames on a tabletop platform with touchscreen which includes:~* Line Crossing~* Patient Reported Outcomes~* Trial Making A \& B-Asteroid Adventure Game~* Usability Questionnaire"
62457832|NCT02999178|EXPERIMENTAL|Nintedanib|
62457833|NCT02999178|PLACEBO_COMPARATOR|Placebo|
62457834|NCT03425968||Knee hyperextension group|athletes who has knee hyperextension
62457835|NCT03425968||Control group|athletes who doesn't have knee hyperextension
62457836|NCT06241378||patient with stress urinary incontinence|"* A hundred twenty-three female with SUI at least once/ week~* Patients were recruited from Kasr Al Aieny women's health outpatient clinic, Giza, Egypt.~* Females with an age range 18-65years.~* Being able to read and write~* Being able to use Internet and phone services.~* All of patients with no history of other neurological manifestation.~* Primiparous and multiparous women."
62457837|NCT05390437|PLACEBO_COMPARATOR|control group|starch (placebo) 4 grams per day for 60 days
62648295|NCT05220423|OTHER|No reminders group|This group will receive no reminders on top of the National annual communication campaign organized by the French Health System authorities
62457838|NCT05390437|EXPERIMENTAL|Interventional group|Prebiotics (GOS) Galactooligosaccharides 4 gram per day for 60 days
62457839|NCT03623048|EXPERIMENTAL|Propolis extract|intervention
62080582|NCT06738784|EXPERIMENTAL|PRPP Evaluation|"T0 to T3 months: Evaluations~* Multi-professional assessment by mobile team or day hospital~* Completion of PRPP on 2 activities~T3 months: First referral~- Decision on the participant's future orientation following the PRPP~T3 months to T9 months: Outpatient psychosocial rehabilitation (standard care)~* Personalized psychosocial rehabilitation program determined in part by the PRPP and carried out in the day hospital for all participants.~* PRPP interventions (occupational therapy)~T9 months: Reassessment and confirmation of orientation~* Second round of PRPP based on activities assessed at T3 months~* Questionnaires to help with referral decisions, completed by the multi-professional teams involved in the program, and by the treating psychiatrist after the second PRPP has been completed."
62457840|NCT03623048|EXPERIMENTAL|Pomegranate extract|intervention
62648296|NCT03096535|EXPERIMENTAL|Cooling|Individualized cooling protocol.
62648297|NCT03096535|EXPERIMENTAL|Thermoneutral|Thermoneutral condition day.
62648298|NCT03164057|EXPERIMENTAL|"AZA+ADE | AZA+FLAG+Ida | AE | MA"|"Part 1 Tolerability with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I \& II and then receive low-risk intensifications I \& II without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA."
62457841|NCT03623048|ACTIVE_COMPARATOR|Chlorhexidine|comparator
62457842|NCT03623048|PLACEBO_COMPARATOR|Saline|comparator
62457843|NCT01512407|EXPERIMENTAL|Hepatectomy plus TACE|Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
62457844|NCT01512407|NO_INTERVENTION|Hepatectomy alone|
62457845|NCT02415023|EXPERIMENTAL|fruquintinib+paclitaxel|fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle.
62457846|NCT03825900|ACTIVE_COMPARATOR|Active tDCS|Active transcranial direct current stimulation
62457847|NCT03825900|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation
62457848|NCT03378466|EXPERIMENTAL|Unfractionated Heparin (UFH)|UFH initiated at 18 IU/kg/hr
62457849|NCT03378466|OTHER|Venous thromboprophylaxis (VTE)|as per local standard
62457850|NCT05017857|EXPERIMENTAL|Simultaneous rTMS and PST|
62457851|NCT05017857|EXPERIMENTAL|Sequential rTMS and PST|
62457852|NCT02622945|EXPERIMENTAL|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
62457853|NCT02622945|SHAM_COMPARATOR|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
62457854|NCT00973700|EXPERIMENTAL|2x7.5adj|Two doses of MF59 adjuvanted (adj) A/H1N1
62080583|NCT06387199|ACTIVE_COMPARATOR|Weekly placebo injections on regular closed-loop insulin pump therapy|
62080584|NCT06387199|EXPERIMENTAL|Weekly semaglutide (Ozempic®) injections on regular closed-loop insulin pump therapy|Semaglutide is a Glucagon-like peptide 1 (GLP-1) receptor agonist. It up regulates GLP-1, which reduces glucagon levels, increases satiety and - in some particular cases - increases insulin production. It will be subcutaneously injected weekly by participants at progressively increasing doses. Once the maximum tolerated dose is achieved, participants will begin the meal strategies.
62648299|NCT03164057|EXPERIMENTAL|"DAC+ADE | DAC+FLAG+Ida | AE | MA"|"Part 1 Tolerability with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and then receive low-risk Intensifications I \& II without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
62648300|NCT03164057|EXPERIMENTAL|"AZA+ADE | AZA+FLAG+Ida+Sor | AZA+AE+Sor | AZA+MA+Sor"|"Part 2 Dose Expansion with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I \& II and low- risk Intensifications I \& II. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
62648301|NCT03164057|EXPERIMENTAL|"DAC+ADE | DAC+FLAG+Ida+Sor | DAC+AE+Sor|DAC+MA+Sor"|"Part 2 Dose Expansion with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and low-risk Intensifications I \& II. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
62648302|NCT03164057|EXPERIMENTAL|"AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with AZA - Intermediate Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I \& II and then receive intermediate risk Intensifications I, II \& III without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA,"
62648303|NCT03164057|EXPERIMENTAL|"DAC+ADE | DAC+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with DAC - Intermediate Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and then receive intermediate-risk Intensifications I, II \& III without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
62648304|NCT03164057|EXPERIMENTAL|"AZA| +ADE | +FLAG+Ida+Sor| +AE+Sor| +MA+Sor| +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - Intermediate-Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I \& II and intermediate-risk Intensification I, II, and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
62648305|NCT03164057|EXPERIMENTAL|"DAC|+ADE | +FLAG+Ida+Sor | +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - Intermediate-Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and intermediate-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
62080585|NCT01617395||GEMS cohort|Individuals at risk for developing MS
62080586|NCT01617395||Healthy volunteer cohort|healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS
62080587|NCT01617395||MS patient cohort|MS patients whose first-degree relatives are enrolled in this study
62080588|NCT06723899|EXPERIMENTAL|Intervention arm|The intervention arm will receive an online occupational therapy intervention, CanWork, to increase knowledge and skills of women with breast cancer to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the group-based modules consists of two components. The first component focuses on education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work. Topics covered each week include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues.
62080589|NCT06723899|NO_INTERVENTION|Comparator group|This group will act as a comparison group to the intervention arm. Study participants (women with breast cancer) in this group will not receive the CanWork intervention but will receive standard supportive care provided in their local community cancer support centre
62080590|NCT06739109|EXPERIMENTAL|eBA intervention|Adults with harmful alcohol use will be offered to complete a therapy-guided internet based intervention.
62080591|NCT04879498|EXPERIMENTAL|Monolithic zirconia|Monolithic zirconia posterior 3-unit fixed partial dentures
62080592|NCT04879498|ACTIVE_COMPARATOR|Veneered zirconia|Veneered zirconia posterior 3-unit fixed partial dentures
62080593|NCT04879498|ACTIVE_COMPARATOR|Metal-ceramic|Metal-ceramic posterior 3-unit fixed partial dentures
62080594|NCT03314649||Observational study|Patients with gastric cancer and non-cancerous disease planned to have laparotomy
62080595|NCT02845687||Participants|All participants are patients within the Quit at Duke Smoking Cessation Program. This is an observational study with no interventions.
62080596|NCT06487533||Opioid Use Disorder|Participants with a history of dependence on prescription or non-prescription opioids
62457855|NCT00973700|EXPERIMENTAL|7.5adj_1_8|MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
62080597|NCT05009992|EXPERIMENTAL|NOT CURRENTLY ENROLLING - ARM 2: ONC201 (Day -1), Radiation+ONC201, Paxalisib+ONC201|Participants may receive a safety lead in of ONC201. During the trial validation phase, participants without prior biopsy receive ONC201 PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, participants without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive ONC201 PO weekly during radiation therapy. During the maintenance phase, participants receive ONC201 PO weekly and paxalisib PO daily (QD). Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity
62457856|NCT00973700|EXPERIMENTAL|7.5adj_1_22|MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
62457857|NCT00973700|EXPERIMENTAL|15_1_22|A/H1N1 on study days 1 and 22
62457858|NCT00973700|EXPERIMENTAL|2x15_1_22|Two doses of A/H1N1 (one in each arm) on study days 1 and 22
62457859|NCT04238442|EXPERIMENTAL|BP oscillometric measurement|Oscillometric BP measurement
62080598|NCT05009992|EXPERIMENTAL|NOT CURRENTLY ENROLLING - ARM 4: ONC201 (Day -1,-2), Radiation+ONC201, Paxalisib+ONC201|Participants may receive a safety lead in of ONC201. During the trial validation phase, participants without prior biopsy receive ONC201 PO on days -2 and -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, participants may receive ONC201 PO weekly during radiation therapy. During the maintenance phase, participants receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable toxicity
62080599|NCT05009992|EXPERIMENTAL|NOT CURRENTLY ENROLLING - ARM 6: Paxalisib (Day -1), Radiation+Paxalisib , Paxalisib+ONC201|Participants may receive a safety lead in of ONC201. During trial validation phase, participants without prior biopsy receive paxalisib PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, participants without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive paxalisib PO daily during radiation therapy. During the maintenance phase, participants receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity
62080600|NCT05009992|EXPERIMENTAL|Cohort 4 - Dose Escalation, Starting Dose 2 (625mg ONC201)|Participants will receive a safety lead in of 625mg ONC201. During the trial validation phase, participants without prior biopsy receive ONC201 PO on days -2 and -1 prior to standard of care biopsy. During any non-interventional radiation/re-irradiation per standard of care treatment, participants will receive 625 mg as the starting dose of ONC201 Days 1 and 2 on a weekly basis. Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable toxicity
62457860|NCT02848326|PLACEBO_COMPARATOR|Placebo|Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
62080601|NCT05009992|EXPERIMENTAL|Cohort 5 - ONC201 + Targeted therapies|Participants will receive a starting dose of 625mg of ONC201 weekly on Day 1 and 2 during any non-interventional radiation/re-irradiation per standard of care treatment, and in combination with targeted agents to be selected from approved/available agents based on a rational therapy approach guided by molecular data from the tumor tissue or cerebral spinal fluid (CSF). Each individual targeted agent will be dosed at the recommended therapeutic dose, if a dose has been issued for the participant's age group. Observations and schedule of events will be issued based on the chosen agent determined to best fit the molecular profile (e.g. BRAFV600E, PDGFRA, FGFR1, NF1).
62648306|NCT03164057|EXPERIMENTAL|"AZA+ADE | AZA+FLAG-Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I \& II and high-risk intensifications I, II \& III without azacitidine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
62080602|NCT05851690|ACTIVE_COMPARATOR|Bilateral Parallel Elliptic Flap|Patients operated with the bilateral parallel elliptic flap technique.
62080603|NCT05851690|ACTIVE_COMPARATOR|Karydakis Flap|Patients operated with the karydakis flap technique.
62080604|NCT06736704|EXPERIMENTAL|SNV4818 Monotherapy|Participants will receive oral, daily doses of SNV4818 as a single agent as part of either dose escalation or dose expansion cohorts. The SNV4818 dose level participants receive will depend upon the study part to which they are assigned. Dose escalation participants will be assigned to small cohorts of ascending SNV4818 dose levels. Dose expansion participants will receive one of the SNV4818 dose levels recommended for further evaluation.
62280102|NCT01780610|OTHER|group HRT-B|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
62280103|NCT01736046||Crohn's Disease patients|All patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
62280104|NCT00112905|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
62280105|NCT05120739|EXPERIMENTAL|Interventional|Skin preparations (the day before and the morning of the operation) with the 2% CHX cloths
62280106|NCT05120739|NO_INTERVENTION|Control|Skin preparations (the day before and the morning of the operation) with the 4% CHX soap (standard of care)
62280107|NCT01052649||Healthy volunteers|
62280108|NCT05982340||Group 1|ICU patients with AKI
62280109|NCT05982340||Group 2|ICU patients with normal renal function
62280110|NCT05982340||Group 3|Healthy controls
62457861|NCT02848326|EXPERIMENTAL|Atogepant 10 mg QD|Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
62457862|NCT02848326|EXPERIMENTAL|Atogepant 30 mg QD|Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
62457863|NCT02848326|EXPERIMENTAL|Atogepant 30 mg BID|Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
62457864|NCT02848326|EXPERIMENTAL|Atogepant 60 mg QD|Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
62457865|NCT02848326|EXPERIMENTAL|Atogepant 60 mg BID|Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
62280111|NCT06438081|ACTIVE_COMPARATOR|Cook double-balloon catheter|Participant is placed in lithotomy position, then to clean vulval and vaginal area, followed by inserting vaginal speculum. Cook double-balloon catheter will be inserted under standard technique. Doctor or midwife guide the cervical ripening balloon with stylet to pass through the cervix. Uterine balloon should be place above level of internal os, then to remove the stylet before further advancing the catheter. Cook double-balloon catheter is further advancing through the cervix until both balloons entered cervical canal. Uterine and vaginal balloons are both inflated with up to 80ml normal saline according to manufacturer recommendation. Maximal duration of balloon placement will be 12 hours. If cervix remains unfavorable after Cook double-catheter balloons, she will be given another Cook double-catheter balloons priming the next day. If cervix remains unfavourable after two balloon priming, elective Caesarean section will be advised.
62280112|NCT06438081|PLACEBO_COMPARATOR|Propess|Participant will be firstly confirmed reactive tracing and without regular contraction by non-stress test for 20mins. Propess will be checked its integrity and applied with lubricating jelly before insertion. Propess is inserted to the posterior vaginal fornix. Woman should inform medical staff if they have leaking sensation. After insertion, woman will be advised to lie down and perform non-stress test for 2 hours. Propess will be removed after 24 hours post insertion. Cervical assessment is performed the next day after removal of Propess. Patient with favourable cervix, i.e. Bishop score \>= 7, will start artificial rupture of membrane and syntocinon infusion. Patient with unfavorable cervix, i.e. Bishop score \<7 is arranged another day of priming by PGE2. If the cervix remains unfavorable after 2 days of pharmacological priming, women will be given a rest day or continued priming by Cook double-balloon catheter.
62280113|NCT01423539|ACTIVE_COMPARATOR|A|
62648307|NCT03164057|EXPERIMENTAL|"DAC+ADE | DAC+FLAG+Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and then receive high-risk Intensifications I, II \& III without decitabine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
62080605|NCT06736704|EXPERIMENTAL|SNV4818+Fulvestrant Combination|Participants will receive oral, daily doses of SNV4818 in combination with a standard dose of Fulvestrant as part of either dose escalation or dose expansion cohorts.. The SNV4818 dose level participants receive will depend upon the study part to which they are assigned. Dose escalation participants will be assigned to small cohorts of ascending SNV4818 dose levels. Dose expansion participants will receive one of the SNV4818 dose levels recommended for further evaluation.
62080606|NCT04215393|EXPERIMENTAL|Conbercept eye drop (0.1mg/ mL)|Subjects in this arm will receive 0.1mg/mL Conbercept eye drop 4 times a day, one drop at a time.
62648308|NCT03164057|EXPERIMENTAL|"AZA | + ADE | +FLAG+Ida+Sor| +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I \& II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
62280114|NCT01423539|EXPERIMENTAL|B|
62457866|NCT04900584|EXPERIMENTAL|Intervention group|The intervention group is managed by applying all three types of intervention.
62457867|NCT04900584|NO_INTERVENTION|non-Intervention group|Non-intervention group is managed by conventional heart failure treatment.
62457868|NCT03797664|EXPERIMENTAL|Experimental: CDX-6114|7.5, 15.0 and 22.5g
62648309|NCT03164057|EXPERIMENTAL|"DAC |+ADE |+FLAG+Ida+Sor |+AE+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
62457869|NCT03797664|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Phosphate Buffer Diluent Solution
62080607|NCT04215393|EXPERIMENTAL|Conbercept eye drop (0.5mg/ mL)|Subjects in this arm will receive 0.5mg/mL Conbercept eye drop 4 times a day, one drop at a time.
62457870|NCT06423066||Pleural ultrasound group|Patients who accept pleural ultrasound preoperatively.
62080608|NCT04215393|EXPERIMENTAL|Conbercept eye drop (1.0mg/ mL)|Subjects in this arm will receive 1.0mg/mL Conbercept eye drop 4 times a day, one drop at a time.
62080609|NCT06129695|EXPERIMENTAL|Computer guided intra sinus approach for Zygomatic implant placement.|"After reflection of mucoperiosteal flap then the non-working tip of the coarse diamond bur will be inserted till the initial marking point and further preparation of osteotomy site will be performed along the lateral wall of maxillary sinus then sinus membrane will be reflected gently to get easily access for 3.5 mm drill or 4-4.5 mm diameter Zygomatic implant. The surgical stent will be inserted inside the patient's mouth; it will be adapted and held in place by the anchoring screws to Zygoma and osteotomy will progressively widened by using standard 2.9 mm diameter drill and 3.5 mm twist diameter drill.~Depth indicator will be used to determine the length of Zygomatic implant. Zygomatic implant will be placed.~The platform of Zygomatic implant will be emerged over and close to the top of the crest of the residual alveolar ridge near to first molar region. Closure will done with 3-0 silk suture."
62080610|NCT06129695|ACTIVE_COMPARATOR|Computer guided extra sinus approach for Zygomatic implant placement.|"After adequate exposure of surgical The surgical stent will inserted inside the patient's mouth; it will adapted and held in place by the anchoring screws to Zygoma and osteotomy will progressively widened by using standard 2.9 mm diameter drill and 3.5 mm twist diameter drill.~Depth indicator will be used to determine the length of Zygomatic implant. Zygomatic implant that will placed.~The platform of Zygomatic implant will be emerged over and close to the top of the crest of the residual alveolar ridge near to first molar region. Closure will done with 3-0 silk suture."
62080611|NCT06739876|NO_INTERVENTION|No wearable device: Control|The control group will not wear the device at times other than completing assessments at baseline, post-intervention, and follow-up.
62080612|NCT06739876|EXPERIMENTAL|Intervention: Device and motivational support via social media|Participants in the Device and motivational support group will wear the device (Garmin tracker) for a month. In addition, they will receive motivational support via social media.
62080613|NCT06739876|EXPERIMENTAL|Intervention: Device|Participants in the Device group will wear the device (Garmin tracker) for a month.
62280115|NCT00090545|EXPERIMENTAL|First Stage - disease progression|"The first stage was to rule out the probability of 4 month progression free survival.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
62280116|NCT00090545|EXPERIMENTAL|Second Stage - increased accrual|"Due to prostatic specific antigen and radiographic discordance during the first stage, the protocol was amended to allow accrual to a second stage.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
62280117|NCT01654679|ACTIVE_COMPARATOR|wIRA irradiation|Patients in Group A received local water-filtered infrared A (wIRA) irradiation once for 20 min preoperatively.
62280118|NCT01654679|SHAM_COMPARATOR|visible light only|Patients assigned to Group B only received normal visible light application for 20 min prior to surgery.
62280119|NCT04568668|EXPERIMENTAL|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized adverse drug event information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The adverse drug event information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the adverse drug event information such that community pharmacists can view the adverse drug event information prior to dispensing medications.
62280120|NCT04568668|NO_INTERVENTION|Standard care (ADE information retained locally)|Patients in the control group will have their adverse drug event information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their adverse drug event information will not be visible to other providers via PharmaNet.
62280121|NCT02049944|EXPERIMENTAL|Cefazolin|All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.
62280122|NCT03897543|EXPERIMENTAL|ABX196|IM injection of 0.1, 0.2, and 0.4 µg of ABX196
62280123|NCT03018574||ADHD-patients|The whole blood sample from diagnoses of the children 6-14 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital and Children's Hospital Affiliated to Soochow University according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
62280124|NCT03018574||Controls-healthy children|The whole blood sample from age- and gender- matched healthy 6-14 years old children
62457871|NCT04743258|EXPERIMENTAL|EXTRACTION|treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
62457872|NCT04743258|EXPERIMENTAL|DISTALIZATION|treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
62457873|NCT06189768||Children with hyperpigmentation disorder|Children aged 0 to 15 with hyperpigmentation due to any cause presenting to Dermatology Outpatient Department of Kanti Children's Hospital
62080614|NCT06186128|NO_INTERVENTION|Control|All participants will receive the following: 1) a ClinCard and instructions for completing a weekly financial journal to record participants' spending patterns and social needs during the first 6 months of the study; 2) materials about financial literacy and community-based resources that provide support to low-income individuals; 3) description and instructions for follow-up assessments and check-ins; 4) a copy of signed medical release, consent, and HIPAA forms; 5) respondent-driven sampling referral cards; 6) 3 study referral cards, and 7) information about voter registration services provided through the Pulaski County Circuit and County Clerk's Office (https://www.pulaskiclerk.com/voter-registration/). Participants will be provided information about the importance of voting, restoration of voting rights, and the process of voting and sealing records.
62080615|NCT06186128|EXPERIMENTAL|Intervention|Participants in Arm 2 will receive a monthly UBI stipend of $500 for 6 months. Study staff will explain that UBI payments will continue for 6 months and that the UBI payments will be suspended if an individual is reincarcerated (e.g. the participant will not receive UBI payments to their ClinCard during months of incarceration and will not receive additional months post-release from incarceration). Participants will receive their monthly UBI payment, along with all study-related compensation for completing baseline and follow-up assessments, through a ClinCard, which is a loadable debit card with an ID number unique to the participant. The UBI will be loaded to the participant's ClinCard on the first day of each month.
62457874|NCT04023409||Severe COPD patients|Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
62457875|NCT03155048|ACTIVE_COMPARATOR|oral estradiol group|patients with the usage of 6 milligrams/day oral estradiol
62457876|NCT03155048|ACTIVE_COMPARATOR|estradiol transdermal patch group|patients with the usage of 3.9 milligrams estradiol transdermal patch
62280125|NCT04432363|ACTIVE_COMPARATOR|M1 stimulation|A 20 minutes 1mA direct current stimulation over left M1.
62280126|NCT04432363|ACTIVE_COMPARATOR|M1+DLPFC stimulation|A 20 minutes 1mA direct current stimulation over left M1 and 1mA direct current stimulation over left DLPFC.
62280127|NCT04432363|SHAM_COMPARATOR|Sham stimulation|A 20 minutes sham stimulation where the device only is working first 30s and last 30s of the intervention and have a 10 seconds fade out in intensity at each ramp.
62280128|NCT02773342||Pathological findings in chest CT|
62280129|NCT00662844|PLACEBO_COMPARATOR|A1 vitamin D3 400IU|Orally for one year
62280130|NCT00662844|PLACEBO_COMPARATOR|A2 vitamin D3 800IU|Orally for one year
62457877|NCT01278849|EXPERIMENTAL|ASA404 + standard therpy|
62080616|NCT04917549||Patients diagnosed with COVID-19|
62280131|NCT00662844|PLACEBO_COMPARATOR|A3 vitamin D3 1600IU|Orally for one year
62280132|NCT00662844|PLACEBO_COMPARATOR|A4 Vitamin D3 2400 IU|Orally for one year
62280133|NCT00662844|PLACEBO_COMPARATOR|Placebo|Placebo for one year
62280134|NCT06436456|EXPERIMENTAL|Online psychological intervention|Online psychological intervention with written support from a psychologist
62457878|NCT01626664|EXPERIMENTAL|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
62457879|NCT01626664|ACTIVE_COMPARATOR|investigator's choice|Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
62457880|NCT03627585|NO_INTERVENTION|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
62648310|NCT03164057|EXPERIMENTAL|"AZA+ADE | AZA+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA- High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I Induction II and high-risk Intensifications I or high risk intensification III without azacitidine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
62457881|NCT03627585|ACTIVE_COMPARATOR|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
62457882|NCT05497414|EXPERIMENTAL|Sleep deprived|Overnight sleep deprivation
62457883|NCT05497414|NO_INTERVENTION|Rested|Well-rested sleep pattern
62457884|NCT03708211|EXPERIMENTAL|Part1: TAK-931 80 mg PIC + TAK-931 80 mg Tablet|TAK-931 80 milligram (mg), PIC, orally, once on Day 1 Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, tablet, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until progressive disease (PD), or unacceptable toxicity or any treatment discontinuation is determined.
62457885|NCT03708211|EXPERIMENTAL|Part1: TAK-931 80 mg Tablet + TAK-931 80 mg PIC|TAK-931 80 mg, tablet, orally, once on Day 1 of Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, PIC, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until PD, or unacceptable toxicity or any treatment discontinuation is determined.
62080617|NCT05099679|OTHER|Psychosocial intervention + Cardiac Rehab Services|Cognitive Behavioral Therapy + Cardiac Rehab
62080618|NCT05580458|EXPERIMENTAL|Shingrix|Shingrix will be administered in two 0.5-mL doses approximately 2 months apart.
62080619|NCT02336581|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
62080620|NCT02336581|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (eTAU)|Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
62080621|NCT04127084|EXPERIMENTAL|normal albuminuria|baseline urinary albumin creatinine ratio \[UACR\]\< 30 mg/g
62280135|NCT06436456|ACTIVE_COMPARATOR|Individual psychological intervention|Individual therapy sessions with a psychologist
62280136|NCT01639833|EXPERIMENTAL|Veriset Hemostatic Patch|Topical Hemostat
62280137|NCT01639833|ACTIVE_COMPARATOR|TachoSil®|Topical Hemostat
62648311|NCT03164057|EXPERIMENTAL|"DAC+ADE | DAC+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and then receive high-risk Intensifications I or high risk intensification III without decitabine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
62648312|NCT03164057|EXPERIMENTAL|"DAC |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I \& II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
62648313|NCT03164057|EXPERIMENTAL|"AZA |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I \& II and high-risk Intensification I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
62648314|NCT02581020||1|Participants who were treated with 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow up from the prior Phase 2 or 3 studies conducted in Japan.
62648315|NCT04206865|EXPERIMENTAL|ARNI therapy|Patient's randomized to this arm will receive sacubitril-valsartan per study protocol and titrated per titration guidelines.
62648316|NCT04206865|ACTIVE_COMPARATOR|Standard Oral Vasodilator|Patient's randomized to this arm will receive the oral vasodilator that the clinician chooses including angiotensin receptor blocker (ARB), isosorbide dinitrate, hydralazine, and angiotensin-converting enzyme inhibitor (ACEi).
62648317|NCT06377423|EXPERIMENTAL|Estelite esteria composite|Half of the patients received composite veneers using direct method
62648318|NCT06377423|EXPERIMENTAL|IPS Emax press ceramic|Half of the patients received ceramic veneers using indirect technique
62080622|NCT04127084|EXPERIMENTAL|moderately increased albuminuria|baseline UACR 30\~300 mg/g
62080623|NCT04127084|EXPERIMENTAL|severely increased albuminuria|baseline UACR\>300mg/g
62080624|NCT04127084|NO_INTERVENTION|blank Comparator|normal participant
62080625|NCT06692335|ACTIVE_COMPARATOR|HIFU group|"All women in the HIFU group will undergo pelvic MRI scans, including T1- and T2-weighted imaging, for fibroid localization and treatment planning. The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W, with treatment energy tailored to participant feedback and ultrasound imaging.~Post-procedure, participants will be monitored for 4-6 hours, with discharge criteria including dietary tolerance and urination. Data on pain, skin condition, and adverse events will be collected.~Before discharge, participants will complete a Client Satisfaction questionnaire and will receive analgesics, along with instructions to document menstrual cycles using the PBAC chart."
62080626|NCT06692335|PLACEBO_COMPARATOR|Myomectomy group|"Myomectomy will be performed using laparoscopic, open, or hysteroscopic techniques by accredited HKCOG gynecologists.~Key metrics such as blood loss, intraoperative and postoperative complications, whether the endometrial cavity was entered, length of hospital stay, need for blood transfusion, and readmissions will be meticulously recorded. A complete blood count will be assessed approximately 6 hours post-surgery. Patients will be monitored for blood pressure and pulse per departmental protocol.~Typically, those undergoing hysteroscopic myomectomy are discharged the same day, while laparoscopic or open myomectomy patients are discharged within 1 to 3 days.~Before discharge, women will complete a Client Satisfaction questionnaire and will receive analgesics, along with instructions to document their menstrual cycle, flow, and dysmenorrhea using the PBAC chart."
62080627|NCT05575115||Peer Comparison|Providers from the BEARI trial who received the Peer Comparison intervention.
62280138|NCT01813890|EXPERIMENTAL|Tapentadol IR 50 mg|
62280139|NCT01813890|EXPERIMENTAL|Tapentadol IR 75 mg|
62280140|NCT01813890|PLACEBO_COMPARATOR|Placebo|
62280141|NCT01964066|EXPERIMENTAL|ERCP & Thoracic epidural analgesia|Used thoracic epidural analgesia (ropivacaine 0.5% -10ml) for pain relief ERCP.
62280142|NCT01964066|ACTIVE_COMPARATOR|ERCP & Premedication|Used Premedication (trimeperidine 2% -1ml intravenously) for pain control ERCP.
62280143|NCT01688050|EXPERIMENTAL|Endovascular Repair|
62280144|NCT00433407|EXPERIMENTAL|trastuzumab|blood sample collected on different days from patients receiving trastuzumab
62280145|NCT03781648|OTHER|WL withdrawal method|Active Comparator: WL was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
62080628|NCT05575115||Control|Providers from the BEARI trial who did not receive the Peer Comparison intervention.
62457886|NCT03708211|EXPERIMENTAL|Part 2: TAK-931 Fed + TAK-931 Fasted + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fed state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fasted state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
62457887|NCT03708211|EXPERIMENTAL|Part 2: TAK-931 Fasted + TAK-931 Fed + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fasted state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fed state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
62457888|NCT00531505||2a|Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.
62457889|NCT03840057|EXPERIMENTAL|Azithromycin|Participants randomized to the azithromycin arm would receive 250mL of reconstituted solution containing 500mg of generic azithromycin to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic or renal impairment. No dose adjustment is made for geriatric population.
62280146|NCT03781648|EXPERIMENTAL|NBI withdrawal method|Experimental: NBI was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
62280147|NCT04901039||Decompensated heart failure|Previously diagnosed heart failure presenting with decompensation to the emergency department
62457890|NCT03840057|EXPERIMENTAL|Metoclopramide|Participants randomized to the metoclopramide arm would receive 2mL of solution containing 10mg of generic metoclopramide to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic impairment. A 50% dose reduction is made for those with creatinine clearance of less than 40mL/minute. No dose adjustment is made for geriatric population.
62457891|NCT03840057|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm during Part 1 (azithromycin) of the study would receive 250mL of 0.9% sodium chloride solution to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. Participants randomized to the placebo arm during Part 2 (metoclopramide) of the current study would receive 2mL of 0.9% sodium chloride solution to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy.
62457892|NCT04500509|EXPERIMENTAL|Group A|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure
62457893|NCT04500509|PLACEBO_COMPARATOR|Group B|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure
62457894|NCT05007795|NO_INTERVENTION|Programmatic MDR TB treatment regimen|Conventional MDR-TB laboratory tests. Sputum culture (and smear microscopy) will be evaluated monthly during the treatment period (and 6 monthly during the follow-up period) for the conventional arm.
62457895|NCT05007795|EXPERIMENTAL|Sequence based resistance testing and individualized treatment|Sputum extracted for targeted sequencing and drug resistance profile provided to clinician for individualized treatment.
62648319|NCT06039163|ACTIVE_COMPARATOR|HH-120|
62080629|NCT05443126|EXPERIMENTAL|RET fusion-positive NSCLC (prior 1st gen SRI)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
62080630|NCT05443126|EXPERIMENTAL|RET mutation-positive MTC (prior 1st gen SRI)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
62080631|NCT05443126|EXPERIMENTAL|Other RET-altered solid tumours (prior 1st gen SRI)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
62080632|NCT05443126|EXPERIMENTAL|RET fusion-positive NSCLC (no prior SRI therapy)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
62280148|NCT01239160|EXPERIMENTAL|Advanced PCD|The use of an advanced PCD device to reduce and maintain limb volume
62280149|NCT01239160|ACTIVE_COMPARATOR|Simple PCD|The use of the Simple PCD is to reduce and maintain limb volume
62280150|NCT05434039|EXPERIMENTAL|diclofenac phonophoresis|the patients will receive diclofenac phonophoresis and traditional therapy three times a week for four weeks
62280151|NCT05434039|EXPERIMENTAL|high power pain threshold ultrasound|the patients will receive high power pain threshold ultrasound and traditional therapy three times a week for four weeks
62280152|NCT05434039|ACTIVE_COMPARATOR|conventional therapy|the patients will receive traditional therapy three times a week for four weeks
62280153|NCT01505998|EXPERIMENTAL|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
62080633|NCT05443126|EXPERIMENTAL|RET mutation-positive MTC (no prior SRI therapy)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
62080634|NCT05443126|EXPERIMENTAL|Other RET-altered solid tumours (no prior SRI therapy)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
62080635|NCT04317716|EXPERIMENTAL|Intervention|Fall prevention program and brochure about falls and fall risk factors
62080636|NCT04317716|OTHER|Control|Bbrochure about falls and fall risk factors
62280154|NCT01505998|ACTIVE_COMPARATOR|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
62080637|NCT04324463|EXPERIMENTAL|Colchicine|"Outpatients:~0.6 mg twice daily for 3 days, then 0.6 mg once daily for 25 days (total 28 days).~Inpatients:~1.2 mg followed by 0.6 mg 2 hours later, then 0.6 mg twice daily for 28 days.~(\*Depending on availability, 0.6 mg tablets can be substituted by 0.5 mg tablets for a regimen in outpatients of 0.5 mg twice daily for 3 days, then 0.5 mg once daily for 25 days \[total 28 days\]; and in inpatients of 1.0 mg followed by 0.5 mg 2 hours later, then 0.5 mg twice daily for 28 days)."
62080638|NCT04324463|EXPERIMENTAL|Interferon Beta [This arm is now closed to recruitment]|"Inpatients Only:~0.25 mg by subcutaneous injection on days 1, 3, 5 \& 7"
62080639|NCT04324463|EXPERIMENTAL|Aspirin (ASA)|"Outpatients:~75 to 100 mg once daily for 28 days.~Inpatients:~75 to 100 mg once daily for 28 days"
62080640|NCT04324463|EXPERIMENTAL|Rivaroxaban|"Inpatients Only:~2.5 mg twice daily for 28 days."
62080641|NCT04324463|NO_INTERVENTION|Usual Care (Control)|Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.
62280155|NCT02201160|ACTIVE_COMPARATOR|omega 3|The subjects will take 4 capsules/day during 6 months. Each capsule of the active n-3 PUFA supplement contained 500 mg of fish oil (each capsule provides 300 mg of n-3 PUFA (EPA+DHA) with 3.75 U vitamin E to prevent peroxidation).
62280156|NCT02201160|PLACEBO_COMPARATOR|Sun Flower|The subjects will take 4 capsules/day during 6 months. The placebo capsule contained 500 mg of sunflower oil with 3.75 U vitamin E.
62080642|NCT06674603||ICU delirium patients|
62280157|NCT02760082||Semi-structured interviews|20 participants (anticipated)
62280158|NCT02760082||Questionnaire survey|400 respondents (anticipated)
62280159|NCT02760082||Focus group interviews|3-5 focus group interviews (anticipated)
62457896|NCT04285749|EXPERIMENTAL|Fluvastatin|"Participants will receive Fluvastatin for 2 weeks.~RNA-sequencing and gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision."
62280160|NCT04628923|EXPERIMENTAL|QLB|"With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.~The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively."
62280161|NCT03015467|ACTIVE_COMPARATOR|treatment for part 1|Fecal Microbiota Transplantation (FMT) and traditional treatments according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 1.
62648320|NCT06039163|PLACEBO_COMPARATOR|placebo|
62648321|NCT04833374|EXPERIMENTAL|1-2-3 Group|Patients in 1-2-3Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
62080643|NCT02348320|EXPERIMENTAL|Personalized polyepitope DNA vaccine|Participants will be treated by electroporation with 4 mg of a personalized polyepitope DNA vaccine at Day 1, Day 29 (+/1- 7 days), and Day 57 (+/- 7 days) with at least 21 days between injection days. Each DNA vaccination with be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device.
62080644|NCT06038227||Robotic Assisted Thoracic Surgery|Participants will undergo robotic assisted thoracic surgery (RATS) for segmentectomy or lobectomy.
62080645|NCT06038227||Video Assisted Thoracic Surgery|Participants will undergo video assisted thoracic surgery (VATS) for segmentectomy or lobectomy.
62080646|NCT06585787|EXPERIMENTAL|KarXT|
62080647|NCT06585787|EXPERIMENTAL|Placebo|
62080648|NCT05955274|ACTIVE_COMPARATOR|mBPT only|
62080649|NCT05955274|EXPERIMENTAL|mBPT and just-in-time adaptive intervention|
62080650|NCT06740565|ACTIVE_COMPARATOR|c-TEVAR|conventional thoracic endovascular aortic repair
62080651|NCT06740565|EXPERIMENTAL|Fabulous|proximal stent graft combined with distal bare stent
62080652|NCT05597267|EXPERIMENTAL|Treatment with the MIRIA Laser|3-4 experimental treatments at 4-6 week intervals
62080653|NCT05966805|EXPERIMENTAL|Exercise Training Group|Exercise intervention group will undergo a 12-week exercise program.
62457897|NCT02899338|EXPERIMENTAL|BI695501 Autoinjector|
62280162|NCT03015467|PLACEBO_COMPARATOR|Placebo for part 2|The traditional treatments and normal saline (NS) according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 2.
62280163|NCT02274610|EXPERIMENTAL|Group A|Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere
62457898|NCT02899338|ACTIVE_COMPARATOR|BI695501 Prefilled syringe|
62280164|NCT02274610|EXPERIMENTAL|Group B|Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP
62080654|NCT05966805|OTHER|Wait-List Control Group|Wait-List control group will participate in visits every 4 weeks for data collection and periodic phone calls for monitoring. They will be offered the exercise training intervention option at conclusion.
62280165|NCT01638780|PLACEBO_COMPARATOR|placebo|A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
62280166|NCT01638780|ACTIVE_COMPARATOR|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
62280167|NCT00804388|ACTIVE_COMPARATOR|1|Uncemented total hip replacement, 32 mm caput
62457899|NCT00148681|EXPERIMENTAL|Lower Risk Regimen|
62457900|NCT00148681|EXPERIMENTAL|Higher Risk Regimen|
62648322|NCT04833374|ACTIVE_COMPARATOR|1-3-5 Group|Patients in 1-3-5 Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-3rd-5th month ,then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
62080655|NCT05898412||Andexanet alfa|Hospitalized patients treated with andexanet alfa
62080656|NCT00692055|EXPERIMENTAL|1|PN400
62280168|NCT00804388|ACTIVE_COMPARATOR|2|Uncemented total hip replacement, 36 mm caput
62280169|NCT00902603||1|Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.
62280170|NCT01001039||control|Patients seen in the Otology clinic who have not had sinus surgery in the past 2 months or a history of sinusitis in the last 6 months.
62280171|NCT01001039||cases|Patients seen in the Rhinology Clinic with a complaint of facial pain. They must have evidence of chronic sinusitis.
62280172|NCT02823158|EXPERIMENTAL|GPi DBS and best medical treatment|
62457901|NCT01444703|PLACEBO_COMPARATOR|sugar solution|Gargle 5 minutes before induction of general anesthesia with sugar solution.
62457902|NCT01444703|ACTIVE_COMPARATOR|licorice|Gargle 5 minutes before induction of general anesthesia with licorice solution.
62457903|NCT02227862|EXPERIMENTAL|Mylan's Insulin Glargine|Receive Mylan's Insulin Glargine plus insulin lispro.
62457904|NCT02227862|ACTIVE_COMPARATOR|Lantus®|Receive Lantus® plus insulin lispro
62457905|NCT01434693|EXPERIMENTAL|TSO 500|
62457906|NCT01434693|EXPERIMENTAL|TSO 2500|
62457907|NCT01434693|EXPERIMENTAL|TSO 7500|
62080657|NCT00692055|ACTIVE_COMPARATOR|2|naproxen 375 mg
62080658|NCT06577935|EXPERIMENTAL|AGA2118 Dose Regimen 1|"AGA2118 selected dose~Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24."
62280173|NCT02823158|ACTIVE_COMPARATOR|Best medical treatment|
62457908|NCT01434693|PLACEBO_COMPARATOR|Placebo|single dose
62457909|NCT04117841||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
62457910|NCT04117841||Arm II: Prior treatment at centre|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
62457911|NCT04117841||Arm III: Prior treatment at outside centre|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
62457912|NCT06342076|EXPERIMENTAL|Group1: Subcostal transversus abdominis plane block(STAPB)|Subcostal transversus abdominis plane block(STAPB)
62457913|NCT06342076|EXPERIMENTAL|Group 2: Rectus sheat block(RSB)|Rectus sheat block(RSB)
62457914|NCT04915352|EXPERIMENTAL|Adult dust mite allergenic rhinitis patients|Nasal Provocation Test administration (725 Dermatophagoides pteronyssinus (5.000 SBE/ml) dosage form: Lyophilisate and solvent for nasal drops, suspension dosage and frequency: 3 nasal sprays at 3 different concentrations per year: 50, 500 and 5000 SBE / ml for 3 years Duration: 36 months
62648323|NCT02139397|EXPERIMENTAL|DFMO and Bortezomib|Subjects will take DFMO by mouth 2 times a day for each day of a 21 day cycle and Bortezomib will be given by IV push on days 1, 4, and 8 of each 21 day cycle.
62280174|NCT04704479|EXPERIMENTAL|combined Russian and EMT|Russian current will be applied over the participant expiratory muscles in addition to application of EMT for more enhancement and strengthening of the expiratory muscles.
62280175|NCT04704479|ACTIVE_COMPARATOR|EMT only|the participant receives EMT only over the whole study period
62457915|NCT01192646|ACTIVE_COMPARATOR|Home based life saving skills training|Home based life saving skills will done in one the study group and in the control group no training will be done
62457916|NCT01192646|NO_INTERVENTION|NO HBLSS|No intervention will be given to the control clusters
62457917|NCT02921737|EXPERIMENTAL|Treatment Arm|TAS-102
62648324|NCT04390347|EXPERIMENTAL|Intervention|The intervention product (Yakult) (supplied as fermented milk) and placebo will be delivered in sealed pots of 65 mL with date stamped expiry. Yakult contains Lactobacillus casei Shirota (a minimum of 6.5 × 109 live cells of Lactobacillus casei Shirota are contained in each pot).
62648325|NCT04390347|PLACEBO_COMPARATOR|Placebo|The placebo will be indistinguishable (identical in taste and colour but will not contain Lactobacillus casei Shirota) to both participants and trial investigators. It will be stored and provided in exactly the same manner as the intervention product.
62457918|NCT00527800|EXPERIMENTAL|1|Treatment for episodes of uncomplicated malaria
62648326|NCT01482559|PLACEBO_COMPARATOR|dextrose 5%|IV Infusion
62648327|NCT01482559|EXPERIMENTAL|Dopamine Hydrochloride|IV Infusion
62648328|NCT05625243|EXPERIMENTAL|Bulk-fill ormocer with Precontoured circumferential matrix system|A suitable size precontoured circumferential matrix band will be selected and placed. Teeth separation will be acquired with a suitable size wedge and a separation ring . Then the bulk-fill ormocer will be applied and light cured according to the manufacturer instructions.
62648329|NCT05625243|EXPERIMENTAL|Bulk-fill ormocer with Precontoured Saddle matrix system|Teeth separation will be acquired with a suitable size wedge (fixing wooden wedges and a separation ring Then the bulk-fill ormocer will be applied and light cured according to the manufacturer instructions.
62648330|NCT05625243|EXPERIMENTAL|X-tra fill, Voco) with Precontoured circumferential matrix (Palodent 360, Dentsply )|.Bulk-fill resin composite (X-tra fill, Voco) with Precontoured circumferential matrix system (Palodent 360) will be applied
62080659|NCT06577935|EXPERIMENTAL|AGA2118 Dose Regimen 2|"AGA2118 selected dose~Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24."
62280176|NCT05536323|EXPERIMENTAL|Bolus|Anesthetic induction with bolus remimazolam administration
62280177|NCT05536323|EXPERIMENTAL|Continuous|Anesthetic induction with continuous remimazolam administration
62280178|NCT05581732||Study|"32 patients in the study group received supplemental nutritional support with ONS Nutrinidrink with Dietary Fiber in a pre-calculated amount daily throughout the study for 14-16 weeks. During the hospital stay, additional nutritional support was added to the patient's standard hospital diet (ATC table). On an outpatient basis, the patient received the required amount of ONS at his disposal and add it as a supplement to his/her usual and habitual diet between main meals."
62457919|NCT00527800|ACTIVE_COMPARATOR|2|Treatment for uncomplicated malaria
62457920|NCT00527800|EXPERIMENTAL|A|Prevention of malaria in HIV uninfected, exposed children
62457921|NCT00527800|NO_INTERVENTION|B|Prevention of malaria in HIV uninfected, exposed children
62457922|NCT01993875|EXPERIMENTAL|Lubiprostone|
62457923|NCT01993875|PLACEBO_COMPARATOR|Placebo|
62457924|NCT01007500|EXPERIMENTAL|Group Dexamethasone|
62457925|NCT01007500|ACTIVE_COMPARATOR|Group Ondansetron|
62457926|NCT05227625|EXPERIMENTAL|Body dissatisfaction management group|ACT-inspired group for the management of body dissatisfaction
62457927|NCT05227625|ACTIVE_COMPARATOR|relaxation group|standardized relaxation program
62457928|NCT05890066|NO_INTERVENTION|4-port laparoscopic surgery|Patients with ectopic pregnancy will receive 4-Port laparoscopic surgery
62457929|NCT05890066|EXPERIMENTAL|1-port laparoscopic surgery|Patients with ectopic pregnancy will receive 1-port laparoscopic surgery
62457930|NCT01909869|EXPERIMENTAL|EXCEL-Ⅱ|A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.
62457931|NCT02158832|EXPERIMENTAL|Acupuncture + Electrical Stimulation|Acupuncture needles are inserted beneath the skin and electrical stimulation applied for 20 minutes.
62457932|NCT02158832|NO_INTERVENTION|Control|Participants who are randomized to receive no intervention will still receive physical assessment.
62457933|NCT04635618|EXPERIMENTAL|Intervention I: Cognitive Behavioral Brief-Telepsychotherapy|Four sessions of cognitive-behavioral therapy (CBT) conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content and content related to CBT technique.
62457934|NCT04635618|EXPERIMENTAL|Intervention II: Brief Interpersonal Telepsychotherapy|Four sessions of interpersonal therapy (IPT) conducted by video call by a psychologist, accompanied by the sending of 2 to 3 minute videos with psychoeducational content and content related to the ITP technique.
62457935|NCT04635618|ACTIVE_COMPARATOR|Active Comparator: Telepsychoeducation group|One single session of psychoeducation conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content for 4 weeks.
62457936|NCT03263637|EXPERIMENTAL|Arm A: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory haematological malignancies excluding AML/ALL/high-risk MDS/CMML/CLL.
62457937|NCT03263637|EXPERIMENTAL|Arm B: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory AML, ALL, high-risk MDS, CMML, CLL and Richter's syndrome.
62457938|NCT04558151|EXPERIMENTAL|Training arm|Patients perform inspiratory muscle training containing of 30 breaths twice a day for 14-18 days before surgery.
62457939|NCT04558151|NO_INTERVENTION|Control arm|No preoperative inspiratory muscle training
62457940|NCT06247657|EXPERIMENTAL|BL0006|Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
62457941|NCT02349165|ACTIVE_COMPARATOR|epithelium off CXL|epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)
62457942|NCT02349165|EXPERIMENTAL|Ricrolin TE CXL|Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).
62457943|NCT02636907|EXPERIMENTAL|BI 695501|
62080660|NCT06577935|EXPERIMENTAL|AGA2118 Dose Regimen 3|"AGA2118 selected dose~Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24."
62080661|NCT06577935|EXPERIMENTAL|AGA2118 Dose Regimen 4|"AGA2118 selected dose~Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24."
62080662|NCT06577935|EXPERIMENTAL|AGA2118 Dose Regimen 5|"AGA2118 selected dose~Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24."
62080663|NCT06577935|EXPERIMENTAL|AGA2118 Dose Regimen 6|"AGA2118 selected dose~Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24."
62080664|NCT06577935|PLACEBO_COMPARATOR|Placebo Regimen|"Placebo selected dose~Participants that complete the double-blind period from study start to Month 12 will continue on to a 12 month open-label period. They will be re-randomized for Months 12 to 24."
62080665|NCT05295433|EXPERIMENTAL|mRNA-3705|Participants will receive mRNA-3705 at the same dose levels at the same dosing interval (every 2 weeks \[Q2W\], or every 3 weeks \[Q3W\]) last received in the clinical study of mRNA-3705 in which they initially participated, unless the Sponsor recommends modification.
62080666|NCT06737029||Primary cohort|All patients included in the study, who are about to start empiric tuberculosis treatment
62080667|NCT06077643||Exchange group|Each patient will participate in a cycle of four sessions, over four months. Each will be carried out with five patients, in order to facilitate exchanges. The aim is to organize eight groups that will each complete a cycle. This will allow to include about forty patients in the study.
62648331|NCT05625243|ACTIVE_COMPARATOR|Bulk-fill resin composite with Precontoured sectional matrix systym|Teeth separation will be acquired with a wooden wedge and a separation ring (Delta ring, TORVM, Moscow, Russia). Then the bulk fill resin composite will be applied and light cured according to the manufacturer instructions.
62648332|NCT05418829|EXPERIMENTAL|AT-007|Open-label AT-007 20 mg/kg once daily
62648333|NCT02005874||Dry eye|
62280179|NCT05581732||Control|24 patients in the control group adhered to the standard hospital diet (ATC table), and at discharge - the usual habitual diet
62080668|NCT06077643||Control group|"Patients who don't want to participate in the exchange groups but agree to be included in the control group. They will have to complete the quality of life questionnaires four months apart.~Estimation of 10 patients included."
62080669|NCT05826132|EXPERIMENTAL|Adjusted Content Intervention Video|Participants will watch a 2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman.
62080670|NCT05826132|EXPERIMENTAL|Non-Adjusted Intervention Video|Participants will watch a 2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics.
62280180|NCT05588635||With live birth group|patients with live birth following frozen-thawed embryo transfer
62080671|NCT05826132|NO_INTERVENTION|Control Arm|Participants will watch a control video discussing daily activities.
62080672|NCT02653924|ACTIVE_COMPARATOR|silk suture|silk suture
62080673|NCT02653924|ACTIVE_COMPARATOR|vicryl suture|vicryl suture
62080674|NCT02653924|ACTIVE_COMPARATOR|nylon suture|nylon suture
62080675|NCT02653924|ACTIVE_COMPARATOR|polypropylene suture|polypropylene suture
62280181|NCT05588635||Without live birth group|patients without live birth following frozen-thawed embryo transfer
62280182|NCT03416361|EXPERIMENTAL|Vitamin D|4000IU Vitamin D3 as two 50mcg tablets per day
62280183|NCT03416361|PLACEBO_COMPARATOR|Control|Placebo - two chewable blackcurrant flavoured tablets per day
62280184|NCT04987138|OTHER|Roll-in Cohort|Each Investigator will be allowed to treat up to 3 roll-in subjects with the Spring Implant prior to initiation of randomization. Roll-in patients will be followed for 60 months.
62280185|NCT04987138|ACTIVE_COMPARATOR|Treatment Arm|Includes all patients who are randomized and start the treatment procedure. During the procedure the patient will be shielded from the treatment area and cystoscopy screen. The patient and site personnel administering follow-up assessments will be blinded to the study arm through the 3-month follow-up visit. Unblinding will occur at 3 months post-procedure after the assessments are completed. Follow up will continue for 60 months.
62648334|NCT02005874||Non-dry eye|
62648335|NCT01441869|EXPERIMENTAL|A|5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet
62648336|NCT01441869|EXPERIMENTAL|B|5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet
62648337|NCT01441869|EXPERIMENTAL|C|5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet
62648338|NCT01441869|EXPERIMENTAL|D|5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet
62648339|NCT00437463|EXPERIMENTAL|1|Ramipril
62648340|NCT00437463|NO_INTERVENTION|2|
62648341|NCT04119687|EXPERIMENTAL|Low Dose FX201|Single low dose FX201 injection
62648342|NCT04119687|EXPERIMENTAL|Mid Dose FX201|Single mid dose FX201 injection
62648343|NCT04119687|EXPERIMENTAL|High Dose FX201|Single high dose FX201 injection
62080676|NCT03620903|EXPERIMENTAL|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:~Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;~Maintenance I (1 cycle = 56 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);~Maintenance II (1 cycle = 84 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);"
62080677|NCT05432206|EXPERIMENTAL|Cannabis Sativa Oil first, then Placebo|This arm will start with the active comparator for the first period and change to the placebo in the second period
62080678|NCT05432206|EXPERIMENTAL|Placebo first, then Cannabis Sativa Oil|This arm will start with the placebo for the first period and change to the active comparator in the second period
62080679|NCT05066061|ACTIVE_COMPARATOR|standard|Only use local anesthetic cream
62080680|NCT05066061|EXPERIMENTAL|anxiolytic gas|Use local anesthetic cream and anesthetic and anxiolytic gas
62080681|NCT05066061|EXPERIMENTAL|virtual reality|Use local anesthetic cream and virtual reality mask
62457944|NCT01239251||breast cancer patients taking endocrine therapy|Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
62280186|NCT04987138|SHAM_COMPARATOR|Control Arm|Includes all patients who receive a sham procedure. Patients will be shielded from the treatment area and cystoscopy screen. A Foley Catheter is placed into the patient's bladder and inflated. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure. Control arm subjects are followed for 3 months and exited from the study unless they elect and qualify for Crossover.
62457945|NCT05577793|EXPERIMENTAL|Mother's Voice|The mothers were asked to sing lullabies, and their voices were recorded in a quiet environment. Which lullaby they would sing was left to the mothers' discretion, and the audio recording process took an average of 2-3 minutes. The voice recordings taken were applied for a total of 15 minutes before, during and after the nasal CPAP application.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
62080682|NCT05707650|ACTIVE_COMPARATOR|Women allocated to this group will deliver by using reverse breech extraction technique.|
62080683|NCT05707650|ACTIVE_COMPARATOR|Women allocated to this group will deliver by using Push technique.|
62080684|NCT03458429|EXPERIMENTAL|Frail, older subjects|Treated subjects are the frail, older subjects who will be treated with Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma (GMFFP) in this protocol.
62080685|NCT06585150|EXPERIMENTAL|Obeldesivir (ODV)|Participants will receive obeldesivir for 5 days
62080686|NCT06585150|EXPERIMENTAL|Placebo comparator: Obeldesivir Placebo|Participants will receive obeldesivir placebo for 5 days
62080687|NCT05953038|EXPERIMENTAL|LSD dose-ranging group|All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects.
62280187|NCT04987138|OTHER|Crossover Cohort|Control Arm (Sham) patients can receive treatment with the Zenflow Spring System after their 3-month follow-up assessments are completed, and their symptoms warrant treatment and enrollment criteria are met. The study visit follow-up schedule will restart and the subject will be followed for 60 months post Zenflow Spring implantation. Unless treated with the Spring System, the subject will be exited from the study once they have completed their 3-month follow-up visit.
62280188|NCT00006388|EXPERIMENTAL|Radiation plus Tamoxifen|
62280189|NCT02035826|ACTIVE_COMPARATOR|Arm 1|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 1 ($2.80) $100 $10 $10
62648344|NCT01953991|ACTIVE_COMPARATOR|Cobalt chrome dentures|Cobalt chrome dentures are used as part of standard care for patients
62280190|NCT02035826|ACTIVE_COMPARATOR|Arm 2|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 2 ($1.40) $50 $5 $5
62648345|NCT01953991|ACTIVE_COMPARATOR|PEEK dentures|PEEK dentures will be used as a comparator denture for patients
62080688|NCT06739434|EXPERIMENTAL|Low dose|Low dose is the first cohort of the study with a low dose level.
62080689|NCT06739434|EXPERIMENTAL|High dose|High dose is the first cohort of the study with a high dose level.
62280191|NCT02035826|ACTIVE_COMPARATOR|Arm 3|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 3 ($0.70) $25 $5 $0
62080690|NCT06740331|EXPERIMENTAL|Bipolar patients|Patients with a diagnosis of bipolar disorder
62080691|NCT06740331|EXPERIMENTAL|Major depressive patients|Patients with a diagnosis of major depressive disorder
62080692|NCT06740331|EXPERIMENTAL|First-degree relatives of bipolar patients|First-degree relatives of bipolar patients
62648346|NCT04355624||ICU patients|COVID-19 patients admitted in Intensive Care Units
62280192|NCT02035826|NO_INTERVENTION|Arm 4|Control Arm
62080693|NCT06740331|EXPERIMENTAL|Bipolar controls|Healthy control participants matched to group 1
62080694|NCT06740331|EXPERIMENTAL|Depressive controls|Healthy control participants matched to group 2
62080695|NCT06740331|EXPERIMENTAL|First-degree controls|Healthy control participants matched to group 3
62080696|NCT06740747|EXPERIMENTAL|iTBS|Active intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex
62080697|NCT06740747|SHAM_COMPARATOR|Sham iTBS|Sham intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex
62280193|NCT02302560||Patients with elective hip surgery|Patients with elective hip surgery (implementation or replacement of hip joint endoprotheses).
62280194|NCT01977235|EXPERIMENTAL|Arm A|Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
62280195|NCT01977235|ACTIVE_COMPARATOR|Arm B|Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
62280196|NCT01291901|EXPERIMENTAL|Active NP2|Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
62457946|NCT05577793|EXPERIMENTAL|Therapeutic Touch|Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
62648347|NCT04355624||Non ICU patients|COVID-19 patients admitted in conventional units
62648348|NCT05110664||Cohort/Intervention 1|Meal test
62080698|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
62080699|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
62080700|NCT05554341|EXPERIMENTAL|Treatment (nilotinib hydrochloride monohydrate, paclitaxel)|Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the study. Patients also undergo collection of blood samples and tumor biopsy on study.
62080701|NCT06741189|ACTIVE_COMPARATOR|standard group|"The usual medical monitoring for the first six months postoperatively is standardized between the 4 university hospital centres concerned and consists of :~1. during the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram.~2. during the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures."
62280197|NCT01291901|PLACEBO_COMPARATOR|Placebo|Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
62648349|NCT05110664||Cohort/Intervention 2|Ad libitum meal
62648350|NCT01104961|EXPERIMENTAL|Contact Lens Packaging Solution #1|Test solution - contact lens packaging solution
62648351|NCT01104961|EXPERIMENTAL|Contact lens packaging solution #2|Test solution - contact lens packaging solution
62280198|NCT01046500|ACTIVE_COMPARATOR|metformin|
62280199|NCT01046500|ACTIVE_COMPARATOR|myo-inositol|
62280200|NCT01654900||Patients age >75 y who underwent open hear surgeary|The cohort study consist of all patients \> 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center.
62280201|NCT04385563|EXPERIMENTAL|TQ-B211 + docetaxel|Participants will be administered TQ-B211 plus docetaxel once every three weeks(Q3W) in cycles up to cycle 8.
62280202|NCT04385563|ACTIVE_COMPARATOR|Herceptin®+docetaxel|Participants will be administered Herceptin® plus docetaxel Q3W in cycles up to cycle 8.
62280203|NCT00878839|OTHER|Toric|AcrySof Toric IOL to assess corneal aberration
62648352|NCT01104961|PLACEBO_COMPARATOR|Balanced salt solution|Control solution
62648353|NCT04659005|EXPERIMENTAL|Nurse-led decision counseling group|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
62648354|NCT04659005|OTHER|Control group|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises.
62648355|NCT01189097|EXPERIMENTAL|dextromethorphan|
62280204|NCT03214484|ACTIVE_COMPARATOR|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
62648356|NCT03580018|EXPERIMENTAL|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
62648357|NCT03580018|PLACEBO_COMPARATOR|Control Group|The control group patients only received ACLRs without TXA injections.
62648358|NCT05171907|NO_INTERVENTION|Control Group|Patients into the control group will receive the same assessments as patients in the intervention group, for the same time (in 1th, 8th, 24, and 48 weeks), but they will not receive nutritional teleconsultation.
62080702|NCT06741189|EXPERIMENTAL|home monitoring group|In addition to the usual post-operative monitoring, OSCAR home monitoring will enable key parameters to be transmitted to the medical team at a discontinuous rate (once a day for 4 weeks, then once a week for 20 weeks) via a brief questionnaire (smartphone application) and measurement sensors (weight, oxygen saturation, heart rate) linked to an interface, from the first day the patient returns home until the 6th month post-operatively. The values entered will be automatically compared with individualized standards established for each child at a multidisciplinary meeting, and any deviation from the standard will generate an alert. and the response of the medical teams will be protocolized.
62280205|NCT03214484|ACTIVE_COMPARATOR|computer|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
62080703|NCT06560320|EXPERIMENTAL|Virtual Reality Glasses Group|Virtual Reality (VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of vaccination procedure.
62080704|NCT06560320|NO_INTERVENTION|Control group|In this group, children received routine vaccination procedure.
62080705|NCT06238401|EXPERIMENTAL|ACR246 for injection|Administered by intravenous infusion on Day 1 every 3 weeks (Q3W).
62080706|NCT02298205|OTHER|Provider-based adjustment|Primary care provider will adjust the dose of asthma controller medication based on asthma control at each encounter
62080707|NCT02298205|ACTIVE_COMPARATOR|Symptom-based adjustment|The dose of asthma controller medication is adjusted based on the symptoms
62080708|NCT01182168|EXPERIMENTAL|gemcitabine and cisplatin plus Everolimus|This is a single-institution phase I study of gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) in patients with advanced urothelial cancer.
62080709|NCT01823614||Naïve patients, >500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is more than 500 cells per mm3
62080710|NCT01823614||Naïve patients, 350-500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is between 350 and 500 cells per mm3
62080711|NCT01823614||Naïve patients, <350|The group contains patients who have not any ARV therapy experience and the level of CD4 count is less than 350 cells per mm3
62280206|NCT00911690||Cognitively Impaired|Patients in this cohort with be diagnosed with mild to moderate cognitive impairment, Alzheimers disease, Dementia, or any other form of cognitive impairment.
62280207|NCT00911690||Non-cognitively impaired|Patients in this cohort will be normal healthy adults over the age of 60 years that have no cognitive impairment.
62457947|NCT05577793|EXPERIMENTAL|Mother's Voice+Therapeutic Touch|Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
62457948|NCT05577793|NO_INTERVENTION|Control|The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
62080712|NCT01823614||ARVT <6 months|The group contains patients who have ARVT experience and obtain ART treatment less than 6 months
62080713|NCT01823614||ARVT from 6 months to 3 years|The group contains patients who have ARVT experience and obtain ART treatment from 6 months to 3 years
62080714|NCT01823614||ARVT >3 years|The group contains patients who have ARVT experience and obtain ART treatment more than 3 years
62080715|NCT06375941||Pathological diagnosis of AS, any site of origin, any age, primary, localized, resectable disease.|"* pathological diagnosis of AS;~* any site of origin;~* any age;~* primary, localized, resectable disease."
62080716|NCT01139905|OTHER|1|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour
62080717|NCT01880060|EXPERIMENTAL|INCENT weight loss program|INCENT: The INCENT intervention is an internet-delivered weight loss program with periodic financial incentives for weight loss. INCENT participants receive daily e-mail support with nutritional and physical activity suggestions to enhance weight loss. Monetary incentives are earned on a quarterly basis for weight loss and participants receive monthly checks that reflect the percent weight loss. A regularly calibrated scale with a built in digital camera captures an image of the participant during a weigh-in, and is used to objectively obtain weight data from participants at each quarterly weigh-in.
62080718|NCT01880060|EXPERIMENTAL|Livin My Weigh|Livin My Weigh: The Livin My Weigh (LMW) intervention is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
62080719|NCT03763396|EXPERIMENTAL|Ketoconazole (KCZ) Single Dose Group|Single dose 400mg oral tablets 4-24 hours prior to surgery
62280208|NCT01197365|EXPERIMENTAL|STUDY GROUP|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
62280209|NCT01197365|OTHER|CONTROL GROUP|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
62457949|NCT01703832|EXPERIMENTAL|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
62457950|NCT01703832|NO_INTERVENTION|No intervention|no tablet intake and subjects will undergo the natural course
62457951|NCT05733572|EXPERIMENTAL|active treatment group|active drug treatment group
62457952|NCT05733572|PLACEBO_COMPARATOR|placebo group|pacebo group
62457953|NCT02246920|EXPERIMENTAL|Investigational Test Product|Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
62457954|NCT02246920|ACTIVE_COMPARATOR|Reference Listed Drug|Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
62457955|NCT02246920|PLACEBO_COMPARATOR|Placebo|Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
62080720|NCT03763396|EXPERIMENTAL|Ketoconazole (KCZ) Repeated Dose Group|400mg oral tablets twice a day (BID) for 2-5 days prior to surgery
62080721|NCT03763396|EXPERIMENTAL|Posaconazole (PCZ) Single Dose group|Single dose 300 mg delayed release oral tablets 4-24 hours prior to surgery
62080722|NCT03763396|EXPERIMENTAL|Posaconazole (PCZ) Repeated Dose group|300 mg delayed release oral tablets twice a day (BID) for day 1; every day thereafter is a single dose of 300 mg delayed release oral tablets. Total treatment time is 7-10 days prior to surgery.
62080723|NCT02243631|EXPERIMENTAL|Probenecid|These patients will receive 5 days of probenecid.
62080724|NCT02243631|NO_INTERVENTION|No intervention|These patients will receive no intervention.
62280210|NCT02456246|EXPERIMENTAL|FLT-PET|"1. Cohort 1: Patients in this cohort would be treatment naïve and will be planned for SBRT treatment according to established institutional practices. FLT-PET in this subgroup will be performed before radiation therapy.~2. Cohort 2: Patients who have had SBRT and demonstrate typical or stable lung fibrosis on follow up CT~3. Cohort 3: Patients who have had SBRT and demonstrate findings suspicious for recurrence on follow up CT or who have biopsy demonstrating disease recurrence."
62080725|NCT04679376|EXPERIMENTAL|Group 1: Atorvastatin Treatment|Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive atorvastatin for 96 weeks
62457956|NCT05701202|EXPERIMENTAL|Super-Whey protein|Both protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
62648359|NCT05171907|OTHER|Intervention Group|Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
62648360|NCT03150459|EXPERIMENTAL|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
62648361|NCT03150459|EXPERIMENTAL|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
62080726|NCT04679376|PLACEBO_COMPARATOR|Group 2: Placebo|Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive a placebo for 96 weeks
62080727|NCT06738017|OTHER|Group A (PiZZ)|5:1 (349:Placebo)
62080728|NCT06738017|OTHER|Group B (PiMZ)|5:1 (349:Placebo)
62457957|NCT05701202|ACTIVE_COMPARATOR|Isonitrogenous whey protein|Both protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
62457958|NCT05232708|EXPERIMENTAL|Semaglutide B, 1.34 mg/mL followed by Semaglutide D, 1.0 mg/mL|
62457959|NCT05232708|EXPERIMENTAL|Semaglutide D, 1.0 mg/mL followed by Semaglutide B, 1.34 mg/mL|
62648362|NCT03150459|PLACEBO_COMPARATOR|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
62457960|NCT03855475|EXPERIMENTAL|Aerobic exercise|Exercise training
62457961|NCT03855475|ACTIVE_COMPARATOR|Stretching|Control
62648363|NCT03159143|EXPERIMENTAL|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m\^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m\^2 as a 2 hour IV infusion.
62648364|NCT04937790|EXPERIMENTAL|Core stabilization group (CSG)|This arm consists core stabilization exercises including abdominal hallowing, supine bride, bride dog, side plank, curl-up and modified push up exercise. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
62648365|NCT04937790|EXPERIMENTAL|Wobble board group ( WBG)|This arm consists balance training exercises which performed on computerized wobble board for primarily lower limb and anti- gravity muscle. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
62648366|NCT04937790|NO_INTERVENTION|Control group (CG)|This arm was planned as a control group. Therefore, any intervention will not be performed. Patients in this arm going to participate only one session of patient education at the beginning of the program
62648367|NCT00947206|EXPERIMENTAL|LHWO about CRC|The intervention group participants will be exposed to 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
62648368|NCT00947206|ACTIVE_COMPARATOR|Nutrition education + CRC brochure|The comparison group will receive a bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
62648369|NCT06094816|EXPERIMENTAL|Salt Resistant Adults|Adults who experience minimal BP change during dietary sodium challenge
62648370|NCT06094816|EXPERIMENTAL|Salt Sensitive|Adults who experience increased BP (mean arterial pressures \>5mmHg) during dietary sodium challenge
62080729|NCT06740786|PLACEBO_COMPARATOR|control group|This group of patients will receive placebo treatment.
62080730|NCT06740786|EXPERIMENTAL|treatment group|Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).
62080731|NCT05143866|EXPERIMENTAL|Self-help CBT|Evidence based book detailing self-help program to follow plus Telephone support from a non specialist guide
62280211|NCT03187600|ACTIVE_COMPARATOR|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
62457962|NCT06148909|EXPERIMENTAL|Small Talk Motivational Interviewing (STMI)|during the 8 session of smoking cessation, the first three sessions will be used to do small talks with the participant. And then from the fourth session onwards, the RA will add 30 minutes of MI about smoking cessation after engaging in small talk.
62457963|NCT06148909|NO_INTERVENTION|Control (only MI)|Another two RA with at least one-year experience on counselling will be delivering the control group. Participant will receive MI for 30 minutes in each of the first three sessions and 1 hour in each of the remaining sessions. The control group will also receive the same duration and content of boosters as in the intervention group.
62457964|NCT04898296||Patients over 55 Years with coronary heart disease|Questionnaire and semistructured Interview 45 -60 minutes
62457965|NCT04898296||physical therapists working with patients with coronary heart disease|Focus group 60 -90 minutes
62457966|NCT05575271|EXPERIMENTAL|Vagus nerve stimulation|The stimulator will be activated 2 weeks after the operation and continue for 24 weeks. The initial parameters of the program is set as: current 0.20mA, pulse width 500us, frequency 20Hz, stimulation time 30s, interval time 5min. A dynamic program control will be started at a speed of 0.20 mA, and the stimulation intensity will be controlled with the range of 0.4- 0.8mA.
62648371|NCT04779177|EXPERIMENTAL|Lumateperone 42 mg once daily for 5 days|
62648372|NCT04779177|EXPERIMENTAL|Lumateperone 28 mg once daily for 5 days|
62648373|NCT02240667||Subjects with atrial fibrillation|
62648374|NCT00774085||Patients with Schizophrenia|Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
62080732|NCT01208415|EXPERIMENTAL|Device Implant|
62080733|NCT06472128|EXPERIMENTAL|DREAMLAND|DREAMLAND is a self-administered, multicomponent mobile psychological intervention application for patients to be used during their hospitalization for intensive chemotherapy.
62648375|NCT02151721|EXPERIMENTAL|vorinostat, gefitinib, combination|single arm vorinostat plus gefitinib
62648376|NCT01224379|OTHER|"Arm1: topping off system"|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
62648377|NCT01224379|OTHER|Arm 2: monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
62648378|NCT03736967|EXPERIMENTAL|REGN3500|
62648379|NCT03736967|EXPERIMENTAL|Dupilumab|
62648380|NCT03736967|EXPERIMENTAL|Combo|
62648381|NCT03736967|EXPERIMENTAL|Placebo|
62648382|NCT01367197|NO_INTERVENTION|No intervention|Observation only
62648383|NCT01367197|EXPERIMENTAL|Exercise training group|Group exercise training, three times weekly high-intensity
62080734|NCT06472128|ACTIVE_COMPARATOR|VITAL WELLNESS|VITAL WELLNESS is a self-administered, multicomponent mobile application containing information on a range of physical health topics that guide patients through education about general wellness, nutrition, exercise, and cancer prevention.
62280212|NCT03187600|EXPERIMENTAL|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
62280213|NCT02137408|ACTIVE_COMPARATOR|200 mg docosahexaenoic acid|Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily (1-200mg capsule of DHA). This is a standard dose used in prenatal vitamins. Participants will be supplemented by mouth daily between 18-20 weeks gestation through 6 weeks post-partum.
62280214|NCT02137408|ACTIVE_COMPARATOR|1000 mg docosahexaenoic acid|Participants will be randomized to 1000 mg of docosahexaenoic acid (DHA) administered PO daily (5- 200mg capsules of DHA). Participants will be supplemented daily PO between 18-20 weeks gestation through 6 weeks post-partum.
62457967|NCT05575271|SHAM_COMPARATOR|Sham stimulation|2 weeks after the operation, the stimulator will be turned off for 12 weeks. Then the stimulator will be turned on for 12 weeks. The initial parameters of the program is set as: current 0.20mA, pulse width 500us, frequency 20Hz, stimulation time 30s, interval time 5min. A dynamic program control will be started at a speed of 0.20 mA, and the stimulation intensity will be controlled with the range of 0.4- 0.8mA.
62457968|NCT02236715||Chronic Obstructive Airways Disease|
62457969|NCT05871736||Parents of children with cerebral palsy|Parents of children with CP 1.5-11 years of age who applied to the Physical Medicine and Rehabilitation Clinic of Ankara City Hospital
62457970|NCT05871736||Parents of children without cerebral palsy|Parents of healthy children without cerebral palsy 1.5-11 years of age who applied to the Physical Medicine and Rehabilitation Clinic of Ankara City Hospital
62080735|NCT02378818|OTHER|Schizophrenia patients|35 patients, Age between 18 and 65 years, with a diagnosis of schizophrenia and unchanged psychotropic treatment for at least three months before inclusion.
62080736|NCT02378818|OTHER|Healthy volunteers (schizophrenia)|35 healthy volunteers
62080737|NCT02378818|OTHER|Depressive patients|
62280215|NCT02630238|EXPERIMENTAL|Branched-Chain Amino Acid group|The branched-chain amino acid group will be on a hypocaloric diet, exercise and receive 0.342g/kg of BCAA per day, partially accounted for through their diet with the rest provided by a BCAA supplement
62457971|NCT02210767|EXPERIMENTAL|Walnut Diet|Provides \~2 oz. walnuts/day (2-3% of total calories from alpha-linolenic acid \[ALA\])
62457972|NCT02210767|ACTIVE_COMPARATOR|Walnut Control Diet|Provides same fatty acid profile (\<7% SFA, 9% MUFA, 14-15% PUFA, 2-3% ALA) as Walnut Diet, but is devoid of walnuts and their bioactives
62457973|NCT02210767|PLACEBO_COMPARATOR|Low ALA Diet|Provides similar macronutrient and linoleic acid profile but replaces ALA with oleic acid (\<7% SFA, 12% MUFA, 12% PUFA, 0.5% ALA)
62457974|NCT02344992|EXPERIMENTAL|Biochaperone Insulin Lispro|
62457975|NCT02344992|ACTIVE_COMPARATOR|Humalog®|
62457976|NCT04892979|EXPERIMENTAL|Centre-based|Centre-based exercise cardiopulmonary rehabilitation program for 6 weeks
62457977|NCT04892979|EXPERIMENTAL|Online-based|Online-based exercise cardiopulmonary rehabilitation program for 6 weeks
62080738|NCT02378818|OTHER|Healthy volunteers (depression)|
62080739|NCT01010217|EXPERIMENTAL|Haploidentical related|Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m\^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m\^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day
62457978|NCT04892979|EXPERIMENTAL|Combined|Combined centre- and online-based exercise cardiopulmonary rehabilitation program for 6 weeks
62648384|NCT05939687|EXPERIMENTAL|mesh|In these patients we will do sublay/interoblique repair for prevention of stoma-site hernias using a polypropylene mesh.
62648385|NCT05939687|ACTIVE_COMPARATOR|non-mesh|In these patients we will close the stoma with standard layered ligature suturing of the abdominal wall without mesh implantation.
62648386|NCT01878799|EXPERIMENTAL|HIV|Subjects with HIV and HCV
62648387|NCT01254812||Bilateral dual TAP-block|
62080740|NCT01010217|EXPERIMENTAL|1 Antigen Mismatch Related or Unrelated|Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.
62080741|NCT01010217|EXPERIMENTAL|Matched Unrelated Donor (MUD)|Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide
62080742|NCT05412342||Patients undergoing elective operations|We will follow a prospective cohort of 558 patients, undergoing any elective surgery at Stanford Hospital. Subjects will undergo baseline and longitudinal testing via a (including NIH Patient-Reported Outcomes Measurement Information System- PROMIS measures of emotional distress). After surgery, participants will report weekly changes in opioid use, pain, and adverse events; and monthly changes in opioid misuse for 1 year.
62080743|NCT05246930||Subjects with a diagnosis of vocal cord dysfunction|Subjects with a confirmed or suspected diagnosis of vocal cord dysfunction (also called inducible laryngeal obstruction). Some subjects will have concomitant diagnosis of asthma.
62080744|NCT05246930||Subjects with diagnosis of asthma|Subjects with physician-diagnosed asthma. Some subjects will have concomitant diagnosis of vocal cord dysfunction.
62080745|NCT06738966|EXPERIMENTAL|BL0175 50 mg|
62080746|NCT06738966|EXPERIMENTAL|BL0175 100 mg|
62080747|NCT06738966|EXPERIMENTAL|BL0175 200 mg|
62080748|NCT02719899||1|Healthy Volunteers
62080749|NCT06737042|EXPERIMENTAL|24 mg GZR18 group|24 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
62080750|NCT06737042|EXPERIMENTAL|36 mg GZR18 group|36 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
62080751|NCT06737042|EXPERIMENTAL|48 mg GZR18 group|48 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
62080752|NCT06737042|ACTIVE_COMPARATOR|Tirzepatide group|Tirzepatide group: 57 participants receiving 15 mg tirzepatide
62280216|NCT02630238|PLACEBO_COMPARATOR|Placebo Group|The placebo will be on a hypocaloric diet, exercise and receive isoenergetic beverage with carbohydrate instead of branched-chain amino acids
62280217|NCT01267708||Study Group|All those tested
62280218|NCT04958538|EXPERIMENTAL|MTX and corticosteroid|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
62280219|NCT03882307|NO_INTERVENTION|group1 (naive)|Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment
62280220|NCT03882307|ACTIVE_COMPARATOR|group2 (sustained responder)|Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens
62280221|NCT01827891|PLACEBO_COMPARATOR|control group|Control participants did not experience the procedure of transient upper-limb ischemia.
62280222|NCT01827891|ACTIVE_COMPARATOR|remote ischemic preconditioning (RIPC) group|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at \< 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
62080753|NCT06444048|EXPERIMENTAL|Cohort 1A|Healthy adult participants will be randomized at a 5:1 ratio. 10 participants to receive a 3 mg/kg single intravenous infusion of EV68-228-N and 2 Participants matching Placebo (20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80)
62080754|NCT06444048|PLACEBO_COMPARATOR|Cohort 1B|Healthy adult participants will be randomized at a 5:1 ratio. 10 participants to receive a 3 mg/kg single intravenous infusion of EV68-228-N and 2 Participants matching Placebo (20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80)
62280223|NCT02652884|EXPERIMENTAL|Group 1|will receive single dose intramuscular corticosteroid deltoid deposit (as phosphate and betamethasone acetate, 2 mL) for immediate postintubation.
62280224|NCT02652884|PLACEBO_COMPARATOR|Group 2|will receive 2 ml saline 0.9% NaCl in deltoid immediately postintubation.
62280225|NCT01431404|ACTIVE_COMPARATOR|Enbrel, prefilled syringe|
62280226|NCT01431404|EXPERIMENTAL|HD203, prefilled syringe|
62080755|NCT06444048|EXPERIMENTAL|Cohort 2A|Healthy adult participants will be randomized at a 5:1 ratio to receive a single intravenous infusion of EV68-228-N and Placebo (20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80) 10 mg/kg. N=2
62648388|NCT01254812||Placebo Bilateral dual TAP-block|
62457979|NCT02636400|NO_INTERVENTION|expectant|7 menstrual cycles of expectant management
62648389|NCT00012116|EXPERIMENTAL|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
62648390|NCT05461066|EXPERIMENTAL|Intervention|Smoking cessation intervention in community pharmacies
62648391|NCT05461066|ACTIVE_COMPARATOR|Control|Usual care of smoking cessation in community pharmacies
62457980|NCT02636400|EXPERIMENTAL|postop IUI|4 IUI cycles within 7 menstrual cycles
62648392|NCT04700865|OTHER|Examination|Continuous ECG monitoring for minimum 3 days
62648393|NCT03460041|PLACEBO_COMPARATOR|Control|
62648394|NCT03460041|ACTIVE_COMPARATOR|Magnesium|
62648395|NCT03460041|ACTIVE_COMPARATOR|Dexmetedomedine|
62080756|NCT06444048|PLACEBO_COMPARATOR|Cohort 2B|Healthy adult participants will be randomized at a 5:1 ratio to receive a single intravenous infusion of EV68-228-N and Placebo (20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80) 10 mg/kg. N=2
62280227|NCT01314950|ACTIVE_COMPARATOR|Best practices primary care|Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
62280228|NCT01314950|EXPERIMENTAL|Home based occupational therapy|The intervention group receives all of the components of best practice primary care in addition to a home-based intervention designed to slow functional decline.
62648396|NCT03328988|EXPERIMENTAL|Quadratus lumborum block|Single shot bilateral QLB, ropivacaine 75 mg (20 mL) per side, placed under ultrasound control, at the end of surgery. 22 patients will be allocated in this group.
62648397|NCT03328988|NO_INTERVENTION|Epidural|"Epidural catheter (placed before anesthesia induction), ropivacaine 75 mg in 50 mL isotonic saline (1,5 mg/mL), induction bolus after surgery 1 mL/10 kg ideal weight and there on continuous infusion 2-8 mL/h according to analgesic need. 22 patients will be allocated in this group.~This is the current standard for postoperative pain relief in cystectomy patients in our hospital"
62648398|NCT05707221|ACTIVE_COMPARATOR|mechanical cleaning method by denture brush and Chlorhexidine toothpaste|patients will be instructed to brush both sides of the removable appliance once a day for 1 minute before bedtime using the toothbrush and the CHX toothpaste provided and water
62648399|NCT05707221|ACTIVE_COMPARATOR|chemical cleaning method with cleaning tablet|patients will be instructed to immerse the appliance in 150 ml cup with tap water and dissolve one cleansing tablet for 20 minutes according to the manufacture instructions.
62648400|NCT05707221|ACTIVE_COMPARATOR|combination of mechanical and chemical cleaning|first submitted to the mechanical method, followed by the chemical method.
62648401|NCT03363906|EXPERIMENTAL|Dulaglutide (Reference)|Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods
62080757|NCT06444048|EXPERIMENTAL|Cohort 3A|Healthy adult participants will be randomized at a 5:1 ratio to receive a single intravenous infusion of EV68-228-N N=10 and Placebo (20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80) 30 mg/kg. N=2
62280229|NCT03914976||patient who will have a high risk digestive surgery|patient who will have a high risk digestive surgery: esophagectomy, major hepatectomy\> 3 segments, duodeno cephalic pancreatectomy
62648402|NCT03363906|EXPERIMENTAL|Dulaglutide (Test)|Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods
62648403|NCT01758952||Beijing Chaoyang Hospital|2000 cases
62648404|NCT01758952||Peking University Hospital|2000 cases
62648405|NCT01758952||Zhongshan Hospital of Fudan University|2000 cases
62648406|NCT01758952||Tongji Hospital, Wuhan|2000 cases
62648407|NCT01758952||Tangdu Hospital, Xi'an|2000 cases
62648408|NCT01758952||The Prince Welsh Hospital|1000 cases
62648409|NCT06414863|EXPERIMENTAL|Invisalign® Palatal Expander System|Invisalign® Palatal Expander System will be delivered.
62648410|NCT06414863|ACTIVE_COMPARATOR|Hyrax-type maxillary expander|Hyrax-type maxillary expander will be delivered. The Hyrax-type maxillary expander will include a midline self-locking screw, which is connected to the conventional molar bands or printed clasps, which are cemented on the maxillary first molars (or on the maxillary primary second molars), via 0.9 mm stainless-steel wire. The framework is soldered to the bands and extends on the palatal side to the primary canines or canines. The expander will be fabricated by a qualified laboratory technician
62648411|NCT05403645|EXPERIMENTAL|Movement With Mobilization among patients with knee osteoarthritis in household females|using the techniques of Movement With Mobilization among patients with knee osteoarthritis in household females
62648412|NCT05403645|EXPERIMENTAL|Exercise Therapy among patients with knee osteoarthritis in household females|using the techniques of Exercise Therapy among patients with knee osteoarthritis in household females
62648413|NCT04933318|ACTIVE_COMPARATOR|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)- analgesic current therapy
62648414|NCT04933318|SHAM_COMPARATOR|shamTENS|shamTranscutaneous electrical nerve stimulation (TENS)- analgesic current therapy
62648415|NCT04933318|ACTIVE_COMPARATOR|Interferential current therapy (IFC)|Interferential current therapy (IFC)- analgesic current therapy
62648416|NCT04933318|SHAM_COMPARATOR|shamIFC|shamInterferential current therapy (IFC)- analgesic current therapy
62648417|NCT00435383||Observational|Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics.
62648418|NCT06005649|EXPERIMENTAL|Single dose of HY004|Patients received a single dose of anti-CD22/CD19 CAR T cells after receiving a conditioning regimen of cyclophosphamide and fludarabine.
62648419|NCT05775380|ACTIVE_COMPARATOR|Pioglitazone|Research participants will be randomized to receive pioglitazone hydrochloride 45mg/day for 5 days prior to coronary artery bypass surgery.
62648420|NCT05775380|NO_INTERVENTION|Placebo|Research participants will be randomized to not receive intervention in the days prior to coronary artery bypass graft surgery.
62648421|NCT01628536|EXPERIMENTAL|Black cohosh|
62457981|NCT06452160|EXPERIMENTAL|Dose Escalation|BGC515 Capsules will be administered orally in 21 day cycles, once daily (QD). Patients will be enrolled into escalating dose levels during the Dose Escalation Phase to determine the Maximum Tolerated Dose (MTD) and the Recommended Dose(s) for Expansion (RDE).
62648422|NCT04447859|ACTIVE_COMPARATOR|label recommended titration|eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy)
62648423|NCT04447859|EXPERIMENTAL|Slow semaglutide titration|A slower 16-week titration regimen (initiate treatment at 0.0675mg/week and increase the dose by 0.0675mg weekly until a dose of 1mg/week is reached)
62080758|NCT06444048|PLACEBO_COMPARATOR|Cohort 3B|Healthy adult participants will be randomized at a 5:1 ratio to receive a single intravenous infusion of EV68-228-N N=10 and Placebo (20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80) 30 mg/kg. N=2
62457982|NCT06452160|EXPERIMENTAL|Dose Expansion|BGC515 Capsules will be administered orally in 21 day cycles at MTD/RDE defined dose,once daily (QD), in patients with malignant mesothelioma (MM), epithelioid hemangioendothelioma (EHE), or other advanced solid tumors.
62457983|NCT03249584|OTHER|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
62648424|NCT00942786||No treatment|Consecutive patients undergoing emergency surgery
62648425|NCT03424148|OTHER|Excel V™ Laser & Micro-Lens Array Attachment|Treatment with Excel V™ Laser and a Micro-Lens Array Attachment for skin quality
62080759|NCT05776927|EXPERIMENTAL|QVM149|"QVM149 (Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg ) od delivered via Breezhaler® and Placebo to Salmeterol Xinafoate 50 μg~/ Fluticasone Propionate 500 μg bid delivered via Girohaler®"
62648426|NCT01616589||Fragile X full mutation (affected)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed \>200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome
62648427|NCT01616589||Fragile X premutation (carriers)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome
62648428|NCT01616589||Fragile X intermediate|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation
62280230|NCT03750851|PLACEBO_COMPARATOR|GPlacebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson \& Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
62280231|NCT03750851|EXPERIMENTAL|GCPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
62280232|NCT03750851|EXPERIMENTAL|GLaser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
62280233|NCT03750851|EXPERIMENTAL|GLaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
62648429|NCT05598567||TCI Group|"Anesthesia induction will be provided by infusion of Propofol and Remifentanil with an infusion pump device called TCI (target controlled infusion). When the bispectral index (processed EEG) levels drop below 60, rocuronium will be administered at a dose of 0.6 mg/kg, and 3 minutes after that, endotracheal intubation will be performed. Propofol and Remifentanil infusion and TCI-TIVA will be continued in the maintenance of anesthesia.~Basal values of CK, CK-MB, Troponin-I will be studied in the preoperative period. In the postoperative period, CK, CK-MB, Troponin-I values will be studied 2 times; immediately at the end of the operation and in the 8th hour from the end of the operation."
62648430|NCT05598567||Sevoflurane Group|"Anesthesia induction will be provided by administration of propofol 2 mg/kg, remifentanil 1 mcg/kg . When the processed EEG levels drop below 60, rocuronium will be administered at a dose of 0.6 mg/kg. 3 minutes after that, endotracheal intubation will be performed. Conventional balanced inhalation-intravenous anesthesia will be provided by administering remifentanil at 0.05 mcg/kg/min and sevoflurane 2% in the maintenance of anesthesia.~Basal values of CK, CK-MB, Troponin-I will be studied in the preoperative period. In the postoperative period, CK, CK-MB, Troponin-I values will be studied 2 times; immediately at the end of the operation and in the 8th hour from the end of the operation."
62280234|NCT02272686|EXPERIMENTAL|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
62280235|NCT03426020|ACTIVE_COMPARATOR|Oral midazolam (Demizolam®)|To prevent emergence agitation patient premedicated by 0.5 mg oral midazolam At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
62648431|NCT03805841|EXPERIMENTAL|Active|tarloxotinib bromide
62648432|NCT00359879|EXPERIMENTAL|1 - exenatide before breakfast and dinner|
62280236|NCT03426020|ACTIVE_COMPARATOR|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|To prevent emergence agitation patient premedicated by watching a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
62648433|NCT00359879|ACTIVE_COMPARATOR|2 - exenatide before lunch and dinner|
62648434|NCT05285111|EXPERIMENTAL|Interoceptive Awareness|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
62648435|NCT05285111|ACTIVE_COMPARATOR|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
62648436|NCT01788761|EXPERIMENTAL|Probiotic Supplemented Group|500,000,0000 cells of Lactobacillus GG (utilizing either Culturelle for Kids or Kids Culturelle preparation) and 500,000,000 cells of Bifidobacterium Infantis (utilizing Align capsule) diluted in 3 ml breastmilk/formula and administered enterally from first day of enteral feeds until term gestation/discharge/transfer/death (whichever occurs first) every day infant is receives enteral feedings
62648437|NCT01788761|SHAM_COMPARATOR|Control Group|3 ml enteral feeding of breastmilk/formula administered once daily in addition to regularly prescribed enteral feedings from day of first feeding until term gestation/discharge/transfer/death (which ever occurs first) and administered every day that infant receives enteral feedings
62648438|NCT05571410|EXPERIMENTAL|Intervention|Patients assigned to intervention arm will a text message notifying them of enrollment, be mailed a BP cuff and receive a recruitment phone call if nonresponsive to text. If the patient does not opt out, the research coordinator will mail a blood pressure cuff and proper measurement instructions and start their remote monitoring program in the Way to Health platform. Intervention arm participants will also receive usual care. Usual care for hypertension is as needed determined by the clinical expertise of the primary care provider and can include regular follow-up visits (in person or virtual), home blood pressure readings, titration of medications during visits or via telephone, referral to specialty care (e.g., Nephrology or Cardiology), blood tests or imaging studies.
62280237|NCT03426020|ACTIVE_COMPARATOR|Play game (PC fishing game)|To prevent emergence agitation patient premedicated by playing a simple PC game (fishing game) At the end of sugery patients postoperatif emergence agitation evaluated PAED(pediatric anesthesia emergence delirium scale).
62280238|NCT01531842|EXPERIMENTAL|Topical antibiotic|Patients will be randomized in a 1:1 fashion to receive a drop of topical antibiotic before and after the intravitreal injection in the +ABX arm (in addition to the typical prep with betadine).
62280239|NCT01531842|OTHER|No Antibiotic Arm|No topical antibiotics in the -ABX arm (only the typical prep with betadine)
62280240|NCT02828410|EXPERIMENTAL|SBI|Serum bovine immunoglobulin protein isolate (SBI)
62080760|NCT05776927|ACTIVE_COMPARATOR|Salmeterol Xinafoate / Fluticasone Propionate Arm|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler® and Placebo to QVM149 (Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg ) od delivered via Breezhaler®.
62080761|NCT05437575|EXPERIMENTAL|Ketamine Hydrochloride|2 blinded doses 2.5mg/ml ketamine hydrochloride in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after 15 minutes if indication for pain management remains and there are no contraindications
62280241|NCT01641939|ACTIVE_COMPARATOR|Standard taxane therapy|Docetaxel will be administered at 75 milligram per meter square (mg/m\^2) intravenous (IV) on Day 1 of a 21-day cycle, or paclitaxel will administered at 80 mg/m\^2 IV weekly (Days 1, 8, and 15 of a 21 day cycle) according to investigator choice until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
62080762|NCT05437575|ACTIVE_COMPARATOR|Fentanyl Citrate|2 blinded doses 10mcg/ml in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after 15 minutes if indication for pain management remains and there are no contraindications
62080763|NCT05399485|EXPERIMENTAL|Rimegepant|Randomization Phase: one 75 mg rimegepant (BHV3000) oral disintegration tablet every other day until Week 12
62280242|NCT01641939|EXPERIMENTAL|trastuzumab emtansine 2.4 mg|Trastuzumab emtansine will be administered on Day 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
62080764|NCT05399485|PLACEBO_COMPARATOR|Placebo|Randomization Phase: one matching placebo every other day until week 12
62080765|NCT06738667|EXPERIMENTAL|acupuncture|Patients in the acupuncture group will receive treatment at specified acupoints, performed by acupuncturists with at least five years of experience. The acupoints include bilateral Hegu (LI4), Yanglingquan (GB34), and affected-side Jiache (ST6), Xiaguan (ST7), and Tinggong (SI19).
62080766|NCT06738667|SHAM_COMPARATOR|sham acupuncture|Patients in the sham group will receive noninvasive acupuncture at the same acupoints as the acupuncture group. Sham needles, which resemble real needles but are blunt and slide within their handles, will be applied using the Park Sham device, secured to the skin with a self-adhesive pad. The procedure of manipulation is the same as for acupuncture, but without Deqi.
62080767|NCT05135169||Contrast administration|
62080768|NCT04826757|NO_INTERVENTION|standard care|standard care for low back pain management by general practioners (GPs). the physiotherapist and occupational health services can be solicited independently by the patient or GP.
62080769|NCT04826757|EXPERIMENTAL|coordinated care|"Coordinated care between general practioners, physiotherapist and occupational health services.~An intervention training will be performed before the start of the study for any care professional's to elaborate coordination tools and have an active communication."
62080770|NCT01337648||TBI prior to stem cell transplantation|
62080771|NCT05097287|EXPERIMENTAL|Dupilumab|Dupilumab administered every 2 weeks (Q2W) after an initial loading dose (2 injections) on Day 1
62080772|NCT05097287|PLACEBO_COMPARATOR|Placebo|Matching placebo administered Q2W after an initial loading dose (2 injections) on Day 1
62080773|NCT00696085|OTHER|I|Pregnant women are recruited and screened for alcohol use using a validated alcoholism screening questionnaire. Those who screen positive are then entered into the next phase of the study.
62080774|NCT06740162|EXPERIMENTAL|PACE Program|The 16-week intervention includes: (1) a weekly group fitness class for adults with ID, (2) web-based training and resources for coaches and exercise professionals; (3) weekly coaching meetings for coaches and adults with ID, and (4) daily/weekly interactions with the PACE interactive web-based dashboard for adults with ID.
62080775|NCT06740162|NO_INTERVENTION|Waitlist Control|Participants assigned to the Waitlist Control Group will not receive any intervention during this interval. Participants will receive the PACE Program after the completion of the 16-weeks for the Intervention Group.
62080776|NCT01960205|EXPERIMENTAL|Standarddose Saxagliptin|Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
62080777|NCT01960205|ACTIVE_COMPARATOR|Lifestyle intervention|Lifestyle intervention for 6 months
62280243|NCT01641939|EXPERIMENTAL|trastuzumab emtansine 3.6 mg|Trastuzumab emtansine will be administered on Day 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
62080778|NCT01960205|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
62080779|NCT01960205|EXPERIMENTAL|low dose Saxagliptin|Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
62080780|NCT02638610|EXPERIMENTAL|Sensation measurement|patients with eyelid pathology going through eyelid surgery.
62080781|NCT00488241|ACTIVE_COMPARATOR|1|Topically applied daily for 2 weeks
62080782|NCT01058330|ACTIVE_COMPARATOR|Plyometric physical training|Individualized plyometric training program to increase strength, coordination, and bone density.
62080783|NCT01058330|NO_INTERVENTION|Control Group|This group will have no intervention
62080784|NCT05961813|EXPERIMENTAL|Intervention group in protesic implant orthopedic surgery|58 patients programmed for knee or hip replacement surgeries, or spinal arthrodesis surgery who will be sent to a specialized preventive medicine consult to quit smoking.
62080785|NCT05961813|EXPERIMENTAL|Intervention group in general and urological surgery|58 patients programmed for colorrectal surgery due to colorrectal cancer, cistectomy, radical prostatectomy and partial or total nefrectomy, who will be sent to a specialized preventive medicine consult to quit smoking.
62080786|NCT05961813|ACTIVE_COMPARATOR|Control group in protesic implant orthopedic surgery|58 patients programmed for knee or hip replacement surgeries, or spinal arthrodesis surgery who will receive a brief intervention for smoking cessation.
62080787|NCT05961813|ACTIVE_COMPARATOR|Control group in general and urological surgery|58 programmed for colorrectal surgery due to colorrectal cancer, cistectomy, radical prostatectomy and partial or total nefrectomy, who will receive a brief intervention for smoking cessation.
62080788|NCT01083160||Non responders to other anti-TNF|Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
62080789|NCT06740214|ACTIVE_COMPARATOR|ACB using 20ml 0.5% standard bupivacaine (SB-ACB)|adductor canal block with 20ml 0.5% standard bupivacaine only
62080790|NCT06740214|EXPERIMENTAL|ACB using 10ml 1.33% liposomal bupivacaine with 10 ml 0.5% standard bupivacaine (LB10-ACB)|adductor canal block with 10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
62080791|NCT06740214|EXPERIMENTAL|ACB using 20ml 1.33% liposomal bupivacaine only (LB20-ACB)|adductor canal block with 20ml 1.33% liposomal bupivacaine (266mg)
62080792|NCT01356173|EXPERIMENTAL|A|
62080793|NCT03308578|EXPERIMENTAL|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
62080794|NCT03308578|PLACEBO_COMPARATOR|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
62080795|NCT01776398||1.1 HEALTHY SUBJECTS|Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
62080796|NCT01776398||1.2 SUBJECTS WITH LUNG DISEASE|Defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population)
62080797|NCT01776398||2. WCMC/NYPH CLINICAL PATIENTS|"Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit.~WCMC/NYPH clinical patients will not undergo any additional procedures listed in this protocol as part of this research study."
62080798|NCT01776398||3. PCNY CLINICAL PATIENTS|Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit. Clinical patients seen at the Pulmonary Consultants of New York will only undergo the nasal sample collection and may be asked to have a blood draw of about 2 teaspoons (9ml).
62280244|NCT03969888|EXPERIMENTAL|ABBV-3067 50 mg + Placebo for ABBV-2222|Participants received ABBV-3067 50 mg tablet orally once daily (QD) plus placebo matching ABBV-2222 capsule, orally QD for 28 days.
62648439|NCT05571410|NO_INTERVENTION|Control|Patients in the usual care arm will not be contacted by study staff at the start of the pilot, they will not receive a blood pressure cuff, and they will not receive any text messaging or any component of the program. They will eventually be contacted by study staff to schedule the 6 month BP check. Usual care for hypertension is as needed determined by the clinical expertise of the primary care provider and can include regular follow-up visits (in person or virtual), home blood pressure readings, titration of medications during visits or via telephone, referral to specialty care (e.g., Nephrology or Cardiology), blood tests or imaging studies.
62648440|NCT02581592|EXPERIMENTAL|Hepatic Impairment|Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.
62080799|NCT01811017|EXPERIMENTAL|755nm Alexandrite Laser|755nm Alexandrite Laser
62080800|NCT01811017|EXPERIMENTAL|Nanosecond 755nm Alexandrite Laser|Nanosecond 755nm Alexandrite Laser
62080801|NCT02502305|EXPERIMENTAL|Intervention group|intervention group receives liveonline course training, 3 questionnaires at an interval of 6 weeks
62080802|NCT02502305|NO_INTERVENTION|Control group|control group receives 3 questionnaires at an interval of 6 weeks
62080803|NCT06686797|EXPERIMENTAL|Cohort 1|Up to 4 dosing periods in healthy adult participants. Each period consists of a single dose of PF-08049820 or placebo.
62080804|NCT06686797|EXPERIMENTAL|Cohort 2|Up to 4 dosing periods in healthy adult participants. Each period consists of a single dose of PF-08049820 or placebo.
62080805|NCT06686797|EXPERIMENTAL|Cohort 3 - Optional|One dosing period with a single dose of PF-08049820 or placebo in healthy adult Japanese participants
62080806|NCT05085288|ACTIVE_COMPARATOR|Intermittent electrical stimulation system (IES) treatment Group|Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10 seconds every 10 minutes.
62080807|NCT05085288|ACTIVE_COMPARATOR|Standard of care Group|Standard inpatient nursing practice for wound care, wound care prevention, and any other wound care or plastic surgery treatments deemed appropriate as per usual care.
62080808|NCT06738082||Control Group|Non-immunocompromised controls
62080809|NCT06738082||CAR-T Cell Recipients|Patients with B-cell malignancies receiving anti-CD19 CAR T-cell therapies
62080810|NCT06738082||Rheumatological Disorders|Patients with rheumatological disorders on methothrexate treatment
62080811|NCT06738082||People living with HIV|People living with HIV on successful antiretroviral treatment
62080812|NCT06738082||Multiple Sclerosis|Patients with multiple sclerosis on treatment with sphingosine-1-phosphate-receptor-agonists
62280245|NCT03969888|EXPERIMENTAL|ABBV-3067 150 mg + Placebo for ABBV-2222|Participants received ABBV-3067 150 mg tablet orally QD plus placebo matching ABBV-2222 capsule, orally QD for 28 days.
62080813|NCT06605703|EXPERIMENTAL|WW Clinic - No medications|Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive no medications.
62080814|NCT06605703|EXPERIMENTAL|WW Clinic + Meds v1|Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.
62280246|NCT03969888|EXPERIMENTAL|ABBV-3067 150 mg + ABBV-2222 10 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 10 mg capsule orally QD for 28 days.
62280247|NCT03969888|EXPERIMENTAL|ABBV-3067 150 mg + ABBV-2222 30 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 30 mg capsule orally QD for 28 days.
62280248|NCT03969888|EXPERIMENTAL|ABBV-3067 150 mg + ABBV-2222 100 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 100 mg capsule orally QD for 28 days.
62080815|NCT06605703|EXPERIMENTAL|WW Clinic + Meds v2|Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.
62080816|NCT05329766|EXPERIMENTAL|A1: First Line - Treatment Naïve Participants|Domvanalimab and zimberelimab once every 4 weeks (Q4W) in addition to FOLFOX chemotherapy by intravenous (IV) infusion once every 2 weeks (Q2W)
62080817|NCT05329766|EXPERIMENTAL|A2: First Line - Treatment Naïve Participants|Zimberelimab Q4W in addition to chemotherapy with FOLFOX administered by IV infusion Q2W
62080818|NCT05329766|EXPERIMENTAL|A3 First Line - Treatment Naïve Participants|"Non-randomized A3 safety run-in cohort: Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 60 minutes in addition to FOLFOX chemotherapy via IV infusion Q2W.~After completion of A3 safety run-in cohort, participants are randomized to the A3 arm. Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W"
62080819|NCT05329766|EXPERIMENTAL|A4 First Line - Treatment Naïve Participants|Zimberelimab administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W
62080820|NCT05329766|EXPERIMENTAL|B1: Second Line or greater Checkpoint Inhibitor Naïve Participants|Domvanalimab and zimberelimab administered once every three weeks (Q3W) by IV infusion
62080821|NCT05329766|EXPERIMENTAL|B2: Second Line or greater Checkpoint Inhibitor Naïve Participants|Quemliclustat Q2W and zimberelimab Q4W administered by IV infusion
62080822|NCT05329766|EXPERIMENTAL|Cohort C1: Second Line or greater - Checkpoint Inhibitor Experienced Participants|Domvanalimab and zimberelimab Q3W administered by IV infusion
62080823|NCT06390267|EXPERIMENTAL|Active tAN for Prophylactic Treatment|Prophylactic Active participants will undergo 30 minutes of active tAN while remaining seated and idle. After stimulation, participants will proceed into the 30-minute stressor protocol.
62280249|NCT03969888|EXPERIMENTAL|ABBV-3067 150 mg + ABBV-2222 200 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 200 mg capsule, orally QD for 28 days.
62280250|NCT03969888|EXPERIMENTAL|ABBV-3067 150 mg + ABBV-2222 300 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 300 mg capsule, orally QD for 28 days.
62280251|NCT03969888|PLACEBO_COMPARATOR|Placebo for ABBV-3067 + Placebo for ABBV-2222|Participants received placebo matching ABBV-3067 tablet orally QD plus placebo matching ABBV-2222 capsule, orally QD for 28 days.
62080824|NCT06390267|SHAM_COMPARATOR|Sham Stimulation for Prophylactic Treatment|Prophylactic Sham participants will undergo 30 minutes of sham stimulation while remaining seated and idle. After stimulation, participants will proceed into the 30-minute stressor protocol.
62080825|NCT06390267|EXPERIMENTAL|Active tAN for Acute Treatment|Acute Active participants will begin the stressor protocol immediately after baseline assessments. After a 5-min period of the stressor protocol without any intervention, active tAN treatment will be delivered concurrently for the remainder of the stressor protocol for a total of 30 minutes of stimulation and approximately 35 minutes of the stressor protocol.
62080826|NCT06390267|SHAM_COMPARATOR|Sham Stimulation for Acute Treatment|Acute Sham participants will begin the stressor protocol immediately after baseline assessments. After a 5-min period of the stressor protocol without any intervention, sham stimulation will be delivered concurrently for the remainder of the stressor protocol for a total of 30 minutes of stimulation and approximately 35 minutes of the stressor protocol.
62080827|NCT06736613|EXPERIMENTAL|Participants with Diffuse large B-cell lymphoma (DLBCL) i|Participants will be deemed clinically high-risk for CNS relapse. Participants will be considered to be high-risk for CNS relapse as determined by CNS-IPI score, pathological characteristics such as the presence of MYC, BCL2 and/or BCL6 translocations and specific extranodal involvement such as breast, renal, adrenal, nasopharyngeal, epidural/paraspinal involvement
62080828|NCT06737523|EXPERIMENTAL|CVA|Chiglitazar Sodium in combination with Venetoclax and Azacitidine
62080829|NCT02390765||All pediatric participants|All pediatric participants in the study will be evaluated as one group
62080830|NCT02390765||Parents of participants|Parents provide information about their children and supply DNA / blood samples for future analyses
62080831|NCT05552976|EXPERIMENTAL|MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)|
62080832|NCT05552976|ACTIVE_COMPARATOR|Kd (Carfilzomib + Dexamethasone)|
62280252|NCT05934266|EXPERIMENTAL|Tissue adhesive|Group of 80 patients in which mesh fixation is done using cyanoacrylate glue
62080833|NCT06720168|ACTIVE_COMPARATOR|Dental prophylaxis with ultrasonic treatment|Dental Prophylaxis with ultrasonics
62080834|NCT06720168|EXPERIMENTAL|Dental prophylaxis with erythritol air polishing|Dental prophylaxis with erythritol air polishing application
62080835|NCT06396338||Experimental: Patient treated at the Toulouse University Hospital for an abortion|Patient treated at the Toulouse University Hospital for an abortion between 10 and 16 weeks (dating by ultrasound) presenting with a single and evolving pregnancy
62080836|NCT05348876|EXPERIMENTAL|Darolutamide (BAY1841788)|Participants with high-risk nmCRPC will receive darolutamide.
62280253|NCT05934266|NO_INTERVENTION|Standard suture|Group of 80 patients who undergo hernioplasty with standard suture
62648441|NCT02581592|EXPERIMENTAL|Normal Hepatic Function|Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.
62080837|NCT06346067|EXPERIMENTAL|Stage 1 Dose selection Lead-in Arm 1|Naporafenib + Trametinib Naporafenib (ERAS-254) 100 mg administered orally twice daily (BID) Trametinib 1 mg once daily (QD)
62080838|NCT06346067|EXPERIMENTAL|Stage 1 Dose selection Lead-in Arm 2|Naporafenib + Trametinib Naporafenib (ERAS-254) 400 mg administered orally twice daily (BID) Trametinib 0.5 mg once daily (QD)
62080839|NCT06346067|ACTIVE_COMPARATOR|Stage 1 Dose selection Lead-in Arm 3 Trametinib monotherapy|Trametinib 2 mg once daily (QD)
62080840|NCT06346067|EXPERIMENTAL|Stage 2 Arm A|Naporafenib + Trametinib Naporafenib (ERAS-254) BID oral administration with Trametinib QD at the dose selected in Stage 1
62080841|NCT06346067|ACTIVE_COMPARATOR|Stage 2 Arm B - Physician's Choice|"* Dacarbazine 1000 mg/m2 intravenously (IV) on Day 1 of each 21-day cycle OR~* Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle OR~* Trametinib monotherapy, 2 mg PO QD"
62080842|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
62080843|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
62080844|NCT06469307||DIVERSE Community Advisory Board (CAB)|"Enrolled participants will complete:~* Confidentiality agreement and demographic questionnaire~* Online training and in-person or remote training with study team~* Timely DIVERSE review of protocols~* Audio recorded meeting (in-person, remote, or via phone call) with study team to present review findings~* Semi-structured exit interview and/or focus group with study staff to provide feedback"
62280254|NCT03204123|ACTIVE_COMPARATOR|Ga-HBED-iPSMA PET with CT or MRI|Participants will have a PET scan with Ga-HBED-iPSMA. PET may be combined with CT or MRI at the discretion of the referring clinician.
62280255|NCT03204123|ACTIVE_COMPARATOR|Ga-HBED-iPSMA PET with MRI|Participants will have a PET scan with Ga-HBED-iPSMA and will be combined with MRI. If PET/MR imaging is not available, PET/CT imaging may be substituted. This arm will be closed to accrual and these patients will be analyzed separately.
62648442|NCT04039724|EXPERIMENTAL|Sequence A|"Period 1 : HCP0605+HGP0816~Period 2 : HCP1305"
62080845|NCT06469307||DIVERSE Investigators|"Enrolled investigator participants will complete:~* Brief Feedback Survey~* Request DIVERSE reviews and complete request form~* Acceptability of Intervention Measure questionnaire~* Semi-structured exit interview and/or focus group with study staff to provide feedback"
62080846|NCT02127905|OTHER|CD34+ selected cells|use of unrelated bone marrow or peripheral blood for hematopoietic stem cell transplantation with CD34+ selected cells
62080847|NCT06736964|EXPERIMENTAL|Predicta|based on dual cure bulk fill bioactive restoration
62080848|NCT06736964|EXPERIMENTAL|Activa presto|based on Bio-glass reinforced glass Ionomer
62080849|NCT06736964|ACTIVE_COMPARATOR|Giomer|based on Pre-reacted glass ionomer (PRG)
62080850|NCT05622201|EXPERIMENTAL|Rituximab|Rituximab 1000 mg, infusion
62080851|NCT05622201|PLACEBO_COMPARATOR|Placebo|Saline infusion
62280256|NCT01195337||Study Group|Newsletters, Physical Activity (PA) Prescription Plan, Pedometer
62080852|NCT05539963|EXPERIMENTAL|STIMULAN VG|Participants will receive STIMULAN VG on Day 1 following surgical debridement. Systemic antibiotics for 3 days ± 2 days following the debridement surgery.
62080853|NCT05539963|ACTIVE_COMPARATOR|Standard of Care|Participants will receive Systemic antibiotics for 4-6 weeks following the debridement surgery.
62080854|NCT06521463|EXPERIMENTAL|Aspirin|Aspirin 81-100 mg, daily post implant for duration of the clinical trial
62080855|NCT06521463|EXPERIMENTAL|Reduced dose non-vitamin K antagonist (VKA) oral anticoagulant (NOAC)|Reduced dose non-vitamin K antagonist (VKA) oral anticoagulant (NOAC) for the first 3 months daily, post implant, followed by aspirin only for the duration of the clinical trial
62080856|NCT06521463|ACTIVE_COMPARATOR|DAPT|DAPT (aspirin 81-100 mg + clopidogrel 75 mg), for the first 6-months daily followed by aspirin only for the duration of the clinical trial
62080857|NCT02309606||Migraine without aura|Migraine patients suffering from migraine 0-4 days per month.
62080858|NCT02309606||Healthy controls|Healthy controls with no history of migraine or other primary headaches.
62080859|NCT02309606||Chronic migraine|Migraine patients with chronic migraine
62080860|NCT06738888||Difficult transoral and submental thyroidectomy|(1) operative time more than 75% of the overall study cases (2) severe intraoperative injuries :: vascular injury, recurrent laryngeal nerve injury, trachea injury, esophagus injury
62080861|NCT06738888||Normal transoral and submental thyroidectomy|the remaining of the entire study cases excluding the difficult cases
62080862|NCT01015014|ACTIVE_COMPARATOR|AN3365|
62080863|NCT01015014|PLACEBO_COMPARATOR|Saline|
62080864|NCT05118204|EXPERIMENTAL|BUP microdose induction|Participants in this arm will receive a novel BUP microdose induction protocol.
62080865|NCT05118204|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants in this arm will receive standard BUP induction protocol.
62080866|NCT00865644|EXPERIMENTAL|Imiquimod|
62648443|NCT04039724|EXPERIMENTAL|Sequence B|"Period 1 : HCP1305~Period 2 : HCP0605+HGP0816"
62648444|NCT03181308|EXPERIMENTAL|TRC105 plus Nivolumab|
62080867|NCT06649201||Allogeneic HCT participants|The cohort will be comprised of participants undergoing allogeneic HCT at the Cleveland Clinic.
62080868|NCT03496415|EXPERIMENTAL|Remote ischemic conditioning|
62080869|NCT03496415|SHAM_COMPARATOR|Sham remote ischemic conditioning|
62648445|NCT02009943|EXPERIMENTAL|Ferric carboxymaltose (FDA IND pending)|15 mg/kg, up to 750 mg IV x 1 on the day of study enrollment.
62648446|NCT02009943|ACTIVE_COMPARATOR|Iron sucrose (FDA IND 109,877)|"Iron sucrose 100 mg IV will be dosed daily using goal-direction up to a total of 700 mg over a 7-day period. Specifically, iron sucrose will be dosed daily if:~1. TSAT \< 25%~2. Serum iron concentration \< 150 ug/mL~3. Serum ferritin concentration \< 1,500 ng/mL"
62080870|NCT06728241|ACTIVE_COMPARATOR|RecoVRy|Patients randomized to this arm will receive CBT assisted artificial intelligence driven Virtual Reality therapy for a total of ten sessions.
62080871|NCT06728241|SHAM_COMPARATOR|VR Games|Patients in the control group will receive ten sessions of different virtual reality games.
62080872|NCT04983979|EXPERIMENTAL|SZC|3 month treatment using Sodium zirconium cyclocilicate. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
62080873|NCT04983979|PLACEBO_COMPARATOR|Placebo|3 month treatment using matched placebo. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
62080874|NCT03847779|EXPERIMENTAL|Non-neuropathy|"Type 2 diabetic without neuropathy:~* Negative findings on Semmes-Weinstein monofilament~* Neuropathy symptom score (NSS) \<3~* Negative findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~* rest cutaneous microcirculation (perfusion and vasomotion)~* Exercise cutaneous microcirculation (perfusion and vasomotion)~* Foot lowering cutaneous microcirculation (perfusion and vasomotion)~* Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~* blood sampling~* heart rate variability at rest~* pedometer during 4 days~* international Physical Activity Questionary~* Qualify of Life questionary (EQVOD)"
62280257|NCT03433222|EXPERIMENTAL|HF-LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
62080875|NCT03847779|EXPERIMENTAL|Neuropathy|"Type 2 diabetic with neuropathy~* Positive findings on Semmes-Weinstein monofilament~* Neuropathy symptom score (NSS) \>3~* Positive findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~* rest cutaneous microcirculation (perfusion and vasomotion)~* Exercise cutaneous microcirculation (perfusion and vasomotion)~* Foot lowering cutaneous microcirculation (perfusion and vasomotion)~* Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~* blood sampling~* heart rate variability at rest~* pedometer during 4 days~* international Physical Activity Questionary~* Qualify of Life questionary (EQVOD)"
62080876|NCT03847779|EXPERIMENTAL|Controls|"matched for age, sexe and BMI with diabetic patients.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~* rest cutaneous microcirculation (perfusion and vasomotion)~* Exercise cutaneous microcirculation (perfusion and vasomotion)~* Foot lowering cutaneous microcirculation (perfusion and vasomotion)~* Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~* blood sampling~* heart rate variability at rest~* international Physical Activity Questionary~* Qualify of Life questionary (EQVOD)"
62080877|NCT01132196|EXPERIMENTAL|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
62080878|NCT01132196|ACTIVE_COMPARATOR|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
62080879|NCT06739031|EXPERIMENTAL|PEF Treatment|
62080880|NCT04165161|OTHER|superior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation without positive tele-expiratory pressure
62080881|NCT04165161|OTHER|superior with 10 cmH2O positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
62080882|NCT04165161|OTHER|inferior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation without positive tele-expiratory pressure
62280258|NCT03433222|SHAM_COMPARATOR|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
62648447|NCT02009943|NO_INTERVENTION|Control|No iron supplementation
62648448|NCT04753632||Cerebral palsy patients and caregivers|Cerebral palsy patients and caregivers
62648449|NCT04753632||Healthy people and their caregivers|Healthy people and their caregivers
62080883|NCT04165161|OTHER|inferior with 10 cmH2O positive tele-expiratory pressur|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
62080884|NCT03923296||HCPs|Health care professional interviews (market research)
62080885|NCT03923296||Patients or caregivers|Patients or caregivers interviews
62080886|NCT01235182||acute dyspnea, field, diagnostic|All patients with shortness of breath as the primary complaint (defined as eitherthe sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea and were age \>18 years.
62080887|NCT06728982|NO_INTERVENTION|Group A|Patients will receive standard chemoradiotherapy(CRT)
62080888|NCT06728982|ACTIVE_COMPARATOR|Group B (Metformin)|"Patients will self-administer 1000mg of metformin twice daily by mouth:~1. beginning 1-2 weeks before standard CRT.~2. during standard CRT.~3. until 30 days after the end of standard CRT."
62457984|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
62648450|NCT05912556|OTHER|Cohort A|Remote-Only subjects
62648451|NCT05912556|OTHER|Cohort B|Remote + Imaging subjects
62648452|NCT05144763|EXPERIMENTAL|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
62080889|NCT04065282|EXPERIMENTAL|neoadjuvant therapy with Sintilimab plus Xelox|3 cycles of neoadjuvant therapy: Sintilimab iv d1 Q3W, Oxaliplatin 130mg/m2 iv d1 Q3W, and Capecitabine 1000mg/m2 po Bid d1-14 Q3W
62080890|NCT06401031|EXPERIMENTAL|Experimental: Press Needle|Device: Press Needle Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
62080891|NCT06401031|SHAM_COMPARATOR|Sham Comparator: Sham Press Needle|Device: Sham Press Needle Sham press needle is a surgical adhesive patch placed on acupuncture points
62080892|NCT04665297|EXPERIMENTAL|Intervention arm|Subjects from intervention clusters will receive the GMCD intervention, delivered in monthly visits to the home by frontline health workers, for 24 months. 0-12 months represents the primary effectiveness study, and 12-24 months a secondary maintenance study.
62080893|NCT04665297|NO_INTERVENTION|Control Arm|Subjects in control clusters will continue to receive usual care from their frontline health workers. After 12 months (primary effectiveness study) control will cross into the intervention for months 12-24.
62080894|NCT00709592|EXPERIMENTAL|ATG 1.7 mg/kg, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 5.1 mg/kg in three divided doses (1.7 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive lower dose anti-thymocyte globulin IV on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
62080895|NCT00709592|EXPERIMENTAL|ATG 2.5 mg/kg/d, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 7.5 mg/kg in three divided doses (2.5 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive higher dose anti-thymocyte globulin intravenously (IV) on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
62080896|NCT06673095|EXPERIMENTAL|Arm I (narrow margin excision)|Patients undergo narrow margin excision on study. Patients may optionally undergo blood sample collection throughout the study.
62080897|NCT06673095|ACTIVE_COMPARATOR|Arm II (wide margin excision)|Patients undergo wide margin excision on study. Patients may optionally undergo blood sample collection throughout the study.
62080898|NCT05656443|EXPERIMENTAL|GST-HG171/Ritonavir|
62080899|NCT05656443|PLACEBO_COMPARATOR|Placebo|
62080900|NCT06435949|EXPERIMENTAL|group Fentanyl|intravenous anesthesia with propofol with fentanyl
62648453|NCT05144763|NO_INTERVENTION|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
62080901|NCT06435949|EXPERIMENTAL|group Oxycodone|intravenous anesthesia with propofol with oxycodone
62080902|NCT06219343|EXPERIMENTAL|Transcervical non-invasive vagus nerve stimulation group|Patient will be treated with non-invasive electrical stimulation of the left vagus nerve in the neck. After routine induction of atrioventricular reentrant tachycardia prior to radiofrequency ablation, the electrode patch was placed on the patient's left cervical vagal body surface localization, i.e., between the sternocleidomastoid muscle and the trachea where the left common carotid artery pulsation could be palpated, and resuscitation was performed using non-invasive electrical stimulation.
62080903|NCT06527040||Usual Care|Control group of contemporary encounters where clinical decision support alert is not active. Usual care.
62080904|NCT06527040||Clinical Decision Support (CDS): Opioid transition alert|Encounters where the opioid transition clinical decision support (CDS) alert fired. CDS logic is programmed to fire the alert when a provider places an order for an opioid that will transition the patient from acute to subacute opioid therapy (at 30 days) or from subacute to chronic opioid therapy (at 90 days).
62080905|NCT06736678|EXPERIMENTAL|Intervention group|
62457985|NCT02545153|ACTIVE_COMPARATOR|Fibrin sealant|Tisseel, Baxter (Aprotinin and Fibrinogen)
62080906|NCT05731947|EXPERIMENTAL|Phase 1a: Dose Escalation|Participants will receive revumenib tablets or capsules three times a day (TID) or two times a day (BID) from Day 1 of each 28-day cycle.
62280259|NCT05489601||Participants|"* Adults between 21 and 59 years of age.~* Males and females; women must practice an effective form of birth control (condoms, diaphragm, birth control pill, IUD).~* Subjects have taken an opioid prescription for pain management within the prior 24 months and have not used any opioids during the preceding 30 days.~* Subjects are required to have a negative urine drug test. At any point during the study, If a subject is found to have a positive drug test, the subject will be discontinued from the study."
62280260|NCT02480933|EXPERIMENTAL|female cadavers|female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
62648454|NCT01987856|ACTIVE_COMPARATOR|aCGH screen|aCGH screen; euploid blastocyst chosen on 23 plus XY chromosome screening plus blastocyst morphology
62648455|NCT01987856|PLACEBO_COMPARATOR|Blastocyst morphology|blastocysts chosen on morphological criteria only; scaled assessment of blastocyst expansion, inner cell mass and trophectoderm morphology
62648456|NCT00386334|PLACEBO_COMPARATOR|Placebo|Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
62080907|NCT05731947|EXPERIMENTAL|Phase 1b: Signal-Seeking|Participants will receive revumenib tablets TID or BID from Day 1 of each 28-day cycle.
62080908|NCT05731947|EXPERIMENTAL|Phase 2: Revumenib|Participants will receive revumenib tablets TID or BID from Day 1 of each 28-day cycle.
62080909|NCT05731947|ACTIVE_COMPARATOR|Phase 2: Chemotherapy|Participants will receive chemotherapy from Day 1 of each 28-day cycle.
62080910|NCT06008808|EXPERIMENTAL|Phase I: Ruxolitinib|"* Ruxolitinib at 5 mg twice per day (BID) beginning on Day -3 and continuing until Day 180 followed by a taper (duration of taper depends on dose of ruxolitinib at Day 180). Once a patient's counts have reached ANC \> 1.5 K/cumm, hemoglobin \> 9.0 g/dL, and platelets \> 50 K/cumm, ruxolitinib dosing will escalate to 10 mg BID.~* Ruxolitinib starting dose for patients receiving fluconazole will be 5 mg QD. Patients who remain on fluconazole and meet the target recovery criteria below can increase ruxolitinib dosing to 5 mg BID and subsequently 10 mg BID."
62280261|NCT02480933|EXPERIMENTAL|Male cadavers|male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
62280262|NCT01235962|EXPERIMENTAL|pazopanib|Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
62457986|NCT02545153|PLACEBO_COMPARATOR|Control|Suturing the incision without fibrin glue
62080911|NCT06008808|EXPERIMENTAL|Expansion Phase: Ruxolitinib|"* Ruxolitinib at 5 mg twice per day (BID) beginning on Day -3 and continuing until Day 180 followed by a taper (duration of taper depends on dose of ruxolitinib at Day 180). Once a patient's counts have reached ANC \> 1.5 K/cumm, hemoglobin \> 9.0 g/dL, and platelets \> 50 K/cumm, ruxolitinib dosing will escalate to 10 mg BID.~* Ruxolitinib starting dose for patients receiving fluconazole will be 5 mg QD. Patients who remain on fluconazole and meet the target recovery criteria below can increase ruxolitinib dosing to 5 mg BID and subsequently 10 mg BID."
62080912|NCT05672082|EXPERIMENTAL|[18F]DPA-714 PET|
62080913|NCT02874066|EXPERIMENTAL|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
62080914|NCT02475213|EXPERIMENTAL|Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
62080915|NCT02475213|EXPERIMENTAL|Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
62080916|NCT02475213|EXPERIMENTAL|Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
62080917|NCT02475213|EXPERIMENTAL|Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg|enoblituzumab 15 mg/kg IV weekly plus MGA012 375 mg
62080918|NCT06541704|EXPERIMENTAL|Pozelimab + Cemdisiran treatment group|Randomized 1:1:1
62080919|NCT06541704|EXPERIMENTAL|Cemdisiran monotherapy treatment group|Randomized 1:1:1
62080920|NCT06541704|PLACEBO_COMPARATOR|Placebo treatment group|Randomized 1:1:1
62080921|NCT03557489|EXPERIMENTAL|Experimental group|Patients use gel pad(in usual) in addition to(Mepilex Border Sacrum)foam pad during surgery.
62080922|NCT03557489|NO_INTERVENTION|Control group|patients use gel pad(in usual) during surgery.
62080923|NCT06738212|EXPERIMENTAL|Aerobic Exercises|
62080924|NCT06738212|ACTIVE_COMPARATOR|Aviva Exercises|
62080925|NCT05444673|EXPERIMENTAL|Paprizumab combined with cisplatin and 5-FU|Patients received four cycles of paprizumab (200mg iv, 21-day cycle) in combination with 5-fu (500mg/m2 iv) plus cisplatin (80mg/m2 iv, 21-day cycle). Reassessment after completion of neoadjuvant chemotherapy was performed in operable patients.
62080926|NCT03942874|EXPERIMENTAL|Treatment|Participants will complete baseline sessions and then complete treatment right away.
62080927|NCT03942874|EXPERIMENTAL|Waitlist Control|Participants will complete a baseline session and then wait for 10 weeks before starting treatment.
62080928|NCT05585307|EXPERIMENTAL|Substudy-01: Bavtavirine|"Participants will receive bavtavirine. After assessments on Day 11 or upon early termination (ET), participants will initiate a regimen of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY)), or other non-nonnucleoside reverse transcriptase inhibitor (NNRTI) based standard of care (SOC) antiretroviral therapy (ART) regimen up to Day 39.~Non-NNRTI SOC ART regimen may include:~* abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC), (ABC/DTG/3TC)~* DTG plus (tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF) plus (emtricitabine (FTC) or 3TC)~Approximately 5 cohorts may enroll. Participants will be enrolled in Cohort 1 initially and then dosing in subsequent cohorts will proceed after safety review team (SRT) review of emerging data."
62080929|NCT05585307|EXPERIMENTAL|Substudy-02: GS-1720|"Participants will receive GS-1720. After assessments on Day 11 or upon ET, participants will initiate a regimen of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY)), or an alternative SOC ART regimen up to Day 60.~SOC ART regimen, example INSTIs: DTG/ABC/3TC or DTG/3TC~Approximately 5 cohorts may enroll. Participants will be enrolled in Cohort 1 initially and then dosing in subsequent cohorts will proceed after safety review team (SRT) review of emerging data."
62080930|NCT05585307|EXPERIMENTAL|Substudy-03: GS-6212|"Participants will receive GS-6212. After assessment on Day 11 or upon ET, participants will initiate a regimen of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY)), or an alternative SOC ART regimen up to Day 25.~Approximately 5 cohorts may enroll. Participants will be enrolled in Cohort 1 initially and then dosing in subsequent cohorts will proceed after safety review team (SRT) review of emerging data."
62080931|NCT06739512|PLACEBO_COMPARATOR|Anatomical Guided Ablation Group|This group will undergo pulmonary vein isolation (PVI) combined with anatomical linear ablation based on predefined anatomical landmarks (a complete posterior wall box isolation to ensure comprehensive atrial substrate modification), including lines such as the mitral isthmus and roofline. The ablation will aim to create bidirectional block without relying on electrogram-based mapping.
62080932|NCT06739512|ACTIVE_COMPARATOR|Electrogram Guided Ablation Group|"This group will undergo PVI and targeted ablation of atrial fibrillation drivers identified through electrogram-guided mapping. The mapping will focus on electrograms with characteristics such as spatial-temporal dispersion, high-frequency potentials, and short local cycle lengths."
62080933|NCT06739512|EXPERIMENTAL|Extensive Electro-Anatomical Guided Ablation Group|This group will receive PVI and a combination of anatomical linear ablation (a complete posterior wall box isolation to ensure comprehensive atrial substrate modification) and electrogram-guided ablation. It represents an extensive strategy that integrates both anatomical and potential-based mapping for optimized ablation targeting.
62080934|NCT05437276||People with mild to moderate Multiple Sclerosis and gait deficit|"All enrolled subjects will go through 14 weeks therapy: Phase 1 (2-week in-clinic supervised PoNS therapy) followed by Phase 2 (12-week period of at-home unsupervised - PoNS therapy).~Six-Month Observation: subjects will be asked to return to the clinic six months after the end of the 14-week course of therapy for an observation visit.~Individual subjects could receive, upon investigator's opinion of need, an ad hoc second 12-week course of PoNS therapy."
62080935|NCT05521048|EXPERIMENTAL|Single Arm Open Label|Open Label
62080936|NCT04019119|EXPERIMENTAL|Intervention: digital intervention Behaviour Change Technique|The assigned participants will receive an intervention based on gamification and the use of behavior change techniques to reduce sedentary lifestyle. Thus, a new mobile application will be used for 12 weeks that proposes to the user the realization of activities with the aim of reducing their sedentary behavior. The development of the application is based on previous analyzes that propose 6 clusters that encompass 33 factors that influence sedentary behavior. In this way, the application is designed to act on the two accessible: social support and behavior. On the social support, he proposes to the user to share his achievements in social networks or in an internal network of game users. In terms of habit modification, behavior modification strategies proposed in the Michie et al. (2013) taxonomy are applied, such as the following: establishment of personalized goals, rewards and reminders, awareness of achievements achieved, among others
62080937|NCT04019119|NO_INTERVENTION|Control Group|The control group will receive the usual indications about the harms of sedentary lifestyle and the benefits of physical activity, not receiving specific intervention. In case the use of the intervention applied in the experimental group is beneficial, the participants assigned to the control group will be offered the opportunity to receive the intervention outside the study to allow the benefit to be used.
62080938|NCT02813460|EXPERIMENTAL|Session 1: Sequence 1|Participants will sequentially receive 5 milliliters (mL) of each 6 ALS-008176 formulations A B F C E D on day 1.
62080939|NCT02813460|EXPERIMENTAL|Session 1: Sequence 2|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations B C A D F E on day 1.
62080940|NCT02813460|EXPERIMENTAL|Session 1: Sequence 3|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations C D B E A F on day 1.
62080941|NCT02813460|EXPERIMENTAL|Session 1: Sequence 4|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations D E C F B A on day 1.
62080942|NCT02813460|EXPERIMENTAL|Session 1: Sequence 5|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations E F D A C B on day 1.
62280263|NCT01235962|PLACEBO_COMPARATOR|placebo|placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
62080943|NCT02813460|EXPERIMENTAL|Session 1: Sequence 6|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations F A E B D C on day 1.
62080944|NCT02813460|EXPERIMENTAL|Session 2: Sequence 1|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G1 G2 H3 G3 H2 H1).
62080945|NCT02813460|EXPERIMENTAL|Session 2: Sequence 2|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G2 G3 G1 H1 H3 H2).
62080946|NCT02813460|EXPERIMENTAL|Session 2: Sequence 3|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G3 H1 G2 H2 G1 H3).
62080947|NCT02813460|EXPERIMENTAL|Session 2: Sequence 4|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H1 H2 G3 H3 G2 G1).
62080948|NCT02813460|EXPERIMENTAL|Session 2: Sequence 5|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H2 H3 H1 G1 G3 G2).
62080949|NCT02813460|EXPERIMENTAL|Session 2: Sequence 6|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H3 G1 H2 G2 H1 G3).
62080950|NCT06305962|EXPERIMENTAL|177Lu-RAD204|Single-arm, open-label study of 177Lu-RAD204 consisting of a Phase 0 Imaging Period (Im) and a Phase 1 Treatment Period (Tr).
62648457|NCT00386334|EXPERIMENTAL|Eszopiclone|Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
62080951|NCT06014385|EXPERIMENTAL|Scopolamine high dose|The target occupancy (TO) of scopolamine at M1 will be evaluated using the radiotracer \[11C\]EMO and positron emission tomography (PET). TO will be measured following a 15-minute IV infusion of 4.0 μg/kg scopolamine in 4-6 anticipated participants.
62280264|NCT04173819|EXPERIMENTAL|Group 1|Single Agent, abdominal subcutaneous injection, 10:2 ratio for Ab:placebo
62280265|NCT04173819|EXPERIMENTAL|Group 2|Single agent, abdominal subcutaneous injection 10:2 ratio for Ab:placebo
62280266|NCT04173819|EXPERIMENTAL|Group 3|Single agent intravenous injection 10:2 ratio for Ab:placebo
62280267|NCT04173819|EXPERIMENTAL|Group 4|Single agent intravenous injection 10:2 ratio for Ab:placebo
62080952|NCT06014385|EXPERIMENTAL|Scopolamine low dose|The target occupancy (TO) of scopolamine at M1 will be evaluated using the radiotracer \[11C\]EMO and positron emission tomography (PET). TO will be measured following a 15-minute IV infusion of 2.0 μg/kg scopolamine in 0-2 anticipated participants.
62648458|NCT02590458|EXPERIMENTAL|Short Breast MRI (SBMRI)|Routine scheduled MRI with contrast performed on women at high risk of developing breast cancer. One day after routine MRI, short breast MRI (SBMRI) with contrast performed. After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan.
62648459|NCT00477009|EXPERIMENTAL|1|Adjustable mandibular repositioning appliance
62080953|NCT06738836|EXPERIMENTAL|Human AME|
62080954|NCT06738251|EXPERIMENTAL|SHR-A2102 group|
62648460|NCT00477009|PLACEBO_COMPARATOR|2|Placebo device in upper jaw
62080955|NCT06738251|ACTIVE_COMPARATOR|Investigator-selected therapy group|
62080956|NCT04266171|EXPERIMENTAL|CGMS Diet Education|
62080957|NCT04266171|ACTIVE_COMPARATOR|Conventional Diet Education|
62080958|NCT06740318|EXPERIMENTAL|Treatment|Standard of Care, medical treatment of alcohol use disorder and motivational enhacement therapy, three interviews within three months.
62080959|NCT01681368|EXPERIMENTAL|Birinapant for Advanced Ovarian,Fallopian Tube & Peritoneal Ca|single arm
62080960|NCT05468125|ACTIVE_COMPARATOR|care bundle|will be subjected to a bundle of care of four elements
62648461|NCT02354768|EXPERIMENTAL|lanreotide and anti-diarrheal treatments|"* Lanreotide: 1 single injection at day 0 (lanreotide 120 mg)~* Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~* Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~* hydration"
62080961|NCT05468125|ACTIVE_COMPARATOR|best-evidenced practice|will be guided according to the best-evidenced performance consisting of three elements
62080962|NCT06161753|EXPERIMENTAL|Cognitive Functional Therapy|The Cognitive Functional Therapy arm will be subject to receiving the intervention, as described in the intervention section.
62080963|NCT03763188||the group BEFORE|Retrospective group. The daily urinary urea excretion was unknown.
62080964|NCT03763188||the group AFTER|Prospective group. Use the daily urinary urea excretion to guide the renal replacement therapy weaning.
62080965|NCT04773249|EXPERIMENTAL|Lateral Epicondylitis Bandage|A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
62080966|NCT04773249|EXPERIMENTAL|Wrist Extension Splint|A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
62080967|NCT04773249|NO_INTERVENTION|Wait-and-see Policy|These patients will be monitored with a wait-and-see policy. No splint or band will be given to the patient.
62080968|NCT06098079|ACTIVE_COMPARATOR|Naltrexone/Bupropion (NB)|Patients will be randomly assigned to NB (naltrexone 8 mg and bupropion 90 mg) extended-release oral tablet.
62080969|NCT06098079|PLACEBO_COMPARATOR|Placebo|Patients will be randomly assigned to placebo.
62080970|NCT01186328|EXPERIMENTAL|Single Arm|Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine).
62080971|NCT05482516|EXPERIMENTAL|Atezolizumab plus Bevacizumab|atezolizumab 1200 mg and bevacizumab 15 mg/kg given intravenously on Day 1 of each 21-day cycle (every 3 weeks \[Q3W\]) for a maximum of 12 months.
62080972|NCT06605599|EXPERIMENTAL|ABBV-932 Dose A|Participants will receive ABBV-932 Dose A.
62080973|NCT06605599|EXPERIMENTAL|ABBV-932 Dose B|Participants will receive ABBV-932 Dose B.
62080974|NCT06605599|EXPERIMENTAL|ABBV-932 Dose C|Participants will receive ABBV-932 Dose C.
62080975|NCT06605599|PLACEBO_COMPARATOR|Placebo for ABBV-932|Participants will receive placebo.
62080976|NCT00564590|EXPERIMENTAL|A|Melatonin treatment group
62080977|NCT00564590|ACTIVE_COMPARATOR|B|Omeprazole 20 mg once a day for 3 months
62080978|NCT00564590|EXPERIMENTAL|C|Placebo once a day for 3 months
62080979|NCT04232748||stage IV colorectal cancer|stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes
62280268|NCT04173819|EXPERIMENTAL|Group 5|Combined agent intravenous injection 10:2 ratio for Ab:placebo
62280269|NCT04173819|EXPERIMENTAL|Group 6|Subcutaneous injection combined ratio 1 with loading dose 30:3 ratio of Ab:Placebo
62280270|NCT04173819|EXPERIMENTAL|Group 7|Subcutaneous injection in abdomen combined ratio 2 with loading dose 30:3 ratio of Ab:Placebo
62280271|NCT04173819|EXPERIMENTAL|Group 8|Subcutaneous injection in abdomen combined ratio 3 with loading dose 30:3 ratio of Ab:Placebo
62280272|NCT04173819|EXPERIMENTAL|Group 9|Subcutaneous injection in abdomen combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
62280273|NCT04173819|EXPERIMENTAL|Group 10|Subcutaneous injection in arm combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
62280274|NCT04395261||Group 0|Patients were divided into groups according to observation in surgery Empty ear in operation
62280275|NCT04395261||Group 1|Patients were divided into groups according to observation in surgery Serous fluid in operation
62280276|NCT04395261||Group 2|Patients were divided into groups according to observation in surgery Mucoid fluid in operation
62280277|NCT04395261||Group 3|Patients were divided into groups according to observation in surgery Adhesive tympanic membrane in operation
62280278|NCT04395261||Group 4|Control group. Subjects with no otitis media with effusion
62280279|NCT05637554|ACTIVE_COMPARATOR|Laparoscopic clipping appendectomy|This group will undergo laparoscopic clipping of the base of the appendix during laparoscopic appendectomy.
62080980|NCT06736665|ACTIVE_COMPARATOR|Orbital atherectomy|The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.
62080981|NCT06736665|ACTIVE_COMPARATOR|Intravascular lithotripsy|The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.
62080982|NCT06738511|OTHER|Blood and Stool sampling|To collect blood sampling (by the medical staff) and stool sampling (by the participant)
62080983|NCT05649072|OTHER|Genetic Testing and Counseling|Participants will be given a saliva collection kit to collect a saliva sample for hereditary cancer and genetic testing. The kit includes all standard paperwork and instructions for collecting the sample and shipping the kit back to the genetic testing company (Invitae).
62080984|NCT05649072|OTHER|Screening Form|Participants will complete a screening form to assess your risk of hereditary breast and colorectal cancers.
62080985|NCT06739759|ACTIVE_COMPARATOR|antagonist|patients with PCOS undergoing ICSI receiving antagonist protocol
62080986|NCT06739759|ACTIVE_COMPARATOR|Modified agonist with additives|Patients with PCOS undergoing ICSI receiving modified agonist protocol with additives
62080987|NCT05730218|EXPERIMENTAL|Treatment Group A|ONL1204 Ophthalmic Solution Dose A administered by intravitreal injection
62080988|NCT05730218|EXPERIMENTAL|Treatment Group B|ONL1204 Ophthalmic Solution Dose B administered by intravitreal injection
62080989|NCT05730218|SHAM_COMPARATOR|Treatment Group C|Sham injection is performed by touching the eye surface with a syringe without a needle
62080990|NCT06738849|EXPERIMENTAL|Intervention Arm|The interventional device EkiYou V2 will be used at inclusion following randomization.
62080991|NCT06738849|NO_INTERVENTION|Control Arm|"Control arm with standard care for the first three months. Participants use their standard basal bolus management method by fixed doses or flexible insulin therapy.~After the initial three-months control period, participants will benefit from the investigational device EkiYou V2."
62080992|NCT05348889|EXPERIMENTAL|Dose Escalation|Open label, single arm trial where 1A46 will be administered
62080993|NCT06735040|ACTIVE_COMPARATOR|Photobiomodulation Therapy Group|All patients diagnosed with HT in the study were receiving LT4 treatment. In the PMBT group, in addition to thyroid hormone replacement therapy, a continuous wave GaAIAs type diode laser device (Intelect® Mobile Laser, Model No: 2779, Production Year: 2016; Chattanooga Group) was also applied to the thyroid gland in a 0.07 cm² treatment area. Continuous mode at 850 nm wavelength, 100 mW output power, 1.43 W/cm2 power density and 28.57 J/cm2 energy density (28.57 J/cm2 =100 Mw x 20 s/0.07) were used during the photobiomodulation therapy.
62080994|NCT06735040|SHAM_COMPARATOR|Sham Group|In the sham PMBT group, the probe was placed similarly to the treatment group. The screen of the laser device was active; however, the energy was set to 0 J and the power to 0 Mw, and the same procedures were also performed.
62080995|NCT01987063||pregnant woman with twins|pregnant woman with twins
62080996|NCT04037384|ACTIVE_COMPARATOR|Eye Yoga group|Eye yoga exercises
62080997|NCT04037384|PLACEBO_COMPARATOR|Reading Group|Passive reading
62080998|NCT03084419|EXPERIMENTAL|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
62080999|NCT03626974|EXPERIMENTAL|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
62081000|NCT03626974|PLACEBO_COMPARATOR|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
62081001|NCT06685146|EXPERIMENTAL|Glucagon infusion followed by glucose-clamp|The first study day is a 240 minutes infusion of glucagon (10ng/kg/min). The second study day is a 240 minutes infusion of glucose (20% w/v). The infusion rate of glucose will be adjusted continuously to match the levels of glucose measured on the glucagon study day.
62081002|NCT06737783|EXPERIMENTAL|Thoracic mobility exercises + Conventional therapy|"mobility exercises comprises of Cat and camel stretch (On hands and knees (supported with knee braces), alternating between arching the back up and dropping it down to stretch thoracic spine), Thoracic rotations in side lying (side lying on the side with knees bent, rotating the upper body to increase thoracic mobility alternatively), Thoracic extension at wall using body weight (Standing with back to wall, gently pushing the upper back into extension while keeping the lower back stable), half kneeling chop thrust (Kneeling on one knee (supported with knee braces), rotating the torso while keeping the pelvis stable to mobilize the thoracic spine) ,Thoracic extension with a foam roller (Lying on the back with foam roller along thoracic spine, rolling gently to extend the thoracic spine in supine position). Adopt these positions with 5 secs hold and 15-20 reps will be performed for 2 sets and 10 reps per set.~hold and 15-20 reps will be performed for 2 sets and 10 reps per set."
62081003|NCT06737783|ACTIVE_COMPARATOR|Self myofascial release with foam roller, T6- T7 Maitland mobilization and conventional therapy|"Hamstring Self myofascial release with foam roller (Sitting with one leg extended, roll the foam roller along the hamstring while applying pressure to tender spots) 3 sets with 30 to 120 secs rolling duration per second for 5 mins T6-T7 grade 3 Maitland mobilization (Lying on the back, the therapist applies a sustained, posterior-to-anterior force on T6-T7 in prone position) 30 repetitions, with 1 min rest between 4 sets for 15 mins.~Conventional therapy includes Hot pack/Cold pack + tens = 15 mins, Frequency 80 Hz, Pulse duration: 100 microseconds, Static quads (10 reps, 10 second hold, 2 sets), Active knee flexion and extension ROMs (10 reps, 5 secs hold, 2 sets), Long Axis Knee traction (5 reps, 30 secs hold, 10sec rest in b/w 2 sets), Kaltenborn Knee Glides Ant and Post direction ( 5 reps, 30 secs hold,10 sec rest interval in b/w 2 sets), Calf stretches (10 reps, 5 secs hold , 2 sets)."
62081004|NCT06739317|EXPERIMENTAL|Experimental group|
62081005|NCT06739317|ACTIVE_COMPARATOR|control group|
62081006|NCT02339649|OTHER|Sepsis/septic Shock|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
62081007|NCT02339649|OTHER|Postoperative ICU Patients|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:~* Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU~* Duration of ICU stay must be a minimum of 24 hours.~* Mini-Mental State Examination (MMSE) Score of 25 or above~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
62081008|NCT02339649|OTHER|Healthy Controls|"Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female.~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
62081009|NCT03763162|EXPERIMENTAL|Treatment (daratumumab, bortezomib, dexamethasone, ixazomib)|Patients receive daratumumab IV over 3.5-6.5 hours on days 1, 8, and 15, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV over 15 minutes on days 1, 8, and 15 and PO on days 2, 4, 5, 9, 11, 12, and 16. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive daratumumab IV over 3.5 hours on days 1 and 15 of cycles 4-7 and day 1 of subsequent cycles, ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO once weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62457987|NCT02173704|EXPERIMENTAL|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
62081010|NCT03114072|ACTIVE_COMPARATOR|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
62081011|NCT03114072|ACTIVE_COMPARATOR|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
62280280|NCT05637554|ACTIVE_COMPARATOR|Laparoscopic extracorporeal ligation appendectomy|This group will undergo laparoscopic extracorporeal ligation of the base of the appendix during laparoscopic appendectomy.
62280281|NCT02890680|EXPERIMENTAL|Platelet-rich fibrin group|Use platelet-rich fibrin after mandibular third molar extraction
62081012|NCT06736925|PLACEBO_COMPARATOR|Placebo: Organic soybean oil pills|We will use organic soybean oil pills ) as a placebo condition for the DHA+EPA group. One capsule contains 485 mg of organic soybean oil, including negligible amounts of DHA (1.1 mg), EPA (1.7 mg), and vitamin E (10 mg). Participants will ingest 5 capsules daily. Soybean oil is one of the most widely used vegetable oils in the world. Soybean oil contains polyunsaturated fats and 18-carbon omega-3 FA (total omega-3 FA of 73.9 mg per capsule), but very low levels of DHA and EPA, which makes it an excellent placebo counterpart when evaluating the effects of DHA/EPA. The placebo capsule's shelf life, composition, shape, size as the DHA+EPA active comparator.
62457988|NCT02173704|ACTIVE_COMPARATOR|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
62081013|NCT06736925|ACTIVE_COMPARATOR|Omega-3 Fatty Acids (EPA plus DHA)|DHA+EPA capsules contain purified deep-sea fish oil, made from 100% wild-caught sardines and anchovies with a 3-year shelf life. The capsule shell is made from bovine limed bone with a size of 20 oblongs. Each soft gel capsule contains 480 mg of DHA, 205 mg of EPA, 145 mg of other omega-3 FA, and 10 mg of vitamin E. Participants in the DHA+EPA group will ingest 5 capsules daily \[a total of 3.4 g/d: DHA (2.4 g), EPA (1.0 g)\].
62081014|NCT02215928||Ancillary-correlative (tumor genomic profiling)|Tissue samples are collected at baseline and blood for liquid biopsy is collected at baseline and every 6-8 weeks during active treatment. Tissue samples are analyzed via sequencing for tumor genomic profiling.
62081015|NCT03306407|NO_INTERVENTION|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
62081016|NCT03306407|ACTIVE_COMPARATOR|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
62081017|NCT06008756|EXPERIMENTAL|Enlicitide Decanoate|Participants receive enlicitide decanoate 20 mg once daily.
62081018|NCT06008756|PLACEBO_COMPARATOR|Placebo|Participants receive placebo once daily.
62280282|NCT02890680|PLACEBO_COMPARATOR|Control group|mandibular third molar extraction
62648462|NCT02354768|ACTIVE_COMPARATOR|Current anti-diarrheal treatments alone|"* Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~* Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~* Hydration"
62648463|NCT03684746||Medial Experts|Including doctors- surgeons - consultants
62648464|NCT03684746||Care specialist|including nurses - before/after care staff
62648465|NCT03922880|EXPERIMENTAL|Advanced Uveal Melanoma|
62648466|NCT03847571||Acetazolamide|Oral administration of acetazolamide 5 mg/kg/day for 4 weeks
62648467|NCT04585919|EXPERIMENTAL|Paired Screening Intervention|
62648468|NCT04585919|NO_INTERVENTION|Usual Care Control|In this stepped wedge design, all sites have a period of being in usual care, and then providing the Paired Screening Intervention. Sites serve as their own controls in this design.
62648469|NCT02858401|EXPERIMENTAL|Vesatolimod 1 mg (Cohort 1)|Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
62648470|NCT02858401|EXPERIMENTAL|Vesatolimod 2 mg (Cohort 2)|Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
62648471|NCT02858401|EXPERIMENTAL|Vesatolimod 4 mg (Cohort 3)|Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
62648472|NCT02858401|EXPERIMENTAL|Vesatolimod 6 mg (Cohort 4)|Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
62648473|NCT02858401|EXPERIMENTAL|Vesatolimod 8 mg (Cohort 5)|Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
62648474|NCT02858401|EXPERIMENTAL|Vesatolimod 10 or 12 mg (Cohort 6)|Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
62648475|NCT02858401|EXPERIMENTAL|Vesatolimod 12 mg (Optional Cohort 7)|Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
62648476|NCT02858401|EXPERIMENTAL|Vesatolimod 6 mg with an acidic solution (Optional Cohort 8)|Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
62648477|NCT02858401|EXPERIMENTAL|Vesatolimod up to 12 mg (Cohort 9)|Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
62648478|NCT02858401|PLACEBO_COMPARATOR|Placebo (Cohorts 1-9)|Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen
62648479|NCT06157450|EXPERIMENTAL|Experimental: young participates|16 young participants(between 18\~45 years old) will be given 600mg of ZSP1273.
62648480|NCT06157450|EXPERIMENTAL|Experimental:elder participates|16 elder participants(Age≥65 years old) will be given 600mg of ZSP1273.
62648481|NCT05348252|EXPERIMENTAL|Interventional group (Patient Journey App)|The interventional group will receive all information and instructions on discontinuing PPI use through the Patient Journey App.
62648482|NCT05348252|ACTIVE_COMPARATOR|Control group (Conventional Care)|The control group will receive all information and instructions on discontinuing PPI use through email as a digital information folder.
62648483|NCT04213443||Women of short stature|Women that are under 1.6 meters.
62648484|NCT02084524|NO_INTERVENTION|Nutritional evaluation|
62648485|NCT00533338|EXPERIMENTAL|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling. Packet of questionnaires will be completed.
62648486|NCT00533338|ACTIVE_COMPARATOR|Standard Care Group|Packet of questionnaires will be completed.
62648487|NCT02184208||Device utlization following extubation|
62648488|NCT02184208||Pulmonary mechanics|
62648489|NCT01472055|EXPERIMENTAL|Fludarabine|Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients
62648490|NCT05294952|EXPERIMENTAL|preeclampsiapregnant women|"Inclusion criteria~A total of 41 women in third trimester pregnancy complicated with PE showing:~* Blood pressure ≥140/90 mmHg and~* Proteinuria ≥300 mg/24 hours with or without~* Edema in pregnant woman after week 20 of gestation (American Congress of Obstetricians and Gynecologists (ACOG2013) (17)~B-Exclusion criteria~* Patients with autoimmune, acute inflammatory, and chronic diseases, are excluded from the study."
62648491|NCT05294952|NO_INTERVENTION|normal pregnant women|This will include age matched 41 normal pregnant women in their third trimester of pregnancy with normal blood pressure, absence of proteinuria, and without any other systemic or endocrine disorder.
62648492|NCT05402709|ACTIVE_COMPARATOR|Posterior mobilization group|Posterior mobilization, classical stretching, strengthening exercises were applied and home exercise program were given
62648493|NCT05402709|ACTIVE_COMPARATOR|Posterior capsule stretching|Posterior capsule stretching, classical stretching, strengthening exercises were applied and home exercise program were given
62081019|NCT04463784|EXPERIMENTAL|Efavirenz 400MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 400mg per day as antiretroviral treatment.
62081020|NCT04463784|ACTIVE_COMPARATOR|Efavirenz 600MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 600mg per day, per standard dose.
62648494|NCT05402709|NO_INTERVENTION|Control group|No treatment was given, only assessment of posterior capsule tightness was applied.
62648495|NCT04539418|ACTIVE_COMPARATOR|Vitamn K2 Treated patients|Vitamin K2 will be given to patients randomized to ARM 1 three times a week at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
62457989|NCT00059852|EXPERIMENTAL|gemcitabine + erlotinib|"Patients receive gemcitabine IV on days 1 and 8 and oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients achieving a complete response are followed every 6 weeks for up to 5 years or until disease progression (PD). Patients discontinuing study therapy for any other reason are followed every 3 months until PD and then every 6 months for up to 5 years."
62648496|NCT04539418|PLACEBO_COMPARATOR|Placebo Group|Placebo will be given to patients randomized three times a week to ARM 2 at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
62648497|NCT04616443|EXPERIMENTAL|Dose escalation|"The HX008 injection is combined with OH2 injections at 10ˆ6 and 10ˆ7 CCID50/mL at a fixed dose of 200 mg, respectively.~OH2 will be injected individually in the first week, followed by every two weeks while HX008 will be injected every three weeks after the first injection which will be in the second week."
62648498|NCT01537172|EXPERIMENTAL|ONO-4053|E Experimental Intervention Drug: ONO-4053
62648499|NCT01537172|PLACEBO_COMPARATOR|Placebo|
62648500|NCT05332223||Chronic Heart Failure Patients|All patients in our specialised heart failure clinic will be screened by the investigator/s.
62457990|NCT03038737|ACTIVE_COMPARATOR|group 1|patients will receive partial denture constructed from breflex material
62457991|NCT03038737|EXPERIMENTAL|group 2|patients will receive partial denture constructed from PEEK material
62081021|NCT04579120||African American|African American participants receiving \[11C\]-Pittsburgh Compound B (\[11C\]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
62081022|NCT04579120||Non-Hispanic White|Non-Hispanic White participants receiving \[11C\]-Pittsburgh Compound B (\[11C\]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
62280283|NCT02319044|EXPERIMENTAL|MEDI4736|MEDI4736 monotherapy
62280284|NCT02319044|EXPERIMENTAL|Tremelimumab|Tremelimumab monotherapy
62648501|NCT00626639|PLACEBO_COMPARATOR|Placebo|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of matching placebo. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of matching placebo after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m\^2 on days 1, 22 and 43.
62648502|NCT00626639|EXPERIMENTAL|Palifermin|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m\^2 on days 1, 22 and 43.
62648503|NCT06208501||Hypertensive patients undergoing renal denervation|
62081023|NCT06738641|EXPERIMENTAL|Pro2col|The experimental group will be enrolled in the Prime Health Technologies software (Pro2col), which provides a digital diagnostic score to calculate healthspan and biological age, along with AI and group community-based coaching dynamics. Subjects will be assigned a 6 week progressive protocol targeting improvements in daily activity levels, nutritional awareness, and overall lifestyle risk factors.
62081024|NCT06738641|ACTIVE_COMPARATOR|Control|The control group will receive subject-facing materials depicting current general activity recommendations as published by the American Heart Association (AHA) and current dietary guidelines provided by the United States Department of Agriculture (USDA).
62081025|NCT02326844|EXPERIMENTAL|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
62081026|NCT02771210|EXPERIMENTAL|AIN457/Secukinumab|Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose was assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
62081027|NCT02771210|PLACEBO_COMPARATOR|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
62081028|NCT03714997|EXPERIMENTAL|High Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates close to 80% of heart rate reserve.
62081029|NCT03714997|ACTIVE_COMPARATOR|Low Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates from 30% to 40% of heart rate reserve.
62081030|NCT02749695|EXPERIMENTAL|Group 1 (Melsmon)|20 women used placental extract Melsmon® (Japan), 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
62648504|NCT04552197|EXPERIMENTAL|Part 1: Treatment A (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.
62081031|NCT02749695|PLACEBO_COMPARATOR|Group 2 (placebo)|20 patients used placebo (normal saline solution): 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
62081032|NCT06475716|EXPERIMENTAL|Immediate treatment group|The immediate treatment group will receive the intervention immediately after randomization. The intervention includes using an online guided self-help programme Spring that is based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps. The user of the programme also receives up to 3 hours of guidance by a trained therapist.
62280285|NCT02319044|EXPERIMENTAL|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
62457992|NCT05834231|ACTIVE_COMPARATOR|Intervention|
62457993|NCT05834231|PLACEBO_COMPARATOR|Control|
62457994|NCT05282160|NO_INTERVENTION|Control Group|The control group (G1) will be composed of puerperal women over 18 years of age attended by Lucila Balalai Municipal Maternity in Londrina. Recruitment will be done through a chart review, which will include single-fetus primiparous that delivered on full term without intercurrence (between 37 and 42 weeks).
62648505|NCT04552197|EXPERIMENTAL|Part 1: Treatment B (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.
62648506|NCT04552197|EXPERIMENTAL|Part 1: Treatment C (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.
62280286|NCT02963376|ACTIVE_COMPARATOR|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
62280287|NCT02963376|PLACEBO_COMPARATOR|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
62280288|NCT02963376|ACTIVE_COMPARATOR|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
62280289|NCT02963376|PLACEBO_COMPARATOR|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
62280290|NCT02963376|ACTIVE_COMPARATOR|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
62280291|NCT02963376|PLACEBO_COMPARATOR|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
62081033|NCT06475716|ACTIVE_COMPARATOR|Delayed treatment control group|The delayed treatment group will receive the same intervention as the immediate treatment group, but 24 weeks after randomization. The intervention includes using an online guided self-help programme Spring that is based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps. The user of the programme also receives up to 3 hours of guidance by a trained therapist.
62280292|NCT02161159||Patients With Urinary Incontinence Due to iOAB|Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.
62648507|NCT04552197|ACTIVE_COMPARATOR|Part 1: Treatment D (JNJ-64251330)|Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.
62280293|NCT02215603|NO_INTERVENTION|Prolonged sitting|9 h of prolonged sitting
62280294|NCT02215603|EXPERIMENTAL|Prolonged sitting + interval standing bouts|Stand bout for 15-min every 30 minutes during the 9 hours of sitting
62280295|NCT02215603|EXPERIMENTAL|Moderate exercise bout + Prolonged sitting|30-min moderate-intensity exercise bout followed by 8 h of sitting
62280296|NCT02215603|EXPERIMENTAL|Moderate exercise bout + Prolonged sitting +Standing bouts|30-min moderate-intensity exercise bout and stand bout for 15-min every 30 minutes during the remaining 8 hours of sitting
62280297|NCT04315896|ACTIVE_COMPARATOR|treatment|Hydroxychloroquine tablet 200mg every 12 hours for 10 days.
62280298|NCT04315896|PLACEBO_COMPARATOR|placebo|identical placebo, one tablet every 12 hours for 10 days
62280299|NCT02244710|EXPERIMENTAL|Ticagrelor|180mg initial dose next day 90mg BID
62280300|NCT02244710|ACTIVE_COMPARATOR|Clopidogrel|600mg po initial dose and 75mg qd starting next day
62280301|NCT02817412|EXPERIMENTAL|Go/No-Go Training|In the go/no go training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. They are told to press response keys as quickly as possible to indicate the side of presentation (go-trials). On half of the trials, the rectangular frame surrounding the image is not solid but hatched, which is a signal for them to withhold their response (no-go trials). This training is divided into 4 blocks of 50 trials.
62081034|NCT01414530|EXPERIMENTAL|oral contraceptive|
62081035|NCT01414530|ACTIVE_COMPARATOR|NSAID|
62280302|NCT02817412|EXPERIMENTAL|Stop-Signal Training|In the stop signal training, participants are shown images in either a dark blue or light gray border. They are told to press the space bar as quickly as possible when the border is blue (go trials) and to withhold a response when the border is gray (no-go trials). This training is divided into 20 blocks of 32 trials.
62648508|NCT04552197|EXPERIMENTAL|Part 2: Treatment EF (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
62648509|NCT04552197|EXPERIMENTAL|Part 2: Treatment FE (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
62648510|NCT06317974|EXPERIMENTAL|Intervention group|Breastfeeding education was given to the intervention group based on the health belief model.
62648511|NCT06317974|NO_INTERVENTION|control group|The control group received standard care.
62648512|NCT04005768|EXPERIMENTAL|Hydroxychloroquine Sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
62648513|NCT04005768|PLACEBO_COMPARATOR|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
62648514|NCT02459626||HFpEF and servere diastolic dysfuntion|Left ventricular ejection fraction (LV-EF) \> 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=\>2, Diagnostic P-V-loops and MRI
62648515|NCT02459626||HFpEF no servere diastolic dysfuntion|LV-EF \> 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=\>2, Diagnostic P-V-loops and MRI
62081036|NCT00895973|EXPERIMENTAL|Stirrups delivery|Mom will be assigned to deliver with legs positioned in stirrups
62081037|NCT00895973|EXPERIMENTAL|Bed delivery|Mom will be assigned to deliver with the legs positioned in bed in the supine position
62081038|NCT03027713|OTHER|NAVA group with a specific catheter|The patients were allocated in the NAVA weaning protocol group
62081039|NCT03027713|OTHER|PSV group without a specific catheter|The patients were allocated in the PSV (pressure-support ventilation) weaning protocol group
62081040|NCT06549595|EXPERIMENTAL|Rituximab, AZD0486 - A|AZD0486 regimen A plus rituximab
62081041|NCT06549595|EXPERIMENTAL|Rituximab, AZD0486 - B|AZD0486 regimen B plus rituximab
62648516|NCT02459626||No HF or diastolic dysfunction|LV-EF \> 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI
62648517|NCT01225549|EXPERIMENTAL|1|AZD5423 75ug
62648518|NCT01225549|EXPERIMENTAL|2|AZD5423 300ug
62648519|NCT01225549|ACTIVE_COMPARATOR|3|Budesonide 200 microgram
62648520|NCT01225549|PLACEBO_COMPARATOR|4|Placebo
62648521|NCT02845583||Retrospective cohort|150 oncologic patients belonging to major complexity DRGs
62648522|NCT02845583||Perspective cohort|150 oncologic patients belonging to major complexity DRGs
62648523|NCT05624853|EXPERIMENTAL|pregabalin sustained release tablet|pregabalin sustained release tablet 150mg qd for 8weeks
62648524|NCT05624853|ACTIVE_COMPARATOR|pregabalin immediate release capsule|pregabalin immediate release capsule 75mg bid for 8weeks
62081042|NCT06549595|ACTIVE_COMPARATOR|Chemoimmunotherapy|Investigator's choice between 3 standard immunochemotherapy regimen (R-CHOP or R-CVP followed by rituximab maintenance, or B-R)
62081043|NCT05111613|ACTIVE_COMPARATOR|Randomized Controlled Trial Cohort - FlowTriever Arm|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
62081044|NCT05111613|ACTIVE_COMPARATOR|Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
62648525|NCT03807635|EXPERIMENTAL|simulation of skin pricking type 450|The evaluator simulated the capillary blood sampling with the safety lancet type 450
62648526|NCT03807635|EXPERIMENTAL|simulation of skin pricking type 610|The evaluator simulated the capillary blood sampling with the safety lancet type 610
62648527|NCT01963871|EXPERIMENTAL|Yoga in Chronic Low Back Pain|12 weeks of no yoga followed by 12 weeks of yoga, 2 times per week for individuals with chronic low back pain
62648528|NCT06473584|OTHER|Detection of glycaemic anomalies|
62648529|NCT01533532|EXPERIMENTAL|KLH-2109, low dose|
62648530|NCT01533532|EXPERIMENTAL|KLH-2109, medium dose|
62648531|NCT01533532|EXPERIMENTAL|KLH-2109, high dose|
62457995|NCT05282160|EXPERIMENTAL|Epino Group|The study group (G2) will be composed of women over 18 years of age, primigravidae, between 30 and 32 weeks of gestation attended by the Basic Health Units of the central region of Londrina. Only those who agree to participate in the study and sign the free and informed consent form will be included.
62457996|NCT05532085||Group: Medical abortion without analgesic protocol|All women over the age of 15, benefiting from a medical abortion between June and October 2020, including oral French.
62457997|NCT05532085||Group: Medical abortion with analgesic protocol|All women over the age of 15, benefiting from a medical abortion between October 2020 and February 2021, including spoken French.
62457998|NCT05532085||Group: Abortion by aspiration under local anesthesia without analgesic protocol|All women over the age of 15, benefiting from an abortion by aspiration under local anesthesia between June and October 2020, including oral French.
62081045|NCT05111613|OTHER|Non-Randomized Absolute Contraindication to Thrombolytics Cohort|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
62081046|NCT04814186|EXPERIMENTAL|Chinese participants treated with Tafamidis|treatment group with tafamidis
62081047|NCT06615986|EXPERIMENTAL|Cardiosyn in Healthy Volunteers|Participants will receive 2 doses of Cardiosyn daily by mouth (2 sachets) for a total of 16.2 grams. Each does (sachet) is 8.1 grams.
62081048|NCT00932490|EXPERIMENTAL|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and an advanced practice nurse will suggest individualized strategies to overcome barriers to adherence
62081049|NCT00932490|NO_INTERVENTION|Control|
62081050|NCT06738979|EXPERIMENTAL|TQF3510|TQF3510: The drug treatment cycle was 44 weeks, including a dose escalation period of 16w and a stable dose period of 28w.
62081051|NCT06738979|ACTIVE_COMPARATOR|Wegovy®|Wegovy® : The drug treatment cycle consisted of a dose escalation period of 16w and a stable dose period of 28w.
62081052|NCT04676230|EXPERIMENTAL|Experimental group|caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
62081053|NCT04676230|ACTIVE_COMPARATOR|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
62081054|NCT02690402|EXPERIMENTAL|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
62081055|NCT04105920|EXPERIMENTAL|hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
62081056|NCT04105920|ACTIVE_COMPARATOR|Conventional brachytherapy|Patients included in this arm will have the conventional brachytherapy.
62081057|NCT06739408|EXPERIMENTAL|Lean Red Meat|Cooked lean beef to provide approx 30g protein and isocalorically matched to be consumed 3x per week immediately following each resistance training session
62081058|NCT06739408|ACTIVE_COMPARATOR|Whey Protein|Whey protein to contain 30g of protein and isocalorically matched to be consumed 3x weekly immediately following each resistance training session
62081059|NCT06739408|PLACEBO_COMPARATOR|Maltodextrin|Isocalorically matched but providing 0g protein to be consumed 3x per week immediately following each resistance training session
62081060|NCT05423717|EXPERIMENTAL|Daridorexant 10 mg|
62081061|NCT05423717|EXPERIMENTAL|Daridorexant 25 mg|
62457999|NCT05532085||Group: Abortion by aspiration under local anesthesia with analgesic protocol|All women over the age of 15, benefiting from an abortion by aspiration under local anesthesia between October 2020 and February 2021, including oral French.
62458000|NCT00726700|ACTIVE_COMPARATOR|Arm I (without rituximab)|Patients receive pegfilgrastim subcutaneously (SC) on day 2 or 4 and CHOP comprising cyclophosphamide IV, doxorubicin IV, vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2 weeks for up to 6-8 courses in the absence of disease progression or unacceptable toxicity.
62458001|NCT00726700|EXPERIMENTAL|Arm II (with rituximab)|Patients receive pegfilgrastim and CHOP for up to 6-8 courses as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.
62458002|NCT02285738|ACTIVE_COMPARATOR|Aspirin+Asprin/Simvastatin+Observation (ASO)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day with daily dose of Simvastatin with a 2-week washout period, ending with 4 weeks of observation
62458003|NCT02285738|EXPERIMENTAL|Aspirin+Observation+Asprin/Simvastatin (AOS)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day with daily dose of Simvastatin
62458004|NCT02285738|EXPERIMENTAL|Aspirin/Simvastatin+Observation+Asprin (SOA)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day
62458005|NCT02285738|EXPERIMENTAL|Aspirin/Simvastatin+Asprin+Observation (SAO)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day and a 2-week washout, ending with observation for 4 weeks.
62648532|NCT01533532|PLACEBO_COMPARATOR|placebo|
62081062|NCT05423717|EXPERIMENTAL|Daridorexant 50 mg|
62081063|NCT05423717|PLACEBO_COMPARATOR|Placebo|
62648533|NCT05164211|EXPERIMENTAL|Didgeridoo|The children will have 6 didgeridoo lessons given by a teacher spread over 3 months.They will have a didgeridoo at home to practice with.
62648534|NCT05164211|NO_INTERVENTION|Absence|The children will have nothing to do.
62280303|NCT02817412|EXPERIMENTAL|Dot-Probe Training|In the dot-probe training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. Immediately after the images disappear, a small dot probe appears in the location of one of the images. Participants are told to press response keys as quickly as possible to indicate whether a visual probe appeared behind the left or right image during the trials. The probe appears in the location occupied by a high-calorie food image 10% of the time and in the location occupied by a low-calorie food image 90% of the time. This training is divided into 6 blocks of 40 trials.
62280304|NCT02817412|PLACEBO_COMPARATOR|Generic Training|In the generic training, participants complete a generic go/no-go training that uses images of flowers and office supplies instead of the images of high-calorie and low-calorie food images. This generic go/no go training is identical in duration and contact time to the go/no-go food training.
62648535|NCT01716273|EXPERIMENTAL|Chronic & Acute infected wounds|Wound will be cleaned with normal saline or tap water and Granulated sugar will be applied directly to the wound and covered with an absorbent pad and held in place with a bandage and tape.
62648536|NCT01716273|ACTIVE_COMPARATOR|Chronic and Acute infected wounds|Wound will be cleaned with normal saline or tap water and an appropriate debridement dressing (Aquacel or Sorbsan) is applied to the wound and secured with a bandage and surgical tape.
62648537|NCT06140290|EXPERIMENTAL|Fixed Sequence|Single oral dose of etrasimod 2mg tablet under fasted conditions with site staff led assessments and training on how to use wearable sensors followed by single oral dose 2mg tablet under fasted conditions with participant led assessments with wearable sensors.
62648538|NCT00667264|ACTIVE_COMPARATOR|Active|3-7 days of perineural local anesthetic infusion
62648539|NCT00667264|PLACEBO_COMPARATOR|Placebo|3-7 days of perineural normal saline infusion
62648540|NCT00823654||Premenopausal Women with Early Stage Breast Cancer|
62648541|NCT00823654||Unaffected High Risk Women with BRCA mutations|
62648542|NCT03448848|EXPERIMENTAL|study|
62081064|NCT02506621|EXPERIMENTAL|ELR monitoring|"Single arm study. All participants with existing permanent dual chamber pacemakers will be monitored with 5 different Loop recorder devices for a 2 week period to assess there sensitivity and specificity in detecting AF burden. The devices used will be~1. R test~2. Nuubo~3. TECHNOMED pocket ECG~4. ZIO xt patch~5. MoMe"
62081065|NCT06739577||Vestibular|Patients with vestibular loss diagnosed by senior ENT doctors with the gold standard ENT measures (caloric testing, head impulse test and/or vestibular evoked myogenic potential, ocular and cervical)
62081066|NCT06739577||Healthy controls|People with no vestibular loss
62081067|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
62081068|NCT06739174|ACTIVE_COMPARATOR|Confidence Be 1-Piece Closed Bag|The reference device is CE Marked and already commercially available
62081069|NCT06739174|ACTIVE_COMPARATOR|Confidence Natural 1-Piece Closed Bag|The reference device is CE Marked and already commercially available
62280305|NCT06228456|EXPERIMENTAL|Low-dose ticagrelor|Stable CAD patients undergoing elective PCI treated with standard of care clopidogrel will be randomly assigned in a 1:1 fashion to either switch to ticagrelor or continue with clopidogrel.
62280306|NCT06228456|ACTIVE_COMPARATOR|Clopidogrel|Stable CAD patients undergoing elective PCI treated with standard of care clopidogrel will be randomly assigned in a 1:1 fashion to either switch to ticagrelor or continue with clopidogrel.
62280307|NCT04957290|EXPERIMENTAL|Part 1: Dose Cohort 1: NOX66 800 mg|
62280308|NCT04957290|EXPERIMENTAL|Part 1: Dose Cohort 2: NOX66 1200 mg|
62280309|NCT04957290|EXPERIMENTAL|Part 1: Dose Cohort 3: NOX66 1600 mg|
62280310|NCT04957290|EXPERIMENTAL|Part 1: Dose Cohort 4: NOX66 2400 mg|
62280311|NCT04957290|EXPERIMENTAL|Part 2: Arm 1: Patients with mCRPC (RP2D NOX66)|
62280312|NCT04957290|EXPERIMENTAL|Part 2: Arm 2: Patients with BC or NSCLC (RP2D NOX66)|
62648543|NCT03448848|PLACEBO_COMPARATOR|control|
62280313|NCT04133961|EXPERIMENTAL|Group A (Phenylephrine)|Phenylephrine infusion started immediately after administration of spinal block
62280314|NCT04133961|PLACEBO_COMPARATOR|Group B (Saline)|Normal saline infusion started immediately after administration of spinal block
62081070|NCT06739174|ACTIVE_COMPARATOR|Confidence Be go 1-Piece Closed Bag|The reference device is CE Marked and already commercially available in Australia
62081071|NCT05292391|EXPERIMENTAL|A|0.5 mL of 100 micrograms of Sm-p80 administered intramuscularly on Days 1, 29, and 57. N=9
62081072|NCT05292391|EXPERIMENTAL|B|0.5 mL of 10 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9
62081073|NCT05292391|EXPERIMENTAL|C|0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 180. N=9.
62081074|NCT05292391|EXPERIMENTAL|D|0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9.
62081075|NCT05292391|EXPERIMENTAL|E|0.5mL of 100 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29 and 57. N=9.
62081076|NCT01991444||TAVI patients of > 79 years|"All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.~Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
62081077|NCT01544491|EXPERIMENTAL|Investigational arm|Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
62081078|NCT01544491|ACTIVE_COMPARATOR|Control arm|MMF continuation (in combination with tacrolimus and standard dose steroids)
62280315|NCT03112239|ACTIVE_COMPARATOR|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
62280316|NCT03112239|PLACEBO_COMPARATOR|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
62280317|NCT05273684|EXPERIMENTAL|4*4 followed by 10*1 or 10*1 followed by 4*4|Following baseline measurements, participants are allocated to the random sequence, by which they will complete the two HIIT protocols ⟨http://www.randomization.com⟩ and based on this, patients are randomized to a specific testing sequence.
62280318|NCT00428649|EXPERIMENTAL|1|20 µg selenium as selenomethionine
62280319|NCT00428649|EXPERIMENTAL|2|40 µg selenium as selenomethionine
62081079|NCT06740604|EXPERIMENTAL|BSD-10CH|The BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
62081080|NCT06740604|SHAM_COMPARATOR|Sham BSD-10CH|The Sham BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
62280320|NCT00428649|EXPERIMENTAL|3|60 µg selenium as selenomethionine
62280321|NCT00428649|EXPERIMENTAL|4|80 µg selenium as selenomethionine
62280322|NCT00428649|EXPERIMENTAL|5|100 µg selenium as selenomethionine
62280323|NCT00428649|EXPERIMENTAL|6|120 µg selenium as selenomethionine
62280324|NCT00428649|PLACEBO_COMPARATOR|7|placebo
62081081|NCT02522975|ACTIVE_COMPARATOR|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight."
62081082|NCT02522975|EXPERIMENTAL|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight."
62081083|NCT05586191|EXPERIMENTAL|Action Observation therapy at home|In action observation therapy, patient will not come to hospital for treatment. He will see a video at home in which therapist will perform different activities then patient will also perform the same movements.
62081084|NCT05586191|ACTIVE_COMPARATOR|Action Observation therapy at hospital|In action observation therapy, patient will come to hospital for treatment. He will see a video in which therapist will perform different activities then patient will also perform the same movements.
62081085|NCT06739603|EXPERIMENTAL|Group 1 : pharmaceutical analysis of the prescription of Direct Oral Anticoagulant|community pharmacist makes every effort to obtain the patient's renal function in order to carry out a pharmaceutical analysis of the prescription of Direct Oral Anticoagulant
62081086|NCT06739603|NO_INTERVENTION|Group 2 : control group|No intervention (the community pharmacist takes no additional action to improve the patient's renal function)
62081087|NCT05339035|EXPERIMENTAL|experimental group|In the first stage, the participants will be trained according to the IMB model. In the second stage, 6 sessions of individual motivational interviews will be held for a total of 7 weeks. Finally, participants will be given hippotherapy 1 hour a week for 8 weeks.
62280325|NCT00476580||Sri Lankan Sinhalese|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area, but born in Sri Lanka.
62280326|NCT00476580||Siblings or Cousins in Sri Lanka|Siblings or the first cousins of the study participants living in Sri Lanka of same sex and of an age plus or minus 10 years.
62280327|NCT04710329||C Vit|The patients who were admitted to the intensive care unit and received a high dose intravenous vitamin C protocol constituted the treatment group
62280328|NCT04710329||non-C Vit|The patients who were admitted to the intensive care unit but did not receive the vitamin C protocol constituted the control group
62280329|NCT05935254|EXPERIMENTAL|ADHD-Electric Toothbrush Group|Children aged 8-10 years who were diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) according to DSM-5 criteria, who applied to Aydın Adnan Menderes University Faculty of Medicine Child Psychiatry Clinic, were randomly assigned to the electric toothbrush group.
62081088|NCT05339035|NO_INTERVENTION|control group|attempt will not be implemented.
62081089|NCT06736873|EXPERIMENTAL|light application|Non-stress test was performed under 100 lx light application.
62081090|NCT06736873|PLACEBO_COMPARATOR|control group|Non-stress test was performed under 440 lx light application.
62648544|NCT00898755||Ancillary-Correlative (tissue sample collection)|"Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:~NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry"
62648545|NCT01571843|EXPERIMENTAL|PHPT/ Walking + Forearm exercise|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
62081091|NCT06736782|EXPERIMENTAL|Self-Empowerment Care Intervention Group|Participants in the experimental group will receive a 12-week intervention based on the Self-Empowerment Care model.
62648546|NCT01571843|PLACEBO_COMPARATOR|PHPT/ Walking alone|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
62648547|NCT01571843|ACTIVE_COMPARATOR|Osteopenia/ Walking + Forearm exercise|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
62648548|NCT01571843|PLACEBO_COMPARATOR|Osteopenia/ Walking alone|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
62648549|NCT03413514|EXPERIMENTAL|experiment group|Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.
62648550|NCT00565864|EXPERIMENTAL|1 (Low-normal TSH target)|Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
62081092|NCT06736782|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive usual care provided in their respective care settings. This includes routine assistance with daily activities, basic medical support, and general health monitoring without the structured interventions specific to the Self-Empowerment Care model.
62280330|NCT05935254|EXPERIMENTAL|ADHD-Manual Toothbrush Group|Children aged 8-10 years who were diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) according to DSM-5 criteria, who applied to Aydın Adnan Menderes University Faculty of Medicine Child Psychiatry Clinic, were randomly assigned to the manual toothbrush group.
62280331|NCT05935254|ACTIVE_COMPARATOR|Healthy- Electric Toothbrush Group|Among the physically and psychologically healthy children aged 8-10 who applied to the Pediatric Dentistry Clinic of ADU Faculty of Dentistry, those assigned to the electric toothbrush group as a result of randomization
62280332|NCT05935254|ACTIVE_COMPARATOR|Healthy- Manual Toothbrush Group|Among the physically and psychologically healthy children aged 8-10 who applied to the Pediatric Dentistry Clinic of ADU Faculty of Dentistry, those assigned to the manual toothbrush group as a result of randomization
62458006|NCT02285738|EXPERIMENTAL|Observation+Aspirin/Simvastatin+Asprin (OSA)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks.
62081093|NCT06539052||migrants|"All migrants, documents or undocumented migrants, and low-income refugees belonging to the infectious disease centers of the university centers participating in the project will be enrolled.~All HBsAg-positive subjects will be linked to the tertiary centers. The cultural mediator will accompany the migrants testing positive to the screening to stage the liver disease and to start the therapeutic management of subjects with HBV infection and HBV HDV co-infection according to international guidelines.~In the Retrospective phase of the project about 2000 stored samples of migrant enrolled in a previous study will be re-tested for HBsAG, HCV Ab and HIV ab. In the same blood sample testing positive for HBsAg, anti-HDV will be tested; in cases of anti-HDV positivity the same serum sample will be collected to test HDV RNA."
62081094|NCT06741046||Radical surgery group|Patients who received radical surgery for cervical cancer in Peking Union Medical College Hospital
62081095|NCT06741046||Concurrent chemoradiotherapy group|Patients who received concurrent chemoradiotherapy in Peking Union Medical College Hospital
62081096|NCT06737328|EXPERIMENTAL|Test. Increased treatment frequency|Submucosal instrumentation will be performed at baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 16 weeks, 24 weeks and 36 weeks.
62081097|NCT06737328|ACTIVE_COMPARATOR|Control. Conventional frequency|Submucosal instrumentation will be performed at baseline, 12 weeks, 24 weeks and 36 weeks
62081098|NCT06720012|EXPERIMENTAL|Patient Specific Instrumentation (PSI)|PSI cutting guides modeled from a MRI preoperatively and based on the patients unique anatomy.
62081099|NCT06720012|ACTIVE_COMPARATOR|Conventional Instrumentation|Conventional jig-based intra- and extramedullary instrumentation for the NexGen Knee System.
62081100|NCT03530046|EXPERIMENTAL|High SID fluid|Group 1: half-normal saline with addition of 75mEq/L sodium bicarbonate
62280333|NCT02421237|EXPERIMENTAL|Experimental condition|Narrative enhancement and cognitive therapy (NECT) groups. Structured psychoeducational and skills-training groups focused on self-stigma and its impact on people with schizophrenia
62280334|NCT02421237|ACTIVE_COMPARATOR|Control condition|Supportive group therapy groups. Unstructured supportive groups not focused on self-stigma.
62280335|NCT00448708|EXPERIMENTAL|Vascular Wrap and Graft|Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.
62280336|NCT00448708|NO_INTERVENTION|Lifespan® ePTFE Vascular Graft|Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.
62280337|NCT06152588|EXPERIMENTAL|Time-restricted eating|TRE group for 1 year: The intervention consists of a 3-month (12 weeks) strict TRE period, where participants follow the same eating window each day with minimal support, followed by a 9-month (40 weeks) period of individually adjusted TRE according to their experiences.
62648551|NCT00565864|EXPERIMENTAL|2 (High-normal TSH target)|"Treatment arm 2 targeting a TSH of 2.5 - 5.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
62081101|NCT03530046|ACTIVE_COMPARATOR|Hartmann's solution|Group 2: Hartmann's Solution
62081102|NCT03257592|EXPERIMENTAL|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with \[11C\] DPA-713
62280338|NCT06152588|NO_INTERVENTION|Control|Control group for 1 year: Participants will be instructed to continue their habitual lifestyle during the study and they will follow standard care with regular visits at the SDCC clinic 3-4 times/year.
62280339|NCT06507163|EXPERIMENTAL|The post-surgical breathing exercise group|Individuals in this group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for 5 days in the postoperative period.
62081103|NCT03257592|EXPERIMENTAL|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with \[11C\] DPA-713
62458007|NCT02285738|EXPERIMENTAL|Observation+Aspirin+Asprin/Simvastatin (OAS)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin.
62081104|NCT03257592|EXPERIMENTAL|Control|Normal volunteers will be imaged with \[11C\] DPA-713
62081105|NCT00338767|EXPERIMENTAL|Treatment|Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
62081106|NCT00338767|NO_INTERVENTION|Control|Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project
62280340|NCT06507163|EXPERIMENTAL|The pre- and post- surgical breathing exercise group|Individuals in this group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for a total of 10 days, 5 days in the preoperative period and 5 days in the postoperative period.
62280341|NCT06507163|NO_INTERVENTION|Control group|Routine practice group
62280342|NCT02658422|EXPERIMENTAL|Sequence A-B (Test Montelukast then Reference Montelukast)|Subjects will receive Treatment A- Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 1 and then Treatment B - Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 2.
62280343|NCT02658422|EXPERIMENTAL|Sequence B-A (Reference Montelukast then Test Montelukast)|Subjects will receive Treatment B- Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 1 and then Treatment A Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 2.
62280344|NCT00711633|EXPERIMENTAL|1|the fermented preterm formula (FPF)
62280345|NCT00711633|PLACEBO_COMPARATOR|2|formula adapted for preterm infants (PF)
62280346|NCT03190057||Consecutive percutaneous coronary intervention|
62648552|NCT00565864|EXPERIMENTAL|3 (Mildly elevated TSH target)|"Treatment arm 3 is targeting a TSH level o f 5.1-12.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
62648553|NCT05387642|EXPERIMENTAL|Double-blind Sequence 1|Double-blind treatment sequence of 10 mg, 20 mg, and placebo in the morning
62280347|NCT02170441||Patients at risk for drug-resistant TB|No intervention
62280348|NCT03262363|EXPERIMENTAL|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
62280349|NCT03262363|PLACEBO_COMPARATOR|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
62280350|NCT03616431||Demographic cohort|A prospective cross-sectional assessment of the prevalence of PEI-related symptoms in up to n=150 patients with pancreatic malignancy.
62280351|NCT03616431||Diagnosis cohort|"A sub-set (up to n=50) of the Demographic cohort patients will be tested to elucidate the most efficient diagnostic panel for PEI in pancreatic malignancy.~An extra assessment for PEI diagnosis consisting of a breath test (Pancreo-KIT breath test) will be carried out during the following 1-2 weeks after the first appointment (which takes around six hours to complete and involves the administration of bread spread with 13C butter followed by collection of the patient's breath in small plastic vials at timed intervals. The vials will subsequently be analyzed for 13C quantity; details in Appendix 6). Following these diagnostic tests, patients will complete an acceptability questionnaire to assess their opinion regarding the burden that these diagnostic tests may add."
62648554|NCT05387642|EXPERIMENTAL|Double-blind Sequence 2|Double-blind treatment sequence of 20 mg, placebo, and 10 mg in the morning
62648555|NCT05387642|EXPERIMENTAL|Double-blind Sequence 3|Double-blind treatment sequence of placebo, 10 mg, and 20 mg in the morning
62648556|NCT05387642|EXPERIMENTAL|Open-label Period PRAX-114|Open-label extension period - 10 mg or 20 mg PRAX-114 once daily in the morning for 28 days
62280352|NCT03616431||Follow-up cohort|Validation of the diagnostic panel designed and tested in Step-1 of this study and evaluation of dietician intervention (including Pancreatic Enzyme Replacement Therapy; PERT) and its impact in weight loss, symptom evolution, chemotherapy receiving rate, quality of life and overall survival.
62280353|NCT06272344|EXPERIMENTAL|Teleconsultation|Teleconsultation at 6 months
62280354|NCT00276575|EXPERIMENTAL|Bevacizumab, Everolimus, and Erlotinib|"Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---~1. 10 5 ---~2. 10 10 ---~3. 10\* 10\* 75~4. 10\* 10\* 150"
62280355|NCT04381208||Sacroiliac joint pain|Patients diagnosed with sacroiliac joint pain on the basis of history, physical examination and diagnostic sacroiliac joint block
62280356|NCT04381208||Lumbar pain|Patients diagnosed with other chronic lumbar pathologies on the basis of history, physical examination and radiographic studies
62280357|NCT03491332|PLACEBO_COMPARATOR|group C|general circuit group
62280358|NCT03491332|ACTIVE_COMPARATOR|group H|warm circuit group
62280359|NCT03491332|EXPERIMENTAL|group SH|new warm circuit group
62648557|NCT05090254|ACTIVE_COMPARATOR|Cardiac output maximization group|"Patients will be treated according to a goal-directed therapy protocol aiming at a cardiac output maximization.~Detailed protocol adapted from Edwards, M.R., et al., Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery. BMJ Open, 2019. 9(1): p. e023455."
62648558|NCT05090254|ACTIVE_COMPARATOR|Cardiac output personalization group|"Patients will be treated according to a goal-directed therapy protocol aiming at a personalized cardiac output goal determined with preoperative cardiac output assessment.~Detailed protocol adapted from Nicklas, J.Y., et al., Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial. Br J Anaesth, 2020. 125(2): p. 122-132."
62648559|NCT05090254|NO_INTERVENTION|Routine management group|Patients will be treated according to routine hemodynamic management.
62648560|NCT01737736||Patients undergoing cartoid endarterectomy surgery|
62648561|NCT01930539|EXPERIMENTAL|Ultraviolet B lamp|Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
62458008|NCT04345965||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
62458009|NCT04326998|ACTIVE_COMPARATOR|non-solvent|mechanical or heat treatment
62648562|NCT01930539|NO_INTERVENTION|Control|Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
62280360|NCT04599062|EXPERIMENTAL|Talimogene Laherparepvec in combination with radiotherapy-Phase I Cohort|"Talimogene Laherparepvec Dose Levels:~Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly~Dose -1 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed every 2 weeks"
62280361|NCT04599062|ACTIVE_COMPARATOR|Talimogene Laherparepvec in combination with radiotherapy-Phase II Cohort|Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly
62280362|NCT01835119|EXPERIMENTAL|chewing gum|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at least 5 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
62280363|NCT01835119|NO_INTERVENTION|control group|no gum
62280364|NCT00433329|EXPERIMENTAL|Bosentan|Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
62280365|NCT03447158|EXPERIMENTAL|15% Dextrose group|4.5cc 15% dextrose and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
62458010|NCT04326998|EXPERIMENTAL|solvent|GuttaClear
62458011|NCT06235398|EXPERIMENTAL|Adults with Myelodysplasic Syndrome diagnosis|Adults (Age ≥ 50 and ≤ 70 years) patients with MDS diagnosis for whom transplantation is indicated from a related donor identified.
62458012|NCT03252470||2D laparoscopic surgeries|Two-Dimensional Laparascopic Surgical Video System
62648563|NCT01688713|EXPERIMENTAL|Icotinib,Brain metastases|
62280366|NCT03447158|PLACEBO_COMPARATOR|control group|4.5cc normal saline and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
62648564|NCT01466361|ACTIVE_COMPARATOR|Lower dose Nicotine|lower dose nicotine lozenge
62280367|NCT02952183|EXPERIMENTAL|PAMS I|During operation, autonomic nerve monitoring will be performed by PAMS I which is composed of two urodynamic systems.
62280368|NCT04481997||Diabetic patients with CAD submitted to PCI|Individuals with type 2 Diabetes mellitus (previously diagnosed or diagnosed at index admission) submitted to PCI
62458013|NCT03252470||3D laparoscopic surgeries|Three-Dimensional Laparascopic Surgical Video System
62648565|NCT01466361|ACTIVE_COMPARATOR|Higher dose Nicotine|higher dose Nicotine lozenge
62648566|NCT01466361|PLACEBO_COMPARATOR|Placebo|Placebo
62648567|NCT05241301|OTHER|One to one interviews with family carers of older people from Turkish and Moroccan origin|one to one interviews
62648568|NCT01061372|PLACEBO_COMPARATOR|Placebo|
62280369|NCT06149234|NO_INTERVENTION|Control Group|Normal panoramic positioning
62280370|NCT06149234|EXPERIMENTAL|Fruit leather on the tongue|The patient holding a stripe of fruit leather on the tongue while acquiring a panoramic image
62458014|NCT01826383|EXPERIMENTAL|Active Video|This is a five-minute video that coaches parents about how to soothe their infant post-immunization.
62458015|NCT01826383|PLACEBO_COMPARATOR|Placebo Video|This is a video identical to that of the active video, except no specific instructions regarding how to soothe an infant post-immunization are given.
62458016|NCT01132976|ACTIVE_COMPARATOR|Goal-based motivational interview|Participants randomised to this group will receive the goal based motivational interview - Personal Concerns Inventory (PCI) in addition to treatment as usual.
62458017|NCT01132976|OTHER|Treatment as usual|Participants randomly allocated to this group will receive treatment as usual only, ie no specific motivational intervention.
62458018|NCT03902171||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
62458019|NCT03902171||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
62458020|NCT05319665|NO_INTERVENTION|Control|The control group will have the standard-of-care treatment.
62458021|NCT05319665|EXPERIMENTAL|Interventional|The interventional group will have a head-mounted display whilst still in the operating theatre airing a live video of their newborn filmed by a 2D 360° camera to enable a visual and auditory contact.
62458022|NCT03605043||Overall cohort|All Persons Living with HIV who enlisted in any one of three high-volume HIV clinics in Tororo District of Eastern Uganda between 2014 and 2017.
62648569|NCT01061372|EXPERIMENTAL|Pregabalin 150 mg/day|
62648570|NCT01061372|EXPERIMENTAL|Pregabalin 300 mg/day|
62648571|NCT01613924|PLACEBO_COMPARATOR|Heat based treatment/no treatment|Split face treatment with handheld acne heat based device and no treatment
62648572|NCT01613924|ACTIVE_COMPARATOR|Heat based treatment/benzoyl peroxide|Split face treatment with handheld acne heat based device and benzoyl peroxide 4%
62648573|NCT03316846|EXPERIMENTAL|Internet-delivered therapy|10 week, guided and individually tailored internet-delivered cognitive behavioral therapy.
62648574|NCT03316846|NO_INTERVENTION|Wait list control group|Wait list control group, receives treatment at later point.
62081107|NCT06740968|EXPERIMENTAL|transcranial alternating current stimulation (tACS)|Participants will receive 5 sessions of tACS. Each session can be active or sham. The stimulation parameters regarding the active and sham will not be disclosed at this time to maintain blind to participants. At the end of the trial the study will be updated to list these.
62081108|NCT04857372|EXPERIMENTAL|Group 1|Malignant pleural mesothelioma
62081109|NCT04857372|EXPERIMENTAL|Group 2|NF2 truncating mutations or deletions
62081110|NCT04857372|EXPERIMENTAL|Group 3|Solid tumors with functional YAP/TAZ fusions
62081111|NCT04857372|EXPERIMENTAL|Group 4|Non-pleural mesothelioma
62081112|NCT06712719|EXPERIMENTAL|CKD patients group 1|assigned to Low P Diet (LP) then High P Diet (HP),
62081113|NCT06712719|EXPERIMENTAL|CKD patients group 2|assigned to HP, then LP.
62081114|NCT06740695|NO_INTERVENTION|Control Group|
62081115|NCT06740695|ACTIVE_COMPARATOR|Education group|
62081116|NCT06525935|PLACEBO_COMPARATOR|Arm 1: Placebo|Placebo administered subcutaneously (SC) once weekly.
62081117|NCT06525935|EXPERIMENTAL|Arm 2: CT-388 Dose Level 1 (Low)|CT-388 Dose Level 1 administered SC once weekly.
62081118|NCT06525935|EXPERIMENTAL|Arm 3: CT-388 Dose Level 2|CT-388 Dose Level 2 administered SC once weekly.
62081119|NCT06525935|EXPERIMENTAL|Arm 4: CT-388 Dose Level 3|CT-388 Dose Level 3 administered SC once weekly.
62648575|NCT02783898|EXPERIMENTAL|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
62648576|NCT02783898|NO_INTERVENTION|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
62648577|NCT00284856|EXPERIMENTAL|1|Arm 1: Montelukast
62081120|NCT06525935|EXPERIMENTAL|Arm 5: CT-388 Dose Level 4|CT-388 Dose Level 4 administered SC once weekly.
62081121|NCT06525935|EXPERIMENTAL|Arm 6: CT-388 Dose Level 5 (High)|CT-388 Dose Level 5 administered SC once weekly.
62081122|NCT05526235|EXPERIMENTAL|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will first receive Psychological First Aid (PFA). PFA consists of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.~Afterwards participants will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2). Step 2 will only be provided if the participant still has elevated levels of psychological distress (i.e. during the second quantitative assessment at 2 weeks after DWM).~Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.~Interventions:~Behavioral: Doing What Matters (DWM) Behavioral: Problem Management Plus (PM+) Behavioral: Psychological First Aid (PFA)"
62081123|NCT05526235|ACTIVE_COMPARATOR|Psychological First Aid (PFA)|"Participants allocated to the control arm will also receive PFA. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.~Intervention: Behavioral: Psychological First Aid (PFA)"
62081124|NCT06739863||Group Desc|
62081125|NCT02885519|NO_INTERVENTION|Control|Standard treatment and standard vocational rehabilitation
62081126|NCT02885519|EXPERIMENTAL|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
62081127|NCT02885519|EXPERIMENTAL|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
62081128|NCT06475196||Group A|sintilimab combined with platinum-containing chemotherapy Q3W for 3 cycles
62081129|NCT06475196||Group B|sintilimab combined with platinum-containing chemotherapy Q3W for 2 cycles + sintilimab for 1 cycle
62081130|NCT06475196||Group C|sintilimab combined with platinum-containing chemotherapy for 1 cycle + sintilimab Q3W for 2 cycles
62081131|NCT06739304|EXPERIMENTAL|Mindfulness-Based Relapse Prevention|250 adult USD females of Intervention group received the 8-week Group mindfulness intervention performed by psychiatrists，and were assessed three times, before, during(1-2 weeks after the MBI began), and after the intervention by a variety of clinical variables, cognitive task(reginal segmental task),fMRI and blood test to verify the effectiveness of the intervention method, attempting to expand the model of addiction and mindfulness.
62081132|NCT06739304|NO_INTERVENTION|Control group|the matched 250 females in Control group were assessed by the by a variety of clinical variables, cognitive task(reginal segmental task),FMRI and blood test.
62648578|NCT00284856|ACTIVE_COMPARATOR|2|Arm 2: Fluticasone
62081133|NCT06737185|OTHER|EA arm|"at 6 month post-activation: evolutionary algorithms to modify the tonotopy-based fitting FS4T to give EAFS4T fitting.~Participant wears EAFS4T during 6 weeks."
62081134|NCT02942004|PLACEBO_COMPARATOR|Placebo|Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
62081135|NCT02942004|EXPERIMENTAL|SAGE-547 60 μg/kg/h|Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
62081136|NCT02942004|EXPERIMENTAL|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
62081137|NCT01121640|OTHER|CA125 every screen, HE4 at confirmatory screen.|CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
62081138|NCT01121640|OTHER|CA125 and HE4 at every screen.|CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
62081139|NCT06739889|EXPERIMENTAL|Interventional group I|
62081140|NCT06739889|ACTIVE_COMPARATOR|Interventional group II|
62081141|NCT04838626|EXPERIMENTAL|PET/CT imaging with [18F]CTT1057|All eligible participants will be enrolled to receive \[18F\]CTT1057 imaging agent on Day 1 and have PET/CT scan
62081142|NCT00113893|EXPERIMENTAL|Scio-469 30 Milligram (mg)|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
62081143|NCT00113893|EXPERIMENTAL|Scio-469 60 mg|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
62081144|NCT00113893|EXPERIMENTAL|Scio-469 90 mg|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
62081145|NCT00113893|EXPERIMENTAL|Scio-469 120 mg|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
62081146|NCT06737978|EXPERIMENTAL|AngioSafe Peripheral-5 CTO Crossing System|AngioSafe Peripheral-5 CTO Crossing System is used to help the doctor to pass a guidewire through the blockage in blood vessels below the knee.
62280371|NCT06149234|EXPERIMENTAL|Chewing gum strip|The patient holding a stripe of chewing gum on the tongue while acquiring a panoramic image
62280372|NCT06149234|EXPERIMENTAL|Celluloid matrix group|The patient holding a stripe of celluloid matrix group on the tongue while acquiring a panoramic image
62648579|NCT00284856|PLACEBO_COMPARATOR|3|Arm 3: Placebo
62280373|NCT05192811|EXPERIMENTAL|probiotic K56|Probiotic capsule (lactobacillus paracasei K56 10\^9CFU) 1capsule/day , for 60days
62280374|NCT05192811|PLACEBO_COMPARATOR|placebo|placebo capsule(maltodextrin, 1capsule/day, 60days
62648580|NCT01235377|ACTIVE_COMPARATOR|Favor Chlorthalidone|Providers randomized to Favor Chlorthalidone will have agreed to prescribe chlorthalidone for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
62648581|NCT01235377|ACTIVE_COMPARATOR|Favor Hydrochlorothiazide|Providers randomized to Favor Hydrochlorothiazide will have agreed to prescribe hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
62648582|NCT02632617||CTA Group|Participants in CTA group will primarily receive computed tomographic angiography examination before surgery. Those with positive findings in CTA (≥50% diameter stenosis in main coronary artery) or uncertain diagnosis caused by motion artifact or calcium artifact are required to undergo ICA, and coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis according to the ICA result. Participants with negative findings in CTA do not need further coronary artery evaluation, and CABG won't be performed during the surgery.
62081147|NCT06682143|EXPERIMENTAL|Virtual reality|Participants will be outfitted with a virtual reality headset. While seated in a recliner chair, participants will engage in a pre-specified VR nature experience called Nature Treks VR for 5 minutes.
62081148|NCT06682143|PLACEBO_COMPARATOR|Control|Participants will be seated in a recliner chair and asked to sit quietly for 5 minutes.
62081149|NCT01039714||Total Thyroidectomy|
62280375|NCT04388306||Study Group|Thirty-two participants with undergone arthroscopic Rotator Cuff repair
62280376|NCT04388306||Control Group|Thirty-two healthy participants
62280377|NCT02402855|EXPERIMENTAL|Group Intervention: Financial support|
62280378|NCT02402855|ACTIVE_COMPARATOR|Group Control: no financial support|
62081150|NCT03930186|EXPERIMENTAL|Apremilast|After a 5-day titration, participants received 30 mg apremilast tablets orally twice daily (BID) for up to 32 weeks in addition to their existing topical therapy. At week 16 participants were permitted to decrease their use of topical therapy at their own discretion under the direction of their physician.
62081151|NCT05773365|EXPERIMENTAL|Pericapsular Nerve Group Block plus local infiltration|"Group A (study group) will receive both PENG block and local infiltration at the end of the surgery.~Spinal anaesthesia will be administered to the patient using 7.5-12.5 mg heavy 0.5% bupivacaine at L3-L5 lumbar spine using 25 G spinal needle.~If spinal anaesthesia is contraindicated or failed, patients will have general anaesthetics.~General anaesthesia will be induced with 2-3 mcg/kg fentanyl, Propofol 1-2 mg/kg titrated to effect, and muscle relaxant if required.~PENG block will be administered according to the description by injecting 20 ml of 0.25% bupivacaine below the psoas tendon.~A 20 ml of 0.25% bupivacaine will be infiltrated by the surgeons to the tissues at the end of the surgery."
62280379|NCT03909360|EXPERIMENTAL|drainage|Placement of subhepatic drainage tube for laparoscopic cholecytetomy
62280380|NCT03909360|NO_INTERVENTION|no drainage|no placement of subhepatic drainage tube for laparoscopic cholecytetomy
62280381|NCT03961360|EXPERIMENTAL|162 mg/day Aspirin|
62280382|NCT03961360|ACTIVE_COMPARATOR|81 mg/day Aspirin|
62280383|NCT05825677|ACTIVE_COMPARATOR|Active tDCS|Active brain stimulation Direct current stimulation of DLPFC for 30min with an intensity of 1mA
62081152|NCT05773365|ACTIVE_COMPARATOR|Pericapsular Nerve Group Block|In Group B, only PENG block will be administered in this arm
62081153|NCT06368440|EXPERIMENTAL|Part 1: Cohort 1 AZD6793|6 Healthy Japanese participants will receive single dose of AZD6793 dose 1 and 2 healthy Japanese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.
62081154|NCT06368440|EXPERIMENTAL|Part 1: Cohort 2 AZD6793|6 Healthy Japanese participants will receive single dose of AZD6793 dose 2 and 2 healthy Japanese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.
62280384|NCT05825677|SHAM_COMPARATOR|Sham tDCS|Sham brain stimulation Direct current stimulation of DLPFC for 30sec with an intensity of 1mA
62280385|NCT00949156||Retrospective cohort|The 198 cases of CP with primary surgery in our hospital (since July, 1997 until now) were divided into three topographical groups based on the pre-operative MRI, intraoperative findings and the tumor-membrane relationship. The presurgical manifestation, the different surgical approach, intraoperative techniques, and postoperative complication were described and analyzed to establish a normalized surgical treatment of individual CP patient, which has the highest rate of the totally tumoral resection and the lowest rate of the hypothalamic injury.
62081155|NCT06368440|EXPERIMENTAL|Part 1: Cohort 3 AZD6793|6 Healthy Chinese participants will receive single dose of AZD6793 dose 1 and 2 healthy Chinese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.
62280386|NCT00949156||Prospective cohort|The anticipated 40 cases of CP were surgical treated by our standard procedure, which is recruited in the prospective cohort. With the long-term follow up, QOL including the cognition, circadian rhythm, endocrine, Water-Electrolyte, and body weight et al were evaluated to assess the rationality of the treatment. Then according to the results, the surgical treatment was modified, and the endocrinic substitution therapy was also been developed.
62280387|NCT03729947|ACTIVE_COMPARATOR|Drain placed|Subfascial drain at end of procedure
62280388|NCT03729947|PLACEBO_COMPARATOR|No drain placed|No drain left at the end of study
62280389|NCT04778280||Group A|1-Group A(Healty group with negative Giardia lamblia or control group) 96 samples
62280390|NCT04778280||Group B|2- Group B(Cases group with positive Giardia lamblia )96 sample
62280391|NCT02372487|ACTIVE_COMPARATOR|fluid therapy and sildenafil citrate|Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
62648583|NCT02632617||ICA Group|Participants in ICA group will undergo ICA as guideline recommend before surgery, coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis
62648584|NCT06288568||Nightshift workers|Nightshift worker in the health care and industrial sector. Night shift is defined as a work schedule that involves working at least 3 hours between 00:00 and 5:00, at least 2 consecutive nights/month.
62280392|NCT02372487|ACTIVE_COMPARATOR|fluid therapy|Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid
62280393|NCT02011191|ACTIVE_COMPARATOR|Biotin|10,000 micrograms biotin daily for 8 weeks
62280394|NCT02011191|PLACEBO_COMPARATOR|Sugar pill|
62648585|NCT06288568||Dayshift workers|Dayshift worker in the health care and industrial sector. No night shifts.
62648586|NCT03037632|EXPERIMENTAL|Communication Tool|
62648587|NCT03037632|NO_INTERVENTION|No Communication Tool|
62081156|NCT06368440|EXPERIMENTAL|Part 2: Cohort 1 AZD6793|6 Japanese participants will receive single dose of AZD6793 and 2 participants will receive matching placebo on Day 1. After a washout of at least 48 hours, participants will receive AZD6793 or placebo once daily from Day 3 to Day 8.
62648588|NCT05761600||Art Therapist|Professionally qualified and HCPC registered Arts Therapists delivering group arts therapy in the community settings in the UK
62081157|NCT06368440|EXPERIMENTAL|Part 2: Cohort 2 AZD6793|6 Chinese participants will receive single dose of AZD6793 and 2 participants will receive matching placebo on Day 1. After a washout of at least 48 hours, participants will receive AZD6793 or placebo once daily from Day 3 to Day 8.
62280395|NCT02997592|EXPERIMENTAL|SpinCare|Patients with partial thickness burns treated with the SpinCare System
62648589|NCT05761600||People with a Learning Disability|Adults (18 years+) currently attending an art therapy group who have a learning disability and can consent and communicate in a way that supports meaningful engagement in the study.
62081158|NCT06173362|EXPERIMENTAL|Arm I (abiraterone, prednisone)|Patients receive abiraterone and prednisone per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.
62081159|NCT06173362|EXPERIMENTAL|Arm II (darolutamide)|Patients receive darolutamide per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.
62081160|NCT06737419||Ofatumumab Cohort|Adult patients diagnosed with MS who started OMB therapy from the time of approval (August 2020).
62081161|NCT06738563||Lactating women|Lactating adult women who donate their milk
62081162|NCT06737536|EXPERIMENTAL|Part A: Single ascending dose (SAD)|Participants will receive a single dose of any of the five different dose levels of NNC0662-0419 or matching placebo in a sequential manner with the dose increasing between cohorts.
62081163|NCT06737536|EXPERIMENTAL|Part B: Multiple ascending dose (MAD)|Participants will receive NNC0662-0419 once-weekly for 4 weeks at any of the four different dose levels or matching placebo in a sequential manner with the dose increasing between cohorts.
62081164|NCT01163149|EXPERIMENTAL|Cohort 1|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
62081165|NCT01163149|EXPERIMENTAL|Cohort 2|Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
62280396|NCT00003665|EXPERIMENTAL|Arm I|Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
62280397|NCT00003665|EXPERIMENTAL|Arm II|Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
62648590|NCT05761600||Identified Support Person|Person who is well-known to the person with a learning disability (e.g. NHS staff, paid support staff or family members who are carers) who provides practical and/or emotional support to the person with a learning disability attending the art therapy group
62081166|NCT01163149|NO_INTERVENTION|Concurrent Control|Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.
62081167|NCT03010735|ACTIVE_COMPARATOR|Probiotics|The patient take two chewing tablet per day, which contain 4.0E+10 CFU of probiotics.
62081168|NCT03010735|PLACEBO_COMPARATOR|Placebo|The patient take two placebo chewing tablet per day.
62081169|NCT06739902|EXPERIMENTAL|Interventional group I|
62458023|NCT03199274|EXPERIMENTAL|Group I (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 1-6 hours and at approximately 7 and 14 days after yttrium Y-90 radioembolization.
62458024|NCT03199274|ACTIVE_COMPARATOR|Group II (standard of care)|Patients undergo standard of care yttrium Y-90 radioembolization.
62458025|NCT03318796|OTHER|Interventional|Coronary artery stenting of De novo bifurcation lesions MB \& SB
62458026|NCT01308593|ACTIVE_COMPARATOR|Juvederm XC|Juvederm XC
62648591|NCT06300502|ACTIVE_COMPARATOR|Kybella Injection|Kybella is sterile 1% deoxycholic acid provided in a 2 mL single-use vial.
62648592|NCT06300502|ACTIVE_COMPARATOR|Asclera Injection|Asclera is sterile 1% polidocanol provided in a 2 mL single-use vial.
62648593|NCT06300502|ACTIVE_COMPARATOR|1064nm laser|The laser used is the GentleMax Pro laser (755/1064 nm wavelength) which targets hemoglobin.
62648594|NCT06300502|ACTIVE_COMPARATOR|755nm laser|The laser used is the GentleMax Pro laser (755/1064 nm wavelength) which targets hemoglobin.
62648595|NCT04678284|EXPERIMENTAL|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
62081170|NCT06739902|ACTIVE_COMPARATOR|Interventional group II|
62081171|NCT04299633|EXPERIMENTAL|Part 1: vadadustat plus sevelamer carbonate|Participants will receive vadadustat 300 milligrams (mg) once on Days 1, 3, 5, and 7. Participants will receive sevelamer carbonate 1600 mg once on Days 3, 5, and 7.
62280398|NCT00003665|EXPERIMENTAL|Arm III|Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
62280399|NCT03705182|EXPERIMENTAL|Interventiongroup|The intervention group will be shown the fluorescent areas on their skin (fluorescence visualization feedback)
62280400|NCT03705182|NO_INTERVENTION|Control group|The control group will not be shown the fluorescent areas on their skin (no feedback)
62458027|NCT01308593|ACTIVE_COMPARATOR|Botox|Medication used to block neuromuscular transmission
62648596|NCT01254370|EXPERIMENTAL|Catioprost|
62648597|NCT01254370|ACTIVE_COMPARATOR|Travatan Z|
62648598|NCT02442219||Coeliac|Persons with coeliac disease on a gluten free diet where diagnosis is confirmed by duodenal biopsy.
62280401|NCT02908880|EXPERIMENTAL|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
62648599|NCT02442219||Non coeliac gluten sensitive|Persons on a gluten free diet where coeliac disease is excluded by duodenal biopsy.
62081172|NCT04299633|EXPERIMENTAL|Part 2: vadadustat plus calcium acetate|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive calcium acetate 1334 mg once on Days 3, 5, and 7.
62280402|NCT03705793|EXPERIMENTAL|Mometasone Furoate Nasal Irrigation|The study intervention will be mometasone furoate powder (1.2 mg/capsule) and placebo nasal spray. The placebo nasal spray will contain the same inert ingredients found in MF nasal spray: glycerin, microcrystalline cellulose and carboxymethylcellulose, sodium citrate, citric acid, benzalkonium chloride, and polysorbate 80. The placebo nasal spray will be packaged identically to the mometasone nasal spray. Participants will be required to dissolve the contents of two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
62280403|NCT03705793|ACTIVE_COMPARATOR|Mometasone Nasal Spray|The study intervention will be mometasone nasal spray (50 mcg/spray) and placebo nasal irrigation. The placebo will contain lactose monohydrate and will be supplied in capsules identical to the budesonide capsules. Participants will be required to dissolve the contents of the two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
62648600|NCT02442219||Healthy control group|Persons on a gluten containing diet without known coeliac disease.
62648601|NCT00889239|EXPERIMENTAL|A|ceramic crown
62081173|NCT04299633|EXPERIMENTAL|Part 3: vadadustat plus Auryxia®|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive Auryxia® 2 grams once on Days 3, 5, and 7.
62081174|NCT06723392|EXPERIMENTAL|Oral nitrofurantoin monohydrate/macrocrystals|Pregnant individuals with AB randomized to receive a 7-day course of oral NM/M 100 mg twice daily (total of 14 doses)
62081175|NCT06723392|PLACEBO_COMPARATOR|Placebo|Pregnant individuals with AB randomized to a receive a 7-day course of oral placebo 100 mg twice daily (total of 14 doses)
62648602|NCT01181167|EXPERIMENTAL|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
62648603|NCT01181167|ACTIVE_COMPARATOR|enoxaparin sodium|enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
62280404|NCT04756375|EXPERIMENTAL|INTERVENTION|Use of virtual reality in the management of sickle cell patients with VOS
62280405|NCT04756375|OTHER|NO INTERVENTION|
62280406|NCT03402997||Resistivity measurements|The resistivity measurements will be done by introducing the needle-probe into fresh healthy, peritumoral, and tumoral ex vivo tissues
62458028|NCT05269381|EXPERIMENTAL|Treatment (cyclophosphamide, vaccine, pembrolizumab)|"Patients receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with sargramostim SC on days 1, 4, 8, and 15 of cycle 1 and day 1 of cycles thereafter. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients may undergo blood sample collection during screening, cycle 1 days -3, 1, 8, 15, 22, cycles 2, 3, 4, 5, 7, 8 and 9+ day 1 and 30 days after last dose of GM-CSF or pembrolizumab and may undergo tissue biopsy during screening, week 25 or at the time of disease progression. Patients also undergo CT or MRI during screening, week 9 then every 9 weeks, and 30 days after last dose of GM-CSF or pembrolizumab."
62458029|NCT00154102|EXPERIMENTAL|Cetuximab Plus FOLFIRI|
62458030|NCT00154102|ACTIVE_COMPARATOR|FOLFIRI Alone|
62081176|NCT03879694|EXPERIMENTAL|Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)|Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
62280407|NCT00704262|EXPERIMENTAL|Calcipotriol plus hydrocortisone (LEO 80190)|
62280408|NCT04473963|EXPERIMENTAL|EGF-Guided Ablation Therapy|"Subjects randomized to therapy will be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software)."
62458031|NCT04133376|EXPERIMENTAL|e-hookah vaping with nicotine|"Participants were invited to vape a 30-minute electronic hookah with nicotine vaping session, followed by a 30-minute electronic hookah without nicotine vaping session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
62648604|NCT03332537|NO_INTERVENTION|Control|Participants will be provided an online interactive platform to access electronic modules (total of 10) on: IBS-related pain neurophysiology and the brain-gut axis and self-management strategies. There is no additional intervention.
62280409|NCT04473963|NO_INTERVENTION|Control - No Ablation Therapy|"Subjects randomized to control will not be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software). The subjects will be cardioverted (as applicable) and the procedure will end."
62280410|NCT02007226||Spinal Cord Injury|Chronic SCI (Duration of Injury \>5 years)
62280411|NCT03073135|EXPERIMENTAL|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
62280412|NCT03073135|ACTIVE_COMPARATOR|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
62280413|NCT01485692|ACTIVE_COMPARATOR|ziprasidone injection|ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
62458032|NCT04133376|EXPERIMENTAL|e-hookah vaping without nicotine|"Participants were invited to vape a 30-minute electronic hookah without nicotine vaping session, followed by a 30-minute electronic hookah with nicotine vaping session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
62648605|NCT03332537|EXPERIMENTAL|Personalized IBS Pain SM|Participants will be enrolled in the online platform. After completion of the modules, they will be scheduled for a consultation with a research nurse about their level of peripheral and central sensitivity, self-evaluation of IBS-pain SM, goal setting and self-monitoring of IBS-pain and physical activity. They will be asked to document their pain and all symptom SM behaviors daily for the next 10 weeks. At the 6-week follow-up visit, the researcher will review the online activities of the participant, go over the previously selected goals with the participants. The study nurse will acknowledge accomplishment of goals and assist in problem-identification and solving.
62081177|NCT06740266|EXPERIMENTAL|Promoting First Relationships in Primary Care (PFR-PC)|PFR is a strengths-based, evidence-based home visiting approach to engage with families in ways that promote positive parenting change. PFR is a manualized training curriculum consisting of a 10-week (1 hour per visit) intervention. Each week has a theme for discussion and an activity. During five of the weekly sessions, the provider videotapes playtime between mother and child. On alternate weeks, the PFR provider and the mother watch the videotaped playtime and reflect about the needs of both the mother and the child. PFR-PC adds two additional visits at the medical home during routine well-child visits. PFR-PC is a manualized primary care delivery model with content that corresponds to developmentally appropriate content aligned with the well-child visits. Each family will receive two sessions at WakeMed during their well-child visits (approximately 20 minutes in length).
62081178|NCT06740266|NO_INTERVENTION|Usual care|Usual care consists of routine pediatric medical well and sick care from WakeMed pediatrics, as well as already existing onsite integrated mental health and social work services.
62081179|NCT05457283|EXPERIMENTAL|Finerenone Open-Label safety Extension|Participants will receive finerenone treatment.
62081180|NCT01990170||ultrasound-guided foam sclerotherapy|This project is ongoing from an original study conducted by our research group looking at short- and mid-term clinical outcomes after UGFS. The original patient cohort from the aforementioned study was made up of 132 patients who underwent UGFS between 1 March 2005 and 31 December 2009 for treatment of a chronic venous ulcer (CEAP classification C5 or C6 disease) with significant (\>0.5s) SVR confirmed with duplex ultrasound.
62081181|NCT06728449|ACTIVE_COMPARATOR|Conventional therapy group|Control group on Carbohydrate Controlled Diet with conventional therapy
62081182|NCT06728449|EXPERIMENTAL|Cumin tea group|Intervention with Carbohydrate Controlled Diet along with Cumin Seeds Tea
62081183|NCT06728449|EXPERIMENTAL|Ginger Tea Group|Intervention with Carbohydrate Controlled Diet along with Ginger Tea
62081184|NCT06728449|EXPERIMENTAL|Lemon Peel Tea Group|Intervention with Carbohydrate Controlled Diet along with Lemon Peel Tea
62081185|NCT06728449|EXPERIMENTAL|Functional tea Group|: Intervention with Carbohydrate Controlled Diet along with Functional Tea
62081186|NCT06627647|EXPERIMENTAL|Arm A|Rilvegostomig in combination with platinum-based doublet chemotherapy followed by rilvegostomig monotherapy plus pemetrexed in maintenance.
62081187|NCT06627647|ACTIVE_COMPARATOR|Arm B|Pembrolizumab in combination with platinum-based doublet chemotherapy followed by pembrolizumab monotherapy plus pemetrexed in maintenance.
62081188|NCT03122886|EXPERIMENTAL|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
62280414|NCT01485692|ACTIVE_COMPARATOR|haloperidol + midazolam, injection|Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
62280415|NCT01485692|ACTIVE_COMPARATOR|haloperidol + promethazine, injection|haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
62280416|NCT01485692|ACTIVE_COMPARATOR|olanzapine, injection|olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
62280417|NCT03301181|EXPERIMENTAL|Arm A|Approximately 20 subjects to receive BGB-3111 and rifampin
62081189|NCT03122886|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
62081190|NCT05489705||Mavacamten|Participants will receive mavacamten as prescribed by a physician according to standard of care for symptomatic oHCM
62081191|NCT05489705||Beta-blocker (BB) / non-dihydropyridine (non-DHP) calcium channel blocker (CCB) / disopyramide|Participants will receive BB/non-DHP CCB/disopyramide as prescribed by a physician according to standard of care for symptomatic oHCM
62458033|NCT03140007|OTHER|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
62458034|NCT03140007|ACTIVE_COMPARATOR|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
62081192|NCT06626399||Patients assessed for ILQ using the standard manual surveillance method|Patients undergoing colorectal surgery enrolled in the nationwide ILQ surveillance programme and assessed for ILQ using the standard manual surveillance method.
62081193|NCT06626399||Patients assessed for ILQ by Open IA's ChatGPT 4 chatbot|Patients undergoing colorectal surgery enrolled in the nationwide ILQ surveillance programme and assessed for ILQ using the Open IA's ChatGPT 4 chatbot.
62280418|NCT03301181|EXPERIMENTAL|Arm B|Approximately 20 subjects to receive BGB-3111 and itraconazole
62280419|NCT05620355|EXPERIMENTAL|BG2109 100mg group|One tablet of BG2109 100mg + one tablet of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
62458035|NCT06202716|EXPERIMENTAL|Cadonilimab plus CapeOX chemotherapy|Efficacy of cadonilimab plus CapeOX as first-line treatment in advanced GC/GEJC with high TMEscore.
62280420|NCT05620355|EXPERIMENTAL|BG2109 200mg+ABT group|Two tablets of BG2109 100mg + one tablet of add-back therapy, oral, once-daily.
62280421|NCT05620355|PLACEBO_COMPARATOR|Placebo group|Two tablets of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
62280422|NCT02631538|PLACEBO_COMPARATOR|Placebo|Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
62081194|NCT04163991|EXPERIMENTAL|VIB4920 1500 mg 4 Times|Participants receive intravenous (IV) infusion of VIB4920 1500 mg on Days 1, 15, 29, and 57
62081195|NCT04163991|EXPERIMENTAL|VIB4920 1500 mg Twice|Participants receive IV infusion of VIB4920 1500 mg on Days 1 and 57, placebo on Days 15 and 29.
62081196|NCT04163991|EXPERIMENTAL|VIB4920 3000 mg Twice|Participants receive IV infusion of VIB4920 3000 mg on Days 1 and 57, placebo on Days 15 and 29.
62280423|NCT02631538|EXPERIMENTAL|Belimumab monotherapy|Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
62280424|NCT02631538|EXPERIMENTAL|Belimumab and Rituximab co-administration therapy|Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
62081197|NCT04163991|EXPERIMENTAL|VIB4920 3000 mg Once|Participants receive IV infusion of VIB4920 3000 mg on Day 1 and placebo on Days 15, 29, and 57.
62648606|NCT04630548|ACTIVE_COMPARATOR|post placental IUD insertion|Following placental delivery, uterine cavity will be examined to exclude the presence of malformations or fibroids. Uterus will be stabilized by grasping it at fundus and the copper IUD (CuT 380 IUD) will be placed (within 10 minutes following the placental delivery) through the uterine wall incision high up in the uterine fundus (either by hand or using its applicator).
62648607|NCT04630548|ACTIVE_COMPARATOR|post puerperal IUD insertion|IUD will be inserted 6 - 8 weeks following caesarean delivery (during the post puerperal visit).
62648608|NCT02600117|OTHER|Tenofovir disoproxil fumarate|300 mg, orally, once a day for 3 years or when sAg+ve seroconverts to sAb+ve whichever comes earlier
62648609|NCT01356095|ACTIVE_COMPARATOR|PALM-Plus control|Health centers randomized to Palm-Plus intervention in larger trial this trial is embedded in, but not receiving the adherence intervention.
62648610|NCT01356095|EXPERIMENTAL|Adherence intervention|Intervention arm.
62081198|NCT04163991|PLACEBO_COMPARATOR|Placebo|Participants receive IV infusion of placebo matched to VIB4920 on Days 1, 15, 29, and 57.
62081199|NCT06739447|EXPERIMENTAL|Consumer Wearable Device Measurement|Consumer wearable devices (CWD)
62081200|NCT06739941|ACTIVE_COMPARATOR|5 g/day of oat fiber|Participants receive 5 g/day of oat fiber (BG-OS) in a single dose
62081201|NCT06739941|ACTIVE_COMPARATOR|10 g/day of oat fiber|Participants receive 10 g/day of oat fiber (BG-OS) in a single dose.
62081202|NCT06739941|ACTIVE_COMPARATOR|20 g/day of oat fiber|Participants receive 20 g/day of oat fiber (BG-OS) in a single dose.
62081203|NCT05415137|EXPERIMENTAL|Efzofitimod 3 mg/kg|
62081204|NCT05415137|EXPERIMENTAL|Efzofitimod 5 mg/kg|
62081205|NCT05415137|PLACEBO_COMPARATOR|Placebo|
62081206|NCT06199076|EXPERIMENTAL|Oxytocin/Placebo, Alcohol Use Disorder|"Visit 1: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures~Visit 2: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures"
62081207|NCT06199076|EXPERIMENTAL|Placebo/Oxytocin, Alcohol Use Disorder|"Visit 1: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures~Visit 2: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures"
62648611|NCT01356095|NO_INTERVENTION|Control|
62648612|NCT05312996|EXPERIMENTAL|Hypertension|Hypertension test group.
62081208|NCT06199076|EXPERIMENTAL|Oxytocin/Placebo, Healthy Control|"Visit 1: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures~Visit 2: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures"
62081209|NCT06199076|EXPERIMENTAL|Placebo/Oxytocin, Healthy Control|"Visit 1: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures~Visit 2: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures"
62081210|NCT06719700|EXPERIMENTAL|The study group|In this single-arm, patients are planned to receive four cycles of etoposide combined with either cisplatin or carboplatin, along with toripalimab and surufatinib. During chemotherapy, patients will undergo concurrent radiotherapy. Following chemoradiotherapy, consolidation treatment with toripalimab and surufatinib will be administered. Prophylactic cranial irradiation (PCI) is recommended prior to the initiation of immunotherapy consolidation.
62280425|NCT02631538|ACTIVE_COMPARATOR|Rituximab monotherapy|Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
62280426|NCT00494091|EXPERIMENTAL|A.|
62280427|NCT00494091|EXPERIMENTAL|B.|
62280428|NCT01450176|ACTIVE_COMPARATOR|Pataday once daily|15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.
62648613|NCT05312996|OTHER|Active Comparator|Non Hypertension compare group.
62081211|NCT06737003|ACTIVE_COMPARATOR|NHFOV group|Nasal high frequency oscillatory ventilation (NHFOV) will be delivered by; SLE 6000 device, Wipro GE Healthcare Private Limited, Bengaluru, Karnataka. Amplitude range (20:35), frequency range (8-12)HZ, Mean air way pressure(MAP) range (6: 10) cmH2O and Inspiration :Expiration (I:E) ratio 1:1 may change to 1:2 in case of air trapping .
62648614|NCT02709317|ACTIVE_COMPARATOR|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
62648615|NCT02709317|EXPERIMENTAL|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
62648616|NCT05138146|EXPERIMENTAL|experimental group|609A combined with doxorubicin hydrochloride
62648617|NCT01089036||survival|ECMO survival patients
62648618|NCT01089036||ECMO non-survival|ECMO non-survivals
62648619|NCT04656990|EXPERIMENTAL|Gross motor and social-emotional integrated intervention group|Participants will receive a nine-month intervention which focuses on gross motor skills, physical activity, and social-emotional skills.
62648620|NCT04656990|NO_INTERVENTION|Control|Participants will receive the center's everyday business as usual curriculum.
62081212|NCT06737003|ACTIVE_COMPARATOR|Vapotherm group|Vapotherm will be delivered by; Vapotherm device,Vapotherm,INC,USA. The recommended starting flow rate is 4-6 L/min. To be titrated to clinical effect to maximum of 8 L/min as needed,with temperature 36-37°C andFraction of inspired oxygen (FiO2) titrated as needed to achieve target Saturation of peripheral oxygen (SpO2)(90% to 94%).
62081213|NCT06737003|ACTIVE_COMPARATOR|Standard noninvasive mechanical ventilation group (CPAP)|CPAP will be delivered by; MEDIN CNO device, medin Medical Innovations GmbH, Olching, Germany . Pressure ranging from 5 to 8 cm H2O,to maintain SpO2 from 90% to 94%.
62081214|NCT00783120|EXPERIMENTAL|1|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold).
62081215|NCT00783120|SHAM_COMPARATOR|2|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session)
62081216|NCT06736769|EXPERIMENTAL|Ketamine Infusion|
62081217|NCT00742196||1|No parapapillary atrophy
62081218|NCT00742196||2|Parapapillary atrophy
62280429|NCT01450176|ACTIVE_COMPARATOR|Bepreve twice daily|Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks
62280430|NCT02852382|ACTIVE_COMPARATOR|scalp block|In this arm, after general anesthesia, before surgery and head pin placement, scalp block will be applied. Scalp block will be performed with bupivacaine (Marcaine 5 mg/mL, 0,5% bupivacaine); nervus supraorbitalis, nervus supratrochlearis, n. auriculotemporalis, nervus zygomaticotemporalis, nervus occipitalis majoris and minoris will be bilaterally blocked with 2-3 ml bupivacaine.
62280431|NCT02852382|ACTIVE_COMPARATOR|local infiltration|In this arm, after general anesthesia, before surgery, 20 ml 0,5% bupivacaine (Marcaine 5 mg/ml, 0,5% bupivacaine) will be infiltrated to head pin points and skin incision area.
62081219|NCT03206060|EXPERIMENTAL|1/Lu-177-DOTATATE|Lu-177-DOTATATE is administered IV every 8 (+/- 2) weeks, for a total of 4 administrations. A Ga-68-DOTATATE PET and F-18-FDG-PET, as well as CT/ MRI for RECIST monitoring, will be obtained post 2 administrations and post 4 administrations. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection.
62081220|NCT05375136||All Participants|Participants who are prescribed with lenvatinib/pembrolizumab combination per approved prescribing information of lenvatinib and pembrolizumab in the post marketing setting will be enrolled and observed for up to 48 weeks or until clinical benefit or unacceptable toxicity occurs or discontinuation of therapy due to any reason, whichever occurs first.
62081221|NCT06737900|ACTIVE_COMPARATOR|traditional physical therapy|Heating pad for 10 minutes and Core stability exercises for 20 minutes with 10 seconds of rest intervals.
62280432|NCT02852382|PLACEBO_COMPARATOR|control|In this arm, neither scalp block, nor local infiltration will be performed.
62280433|NCT04009993|EXPERIMENTAL|A-BIRTHPERFORM digital tool|interactive partogram that maternity care professionals of the experimental group use, in interactive and device will guide the professional thought the NICE guidelines on labour care
62280434|NCT04009993|NO_INTERVENTION|control group with conventional partogram use|Conventional care in each participant hospital, with conventional partogram in each centre
62648621|NCT06088641||Lower BNP|preoperative Lower BNP
62648622|NCT06088641||Higher BNP|preoperative higher BNP
62648623|NCT00694772|ACTIVE_COMPARATOR|Electrocautery|
62648624|NCT00694772|EXPERIMENTAL|Coblation|
62648625|NCT00244439|EXPERIMENTAL|1|MALG
62648626|NCT00244439|ACTIVE_COMPARATOR|2|Ovide
62648627|NCT00244439|ACTIVE_COMPARATOR|3|Permethrin 1%
62648628|NCT05029492|ACTIVE_COMPARATOR|Diet group|Giving a low caloric diet
62648629|NCT05029492|EXPERIMENTAL|Visceral manipulation with diet group|Giving visceral manipulation added to a low-calorie diet
62648630|NCT00492011|EXPERIMENTAL|Ramelteon 1 mg QD|
62648631|NCT00492011|EXPERIMENTAL|Ramelteon 4 mg QD|
62648632|NCT00492011|EXPERIMENTAL|Ramelteon 8 mg QD|
62648633|NCT00492011|PLACEBO_COMPARATOR|Placebo|
62648634|NCT02938663||Questionnaires and measurements|assessment of physical activity, dietary intake, psychosocial factors, weight status
62648635|NCT02014272|EXPERIMENTAL|Test|RIN 150 contains 150 rifampicin and 75 mg isoniazid
62280435|NCT03145298|EXPERIMENTAL|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
62648636|NCT02014272|ACTIVE_COMPARATOR|Reference|Individual references of rifampicin and isoniazid
62648637|NCT02644746|EXPERIMENTAL|Acupuncture group|Acupuncture has a long time used for chronic pain including low back pain, sciatica, and other pain related to spina via stimulating specific acupuncture points.
62648638|NCT02644746|PLACEBO_COMPARATOR|Placebo needle group|The placebo needle using in this trial will be unpenetrated needles. Based on our previous research, the placebo needle is a valid control for acupuncture research and may eliminate the placebo effect of acupuncture.
62081222|NCT06737900|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation technique|Heating pad for 10 minutes and core stability exercises for 20 minutes along with Proprioceptive Neuromuscular Facilitation technique was used for stretching and rhythmic stabilization technique for strengthening. Stretching was performed using contract-relax technique.
62081223|NCT05443620|ACTIVE_COMPARATOR|High Load|Participants will be standing with a heavy weight vest (11 percent of body weight).
62280436|NCT03145298|PLACEBO_COMPARATOR|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
62081224|NCT05443620|PLACEBO_COMPARATOR|No Load|Participants will be sitting.
62280437|NCT05116124||Group 1 - uncomplicated appendicitis|
62280438|NCT05116124||Group 2 - complicated appendicitis|
62280439|NCT03450083|ACTIVE_COMPARATOR|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
62280440|NCT03450083|PLACEBO_COMPARATOR|Placebo group|Placebo treatment group delivered subcutaneously
62280441|NCT03892447|EXPERIMENTAL|Alprostadil|Alprostadil 0.2\~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
62648639|NCT03528421|EXPERIMENTAL|IM19 CAR-T cells|3\*10\^5/kg，1\*10\^6/kg，3\*10\^6/kg IM19 CAR-T cell.Two days before cell infusion, all patients will be treated with fludarabine and Cyclophosphamide for 3 days
62648640|NCT03263013||FMD patients|patients with a diagnosis of clinically definite FMD who have been assessed at the HMCS clinic, and who have completed protocol 07-N-0190.
62648641|NCT01988207|EXPERIMENTAL|12 Exercise Sessions|Patients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
62648642|NCT01988207|ACTIVE_COMPARATOR|6 Hygiene and 6 Exercise|Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
62648643|NCT03804281|EXPERIMENTAL|Test group|esthetic crown lengthening with microsurgical approach
62648644|NCT03804281|ACTIVE_COMPARATOR|Control group|esthetic crown lengthening with conventional approach.
62648645|NCT00676949|EXPERIMENTAL|1|cyclophosphamide dose escalation, level 1:150mg/m2,level 2: 300mg/m2, level 3: 300mg/m2x2, with 5 kinds o tumor specific antigen peptides followed by low dose IL-2, 6 patients will be enrolled for each level.
62081225|NCT05125042|EXPERIMENTAL|group A|Amiodarone hydrochloride tablet + acupoint catgut embedding of Neiguan and Zusanli
62081226|NCT05125042|ACTIVE_COMPARATOR|group B|Amiodarone hydrochloride tablet
62081227|NCT01080963|ACTIVE_COMPARATOR|Daptomycin|
62081228|NCT01080963|ACTIVE_COMPARATOR|Cefuroxime|
62081229|NCT01005628||001|bortezomib Injection into a vein 1.3 mg/m2 twice a week for 21 days
62081230|NCT06699797|EXPERIMENTAL|Acclaim CI|Participants who receive the Acclaim CI, or who have the implant procedure attempted.
62081231|NCT06377761|EXPERIMENTAL|Qishen Granules|On the basis of standardized drug treatment for HFpEF, participants who met the inclusion criteria were randomly given Qishen Granule intervention on the day of inclusion, taking it twice a day for 90 days.
62648646|NCT02153918|EXPERIMENTAL|Vaccine Plus Booster Shots|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectomy or off therapy PROSTVAC
62648647|NCT04150315||Coronary bypass with DM type 2|
62280442|NCT03892447|ACTIVE_COMPARATOR|Sodium Ferulate|Sodium Ferulate 2\~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
62081232|NCT06377761|PLACEBO_COMPARATOR|Placebo|On the basis of standardized drug treatment for HFpEF, participants who met the inclusion criteria were randomly given placebo granules on the day of inclusion, which were taken twice a day for 90 days (the placebo was basically the same as Qishen granules in terms of appearance, shape, color, taste, etc.)
62081233|NCT04341350|ACTIVE_COMPARATOR|Usual sedation|Sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug.
62081234|NCT04341350|EXPERIMENTAL|Inhaled sedation|Sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of an analgesic drug.
62081235|NCT06383845|EXPERIMENTAL|Lidocaine-IV|Intravenous Lidocaine dose loading than continuous infusion
62081236|NCT06383845|ACTIVE_COMPARATOR|Erector spinae Block|An ultrasound guided Erector Spinae Block is performed with injection of 30 ml of Ropivacaine 3.75%
62081237|NCT06737393|EXPERIMENTAL|Backfill|Participants will receive 200 mL of room temperature, sterile normal saline instilled retrograde into the bladder at the completion of the surgery prior to Foley catheter removal and the Foley subsequently removed intraoperatively.
62081238|NCT06737393|NO_INTERVENTION|No bladder filling|Participants will have the Foley catheter removed intraoperatively at completion of the procedure.
62081239|NCT05784714|EXPERIMENTAL|Intervention|This arm will include daily diary assessment and GPS phone tracking, access to psychoeducational modules, skills practice, and tools to help with coping and stress reduction. Enhancements include geofencing alerts for risky environments; progress tracking and feedback reports; self-initiated tool engagement (e.g. push button to engage in coping exercise), robust JITAI programming that recommends skills for participants to use in the moment based on daily diary responses, positive mood building exercises, and support.
62081240|NCT05784714|NO_INTERVENTION|GEMA|This arm will include daily diary and phone tracking. Participants in this arm will also respond to daily diary assessments twice daily but will not receive the psychoeducation interactive components such as tracking and feedback, alerts, or capacity to send alerts that connect them to tools. This arm will have access to resources.
62081241|NCT06740513||Endovascular Treatment Group|all the participants in this group will be performed with endovascular treatment
62081242|NCT00368446||1|Normal
62280443|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
62280444|NCT00343031||Pregnant women delivering male infants|Male newborns and their mothers living in Tapachula (Chiapas, Mexico) and surrounding areas exposed to DDT through house spraying programs to control malaria, grouped by level of DDT exposure.
62280445|NCT03884400||Subjects who have provided consent for specimen collection|Re-consent will not be required. This protocol allows distribution of the specimens following the terms agreed to by the subject in the original consent.
62280446|NCT06186687|EXPERIMENTAL|Myofunctional Therapy Exercise|Seventeen patients whom already diagnosed by an Ear, Nose and Throat specialist as having risk of obstructive sleep apnea based on the questionnaire and FN study that showed pharyngeal muscle collapse in the pharyngeal area (velopharyngeal area/retropalatal), performed MT two times per day for 20 minutes every day for six weeks. Exercises were performed at home with monitoring by the exercise log book, submitting a clear video of each exercise, and being evaluated once a week by the doctor. Patient compliance was classified as good if the patient performed \>75% of the exercises weekly. This study evaluated the velopharynx/retropalatal area (with FN), symptoms of daytime sleepiness with the Epworth Sleepiness Scale (ESS) questionnaire, and snoring intensity and frequency taken from the Berlin questionnaire that were filled out before and after undergoing training for 6 weeks.
62081243|NCT00368446||2|patients with Genetic Disorders of Mucociliary Clearance
62081244|NCT06602479|EXPERIMENTAL|CGRP-N_MEDI0618 (Dose A)|In the CGRP-N cohort, there will be 1:1 randomisation to the MEDI0618 and placebo arms until 32 participants have been randomised per arm (32 MEDI0618 Dose A and 32 to placebo) triggering the interim analysis. After 32 participants/arm have been randomised, the randomization will continue with 28 participants on active dose arm.
62081245|NCT06602479|PLACEBO_COMPARATOR|CGRP-N_Placebo|In the CGRP-N cohort, there will be 1:1 randomisation to the MEDI0618 Dose A and placebo arms until 32 participants have been randomised per arm (32 to MEDI0618 Dose A and 32 to placebo) triggering the interim analysis. After 32 participants/arm have been randomised, the randomization will continue with 28 participants with corresponding volume matched placebo for all arms.
62648648|NCT04150315||Coronary bypass without DM type 2|
62648649|NCT04976725|EXPERIMENTAL|Ostepathic manipulative treatment|The effects of osteopathy treatment method on the migraine
62648650|NCT04976725|EXPERIMENTAL|Myofascial relaxation Treatment|The effects of myofascial treatment method on the migraine
62648651|NCT04976725|EXPERIMENTAL|Control treatment|Control group will have just medication treatment
62648652|NCT04454424|EXPERIMENTAL|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
62081246|NCT06602479|EXPERIMENTAL|CGRP-N_MEDI0618 (Dose B)|After 32 participants/arm have been randomized in the Dose A and placebo arms, the randomization will continue with 56 participants on active dose arm.
62081247|NCT06602479|EXPERIMENTAL|CGRP-N_MEDI0618 (Dose C)|After 32 participants/arm have been randomized in the Dose A and placebo arms, the randomization will continue with 56 participants on active dose arm.
62081248|NCT06602479|EXPERIMENTAL|CGRP-N_MEDI0618 (Dose D)|After 32 participants/arm have been randomized in the Dose A and placebo arms, the randomization will continue with 56 participants on active dose arm.
62081249|NCT06602479|EXPERIMENTAL|CGRP-IR_MEDI0618 (Dose A)|In the CGRP-IR cohort there will be 1:1 randomisation of participants to the two arms (60 to MEDI0618 and 60 to placebo) .
62081250|NCT06602479|PLACEBO_COMPARATOR|CGRP-IR_Placebo|In the CGRP-IR cohort there will be 1:1 randomisation of participants to the two arms (60 to MEDI0618 and 60 to placebo).
62081251|NCT06736886|EXPERIMENTAL|Intervention group|Light application
62280447|NCT04364919|EXPERIMENTAL|aerobic exercise intervention|The intervention group received a DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercise program requires twenty minutes to complete. Women were instructed to use the DVD 3 times a week for 3 months.
62280448|NCT04364919|NO_INTERVENTION|control group|The control group received routine prenatal care only.
62280449|NCT05606133|EXPERIMENTAL|Circulating HPV DNA|
62081252|NCT06736886|PLACEBO_COMPARATOR|control group|Light application
62081253|NCT06170307||COVID-19 group|Patients diagnosed with SARS-CoV-2 Omicron variant infection by SARS-CoV-2 RT-PCR test within 3 months who came to our hospital for echocardiography were included in the case group .
62081254|NCT06170307||Control group|Healthy participants were confirmed free of COVID-19 disease by reverse transcriptase-polymerase chain reaction (RT-PCR) testing and computed tomography (CT) imaging.
62081255|NCT06050915|EXPERIMENTAL|Single Ascending Dose of DISC-3405|
62081256|NCT06050915|PLACEBO_COMPARATOR|Single Ascending Dose of Placebo|
62081257|NCT06050915|EXPERIMENTAL|Multiple Ascending Dose of DISC-3405|
62081258|NCT06050915|PLACEBO_COMPARATOR|Multiple Ascending Dose of Placebo|
62081259|NCT05134389||Israel|OAGB patients from Israel
62280450|NCT01637142|EXPERIMENTAL|LY2140023 + [14C]-LY2140023|Treatment Period 1: On Day 1, a single oral dose of 80 milligrams (mg) LY2140023 (parent compound) followed by a single 2-hour intravenous (IV) infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nanocuries (nCi) \[14C\]-LY2140023.
62648653|NCT04454424|EXPERIMENTAL|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
62081260|NCT05134389||Spain|OAGB patients from Spain
62081261|NCT05134389||Portugal|OAGB patients from Portugal
62081262|NCT05367440|EXPERIMENTAL|Arm 1 (AZD5305 in combination with enzalutamide)|Patients will receive an oral dose of AZD5305 and Enzalutamide once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
62081263|NCT05367440|EXPERIMENTAL|Arm 2 (AZD5305 in combination with abiraterone acetate)|Patients will receive an oral dose of AZD5305 and Abiraterone Acetate once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
62081264|NCT05367440|EXPERIMENTAL|Arm 3 (AZD5305 in combination with darolutamide)|Patients will receive an oral dose of AZD5305 once daily and Darolutamide twice daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
62081265|NCT05367440|EXPERIMENTAL|Arm 4 (AZD5305 in combination with apalutamide)|Patients will receive an oral dose of AZD5305 and Apalutamide once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
62081266|NCT06738732|EXPERIMENTAL|Active Therapy|CBD: GT4 Transdermal Delivery System
62081267|NCT06715241|EXPERIMENTAL|Arm A: Nivolumab and relatlimab|
62081268|NCT06715241|OTHER|Arm B: Nivolumab only|
62081269|NCT00816660|EXPERIMENTAL|1|
62081270|NCT00816660|ACTIVE_COMPARATOR|2|
62280451|NCT01637142|EXPERIMENTAL|LY2140023 + [14C]-LY404039|Treatment Period 2: On Day 1, a single oral dose of 80 mg LY2140023 (parent compound) followed by a single 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi \[14C\]-LY404039 (active metabolite).
62648654|NCT04454424|EXPERIMENTAL|Arm C: Child-Pugh C|Participants with severely impaired hepatic function (Child-Pugh C)
62648655|NCT04454424|EXPERIMENTAL|Arm D: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
62648656|NCT04454424|EXPERIMENTAL|Arm E: Normal hepatic (Matched to C)|Participants with normal hepatic function matched to Arm C
62280452|NCT05417958|EXPERIMENTAL|Extremely Thick - Mildly Thick - Extremely Thick - Mildly Thick|Participants will receive 4 weeks Extremely Thick, 4 weeks Mildly Thick, 4 weeks Extremely Thick and 4 weeks Mildly Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
62648657|NCT02688790|EXPERIMENTAL|Cohort 1|One dose of intravenous dalbavancin infusion 22.5 mg/kg in young infants aged greater than 28 days to 3 months
62648658|NCT02688790|EXPERIMENTAL|Cohort 2|One dose of intravenous dalbavancin infusion 22.5 mg/kg in term neonates (defined as gestational age at or greater than 37 weeks) aged up to 28 days
62648659|NCT02688790|EXPERIMENTAL|Cohort 3|One dose of intravenous dalbavancin infusion 22.5 mg/kg in preterm neonates (defined as gestational age of 32 weeks, up to 37 weeks) aged no more than 28 days
62648660|NCT01563939|ACTIVE_COMPARATOR|Continuous infusion|Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
62648661|NCT01563939|ACTIVE_COMPARATOR|Demand Bolus|Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.
62648662|NCT06516432|EXPERIMENTAL|Case group|with parasternal block
62648663|NCT06516432|NO_INTERVENTION|Control group|without parasternal block
62648664|NCT01901185|EXPERIMENTAL|Etanercept / Autoinjector A|Participants self-injected 50 mg etanercept subcutaneously using autoinjector A at the study center on Day 1 and then once a week from Weeks 1 to 5 (total of 6 injections).
62648665|NCT05777655|EXPERIMENTAL|Medication management app|Standard of care (statin prescription, targeted monitoring of individual LDL-C values by primary care physician) + medication management app and follow-up visits at our institution at 6 and 18 months
62648666|NCT05777655|NO_INTERVENTION|Standard of care|Statin prescription, targeted monitoring of individual LDL-C values by primary care physician and follow-up visits at our institution at 6 and 18 months
62081271|NCT06183515|PLACEBO_COMPARATOR|non-CPAP (Control)|The non-CPAP group received Fi02:0.6, and oxygen support was provided at a rate of 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a tracheostomy cannula.
62081272|NCT06183515|ACTIVE_COMPARATOR|CPAP group|During the postoperative period, the CPAP group received Fi02:0.6 and 8 to 12 mmHg of nasal CPAP, or CPAP was initiated through the tracheostomy cannula.
62280453|NCT05417958|EXPERIMENTAL|Extremely Thick - Mildly Thick - Mildly Thick - Extremely Thick|Participants will receive 4 weeks Extremely Thick, 4 weeks Mildly Thick, 4 weeks Mildly Thick and 4 weeks Extremely Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
62280454|NCT05417958|EXPERIMENTAL|Mildly Thick - Extremely Thick - Extremely Thick - Mildly Thick|Participants will receive 4 weeks Mildly Thick, 4 weeks Extremely Thick, 4 weeks Extremely Thick and 4 weeks Mildly Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
62280455|NCT05417958|EXPERIMENTAL|Mildly Thick - Extremely Thick - Mildly Thick - Extremely Thick|Participants will receive 4 weeks Mildly Thick, 4 weeks Extremely Thick, 4 weeks Mildly Thick and 4 weeks Extremely Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
62280456|NCT02242500|EXPERIMENTAL|Coronally advanced flap + Mucograft|coronally advanced flap associated with a porcine collagen matrix graft as a subepithelial graft
62280457|NCT02242500|OTHER|Coronally advanced flap|Coronally advanced flap procedure alone
62280458|NCT04736654||Patients group|Individuals with headache
62081273|NCT05880589|EXPERIMENTAL|Milk secretory supplement|Milk secretory supplement composes of fenugreek, banana flower, ginger extract, docosahexaenoic acid, iron, folate, and iodine.
62081274|NCT05880589|PLACEBO_COMPARATOR|Placebo group|Placebo is tablet without fenugreek, banana flower, ginger extract, docosahexaenoic acid, iron, folate, and iodine.
62280459|NCT00999908|EXPERIMENTAL|Indacaterol 150 μg-tiotropium 18 μg-placebo|Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62648667|NCT02758418|EXPERIMENTAL|Online Computerized Program group.|"Intervention group that uses TAO program."
62648668|NCT02758418|NO_INTERVENTION|Waiting list control group.|Participants of this group are able to access the treatment program after 7 weeks of waiting period. After this waiting period of 7 weeks, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (Online Computerized Program group or Bibliotherapy group).
62648669|NCT05906368|SHAM_COMPARATOR|Conventional Care|Patients are wearing both a conventional blood pressure cuff and the ClearSight finger cuff blood pressure monitoring system. Only measures from the conventional blood pressure cuff are sent/received by the clinical staff in the central and local nursing and anesthesia staff areas. The ClearSight monitoring system data is collected but not used by the clinical staff team for hypotensive monitoring.
62648670|NCT05906368|EXPERIMENTAL|ClearSight Monitoring|Patients are wearing both a conventional blood pressure cuff and the ClearSight finger cuff blood pressure monitoring system. Measures from BOTH the conventional blood pressure cuff and ClearSight monitoring system are sent/received by the clinical staff in the central and local nursing and anesthesia staff areas. ClearSight monitoring will add additional information regarding hypotensive events for clinical staff to respond to.
62648671|NCT00562406|ACTIVE_COMPARATOR|1|laser photocoagulation to the retina at the area of edema
62648672|NCT00562406|EXPERIMENTAL|2|intravitreal injection of ranibizumab
62648673|NCT00562406|EXPERIMENTAL|3|laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
62280460|NCT00999908|EXPERIMENTAL|Tiotropium 18 μg-placebo-indacaterol 150 μg|Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62648674|NCT05722691|EXPERIMENTAL|Double-stranded RNA sodium salt|Arm 1 (n=400) received the study drug RADAMIN®VIRO once intramuscularly, 5 mg (1 vial).
62648675|NCT05722691|PLACEBO_COMPARATOR|Placebo|Arm 2 (n = 400) received 1 vial of placebo once intramuscularly
62648676|NCT02191826|EXPERIMENTAL|SOM0226 single dose|
62081275|NCT05683236|EXPERIMENTAL|intervention group|The patients in the intervention group received multidisciplinary collaborative team care combined with palliative care.
62081276|NCT05683236|ACTIVE_COMPARATOR|control group|The control group was given routine nursing intervention.
62648677|NCT02191826|EXPERIMENTAL|SOM0226 multiple doses|
62081277|NCT02833662|OTHER|Patients suspected to present a Sleep Apnea Syndrom|"Record nocturnal respiratory and cardiac parameters before and after surgery :~Severity of sleep respiratory disorders and relationship with cardiac rhythm abnormalities will be assessed in patients suspected to present Sleep Apnea, before and after surgery under general anesthesia."
62081278|NCT04840602|ACTIVE_COMPARATOR|Arm I (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24 and rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm I may receive rituximab and venetoclax as in Arm II for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection during screening and on the trial.
62648678|NCT00945737|ACTIVE_COMPARATOR|Soy protein|
62648679|NCT00945737|PLACEBO_COMPARATOR|Milk protein|
62648680|NCT00002844|EXPERIMENTAL|Cyclophosphamide + TBI + BMT|TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)
62648681|NCT02691715|EXPERIMENTAL|Endometrial saline plus curettage|5 cc saline infused to the endometrial cavity and aspirated. Then routine endometrial curettage performed for same participant.
62081279|NCT04840602|EXPERIMENTAL|Arm II (venetoclax, rituximab)|Patients receive venetoclax PO QD on days 1-28 of each cycle and rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm II may receive ibrutinib and rituximab as in Arm I for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection during screening and on the trial.
62280461|NCT00999908|EXPERIMENTAL|Placebo-indacaterol 150 μg-tiotropium 18 μg|Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62280462|NCT01443780|EXPERIMENTAL|sellenium + Q10|Active dietary supplement that is compared against a placebo arm
62280463|NCT01443780|PLACEBO_COMPARATOR|Sugar pills|Placebo arm that is compared against active intervention with a dietary supplement with selenium + Q10
62280464|NCT03779022||Sensitive|Sensitive group was defined ad complete response (CR) and/or partial response (PR). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
62081280|NCT06740110|EXPERIMENTAL|Split-mouth - investigational medical device on the one side of arch|When using the split-mouth model, which is one variant of randomized trials known as parallel group studies, each patient should receive treatment in different parts of the body. The split-mouth design indicates that each side should receive a different treatment.
62280465|NCT03779022||Resistant|Resistant group was defined ad progression disease (PD) and/or stable disease (SD). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
62280466|NCT02424838|ACTIVE_COMPARATOR|22 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
62648682|NCT02691715|ACTIVE_COMPARATOR|Endometrial curettage|Only routine endometrial curettage performed
62648683|NCT06294561|EXPERIMENTAL|Itraconazole|healthy subjects will be given Itraconazole 200 mg orally with TGRX-326 60 mg
62648684|NCT06294561|EXPERIMENTAL|Efavirenz|healthy subjects will be given Efavirenz 600 mg orally with TGRX-326 60 mg
62648685|NCT02601755|EXPERIMENTAL|iCanCope app and website|Intervention: Behavioral: iCanCope app and website
62648686|NCT02601755|ACTIVE_COMPARATOR|Attention control group|Intervention: Behavioral: Attention control group
62648687|NCT04675892|ACTIVE_COMPARATOR|A1 pulley group|A1 pulley division only
62648688|NCT04675892|EXPERIMENTAL|A1 pulley + FDS group|Combination of A1 pulley division and excision of one or both slips of the flexor digitorum superficialis tendon
62648689|NCT00003819|EXPERIMENTAL|vaccine|This is a dose escalation study. Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19. Cohorts of 5 patients each receive escalating doses of TF(c)-KLH vaccine until the optimal dose, based on antibody response, is reached. Patients are followed monthly for 6 months, then every 3 months for 1 year.
62648690|NCT02991079|ACTIVE_COMPARATOR|Control: Lifestyle counseling|Counseling on physical activity and Mediterranean diet.
62648691|NCT02991079|EXPERIMENTAL|Intervention group|Add for three months a smartphone with an app (EVIDENT) to improve alimentation and physical activity, five cardio-health rides and feeding workshop.
62648692|NCT00472420|EXPERIMENTAL|1|
62648693|NCT05676554|EXPERIMENTAL|Intervention|This arm will watch the growth mindset session
62648694|NCT05676554|NO_INTERVENTION|Waitlist|This arm will receive the intervention once they have completed the follow up at 4 weeks.
62458036|NCT05067764|EXPERIMENTAL|Aponeurectomy with grafting|The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.
62458037|NCT05067764|ACTIVE_COMPARATOR|Aponeurectomy alone|The control group evaluates the aponeurectomy alone.
62458038|NCT01762748|EXPERIMENTAL|S. boulardii 200mg (Floratil®)|"The patients received S. boulardii every 8h during 30 days as an oral capsule formulation which contained 200 mg lyophilized S. boulardii-17 (Floratil®).~The patients enrolled in the study were evaluated immediately before the beginning of treatment, after a thirty-day period of treatment with probiotic and at the end of the second study month (after a thirty-day period without treatment with probiotic)."
62648695|NCT02901223|ACTIVE_COMPARATOR|Quadrantectomy group|35 female patients with non metastatic breast cancer who had standard conservative breast surgery by general breast surgeons.
62648696|NCT02901223|ACTIVE_COMPARATOR|oncoplastic group|35 female patients with non metastatic breast cancer who had oncoplastic techniques for tumor resection by well trained oncoplastic breast surgeons.
62648697|NCT02838745|EXPERIMENTAL|Pemetrexed (300 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
62081281|NCT06740110|ACTIVE_COMPARATOR|Split-mouth - standard of care medical device on the second side of arch|When using the split-mouth model, which is one variant of randomized trials known as parallel group studies, each patient should receive treatment in different parts of the body. The split-mouth design indicates that each side should receive a different treatment.
62280467|NCT02424838|ACTIVE_COMPARATOR|22 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
62280468|NCT02424838|ACTIVE_COMPARATOR|25 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
62280469|NCT02424838|ACTIVE_COMPARATOR|25 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
62458039|NCT02563197|EXPERIMENTAL|T-326|Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
62458040|NCT00458900|EXPERIMENTAL|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
62648698|NCT02838745|EXPERIMENTAL|Pemetrexed (400 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
62648699|NCT05053581||Patient|
62648700|NCT04836377||Subjects with Gaucher 1 Disease|This is a long-term follow-up study of subjects who previously received AVR-RD-02 (single dose administration) in a preceding treatment study. No investigational product will be administered in this study.
62648701|NCT02265003||Healthy young age|Healthy subjects in age of 18-35 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
62648702|NCT02265003||Healthy middle age|Healthy subjects in age of 35-45 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
62648703|NCT02265003||Healthy old|Healthy subjects in age of \>70 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
62648704|NCT02265003||Patients|Patients with atherosclerosis
62081282|NCT03981445|EXPERIMENTAL|On-site Integrated Care with Adherence Counseling|Participants randomized to the on-site integrated care with adherence counselling arm will be prescribed pre-exposure prophylaxis (PrEP) (Truvada®) and, if indicated, Hepatitis C (HCV) treatment (Epclusa®) at the OAT clinic or SAP from which they were recruited. In addition to PrEP and, if indicated, HCV care, participants in the on-site integrated care arm will receive any required health care services as per local standard of care. Addiction treatment, OAT, and mental health services will be provided, if necessary and available. Participants recruited at syringe access programs (SAP) will be offered addiction counseling and treatment, including OAT when in the integrated care arm in addition to site standard of care.
62280470|NCT01363687|EXPERIMENTAL|Remote ischemic postconditioning group|Recipients receive remote ischemic postconditioning after declamping of renal artery during kidney transplantation
62280471|NCT01363687|NO_INTERVENTION|Control group|Patients who have a deflated cuff placed on the upper limb free of arteriovenous fistula during the surgery
62458041|NCT00957814|EXPERIMENTAL|Control|Usual care with medical and nursing staff
62458042|NCT00957814|EXPERIMENTAL|Intervention|Usual care with medical and nursing staff and additional nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats. Enforcement of the nutritional guidance was performed after 4 weeks.
62458043|NCT04668105|EXPERIMENTAL|High volume nordic hamstring exercise|High volume Nordic hamstring exercise
62458044|NCT04668105|EXPERIMENTAL|Low volume Nordic Hamstring exercise|Low volume Nordic Hamstring exercise
62648705|NCT06395467|EXPERIMENTAL|InTEGRA|10 weekly, in-person treatment sessions (2 individually-delivered and 8 group sessions). InTEGRA contains many primary treatment elements of MET/CBT, but comparatively less time is spent on these elements to allow for the integration of the TSF content (about 50%). As part of this TSF, for example speakers from 12-step fellowships such as Marijuana Anonymous (MA), Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) are invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships. During an orientation session, parents of youth in the InTEGRA condition only (not MET/CBT alone) are given information about the potential benefits of 12-step meeting participation and a list of Young Person's 12-step meetings and encouraged to facilitate their child's participation during and after treatment.
62648706|NCT06395467|ACTIVE_COMPARATOR|MET/CBT|10 weekly, in-person treatment sessions (2 individually-delivered and 8 group sessions) modified from MET/CBT approaches (Webb, Scudder, Kaminer, \& Kadden, 2002; Sampl \& Kadden 2001) tested in the Cannabis Youth Treatment Study (Dennis et al. 2004).
62648707|NCT03173274|EXPERIMENTAL|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO \< 6 ppm).
62648708|NCT03173274|ACTIVE_COMPARATOR|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
62280472|NCT03587532|EXPERIMENTAL|Indocyanine Green Angiography|ICG based angiography after creation of the stomach graft and after thoracic pull-up of the graft. Dynamic digital images will be obtained starting immediately after intravenous bolus administration of 0.5 mg/kg of ICG.
62280473|NCT00624390|EXPERIMENTAL|Sepraspray|Sepraspray applied directly to both sides of the uterus, Fallopian tubes, and ovaries (or opposing sites if not possible to apply directly). Sepraspray was applied via a sterile cannula at a tissue concentration of approximately 5 mg/cm\^2.
62280474|NCT00624390|NO_INTERVENTION|Control|No anti-adhesion treatment was used.
62280475|NCT01635790|ACTIVE_COMPARATOR|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
62280476|NCT01635790|ACTIVE_COMPARATOR|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
62280477|NCT06269250||sample assessed in Wave 2023|Participants can be any healthcare worker, including dental and medical assistants, aged 18 or older.
62280478|NCT06269250||sample assessed in Wave 2024|Participants can be any healthcare worker, including dental and medical assistants, aged 18 or older.
62280479|NCT01409109||Patient volunteers|This group is comprised of persons with Schizophrenia and Schizoaffective.
62280480|NCT01409109||Healthy volunteers|This group is comprised of individuals who have no current or past psychiatric diagnosis.
62280481|NCT04226391||RAS Partial Nephrectomy|
62648709|NCT02183363|EXPERIMENTAL|BI 1356 - Tablet TFII|
62648710|NCT02183363|EXPERIMENTAL|BI 1356 - Tablet iFF|
62648711|NCT02183363|ACTIVE_COMPARATOR|BI 1356 - Tablet TFIIb|
62648712|NCT00926523||Healthy Controls|Subjects are made up of healthy adults
62280482|NCT04226391||RAS Radical Prostatectomy|
62280483|NCT02549339|EXPERIMENTAL|LEO 43204 gel|Treatment once daily for 3 days
62280484|NCT02549339|PLACEBO_COMPARATOR|Vehicle gel|Treatment once daily for 3 days
62280485|NCT01951001|ACTIVE_COMPARATOR|group 1|Fixed-dose Prasugrel of 10 mg/d
62280486|NCT01951001|ACTIVE_COMPARATOR|group 2|Fixed-dose Prasugrel of 5 mg/d
62280487|NCT01951001|ACTIVE_COMPARATOR|group 3|"Phenotype-based prasugrel dose~* If patients show PRU \< 85, prasugrel dose will be reduced by 5 mg/d.~* If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d."
62280488|NCT05203731|EXPERIMENTAL|Exercise Group|Participants who will be randomized to moderate intensity exercise after extinction (Day 1)
62648713|NCT00926523||Affected|Subjects have Pulmonary Hypertension
62648714|NCT04952259|EXPERIMENTAL|Intervention group|Shexiang Tongxin dripping pills + routine treatment
62648715|NCT04952259|ACTIVE_COMPARATOR|Control group|routine treatment
62648716|NCT01248416|ACTIVE_COMPARATOR|Aromatase Inhibitor|Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
62648717|NCT01248416|ACTIVE_COMPARATOR|Growth Hormone|Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
62648718|NCT01248416|ACTIVE_COMPARATOR|Aromatase Inhibitor and Growth Hormone|Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
62648719|NCT00689065|EXPERIMENTAL|CALAA-01|
62280489|NCT05203731|SHAM_COMPARATOR|Seated group|Participants who will be randomized to sitting after extinction (Day 1)
62280490|NCT03468309||Genecept Assay and G-DIG decision tool|Veterans who have been prescribed 5 or more medications, with at least two being for a mental health diagnosis. Also allowable would be one medication for a mental health diagnosis and another medication for side effects related to a medication prescribed for the mental health diagnosis.
62280491|NCT05345925|EXPERIMENTAL|Experimental group|Eligible subjects instrumented for CNT testing
62280492|NCT03598387|EXPERIMENTAL|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment.
62280493|NCT03598387|ACTIVE_COMPARATOR|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent intermittent hemodialysis.
62280494|NCT02624037|EXPERIMENTAL|Individualized Dosage Precision IFX Dashboard|A clinician will select a dose and dosing frequency that is populated by a pharmacokinetic dashboard system that monitors and aims to dose patients to maintain a target trough infliximab concentration. Dosage and dosing frequency may vary from each patient.
62280495|NCT01515033|EXPERIMENTAL|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
62280496|NCT01515033|EXPERIMENTAL|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
62280497|NCT05491785|EXPERIMENTAL|Cebranopadol 600 µg|3 x 200 µg cebranopadol tablets
62280498|NCT05491785|EXPERIMENTAL|Cebranopadol 800 µg|4 x 200 µg cebranopadol tablets
62280499|NCT05491785|EXPERIMENTAL|Cebranopadol 1000 µg|5 x 200 µg cebranopadol tablets
62280500|NCT05491785|ACTIVE_COMPARATOR|Oxycodone 30 mg|3 x 10 mg Oxycodone tablets
62648720|NCT01982864|EXPERIMENTAL|hemodialysis patients|The administration of gentamicin at the beginning of the hemodialysis.
62280501|NCT05491785|ACTIVE_COMPARATOR|Oxycodone 60 mg|3 x 20 mg Oxycodone tablets
62280502|NCT05491785|PLACEBO_COMPARATOR|Cebranopadol placebo tablets/ Oxycodone placebo capsules|Cebranopadol placebo tablets/ Oxycodone placebo capsules
62280503|NCT01724528|EXPERIMENTAL|Febuxostat|Febuxostat for 7-9 days
62280504|NCT01724528|ACTIVE_COMPARATOR|Allopurinol|Allopurinol for 7-9 days
62458045|NCT05129852|ACTIVE_COMPARATOR|sage oil group|The participants in the sage oil massage group (30 participants in total) had pain in the first 3 days of their menstrual cycle; when the pain started, pain levels were scored by the participants using visual analog scale (VAS). In addition, their blood pressure, body temperature, and pulse rate were measured. The researchers massaged the abdomen with sage oil for 30 minutes, and 30 minutes after the massage, VAS evaluation and blood pressure, body temperature, and pulse rate measurements were performed again. This application was repeated for two menstrual periods.
62280505|NCT02310620|EXPERIMENTAL|Cognitive Training|
62280506|NCT00868101|EXPERIMENTAL|Preconditioning|Children who received the preconditioning stimulus
62648721|NCT05302011|EXPERIMENTAL|Neoadjuvant Pembrolizumab Plus Chemotherapy|Neoadjuvant Pembrolizumab Plus Chemotherapy
62648722|NCT03335046|EXPERIMENTAL|Intervention|The intervention arm will receive the home visit intervention, consisting of 2 visits to the home by a team consisting of a pediatric medical provider and a school teacher or school support staff member. This team will evaluate the child's home environment to assess for potential asthma triggers that may lead to school absenteeism, and provide strategies and material goods to help reduce those triggers.
62648723|NCT03335046|OTHER|Wait-List Control|The control group will receive standard interventions carried out by the school system for students at risk for chronic absenteeism. Following the study observation period, this control group will then receive the home visits performed for the intervention group.
62648724|NCT03477162|EXPERIMENTAL|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
62648725|NCT05283746|EXPERIMENTAL|Open Label|All subjects in Cohorts 1-4 receive 500 mg epetraborole once; Subjects on Cohort 5 receive 500 mg epetraborole twice
62280507|NCT00868101|NO_INTERVENTION|Control|Children who did not receive the preconditioning stimulus
62280508|NCT04340622|ACTIVE_COMPARATOR|Reduction in opioid cravings and use|These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.
62280509|NCT04340622|PLACEBO_COMPARATOR|Small reduction in opioid cravings and use|Sham condition.
62280510|NCT04502303|EXPERIMENTAL|Crohn's disease: patients with intestinal stricture|Patients with intestinal strictures confirmed by other modalities, e.g. CT, MR, ultrasound, and endoscopy, will be recruited in the study.
62280511|NCT06066892|EXPERIMENTAL|Digital impression|Digital impression using intraoral scanner
62280512|NCT06066892|EXPERIMENTAL|One stage open impression technique|Splinting impression long transfer and open tray impression technique
62280513|NCT06066892|EXPERIMENTAL|Two stage closed tray and open tray|Primary impression with closed tray impression techniques then secondary impression by open tray technique
62280514|NCT01316393|EXPERIMENTAL|XER2020|mucoprotective product
62280515|NCT01316393|ACTIVE_COMPARATOR|Saliva Natura|salivary substitute
62280516|NCT01316393|PLACEBO_COMPARATOR|XER2020 placebo|
62280517|NCT01935843|EXPERIMENTAL|Anti-tumor responses of CART-HER-2|
62280518|NCT06046703||Vegan|Pregnant women with a strict plant-based diet
62081283|NCT03981445|EXPERIMENTAL|Off-site Referral to Specialized Care with Patient Navigation|Participants randomized to the off-site referral to specialized care and patient navigation group will be linked to primary care for PrEP and, if necessary, HCV treatment by a patient navigator. Given the replicated success of the AntiRetroviral Treatment Access Study (ARTAS) intervention regarding linking HIV-infected individuals to HIV primary care, we adapted ARTAS to facilitate people who inject drugs linkage with PrEP and, if necessary, HCV treatment services. Participants in the off-site care arm will be prescribed PrEP and, if necessary, HCV treatment by their off-site physician. All necessary care will also be provided to participants by their off-site physician. Off-site physicians will be notified that if their patients are placed on a waiting list, unable to afford, or are otherwise unable to immediately access PrEP or HCV treatment, Truvada® and Epclusa® are available to participants of the M2HepPrEP study immediately and free of charge.
62081284|NCT02158624|EXPERIMENTAL|Ranibizumab|
62081285|NCT06740071|ACTIVE_COMPARATOR|standard pelvic floor muscle training group|
62081286|NCT06740071|ACTIVE_COMPARATOR|somatosensory interactive pelvic floor muscle training group|
62081287|NCT06740071|EXPERIMENTAL|standard pelvic floor muscle training combined with pelvic floor magnetic stimulation therapy group|
62081288|NCT02202694|EXPERIMENTAL|Intervention|Culturally Adapted Cognitive Behavior Therapy
62081289|NCT02202694|NO_INTERVENTION|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
62081290|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
62081291|NCT01585922|EXPERIMENTAL|NPPV|Use the NPPV to treat moderate ARDS
62081292|NCT01585922|ACTIVE_COMPARATOR|IMV|Use invasive mechanical ventilation in treating the patients allocated to this group.
62081293|NCT05416775|EXPERIMENTAL|SHR-8068 in combination with adebrelimab|
62081294|NCT05416775|EXPERIMENTAL|SHR-8068 in combination with adebrelimab and platinum-based chemotherapy|
62081295|NCT05416775|EXPERIMENTAL|Adebrelimab in combination with platinum-based chemotherapy|
62081296|NCT02053779|EXPERIMENTAL|GnRH-agonist|Experimental Arm: Triptorelin 0.1 mg
62081297|NCT02053779|NO_INTERVENTION|Control Arm|Control Arm: No intervention
62081298|NCT06725212|ACTIVE_COMPARATOR|Treatment group|Subjects with BPH with LUTS will be randomized into the treatment group to receive the Water Vapor Thermal treatment via cystoscope.
62081299|NCT06725212|SHAM_COMPARATOR|Sham control group|"Subjects with BPH with LUTS will be randomized into the control group to receive a cystoscopy as the sham treatment.~Crossover treatment: 3 months after the sham treatment, qualified subjects in the control group can choose to receive the crossover Water Vapor Thermal treatment via cystoscope."
62081300|NCT06740201|EXPERIMENTAL|Cp=0.9μg/ml|Plasma target-controlled concentration 0.9μg/ml
62081301|NCT06740201|EXPERIMENTAL|Cp=1.2μg/ml|Plasma target-controlled concentration 1.2μg/ml
62081302|NCT06097156||Healthy donors|Participants who are in good health and without history of cancer disease
62081303|NCT06097156||Metastatic Breast Cancer patients|Metastatic breast cancer category is based on the definition of the European Society of Medical Oncology and is defined as disease spread to other parts of the body, such as bones, liver or lungs (also called stage IV). Tumours at distant sites are called metastases.
62081304|NCT06588608|EXPERIMENTAL|aVNS followed by no aVNS in subjects with SCI|Auricular vagal nerve stimulation (aVNS) will be provided by a device that is placed around the ear. A low-voltage electrical signal will be given for 30 minutes. In the following visit, subjects will complete all study assessments without the aVNS. Participation will be up to 2 weeks.
62081305|NCT06588608|EXPERIMENTAL|no aVNS followed by aVNS in subjects with SCI|Subjects will complete all study assessments without the aVNS. In the following visit, Auricular vagal nerve stimulation (aVNS) will be provided by a device that is placed around the ear. A low-voltage electrical signal will be given for 30 minutes. Participation will be up to 2 weeks.
62081306|NCT06226077|EXPERIMENTAL|sleep extension intervention arm|sedentary and short sleep (=\<6 hrs/night) African American adults with overweight/obesity randomized to the sleep extension intervention.
62081307|NCT06226077|ACTIVE_COMPARATOR|education contact control arm|sedentary and short sleep (=\<6 hrs/night) African American adults with overweight/obesity randomized to contact control intervention.
62081308|NCT03464214|ACTIVE_COMPARATOR|Vibration Group|Local vibration on neck muscles
62280519|NCT06046703||Omnivorous|Pregnant women with an omnivorous diet.
62458046|NCT05129852|ACTIVE_COMPARATOR|Reiki group|visual analog scale (VAS) pain scores were also evaluated in the Reiki group (30 participants) when the pain started. The participants experienced pain on the first 3 days of their menstruation. Their blood pressure, body temperature, and pulse rate were also measured. Reiki was applied by a researcher with a Reiki certificate. Thirty minutes after the Reiki application, VAS evaluation and blood pressure, body temperature, and pulse rate measurements were repeated. This application was repeated for two menstrual periods.
62458047|NCT05129852|NO_INTERVENTION|control group|Similarly, in the control group (30 participants),visual analog scale (VAS) pain scores were evaluated when the pain started on the first three days of their menstruation, and their blood pressure, body temperature, and pulse rate were measured. No application was performed; they were only asked to rest. VAS evaluation and blood pressure, body temperature, and pulse rate measurements were performed again after 30 minutes. These measurements were repeated for two menstrual cycles.
62458048|NCT03328260|EXPERIMENTAL|Treatment|
62648726|NCT06523179|EXPERIMENTAL|Risk factors for NAFLD-HCC|"The study will be divided into:~* In the first phase, the impact of a score based on the evaluation of common genetic variants in genes predisposing to the development of NAFLD-HCC (PNPLA3, TM6SF2, and MBOAT7), and rare mutations determining high risk of NAFLD-HCC, e.g. . in genes involved in telomere shortening (TERT) and lipid metabolism (APOB) on the risk of developing HCC and on survival, in the entire cohort of patients and in the individual groups listed above.~* In the second phase we will use next generation sequencing techniques (whole exome / genome sequencing) to identify new genetic risk variants for the development of HCC."
62648727|NCT03738735|NO_INTERVENTION|Control|Patients will receive standard of care lactated ringer's solution for the arthroscopic irrigation during surgery.
62648728|NCT03738735|EXPERIMENTAL|Intervention|Patients will receive hyperosmolar saline for the arthroscopic irrigation during surgery.
62648729|NCT05912868||Ventral hernia repair|Endoscopic Mini/Less Open Repair
62648730|NCT06039202|EXPERIMENTAL|CA102N plus Trifluridine/tipiracil (TAS-102)|CA102N administered as 0.72 mg/kg of nimesulide equivalents on Days 1 and 15 of each 28-day cycle in combination with TAS-102 at 35 mg/m2/dose orally twice daily (BID) on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. Administration sequence will be CA102N then TAS-102 (IV then oral)
62648731|NCT06039202|ACTIVE_COMPARATOR|Bevacizumab plus Trifluridine/tipiracil (TAS-102)|bevacizumab 5 mg/kg on Days 1 and 15 of each 28-day cycle in combination with 35 mg/m2 of TAS-102 orally twice daily (BID) on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. Administration sequence will be bevacizumab then TAS-102 (IV then oral)
62648732|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
62648733|NCT00465179|EXPERIMENTAL|Sunitinib Malate|Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off.
62648734|NCT05695703|EXPERIMENTAL|Core Strength Training Group|The participants of core strength training group will perform core strength training for 6 weeks (3 days per week).
62648735|NCT05695703|ACTIVE_COMPARATOR|Conventional Training Group|The participants of conventional training group will perform conventional exercises for 6 weeks (3 days per week).
62648736|NCT00624091|EXPERIMENTAL|1|Early-surgery, within 48 hours from randomization
62081309|NCT03464214|ACTIVE_COMPARATOR|Stabilization Group|Cervical stabilization exercises on cervical region
62280520|NCT02512185||Chemotherapy|Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
62280521|NCT02512185||Abiraterone|Men with mCRPC starting Abiraterone
62458049|NCT03879239|ACTIVE_COMPARATOR|Vibrant Capsule mode A|Vibrant Capsule mode A administered 5 times per week
62458050|NCT03879239|ACTIVE_COMPARATOR|Vibrant Capsule mode B|"Vibrant Capsule mode B administered 5 times per week.~Based on the analysis of the first pre-define phase of the study, active mode B was discontinued, and the trial was completed using mode A. Therefore, study results are not available for arm B."
62458051|NCT03879239|PLACEBO_COMPARATOR|Placebo Capsule|Placebo Capsule administered 5 times per week
62458052|NCT03151278|EXPERIMENTAL|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of three-dimensional mapping system without fluoroscopy.
62648737|NCT00624091|ACTIVE_COMPARATOR|2|State-to-the-art group. Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
62081310|NCT03464214|NO_INTERVENTION|Control Group|Individuals performed only daily living activities
62280522|NCT02512185||Enzalutamide|Men with mCRPC starting Enzalutamide
62458053|NCT03151278|ACTIVE_COMPARATOR|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under fluoroscopic guidance plus three-dimensional mapping system.
62458054|NCT06159803||Patient|"Adult patients with difficult asthma:~1. To carry out semi-structured interviews with PDA to explore their experiences, beliefs and attitudes to exercise, diet and emotional self-management support.~2. To carry out semi-structured interviews with PDA that explores the barriers and facilitators to key behaviours that will be targeted in the intervention.~3. To carry out iterative think aloud with PDA to elicit feedback on drafts of the intervention to optimise the intervention."
62648738|NCT01836237|EXPERIMENTAL|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
62648739|NCT01836237|NO_INTERVENTION|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
62648740|NCT03513952|EXPERIMENTAL|Group 1 (CYT107, atezolizumab)|Patients receive CYT107 IM on days 1, 8, 15, and 22, and atezolizumab IV over 60 minutes on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study.
62081311|NCT04873778|EXPERIMENTAL|Dynamic taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
62081312|NCT04873778|EXPERIMENTAL|kinesio taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
62081313|NCT04873778|PLACEBO_COMPARATOR|control group|use Kinesio taping for placebo effect
62081314|NCT06442020|EXPERIMENTAL|GROUP 1: LiESWT in association with PDE5i|Therapeutic association between low intensity extracorporeal shock waves LiESWT and the early introduction of the phosphodiesterase 5 inhibitor PDE5i
62081315|NCT06442020|ACTIVE_COMPARATOR|GROUP 2: PDE5i alone|Control group, administration of the phosphodiesterase 5 inhibitor PDE5i, as per clinical practice
62081316|NCT06084104|EXPERIMENTAL|Hepatic impairment|Subjects with hepatic impairment
62081317|NCT06084104|EXPERIMENTAL|Healthy Subject|Subjects with normal hepatic function
62280523|NCT02109341|EXPERIMENTAL|Nab-FOLFIRI|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFIRI: Irinotecan, 180 mg per square meter of body surface area (m2 ) + Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2 every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm A for phase II will receive the dose of Nab-FOLFIRI as determined in the Phase I and in the same sequence."
62458055|NCT06159803||NHS professionals/Exercise professionals|"NHS professionals working with people living with difficult asthma:~Exercise professionals working with people living with difficult asthma:~1. To carry out semi-structured interviews with health care and exercise professionals who work with patients living with severe asthma to explore their experiences, beliefs and attitudes to providing exercise, diet and emotional self-management support to this patient group~2. To carry out semi-structured interviews with health care and exercise professionals who work with patients living with severe asthma that explores the barriers and facilitators to key components that are planned to be included in the intervention.~3. To carry out iterative think aloud with health care and exercise professionals who work with patients living with severe asthma to elicit feedback on drafts of the intervention to optimise the intervention"
62458056|NCT04112082|EXPERIMENTAL|Home-Based Neurofeedback Training|
62648741|NCT03513952|ACTIVE_COMPARATOR|Group 2 (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study.
62648742|NCT03513952|EXPERIMENTAL|Safety run in phase|Patients assigned to the experimental arm (atezolizumab + CYT107). If the treatment combination of the experimental arm demonstrates an acceptable safety profile in the Safety Run-In (one or fewer patient experiences a protocol-defined Dose Limiting-Toxicity), randomized enrollment into the trial will begin. The Run-in phase patients will be analyzed and reported separately both for safety and for efficacy.
62648743|NCT06201104|EXPERIMENTAL|Experimental group|Patients in the experimental group will be given patient empowerment training as an intervention. The aim of the training is to ensure that patients have the knowledge, skills and attitudes necessary to manage the care and treatment processes both during their hospitalization and in their daily lives after discharge.
62081318|NCT05417789|EXPERIMENTAL|Group 1 in Part 1/Part 2: Emactuzumab|Group 1: Subjects receiving emactuzumab administered intravenously (i.v) on Day(D)1 and repeated once every two weeks (Q2W) for a total of 5 times, followed by an observation period of 3 months leading to a total period of 24 weeks in Part 1 and continued with a follow-up phase in Part 2. Eligible Subjects assigned to active drug in Part 1 have the option to receive open-label retreatment in Part 2.
62280524|NCT02109341|EXPERIMENTAL|Nab-FOLFOX|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFOX: Oxaliplatin 85 mg/m2 +Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2, every 2 weeks.~Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm B for phase II will receive the dose of Nab-FOLFOX as determined in the Phase I and in the same sequence"
62280525|NCT05352542|EXPERIMENTAL|GPC3 Targeting CART Cells|Each subject will receive GPC3 Targeting CART cells
62458057|NCT04112082|ACTIVE_COMPARATOR|Treatment as Usual|
62458058|NCT05277753|EXPERIMENTAL|CART/CTL/DCvac cells to treat T-ALL|
62458059|NCT00105196|EXPERIMENTAL|A1|
62648744|NCT06201104|NO_INTERVENTION|Control group|After the pre-test data is collected from the control group by face-to-face interview method, no intervention will be made to the control group. At the end of the second month, the same scales will be re-administered over the phone as post-test data.
62648745|NCT01933594|EXPERIMENTAL|Cohort 1-Arm 1A (Romidepsin)|Participants in Cohort 1, Arm 1A received Romidepsin intravenously (IV) over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 0.5 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62458060|NCT00105196|PLACEBO_COMPARATOR|A2|
62458061|NCT02480465|EXPERIMENTAL|Lobelitazone 0.5mg|Lobelitazone 0.5mg
62081319|NCT05417789|PLACEBO_COMPARATOR|Group 2 in Part 1 and Part 2: Placebo|Group 2: Subjects receiving placebo administered intravenously (i.v) on D1 and repeated once every two weeks (Q2W) for 5 times followed by an observation period of 3 months to a total period of 24 weeks in Part 1. In Part 2, Eligible Subjects will have the option to receive open-label emactuzumab, administered by i.v once every 2 weeks (Q2W) for a total of 5 times.
62280526|NCT01825096||baseline|No intervention. Participants are scanned at baseline.
62280527|NCT02419508|EXPERIMENTAL|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
62280528|NCT02419508|OTHER|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
62280529|NCT04428606|EXPERIMENTAL|Metabolic Rheostat™|Participants will take 6 capsules of Rheostat daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
62280530|NCT04428606|EXPERIMENTAL|Butyrate Ultra|Participants will take 6 capsules Butyrate Ultra daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
62081320|NCT05907928|EXPERIMENTAL|Radio-opaque universal adhesive|Radio-opaque universal adhesive
62081321|NCT05907928|ACTIVE_COMPARATOR|Conventional universal adhesive|Conventional universal adhesive
62081322|NCT06441227|EXPERIMENTAL|Part 1|HRS-5346 tablets or placebo single dose
62081323|NCT06441227|EXPERIMENTAL|Part 2|HRS-5346 tablets or placebo single dose with food effects
62458062|NCT02480465|ACTIVE_COMPARATOR|Sitagliptin 100mg|Sitagliptin 100mg
62081324|NCT06441227|EXPERIMENTAL|Part 3|HRS-5346 tablets or placebo multiple doses
62081325|NCT06035237|EXPERIMENTAL|Experimental Group|Patients in the experimental group were informed that cold spray would be applied to their arm in a supine position to reduce procedure-related pain. For femoral artery angiography, the central part of the inguinal access area was targeted, and for radial angiography, 2 cm above the styloid process of the radial bone was targeted, and cold spray (Chloroethyl spray) was applied for approximately 3 seconds from a height of 10 cm.
62081326|NCT06035237|NO_INTERVENTION|Control Group|Pain levels recorded with the VAS were evaluated for patients after the procedure using the state anxiety scale. Pain levels for control group patients were also assessed and recorded within the sheath after intravenous solutions were given. Anxiety levels were recorded after the procedure was completed.
62081327|NCT05698654|EXPERIMENTAL|Fasting-mimicking diet (FMD)|The fasting-mimicking diet (FMD) group, will be instructed on the benefits and use of the fasting-mimicking diet and how it should be used. This group will have to perform the fasting-mimicking diet once every 3 months (3 cycles in 6 months).
62458063|NCT01722448|EXPERIMENTAL|Choline|Phosphatidyl choline
62648746|NCT01933594|PLACEBO_COMPARATOR|Cohort 1-Arm 1B (Placebo for Romidepsin)|Participants in Cohort 1, Arm 1B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 0.5 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62648747|NCT01933594|EXPERIMENTAL|Cohort 2-Arm 2A (Romidepsin)|Participants in Cohort 2, Arm 2A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 2 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62648748|NCT01933594|PLACEBO_COMPARATOR|Cohort 2-Arm 2B (Placebo for Romidepsin)|Participants in Cohort 2, Arm 2B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 2 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62648749|NCT01933594|EXPERIMENTAL|Cohort 3-Arm 3A (Romidepsin)|Participants in Cohort 3, Arm 3A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 5 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62648750|NCT01933594|PLACEBO_COMPARATOR|Cohort 3-Arm 3B (Placebo for Romidepsin)|Participants in Cohort 3, Arm 3B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 5 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62648751|NCT01933594|EXPERIMENTAL|Cohort 4-Arm 4A (Romidepsin)|Participants in Cohort 4, Arm 4A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of Romidepsin was 5 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62081328|NCT05698654|EXPERIMENTAL|Longevity diet and Fasting-mimicking diet (LD + FMD)|This group will undergo both nutritional interventions (LD + FMD); the nutritionist will provide information on the longevity diet andpotential the fasting-mimicking diet, highlighting the advantages of following them. The subjects will be instructed to follow 3 FMD cycles (one cycle every 3 months as for arm 1) combined with the longevity diet plan. The longevity diet includes parts unrelated to diet and involving physical exercise.
62280531|NCT04428606|PLACEBO_COMPARATOR|Placebo|Participants will take 6 capsules of placebo daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
62280532|NCT05836376||Function Atrial MR|
62280533|NCT05836376||Functiona Non-atrial MR|
62458064|NCT01722448|PLACEBO_COMPARATOR|Placebo|Vegetable oil
62458065|NCT00055978|EXPERIMENTAL|Arm I|Patients receive oral placebo twice daily for 6 months.
62458066|NCT00055978|EXPERIMENTAL|Arm II|Patients receive oral celecoxib twice daily for 6 months.
62458067|NCT01881048|NO_INTERVENTION|Arm I|Patients undergo observation.
62458068|NCT01881048|EXPERIMENTAL|Arm II (fish oil)|Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
62458069|NCT01881048|EXPERIMENTAL|Arm III (celecoxib)|Patients receive celecoxib by mouth twice a day until the morning of surgery.
62280534|NCT00817011|EXPERIMENTAL|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
62280535|NCT00817011|ACTIVE_COMPARATOR|non-SSRI treated group|non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
62648752|NCT01933594|PLACEBO_COMPARATOR|Cohort 4-Arm 4B (Placebo for Romidepsin)|Participants in Cohort 4, Arm 4B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo was 5 mg/m\^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
62648753|NCT04801212|EXPERIMENTAL|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
62648754|NCT04801212|ACTIVE_COMPARATOR|core stability exercises alone|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
62648755|NCT05148728|NO_INTERVENTION|Active surveillance|After a recurrence in patient with previous low grade bladder cancer tumor, strict follow up with cystoscopy and cytology, avoiding immediate surgery
62648756|NCT05148728|ACTIVE_COMPARATOR|endoscopic fulguration|After a recurrence in patient with previous low grade bladder cancer tumor, fulguration under local anesthesia and sedation will be performed using a flexible cystoscope and a monopolar electrode
62648757|NCT04739228|EXPERIMENTAL|Guided Written Disclosure Protocol Group|Guided Written Disclosure Protocol is a short-term psychological intervention that stimulates emotional expression, promotes a cognitive reworking of stressful illness events and facilitates the integration between emotional and cognitive processing of traumatic experiences. Intervention aimed at enhancing patients' quality of life, psychological well-being, and emotional regulation, and reducing psychosocial distress.
62648758|NCT04739228|ACTIVE_COMPARATOR|Active Control Group|
62648759|NCT05046600||All Products listed in Descriptions|Biocomposite™ or PEEK PushLock, DX SwiveLock SL, Headless Compression Screws, Tenodesis Screw (Biocomposite and PEEK), Corkscrew® Titanium (Nano and Micro-Corkscrew), DynaNite Nitinol Staples
62648760|NCT06221709|ACTIVE_COMPARATOR|Control Group|This group will be submitted to an intraarticular infiltration of corticosteroid + anesthetic.
62280536|NCT03760484|EXPERIMENTAL|fecal transplant with fidaxomicin|FMT per rectum x 3 days in conjunction with fidaxomicin (dificid) PO 200 mg bid x 7-10 days
62280537|NCT04557852||Anterior transvaginal mesh group|Women received anterior transvaginal mesh surgery without concomitant mid-urethral sling surgery.
62280538|NCT04780542|EXPERIMENTAL|Clinician-Guided iCBT|Both help-seeking students recruited from university clinics and non-help-seeking students recruited from needs assessment survey and outreach will receive internet delivered cognitive behavioral therapy guided by clinicians
62458070|NCT01436422|EXPERIMENTAL|TetraVax-DV Vaccine - Admixture TV003|Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
62458071|NCT01436422|EXPERIMENTAL|TetraVax-DV Vaccine - Admixture TV005|Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
62280539|NCT04780542|ACTIVE_COMPARATOR|Self-guided iCBT|Help-seeking students recruited from university clinics will receive self-guided internet delivered cognitive behavioral therapy while on waitlist. Non-help seeking students recruited from needs assessment survey and outreach will receive the self-guided version of internet delivered cognitive behavioral therapy.
62280540|NCT00661271|EXPERIMENTAL|Mindfulness-Based Stress Reduction|8-week mindfulness-based stress reduction program with one retreat session
62458072|NCT01436422|PLACEBO_COMPARATOR|Placebo|Participants will receive the placebo at Day 0 and Day 180.
62458073|NCT05559996|EXPERIMENTAL|Hyaluronic acid injection|Hyaluronic acid injection
62458074|NCT03380819|EXPERIMENTAL|Genome sequencing|Patients undergo exome or whole-genome sequencing, and their patients receive an interpreted clinical report.
62458075|NCT02173236|EXPERIMENTAL|platform-switched implants|platform-switched implants vs. platform-matched implants
62458076|NCT02173236|ACTIVE_COMPARATOR|platform-matched implants|platform-switched implants vs. platform-matched implants
62648761|NCT06221709|EXPERIMENTAL|CRF group|This group will be submitted to radiofrequency for sensitive hip branches from the Femoral and Obturator nerves followed by an intraarticular infiltration of corticosteroid + anesthetic similar to the control group.
62648762|NCT04066374|EXPERIMENTAL|Treatment Arm|Intrathoracic placement of neurostimulation device
62648763|NCT03895801|EXPERIMENTAL|Group A Experimental + active comparator|IFX-1 + reduced dose GC
62648764|NCT03895801|ACTIVE_COMPARATOR|Group B Placebo + active comparator|Placebo-IFX-1 + standard dose GC
62648765|NCT03895801|PLACEBO_COMPARATOR|Group C Experimental + placebo comparator|IFX-1 + Placebo-GC
62648766|NCT01330082|EXPERIMENTAL|Photodynamic therapy|will be treated by PDT using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
62648767|NCT01330082|EXPERIMENTAL|Light-emitting diode Irradiation|will be treated only by using Light-emitting diode(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark)
62648768|NCT01330082|EXPERIMENTAL|applying photosensitizer|will be treated only by toluidine blue O
62648769|NCT00927407|EXPERIMENTAL|Malathion gel 0.05%|Malathion gel 0.5% topical treatment for head lice
62648770|NCT00927407|ACTIVE_COMPARATOR|Malathion lotion 0.5%|Malathion lotion 0.5% treatment for head lice
62648771|NCT05143697|OTHER|Wellness Coaching for Families and Kids|For clinics assigned to mBMI2Kids intervention, Pediatricians will be trained in Motivational Interviewing (MI) and behavioral intervention. Pediatricians will conduct up to 3 sessions with each parent (3 x 10 min) and refer patients electronically to experienced MI-trained lifestyle coaches. With full access to the electronic medical record coaches will call referred families (child's BMI-for-age ≥85th percentile) and deliver a telephonic MI counseling over two years (6 x 45 min) simultaneous with pediatricians. 49 clinics will be selected with 24 participating in the intervention and 25 providing patients with usual care.
62458077|NCT04963192|EXPERIMENTAL|OSA or COPD patients having an integrated management at home|OSA or COPD patients having an integrated management at home using connected devices, during 6 months
62458078|NCT03532685|ACTIVE_COMPARATOR|Severe Asthma Obese Patients Surgery|Bariatric surgery
62458079|NCT03532685|NO_INTERVENTION|Severe Asthma Obese Patients|usual care
62648772|NCT05003674|EXPERIMENTAL|Adults cochlear implant recipients receiving alternative stimulation strategy|ACE strategy, 8 maxima, alternative mode
62648773|NCT05003674|ACTIVE_COMPARATOR|Adults cochlear implant recipients receiving Standard-of-Care stimulation strategy.|ACE strategy, 8 maxima, monopolar mode.
62081329|NCT05698654|NO_INTERVENTION|Control Group|Participants in this arm will undergo the same testing as the intervention groups but will be instructed to continue their usual diet. Participants belonging to the control arm will be given an opportunity to follow a 6-month additional LD program starting at the end of 6 months. This trial makes use of a control group to provide robust evidence on the effects of nutritional interventions on the primary and secondary endpoints.
62081330|NCT03821415|EXPERIMENTAL|1 - RP101 0.05%|RP101 0.05% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
62081331|NCT03821415|EXPERIMENTAL|2 - RP101 0.1% / Placebo|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye in the morning (q.d.) followed by one drop of placebo each eye in the evening for 90 consecutive days
62081332|NCT03821415|EXPERIMENTAL|3 - RP101 0.1%|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
62081333|NCT03821415|PLACEBO_COMPARATOR|4 - Placebo|RP101 matching placebo, ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
62648774|NCT05122481|EXPERIMENTAL|Care home residents|On the test days, the participant will be asked to provide a urine sample before taking the supplement, this sample will be used as a baseline and assessed for Vitamin C and creatinine/protein and specific gravity, with the same testing strips as mentioned above. Once collected, the participant will be provided with a drink containing an increasing daily dose of vitamin C (0 - 500 mg). A second urine sample will then be collected approx. 3 - 4 hours later to assess the extent of vitamin C excretion in urine with an increase in vitamin C supplement. Another urine test strip will also be used to determine creatinine concentrations, the presence of albumin/protein, and specific gravity (to determine urine concentration). Up to 3 days will be allowed between daily testing to allow for long weekends, absences, illness, etc. Therefore, the participants are expected to complete the study within 4 weeks.
62081334|NCT06266364|ACTIVE_COMPARATOR|Immediate VNS Group|The participants in this arm will be implanted with the device and will receive active VNS stimulations in phase 1 as well as phase 2 of the study.
62081335|NCT06266364|SHAM_COMPARATOR|Delayed VNS Group|The participants in this arm will be implanted with the device but will receive sham VNS stimulations in phase 1 of the study and active VNS in phase 2 of the study.
62081336|NCT04082429|EXPERIMENTAL|Arm 1: No prophylaxis (PPX)|Haemophilia A (HA) and haemophilia B (HB) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension phase, this group will receive treatment with concizumab.
62081337|NCT04082429|EXPERIMENTAL|Arm 2: Concizumab prophylaxis|HA and HB patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
62648775|NCT01470534|EXPERIMENTAL|Normal body weight|
62081338|NCT04082429|EXPERIMENTAL|Arm 3: Concizumab prophylaxis|The HA patients enrolled into the concizumab phase 2 trial NN7415-4255 (explorer 5) will be offered enrolment into this arm.
62081339|NCT04082429|EXPERIMENTAL|Arm 4: Concizumab prophylaxis|"Arm 4 will include patients previously on prophylaxis with factor products with a minimum of 24 weeks observation in NN7415-4322 (explorer 6) (at least 30 HA and 30 HB patients).~In addition, arm 4 will also include: 1) Patients who were randomised to arms 1 and 2 before the treatment pause. 2) HA patients who were in NN7415-4255 (explorer 5) at the time of the treatment pause, and who have now completed explorer 5. 3) On demand patients included after arms 1 and 2 are closed."
62081340|NCT06729112||Behçet's disease|"Adult Behçet's disease patients who fulfilling the criteria for the diagnosis by International Team for the Revision of the International Criteria for Bechet's Disease.~and Accept to participate in the current study."
62081341|NCT06729112||control group|healthy matched controls
62648776|NCT01470534|EXPERIMENTAL|Obese|
62648777|NCT01470534|PLACEBO_COMPARATOR|Normal Body Weight placebo|Participants of mormal body weight given placebo
62648778|NCT01470534|PLACEBO_COMPARATOR|Obese placebo|Participants who are obese given placebo
62648779|NCT00611052|EXPERIMENTAL|1|Group cognitive intervention (the Adolescent Coping with Stress)
62648780|NCT00611052|ACTIVE_COMPARATOR|2|Treatment as usual
62648781|NCT00611052|ACTIVE_COMPARATOR|3|Healthy controls, receive usual health education in school health care
62648782|NCT05297357|EXPERIMENTAL|Mediterranean Diet group|
62648783|NCT05297357|NO_INTERVENTION|Control group|
62081342|NCT05012111||Cohort 1|Severe Aplastic Anemia(SAA): Age 2 and older; Previous diagnosis of bone marrow failure
62081343|NCT05012111||Cohort 2|Other Marrow Failure: Age 2 and older; Previous diagnosis of bone marrow failure;
62081344|NCT05012111||Cohort 3|Telomere Biology Disorders(TBD): Age 2 and older; Previous diagnosis of bone marrow failure
62280541|NCT00661271|ACTIVE_COMPARATOR|Healthy Topics|8-week health education program with one retreat session - based on a health curriculum developed by McGraw/Hill
62280542|NCT02648126|OTHER|Pure red cell aplasia participants|Group of participants with pure red cell aplasia and chronic kidney disease, that have resistance criteria to treatment with epoetin alfa produced by Bio-Manguinhos / Fiocruz. The Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation.
62458080|NCT03532685|NO_INTERVENTION|Severe Obese Patients|usual care
62081345|NCT05012111||Cohort 4|Inherited Bone Marrow Failure(IBMF)Syndromes: Age 2 and older; Previous diagnosis of bone marrow failure
62081346|NCT05012111||Cohort 5|Family Screening: Age 2 and older; First degree family member with a known or suspected inherited bone marrow failure syndrome
62081347|NCT06738589|NO_INTERVENTION|MRI without positive pressure therapy|Healthy volunteers having their upper airway scanned with MRI without the addition of positive airway pressure therapy (NIV)
62081348|NCT06738589|EXPERIMENTAL|MRI with positive pressure|Healthy volunteers having their upper airway scanned with MRI with the addition of positive airway pressure therapy (NIV)
62081349|NCT05039229|EXPERIMENTAL|Nozzles (NZ)|Intervention with the aim of reducing bioaerosol exposure for the employees, targeting alteration of nozzles or nozzle function along the production line.
62458081|NCT06367452|EXPERIMENTAL|Taking the medication|Participants take the standard breakfast and 30 minutes later the 10 mL suspension containing 500 mg of sodium alginate, 267 mg of sodium bicarbonate, 800 mg of magaldrate and 120 mg of simeticone
62458082|NCT06367452|NO_INTERVENTION|Not taking the medication|Participants take the standard breakfast but don't take the medication
62458083|NCT06277193||Non-sarcopenia group|The diagnosis of sarcopenia was determined using EWGSOP2(The European Working Group on Sarcopenia in Older People) criteria. To evaluate walking speed, muscle strength and muscle mass, hand grip test, bioimpedance and 4-meter walking test were performed on each patient, respectively. Those who had results above the critical values determined in muscle strength measurement according to criteria were defined as the group without sarcopenia.
62081350|NCT05039229|EXPERIMENTAL|Cleaning of surfaces (CS)|Intervention with the aim of reducing bioaerosol exposure for the employees while cleaning their personal operating areas (work benches and part of production lines) during work operations or while cleaning floor areas.
62081351|NCT05039229|NO_INTERVENTION|Control (CTR)|Work is to be carried out as usual without any intervention measures. Follow-up according to the same schedule as for the other intervention groups.
62081352|NCT06731699|EXPERIMENTAL|FD-001|
62280543|NCT02736032|ACTIVE_COMPARATOR|With GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using GnRHa followed by external estradiol and progesterone. The GnRHa depot from will be given on day 21 of the preceding cycle, on day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol followed up on day 12 of the cycle, if the endometrium is less than 8 mm, till day 15 of the cycle estradiol will be increased to 8 mg/day until 8 mm or more. Then, serum estradiol and progesterone levels are collected, and progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
62280544|NCT02736032|ACTIVE_COMPARATOR|Without GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
62280545|NCT05501119|EXPERIMENTAL|SUPPORT-D Group|
62280546|NCT01960322|EXPERIMENTAL|Telemetric|Enrolled patients will be followed for 12 months during which they will receive the study telemetry intervention.
62280547|NCT03932071|EXPERIMENTAL|experimental group|
62280548|NCT03932071|NO_INTERVENTION|control group|
62280549|NCT01430650|EXPERIMENTAL|Oral strogen|
62280550|NCT01430650|EXPERIMENTAL|Transdermal strogen|
62280551|NCT06286865|ACTIVE_COMPARATOR|Easy-ICD interface|This arm uses our AI-based computer-assisted clinical coding (CAC) system, Easy-ICD
62458084|NCT06277193||Probable sarcopenia group|Individuals with results below the critical values determined in muscle strength measurement were defined as the probable sarcopenia group if their muscle mass and physical performance values were normal.
62458085|NCT06277193||Sarcopenia group|If low muscle mass is present in addition to the decrease in muscle strength, this condition is classified as sarcopenia.
62458086|NCT06277193||Severe sarcopenia group|If there is a decrease in muscle mass and physical performance along with muscle strength, this condition can be classified as severe sarcopenia.
62458087|NCT03305237|EXPERIMENTAL|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
62458088|NCT03305237|EXPERIMENTAL|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
62458089|NCT05851131||Family physicians|Family physicians working in Turkey who gave consent to participate in the study.
62458090|NCT03700242|EXPERIMENTAL|Group 1|1 IM dose of human diploid cell vaccine (HDCV) on D0 and D7 (short HDCV IM PrEP regimen), followed by 1 IM dose of HDCV on Year (Y)1 and Y1 + 3 days
62081353|NCT06730672|EXPERIMENTAL|Volonib combined with Everolimus Formation|Volonib 200mg once daily and Everolimus 5mg once daily
62081354|NCT05280548|EXPERIMENTAL|Venglustat|Participants will receive venglustat once daily, orally
62081355|NCT05280548|ACTIVE_COMPARATOR|Standard of Care Therapy|Participants will receive a locally approved Fabry therapy at the standard dose and schedule (in accordance with the locally approved prescribing information)
62081356|NCT03232138|EXPERIMENTAL|Sulforaphane (Study Drug)|Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
62280552|NCT06286865|NO_INTERVENTION|Control interface|This control arm uses an interface similar to Easy-ICD, but without the AI functionality
62280553|NCT05771727||Parents of children with pediatric neuromuscular diseases|Parents of a total of 169 children with pediatric neuromuscular diseases, including 63 Duchnenne Muscular Dystrophy, 53 Spinal Muscular Atrophy and 18 other pediatric neuromuscular diseases (Congenital Muscular Dystrophy, Hereditary Motor and Sensory Neuropathy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, etc.) were included in the study
62280554|NCT02673645|NO_INTERVENTION|Control group|These youth will receive standard mathematics instruction and support, but not the intensive tutoring offered through the intervention.
62280555|NCT02673645|EXPERIMENTAL|SAGA Innovations|These youth will receive the intensive mathematics tutoring by SAGA Innovations, with students randomized to tutors.
62280556|NCT02944019||Edoxaban|Patients with established Non Valvular Atrial Fibrillation (NVAF) treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
62280557|NCT05081284|NO_INTERVENTION|Control group|Immediate implant insertion in fresh-extraction site, will be performed. Peri-implant bone defect will be grafted with a deproteinized bovine bone mineral with 10% collagen and covered with a collagen matrix. After the surgical procedures, each implant will receive a healing abutment until prosthetic restorative procedures.
62458091|NCT03700242|ACTIVE_COMPARATOR|Group 2|1 IM dose of HDCV on D0, D7, and D21 (reference), followed by 1 IM dose of HDCV on Y1 and Y1 + 3 days
62458092|NCT03700242|EXPERIMENTAL|Group 3|2 intradermal (ID) doses of HDCV on D0 and D7 (short HDCV ID PrEP regimen), followed by 1 ID dose of HDCV on Y1 and Y1 + 3 days
62280558|NCT05081284|EXPERIMENTAL|Test Group|Immediate implant insertion in fresh-extraction site, will be performed. Peri-implant bone defect will be grafted with a deproteinized bovine bone mineral with 10% collagen and covered with a collagen matrix, and then a volume-stable collagen matrix will be buccally inserted with a split-thickness flap preparation. Subsequently, the collagen matrix graft will be stabilized with a horizontal mattress suture to the buccal flap. After the surgical procedures, each implant will receive healing abutment connection until the prosthetic restorative procedures
62458093|NCT03700242|EXPERIMENTAL|Group 4|1 IM dose of purified Vero cell rabies vaccine (PVRV) on D0 and D7 (short PVRV IM PrEP regimen), followed by 1 IM dose of PVRV on Y1 and Y1 + 3 days
62458094|NCT03700242|EXPERIMENTAL|Group 5|2 ID doses of PVRV on D0 and D7 (short PVRV ID PrEP regimen), followed by 1 ID dose of PVRV on Y1 and Y1 + 3 days
62458095|NCT02441972|EXPERIMENTAL|18F-Al-NOTA-PRGD2 PET/CT|Imaging with 18F-Al-NOTA-PRGD2 PET/CT.
62648784|NCT04084496|EXPERIMENTAL|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
62648785|NCT06124508|EXPERIMENTAL|Lung Cancer Screening Education Group|Participants in this group will receive intensive lung cancer screening and tobacco cessation education for up to two years.
62648786|NCT06124508|OTHER|Standard of Care Control Group|Participants in this group will receive the standard of care treatment for up to two years.
62081357|NCT03232138|PLACEBO_COMPARATOR|Placebo|Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
62280559|NCT05135832|EXPERIMENTAL|Patient-reported outcomes arm (experimental arm)|"This arm will be assigned to intervention by weekly electronic reporting of symptoms and side effects in an app. A specifically developed alert-algorithm will in real-time guide the patient to adjust supportive care or contact the hospital.~The reported symptoms are sent to the hospital to a healthcare professional - depending on the severity of the reported symptoms the healthcare professional can schedule a visit at the clinic.~The patient will also receive a health-related quality of life questionnaire (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire) including the Physical Function domain in the app each month.~Patient satisfaction regarding the patient-reported outcomes will be measured with the validated Patient-Reported Experience Measurement questionnaire at termination of participation."
62648787|NCT04611880|OTHER|Single Arm Study|Single arm study: crizanlizumab will be supplied in single use vials containing 10 mL at a concentration of 10 mg/mL for administration by IV infusion. Each patient will receive one dose of crizanlizumab on day 1 of Week 1, day 1 of Week 3, day 1 of Week 7, and then day 1 of every 4-week cycle. On infusion day, the pharmacist or designated personnel will prepare individual doses of crizanlizumab for subjects on a milligram per kilogram basis (5 mg/kg) in a 100 mL infusion bag in accordance with the Pharmacy Manual. Crizanlizumab will be administered over 30 minutes by IV infusion
62648788|NCT03176771|EXPERIMENTAL|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
62648789|NCT03176771|EXPERIMENTAL|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
62648790|NCT03176771|EXPERIMENTAL|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
62648791|NCT03176771|EXPERIMENTAL|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
62280560|NCT05135832|NO_INTERVENTION|Standard of care|"This arm will continue standard procedure regarding side effect registration and handling.~The patients will receive a health-related quality of life questionnaire (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, EORTC QOL-C30) at baseline, after 1, 3, and 6 months of participation in the study."
62081358|NCT04890834|ACTIVE_COMPARATOR|Arm I (Standard of care)|Patients and caregivers receive standard care including education pertaining to symptom management, prophylactic dental hygiene and possible extraction, speech pathology for baseline swallowing assessment and prophylactic treatment, and dietary services for regular nutrition consults during CRT. Psychiatry, social work, interventional radiology and supportive care services are consulted as needed.
62081359|NCT04890834|OTHER|Arm II (exercise, yoga sessions)|Patients and caregivers receive standard care as in arm I. Patients and caregivers also participate in yoga sessions 3 times per week over 60 minutes each for a total of 15 sessions.
62280561|NCT03474679|EXPERIMENTAL|Ibrutinib|Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
62280562|NCT02769624|EXPERIMENTAL|Treprostinil|A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
62458096|NCT00535808|EXPERIMENTAL|1|Administration of nitroprusside
62458097|NCT00535808|EXPERIMENTAL|2|Administration of nitroglycerine
62458098|NCT00535808|EXPERIMENTAL|3|Administration of sevoflurane
62458099|NCT05873023|EXPERIMENTAL|Intervention|"The intervention group chew one unscented gum provided by the study for 12 weeks. The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side.~After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting a proof photo in the KakaoTalk chat room."
62458100|NCT05873023|NO_INTERVENTION|Control|The control group does not participate in chewing gum.
62648792|NCT03176771|EXPERIMENTAL|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
62648793|NCT02029417|EXPERIMENTAL|Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)|"INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
62648794|NCT02330341|EXPERIMENTAL|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
62648795|NCT02330341|PLACEBO_COMPARATOR|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
62648796|NCT00523211|EXPERIMENTAL|Test Arm|Vicriviroc 30 mg QD
62648797|NCT00523211|PLACEBO_COMPARATOR|Placebo Control Arm|Placebo
62648798|NCT02650375|EXPERIMENTAL|Metatinib Tromethamine|
62648799|NCT01893606|PLACEBO_COMPARATOR|Starch capsule|During the two weeks screening phase of the study, the daily dose of 3 tablets will be taken before breakfast, lunch and supper.
62648800|NCT01893606|EXPERIMENTAL|N-acetyl-D-glucosamine|During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.
62648801|NCT03351803||Participants with Ashkenazi ancestry|
62648802|NCT01102634|EXPERIMENTAL|Acu-TENS|Application of TENS over acupuncture points
62648803|NCT01102634|PLACEBO_COMPARATOR|Placebo-TENS|Application of Acu-TENS but with no electricity
62648804|NCT05158569|EXPERIMENTAL|Slow breathing exercise group|Slow breathing 5-6 breaths/minute, 3 sets of 5 minutes 2 times/day for 4 weeks.
62648805|NCT05158569|EXPERIMENTAL|Diaphragmatic breathing exercise group|Diaphragmatic breathing, 3 sets of 5 minutes 2 times/day for 4 weeks.
62648806|NCT05017844|PLACEBO_COMPARATOR|KSR-001-04|KSR-001-04 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
62648807|NCT05017844|EXPERIMENTAL|KSR-001-02|KSR-001-02 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
62648808|NCT05017844|EXPERIMENTAL|KSR-001-03|KSR-001-03 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
62648809|NCT03928366|EXPERIMENTAL|Volunteers receiving propofol and remifentanil|Volunteers receive propofol to the loss of consciousness. Then they receive remifentanil during 12 min (pain stimuli in their finger also)
62648810|NCT04236284|EXPERIMENTAL|Home-based tDCS + Prolonged Exposure Therapy|Participants will come in person to the clinic office to complete the baseline visit and the in-person training for the use of both home-based self-administered tDCS and the home-based telehealth device (iPad) for the PE sessions. They understand that they will start the sessions of tDCS once they start the in vivo and imaginal exposures assignments at home. They will self-administer (under televideo supervision) the tDCS session before doing in vivo and/or imaginal exposures assignments. The participants will be remotely supervised by trained research staff at each stimulation to ensure the technique is correct and to monitor any adverse events. We will provide secure videoconferencing software (e.g., WebEx) and ensure the participants are comfortable using the telehealth software.
62648811|NCT03881683|EXPERIMENTAL|HRD and BRCA mutations|
62648812|NCT05647187|ACTIVE_COMPARATOR|NB-UVB group|fourty patients will be treated with NB-UVB. The initial radiation dose was determined according to the patient's skin type; initial dose will be increased by 20% per session. Sessions will be given three times weekly with 48 hours apart for three months.
62648813|NCT05647187|NO_INTERVENTION|Control group|fourty healthy controls without psoriasis , any family history of psoriasis or any dermatological diseases.
62648814|NCT06419491|NO_INTERVENTION|Digital notification tool|A partner notification digital tool allowing the sending of anonymous or personalised standardised text messages to partners and an information leaflet are provided to index patients
62280563|NCT02769624|PLACEBO_COMPARATOR|Placebo|A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.
62648815|NCT06419491|EXPERIMENTAL|Digital notification tool and counseling|In addition to the provision of the partner notification digital tool and the leaflet, a partner notification approach assisted by a trained counsellor during a specific counselling interview is offered to index patient.
62648816|NCT03456661|ACTIVE_COMPARATOR|Levobupivacaine|Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al\[1\]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
62648817|NCT03456661|ACTIVE_COMPARATOR|Levobupivacaine + Dexmedetomidine|Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al\[1\]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
62648818|NCT06082479|NO_INTERVENTION|control group|no application of any type of cryotherapy.
62648819|NCT06082479|ACTIVE_COMPARATOR|cryotherapy group|after the completion of the mechanical preparation. A 2.5 x5 centimetre gel pack was placed in the mouth on the vestibular surface of the treated tooth.
62648820|NCT03281044|EXPERIMENTAL|FMT group|Patient group receiving active FMT capsules
62648821|NCT03281044|PLACEBO_COMPARATOR|Placebo group|Patient group receiving placebo capsules
62648822|NCT04442711||PFBIO-EXA|All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.
62648823|NCT02969785|EXPERIMENTAL|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
62648824|NCT02969785|ACTIVE_COMPARATOR|G2: back strengthening exercises|Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
62280564|NCT04228185|EXPERIMENTAL|Laparoscopic banded sleeve gastrectomy|Group undergoing banded sleeve
62280565|NCT04228185|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy|Group undergoing standard sleeve
62280566|NCT01469559|ACTIVE_COMPARATOR|Novolin Toronto insulin|
62280567|NCT01469559|PLACEBO_COMPARATOR|Normal saline|
62280568|NCT02026063|EXPERIMENTAL|250 mg Telotristat Etiprate|One telotristat etiprate (250 mg) tablet administered three times daily.
62280569|NCT02026063|EXPERIMENTAL|500 mg Telotristat Etiprate|Two telotristat etiprate (250 mg) tablets administered three times daily.
62280570|NCT01613326|EXPERIMENTAL|NVA237|NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
62648825|NCT01077336||Hospitalized patients with candidemia|
62648826|NCT02169882|ACTIVE_COMPARATOR|Rifampicin 450 mg (standard dose)|"Twenty patients will receive 1 tablet of 450 mg Rifampicin and 2 tablets of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT).~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
62648827|NCT02169882|EXPERIMENTAL|Rifampicin 900 mg per oral|"Twenty patients will receive 2 tablets of 450 mg Rifampicin and 1 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
62280571|NCT01613326|ACTIVE_COMPARATOR|Tiotropium|Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
62280572|NCT03493360|EXPERIMENTAL|Visual feedback|Participants will be asked to perform movements of the low back while looking at a mirror for visual feedback.
62280573|NCT03493360|ACTIVE_COMPARATOR|No visual feedback|Participants will be asked to perform movements of the low back while the mirrors are covered and no visual feedback is provided.
62280574|NCT06107010|EXPERIMENTAL|Exo group|"During the 6-week intervention period, the Exo group will complete 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy.~During sessions with the exoskeleton, the patient will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.~Conventional therapy corresponds to physiotherapy as part of post stroke standard of care of the center (tasks such as lower and upper limb practice, walking in parallel bars, etc., but this list is not exhaustive and depends on the practice of the therapists/centers)."
62280575|NCT06107010|NO_INTERVENTION|Control group|During the 6-week intervention period, the Control group will complete 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).
62458101|NCT02597543|EXPERIMENTAL|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
62458102|NCT02597543|EXPERIMENTAL|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
62648828|NCT02169882|EXPERIMENTAL|Rifampicin 1350 mg per oral|"Twenty patients will receive 3 tablets of 450 mg Rifampicin and 0 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
62648829|NCT03444558|EXPERIMENTAL|Dietary Supplement|50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
62648830|NCT03444558|PLACEBO_COMPARATOR|Placebo|50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
62648831|NCT06104397|NO_INTERVENTION|Standard Care|Standard care patient's with Parkinson's Disease are receiving at each site.
62648832|NCT06104397|ACTIVE_COMPARATOR|Written exercise guidance by neurologist|Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease.
62648833|NCT06104397|EXPERIMENTAL|Physical therapy|A consultative model of physical therapy will be implemented at each site for patient's with Parkinson's Disease.
62648834|NCT02147626|ACTIVE_COMPARATOR|Information and Screening Group|Intervention: The patient website will include the American Heart Association (AHA) Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) Dietary Approaches to Stop Hypertension (DASH) website, and the NIH smoking cessation website
62648835|NCT02147626|EXPERIMENTAL|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
62648836|NCT04506736|ACTIVE_COMPARATOR|SPV spontanous ventilation|The patients will be ventilated using volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
62648837|NCT04506736|ACTIVE_COMPARATOR|OLA open lung ventilation|The patients will undergo ARM followed by personalized PEEP.
62648838|NCT02111083|ACTIVE_COMPARATOR|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test \[T\]).
62648839|NCT02111083|EXPERIMENTAL|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference \[R\]).
62648840|NCT03795415||Immediate Arm (G1)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G1 will receive the intervention Gundo-So immediately. (From month 3 to month 6).~112 women will be in immediate arm in 14 groups of 8 women."
62648841|NCT03795415||Delayed Arm (G2)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G2 will receive the intervention Gundo-So 3 months after. (From month 6 to month 9).~112 women will be in delayed arm in 14 groups of 8 women."
62280576|NCT03850197||TMM followed by EarPopper + Tympanometry|"Participants will be asked to complete the tubomanometry (TMM) then EarPopper plus tympanometry tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize Eustachian tube (ET) pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
62280577|NCT03850197||EarPopper + Tympanometry followed by TMM|"Participants will be asked to complete the EarPopper plus tympanometry then TMM tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize ET pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
62081360|NCT04802954|EXPERIMENTAL|High risk group|Patients with hepatocellular carcinoma greater than 1 cm in size. All patients from an ultrasound screening programme who have been diagnosed with a nodule larger than 1 cm and referred to our centres will be included in this group. They will then be excluded of this group if the diagnosis of hepatocellular carcinoma is not retained according to the radiological or histological reference diagnostic standards (gold standard).
62081361|NCT04802954|EXPERIMENTAL|Low risk group|Patients without hepatocellular carcinoma. A 1-year interval ultrasound will be performed to confirm the absence of new nodule in the year following inclusion.
62081362|NCT06068049||Cohort 1|Patients diagnosed with locally advanced or metastatic NSCLC with activating EGFR mutations that received first line treatment with osimertinib (FLAURA regimen).
62081363|NCT06068049||Cohort 2|Patients with stage IB-IIIA NSCLC after complete tumour resection that has activating mutations in the EGFR (deletion of exon 19 or substitution of exon 21 \[L858R\]) that received adjuvant treatment with osimertinib (ADAURA regimen).
62081364|NCT06068049||Cohort 3|Patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, that received osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first- line treatment (FLAURA2 regimen).
62280578|NCT04276584|ACTIVE_COMPARATOR|Positive expiratory pressure|Deep inspiration followed by expiration to a resistance of 10-15 cm of water pressure. Done three times, each time with 10 inspiration/expiration cycles
62280579|NCT04276584|EXPERIMENTAL|Speaking loudly|Speaking loudly during 3 minutes.
62280580|NCT01258959||Ophthalmic surgery patients|Patients (men and women) of at least 18 years of age undergoing an ophthalmic procedure on the posterior section of the eye under local anaesthesia, i.e. with a peribulbar block. Inclusion and exclusion criteria for the study are the same as for the peribulbar anaesthesia.
62280581|NCT05048160|EXPERIMENTAL|6MW3211|"* Dosage form: injection~* Specification: 240 mg / 8 ml/Vial"
62648842|NCT02333253|ACTIVE_COMPARATOR|Delayed start protocol|First group received 300 U r FSH +150 U urinary GN from day 2 till day of HCG ,dose adjusted according to the response then 0.25 cetrotide S.c was added on when leading follicle reach \>12 mm, HCG was given only if we have at least 3 mature follicles \>14 mm and the leading one \>17mm then OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if \> 5miu/ML
62280582|NCT01718184|EXPERIMENTAL|Sulcoflex|Sulcoflex intraocular lens implantation
62081365|NCT06602726|EXPERIMENTAL|REGN1908-1909|
62081366|NCT06602726|PLACEBO_COMPARATOR|Placebo|
62081367|NCT05671835|EXPERIMENTAL|TTI-101 400 mg/day|Participants will receive 400 mg/day of TTI-101 twice daily (BID) for 12 weeks.
62081368|NCT05671835|EXPERIMENTAL|TTI-101 800 mg/day|Participants will receive 800 mg/day of TTI-101 BID for 12 weeks.
62081369|NCT05671835|PLACEBO_COMPARATOR|Placebo|Participants will receive a matching placebo BID for 12 weeks.
62280583|NCT01209026|EXPERIMENTAL|FF/GW642444M (200/25mcg)|Inhaled fluticasone furoate (200mcg) /GW642444M (25mcg) combination Days 1- 7; placebo tablet taken orally single dose (po SD) on Day 7.
62280584|NCT01209026|EXPERIMENTAL|FF/GW642444M (800/100 mcg)|Inhaled fluticasone furoate (800mcg) /GW642444M (100mcg) combination Days 1- 7; placebo tablet (po SD) on Day 7.
62280585|NCT01209026|ACTIVE_COMPARATOR|Moxifloxacin|Inhaled placebo on Days 1-7; moxifloxacin (400mg po SD) on Day 7
62081370|NCT04981509|EXPERIMENTAL|Treatment (bevacizumab, atezolizumab, erlotinib)|Patients receive bevacizumab IV over 30-90 minutes and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Patients also receive erlotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT with or without contrast and MRI throughout the trial. Patients undergo collection of blood throughout the trial, and may undergo a biopsy during screening, as well as a brain MRI/CT scan with contrast, bone scan, and/or F-18 sodium fluoride PET scan as clinically indicated.
62081371|NCT05443048|EXPERIMENTAL|Ivoclar Ivotion Denture System|
62081372|NCT06679270|EXPERIMENTAL|Metreleptin|Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
62081373|NCT05971251|EXPERIMENTAL|Dose Level 1:|45 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
62081374|NCT05971251|EXPERIMENTAL|Dose Level 2|60 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
62081375|NCT05971251|EXPERIMENTAL|Dose Level 3|75 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
62081376|NCT05971251|EXPERIMENTAL|Dose level 4:|90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent 10 cycles) + Acalabrutinib 100 mg BID for a total of 12 cycles.
62081377|NCT06458153|EXPERIMENTAL|Speech behavior and functional imaging|Assessing the neural correlates of speaking-induced sensory modulation in all three cohorts using behavior and neuroimaging tasks in up to 6 sessions.
62280586|NCT01209026|PLACEBO_COMPARATOR|Placebo|Inhaled placebo on Days 1-7; placebo tablet (po SD) on Day 7.
62280587|NCT06519591|EXPERIMENTAL|Experimental|Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
62081378|NCT06740669|NO_INTERVENTION|Control Group|Women in the control group will receive routine care and breastfeeding support will be provided to these women.
62081379|NCT06740669|ACTIVE_COMPARATOR|Virtual reality glasses (VR) application|
62081380|NCT06740669|ACTIVE_COMPARATOR|Expressive touch applications|
62081381|NCT06740669|ACTIVE_COMPARATOR|Focusing|
62081382|NCT06720714|EXPERIMENTAL|Rozanolixizumab arm|Study participants enrolled in this arm will receive a single dose of subcutaneous rozanolixizumab
62081383|NCT06741072|EXPERIMENTAL|Group I (OSU-2131, QS-21)|Healthy volunteers and patients receive OSU-2131 SC with QS-21 SC on day 0, and weeks 2 and 4 in the absence of unacceptable toxicity or patient proceeds to transplant. Healthy volunteers and patients additionally undergo blood sample collection throughout the study.
62081384|NCT06741072|PLACEBO_COMPARATOR|Group II (placebo)|Healthy volunteers receive PBS SC on day 0, and weeks 2 and 4 in the absence of unacceptable toxicity. Healthy volunteers additionally undergo blood sample collection throughout the study.
62081385|NCT05553938|EXPERIMENTAL|Empagliflozin|Empagliflozin 10 mg daily for weeks 1-6
62081386|NCT05553938|EXPERIMENTAL|Placebo, Then Empagliflozin|Participants first receive matching placebo daily for weeks 1-6, then will receive Empagliflozin 10 mg daily for weeks 7-12
62280588|NCT04002544|ACTIVE_COMPARATOR|NTG group|In this group, nitroglycerin patch will be applied near the radial artery pulsation covered with a gauze.
62280589|NCT04002544|PLACEBO_COMPARATOR|Control group|In this group, no patch as applied to the patient. However, a gauze will be applied to confirm blinding
62280590|NCT00488787|EXPERIMENTAL|A|Intranasal ketamine low dose
62081387|NCT04418037|EXPERIMENTAL|Single arm using the Digital Health Feedback System|This protocol is designed to evaluate a novel technology that employs an ingestible sensor to detect medication ingestion for use by persons initiating or restarting antiretroviral (ARV) treatment for HIV infection during a hospital admission.
62081388|NCT04706507|EXPERIMENTAL|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge
62081389|NCT04706507|PLACEBO_COMPARATOR|Placebo|normal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge
62081390|NCT06229080|EXPERIMENTAL|Test group|short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver.
62081391|NCT03815656|EXPERIMENTAL|Implanted RC+S|Implanted Medtronic RC+S IPG with dual DBS electrodes in STN and GPi. DBS stimulation will be administered to: 1) STN alone, 2) GPi alone, 3) cooperative STN + GPi, and 4) adaptive, closed-loop stimulation of STN and/or GPi.
62280591|NCT00488787|EXPERIMENTAL|B|intranasal ketamine medium dose
62280592|NCT00488787|EXPERIMENTAL|C|intranasal ketamine high dose
62280593|NCT00488787|PLACEBO_COMPARATOR|D|placebo
62280594|NCT03948230|ACTIVE_COMPARATOR|Sodium chloride / Water|300mg sodium chloride consumed in a capsule on two occasions with 300ml water
62458103|NCT01471522|ACTIVE_COMPARATOR|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
62458104|NCT01471522|ACTIVE_COMPARATOR|Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
62280595|NCT03948230|ACTIVE_COMPARATOR|Sodium chloride / no water|300 mg sodium chloride consumed
62280596|NCT03948230|ACTIVE_COMPARATOR|Sodium chloride / colored water|300mg sodium chloride consumed in a capsule on two occasions with 300ml coloured water
62280597|NCT03948230|PLACEBO_COMPARATOR|Placebo / water|Placebo consumed in a capsule on two occasions with 300ml water
62280598|NCT03948230|PLACEBO_COMPARATOR|Placebo / no water|Placebo capsule consumed
62280599|NCT03948230|PLACEBO_COMPARATOR|Placebo / coloured water|Placebo consumed in a capsule on two occasions with 300ml colored water
62280600|NCT00918814|EXPERIMENTAL|LIPO-102|LIPO-102
62280601|NCT00918814|EXPERIMENTAL|Placebo|Placebo
62280602|NCT00584870|ACTIVE_COMPARATOR|Naproxen|
62458105|NCT00643877|EXPERIMENTAL|B|PHRAC was performed 7 days before surgery. Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
62458106|NCT00643877|NO_INTERVENTION|A|Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
62081392|NCT06741059|EXPERIMENTAL|The group receiving the TENS treatment|The group has received the TENS treatment.
62081393|NCT06741059|PLACEBO_COMPARATOR|Placebo Comparator|It is the placebo group where the TENS device is applied, but no treatment is given.
62081394|NCT06741059|NO_INTERVENTION|Control Group|It is the control group, which receives no intervention or standard treatment.
62081395|NCT06271616|EXPERIMENTAL|Prevention (ibrutinib)|Patients receive ibrutinib PO QD on days 1-30 of each cycle. Cycles repeat every 30 days for up to 12 cycles on study. Additionally, patients undergo an echocardiography prior to registration and blood sample collection throughout study.
62280603|NCT00584870|PLACEBO_COMPARATOR|Placebo|
62280604|NCT00584870|EXPERIMENTAL|RN624|
62081396|NCT05565560|EXPERIMENTAL|Apremilast|Participants with a weight between ≥ 15 kg to \< 50 kg will receive apremilast 20 mg twice daily (BID) tablet. Participants weighing ≥ 50 kg will receive apremilast 30 mg BID tablet.
62280605|NCT04647292|EXPERIMENTAL|Home Blood Pressure Measurement, Telemonitoring and Medication titration|Medication titration to guideline SBP \<130mmHg
62280606|NCT04647292|ACTIVE_COMPARATOR|Control Group: Standard of Care Blood Pressure Management|Standard of Care Management by GP/physician to SBP \<130mmHg by current European Stroke Organisation, American Stroke Association and UK NICE guidelines
62280607|NCT05742555|EXPERIMENTAL|Experimental Group|
62280608|NCT05742555|NO_INTERVENTION|Control Group|
62280609|NCT01484067|EXPERIMENTAL|Patch|At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
62280610|NCT01484067|NO_INTERVENTION|No Patch|No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
62458107|NCT02841826|OTHER|Group I: IUD without uterine sound group|Transvaginal ultrasound before to intrauterine contraceptive device insertion without uterine sounding.
62458108|NCT02841826|OTHER|Group II: IUD with uterine sound|Intrauterine contraceptive device inserted by classic method
62458109|NCT04533022|EXPERIMENTAL|C21|
62458110|NCT00977288|EXPERIMENTAL|1|MK0859 10 mg + placebo
62458111|NCT00977288|EXPERIMENTAL|2|MK0859 40 mg + placebo
62458112|NCT00977288|EXPERIMENTAL|3|MK0859 100 mg + placebo
62458113|NCT00977288|EXPERIMENTAL|4|MK0859 300 mg + placebo
62458114|NCT00977288|EXPERIMENTAL|5|MK0859 10 mg + atorvastatin 10mg
62081397|NCT06739850||Group|
62081398|NCT06258837|EXPERIMENTAL|Drug-Induced Sleep Endoscopy|DISE will be performed at the time of surgery under the same sedation. The decision on specific surgical approach will be made at that time based on DISE findings. Prior to intubation, patients will be sedated with either a propofol infusion or a combination of ketamine and dexmedetomidine. Once adequate sedation is achieved, endoscopy will be performed using a flexible endoscope advanced through the nose. The nasal airway will be evaluated on both sides, then the endoscope will be advanced into the pharynx. The degree of obstruction is scored on a 3-point rating scale. Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery. Caregivers will be consented for all possible procedures with the understanding that only those needed based on DISE will be performed. Importantly, these procedures are all established treatments with published outcomes data.
62081399|NCT06258837|ACTIVE_COMPARATOR|Adenotonsillectomy|Adenotonsillar hypertrophy is the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment. An adenotonsillectomy is an operation to remove both the adenoids and tonsils.
62648843|NCT02333253|ACTIVE_COMPARATOR|conventional antagonist protocol|Second group were received cetrotide 0.25 mg s.c alone from day 2 to day 8then we initiate GN therapy by same initial GN dose (300FSH+150U urinary GN).same adjustment of dose were done and antagonist restarted when DF \>12mm, till day of HCG, OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if \> 5miu/ML
62648844|NCT01719653|ACTIVE_COMPARATOR|MiraLAX 306 g (Day-Prior)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
62648845|NCT01719653|EXPERIMENTAL|MiraLAX 357 g (Day-Prior)|MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
62648846|NCT01719653|EXPERIMENTAL|MiraLAX 306 g (Split-Dose)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
62648847|NCT01719653|ACTIVE_COMPARATOR|MoviPrep (Split-Dose)|MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
62280611|NCT04992975||Alzheimer's disease|"Patients with Early Onset Alzheimer's disease (with known cerebrospinal fluid Amyloid/tau status) during prodromal or mild phase will have MRI of the brain at 7T, neurocognitive assessments, and blood test to check APOe status.~Repeat neuroimaging and neurocognitive tests after one year."
62280612|NCT04992975||Control group|"Age and gender matched individuals with normal cognition will have MRI of the brain at 7T, neurocognitive assessments and blood test to check APOe status.~Repeat neuroimaging, neurocognitive tests after one year."
62280613|NCT05628194||Men who have sex with men (MSM)|
62280614|NCT02495727|EXPERIMENTAL|Control Group|This group will undertake two-weeks of step-reduction to \<1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
62280615|NCT02495727|EXPERIMENTAL|Pre-Training Group|This group will undertake four weeks of strength training exercise (10 sessions) before two-weeks of step-reduction to \<1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
62280616|NCT02495727|EXPERIMENTAL|Exercise Snacking Group|This group will undertake home-based 'exercise snacks' of simple lower limb movement (5 minutes, 3 times a day) whilst undertaking two-weeks of step-reduction to \<1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
62458115|NCT00977288|EXPERIMENTAL|6|MK0859 40 mg + atorvastatin 10mg
62458116|NCT00977288|EXPERIMENTAL|7|MK0859 100 mg + atorvastatin 10mg
62648848|NCT01719653|ACTIVE_COMPARATOR|SUPREP (Split-Dose)|SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.
62280617|NCT06548711|EXPERIMENTAL|TEAS group|The patient takes a sitting position, uses alcohol to wipe the skin at the selected acupoint, waits for it to dry, and then applies the electrode patch. Connect the percutaneous acupoint electric stimulator and provide transcutaneous acupoint electric stimulation, selecting a continuous wave at 2 Hz.
62280618|NCT06548711|SHAM_COMPARATOR|Sham TEAS group|The electrode patch is placed on the acupoint, similar to the TEAS group patients, but without starting the electric stimulation, and indicates to the patient that there will be no special sensation during the treatment process. The electrode is well protected during the operation and will not come off.
62458117|NCT00977288|EXPERIMENTAL|8|MK0859 300 mg + atorvastatin 10mg
62458118|NCT00977288|PLACEBO_COMPARATOR|9|Placebo + atorvastatin 10mg
62648849|NCT00076570|EXPERIMENTAL|Sirolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to sirolimus monotherapy and followed up for 4 years.
62081400|NCT04494113|EXPERIMENTAL|Treatment (triapine, surgical resection)|Patients receive triapine IV over 2 hours on day 1. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion. Patients also undergo biopsy and collection of blood samples on study.
62081401|NCT06595238|EXPERIMENTAL|Arm 1|Dose 1
62081402|NCT06595238|EXPERIMENTAL|Arm 2|Dose 2
62081403|NCT06595238|EXPERIMENTAL|Arm 3|Dose 3
62458119|NCT00977288|PLACEBO_COMPARATOR|10|Placebo
62458120|NCT06091878||Cohort 1|
62458121|NCT06089538|EXPERIMENTAL|Delirium patients group|Patients admitted for acute respiratory distress syndrome (ARDS) who developed delirium
62648850|NCT00076570|ACTIVE_COMPARATOR|Tacrolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to tacrolimus monotherapy and followed up for 4 years.
62648851|NCT00485355|ACTIVE_COMPARATOR|1|Conventional Laparoscopic Hysterectomy
62648852|NCT00485355|ACTIVE_COMPARATOR|2|Robotic Assisted Laparoscopic Hysterectomy
62648853|NCT04222491|EXPERIMENTAL|active peanut OIT|active peanut oral immunotherapy
62648854|NCT03370952|ACTIVE_COMPARATOR|new approach|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:~Delivery of affected ovary outside the abdominal cavity:~A transverse mini-laparotomy is done (2-3 cm) in the midline 2 cm above the symphysis pubis.~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
62648855|NCT03370952|ACTIVE_COMPARATOR|Laproscopic ovarian cystectomy|classic laparoscopic ovarian cystectomy
62458122|NCT06089538|ACTIVE_COMPARATOR|Patients without delirium|Patients admitted for acute respiratory distress syndrome (ARDS) who did not developed delirium
62458123|NCT02486822|EXPERIMENTAL|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
62458124|NCT02486822|ACTIVE_COMPARATOR|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
62648856|NCT03945630|EXPERIMENTAL|anterior Quadratus Lumborum Block (QLB)|"Anterior QLB will be performed in the sitting position. This block is also known as TQL- Transmuscular QLB or QLB 3. A convex transducer will be placed in a transverse position, in the posterior axillary line and tilted caudad until the 'shamrock sign' at L4 level will be obtained. An 80-110 mm SonoTAP (PAJUNK Medizintechnologie, Geisingen, Germany) will be inserted in-plane from the lateral end of the transducer and advanced until the needle tip will be inside the interfascial plane between the Quadratus Lumborum and the Psoas muscles. The successful needle placement will be confirmed by observing the spread of 5 mls 0,9%NaCl. Subsequently, 30 ml 0.5% ropivacaine with 100 mcg dexmedetomidine and adrenaline 1:200,000 will be injected. Satisfactory interfascial spread will be assessed by longitudinal probe orientation.~Following QLB, a spinal anaesthetic will be sited and a THA via posterior approach will be performed."
62648857|NCT03945630|ACTIVE_COMPARATOR|Standard of Care (no QLB)|A spinal anaesthetic will be sited and a THA via posterior approach will be performed.
62648858|NCT05516303||Case|MS patients treated with fingolimod who experienced liver enzymes elevation
62648859|NCT05516303||Control|MS patients treated with fingolimod not experiencing elevated liver enzymes
62648860|NCT02519725|ACTIVE_COMPARATOR|With diary|a ICU diary is open by staff for the patient and his relatives during the ICU stay
62648861|NCT02519725|NO_INTERVENTION|Without diary|No diary is open during the ICU stay
62648862|NCT00321763|EXPERIMENTAL|GSK1247446A Lot 1 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62648863|NCT00321763|EXPERIMENTAL|GSK1247446A Lot 2 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62648864|NCT00321763|EXPERIMENTAL|GSK1247446A Lot 3 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62081404|NCT06595238|PLACEBO_COMPARATOR|Arm 4|Placebo - Dose matched with each Experimental arm
62648865|NCT00321763|EXPERIMENTAL|GSK1247446A Pooled Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
62648866|NCT00321763|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
62458125|NCT04527809|EXPERIMENTAL|tDCS-active|tDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area.
62081405|NCT03212170|EXPERIMENTAL|FFNP PET/MRI|18F-Fluorofuranylnorprogesterone (FFNP) administration for PET/MRI imaging to assess biopsy-proven primary PR+ breast malignancies.
62458126|NCT04527809|SHAM_COMPARATOR|tDCS-sham|tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
62280619|NCT03007212|EXPERIMENTAL|HCC patients with Pranch portal vein thrombosis|Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT. Follow up was done at 1, 3, 6 and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions, triphasic spiral CT to assess radiological response according to mRECIST criteria. Survival analysis was performed using Kaplan-Meier estimations.
62280620|NCT05752214||Group A|
62280621|NCT03491410|PLACEBO_COMPARATOR|1|Arm 1: standard Unit´s protocol + placebo
62648867|NCT04547400||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
62648868|NCT04547400||Healthy group|Healthy individuals without chronic disease
62280622|NCT03491410|EXPERIMENTAL|B|Arm 2: standard Unit´s protocol + aspirin
62280623|NCT01178645|EXPERIMENTAL|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
62280624|NCT00754897||1|"We will do a database search to identify children less than 1 year of age that have undergone inguinal hernia surgery during the years of 1999-2007, and children who have had inguinal hernia surgery between the ages of 1 and 3 years during the years 1999-2007.~We will then do a telephone interview of the parents of these children to determine if there are siblings that are within three years of age and have not have any exposure to anesthetics agents or sedatives before their 3rd birthday."
62648869|NCT05485311||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
62648870|NCT05485311||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
62648871|NCT00599560|EXPERIMENTAL|1. Meniere's disease|Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
62648872|NCT00599560|NO_INTERVENTION|2. Acoustic neurinoma|Diagnosed by CT and/or MRI
62648873|NCT00880217|EXPERIMENTAL|001|JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
62648874|NCT00880217|EXPERIMENTAL|002|JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
62648875|NCT00880217|EXPERIMENTAL|003|JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
62648876|NCT00880217|ACTIVE_COMPARATOR|004|Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
62648877|NCT00880217|ACTIVE_COMPARATOR|005|OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
62648878|NCT00880217|PLACEBO_COMPARATOR|006|Placebo capsule once daily for 42 days
62081406|NCT06148935||Korean adult participants with HFrEF|Korean heart failure participants with reduced ejection fraction (HFrEF) who are prescribed Verquvo (Vericiguat) for an approved indication by the Ministry of Food and Drug Safety (MFDS) in Korea
62280625|NCT05811403|EXPERIMENTAL|EGCG as a flushing fluid, MTA as a pulp capping material|
62280626|NCT05811403|EXPERIMENTAL|EGCG as a flushing fluid, Premixed BC putty as a pulp capping material|
62280627|NCT05811403|EXPERIMENTAL|NaOCl as a flushing fluid, Premixed BC putty as a pulp capping material|
62648879|NCT04998708|EXPERIMENTAL|Intervention|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM). We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
62081407|NCT04605770|EXPERIMENTAL|pemetrexed+cisplatin|Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.
62081408|NCT06235892|EXPERIMENTAL|Ultra-low TACROLIMUS arm|Ultra-low TACROLIMUS (TAC) arm based on MMF/MPA (Mycophenolate Mofetil/ Mycophénolic Acid) with or without CS (Cortico Steroid ) and TACROLIMUS to achieve 2-3.5 ng/ml trough levels during all the duration of the study.
62280628|NCT05811403|ACTIVE_COMPARATOR|NaOCl as a flushing fluid, MTA as a pulp capping material|
62280629|NCT02322710|ACTIVE_COMPARATOR|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
62280630|NCT02322710|ACTIVE_COMPARATOR|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
62280631|NCT01648257|EXPERIMENTAL|GSK1265744 Na Salt Tablets|Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.
62280632|NCT01648257|EXPERIMENTAL|GSK1265744 Free Acid Nanomilled Capsules|Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
62458127|NCT00005576|EXPERIMENTAL|Treatment (monoclonal antibody Ch14.18, aldesleukin)|Patients receive MOAB IV over 5 hours on days 7-10 during courses 2 and 4 and on days 3-6 during courses 1, 3, and 5; sargramostim (GM-CSF) IV over 2 hours or subcutaneously daily on days 0-13 during courses 1, 3, and 5; interleukin-2 IV continuously on days 0-3 and 7-10 during courses 2 and 4; and oral isotretinoin twice daily on days 14-27 during courses 2 and 4 and on days 10-23 during courses 3 and 5. Treatment repeats every 24-32 days for 5 courses in the absence of unacceptable toxicity.
62458128|NCT02164838|EXPERIMENTAL|Axitinib|
62458129|NCT02029105||Mesothelin, hyaluronan, osteopontin, syndecan|The patients with pleural diseases
62458130|NCT02080923|EXPERIMENTAL|Brief Motivational Interview|Health-related counseling that takes place in as little as one hour or up to a few sessions.
62648880|NCT04998708|NO_INTERVENTION|Control|
62280633|NCT01648257|EXPERIMENTAL|GSK1265744 Free Acid Micronized Capsules|Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
62280634|NCT02601924|ACTIVE_COMPARATOR|Topical Pressure Massage Block injection|Topical pressure massage at site of alveolar nerve block injection.
62280635|NCT02601924|ACTIVE_COMPARATOR|Topical Anesthetic Gel Block injection|Topical anesthetic gel (20% Benzocain) at site of inferior alveolar nerve block injection.
62458131|NCT02080923|NO_INTERVENTION|Standard Care|Participant will receive information about dating abuse in a handout and referrals to a national domestic violence hotline.
62458132|NCT04472390||Tapering|TNF-α inhibitors
62648881|NCT00005793|EXPERIMENTAL|Combination Chemotherapy|Patients receive induction chemotherapy with daunorubicin IV over 10-15 minutes on days 1-3, cytarabine IV continuously on days 1-5, topotecan IV continuously on days 6-8, and etoposide IV over 60 minutes on days 9 and 10. Within 4 weeks of hematologic recovery, patients achieving remission after induction receive consolidation chemotherapy with cytarabine IV over 1 hour every 12 hours on days 1, 3, and 5. Subsequent courses of consolidation chemotherapy begin within 2 weeks of documentation of hematologic recovery from the prior consolidation course. Consolidation chemotherapy continues for 4 courses in the absence of unacceptable toxicity or disease progression.
62280636|NCT02601924|ACTIVE_COMPARATOR|Topical Pressure Massage Infiltration|Topical pressure massage at site of maxillary anterior infiltration
62280637|NCT02601924|ACTIVE_COMPARATOR|Topical Anesthetic Gel Infiltration|Topical anesthetic gel (20% Benzocain) at site of maxillary anterior infiltration
62280638|NCT00891579|ACTIVE_COMPARATOR|Alimta|Treatment of Alimta
62280639|NCT00891579|ACTIVE_COMPARATOR|IRESSA|Treatment of IRESSA
62081409|NCT06235892|NO_INTERVENTION|SOC ( Standard of care)-TACROLIMUS arm|SOC-TAC arm based on MMF/MPA with or without CS and TACROLIMUS to achieve 4 and 7 ng/ml trough levels during all the duration of the study
62081410|NCT04729049|EXPERIMENTAL|Erector spinae plane block + patient controlled analgesia (PCA) with intravenous morphine|"Preoperative bilateral ESP block with ropivacaine 0,4% + dexamethasone 4 mg, 20 mL per side, at the median spinal level of intervention.~End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day."
62081411|NCT04729049|ACTIVE_COMPARATOR|Patient controlled analgesia (PCA) with intravenous morphine|"End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day."
62081412|NCT06694584|NO_INTERVENTION|Control group|Receives no intervention
62081413|NCT06694584|EXPERIMENTAL|Tea(m)Time|"Tea(m)Time intervention: Tea(m)Time is divided into two phases, starting with the qualification of team leaders.~The qualification is followed by the implementation of Tea(m)Time in the various teams."
62081414|NCT06097260|EXPERIMENTAL|Placebo|Placebo
62081415|NCT06097260|EXPERIMENTAL|Bexotegrast (PLN-74809) 160 mg Dose|Bexotegrast (PLN-74809) 160 mg Dose - 52 weeks
62081416|NCT06097260|EXPERIMENTAL|Bexotegrast (PLN-74809) 320 mg Dose|Bexotegrast (PLN-74809) 320 mg Dose - 52 weeks
62081417|NCT03971253||Peficitinib|Participants will receive peficitinib once daily after meal.
62081418|NCT06738108||ECOS group|ECOS
62081419|NCT06738108||Control group|IV infusion tpa
62081420|NCT00401674|EXPERIMENTAL|SINGLE ARM|
62081421|NCT06561854|EXPERIMENTAL|Dexamethasone-free|"Dexamethasone will be stopped after the first 2 cycles (in both ICARIA and IKEMA schemas).~ICARIA shemas :~dexamethasone isatuximab pomalidomide~IKEMA shemas :~dexamethasone isatuximab carfilzomib"
62081422|NCT06561854|NO_INTERVENTION|Dexamethasone|"Dexamethasone will not be discontinued (in both ICARIA and IKEMA shemas).~ICARIA schema :~dexamethasone isatuximab pomalidomide~IKEMA schema :~dexamethasone isatuximab carfilzomib"
62081423|NCT02699697|EXPERIMENTAL|ARM I (palliative radiation therapy)|Patients undergo 1 fraction of EBRT over 30 minutes.
62081424|NCT02699697|EXPERIMENTAL|ARM II (palliative radiation therapy)|Patients undergo 2 fractions of EBRT over 30 minutes. The 2 fractions will be separated by 3-7 days.
62081425|NCT04262141|EXPERIMENTAL|IMG-7289 in ET and PV Patients|"Oral daily dose of 0.6 mg/kg/day IMG-7289 will be administered:~* The initial pilot period will enroll 8 participants to receive oral daily dose of IMG-7829 for 24 weeks, iteratively as long as there is clinical benefit in the absence of excess toxicity.~* The second stage group will enroll an additional 16 participants to receive IMG-7829 for over 2 years, iteratively as long as there is clinical benefit in the absence of toxicity."
62081426|NCT03701100|ACTIVE_COMPARATOR|Active tDCS|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
62081427|NCT03701100|SHAM_COMPARATOR|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
62081428|NCT06738771||1|patients with invasive P. aeruginosa DTR infection requiring definitive intravenous antibiotic therapy
62280640|NCT00621504|EXPERIMENTAL|Ceftaroline fosamil for Injection|"Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
62081429|NCT05567796|EXPERIMENTAL|Cagrisema s.c. 2.4 mg/2.4 mg|Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.
62081430|NCT05567796|ACTIVE_COMPARATOR|Cagrilintide s.c. 2.4 mg|Participants will receive cagrilintide s.c. 2.4 mg and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.
62081431|NCT05567796|ACTIVE_COMPARATOR|Semaglutide s.c. 2.4 mg|Participants will receive semaglutide s.c. 2.4 mg and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.
62081432|NCT05567796|PLACEBO_COMPARATOR|Placebo s.c.|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.
62081433|NCT04612049|EXPERIMENTAL|Children with hemiplegia|40 children with hemiplegia, 7-16 years-old at Gross Motor Function Classification System (GMFCS) Levels I-III and Manual Ability Classification System (MACS) Levels I-II will be recruited as participants. This age range was chosen based on our preliminary research in which children under the age of 7 had difficulty attending to repetitive task practice. Individuals will be recruited without regard to race or ethnicity. Our goal is to have a study sample that is 50% male and 50% female, and approximates the population of the Greater Boston, MA region.
62458133|NCT04472390||Discontinuing|TNF-α inhibitors
62081434|NCT04612049|EXPERIMENTAL|Typically developing children|40 typically developing children, 7-16 years-old.
62458134|NCT04182009|OTHER|Omron|Omron group will undergo sputum induction with the Omron nebuliser at Visit 1, followed by the Akita Jet nebuliser at Visit 2.
62458135|NCT04182009|ACTIVE_COMPARATOR|Akita|Akita group will undergo sputum induction with the Akita Jet nebuliser at Visit 1, followed by the Omron nebuliser at Visit 2.
62458136|NCT03220867|EXPERIMENTAL|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1\*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1\*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
62648882|NCT01782339|EXPERIMENTAL|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
62458137|NCT03220867|EXPERIMENTAL|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
62648883|NCT01217996|OTHER|Intervention Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (intervention).
62648884|NCT01217996|OTHER|Control Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (control).
62648885|NCT02904746|EXPERIMENTAL|Intervention|Participants receiving the Make It! intervention
62648886|NCT02904746|NO_INTERVENTION|Control|Care as usual
62081435|NCT04431011||Participants|Healthy right-handed participants aged 18-50
62458138|NCT05939180|EXPERIMENTAL|VA regimen|VA regimen: azacytidine and venetoclax
62458139|NCT05939180|ACTIVE_COMPARATOR|DA regimen|DA regimen: daunorubicin and cytarabine
62648887|NCT05808985|EXPERIMENTAL|Butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭ per day)
62648888|NCT06367543||Patients with stroke admitted to an NICU|Patients with neurovascular disease necessitating NICU-treatment. Neurovascular disease includes all stroke subcategorized into ischemic stroke and hemorrhagic stroke (i.e. subarachnoid hemorrhage and intracerebral hemorrhage)
62648889|NCT03236454|ACTIVE_COMPARATOR|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
62648890|NCT03236454|SHAM_COMPARATOR|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
62280641|NCT00621504|ACTIVE_COMPARATOR|IV Ceftriaxone|"Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
62458140|NCT05282485|EXPERIMENTAL|Synbiotic Group|A synbiotic combining 2'-Fucosyllactose (2'-FL) human milk oligosaccharides (HMO) with B.infantis (probiotic) will be administered to infants from 4 to 24 weeks of age.
62458141|NCT05282485|PLACEBO_COMPARATOR|Placebo Group|Maltodextrin will be administered to infants from 4 to 24 weeks of age.
62458142|NCT01362725|EXPERIMENTAL|Spinal cord stimulation|
62458143|NCT03535207|EXPERIMENTAL|high dose chemoradiotherapy|all eligible patients receive intensity-modulated radiotherapy 50 Gy in 25 fractions over 5 weeks and concurrent paclitaxel and cisplatin once weekly for 5 weeks，followed by hyperfractionated intensity-modulated radiotherapy boost to gross tumor volume concurrent with the same chemotherapy
62081436|NCT04170634||Patients with bone metastases at risk of fracture|Adult patients with tumor osteolytic bone lesions located in proximal femur and/or vertebrae secondary to a myeloma or a breast, lung (NSCL: Non-Small Cell Lung), bladder, thyroid or kidney cancer. The target vertebrae or femur has to be naïve of localized treatment (interventional radiology - cementoplasty, cryotherapy, radiofrequency...). Previous exposure to systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy...) and bone treatments are allowed if administered for less than 3 months.
62280642|NCT01950832||polycystic ovary syndrome (PCOS) group|Patients who were diagnosed as PCOS according to 2003 Rotterdam Criteria.
62081437|NCT06739837|EXPERIMENTAL|Interventional group I|
62458144|NCT03252964|EXPERIMENTAL|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
62458145|NCT01648166||lung cancer cases|subjects with lung cancer who are greater than 17 years of age and live in Appalachian Kentucky
62458146|NCT01648166||control subjects|subjects without lung cancer, greater than 17 who reside in Appalachian Kentucky
62458147|NCT01479400||infants who were exposed to antipsychotics as fetus|
62458148|NCT01479400||infants who were not exposed to antipsychotics as fetus|
62458149|NCT03528200|OTHER|Dyna Embo|Contrast dye injected through the IV in their arm which helps to see the blood in the arteries using x-ray pictures
62458150|NCT01173042|PLACEBO_COMPARATOR|Control|Shake containing heavy whipping cream, glucose and chocolate syrup
62081438|NCT06739837|ACTIVE_COMPARATOR|Interventional group II|
62458151|NCT01173042|EXPERIMENTAL|Peanut|Shake containing control (whipping cream, glucose and chocolate syrup) + 3oz of peanuts
62081439|NCT04997148||Cladribine|No intervention was administered as a part of this study. Participants with Highly-active Disease Relapsing-remitting Multiple Sclerosis (HDA-RRMS), who completed at least Year 1 of treatment with cladribine tablets in routine clinical practice were enrolled into this study and assessed up to maximum 5 years after cladribine tablets initiation.
62081440|NCT06287463|EXPERIMENTAL|DCC-3084 Module A Escalation Phase (ModA Part 1)|Participants will receive DCC-3084 in ModA Part 1, Escalation Phase.
62280643|NCT01950832||Control|60 healthy volunteers
62280644|NCT00760357||Retrospective Anaylsis|Once the patients are identified that have a full thickness wound on a limb clearly identified as having critical limb ischemia, these patients will be evaluated
62458152|NCT01173042|EXPERIMENTAL|Oil blend|Shake containing control (heavy whipping cream, glucose and chocolate syrup) + oil blend (equivalent to fatty acids provided in 3oz peanuts)
62280645|NCT06113874|EXPERIMENTAL|Composite with Hurriseal desensitizer|
62458153|NCT02075437|EXPERIMENTAL|Functional Abdominal Pain (FAP)|To access (FAP) subjects will participate in: 10 therapy sessions; and the following treatments: 1) identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis: 2) adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children; and 3) incorporate caregivers as role models and facilitators based on attachment research.
62458154|NCT02031978||WIC Program Participants|The cohort is made up of infants. Pregnant women enrolling in WIC for the first time for that pregnancy and mothers/caregivers of infants younger than 2.5 months of age enrolling in WIC for the first time are recruited to participate.
62648891|NCT06007976|EXPERIMENTAL|2 treatment|Subjects will receive 2 low-level laser therapy treatments of 20 minutes for low back pain.
62648892|NCT06007976|EXPERIMENTAL|4 treatment|Subjects will receive 4 low-level laser therapy treatments of 20 minutes over 2 weeks for low back pain.
62648893|NCT06007976|EXPERIMENTAL|6 treatment|Subjects will receive 6 low-level laser therapy treatments of 20 minutes over 3 weeks for low back pain.
62648894|NCT06007976|EXPERIMENTAL|8 treatment|Subjects will receive 8 low-level laser therapy treatments of 20 minutes over 4 weeks for low back pain.
62280646|NCT06113874|ACTIVE_COMPARATOR|Composite with Gluma Desensitizer|
62280647|NCT06113874|NO_INTERVENTION|Composite without desensitizer|
62648895|NCT04376281|EXPERIMENTAL|Noradrenaline group|
62648896|NCT00971113|EXPERIMENTAL|sc-FOS+Sideritis euboea group|Jelly supplemented with short chain fructooligosaccharides and Sideritis euboea extract
62458155|NCT02548637|EXPERIMENTAL|Acupuncture Therapy|Based on the Traditional Chinese Medicine theory, investigators will use the systemic treatment methods (full body treatment with the joint specifications). Every patient will receive the standard protocols of these points uniformly regardless of their symptoms. The only variable will be the location of placement of the four electrodes (two positive charges and two negative charges) to the needle points at the most painful joints bilaterally. Needles will be in place a total of 45 minutes per session. The Thermal Design Power (TDP) infrared heat lamp will be applied concurrently to the most painful joint(s) for the entire 45 minutes. Acupuncture will be administered twice a week for 6 weeks, then once a week for an additional 4 weeks.
62648897|NCT00971113|PLACEBO_COMPARATOR|placebo group|Jelly without short-chain fructooligosaccharides and Sideritis euboea
62648898|NCT05285839|EXPERIMENTAL|Dupixent and Narrowband UVB|Dupixent and Narrowband UVB
62458156|NCT05582460||PJI|Patients diagnosed with a PJI based on the EBJIS criteria ('Infection confirmed')
62458157|NCT05582460||No PJI|Patients not diagnosed with a PJI based on EBJIS criteria
62648899|NCT01905696|EXPERIMENTAL|N-Acetylcysteine (NAC)|After initial measurements of SNO-Hb level, forearm blood flow in response to exercise and hypoxia, subjects will take oral NAC 600 mg twice daily. Measurements will then be repeated.
62648900|NCT03415516|EXPERIMENTAL|Gluma Universal, self-etch mode (GSE)|
62648901|NCT03415516|EXPERIMENTAL|Gluma Universal, selective etching (GSL)|
62648902|NCT03415516|EXPERIMENTAL|Gluma Universal, etch&rinse (GER)|
62458158|NCT02780336||Blepharospasm (BL)|Participants in this group should be diagnosed with blepharospasm, but may have dystonia in other body parts as well.
62458159|NCT02780336||Disease Control Group|Participants in this group should be diagnosed with a disorder affecting their eyes or face, such as hemifacial spasm, facial tics, or apraxia.
62458160|NCT02780336||Normal Control Group|Participants in this group should not have any neurologic problems or other disorders affecting patients eyes or face.
62648903|NCT03415516|EXPERIMENTAL|All Bond Universal, self-etch (ASE)|
62648904|NCT03415516|EXPERIMENTAL|All Bond Universal, selective etching (ASL)|
62648905|NCT03415516|EXPERIMENTAL|All Bond Universal, etch&rinse (AER)|
62458161|NCT00323193|EXPERIMENTAL|Arm 1|The intervention group completes approximately 8 individual level sessions with a MOVE specialist as well as approximately 8 group level intervention sessions.
62648906|NCT03415516|EXPERIMENTAL|Single Bond2, etch&rinse (SBU)|
62648907|NCT04710732|ACTIVE_COMPARATOR|Control|Peri-operative VTE prophylaxis with a standard once-daily dose of enoxaparin 40 mg and anti-embolic stockings
62648908|NCT04710732|EXPERIMENTAL|Experimental|Peri-operative VTE prophylaxis with an escalated twice-daily dose of enoxaparin 30 mg and anti-embolic stockings
62648909|NCT01218308|EXPERIMENTAL|FluLaval® Quadrivalent Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of FluLaval® Quadrivalent vaccine at Day 0 and, if unprimed, 2 doses of FluLaval® Quadrivalent vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
62648910|NCT01218308|ACTIVE_COMPARATOR|Havrix Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of Havrix™ vaccine at Day 0 and, if unprimed, 2 doses of Havrix™ vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
62648911|NCT00381212|EXPERIMENTAL|1|AGS-004 immunotherapeutic injections.
62648912|NCT03288038|EXPERIMENTAL|RSV5mg + EZE 10mg|Rosuvastatin 5mg/Ezetimibe 10mg
62648913|NCT03288038|ACTIVE_COMPARATOR|RSV5mg|Rosuvastatin 5mg
62648914|NCT03288038|EXPERIMENTAL|RSV10mg + EZE10mg|Rosuvastatin 10mg/ Ezetimibe 10mg
62648915|NCT03288038|ACTIVE_COMPARATOR|RSV10mg|Rosuvastatin 10mg
62648916|NCT03288038|EXPERIMENTAL|RSV20mg + EZE10mg|Rosuvastatin 20mg/Ezetimibe 10mg
62648917|NCT03288038|ACTIVE_COMPARATOR|RSV20mg|Rosuvastatin 20mg
62648918|NCT04538508|EXPERIMENTAL|Diathermy|Participants that receive 10 sessions of radiofrequency diathermy of 12 minutes of duration
62280648|NCT01710488|ACTIVE_COMPARATOR|Levofloxacin 1 tablet 500 mg once a day|Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
62280649|NCT01710488|EXPERIMENTAL|Prulifloxacin 1 tablet 600 mg once a day|Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
62458162|NCT00323193|NO_INTERVENTION|Arm 2|The control group offers basic information about diet and exercise every month for six months.
62458163|NCT01144936|EXPERIMENTAL|Panel 1: VX-985 Dose 1|
62280650|NCT04438447|EXPERIMENTAL|ERAS plus artificial nutrition|"Patients randomised in the treatment arm will be treated with a full ERAS protocol that establishes oral food at will plus parenteral nutrition (PN) from postoperative day 1. A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation. In case of the occurrence of any complication impairing the full or partial recovery of oral food, the treatment will be continued until clinically indicated"
62458164|NCT01144936|EXPERIMENTAL|Panel 2: VX-985 Dose 2|
62458165|NCT01144936|EXPERIMENTAL|Panel 3: VX-985 Dose 3|
62081441|NCT06287463|EXPERIMENTAL|DCC-3084 Module A Expansion Phase (ModA Part 2)|Participants will receive DCC-3084 in ModA Part 2, Expansion Phase.
62081442|NCT06558253|EXPERIMENTAL|Coenzyme I for Injection|Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection with three dose groups.
62081443|NCT05104775|EXPERIMENTAL|study treatment|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
62081444|NCT02523040|EXPERIMENTAL|Lenalidomide|"After the screening procedures confirm participation in the research study.~- Lenalidomide Oral, Daily for 21 days of each cycle"
62081445|NCT04581824|EXPERIMENTAL|Participants receiving dostarlimab plus chemotherapy|Participants will receive dostarlimab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
62081446|NCT04581824|ACTIVE_COMPARATOR|Participants receiving pembrolizumab plus chemotherapy|Participants will receive pembrolizumab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
62458166|NCT04845165||Patients with FPL2 genetically confirmed|patients suffering with FPL2 with the R482 codon mutation of the LMNA gene.
62648919|NCT04538508|ACTIVE_COMPARATOR|Control|Participants that perform supervised exercises for three weeks
62648920|NCT03273062|ACTIVE_COMPARATOR|Study Period 1|"15 days of Tolcapone 200mg TID~OR~Placebo Comparator 15 days of Placebo pill TID"
62648921|NCT03273062|PLACEBO_COMPARATOR|Study Period 2|"15 days of Placebo pill TID~OR~Active Comparator 15 days of Tolcapone 200mg TID"
62648922|NCT02701634|EXPERIMENTAL|ENTO|ENTO 400 mg or 200 mg tablet twice daily for 48 weeks
62648923|NCT02701634|PLACEBO_COMPARATOR|Placebo|Placebo to match tablet twice daily for 48 weeks
62648924|NCT03543163|ACTIVE_COMPARATOR|subepithelial connective tissue graft|Subepithelial Connective Tissue graft from the hard palate with Coronally Advanced flap at the site of gingival recession.
62648925|NCT03543163|EXPERIMENTAL|non pedicled buccal fat pad graft|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap at the site of gingival recession
62081447|NCT02315612|EXPERIMENTAL|Arm 1|dose escalation of CD22-CAR
62081448|NCT02315612|EXPERIMENTAL|Arm 2|dose expansion of CD22-CAR
62081449|NCT04969835|EXPERIMENTAL|AVA6000 Phase 1a Dose Escalation Q3W|Patients in this arm will receive escalating doses of AVA6000 following a 3+3 design, Q3W until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
62458167|NCT04813263||Participants Treated With Venetoclax|Participants who are administrated venetoclax for treatment of AML under routine clinical practice.
62458168|NCT01139164|EXPERIMENTAL|Single Arm, non-randomized study|
62458169|NCT05319990||PANDA, T1D|New participants with T1D will be enrolled at the University of Colorado and University of Washington.
62458170|NCT05319990||PANDA Sub Study, Former CROCODILE Participants|Participants will be enrolled from the existing CROCODILE study (COMIRB # 19-1282), adding longitudinal follow-up to completed kidney biopsies and baseline data and biosample acquisition.
62458171|NCT05020548|ACTIVE_COMPARATOR|pressure 10|mask ventilation with peak inspiratory pressure of 10 cmH2O
62458172|NCT05020548|ACTIVE_COMPARATOR|pressure 15|mask ventilation with peak inspiratory pressure of 15 cmH2O
62458173|NCT05020548|ACTIVE_COMPARATOR|pressure 20|mask ventilation with peak inspiratory pressure of 20 cmH2O
62648926|NCT06359899|EXPERIMENTAL|AK0901 cohort|13.1 mg/2.6 mg AK0901, 26.1 mg/5.2 mg AK0901, 39.2 mg/7.8 mg AK0901
62648927|NCT06359899|PLACEBO_COMPARATOR|Placebo cohort|Matching placebo
62648928|NCT04228224|EXPERIMENTAL|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 2 sessions per week for 12 weeks, each lasting about 1 hour.
62648929|NCT04228224|ACTIVE_COMPARATOR|Conventional Gait Rehabilitation|Participants in this group will perform conventional gait rehabilitation on a rehabilitation institution with assistance of a physical therapist. Training involve 24 sessions, 2 sessions per week, each session lasting about 1 hour.
62648930|NCT02415972||All study participants|Patients with Stroke
62081450|NCT04969835|EXPERIMENTAL|AVA6000 Phase 1a Dose Escalation Q2W|Patients in this arm will receive escalating doses of AVA6000 following a 3+3 design, Q2W until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
62081451|NCT04969835|EXPERIMENTAL|AVA6000 Phase 1b Dose Expansion|Patients in this arm will receive AVA6000 at the recommended dose for expansion, until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
62081452|NCT06408298|EXPERIMENTAL|Hydroxychloroquine|Loading dose 400mg three times a day then 400mg twice daily for up to 28 days prior to surgical resection, taken orally
62081453|NCT06408298|PLACEBO_COMPARATOR|Placebo|Loading dose three times a day then twice daily for up to 28 days prior to surgical resection, taken orally
62280651|NCT04438447|ACTIVE_COMPARATOR|Enhanced recovery protocol|"Patients randomised in the control arm will be treated with a full ERAS protocol that establishes oral food at will. In case of the occurrence of any complication impairing the full recovery of oral food within postoperative day 7, patients will receive parenteral nutrition as in the treated arm until clinically indicated"
62280652|NCT03396016||Factor V|liver transplant patients having Factor V levels measured during their first postoperative week.
62280653|NCT00598299||A|Healthy adult serum
62280654|NCT00598299||B|cord blood serum
62458174|NCT04647604|ACTIVE_COMPARATOR|Omega|Omegaven® (2 mL/kg/day, equivalent to 6 g Docosahexaenoic Acid (DHA)+Eicosapentaenoic Acid (EPA) in a 70 kg individual) once daily for 5 days
62458175|NCT04647604|PLACEBO_COMPARATOR|Sodium chloride (NaCl)|2 mL/kg/day) once daily for 5 days
62458176|NCT03174119|ACTIVE_COMPARATOR|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
62648931|NCT04341090|EXPERIMENTAL|Arm 1|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after low-fat meal, the third dose will be after high-fat meal
62648932|NCT04341090|EXPERIMENTAL|Arm 2|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after fasted, the third dose will be after low-fat meal
62081454|NCT04594005|EXPERIMENTAL|abemaciclib+paclitaxel|
62280655|NCT06446557|EXPERIMENTAL|Arm A|After 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3
62280656|NCT06446557|ACTIVE_COMPARATOR|Arm B|At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
62280657|NCT06550154||OLP patients|60 subjects with oral lichen planus
62280658|NCT06550154||Control group|60 subjects without oral lichen planus. Each control subject was matched by age and sex to its corresponding paired OLP subject
62280659|NCT01639872|EXPERIMENTAL|Clozapine|The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.
62280660|NCT01639872|ACTIVE_COMPARATOR|Risperidone|The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.
62280661|NCT02483741|EXPERIMENTAL|Manuka Honey|Manuka Honey will be placed in the sockets of the extracted third molars in this group
62280662|NCT02483741|NO_INTERVENTION|Traditional Extraction|No any special material will be placed in the sockets of the extracted third molars in this group
62081455|NCT06461013|NO_INTERVENTION|routine rehabilitation|Bridge exercise: Before conducting specific tests, participants should familiarize themselves with the relevant test actions and procedures. The key points of bridge exercise are: the subject is placed in a supine position, with both hands crossed in the center of the abdomen, the knee joint flexed, both feet flat on the bed surface, and the buttocks lifted off the bed surface with force. The patient is instructed to do bridge exercise as much as possible until the knee joint, hip joint, and neck are on the same line, which is considered qualified for bridge exercise;
62648933|NCT04341090|EXPERIMENTAL|Arm 3|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after high-fat meal, the third dose will be after fasted
62648934|NCT04341090|EXPERIMENTAL|Arm 4|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after high-fat meal, the third dose will be after low-fat meal
62280663|NCT02639663|EXPERIMENTAL|women whom are interested in breastfeeding and have not begun.|"Post-partum primi and multiparous women Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~2. Control group: participants will not receive any device for breastfeeding pain control"
62081456|NCT06461013|EXPERIMENTAL|routine rehabilitation+blood flow restriction training|Bridge exercise: Before conducting specific tests, participants should familiarize themselves with the relevant test actions and procedures. The key points of bridge exercise are: the subject is placed in a supine position, with both hands crossed in the center of the abdomen, the knee joint flexed, both feet flat on the bed surface, and the buttocks lifted off the bed surface with force. The patient is instructed to do bridge exercise as much as possible until the knee joint, hip joint, and neck are on the same line, which is considered qualified for bridge exercise;
62081457|NCT04200391|EXPERIMENTAL|Very low carbohydrate diet|Dietary Intervention, food delivery
62081458|NCT03487822|EXPERIMENTAL|Path Pain|Path Pain participants will be receiving 8 weekly therapy session by license clinicians trained in the Path Pain intervention. Participants will also receive 4, 15-minute phone booster sessions, on a monthly basis after their final therapy session. Participants will also be invited to monthly group educational sessions. Both intervention and usual care participants will be receiving a pain educational booklet.
62280664|NCT02639663|EXPERIMENTAL|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
62280665|NCT05914701|EXPERIMENTAL|treatment arm|
62280666|NCT03654846|NO_INTERVENTION|Conventional emergency call|"Emergency call with conventinal cell phone:~* verbal description of location~* telephone-assisted CPR"
62280667|NCT03654846|EXPERIMENTAL|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:~* automated geolocalisation~* video-assisted CPR"
62280668|NCT02631200|EXPERIMENTAL|Advance care plan|Participants will be offered the opportunity to complete an advance care plan.
62280669|NCT02631200|NO_INTERVENTION|Usual care|Participants will be offered usual care for 12 weeks (and only then be offered the opportunity to complete an advance care plan).
62280670|NCT06541405|EXPERIMENTAL|Group A(low-dose group)|NK520: 5x10\^7 NK/kg
62280671|NCT06541405|EXPERIMENTAL|Group B(medium-dose group)|NK520: 1.5×10\^8NK/kg
62280672|NCT06541405|EXPERIMENTAL|Group C(high-dose group)|NK520: 3×10\^8NK/kg
62280673|NCT01243905|ACTIVE_COMPARATOR|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the child (TAU)
62280674|NCT01243905|PLACEBO_COMPARATOR|Treatment as usual|Treatment as usual for the child (TAU)
62280675|NCT00864266|EXPERIMENTAL|1|After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website www.elcwp.org)
62280676|NCT06182735|EXPERIMENTAL|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|"Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC729 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2; Dose level 3: 4.5×107 CAR- NKT cells/m2."
62648935|NCT04341090|EXPERIMENTAL|Arm 5|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after fasted, the third dose will be after high-fat meal
62648936|NCT04341090|EXPERIMENTAL|Arm 6|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after low-fat meal, the third dose will be after fasted
62648937|NCT00320047|EXPERIMENTAL|1|Participants will take baclofen for 10 weeks.
62280677|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
62648938|NCT01491516|EXPERIMENTAL|Investigational|
62081459|NCT03487822|NO_INTERVENTION|Usual Care with Education|Usual Care with Education (UCE) will receive a pain educational booklet. Following completion of 24 weeks in the study, participants will also be invited to attend the monthly group educational sessions.
62081460|NCT03487822|NO_INTERVENTION|Provider Feedback|Providers of patients in the study will take part in a short interview on their impressions of the intervention.
62280678|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
62280679|NCT03460431|EXPERIMENTAL|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm one session every month for 4 months
62458177|NCT03174119|PLACEBO_COMPARATOR|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
62458178|NCT06141070|ACTIVE_COMPARATOR|A, standard systemic therapy|Standard systemic chemoimmunotherapy
62458179|NCT06141070|EXPERIMENTAL|B, Radiotherapy + systemic therapy|Standard systemic chemoimmunotherapy and radiation to all known lesions
62458180|NCT05877170|EXPERIMENTAL|PEA|PEA-containing nutraceutical agent in oral formulation
62458181|NCT05877170|PLACEBO_COMPARATOR|Placebo|Patients treated with a placebo
62280680|NCT03460431|EXPERIMENTAL|Nd YAG laser 1064nm|Nd YAG laser 1064nm
62280681|NCT03460431|EXPERIMENTAL|combined two laser types|combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid
62280682|NCT06037668|EXPERIMENTAL|BVR-100|Experimental at-home VR intervention for the treatment of SAD
62280683|NCT06037668|ACTIVE_COMPARATOR|BES-100|Active at-home VR intervention comparator
62458182|NCT02041169|EXPERIMENTAL|Subsequent walking performance|Subsequent walking performance
62458183|NCT01790568|EXPERIMENTAL|Vorinostat|Vorinostat, in combination with standard of care medications tacrolimus and methotrexate, for GVHD prophylaxis after unrelated donor stem cell transplant.
62458184|NCT02572921|EXPERIMENTAL|Positive Psychotherapy|Experimental Group (Positive Psychotherapy)
62458185|NCT02572921|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Active Control Group (Cognitive Behavioral Therapy)
62081461|NCT06539741||Complete Responders|Patients who do not require supplemental opioids, in addition to ibuprofen 400 mg + acetaminophen 500 mg every 4 hours, for pain relief following third molar extraction
62081462|NCT06539741||Partial Responders|Patients who require supplemental opioids (oxycodone 5 mg), in addition to ibuprofen 400 mg + acetaminophen 500 mg every 4 hours, for pain relief following third molar extraction
62280684|NCT02714114||Cases: HPV vaccinated group|"Women (18-26 years old) whom are previously vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
62280685|NCT02714114||Controls: HPV unvaccinated group|"Women (18-26 years old) whom are not vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
62280686|NCT02328898|EXPERIMENTAL|Cre8 stent|PCI with the Polymer Free Amphilimus Eluting Stent 'Cre8™'
62280687|NCT02328898|ACTIVE_COMPARATOR|Resolute Integrity Stent|Comparison of the Cre8 stent with the Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™'
62280688|NCT02662647|EXPERIMENTAL|DCAG plus HLI|Patient will be treated with decitabine and modified CAG regimen followed by HLA haploidentical peripheral mononuclear blood cells infusion.
62280689|NCT02662647|EXPERIMENTAL|DCAG|Patient will be treated with decitabine combining modified CAG regimen without other treatments.
62280690|NCT06547970|PLACEBO_COMPARATOR|Control (no education)|a group of DM patients we will record their HbA1C , FBG \& their QOL by filling the questionnaire (will be filled by the researcher herself then after 3 months we are going to record the same variables
62458186|NCT05575414|EXPERIMENTAL|Didactic Sessions|Women will receive online nutrition education by a registered dietitian, in addition to the same standard patient education tool as the other arm.
62458187|NCT05575414|EXPERIMENTAL|Education Tool|Women will receive a standard patient education tool in the form of a leaflet.
62458188|NCT05618470|EXPERIMENTAL|Wumeiwan Jiawei Fang|This group will take Wumei pill granule orally.
62458189|NCT05618470|ACTIVE_COMPARATOR|botulinum toxin A|In this group, Botulinum toxin type A (Lanzhou Biopharmaceutical Co. LTD.) was injected locally around the eye.
62458190|NCT01622998|ACTIVE_COMPARATOR|Standard transdermal NRT group (UC)|10 week standard transdermal nicotine replacement therapy patch protocol
62280691|NCT06547970|ACTIVE_COMPARATOR|Patient education|a group of DM patients we will record their HbA1C , FBG \& their QOL, medication adherence , insulin taking technique form ( the questionnaire \& form will be filled by the researcher herself) then an educational session will last about 30 min. will be given to each patient face to face at the last the recearcherr and the patients will share their phone numbers for following up then after 3 months all the variables will be recorded again
62280692|NCT06201507|EXPERIMENTAL|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
62280693|NCT06201507|EXPERIMENTAL|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
62280694|NCT00876993|EXPERIMENTAL|Dose Level 0|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m\^2 IV Temozolomide 75 mg/m\^2 PO
62280695|NCT00876993|EXPERIMENTAL|Dose Level 1|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m\^2 IV Temozolomide 125 mg/m\^2 PO
62280696|NCT00876993|EXPERIMENTAL|Dose Level 2|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m\^2 IV Temozolomide 175 mg/m\^2 PO
62280697|NCT00876993|EXPERIMENTAL|Dose Level 3|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m\^2 IV Temozolomide 200 mg/m\^2 PO
62081463|NCT05443347|EXPERIMENTAL|Structured exercise|Adolescents randomized to the exercise will participate in a supervised structured exercise program (walking on a treadmill, cycling on a stationary bicycle, etc.) and expend an equivalent of 400 kcals/session (approximately 45-60 min/session) on three days/week. We will follow the protocol of Mentor Dr. Joseph Donnelly, with exercise prescriptions progressing from 150 kcal/session at intervention onset to reach the target exercise energy expenditure (EEEx) (400 kcal/session) at the end of month 3. EEEx will be assessed at baseline and monthly during the intervention to determine the duration of treadmill exercise required to achieve the EEEx goals. All supervised exercise will occur at the CCHLN on a treadmill with heart rate, speed, and grade monitored by an exercise specialist every five minutes.
62081464|NCT05443347|ACTIVE_COMPARATOR|Newsletter control|"Adolescents randomized to the newsletter control will receive with biweekly newsletters with parenting tips, sample praise statements, and age-appropriate activities and recipes identical to what has been used by others (Epstein et al., 2008), including existing group-based interventions with overweight/obese adolescents."
62081465|NCT06610032|ACTIVE_COMPARATOR|Mesotherapy|A total of 3 sessions of mesotherapy will be applied to the shoulder area, 7 days apart.
62280698|NCT00876993|EXPERIMENTAL|Dose Level 4|Bevacizmuab 10 mg/kg IV Irinotecan 150 mg/m\^2 IV Temozolomide 200 mg/m\^2 PO
62280699|NCT01500356|EXPERIMENTAL|Diet alone|Weight loss intervention that focuses only on reducing energy intake of the diet.
62280700|NCT01500356|EXPERIMENTAL|Diet plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
62280701|NCT01500356|EXPERIMENTAL|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
62280702|NCT03558347|EXPERIMENTAL|short implants with splinted crowns|Patients of that group received splinted crowns on the two adjacent implants Intervention: short implants with splinted crowns
62081466|NCT06610032|ACTIVE_COMPARATOR|Steroid|A single-session intra-articular 20 mg triamcinolone hexacetonide injection will be administered.
62081467|NCT05250804|EXPERIMENTAL|Experimental|All registered participants in the intervention group, will receive the intramuscular injection with Helfer Skin Tap Technique.
62081468|NCT05250804|NO_INTERVENTION|No intervention|All registered participants in the intervention group, will receive the intramuscular injection with Routine Technique. Routine Technique involved inserting the injection intra muscularly at 90 degree angle into Dorso gluteal muscles without tapping after cleaning with alcohol swab.
62081469|NCT02675491|EXPERIMENTAL|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
62081470|NCT04493034|EXPERIMENTAL|Art Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
62280703|NCT03558347|EXPERIMENTAL|short implants with non-splinted crowns|Patients of that group received single crowns on the two adjacent implants Intervention: short implants with non-splinted crowns
62280704|NCT05558150|EXPERIMENTAL|ilaprazole & aceclofenac 1|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
62280705|NCT05558150|EXPERIMENTAL|ilaprazole & aceclofenac 2|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days~Period 3 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day"
62458191|NCT01622998|EXPERIMENTAL|Titrated transdermal NRT group (EXP)|10 week titrated transdermal nicotine replacement therapy patch dose regimen based on smoking history with the option to increase dose, if withdrawal symptoms are unmanageable.
62458192|NCT01743378|EXPERIMENTAL|TAP Block Ropivacaine 0,75 %|Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 %
62458193|NCT01743378|PLACEBO_COMPARATOR|TAP Block Saline 0,9 %|Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 %
62081471|NCT04493034|EXPERIMENTAL|Music Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
62081472|NCT04493034|NO_INTERVENTION|Standard Of Care|A list of support services is provided. No requirement to attend sessions and no home assignments
62081473|NCT06734819|ACTIVE_COMPARATOR|Control|Standard of care patient education materials
62081474|NCT06734819|EXPERIMENTAL|Experimental|2 storytelling videos in addition to standard of care patient education materials
62081475|NCT04909034|EXPERIMENTAL|MS-20 oral solution|Oral Solution 4 c.c, divided twice daily (BID) for 48 weeks.
62081476|NCT04909034|PLACEBO_COMPARATOR|Placebo|Oral Solution 4 c.c, divided twice daily (BID) for 48 weeks.
62081477|NCT06072807|EXPERIMENTAL|ER Positive Breast Cancer Patients with Brain Metastases|A diagnostic intervention where this group will undergo an additional 18F- FES PET/CT scan in addition to their standard of care MRI and FDG PET/CT scan.
62081478|NCT06735079|EXPERIMENTAL|REL 1017-305|
62081479|NCT06735079|PLACEBO_COMPARATOR|Placebo|
62081480|NCT06529094|OTHER|Preparation to implement the CAPP-FIT per site|Complete clinic workflow designs and redesigns to integrate CAPP-FIT into clinic workflow per site. Recruit and train providers in use of the CAPP-FIT through TMS training, demonstration, and simulation with a standardized patient.
62081481|NCT06529094|ACTIVE_COMPARATOR|Implement CAPP-FIT with RA facilitation|Veteran completes Veteran Survey and Provider uses Provider report around an established clinic visit per site
62081482|NCT06529094|OTHER|Implement CAPP-FIT without RA facilitation|Each site will determine how they will integrate use of the CAPP-FIT in clinic workflow.
62458194|NCT00662753|ACTIVE_COMPARATOR|home monitoring|home blood pressure monitor
62458195|NCT00662753|EXPERIMENTAL|monitor & phone call|home blood pressure monitor + phone calls
62458196|NCT02005536|EXPERIMENTAL|Study Group|Participants will receive one booster dose of SP059 (IMOVAX POLIO®)
62458197|NCT03325114|OTHER|Chlorthalidone|Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks
62458198|NCT03980288|EXPERIMENTAL|CAR-GPC3 T Cells|The subjects enrolled will be sequentially assigned to Part 1 at 3 dose levels via typical 3+3 dose escalation method and then Part 2, cohort expansion stage, 3 cohorts of CAR T therapy combination with currently available treatment for HCC. stage Part 1: Dose escalating: 3 dose level Part 2: 3 cohorts Cohort 1. Combination with tyrosine kinase inhibitors Cohort 2. Combination with PD-1 / PD-L1 monoclonal antibody Cohort 3. Combination with the drugs may benefit for patient at investigator's discretion
62081483|NCT06740292|ACTIVE_COMPARATOR|Patients with anterior mandibular fracture managed with conventional miniplates|Patients with anterior mandibular fracture managed with conventional miniplates
62081484|NCT06740292|EXPERIMENTAL|Patients with anterior mandibular fracture managed with InterFlex plates|Patients with anterior mandibular fracture managed with InterFlex plates
62081485|NCT05806346|ACTIVE_COMPARATOR|Empirical 1: TXA and Placebo administration|"Tranexamic acid administration, regardless of the result of rotational thromboelastometry.~Placebo administration, at LI60 \< 85 % or A10\< 40 mm in EXTEM of rotational thromboelastometry"
62081486|NCT05806346|ACTIVE_COMPARATOR|Empirical 2: TXA administration|"Tranexamic acid administration, regardless of the result of rotational thromboelastometry.~Placebo discard, at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry"
62081487|NCT05806346|EXPERIMENTAL|Goal-directed 1: Placebo administration|"Placebo administration, regardless of the result of rotational thromboelastometry.~Tranexamic acid administration at LI60 \< 85 % or A10 \< 40 mm in EXTEM of rotational thromboelastometry"
62081488|NCT05806346|EXPERIMENTAL|Goal-directed 2: TXA and Placebo administration|"Placebo administration, regardless of the result of rotational thromboelastometry.~Tranexamic acid discard at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry"
62081489|NCT05006716|EXPERIMENTAL|Part 1a (Monotherapy Dose Escalation)|Dose escalation in specific subtypes of non-Hodgkin lymphoma (NHL), including relapsed or refractory (R/R) marginal zone lymphoma (MZL), relapsed or refractory (R/R) follicular lymphoma (FL) Grades 1, 2, and 3a, relapsed or refractory (R/R) mantle cell lymphoma (MCL), relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), relapsed or refractory (R/R) Richter's transformation (RT), and relapsed or refractory (R/R) Waldenström macroglobulinemia (WM), to evaluate the safety and tolerability of BGB-16673.
62081490|NCT05006716|EXPERIMENTAL|Part 1b (Monotherapy Safety Expansion)|Participants with R/R MZL, MCL, CLL/SLL, and WM will be enrolled at selected doses to help determine the recommended dose(s) for expansion (RDFE(s)) for BGB-16673.
62081491|NCT05006716|EXPERIMENTAL|Part 1c (Additional Monotherapy Safety Expansion)|Additional safety data will be collected from participants with R/R MZL, WM, RT, DLBCL, or FL to confirm the RDFE(s) of BGB-16673 for those with non-CLL/SLL/MCL histologies.
62081492|NCT05006716|EXPERIMENTAL|Part 1d (Additional Monotherapy Safety Expansion in R/R CLL/SLL)|Participants with R/R CLL/SLL will be enrolled at selected RDFE(s) to generate additional safety and efficacy data for BGB-16673.
62081493|NCT05006716|EXPERIMENTAL|Part 1e (Japan-only Cohort)|Japanese participants with R/R MZL, FL, MCL, CLL/SLL, and WM will be enrolled at selected RDFE(s) to assess the safety and tolerability of BGB-16673.
62081494|NCT05006716|EXPERIMENTAL|Part 1f (Additional Monotherapy Safety Expansion in BTKi Naive B-Cell Malignancies)|Participants with CLL/SLL, MCL, WM, MZL, or Richter's transformation to DLBCL who have not received a prior BTKi (either covalent or noncovalent) will be enrolled at selected dose levels.
62081495|NCT05006716|EXPERIMENTAL|Phase 2 (Monotherapy Expansion)|Cohorts of participants with R/R CLL/SLL, R/R MCL, R/R WM, R/R MZL, R/R FL, R/R RT, and R/R DLBCL will be enrolled to recieve the RDFE(s) identified in Phase 1 to further evaluate the safety and efficacy of BGB-16673.
62081496|NCT01807143||Correlative studies|Tissue samples are analyzed for translocations and deletions and analyzed using PCR or FISH.
62081497|NCT04742205|ACTIVE_COMPARATOR|tranexamic acid|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
62081498|NCT04742205|PLACEBO_COMPARATOR|Sodium Chloride|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
62280706|NCT05558150|EXPERIMENTAL|ilaprazole & aceclofenac 3|"Period 1 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 2 : Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days"
62458199|NCT03974256|NO_INTERVENTION|Group standard method|Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
62458200|NCT03974256|EXPERIMENTAL|Group automated method|Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
62458201|NCT04774432|ACTIVE_COMPARATOR|GM-CSF group|"Patients will be randomly allocated to intervention group with GM-CSF added to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
62081499|NCT05301907||Health Care Professionals (HCPs)|HCPs who prescribe, monitor and oversee the management / or provide in person medical supervision of patients on Mayzent (siponimod).
62081500|NCT05301907||Patients/Caregivers|Patients/Caregivers of patients who are taking Mayzent (siponimod) to treat their MS and according to the prescription of their neurologists across EU countries and Canada that will be included in the launch program
62081501|NCT06630325|EXPERIMENTAL|Arm I (abemaciclib, gemcitabine)|Patients receive abemaciclib PO BID on days 1-21 and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62280707|NCT05558150|EXPERIMENTAL|ilaprazole & aceclofenac 4|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 3 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day"
62280708|NCT05558150|EXPERIMENTAL|ilaprazole & aceclofenac 5|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days"
62081502|NCT06630325|EXPERIMENTAL|Arm II (abemaciclib, pemetrexed)|Patients receive abemaciclib PO BID on days 1-21 and pemetrexed IV over 10 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081503|NCT06630325|EXPERIMENTAL|Arm III (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62648939|NCT02399332|EXPERIMENTAL|Community Pharmacist Involvement|"Patients would have a complex care plan completed by their clinical team, which will involve chronic disease management nurse and the family physician. This complex care plan would also involve discussion with the patient's community pharmacist who would follow-up with the patient monthly and send a report to the patient's physician. Patients would also continue to receive routine care at the clinic.~The monthly follow-ups with the community pharmacist would involve review of the goals of complex care plan and monitoring clinical targets, medication review and discussing adherence as well as patient education. This follow-up can be completed in person or by telephone. The pharmacist would then send a monthly report to patient's family physician."
62081504|NCT06630325|EXPERIMENTAL|Arm IV (abemaciclib, exemestane)|Patients receive abemaciclib PO BID and exemestane PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081505|NCT06630325|EXPERIMENTAL|Arm V (abemaciclib, letrozole)|Patients receive abemaciclib PO BID and letrozole PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081506|NCT06630325|EXPERIMENTAL|Arm VI (abemaciclib, tamoxifen)|Patients receive abemaciclib PO BID and tamoxifen PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081507|NCT06630325|EXPERIMENTAL|Arm VII (gefitinib, pemetrexed, carboplatin)|Patients receive gefitinib PO QD on days 1-21, pemetrexed IV on day 1 of each cycle and carboplatin IV on day 1 of cycles 1-6. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62458202|NCT04774432|ACTIVE_COMPARATOR|Control group|"Patients will be randomly allocated to control group without the addition of GM-CSF to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
62280709|NCT05558150|EXPERIMENTAL|ilaprazole & aceclofenac 6|"Period 1 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
62458203|NCT03201302|EXPERIMENTAL|School physical education class|Children who participated only in their school physical activity classes only for the entire school year.
62458204|NCT03201302|EXPERIMENTAL|Taekwondo|Children who participated in organized Taekwondo training for the entire school year.
62458205|NCT03201302|EXPERIMENTAL|Martial arts|Children who participated in organized Martial arts training for the entire school year.
62458206|NCT03201302|EXPERIMENTAL|Climbing|Children who participated in organized climbing training for the entire school year.
62458207|NCT03201302|EXPERIMENTAL|Volleyball|Children who participated in organized volleyball training for the entire school year.
62081508|NCT06630325|EXPERIMENTAL|Arm VIII (olaparib, temozolomide)|Patients receive olaparib PO BID and temozolomide PO QD on days 1-7 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081509|NCT06630325|EXPERIMENTAL|Arm IX (fulvestrant)|Patients receive fulvestrant IM on days 1, 15 and 29 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081510|NCT06630325|EXPERIMENTAL|Arm X (gefitinib)|Patients receive gefitinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081511|NCT06630325|EXPERIMENTAL|Arm XI (olaparib)|Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62458208|NCT03201302|EXPERIMENTAL|Artistic gymnastics|Children who participated in organized artistic gymnastics training for the entire school year.
62458209|NCT03201302|EXPERIMENTAL|Swimming|Children who participated in organized swimming training for the entire school year.
62458210|NCT03201302|EXPERIMENTAL|Dance|Children who participated in organized dance training for the entire school year.
62458211|NCT03201302|EXPERIMENTAL|Basketball|Children who participated in organized basketball training for the entire school year.
62458212|NCT03201302|EXPERIMENTAL|Wrestling|Children who participated in organized wrestling training for the entire school year.
62458213|NCT03201302|EXPERIMENTAL|Football (soccer)|Children who participated in organized football (soccer) training for the entire school year.
62648940|NCT02399332|NO_INTERVENTION|Usual care|Patients have a complex care plan completed by their clinical team, which will involve the chronic disease management nurse and the family physician and then receive routine care and follow up. They will receive usual care from their community pharmacist.
62458214|NCT03201302|EXPERIMENTAL|Rhythmic gymnastics|Children who participated in organized rhythmic gymnastics training for the entire school year.
62458215|NCT03201302|EXPERIMENTAL|Track and field|Children who participated in organized track and field training for the entire school year.
62458216|NCT03201302|EXPERIMENTAL|Tennis|Children who participated in organized tennis training for the entire school year.
62458217|NCT03201302|EXPERIMENTAL|Combination of activities 1|Children who participated in two different weight-bearing activities for the entire school year.
62458218|NCT03201302|EXPERIMENTAL|Combination of activities 2|Children who participated in one weight-bearing and in one non weight-bearing activity for the entire school year.
62458219|NCT06315426|EXPERIMENTAL|Interleukin-4 receptor responder 1|
62458220|NCT06315426|EXPERIMENTAL|Interleukin-4 receptor responder 2|
62458221|NCT06315426|PLACEBO_COMPARATOR|Placebo|
62458222|NCT00431691|ACTIVE_COMPARATOR|1|
62458223|NCT00431691|PLACEBO_COMPARATOR|2|
62458224|NCT04631770|EXPERIMENTAL|Mediastinal lymph node dissection group|A
62081512|NCT06630325|EXPERIMENTAL|Arm XII (olaparib, carboplatin, paclitaxel)|Patients receive olaparib PO BID on days 1-3, 8-10, 15-17, 21-23 and carboplatin IV and paclitaxel IV on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study. Patients also undergo tumor biopsy on study, as clinically indicated, and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62081513|NCT06630325|EXPERIMENTAL|Arm XIII (olaparib, liposomal doxorubicin)|Patients receive olaparib PO BID on days 1-28 and liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography or MUGA scan and blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62458225|NCT04631770|ACTIVE_COMPARATOR|Spared mediastinal lymph node dissection group|B
62458226|NCT05893264||Epidural placement|All patients undergoing epidural placement will be enrolled.
62458227|NCT03955536|ACTIVE_COMPARATOR|Group A|Routine cardiac rehabilitation program (RCRP)atient education
62458228|NCT03955536|EXPERIMENTAL|Group B|routine cardiac rehabilitation program + virtual reality
62458229|NCT03955536|EXPERIMENTAL|Group C|RCRP + inspiratory muscle training
62458230|NCT02812849||Suspected cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
62458231|NCT02812849||Known cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
62458232|NCT02812849||Other inflammatory cardiac disease|Cu-64 DOTATATE PET/CT or PET/MRI
62458233|NCT04466085|EXPERIMENTAL|Population I|In population I, there were 150 subjects who injected with 2 doses of low-dose test vaccine into the deltoid muscle of the upper arm according to the 0 and 1 month immunization schedule.
62458234|NCT04466085|EXPERIMENTAL|Population II|In population II, there were 150 subjects who injected with 2 doses of high-dose test vaccine in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
62458235|NCT04466085|PLACEBO_COMPARATOR|Population Ⅲ|In population Ⅲ, there were 150 subjects who injected with 2 doses of placebo in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
62458236|NCT04466085|EXPERIMENTAL|Population Ⅳ|In population Ⅳ, there were 150 subjects who injected with 3 doses of low-dose test vaccine in the upper arm deltoid muscle according to the 0, 1, and 2 month immunization schedule.
62458237|NCT04466085|EXPERIMENTAL|Population Ⅴ|In population Ⅴ, there were 150 subjects who injected with 3 doses of high-dose test vaccine into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
62648941|NCT00706316|EXPERIMENTAL|EBV-Specific CTLs and CD45 Mab|A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10\^7 cells/m2. Dose Level II: 5 x 10\^7 cells/m2. Dose Level III: 1 x 10\^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.
62648942|NCT06281509|EXPERIMENTAL|Patients with Dupuytren disease|120 individuals diagnosed with Dupuytren disease (primary or recurrent).
62081514|NCT06630325|EXPERIMENTAL|Arm XIV (osimertinib)|Patients receive osimertinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography or MUGA scan and blood sample collection throughout the study. Patients also undergo tumor biopsy on study and optionally at the end of treatment. Additionally, prostate cancer patients undergo bone scan on study.
62458238|NCT04466085|PLACEBO_COMPARATOR|Population Ⅵ|In Population Ⅵ, there were 150 subjects who injected with 3 doses of placebo into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
62458239|NCT03143400|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
62458240|NCT03143400|ACTIVE_COMPARATOR|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
62458241|NCT01101230|EXPERIMENTAL|Almond|
62458242|NCT01101230|PLACEBO_COMPARATOR|Muffin|
62648943|NCT06281509|EXPERIMENTAL|Healthy controls|120 participants with no other medical conditions affecting the function of the hand (musculoskeletal pathology, vascular or neurological conditions such as CRPS, rheumatoid arthritis and paralysis).
62458243|NCT05435300||Schizophrenia/Schizoaffective Disorder|Participants with Schizophrenia/Schizoaffective Disorder and currently enrolled in the tDCS-adherence parent study (REB# 103-2018).
62458244|NCT03227445|EXPERIMENTAL|Treatment sequence A|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
62458245|NCT03227445|EXPERIMENTAL|Treatment sequence B|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
62280710|NCT03537391|EXPERIMENTAL|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:~Traditional imaging (clinical standard imaging);~1. Whole-body contrast enhanced computer tomography~2. Planar bone scintigraphy~   Novel imaging (investigational imaging);~3. SPECT/CT (investigational imaging)~4. 18F-PSMA-PET/CT (investigational imaging)~5. Whole-body MRI (investigational imaging)~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
62280711|NCT03479632|EXPERIMENTAL|Intervention Group|The intervention group will undergo an aerobic walking program using a treadmill, a body-weight support system, and an assistive device.
62280712|NCT03479632|ACTIVE_COMPARATOR|Control Group|The control group will receive standard physical therapy (PT).
62280713|NCT00634569|EXPERIMENTAL|Flebogamma 5% DIF|
62280714|NCT02305693|ACTIVE_COMPARATOR|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding
62280715|NCT02305693|ACTIVE_COMPARATOR|Ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary.
62280716|NCT04421690|EXPERIMENTAL|Cognitive Training|8 week computerized cognitive training
62280717|NCT04421690|ACTIVE_COMPARATOR|Trivia Training|8 week computerized trivia training
62280718|NCT03757104|EXPERIMENTAL|micro-incentives|micro-incentives only (8 communities)
62280719|NCT03757104|EXPERIMENTAL|EPIC-HIV|Empowered through informed choice for HIV \[male sensitive HIV specific decision support app\] (males only in 8 communities)
62280720|NCT03757104|EXPERIMENTAL|micro-incentive and EPIC-HIV|micro-incentives as well as EPIC \[male sensitive HIV specific decision support app\] (8 communities)
62458246|NCT03227445|EXPERIMENTAL|Treatment sequence C|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
62458247|NCT03227445|EXPERIMENTAL|Treatment sequence D|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
62280721|NCT03757104|NO_INTERVENTION|control|standard of care
62458248|NCT06252025|EXPERIMENTAL|"VR reminiscence therapy system Memo-gration"|This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.
62280722|NCT02800187|EXPERIMENTAL|three-sessions of ESWT|Active three-sessions of ESWT ( once a week for 3 weeks) was given.
62280723|NCT02800187|ACTIVE_COMPARATOR|one-session of ESWT|One-session of ESWTactive ESWT was given.
62280724|NCT02800187|ACTIVE_COMPARATOR|Night splint|The night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study. Another 3 sessions of sham ESWT was given.
62280725|NCT01745640|EXPERIMENTAL|POMALIDOMIDE and dexamethasone treatment|All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
62081515|NCT05780723|EXPERIMENTAL|The TCM group is treated with QHQYP by rectal instillation.|QHQYP is decocted in water, with a dose of 100ml each time, and rectal instillation before going to bed, once a night, for 8 weeks.
62081516|NCT05780723|ACTIVE_COMPARATOR|The control group is treated with mesalazine enema.|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, for 8 weeks.
62458249|NCT06252025|ACTIVE_COMPARATOR|Picture reminiscence therapy|The picture reminiscence therapy group utilized a series of color images depicting screenshots of the Memo-gration, ensuring that the screenshots remained as consistent as feasible with the presented memory cues.
62458250|NCT04540640|EXPERIMENTAL|Subnormothermic Perfusion|Kidneys retrieved for transplantation will undergo subnormothermic oxygenated perfusion using the study device and perfusion solution for at least 1 hour prior to transplantation into the recipient.
62081517|NCT06373497|EXPERIMENTAL|Single Arm|Fluorine-18-sodium fluoride (18F-NaF) PET/MRI imaging with CT angiography
62081518|NCT06580587|EXPERIMENTAL|MK-8527|Participants receive single oral dose of MK-8527 on Day 1
62280726|NCT01044966|EXPERIMENTAL|ITV DepoCyt + Temozolomide|Patients will undergo an induction phase of intraventricular (ITV) DepoCyt, using the dosage determined from the Phase I portionPatients with stable disease (clinically and radiographically), not exhibiting systemic toxicity, will undergo a three month consolidation phase of ITV DepoCyt, for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues. Oral metronomic Temozolomide dosing of 75 mg/m2 daily for 21 days followed by 7 days off will be given throughout the Induction, Consolidation, and Maintenance Phases of the ITV DepoCyt described above.
62648944|NCT04120935||Cohort of CRC patients|Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.
62280727|NCT01226238|EXPERIMENTAL|Online self-help|Provision of online self-help while waiting for psychotherapy
62280728|NCT01226238|NO_INTERVENTION|Waiting list alone|Waiting for psychotherapy alone
62458251|NCT00355628|EXPERIMENTAL|1|KW-2246 (fentanyl citrate)
62458252|NCT05303909|EXPERIMENTAL|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg (rounded up to the nearest 10mg) diluted in 100mls of 0.9% normal saline infused over 30 minutes via a peripheral vein
62081519|NCT05679921|EXPERIMENTAL|PP1|pembrolizumab in combination with pazopanib
62458253|NCT05303909|PLACEBO_COMPARATOR|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein
62648945|NCT01559441|EXPERIMENTAL|Beetroot juice|
62648946|NCT01559441|PLACEBO_COMPARATOR|Carbohydrate control drink|
62458254|NCT02164279||Progressor (ND)|Group of patients with an albuminuria \> 100mg/L, by Urinary sample collection
62458255|NCT02164279||Non-Progressor (non-ND)|Group of patients without an albuminuria \> 100mg/L, by Urinary sample collection
62458256|NCT05467306|EXPERIMENTAL|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
62458257|NCT05467306|NO_INTERVENTION|Standard PrEP services|Standard PrEP services
62648947|NCT00748241|EXPERIMENTAL|Astra Tech Fixture ST|
62648948|NCT01033136|EXPERIMENTAL|MCET-V|Multiple Channel Exposure Therapy -Veterans (MCET-V) is a 12-session cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks. It is an integrated treatment designed to target panic and PTSD symptoms simultaneously.
62648949|NCT01033136|ACTIVE_COMPARATOR|CPT|Cognitive Processing Therapy (CPT) is a 12-session cognitive-behavioral treatment for persons with PTSD. It is a gold-standard cognitive behavioral intervention designed to target PTSD symptoms.
62648950|NCT05955482||NuvoAir Clinical service|Patients with COPD receiving usual care plus NuvoAir clinical services.
62648951|NCT05955482||Standard Care|Propensity matched controls with COPD who receive usual care.
62648952|NCT00835718|EXPERIMENTAL|Stage I, Arm 1|MK0594 5 mg/day
62648953|NCT00835718|PLACEBO_COMPARATOR|Stage I, Arm 2|Placebo
62648954|NCT00835718|EXPERIMENTAL|Stage II, Arm 2|MK0594 1 mg/day
62648955|NCT00835718|EXPERIMENTAL|Stage II, Arm 3|MK0594 1 mg/week
62081520|NCT05679921|EXPERIMENTAL|PP2|pembrolizumab for patients progressing on pazopanib.
62081521|NCT06364319|EXPERIMENTAL|Anti-CD25 rhMAb + traditional therapy|
62081522|NCT06364319|PLACEBO_COMPARATOR|traditional therapy|
62081523|NCT05610280|EXPERIMENTAL|Olezarsen|Participants will be randomized to receive multiple doses of olezarsen, once every 4 weeks by subcutaneous (SC) injection up to Week 49.
62081524|NCT05610280|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive olezarsen-matching placebo, once every 4 weeks by SC injection up to Week 49.
62081525|NCT02021461|EXPERIMENTAL|ESL Banana taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were \<7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
62280729|NCT05012072|EXPERIMENTAL|MLI Experimental group|6 group sessions over 6 weeks with pregnant Latinas and African Americans starting at 14-20 weeks to 20-26 weeks in their prenatal care setting.
62280730|NCT05012072|NO_INTERVENTION|Control usual prenatal care|Only data collection but no intervention
62280731|NCT04128540|OTHER|Control group|This group will receive fentanyl infusion only
62280732|NCT04128540|ACTIVE_COMPARATOR|ESPB group|This group will receive fentanyl infusion plus Ultrasound guided ESPB
62648956|NCT00835718|PLACEBO_COMPARATOR|Stage II, Arm 4|Placebo
62081526|NCT02021461|EXPERIMENTAL|ESL Grape taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were \<7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
62648957|NCT06258252||Patients who are diagnosed as sepsis, with type 2 diabetes.|1. myocardial injury-related biomarkers: troponin T and B natriuretic peptide levels; 2. cardiac structure-related indicators: the size of the left and right ventricle, left ventricular ejection fraction, etc.3. septic cardiomyopathy incidence: Troponin T\>0.01ng/ml is the standard for the diagnosis of septic cardiomyopathy.
62648958|NCT06258252||Patients who are diagnosed as sepsis, without type 2 diabetes.|1. myocardial injury-related biomarkers: troponin T and B natriuretic peptide levels; 2. cardiac structure-related indicators: the size of the left and right ventricle, left ventricular ejection fraction, etc.3. septic cardiomyopathy incidence: Troponin T\>0.01ng/ml is the standard for the diagnosis of septic cardiomyopathy.
62081527|NCT02021461|EXPERIMENTAL|ESL Tutti-Frutti taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were \<7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
62081528|NCT03167216|EXPERIMENTAL|Treatment arm|Treated arm with cromolyn sodium and cetirizine hydrochloride
62648959|NCT02844478|ACTIVE_COMPARATOR|SBP ENGLISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in English
62081529|NCT04487717||PREDICT cohort|Patients with pathologic stage II, III advanced gastric cancer
62081530|NCT04842682|EXPERIMENTAL|Part 1: Active intervention|"Solo groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml)~Combi groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml) and combined with DNA-HIV-PT123 HIV-1 vaccine (solution at 4.0 mg/ml)"
62280733|NCT05481866|EXPERIMENTAL|The intervention group will be given colostrum for oropharyngeal administration|The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours, which will start between the first 48 to 72 hours and continue for 5 consecutive days.
62458258|NCT02798484|EXPERIMENTAL|Breast cancer|Patients diagnosed with breast cancer and placed under neo-adjuvant treatment (hormonotherapy, chemotherapy) within the CHU Brugmann hospital.
62458259|NCT03508622|EXPERIMENTAL|Telehealth|This group will receive weight management treatment via 12 online group sessions, over 6 months. They will have Bluetooth-enabled scales that will allow them to transmit their weight data to the PI in between research visits. They will answer questionnaires and have research visits at baseline, 3 months, and 6 months.
62648960|NCT02844478|EXPERIMENTAL|SBP SPANISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in Spanish
62458260|NCT03508622|OTHER|Empower|This retrospective control group received standard in-clinic individualized weight management with a multi-disciplinary group of providers, via 6 monthly clinic visits, over 6 months.
62648961|NCT05151185|NO_INTERVENTION|Control group|The dementia case manager in the control group undergo existing training. The family caregiver in the control group receive routine service.
62081531|NCT04842682|PLACEBO_COMPARATOR|Part 1: Placebo|Commercial Sodium Chloride at 0.9% (NaCl 0.9%)
62081532|NCT04842682|EXPERIMENTAL|Part 2: Active intervention|CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted or not with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml)
62081533|NCT03869736|EXPERIMENTAL|Nitrous Oxide 50% or 25%|Nitrous oxide at an inhaled concentration of 50% or 25%
62081534|NCT03869736|SHAM_COMPARATOR|Placebo|Oxygen-air mixture
62458261|NCT01779323||Pre and Post Sling Pelvic MRI|Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI.
62648962|NCT05151185|EXPERIMENTAL|training program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program.
62081535|NCT05499130|EXPERIMENTAL|TEV-48574 Dose A (UC)|Dose regimen A administered by subcutaneous infusion for participants with UC
62081536|NCT05499130|EXPERIMENTAL|TEV-48574 Dose B (UC)|Dose regimen B administered by Subcutaneous infusion for participants with UC
62081537|NCT05499130|EXPERIMENTAL|TEV-48574 Dose A (CD)|Dose regimen A administered by subcutaneous infusion for participants with CD
62081538|NCT05499130|EXPERIMENTAL|TEV-48574 Dose B (CD)|Dose regimen B administered by subcutaneous infusion for participants with CD
62081539|NCT05499130|PLACEBO_COMPARATOR|Placebo UC|Matching Placebo
62081540|NCT05499130|PLACEBO_COMPARATOR|Placebo CD|Matching Placebo
62081541|NCT05177523||MS patient group|Recruitment of 200 MS patients at the MS Clinic of the Department of Neurology (Neurologische Klinik und Poliklinik), University Hospital Basel (Universitätsspital Basel)
62081542|NCT05177523||control group (HC)|Recruitment of 100 healthy controls (HC) by public announcements (i.e. advertisement/flyer) on the University Hospital's and the University's notice board.
62081543|NCT06085625|EXPERIMENTAL|Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy|"Participants will first complete a survey about the severity of your symptoms. This will be done at your pre-surgery (pre-operative) visit and should take about 5-10 minutes to complete.~Study Groups~At your pre-surgery visit, you will be assigned to either be sent home on the same day as surgery or to stay in the hospital overnight (or longer) for observation. This will be determined based on which group your surgeon has been assigned to. Participants will be told which group you are in."
62081544|NCT05658341|EXPERIMENTAL|ADA intervention|The ADA intervention arm
62081545|NCT05658341|ACTIVE_COMPARATOR|Usual Care|The usual care arm
62280734|NCT05481866|PLACEBO_COMPARATOR|The control group will be given sterile water for oropharyngeal administration|The control group will be given sterile water for oropharyngeal administration, and the administration scheme will be the same as above.
62280735|NCT01425112|EXPERIMENTAL|Topical/Subconjunctival|Depending upon the mode of administration
62280736|NCT01124487|EXPERIMENTAL|palm olein|
62280737|NCT01124487|EXPERIMENTAL|olive oil|
62280738|NCT01124487|EXPERIMENTAL|lard|
62280739|NCT04482946|EXPERIMENTAL|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
62280740|NCT04394442|EXPERIMENTAL|Hydroxycholoroquine group|
62458262|NCT01936922|EXPERIMENTAL|Virtual reality device (GaitAid®)|This will be a within-subjects design. Each subject will first walk in a controlled laboratory setting as she or he would in daily life. After this, each participant will walk while using the virtual reality device (GaitAid®) for a brief period of time. The session will end with walking as usual.
62458263|NCT06240390|EXPERIMENTAL|Epte Bipolar System 2.0 - Ultrasound-guided percutaneous neuromodulation (NMP)|Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. Ultrasound-guided percutaneous neuromodulation (NMP)
62458264|NCT06240390|EXPERIMENTAL|pharmacological treatment by Opioids|"Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.~Tramadol (Ultram®) Hydromorphone (Dilaudid®) Methadone (Dolophine®, Methadose®) Morphine (Apokyn®, Avinza®, Kadian®, MS-Contin®, among others) Oxycodone (OxyContin®, OxyIR®, Roxicodone®) Hydrocodone Oxymorphone (Opana®) Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others) Tapentadol (Nucynta®)"
62280741|NCT04394442|NO_INTERVENTION|Control group|
62280742|NCT02326519|OTHER|Intracardiac electrode catheter|All patient in the study will have same data collected during the procedure using the Steerable intracardiac electrode catheter.
62280743|NCT00136591|ACTIVE_COMPARATOR|A|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
62280744|NCT00136591|EXPERIMENTAL|B|
62280745|NCT05722379||high-grade AVB patients undergoing permanent pacemaker implantations|
62280746|NCT02100605|ACTIVE_COMPARATOR|Phytosun, decongestant, nasal spray|"Phytosun, decongestant, nasal spray~Nasal spray 20 ml contains:~22g/l hypertonic seawater Essential oils of Eucalyptus, Niaouli and Wild menthol~Instructions for use:~* Shake the bottle before use~* Tilt the bottle to one side; press the nozzle firmly for at least one second, repeat until obtaining the 1st spray.~* Spray in each nostril with the head upright"
62280747|NCT02100605|PLACEBO_COMPARATOR|Isotonic saline, nasal spray|"Isotonic saline, nasal spray~20 ml nasal spray contains Isotonic water solution 0.9% sodium chloride"
62280748|NCT03395379||Group 1|RFA without air dissection protection
62280749|NCT03395379||Group 2|RFA with air dissection protection
62458265|NCT05273866|EXPERIMENTAL|Virtual reality|Virtual reality video application
62280750|NCT04297215|PLACEBO_COMPARATOR|Control group|This group will receive therapeutic clothing without antimicrobial agents
62458266|NCT05273866|NO_INTERVENTION|control group|control group
62280751|NCT04297215|ACTIVE_COMPARATOR|Chitosan group|This group will receive antimicrobial therapeutic clothing based on chitosan
62280752|NCT04297215|ACTIVE_COMPARATOR|Silver group|This group will receive antimicrobial clothing based on silver.
62280753|NCT00689572|EXPERIMENTAL|Ondansetron|Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
62280754|NCT00689572|PLACEBO_COMPARATOR|Placebo|Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
62458267|NCT01188746|EXPERIMENTAL|Questionnaire or interview|A pre-experimental design was chosen to examine changes in QoL following a palliative intervention.
62458268|NCT00760266|EXPERIMENTAL|Aliskiren/HCTZ 300/25 mg|
62458269|NCT00760266|ACTIVE_COMPARATOR|HCTZ 25 mg|
62458270|NCT02092922|EXPERIMENTAL|Filanesib|
62458271|NCT04900090|EXPERIMENTAL|Case group : gout patients|Epidemiological study
62458272|NCT04900090|EXPERIMENTAL|Control group|Epidemiological study
62458273|NCT00620009|NO_INTERVENTION|Control|Therapists and patients record their estimates of the patient's Global Assessment of Functioning, but do not discuss these estimates in therapy sessions.
62458274|NCT00620009|EXPERIMENTAL|Empathy Feedback|Therapists and patients record their ratings of the patient's Global Assessment of Functioning and discuss these ratings.
62458275|NCT03657056|EXPERIMENTAL|BX Pulsar 1002|Low-Intensity Focused Ultrasound Pulsation (LIFUP) sonications will be conducted using the LIFUP experimental device BX Pulsar 1002 produced by the Brainsonix Corporation. For the purposes of safety LIFUP sonications will be initiated at the FDA limit for diagnostic ultrasound. However, the minimally effective dose in humans applications, according to (Lee et al., 2015), when derated is approximately 1125mW/cm2.
62280755|NCT00266253|EXPERIMENTAL|1|
62280756|NCT00266253|EXPERIMENTAL|2|
62280757|NCT00266253|EXPERIMENTAL|3|
62280758|NCT00266253|EXPERIMENTAL|4|
62280759|NCT00266253|EXPERIMENTAL|5|
62280760|NCT00266253|ACTIVE_COMPARATOR|6|
62280761|NCT06500806|EXPERIMENTAL|Scroth and brace Group|Participants allocated to this group will receive bracing and Schroth exercises for 12 months
62458276|NCT00153803|EXPERIMENTAL|1|Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
62458277|NCT00153803|PLACEBO_COMPARATOR|2|Matched Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
62458278|NCT01509300|EXPERIMENTAL|HAPLO|
62081546|NCT06565650|EXPERIMENTAL|Miebo|100% perfluorohexyloctane 4 times daily (QID)
62081547|NCT06565650|PLACEBO_COMPARATOR|Saline solution|(0.6% sodium chloride solution) 4 times daily (QID)
62280762|NCT06500806|ACTIVE_COMPARATOR|Brace group|Participants in this group will follow brace treatment.
62280763|NCT03054610|ACTIVE_COMPARATOR|Control|5 ml of local anesthetic (ropivacaine 7.5%)
62280764|NCT03054610|ACTIVE_COMPARATOR|Steroid|1ml of steroid Betamethason Sodium Phosphate (Celestone®) and local anesthetic (ropivacaine 7.5%)
62280765|NCT03054610|EXPERIMENTAL|BTX-A|200U Botulinum Toxins, Type A
62280766|NCT06420310||Cases|Subjects exposed to pesticides
62280767|NCT06420310||Controls|Subjects without any exposure to pesticides
62280768|NCT02975687|EXPERIMENTAL|Arm A|"CD19 CAR T cells will be administered by i.v. injection as a using a split dose (total dose of 5x10\^6/kg-5x10\^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2."
62280769|NCT04882176|EXPERIMENTAL|LM061 Dose Escalation Level 1, 2.5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 2.5mg QD, n=1;"
62280770|NCT04882176|EXPERIMENTAL|LM061 Dose Escalation Level 2, 5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 5mg QD, n=3;"
62280771|NCT04882176|EXPERIMENTAL|LM061 Dose Escalation Level 3, 10mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 10mg QD, n=3;"
62280772|NCT04882176|EXPERIMENTAL|LM061 Dose Escalation Level 4, 20mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 20mg, n=3;"
62280773|NCT04882176|EXPERIMENTAL|LM061 Dose Escalation Level 5, 30mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 30mg, n=3;"
62280774|NCT04882176|EXPERIMENTAL|LM061 Dose Escalation Level 6, 40mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 40mg, n=9;"
62280775|NCT04882176|EXPERIMENTAL|LM061 Dose Escalation Level 7, 60mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~seventh dose: 60mg, n=15;"
62280776|NCT06541223||Standard Informed Consent Procedure|Face-to-face informed consent procedure supported by an informational brochure approved by the hospital committee
62280777|NCT06541223||Multimedia Assisted Informed Consent Procedure|Face-to-face informed consent procedure supported by an informational brochure approved by the hospital committee, followed by a multimedia presentation on implant-based reconstruction
62280778|NCT03315832|EXPERIMENTAL|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
62458279|NCT06191900|EXPERIMENTAL|GT201 treatment group|
62458280|NCT03755609|ACTIVE_COMPARATOR|patients with oxycodone|
62458281|NCT03755609|SHAM_COMPARATOR|patients with fentanyl|
62458282|NCT02031393||singelton pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
62458283|NCT02031393||twin pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
62458284|NCT00595608|ACTIVE_COMPARATOR|1|Nasal Sterimar spray
62458285|NCT00595608|ACTIVE_COMPARATOR|2|Nasal saline spray
62458286|NCT02530762|PLACEBO_COMPARATOR|Negative control|No added fiber
62458287|NCT02530762|ACTIVE_COMPARATOR|Positive Fiber control|50g positive control fiber
62458288|NCT02530762|EXPERIMENTAL|Novel Fiber 10g|10g novel fiber
62458289|NCT02530762|EXPERIMENTAL|Novel Fiber 30g|30g novel fiber
62458290|NCT02530762|EXPERIMENTAL|Novel Fiber 50g|50g novel fiber
62081548|NCT06121050|EXPERIMENTAL|Pet visit|Intensive care patients visited by their pets for 20 minutes
62081549|NCT06419361|EXPERIMENTAL|[68Ga]Ga-Sa-DABI-4|Patients will receive a single administration of \[68Ga\]Ga-Sa-DABI-4.
62081550|NCT04606433|EXPERIMENTAL|Study treatment|The patients received intravenous infusion of GNC-038 for 1 cycle. After the completion of 2 cycles of treatment, participants with no unbearable ae could proceed to the 3rd and 4th cycles of treatment. After four cycles of treatment, participants with clinical benefits could also receive four additional cycles of the same dose.
62280779|NCT03315832|PLACEBO_COMPARATOR|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
62280780|NCT06500416|EXPERIMENTAL|Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL|This prospective, non-comparative, interventional study will include 15 cataract patients (30 eyes) who will undergo femtosecond laser-assisted cataract surgery with implantation of the Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL in both eyes.
62280781|NCT01699256|EXPERIMENTAL|Enhanced strategy|Enhanced implementation strategy
62280782|NCT01699256|ACTIVE_COMPARATOR|Strategy as usual|Normal implementation strategy
62280783|NCT01311700|ACTIVE_COMPARATOR|Early metoprolol initiation strategy|
62280784|NCT01311700|NO_INTERVENTION|Delayed metoprolol initiation strategy|
62280785|NCT02772861|EXPERIMENTAL|Citrulline|Citrulline is a non-protein amino acid that is present in substantial amounts in watermelon (Citrullus vulgaris), with a mean content of 2.1 mg/g fresh weight, ranging from 0.5 to 3.6 mg/g according to variety. The oral dose can reach 20 g, which was administered orally in the present study in one single dose, followed by a washout period of one week Amino Acid Supplement - One dose
62280786|NCT02772861|EXPERIMENTAL|Glutamine|"L-glutamine is a protein amino acid found in proteins of all life forms. It is classified as a semi-essential or conditionally essential amino acid. This means that under normal circumstances the body can synthesize sufficient l-glutamine to meet physiological demands. However, there are conditions where the body cannot do so. Recently, l-glutamine has come to be regarded as one of the most important of the amino acids when the body is subjected to such metabolic stress situations as trauma (including surgical trauma), cancer, sepsis and burns. In the present study, glutamine was administered orally in one single dose of 20 g, followed by a washout period of one week.~Amino Acid Supplement - One dose"
62280787|NCT02772861|EXPERIMENTAL|Arginine|"Arginine was administered orally in 20 g for one single dose, followed by a washout period of 1 week.~Amino Acid Supplement - One dose"
62280788|NCT02772861|EXPERIMENTAL|3-Methyl-Histidine|"This amino acid is made by methylation of the actin and myosin peptide chains in the muscle. Metabolism after intravenous administration of L-3-methylhistidine involves excretion in the urine of 75% of the administered dose in 24 h and 95% in 48 h.~3-Methyl-Histidine was administered orally in 120 mg for one single dose, followed by a washout period of 1 week."
62280789|NCT02772861|PLACEBO_COMPARATOR|Placebo|Dextrose (glucose) was used in a dose of 20 g in this study.
62648963|NCT04764045|ACTIVE_COMPARATOR|Ropivacaine injection in trigger points|Ropivacaine injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
62280790|NCT03653598||AF patients|Patients with Atrial Fibrillation
62648964|NCT04764045|PLACEBO_COMPARATOR|Placebo injection in trigger points|Saline injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
62081551|NCT06411756|OTHER|Intervention Arm|Subjects will receive access to the video library, a Fitbit, a daily adaptive step goal that will be sent via text message with a short positive message; and monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
62081552|NCT06411756|OTHER|Control Arm|Subjects will receive access to the video library after the study period (after the 9-month assessment).
62280791|NCT05659446|ACTIVE_COMPARATOR|endoscopic group|Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical \& mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
62458291|NCT05323864|EXPERIMENTAL|Normobaric hypoxia|Normobaric hypoxia equivalent to 3800m terrestrial altitude. The chamber located on the campus of the University of Innsbruck's Department of Sport Science. The chamber dimension is 5 x 3m.
62648965|NCT05504057||Patients with chronic treatment with antihistamines or amantadine|The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups.
62648966|NCT05504057||Other population of the THC|The % of patients of the Terrassa Health Consortium that suffered COVID19 infection of the same age groups.
62081553|NCT05082025|EXPERIMENTAL|Part 1: Dose confirmation|Up to 6 evaluable patients to confirm a single combination dose of copanlisib and fulvestrant
62081554|NCT05082025|EXPERIMENTAL|Part 2: Dose expansion:|The dose expansion part will enroll in 3 indication-specific cohorts with 13 to 26 patients
62280792|NCT05659446|NO_INTERVENTION|surgical group|Patients involved in surgical group were subjected to either redo of resection anastomosis manually or by circular stapler or primary repair of the defect with ileostomy. This was done under general anesthesia after colonic preparation.
62280793|NCT04758494||Stroke1-hemiparesis|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis.
62458292|NCT05323864|SHAM_COMPARATOR|Sham hypoxia|The chamber located on the campus of the University of Innsbruck's Department of Sport Science. The chamber dimension is 5 x 3m.
62458293|NCT04347837|EXPERIMENTAL|Investigational device|The investigational device will be used for all participants
62648967|NCT02891512|EXPERIMENTAL|ELF and Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® is a dietary supplement containing alpha-lipoic acid, N-acetyl-L-carnitine, turmeric, vitamins B, E and C. They have an antioxidant and anti-inflammatory action on nervous system and they act on cellular energy metabolism.
62648968|NCT02891512|PLACEBO_COMPARATOR|ELF and Placebo Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® without its specific activity for the condition being treated.
62648969|NCT05681988|EXPERIMENTAL|Study Intervention|Early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT performed within 24 hours after SSICH symptom onset.
62648970|NCT05681988|ACTIVE_COMPARATOR|Control Intervention|Best medical treatment i.e. active blood pressure control, seizure prophylaxis and care as according to the current guidelines.
62458294|NCT04281563|EXPERIMENTAL|the MCT oil massage|The neonates received massage with MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
62081555|NCT02945722|ACTIVE_COMPARATOR|Decolonization|persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.
62081556|NCT02945722|PLACEBO_COMPARATOR|No decolonization|HD patients in which decolonization is not performed including impersistent carriers.
62081557|NCT06646627|EXPERIMENTAL|Intraperitoneal (IP) Administration|"At the time of enrollment, based on imaging studies, clinical history and physical exams, the principal investigator will make a preliminary decision regarding Arm Assignment.~Participants with ovarian cancer confined to the peritoneum will undergo laparoscopic placement of an intraperitoneal catheter (PowerPort™ device and catheter) for cell infusion. When feasible, a Tenckhoff catheter for research sample collection of ascites, will also be placed. If laparoscopic placement is not possible, the PowerPort catheter may be inserted in interventional radiology. If adhesions within the peritoneum would preclude effective distribution of CAR cells throughout the peritoneum, the participant may be placed in Arm B."
62081558|NCT06646627|EXPERIMENTAL|Intravenous (IV) Administration|"At the time of enrollment, based on imaging studies, clinical history and physical exams, the principal investigator will make a preliminary decision regarding Arm Assignment.~Arm B will consist of participants with disease outside the peritoneum and with participants who either cannot undergo IP catheter insertion or who, in the judgement of the principal investigator do not have an intraperitoneal environment that would allow for adequate product distribution. Participants in Arm B will have a Tenckhoff catheter inserted in Interventional Radiology at least 7 days before the start of conditioning lymphodepletion."
62081559|NCT05877196|EXPERIMENTAL|Moderate Intensity Continuous Training (MICT)|Cycling on recumbent stationary cycle at moderate intensity for 30-50 minutes, 3 times per week for 3-6 months
62081560|NCT05877196|SHAM_COMPARATOR|Chair-based Stretch|Stretching at low intensity for 30-50 minutes, 3 times per week for 6 months
62081561|NCT05877196|ACTIVE_COMPARATOR|High-Intensity Interval Training (HIIT)|MICT for 3 months, and then cycling on recumbent stationary cycle at alternate high and moderate intensity for 40 minutes, 3 times per week for 3 months.
62081562|NCT05877196|ACTIVE_COMPARATOR|Combined Aerobic Resistance Exercise (CARE)|MICT for 3 months, and then cycling on recumbent stationary cycle at moderate intensity for 30 minutes, followed by 20-minute strength-building exercise, 3 times per week for 3 months.
62648971|NCT02936999|EXPERIMENTAL|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
62648972|NCT02410759|ACTIVE_COMPARATOR|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly IM
62648973|NCT02410759|ACTIVE_COMPARATOR|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5mg IM
62648974|NCT02347618|EXPERIMENTAL|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
62648975|NCT04576000||Open-Label Group|Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.
62648976|NCT01776957||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
62081563|NCT03817502|EXPERIMENTAL|Cariprazine 1.5 mg/d|Cariprazine capsules, oral administration, once daily.
62280794|NCT04758494||Stroke 2-mild stroke|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a mild stroke.
62081564|NCT03817502|EXPERIMENTAL|Cariprazine 4.5 mg/d|Cariprazine capsules, oral administration, once daily.
62081565|NCT03817502|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules, oral administration, once daily.
62081566|NCT04495751|EXPERIMENTAL|Muscadine Grape Extract Arm|Muscadine grape extract pill (12 week supply)
62081567|NCT04495751|PLACEBO_COMPARATOR|Placebo Arm|Placebo provided (12 week supply)
62081568|NCT06342375|EXPERIMENTAL|Live Outreach|People in this cohort will receive a live outbound call from a Navigator
62081569|NCT06342375|EXPERIMENTAL|Pre-recorded Outreach|People in this cohort will receive a pre-recorded outbound call providing a hotline number
62280795|NCT04758494||Stroke 3-speech disorder|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a speech disorder.
62280796|NCT04758494||Stroke 4-hemiparesis mainly of upper limb|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis mainly of upper limb.
62280797|NCT04758494||Stroke 5-memory loss and depression|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of memory loss and depression.
62280798|NCT04758494||Multiple Sclerosis|Patients diagnosed with multiple sclerosis.
62280799|NCT02479802|EXPERIMENTAL|Albumin|Plasma exchange with Albumin
62648977|NCT00505921|EXPERIMENTAL|Campath-1H|"3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.~Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)~Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0."
62648978|NCT03500978|EXPERIMENTAL|Peer CBT Intervention|Women allocated to the peer-specialist delivered CBT intervention group will be mailed an intervention workbook (CBT exercises) and have their first telephone-based intervention session scheduled. The CBT intervention group will receive 8 telephone-based CBT intervention sessions (over 9 weeks) delivered by peer specialists. Each session will last up to 30 minutes.
62648979|NCT03500978|NO_INTERVENTION|Control|Women allocated to the observation-only control group will not receive any intervention.
62081570|NCT06342375|NO_INTERVENTION|No outreach|People in this cohort will not receive outreach of any kind
62280800|NCT02990260|ACTIVE_COMPARATOR|Live Saccharomyces cerevisiae|Live Saccharomyces cerevisiae. 2 capsules per day (1 g).
62280801|NCT02990260|ACTIVE_COMPARATOR|Yeast cell wall|Yeast cell wall. 2 capsules a day (700 mg).
62280802|NCT02990260|PLACEBO_COMPARATOR|Placebo|Maize starch and magnesium stearate. 2 capsules a day.
62280803|NCT03887130|EXPERIMENTAL|Vinorelbine-Capecitabine (arm A)|oral vinorelbine (OV) with capecitabine (CAP)
62280804|NCT03887130|ACTIVE_COMPARATOR|Gemcitabine-Paclitaxel (arm B)|gemcitabine (GEM) in combination with paclitaxel (PAC)
62280805|NCT03887130|ACTIVE_COMPARATOR|Gemcitabine-Docetaxel (arm C)|gemcitabine (GEM) in combination with docetaxel (DOC)
62280806|NCT04428801|EXPERIMENTAL|Phase 2 AdMSC group|"Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days~Other Names: Celltex-AdMSCs Celltex-AdMSCs"
62648980|NCT05313308||Midazolam|Participants will receive a single age-specific dose midazolam oromucosal solution through buccal mucosa upon onset of seizures. Dose will be dependent by age of participants as follows: \>= 52 weeks and \< 1 year; 2.5 mg/dose of midazolam, for \>= 1 year and \< 5 years; 5 mg/dose of midazolam, for \>= 5 years and \< 10 years; 7.5 mg/dose of midazolam, for \>= 10 years and \< 18 years; 10 mg/dose of midazolam. Participants received interventions as part of routine medical care.
62648981|NCT01482611|EXPERIMENTAL|Panel 1: Caucasian|10, 75 and 300 mg JNJ-47910382 or placebo
62648982|NCT01482611|EXPERIMENTAL|Panel 2: Caucasian|30, 150, 600 mg JNJ-47910382 or placebo
62648983|NCT01482611|EXPERIMENTAL|Panel 3: Japanese|Session VIII and X: Doses of JNJ-47910382 or placebo to be determined
62648984|NCT01482611|EXPERIMENTAL|Panel 4: Japanese|Session IX: Dose of JNJ-47910382 or placebo to be determined
62648985|NCT05941806|ACTIVE_COMPARATOR|Group receiving Tamsulosin|Patients randomized to the intervention group will receive 0.4 mg tamsulosin capsules, administered orally, once a day for 5 days before surgery, the morning of surgery and the day after surgery. The steady-state plasma concentration of tamsulosin is reached after 4 to 5 consecutive doses, which justify the administration duration of 5 days preoperatively. The total duration of administration of tamsulosin was established at 7 days since the study of Patel et al. showed a significant reduction in POUR after 7 days of administration.
62648986|NCT05941806|PLACEBO_COMPARATOR|Group receiving Placebo|Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec.
62648987|NCT04172740|EXPERIMENTAL|Treatment|
62648988|NCT01328015|ACTIVE_COMPARATOR|Oxybuynin, hyperhidrosis|
62648989|NCT01328015|PLACEBO_COMPARATOR|placebo - sugar pill|
62648990|NCT03678077||Mild traumatic brain injury|"Patients between 18-60 years, who were hospital admitted, emergency or outpatient treated with mild traumatic brain injury (ICD-10 S06.0). Data were extracted from the Danish national patient register from January 2003 - December 2007.~Patients who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
62648991|NCT03678077||Matching controls|"Matching controls without concussion of the same age, from the same municipality and of same gender as the included cases. Controls were included during 2003 - 2007. Data were extracted from the population register.~Controls who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
62081571|NCT05952024|EXPERIMENTAL|Acalabrutinib and Rituximab|Patients will receive Dose A of acalabrutinib orally in X dosing schedule beginning on Cycle 1 Day 1 for a maximum of 28 cycles or until 2014 Lugano Classification for Non-Hodgkin's Lymphoma (NHL)-defined disease progression or another discontinuation criterion is met. Patients will also receive an intravenous (IV) infusion of Dose B rituximab on Cycle 1 Day 15 and Dose C of rituximab as an subcutaneous (SC) injection on Day 1 of Cycle 2 through Cycle 8.
62648992|NCT02198196|EXPERIMENTAL|Weight Talk-Mindfulness|WT-M retain the evidence-based elements of WT-S (control condition), including the DASH diet, physical activity components, and an emphasis on self-monitoring. However, each call in WT-M will include an emphasis on mindfulness and stress management that will not be included in the control condition.
62081572|NCT06739980|EXPERIMENTAL|INZ-701|"INZ-701 will be administered by SC injection on a once-weekly basis as follows:~* Study participants from 1 year to \<18 years of age will receive a dose of 2.4 mg/kg~* Study participants ≥18 years and:~weighing \<50 kg or \>100 kg will receive a 1.8 mg/kg dose,~OR~weighing ≥50 and ≤100 kg will receive a 150 mg dose of INZ-701"
62648993|NCT02198196|NO_INTERVENTION|Weight Talk-Standard|Weight Talk-Standard is a phone and web-based weight loss intervention offered by employers as a benefit to their employees. Weight Talk is based on the NIH Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in Adults and utilizes the curriculum developed for the Diabetes Prevention Program. Weight Talk-S contains no additional stress management techniques.
62648994|NCT04151511|OTHER|Continuous Thoracic Epidural|Continuous Thoracic Epidural Analgesia for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
62648995|NCT04151511|EXPERIMENTAL|Continuous Erector Spinae Plane Block|Continuous Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
62081573|NCT05882266|EXPERIMENTAL|Treatment|Receive standard dietary therapy and plant-based omega-3 supplemental beverage consumed once daily during breakfast.
62081574|NCT05882266|PLACEBO_COMPARATOR|Control|Receive only standard dietary therapy
62081575|NCT06029010||Long-term responders of regorafenib ≥5 months|Defined as treatment duration ≥5 months after treatment initiation.
62081576|NCT06029010||Long-term responders of regorafenib ≥4 months|Defined as treatment duration ≥4 months after treatment initiation.
62280807|NCT04428801|PLACEBO_COMPARATOR|Phase 2 Placebo group|The control group- receive three doses of placebo via intravenously infusion every three days.
62081577|NCT05229874|EXPERIMENTAL|Carbon nanoparticle suspension injection (CNSI) group|CNSI (50 mg/dose) was produced by Chongqing Lesmei Pharmaceutical Co., Ltd.: Carbon nanoparticles were marked in the endoscopy division 1 day before surgery, and CNSI was injected submucosally at 4 points (proximal side, distal side, and left and right sides) 0.5-1 cm from the tumor edge under endoscopy. The test dose for each point was approximately 0.25 ml.
62458295|NCT04281563|PLACEBO_COMPARATOR|massage alone|The neonates received massage without MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
62648996|NCT03424135|EXPERIMENTAL|Test product + Reference product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
62081578|NCT05229874|ACTIVE_COMPARATOR|Indocyanine green (ICG) group|"ICG (25 mg/dose) was produced by Dandong Yichuang Pharmaceutical. ICG was marked in the endoscopy division 1 day before surgery and injected submucosally at 4 points (proximal side, distal side, and left and right sides) 0.5-1 cm from the tumor edge under endoscopy. The test dose for each point was approximately 0.5 ml.~Both procedures were performed by a designated medical practitioner."
62081579|NCT06495996|EXPERIMENTAL|Protrieve Sheath|The Protrieve Sheath is intended for embolic protection in the inferior vena cava (IVC) to prevent clinically significant intraprocedural pulmonary embolism during mechanical thrombectomy procedures in patients with high risk of embolization.
62280808|NCT03488160|EXPERIMENTAL|Single arm|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:the first day,the second day Duration:total two times
62280809|NCT05083455||Enoxaparin|Reference group
62280810|NCT05083455||Rivaroxaban|Exposure group
62280811|NCT05098041|EXPERIMENTAL|Soticlestat 300 mg + Rifampin 600 mg|Soticlestat 3\*100 mg tablets, orally, administered once on Day 1 in fasted state in Period 1, followed by a washout period of 4 days, further followed by Rifampin 600 mg, administered as 2\*300mg capsules, orally, once daily for 13 consecutive days, from Day 1 to Day 13 in fasted state in Period 2. Soticlestat 3\*100 mg tablets, will be administered orally along with rifampin 600 mg (2\*300mg) capsules, orally in the morning of Day 11 in Period 2.
62280812|NCT05025826|EXPERIMENTAL|Phycocare|PHYCOCARE during 12 cycles of 14 days from day -3 before oxaliplatin based chemotherapy until cycle 3 months after the last dose of oxaliplatin (18 cycles, about 9 months) From D-3 to D14 before cycle 1 chemotherapy: patient will take Phycocare From D1 to D14 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Phycocare On days of chemotherapy the patient does not take Phycocare
62648997|NCT03424135|EXPERIMENTAL|Reference product + Test product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
62648998|NCT01627665|ACTIVE_COMPARATOR|D->R->C+R|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban
62648999|NCT01627665|ACTIVE_COMPARATOR|D->R->C+D|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran
62280813|NCT05025826|PLACEBO_COMPARATOR|Placebo|"Placebo during 12 cycles of 13 days from day -3 before cycle 1 of oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months).~From D-3 to D13 before cycle 1 chemotherapy: patient will take Placebo From D1 to D13 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Placebo.~On days of chemotherapy the patient does not take Placebo"
62649000|NCT01627665|ACTIVE_COMPARATOR|R->D->C+D|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran
62081580|NCT06726954|EXPERIMENTAL|First Group|High-frequency real-time rTMS protocol It was planned to apply the dorsolateral prefrontal cortex daily at a frequency of 10 Hz for 20 sessions.
62280814|NCT04355598|EXPERIMENTAL|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
62458296|NCT04281563|NO_INTERVENTION|no massage groups|no intervention
62458297|NCT05126056|ACTIVE_COMPARATOR|Active Comparator|Products that contain plant stanol ester. Product with active ingredient
62458298|NCT05126056|PLACEBO_COMPARATOR|Placebo comparator|Placebo product. Product without active ingredient
62458299|NCT01894178|ACTIVE_COMPARATOR|Parker Flex-Tip® Tracheal Tube|Intubation of obese patients with the Parker Flex-Tip® Tracheal Tube
62649001|NCT01627665|ACTIVE_COMPARATOR|R->D->C+R|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban
62081581|NCT06726954|EXPERIMENTAL|Second Group|High-frequency real-time rTMS protocol It was planned to apply the M1 motor cortex daily at a frequency of 10 Hz for 20 sessions.
62081582|NCT06726954|SHAM_COMPARATOR|Third Group|Sham rTMS Protocol It was planned to apply daily sham rTMS for 20 sessions.
62280815|NCT04355598|ACTIVE_COMPARATOR|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
62280816|NCT04355598|PLACEBO_COMPARATOR|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
62458300|NCT01894178|ACTIVE_COMPARATOR|Portex® Tracheal Tube|Intubation of obese patients with the Portex® Tracheal Tube
62458301|NCT00906425|ACTIVE_COMPARATOR|Submerged healing|The Straumann Bone Level Implant(s) will be placed using a submerged healing treatment
62649002|NCT02329717|EXPERIMENTAL|PBI 05204|PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
62649003|NCT01900444|EXPERIMENTAL|IMOJEV Group|Participants who received a single dose of IMOJEV in study JEC12 (NCT01396512) will receive a booster dose in this study.
62081583|NCT05491343|NO_INTERVENTION|Conservative management|
62280817|NCT00890838|ACTIVE_COMPARATOR|Omegaven|will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively
62280818|NCT00890838|NO_INTERVENTION|Without Omegaven|will not receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperativel
62280819|NCT06412874||Screening tool group|
62280820|NCT06412874||Focus group|
62280821|NCT06530784|EXPERIMENTAL|treatment group|Cryoablation combined with PD-1 antibody and bevacizumab
62280822|NCT06040983|EXPERIMENTAL|FR-101 Dressing use|Subject will use FR-101 chest dressing on the target skin area accepted radiation therapy once every 2 days.
62458302|NCT00906425|ACTIVE_COMPARATOR|Trans-mucosal healing|The Straumann Bone Level Implant(s) will be placed using a trans-mucosal healing treatment
62458303|NCT04018625|EXPERIMENTAL|Intervention|Participants (n = 30) will be randomized to receive the SMART Pregnancy stress management program via an online portal.
62458304|NCT04018625|ACTIVE_COMPARATOR|Treatment as usual|Participants (n = 30) will be randomized to receive treatment as usual, including referrals to community based support groups and individual mental health providers.
62649004|NCT03851575|ACTIVE_COMPARATOR|Control arm|Usual guideline therapy
62081584|NCT05491343|EXPERIMENTAL|Progesterone treatment|
62081585|NCT05658835||Patient suffering from ischemic stroke|
62649005|NCT03851575|EXPERIMENTAL|Accelerated arm|Accelerated treatment of endocarditis
62081586|NCT03418896|EXPERIMENTAL|human chorion gonadotropin|Pregnyl, hCG, 5000 IU times one im.
62081587|NCT06738823|EXPERIMENTAL|Experimental group A|"The participants will receive intervention through Wii fit training which includes games tight rope tension, ski slalom, penguin slide, table tilt, and heading for 6 total 6 weeks.~3 days per week session will be given for 30 minutes including 5-minutes warmup and cool down and 5 minutes of break in between to avoid fatigue."
62081588|NCT06738823|ACTIVE_COMPARATOR|Experimental group B|"The participants will receive vestibular rehabilitation training. The rehabilitation programme will include weight shifting, neck rotations, sit to stand exercises on padded mat, and head movements with eyes closed.~The intervention will be given for 3 minutes, 3 days a week for total 6 weeks of time period."
62280823|NCT01613755|ACTIVE_COMPARATOR|Metformin therapy with concomitant use of dipyridamole|Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days
62280824|NCT01613755|ACTIVE_COMPARATOR|Metformin therapy|Metformin 500 mg twice daily for four days
62280825|NCT00134628|ACTIVE_COMPARATOR|A|Hyperbaric Oxygen Therapy
62458305|NCT01893905|EXPERIMENTAL|CS+SG|Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
62649006|NCT01622322|EXPERIMENTAL|Nitrous oxide|Subjects will receive General anesthesia with Nitrous Oxide.
62649007|NCT01622322|PLACEBO_COMPARATOR|Oxygen|Subjects will receive General anesthesia with oxygen.
62081589|NCT02907554|PLACEBO_COMPARATOR|control group|control group receives a placebo
62081590|NCT02907554|EXPERIMENTAL|intervention group|the intervention group receives 2.5 mg/kg of cyclosporine
62280826|NCT00134628|SHAM_COMPARATOR|B|Normal Air
62280827|NCT04244929|EXPERIMENTAL|PCL removal|Patients will undergo surgery by sacrificing the PCL
62280828|NCT04244929|ACTIVE_COMPARATOR|PCL preservation|Patients will undergo surgery with retaining the PCL
62280829|NCT02211391|EXPERIMENTAL|Casein Protein|Casein protein (30g) will be consumed as the last food/caloric beverage and within 30 minute of sleep
62280830|NCT02211391|PLACEBO_COMPARATOR|Non-caloric Placebo|The non-caloric placebo beverage will will be consumed as the last food/caloric beverage and within 30 minute of sleep
62280831|NCT06421220|EXPERIMENTAL|Indocyanine green tracer 3D laparoscopic gastric cancer lymph node dissection group|
62280832|NCT06421220|NO_INTERVENTION|Indocyanine green tracer-free 3D laparoscopic gastric cancer lymph node dissection group|
62280833|NCT03439033|EXPERIMENTAL|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
62280834|NCT03439033|EXPERIMENTAL|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
62280835|NCT03439033|EXPERIMENTAL|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. PET/CT occurs if a) an MRI can't be performed concurrently; or b) the participant already had an MRI of the abdomen/pelvis or pelvis only.
62280836|NCT04511728|EXPERIMENTAL|HSK3486|
62280837|NCT04511728|ACTIVE_COMPARATOR|Propofol|
62280838|NCT06548698|EXPERIMENTAL|Intervention group|
62458306|NCT01893905|PLACEBO_COMPARATOR|Placebo|Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks
62458307|NCT02556944|EXPERIMENTAL|Mix and matched patients|Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.
62458308|NCT03629093||Long-time anesthesia exposure|Infants receive general anesthetics longer than 3 hours in total.
62081591|NCT06739590|PLACEBO_COMPARATOR|Control Group|21 participants were allocated to this group. They completed a background questionnaire and assessed their baseline emotions using the Medical Emotions Scale (MES) before commencing the study. Participants then took a pre-study test assessing their spatial knowledge of hepatobiliary anatomy and a surgical planning component, based on their assigned group. Following the learning process on a sample case, they retook the MES and subsequently completed a test on the designated test cases.
62280839|NCT06548698|NO_INTERVENTION|Control group|
62280840|NCT01076465|EXPERIMENTAL|Lifestyle counselling|Educational intervention, monitoring of clinical status, monitoring of treatment adherence
62280841|NCT01076465|ACTIVE_COMPARATOR|Comparator|Usual care
62280842|NCT06351930|EXPERIMENTAL|cognitive behaviour therapy for insomnia (CBT-I) + usual care (UC) group|The intervention for the CBT-I + UC group will involve five weekly 50-minute individual, face-to-face sessions of CBT-I. The treatment components aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia whilst considering the clinical context of ADHD and include: psycho-education about ADHD, sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
62280843|NCT06351930|NO_INTERVENTION|UC group|Participants will continue their usual clinical follow-up and receive standard treatment at the clinic.
62280844|NCT05329935||Main cohort|All eligible patients
62280845|NCT05329935||Secondary cohort|All eligible patients who survived 1 year post treatment
62280846|NCT00087646|EXPERIMENTAL|1|
62280847|NCT00087646|EXPERIMENTAL|2|
62280848|NCT00087646|EXPERIMENTAL|3|
62280849|NCT00087646|ACTIVE_COMPARATOR|4|
62280850|NCT00909311|ACTIVE_COMPARATOR|1|Non-fasting
62280851|NCT00909311|ACTIVE_COMPARATOR|2|Fasting
62280852|NCT01874171|ACTIVE_COMPARATOR|Cisplatin|Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.
62081592|NCT06739590|EXPERIMENTAL|3D Group|"23 participants were allocated to this group. They completed a background questionnaire and assessed their baseline emotions using the MES prior to the study. They then completed a pre-study test focused on spatial knowledge of hepatobiliary anatomy and surgical planning. After engaging with the sample case, participants retook the MES and completed a test on the specified test cases.~Intervention：Learning anatomical structures using three-dimensional visualization models displayed on a computer."
62081593|NCT06739590|EXPERIMENTAL|MR Group|"22 participants were allocated to this group. Participants completed a background questionnaire and assessed their baseline emotions using the MES before the study commenced. They participated in a training tutorial on utilizing the MR headset and completed a pre-study test evaluating spatial knowledge of hepatobiliary anatomy and surgical planning. After the learning process with the sample case, participants retook the MES, completed a test on the designated test cases, and filled out a post-use adverse reaction scale for the MR device.~Intervention：Viewing and manipulating 3D visualization models to learn anatomical structures using the MR headset."
62081594|NCT06571669|EXPERIMENTAL|Treatment Arm|Patients implanted with neuromodulation
62081595|NCT06739681|NO_INTERVENTION|Control group (CG)|Only routine exercise program will be applied
62081596|NCT06739681|ACTIVE_COMPARATOR|Imagination Group (IG)|In addition to routine exercises, a 15-minute visualization session will be applied.
62081597|NCT06739681|ACTIVE_COMPARATOR|Respiratory Group (RG)|Breathing exercises will be applied in addition to routine exercises.
62081598|NCT06730958||Behçet's disease|patients with who fulfilling the criteria for the diagnosis by International Team for the Revision of the International Criteria for Bechet's Disease
62081599|NCT06730958||control group|healthy matched controls
62081600|NCT05313191|EXPERIMENTAL|Cohort 1: Central Nervous System|"Group 1 Definitive Reirradiation Phase II~* Patients w/history of intracranial or spinal (extradural, intradural, and/or intramedullary) CNS tumors for which radiation therapy was prev. delivered either to gross disease or in the postoperative setting~* Min. 6 month interval b/w RT courses~* Overlap of prior RT field (50% IDL)~* Subgroup analysis: receipt of surgery for recurrence/second IC tumor; concurrent ST; tumor histology~Group 2 CNS Reirradiation Registry~* Patients for whom a repeat course of RT to the CNS is indicated for recurrent disease or secondary primary~* Postop or intact setting~* Min. 6 month interval b/w RT courses~* Overlap of prior RT field (50% IDL)~* Histologically/clinically documented recurrent CNS tumor (benign or malignant)~* Glioblastoma (histologic or molecular including IDH wildtype)~* Astrocytoma (molecular IDH1 mutant)~* Oligodendroglioma (molecular 1p19q co deleted)~* Meningioma~* Ependymoma~* Chordoma/chondrosarcoma"
62280853|NCT01874171|EXPERIMENTAL|Cetuximab|Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.
62280854|NCT00809380|EXPERIMENTAL|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
62081601|NCT05313191|EXPERIMENTAL|Cohort 2: Head/Neck|"Group 1 Full Dose Reirradiation Phase II~* Patients w/history of HNC for which RT was delivered definitively, now with recurrence to h/n amenable to full dose reRT~* Gross unresected disease or PORT 2/2 RF~* Received at least 40 Gy overlapping w/new target region~* Min. 6 month interval b/w RT courses~* Overlap of prior RT field (50% IDL)~* Subgroup analysis: surgery, HPV status, concurrent ST~Group 2 Early (\<6months for prior RT) Palliative H/N ReRT Phase I~* Patients w/history of HNC for which RT was delivered definitively/adjuvant setting, now with biopsy proven recurrence to h/n with indication for palliative RT~* At least 30 Gy prior RT overlapping with new treatment volume~* \<6 month interval between RT courses~Group 3 Head/Neck ReRT Registry~* Patients w/history of HNC for which RT was delivered now with recurrence/secondary primary requiring reRT~* Postop or definitive~* Prior RT dose at least 30 Gy overlapping w/new treatment volume~* Min.6 month interval b/w RT courses"
62280855|NCT00809380|ACTIVE_COMPARATOR|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
62280856|NCT04137783||homozygous or compound heterozygous ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated homozgyous or compound heterozygous ABCA3 mutations.
62081602|NCT05313191|EXPERIMENTAL|Cohort 3: Breast|"Group 1 Partial Breast Reirradiation (Phase II)~* Patients with a history of breast cancer s/p BCT, now with small (≤3cm), unicentric, ipsilateral breast cancer recurrence receiving repeat BCT~* Node negative~* Negative margins~* No LVI~* Lumpectomy cavity:whole breast \<30%~* Minimum 1 year interval between RT courses~Group 2: Regional LN and Breast/CW ReRT (Phase II)~* Patients with a history of breast cancer s/p RT , now with recurrence or new primary with indication for reirradiation to the breast/chest wall and regional LN~* Minimum 1 year interval between RT courses~* Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~* Excludes concurrent chemotherapy~Group 3: Breast Reirradiation Registry~* Patients with a history of breast cancer s/p RT , now with recurrence or new primary breast cancer with indication for reirradiation~* Some overlaps of dose with prior RT course~* Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~* Excludes concurrent chemotherapy"
62280857|NCT04137783||single ABCA3 mutation|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated single mutations.
62649008|NCT03563222|EXPERIMENTAL|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
62280858|NCT04137783||no ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which exclude all gene mutations involving in the respiratory disease.
62280859|NCT02656602|NO_INTERVENTION|Nurse Counseling|A trained endoscopy nurse provided patients with all information on their scheduled colonoscopy.
62280860|NCT02656602|EXPERIMENTAL|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI.All elements of informed consent for colonoscopy (risks, alternatives) were included.
62280861|NCT03116945|EXPERIMENTAL|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
62280862|NCT05565963|EXPERIMENTAL|Intervention group.|12-week intervention, with a 12-week follow-up. Device:1 computer virtual reality online software and 3 large projectors were used to project videos on the wall in a wrap-around state.
62280863|NCT05565963|NO_INTERVENTION|Control group.|No intervention with a 12 week follow-up.
62280864|NCT01497977|EXPERIMENTAL|soya phytoestrogens|
62280865|NCT01497977|EXPERIMENTAL|red clover phytoestrogens|
62280866|NCT01497977|NO_INTERVENTION|No drugs|
62280867|NCT02260518|EXPERIMENTAL|Lifestyle Intervention|The intervention will focus on women gaining the recommended amount of weight, increasing physical activity to 150 minutes per week, and meeting healthy eating guidelines.
62280868|NCT02260518|OTHER|Standard Care|Women in the standard care group will attend their regularly scheduled obstetric (OB) visits with their prenatal care providers and will receive monthly mailings and matched number of podcasts.
62280869|NCT02641509|EXPERIMENTAL|NBI to perform the polipectomy|this arm will undergo polypectomy with the use of NBI to define the margins of the lesion
62280870|NCT02641509|EXPERIMENTAL|no NBI to perform the polypectomy|this arm will undergo polipectomy without the use of NBI to define the margins of the lesion
62280871|NCT05401266|NO_INTERVENTION|normal blood carbonic acid level|After propofol infusion was stopped, ventilation parameters were adjusted to maintain end-expiratory carbon dioxide (ETCO2) 35-40 mmHg until spontaneous respiration was restored.
62280872|NCT05401266|EXPERIMENTAL|mild hypercapnia|After propofol infusion was stopped, ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored.
62280873|NCT02482155|EXPERIMENTAL|ibuprofen|ibuprofen 400 mg granules, oral solution, single administration under fasting conditions
62280874|NCT02714166|EXPERIMENTAL|Sunscreen lotion Sun Protection Factor 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
62280875|NCT02714166|OTHER|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
62458309|NCT03629093||Short-time anesthesia exposure|Infants receive general anesthetics shorter than 3 hours in total.
62280876|NCT03459027|ACTIVE_COMPARATOR|Nitrate Rich Beetroot Powder (nitrate)|Dietary nitrate in the form of beetroot powder (10g) mixed in water will be administered acutely
62280877|NCT03459027|PLACEBO_COMPARATOR|Placebo Beetroot Powder|Beetroot powder devoid of nitrate (10g) will be mixed in water and administered acutely
62280878|NCT02576314|ACTIVE_COMPARATOR|Sofosbuvir and Daclatasvir|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
62280879|NCT02576314|ACTIVE_COMPARATOR|Ledipasvir/sofosbuvir|Participants will receive Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet daily for 12 weeks.
62280880|NCT01966549|EXPERIMENTAL|CNTO 6785|
62280881|NCT01966549|PLACEBO_COMPARATOR|Placebo|
62280882|NCT04400474|EXPERIMENTAL|Cabozantinib 40 mg + Atezolizumab 1200 mg|"* Cabozantinib 40 mg tablets, oral administration, once daily, continuously.~* Atezolizumab 1200 mg administered intravenously, every three weeks (cycle)."
62280883|NCT05265403||Below knee amputees|Adult, unilateral trans-tibial amputees (amputation is below the knee and only on one side) who will wear and test our prototype prosthetic feet
62081603|NCT05313191|EXPERIMENTAL|Cohort 4: Thoracic|"Group 1: Definitive Reirradiation for Locally Advanced Disease~* Single arm, prospective, phase II study~* Patients with a history of lung cancer s/p definitive RT , now with local recurrence of new primary centrally located and w/I 50% IDL of prior RT field~* Definitive reRT concurrent systemic therapy~* Adequate pulmonary function defined as an FEV1 of \>35% (with or without bronchodilator) within 90 days prior to registration~* Minimum 6 month interval between RT courses~* Negative metastatic workup~Group 2: Thoracic Registry Study~* Registry design~* Patients with histologically confirmed thoracic malignancy (NSCLC, SCLC , mesothelioma, thymoma, carcinoid, intrathoracic sarcoma) with prior thoracic RT~* Minimum 3 month interval between RT courses~* Negative metastatic workup"
62081604|NCT05313191|EXPERIMENTAL|Cohort 5: Gastrointestinal|"Group 1 Esophagus \& GEJ Reirradiation Phase II~* Patients w/history of E/GEJ cancer s/p RT, now w/recurrent/new primary nonmetastatic E/GEJ cancer for which salvage RT is recommended~* Negative metastatic workup~Group 2 Liver Reirradiation Phase II~* Patients w/history of HCC, cholangiocarcinoma or liver mets (any histology), s/p prior EBRT, now with in field recurrence/new primary/met, for which definitive reRT is recommended~* CTP A or B7~* Excl. prev. Y 90/radioembolization~* Allow prior TACE~* Overlap w/50% IDL prior RT~* Adequate bone marrow function~Group 3 Lower GI Reirradiation Phase II~* Patients w/history of rectal/anal cancer s/p RT now w/recurrent/new primary nonmetastatic rectal/anal cancer for whom salvage RT is recommended +/ chemotherapy~* Negative metastatic workup (PET/CT or CT C/A/P)~Group 4 GI Reirradiation Registry~•Patients w/histologically document recurrent or new GI malignancy with prior history of RT w/overlap of current RT volume by the 50% IDL"
62280884|NCT01325012|ACTIVE_COMPARATOR|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle.
62280885|NCT01325012|ACTIVE_COMPARATOR|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
62280886|NCT04809610|EXPERIMENTAL|Intervention group: Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises, and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
62280887|NCT04809610|NO_INTERVENTION|Control group: Waiting list control group.|Participants in this condition will be informed that they will have access to the intervention at 3 months (after the intervention group).
62280888|NCT03442673|ACTIVE_COMPARATOR|CG (Chemotherapy/G-CSF) - Regime|Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
62280889|NCT03442673|EXPERIMENTAL|G (G-CSF) - Regime|G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.
62280890|NCT03351777|EXPERIMENTAL|PR022 topical gel, 0.05%|Applied twice daily for 28 days
62280891|NCT03351777|EXPERIMENTAL|PR022 topical gel, 0.1%|Applied twice daily for 28 days
62280892|NCT03351777|PLACEBO_COMPARATOR|PR022 topical gel vehicle|Applied twice daily for 28 days
62649009|NCT03563222|ACTIVE_COMPARATOR|Intralipid, 20%|Intralipid 20% is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
62649010|NCT03886909|ACTIVE_COMPARATOR|Home-Based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and periodical phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of transplant.
62649011|NCT03886909|ACTIVE_COMPARATOR|Prehabilitation Education|Will be offered a prehabilitation and stem cell education class at the Penn State Hershey Cancer Institute.
62649012|NCT03750721||Role of rifampin in staphylococcal PJI|retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (\< 1 month) PJI treated with DAIR in 2011-2016 period
62280893|NCT02814565|EXPERIMENTAL|Cyclobenzaprine HCl 15 mg|Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.
62280894|NCT02814565|PLACEBO_COMPARATOR|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.
62280895|NCT02571010|EXPERIMENTAL|Vibrotactile stimulation|"Patients in this arm will have~* treatment by medications and rehabilitation~* treatment by vibrotactile at medical center~* stimulation at home by soft tissue~* non stimulation on allodynia area"
62280896|NCT02571010|SHAM_COMPARATOR|Sham Stimulation with Vibradol device switched off|"Patients in this arm will have~* treatment by medications and rehabilitation~* Sham vibrotactile treatment at medical center but with Vibradol device switched off~* abdominal breath exercises at home~* non stimulation on allodynia area"
62280897|NCT02571010|OTHER|Standard Medical treatment|Observational group, treated as usually by medications and rehabilitation.
62280898|NCT01707615|OTHER|control group|In the control group, all patients were enrolled in a lifestyle intervention
62280899|NCT01707615|ACTIVE_COMPARATOR|GSPE group|GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention.
62280900|NCT03595540|EXPERIMENTAL|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
62280901|NCT01316250|OTHER|Nilotinib, cytogenetic response|Newly diagnosed CML patients
62280902|NCT03734757|EXPERIMENTAL|Trimodality|PET-CT with fluorocholine and MRI
62280903|NCT01518595|PLACEBO_COMPARATOR|placebo|Patients will receive placebo tablets twice daily for 3 months.
62280904|NCT01518595|ACTIVE_COMPARATOR|bosentan|pts. will receive bosentan for 3 months
62280905|NCT00647556|ACTIVE_COMPARATOR|adapalene|adapalene
62280906|NCT00647556|ACTIVE_COMPARATOR|tretinoin|Tretinoin
62649013|NCT05966103|ACTIVE_COMPARATOR|Conventional Exercise Group (Control Group)|Conventional neck exercises were applied to the control group.
62280907|NCT04397705|EXPERIMENTAL|Ambulatory monitoring|Participants will be asked to wear the sensors (heart rate, respiratory rate, temperature, and pulse oximetry) for three weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care.
62280908|NCT02979210|OTHER|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline)
62458310|NCT06242405|EXPERIMENTAL|Single-infusion group|Single peripheral venous infusion of stem cells
62458311|NCT06242405|EXPERIMENTAL|Double-infusion group|Repeated peripheral venous infusion of stem cells within one month
62458312|NCT01575223|ACTIVE_COMPARATOR|High volume saline irrigation|Patients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
62649014|NCT05966103|EXPERIMENTAL|Scapulothoracic Exercise (Treatment Group)|In the treatment group, scapulothoracic exercises were applied in addition to conventional neck exercises.
62458313|NCT01575223|PLACEBO_COMPARATOR|Placebo|Patients in this group will receive low volume saline irrigation (Salinex)
62458314|NCT05063500|EXPERIMENTAL|Experimental group|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
62458315|NCT05063500|ACTIVE_COMPARATOR|Control group|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
62458316|NCT05265806|EXPERIMENTAL|Intranasal oxytocin|Participants will be randomly assigned to the administration of oxytocin intranasal spray (24 IU).
62649015|NCT03432832|EXPERIMENTAL|Emotion Awareness/Skills Enhancement|"EASE Therapy includes 16 weekly sessions focused on mindfulness exercise, review of prior content, practicing prior skills, outline of current session, discussion of the new skill, handouts, practice and plan for out of session practice held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The investigators will apply a multimodal teaching approach, where individual therapy is buttressed by parent involvement and practice sessions in the youth's community. A secure website developed for this project (emotion-Coach or e-Coach) will augment the intervention by providing online supports to increase treatment intensity or dosage. There will be specific information on how to reinforce the skills at home and in the community."
62458317|NCT05265806|EXPERIMENTAL|Oral oxytocin|Participants will be randomly assigned to the administration of oxytocin lingual spray (24 IU).
62458318|NCT05265806|PLACEBO_COMPARATOR|Placebo|Participants will be randomly assigned to the administration of placebo.
62458319|NCT03960970|ACTIVE_COMPARATOR|One-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once
62458320|NCT03960970|EXPERIMENTAL|Two-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once and Azithromycin 500mg IV, Piggyback, once
62649016|NCT03432832|ACTIVE_COMPARATOR|Supportive Therapy|Supportive Therapy will involve attending 16 weekly therapy sessions held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The intervention will not involve mindfulness or other emotion regulation strategies used in EASE. The therapy will be tailored to the individual's needs and will include aspects common in supportive therapy such as reflective listening, antecedent management, and problem-solving. This program does not have an online component.
62649017|NCT05963399|EXPERIMENTAL|older adults|Elderly adults who live independently in their own home in rural or urban areas.
62649018|NCT02765035|EXPERIMENTAL|C-Leg 3, then C-Leg 4|Participants are first fitted with a C-Leg 3, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 4, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
62458321|NCT04752748||Woman with Early Rheumatoid Arthritis|
62458322|NCT05019469|EXPERIMENTAL|Single arm of study|Single Arm. During each study session the participant undertakes 4 walking/activity circuits. During each circuit the participant receives either continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. The ordering of the interventions/circuits are systematically alternated for each participant.
62458323|NCT05986383||Guoup 1|Liver function is Child Pugh A：If ICG-R15\<10%, the standardized residual functional liver volume ratio (RRS) ≥ 40%
62458324|NCT05986383||Guoup 2|Liver function is Child Pugh A：If ICG-R15 is 10% - 20%, RRS ≥ 60%
62458325|NCT05986383||Guoup 3|Liver function is Child Pugh A：If ICG-R15 is 21% - 30%, RRS ≥ 80%
62458326|NCT05986383||Guoup 4|Liver function is Child Pugh A：If ICG-R15 is 31%\~40%, only minimal hepatectomy with hepatectomy rate less than 5% can be performed
62458327|NCT05986383||Guoup 5|Liver function is Child Pugh A：If ICG-R15\>40%, only tumor resection is feasible
62458328|NCT05986383||Guoup 6|Liver function is Child Pugh B: only tumor resection is allowed
62081605|NCT05313191|EXPERIMENTAL|Cohort 6: Genitourinary|"Group 1 Locally recurrent prostate cancer w/in prev. radiation field Phase II~* Patients w/recurrent prostate adenocarcinoma w/in prev. irradiated field w/indication for repeat course of radiation~* Min. 1 year interval b/w RT courses~* Prostate gland or recurrent tumor \<100 cc or 6 cm in largest dimension~* No persistent grade 2+ toxicity from prior radiation~* Negative metastatic workup (bone scan, CT scan or PSMA/axumin scan~Group 2 Regional prostate cancer recurrence adjacent to the previous field Phase II~* Patients w/recurrent prostate adenocarcinoma beyond prior RT field (outside 50% IDL) but w/in pelvis)~* Min.1 year interval b/w RT courses (EBRT or brachy)~* No persistent grade 2+ toxicity from prior radiation~Group 3 Prostate Reirradiation Registry~* Patients w/recurrent prostate adenocarcinoma (prostate gland, postop bed, or pelvi c LN) who require RT to the prostate or pelvis in the setting of prior pelvis RT~* No DM~* Concurrent chemotherapy excl."
62081606|NCT05313191|EXPERIMENTAL|Cohort 7: Gynecological|"Group 1: Locally recurrent gynecological cancer within previous field~* Single arm, prospective, phase II study design~* Patients with history of gyn cancer for which definitive or adjuvant/salvage PORT was given, now with recurrence within 50% IDL recommended for radiotherapy~* At least 1 year between RT courses~* No persistent grade 3+ toxicity from prior RT~* Concurrent chemotherapy excluded~* Uncontrolled or widely metastatic disease~* Life expectancy \>6 months"
62081607|NCT05313191|NO_INTERVENTION|Cohort 8: Registry|"* Registry design~* Any cancer patient for whom RT is indicated in the setting of prior RT and do not meet eligibility criteria for other cohorts~* Overlap of 50% IDL of current treatment volume with prior RT field"
62081608|NCT06249984|PLACEBO_COMPARATOR|Prevention (Smokeless tobacco use: Usual Brand)|Participants use their usual brand of moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
62280909|NCT03608917|EXPERIMENTAL|Treatment group|"Drug:Total Glucosides of Paeony (TGP)~1. Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day)~2. Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally."
62081609|NCT06249984|ACTIVE_COMPARATOR|Prevention (Smokeless tobacco use: Low FBN Long Cut)|Participants use low FBN long cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
62081610|NCT06249984|ACTIVE_COMPARATOR|Prevention (Smokeless tobacco use: Low FBN Fine Cut)|Participants use low FBN fine cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
62081611|NCT06249984|ACTIVE_COMPARATOR|Prevention (Smokeless tobacco use: High FBN Long Cut)|Participants use high FBN long cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
62458329|NCT03567642|EXPERIMENTAL|Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide|Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued. Patients will present every 2 cycles post-chemo (Cycles 8, 10, 12, etc.)
62458330|NCT06521983|EXPERIMENTAL|LORDOSİS|30-40
62458331|NCT06521983|EXPERIMENTAL|HYPERLORDOSİS|40\<
62458332|NCT05488197||Group 1 participants with gestational diabetes|
62458333|NCT05488197||Group 2 participants without gestational diabetes|
62458334|NCT01130688|EXPERIMENTAL|single arm of experimental drug combination|
62081612|NCT06249984|ACTIVE_COMPARATOR|Prevention (Smokeless tobacco use: High FBN Fine Cut)|Participants use high FBN fine cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
62081613|NCT00059748||Patients affected with autoinflammatory diseases|Subjects with known or suspected diagnosis of NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still s disease, Behcet s disease, JDM, and other autoinflammatory diseases.
62081614|NCT04090398|EXPERIMENTAL|Arm I (paclitaxel, radium Ra 223 dichloride)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and radium Ra 223 dichloride IV over 1 minute on day 1 of each cycle. Treatment with radium Ra 223 dichloride repeats every 28 days for 6 cycles and treatment with paclitaxel repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, bone scan and/or MRI, as well as collection of blood samples throughout trial. Patients may optionally undergo SPECT on trial.
62081615|NCT04090398|ACTIVE_COMPARATOR|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, bone scan, and/or MRI, as well as collection of blood samples throughout trial. Patients may optionally undergo SPECT on trial.
62081616|NCT03394365|EXPERIMENTAL|Cohort SOT-R (C-SOT-R)|Participants with EBV+ PTLD following SOT that has failed rituximab will receive IV tabelecleucel.
62081617|NCT03394365|EXPERIMENTAL|Cohort SOT-R+C (C-SOT-R+C)|Participants with EBV+ PTLD following SOT that has failed both rituximab and chemotherapy will receive IV tabelecleucel.
62081618|NCT03394365|EXPERIMENTAL|Cohort HCT (C-HCT)|Participants with EBV+ PTLD following HCT that has failed rituximab containing regimen will receive IV tabelecleucel.
62280910|NCT03608917|PLACEBO_COMPARATOR|Control group|"Drug:Total Glucosides of Paeony (TGP) analogue~1. Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day)~2. Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally."
62280911|NCT05840939|EXPERIMENTAL|pranayama|At the beginning, each patient in this group was shown one-on-one by the researcher and taught by applying them together, taking into account the application steps, how to practice pranayama. In the next step, the patients were asked to do this application themselves. Sleep quality, pain and fatigue levels of the patients were determined after 6 weeks.
62081619|NCT06736730|EXPERIMENTAL|Active Arm|"Intervention: It includes three key components:~1. Unrestricted Cash Assistance provided to individuals to support their immediate needs,~2. Mobile Community Support Services that offer on-site assistance and resources, and~3. Activation of Operation Good with coordination between hospital and community services to ensure seamless support for individuals affected by violence, promoting recovery and reducing the risk of re-injury or retaliation."
62081620|NCT06736730|NO_INTERVENTION|In-Active Arm|This group will receive no intervention beyond the standard care provided in the hospital setting. No additional services, cash assistance, or community-based support will be offered. This arm will serve as a comparison group to evaluate the effectiveness of the intervention.
62081621|NCT02928094|EXPERIMENTAL|A: Ad5FGF-4|Ad5FGF-4, administered one time at 6x10e9 viral particles in buffer, and maximally-tolerated medical therapy for angina.
62081622|NCT02928094|PLACEBO_COMPARATOR|B: Placebo|Placebo buffer, administered one time, and maximally-tolerated medical therapy for angina.
62081623|NCT05656105|EXPERIMENTAL|Healty Volunteers|
62081624|NCT05656105|EXPERIMENTAL|PASC|Patients meeting the case definition criteria for PASC
62081625|NCT04504136|EXPERIMENTAL|Healthy Controls|Participants in this group will be healthy (not diagnosed with inflammatory bowel disease).
62081626|NCT04504136|EXPERIMENTAL|Inflammatory Bowel Disease|Participants in this group will have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and have either failed treatment with biologics or be naive to biologic therapy.
62081627|NCT04504136|EXPERIMENTAL|Rheumatoid/Psoriatic Arthritis|Participants in this group will have been diagnosed with rheumatoid (RA) or psoriatic arthritis (PsA) and will be receiving anti-TNF antibody therapy at the time of enrollment.
62081628|NCT02275416|EXPERIMENTAL|Ipilimumab & UV1 vaccine & GM-CSF|Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
62081629|NCT05876377||Patient had Pfizer-BioNTech COVID-19 mRNA vaccine of interest|Patient identified in the vaccine registry having one or more dose of Pfizer-BioNTech COVID-19 mRNA vaccine of interest
62081630|NCT05876377||Patient did not have a Pfizer-BioNTech COVID-19 mRNA vaccine of interest|Patient not located in the vaccine registry having one or more dose of Pfizer-BioNTech COVID-19 mRNA vaccine of interest
62081631|NCT06173349|EXPERIMENTAL|PLZ4-coated paclitaxel loaded micelles (PPM)|Patients receive PPM intravesically over 1 hour QW for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, or PET, and cystoscopy with biopsy at screening and follow up and undergo collection of blood samples throughout the trial.
62081632|NCT06739382|ACTIVE_COMPARATOR|extended meropenem infusion in combination with other options|a) Patients treatment was modified to extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin
62280912|NCT05840939|EXPERIMENTAL|diaphragm breathing exercise group|At the beginning, the patients in this group were shown how to do the diaphragm breathing exercise and how to do the diaphragm breathing exercise, taking into account the application steps, each patient was shown individually by the researcher and taught by applying them together. In the next step, the patients were asked to do this application themselves. Sleep quality, pain and fatigue levels of the patients were determined after 6 weeks.
62458335|NCT05193019||Patients undergoing PCI|
62458336|NCT05773183||OBS1 [Observational Cohort 1]|20 Eugonadal Healthy men 20 Men with Testosterone Deficiency not currently on Testosterone replacement therapy
62081633|NCT06739382|ACTIVE_COMPARATOR|two β-lactam antibiotics plus a single non-β-lactam antibiotic|b) Patient treatment was adjusted to include two β-lactam antibiotics plus a single non-β-lactam antibiotic, or a combination of double β-lactam antibiotics, with the aim of avoiding aggressive and toxic antibiotics
62081634|NCT06739382|OTHER|c) Patients treatment was adjusted to the second-line empirical antibiotic|c) Control group in which patients treatment was adjusted to the second-line empirical anti-biotic according to the hospital's local policy.
62081635|NCT06728085|EXPERIMENTAL|Mother-Daughter Day HPV Campaign|Each of the 18 local government areas begin as part of the control condition and are block-randomized into four waves in the pre-implementation phase, with each wave beginning 2 months after the start of the prior wave and lasting for 6 months. The local government areas will implement the intervention for 6 months, followed by a post implementation phase.
62081636|NCT05325866|EXPERIMENTAL|Part 1: Monotherapy Dose Exploration|Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive 1 of 2 dose regimens of bemarituzumab to determine recommended Phase 2 dose.
62280913|NCT05840939|NO_INTERVENTION|control group|It is the group where no application has been made.
62280914|NCT05654844|OTHER|Digital Lateral Cephalometry|Patients justifying the indication for LC and CBCT exposure
62280915|NCT00516555||A, 07, 001|Pregnant women at term with a baby in breech presentation who will have an external cephalic version.
62458337|NCT05773183||IC1 [Interventional Cohort 1]|20 Men with Testosterone Deficiency progressed from OBS1 6 months post initiation of testosterone replacement therapy
62458338|NCT05773183||IC2 [Interventional Cohort 2]|20 men with prostate cancer planned for GnRH analogue therapy
62458339|NCT04688697|EXPERIMENTAL|Prepectoral Group|Prepectoral implant-based reconstruction applied for patients in this group
62081637|NCT05325866|EXPERIMENTAL|Part 2: Monotherapy Dose Expansion|Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive the dose of bemarituzumab identified as the recommended Phase 2 dose during Part 1.
62280916|NCT05601557||hyperbilirubinemia|Gilbert syndrome Crigler-Najjar syndrome Dubin-Johnson syndrome Rotor syndrome PFIC BIRC
62458340|NCT04688697|ACTIVE_COMPARATOR|Subpectoral Group|Subpectoral implant-based reconstruction applied for patients in this group
62458341|NCT03344510|EXPERIMENTAL|Kinetic anesthesia device, then no intervention|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device, then will receive an injection without the kinetic anesthesia device intervention
62458342|NCT03344510|EXPERIMENTAL|No intervention, then kinetic anesthesia device|In this arm of the crossover study, participants will receive lidocaine injection without the kinetic anesthesia device intervention, then will receive an injection in conjunction with the kinetic anesthesia device.
62458343|NCT05209009|EXPERIMENTAL|Group A|COVAC-2 25 µg: 200 generally healthy adults \> 18 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
62649019|NCT02765035|EXPERIMENTAL|C-Leg 4, then C-Leg 3|Participants are first fitted with a C-Leg 4, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 3, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
62649020|NCT02303665|NO_INTERVENTION|The control group|No Intervention
62649021|NCT02303665|EXPERIMENTAL|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
62649022|NCT02303665|EXPERIMENTAL|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
62649023|NCT00827567|EXPERIMENTAL|RAD 001|RAD001-10 mg by mouth once everyday
62649024|NCT03758469|EXPERIMENTAL|HSK3486|0.4 mg/kg
62649025|NCT03758469|EXPERIMENTAL|rifampin , HSK3486|600 mg;0.4 mg/kg
62649026|NCT03274817|ACTIVE_COMPARATOR|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
62458344|NCT05209009|PLACEBO_COMPARATOR|Group B|100 generally healthy adults \> 18 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
62458345|NCT01988922|EXPERIMENTAL|Ketamine arm- *1/*1|1.\*1/\*1- oral racemic ketamine 0.4 mg/kg
62649027|NCT03274817|ACTIVE_COMPARATOR|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
62649028|NCT03274817|PLACEBO_COMPARATOR|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
62649029|NCT02879058|NO_INTERVENTION|Without Ultrasound|Laparoscopic or robotic myomectomy will be performed without aid of intraoperative contact ultrasonography
62649030|NCT02879058|EXPERIMENTAL|With Ultrasound|Laparoscopic or robotic myomectomy will be performed with aid of intraoperative contact ultrasonography
62649031|NCT02727712|EXPERIMENTAL|TPVB T2/3+T5/6+GA|the group A of patients has been received bilateral thoracic paravertebral block (TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml\*4), before general anesthesia management
62649032|NCT02727712|EXPERIMENTAL|TPVB T3/4+GA|the group Bof patients has been received bilateral thoracic paravertebral block (TPVB 3/4) by ropivacaine(0.3%,10ml\*4), before general anesthesia management Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
62649033|NCT02727712|PLACEBO_COMPARATOR|GA|group C under control (without TPVB)program Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
62649034|NCT01530542|EXPERIMENTAL|Treatment A|
62649035|NCT01530542|EXPERIMENTAL|Treatment B|
62649036|NCT01530542|EXPERIMENTAL|Treatment C|
62649037|NCT01530542|EXPERIMENTAL|Treatment D|
62649038|NCT01530542|EXPERIMENTAL|Treatment E|
62649039|NCT04920435||training population|patients from which we will develop the prediction model
62081638|NCT05773781|ACTIVE_COMPARATOR|PuraBond®|Surgery with PuraBond® application to surgical field.
62081639|NCT05773781|NO_INTERVENTION|No PuraBond®|Surgery without PuraBond® application to surgical field.
62081640|NCT06506773||Cohort A|Observational follow-up study to characterize the natural history of exocrine pancreatic function by measuring FE-1 in infants with CF.
62280917|NCT05601557||Wilson disease|Leipzig score system was used for diagnosis, and the total score ≥4 points could be confirmed. The total score of 3 is suspected diagnosis, which requires further examination. A total score of 2 or less is not considered for diagnosis.
62458346|NCT01988922|EXPERIMENTAL|Ketamine arm - *1/*6|2. \*1/\*6- oral racemic ketamine 0.4 mg/kg
62458347|NCT01988922|EXPERIMENTAL|Ketamine arm - *6/*6|3. \*6/\*6- oral racemic ketamine 0.4 mg/kg
62458348|NCT00004769||Myotonic dystrophy|Subjects with myotonic dystrophy
62458349|NCT00004769||Healthy controls|Healthy subjects
62458350|NCT00004769||Disease controls 1|Subjects with FSHD
62458351|NCT00004769||Disease controls 2|Subjects with CMT
62649040|NCT04920435||testing population|patients on whom we will test the prediction model
62649041|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
62649042|NCT06440928|EXPERIMENTAL|intervention grup: standart treatment and segmental mobilization grup|Mobilisation specifically on the C7 segment will be performed by the physiotherapist 2 times a week for 3 weeks, making decisions on the choice of key parameters including treatment technique, spinal level, degree, direction, side and duration.
62081641|NCT03656549|EXPERIMENTAL|Impaired renal function|patients will be treated with pemetrexed, with dosing based on renal function in combination with oral folinic acid rescue
62081642|NCT05748600|EXPERIMENTAL|150 mg BID|Dexpramipexole 150 mg oral tablet taken twice a day
62081643|NCT05748600|EXPERIMENTAL|75 mg BID|Dexpramipexole 75 mg oral tablet taken twice a day
62081644|NCT05748600|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet taken twice a day
62280918|NCT05601557||Hemochromatosis|① clinical manifestations of extensive skin pigmentation, bronzing; Decline to disappearance of sexual function; Mild hepatosplenomegaly, may appear jaundice; The heart is enlarged; Pain and swelling mainly in metacarpophalangeal joints; Decreased glucose tolerance and increased blood glucose; ② Serum iron was significantly increased, serum transferrin was normal or decreased, transferrin saturation was significantly increased, often more than 62%, serum ferritin was significantly increased, often more than 500ug/L; (3)/HJV/HAMP TFR2 / SLC40A1 HFE gene mutation.
62649043|NCT06440928|EXPERIMENTAL|intervention grup : standart treatment and deep friction|The patients were asked to stretch for 20 s with the other hand with the shoulder in internal rotation, elbow in extension, forearm in pronation, wrist in flexion and ulnar deviation. In the first week, stretching exercises were recommended to be performed 3 sets a day, 5⨯20 s in one set and 45 s rest interval before strengthening exercises. The application will be performed with the thumb in the transverse direction, with the pressure tolerated by the individual, for 10 minutes after numbness is obtained, the treatment lasts approximately 10-15 minutes.
62280919|NCT05601557||Glycogen accumulation disease|According to different types, there may be the following manifestations, which need specific analysis. ① Clinical manifestations of abdominal distension, fasting hypoglycemia and other symptoms; ② Laboratory examination showed metabolic acidosis, hyperlactic acidemia, hyperuricemia and hyperlipidemia; ③ Abdominal CT showed enlarged liver volume; ④ Serum glucosidase activity decreased; (5) the GAA/G6PC/SLC374A/AGL/PYG/PHK gene mutations.
62280920|NCT05601557||Other types of inherited metabolic liver disease|
62280921|NCT00574574|EXPERIMENTAL|1|500mg/d of anthocyanin, contained in 4 X 250mg capsules (125mg anthocyanin/ capsule). 2 capsules to be taken with food, twice per day (n=4 in total).
62280922|NCT00574574|PLACEBO_COMPARATOR|2|500mg/d of placebo control containing no anthocyanin, 2 X 250mg capsules to be taken with food, twice per day (n=4, 250mg capsules in total / d).
62280923|NCT01602341|EXPERIMENTAL|AN2728 Topical Ointment, 2% QD vs 0.5% QD|"AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied once daily for 29 days to a target lesion~Treatments will be randomly assigned to target lesions A and B."
62280924|NCT01602341|EXPERIMENTAL|AN2728 Topical Ointment, 2% BID vs 0.5% BID|"AN2728 Topical Ointment, 2% applied twice daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied twice daily for 29 days to a target lesion.~Treatments will be randomly assigned to target lesions A and B."
62280925|NCT05431257|EXPERIMENTAL|Elderly/unfit AML patients or sec. and R/R AML patients|
62280926|NCT01707849|ACTIVE_COMPARATOR|MMF arm|"MMF arm (n=20)~They will receive immunosuppression as stipulated by hospital protocol:~Tacrolimus (levels 8-10ng/mL) and Mycophenalate mofetil 1mg bid(levels 1-3ng/mL)."
62458352|NCT00147030|ACTIVE_COMPARATOR|cooled|Whole body mild induced hypothermia for 72 hours, starting by 6 hours of age, in addition to standard intensive care. After 72 hours of cooling, rewarming by a maximum of 0.5 degree C / hour to normothermia.
62458353|NCT00147030|NO_INTERVENTION|non-cooled|Standard intensive care
62649044|NCT06440928|EXPERIMENTAL|intervention grup: standart treatment.|The patients were asked to stretch for 20 s with the other hand with the shoulder in internal rotation, elbow in extension, forearm in pronation, wrist in flexion and ulnar deviation. In the first week, stretching exercises were recommended to be performed 3 sets a day, 5⨯20 s in one set and 45 s rest interval before strengthening exercises. Starting from the 2nd week of treatment, it will be requested to be performed 3 sets a day, 5⨯20 s in one set, 5⨯20 s before exercise and 5⨯20 s after exercise.
62081645|NCT06062576|NO_INTERVENTION|control group 1|The optimal clinical treatment scheme was used to treat the wound of progressive infection period patients for 2 weeks
62458354|NCT03340727|EXPERIMENTAL|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
62081646|NCT06062576|EXPERIMENTAL|powder group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of progressive infection period patients for 2 weeks
62081647|NCT06062576|EXPERIMENTAL|ointment group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of progressive infection period patients for 2 weeks
62081648|NCT06062576|NO_INTERVENTION|control group 2|The optimal clinical treatment scheme was used to treat the wound of granulation period patients for 2 weeks
62081649|NCT06062576|EXPERIMENTAL|powder group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of granulation period patients for 2 weeks
62081650|NCT06062576|EXPERIMENTAL|ointment group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of granulation period patients for 2 weeks
62081651|NCT00632710|EXPERIMENTAL|b|laser
62081652|NCT00632710|PLACEBO_COMPARATOR|a|laser placebo
62081653|NCT06649006|EXPERIMENTAL|Blinatumomab|Participants affected by B-ALL will receive blinatumomab as an intravenous (IV) infusion.
62081654|NCT06184256|EXPERIMENTAL|Core Curriculum|Participants will receive core curriculum
62081655|NCT06184256|EXPERIMENTAL|Core Curriculum and Group Support|Participants will receive core curriculum and group support
62081656|NCT06184256|EXPERIMENTAL|Core Curriculum and Behavioral Skills|Participants will receive core curriculum and behavioral skills
62081657|NCT06184256|EXPERIMENTAL|Core Curriculum, Behavioral Skills, and Group Support|Participants will receive core curriculum, behavioral skills, and group support
62081658|NCT06184256|EXPERIMENTAL|Core Curriculum and 1:1 Counseling|Participants will receive core curriculum and 1:1 counseling
62280927|NCT01707849|EXPERIMENTAL|EVL arm|"EVL arm (n=20):~Tacrolimus (levels 8-10ng/ml) + everolimus 1mg bid (levels 2-4 ng/mL)"
62280928|NCT03390413|ACTIVE_COMPARATOR|Robot|
62280929|NCT03390413|EXPERIMENTAL|Cryo|
62458355|NCT03340727|PLACEBO_COMPARATOR|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
62458356|NCT01295372|EXPERIMENTAL|Zicronapine|
62458357|NCT01295372|ACTIVE_COMPARATOR|Risperidone|
62458358|NCT05942703||obese patients|Patients with a body mass index superior or equal at 30 and with a periodontitis
62649045|NCT03549026|EXPERIMENTAL|duloxitine group|Patients will receive single oral dose of duloxetine capsule, 60 mg, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
62649046|NCT03549026|PLACEBO_COMPARATOR|placebo group|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
62649047|NCT00921024|EXPERIMENTAL|1|CXA-101
62649048|NCT00921024|ACTIVE_COMPARATOR|2|Ceftazidime
62649049|NCT04653311|EXPERIMENTAL|Endomina procedure + lifestyle intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. This group will also receive the medical standard treatment defined as lifestyle intervention.
62458359|NCT05942703||non-obese (BMI<30) patients|Patients with a body mass index inferior at 30 with a periodontitis
62458360|NCT04700254||working condition|In order to further explore the differences among working status the data will be categorized into three different groups: suspension of work, employment and unemployment.
62649050|NCT04653311|NO_INTERVENTION|Lifestyle intervention|The group will receive the medical standard treatment defined as lifestyle therapy combining diet (mediterranean diet) with increased physical activity
62649051|NCT01813266||Usual practice in screening for Hepatitis C virus.|Three clinics in this group will use this approach.
62081659|NCT06184256|EXPERIMENTAL|Core Curriculum,1:1 Counseling, and Group Support|Participants will receive core curriculum, 1:1 counseling, and group support
62081660|NCT06184256|EXPERIMENTAL|Core Curriculum, 1:1 Counseling, and Behavioral Skills|Participants will receive core curriculum, 1:1 counseling, and behavioral skills
62081661|NCT06184256|EXPERIMENTAL|Core Curriculum, 1:1 Counseling, Behavioral Skills, and Group Support|Participants will receive core curriculum, 1:1 counseling, behavioral skills, and group support
62280930|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
62280931|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
62280932|NCT03378063|EXPERIMENTAL|transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be given to the infants with BPD.
62280933|NCT03378063|ACTIVE_COMPARATOR|no transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be not given to the infants with BPD.
62280934|NCT00785057||1|Hypertension patients with history of stroke
62280935|NCT00785057||2|Hypertension patients without history of stroke
62280936|NCT02486315||AXXESS stent|"all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the Sapienza University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) \<70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation"
62458361|NCT04700254||Family status|In order to xplore the differences among the family status, the data will be categorized into the married and the singles DM patients.
62458362|NCT04700254||BMI status|In order to further explore BMI scale results, we divided the data obtained from the participants into normal (18.50 - 24.99 kg/m2), overweight (25-29.99 kg/m2) and obese (≥30 kg/m2), according to the international classification of the World Health Organisation (WHO).
62458363|NCT02930005|EXPERIMENTAL|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
62458364|NCT02930005|EXPERIMENTAL|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
62458365|NCT02995057||Nickel allergic|Participants have proven nickel allergy
62458366|NCT01572948|PLACEBO_COMPARATOR|Placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
62458367|NCT01572948|ACTIVE_COMPARATOR|Daliresp|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
62081662|NCT06184256|EXPERIMENTAL|Program Provider|Providers will deliver and evaluate one or more components of the diet or exercise interventions
62458368|NCT06393088|EXPERIMENTAL|IR REHAB Device|Participants will receive 6 treatments of 15 minutes each with an active IR REHAB device over the period of three weeks.
62649052|NCT01813266||USPTF risk factors to screen for chronic HCV infection.|3 internal medicine clinics will use this screening strategy.
62649053|NCT01813266||USPTF/CDC recommendations to screen for chronic HCV infection.|3 internal medicine clinics.
62649054|NCT03826615|EXPERIMENTAL|Gabapentin|Gabapentin premedication group
62649055|NCT03826615|NO_INTERVENTION|No medication|Control group
62081663|NCT05797740||Single cohort|This is a single cohort study enrolling Participants with relapsing multiple sclerosis (RMS), who are prescribed treatment with cladribine tablets in routine clinical practice following the summary of product characteristics (SmPC).
62081664|NCT06634836||Hemophilia A and Hemophilia B patients|Patients who are participating in the Pfizer's gene therapy clinical trials for Hemophilia A or Hemophilia B or are in the long-term follow up for these clinical programs
62649056|NCT01576848|EXPERIMENTAL|GROUP 1 (OLD-PRO)|test drink contains intrinsically labeled protein alone
62649057|NCT01576848|EXPERIMENTAL|GROUP 2 (OLD-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
62081665|NCT06319222|NO_INTERVENTION|Standard of Care Arm|Primary care providers will treat subject per standard of care utilizing the Interactive Care Plan program.
62081666|NCT06319222|OTHER|Digital Clinic Arm|The Ria Treatment Platform (RTP) application will be downloaded onto the patient's smart phone or tablet.
62081667|NCT06739460||P group|This group consists of hysteroscopy cases in which sedation was given using fentanyl, midazolam, propofol and remifentanil.
62458369|NCT06393088|SHAM_COMPARATOR|Sham Device|Participants will receive 6 treatments of 15 minutes each with a disabled (sham) IR REHAB device over the period of three weeks.
62458370|NCT02238145||Chronic Obstructive Airways Disease|
62458371|NCT05411692|EXPERIMENTAL|Functional electrical stimulations and motor priming exercise|Functional electrical stimulations and motor priming exercise • Palmar Grasp (holding a ball) of Lateral Grasp (holding a tray),Tripod grip (thumb, index, and middle finger: holding a pen), Two finger opposition (thumb and index finger: holding a peg, Lateral Pinch (thumb and index finger: holding a credit card), lateral pinch, two fingers (index and middle finger: smoker's grip
62458372|NCT05411692|ACTIVE_COMPARATOR|Functional electrical stimulations|Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve
62458373|NCT05411692|PLACEBO_COMPARATOR|Convetional phyusical therapy|The prescription of resistance load for strength training will be performed with fine motor exercise , based on sub maximal repetitions
62458374|NCT04526496|EXPERIMENTAL|Single Ascending Doses|50mg-600mg
62649058|NCT01576848|EXPERIMENTAL|GROUP 3 (YOUNG-PRO)|test drink contains intrinsically labeled protein alone
62081668|NCT06739460||K group|This group consists of hysteroscopy cases in which sedation was given using fentanyl, midazolam, ketamine, propofol and remifentanil.
62081669|NCT06739460||KM group|This group consists of hysteroscopy cases that received preoperative magnesium sulfate and sedation using fentanyl, midazolam, ketamine, propofol and remifentanil.
62081670|NCT05141487||Conditional SNM|This group receives conditional sacral neuromodulation, applied intermittently based on sensor data describing bladder activity.
62458375|NCT04526496|EXPERIMENTAL|Multiple Ascending Doses|dose to be determined
62458376|NCT04180007|EXPERIMENTAL|Neoadjuvant arm|Patients receive Apatinib orally qd up to 12 wk.
62081671|NCT05141487||Continuous SNM|This group receives continuous SNM, applied constantly throughout the bladder filling cycle.
62081672|NCT02988128||Intracranial aneurysm|Patients undergoing treatment for intracranial aneurysms (IA) with Medtronic market approved device(s).
62458377|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
62458378|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
62649059|NCT01576848|EXPERIMENTAL|GROUP 4 (YOUNG-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
62649060|NCT01579214|ACTIVE_COMPARATOR|Direct Text Message|Participants in the intervention period (September 2012 - November 2013) received daily short message service (SMS) messages for up to seven days with messages reporting an abnormal result
62649061|NCT01579214|NO_INTERVENTION|Pre-Intervention|Participants enrolled in the pre-intervention period (January - August 2012) served as a control group.
62649062|NCT04791176|EXPERIMENTAL|Lenvatinib and IMRT|Concurrent Lenvatinib and IMRT, followed Lenvatinib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
62649063|NCT06018012||1 or acute bilirubin encephalopathy|Group (1): included 26 cases with BIND or acute bilirubin encephalopathy (ABE).
62649064|NCT06018012||2 or neonatal hyperbilirubinemia|Group (2): included 30 cases with neonatal hyperbilirubinemia on
62649065|NCT06018012||Control|control group: 20 healthy, age-matched neonates
62649066|NCT04292236|PLACEBO_COMPARATOR|Placebo|Administered at time 0 min and 300 min. Cellulose was used as the placebo.
62081673|NCT02988128||Acute Ischemic Stroke|Patients undergoing treatment for acute ischemic stroke (AIS) with Medtronic market approved device(s).
62081674|NCT06050252|EXPERIMENTAL|Treatment (durvalumab, gemcitabine, cisplatin)|Patients receive durvalumab IV over 60 minutes on day 1 with gemcitabine IV over 30 minutes and cisplatin IV over 60 minutes on days 1 and 8 for 4 cycles and then undergo surgical resection on study. Following surgery, patients may continue the durvalumab, gemcitabine and cisplatin regimen for up to 4 additional cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scans and/or MRI scans and blood sample collection throughout study, as well as tissue biopsies during screening and on study.
62081675|NCT06112418|NO_INTERVENTION|Risk Factor-Based Care|The risk factor-based care group will be managed by their usual care providers, with an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. During the trial, the centralized cardiology team will monitor the provision of medications prescribed and lab values relative to guidelines, and provide feedback and education to site investigators to support optimization. CCTA results will be centrally archived and will remain blinded to the usual care provider until the end of the study.
62081676|NCT06112418|EXPERIMENTAL|Cleerly Stage-Based Care|The Cleerly Stage-Based Care group will receive personalized care centrally managed by a remote cardiologist-led team. They will also receive an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. Cleerly CAD Staging System results will be discussed with participants and serve as the basis for standardized algorithm-supported pharmacotherapy \& education, which will be intensified if plaque burden has progressed at 24 months.
62081677|NCT05396625|EXPERIMENTAL|Family Strengthening, Mental Health, Economic Empowerment|Group will receive: 1) Usual Care, 2) Family Strengthening, 3) Mental Health Screening \& Referral, and 4) Economic Empowerment Interventions
62081678|NCT05396625|EXPERIMENTAL|Family Strengthening, Mental Health|Group will receive: 1) Usual Care, 2) Family Strengthening, and 3) Mental Health Screening \& Referral Interventions
62081679|NCT05396625|EXPERIMENTAL|Family Strengthening, Economic Empowerment|Group will receive: 1) Usual Care, 2) Family Strengthening, and 3) Economic Empowerment Interventions
62081680|NCT05396625|EXPERIMENTAL|Family Strengthening Only|Group will receive: 1) Usual Care and 2) Family Strengthening Interventions
62081681|NCT05396625|EXPERIMENTAL|Mental Health, Economic Empowerment|Group will receive: 1) Usual Care, 2) Mental Health Screening \& Referral, and 3) Economic Empowerment Interventions
62081682|NCT05396625|EXPERIMENTAL|Mental Health Only|Group will receive: 1) Usual Care and 2) Mental Health Screening \& Referral Interventions
62081683|NCT05396625|EXPERIMENTAL|Economic Empowerment Only|Group will receive: 1) Usual Care and 2) Economic Empowerment Interventions
62081684|NCT05396625|EXPERIMENTAL|Usual Care Only|Group will receive: Usual Care Intervention only
62081685|NCT05315167|EXPERIMENTAL|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level. PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
62081686|NCT05315167|EXPERIMENTAL|Monotherapy Exploration of the recommended dose|Upon completing Phase 1 and depending on data obtained, dose expansion may proceed in Phase 2 with several cohorts enrolled to confirm the tolerability of the RP2D of PRJ1-3024 (determined in Phase 1). PRJ1-3024 is administered orally once daily. The starting dose is determined by clinical effecacy data from Phase 1, and treatment may continue for up to 2 years as long as the subject experiences clinical benefit in the opinion of the Investigator and shows no signs or symptoms of unequivocal progression of disease.
62458379|NCT02070185|EXPERIMENTAL|2 exposures|During the conditioning period, the children of this group was exposed only twice to the beverages
62458380|NCT02070185|EXPERIMENTAL|7 exposures|During the conditioning period, children of this group were exposed exposed 7 times to the beverages
62458381|NCT01697878|EXPERIMENTAL|Randomization Group 1|CPAP first followed by standard of care
62458382|NCT01697878|ACTIVE_COMPARATOR|Randomization group 2|Standard of care followed by CPAP
62081687|NCT00967863|EXPERIMENTAL|Arm I|Patients undergo 80 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
62081688|NCT00967863|EXPERIMENTAL|Arm II|Patients undergo 70 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
62081689|NCT05519085|EXPERIMENTAL|MeziVd (mezigdomide, bortezomib and dexamethasone)|
62081690|NCT05519085|EXPERIMENTAL|PVd (pomalidomide, bortezomib and dexamethasone)|
62081691|NCT05376267|EXPERIMENTAL|Cooling 0 hours|Participants will be kept at a normal temperature for the whole 5 days.
62081692|NCT05376267|EXPERIMENTAL|Cooling 12 hours|The participant will be cooled to 33°Celsius (C) for 12 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62081693|NCT05376267|EXPERIMENTAL|Cooling 18 hours|The participant will be cooled to 33°C for 18 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62081694|NCT05376267|EXPERIMENTAL|Cooling 24 hours|The participant will be cooled to 33°C for 24 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62458383|NCT05911139||pediatric patients|Patients indicated for surgical treatment of single-layer craniosynostosis will be selected for the study, anticipated 15 patients per calendar year
62458384|NCT00912288|EXPERIMENTAL|Dimebon|
62649067|NCT04292236|ACTIVE_COMPARATOR|Dietary Supplement|Administered at 0 min and 300 min. Combination of lauric acid, perilla oil and diindolylmethane was used as the dietary supplement.
62081695|NCT05376267|EXPERIMENTAL|Cooling 36 hours|The participant will be cooled to 33°C for 36 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62081696|NCT05376267|EXPERIMENTAL|Cooling 48 hours|The participant will be cooled to 33°C for 48 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62081697|NCT05376267|EXPERIMENTAL|Cooling 60 hours|The participant will be cooled to 33°C for 60 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62081698|NCT05376267|EXPERIMENTAL|Cooling 72 hours|The participant will be cooled to 33°C for 72 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62081699|NCT05376267|EXPERIMENTAL|Cooling 84 hours|The participant will be cooled to 33°C for 84 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62081700|NCT05376267|EXPERIMENTAL|Cooling 96 hours|The participant will be cooled to 33°C for 96 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
62649068|NCT05058963|EXPERIMENTAL|Mantram repetition program|Weekly 90 minute virtual group therapy sessions for 8 weeks run by two faciliators and will consist of 5-8 participants.
62081701|NCT05053503|PLACEBO_COMPARATOR|Active tAN + placebo|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for up to 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
62081702|NCT05053503|ACTIVE_COMPARATOR|Active tAN + lofexidine|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for up to 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
62458385|NCT00912288|PLACEBO_COMPARATOR|Placebo|
62458386|NCT02845128||HFNC failure|requiring intubation and invasive mechanical ventilation
62458387|NCT02845128||HFNC success|not requiring intubation nor invasive mechanical ventilation
62458388|NCT03009448||Late onset depression|
62458389|NCT05308043||Retinoblastoma patients|Retinoblastoma patients who undergo standard medical care in Beijing Tongren Hospital. The anonymous image of these patients will be prospectively collected and labelled by senior ophthalmologists.
62649069|NCT06429241|EXPERIMENTAL|MSCs treatment group|Intralesional injection of expanded human umbilical cord-derived mesenchymal stem cells suspension.
62458390|NCT05098379|EXPERIMENTAL|Tele-Rehabilitation Home Exercise Program|Subjects will participate in an 8-week customized home exercise program with weekly virtual exercise coaching sessions.
62649070|NCT00535470|EXPERIMENTAL|1|Open label 0.04% Mechlorethamine gel
62649071|NCT01727921|ACTIVE_COMPARATOR|22 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 22 gauge ProCore biopsy needle.
62649072|NCT01727921|ACTIVE_COMPARATOR|25 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 25 gauge ProCore biopsy needle.
62649073|NCT06285500||Group 1|N-of-1 treatment with marketed drugs used on or off-label as per SOC.
62081703|NCT05053503|NO_INTERVENTION|Sham tAN + placebo|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
62081704|NCT05053503|SHAM_COMPARATOR|Sham tAN + lofexidine|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
62081705|NCT05053503|ACTIVE_COMPARATOR|extended-release injectable naltrexone|Extended-release injectable naltrexone will be administered according to the clinical site's standard of care.
62081706|NCT05053503|EXPERIMENTAL|Active tAN + extended-release injectable naltrexone|"Extended-release injectable naltrexone will be administered according to the clinical site's standard of care. Participants will be provided with a Spark Sparrow Ascent Therapy System and instructed to administer therapy according to the specified frequencies:~* Month 1 (Days 1 - 28): a minimum of 2 hours per day at least 5 days a week~* Month 2 (Days 29 - 56): a minimum of 2 hours per day at least 3 days a week~* Month 3 (Days 57 - 90: a minimum of 2 hours per day at least 1 day per week"
62458391|NCT01775592|OTHER|Arterakin|"Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - \< 8 years: 1.0, 1.0, 1.0, 1.0 8 - \< 15 years:1.5, 1.5, 1.5, 1.5~≥ 15 years:2.0, 2.0, 2.0, 2.0"
62458392|NCT04569682|ACTIVE_COMPARATOR|transrenal artery perfusion group|
62081707|NCT02642471|EXPERIMENTAL|Arm 1|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
62081708|NCT02642471|NO_INTERVENTION|Arm 2|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
62458393|NCT04569682|EXPERIMENTAL|transrenal vein perfusion group|
62458394|NCT02199548||Study Participants|All enrolled participants will take part in a face-to-face interview.
62458395|NCT03614195|EXPERIMENTAL|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
62458396|NCT03614195|ACTIVE_COMPARATOR|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
62649074|NCT06285500||Group 2|N-of-1 treatment with drugs accessed from SAP.
62081709|NCT02642471|EXPERIMENTAL|Arm 3|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
62081710|NCT02642471|NO_INTERVENTION|Arm 4|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
62081711|NCT06729775|ACTIVE_COMPARATOR|adolescence - graphical|adolescence (10\~19 yrs.) that receives a traditional graphical (figures/charts/tables) representation of environmental health/quality data
62280937|NCT02486315||Control group|"The control group is represented by patients with coronary bifurcation lesions treated with conventional techniques and standard balloon expandable drud eluting stents.~This group was found retrospectively through a propensity score matching."
62280938|NCT00707798|EXPERIMENTAL|Formulation 1|
62458397|NCT03614195|ACTIVE_COMPARATOR|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
62458398|NCT02445456|EXPERIMENTAL|Ex-vivo|Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
62081712|NCT06729775|ACTIVE_COMPARATOR|adolescence - art-infused|adolescence (10\~19 yrs.) that receives an environment art representation of environmental health/quality data
62081713|NCT06729775|ACTIVE_COMPARATOR|adolescence - geospatial|adolescence (10\~19 yrs.) that receives a geospatial representation of environmental health/quality data
62081714|NCT06729775|ACTIVE_COMPARATOR|young adults - graphical|young adults (18-26 yrs.) that receives a traditional graphical (figures/charts/tables) representation of environmental health/quality data
62081715|NCT06729775|ACTIVE_COMPARATOR|young adults - art-infused|young adults (18-26 yrs.) that receives an environment art representation of environmental health/quality data
62280939|NCT00707798|EXPERIMENTAL|Formulation 2|
62280940|NCT00707798|EXPERIMENTAL|Formulation 3|
62280941|NCT00707798|EXPERIMENTAL|Formulation 4|
62458399|NCT02445456|EXPERIMENTAL|In-vivo|Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.
62458400|NCT06061666|EXPERIMENTAL|Treated group|Group treated with MG-C of Tilia tomentosa
62458401|NCT06061666|PLACEBO_COMPARATOR|Placebo Group|Group treated with placebo
62458402|NCT02529280|EXPERIMENTAL|Intervention|The intervention group will receive three components: 1) a culturally sensitive, individually tailored, 30-minute computer-based BCCT video; 2) a bilingual, low-literacy booklet aimed at encouraging patients to communicate with family and friends and 3) assistance from a patient navigator.
62458403|NCT02529280|NO_INTERVENTION|Usual Care|The usual care control group will receive the usual care breast cancer clinical trial information materials offered by the CTRC to their eligible patients.
62458404|NCT04568408||Sleep study participants|Adults presenting sleep difficulties or poor sleep quality that are performed a Polisomnography study in a Sleep Unit at hospital.
62280942|NCT00707798|EXPERIMENTAL|Formulation 5|
62280943|NCT00707798|EXPERIMENTAL|Formulation 6|
62280944|NCT00707798|ACTIVE_COMPARATOR|23 valent pneumococcal vaccine|
62280945|NCT03354182|ACTIVE_COMPARATOR|Control group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen + Bio-gide
62280946|NCT03354182|ACTIVE_COMPARATOR|Test group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen alone
62280947|NCT02617810|EXPERIMENTAL|JNJ-42847922 Plus Midazolam Plus Warfarin|Participants will receive Treatment A (midazolam 4 milligram \[mg\] syrup once on Day 1 and warfarin 25 mg tablet once on Day 3) followed by Treatment B (JNJ-42847922 20 mg once daily from Day 1 to Day 9, midazolam 4 mg syrup once on Day 7 and warfarin 25 mg tablet once on Day 9). A washout period of 14 to 21 days will be maintained between each treatment period.
62081716|NCT06729775|ACTIVE_COMPARATOR|young adults - geospatial|young adults (18-26 yrs.) that receives a a geospatial representation of environmental health/quality data
62081717|NCT06729775|ACTIVE_COMPARATOR|adults - graphical|adults (27 yrs.+) that receives a traditional graphical (figures/charts/tables) representation of environmental health/quality data
62081718|NCT06729775|ACTIVE_COMPARATOR|adults - art-infused|adults (27 yrs.+) that receives an environment art representation of environmental health/quality data
62081719|NCT06729775|ACTIVE_COMPARATOR|adults - geospatial|adults (27 yrs.+) that receives a geospatial representation of environmental health/quality data
62081720|NCT04917796|EXPERIMENTAL|Electroacupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
62081721|NCT04917796|PLACEBO_COMPARATOR|Sham Acupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
62081722|NCT05912543|NO_INTERVENTION|Conventional arm|"Moderate hyperoxia as determined by T1 arterial blood gas. For moderate hyperoxemia (PaO2 \> 300 mmHg), reduce the inspired oxygen concentration to 80% and for severe hyperoxemia to 70%.~In the situation of hypoxia, where the peripheral oxygen saturation decreases to less than 95% even in 100% of FiO2, the following treatment is indicated: Fluid administration, inotropes administration (dopamine), alveolar recruitment, return to two-lung ventilation, and application of continuous positive airway pressure."
62081723|NCT05912543|EXPERIMENTAL|ORI arm|Target ORi™ of 0.15, check the ORi™ every 5 minutes and adjust the inspired oxygen concentration in 5% increments. If the ORi™ decreases to less than 0.15, treat it in the same way as if hypoxia occurred in the conventional group.
62081724|NCT04842890|OTHER|Stereotactic body radiation therapy (SBRT) with Pencil Beam Scanning (PBS) proton therapy|
62081725|NCT05918328|EXPERIMENTAL|Nab-PH+pyrrolitinib regimen group|Drug dose of Nab PH+pyrrolitinib scheme: albumin paclitaxel 260mg/m 2+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+pyrrolitinib (320mg, QD), one cycle every 21 days.
62081726|NCT05918328|PLACEBO_COMPARATOR|TCbHP regimen group|The drug dose of TCbHP protocol: docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial load dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial load dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days.
62280948|NCT03208231|EXPERIMENTAL|VRC01 (Arm 1)|Infants received VRC01 subcutaneous injections (40 mg/kg) at Weeks 0, 2, 6, and 10.
62280949|NCT03208231|ACTIVE_COMPARATOR|No-VRC01 (Arm 2)|Infants did not receive VRC01.
62458405|NCT03895684|EXPERIMENTAL|Sp-2577|Twice-daily administration of oral SP-2577
62458406|NCT01220830|EXPERIMENTAL|RFQMR on Multiple Sclerosis lesions|
62081727|NCT06232902|EXPERIMENTAL|QL1101|QL1101, intravenous infusion 90 min (±5min), D1 (Day 1, single dose)
62081728|NCT06232902|ACTIVE_COMPARATOR|Avastin®|Avastin®, intravenous infusion 90 min (±5min), D1 (Day 1, single dose)
62081729|NCT06738381|EXPERIMENTAL|Digital intervention and motivational counselling|A single in-hospital motivational counselling session and access to a digital platform for a 6 months period with patient information, videos and an individualized treatment plan and follow-up plan.
62081730|NCT06738381|ACTIVE_COMPARATOR|Control group|Brief advices, tailored discharge information to patients and their general practitioners, and a nurse-led outpatient visit at six months follow-up
62081731|NCT00001471||Healthy Volunteers|Healthy Volunteers
62081732|NCT00001471||HIV-infected|HIV-infected individuals
62081733|NCT00001471||ICL|Idiopathic CD4 lymphopenia
62458407|NCT02778919|EXPERIMENTAL|KLH-2109, lowest dose|
62458408|NCT02778919|EXPERIMENTAL|KLH-2109, low dose|
62280950|NCT05169528|OTHER|Colorectal Cancer Prehabilitation Program|This is a before-after trial. The same group of participants will have a series of outcome measures taken at baseline, which will then be compared to these same outcome measures when repeated after undergoing prehabilitation and at 3 months' post-operatively
62280951|NCT05449704|EXPERIMENTAL|Sequence A|
62280952|NCT05449704|EXPERIMENTAL|Sequence B|
62280953|NCT02543138|EXPERIMENTAL|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
62081734|NCT04548778||exocrine pancreatic insufficiency (PEI)|Established diagnosis of PEI based on a routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
62280954|NCT03219866|EXPERIMENTAL|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
62280955|NCT03219866|EXPERIMENTAL|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
62280956|NCT02282969||Lung Cancer Screening Decision Aids|Participants are asked to look over education materials about lung cancer screening, and interviewed. Some participants will look at a video patient decision aid, with an interview and questionnaire completion. Some participants complete lung cancer screening knowledge questionnaire at first visit, and then again in one month.
62280957|NCT01060657||conventional (C) group|
62280958|NCT01060657||low dose (L) groups|
62280959|NCT03295864|EXPERIMENTAL|Patients with Chiari type 1 malformation|Tympanometry measurement at inclusion and 6 months after surgery
62280960|NCT03295864|EXPERIMENTAL|Healthy volunteers|Tympanometry measurement at inclusion. Every healthy volunteer will be match with a patient for his age and his BMI (body mass index).
62280961|NCT03648632|EXPERIMENTAL|Stereotactic Radiotherapy|50 Gy in 5 fractions within a total of 7 - 8 days
62280962|NCT04519723|OTHER|Alma Harmony Laser System|There is only one arm. Three hand modules; Dye-VL 500-600nm, High Power QSW 1064nm, and High power Pixel ER:YAG 2940nm laser module with rollers will be utilized in combination in a series of treatments intended to improve skin color, tone, texture and laxity. Subjects will receive up to four treatments administered in intervals of 28 +/- 2 days. Treatment duration of approximately 60 minutes.
62280963|NCT05083637|ACTIVE_COMPARATOR|Intervention Arm|Children randomized to this arm will receive L- carnitine oral solution (100mg/ml) (Generic Name) with the dosage- 100 mg/kg/day, divided into 3 doses per day for 15 days.
62280964|NCT05083637|PLACEBO_COMPARATOR|Control Arm|Children randomized to this arm will receive placebo in same quantity, divided into 3 doses per day for 15 days.Placebo solution will be identical in appearance, smell and taste to the active preparation (L-carnitine syrup) with no therapeutic value.
62280965|NCT03162679|EXPERIMENTAL|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
62458409|NCT02778919|EXPERIMENTAL|KLH-2109, medium dose|
62458410|NCT02778919|EXPERIMENTAL|KLH-2109, high dose|
62280966|NCT03162679|NO_INTERVENTION|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
62280967|NCT05790265|EXPERIMENTAL|Comparison of ANNE One system blood pressure measurements to arterial line|
62280968|NCT04855773|EXPERIMENTAL|PrEPmate|Participants randomized to this study arm will receive the PrEPmate mHealth intervention (bi-directional text messaging with PrEP navigators/clinic staff) to support PrEP adherence and continuation.
62458411|NCT02778919|PLACEBO_COMPARATOR|Placebo|First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels
62458412|NCT02778919|OTHER|Leuprorelin acetate|Active reference
62458413|NCT01357707||West Syndrome (idiopathic)|Patients with idiopathic infantile seizures
62081735|NCT04548778||no exocrine pancreatic insufficiency (no PEI)|No evidence of PEI according to routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
62280969|NCT04855773|EXPERIMENTAL|Dot Diary mobile application|Participants randomized to this study arm will download and use the Dot Diary mobile application on a personal device, to support PrEP adherence and continuation.
62280970|NCT00564811|NO_INTERVENTION|G1|
62280971|NCT00564811|EXPERIMENTAL|G2|
62458414|NCT00876200|EXPERIMENTAL|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
62458415|NCT00876200|PLACEBO_COMPARATOR|Placebo|Placebo = lactose
62458416|NCT05331222|EXPERIMENTAL|Jantar-1 (JT-1), 7% (w/w) aqueous solution|Dosing regimen: ad libitum between at least 2 doses, in the morning and in the evening, and at most 10 doses per day. A dose corresponds to two strokes of 100ul each per nostril.
62280972|NCT01175785|EXPERIMENTAL|Treatment (chemo, radiation, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI twice daily on days -4 to -1. Patients undergo unmanipulated single- or double-unit umbilical cord blood transplantation on day 0 and receive ex vivo-expanded cord blood progenitor cells IV over 4 hours following the last unmanipulated cord blood infusion. Patients initially receive CSP IV over 1 hour beginning on day -3. CSP may be given PO when the patient can tolerate oral medications and has a normal gastrointestinal transit time. CSP is given until day 100, and may taper on day 101 if there is no graft versus host disease. Patients also receive MMF IV every 8 hours on days 0 to 7 and then may receive MMF PO beginning day 8 to 30. MMF is continued for a minimum of 30 days or until 7 days after blood counts recover whichever is later. If there is no evidence of acute GVHD and donor CD3 engraftment is at least 50% from one donor MMF may be tapered.
62280973|NCT02602730|EXPERIMENTAL|Break the Chain|Access during the evaluation study period to an Internet smoking cessation intervention that included digital coaching messages sent at prescribed times during the participant's quit process and as needed in response to participant questions or comments.
62280974|NCT02602730|ACTIVE_COMPARATOR|Clearing the Air PDF|"Control users were e-mailed a copy of the National Cancer Institute's PDF smoking cessation booklet, Clearing the Air."
62280975|NCT03459573|ACTIVE_COMPARATOR|T2D: One Drop with Fitbit Ionic|
62280976|NCT03459573|ACTIVE_COMPARATOR|T2D: One Drop without Fitbit Ionic|
62280977|NCT03459573|NO_INTERVENTION|T2D: Waitlist Control|
62280978|NCT03459573|ACTIVE_COMPARATOR|T1D: One Drop with Fitbit Ionic|
62280979|NCT03459573|ACTIVE_COMPARATOR|T1D: One Drop without Fitbit Ionic|
62280980|NCT03459573|ACTIVE_COMPARATOR|PD: One Drop with Fitbit Charge 2|
62280981|NCT03459573|ACTIVE_COMPARATOR|PD: One Drop without Fitbit Charge 2|
62280982|NCT02271165|ACTIVE_COMPARATOR|IVIg naive|Patients naïve to IVIg who have active disease responding to corticosteroids or are corticosteroid-dependent, will be also included. Before these patients enter the study, they will receive 3 monthly infusions of IVIg starting with the standard dose of 2gram/kg/month and followed with monthly maintenance of 1 or 2gram/kg according to their response.
62081736|NCT05268887|EXPERIMENTAL|Parkinson's Active Arm|Exposure to active sensory stimulation (40Hz) for 30-60 minutes.
62081737|NCT05268887|SHAM_COMPARATOR|Parkinson's Control Arm|Exposure to control stimulation (sham) for 30-60 minutes.
62081738|NCT03935854|EXPERIMENTAL|Ketogenic Diet 16 Week Group|Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support
62280983|NCT02271165|ACTIVE_COMPARATOR|non-IVIg naive|Participants already on IVIg will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their muscle strength, skin changes, assessments of their daily activities and quality of life (QoL) every 4 weeks at scheduled visits for monthly maintenance IVIg infusions (weeks 0,4,8,12).
62280984|NCT05055180||HFpEF with pulmonary hypertension|Invasively diagnosed HFpEF and pulmonary hypertension according to current guidelines
62458417|NCT02769637||ON PPI|Subjects on proton pump inhibitor (PPI) treatment
62458418|NCT02769637||OFF PPI|Subjects off proton pump inhibitor (PPI) treatment
62458419|NCT01880970|ACTIVE_COMPARATOR|Starter infant formula with pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
62280985|NCT05055180||HFpEF without pulmonary hypertension|Invasively diagnosed HFpEF without pulmonary hypertension according to current guidelines
62081739|NCT04772989|EXPERIMENTAL|Dose Escalation Q3W Cohorts|Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
62280986|NCT05055180||Patients without HFpEF|Patients without invasive evidence of HFpEF
62280987|NCT02212132||Patient|Neuropsychological evaluation, psychopathological assessment and fatigue
62280988|NCT02212132||Control group|Neuropsychological evaluation, psychopathological assessment and fatigue
62280989|NCT06182592|EXPERIMENTAL|Arm A (liposomal cytarabine-daunorubicin for injection)|Patients are eligible to receive up to 2 inductions and up to 2 consolidations with liposomal cytarabine-daunorubicin for injection. The number of inductions and consolidations a patient received will depend on response.
62280990|NCT06182592|EXPERIMENTAL|Arm B (7+3)|Patients are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7+3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received will depend on response.
62081740|NCT04772989|EXPERIMENTAL|Dose Escalation Q4W Cohorts|Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
62081741|NCT04772989|EXPERIMENTAL|Dose Escalation Q6W Cohort|Selected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies.
62081742|NCT04772989|EXPERIMENTAL|Dose Expansion Cohort 1|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
62081743|NCT04772989|EXPERIMENTAL|Dose Expansion Cohort 2|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
62081744|NCT04772989|EXPERIMENTAL|Dose Expansion Cohort 3|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
62280991|NCT05623293||Carotid endarterectomy|he population corresponds to patients submitted to elective CEA. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) under regional anesthesia will be prospectively recruited from September 2021 - December 2022. The expected patient follow-up will be of 2years.
62280992|NCT06170996|EXPERIMENTAL|Internet-based behavioral parent training (I-BPT+RCC)|Internet-based behavioural parent training in a group format in addition to routine clinical care, 8 sessions over 2 months, delivered by a systematically trained and supervised therapist.
62280993|NCT06170996|NO_INTERVENTION|Routine clinical care (RCC)|Routine clinical care for 2 months, delivered by experienced child psychiatrists, including medication treatment and examinations, crisis interventions, parent counselling and support.
62280994|NCT01078805||FORTEO (teriparatide)-treated|FORTEO-treated
62280995|NCT04166279|EXPERIMENTAL|Single rehabilitative Treatment|Patients treated within single rehabilitative protocol
62280996|NCT04166279|EXPERIMENTAL|Group rehabilitative Treatment|Patients treated within group rehabilitative protocol
62081745|NCT04772989|EXPERIMENTAL|Dose Expansion Cohort 4|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
62081746|NCT04772989|EXPERIMENTAL|Dose Expansion Cohort 5|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
62081747|NCT06720961||CD Patients|CD patients with established diagnosis and additionally classified according to 3 stages: B1 (more inflammatory, non-stricturing), B2 (stricturing, non-penetrating) and B3 (stricturing and penetrating). Patients will be stratified on the basis of CT, MRI or ultrasound analysis (stratification already known before surgery)
62081748|NCT06720961||Non-IBD Patients|Patients with other pathologies but not affected by IBD according to the previously reported clinical and endoscopic evaluation criteria (ex. diverticulitis)
62280997|NCT00639938|ACTIVE_COMPARATOR|1|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery"
62280998|NCT00639938|EXPERIMENTAL|2|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6"
62280999|NCT00639938|EXPERIMENTAL|3|"Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery"
62281000|NCT04436146|OTHER|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
62281001|NCT05837741|ACTIVE_COMPARATOR|Standard hypercaloric, hyperproteic oral supplement|Patients will receive 2 supplements per day (Standard hypercaloric, hyperproteic oral supplement)
62281002|NCT05837741|ACTIVE_COMPARATOR|Leucin-enriched hypercaloric, hyperproteic oral supplement|Patients will receive 2 supplements per day (Leucin-enriched hypercaloric, hyperproteic oral supplement)
62281003|NCT03265912||Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), mTBI (Mild Traumatic Brain Injury) patient group also called as Arm 1 in this study.
62649075|NCT06285500||Group 3|N-of-1 treatment with non-marketed investigational agents.
62649076|NCT01857752|EXPERIMENTAL|temozolomide|
62458420|NCT01880970|PLACEBO_COMPARATOR|starter infant formula without pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
62281004|NCT03265912||Non Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study, Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), non-TBI (Non Mild Traumatic Brain Injury) patients also called as Arm 2 in this study.
62281005|NCT04627909||Group under Robot treatment|Interaction with the Humanoid Robot for 15 minutes
62281006|NCT04627909||Group involved with medical personnel|Interaction with medical personnel for 15 minutes
62081749|NCT04724018|EXPERIMENTAL|Dose Escalation Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV),|Participants will be given the study drugs Enfortumab Vedotin and then Sacituzumab Govitecan on Days 1 and 8 of a 21-day study cycle. Dose escalation and de-escalation for the Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) combination will be guided using the Bayesian optimal interval (BOIN) design with up to 4 dose level escalations.
62281007|NCT04627909||Control group|Exclusive interaction with the caregiver for 15 minutes
62458421|NCT01880970|NO_INTERVENTION|Breastfeeding group|exclusively breastfeeding during the first 3 months of age, followed by a commercially available Nestlé starter infant formula from 4 to 6 months of age (if applicable) and the follow-up infant formula from 6 to 12 months of age
62281008|NCT03814200|EXPERIMENTAL|Treatment period A|"Treatment A1: saline 0.9%~followed by~Treatment A2: ACT-246475"
62281009|NCT03814200|EXPERIMENTAL|Treatment period B|"Treatment B1: rifampicin~followed by~Treatment B2: ACT-246475"
62281010|NCT01424696||Cystic Fibrosis in 1st 3 months of life|Early Diagnosis: Children diagnosed with CF in first 3 months of life
62281011|NCT00653237|OTHER|1|crossover trial. insertion of both devices consecutively, computer randomized order
62281012|NCT04834869||Pfizer-BioNTech COVID-19 Vaccine|Recently vaccinated individuals by Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
62458422|NCT00590395|EXPERIMENTAL|FDG-PET/CT to determine Cholecystitis|19 patients with suspected acute cholecystitis and a positive HIDA will be included in the study. This is purposely a highly selective population which most likely will have surgical proof of the findings. Subjects will receive an FDG PET/CT exam to determine the presence of gallbladder inflammation/infection(cholecystitis). Please note that 18FDG is an FDA approved radiopharmaceutical.
62081750|NCT05882578|EXPERIMENTAL|Intervention Group|Patients will be assessed and screened prior the intervention. After the physical assestment they will attend 2 days a week for the supervised, and controlled sessions of physical exercise, performed in the nature (Retiro park in Madrid). To meassure the intensity of the program, they will use the 1-10 Borg ratio of perceived exertion (RPE).
62081751|NCT05882578|ACTIVE_COMPARATOR|Control Group|Patients will be asked to mantain an active lifestyle, performing physical activity regularly.
62081752|NCT06487273|OTHER|Control|Remote Physiotherapy + standard of care
62081753|NCT06487273|EXPERIMENTAL|SIMEOX|SIMEOX device combined with Remote Physiotherapy + standard of care
62081754|NCT06083948|EXPERIMENTAL|Noradrenaline|Noradrenaline
62281013|NCT04834869||Moderna COVID-19 Vaccine|Recently vaccinated individuals by Moderna COVID-19 Vaccine
62281014|NCT04834869||AstraZeneca-Oxford University COVID-19 Vaccine|Recently vaccinated individuals by AstraZeneca-Oxford University COVID-19 Vaccine (Vaxzevria)
62281015|NCT04834869||CoronaVac|Recently vaccinated individuals by CoronaVac (Sinovac COVID-19 Vaccine)
62458423|NCT02771015|ACTIVE_COMPARATOR|Mepilex Border®|Mepilex Border® wound dressing at patients after hip-knee or primary spine surgery
62458424|NCT02771015|ACTIVE_COMPARATOR|Cosmopor steril®|Standard wound dressing at patients after hip-knee or primary spine surgery
62458425|NCT00551499|NO_INTERVENTION|CRT for patients with CSA|Patients suffering from HF with central Sleep Apnea (CSA) programmed to DDD/45 (CRT) for 12 weeks. Intervention is CRT.
62458426|NCT00551499|ACTIVE_COMPARATOR|CRT + AOP for patients with CSA|Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
62458427|NCT03423849|EXPERIMENTAL|The original program (NG/NP)|Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）
62649077|NCT04627636|EXPERIMENTAL|study group|which treated with MTrPs release combined with shockwave therapy and conventional program
62281016|NCT04834869||Sinopharm|Recently vaccinated individuals by Vero Cells (Sinopharm COVID-19 Vaccine)
62281017|NCT04834869||Sputnik V|Recently vaccinated individuals by Sputnik V COVID-19 Vaccine
62281018|NCT04834869||Janssen|Recently vaccinated individuals by Janssen COVID-19 Vaccine
62281019|NCT04834869||CureVac|Recently vaccinated individuals by CureVac COVID-19 Vaccine
62281020|NCT04834869||Novavax|Recently vaccinated individuals by Novavax COVID-19 Vaccine
62281021|NCT04834869||Covaxin|Recently vaccinated individuals by Covaxin COVID-19 Vaccine
62281022|NCT04834869||CanSino|Recently vaccinated individuals by CanSino COVID-19 Vaccine
62281023|NCT06109480|ACTIVE_COMPARATOR|ECT combined with real stimulation tDCS group|Bifrontal short-pulse ECT was performed once a day for 3 consecutive days. Then,tDCS stimulates the dorsomedial prefrontal cortex. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. 2-mA (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes Twice a day over 10 consecutive sessions.
62281024|NCT06109480|SHAM_COMPARATOR|ECT combined with sham stimulation tDCS group|Bifrontal short-pulse ECT was performed once a day for 3 consecutive days. Then,Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
62458428|NCT03423849|EXPERIMENTAL|One of the original program (N)|Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.
62458429|NCT03423849|EXPERIMENTAL|Capecitabine monotherapy|Capecitabine oral 1250mg/m2,bid,for 6 cycles
62081755|NCT06083948|ACTIVE_COMPARATOR|Phenylephrine|Phenylephrine
62081756|NCT06257277||Patients require GBCA-enhanced MRI|Patients who are scheduled to undergo magnetic resonance imaging (MRI) with gadolinium-based contrast agent (GBCA) enhancement as per routine clinical practice.
62081757|NCT06474182|EXPERIMENTAL|Blood sampling of patients with de novo multiple myeloma|Description: Blood sampling of patients with de novo multiple myeloma
62081758|NCT06474182|EXPERIMENTAL|Blood sampling of patients undergoing total knee replacement|Description: Blood sampling of patients undergoing total knee replacement
62081759|NCT06737731|EXPERIMENTAL|SHR-1681|
62281025|NCT06109480|OTHER|ECT full course group|The ECT full corse group was used as a standard control.Bifrontal short-pulse ECT was performed once a day for 3 consecutive days,and then once every other day, for a total of 6 times.
62281026|NCT05425563|EXPERIMENTAL|Cue-established expectations|"Prior to experiencing the stimuli from three tasks (somatic pain/cognitive effort/vicarious pain), the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no effort to strongest effort of any kind. Subsequently, participants report expectation ratings and outcome ratings."
62458430|NCT04218903|EXPERIMENTAL|Combined Training 4 times per week (CT4)|The CT4 group will perform four sessions per week of combined exercise program. This intervention will last 12 weeks.
62081760|NCT05039554|ACTIVE_COMPARATOR|Valera smartphone application (app) alone|Participants randomized to this cohort will receive the Valera app and will receive a smartphone with network connectivity if necessary.
62081761|NCT05039554|EXPERIMENTAL|ACT + Valera app|Participants randomized to this cohort will receive both acceptance and commitment therapy (ACT) and the Valera app (and a smartphone with network connectivity if necessary).
62081762|NCT05039554|PLACEBO_COMPARATOR|treatment as usual (TAU)|Participants randomized to this cohort will not receive any experimental treatments.
62081763|NCT06737094||Chronic Kidney Disease (CKD) Patients|Patients with CKD stade III to V (dialysis and non dialysis)
62081764|NCT06738602||Progestin Primed Ovarian Stimulation Protocol group|
62081765|NCT06738602||Antagonist Protocol group|
62081766|NCT04507841|EXPERIMENTAL|Niraparib group|Niraparib was used in patients with newly diagnosed ovarian cancer before any treatment with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count.
62081767|NCT06736821|EXPERIMENTAL|group a: xenograft mixed with melatonin|in this group, the patients underwent open sinus lifting surgery and augmentation of the sinuses by xenograft mixed with melatonin gel to enhance the bone healing
62281027|NCT02802605|EXPERIMENTAL|Bemiparin|Bemiparin 3.500 U, once a day during hospitalization
62458431|NCT04218903|ACTIVE_COMPARATOR|Combined Training 2 times per week (CT2)|The CT2 group will perform two sessions per week of combined exercise program. This intervention will last 12 weeks.
62458432|NCT06234163|NO_INTERVENTION|Control Group|"No intervention was made to the nurses in the control group (n = 35). In-service training is provided to nurses in this group in the clinic. After the study is completed, written material (brochure) was given to the nurses in the control group.Descriptive Survey Form was applied at the beginning of the study. Other measurement tools, Enteral and Parenteral Nutrition Care Knowledge Test and Care Behavior Scale-24 (BDI-24) were applied three times as pre-test, post-test and follow-up test (three weeks later)."
62649078|NCT04627636|EXPERIMENTAL|control group|which treated with conventional physical therapy program
62649079|NCT02178514|EXPERIMENTAL|Formula Feeding group by BabyNes Nutrition System|In this arm, all infants will be fed with BabyNes Nutrition System since enrollment until 12 month of age
62281028|NCT02802605|NO_INTERVENTION|No drug|Clinical practice as usual
62649080|NCT02178514|NO_INTERVENTION|Breastfeeding group|used as reference to compare with formula feeding group
62281029|NCT03573713|EXPERIMENTAL|IPT-G (Treatment arm)|This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
62458433|NCT06234163|EXPERIMENTAL|Nutrition education group|"It was planned to give Enteral and Parenteral Nutrition Training to the nurses in the experimental group, based on the literature. The content of the training guide was sent to ten experts in the field and content validity was made. Enteral and parenteral nutrition training was given face to face, in 15-20 minutes, using verbal presentation and written materials (brochures). Descriptive Survey Form was applied to the experimental group (n=35) at the beginning of the research. Other measurement tools, Enteral and Parenteral Nutrition Care Knowledge Test and Care Behavior Scale-24 (BDI-24) were administered three times: before the training, within one or two days of the training and three weeks after the training."
62458434|NCT02001948|ACTIVE_COMPARATOR|intrathecal morphine 0.1 mg|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive a spinal anaesthesia with 0.1 mg morphine combined with 7.5 mg heavy bupivacaine
62458435|NCT02001948|ACTIVE_COMPARATOR|0.4 mg of intrathecal morphine|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive spinal anesthesia with 0.4 mg of morphine combined with 7.5 mg of heavy bupivacaine.
62458436|NCT04008979|EXPERIMENTAL|PL-ASA 325 mg|Novel aspirin formulation being tested
62081768|NCT06736821|ACTIVE_COMPARATOR|group b: xenograft|in this group, the patients underwent open sinus lifting surgery and augmentation of the sinuses by xenograft without any additives
62081769|NCT06177067|EXPERIMENTAL|All Eligible Participants|"All eligible patients receive the following intervention:~Revumenib, Venetoclax, Azacitidine, Intrathecal chemotherapy"
62081770|NCT06036641||Colorectal surgery|Individuals scheduled for colorectal surgery in the HDTL position
62081771|NCT05359731|ACTIVE_COMPARATOR|Perineural Bupivacaine|Bupivacaine without Dexamethasone in axillary brachial plexus blockade
62081772|NCT05359731|EXPERIMENTAL|Perineural Bupivacaine plus Dexamethasone|Bupivacaine with Dexamethasone in axillary brachial plexus blockade
62281030|NCT03573713|OTHER|Control arm (Treatment as usual - Care Group)|This arm will receive assessment only at the beginning of the study (parallel to the start of IPT-G) and then receive the Care Group intervention after 12 weeks together with the IPT-G arm.
62281031|NCT04126655|EXPERIMENTAL|Arfolitixorin.|Drug: Arfolitixorin Drug: 5-FU Per operative i.v. bolus injection of Arfolitixorin in combination with 5-FU
62281032|NCT04126655|ACTIVE_COMPARATOR|Calciumfolinate.|Drug: Calciumfolinate Drug: 5-FU Per operative i.v. bolus injection of Calciumfolinate in combination with 5-FU
62281033|NCT01409720|EXPERIMENTAL|A|patients in arm A carry out daily physical training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home.
62281034|NCT01409720|NO_INTERVENTION|B|Patients in arm B (control group) receive 10 daily sessions of 15 min manual therapy (i.e. massage, etc) starting from day one of radiotherapy.
62281035|NCT02771522|OTHER|Active post-othodontic lesions|Imaging with the Calcivis System
62281036|NCT05054452|EXPERIMENTAL|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
62081773|NCT05267821|ACTIVE_COMPARATOR|Anakinra 4 mg/kg/day|IV Anakinra 4mg/kg/day x 7 days
62081774|NCT05267821|ACTIVE_COMPARATOR|Anakinra 8 mg/kg/day|IV Anakinra 8 mg/kg/day x 7 days
62081775|NCT05267821|ACTIVE_COMPARATOR|Anakinra 12 mg/kg/day|IV Anakinra 12 mg/kg/day x 7 days
62281037|NCT03895125|EXPERIMENTAL|[year1] PD group|
62281038|NCT03895125|ACTIVE_COMPARATOR|[year1] healthy control group|
62281039|NCT03895125|EXPERIMENTAL|[year2-3] freezer|
62281040|NCT03895125|EXPERIMENTAL|[year2-3] non-freezer|
62081776|NCT05267821|ACTIVE_COMPARATOR|Anakinra 16 mg/kg/day|IV Anakinra 16 mg/kg/day x 7 days
62081777|NCT05267821|PLACEBO_COMPARATOR|Placebo|IV placebo x 7 days
62281041|NCT04789356|ACTIVE_COMPARATOR|High-risk individuals (with comorbidities)|Public safety and security (police officers and law enforcement, fire department), and high school and college/university professionals of the state government public education network who present at least one of the comorbidities included in the National Plan for the Operationalization of Vaccination Against COVID-19 will be invited to receive the CoronaVac vaccine
62281042|NCT04789356|NO_INTERVENTION|Low-risk individuals (without comorbidities)|Participants with low risk (without comorbidities as a risk factor for severe COVID-19 according to the national plan for the implementation of vaccination against COVID-19) will not receive the vaccine within the scope of the research project.
62281043|NCT01897246|ACTIVE_COMPARATOR|Computer-assisted pre-operative planning|Patients enrolled in this arm will undergo corrective surgery of the distal radius, with pre-operative computer-assisted planning and virtual osteotomy.
62458437|NCT04008979|ACTIVE_COMPARATOR|IR 325 mg|Immediate release aspirin
62458438|NCT04008979|EXPERIMENTAL|PL-ASA-650|Novel aspirin formulation being tested
62458439|NCT04008979|ACTIVE_COMPARATOR|IR 650|Immediate release aspirin
62458440|NCT01909557|ACTIVE_COMPARATOR|Acetyl-L-carnitine|Acetyl-L-carnitine 2 gr tablets
62458441|NCT01909557|PLACEBO_COMPARATOR|placebo|
62458442|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
62281044|NCT01897246|ACTIVE_COMPARATOR|Conventional pre-operative planning|Patients in this group will undergo corrective osteotomy of the distal radius wit conventional pre-operative planning.
62281045|NCT06444646||EVO participants with obesity|From each patient, two adipose tissue biopsies will be taken during bariatric surgery; one from the subcutaneous and one from the visceral adipose tissue.
62281046|NCT06444646||EVO participants without obesity|From each lean patient, two adipose tissue biopsies will be taken during abdominal surgery; one from the subcutaneous and one from the visceral adipose tissue.
62281047|NCT05032820|EXPERIMENTAL|Lenalidomide and bb2121|Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m2 and fludarabine 30mg/m2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x106 cells. Maintenance lenalidomide, starting at 10mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.
62281048|NCT02286531|EXPERIMENTAL|FET imaging|FET Imaging. Patient 0.1 mCi / kg (maximum 185 MBq) of FET with 'O-(2\[18F\]FLUOROETHYL)-L-TYROSINE' will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
62281049|NCT05919602|NO_INTERVENTION|Control group|Subjects on the waiting list for upper limb surgery that on the day of surgery, only anxiety will be evaluated before the operation and no intervention would be performed before the operation.
62649081|NCT02844595|ACTIVE_COMPARATOR|Standard cognitive-behavioural smoking cessation treatment|
62458443|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
62458444|NCT02151032||Colorectal Cancer Screening Booklet + Audio CD|Participants read the booklet about colorectal cancer screening tests, and listen to an audio CD that will narrate the booklet. Questionnaire completion before and after viewing the program.
62458445|NCT02151032||Video with Non-Moving Images on iPad|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
62458446|NCT02151032||Video with Animated Images on iPad|Participants watch a video with animated images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
62649082|NCT02844595|ACTIVE_COMPARATOR|Standard smoking cessation treatment and behavioral activation|
62649083|NCT02844595|NO_INTERVENTION|Control group|It will be a delayed treatment control group for a period of 3 months.
62649084|NCT00607217|EXPERIMENTAL|CAD-Exp|Enrolled coronary artery disease patients who are randomly assigned to receive influenza vaccine
62649085|NCT00607217|PLACEBO_COMPARATOR|CAD-Control|Enrolled coronary artery disease patients who are randomly assigned to receive placebo of influenza vaccine
62649086|NCT00607217|EXPERIMENTAL|Healthy-Control|Enrolled healthy subjects serve as control for CAD-Exp
62649087|NCT00881166|EXPERIMENTAL|1|oral MP-470 + paclitaxel/carboplatin
62649088|NCT00881166|EXPERIMENTAL|2|oral MP-470 + carboplatin/etoposide
62649089|NCT00881166|EXPERIMENTAL|3|oral MP-470 + topotecan
62649090|NCT00881166|EXPERIMENTAL|4|oral MP-470 + docetaxel
62649091|NCT00881166|EXPERIMENTAL|5|oral MP-470 + Erlotinib
62649092|NCT05426785|ACTIVE_COMPARATOR|Treatment Group(Early Multiple ATP Group)|Set to perform multiple ATP early
62281050|NCT05919602|EXPERIMENTAL|Intervention group|Subjects on the waiting list for upper limb surgery on the day of surgery, anxiety will be evaluated before the operation and intervention would be performed before the operation.
62281051|NCT02101970|EXPERIMENTAL|Weight Loss + Omega-3 FA|Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
62458447|NCT01807208|EXPERIMENTAL|Educational tool|Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
62281052|NCT02101970|ACTIVE_COMPARATOR|Weight Loss + Placebo|Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
62281053|NCT00492973|ACTIVE_COMPARATOR|Control|Patients in the active comparator group will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
62281054|NCT00492973|EXPERIMENTAL|Corticosteroid|Patients in the Corticosteroid group will have the same medications as the Control Group with the addition of a corticosteroid (methylprednisolone acetate)
62281055|NCT06213922||Adolescent|
62649093|NCT05426785|ACTIVE_COMPARATOR|Control Group|"Set the extended detection time for the conventional ATP (Refer to the settings of Delayed Therapy-arm C in Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy (MADIT-RIT) study)"
62649094|NCT03880513||Longitudinal study|Patients during overt and after cure of endogenous Cushing's syndrome.
62649095|NCT03880513||Cross-sectional study|Patients with proven endogenous Cushing's syndrome (overt or subclinical).
62649096|NCT00243243|EXPERIMENTAL|rFVIIa|intravenous administration of rFVIIa (Novoseven; 90 micrograms/kg, IV push, given at start of first surgical incision and again at 1 hr after start of surgery)
62281056|NCT01308866|NO_INTERVENTION|Control|Usual care
62649097|NCT00243243|PLACEBO_COMPARATOR|Control|intravenous administration of placebo (sterile water, IV push, given at first surgical incision and again at 1 hr after start of surgery)
62649098|NCT01679743|EXPERIMENTAL|A|Breast Cancer Cohort
62649099|NCT01679743|EXPERIMENTAL|B|Non-Small Cell Lung Cancer Cohort
62649100|NCT03721354|EXPERIMENTAL|NAVA vs PSV -TCCD|Ultrasound evaluation, using trans cranial doppler technique will be performed to evaluate the cerebral blood flow speed (average/systolic speed) near the point of emergency, in the middle tract and at the bifurcation of M1 bilaterally, at the end of every ventilation trial (NAVA and PSV).
62649101|NCT01611519||Early (within 48 hours of surgery)|Patients will have their urinary catheter removed within 48 hours of surgery
62281057|NCT01308866|EXPERIMENTAL|Intervention|Intervention arm using a share-decision tool for cardiovascular patients
62281058|NCT01265771|EXPERIMENTAL|Telemetry ordered by a Cardiologist|
62281059|NCT01265771|EXPERIMENTAL|24 hours standard Holter monitoring|
62281060|NCT01265771|EXPERIMENTAL|Telemetry ordered by a Pediatrician|
62649102|NCT01611519||Late (6 hours after epidural removal)|Patients will have their urinary catheter removed 6 hours after their epidural is removed
62649103|NCT02026349|ACTIVE_COMPARATOR|favipiravir|
62281061|NCT05519735|OTHER|Multimodal imaging|Multimodal imaging approach. This includes a CXCR4 targeted PET/CT (\[68Ga\]Pentixafor) during the acute hospital stay, and serial CMR and Echo imaging.
62281062|NCT03042000|EXPERIMENTAL|Group A1|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'radical surgery + adjuvant chemotherapy (ACT)'
62281063|NCT03042000|ACTIVE_COMPARATOR|Group A2|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'NCRT + radical surgery + ACT'
62458448|NCT01807208|NO_INTERVENTION|Usual care|Patients in this arm of the study will receive usual care.
62649104|NCT02026349|PLACEBO_COMPARATOR|placebo|
62649105|NCT01375543||Enrollees|Enrolled study participants in whom genetic sequencing was done
62649106|NCT01712178|EXPERIMENTAL|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
62649107|NCT01712178|ACTIVE_COMPARATOR|Current formulation adalimumab 40 mg every other week|Current formulation adalimumab 40 mg every other week
62649108|NCT00764634|PLACEBO_COMPARATOR|1 Placebo|
62649109|NCT00764634|ACTIVE_COMPARATOR|2 rBV A/B Vaccine|
62649110|NCT00764634|PLACEBO_COMPARATOR|3 Placebo|
62649111|NCT00764634|ACTIVE_COMPARATOR|4 rBV A/B Vaccine|
62649112|NCT02860052|EXPERIMENTAL|SB208 2%|Apply once daily to one or both feet for 14 days
62649113|NCT02860052|EXPERIMENTAL|SB208 4%|Apply once daily to one or both feet for 14 days
62649114|NCT02860052|EXPERIMENTAL|SB208 16%|Apply once daily to one or both feet for 14 days
62649115|NCT02860052|PLACEBO_COMPARATOR|Vehicle Gel|Apply once daily to one or both feet for 14 days
62649116|NCT03980119|EXPERIMENTAL|HITSystem 3.0 Intervention|All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.
62649117|NCT03980119|NO_INTERVENTION|Control|All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.
62649118|NCT03675217|EXPERIMENTAL|PE and PCFPC|Physical Exercise and primary care family caregivers program
62649119|NCT03675217|ACTIVE_COMPARATOR|Usual Care|Usual Care: PCFPC (primary care family caregivers program)
62649120|NCT02683343||carpal tunnel syndrome|No intervention
62649121|NCT02683343||normals|no intervention
62081778|NCT04974099|EXPERIMENTAL|RoadMAB dashboard system|The intervention includes utilizing Clinical and Patient Decision Support Software (RoadMABTM) that will guide the selection of the first infliximab dose followed by subsequent infliximab dose and dosing interval during the maintenance phase. During induction, three infusions will occur at 0, 2 and 6 weeks, respectively. The RoadMABTM dashboard will utilize PK modeling software to provide an infliximab starting dose recommendation (range of 5-12 mg/kg) based on the patients biochemical profile. As noted, dosing frequency (weeks) during induction will not be altered during this study. Following the first three doses, the clinician will be informed of their patients PK profile within the RoadMABTM program and with a shared document (paper). RoadMABTM will provide additional dosing recommendations after each infusion (based on the latest drug concentration measures and blood biomarkers) with the final dose and interval selected by the treating physician.
62081779|NCT06739291|EXPERIMENTAL|SIGX1094R|Oral SIGX1094R administered once daily.
62281064|NCT03042000|EXPERIMENTAL|Group B1|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with combined chemotherapy (Capox regimen) + radical surgery + ACT'
62281065|NCT03042000|ACTIVE_COMPARATOR|Group B2|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with single-agent chemotherapy (Capecitabine) + radical surgery + ACT'
62281066|NCT03042000|EXPERIMENTAL|Group C1|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the transanal endoscopic microsurgery (TEM) excision of the lesion.
62281067|NCT03042000|ACTIVE_COMPARATOR|Group C2|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the radical resection of the lesion.
62281068|NCT05464433|EXPERIMENTAL|liposomal mitoxantrone hydrochloride|Patients with recurrent and refractory Extranodal Natural Killer/T Cell Lymphoma（NKTCL）will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with tislelizumab for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 16 mg/m2.
62281069|NCT06548737||Patients with primary intracerebral hemorrhage|We included adult patients who (1) admitted for primary ICH; (2) underwent blood routine test (hemoglobin included) and CT scan as soon as they arrived at hospital; (3) were not treated with neurosurgical procedures. We excluded patients who (1) had ICH secondary to known causes, including trauma, intracranial neoplasm and systemic diseases, as well as anticoagulative agents; or had isolated intraventricular hemorrhage (IVH); (2) mRS \>2 before the current ICH episode (according to past medical records or description from guardians.
62649122|NCT03311906|EXPERIMENTAL|Test side|Scaling and Root Planing 0.8% Hyaluronic acid gel
62081780|NCT02723591|ACTIVE_COMPARATOR|Tacrolimus, Extended Release (Astagraf XL®) Once Daily|Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
62281070|NCT03071783|EXPERIMENTAL|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
62281071|NCT03071783|NO_INTERVENTION|conventional|conventional handle
62281072|NCT02277717|EXPERIMENTAL|SYD985 (trastuzumab vc-seco-DUBA)|HER2-targeting Antibody-Drug Conjugate
62281073|NCT03663088|ACTIVE_COMPARATOR|GPR-A|The 6-months supervised GPR-A group will receive a 1-hour-long individual session once a week plus a home program (1 or 2 exercises, 2 times a week).
62281074|NCT03663088|EXPERIMENTAL|GPR-B|The 6-months supervised GPR-B group will receive a 1-hour long individual session once per two weeks alternately with a 1-hour-long class of exercises once per two weeks plus a home program (1 or 2 exercises, 2 times a week).
62649123|NCT03311906|ACTIVE_COMPARATOR|Control Side|Scaling and Root Planing
62649124|NCT00336544|EXPERIMENTAL|Cethromycin|
62649125|NCT00336544|ACTIVE_COMPARATOR|Clarithromycin|
62649126|NCT01240746|ACTIVE_COMPARATOR|Group 1: Licensed 2010-2011 TIV|Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.
62649127|NCT01240746|EXPERIMENTAL|Group 2: Investigational TIV|Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain
62649128|NCT01240746|EXPERIMENTAL|Group 3: Investigational QIV|Participants will receive the investigational Quadrivalent Influenza Vaccine
62649129|NCT06456385|ACTIVE_COMPARATOR|Auricular Neurostimulation (Active)|Participants will receive auricular stimulation of both the 15Hz on cymba conchae and 100Hz on tragus.
62281075|NCT04172051|EXPERIMENTAL|Experimental Group|"Subjects will be admitted into the Tony Robbins event for free, or receive a voucher for an event in the future. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
62281076|NCT04172051|NO_INTERVENTION|Control Group|"The control group will be asked to engage in gratitude journaling every day for a month. The control group will NOT attend the event. This exercise will take 10 minutes to complete. The subject will write down three things that went well each day and provide an explanation about why they went well. This will be written down in a journal. The subjects will follow these instructions:~1. Give the event a title (e.g., co-worker complimented my work on a project)~2. In the space below, write down exactly what happened in as much detail as possible, including what you did or said, and if other people were involved, what they did or said.~3. Include how this event made you feel at the time and how this event made you feel later (including now, as you remember it)."
62281077|NCT04172051|ACTIVE_COMPARATOR|Motivated Experimental Group|"The Motivated Experimental Group (M Experimental) will consist of participants who registered and paid for Tony Robbins Date with Destiny (DWD). They are chosen as the motivated experimental as they will be paying full price for the event. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
62281078|NCT02713568|ACTIVE_COMPARATOR|Ultrasound|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~An Ultrasound scan to estimate the fetal weigth will be carried out during the 36th week of gestation."
62458449|NCT04114448|EXPERIMENTAL|Therapeutic exercise|Patients will be trained to perform a therapeutic exercise intervention protocol. The program will be based on active physical activity including strength, balance an coordination exercises, among others. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
62649130|NCT06456385|SHAM_COMPARATOR|Auricular Neurostimulation (Sham)|Participants will receive auricular stimulation of 15Hz on their earlobe.
62649131|NCT04058496||1|Coronary artery bypass surgery off-pump (n=24)
62649132|NCT04058496||2|Coronary artery bypass surgery on-pump (n=16)
62649133|NCT04058496||3|Coronary artery bypass surgery plus valve surgery (n=20)
62649134|NCT01938326|ACTIVE_COMPARATOR|Multi-port laparoscopic distal gastrectomy|Laparoscopic distal gastrectomy using the conventional 5-port access
62649135|NCT01938326|ACTIVE_COMPARATOR|Single incision distal gastrectomy|Pure single incision distal gastrectomy using one transumbilical incision
62281079|NCT02713568|EXPERIMENTAL|Magnetic Resonance|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~A Magnetic Resonance examination to estimate the fetal weigth will be carried out during the 36th week of gestation."
62081781|NCT02723591|ACTIVE_COMPARATOR|Tacrolimus, Immediate Release Twice Daily (BID)|Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
62281080|NCT06114173|EXPERIMENTAL|drug-dosing group|Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
62281081|NCT01012492|EXPERIMENTAL|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
62281082|NCT01014403|EXPERIMENTAL|enoxaparin 30 mg SQ q12 hours|Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.
62281083|NCT01014403|PLACEBO_COMPARATOR|placebo|vehicle administered sq q 12 hours
62281084|NCT00632801|OTHER|A|Chewing gum or not
62281085|NCT02710409|EXPERIMENTAL|Quadrivalent influenza vaccine|
62649136|NCT01064544|EXPERIMENTAL|Starting with light therapy|Starts with 3 weeks of light therapy, followed by a control period
62649137|NCT01064544|EXPERIMENTAL|Ending with light therapy|Ends with 3 weeks of light therapy after a control period.
62081782|NCT05969002||Adult|Participants \>/=18 years old with relapsed/refractory B cell ALL proceeding to CAR therapy at the NIH
62081783|NCT05969002||Pediatric|Participants \<18 proceeding to CAR therapy at the NIH with a clinical indication for FDG PET-CT prior to CAR infusion
62649138|NCT01072591|EXPERIMENTAL|1|
62649139|NCT01072591|PLACEBO_COMPARATOR|2|
62649140|NCT00848016|EXPERIMENTAL|Treatment (R-(-)-gossypol acetic acid)|Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62649141|NCT02033798|EXPERIMENTAL|Tamsulosin|The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.
62081784|NCT05560724|ACTIVE_COMPARATOR|Anodal M1 tDCS|20 minutes of anodal tDCS (C3 or C4 depending on side of lesion) to the ipsilesional M1: 2mA Combined with 45min of structured motor training.
62081785|NCT05560724|ACTIVE_COMPARATOR|Combined M1 and cerebellar anodal tDCS|20 minutes of anodal tDCS (C3 or C4 depending on side of lesion) to the ipsilesional M1 combined with contralesional cerebellar montage (2cm lateral to Inion): 2mA per anode Combined with 45min of structured motor training.
62081786|NCT05560724|SHAM_COMPARATOR|Sham tDCS|Sham stimulation. Combined with 45min of structured motor training.
62081787|NCT06474169||n°1 (ESKD)|end-stage chronic kidney disease
62081788|NCT06474169||n°2 (stage 3 CKD)|stage 3 chronic kidney disease
62081789|NCT06474169||n°3 (healthy donors)|healthy donors
62081790|NCT00170573|EXPERIMENTAL|Caelyx|40 mg/m² biweekly
62281086|NCT02710409|ACTIVE_COMPARATOR|Trivalent influenza vaccine A|Active Comparator A
62649142|NCT02378272|EXPERIMENTAL|Care manager for depression|A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression
62649143|NCT02378272|NO_INTERVENTION|Treatment As Usual|Management of recruited patients with depression continued as usually applied at PCC
62081791|NCT03677128|EXPERIMENTAL|mNavigator|Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
62081792|NCT03677128|NO_INTERVENTION|Historical controls|BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.
62081793|NCT05693571|EXPERIMENTAL|Valera Pilot Study|All participants in the open-label pilot study will be provided with the Valera smart phone application and online care manager dashboard
62081794|NCT06738992|ACTIVE_COMPARATOR|Warfarin Group|Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.
62081795|NCT06738992|EXPERIMENTAL|Aspirin Group|Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.
62281087|NCT02710409|ACTIVE_COMPARATOR|Trivalent influenza vaccine B|Active Comparator B
62281088|NCT03979326|EXPERIMENTAL|Young women during various of phases of menstrual cycle.|The group of 40 young women will have their hamstring muscle stretched in different phases of the menstrual cycle: follicular, ovulatory and luteal. Static stretching will last 3x 45 seconds with a 15 second break between repetitions. Before and after the intervention a series of tests will be performed.
62281089|NCT02409238|EXPERIMENTAL|Lifestyle Intervention and Metformin|Intensive lifestyle interventions at Lifestyle Intervention Centres and Metformin (if Diabetic)
62281090|NCT02409238|ACTIVE_COMPARATOR|Standard Level of Care|Standard lifestyle recommendations for the Control groups
62281091|NCT02821858|EXPERIMENTAL|Panel 1: Treatment A|Participants will receive odalasvir (ODV) 50 milligram (mg) (n=8) or placebo (n=2) on Day 1.
62281092|NCT02821858|EXPERIMENTAL|Panel 1: Treatment B|Participants will receive ODV 100 mg (n=8) or placebo (n=2) on Day 1.
62281093|NCT02821858|EXPERIMENTAL|Panel 1: Treatment C|Participants will receive ODV 300 mg (n=8) or placebo (n=2) on Day 1.
62281094|NCT02821858|EXPERIMENTAL|Panel 2: Treatment D|Participants will receive AL-335 400 mg (n=8) or placebo (n=2) on Day 1 of Period 1. Each treatment period will be separated by a washout period of 7 days.
62281095|NCT02821858|EXPERIMENTAL|Panel 2: Treatment E|Participants will receive AL-335 800 mg (n=8) or placebo (n=2) on Day 1 of Period 2. Each treatment period will be separated by a washout period of 7 days.
62281096|NCT02821858|EXPERIMENTAL|Panel 2: Treatment F|Participants will receive AL-335 1,200 mg (n=8) or placebo (n=2) on Day 1 of Period 3. Each treatment period will be separated by a washout period of 7 days.
62281097|NCT03317951|EXPERIMENTAL|Novel integrated care concept (NICC)|The care center is at the heart of the NICC structure. It will be available 24/7. It is the core platform to share information for all NICC patients in the care process and serves as integration point between the professional groups. The care center is utilizing the NICC platform for care coordination and patient monitoring. The NICC platform enables patient management from the distance and allows treating physicians to observe and follow the health status of patients daily. Using the NICC tablet, patients provide information from home about their health status. They will receive feedback about their therapy, measurements and reminders and motivation to follow care plans. The communication allows for a regular evaluation of the patient's situation, a review of the therapy and coordination of necessary adjustments with care providers. The general intervention rules are based on the current European Society of Cardiology (ESC) guidelines for treating AF, HF and TRH patients.
62649144|NCT03434288||Diabetic patients with foot osteomyelitis|Biological and MRI signs of foot osteomyelitis
62649145|NCT02318199||Agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 5-7 during the first 12 hours after surgery.
62649146|NCT02318199||Non-agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 1-4 during the first 12 hours after surgery.
62081796|NCT03138512|EXPERIMENTAL|Part A, Arm A: nivolumab + ipilimumab|
62081797|NCT03138512|PLACEBO_COMPARATOR|Part A, Arm B: nivolumab placebo + ipilimumab placebo|
62081798|NCT03138512|EXPERIMENTAL|Part B, Arm A: nivolumab + ipilimumab|
62081799|NCT03138512|PLACEBO_COMPARATOR|Part B, Arm B: nivolumab placebo + ipilimumab placebo|
62081800|NCT03138512|EXPERIMENTAL|Part B, Arm C: nivolumab + ipilimumab placebo|
62081801|NCT06739954|EXPERIMENTAL|Interventional group I|
62081802|NCT06739954|ACTIVE_COMPARATOR|Interventional group II|
62081803|NCT05573893||Cohort 1|Cohort 1 containing patients with documented HER2-positive unresectable or metastatic BC receiving T-DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.
62081804|NCT05573893||Cohort 2|Cohort 2 containing patients with documented HER2-low unresectable or metastatic BC receiving T-DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.
62081805|NCT05226663|EXPERIMENTAL|Treatment ([18F]FTT PET/CT)|Patients receive \[18F\]FTT IV over a few seconds to a minute and then undergo PET/CT scan over 20-30 minutes at baseline and another optional scan 1 week later. During the \[18F\]FTT PET/CT scan patients.
62281098|NCT03317951|ACTIVE_COMPARATOR|Standard care|Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
62281099|NCT03429127||Normal saline fluid group|The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.
62281100|NCT03429127||Balanced fluid group|The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.
62649147|NCT03225430|ACTIVE_COMPARATOR|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
62649148|NCT03225430|EXPERIMENTAL|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
62649149|NCT00641056|EXPERIMENTAL|1|
62649150|NCT00641056|ACTIVE_COMPARATOR|2|
62649151|NCT02460510|EXPERIMENTAL|Mannitol|Treatment with mannitol intravenous (IV) bolus over 20 to 30 minutes. The dose is 0.25 g/kg IV as a 20% solution repeated every 4th hourly.(8) Mannitol infusion to be stopped if s osmolarity \>320mm
62649152|NCT02460510|ACTIVE_COMPARATOR|3% hypertonic saline|Treatment with 3% hypertonic saline as continuous infusion. Continuous 3% NaCl infusion to be started at a rate of 25ml /hr and titrated q4hrs per sliding scale to achieve a target serum sodium level of \<160 mmol/L.
62649153|NCT01939912|EXPERIMENTAL|Stimulation of carotid body chemoreceptors|Adenosine boluses will be administered through an intravascular catheter used to administer the contrast agent during the carotid artery arteriography.
62649154|NCT02980016|ACTIVE_COMPARATOR|3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
62649155|NCT02980016|ACTIVE_COMPARATOR|p3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
62649156|NCT02980016|ACTIVE_COMPARATOR|6H|Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
62649157|NCT01849614||Patient group|Women with left-sided breast cancer
62649158|NCT05141032||Research Subject|Only one group will be made which will contain all subjects recruited into research study.
62281101|NCT00288574|EXPERIMENTAL|fluoxetine|fluoxetine up to 80 mg per day
62281102|NCT00288574|PLACEBO_COMPARATOR|Placebo|Placebo
62281103|NCT04289896|EXPERIMENTAL|Experimental group|Each session will last 20 minutes, taking place 2 days a week, for a period of 4 weeks. Prior to the completion of the routine training of each team, the plyometric exercise program will be carried out in the experimental group. When the intervention ends, the members of the experimental group will perform the usual training
62281104|NCT04289896|NO_INTERVENTION|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
62281105|NCT06419764|ACTIVE_COMPARATOR|nutrition intervention group|Postoperative patients are routinely provided with meal replacement recommendations and dietary plans.
62649159|NCT01935115|ACTIVE_COMPARATOR|Propofol|The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
62649160|NCT01935115|EXPERIMENTAL|Ketamine|Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously
62649161|NCT02016846|PLACEBO_COMPARATOR|Placebo|
62649162|NCT02016846|ACTIVE_COMPARATOR|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
62649163|NCT01196780||Cohort|
62281106|NCT06419764|EXPERIMENTAL|Traditional Chinese Medicine combined with nutritional intervention|Chinese herbal treatment is given on the basis of routine dietary intervention.
62281107|NCT03436615|EXPERIMENTAL|SB206 4%|SB206 4% topically twice daily
62281108|NCT03436615|EXPERIMENTAL|SB206 8%|SB206 8% topically twice daily
62281109|NCT03436615|EXPERIMENTAL|SB206 12%|SB206 12% topically once or twice daily
62281110|NCT03436615|PLACEBO_COMPARATOR|Placebo (vehicle gel)|Vehicle Gel topically once or twice daily
62281111|NCT05116241|EXPERIMENTAL|BPZE1 intranasal and Placebo intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular placebo.
62458450|NCT04114448|ACTIVE_COMPARATOR|Usual care|Patients will be instructed to perform an usual care physical therapy intervention protocol. Participants in this group will be told to undergo gentle self-performed joint mobilization and stretching exercises. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
62458451|NCT01872546|EXPERIMENTAL|Adalimumab|
62649164|NCT04327778|EXPERIMENTAL|Music therapy|Patients will be exposed every two weeks
62649165|NCT01004614|EXPERIMENTAL|Cohort 1|24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.
62281112|NCT05116241|EXPERIMENTAL|BPZE1 intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular Boostrix (acellular pertussis \[aP\] vaccine).
62281113|NCT05116241|ACTIVE_COMPARATOR|Placebo intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of placebo via the mucosal atomization device and a dose of intramuscular Boostrix (aP vaccine comparator).
62281114|NCT00875069|EXPERIMENTAL|ethanol|
62281115|NCT00875069|PLACEBO_COMPARATOR|placebo|
62281116|NCT06549400|OTHER|Mexiletine prolonged-release (PR)|Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)
62649166|NCT01004614|ACTIVE_COMPARATOR|Cohort 2|24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water
62281117|NCT00479154|EXPERIMENTAL|Botulinum Toxin A|Injection of onabotulinumtoxinA
62649167|NCT01994200|EXPERIMENTAL|Interdisciplinary Team-Based Approach|The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
62281118|NCT00479154|PLACEBO_COMPARATOR|Placebo (saline)|Injection of saline placebo
62281119|NCT04780269|EXPERIMENTAL|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group.
62281120|NCT04780269|EXPERIMENTAL|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix.
62458452|NCT01471847|EXPERIMENTAL|BEZ235 + Trastuzumab (Phase l /Phase ll)|"Phase l: Eligible patients will receive increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly trastuzumab at a fixed dose of 2 mg/kg. Treatment will be organized into cycles of 28 days.~Phase ll: Eligible patients will receive weekly trastuzumab (2 mg/kg) + oral BEZ235 on a continuous twice daily (BID schedule) at the MTD or RP2D.~Treatment will be organized into cycles of 21 days."
62081806|NCT04551703|EXPERIMENTAL|Adrenaline saline irrigation|Adrenaline saline irrigation will be prepared by adding one ampule of 0.1 percent adrenaline in one liter bag of normal saline, which made the adrenaline concentration in the solution 1:100 000
62281121|NCT05488847|EXPERIMENTAL|Multimodal, Non-Narcotic|This group will be given the preoperative, intraoperative, and discharge meds described below. This group will NOT receive any opioid-containing meds. Preoperative meds: Celecoxib: 400 mg by mouth, Pregabalin: 75 mg by mouth, Tramadol: 50 mg by mouth. Intraoperative meds: Dexamethasone: 10 mg IV, Acetaminophen: 1,000 mg IV, Ropivacaine 5 mg/mL (0.5%): 300 mg local infiltration, Epinephrine 1 mg/mL (1:1000): 1 mg local infiltration, Ketorolac 30 mg/mL: 30 mg local infiltration. Discharge meds: Dexamethasone: 4 mg by mouth twice per day for 4 days (for same day discharge only), 10 mg IV on postoperative day 1 (for overnight patients only), Pregabalin: 75 mg by mouth twice per day for 14 days, Tizanidine: 2 mg by mouth every 6 hours for 14 days, Magnesium: 200 mg by mouth twice per day for 14 days, Ibuprofen: 600 mg by mouth every 6 hours not to exceed 3200 mg per day for 1 month, Acetaminophen: 975 mg by mouth every 8 hours not to exceed 3000 mg per day for 1 month.
62281122|NCT05488847|ACTIVE_COMPARATOR|Multimodal Plus Narcotic|This group will be given the preop, intraop, and discharge meds described below. They will also be given 35 pills of oxycodone hydrochloride 5mg to be taken every 6 hours as needed at discharge. Preoperative: Celecoxib: 400 mg PO, Pregabalin: 75 mg PO, Tramadol: 50 mg PO. Intraoperative: Dexamethasone: 10 mg IV, Acetaminophen: 1,000 mg IV, Ropivacaine 5 mg/mL (0.5%): 300 mg local infiltration, Epinephrine 1 mg/mL (1:1000): 1 mg local infiltration, Ketorolac 30 mg/mL: 30 mg local infiltration. Discharge: Dexamethasone: 4 mg PO twice per day for 4 days (for same day discharge only), 10 mg IV on postop day 1 (for overnight patients only), Pregabalin: 75 mg PO twice per day for 14 days, Tizanidine: 2 mg PO every 6 hours for 14 days, Magnesium: 200 mg PO twice per day for 14 days, Ibuprofen: 600 mg PO every 6 hours not to exceed 3200 mg per day for 1 month, Acetaminophen: 975 mg PO every 8 hours not to exceed 3000 mg per day for 1 month.
62281123|NCT00859703|PLACEBO_COMPARATOR|2|"Patients receive placebo 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
62281124|NCT00859703|ACTIVE_COMPARATOR|1|"Patients receive risedronate 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
62281125|NCT05079360|EXPERIMENTAL|Sabizabulin Treatment Group|Subjects in the Sabizabulin Treatment Group will receive sabizabulin 32mg each day by mouth until disease progression is observed and confirmed by BICR.
62281126|NCT05079360|ACTIVE_COMPARATOR|Control Treatment Group|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
62458453|NCT01471847|ACTIVE_COMPARATOR|Lapatinib + Capecitabine (Phase II)|Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
62649168|NCT01994200|OTHER|Usual Care Control Group|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
62081807|NCT04551703|NO_INTERVENTION|Normal saline irrigation|Normal saline bag will be used for irrigation during the procedure
62081808|NCT04953884|EXPERIMENTAL|wilate treatment|PK: Single dose of 80 IU/kg body weight (BW). Prophylactic treatment: 30-50 IU/kg BW administered 2-3 times per week at the recommended dose of over 12 months. Minor haemorrhage: loading dose 30-50 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours to achieve von Willebrand factor activity (VWF:Ac) and FVIII:C trough levels of \>30%. Major haemorrhage: loading dose 50-80 IU/kg BW followed by a maintenance dose of 30-50 IU/kg BW every 12-24 hours to achieve VWF:Ac and FVIII:C trough levels of \>50%. Minor surgery: loading dose of 40-60 IU/kg BW followed by a maintenance dose of 20-30 IU/kg BW every 12- 24 hours for up to 3 days, to achieve VWF:Ac peak levels of 50% after loading dose and trough levels \>30% during maintenance. Major surgery: loading dose of 60-80 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours for up to 6 days or longer, to achieve VWF:Ac peak levels of 100% after loading dose and trough levels \>50% during maintenance
62081809|NCT04056728|EXPERIMENTAL|Eupenta Inj.|
62281127|NCT03522441|EXPERIMENTAL|Clindamycin 1% gel (Akorn Pharmaceuticals)|
62649169|NCT05262374||Laparoscopic Arm|This cohort of participants will have their procedure completed by a human surgeon
62281128|NCT03522441|ACTIVE_COMPARATOR|Clindamycin 1% gel (Greenstone LLC)|
62458454|NCT02737436|EXPERIMENTAL|Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
62458455|NCT02737436|EXPERIMENTAL|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
62458456|NCT03883906|EXPERIMENTAL|Viral Specific T-cells (VSTs)|
62458457|NCT00849953||FinESS Treatment|Subjects undergoing treatment with the FinESS Sinus Treatment System
62281129|NCT03522441|PLACEBO_COMPARATOR|Placebo|
62281130|NCT04506697|EXPERIMENTAL|Patients with LUTS|Patients who are indicated for uroflowmetry
62081810|NCT06734975|EXPERIMENTAL|Superior laryngeal nerve block|Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.
62281131|NCT04785365|OTHER|Experimental: ATL001|Patients who have previously received ATL001 in a clinical trial will be evaluated in this trial for long-term safety and clinical activity.
62458458|NCT02420210|EXPERIMENTAL|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62081811|NCT06734975|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo of 2mL saline injection to the neck on the side of the vocal cord lesion during their surgery.
62081812|NCT04447989|ACTIVE_COMPARATOR|Cohort 1, sildenafil|Sildenafil (0.5 mg/kg IV or 1 mg/kg enteral) every 8 hours for 28 days
62081813|NCT04447989|PLACEBO_COMPARATOR|Cohort 1, placebo|Placebo (IV or enteral) every 8 hours for 28 days
62081814|NCT04447989|ACTIVE_COMPARATOR|Cohort 2, sildenafil|Sildenafil (1 mg/kg IV or 2 mg/kg enteral) every 8 hours for 28 days
62081815|NCT04447989|PLACEBO_COMPARATOR|Cohort 2, placebo|Placebo (IV or enteral) every 8 hours for 28 days
62081816|NCT04447989|ACTIVE_COMPARATOR|Cohort 3, sildenafil|Sildenafil (2 mg/kg IV or 4 mg/kg enteral) every 8 hours for 28 days
62081817|NCT04447989|PLACEBO_COMPARATOR|Cohort 3, placebo|Placebo (IV or enteral) every 8 hours for 28 days
62081818|NCT06101290|EXPERIMENTAL|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
62081819|NCT05294731|EXPERIMENTAL|Part 1a Monotherapy Dose Escalation|BGB-16673 will be orally administered
62081820|NCT05294731|EXPERIMENTAL|Part 1b Monotherapy Safety Expansion|BGB-16673 will be orally administered
62281132|NCT04785365|OTHER|Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001|Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001
62281133|NCT06471582|EXPERIMENTAL|Fed with Carbohydrates|Participants will complete 3, 90-minute stationary cycle or treadmill exercise sessions 1 h after consuming a meal containing 1 g carbohydrate/ kg body weight. During exercise, they will consume an artificially sweetened beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose.
62458459|NCT01781637|EXPERIMENTAL|omalizumab group|Patients will receive omalizumab.
62649170|NCT05262374||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
62281134|NCT06471582|PLACEBO_COMPARATOR|Fasted without Carbohydrates|Participants will complete 3, 90-minute stationary cycle or treadmill exercise sessions following an overnight fast. During exercise, they will consume an artificially sweetened beverage containing no carbohydrates.
62649171|NCT02055586||Diagnostic (FLT-PET/MRI)|Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.
62649172|NCT05737511|EXPERIMENTAL|Hydroxyzine|Hydroxyzine (25 mg/day) for eight weeks, the dose of hydroxyzine may be adjusted based on tolerability and clinical judgment, max 100mg/day
62081821|NCT05294731|EXPERIMENTAL|Part 2 Monotherapy Dose Expansion|BGB-16673 will be administered at the recommended Phase 2 dose (RP2D) that was identified in Part 1
62081822|NCT04716881|EXPERIMENTAL|Vivitrol (naltrexone)|Intramuscular injection of Vivitrol (naltrexone), 380 mg. Six doses given 28 days apart.
62281135|NCT02354703|EXPERIMENTAL|ondansetron-responsive genotype|"ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
62281136|NCT02354703|EXPERIMENTAL|ondansetron--non-responsive genotype|ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
62458460|NCT01781637|PLACEBO_COMPARATOR|placebo|Patients will receive placebo.
62458461|NCT05894577|EXPERIMENTAL|Arm F - Montelukast|Montelukast will be self-administered orally by each participant at a dose of 10 mg once a day for 14 days.
62458462|NCT05894577|PLACEBO_COMPARATOR|Arm F - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
62649173|NCT05737511|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual includes the currently approved treatment according to CANMAT and Muadesly guidelines
62649174|NCT01777841|OTHER|Electronic Care plan delivery|
62081823|NCT05211869|EXPERIMENTAL|T1D-CATCH|The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.
62081824|NCT05211869|NO_INTERVENTION|Usual Care Control Condition|Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.
62081825|NCT06738550|EXPERIMENTAL|Inulina|In the patients of the experimental group, the nutritional intervention is personalized, agave inulin supplementation is provided 9 gr per day, A 6-month follow-up is provided
62081826|NCT06738550|PLACEBO_COMPARATOR|Lactulosa|In the patients of the control group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours
62081827|NCT05307900|EXPERIMENTAL|All patients requiring intubations|All intubated patients with feeding tube
62081828|NCT06738290||Parkinson's disease|Only one cohort will be observed. All participants have been diagnosed with Parkinson's disease, according to the criteria of the Movement Disorders Society by a movement disorders specialist. Other eligibility criteria are described below.
62081829|NCT06612268|EXPERIMENTAL|Etavopivat|Participants will be randomised to receive oral dose of Etavopivat.
62649175|NCT02865863|EXPERIMENTAL|Eurycomalongifoliawater extract (Physta®) +Multivitamin|
62649176|NCT02865863|PLACEBO_COMPARATOR|Placebo|
62649177|NCT00636727|ACTIVE_COMPARATOR|1|arthrocentesis
62649178|NCT00636727|ACTIVE_COMPARATOR|2|arthroscopy
62649179|NCT00636727|ACTIVE_COMPARATOR|3|arthroplasty
62081830|NCT06612268|PLACEBO_COMPARATOR|Placebo|Participants will be randomised to receive oral dose of placebo.
62081831|NCT05513001|EXPERIMENTAL|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)
62649180|NCT03189082|EXPERIMENTAL|Intervention group|
62649181|NCT04069117|ACTIVE_COMPARATOR|• Study group|It contains 100 patients will undergo ovarian stimulation with letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) for 5 days starting from the first day of menstruation in combination with low dose step up stimulation with recombinant FSH starting in the third day of menstruation.
62649182|NCT04069117|NO_INTERVENTION|• Control group|It contains 100 patients will undergo ovarian stimulation with low dose step up stimulation with recombinant FSH starting in the third day of menstruation
62649183|NCT03913234|EXPERIMENTAL|Combination of Letrozole, Trastuzumab with Ribociclib|Phase IB (dose escalation of ribociclib with fixed dose of letrozole and Ribociclib) Phase II (ribociclib of RPIID with fixed dose of letrozole and ribociclib)
62649184|NCT04780321|ACTIVE_COMPARATOR|Anti-SARS-CoV-2 Monoclonal Antibody dose 1/2/3|use Anti-SARS-CoV-2 Monoclonal Antibody,dose 1/2/3 to treat COVID-19
62649185|NCT04780321|PLACEBO_COMPARATOR|Placebo|use placebo to treat COVID-19
62649186|NCT02084823|PLACEBO_COMPARATOR|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62649187|NCT02084823|EXPERIMENTAL|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62649188|NCT02084823|EXPERIMENTAL|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62649189|NCT02084823|EXPERIMENTAL|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
62649190|NCT04503044||CT Lung Cancer Screening Patients|All CT Lung Cancer Screening patients at LHMC from January 1st, 2012 to September 30th, 2014 with an in-network PCP that had baseline CT scans will be scored. A subset of these patients with T4 screening scans will be scored for progression.
62081832|NCT05513001|PLACEBO_COMPARATOR|Arm 2: LOU064 Placebo (blinded)|LOU064 placebo (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)
62649191|NCT04716244||Gestational diabetes|Women who were diagnosed with gestational diabetes within the least year
62649192|NCT04716244||Pre-eclampsia|Women who were diagnosed with pre-eclampsia within the past year
62081833|NCT05513001|EXPERIMENTAL|Arm 3: LOU064 (Open Label)|LOU064 (open-label) taken orally for 24 weeks per treatment cycle (Arm 3)
62081834|NCT06578455|EXPERIMENTAL|CBD-NE Under Fed Condition|A single dose of CBD-NE (6 capsules) following consumption of a high-fat, high-calorie breakfast
62081835|NCT06578455|EXPERIMENTAL|TP Under Fasted Condition|A single dose of CBD-NE (6 capsules) after a minimum 10-hour fast
62281137|NCT02354703|PLACEBO_COMPARATOR|placebo--responsive genotype|"placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
62649193|NCT03807024||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
62649194|NCT03807024||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
62649195|NCT01192178|ACTIVE_COMPARATOR|FLOVENT™ DISKUS™ 100 mcg|FLOVENT™ DISKUS™ 100 mcg is an inhaled corticosteroid indicated in the US for maintenance treatment of asthma as prophylactic therapy in patients 4 years and older.
62081836|NCT06578455|ACTIVE_COMPARATOR|Epidyolex Under Fed Condition|A single dose of Epidyolex (4 mL oil) following consumption of a high-fat, high-calorie breakfast
62081837|NCT06578455|ACTIVE_COMPARATOR|Epidyolex Under Fasted Condition|A single dose of Epidyolex (4 mL oil) after a minimum 10-hour fast
62081838|NCT06508164||CRDS|Possesses a rare RYR2 variant characterized to be loss-of-function based on in vitro testing consistent with a CRDS diagnosis
62081839|NCT06508164||Carrier of an RYR2 truncating variant or large copy number variant|Possesses a rare RYR2 truncating variant and/or large copy number variant involving the RYR2 gene.
62281138|NCT02354703|PLACEBO_COMPARATOR|placebo--non-responsive genotype|placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
62649196|NCT01192178|EXPERIMENTAL|ADVAIR™ DISKUS™ 100/50 mcg|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a corticosteroid and a long acting beta2 adrenergic agonist indicated for; maintenance treatment of asthma in patients 4 years of age and older.
62649197|NCT01578265|EXPERIMENTAL|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
62649198|NCT01578265|ACTIVE_COMPARATOR|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
62649199|NCT02810782|EXPERIMENTAL|Phenobarbital|Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
62649200|NCT02810782|ACTIVE_COMPARATOR|Chlorpromazine|Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
62649201|NCT02810782|ACTIVE_COMPARATOR|Morphine|Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
62649202|NCT01182025|ACTIVE_COMPARATOR|Western therapy|
62081840|NCT06508164||Carrier of a non-functional RYR2 rare variant|Possesses a rare RYR2 variant that is NOT loss-of-function based on in vitro testing and has a clinical phenotype that was considered compatible with CRDS
62081841|NCT06140147|EXPERIMENTAL|Protocolised reduction of non-resuscitation fluids|Participants receive non-resuscitation fluids according to a pre-defined protocol starting within two hours of randomization. The intervention is continued for the duration of the ICU admission up to a maximum of 90 days.
62081842|NCT06140147|OTHER|Usual Care|Participants receive non-resuscitation fluids according to local routines.
62081843|NCT05608837|EXPERIMENTAL|High Dose UME - 6 drops OCS-01|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
62649203|NCT01182025|EXPERIMENTAL|Xiyanping Injection|
62649204|NCT01182025|EXPERIMENTAL|Xiyanping Injection with western medicine|
62649205|NCT01064011|OTHER|External Ventricular drainage, Intraventricular Thrombolysis|
62281139|NCT05543668||preexisting preoperative chronic pain|Patients with preexisting preoperative chronic pain (more than 3 months duration).
62649206|NCT01064011|OTHER|External Ventricular Drainage and Endoscopic Evacuation|
62281140|NCT05543668||preexisting preoperative sub-acute pain|Patients with preexisting preoperative sub-acute pain (less than 3 months duration).
62649207|NCT00720499|EXPERIMENTAL|BI 1744 CL low dose+tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
62649208|NCT00720499|EXPERIMENTAL|BI 1744 CL medium dose+tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
62649209|NCT03984357|EXPERIMENTAL|PD-1 blocking antibody combined with IC+IMRT|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blocking antibody (360 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of PD-1 blocking antibody are administrated concurrently with IC and IMRT, respectively. After 4 weeks of the completion of IMRT, adjuvant PD-1 blocking antibody (480 mg per cycle) will begin every 4 weeks for 6 cycles.
62649210|NCT01565577|EXPERIMENTAL|Bras A|
62649211|NCT00737178|ACTIVE_COMPARATOR|Immediate IUD insertion|Insertion of CuT380A at the routine medication abortion follow-up visit one week after initiation of a medication abortion
62649212|NCT00737178|ACTIVE_COMPARATOR|Delayed IUD insertion|Insertion of CuT380A four to six weeks after initiation of a medication abortion
62281141|NCT05543668||No pain preoperatively|Patients without preexisting preoperative pain.
62649213|NCT03615963||normal|patient complains of anginal chest pain but coronary angiography is normal
62649214|NCT03615963||coronary artery disease|patient complains of chest pain with coronary angiography showing atherosclerotic plaques causing luminal obstruction
62649215|NCT04429958||GDM|125 mothers with a history of GDM in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
62081844|NCT05608837|EXPERIMENTAL|Low Dose UME 3 drops OCS-01 and 3 drops Placebo|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day,( total 6 drops each day) until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
62081845|NCT05608837|EXPERIMENTAL|High dose PSME - 6 drops of OCS-01|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
62081846|NCT05608837|EXPERIMENTAL|Low dose PSME - 3 drops of OCS-01 and 3 drops of Placebo|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day, (total 6 drops each day) until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
62081847|NCT06297265|EXPERIMENTAL|Supportive care (MLD breast massage)|Patients undergo MLD breast massage over 30-60 minutes BIW for the duration of SOC radiation therapy and for 1 month thereafter.
62081848|NCT01351545||Unlicensed CBU|The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.
62081849|NCT05812144|OTHER|Patient with type 1 facioscapulohumeral muscular dystrophy|
62081850|NCT06232109|NO_INTERVENTION|ASN51|
62081851|NCT06232109|EXPERIMENTAL|ASN51 + Fluvoxamine|
62081852|NCT06232109|EXPERIMENTAL|ASN51 + Itraconazole|
62081853|NCT06232109|EXPERIMENTAL|ASN51 + Paroxetine|
62081854|NCT05800990|EXPERIMENTAL|Dietary A-B Intervention|The Dietary A first, then the Dietary B intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
62081855|NCT05800990|EXPERIMENTAL|Dietary B-A Intervention|The Dietary B first, then the Dietary A intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
62081856|NCT04988074|EXPERIMENTAL|De-Escalated Therapy|Surgery (TORS) or Low-dose Radiation Therapy (42 Gy)
62458463|NCT02929979|EXPERIMENTAL|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
62458464|NCT02929979|PLACEBO_COMPARATOR|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
62081857|NCT04988074|EXPERIMENTAL|Non/Minimally De-Escalated Therapy|Surgery + Post-Operative Radiation Therapy (PORT) or 60 Gy Chemo-Radiation Therapy (CRT)
62081858|NCT06716645|EXPERIMENTAL|Robitussin Cough Syrup (Daytime)|Participants will be instructed to take up to 20 milliliters (ml) of Robitussin Maximum Strength Cough and Chest Congestion DM syrup orally (not to exceed 6 doses in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurs first.
62081859|NCT06716645|EXPERIMENTAL|Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)|Participants will be instructed to take up to 20 ml of Robitussin Maximum Strength Cough and Chest Congestion DM syrup and up to 20 ml of Robitussin Maximum Strength Nighttime Cough DM syrup orally (not to exceed 4 doses of daytime + 1 dose of nighttime or 3 doses of daytime + 2 doses of nighttime in any 24-hour period) for up to 8 days or until resolution of symptoms, whichever occurs first.
62081860|NCT03806296|EXPERIMENTAL|Manipulation|"For \~2 weeks, participants will be asked to adhere to the following:~* Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration)~* Decrease evening blue light exposure via blue blocker goggles (2 h before bed)~* Increase morning bright light exposure via bright light goggles (30 m after rise)~* Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
62081861|NCT03806296|ACTIVE_COMPARATOR|Control|"For \~2 weeks, participants will asked to adhere to the following:~- Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
62081862|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
62081863|NCT06513884|EXPERIMENTAL|HB-202/HB-201 alternating 2-vector therapy with pembrolizumab|Intravenous injection of HB-202 followed by pembrolizumab alternating with HB-201 followed by pembrolizumab.
62081864|NCT06513884|PLACEBO_COMPARATOR|Matched placebo with pembrolizumab|Intravenous injection of matched placebo for HB-202 followed by pembrolizumab alternating with matched placebo for HB-201 followed by pembrolizumab.
62081865|NCT05220033|EXPERIMENTAL|Journey Ahead|Experimental: Journey Ahead intervention focusing on coping and communication skill development during the course of 8 sessions and 6 phone calls.
62081866|NCT06661031|OTHER|Enhanced Usual Care arm|Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
62081867|NCT06661031|EXPERIMENTAL|Intervention arm|Participants meet with a counselor 1-on-1 via videoconference and receive MOMENT-V (mHealth intervention involving 2 Motivational Enhancement Therapy \[MET\] sessions with a trained counselor and 2 weeks of smartphone-based Ecological Momentary Assessment \[EMI\]).
62649216|NCT04429958||abnormal GCT group|125 mothers with an abnormal glucose challange test (GCT of 130mg/dl or more) in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
62649217|NCT04429958||normal group|125 mothers with both a normal GCT and OGT in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
62649218|NCT02053103|EXPERIMENTAL|PF-05175157|
62081868|NCT06661031|NO_INTERVENTION|Oral fluid test pilot|Prior to RCT, single-arm pilot to test feasibility and acceptability of remote oral fluid testing.
62081869|NCT06740760|ACTIVE_COMPARATOR|Clinician led genetic information session|Clinician led structured genetic information session either in person or through online video link. Participant with genetic information available (clinically significant rare variants from exome sequencing and copy number variant analysis and polygenic scores (autism, ADHD, depression and anxiety), these will be also communicated as last part of the session.
62649219|NCT02053103|PLACEBO_COMPARATOR|Placebo|
62649220|NCT04909944|EXPERIMENTAL|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation and ventilation
62649221|NCT04909944|EXPERIMENTAL|laryngeal tube suction disposable supraglottic insertion for oxygenation|laryngeal tube suction disposable insertion for oxygenation and ventilation
62649222|NCT03168373|EXPERIMENTAL|Intensive group|language rehabilitation therapy by language therapist for 1 hours on every working day for 4 weeks
62649223|NCT03168373|ACTIVE_COMPARATOR|Conventional group|language rehabilitation therapy by language therapist for 30 minutes on every working day for 4 weeks
62649224|NCT02244632|EXPERIMENTAL|Modufolin / Nordic FLV|Modufolin in combination with 5-Fluorouracil only.
62458465|NCT04872257|EXPERIMENTAL|Oral Vitamin D + NB-UVB Phototherapy|
62081870|NCT06740760|ACTIVE_COMPARATOR|Leaflet genetic information|the participants receive leaflet with genetic information without in-person contact
62081871|NCT04064424|EXPERIMENTAL|Prevention Advertisement|Participants will be exposed to prevention videos and images through Facebook Advertising
62281142|NCT00616109|EXPERIMENTAL|Maintenance Sunitinib|"Main interventional arm of study. Subjects who received maintenance sunitinib experimentally on this study were from a population of (consenting) patients with histologically or cytologically documented Extensive-State Small Cell Lung Cancer (ES-SCLC) who did not progress (were classified as Complete Response or CR, Partial Response or PR, or Stable Disease or SD) after an induction chemotherapy (Cisplatin and etoposide)"
62081872|NCT04064424|ACTIVE_COMPARATOR|No Advertisement|No prevention videos and images will be shown through Facebook Advertising
62081873|NCT05630014|EXPERIMENTAL|Family Caregivers of PLWD at High Risk for Delirium|Participants will complete the Aliviado DSD Caregiving Mastery Program. This involves a caregiver education/training period from Week 0 to Week 2, and an implementation period from Week 3 to Week 6.
62281143|NCT02713308||Group1-CRT|Patients with RV-to-LV delay≥80ms, CRT standard programming (single-point)
62281144|NCT02713308||Group2-MPP|Patients with RV-to-LV delay\<80ms, CRT programming with MPP (multi-point)
62458466|NCT04872257|PLACEBO_COMPARATOR|Placebo + NB-UVB Phototherapy|
62458467|NCT04033809|ACTIVE_COMPARATOR|Multigrain powder (S)|Oral high fiber multigrain supplements
62458468|NCT04033809|NO_INTERVENTION|Standard care (C)|Standard care without oral high fiber multigrain supplements
62081874|NCT06400472|EXPERIMENTAL|LY4170156 (Dose-escalation, Cohort A1)|Escalating doses of LY4170156 administered intravenously (IV).
62281145|NCT04941144||COVID-19 Vaccine Intramuscular Injection 0.5 milliliters (mL)|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
62281146|NCT01815931||ED patients|
62458469|NCT00821028|EXPERIMENTAL|Paclitaxel|Participants will receive Paclitaxel.
62458470|NCT03371290|EXPERIMENTAL|Mirror Therapy Intervention|
62458471|NCT03371290|ACTIVE_COMPARATOR|Control Intervention|
62458472|NCT01170286|EXPERIMENTAL|DBV712 Viaskin|The experimental arm is composed of subjects treated with whole peanut extract on an epicutaneous delivery system (Viaskin patch)
62458473|NCT01170286|PLACEBO_COMPARATOR|Placebo Viaskin|The placebo arm is composed of subjects treated with a placebo formulation on an epicutaneous delivery system (Viaskin patch)
62458474|NCT06021821|EXPERIMENTAL|Intervention Group|Participants will listen to the SoundMind app for 20 minutes per day, ideally during a moment of stress.
62649225|NCT02244632|EXPERIMENTAL|Modufolin / Nordic FLOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
62458475|NCT06021821|ACTIVE_COMPARATOR|Spotify Group|Participants will listen to a specified Spotify playlist for 20 minutes per day, ideally during a moment of stress.
62081875|NCT06400472|EXPERIMENTAL|LY4170156 (Dose-optimization, Cohort A2)|Comparing 2 or more doses (evaluated during dose escalation) of LY4170156 administered IV.
62458476|NCT06021821|NO_INTERVENTION|Control Group|This group will have no tasks prescribed.
62458477|NCT01989091|EXPERIMENTAL|B-Lock (IMD)|Investigational Medical Device (IMD)
62081876|NCT06400472|EXPERIMENTAL|LY4170156 (Dose-expansion, Cohort B1, B2, C1, C2)|LY4170156 administered IV.
62081877|NCT06183684|EXPERIMENTAL|Tricuspid Valve Replacement|Transcatheter replacement of the native tricuspid valve with the Laplace bioprosthesis
62081878|NCT04380051|EXPERIMENTAL|Arm 1 : skin-to-skin contact associated with a sensory-tonic s|skin-to-skin contact left free for parents associated with a sensory-tonic stimulation five times a week during 15 minutes at each time
62081879|NCT04380051|ACTIVE_COMPARATOR|Arm 2 : skin-to-skin contact only|skin-to-skin contact left free for parents
62458478|NCT01989091|ACTIVE_COMPARATOR|Heparin 5,000 U/mL (ACH)|Active Comparator Heparin (ACH)
62649226|NCT02244632|EXPERIMENTAL|Modufolin / Nordic FLIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan.
62649227|NCT02244632|EXPERIMENTAL|MOFOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
62649228|NCT02244632|EXPERIMENTAL|MOFOX / Bevacizumab|Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
62649229|NCT02244632|EXPERIMENTAL|MOFIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan
62649230|NCT01281696|EXPERIMENTAL|Bevacizumab, etoposide, cisplatin (BEEP)|
62649231|NCT01649219|EXPERIMENTAL|Exercise intervention|3-month supervised exercise intervention 3 times per week; 60min per time.
62649232|NCT01649219|NO_INTERVENTION|No intervention|Standard couselling at baseline
62649233|NCT04059718|EXPERIMENTAL|Treatment|Treatment arm will be enrolled in the SCI Thrive Peer-Led Online Self-Management program and will take part in the next available group session.
62281147|NCT03624946|EXPERIMENTAL|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
62649234|NCT04059718|NO_INTERVENTION|Wait-list Control|Wait-list control arm will only complete assessments during the 6 week group period. Subjects will be offered a place in the SCI Thrive Peer-Led Online Self-Management program after 6 weeks and completing the assessments.
62081880|NCT03618550|EXPERIMENTAL|Safety Window and DLT definition (Part 1)|Initially, 6 patients will be treated on the safety portion of the study and observed for dose limiting toxicities (DLTs). If 1 or fewer patients experience dose\[1\]limiting toxicity (DLT), enrollment onto the study will proceed according to a phase II, Simon 2- stage design.
62281148|NCT03624946|PLACEBO_COMPARATOR|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
62281149|NCT06489717|EXPERIMENTAL|Assessments at 3200 m and 760 m, respectively|Participants will have a SDB assessment near their resident altitude at 3200 m and after relocation to 760 m after 1 and 7 days
62281150|NCT01337973|EXPERIMENTAL|Arm 1: MI-CBT|MI-CBT (six sessions during acute treatment phase integrating motivational interviewing and cognitive behavioral approaches)
62281151|NCT01337973|EXPERIMENTAL|Arm 2: MI-CBT+CC|MI-CBT+CC (acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention)
62281152|NCT01337973|ACTIVE_COMPARATOR|Arm 3: E-TAU|E-TAU (enhanced treatment as usual - includes brief session and provision of resources)
62281153|NCT03436355|EXPERIMENTAL|Physical activity|60 minutes of daily physical activity (see intervention)
62281154|NCT05844215||Non-Severe|Non-severe groups consisted of mild and moderate severity of COVID-19. Mild-degree are patients with symptoms of COVID-19 but do not require oxygen with normal X-ray images. Moderate-degree are patients with symptoms of COVID-19 that require a low oxygen flow rate with minimal pneumonia on chest X-Ray.
62281155|NCT05844215||Severe|Severe groups consisted of Severe and Critical Ill of COVID-19. Severe-degree are patients that require high oxygen flow rate with diffuse lung infiltrates. Critical-Ill are COVID-19 patients that suffered shock sepsis or respiratory failure.
62281156|NCT04269395|ACTIVE_COMPARATOR|MAL Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit of the active cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
62281157|NCT04269395|PLACEBO_COMPARATOR|Vehicle Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit in the vehicle cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
62649235|NCT02442609||patient|patient schedulled for elective surgery, adult (\> 18yrs), non emergency procedure, able to read questionaire
62649236|NCT03885557|EXPERIMENTAL|Group I Experimental Dynamic oscillatory stretch(DOS)|Dynamic oscillatory stretch technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group.
62649237|NCT03885557|ACTIVE_COMPARATOR|Group II Static Stretching(SS) Group|Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group.
62649238|NCT02251353||lung and/or hepatic metastasis|intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)
62649239|NCT01926158|EXPERIMENTAL|Denosumab|Subcutaneous injection of denosumab 60 mg 4 weeks before surgery and 22 weeks after surgery
62649240|NCT01926158|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection of placebo 4 weeks before surgery and 22 weeks after surgery
62649241|NCT03353220|EXPERIMENTAL|Arm A|Participants receive lorcaserin (Belviq) 10 mg twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive placebo twice a day for 7 days.
62281158|NCT04218097||Addict patients|"Obese type 2 and 3 with food addict according to the Yale Food Addiction Scale (YFAS) questionnaire.~Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
62081881|NCT03618550|EXPERIMENTAL|Safety monitoring beyond after completion of safety window (PART 1)|During the phase II portion of the study, patients will continue to be monitored for DLTs, adverse events, and events of interest throughout treatment with pembrolizumab-GVD, ASCT (part 1, if applicable), and 100 days following the last dose of pembrolizumab. Total planned enrollment is 39 patients
62081882|NCT03618550|EXPERIMENTAL|Autologous Stem Cell Transplant (ASCT) (PARTS 1 and 3)|Stem cell mobilization and collection will be performed as per institutional guidelines after 2-4 cycles of pembrolizumab-GVD.
62081883|NCT03618550|EXPERIMENTAL|Pembrolizumab maintenance (PART 2)|In part 2 of the study, patients who achieve complete response after 4 cycles of pembrolizumab\[1\]GVD will receive single-agent pembrolizumab for 13 cycles, which will begin 3-5 weeks after cycle 4 of pembrolizumab-GVD.
62281159|NCT04218097||Control patients|"Obese type 2 and 3, non food addict Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
62081884|NCT03618550|EXPERIMENTAL|Pembrolizumab maintenance, third-line therapy, and HDT/ASCT (PART 3)|In part 3 of the study, patients who achieve complete response after 2 cycles of pembrolizumab\[1\]GVD will be randomized to either consolidation with autologous stem cell transplant (after an additional optional 1-2 cycles of pembro-GVD) or 2 cycles of pembro-GVD followed by single agent pembrolizumab maintenance for 13 cycles.
62081885|NCT03618550|EXPERIMENTAL|Involved-site radiation therapy (ISRT) (PART 3)|Patients with limited sites of disease prior to initiation of pembro-GVD are eligible to receive ISRT prior to ASCT with pembrolizumab maintenance.
62081886|NCT06737198||chronic rhinosinusitis|chronic rhinosinusitis with/without nasal polys.
62081887|NCT05252754|EXPERIMENTAL|Oral Tacrolimus + Indomethacin|"* Tacrolimus Capsule 1-2 hours prior to the endoscopy~* Rectal Indomethacin immediately after ERCP, in high-risk patients"
62081888|NCT05252754|PLACEBO_COMPARATOR|Oral Placebo + Indomethacin|"* Placebo Capsule 1-2 hours prior to the endoscopy~* Rectal Indomethacin immediately after ERCP, in high-risk patients"
62281160|NCT03632980|EXPERIMENTAL|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
62649242|NCT03353220|EXPERIMENTAL|Arm B|Participants receive placebo twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive lorcaserin (Belviq)10 mg twice a day for 7 days.
62281161|NCT04039997|EXPERIMENTAL|Chest compression without cpr feedback device|teaching resuscitation without application of cpr feedback device
62081889|NCT06486506||Patients|Male and female patients surgically treated with an oncological reconstruction of the proximal femur at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2023
62281162|NCT04039997|EXPERIMENTAL|Chest compression with cpr feedback device|teaching resuscitation with application of CPRMeter - cpr feedback device
62081890|NCT05389462|EXPERIMENTAL|Part 1: Dose Escalation, ADCT-601 Combination Therapy|In Part 1 (dose escalation), participants with selected sarcoma indications will receive escalating doses of ADCT-601 in combination with gemcitabine.
62081891|NCT05389462|EXPERIMENTAL|Part 1: Dose Escalation, ADCT-601 Monotherapy|In Part 1 (dose escalation), participants with sarcoma indications (regardless of AXL gene amplification status), non-small-cell lung cancer (NSCLC) (regardless of AXL gene amplification status), and solid tumors with AXL gene amplification, will receive ADCT-601 monotherapy.
62281163|NCT02859909|EXPERIMENTAL|2 day treatment schedule|Patients will receive a dosage of 1 g/kg bw per day of BT595 for 2 consecutive days
62649243|NCT01737801|EXPERIMENTAL|Lung function test|Lung function test
62649244|NCT00880126|EXPERIMENTAL|CDT|Community Development Teams bring together counties who are implementing a new practice
62649245|NCT04052828|EXPERIMENTAL|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
62649246|NCT03111290|SHAM_COMPARATOR|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
62081892|NCT05389462|EXPERIMENTAL|Part 2: Dose Expansion, ADCT-601 Combination Therapy|"In Part 2 (dose expansion), participants with selected sarcoma indications will receive ADCT-601 in combination with gemcitabine.~Participants will be split into 3 cohorts:~Cohorts 5 and 6: Sarcoma indications.~Cohort 7: Pancreatic cancer."
62649247|NCT03111290|ACTIVE_COMPARATOR|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
62649248|NCT04938791|EXPERIMENTAL|Isometric activity|All participants will be included in this arm
62649249|NCT03556033|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin 10 mg capsule once daily for 8 weeks
62649250|NCT03556033|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
62649251|NCT00643175||1|Osteoporosis in patients with fragility hip fractures.
62649252|NCT00501631|ACTIVE_COMPARATOR|VIVITROL 380 mg|Administered via intramuscular (IM) injection once every 4 weeks.
62649253|NCT00501631|PLACEBO_COMPARATOR|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
62649254|NCT04751617|EXPERIMENTAL|Pulmonary rehabilitation (intervention)|This group will be covered by pulmonary rehabilitation.
62649255|NCT00374634|ACTIVE_COMPARATOR|"Individual or standard rFSH dose"|"Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64)."
62649256|NCT00374634|ACTIVE_COMPARATOR|"Standard rFSH dose"|"Standard dose of rFSH"
62649257|NCT05246449|NO_INTERVENTION|Standard of care group|with patients starting their regular CPAP/APAP treatment without stratification, with medical follow-up, and with standard home CPAP/APAP service provided by home healthcare,
62081893|NCT05389462|EXPERIMENTAL|Part 2: Dose Expansion, ADCT-601 Monotherapy|"In Part 2 (dose expansion), participants with a selected indication will receive ADCT-601 monotherapy.~Participants will be split into cohorts:~Cohort 1: Soft tissue sarcoma (STS).~Cohort 2: Pancreatic adenocarcinoma (PAAD).~Cohort 3: NSCLC.~Cohort 4: Solid tumors with known AXL expression."
62081894|NCT06085807||Patients with ADPKD|The participants will receive a survey.
62081895|NCT06085807||Family members of patients with ADPKD|The family members of participants will receive a survey.
62281164|NCT02859909|EXPERIMENTAL|5 day treatment schedule|Patients will receive a dosage of 0.4 g/kg bw per day of BT595 for 5 consecutive days
62281165|NCT00731874|ACTIVE_COMPARATOR|Arm 1 (6 to 8 ng/mL)|Target tacrolimus trough concentration of 6 to 8 ng/mL
62281166|NCT00731874|ACTIVE_COMPARATOR|Arm 2 (3 to 5 ng.mL)|Target tacrolimus trough concentration of 3 to 5 ng/mL
62281167|NCT03590509|EXPERIMENTAL|Telemedicine Program*|"Integrated Telemedicine-Home Visitation\* Program.~\*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
62281168|NCT03590509|ACTIVE_COMPARATOR|Control|Usual Comprehensive Care
62458479|NCT04374084|EXPERIMENTAL|Moxibustion plus Cupping|"Moxibustion plus cupping and basic therapy (rehabilitation direction and basic breathing exercise) once a day for 4 weeks (28 sessions).The moxibustion plus cupping treatments were divided into 2 alternating formulas:~A: Monday, Wednesday, Friday and Sunday: moxibustion on bilateral Fengmen (BL12), Feishu (BL13) and Pishu(BL20) B: Tuesday, Thursday and Saturday: moxibustion on Zhongwan (RN12), Qihai (RN6), bilateral Tianshu(ST25) and Zusanli(ST36) + cupping on bilateral Feishu(BL13) Geshu(BL17) Pishu(BL20) The 2 formulas were used alternatively every other day, 7 times per week, for 4 weeks. Moxibustion acupoint addition: profuse sweating added Fuliu (KI7), insomnia added Shenmen(HT7) anxiety or depression added Neiguan (PC6)."
62649258|NCT05246449|EXPERIMENTAL|VitalCare group|with patients starting their CPAP/APAP treatment and with a personalized follow-up by the homecare provider.
62281169|NCT01734655||All Participants|Participants will be asked to complete the MEQ, the Eating Inventory Questionnaire, The Mindful Attention Awareness Scale (MAAS), and the Neighborhood Environment Walkability Scale (NEWS). Participants will then be asked to sequentially respond to each of the 28 items and the response choices from the MEQ and briefly discuss their reaction to the items and response choices. Finally, participants will either participate in a focus group or an individual cognitive interview, giving them the opportunity to elaborate on their responses to the MEQ. The first 11 participants completed focus groups and the remaining 29 participants completed individual cognitive interviews.
62281170|NCT06158165||General Anesthesia|Patients undergoing elective unilateral total knee arthroplasty with tourniquet application under the general anesthesia technique
62458480|NCT04374084|NO_INTERVENTION|Basic therapy|Basic therapy: rehabilitation direction and basic breathing exercise.
62458481|NCT01651702|ACTIVE_COMPARATOR|Carto|Patients in whom Carto system will be used
62649259|NCT03468621|OTHER|Intradermal wound closure|Intradermal wound closure of the groin wound
62649260|NCT03468621|OTHER|Transdermal wound closure|Wound closure of the groin wound with metal staples
62649261|NCT04496232|NO_INTERVENTION|Normal SDF|Using routine semen processing method
62281171|NCT06158165||Combined Spinal Epidural Anesthesia|Patients undergoing elective unilateral total knee arthroplasty with tourniquet application under the combined spinal epidural anesthesia technique
62281172|NCT02803073|EXPERIMENTAL|Testosterone Replacement|The experimental group will receive 0.5 ml (100 mg) testosterone cypionate Intramuscular injections each week for 11 weeks.
62281173|NCT02803073|PLACEBO_COMPARATOR|Control|Patients in the control group will receive intramuscular normal saline injections.
62281174|NCT02288273|EXPERIMENTAL|Bydureon|Once weekly injected exenatide
62281175|NCT02288273|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62281176|NCT04349046||Patient who received the Exception stem|Patient who received the Exception stem between January 2008 and September 2012 and consented to the original data collection.
62281177|NCT00870246||1|High mobility
62281178|NCT00870246||2|Lower mobility
62281179|NCT02488304|EXPERIMENTAL|HRCT scans|High Resolution Computed Tomography scans will be taken
62281180|NCT01658657|EXPERIMENTAL|PRA-guided therapy|Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
62281181|NCT01658657|ACTIVE_COMPARATOR|Fixed-dose combination treatment-guided therapy|Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
62281182|NCT02271412|EXPERIMENTAL|LY03005|LY03005 40, 80, 120, or 160 mg
62649262|NCT04496232|ACTIVE_COMPARATOR|Physiological ICSI (PICSI)|Sperm selection using PICSI dishes for selecting sperm with lower DNA fragmentation index for ICSI
62649263|NCT04496232|ACTIVE_COMPARATOR|Second ejaculate|Using the second ejaculate as a way of reducing SDF in the semen sample used for ICSI
62649264|NCT02177500|EXPERIMENTAL|Telmisartan + hydrochlorothiazide and matching placebo|
62281183|NCT02271412|PLACEBO_COMPARATOR|Placebo|Placebo at 40, 80, 120, or 160 mg
62649265|NCT02177500|EXPERIMENTAL|Telmisartan and matching placebo|
62649266|NCT03957616||Paraneoplastic neurological syndromes patients|Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
62649267|NCT02108301|EXPERIMENTAL|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
62458482|NCT01651702|ACTIVE_COMPARATOR|Ensite|Patients in whom Ensite system will be used
62458483|NCT01891409|OTHER|Single arm|Single arm study study for use of Shang Ring device for male circumcision in children
62458484|NCT00818883|EXPERIMENTAL|Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD|
62458485|NCT00818883|EXPERIMENTAL|Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD|
62458486|NCT06314503|EXPERIMENTAL|WEAKID|Six treatments over the course of two weeks with the WEAKID system
62458487|NCT03486990|EXPERIMENTAL|Part A, Cohort 1: 0.1 mg/kg|TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
62458488|NCT03486990|EXPERIMENTAL|Part A, Cohort 2: 0.5 mg/kg|TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
62458489|NCT03486990|EXPERIMENTAL|Part A, Cohort 3: 1.0 mg/kg|TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
62458490|NCT03486990|EXPERIMENTAL|Part A, Cohort 4: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
62458491|NCT03486990|EXPERIMENTAL|Part A, Cohort 5: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
62649268|NCT00888654|EXPERIMENTAL|B-Dim, Radical Prosatectomy|"B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)~Radical Prostatectomy"
62649269|NCT01741415|EXPERIMENTAL|SIDI|Skills for Improving Distress Intolerance treatment protocol: individual, manualized treatment aimed at improving distress intolerance
62649270|NCT01741415|PLACEBO_COMPARATOR|SC|supportive counseling; psychological placebo/talk therapy - aimed at controlling for non-specific therapeutic factors
62281184|NCT04654858|ACTIVE_COMPARATOR|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used after infiltration or block anaesthesia for affected molar, following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
62281185|NCT04654858|ACTIVE_COMPARATOR|Performed metal crowns|PMCs (3M Espe, Seefeld, Germany) will be placed after infiltration or block anaesthesia for affected molar, followed by removal of carious dentin and enamel, Tooth preparation for fitting the crown, The correct size of crown will be chosen, and then Cemented with glass ionomer luting cement (KetacCem, 3M Espe).
62458492|NCT03486990|EXPERIMENTAL|Part A, Cohort 6: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
62458493|NCT03486990|EXPERIMENTAL|Part B, Cohort 1: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
62458494|NCT03486990|EXPERIMENTAL|Part B, Cohort 2: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
62458495|NCT03486990|EXPERIMENTAL|Part B, Cohort 3: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
62458496|NCT03579771|EXPERIMENTAL|Gemcitabine, cisplatin, nab-paclitaxel|Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
62458497|NCT01631422|EXPERIMENTAL|Single Arm|
62458498|NCT05773079|EXPERIMENTAL|Toripalimab|Toripalimab 240mg, VD, Q3W (treatment time: maintain for 1 year or until disease progression or intolerance requires drug withdrawal)
62458499|NCT00379340|EXPERIMENTAL|Treatment (chemotherapy, surgery, radiotherapy)|"REGIMEN DD4A (weeks 1-6): Patients receive dactinomycin IV; vincristine IV; and doxorubicin hydrochloride IV. Patients with pulmonary and extra-pulmonary metastases at diagnosis undergo radiotherapy.~Patients with initially unresectable or incompletely resected tumors are reevaluated at week 6, and if resectable, undergo surgery and then proceed to either regimen DD4A or regimen M.~REGIMEN DD4A (weeks 7-25): Patients receive dactinomycin IV; vincristine IV; and doxorubicin hydrochloride IV.~REGIMEN M (weeks 7-31): Patients receive cyclophosphamide IV; vincristine IV; and dactinomycin IV and doxorubicin hydrochloride IV. Patients with pulmonary metastases only who are SIR also undergo whole lung radiotherapy."
62081896|NCT04478643|PLACEBO_COMPARATOR|PLACEBO|"* Collection of microbiological samples from the two deepest sites in two different quadrants.~* All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).~* Study lozenges without live bacteria are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
62281186|NCT02194439||hematopoietic stem cell transplant|procedure
62281187|NCT02471716|EXPERIMENTAL|Phase 1 FPA008 Dose Escalation|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose or lower dose that provide adequate PK exposure and biologic activity with tolerability.
62281188|NCT02471716|EXPERIMENTAL|Phase 2 FPA008 Dose Expansion|IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
62281189|NCT01909284|EXPERIMENTAL|Acupuncture & Epidural nerve block|acupuncture plus epidural block
62281190|NCT01909284|ACTIVE_COMPARATOR|Epidural nerve block|epidural block alone
62458500|NCT02581345|EXPERIMENTAL|M923|Participants assigned to receive M923
62458501|NCT02581345|ACTIVE_COMPARATOR|Humira|Participants assigned to receive Humira
62458502|NCT02581345|OTHER|M923 and Humira|Participants assigned to receive M923 and Humira
62281191|NCT02715687|PLACEBO_COMPARATOR|Placebo|Will receive 30 days treatment with oral placebo of 200mg
62281192|NCT02715687|ACTIVE_COMPARATOR|Interventional|Will receive 30 days treatment with oral Amiodarone of 200mg
62649271|NCT02332265||Program Participant Study SAFE area, control area|"Participants from two types of areas of rural central Malawi: traditional authorities (TA) selected by CARE to receive the SAFE program (intervention group) and TAs receiving other unrelated CARE programming (controls).~Intervention TAs: 598 program participants (398 women, 200 men) were interviewed at baseline and 18- and 36-month follow-ups;~Control TAs: 301 control households were interviewed at baseline and 18- and 36-month follow-ups"
62458503|NCT05017298|EXPERIMENTAL|Study Group|Each subject receives three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.
62458504|NCT05017298|PLACEBO_COMPARATOR|Control Group|The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care.
62458505|NCT01001845|NO_INTERVENTION|Lifestyle counseling|
62458506|NCT01001845|ACTIVE_COMPARATOR|vit E|200mg 2 times per day for 3 weeks
62458507|NCT01001845|EXPERIMENTAL|Milk Thistle extract|1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks
62649272|NCT02332265||Community Impact Study, non-SAFE participants|We conducted random surveys (n = 1002)--501 living in the intervention areas but not directly receiving the SAFE intervention and 501 living in the control areas not receiving the SAFE intervention with a 36-month assessment interval, prior to and after implementation of SAFE. Thus, we examined intervention outcomes both in direct SAFE program participants and their larger communities. We used multilevel modeling to examine mediators and moderators of the effects of SAFE on HIV outcomes at the individual and community levels and determine the ways in which changes in HIV outcomes feed back into economic outcomes and food security at later interviews.
62649273|NCT02332265||Qualitative SAFE program participant in-depth interview & FGD|We conducted a qualitative end-of-program evaluation consisting of in-depth interviews with 90 SAFE participants.
62649274|NCT01549158|EXPERIMENTAL|Torasemide PR 10 mg|
62281193|NCT02809066|EXPERIMENTAL|Interventional group|8-week follow- up with dietary sufficient calcium intake
62649275|NCT01549158|ACTIVE_COMPARATOR|Furosemide-IR 40 mg|
62649276|NCT01549158|ACTIVE_COMPARATOR|Torasemide-IR 10 mg|
62649277|NCT01426581|EXPERIMENTAL|Educational Intervention A|Intervention: Teach to Goal
62649278|NCT01426581|EXPERIMENTAL|Educational Intervention B:|Brief Intervention
62281194|NCT02809066|NO_INTERVENTION|Control group|8-week follow- up with no specific diet
62281195|NCT03512548|EXPERIMENTAL|Part 1 Period 1|Part 1 Period 1: Relacorilant 350mg will be given once on Day 1
62281196|NCT03512548|EXPERIMENTAL|Part 1 Period 2|Part 1 Period 2: Itraconazole 200mg will be given for three days
62458508|NCT01001845|EXPERIMENTAL|vit E + Milk Thistle Extract|200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks
62458509|NCT06051240|EXPERIMENTAL|Lithium|Lithionit 42 mg (lithium sulphate, 6 mmol), start dose 1x1, then slow dose escalation using therapeutic drug monitoring (TDI) to establish a target serum level of 0.5-1.0 mmol/liter.
62281197|NCT03512548|EXPERIMENTAL|Part 1 Period 3|Part 1 Period 3: Relacorilant 350mg will be given once with concomitant itraconazole and itraconazole will continue for three additional days
62281198|NCT03512548|EXPERIMENTAL|Part 2 Period A|Part 2 Period A: Relacorilant 300mg will be given once daily for 10 days
62458510|NCT06051240|PLACEBO_COMPARATOR|Placebo|Identical looking placebo (white round tablet, 10 mm diameter) will be dose escalated and monitored the same way as lithium, with sham values guiding the dosing.
62458511|NCT00076102|EXPERIMENTAL|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).
62281199|NCT03512548|EXPERIMENTAL|Part 2 Period B|Part 2 Period B: Relacorilant 300mg will be given once daily in combination with itraconazole 200mg once daily for 10 days
62281200|NCT02796573|EXPERIMENTAL|B-CBT|6 face-to-face consultations plus 6 online modules.
62281201|NCT02796573|ACTIVE_COMPARATOR|Face-to-Face CBT|12 face-to-face consultations.
62281202|NCT05392452|EXPERIMENTAL|Closed-loop insulin therapy|"Intervention:~Use of a fully-automated closed-loop insulin delivery system from day of admission until hospital discharge (or maximum 20 days)."
62281203|NCT05392452|ACTIVE_COMPARATOR|Standard insulin therapy|The control group will receive insulin therapy in accordance with local practice. The insulin regimen during the study period may involve subcutaneous and/or insulin intravenous insulin administration. The modality of insulin treatment, dose adjustment and frequency of glucose monitoring will be at the discretion of the clinical team. No active treatment optimisation will be undertaken by the study team. Participants in the control group will be fitted with the identical study CGM system. The CGM system will be blinded upon hospital admission.
62281204|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
62281205|NCT02017574|EXPERIMENTAL|Implicit Group|Receives little feedback about task performance during learning
62281206|NCT02017574|ACTIVE_COMPARATOR|Control|Receives detailed feedback about task performance during learning
62281207|NCT05129397|EXPERIMENTAL|Treatment|The experimental arm of Virtual Mom Power is a manualized multi-family group intervention consisting of 10, 90-minute virtual group + 2 individual sessions led by two co-facilitators. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice; (4) Social Support; \& (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. We will work with mothers in individual coaching to problem-solve childcare and privacy during group time. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs. Data regarding attendance will be recorded and total dosage examined in treatment effects.
62281208|NCT05129397|ACTIVE_COMPARATOR|Informational control|The control arm of this study consists of two individual sessions with mothers, along with 10 weeks of virtual informational mailings. The mailings will contain Mom Power curriculum about attachment-based parenting and self-care. The individual sessions will focus on individual goal-setting related to parenting and reflection on the parent-child relationship. The control group does not include the components of social support, affect regulation skills coaching, or guided parent-child interaction that are part of the experimental arm.
62281209|NCT03222466|EXPERIMENTAL|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
62281210|NCT03222466|NO_INTERVENTION|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
62081897|NCT04478643|EXPERIMENTAL|PROBIOTIC (L. Reuteri)|"* Collection of microbiological samples from the two deepest sites in two different quadrants.~* All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).~* Study lozenges containing Lactobacillus Reuteri are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
62081898|NCT06696443|EXPERIMENTAL|Suzetrigine (SUZ)|Participants will receive SUZ once daily (qd) up to 52 weeks.
62081899|NCT00339911||1/ single cohort|Healthy NCI Frederick Cancer Research and Development Center employees
62081900|NCT01134770||Prenatal Cocaine|Use of cocaine at anytime during pregnancy. Subjects may also have used other drugs in combination with Cocaine
62281211|NCT05218616|OTHER|Sequence TR|
62281212|NCT05218616|OTHER|Sequence RT|
62081901|NCT01134770||Prenatal Nicotine-Alcohol-Marijuana|Subjects may have used any of these drugs during pregnancy, alone or in combination. This group has not used cocaine during pregnancy.
62081902|NCT01134770||Drug-Free Pregnancy|"Subjects did not use any of the following drugs during pregnancy:~cocaine, nicotine, alcohol, marijuana."
62081903|NCT06191159|ACTIVE_COMPARATOR|Standard of Care|The Standard of Care arm will consist of the scalpel for the initial skin incision and further randomization to have completion of the surgery with standard electrocautery or PEAK PlasmaBlade.
62081904|NCT06191159|EXPERIMENTAL|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the surgery, including the initial skin incision.
62281213|NCT00305578|PLACEBO_COMPARATOR|Placebo|Placebo daily
62281214|NCT00305578|ACTIVE_COMPARATOR|Memantine|Daily dose Memantine
62281215|NCT02629159|PLACEBO_COMPARATOR|Placebo followed by ABT-494|"Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).~Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2."
62081905|NCT06191159|EXPERIMENTAL|Standard Electrocautery|Standard electrocautery will be used for the entirety of the surgery, including the initial skin incision.
62081906|NCT05591703||Participants randomized to receive tAN therapy in SBM-OWP-03 Phase II|
62081907|NCT05591703||Participants not randomized to receive tAN therapy in SBM-OWP-03 Phase II|
62081908|NCT03786016|EXPERIMENTAL|8-Days in an Isolation, Confinement Unit|Subjects will spend 7-night/8-day in an isolated and confined unit with up to 3 other subjects.
62081909|NCT05580211|OTHER|Investigational Stimulation Pattern 1-Randomized|
62081910|NCT05580211|OTHER|Investigational Stimulation Pattern 2-Randomized|
62081911|NCT05580211|OTHER|Investigational Stimulation Pattern-Open Label|
62281216|NCT02629159|ACTIVE_COMPARATOR|Adalimumab|"Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index \[CDAI\] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
62649279|NCT04740307|EXPERIMENTAL|Pembrolizumab/Quavonlimab + Lenvatinib|Participants receive pembrolizumab/quavonlimab via intravenous (IV) infusion every 6 weeks (Q6W) for up to 2 years, plus lenvatinib orally (based on actual body weight at screening) until progressive disease or unacceptable toxicity for up to 5 years. In the event of discontinuation of pembrolizumab/quavonlimab due to intolerable toxicity, re-initiation of treatment with pembrolizumab may be considered.
62649280|NCT02526238|EXPERIMENTAL|TMS and trunk rotation|TMS and trunk rotation
62081912|NCT06740240|EXPERIMENTAL|68Ga-FAPI-Biotin PET/ CT|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT.
62281217|NCT02629159|EXPERIMENTAL|Upadacitinib|"Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
62281218|NCT03898063|ACTIVE_COMPARATOR|Control|participants will receive a standard-of-care brochure detailing HIV status disclosure.
62281219|NCT03898063|EXPERIMENTAL|intervention: 90 DAYS film|participants will watch the film, 90 DAYS
62649281|NCT02526238|SHAM_COMPARATOR|Sham TMS and trunk rotation|Sham TMS and trunk rotation
62081913|NCT06740240|ACTIVE_COMPARATOR|68Ga-FAPI/18F-FDG PET/CT|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg18F-FDG. Tracer of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
62081914|NCT06738810|OTHER|type 2 diabetes with a hepatic check-up patients|For the study, a blood sample will be collected from the patient in order to do Fibrotest-actitest/NASHtest.
62081915|NCT04781231|EXPERIMENTAL|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
62081916|NCT04781231|ACTIVE_COMPARATOR|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
62081917|NCT04781231|OTHER|Usual management of anxiety|
62081918|NCT06526286||Usual Care|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
62081919|NCT06526286||CDS Notification|Providers will see a clinical decision support tool within the electronic health record when treating a patient at risk for opioid use disorder to encourage the provider to use a clinical care pathway to assess for opioid use disorder and when applicable, treat opioid use disorder with buprenorphine. Smart text will also be available in the electronic health record so that the provider can easily document screening and treatment discussions with the patient.
62081920|NCT05185180||Males with Category III Chronic Pelvic Pain Syndrome|Category III is subdivided into inflammatory (IIIa) and noninflammatory (IIIb) subtypes, based on the presence of white blood cells in expressed prostatic secretions (EPS). Category III prostatitis or chronic pelvic pain syndrome (CPPS) is the most common prostatitis observed in medical practice with a prevalence rate in the general population from 5% to 14.2%. CPPS is a poorly understood entity characterized by pelvic or perineal pain, irritative voiding symptoms, and sexual dysfunction.
62081921|NCT05185180||Control Group|The control group will consist of men with no history of Chronic Pelvic Pain or any underlying condition.
62281220|NCT04613115||Group A|patients without uremia and variant arteries
62649282|NCT06140186|ACTIVE_COMPARATOR|Timolol combination treatment|Patients will received topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month
62649283|NCT06140186|ACTIVE_COMPARATOR|Routine arm|Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion.
62081922|NCT06146335|EXPERIMENTAL|Kono-S anastomosis (KSa)|Randomized enrollment of preoperative patients undergoing surgical resection for Crohn's ileitis or ileocolitis
62081923|NCT06146335|ACTIVE_COMPARATOR|side-to-side anastomosis (SSa)|Randomized enrollment of preoperative patients undergoing surgical resection for Crohn's ileitis or ileocolitis
62081924|NCT04158648|EXPERIMENTAL|Emicizumab|Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.
62281221|NCT04613115||Group B|patients without uremia, but with variant arteries
62281222|NCT04613115||Group C|patients with uremia ,without variant arteries
62281223|NCT04613115||Group D|patients with uremia and variant arteries
62281224|NCT01505907|EXPERIMENTAL|CXB909 15mg|CXB909 15mg
62281225|NCT01505907|EXPERIMENTAL|CXB909 30mg|
62281226|NCT01505907|EXPERIMENTAL|CXB909 60mg|
62649284|NCT04149080|EXPERIMENTAL|SIM Group|Alveolar socket post-extraction filled with Simvastatin covered with polypropylene membrane
62649285|NCT04149080|PLACEBO_COMPARATOR|Control Group|Alveolar socket post-extraction covered with polypropylene membrane
62649286|NCT02495389|EXPERIMENTAL|Mirabegron|Participants received mirabegron (Myrbetriq) daily for 12 weeks
62649287|NCT01427140|ACTIVE_COMPARATOR|Saturated fatty acid group|Addition of saturated fatty acids to the diet inte the form of pastries
62649288|NCT01427140|ACTIVE_COMPARATOR|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
62281227|NCT01505907|EXPERIMENTAL|CXB909 120mg|Dose
62281228|NCT01505907|EXPERIMENTAL|CXB909 250mg|
62281229|NCT03544073|PLACEBO_COMPARATOR|Saline Solution for Injection|This arm will receive a one-time subcutaneous injection of 0.4mL normal saline solution at the time of embryo transfer. This arm will continue to receive all the same treatments that everyone routinely receives for the IVF cycle, e.g. estrogen and progesterone supplements.
62649289|NCT06233708||NSBB group|The NSBB group was defined as those who received NSBBs for at least 30 consecutive days within the 3 months prior to LT.
62281230|NCT03544073|EXPERIMENTAL|Leuprolide Acetate|This arm will receive a one-time subcutaneous injection of 0.4U (0.2mg=0.4mL) Leuprolide acetate at the time of embryo transfer. This arm will continue to receive all the same routine treatments for the IVF cycle, e.g. estrogen and progesterone supplements.
62281231|NCT05642858|EXPERIMENTAL|Intervention Arm|The intervention arm will receive education about HIV and heart disease risk via mobile phone text messages for up to 6 months. They will receive the text messages 3-5 times per week. The messages will include information about HIV and risk of heart disease and information about how to reduce heart disease risk. The intervention arm will also receive brief monthly surveys via a digital research platform.
62281232|NCT05642858|NO_INTERVENTION|Control Arm|The control arm will not receive the educational text messages. They will receive brief monthly surveys via a digital research platform.
62281233|NCT02614079|EXPERIMENTAL|DSSEP|DSSEP testing after SCS trial lead placement
62458512|NCT02392793|ACTIVE_COMPARATOR|Arm A: Talazoparib Plus Irinotecan|"Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.~Arm A is closed to enrollment."
62281234|NCT04723576|EXPERIMENTAL|Stress First Aid|"The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. SFA sites will implement SFA through a train-the-trainer model."
62649290|NCT06233708||Control group|Those who did not meet the above criteria were classified as the control group.
62649291|NCT02890862||20 healthy volunteers|
62081925|NCT02709226|EXPERIMENTAL|1/Radiation|Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
62081926|NCT03770273|ACTIVE_COMPARATOR|Drug: sarilumab|Participants with indolent systemic mastocytosis receive sarilumab 200 mg (1.14 ml) subcutaneous injection every two weeks for 16 weeks (8 doses total)
62081927|NCT03770273|ACTIVE_COMPARATOR|Placebo|Participants with indolent systemic mastocytosis receive placebo subcutaneous injection every two weeks for 16 week (8 doses total)
62081928|NCT06738654|ACTIVE_COMPARATOR|Control Group|Breast-conserving surgery for breast cancer using traditional open surgery.
62458513|NCT02392793|ACTIVE_COMPARATOR|Arm B: Talazoparib Plus Irinotecan Plus Temozolomide|Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
62458514|NCT04168463|EXPERIMENTAL|Immediate Intervention|This cluster of four homes will receive robot animals immediately at commencement of the eight month trial.
62649292|NCT02890862||Dupuytren disease|10 patients dupuytren disease
62649293|NCT02890862||Tendon pathology|10 patients with tendon pathology
62649294|NCT02890862||wrist osteoarthritis|10 patients with wrist osteoarthritis
62649295|NCT04020536||kala-azar group|
62649296|NCT04020536||epidemic hemorrhagic fever group|
62649297|NCT04020536||brucellosis group|
62649298|NCT04221529|EXPERIMENTAL|Atezolizumab|Four 21-day cycles of induction therapy with atezolizumab+carboplatin+etoposide followed by 21-day cycles of maintenance therapy with atezolizumab.
62649299|NCT03447834|EXPERIMENTAL|Selective intracoronary hypothermia + PPCI|Patients will be eligible for this study if they are admitted for acute anterior wall ST-elevation myocardial infarction with total ST-segment deviation of at least 5 mm. If the patient has TIMI grade flow 0 or 1, the experimental arm will be treated by selective intracoronary hypothermia just before and after reperfusion, in addition to routine PPCI.
62649300|NCT03447834|OTHER|Standard PPCI|The control group will receive routine PPCI.
62081929|NCT06738654|EXPERIMENTAL|Experimental Group|Breast-conserving surgery for breast cancer using single-port robotic surgery.
62081930|NCT06739538|EXPERIMENTAL|Bobath exercises|
62081931|NCT06739538|ACTIVE_COMPARATOR|Gasotransmitters|
62081932|NCT06638632|EXPERIMENTAL|Decision Aid|Participants provide feedback on the development of a decision aid for dementia therapies.
62081933|NCT01809288||1|Healthy African, African-American, and white women between 30 and 65 years of age who are federal employees or contractors.
62081934|NCT06214156|EXPERIMENTAL|T3011|
62081935|NCT06103955|EXPERIMENTAL|Digital Breathing Biofeedback system|Patients will receive 4 physiotherapist-guided breathing retraining sessions with the digital breathing biofeedback system.
62081936|NCT05508971|EXPERIMENTAL|Drug-Induced Sleep Endoscopy|DISE will be performed at the time of surgery under the same sedation. The decision on specific surgical approach will be made at that time based on DISE findings. Prior to intubation, patients will be sedated with either a propofol infusion or a combination of ketamine and dexmedetomidine. Once adequate sedation is achieved, endoscopy will be performed using a flexible endoscope advanced through the nose. The nasal airway will be evaluated on both sides, then the endoscope will be advanced into the pharynx. The degree of obstruction is scored on a 3-point rating scale. Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery. Caregivers will be consented for all possible procedures with the understanding that only those needed based on DISE will be performed. Importantly, these procedures are all established treatments with published outcomes data.
62081937|NCT05508971|ACTIVE_COMPARATOR|Adenotonsillectomy|Adenotonsillar hypertrophy is the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment. An adenotonsillectomy is an operation to remove both the adenoids and tonsils.
62081938|NCT06049407|EXPERIMENTAL|Experimental: Intervention group|
62281235|NCT04723576|NO_INTERVENTION|Usual Care|The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. UC sites will not implement SFA during the study period but will be given full access to all implementation materials following the conclusion of their participation.
62281236|NCT04587674|OTHER|Spinal Cord Stimulation|
62281237|NCT02676687|ACTIVE_COMPARATOR|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
62281238|NCT02676687|EXPERIMENTAL|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
62281239|NCT03457675|EXPERIMENTAL|Activa PC+S DBS implant for OCD|all subjects will receive surgical implantation of DBS system
62281240|NCT03457675|EXPERIMENTAL|One Month Blinded Discontinuation Period|all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
62281241|NCT00928421|EXPERIMENTAL|Varisolve 0.125%|
62281242|NCT05675137|EXPERIMENTAL|Mobile-based multidomain intervention|
62281243|NCT05675137|ACTIVE_COMPARATOR|paper-based intervention group|
62281244|NCT02516670|EXPERIMENTAL|Arm A (docetaxel, ascorbic acid)|Patients receive docetaxel IV on day 1 and ascorbic acid IV twice weekly. The first ascorbic acid treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62281245|NCT02516670|PLACEBO_COMPARATOR|Arm B (docetaxel, placebo)|Patients receive docetaxel IV on day 1 and placebo IV twice weekly.The first placebo treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62081939|NCT06049407|NO_INTERVENTION|No Intervention: Control group|
62081940|NCT06046222|EXPERIMENTAL|NS-229|Self-administer NS-229 in consecutive 28 weeks.
62081941|NCT06046222|PLACEBO_COMPARATOR|Placebo|Self-administer matching placebo in consecutive 28 weeks.
62081942|NCT06462443|EXPERIMENTAL|Intervention Group|Intervention group will attend the RISE for Physicians program, a 2.5 day retreat-style psychoeducational group program facilitated by licensed mental health professionals (LMHPs)
62081943|NCT06534502|EXPERIMENTAL|Zonisamide Oral Suspension|"Zonisamide Oral Suspension, 100 mg/5 ml administered orally twice daily~* Titration Period: 1 mg/kg/day administered as a divided dose of 0.5 mg/kg twice daily for 2 weeks, then increased by 1 mg/kg/day (as divided doses) at weekly intervals in Weeks 3 to 8.~* Maintenance Period: Up to 8 mg/kg/day given as a divided dose twice a day for 4 weeks (i.e., Weeks 9 to 12)."
62081944|NCT04875416||Primary participants|Patients that have or are suspected to have ALS or a related neurodegenerative disease
62081945|NCT04875416||Secondary Participants|Family members of primary participants enrolled in the study
62081946|NCT06494488|EXPERIMENTAL|DHA group|"Participants will receive DHA supplement. 3 gelcaps, three times per day with meals (breakfast, lunch, and dinner). DHA supplement regimen contains 450 mg DHA and minimal EPA (60 mg) per pill.~Participants will be given 28-day food and activity log."
62081947|NCT06494488|EXPERIMENTAL|EPA group|"Participants will receive EPA supplement. 2 gelcaps, two times per day with meals (breakfast and dinner). 1 gelcap consists of 1 gram of EPA.~Participants will be given 28-day food and activity log."
62081948|NCT04853251|EXPERIMENTAL|SUSVIMO|Participants will have the implant (filled prior to implantation with approximately 20 microlitres (uL) of the 100 milligrams/millilitres (mg/ml) formulation of ranibizumab \[approximately 2 milligrams (mg) dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their enrollment visit. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed Q24W intervals.
62081949|NCT06056830|EXPERIMENTAL|64Cu-SAR-bisPSMA|200MBq 64Cu-SAR-bisPSMA.
62281246|NCT05674474|EXPERIMENTAL|Group A: Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of 20 mg (2 × 10 mg) vorasidenib tablets on Day 1.
62281247|NCT05674474|EXPERIMENTAL|Group B: Moderate or Mild Hepatic Impairment|"Stage 1: Participants with moderate hepatic impairment (Child-Pugh \[C-P\] Class B, score of 7 to 9) will receive a single oral dose of 20 mg (2 × 10 mg) vorasidenib tablets on Day 1.~Stage 2: Participants with mild hepatic impairment (C-P Class A, score of 5 to 6) will receive a single oral dose of 20 mg (2 × 10 mg) vorasidenib tablets on Day 1. Stage 2 will be conducted if a clinically meaningful increase in exposure of vorasidenib is observed in participants with moderate hepatic impairment in Stage 1."
62281248|NCT05542238|ACTIVE_COMPARATOR|CON|Age-and sex-matched healthy controls with exercise intervention
62649301|NCT03703895|ACTIVE_COMPARATOR|Active Comparator|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule. Subjects will complete up to 4 study visits where Topical AFX5931 will be applied twice daily for 28 days.
62649302|NCT03703895|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Comparator, Topical Placebo. Subjects will complete up to 4 study visits where Topical Placebo will be applied twice daily for 28 days.
62649303|NCT03713099|EXPERIMENTAL|Microwave Ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach performed by an interventional pulmonologist or thoracic surgeon.
62081950|NCT03883945|PLACEBO_COMPARATOR|Cohort 1 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
62081951|NCT03883945|ACTIVE_COMPARATOR|Cohort 1 - 0.033%|Subjects randomized to vehicle will receive AIV001 0.033% administration to the target area.
62081952|NCT03883945|PLACEBO_COMPARATOR|Cohort 2 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
62081953|NCT03883945|ACTIVE_COMPARATOR|Cohort 2 - 0.1%|Subjects randomized to vehicle will receive AIV001 0.01% administration to the target area.
62649304|NCT03468504|EXPERIMENTAL|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
62649305|NCT03468504|PLACEBO_COMPARATOR|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
62081954|NCT03883945|PLACEBO_COMPARATOR|Cohort 3 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
62081955|NCT03883945|ACTIVE_COMPARATOR|Cohort 3 - 0.3%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
62081956|NCT03883945|PLACEBO_COMPARATOR|Cohort 4 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
62081957|NCT03883945|ACTIVE_COMPARATOR|Cohort 4 - 1%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
62081958|NCT00434837|EXPERIMENTAL|Low-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the Low-tension group will receive the low-tension treatment with initial graft tension set so that the anterior-posterior (A-P) displacement of the reconstructed knee is equal to that of the uninjured knee.
62281249|NCT05542238|EXPERIMENTAL|SCI|Individuals with spinal cord injury
62281250|NCT04082260||De novo patients with alemtuzumab|De novo patients prior and after alemtuzumab treatment initiation
62281251|NCT04082260||Alemtuzumab treatment|Patients under alemtuzumab treatment
62281252|NCT04082260||Extended alemtuzumab treatment|Patients requiring more than two alemtuzumab infusions
62649306|NCT02903979|EXPERIMENTAL|HVGIC|Restorations with only HVGIC in deep caries lesion of primary teeth.
62081959|NCT00434837|EXPERIMENTAL|High-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the High-tension group will receive the high-tension treatment with the initial graft tension set to reduce A-P displacement by 2 millimeters relative to that of the uninjured knee.
62081960|NCT00434837|NO_INTERVENTION|Uninjured Control Group|Uninjured age, sex, and race matched control group
62081961|NCT06738043|EXPERIMENTAL|Dexmedetomidine Group|Participants in this group will receive a bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of dexmedetomidine at 0.5 µg/kg/h until 10 minutes before the end of surgery.
62081962|NCT06738043|EXPERIMENTAL|Ketamine Group|Participants in this group will receive a bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of ketamine at 0.3 mg/kg/h until 10 minutes before the end of surgery.
62281253|NCT02608918|EXPERIMENTAL|BMS-955176|BMS-955176 specified dose on specified days
62649307|NCT02903979|ACTIVE_COMPARATOR|Indirect pulp capping|Indirect pulp capping with calcium hydroxide cement, restored with HVGIC:
62649308|NCT05840445|PLACEBO_COMPARATOR|Onabotulinum Group|This group received an intramuscular application of onabotulinum toxin-A in the upper facial third.
62649309|NCT05840445|ACTIVE_COMPARATOR|Prabotulinum Group|This group received an intramuscular application of prabotulinum toxin-A in the upper facial third.
62649310|NCT02388451|EXPERIMENTAL|Feuerstein Program|15 subjects conforming to inclusion and exclusion criteria with a known clinical diagnosis of MCI and who provide informed consent will undergo cognitive and functional assessment to confirm the diagnosis of MCI. Baseline assessment using the Mindstreams Mild Cognitive Impairment Computerized Assessment Battery will be performed. Subjects will then participate 30 twice weekly meetings of 90 minutes duration each (for a total of 15 weeks). Mindstreams testing will be repeated after 15 sessions and at completion of the study.
62649311|NCT04620499|EXPERIMENTAL|Experimental|EEG-guided drug prescription
62649312|NCT04620499|NO_INTERVENTION|Control|Will receive EEG, but drugs will be prescribed as usual
62081963|NCT06738043|PLACEBO_COMPARATOR|Control Group|Participants in this group will receive a bolus dose of 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
62281254|NCT01558063|ACTIVE_COMPARATOR|Ketamine Dose 1|0.1 mg/kg, IV (in the vein) of Ketamine and MRI scan
62281255|NCT01558063|ACTIVE_COMPARATOR|Ketamine Dose 2|0.2 mg/kg, IV (in the vein) of Ketamine and MRI scan
62281256|NCT01558063|ACTIVE_COMPARATOR|Ketamine Dose 3|0.3 mg/kg, IV (in the vein) of Ketamine and MRI scan
62281257|NCT01558063|ACTIVE_COMPARATOR|Ketamine Dose 4|0.4 mg/kg, IV (in the vein) of Ketamine and MRI scan
62281258|NCT01558063|ACTIVE_COMPARATOR|Ketamine Dose 5|0.5 mg/kg, IV (in the vein) of Ketamine and MRI scan
62281259|NCT01558063|PLACEBO_COMPARATOR|Saline Solution|Saline infused over 40 minutes and MRI scan
62281260|NCT00522795|EXPERIMENTAL|PPX with cisplatin and radiation|PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
62281261|NCT04788940||AMI patients treated with PCI|Acute myocardial infarction patients who underwent percutaneous coronary intervention and cardiac magnetic resonance imaging
62281262|NCT04617366|EXPERIMENTAL|Individualized rTMS strategy|The individualized strategy will adjust the rTMS parameters promptly based on the results of fNIRS. This arm selects either the high-frequency rTMS to the contralesional dorsal premotor cortex (PMd) or the low-frequency rTMS to the contralesional primary motor cortex (M1) based on the lateralization index of the PMd measured by fNIRS.
62281263|NCT04617366|ACTIVE_COMPARATOR|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1.
62281264|NCT05253417|EXPERIMENTAL|50 mg CBD|50 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Two capsules to be taken (plus two placebo capsules)
62281265|NCT05253417|EXPERIMENTAL|100 mg CBD|100 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Four capsules to be taken.
62281266|NCT05253417|PLACEBO_COMPARATOR|Placebo|Placebo capsules contain no CBD. Four capsules to be taken as a single oral dose.
62281267|NCT05450588||Sedentary|It will be obtained by open call for both students and administrative staff at the CES University.
62458515|NCT04168463|OTHER|Delayed Intervention|This cluster of four homes will receive robot animals four months after commencement of the 8 month trial. The four months without robots will serve as a control period.
62458516|NCT03116386|OTHER|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of~* reporting all the falls occurring during the night~* tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night~* and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
62081964|NCT06582602|EXPERIMENTAL|Panel A: MK-2060 IV (20 minutes)|Participants will receive a single dose of MK-2060 via intravenous (IV) infusion over 20 minutes on Day 1.
62081965|NCT06582602|EXPERIMENTAL|Panel B: MK-2060 IV (10 minutes)|Participants will receive a single dose of MK-2060 via IV infusion over 10 minutes on Day 1.
62081966|NCT06582602|EXPERIMENTAL|Panel C: MK-2060 IV (5 minutes)|Participants will receive a single dose of MK-2060 via syringe over 5 minutes on Day 1.
62081967|NCT06582602|EXPERIMENTAL|Panel D: MK-2060 IV (2.5 minutes)|Participants will receive a single dose of MK-2060 via syringe over 2.5 minutes on Day 1.
62081968|NCT06582602|EXPERIMENTAL|Panel E: MK-2060 IV (1 minute)|Participants will receive a single dose of MK-2060 via syringe over 1 minute on Day 1.
62081969|NCT06582602|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of saline via IV infusion or syringe over MK-2060-matched time period on Day 1.
62081970|NCT05966740||Pediatric patients with VTE and/or at risk for VTE|
62281268|NCT05450588||Physically active|Under the collaboration framework bet ween DBSS international SAS and Smart Fit Colombia, a sample of personal trainers who reside and work in Medellín, or its metropolitan area will be invited to participate.
62281269|NCT05450588||Athletes|Under the collaboration framework between DBSS international SAS and ARTHROS Physiotherapy and Exercise Center, a sample of professional athletes from different sports disciplines will be invited to participate.
62281270|NCT03693248|EXPERIMENTAL|Two cycles of neoadjuvant chemotherapy|"* Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~* Two cycles of neoadjuvant chemotherapy and four cycles of adjuvant chemotherapy."
62281271|NCT03693248|NO_INTERVENTION|Three cycles of neoadjuvant chemotherapy|"* Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~* Three cycles of neoadjuvant chemotherapy and three cycles of adjuvant chemotherapy."
62281272|NCT05334446|EXPERIMENTAL|The Effect ''of Follow-up with the Mobile Application'' in Patients with Hypertension|Intervention Group:mobile application for 4 weeks; This is the training group in which individual motivational messages will be sent to the mobile phones every week for compliance with the diet, exercise and drug therapy of the patients, and the weekly average of blood pressure follow-ups is monitored over the system.
62458517|NCT03116386|SHAM_COMPARATOR|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
62649313|NCT03812419|ACTIVE_COMPARATOR|group I|Esomeprazole 40 mg capsules once daily for 6 months
62081971|NCT05775094|EXPERIMENTAL|Romosozumab|Romosozumab will be given on-label for osteoporosis at 210 mg administered SC once monthly for 12 months in conjunction with antimyeloma therapy.
62281273|NCT05334446|NO_INTERVENTION|The Effect ''of Follow-up with the Mobile Application'' in Hypertension control group|It is the control group whose routine outpatient follow-up will continue and no training is given
62649314|NCT03812419|ACTIVE_COMPARATOR|group II|Pantoprazole 40 mg tablets once daily for 6 months
62649315|NCT06211023|EXPERIMENTAL|Treatment group 1: SHR-1921|
62649316|NCT06211023|EXPERIMENTAL|Treatment group 2: SHR-1921 + carboplatin dose level 1|
62081972|NCT05632562|EXPERIMENTAL|PET imaging of system L amino acid transport with FET and hypoxia imaging with FMISO|The participant will have a plastic peripheral intravenous (IV) catheter placed in the arm for Positron emission tomography (PET) tracer and MR contrast administration. FET O-(\[2-\[18F\]fluoroethyl)-L-tyrosine and FMISO 1H-1-(3-\[18F\]fluoro-2-hydroxypropyl)-2-nitroimidazole will be produced by the UAB Cyclotron PET Production Facility. PET/MRI will be performed using a GE Signa PET/MRI system in the AIF with specific imaging protocols for FET and FMISO studies. Upon completion of imaging, the peripheral IV catheter will be removed. The participant will be asked to urinate to reduce bladder dose after completion of each PET acquisition.Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies.
62081973|NCT05130450|EXPERIMENTAL|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 153.
62081974|NCT06420518||Continuous ketone monitoring (CKM) system|All study participants will wear the CKM system for the 2-week study duration. This timeframe is overlapped with both the outpatient phase (sequential ketogenic diets) and, inpatient phase (insulin-suspension period) of the study. The accuracy of the ketone values from the CKM will be assessed using standard point-of-care capillary ketone measurements as reference (control).
62649317|NCT06211023|EXPERIMENTAL|Treatment group 3: SHR-1921 + carboplatin dose level 2|
62649318|NCT06211023|OTHER|Treatment group 4: platinum-based doublet chemotherapy|
62649319|NCT01879293|EXPERIMENTAL|Metformin group|In this group, metformin 0.5 three times daily for one year.
62649320|NCT01879293|PLACEBO_COMPARATOR|Placebo group|In this group, placebo will be given twice daily for one year.
62081975|NCT06420518||Standard point-of-care capillary ketone meter|All study participants will be asked to measure their ketone levels with a standard point-of-care capillary ketone meter once upon waking, before a meal and, 2-hours post-meal for the entire 2-week study duration. These ketone measurements will be used as reference values (control) for comparison with the readings from the CKM.
62081976|NCT05394519|EXPERIMENTAL|CagriSema|Cagrilintide + semaglutide once weekly
62281274|NCT06349057|NO_INTERVENTION|Standard of care|There will be no intervention in the perioperative period, data will be collected only by observation. Anesthesia management, surgical procedure and postoperative care will be applied as routine.
62281275|NCT06349057|ACTIVE_COMPARATOR|Remifentanyl, Propofol, Sevoflurane / Desflurane, Propofol|"Preoperative period : There will be no intervention.~Intraoperative period : An erector spinae plane block will be applied before anesthesia induction. Drugs with cholinergic burden will not be preferred. Lower anticholinergic drugs will be used. There will be no intervention in the surgical procedure.~Postoperative period : Drugs with high cholinergic burden will not be used. Lower anticholinergic drugs will be used.~Intraoperative and postoperative periods, instead of drugs with high anticholinergic burden; lower burden drugs will be preferred.~High anticholinergic burden drugs: (Fentanyl - Talinat®, Tramadol- Contamal®, Midazolam - Dormicum®, Pancuronium-Mivacron®)~Lower burden drugs : (Remifentanyl-Ultiva®, Sevoflurane-Sevoflurane USP® , Desflurane-Suprane®, Propofol-Propofol®, Rocuronium-Esmeron®, Lidocaine-Aritmal®)"
62649321|NCT04971603|EXPERIMENTAL|Acupuncture treatment group|The patients will receive 24-week acupuncture treatment and 12-week follow up. Seven visits will be arranged within the 24-wk treatment period and at the end of study at wk 6, 10, 14, 18, 22, 26 and 38 for medical consultation and investigation.
62081977|NCT05394519|PLACEBO_COMPARATOR|Placebo|Placebo cagrilintide + semaglutide once weekly
62081978|NCT02964611||Alzheimer's disease|Observational Study
62081979|NCT02964611||Parkinson's disease|Observational Study
62081980|NCT02964611||Frontotemporal Lobar Degeneration|Observational Study
62281276|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
62081981|NCT02964611||Healthy Controls|Observational Study
62081982|NCT05577702|EXPERIMENTAL|Arm 1A: Tislelizumab Monotherapy|Tislelizumab on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days)
62281277|NCT00133523|PLACEBO_COMPARATOR|Group 4: Placebo: Intramuscular|N=165 subjects administered placebo intramuscularly.
62281278|NCT00133523|PLACEBO_COMPARATOR|Group 3: Placebo: Nasal|N=165 subjects administered placebo intranasally.
62281279|NCT00133523|EXPERIMENTAL|Group 1: FluMist™|N=825 subjects administered live attenuated vaccine intranasally.
62081983|NCT05577702|EXPERIMENTAL|Arm 1B: Tislelizumab and Ociperlimab|Tislelizumab + ociperlimab on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days)
62081984|NCT05577702|EXPERIMENTAL|Arm 1C: Tislelizumab and LBL-007|Tislelizumab + LBL-007 on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days)
62281280|NCT00133523|EXPERIMENTAL|Group 2: Fluzone®/Fluvirin|N=825 subjects administered inactivated vaccine intramuscularly.
62281281|NCT05816863||Experimental|pabolizumab
62281282|NCT04396899|OTHER|EHM Implantation|All patients will receive EHM implant
62281283|NCT04044755|EXPERIMENTAL|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
62281284|NCT04044755|NO_INTERVENTION|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
62281285|NCT06020235|EXPERIMENTAL|5% Nu-3 gel once daily|The 5% Nu-3 gel is applied once per day and placebo is applied once per day.
62281286|NCT06020235|EXPERIMENTAL|5% Nu-3 gel twice daily|The 5% Nu-3 gel is applied twice per day.
62281287|NCT06020235|EXPERIMENTAL|10% Nu-3 gel once daily|The 10% Nu-3 gel is applied once per day and placebo is applied once per day.
62281288|NCT06020235|EXPERIMENTAL|10% Nu-3 gel twice daily|The 10% Nu-3 gel is applied twice per day.
62281289|NCT06020235|PLACEBO_COMPARATOR|Placebo|The placebo is applied twice per day.
62281290|NCT03416283|EXPERIMENTAL|Remote Monitoring (RM)|Remote Monitoring subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence.
62281291|NCT03416283|EXPERIMENTAL|Remote Monitoring + Social Support (RM+SS)|Remote Monitoring + Social Support subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence, as well as a social support partner to provide additional feedback to the participant on their monitoring and adherence practices.
62081985|NCT05577702|EXPERIMENTAL|Arm 2A: Tislelizumab and Chemotherapy|"Tislelizumab + chemotherapy on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days); Platinum-based doublet chemotherapy options may include:~* Cisplatin/carboplatin + pemetrexed (nonsquamous)~* Cisplatin/carboplatin + paclitaxel (squamous)"
62081986|NCT05577702|EXPERIMENTAL|Arm 2C: LBL-007 and Tislelizumab and Chemotherapy|"LBL-007 + tislelizumab + chemotherapy on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days); Platinum-based doublet chemotherapy options may include:~* Cisplatin/carboplatin + pemetrexed (nonsquamous)~* Cisplatin/carboplatin + paclitaxel (squamous)"
62081987|NCT06106828|EXPERIMENTAL|Satralizumab|In the Part I period, participants will receive satralizumab every 4 weeks (q4w) followed by proptosis response-based individualized treatment in Part II of the study.
62458518|NCT03116386|EXPERIMENTAL|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
62081988|NCT06106828|PLACEBO_COMPARATOR|Placebo|In the part I period, participants will receive placebo q4w followed by proptosis response-based individualized treatment in part II of the study.
62081989|NCT05467735|EXPERIMENTAL|Interventional: Compression Arm|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
62281292|NCT03416283|NO_INTERVENTION|Usual Care|Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
62281293|NCT01356550|EXPERIMENTAL|Healthy subjects|
62281294|NCT01356550|EXPERIMENTAL|Hepatic impairment|
62281295|NCT00469612|EXPERIMENTAL|A|NeuroVision's NVC treatment for low myopia
62281296|NCT00469612|NO_INTERVENTION|B|The subjects in this group will serve as controls and will be the no intervention group.
62281297|NCT05788185|EXPERIMENTAL|RVM-V001 30 µg -BNT162b2 subjects|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1 on BNT162b2 subjects
62281298|NCT05788185|EXPERIMENTAL|RVM-V002 30 µg -BNT162b2 subjects|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1 on BNT162b2 subjects
62281299|NCT05788185|EXPERIMENTAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration -BNT162b2 subjects|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration; a single dose of RVM-V001 in the left arm deltoid muscle and then followed immediately with a single dose of RVM-V002 in the right arm deltoid muscle on Day 1 on BNT162b2 subjects
62281300|NCT05788185|EXPERIMENTAL|RVM-V001 30 µg|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1 on BBIBP-CorV or CoronaVac subjects
62281301|NCT05788185|EXPERIMENTAL|RVM-V002-30 µg|RVM-V002-30 µg administered as a single dose of by intramuscular injection on Day 1 on BBIBP-CorV or CoronaVac subjects
62281302|NCT05788185|EXPERIMENTAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration; a single dose of RVM-V001 in the left arm deltoid muscle and then followed immediately with a single dose of RVM-V002 in the right arm deltoid muscle on Day 1 on BBIBP-CorV or CoronaVac subjects
62281303|NCT02468336|EXPERIMENTAL|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after BA occlusion by a standard upper arm sphygmomanometric blood pressure (BP) cuff. The procedure is non-invasive and employs neither ultrasound nor Doppler flow analysis.
62458519|NCT05602064|EXPERIMENTAL|Group I (Ibuprofen)|"Participants will receive ibuprofen 100 mg/5 ml (BRUFEN®, Kahira Pharmaceuticals \& Chemical Industries Co.) The solution will be administered Once, 1 hour prior to the local anesthesia administration.~The participant will receive a weight-dosed volume Effective dosages range from 10 mg/kg/day to a maximum of 40 mg/kg/day"
62081990|NCT05467735|NO_INTERVENTION|Control Arm|The inflatable sleeves of a sequential compression device would be placed in bilateral lower extremities of patients, but the device would not be turned on, thus no external pressure would be applied.
62081991|NCT04214418|EXPERIMENTAL|Phase 1: Maximum Tolerated Dose (MTD)|"Subjects will be treated with combination therapy at the designated dose levels:~Dose 1 - Hydroxychloroquine 600mg twice per day, Cobimetinib 40mg, no Atezolizumab Dose 2 - Hydroxychloroquine 600mg twice per day, Cobimetinib 40mg, Atezolizumab 840mg Dose 3 - Hydroxychloroquine 600mg twice per day, Cobimetinib 60mg, Atezolizumab 840mg"
62081992|NCT04214418|EXPERIMENTAL|Phase 2: Cohort 1|Advanced Pancreatic Adenocarcinoma (N = 23-67) subjects will receive study treatment based on the MTD determined from Phase 1
62081993|NCT04214418|EXPERIMENTAL|Phase 2: Cohort 2|Advanced Colorectal Adenocarcinoma (N = 20-34) subjects will receive study treatment based on the MTD determined from Phase 1
62081994|NCT04214418|EXPERIMENTAL|Phase 2: Cohort 3|Histology Agnostic Adenocarcinoma (N = 23-56) subjects will receive study treatment based on the MTD determined from Phase 1
62649322|NCT05399797|EXPERIMENTAL|Pharmacists in the intervention group|The pharmacist will be given an online educational training on management of acute uncomplicated urinary tract infections
62281304|NCT02468336|ACTIVE_COMPARATOR|Brachial Artery Ultrasound Imaging|A non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery (BA) using high resolution continuous ECG-gated B-mode (2D) ultrasound imaging during reactive hyperemia, a state of transient increase in tissue blood flow that occurs following a brief period of ischemia, e.g., BA occlusion. BA diameter is measured at end-diastole, coincident with the R wave of a simultaneously recorded ECG.
62281305|NCT06473909|EXPERIMENTAL|treatment arm|
62281306|NCT03325946||Children and Adults with Cerebral Palsy|
62281307|NCT03325946||Children and Adults with Microcephaly|
62281308|NCT03325946||Children and Adults with other Neuromotor Impairments|
62281309|NCT03325946||Children who have had a stroke|
62281310|NCT02705898|EXPERIMENTAL|LPA+Fitbit|A 12-week LPA+Fitbit intervention for depressed women in intensive alcohol treatment. This will include: 1) a single in-person physical activity (PA) counseling orientation session; 2) 6 brief, phone-based PA counseling sessions focused on increasing PA and strategically using bouts of PA to cope with affect and alcohol cravings; 3) use of the Fitbit fitness tracker for physical activity goal-setting and daily self-monitoring; and 4) weekly supportive messages delivered by email.
62281311|NCT02705898|ACTIVE_COMPARATOR|Health Education Contact Control (HEC)|The HEC condition will include: 1) an in-person orientation session, 2) 6 telephone-delivered health education sessions, and 3) weekly health-related e-mails. A variety of health and lifestyle topics will be addressed including the following: Session 1 (week 1) - Nutrition-What to Eat and What Not to Eat; Session 2 (week 2) - Sleep Problems and Sleep Hygiene; Session 3 (week 4) - Alcohol Use among Women; Session 4 (week 6) - Relaxation training; Session 5 (week 8) - Time Management and Assertiveness; and Session 6 (week 10) - Being a Smart Patient when Coordinating your Healthcare.
62281312|NCT03129074|EXPERIMENTAL|Varlitinib given in combination with capecitabine|"* PO varlitinib 300 mg BID~* PO capecitabine 1000 mg/m2 BID"
62281313|NCT02722681||Symptomatic spinal lipoma patients|Spinal lipoma patients undergoing surgery due to symptomatic lipoma. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intraoperatively and usually discarded, some will be kept for research.
62281314|NCT02722681||Asymptomatic spinal lipoma patients|Spinal lipoma patients who remain asymptomatic. Routine blood and urine samples will be taken as part of routine clinical care, some will be kept for research.
62281315|NCT02722681||Non-lipoma spinal conditions|Patients undergoing spinal surgery for a non-lipoma related condition. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intra-operatively and usually discarded, some will be kept for research.
62281316|NCT06193941||Case group （bladder cancer）|Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
62281317|NCT06193941||Control group （benigh）|Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
62281318|NCT06193941||Healthy people group|Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
62281319|NCT04516473||Experimental/Body Contouring Intervention|These are participants who have self-selected to undergo an abdominal body contouring procedure within the course of the study.
62649323|NCT05399797|NO_INTERVENTION|Pharmacists in the control group|pharmacists in this group will not be trained, until after the completion of the study.
62649324|NCT04850989|EXPERIMENTAL|Virtual reality exposure therapy|Participants were allowed to choose one of two themes. For both themes, each scene was developed to be more anxiety-provoking as the VRE progressed. Greater anxiety-inducing scenes had interviewers and other actors who displayed less compassionate, friendly, humorous, and pleasant verbal and non-verbal behaviors and demeanors to elicit elevated anxiety (Carless \& Imber, 2007). Also, a virtual therapist was embedded within the VRE. It functioned to coach the participant through each distinct scene by orienting and prompting them to the exposure therapy task(s), continually conveying core principles of exposure therapy, and repeating the instructions if the participant was not responsive within five seconds. Each scene started with a paused video, during which participants were oriented by the virtual therapist to the context.
62281320|NCT04516473||Control/Post Massive Weight Loss Matched Control|"These are participants who have similar characteristics to the body contouring intervention group, but they will not undergo any surgical procedure during the course of the study.~The addition of this matched control group with a similar degree of excess skin but who will not be undergoing body contouring surgery will control for any changes in physical function which may occur without any intervention within the testing sessions. This group will also control for any learning effects between testing sessions."
62281321|NCT02456688|EXPERIMENTAL|Patients with im paired hepatic function|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
62281322|NCT02456688|EXPERIMENTAL|Healthy Volunteers|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
62281323|NCT03222349|EXPERIMENTAL|Interictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
62281324|NCT03222349|EXPERIMENTAL|Ictal/Peri-ictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
62281325|NCT02981069|ACTIVE_COMPARATOR|Byetta / Bydureon|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
62281326|NCT02981069|ACTIVE_COMPARATOR|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
62281327|NCT02981069|ACTIVE_COMPARATOR|Byetta/Bydureon plus Dapagliflozin|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS~Dapagliflozin:~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
62281328|NCT02981069|PLACEBO_COMPARATOR|Placebo|Placebo group (4 weeks and 12 weeks)
62281329|NCT01242644|EXPERIMENTAL|pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour;
62281330|NCT01242644|ACTIVE_COMPARATOR|saline pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
62281331|NCT01242644|ACTIVE_COMPARATOR|injectable medication only|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected and no pain pump.
62281332|NCT00836355|EXPERIMENTAL|Enoxaparin|
62281333|NCT00836355|EXPERIMENTAL|Minocycline|Minocycline 200 mg orally once daily for 5 days
62281334|NCT00836355|EXPERIMENTAL|Enoxaparin and minocycline|
62281335|NCT00836355|NO_INTERVENTION|Control|
62281336|NCT05772845|OTHER|Daily Users of ENDS|Participants who use nicotine-containing ENDS daily or near-daily but who do NOT smoke combustible cigarettes daily or near-daily.
62281337|NCT05772845|OTHER|Daily Users of Combustible Cigarettes|Participants who smoke combustible cigarettes daily or near-daily but do NOT use nicotine-containing ENDS daily or near-daily.
62281338|NCT05772845|OTHER|Daily Dual Users of ENDS and Combustible Cigarettes|Participants who both use nicotine-containing ENDS and combustible cigarettes daily or near-daily
62281339|NCT05060757|EXPERIMENTAL|colonoscopy|Participants will be patients undergoing colonoscopy
62281340|NCT06178549|EXPERIMENTAL|Intervention arm (single arm)|Intervention arm to complete HPV self-sampling
62281341|NCT02989935|EXPERIMENTAL|Fluticasone vilanterol bronchodilator|"Inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, bronchodilator,using standard dry powder inhaler.~Interventions include ventilation, parasternal EMG, and phrenic magnetic stimulation."
62281342|NCT06454526|EXPERIMENTAL|Experiment|The group to which the 8-week Mindfulness-Based program will be applied.
62281343|NCT06454526|NO_INTERVENTION|Control|The group in which the 8-week Mindfulness-Based program will not be applied.
62281344|NCT02159300||Patients|Patients with fibromyalgia pain Intervention: experience brain activity recording
62281345|NCT02159300||Healthy Controls|Healthy controls without chronic pain of any type.
62281346|NCT01445769|EXPERIMENTAL|Ruxolitinib|Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.
62649325|NCT04850989|NO_INTERVENTION|Waiting list|Participants started treatment 2-4 weeks post-randomization.
62649326|NCT04035616|PLACEBO_COMPARATOR|Placebo|placebo were manufactured and supplied by B-Crobes Laboratory Sdn. Bhd. as powder in identical sachets with active comparator and labelled as A
62081995|NCT06664957|EXPERIMENTAL|Vitamin C group|Participants in this group will receive 400 mg of a nutrient supplement (Vitamin C) daily, administered as two 100 mg tablets in the morning and two 100 mg tablets in the evening for 12 months. Vitamin C is provided as a dietary supplement with the goal of supporting antioxidant defense, potentially reducing oxidative stress and improving clinical outcomes in COPD patients. Regular follow-ups will occur every 3 months to monitor exacerbations, quality of life, and safety.
62081996|NCT06664957|PLACEBO_COMPARATOR|Placebo group|Participants in this group will receive a matching placebo, administered as two tablets in the morning and two tablets in the evening for 12 months. The placebo is identical in appearance to the Vitamin C supplement but contains no active ingredients. Follow-up visits will occur every 3 months, identical to the Vitamin C group, to monitor clinical outcomes, quality of life, and safety.
62081997|NCT06737146|EXPERIMENTAL|MT027|
62281347|NCT00632853|ACTIVE_COMPARATOR|Arm A - Standard Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~* Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~* Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days"
62281348|NCT00632853|EXPERIMENTAL|Arm B - High Dose Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~* Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~* Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days"
62281349|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool, an Epworth sleepiness scale and have overnight oximetry recorded.
62458520|NCT05602064|EXPERIMENTAL|Group II (Paracetamol)|"Participants will receive paracetamol 250 mg/5 ml (CETAL®, EGYPTIAN INT. PHARMACEUTICAL INDUSTRIES CO.) The solution will be administered once, 1 hour prior to the local anesthesia administration.~The participant will receive a weight-dosed volume Effective dosages are between 15-20mg/kg/day to a maximum of 60 mg/kg/day"
62458521|NCT05602064|PLACEBO_COMPARATOR|Group III (Placebo)|The placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
62081998|NCT06427941|EXPERIMENTAL|Part A (Monotherapy Dose Escalation and Safety Expansion)|Ascending dose levels of BGB-B2033 monotherapy
62281350|NCT04444232|EXPERIMENTAL|Health services research (educational video, survey)|Participants view an educational video on cancer and cancer screening options over 12 minutes. Participants also complete a phone survey over 10-15 minutes before attending the video session and 2 months after the video session.
62281351|NCT03932994|EXPERIMENTAL|ACT on Health Intervention|Those assigned to ACT on Health will use the program over the next 8 weeks, completing weekly modules and coaching calls.
62081999|NCT06427941|EXPERIMENTAL|Part B (Combination Dose Escalation and Safety Expansion)|Cohorts of BGB-B2033 in combination with tislelizumab
62082000|NCT04280926||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
62458522|NCT01395186|OTHER|varicocelectomy|varicocelectomy for patients complaining of pain
62082001|NCT04542499|EXPERIMENTAL|Tavapadon|Participants will receive a tavapadon tablet titrated 5 to 15 milligrams (mg) once daily (QD) orally for 27 weeks.
62458523|NCT05393960|EXPERIMENTAL|Mobilization|Lumbosacral manual therapy mobilization
62458524|NCT05393960|OTHER|Stretching program|home based self strechings program
62458525|NCT02673580|OTHER|Open Access telePRO|Intervention: In open access, contact to the outpatient clinic is initiated by the patient by filling in a PRO questionnaire.
62458526|NCT02673580|OTHER|Standard telePRO|No intervention: In standard telePRO, outpatient follow-up activity is determined by a clinician and patients receive a questionnaire at fixed intervals.
62082002|NCT04542499|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
62082003|NCT06741267|OTHER|RBS group|physicians control robotic bronchoscopy system(RBS)
62082004|NCT06741267|OTHER|AB group|physicians control automatic bronchoscopy(AB)
62082005|NCT06741267|OTHER|ENB groups|physicians control electromagnetic navigation bronchoscopy(ENB)
62082006|NCT04636710|EXPERIMENTAL|Sentinal Node Identification|"Within standard of care treatment for inflammatory breast cancer, participants will undergo a series of Lymphoscintigraphies: an imaging procedure to determine where their lymphatic system drains from their breast.~* Prior to neoadjuvant chemotherapy~* Day before surgery~These two imaging studies will be compared and the information used during participant's surgery to perform the sentinel node biopsy procedure.~During surgery participants will have a blue dye injected to affected breast to map drainage and identify sentinal nodes. The sentinal nodes will be removed first, followed by standard of care procedure to remove all axillary lymph nodes.~After surgery, a small amount of tissue from the tumor removed during surgery will be evaluated.~Participants will complete a Lymphedema Questionnaire after each Lymphoscintigraphy then every 6 months for 2 years post surgery."
62281352|NCT03932994|NO_INTERVENTION|Waitlist|Those assigned to the waitlist will simply wait 8 weeks. A second online assessment will be completed 8 weeks after baseline in both conditions (for a between condition comparison). After the second assessment, waitlist participants will gain access to ACT on Health.
62281353|NCT00670410|EXPERIMENTAL|Arm A - Related Donor|Related donor transplant: Patients with a related donor (5/6 or 6/6 HLA matched) will receive immunotherapy with a non-myeloablative preparative regimen of Busulfan and Fludarabine followed by allogeneic stem cell transplant (AlloSCT).
62281354|NCT00670410|EXPERIMENTAL|Arm B - Cord Blood Donor|Unrelated cord blood transplant: Patients without a related donor will receive immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by allogeneic stem cell transplant (AlloSCT) with either an unrelated umbilical cord blood donor (4/6, 5/6, or 6/6 HLA matched), or a related umbilical cord blood donor (3/6, 4/6, 5/6, or 6/6 HLA matched). Patients will receive Thymoglobulin ((rabbit) Anti-Thymocyte Globulin (ATG)) during the preparative regimen. GVHD prophylaxis will be Tacrolimus and mycophenolate mofetil (MMF).
62281355|NCT01380808|EXPERIMENTAL|experimental arm|capecitabine and pseudomonas aeruginosa combination
62082007|NCT05847478|EXPERIMENTAL|Auricular acupressure therapy group (AAT)|The participants will be randomly assigned to receive the auricular point patch therapy. The intervention period is 3 months.
62281356|NCT04484532|EXPERIMENTAL|Supportive Care (trivalent influenza vaccine)|Within 14 days of baseline influenza titer, patients receive trivalent influenza vaccine IM on day 0 (patients in cohorts 1 and 5 receive the vaccine at any time, patients in cohorts 2 and 3 receive the vaccine between days 14-25 of hypomethylating agent therapy course, and patients in cohort 4 receive the vaccine between days 21-365 from onset of cytotoxic chemotherapy). Patients then undergo titer assessment at days 25-90 and days 115-185.
62281357|NCT04193930|OTHER|Soft ovarian stimulation protocol|
62082008|NCT05847478|EXPERIMENTAL|Intermittent low carbohydrate diet group (ILCD)|The participants will be randomly assigned to receive the intermittent low carbohydrate diet. The duration of the study is 3 months, including 1-month intervention period and 2-month self maintenance period.
62082009|NCT02698254|EXPERIMENTAL|Arm I (conventional fractionation)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
62082010|NCT02698254|ACTIVE_COMPARATOR|Arm II (conventional fractionation, bevacizumab)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
62281358|NCT04193930|OTHER|conventional ovarian stimulation protocol|
62281359|NCT02651428|EXPERIMENTAL|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
62458527|NCT01350765|EXPERIMENTAL|Intervention|This would be the interventional arm of the study, where the LHWs would receive additional training for identification and management of birth asphyxia, lbw, and sepsis.
62649327|NCT04035616|ACTIVE_COMPARATOR|Hexbio® MCP|The treatment sample is labelled as B.This is an orange-flavoured, granulated microbial cell preparation containing 30 billion colony forming units (cfu) of Lactobacilli and Bifidobacteria strains: Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC® 02120. The placebo sample was similar in appearance and taste, but contained no microbial cells.
62649328|NCT03918317|EXPERIMENTAL|AirXpanders AeroFormtissue expander + Radiation therapy|AirXpanders AeroFormtissue expander in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate.
62649329|NCT05782153|ACTIVE_COMPARATOR|Intervention A (hearing aid self-fitting with direct adjustment)|
62649330|NCT05782153|ACTIVE_COMPARATOR|Intervention B (hearing aid self-fitting with in-situ fitting)|
62649331|NCT02818504|EXPERIMENTAL|Repeatability and reproducibility study|"Monitoring of system (Wize MIrror) measurements with changes in environmental conditions (fasting state, light, temperature)"
62649332|NCT02818504|EXPERIMENTAL|Validation study|"Longitudinal monitoring of cardiometabolic risk factors through an user---friendly, unobtrusive, personalized system for lifestyle self---management (the Wize Mirror)"
62082011|NCT05882877|EXPERIMENTAL|ARM A: Dose 1 to Dose 1|Participants from parent Rocatinlimab studies ROCKET-Ignite, ROCKET-Horizon, ROCKET-SHUTTLE, or ROCKET-ASTRO who received Dose 1 will be randomized or assigned to receive Dose 1 Every 4 Weeks (Q4W) or Every 8 Weeks (Q8W). Participants from parent Rocatinlimab study ROCKET-VOYAGER who received Dose 1 will be assigned to receive Dose 1 Q4W.
62281360|NCT02651428|ACTIVE_COMPARATOR|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
62281361|NCT02743247|EXPERIMENTAL|Tacrolimus and Mycophenolate mofetil|Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
62649333|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
62649334|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
62649335|NCT00864110|EXPERIMENTAL|99mTc EC-DG|99mTc-EC-DG with SPECT/CT imaging
62649336|NCT00864110|ACTIVE_COMPARATOR|18F FDG|18F FDG with PET/CT imaging
62649337|NCT03863353|EXPERIMENTAL|Education Intervention|This group will receive the scenario-tailored STOMP educational feedback
62281362|NCT03343015||Traditional CR establishing|establishing a CR in traditional way with occlusal wax rims during complete dentures therapy
62281363|NCT03343015||Gothic arch method|establishing a CR with gothic arch tracing device during complete dentures therapy
62281364|NCT01631305|EXPERIMENTAL|Levothyroxine|3 mcg/kg/day
62281365|NCT01631305|PLACEBO_COMPARATOR|Control|Calcium magnesia.
62281366|NCT04106622||Wolff Parkinson White patients|"The investigators will decide the location of the AP by:~- Invasively: if the patient is subjected to (EPS)~• There are different locations of AP To assess whether the AP is of high risk or not, for all patients the Antegrade refractory period of the APAERP of the AP will be determined by one of the following ways: ( AERP) is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval (SPERRI) during spontaneous or induced AF.~The AERP and the risk category of the AP according to its value, will be recorded in relation to the site of the AP determined in every case and compared between different accessory Locations to see whether some of these positions are more liable to be of higher risk or there is no differerence between different positions."
62281367|NCT02893449|OTHER|SICRPPD group|(Specific Individual Cognitive Remediation Program in Parkinson's Disease). Group of patients profiting from a structured program of preoperative cognitive remediation
62281368|NCT02893449|OTHER|ICM group: Intensive Care Management|Group of patients profiting from a preoperative non structured support
62281369|NCT02893449|OTHER|CG group: Control Group|No supplementary support
62281370|NCT06197061|EXPERIMENTAL|Robot-assisted modified Soave group|The robotic arms were oriented from the caudal direction. Dissection was begun circumferentially at 1.0 cm above the peritoneal reflection. The rectum was mobilized outside the longitudinal muscle layer, with the anatomical plane farther away from Denonvillier's fascia and the nerve plexus anterior or lateral to the rectum. The mobilization of the rectum reached 4-7 cm into the pelvis. After the robot was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
62458528|NCT01350765|ACTIVE_COMPARATOR|Control|This would be the comparative group of the study in which the LHWs would perform the usual routine tasks assigned to them by their program.
62458529|NCT01735630|EXPERIMENTAL|ELND005|ELND005 film coated tablets, BID for 12 weeks
62458530|NCT01735630|PLACEBO_COMPARATOR|Placebo|Matched placebo BID for 12 weeks
62458531|NCT02877186|EXPERIMENTAL|Diet Soda|Consumption of diet soda three times daily for one week
62649338|NCT03863353|NO_INTERVENTION|Control|This group will receive only standard of care information.
62649339|NCT03627104|OTHER|Normoprotein diet with animal protein|The patient will intake the diet assigned for a month
62082012|NCT05882877|EXPERIMENTAL|ARM B: Dose 2 to Dose 2|Participants from parent Rocatinlimab studies ROCKET-Ignite, ROCKET-SHUTTLE, or ROCKET-ASTRO who received Dose 2 will be randomized or assigned to receive Dose 2 Q4W or Q8W.
62458532|NCT02877186|PLACEBO_COMPARATOR|Carbonated Water|Consumption of plain, unsweetened, carbonated water three times daily for one week
62458533|NCT03232008|EXPERIMENTAL|Experiment A- experimental|3g Canderel in 250ml water
62458534|NCT03232008|NO_INTERVENTION|Experiment A- control|3g of maltodextrin in 250 ml of water
62649340|NCT03627104|OTHER|Normoprotein diet with vegetable protein|The patient will intake the diet assigned for a month
62649341|NCT03627104|OTHER|High-protein diet with animal protein|The patient will intake the diet assigned for a month
62082013|NCT05882877|PLACEBO_COMPARATOR|ARM C: Dose 1 or Dose 2 to Placebo|Participants from parent Rocatinlimab studies ROCKET-Ignite or ROCKET-Horizon who received Dose 1 will be randomized to receive placebo Q4W. Participants from parent Rocatinlimab study ROCKET-Ignite who received Dose 2 will be randomized to receive placebo Q4W.
62649342|NCT03627104|OTHER|High-protein diet with vegetable protein|The patient will intake the diet assigned for a month
62082014|NCT05882877|PLACEBO_COMPARATOR|ARM D: Placebo to Placebo|Participants from parent Rocatinlimab studies ROCKET- Ignite, ROCKET-Horizon, ROCKET-SHUTTLE, ROCKET-ASTRO, or ROCKET-VOYAGER who received placebo will be randomized or assigned to receive placebo Q4W.
62082015|NCT05882877|EXPERIMENTAL|ARM E: Dose 1, Dose 2, Placebo, or Open-label (OL) to OL Dose 1|"Participants from parent Rocatinlimab studies ROCKET- Ignite, ROCKET-Horizon, ROCKET- SHUTTLE, ROCKET-ASTRO, or ROCKET-VOYAGER who received Dose 1, Dose 2, or placebo will be assigned to receive OL Rocatinlimab Dose 1 Q4W.~Participants who received OL in parent Rocatinlimab study ROCKET- ASTRO will continue to receive OL Rocatinlimab Dose 1 Q4W.~All participants from parent Rocatinlimab study ROCKET-Orbit will be assigned to receive OL Rocatinlimab Dose 1 Q4W."
62082016|NCT04585815|EXPERIMENTAL|Sub-Study A|Sasanlimab will be administered subcutaneously. Encorafenib \& binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
62082017|NCT04585815|EXPERIMENTAL|Sub-Study B|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.
62281371|NCT06197061|ACTIVE_COMPARATOR|laparoscopic-assisted modified Soave group|The mesentery of the colon was separated by laparoscopy with the vessel of the pull-through bowel preserved. Under the rectal peritoneal reflex, close to the rectal wall separate with the electric hook, the anterior wall of the rectum was separated to the bladder neck or the posterior wall of the vagina. The posterior wall of the rectum can be separated down to 1cm above the dentate line .a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis with interrupted 5-0 or 4-0 absorbable sutures.
62281372|NCT02239822|ACTIVE_COMPARATOR|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
62649343|NCT01324102|ACTIVE_COMPARATOR|1. Yoga therapy|The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
62281373|NCT02239822|PLACEBO_COMPARATOR|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
62649344|NCT01324102|NO_INTERVENTION|2. Wait list|The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.
62649345|NCT00742950|ACTIVE_COMPARATOR|I|Nasal 2.8-mm corneal incision
62649346|NCT00742950|ACTIVE_COMPARATOR|II|Temporal 2.8-mm corneal incision
62649347|NCT00742950|ACTIVE_COMPARATOR|III|Superior 2.8-mm corneal incision
62649348|NCT01548365|NO_INTERVENTION|Control Group|routine care for the selection, placement and maintenance of venous access devices (VAD).
62281374|NCT01640457|EXPERIMENTAL|NDplus|NOVOCART® Disc plus (Autologous Disc Chondrocyte Transplantation System)
62649349|NCT01548365|EXPERIMENTAL|Infusion Therapy Nursing Expert|Patients in this group will receive the infusion therapy nursing expert (ITNE) service.
62281375|NCT01640457|PLACEBO_COMPARATOR|NDbasic|NOVOCART® Disc basic (media with no active cell component)
62281376|NCT01640457|NO_INTERVENTION|Sequestrectomy only (SC)|Sequestrectomy (standard of care)
62281377|NCT04557280|EXPERIMENTAL|Treatment A: liquid formulation via auto-injector|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an auto-injector forming an integral ready-to-use single-dose drug delivery system.
62649350|NCT02322736||WT RAS mCRC|Wild Type RAS metastatic colorectal cancer patients
62649351|NCT00560729|NO_INTERVENTION|I|
62649352|NCT00560729|ACTIVE_COMPARATOR|II|oral nutrition
62649353|NCT00560729|EXPERIMENTAL|III|oral nutrition
62649354|NCT00560729|EXPERIMENTAL|IV|oral nutrition
62649355|NCT02359240||sepsis|Patients with a diagnosis of sepsis or severe sepsis,immobilization for 3 days at least. Therapy according to the SSC guidelines will be applied. therapy according to SSC guidelines and muscle biopsy
62649356|NCT02359240||Patients with femoral fractures|non septic patients with a femoral fracture,who need an fixation surgery.standard surgery for femoral fracture and muscle biopsy will be performed.
62649357|NCT05553327|NO_INTERVENTION|Control|This group of patients will not receive a pre-hab program
62649358|NCT05553327|EXPERIMENTAL|Multimodal prehabilitation|This patients will receive the pre-hab program
62649359|NCT00385840|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62082018|NCT06444880|EXPERIMENTAL|Stage I|"Stage 1 of study treatment involves being given ubamatamab by itself by vein. The first dose will be given over about 4 hours. Depending on how participants respond, later doses may be given over shorter periods of time (possibly down to 30 minutes per infusion). Participants dose of ubamatamab will be increased from a starting dose on Day 1 to a full dose on Day 15.~Participants will receive ubamatamab 1 time every week for the first 4 weeks, then every 3 weeks after that, unless the disease gets worse or intolerable side effects occur.~• If the disease gets worse after completing 6 weeks of treatment, participants will move to Stage 2 and receive combination therapy."
62082019|NCT06444880|EXPERIMENTAL|Stage 2|"Participants in Stage 2 will begin receiving ubamatamab and cemiplimab.~* If participants are enrolled directly into Stage 2, but did not have therapy with ubamatamab alone, participants will receive ubamatamab 1 time each week for 4 weeks, before beginning combination therapy.~* If participants have already completed Stage 1 and are moving on to Stage 2, participants will begin with combination therapy.~During Stage 2, ubamatamab is given by vein over 30 minutes to 4 hours, as described above. Cemiplimab is given by vein over 30 minutes."
62082020|NCT04630301||Measurement of pleural pressure|a. Patients admitted to the Johns Hopkins Hospital with spontaneous, iatrogenic, or tension pneumothorax referred to the Division of Interventional Pulmonology for thoracostomy will be recruited. Using standard sterile technique, a 14fr catheter will be inserted into the pleural space. An electronic manometer (Compass, Medline Industries, Inc.) will be connected in-line to the introducer needle and Ppl will be recorded for 3-5 respiratory cycles. After measurement, the manometer will be removed and the catheter will remain in place per routine standards of practice.
62082021|NCT03443323|EXPERIMENTAL|OST-T2 Intervention group|Small group skills training for students in grades 3 through 5 with difficulties with organization, time management, and planning skills. Includes parent and teacher involvement to support student skills use.
62082022|NCT03443323|NO_INTERVENTION|Treatment as usual control group|Strategies currently in use by schools to address organization, time management, and planning skills problems.
62281378|NCT04557280|EXPERIMENTAL|Treatment B: liquid formulation via syringe|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe.
62649360|NCT00385840|EXPERIMENTAL|GSK1247446A Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62649361|NCT04093856||Diabetic|20 men and women with type 2 diabetes and obesity
62082023|NCT05345197|EXPERIMENTAL|Experimental-treatment|Treatment with emicizumab
62649362|NCT04093856||Non-diabetic|20 normoglycemic men and women with obesity matched for age and sex with diabetic group
62082024|NCT06705192|OTHER|a single cohort, investigating 2 distinct dose levels (Dose 1: 360 mg and Dose 2: 900 mg)|"The study follows a MAD design within a single cohort, investigating 2 distinct dose levels (Dose 1: 360 mg and Dose 2: 900 mg), consecutively over a 3-month period.~Dose 1 at 360 mg (2 capsules of 180 mg in the morning) Dose 2 at 900 mg (2 capsules of 180 mg in the morning \[360 mg\], 3 capsules of 180 mg in the evening \[540 mg\])"
62082025|NCT05007730|EXPERIMENTAL|Intervention Arm|
62082026|NCT05004233|EXPERIMENTAL|Ischemic stroke patients|Patients hospitalized for an ischemic stroke.
62082027|NCT05990426|EXPERIMENTAL|FAST Group|The FAST intervention will consist of one week of alternate day fasting (ADF) using the sandwich model at the start of each cycle of chemotherapy, for a total of 6 weeks of ADF. Patients will be instructed on how and what they may consume on fasting days.
62281379|NCT04557280|EXPERIMENTAL|Treatment C: lyophilizate-based formulation via syringe|Selatogrel will be administered as a reconstituted lyophilizate-based formulation for injection.
62281380|NCT05347641|EXPERIMENTAL|Penpulimab combined with RMA was used for first-line treatment of PCNSL|One course of treatment was performed every 21 days. After 3 courses, patients underwent cranial MR+ whole-body enhanced CT for disease assessment. Patients who did not achieve partial response (PR) were withdrawn, and patients who achieved PR or complete response (CR)/uncertain CR (CRu) were given 3 courses of treatment.
62281381|NCT03455699||Experimental: VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
62281382|NCT03455699||Active Comparator: RFA|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
62281383|NCT03455699||Experimental: Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
62649363|NCT01168388||Movement disorder|
62649364|NCT01170585|PLACEBO_COMPARATOR|Placebo|randomised to placebo.
62649365|NCT01170585|ACTIVE_COMPARATOR|Active|randomised to rosuvastatin.
62082028|NCT05990426|NO_INTERVENTION|Control Group|Participants in the control arm will be instructed to eat as desired throughout their entire chemotherapy treatment course. Control group participants will not receive any special study- related instructions or direction regarding food and drinks consumed during chemotherapy.
62649366|NCT03952819||Diabetic group,|The study was designed with 28 chronic hemodialysis patients (17 men, 11 women) receiving treatment at our hospital. Of the 28 hemodialysis patients, 14 had Type 2 diabetes mellitus. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
62649367|NCT03952819||Non-Diabetic group,|Of the 28 hemodialysis patients, the other 14 were not diabetic. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
62649368|NCT03952819||Control group,|The study was designed with 56 individuals; 28 healthy volunteers as a control group. Venous blood samples of the control group were obtained at the blood sampling unit by the healthcare personnel during morning hours following overnight fasting while they were sitting after being rested. The intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
62082029|NCT06470659|NO_INTERVENTION|Meds alone|Participants in this group do not receive behavioral or lifestyle support alongside their medications. The medications are not part of the intervention (it is part of the eligibility criteria).
62082030|NCT06470659|EXPERIMENTAL|Meds plus WW|Participants in this group receive behavioral or lifestyle support from WW Clinic alongside their medications. The medications are not part of the intervention (it is part of the eligibility criteria).
62281384|NCT03720132|EXPERIMENTAL|Patients with port catheter: flushing|In patients with a catheter-related blood stream infection (CRBSI) and a port catheter, being treated with vancomycin intravenously, we will flush the catheter with 30 ml of sodium chloride 0.9 % prior to blood sampling to determine vancomycin concentrations, in order to decrease residuel vancomycin in the port.
62281385|NCT06277752|EXPERIMENTAL|IBI128|IBI128 po. QD(Quaque Die)
62649369|NCT02247388|EXPERIMENTAL|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
62281386|NCT00742469|ACTIVE_COMPARATOR|1|Rifaximin
62281387|NCT00742469|PLACEBO_COMPARATOR|2|Placebo
62281388|NCT02012530|ACTIVE_COMPARATOR|HA|Patients in this arm will have hyaluronic acid (HA) injected into their knee along with 3 ml local anaesthetic. The HA injection is in the form of 2 ml aqueous sodium hyaluronate. The exact constituents of the HA change in a proprietary manner. All HA injections used will have the CE marking on them.
62281389|NCT02012530|ACTIVE_COMPARATOR|PRP|Patients in this arm will have platelet rich plasma (PRP) injected into their knee. The PRP sample will be produced at the time of the injection. 30 ml of blood is drawn fro the patient a few minutes before the injection. Using a CE marked differential centrifugation device, the platelets are isolated. This concentrated sample of platelets is injected into the knee after the skin around the injection site is anaesthetised with local anaesthetic.
62281390|NCT03118297|EXPERIMENTAL|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
62281391|NCT03118297|PLACEBO_COMPARATOR|Placebo|Identical placebo (capsule) daily for 7 days
62458535|NCT03232008|EXPERIMENTAL|Experiment B- experimental|3g Canderel + 35g Lyle's Golden Syrup in 250 ml water
62458536|NCT03232008|NO_INTERVENTION|Experiment B- control|3g Lyle's Golden Syrup + 35g of maltodextrin in 250 ml of water
62458537|NCT06242288|NO_INTERVENTION|control group|age and sex matched healthy control
62458538|NCT06242288|ACTIVE_COMPARATOR|Comparative group|20 acne patients taking isotretinoin 20 mg once daily
62649370|NCT02247388|NO_INTERVENTION|Standard Care|Standard Care
62082031|NCT02988960|EXPERIMENTAL|Escalating Arm 1: ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
62082032|NCT02988960|EXPERIMENTAL|Escalating Arm 2: ABBV-927|Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
62082033|NCT02988960|EXPERIMENTAL|Escalating Arm 3: ABBV-927+ABBV-181|Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
62649371|NCT06051513|EXPERIMENTAL|colistin group|"For patients in this group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.~At the beginning of the intravenous use of Colistimethate Sodium for Injection，the load dose is 300mg CBA(about 9 million U)，and after 12-24 hours，the first maintenance dose should be given. The daily maintenance dose was 300-360mg CBA(9 million-10.9 million U), divided into two times (1/12h), for each time, 0.5-1 hour is needed to complete the infusion.~Drug: colistin, other name: Colistimethate Sodium for Injection"
62649372|NCT06051513|ACTIVE_COMPARATOR|control group|For patients in this group,best available treatment without colistin is used. Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.Dose of other drugs are listed below: 1-2g meropenem should be given every 8 hours，1g Imipenem every 8 hours or 6 hours，0.8g Amikacin everyday，2.5g ceftazidime-avibactam every 8 hours. A load dose of 200mg tigecycline is needed, followed by 100mg every 12 hours.
62649373|NCT00822848|EXPERIMENTAL|Sorafenib, Epirubicin, Ifosfamide|
62082034|NCT02988960|EXPERIMENTAL|Escalating Arm 4: ABBV-927+ABBV-181|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
62082035|NCT02988960|EXPERIMENTAL|Escalating Arm 5 (Japan): ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
62082036|NCT02988960|EXPERIMENTAL|Escalating Arm 6 (Japan): ABBV-927+ABBV-181|Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
62082037|NCT02988960|EXPERIMENTAL|Expansion Arm A: ABBV-927|Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
62082038|NCT02988960|EXPERIMENTAL|Expansion Arm B: ABBV-927+ABBV-181|Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
62082039|NCT02988960|EXPERIMENTAL|Expansion Arm C: ABBV-927+ABBV-181|Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
62082040|NCT06066580|EXPERIMENTAL|Treatment|Drug: Sevasemten
62649374|NCT00699868|EXPERIMENTAL|1|Infection to CMV
62082041|NCT06648759|EXPERIMENTAL|Vagal Nerve Stimulator Group|This arm of the study will be randomly assigned to receive the active vagal nerve stimulator device which is placed via electrodes on each side of the neck. The active device will experience two 45-minute sessions daily of vagal nerve stimulation until their Nasogastric (NG) tube is removed.
62082042|NCT06648759|SHAM_COMPARATOR|Placebo Vagal Nerve Stimulator Group|This arm of the study will be randomly assigned to receive a sham device that mirrors that of the active vagal nerve stimulator devices. The sham device arm will experience two 45-minute sessions daily of placebo vagal nerve stimulation until their Nasogastric (NG) tube is removed.
62082043|NCT05601440|EXPERIMENTAL|Substudy A - Monitoring|
62082044|NCT05601440|EXPERIMENTAL|Substudy B - RP-6306 + Gemcitabine|
62082045|NCT05601440|EXPERIMENTAL|Substudy C - Niraparib + Fulvestrant|
62082046|NCT05601440|EXPERIMENTAL|Substudy D - RP-6306 + RP-3500|
62082047|NCT06555731||Healthy Volunteers|
62082048|NCT06448026|EXPERIMENTAL|Cemiplimab + Cetuximab|Participants will receive cemiplimab and cetuximab together for 6 weeks, and then you will have salvage surgery. Based on how the tumor responds to the study therapy, you may also receive cemiplimab alone for up to 1 year after surgery.
62082049|NCT06191263|EXPERIMENTAL|RVU120 + Venetoclax|RVU120 oral capsule, 125 or 250 mg administered every other day on Days 1-13 of each 21-day cycle of treatment, combined with venetoclax oral tablet, 200 or 400 mg administered once daily on Days 1-14 of each 21-day cycle of treatment
62082050|NCT06740643|EXPERIMENTAL|intracanal reinforcement with short compsite post|
62649375|NCT00699868|OTHER|2|"Group control CMV"
62082051|NCT06740643|ACTIVE_COMPARATOR|no intracanal reinforcement|
62082052|NCT05774678|EXPERIMENTAL|Group 1 (preoperative radiation hypofractionated)|Participants will receive the standard number of radiation treatment doses
62082053|NCT05774678|EXPERIMENTAL|Group 2 (preoperative radiation conventionally fractionated)|Participants will receive the standard number of radiation treatment doses
62649376|NCT01500980|EXPERIMENTAL|Pilot Phase|Pilot phase will include 6 subjects and will investigate the timing of PQ dosing relative to parasite exposure.
62649377|NCT01500980|EXPERIMENTAL|Chloroquine, ITV, primaquine, malaria challenge|
62649378|NCT01500980|ACTIVE_COMPARATOR|Sporozoite negative vaccine|
62082054|NCT05669664|EXPERIMENTAL|Treatment (darolutamide, leuprolide acetate)|Patients receive darolutamide PO BID on days 1-28 of each cycle and leuprolide acetate IM every 4 or 12 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, collection of blood samples, and CT/MRI throughout the trial.
62082055|NCT05129020|EXPERIMENTAL|Active tAN + Morphine|
62082056|NCT05129020|SHAM_COMPARATOR|Sham tAN + Morphine|
62281392|NCT04755959||Stroke|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of Ischemic Stroke, between the years 2016-2020 as documented in an institutionally approved data base of stroke, who will consent to provide access to their data from Google Take Out service.
62082057|NCT03964571|EXPERIMENTAL|Diabetic foot patients|
62082058|NCT04613635|EXPERIMENTAL|Stratafix|
62082059|NCT04613635|ACTIVE_COMPARATOR|Vicryl|
62281393|NCT04755959||Acute myocardial infarction|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of acute myocardial infarction as documented in an institutionally approved data base of myocardial infarction, who will consent to provide access to their data from Google Take Out service.
62281394|NCT04755959||Healthy controls|Unaffected spouses or volunteers who will consent to provide access to their data from Google Take Out service.
62281395|NCT05219955|EXPERIMENTAL|Active condition (SAMM Protocol)|The goal of the SAMM protocol is to increase morning activity engagement over a 6-week period. Participants in this condition will review their morning routine, and make a list of potential morning activities to add. They will choose one activity and develop a plan for doing it. Each day, participants are asked to track if they do the morning activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one.
62281396|NCT05219955|ACTIVE_COMPARATOR|Attention-matched supportive control condition|Participants in this condition will receive sessions in the same number and duration as the SAMM experimental condition. Therapists will create a comfortable environment by demonstrating interest, empathy, and acceptance without judgment. Caregivers will be encouraged to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials.
62281397|NCT01867229||FEC- TC|Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
62281398|NCT00847587|EXPERIMENTAL|1|Early postpartum insertion
62082060|NCT06706739|EXPERIMENTAL|Online art game intervention group|Participants in this experimental group engaged in a three-month, twice-weekly, 1-hour group online art game intervention for a total of 24 sessions
62082061|NCT06706739|NO_INTERVENTION|Health education control group|Participants in the control group had health education and did not participate in the online art game. All others were the same as the experimental group.
62082062|NCT05728944|EXPERIMENTAL|Aceclidine + Brimonidine (LNZ101) dosed bilaterally|LNZ101: Aceclidine + Brimonidine ophthalmic solution
62082063|NCT05728944|EXPERIMENTAL|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LNZ100: Aceclidine ophthalmic solution
62082064|NCT05728944|EXPERIMENTAL|Vehicle Ophthalmic Solution dosed bilaterally|Vehicle ophthalmic solution
62082065|NCT06737692|EXPERIMENTAL|Exercise group|"The exercise group will participate in a supervised and home-based exercise program consisting of aerobic and resistance exercises over 12 weeks.~Supervised Aerobic Exercises: Conducted every two weeks, 3 days/week (on days 11-13 post-systemic treatment). The supervised aerobic exercises will consist of 20 minutes on a treadmill at a heart rate corresponding to 55-75% of the Karvonen formula. Warm-up and cool-down will be performed at 30-40% of the Karvonen heart rate for 5 minutes.~Supervised Resistance Exercises: Conducted every 2 weeks on consecutive days (days 11 and 13 post-systemic treatment). Resistance training will involve 12 different exercises targeting major muscle groups, using body weight and resistance bands, at an effort level of 5-7 on the Borg scale, with 8-12 repetitions and 1-3 sets.~On weeks without supervised exercises, participants will follow a home exercise program that includes breathing exercises, walking for 20-30 minutes, and resistance exercises."
62082066|NCT06737692|NO_INTERVENTION|Control group|Participants in the control group will be instructed to maintain their daily lifestyle, including physical activity, during their participation in the study. After completion of the study, participants in the control group will be offered a supervised aerobic and resistance exercise program and will be administered the same exercise program.
62082067|NCT06015282|EXPERIMENTAL|Investigational aQIVc group|
62281399|NCT00847587|ACTIVE_COMPARATOR|2|Standard postpartum insertion
62458539|NCT02464709|EXPERIMENTAL|Actinic keratosis patients|Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.
62649379|NCT01500980|ACTIVE_COMPARATOR|Primaquine placebo|
62082068|NCT06015282|ACTIVE_COMPARATOR|licensed QIV1 group|
62281400|NCT03311048|EXPERIMENTAL|Hospital|Hospital cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
62082069|NCT06015282|ACTIVE_COMPARATOR|licensed QIV2 group|
62082070|NCT03958565||Actionable driver oncogene|One group will have an actionable driver oncogene and initiate treatment in any line with a TKI as standard of care and concurrent to participation to this study; expected to have an objective response rate in ≥40% who have not previously seen anti-bone resorptive therapy.
62458540|NCT00927992||Patients with haemophilia who undergo liver transplantation|Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.
62082071|NCT03958565||No Actionable Mutations|The other group will not have actionable mutations and initiate treatment with chemotherapy/immunotherapy along with new onset therapy with IV zoledronic acid 4mg Q4 weeks or subcutaneous denosumab 120 mg Q12 weeks for bone disease, which is standard of care and would be concurrent to participation in this study.
62082072|NCT06646848|EXPERIMENTAL|Vibration Group|Vibration was applied to the infants in this group before and during the heel lance procedure.
62281401|NCT03311048|EXPERIMENTAL|University|Campus (university) cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
62458541|NCT04817709||Arm 1|Patients view a video and read a workbook over 30 minutes about breast reconstruction surgery before their appointment. Patients also complete a questionnaire over 5-10 minutes before and after the video and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
62281402|NCT03311048|EXPERIMENTAL|Housekeeper|Housemaid (cleaning workers) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
62649380|NCT01500980|NO_INTERVENTION|malaria challenge|
62082073|NCT06646848|EXPERIMENTAL|Heel Warming Group|Heel warming was applied to the infants in this group before and during the heel lance procedure.
62082074|NCT06646848|EXPERIMENTAL|Shotblocker Group|ShotBlocker was applied to the infants in this group before and during the heel lance procedure.
62082075|NCT06646848|NO_INTERVENTION|Control Group|In this group, infants received routine heel blood collection procedure.
62082076|NCT05727670|EXPERIMENTAL|main group|This group consists of patients with dental retention who will be treated using digital technologies and devices to create a place in the dentition
62281403|NCT03311048|EXPERIMENTAL|Control|Office workers (no relationship to cleaning) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
62281404|NCT06342674|EXPERIMENTAL|Experimental Group|While the mothers' babies are in the neonatal intensive care unit, the babies in the circadian rhythm group will be fed by taking into account the date and day/night practice. The milk that the mother expresses at night will be given to her baby at night, and the milk that she expresses during the day will be used for daytime feeding. Milk expressed 24 hours a day is delivered to the baby in 4 time periods (06:00-12:00, 12:00-18:00, 18:00-24:00, 24:00-06:00) in coordination with the time it is expressed. It is planned to be given (Italianer et al., 2020).For example, the milk expressed at 02:00 at night on 15.08.2023 and at 05:00 at night on 16.08.2023 will be given to the baby first with the milk of the previous date of 15.08.2023, in the period of 24:00-06:00 at night. Breast milk will be given according to both date and day/night milk concept.
62082077|NCT05446870|EXPERIMENTAL|Pembrolizumab + Standard of Care (SOC) + MK-4830|Before surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m\^2, carboplatin Area Under the Curve (AUC) 5 to 6, (or docetaxel 75 mg/m\^2), and MK-4830 800 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles. After surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m\^2, carboplatin AUC 5 to 6, (or docetaxel 75 mg/m\^2), MK-4830 800 mg, and avastin (or biosimilar) by IV infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles.
62082078|NCT05446870|ACTIVE_COMPARATOR|Pembrolizumab + SOC|Before surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m\^2, carboplatin AUC 5 to 6 and (or docetaxel 75 mg/m\^2) by IV infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles. After surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m\^2, carboplatin AUC 5 to 6, (or docetaxel 75 mg/m\^2) and avastin (or biosimilar) by IV infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles.
62082079|NCT06739161|EXPERIMENTAL|Sintilimab combined with chemotherapy and local treatment|"①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment : Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs."
62082080|NCT06739161|ACTIVE_COMPARATOR|Sintilimab combined with chemotherapy|"①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy."
62082081|NCT06350071|EXPERIMENTAL|Kangaroo Care Group|Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.
62649381|NCT06516770|EXPERIMENTAL|Transcranial direct current stimulation|The subject will receive transcranial direct current stimulation for 20 minutes.
62649382|NCT06516770|EXPERIMENTAL|Neuromuscular electrical stimulation|The subject will receive neuromuscular electrical stimulation for 20 minutes.
62082082|NCT06350071|EXPERIMENTAL|Swaddling Group|Heel blood will be taken while the infant was swaddled in the maternal holding.
62082083|NCT06350071|NO_INTERVENTION|Control Group|In this group, infants received routine heel blood collection procedure.
62458542|NCT04817709||Arm 2|Patents receive an educational booklet about breast reconstruction surgery during appointment. Patients also complete a questionnaire over 5-10 minutes before and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
62082084|NCT04158154|EXPERIMENTAL|Primary Health Care Centers|Selected primary health care centers in Abuja will implement a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for hypertension diagnosis and treatment.
62082085|NCT05597306|EXPERIMENTAL|Part 1: VenBom Dose Escalation/De-Escalation Cohort|"Participants in this group will receive Venetoclax and Bomedemstat (VenBom) in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD). Participants will receive VenBom for 21 days on (Days 1-21) and seven days off (Days 22-28) during a 28-day cycle for three months. Doses will be administered as follows:~* Dose Level -2: 0.375 mg/kg daily (d) Bomedemstat and 200 mg/d Venetoclax;~* Dose Level -1: 0.75 mg/kg/d Bomedemstat and 200 mg/d Venetoclax;~* Dose Level 1 (Starting): 1.5 mg/kg/d Bomedemstat and 200 mg/d Venetoclax;~* Dose Level 2: 3 mg/kg/d Bomedemstat and 200 mg/d Venetoclax;~* Dose Level 3: 3 mg/kg/d Bomedemstat and 400 mg/d Venetoclax.~Participants will receive three cycles of VenBom, but may continue to receive treatment as long as receiving clinical benefit or until disease progression. Participants starting at dose levels -2, -1, or 1 receive 100 mg Venetoclax on Cycle 1 Day 1."
62082086|NCT05597306|EXPERIMENTAL|Part 2: VenBom Expansion Cohort|Participants in this group will receive VenBom therapy at the most appropriate dose determined in Part 1. Participants will continue to receive treatment as long as receiving clinical benefit or until disease progression.
62082087|NCT01087320||Genetic Disorders|Patients or family probands with genetic cause of disorders that are intractable or difficult to identify with existing technique.
62082088|NCT05022485||Investigational group|Subjects that will be implanted with the ZNN Bactiguard tibia device.
62458543|NCT03309709|NO_INTERVENTION|watch-and-wait patients|patients who receive a watch-and-wait approach
62649383|NCT06516770|EXPERIMENTAL|Motor control exercise|The subject will receive motor control exercise for 20 minutes.
62649384|NCT06516770|ACTIVE_COMPARATOR|Isometric exercise|The subject will receive isometric exercise for 20 minutes.
62649385|NCT05076734|OTHER|Analysis of blood samples from healthy pregnant women|A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.
62649386|NCT03933059|ACTIVE_COMPARATOR|R&R Park City, Utah|This group will receive 12 daily individual sessions of CPT at the National Ability Center in Park City, Utah. They will also participate in daily recreational activities.
62082089|NCT05022485||Control group|Subjects that have received an uncoated titanium-alloy tibia nail in the past (data collection is retrospective; patients will not have to undergo any study-related procedure).
62082090|NCT04975230|EXPERIMENTAL|Sleep Self-Management|The Sleep Self-Management Intervention involves an initial 50-minute face-to-face interactive session in a private location. Participants are asked to extend time in bed by 1 hour and consistently maintain the extension on both weekends and weekdays. Bedtimes and waketimes will be assessed to ascertain which time is most modifiable for the participant's lifestyle and routine. There will be weekly follow-ups and in-person 3-week booster sessions. Sleep reports generated by the actigraphy will be shared with participants with brief action planning and goal setting to address progress towards goal achievement. A need to revise plans for future weeks will be the booster sessions' major goal.
62082091|NCT04975230|NO_INTERVENTION|Diabetes Self-Management Education|The Attention Control arm will receive Diabetes Self-Management Education at the initial consultation visit via in-person contact at T1. There will be weekly follow-ups and in-person 3-week sessions. A Diabetes Self-Management Tracking Form will be used to monitor the weekly acquisition of information and plans for the 6-week intervention and at the 3-month and 6-month data points.
62649387|NCT03933059|ACTIVE_COMPARATOR|R&R Salt Lake City, Utah|This group will receive 12 daily individual sessions of CPT at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
62649388|NCT03933059|ACTIVE_COMPARATOR|Weekly Treatment Salt Lake City, Utah|This group will receive 12 individual sessions of CPT on a weekly basis at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
62649389|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
62649390|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
62649391|NCT00089219|EXPERIMENTAL|Arm A. 6MHP vaccine 200 mcg|vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
62649392|NCT00089219|EXPERIMENTAL|Arm B. 6MHP vaccine 400 mcg|vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
62082092|NCT06739720|EXPERIMENTAL|Intervention group|Participants receive CP003 capsules (5 capsules once daily) for 6 weeks, followed by a 6-week follow-up period.
62082093|NCT06739720|NO_INTERVENTION|Waitlist group|Participants initially wait for 6 weeks after randomization without intervention. After the waiting period, they receive the same CP003 supplement regimen (5 capsules once daily) for 6 weeks, followed by a 6-week follow-up period.
62082094|NCT05151341|EXPERIMENTAL|Case|Patient in whom newly diagnosed, or recurring / progressing bladder cancer is strongly suspected after initial fibroscopy
62082095|NCT05151341|EXPERIMENTAL|Control|Patient attending or hospitalized for urolithiasis, urinary infections, superior excretory stones or with non suspect urinary symptomatology
62082096|NCT06609590|EXPERIMENTAL|Group A|Patients will receive Anterior glenoid block combined with suprascapular nerve block.
62082097|NCT06609590|EXPERIMENTAL|Group B|The patients will Interscalene brachial plexus block.
62458544|NCT03309709|EXPERIMENTAL|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
62649393|NCT00089219|EXPERIMENTAL|Arm C. 6MHP vaccine 800 mcg|vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
62649394|NCT03211065|EXPERIMENTAL|Immunoglobulin therapy|Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.
62649395|NCT01831843|PLACEBO_COMPARATOR|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
62649396|NCT01831843|EXPERIMENTAL|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer \& Paykel)was used in group E patient
62649397|NCT01831843|EXPERIMENTAL|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
62649398|NCT06076785||OdySight users|OdySight users between 07/21/2021 and 11/14/2022 who performed Visual Acuity testing through OdySight and according to standard practice.
62649399|NCT04664218|EXPERIMENTAL|patients with Peritoneal carcinomatosis|Peritoneal carcinomatosis (PC) is a well-known sequel of multiple abdominal malignancies either arising from the gastro-intestinal tract or of gynaecologic origin. On occurrence, PC is mostly considered as a very bad prognostic sign hence it affects the overall survival with very poor response to systemic chemotherapy.
62649400|NCT04409613|ACTIVE_COMPARATOR|Clinical pharmacist-provided services+standard care group|that receive clinical pharmacist-provided services at the Warfarin Counseling Clinic plus standard medical care
62281405|NCT06342674|EXPERIMENTAL|Control Groups|"In the control group, the condition of expressed milk is given first, which is used in routine practice, will be fulfilled, regardless of the day and night characteristics of expressed breast milk. The routine practice of the clinic will continue."
62458545|NCT04916938|EXPERIMENTAL|Interactive Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
62458546|NCT04916938|ACTIVE_COMPARATOR|Treatment as usual|Mother child psychotherapeutic sessions without video feed back.
62458547|NCT00005520||African American hydrochlorothiazide|300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.
62458548|NCT00005520||European American hydrochlorothiazide|300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks
62458549|NCT00005520||African American candesartan|300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
62458550|NCT00005520||European American candesartan|300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
62458551|NCT03011684|EXPERIMENTAL|ER Positive - Letrozole|
62458552|NCT03011684|EXPERIMENTAL|ER Positive - Tamoxifen|
62458553|NCT03011684|NO_INTERVENTION|ER Negative|
62458554|NCT02143765|EXPERIMENTAL|Mitiglinide|Mitiglinide 10 mg three times a day, orally, for 12 weeks
62082098|NCT06734728|EXPERIMENTAL|Profilm Cold Sores|"Profilm Cold Sores is a liquid dressing indicated for topical application after the first symptoms of cold sores appear. It is a hydrogel based on a carboxymethylcellulose polymer matrix combined with sodium alginate, supplemented with natural extracts, that forms a protective film which alleviates symptoms, reduces the duration of the outbreak, and lowers the risk of contagion. It contains no animal-derived compounds and is mostly of plant origin. The product is enriched with stabilized vitamin C.~Being a topical product, its pH is between 5 and 5.5 (the typical pH of healthy skin). Additionally, at a pH \<5.5, the effectiveness of the preservative system is optimal. It features a buffering system to achieve this pH, composed of citric acid and stabilized vitamin C.~The product is presented in a 5 mL airless container, where the absence of air inside the packaging helps preserve the organoleptic, physicochemical, and microbiological properties of the product. The product is packa"
62082099|NCT05772104|EXPERIMENTAL|Experimental: Shugan Jieyu Capsules|Participants received Shugan Jieyu Capsules 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
62082100|NCT05772104|PLACEBO_COMPARATOR|Experimental: Shugan Jieyu Capsules Placepo|Participants received Shugan Jieyu Capsules Placebo 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
62082101|NCT06522165||patients|Male and female patients surgically treated with an oncological reconstructions at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2023
62082102|NCT05652205|EXPERIMENTAL|Part 1 Linaclotide|Participants will receive linaclotide for 12 weeks.
62082103|NCT05652205|EXPERIMENTAL|Part 1 Placebo|Participants will receive placebo for 12 weeks.
62281406|NCT02505399|EXPERIMENTAL|ticagrelor|"In the intervention group, Ticagrelor will be administered orally, according to the following scheme:~* 180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 90 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 90 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
62458555|NCT02143765|ACTIVE_COMPARATOR|Acarbose|Acarbose 50 mg three times a day, orally, for 12 weeks
62458556|NCT03174756|EXPERIMENTAL|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
62458557|NCT03174756|EXPERIMENTAL|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
62458558|NCT03174756|ACTIVE_COMPARATOR|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
62458559|NCT03174756|ACTIVE_COMPARATOR|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
62458560|NCT03174756|PLACEBO_COMPARATOR|Placebo|15 ml of Sterile water
62649401|NCT04409613|NO_INTERVENTION|Standard care group|that will receive standard medical care
62458561|NCT05077566|ACTIVE_COMPARATOR|Exercise at 60% vo2|This arm will receive 15 minutes of exercise at 60% VO2 max.
62649402|NCT05116553|ACTIVE_COMPARATOR|SDT (MI)|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews.
62649403|NCT05116553|EXPERIMENTAL|SDT (MI) + CA|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews; moreover they will use an APP with a CA (Conversational Agent), an Artificial Intelligence.
62082104|NCT05652205|EXPERIMENTAL|Part 2 Linaclotide|Participants who completed study intervention in Part 1 of this study or the Phase 2 Study LIN-MD-67 will receive 24 weeks of linaclotide exposure.
62082105|NCT06741241|EXPERIMENTAL|eHealth Promotora|Intervention arm participants will participate in a eHealth promotora group education session to receive a presentation on cervical cancer screening education, view an educational video, and complete baseline and 6-month follow-up surveys.
62082106|NCT06741241|ACTIVE_COMPARATOR|eHealth Healthy Nutrition|Control group participants will participate in an eHealth group education session to receive a presentation on healthy nutrition information, view an educational video, and complete baseline and 6-month surveys.
62082107|NCT06407063||Patients treated for Degenerative Spondylolisthesis|Patients operated for Degenerative Spondylolisthesis with Lumbar Spinal Stenosis
62082108|NCT06740825|EXPERIMENTAL|Treatment Group A (Test)|On Day 1 through Day 32, participants will receive an oral dose of 400-mg of rufinamide twice daily (BID). In addition, on Day 12, subjects will receive an oral single dose of 60-mg quizartinib
62082109|NCT06740825|EXPERIMENTAL|Treatment Group B (Reference)|On Day 1, participants will receive an oral dose of 60-mg quizartinib
62082110|NCT06028529|OTHER|Feasibility and Safety|This is a feasibility study to assess the safety and potential utility of a lightweight ground exoskeleton (Keeogo, B-Temia, Inc.) to enhance mobility in people with Parkinson's disease (PD).
62281407|NCT02505399|ACTIVE_COMPARATOR|clopidogrel|"In the control group, Clopidogrel will be administered orally, according to the following scheme:~* 300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 75 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 0 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
62458562|NCT05077566|EXPERIMENTAL|Exercise at 90% vo2|This arm will receive 15 minutes of exercise at 90% VO2 max.
62458563|NCT05077566|NO_INTERVENTION|No intervention|No intervention
62458564|NCT04423237||Severe Iron Overload (SIO)|Children affected by Severe Iron Overload who received DEFERASIROX
62458565|NCT04423237||Severe Iron Overload + Ductopenia (SIO+D)|Children affected by Severe Iron Overload + Ductopenia who received DEFERASIROX
62458566|NCT02684344|EXPERIMENTAL|Tamsulosin Group|"Subjects will receive:~1. 0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery~2. education about signs and symptoms of urinary retention"
62458567|NCT02684344|ACTIVE_COMPARATOR|Education Group|"Subjects will receive:~1) education about signs and symptoms of urinary retention"
62458568|NCT03432845||Sugammadex reversal group|Surgical patients will have their muscle relaxant reversed with sugammadex
62458569|NCT03432845||Glycopyrrolate / Neostigmine reversal group|Surgical patients will have their muscle relaxant reversed with glycopyrrolate and neostigmine
62281408|NCT03887299|PLACEBO_COMPARATOR|Standard Wound Care|Wound dressing and care as per our current practice. Compression dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively. Dressing will be removed after 24 hours from surgery completion and subjects will have an absorption pad with overlying garments for the remaining postoperative days until standard postoperative visit for wound check.
62082111|NCT06701617|EXPERIMENTAL|Visual rehabilitation group|This study includes two distinct groups: one comprising individuals with non-severe visual impairment and the other consisting of individuals with severe or profound visual impairment. The severe/profound visual impairment group receives passive visual stimulation, while the non-severe visual impairment group undergoes visual stimulation using a checkerboard pattern. The latter approach incorporates perceptual learning theories, emphasizing attentional modulation and leveraging the oddball design concept to enhance visual processing and rehabilitation outcomes.
62082112|NCT06701617|NO_INTERVENTION|Usual care group|Usual care includes physical games and teaching methods that utilize auditory and tactile senses to compensate for vision.
62082113|NCT00039689||HIV chronic infection|For example, an individual infected with HIV-1 for an indeterminate amount of time.
62082114|NCT00039689||HIV early infection|For example, a negative HIV antibody immunoassay within 6 months of a positive HIV antibody assay and confirmatory test (as defined by current CDC criteria).
62082115|NCT06740149|PLACEBO_COMPARATOR|Phase 2: Placebo Control|The control group received placebo + conventional treatment. Placebo was solubilizer of CG-BM1. Conventional treatment included hepatoprotection, antiviral therapy or other etiologic treatments, supplementation of plasma and albumin, supplementation of coagulation factors, treatment of complications, and nutritional support.
62082116|NCT06740149|EXPERIMENTAL|Phase 2: Low Dose Group|Patients in low dose group receive CG-BM1 + conventional treatment. Administration procedure of CG-BM1 is 1.0×10\^6 cells/kg CG-BM1 once a week for a total of 4 administrations.
62082117|NCT06740149|EXPERIMENTAL|Phase 2: Medium Dose Group|Patients in medium dose group receive CG-BM1 + conventional treatment. Administration procedure of CG-BM1 is 2.0×10\^6 cells/kg CG-BM1 once a week for a total of 4 administrations.
62281409|NCT03887299|ACTIVE_COMPARATOR|CHG Wound Care|ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's instructions intraoperatively. The dressing will be in place until the postoperative clinic visit on postoperative day 7.
62281410|NCT01897467|PLACEBO_COMPARATOR|Control|"The control is a wait-list control, and will have the option to participate in the intervention at the end of the initial 12-week study period. The control group will be asked to not change any of their dietary or exercise habits over the course of the 12 weeks."
62649404|NCT05512663|EXPERIMENTAL|Irreversible Electroporation (IRE) treatment|Focal Irreversible Electroporation (IRE) delivered by NanoKnife System is composed of the NanoKnife Generator and NanoKnife Single Electrode Probes.With the NanoKnife System, electrical current is delivered between pairs of probes in a series of pulses. The waveform of the current is adjustable as determined by clinician chosen parameters. Up to six probes may be placed in an array within the tissue. The probes of the array are matched as pairs by the system. When probes are activated via a foot pedal, the scheduled current is delivered to tissue between subsequent pairs of probes. Soft tissue between the probes is ablated.
62649405|NCT05720403|EXPERIMENTAL|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. The individuals in pilates exercise groups will be divided into six small groups to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes cool-down and stretching exercises. The exercises will be performed in ten repetitions.
62649406|NCT05720403|NO_INTERVENTION|control group|The group received breathing and relaxation exercises with a home program.
62649407|NCT00591877|ACTIVE_COMPARATOR|AC|"Acupuncture:~The patients will receive acupuncture by a trained doctor with acupuncture expertise, at 3 points relevant to reflux symptoms. Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation."
62458570|NCT01062256|PLACEBO_COMPARATOR|Placebo|Placebo
62458571|NCT01062256|EXPERIMENTAL|Guaifenesin|Guaifenesin
62458572|NCT01062256|EXPERIMENTAL|Buckwheat Honey|Buckwheat Honey
62458573|NCT00845156|ACTIVE_COMPARATOR|Anti-Oxidant|Alpha Lipoic Acid
62458574|NCT00845156|PLACEBO_COMPARATOR|Placebo|Placebo
62458575|NCT01247948|EXPERIMENTAL|navigation assisted spine surgery|
62458576|NCT06369805||one group|
62458577|NCT02007122|EXPERIMENTAL|IRRT|Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy
62082118|NCT06740149|EXPERIMENTAL|Phase 1: Low Dose Group|"The trial group with a low dose (1.0×10\^6 cells/kg) will first enroll one subject, who will be infused with single dose CG-BM1 and then observed for at least 28 days. The clinical data of the first subject will be reviewed by the SRC.~* If the first subject in the low-dose trial group experiences DLT, enrollment will be suspended. After discussion, recommendations will be made. If the trial is to continue, two additional subjects will be enrolled for observation. If no DLT occurs, the dose trial group will need to enroll three more subjects.~* If the first subject in the dose trial group does not experience DLT after 28 days, - the remaining two subjects in that dose trial group will be enrolled.~Once all subjects in the dose trial group have completed the infusion and have been observed for 28 days, the clinical data of all subjects will be submitted to the SRC. After a comprehensive evaluation, the SRC will provide recommendations for dose escalation."
62082119|NCT06740149|EXPERIMENTAL|Phase 1: Medium Dose Group|"The trial group with a low dose (2.0×10\^6 cells/kg) will first enroll one subject, who will be infused with single dose CG-BM1 and then observed for at least 28 days. The clinical data of the first subject will be reviewed by the SRC.~* If the first subject in the low-dose trial group experiences DLT, enrollment will be suspended. After discussion, recommendations will be made. If the trial is to continue, two additional subjects will be enrolled for observation. If no DLT occurs, the dose trial group will need to enroll three more subjects.~* If the first subject in the dose trial group does not experience DLT after 28 days, - the remaining two subjects in that dose trial group will be enrolled.~Once all subjects in the dose trial group have completed the infusion and have been observed for 28 days, the clinical data of all subjects will be submitted to the SRC. After a comprehensive evaluation, the SRC will provide recommendations for dose escalation."
62082120|NCT06740149|EXPERIMENTAL|Phase 1: High Dose Group|"The trial group with a low dose (4.0×10\^6 cells/kg) will first enroll one subject, who will be infused with single dose CG-BM1 and then observed for at least 28 days. The clinical data of the first subject will be reviewed by the SRC.~* If the first subject in the low-dose trial group experiences DLT, enrollment will be suspended. After discussion, recommendations will be made. If the trial is to continue, two additional subjects will be enrolled for observation. If no DLT occurs, the dose trial group will need to enroll three more subjects.~* If the first subject in the dose trial group does not experience DLT after 28 days, - the remaining two subjects in that dose trial group will be enrolled.~Once all subjects in the dose trial group have completed the infusion and have been observed for 28 days, the clinical data of all subjects will be submitted to the SRC. After a comprehensive evaluation, the SRC will provide recommendations for dose escalation."
62082121|NCT06738797||Patients with urothelial carcinoma|
62082122|NCT06581627|EXPERIMENTAL|Etavopivat|Participants will be administered a single dose of 2 tablets of etavopivat together.
62082123|NCT04274543|EXPERIMENTAL|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of normal saline (0.9%) solution into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
62082124|NCT04274543|ACTIVE_COMPARATOR|Saline|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
62082125|NCT00686335|EXPERIMENTAL|Lodotra|After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
62458578|NCT02007122|EXPERIMENTAL|CRRT|Ceftaroline levels are measured in patients receiving continuous renal replacement therapy
62458579|NCT00189709|EXPERIMENTAL|1|
62458580|NCT00189709|ACTIVE_COMPARATOR|2|
62458581|NCT01210001|EXPERIMENTAL|BI 10773 low dose|BI 10773 tablets once daily
62458582|NCT01210001|EXPERIMENTAL|BI 10773 high dose|BI 10773 tablets once daily
62458583|NCT01210001|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching BI 10773
62458584|NCT05571878|EXPERIMENTAL|Crossover: Insulin and Placebo|"Twelve adolescents who have a confirmed depression diagnosis or experiencing depression will be used as the study population group against 12 healthy adolescents who will be used as the healthy study population group.~Both the health control group and medication-free adolescents with depression will receive the same drug conditions (intranasal insulin and intranasal placebo)."
62458585|NCT01208363|NO_INTERVENTION|Unfortified Toubani|Children in the school will receive, 3 times per week 66g of raw unfortified (no added Fe) cowpea in form of Toubani (a cowpea based snack).
62458586|NCT01208363|ACTIVE_COMPARATOR|Fortified Cowpea|Study subjects will receive 3 times per week, as part of the school feeding programme 66g of raw fortified cowpea (with added 10mg Fe as NaFeEDTA)in form of Toubani (a cowpea based snack).
62458587|NCT01402947|EXPERIMENTAL|Ciprofloxacin + MMX placebo|
62458588|NCT01402947|EXPERIMENTAL|MMX Mesalazine/mesalamine + Ciprofloxacin|
62458589|NCT01935440|ACTIVE_COMPARATOR|Prevention & Testing Control|The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
62458590|NCT01935440|EXPERIMENTAL|Prevention & Testing Intervention|The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
62458591|NCT00090857|EXPERIMENTAL|Letrozole|Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
62458592|NCT00090857|PLACEBO_COMPARATOR|Placebo|Participants in this arm received 1 tablet per day which contained the inert ingredients from the letrozole tablet, for a duration of 12 months; followed by an optional 5 years of letrozole.Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
62649408|NCT00591877|SHAM_COMPARATOR|SAC|The patients randomized to this arm will receive acupuncture for a similar duration and number of sessions. The sham acupoints are at least 2 cm away from the actual acupoints to prevent acupressure effects
62649409|NCT00591877|ACTIVE_COMPARATOR|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
62649410|NCT01556217|EXPERIMENTAL|JNJ-39393406|
62082126|NCT00686335|ACTIVE_COMPARATOR|Cortancyl|During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.
62082127|NCT03785873|EXPERIMENTAL|Nal-Irinotecan and Nivolumab|
62082128|NCT05737940|EXPERIMENTAL|AZD3427 Dose A|The participants will receive single dose of AZD3427 Dose A every 2 weeks for 24 weeks from Day 1 to Day 155.
62082129|NCT05737940|EXPERIMENTAL|AZD3427 Dose B|The participants will receive single dose of AZD3427 Dose B every 2 weeks for 24 weeks from Day 1 to Day 155.
62082130|NCT05737940|EXPERIMENTAL|AZD3427 Dose C|The participants will receive single dose of AZD3427 Dose C every 2 weeks for 24 weeks from Day 1 to Day 155.
62082131|NCT05737940|PLACEBO_COMPARATOR|Placebo|The participants will receive single dose placebo every 2 weeks for 24 weeks from Day 1 to Day 155.
62082132|NCT06729424|EXPERIMENTAL|Digital patient education program|Digital patient education program for 5 weeks
62082133|NCT03625323|EXPERIMENTAL|1st line NSCLC|"eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks."
62082134|NCT03625323|EXPERIMENTAL|2nd line NSCLC|"eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks."
62082135|NCT03625323|EXPERIMENTAL|HNSCC|"eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~pembrolizumab (KEYTRUDA®): 200 mg every 3 weeks."
62458593|NCT02060110||MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study
62649411|NCT01556217|PLACEBO_COMPARATOR|Placebo|
62082136|NCT06636149|EXPERIMENTAL|Circuit Intervention Arm|The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be: 10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5
62458594|NCT02060110||MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study
62458595|NCT05823207|EXPERIMENTAL|Sage essential oil|Sage essential oil is applied twice a day for a total of 6 drops for 5 days in each cycle.
62458596|NCT05823207|NO_INTERVENTION|control group|No application was made to this group. Personal information form and PMS scale and quality of life scale will be applied to this group at the end of each cycle.
62458597|NCT01272336|ACTIVE_COMPARATOR|AIH/Sham|Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
62649412|NCT01655875|EXPERIMENTAL|bone marrow transplant|
62649413|NCT03694704|EXPERIMENTAL|CI with FineHearing Strategy|cochlear implant with FineHearing strategy
62082137|NCT06636149|NO_INTERVENTION|Control Arm|Patients randomized to the control arm will have their labor courses managed per current best practice recommendations. This will include nurse or patient facilitated position changes per the discretion of the patient's clinical care team. Routine position changes allowed in this control group will include walking, sitting, squatting, thrones, supine, hands and knees, and lateral decubitus with or without peanut ball. No positions in the circuit intervention group will be permitted to be used in the control group. Any circuit positions used in the control group will be tracked and documented.
62082138|NCT06644261|OTHER|Transvaginal pudendal nerve block|Participants in this arm will receive 10 mL bupivacaine injected into bilateral pudendal nerves via transvaginal approach. This is performed by palpating 1 cm superior and medial to the ischial spine. Participants will receive an injection each 2 weeks, for a total of 3 injections over 6 weeks.
62082139|NCT06644261|OTHER|Fluoroscopy guided pudendal nerve block|Participants in this arm will receive 5 mL bupivacaine injected into bilateral pudendal nerves via fluoroscopic guided trans gluteal approach. They will receive one injection over the 6-week duration.
62082140|NCT03702270|EXPERIMENTAL|Penicillin Allergic Floor Patients- Experimental|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
62082141|NCT03702270|NO_INTERVENTION|Penicillin Allergic Floor Patients- Control|Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.
62082142|NCT05959863||Primary Aldosteronism Group|Patients diagnosed with primary aldosteronism
62281411|NCT01897467|EXPERIMENTAL|Wii Fit|"Participants in the intervention group will be assigned a Wii console and a Wii Fit balance board. The intervention group will be asked to play for 30 minutes a day, 3 times per week, using only the participant profile pre-programmed for them. They will complete yoga poses and strength training exercises for the first 10 minutes and balance coordination games for the remaining 20 minutes. They will be asked to complete each exercise at least twice, preferably by cycling through all exercises. Participants will be asked to do all of the exercises in one 30-minute session, rather than breaking them up throughout the day.~All participants will be asked to keep a record of which games they play and for how long. The Wii Fit software also keeps a digital record of which exercises were completed and how long they were performed. At the end of the intervention the investigator will use the information stored in the Wii, as well as activity logs, to assess compliance."
62281412|NCT05457192||Moderate diabetic polyneuropathy (DPN)|65 patients of both sexes (males \& females) with type II DM with moderate polyneuropathy will be included. Patients will be enrolled and assessed for their eligibility to participate in this study. Their body mass index (BMI) will range from 20:30 kg/m2, age will range from 40-60 years, postprandial blood sugar more than 200 mg/dl, duration of diabetic illness five years ago or more and serum Hb1AC will be between 7% and 14%. All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS) (score nine to 11 points), and Neuropathy Impairment Score in the lower limbs (NIS-LL) (The muscle power of the lower limbs will be more than grade 2 and less than grade 4)
62281413|NCT01181414|EXPERIMENTAL|Atrioventricular junction ablation|Atrioventricular junction ablation by using radiofrequency energy.
62082143|NCT05959863||Essential Hypertension Group|Patients diagnosed with essential hypertension
62082144|NCT06275815|NO_INTERVENTION|Untreated Control|Caregivers read to child as usual over 15 week period.
62082145|NCT06275815|EXPERIMENTAL|STAR Only|Typical implementation of Sit Together and Read (STAR)
62082146|NCT06275815|EXPERIMENTAL|STAR + Reward|Typical implementation of Sit Together and Read (STAR) plus additional small monetary incentives for caregivers
62082147|NCT06275815|EXPERIMENTAL|STAR + text encouragement|Typical implementation of Sit Together and Read (STAR) plus caregivers receive encouraging text messages
62281414|NCT01181414|ACTIVE_COMPARATOR|Drug control of ventricular rate|Drug control of ventricular rate.
62281415|NCT04285385|EXPERIMENTAL|Aromatherapy|0.10 ml of lavender essential oil 30 minutes prior surgery
62458598|NCT01272336|ACTIVE_COMPARATOR|Sham/AIH|Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH
62458599|NCT02175264||Patients and Families with isolated non syndromic CDH cases|
62458600|NCT05046548|EXPERIMENTAL|Vaccine|"At Stage I:~Group 1 - 10 volunteers, Vaccine 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage II:~Group 1 - 140 volunteers,Vaccine0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage III:~Group 3 - 150 volunteers, Vaccine 0.5 ml, 14 days interval, post-vaccination observation for 6 months."
62649414|NCT00488397||1|
62649415|NCT04434508|ACTIVE_COMPARATOR|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
62082148|NCT02902328||MRI data collection|A group of 30 subjects will be scanned on a 3 Tesla (T) and on a 7T MRI scanners. The images will be compared.
62082149|NCT06644157|EXPERIMENTAL|Using the Aerolase laser|All patients applied to the entire face the cosmetic depigmenting agent Mela B3 (La Roche Posay) cream twice daily for 3 months. One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
62082150|NCT05645536|EXPERIMENTAL|TOL2506|TOL2506 in combination with standard endocrine therapy (Tamoxifen \& Aromatase Inhibitors)
62649416|NCT04434508|ACTIVE_COMPARATOR|open right hemicolectomy with CME and central v|open right hemicolectomy with CME and central v
62458601|NCT05046548|PLACEBO_COMPARATOR|Placebo|"No active ingredient in the placebo~At Stage I:~Group 2 - 5 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage II:~Group 2 - 45 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage III:~Group 4 - 50 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 6 months."
62458602|NCT03375593|EXPERIMENTAL|Narcotic|Hydrocodone 5mg/Acetaminophen 500 mg Tab
62649417|NCT04369417|EXPERIMENTAL|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
62082151|NCT05457998||Main study population: Cognitively unimpaired individuals (50-80 y)|"Participants will be enrolled based on a predetermined ratio of Alzheimer's Disease plasma and PET biomarker risk levels (e.g., as P-tau217 and amyloid PET).~FOLLOW-UP FOR 4 YEARS: Cognitive testing, blood draws and retinal imaging will be conducted at baseline and 12 months. Cognitive testing and blood draws will be conducted at 24 months and 36 months.~MRI and amyloid PET scans will be performed at screening/baseline and 24 months. An additional amyloid PET scan will be performed at 48 months."
62281416|NCT04285385|SHAM_COMPARATOR|Sham Aromatherapy|0.10 ml mineral oil 30 minutes prior surgery
62281417|NCT05618873|EXPERIMENTAL|flutter device therapy|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
62281418|NCT05618873|EXPERIMENTAL|Positive Expiratory Pressure Mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
62281419|NCT01327651|ACTIVE_COMPARATOR|Daily dosing|Participants will receive oral FTC/TDF daily.
62281420|NCT01327651|EXPERIMENTAL|Time-driven dosing|Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
62281421|NCT01327651|EXPERIMENTAL|Event-driven dosing|Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.
62281422|NCT00967720||Barriers, Adherence, Asthma|
62281423|NCT02287987|ACTIVE_COMPARATOR|Clamp|Laparoscopic robot-assisted partial nephrectomy with clamping the renal pedicle during the resection of the tumor
62281424|NCT02287987|EXPERIMENTAL|Off clamp|Laparoscopic robot-assisted partial nephrectomy without clamping the renal pedicle during the resection of the tumor
62281425|NCT01289015|EXPERIMENTAL|NAFT-600 ( naftin 2 % gel)|
62458603|NCT03375593|EXPERIMENTAL|Non Narcotic|Ibuprofen 600mg Tab + acetaminophen 500 mg Tab
62281426|NCT01289015|PLACEBO_COMPARATOR|Placebo|
62458604|NCT03661528|EXPERIMENTAL|andexanet alfa|Patients will receive one of two dosing regimens of andexanet alfa based on which FXa inhibitor they received and the amount and timing of the most recent dose.
62458605|NCT03661528|OTHER|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
62458606|NCT02601495||Women in a court diversion program|Women enrolled in the court diversion program in Tulsa, Oklahoma called Women in Recovery who report symptoms related to anxiety or depressive symptoms (Patient Health Questionnaire score ≥ 10 and/or Overall Anxiety Severity and Impairment Scale ≥ 8), problematic eating behavior(Eating Disorder Screen score ≥ 2), problems related to substance use (Drug Abuse Screening Test score \> 2), or post traumatic stress disorder symptoms (PTSD Checklist score ≥ 30).
62281427|NCT06235476|EXPERIMENTAL|animal-based protein (WP)|Supplements and control (MPP, WP, CON) will be consumed as a drink or in a recipe for five subsequent weeks (30 g/day); four weeks preload and one week during the Four Days Marches. With this amount, we aim to increase the protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d. Participants are allowed to dissolve the powder in a liquid of choice: we will provide several examples to the participants during the instructions.
62649418|NCT04369417|ACTIVE_COMPARATOR|Active Comparator: Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
62649419|NCT02239211|EXPERIMENTAL|BTT1023|BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
62649420|NCT05773742|EXPERIMENTAL|Low-volume irrigation|The patients will be instructed to irrigate once daily at a fixed time for 6 weeks. The patients will be instructed to use the irrigation 30 min after breakfast, capitalizing on the gastrocolic response; however, should this not fit in with the individual's lifestyle, then an alternative time of the day may be used. Preferably shortly after a large meal. The patients should fill the pump with 180 milliliters (a full pump) and irrigate with a volume of 160 milliliters of water.
62649421|NCT01459926|EXPERIMENTAL|Dose 1|
62649422|NCT01459926|EXPERIMENTAL|Dose 2|
62649423|NCT01459926|EXPERIMENTAL|Dose 3|
62649424|NCT01459926|EXPERIMENTAL|Placebo|
62649425|NCT06032728|EXPERIMENTAL|A|sunitinib 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
62649426|NCT06032728|NO_INTERVENTION|B|Patients with radical nephrectomy are observed without intervention
62649427|NCT03865823||anal Fistula|patient with anal fistula with indication to surgical treatment
62649428|NCT01231217|OTHER|green (or white) tea|Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee
62082152|NCT05457998||Sub-group 1: Optional Tau PET imaging sub-study|"An optional tau PET imaging sub-study will be conducted in 70 subjects from the main study population who elect to participate.~If enrolled in the optional tau PET imaging sub-study, participants will have three tau PET scans with \[18F\]RO-948: at baseline, 24 months, and 48 months."
62082153|NCT05457998||Sub-group 2: Optional Tau PET tracer comparison sub-study|"An optional tau PET tracer comparison sub-study will be conducted in 30 subjects from the main study population who elect to participate.~Tau PET scans with 2 tracers (\[18F\]RO-948 and \[18F\]MK-6240) will be performed at baseline and 24 months. An additional Tau PET scan with \[18F\]RO-948 will be performed at 48 months."
62281428|NCT06235476|EXPERIMENTAL|plant-based protein (MPP)|Supplements and control (MPP, WP, CON) will be consumed as a drink or in a recipe for five subsequent weeks (30 g/day); four weeks preload and one week during the Four Days Marches. With this amount, we aim to increase the protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d. Participants are allowed to dissolve the powder in a liquid of choice: we will provide several examples to the participants during the instructions.
62649429|NCT01231217|OTHER|coffee|Patients are recommended to drink coffee but are not allowed to consume any tea
62649430|NCT02631941|EXPERIMENTAL|A-B1-B2-C-D|"Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 days followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62649431|NCT02631941|EXPERIMENTAL|B1-C-A-D-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62082154|NCT06649149|OTHER|CONTROL|Students in the control group will be given a case discussion in a classroom environment.
62082155|NCT06649149|EXPERIMENTAL|EXPERIMENTAL|The students in the experimental group will play the game prepared for the case at https://genially.com/.
62082156|NCT05960734||Samples group|Samples collected regarding the online information about incontinence after cancer surgery.
62082157|NCT05459688|EXPERIMENTAL|Experimental 2 mg CIN-107 tablets QD|Treatment with 2 mg CIN-107 tablets, by mouth, once per day. Starting at Visit 1 and concluding at EOT (Visit 7).
62082158|NCT05271409|EXPERIMENTAL|Group A: Satralizumab|In the double-blind treatment period, participants will receive satralizumab at Weeks 0, 2, 4 (loading doses) and maintenance doses every 4 weeks (Q4W) thereafter. In the OLE period, all participants will receive open label treatment with satralizumab.
62281429|NCT06235476|EXPERIMENTAL|protein-rich food products (PFP)|PFP will receive digitally supported dietary intake counselling, with a focus on the use of protein-enriched food products in order to increase protein intake up to \>1.2 k/kg/bw/d.
62082159|NCT05271409|PLACEBO_COMPARATOR|Group B: Placebo|In the double-blind treatment period, participants will receive satralizumab matching placebo at Weeks 0, 2, 4 (loading doses) and maintenance doses every 4 weeks (Q4W) thereafter. In the OLE period, all participants will receive open label treatment with satralizumab.
62082160|NCT06483204|EXPERIMENTAL|Medrol dosepak group|For the experimental group, they will be given a medrol dosepak which is a prescription of oral steroids taken over a week long period. The dosage of steroids decreases each day. They will also complete a study survey each day remarking on our outcomes of interest such as facial swelling, bruising, pain, and nausea.
62082161|NCT06483204|NO_INTERVENTION|No medrol dosepak group|This group will not receive the medrol dosepak. They will still complete the daily survey until they return for their postoperative appointment, one week after their surgery.
62082162|NCT06630234|EXPERIMENTAL|DCC-3009 Module A|Participants will receive DCC-3009 in 28 day cycles in Module A Part 1 dose escalation and Part 2 dose expansion.
62649432|NCT02631941|EXPERIMENTAL|C-D-B1-B2-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62281430|NCT06235476|ACTIVE_COMPARATOR|control (CON)|Supplements and control (MPP, WP, CON) will be consumed as a drink or in a recipe for five subsequent weeks (30 g/day); four weeks preload and one week during the Four Days Marches. With this amount, we aim to increase the protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d. Participants are allowed to dissolve the powder in a liquid of choice: we will provide several examples to the participants during the instructions.
62281431|NCT00868686|ACTIVE_COMPARATOR|Volar aluminum splint|
62281432|NCT00868686|ACTIVE_COMPARATOR|Dorsal aluminum splint|
62281433|NCT00868686|ACTIVE_COMPARATOR|Custom thermoplastic|
62281434|NCT03879564|PLACEBO_COMPARATOR|control|0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
62281435|NCT03879564|EXPERIMENTAL|ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
62281436|NCT02055404|EXPERIMENTAL|Delefilcon A|Delefilcon A spherical contact lens with molded marks randomly assigned to one eye, with etafilcon A toric contact lens in the fellow eye for contralateral wear approximately 2 hours in duration
62281437|NCT02055404|OTHER|Etafilcon A|Etafilcon A toric contact lens randomly assigned to one eye, with delefilcon A spherical contact lens with molded marks in the fellow eye for contralateral wear approximately 2 hours in duration
62281438|NCT03261531|EXPERIMENTAL|Transcutaneous electrical nerve stimulation (TENS)|Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
62649433|NCT02631941|EXPERIMENTAL|D-B2-C-A-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62281439|NCT05797272|EXPERIMENTAL|Fetuses with BHFS|Fetuses of pregnant women confirmed with BHFS
62281440|NCT04823351|OTHER|FFP2 Mask|Universal FFP2-masking for every healthcare worker with patient contact, compared to selective FFP2-masking, which means that FFP2 masks are worn only during aerosol-generating procedures such as tube manipulation;
62082163|NCT05298904||Kidney Transplants|Kidney transplant patients who are within one-year post transplant.
62082164|NCT06740383||Individuals with Early Psychosis enrolled in Coordinated Specialty Care Clinics|In this naturalistic longitudinal study, we administer the B-SNIP biomarker batter to individuals with Early Psychosis (EP) in EP clinics with Coordinated Specialty Care treatment programs to characterize outcome trajectories and biotypes. EP individuals of both sexes, age 18-35 will be included after they meet study criteria and provide informed consent. Individuals with psychosis duration \< 3 years will be included. Individuals in this cohort of EP are diagnosed with Schizophrenia, Schizoaffective Disorder, Schizophreniform, Bipolar I Disorder with psychotic features, Delusional Disorder, Major Depressive Disorder with psychotic features, and Psychosis Not Otherwise Specified.
62082165|NCT06215586|EXPERIMENTAL|Tovinontrine (CRD-750)|
62281441|NCT04823351|OTHER|Surgical Mask|Universal surgical mask IIR type masking for healthcare workers in contact with COVID-19 patients.
62281442|NCT03436186||no arm|no arm
62281443|NCT00145847|ACTIVE_COMPARATOR|Naltrexone|Naltrexone 50 mg per day, directly administered as 100 mg on Mondays, 100 mg on Wednesdays and 150 mg on Fridays
62281444|NCT00145847|PLACEBO_COMPARATOR|Lactose pill|
62281445|NCT01015833|EXPERIMENTAL|Arm I (doxorubicin hydrochloride, sorafenib tosylate)|Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
62281446|NCT01015833|EXPERIMENTAL|Arm II (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62281447|NCT05798845|EXPERIMENTAL|Experimental: Arm A|Radiation: primary tumor SBRT, DT: 24Gy/3Fx, d1-3; positive lymph nodes LDRT, DT: 2Gy/4Fx, d1-4, d22-25 (2 cycles) ; Drug: toripalimab 240mg ivgtt d5, d26 (2 cycles)
62458607|NCT05084001|EXPERIMENTAL|38% SDF (Saforide, Toyo Seiyaku Kasei Co. Ltd., Japan)|application of silver diamine fluoride solution on occlusal surface of primary molars
62082166|NCT06215586|PLACEBO_COMPARATOR|Placebo|
62458608|NCT05084001|ACTIVE_COMPARATOR|5% NaF varnish (Duraphat, Colgate Palmolive, USA)|application of sodium fluoride varnish on occlusal surface of primary molars
62458609|NCT05084001|PLACEBO_COMPARATOR|Tonic water|application of tonic water on occlusal surface of primary molars
62281448|NCT05798845|ACTIVE_COMPARATOR|Conrol: Arm B|"Drug: Chemotherapy + toripalimab 240mg ivgtt d1, d22 (2 cycles)~Chemotherapy regimen:~Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum. Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum"
62281449|NCT00440505|PLACEBO_COMPARATOR|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
62281450|NCT00440505|EXPERIMENTAL|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
62281451|NCT00440505|EXPERIMENTAL|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
62649434|NCT02631941|EXPERIMENTAL|B2-A-D-B1-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62649435|NCT02631941|EXPERIMENTAL|D-C-B2-B1-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62649436|NCT02631941|EXPERIMENTAL|B2-D-A-C-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62281452|NCT02002260|ACTIVE_COMPARATOR|Levonorgestrel intrauterine system|levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
62281453|NCT02002260|ACTIVE_COMPARATOR|Combined oral contraceptives|A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
62281454|NCT03419715|EXPERIMENTAL|Bimatoprost Topical Solution|0.03% bimatoprost topical solution applied daily to the nail bed of fingers on one hand for 12 weeks
62281455|NCT03419715|PLACEBO_COMPARATOR|Control|Saline placebo topically applied daily to the nail be of fingers on one hand for 12 weeks
62281456|NCT04241614||The First Hospital of Ji Lin University|CT data and corresponding CT raw data of patients with lung nodule will be collected.
62281457|NCT05922748|EXPERIMENTAL|Patient|suffering from brain damage
62281458|NCT05922748|ACTIVE_COMPARATOR|healthy control subjects for imaging|healthy control subjects for imaging
62281459|NCT05922748|ACTIVE_COMPARATOR|healthy control subjects for purely behavioural studies|healthy control subjects for purely behavioural studies
62281460|NCT01276236|EXPERIMENTAL|Treatment Arm (Maraviroc)|The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen.
62281461|NCT06357650||Medical schools|Medical schools are institutions offering medical professional degrees like MD, MBBS, or MBChB.
62458610|NCT05389943|EXPERIMENTAL|Postmenopausal women with low BMD|patient with serum 25-hydroxy vitamin D \[25(OH)D\] less than 32 ng/ml. Vitamin D3 5000 IU/d per oral for the period of 3 months will be administered
62082167|NCT06738485|EXPERIMENTAL|rVIII-SingleChain|Participants will receive rVIII-SingleChain as an intravenous (IV) infusion for a minimum of 50 exposure days (EDs).
62281462|NCT06357650||Dental schools|Dental schools grant dental professional degrees such as DMD, DDS, or BDS.
62281463|NCT06357650||Nursing schools|Nursing schools provide degrees or certificates in nursing, including RN and BSc nursing.
62281464|NCT06357650||Pharmacy schools|Pharmacy schools offer pharmacy professional degrees, like BPharm or DPharm
62281465|NCT06357650||Public health schools|Public health schools encompass programs that confer degrees related to public health practice or research, covering disciplines like epidemiology, biostatistics, health policy, environmental health, ethics, occupational health, global health, and others, including BSc, MPH, DrPH, and MSc.
62281466|NCT00744445|ACTIVE_COMPARATOR|0800|r-HuEPO administered at 0800 hrs
62649437|NCT02631941|EXPERIMENTAL|A-B2-B1-D-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62082168|NCT05129631|EXPERIMENTAL|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD. HEARTPrep consists of three distinct modules: Adjusting, Connecting, and Preparing. Each module targets one distinct primary outcome (emotional distress, social isolation, parenting self-efficacy) and a common secondary outcome (hope) through a suite of evidence-based intervention elements (e.g., psychoeducation, cognitive restructuring, mindfulness) for addressing emotional problems in other populations, including pregnant women. HEARTPrep elements include: a) telehealth with a psychosocial provider, b) recorded videos, c) educational tools, and d) links to resources.
62082169|NCT06094010|EXPERIMENTAL|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
62082170|NCT06056219|ACTIVE_COMPARATOR|Mirror therapy using a mirror box|30 minutes' exercise of mirror therapy followed by 20 minutes' task-oriented training
62082171|NCT06056219|EXPERIMENTAL|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' activity of virtual reality-based mirror therapy with rhythmic skill training followed by 20 minutes' task-oriented training
62281467|NCT00744445|ACTIVE_COMPARATOR|1500|r-HuEPO administered at 1500 hrs
62281468|NCT00744445|ACTIVE_COMPARATOR|2200|r-HuEPO administered at 2200 hrs
62281469|NCT02986087|EXPERIMENTAL|Fetal Tracheal Occlusion|Fetuses with severe or moderate congenital diaphragmatic hernia will be offered fetal tracheal occlusion to increase lung growth.
62281470|NCT05434832|EXPERIMENTAL|Virtual Reality Group|watching the cartoon by wearing virtual reality glass to the child during the intramuscular injection
62458611|NCT05389943|ACTIVE_COMPARATOR|Postmenopausal women|Postmenopausal women having serum 25-hydroxy vitamin D \[25(OH)D\] greater than 32 ng/ml will provided with milk and dietary modifications.
62281471|NCT05434832|EXPERIMENTAL|Local cold-vibration Group|The local cold-vibration device is placed 5 cm above the area to be injected
62281472|NCT05434832|NO_INTERVENTION|Control Group|standart care
62281473|NCT01381159|EXPERIMENTAL|Motivational Communication|Up to 3 x 30 minute brief MC sessions within 4-6 week period
62281474|NCT01381159|PLACEBO_COMPARATOR|Control|Usual care
62281475|NCT05104047|ACTIVE_COMPARATOR|Traditional Moxibustion|Participants receive Active Traditional Moxibustion - a protocol aimed at reducing neuropathic pain/discomfort.
62458612|NCT03400930||OptiDiag-Cohort, Liberia|A respresentative population of 275 Liberian children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC \< 115, 75 of which have a WHZ \< -3 and 75 of which have both a MUAC \< 115 mm and a WHZ \< -3).
62082172|NCT05554367|EXPERIMENTAL|Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)|Patients receive palbociclib PO QD on days 1-21 and binimetinib PO BID on days 1-28 of each cycle. throughout the trial. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 3 years. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
62281476|NCT05104047|ACTIVE_COMPARATOR|Smokeless Moxibustion|Participants receive Active Smokeless Moxibustion - a protocol aimed at reducing neuropathic pain/discomfort.
62649438|NCT02631941|EXPERIMENTAL|B1-A-C-B2-D|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62649439|NCT02631941|EXPERIMENTAL|C-B1-D-A-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~1. Treatment A: Z7200 without oral activated charcoal~2. Treatment B1: Symbicort 1 without oral activated charcoal~3. Treatment B2: Symbicort 2 without oral activated charcoal~4. Treatment C: Z7200 with oral activated charcoal~5. Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
62082173|NCT05554367|EXPERIMENTAL|Monotherapy Cohort 1 (binimetinib)|Patients receive binimetinib PO BID daily, in the absence of disease progression or unacceptable toxicity, for up to 3 years. Patients who experience disease progression may elect to migrate to the combination cohort. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
62082174|NCT04666129|EXPERIMENTAL|Part 1: Relugolix plus Abiraterone plus a Corticosteroid|Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.
62649440|NCT02789371|OTHER|Arm A|the first pass is made with 5ml suction technique
62649441|NCT02789371|OTHER|Arm B|the first pass is made with modified wet suction technique
62649442|NCT02433990||Adult Congenital Heart Disease|18 years and older with congenital heart disease
62649443|NCT06228404|EXPERIMENTAL|Enhanced autologous PSMA-CAR T:|Enhanced autologous PSMA-CAR T is an electrotransfer system based on non-viral transposons that integrates the CAR gene into the genome of host cells by electrotransfer using PMSA as a target, while this CAR vector co-expresses enhanced factors and plays a strong regulatory role in innate and adaptive immunity.
62649444|NCT02808988|ACTIVE_COMPARATOR|group A|periodontal phase 1 therapy consisted of scaling and root planning, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
62649445|NCT02808988|ACTIVE_COMPARATOR|group B|periodontal phase 1 therapy consisted of scaling and root planning, no bisphosphonate therapy,gingival crevicular fluid collection
62649446|NCT02808988|ACTIVE_COMPARATOR|group C|no periodontal phase 1 therapy, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
62281477|NCT05104047|PLACEBO_COMPARATOR|Placebo Moxibustion Control|"Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not.~Note. All participants randomized to the Control will be offered active protocol moxibustion treatments, at no cost, at the end of their study participation."
62281478|NCT05104047|NO_INTERVENTION|Waitlist Control|"WaitList (Control) No treatment. Subjects receive all aspects of study participation with the exception of exposure to Moxibustion.~Note. All participants randomized to the Control will be offered active protocol moxibustion treatments, at no cost, at the end of their study participation."
62649447|NCT02808988|ACTIVE_COMPARATOR|group D|no periodontal phase 1 therapy, no bisphosphonate therapy,gingival crevicular fluid collection
62649448|NCT01872962|EXPERIMENTAL|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
62649449|NCT01872962|ACTIVE_COMPARATOR|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
62649450|NCT00681200|ACTIVE_COMPARATOR|Enhanced health education program|This active treatment group consists of classes in health education and a social support group to enhance participant motivation and positive reinforcement to make healthier lifestyle choices (e.g. wholesome diet, increased exercise, reduced salt intake, and decreased use of alcohol and smoking). Note that this comparison group does not have a stress management component.
62649451|NCT00681200|EXPERIMENTAL|Transcendental Meditation program|Transcendental Meditation program plus health education. Basic American Heart Association (AHA) recommendations for lifestyle modification to reduce risk of heart disease will be given in a didactic classroom context.
62082175|NCT04666129|EXPERIMENTAL|Part 2: Relugolix plus Apalutamide|Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.
62082176|NCT04666129|EXPERIMENTAL|Part 3: Relugolix plus Docetaxel with or without Prednisone|Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.
62082177|NCT06211036|EXPERIMENTAL|Tarlatamab in Combination With Durvalumab|Participants will receive tarlatamab once every 2 weeks (Q2W) and durvalumab once every 4 weeks (Q4W).
62082178|NCT06211036|ACTIVE_COMPARATOR|Durvalumab Alone|Participants will receive durvalumab Q4W alone.
62082179|NCT06049797||Neurokinin 3 Receptor (NK3-R) Antagonist|Participants prescribed NK3-R Antagonist for the treatment of VMS.
62649452|NCT06378177|EXPERIMENTAL|LVGN6051combined with toripalimab and paclitaxel|LVGN6051 in combination with toripalimab and paclitaxel
62649453|NCT02825823|EXPERIMENTAL|Ketone Salts|Acute dose of beta-hydroxybutyrate potassium/sodium salt (0.2g beta-hydroxybutyrate/kg, 0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
62649454|NCT02825823|PLACEBO_COMPARATOR|Placebo|Acute dose of taste-matched placebo (0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
62082180|NCT06049797||Selective serotonin reuptake inhibitor (SSRI)/Serotonin and norepinephrine reuptake inhibitor (SNRI)|Participants prescribed SSRI/SNRI for the treatment of VMS.
62082181|NCT06049797||Other|Participants prescribed something other than NK3-R Antagonist or SSRI/SNRI for the treatment of VMS.
62082182|NCT06148532||PRC Database|EHR records for hospital delivery admissions and postpartum readmissions obtained from Perinatal Research Consortium (PRC) sites to be harmonized with SDoH data and analyze to optimize sepsis risk prediction.
62082183|NCT01282021||Region 1|Northern part: Gonder, Gojam, Tigray
62082184|NCT01282021||Region 2|Southern Ethiopia: Bale, Sidamo, Gambela
62082185|NCT01282021||Region 3|Northeastern and Southeastern Ethiopia
62082186|NCT06736912|EXPERIMENTAL|Part I(Cohort I) IN-114199 2.5 mg or Placebo|SAD
62281479|NCT01898182|EXPERIMENTAL|Kinerase|Kinetin (N6-furfuryladenine) is an essential bio growth factor that regulates cell growth and is proven to delay and reverse the signs of aging. Kinerase has been found out to significantly improve the appearance of skin texture, mottled hyperpigmentation and fine wrinkles. It does not cause the cutaneous side effects that result from other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin.
62082187|NCT06736912|EXPERIMENTAL|Part I(Cohort 2) IN-114199 5 mg or Placebo|SAD and FES
62082188|NCT06736912|EXPERIMENTAL|Part I(Cohort 3) IN-114199 10 mg or Placebo|SAD and FES
62082189|NCT06736912|EXPERIMENTAL|Part I(Cohort 4) IN-114199 20 mg or Placebo|SAD and FES
62082190|NCT06736912|EXPERIMENTAL|Part I(Cohort 5) IN-114199 40 mg or Placebo|SAD
62082191|NCT06736912|EXPERIMENTAL|Part II(Cohort I) IN-114199 2.5 mg or Placebo|MAD
62281480|NCT02350803|PLACEBO_COMPARATOR|distraction osteogenesis|treatment of maxillary deficiency was done just by distraction osteogenesis and no mini plate was used after removal of distractor
62281481|NCT02350803|ACTIVE_COMPARATOR|distraction osteogenesis+ mini plate|treatment of maxillary deficiency was done just by distraction osteogenesis and after removal of distractor 4 mini plate L shaped was used after removal of distractor as an intervention
62281482|NCT04630379|EXPERIMENTAL|Group A (visit with neuro-oncologist)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months to address concerns that are identified via the survey and the domain of concern identified by patient and caregiver.
62281483|NCT04630379|EXPERIMENTAL|Group B (visit with neuro-oncologist and palliative care team)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist and palliative care team monthly for 6 months to address concerns that are identified by the survey and domains of concerns. Caregivers also attend support sessions led by a social worker monthly for 6 months.
62082192|NCT06736912|EXPERIMENTAL|Part II(Cohort 2) IN-114199 5 mg or Placebo|MAD
62082193|NCT06736912|EXPERIMENTAL|Part II(Cohort 3) IN-114199 10 mg or Placebo|MAD
62082194|NCT06736912|EXPERIMENTAL|Part II(Cohort 4) IN-114199 20 mg or Placebo|MAD
62082195|NCT01313442||1/ Cohort 1|Subjects with a diagnosis of cancer
62082196|NCT03604978|EXPERIMENTAL|Cohort A (nivolumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.
62082197|NCT03604978|EXPERIMENTAL|Cohort B (nivolumab, ipilimumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.
62082198|NCT05594992|EXPERIMENTAL|JR-141 2.0 mg/kg/week|
62082199|NCT06097650|EXPERIMENTAL|cold snare polypectomy|cold snare polypectomy for resection of small pedunculated colorectal polyps
62082200|NCT06097650|ACTIVE_COMPARATOR|hot snare polypectomy|hot snare polypectomy for resection of small pedunculated colorectal polyps
62082201|NCT05136651|EXPERIMENTAL|Immediate Treatment|Couples assigned to the Immediate Treatment condition will begin the OurRelationship program immediately following random assignment.
62082202|NCT05136651|OTHER|Waitlist Control|Couples assigned to the Waitlist Control condition will begin the OurRelationship program following a 2-month delay after random assignment.
62082203|NCT01031407||Group 1|Healthy Volunteers
62281484|NCT04630379|ACTIVE_COMPARATOR|Group C (visit with neuro-oncologist, palliative care team)|Patients and primary caregiver complete quality of life portion of the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months and address important concerns that come up on the survey. Patients may also receive palliative care consultation as deemed appropriate by the neuro-oncologist.
62281485|NCT00984750|EXPERIMENTAL|1|Statin and acetyl-L-carnitine
62281486|NCT00984750|PLACEBO_COMPARATOR|2|Statin and placebo
62281487|NCT05683483|EXPERIMENTAL|Surgical WEsleep|Patients admitted into the 3 surgical departments/clusters where the WEsleep interventions are implemented.
62281488|NCT05683483|EXPERIMENTAL|Medical WEsleep|Patients admitted into the 3 non-surgical departments/clusters where the WEsleep interventions are implemented
62281489|NCT05683483|NO_INTERVENTION|Surgical Standardcare|Patients admitted into the 3 surgical departments/clusters where the WEsleep interventions are NOT implemented, and patients are receiving standardcare
62082204|NCT01031407||Group 2|Individuals with Autism Spectrum Disorders
62082205|NCT01031407||Group 3|Parents of Healthy Volunteers, or Individuals with Autism Spectrum Disorders
62082206|NCT05784740|EXPERIMENTAL|Exercise Intervention|Patients will participate in a 12-week (36 sessions) precision exercise training intervention
62082207|NCT05784740|NO_INTERVENTION|Attention Control|Patients will not receive exercise training but will be contacted 1x per week via phone to document self-reported physical activity and general wellbeing.
62082208|NCT06170671||Cohort 1|December 2023 - collecting data retrospectively from patients routinely initiated on acalabrutinib between January - December 2023
62082209|NCT06170671||Cohort 2|December 2024-collecting data retrospectively from patients routinely initated on acalabrutinib between January - December 2024
62082210|NCT05384561|EXPERIMENTAL|Chemosensory training group 1|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, Orange, and eugenol, for a total of five minutes per session.
62281490|NCT05683483|NO_INTERVENTION|Medical Standardcare|Patients admitted into the 3 non-surgical departments/clusters where the WEsleep interventions are NOT implemented, and patients are receiving standardcare
62281491|NCT00699348|EXPERIMENTAL|C.E.R.A.|
62649455|NCT01592214|EXPERIMENTAL|Part 1 #2-XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|4 subjects: 2.0 mg/g concentrations of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 2.4 mg.
62082211|NCT05384561|EXPERIMENTAL|Chemosensory training group 2|For 12 weeks, morning and evening, smell four odors namely coffee aroma, cheese aroma, strawberries, and limon, for a total of five minutes per session.
62082212|NCT05522868|OTHER|Cohort 1|SB17170 initial dose: 300 mg/d per day, 3 to 6 subjects per cohort
62281492|NCT03575715|EXPERIMENTAL|EBUS group|EBUS and guide sheath (GS) are inserted into bronchi in the assistance of navigation bronchoscopy. The EBUS probe and GS are confirmed to reach the lesion by EBUS images, cytologic and pathologic specimens are obtained with or without fluoroscopic guidance.
62281493|NCT02670265|ACTIVE_COMPARATOR|Parenteral nutrition|Active Comparator: Olimel peri 2.5% ® 1l/d (700 kcal/d) (Baxter GmbH, Unterschleißheim, Germany)
62281494|NCT02670265|PLACEBO_COMPARATOR|Isotonic fluid|Isotonic fluid 1l/d (E153, Berlin-Chemie AG, Berlin, Germany)
62281495|NCT03742349|EXPERIMENTAL|1: spartalizumab + LAG525 + NIR178|phase Ib (escalation and expansion)
62281496|NCT03742349|EXPERIMENTAL|2: spartalizumab +LAG525 +capmatinib|phase Ib (escalation and expansion)
62281497|NCT03742349|EXPERIMENTAL|3: spartalizumab + LAG525 + MCS110|phase Ib (escalation and expansion)
62082213|NCT05522868|OTHER|Cohort 2|SB17170 dose: 600 mg/d per day, 3 to 6 subjects per cohort
62082214|NCT05522868|OTHER|Cohort 3|SB17170 dose: 1000 mg/d per day, 3 to 6 subjects per cohort
62082215|NCT05522868|OTHER|Cohort 4|SB17170 dose: 1500 mg/d per day, 3 to 6 subjects per cohort
62082216|NCT05522868|OTHER|Cohort 5|SB17170 dose: 2000 mg/d per day, 3 to 6 subjects per cohort
62082217|NCT05008042|ACTIVE_COMPARATOR|Mecobalamine 5 mg/ml|The active substance of vitamin B12 given in the study is Mecobalamin 5mg / ml 2 ml ie 10 mg and is given intramuscularly.
62082218|NCT05008042|PLACEBO_COMPARATOR|NaCl 9mg/ml|Placebo substance given in the study is Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) given intramuscularly.
62082219|NCT04306367|EXPERIMENTAL|Experimental|"Pembrolizumab Q3W, IV infusion (day 1 of each 3 week cycle)~Olaparib bid, Oral tablet continuously"
62082220|NCT05324371|EXPERIMENTAL|Device Arm|WATCHMAN FLX™ device implantation
62281498|NCT03742349|EXPERIMENTAL|4: spartalizumab +LAG525 +canakinumab|phase Ib (escalation and expansion)
62281499|NCT02132104|EXPERIMENTAL|amnion graft in severe IUA|patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
62281500|NCT02132104|SHAM_COMPARATOR|non-amnion graft in severe IUA|patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
62281501|NCT05933538|EXPERIMENTAL|Cariprazine monotherapy|
62281502|NCT05933538|ACTIVE_COMPARATOR|Treatment as usual|
62281503|NCT01132209|ACTIVE_COMPARATOR|Large tissue bites|As control the conventional large bites technique (mass closure) will be applied in with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
62082221|NCT06225297|EXPERIMENTAL|Intervention clusters|"will receive the following interventions:~1. Distribution of meganets, defined as conventional insecticide-treated nets (ITNs) sewn together to adapt to taalibés sleeping conditions~2. Three monthly cycles of targeted chemoprevention with dihydroartemisinin-piperaquine (DHA-PQ) for all daara residents, regardless of resident age~3. Social behavior change (SBC) to promote intervention uptake"
62082222|NCT06225297|NO_INTERVENTION|Control clusters|"will receive standard-of-care malaria interventions, which include:~1. Distribution of conventional ITNs~2. Three monthly cycles of SMC with sulfadoxine-pyrimethamine- amodiaquine (SP-AQ) given to children 3-120 months"
62082223|NCT03759522|EXPERIMENTAL|Healthy Controls|
62082224|NCT03759522|EXPERIMENTAL|Fibromyalgia Subjects|
62082225|NCT03759522|EXPERIMENTAL|Chronic Fatigue Syndrome Subjets|
62082226|NCT03759522|EXPERIMENTAL|Multiple Sclerosis Subjects|
62082227|NCT02310399|EXPERIMENTAL|Pre-lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years
62082228|NCT02310399|EXPERIMENTAL|Post-Lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children \< 21 years of age
62082229|NCT06740994|EXPERIMENTAL|paramedian landmark group|conventional landmark paramedian approach will be performed. isobar bupivacaine will be injected for continuous spinal anesthesia.
62082230|NCT06740994|ACTIVE_COMPARATOR|Midline ultrasound group|preprocedural ultrasound guided midline approach will be performed. isobar bupivacaine will be injected for continuous spinal anesthesia.
62082231|NCT04936321|ACTIVE_COMPARATOR|Sleep Education + CBT for Pain|Participants will receive access to internet-delivered sleep education during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
62649456|NCT01592214|PLACEBO_COMPARATOR|Part 2 #4-Placebo in 4% Klucel® gel, concentration 0 mg/g|12 subjects: a placebo in 4% Klucel® gel intranasally to both nares in a volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5.
62082232|NCT04936321|EXPERIMENTAL|CBT for Insomnia + CBT for Pain|Participants will receive access to internet-delivered CBT for insomnia during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
62082233|NCT01265641|EXPERIMENTAL|1|
62082234|NCT01265641|EXPERIMENTAL|2|
62082235|NCT01265641|EXPERIMENTAL|3|
62082236|NCT01265641|PLACEBO_COMPARATOR|4|
62082237|NCT05348733||Participants diagnosed with CKD and T2D|Participants who are newly prescribed finerenone under routine treatment conditions.
62082238|NCT06643169|EXPERIMENTAL|Experimental Group|8-week home-based fall prevention program with multifactorial intervention
62082239|NCT06643169|NO_INTERVENTION|Control Group|
62082240|NCT06362967|EXPERIMENTAL|antibody desensitisation group|Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG
62082241|NCT06738537||Patients with MR|We will recruit patients with degenerative mitral regurgitation (MR) who are presenting to a surgeon or cardiologist for consultation regarding management of their valve disease.
62458613|NCT03400930||OptiDiag/MANGO-Cohort, Burkina Faso|A respresentative population of 275 Burkinabé children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC \< 115, 75 of which have a WHZ \< -3 and 75 of which have both a MUAC \< 115 mm and a WHZ \< -3).
62082242|NCT06738537||Health Care Providers|We will recruit Health Care providers (cardiac surgeons and cardiologists) who evaluate and treat patients with mitral regurgitation.
62082243|NCT06738537||Multidisciplinary Mitral Valve Heart Team|We will recruit members of multidisciplinary mitral valve heart teams including cardiac surgeons, cardiologists, nurses, and ancillary staff. These providers will be involved in caring for patients who presents to multidisciplinary heart teams for evaluation of their mitral valve disease.
62082244|NCT05975099|EXPERIMENTAL|mRNA-1975: Dose 1|Participants will receive 3 intramuscular (IM) injections of the mRNA-1975 vaccine at Dose Level 1 on Days 1, 57, and 169.
62082245|NCT05975099|EXPERIMENTAL|mRNA-1975: Dose 2|Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 2 on Days 1, 57, and 169.
62082246|NCT05975099|EXPERIMENTAL|mRNA-1975: Dose 3|Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose Level 3 on Days 1, 57, and 169.
62082247|NCT05975099|EXPERIMENTAL|mRNA-1975: Dose 4|Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 4 on Days 1, 57, and 169.
62458614|NCT03400930||OptiDiag-cohort, Bangladesh|A respresentative population of 275 Bangladeshi children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC \< 115, 75 of which have a WHZ \< -3 and 75 of which have both a MUAC \< 115 mm and a WHZ \< -3).
62082248|NCT05975099|EXPERIMENTAL|mRNA-1982: Dose 1|Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 1 on Days 1, 57, and 169.
62082249|NCT05975099|EXPERIMENTAL|mRNA-1982: Dose 2|Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 2 on Days 1, 57, and 169.
62082250|NCT05975099|EXPERIMENTAL|mRNA-1982: Dose 3|Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose level 3 on Days 1, 57, and 169.
62082251|NCT05975099|PLACEBO_COMPARATOR|Placebo|Participants will receive 3 IM injections of vaccine-matching placebo on Days 1, 57, and 169.
62082252|NCT04261712|EXPERIMENTAL|Paltusotine|
62082253|NCT04612751|EXPERIMENTAL|Cohort 1|Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
62082254|NCT04612751|EXPERIMENTAL|Cohort 2|Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
62281504|NCT01132209|EXPERIMENTAL|small tissue bites|In the other group of 288 patients the small bites technique will be applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
62281505|NCT05313867|PLACEBO_COMPARATOR|Placebo|1 sequence of 10 tablets containing only excipients
62281506|NCT05313867|EXPERIMENTAL|Trace elements|Nutri VX1 in a single dose (1 sequence of 10 tablets). Nutri VX1 is a complex of trace elements with the status of a food supplement.
62082255|NCT04612751|EXPERIMENTAL|Cohort 3|Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
62082256|NCT04612751|EXPERIMENTAL|Cohort 4|Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
62082257|NCT04612751|EXPERIMENTAL|Cohort 5|Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC
62082258|NCT04612751|EXPERIMENTAL|Cohort 6|Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC
62082259|NCT04612751|EXPERIMENTAL|Cohort 7|Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC
62082260|NCT04612751|EXPERIMENTAL|Cohort 8|Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC
62082261|NCT04612751|EXPERIMENTAL|Cohort 9|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC
62082262|NCT04612751|EXPERIMENTAL|Cohort 10|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC
62082263|NCT04612751|EXPERIMENTAL|Cohort 11|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 in participants with treatment-naïve NSCLC
62082264|NCT04612751|EXPERIMENTAL|Cohort 12|Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC
62082265|NCT04612751|EXPERIMENTAL|Cohort 13|Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC
62082266|NCT04612751|EXPERIMENTAL|Cohort 14|Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with treatment-naïve NSCLC
62082267|NCT04612751|EXPERIMENTAL|Cohort 4A|Datopotamab deruxtecan (Dato-DXd) + Durvalumab + carboplatin in participants with treatment-naïve NSCLC
62082268|NCT06731062|EXPERIMENTAL|EF192A|EF192A will be distributed on a contact test filter paper disc, appropriately identified, in the letter of the alphabet corresponding to the experimental product.
62082269|NCT06731062|SHAM_COMPARATOR|Saline Solution|Saline solution - The sterile saline solution (NaCl 0.9%) will be used as control in another contact test filter paper disc, appropriately identified, in the letter of the alphabet corresponding to the control.
62082270|NCT06734962|OTHER|Control group (Without A-PRF)|During the surgery procedure A-PRF application is not intended.
62082271|NCT06734962|EXPERIMENTAL|Test group ( With A-PRF)|During the surgery procedure A-PRF application is intended.
62082272|NCT06035120|EXPERIMENTAL|AeriSeal|All enrolled subjects meeting final eligibility will undergo the AeriSeal procedure to block collateral ventilation by closing the lobar fissure gaps or collateral air channels.
62082273|NCT04699188|EXPERIMENTAL|Arm A|JDQ443
62082274|NCT04699188|EXPERIMENTAL|Arm B|JDQ443 in combination with TNO155
62082275|NCT04699188|EXPERIMENTAL|Arm C|JDQ443 in combination with tislelizumab
62082276|NCT04699188|EXPERIMENTAL|Arm D|JDQ443 in combination with TNO155 and tislelizumab
62082277|NCT05144061|EXPERIMENTAL|Single Arm|HRS2398 Tablets
62082278|NCT05238961|EXPERIMENTAL|Cohort 1 - Critical Asymptomatic Carotid Stenosis Group|Critical Stenosis Group: Diagnosis of Asymptomatic Carotid Artery Disease (aCAD) with \>70% stenosis or peak systolic velocity on duplex ultrasound (DUS) ≥ 230 cm/s plus computed tomography angiography (CTA) or magnetic resonance angiography (MRA) confirmation.
62082279|NCT05238961|EXPERIMENTAL|Cohort 2 - Controls-Non-Critical Asymptomatic Carotid Stenosis Group|\<40% carotid stenosis No planned revascularization
62082280|NCT00001281||Individuals living with HIV|Individuals living with HIV
62082281|NCT00001281||Individuals living with/without HIV|Individuals living with/without HIV
62082282|NCT00001281||Individuals living with/without infectious diseases|Individuals living with/without infectious diseases of interest
62082283|NCT00001281||Individuals with/without Immunodeficiencies|Individuals with/without immunodeficiencies
62082284|NCT04876053|NO_INTERVENTION|Standard Care|
62082285|NCT04876053|EXPERIMENTAL|Healthy Food Delivery Intervention|9000 calorie / week food box
62082286|NCT00233272||Healthy Volunteers|Healthy volunteers over a wide age-range
62082287|NCT06666764|EXPERIMENTAL|NBO|NBO will be conducted with inhalation of 100% oxygen. NBO will be used in conjunction with best medical practice.
62082288|NCT06666764|OTHER|Control|Best medical treatment
62082289|NCT04910087|ACTIVE_COMPARATOR|Group K: Ketofol|"A ketofol mixture of 15 cc propofol 2%, 2 cc ketamine 50 mg/ml, and 13 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through perfuser device. (at a ratio of 100 mg ketamine/300 mg propofol) After the loading dose is administered at 1 mg/kg IV in 5 minutes based on propofol, 0.5 cc/kg/hour ketofol infusion will be initiated.~If patients cannot tolerate the ERCP procedure or have a BIS value \>85 or FPS (Faces Pain Scale)\> 3, 0.25 mg/kg propofol will be administered as a separate IV push."
62082290|NCT04910087|ACTIVE_COMPARATOR|Group P: Propofol|"A propofol mixture of 15 cc propofol 2% and 15 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through the perfuser device.~After the loading dose is administered at 1 mg/kg IV propofol in 5 minutes ,0.5 cc/kg/hour propofol infusion will be initiated.~If patients cannot tolerate the ERCP procedure or have a BIS value \>85 or FPS (Faces Pain Scale)\> 3, 0.25 mg/kg propofol will be administered as a separate IV push"
62082291|NCT05992896|EXPERIMENTAL|Liposomal Bupivacaine Group|Subjects will receive an injection of liposomal bupivacaine during clinically indicated lower extremity revascularization surgery.
62082292|NCT05992896|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive an injection of placebo during clinically indicated lower extremity revascularization surgery.
62458615|NCT02925364||No pain|patients who are enrolled in the parent study and report no chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
62458616|NCT02925364||Pain|Patients who are enrolled in the parent study and report chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
62649457|NCT01592214|ACTIVE_COMPARATOR|Part 2 # 3-XF-73 in 4% Klucel® gel, concentration 0.5 mg/g:|12 subjects: a modified 4% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
62082293|NCT01375114|EXPERIMENTAL|Panax Ginseng|Panax ginseng 400 mg by mouth twice a day from Day 1-29 for first 30 participants in Part 1. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
62082294|NCT01375114|EXPERIMENTAL|Ginseng (Part 2)|Panax ginseng 400 mg by mouth twice a day from Day 1-29. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
62649458|NCT01592214|EXPERIMENTAL|Part 2 #2- XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|12 subjects; a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 2.0 mg/g and volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 3.6 mg on Day 1 and 2.4 mg on Days 2 to 5.
62649459|NCT01592214|EXPERIMENTAL|Part 2 #1- XF-73 in 2 % Klucel® gel, concentration 0.5 mg/g|12 subjects: a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
62649460|NCT01592214|EXPERIMENTAL|Part 1 #1-XF-73 in 2% Klucel® gel, concentration 0.5 mg/g:|4 subjects: 0.5 mg/g concentration of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 0.6 mg.
62458617|NCT01424644|PLACEBO_COMPARATOR|Placebo + Tdap + HPV|This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
62082295|NCT01375114|PLACEBO_COMPARATOR|Placebo (Part 2)|Oral placebo twice daily for 4 weeks. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
62082296|NCT06473779|EXPERIMENTAL|Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS|Asthma Control or Low Biomarkers - Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2
62082297|NCT06473779|EXPERIMENTAL|Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS|Asthma Control or Low Biomarkers - No Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2
62082298|NCT06473779|EXPERIMENTAL|Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS|No Asthma Control or Low Biomarkers - No Step-down of ICS
62082299|NCT04193293|EXPERIMENTAL|Duvelisib + Pembrolizumab|"Stage 1: Duvelisib twice daily (BID) for 1 week followed by combination therapy with duvelisib BID + pembrolizumab every 3 weeks (q3w) (Cycle 1 was 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib; subsequent cycles were 3 weeks).~Stage 2: Duvelisib BID + pembrolizumab q3w in 3-week cycles."
62082300|NCT06736860|ACTIVE_COMPARATOR|1+1 control group|Early prehospital administration of TXA 1 g intravenously followed by a continuous infusion of 1 g tranexamic acid (TXA) over 8 hours
62082301|NCT06736860|EXPERIMENTAL|1+X the case group|Early prehospital administration of TXA 1 g , then using thromboelastography (TEG) to assess the need for a second or even multiple administrations of TXA ( 1+X regimen) in addition to the administration of 1 g of TXA intravenously
62082302|NCT06713304|EXPERIMENTAL|A Community-Based Protective Behavioral Strategies Program|Participants receive the community-based Protective Behavioral Strategies program
62082303|NCT06713304|NO_INTERVENTION|Control Group|Participants receiving the usual care
62082304|NCT06188208|EXPERIMENTAL|Dose Escalation: VVD-130850 Single Agent|Participants will receive ascending doses of VVD-130850, orally, once daily in 21-day treatment cycles during the dose escalation phase.
62082305|NCT06188208|EXPERIMENTAL|Dose Escalation: VVD-130850 + Pembrolizumab Combination Therapy|Participants will receive ascending doses of VVD-130850, orally, once daily, along with pembrolizumab intravenous (IV) infusion, every 3 weeks (Q3W) in 21-day treatment cycles during the dose escalation phase.
62082306|NCT06188208|EXPERIMENTAL|Dose Expansion: VVD-130850 Single Agent|Participants will receive VVD-130850 at recommended dose for expansion (RDE), orally, once daily in 21-day treatment cycles during the dose expansion phase.
62281507|NCT03228160|EXPERIMENTAL|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
62281508|NCT03228160|SHAM_COMPARATOR|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
62281509|NCT03504592|EXPERIMENTAL|Glooko App|Glooko application and meter compatibility device (if required)
62281510|NCT03504592|ACTIVE_COMPARATOR|Traditional Care|Traditional clinic reporting system: paper/MyChart/emailed glucose logs
62649461|NCT02643277|OTHER|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
62082307|NCT06188208|EXPERIMENTAL|Dose Expansion: VVD-130850 + Pembrolizumab Combination Therapy|Participants will receive VVD-130850 at RDE orally, once daily along with pembrolizumab IV infusion, Q3W in 21-day treatment cycles during the dose expansion phase.
62082308|NCT06739733|EXPERIMENTAL|SRG|
62082309|NCT06739733|ACTIVE_COMPARATOR|EMS|
62082310|NCT06587035||Patients of pediatric growth hormone deficiency|
62082311|NCT06464289||Operative|Patients receiving surgical stabilisation of rib fractures (SSRF) by any operative technique
62082312|NCT06464289||Non-operative|Patients not receiving surgical stabilisation of rib fractures (SSRF)
62082313|NCT03141528|ACTIVE_COMPARATOR|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
62082314|NCT03141528|EXPERIMENTAL|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
62082315|NCT00614198|EXPERIMENTAL|Gluten- and casein-free diet|Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
62281511|NCT01228903|PLACEBO_COMPARATOR|Control|Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
62281512|NCT01228903|ACTIVE_COMPARATOR|Allopurinol|Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
62281513|NCT00264004|EXPERIMENTAL|1|30 mg AZD2171
62281514|NCT00264004|EXPERIMENTAL|2|45 mg AZD2171
62082316|NCT00614198|NO_INTERVENTION|No dietary intervention|Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).
62082317|NCT05956938|EXPERIMENTAL|Action Video game Group|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
62082318|NCT05956938|EXPERIMENTAL|Stroboscopic Glasses Group|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus). The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz).
62281515|NCT04396509||women giving birth by normal vaginal delivery|100 women delivered vaginally. . They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
62281516|NCT04396509||women giving birth by c-section|100 delivered with cesarean section. They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
62281517|NCT01916629|ACTIVE_COMPARATOR|Photocil for Psoriasis|Active Drug - Photocil for Psoriasis
62281518|NCT01916629|PLACEBO_COMPARATOR|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
62281519|NCT04205890|EXPERIMENTAL|Ketamine|The present study is designed as a prospective data analysis of patient response to the use of ketamine to treat treatment-resistant depression. For Phase I trail, 10 patients of any gender with an age range of 18 to 70 who have undergone the outlined procedure will be recruited for inclusion. A week before the scheduled ketamine treatment, the patients will have fMRI scans, including structural T1, Arterial Spin Labeling, and Resting BOLD. The scans take around 30 minutes at no charge to the patients. The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage will vary (see below) depending on every individual's unique treatment plan. The same scans will be taken two days after treatment.
62281520|NCT02924662||Kellgren and Lawrence classification I|Grade I Kellgren and Lawrence radiographic changes.
62649462|NCT02643277|EXPERIMENTAL|Mobile phone text messaging|The intervention will receive text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring. The messages provide tips and suggestions, and positive reinforcement or encouragement, for improving lifestyle behaviors and compliance with therapy.
62649463|NCT05928923|EXPERIMENTAL|cpap|usage cpap 3 months
62082319|NCT05956938|NO_INTERVENTION|Control Group|Participants in the control group will watch 1 video clip/series/film of 1 hour duration on a television located at least 1.5 meters away.
62082320|NCT06329518|EXPERIMENTAL|Rezafungin|Participants will receive one dose of rezafungin as per current prescribing information.
62082321|NCT03866772|ACTIVE_COMPARATOR|MISOPROSTOL|"* oral misoprostol, 50 microgram, every 4 hours~* Repeat treatment every 4 hours until active labour begins: regular painful contractions (≥ 3 in 10 min), cervical dilatation ≥ 3 cm~* maximal number of doses: 6~* Oxytocin infusion can be initiated 4 hours after the last dose of Misoprostol.~* Failure of induction will be considered if no cervical change nor uterine contractions have begun during 24 hours of treatment.~* Electronic fetal monitoring should be performed for 30 min after administration of misoprostol and 60 min after any tachysystole."
62082322|NCT03866772|ACTIVE_COMPARATOR|DOUBLE BALLOON|"* Insertion of the DBD as instructed by the manufacturer, removal after 6 hours.~* Artificial rupture of membranes (AROM) if suitable + IV oxytocin administration~* If AROM cannot be performed- oxytocin infusion will be initiated at first.~* If Bishop \<3 after DBD removal, clinical evaluation and lag time before considering other methods for ripening is suitable and is up to the physician on call."
62082323|NCT03866772|ACTIVE_COMPARATOR|MISOPROSTOL+DOUBLE BALLOON|
62082324|NCT03027505|EXPERIMENTAL|MUAC<125mm|no medical complication
62281521|NCT02924662||Kellgren and Lawrence classification II|Grade II Kellgren and Lawrence radiographic changes.
62281522|NCT02924662||Kellgren and Lawrence classification III|Grade III Kellgren and Lawrence radiographic changes.
62281523|NCT02924662||Kellgren and Lawrence classification IV|Grade IV Kellgren and Lawrence radiographic changes.
62281524|NCT05348798||Ultra endurance athletes|Individual participating in ultra endurance sports (events exceeding 6 hours) including running, cycling, triathlon, swimming and Nordic skiing. Participants are above 18 years of age and volunteer to participate in this web-based survey.
62281525|NCT05618743|NO_INTERVENTION|Control Group|Periodontally and systemically healthy participants (Control group)
62281526|NCT05618743|EXPERIMENTAL|Periodontitis without Cardiovascular disease|Periodontitis participants without cardiovascular disease
62281527|NCT05618743|EXPERIMENTAL|Periodontitis with cardiovascular disease|Periodontitis participants with cardiovascular disease
62281528|NCT04882397|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|In the application group, Instrument Assisted Soft Tissue Mobilization will be applied to the Trapezius and Sternocleideomastoideus muscles for 90 seconds.
62649464|NCT05928923|NO_INTERVENTION|Usual care|Usual care 3smonths
62082325|NCT06741007|EXPERIMENTAL|Single arm study using ICG as a sentinel lymph node agent in early stage endometrium cancer|Single arm study using ICG as a sentinel lymph node agent to detect the location of SLN in correlation with the presence or absence of superficial or deep uterine vein in early stage endometrial cancer
62082326|NCT06134128|EXPERIMENTAL|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|Motivationally Enhanced Compensatory Cognitive Training for Addictions (ME-CCT-A) is a manualized group-based behavioral intervention (8 weeks, 2 hour per week) designed to improve cognitive functioning in Veterans with substance use disorders (SUDs) and cognitive complaints.
62281529|NCT04882397|SHAM_COMPARATOR|Sham Instrument Assisted Soft Tissue Mobilization|In the sham application group, 90 degrees to 90 seconds will be applied to the Trapezius and Sternocleideomastoideus muscles without applying pressure.
62281530|NCT04882397|NO_INTERVENTION|Control|No application will be made to the control group.
62281531|NCT03783260|EXPERIMENTAL|Single|All participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
62281532|NCT03135847|EXPERIMENTAL|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
62082327|NCT06736938|ACTIVE_COMPARATOR|Interventional Bronchoscopy|eg., laser therapy, endotracheal/endobronchial debulking, visual biopsies, mucosal biopsies, or transbronchial biopsies guided by echo-endoscopy such as EBUS or EUS
62281533|NCT02176707||Idiopathic pulmonary fibrosis sufferers|
62281534|NCT02667080|ACTIVE_COMPARATOR|Ejaculate 1|Semen sample after 2-7 days of sexual abstinence
62281535|NCT02667080|ACTIVE_COMPARATOR|Ejaculate 2|Semen sample after 2 hours of sexual abstinence
62281536|NCT05560932|EXPERIMENTAL|HIV Medications and Alcohol Use|Participants with HIV who take 5 or more medications and currently (within the past month) consume alcohol
62281537|NCT05849870|ACTIVE_COMPARATOR|Comprehensive Geriatric Assessment (CGA)|Participants in this arm will undertake a Comprehensive Geriatric Assessment, and will be implemented based on Comprehensive Geriatric Assessment Toolkit for Primary Care Practitioners from the British Geriatrics Society. A personalised action plan will be developed and implemented based on the CGA.
62281538|NCT05849870|EXPERIMENTAL|Integrated Care for Older PEople (ICOPE)|Participants in this arm will undertake the assessment recommended by the World Health Organisation, and will be implemented by the publicly available app. A personalised action plan will be developed and implemented based on the ICOPE.
62281539|NCT05849870|EXPERIMENTAL|Identification and Management of frailty and sarcopenia|Participants in this arm will undertake the assessment recommended by the International Conference on Frailty and Sarcopenia Research Clinical Practice Guidelines for Identification and Management of physical frailty (ICFSR). A personalised action plan will be developed and implemented based on the ICFSR.
62281540|NCT05849870|EXPERIMENTAL|Functional Fitness Battery (FFB)|Participants in this arm will undertake a Functional Fitness Battery, comprising physical assessments on the intrinsic capacity, lifestyle and nutritional status
62281541|NCT05849870|NO_INTERVENTION|Usual Care|Participants in this arm will not receive an intervention, but the usual care provided by the primary care provider.
62281542|NCT02307682|EXPERIMENTAL|Brolucizumab 3 mg|Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
62082328|NCT06736938|ACTIVE_COMPARATOR|Non-bioptic Bronchoscopy|such as bronchial lavage, bronchoalveolar lavage or endobronchial lavage.
62281543|NCT02307682|EXPERIMENTAL|Brolucizumab 6 mg|Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
62281544|NCT02307682|ACTIVE_COMPARATOR|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
62281545|NCT01332682|EXPERIMENTAL|Resistance Training and Nutrition Counseling|
62281546|NCT01332682|OTHER|Nutrition Counseling|
62281547|NCT04880928|EXPERIMENTAL|injection solution|Mydrane, Tropicamid 0,02%, Phenylephrine 0,31%, Lidocain 1%, injection solution
62281548|NCT04880928|ACTIVE_COMPARATOR|Standard eye Drops|Phenylephrine 10% and Tropicamid 0,5% eye drops
62281549|NCT04803760||mild disability|Those whose neck disability index value is 25 and below
62281550|NCT04803760||high disability|Those whose neck disability index value is 25 and above
62649465|NCT04693403|EXPERIMENTAL|High-flow oxygen nasal cannula (HFNC)|In the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier and applied continuously through large-bore bi-nasal prongs, with a gas flow rate of 40-60 liters per minute and adjusted based on the clinical response.
62082329|NCT05107401|EXPERIMENTAL|Crowdsourced Intervention|The digital crowdsourced intervention will be presented to participants in the intervention arm.
62281551|NCT00911131|ACTIVE_COMPARATOR|Screening esophagoduodenoscopy (EGD)|"EGD will be performed utilizing conscious sedation. During EGD, the endoscopist will capture pictures of the esophageal body, Z-line, lower esophagus and proximal gastric folds. Grading of esophageal varices will be performed by all investigators using the Italian Liver cirrhosis project.~Patients who are found to have small grade varices and meet the inclusion and exclusion criteria will be enrolled in the study."
62458618|NCT01424644|EXPERIMENTAL|MenACWY-CRM + Tdap + HPV|This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
62458619|NCT05318157|EXPERIMENTAL|Sublingual Immunotherapy group|
62458620|NCT05318157|EXPERIMENTAL|Drugs treatment group|
62458621|NCT05778513||Cases|Male subjects with obesity
62082330|NCT05107401|NO_INTERVENTION|Standard of Care|Standard HIV informational materials currently used by the Kazakhstan Ministry of Health will be presented to participants in the control arm.
62082331|NCT06533098|EXPERIMENTAL|Arm 1: Nipocalimab|Maternal participants with alloantibodies against HPA-1a and/or HPA-5b will be randomized to receive nipocalimab starting at gestational age (GA) week 13 to 16 until before delivery.
62082332|NCT06533098|EXPERIMENTAL|Arm 2: Intravenous Immunoglobins (IVIG)|Maternal participants with alloantibodies against HPA-1a and/or HPA-5b will be randomized to receive IVIG from GA week 12 for high-risk pregnancies or GA week 20 for standard-risk pregnancies. Additionally, prednisone will be added per study protocol.
62082333|NCT06032416|OTHER|Shoulder Arthroplasty|Patients in need of a shoulder arthroplasty
62082334|NCT05105009|EXPERIMENTAL|All KDIGO stages and healthy volunteers|15 healthy volunteers and 35 through all KDIGO stages.
62082335|NCT06385210|EXPERIMENTAL|Semi structured interviews|Semi-structured interviews with topic guides centred around the Non adoption, abandonment, scale-up, spread, and sustainability (NASSS) framework will be led by a member of the research team and conducted with all participants. The aim of the interviews is to explore perceived barriers to the uptake of routine surgical video recording. Transcripts will be subsequently thematically analysed using an inductive approach to determine key themes to the barriers of routine surgical video recording.
62082336|NCT06469359|EXPERIMENTAL|FLOQSwab, Copan Diagnostics|Nasal cells are collected in both nostrils using one FLOQSwab per nostril
62082337|NCT06469359|EXPERIMENTAL|Rhino-Pro Curette, Arlington Scientific|Nasal cells are collected in both nostrils using one curette per nostril
62082338|NCT06469359|EXPERIMENTAL|Cervical brush, Microm Microtech|Nasal cells are collected in both nostrils using one brush per nostril
62082339|NCT05419830|ACTIVE_COMPARATOR|AM (morning) antihypertensive dosing arm or Control arm|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
62082340|NCT05419830|EXPERIMENTAL|BBTI arm|participants will receive the behavioral treatment for insomnia BBTI by the study nurse. Participants will also be asked to take their antihypertensive medication within an hour of awakening
62281552|NCT00911131|ACTIVE_COMPARATOR|Capsule Endoscopy|The capsule endoscope will be swallowed by the participant with 100cc of water and simethicone in the supine position. Recording is done for 2 minute in this position and then the head will be elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient will sip10cc of water and after 15 seconds, they will sit upright and sip water again. They can then walk and resume normal activity for 15 minutes. The videos will be reviewed and graded by a gastroenterologist experienced with capsule endoscopy and will be blinded to the patient's clinical and procedural history as well as the most recent EGD. The varices will be graded using the Given Imaging software that grades varices as no varices (C0), small varices or \< 25% of esophageal circumference (C1), and large varices or \> 25% of esophageal circumference (C2).
62458622|NCT05778513||Controls|Male subjects without obesity
62082341|NCT05419830|EXPERIMENTAL|PM (evening) antihypertensive dosing or Chronotherapy arm|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
62458623|NCT05178407|EXPERIMENTAL|Multiple micronutrient-fortified bouillon cube|"10-gram shrimp-flavoured bouillon cube, fortified with 6 micronutrients~Enrolled participants will receive a household bouillon ration for use in daily cooking (ad lib). Bouillon rations will be replenished every 2 weeks for the study duration of 38 weeks (non-pregnant, non-lactating women 15-49 y and children 2-5 y) or 12 weeks (lactating women 15-49 y and 4-18 mo postpartum)."
62458624|NCT05178407|PLACEBO_COMPARATOR|Control bouillon cube (iodine only)|"10-gram shrimp-flavoured bouillon cube, fortified with iodine~Enrolled participants will receive a household bouillon ration for use in daily cooking (ad lib). Bouillon rations will be replenished every 2 weeks for the study duration of 38 weeks (non-pregnant, non-lactating women 15-49 y and children 2-5 y) or 12 weeks (lactating women 15-49 y and 4-18 mo postpartum)."
62082342|NCT06602232|EXPERIMENTAL|DL1 of DR-01|Subjects in this arm will receive up to 6 months of dosing with DR-01 at dose level 1
62082343|NCT06602232|EXPERIMENTAL|DL2 of DR-01|Subjects in this arm will receive up to 6 months of dosing with DR-01 at dose level 2
62082344|NCT06602232|EXPERIMENTAL|DL-3 of DR-01|Subjects in this arm will receive up to 6 months of dosing with DR-01 at dose level 3
62082345|NCT05881005|OTHER|open-label study|hepatic MRI, Fibroscan
62082346|NCT03595787|EXPERIMENTAL|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
62082347|NCT03935750|EXPERIMENTAL|BPTB + LET|Patients will undergo anterior cruciate ligament reconstruction (ACLR) using a bone patellar bone tendon (BPTB) autograft with lateral extra-articular tenodesis (LET).
62082348|NCT03935750|ACTIVE_COMPARATOR|BPTB alone|Patients will undergo ACLR using a BPTB autograft without LET.
62082349|NCT03935750|EXPERIMENTAL|QT + LET|Patients will undergo ACLR using a quadriceps tendon (QT) autograft with LET.
62082350|NCT03935750|ACTIVE_COMPARATOR|QT alone|Patients will undergo ACLR using a QT autograft without LET.
62082351|NCT06364163|EXPERIMENTAL|Herring oil concentrate|Dietary supplement: herring oil concentrate in capsules, 4 g oil daily for 8 weeks
62082352|NCT06364163|PLACEBO_COMPARATOR|Control oil|Dietary supplement: control oil in capsules, 4 g oil daily for 8 weeks
62082353|NCT06215911|EXPERIMENTAL|Tovinontrine (CRD-750) - low dose|
62082354|NCT06215911|EXPERIMENTAL|Tovinontrine (CRD-750) - medium dose|
62082355|NCT06215911|EXPERIMENTAL|Tovinontrine (CRD-750) - high dose|
62281553|NCT00911131|ACTIVE_COMPARATOR|Capsule Endoscopy with abdominal binder|Before swallowing the capsule endoscope, an inflatable girdle is wrapped around the waist above the umbilicus and held in place by a an abdominal binder. The pressure is increased by 10mmHg for 10 minutes. The PillCam ESO is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
62281554|NCT02678715|EXPERIMENTAL|Sequence SB-CA-SM|Solubrux®+ Customized Appliance + Somatics®
62281555|NCT02678715|EXPERIMENTAL|Sequence SB-SM-CA|Solubrux®+Somatics®+Customized Appliance
62281556|NCT02678715|EXPERIMENTAL|Sequence CA-SB-SM|Customized Appliance+Solubrux®+Somatics®
62281557|NCT02678715|EXPERIMENTAL|Sequence CA-SM-SB|Customized Appliance+Somatics®+Solubrux®
62281558|NCT02678715|EXPERIMENTAL|Sequence SM-SB-CA|Somatics®+Solubrux®+Customized Appliance
62281559|NCT02678715|EXPERIMENTAL|Sequence SM-CA-SB|Somatics®+ Customized Appliance+Solubrux®
62649466|NCT04693403|EXPERIMENTAL|Continuous positive airway pressure (CPAP)|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment. CPAP will be started at 7.5 cm of water. The level will be decreased to 5 cm of water or increased to 10 cm of water as needed based on the clinical response and tolerance.
62649467|NCT04693403|ACTIVE_COMPARATOR|Standard Low flow Oxygen Arm|Patients assigned to the standard treatment group will receive oxygen delivered through a Non-rebreather face mask until endotracheal intubation, death, or fulfillment of oxygen delivery cessation criteria (an oxygen saturation by pulse oximetry (SpO2) above 92% without oxygen and a respiratory rate below 25 cycles/min).
62649468|NCT01868646|EXPERIMENTAL|Subetta|
62281560|NCT03132584|EXPERIMENTAL|Cyclophosphamide and Alemtuzumab|"After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~* Cyclophosphamide~* Alemtuzumab"
62281561|NCT00375102|EXPERIMENTAL|Acup|Acupuncture
62281562|NCT00375102|EXPERIMENTAL|RR|Relaxation Response
62281563|NCT00375102|NO_INTERVENTION|UC|Usual Care
62281564|NCT04491656|ACTIVE_COMPARATOR|7 minutes group|surgeries performed with this group would wait 7 minutes after lidocaine+epinephrine injection prior to skin incision
62281565|NCT04491656|ACTIVE_COMPARATOR|30 minutes group|surgeries performed with this group would wait 30 minutes after lidocaine+epinephrine injection prior to skin incision
62281566|NCT03072693|ACTIVE_COMPARATOR|Group 1|Home-based remote heart failure management
62281567|NCT03072693|PLACEBO_COMPARATOR|Group 2|Home-based physiological parameter recording only
62281568|NCT04177719|EXPERIMENTAL|Oxytocin|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
62281569|NCT04177719|PLACEBO_COMPARATOR|Placebo|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
62281570|NCT02765451|ACTIVE_COMPARATOR|A : 1 year of intervention|interventions of Cancéropôle Nord-Ouest during 1 year after an observational period of 2 years.
62649469|NCT01868646|PLACEBO_COMPARATOR|Placebo|
62082356|NCT06215911|PLACEBO_COMPARATOR|Placebo|
62082357|NCT06128564|EXPERIMENTAL|Delandistrogene Moxeparvovec|Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1.
62082358|NCT05166811|ACTIVE_COMPARATOR|75 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 75 mg/kg arm, this will be accomplished by mixing 37.5 mL of IVMg (80 mg/mL) with 2.5 mL of sterile water for a final concentration of 75 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
62082359|NCT05166811|ACTIVE_COMPARATOR|50 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 50 mg/kg arm, this will be accomplished by mixing 25 mL of IVMg (80 mg/mL) with 15 mL of sterile water for a final concentration of 50 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
62082360|NCT05166811|PLACEBO_COMPARATOR|Placebo|For the placebo arm, 40 mL of 0.9% sodium chloride solution will be drawn into a polyvinylchloride container identical in appearance to the containers used for the IVMg arms. After randomization the institutional pharmacist will draw dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
62082361|NCT05716763|EXPERIMENTAL|Tramadol hydrochloride 5mg/mL oral solution (IMP 08P1902F0)|
62082362|NCT05716763|ACTIVE_COMPARATOR|Tramadol hydrochloride 100mg/mL oral solution (Contramal(r))|
62082363|NCT06492512|EXPERIMENTAL|1) Daily dose of ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|daily (Group 1) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
62082364|NCT06492512|EXPERIMENTAL|2) Alternate daily dose of ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|alternate day (Group 2) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
62082365|NCT04843813|EXPERIMENTAL|Lutein|
62649470|NCT05429840|EXPERIMENTAL|Part 1 MT1980|
62649471|NCT05429840|PLACEBO_COMPARATOR|Part 1 Placebo|
62649472|NCT05429840|EXPERIMENTAL|Part 2 MT1980 Dose Level 1|
62649473|NCT05429840|EXPERIMENTAL|Part 2 MT1980 Dose Level 2|
62649474|NCT05429840|PLACEBO_COMPARATOR|Part 2 Placebo|
62649475|NCT05748899|EXPERIMENTAL|group number 1|Group number 1 will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
62082366|NCT04843813|PLACEBO_COMPARATOR|Safflower Oil|
62082367|NCT06738355|EXPERIMENTAL|Automated Intervention (Auto)|Auto intervention participants will be eligible for outreach delivered using automated phone calls, text, or email messages with the mode, frequency, timing of reminders, and message content refined using BCT. Automated outreach may also include innovative communication strategies, such as text-linked videos, P/C, or patient narratives (based on BCT). Auto outreach to P/C will invite P/Cs to attend free HPV vaccination visits and emphasize family-friendly hours.
62649476|NCT05748899|NO_INTERVENTION|group number 2|The group number 2 will not receive pranayama training, so it serves as control lupus group
62649477|NCT05084391|EXPERIMENTAL|Phase I:|Phase I there will be up to 15 patients treated with SABR and followed for 6 months post-treatment to ensure no significant acute grade 3 or 4 toxicity from SABR treatment.
62082368|NCT06738355|EXPERIMENTAL|Automated Intervention Plus (Auto-Plus)|Auto-Plus intervention participants will be eligible for automated reminders, plus additional P/C prompts for patients who do not undergo vaccination within three weeks. These prompts may be delivered via live phone call outreach or patient navigation. Working with clinic leadership and using the findings of BCT, activities will be selected from a list of possible options from the National HPV Vaccination Roundtable (previously chaired by Dr. Brewer) and our ranking of the effectiveness of language- and culturally- tailored intervention materials.
62082369|NCT06738355|NO_INTERVENTION|Usual Care (UC)|The UC group will not receive tailored reminders but will only receive opportunistic vaccine reminders that are delivered during clinic visits or MyChart EHR-based patient portal reminders.
62281571|NCT02765451|ACTIVE_COMPARATOR|B : 2 years of intervention|interventions of Cancéropôle Nord-Ouest during 2 years after an observational period of 1 year.
62281572|NCT01136499|EXPERIMENTAL|LBH PANOBINOSTAT|40 mg 3 days per week
62281573|NCT02735629|EXPERIMENTAL|CX1739 - 300 mg|Study Drug - low dose
62281574|NCT02735629|PLACEBO_COMPARATOR|Placebo|Placebo
62281575|NCT02735629|EXPERIMENTAL|CX1739 - 600 mg|Study drug - mid Dose
62281576|NCT02735629|EXPERIMENTAL|CX1739 - 900 mg|Study drug - high dose
62281577|NCT04135898|EXPERIMENTAL|SIBP-04|
62281578|NCT04135898|ACTIVE_COMPARATOR|Bevacizumab|
62281579|NCT00289107|ACTIVE_COMPARATOR|1|P.F.C.® Sigma™ Rotating Platform Cruciate Substituting Knee System
62281580|NCT00289107|ACTIVE_COMPARATOR|2|P.F.C.® Sigma™ Fixed Cruciate Substituting Knee System
62281581|NCT04202731|EXPERIMENTAL|Sleep Extension|Participants will be asked to extend their time in bed with the goal of improving the total time they sleep each night.
62649478|NCT05084391|EXPERIMENTAL|Phase II|Phase II portion with 25 patients in each arm assigned to SABR or current practice (standard of care)
62281582|NCT00690885|EXPERIMENTAL|1|lozenges containing 150 IU of natural human interferon-alpha
62281583|NCT00690885|PLACEBO_COMPARATOR|2|matching placebo lozenges
62281584|NCT00807755|EXPERIMENTAL|Phase I Dose-Escalation|This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.
62281585|NCT04424069|ACTIVE_COMPARATOR|LASIK group|Patients will do excimer laser LASIK operation for correction of myopia with flap creation by mechanical keratome
62281586|NCT04424069|ACTIVE_COMPARATOR|SMILE group|Patients will do Femtosecond laser assisted corneal refractive surgery for correction of myopia
62281587|NCT04424069|ACTIVE_COMPARATOR|Photorefractive keratectomy group|Patients that will undergo photorefractive keratectomy for correction of myopia
62281588|NCT04424069|ACTIVE_COMPARATOR|Refractive lens exchange|Include eyes that will undergo refractive lens exchange
62281589|NCT04424069|NO_INTERVENTION|Control group|Myopic control eyes with no surgical intervention
62458625|NCT06198374|EXPERIMENTAL|PA Intervention.|The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.
62649479|NCT02899520|ACTIVE_COMPARATOR|Group A|Reference method
62649480|NCT02899520|EXPERIMENTAL|Group B|CMP ® method (Knowledge and Control of Perineum)
62649481|NCT06517381|EXPERIMENTAL|Digital Online Warning Signs of Mental Illness Literacy Program|30-minute pre-recorded educational video with interactive question-and-answer sessions
62649482|NCT06551402|ACTIVE_COMPARATOR|dabigatran|100 CVT patients will receive dabigatran 150mg Bid for 6 months.
62082370|NCT06509152|EXPERIMENTAL|ToM-SCGI-12|The ToM-SCGI-12 is designed as a 12-week group intervention, with 60-minute sessions held weekly and led by trained therapists. Each group consists of 3 to 6 children with ASD, assigned based on assessments of children's age, verbal IQ, theory of mind abilities, and social skills. Caregivers can observe the children's performance in the group and document the group's themes and contents using observation and feedback forms. Caregiver meetings are conducted in the 6th and 12th weeks of the intervention to discuss the children's progress, enhance caregivers' interaction skills, and motivate continued practice at home. After the intervention concludes, caregivers' feedback is also collected through questionnaires to emphasize the role of family in the intervention.
62281590|NCT04756713|ACTIVE_COMPARATOR|Chemotherapy|Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
62281591|NCT04756713|EXPERIMENTAL|Uterine evacuation|Patients randomized to undergo a second curettage will undergo manual or electronic vacuum aspiration under ultrasound guidance. Following discharge after the second curettage patients will return to weekly hCG monitoring. If hCG levels are decreasing, patients will remain on weekly hCG follow-up until the first normal hCG (\<5 IU/L) is achieved. Then they will have monthly hCG monitoring for 12 months. If patients do not attain remission and develop persistent GTN as established by FIGO 2000, the tumor will be re-staged and appropriate chemotherapy will be initiated.
62281592|NCT01230957|EXPERIMENTAL|Group 1|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
62281593|NCT01230957|EXPERIMENTAL|Group 2|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
62281594|NCT01230957|EXPERIMENTAL|Group 3|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
62281595|NCT01230957|EXPERIMENTAL|Group 4|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
62281596|NCT01230957|PLACEBO_COMPARATOR|Group 5|Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
62281597|NCT01230957|EXPERIMENTAL|Group 6|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
62281598|NCT01230957|EXPERIMENTAL|Group 7|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
62458626|NCT06198374|PLACEBO_COMPARATOR|Placebo Intervention|The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.
62082371|NCT06509152|ACTIVE_COMPARATOR|ToM-SCGI-6|The ToM-SCGI-6 is designed as a 6-week group intervention, with two 60-minute sessions held weekly and led by trained therapists. Each group consists of 3 to 6 children with ASD, assigned based on assessments of children's age, verbal IQ, theory of mind abilities, and social skills. Caregivers can observe the children's performance in the group and document the group's themes and contents using observation and feedback forms. Caregiver meetings are conducted in the 6th and 12th weeks of the intervention to discuss the children's progress, enhance caregivers' interaction skills, and motivate continued practice at home. After the intervention concludes, caregivers' feedback is also collected through questionnaires to emphasize the role of family in the intervention.
62082372|NCT06509152|NO_INTERVENTION|Control group|The control group participated in conventional occupational therapy that did not focus on theory of mind or social competence. The duration and length of the intervention were the same as those of the experimental group.
62082373|NCT04622020||Adult patients with chronic neck pain (> 3 months) following whiplash injury|Cervical plexus block with local anaesthesia followed by Cervical Plexus block with depot steroids
62082374|NCT05879068|EXPERIMENTAL|PM8002+Paclitaxel|Subjects will be administered with PM8002 plus Paclitaxel via intravenously (IV) Q3W for 5 cycles, followed by PM8002 until disease progression or intolerable toxicity for a maximum of 2 years.
62281599|NCT04658394|EXPERIMENTAL|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.
62281600|NCT04658394|NO_INTERVENTION|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
62281601|NCT05029063|EXPERIMENTAL|Experimental|Rivaroxaban 10mg OD
62281602|NCT05029063|PLACEBO_COMPARATOR|Control|Identical Placebo 10mg OD
62281603|NCT06108362|EXPERIMENTAL|experimental group|Continuous terlipressin infusion，Use a syringe to dilute to 50ml Infusion speed is 2ug/kg\*h, From the beginning to the end of the surgery.
62281604|NCT06108362|PLACEBO_COMPARATOR|control group|Continuous normal saline infusion，Use a syringe to draw 50ml Infusion speed is 4ml/h, From the beginning to the end of the surgery.
62082375|NCT05934448|EXPERIMENTAL|PEMBROLIZUMAB|"* Participants will undergo (leukapheresis) for manufacturing of commercial product as per standard of care (SOC) Cycle 1 Day -21or earlier~* Pembrolizumab will be administered per protocol on cycle 1 day -20 and on day +1 following Chimeric Antigen Receptor (CAR) Therapy Infusion infusion, every 3 weeks for up to 2 years, unless there is confirmed progression of disease or unacceptable toxicity.~* Upon the completion of successful manufacturing, patients will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for chimeric antigen receptor (CAR) therapy infusion as per SOC.~* Participants will receive Chimeric Antigen Receptor (CAR) Therapy Infusion (SOC) on day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator."
62082376|NCT06740708|EXPERIMENTAL|SCALE-NCD (Intervention)|"Intervention arm will receive the following two components of the SCALE-NCD intervention package:~1. FCHV home visits every three months, including measurements, counseling and referral;~2. Mobile phone messages, including lifestyle modification"
62082377|NCT06740708|NO_INTERVENTION|Control|Control arm will receive the usual care in Pokhara Metropolitan City in Nepal.
62082378|NCT05921760|EXPERIMENTAL|Safety Lead-In Phase - ivosidenib|First phase of the study.
62458627|NCT00605930|ACTIVE_COMPARATOR|Pyruvate, creatine, niacinamide|Pyruvate, creatine, niacinamide administered
62458628|NCT00605930|PLACEBO_COMPARATOR|Placebo|placebo
62458629|NCT04791150|EXPERIMENTAL|Patient with cancer immunotherapy treatment|All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment.
62649483|NCT06551402|ACTIVE_COMPARATOR|rivaroxaban|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months.
62082379|NCT05921760|EXPERIMENTAL|Experimental Phase - Cohort 1|Second phase of the study. Cohort 1 will include the anti-PD1/L1-naïve subpopulation.
62082380|NCT05921760|EXPERIMENTAL|Experimental Phase - Cohort 2|Second phase of the study. Cohort 2 will include the anti-PD1/L1 previously treated subpopulation.
62649484|NCT04422067||Case group (Retrognatism)|All pregnant patients with one or more fetuses suffering from a microretrognathia, diagnosed prenatally and integrated into a Pierre Robin Sequence, were included. All cases were confirmed postnatally, either by a pediatric examination or by a fetopathological examination in the case of a medical termination of the pregnancy. We had 21 cases.
62649485|NCT04422067||Control group|47 pregnant patients with fetus without facial abnormalities
62281605|NCT04208854||VINORELBINA|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
62281606|NCT04154059|EXPERIMENTAL|Intervention Group|Patients will receive a physical therapy intervention three times per week, for 8 weeks.
62458630|NCT02048306|EXPERIMENTAL|Family-based PR group|
62458631|NCT02048306|ACTIVE_COMPARATOR|Conventional PR group|
62458632|NCT00677365|PLACEBO_COMPARATOR|Placebo|Placebo inhaled either once or twice daily via the PARI eFlow nebulizer for 28 days
62082381|NCT05009979|EXPERIMENTAL|1/Baseline and Post-treatment Imaging|18F-DCFPyL PET/CT imaging, CT and/or MRI and standard of care local ablative treatment
62082382|NCT05121038|EXPERIMENTAL|Cohort 1 Pancreatic Cancer|Biopsy for tissue immune profile if archived tissue not available. Folfirinox infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus CEND-1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
62281607|NCT04154059|NO_INTERVENTION|Control Group|Patients will not receive any exercise treatment but they will keep their recommended clinical treatment.
62281608|NCT00721084||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
62281609|NCT00721084||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
62281610|NCT01906125|EXPERIMENTAL|Palbociclib given to Healthy Volunteers|
62281611|NCT00062387|EXPERIMENTAL|Arm I|Patients receive oral perifosine 4 times daily on days 1 and 2 and once daily on days 3-28 during course 1. Patients receive oral perifosine once daily on days 1-28 for all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62281612|NCT00454805|ACTIVE_COMPARATOR|2|Fulvestrant Monotherapy
62281613|NCT00454805|EXPERIMENTAL|3|AZD2171 + Fulvestrant
62281614|NCT00916240|EXPERIMENTAL|1|Participants will receive Multisystemic Therapy (MST).
62281615|NCT00916240|ACTIVE_COMPARATOR|2|Participants will receive home-based, non-directive family support.
62281616|NCT00382993|OTHER|Combination Product - Placebo|Combination Product (sumatriptan and naproxen sodium) \[Attack 1\] followed by Placebo \[Attack 2\]
62281617|NCT00382993|OTHER|Placebo - Combination Product|Placebo \[Attack 1\] followed by Combination Product (sumatriptan and naproxen sodium) \[Attack 2\]
62281618|NCT04503876|ACTIVE_COMPARATOR|Decremental PEEP titration following an ARM|PEEP will be titrated in a stepwise decremental fashion following a standardized alveolar recruitment maneuver (ARM). The ARM is a progressive increase of intra-thoracic pressure (pressure controlled mode), with a constant driving pressure of 10 cmH2O and PEEP steps (10-15-20-25-30-35 and 40 cmH2O), reaching a maximum pressure of 50 cmH2O, allowing full recruitment. PEEP steps will be conducted every 2 cmH2O (from 20 to 6 cmH2O), every 5 minutes.
62281619|NCT04503876|ACTIVE_COMPARATOR|Incremental PEEP titration without any previous ARM|PEEP will be titrated in a stepwise incremental fashion without any previous alveolar recruitment maneuver (ARM). PEEP steps will be conducted every 2 cmH2O (from 6 to 20 cmH2O), every 5 minutes.
62281620|NCT05780671||Oxygen receiving group|patients diagnosed as headcahe related to migraine without aura who received supplemental oxygen together with the standart theraphy
62281621|NCT05780671||standart group|patients diagnosed as headcahe related to migraine without aura who received standart theraphy only.
62281622|NCT05399316|ACTIVE_COMPARATOR|Inulin|15g of powdered inulin is given in a sachet. The powder is dissolved in water and consumed
62281623|NCT05399316|PLACEBO_COMPARATOR|Maltodextrin|15g of powdered maltodextrin is given in a sachet. The powder is dissolved in water and consumed
62281624|NCT01270399||malignant neoplasm's cells|
62649486|NCT03553147|EXPERIMENTAL|Group/Cohort 1|all patient SARC-F score, handgrip test and impedancemetry
62082383|NCT05121038|EXPERIMENTAL|Cohort 2 Peritoneal Mets|Biopsy for tissue immune profile if archived tissue not available. Folfirinox plus Panitumumab (if RAS/BRAF) infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus Panitumumab (if RAS/BRAF positive) and CEND-1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
62082384|NCT05121038|EXPERIMENTAL|Cohort 3 Oligomets Colon Cancer|Biopsy for tissue immune profile if archived tissue not available. Folfirinox plus Panitumumab (if RAS/BRAF) infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus Panitumumab (if RAS/BRAF positive) and CEND-1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
62082385|NCT06229236|EXPERIMENTAL|Diabetes Navigator|Support and guidance of Diabetes Navigator in addition to standard care
62082386|NCT06229236|NO_INTERVENTION|Standard of Care|Standard care provided by the healthcare staff during routine diabetes clinic visits.
62082387|NCT02724878|EXPERIMENTAL|Bevacizumab And Atezolizumab Combination|"1200 mg of Atezolizumab intravenously x 3 weeks~15 mg/kg of Bevacizumab intravenously x 3 weeks.~One cycle will be 3 weeks in duration."
62649487|NCT03210740|EXPERIMENTAL|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
62649488|NCT03210740|PLACEBO_COMPARATOR|Vehicle Cream|A white to off-white Cream free from any foreign particles
62281625|NCT01270399||natural cells|
62281626|NCT04193371|EXPERIMENTAL|active acupuncture + lifestyle management|Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.
62281627|NCT04193371|SHAM_COMPARATOR|control acupuncture + lifestyle management|Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.
62281628|NCT01540799|EXPERIMENTAL|Treatment|
62281629|NCT01540799|OTHER|Other|Stimulation not able to be felt
62281630|NCT04911010|EXPERIMENTAL|Experimental: Prolonged Exposure + Treatment as usual|"Participants in this arm will receive 16 weekly sessions with Prolonged Exposure Therapy (RT) over 4 months in addition to their treatment as usual.~Interventions:~Behavioral: Prolonged Exposure Therapy Other: Treatment as usual"
62649489|NCT04881643|EXPERIMENTAL|Blended treatment for PTSD|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
62649490|NCT02411643|OTHER|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
62649491|NCT00587067|EXPERIMENTAL|1|
62649492|NCT01860859|OTHER|Unlocked double layer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium.
62649493|NCT01860859|OTHER|Locked single layer closure|As reported in Williams Obstetrics textbook
62649494|NCT01860859|OTHER|Locked double layer|Double layer closure with a first continuous locked suture and a second imbricating continuous suture.
62082388|NCT04298281||Parents of patients who have a family care conference criteria|These will be parents of patient who have one of our defined family care conference criteria
62281631|NCT04911010|NO_INTERVENTION|Waiting-Controll-Group|"Treatment as usual Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally.~Intervention: Other: Treatment as usual"
62281632|NCT03078465|EXPERIMENTAL|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
62458633|NCT00677365|EXPERIMENTAL|MP-376 120 mg QD|MP-376 120 mg inhaled Once Daily (QD) via the PARI eFlow nebulizer for 28 days
62458634|NCT00677365|EXPERIMENTAL|MP-376 240 mg QD|MP-376 240 mg inhaled QD bia the PARI eFlow nebulizer for 28 days
62082389|NCT04298281||Parents of patients who do not have a family care conference criteria|These will be parents of patients who do not have one our defined family care conference criteria
62281633|NCT03078465|ACTIVE_COMPARATOR|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
62458635|NCT00677365|EXPERIMENTAL|MP-376 240 mg BID|MP-376 240 mg inhaled twice daily (BID) via the PARI eFlow nebulizer for 28 days
62458636|NCT00932750|PLACEBO_COMPARATOR|MOS Weight maintenance|
62458637|NCT00932750|PLACEBO_COMPARATOR|MOS weight loss|
62281634|NCT03326141|ACTIVE_COMPARATOR|Otago+PAM+Health / Wellness topics|"Condition 1:~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
62281635|NCT03326141|EXPERIMENTAL|Otago + PAM + Interpersonal strategies|"Condition 2:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
62281636|NCT03326141|EXPERIMENTAL|Otago, PAM, Intrapersonal strategies|"Condition 3:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
62458638|NCT02569073|EXPERIMENTAL|Dronabinol|Patients who receive Dronabinol 5 mg, every other night, orally.
62458639|NCT02569073|PLACEBO_COMPARATOR|Placebo|Patients who receive Placebo every other night, orally
62458640|NCT05425888||Hemophilia group|Group of adult patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy
62458641|NCT05425888||Control group|Group of healthy subjects with sociodemographic characteristics similar to patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy.
62458642|NCT04500470|EXPERIMENTAL|Group A|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
62458643|NCT04500470|PLACEBO_COMPARATOR|Group B|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table vaginal placebo by the patient 12 hours before the procedure
62082390|NCT06298552|EXPERIMENTAL|Efgartigimod IV|Patients receiving efgartigimod IV in both part A and part B
62082391|NCT06298552|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo during part A and receiving efgartigimod IV during part B
62082392|NCT06727721|PLACEBO_COMPARATOR|The placebo group|The control group was given albumin
62082393|NCT06727721|ACTIVE_COMPARATOR|The control group|The control group was given mesenchymal stem cells
62082394|NCT06727721|EXPERIMENTAL|The experimental group|The experimental group was given OCN-19 stem cells
62082395|NCT06578728|EXPERIMENTAL|Intralesional Methotrexate|Participants receive intralesional methotrexate injections into 1 nail bed/nail matrix every 6 weeks for 3 sessions.
62082396|NCT06578728|ACTIVE_COMPARATOR|Intralesional Triamcinolone Acetonide|Participants receive intralesional triamcinolone acetonide injections into 1 nail bed/nail matrix every 6 weeks for 3 sessions.
62082397|NCT06578728|PLACEBO_COMPARATOR|Intralesional Placebo (saline)|Participants receive intralesional saline injections into 1 nail bed/nail matrix every 6 weeks for 3 sessions.
62281637|NCT03326141|EXPERIMENTAL|Otago,PAM, Inter+Intra strategies|"Condition 4:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
62458644|NCT05748288||Personal Equipment|Participants assigned to use technology they currently own
62458645|NCT05748288||HSG Equipment|Participants provided technology by the sponsor
62458646|NCT00414297|ACTIVE_COMPARATOR|1 ECP|active ECP Therapy
62458647|NCT00414297|PLACEBO_COMPARATOR|2|Sham ECP Treatment
62458648|NCT00301756|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62082398|NCT05274347|EXPERIMENTAL|Multi-faceted virtual, remote intervention|"The intervention will use the Aetonix - aTouchAwayTM software platform (AETONIX Systems Inc). Each study participant will receive a tablet with Aetonix software. Interventions Components:~1. Cognitive behavioral therapy (CBT): After discharge, patients will receive weekly group CBT sessions delivered virtually by a psychologist. Throughout the series of CBT sessions, patients will learn strategies for problem-solving, assertive communication, relaxation, behavioural activation, time-based pacing, challenging unhelpful thinking, building motivation, and goal setting.~2. Remote monitoring of vital signs and symptoms: Messages will be sent to patients asking them to measure their vitals, to report symptoms, and answer questions about medications. Concerning responses will be flagged for review by the patient's healthcare team."
62649495|NCT05802433|EXPERIMENTAL|Control (Low risk genotype)|Participants with no genetic variation in their VDR, GC and CYP2R1 genes that would increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group is a control against the medium and high-risk intervention groups.
62649496|NCT05802433|EXPERIMENTAL|Intervention (Medium risk genotype)|Participants with genetic variation in their VDR, GC and CYP2R1 genes that moderately increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.
62649497|NCT05802433|EXPERIMENTAL|Intervention (High risk genotype)|Participants with genetic variation in their VDR, GC and CYP2R1 genes that increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.
62649498|NCT06249230||Pregnancy success|Patients followed up with a live intrauterine pregnancy beyond 32 weeks were judged as pregnancy success.
62649499|NCT06249230||Pregnancy loss|Patients with histologically confirmed spontaneous abortion by ultrasound or curettage before 28 weeks of gestation, including biochemical pregnancies and embryonic arrests, were judged as pregnancy loss
62649500|NCT05675163|PLACEBO_COMPARATOR|Placebo|matched dose of sunflower oil
62649501|NCT05675163|EXPERIMENTAL|Vitamin K2 low dose|333 μg/d Vitamin K2 (MK-7)
62649502|NCT05675163|EXPERIMENTAL|Vitamin K2 high dose|666 μg/d Vitamin K2 (MK-7)
62649503|NCT02256098|EXPERIMENTAL|ATTUNE™|Total Knee Replacement Surgery with ATTUNE™ Knee Prosthesis by DePuy
62649504|NCT02256098|ACTIVE_COMPARATOR|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
62281638|NCT06237231|EXPERIMENTAL|DIT112|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet DIT112, oral;~1 capsule tramadol placebo, oral;~1 tablet dipyrone placebo, oral."
62649505|NCT05362201|ACTIVE_COMPARATOR|"the therapeutic position of the ARS were determinded by the minimum protrusive position"|"the therapeutic position of the ARS were determinded by the minimum protrusive position,which was the traditional method to fabricate the anterior repositioning splints,the patients were instructed to protrusive the mandible in a therapeutic position in which the click is eliminated."
62281639|NCT06237231|ACTIVE_COMPARATOR|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet dipyrone, oral;~1 tablet DIT112 placebo, oral;~1 capsule tramadol placebo, oral."
62281640|NCT06237231|ACTIVE_COMPARATOR|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 capsule tramadol, oral;~1 tablet dipyrone placebo, oral;~1 tablet DIT112 placebo, oral."
62281641|NCT04272567|SHAM_COMPARATOR|Control group|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
62281642|NCT04272567|EXPERIMENTAL|0.025 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).
62281643|NCT04272567|EXPERIMENTAL|0.05 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).
62281644|NCT04272567|EXPERIMENTAL|0.075 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).
62281645|NCT04272567|EXPERIMENTAL|0.1 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).
62281646|NCT04576598|EXPERIMENTAL|Self-management group to increase physical activity levels|This group will perform a self-management program along 6 months. This program will aim to increase the level of physical activity and adherence to healthier lifestyle habits and will be carried out through several sessions that will incorporate: education, goal setting, identification of barriers, self-control and feedback.
62281647|NCT04576598|ACTIVE_COMPARATOR|Control group|This group will participate in the initial educational session and will be given a leaflet with recommendations for physical activity to follow throughout the six months.
62458649|NCT00613470|EXPERIMENTAL|Citalopram and escitalopram|"Citalopram tablet or solution starting at 20 mg, increase to 40 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5.~Escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5."
62649506|NCT05362201|EXPERIMENTAL|the therapeutic position of the ARS were determinded by the VTO analyse|the therapeutic position of the ARS were determinded by the VTO analyse,first,the participants were constructed to take CBCT and MRI scans,the ideal therapeutic position of the ARS were located in which the temporomandibular joint space distribute well and the condylar recapture the disc,the dentist could determine the amount of condylar movement and performed VTO analyse by assessing the CBCT and MRI scans ,then it could easily realize the final condylar movements with the application of the dental articulator.
62082399|NCT06213272|EXPERIMENTAL|Aerobic Exercise Treatment (AET) combined with Phono-Motor Therapy (PMT)|Patients will receive 40, once-daily 2-hour intervention sessions administered 4-5 times per week by trained research assistants. Sessions will begin with a 5-min warm-up, followed by 20 min of aerobic exercise (cycling, 60% heart rate range), and a 5-min cool-down. Participants will rate their perceived effort every 5 minutes and complete a log at the end of each session to characterize their experience. When HR returns to near resting levels (i.e., 5-min after cool-down), participants will undertake the PMT for the remaining 90 min.
62082400|NCT06213272|ACTIVE_COMPARATOR|Stretching and PMT|Patients will receive 40, once-daily 2-hour intervention sessions administered 4-5 times per week by trained research assistants. Sessions will begin with a 5-min warm-up, followed by 20 min of stretching and a 5-min cool-down. Stretching activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. Participants will complete a log at the end of each session to characterize their experience, and within 5 min of completing the last stretching activity, participants will undertake PMT for the remaining 90 min of a given session.
62082401|NCT06738745|EXPERIMENTAL|HRS-2189 + HRS-5041|All subjects enrolled will receive HRS-2189 + HRS-5041 combination therapy.
62281648|NCT05150548||Entire Cohort|"Patients undergoing elective colectomy with data that has been collected in the NSQIP® Procedure Targeted Colectomy dataset from 2014-2019 with American Society of Anesthesiologists (ASA) Physical Status I-IV.~Patients will not be included in this cohort with urgent or emergency colectomy or indication for colectomy consisting of Acute diverticulitis, Enterocolitis (e.g. C. Difficile), and Volvulus, patients with disseminated cancer, wound infection, systemic sepsis or ventilator-dependence preoperatively."
62281649|NCT05666778|OTHER|Intervention Arm|After completing 12 months observation of usual practices of menstrual hygiene management, all participants will be provided reusable menstrual cups that can be worn during sex. The menstrual cup training is comprised of a 2 hour group session that covers basic information on reproductive health, menstrual health, and menstrual hygiene, cup use (insertion/removal), storage, cleaning. In the first three months after intervention delivery, there are monthly phone calls to assess usage and for trouble shooting. There are 12 months of observation in the menstrual cup arm, with Bacterial vaginosis (BV) and vaginal microbiome (VMB) assessment at the beginning of the 12-month period, at 6 months, and at 12 months. Sexually transmitted infection (STI) is measured at the beginning of the 12- month intervention period, and then at 12 months.
62281650|NCT00727363|PLACEBO_COMPARATOR|1|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
62458650|NCT03377881|OTHER|Standard arm (One testing with PSA and standard biopsy)|The traditional/control arm consists of PSA testing and if PSA\>3ng/ml a systematic biopsy of the prostate is performed. Only one screening is offered for participants.
62458651|NCT03377881|EXPERIMENTAL|STHLM3+MRI/Fusion including repeat screening.|The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions. Participants with PSA\<1.5ng/ml are reinvented for prescreen after 6 years. Remaining participants with no prostate cancer detected are reinvited for re-screen at 2-3 years.
62458652|NCT01375166||Diabetic retinopathy|Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
62458653|NCT01375166||healthy|healthy control subjects
62458654|NCT02401386|EXPERIMENTAL|EB group|Trained and guided by EB certified physicians, patients in EB group received closely supervised, group-format EB program and practiced EB for one hour, twice weekly for 12 weeks in the Guang'anmen Hospital.
62458655|NCT02401386|NO_INTERVENTION|Control group|The participants in usual therapy-controlled group will stay on their previous treatment through 12 weeks. As compensation, they will be invited to receive LEB training for 12 weeks after the end of the study.
62458656|NCT05960409||blunt chest trauma patients|patients with chest injuries due to a blunt trauma
62649507|NCT02657330|EXPERIMENTAL|SBP-101|SBP-101 is administered as a subcutaneous injection once daily, Monday through Friday for 3 weeks (total of 15 doses) followed by a 5-week rest period (3 weeks on, 5 weeks off = 1 treatment cycle). Dose escalation in phase 1a will continue until the maximum tolerated dose is determined.
62458657|NCT05960409||penetrating chest trauma patients|patients with chest injuries due to penetrating trauma
62458658|NCT05960409||polytraumatized patients|patients with multible traumas beside the chest injury
62458659|NCT05960409||chest trauma only patients|patients with only chest injuries
62082402|NCT05520567|EXPERIMENTAL|Dose Ranging Cohort (Phase 1)|Participants will receive daily dose of gilteritinib and venetoclax for 28 days, and azacitidine for 7 days in each 28-day cycle.
62082403|NCT05520567|EXPERIMENTAL|Dose Expansion Cohort (Phase 2)|Participants will receive daily dose of gilteritinib, venetoclax, and azacitidine at an optimized dose established from dose ranging cohort (Phase 1)
62281651|NCT00727363|EXPERIMENTAL|2|5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.
62458660|NCT06484114|OTHER|Training|Sites will gain experience with the study protocol and the Revita DMR procedure in an open-label, single-arm treatment assignment for participants who previously achieved 15% weight loss using a GLP-1
62281652|NCT01612715||Study Population|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the study.
62458661|NCT06484114|ACTIVE_COMPARATOR|Active|Patients who have achieved \>15% weight loss from baseline will receive the Revita DMR Procedure
62458662|NCT06484114|SHAM_COMPARATOR|Sham|Patients who have achieved \>15% weight loss from baseline will receive and endoscopic evaluation and will have a catheter introduced but the Revita DMR procedure will not be performed
62082404|NCT03951467|EXPERIMENTAL|Interventional arm|
62082405|NCT03951467|NO_INTERVENTION|Controlled arm|Patients within this arm will be follow as usual care of the cardiologic unit
62082406|NCT04488055|EXPERIMENTAL|Crisis Line Facilitation (CLF)|This single-session intervention addresses the individuals' perceived barriers and facilitators of crisis line use during periods of suicidal crisis.
62458663|NCT02201225|ACTIVE_COMPARATOR|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
62281653|NCT03369145|EXPERIMENTAL|High-fat diet|Participants will consume a hypercaloric, high-fat diet. Participants will be provided with all the food during the week and will be instructed to consume all of the foods provided and no extra calorie containing food or drink. In the event of leftover food, participants will be asked to return the food for measurement and subsequent subtraction from their total energy intake.
62281654|NCT03369145|NO_INTERVENTION|Control diet|Participants will consume their normal 'habitual' diet for seven days which will be compared to their habitual diet recorded by a three day food diary before commencing the two diets. Participants will be instructed to carry on as normal and eat their usual diet and this period will be used as a comparator to the high-fat diet. They will also be told to record their food intake for 3 days during the diet to quantify their control diet.
62281655|NCT05873985|EXPERIMENTAL|Dynamic tape on experimental group|As a result of randomization, dynamic tape was applied to 25 people with a special technique.
62082407|NCT04488055|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with the NSP Lifeline and a list of outpatient mental health and substance use resources and encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms.
62082408|NCT01834300|EXPERIMENTAL|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
62281656|NCT05873985|PLACEBO_COMPARATOR|Sham tape on placebo group|As a result of randomization, dynamic tape was applied to 26people with a sham technique.
62281657|NCT05438381|ACTIVE_COMPARATOR|ART group|Atraumatic restorative technique: excavation of caries then application of Glass ionomer capsule (GC, USA)
62281658|NCT05438381|EXPERIMENTAL|SMART group|SMART technique: excavation of caries and application of silver diamine fluoride (SDF 38%) then glass ionomer cement
62281659|NCT02425098|EXPERIMENTAL|High-dose Tetravalent Dengue Vaccine (HD-TDV)|High-dose Tetravalent Dengue Vaccine \[HD-TDV\], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2\*10\^4 plaque forming units (PFU), 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
62458664|NCT02201225|SHAM_COMPARATOR|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
62458665|NCT00954915|EXPERIMENTAL|teplizumab|Anti CD-3 monoclonal antibody
62458666|NCT06375408|EXPERIMENTAL|The intervention group|The intervention group was treated with real transcranial alternating electrical stimulation.
62458667|NCT06375408|SHAM_COMPARATOR|The control group|The control group was treated with sham transcranial alternating electrical stimulation.
62082409|NCT01834300|EXPERIMENTAL|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
62082410|NCT06726044|ACTIVE_COMPARATOR|Standard rehabilitation|12 subjects after ACL reconstruction. Subjects participated in standard rehabilitation program twice a week for 12 weeks. Each session lasted approximately 60 minutes.
62082411|NCT06726044|EXPERIMENTAL|Standard rehabilitation and inertial exercises|12 subjects after ACL reconstruction. Subjects participated in standard rehabilitation program twice a week for 12 weeks and additionally performed inertial exercises from the fifth week of rehabilitation. Then each session lasted approximately 70 minutes.
62082412|NCT04590326|EXPERIMENTAL|Module 1|REGN5668 and cemiplimab
62281660|NCT02425098|EXPERIMENTAL|Tetravalent Dengue Vaccine (TDV)|Tetravalent Dengue Vaccine \[TDV\], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2\*10\^4 plaque forming units (PFU), 5\*10\^3 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
62458668|NCT06210269|ACTIVE_COMPARATOR|Antibiotic treatment|Oral moxifloxacin 400 mg once daily for seven days
62458669|NCT06210269|ACTIVE_COMPARATOR|Placebo|Identical oral administration and treatment duration of seven days
62649508|NCT06209918|EXPERIMENTAL|group that recieve bioptron light and advice and patient education|patients will recieve bioptron light therapy for 10 minutes per session, 3 sessions per week, for 4 weeks.
62082413|NCT04590326|EXPERIMENTAL|Module 2|REGN5668 and REGN4018
62082414|NCT04111419|EXPERIMENTAL|Intensive blood pressure and cholesterol control|
62082415|NCT04111419|ACTIVE_COMPARATOR|Intensive blood pressure and routine cholesterol control|
62082416|NCT04111419|ACTIVE_COMPARATOR|Routine blood pressure and intensive cholesterol control|
62082417|NCT04111419|ACTIVE_COMPARATOR|Routine blood pressure and cholesterol control|
62082418|NCT03682991|EXPERIMENTAL|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
62458670|NCT01317927|EXPERIMENTAL|Warfarin, Belinostat|Warfarin 5 mg po will be given on Day -14 and Day 3. Belinostat 1000 mg/m² will be given as a 30 minute IV infusion on Days 1 - 5
62649509|NCT06209918|OTHER|control group that recieve advice and patient education and wrist brace|will keep the wrist in a neutral position, not bent back or bent down too far
62082419|NCT03682991|ACTIVE_COMPARATOR|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
62082420|NCT06586606|EXPERIMENTAL|Period 1: MK-1708|Participants will receive a single oral dose of MK-1708 on Day 1.
62458671|NCT03179345|ACTIVE_COMPARATOR|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
62649510|NCT06474533||Population 1: Participants with intracranial neoplasms|Participants with intracranial neoplasms (glial or metastatic disease) with concern for recurrence or progression on conventional imaging.
62649511|NCT06474533||Population 2: Participants with suspected glial neoplasms|Participants with suspected glial neoplasms (Grade 2 - 4) planning to undergo biopsy or surgery prior to non-investigational, standard-of-care, primary treatment (radiation therapy and/or surgery)
62649512|NCT04726553|EXPERIMENTAL|Anifrolumab plus Standard of Care|Anifrolumab will be added to Standard of Care Treatments for SLE
62082421|NCT06586606|EXPERIMENTAL|Period 2: MK-1708 and Itraconazole|A washout period of at least 10 days will occur between MK-1708 dosing in Period 1 and the first itraconazole dosing in Period 2. In Period 2, participants will receive itraconazole twice daily on Day 1 and once daily on Days 2 through Day 19. Participants will also receive a single oral dose of MK-1708 on Day 4.
62082422|NCT04875078|EXPERIMENTAL|UVA-1 Treated hand|This hand will be treated with UVA-1 phototherapy.
62082423|NCT04875078|NO_INTERVENTION|The untreated hand|This hand will be gloved when the patient undergoes UVA-1 phototherapy treatments.
62281661|NCT02121366|EXPERIMENTAL|Insulinoma|Patients with Insulinomas will received EUS-guided ethanol ablation therapy
62281662|NCT03113305||Gastric bypass patients|Patients planned to undergo Gastric bypass procedure. Patients will be assessed -1 month, 3-, 24-, 48- and 60 months post surgery.
62281663|NCT03113305||Healthy controls|Healthy controls with no planned weight loss/gain. Control participant assessments will be time-matched with patients.
62281664|NCT00865215|EXPERIMENTAL|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
62649513|NCT04726553|PLACEBO_COMPARATOR|Standard of Care|Standard of Care Treatments for SLE
62649514|NCT06190340|EXPERIMENTAL|100 mg TNP-2092 capsules|
62281665|NCT00865215|ACTIVE_COMPARATOR|B|INDERAL® LA 160 mg Capsules, single dose
62458672|NCT03179345|ACTIVE_COMPARATOR|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
62649515|NCT06190340|EXPERIMENTAL|300 mg TNP-2092 capsules|
62649516|NCT06190340|EXPERIMENTAL|600 mg TNP-2092 capsules|
62649517|NCT06190340|PLACEBO_COMPARATOR|Placebo|
62082424|NCT06348719|EXPERIMENTAL|Randomized study: Robot-assisted laparoscopy|Robot-assisted laparoscopic hysterectomy
62082425|NCT06348719|ACTIVE_COMPARATOR|Randomized study: conventional laparoscopy|Conventional laparoscopic hysterectomy
62649518|NCT04270188||anterior sacrospinofixation with autologous tissue|patients with middle and / or anterior prolapse ≥ II in the POP-Q classification and for whom an intervention by anterior sacrospinofixation by autologous tissues is planned.
62082426|NCT06348719|OTHER|Prospective cohort study|Prospective cohort study backed by randomized controlled trial (for patients not included in the trial due to surgeon refusal, absence of learning curve criteria for the surgeon or patient refusal, center unable to participate in the randomized study).
62281666|NCT01052025|EXPERIMENTAL|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
62649519|NCT05016596|PLACEBO_COMPARATOR|placebo|Acacia gum
62649520|NCT05016596|EXPERIMENTAL|turmeric|Turmeric supplement
62649521|NCT02070510|EXPERIMENTAL|Victim and perpetrator compounds|Subjects receive two different victim compounds (lisinopril and warfarin) and two different perpetrator compounds (placebo semaglutide with carrier and oral semaglutide). Each dosing occasion is separated by a 7-day wash-out period.
62281667|NCT01052025|NO_INTERVENTION|Placebo|
62281668|NCT01155700|EXPERIMENTAL|Omalizumab|Omalizumab treatment
62281669|NCT06471881|EXPERIMENTAL|Zirconia bars with distal extensions|Two mandibular implants and a mandibular implant overdenture supported by a computer-aided design
62281670|NCT02091609|EXPERIMENTAL|group : implants and oral hygiene|dental floss
62281671|NCT02091609|EXPERIMENTAL|implants and oral hygiene|dental interproximal brush
62649522|NCT02579629|ACTIVE_COMPARATOR|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
62649523|NCT02579629|EXPERIMENTAL|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
62649524|NCT02579629|ACTIVE_COMPARATOR|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
62649525|NCT05540119||SWEGASS|Gastric cancer patients.
62649526|NCT05540119||SESS|Oesophageal cancer patients.
62649527|NCT01256515|EXPERIMENTAL|Health Education Training Group 1|One form of health education training
62649528|NCT01256515|ACTIVE_COMPARATOR|Health Education Training Group 2|Another form of health education training
62281672|NCT04316169|EXPERIMENTAL|Abemaciclib and HCQ 200 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
62281673|NCT04316169|EXPERIMENTAL|Abemaciclib and HCQ 400 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
62281674|NCT04316169|EXPERIMENTAL|Abemaciclib and HCQ 600 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
62281675|NCT04316169|EXPERIMENTAL|Abemaciclib + HCQ (Optimal Dose) + endocrine therapy|"This group will be divided into two cohorts:~1. eligible participants who are endocrine therapy naive.~2. eligible participants who had one prior line of endocrine therapy."
62649529|NCT00627692|ACTIVE_COMPARATOR|1|Prucalopride
62649530|NCT00627692|ACTIVE_COMPARATOR|2|Prucalopride
62281676|NCT01501058|EXPERIMENTAL|case group|
62281677|NCT01501058|OTHER|waitlist control group|For this group, same intervention with the Experimental group will be provided after waiting for 14 weeks.
62281678|NCT04714515||Hydroxychloroquine and Montelukast|Group 1 was given Standard of care (SOC) + HCQ + Montelukast
62281679|NCT04714515||Montelukast|Group 2 was given Standard of care (SOC) + Montelukast
62281680|NCT04714515||Hydroxychloroquine|Group 3 was given Standard of care (SOC) + HCQ
62281681|NCT04714515||Hydroxychloroquine, Montelukast and Invermectin|Group 4 was given Standard of care (SOC) + Montelukast + HCQ and Ivermectin
62281682|NCT00999895||Antipsychotic outpatients with schizophrenia|Switched treatment of antipsychotic outpatients with schizophrenia
62649531|NCT00627692|ACTIVE_COMPARATOR|3|Prucalopride
62649532|NCT00627692|PLACEBO_COMPARATOR|5|Placebo
62649533|NCT00627692|ACTIVE_COMPARATOR|4|Prucalopride
62649534|NCT03546465|EXPERIMENTAL|Cohorts 1C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 100 μg
62649535|NCT03546465|EXPERIMENTAL|Cohorts 1J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 100 μg
62649536|NCT03546465|EXPERIMENTAL|Cohorts 2C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 200 μg
62649537|NCT03546465|EXPERIMENTAL|Cohorts 2J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 200 μg
62649538|NCT03546465|EXPERIMENTAL|Cohorts 3C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 300 μg
62649539|NCT03546465|EXPERIMENTAL|Cohorts 3J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 300 μg
62649540|NCT03546465|EXPERIMENTAL|Cohorts 4C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 450 μg
62082427|NCT06348719|OTHER|Retrospective cohort study|a retrospective cohort will be set up to provide an exhaustive overview of the approaches used for endometrial cancer, according to patient characteristics (age and BMI). It will include all patients not included in the randomized controlled trial and in the prospective cohort because the surgeon did not propose it to them, because they did not wish to be followed up for the study for 6 months, or because the surgeon considered that minimally invasive surgery was not indicated; up to a limit of 1000 inclusions.
62082428|NCT04970901|EXPERIMENTAL|Part 1 (Dose Escalation): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on Day (D) 1 of each cycle (where each cycle is 21 days).~Participants will also receive polatuzumab vedotin at a dose of 1.8 mg/kg on D1 of each cycle, infusion will be started one hour after end of loncastuximab tesirine infusion."
62082429|NCT04970901|EXPERIMENTAL|Part 1 (Dose Escalation): Loncastuximab Tesirine + Glofitamab (Arm E)|"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on D2 of Cycle (C) 1 and then D1 of all other cycles (where each cycle is 21 days).~Participants will also receive glofitamab 2.5 mg on C1 D8, 10 mg on C1 D15 and 30 mg for cycles 2-12 D1.~In addition participants will receive obinutuzumab pre-treatment 1000 mg on C1 D1."
62082430|NCT04970901|EXPERIMENTAL|Part 1 (Dose Escalation): Loncastuximab Tesirine + Mosunetuzumab (Arm F)|"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on Day (D) 1 of each cycle (where each cycle is 21 days).~Participants will also receive mosunetuzumab 5 mg on C1 D1, 45 mg for C1 D8, C1 D15 and cycles 2-8 D1."
62082431|NCT04970901|EXPERIMENTAL|Part 2 (Dose Expansion): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|Participants with B-NHL will receive loncastuximab tesirine in combination with polatuzumab vedotin at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.
62082432|NCT04970901|EXPERIMENTAL|Part 2 (Dose Expansion): Loncastuximab Tesirine + Glofitamab (Arm E)|Participants with B-NHL will receive loncastuximab tesirine in combination with glofitamab at the MTD and/or RDE if favorable results of Part 1 are received. In addition participants will receive obinutuzumab pre-treatment 1000 mg on C1 D1.
62082433|NCT04970901|EXPERIMENTAL|Part 2 (Dose Expansion): Loncastuximab Tesirine + Mosunetuzumab (Arm F)|Participants with B-NHL will receive loncastuximab tesirine in combination with mosunetuzumab at the MTD and/or RDE if favorable results of Part 1 are received.
62082434|NCT05586711|ACTIVE_COMPARATOR|Vaginal estradiol 10 μg|
62082435|NCT05586711|ACTIVE_COMPARATOR|Vaginal DHEA 6,5 mg|
62082436|NCT06312020|EXPERIMENTAL|HZN-1116 Dose 1 in Population 1|Participants will receive Dose 1 of HZN-1116
62082437|NCT06312020|EXPERIMENTAL|HZN-1116 Dose 2 in Population 1|Participants will receive Dose 2 of HZN-1116
62082438|NCT06312020|PLACEBO_COMPARATOR|Placebo in Population 1|Participants will receive Placebo matched to HZN-1116
62649541|NCT03546465|EXPERIMENTAL|Cohorts 4J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 450 μg
62649542|NCT01548599|EXPERIMENTAL|Multi-sectoral agricultural intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
62649543|NCT01548599|NO_INTERVENTION|Control|Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.
62082439|NCT06312020|EXPERIMENTAL|HZN-1116 Dose 1 in Population 2|Participants will receive Dose 1 of HZN-1116
62082440|NCT06312020|EXPERIMENTAL|HZN-1116 Dose 2 in Population 2|Participants will receive Dose 2 of HZN-1116
62649544|NCT00494663|EXPERIMENTAL|1|150mg DIO-902 + 10mg atorvastatin
62649545|NCT00494663|EXPERIMENTAL|2|300mg DIO-902 + 10mg atorvastatin
62649546|NCT00494663|EXPERIMENTAL|3|450mg DIO-902 + 10mg atorvastatin
62649547|NCT00494663|PLACEBO_COMPARATOR|4|DIO-902 Placebo + 10mg atorvastatin
62649548|NCT00494663|EXPERIMENTAL|5|150mg DIO-902 + atorvastatin placebo
62082441|NCT06312020|EXPERIMENTAL|HZN-1116 Dose 3 in Population 2|Participants will receive Dose 3 of HZN-1116
62082442|NCT06312020|EXPERIMENTAL|HZN-1116 Dose 4 in Population 2|Participants will receive Dose 4 of HZN-1116
62082443|NCT06312020|PLACEBO_COMPARATOR|Placebo in Population 2|Participants will receive Placebo matched to HZN-1116
62082444|NCT05908175|OTHER|Intervention group|FES-assisted gait training intervention group
62082445|NCT05537467|EXPERIMENTAL|Music|Music arm will listen to pre-selected music during their duration of the exercise testing via headphones that will be provided to the patients by the study personnel.
62082446|NCT05537467|NO_INTERVENTION|Non-music|Non-music arm will not have pre-selected music playing during their duration of the exercise testing via the headphones provided to the patients by the study personnel.
62082447|NCT04143724|EXPERIMENTAL|Cohort 1: TD Dose Escalation Cohort: 12 to < 18 years Luspatercept 0.75 mg/kg|
62082448|NCT04143724|EXPERIMENTAL|Cohort 2: TD Dose Escalation Cohort: 12 to < 18 years: Luspatercept 1.0 mg/kg|
62082449|NCT04143724|EXPERIMENTAL|Cohort 3: TD Dose Expansion Cohort: 12 to <18 years Luspatercept 1.0 mg/kg|
62649549|NCT00494663|EXPERIMENTAL|6|300mg DIO-902 + atorvastatin placebo
62649550|NCT00494663|EXPERIMENTAL|7|450mg DIO-902 + atorvastatin placebo
62649551|NCT00494663|PLACEBO_COMPARATOR|8|DIO-902 placebo + atorvastatin placebo
62649552|NCT05297682||singal group|Patients receiving less than two anesthesia in a year
62649553|NCT05297682||repeat group|Patients who received two or more anesthesia in a year
62082450|NCT04143724|EXPERIMENTAL|Cohort 4: TD Dose Escalation Cohort: 6 to < 12 years Luspatercept 1.0 mg/kg|
62082451|NCT04143724|EXPERIMENTAL|Cohort 5: TD Dose Escalation Cohort: 6 to <12 years Luspatercept 1.2 mg/kg|
62082452|NCT04143724|EXPERIMENTAL|Cohort 6: NTD Dose Confirmation Cohort: 12 to < 18 years Luspatercept 1.0 mg/kg|
62082453|NCT04143724|EXPERIMENTAL|Cohort 7: NTD Dose Expansion Cohort: NTD 12 to < 18 years|
62082454|NCT04143724|EXPERIMENTAL|Cohort 8: NTD Dose Escalation Cohort: 6 to < 12 years Luspatercept 1.0 mg/kg|
62082455|NCT04143724|EXPERIMENTAL|Cohort 9: NTD Dose Escalation Cohort: 6 to < 12 years Luspatercept 1.2 mg/kg|
62082456|NCT06492291|EXPERIMENTAL|Enlicitide Decanoate|Participants will receive 20 mg of enlicitide decanoate orally once daily (QD)
62082457|NCT04658342||Oral Cancer Patients|
62649554|NCT04802200||Patients operated from minimally invasive cardiac surgery|Patients operated between December 16, 2019 and june 30, 2021 from minimally invasive cardiac surgery with femoral cannulation for cardiopulmonary bypass in Dijon University hospital and in whom the MANTA device has been used for femoral artery closure
62649555|NCT01683461|EXPERIMENTAL|Enhanced Counseling|Women in the intervention arm receive: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focused on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.
62649556|NCT01683461|ACTIVE_COMPARATOR|Standard of Care|Women in the control arm receive the standard of care in terms of HIV counseling and testing during pregnancy. The standard of care for HIV counseling adheres to guidelines provided by the US Centers for Disease Control and the World Health Organization. Women receive one individual pre-test counseling session immediately before they are tested for HIV, and one individual post-test counseling session the same day that they are tested.
62649557|NCT05012267|NO_INTERVENTION|Control group|48 hours of PP
62649558|NCT05012267|EXPERIMENTAL|Experimental group|Anytime from 16 hours when PaO2/FiO2 ≥ 150 mmHg with a FiO2 \< 60%
62649559|NCT00216255|EXPERIMENTAL|Pagoclone|.15mg, .30mg, .60mg
62649560|NCT00216255|PLACEBO_COMPARATOR|Placebo|Placebo
62649561|NCT05131763|EXPERIMENTAL|KD-025|NKG2D-based CAR T-cells Injection; Dosage:1-10x10\^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
62649562|NCT05052580|OTHER|COVID-19 Exposure Testing|
62082458|NCT05627856|EXPERIMENTAL|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62082459|NCT05616013|PLACEBO_COMPARATOR|Placebo to bimagrumab 30 mg/kg + no semaglutide|Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28 and 40 during the core treatment period and will switch during the extension period to receive bimagrumab 30 mg/kg at Weeks 52 and 64.
62082460|NCT05616013|OTHER|Placebo + semaglutide 1.0 mg|Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.
62082461|NCT05616013|OTHER|Placebo + semaglutide 2.4 mg|Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28 and 40, 52 and 64, and s.c. semaglutide 2.4 mg weekly per the dose escalation schedule.
62082462|NCT05616013|EXPERIMENTAL|Bimagrumab 10 mg/kg to bimagrumab 30 mg/kg + no semaglutide|Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28 and 40 during the core treatment period and will switch during the extension period to receive bimagrumab 30 mg/kg at Weeks 52 and 64.
62082463|NCT05616013|OTHER|Bimagrumab 10 mg/kg + semaglutide 1.0 mg|Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.
62082464|NCT05616013|OTHER|Bimagrumab 10 mg/kg + semaglutide 2.4 mg|Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 2.4 mg weekly per the dose escalation schedule.
62082465|NCT05616013|EXPERIMENTAL|Bimagrumab 30 mg/kg + no semaglutide|Participants will receive i.v. bimagrumab 30 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64.
62082466|NCT05616013|OTHER|Bimagrumab 30 mg/kg + semaglutide 1.0 mg|Participants will receive i.v. bimagrumab 30 mg/kg at baseline, and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.
62281683|NCT02755194||Breastfeeding women on the study medications|The study population consists of lactating/breastfeeding women over the age of 18, who are able to communicate in English and are taking one or more of the study drugs (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept, Methotrexate, Ezetimibe, Bupropion, Citalopram, Venlafaxine)
62281684|NCT00746967|OTHER|Arm 1|
62649563|NCT01349595|EXPERIMENTAL|Bortezomib|Bortezomib is a type of targeted chemotherapy
62649564|NCT01349595|NO_INTERVENTION|Standard Post-transplant Treatment|Mayo Clinic standard post kidney transplant follow-up.
62649565|NCT05550324||Affected Subjects|The subjects must have the diagnosis of cardiovascular disease
62649566|NCT05550324||Syndromes associated with Cardiovascular Disease|The subject must have a syndrome associated with cardiovascular disease
62649567|NCT05550324||Family Members|The subject must be related to an individual in cohort 1 or 2
62649568|NCT05550324||Controls|The subject is considered a control and does not fall into any of the other cohorts
62649569|NCT03307421|OTHER|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
62649570|NCT03307421|OTHER|debriefing with instructor|"The team debriefing with an instructor will begin immediately after the simulator run and will be governed by the principle of no judgment described by Rudolph .~A portion of the video of the participants' pass may be reviewed and used to support the debriefing (depending on the utility judged by the debrief). Each center will use its own team of trainers, but it will have a predefined plan and predefined objectives, which are provided in advance in order to obtain a standardized debriefing. Moreover, these trainers will not be beginners but will have some expertise in the pedagogy of simulation. They will have to have a DU in a simulation or pedagogy trainer (recommendations from SofraSim) and will have to carry out 15 debriefings per year"
62281685|NCT02076542|EXPERIMENTAL|Education - Diabetes and Sports|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Sports"
62458673|NCT03179345|ACTIVE_COMPARATOR|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
62649571|NCT05366855|ACTIVE_COMPARATOR|IV +SC Imsidolimab|IV loading dose followed by subcutaneous Imsidolimab
62649572|NCT05366855|ACTIVE_COMPARATOR|SC Imsidolimab|Subcutaneous Imsidolimab
62649573|NCT05366855|PLACEBO_COMPARATOR|SC Placebo|Subcutaneous Placebo
62458674|NCT03179345|PLACEBO_COMPARATOR|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
62458675|NCT01601678|ACTIVE_COMPARATOR|Peroral Endoscopic Myotomy POEM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the POEM therapy group
62649574|NCT05366855|NO_INTERVENTION|Standard of Care|Any available therapy
62649575|NCT05543304||patients with response to systemic therapies|Patients shown complete response (CR) and partial response (PR) after treatments. The clinical data and radiomics data are collected through electronic medical record system.
62281686|NCT02076542|NO_INTERVENTION|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
62281687|NCT03682315|ACTIVE_COMPARATOR|Biphasic phycogenic biomaterial|Biphasic phycogenic biomaterial and Autogenous cortical bone
62281688|NCT03682315|EXPERIMENTAL|Xenograft bovine hydroxyapatite|Xenograft bovine hydroxyapatite and Autogenous cortical bone
62281689|NCT01946815|EXPERIMENTAL|Atorvastatin|Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
62281690|NCT04355780||Subgroup 1|Composed of HCT patients with respiratory failure requiring intubation and mechanical ventilation.
62281691|NCT04355780||Subgroup 2|Composed of oncology patients (solid tumor or leukemia patients) who have not undergone HCT and who have respiratory failure requiring intubation and mechanical ventilation.
62649576|NCT05543304||patients with no response to systemic therapies|Patients shown progressive disease (PD) and stable disease (SD) after treatments. The clinical data and radiomics data are collected through electronic medical record system.
62649577|NCT03540862||NPV|a hospital-based maintenance NPV program including NPV support, breathing training and an educational program (relaxation techniques, and home pacing walking exercise) in daily clinical practice. Patients received NPV with breathing training via the cuirass ventilator (Philips Respironics Lifecare NEV-100) settings for 60 min. The ventilator was set to control model with frequency of 12 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot) and delivered negative pressures ranging -20 to -30 cm H2O. In the NPV group, patients underwent the hospital-based NPV once every week as the maintenance program.
62649578|NCT03540862||Control|If patients do not wish to enter the hospital-based NPV program, they are placed in the control group and are trained to perform breathing training, relaxation techniques and home pacing walking exercise.
62281692|NCT04355780||Subgroup 3|Composed of chimeric antigen T-cell receptor infusion recipients who have respiratory failure requiring intubation and mechanical ventilation.
62082467|NCT05616013|OTHER|Bimagrumab 30 mg/kg + semaglutide 2.4 mg|Participants will receive i.v. bimagrumab 30 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 2.4 mg per the dose escalation schedule.
62082468|NCT00650078|EXPERIMENTAL|NP01|Modified Release (MR) prednisone 5 mg
62082469|NCT00650078|PLACEBO_COMPARATOR|Placebo|
62082470|NCT04660929|EXPERIMENTAL|Group 1 and Group 2|Both groups will receive the full dose manufactured per patient. Group 1 will undergo intra subject dose escalation of IV administrations of up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5. Group 2 will receive the full dose IV on Day 1 of up to 5 billion cells total.
62082471|NCT04660929|EXPERIMENTAL|Intraperitoneal Administration|"All cohorts will receive the full dose manufactured per patient. Cohorts 1-3 will undergo intrasubject dose escalations of IP administration as follows:~Cohort 1 up to 500 million total cells on Day 1, up to 1 billion total cells on Day 3 and up to 1.5 billion total cells on Day 5.~Cohort 2 up to 1.5 billion total cells on Day 1, up to 2 billion total cells on Day 3 and any remaining cells on Day 5.~Cohort 3 up to 2.5 billion total cells on Day 1 and up to 2.5 billion total cells on Day 3.~Cohort 4 will 1 dose on Day 1 of up to 5 billion total cells."
62082472|NCT04660929|EXPERIMENTAL|89[Zr]radiolabeled CT-0508|89\[Zr\] radiolabeled group will receive a full dose IV on Day 1 of up to 500 million total cells of 89\[Zr\] radiolabeled CT-0508 and non-radiolabeled CT-0508 of up to 4.5 billion total cells (Univ of Penn Abramson Cancer Center only).
62082473|NCT04660929|EXPERIMENTAL|CT-0508 in Combination with Pembrolizumab|"All regimen levels will receive the full dose manufactured per patient up to 5 billion total cells. Regimen Levels 1 and 2 will undergo intrasubject dose escalations of IV administration as follows:~Regimen Level 1: up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5 plus pembrolizumab 200 mg q3w starting on Day 8.~Regimen Level 2: up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5 plus pembrolizumab 200 mg q3w starting on Day 1.~Regimen Level 3 will receive the full dose IV on Day 1 of up to 5 billion total cells plus pembrolizumab 200 mg q3w starting on Day 1."
62082474|NCT06075095|EXPERIMENTAL|Treatment Sequence 1|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 1:~BGF MDI HFO 320/14.4/9.6 μg BGF MDI HFA 320/14.4/9.6 μg Placebo MDI HFA"
62082475|NCT06075095|EXPERIMENTAL|Treatment Sequence 2|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 2:~BGF MDI HFO 320/14.4/9.6 μg Placebo MDI HFA BGF MDI HFA 320/14.4/9.6 μg"
62458676|NCT01601678|ACTIVE_COMPARATOR|Laparoscopic Heller Myotomy LHM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the LHM therapy group.
62082476|NCT06075095|EXPERIMENTAL|Treatment Sequence 3|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 3:~BGF MDI HFA 320/14.4/9.6 μg BGF MDI HFO 320/14.4/9.6 μg Placebo MDI HFA"
62082477|NCT06075095|EXPERIMENTAL|Treatment Sequence 4|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 4:~BGF MDI HFA 320/14.4/9.6 μg Placebo MDI HFA BGF MDI HFO 320/14.4/9.6 μg"
62082478|NCT06075095|EXPERIMENTAL|Treatment Sequence 5|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 5:~Placebo MDI HFA BGF MDI HFO 320/14.4/9.6 μg BGF MDI HFA 320/14.4/9.6 μg"
62458677|NCT05226169|EXPERIMENTAL|Active treatment arm : IV FCM|Intravenous ferric carboxymaltose
62458678|NCT05226169|ACTIVE_COMPARATOR|Control treatment arm: Conservative management|"Conservative management~* Absolute IDA: oral ferrous sulfate~* Functional IDA: no treatment or oral ferrous sulfate according to the physician's choice~* Other IV iron or PRC transfusion or ESA therapy is not allowed"
62458679|NCT05436002|ACTIVE_COMPARATOR|With Cross-linked Hyaluronic Acid|Tunnel Technique in Conjunction With Cross-linked Hyaluronic Acid and Subepithelial Connective Tissue Graft.
62281693|NCT02846103|EXPERIMENTAL|Biological samples|"Blood samples will be collected at baseline, after the first-line therapy and at 12 months.~Tumor tissues will be collected if available."
62458680|NCT05436002|PLACEBO_COMPARATOR|Whitout Cross-linked Hyaluronic Acid|Tunnel Technique in Conjunction With Subepithelial Connective Tissue Graft.
62458681|NCT06150495||Healthy control|The controls included patients without DM who presented for regular ophthalmic examination.
62649579|NCT01448733|EXPERIMENTAL|Acanya Plus Atralin|A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.
62082479|NCT06075095|EXPERIMENTAL|Treatment Sequence 6|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions in the following sequence.~Sequence 6:~Placebo MDI HFA BGF MDI HFA 320/14.4/9.6 μg BGF MDI HFO 320/14.4/9.6 μg"
62082480|NCT06739421|EXPERIMENTAL|nCLE-NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
62082481|NCT06739421|EXPERIMENTAL|nCLE-NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB) , under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
62082482|NCT06739421|ACTIVE_COMPARATOR|NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
62082483|NCT06739421|ACTIVE_COMPARATOR|NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB) , under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
62082484|NCT05252962|EXPERIMENTAL|marine collagen peptide production process I|standardized to 10 g provided as single dose. Orally applied in water.
62082485|NCT05252962|EXPERIMENTAL|marine collagen peptide production process II|standardized to 10 g provided as single dose. Orally applied in water.
62082486|NCT05252962|EXPERIMENTAL|marine collagen peptide fish source I|standardized to 10 g provided as single dose. Orally applied in water.
62082487|NCT05252962|EXPERIMENTAL|marine collagen peptide fish source II|standardized to 10 g provided as single dose. Orally applied in water.
62281694|NCT06133660||PPV（pars plana vitrectomy） group|
62281695|NCT06133660||Silicone oil removal group|
62281696|NCT01900093|EXPERIMENTAL|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
62458682|NCT06150495||intensive control (IC) group|The mean HbA1c level was calculated during the 12 months prior to the OCT and OCTA. Based on the mean HbA1c level, T2DM patients were divided into intensive control (IC; mean HbA1c ≤ 7.0%) and moderate control (MC; mean HbA1c \> 7.0%) groups
62458683|NCT06150495||moderate control (MC) group|The mean HbA1c level was calculated during the 12 months prior to the OCT and OCTA. Based on the mean HbA1c level, T2DM patients were divided into intensive control (IC; mean HbA1c ≤ 7.0%) and moderate control (MC; mean HbA1c \> 7.0%) groups
62458684|NCT04359641|EXPERIMENTAL|CoMET Display|Display of Continuous Monitoring of Event Trajectories (CoMET) predictive monitoring score, with standard CoMET device training.Risk scores will also be presented daily during rounds to members of the care team.
62458685|NCT04359641|NO_INTERVENTION|No Display|Standard CoMET device training but no display or presentation of predictive monitoring score.
62649580|NCT00505635|EXPERIMENTAL|Biochemotherapy with Temozolomide|Temozolomide 250 mg/m\^2 every 4 hours Day 1; Biochemotherapy of Velban 1.5 mg/m\^2 intravenous (IV) Days 1-4; Cisplatin 20 mg/m\^2 IV Days 1-4; + Interleukin-2 9 MIU/m\^2 IV over 24 Hours for 4 Doses Days 1-4; Intron-A 5 mu/m\^2 subcutaneously daily Days 1-5; + Oral Thalidomide 400 mg daily.
62082488|NCT03270111|EXPERIMENTAL|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
62082489|NCT03270111|EXPERIMENTAL|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
62082490|NCT05444504|OTHER|Group 1|24 hours of use each of leaking freely, leaking freely, cup, and then cup+
62082491|NCT05444504|OTHER|Group 2|24 hours of use each of leaking freely, cup, cup+, and then cup
62281697|NCT03942432|EXPERIMENTAL|Patients with dysmetabolic iron overload syndrome|
62281698|NCT03128957|EXPERIMENTAL|Varying cerebral oxygenation with varying ventilation|Compare oxygenation under conditions of varying ventilation strategy. Low end tidal CO2/Low inspired oxygen vs High end tidal CO2/high inspired oxygen
62281699|NCT02615743|EXPERIMENTAL|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
62082492|NCT06740955|EXPERIMENTAL|Experimental group|subjects randomly assigned to the experimental group were required to start treatment within 7 working days. The experimental group received hypofractionated radiotherapy with a total dose of 52.5Gy, 3.5 Gy/ fraction, 15 fractions, 5 fractions per week, and temozolomide was given for 21 days. Sequential temozolomide chemotherapy was started 4 weeks after the end of chemoradiotherapy. Sequential chemotherapy was given 5 days before each 28-day cycle.
62082493|NCT06740955|OTHER|Control group|subjects randomly assigned to the experimental group were treated within 7 working days. The control group received conventional fractionated radiotherapy with a dose of 60Gy, 2Gy per fraction, 30 fractions, 5 fractions per week, and temozolomide was given for a total of 42 days. Sequential temozolomide chemotherapy was started 4 weeks after the end of chemoradiotherapy. Sequential chemotherapy was given 5 days before each 28-day cycle.
62082494|NCT02422147||Ablation of PCL|Patients with pancreatic cysts will undergo ablation using alcohol under EUS-guidance
62281700|NCT02615743|OTHER|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
62458686|NCT04753788||Suspected Yaws Cases|Individuals with a lesion clinically suspected to be yaws and with evidence of positive treponemal and non-treponemal serology as assessed by point of care lateral flow tests (DPP Syphilis Screen and Confirm, Chembio)
62649581|NCT03423069|EXPERIMENTAL|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
62649582|NCT03423069|ACTIVE_COMPARATOR|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
62649583|NCT05047744|EXPERIMENTAL|Prosthesis Cohort|Surgery dual mobility Prosthesis
62649584|NCT01019993|ACTIVE_COMPARATOR|good pulmonary functions (group N)|The patients were allocated if they have forced vital capacity (FVC %) and/or forced expiratory volume in 1 sec (FEV1%) of 80% of predicted or more
62281701|NCT06309056|EXPERIMENTAL|Interventional Group|
62281702|NCT06309056|NO_INTERVENTION|Control Group|
62281703|NCT01361997|EXPERIMENTAL|Chlorhexidine in isopropyl alcohol|This arm is composed of 545 hospitalized patients with suspected blood stream infection, to test 2% chlorhexidine gluconate in 70% isopropyl alcohol.
62281704|NCT01361997|EXPERIMENTAL|Isopropyl alcohol|This arm is composed of 572 hospitalized patients with suspected blood stream infection, to test 70% isopropyl alcohol.
62281705|NCT00604968|EXPERIMENTAL|Caelyx|
62281706|NCT01367730||osteoporosis and osteopenia|Subjects will be stratified based on DXA BMD T-scores.
62281707|NCT05902000|EXPERIMENTAL|Thrombectomy + Carotid Stenting|"After emergency admission,intravenous thrombolysis will be administered if possible. Standard endovascular thrombectomy (EMT) and balloon angioplasty will be performed. The method of EMT and the order of endovascular treatment were selected by each center. After EMT and balloon angioplasty, patients with eTICI≥2b_50 were maintained for more than 10 minutes for randomization. In the intervention arm, emergent carotid stenting will be performed. Standardized treatment with antiplatelet and other drugs will be given. A loading dose of antiplatelet agents (aspirin 300 mg and clopidogrel 300 mg) or Tirofiban was given as an intraoperative drug treatment to endovascular therapy prior to emergency balloon dilation or stenting. Intravenous sedation or general anesthesia will be permitted.~Oral dual antiplatelet treatment for more than 1 month. Tirofiban is maintained for 24-48 hours, overlapping with oral antiplatelet for 4-6 hours, after excluding intracranial hemorrhage."
62281708|NCT05902000|NO_INTERVENTION|Thrombectomy alone|Intracranial thrombectomy alone（balloon dilation of the ipsilateral internal carotid artery if necessary）
62649585|NCT01019993|ACTIVE_COMPARATOR|pulmonary dysfunction (group PD)|The patients were allocated if they have FVC and/or FEV1 of 50%-79% of predicted
62649586|NCT03776279|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|4 weeks is a treatment cycle, and the first day of each cycle is administered.
62649587|NCT04901624|EXPERIMENTAL|Personal Risk + Loss Protection|Personal Risk + Loss Protection
62082495|NCT04306315|EXPERIMENTAL|Brodalumab 210 mg + brodalumab 70 mg add-on* (adjusted brodalumab dosing regimen)|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. \*Participants not fulfilling a predefined response at any visit with efficacy assessments after Week 16 will receive a dose adjustment to 280 mg brodalumab every 2 weeks.
62082496|NCT04306315|PLACEBO_COMPARATOR|Brodalumab 210 mg + placebo add-on* (standard brodalumab treatment)|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. \*Participants not fulfilling a predefined response at any time visit with efficacy assessments Week 16 will receive a dose adjustment to 210 mg brodalumab + placebo every 2 weeks.
62082497|NCT05673304|EXPERIMENTAL|Interventional group|Patients will be treated on the primary tumour with a total dose of 24 Gy (8 Gy x 3 fractions QD) within 2 weeks from the start of neoadjuvant chemotherapy
62082498|NCT05673304|NO_INTERVENTION|observational cohort|This cohort will include patients fulfilling inclusion criteria who refuse enrollment in the interventional cohort and patients where SBRT boost appears not feasible after enrollment for technical issues
62082499|NCT06568458|EXPERIMENTAL|Part I: Period A|
62082500|NCT06568458|EXPERIMENTAL|Part I: Period B|
62082501|NCT06568458|EXPERIMENTAL|Part I: Period C|
62082502|NCT06568458|EXPERIMENTAL|Part II: Period 1|
62082503|NCT06568458|EXPERIMENTAL|Part II: Period 2|
62082504|NCT06568458|EXPERIMENTAL|Part II: Period 3|
62082505|NCT06568458|EXPERIMENTAL|Part III: Period 1|
62082506|NCT06568458|EXPERIMENTAL|Part III: Period 2|
62082507|NCT04899310|EXPERIMENTAL|mRNA-3705|Participants in Part 1 will receive a weight based dose of mRNA-3705, administered intravenously (IV), once every 2 weeks (Q2W) or once every 3 weeks (Q3W) for up to 10 doses over approximately 40 weeks. Participants in Part 2 will receive mRNA 3705 at the selected dose level and frequency for up to 12 months.
62649588|NCT04901624|EXPERIMENTAL|Personal Risk + Lottery Incentive|Personal Risk + Lottery Incentive
62649589|NCT04901624|EXPERIMENTAL|Family Risk + Loss Protection|Family Risk + Loss Protection
62082508|NCT06585631|EXPERIMENTAL|Intervention|Participants randomized to CC PrTNER will be assigned a peer coach, complete interviewer-administered behavioral surveys, receive psychoeducation, identify health goals.
62082509|NCT06585631|NO_INTERVENTION|Standard of Care|The participant's provider will receive an electronic alert in real time of the participant's positive screen for SU and a list of area substance treatment resources. The provider at their discretion will provide counseling or initiate a referral to in-clinic or community-based resources for SU assessment and treatment. Each of our clinical sites has case management resources for counseling and support for linkage to co-located SU treatment or community-based resources for inpatient or outpatient SU treatment as indicated at the discretion of the HIV/PrEP provider. SOC arm participants will not be assigned a coach. Study visit surveys and sample collection at baseline, 3, 6, 9, and 12 months are identical for intervention and SOC arm participants. Research personnel will make no attempts to provide brief intervention, motivational interviewing (MI), or case management.
62082510|NCT05990335|EXPERIMENTAL|Cognition exercises group I|Subjects enrolled in this arm are exposed to an active task intervention designed for higher cognitive effort training functions
62458687|NCT03467165|EXPERIMENTAL|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
62082511|NCT05990335|ACTIVE_COMPARATOR|Cognition exercises group C|Subjects enrolled in this arm are exposed to an active task intervention designed for lower cognitive effort training functions
62082512|NCT05378347|EXPERIMENTAL|Medtronic Endurant II/IIs|Subjects are randomized on a 1:1 basis to receive an EVAR procedure with either a Medtronic Endurant II/IIs endoprothesis or Gore's Excluder / Excluder Conformable.
62082513|NCT05378347|EXPERIMENTAL|Gore Excluder / Excluder Conformable|Subjects are randomized on a 1:1 basis to receive an EVAR procedure with either a Medtronic Endurant II/IIs endoprothesis or Gore's Excluder / Excluder Conformable.
62281709|NCT03799900|EXPERIMENTAL|Part 1, Cohort 1: Ketamine Low Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
62281710|NCT03799900|PLACEBO_COMPARATOR|Part 1, Cohort 1: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
62458688|NCT03467165|EXPERIMENTAL|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
62458689|NCT01826123|ACTIVE_COMPARATOR|Conventional laboratory testing|"After being randomized to the group conventional coagulating testing, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
62458690|NCT01826123|ACTIVE_COMPARATOR|POC testing (ROTEM and Multiplate)|"After being randomized to the group POC testing, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
62458691|NCT05479630|EXPERIMENTAL|Adolescents and their parent of the intervention group|Adolescents and their parent who are participating in TWAH
62458692|NCT05479630|NO_INTERVENTION|Adolescents and their parent of the control group|Adolescents and their parent who are not participating in TWAH
62458693|NCT01044732|EXPERIMENTAL|Group A - COLO, then TER|"Complete examination with standard colonoscope (COLO) followed by complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope"
62458694|NCT01044732|ACTIVE_COMPARATOR|Group B - TER, then COLO|"Complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (COLO) alone"
62458695|NCT01126736|EXPERIMENTAL|Low Dose E7389 in Combination with Pemetrexed|
62458696|NCT01126736|ACTIVE_COMPARATOR|Pemetrexed|
62649590|NCT04901624|EXPERIMENTAL|Family Risk + Lottery Incentive|Family Risk + Lottery Incentive
62649591|NCT04808583|ACTIVE_COMPARATOR|Group (A)|conventional TLH with uterine artery ligation after the cornual pedicles
62649592|NCT04808583|EXPERIMENTAL|Group (B)|TLH with uterine artery ligation at its origin at the beginning of the operation
62649593|NCT01850316|EXPERIMENTAL|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
62649594|NCT03597438||Patient|patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery
62082514|NCT04963153|EXPERIMENTAL|Treatment (erdafitinib, enfortumab vedotin)|Patients receive erdafitinib PO QD on days 1-28 of each cycle and enfortumab vedotin IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and blood sample collection throughout the trial and may undergo echocardiography or MUGA scan during screening and bone scan throughout the study.
62649595|NCT03597438||Volunteer|Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study
62649596|NCT01496456|PLACEBO_COMPARATOR|Preventative measures|Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
62649597|NCT01496456|ACTIVE_COMPARATOR|Lesion infiltration|Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
62649598|NCT02897349|EXPERIMENTAL|linagliptin|
62649599|NCT02897349|PLACEBO_COMPARATOR|Placebo|
62082515|NCT05475171|EXPERIMENTAL|Lorigerlimab|Participants will receive Lorigerlimab by vein over about 30 minutes on Day 1 of each cycle
62082516|NCT06060665|EXPERIMENTAL|Seladelpar 10 mg|
62082517|NCT06060665|EXPERIMENTAL|Placebo|
62082518|NCT06542588|EXPERIMENTAL|Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy|"Radiotherapy will employ conformal or intensity-modulated radiation therapy, with a pelvic irradiation dose of 25 Gy/5 Fractions/1 week. Then rest for 1 week after radiotherapy and begin to receive neoadjuvant chemotherapy CAPOX, HLX07 and Serplulimab, for 6 cycles.~The patients were operated within 10 weeks after the last treatment, and the surgical method is total mesorectal excision. For patient who achieve CR can choose non-operation management."
62649600|NCT04941872|EXPERIMENTAL|68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of and 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
62649601|NCT04513509|EXPERIMENTAL|rate control|
62649602|NCT05352646|EXPERIMENTAL|NewishT|This study is divided into two dose groups and two phases. Phase Ia climbed from low-dose group to high-dose group in turn according to the 3+3 dose escalation principle. Phase Ib extended 10 subjects each group.
62649603|NCT03751813|PLACEBO_COMPARATOR|Placebo|placebo supplement
62649604|NCT03751813|EXPERIMENTAL|Supplement|actual supplement
62649605|NCT06369064|EXPERIMENTAL|CVVHD|Patient requiring renal remplacement therapy treated with by continuous venovenous hemodialysis (CVVHD) method.
62649606|NCT06369064|ACTIVE_COMPARATOR|CVVHDF|Patient requiring renal remplacement therapy treated with by continuous venovenous hemodiafiltration (CVVHDF) method.
62649607|NCT06522425|EXPERIMENTAL|professionals|This arm includes 9 professionals (including medical staff, child development specialists, and psychologists). All participants will use the mindfulness-based serious game designed for pain management and will complete usability surveys and participate in interviews to provide feedback on their experience.
62281711|NCT03799900|EXPERIMENTAL|Part 1, Cohort 2: Ketamine Medium Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
62281712|NCT03799900|PLACEBO_COMPARATOR|Part 1, Cohort 2: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
62281713|NCT03799900|EXPERIMENTAL|Part 1, Cohort 3 (Optional): Ketamine High Dose|Optional: some participants will be administered a single IV dose of ketamine on Day 1.
62281714|NCT03799900|PLACEBO_COMPARATOR|Part 1, Cohort 3 (Optional): Placebo|Optional: some participants will be administered a single IV dose of placebo on Day 1.
62281715|NCT03799900|EXPERIMENTAL|Part 2, Qualification Phase: Ketamine|Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.
62281716|NCT03799900|PLACEBO_COMPARATOR|Part 2, Qualification Phase: Placebo|Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.
62281717|NCT03799900|EXPERIMENTAL|Part 2, Treatment Phase: Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
62281718|NCT03799900|EXPERIMENTAL|Part 2, Treatment Phase: Rapastinel Medium Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
62281719|NCT03799900|EXPERIMENTAL|Part 2, Treatment Phase: Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
62281720|NCT03799900|ACTIVE_COMPARATOR|Part 2, Treatment Phase: Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
62281721|NCT03799900|PLACEBO_COMPARATOR|Part 2, Treatment Phase: Placebo|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
62281722|NCT05894954|EXPERIMENTAL|Group A (Precision Medicine)|Precision Medicine approach starts with a battery of tests and questionnaires to determine a person's underlying causes of cognition impairment. A custom treatment program is developed and prescribed by the investigator based on the test results and includes a combination of: supplements, medications, hormone therapy, dietary changes, exercise program, brain exercises, stress management, sleep tracking. Additional treatments may include QEEG and photobiomodulation, neurostimulation, neurofeedback and/or hyperbaric oxygen treatment (additional treatment are only available at select sites). Participants in this Group will also be supported in their program by a nutritionist, health coach, and fitness trainer, in addition to the study doctor. Tracking of study activities may also be required in the form of diaries, and devices will be used to track some of their activities such as sleep, stress, diet and exercise.
62649608|NCT06522425|EXPERIMENTAL|Users(pediatric patients)|This arm includes 10 users (pediatric patients aged 5-17 years who are taking adjuvant analgesics or narcotic/non-narcotic analgesics for pain control). All participants will use the mindfulness-based serious game designed for pain management and will complete usability surveys and participate in interviews to provide feedback on their experience.
62649609|NCT03105011|EXPERIMENTAL|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
62281723|NCT05894954|ACTIVE_COMPARATOR|Group B (Standard-of-Care)|"Standard-of-care treatment will be based on the practice guideline of hte Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Participants in this group will be guided according to the recommendations which include recommending:~* participation in cognitively and socially-stimulation activities~* regular exercise~* ensuring quality sleep including treatment of any sleep apnea~* control of any modifiable risk factors such as blood pressure, diabetes, cholesterol, and avoidance of tobacco use~* evaluation by a primary care physician~* adherence to a healthy and balanced diet~* consult a neurologist or primary care physician regarding use of medications~* consult with their primary care physician to identify any worsening conditions"
62281724|NCT01818297|ACTIVE_COMPARATOR|Treatment|Treatment settings of Medtronic PrimeAdvanced® neurostimulator system implant
62281725|NCT01818297|OTHER|Control|Control settings of Medtronic PrimeAdvanced® neurostimulator system implant
62458697|NCT01126736|EXPERIMENTAL|High Dose E7389 in Cominbation with Pemetrexed|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
62649610|NCT01918228|EXPERIMENTAL|Intervention group|Talks on scientific status on back pain with the purpose of reducing LBP-related insecurity/fear, reducing the focus on the pain and providing participants with alternative explanation to their LBP. They were also provided with a folder (general stretching exercises) and had telephone access to health professional if they had questions about LBP during the follow-up year.
62649611|NCT01918228|NO_INTERVENTION|Control group|No intervention will be provided by the study team.
62082519|NCT05245513|EXPERIMENTAL|Recovery Community Center Linkage (RCCL)|The RCCL arm will involve a brief (\~20 minutes) meeting with a recovery coach (i.e. linkage manager), in which the recovery coach will inform the participant of recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (i.e. peer facilitator). The linkage manager will also provide the participant with a list of recovery support service resources.
62082520|NCT05245513|ACTIVE_COMPARATOR|Control Condition (CC)|The CC arm will involve a time-matched meeting with a recovery coach (i.e. linkage manager), in which the recovery coach will broadly inform the participant of recovery support services, including recovery community centers, and provide them with a list of recovery support service resources.
62082521|NCT02616484|ACTIVE_COMPARATOR|Dichloroacetate, then Placebo|"This group will start on the Dichloroacetate (DCA) treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the placebo treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
62082522|NCT02616484|PLACEBO_COMPARATOR|Placebo, then Dichloroacetate|"This group will start on the placebo treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the Dichloroacetate (DCA) treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
62082523|NCT06446024||Group 1: Indigo Aspiration System treatment|Mechanical aspiration thrombectomy
62082524|NCT06565221|EXPERIMENTAL|Heat and negative pressure|Forearm and quadriceps blood flow at baseline and during intervention
62082525|NCT06476834|EXPERIMENTAL|Deucravacitinib Administration|
62082526|NCT06730074|EXPERIMENTAL|Gamified rehabilitation system involving robot for individuals with Parkinson's|We will run a robotic exercise game with 15 PD patients who will use the system in a sitting position. Each patient will use the system 5 times, each time for 30 min. Principles of effective rehabilitation practice such as repetitive practice, goal-oriented practice, variable difficulty, rhythmic cueing, and social interaction are implemented in our design
62082527|NCT05678998|EXPERIMENTAL|WTX-330 dose escalation|Patients with relapsed/refractory advanced or metastatic solid tumors
62281726|NCT04553211|EXPERIMENTAL|Expedited Partner Therapy (EPT)|Participants in the EPT arm will receive up to five partner antibiotic treatment packets to deliver to their recent sexual partners following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The intervention will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
62281727|NCT04553211|NO_INTERVENTION|Control|Participants in the control arm will receive standard-of-care counseling on partner notification following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The same counseling will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
62281728|NCT04375774|OTHER|FFP2|
62281729|NCT04375774|OTHER|Facial mask|
62281730|NCT04375774|OTHER|Modified full-face snorkeling|
62281731|NCT00820573|PLACEBO_COMPARATOR|Placebo|Placebo to be provided for 6 weeks
62281732|NCT00820573|EXPERIMENTAL|Sitagliptin|Sitagliptin to be provided for 6 weeks
62281733|NCT00820573|EXPERIMENTAL|Metformin|Metformin to be provided for 6 weeks
62281734|NCT00820573|EXPERIMENTAL|Sitagliptin+Metfromin|Sitagliptin + Metformin combined will be provided for 6 weeks
62281735|NCT04514679||Healthy Lifestyles Program|Usual care in the Healthy Lifestyles Program.
62281736|NCT04514679||Obesity Medicine Program|Usual care in the Obesity Medicine program.
62281737|NCT01370460|EXPERIMENTAL|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.
62281738|NCT01370460|PLACEBO_COMPARATOR|Placebo|100mL 0.9% NS, applied topically
62281739|NCT05764148|EXPERIMENTAL|Behavioral activation|Behavioral activation
62281740|NCT05764148|PLACEBO_COMPARATOR|Traatment as usual|
62281741|NCT01311466|EXPERIMENTAL|Liver transplantation|The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
62281742|NCT04779151|EXPERIMENTAL|1.A - Urothelial Bladder Cancer|
62281743|NCT04779151|EXPERIMENTAL|1.B - Gastric or gastro-esophageal junction adenocarcinoma|
62281744|NCT04779151|EXPERIMENTAL|1.C - Head and Neck Cancer|
62281745|NCT04779151|EXPERIMENTAL|1.D - Biliary Tract Cancer and pancreatic ductal adenocarcinoma (PDAC)|
62281746|NCT04779151|EXPERIMENTAL|1.E - Others: any histology, excepted breast cancer, prostate cancer or serous ovarian cancer|
62082528|NCT05678998|EXPERIMENTAL|WTX-330 dose expansion in patients for whom CPI therapy is indicated (Arm A)|WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen
62082529|NCT05678998|EXPERIMENTAL|WTX-330 dose expansion in patients for whom CPI therapy is not indicated (Arm B)|WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved
62082530|NCT04002830|EXPERIMENTAL|Taliglucerase Alpha|Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease
62082531|NCT06023199|EXPERIMENTAL|Voxeletor|
62082532|NCT01518114|EXPERIMENTAL|Exercise Training|"Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.~Exercise prescription will be based upon cardiopulmonary test done at baseline."
62082533|NCT01518114|ACTIVE_COMPARATOR|Best Medical Care|Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.
62082534|NCT04656652|EXPERIMENTAL|DS-1062a 6.0 mg/kg|Participants will be randomized to receive 6.0 mg/kg of DS-1062a.
62082535|NCT04656652|ACTIVE_COMPARATOR|Docetaxel 75 mg/m^2|Participants will be randomized to receive 75 mg/m\^2 docetaxel.
62082536|NCT05568355|NO_INTERVENTION|Standard Hospital-Based Care Coordination|Patients and families randomized to this arm will receive best practice standard of care hospital-based transition planning in the hospital with routine outpatient care team follow-up post-discharge.
62082537|NCT05568355|EXPERIMENTAL|GET2HOME Intervention|The GET2HOME intervention includes: 1) a pre-discharge telehealth huddle with the family, inpatient team, primary care team, and home care nursing; 2) a visual discharge task tracker (DTT) to monitor progress across care management tasks; and if desired by family and primary care 3) a post-discharge telehealth huddle 2-7 days after discharge with the family, inpatient team, primary care team, and home care nursing
62082538|NCT05567172|EXPERIMENTAL|Watchman FLX Pro|
62082539|NCT05649410|EXPERIMENTAL|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
62082540|NCT05649410|EXPERIMENTAL|sleeper stretch along with conventional therapy|IT will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
62082541|NCT05642221||1|individuals without known health or medical issues (i.e. healthy volunteers)
62082542|NCT05642221||2|individuals with known neurocognitive disorders (i.e. affected)
62281747|NCT04779151|EXPERIMENTAL|Cohort 2 - Platinum-sensitive urothelial bladder cancer|
62281748|NCT04779151|EXPERIMENTAL|Cohort 3 - Clear Cell Renal Cell Carcinoma|
62281749|NCT00939692|EXPERIMENTAL|Torrent Topiramate|tablet containing 25 mg of topiramate (Torrent Pharmaceuticals)
62281750|NCT00939692|ACTIVE_COMPARATOR|Topamax|tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)
62281751|NCT02847598|EXPERIMENTAL|Part A: BIIB059 450 mg|BIIB059 450 mg administered SC, Q4W with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with SLE with active skin manifestations and joint involvement.
62649612|NCT00033280|EXPERIMENTAL|Pre-RT temozolomide, RT plus temozolomide|Pre-radiation therapy (RT) temozolomide, RT plus temozolomide
62649613|NCT00972764||Control|
62082543|NCT06641232|EXPERIMENTAL|Inferior dental nerve block|One articaine cartridge (1.8 mL of articaine 4% at 1:100,000) with the direct technique for the inferior dental nerve block and half a cartridge (0.9 mL) for the buccal nerve block.
62649614|NCT00972764||Laryngomalacia Cases|
62082544|NCT06641232|ACTIVE_COMPARATOR|Infiltrative|One anesthetic cartridge (1.8 mL of articaine 4% 1:100,000) using the vestibular infiltrative technique (supraperiosteal paraapical). Subsequently administer half a cartridge of anesthetic (0.9 mL of articaine 4% 1:100,000) using the infiltrative technique (supraperiosteal paraapical) lingually in the sublingual area of the tooth to be treated.
62281752|NCT02847598|PLACEBO_COMPARATOR|Part A: Placebo|BIIB059 matching placebo administered SC, Q4W with an additional dose at Week 2 for total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with SLE with active skin manifestations and joint involvement.
62281753|NCT02847598|EXPERIMENTAL|Part B: BIIB059 50 mg|BIIB059 50 mg administered SC, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
62082545|NCT00984815|EXPERIMENTAL|HZT-501|Open-label treatment with HZT-501
62082546|NCT04493853|EXPERIMENTAL|Capivasertib + Abiraterone|Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
62082547|NCT04493853|PLACEBO_COMPARATOR|Placebo + Abiraterone|Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
62082548|NCT02617563||Minimally invasive lumbar fusion|A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.
62082549|NCT04782375|EXPERIMENTAL|Treatment Arm A|discontinue antiviral treatment
62082550|NCT06178354|EXPERIMENTAL|Treatment (cryosurgery, high intensity focused ultrasound)|Patients undergo focal cryotherapy or high intensity focused ultrasound on study.
62281754|NCT02847598|EXPERIMENTAL|Part B: BIIB059 150 mg|BIIB059 150 mg administered SC, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
62281755|NCT02847598|EXPERIMENTAL|Part B: BIIB059 450 mg|BIIB059 450 mg administered, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
62281756|NCT02847598|PLACEBO_COMPARATOR|Part B: Placebo|BIIB059 matching placebo administered SC, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
62458698|NCT05554653|ACTIVE_COMPARATOR|Leucine enriched essential amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.
62649615|NCT01252368||RAS active drugs|ACE inhibitors and sartanes
62649616|NCT01252368||healthy participants|
62649617|NCT00932932||PWS not receiving Growth Hormone|
62649618|NCT00932932||Control subjects healthy or obese|
62458699|NCT05554653|PLACEBO_COMPARATOR|Carbohdyrate Placebo|Iso-caloric placebo (4g maltodextrin to replace LEAA). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.
62649619|NCT00932932||PWS subjects starting Growth Hormone|
62649620|NCT05811481||Two treatment groups|Regorafenib + TACE
62649621|NCT05811481||Treatment ate group|Regorafinib
62649622|NCT04382534||Rehabilitation guidance group|1 to 2 times of rehabilitation instruction according to the rehabilitation instruction program, either online or in person.According to the rehabilitation instruction, the patient performed self-rehabilitation exercises in the isolation point.
62649623|NCT04382534||Systematic rehabilitation treatment|According to the systematic rehabilitation treatment program, the rehabilitation therapist entered the home for one-to-one rehabilitation treatment, once a day, for a total of 10 days.
62649624|NCT01641042|EXPERIMENTAL|Healthy Group|The subjects in the Healthy group will be age-matched to the subjects in the At-risk group. Subjects will receive 2 doses of the investigational vaccine.
62649625|NCT01641042|EXPERIMENTAL|At-risk Group|This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
62649626|NCT05981924|EXPERIMENTAL|Oxycodone with Perioperative Music Therapy|Using perioperative music therapy plus oxycodone to manage the postoperative pain
62082551|NCT06740539|EXPERIMENTAL|Ablation Group|Ablation Group: Received heart failure treatment combined with ablation
62082552|NCT06740539|NO_INTERVENTION|Drug Control Group|Received heart failure treatment combined with heart rate control.
62082553|NCT00597909|EXPERIMENTAL|Arm 1|
62082554|NCT00597909|EXPERIMENTAL|Arm 2|
62082555|NCT00597909|PLACEBO_COMPARATOR|Arm 3|
62649627|NCT05981924|NO_INTERVENTION|Oxycodone without Perioperative Music Therapy|Using oxycodone only to manage the postoperative pain
62649628|NCT03564990|EXPERIMENTAL|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
62649629|NCT03564990|SHAM_COMPARATOR|conventional approach|conventional follow-up with oral healthy education
62649630|NCT02523209||Bone quality and quantity|measure of bone quality and quantity parameters by HRpQCT and by DEXA
62082556|NCT04120805|EXPERIMENTAL|Group 1 (Hemostatic Agents Plus +)|
62458700|NCT03048500|EXPERIMENTAL|Treatment (metformin hydrochloride, nivolumab)|Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
62458701|NCT05898919|EXPERIMENTAL|Acupuncture|
62458702|NCT05898919|PLACEBO_COMPARATOR|Sham acupuncture|
62649631|NCT01055990|OTHER|Heathy,aged 18-60 years,|They are healthy, are 18-60 years of age, did not have a history of infection with the 2009 H1N1 virus, and are appropriate to vaccination, without any interdictions. And they guardians confirmed that they understood the study procedures, provided written informed consent, and agreed to comply with the following visit schedule. Woman participants all are not pregnant,with a negative pregnancy test before vaccination.
62649632|NCT01055990|EXPERIMENTAL|clinically critical H1N1 patients|The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
62649633|NCT01534793||HoLEP|Holmium Laser Enucleation of the Prostate
62649634|NCT00978952|EXPERIMENTAL|Investigational Group|Use of Large Diameter Advanta™ V12 Covered Stent.
62649635|NCT00158353|EXPERIMENTAL|1|GirlPOWER! mentoring program
62649636|NCT00158353|ACTIVE_COMPARATOR|2|Big Brothers Big Sisters community-based mentoring program
62649637|NCT00499122|EXPERIMENTAL|NOV-002 and Chemotherapy|"* NOV-002:~  * Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart~ * Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration~ * Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections~* Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1~* Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1~* Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1"
62649638|NCT03361046||Transcatheter Aortic Valve-in-Valve Implantation Cohort|
62649639|NCT03506477|EXPERIMENTAL|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
62649640|NCT03506477|PLACEBO_COMPARATOR|Vehicle foam|does not contain the active ingredient
62649641|NCT06454786|EXPERIMENTAL|simülation intervention group|The Student Diagnosis Form, Self-Confidence/Efficacy Scale in Patient Intervention and Perceived Stress Scale will be applied first to this group. Then, face-to-face theoretical training will be given. Following the theoretical training, simulation training will be given in the Simulation Laboratory in line with the Nursing Care Scenario in Cardiogenic Shock. Simulation training will be conducted in 10 groups of 5 people and will be completed in 2 days. Each student in the group will actively participate in the simulation training within the scope of their role in the scenario. Posttests will be administered to both groups 2 weeks after the simulation training.
62649642|NCT06454786|NO_INTERVENTION|Control group|The Student Diagnosis Form, Self-Confidence/Efficacy Scale in Patient Intervention and Perceived Stress Scale will be applied first to this group. Then, face-to-face theoretical training will be given. Post-tests will be administered 2 weeks after the theoretical training.
62649643|NCT05252858|EXPERIMENTAL|nCAP + ERAS|Participants will have the nCAP Signal Relief Patch and complete Enhanced Recovery After Surgery (ERAS) standard of care. After surgery, the subjects randomized to the intervention group will have the nCAP Signal Relief patch applied to their surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU).
62082557|NCT04120805|ACTIVE_COMPARATOR|Group 2 (Hemostatic Agents Negative -)|No Hemostatic Agent
62649644|NCT05252858|ACTIVE_COMPARATOR|ERAS alone|Participants randomized into the control group will receive complete Enhanced Recovery After Surgery (ERAS) standard of care and no nCAP patch.
62649645|NCT05224830||Presence of Hyperventilation Syndrome (HVS+)|Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS +- : Nijmegen questionnaire score \> 23/64
62082558|NCT03519581|ACTIVE_COMPARATOR|Micropulse Laser Treatment|"Subjects assigned to the micropulse laser arm of the trial will undergo the following procedures:~1. Confirmation of the subject's identity and eye to be treated~2. Subject's eye will be dilated~3. Subject will be positioned at the slit lamp for treatment~4. Application of subthreshold micropulse laser using the Iridex IQ577 laser unit. (intermittent pulsed energy) in a 7 X 7 grid pattern surrounding the fovea."
62082559|NCT03519581|PLACEBO_COMPARATOR|Sham Treatment|"Subjects assigned to the sham arm of the trial will undergo the following procedures:~1. Confirmation of the subject's identity and eye to be treated~2. Subject's eye will be dilated~3. Subject will be positioned at the slit lamp for treatment~4. No Actual laser treatment will occur"
62458703|NCT05898919|ACTIVE_COMPARATOR|Neostigmine|
62458704|NCT00683202|ACTIVE_COMPARATOR|1|Acetylsalicylic acid 100 mg daily perorally
62458705|NCT00683202|PLACEBO_COMPARATOR|2|Placebo daily perorally
62458706|NCT01283919|EXPERIMENTAL|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
62458707|NCT01283919|ACTIVE_COMPARATOR|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
62082560|NCT04219709|EXPERIMENTAL|Very low carbohydrate diet|Dietary Intervention, food delivery
62082561|NCT04219709|ACTIVE_COMPARATOR|Standard diet|Dietary Intervention, food delivery
62082562|NCT06284694|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants will undergo high frequency rTMS sessions 5 days a week for 4 weeks (20 treatments total). Treatment intensity will be applied at 100-120% of the participant's resting motor threshold. The neurostimulation protocol will be 10 trains of 60 pulses (600 pulses total) at a frequency of 10 Hz, with inter-train interval of 45-seconds. The rTMS will be administered to the dorsolateral prefrontal cortex (DLPFC) which will be located using Montreal Neurologic Institute (MNI) coordinates (-50, 30, 36) on a standardized brain. Participants will be seated in a comfortable chair or their wheelchair for each rTMS session.
62082563|NCT04872309||Asthma Patients|Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above).
62649646|NCT05224830||No presence of Hyperventilation Syndrome (HVS-).|Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS - : Nijmegen questionnaire score \< 24/64
62649647|NCT01943617|ACTIVE_COMPARATOR|Entecavir Therapy|Entecavir, 0.5mg, qd, oral, for 2 years
62082564|NCT04872309||COPD Patients|Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018)
62281757|NCT05891054|EXPERIMENTAL|Active breaks|"Active breaks consist of short breaks during academic classes other than physical education that include moderate to vigorous physical activity, usually unrelated to curricular content.~In this type of intervention, 2 active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity."
62281758|NCT05891054|EXPERIMENTAL|Physically active learning|"Physically active learning consists of the incorporation of physical activity (usually of moderate-vigorous intensity) into the educational content taught in academic lessons that do not refer to physical education.~This type of intervention is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed."
62281759|NCT05891054|NO_INTERVENTION|Control Group|The control group will receive the usual academic classes without any methodological modification during the intervention period.
62082565|NCT04872309||ICU COVID-19|Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation)
62649648|NCT01943617|EXPERIMENTAL|Entecavir plus thymosin therapy|Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
62082566|NCT04872309||Moderate/Severe COVID-19|Adults hospitalised with COVID-19
62082567|NCT04872309||Mild- Non-hospitalised COVID-19|Adult with proven COVID-19 infection, not hospitalised for COVID-19
62082568|NCT04872309||Non-hospitalised symptomatic (long-COVID group)|Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms.
62458708|NCT00728949|ACTIVE_COMPARATOR|IMC-A12 (cixutumumab) + antiestrogen therapy|Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory.
62649649|NCT00861081|EXPERIMENTAL|1: Care management|
62649650|NCT00861081|ACTIVE_COMPARATOR|2: Written Materials|
62649651|NCT05129696|NO_INTERVENTION|Control (C): Status quo health and nutrition program|
62649652|NCT05129696|EXPERIMENTAL|Treatment (T): adaption of Reach Up and Learn home visiting program to a group setting|
62458709|NCT00728949|EXPERIMENTAL|IMC-A12 (cixutumumab)|Participants will receive only IMC-A12 (10 mg/kg over 1 hour every 2 weeks).
62458710|NCT04111731|ACTIVE_COMPARATOR|Group one|Cryoballoon pulmonary vein isolation
62458711|NCT04111731|ACTIVE_COMPARATOR|Group two|Radiofrequency pulmonary vein isolation
62458712|NCT04066309|EXPERIMENTAL|Abutment removal|At the time of surgery, customizable healing abutments will be placed on implants. These will be replaced by Pro PEEK Abutments 21 days later to placement of temporary prostheses (loading). The final abutments (Titanium Bases) and final prostheses will be inserted 2 months after loading.
62649653|NCT05129696|EXPERIMENTAL|Treatment + (T+): Enhanced play materials/activities package|
62649654|NCT02530775|ACTIVE_COMPARATOR|instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion with use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
62458713|NCT04066309|EXPERIMENTAL|Final abutment|The final abutments (Titanium Bases) will be placed at the time of the implant placement surgery and will stay at mouth during all period of the study. Temporary and final prosthesis will be placed on Titanium Bases.
62458714|NCT04999553|ACTIVE_COMPARATOR|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
62082569|NCT06147401|EXPERIMENTAL|PENG - LFCN Block|group in which PENG and LFCN Block was performed. After performing neuraxial anesthesia, the PENG associated with LFCN block will be performed. Under ultrasound guidance, 20ml and 5ml of Ropivacaine 0.5% will be administered respectively.
62281760|NCT02521701|EXPERIMENTAL|NFL101|"Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
62458715|NCT04999553|ACTIVE_COMPARATOR|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
62458716|NCT03401112|EXPERIMENTAL|IMR-687 50 mg/100 mg|A starting dose of IMR-687 50 mg with dose escalation after 4 or 12 weeks, up to 100 mg was administered to participants. Duration of administration was 16 (Week 17) or 24 weeks (Week 25).
62458717|NCT03401112|EXPERIMENTAL|IMR-687 100 mg/200 mg|A starting dose of IMR-687 100 mg with dose escalation after 4 or 12 weeks, up to 200 mg was administered to participants. Duration of administration was 24 weeks (Week 25).
62458718|NCT03401112|PLACEBO_COMPARATOR|Placebo|Matching placebo was administered for 16 (Week 17) or 24 weeks (Week 25).
62458719|NCT02183064|EXPERIMENTAL|Meloxicam|
62458720|NCT02183064|ACTIVE_COMPARATOR|Usual care prescription NSAID|
62458721|NCT02097290|EXPERIMENTAL|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
62458722|NCT01578837|EXPERIMENTAL|Ginseng|Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule
62458723|NCT01578837|PLACEBO_COMPARATOR|Wheat Bran|100 % Natural Wheat Bran capsule
62458724|NCT00463606|EXPERIMENTAL|ABT-335 and Rosuvastatin Calcium|ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
62458725|NCT00463606|ACTIVE_COMPARATOR|ABT-335|ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
62458726|NCT00463606|ACTIVE_COMPARATOR|Rosuvastatin Calcium|Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks
62458727|NCT04205942|EXPERIMENTAL|Plasma|regular treatment with Argon Plasma Jet according to manufacturer's instructions, 8 times within 14 days
62281761|NCT03676127||Study Group|ultrasonographic dermal thickness measurements in patients with unilateral breast cancer related lymphedema
62458728|NCT04205942|SHAM_COMPARATOR|Placebo|Sham-treatment with Argon Plasma Jet, Plasma producing electric field switched off - no Plasma is produced, just argon gas as effluent, 8 times within 14 days
62458729|NCT03681509|EXPERIMENTAL|Pramipexole|Maximum daily dose: 1.0 mg of pramipexole salt
62458730|NCT03681509|PLACEBO_COMPARATOR|Placebo|Lactose
62082570|NCT06147401|ACTIVE_COMPARATOR|FIC Block|group in which FIC Block was performed After performing neuraxial anesthesia, FIC block will be performed. Under ultrasound guidance, 20 ml of Ropivacaine 0.5% will be administered.
62458731|NCT03865654|EXPERIMENTAL|Surveillance Mammography Communication Tool|"* Conduct 30 telephone-based patient interviews~* 4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography~* Perform cognitive testing of the communication tool"
62458732|NCT04461665|NO_INTERVENTION|Control|Enroll 6 months old breast feeding infant, who have not supplement vitamin D at pediatric clinic.
62458733|NCT04461665|EXPERIMENTAL|VitD supplement|Enroll 4 months old breast feeding infant, and provide 10 μg vitamin D daily for 2 months.
62458734|NCT01288664|EXPERIMENTAL|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months
62458735|NCT01051232|PLACEBO_COMPARATOR|Cohort 1|PF-00868554 (filibuvir) 100 mg or placebo
62458736|NCT01051232|PLACEBO_COMPARATOR|Cohort 2|PF-00868554 (filibuvir) 300 mg or placebo
62458737|NCT01051232|PLACEBO_COMPARATOR|Cohort 3|PF-00868554 (filibuvir) 500 mg or placebo
62458738|NCT04422626||Critically ill COVID-19 patients, who receive CytoSorb therapy|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) CytoSorb therapy on consultant's discretion.
62458739|NCT03542422|EXPERIMENTAL|Apatinib|Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
62458740|NCT02122796|EXPERIMENTAL|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
62458741|NCT02122796|NO_INTERVENTION|Standard of Care|Standard of care post-mastectomy.
62649655|NCT02530775|ACTIVE_COMPARATOR|non-instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion without the use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
62458742|NCT05261685|EXPERIMENTAL|Hyperopic patients planned to undergo single-step transepithelial PRK|Patients with moderate hyperopia or hyperopic astigmatism were planned to undergo transepithelial PRK using the new single-step StreamLight PRK Technology.
62649656|NCT04741048|EXPERIMENTAL|CI624 Slim 20 Electrode|
62649657|NCT00453687|EXPERIMENTAL|Arm 1|Drug
62649658|NCT03794739||Healthy subjects|"Healthy subjects without diabetes, no recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
62281762|NCT01705847|EXPERIMENTAL|GS-9820|Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of \< 33% during the first 4 weeks of therapy.
62281763|NCT02205684|EXPERIMENTAL|Physical activity|Aerobic High Intensity Training (HIT)
62458743|NCT00000588|EXPERIMENTAL|Chronic therapy of PIH according to medical condition|"Half of overall participants will get one of the following doses according to their medical condition:~1. Reducing the body iron burden to near-normal levels in non- transfusion-dependent patients with iron-loading anemias (requires chelate- induced iron excretion of at least 0.10 to 0.20 mg Fe/kg/day);~2. Maintaining near-normal body iron stores in transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine (requires chelate-induced iron excretion of at least 0.25 to 0.40 mg Fe/kg/day);~3. Reducing the body iron burden to near-normal levels in iron-loaded, transfusion-dependent patients (requires chelate-induced iron excretion greater than 0.40 mg Fe/kg/day)."
62458744|NCT00000588|PLACEBO_COMPARATOR|Placebo|"Half of the participants will receive a Placebo:~1. Non-transfusion-dependent patients~2. Transfusion-dependent patients~3. Iron-loaded, transfusion-dependent patients"
62082571|NCT06204029|EXPERIMENTAL|Everyone can sing|Students from 0-3rd grade receive class choir two lessons every week as part of their regular school schedule
62281764|NCT02205684|ACTIVE_COMPARATOR|Computer game skills training|Playing Nintendo Wii Sports
62281765|NCT01166451|EXPERIMENTAL|Low-iron|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age.
62458745|NCT00113425|EXPERIMENTAL|Laser Therapy|V-Beam laser, Candela Corp., 595 nm wavelength
62458746|NCT00113425|NO_INTERVENTION|Control|Untreated
62458747|NCT02480764|EXPERIMENTAL|Azilsartan medoxomil 40 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
62649659|NCT03794739||T1D individuals|"Type 1 diabetic individuals with at least 3-year of duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
62082572|NCT01658930|ACTIVE_COMPARATOR|Radical Hysterectomy|
62281766|NCT01166451|EXPERIMENTAL|High-iron|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age.
62082573|NCT01658930|EXPERIMENTAL|Simple Hysterectomy|
62082574|NCT04134572||Ollier Disease and Maffucci Syndrome patients|The group comprises all patients affected by Ollier Disease and Maffucci Syndrome.
62458748|NCT02480764|EXPERIMENTAL|Azilsartan medoxomil 80 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
62281767|NCT04835012||Treatment|"Subjects in this treatment group had their medical debt forgiven by a non-profit charity, RIP Medical Debt. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
62281768|NCT04835012||Control|"No intervention was given to subjects in this control group. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
62281769|NCT04902365|ACTIVE_COMPARATOR|Patients group 1|This group will regulate a brain region by real-time functional magnetic resonance imaging that is centrally involved in the visual snow syndrome
62281770|NCT04902365|PLACEBO_COMPARATOR|Patients group 2|This group will regulate a brain region by real-time functional magnetic resonance imaging that is not centrally involved in the visual snow syndrome
62281771|NCT06335056|EXPERIMENTAL|ProudMe|The ProudMe condition involves three key components: (a) artificial intelligence (AI)-assisted behavior management system (i.e., ProudMe Tech), (b) ProudMe physical/health education (PE) and lunchroom reform (ProudMe Cafeteria), (c) customized implementation training (ProudMe Training).
62281772|NCT06335056|ACTIVE_COMPARATOR|Waitlist Control|The waitlist control involves (a) regular physical/health education and lunchroom, (b) professional development training on the importance of quality physical/health education, health eating and foot environment. It does not involve AI-assisted behavior management system.
62458749|NCT02480764|ACTIVE_COMPARATOR|Valsartan 160 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.
62082575|NCT05073679|EXPERIMENTAL|Intervention|Oral naltrexone, to start as 25mg for three days then 50mg a day for 6 weeks. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler
62082576|NCT05073679|PLACEBO_COMPARATOR|Control|Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for six weeks
62649660|NCT03794739||T2D individuals|"Type 2 diabetic individuals with at least 5-year duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
62649661|NCT03794739||AutoAb+ individuals|"Individuals at risk for type 1 diabetes, with one or more autoantibody detected. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
62649662|NCT04725669|OTHER|Seroprevalence of pertussis among children and adolescents in Croatia|For all patients participating in the study one serum sample will be collected for serological analysis.
62082577|NCT04024761|EXPERIMENTAL|CIML NK|"* CIML NK cells will be administered intravenously on day 0.~* Fludarabine will be administered as IV infusion once daily for 3 doses beginning on day -5.~* Cyclophosphamide will be administered as IV infusion on days -5 and -4."
62082578|NCT06740084|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced Usual Care (EUC): Guidance and counselling coordinators in the schools provide some counselling to students who need it. Building on the existing structure, enhanced usual care in the Y-MIND programme, will be enhanced in three ways 1) Teaching staff will receive basic training on common mental health conditions affecting youth in Ghana with an emphasis on depression and suicidal symptoms and treatment. 2) Nurses in all schools and other relevant local health care professionals will be trained in mental health, substance-use and self-harm including guidelines on when and where to refer young people for psychiatric care. 3) The study team will provide a letter for the Guidance and Counselling Coordinators for the participant.
62082579|NCT06740084|EXPERIMENTAL|Y-MIND Intervention|All participants in the intervention arm will receive the EUC plus the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised Guidance and Counselling Coordinators (GCC) at schools in 6 sessions. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the GCC helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
62082580|NCT06342310|ACTIVE_COMPARATOR|1.5 mg RE104|A single subcutaneous injection of 1.5 mg RE104 for Injection
62082581|NCT06342310|EXPERIMENTAL|30 mg RE104|A single subcutaneous injection of 30 mg RE104 for Injection
62281773|NCT01756729|ACTIVE_COMPARATOR|Best Standard of Care|Patients recruited to the BSC group will be treated according to the BSC practiced at each center.
62281774|NCT01756729|EXPERIMENTAL|NovoTTF-100A (monotherapy)|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
62281775|NCT01463813|PLACEBO_COMPARATOR|Placebo|Placebo, no Vitamin D3
62281776|NCT01463813|EXPERIMENTAL|Vitamin D3 80|Vitamin D3 80 micrograms (3200 IU) per day
62281777|NCT01463813|EXPERIMENTAL|Vitamin D3 40|Vitamin D3 40 micrograms (1600 IU) per day
62281778|NCT03687502|EXPERIMENTAL|Experimental|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, up to 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
62649663|NCT04865809|EXPERIMENTAL|Trial Group|Patients from this group will use Peribioma Toothpaste and Mousse for home oral care.
62649664|NCT04865809|ACTIVE_COMPARATOR|Control Group|Patients from this group will use Biorepair Plus Parodontgel for home oral care.
62082582|NCT03030261|EXPERIMENTAL|Elotuzumab + Pomalidomide + Dexamethasone|"* Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study.~* Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol.~* Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT:~  * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+~ * 2 mg pomalidomide daily on Days 1-21 of all cycles~ * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+~* Continuation therapy may continue until relapse or progression."
62082583|NCT06719635|ACTIVE_COMPARATOR|Laparoscopic Presacral Neurectomy|The patients will undergo Laparoscopic Presacral Neurectomy under general anesthesia.
62082584|NCT06719635|ACTIVE_COMPARATOR|Fluoroscopically guided Superior Hypogastric Neurolysis|The patients will receive fluoroscopically guided Superior Hypogastric Plexus Neurolysis with Radiofrequency of the Sacral Roots 2,3,4.
62082585|NCT05685238|EXPERIMENTAL|Arm 1|Participants entering from the multiple ascending dose (MAD) part of study NN7769-4513. In part 1, participants will receive Mim8 prophylaxis (PPX) once every two weeks (Q2W) with subcutaneous (s.c.) administration using enhanced cartridge for 26 weeks. In part 2, participants will receive Mim8 PPX once-weekly (QW), Q2W or once-monthly (QM) with s.c. administration using enhanced cartridge or DV3407 pen-injector once it is approved.
62281779|NCT01274884|ACTIVE_COMPARATOR|Acromioclavicular joint dislocation|Surgery: Arthroscopic repair using the Tightrope fixation device
62281780|NCT05305807|EXPERIMENTAL|Study group|Postural exercises will be done to this group
62281781|NCT05305807|NO_INTERVENTION|Control group|Postural exercises will not be done to this group
62281782|NCT03513653||Acute heart failure|Patients hospitalized for acute heart failure and underwent echocardiography with speckle-tracking imaging
62281783|NCT01602588|EXPERIMENTAL|Arm B|Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.
62281784|NCT01602588|ACTIVE_COMPARATOR|Arm A: SCRT alone|Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy
62281785|NCT01560065|OTHER|Normospermic patients|
62281786|NCT01560065|OTHER|Oligoasthenospermic patients|
62281787|NCT01560065|NO_INTERVENTION|Control|
62082586|NCT05685238|EXPERIMENTAL|Arm 2|Participants entering from study NN7769-4514 or NN7769-4516. In part 1, participants will receive Mim8 PPX QW or QM with s.c. administration using DV3407 pen-injector for 26 weeks. In part 2, participants will receive Mim8 PPX QW, Q2W or QM with s.c. administration using DV3407 pen-injector.
62281788|NCT06131619||Experimental|Parkinson's disease patients with cognitive impairment
62281789|NCT06131619||Active Comparator|Parkinson's disease patients without cognıtıve impairment
62281790|NCT06131619||other|Health geriatric persons
62281791|NCT05181995|EXPERIMENTAL|50 mg NYX-783 QD|50 mg NYX-783 QD
62281792|NCT05181995|PLACEBO_COMPARATOR|Placebo|Placebo QD
62281793|NCT00626743|EXPERIMENTAL|SK3530|Active Drug
62281794|NCT00626743|PLACEBO_COMPARATOR|Placebo|Tablet which has the same appearance and taste but doesn't contain active ingredient
62281795|NCT01757717|EXPERIMENTAL|Ir-192 high dose rate (HDR)|This pilot study is an investigation into the use of Ir-192 high dose rate (HDR) afterloader-based brachytherapy with catheter placement using image-guided surgical navigation techniques for patients with painful/symptomatic metastatic or recurrent lesions in the spine and/or pelvis that have been maximally treated with external beam radiation therapy.
62281796|NCT03569852|EXPERIMENTAL|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
62281797|NCT03569852|EXPERIMENTAL|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
62281798|NCT00413959|EXPERIMENTAL|Velcade, Rituximab,Cyclophosphamide & Decadron|Velcade 375 mg/m\^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
62281799|NCT03213301|EXPERIMENTAL|Lurbinectedin|Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
62281800|NCT04775511|EXPERIMENTAL|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
62281801|NCT04775511|EXPERIMENTAL|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
62281802|NCT04775511|OTHER|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
62649665|NCT06032806|EXPERIMENTAL|Group A (Moderate Intensity)|Warm up protocol to reach max HR 50% than moderate intensity exercise. Group A will be given moderate intensity exercise i.e Brisk walk (HR will be in between 50-60% of max HR) .
62281803|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
62281804|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
62281805|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
62281806|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
62082587|NCT06392230|EXPERIMENTAL|Cohort 1|Participants will receive one dose of \[14C\] PF-06821497 by mouth in Period 1. After a washout, participants will receive one dose of PF-06821497 by mouth and one intravenous (IV) infusion of \[14C\] PF-06821497 in Period 2
62082588|NCT03941730|EXPERIMENTAL|Treatment (estradiol)|Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tissue biopsy at the end of cycle 1, collection of blood samples on C1D1, at the end of cycle 1, and at the end of treatment. In addition, patients undergo CT, MRI, or PET scans at baseline, at the end of cycles 2, 4, and 6, and then every 8 weeks until disease progression.
62281807|NCT02776163|EXPERIMENTAL|ACC|Intensity-modulated radiotherapy+concurrent chemotherapy with docetaxel and Nedaplatin
62281808|NCT02776163|EXPERIMENTAL|Non-ACC|Intensity-modulated radiotherapy+concurrent chemotherapy with docetaxel and Nedaplatin
62281809|NCT02154425|EXPERIMENTAL|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
62281810|NCT00052195|PLACEBO_COMPARATOR|B|
62281811|NCT00052195|EXPERIMENTAL|A|
62281812|NCT06473038|ACTIVE_COMPARATOR|Group that experience lower sodium intake|Lowering the salt and sugar in selected samples of foods this will be performed using dry ashing method, followed by flame atomic absorption spectrometry (FAAS) at the Department of Nutrition, Universiti Putra Malaysia.
62649666|NCT06032806|EXPERIMENTAL|Group B (High Intensity)|Warm up protocol achieve 70% of max HR. Group B will be given high intensity exercise i.e Skipping rope (HR will be in between 70-85% of max HR).
62082589|NCT06636864|EXPERIMENTAL|Intrathecal morphine group|Before induction of anesthesia, the experimental group received intrathecal morphine in the lumbar segment (L3/4).For our preliminary clinical application, the intrathecal morphine was 250ug for men and 200ug for women.
62649667|NCT03147326|OTHER|FDG-NaF-MRI|"All participants will undergo three project scans/the following interventions:~FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice."
62649668|NCT05968105||Group 1|Inferior vena cava diameter \<1.5 cm and VCI-CI \> 50% according to Vena Cava Inferior Collapsibility Index (VCI-CI)
62649669|NCT05968105||Group 2|Inferior vena cava diameter \>1.5 cm and VCI-CI \< 50% according to Vena Cava Inferior Collapsibility Index (VCI-CI)
62649670|NCT02432599|EXPERIMENTAL|F18-choline PET|F18-choline PET examination will be performed before surgery
62649671|NCT02105324|EXPERIMENTAL|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
62649672|NCT02105324|EXPERIMENTAL|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
62649673|NCT06115655||malignant patients|The presence of biliary stricture due to malignant diseases, such as cholangiocarcinoma.
62649674|NCT06115655||benign patients|The presence of biliary stricture due to benign diseases, such as inflammation.
62649675|NCT03206125||Controls|Controls
62649676|NCT03206125||ESCC Cases|ESCC Cases
62649677|NCT03884010||Participants|Professional male soccer players from the second professional Mexican division
62649678|NCT05063994|EXPERIMENTAL|Chronocort|Hydrocortisone modified-release capsule - Chronocort®. 25 subjects will be randomised to this group using an interactive response technology (IRT).
62649679|NCT05063994|ACTIVE_COMPARATOR|Cortef|Immediate-release hydrocortisone capsule (IRHC) - Cortef. 25 subjects will be randomised to this group using an interactive response technology (IRT).
62649680|NCT02979704|ACTIVE_COMPARATOR|Rosuvastatin|Intervention: Tablet Rosuvastatin (5-10) mg orally once daily dose for 08 weeks.
62649681|NCT02979704|ACTIVE_COMPARATOR|Atorvastatin|Intervention: Tablet Atorvastatin (10-20) mg orally once daily dose for 08 weeks
62649682|NCT05307393|NO_INTERVENTION|A|
62649683|NCT05307393|EXPERIMENTAL|B|Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement.
62649684|NCT05307393|EXPERIMENTAL|C|Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
62649685|NCT01719432||Obese patients|
62649686|NCT01719432||Non-obese patients|
62649687|NCT05598697|ACTIVE_COMPARATOR|Cash Transfers only|Participants allocated to this arm receive cash transfers. They are clients of a nation-wide cash transfer program.
62082590|NCT06636864|ACTIVE_COMPARATOR|Normal saline group|Before anesthesia induction, the control group received intrathecal injection of normal saline.
62082591|NCT05919264|EXPERIMENTAL|Part 1a|Solid Tumors with any WNT-Pathway Activating Mutation (WPAM) or Microsatellite Stable (MSS) Colorectal Cancer (CRC), irrespective of WPAM status
62082592|NCT05919264|EXPERIMENTAL|Part 1b|MSS CRC (known WPAM negative participants are not eligible)
62649688|NCT05598697|EXPERIMENTAL|Cash Transfers + LSB curriculum for females clients only|Participants allocated to this arm receive cash transfers and access to LSB curriculum training. Female cash transfer recipients attend 10 life-skills building sessions. Sessions are held weekly and are 90 minutes long. Two trained facilitators run the session for groups of 10 women over a ten-week period.
62649689|NCT05598697|EXPERIMENTAL|Cash Transfers + LSB curriculum for females clients and their husbands|Participants allocated to this arm receive cash transfers and access to LSB curriculum training in gender-segregated groups. Men and women attend 10 life-skills building sessions in parallel. Sessions are held weekly and are 90 minutes long. Two trained facilitators, whose gender matches the participants', run the session for groups of 10 women or men over a ten-week period.
62649690|NCT06134063|EXPERIMENTAL|Experimental group|
62649691|NCT06134063|PLACEBO_COMPARATOR|Control group|
62649692|NCT03938571|EXPERIMENTAL|Standard DS|"Standard duodenal switch:~1. Sleeve gastrectomy over a 35 Fr bougie~2. Division of the duodenum 2-3 cm distally of the pylorus~3. Measurement of the small bowel. 100 cm common channel. 150 cm alimentary limb.~4. Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~5. Entero-entero-anastomosis linear stapled and handsewn.~6. Division between the two anastomosis.~7. Closure of the mesenteric defects."
62649693|NCT03938571|ACTIVE_COMPARATOR|SADI-DS|"Duodenal switch with Single anastomosis duodeno-ileostomy:~1. Sleeve gastrectomy over a 35 Fr bougie~2. Division of the duodenum 2-3 cm distally of the pylorus~3. Measurement of the small bowel. 250 cm alimentary limb/common channel.~4. Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~5. Closure of the mesenteric defects."
62649694|NCT00496561|ACTIVE_COMPARATOR|1|subcutaneous immunotherapy (House Dust Mites)
62649695|NCT00496561|PLACEBO_COMPARATOR|2|placebo of subcutaneous immunotherapy (House Dust Mites)
62649696|NCT06550908|ACTIVE_COMPARATOR|Training with real images|Physicians train using the Paris classification with real colon polyp images
62281813|NCT06473038|OTHER|Control group|Participants have to provide urine samples for the measurement of urinary sodium, potassium, chloride, and creatinine, have body composition and anthropometric measurements taken, perform 24-hour dietary records, perform saltiness intensity perception and pleasantness ratings of the foods on campus, at three timepoints - at the start of the study, after 3 months and after 6 months.
62458750|NCT05916664|EXPERIMENTAL|Intervention|"The intervention is a care coaching program that assists caregivers with their general caregiving goals and financial caregiving goals. Caregivers will attend a one-on-one care coaching session conducted via Zoom for 60-75 minutes with a care coach and will engage with their care coach through chat-based interactions after completing the session. If requested, up to two additional care coaching sessions will be scheduled.~Caregivers also will have the opportunity to attend up to 6 weekly support groups with other caregivers facilitated by a care coach and receive a variety of digital resources through the mobile app."
62649697|NCT06550908|EXPERIMENTAL|Training with artificial images|Physicians train using the Paris classification with artificial colon polyp images
62649698|NCT00671268|EXPERIMENTAL|1|strict subcutaneous
62649699|NCT00671268|PLACEBO_COMPARATOR|2|strict subcutaneous
62649700|NCT00930618|EXPERIMENTAL|IMN|Isosorbide mononitrate
62649701|NCT00930618|PLACEBO_COMPARATOR|Placebo|Administration of placebo of IMN
62649702|NCT02830139|SHAM_COMPARATOR|Radical colorectal resection without HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and postoperative chemotherapy (XELOX)
62649703|NCT02830139|EXPERIMENTAL|Radical colorectal resection with HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (XELOX)
62649704|NCT02365883||Prostate Cancer Group|
62649705|NCT05493631|ACTIVE_COMPARATOR|Cohort 1 (2.0 mg/kg, once weekly)|"* Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~* Each vial contains 1mL of study drug~* The subjects will be treated with 2.0 mg/kg once weekly in cohort 1."
62649706|NCT05493631|ACTIVE_COMPARATOR|Cohort 2 (A mg/kg, once weekly)|"* Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~* Each vial contains 1mL of study drug~* The subjects will be treated with A mg/kg once weekly in cohort 2.~* The Dose A mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 1)."
62649707|NCT05493631|ACTIVE_COMPARATOR|Cohort 3 (B mg/kg, once weekly)|"* Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~* Each vial contains 1mL of study drug~* The subjects will be treated with B mg/kg once weekly in cohort 3.~* The Dose B mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 2)."
62649708|NCT02328508|EXPERIMENTAL|hyperbaric oxygen therapy|The experimental group received treatments in a hyperbaric chamber for 120-min per session, once per day, and five days per week for four consecutive weeks (20 treatment sessions).
62649709|NCT02328508|NO_INTERVENTION|Control|The control group received only routine care.
62649710|NCT01201863|EXPERIMENTAL|Low T Intervention - Androgel Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Androgel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
62082593|NCT05919264|EXPERIMENTAL|Part 1c|Hepatocellular Carcinoma (documented WPAM in APC or CTNNB1 required)
62458751|NCT05916664|NO_INTERVENTION|Control|Control group that does not receive the Caregiver Support Intervention
62458752|NCT00921336|EXPERIMENTAL|KW-2450|
62649711|NCT01201863|PLACEBO_COMPARATOR|Low T Intervention - Placebo Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Placebo gel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
62082594|NCT05919264|EXPERIMENTAL|Part 1d|Desmoid Tumors (documented WPAM in APC or CTNNB1 required)
62281814|NCT05536661|EXPERIMENTAL|Study group|Preservative free Hyaluronic acid 0.15% artificial tear instilled in both eyes 4 times daily for 3 days
62649712|NCT01201863|NO_INTERVENTION|Normal T|A subset of men with TBI meeting study criteria with normal T at screening were assessed at all data collection time points to provide a control group. Thirty-eight men obtained normal T levels at screening of which 24 were followed.
62649713|NCT01515124|NO_INTERVENTION|Lymphedema Care Only|"All 4 groups receive lymphedema care as follows:~1. 2 custom fitted compression garments (baseline and 6 months)~2. evaluations for flare-ups at request (and at each measurement time point)~3. lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions."
62649714|NCT01515124|EXPERIMENTAL|Exercise only|The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.
62649715|NCT01515124|EXPERIMENTAL|Weight loss only|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.
62649716|NCT01515124|EXPERIMENTAL|Exercise and Weight loss combined|Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.
62649717|NCT00922636|ACTIVE_COMPARATOR|Methylphenidate|Extended-release methylphenidate 18 milligrams per day (mg/day) to 54 mg/day, based on weight, given once daily (QD) and orally (po) as a capsule for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
62649718|NCT00922636|PLACEBO_COMPARATOR|Placebo|
62649719|NCT00922636|EXPERIMENTAL|LY2216684 (0.1 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
62649720|NCT00922636|EXPERIMENTAL|LY2216684 (0.2 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
62649721|NCT00922636|EXPERIMENTAL|LY2216684 (0.3 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
62649722|NCT05791617||Cases (Ischemic stroke)|Left and right middle cerebral artery ischemic stroke Patients presenting with acute onset focal neurological deficits and DWI-MRI evidence of an acute brain infarct of the left or right middle cerebral artery ischemic stroke.
62649723|NCT05791617||Controls (TIA)|Patients with acute focal neurological symptoms without brain infarct on MRI. Patients presenting with acute onset focal neurological deficits presumed to be of vascular origin, WITHOUT DWI-MRI evidence of an acute brain infarct.
62082595|NCT05919264|EXPERIMENTAL|Part 1e-1|Solid Tumors with documented WPAM or MSS CRC, irrespective of WPAM status
62082596|NCT05919264|EXPERIMENTAL|Part 1e-2|Solid Tumors with documented WPAM or MSS CRC, irrespective of WPAM status
62082597|NCT05919264|EXPERIMENTAL|Part 1f-1|MSS CRC (known WPAM negative participants are not eligible)
62082598|NCT05919264|EXPERIMENTAL|Part 1f-2|Solid Tumors with documented WPAM or MSS CRC (known WPAM negative participants are not eligible)
62082599|NCT05919264|EXPERIMENTAL|Part 1f-3|MSS CRC (known WPAM negative participants are not eligible)
62082600|NCT05919264|EXPERIMENTAL|Part 2a|MSS CRC, irrespective of WPAM status
62082601|NCT05919264|EXPERIMENTAL|Part 2b|Solid Tumors with documented WPAM
62649724|NCT03355144|EXPERIMENTAL|Internal Medicine residents at NYU|effect of supplying Internal Medicine residents at NYU with free coffee on self reported features of psychological health, energy and burnout
62649725|NCT05414188|ACTIVE_COMPARATOR|Pulmonary rehabilitation group|Patients will receive the radiation therapy according to the existing schedule. Additionally, patients in pulmonary rehabilitation group will participate pulmonary rehabilitation program more than two times per week.
62082602|NCT05919264|EXPERIMENTAL|Part 2c|Hepatocellular Carcinoma (documented WPAM in APC or CTNNB1 required)
62281815|NCT05536661|NO_INTERVENTION|Control group|No artificial tear instilation
62649726|NCT05414188|NO_INTERVENTION|Control group|Patients will receive the radiation therapy according to the existing schedule. There will be no additional treatment
62649727|NCT01911832|EXPERIMENTAL|Gastrectomy and subtotal gastrectomy|to compare the quality of life between esophagojejunostomy after total gastrectomy(TG group) and Roux-en-Y gastrojejunostomy after subtotal gastrectomy(SG group)
62649728|NCT01911832|EXPERIMENTAL|Wide and narrow reconstruction tube|to compare the quality of life between wide tube reconstruction after subtotal gastrectomy(WG group) and narrow tube reconstruction after subtotal gastrectomy(NG group) in Roux-en-Y gastrojejunostomy
62082603|NCT05919264|EXPERIMENTAL|Part 2d|Desmoid Tumors (documented WPAM in APC or CTNNB1 required)
62082604|NCT05919264|EXPERIMENTAL|Part 2e|Metastatic Castration-Resistant Prostate Cancer (documented WPAM in APC or CTNNB1 required)
62082605|NCT05919264|EXPERIMENTAL|Part 2f-1|MSS CRC (known WPAM negative participants are not eligible)
62082606|NCT05919264|EXPERIMENTAL|Part 2f-2|Solid Tumors with documented WPAM or MSS CRC (known WPAM negative participants are not eligible)
62082607|NCT05919264|EXPERIMENTAL|Part 2f-3|MSS CRC (known WPAM negative participants are not eligible)
62082608|NCT06737263|EXPERIMENTAL|BioHPP|High Performance Polymer as abutment material
62082609|NCT06737263|ACTIVE_COMPARATOR|Titanium|Titanium as abutment material
62281816|NCT05236803|OTHER|Epidemiology|Recording of participant's performance during eye, fine motor and gross motor tests Passing self and hetero questionnaires.
62082610|NCT06737263|ACTIVE_COMPARATOR|Zirconia|Zirconia as abutment material
62082611|NCT06481436|EXPERIMENTAL|Pre-Visit ChatGPT Use|After being consented, the participant will be provided with ChatGPT-4 application and a brief orientation to the program. The participant will then be instructed to ask ChatGPT about the participant's primary presenting problem with will be discussed at their urogynecology consultation. The participant will be allowed up to five follow-up/clarification entries into the Chat GPT program, but may finish asking questions at any time. This should take no more than five minutes of the participant's time. After completing this, the participant will be returned to the waiting room, and will proceed through the urogynecology visit as normal.
62082612|NCT06481436|EXPERIMENTAL|Post-Visit ChatGPT Use|After being consented, the participant will be returned to the waiting room and will proceed through the urogynecology visit as normal. After the visit, the participant will be provided with ChatGPT-4 application and a brief orientation to the program. The participant will then be instructed to ask ChatGPT about the participant's primary presenting problem with will be discussed at their urogynecology consultation. The participant will be allowed up to five follow-up/clarification entries into the Chat GPT program, but may finish asking questions at any time. This should take no more than five minutes of the participant's time. After completing this, the participant will be allowed to leave the visit.
62082613|NCT06481436|NO_INTERVENTION|No ChatGPT Use|After undergoing the consent process, participants will be returned to the waiting room to await the beginning of the appointment. The participant will complete the urogynecology visit as normal.
62082614|NCT06501729|NO_INTERVENTION|Control|The couples in the control group will not kiss; they will only wait for the salivary pH to neutralize physiologically.
62082615|NCT06501729|EXPERIMENTAL|Only one person consumes the drink|the group in which only one person in the couple consumes the sugary or fermented drink and they kiss
62082616|NCT06501729|EXPERIMENTAL|Both people consume the drink|In this group, both people will consume the drinks and then kiss.
62082617|NCT06737068|EXPERIMENTAL|Low Pressure Pneumoperitoneum (8-10 mmHg)|Elective robot assisted hiatal hernia repair with pneumoperitoneum pressures of 8-10 mmHg throughout the case
62082618|NCT06737068|OTHER|Standard Pressure Pneumoperitoneum (13-15 mmHg)|Elective robot assisted hiatal hernia repair with pneumoperitoneum pressures of 13-15 mmHg throughout the case
62082619|NCT06004388|EXPERIMENTAL|ReMMiD-C Therapeutic Arm A|Mobile application A (ReMMiD-C Digital Therapeutic) as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.
62082620|NCT06004388|EXPERIMENTAL|ReMMiD-C Therapeutic Arm B|Mobile application B as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.
62082621|NCT06409663|EXPERIMENTAL|NVX-CoV2705 vaccine (5 µg )|NVX-CoV2705 COVID-19 vaccine will contain rS antigen from the JN.1 subvariant of SARS-CoV-2
62082622|NCT03829631|EXPERIMENTAL|Intervention|Participants will be instructed to follow their current low back pain management program, in addition, they will be instructed to wear a lumbar brace (Horizon 627 Lumbar Brace) during the day for four weeks only when they are in pain in addition to their current management program.
62082623|NCT03829631|NO_INTERVENTION|Control|Participants will be instructed to follow their current low back pain management program.
62458753|NCT03386422|EXPERIMENTAL|Mindfulness Self-Compassion Intervention MSC|"Mindfulness Self-Compassion (MSC) is a standardized program to increase self-compassion. It has been developed by Neff and Germer. The structure of the program is similar to de Mindfulness-Based Stress Reduction program (MBSR), with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with practical and experiential exercices in sessions and between sessions.~The MSC program focuses primary on helping patients to develop self-compassion, and it includes Mindfulness just as a secondary component.~The MSC program will be conducted by a clinician trained in this specific program."
62649729|NCT06195085||CT-guided radioactive iodine-125 seed implantation|The patients, diagnosed with recurrent desmoid tumor, undergoing CT-guided radioactive iodine-125 seed implantation in 3 different centers including Peking University Third Hospital, First Affiliated Hospital of the Army Medical University, and Shengli Oilfield Central Hospital from July 2013 to July 2021.
62082624|NCT05398770|EXPERIMENTAL|Vitamin D3 (30 µg/d)|Subjects will take 30 µg vitamin D3 per day
62649730|NCT06082440|EXPERIMENTAL|Human Umbilical Mesenchymal Stem Cells|Participants received a single administration for Human Umbilical Mesenchymal Stem Cells during the treatment period.The specification is 2.5 × 10\^7cells/2ml suspension/branch.
62649731|NCT02111018|ACTIVE_COMPARATOR|CVVH|
62649732|NCT02111018|EXPERIMENTAL|CytoSorb Device|
62082625|NCT05398770|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo
62281817|NCT02504554|EXPERIMENTAL|Oral Group|This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
62281818|NCT02504554|EXPERIMENTAL|Rectal Group|This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
62649733|NCT03571035|EXPERIMENTAL|Example|Mandibular movements recordings by a mono vision system.
62649734|NCT06472479|EXPERIMENTAL|LCAR-M61S and LCAR-M61D|Each subject will be given a single-dose LCAR-M61S or LCAR-M61D cells infusion at each dose level.
62649735|NCT02770703|EXPERIMENTAL|Open inguinal hernia repair (Lichtenstein)|Open inguinal hernia repair using a DynaMesh visible mesh
62082626|NCT05681442|EXPERIMENTAL|continuous infusion dosing of a pivotal AND AG infusion for 5 days|continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT group)
62082627|NCT05681442|EXPERIMENTAL|intermittent infusion dosing of a pivotal βL-AB ND AG infusion for 5 days|intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)
62082628|NCT05681442|EXPERIMENTAL|continuous infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose|continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group )
62281819|NCT05495204||IBA+OBR (trials)|Participants in TMB-202 or TMB-301/311 trials who received 800 mg ibalizumab every 2 weeks, with or without a loading dose
62649736|NCT02770703|EXPERIMENTAL|Total extraperitoneal inguinal hernia repair (TEP)|Total extraperitoneal inguinal hernia repair using a DynaMesh visible mesh
62082629|NCT05681442|EXPERIMENTAL|intermittent infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose|intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)
62082630|NCT04867278|EXPERIMENTAL|External Beam Radiation (XRT) with Debridement|Patients will receive gluteus minimus debridement in the OR, which is the standard of care at Shock Trauma. If randomized to the treatment group, patients that undergo surgical fixation of an acetabular fracture via a posterior or combined anterior and posterior approach will undergo a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery. This treatment is currently the standard procedure performed for all patients who undergo a posterior or combined approach at our institution.
62649737|NCT02770703|EXPERIMENTAL|Trans abdominal preperitoneal hernia repair (TAPP)|Trans abdominal preperitoneal hernia repair using a DynaMesh visible mesh
62458754|NCT03386422|ACTIVE_COMPARATOR|Cognitive-Behavioural Intervention CBT|"It has been adapted a Cognitive-Behavioural Intervention for Chronic Pain by Moix and Kovacs. Our program will have 8 sessions, with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with homework between sessions.~During these 8 sessions we will train the following techniques: psychoeducation about pain, relaxation training, cognitive restructuring training, solving problem training, psychoeducation about emotions, interpersonal skills and time organization."
62649738|NCT04673929||patients with HNC recurrence treated with TORS|Report of disease-free survival at 2 years for patients with HNC recurrence treated with TORS
62649739|NCT00175227|EXPERIMENTAL|Intervention|Saline hydration + mannitol + furosemide
62649740|NCT00175227|PLACEBO_COMPARATOR|Controls|Saline hydration without mannitol or furosemide
62649741|NCT05267704|EXPERIMENTAL|VR Arm|Pediatric patients age 5-17 using the VR headset during renal biopsy.
62649742|NCT03477656|EXPERIMENTAL|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption according to the initial isoagglutinin titer.
62649743|NCT03477656|EXPERIMENTAL|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis according to the initial isoagglutinin titer.
62649744|NCT06366789|EXPERIMENTAL|ZE46-0134 Dose Level -1|Optional and would only be performed Dose Level 1 is poorly tolerated
62082631|NCT04867278|ACTIVE_COMPARATOR|Debridement Alone (Control)|The control treatment arm will only include gluteus minimus debridement in the OR and will not receive XRT.
62082632|NCT05109494|ACTIVE_COMPARATOR|Conventional Fractionated|radiation treatments will be delivered daily, delivered over a maximum of 7 weeks from the first treatment, surgery will be within 5-14 days of completion of RT
62082633|NCT05109494|EXPERIMENTAL|Hypofractionated|the maximum frequency of treatment will be every day and the minimum frequency will be every other day, delivered over a maximum of 3 weeks from the first treatment, surgery will be within 5-14 days of completion of RT
62082634|NCT05691283|EXPERIMENTAL|transcranial direct current stimulation (tDCS), then sham stimulation|Participants receives three weeks of 20-minute tDCS stimulation. After a washout period of 3 months, they then receive three weeks of sham stimulation
62082635|NCT05691283|EXPERIMENTAL|Sham stimulation, then transcranial direct current stimulation (tDCS)|Participants receives three weeks of sham stimulation. After a washout period of 3 months, they then receive three weeks of 20-minute tDCS stimulation
62281820|NCT05495204||Non-IBA+OBR (OPERA)|Heavily treatment experienced adults living with HIV in care in OPERA, with documented resistance to ≥1 ARV from each of three ARV classes switching to a new regimen that does not include ibalizumab
62458755|NCT04370665|EXPERIMENTAL|Open label single arm|Using Exablate Model 4000 Type-2 to temporarily disrupt the blood brain barrier to deliver Cerezyme in patients with Parkinson's Disease.
62649745|NCT06366789|EXPERIMENTAL|ZE46-0134 Dose Level 1|
62649746|NCT06366789|EXPERIMENTAL|ZE46-0134 Dose Level 2|
62649747|NCT06366789|EXPERIMENTAL|ZE46-0134 Dose Level 3|
62281821|NCT04451707||non-cholera Vibrio infection|Patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019
62649748|NCT06366789|EXPERIMENTAL|ZE46-0134 Dose Level 4|
62649749|NCT06366789|EXPERIMENTAL|ZE46-0134 Dose Level 5|
62649750|NCT06366789|EXPERIMENTAL|ZE46-0134 Selected dose 1|The doses used in Part 2 of the study will be determined based on the data from Part 1 of the study and will not exceed a loading dose of 150 mg x 2 days and maintenance dose of 50 mg QD
62649751|NCT06366789|EXPERIMENTAL|ZE46-0134 Selected dose 2|The doses used in Part 2 of the study will be determined based on the data from Part 1 of the study and will not exceed a loading dose of 150 mg x 2 days and maintenance dose of 50 mg QD
62649752|NCT00197678|EXPERIMENTAL|Multivitamins-Single RDA|Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
62649753|NCT00197678|ACTIVE_COMPARATOR|Multivitamins-Multiples of RDA|Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
62649754|NCT02104440|EXPERIMENTAL|Patients with cytopenia after allo-HSCT|Patients with cytopenia after allo-HSCT
62082636|NCT03899103|EXPERIMENTAL|Repeated Courses of Rituximab Only|First course Course Rituximab at Randomization. Prophylactic 2nd and 3rd course rituximab re-administration will be done at 8 months and 16 months of follow-up if B cell count normalize.
62082637|NCT03899103|ACTIVE_COMPARATOR|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
62082638|NCT05431010|EXPERIMENTAL|electroacupuncture and rehabilitation training|Participants in this group will received electroacupuncture（EA） combined with Otago exercise program(OEP). Acupuncture will be executed with size 0.30×40mm needle. EA will be performed with electronic acupuncture instruments
62281822|NCT01894204|OTHER|HTPPE|No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.
62082639|NCT05431010|ACTIVE_COMPARATOR|rehabilitation training only|The rehabilitation group will be only treated with the Otago exercise program(OEP). The Otago Exercise is a program developed by the research group of fall prevention in the elderly led by Campbell of Otago Medical University in the 1990s. It is a home exercise program aimed at strengthening lower extremity muscle, balance and preventing falls in the elderly. Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia (details are as follows).
62082640|NCT06064877|EXPERIMENTAL|Arm 1 (Investigational Arm: ficlatuzumab plus cetuximab)|Intravenous (IV) ficlatuzumab dose A on Day 1 (D1) and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
62082641|NCT06064877|EXPERIMENTAL|Arm 2 (Investigational Arm: ficlatuzumab plus cetuximab)|IV ficlatuzumab dose B on D1 and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
62082642|NCT06064877|PLACEBO_COMPARATOR|Arm 3 (Comparator Arm: placebo plus cetuximab)|IV placebo (saline, ficlatuzumab-matched) on D1 and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
62082643|NCT05676489|EXPERIMENTAL|Healthy Volunteers (cohort 1)|Whole Body Dosimetry for healthy volunteers
62082644|NCT05676489|EXPERIMENTAL|High Grade Glioma (cohort 2)|Recurrent high grade glioma after radiation therapy
62082645|NCT05676489|EXPERIMENTAL|Brain Metastasis (cohort 3)|Brain metastases from extra-cranial solid tumors before and after radiation therapy
62082646|NCT06249334|EXPERIMENTAL|Whole-body electrical stimulation (WB-EMS)|WB-EMS will be performed with ReCare® equipment (Visuri, Minas Gerais, Brazil). Patients will perform sessions once a day, totaling a maximum of 15 sessions. In addition to the WB-EMS protocol, the patients will receive routine physiotherapy at the hospital.
62082647|NCT06249334|ACTIVE_COMPARATOR|Routine physical therapy|"Patients in the control group (active comparator) will receive routine hospital physical therapy until the moment of hospital discharge.~No intervention with electrical stimulation will be performed in this group."
62458756|NCT01468090||Disease course|562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
62082648|NCT06360354|EXPERIMENTAL|Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A|"Part 1: Participants with MTAP-deleted PDAC will receive escalating doses of AMG 193 orally in combination with gemcitabine and nab-paclitaxel IV.~Part 2: Participants with MTAP-deleted PDAC will receive the recommended dose of AMG 193 in combination with gemcitabine and nab-paclitaxel."
62082649|NCT06360354|EXPERIMENTAL|Subprotocol B: PDAC Arm B|"Part 1: Participants with MTAP-deleted PDAC will receive escalating doses of AMG 193 orally in combination with mFOLFIRINOX (irinotecan, fluorouracil, leucovorin calcium, oxaliplatin) IV.~Part 2: Participants with MTAP-deleted PDAC will receive the recommended dose of AMG 193 in combination with mFOLFIRINOX."
62082650|NCT05907707|EXPERIMENTAL|First gamma (40Hz) stimulation, then active control (21Hz) stimulation|After collecting sleep EEG at home for one night to acclimate to the data collection during sleep, participants first receive gamma (40Hz) tACS on Day 1 followed by a 5-9 day washout. Participants then receive active control (21Hz) stimulation.
62082651|NCT05907707|EXPERIMENTAL|First active control (21 Hz) stimulation, then gamma (40 Hz) stimulation|After collecting sleep EEG at home for one night to acclimate to the data collection during sleep, participants first receive active control (21Hz) tACS on Day 1 followed by a 5-9 day washout. Participants then receive gamma (40Hz) stimulation.
62082652|NCT06737276|EXPERIMENTAL|Experimental Group 1 (EG1)|Participants received a multimodal intervention (intervention order: interactive fiction activities and role-play simulation).
62082653|NCT06737276|EXPERIMENTAL|Experimental Group 2 (EG2)|Participants received a multimodal intervention (intervention order: role-play simulation and interactive fiction activities).
62082654|NCT06737276|NO_INTERVENTION|Control Group (CG)|Participants received a conventional practical teaching based on lectures.
62281823|NCT05135715|EXPERIMENTAL|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62281824|NCT04772027||Muscular dystrophies group|40 patients with limb girdle muscular dystrophie
62458757|NCT05540509|EXPERIMENTAL|Community-based intervention|This program consisted of 12 group exercise sessions over a three-month period that were offered in Spanish and English. Each two-hour session consisted of 90 minutes of flexibility, cardiovascular, and strength exercises to meet physical activity recommendations and 30 minutes of group discussions that focused on topics related to the adoption and maintenance of physical activity.
62649755|NCT04887363|EXPERIMENTAL|Core exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
62082655|NCT06155279|EXPERIMENTAL|Single arm|"Single arm Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab~The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
62082656|NCT03630562|OTHER|Patients with exudative AMD|
62082657|NCT05683418|EXPERIMENTAL|TOS-358 Single Agent Arm|Multiple doses of TOS-358 for oral administration.
62082658|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
62082659|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
62082660|NCT06183892|EXPERIMENTAL|Prolonged-release tacrolimus|
62082661|NCT05464719|EXPERIMENTAL|Loncastuximab Tesirine|Participants will receive Loncastuximab Tesirine (lonca) by vein.
62082662|NCT04006717|NO_INTERVENTION|Control|Routine root canal treatment
62082663|NCT04006717|PLACEBO_COMPARATOR|Low-Level Laser Placebo|Patient informed that laser will be applied but device won't be turned on
62082664|NCT04006717|EXPERIMENTAL|Low-Level Laser Therapy|Low-Level Laser Therapy following root canal treatment
62082665|NCT04006717|EXPERIMENTAL|Intracanal Cryotherapy|Cold saline irrigation before obturation
62082666|NCT04006717|EXPERIMENTAL|Combination of LLLT and ICCT|Both cold saline irrigation before obturation and Low-level laser Therapy after root canal treatment
62082667|NCT00798070|EXPERIMENTAL|Arm A: dtEC→dtT|Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week
62458758|NCT05540509|ACTIVE_COMPARATOR|Home-based intervention|Mothers randomized to the HBI group participated in a three-month program where they were given print-based materials (offered in Spanish or English) at each monthly assessment time point. The print-based materials provided information on multiple cardiovascular, strength training, and flexibility exercises that they could do at home.
62082668|NCT00798070|ACTIVE_COMPARATOR|Arm B: FEC→T|Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel
62082669|NCT06736587|EXPERIMENTAL|Cohort2|SAD
62082670|NCT06736587|EXPERIMENTAL|Cohort3|SAD
62082671|NCT06736587|EXPERIMENTAL|Cohort4|SAD
62082672|NCT06736587|EXPERIMENTAL|Cohort5|SAD
62082673|NCT06736587|EXPERIMENTAL|Cohort6|SAD
62082674|NCT06736587|EXPERIMENTAL|Cohort7|MAD
62082675|NCT06736587|EXPERIMENTAL|Cohort8|MAD
62082676|NCT06736587|EXPERIMENTAL|Cohort9|MAD
62082677|NCT06736587|EXPERIMENTAL|Cohort10|MAD
62082678|NCT06736587|EXPERIMENTAL|Cohort1|SAD
62281825|NCT04772027||Comparator group|40 healthy volunteers without neuromuscular or squeletic disorder
62458759|NCT00890877|EXPERIMENTAL|1|
62649756|NCT04887363|EXPERIMENTAL|Tai Chi exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
62649757|NCT04887363|NO_INTERVENTION|Young adults group|The healthy young adults who have not any neurological, musculoskeletal or rheumatic disease were recruited as a reference group. They would not receive any training program in the study.
62082679|NCT06501365|EXPERIMENTAL|PIC-TRFS Intervention|Post-Intensive Care Transitions, Rehabilitation and Family Support (PIC-TRFS) is a complex dyadic intervention consisting of 4 essential elements: (1) rehabilitation; (2) health and symptom management; (3) social support; (4) healthcare coordination. It is delivered by an interventionist team. One trained interventionist leads the healthcare coordination, health and symptom management, and social support. An occupational therapist interventionist leads the rehabilitation. Following a Run-In period in the hospital, the interventionists deliver PIC-TRFS via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS.
62458760|NCT00890877|EXPERIMENTAL|2|
62458761|NCT00890877|EXPERIMENTAL|3|
62458762|NCT00890877|EXPERIMENTAL|4|
62458763|NCT05993156|ACTIVE_COMPARATOR|Removable twin block group|participants would receive conventional removable twin block for correction of class II malocclusion for 9 months
62649758|NCT03095235|EXPERIMENTAL|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
62082680|NCT06501365|ACTIVE_COMPARATOR|Enhanced Usual Care Control|After receiving the Run-In and being randomized to control, this group will receive a brochure on critical illness survivorship, outcome ascertainment on the same schedule as the intervention group, and intervention for serious adverse events (e.g., suicidal ideation) identified during study conduct. This design limits exposure of the control group to the hypothesized essential elements of the PIC-TRFS intervention, while maintaining regular contact to enhance retention and outcomes ascertainment, and addressing safety concerns among participants.
62458764|NCT05993156|EXPERIMENTAL|Fixed twin block group|participants would receive a modified fixed twin block for correction of class II malocclusion for 9 months
62458765|NCT01199861|EXPERIMENTAL|Fingolimod|Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
62082681|NCT06381492||Bone-patellar tendon-bone (BPTB)|This group will have patellar injury confirmed through self-reported surgical history and evidence of ipsilateral BPTB graft harvest on ultrasound.
62082682|NCT06381492||Patellar tendinopathy group|"This group will have patellar tendinopathy confirmed based on International Scientific Tendinopathy Symposium Consensus on Clinical Terminology (ICON) statement, which defines patellar tendinopathy as persistent patellar tendon pain and loss of function related to mechanical loading. Ultrasound diagnosis must confirm alteration of tendon macrostructure."
62281826|NCT05673343||Complete blood count|"Complete blood count with differential should be done within 2 weeks before starting CCRT. We will calculate NLR as total neutrophilic count divided by total lymphocytic count for each patient before starting the treatment.~Two protocols of the treatment: first is by starting with CCRT then surgery (Total Neoadjuvant Therapy), second is CCRT then surgery then continue chemotherapy: FOLFOX , Xeloda or CAPOX.~Radiotherapy dose: long course radiation therapy at the dose of 45 to 50 Gray (Gy) in 25 to 28 fractions to the pelvis by NCCN recommendation. Short-course radiation therapy (25 Gy in 5 fractions).~Patients should be kept on follow up after complete their treatment every three months till disease progression occur, death of the patient or at least 12 months of follow up."
62082683|NCT06381492||Healthy knees|Control group of participants with healthy knees
62281827|NCT05284409|ACTIVE_COMPARATOR|Pethidine|(control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia.
62458766|NCT01199861|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
62082684|NCT01812343|OTHER|Exercise test|Ankle pressure Index measure before and after Maximal Exercise Tests
62082685|NCT06723470||Group 1: Passive Smokers|This group includes children aged 6-11 years who are exposed to secondhand smoke at home. At least one parent or caregiver is a smoker, with a smoking history of no less than six years. The level of exposure is categorized as moderate to high based on the smoking index (number of cigarettes per day multiplied by years of smoking).
62082686|NCT06723470||Group 2: Non-Smokers|This group includes children aged 6-11 years who are not exposed to secondhand smoke at home or in other environments. Neither parent nor caregiver is a smoker, ensuring no passive smoke exposure.
62281828|NCT05284409|EXPERIMENTAL|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia.
62458767|NCT00193037|EXPERIMENTAL|Liposomal Doxorubicin|Liposomal doxorubicin 40 mg/m2 by 1 hour IV infusion repeated every 28 days.
62458768|NCT00193037|EXPERIMENTAL|Docetaxel|Weekly docetaxel 36 mg/m2 by 30 minute IV infusion on days 1, 8, and 15 of the 28 day cycle
62458769|NCT01919190|ACTIVE_COMPARATOR|EXPAREL|EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
62458770|NCT01919190|SHAM_COMPARATOR|Placebo|The placebo control will be established using a grade-2 sham, no infiltration will occur
62458771|NCT01740661|EXPERIMENTAL|Cryotherapy|The subjects will be exposed to a cold (\~ 12° C) water immersion tub at the umbilical level for 20 minutes.
62458772|NCT01740661|PLACEBO_COMPARATOR|Control|The subjects will be exposed to a non-cold (\~ 26° C) water immersion tub at the umbilical level for 20 minutes.
62458773|NCT01520948|EXPERIMENTAL|Exercise-based behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
62458774|NCT01520948|PLACEBO_COMPARATOR|Behavioral control|Mirrored Star Drawing
62649759|NCT03498677|ACTIVE_COMPARATOR|Method of presentation one|
62649760|NCT03498677|ACTIVE_COMPARATOR|Method of presentation two|
62649761|NCT01242982|EXPERIMENTAL|Operation|Closed reduction and operated for fixation with 2 antegrade intramedullary Kirschner wires.
62649762|NCT01242982|ACTIVE_COMPARATOR|Conservative treatment|Treated conservatively with reduction and then Plaster of Paris.
62649763|NCT04913831|EXPERIMENTAL|Cerebrolysin|
62649764|NCT04913831|PLACEBO_COMPARATOR|Placebo|
62649765|NCT04879368|EXPERIMENTAL|RegoNivo|"Participants in the RegoNivo arm will;~1. self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and;~2. receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion.~After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days."
62082687|NCT06632496||USGPIV|Patient who is a candidate for an ultrasound-guided peripheral intravenous catheter (USGPIV) placement procedure (midline catheters included) using BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology as assessed per their clinician(s)
62649766|NCT04879368|ACTIVE_COMPARATOR|Standard of Care|"Participants in the control arm will receive investigator choice chemotherapy with any of the following agents~* taxane (paclitaxel or docetaxel)~* irinotecan or~* oral trifluridine/tipiracil (TAS102)~All treatment groups will receive Best Supportive Care (BSC)."
62281829|NCT05284409|EXPERIMENTAL|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
62281830|NCT04178772|EXPERIMENTAL|JJVC Marketed Contact Lens|Eligible subjects that have no experience with soft multifocal lenses for more than 2 years will be assigned to a single study lens type worn in both eyes daily for at least 6 hours per day, everyday for approximately 12 weeks.
62082688|NCT04522843||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
62082689|NCT04522843||Colitis|Patients with active colitis
62082690|NCT04522843||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
62082691|NCT04623502|EXPERIMENTAL|13C-Glucose|
62281831|NCT02647073|EXPERIMENTAL|Mobile monitoring device arm|Canary 01 Mobile Vital Signs Monitoring Device
62281832|NCT06548191|ACTIVE_COMPARATOR|Delayed-Start Intervention|Participants will continue thier regular eating schedule (nightly fasting for less than 10 h) during the first 6 months and start time-restricted eating intervention ( 14 h of nightly fasting) for the next 6 months.
62281833|NCT06548191|ACTIVE_COMPARATOR|Intervention|Participants will follow the time-restricted regimen (14 h of nightly fasting) for 12 months.
62281834|NCT01263041|EXPERIMENTAL|glutamine, PT, sepsis|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
62082692|NCT04623502|EXPERIMENTAL|13C-Acetate|
62082693|NCT04623502|EXPERIMENTAL|13C-Lactate|
62649767|NCT04867759||Study group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
62649768|NCT04867759||Control group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
62649769|NCT02384447||Knee Amputation|Patients that are scheduled to undergo above knee amputation due to complications associated with diabetes will be enrolled
62649770|NCT05423951|EXPERIMENTAL|Remimazolam|
62649771|NCT05423951|ACTIVE_COMPARATOR|Propofol|
62649772|NCT03125174||control|healthy individuals with no history of lung disease
62281835|NCT01263041|NO_INTERVENTION|Control|after been allocated, will receive nothing and observed for the same outcomes
62281836|NCT01263041|EXPERIMENTAL|L-arginine,NEC, PT|enteral or via NG tube dose of 260 mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
62281837|NCT05070884||non respondants of neo treatment|those patients with no response or partial response when administered with Chemotherapy prior to sugery
62281838|NCT05501600|EXPERIMENTAL|Lidocaine|Subjects will receive lidocaine during the drug portion of the experiment.
62281839|NCT00087373|EXPERIMENTAL|Treatment (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM intratumorally on day 1 of weeks 1, 4, and 7 (maximum of 3 injections for a single lesion) (course 1). After 3 injections (course 1), patients with stable or responding disease receive additional injections into new lesions following the same schedule as above. Treatment repeats every 9 weeks for a maximum total of 9 injections (3 injections total into a maximum of 3 different tumors) (total of 3 courses) in the absence of disease progression or unacceptable toxicity
62649773|NCT03125174||bronchiectasis patients|individuals with a diagnoses of bronchiectasis
62082694|NCT04623502|EXPERIMENTAL|13C-Glutamine|
62082695|NCT04623502|EXPERIMENTAL|13C-Fructose|
62281840|NCT02528240|EXPERIMENTAL|+ L-PRF|With leukocyte and platelet rich fibrin
62082696|NCT02654379||Cohort|Cohort consisting of participants who are in the center to receive an infusion for rituximab for a non-oncology indication.
62082697|NCT04023422|ACTIVE_COMPARATOR|Clinical intervention|Clinical health navigator, a community health worker, facilitates preparation for, attends, and confirms patients's understanding of an office visit.
62082698|NCT04023422|EXPERIMENTAL|Clinical intervention AND Home Visit|Patient receives Clinical intervention and Home visits. Care coordination activities occur taking into account the home environment, its social and physical characteristics.
62082699|NCT04023422|EXPERIMENTAL|Clinical intervention AND Feedback|
62082700|NCT04023422|EXPERIMENTAL|Clinical intervention AND Home Visit AND Feedback|
62082701|NCT06191133|EXPERIMENTAL|Excisional procedure + Fenofibrate|Participants with high-grade dysplasia will receive 200mg of Fenofibrate starting on the day of enrollment and will continue the drug administration daily for 2-4 weeks +/- 7 days until their excisional procedure
62082702|NCT06191133|EXPERIMENTAL|Hysterectomy or chemoradiation + fenofibrate|Participants with invasive cervical cancer will receive 200mg of Fenofibrate starting on the day of enrollment and will continue the drug administration daily for 2-4 weeks +/- 7 days until their definitive hysterectomy or chemoradiation
62082703|NCT04755140||Endoprosthesis|Patients with a endoprosthesis
62281841|NCT02528240|ACTIVE_COMPARATOR|- L-PRF|Without leukocyte and platelet rich fibrin
62649774|NCT02426099|EXPERIMENTAL|Low dose Spironolactone|Add-on low dose 25 mg Spironolactone to current hypertension treatment
62649775|NCT02426099|ACTIVE_COMPARATOR|Routine|Routine intensification of anti hypertensive treatment based on existing guidelines
62649776|NCT04077762|ACTIVE_COMPARATOR|Radial access|Radial access for cardiac catheterization. Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
62649777|NCT04077762|ACTIVE_COMPARATOR|State-of-the-art femoral access|Femoral access for cardiac catheterization. Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
62649778|NCT05198141|ACTIVE_COMPARATOR|Control group I (GI)|Patients who were undergoing surgical treatment
62649779|NCT05198141|EXPERIMENTAL|low dose letrozole group II (GII)|patients who were medically treated with 5 mg of letrozole
62649780|NCT05198141|EXPERIMENTAL|High dose letrozole group (GIII)|patients who were medically treated with 10 mg of letrozole using
62649781|NCT04290104|EXPERIMENTAL|1gr oral ampicillin/sulbactam group|The group to be prescribed 1 g oral ampicillin/sulbactam twice a day while discharged after laparoscopic cholecystectomy due to ACC.
62649782|NCT04290104|NO_INTERVENTION|Antibiotic not prescribed group|Antibiotics not prescribed when discharged after laparoscopic cholecystectomy due to ACC.
62649783|NCT04482634|ACTIVE_COMPARATOR|Tele-rehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection.
62649784|NCT04482634|ACTIVE_COMPARATOR|Home exercise group|This group will perform the exercises at their home on their own, the first exercise program will be given at hospital and the patients will be followed up regular weekly by phone call.
62281842|NCT02831465|EXPERIMENTAL|healthy subjects|Subjects with normal lung function between 40 and 70 years old.
62458775|NCT02523105|OTHER|Participants diagnosed with depression.|EEG monitoring and evaluation
62458776|NCT02523105|OTHER|Healthy participants.|EEG monitoring and evaluation
62458777|NCT04638153|EXPERIMENTAL|Low Dose|Low Dose
62458778|NCT04638153|EXPERIMENTAL|Medium Dose|Medium Dose
62458779|NCT04638153|EXPERIMENTAL|High Dose|High Dose
62458780|NCT04638153|EXPERIMENTAL|PK Phase 2 Formulation|Phase 2 formulation \[process 1c\] 3mg/kg
62649785|NCT05719168|EXPERIMENTAL|Patients with medical refractory GERD|"Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.~Participants undergo a hydrogen and emthane breath test on a seperate day."
62649786|NCT05719168|ACTIVE_COMPARATOR|Healthy controls without gastrointestinal symptoms|Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.
62649787|NCT01813747|EXPERIMENTAL|1440 nm wavelength laser with hand piece|To assess the effectiveness of the 1440 nm wavelength laser with handpiece for skin tightening and laser lipolysis for the mandibular and sub-mandibular areas
62082704|NCT06738953|EXPERIMENTAL|Behavioral: Cognitive-behavioral intervention to increase self-efficacy|n = 189 participants will be allocated randomly to this study arm.
62082705|NCT06738953|PLACEBO_COMPARATOR|Behavioral: Group Discussion on Psychological Experiments as active Control|n = 189 participants will be allocated randomly to this study arm.
62082706|NCT01508299|EXPERIMENTAL|raw food skin test|skin test with the suspected raw food
62281843|NCT02167945|EXPERIMENTAL|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.
62281844|NCT04801628|ACTIVE_COMPARATOR|Active Tecar|"Transfer Electrode Capacitive and Resistive (TECAR) Therapy (radio frequency therapy; INDIBA, Spain) will be used. In CET mode, heat transfer is concentrated on the skin and superficial muscles, which are tissue with high electrolytes, while the RET mode focuses heat transfer on bones, tendons, joints, and deep muscles. In this study, both CET and RET modes will be applied to the participant' quadriceps for 15-20 minutes at stable frequency of 448 KHz. According to the manufacturer's guidelines for safety, the CET mode will be first implemented for 5 minutes. Then will be continued in RET mode using for the rest of the treatment. Participants will be asked to lie down comfortably, and treatment will be beginning.~The intensity of the current will be set at the level of comfort between 0%-100%, averaging about 40%. TECAR therapy will be applied by a physical therapist for all participants."
62458781|NCT04638153|EXPERIMENTAL|PK Phase 3 Formulation|Phase 3 formulation \[process 2\] 3mg/kg
62458782|NCT00721604||1|patients with mean arterial pressure lower than 65 mmHg
62281845|NCT04801628|PLACEBO_COMPARATOR|Placebo Tecar|the same procedure as in active Tecar but the device not provide any radio frequency
62649788|NCT06493916||Endotracheal Intubated Group|Endotracheal tube insertion applied group
62082707|NCT06720311|ACTIVE_COMPARATOR|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy|
62458783|NCT03925870|EXPERIMENTAL|KN046 monotherapy|Eligible subjects will be enrolled and receive KN046 monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first.
62458784|NCT03354026|EXPERIMENTAL|Experimental: AICH-PXZY|Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
62458785|NCT03354026|EXPERIMENTAL|Experimental: AICH-without PXZY|Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
62458786|NCT03354026|PLACEBO_COMPARATOR|Placebo: AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
62458787|NCT01316562||Group 1|Healthy controls
62649789|NCT02426684|EXPERIMENTAL|IdeS®|Twenty patients will receive 0.24mg/kg (n=20)
62649790|NCT03495518|ACTIVE_COMPARATOR|Symptom feedback to Health Care Provider|"For those randomized to the intervention arm, symptom screening using SPARK will be completed once daily for 5 days on an iPad using the approach refined in aim 2. Daily SSPedi reports will be printed and provided in the patient chart. On days 1 and 3±1, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical care"
62649791|NCT03495518|ACTIVE_COMPARATOR|Standard of care|For those randomized to the control arm, a clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
62649792|NCT01913301|EXPERIMENTAL|Alagebrium|
62649793|NCT00913601|EXPERIMENTAL|Dextra|Unilateral sacral nerve stimulation dextra for 4 weeks
62649794|NCT00913601|EXPERIMENTAL|Sinistra|Unilateral sacral nerve stimulation sinistra 4 weeks
62649795|NCT00913601|EXPERIMENTAL|Bilateral|Bilateral sacral nerve stimulation 4 weeks
62082708|NCT06720311|ACTIVE_COMPARATOR|Flexible Ureterorenoscopy|
62082709|NCT06720311|ACTIVE_COMPARATOR|Shockwave Lithotripsy|
62082710|NCT06401538|EXPERIMENTAL|BMB-101|BMB-101 10 mg/ml liquid
62458788|NCT01316562||Group 2|Patients with an Alzheimer's disease or related disorders
62458789|NCT03156062|EXPERIMENTAL|study group|
62458790|NCT03156062|ACTIVE_COMPARATOR|control group|
62649796|NCT05920005|EXPERIMENTAL|Association of candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg|The participant will take, once a day, 01 tablet of the active experimental drug (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg), plus 01 placebo, both orally.
62649797|NCT05920005|ACTIVE_COMPARATOR|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|The participant will take 01 tablet of Exforge HCT® active comparator (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) plus 01 placebo, both orally.
62649798|NCT01835106|ACTIVE_COMPARATOR|Epidural|Epidural catheter is used postoperatively
62649799|NCT01835106|EXPERIMENTAL|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
62649800|NCT05440032||Synovial fluid testing with semi-quantitative leukocyte esterase test strip|Using a drop of synovial fluid, sample will be analyzed via the point-of-care device to measure amount of leukocyte esterase in the sample
62649801|NCT05440032||Synovial fluid testing with Roche Chemstrip|Using a drop of synovial fluid, sample will be analyzed via a urine test-strip to measure amount of leukocyte esterase in the sample
62649802|NCT02879214|EXPERIMENTAL|SIDE cervical trial|To Maximal downstage locally advanced squamous cell cervical cancer before minimal invasive surgical resection. The SIDE study is to use both RT dose escalation to the biological target defined by PET and Chemo dose escalation composited with two drugs to achieve maximal reduction of tumor burden, providing feasibility of minimal invasive surgical resection.
62649803|NCT02686996|ACTIVE_COMPARATOR|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (2 tablets twice daily) for 14 weeks
62649804|NCT02686996|PLACEBO_COMPARATOR|Control|Each participant will be given a daily oral dose 2 g of identical placebo tablets ( 2 tablets twice daily) for 14 weeks
62649805|NCT05216484|EXPERIMENTAL|two doses CoronaVac group|the third does was given 6 months after two doses CoronaVac group
62082711|NCT05620914|EXPERIMENTAL|Patritumab deruxtecan|15 participants with surgically-resectable brain metastases from multiple solid tumor primary histologies known to express HER3 will be treated. Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of BrM. Participants will undergo specimen collection prior to and during the planned craniotomy, including tumor, blood, and cerebrospinal fluid (CSF).
62082712|NCT06036121|EXPERIMENTAL|Phase 1a Dose Escalation|Increasing doses of ADRX-0706 will be administered to identify the maximum tolerated dose (MTD) and the recommended dose to be used in the Phase 1b part.
62082713|NCT06036121|EXPERIMENTAL|Phase 1b Dose Expansion|ADRX-0706 will be initially administered to patients at the dose recommended from the Phase 1a part in 3 disease-specific cohorts: urothelial cancer, triple negative breast cancer, and cervical cancer.
62082714|NCT01780168||healthy volunteers|Healthy volunteers
62082715|NCT01780168||Inborn errors of metabolism/mitochondrial disease|patients with inborn errors of metabolism including those with mitochondrial disease
62082716|NCT05753189|EXPERIMENTAL|Combination ophthalmic solution (LNZ101) dosed bilaterally|LNZ 101: Aceclidine/Brimonidine Ophthalmic Solution
62458791|NCT03654625|EXPERIMENTAL|Standard Written Exposure|Four writing sessions at the laboratory
62458792|NCT03654625|EXPERIMENTAL|Enhanced Written Exposure|Four writing sessions at the laboratory
62082717|NCT05753189|PLACEBO_COMPARATOR|Placebo (Vehicle) ophthalmic solution dosed bilaterally|Placebo: Proprietary Vehicle Ophthalmic Solution
62082718|NCT05753189|EXPERIMENTAL|Aceclidine ophthalmic solution dosed bilaterally|LNZ 100: Aceclidine ophthalmic solution
62082719|NCT05643287|EXPERIMENTAL|Periodontitis patients|Periodontitis patients receiving non-surgical periodontal treatment.
62082720|NCT05331729|EXPERIMENTAL|Patients with idiopathic pulmonary fibrosis|
62082721|NCT05331729|ACTIVE_COMPARATOR|Healthy volunteers|
62082722|NCT06119295|EXPERIMENTAL|Control Condition|Participants will be served a lunch - this will be of a fixed portion - this portion size will be the same amount of food as was consumed in the ad libitum lunch meal in the baseline session (participants will be told that the amount of food served is the same as the amount they consumed in the baseline session).
62458793|NCT03654625|PLACEBO_COMPARATOR|Control Condition|Four writing sessions at the laboratory
62458794|NCT06150976|EXPERIMENTAL|MAAT-YS Group|This group will be treated with the MAAT-YS cognitive-behavioral therapy.
62649806|NCT05216484|EXPERIMENTAL|two doses BBIBP-CorV|the third does was given 6 months after two doses BBIBP-CorV
62649807|NCT05216484|EXPERIMENTAL|first does CoronaVac and second does BBIBP-CorV|the third does was given 6 months after first does CoronaVac and second does BBIBP-CorV
62649808|NCT05216484|EXPERIMENTAL|first does BBIBP-CorV and second does CoronaVac|the third does was given 6 months after first does BBIBP-CorV and second does CoronaVac
62649809|NCT03045172|ACTIVE_COMPARATOR|Group 1|20 subjects with Platelet Rich Plasma injections
62649810|NCT03045172|PLACEBO_COMPARATOR|Group 2|10 subjects with placebo injections
62649811|NCT04474483|PLACEBO_COMPARATOR|Control|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
62082723|NCT06119295|EXPERIMENTAL|Reduce aware condition|Participants will be served a lunch - this will be of a fixed portion - this portion size will be 15% less than the amount of food consumed in the ad libitum lunch meal in the baseline session (participants will be told that the amount of food served has been reduced from the amount they consumed in the baseline session).
62082724|NCT06119295|EXPERIMENTAL|Reduced unaware condition|Participants will be served a lunch - this will be of a fixed portion - this portion size will be 15% less than the amount of food consumed in the ad libitum lunch meal in the baseline session (participants will be told that the amount of food served is the same as the amount they consumed in the baseline session).
62082725|NCT06739993|EXPERIMENTAL|Resonance frequency breathing with heart rate variability biofeedback training (RFB-HRV-BF)|"The mobile system eSense Pulse by Mindfield Biosystems Ltd. (Gronau, Germany) was used for RFB-HRV-BF training. The participants sat in an upright position, started the training via the eSense app on their smartphone, and were instructed to practice breathing at their individually determined resonance frequency.During training, a ball that expands (breathe in) and shrinks (breathe out) on the screen specified the breathing frequency goal to a value of six cycles per minute (five seconds inspiration, five seconds expiration). The HRV was visualized by new symbols varying in color depending on the respectively measured values, which appeared every ten seconds."
62082726|NCT06739993|ACTIVE_COMPARATOR|Anti-Stress program|The mobile system eSense Pulse from Mindfield Biosystems is used for the digital anti-stress program. To do this, the participants put on a chest strap with a sensor and can start training via the eSense app. The anti-stress program is carried out using a procedure generated for the study. During the anti-stress program units, the participants receive application-related information and tips to better understand the topic of stress, identify stressors in their own lives and reduce stress. The active control intervention of the anti-stress program was selected to investigate the effect of a specific stress level reduction without the direct modulation of physiological mechanisms of action as with HRV-BF-RFA.
62458795|NCT03970564||Suspected lung cancer|Suspected and later on confirmed lung cancer with evidence of mediastinal lymphadenopathy on computerised tomography
62082727|NCT06397313|EXPERIMENTAL|RVU120|Cohort 1 RVU120 is administered at 250 mg as a single agent every other day on days 1, 3, 5, 7, 9, 11, and 13 of 21-day treatment cycles, or at an adjusted dose, to participants with intermediate or high-risk, primary or secondary MF who have been previously treated with or are ineligible for treatment with a JAK inhibitor.
62082728|NCT06397313|EXPERIMENTAL|RVU120 + ruxolitinib|Cohort 2 RVU120 is administered at 250 mg every other day on days 1, 3, 5, 7, 9, 11, and 13 of 21-day treatment cycles or at an adjusted dose, in combined with ruxolitinib administered orally twice daily following the dosing instructions in current prescribing information, to participants with intermediate or high risk, primary or secondary MF experiencing suboptimal response to JAK inhibitor.
62082729|NCT05656027|EXPERIMENTAL|Aceclidine + Brimonidine (LNZ101) dosed bilaterally|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
62082730|NCT05656027|EXPERIMENTAL|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LNZ100 (Aceclidine) ophthalmic solution
62082731|NCT05656027|EXPERIMENTAL|Brimonidine ophthalmic solution dosed bilaterally|Brimonidine ophthalmic solution
62082732|NCT06718803|EXPERIMENTAL|Hypnotherapy App - Evia|The Evia app (https://www.eviamenopause.com/), developed by Mindset Health, provides hypnotherapy and educational resources tailored for managing hot flashes. The Evia app offers a structured 5-week program adapted from a hypnosis protocol that has been tested in various randomized clinical trials (Elkins et al., 2008; Elkins et al., 2013). During the 5-week program, users engage in daily activities such as reading brief educational materials, undergoing hypnotic sessions, and tracking their hot flashes. The app also offers users with optional hypnotherapy to improve sleep quality. The Evia app uses audio recordings to deliver hypnotherapy remotely, these are composed of mental imagery techniques focused on sensations of coolness, such as imagining cool breezes, snow, and a sense of calmness.
62082733|NCT06718803|PLACEBO_COMPARATOR|Health-tracker app - Talli Care|For the health tracker app, participants will access the Talli Care app (https://talli.me/talli-care-app). The Talli Care app is a free-of-charge mobile-health application designed by Baby Logger, LLC that provides users with an interface that facilitates tracking of symptoms, physical activity, medications, water intake, and more. With the Talli Care app, participants can track their number of hot flashes, sleep quality, and additional symptoms and habits related to the management of hot flashes. Instructions regarding suggestions on what to track and how to maximize app usage will be provided to the participants by our research coordinator.
62082734|NCT05906303|EXPERIMENTAL|Caffeine and sodium benzoate|Patients will received 250 mg IV caffeine and sodium benzoate (125 mg each) dissolved in 500 cc normal saline which will be administered over the course of two hours upon determination the patient is 10 cm in cervical dilation.
62082735|NCT05906303|PLACEBO_COMPARATOR|Placebo|Patients will received 500 cc normal saline which will be administered over the course of two hours upon determination the patient is 10 cm in cervical dilation.
62458796|NCT01806688|EXPERIMENTAL|Experimental Snack #1|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
62082736|NCT06340503|EXPERIMENTAL|Exercise Group|Participants randomized into the exercise group will receive a pre-exercise screening call about two weeks after enrolling into the study and complete the six (6) study visits and pre-determined test and procedures for the patient intervention arm.
62082737|NCT06340503|ACTIVE_COMPARATOR|Delayed Exercise Group|Participants randomized to the delayed exercise group, will have vitals collected and complete surveys at the first (baseline), 3-month, and 6-month visits pre-determined test and procedures for the waitlist control arm. The pre-exercise consultation will begin after the 6-month visit.
62082738|NCT06368856|ACTIVE_COMPARATOR|Single dose part : 50mg mupirocin|- Single dose part = single dose of 50 mg mupirocin in each nostril
62082739|NCT06368856|EXPERIMENTAL|Single dose part : 500mg mupirocin|Single dose part = single dose of 500 mg mupirocin in each nostril
62082740|NCT06368856|EXPERIMENTAL|Repeated dose part: Group 1 - 50 mg of mupirocin twice a day|50 mg of mupirocin in each nostril twice a day (morning and evening) for 5 days
62082741|NCT06368856|EXPERIMENTAL|Repeated dose part: Group 2 50 mg of mupirocin 3 times a day|50 mg of mupirocin in each nostril 3 times a day (morning, noon and evening) for 5 days
62082742|NCT06368856|EXPERIMENTAL|Repeated dose part: Group 3 500 mg of mupirocin twice a day|500 mg of mupirocin in each nostril twice a day (morning and evening) for 5 days
62082743|NCT06368856|EXPERIMENTAL|Repeated dose part: Group 4 500 mg of mupirocin 3 times a day|500 mg of mupirocin in each nostril 3 times a day (morning non and evening) for 5 days
62082744|NCT04134858|EXPERIMENTAL|The health coaching group|The experimental group (n = 52) consisted of frequent attenders who had chosen the health-coaching program. The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
62082745|NCT04134858|NO_INTERVENTION|The control group|The control group consisted of 58 frequent attenders. They, along with the experimental group, received the usual care regarding their health problems from the physicians and nurses at the primary healthcare centres if they needed it. The usual care for frequent attenders included assessment for the need of treatment, physical examination, problem assessment, laboratory and X-ray tests, medical advice and patient support and education during their visits.
62082746|NCT06740591|EXPERIMENTAL|Experimental : HD-tDCS|The HD-tDCS stimulation was applied for 20 minutes, 5 times a week, over a total of 10 sessions.
62082747|NCT06740591|SHAM_COMPARATOR|Sham HD-tDCS|The Sham HD-tDCS stimulation was applied for 20 minutes, 5 times a week, over a total of 10 sessions.
62082748|NCT05586763|ACTIVE_COMPARATOR|Metoclopramid|IM Metoclopramid 10mg
62082749|NCT05586763|ACTIVE_COMPARATOR|Promethazine|IM Promethazine 25mg
62082750|NCT05586763|ACTIVE_COMPARATOR|prochloraperazine|IM prochloraperazine 12.5mg
62082751|NCT06737770|EXPERIMENTAL|patients undergoing osseointegration surgery for transfemoral amputation|
62082752|NCT06529770|NO_INTERVENTION|Control Group|The group receives no intervention
62082753|NCT06529770|EXPERIMENTAL|NMP-e 3 sessions|The group receives 1 session of ultrasound-guided percutaneous neuromodulation. The session wil be received at day 1 of the study.
62082754|NCT06529770|EXPERIMENTAL|NMP-e 1 session|The group receives 3 sessions of ultrasound-guided percutaneous neuromodulation. The sessions wil be received at day 1, 7 and 14 of the study.
62082755|NCT00009243||Patients|Patients with acute stroke symptoms
62458797|NCT01806688|EXPERIMENTAL|Experimental Snack #2|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of a buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density, but less protein and fibre than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
62082756|NCT03729349||Participants with Diagnosis of Rheumatoid Arthritis|Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.
62082757|NCT05939518|EXPERIMENTAL|Liberal Lactated Ringer Fluid Protocol with Ephedrine and Phenylephrine Boluses|IV Infusion of 500 ml of lactated Ringer's (RL) solution during the induction of anesthesia followed by an infusion of RL at a rate of 8.0 ml/kg/h throughout the maintenance phase of anesthesia. The anesthesia care provider will be allowed free use of IV boluses of ephedrine or phenylephrine to target a mean arterial blood pressure of \>60 mmHg.
62649812|NCT04474483|EXPERIMENTAL|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
62082758|NCT05939518|ACTIVE_COMPARATOR|Restrictive Lactated Ringer Fluid Protocol with Noradrenaline Infusion|IV Infusion of 200 ml of lactated Ringer's (RL) solution during the induction of anesthesia followed by an infusion of RL at a rate of 2.0 ml/kg/h + an infusion of noradrenaline throughout the maintenance phase of anesthesia, through a large peripheral vein. The noradrenaline infusion rate will be titrated after an initial bolus of 10 μg, from an initial rate of 2.0 μg/kg/h, which may be raised up to 8.0 μg/kg/h, to target a mean arterial blood pressure (MBP) of \>60 mmHg. If the MBP target is still not achieved, the RL infusion rate may be increased up to 4.0 ml/kg/h.
62458798|NCT04003090|EXPERIMENTAL|Citicoline eyes|Patients had to administer 3 drops/day of an ophthalmic solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride for 14 days before surgery and 2 hours prior to surgery.
62649813|NCT06088693|NO_INTERVENTION|Control|Patients diagnosed with Oligozoospermia who only receive standard therapy from an Andrologist as a standard therapy.
62649814|NCT06088693|EXPERIMENTAL|Intervention|Patients diagnosed with Oligozoospermia receive standard therapy from an Andrologist and Electroacupuncture.
62649815|NCT01950962|OTHER|slight periodontal disease|
62649816|NCT01950962|OTHER|moderate periodontal disease|
62649817|NCT01950962|OTHER|severe periodontal disease|
62082759|NCT06253858|EXPERIMENTAL|Catheter placement with Solopass system|The Solopass US system will be used during catheter placement procedure to guide the placement of the catheter.
62082760|NCT06555822|EXPERIMENTAL|Part A: Multiple Ascending dose (MAD) (AZD5004)|Participants will receive repeated dosing of AZD5004 orally.
62082761|NCT06555822|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive matching Placebo orally.
62082762|NCT06555822|EXPERIMENTAL|Part B: Treatment 1 (AZD5004)|Participants in Group 1 will receive Treatment 1 of AZD5004 and then Treatment 2 of AZD5004. Participants in Group 2 will receive Treatment 2 of AZD5004 and then Treatment 1 of AZD5004.
62082763|NCT06555822|EXPERIMENTAL|Part B: Treatment 2 (AZD5004)|Participants in Group 1 will receive Treatment 1 of AZD5004 and then Treatment 2 of AZD5004. Participants in Group 2 will receive Treatment 2 of AZD5004 and then Treatment 1 of AZD5004.
62082764|NCT04574024|OTHER|MS study cohort|"Baseline: 7 MS patients enrolled for the study. No treatment or before treatment.~NBT-NM108-Treatment for 8 weeks: 3 out of 7 MS patients consumed the NBT-NM108 for 8 weeks.~NBT-NM108-Treatment for 12 weeks: 2 MS patients further consumed the NBT-NM108 for four more weeks.~Patients consumed dietary fiber three times a day at 60 g/day"
62281846|NCT03685461|OTHER|Arm 1: Audible ECochG Response Off|Arm 1: Audible ECochG Response Off This condition is identical to the current standard-of-care for conventional CI surgery used worldwide. The surgeon will perform his or her electrode insertion without ECochG monitoring. Minute manipulations of the electrode are a normal part of conventional electrode insertion; manipulations such as redirecting the insertion vector or slowing down insertion speed will be made, as deemed necessary by the surgeon. A full electrode insertion will be performed, as appropriate. The ECochG responses will be recorded, but the surgeon will be blinded to this information during surgery.
62281847|NCT03685461|EXPERIMENTAL|Arm 2: Audible ECochG Response On|This condition will have the audible ECochG response on and available to the surgeon. In this condition, the surgeon perform a conventional electrode insertion while listening to the running ECochG signal for drop in amplitude (suggesting impending trauma). If no drop is detected, insertion will proceed to the full electrode length according to the standard-of-care. If an ECochG amplitude drop is observed, the surgeon will place this observation in its clinical context and evaluate insertion parameters, (i.e., insertion vector, insertion speed, etc.), customary practice with conventional CI surgery, but here supplemented by the ECochG response. In the case of an ECochG amplitude drop that does not recover, the standard-of-care practice of achieving a full electrode insertion will be followed.
62281848|NCT03429478|EXPERIMENTAL|Music|Preoperative application of a Bluetooth enabled headphones with standard music played for atleast 2 hours preoperatively.
62281849|NCT03429478|ACTIVE_COMPARATOR|No Music|Preoperative application of a Bluetooth enabled headphones with no music played and headphones will just mask the surrounding noise.
62281850|NCT01865058||DLBCL|Patients with newly diagnosis of diffuse large B-cell lymphoma is offered enrollment in this protocol.
62281851|NCT03168984|EXPERIMENTAL|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
62281852|NCT03168984|PLACEBO_COMPARATOR|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
62649818|NCT04958967|EXPERIMENTAL|treated subjects will receive Furmonertinib 240mg/day,|treated subjects will receive Furmonertinib 240mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
62649819|NCT04958967|EXPERIMENTAL|treated subjects will receive Furmonertinib 160mg/day|treated subjects will receive Furmonertinib 160 mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
62649820|NCT04614506||Subject with DS|Participants will complete two visits spaced out by 4 - 8 weeks to undergo neurophysiological assessments (Electroencephalogram \[EEG\], and Transcranial magnetic stimulation \[TMS\]).
62649821|NCT01408823||Idiopathic Scoliosis|
62649822|NCT01408823||Non-idiopathic Scoliosis|
62082765|NCT06738329|EXPERIMENTAL|Carrageenan gummy|Gummies have been produced using carrageenan as a gelling agent. Each dose will consist of two carrageenan containing gummies
62458799|NCT02330848|ACTIVE_COMPARATOR|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
62458800|NCT02330848|ACTIVE_COMPARATOR|Walnut Calorie Controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan. Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts. The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant. The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
62458801|NCT05290181|EXPERIMENTAL|Pilates exercise and whatsapp text message group|A support program including pilates exercises and sending text messages will be applied to the students in the intervention group for 8 weeks. Online pilates exercises will be done 2 days a week and individual short messages will be sent to their smartphones via the Whatsapp application 3 days a week. Participants will be provided with Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises. The exercises will be done online in the presence of a research physiotherapist with The Australian Physiotherapy \& Pilates InstituteMatwork Level 1 (APPI) certificate.
62281853|NCT01422993|EXPERIMENTAL|Excercise and Questionnaire|12 week exercise program followed by questionnaire.
62281854|NCT04524611|EXPERIMENTAL|Risankizumab Dose A Followed by Dose B|Participants will receive intravenous risankizumab dose A at Week 0, 4 ,8 followed by subcutaneous (SC) risankizumab dose B every 8 weeks through Week 48. Participants who complete the Week 48 visit will continue SC risankizumab for up to an additional 220 weeks.
62281855|NCT04524611|ACTIVE_COMPARATOR|Ustekinumab|Participants will receive weight-based intravenous ustekinumab at Week 0 followed by subcutaneous ustekinumab every 8 weeks through Week 48.
62458802|NCT05290181|NO_INTERVENTION|Control group|No intervention will be made in the control group.
62458803|NCT06227247|EXPERIMENTAL|Meals 4 Moms intervention|"Participants randomized to the M4M condition will receive:~* Food budget of $266 per week in credits to spend towards medically-tailored GDM meals~* Enhanced educational GDM-specific education on exercise, nutrition, and blood sugar glucose management~* Activity tracker and digital scale~* Usual GDM care"
62458804|NCT06227247|NO_INTERVENTION|Usual GDM Care|Usual care (UC) will consist of the current treatment care that is provided by the participant's prenatal care provider. Usual care consists of a special diet, monitoring of blood glucose levels and encouragement/guidance of increasing a participant's exercise.
62458805|NCT02019810|ACTIVE_COMPARATOR|Noradrenaline alone|Treatment for 30 minutes with noradrenaline alone
62458806|NCT02019810|EXPERIMENTAL|Noradrenaline + dobutamine|Treatment with noradrenaline and dobutamine for 30 minutes
62458807|NCT04448223|EXPERIMENTAL|CKD-351|CKD-351
62458808|NCT04448223|ACTIVE_COMPARATOR|Latanoprost+Dorzolamide|Latanoprost(50ul/ml) Dorzolmamide(20mg/ml)
62649823|NCT01218802|ACTIVE_COMPARATOR|Rosuvastatin|Participants will take Rosuvastatin 10 mg. daily for 96 weeks
62649824|NCT01218802|PLACEBO_COMPARATOR|Sugar Pill placebo|Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.
62082766|NCT06738329|EXPERIMENTAL|Prebiotic arm|The prebiotic fibre, inulin, has been added into the carrageenan gummies. Each dose with consist of two gummy sweets.
62082767|NCT06738329|PLACEBO_COMPARATOR|Placebo|An alternative gelling agent, agar has been added to the gummy sweets as a placebo.
62082768|NCT00570258|PLACEBO_COMPARATOR|2|"Fulvestrant: 250 mg IM Q 4 weeks~Placebo: 150 mg PO QD"
62082769|NCT00570258|ACTIVE_COMPARATOR|1|"Fulvestrant: 250 mg IM Q 4 weeks~Erlotinib: 150 mg PO QD"
62082770|NCT05138796|EXPERIMENTAL|TP-05 SAD|Single dose of TP-05 (lotilaner oral capsules) at 4 dose levels in ascending order
62082771|NCT05138796|EXPERIMENTAL|Placebo SAD|Single dose of Placebo
62082772|NCT05138796|EXPERIMENTAL|TP-05 MAD|Four doses of TP-05 (lotilaner oral capsules) at 3 dose levels in ascending order
62082773|NCT05138796|EXPERIMENTAL|Placebo MAD|Four doses of Placebo
62281856|NCT03504202|EXPERIMENTAL|Trimetazidine|
62281857|NCT02167178||Volunteers receiving 0.9% NaCl|Volunteers receiving 0.9% NaCl to optimise stroke volume
62281858|NCT02167178||Volunteers receiving gelofusine|Volunteers receiving gelofusine to optimise stroke volume
62281859|NCT05234580|EXPERIMENTAL|PA9159 10 μg|Fifty subjects will be randomly assigned to receive 10 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 5 μg/spray; Spray Bottle B: 0 μg/spray.
62281860|NCT05234580|EXPERIMENTAL|PA9159 20 μg|Fifty subjects will be randomly assigned to receive 20 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 0 μg/spray; Spray Bottle B: 10 μg/spray.
62281861|NCT05234580|EXPERIMENTAL|PA9159 40 μg|Fifty subjects will be randomly assigned to receive 40 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 10 μg/spray; Spray Bottle B: 10 μg/spray.
62281862|NCT05234580|PLACEBO_COMPARATOR|Placebo|Fifty subjects will be randomly assigned to receive placebo Nasal Spray without active of PA9159 for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 0 μg/spray; Spray Bottle B: 0 μg/spray.
62281863|NCT00310830|NO_INTERVENTION|1|
62281864|NCT00310830|EXPERIMENTAL|2|
62281865|NCT04738357|EXPERIMENTAL|HSK21542|
62281866|NCT04738357|PLACEBO_COMPARATOR|placebo|
62281867|NCT04130802|EXPERIMENTAL|OCS-01 1.5% mg/mL QD|eye drops
62281868|NCT04130802|EXPERIMENTAL|OCS-01 1.5% mg/mL BID|eye drops
62082774|NCT05138796|EXPERIMENTAL|TP-05 Fasted|Single dose of TP-05 (lotilaner oral capsules) in a fasted state
62082775|NCT05138796|EXPERIMENTAL|Placebo Fasted|Single dose of placebo in a fasted state
62082776|NCT00708838||1|
62082777|NCT00708838||2|
62281869|NCT04130802|PLACEBO_COMPARATOR|Placebo (Vehicle) BID|eye drops
62281870|NCT04759300|ACTIVE_COMPARATOR|Group C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS.
62082778|NCT00708838||3|
62082779|NCT00708838||4|
62082780|NCT00708838||5|
62082781|NCT03888170||Non-pregnant|Women aged 18-45 years old undergoing elective hysterectomy (either vaginal, laparoscopic, or open routes) for benign indications.
62082782|NCT03888170||Pregnant|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age.
62082783|NCT03888170||Pregnant with hypertension|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age with pregnancy complicate by chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, or superimposed preeclampsia.
62281871|NCT04759300|PLACEBO_COMPARATOR|Group C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
62082784|NCT06576479|EXPERIMENTAL|Arm Intervention|Intervention group: The specialized oral supplement is provided, with the consumption of 1 serving (70g-dissolved in 237 ml natural water) per day in conjunction with individualized nutritional counseling. For 4 months
62082785|NCT06576479|OTHER|Arm no Intervention|Control group: They receive specialized nutrition considering the recommendations of the clinical practice guidelines for CKD. For 4 months
62082786|NCT03678441|EXPERIMENTAL|Group I (BrainCheck and paper and pen cognitive assessment)|Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.
62281872|NCT01769755|EXPERIMENTAL|Human Placenta-Derived Cells PDA001 Intravenous Infusion|Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours.
62281873|NCT01769755|PLACEBO_COMPARATOR|Vehicle controlled placebo|Intravenous infusion of Vehicle Controlled Placebo over the course of 2 hours
62281874|NCT04922411|EXPERIMENTAL|Post-Surgical Group|STN DBS: Subjects with PD and DBS STN implanted will be scanned and tested with DBS ON and OFF
62281875|NCT04886934|EXPERIMENTAL|Safety and clinical performance of the CS1 system|Placement of the CS1 device on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery.
62281876|NCT01923688|EXPERIMENTAL|Informatics Real-Time Alert|Alert/Nurse and Physician Intervention
62281877|NCT01923688|NO_INTERVENTION|control-no intervention|
62281878|NCT00070941|EXPERIMENTAL|SAM-e|40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo escitalopram.
62281879|NCT00070941|ACTIVE_COMPARATOR|Escitalopram|40 subjects receiving oral escitalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.
62281880|NCT00070941|PLACEBO_COMPARATOR|Placebo Comparator|20 subjects receiving oral placebo escitalopram and placebo SAM-3 daily in two divided doses.
62281881|NCT00599807|ACTIVE_COMPARATOR|1: 2000 IU D3/day|2000 IU vitamin D3 taken orally each day for 2 years
62281882|NCT00599807|ACTIVE_COMPARATOR|2: 800 IU D3 / day|800 IU vitamin D3 taken orally each day for 2 years
62281883|NCT01113203|EXPERIMENTAL|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
62281884|NCT01871090|ACTIVE_COMPARATOR|Interrogation with unpaired remote transmitter|Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
62281885|NCT01871090|NO_INTERVENTION|Interrogation with programmer|Interrogation with programmer according to usual standard of care
62281886|NCT03575104|EXPERIMENTAL|Daridorexant 10 mg|
62281887|NCT03575104|EXPERIMENTAL|Daridorexant 25 mg|
62281888|NCT03575104|PLACEBO_COMPARATOR|Placebo|
62649825|NCT06015100|EXPERIMENTAL|Label 1|Inetetamab plus pyrotiniband and capecitabine
62082787|NCT03678441|ACTIVE_COMPARATOR|Group II (pen and paper and BrainCheck cognitive assessment)|Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.
62082788|NCT05800366|EXPERIMENTAL|Polatuzumab + Glofitamab + R-CH|"-Participants will receive treatment interventions as outlined: Experimental: Safety Lead-In Phase of 6 Participants, Total Enrollment of 40 Participants~* Polatuzumab, once, predetermined day and dosage per cycle, per protocol Cycles 1 - 6~* R-CHP (Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone~  * Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride once, predetermined day and dosage per cycle, per protocol Cycles 1 - 6:~ * Prednisone) 5 days, predetermined day and dosage per cycle, per protocol Cycles 1 - 6:~* Glofitamab~  * twice, predetermined day and dosage per cycle, per protocol Cycle 3-6~ * once, predetermined day and dosage per cycle, per protocol Cycle 7-8~* Participants who need urgent therapy are also allowed to proceed with one cycle of R-CHOP for 1 cycle per standard of care.~* Participants will be followed for up to 5 years post-treatment."
62082789|NCT04008030|EXPERIMENTAL|Arm A: Nivolumab Monotherapy|
62082790|NCT04008030|EXPERIMENTAL|Arm B: Nivolumab + Ipilimumab Combination|
62082791|NCT04008030|ACTIVE_COMPARATOR|Arm C: Investigator's Choice Chemotherapy|Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress
62082792|NCT06345729|EXPERIMENTAL|MK-1084 with Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and MK-1084 by oral tablets once daily until discontinuation criterion is met.
62082793|NCT06345729|ACTIVE_COMPARATOR|Placebo with Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and placebo by oral tablets once daily until discontinuation criterion is met.
62082794|NCT05247502||ICU patients without Acute Kidney Injury|"Intensive care unit (ICU) patients who do not develop acute kidney injury (AKI) during their stay.~AKI will be defined by KDIGO stage 1.~The baseline serum creatinine (sCr) measurement will be defined as the sCr at admission if the corresponding estimation of glomerular filtration rate (GFR) by CKD-EPI formula is at least 90ml/min/1.73m2. Otherwise, the most recent sCr measured from 7-365 days prior to admission will be used. If there is no sCr measurement available from this period, it will be estimated using a reverse CKD-EPI formula for a GFR of 75 ml/min/1.73m2.~No intervention is foreseen out of the observation of data relative to kidney function during ICU stay, at 3 month and 12 month of ICU admission.~There will be no biological sample collection."
62281889|NCT04575701||Ulcerative Colitis (UC)|This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
62281890|NCT04575701||Crohn's disease (CD)|This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
62281891|NCT04575701||IBD unclassified|This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
62281892|NCT04199325|EXPERIMENTAL|Intervention group|
62281893|NCT04199325|PLACEBO_COMPARATOR|Control group|
62281894|NCT03498157|EXPERIMENTAL|Partly Supervised Prehabilitation|Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
62281895|NCT03498157|ACTIVE_COMPARATOR|Home-based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and weekly phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of surgery. Furthermore, a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute will be offered.
62281896|NCT03498157|ACTIVE_COMPARATOR|Control Group|Will be offered a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute.
62082795|NCT05247502||ICU patients with transient Acute kidney injury|"Transient AKI will be defined as a complete renal recovery within 48 hours after the start of AKI.~Complete renal recovery will be defined as a return to within 25% of the baseline serum creatinine measurement. TIf several AKI episodes occur during the patient's ICU stay, only the longest episode will be considered.~No intervention is foreseen out of the observation of data relative to kidney function during ICU stay, at 3 month and 12 month of AKI start.~There will be no biological sample collection."
62458809|NCT02786030|EXPERIMENTAL|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions.
62082796|NCT05247502||ICU patients with persistent Acute kidney injury|"If the AKI episode lasts longer than 48 hours, it will be classified as persistent AKI. If several AKI episodes occur during the patient's ICU stay, only the longest episode will be considered.~No intervention is foreseen out of the observation of data relative to kidney function during ICU stay, at 3 month and 12 month of AKI start.~There will be no biological sample collection."
62082797|NCT01196130||Biomarker Assessment|Leftover sample of tumor tissue from a previous procedure used for biomarker testing. Blood drawn for biomarker testing, to check for levels of cytokines, and to check the circulating tumor cells (CTCs). Cancer Symptom Questionnaire completion about cancer symptoms.
62649826|NCT06022913|OTHER|2 week wait|Participant waits for 2 weeks after their baseline assessment before commencing therapy.
62082798|NCT06688578|SHAM_COMPARATOR|Sham|During each testing session there will be a sham and stimulation trial of each test. The order of the sham/stim trials will be randomized.
62281897|NCT03498157|NO_INTERVENTION|Comparison group- women too active|Added comparison group: Women who are ineligible on the basis of 'engaging in systematic intense exercise training (at least 1h twice a week) will be recruited to complete measures only, with no randomization
62281898|NCT02149030|ACTIVE_COMPARATOR|A1|A1) Cytological screening in A1 and A3. Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.
62458810|NCT02786030|ACTIVE_COMPARATOR|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will not receive outreach education training.
62458811|NCT01720264|EXPERIMENTAL|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
62649827|NCT06022913|OTHER|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
62649828|NCT06022913|OTHER|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
62649829|NCT06022913|OTHER|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
62649830|NCT01882452|EXPERIMENTAL|Memory Specificity Training|Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
62082799|NCT06688578|EXPERIMENTAL|Stim|Three different methods will be used to determine the level of stimulation that produces the greatest improvement in gait. The basic concept is that to determine the optimal level of stimulus the investigators apply various levels of random subperceptual electrical stimulation while measuring either vestibular ocular reflex, static sway or gait. Then the investigators will compare the performance of the selected variable at each level of stimulation to determine which amount of stimulation produced the greatest improvement in the selected variable. Once that is determined
62082800|NCT06737874||group A|polytrauma patients
62082801|NCT04818632|EXPERIMENTAL|AZD9833 monotherapy dose escalation|
62082802|NCT04818632|EXPERIMENTAL|AZD9833 monotherapy dose expansion|
62082803|NCT04818632|EXPERIMENTAL|AZD9833 with palbociclib dose expansion|
62082804|NCT04818632|EXPERIMENTAL|AZD9833 with everolimus dose expansion|
62082805|NCT06737510|EXPERIMENTAL|Phone-based household emergency preparedness|A phone-based intervention will consist of 15 - 20 minutes discussion covering the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, including a family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies); and (5) resources (including providing NYC Emergency Management website: NYC.gov/hazards, i which includes specific information related to the participants New York City hurricane evacuation zones) .
62281899|NCT02149030|NO_INTERVENTION|A2|A2) infrequent information of screening results, only at the age 30 years.
62281900|NCT02149030|OTHER|A3|A3) Cytological screening in A1 and A3. With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.
62281901|NCT00732095|EXPERIMENTAL|Experimental|Immediate Ad
62281902|NCT01551784||1|
62281903|NCT06315075|EXPERIMENTAL|DBT-A|Single group uncontrolled study. All participants will receive DBT-A
62281904|NCT05301075|SHAM_COMPARATOR|control group|patients will receive sham block.
62281905|NCT05301075|ACTIVE_COMPARATOR|RISS group|will receive Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
62281906|NCT06437938|PLACEBO_COMPARATOR|Placebo group 1|Corresponding to dietary supplement groups B and C
62281907|NCT06437938|PLACEBO_COMPARATOR|Placebo group 2|Corresponding to dietary supplement A
62649831|NCT01882452|ACTIVE_COMPARATOR|Education and Support|Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
62649832|NCT03040726|EXPERIMENTAL|Group I (netupitant, palonosetron hydrochloride)|Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.
62649833|NCT03040726|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo PO on days 1, 6, and 11.
62082806|NCT06737510|EXPERIMENTAL|Informational brochure on household emergency preparedness|"An informational brochure will be mailed to participants and will cover the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies, including preparing a go bag); and (5) resources (including disaster contact numbers for emergency and non-emergency calls (911 and 311), how to register for emergency notifications (Notify NCY), NYC Emergency Management, as well as a website for additional information on preparedness (NYC.gov/hazards) that includes New York City hurricane evacuation zones ."
62458812|NCT03437148|EXPERIMENTAL|patients with Atrial septal defect type Ostium Secundum|patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure
62281908|NCT06437938|EXPERIMENTAL|Dietary supplement group A|Wasabi leaf powder
62281909|NCT06437938|PLACEBO_COMPARATOR|Dietary supplement group B|Berberin Phytoactive Gold
62281910|NCT06437938|PLACEBO_COMPARATOR|Dietary supplement group C|DiaPhyt® Formula 3.0
62281911|NCT00764556|EXPERIMENTAL|Tight glycaemic control|Intravenous or subcutaneous insulin to control blood glucose to 4.4-6.5mM
62281912|NCT05998837|ACTIVE_COMPARATOR|Type 2 Diabetes Dapagliflozin 10 mg|Patients with Type 2 Diabetes allocated to Dapagliflozin 10 mg
62281913|NCT05998837|PLACEBO_COMPARATOR|Type 2 Diabetes Placebo|Patients with Type 2 Diabetes allocated to Placebo
62458813|NCT04534010|EXPERIMENTAL|NACgraft patients|uni- or bilateral engraftment surgery will be performed
62458814|NCT02767232|ACTIVE_COMPARATOR|Standard Anticoagulation Therapy|Anticoagulant therapy will be prescribed in accordance with 2012 ACCP Guidelines for children. Initial therapy generally will consist of low molecular weight heparin (LMWH) or unfractionated heparin (UFH), monitored to achieve and maintain a target anti-Xa activity of 0.5-1.0 IU/mL for LMWH and 0.35-0.7 IU/mL for UFH. Long-term therapy generally will consist of warfarin/coumadin, monitored to achieve and maintain a target INR of 2.0-3.0. The use of novel anticoagulants is permitted based on investigator preference.
62082807|NCT01307280|EXPERIMENTAL|Basic HEALTH|Participants received the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
62281914|NCT05998837|ACTIVE_COMPARATOR|Without Diabetes Dapagliflozin 10 mg|Patients without Type 2 Diabetes allocated to Dapagliflozin 10 mg
62281915|NCT05998837|PLACEBO_COMPARATOR|Without Diabetes Placebo|Patients without Type 2 Diabetes allocated to Placebo
62281916|NCT05624463|EXPERIMENTAL|Modified intubation protocol+early resumption of oral intake|Participants receive modified intubation protocol and early resumption of oral intake.
62281917|NCT05624463|OTHER|Modified intubation protocol+delayed resumption of oral intake|Participants receive modified intubation protocol and delayed resumption of oral intake.
62281918|NCT05624463|OTHER|Conventional intubation protocol+early resumption of oral intake|Participants receive conventional intubation protocol and early resumption of oral intake.
62281919|NCT05624463|OTHER|Conventional intubation protocol+delayed resumption of oral intake|Participants receive conventional intubation protocol and delayed resumption of oral intake.
62458815|NCT02767232|EXPERIMENTAL|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis (CDT) with intrathrombus delivery of Recombinant tissue plasminogen activator (rt-PA) (maximum allowable total dose 35 mg/24 hours) into the DVT over a period of up to 24 hours. CDT will be initiated within 72 hours of diagnosis. Two methods of initial rt-PA delivery will be used: 1.) AngioJet Thrombectomy System- maximum first-session rt-PA dose 25 mg; or 2.) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole catheter. Before and after CDT, patients will receive standard DVT therapy as in the standard anticoagulation group
62458816|NCT02916290|EXPERIMENTAL|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
62458817|NCT02916290|ACTIVE_COMPARATOR|Monotherapy|UDCA monotherapy
62458818|NCT03185065|EXPERIMENTAL|Arm A|amantadine, placebo, modafinil, methylphenidate
62458819|NCT03185065|EXPERIMENTAL|Arm B|placebo, methylphenidate, amantadine, modafinil
62458820|NCT03185065|EXPERIMENTAL|Arm C|modafinil, amantadine, methylphenidate, placebo
62458821|NCT03185065|EXPERIMENTAL|Arm D|methylphenidate, modafinil, placebo and amantadine
62281920|NCT05682872|EXPERIMENTAL|Experimental Group|"Experimental group receive multifactorial intervention (based on the GBPC Prevention of Falls and reduction of Injuries derived from falls - RNAO)."
62281921|NCT05682872|ACTIVE_COMPARATOR|Control Group|Control group receive activities on falls prevention by Primary Care professionals on a care routine.
62281922|NCT01703858|ACTIVE_COMPARATOR|1 BI 113608|powder in the bottle for oral solution, oral administration with 240 mL water
62281923|NCT01703858|EXPERIMENTAL|2 BI 113608|conventional tablet formulation
62281924|NCT01703858|EXPERIMENTAL|3 BI 113608|conventional tablet formulation, fed
62281925|NCT01703858|EXPERIMENTAL|4 BI 113608|conventional tablet after pantoprazole administration
62281926|NCT01703858|EXPERIMENTAL|5 BI 113608|conventional tablet formulation, fasted, 0:30 min before fat breakfast
62458822|NCT05459727|EXPERIMENTAL|Intervention arm|"1. Basic oral hygiene instructions.~2. Full-mouth subgingival scaling and root planing under local anesthesia.~3. Additional full-mouth subgingival scaling and root planing under local anesthesia every 3 months during the follow-up period if necessary."
62082808|NCT01307280|EXPERIMENTAL|Interactive Internet|Intervention intensity increased in RCT2, which included bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments.
62082809|NCT01307280|EXPERIMENTAL|Behavioral Counseling|RCT3 included bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
62082810|NCT05313893|EXPERIMENTAL|Quadrivalent influenza vaccine|Subjects received 2 doses of 0.5 mL of quadrivalentinfluenza vaccine, 4 weeks apart. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
62082811|NCT04283045|ACTIVE_COMPARATOR|JASPER (6 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 6 weeks. If child is an early responder, he/she will continue to do JASPER daily, 5 times a week, for the remaining 18 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 18 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 18 weeks of the study."
62082812|NCT04283045|ACTIVE_COMPARATOR|JASPER (12 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 12 weeks. If child is an early responder, he/she will do JASPER for 60 minutes with TA, 5 times a week, for the remaining 12 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 12 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 12 weeks of the study."
62082813|NCT06556823|EXPERIMENTAL|Contralateral Leg Neuro Dynamic+ Conventional PT in Diabetic Population):|"The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set.~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set)."
62082814|NCT06556823|EXPERIMENTAL|contralateral Leg Neuro Dynamic+ Conventional PT in non Diabetic Population):|The patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set.
62082815|NCT06556823|EXPERIMENTAL|Spine Mobilization With Leg Movement+ Conventional PT in Diabetic Population)|"the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec.~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set)"
62082816|NCT06556823|EXPERIMENTAL|Spine Mobilization With Leg Movement+ Conventional PT in non Diabetic Population)|The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec.
62082817|NCT02321085|ACTIVE_COMPARATOR|Sinus Rhythm Control group|"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA"
62082818|NCT02321085|ACTIVE_COMPARATOR|Pulse Rate Control Group|"1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study."
62082819|NCT05348395|EXPERIMENTAL|Experimental diet|The experimental diet will provide 15% of calories from saturated fat and 14% of calories from fructose with a goal of providing 1.25x total energy needs
62281927|NCT02983487||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing"
62281928|NCT02983487||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing~Blood sampling:~A blood sample collected by fingerprick"
62281929|NCT02983487||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
62281930|NCT02679469|EXPERIMENTAL|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
62281931|NCT04710095|ACTIVE_COMPARATOR|Brief Alcohol Intervention|A brief intervention consisting of a 30-45 minute individual face-to-face session based on the principles of motivational interviewing.
62458823|NCT05459727|PLACEBO_COMPARATOR|Control arm|"1. Basic oral hygiene instructions.~2. Full-mouth supragingival ultrasonic scaling."
62458824|NCT00057109||Group 1|
62458825|NCT00766688|EXPERIMENTAL|25 mg/day AVE5530|
62458826|NCT00766688|EXPERIMENTAL|50 mg/day AVE5530|
62458827|NCT00766688|PLACEBO_COMPARATOR|Placebo|
62458828|NCT01626079|EXPERIMENTAL|MitraClip System|Percutaneous mitral valve repair using MitraClip System
62458829|NCT01626079|NO_INTERVENTION|Control Group|Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.
62082820|NCT06730360|ACTIVE_COMPARATOR|MTA Pulpotomy without Photobiomodulation|Participants will receive MTA (Mineral Trioxide Aggregate) pulpotomy as a standard treatment without the application of photobiomodulation (low-level laser therapy).
62082821|NCT06730360|EXPERIMENTAL|MTA Pulpotomy with Photobiomodulation|"Participants will receive MTA (Mineral Trioxide Aggregate) pulpotomy treatment enhanced with photobiomodulation (low-level laser therapy). The laser will be applied to pulp stumps before the placement of MTA to promote healing and reduce inflammation.~These entries should resolve the error and align with your protocol."
62649834|NCT04923425||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
62082822|NCT04100564|ACTIVE_COMPARATOR|Standard airway method arm|Standard airway management strategy
62649835|NCT04923425||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
62649836|NCT04923425||Non exposure|Non-pharmacological treatment (psychotherapy)
62281932|NCT04710095|SHAM_COMPARATOR|Attention-Matched Control Condition|Brief attention-matched control condition.
62281933|NCT02183090|EXPERIMENTAL|Meloxicam ampoule|
62281934|NCT02183090|ACTIVE_COMPARATOR|Meloxicam tablet|
62281935|NCT04244565||Self-directed clinical learning|examining the effect of Self-directed clinical learning model as compared to the traditional models to improve nurses' Airway management competencies and minimize airway related incidents.
62649837|NCT02466399|EXPERIMENTAL|POLAT-001|Latanoprost liposome ophthalmic injection
62281936|NCT00372437|EXPERIMENTAL|1|
62281937|NCT01762566|ACTIVE_COMPARATOR|wheat|wheat is administered blindly versus placebo in capsules once
62281938|NCT01762566|PLACEBO_COMPARATOR|xylose|placebo (xylose) will be administered blindly versus wheat in capsules once
62281939|NCT02594436||Ingenol mebutate gel 0.015 percent|Topical treatment of face or scalp once daily for three consecutive days
62281940|NCT02594436||Ingenol mebutate gel 0.05 percent|Topical treatment of trunk or extremities once daily for two consecutive days
62281941|NCT05797077|EXPERIMENTAL|Adjuvant chemotherapy combined with maintenance therapy|
62649838|NCT02466399|ACTIVE_COMPARATOR|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
62281942|NCT05797077|SHAM_COMPARATOR|Single adjuvant chemotherapy|
62281943|NCT04087226|ACTIVE_COMPARATOR|Conventional Retraction Cord|
62281944|NCT04087226|EXPERIMENTAL|PTFE Retraction Cord|
62281945|NCT05998915||Colorectal Cancer(CRC)|People who is diagnosed with CRC by colonoscopy and pathological biopsy
62281946|NCT05998915||Inflammatory Bowel Disease|People who is diagnosed with IBD by colonoscopy and pathological biopsy
62281947|NCT05998915||Colorectal adenoma(CRA)/adenomatous polyposis|People who is diagnosed with CRA by colonoscopy and pathological biopsy
62281948|NCT05998915||Non-adenomatous polyps|People who is diagnosed with non-adenomatous polyps by colonoscopy and pathological biopsy
62281949|NCT05998915||Irritable bowel syndrome|People who is diagnosed with IBS by colonoscopy and pathological biopsy
62281950|NCT05998915||normal|People who has no obvious abnormality in the whole colon
62281951|NCT04191915||Frail|Participants with 3 or more components of Fried frailty scale
62649839|NCT02287077|NO_INTERVENTION|Immediate cord clamping|At birth, neonate will be held at the level of placenta and umbilical cord will be clamped immediately (standard of care for depressed neonates).
62649840|NCT02287077|EXPERIMENTAL|Umbilical cord milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
62649841|NCT01418469|EXPERIMENTAL|Caseinate protein intake|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
62649842|NCT01418469|EXPERIMENTAL|Whey protein isolate intake|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
62649843|NCT01418469|EXPERIMENTAL|Soy protein intake|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
62082823|NCT04100564|EXPERIMENTAL|Supraglottic airway method arm|Supraglottic first airway management strategy
62082824|NCT06738719|EXPERIMENTAL|CT-P13 Auto-Injector|CT-P13 SC(Subcutaneous) Auto-Injector
62082825|NCT06738719|PLACEBO_COMPARATOR|Placebo Auto-Injector|Placebo Auto-Injector
62281952|NCT04191915||Moderately Frail|Participants with 1-2 components of Fried frailty scale
62281953|NCT04191915||Not Frail|Participants without any components of Fried frailty scale
62281954|NCT01371669||IPAH or CPEPH|Idiopathic pulmonary arterial hypertension (IPAH) or pulmonary hypertension associated with chronic post-embolic pulmonary hypertension (CPEPH)
62281955|NCT06538285|EXPERIMENTAL|Ketamine-Assisted Psychotherapy|Participants will receive 3 administrations of intramuscular (IM) ketamine, dosed approximately once weekly, in combination with 7 psychotherapy visits over a 5-week treatment period. All ketamine dosing and psychotherapy visits will be conducted in-person in a designated therapy room.
62281956|NCT03980938|EXPERIMENTAL|neflamapimod first|"neflamapimod in Treatment Period 1, placebo in Treatment Period 2~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food.~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food."
62281957|NCT03980938|PLACEBO_COMPARATOR|placebo first|"placebo in Treatment Period 1, neflamapimod in Treatment Period 2~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food."
62281958|NCT02296242|EXPERIMENTAL|BVD-523|
62281959|NCT05748379|OTHER|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper after tooth extraction with bone augmentation by using allogeneic bone.
62281960|NCT05748379|OTHER|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment after tooth extraction with bone augmentation by using allogeneic bone.
62281961|NCT02829021|OTHER|Thermography and mammography|"All participants will be examined with~1. Dynamic infrared thermography (FLIR ThermaCAM P-65)~2. Mammography, clinical examination and if necessary breast tissue biopsy to diagnose breast cancer."
62082826|NCT06431347||Transplant and Cell Therapy Candidates and Recipients|"Participants that agree to take part in this study, the study staff will first verify your demographic information (such as age, sex, race, and so on). Participants will then be asked about social barriers to care, including but not limited to:~* primary language and confidence speaking English~* education level~* employment history~* health literacy~* legal history~* caregiver status and literacy"
62082827|NCT06524804|EXPERIMENTAL|BY101298 in combination with palliative radiotherapy|Patients in Phase I undergo palliative radiotherapy for 5 fractions per week and receive BY101298 PO QD concomitant with radiation therapy.
62082828|NCT06524804|EXPERIMENTAL|BY101298 in combination with curative radiotherapy|Patients in Phase I undergo curative radiotherapy for 5 fractions per week and receive BY101298 PO QD concomitant with radiation therapy.
62281962|NCT06047509|EXPERIMENTAL|Arm I Treatment|After inserting the laser, a thermal-optical probe will be inserted via a multichannel needle guide or tranperineal grid in the prostate using transrectal ultrasound guidance. The sensor probe will be placed at a pre-determined depth and location based on the treatment zone. Targets will be identified prior to laser treatment using multi-parametric MRI and delineated by the radiologist for visualization by the treatment operator. The lesion will be visible both on a 3D reconstruction and during real-time ultrasound imaging. Applications of laser energy up to 15 watts of power will be used to treat the target region. Confirmation of appropriate laser position will be made with real-time ultrasound prior to application of laser energy and repeatedly during activation of the laser. Energy delivery will be planned specific to each patient's tumor geometry, with the assistance of the Avenda Health Unfold-AI Software.
62281963|NCT01358032|EXPERIMENTAL|Cognitive behavioral program|an in-home cognitive behavioral program on managing concerns about falling and associated activity avoidance in frail community-dwelling older people facilitated by trained community nurses.
62281964|NCT01358032|NO_INTERVENTION|Control group|no program, only care as usual
62281965|NCT00605085|EXPERIMENTAL|1|IC51
62082829|NCT01222741||Healthy Voluntary|Healthy voluntary
62082830|NCT01222741||Patients|affected patient
62281966|NCT00605085|PLACEBO_COMPARATOR|2|Placebo
62281967|NCT04416880|EXPERIMENTAL|Press Tack Needle Acupuncture|Patients in this group were given seirin pyonex press tack needle treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
62082831|NCT01222741||relatives|family member to patient
62281968|NCT04416880|SHAM_COMPARATOR|Sham Control Press Tack Needle Acupuncture|Patients in this group were given sham treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
62281969|NCT01608035|EXPERIMENTAL|sciatic catheter|
62281970|NCT01608035|ACTIVE_COMPARATOR|Stump catheter|
62281971|NCT06540404|NO_INTERVENTION|Control group|Participants in this group did not undergo any therapy.
62281972|NCT06540404|EXPERIMENTAL|Pulse traction group|Participants assigned to this group underwent second degree impulse traction of the knee joint according to the Kaltenborn concept.
62281973|NCT06540404|EXPERIMENTAL|Continuous traction group|Participants assigned to this group underwent continuous traction of the knee joint in the third degree according to the Kaltenborn concept.
62281974|NCT06540404|SHAM_COMPARATOR|Sham therapy group|The therapist did not use traction force, the knee joint was kept in a flexed position of 40 degrees.
62281975|NCT00821678|EXPERIMENTAL|Arm 1 Telemedicine Outreach for PTSD|Telemedicine-Based Collaborative Care
62281976|NCT00821678|NO_INTERVENTION|Arm 2 Treatment as usual|Usual Care
62281977|NCT04863274||Expanded consultation group|In an expanded consultation group is being conducted in the study group on the importance of primary prevention of cardiovascular diseases and on the reduction of cardiovascular risk by taking statins. Patients are given brochures and information materials on the risk factors for cardiovascular diseases and the possibility of their correction. Also, the patients of the study group are regularly reminded (2 times a month) with the help of SMS mailings and calls of health workers about the need to follow the doctor's recommendations for taking atorvastatin and returning to the medical institution.
62649844|NCT01418469|EXPERIMENTAL|soy+BCAA protein intake|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
62649845|NCT01396564|ACTIVE_COMPARATOR|Metformin|Randomized patients are given 850 mg of metformin daily, increased to 1700 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
62649846|NCT01396564|ACTIVE_COMPARATOR|Pioglitazone|Randomized patients are given 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
62649847|NCT06328088||Non vegetarian diet|Non vegetarian diet
62649848|NCT06328088||Vegetarian diet|Vegetarian diet
62649849|NCT05632614|ACTIVE_COMPARATOR|High-intensity IMST|Participants who will be trained with high-intensity IMST
62649850|NCT05632614|SHAM_COMPARATOR|Low-intensity IMST|Participants who will be trained with low-intensity IMST
62649851|NCT05613348|EXPERIMENTAL|humanized CAR19T2 T cell to B-cell acute lymphoblastic leukemia/lymphoma|Patients received fludarabine and cyclophosphamide (Flu/Cy) for lymphodepletion (Cy at 300-500 mg/m2/dose for four days and Flu at 20-30 mg/m2/dose for two days) before CAR19T2 T cells administration. This CAR19T2 T cell will be infused over 30 minutes on days Day 0.
62649852|NCT06017271||PE group|The CTPA diagnosis suggest pulmonary embolism
62649853|NCT06017271||control group|The CTPA diagnosis did not suggest pulmonary embolism
62649854|NCT02230215|EXPERIMENTAL|Patient-Specific Instrumentation|Patients to have a total knee replacement surgery completed using Patient-Specific Instrumentation
62649855|NCT02230215|NO_INTERVENTION|Traditional Instrumentation|Patients to have a total knee replacement surgery done using traditional instrumentation.
62281978|NCT04475614|NO_INTERVENTION|informative|The patients in this group received only verbal and written information about their condition.
62281979|NCT04475614|EXPERIMENTAL|oral probiotics|The patients in this group, beside verbal and written information about their condition, received also oral probiotics. They were instructed to melt one lozenge in the mouth in the evening, after tooth brushing and flossing, for one month.
62281980|NCT04475614|EXPERIMENTAL|low level laser treatment|The patients in this group, beside verbal and written information about their condition, received a total of ten low level laser treatments, for ten days consecutively excluding weekends.
62281981|NCT04475614|EXPERIMENTAL|B-vitamin injections|The patients in this group, beside verbal and written information about their condition, received a total of nine B vitamin injections, every other day, intra muscular.
62458830|NCT01626079|EXPERIMENTAL|COAPT CAS Group|Percutaneous mitral valve repair using MitraClip System
62082832|NCT05546411|EXPERIMENTAL|mFOLFIRINOX + NIS793|"Participants will be randomly assigned to receive:~* FOLFIRINOX + NIS793 on day 1 of each 14 day cycle up to 8 cycles/16 weeks~* Cycles 9+: Based on study team determination, some participants may be offered chemoradiation following completion of chemotherapy and/or surgery following either completion of chemotherapy or chemoradiation"
62082833|NCT05546411|ACTIVE_COMPARATOR|mFOLFIRINOX|"Participants will be randomly assigned to receive:~* FOLFIRINOX on day 1 of each 14 day cycle up to 8 cycles/16 weeks~* Cycles 9+: Based on study team determination, some participants may be offered chemoradiation following completion of chemotherapy and/or surgery following either completion of chemotherapy or chemoradiation"
62082834|NCT02631603|EXPERIMENTAL|Placebo|Capsules of placebo will be taken for 3 months, same schedule as verum.
62082835|NCT02631603|ACTIVE_COMPARATOR|Prednisolone|"Oral prednisolone, anticipated dose:~first month 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.~Individual capsules will be prepared using rounded dose."
62281982|NCT05286060|EXPERIMENTAL|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; GX-I7 1200㎍/kg|"IV:1st day of week 1 and 4, IV:1st day of week 1 and 4~Triple combination of GX-188E HPV DNA Vaccine, GX-I7, and Pembrolizumab"
62082836|NCT06737744|EXPERIMENTAL|AG4C intervention group|
62082837|NCT04982653|EXPERIMENTAL|Arm I (hepatectomy using small bites fascial closure)|Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.
62082838|NCT04982653|ACTIVE_COMPARATOR|Arm II (hepatectomy using conventional fascial method)|Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.
62082839|NCT01565018|EXPERIMENTAL|Treatment A - Treatment B|"Treatment A: Test; drug product PR 2.2.1~Treatment B: Reference; drug product PR 2.1.4~Sequence of two single applications of Rotigotine transdermal patches (PR 2.2.1 first) for 24 hours separated by a Washout Period of 5 days."
62281983|NCT05286060|EXPERIMENTAL|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; Pembrolizumab 200mg, IV:1st day of week 1 and 4|Combination of GX-188E HPV DNA Vaccine and Pembrolizumab as an Expanded Cohort
62082840|NCT01565018|EXPERIMENTAL|Treatment B - Treatment A|"Treatment B: Reference; drug product PR 2.1.4~Treatment A: Test; drug product PR 2.2.1~Sequence of two single applications of Rotigotine transdermal patches (PR 2.1.4 first) for 24 hours separated by a Washout Period of 5 days."
62082841|NCT04281498|EXPERIMENTAL|Patients with MPN|Ruxolitinib and Enasidenib combination therapy
62082842|NCT06719661|EXPERIMENTAL|Dapagliflozin as add on therapy group|Patients with uncontrolled type 2 diabetes receive dapagliflozin 10 mg once daily for 3 months as add-on therapy to their dual or triple standard therapy without receiving clinical pharmacist-led intervention.
62281984|NCT05286060|EXPERIMENTAL|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; GX-I7 360㎍/kg,GX-188E 2mg,|"IM: 1st day of week 1, 2, and 4; GX-I7 360㎍/kg, IM: 1st day of week 2; Pembrolizumab 200mg, IV:1st day of week 1 and 4~Triple combination of GX-188E HPV DNA Vaccine, GX-I7, and Pembrolizumab as an Expanded Cohort"
62281985|NCT05286060|EXPERIMENTAL|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; GX-I7 360㎍/kg, IM: 1st day of week 2|Combination of GX-188E HPV DNA Vaccine and GX-I7 as an Expanded Cohort
62458831|NCT06015126|EXPERIMENTAL|Label 1|metronomic oral vinorelbine plus anlotinib
62082843|NCT06719661|EXPERIMENTAL|Clinical pharmacist-led intervention group|Patients with uncontrolled type 2 diabetes receive clinical pharmacist-led intervention, including dosage adjustment, dietary modification, education on the importance of adherence, strategies to improve adherence, and regular follow-up along with their standard dual or triple oral hypoglycemic medicines
62082844|NCT06719661|OTHER|Standard therapy group|Patients with uncontrolled type 2 diabetes receiving their standard dual or triple therapy only
62082845|NCT06330961|EXPERIMENTAL|Pain-free participants|Aerobic exercise, Biering-Sorensen test and placebo interventions will be administered to a group of subjects with no past history of low back pain. They will serve as a control group.
62649856|NCT04158765||Infertile men|Men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
62082846|NCT06330961|EXPERIMENTAL|Low back pain patients|Aerobic exercise, Biering-Sorensen test and placebo interventions will be administered to a group of non-specific low back pain patients. They will serve as the primary intervention group.
62281986|NCT05329675|SHAM_COMPARATOR|Arm A|one capsule /day
62649857|NCT01677286|EXPERIMENTAL|doxycycline 100 mg po bid x 12 months|Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
62649858|NCT03758508|ACTIVE_COMPARATOR|HFO|Continuous high flow oxygen through nasal cannula for 45 hours; longer if the clinical need persists
62649859|NCT03758508|ACTIVE_COMPARATOR|NIV/HFO|Alternating noninvasive ventilation (3 hours) and high flow oxygen through nasal cannula (3 hours) for 45 hours; longer if the clinical need persists
62281987|NCT05329675|EXPERIMENTAL|Arm B|two capsule/day
62281988|NCT05329675|EXPERIMENTAL|Arm C|Three capsule /day
62281989|NCT00033865|EXPERIMENTAL|1|Yoga treatment for 8 weeks
62281990|NCT00033865|NO_INTERVENTION|2|Sleep hygiene instructions only
62281991|NCT02374866|NO_INTERVENTION|Conventional monitoring|The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year.
62281992|NCT02374866|EXPERIMENTAL|Closer monitoring|"The experimental group will follow a closer monitoring than the control group : every two months for one year in,stead of every 4 months for a year.~Follow by email or mail is identical to the control group."
62281993|NCT00110019|EXPERIMENTAL|Arm I (paclitaxel, carboplatin, sorafenib tosylate)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive sorafenib tosylate PO BID (approximately every 12 hours) on days 2-19.
62458832|NCT03604419|EXPERIMENTAL|PB-119 100 μg|PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)
62458833|NCT03604419|EXPERIMENTAL|PB-119 150 μg|PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
62458834|NCT03604419|EXPERIMENTAL|PB-119 200 μg|PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
62458835|NCT03604419|PLACEBO_COMPARATOR|PB-119 Placebo|PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
62458836|NCT02448927|OTHER|TAVI patients without balloon aortic valvuloplasty|Patients that will not undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
62649860|NCT05881811|EXPERIMENTAL|A1|Period 1: HSK16149 single dose on D1, 40mg, fasted; Period 2: HSK16149 single dose on D2, 40mg, fasted; Probenecid QID (500mg) on D1\~D4. HSK16149 would be administered 2 hours after the first dose of probenecid on D2.
62649861|NCT05881811|EXPERIMENTAL|A2|"Period 1: HSK16149 single dose on D2, 40mg, fasted；probenecid QID (500mg) on D1\~D4. HSK16149 would be administered 2 hours after the first dose of Probenecid on D2.~Period 2: HSK16149 single dose on D1, 40mg, fasted;"
62649862|NCT05881811|EXPERIMENTAL|B1|Period 1: HSK16149 single dose on D1, 40mg, fasted; Period 2: HSK16149 single dose on D2, 40mg, fasted; Cimetidine QID (200mg) on D1\~D4. HSK16149 would be administered 1 hour after the first dose of Cimetidine on D2.
62649863|NCT05881811|EXPERIMENTAL|B2|"Period 1: HSK16149 single dose on D2, 40mg, fasted; Cimetidine QID (200mg) on D1\~D4. HSK16149 would be administered 1 hour after the first dose of Cimetidine on D2.~Period 2: HSK16149 single dose on D1, 40mg, fasted;"
62082847|NCT06639958|EXPERIMENTAL|Adherers arm III (EDU)|Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. Additionally, patients undergo blood sample collection on the study.
62082848|NCT06639958|EXPERIMENTAL|Adherers arm IV (pIP)|See Detailed Description.
62082849|NCT06639958|EXPERIMENTAL|Non-adherers arm I (IP)|See Detailed Description.
62082850|NCT06639958|EXPERIMENTAL|Non-adherers arm II (U-iIP)|See Detailed Description.
62082851|NCT06561555|EXPERIMENTAL|Study group|
62082852|NCT02928497|EXPERIMENTAL|WATCHMAN (Device)|WATCHMAN LAAC Device implant including modified post-implant drug regimen.
62082853|NCT02928497|ACTIVE_COMPARATOR|Control|Single antiplatelet therapy or no therapy (Control) at the discretion of the study physician for the duration of the trial.
62082854|NCT00271622||healthy volunteers|healthy volunteers
62082855|NCT00271622||individuals at risk|individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders.
62281994|NCT00110019|ACTIVE_COMPARATOR|Arm II (carboplatin, paclitaxel, placebo)|Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.
62281995|NCT00216970|NO_INTERVENTION|1|"Patients will receive nutritional support in which the contents of arginine = 0, glutamate = 0 and proline = 0.~Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients."
62649864|NCT03809390|EXPERIMENTAL|Vaginal seeding group|Swabbing infants born by C-section with a gauze incubated in the maternal vagina about an hour before the C-section. The gauze will be extracted prior to the C-section, kept in a sterile container in an incubator (37 ℃), and taken out from the incubator immediately before the swabbing. The infant will be swabbed with the gauze, starting from the lips, followed by the face, thorax, arms, legs, genitals and anal region, and finally the back. The swabbing will take around 15-20 seconds.
62082856|NCT06727526|EXPERIMENTAL|Acupressure Group|Infants in this group will undergo acupressure both before and after cardiac catheterization. The initial session will be administered by the researcher 30 minutes prior to the procedure. Acupressure will target three specific points: the seventh point of the heart meridian (HT7), the fourth point of the large intestine meridian (LI4), and the sixth point of the pericardial meridian (PC6). The areas will be warmed for approximately 20 seconds to minimize tissue sensitivity, avoiding direct pressure on the acupressure points. Each point will receive 12 minutes of treatment, comprising 10 seconds of compression followed by 2 seconds of relaxation, applied symmetrically. After this initial session, the infant will undergo cardiac catheterization. Upon return to the ward post-catheterization, a second acupressure session will be conducted one hour after the administration of the final dose of ketamine hydrochloride.
62649865|NCT03809390|NO_INTERVENTION|Control group|Managed based on the standard practice in the study site
62649866|NCT00938938|EXPERIMENTAL|Press guide plus press release|Participants in the intervention group will receive a press guide (a one-page summary of study findings written by the investigators) in addition to the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
62649867|NCT00938938|NO_INTERVENTION|Press release only|Participants in the control group will receive the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
62649868|NCT05277207|EXPERIMENTAL|MESH|Participants assigned to this group will receive a treatment that includes personalized smoking cessation facilitation meetings with cognitive-behavioral therapy, personalized smoking cessation pharmacotherapy, and personalized text messaging.
62649869|NCT05277207|ACTIVE_COMPARATOR|Best Practice Telehealth Group|Participants assigned to this group will be referred to Quit Vet (VA's quitline for stopping tobacco) and SmokefreeVET (a free text messaging program to help you quit), and will receive information about getting quit medications.
62649870|NCT02518334|EXPERIMENTAL|Alcohol consumption|Alcohol consumption and wine consumption
62649871|NCT04081688|EXPERIMENTAL|Treatment (varlilumab, atezolizumab, SBRT)|Patients receive varlilumab IV over 90 minutes and atezolizumab IV over 30-60 minutes every cycle. Cycles repeat every 21 days for up to 1 year (18 cycles) in the absence of disease progression or unacceptable toxicity. Between cycle 1 and 2, patients also receive SBRT.
62649872|NCT06122558|EXPERIMENTAL|Probiotic|Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks
62649873|NCT06122558|PLACEBO_COMPARATOR|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
62649874|NCT03186755|EXPERIMENTAL|Hylo-Dual|Hyaluronic acid 0.05% \& Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
62649875|NCT03186755|ACTIVE_COMPARATOR|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
62649876|NCT01547715|EXPERIMENTAL|MenACWY - 2 - 10 Years old|Subjects between 2 and 10 years of age who received one injection of Meningococcal ACWY conjugate vaccine -CRM vaccine on day 1.
62649877|NCT01547715|EXPERIMENTAL|MenACWY - 11 - 18 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
62649878|NCT01547715|EXPERIMENTAL|MenACWY - 19 - 75 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
62649879|NCT01203696|ACTIVE_COMPARATOR|non-amlodipine|For patient with suboptimal angina control: anti-anginal agent excluding calcium channel blocker
62649880|NCT01203696|ACTIVE_COMPARATOR|non - amlodipine|For patient with suboptimal BP control: anti-hypertensive agent excluding calcium channel blocker
62649881|NCT05105256|ACTIVE_COMPARATOR|Corticosteroids|Lumbar facet joint injection with corticosteroids
62649882|NCT05105256|EXPERIMENTAL|PRP|Lumbar facet joint injection with PRP
62649883|NCT02426697|EXPERIMENTAL|Pecfent|Patients will receive 100 µg of transmucosal Pecfent before radiotherapy session (or 200 µg in patients with a stable opioid background pain treatment)
62649884|NCT02426697|PLACEBO_COMPARATOR|Placebo|Patients will receive 100 µg of transmucosal placebo before radiotherapy session or 200 µg in patients with a stable opioid background pain treatment)
62082857|NCT06727526|PLACEBO_COMPARATOR|Plasebo|Infants in this group will receive placebo acupressure before and after cardiac catheterization. The initial session will be administered 30 minutes before the procedure, targeting areas approximately 1-1.5 cm away from HT7, LI4, and PC6 points, where meridians do not pass. The areas will be warmed for 20 seconds to minimize tissue sensitivity, avoiding direct pressure on acupressure points. Each site will receive 12 minutes of treatment, alternating 10 seconds of compression and 2 seconds of relaxation, applied symmetrically. Post-catheterization, a second placebo session will be conducted an hour after the last dose of ketamine hydrochloride.
62082858|NCT06727526|NO_INTERVENTION|Control Group|Infants in this group will not receive any specific intervention and will be provided routine care in the ward.
62082859|NCT06735924|EXPERIMENTAL|Estimation of endogenous oxalate production|Fasted hourly urine collections after equilibration on a low-oxalate diet
62082860|NCT06195332|ACTIVE_COMPARATOR|open TAR|Open transversus abdominis release procedure will be use as combine open procedure Rives-Stoppa hernia repair in combination with bilateral transversus abdominis release with retromuscular mesh placement
62281996|NCT00216970|NO_INTERVENTION|2|In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
62281997|NCT03629548|ACTIVE_COMPARATOR|early amniotomy plus dinoprostone|10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
62458837|NCT02448927|ACTIVE_COMPARATOR|TAVI patients with balloon aortic valvuloplasty|Patients that will undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
62649885|NCT01381497||Employed migraine sufferers|Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
62281998|NCT03629548|EXPERIMENTAL|foley balloon catheter plus dinoprostone|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix
62649886|NCT01780623|EXPERIMENTAL|Bright White Light|Bright white light exposure every morning for 30 minutes for 28 consecutive days
62649887|NCT01780623|ACTIVE_COMPARATOR|Dim Red Light|Dim red light exposure every morning for 30 minutes for 28 consecutive days
62649888|NCT06050681|EXPERIMENTAL|Mindfulness Intervention|Participants will engage with a mobile application to complete 21 sessions lasting approximately 11 minutes of mindfulness training over 6 weeks.
62649889|NCT05339958|EXPERIMENTAL|Nutraceutical Dietary Supplement Capsule|The nutraceutical capsules are comprised of standardized, natural, medical-grade ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
62649890|NCT05339958|PLACEBO_COMPARATOR|Placebo Capsule|The placebo capsules contain no active ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
62082861|NCT06195332|ACTIVE_COMPARATOR|endoscopic TAR|Endoscopic transversus abdominis release procedure will be use as combine minimally invasive Rives-Stoppa hernia repair in combination with bilateral transversus abdominis release via endoscopic technique with retromuscular mesh placement
62281999|NCT01428466|EXPERIMENTAL|GSK2585823|external preparation
62282000|NCT01428466|ACTIVE_COMPARATOR|Benzoic peroxide 3%|external preparation
62282001|NCT01428466|ACTIVE_COMPARATOR|Benzoic peroxide 5%|external preparation
62282002|NCT01428466|PLACEBO_COMPARATOR|Vehicle|external preparation
62282003|NCT05740956|EXPERIMENTAL|HS-10502|HS-10502 Tablets，PO，QD
62649891|NCT01607658|PLACEBO_COMPARATOR|Placebo|Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
62649892|NCT01607658|EXPERIMENTAL|Experimental 1|Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
62282004|NCT02153762|EXPERIMENTAL|Right side|Patients were randomized to apply Locoid Lipocream on the right side of the target lesion followed by Hylatopic Plus lotion on the left side of the target lesion with the reverse order on the other side.
62282005|NCT02153762|ACTIVE_COMPARATOR|Left first|Patients were randomized to apply Locoid Lipocream on the left side of the target lesion followed by Hylatopic Plus lotion on the right side of the target lesion with the reverse order on the other side.
62282006|NCT00054587|ACTIVE_COMPARATOR|6 FEC|Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
62282007|NCT00054587|EXPERIMENTAL|6 DE|Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I
62649893|NCT01607658|EXPERIMENTAL|Experimental 2|Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
62649894|NCT01607658|EXPERIMENTAL|Experimental 3|High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
62649895|NCT05475145|EXPERIMENTAL|Child|Each patient receives treatment of dental caries in two primary molars using two diffferent methods - Resin based sealing \[RBS\] or Glassionomer cement \[GIC\].
62649896|NCT04333693||Cases|Adults (age\>18years) undergoing any type of vascular surgery (open surgery, endovascular surgery or hybrid procedure) in an operating theatre and either before or after surgery: lab test confirmed COVID-19 or clinical diagnosis of COVI-19 infection (no test performed)
62082862|NCT04028843|NO_INTERVENTION|WIC Nutrition|Participants will receive weight management advice and care through the standard Women, Infants, and Children program. They will also receive weekly health information related to pregnancy, birth, and infant health through a closed Facebook group.
62282008|NCT02445833|EXPERIMENTAL|Lifestyle on-line intervention|"The self-applied on-line intervention will received acces to the web and the Vivir mejor modules."
62282009|NCT05776069|PLACEBO_COMPARATOR|Part 1|Cohorts 1-8 IV or SC VGA039 or Placebo dose to be determined
62282010|NCT05776069|EXPERIMENTAL|Part 2|Cohorts A-H IV or SC VGA039 dose to be determined
62458838|NCT04247308|EXPERIMENTAL|experimental group|"Sensory stimulations (ATVV) will be consisting of Soft lullaby between of 30-40 dB for Auditory, Gentle stroking massage in supine position(upper and lower limb)for Tactile, Visual Stimulations with Black and white card (distance of 8-10 in), gentle rocking (vertical and horizontal direction) for the stimulation of vestibular system and oral stimulation including stocking cheeks, lips, jaw and tongue, rubbing gum.Each stimulation will be given for 3 minutes.~Movement therapy will include: Guided range of motion: flexion-extension movements of lower limb (bicycle riding pattern). Hand should be placed around knee joint. Care must be taken as PI consist the cartilaginous joints at wrist and ankle. Anti gravity movements in prone (neck and spinal extension), Anti gravity movements in sitting (supported) and Upright positioning for 3min each"
62649897|NCT00781950|PLACEBO_COMPARATOR|Placebo|Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.
62649898|NCT00781950|EXPERIMENTAL|Flaxseed|Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
62649899|NCT00551369|EXPERIMENTAL|SBRT|Stereotactic body radiation therapy (SBRT)
62649900|NCT04989673||Exposed group (GE)|Pregnant women with symptomatic dengue fever, confirmed biologically between the presumed date of conception and the date of delivery.
62282011|NCT01004757|ACTIVE_COMPARATOR|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled, aerobic exercise
62649901|NCT04989673||Unexposed group with fever (GNEF)|Pregnant women presenting a febrile syndrome not due to the dengue virus between the presumed date of conception and the date of delivery, excluding malaria, rubella, toxoplasmosis, chickenpox, listeriosis, CMV infection and primary HIV infection.
62649902|NCT04989673||Unexposed group without fever or dengue (GNES)|Pregnant women exhibiting neither febrile syndrome nor asymptomatic dengue fever between the presumed date of conception and the date of delivery.
62282012|NCT01004757|ACTIVE_COMPARATOR|Low Fat diet|cross over design of three weeks Low Fat diet followed by two weeks LOGI diet always combined with heart rate controlled aerobic exercise
62282013|NCT01893567|EXPERIMENTAL|Clobex spray|
62282014|NCT01260454|EXPERIMENTAL|Qutenza patch|All participants actively treated with Qutenza
62282015|NCT00649103|EXPERIMENTAL|1|Quinapril Hydrochloride Tablets 40 mg
62282016|NCT00649103|ACTIVE_COMPARATOR|2|Accupril® Tablets 40 mg
62282017|NCT03196128|ACTIVE_COMPARATOR|Digital|
62282018|NCT03196128|ACTIVE_COMPARATOR|Non Digital|
62282019|NCT05058183|EXPERIMENTAL|All participants|All participants
62282020|NCT01984021|EXPERIMENTAL|traditional acupuncture (tACP)|In the upper trapezius muscle with the greatest area pain and lowest PPT score will be chosen for acupuncture. Sterile acupuncture needles measuring 0.25 x 13 mm (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd.®) will be inserted in TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and LI-11 (located at the outermost point of the skinfold of elbow flexion in the direction of the lateral epicondyle of the elbow).
62282021|NCT01984021|PLACEBO_COMPARATOR|sham acupuncture (sACP)|The needles will be inserted 1 cm to the side of TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and 1 cm to the side of LI-11 (in the direction of the styloid process of the radius).The acupuncture needles are positioned at different acupoints.
62458839|NCT04247308|ACTIVE_COMPARATOR|control group|receives routine care from the nursing team as well as daily maternal care, such as being held in the mother's arms
62649903|NCT00957359|EXPERIMENTAL|Psilocybin|Drug intervention
62649904|NCT00957359|ACTIVE_COMPARATOR|Niacin|Active control
62649905|NCT04918823|OTHER|Single arm|All subjects will receive Restasis in this study
62282022|NCT01406067|EXPERIMENTAL|Social Skills Training|
62282023|NCT01406067|ACTIVE_COMPARATOR|Play group|
62282024|NCT04144439|NO_INTERVENTION|Before treatment|no intervention
62282025|NCT04144439|ACTIVE_COMPARATOR|After treatment|GABA
62649906|NCT01363635||severe sepsis|severe sepsis/septic shock, organ failure, ICU death
62649907|NCT00102323|PLACEBO_COMPARATOR|Placebo|
62649908|NCT00102323|EXPERIMENTAL|AMG 531|Active Investigational Product
62649909|NCT01868568|EXPERIMENTAL|IDegAsp 30 + placebo|
62649910|NCT01868568|EXPERIMENTAL|Insulin aspart + insulin degludec - low concentration 1|
62649911|NCT01868568|EXPERIMENTAL|IDegAsp 40 + placebo|
62649912|NCT01868568|EXPERIMENTAL|Insulin aspart + insulin degludec - high concentration 1|
62649913|NCT01868568|EXPERIMENTAL|IDegAsp 45 + placebo|
62649914|NCT01868568|EXPERIMENTAL|Insulin aspart + insulin degludec|
62649915|NCT01868568|EXPERIMENTAL|IDegAsp 55 + placebo|
62649916|NCT01868568|EXPERIMENTAL|Insulin aspart + insulin degludec - high concentration|
62649917|NCT01868568|ACTIVE_COMPARATOR|BIAsp 30 + placebo|
62649918|NCT05094427||Lumbar spine surgery with preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery with a fluoroscopically-guided DR block placed by the operative neurosurgeon prior to surgery. These patients subsequently received standard of care general anesthesia and standard multimodality postoperative pain control.
62282026|NCT05926310|EXPERIMENTAL|Exoskeleton assisted ambulation|"Phase 1: Five participants will undergo a training programme with the TWIICE Rise 0.0 two times a week for up to 6 weeks for a total of 6 sessions.~Phase 2: Ten participants will undergo a training programme with the TWIICE Rise 1.0 two times a week for up to 20 weeks for a total of 24 sessions."
62458840|NCT01494506|EXPERIMENTAL|MM-398|MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
62282027|NCT03581331|EXPERIMENTAL|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
62282028|NCT05996796|EXPERIMENTAL|Opt-out first-void urine|"Women will receive a first-void urine self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
62282029|NCT05996796|EXPERIMENTAL|Opt-in first-void urine|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a first-void urine self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
62458841|NCT01494506|ACTIVE_COMPARATOR|5 Fluorouracil and Leucovorin IV|5 Fluorouracil and Leucovorin IV
62458842|NCT01494506|EXPERIMENTAL|MM-398, 5-FU and Leucovorin|MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
62458843|NCT00553280|EXPERIMENTAL|pregabalin|
62458844|NCT03806439||Patients undergoing radical cystectomy.|After approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6, 9 and 12 months after surgery.
62649919|NCT05094427||Lumbar spine surgery without preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery without placement of a fluoroscopically-guided DR block. These patients received standard of care general anesthesia and standard multimodality postoperative pain control.
62458845|NCT04219566|ACTIVE_COMPARATOR|Active VeNS|The VeSTAL device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
62649920|NCT00976339|EXPERIMENTAL|Cholecalciferol 20,000 IU|Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.
62458846|NCT04219566|SHAM_COMPARATOR|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
62649921|NCT00976339|EXPERIMENTAL|Cholecalciferol 30,000 IU|Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.
62649922|NCT06062992||Patients with 'recombined imaging only lesions' or ROLs|Women that recently underwent CEM, which showed a suspicious breast lesion only on the recombined (enhancement) images: a 'recombined image only lesions' or ROL. These women are indicated to undergo CESB.
62649923|NCT03002896|EXPERIMENTAL|Pep-Pal + Treatment as Usual|If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
62649924|NCT03002896|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.
62649925|NCT01198405|EXPERIMENTAL|Enhanced External Counterpulsation|Treatment of Enhanced External Counterpulsation (EECP) with a prespecified protocol on top of guideline-driven standard medical therapy.
62649926|NCT01198405|ACTIVE_COMPARATOR|Control|Guideline-driven standard medical therapy.
62649927|NCT01478659|ACTIVE_COMPARATOR|Control bar and yogurt|
62649928|NCT01478659|EXPERIMENTAL|Fiber bar and yogurt|
62082863|NCT04028843|EXPERIMENTAL|Healthy Beginnings|Participants will receive the SmartMoms smartphone application, a wireless connected scale, and a Fitbit. The Healthy Beginnings program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the SmartMoms smartphone application, personalized feedback from counselors, and evidence-based behavioral intervention delivered throughout pregnancy.
62082864|NCT03441074|EXPERIMENTAL|Intervention Group|Patients randomly assigned to intervention group will get enhanced olfactory stimuli during the perioperative period
62082865|NCT03441074|NO_INTERVENTION|Non-intervention Group|Patients randomly assigned to non-intervention group will not get any olfactory stimuli during the perioperative period
62082866|NCT00001846||research donors|healthy volunteers (age 18 years or greater) who donate blood for in vitro research purposes
62082867|NCT05257642|EXPERIMENTAL|Cognitive Change Groups|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on cognitive change. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements.
62082868|NCT05257642|EXPERIMENTAL|Mindfulness Groups|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on mindfulness and relaxation. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements
62458847|NCT02270970|ACTIVE_COMPARATOR|Responders to Belimumab|This Arm is defined as patients who complete 6 months of belimumab without and meet the primary endpoint
62649929|NCT04315402||Group 1 (provider-patient concordant)|
62649930|NCT04315402||Group 2 (provider-patient discordant)|
62082869|NCT05257642|EXPERIMENTAL|Positive bias Group|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on problem-solving. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements
62282030|NCT05996796|EXPERIMENTAL|Opt-out vaginal self-sample|"Women will receive a vaginal self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
62649931|NCT04698811|OTHER|VIRTUAL ENEAGRAM: QUALITY OF LIFE, STRESS AND ANXIETY.|Training and testing battery.
62649932|NCT02243657|PLACEBO_COMPARATOR|1: Placebo dose level|
62649933|NCT02243657|EXPERIMENTAL|2: ASP3652 lowest dose level twice daily|
62649934|NCT02243657|EXPERIMENTAL|3:ASP3652 low dose level twice daily|
62649935|NCT02243657|EXPERIMENTAL|4: ASP3652 medium dose level twice daily|
62649936|NCT02243657|EXPERIMENTAL|5: ASP3652 high dose level twice daily|
62649937|NCT02243657|EXPERIMENTAL|6: ASP3652 highest dose level once daily|
62082870|NCT05257642|NO_INTERVENTION|Control Group|The participants in this group will complete the pre-test measurements, then they will receive an experimental task Cyberball and complete the post-test measurements
62082871|NCT06498128||QUIVIQ (Cohort A)|Women with insomnia exposed to QUVIVIQ during pregnancy or within 5 half-lives prior to conception.
62082872|NCT06498128||Non-orexin receptor antagonist medications for insomnia (Cohort B1)|Women exposed to other, non-orexin receptor antagonist medications for insomnia during pregnancy or within 5 half-lives of the respective insomnia medication prior to conception.
62082873|NCT06498128||No insomnia medications (Cohort B2)|Women who had no exposure to any insomnia medication during pregnancy and within 5 half-lives of any insomnia medication taken prior to conception.
62082874|NCT06739369||Ankylosing spondylitis|
62458848|NCT02270970|ACTIVE_COMPARATOR|Non Responders to Belimumab|This Arm is defined as patients who complete 6 months of study and do not meet the primary endpoint
62458849|NCT00738803|EXPERIMENTAL|1|Leg Length and offset measurement arm
62458850|NCT03169348|EXPERIMENTAL|study group|Hepatitis- C virus with thrombocytopenia
62458851|NCT03933956|EXPERIMENTAL|Empagliflozin-treated|Oral empagliflozin tablets 10mg daily, taken for 30 days.
62458852|NCT01190748|EXPERIMENTAL|A|Galantamine 4 mg Tablet, single dose
62458853|NCT01190748|ACTIVE_COMPARATOR|B|Reminyl 4 mg Tablet, single dose
62649938|NCT00744341|EXPERIMENTAL|1|
62649939|NCT00744341|EXPERIMENTAL|2|
62649940|NCT00744341|EXPERIMENTAL|3|
62649941|NCT00744341|EXPERIMENTAL|4|
62649942|NCT00744341|PLACEBO_COMPARATOR|5|
62649943|NCT01052948||Cohort 1|All persons who newly start one of the dopamine agonists (DA) after start of eligibility period
62649944|NCT01052948||Cohort 2|All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.
62649945|NCT01052948||Cohort 3|All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.
62649946|NCT01052948||Cohort 4|healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists
62649947|NCT03023995|EXPERIMENTAL|CAF with Platelet Rich Fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it.
62649948|NCT03023995|ACTIVE_COMPARATOR|CAF with connective tissue graft|In control group, connective tissue graft harvesting was carried out which was followed by placement of connective tissue graft on the recipient site. The connective tissue graft was placed on the recipient site and secured in position with 5-0 vicryl sutures
62082875|NCT06735859|ACTIVE_COMPARATOR|Daytime eating window (7 am - 7 pm)|Participants will be instructed to follow the assigned eating window for a period of 12 months. In the daytime eating window, there will also be encouragement for sleep hygiene practices.
62082876|NCT06735859|ACTIVE_COMPARATOR|Nighttime eating window (12 pm - 12 am)|Participants will be instructed to follow the assigned eating window for a period of 12 months.
62082877|NCT06720610|EXPERIMENTAL|Vonoprazan|Each randomized patients will consume 20mg of vonoprazan once a day for 14 days consecutively
62082878|NCT06720610|ACTIVE_COMPARATOR|Esomeprazole|Each randomized patients will consume 40mg of esomeprazole once a day for 14 days consecutively
62082879|NCT01650675|PLACEBO_COMPARATOR|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
62082880|NCT01650675|EXPERIMENTAL|Indirect intervention|Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
62082881|NCT03482674|NO_INTERVENTION|Control Group|The control group will receive standard care as provided by the German statutory health insurance.
62082882|NCT03482674|EXPERIMENTAL|Intervention group|The intervention group receives the DIMINI lifestyle intervention for a period of three months.
62082883|NCT05345912|EXPERIMENTAL|Cohort 1|Subjects received 125 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 125 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
62082884|NCT05345912|EXPERIMENTAL|Cohort 2|Subjects received 250 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 375 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
62082885|NCT05345912|EXPERIMENTAL|Cohort 3|Subjects received 125 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 750 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
62282031|NCT05996796|EXPERIMENTAL|Opt-in vaginal self-sample|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a vaginal self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
62282032|NCT04888663|EXPERIMENTAL|Study treatment|(Phase Ib part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel 80 or 70 mg/m2 IV (according to dose level) (Phase II part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel at RP2D (80 or 70 mg/m2 IV)
62082886|NCT06393998|ACTIVE_COMPARATOR|Breathing with CO2 during daytime and night at high altitude|Subjects will sleep and perform exercise tests under inhalation of low concentration of CO2 supplied by a novel device at high altitude.
62282033|NCT05965674|ACTIVE_COMPARATOR|The sacral ESPB group (Group S)|Patients in Group S underwent a procedure where a high-frequency linear ultrasound probe (Clarius, 205-2980 Virtual Way, Vancouver, BC, Canada V5M 4X3 MyLabFive; Esaote Europe BV Philipsweg 1 6227 AJ, Maastricht, the Netherlands) was positioned on the transverse plane, specifically on the fifth spinous process. The probe was then moved downwards to visualize the first and second median sacral crest. Next, the transducer was placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) was injected between the erector spinae muscles and the intermediate sacral crest. The same procedure was performed on the contralateral side.
62282034|NCT05965674|NO_INTERVENTION|The control group (Group N)|It will not be performed any extra intervention, just rutin clinic protocol.
62282035|NCT01554579|PLACEBO_COMPARATOR|Sugar pill|
62082887|NCT06393998|PLACEBO_COMPARATOR|Breathing with air during daytime and night at high altitude|Subjects will sleep and perform exercise tests under inhalation of air at high altitude.
62282036|NCT01554579|EXPERIMENTAL|Gefapixant|
62282037|NCT05194254|EXPERIMENTAL|ASD|people with Autism Spectrum Disorders
62282038|NCT05194254|ACTIVE_COMPARATOR|TD|Typical Development) group of people
62282039|NCT06547476|EXPERIMENTAL|Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), Anlotinib|
62649949|NCT00581217||Single arm study|Burn patients or patients with skin loss requiring split-thickness skin graft
62649950|NCT06044987|ACTIVE_COMPARATOR|Group I (TOT alone)|49 Female Patients diagnosed with Stress urinary incontinence and cystocele and offered repair by Trans obturator tape procedure
62282040|NCT03536351|EXPERIMENTAL|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists, and target understanding emotion, intentions and appropriate social interactions.
62649951|NCT06044987|EXPERIMENTAL|Group II (TOT+ Cystocele Repair)|49 Female Patients diagnosed with Stress urinary incontinence and cystocele and offered repair by Trans obturator tape procedure concurrently with cystocele repair.
62649952|NCT05093868|EXPERIMENTAL|FIRMap™ (Abbott Laboratories, Abbott Park, IL)|A 64-pole basket mapping catheter (FIRMap™, Abbott Laboratories, Abbott Park, IL) will be used to passively acquire electrical signals
62649953|NCT00106002|EXPERIMENTAL|A|
62649954|NCT03019380|EXPERIMENTAL|Impacted cerumen|removing cerumen from external ears of patients with impacted cerumen, obscuring the canal and the tympanic membrane.
62082888|NCT06739473|EXPERIMENTAL|TOTAL dose test|The aim of the studies performed in this arm (8 subjects) is to test the lowest dose of H2\[15O\]O (radiowater) for the Siemens Quadra PET/CT scanner. Each participant will be studied once with the scanner with 4 different doses (25-700 MBq) of H2\[15O\]O, each repeated 2 times
62082889|NCT06739473|EXPERIMENTAL|TOTAL|The participants in this arm will undergo two PET visits. On one visit the effects of visual stimuli or cold on whole body perfusion will be studied with H2\[15O\]O PET/CT. On the second visit whole-body insulin sensitivity is studied with \[18F\]fluorodeoxyglucose PET/CT, and the acute and delayed effects of intravenous insulin on blood flow will be studied with H2\[15O\]O PET/CT.
62082890|NCT05180552|EXPERIMENTAL|Experimental|Participants will wear HEALiX Device while intubated and sedated in the critical care setting
62082891|NCT05180552|ACTIVE_COMPARATOR|Control|Participants will wear wrist restraints while intubated and sedated in the critical care setting
62082892|NCT05309928|EXPERIMENTAL|Amox 500 mg|Amoxicillin 500 mg PO
62082893|NCT05625425|EXPERIMENTAL|LabyrinthVR Scoot|Multi-session cognitive intervention with VIVE high-resolution head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via handheld controllers.
62082894|NCT05625425|PLACEBO_COMPARATOR|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
62082895|NCT05625425|EXPERIMENTAL|Labyrinth Tablet|Multi-session cognitive intervention with tablet computer, displaying 2.5D version of Labyrinth game in an adaptive spatial wayfinding challenge. Game movement via on-screen control buttons.
62082896|NCT05625425|EXPERIMENTAL|Labyrinth VR wireless|Multi-session cognitive intervention with QUEST head-mounted display virtual reality computer game using wireless technology to present an adaptive spatial wayfinding challenge. Game movement via handheld controllers.
62082897|NCT05088694|EXPERIMENTAL|Intervention|Classrooms assigned to the intervention group will receive the Peaceful Coexistence (middle school) or Anti-extremism (high school) curricula.
62082898|NCT05088694|NO_INTERVENTION|No intervention|Classrooms assigned to the No intervention group will receive general information during their sessions.
62649955|NCT03242785|EXPERIMENTAL|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
62082899|NCT06741033|EXPERIMENTAL|Interventional group I|
62082900|NCT06741033|ACTIVE_COMPARATOR|Interventional group II|
62082901|NCT05056376|EXPERIMENTAL|Fully-Automated Digital Diabetes Prevention Program|Participants will receive Sweetch Digital Diabetes Prevention Program consists of a smartphone app and bluetooth-enabled digital body weight scale that syncs with the app.
62282041|NCT03827759||septic arthritis (group A)|Patients with acute juvenile arthritis with suspicion of bacterial infection,confirmed on a bacteriological plan, either by culture of the articular liquid or by blood culture, or by molecular biology in the articular liquid;
62282042|NCT03827759||inflammatory arthritis (group B)|Patients with idiopathic juvenile arthritis
62282043|NCT03827759||control (group C)|Healthy children who are matched by the age and at the sex in the groups A and B, to analyze elements studied in the blood.
62282044|NCT06467812|NO_INTERVENTION|Control|A typical water and meal schedule will be followed on the Control day.
62282045|NCT06467812|EXPERIMENTAL|Water plus Salt Tablets|A typical water and meal schedule will be followed, with the addition of Fluid Loading water plus salt tablets.
62282046|NCT06467812|EXPERIMENTAL|Electrolyte Solution over 4 hours|A typical water and meal schedule will be followed, with the addition of Fluid Loading electrolyte solution over 4 hours.
62649956|NCT03242785|NO_INTERVENTION|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
62649957|NCT00714701||High Risk Group 1|familial Peutz-Jeghers syndrome
62082902|NCT05056376|ACTIVE_COMPARATOR|Human Coach-Based Diabetes Prevention Program|Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
62082903|NCT03092674|ACTIVE_COMPARATOR|Arm A (azacitidine)|Patients receive azacitidine SC or IV daily on days 1-7 or on an interrupted schedule which ensures that all 7 days of therapy are received within a 12 day period. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62082904|NCT03092674|EXPERIMENTAL|Arm B (azacitidine, nivolumab)|Patients receive azacitidine as in Arm A and nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62082905|NCT03092674|EXPERIMENTAL|Arm C (azacitidine, midostaurin)|Patients receive azacitidine as in Arm A and midostaurin orally (PO) twice daily (BID) on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62082906|NCT03092674|EXPERIMENTAL|Arm D (decitabine, cytarabine)|"INDUCTION: Patients receive decitabine IV over 2 hours on days 1-5 and cytarabine IV continuously on days 6-11. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients deemed stable at the discretion of the treating physician receive decitabine as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62282047|NCT06467812|EXPERIMENTAL|Electrolyte Solution Single Bolus|A typical water and meal schedule will be followed, with the addition of Fluid Loading electrolyte solution single bolus.
62282048|NCT05603429||CABG with cold blood cardioplegia|Subjects undergo Elective Coronary Artery Bypass Grafting with the use of cold blood cardioplegia solution for myocardial protection
62282049|NCT05603429||CABG with Del Nido|Subjects undergo Elective Coronary Artery Bypass Grafting with the use of Del Nido cardioplegia solution as myocardial protection
62282050|NCT05603429||AVR with cold blood cardioplegia|Subjects undergo Aortic Valve Replacement with the use of cold blood cardioplegia solution as myocardial protection
62282051|NCT05603429||AVR with Del Nido|Subjects undergo Aortic Valve Replacement with the use of Del Nido cardioplegia solution as myocardial protection
62649958|NCT00714701||High Risk Group 2|familial pancreatic cancer relatives
62649959|NCT00714701||High Risk Group 3|germline mutation carriers BRCA1, BRCA2, PRSS, PALB2, p16
62082907|NCT04832412|EXPERIMENTAL|BrainPhyt Low dose|2 capsules of 275mg BrainPhyt for 24 weeks
62082908|NCT04832412|PLACEBO_COMPARATOR|Placebo|2 capsules of 275mg Maltodextrin
62082909|NCT02531880|EXPERIMENTAL|1|Patients will be given the study drug
62082910|NCT00669747|EXPERIMENTAL|A|Carboplatin infused into DCIS-involved duct on Days 1 \& 15
62082911|NCT00669747|EXPERIMENTAL|B|Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15
62082912|NCT00669747|PLACEBO_COMPARATOR|C|Normal Saline infused into DCIS-involved duct Days 1 \& 15
62082913|NCT02343575|EXPERIMENTAL|Valproic Acid|"1. Start:~   VPA PO/NGT 500 mg BID~2. If need to increase in 24 or more hours:~   VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3. If need to increase in 24 or more hours:~   VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4. If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
62082914|NCT02343575|PLACEBO_COMPARATOR|Placebo|"Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN"
62082915|NCT02742506|EXPERIMENTAL|Brain-damaged patients|Electroencephalography (EEG) will be performed in patients in coma, in a vegetative state or in a minimally conscious state to assess the P300 response after different auditive stimulations
62082916|NCT02742506|ACTIVE_COMPARATOR|Healthy volunteers|Electroencephalography (EEG) will be performed in healthy participants to assess the P300 response and medial prefrontal cortex activity after different auditive stimulations
62082917|NCT04963764|PLACEBO_COMPARATOR|Placebo|Randomization to receive either oral placebo or amoxicillin for a standard course (10 days)
62082918|NCT04963764|ACTIVE_COMPARATOR|Amoxicillin|Randomization to receive either oral amoxicillin or placebo for a standard course (10 days)
62082919|NCT05834582|EXPERIMENTAL|Cohort1: Epirubicin+Cyclophosphamide|2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is CR or PR: Epirubicin+Cyclophosphamide for 2 cycles Fluzoparib+Paclitaxel for 2 cycles
62082920|NCT05834582|EXPERIMENTAL|Cohort2: Fluzoparib+Paclitaxel|2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is SD: Fluzoparib+Paclitaxel for 4 cycles
62082921|NCT03562169|ACTIVE_COMPARATOR|Conventional Autologous Stem Cell Transplant (ASCT)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0
62082922|NCT03562169|EXPERIMENTAL|Augmented Autologous Stem Cell Transplant (ASCT)|Melphalan 100mg/m2 IV infusion on Day -3 and -2 plus ixazomib 4mg capsules on Day -4 and -1. ASCT will then be given on Day 0.
62082923|NCT00747383|ACTIVE_COMPARATOR|1|
62082924|NCT00747383|ACTIVE_COMPARATOR|2|
62282052|NCT04336904|EXPERIMENTAL|Favipiravir|"Experimental: Favipiravir Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction."
62282053|NCT04336904|PLACEBO_COMPARATOR|Placebo|"Comparator: Placebo Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
62649960|NCT00714701||High Risk Group 4|young-onset pancreatic cancer relative
62649961|NCT00714701||High Risk Group 5|both parents affected
62082925|NCT05297903|EXPERIMENTAL|XmAb20717|Study participants will receive the recommended phase II dose (10mg/kg) of XmAb20717 by intravenous infusion on days 1 and 15 of a 28-day cycle for up to 2 years.
62082926|NCT06737991|EXPERIMENTAL|Quasi Group|A group of 33 children of age 5-10 years with chest burn. The techniques include deep breathing with shoulder abduction, deep breathing and relaxing with hip external rotation with slight knee flexion, floor polishing motion; rounded hands to draw small circles on the floor etc.
62282054|NCT02546986|EXPERIMENTAL|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
62649962|NCT00714701||Control 1|negative controls
62649963|NCT00714701||Control 2|chronic pancreatitis
62649964|NCT00714701||Control 3|pancreatic cancer
62649965|NCT00714701||Control 4|intraductal papillary mucinous neoplasm (IPMN)
62649966|NCT01162343||Older Emergency Department Patients|Patients who were 65 years or older from the emergency department were enrolled.
62649967|NCT01785381|NO_INTERVENTION|usual care|usual care
62649968|NCT01785381|OTHER|Added value of coordinator|Added value of coordinator
62082927|NCT05992909||Lymphovenous bypass procedure (LBP)|A surgical procedure for treating lymphedema called lymphovenous bypass procedure (LBP), but it is usually only done after a patient develops lymphedema
62082928|NCT05175105|EXPERIMENTAL|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
62082929|NCT05175105|PLACEBO_COMPARATOR|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
62082930|NCT05175105|EXPERIMENTAL|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the OLE period will first receive blinded mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment before being transitioned to only receive active, open-label drug (mitapivat).
62082931|NCT06633913|EXPERIMENTAL|spTMS-TBS-spTMS|"This is an open-label, single-arm study. The intervention will be delivered in spTMS-TBS-spTMS order to the dorsolateral prefrontal cortex (dlPFC) and vertex for each participant as described in the Interventions section. The order of the stimulation sites will be counterbalanced across participants."
62082932|NCT06736808|EXPERIMENTAL|Below Sixth Grade Reading Level|Participants randomized to this experimental arm will read a simplified handout on pelvic organ prolapse written at below a sixth grade reading level.
62082933|NCT06736808|ACTIVE_COMPARATOR|Above Sixth Grade Reading Level|Participants randomized to this control arm will read a standard handout on pelvic organ prolapse written at above a sixth grade reading level.
62082934|NCT06188468|EXPERIMENTAL|68Ga-MY6349|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
62082935|NCT02719847||EBUS-TBNA|"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.~A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope."
62082936|NCT06737549|EXPERIMENTAL|EA + NGF group|
62282055|NCT02546986|EXPERIMENTAL|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
62282056|NCT05351580||Advanced Parkinson's disease patients who receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who receive advance therapy during the study.
62282057|NCT05351580||Advanced Parkinson's disease patients who do not receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who do not receive advance therapy during the study.
62282058|NCT00945360|EXPERIMENTAL|aromatase inhibitors: Letrozole|All consenting patients will be started on Letrozole at a dose of 2.5 mg/day for 8 weeks.
62282059|NCT05103865|EXPERIMENTAL|Experimental group (EG)|
62649969|NCT04018066|EXPERIMENTAL|GP-SPI intervention|20 g of GP-SPI taken twice per day for 10 days
62649970|NCT04321889|EXPERIMENTAL|BEO|Subjects of both sexes of age \>65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
62649971|NCT04321889|PLACEBO_COMPARATOR|Placebo|Subjects of both sexes of age \>65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
62649972|NCT05043740|NO_INTERVENTION|Control|Standard of care: management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
62282060|NCT05103865|ACTIVE_COMPARATOR|Control group|
62282061|NCT05066672|EXPERIMENTAL|NV-5138 400 mg oral capsules|Either 2 or 4 400 mg oral capsules administered once daily
62649973|NCT05043740|EXPERIMENTAL|treatment|On top of Standard of care, Evolocumab (Repatha®) 140 mg or Alirocumab(Praluent) 75mg every two weeks: first subcutaneous injection at the time of randomization, followings during 12 months.
62649974|NCT06432348|EXPERIMENTAL|Reformer Pilates|Before starting the exercises, a 5-minute warm-up session was performed. The reformer Pilates exercise program included movements such as the Footwork Series (Toes, Heels, Tendon Stretch, V Position), Supine Arm Series (Pull, Circle, Pull Head Up, Triceps Press), Short Box Series (Round, Flat Back, Twist), Short Box and Arm Series (Chest Fly, The Gift, Rhomboid, Biceps Curl, Rowing, Triceps), Long Box Series (Swan, Pulling Fly), Stomach Massage (Round, Twist), Knee Stretch (Round, Flat Back), Hip Work Series (Double Leg Press, Hamstring Pulls, Leg Circle, Frog), Elephant, and Side Stretch. Participants had two-minute rest intervals after the Supine Arm Series, Short Box, Arm Series, and Knee Stretch movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks.
62082937|NCT06737549|PLACEBO_COMPARATOR|EA + placebo group|
62082938|NCT06737549|SHAM_COMPARATOR|Acupuncture + NGF group|
62082939|NCT06737549|SHAM_COMPARATOR|Acupuncture + placebo group|
62082940|NCT05074693|EXPERIMENTAL|EASE App|EASE is a intervention designed to address anxiety and depression symptoms in its users through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress.
62082941|NCT05074693|OTHER|INSIGHT (Control) APP|The Insight app provides users with educational videos on mindfulness and meditation techniques.
62282062|NCT05066672|PLACEBO_COMPARATOR|matched placebo|2 or 4 oral capsules administered once daily
62282063|NCT06501053|ACTIVE_COMPARATOR|CXB + CRT|Contact x-ray brachytherapy (CXB) (90Gy/3 fractions/4 weeks) and chemoradiotherapy (CRT) 45/50 Gy (1.8/2 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (900 mg/m2 bid, on radiation days).
62282064|NCT06501053|EXPERIMENTAL|CXB + SCRT|Contact x-ray brachytherapy (CXB) (90Gy/3 fractions/4 weeks) and a short-course radiotherapy (SCRT) (25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days).
62282065|NCT00769288|EXPERIMENTAL|I|Patients will receive a 1-hour infusion of FAU on days 1-5.
62082942|NCT06728761|EXPERIMENTAL|Calvados|Ingestion of test drink: Calvados. The volunteer will be invited to drink 2.5 cl of Calvados 40° at the 70th minute of the meal, before the cheese and dessert
62082943|NCT06728761|ACTIVE_COMPARATOR|Water|Ingestion of Control drink: Water. The volunteer will be invited to drink 2.5 cl of water at the 70th minute of the meal, before the cheese and dessert
62082944|NCT06716957|ACTIVE_COMPARATOR|control|Schroth exercises
62082945|NCT06716957|EXPERIMENTAL|exercise|Schroth exercise and dynamic stabilization exercises
62082946|NCT02035787|EXPERIMENTAL|Metformin|Metformin, 850 mg. twice daily.
62282066|NCT00235131|EXPERIMENTAL|1|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
62282067|NCT00235131|ACTIVE_COMPARATOR|2|Bard® Luminexx™ 6F Vascular Stent
62458854|NCT04734288|EXPERIMENTAL|Immune response|This is a single-arm study. All subjects will be treated equally and will receive the same type and amount of nutritional supplements.
62082947|NCT04915612|EXPERIMENTAL|Treatment (CPX-351, GO)|"INDUCTION 1 (28 days): Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.~INDUCTION 2: Patients who do not attain a defined clinical response after cycle Induction 1 receive CPX-351 IV on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Beginning 4 weeks after last induction, patients receive CPX-351 IV over 90 minutes on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity."
62082948|NCT06737107||Case group : Robotic Approach|Patients with a pre or post-operative diagnosis of NSCLC surgically treated with robotic segmentectomy from 1st January 2010 to the 31st to December 2023
62282068|NCT05576571||HCC case|Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital. Which excludes weakness and inability to cooperate Patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (AFP and methylation analysis). The two data are then counted Compare.
62282069|NCT04213755||patients with risks of intraoperative massive bleeding|patients with risks of intraoperative massive bleeding
62282070|NCT01200745|ACTIVE_COMPARATOR|capsaicin patch|
62282071|NCT01200745|PLACEBO_COMPARATOR|Hydrogel patch|
62649975|NCT06432348|EXPERIMENTAL|Mat Pilates|Before the exercises, a 5-minute warm-up session was performed. The mat Pilates exercise program included movements such as Rol Up, One Leg Circle, Double Leg Straight Lower, One Leg Stretch, Criss Cross, Toe Top, Shoulder Bridge, Seated Tracking, Spine Twist, Up-Down Side Kick, Front-Back Side Kick, Circle Side Kick, Flight, Swan, Rest Position, Swimming, Push Up, Long Stretch, Cat Cow, Mermaid Stretch. The participants had two-minute rest breaks after the toe-top, spine twist, and circle side-kick movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks.
62649976|NCT06432348|NO_INTERVENTION|Control|
62649977|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
62649978|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
62649979|NCT03279458|EXPERIMENTAL|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
62082949|NCT06737107||Control group: video-assisted thoracoscopic surgery (VATS) and open|Patients with a pre or post-operative diagnosis of NSCLC surgically treated with video-assisted thoracoscopic surgery (VATS) and open segmentectomy from 1st January 2010 to the 31st to December 2023
62082950|NCT06209606|EXPERIMENTAL|Rux + Steroid|Subject will receive Ruxolitinib Oral Tablet \[Jakafi\] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
62082951|NCT06209606|EXPERIMENTAL|Rux + Steroid + Len|Ruxolitinib Oral Tablet \[Jakafi\] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
62082952|NCT06555783|EXPERIMENTAL|ALKS 2680, 10 mg|Oral tablet containing 10mg of ALKS 2680 for once daily administration
62082953|NCT06555783|EXPERIMENTAL|ALKS 2680, 14 mg|Oral tablet containing 14mg of ALKS 2680 for once daily administration
62082954|NCT06555783|EXPERIMENTAL|ALKS 2680, 18 mg|Oral tablet containing 18mg of ALKS 2680 for once daily administration
62282072|NCT00223899|EXPERIMENTAL|A|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
62282073|NCT01627587|EXPERIMENTAL|Ketoconazole-Part A|Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
62282074|NCT01627587|EXPERIMENTAL|Food-Part B|Healthy Female Volunteers of child bearing potential will receive Treament D and E
62282075|NCT01522846||Heparin|
62649980|NCT03279458|ACTIVE_COMPARATOR|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
62649981|NCT03635918|OTHER|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a benchmark HSAT monitor.
62649982|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
62649983|NCT03409744|EXPERIMENTAL|evinacumab|
62082955|NCT06555783|PLACEBO_COMPARATOR|Placebo|Oral tablet containing matching placebo for once daily administration
62082956|NCT05603819||Bipolar disorder|Patients with depression suffering from bipolar disorder.
62082957|NCT05603819||Major depressive disorder|Patients with depression suffering from major depressive disorder.
62082958|NCT01579019|ACTIVE_COMPARATOR|1000 mg 24 weeks|
62082959|NCT01579019|ACTIVE_COMPARATOR|1000 mg 26 weeks|
62082960|NCT01579019|EXPERIMENTAL|1500 mg 24 weeks|
62082961|NCT01579019|EXPERIMENTAL|1500 mg 26 weeks|
62082962|NCT06374797|EXPERIMENTAL|Auxora|
62082963|NCT06374797|PLACEBO_COMPARATOR|Placebo|
62082964|NCT06153888|ACTIVE_COMPARATOR|Standard hemodialysis prescription|Short dialysis time and higher ultrafiltration rate/hour dialysis (speed) is used
62082965|NCT06153888|EXPERIMENTAL|Modified hemodialysis prescription|Prolonged dialysis time and less ultrafiltration rate/hour dialysis
62082966|NCT02453087|EXPERIMENTAL|DCDS0780A Monotherapy|Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
62082967|NCT02453087|EXPERIMENTAL|DCDS0780A + Rituximab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m\^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
62082968|NCT02453087|EXPERIMENTAL|DCDS0780A + Obinutuzumab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
62282076|NCT05821140|EXPERIMENTAL|children with ECC|Children under 6 with early childhood caries receiving comprehensive dental treatment under general anesthesia
62282077|NCT05821140|EXPERIMENTAL|Children with orofacial dysmorphologies/malocclusion|Children with orofacial dysmorphologies/malocclusion associated or not with a general condition and in need of a functional or orthodontic treatment
62282078|NCT05821140|EXPERIMENTAL|Children with dental abnormalities|Children with dental abnormalities associated or not with a general condition and in need of conservative, orthodontic or prosthetic treatment
62282079|NCT05821140|EXPERIMENTAL|children with healthy oral state|children with healthy oral state in the course of their annual follow-up visits.
62282080|NCT01318122|ACTIVE_COMPARATOR|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD|
62082969|NCT03851874|ACTIVE_COMPARATOR|Gastric bypass bariatric surgery|Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity
62282081|NCT01318122|ACTIVE_COMPARATOR|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
62282082|NCT05197803|EXPERIMENTAL|Hearing aid model|Unaided, Unitron RIC and Unitron BTE hearing aid styles during one-time visit.
62282083|NCT02788500||Swedish para-athletes|The total population of athletes in the Swedish Paralympic program, which covers candidates for the Paralympic Summer or Winter Games, will be invited by mail to participate in the study and report their incidence of sports-related injuries and illnesses
62282084|NCT04024800|EXPERIMENTAL|Arm 1|AE37 peptide vaccine every 21 days for 5 doses + Pembrolizumab every 21 days for 2 years (Maximum 35 cycles)
62282085|NCT03892161|EXPERIMENTAL|Standard dose DRV/r|Standard dose DRV/r 800/100mg without Rifampicin
62082970|NCT03851874|ACTIVE_COMPARATOR|Sleeve gastrectomy bariatric surgery|Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity
62082971|NCT01941992|EXPERIMENTAL|SAMITAL® sachets, oral suspension|SAMITAL® sachets for oral suspension, 20 mL, four times a day.
62082972|NCT01941992|PLACEBO_COMPARATOR|Placebo sachets|Placebo sachets for oral suspension, 20 mL, four times a day.
62082973|NCT01021163|PLACEBO_COMPARATOR|N-acetylcysteine , saline|
62082974|NCT03944980|EXPERIMENTAL|Arm 1: CIK|"Docetaxel \& PD1-T cells~Docetaxel,60mg/m2,intravenous infusion,d1; PD1-T cells, 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W."
62082975|NCT03944980|ACTIVE_COMPARATOR|Arm 2: Control|"Docetaxel~Docetaxel,60mg/m2,intravenous infusion,d1; Q3W."
62082976|NCT01783093||Sickle cell and pulmonary hypertension|
62082977|NCT05797519|EXPERIMENTAL|VDyne System Treatment Arm|
62082978|NCT06738446|NO_INTERVENTION|control group|This group is used only as a control.
62082979|NCT06738446|EXPERIMENTAL|Multicomponent Dietary Supplement group|45 mg/day EPA, 30 mg/day DHA, 30 mg/day lutein, and 1.8 mg/day zeaxanthin
62082980|NCT02674243|EXPERIMENTAL|Iodopovidone group|Patients who will be randomized for using iodopovidone solution for pleurodesis.
62082981|NCT02674243|ACTIVE_COMPARATOR|Talc group|Patients who will be randomized for using Talc for pleurodesis.
62282086|NCT03892161|EXPERIMENTAL|Standard DRV/r with Rifampicin|Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
62282087|NCT03892161|EXPERIMENTAL|Boosed ritonavir 200mg|Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
62282088|NCT03892161|EXPERIMENTAL|Double dose DRV/r 1600/200mg QD|Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
62282089|NCT03892161|EXPERIMENTAL|Double dose DRV/r 800/100mg BD|Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
62282090|NCT05212740|EXPERIMENTAL|Corticosteroid|The participants will receive prednisolone for four weeks.
62282091|NCT05212740|ACTIVE_COMPARATOR|Exercise|The participants will receive joint mobilization techniques, stretching and home exercise.
62282092|NCT02619500|EXPERIMENTAL|Thrust Manipulation|Subjects in this arm will receive spinal thrust manipulation to both the cervical and thoracic spines.
62282093|NCT02619500|ACTIVE_COMPARATOR|Non-thrust Mobilizations|Subjects in this arm will receive spinal non-thrust mobilizations to both the cervical and thoracic spines
62282094|NCT03595280|NO_INTERVENTION|Control|Participants in the control group receive no study messages
62282095|NCT03595280|EXPERIMENTAL|Untailored Messages|Participants in the untailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones.
62649984|NCT02944292|EXPERIMENTAL|All enrolled patients|"Study population:~Adult, mechanically ventilated patients with IAP between 12 and 20 mmHg in at least two consecutive measurements, spontaneous breathing activity of at least 6 breaths/minute, RASS score between 0 and -4, if no contraindications to propofol administration are present and no other immediate interventions to reduce IAP are planned~Intervention: Deepening of sedation Deepening of sedation will be achieved with a bolus of propofol followed by continuous infusion for one hour."
62649985|NCT05646914|EXPERIMENTAL|Complex training group|Plyometric exercises along with resistance exercises were performed.
62649986|NCT05646914|ACTIVE_COMPARATOR|Plyometric training group|Plyometric exercises were performed.
62649987|NCT05646914|NO_INTERVENTION|Control group|Routine training was performed.
62649988|NCT01646437|EXPERIMENTAL|Polycap vs. matching placebo|Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo
62649989|NCT01646437|EXPERIMENTAL|Aspirin vs. matching placebo|Once daily 75mg tablet of Aspirin vs. matching placebo
62649990|NCT01646437|EXPERIMENTAL|Vitamin D vs. matching placebo|Monthly oral dosage of 60,000IU vs. matching placebo
62649991|NCT05966233|ACTIVE_COMPARATOR|R-DHAP|R-DHAP x4 + autologous transplant/salvage treatment (based on centrally review response)
62649992|NCT05966233|EXPERIMENTAL|Pola-R-DHAP|Pola-R-DHAP x4 + autologous transplant/salvage treatment (based on centrally review response)
62082982|NCT05327010|EXPERIMENTAL|Treatment (ZEN-3694, talazoparib)|Patients receive ZEN-3694 PO QD and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging, blood sample collection, and tumor biopsy throughout the study.
62082983|NCT06276491|EXPERIMENTAL|Dose escalation and Dose Expansion of XmAb541|Intravenous or Subcutaneous administration
62282096|NCT03595280|EXPERIMENTAL|Tailored Messages|Participants in the tailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones that are personalized to their hookah tobacco use behavior and beliefs.
62282097|NCT03256045|EXPERIMENTAL|Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay|Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
62282098|NCT00681239|EXPERIMENTAL|A|Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
62282099|NCT04870073|EXPERIMENTAL|Retrograde autologous priming + mannitol|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
62649993|NCT03708146|EXPERIMENTAL|Cohort 1 (BIA 5-1058 /50 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62649994|NCT03708146|EXPERIMENTAL|Cohort 2 (BIA 5-1058 /25 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 25 mg (as 1 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62649995|NCT03708146|EXPERIMENTAL|Cohort 3 (BIA 5-1058 /100 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62649996|NCT03708146|EXPERIMENTAL|Cohort 4 (BIA 5-1058 /50 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo 12 active and 3 placebo)
62649997|NCT03708146|EXPERIMENTAL|Cohort 5 (BIA 5-1058 /150 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 150 mg (as 1 x 100 mg and 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62649998|NCT03708146|EXPERIMENTAL|Cohort 6 (BIA 5-1058 /75 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 75 mg (as 3 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62649999|NCT03708146|EXPERIMENTAL|Cohort 7 (BIA 5-1058 /200 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62650000|NCT03708146|EXPERIMENTAL|Cohort 8 (BIA 5-1058 /100 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62650001|NCT03708146|EXPERIMENTAL|Cohort 9 (BIA 5-1058 /400 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62650002|NCT03708146|EXPERIMENTAL|Cohort 10 (BIA 5-1058 /200 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62650003|NCT03708146|EXPERIMENTAL|Cohort 11 (BIA 5-1058 /400 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
62650004|NCT02889419|EXPERIMENTAL|Evaluation of underwear Selfia®|Every patient is his own control.
62650005|NCT05074901|EXPERIMENTAL|digital behavioral intervention|Digital behavioral interventions to improve mood and decrease fatigue, sleep complaints and substance usage.
62650006|NCT05074901|NO_INTERVENTION|e-diaries|Ecological momentary assessment based on e-diaries on a weekly basis to evaluate sleep/wake schedules, physical activity, substance usage and nutrition.
62082984|NCT04234048|EXPERIMENTAL|Phase 1|"Accelerated Phase 1a + Standard Phase 1a + Phase 1b~Accelerated Phase 1a~Up to 9 patients for accelerated phase 1a (single patient cohort); dose levels of ST-001 nanoFenretinide (mg/m\^2/day X 5 days every 21 days):~Dose Level 1 1.25 (1 patient) Dose Level 2 2.5 (1 patient) Dose Level 3 5.0 (1 patient) Dose Level 4 10 (1 patient) Dose Level 5 20 (1 patient) Dose Level 6 40 (1 patient) Dose Level 7 80 (1 patient) Dose Level 8 160 (1 patient) Dose Level 9 320 (1 patient)~Standard Phase 1a~Up to 15 patients for standard phase 1a (3+3 design); dose level (mg/m2/day X 5 days every 21 days):~Dose Level 10 640 (3-6 patients) Dose Level 11 896 (3-6 patients) Dose Level 12 1,254 (3-6 patients) Dose Level 13 1,756 (3-6 patients)~Phase 1b~20 patients for phase 1b at the maximum tolerated dose (MTD)"
62082985|NCT04642885||dyad|parent with dementia and an adult child who is a caregiver
62082986|NCT06467357|EXPERIMENTAL|Trastuzumab deruxtecan + rilvegostomig|Trastuzumab deruxtecan (T-DXd; DS-8201a) in combination with rilvegostomig arm
62082987|NCT06467357|EXPERIMENTAL|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
62082988|NCT06467357|ACTIVE_COMPARATOR|Standard of Care|Gemcitabine and cisplatin in combination with durvalumab arm
62082989|NCT05035654|EXPERIMENTAL|Part 1: Treatment Arm LYR-220 Design 1|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
62082990|NCT05035654|EXPERIMENTAL|Part 1 and Part 2: Treatment Arm LYR-220 Design 2|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
62082991|NCT05035654|SHAM_COMPARATOR|Part 2: Treatment Arm Bilateral sham procedure control|Bilateral sham procedure control
62082992|NCT05884658|ACTIVE_COMPARATOR|laparoscopic hysterectomy|Laparoscopic Hysterectomy will be performed in a standardized manner with or without surgical robot
62082993|NCT05884658|EXPERIMENTAL|natural vaginal orifice transluminal endoscopic system for hysterectomies (vNOTES)|Vaginal hysterectomy will be performed in a standardized manner using transluminal endoscopic system
62282100|NCT04870073|EXPERIMENTAL|Retrograde autologous priming alone|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
62282101|NCT04870073|EXPERIMENTAL|Conventional priming + mannitol|Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
62082994|NCT05079919|EXPERIMENTAL|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
62082995|NCT05079919|PLACEBO_COMPARATOR|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
62082996|NCT06738433|EXPERIMENTAL|ABB i5|Prebiotic ABB i5 (NextDext®, 5g)
62082997|NCT06738433|EXPERIMENTAL|ABB C24|ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g
62282102|NCT04870073|ACTIVE_COMPARATOR|Conventional priming alone|Participants will receive conventional priming alone.
62282103|NCT03014960|EXPERIMENTAL|Experimental Condition|Online Cognitive Behavioral Therapy for Insomnia Intervention
62282104|NCT03014960|NO_INTERVENTION|Control Condition|No intervention
62282105|NCT03686969|EXPERIMENTAL|Octanorm|0.5g/kg/week octanorm 16.5%
62282106|NCT03686969|PLACEBO_COMPARATOR|Placebo|Placebo
62282107|NCT02656927|EXPERIMENTAL|Yoga Condition|
62282108|NCT02656927|PLACEBO_COMPARATOR|Wait-list Control Condition|
62282109|NCT06333873|OTHER|Patients with early-stage AMD|30Patients with early-stage AMD
62282110|NCT06333873|OTHER|Patients with intermediate-stage AMD|30 with intermediate-stage AMD
62082998|NCT01005654||1/ Cohort 1|Subjects with endocrine neoplasm or pre or potentially malignant condition of the endocrine system, scheduled to have surgery or biopsy
62082999|NCT00781144||1|first year osteopathic students
62083000|NCT00781144||2|fourth and fifth year osteopathic students
62083001|NCT00781144||3|experienced osteopathic clinicians
62083002|NCT04260126|EXPERIMENTAL|Pembrolizumab and PDS0101|Pembrolizumab will be administered via IV Infusion followed by subcutaneous injections of PDS0101 five times throughout the course of the study. Pembrolizumab monotherapy will be administered every cycle there is not a combination treatment until disease progression or up to Cycle 35.
62083003|NCT03237013|NO_INTERVENTION|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
62282111|NCT06333873|OTHER|30 healthy volunteers|Without AMD risk
62282112|NCT06333873|OTHER|30 healthy volunteers with central microdrusens (at risk of developing AMD)|with central microdrusens (at risk of developing AMD)
62282113|NCT04991337|EXPERIMENTAL|Detraining group|Will be instructed to avoid high-intensity exercise corresponding to a heart rate \>75% of maximum heart rate, and a total duration of exercise (hours/week) corresponding to \>80% of the self-reported average weekly amount of exercise (hours/week) during the past six months, for a period of 16 week.
62282114|NCT04991337|EXPERIMENTAL|Control group|Will be instructed to perform at least three weekly sessions of high intensity exercise, corresponding to a HR ≥85% of maximum heart rate, and otherwise continue endurance exercise as usual.
62282115|NCT01292655|EXPERIMENTAL|Arm A1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
62282116|NCT01292655|EXPERIMENTAL|Arm A2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
62282117|NCT01292655|EXPERIMENTAL|Arm B1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
62282118|NCT01292655|EXPERIMENTAL|Arm B2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
62282119|NCT05723432|EXPERIMENTAL|KD6001+Toripalimab|KD6001 combined with toripalimab in patients with advanced melanoma
62083004|NCT03237013|EXPERIMENTAL|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
62083005|NCT03237013|PLACEBO_COMPARATOR|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman \& Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
62650007|NCT04793945|ACTIVE_COMPARATOR|light therapy twice weekly|15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light twice weekly and topical steroid twice daily the second patch will be treated by topical steroid twice daily. the third patch will be left as a control.
62650008|NCT04793945|ACTIVE_COMPARATOR|light therapy once weekly|"15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light once weekly and topical steroid twice daily.~the second patch will be treated by topical steroid twice daily. the third patch will be left as a control."
62458855|NCT03255148|EXPERIMENTAL|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
62458856|NCT03255148|PLACEBO_COMPARATOR|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
62458857|NCT03893539|OTHER|Robotic Bronchoscopy|The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.
62458858|NCT03405402|EXPERIMENTAL|Experimental group|Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
62650009|NCT01036802|ACTIVE_COMPARATOR|Warfarin|Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
62650010|NCT01036802|PLACEBO_COMPARATOR|Placebo|matching active products
62650011|NCT06426745|EXPERIMENTAL|Split-dose bowel preparation|About 90 participants underwent Split-dose bowel preparation for colonoscopy
62650012|NCT06426745|EXPERIMENTAL|single-dose bowel preparation|About 90 participants underwent single-dose bowel preparation for colonoscopy
62650013|NCT03767127||Appropriate transfusion policy|Patients transfused with high arterial-venous oxygen difference (≥3.7 ml/dl) or non-transfused with low arterial-venous oxygen difference (\<3.7 ml/dl)
62083006|NCT03744559|EXPERIMENTAL|R-E (Retrieval Extinction)|83 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a lab-based smoking-related cue-reactivity experience during the baseline assessment and 24-hour follow-up test.
62458859|NCT03405402|OTHER|Control group|Allo-immunization not detected
62458860|NCT01465477|EXPERIMENTAL|Fibromyalgia arm|Patients fulfilling ACR 1990 Criteria for classification of Fibromyalgia, receiving the vaccination.
62083007|NCT03744559|OTHER|NR-E (No R-E)|83 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a lab-based non-smoking or neutral cue-reactivity experience during the baseline assessment and 24-hour follow-up test.
62458861|NCT01465477|EXPERIMENTAL|Heathy controls|Healthy controls receiving Influenza vaccination
62458862|NCT00677196|ACTIVE_COMPARATOR|1|The LMA StoneBreakerTM
62458863|NCT00677196|ACTIVE_COMPARATOR|2|Pneumatic Lithotripsy
62650014|NCT03767127||Non-Appropriate transfusion policy|Patients transfused despite low arterial-venous oxygen difference or non-transfused with high arterial-venous oxygen difference
62650015|NCT03250273|EXPERIMENTAL|Arm A - Cholangiocarcinoma|
62083008|NCT05709535||Experimental: [18F]PSMA-1007 Injection|A single intravenous dose of 3 - 4 MBq/kg (up to a maximum of 400 MBq) of \[18F\]PSMA-1007 Injection will be administered followed by PET/CT imaging.
62083009|NCT01190176|EXPERIMENTAL|HPV-062 study subjects Group|HPV-015 (NCT00294047) study subjects who had normal cervical cytology, but tested positive for oncogenic HPV infection at their concluding HPV-015 (NCT00294047) study visit or were pregnant, so that no cervical sample could be collected at their concluding HPV-015 (NCT00294047) study visit.
62083010|NCT05561244|NO_INTERVENTION|CONTROL GROUP|Control group (n = 16 nursing homes, 64 patients): Patients will be monitored as usual using the Venous International Normalised Ratio strategy. Practices will not be changed (i.e. prospective observation of real-life practices; according to recommendations, at least 1 Venous International Normalised Ratio per month will usually be performed) and patients will not receive any supplementary intervention specific to the trial. A reminder of good International Normalised Ratio practices will be provided to nurses and prescribers.
62282120|NCT01039532||Basal Bolus regimen|Basal Bolus regimen
62282121|NCT01039532||Biphasic human insulin|Biphasic human insulin
62282122|NCT03399266|EXPERIMENTAL|Double balloon catheter for induction of labor|in this group a trans-cervical double balloon catheter will be inserted. Following device insertion, 20 minutes of external monitoring is performed. The patient will be transferred to the Ob/Gyn ward for hospitalization. 12 hours after insertion of the device the balloons are deflated and the device removed. At this stage the patient is assessed for a second Bishop score and expectant management is resuming.
62282123|NCT03399266|NO_INTERVENTION|Expectant management|Women in the expectant management group will be transferred to the Ob/Gyn ward for hospitalization and conservative management until spontaneous labor ensues.
62282124|NCT05340985|EXPERIMENTAL|25(OH)D3 (Calcifediol)|50 micrograms per day 25(OH)D3 or vitamin D hydroxylated for 24 weeks
62282125|NCT05340985|EXPERIMENTAL|Cholecalciferol|50 micrograms (2000IU) per day Cholecalciferol for 24 Weeks
62458864|NCT03157622|ACTIVE_COMPARATOR|Exposure in vivo|In the Exposure in vivo (EXP) condition, patients are given a careful explanation of the fear-avoidance model. Patients are encouraged to adopt the model to their individual situation. Factors for the maintenance of chronic pain (such as pain cognitions and pain-related fear) are discussed. Especially, negative consequences of avoidance behavior are highlighted. In preparation of the exposure sessions, patients develop an individual fear hierarchy using the Photo Series of Daily Actives. Subsequently, patients are encouraged to test their fear-avoidance beliefs during behavioral experiments and to reduce avoidance behaviors during individually tailored exposure exercises.
62458865|NCT03157622|ACTIVE_COMPARATOR|Cognitive Behavioral Psychotherapy|In the Cognitive Behavioral Psychotherapy (CBT) condition, patients are introduced to several strategies to improve their pain management. The principle of graded activity encourages patients to re-engage in former activities by dividing these activities into smaller steps. Predetermined resting periods are offered as a form to prevent patients from phases of excessive demands followed by long terms of recovery. Progressive muscle relaxation is introduced as a technique to improve the experience of pain. The strategy of attention shifting is presented to change their perception of pain. Maladaptive pain-related cognitions are identified and challenged by cognitive interventions.
62650016|NCT03250273|EXPERIMENTAL|ARM B - Pancreatic Cancer|
62650017|NCT02737358|PLACEBO_COMPARATOR|Placebo|Matched placebo will be given to half of the study participants.
62650018|NCT02737358|ACTIVE_COMPARATOR|N-Acetylcysteine (NAC)|NAC will be given to half of the study participants. The dose of NAC will be 2400 mg per day (1200 mg taken twice per day as two 600 mg capsules)
62650019|NCT01824667|EXPERIMENTAL|B-GOS|2.75g daily for 4 weeks
62282126|NCT02258880|EXPERIMENTAL|SUN13837|Drug: SUN13837 daily for 28 days.
62650020|NCT01824667|PLACEBO_COMPARATOR|Maltodextrin|2.75g daily for 4 weeks
62650021|NCT04324749|EXPERIMENTAL|Group A (roasted peanuts)|Group A: Habitual diet + 25 g/day of whole skin roasted peanuts (RP)
62650022|NCT04324749|EXPERIMENTAL|Group B (peanut butter)|Group B: Habitual diet+ 2 tbsp/day (32 g/day) of peanut butter (PB)
62650023|NCT04324749|EXPERIMENTAL|Group C (control)|Group C: Habitual diet + 2 tbsp/day (32 g/day) of control supplement
62650024|NCT01715051|ACTIVE_COMPARATOR|D-serine|Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target \~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
62650025|NCT01715051|PLACEBO_COMPARATOR|Placebo|The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
62282127|NCT02258880|PLACEBO_COMPARATOR|Placebo|Placebo: Matching Placebo daily for 28 days
62282128|NCT03321448|EXPERIMENTAL|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this TMTP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
62083011|NCT05561244|EXPERIMENTAL|INTERVENTIONAL GROUP|Intervention group (n = 16 nursing homes, 64 patients): Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
62083012|NCT06165445|ACTIVE_COMPARATOR|conventional tDCS group|The conventional tDCS group will receive 30 session of 20-minute stimulation at 2 mA intensities using standard electrodes (7 x 5 cm) over the target region
62282129|NCT03321448|ACTIVE_COMPARATOR|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
62282130|NCT05302687|EXPERIMENTAL|probiotic 9 log CFU/day|Intervention consists of daily administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
62282131|NCT05302687|PLACEBO_COMPARATOR|placebo|placebo contains primarily carrier and without probiotic. The placebo are identical in taste and appearance and appear as light-yellow powder.
62083013|NCT06165445|ACTIVE_COMPARATOR|multi-channel tDCS group|The multi-channel tDCS group will receive 30 session of 20-minute stimulation at 2 mA intensities using 8 electrodes (2.5 x 2.5 cm) over the target region
62083014|NCT06165445|PLACEBO_COMPARATOR|sham tDCS group|The conventional tDCS group will receive 30 session of 20-minute placebo stimulation using standard electrodes (7 x 5 cm) over the target region
62282132|NCT03932799||Washington|Workers in the Washington Department of Labor and Industries state fund insurance system.
62083015|NCT04543591|EXPERIMENTAL|Ravulizumab|"In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC).~In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC)."
62083016|NCT04543591|PLACEBO_COMPARATOR|Placebo|In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.
62083017|NCT01902589||Patients with Helicobacter pilorii in biopsy|Patients with Helicobacter pylori in biopsy, cultures will be obtained and subsequently sensitivity to antibiotics studied.
62282133|NCT03932799||Ohio|Workers in the Ohio Bureau of Workers' Compensation state fund insurance system.
62282134|NCT04545905||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Gaoua, Banfora, and Orodara districts.
62282135|NCT05936320|EXPERIMENTAL|Intervention group|Verbal information along with information leaflets containing text with illustrations about hearing aid functions
62083018|NCT06641323|EXPERIMENTAL|Ozone gel group|
62282136|NCT05936320|EXPERIMENTAL|Control group|Verbal information along with information leaflets containing text-only about hearing aid functions
62650026|NCT06394258|EXPERIMENTAL|SBRT to the vaginal cuff|SBRT to the vaginal cuff
62083019|NCT06641323|ACTIVE_COMPARATOR|Gaseous ozone group|
62083020|NCT01778569||Group 1|Patient with a diagnosis of chronic plaque psoriasis, psoriatic arthritis, or pustular psoriasis
62083021|NCT06442761|EXPERIMENTAL|Treatment-Arm A-Single Dose|Part A: Participants who enroll early will be assigned to Part A. Part A participants will get one dose of the study drug and one stem cell collection process.
62282137|NCT06153212|EXPERIMENTAL|PTFE Mesh Membrane|A reinforced PTFE Mesh membrane will be used to cover the bone graft.
62282138|NCT06153212|ACTIVE_COMPARATOR|Collagen membrane|A collagen membrane will be used to cover the bone graft.
62083022|NCT06442761|EXPERIMENTAL|Treatment-Arm B-Two Daily Doses|Part B: Participants who enroll later in the study will be assigned to Part B. Part B participants will get two doses of the study drug and two stem cell collection processes over two days (one on each day).
62083023|NCT06739746||Medical staff group|Investigate the demographic information and subjective perception of noise among medical staff in the post anesthesia care unit.
62083024|NCT06739746||Hospital Group|Investigate the staffing, size, number of beds, noise levels, etc. of post anesthesia care unit in different hospitals.
62083025|NCT06602193|EXPERIMENTAL|BIIB122 225 mg|Oral 225 mg dose, once daily (QD)
62282139|NCT01699139|ACTIVE_COMPARATOR|positional device|
62458866|NCT00264797|ACTIVE_COMPARATOR|Methylphenidate|
62083026|NCT06602193|PLACEBO_COMPARATOR|BIIB122 Matching Placebo|Oral BIIB122 matching placebo, once daily (QD)
62083027|NCT05723614|NO_INTERVENTION|Control|
62083028|NCT05723614|EXPERIMENTAL|Intervention|The two components in the intervention arm of TRUE HAVEN are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
62282140|NCT01699139|SHAM_COMPARATOR|lumbar corset|
62282141|NCT00944034|EXPERIMENTAL|B+R246_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
62282142|NCT00944034|EXPERIMENTAL|B+R246_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
62282143|NCT00944034|EXPERIMENTAL|B+R246_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
62458867|NCT00264797|PLACEBO_COMPARATOR|Methylphenidate (Placebo)|
62083029|NCT06737120|EXPERIMENTAL|modified free gingival graft|A connective tissue pedicle flap will be applied before a free gingival graft is placed in the recipient area.
62083030|NCT06737120|EXPERIMENTAL|traditional free gingival graft|
62282144|NCT00944034|EXPERIMENTAL|B246_12|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
62650027|NCT01466868|EXPERIMENTAL|MK2206|Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
62650028|NCT02823119|EXPERIMENTAL|Mini-hysteroscopy|A rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm.
62650029|NCT02823119|ACTIVE_COMPARATOR|Conventional Office Hysteroscopy|A rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm
62282145|NCT00944034|EXPERIMENTAL|B246_18|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
62458868|NCT02402348|EXPERIMENTAL|Metformin|Metformin 850 mg orally once a day for 3 days, then 850 mg orally twice daily starting day 4 until 24hrs before surgery.
62458869|NCT02079753|ACTIVE_COMPARATOR|combined system|During the first visit, the technician installed a reservoir of liquid oxygen (Liberator 30, Caire) and a liquid Stroller oxygen pack (Caire) for patients using liquid oxygen, or a VisionAire5 (Airsep) stationary concentrator and an Inogen One G2 portable (Inogen) concentrator for patients using concentrators.
62083031|NCT06737939|EXPERIMENTAL|Ibuprofen group|Each patient in Group 1 received 400 mg of IV ibuprofen diluted in 100 mL of solution. The infusion was administered over a 30-minute period to ensure proper absorption and minimize adverse effects.
62282146|NCT00944034|EXPERIMENTAL|B246_24|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
62282147|NCT00944034|EXPERIMENTAL|B+R234_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
62458870|NCT02079753|EXPERIMENTAL|single system|Inogen One G2 portable concentrator (Inogen)
62458871|NCT04172649|EXPERIMENTAL|Acu Arm|press tack needle acupuncture (ACU) and routine postoperative analgesic care
62650030|NCT02650817|EXPERIMENTAL|Elacestrant (formerly RAD1901)|To receive daily oral elacestrant
62650031|NCT05412134|EXPERIMENTAL|Active inspiratory muscle rehabilitation (IMR) group|"Each participant will be provided a PrO2™ device and trained on its use and its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed at Visit 1 and Visit 2 to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide a precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
62458872|NCT04172649|SHAM_COMPARATOR|SHAM Arm|press tack placebo acupressure (SHAM) and routine postoperative analgesic care
62083032|NCT06737939|EXPERIMENTAL|Periprostatic nerve block|Periprostatic Nerve Block (PPNB) using 2% lidocaine was administered for pain relief during the prostate biopsy procedure.
62083033|NCT01021033||Chronic stroke patients|Chronic stroke patients
62083034|NCT05501704|EXPERIMENTAL|Window Phase Arm A: Tamoxifen|Participants will be randomly assigned to receive Tamoxifen 1x daily for 3 weeks (21days).
62458873|NCT04172649|NO_INTERVENTION|CONTROL Arm|Patients in the control group will receive only routine postoperative analgesic care
62458874|NCT03370068|EXPERIMENTAL|ICSI|All the oocytes in this group (from one ovary) will undergo insemination by ICSI.
62458875|NCT03370068|ACTIVE_COMPARATOR|Conventional IVF|All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.
62458876|NCT05991726||Cohort 1: Professional Expert|This includes Healthcare professionals (HCPs) who look after people with CKD in the UK, anyone involved in designing, developing, managing and commissioning of CKD healthcare in the UK and researchers interested in self-management or CKD
62650032|NCT05412134|ACTIVE_COMPARATOR|SHAM|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
62650033|NCT06157229|EXPERIMENTAL|Multifactorial Approach Training (MAT)|MAT involves an evidence-based core outcome-set of interventions aimed at both regaining functional stability of the shoulder and also diminishing fear of (recurrent) dislocation and kinesiophobia. The protocol is based on a recent international Delphi-based consensus study, initiated since no protocol yet existed focusing on this psychological component of traumatic anterior shoulder instability.
62650034|NCT06157229|ACTIVE_COMPARATOR|Conventional Arthroscopic Bankart Repair Rehabilitation (CABRR)|The original guidelines which most physiotherapists use throughout the rehabilitation of their patients following ABR is the ASSET guideline \[2\].
62650035|NCT04820907|EXPERIMENTAL|HCP1904-1|
62083035|NCT05501704|EXPERIMENTAL|Window Phase Arm B: Anastrozole|Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days).
62083036|NCT05501704|EXPERIMENTAL|Window Phase Arm C: Anastrozole + Degarelix|Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days) and Degarelix on day 1 only.
62083037|NCT05501704|EXPERIMENTAL|Neoadjuvant Phase Arm D: Tamoxifen|Participants will be randomly assigned to receive Tamoxifen 1x daily for 4 cycles (4 months); each study cycle is 28 days.
62083038|NCT05501704|EXPERIMENTAL|Neoadjuvant Phase Arm E: Tamoxifen + Abemaciclib|Participants will be randomly assigned to receive Tamoxifen 1x daily and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.
62083039|NCT05501704|EXPERIMENTAL|Neoadjuvant Phase Arm F: Anastrozole and Degarelix|Participants will be randomly assigned to receive Anastrozole 1x daily and Degarelix on day 1 of each cycle for 4 cycles (4 months); each study cycle is 28 days.
62083040|NCT05501704|EXPERIMENTAL|Neoadjuvant Phase Arm G: Anastrozole + Degarelix + Abemaciclib|Participants will be randomly assigned to receive Anastrozole 1x daily, Degarelix on day 1 of each cycle and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.
62282148|NCT00944034|EXPERIMENTAL|B+R234_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
62650036|NCT04820907|ACTIVE_COMPARATOR|RLD2001-1|
62650037|NCT04894708|OTHER|AI colonoscopy|colonoscopy with artificial intelligence added
62650038|NCT04894708|SHAM_COMPARATOR|conventional colonoscopy|conventional colonoscopy
62282149|NCT00944034|EXPERIMENTAL|B+R234_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
62083041|NCT06736951|EXPERIMENTAL|MMSH (Multi-Modal Sleep Hygiene) Bundle|We will implement an MMSH bundle, enhancing a previously reported sleep focused intervention, in order to increase quality/quantity of sleep during Z-time (i.e., 10pm to 5am) in our intervention units, subsequently mitigating the burden of delirium in hospitalized older adults. Our proposed intervention domains perfectly align with the expressed patient suggestions to improve patient experience. Sleep disruption issues were raised at similar rates across the age span suggesting our MMSH will positively impact patients of all ages, including those with lower risk of delirium. The intervention components are outlined below and a comparison to the current standard of care and the components that are relevant to the fidelity aspects of the study are highlighted in the table. The main focus of the sleep interventions will focus on Noise, Light, Staff-Patient Interactions, Daytime Activity and Medications.
62083042|NCT06736951|NO_INTERVENTION|Standard of Care|This study arm reflects patients receiving standard of care treatment without any modification of in-hospital sleep environment
62083043|NCT05037097|EXPERIMENTAL|Study Group 1, Adult Participants Seronegative, Not Previously Vaccinated randomized to ARCT-165|Participants will receive one dose of ARCT-165 on Day 1 and one dose of ARCT-165 on Day 29
62083044|NCT05037097|EXPERIMENTAL|Study Group 2, Adult Participants Seronegative, Not Previously Vaccinated randomized to ARCT-154|Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
62282150|NCT00944034|EXPERIMENTAL|B12 14|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
62282151|NCT00944034|EXPERIMENTAL|B18 20|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
62650039|NCT04093271|EXPERIMENTAL|Randomized to consume Rest-ZZZ, comparator, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Rest-ZZZ dietary supplement in Study Period 1, Comparator (Diphenhydramine HCl) in Study Period 2, and Placebo in Study Period 3.
62650040|NCT04093271|EXPERIMENTAL|Randomized to consume comparator, placebo, then Rest-ZZZ|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Comparator (Diphenhydramine HCl) in Study Period 1, Placebo in Study Period 2, and the Dietary Supplement, Rest-ZZZ in Study Period 3.
62650041|NCT04093271|EXPERIMENTAL|Randomized to consume placebo, Rest-ZZZ, then comparator|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Dietary Supplement, Rest-ZZZ in Study Period 2, and Comparator (Diphenhydramine HCl) in Study Period 3.
62650042|NCT03072186|EXPERIMENTAL|near-infrared light nasal endoscope used with ICG|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery and tumor dissection: before intradural dissection and during tumor dissection.
62650043|NCT03817528|EXPERIMENTAL|ITI-007|Open-Label ITI-007 40-60 mg
62083045|NCT05037097|EXPERIMENTAL|Study Group 3, Adult Participants Seronegative, Not Previously Vaccinated to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
62083046|NCT05037097|EXPERIMENTAL|Study Group 4, Adult Participants Seropositive, Not Previously Vaccinated to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
62650044|NCT06094465||learning phase|According to the CUSUM curve, the phase before the peak of the curve is defined as the learning phase.
62650045|NCT06094465||proficiency phase|According to the CUSUM curve, the phase after the peak of the curve is defined as the learning phase.
62650046|NCT00697320||A|
62650047|NCT04301973|OTHER|Healthy people|
62650048|NCT01376219||All patients|All patients entered in the study
62650049|NCT02333643|EXPERIMENTAL|CLS003|Topical digoxin/furosemide
62650050|NCT02333643|EXPERIMENTAL|Digoxin topical formulation|
62650051|NCT02333643|EXPERIMENTAL|Furosemide topical formulation|
62083047|NCT05037097|EXPERIMENTAL|Study Group 5, Adult Participants Seropositive, Not Previously Vaccinated randomized to ARCT-154|Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
62083048|NCT05037097|EXPERIMENTAL|Study Group 6, Adult Participants Previously Vaccinated randomized to receive ARCT-165|Participants will receive one dose of ARCT-165 on Day 1
62282152|NCT00944034|EXPERIMENTAL|B24 26|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.
62650052|NCT02333643|PLACEBO_COMPARATOR|Vehicle topical formulation|
62650053|NCT05087589|EXPERIMENTAL|tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
62650054|NCT02020941|EXPERIMENTAL|Treatment (carfilzomib, dexamethasone)|"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.~MAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
62650055|NCT02548871|EXPERIMENTAL|Teen Outreach Program|Teen Outreach Program
62650056|NCT02548871|NO_INTERVENTION|Comparison|Business as usual
62650057|NCT00302900|EXPERIMENTAL|1|Pre-donation water and muscle tension during donation
62650058|NCT00302900|EXPERIMENTAL|2|Pre-donation water
62650059|NCT00302900|SHAM_COMPARATOR|3|Pre-donation muscle tension
62650060|NCT00302900|NO_INTERVENTION|4|Standard donation
62083049|NCT05037097|EXPERIMENTAL|Study Group 7, Adult Participants Previously Vaccinated randomized to receive ARCT-154|Participants will receive one dose of ARCT-154 on Day 1
62083050|NCT05037097|EXPERIMENTAL|Study Group 8, Adult Participants Previously Vaccinated randomized to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1
62282153|NCT01721499|EXPERIMENTAL|Mindfulness intervention|"The mindfulness intervention consists of weekly group format mindfulness instruction and skills development, weekly individual therapy sessions, and 6 nutritional sessions.~The control group receives 6 nutritional sessions only."
62282154|NCT01721499|ACTIVE_COMPARATOR|Nutrition Control Group|The control group receives 6 nutritional counseling sessions.
62282155|NCT05416008||Group 1: treatment with ETV|"The patients in this group were composed of patients with chronic hepatitis B who firstly take entecavir for the treatment of chronic hepatitis B.~Take Entecavir capsule orally for a long time, once a day, 0.5mg each time."
62282156|NCT05416008||Group 2: treatment with TAF|"The patients in this group were composed of patients with chronic hepatitis B who firstly take Tenofovir alafenamide Fumarate for the treatment of chronic hepatitis B.~Take Tenofovir alafenamide Fumarate tablets orally for a long time, 25mg once a day."
62282157|NCT05416008||Group 3: treatment with TDF|"The patients in this group were composed of patients with chronic hepatitis B who firstly take Tenofovir disoproxil Fumarate for the treatment of chronic hepatitis B.~Tenofovir disoproxil fumarate was orally administered for a long time, once a day, 300mg each time."
62650061|NCT05531877|EXPERIMENTAL|Patients undergoing Penile Implant Surgery|"All intraoperative measurements are documented in real time. Measurements recorded are as follows:~Preoperative Pre-ICI penile length and circumference, both in relaxed and stretched states. Preoperative post-ICI penile length and circumference, both in relaxed and stretched states. Postoperative penile length and circumference. Penile implant length and girth."
62282158|NCT03122431|OTHER|SLE/cutaneous lupus with thalidomide|This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
62458877|NCT05991726||Cohort 2: Non-Professional Expert|People living with a diagnosis of CKD. This survey focusses on people with non-dialysis CKD, typically stages 3-4. However, this study does not exclude participation by those at a more advanced stage or receiving renal replacement therapy (dialysis or transplant) as these people also have lived experience of earlier stages to draw on. This will also include 'significant others' whom are supporters or carers of people with CKD such as a family member or a partner of a person with CKD.
62458878|NCT04867252|ACTIVE_COMPARATOR|Combination Therapy Group|ARM 1: Resveratrol (1000mg Twice a day) Myoinositol (1000mg Twice a day)
62650062|NCT02593500|EXPERIMENTAL|Pulmictan+Test (Treatment Sequence AB)|"Treatment period 1:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs)per treatment period under fasting conditions.~Treatment period 2:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) per treatment period under fasting conditions."
62650063|NCT02593500|EXPERIMENTAL|Test+Pulmictan (treatment sequence BA)|"Treatment period 1:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions.~Treatment period 2:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions."
62650064|NCT02439164|EXPERIMENTAL|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
62083051|NCT06728280|ACTIVE_COMPARATOR|H1 coil|First, the 'hot spot' for activation of the abductor pollicis brevis muscle was established and motor threshold (MT) determined. Then, the H1 coil was advanced 6 cm anterior to the scalp surface.The rMT was rechecked at least once a week. Treatment intensity was 80% of rMT.During 4 consecutive weeks (5 sessions/wk) patients were treated daily . Patients in the treatment group will receive the Deep TMS protocol (80% of rMT, 18 Hz, 2 seconds on and 20 seconds off over a 20-minute period; total of 1,980 stimuli per session), applied over the left dorsolateral prefrontal cortex.
62282159|NCT03122431|ACTIVE_COMPARATOR|Inactive SLE with standard dose of HCQ|This subproject includes one arm of lupus patients with inactive disease, in which will be maintained on standard dose of Hydroxychloroquine (400mg/day).
62282160|NCT03122431|ACTIVE_COMPARATOR|Inactive SLE with reduced dose of HCQ|This subproject includes one arm of lupus patients with inactive disease: in which the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced).
62282161|NCT04210466|EXPERIMENTAL|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|an ACT intervention + 2 sessions of explicit self-compassion meditation exercises.
62458879|NCT04867252|OTHER|Standard Therapy Group|ARM 2:Metformin 500mg (Twice a day) Pioglitazone (15mg Twice a day)
62458880|NCT06484933||Healthcare professionals and users of primary care|Health professionals and users of primary care will be asked during focus groups on the definition of the professional team in primary care and on the risk management procedures put in place in primary care organisations.
62458881|NCT00002994|EXPERIMENTAL|Monoclonal antibody + interleukin 2|"Cycle 1: low dose IL2 days 1-7; MoAb day 7; intermediate dose IL-2 days 8-10; Low dose IL2 days 11-20.~Cycle 2 \& all subsequent cycles: MoAb day 1; intermediate dose IL2 days 1-3; low dose IL2 days 4-14"
62458882|NCT03299296|EXPERIMENTAL|Rivaroxaban arm|Rivaroxaban 10 Milligrams
62650065|NCT02439164|ACTIVE_COMPARATOR|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
62282162|NCT04210466|ACTIVE_COMPARATOR|Acceptance & Commitment Therapy (ACT)|an ACT intervention + 2 Q\&A sessions.
62282163|NCT03529877|EXPERIMENTAL|allo-APZ2-EB|intravenous infusion, three doses of allo-APZ2-EB (2 x 10\^6 cells/kg)
62650066|NCT00801944|EXPERIMENTAL|I|Solifenacin succinate 5/10mg
62650067|NCT00801944|EXPERIMENTAL|II|Placebo
62650068|NCT02787499|NO_INTERVENTION|Standard of Care|Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load \<1,000 copies/mL at repeat testing will be retained on first-line therapy.
62650069|NCT02787499|EXPERIMENTAL|HIV-1 RNA Resistance Testing|Participants will receive HIV-1 RNA drug resistance testing at study enrollment. ART treatment regimen decisions will be determined based on the results of resistance testing.
62650070|NCT01769547|EXPERIMENTAL|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
62282164|NCT01579695||Exposed Group will receive Tesamorelin|
62282165|NCT01579695||Control Group will not receive Tesamorelin|
62282166|NCT01214785|ACTIVE_COMPARATOR|Sanitation intervention|
62282167|NCT01214785|NO_INTERVENTION|Control|
62282168|NCT02024971||Pioglitazone/Metformin Hydrochloride|Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.
62282169|NCT02668146|EXPERIMENTAL|perampanel|Perampanel administration
62282170|NCT02668146|PLACEBO_COMPARATOR|placebo|Placebo administered to subjects.
62458883|NCT03299296|ACTIVE_COMPARATOR|Enoxaparin Arm|'Enoxaparin 40 Milligrams /0.4 Milliliters Prefilled Syringe
62650071|NCT01940848|EXPERIMENTAL|STW5|2/3 patients with irritable bowel syndrome will be randomized in this arm
62650072|NCT01940848|PLACEBO_COMPARATOR|Placebo|1/3 patients with irritable bowel syndrome will be randomized in this arm
62650073|NCT04596319|EXPERIMENTAL|AP-PA02|Anti-pseudomonal bacteriophage
62458884|NCT02391064|EXPERIMENTAL|Patient|MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
62458885|NCT02391064|EXPERIMENTAL|Control|healthy subject
62650074|NCT04596319|PLACEBO_COMPARATOR|Placebo|Inactive isotonic solution
62650075|NCT01806181|OTHER|Cancer Treatment|
62650076|NCT00722020|EXPERIMENTAL|Vest Arm|HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
62650077|NCT00722020|NO_INTERVENTION|Control|Historical control for PICU asthma patients
62650078|NCT00606008|EXPERIMENTAL|Sutent Treatment|Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
62083052|NCT06728280|EXPERIMENTAL|H7 coil|First, the 'hot spot' for activation of the abductor pollicis brevis muscle was established and motor threshold (MT) determined. Then, the H7 coil was advanced 4 cm anterior to 'hot spot' and aligned symmetrically over the dmPFC. The rMT was rechecked at least once a week.The rMT was rechecked at least once a week. Treatment intensity was 80% of rMT.During 4 consecutive weeks (5 sessions/wk) patients were treated daily . Patients in the treatment group will receive the Deep TMS protocol (80% of rMT, 18 Hz, 2 seconds on and 20 seconds off over a 20-minute period; total of 1,980 stimuli per session), applied over themedial prefrontal cortex.
62083053|NCT02919956||Group I: CBF-I Single Ventricles|The 1st group (cohort group) will be patients who were enrolled in the original NIH CBF grant. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
62083054|NCT02919956||Group II: Prospective Single Ventricles|The 2nd group (cross sectional group) will be prospectively recruited from SV patients after Fontan operation but were not participants in the original study and will be age matched to Group I to enrich the patient population. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
62083055|NCT02919956||Group III: CBF-I Normal Controls|The 3rd group (cohort group) will be normal controls who were enrolled in the original CBF grant. These patients will have Neurodevelopmental Testing. The data from these patients' MRI from CBF-I (original CBF grant) will be used.
62083056|NCT02919956||Group IV: Prospective Normal Controls|The 4th group (cross sectional group) will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for clinically indicated MRIs and found to have structurally normal cardiac and brain anatomy. These patients will have an abbreviated research MRI, lasting 15-20 minutes, added onto their clinically-indicated MRI at CHOP. They will also have Neurodevelopmental Testing.
62083057|NCT02919956||Volunteer Group|There will also be a volunteer group of one to five volunteers that will be enrolled prior to enrollment in the other four study groups. These volunteers will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for a clinically-indicated MRI and consent to have an additional 15-20 minutes of research MRI scanning. The purpose will be to ensure that the brain MRI sequences run correctly and produce useful information before the patient and normal control enrollment begins. The volunteers will not undergo neurodevelopmental testing.
62083058|NCT05972889|EXPERIMENTAL|Device TENS|
62083059|NCT05972889|EXPERIMENTAL|Device IFC|
62083060|NCT05972889|SHAM_COMPARATOR|Sham TENS|
62083061|NCT05972889|SHAM_COMPARATOR|Sham IFC|
62083062|NCT05972889|NO_INTERVENTION|Control|Subjects continue with current standard of care only for 4 weeks with the option to crossover to the NexWave Device group for an additional 4 weeks (up to 8 total weeks).
62083063|NCT01859299||Affected|Participants with various types of uveitis
62083064|NCT01859299||Healthy controls|Participants without uveitis
62458886|NCT03732105|EXPERIMENTAL|Surgery-radiotherapy|Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after surgery. After radiotherapy, patients will be actively monitored.
62458887|NCT03732105|NO_INTERVENTION|Surgery group|Patients in the surgery group will be actively monitored after randomization.
62458888|NCT00674999|EXPERIMENTAL|1|Amnion with processing procedures involving the use of trypsin-Edetic Acid(EDTA)
62458889|NCT00674999|EXPERIMENTAL|2|Amnion with processing procedures involving the use of Dispase II
62458890|NCT00674999|ACTIVE_COMPARATOR|3|Prepared Antibiotic ointment Polysporin, Bacitracin and Mycostatin
62458891|NCT04343690|EXPERIMENTAL|Health Care Workers|Faculty, staff, and trainees dealing with COVID-19 pandemic
62458892|NCT02707653|OTHER|Miso|Misoprostol 400 s/l
62458893|NCT00583700|NO_INTERVENTION|1|Control for study - watchful waiting.
62458894|NCT00583700|EXPERIMENTAL|2|Combined treatment with Pentoxifylline and Vitamin E.
62458895|NCT05796310||Autism Spectrum Disorder Patients|This group is comprised of 3-17 years children with an expert clinical diagnosis of autism spectrum disorders.
62650079|NCT03387293|EXPERIMENTAL|LGI-LII Breakfast|Low glycemic index, low insulin index (LGI-LII) breakfast as a test meal
62650080|NCT03387293|EXPERIMENTAL|LGI-HII Breakfast|Low glycemic index, high insulin index (LGI-HII) breakfast as a test meal
62650081|NCT00460967|EXPERIMENTAL|1|Rheopheresis treatment
62650082|NCT00460967|SHAM_COMPARATOR|2|Sham treatment
62650083|NCT02458066|ACTIVE_COMPARATOR|Bendiocarb|IRS: bendiocarb
62650084|NCT02458066|ACTIVE_COMPARATOR|Deltamethrin|IRS: deltamethrin
62650085|NCT01059331|EXPERIMENTAL|Pregabalin|
62650086|NCT01059331|PLACEBO_COMPARATOR|Sugar pill|
62650087|NCT06467721|EXPERIMENTAL|Self-adhesive silicone gel waterproof dressing group|Self-adhesive silicone gel waterproof dressing is used after artificial joint replacement surgery
62650088|NCT06467721|ACTIVE_COMPARATOR|Sterile gauze dressing group|Sterile gauze dressing is used after artificial joint replacement surgery
62458896|NCT05796310||Siblings of children with Autism Spectrum Disorders|This group is comprised of 3-17 years old siblings, with typical development, of a child with an expert clinical diagnosis of autism spectrum disorders.
62458897|NCT05796310||Typical Development children|This group is comprised of 3-17 years children with typical development.
62458898|NCT04855786|EXPERIMENTAL|Thoracic Duct Drainage|This is the main study group of patients with thoracic duct drainage
62458899|NCT02433678|PLACEBO_COMPARATOR|Placebo|Patients will be treated for 12 weeks with placebo once daily
62458900|NCT02433678|ACTIVE_COMPARATOR|Dapagliflozin|10 mg daily for the 12 weeks
62458901|NCT02170688|ACTIVE_COMPARATOR|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
62282171|NCT00282841|EXPERIMENTAL|All stroke code patients|After written informed consent Code Stroke patients will undergo a contrast-enhanced transcranial ultrasound study to visualize the intracranial arteries. To do so, an ultrasound contrast agent (Definity) will be administered intravenously and transcranial ultrasound will be applied via the temporal bone window on both sides. Goal is to visualize and assess the intracranial arteries bilaterally. This includes the following vessel segments on both sides: middle cerebral artery (M1,M2,M3 segments), anterior cerebral artery (A1,A2 segments), posterior cerebral artery (P1,P2 segments), internal carotid artery (C1/2,C3/4 segments).
62458902|NCT02170688|ACTIVE_COMPARATOR|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
62458903|NCT02170688|ACTIVE_COMPARATOR|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
62458904|NCT02170688|ACTIVE_COMPARATOR|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
62282172|NCT02530931|EXPERIMENTAL|patients with Meniere's disease|
62458905|NCT02170688|ACTIVE_COMPARATOR|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
62458906|NCT05951049|EXPERIMENTAL|A (AT-02)|Subjects will receive AT-02 via intravenous infusion once every two or 4 weeks for 104 weeks (52 total AT-02 administrations).
62458907|NCT01997203|EXPERIMENTAL|HCV patients under treatment|"Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.~Dose of vitamin D 15,000 IU/week"
62458908|NCT01997203|NO_INTERVENTION|HCV without Vit D|
62282173|NCT03786432|EXPERIMENTAL|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
62458909|NCT06059326|EXPERIMENTAL|HSK7653 10 mg|
62083065|NCT05388708||Usual care ECMO Cohort|"The cohort will be comprised of 550 patients, aged 14 days to 20 years, who go on extracorporeal membrane oxygenation (ECMO) support due to pediatric acute respiratory distress syndrome (PARDS) at physician discretion. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to \< 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to \< 16 and one OSI \> 10 (at least 4 hours apart) Subjects must be on mechanical ventilation for less than 240 hours (10 days) prior to cannulation. These measures must be after endotracheal intubation and before ECMO start. Chest radiograph prior to ECMO must show bilateral lung disease.~Subjects cannulated on ECMO for no more than 96 hours prior to gaining consent."
62083066|NCT05388708||PROSpect protocolized therapies cohort|"The cohort will be comprised of 1000 patients, aged 14 days to 20 years, who are endotracheally intubated for PARDS. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to \< 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to \< 16 and one OSI \> 10 (at least 4 hours apart). These measures must be after endotracheal intubation. Chest radiograph must show bilateral lung disease. Patient must be enrolled in a clinical trial Prone and Oscillation Pediatric Clinical Trial (PROSpect) NCT01515787 which is distinct from ASCEND.~PROSpect is a response adaptive randomized clinical trial, testing the impact of supine/prone positioning and conventional mechanical ventilation/high-frequency oscillatory ventilation on short and long-term clinical outcomes in children with severe PARDS. PROSpect manages severe PARDS subjects using a rigorous protocol that reserves ECMO for protocol failure."
62083067|NCT06728254|EXPERIMENTAL|Intervention (using Linked Care system)|"All nurses and caregivers participating in the intervention group use the newly installed mynevaToGo app to reorder medication. Nurses and nursing assistant level 2 also use the myneva Care Center software to keep the medication list prescribed by the GP.~The solution is installed in advance on the duty cell phones by the IT department of the relevant care organization. Participating nurses and caregivers in the intervention group are instructed to handle the medication ordering process electronically (i.e., medication orders will be sent to the GPs via the Linked Care platform)."
62282174|NCT04420364|EXPERIMENTAL|Maintenance of Immunosuppression|Maintenance of immunosuppression (defined as no change to pre-admission immunosuppression, or reduction in anti-metabolite by up to 50% (to a minimum of MMF 500 mg per day or azathioprine 50 mg per day)
62282175|NCT04420364|ACTIVE_COMPARATOR|Reduction of Immunosuppression|Reduction of immunosuppression (defined as anti-metabolite withdrawal plus reduction of tacrolimus or cyclosporin, to a minimum target trough concentration of 3 ng/mL for tacrolimus and 50 ng/mL for cyclosporin).
62282176|NCT00421330|ACTIVE_COMPARATOR|OR|Open Aneurysm Repair
62282177|NCT00421330|EXPERIMENTAL|EVAR|Endovascular Aneurysm Repair
62282178|NCT03976622||vitiligo|Patients aged 18 to 75 years with non-segmental vitiligo;
62282179|NCT03976622||psoriasis|Patients aged 18 to 75 years with plaque psoriasis;
62282180|NCT03976622||atopic dermatitis|Patients aged 18 to 75 years with atopic dermatitis;
62083068|NCT06728254|ACTIVE_COMPARATOR|Control|Care professionals in the convenience sampled control group continue to handle the usual medication process.
62083069|NCT06741280|EXPERIMENTAL|Profilm Mouth Sores|"Profilm Mouth Sores is a liquid dressing for topical application, providing temporary relief from the pain caused by certain oral mucosa lesions such as minor mouth sore. It is a polymer-based hydrogel, supplemented with natural extracts and enriched with stabilized vitamin C.~After application, and thanks to its technology, a protective physical barrier forms that adapts to the shape of the mucosa, preventing contact with food, saliva, and other irritating or sensitizing substances, thus relieving pain and creating an environment that promotes the healing of lesions. The product comes in a 5ml amber glass container with a screw cap and an applicator spatula. The product is packaged in a box along with the instructions for use (IFUs)."
62083070|NCT03442023|EXPERIMENTAL|Chlorhexidine 2%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 2% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 2%
62083071|NCT03442023|ACTIVE_COMPARATOR|Chlorhexidine 0.12%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 0.12% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 0.12%
62458910|NCT06059326|EXPERIMENTAL|HSK7653 25 mg|
62282181|NCT03976622||alopecia areata|Patients aged 18 to 75 years with alopecia areata sclerosis;
62650089|NCT02675166||Pediatric cancer young adult survivors|544 patients alive and that are min 18 years old, included in the ARCERRA population register, for a primary cancer (not leukemia), diagnosed between 15 years old, between January the 1st 1993, and December the 31st 1999, in Rhône-Alpes.
62650090|NCT02254642|EXPERIMENTAL|Ischemic preconditioning arm|Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
62650091|NCT02254642|OTHER|Control patients|Usual surgery assigned to control patients
62282182|NCT02946801|ACTIVE_COMPARATOR|Essential oils mouthwash|20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1).
62282183|NCT02946801|EXPERIMENTAL|essential oils without mouthwash|20 mL rinses for 30 seconds with essential oils without alcohol/2 times daily (1/0/1)
62650092|NCT02366871|EXPERIMENTAL|Oral apixaban|Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
62650093|NCT02366871|ACTIVE_COMPARATOR|Subcutaneous enoxaparin|Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
62083072|NCT01105858||Volunteers|Adult volunteers \&amp; family members recruited from the Phoenix metropolitan area
62083073|NCT05877885|EXPERIMENTAL|Targeted Cognitive Training Intervention|
62282184|NCT02946801|SHAM_COMPARATOR|sterile water mouthwash|20 mL rinses for 30 seconds with sterile water/2 times daily (1/0/1)
62650094|NCT04845230|ACTIVE_COMPARATOR|Enhanced Usual Care|"The control group in this study will still receive some services above and beyond the usual standard of care offered to pregnant women on Medicaid. In addition to the case management services offered through their managed care provider, Operation Food Search will offer this group access to the hunger hotline, a service provided by Operation Food Search to help them find food assistance around St. Louis; assistance in enrolling in public nutrition assistance programs like SNAP and WIC; and guidance on food pantry access in St. Louis."
62282185|NCT04992143|EXPERIMENTAL|TACE combined Tilelizumab and Sorafenib|TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)
62650095|NCT04845230|EXPERIMENTAL|Treatment 1: Nutrition Services|"This treatment group will receive all the services offered to the control group, as well as the following services:~Weekly food deliveries of fresh food meal kits with step-by-step recipes from the time of program enrollment through 60 days post-partum. Access to necessary cooking tools for their kitchen (e.g., spatulas, cutting boards , etc.), should they need them. Access to online cooking resources to help guide them on culinary skills and recipe preparation. Nutrition education and counseling provided by a registered dietitian."
62650096|NCT04845230|EXPERIMENTAL|Treatment 2: Integrated Care Services|This treatment group will receive all the services offered to Treatment Group 1, as well as the services of a Licensed Masters Social Worker who will provide trauma-informed integrative care services to participants. These services will focus on an array of potential needs that may emerge in participants' lives, such as assistance in finding stable housing, assistance navigating social services, connections with other community organizations, and other needs.
62650097|NCT04796701|EXPERIMENTAL|Follow Home Intervention|If possible, all included participants are physically followed home by a hospital-based project worker on the day of discharge. During the visit, the focus is on: basic human needs, medication review reconciliation, and a comprehensive geriatric assessment. Problems, challenges and concerns are discussed. Finally, a conference for the following working day is arranged either as a physical visit or a video conference. The patient, relatives, community-based nurse and project worker are invited to participate and health status and challenges are discussed They are recommended to contact the project worker about health and practical issues up to 7 days after discharge where the intervention ends. Subsequently, the responsibility for treatment and care is assigned to the GP and home healthcare provider.
62282186|NCT02849639|PLACEBO_COMPARATOR|Placebo|"Participants enrolled into this arm will only receive educational materials, but will not receive specific recommendations to make changes to the medications they are taking.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
62282187|NCT02849639|ACTIVE_COMPARATOR|Medication Therapy Management (MTM)|"Participants enrolled into this arm will receive educational materials and will have their medications assessed; recommendations for changes in the medications taken will be made when appropriate.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
62282188|NCT04433507|ACTIVE_COMPARATOR|Sleeve Gastrectomy group|This group will receive a Sleeve Gastrectomy only, a mainly restrictive procedure which consists in creating a narrow tube-like stomach based on its lesser curvature.
62282189|NCT04433507|EXPERIMENTAL|Sleeve Gastrectomy + Hiatal Hernia repair group|This group will receive a Sleeve Gastrectomy combined with hiatal hernia repair. Hiatal Hernia repair consists of a peri-esophageal dissection proximal to the diaphragmatic crura to achieve an intra-abdominal esophageal length of 2-3 cm. The pillars will then be closed anteriorly and posteriorly using nonabsorbable sutures.
62282190|NCT00568555|EXPERIMENTAL|Low Dose Naltrexone first|LDN first, then placebo.
62282191|NCT00568555|PLACEBO_COMPARATOR|Placebo - sugar pill first|Placebo first, then LDN.
62282192|NCT05535179|EXPERIMENTAL|treatment group|
62458911|NCT06059326|EXPERIMENTAL|HSK7653 50 mg|
62282193|NCT05535179|NO_INTERVENTION|control group|
62458912|NCT06059326|PLACEBO_COMPARATOR|Placebo|
62458913|NCT01740609|PLACEBO_COMPARATOR|1. Placebo|Placebo
62083074|NCT05877885|ACTIVE_COMPARATOR|General Cognitive Training Intervention|
62458914|NCT01740609|EXPERIMENTAL|2.0|
62458915|NCT02716025||Case Group|
62458916|NCT02716025||Control Group|
62458917|NCT05372666|PLACEBO_COMPARATOR|Control IG100|1 small bread loaf using T55 standard white flour for a final content of 50 g equivalent digestible carbohydrates
62083075|NCT06447805|EXPERIMENTAL|Double Sequential Defibrillation (DSD)|"If the patient is randomized to the DSD group, the ambulance crew team will apply the second defibrillator with electrodes placed in the A-P position as soon as possible.~Defibrillation is performed by one person defibrillating both defibrillators in a sequential manner Double Sequential Defibrillation (DSD). All consecutive defibrillations will thereafter be performed with the DSD strategy until ROSC, termination of resuscitation or decision to move the patient to hospital."
62282194|NCT06097520|ACTIVE_COMPARATOR|Intervention group|Patients receive a VR headset (Pico G2 4K) for 15 minutes in the time between the 2. and 3. pain assessment and will experience non-interactive videos with different immersive scenarios of nature scenes. Nature sounds, meditation or classical music accompanying the scenarios are played through noise-cancelling headphones. Additionally, a wearable with an optical PPG- and EDA-Sensor (Empatica EmbracePlus) is put on the wrist of each participant in both groups 15 minutes before the inhalation until 15 minutes after the third pain intensity assessment, which enables the tracking of vital signs and monitoring of physiological responses. In both groups the study procedure starts with determining the pain intensity immediately before and after the 15 minutes inhalation procedure which is part of the standard of care. 15 minutes after the second assessment, the pain intensity is determined a third time in both groups.
62282195|NCT06097520|NO_INTERVENTION|Control group (standard care)|Patients in the control group do not receive any intervention in the time between the second and third pain assessment. Additionally, a wearable with an optical PPG- and EDA-Sensor (Empatica EmbracePlus) is put on the wrist of each participant in both groups 15 minutes before the inhalation until 15 minutes after the third pain intensity assessment, which enables the tracking of vital signs and monitoring of physiological responses. In both groups the study procedure starts with determining the pain intensity using the Numeric Rating Scale (NRS) immediately before and after the 15 minutes inhalation procedure which is part of the standard of care. 15 minutes after the second assessment, the pain intensity is determined a third time in both groups.
62282196|NCT00808041||Treatment|Breast cancer patients undergoing hormonal therapy before surgery.
62282197|NCT03715426|EXPERIMENTAL|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
62282198|NCT03715426|NO_INTERVENTION|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
62458918|NCT05372666|EXPERIMENTAL|Reference WB|1 small bread loaf using T55 Qualista white flour for a final content of 50 g equivalent digestible carbohydrates
62650098|NCT04796701|NO_INTERVENTION|Control|On the day of discharge, the hospital-based nurse digitally sends a summary of the hospital stay and a treatment and care plan to the community-based nurse. If needed, the hospital-based nurse contacts the community-based nurse by phone as a supplement to the plan. Finally, a discharge letter conducted by the hospital-based doctor is digitally sent to the GP
62083076|NCT06447805|ACTIVE_COMPARATOR|Standard defibrillation|If the patient is randomized to the standard defibrillation group, the ambulance crew team will continue Advanced life support in accordance with standard of care and continue to perform standard defibibrillation using one defibrillator. All consecutive defibrillations will thereafter be performed with the standard defibrillation strategy until ROSC, termination of resuscitation or decision to move the patient to hospital.
62083077|NCT04927364|EXPERIMENTAL|Active dTMS|Participants will receive 30 dTMS treatments, administered 3 times per day over 10 consecutive business days, Each treatment visit will last approximately 30 minutes in total.
62083078|NCT06713239|EXPERIMENTAL|Coronary Plaque-Based Care|Patients randomized to the Coronary Plaque-Based Care arm will undergo CCTA with AI-enabled quantitative assessment of the morphology and composition of coronary atherosclerotic plaque and will receive medical and interventional management informed by CCTA findings and per discretion of the treating physician. All patients will receive a standardized assessment of clinical and risk factor status at baseline and 180 days.
62083079|NCT06713239|NO_INTERVENTION|Usual Care|Patients randomized to the Usual Care arm will be referred to their usual care providers for standard of care management post stress test findings, possibly including coronary angiography and/or revascularization per the treating provider's recommendation. All patients will receive a standardized assessment of clinical and risk factor status at baseline and 180 days.
62083080|NCT04436107|EXPERIMENTAL|Part 1 : Zanubrutinib + Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide on Days 1 - 21 of each 28-Day cycle for up to 48 months"
62083081|NCT04436107|EXPERIMENTAL|Part 2 : Zanubrutinib+Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide at the RP2D dose determined from Part 1 administered on Days 1 - 21 of each 28-Day cycle for up to 48 months"
62083082|NCT05795842||AFib monitoring learning algorithms|Participants will wear a prescribed (standard of care) ambulatory ECG monitoring (Biotel Patch or LINQ insertable cardiac monitor) and either a MOTO 360 smartwatch, fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting or a Samsung Galaxy watch 6 paired with the Samsung Galaxy phone S21 to continuously record PPG and/or ECG data that can transmit data.
62083083|NCT06729762||ultrasound-guided thermal ablation|ultrasound-guided thermal ablation
62083084|NCT06627179|EXPERIMENTAL|Ultevursen 180/60 μg|Subjects will receive an intravitreal injection (IVT) of Ultevursen with concentrations of 3.6 mg/mL for initial dose and 1.2 mg/mL for maintenance doses every 6 months thereafter through Month 18 (up to 4 doses).
62083085|NCT06627179|SHAM_COMPARATOR|Sham Procedure|Sham-procedure (no experimental drug administered)
62650099|NCT04676373|EXPERIMENTAL|Alglucosidase Alfa|A dose of 20 mg/kg body weight once every 2 weeks for a minimum of 52 weeks
62650100|NCT00573924|ACTIVE_COMPARATOR|1|Oral PPI
62083086|NCT05482932||Patients with IBD|100 patients with IBD; either Ulcerative Colitis (N=50) or Crohns disease (N=50)
62083087|NCT05482932||Healthy volunteers without IBD|100 healthy volunteers (without IBD)
62083088|NCT06565169|EXPERIMENTAL|Intervention: Advance Care Planning Training|"1. Dementia-specific education: Stage-specific findings and challenges, including AD/ADRD staging, capacity assessment, symptom burden, hospice guidelines, etc - 10-minute didactics, delivered via video conferencing and via the website~2. ACP communication skills: Context-specific skills and tips on how to slow down, set the communication stage, active listening, respect for personhood and cultural norms, and common, useful language to prepare patients and families- 10-minute didactics, delivered via video conferencing and via the website~3. Clinical implementation support: Coding and billing information for ACP and ACP templates, an action plan for each team member participant, monthly ACP audit-and-feedback to participants, monthly coaching sessions, site champion, refresher sessions, and educational in-services as needed - Resources at the end of the training session, available on the website, monthly feedback reports on ACP practices, periodic coaching"
62282199|NCT06522776|EXPERIMENTAL|Remote cognitive behavioral therapy|A single-case experimental design A-B with prospective follow-up. We used the Patient Health Questionnaire-9 (PHQ-9) and the General Anxiety Disorder Scale-7 (GAD-7) to screen for depressive and anxiety symptoms, one week later after hospital discharge. Those with moderate or severe symptoms received cognitive behavioral therapy (CBT) and were evaluated over time with the instruments and daily self-report of symptoms.
62650101|NCT00573924|ACTIVE_COMPARATOR|2|Intravenous PPI
62650102|NCT06078618||cohort|Mothers and their newborn babies (live or stillborn) who were delivered between 32 and 36 weeks' gestation
62650103|NCT05002803|EXPERIMENTAL|Otago Exercise Program|Older adults will receive the Arabic Otago Exercise Program for 8 weeks plus health awareness videos.
62650104|NCT05002803|NO_INTERVENTION|Control group|Older adults will receive only health awareness videos every 2 weeks.
62650105|NCT05906849|NO_INTERVENTION|Control Group|Group of participants with a main diagnosis of social anxiety disorder (n≥13) or generalized anxiety disorder (n≥13) not subjected to any psychological intervention within the current trial. They will be asked to fill in the self-report protocol at 2 different time points (12 weeks interval) mimicking the pre- and post-intervention assessment moments; these adolescents will be assessed after the second time point and referred to the school psychology services if the difficulties persist.
62650106|NCT05906849|EXPERIMENTAL|SAD Intervention Group|Group of participants with a main diagnosis of social anxiety disorder (n=26) subjected to individual online delivered 12 sessions ACT psychotherapy. Participants pertaining to this group will be assessed at 4 different time points (pre- and post-treatment and at a 3- and 6- month follow-up).
62083089|NCT06565169|ACTIVE_COMPARATOR|Care as Usual: No Training|These primary care teams will not receive the Advance Care Planning training. Clinics randomized to the control arm will have access to voluntary, routine ACP training sessions provided by UNC HEALTH. We will provide the control clinics summary reports of their ACP practice outcomes at the end of the 18-month follow-up period, which can be used in future practice improvement efforts.
62083090|NCT06739148|EXPERIMENTAL|LLLT+BFR+NMES|"LLLT: low-level laser therapy BFR: blood flow restriction NMES:neuromuscular Electrical Stimulation~35 min/time, 3 times/weeks, 3 weeks"
62083091|NCT06739148|EXPERIMENTAL|BFR+NMES|"BFR: blood flow restriction NMES:Neuromuscular Electrical Stimulation~35 min/time, 3 times/weeks, 3 weeks"
62083092|NCT06631417|EXPERIMENTAL|BI 1291583 formulation 1 then formulation 2 then formulation 3 (part A)|
62458919|NCT05372666|ACTIVE_COMPARATOR|Reference HFB|1 small bread loaf using T55 standard white flour supplemented with 11 % standard wheat bran (6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
62650107|NCT05906849|EXPERIMENTAL|GAD Intervention Group|Group of participants with a main diagnosis of generalized anxiety disorder (n=26) subjected to individual online delivered 12 sessions ACT psychotherapy. Participants pertaining to this group will be assessed at 4 different time points (pre- and post-treatment and at a 3- and 6- month follow-up).
62650108|NCT01042626|EXPERIMENTAL|Normocalcemic Hyperparathyroidism|
62083093|NCT06631417|EXPERIMENTAL|BI 1291583 formulation 1 then formulation 2 then formulation 3 (part B)|
62083094|NCT02398747|EXPERIMENTAL|AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD|50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
62458920|NCT05372666|EXPERIMENTAL|Qualista HFB 01|1 small bread loaf using T55 Qualista white flour supplemented with 13 % untreated Qualista wheat bran (6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
62650109|NCT01042626|EXPERIMENTAL|Hypercalcemic Hyperparathyroidism|
62650110|NCT01042626|ACTIVE_COMPARATOR|Healthy subjects|
62650111|NCT05238623||Control cohort|lung-healthy volunteers get a EIT measurement
62083095|NCT06501794|OTHER|Myasthenia Gravis|Participants with a confirmed diagnosis of Myasthenia Gravis
62083096|NCT06532747|EXPERIMENTAL|Integrated Lifestyle Intervention (ILI)|"ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.~All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months."
62083097|NCT06532747|EXPERIMENTAL|Behavioral Weight Loss (BWL)|All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
62650112|NCT05238623||Case cohort|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement
62083098|NCT05704322|NO_INTERVENTION|Usual care group|The control group will not receive any intervention, they will receive usual care and only participate in the pre and post tests.
62083099|NCT05704322|EXPERIMENTAL|Wim Hof Method - breathing and mindset exercise|The first intervention group will practice the breathing and mindset exercise.
62083100|NCT05704322|EXPERIMENTAL|Wim Hof Method - breathing and mindset exercise and cold exposure|The second intervention group will also practice the cold exposure (i.e, breathing, mindset and cold exposure)
62083101|NCT04871919||Filgotinib|Individuals will receive treatment for moderate to severe active rheumatoid arthritis with at least one dose of filgotinib in accordance with the product label
62650113|NCT02246933|EXPERIMENTAL|PUFA Diet|
62650114|NCT02246933|PLACEBO_COMPARATOR|Control Diet|
62650115|NCT05596799|EXPERIMENTAL|Facing Eating Disorder Fears Condition|Participants will complete 1 session of education about the treatment. After completion of treatment education and baseline questionnaires, participants will complete sessions 2 through 12 of virtual treatment for anorexia nervosa and mobile assessments.
62083102|NCT02807805|EXPERIMENTAL|Treatment (abiraterone acetate, niclosamide, prednisone)|Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
62083103|NCT06738901|EXPERIMENTAL|Prophylactic treatment|
62458921|NCT05372666|EXPERIMENTAL|Qualista HFB 02|1 small bread loaf using T55 Qualista white flour supplemented with 13 % pretreated Qualista wheat bran (treatment A - 6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
62458922|NCT05372666|EXPERIMENTAL|Qualista HFB 03|1 small bread loaf using T55 Qualista white flour supplemented with 13 % pretreated Qualista wheat bran (treatment B - 6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
62650116|NCT05596799|NO_INTERVENTION|Treatment as Usual|Participants will complete baseline measures, mobile assessments and treatment as usual.
62650117|NCT03927443|EXPERIMENTAL|Test|
62650118|NCT03927443|ACTIVE_COMPARATOR|Reference|
62650119|NCT05776667|EXPERIMENTAL|Hypofractionated Radiation Therapy|
62650120|NCT01664091|EXPERIMENTAL|TE-ADM with PMRT|Participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling placed during the same surgery. This was followed by post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months, if adjuvant chemotherapy was required. The prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. Permanent reconstruction was performed at least 5 months after completion of PMRT.
62650121|NCT03108482|EXPERIMENTAL|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
62083104|NCT05234177||Participants with stage I-IV colorectal cancer (CRC)|This protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.
62083105|NCT02712840|EXPERIMENTAL|Freeze-All Protocol|Participants freezing all good quality embryos, with subsequent frozen embryo transfer of best quality blastocyst.
62458923|NCT05372666|EXPERIMENTAL|Qualista HFB 04|1 small bread loaf using T55 Qualista white flour supplemented with 13 % pretreated Qualista wheat bran (treatment C - 6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
62650122|NCT03108482|ACTIVE_COMPARATOR|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
62650123|NCT03108482|ACTIVE_COMPARATOR|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
62650124|NCT03108482|PLACEBO_COMPARATOR|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
62650125|NCT02364557|NO_INTERVENTION|Standard of Care (SOC)|Standard of care systemic therapy at the discretion of the treating physician.
62650126|NCT02364557|EXPERIMENTAL|Standard of Care + Ablation|Standard of care systemic therapy plus ablation of all metastases by stereotactic body radiotherapy or surgery at the discretion of the treating physician.
62650127|NCT03971760|ACTIVE_COMPARATOR|Group 1: 30cc/24h|This group represents the currently used value of drain output used to determine the timing of drain removal
62650128|NCT03971760|EXPERIMENTAL|Group 2: 50cc/24h|This group represents the experimental value of drain output used to determine the timing of drain removal
62650129|NCT01389739|EXPERIMENTAL|Exposed to the intervention|Patients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
62650130|NCT01389739|NO_INTERVENTION|Usual care|
62650131|NCT04235946|EXPERIMENTAL|accompanied and adapted water polo program|"16 and 20 aqua polo sessions (adapted water polo) over a period of 20 weeks, at the rate of one session per week at the Cercle des Nageurs de Marseille (CNM). They will be divided into 3 cycles imitating the preparation of the season of a high-level athlete: a first cycle intended for physical preparation, a second cycle intended for practical learning (technique and tactics) and the third cycle for preparation of a mini tournament.~Each session will be organized as follows: 1 hour of training in the water followed by 30 min of debriefing as a team or individually with the coach. The announced duration of the session will be 2 hours, transport and changing rooms included."
62650132|NCT00966368|EXPERIMENTAL|IDeg E|
62650133|NCT00966368|EXPERIMENTAL|IDeg M|
62458924|NCT04852003|EXPERIMENTAL|SHR0410 Injection|
62083106|NCT02712840|ACTIVE_COMPARATOR|Fresh Protocol|Participants receiving fresh embryo transfer of best quality blastocyst and freezing of all good quality supernumerary embryos.
62282200|NCT05463809|EXPERIMENTAL|Experimental group: Ropivacaine-controlled analgesia pump|A single injection of 0.375% Ropivacaine 15 milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Than，a catheter was placed in the gastrocnemius plane, and a 0.125% ropivacaine-controlled analgesic pump was applied.(The formulation was 0.125% ropivacaine at 300 milliliters, with a background dose of 3 milliliters/hours, a patient-controlled analgesia(PCA) dose of 8 milliliters, and a locking time of 25 minutes.）
62458925|NCT04852003|PLACEBO_COMPARATOR|Placebo for SHR0410 Injection|
62458926|NCT04852003|ACTIVE_COMPARATOR|Morphine|
62650134|NCT03265561|EXPERIMENTAL|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
62650135|NCT03265561|ACTIVE_COMPARATOR|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
62650136|NCT04609137|EXPERIMENTAL|Early drain removal|Participants will have an early drain removal (before postoperative day 3 (POD 3)) if specific conditions will be verified
62650137|NCT04609137|ACTIVE_COMPARATOR|Standard drain removal|Participants will receive the current standard of care at San Raffaele Hospital.
62650138|NCT02817139|ACTIVE_COMPARATOR|active tDCS over primary motor cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left primary motor cortex.
62650139|NCT02817139|EXPERIMENTAL|active tDCS over prefrontal cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left prefrontal cortex.
62458927|NCT03553160|OTHER|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
62650140|NCT02817139|PLACEBO_COMPARATOR|sham tDCS over primary motor cortex|Duration: 20 minutes; The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham; Placement: left primary motor cortex.
62650141|NCT00576511|ACTIVE_COMPARATOR|1|Prucalopride
62650142|NCT00576511|PLACEBO_COMPARATOR|2|
62650143|NCT05630196|EXPERIMENTAL|LY3857210|Participants received 45 milligrams (mg) of LY3857210 orally once daily for up to 8 weeks.
62650144|NCT05630196|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once daily for up to 8 weeks.
62650145|NCT00619827|EXPERIMENTAL|300 IR|300 IR grass pollen allergen extract tablet
62650146|NCT00619827|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62650147|NCT03659630|EXPERIMENTAL|Intervention group|The intervention group receives the MyCompass intervention, an automated self-help intervention for mild to moderate mental ill-health.
62083107|NCT06357182|EXPERIMENTAL|Treatment Dose Level -2(iadademstat, azacitidine, venetoclax)|"Iadademstat (75 mcg, 5+2 days, 2 out of 4 weeks per cycle), Venetoclax (400 mg, day 1-7), Azacitidine (50 mg/m2, day 1-7)~Patients receive iadademstat PO QD on days 1-5 of cycle 0 and then days 1-5, 8-12, and 15-19. Patients also receive venetoclax PO QD days 1-21 and azacitidine SC QD days 1-7. Patients with CR, CRh, CRi, or MLFS after cycle 1 continue to receive IADA PO QD on days 1-5, 8-12, and 15-19, azacitidine SC QD days 1-7 and venetoclax PO QD days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening as clinically indicated on study. Patients under bone marrow biopsy throughout the trial. Additionally, patients undergo blood sample collection during screening and on the trial."
62083108|NCT06357182|EXPERIMENTAL|Treatment Dose Level -1 (iadademstat, azacitidine, venetoclax)|"Iadademstat (75 mcg, 5+2 days, 2 out of 4 weeks per cycle), Venetoclax (400 mg, day 1-14), Azacitidine (75 mg/m2, day 1-7)~Patients receive iadademstat PO QD on days 1-5 of cycle 0 and then days 1-5, 8-12, and 15-19. Patients also receive venetoclax PO QD days 1-21 and azacitidine SC QD days 1-7. Patients with CR, CRh, CRi, or MLFS after cycle 1 continue to receive IADA PO QD on days 1-5, 8-12, and 15-19, azacitidine SC QD days 1-7 and venetoclax PO QD days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening as clinically indicated on study. Patients under bone marrow biopsy throughout the trial. Additionally, patients undergo blood sample collection during screening and on the trial."
62083109|NCT06357182|EXPERIMENTAL|Treatment Dose Level 1 (iadademstat, azacitidine, venetoclax)|"Iadademstat (100 mcg, 5+2 days, 2 out of 4 weeks per cycle), Venetoclax (400 mg, day 1-21), Azacitidine (75 mg/m2, day 1-7)~Patients receive iadademstat PO QD on days 1-5 of cycle 0 and then days 1-5, 8-12, and 15-19. Patients also receive venetoclax PO QD days 1-21 and azacitidine SC QD days 1-7. Patients with CR, CRh, CRi, or MLFS after cycle 1 continue to receive IADA PO QD on days 1-5, 8-12, and 15-19, azacitidine SC QD days 1-7 and venetoclax PO QD days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening as clinically indicated on study. Patients under bone marrow biopsy throughout the trial. Additionally, patients undergo blood sample collection during screening and on the trial."
62083110|NCT06357182|EXPERIMENTAL|Treatment Dose Level 2 (iadademstat, azacitidine, venetoclax)|"Iadademstat (150 mcg, 5+2 days, 2 out of 4 weeks per cycle), Venetoclax (400 mg, day 1-21), Azacitidine (75 mg/m2, day 1-7)~Patients receive iadademstat PO QD on days 1-5 of cycle 0 and then days 1-5, 8-12, and 15-19. Patients also receive venetoclax PO QD days 1-21 and azacitidine SC QD days 1-7. Patients with CR, CRh, CRi, or MLFS after cycle 1 continue to receive IADA PO QD on days 1-5, 8-12, and 15-19, azacitidine SC QD days 1-7 and venetoclax PO QD days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening as clinically indicated on study. Patients under bone marrow biopsy throughout the trial. Additionally, patients undergo blood sample collection during screening and on the trial."
62083111|NCT03863899|EXPERIMENTAL|Nerve block|ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)
62650148|NCT03659630|PLACEBO_COMPARATOR|Comparison group|The control group receives a brief email each week, describing the most common mental health issues.
62650149|NCT04796415|EXPERIMENTAL|DEMA-Pro|The DEMA-Pro intervention will be administrated. Subjects will attend six weekly, 1-hour telephone sessions.
62458928|NCT06198881||induction of labor|Patient having been induced by cervical ripening (prostin gel (2mg/24h), intravaginal prostaglandin (10mg/24h), balloon (\<12h exposure time) or oral misoprostole (50µg/4h until induction of labor) or induction of contractions by oxytocin (gradual increase in dose) for suspected ultrasound macrosomia (according to the criteria of the DAME study)
62083112|NCT03863899|ACTIVE_COMPARATOR|Local infiltration|local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)
62083113|NCT01398501|EXPERIMENTAL|Post-SCT Sorafenib|Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.
62083114|NCT06719778|EXPERIMENTAL|Application of a two-stage nutritional therapy concept|Sequencing of the inpatient integrative medicinal lifestyle modification program applied at the clinic for internal and integrative medicine in Bamberg into a two-stage nutritional therapy concept
62083115|NCT00075803|ACTIVE_COMPARATOR|Fluconazole|The dose of fluconazole is 400 mg by mouth or intravenous drip.
62083116|NCT00075803|EXPERIMENTAL|Voriconazole|The dose of oral voriconazole is 200 mg twice daily. When voriconazole must be given intravenously, it will be given at a dose of 200 mg every 12 hours for the duration of intravenous therapy.
62083117|NCT05257551||Patients with Small Cell Lung Cancer (SCLC)|This protocol will include participants with newly diagnosed extensive stage (stage IV) small cell lung cancer with tissue collected from the primary lung tumor, or metastatic sites outside of the liver or biliary system.
62083118|NCT06737172||Survivors of childhood bone or soft tissue sarcomas of the lower extremity|Survivors aged 6-18 years who were treated for bone or soft tissue sarcoma of the lower extremity in one of the recruiting study sites, 1-5 years following the end of therapy
62458929|NCT06198881||natural labor|Patient presenting with spontaneous labor after 37 weeks of gestation.
62458930|NCT01490944|ACTIVE_COMPARATOR|Iron and Folic Acid|
62458931|NCT01490944|EXPERIMENTAL|Iron, Folic acid and cyanocobalamin|
62458932|NCT06083337|NO_INTERVENTION|Standard of care management|Patients will receive standard of care treatment.
62650150|NCT05355155|EXPERIMENTAL|Bevacizumab combine with FOLFOX4|"Bevacizumab biosimilar：7.5mg/kg，IV，D1，Q2W FOLFOX4：~1. Oxaliplatin: 85 mg/m2 , IV, D1，Q2W~2. Calcium leovorin: 200 mg/m2 ,IV, D1、D2，Q2W~3. Fluorouracil: 400 mg/m2 push infusion and given 600mg/m2 intravenously 22 hours later， D1、D2, Q2W Treatment will continue until disease progression, an unacceptable toxicity, or the patient voluntarily discontinues the study, whichever comes first."
62650151|NCT01524835||Live lung donors|Live lung donors who participated in donation from 1993 through 2006
62650152|NCT00590499||agitation group|The Riker sedation-agitated scale (SAS) levels 5-7.
62650153|NCT00590499||non-agitation group|The Riker sedation-agitated scale (SAS) levels 1-4.
62083119|NCT06739772|EXPERIMENTAL|HPV Self sampling|Participants in the intervention group will receive HPV self sampling and behavioral intervention
62083120|NCT06739772|NO_INTERVENTION|Control Group|Participants in the control group will receive enhance standard care
62083121|NCT06177795|NO_INTERVENTION|Penn: Control|Clinics randomized to the control arm will receive standard of care.
62083122|NCT06177795|EXPERIMENTAL|Penn: Intervention|Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be post-visit text message reminders (standard messaging content). Clinician nudges will be default pended orders.
62650154|NCT01562899|EXPERIMENTAL|Dose escalation|Dose finding group chosen in order to establish a safe and tolerated dose of binimetinib in combination with ganitumab in patients with selected advanced solid tumors.
62650155|NCT01562899|EXPERIMENTAL|KRAS mutated colorectal adenocarcinoma|"Patients with KRAS mutant colorectal cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
62650156|NCT01562899|EXPERIMENTAL|Metastatic pancreatic adenocarcinoma|"Patients with metastatic pancreatic cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
62650157|NCT01562899|EXPERIMENTAL|BRAF mutated melanoma|"Patients with mutant BRAF V600 melanoma.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
62083123|NCT06177795|EXPERIMENTAL|Penn: High Risk Intensification|Patients in the intervention clinics identified as high risk for noncompletion of mammogram will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.
62083124|NCT06177795|NO_INTERVENTION|UH: Control|Primary care providers randomized to the control arm will receive standard of care.
62083125|NCT06177795|EXPERIMENTAL|UH: Intervention|Primary care providers randomized to the intervention arm will receive default pended orders for a mammogram.
62083126|NCT05723575|EXPERIMENTAL|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
62083127|NCT06739525|EXPERIMENTAL|interventional group|
62083128|NCT06739525|ACTIVE_COMPARATOR|Control Group|
62083129|NCT02055248||Subjects with Moebius or related syndromes and their family me|Subjects with Moebius or related syndromes and their family members and healthy volunteers.
62650158|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
62461776|NCT02885077|EXPERIMENTAL|High-intensity IMT + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). Training will progress to 80% maximal inspiratory pressure (PiMax). IMT will perform for 12 weeks with two sessions per week. The training protocol will consists of five series with ten repetitions with two minutes or according to patient feedback using the modified Borg scale.The initial charge of training will be 50% of PiMax in the first 2 weeks, with an increase of 55% of PiMax in the 3 week, 60% of PiMax in the 4 week, 65% of PiMax in the 5 week, 70% of PiMax in the 6 week, 75% of PiMax in the 7 week and 80% of PiMax in the 8 week. After the 9 and 12 week training period, the PiMax measurements will be performed weekly to keep 80% of the new PiMax.
62650159|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
62650160|NCT02352194||Assessment|"One part of this study is to quantify physical capacity of patients with Multiple sclerosis.~Thirty patients will be enrolled in this study and performed assessments."
62650161|NCT02352194||Rehabilitation|A second part of this study is to quantify the benefit of a usual rehabilitation program in the day hospital. Thirty patients will be enrolled in this study and receive rehabilitation. They will be assessed before and after the rehabilitation program (physiotherapy and physical activity)
62650162|NCT05604898|EXPERIMENTAL|Part 1：608 40 mg|Randomized in a 6:2 ratio to 608 40mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 40mg or placebo 4-weekly.
62650163|NCT05604898|EXPERIMENTAL|Part 1：608 80 mg|Randomized in a 10:2 ratio to 608 80mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 80mg or placebo 4-weekly.
62650164|NCT05604898|EXPERIMENTAL|Part 1：608 160 mg|Randomized in a 10:2 ratio to 608 160mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 160mg or placebo 4-weekly.
62083130|NCT04607421|EXPERIMENTAL|Safety Lead-in Cohort 1|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
62083131|NCT04607421|EXPERIMENTAL|Safety Lead-in Cohort 2|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
62083132|NCT04607421|EXPERIMENTAL|Phase 3 Arm A|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks
62083133|NCT04607421|EXPERIMENTAL|Phase 3 Arm B|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
62650165|NCT05604898|EXPERIMENTAL|Part 2：608 160 mg W0+80 mg Q2W+80 mg Q4W|Participants will receive starting dose of 160 mg 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period. During the maintenance period, participants will receive 80mg 608 once every four weeks (Q4W).
62650166|NCT05604898|EXPERIMENTAL|Part 2：608 160 mg Q2W+160 mg Q4W|Participants will receive 160mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period followed by 160mg 608 once every four weeks (Q4W) during maintenance period.
62650167|NCT05604898|EXPERIMENTAL|Part 2：608 160 mg Q4W+160 mg Q8W|Participants will receive 160mg 608 once every four weeks (Q4W) by subcutaneous injection during induction period followed by 160mg 608 once every eight weeks (Q8W) during maintenance period.
62650168|NCT05604898|PLACEBO_COMPARATOR|Part 2：Placebo|Participants will receive Placebo by subcutaneous injection.
62650169|NCT03862638|EXPERIMENTAL|Yoga Therapy|Yoga therapy session lasted for 60 minutes consisting physical posture, Breath work, Relaxation, guided meditation, chants and combination techniques for groups sessions.
62650170|NCT04562974|EXPERIMENTAL|One group of 30 healthy subjects|Perception and memory tasks inside a MRI-scanner for all participants
62650171|NCT06032663|EXPERIMENTAL|PET-MRI within 1 week of planning scan.|Patients would not normally have a PET-MRI as well as planning scan. In this experimental arm, patients will be given a PET-MRI within 1 week of the planning scan.
62083134|NCT04607421|ACTIVE_COMPARATOR|Phase 3 Arm C|Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
62282201|NCT05463809|EXPERIMENTAL|Control group: oxycodone-controlled analgesia pump|No treatment was given preoperatively, and postoperative oxycodone patient-controlled intravenous analgesia(PCIA). After awakening, intravenous oxycodone was titrated according to numerical rating scale(NRS) score, providing analgesia without background dose of oxycodone patient-controlled intravenous analgesia(PCIA) pump (single dose 1 milligram, locking time 5 minutes, 14 hours limit 12 milligrams)
62282202|NCT05544890|ACTIVE_COMPARATOR|Therapeutic exercise Group (ET)|The ET group is going to follow a program of core stabilization through specific therapeutic exercise. Two weekly sessions will be programmed for 12 weeks, making a total of 24 sessions. Each session will have a duration of 60 minutes. All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.
62282203|NCT05544890|ACTIVE_COMPARATOR|Manual Therapy group (ETmanualtherapy)|Prior the core exercise previously exposed in group ET, group ETmanualtherapy will lay on the stretcher, where the physiotherapist will work on a manual therapy thrust. The participant will receive a high velocity and low range impulse technique in lateral position on both sides.
62282204|NCT05544890|ACTIVE_COMPARATOR|Kinesiotape Group (ETkinesiotape)|"The ETkinesiotape will go previously through physiotherapy, where a kinesiotape band will be applied (Kinesiotape Nondolens 5cmx5cm black color), in Y technique, by applying the kinesiotape base in neutral position of the lumbar spine without any tension on the tape. The participants realize the same exercise program than the other groups plus the kinesiotape applied."
62282205|NCT05590598|EXPERIMENTAL|Group 1: Azelastine + Mometasone, nasal spray|Participants will receive test product Azelastine + Mometasone, nasal spray, 140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
62282206|NCT05590598|ACTIVE_COMPARATOR|Group 2: Momat Rhino Advance, nasal dosed spray|Participants will receive reference product Momat Rhino Advance, nasal dosed spray, 140 mcg + 50 mcg mcg/dose (Glenmark Pharmaceuticals Limited., India), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
62282207|NCT02194153||Metalyse|Metalyse weight-adjusted
62282208|NCT03237468|EXPERIMENTAL|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
62282209|NCT04181879|EXPERIMENTAL|Intervention|GPs will receive the intervention package and conduct medication reviews with recruited patients
62650172|NCT00017251|EXPERIMENTAL|Treatment (oblimersen sodium, carboplatin, etoposide)|Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
62282210|NCT04181879|NO_INTERVENTION|Usual care|GPs will continue to treat recruited patients as usual
62282211|NCT01183624|EXPERIMENTAL|Experimental Patch|Herbal Patch
62282212|NCT01183624|PLACEBO_COMPARATOR|Control Patch|Placebo Patch
62282213|NCT04532710|PLACEBO_COMPARATOR|Placebo low dose|Application of 2 placebo eye drops once daily for 8 days.
62282214|NCT04532710|ACTIVE_COMPARATOR|Tacrosolv low dose|Application of 1 Tacrosolv eye drop once daily for 8 days.
62282215|NCT04532710|PLACEBO_COMPARATOR|Placebo high dose|Application of 1 placebo eye drop once daily for 8 days.
62282216|NCT04532710|ACTIVE_COMPARATOR|Tacrosolv high dose|Application of 2 Tacrosolv eye drops once daily for 8 days.
62282217|NCT05689931||Asthma patients initiating Mepolizumab treatment|Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection
62282218|NCT05689931||Asthma patients already on Mepolizumab treatment|Patients that have been selected and given Mepolizumab treatment for \> 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for \> 4 weeks will be included. Exclusion criteria: any infections
62650173|NCT03927170|EXPERIMENTAL|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
62458933|NCT06083337|EXPERIMENTAL|Coronary inflammation-based management|Participants classified as moderate risk (FAI-Score 75th-89th percentile for the RCA or the LAD or ≥ 95th percentile for the LCx) or CaRi-Heart risk≥ 5% and \<10%) will receive atorvastatin 40mg daily, if they do not already receive statin therapy, while if they already receive statin, it will be discontinued and they will be given atorvastatin 80 mg daily. Participants classified as high risk (FAI-Score≥ 90th percentile for the RCA or the LAD or CaRi-Heart risk≥ 10%) will receive atorvastatin 80 mg daily and colchicine 0.5 mg daily. Tolerance and compliance will be monitored during the study follow-up and participants will be informed at enrollment about possible treatment side effects. In case of colchicine intolerance, colchicine will be discontinued. If the patient cannot tolerate atorvastatin, then half dose may be prescribed daily. In case of severe adverse events related to atorvastatin, atorvastatin will be discontinued and the participant will withdraw from the study.
62650174|NCT03927170|ACTIVE_COMPARATOR|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
62650175|NCT05654038|EXPERIMENTAL|Target CD19 UCAR-NK cells|Subjects who meet the enrollment conditions will receive intravenous infusion of anti-CD19 UCAR-NK Cells within 1 week after hematopoietic stem cell infusion.
62083135|NCT04607421|EXPERIMENTAL|Cohort 3 Arm D|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
62083136|NCT04607421|ACTIVE_COMPARATOR|Cohort 3 Arm E|Irinotecan 180 mg/m2 (90-minute IV infusion) every 2 weeks, Leucovorin 400 mg/m2 (120-minute IV infusion) every 2 weeks, 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks, Bevacizumab (optional; given per prescribing instructions)
62083137|NCT01117597|ACTIVE_COMPARATOR|low RF exposure level|Intervention with low RF exposure level SAR 1.5 W/kg
62083138|NCT01117597|SHAM_COMPARATOR|sham RF exposure|Intervention with sham RF exposure
62083139|NCT01117597|ACTIVE_COMPARATOR|high RF exposure level|intervention with high RF exposure level SAR 6W/kg
62083140|NCT05854836|EXPERIMENTAL|CHOICES-PLEAS|Participants in the experimental arm will receive the motivational interviewing intervention, CHOICES-PLEAS which consists of three one-on-one sessions and one family planning referral visit during incarceration and one booster session at one month after release from jail.
62083141|NCT05854836|NO_INTERVENTION|Control condition|Participants in the active comparator will receive a control condition that consists of a booklet with general information about healthy lifestyle for women as well as a referral guide to local resources.
62083142|NCT03857711|ACTIVE_COMPARATOR|Conventional CABG|Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)
62083143|NCT03857711|ACTIVE_COMPARATOR|CABG+ PVI|CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)
62083144|NCT03857711|ACTIVE_COMPARATOR|CABG+ PVI+amiodarone|CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)
62083145|NCT03857711|ACTIVE_COMPARATOR|CABG+amiodarone|CABG+class III antiarrhythmic drug- amiodarone, group, n=70
62083146|NCT06042257|ACTIVE_COMPARATOR|Guanfacine Hydrochloride Immediate Release|Eligible participants will receive GIR for up to 8 weeks. The treatment period will consist of study product administration from day 0 through day 56 with a masked dose-escalation period from day 0 through day 49.
62083147|NCT06042257|PLACEBO_COMPARATOR|Placebo|Eligible participants will receive Placebo for up to 8 weeks.The treatment period will consist of study product administration from day 0 through day 56 with a masked dose-escalation period from day 0 through day 49.
62282219|NCT05689931||Asthma patients without Mepolizumab treatment|Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections
62282220|NCT05689931||Healthy non-asthmatic control subjects|Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling
62282221|NCT03640832|EXPERIMENTAL|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
62282222|NCT03640832|ACTIVE_COMPARATOR|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
62083148|NCT06572930||FSH Monitoring Group|"Women undergoing ovarian stimulation will be given preselected constant gonadotropin dosage and an association between serum FSH (follicular stimulating hormone) levels during stimulation and response will be assessed.~Blood samples will be taken (along with clinical standard routine) on day 2/3 of cycle, day 5 / 8 and 10 of stimulation and on the day of trigger (DoT). Urine samples will be taken additionally.~Final oocyte maturation will be triggered with 250 mcg recombinant human Choriogonadotropin and 0.2 mg Decapeptyl as soon as \>2 follicles reach 17 mm diameter.~Women who have more than 30 follicles ≥12 mm and or serum estradiol levels above\>5000 pg/ml on the day of trigger will only be triggered with Decapeptyl. OPU (oocyte pick up) will be 36 h after trigger.~On the day of oocyte collection (OPU), follicular fluid from the largest follicle will be checked for FSH level after the cumulus oocyte complex is removed."
62083149|NCT05144256|EXPERIMENTAL|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
62083150|NCT05144256|PLACEBO_COMPARATOR|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
62282223|NCT03303911|EXPERIMENTAL|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:~* Days 1-3 (6 times daily)~* Days 4-12 (5 times daily)~* Days 13-16 (4 times daily)~* Days 17-20 (3 times daily)~* Days 21-24 (2 times daily)~* Day 25 (Once daily)"
62282224|NCT03303911|EXPERIMENTAL|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:~* Days 1-3 (6 times daily)~* Days 4-12 (5 times daily)~* Days 13-16 (4 times daily)~* Days 17-20 (3 times daily)~* Days 21-24 (2 times daily)~* Day 25 (Once daily)"
62282225|NCT01448395|EXPERIMENTAL|1|
62282226|NCT03335085|ACTIVE_COMPARATOR|Oxytocin|Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland)
62282227|NCT03335085|PLACEBO_COMPARATOR|Placebo|All ingredients except for oxytocin.
62282228|NCT02061852|ACTIVE_COMPARATOR|Physiotherapy|Traditional techniques
62282229|NCT02061852|EXPERIMENTAL|simeox|Medical device
62282230|NCT05670080|EXPERIMENTAL|The Motor Imagery (MI) Group|"MI training will be prepared using the Microsoft PowerPoint program which includes written, visual and audio materials, as well as features that can be sent to participants ' phones/tablets/computers. The MI training will allow the participant to perform visual and kinesthetic imagery with visual and audible notifications and will include 6 exercises for the muscles around the shoulder, 3 exercises for strengthening, and dynamic stabilization for the muscles around the scapula. In each presentation, verbal cues will be given to explain how to imagine the movement while a visual of the motor movement is displayed on the screen. During MI exercises, participants will be called once a week and their MI practices will be followed up.~After the first four weeks of MI training, the MI group will also participate in a four-week physical therapy program."
62282231|NCT05670080|EXPERIMENTAL|Physical Therapy (PT) Group|"Following the preoperative evaluations, both groups will be shown remedial exercises (pumping exercises that activate the circulation), flexion, and extension wrist exercises, which they should do for four weeks.~After a 4-week immobilization period, participants in the PT Group will begin a physical therapy program that includes routine electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder."
62282232|NCT00602355|PLACEBO_COMPARATOR|1 (Placebo)|Participants receiving placebo pill with clinical management plus mothercrafting
62282233|NCT00602355|ACTIVE_COMPARATOR|2 (Sertraline)|Participants receiving active medication sertraline with clinical management plus mothercrafting
62282234|NCT00602355|ACTIVE_COMPARATOR|3 (IPT)|Participants receiving interpersonal psychotherapy (IPT) alone
62282235|NCT01846286||Newly Diagnosed HNC|For AIM 2 and AIM3, Newly diagnosed and previously untreated patients with locoregional squamous cell carcinoma of the head and neck recruited at MD Anderson: Pain assessed at baseline, weekly during treatment, and during clinic visits (every 6-8 weeks) for a period of 3 months after treatment. Quantitative sensory testing performed at baseline and at 3 months from completion of treatment to determine nociceptive versus neuropathic component.
62282236|NCT02366000|EXPERIMENTAL|Brief Parental Training Intervention|Participants will have to attend two 3-hour Brief Parental Training Intervention Programme, with three weeks apart. There will also be two telephone follow-up sessions to reinforce learnt strategies and skills for home practice between workshops.
62282237|NCT02366000|OTHER|Wait-list Group|Participants will receive the same Brief Parental Training Intervention Programme as the intervention group. However, they will wait until the questionnaires have been completed by the intervention group for the second time (i.e. immediately after intervention) before they receive their programme.
62083151|NCT05144256|EXPERIMENTAL|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the OLE period will first receive blinded mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment before being transitioned to only receive active, open-label drug (mitapivat).
62083152|NCT06137183|EXPERIMENTAL|Vixarelimab Dose Regimen 1|Participants will receive vixarelimab subcutaneously (SC) during the induction period and the optional ATE period.
62458934|NCT05865639|EXPERIMENTAL|Aerobic Exercise|Aerobic exercise for eight weeks. Three weekly, supervised training sessions.
62458935|NCT05865639|EXPERIMENTAL|Time Restricted Fasting|Time restricted fasting for eight weeks. Maximal daily eating window of 8 hours.
62083153|NCT06137183|EXPERIMENTAL|Vixarelimab Dose Regimen 2|Participants will receive vixarelimab SC during the induction period and the optional ATE period.
62282238|NCT01441063|EXPERIMENTAL|Tocilizumab|Tocilizumab 8 mg/kg on Day 1 of a 14 day cycle a maximum of 6 cycles. If indicated, zidovudine (AZT) and valganciclovir (VGC) will be administered concurrently with tocilizumab, with day 1 of the cycle being the day tocilizumab is administered.
62282239|NCT01230879|EXPERIMENTAL|60 - 70 years old|EFR and TDM
62458936|NCT05865639|EXPERIMENTAL|Aerobic exercise & Time Restricted Fasting|
62458937|NCT05865639|NO_INTERVENTION|Control|Will be given information about the recommended level of physical activity for health benefits and a healthy diet.
62083154|NCT06137183|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo SC during the induction period and vixarelimab SC during the optional ATE period.
62083155|NCT05785624|EXPERIMENTAL|DBT: Cohort 1: Vixarelimab|Participants with IPF will receive vixarelimab, subcutaneously (SC), once every two weeks (Q2W) for 52 weeks in the DBT period.
62083156|NCT05785624|PLACEBO_COMPARATOR|DBT: Cohort 1: Placebo|Participants with IPF will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
62282240|NCT01230879|EXPERIMENTAL|71 - 80 years old|EFR and TDM
62282241|NCT01230879|EXPERIMENTAL|81 - 95 years old|EFR and TDM
62458938|NCT00414531|OTHER|SIM|Patients diagnosed to have or not to have Statin induced Myopathy
62458939|NCT03831048|EXPERIMENTAL|DCD Heart Possible|
62458940|NCT03831048|ACTIVE_COMPARATOR|Standard of Care Heart Only|
62458941|NCT01789164||Healthy group|Healthy group with no history of TBI or concussion. Gender matched non-TBI volunteers
62083157|NCT05785624|EXPERIMENTAL|DBT: Cohort 2: Vixarelimab|Participants with SSC-ILD will receive vixarelimab, SC, Q2W for 52 weeks in the DBT period.
62282242|NCT00996203|EXPERIMENTAL|1|
62282243|NCT05753826|EXPERIMENTAL|Adebrelimab Combined With Fuzuloparib|
62282244|NCT04408807|EXPERIMENTAL|Study Group|ROPEE screening with speculum-free fundoscopy
62282245|NCT04408807|ACTIVE_COMPARATOR|Control Group|ROPEE screening with speculum fundoscopy
62282246|NCT00384241||Children|Children age 15-19, self reported as African American of European Origin, healthy non-smoker, with normal blood pressure, exposed to an activity to that results in induced stress
62282247|NCT00384241||Parents|Collection of buccal swab Parent of participants in the Children Arm
62458942|NCT01789164||TBI group|Males and females between 18 and 60 years who have a diagnosis of TBI and are symptomatic with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched non-TBI volunteers
62458943|NCT02115646|EXPERIMENTAL|fractionated carbon dioxide laser|fractionated carbon dioxide laser
62458944|NCT03057392|EXPERIMENTAL|immersion and them sham procedure|"hemodialysis patients will do a 3 hours dialysis session while sitting in a bath and then have a dry session outside the bath"
62458945|NCT03057392|SHAM_COMPARATOR|sham session and then immersion|dialysis patients will have a 3 hour dialysis session (dry session) and then immersion
62458946|NCT02154321||Attention Deficit Hyperactivity Disorder|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
62458947|NCT02154321||Healthy Control|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
62083158|NCT05785624|PLACEBO_COMPARATOR|DBT: Cohort 2: Placebo|Participants with SSC-ILD will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
62083159|NCT05785624|EXPERIMENTAL|OLE Period: Cohort 1: Vixarelimab|Participants with IPF who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
62083160|NCT05785624|EXPERIMENTAL|OLE Period: Cohort 2: Vixarelimab|Participants with SSC-ILD who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
62083161|NCT05195710|EXPERIMENTAL|Yttrium-90|Help to control the tumor(s) on the right side of the liver while the remaining left side of the liver, which is clear of cancer, grows.
62282248|NCT00723788|EXPERIMENTAL|Only one arm|All patients enrolled will receive an MRI of the abdomen with detailed views of the appendix
62282249|NCT03404466|EXPERIMENTAL|experimental group one|10 mg of Hypidone Hydrochloride tablets
62282250|NCT03404466|EXPERIMENTAL|experimental group two|20 mg of Hypidone Hydrochloride tablets
62282251|NCT03891550|EXPERIMENTAL|SOF/VEL|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks
62282252|NCT00600015|EXPERIMENTAL|Combination Therapy|Erlotinib + Sorafenib
62282253|NCT00600015|PLACEBO_COMPARATOR|Placebo|Erlotinib + Placebo
62282254|NCT04428411||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease
62282255|NCT06136936|ACTIVE_COMPARATOR|CT-156|Study app investigational treatment for adult patients diagnosed with schizophrenia.
62282256|NCT06136936|EXPERIMENTAL|CT-156 + UXR|Study app investigational treatment for adult patients diagnosed with schizophrenia with up to five in-patient visits with three interviews for UXR (user experience research) arm.
62458948|NCT05799781|EXPERIMENTAL|MPC Arm|Participants will use the MPC closed-loop system for 7 days using Fiasp insulin. The first 6 hours will be spent in clinic being trained on the system, then eating a meal. Then the participant will take the system home to continue using for 7 days.
62083162|NCT06739343|ACTIVE_COMPARATOR|PHACO-Trabeculectomy Group|"Participants in this group underwent Phaco-Trabeculectomy, a combined surgical procedure that involves phacoemulsification (modern cataract extraction technique) and trabeculectomy (a glaucoma filtration surgery). This procedure is designed to address both cataract removal and intraocular pressure (IOP) reduction in a single surgery.~Interventions:~Phacoemulsification: Ultrasound-based cataract removal. Trabeculectomy: Creation of a filtration bleb to lower IOP."
62083163|NCT06739343|ACTIVE_COMPARATOR|MSICS-Trabeculectomy Group|"Participants in this group underwent Manual Small Incision Cataract Surgery (MSICS) combined with trabeculectomy. This procedure, which uses a manual technique for cataract extraction, is often more cost-effective and suitable for resource-limited settings while also addressing IOP reduction.~Interventions:~Manual Small Incision Cataract Surgery (MSICS): A manual extracapsular cataract extraction technique.~Trabeculectomy: Same filtration procedure as in the Phaco-Trabeculectomy group to manage glaucoma."
62083164|NCT05601726|EXPERIMENTAL|Single Administration Dose (SAD) of ABD-3001|Dose escalation of 6 doses level using a 3+3 design.
62083165|NCT05601726|EXPERIMENTAL|Multiple Administration Dose (MAD) of ABD-3001|3 doses regimens in parallel during 3 cycles of 28 days
62083166|NCT06740682|NO_INTERVENTION|Control Group|
62083167|NCT06740682|ACTIVE_COMPARATOR|Potcost Stories|
62083168|NCT02367014|EXPERIMENTAL|Low Dose|elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
62282257|NCT02574533|EXPERIMENTAL|Vigil™ + Pembrolizumab|"Biological: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens.~Drug: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter"
62282258|NCT05563896||China|We plan to enroll 200 healthy adults in this study at five different international sites (China, Iran, Kenya, Senegal, UAE). Forty subjects will be enrolled at each site. Previous studies showed energy requirements varied with sex and age of the participants. Therefore, in each site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
62282259|NCT05563896||Sénégal|Forty subjects will be enrolled at Senegal site.In Senegal site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
62282260|NCT05563896||Kenya|Forty subjects will be enrolled at Kenya site.In Kenya site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
62282261|NCT05563896||United Arab Emirates|Forty subjects will be enrolled at UAE site.In UAE site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
62282262|NCT05563896||Iran|Forty subjects will be enrolled at Iran site.In Iran site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
62282263|NCT01565980|ACTIVE_COMPARATOR|symptom assessment|6 weeks of symptom assessment phone calls.
62282264|NCT01565980|EXPERIMENTAL|Mindfulness intervention|Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
62282265|NCT04995874|EXPERIMENTAL|Intervention|KOKOPlus protein and micronutrient powder , a complementary food supplement containing soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix was formulated. Two weeks' supply of KOKOPlus sachets will be given to intervention arm participants every fortnight for 6 months to be mixed into any cereal, soup, stew, or other food given to the children.
62083169|NCT02367014|EXPERIMENTAL|Intermediate dose|elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
62083170|NCT02367014|EXPERIMENTAL|High dose|elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
62083171|NCT02367014|PLACEBO_COMPARATOR|Placebo|In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
62083172|NCT06560138|EXPERIMENTAL|SHR-4602 Dose level 1 : 2.0 mg/kg, Dose level 2 : 2.5mg/kg|
62083173|NCT05471843|EXPERIMENTAL|Single Arm|Participants will receive sonrotoclax
62083174|NCT05540665|EXPERIMENTAL|Daxdilimab Arm 1|Daxdilimab injections over a total of 104 weeks
62083175|NCT05540665|EXPERIMENTAL|Daxdilimab Arm 2|Daxdilimab injections over a total of 104 weeks
62083176|NCT05540665|PLACEBO_COMPARATOR|Placebo|Placebo injections over a total of 104 weeks
62083177|NCT01155726|ACTIVE_COMPARATOR|Nelfilcon A, Masked, Unmasked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
62083178|NCT01155726|ACTIVE_COMPARATOR|Nelfilcon A, Masked, Partially Masked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
62282266|NCT04995874|NO_INTERVENTION|Control|This arm will receive no supplement and no placebo for the duration of the study.,
62282267|NCT03831568||Children with given device for mechanical cough|
62282268|NCT05320575|EXPERIMENTAL|zanubrutinib|
62650176|NCT04271215||Overweight/Obesity|BMI at diagnosis will be used. Using WHO software (version 3.2.2, World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient. According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999), overweight (2 to 2.9999) and obesity (≥3). In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999), underweight (\< p5), overweight (p85-94.9999), and obese (≥ p95). The nutritional classification and measurements regarding weight and height recorded in clinical files will be used to classify patients' nutritional status in present research has been previously described.
62083179|NCT01155726|ACTIVE_COMPARATOR|Etafilcon A, Masked, Unmasked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
62083180|NCT01155726|ACTIVE_COMPARATOR|Etafilcon A, Masked, Partially Masked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
62282269|NCT03789591|ACTIVE_COMPARATOR|Standard Arm|Participants randomized to the standard arm will receive a starting dose of hydroxyurea of 20 mg/kg/day.
62083181|NCT06724432|EXPERIMENTAL|Melatonin arm|Mel treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg). Melatonin (Dicoson, Dicofarm, Italy) is prepared by a dedicated resident in a fixed volume of 5 mL by adding water to a syringe without a needle.
62083182|NCT06724432|PLACEBO_COMPARATOR|Control arm|Children in the Control group receive 5 ml of 5% dextrose solution.
62282270|NCT03789591|EXPERIMENTAL|Alternative Arm|Participants randomized to the alternative arm will receive a pharmacokinetic guided starting dose of hydroxyurea based on PK labs drawn at a baseline visit to target an area under the curve (AUC) of 115 mg\*h/L in an attempt to approximate maximum tolerated dose (MTD). This dose will not exceed the maximum tolerated dose of 35 mg/kg/day.
62282271|NCT01746771|EXPERIMENTAL|HM781-36B, Paclitaxel, Trastuzumab|HM781-36B(Poziotinib): QD\*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg
62282272|NCT02509091|EXPERIMENTAL|The experimental group|fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
62282273|NCT02509091|NO_INTERVENTION|The controlled group|fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)
62282274|NCT04615143|EXPERIMENTAL|Tislelizumab|Tislelizumab is one kind of PD-1 inhibitors. Patients enrolled will receive Tislelizumab as neoadjuvant treatment before surgery (200mg q3w\*2 cycles) and as adjuvant treatment after surgery for 1 year
62282275|NCT04615143|EXPERIMENTAL|Tislelizumab Combined Lenvatinib|Patients enrolled will receive Tislelizumab combined Lenvatinibas neoadjuvant treatment before surgery (Tislelizumab: 200mg q3w\*2 cycles+Lenvatinib 8/12mg qd\*4weeks) and as adjuvant treatment after surgery for 1 year
62282276|NCT01926184|EXPERIMENTAL|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
62282277|NCT01926184|PLACEBO_COMPARATOR|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
62282278|NCT05630157|EXPERIMENTAL|Unplugged plus gambling component|The experimental arm will receive the Unplugged curriculum plus a gambling component
62650177|NCT04322136|OTHER|IPC (with talc pleurodesis if suitable)|"The patients will undertake daily drainage to day 14 post insertion. The drainage will either be performed by the participant's carer or nurses in the community. A bottle or bag will be attached to the drain to allow for removal of accumulated pleural fluid. Once completed the drain will be reattached to the pleural catheter.~Participants will be taught how to perform pleural drainage by the main study doctor at the hospital or a specialist nurse. They will drain their own IPCs at home with the either the help of a family member or friend or have access to community nursing support systems."
62282279|NCT05630157|NO_INTERVENTION|Usual curriculum|The Usual curriculum arm won't receive any specific prevention program
62083183|NCT05157204||adult 20 patients with moderate to severe covid-19|adult 20 covid-19 patients with moderate to severe covid-19. for measurment of interleukin-6 from exhaled condensate during first 10 days of postive PCR
62083184|NCT05157204||20 healthy controls adult non pregnant humans f|20 healthy adults above 18 years non pregnant for measurment of interleukin-6 from exhaled condensate
62282280|NCT01653041|EXPERIMENTAL|Everolimus|Single arm
62282281|NCT03633357|EXPERIMENTAL|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
62282282|NCT03633357|PLACEBO_COMPARATOR|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
62282283|NCT04270760|ACTIVE_COMPARATOR|Arm 1 Olpasiran Dose 1|
62282284|NCT04270760|ACTIVE_COMPARATOR|Arm 2 Olpasiran Dose 2|
62282285|NCT04270760|ACTIVE_COMPARATOR|Arm 3 Olpasiran Dose 3|
62282286|NCT04270760|ACTIVE_COMPARATOR|Arm 4 Olpasiran Dose 4|
62083185|NCT05157204||adult 20 patients with moderate to severe postcovid-19|adult 20 post covid-19 patients with moderate to severe covid-19 for measurment of interleukin-6 from exhaled condensate
62083186|NCT06276140||Iron deficiency anaemia|Defined as: decreased serum iron concentration and TSAT, increased TIBC, UIBC, as well as decreased haemoglobin concentration (HGB)
62083187|NCT06276140||Iron deficiency in the latent phase|Defined as: decreased serum iron concentration and TSAT, increased TIBC, UIBC, as well as normal HGB
62282287|NCT04270760|PLACEBO_COMPARATOR|Arm 5 Placebo Dose 5|
62282288|NCT02380755|PLACEBO_COMPARATOR|Placebo|One pill every other day during 12 weeks
62282289|NCT02380755|ACTIVE_COMPARATOR|Clomiphene Citrate|Clomiphene citrate 50 mg orally daily (Serophene) during 12 weeks
62282290|NCT06011720||Stroke Patients July 1st 2015 - June 30th 2017|Stroke patients that have undergone hospitalization within the time frame July 1st 2015 - June 30th 2017 to be used as a baseline.
62458949|NCT05799781|ACTIVE_COMPARATOR|Control IQ arm|Participants will continue their normal diabetes regimen which includes the t:slim X2 pump with Dexcom G6 CGM and Control IQ for 7 days. Participants will share their pump download and Dexcom Clarity data with study staff after the 7 days is complete.
62458950|NCT03299400|EXPERIMENTAL|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
62282291|NCT06011720||Stroke Patients January 1st 2018 - December 31st 2019|Stroke patients that have undergone hospitalization and undergone improvements to transition of care within the time frame January 1st 2018 - December 31st 2019.
62458951|NCT05556109||Epileptic seizure|patients diagnosed as epileptic seizure are aged \>12 years
62458952|NCT05556109||Psychogenic non-epileptic seizure|patients diagnosed as psychogenic non-epileptic seizure are aged \>12 years
62083188|NCT06276140||Control group|Defined as: normal serum iron concentration, TSAT, TIBC, UIBC and HGB
62083189|NCT05644561|EXPERIMENTAL|Ravulizumab Intravenous (IV) Infusion|All participants will receive a weight-based loading dose of ravulizumab IV on Day 1, followed by weight-based maintenance dose of ravulizumab on Day 15 and once every 8 weeks (q8w) thereafter for participants weighing ≥ 20 kg, or once every 4 weeks (q4w) for participants weighing \< 20 kg, for a total of 122 weeks of treatment.
62083190|NCT06391242|ACTIVE_COMPARATOR|Standard Conventional Radiotherapy|
62083191|NCT06391242|EXPERIMENTAL|Stereotactic Body Radiotherapy|
62282292|NCT00002944|EXPERIMENTAL|Regimen A (CV Chemotherapy)|Induction will consist of 10 weeks of therapy (carboplatin, vincristine sulfate),followed by 2 weeks without chemotherapy. Induction should only be interrupted in the event of grade 3 neurotoxicity, grade 2 renal toxicity, grade 4 hematologic toxicity, or tumor progression. Maintenance-Four Courses (2 cycles/course) commences on Day 84 (week 12) of Induction or when peripheral counts recover with ANC \>1,000/$L and platelet count \>100,000/$L. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine sulfate (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
62458953|NCT05556109||Normal healthy control|Heathy control are aged \>12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw
62650178|NCT04322136|OTHER|Pleurodesis via VATS|Participants will undergo VATS within two weeks of randomisation. VATS is usually performed in an operating theatre, using either general anaesthesia or local anaesthesia with sedation. The pleural fluid will be removed and adhesions can be divided (adhesiolysis). Assessment of lung re-expansion will be performed intra-operatively. If lung re-expansion is adequate (as judged by the operating surgeon), a variety of techniques may be employed to induce a pleurodesis, including, but not limited to, talc poudrage and mechanical abrasion. Decortication may be performed if deemed appropriate and feasible by the operating surgeon. A chest drain will be left in situ after the surgery. Post-operative care will be administered as per local practice.
62650179|NCT00490035|PLACEBO_COMPARATOR|Placebo|Matching Placebo tablets administered twice a day
62650180|NCT00490035|EXPERIMENTAL|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
62083192|NCT06525220|EXPERIMENTAL|Petosemtamab + Pembrolizumab|Combination Therapy
62083193|NCT06525220|ACTIVE_COMPARATOR|Pembrolizumab|Monotherapy
62458954|NCT02689297|OTHER|group A|Mouthwash (chlorine dioxide 12ml two times per day, for three weeks)
62083194|NCT00811148||Tissue Bank|Collection of clinical data and tumor tissue removed during brain surgeries for future research.
62458955|NCT02689297|OTHER|group B|Small toothbrush for tongue cleaning two times per day for three weeks
62083195|NCT05389319|EXPERIMENTAL|Cohort 1|Prime-2-CoV_Beta, dose: 30 000 PFUs
62083196|NCT05389319|EXPERIMENTAL|Cohort 2|Prime-2-CoV_Beta, dose: 300 000 PFUs
62083197|NCT05389319|EXPERIMENTAL|Cohort 3|Prime-2-CoV_Beta, dose: 3 000 000 PFUs
62083198|NCT05389319|EXPERIMENTAL|Cohort 4|Prime-2-CoV_Beta, dose: 150 000 000 PFUs
62083199|NCT05389319|EXPERIMENTAL|Cohort 5|Prime-2-CoV_Beta, dose: 30 000 000 PFUs
62083200|NCT06425029|EXPERIMENTAL|Music Piece A|Participants will be asked to listen to a musical excerpt previously shown to have a positive effect on epileptic activity in human brain.
62458956|NCT02782624|EXPERIMENTAL|Treatment A: Empagliflozin|5 mg bid
62458957|NCT02782624|EXPERIMENTAL|Treatment B: Empagliflozin|10 mg qd
62458958|NCT00591643|EXPERIMENTAL|Imaging, Adrenal acans & Radiation|
62650181|NCT00490035|EXPERIMENTAL|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
62650182|NCT00490035|EXPERIMENTAL|Brivaracetam 100 mg/day|Brivaracetam 100 mg/day, 50 mg administered twice a day
62282293|NCT00002944|EXPERIMENTAL|Regimen B (TPCV Chemotherapy)|Each cycle of chemotherapy consists of 4 days of oral chemotherapy (Thioguanine, procarbazine hydrochloride, Lomustine and Vincristine sulfate beginning Day 0, followed by vincristine sulfate IV on Days 14 and 28. The cycle is repeated every 6 weeks (42 days). A total of 8 cycles will be given.
62282294|NCT01715584|OTHER|Angiotensin Converting Enzyme Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm.~Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)"
62282295|NCT01715584|OTHER|Angiotensin Receptor Blocker Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs).~Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)"
62282296|NCT01715584|OTHER|Non ACE/ARB Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm."
62282297|NCT04550130|EXPERIMENTAL|low dose (1.8 L)|Patients in this arm will be treated with one column (Leukapheresis) and 1.8 L blood will be filtered.
62650183|NCT02152007|EXPERIMENTAL|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
62282298|NCT04550130|EXPERIMENTAL|high dose (3.6 L)|Patients in this arm will be treated with Two column (Leukapheresis) and 3.6 L blood will be filtered.
62650184|NCT00329108|EXPERIMENTAL|A|
62650185|NCT00329108|ACTIVE_COMPARATOR|B|
62650186|NCT02629783|EXPERIMENTAL|Physiotherapy + Corticosteroid injection + Psychomotor therapy|Usual care + intervention
62650187|NCT02629783|ACTIVE_COMPARATOR|Physiotherapy + Corticosteroid injection|Usual care
62083201|NCT06425029|ACTIVE_COMPARATOR|Music Piece B|Participants will be asked to listen to a musical except very similar to the experimental stimuli that has not been shown to have a positive effect on epileptic activity.
62282299|NCT01884831|EXPERIMENTAL|cell therapy|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
62282300|NCT04290702|ACTIVE_COMPARATOR|epidural|
62282301|NCT04290702|ACTIVE_COMPARATOR|combined|
62282302|NCT04290702|ACTIVE_COMPARATOR|dural puncture epidural|
62282303|NCT05278182|EXPERIMENTAL|Naoxintong Capsule|Naoxintong Capsule
62650188|NCT01308619|ACTIVE_COMPARATOR|Oracea®|Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
62650189|NCT01308619|ACTIVE_COMPARATOR|placebo|placebo
62282304|NCT05278182|PLACEBO_COMPARATOR|Placebo|Placebo
62282305|NCT01592760|EXPERIMENTAL|air-Q SP|air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
62282306|NCT01592760|ACTIVE_COMPARATOR|air-Q|air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
62282307|NCT01592760|ACTIVE_COMPARATOR|i-gel|i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA)
62650190|NCT02693067|EXPERIMENTAL|PV-10|Intralesional rose bengal disodium (PV-10) to one or more neuroendocrine tumor metastases to the liver
62650191|NCT05774314|EXPERIMENTAL|Community Health Worker Intervention|
62282308|NCT06158646|EXPERIMENTAL|patients with kinematic aligned knee prosthesis|
62650192|NCT05774314|NO_INTERVENTION|No Community Health Worker Intervention|
62650193|NCT01712711|NO_INTERVENTION|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
62650194|NCT01712711|EXPERIMENTAL|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
62650195|NCT04297020||Pre-menopausal BCS + ET|Pre-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
62083202|NCT06425029|ACTIVE_COMPARATOR|Music Piece C|Participants will select a preferred excerpt from several popular musical genres. This piece is modified to have some similarities to the experimental musical excerpt.
62083203|NCT06163547|NO_INTERVENTION|Arm 1 - Surgery - No embolization (control)|Patients who undergo surgical treatment will be randomized into receiving embolization within 72 hours post-surgery (Arm 2) or no-embolization post-surgery (conventional management, Arm 1). Patients will be randomized at rate of 2 MMA embolization to 1 conventional management.
62083204|NCT06163547|EXPERIMENTAL|Arm 2 - Surgery - MMA embolisation|Patients who undergo surgical treatment will be randomized into receiving embolization within 72 hours post-surgery (Arm 2) or no-embolization post-surgery (conventional management, Arm 1). Patients will be randomized at rate of 2 MMA embolization to 1 conventional management.
62083205|NCT06163547|ACTIVE_COMPARATOR|Arm 3 - No surgery - Embolization accepted|Patients who are excluded for surgery due to significant medical contraindications or patients who refuse surgery, will be considered for embolization only. Embolization accepted : Arm 3.
62083206|NCT06163547|NO_INTERVENTION|Arm 4 - No surgery - Embolization not accepted|Patients who are excluded for surgery due to significant medical contraindications or patients who refuse surgery, will be considered for embolization only. Embolization refused : Arm 4.
62083207|NCT01925781|EXPERIMENTAL|e-Cigarette|STAM 1100mAh CE4 eGo Clearomizer e-Cigarette
62083208|NCT01925781|ACTIVE_COMPARATOR|Nicotine polacrilex|Nicotine Replacement gum
62083209|NCT05980949|EXPERIMENTAL|KarXT|Xanomeline and Trospium Chloride Capsules
62083210|NCT00737061|EXPERIMENTAL|Adiana Transcervical Sterilization System|Single arm treatment
62282309|NCT06158646|ACTIVE_COMPARATOR|patients with biomechanic aligned knee prosthesis|
62282310|NCT01246544||Data collection group: physicians|Online survey for physicians/members of the innovation alliance Berlin-Brandenburg (INABBRA)
62282311|NCT02733874|EXPERIMENTAL|test group|Compound Clobetasol Propionate Ointment
62083211|NCT05561764|EXPERIMENTAL|Imipenem/cilastatin/relebactam|Adult participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with the current prescribing information and according to estimated renal function. Adolescent participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with Phase I data \[37.5 (15/15/7.5) mg/kg, up to a maximum dose of 1.25g\]. Each dose will be infused over 30 minutes.
62083212|NCT06737822|ACTIVE_COMPARATOR|Surg Arm|Wide Local Excision (WLE) with Comprehensive neck dissection Adjuvant Treatment as per current standard Guidelines
62083213|NCT06737822|EXPERIMENTAL|ICT Arm|2# of Chemotherapy before the Stadrard Surery: Either TPF or TPX Wide Local Excision (WLE) with Comprehensive neck dissection Adjuvant Treatment as per current standard Guidelines
62083214|NCT02146950||LCS12|New users of LCS12
62083215|NCT02146950||Mirena|New users of Mirena
62282312|NCT02733874|ACTIVE_COMPARATOR|control group|Calcipotriol Betamethasone Ointment
62282313|NCT06540469|EXPERIMENTAL|Iodine Supplementation in Whole Course of Treatment with ATDs|
62282314|NCT06540469|EXPERIMENTAL|Iodine Supplementation During Maintenance Treatment with ATDs|
62282315|NCT06540469|OTHER|Iodine Restriction in Whole Course of Treatment with ATDs|
62282316|NCT03043833|EXPERIMENTAL|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
62650196|NCT04297020||Post-menopausal BCS + ET|Post-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
62650197|NCT04297020||Pre-menopausal Healthy Control|Pre-menopausal healthy control group
62650198|NCT04297020||Post-menopausal Healthy Control|Post-menopausal healthy control group
62650199|NCT03380286||Coronary Stenosis|
62650200|NCT04773132|EXPERIMENTAL|Low Protein Diet|All subjects will be given a low protein/protein-free diet in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
62650201|NCT04295252||cardiogenic shock patients|All-comers cardiogenic shock patients Admitted to the Intensive Coronary Care Units
62650202|NCT00963508|EXPERIMENTAL|Malathion Gel|Malathion gel 0.5% 30 minute application
62650203|NCT00963508|ACTIVE_COMPARATOR|Nix Crème Rinse|Nix Crème Rinse applied to scalp for 10 minutes
62083216|NCT02146950||Copper IUD|New users of copper IUDs
62458959|NCT06315179||Inflammatory Bowel Disease|"Participants will enroll before their initial diagnostic procedure. After pathology results are reported, participants will be categorized based on the assigned diagnoses: Inflammatory Bowel Disease (IBD) \[Crohn's disease (CD), ulcerative colitis (UC), and Indeterminate Colitis (IC)\] vs Disorders of the Brain-Gut Interactions (DGBI).~Participation in the IBD cohort will last for three years."
62282317|NCT03043833|NO_INTERVENTION|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
62282318|NCT01817738|ACTIVE_COMPARATOR|CV9104|CV9104 intradermal injection
62282319|NCT01817738|PLACEBO_COMPARATOR|Placebo|Placebo intradermal injection
62282320|NCT06548867||Group A: long-lasting responders|Patient long-lasting responders (PFS ≥9 months) to cabozantinib
62282321|NCT06548867||Group B: primary refractories|Patient progressed from the start to cabozantinib therapy within 3 months
62458960|NCT06315179||Disorders of the Brain-Gut Interactions|"Participants will enroll before their initial diagnostic procedure. After pathology results are reported, participants will be categorized based on the assigned diagnoses: Inflammatory Bowel Disease (IBD) \[Crohn's disease (CD), ulcerative colitis (UC), and Indeterminate Colitis (IC)\] vs Disorders of the Brain-Gut Interactions (DGBI).~-The DGBI cohort will be subdivided into: Esophageal Disorder, Gastroduodenal Disorder, Bowel Disorder, Centrally Mediated Disorders of GI Pain, Gallbladder and Sphincter of Oddi Disorder, Anorectal Disorder, Childhood Functional GI Disorders: Neonate/Toddler, Childhood Functional GI Disorders: Child/Adolescent~Participation in the DGBI cohort will include the initial sample and data collection as well an one further medical record extraction at month 24."
62458961|NCT05474248|EXPERIMENTAL|Diaphragmatic Breathing Training|The experimental group will undergo the diaphragmatic breathing training assisted with StressEraser to breath slowly 4-6 times per minute and practice 15 minutes twice daily.
62458962|NCT05474248|NO_INTERVENTION|Control group|Usual care
62458963|NCT02945215|EXPERIMENTAL|IBI301|
62650204|NCT05346029|NO_INTERVENTION|Standard of care|Patients will be followed-up according to standard clinical practices
62650205|NCT05346029|EXPERIMENTAL|Lifestyle intervention|Patients will undergo a 12 week lifestyle intervention (physical therapy and nutritional assessment)
62083217|NCT02146950||Kyleena|New users of Kyleena
62083218|NCT02146950||Other hormonal IUD (OHIUD)|New users of other hormonal IUDs (e.g. Levosert, Fibroplant)
62282322|NCT04418856|EXPERIMENTAL|Experimental light: Breast cancer surgery and chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
62083219|NCT05215600||Anaverse Shoulder System subjects|Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed.
62083220|NCT00186147||Graft recipients and donors|
62282323|NCT04418856|ACTIVE_COMPARATOR|Comparison Light:Breast cancer surgery and chemotherapy|Exposed to comparison systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
62282324|NCT04418856|EXPERIMENTAL|Experimental light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
62282325|NCT04418856|ACTIVE_COMPARATOR|Comparison light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
62650206|NCT03220503|EXPERIMENTAL|Group (A)|consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.
62083221|NCT04421014|ACTIVE_COMPARATOR|Ketone Ester drink/ Arm 1|25 participants
62083222|NCT04421014|PLACEBO_COMPARATOR|Placebo/ Arm 2|25 participants
62083223|NCT06738056||Nerivio users|Patient with migraine who were prescribed for treatment with the Nerivio REN device from 2019 to 2024
62083224|NCT06728462|OTHER|A arm|Subject who meet National Health Insurance (NHI) reimbursement criteria for use of denosumab
62083225|NCT06728462|OTHER|B arm|Subject who does not meet NHI reimbursement criteria for use of denosumab, or who is no willing to receive denosumab treatment during study period, even meet NHI reimbursement criteria
62083226|NCT06197295|EXPERIMENTAL|Solifenacin with vaginal estrogen cream|Solifenacin 5mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.
62083227|NCT06197295|ACTIVE_COMPARATOR|Combination pharmacotherapy|Combined solifenacin 5mg and mirabegron 25mg once per day.
62083228|NCT06740422|EXPERIMENTAL|Xuanhuang Runtong Tablet group|Xuanhuang Runtong Tablet, 4 tablets (1.84 g herb per tablet) per dose, three times a day
62458964|NCT02945215|ACTIVE_COMPARATOR|Rituximab|
62083229|NCT06740422|PLACEBO_COMPARATOR|Placebo group|Xuanhuang Runtong Tablet Simulator, 4 tablets (0 g herb content per bottle) per dose, three times a day
62083230|NCT04221542|EXPERIMENTAL|Part 1: AMG 509 Intravenous (IV) Monotherapy|"Part 1 will evaluate AMG 509 in participants with metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with novel hormonal therapy (NHT) and 1 to 2 prior taxanes.~The dose exploration phase of the study will estimate the MTD of AMG 509 using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).~RP2D may be identified based on emerging safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) data, as well as patient experience prior to reaching an MTD. Alternative dosing schedule(s) (including a third step dose) may be explored based on emerging efficacy, safety, PK data and patient experience.~During the dose expansion phase, individual cohorts of participants from China will be enrolled with a safety lead-in at 1 dose level below the MTD or RP2D followed by evaluation at the MTD or RP2D to confirm the safety, tolerability, MTD and/or RP2D of AMG 509 in Chinese participants."
62650207|NCT03220503|NO_INTERVENTION|Group (B)|consists of 25 patients will receive frozen embryo without endometrial scratching as control group.
62083231|NCT04221542|EXPERIMENTAL|Part 2: AMG 509 Subcutaneous (SC) Monotherapy|"Part 2 will explore the safety, tolerability, and PK of AMG 509 SC dosing in participants with mCRPC who have been previously treated with NHT and 1 to 2 prior taxanes.~Recommended phase 2 dose for SC monotherapy may be identified based on emerging safety, efficacy, PK, and PD data, as well as patient experience prior to reaching an MTD."
62282326|NCT04418856|NO_INTERVENTION|Healthy control group|The healthy control group and the breast cancer patients undergo the same assessments (questionnaires, neuropsychological assessments and actigraphy) at the same time points
62458965|NCT01666730|EXPERIMENTAL|Treatment (metformin hydrochloride, FOLFOX)|Patients receive metformin hydrochloride PO BID on days 1-14 and FOLFOX therapy comprising leucovorin calcium IV over 120 minutes, fluorouracil IV continuously over 46 hours, and oxaliplatin IV over 120 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62458966|NCT01171690|EXPERIMENTAL|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
62650208|NCT05557864|EXPERIMENTAL|Parkinson's disease with DBS|Participants will have a diagnosis of idiopathic PD and have undergone/will undergo neurosurgery to implant deep brain stimulators in the globus pallidus (GP DBS) or subthalamic nucleus (STN)
62282327|NCT04687644|EXPERIMENTAL|Online Education|The education program developed within the scope of the research consists of five modules. In order to use the question and answer method in education, to make the education interactive and to receive feedback, 4 separate training groups of 7 people will be formed. The training will take place on the online platform, not face to face. Midwives will be contacted by phone and / or e-mail and the researcher will give a brief information about the research after introducing himself. A social media group will be created for each training group in order to communicate, announce trainings and inform changes.
62282328|NCT04687644|ACTIVE_COMPARATOR|Control|Midwives who attend the online forms of study will complete the survey. In the survey there are demographic and their view about woman centred care question forms. There are also Patient Centred Care Competency Scale and Minnesota Job Satisfaction Questionnaire. They will complete the survey.
62458967|NCT03934073|EXPERIMENTAL|DEXTRAIN|The DexTrain group sessions will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting dexterity components.
62458968|NCT03934073|ACTIVE_COMPARATOR|CONVENTIONNELLE|Conventional training involving stretching of the spastic muscles as well as a set of exercises conventionally used in the protocols of post-stroke rehabilitation (repeated movements, manipulation of objects).
62458969|NCT03934073|OTHER|CONTROLE|To compare the results of SMT and functional MRI.
62458970|NCT01867723|EXPERIMENTAL|Internet communication application|Experiment 1 Effect of internet support program on cancer patients and their caregivers
62282329|NCT01459536||Rotator Cuff Tear-surgical|
62282330|NCT01459536||Health Older Adult Control|
62282331|NCT01459536||Rotator cuff tear - non surgical|
62458971|NCT01867723|NO_INTERVENTION|Control group|Control group get usual care
62458972|NCT03842306||Study Cohort|Patients undergoing rapid sequence intubation in the emergency department for which end tidal oxygen was monitored.
62282332|NCT01428401|EXPERIMENTAL|Arm A|
62282333|NCT01428401|PLACEBO_COMPARATOR|Arm B|
62282334|NCT06218472||Day hospital patient|Acceptance of the DH program (DH group): scheduling of 10 to 12 sessions over 12 weeks during a program session, followed by a reassessment at the end of the program. Outpatient follow-up thereafter.
62461777|NCT02885077|SHAM_COMPARATOR|H-IMT sham + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). The sham group will perform for 12 weeks with two sessions per week. The protocol will consists of five series with ten repetitions with two minutes and will train at a constant inspiratory load of no more than 10% of their initial Pimax.
62461778|NCT04672291|EXPERIMENTAL|Safety Cohort|A randomized (4:1) initial safety cohort of 13 patients will receive 2 cycles of drug (N=10) or placebo (N=3)
62650209|NCT05563558|EXPERIMENTAL|Study Arm|6 cycles of Pembrolizumab+Cabazitaxel+Carboplatin + 15 cycles of Pembrolizumab
62650210|NCT04896671|EXPERIMENTAL|Intervention group|Each participant joins a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes.
62282335|NCT06218472||Outpatient|"Refusal or inability to participate in the DH program: multidisciplinary follow-up as usual within the service (outpatient group)."
62282336|NCT06218472||Parents|
62458973|NCT05124574||mothers infected with SARS-COV-2 at the time of delivery.|"Maternal-fetal transmission of SARS-COV-2 is likely and may require co-expression of the virus receptor (ACE2) and at least one activator of virus internalization (TMPRSS2 and/or cathepsin) in a cell to make it susceptible to SARS-COV-2 infection.~To confirm these hypotheses, it is necessary to explore these mechanisms of fetal transmission in a larger number of mothers infected with SARS -CoV-2 at the time of delivery.~Informed information will be given in the delivery room, initially orally by the midwives, to any mother presenting with an SARS-COV-2 infection (symptomatic or not) (whatever the variant involved). An information leaflet will also be given to the patient and consent will be systematically obtained."
62458974|NCT04276883|EXPERIMENTAL|120 Micrograms|Sublingual film containing 120 Micrograms Dexmedetomidine
62282337|NCT01974609|EXPERIMENTAL|Narcotic|Hydrocodone + acetaminophen 4 times per day 1 week after surgery
62282338|NCT01974609|ACTIVE_COMPARATOR|non-narcotic|ibuprofen + acetaminophen 4 times per day 1 week after surgery
62282339|NCT04623645|EXPERIMENTAL|ultrasound group|patient using ultrasound technique.probe will be placed over submandibular area, the thyrohoid muscle and thyrohyoid membrane will be identified between greater horn fo hyoid bone and thyroid cartilage , 3 ml of lignocaine will be placed on space between thim and the procedure will repeated on contra lateral side.
62282340|NCT04623645|ACTIVE_COMPARATOR|anatomical blind group|patient using anatomical land mark technique, internal branch of superior laryngeal nerve will be blocked slightly anterior to greater horn of hyoid bone . by 3 ml lignocaine . the procdure will be repeated on contra lateral side .
62650211|NCT04896671|NO_INTERVENTION|Waitlist control group|They receive no treatments.
62282341|NCT00728221|PLACEBO_COMPARATOR|1|Placebo capsules (3g)
62282342|NCT00728221|EXPERIMENTAL|2|Whole Korean Red Ginseng root (3g)
62282343|NCT00728221|EXPERIMENTAL|3|Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
62282344|NCT00728221|EXPERIMENTAL|4|Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
62282345|NCT03246633|OTHER|Perceptual Training|Single-Arm study, all participants will receive educational training via online modules and will be assessed after completion of the training.
62650212|NCT02327845||Affected|Affected with any of the diseases that are the focus of study by the CReATe Consortium, including ALS, ALS-FTD, HSP, PLS, PMA and MSP.
62650213|NCT02327845||Unaffected|Unaffected family members of enrolled affected individuals.
62282346|NCT00883675|EXPERIMENTAL|Treatment|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
62282347|NCT02065453|OTHER|Disposable Device - Left & Reusable Devices - Right|One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien).
62282348|NCT02065453|OTHER|Disposable Device - Right & Reusable Devices - Left|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
62650214|NCT04424979|EXPERIMENTAL|High power prisms|Various configurations of high power prisms will be developed for each individual and custom fit into spectacles lenses.
62282349|NCT00364689|EXPERIMENTAL|lactulose given with a placebo (sugar pill)|
62282350|NCT00364689|EXPERIMENTAL|lactulose given with rifaximin|
62282351|NCT00364689|ACTIVE_COMPARATOR|rifaximin given alone|
62282352|NCT03611426|EXPERIMENTAL|rhThrombin ( Topical )|Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
62282353|NCT03611426|PLACEBO_COMPARATOR|placebo|Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy;
62650215|NCT00825240||Cancer Survivorship Study|Survey of colorectal cancer patients within one year from treatment end.
62650216|NCT04776603||Group 1|group 1 includes patients who axial length(AL)\<26mm
62650217|NCT04776603||Group 2|group 2 includes patients who axial length（AL）≥26mm
62650218|NCT02283398|EXPERIMENTAL|with RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
62650219|NCT02283398|SHAM_COMPARATOR|without RIPC|the cuff will be placed around the left arm without being inflated
62282354|NCT02342132|EXPERIMENTAL|Respiratoy Therapy Devices|Non-Invasive Bipap Ventilator, Mechanical Insufflator-Exsufflator, and High Frequency Percussive Oscillator are the three respiratory therapy devices that all participants will be using in a random order, in three consecutive days, one device per day.
62282355|NCT02404103|ACTIVE_COMPARATOR|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
62282356|NCT02404103|ACTIVE_COMPARATOR|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
62282357|NCT01120119|EXPERIMENTAL|Calcitriol|
62282358|NCT01120119|PLACEBO_COMPARATOR|placebo|
62282359|NCT06092294|EXPERIMENTAL|Tactical training in numerical superiority and numerical inferiority|"Participants will carry out a specific training program, with the objective of improving both offensive and defensive Tactical-Technical Actions (ATT) that will allow the increase of effectiveness indexes (EI) (offensive and defensive). The formats through which will train are Small Sided Games (SSGs) and ATT 2 against 1, 3 against 2 and 4 against 3 alternating them during the week (SSGs on Tuesdays and ATT on Thursdays).~The characteristics of this training program are: training frequency 5 times/week, plus 1 competition on weekends, frequency of stimulation of the SSGs and ATT of numerical superiority and numerical inferiority 2 times/week, the specific training time assigned to the development of these formats and exercises will be 30 to 42 minutes/training session and will be carried out after the warm-up."
62282360|NCT06092294|ACTIVE_COMPARATOR|Conventional training in numerical equality|"On the other hand, the CG participants will perform conventional training. In the present study, conventional training is defined as ATTs performed in equal numbers in 1 against 1, 2 against 2 and 3 against 3 formats. Likewise, coaches will be asked not to carry out additional specific training with these formats, nor of SSGs or offensive or defensive ATT in numerical superiority and inferiority, specifically in 2 against 1, 3 against 2, or 4 against 3 formats, during the time of the study, to avoid confusion biases due to possible co-interventions. This CG training program will include individual, couples, and groups of three ATTs .~The characteristics of this training program are: training frequency 5 times/week, 1 official competition on weekends, frequency of ATT stimulation in 1v1, 2v2 and 3v3 formats is 2 times/week, the specific training time allocated will be 40 minutes per training session and will be performed after the warm-up."
62282361|NCT02221544|EXPERIMENTAL|rTMS treatment followed by Sham|A course of low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) followed by rTMS maintenance period (1 month) and followed by sham treatment in order to show the efficacy of treatment
62282362|NCT02221544|EXPERIMENTAL|Sham treatment followed by rTMS|A course of sham followed by followed by sham maintenance period (1 month) and than followed by low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) in order to show the effectiveness of rTMS
62282363|NCT03312517|ACTIVE_COMPARATOR|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
62282364|NCT03312517|ACTIVE_COMPARATOR|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
62282365|NCT03312517|SHAM_COMPARATOR|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
62282366|NCT00858429|EXPERIMENTAL|Cohort 1 (capecitabine, Y90)|2,000mg/m2 capecitabine +110 Y90
62282367|NCT00858429|EXPERIMENTAL|Cohort 2 (capecitabine , Y90)|2,000mg/m2 capecitabine + 130 Y90
62282368|NCT00858429|EXPERIMENTAL|Cohort 3 (capecitabine, Y90)|2,000mg/m2 Capecitabine + 150 Y90
62282369|NCT00858429|EXPERIMENTAL|Cohort 4 (capecitabine, Y90)|2,000 mg/m2 capecitabine = 170 Y90
62282370|NCT02689323|EXPERIMENTAL|Open label|Participants will undergo 5 sessions of active rTMS
62282371|NCT01472120||P and C|"P: NAFLD patients~C: Healthy controls"
62282372|NCT00305942|EXPERIMENTAL|1|"Topotecan 4mg/m2 IV on days 1, 8.~Carboplatin AUC=5 IV day 1 only .~- Cycles are repeated every 21 days for \> 4 cycles of topotecan and carboplatin (maximum 6 courses). Restaging studies will be performed every 2 cycles (or 6 weeks.)"
62458975|NCT04276883|EXPERIMENTAL|180 Micrograms|Sublingual film containing 180 Micrograms Dexmedetomidine
62650220|NCT06237270||Successful biceps recovery|Motor power more than or equal to grade 3 at 24 months after surgery
62083232|NCT04221542|EXPERIMENTAL|Part 3: AMG 509 IV Monotherapy in Earlier Lines of Treatment|Part 3 will explore AMG 509 in participants with mCRPC who have received 1 prior NHT (may have been given for HSPC) and no prior taxanes (may have been given for HSPC). This dose expansion will be conducted to confirm safety, PK, and PD of AMG 509 at the MTD or RP2D determined in Part 1 dose exploration, and to obtain further safety and efficacy data and correlative biomarker analysis.
62282373|NCT03342950|ACTIVE_COMPARATOR|Active drug group|Treatment with the topical solution of clonidine + pentoxifylline (0.1%/5%)
62650221|NCT06237270||Failure of biceps recovery|Motor power less than grade 3 at 24 months after surgery
62282374|NCT03342950|PLACEBO_COMPARATOR|Placebo group|Treatment with placebo solution with out active drug ingredients
62458976|NCT04276883|PLACEBO_COMPARATOR|Placebo|Sublingual placebo film
62458977|NCT05735977|OTHER|Indocyanine Green|Cohort study using one arm, no comparator group is possible or feasible
62458978|NCT05675332|PLACEBO_COMPARATOR|no stress exposure|no threat stress
62458979|NCT05675332|ACTIVE_COMPARATOR|stress exposure|exposure to stress threat
62458980|NCT01051505|EXPERIMENTAL|1|
62282375|NCT02087787|NO_INTERVENTION|Control|The control group will be provided the standard method, which is providing the Cancer Legal Line (CALL) brochure with a short explanation of the resource.
62282376|NCT02087787|EXPERIMENTAL|Intervention|The intervention group will be provided with a 2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
62282377|NCT03426098|EXPERIMENTAL|Treatment|After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
62282378|NCT06109194|EXPERIMENTAL|Intervention|Pre-assessment of active and passive range of motion in the paretic ankle, and five strides of gait assessment on a pressure-sensitive mat. Intervention will be moderate grade III anterior-to-posterior directed ankle mobilization for 2 minutes while supine, ankle muscle stretch for 75 seconds in standing, ankle muscle training for 3 minutes while seated. Post-assessment is repeated in the same sequence and content as pre-assessment.
62282379|NCT02388373|ACTIVE_COMPARATOR|Seretide 250|Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
62458981|NCT01051505|PLACEBO_COMPARATOR|2|
62458982|NCT01441609||the value of anti-HBs =0 mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
62650222|NCT00630916|NO_INTERVENTION|A|
62650223|NCT05720819|EXPERIMENTAL|Intervention Group (Biofeedback-VR intervention plus standard clinical care)|This arm includes individuals with chronic migraine receiving the home-based biofeedback-VR intervention plus standard medical care as treatment for chronic migraine
62282380|NCT02388373|ACTIVE_COMPARATOR|Flutiform 250|flutiform® 250 microgram/10 microgram per actuation pressurised inhalation, suspensions. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 1 and 12 weeks in Phase 2.
62282381|NCT02388373|ACTIVE_COMPARATOR|Flutiform 125|flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspensions. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 2.
62282382|NCT03996915|EXPERIMENTAL|experimental PDT group|G1-20 patients Photodynamic therapy with methylene blue as photosensitizer device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point (6 points) and radiant 90 seconds. Photosensitiser (PS) will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.Six points with the distances of 1 cm between them will be irradiated.
62458983|NCT01441609||the value of anti-HBs≤5mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
62458984|NCT01441609||5mIU≤anti-HBs≤10mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
62458985|NCT01441609||anti-HBs≥1000mIU|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
62458986|NCT04249973||IgE-mediated cow's milk allergy|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
62458987|NCT04249973||Suspected of cow's milk allergy, but with negative diagnosis|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
62458988|NCT04249973||IgE-mediated food allergy, other than cow's milk|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
62458989|NCT04249973||Healthy brothers and sisters|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
62458990|NCT00872079|ACTIVE_COMPARATOR|Genomics|"Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.~Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial."
62458991|NCT01045096|EXPERIMENTAL|Dexlansoprazole 15 mg QD|
62650224|NCT05720819|NO_INTERVENTION|Control Group (standard clinical care alone)|This arm, a wait-list control group, includes individuals with chronic migraine receiving standard medical care alone as treatment for chronic migraine.
62650225|NCT01231269|EXPERIMENTAL|MRI|diffusion-weighted MRI
62282383|NCT03996915|ACTIVE_COMPARATOR|control tongue scrapper group|G2-20 patients Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum in order to promote the mechanical removal of tongue coating
62458992|NCT01045096|EXPERIMENTAL|Dexlansoprazole 30 mg QD|
62650226|NCT02650739||SS-OCTdetermined group|Eyes with macular hole surgery that the postoperative prone positioning was discontinued after detecting a closure by SS-OCT
62650227|NCT02650739||Control group|Eyes with macular hole surgery that the halting of the prone position was determined by the surgeon
62650228|NCT02785263|OTHER|Standard radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
62650229|NCT02785263|OTHER|High dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
62650230|NCT02785263|OTHER|Low dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 25 treatments
62650231|NCT00952198|EXPERIMENTAL|ARRY-403|
62650232|NCT00952198|PLACEBO_COMPARATOR|Placebo|
62282384|NCT02198248|EXPERIMENTAL|Low-dose glucocorticoid|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy."
62282385|NCT02198248|ACTIVE_COMPARATOR|High-dose glucocorticoid|"Prednisolone will be commenced with dose of 1.0mg/kg/day and will be tapered to 10mg/day within 6 months. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy. There's no limitation by the protocol regarding further prednisolone tapering."
62458993|NCT01045096|EXPERIMENTAL|Dexlansoprazole 60 mg QD|
62458994|NCT03213886|EXPERIMENTAL|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
62282386|NCT02338102|EXPERIMENTAL|Treatment Group|Subjects in this group will perform twice daily nasal irrigations. Nasal irrigations will be performed by using premeasured salt packets mixed with distilled water in NeilMed irrigation bottles. The subject will be instructed to lean forward over the sink, place the bottle up to the nostril, and hold their breath while gently squeezing the bottle. One bottle is used to irrigate both nostrils, using half the solution on each side.
62650233|NCT04451278||Resting-state functional MRI (r-fMRI)|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional fMRI-r sequence, called resting state, and performed before injection of gadoline contrast.~A neuropsychological evaluation is performed as part of the 6 months prior to the procedure. These data will be used as a basis for the evaluation of language visual and language recovery."
62282387|NCT02338102|NO_INTERVENTION|Control Group|Subjects randomized to this arm receive no intervention.
62282388|NCT01272466|EXPERIMENTAL|peptides from antiapoptotic proteins|
62458995|NCT03213886|ACTIVE_COMPARATOR|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
62458996|NCT01214226|ACTIVE_COMPARATOR|Pentoxifylline + Prednisolone|"Pentoxifylline 400 mg prolonged-released tablets 3 time a day \[1200 mg/day\]~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY \[40 mg/day\]"
62458997|NCT01214226|PLACEBO_COMPARATOR|Placebo + Prednisolone|"Placebo prolonged-release tabled 3 time a day~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY \[40 mg/day\]"
62650234|NCT06170710|EXPERIMENTAL|RT+ cisplatin+Anti-PD-1 antibody|Concurrent cisplatin-RT followed by PD-1 antibody
62282389|NCT02838173|EXPERIMENTAL|SPB|Serratus Plane Bloc with Ropivacaine 2mg/ml (0,3ml/kg) and tissue infiltration with placebo made once, by the anesthetist in the operating theater before surgical incision
62282390|NCT02838173|ACTIVE_COMPARATOR|tissue infiltration|tissue infiltration with Ropivacaine 2mg/ml (0,3ml/kg) and Serratus Plane Bloc with placebo made once, by the anesthetist in the operating theater before surgical incision
62458998|NCT02005965||Staging and outcomes for patients with Low Rectal Cancer|Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge
62458999|NCT04031300|EXPERIMENTAL|RSP-20|Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 48 days.
62459000|NCT01548677|NO_INTERVENTION|observation|18 weeks
62282391|NCT01457183|EXPERIMENTAL|Lavage group|Healthy subjects with intact skin will be lavaged within the device in 3 locations on their bodies.
62459001|NCT01548677|EXPERIMENTAL|Herceptin (trastuzumab)|18 weeks
62459002|NCT05669768|EXPERIMENTAL|pamiparib+tamoxifen|
62459003|NCT05839613|EXPERIMENTAL|PG/TDM group|experimental group with PG/TDM analysis results avalaible
62282392|NCT03390179||diabetes|Patient with non insulin diabetes
62282393|NCT03390179||control|Patient without diabete
62282394|NCT03775876|ACTIVE_COMPARATOR|Propofol|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Propofol. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 2mg/Kg/h and modified to a maximum of 4 mg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four.
62282395|NCT03775876|ACTIVE_COMPARATOR|Dexmedetomidine|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
62282396|NCT00784797|ACTIVE_COMPARATOR|pitocin|high dose pitocin drip 48 hours after mifepristone preparation.
62650235|NCT06170710|ACTIVE_COMPARATOR|RT+ cisplatin|Concurrent cisplatin-RT
62083233|NCT04221542|EXPERIMENTAL|Part 4: AMG 509 IV Combination Therapy|"Part 4 will explore the safety, tolerability, and PK of AMG 509 for participants with mCRPC who have received no or 0/2 prior NHT (for hormone sensitive or castration-resistant disease) at dose regimens previously determined to be safe and tolerable in Part 1, in combination with abiraterone (Part 4A), or enzalutamide (Part 4B) and no or 1 prior taxane for hormone sensitive disease in Parts 4A and 4B. Part 4 consists of a dose exploration phase and a dose expansion phase.~This dose exploration study will estimate the MTD and/or RP2D of AMG 509 in combination with abiraterone or enzalutamide using a modified toxicity probability interval design. The dose-expansion phase will confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and correlative biomarker analysis."
62083234|NCT04221542|EXPERIMENTAL|Part 5: AMG 509 IV Monotherapy in Outpatient Setting|"Part 5 will evaluate the safety and tolerability of AMG 509 IV dosing in participants with mCRPC who have been previously treated with NHT and 1 to 2 prior taxanes, when administered in outpatient infusion centers.~The Part 5 dosing regimen and schedule was selected based on emerging data and DLRT recommendations and will utilize the doses explored in Part 1 dose-expansion phase"
62282397|NCT00784797|ACTIVE_COMPARATOR|misopristol|vaginal and oral misopristol 48 hours after mifepristone preparation.
62650236|NCT01145482|EXPERIMENTAL|insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
62650237|NCT01145482|PLACEBO_COMPARATOR|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
62650238|NCT00379106|ACTIVE_COMPARATOR|Group1|
62650239|NCT00379106|EXPERIMENTAL|Group 2|
62650240|NCT02751229|EXPERIMENTAL|Honest Open Proud|"The group program is about disclosure ('coming out') versus secrecy of one's mental illness. The groups are facilitated by peers (young adults with mental illness) and mental health professionals. Each group runs for three weeks, one meeting per week, and two hours per meeting.~Fidelity to manual: rated by PhD student in each session as proportion of key topics covered"
62650241|NCT02751229|NO_INTERVENTION|Control Group|treatment as usual (TAU)
62282398|NCT04970004||Patients Diagnosed with HSCT-TMA|
62282399|NCT01864408|OTHER|Group 1|"Group 1: subjects will receive usual practice counseling regarding pelvic organ prolapse after new patient history and physical exam."
62282400|NCT01864408|EXPERIMENTAL|Group 2|"Group 2: subjects will receive usual practice counseling in addition to interactive patient/provider counseling using the pelvic organ prolapse web-based tool (iPad) after new patient history and physical exam."
62459004|NCT05839613|EXPERIMENTAL|blinded group|experimental group with PG/TDM analysis results blinded
62459005|NCT01408966|EXPERIMENTAL|DarkChocolate|11 patients were randomized to receiving dark chocolate 0.55 g/kg of body weight (Lindt Excellence 85% Cocoa, Lindt \& Sprüngli España) together with the test meal
62459006|NCT01408966|PLACEBO_COMPARATOR|White chocolate supplementation|11 patients received 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt \& Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight.
62459007|NCT01653626|EXPERIMENTAL|package|
62459008|NCT02715869|ACTIVE_COMPARATOR|A pharmacologic cardiac preconditioning|Sevoflurane as a pharmacologic preconditioner for the heart
62650242|NCT05318664|EXPERIMENTAL|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
62650243|NCT05318664|NO_INTERVENTION|Control|20 minutes of rest
62650244|NCT04127370|EXPERIMENTAL|Obese Patients With NAFALD Undergoing Bariatric Surgeries|
62083235|NCT04698889|ACTIVE_COMPARATOR|Cow milk|Administration of natural cow whole milk
62083236|NCT04698889|ACTIVE_COMPARATOR|Human milk|Administration of natural human milk
62083237|NCT04698889|ACTIVE_COMPARATOR|Modified cow milk - low protein|Administration of modified cow milk at low protein content
62083238|NCT04698889|ACTIVE_COMPARATOR|Modified cow milk - high protein|Administration of modified cow milk at high protein content
62282401|NCT01409460|EXPERIMENTAL|True Obturator Nerve Block|
62282402|NCT01409460|SHAM_COMPARATOR|Sham Block|
62282403|NCT06545162|EXPERIMENTAL|SAD Cohort 1|
62650245|NCT04194112|OTHER|NMIBC patients|Patients with primary or recurrent NMIBC for whom complete TURBT was done.
62650246|NCT00458237|EXPERIMENTAL|Ph I: Everolimus L1 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg \[8 mg/kg loading dose\] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
62650247|NCT00458237|EXPERIMENTAL|Ph I: Everolimus L2 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg \[8 mg/kg loading dose\] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
62650248|NCT00458237|EXPERIMENTAL|PhII: Everolimus MTD + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg \[8 mg/kg loading dose\] IV once every three weeks and take everolimus at the MTD by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
62650249|NCT00461058|ACTIVE_COMPARATOR|Actos|
62650250|NCT00461058|EXPERIMENTAL|Aleglitazar|
62282404|NCT06545162|EXPERIMENTAL|SAD Cohort 2|
62282405|NCT06545162|EXPERIMENTAL|SAD Cohort 3|
62282406|NCT06545162|EXPERIMENTAL|MAD Cohort 1|
62282407|NCT06545162|EXPERIMENTAL|MAD Cohort 2|
62282408|NCT06545162|EXPERIMENTAL|MAD Cohort 3|
62282409|NCT06545162|EXPERIMENTAL|MAD Cohort 4|
62282410|NCT01072292|EXPERIMENTAL|CBT-I|CBT-I
62282411|NCT01072292|ACTIVE_COMPARATOR|Wellness Education|Wellness Education
62282412|NCT01099228|ACTIVE_COMPARATOR|131-I MIBG and 111I-n pentetreotide|131-I MIBG and 111I-n pentetreotide
62282413|NCT01099228|ACTIVE_COMPARATOR|131-I MIBG and In-111 DOTATATE|131-I MIBG and In-111 DOTATATE
62083239|NCT06290206|EXPERIMENTAL|English Language Session and Messaging|"The in-person or live Zoom presentation in English will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).~Participants in the English-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period."
62083240|NCT06290206|EXPERIMENTAL|Spanish Language Session and Messaging|"The in-person or live Zoom presentation in Spanish will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).~Participants in the Spanish-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period."
62083241|NCT06482892|EXPERIMENTAL|Treatment group|
62083242|NCT03749902|OTHER|Oxytocin infusion|"* Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured."
62083243|NCT03749902|OTHER|Oral misoprostol|"* An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
62083244|NCT06102863|NO_INTERVENTION|control group|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or mirena +GnRHa 3.75mg subcutaneous injection monthly);
62282414|NCT04070482||HIV-exposed uninfected infants|These are children to women who are living with HIV but who are not infected with the virus (HIV PCR results at 6 weeks is negative)
62650251|NCT01452620||EVAR cohort|All consecutive patients undergoing endovascular AAA repair (EVAR) in our community setting were followed for outcomes.
62083245|NCT06102863|EXPERIMENTAL|experimental group|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
62083246|NCT06641089|EXPERIMENTAL|sonelokimab dose 1 with an induction regimen|Subjects randomized to this arm will receive sonelokimab dose 1 subcutaneously (SC) as an induction regimen of 4 doses , followed by sonelokimab SC every 4 weeks (Q4W) maintenance dosing starting at Week 8.
62083247|NCT06641089|EXPERIMENTAL|sonelokimab dose 2 with an induction regimen|Subjects randomized to this arm will receive sonelokimab dose 2 SC as an induction regimen of 4 doses, followed by sonelokimab SC Q4W maintenance dosing starting at Week 8.
62083248|NCT06641089|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo SC
62083249|NCT06641089|ACTIVE_COMPARATOR|risankizumab|Subjects randomized to this arm will receive risankizumab SC
62083250|NCT04714905||Pregnant Cohort|Pregnant (up to and including 15 weeks), 18+ years of age.
62083251|NCT04714905||Pre-pregnancy Cohort|Anticipating to be pregnant, 18-40 years of age.
62083252|NCT04708691|EXPERIMENTAL|Aerobic exercise|aerobic exercise for 30 mins
62083253|NCT04708691|NO_INTERVENTION|Control|sitting for 30 mins
62083254|NCT02096120||All patients|
62650252|NCT06479902|EXPERIMENTAL|Core stabilization and Diaphragmatic Exercise Group|The intervention consisted of 18 sessions over three weeks, following the FITT protocol. Each session included a warm-up (5 minutes), core stability exercises (15 minutes), diaphragmatic strengthening exercises (10 minutes), and cool-down (5 minutes), with rest intervals. Exercises progressed in difficulty on stable surfaces, tailored to each participant's tolerance. Warm-up exercises included activities like hopping and knee circles, while core stability exercises featured moves such as planks and side planks. Diaphragmatic exercises included diaphragmatic breathing in various positions.
62282415|NCT04070482||HIV-unexposed uninfected infants|These are children born to women who are not infected with HIV
62282416|NCT02529579|ACTIVE_COMPARATOR|Gemcitabine|Standard Gemcitabine Therapy
62282417|NCT02529579|EXPERIMENTAL|cellular immunotherapy & Gemcitabine|iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
62650253|NCT03248297|EXPERIMENTAL|Azithromycin and amoxicillin placebo|Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
62650254|NCT03248297|EXPERIMENTAL|Azithromycin + amoxicillin|Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
62650255|NCT03248297|PLACEBO_COMPARATOR|Usual Care|This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
62083255|NCT05345093|EXPERIMENTAL|Ialuxid Gel|twenty-two patients affected by acne vulgaris; twenty-two patients affected by folliculitis.
62083256|NCT03746756|EXPERIMENTAL|SBIRT as Usual|The follow-up team will (a) contact participants within 24-48 hours to collect additional locator information and mailing a schedule card for the next interview, (b) receipt information in a management information system (MIS), (c) assign each case to a follow-up case tracker, (d) verify locator data, (e) conduct outreach for unverified cases and discussing them at weekly meetings, (f) mail thank-you cards to participants and collaterals, (g) schedule follow-up appointments, (h) mail 3 and 6 week post-enrollment flyers, (i) implement returned-mail procedures, (j) call participants 6 weeks before appointment to confirm date and location (phone vs. research office), (k) conduct outreach for unconfirmed cases and review them at weekly meetings, (l) complete follow-up interviews and scheduling next appointments, and (m) implement a no-show protocol.
62459009|NCT02715869|ACTIVE_COMPARATOR|B ischeamic preconditioning|ischemic preconditioning by inflation the cuff of blood pressure
62459010|NCT05670171|ACTIVE_COMPARATOR|Debulking Atherectomy|Excimer laser atherectomy combined with drug-coated balloon angioplasty
62459011|NCT05670171|ACTIVE_COMPARATOR|Stent Angioplasty|Nickel-titanium self-expanding bare stent
62459012|NCT04206644||Systemic sclerosis patients|SSc patients according to the ACR/EULAR 2013 classification criteria
62459013|NCT04206644||Healthy donors|HD healthy donors from EFS (Etablissement Français du sang)
62459014|NCT04206644||LUPUS Patiets|Lupus patients according to the ACR 2019 classification criteria
62459015|NCT04639765|NO_INTERVENTION|No video|This condition involves no video presentation.
62459016|NCT04639765|EXPERIMENTAL|CBT without Personalization|Video provides information about cognitive behavioral therapy.
62650256|NCT00653874|EXPERIMENTAL|1: TcB|transcutaneous bilirubinometry (TcB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
62459017|NCT04639765|EXPERIMENTAL|CBT with Personalization|Video provides information about cognitive behavioral therapy and describes how treatment can be personalized.
62459018|NCT04639765|EXPERIMENTAL|ADM without Personalization|Video provides information about antidepressant medications.
62650257|NCT00653874|ACTIVE_COMPARATOR|2: CaB|clinical assessment of jaundice (CaB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
62650258|NCT04020562|EXPERIMENTAL|Mild Resistive Expiratory Technique|Mild resistive Expiratory Technique from EMST150- five-week training protocol.
62083257|NCT03746756|EXPERIMENTAL|SBIRT + RMC-PC|Patients will receive SBIRT plus the RMC protocol. The Linkage Manager (LM) will: 1) provide personalized feedback to participants about the status of their condition based on responses from the Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3), 2) help participants resolve ambivalence about their dependence and moving them toward a commitment to change by accessing additional care, 3) address existing barriers to treatment, 4) schedule an assessment, and 5) facilitate reentry and engagement. The LM will stay in contact 2-3 times per week for two weeks to ensure that individuals both initiate and remain engaged in treatment.
62083258|NCT06136832|NO_INTERVENTION|Control|Patients randomized into this arm DO NOT RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.
62083259|NCT06136832|EXPERIMENTAL|Treatment|Patients randomized into this arm RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.
62083260|NCT03877263|OTHER|OB/GYN physician-collected vaginal swab|"Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
62083261|NCT03877263|OTHER|Patient-collected vaginal swab|"Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
62459019|NCT04639765|EXPERIMENTAL|ADM with Personalization|Video provides information about antidepressant medications and describes how treatment can be personalized.
62083262|NCT05048238|EXPERIMENTAL|Tofacinitib|10 participants receiving 11 mg of Tofacitinib administered orally and daily, from Day 2 to Day 26
62282418|NCT02051010||Metastatic Breast Cancer|
62282419|NCT03623867|EXPERIMENTAL|Secukinumab|Subject will received secukinumab 150mg at week 0-4, and once monthly till week 48
62282420|NCT03623867|PLACEBO_COMPARATOR|Placebo|Subject will received placebo 150mg at week 0-4, and once monthly till week 48
62282421|NCT05510505|ACTIVE_COMPARATOR|ATG arm (control group)|"4.2.1 Matched sibling donor 1) ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~4.2.2 Unrelated donor and haploidentical donor~1) ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）"
62083263|NCT04157790|NO_INTERVENTION|Neutral|Suggested to follow European Society of Cardiology guidelines for NSTEMI
62459020|NCT04639765|EXPERIMENTAL|Combined Treatment without Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications.
62459021|NCT04639765|EXPERIMENTAL|Combined Treatment with Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications and describes how treatment can be personalized.
62650259|NCT04020562|ACTIVE_COMPARATOR|Conventional Training|Breathing exercise, Assistive Coughing, ROM Exercises, Sustained stretching, Splinting, Bracing, Functional Mobility, Tilt table standing
62650260|NCT03485625|EXPERIMENTAL|Lidocaine|Patients in group C will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
62083264|NCT04157790|ACTIVE_COMPARATOR|CARE score|calculation of the CARE score and prescription for troponins assays or not according to the result (score \> 1: troponins assays ; score \< 2: no troponins assays)
62083265|NCT00810641|ACTIVE_COMPARATOR|Gufoni maneuver|Gufoni maneuver for apogeotropic HC-BPPV
62083266|NCT00810641|ACTIVE_COMPARATOR|Headshaking maneuver|headshaking maneuver for apogeotropic HC BPPV
62650261|NCT03485625|EXPERIMENTAL|Lidocaine+ Ketorolac|Patients in group K receive 3 mg/kg of lidocaine 2% + 20 mg ketorolac diluted with saline to a total volume of 40 ml.
62650262|NCT03485625|EXPERIMENTAL|Lidocaine+Paracetamol|Patients in group P will receive 3 mg/kg of lidocaine 2% + 300 mg paracetamol diluted with saline to a total volume of 40 ml.
62650263|NCT02673749|EXPERIMENTAL|RP-G28 Dose 1|
62650264|NCT02673749|EXPERIMENTAL|RP-G28 Dose 2|
62650265|NCT02673749|PLACEBO_COMPARATOR|Placebo|
62650266|NCT02870491|NO_INTERVENTION|Control|Existing standard of care.
62650267|NCT02870491|EXPERIMENTAL|Free Distribute+Preemptive Delivery|Community health workers (CHWs) will deliver oral rehydration salts (ORS) and zinc for free to all households in their catchment area with a child under 5-years-old at the beginning of the study.
62650268|NCT02870491|EXPERIMENTAL|Cost Sharing + Preemptive Delivery|CHWs will visit all households with a child under 5-years-old at the beginning of the study and offer to sell ORS and zinc to caretakers at the time of the visit for them to store in their homes.
62650269|NCT02870491|EXPERIMENTAL|Free Distribution Upon Retrieval|CHWs will visit all households with a child under 5-years-old at the beginning of the study and inform caretakers that they have ORS and zinc available for free that caretakers can retrieved from the CHWs home if needed.
62650270|NCT01220570|EXPERIMENTAL|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
62650271|NCT01220570|EXPERIMENTAL|Ridaforolimus|Ridaforolimus (MK-8669)
62083267|NCT00810641|SHAM_COMPARATOR|sham maneuver|sham maneuver for apogeotropic HC BPPV
62083268|NCT02854215|OTHER|Ovarian cancer|Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014
62650272|NCT01220570|EXPERIMENTAL|Dalotuzumab|Dalotuzumab (MK-0646)
62650273|NCT05981846|EXPERIMENTAL|BIMERVAX + SIIV|
62650274|NCT05981846|ACTIVE_COMPARATOR|BIMERVAX + PLACEBO|
62650275|NCT05981846|ACTIVE_COMPARATOR|SIIV + PLACEBO|
62650276|NCT01704365|EXPERIMENTAL|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
62459022|NCT03407365|EXPERIMENTAL|Home Exercises|Patients will be given a set of home exercises to perform as part of their rehabilitation home exercise program. They will be initially trained by a research team member and will be given a DVD home exercise video with instructions on how to perform the exercises.
62083269|NCT03093844|EXPERIMENTAL|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
62282422|NCT05510505|EXPERIMENTAL|ATG + CD20 monoclonal antibody (test arm)|"4.2.1 Matched sibling donor 2) ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor 2) ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
62282423|NCT00556426|EXPERIMENTAL|Filter|All subjects enrolled to the study are in this arm. All subjects receive a filter.
62083270|NCT05630989||Therapy with no MEKi|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive therapy with no MEKi.
62083271|NCT05630989||Therapy with MEKi- Hydroxychloroquine (HCQ)|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive therapy with MEKi and HCQ.
62083272|NCT05630989||Therapy with MEKi- Epidermal growth factor receptor inhibitor (EGFRi)|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive combination therapy with MEKi and EGFRi.
62083273|NCT05630989||Therapy with MEKi-Other|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive combination therapy with MEKi and a specified drug combination.
62083274|NCT03756454|EXPERIMENTAL|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
62083275|NCT03756454|PLACEBO_COMPARATOR|Normal Saline|Patients receiving normal saline as a placebo post-operatively.
62083276|NCT02498743|EXPERIMENTAL|Intervention group with television|Animated cartoons with sound were reproduced during the echocardiography
62083277|NCT02498743|NO_INTERVENTION|control group with usual care|Echocardiography was performed by using the distractions available at the time of test.
62083278|NCT04509830|EXPERIMENTAL|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator will be performed.cuff weights will be used with 80% of 1 repetition maximum at 3 sets of 8 repetitions with 10-15 second rest between repetitions and 1-2 minute rest between sets.
62083279|NCT04509830|ACTIVE_COMPARATOR|quadriceps strengthening, stretch for hamstring,cuff muscles|"quadriceps strengthening: multi-angle isometric exercise from sitting position will be performed. cuff weights will be used with 3 sets of 12 repetitions at 40% of 1 reprtition maximum.~self stretch for hamstring and cuff muscles from supine position. the procedure will be repeated 4 times."
62083280|NCT06423599|EXPERIMENTAL|Semaglutide intervention group|Dose-escalation of semaglutide will take place during the first 16 weeks after randomisation (week 0). Patients will start at the 0.25 mg once-weekly dose and follow dose-escalation schedule (0.25, 0.5, 1.0, 1.7 and 2.4 mg). For all subjects we aim at reaching the recommended target dose of 2.4 mg semaglutide once weekly for the rest of the period of total 52 weeks.
62083281|NCT06423599|ACTIVE_COMPARATOR|Calorie-restricted diet intervention group|In short, the weight loss program in the calorie-restricted diet group consists of 3 phases after randomisation (week 0). An initial weight loss phase of 8 weeks with 800 calories/day, a food re-introduction phase for 8 weeks and a weight loss maintenance phase for the rest of the period of total 52 weeks.
62282424|NCT06232200|NO_INTERVENTION|CONTROL GROUP|REGULAR TREATMENT
62282425|NCT06232200|EXPERIMENTAL|ACUPUNCTUR GROUP|"Acupuncture application will be performed by bilateral needling of The Sanyinjiao (SP6), Yin Ling Quan (SP9), Zu San Li, Leg Three Mile (ST36) , Tai Chong (LIV3), Hegu (LI4), Taixi (KID3) , Zhongliao (BL33) and Guan Yuan (CV4) acupuncture points using sterile, disposable metal acupuncture needles. The needles will remain in place for approximately 20 minutes during the treatment, a total of 8 sessions are planned, 2 per week."
62459023|NCT03407365|ACTIVE_COMPARATOR|DVD Program|Weeks 1-10, subjects will not be prescribed exercise at home. If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
62459024|NCT00556127|EXPERIMENTAL|1|
62459025|NCT00448175|EXPERIMENTAL|Urgent PC treatment arm|
62459026|NCT03538587|ACTIVE_COMPARATOR|Arm 1 Enhanced Mindfulness Intervention (EMI) - Immediate Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions.
62650277|NCT01704365|EXPERIMENTAL|Group B|Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
62650278|NCT01704365|EXPERIMENTAL|Group C|Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
62650279|NCT01704365|EXPERIMENTAL|Group D|Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
62083282|NCT05445687|EXPERIMENTAL|Hearing Impairment cases|"Hearing impaired children who will receive the proposed narrative intervention program.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.The narrative intervention program will be applied on the cases groups by a phoniatrician in 24 sessions, 60 minutes in duration, one session per week, for 3 months."
62083283|NCT05445687|ACTIVE_COMPARATOR|Hearing Impairment control|The Hearing impairment control group will receive the conventional language rehabilitation sessions in 30 minute sessions twice a week, for 3 months. Conventional language therapy targets semantics, syntax, prosody, pragmatics, and phonology.
62083284|NCT05445687|EXPERIMENTAL|Developmental language disorder cases|Developmental language disorder children who will receive the proposed narrative intervention program. The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.The narrative intervention program will be applied on the cases groups by a phoniatrician in 24 sessions, 60 minutes in duration, one session per week, for 3 months.
62083285|NCT05445687|ACTIVE_COMPARATOR|Developmental language disorder control|The developmental language disorder control group will receive the conventional language rehabilitation sessions in 30 minute sessions twice a week, for 3 months. Conventional language therapy targets semantics, syntax, prosody, pragmatics, and phonology.
62083286|NCT04253704|EXPERIMENTAL|2% IDL lotion|The left arm of each subject was used for the test material hydrating lotion (IDL).
62083287|NCT04253704|PLACEBO_COMPARATOR|Control lotion|The right arm of each subject was used for control lotion lacking the IDL component.
62083288|NCT00519246|PLACEBO_COMPARATOR|I|No drug was delivered.
62083289|NCT00519246|ACTIVE_COMPARATOR|II|Butorphanol tartrate 1mg was given intravenously.
62083290|NCT00519246|ACTIVE_COMPARATOR|III|Butorphanol tartrate 2 mg was given intravenously.
62083291|NCT00519246|ACTIVE_COMPARATOR|IV|Flurbiprofen Axetil 50 mg was given intravenously.
62083292|NCT00519246|ACTIVE_COMPARATOR|V|Flurbiprofen Axetil 100 mg was given intravenously.
62650280|NCT01704365|EXPERIMENTAL|Group E|High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
62083293|NCT00519246|ACTIVE_COMPARATOR|VI|Tramadol Hydrochloride 10 mg was given intravenously.
62083294|NCT00519246|ACTIVE_COMPARATOR|VII|Tramadol Hydrochloride 20 mg was given intravenously.
62083295|NCT03627988|EXPERIMENTAL|Patients with breast cancer|
62083296|NCT04763135|EXPERIMENTAL|Oral mirtazapine|Arm 1 patients will be treated using a daily mirtazapine treatment. Treatment will be taken on the evening. Treatment will be initiated at 15 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for old patients and those with liver failure.
62083297|NCT04763135|ACTIVE_COMPARATOR|Oral escitalopram|Arm 2 patients will be treated using a daily escitalopram treatment. Treatment will be taken in the morning. Treatment will be initiated at 10 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for 5 mg for old patients.
62083298|NCT05553574|EXPERIMENTAL|Food response|
62083299|NCT05553574|EXPERIMENTAL|Food stop|
62083300|NCT05553574|EXPERIMENTAL|Food response-inhibition|
62083301|NCT03477461||terlipressin group|patients presented with oliguria or high levels creatinine
62083302|NCT01704885|SHAM_COMPARATOR|Active Control Group|Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
62083303|NCT01704885|EXPERIMENTAL|Play Intervention|"children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session."
62650281|NCT01704365|EXPERIMENTAL|Group F|High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
62650282|NCT01704365|EXPERIMENTAL|Group G|High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
62650283|NCT01704365|EXPERIMENTAL|Group H|High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
62282426|NCT04146142|ACTIVE_COMPARATOR|Transperineal prostate biopsy with antibiotic profylaxis|Cefuroxim 1.5 g will be applied intramuscularly before prostate biopsy
62650284|NCT01704365|EXPERIMENTAL|Group J|Low dose RSV-F Vaccine with Adjuvant \[Bedside Mixing\] (Day 0 \& Day 28)
62650285|NCT01704365|PLACEBO_COMPARATOR|Group K|Placebo (Day 0 and Day 28)
62650286|NCT03342066||A|Cariogram
62650287|NCT03342066||B|CAMBRA
62650288|NCT04087512|EXPERIMENTAL|Instrumented perturbation-based balance training|
62083304|NCT00180518|EXPERIMENTAL|1|"To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) To evaluate the efficacy of the OTW ACCUNET System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA).~To demonstrate equivalence in the safety and performance of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System and the corresponding OTW devices."
62083305|NCT03035071|EXPERIMENTAL|minimally invasive esophagectomy|minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.
62459027|NCT03538587|ACTIVE_COMPARATOR|Arm 2 Control Group - Psychoeducation Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
62083306|NCT03035071|ACTIVE_COMPARATOR|open esophagectomy|open gastric mobilization and gastric tube formation
62083307|NCT01055106|ACTIVE_COMPARATOR|1D|
62083308|NCT01055106|ACTIVE_COMPARATOR|3D|
62083309|NCT01055106|ACTIVE_COMPARATOR|5D|
62083310|NCT01055106|ACTIVE_COMPARATOR|Metronidazole|
62083311|NCT01574911||healthy adults|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
62083312|NCT01574911||Adults Chronic venous insufficiency|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
62083313|NCT01574911||patients primary lymphedema|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D
62083314|NCT06575192|EXPERIMENTAL|Acellular Dermal Matrix|Breast reconstruction with ARTIA Tissue Matrix.
62083315|NCT06575192|OTHER|Non-Acellular Dermal Matrix (ADM) Control Group|Breast reconstruction without ADM.
62083316|NCT06198660|EXPERIMENTAL|positional release|positional release techniques in addition to conventional physical therapy
62083317|NCT06198660|EXPERIMENTAL|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional physical therapy
62083318|NCT06198660|ACTIVE_COMPARATOR|conventional physical therapy|conventional physical therapy in control group
62083319|NCT05679700|EXPERIMENTAL|Chronic stroke patients with knee hyperextension|
62083320|NCT03251404|ACTIVE_COMPARATOR|Knee Control original|The Knee Control program exercise program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
62083321|NCT03251404|EXPERIMENTAL|Knee Control+|The Knee Control+ is an extension of the original Knee Control exercise program offering a wider selection of exercises (to increase adherence) and more physically challenging exercises (adapted for athletes in the late teens and provide further stimuli to increase player performance and neuromuscular function). The program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
62461779|NCT04672291|EXPERIMENTAL|Expansion Cohort|A randomized (4:1) expansion cohort will receive 3 cycles of drug (N=24) or placebo (N=6). A total of 30 patients will be accrued.
62083322|NCT02026713|EXPERIMENTAL|smokers on dual antiplatelet therapy with ASA and Prasugrel or|All patients quit smoking for a 2 weeks period
62083323|NCT02026713|EXPERIMENTAL|smokers on dual antiplatelet therapy with ASA and ticagrelor|All patients on chronic dual antiplatelet therapy (\>1 month) quit smoking for a 2 weeks period
62083324|NCT02026713|ACTIVE_COMPARATOR|smokers on dual antiplatelet therapy with ASA and Clopidogrel|All patients on chronic dual antiplatelet therapy (\>1 month) quit smoking for a 2 weeks period
62083325|NCT03072082|EXPERIMENTAL|Danlou Tablet|Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months \& conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
62083326|NCT03072082|PLACEBO_COMPARATOR|Danlou Tablet placebo|Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months \& conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
62083327|NCT06160349||Patient Interviews|Patients with risk factors for maternal sepsis interviewed about pregnancy, labor/delivery, and postpartum via Zoom.
62083328|NCT06160349||Community Stakeholders|Community stakeholders with professional and/or academic backgrounds relevant to maternal health who participate in focus group discussion.
62083329|NCT02380521|EXPERIMENTAL|60 patients with T2DM|These patients will be treated with exenatide once weekly for a period of 8 months
62650289|NCT04087512|EXPERIMENTAL|Conventional perturbation-based balance training|
62650290|NCT04087512|NO_INTERVENTION|Control|
62083330|NCT05124249||Invasive coronary angiography (ICA)|Patients who undergoing invasive coronary angiography with intravascular imaging or invasive physiologic assessment
62083331|NCT05124249||Percutaneous coronary intervention (PCI)|Patients who undergoing percutaneous coronary intervention with intravascular imaging or invasive physiologic assessment
62083332|NCT00610675|EXPERIMENTAL|Esmirtazapine|One tablet of Esmirtazapine, 4.5 mg orally, daily for up to 52 weeks
62083333|NCT05906537|EXPERIMENTAL|Phase Ia (Dose Escalation Phase)+Phase Ib (Dose Expansion Phase)|Several dose levels are planned for Phase1a and administered every 2 weeks.The dose of SKB410 for injection in Phase 1b is selected based on the Phase 1a.
62083334|NCT02580773|OTHER|Prophylactic anticoagulation|
62083335|NCT02580773|EXPERIMENTAL|Curative anticoagulation|
62282427|NCT04146142|EXPERIMENTAL|Transperineal prostate biopsy without antibiotic profylaxis|No antibiotics will be used before or after prostate biopsy
62282428|NCT00109473|EXPERIMENTAL|Growth Hormone plus cortecosteroid|Growth Hormone (nutropin AQ 0.075 mg/kg/day subcutaneously daily)
62282429|NCT00109473|ACTIVE_COMPARATOR|Cortecosteroids alone|Cortecosteroid therapy as prescribed by the referring gastroenterologist
62083336|NCT00074763|EXPERIMENTAL|Platelet Transfusion|ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.
62083337|NCT00802841|EXPERIMENTAL|Nilotinib|Participants received 400 mg nilotinib twice daily (BID).
62083338|NCT00802841|ACTIVE_COMPARATOR|Imatinib|Participants received 600 mg imatinib once daily (QD).
62083339|NCT02546687||Canidate for elective esophagectomy|Venous blood sampling from gastric tube during elective esophagectomy
62083340|NCT01994720|EXPERIMENTAL|ticagrelor|
62083341|NCT01994720|ACTIVE_COMPARATOR|Acetylsalicylic acid (ASA)|
62083342|NCT01662427||Questionniare|
62083343|NCT02148718|EXPERIMENTAL|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
62083344|NCT06378502|EXPERIMENTAL|Long-span therapy|1 g Amoxicillin every 8 h starting 1 day before surgery and for 5 days after surgery
62083345|NCT06378502|EXPERIMENTAL|Short-span therapy|2 g Amoxicillin 1 h before surgery
62083346|NCT05555095||OSF HealthCare|Subjects from OSF HealthCare
62083347|NCT05555095||Federally Qualified Health Center (FQHC) - 1|Subjects from Eagle View Community Health System enrolled in MIC Program
62282430|NCT00135603|ACTIVE_COMPARATOR|A|appendectomy, actual usual treatment
62282431|NCT00135603|ACTIVE_COMPARATOR|B|antibiotic therapy
62282432|NCT02135380|OTHER|Autologous Stromal Vascular Fraction|Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
62282433|NCT02135380|OTHER|Autologous Adipose Derived MSCs|3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
62282434|NCT02135380|ACTIVE_COMPARATOR|Control|"* corticosteroids i.e. Prednisolone ≤10mg/day or ≤20 mg every alternate day~* Immunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day~* Antioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.~* Pirfenidone at dose upto 1200 to 1800 mg/day"
62459028|NCT01669538|EXPERIMENTAL|Galantamine|"Galantamine hydrobromide-ER (extended release) is currently marketed for the treatment of Alzheimer's disease. The dosing regimen follows the FDA-approved guidelines. For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.~Galantamine will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
62459029|NCT01669538|PLACEBO_COMPARATOR|Placebo|"Participants assigned to the placebo (sugar pill) arm will take one capsule daily, preferably with food, for a total of 23 days. They will follow the same instructions and complete the same procedures as those in the active treatment.~Placebo ingredients (sucrose filler and gel capsules) will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
62650291|NCT04113135|EXPERIMENTAL|Journaling, meditations, education, yoga intervention Arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post testing will take approximately 45 minutes to one hour. Session 1 for all participants will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The intervention sessions (2-6) for the experimental group participants consist will include a group discussion of the objectives for the week, 20-30 minutes of education and journaling (Attachment B), 45-60 minutes of PA consisting of various yoga poses followed by SMART goal setting and guided relaxation..
62083348|NCT05555095||Federally Qualified Health Center (FQHC) - 2|Subjects from Chestnut Health System Inc. enrolled in MIC Program
62282435|NCT04563065|EXPERIMENTAL|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy (11,13) and published by Barakat model (10).~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
62282436|NCT04563065|NO_INTERVENTION|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
62282437|NCT02945956|PLACEBO_COMPARATOR|Entecavir|Tablet with Entrcavir
62083349|NCT05555095||Federally Qualified Health Center (FQHC) - 3|Subjects from Heartland Community Health System enrolled in MIC Program
62083350|NCT05555095||Federally Qualified Health Center (FQHC) - 4|Subjects from Aunt Martha's enrolled in MIC Program
62282438|NCT02945956|EXPERIMENTAL|Entecavir + Fuzheng Huayu|Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu
62282439|NCT00374803|EXPERIMENTAL|Mycophenolic Acid (Myfortic) Preload|Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
62282440|NCT00374803|ACTIVE_COMPARATOR|Mycophenolic Acid (Myfortic) Standard|Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
62282441|NCT03803332|ACTIVE_COMPARATOR|Exposure Therapy|Participants receive 10 90-minute exposure therapy sessions for PTSD following the treatment procedures as outlined in the standard Prolonged Exposure therapy manual.
62459030|NCT00322257|EXPERIMENTAL|A|
62459031|NCT00322257|ACTIVE_COMPARATOR|B|
62459032|NCT06002048||Healthy|Participants who do not have Type 1 or Type 2 Diabetes
62083351|NCT03261544||Proximal Femur Replacement|The proximal femur is a common site for primary bone sarcomas and metastatic disease. The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
62083352|NCT01339611|EXPERIMENTAL|Educational Program|Patients who are going to use of oral anticoagulant will participate in an individual orientation, using instructional material (slides and illustrative booklet) during hospitalization period and the telephone follow-up at a week and four weeks after discharge
62083353|NCT01339611|OTHER|usual care|Patients who are going to use of oral anticoagulant will have usual orientation from the health service (illustrative booklet) during hospitalization time. No telephone follow-up after discharge.
62282442|NCT03803332|ACTIVE_COMPARATOR|Interpersonal Psychotherapy|Participants receive 14 weekly 50-minute Interpersonal Psychotherapy sessions focused on the interpersonal sequelae of trauma in current daily life.
62459033|NCT06002048||Pre-diabetes/Diet Controlled|Participants with pre-Type 2 Diabetes and those with Type 2 Diabetes whose blood sugar is controlled by diet
62083354|NCT02763891|EXPERIMENTAL|Intervention group|Subjects submitted to a 30-minute session of suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks.
62282443|NCT00865384|EXPERIMENTAL|A|Mirtazapine 15 mg tablets, single dose
62282444|NCT00865384|ACTIVE_COMPARATOR|B|REMERON® 15 mg tablets, single dose
62282445|NCT04226794|EXPERIMENTAL|a-tDCS and nutritional counseling|a-tDCS and nutritional counseling
62282446|NCT04226794|ACTIVE_COMPARATOR|s-tDCS and nutritional counseling|s-tDCS and nutritional counseling
62282447|NCT04226794|ACTIVE_COMPARATOR|a-tDCS|a-tDCS
62282448|NCT04226794|ACTIVE_COMPARATOR|Nutritional counseling|Nutritional counseling
62282449|NCT05252793|EXPERIMENTAL|Diabetes Education Program Based on Health Belief Model|"Experimental: Intervention Patients will be given links to training videos once or twice a week depending on the length of the training module for 6 weeks.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
62282450|NCT05252793|NO_INTERVENTION|Control|"No intervention will be taken against the patients.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
62282451|NCT01144598||Turkish patients with rheumatoid arthritis|
62282452|NCT02058602|EXPERIMENTAL|Arm 1|This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Approximately 30 subjects will be enrolled so that at least 20 subjects complete all critical assessments.
62282453|NCT06399926||Pemetrexed 20mg|Pemetrexed 20mg every 24 hours for 72 hours every 2 weeks until efficacy evaluated remission or stable ; change to every 3 weeks.
62459034|NCT06002048||Oral Medication and/or Non-insulin-injectable Medication Controlled|Participants with Type 2 Diabetes whose blood sugar is controlled by oral or injectable medications other than insulin
62459035|NCT06002048||Insulin Dependent|Participants with Type 2 Diabetes whose blood sugar is controlled by insulin
62459036|NCT01541150|ACTIVE_COMPARATOR|patient suffering pedophilia|This group is the active comparator because patients suffering pedophilia with neuropsychological questionnaires
62459037|NCT01541150|PLACEBO_COMPARATOR|control group|This group is the placebo comparator
62459038|NCT03859388||Chronic ABMR|Single arm; patients with chronic ABMR diagnosed by Banff 2017 criteria and recommended for monthly treatment with tocilizumab will undergo monthly testing for donor-derived cell-free DNA (Allosure) and then have a follow-up biopsy after six monthly infusions of tocilizumab
62083355|NCT02763891|SHAM_COMPARATOR|Control group|Subjects submitted to a 30-minute passive muscle stretching session twice a week for eight weeks.
62083356|NCT03366883|EXPERIMENTAL|"Paclitaxel, Cisplatin Plus 5-FU (TCF)"|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks
62083357|NCT03366883|EXPERIMENTAL|Preoperative radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week
62083358|NCT05620017|EXPERIMENTAL|A/0.8mg/kg|Drug：BAT8008 for Injection,0.8mg/kg
62083359|NCT05620017|EXPERIMENTAL|B/1.2mg/kg|Drug：BAT8008 for Injection,1.2mg/kg
62083360|NCT05620017|EXPERIMENTAL|C/2.4mg/kg|Drug：BAT8008 for Injection,2.4mg/kg
62083361|NCT05620017|EXPERIMENTAL|D/3.6mg/kg|Drug：BAT8008 for Injection,3.6mg/kg
62083362|NCT05620017|EXPERIMENTAL|E/4.8mg/kg|Drug：BAT8008 for Injection,4.8mg/kg
62459039|NCT02396875|EXPERIMENTAL|Group 1|40 patients undergoing CRT will have venous samples taken from two CS tributaries, peripheral venous and peripheral arterial sites at the time of CRT insertion at the time of device implant. Blood samples will be analysed for metabolites and novel biomarkers They will then undergo repeat sampling at 6 months to assess for changes in the biomarker profile including CS sampling.
62083363|NCT05620017|EXPERIMENTAL|F/6.0mg/kg|Drug：BAT8008 for Injection,6.0mg/kg
62083364|NCT05620017|EXPERIMENTAL|G/7.2mg/kg|Drug：BAT8008 for Injection,7.2mg/kg
62083365|NCT01615991|OTHER|radiosynoviorthesis with yttrium-90 or rhenium -186|Patients suffering from arthritis or chronic inflammatory joint disease.
62083366|NCT04313348|ACTIVE_COMPARATOR|Control Arm|Study participants in this arm will receive no SMS reminders nor social supporter notifications.
62083367|NCT04313348|EXPERIMENTAL|Intervention Arm 1|"Participants will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery at their preferred time and day of the week will be sent to study participants. The content of the SMS reminders will be customized and determined by each individual at enrollment. If the participant has no preference, we will suggest This is your ANC visit reminder, encouraging you to attend. This technology is already integrated and running in Uganda via the Yo! Uganda Gateway."
62083368|NCT04313348|EXPERIMENTAL|Intervention Arm 2|"Participants will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information and SMS reminders same as those of scheduled SMS arm above + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for the study participant they are supporting for all the study follow-up period (also called the social support engagement arm). Social supporters will be able to personalize the SMS content at enrollment. They will be advised to assist study participants with any problems that may affect ANC attendance or facility delivery, but will not be given specific instructions on what to do."
62083369|NCT05675917|EXPERIMENTAL|MacuTest website|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
62083370|NCT04530474|EXPERIMENTAL|Ivermectin|Single dose of 0.15-2 mg/kg/dose to a maximum of 12 mg
62083371|NCT04530474|PLACEBO_COMPARATOR|Placebo|Single dose of 2-4 placebo pills
62083372|NCT04064554|EXPERIMENTAL|MicronJet600|BCG vaccination with MicronJet600
62083373|NCT04064554|ACTIVE_COMPARATOR|Conventional needle|BCG vaccination with conventional needle
62083374|NCT01500226|PLACEBO_COMPARATOR|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
62459040|NCT02396875|ACTIVE_COMPARATOR|Group 2|A control arm of 15 patients with heart failure and no dyssynchrony will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
62459041|NCT02396875|ACTIVE_COMPARATOR|Group 3|A control arm of 15 patients with normal hearts will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
62461780|NCT06294080|EXPERIMENTAL|Dance|Participants will be provided with three dance genre options to choose from, ballroom dance, street dance/Hip-pop and ballet, and the most-voted genre will be delivered. Dance sessions are instructed twice a week for eight weeks. Every session lasts 45-60 minutes, containing 5-10 minutes of warm-up and 35-55 minutes of learning or practicing. In the first four weeks, a short dance sequence will be taught and in the following four weeks, participants will mainly practicing the learnt sequence along with music.
62083375|NCT01500226|EXPERIMENTAL|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
62083376|NCT06008691||B-cell NHL patients treated with novel MAB in Italian real life (approved by EMA and AIFA).|"B-cell NHL patients treated with novel MAB in Italian real life (approved by EMA since 2020 and prescribed according to the indications for use authorized for marketing in Italy).~Patients first-line and relapsed or refractory who had received at least 1 dose of MAB.~Different cohorts will be analyzed according to approved treatment indications, type of antibody employed and NHL hystotypes."
62083377|NCT04504084|EXPERIMENTAL|Decision aid group|Shared decision making using decision aid
62083378|NCT04504084|NO_INTERVENTION|Controlled group|Standard oral explanation the details of treament options
62083379|NCT06563895|EXPERIMENTAL|acoramidis|Participants will receive acoramidis 712 mg orally BID (which is equivalent to 800 mg acoramidis HCl BID)
62461781|NCT06294080|EXPERIMENTAL|Tai Chi|The Tai Chi Group will be given the essential 18-form of Chen's style Tai Chi Chuan. Each session lasts 45-60 minutes, twice a week for 8 weeks. Every session contains 5-10 minutes of warm-up, 5 minutes of standing exercise (站桩) with calming music, and 30-45 minutes of learning or practicing. In the first 8 sessions, 15 forms will be taught in total, averagely two forms are taught every session. In the next 8 sessions, participants will practise the complete 18-form repeatedly following the lead of an instructor with background music. Each repetition takes approximately 2 minutes 20 seconds. Apart from movements, the Taoism philosophy as the origin of Tai Chi will also be embedded during the intervention
62083380|NCT06563895|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo to match twice daily
62282454|NCT06399926||Pemetrexed 30mg|Pemetrexed 30mg D1 every week until efficacy evaluated remission or stable ; change to every 3 weeks.
62461782|NCT06294080|NO_INTERVENTION|Control|Participants will be told to maintain their usual lifestyle and only attend for physical assessments
62461783|NCT04706104||Propofol-Ketamine|2-3 mg/kg propofol and 1-2 mg/kg ketamine will be used for anesthesia induction
62461784|NCT04706104||Midazolam-Fentanyl|0.15 mg/kg midazolam and 10-15 mcg/kg fentanyl will be used for anesthesia induction
62461785|NCT01543880||Users of somatropin|
62461786|NCT04932252|EXPERIMENTAL|A4368 - Dose 1|Single dose of A4368 or placebo tablet, orally administered
62461787|NCT04932252|EXPERIMENTAL|A4368 - Dose 2|Single dose of A4368 or placebo tablet, orally administered
62461788|NCT04932252|EXPERIMENTAL|A4368 - Dose 3|Single dose of A4368 or placebo tablet, orally administered
62650292|NCT04113135|ACTIVE_COMPARATOR|Journaling, meditation, education arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post-testing will take approximately 45 minutes to one hour. Session 1 for all participants (control and experimental) will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The control group will participate in a 45-60 minute session for weeks 2-6 consisting of goal setting to facilitate behavior change, education on MS, and meditation. Session 7 will conclude the study with reassessment of all outcome measurements as listed above.
62282455|NCT01622569|ACTIVE_COMPARATOR|OPN-375 100 μg BID|"Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
62282456|NCT01622569|PLACEBO_COMPARATOR|Placebo|"Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
62282457|NCT01622569|ACTIVE_COMPARATOR|OPN-375 200 μg BID|"Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
62282458|NCT01622569|ACTIVE_COMPARATOR|OPN-375 400 μg BID|"Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
62282459|NCT00503204|EXPERIMENTAL|1|Lomustine + Cediranib (AZD2171)
62459042|NCT02396875|EXPERIMENTAL|Group A|"10 patients from Group 1~On the day preceding the CRT implant will attend hospital for a temporary invasive catheter study. The patient will have a radial sheath positioned in the arterial system. A pacing protocol will be performed using a pacing wire inserted into the right atrium. Coronary sinus venous blood sampling will be performed using a catheter placed via the femoral or internal jugular vein. At the chief investigator's discretion a specially designed exercise bicycle that allow supine exercise in the catheter lab will be used rather than the atrial pacing wire.~6 months post implant the patients will return to the catheter laboratory for a further study. This will repeat the protocol but with the device having been on for 6 months. This will require further study as described above."
62459043|NCT02396875|ACTIVE_COMPARATOR|Group B|"5 patients form Group 2.~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 2 for 6 month follow up"
62459044|NCT02396875|ACTIVE_COMPARATOR|Group C|"5 patients form Group 3~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 3 for 6 month follow up"
62282460|NCT00146263|ACTIVE_COMPARATOR|Savyon|Computerized cognitive training using the Savyon software
62459045|NCT00628888|EXPERIMENTAL|Unified Protocol for Adolescents (UP-A)|Participants receive the UP-A intervention for 8-21 weeks immediately following randomization.
62459046|NCT00628888|EXPERIMENTAL|Delayed Treatment/Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the UP-A treatment for 8-21 weeks.
62650293|NCT05446103|EXPERIMENTAL|BFR|20 healthy individuals will be assigned to perform elbow flexion exercises with low-load resistance BFR training (30% of 1 RM)
62083381|NCT01054911|EXPERIMENTAL|Sunitinib pill|Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.
62083382|NCT01286974|EXPERIMENTAL|ADME|\[14C\]linifanib
62083383|NCT01286974|EXPERIMENTAL|Extension|linifanib
62083384|NCT06283043||experimental group|Parkinson's patients will be included and the evaluations specified in the method section will be applied.
62083385|NCT06283043||control group|The healthy group will be included and the evaluations specified in the method section will be applied.
62282461|NCT00146263|PLACEBO_COMPARATOR|Control|Usual activity
62282462|NCT04864873|ACTIVE_COMPARATOR|Standard diagnostic pathway|Part of each patient sample will be tested using current standard microbiological techniques.
62282463|NCT04864873|EXPERIMENTAL|mNGS pathway|Part of each sample will be testing using mNGS methodology, which will be compared to the standard diagnostic pathway.
62282464|NCT03900390|EXPERIMENTAL|Cross Ischemic Preconditioning Group|the ascending aorta of the CIP group will be crossclamped to cease the blood supply for 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions
62282465|NCT03900390|NO_INTERVENTION|Control Group|The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation without Ischemic Preconditioning manoeuvre.
62282466|NCT03440593|EXPERIMENTAL|Measured Arm|Patients allocated to the measured energy expenditure (group M) will receive the intervention. Caloric delivery will target results of IC measurement.
62282467|NCT03440593|NO_INTERVENTION|Estimated Arm|Patients allocated to the estimated energy expenditure (group E) will receive nutrition with caloric intake calculated based on the Penn State equation.
62282468|NCT00317148|EXPERIMENTAL|Placebo|
62282469|NCT00317148|EXPERIMENTAL|DHEA|
62282470|NCT01992809|ACTIVE_COMPARATOR|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA \[α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%\], in 3 capsules/ day
62282471|NCT01992809|PLACEBO_COMPARATOR|placebo mineral oil|placebo mineral oil 3 ml/day
62282472|NCT05065398|EXPERIMENTAL|HLX208|
62083386|NCT06363435||Patients with prostate cancer|Patients referred to clinically indicated PSMA PET-CT due to initial or secondary staging of prostate cancer
62083387|NCT00872469|ACTIVE_COMPARATOR|Tranexamic acid|
62083388|NCT00872469|PLACEBO_COMPARATOR|placebo|
62083389|NCT02338713|EXPERIMENTAL|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
62083390|NCT04994574|EXPERIMENTAL|tiotropium/olodaterol|
62282473|NCT06342869|EXPERIMENTAL|buccal infiltration with 4% articaine containing 1:100,000 epinephrine|
62282474|NCT06342869|EXPERIMENTAL|buccal infiltration with 2% lidocaine containing 80,000 epinephrine|
62083391|NCT04890522|EXPERIMENTAL|Experimental group|5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days, and intravenous infusion of cisplatin 80 mg/m2 on day 1 and day 28, and intravenous infusion of JS001 240mg on day 1 and day 21, every 60 days.
62083392|NCT04890522|ACTIVE_COMPARATOR|Control group|gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1, and intravenous infusion of JS001 240mg on day 1, every 21 days.
62083393|NCT03856021|ACTIVE_COMPARATOR|Microfracture|
62083394|NCT03856021|ACTIVE_COMPARATOR|Microfracture with Bone Marrow Aspirate Concentrate|
62282475|NCT06342869|EXPERIMENTAL|buccal and palatinal infiltration with 4% articaine containing 1:100,000 epinephrine|
62282476|NCT06342869|EXPERIMENTAL|buccal and palatinal infiltration with 2% lidocaine containing 80.000 epinephrine|
62650294|NCT05446103|SHAM_COMPARATOR|Sham BFR|20 healthy individuals will be assigned to perform elbow flexion exercises with high-load resistance training with sham BFR (65% of 1 RM)
62650295|NCT06551740|EXPERIMENTAL|After a single dose of HUC2-344, co-administration of HUC2-344-R1 and HUC2-344-R2|Take 2 pills of comparative drugs first, and take 1 pill of IP after a 1 week of the break.
62083395|NCT05719285|ACTIVE_COMPARATOR|1: Single-Dose Antibiotic Prophylaxis|Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection.
62282477|NCT05633810|ACTIVE_COMPARATOR|Anti-thrombotic arm|For patients eligible for aspirin therapy arm.
62282478|NCT05633810|PLACEBO_COMPARATOR|Anti-thrombotic arm (Placebo)|For patients eligible for aspirin therapy arm.
62282479|NCT05633810|ACTIVE_COMPARATOR|Anti-inflammatory arm|For patients ineligible for aspirin therapy arm.
62083396|NCT05719285|ACTIVE_COMPARATOR|2: Multi-Dose Antibiotic Prophylaxis|Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection. The same antibiotic will be continued for 3 days of total antibiotic administration with additional doses prescribed to the patient's pharmacy.
62083397|NCT04028115|EXPERIMENTAL|Interventional|Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. In this, study no randomisation will occur. All patients will receive the same treatment.
62083398|NCT02249871|EXPERIMENTAL|Semaglutide|
62083399|NCT02249871|EXPERIMENTAL|Semaglutide + Omeprazole|
62282480|NCT05633810|PLACEBO_COMPARATOR|Anti-inflammatory arm (Placebo)|For patients ineligible for aspirin therapy arm.
62282481|NCT03269344|PLACEBO_COMPARATOR|Control Arm|Standard supportive care during definitive treatment plus placebo
62282482|NCT03269344|EXPERIMENTAL|Experimental Arm|Gabapentin plus standard supportive care
62282483|NCT01504555||Patients under investigation for hypercortisolism|Patients undergoing routine evaluation for hypercortisolism at Haukeland University Hospital, Bergen, Norway, will be asked to participate.
62282484|NCT01600872||Gruop 1|
62650296|NCT06551740|EXPERIMENTAL|After co-administering HUC2-344-R1 and HUC2-344-R2 once, take single dose of HUC2-344 once.|Take 1 pill of IP first, and take 2 pills of comparative drugs after a 1 week of the break.
62282485|NCT01600872||Group 2|
62650297|NCT05054634||Experimental Group (EG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
62282486|NCT01097304|EXPERIMENTAL|Treatment (ursodiol)|Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
62459047|NCT05129098|EXPERIMENTAL|Left Bundle Branch Pacing|Implantation of a left bundle branch lead via sheath, to perform left bundle branch pacing
62459048|NCT05129098|ACTIVE_COMPARATOR|Conventional Right Venticular Pacing|The ventricular lead will be implanted in the right ventricle in the conventional way
62083400|NCT06416618|EXPERIMENTAL|Non-surgical treatment|Patients in the non-surgical group will be offered an optional sling for comfort for an additional 1-2 weeks at their first visit,
62459049|NCT03772496|EXPERIMENTAL|circulating tumor cells|circulating tumor cells test and FNAB will be performed at the same time
62461789|NCT04932252|EXPERIMENTAL|A4368 - Dose 4|Single dose of A4368 or placebo tablet, orally administered
62650298|NCT05054634||Control Group (CG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
62282487|NCT01572090|ACTIVE_COMPARATOR|Conventional weight loss: CONV-NG|"Obese normoglycemic (NG) patients evidenced by a body fat ≥ 35% in women and ≥ 25% in men and a 2-h oral glucose tolerance test.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
62083401|NCT06416618|ACTIVE_COMPARATOR|Procedure: Surgical treatment|The surgical group will receive osteosynthesis with a locking plate or an intramedullary locking nail, according to the surgeon's choice
62083402|NCT00554983|PLACEBO_COMPARATOR|2|
62459050|NCT03417128|NO_INTERVENTION|Control|Participants in the control group will receive a one-time personalised nutrition and lifestyle advised based from the Malaysian Dietary Guideline 2010. They will be assured to be followed up twice for the next six month.
62459051|NCT03417128|EXPERIMENTAL|Peer support|This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering.
62650299|NCT00720135|EXPERIMENTAL|Arm I|Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
62083403|NCT00554983|EXPERIMENTAL|1|
62083404|NCT04097561|EXPERIMENTAL|Single arm, open-label|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
62083405|NCT04491643|EXPERIMENTAL|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months. Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.~Due to personal reasons, patients may not accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
62083406|NCT05197075|EXPERIMENTAL|Darunavir/Cobicistat (DRV/COBI) Fixed Dose Combination (FDC)|Participants will receive the DRV/COBI FDC tablet for oral use, dispersed in water on Day 1.
62083407|NCT06493838|PLACEBO_COMPARATOR|Control group|intravenous 50 mL of sterile saline 0.9% injection of 0.9% after umbilical cord clamping.
62083408|NCT06493838|ACTIVE_COMPARATOR|Neostgmine group|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.
62459052|NCT02051309|EXPERIMENTAL|Guanfacine 6mg/day ER|Guanfacine 6mg/day extended release
62459053|NCT02051309|PLACEBO_COMPARATOR|Placebo|Placebo matching capsule
62459054|NCT00377871|ACTIVE_COMPARATOR|1|Valve design 1
62650300|NCT05445089|EXPERIMENTAL|Isothymol or Carvacrol group|"* Each ml contains 6mg of Isothymol or Carvacrol (2-Methyl-5-(1-methylethyl)-phenol modified) at 1% v/v. (GRAS lipophilic modified with isothymol).~* Oral solution (dispersion L/L). Dilute lipophilic aqueous solution of light or medium yellow.~* Excipients: Cis-9-octadecenoic acid with Squalene (99%)."
62650301|NCT05445089|PLACEBO_COMPARATOR|Control|•Placebo
62650302|NCT00512525|PLACEBO_COMPARATOR|2|
62650303|NCT03006432|ACTIVE_COMPARATOR|FOLFOX|Cycles every 15 days until progression desease
62459055|NCT00377871|ACTIVE_COMPARATOR|2|Valve design 2
62459056|NCT00377871|NO_INTERVENTION|Control|Healthy control
62650304|NCT03006432|EXPERIMENTAL|TFOX|Cycles every 15 days until progression desease
62459057|NCT03280797|OTHER|Control|
62459058|NCT03280797|OTHER|Rheumatoid arthritis patients|
62459059|NCT02359331|ACTIVE_COMPARATOR|14 days PBMT group|Giving the 14 days bismuth quadruple regimen as 2nd rescue therapy for eradication of persistent H. pylori infection Drug regimen Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
62650305|NCT04412889|EXPERIMENTAL|CAR-T treatment group|The patients will receive BCMA/CD19 dual-target CAR-T cell treatment. BCMA/CD19 dual-target CAR-T cell dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg.
62650306|NCT04615936|EXPERIMENTAL|Methylene Blue-Photodisinfection|The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
62650307|NCT00747214|EXPERIMENTAL|CRx-102 plus DMARD therapy|
62650308|NCT00747214|PLACEBO_COMPARATOR|Placebo plus DMARD therapy|
62461790|NCT04932252|EXPERIMENTAL|A4368 - Dose 5|Single dose of A4368 or placebo tablet, orally administered
62461791|NCT04932252|EXPERIMENTAL|A4368 - Dose 6|Single dose of A4368 or placebo tablet, orally administered
62282488|NCT01572090|ACTIVE_COMPARATOR|Conventional weight loss: CONV-T2D|"Obese type 2 diabetic (T2D) patients evidenced by a body fat \>35% in women and ≥ 25% in men and proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
62282489|NCT01572090|ACTIVE_COMPARATOR|Laparoscopic Sleeve gastrectomy: SG-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing a sleeve gastrectomy (SG). The Sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach. Via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
62083409|NCT01589302|EXPERIMENTAL|Treatment (ibrutinib)|Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.
62282490|NCT01572090|ACTIVE_COMPARATOR|Laparoscopic Sleeve gastrectomy: SG-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
62459060|NCT02359331|EXPERIMENTAL|7 days tailored therapy group|According the antimicrobial susceptibility testing, the H. pylori isolates were resistant to moxifloxacin, 7 days PBMT regimen were prescribed; if the isolates were resistant to metronidazole, 7 days moxiflxacin based triple regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d) were prescribed.
62650309|NCT02696798|EXPERIMENTAL|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
62083410|NCT03753971|EXPERIMENTAL|Apneas with and without intervention|Each patient will be his own control.
62459061|NCT01913990|OTHER|Arm A: Standard Anti-emetic regimen|"The standard anti-emetic arm:~In this arm the treating medical oncologist will determine the choice of anti-emetic regimen that they perceive the patient would require and prescribe it. The treating physician will be blinded to result of the personalized composite emesis score. The physician may or may not choose to prescribe an NK-1 inhibitor as the study will not predetermine the type of anti-emetics used. In the event that the patient experienced chemo induced nausea and vomiting (CINV), modifications to the initial anti emetic regimen would be left to the treating physician."
62459062|NCT01913990|EXPERIMENTAL|Arm B: Dexamethasone, Ondansetron, Aprepitant|"The emesis risk model arm:~Prior to the start of intravenous chemotherapy an emesis risk score will be calculated for both acute and delayed emesis. The anti-emetic prophylaxis treatment will follow the emesis risk score. Whereby either an acute emesis score of ≥7 and/or a delayed emesis score of \>16 will be considered high-risk. The anti-emetics will be prescribed reflecting this risk for pre-chemotherapy, 8 hrs post chemotherapy and day 2-3 post chemotherapy. Dexamethasone, Ondansetron and Aprepitant will be given in different combination and doses depending on what score the participant receives based on their responses to the diary. For subsequent cycle the anti-emetic score will be re-calculated prior to each cycle and the choice of anti-emetics adjusted if necessary."
62083411|NCT04730934||Healthy population|Healthy individuals aged between 18-65
62282491|NCT01572090|ACTIVE_COMPARATOR|Laparoscopic R-Y gastric bypass: RYGB-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
62459063|NCT03229005|ACTIVE_COMPARATOR|A1 thick-high|group with thick tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
62459064|NCT03229005|EXPERIMENTAL|A2 thick-low|group with thick tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
62459065|NCT03229005|ACTIVE_COMPARATOR|B1 thin-high|group with thin tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
62459066|NCT03229005|EXPERIMENTAL|B2 thin-low|group with thin tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
62650310|NCT02696798|EXPERIMENTAL|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
62650311|NCT02696798|PLACEBO_COMPARATOR|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
62650312|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group1|Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 8 weeks.
62459067|NCT04661748|ACTIVE_COMPARATOR|Intervention arm|Active alarms
62459068|NCT04661748|NO_INTERVENTION|no intervention|No alarms
62650313|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group2|Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 16 weeks.
62650314|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group3|Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 24 weeks.
62650315|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group4|Tai Chi Chuan 1 hour/session, 5 sessions/week for 8 weeks.
62650316|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group5|Tai Chi Chuan 1 hour/session, 5 sessions/week for 16 weeks.
62650317|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group6|Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks.
62650318|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group7|Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 8 weeks.
62650319|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group8|Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 16 weeks.
62650320|NCT06372535|EXPERIMENTAL|Tai Chi Chuan Group9|Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 24 weeks.
62650321|NCT03799861||Epoch 1: Care prior to HBB training|A period of demographic and birth outcome data collection for a retrospective cohort of all infants born in the three study hospitals during the 18 months prior to the start of Epoch 2, reflecting care prior to HBB training.
62650322|NCT03799861||Epoch 2: HBB with NeoBeat|Implementation of Helping Babies Breathe training in combination with NeoBeat for detection of HR in non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for prospective cohort of all infants born in the three study hospitals for a 9-month period.
62650323|NCT03799861||Epoch 3: HR-guided HBB|Implementation of HR-guided Helping Babies Breathe training with NeoBeat for measurement of HR throughout resuscitation of non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for a prospective cohort of all infants born in the three study hospitals for a 9-month period.
62083412|NCT04730934||Chronic Low Back Pain Group|Patients aged between 18 and 65 and has at least 3 months of low back pain which started before pandemic.
62083413|NCT04730934||Fibromyalgia Group|Patients aged between 18 and 65 and has a diagnosis of fibromyalgia for at least 6 months
62083414|NCT03978754||Patients who visit clinic|Postoperative patients who have undergone axillary surgery for breast cancer and went to clinic due to complaints of upper limb discomfort.（The expected number of subjects in this group is 300）
62083415|NCT03978754||Preoperative breast cancer patients|Preoperative subjects diagnosed with breast cancer were enrolled as non-lymphedema group. （The expected number of subjects in this group is 1300）
62282492|NCT01572090|ACTIVE_COMPARATOR|Laparoscopic R-Y gastric bypss: RYGB-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
62282493|NCT03551587|EXPERIMENTAL|Irrigant delivered by the Vibringe|"Experimental group:~The irrigant will be delivered and sonically activated with the Vibringe system."
62459069|NCT05944705||Symptomatic individuals using hemp or cannabis products for immune support|Individuals with symptomatic illness that utilize a proprietary hemp or cannabis product to aid in their recovery
62459070|NCT05944705||Symptomatic individuals not currently using hemp or cannabis products for immune support|Individuals without symptomatic illness that do not utilize the proprietary hemp or cannabis product to aid in their recovery
62459071|NCT00659321|ACTIVE_COMPARATOR|1|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
62459072|NCT00659321|PLACEBO_COMPARATOR|2|16 weeks treatment with placebo
62459073|NCT02603783|ACTIVE_COMPARATOR|Capsaicin|1,5 mg capsaicin in 30 minutes
62650324|NCT05976945|EXPERIMENTAL|Baseline-Preparation-Imagery Rescripting-Post Treatment|Each participant follows this sequence: (1) 6-10 weeks waitlist during which no treatment is offered; (2) 5 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 8 to 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The stand-alone ImRs treatment will be based upon the protocol described by Arntz \& Weertman (1999). (This protocol can be modified to tailor the needs of this study more specifically. Possible adaptations shall be based upon the manual developed by Brewin and colleagues (2009) for their study of applying ImRs to depression.); (4) After end of active treatment (ImRs) 5 weeks follow during which only weekly assessments are done.
62650325|NCT00841984||1|patients with complex neurological disease of unknown cause
62650326|NCT00841984||2|positive controls : patients with already known metabolic disease for whom we already have CSF or urines
62459074|NCT02603783|PLACEBO_COMPARATOR|Placebo|75 ml placebo (0,9 % saline) in 30 minutes
62459075|NCT02231645|EXPERIMENTAL|STN DBS group|Experimental protocol is executed in PD patients with STN DBS implant in STN DBS ON and OFF conditions
62083416|NCT04833309|EXPERIMENTAL|Pharmacopuncture therapy|Pharmacopuncture will be administered to the subjects in the pharmacopuncture therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
62083417|NCT04833309|ACTIVE_COMPARATOR|Physical therapy|Physical therapy will be applied to the subjects in the physical therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
62459076|NCT02231645|NO_INTERVENTION|Control group|Experimental protocol is executed in PD patients without STN DBS implant twice without experimental variable manipulation.
62459077|NCT06114706|ACTIVE_COMPARATOR|Initial assessement by physicians|Patients attending with an acute sore throat are initially assessed by a physician. This is one variant of current standard practice.
62459078|NCT06114706|ACTIVE_COMPARATOR|Initial assessement by nurses|Patients attending with an acute sore throat are initially assessed by a nurse. This is one variant of current standard practice.
62459079|NCT06114706|EXPERIMENTAL|Initial assessement by pharmacists|Patients attending with an acute sore throat are initially assessed by a pharmacist. This is officially not standard practice in Sweden, although it happens.
62461792|NCT04932252|EXPERIMENTAL|A4368 - Dose 1 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
62461793|NCT04932252|EXPERIMENTAL|A4368 - Dose 2 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
62461794|NCT03005522|PLACEBO_COMPARATOR|placebo|dosed with placebo
62459080|NCT06261866||Patients with chronic coronary syndromes identified with intermediate grade coronary stenosis|Patients chronic coronary syndrome identified with intermediate grade coronary stenosis undergo coronary angiography according to current practice and guidelines recommendations. FFR will be measured, in consistency with the guidelines and recommended clinical practice. In case of FFR \> 0.8 optimal pharmacotherapy will be prescribed; on the contrary, in case of FFR ≤ 0.8 PCI will be performed. OCT imaging will be performed with commercially available device (Abbott, C7XR Dragonfly TM LightLab Imaging Inc., MA, USA) using the non-occlusive flushing technique.
62083418|NCT00994136|EXPERIMENTAL|Normal saline|In the intervention group the use of heparin as locking solution in the catheter lumen (or lumina) when the catheter is not longer in use is omitted. Catheters are locked under positive pressure with normal saline in stead injecting an extra volume of heparinised saline (100IU/ml).
62083419|NCT00994136|NO_INTERVENTION|Heparin lock|
62083420|NCT01259336|ACTIVE_COMPARATOR|Itraconazole|Role of itraconazole in CCPA
62083421|NCT01259336|EXPERIMENTAL|treatment in cavitary pulmonary aspergillosis|Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
62083422|NCT04052971|EXPERIMENTAL|Escalation phase|"Drug: ABN401~Route of Administration: Oral~The study will follow a single patient cohort approach for the first 3 regular dose levels followed by classic 3+3 design. The starting dose is 50mg QD."
62282494|NCT03551587|NO_INTERVENTION|Irrigation by Conventional needle|"Control group:~Irrigation procedures will br performed with a conventional method using conventional gauge 24 needle."
62282495|NCT02344225|ACTIVE_COMPARATOR|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
62282496|NCT02344225|EXPERIMENTAL|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
62282497|NCT02344225|EXPERIMENTAL|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
62282498|NCT05192369|EXPERIMENTAL|Treatment A: Therapeutic Dose|Single oral dose of 12mg CTP-543
62650327|NCT00841984||3|negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture
62083423|NCT04052971|EXPERIMENTAL|Expansion phase|"Drug: ABN401~Route of Administration: Oral~Once the maximum tolerated dose (MTD) or highest escalation cohort has been reached, or notable efficacy has been observed at a given dose level, a decision as to Recommended Phase 2 dose (RP2D) will be determined. Up to 40 patients with Non-Small Cell Lung Cancer Harboring c-MET Dysregulation will be recruited."
62083424|NCT01702428|EXPERIMENTAL|INV_MMR_L1 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
62282499|NCT05192369|EXPERIMENTAL|Treatment B: Supratherapeutic Dose|Single oral dose of 48mg CTP-543
62282500|NCT05192369|PLACEBO_COMPARATOR|Treatment D: Placebo|Single oral dose of 1 Placebo tablet
62282501|NCT05192369|ACTIVE_COMPARATOR|Treatment C: Positive Control|Single oral dose of 400mg Moxifloxacin
62282502|NCT04830267|ACTIVE_COMPARATOR|Camrelizumab alone|Camrelizumab 200mg IV every 2 weeks
62282503|NCT04830267|EXPERIMENTAL|Stereotactic body radiotherapy plus Camrelizumab|Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks
62282504|NCT04456452|EXPERIMENTAL|Ampion|Ampion
62459081|NCT01843608|NO_INTERVENTION|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.~They cannot change physical activity and nutritional habits."
62650328|NCT04155801|EXPERIMENTAL|Salix Probiotic Blend|Participants will receive a Salix Probiotic Blend capsule orally once a day for 30 days.
62282505|NCT04456452|OTHER|Standard of Care|Standard of Care
62282506|NCT02303717|ACTIVE_COMPARATOR|Xience|Percutaneous coronary intervention utilising a cobalt chromium everolimus eluting stent with durable polymer (Xience) plus oral dual antiplatelet therapy (DAPT) for 12 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
62282507|NCT02303717|EXPERIMENTAL|Synergy|Percutaneous coronary intervention utilising a platinum chromium everolimus eluting stent with bioresorbable polymer (Synergy) plus oral dual antiplatelet therapy (DAPT) for 4 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
62282508|NCT02093702|ACTIVE_COMPARATOR|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
62282509|NCT02093702|EXPERIMENTAL|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
62282510|NCT00606242|ACTIVE_COMPARATOR|Low dose steroid|Fluticasone, 100 mcg per day
62459082|NCT01843608|EXPERIMENTAL|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.~They have to present an attendance above or equal to 80%."
62459083|NCT04012632||cases|Early puberty cases of Han Chinese
62650329|NCT02678117|ACTIVE_COMPARATOR|Pregabalin & placebo|: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.
62650330|NCT02678117|ACTIVE_COMPARATOR|Magnesium sulphate & Placebo|will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.
62282511|NCT00606242|ACTIVE_COMPARATOR|High dose steroid|Fluticasone, 1000 mcg per day
62282512|NCT01952587|OTHER|HIV-infected women|A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
62282513|NCT01952587|OTHER|Healthy control women|A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
62282514|NCT00004029|EXPERIMENTAL|Arm I|atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
62282515|NCT04804592|EXPERIMENTAL|Group A: SiHy CL|Silicone hydrogel (SiHy) CL wear at least 3 days per week and at least 8 hours per day;
62282516|NCT04804592|EXPERIMENTAL|Group B: RGP CL|Rigid gas permeable (RGP) CL wear at least 3 days per week and at least 8 hours per day;
62282517|NCT04804592|EXPERIMENTAL|Group C: no CL wear|No current CL wear for at least 3 months;
62459084|NCT04012632||controls|Controls were matched to cases at 1:1 by age (± 3 months)
62459085|NCT00998023|EXPERIMENTAL|Mynx VCD|Mynx Vascular Closure Device
62459086|NCT00998023|ACTIVE_COMPARATOR|AngioSeal VCD|AngioSeal Vascular Closure Device
62650331|NCT02678117|ACTIVE_COMPARATOR|Pregabalin & Magnesium sulphate|: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.
62650332|NCT02678117|PLACEBO_COMPARATOR|Placebo|will receive placebo medications at the same time and route of administration of other groups.
62650333|NCT03146390|ACTIVE_COMPARATOR|Essential oils (Listerine Mentol)|"1. a single mouthwash with 20 ml of essential oils for 30 seconds~2. 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1)."
62650334|NCT03146390|PLACEBO_COMPARATOR|Water|"1. a single mouthwash with 20 ml of sterile water for 30 seconds~2. 20 ml rinses for 30 seconds with sterile water/2 times daily (1/0/1)."
62650335|NCT03146390|EXPERIMENTAL|Alcohol free essential oils|"1. a single mouthwash with 20 ml of alcohol free essential oils for 30 seconds~2. 20 ml rinses for 30 seconds with alcohol free essential oils/2 times daily (1/0/1)."
62650336|NCT06001671|EXPERIMENTAL|BEBT-109 120mg|BEBT-109 orally at an initial dose of 120 mg once daily.
62650337|NCT06001671|EXPERIMENTAL|BEBT-109 180mg|BEBT-109 orally at an initial dose of 180 mg once daily.
62650338|NCT06001671|EXPERIMENTAL|BEBT-109 240mg|BEBT-109 orally at an initial dose of 240mg (120mg bid) once daily.
62650339|NCT04451096|ACTIVE_COMPARATOR|Probiotic with prebiotic|Drug: Probiotic sachet containing granulated multiple strains of Lactobacillus and Bifidobacterium, granulated fermented milk, lactose, fructo-oligosaccharide (FOS) with orange flavouring.
62282518|NCT06241586||the early period group|Patients admitted before January 2021 received the hybrid strategy of traditional and novel surgical strategies.
62282519|NCT06241586||the late period group|Patients admitted during and after January 2021 received the complete novel PMMI surgical strategy.
62459087|NCT02514265||UCPPS patients|"All participants in this study are men or women who have been diagnosed with Urologic Chronic Pelvic Pain Syndrome (UCPPS). Approximately one-half of the participants will be male, and one-half will be enriched to meet the body map pain location criteria of pelvic pain (PP) only. In addition, enrichment recruitment of 240 UCPPS patients (120 males; 120 females) will also be targeted for those who answer no to questionaire question about specific Bladder pain symptoms."
62650340|NCT04451096|PLACEBO_COMPARATOR|Placebo|Drug : Placebo sachet of granulated milk, lactose and orange flavouring, without FOS or microbial cells which appeared similar to the probiotics
62650341|NCT03786835|NO_INTERVENTION|Control (No intervention)|Participants will not undergo any treatment. Continue with usual daily activities and diet for 6 months.
62650342|NCT03786835|EXPERIMENTAL|Nutrition group|Participants will receive protein enriched food to supplement the diet for 6 months.
62650343|NCT03786835|EXPERIMENTAL|Exercise group|Participants will exercise 3 times a week for 60 minutes each time over 6 months.
62282520|NCT02901431|PLACEBO_COMPARATOR|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
62282521|NCT02901431|EXPERIMENTAL|Balovaptan (RO5285119) 10 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
62650344|NCT03786835|EXPERIMENTAL|Nutrition + Exercise group|Participants will receive protein enriched food to supplement the diet and exercise 3 times a week for 60 minutes each time over 6 months.
62653063|NCT05205356||Neonates and Parents/Caregivers|"Providers caring for newborns that meet eligibility criteria will approach parents to assess interest. The VIGOR study staff will remotely contact parents to complete consent for genomic sequencing (GS). We will also invite 1 additional primary caregiver (e.g. father, co-mother etc.) to participate even if that caregiver is not biologically related to the child.~We will administer surveys at baseline enrollment to assess sociodemographics, obstetrical history, family genetic history \& mental health; within 1 week of disclosure of findings to assess satisfaction \& mental health; \& at 3 \& 6 months to further assess mental health \& newborn clinical outcomes. We will approach a subset of the families for qualitative interviews to assess satisfaction with VIGOR \& receipt of GS results with their physician in more detail."
62083425|NCT01702428|EXPERIMENTAL|INV_MMR_L2 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
62083426|NCT01702428|EXPERIMENTAL|INV_MMR_L3 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
62083427|NCT01702428|ACTIVE_COMPARATOR|COM_MMR Group|Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively. Pooled analysis is conducted for this group.
62083428|NCT04507672|PLACEBO_COMPARATOR|saline group|Use saline for fluid resuscitation during the first 72 hours after enrollment
62083429|NCT04507672|EXPERIMENTAL|Acetated Ringer's solution group|Use acetated Ringer's solution for fluid resuscitation during the first 72 hours after enrollment
62083430|NCT03807492||EMPOWeR Study|This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
62083431|NCT02254096|EXPERIMENTAL|BIRT 1696 BS|single escalating dose phase
62083432|NCT02254096|EXPERIMENTAL|BIRT 1696 BS + GFJ|single dose grapefruit effect arm
62083433|NCT02254096|EXPERIMENTAL|BIRT 1696 BS + HFM|single dose food effect arm
62083434|NCT02254096|PLACEBO_COMPARATOR|Placebo|
62650345|NCT05126693|EXPERIMENTAL|Intervention group|The children in the intervention group will receive BoNT injections in the medial gastrocnemius and/or the semitendinosus muscle(s). As part of the standard treatment approach of the CP Reference Centre of the University Hospitals Leuven, the injections are followed by a period of bilateral stretching casts if indicated (below the knee walking casts and removable knee extension casts when necessary) and all children will receive intensive physical therapy and application of ankle foot orthoses following BoNT injections. The follow-up period for the current study is 8-10 weeks. During this intensive physical therapy period post-BoNT, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (that is scheduled prior to the BoNT injections).
62083435|NCT04946305||Lutathera|Patients administered Lutathera by prescription
62083436|NCT00600743|PLACEBO_COMPARATOR|1 'Instructions to eat normally'|'Instructions to eat normally' Placebo 1 mg dose
62083437|NCT00600743|ACTIVE_COMPARATOR|2 'Instructions to eat normally'|'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
62083438|NCT00600743|PLACEBO_COMPARATOR|3 'Instructions to eat normally'|'Instructions to eat normally' 2 mg placebo
62083439|NCT00600743|ACTIVE_COMPARATOR|4 'Instructions to eat normally'|'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
62083440|NCT00600743|PLACEBO_COMPARATOR|5 'Instructions to eat normally'|'Instructions to eat normally' 4 mg placebo
62083441|NCT00600743|ACTIVE_COMPARATOR|6 'Instructions to eat normally'|'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
62083442|NCT00600743|PLACEBO_COMPARATOR|7 Instructions to binge eat|Instructions to binge eat 4 mg placebo
62461795|NCT03005522|ACTIVE_COMPARATOR|intervention|10mg oral dexamethasone
62083443|NCT00600743|ACTIVE_COMPARATOR|8 Instructions to binge eat|Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'
62083444|NCT00951561|EXPERIMENTAL|Vipon|
62083445|NCT00951561|ACTIVE_COMPARATOR|Ibuprofen|
62083446|NCT00730990|EXPERIMENTAL|Cohort 1|This arm will have no active treatment.
62083447|NCT00730990|EXPERIMENTAL|Cohort 2|
62083448|NCT05881083|EXPERIMENTAL|Intervention group|1-week nicotine replacement therapy sample + Brief cessation advice
62083449|NCT05881083|ACTIVE_COMPARATOR|Control group|Brief cessation advice
62282522|NCT02901431|EXPERIMENTAL|Balovaptan (RO5285119) 4 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.
62282523|NCT00002520|EXPERIMENTAL|Quit Smoking Intervention|Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.
62282524|NCT00002520|ACTIVE_COMPARATOR|Usual Care|"No special intervention after randomization. Usual care may or may not include advice or assistance to stop smoking. Physicians were reassured that usual care did not preclude quit smoking counseling."
62282525|NCT03075085|ACTIVE_COMPARATOR|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
62282526|NCT03075085|EXPERIMENTAL|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
62282527|NCT05764486|OTHER|treatment plan|Treatment plan performed by Hitachi's Heavy Ion Beam Therapy System HyBEAT will be designed to suit the particular needs of each subject and the course of treatment will differ for each subject depending on the type of tumor, varying from 1 day to 4 weeks. All subjects will be monitored for 12 weeks after receiving the last treatment.
62459088|NCT06412549|NO_INTERVENTION|Baseline|"Participants over 18 years of age admitted to the ICU in the selected hospitals during the study period, using intracranial pressure monitoring catheters and/or external ventricular drain. Baseline database obtained from the study Device-related Central Nervous System Infections in Adult Intensive Care Units in Brazil (IMPACTO-SNC), Carried out during the period from 2022 to 2023."
62282528|NCT01002079|EXPERIMENTAL|BMS-708163|
62282529|NCT01002079|OTHER|Rifampin|
62282530|NCT01002079|EXPERIMENTAL|Rifampin + BMS-708163|
62459089|NCT06412549|EXPERIMENTAL|Intervention|Participants over 18 years old admitted to the ICU in the selected hospitals and trained in the intervention bundle during the study period, using intracranial pressure monitoring catheters and/or external ventricular shunt. Participants included in the period from 2024 to 2026
62282531|NCT05237895|OTHER|Patients with Gestational Diabetes|pregnant women who are at 24-26 weeks of gestational age with positive oral glucose tolerance screening test.
62282532|NCT05237895|OTHER|Healty Pregnants|pregnant women who are at 24-26 weeks of gestational age with normal oral glucose tolerance screening test.
62282533|NCT03183128|EXPERIMENTAL|SER-109|Received oral dose of SER-109
62083450|NCT01080196|EXPERIMENTAL|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
62083451|NCT01080196|NO_INTERVENTION|TRADITIONAL|"The TRAD group will perform their lower extremity resistance exercise for 15 minutes per session with isotonic weight machines and cuff weights as part of their multicomponent exercise fall reduction program (MCERFP). The progression of the 3 x/week, 12 week TRAD program will be determined as a relative function of their 1 repetition maximum (1RM) weight that can be lifted in a safe and successful manner. The 1RM will be measured before the 12 week training program and every 2 weeks thereafter. A target resistance workload (i.e., weight level) commensurate with 60-70% of the 1RM of the knee and hip extensors will be calculated bi-monthly and 3 sets of 15 repetitions of 3-4 different knee and hip exercises will be used over a 15 minute time period."
62083452|NCT02909101|EXPERIMENTAL|Active Cognitive Training (ACT)|Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
62083453|NCT02909101|SHAM_COMPARATOR|Control Training (CON)|Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.
62282534|NCT03183128|PLACEBO_COMPARATOR|Placebo|Received matching placebo
62282535|NCT03856151|ACTIVE_COMPARATOR|Group 1|"For Group 1, each subject will receive Treatment 1# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 2#.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks."
62459090|NCT03187678|EXPERIMENTAL|Selexipag|Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.
62459091|NCT03443778|ACTIVE_COMPARATOR|Nacl 0,9% (Control) group|Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
62459092|NCT03443778|ACTIVE_COMPARATOR|Bupivacaine 0,5%|Bupivacaine 0.5% 1 mg/kg with in Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
62459093|NCT03443778|ACTIVE_COMPARATOR|Bupivacaine 0,5% , Dexamethasone|Bupivacaine 0,5% 1 mg/kg,dexamethasone 0.5 mg/kg (max dosage 8mg) 3-5 ml separately two part for each tonsil before surgery
62459094|NCT02710201|NO_INTERVENTION|Control|No feedback on progress of other participants.
62083454|NCT01811563|ACTIVE_COMPARATOR|Stryker|Subjects will be receiving the Stryker Triathlon total knee replacement
62083455|NCT01811563|ACTIVE_COMPARATOR|Zimmer|Subjects will be receiving a Zimmer NexGen total knee replacement
62083456|NCT01615588|EXPERIMENTAL|honey|Manuka honey
62083457|NCT01570179|EXPERIMENTAL|deep block ideal body weight|
62083458|NCT01570179|ACTIVE_COMPARATOR|deep block real body weight|
62083459|NCT01570179|EXPERIMENTAL|moderate block ideal body weight|
62083460|NCT01570179|ACTIVE_COMPARATOR|moderate block real body weight|
62282536|NCT03856151|ACTIVE_COMPARATOR|Group 2|"For Group 2, each subject will receive Treatment 2# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 1#.~Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks."
62282537|NCT05870904|EXPERIMENTAL|Dry Needling Group|Received dry needling through the insertion of fusiform needle for the trigger point release on 3 days a week aimed at pain relief.
62282538|NCT05870904|ACTIVE_COMPARATOR|Ischemic Compression Group|Received ischemic compression release through thumb pressure for trigger points on 3 days a week.
62282539|NCT04464213|EXPERIMENTAL|Single dose experiments|
62282540|NCT04464213|EXPERIMENTAL|Multi-dose experiments|
62282541|NCT00434135|EXPERIMENTAL|A|Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks
62282542|NCT00434135|ACTIVE_COMPARATOR|B|Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks
62282543|NCT06056258|ACTIVE_COMPARATOR|VL-NL-02|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days.
62282544|NCT06056258|PLACEBO_COMPARATOR|Placebo|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days.
62459095|NCT02710201|EXPERIMENTAL|Descriptive Social Norm|Average physical activity of other participants in study conveyed to this group.
62650346|NCT05126693|NO_INTERVENTION|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic management during a period of 8-10 weeks.
62650347|NCT04188054|EXPERIMENTAL|Intervention|Will be asked to change the position they lie on their bed when sleeping; that is, to re-position themselves when lying on their back so that their feet (and ankles) hang over the end of the mattress.
62650348|NCT04188054|PLACEBO_COMPARATOR|Control|Will be asked to make no change in the way they normally lie on their mattress when sleeping
62282545|NCT01934140|EXPERIMENTAL|ACWY-TT group|All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study.
62282546|NCT01934140|ACTIVE_COMPARATOR|MenPS group|All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
62282547|NCT02770937|ACTIVE_COMPARATOR|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
62282548|NCT02770937|ACTIVE_COMPARATOR|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on box trainer.
62282549|NCT02770937|NO_INTERVENTION|Control|The control group will not receive further training.
62459096|NCT02710201|EXPERIMENTAL|Descriptive-plus-Injunctive Social Norm|Average physical activity of other participants in study and message of approval or disapproval (depending on how one is faring compared to others) conveyed to this group.
62459097|NCT03157388|EXPERIMENTAL|Intervention|Combined Vancomycin and Gentamycin and Meropenem
62282550|NCT03671928|OTHER|bowel ischemia|
62282551|NCT03671928|OTHER|non-digestive abdominal pain|
62459098|NCT00477347|ACTIVE_COMPARATOR|1|Manual administration
62459099|NCT00477347|EXPERIMENTAL|2|Closed-loop administration
62459100|NCT04137393|EXPERIMENTAL|Salvadora persica|"brush teeth with Salvadora persica Miswak"
62459101|NCT04137393|ACTIVE_COMPARATOR|tooth brush|brush with fluoridated tooth paste
62459102|NCT02696070|OTHER|Sham of Provant|Sham of Provant
62459103|NCT02696070|OTHER|Active Treatment|Active Provant Treatment
62459104|NCT00996671|EXPERIMENTAL|Dose Escalation Cohorts|single dose administration escalating doses starting at 20 mg and continue escalation; the highest dose in this study will not exceed the mean Day 1 exposure in male dogs at the NOAEL dose (6 mg/kg/day).
62459105|NCT00996671|EXPERIMENTAL|Food effect Cohort|Dose to be selected based on emerging safety and PK data; subjects will be given FDA standard high fat meal followed by single dose of study drug.
62459106|NCT02592967|EXPERIMENTAL|Cohort 1A and 1B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
62459107|NCT02592967|EXPERIMENTAL|Cohort 2A and 2B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
62459108|NCT01261078|PLACEBO_COMPARATOR|Placebo|8 mg bupivacaine only
62459109|NCT01261078|ACTIVE_COMPARATOR|Epi 25|8 mg of bupivacaine mixed with 25 mcg of epinephrine
62459110|NCT01261078|ACTIVE_COMPARATOR|Epi 50|8 mg of bupivacaine mixed with 50 mcg of epinephrine
62459111|NCT01261078|ACTIVE_COMPARATOR|Epi 100|8 mg of bupivacaine mixed with 0.1 mg of epinephrine
62459112|NCT01261078|ACTIVE_COMPARATOR|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
62282552|NCT01154933|EXPERIMENTAL|exenatide 5 mcg|exenatide 5 mcg
62282553|NCT01154933|EXPERIMENTAL|exenatide 10 mcg|exenatide 10 mcg
62282554|NCT01154933|PLACEBO_COMPARATOR|placebo|placebo
62459113|NCT05214768|EXPERIMENTAL|CC-93538|
62459114|NCT05214768|PLACEBO_COMPARATOR|Placebo|
62459115|NCT06007456||Patients at onset of juvenile arthritis|New diagnosis of JIA
62459116|NCT06007456||Patients with juvenile arthritis in follow up|Subjects with JIA already followed at Rheumatologic Service
62459117|NCT01973049|EXPERIMENTAL|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
62459118|NCT01973049|EXPERIMENTAL|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200mg tablet orally twice a day for 12 weeks"
62459119|NCT01973049|EXPERIMENTAL|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
62459120|NCT01973049|EXPERIMENTAL|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If \< 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
62459121|NCT03257085|EXPERIMENTAL|Low-carbohydrate, high-fat|Participants adhering to low-carbohydrate, high-fat diet for 8 weeks.
62650349|NCT02071498|EXPERIMENTAL|Pillbox app named ALICE|pillbox app for elderly patients taking multiple medications. App was used during three months
62650350|NCT02071498|ACTIVE_COMPARATOR|oral and written information|oral and written information regarding the main risks related to their medications and the most common errors of patients
62650351|NCT06517992|EXPERIMENTAL|Health education for cadre|Health education for cadre (Health Community Volunteer) to support metastatic breast cancer patients and their family caregivers
62459122|NCT03257085|EXPERIMENTAL|High-carbohydrate, moderate fat|Participants following high-carbohydrate, moderate-fat diet for 8 weeks.
62459123|NCT01840969||CAOD group|Single arm study group
62083461|NCT02234310|EXPERIMENTAL|Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)|Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (\>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
62083462|NCT02117674|ACTIVE_COMPARATOR|standard forward-viewing colonoscopy|polyp detection with standard forward-viewing colonoscopy polyp detection in the right colon with scope retroflexion
62083463|NCT02117674|ACTIVE_COMPARATOR|full-spectrum colonoscopy|polyp detection with full-spectrum colonoscopy polyp detection in the right colon with scope retroflexion
62083464|NCT02378064|EXPERIMENTAL|Fimasartan and vytorin|fimasartan(60mg,QD)+Vytorin(10mg,QD)
62282555|NCT02934009|EXPERIMENTAL|Dialysis patients|In this group dialysis patients are measured by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) during their routine dialysis sessions. After a 5 min rest period the arm of the patients is placed onto the NMR-Mouse and measured before the beginning of dialysis. The arm examined is not the shunt arm. The area selected should not display any signs of skin disease or scars from previous surgeries. After the dialysis the same area is measured again in a second measurement. The measurement will be repeated on three different days with each patient.
62282556|NCT02934009|EXPERIMENTAL|Healthy volunteers|"In this group kidney-healthy volunteers will be examined by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) at three different days. The right/left arm or leg will be used for repeated measurement. Altogether 2 measurements per day are reformed in order to evaluate the reproducibility and variability."
62459124|NCT02793453|OTHER|Diseased|Patients suffering of moderate to severe chronic periodontitis
62459125|NCT02793453|OTHER|Healthy|Healthy Patients not suffering of any periodontal disease a
62459126|NCT02501057|ACTIVE_COMPARATOR|Clinician's Guide|"The Baseline intervention includes a brief meeting (20 minutes or less) with a clinic staff member to discuss drinking and HIV medication adherence. The clinic staff member provides feedback on the participant's drinking, helps the participant set a drinking goal, and make suggestions to help the participant reduce their drinking. Participant receives a booklet called Rethinking Drinking that includes information about alcohol and tips for cutting down on alcohol use or quitting drinking. 30- and 60-day visits last about 10 minutes each, and include a meeting with the clinic staff member again to discuss drinking and HIV medication adherence, and to get additional feedback."
62459127|NCT02501057|ACTIVE_COMPARATOR|Enhanced Motivational Interviewing|Participants meet with a counselor to discuss their alcohol use, the impact it has on their health, and the possibility of reducing their drinking. The first counseling session is intended to help participants reduce their alcohol use. They are asked to describe the pros and cons of their alcohol use and whether it might be important to reduce or quit drinking. After, they are given a study smartphone and asked to use HealthCall-S daily to help keep track of their drinking. At 30 days, participants review a graph showing the results of HealthCall-S use and discuss it with the counselor. They also have a brief discussion about drinking patterns and goals for reduction. They are then asked to continue using HealthCall-S for the next 30 days, after which the counselor meets with the participant for another brief interview to go over the updated graph, and to discuss their experience with HealthCall-S. They will also have a brief discussion about drinking patterns and goals for reduction.
62459128|NCT02501057|EXPERIMENTAL|Enhanced Clinician's Guide|Participants in this group receive the Clinician's Guide intervention paired with daily use of HealthCall-S, which includes two cycles of daily use of HealthCall for 30 days, followed by personalized feedback in the form of a graph with a clinic staff member.
62461796|NCT00262964|EXPERIMENTAL|NAFLD-Niacin|Subjects, having previously diagnosed with NAFLD, were given Niacin for 16 weeks. The dosage was 500mg/day for week 1, 1000mg/day for week 2, 1500mg/day for week three and 2000mg/day for weeks 4 through 16.
62083465|NCT02378064|EXPERIMENTAL|Fimasartan and rosuvastatin|fimasartan(60mg,QD)+rosuvastatin(5mg,QD)
62083466|NCT02378064|ACTIVE_COMPARATOR|amlodipine and vytorin|amlodipine(5mg,QD)+Vytorin(10mg,QD)
62650352|NCT05786313|ACTIVE_COMPARATOR|Centerpiece titanium plate|All surgical operations were performed by the same group of senior spine surgeons. The range of open door decompression involved C3 \~ C7. For convenient operation and more accurate statistics, the right side of the door axis and the left side of the door seam were selected for all operations. Centerpiece titanium plates were used for intraoperative fixation.
62282557|NCT01074138|EXPERIMENTAL|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
62083467|NCT02378064|ACTIVE_COMPARATOR|amlodipine and rosuvastatin|amlodipine(5mg,QD+rosuvastatin(5mg,QD)
62282558|NCT03546855|EXPERIMENTAL|treatment group|apatinib 500mg/d po.28d as one cycle
62083468|NCT01971320|EXPERIMENTAL|active stimulation|"sensitive electrical stimulation applied during meals with Urostim I for 6 weeks~Urostim I stimulation will be done during meals for 6 weeks"
62083469|NCT01971320|PLACEBO_COMPARATOR|fake stimulation|"Urostim I stimulation will be done during meals for 6 weeks~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks"
62282559|NCT00159432|EXPERIMENTAL|Oxaliplatin, followed by Bevacizumab with Capecitabine|oxaliplatin 85 mg/m2 q 14 days, followed by bevacizumab 5 mg/kg q 14 days, with capecitabine 750 mg/m2 bid daily
62282560|NCT03639948|EXPERIMENTAL|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve \[AUC\] 6 intravenously \[IV\]) and Docetaxel (75 milligrams per meter squared \[mg/m2\], IV) plus Pembrolizumab (200 milligrams \[mg\], IV) every 21 days for 6 cycles.~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
62282561|NCT04148261|ACTIVE_COMPARATOR|Healthy Arm, CORT + EPI, then PLB + EPI|Healthy participant will receive cortisol pill and epinephrine infusion
62282562|NCT04148261|ACTIVE_COMPARATOR|Healthy Arm, PLB + EPI, then CORT + EPI|Healthy participant will receive placebo pill and epinephrine infusion
62282563|NCT04148261|EXPERIMENTAL|Depression Arm, CORT + EPI, then PLB + EPI|Depressed participant will receive cortisol pill and epinephrine infusion
62282564|NCT04148261|EXPERIMENTAL|Depression Arm, PLB + EPI, then CORT + EPI|Depressed participant will receive placebo pill and epinephrine infusion
62459129|NCT04757090|EXPERIMENTAL|89Zr-trastuzumab PET/CT imaging|"* Enrolled subjects will be asked to undergo 18F-FDG PET/CT imaging (if not performed within the previous 90 days) and 89Zr-trastuzumab PET/CT imaging at baseline prior to the start of monotherapy MT-5111 treatment. Standard of care 18F-FDG PET/CT examinations performed within 90 days of 89Zr-trastuzumab administration can be used in place of a study specific 18F-FDG PET/CT scan. Baseline 89Zr-trastuzumab imaging should be completed no more than 30 days prior to initiating treatment with MT-5111.~* Cold trastuzumab and 89Zr-trastuzumab will be administered at Visit 1 and the 89Zr-trastuzumab PET/CT (Visit 2) will take place 4 days (+/-1 day) after administration of 89Zr-trastuzumab."
62083470|NCT04477850|EXPERIMENTAL|Luspatercept Administration|
62282565|NCT01439945|EXPERIMENTAL|Arm I|Patients receive a low-dose of magnesium oxide orally (PO) daily (QD).
62459130|NCT03096821||ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
62459131|NCT00969566|EXPERIMENTAL|Metformin+Sitagliptin|Initial combination of metformin and sitagliptin
62459132|NCT00683293|ACTIVE_COMPARATOR|1|Randomized group of patients receiving conventional laparoscopic hysterectomy
62459133|NCT00683293|ACTIVE_COMPARATOR|2|Randomized group of patients receiving robot-assisted laparoscopic hysterectomy
62459134|NCT02679183|PLACEBO_COMPARATOR|Control 0|No Intervention. This group received Premature Milk Formula. This group did not receive any Medically-Graded Honey.
62083471|NCT04033224||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.
62083472|NCT01484158||Myocardial Infarction|Patients with myocardial infarction
62282566|NCT01439945|EXPERIMENTAL|Arm II|Patients receive a high-dose of magnesium oxide PO QD.
62282567|NCT01439945|PLACEBO_COMPARATOR|Arm III|Patients receive a low-dose of placebo PO QD.
62282568|NCT01439945|PLACEBO_COMPARATOR|Arm IV|Patients receive a high-dose of placebo PO QD.
62282569|NCT01958957|EXPERIMENTAL|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 \~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
62083473|NCT03841825|NO_INTERVENTION|Control|No messages or oral hygiene instructions
62282570|NCT05617287|EXPERIMENTAL|Semaine Supplement|Participants are provided with a dietary supplement and are instructed to take 1 capsule per day. Participants are to take the supplement at the same time every day. If forgotten, they are to take it with the next meal. Participants will take a well-being assessment after each month (4 surveys total including the baseline.)
62650353|NCT05786313|EXPERIMENTAL|3D printed arch titanium plate|Before surgery, according to the imaging results, according to the effective imaging indicators screened in the early stage and the calculated door opening Angle formula, the door opening Angle of the patient's posterior cervical vertebra and the size of the fitted arch titanium plate were designed by mimics 10.0 software, and the titanium plate was printed using 3D printing technology. During the operation, the developed laminae opener was used to accurately control the door opening Angle and appropriate size titanium plate was installed for internal fixation. The standardized laminae door opening guide was used to complete the preparation of the door shaft side and door opening side of the lamina
62282571|NCT03102229|EXPERIMENTAL|Activity Monitoring|"1. Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks~2. Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
62650354|NCT06208813|NO_INTERVENTION|Control Group|Participants will consume their normal daily diet.
62650355|NCT06208813|EXPERIMENTAL|Creatine supplementation|The intervention group will consume their usual diet plus 5 grams of creatine for the first four days following the initial meeting, and then 3 grams of creatine once per day thereafter until asymptomatic.
62650356|NCT06269835|EXPERIMENTAL|The observation group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
62650357|NCT06269835|ACTIVE_COMPARATOR|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
62650358|NCT03573297|EXPERIMENTAL|Double-Blind Cariprazine 3.0 mg/day|Participants randomized to receive cariprazine 3.0 mg once daily (QD) for up to 39 weeks.
62650359|NCT03573297|EXPERIMENTAL|Double-Blind Cariprazine 1.5 mg/day|Participants randomized to receive cariprazine 1.5 mg QD for up to 39 weeks.
62650360|NCT03573297|PLACEBO_COMPARATOR|Double-Blind Placebo|Participants randomized to receive placebo QD for up to 39 weeks.
62650361|NCT03573297|EXPERIMENTAL|Open Label Treatment|Participants started on cariprazine 1.5 mg QD, with a target dose of 3.0 mg QD, for up to 16 weeks.
62650362|NCT01554124|EXPERIMENTAL|Meropenem|"Infants will received Meropenem 40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
62650363|NCT03136393|ACTIVE_COMPARATOR|Control|Community based antenatal counselling
62083474|NCT03841825|EXPERIMENTAL|Text message reminders|Standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays
62083475|NCT03841825|ACTIVE_COMPARATOR|In-person oral hygiene instructions|Oral hygiene instructions and motivation during visit
62083476|NCT03841825|EXPERIMENTAL|Text messages and in-person instructions|standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays and oral hygiene instructions and motivation during visit
62083477|NCT04735250||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
62083478|NCT04735250||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
62282572|NCT06326242||Solid Tumor|Phase 1 patient with solid tumor
62282573|NCT04531475|EXPERIMENTAL|X842 50 mg QD|X842 50 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
62282574|NCT04531475|EXPERIMENTAL|X842 100 mg QD|X842 100 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
62282575|NCT04531475|EXPERIMENTAL|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, orally, once daily and X842 placebo-matching capsule, orally, once daily up to 4 weeks.
62459135|NCT02679183|EXPERIMENTAL|Group 1|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 5 gram/day) for 2 weeks
62459136|NCT02679183|EXPERIMENTAL|Group 2|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 10 gram/day) for 2 weeks
62459137|NCT02679183|EXPERIMENTAL|Group 3|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 15 gram/day) for 2 weeks
62459138|NCT00569062|EXPERIMENTAL|Arm 1|GW856553X 7.5mg BID for 6 weeks
62459139|NCT00569062|PLACEBO_COMPARATOR|Placebo|Placebo to match, BID, 6 weeks
62459140|NCT01022047|EXPERIMENTAL|Noex|The patients shall use the NOEX drug only once a day (one application in each nostril) during the 12 weeks of treatment
62459141|NCT01022047|ACTIVE_COMPARATOR|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
62083479|NCT04735250||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
62083480|NCT01877096|EXPERIMENTAL|Motivational Interviewing|Participants will undergo a brief (20-30 minutes) motivational interviewing session after their primary care appointment
62459142|NCT04799028|ACTIVE_COMPARATOR|Traditional children's fortified cow's milk|
62459143|NCT04799028|EXPERIMENTAL|New toddler milk with synbiotics and fat blend|
62459144|NCT04799028|OTHER|Toddlers consuming habitual diet|
62459145|NCT04665947|EXPERIMENTAL|[177Lu]Lu DOTA-ABM-5G dose escalation therapy study|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Escalating doses of 25-200 mCi of \[177Lu\]Lu DOTA-ABM-5G will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
62459146|NCT04665947|EXPERIMENTAL|Recommended Phase 2 dose [177Lu]Lu DOTA-ABM-5G therapy study|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy.10 patients will be enrolled in the dose expansion cohort and recieve the highest dose achieved in the \[177Lu\]Lu DOTA-ABM-5G dose escalation therapy study
62650364|NCT03136393|EXPERIMENTAL|Intervention|Community based dietary counselling
62650365|NCT06313645||Patients with coronary artery diseases|Patients with acute coronary syndromes \[unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI)\] and with stable angina or non-angiographically coronary diseases recovered for elective diagnostic or interventional procedures are included in the study
62650366|NCT03054623||DRIL procedure|Adult (\>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
62083481|NCT01877096|ACTIVE_COMPARATOR|Attention Control|Participants will undergo a brief (20-30 minutes) attention control session after their primary care appointment
62459147|NCT05339100|EXPERIMENTAL|Anifrolumab administered using AI|Randomized participants will receive a single SC dose of anifrolumab via AI.
62459148|NCT05339100|ACTIVE_COMPARATOR|Anifrolumab administered using APFS|Randomized participants will receive a single SC dose of anifrolumab via APFS.
62459149|NCT06268522|EXPERIMENTAL|Mindfulness-Oriented Recovery Enhancement: (MORE) group|
62459150|NCT06268522|PLACEBO_COMPARATOR|Psychoeducation|
62459151|NCT02506582|EXPERIMENTAL|Test group|jerusalem artichoke and fermented soybeans powder mixture supplementation
62459152|NCT02506582|PLACEBO_COMPARATOR|Placebo group|placebo supplementation
62459153|NCT05097326|ACTIVE_COMPARATOR|Mifepristone|Participants will be given mifepristone with insertion of the cervical Cook balloon for labor induction
62282576|NCT00481065|EXPERIMENTAL|Concomitant alone|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
62459154|NCT05097326|ACTIVE_COMPARATOR|Misoprostol|Participants will be given misoprostol with insertion of the cervical Cook balloon for labor induction
62459155|NCT01870180|EXPERIMENTAL|EyeBag|Eye self-treated with heated eyebag in the morning and evening each day as per manufacturer's instructions (see http://www.eyebagcompany.com/how)
62650367|NCT04483765||post-spinal hypotension|Patients with a fall in SBP by 25% of the preoperative baseline or an absolute value \<90 mm of Hg; MAP ≤65 mmHg after spinal anesthesia
62083482|NCT01554254|EXPERIMENTAL|300mcg/kg/day for 28 days|
62083483|NCT04201522|ACTIVE_COMPARATOR|Training intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance
62083484|NCT04201522|SHAM_COMPARATOR|Sham intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance in the training group compared to the sham group.
62282577|NCT00481065|EXPERIMENTAL|Concomitant +Mixed|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
62282578|NCT00481065|EXPERIMENTAL|Concomitant +MF59-eH5N1|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
62459156|NCT01870180|PLACEBO_COMPARATOR|Placebo|Non-heated EyeBAG: As with eyebag arm but second eyebag applied on other eye at same time BUT not heated
62459157|NCT03605238|EXPERIMENTAL|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone to reduce acute inflammation, then infuse anti-CD19/20-CAR retroviral vector-transduced autologous derived T cells only once.
62650368|NCT04483765||post-spinal normotension|Patients with Fall of SBP\<%25 of the preoperative value or absolute value \>90 mm Hg, MAP\>65 mmHg
62650369|NCT04021433|EXPERIMENTAL|MDD|Treatment resistant patients will be treated with multiple doses of IM/SC ketamine \[dose range 0.3-1.5mg/kg\]
62650370|NCT06514339|EXPERIMENTAL|Treatment group|Sepsis cluster therapy + Shenhuang granules for 5 days. For the treatment of sepsis cluster, refer to the 2021 International Guidelines for Severe Sepsis and Septic Shock. Shenhuang Granules (Tianjin Hongri Pharmaceutical Co., LTD.) : 2 times a day, 1 pack each time, 100ml of warm water (temperature about 40°C) after dissolution, oral or nasal feeding (stomach tube or intestinal tube).
62650371|NCT06514339|SHAM_COMPARATOR|Control group|Sepsis cluster therapy + placebo for 5 days. For the treatment of sepsis cluster, refer to the 2021 International Guidelines for Severe Sepsis and Septic Shock. Placebo (Tianjin Hongri Pharmaceutical Co., LTD.) : After dissolution of 100ml warm water (temperature about 40°C) in 1 pack twice a day, oral or nasal feeding (gastric tube or intestinal tube).
62650372|NCT01855022|EXPERIMENTAL|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
62083485|NCT01607814||Cirrhotic Patients|Patients affected by cirrhosis of any etiology and severity
62083486|NCT01607814||Control Group|Subjects age, sex and comorbidities matched
62282579|NCT00481065|EXPERIMENTAL|Mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
62282580|NCT00481065|EXPERIMENTAL|Mixed and mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
62282581|NCT00481065|EXPERIMENTAL|Mixed+MF59-eH5N1|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
62282582|NCT00481065|EXPERIMENTAL|MF59-eH5N1+eTIV_a|1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
62083487|NCT06313983|EXPERIMENTAL|Hemay022 and AI|Hemay022 in combination with AI will be taken orally once daily. Planned dose of Hemay022 will be 500mg daily for 21 days.
62083488|NCT06313983|ACTIVE_COMPARATOR|Lapatinib and Capecitabine|lapatinib in combination with capecitabine will be taken in suitable dose until disease progression or death, etc.
62282583|NCT00481065|EXPERIMENTAL|eTIV_a+MF59-eH5N1|1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
62459158|NCT06160037|ACTIVE_COMPARATOR|Arm 1. Transportation and Screening|Free transportation for scheduled prenatal care, developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
62083489|NCT02726178|EXPERIMENTAL|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
62083490|NCT02726178|PLACEBO_COMPARATOR|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
62282584|NCT06469060|EXPERIMENTAL|neoadjuvant anti-PD-1 with DOC chemotherapy|Drug: Immuno-chemotherapy. Patients will receive neoadjuvant therapy (one cycle of Tislelizumab monotherapy followed by four cycles of Tislelizumab plus Docetaxel, Oxaliplatin and Capecitabine) followed by the esophagectomy.
62282585|NCT00598975|ACTIVE_COMPARATOR|NKTR-102 100 mg/m2 + Cetuximab|"NKTR-102 100 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
62282586|NCT00598975|ACTIVE_COMPARATOR|NKTR-102 125 mg/m2 + Cetuximab|"NKTR-102 125 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
62282587|NCT01903499|ACTIVE_COMPARATOR|Bean patty|Bean Patty
62282588|NCT01903499|ACTIVE_COMPARATOR|Beef patty|Beef patty
62282589|NCT02455635|ACTIVE_COMPARATOR|women with pain|women who felt pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
62282590|NCT02455635|ACTIVE_COMPARATOR|women without pain|women who didn't feel pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
62282591|NCT05461079||subfertile men|10 infertile men with shortened AGD (\< 40 mm)
62282592|NCT05461079||fertile semen donors|10 fertile semen donors with normal AGD (\>40 mm)
62282593|NCT02598765|ACTIVE_COMPARATOR|Standard Trabeculectomy|Patients in the Standard Trabeculectomy arm will undergo regular trabeculectomy
62282594|NCT02598765|EXPERIMENTAL|Microtrabeculectomy|Patients in the Microtrabeculectomy arm will undergo microtrabeculectomy
62459159|NCT06160037|EXPERIMENTAL|Arm 2. Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|Free transportation for scheduled prenatal care; intensive nurse home-visitation services during pregnancy and through the child's second birthday; and developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
62459160|NCT03889756|EXPERIMENTAL|Ketamine|Ketamine is an FDA-approved anesthetic agent that is commonly used to induce surgical anesthesia due to its low incidence of significant respiratory depression and hypotension. It as a N-methyl-D-aspartate (NMDA) receptor antagonist and glutamatergic modulator, and has been demonstrated in multiple controlled clinical trials to have rapidly acting antidepressant and anti-suicidal effects in adults.
62650373|NCT01855022|NO_INTERVENTION|Usual Care|Usual care that a patient would receive absent the intervention
62083491|NCT06480643|EXPERIMENTAL|High load exercise type|The patients will perform 6-8 full-body exercises using a load of 60-75% of their 1RM. The exercises will comprise of both compound (multi-joint movement that works multiple muscle groups at the same time) and isolation (movement that targets a single muscle group and involves the movement of a single joint) exercises. Each training session will be preceded by a 3-5mins warm-up. Total exercise duration will vary between 45-60mins, comprising of 3 sets of 10 repetitions with 1 min periods of recovery. Patients will be required to maintain an intensity of 7-8 on a 10-point physical exertion scale
62282595|NCT03121391|NO_INTERVENTION|Control|The medical intensive care unit in four hospitals will comprise the clusters. All four clusters begin the study under the control condition. Ventilator withdrawal is conducted by the usual personnel in those units. Data is collected through observation of the process and the respiratory comfort of the enrolled patients. Each cluster is randomly selected to sequentially cross over to the intervention. The remaining clusters continue with usual care (control) until selected for crossover.
62282596|NCT03121391|ACTIVE_COMPARATOR|Intervention|Each cluster is randomly selected to sequentially crossover to the intervention. When crossed over to the intervention the assigned intensive care nurse conducts the ventilator withdrawal according to the algorithm. The algorithm is informed by an objective measure of patient respiratory comfort. Data is collected through observation of the process and the respiratory comfort of the enrolled patients.
62459161|NCT03889756|PLACEBO_COMPARATOR|Midazolam|Midazolam, the active control in this study, is a medication that is approved by the Food and Drug Administration as a sedative for both children and adults.It is a benzodiazepine with a short half-life that was chosen so as to blind the psychotomimetic effects of Ketamine.
62459162|NCT05240196|NO_INTERVENTION|Control|participant will receive standard care only
62459163|NCT05240196|OTHER|Binaural music|Participants will listen to binaural music whilst having a routine mammogram
62459164|NCT05240196|OTHER|Non-binaural music|Participants will listen to non-binaural music whilst having a routine mammogram
62459165|NCT05681208|EXPERIMENTAL|Intervention group|The training, which is prepared based on the motivational interview method, will be given individually, starting when baby is 4 months old, will be interviewed once a week for nine weeks. In first meeting; before starting motivational interview, mothers were interviewed face-to-face with the Baby, Mother Introductory Information Form, Mothers', Babies' Food Consumption Frequency Registration Form, Microbiota Awareness Scale (MFI), Infant Nutrition Attitude Scale (LOWA), Behavior Change Stage Diagnostic Form, Motivational Interview rating the schedule will be applied. At the end of this meeting, which lasts for 45-50 minutes, next meeting date will be determined, the meeting will be terminated. Second interview is planned to last 60-90 minutes. After the second meeting, Motivational interviews will provide information on nutritional posters, brochures of the Ministry of Health, complementary nutrition, nutrition for microbiota. The scales to be used will be re-administered.
62459166|NCT05681208|NO_INTERVENTION|Control group|Within the scope of the research, no intervention will be made to the mothers in the control group other than routine family health center practices. In Turkey, 4-month-old baby follow-up continues at the Family Health Center, followed by midwives, nurses and doctors. Scales will be applied to mothers by face-to-face interview method when they come for routine baby follow-up. The training content given in the Family Health Center will be presented to the control group.
62459167|NCT05907616|EXPERIMENTAL|pregnant Latina women|Pregnant Latina women in Hartford CT enrolled during the first or second trimester of pregnancy. Participants will be provided with up to three nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
62459168|NCT01061125||Unblinded|Transtelephonic (TTM) monitoring weekly for 5 months Holter monitor recording at 4 months and at 12 months Implantable Loop Recorder (ILR) weekly reports
62459169|NCT01061125||Blinded|TTM and Holter Monitor conventional follow up Implantable Loop Recorder (ILR) unblinded at 5 months
62459170|NCT00757874|EXPERIMENTAL|Tacrolimus cream|
62650374|NCT00042211|EXPERIMENTAL|1|Problem Solving Treatment
62282597|NCT03175341|EXPERIMENTAL|Vitamin C Supplement|"Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.~Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1"
62282598|NCT03175341|ACTIVE_COMPARATOR|Placebo|"Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.~Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician."
62282599|NCT02817087|ACTIVE_COMPARATOR|repetitive Transcranial Magnetic Stimulation -On|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.
62459171|NCT00757874|ACTIVE_COMPARATOR|Clobetasol cream|
62650375|NCT00042211|ACTIVE_COMPARATOR|2|Control
62650376|NCT01997125|EXPERIMENTAL|Open Label|Neural bridge system implant and external stimulator
62650377|NCT05903352|PLACEBO_COMPARATOR|Antibiotic treatment|Antibiotic treatment duration left to the physician's judgment (usual practice: total treatment duration between 5 to 10 days according to French guidelines; more than 7 days of treatment should be justified).
62083492|NCT06480643|EXPERIMENTAL|Low load exercise type|Patients will perform 6-8 full-body exercises with a load of 30-45% of their 1RM. This training session will include both bodyweight and circuit training types. Each training session will be preceded by a 5-10mins warm-up. Total exercise duration will vary between 45-60mins (including the warm-up and cool down), with each exercise comprising of 3 sets of 20 repetitions with 1 min periods of recovery. A 5-min cool-down will follow the final rest period. Patients will be required to maintain an intensity of 7-8 on a 10-point physical exertion scale
62083493|NCT05800119|EXPERIMENTAL|Brain-level condition|Participants assigned to this condition received a brief reading passage (126 words) that provided psychoeducation about how psychotherapy can change the brain of those with depression, and specifically how psychotherapy can change the functioning of the prefrontal cortex and the amygdala, and affect neurotransmitters.
62083494|NCT05800119|ACTIVE_COMPARATOR|Mind-level condition|Participants assigned to this condition received a brief reading passage (115 words) that provided psychoeducation about the effectiveness of psychotherapy for depression, and specifically how psychotherapy can improve maladaptive thought processes and teach people with depression how to regulate negative emotions.
62282600|NCT02817087|SHAM_COMPARATOR|repetitive Transcranial Magnetic Stimulation -Off|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.
62083495|NCT05800119|NO_INTERVENTION|Control condition|Participants assigned to this condition received no additional materials.
62083496|NCT05697432|EXPERIMENTAL|Education|The children with special needs will receive a complete oral examination and then their parent/guardian will be subjected to education about oral hygiene, brushing and dietary guidance.
62282601|NCT01265680|EXPERIMENTAL|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital
62282602|NCT01265680|NO_INTERVENTION|Control|No added administration other than our standard of care.
62282603|NCT02638636|EXPERIMENTAL|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
62282604|NCT02638636|NO_INTERVENTION|Waitlist|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment when the first group has finished (i.e. week 10).
62459172|NCT04947748|ACTIVE_COMPARATOR|24 hour intravenous antibacterial therapy|S.Augmentin 1,2g x 3 i/v
62459173|NCT04947748|EXPERIMENTAL|24 hour oral antibacterial therapy|T.Augmentin 1g x 3 p/o
62459174|NCT03165552|EXPERIMENTAL|Educational Arm|This group will receive an acute kidney injury educational intervention
62459175|NCT06225232|EXPERIMENTAL|Single Arm|This is an open-label single arm intervention trial. Participants in this arm will be offered both drug and psychotherapy as part of their 9-week intervention.
62083497|NCT02391038|EXPERIMENTAL|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
62459176|NCT02183571|EXPERIMENTAL|Glucophage® high dose|Part I: Treatment A + B
62459177|NCT02183571|EXPERIMENTAL|Glucophage® low dose|Part II: Treatment C+ D
62083498|NCT02729636|EXPERIMENTAL|FES:a|The group will be treated with multipad electrical stimulation device.
62282605|NCT05274230|EXPERIMENTAL|MDMA-Assisted Psychotherapy Participants|Participants who have completed the MDMA-Assisted Psychotherapy and consented to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
62282606|NCT00003793||Identification of Genetical suceptibility prior to therapy|"Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a mutator phenotype as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML."
62282607|NCT00003793||Increased Risk Of T-MDS/AML before/after Therapy|Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.
62282608|NCT06429930|EXPERIMENTAL|L608 Liposomal inhalation solution|Eight participants will be enrolled in each cohort and be randomized to receive assigned dose of L608 or placebo (6:2).
62282609|NCT06429930|PLACEBO_COMPARATOR|Placebo|Eight participants will be enrolled in each cohort and be randomized to receive assigned dose of L608 or placebo (6:2).
62282610|NCT06101576||Transurethral incision of the prostate (TUIP)|Patients who underwent TUIP using electrocautery or Laser.
62282611|NCT06101576||Transurethral resection of the prostate (TURP)|Patients who underwent TURP using monopolar or bipolar electrocautery.
62282612|NCT06101576||Prostate Vaporization|Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).
62282613|NCT06101576||Anatomical endoscopic enucleation of the prostate (AEEP)|Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.
62459178|NCT06182020|EXPERIMENTAL|Integrated care|Participants in this group will receive both the peripheral functional magnetic stimulation to both the upper and lower limbs and nutritional supplement for consecutive 8 weeks.
62459179|NCT06182020|ACTIVE_COMPARATOR|Usual care|Participants in this group will receive an educational DVD and one session of oral instructions on general care and exercise suggestions for sarcopenia.
62459180|NCT00584298|EXPERIMENTAL|1|
62459181|NCT00584298|PLACEBO_COMPARATOR|2|
62459182|NCT04855981|EXPERIMENTAL|whole body vibration|the subjects will receive whole-body vibration three times per week for twelve weeks +supplementations
62459183|NCT04855981|EXPERIMENTAL|aerobic exercise|the subjects will receive aerobic exercise three times per week for twelve weeks+supplementations
62459184|NCT04855981|ACTIVE_COMPARATOR|supplementations|the subjects will receive supplementations three times per week for twelve weeks
62459185|NCT04986332|EXPERIMENTAL|"GROUP COPD"|100 participants, 50 males and 50 females with COPD and multiple chronic conditions
62459186|NCT04986332|ACTIVE_COMPARATOR|"GROUP HF"|100 participants, 50 males and 50 females with HF and multiple chronic conditions
62650378|NCT05903352|EXPERIMENTAL|Interruption of treatment|Interruption of treatment based on the patient reaching all of the following stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure \> 90mmHg; oxygen saturation ≥ 92%; respiratory rate \< 24/min; normal mental status (27)), with a treatment duration no shorter than 48 h.
62650379|NCT03020368|EXPERIMENTAL|Leeches|"One-time topical application of 2-3 leeches (medileech, Hirudo verbana) periarticularly on the painful thumb base"
62650380|NCT03020368|ACTIVE_COMPARATOR|Diclofenac|3 times daily topical application of Diclofenac gel (1 g with 10 mg diclofenac-Na) over 4 weeks
62083499|NCT02729636|ACTIVE_COMPARATOR|control|The group will be treated with conventional treatment.
62083500|NCT02622971|ACTIVE_COMPARATOR|PBMT and Cryotherapy|Volunteers allocated in this group received phototherapy (PBMT - applied in six points of quadriceps) and cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
62650381|NCT05723926|EXPERIMENTAL|Vine Filter and oral anticoagulant|Participants randomized to the intervention will undergo implantation of bilateral carotid filters and OAC therapy. In addition, participants will receive additional single antiplatelet therapy with OAC for 6 months.
62650382|NCT05723926|NO_INTERVENTION|Usual Care (oral anticoagulant only)|Participants randomized to control will not receive carotid filter implants but will receive usual care including OAC, throughout the course of the study.
62083501|NCT02622971|ACTIVE_COMPARATOR|Cryotherapy and PBMT|Volunteers allocated in this group received cryotherapy (20 minutes in PRICE protocol) and phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
62282614|NCT05499962|OTHER|PrEP-using Black SMM as Recruiters|Recruit 30 PrEP-using Black SMM, including those who use substances, as Recruiters to identify and refer Network Associates to PrEP services. The pilot will occur in six blocks of up to 5 Recruiters to further develop all intervention procedures and enhance the SNS intervention's feasibility and acceptability.
62282615|NCT04821583|EXPERIMENTAL|Hydrocortisone|Hydrocortisone (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The hydrocortisone periods last 10 weeks per period. In total, there are two hydrocortisone periods.
62282616|NCT04821583|PLACEBO_COMPARATOR|Placebo|Placebo (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The placebo periods last 10 weeks per period. In total, there are two placebo periods.
62650383|NCT04499885|ACTIVE_COMPARATOR|Paraffin oil gastric lavafe|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
62650384|NCT04499885|ACTIVE_COMPARATOR|Saline gastric lavage|Gastric lavage with saline and sodium bicarbonate
62650385|NCT03534674|EXPERIMENTAL|Intervention|Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.
62650386|NCT03534674|NO_INTERVENTION|Control|Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).
62650387|NCT04015362|EXPERIMENTAL|Pulsed magnetic stimulation of the spinal cord|Sub-threshold intermittent pulsed magnetic stimulation of spinal cord
62650388|NCT04015362|SHAM_COMPARATOR|Sham magnetic stimulation|Sham - patient and machinery placed in same position as intervention arm but no magnetic stimulation delivered
62083502|NCT02622971|ACTIVE_COMPARATOR|PBMT (active phototherapy)|Volunteers allocated in this group received active phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
62282617|NCT06388473|EXPERIMENTAL|Tailored implementation intervention|The tailored implementation intervention comprised of six implementation strategies: 1) Involve executive boards, 2) Mandate change, 3) Provide education and training, 4) Identify and prepare champions, 5) The use of information and communication technology and 6) Audit and provide feedback.
62282618|NCT03090685|EXPERIMENTAL|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
62282619|NCT03090685|PLACEBO_COMPARATOR|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
62083503|NCT02622971|PLACEBO_COMPARATOR|PBMT (placebo phototherapy)|Volunteers allocated in this group received placebo phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. The placebo PBMT device was identical to the active devices and displayed the same settings and emitted the same sound regardless of the comparator.
62650389|NCT04347772|EXPERIMENTAL|Supplements Group - SS|"The SS will be received tailored and more intensive and ongoing nutrition support and lifestyle advice as compared with the NN and will be supplemented with ONS, available in 400g/can, providing 226 kcal/serving and 9.6 g protein/serving. Participants will be encouraged to consume the ONS in small, frequent, in between meals.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
62282620|NCT01099787||FAP IBS|
62282621|NCT03242330|EXPERIMENTAL|Two-piece subperiosteal implant|The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body.
62282622|NCT03242330|ACTIVE_COMPARATOR|Single-piece subperiosteal implant|The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery.
62282623|NCT02170116|EXPERIMENTAL|BIBR 1048 MS dose 1|
62282624|NCT02170116|EXPERIMENTAL|BIBR 1048 MS dose 2|
62282625|NCT02170116|EXPERIMENTAL|BIBR 1048 MS dose 3|
62282626|NCT02170116|EXPERIMENTAL|BIBR 1048 MS dose 4|
62282627|NCT02170116|EXPERIMENTAL|BIBR 1048 MS dose 5|
62282628|NCT02170116|PLACEBO_COMPARATOR|Placebo|
62282629|NCT03668509|EXPERIMENTAL|Cohort 1|oral adminstration of SHR1459, dose 1
62282630|NCT03668509|EXPERIMENTAL|Cohort 2|oral adminstration of SHR1459, dose 2
62083504|NCT02622971|ACTIVE_COMPARATOR|Cryotherapy|Volunteers allocated in this group cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. Two flexible ice packs filled with ice cubes and water (with a volume of 1.15 liters each) were used in order to cover the entire quadriceps. Rubber belts were used to apply compression and to affix the packs tightly to the volunteers' quadriceps.
62282631|NCT03668509|EXPERIMENTAL|Cohort 3|oral adminstration of SHR1459, dose 3
62650390|NCT04347772|NO_INTERVENTION|Control Group - NN|"While participants in NN which referred as control group will received the standard care of the clinic without supplemented with ONS. Nutritional advice will be based on a guideline specifically focused on treatment of symptoms such as nausea, vomiting, loss of appetite and diarrhoea, and how to deal with the symptoms through nutritional approaches. Basically, the advice will be given by the oncologist or nurses in the clinic.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
62083505|NCT05760430|EXPERIMENTAL|Experimental Group|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
62083506|NCT05760430|ACTIVE_COMPARATOR|Control group|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
62650391|NCT04025424||Skin melanoma, retrospective|"* 1) Clinically and morphologically verified diagnosis of skin melanoma or melanoma metastases without an identified primary lesion;~* 2) The availability of basic clinical information about the patient and the course of his illness;"
62650392|NCT04025424||Hodgkin disease, retrospective|"* 1) Clinically and morphologically verified diagnosis of Hodgkin disease (any histological variant);~* 2) The availability of basic clinical information about the patient and the course of his illness;"
62650393|NCT04025424||Uveal melanoma, retrospective|"* 1) Clinically and morphologically verified diagnosis of uveal melanoma (any histological variant);~* 2) The availability of basic clinical information about the patient and the course of his il"
62083507|NCT04916899||Group A: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Pharmaceutical Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Administration way: oral
62083508|NCT01253382|ACTIVE_COMPARATOR|ecallantide|
62083509|NCT01253382|PLACEBO_COMPARATOR|placebo|phosphate buffered saline
62083510|NCT00641160|EXPERIMENTAL|Cohort 1|
62282632|NCT01976780|ACTIVE_COMPARATOR|AS/MQ|Treatment of P.falciparum mono-infection with 4 mg/kg of Artesunate daily for three days followed by 25mg/kg of Mefloquine split over two days.
62083511|NCT00641160|EXPERIMENTAL|Cohort 2|
62083512|NCT00641160|EXPERIMENTAL|Cohort 3|
62282633|NCT01976780|ACTIVE_COMPARATOR|AL|Treatment of P. falciparum mono-infection with Artemether Lumefantrine administered at the standard dosage according to pre-defined weight bands (5-14 kg: 1 tablet; 15-24 kg: 2 tablets; 25-34 kg: 3 tablets; and \> 34 kg: 4 tablets) given twice a day for 3 days.
62282634|NCT04853628|EXPERIMENTAL|Alerta Alcohol|The EC-1 receives Alerta Alcohol, which consists of session 1 or baseline, two sessions in three scenarios: at home, celebrations, and public places, and two follow-up evaluations. The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, four booster sessions are given at home to reinforce the contents of the three scenarios. Evaluations take place after six and twelve months.
62282635|NCT04853628|EXPERIMENTAL|Alerta Alcohol 2.0|The EC-2 receives an improved version of Alerta Alcohol (Alerta Alcohol 2.0) using animated videos and new gamification strategies. Evaluations take place after six and twelve months.
62459187|NCT04986332|ACTIVE_COMPARATOR|"GROUP HEALTHY PARTICIPANTS"|"100 healthy participants or control group which will be compared to Group A and Group B by age and sex"
62459188|NCT01391793|ACTIVE_COMPARATOR|Adjuvant dexamethasone|
62459189|NCT01391793|PLACEBO_COMPARATOR|Placebo|
62459190|NCT03388320|EXPERIMENTAL|Participants receiving A-CHESS|Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.
62459191|NCT02351154|OTHER|Atrophic gastritis|gastric glands (crypts) with atrophic gastritis were measured using the Cellvizio Viewer software
62459192|NCT00708019|EXPERIMENTAL|Low dose|Low dose of the psychoeducational intervention (i.e., 8.0 hours with the intervention nurse over 10 weeks)
62459193|NCT00708019|EXPERIMENTAL|High dose|High dose of the psychoeducational intervention (i.e., 12.3 hours with the intervention nurse over 10 weeks)
62459194|NCT06233383||Adopters|Individuals responsible for deciding to institute screening CBE in Soweto's primary care clinics (e.g., policymakers, clinic administrators, nurse managers)
62650394|NCT04025424||Skin melanoma, proscpective|"* 1) Clinically and morphologically verified diagnosis of metastatic melanoma;~* 2) The availability of basic clinical information about the patient and the course of his illness;"
62650395|NCT04025424||Lung cancer, procpective|"* 1) Clinically and morphologically verified diagnosis of metastatic or inoperable squamous cell lung cancer;~* 2) The availability of basic clinical information about the patient and the course of his illness;~* 3) The presence of indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;"
62650396|NCT05589974||Acute|Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months.
62650397|NCT05589974||Chronic|Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.
62650398|NCT05608057|EXPERIMENTAL|Vitamin C mesotherapy|
62650399|NCT05608057|ACTIVE_COMPARATOR|Diode laser|
62650400|NCT03077217|ACTIVE_COMPARATOR|the high-dose rifaximin|The high-dose rifaximin group was given rifaximin 1200 mg/day for 8 weeks.
62650401|NCT03077217|ACTIVE_COMPARATOR|the low-dose rifaximinl group|The low-dose rifaximin group was given rifaximin 800 mg/day for 8 weeks.
62650402|NCT03077217|PLACEBO_COMPARATOR|the control group|The control group didn't receive rifaximin treatment
62459195|NCT06233383||Implementers|Individuals responsible for actually performing the screening CBE in Soweto's primary care clinics (e.g., nurses, doctors, fieldworkers, clerical workers)
62459196|NCT06233383||Recipients|Individuals eligible for a screening CBE (e.g., women over the age of 40 years from the community surrounding study clinics)
62459197|NCT02171754|EXPERIMENTAL|BIBW 2992 + Ritonavir|
62459198|NCT02171754|ACTIVE_COMPARATOR|BIBW 2992|
62459199|NCT02854579|EXPERIMENTAL|Neural progenitor cell|Three doses of Neural progenitor cell (4\*10\^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
62459200|NCT02854579|EXPERIMENTAL|Paracrine factors|Three doses of concentrated paracrine factors of human mesenchymal stem cell （0.5ml） intrathecally at 12h,24h,48h after birth.+routine therapy
62650403|NCT01026493|EXPERIMENTAL|Phase I: Dose Level 1|ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days
62650404|NCT01026493|EXPERIMENTAL|Phase I: Dose Level 2a|ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days
62650405|NCT01026493|EXPERIMENTAL|Phase I: Dose Level 2b|ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days
62650406|NCT01026493|EXPERIMENTAL|Phase I: Dose Level 3|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
62650407|NCT01026493|EXPERIMENTAL|Phase II: Arm 1/BEV-NAIVE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
62459201|NCT02854579|EXPERIMENTAL|Progenitor cell and paracrine factors|Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4\*10\^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
62083513|NCT03342781|ACTIVE_COMPARATOR|Diffuser-mask group|The patients received oxygen therapy (8-15 L/min) from an OxyMask (Southmedic, Inc., Barrie, ON, Canada) to maintain oxygen saturation (SpO2) \> 92%. Oxygen therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h. The oxygen flow rate was then decreased to 2 L/min and the patient was monitored while breathing room air.
62459202|NCT02854579|NO_INTERVENTION|Routine therapy|neonates only receive routine therapy
62459203|NCT05211297||Exposed cohort:|Children whose mothers suffered a suspected preterm labour during pregnancy.
62282636|NCT04853628|NO_INTERVENTION|Control condition|The CC just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list). Evaluations take place after six and twelve months from baseline.
62083514|NCT03342781|ACTIVE_COMPARATOR|HFNC group|The patients received oxygen therapy at a high flow rate from a Precision Flow nasal cannula (Vapotherm, Inc., Stevensville, MD, USA). We selected a 1.9 mm pediatric cannula, which can dispense 1-20 L/min of oxygen. The initial oxygen flow rate was 1 L/kg/min and the FiO2 was 100%. The initial flow rate was increased by 1 L/kg/min until the SpO2 reached 92%. The initial FiO2 was decreased once the SpO2 was greater than 92% and the oxygen flow rate was maintained. HFNC therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h at a FiO2 value of 21%, and the patient was transferred to a ward.
62083515|NCT02171364|EXPERIMENTAL|virtual simulation|This intervention group is to choose the best effective method operation to patients by simulating 3D atrial computer model which consider patient's heart size and shape.
62083516|NCT02171364|ACTIVE_COMPARATOR|conventional ablation|The other intervention group is to operate the atrial fibrillation by physician's personal experience, not by virtual simulation.
62083517|NCT01817543|EXPERIMENTAL|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
62282637|NCT02161887||Complementary Medicine Group|Patients receiving chiropractic care, acupuncture, or meditation for chronic pain
62282638|NCT02161887||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management) for chronic pain.
62459204|NCT05211297||Unexposed cohort|Children born at term (\> 37 weeks) whose mothers did not suffer a suspected preterm labour during pregnancy.
62282639|NCT00860158|EXPERIMENTAL|Single Arm Assignment|Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
62459205|NCT02398071|EXPERIMENTAL|PEP interventon|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 5 cmH2O
62459206|NCT02398071|SHAM_COMPARATOR|Sham intervention|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 0 cmH2O
62459207|NCT01402037|OTHER|NDP 12-39 y|In newly diagnosed patients a hyperglycemic clamp tests will be performed within 4 weeks after diagnosis and 6, 12, 18 and 24 months later in 40 patients. The clamp will not be carried out in participants who became Cpeptide negative (defined as AUC C-peptide ≤ 0.03 nmol/L x min.) at a previous visit. HbA1c will be determined at the day of the clamp and glycemic variability during 5 days starting immediately after the clamp procedure. Insulin requirements and severe hypoglycemia (defined as an episode in which a patient required the assistance of another person and which was associated with a blood level of \< 50 mg/dL or prompt recovery following intravenous glucose, glucagon or oral carbohydrate) will be recorded
62650408|NCT01026493|EXPERIMENTAL|Phase II: Arm 2/BEV-NAIVE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
62282640|NCT02470455||Normoglycemic group|25 patients were recruited who were on Atorvastatin and with normal blood glucose and Hb1Ac level.
62282641|NCT02470455||Prediabetic with normal GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with normal GTT.
62282642|NCT02470455||Prediabetic with impaired GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with impaired GTT.
62282643|NCT00391404|ACTIVE_COMPARATOR|Alendronate|Oral alendronate 70 mg weekly
62282644|NCT00391404|PLACEBO_COMPARATOR|Placebo|Conventional drug treatment
62282645|NCT05836792|EXPERIMENTAL|Cycle Ergometer Group (CEG)|Isometric exercises Transcutaneous electrical nerve stimulation Ultrasound Cycle ergometer
62282646|NCT05836792|ACTIVE_COMPARATOR|Control Group|Isometric exercises Transcutaneous electrical nerve stimulation Ultrasound
62459208|NCT01402037|OTHER|NDP 5-12 y|Ten childhood-onset patients (under age 12) will be tested for 5 days with CGM (without clamp) and their glycemic variability compared with that of 10 patients aged 12-17 years at diagnosis.
62282647|NCT05548088|EXPERIMENTAL|LILRB4 STAR-T cells|LILRB4 STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 25-30mg/m2/day and cyclophosphamide treatment at dose 250-300mg/m2 for 3 days and take a rest for 2 days before infusion. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg.
62650409|NCT01026493|EXPERIMENTAL|Phase II: Arm 1/BEV-FAILURE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
62650410|NCT01026493|EXPERIMENTAL|Phase II: Arm 2/BEV-FAILURE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
62083518|NCT02163447|ACTIVE_COMPARATOR|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
62282648|NCT04156555|EXPERIMENTAL|Study drug|
62282649|NCT00372879|EXPERIMENTAL|Crossover group 1|Vitamin E first and placebo second
62282650|NCT00372879|EXPERIMENTAL|Crossover group 2|Placebo first then vitamin E
62282651|NCT00826319||Bioimpedance sub-study cohort|Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
62282652|NCT00826319||Ethnic enrichment cohort|Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
62650411|NCT03448198|OTHER|Knee arthritis|Total knee replacement
62650412|NCT06369636||Difficult Intubation Expected|Patients whose EGRI scores are equal or greater than 4, or whose skin to epiglottis measurement are greater than 18 mm, skin to hyoid bone measurement are greater than 14 mm, skin to anterior commissure of vocal cords are greater than 13 mm, tongue thickness are greater than 60 mm and tongue volume greater than 100 cm3.
62650413|NCT06369636||Difficult Intubation Not Expected|Patients who do not meet the criteria just mentioned
62650414|NCT05209919||Pulmonary arterial hypertension|All patients with pulmonary arterial hypertension and significant functional tricuspid regurgitation
62650415|NCT05209919||HFrEF|All patients with HFrEF and significant functional tricuspid regurgitation
62650416|NCT05209919||HFpEF|All patients with HFpEF and significant functional tricuspid regurgitation
62083519|NCT02163447|ACTIVE_COMPARATOR|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
62282653|NCT00826319||Original CanPreddict cohort|The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
62282654|NCT03784183|EXPERIMENTAL|moderate AD-experimental|Experimental Intervention: The CS shall be carried out in groups (5-7 participants), twice a week. Each session lasts 90 minutes. CS sessions begin with a training for temporal and spatial orientation in which participants are asked to recognize and recall the date and the place with the help of some environmental aids (calendars, clocks, pictures and maps). Then the participants complete an array of cognitive tasks for memory, attention, language, visuo-spatial functions and executive functions. These tasks range from individual paper-and-pencil exercises to verbal-learning exercises that have to be solved by the group.
62282655|NCT03784183|EXPERIMENTAL|mild AD-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
62282656|NCT03784183|EXPERIMENTAL|MCI-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
62282657|NCT03784183|NO_INTERVENTION|moderate AD-placebo|
62282658|NCT03784183|NO_INTERVENTION|mild AD-placebo|
62282659|NCT03784183|NO_INTERVENTION|MCI-placebo|
62282660|NCT03790592|EXPERIMENTAL|trifocal IOL|patients implanted with a trifocal intraocular lens
62282661|NCT00898222|EXPERIMENTAL|aspirin|Low dose daily aspirin in healthy volunteers for two weeks
62282662|NCT05452967|NO_INTERVENTION|Conventional analgesia group Group C|this group will receive rescue analgesia as per need
62282663|NCT05452967|EXPERIMENTAL|Distraction group: Group CD|This group will be distracted with the help of mobile or tablet and then will assess that rescue analgesia will be needed in post anaesthesia care unit or not
62282664|NCT05365763||Medical oncologists|5 medical oncologists; trained in the serious illness conversation guide
62282665|NCT05365763||specialty palliative care|6 specialty palliative care physicians; trained in serious illness conversation guide
62282666|NCT04697329|EXPERIMENTAL|Local infiltration|
62282667|NCT04697329|NO_INTERVENTION|No local infiltration|
62282668|NCT04728490|EXPERIMENTAL|Allogenic transplantation using treosulfan in conditioning regimen|"Haplo-identical transplantation using treosulfan in conditioning regimen Treosuflan, in the conditioning regimen will be administrated as followed 10 gr/m2 per day -4, -3 and -2 IV route~In combination with:~Thiotepa 5 mg/kg on day -6 Fludarabine 30 mg/m2 per day from day -5 to day -1"
62282669|NCT04981275||Women with PCOS|Women previously diagnosed with PCOS not using hormonal therapy and without other significant health or endocrine issues
62282670|NCT04981275||Healthy controls|Women self-identifying as generally healthy, not using hormonal therapy, and without any significant health or endocrine issues
62282671|NCT01178138|OTHER|Prazosin effects on methamphetamine|Randomized placebo controlled trial of prazosin effects on methamphetamine
62282672|NCT01194440|EXPERIMENTAL|Arm I - IV Zoledronic Acid Prophylaxis|Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
62282673|NCT00694291|EXPERIMENTAL|1|Sorafenib 400 mg orally twice daily
62282674|NCT00694291|PLACEBO_COMPARATOR|2|Placebo
62282675|NCT02429531|EXPERIMENTAL|Healthy controls|Healthy volunteers who consented to participate in the study will be immunized with both Pneumovax 23 and Typhim Vi .
62282676|NCT02429531|EXPERIMENTAL|Patients|Patients presenting for immune evaluation because of recurrent ENT/lung infection or invasive infection with encapsulated bacteria, in whom evaluation of pneumococcal antibody response is indicated, will be immunized with both Pneumovax 23 and Typhim Vi .
62282677|NCT03915145|EXPERIMENTAL|Kinesio tape group|Kinesio tape application has been applied
62282678|NCT03915145|SHAM_COMPARATOR|Sham group|Sham kinesio tape application has been applied
62282679|NCT03915145|OTHER|Control group|No intervention has been applied
62282680|NCT05149170|EXPERIMENTAL|Inductive and concurrent anti-PD-1 antibody combined with radiotherapy|All the enrolled patients receive 2 doses of inductive anti-PD-1 antibody (Tislelizumab 200mg) every two weeks, and then Involved-site radiotherapy (50±6-10 Gy) with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
62282681|NCT00319969|EXPERIMENTAL|1|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
62282682|NCT00319969|ACTIVE_COMPARATOR|2|Topotecan 1.5mg/m\<2\> IV, days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
62282683|NCT01460823|EXPERIMENTAL|Use of image guided surgery|
62282684|NCT01885780|EXPERIMENTAL|Astigmatic keratotomy|
62282685|NCT00845195|EXPERIMENTAL|Olopatadine HCl Nasal Spray, 0.6%|
62282686|NCT00845195|ACTIVE_COMPARATOR|Azelastine HCl Nasal Spray, 0.1%|
62282687|NCT05708391|EXPERIMENTAL|Experimental arm: Radiotherapy, Realgar-Indigo naturalis formula|
62282688|NCT03033771|EXPERIMENTAL|Treatment|Patients presenting with chronic type B aortic dissection will have the MFM implanted.
62282689|NCT00592475|EXPERIMENTAL|Regimen 1 Conivaptan 12.5 mg|Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours
62282690|NCT00592475|EXPERIMENTAL|Regimen 2 Conivaptan 25 mg|Conivaptan intravenous loading dose (20 mg) + 5 mg continuous infusion over 6.5 hours
62282691|NCT00592475|PLACEBO_COMPARATOR|Regimen 3 Placebo|Placebo continuous intravenous infusion over 6.5 hours
62650417|NCT05209919||Heart Failure mildly-reduced ejection fraction|All patients with Heart Failure mildly-reduced ejection fraction and significant functional tricuspid regurgitation
62650418|NCT05965414|ACTIVE_COMPARATOR|CS6253 Solution for Injection|"SAD: Single ascending doses: CS6253 Solution for Injection dosing, 50 mg/mL, will be weight based and provided from single use 2 mL vials containing approximately 100 mg CS6253 in phosphate buffered saline (PBS) solution~MAD: Multiple ascending doses (4x every 72 hours): CS6253 Solution for Injection dosing, 50 mg/mL, will be weight based and provided from single use 2 mL vials containing approximately 100 mg CS6253 in phosphate buffered saline (PBS) solution"
62282692|NCT03088865|EXPERIMENTAL|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
62650419|NCT05965414|PLACEBO_COMPARATOR|Placebo|SAD and MAD: Placebo control will be provided from vials containing physiological saline for injection in an equal amount as necessary for the active arm.
62650420|NCT02703766|ACTIVE_COMPARATOR|Lean|"Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
62650421|NCT02703766|EXPERIMENTAL|Obese|"obese individuals are defined as having body fat content more than 25% in men and more than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
62650422|NCT03647592||Cohorts 1|patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
62282693|NCT03088865|ACTIVE_COMPARATOR|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
62282694|NCT05286606||Focus groups|Health Care Professionals (HCP), facilitators, participants in the exercise program will be invited to participate in focus groups to comment on usability/acceptability.
62282695|NCT05286606||App users|Users of the exercise program with musculoskeletal conditions have been referred to the exercise program via the charities, all will be participating in a three-month program using the beta version of the app. They will be invited to participate in the program evaluation
62282696|NCT05286606||Facilitators|Facilitators of the exercise program: The facilitators for the virtual groups have been recruited equally by the charities and are working for GoodBoost to facilitate the exercise program for the app users. They will be invited to participate in the program evaluation
62282697|NCT05406856|ACTIVE_COMPARATOR|IMRT/VMAT group|This group receives standard of care curative treatment with primary external beam radiation therapy (IMRT/VMAT), combined with chemotherapy, followed by 3D image (MRI)-guided adaptive brachytherapy.
62282698|NCT05406856|EXPERIMENTAL|IMPT group|This group receives curative treatment with primary external beam radiation therapy (IMPT), combined with chemotherapy, followed by 3D image (MRI)-guided adaptive brachytherapy.
62282699|NCT04469192|EXPERIMENTAL|cryotherapy + education|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
62650423|NCT03429413|ACTIVE_COMPARATOR|Parents|Parents of 11-12 year old children who visit participating interventional clinics during study period.
62650424|NCT03429413|ACTIVE_COMPARATOR|Health Care Provider|Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
62650425|NCT03429413|NO_INTERVENTION|Adolescents at Intervention clinics|Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
62650426|NCT03429413|NO_INTERVENTION|Adolescents at Control Clinic|Parents of 11-12 year old children who visit participating control clinics during study period.
62650427|NCT03429413|NO_INTERVENTION|Health Care Provider at Control Clinic|Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
62282700|NCT04469192|ACTIVE_COMPARATOR|education alone|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
62282701|NCT01416363|EXPERIMENTAL|Treatment Arm ACB: Part 1|Subjects will receive treatment sequence ACB; A : Firategrast immediate release tablet 1200 milligram (mg) once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
62282702|NCT01416363|EXPERIMENTAL|Treatment Arm BAC: Part 1|Subjects will receive treatment sequence BAC; B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
62282703|NCT01416363|EXPERIMENTAL|Treatment Arm CBA: Part 1|Subjects will receive treatment sequence CBA; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
62650428|NCT04487990|NO_INTERVENTION|Control group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l.
62650429|NCT04487990|EXPERIMENTAL|Intervention group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l associated with unfractionated heparin at 10U / Kg / h.
62650430|NCT02426801|NO_INTERVENTION|Control|Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
62282704|NCT01416363|EXPERIMENTAL|Treatment Arm BCA: Part 1|Subjects will receive treatment sequence BCA; B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
62650431|NCT02426801|SHAM_COMPARATOR|Medication Sensor Only|"These patients received the medication use sensor (sham intervention) and downloaded a sham version of the mobile app. Thus, the medication use from these patients was able to be recorded but the patients did not receive reminders or incentives or the ability to see their medication use via the real mobile app.~Intervention: inhaler sensor"
62650432|NCT02426801|EXPERIMENTAL|Medication Sensor and Mobile App|"These patients received the medication use sensor and the mobile app with reminders (intervention arm).~Interventions: inhaler sensor and mobile application for asthma adherence"
62282705|NCT01416363|EXPERIMENTAL|Treatment Arm CAB: Part 1|Subjects will receive treatment sequence CAB; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
62282706|NCT01416363|EXPERIMENTAL|Treatment Arm ABC: Part 1|Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
62282707|NCT01416363|EXPERIMENTAL|Treatment Arm D: Part 2|Subject will receive D: Firategrast immediate release tablet 600 mg twice daily for 7 days
62282708|NCT01416363|EXPERIMENTAL|Treatment Arm E: Part 2|Subject will receive E: Firategrast 3 hour release tablet 1200 mg twice daily for 7 days
62282709|NCT01416363|EXPERIMENTAL|Treatment Arm F: Part 2|Subject will receive F: Firategrast simulated gastro-retentive solution 1200 mg twice daily for 7 days
62282710|NCT01542645|EXPERIMENTAL|Methadone|Long-acting opioid
62282711|NCT01542645|ACTIVE_COMPARATOR|Fentanyl|Shorter-acting opioid
62282712|NCT06549140|NO_INTERVENTION|Control group|Participants were not enrolled in organized exercise programs during the study (12 weeks).
62282713|NCT06549140|EXPERIMENTAL|Traditional exercise program|Participants enrolled in a traditional organized exercise program (group sessions) based on two weekly sessions of 45 to 60 minutes each for 12 weeks. These sessions are supervised by sports and exercise professionals, targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time and decision-making).
62459209|NCT01402037|OTHER|FDR 12-39 y|In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
62459210|NCT01402037|OTHER|FDR 5-12 y|"Ten high-risk first-degree relatives (see criteria) aged 5 to 12 years will also be tested for CGM and their results correlated with beta-cell function derived from a mini-clamp procedure (first 10 min. C-peptide release in hyperglycemic clamp) and results (CGM and first clamp phase) from relatives aged 12-17 years."
62459211|NCT04978532|EXPERIMENTAL|Guided Imagery Group|One minute before venipuncture and during venipuncture, the children in the guided imagery group listened to a voice recording prepared in a studio. This voice recording named 'Stroll in the Forest' helped the children to imagine that they are strolling in a forest and guided them.
62650433|NCT01837745|ACTIVE_COMPARATOR|Ablation group|"* Administration of 1.1 GBq of I131 is given after the second intramuscular injections of rhTSH (0.9 mg). A whole body scan (WBS) is performed 2 to 5 days after the administration or I131 with determination of the neck uptake.~* Follow-up consists in:~  * 10 (+/- 2 months) after randomization: neck ultrasound + a serum Tg measurement after rhTSH stimulation~ * 2 years (+/- 2 months) after randomization: serum Tg measurement under LT4 treatment (Tg/LT4)~ * 3 years (+/- 2 months) after randomization: neck ultrasound and a serum Tg/LT4~ * 4 years (+/- 2 months) after randomization: a serum Tg/LT4~ * 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~ * 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~ * 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~ * 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
62650434|NCT01837745|EXPERIMENTAL|Follow up group|Patients randomized in the follow up group neither received 131I nor rhTSH. Patients will undergo the same followup procedures as patients randomized to the ablation group, except that at 10 months after randomization, Tg will be measured under LT4 treatment and not after rhTSH stimulation.
62650435|NCT04152590|EXPERIMENTAL|Uincare|Exercise using Uincare
62650436|NCT05063240|EXPERIMENTAL|Mobile phone text messaging plus prospective motivational interviewing|Experimental: Text messaging-motivational interviewing. Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding the infants. Participants will be asked to respond within 48 hours, indicating no problem or a problem with breastfeeding that requires help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, and 10. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
62650437|NCT05063240|ACTIVE_COMPARATOR|Standard infant feeding counselling|Standard infant feeding counselling as part of routine primary healthcare practice
62650438|NCT02457975|ACTIVE_COMPARATOR|Intravitreous VEGF-inhibitors|Three intravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
62282714|NCT06549140|EXPERIMENTAL|Augmented reality exercise program|Participants enrolled in an organized exercise program based on two weekly sessions of 45 to 60 minutes each for 12 weeks: one traditional session (group session) and one augmented reality (AR) session (individual session), both supervised by sports and exercise professionals. The AR session was designed to provide a full exercise session targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time, decision-making, and memory).
62282715|NCT06098859|ACTIVE_COMPARATOR|Thoracic epidural analgesia|Thoracic epidural analgesia have been started preoperatively and coninuoed until postoperative 48 hours
62282716|NCT06098859|ACTIVE_COMPARATOR|Erector spinae plane block|Erector spinae plane blockwas applied preoperatively
62282717|NCT06098859|NO_INTERVENTION|Intravenous opioid analgesia|Intravenous opioid analgesia was administered during the surgery
62282718|NCT06054295||Ancillary-Correlative|Twins with CNS tumors, identified through the Children's Oncology Group's Project:EveryChild (PEC) registry, will have both blood and saliva samples collected at the time of study enrollment.
62459212|NCT04978532|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
62459213|NCT06443307||Second-line treatment for colorectal cancer|Cohort 1 is a concurrent control design, including patients treated with irinotecan liposome (Nal-IRI) or irinotecan (IRI) plus fluorouracils as second-line treatment for metastatic colorectal cancer.
62459214|NCT06443307||Posterior line treatment of colorectal cancer|Cohort 2 is a Simon two-stage design, is planned to include patients who are treated with a NAL-IRI based combination regimen and have used IRI as a late-line treatment for metastatic colorectal cancer.
62459215|NCT06443307||Neoadjuvant therapy for colorectal cancer|Cohort 3 is a single-arm design and planned to enroll patients who received Nal-IRI+ oxaliplatin + fluorouracils as neoadjuvant chemotherapy for colorectal cancer.
62459216|NCT06443307||Patients with non-pancreatic and non-colorectal cancer received second-line or above treatment|Cohort 4 is a single-arm design and is planned to enroll patients who are treated with the NAL-IRI containing regimen as second-line or beyond treatment for nonpancreatic, noncolorectal cancers.
62459217|NCT01553838|EXPERIMENTAL|Sequentially MRI guided and TRUS guided biopsy|Targeted MRI guided biopsy according to findings in a multiparametric MRI followed by transrectal guided biopsy
62459218|NCT05833386|ACTIVE_COMPARATOR|Silodosin group|all patients will receive oral silodosin 8 mg orally for 0ne week prior to surgery
62083520|NCT02163447|ACTIVE_COMPARATOR|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
62083521|NCT02163447|ACTIVE_COMPARATOR|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
62083522|NCT02163447|ACTIVE_COMPARATOR|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
62083523|NCT02505139||Study Group|
62083524|NCT01315743|EXPERIMENTAL|Intervention|
62282719|NCT03880500|SHAM_COMPARATOR|Patient|25 Patients will receive a spinal manipulative therapy Intervention, the other 25 Patients receive a sham Intervention.
62650439|NCT02457975|EXPERIMENTAL|670nm PBM plus VEGF-inhibitors|Subjects in the 670 nm Photobiomodulation (PBM) intervention arm will be treated (in addition to Anti-VEGF treatment) with 670nm light (WARP10, Quantum, Devices, Inc, Barneveld, WI). The portable, battery-operated 670 nm LED array specifically designed not to generate heat will be held 1 inch from the closed treatment eye. A 90-sec light treatment will be delivered. After 90 sec a timer turns off the light. The dose of light delivered at the surface of the cornea is calculated to be 4.5 J/cm2 (90 sec x 0.05 W/cm2 = 4.5 J/cm2). PBM treatment will be applied for 90 sec once per day, three consecutive days per week for 8 weeks. Previous clinical studies, have shown this treatment regimen and dose to be safe and effective in the treatment of dry AMD and non-center involving DME
62650440|NCT05811364|ACTIVE_COMPARATOR|VBX Device Group|Subject in this group will receive treatment with the GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)
62650441|NCT05811364|ACTIVE_COMPARATOR|BMS Control Group|Subjects in this group will receive treatment with a commercially available bare metal stent (BMS) that is approved for treatment of the disease
62650442|NCT01712282|EXPERIMENTAL|High dose training|2 x 30 minutes/day on a weight-bearing treadmill
62282720|NCT03880500|NO_INTERVENTION|Control|No intervention
62282721|NCT02947867|EXPERIMENTAL|"aganirsen low-dose:"|43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
62282722|NCT02947867|EXPERIMENTAL|"aganirsen high-dose"|86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
62282723|NCT02947867|PLACEBO_COMPARATOR|aganirsen placebo (vehicle)|one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
62282724|NCT04846244||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for axial spondyloarthritis (axSpA).
62282725|NCT02095821||Humoral rejection, TPE|
62282726|NCT04473417|EXPERIMENTAL|Part A, Sequence I|Period I: Forxiga® → DA-2811, Period II: DA-2811 → Forxiga®
62282727|NCT04473417|EXPERIMENTAL|Part A, Sequence II|Period I: DA-2811 → Forxiga®, Period II: Forxiga® → DA-2811
62282728|NCT04473417|EXPERIMENTAL|Part B, Sequence I|Period I: DA-2811 under fasting state → DA-2811 under fed state, Period II:DA-2811 under fed state → DA-2811 under fasting state
62282729|NCT04473417|EXPERIMENTAL|Part B, Sequence II|Period I: DA-2811 under fed state → DA-2811 under fasting state, Period II: DA-2811 under fasting state → DA-2811 under fed state
62459219|NCT05833386|ACTIVE_COMPARATOR|Non premedicated group|None of this group will receive alpha blocker prior to surgery
62282730|NCT03324204|EXPERIMENTAL|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis is placed on proper knee alignment during exercise. Most of the women exhibit excessive medial rotation and adduction of the femur, resulting in knee valgus. The women will be instructed how to correct their abnormalities using mirrors as visual feedback. All exercises will be completed without pain. If the exercises are too easy, the level of difficulty will be increased individually in accordance with the rehabilitation protocol
62282731|NCT03324204|ACTIVE_COMPARATOR|Shock Wave Therapy|The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.
62282732|NCT05642442|PLACEBO_COMPARATOR|Placebo|Participants who will receive a matching placebo during the Dose Titration, Optimization Period, and Maintenance Period.
62459220|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
62459221|NCT02381171|SHAM_COMPARATOR|Both Sham rTMS and Neuroacupuncture|Subjects will be randomized to receive 10 sessions of both sham treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMSat 10hHz (1600pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
62083525|NCT05909787|EXPERIMENTAL|Auto-questionnaire MCH (Montreal Children's Hospital)|Auto-questionnaire MCH (Montreal Children's Hospital)
62083526|NCT02425475||Mole|Patients with suspicious moles
62083527|NCT02189863|OTHER|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
62083528|NCT02189863|OTHER|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
62459222|NCT02381171|SHAM_COMPARATOR|Active rTMS and sham Neuroacupuncture|Subjects will be randomized to receive 10 sessions of active rTMS and sham neurofunctional electrical acupuncture treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
62083529|NCT01169259|ACTIVE_COMPARATOR|Vitamin D + fish oil|
62083530|NCT01169259|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|
62083531|NCT01169259|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|
62282733|NCT05642442|EXPERIMENTAL|Sulvecaltamide|Participants who will receive an optimal dose of suvecaltamide during the Dose Titration, Optimization Period, and Maintenance Period.
62282734|NCT05131607|EXPERIMENTAL|Supine MRI|
62282735|NCT02315924|EXPERIMENTAL|coronary and cerebral stenosis|
62083532|NCT01169259|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|
62083533|NCT03350477|ACTIVE_COMPARATOR|Cancer ablation|In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (\>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62282736|NCT02315924|ACTIVE_COMPARATOR|coronary or cerebral stenosis|
62459223|NCT02381171|SHAM_COMPARATOR|Sham rTMS and Active Neuroacupuncture|Subjects will be randomized to receive 10 sessions of sham rTMS and active Neurofunctional Electrical Acupuncture. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS placebo coil over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
62282737|NCT03140904|OTHER|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
62282738|NCT03140904|OTHER|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
62282739|NCT06545487||CONTROL|
62282740|NCT06545487||FRACTURA|
62282741|NCT04722211|EXPERIMENTAL|PS128|Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
62282742|NCT04722211|PLACEBO_COMPARATOR|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
62282743|NCT01590147|EXPERIMENTAL|Arm 1 (YST)|Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
62650443|NCT03521310|EXPERIMENTAL|Skin-to-skin Contact group|Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
62282744|NCT01590147|ACTIVE_COMPARATOR|Arm 2 (CE)|Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.
62650444|NCT03521310|ACTIVE_COMPARATOR|Conventional care group|Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.
62650445|NCT04662333|ACTIVE_COMPARATOR|Crestal sinus lift|Implant site preparation with detachment of Schneiderian membrane and subsequent implant placement. The corresponding healing abutment is made up of PEEK (poly-ether-ether-ketone)
62282745|NCT01551979|ACTIVE_COMPARATOR|Active rTMS|High frequency rTMS stimulation of the vermis(lobule VII) of the cerebellum.
62282746|NCT01551979|SHAM_COMPARATOR|Sham rTMS|Sham rTMS to the vermis (lobule VII) of the cerebellum.
62282747|NCT01356004|EXPERIMENTAL|chicken pox vaccine, efficacy|
62282748|NCT01356004|PLACEBO_COMPARATOR|saline, efficacy|
62282749|NCT01681420|EXPERIMENTAL|Approved Intervention Counseling|Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.
62282750|NCT01681420|EXPERIMENTAL|Approved Intervention Donation|Approved blood donors randomized to intervention and choosing donation with no HIV counseling.
62282751|NCT01681420|EXPERIMENTAL|Deferred Intervention|Deferred blood donors randomized to intervention with HIV counseling.
62282752|NCT02685709|EXPERIMENTAL|Run-in phase|Oral octreotide capsules
62282753|NCT02685709|EXPERIMENTAL|RCT phase - Oral|Oral octreotide capsules
62282754|NCT02685709|ACTIVE_COMPARATOR|RCT phase - Injectables|Injectable somatostatin analogs (octreotide or lanreotide)
62282755|NCT02685709|EXPERIMENTAL|Combination phase (sub-study)|Octreotide capsules plus cabergoline
62282756|NCT03603769|EXPERIMENTAL|Group A: Food Supplement (Salmon Polar Lipids) Intervention|"Experimental: After fasting overnight, subjects will come to our metabolic unit where in a randomized and double blinded way they will be provided several versions of the food supplement either of stomach resistant (intestine release) or stomach non-resistant (stomach release) each containing either 0.25 (Low Dose) or 0.50 g (High Dose) of Salmon Polar Lipids (SPL)~Assessment \& outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the SPL-food supplement intervention. Aggregation of platelets will be assessed in these samples as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
62459224|NCT02381171|ACTIVE_COMPARATOR|Both Active rTMS and Neuroacupuncture|Experimental Subjects will be randomized to receive 10 sessions of both active treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10 Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
62650446|NCT04662333|EXPERIMENTAL|Crestal sinus lift with adjunctive xenograft|Implant site preparation with detachment of Schneiderian membrane. After that, collagen membrane plus xenogenic bone substitute will be placed into the site before implant placement. The corresponding healing abutment is made up of titanium.
62650447|NCT01553929|EXPERIMENTAL|Physical and cognitive activity group|
62650448|NCT01553929|ACTIVE_COMPARATOR|Physical activity group|
62650449|NCT01553929|PLACEBO_COMPARATOR|control group|
62650450|NCT02559167|ACTIVE_COMPARATOR|Cannabidiol|Participants will receive CBD 800 mg for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
62650451|NCT02559167|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
62650452|NCT02577029|EXPERIMENTAL|Cohort 1|"Treatment-naïve, hepatitis B e antigen (HBeAg)-positive participants with chronic hepatitis B (CHB) of any genotype administered ARC-520 (2 mg/kg intravenous \[IV\]) every 4 weeks for 48 weeks (13 doses)."
62650453|NCT02577029|EXPERIMENTAL|Cohort 2|Treatment-naïve, HBeAg-positive, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered peginterferon (PEG IFN) alpha 2a for 48 weeks starting Day 87.
62650454|NCT02577029|EXPERIMENTAL|Cohort 3|Treatment-naïve, HBeAg-negative, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
62650455|NCT02577029|EXPERIMENTAL|Cohort 4|Treatment-naïve, HBeAg-positive, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
62650456|NCT02577029|EXPERIMENTAL|Cohort 5|Treatment-naïve, HBeAg-negative, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
62650457|NCT02577029|EXPERIMENTAL|Cohort 6|Treatment-naïve, HBeAg-negative, Genotype D participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
62650458|NCT02577029|EXPERIMENTAL|Cohort 7|Treatment-naïve, HBeAg-negative or HBeAg-positive participants with hepatitis delta virus (HDV) administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 15.
62650459|NCT02577029|EXPERIMENTAL|Cohort 8|Treatment-naïve, HBeAg-positive participants with CHB of any genotype administered ARC-520 (4 mg/kg IV) every 4 weeks for 48 weeks (13 doses).
62282757|NCT03603769|PLACEBO_COMPARATOR|Group B: Consumption of Placebo Comparator|"Experimental: After fasting overnight subjects will come to the metabolic unit in UL at 08.00 am where in a randomized and double blinded way they will be provided a placebo capsule containing only glycerin.~Assessment \& outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the placebo administration. Aggregation of their platelets will be assessed as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
62459225|NCT05938556|EXPERIMENTAL|Group Coaching Program|The study intervention is a hybrid asynchronous-synchronous group coaching treatment that will occur over four months. Participants will be given access to a members-only, web-based platform to access the intervention.
62459226|NCT05938556|PLACEBO_COMPARATOR|Usual Treatment|This group will participate in the study intervention following a 4-month waitlist/control group.
62282758|NCT05030688|ACTIVE_COMPARATOR|Group FICB = Fascia iliaca compartment block|FICB will be performed with a suprainguinal approach under US guidance. The probe will be placed sagittally to view the ilium and iliacus muscle. The probe will be moved medially and inferiorly along the inguinal ligament to view the femoral artery. The probe will then be moved superiorly and laterally along the inguinal ligament towards the anterior superior iliac crest to reach the lateral aspect of the femoral nerve. The deep circumflex artery will be visualized 1-2 cm cephalad to the inguinal ligament and superficial to the iliac fascia. The needle will be inserted with in-plane method 2-4 cm caudal to the inguinal ligament to reach below the fascia ilica. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
62282759|NCT05030688|ACTIVE_COMPARATOR|Group PENG|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
62282760|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI \> or = 18.5 kg/m2)
62282761|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
62282762|NCT02591433|EXPERIMENTAL|Supportive care (JeffQuit group therapy)|Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
62282763|NCT03840330|EXPERIMENTAL|High-intensity interval training group|Frequency: 2 days/weeks; Intensity: 16-18 Börg/85-100%VO2max; Recovery: Active; Duration: 1 hour.
62282764|NCT03840330|EXPERIMENTAL|Moderate-intensity interval training group|Frequency: 2 days/weeks; Intensity: 12-14 Börg/60-70% VO2max; Recovery: Active; Duration: 1 hour.
62282765|NCT03840330|NO_INTERVENTION|Control group|Maintain their normal daily activities throughout the sixteen-week experimental period.
62650460|NCT01220791|ACTIVE_COMPARATOR|Follicular Medrol|In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
62650461|NCT01220791|PLACEBO_COMPARATOR|No medrol group|Patients will receive only Antagonist protocol for IVF as usual
62650462|NCT00826839|EXPERIMENTAL|OCP/MDL|Oral contraceptive pills/microdose lupron
62650463|NCT00826839|EXPERIMENTAL|E2/antagonist|Estradiol patch/gonadotropin-releasing hormone antagonist
62650464|NCT01399307|OTHER|Elective Liposuction|
62282766|NCT01307930|EXPERIMENTAL|Anidulafungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
62282767|NCT05150366|EXPERIMENTAL|Patient scheduled for percutaneous closure of the left auricle by St Jude AMULET device|
62650465|NCT00423046|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of GSK Biologicals human papillomavirus \[HPV\]16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
62650466|NCT00423046|ACTIVE_COMPARATOR|Gardasil Group|Subjects received 3 doses of Gardasil® (Merck's human papillomavirus \[HPV\] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
62650467|NCT06050213|ACTIVE_COMPARATOR|three implant group|Maxillary overdenture retained by 3 unsplinted implants in midline and canines regions.
62083534|NCT03350477|ACTIVE_COMPARATOR|Life information rehabilitation therapy|"In this group,the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62083535|NCT03350477|EXPERIMENTAL|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(\>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62083536|NCT03350477|NO_INTERVENTION|Control|In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62083537|NCT00030654|EXPERIMENTAL|Androgen blockade + immediate chemotherapy|Androgen blockade with immediate chemotherapy
62282768|NCT01039857|OTHER|Structured solution focused therapy|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy
62282769|NCT01039857|EXPERIMENTAL|Integrative clarification therapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
62650468|NCT06050213|ACTIVE_COMPARATOR|five implant group|Maxillary overdenture retained by 5 unsplinted implants in midline, canines and molar regions.
62650469|NCT06050213|ACTIVE_COMPARATOR|four implant group|Maxillary overdenture retained by 4 unsplinted implants in canines and molar regions.
62083538|NCT00030654|EXPERIMENTAL|Androgen blockade + delayed chemotherapy|Androgen blockade with delayed chemotherapy
62083539|NCT02933463|EXPERIMENTAL|embrace wetbond sealant|moisture tolerant resin based, have same properties of other sealant
62282770|NCT06061198|ACTIVE_COMPARATOR|group of patients who underwent surgery with the virtual reality experience|patients underwent surgery wearing a virtual reality mask
62282771|NCT06061198|NO_INTERVENTION|patients who underwent surgery in standard conditions without the virtual reality experience|patients underwent surgery without a virtual reality mask
62282772|NCT02944916|EXPERIMENTAL|IryPump R Set|A new set for transanal irrigation composed by 2 parts : 1 pump and 1 rectal catheter . 1 rectal catheter used per irrigation respecting the patient usual frequency of transanal irrigation
62650470|NCT02596048|OTHER|Iomeron|Patients will undergo a injection of Iomeron if they are scheduled to undergo an elective thoraco-abdominal aorta, carotid, pulmonary or peripheral MDCTA examination
62282773|NCT02015169|EXPERIMENTAL|XELOX+lapatinib|"D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs~D1-D14 Capecitabine 850mg/m2 p.o bid~D1 \~ Lapatinib 1250 mg qd dailiy"
62282774|NCT01570647||Healthy controls|
62282775|NCT01570647||Chronic low back pain|
62282776|NCT01570647||restricted hamstrings|
62650471|NCT05584098|OTHER|qSOFA and MEWS|Modified Early Warning Score(MEWS) and quick Sequential Organ Failure Assessment(qSOFA) are used in prediction of occurrence of sepsis
62650472|NCT04079790|EXPERIMENTAL|Subjects receiving Gepotidacin in Part 1|Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
62282777|NCT01570647||systemic scleroderma|
62282778|NCT01570647||joint hyperlaxity|
62282779|NCT03087006|ACTIVE_COMPARATOR|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
62459227|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
62459228|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
62650473|NCT04079790|PLACEBO_COMPARATOR|Subjects receiving Placebo in Part 1|Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
62650474|NCT04079790|EXPERIMENTAL|Subjects receiving Gepotidacin in Part 2|Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
62650475|NCT04079790|PLACEBO_COMPARATOR|Subjects receiving Placebo in Part 2|Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
62282780|NCT03087006|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
62282781|NCT03754907|EXPERIMENTAL|stapled anastomosis group|Following the first side-to-side anastomosis at the antimesenteric border in both intestinal limbs, the staple lines are oversewn to reinforce the crotch. Thereafter, the stapler is again fired across the joined intestinal limbs to close the enterotomies. The suture line of the side-to-side anastomosis should not overlap, and the staple lines are oversewn to reinforce the double-stapled areas.
62282782|NCT03754907|ACTIVE_COMPARATOR|hand-sewn anastomosis group|Patients chose HA group will performed in an end-to-end manner using absorbable suture material.
62282783|NCT03671057|EXPERIMENTAL|HospiAvontuur|Intervention group - Non-pharmacological (HospiAvontuur) preparation HospiAvontuur is a simple point and click adventure game on a I-pad. The game describes the pathway which a child and his parents will take before, during and just after a hospital admission for an elective otorhinolaryngeal procedure under general anaesthesia.
62282784|NCT03671057|ACTIVE_COMPARATOR|Midazolam|control group: The children of the control group will not play the game HospiAvontuur as an at home preparation for surgery. These children will be prepared for surgery according to the current practice at the Jessa hospital. Children receive only the basic information during the consultation with the surgeon. There is no specific at home preparation required. When admitted at the hospital, children receive a pharmacological preparation, 45 - 60 minutes prior to the induction of the anaesthesia. The medication is administered orally by a small syringe in the mouth and contains Dormicum 0.3mg/kg body weight and atropine 0.02mg/kg body weight supplemented with raspberry syrup.
62282785|NCT02665429|NO_INTERVENTION|Control|Providers who are subject only to the routine implementation of clinical practice guidelines without additional experimental intervention
62282786|NCT02665429|EXPERIMENTAL|Intervention|"Providers who are subject to routine clinical practice guideline implementation AND receive provider's own individual prescribing data profile intervention (Individual prescribing data profile and self-assessment)"
62282787|NCT00441545|EXPERIMENTAL|1|Fosrenol (Lanthanum carbonate)
62459229|NCT02472522|PLACEBO_COMPARATOR|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
62459230|NCT02472522|EXPERIMENTAL|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
62650476|NCT01217346||cardiac syndrome X|subjects fulfilling the clinical triad of cardiac syndrome X
62083540|NCT02933463|ACTIVE_COMPARATOR|clinpro sealant|is a dental resin, with low viscosity , fluoride releasing with a unique patented color change.
62282788|NCT00441545|ACTIVE_COMPARATOR|2|Sevelamer hydrochloride
62650477|NCT06002100||Ketamine|Adult participants starting ketamine treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
62282789|NCT04844255|OTHER|Pre and post intervention group|Same individuals are examined before and after taking 2 tablets of salt
62282790|NCT02904980|EXPERIMENTAL|Technical Training Group|15 children diagnosed with DCD
62282791|NCT02904980|EXPERIMENTAL|Quiet Eye Training Group|15 children diagnosed with DCD
62282792|NCT01645267|EXPERIMENTAL|Osteotomy|Using hydroxyapatite bone graft material
62282793|NCT01822808|ACTIVE_COMPARATOR|Hydralazine|24 week course of Hydralazine 25mg 3 times daily for 4 weeks, thereafter uptitrating to 50mg hydralazine 3 times daily up to week 24. Those assigned to the Hydralazine control arm will receive the same number of identical placebo tablets.
62282794|NCT01822808|ACTIVE_COMPARATOR|Isosorbide dinitrate|24 week course of Isosorbide dinitrate 10mg 3 times daily for 4 weeks, thereafter uptitrating to 20mg isosorbide dinitrate 3 times daily up to week 24. Those assigned to the Isosorbide dinitrate control arm will receive the same number of identical placebo tablets.
62282795|NCT05874531||Responders to fluid challenge|Responders to fluid loading after an increase in sub-aortic VTI of more than 10% following a volume expansion.
62282796|NCT05874531||Non responders to fluid challenge|Non responders to fluid loading after an increase in sub-aortic VTI of more than 10% following a volume expansion.
62282797|NCT05770986|EXPERIMENTAL|Group A ( power's group)|Patients will receive the eight phases of the power's program plus a conventional treatment of flexibility exercises, hot pack, transcutaneous electrical stimulation (TENS), prone resisted hip extension for 12 sessions (3 sessions per week for 4 weeks).
62459231|NCT02684578|EXPERIMENTAL|Metformin|This arm will be receiving the study drug, Metformin, for the duration of the 24 month study. They will begin this drug on a low dose of Metformin, increasing the dosage in a step-wise fashion to avoid unwanted gastrointestinal discomfort, a common side effect when patients begin taking Metformin. During the 24 month study, subjects assigned to this arm will have 4 follow-up exams after the initial enrollment exam, at 6 month intervals.
62459232|NCT02684578|NO_INTERVENTION|Observe|This arm will maintain standard of care for dry AMD, which is observation. During the 24 month study, subjects assigned to this arm will have 4 follow-up exams after the initial enrollment exam, at 6 month intervals.
62459233|NCT02796664|EXPERIMENTAL|Ginseng|
62083541|NCT04895020|EXPERIMENTAL|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
62083542|NCT06530524|PLACEBO_COMPARATOR|Placebo|The treating physician will perform the injection of normal saline under ultrasound guidance using a 30-gauge needle introduced into the salivary gland tissue. 30 units of normal saline will be infiltrated the major salivary glands at-risk.
62282798|NCT05770986|ACTIVE_COMPARATOR|Group B ( control)|Patients will receive a conventional treatment of flexibility exercises, hot pack, transcutaneous electrical stimulation (TENS), prone resisted hip extension for 12 sessions (3 sessions per week for 4 weeks).
62282799|NCT06454084|EXPERIMENTAL|Acetylcholine 0,1 mg/mL and 1 mg/mL and 10 mg/mL|"Vasodilator solution is dropped on the labial surface of the lateral incisor, which penetrates into the gingival sulcus.~In the dose-response study, 0,1 mg/mL, 1 mg/mL, and 10 mg/mL acetylcholine solution is dropped into the gingival sulcus, and every solution remains there for 2:30 minutes between them is always a 30-second long pause.~In the second phase of the study, where the sex differences are monitored, 10 mg/mL acetylcholine solution is dropped into the gingival sulcus for 15 minutes"
62459234|NCT02796664|PLACEBO_COMPARATOR|Placebo|
62459235|NCT00770510|EXPERIMENTAL|Eszopiclone 1 mg|
62459236|NCT00770510|EXPERIMENTAL|Eszopiclone 2 mg|
62459237|NCT00770510|EXPERIMENTAL|Eszopiclone 3 mg|
62459238|NCT00770510|PLACEBO_COMPARATOR|Placebo|
62459239|NCT00770510|ACTIVE_COMPARATOR|Zolpidem Tartrate 10 mg|
62459240|NCT02385396|PLACEBO_COMPARATOR|Group I|60 patients diagnosed with PCOS, not myo-inositol treated undergoing ICSI
62459241|NCT02385396|EXPERIMENTAL|Group II|52 patients diagnosed with PCOS undergoing ICSI, taking Inofolic (myo-inositol + folic acid)
62459242|NCT02385396|PLACEBO_COMPARATOR|Group III|105 patients not diagnosed with PCOS undergoing ICSI, not taking myo-inositol
62459243|NCT05437809|OTHER|Adults with obesity|All participants (n=50 adults with obesity) will complete each of the four food consumption appointments (order of the four appointments will be randomized/counterbalanced).
62650478|NCT06002100||SPRAVATO|Adult participants starting SPRAVATO treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
62650479|NCT06002100||TMS|Adult participants starting TMS treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
62459244|NCT00762307|EXPERIMENTAL|Treatment Group 1|Cooling Intensity Factor = 33 Duration = 60 minutes
62459245|NCT00762307|EXPERIMENTAL|Treatment Group 2|Cooling Intensity Factor = 37 Duration = 30 minutes
62459246|NCT00762307|EXPERIMENTAL|Treatment Group 3|Cooling Intensity Factor = 37 Duration = 45 minutes
62459247|NCT00762307|EXPERIMENTAL|Treatment Group 4|Cooling Intensity Factor = 42 Cooling Duration = 30 minutes
62459248|NCT00813046|EXPERIMENTAL|gpASIT+TM|
62459249|NCT03213119|EXPERIMENTAL|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
62459250|NCT03213119|EXPERIMENTAL|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
62459251|NCT03213119|SHAM_COMPARATOR|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
62459252|NCT05639062|ACTIVE_COMPARATOR|Narrative-based card game|
62459253|NCT05639062|NO_INTERVENTION|PUKE card game|
62459254|NCT00665730|EXPERIMENTAL|Sepraspray|Sepraspray Powder applied on the viscera directly under the midline incision followed by incision closure. Sepraspray dose applied was between 2 g and 4 g per patient.
62282800|NCT01106040|EXPERIMENTAL|Lymphoseek, Lymphatic mapping, Injection|
62459255|NCT00665730|NO_INTERVENTION|Control|No anti-adhesion treatment used.
62459256|NCT06497322|EXPERIMENTAL|Experimental group|All women in the experimental group receive standardized high-intensity interval training over a period of 6 months in combination with neoadjuvant therapy (immunochemotherapy). The individual training sessions are guided and monitored by qualified exercise therapists, taking into account the side effects of ongoing treatment. Each training session will last about one hour, with the effective training time being 30 minutes. Bike training begins 1 hour before neoadjuvant therapy and then at the same time of day between therapies. The TNBC patients start with 5 minutes of cycling followed by 3 × 3 - minute HIIT training sequences, constantly alternating: i) 30 s at 90% of maximal PO (70 rpm for 30 s) and ii) 30 s of light pedaling at 20% of PO). The training session will be concluded with a 5-min cool-down cycling (easy pedaling) and stretching. This protocol will be performed twice a week throughout the study.
62459257|NCT06497322|NO_INTERVENTION|Control group|The control group will receive the standard care during their neoadjuvant therapy (immunochemotherapy) over a 6-month period.
62459258|NCT05064462||All the patients included in the study|50 patients, at least 18 years old, first heart transplant
62650480|NCT06002100||Antidepressants|Adult participants starting antidepressant treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment and short-term efficacy visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
62650481|NCT04596904|EXPERIMENTAL|Lavender oil group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
62083543|NCT06530524|EXPERIMENTAL|onabotulinumtoxinA|The treating physician will perform the injection of onabotulinumtoxinA under ultrasound guidance using a 30-gauge needle introduced into the salivary gland tissue. 30 units of onabotulinumtoxinA will be infiltrated the major salivary glands at-risk.
62083544|NCT05040490|EXPERIMENTAL|SUG group|sugammadex as reversal drugs
62083545|NCT05040490|NO_INTERVENTION|NEO group|neostigmine as reversal drugs
62083546|NCT06385470|EXPERIMENTAL|DTTC treatment|Four Cantonese-English bilingual children with be randomly assigned to receive either one of the two versions of DTTC (i.e., DTTC in Cantonese \[DTTC-C\] and DTTC in English \[DTTC-E\]) in the first 6-week treatment phase. Then, there will be a 2-week washout period followed by the second 6-week treatment phase with another version of DTTC.
62083547|NCT03693599|EXPERIMENTAL|carbetocin|600 women received single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
62083548|NCT03693599|ACTIVE_COMPARATOR|Syntometrine|600 women received one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 micrograms of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
62083549|NCT06233942|EXPERIMENTAL|Phase 1a: Part A (Monotherapy Dose Escalation)|BG-C9074 monotherapy dose escalation
62083550|NCT06233942|EXPERIMENTAL|Phase 1a: Part B (Monotherapy Safety Expansion)|BG-C9074 dose levels that have been determined to be safe and tolerable in Part A will be investigated.
62083551|NCT06233942|EXPERIMENTAL|Phase 1a: Part C (Combination Therapy Dose Escalation)|BG-C9074 plus tislelizumab combination at the recommended dose for expansion (RDFE).
62083552|NCT06233942|EXPERIMENTAL|Phase 1b: Monotherapy Dose Expansion|The monotherapy dose expansion phase will begin once the BG-C9074 monotherapy RDFE and dosing schedule have been determined from Parts A and B in Phase 1a.
62282801|NCT00749008||Term Infants|High risk infants with history of respiratory insufficiency requiring NICU care.
62282802|NCT00749008||Preterm Infants|Infants less than 37 weeks gestational age.
62282803|NCT04111614|EXPERIMENTAL|Arm 1|Single dose of 5 mL tofacitinib oral solution on Day 1 of Period 1 and Singe dose of 5 mg tofacitinib tablet on Day 1 of Period 2
62459259|NCT01820026|EXPERIMENTAL|Imipenem & Vancomycin & Azithromycin|"Tienam combined with vancomycin (1g/12 h) for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of a source of infections.~Tienam combined with vancomycin (1g/12 h)and azythromycin (500 mg/24 h)for pneumonia"
62282804|NCT04111614|EXPERIMENTAL|Arm 2|Single dose of 5 mg tofacitinib tablet on Day 1 of Period 1 and Singe dose of 5 mL tofacitinib oral solution on Day 1 of Period 2
62083553|NCT00524238|OTHER|1|11 hypothyroid patients, newly diagnosed, examined before and after treatment
62083554|NCT00524238|NO_INTERVENTION|2|10 healthy controls
62083555|NCT00894751|ACTIVE_COMPARATOR|dexmedetomidine|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
62083556|NCT00894751|ACTIVE_COMPARATOR|propofol|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
62083557|NCT02765243|EXPERIMENTAL|effectiveness of Anti-GD2 CART|Anti-GD2 CART cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the side effects and effective doses of Anti-GD2 CART cells in treating refractory and/or recurrent neuroblastoma
62282805|NCT05613413|EXPERIMENTAL|Single|"All subjects will receive carbozantinib 40mg PO once daily Days 1-21 Q3W and pembrolizumab 200mg IV infusion Q3W or 400mg IV infusion Q6W per the treating physician's discretion as maintenance therapy following 4 cycles of induction therapy with disease control~Note: Cabozantinib should be stopped at least 3 weeks prior to elective surgery. Do not administer cabozantinib for at least 2 weeks after major surgery and until complete wound healing."
62282806|NCT02421341|EXPERIMENTAL|Drug - Fentanyl|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
62282807|NCT02421341|PLACEBO_COMPARATOR|Placebo|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
62282808|NCT01461044||Cohort|
62282809|NCT06549244||Block, Non-obese|Non-obese, Body Mass Index (BMI)\<30, receiving interscalene block and general anesthesia for shoulder surgery
62282810|NCT06549244||Block, Obese|Class 2 or higher Obese, BMI\>35, receiving interscalene block and general anesthesia for shoulder surgery
62282811|NCT06549244||Control|control group, included non-shoulder surgery patients receiving general anesthesia only
62282812|NCT03893149|EXPERIMENTAL|Active-Start intervention|Supervised exercise training
61978531|NCT05519423|EXPERIMENTAL|Morbid obesity individuals|"All subjects participating in the study will be given physical activity incentive program (PAI) individually. After evaluating it is aimed to provide information transfer and motivation support to increase physical activity levels before bariatric surgery within the scope of PAI.~For this purpose, individual face-to-face interviews will conduct with all cases; verbal information will be given about the importance of physical activity, its effects and different levels of severity. The progress of the program will be made with the whats app application.~8-week follow-up chart will be given to the individuals, about the completion of the physical activity follow-up chart prepared in order to raise awareness about the activity levels of individuals in daily life and to increase their physical activity levels.~All subjects will record daily step counts, low, moderate, and vigorous activities on the chart at the end of the day, every day for 8 weeks."
62083558|NCT03113760|EXPERIMENTAL|Tadekinig alfa|Patients that showed response to treatment in the SAOL phase will receive Tadekinig alfa for up to 16 weeks.
62083559|NCT03113760|PLACEBO_COMPARATOR|0.9% sodium chloride|Patients that showed response to treatment in the SAOL phase will receive placebo comparator for up to 16 weeks.
62083560|NCT02638064|EXPERIMENTAL|Surgiflo injection|Injection of surgiflo in the pilonidal sinus cavity after curettage of its content
62282813|NCT03893149|NO_INTERVENTION|Control group|No-exercise
62282814|NCT05199324|EXPERIMENTAL|Early step-down to oral antibiotic therapy|The oral antibiotic options are fluoroquinolones (most commonly, ciprofloxacin) or trimethoprim-sulfamethoxazole. The recommended doses for patients with normal renal function would be ciprofloxacin 750 mg twice daily (if body weight ≥70 kg) or ciprofloxacin 500 mg twice daily (if body weight \<70 kg) or trimethoprim-sulfamethoxazole 5 mg/kg (for trimethoprim component) every 12 hourly or trimethoprim-sulfamethoxazole (160 mg / 800 mg; double strength) two tablets twice daily. Doses may be adjusted in the setting of renal dysfunction. The recommended treatment duration by the study team is 7 days of active antibiotics (including empiric therapy), although treatment regimen may be longer than 7 days due to regimen extension or requirement for prolonged regimen as clinically indicated.
62282815|NCT05199324|ACTIVE_COMPARATOR|Continuing intravenous antibiotic therapy|The intravenous antibiotic(s) to be administered will be determined by the treating doctor according to what would be considered standard of care in the hospital site. Commonly used intravenous antibiotics (and doses) for treatment of Gram-negative bacteraemia include ceftriaxone 2 g daily or cefazolin 2 g three times daily. The recommended treatment duration by the study team is 7 days of active antibiotics (including empiric therapy), although treatment regimen may be longer than 7 days due to regimen extension or requirement for prolonged regimen as clinically indicated.
62282816|NCT01175746|EXPERIMENTAL|nicardipine|
62282817|NCT01175746|ACTIVE_COMPARATOR|remifentanil|
62282818|NCT03341676|EXPERIMENTAL|Dexamethasone|8ml IV 3.3mg/mL dexamethasone
62282819|NCT03341676|PLACEBO_COMPARATOR|Placebo|8ml IV 0.9% w/v saline
62282820|NCT02793362||Normal subjects without stroke|"1. subjects who can walk independent without any difficult~2. subjects without history of CNS or PNS lesion~3. Modified ranking scale (MRS) \<=2~4. Functional ambulation category (FAC) \>=2"
62083561|NCT06236581|EXPERIMENTAL|GEM Intervention|A lifestyle coach will deliver the GEM intervention over 4 weeks in person and/or virtually (synchronously) to permit interaction with participants. A pocket-sized manual will be provided with 4 units corresponding to session topics, and diary pages to record glucose responses to food and physical activity (PA). Session 1: Introduce GEM, identify personal motivation, learn about foods that cause glucose to go high (high glycemic load (GL) foods) and those that do not (low GL foods), learn how physical activity affects glucose, and begin monitoring how these choices affect glucose. Session 2: Replacement, substitution, and portion control to reduce consumption of high GL foods. Session 3: Increasing PA and reducing sedentary behavior, esp. after a meal. Session 4: Ways to continue lifestyle changes over a lifetime, handle relapses, and thank loved ones for their support. Text message reminders may be sent to participants between sessions to prompt diary entries and for encouragement.
62083562|NCT06236581|NO_INTERVENTION|Waitlist|Participants will be invited to receive the GEM intervention after they posttest, the next time it is offered.
62282821|NCT02793362||Post stroke patients with sarcopenia(by sarcopenia index)|Existence of sarcopenia will be determined by DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
62459260|NCT01820026|ACTIVE_COMPARATOR|Cefotaxime & Amoxicillin & Azithromycin|Cefotaxime IV(2g/12 h): for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of specific site of infection Amoxicillin/clavulanic acid (2,2 g/8 h)or Ciprofloxacin (500 mg/12 h: urinary tract infections Amoxicillin/clavulanic acid (2,2 g/8 h)and azithromycin (500 mg/24 h): pneumonia Amoxicillin/clavulanic acid (2,2 g/8 h)for skin or soft tissue infection
62459261|NCT02844803|OTHER|Active drug-> Placebo|Metformin + S. Baicalensis --\> Metformin + Placebo
62459262|NCT02844803|OTHER|Placebo -> Active drug|Metformin + Placebo --\> Metformin + S. Baicalensis
62459263|NCT05933005|EXPERIMENTAL|D-kit/EF1 group|"The experimental group will use the D-kit/EF1 program on a mobile tablet device at least 5 times a week for 30 minutes each session, for a duration of 12 weeks.~The program will be performed under the supervision of the participant's parents or primary caregivers, following the provided program usage guide."
62083563|NCT01699893|EXPERIMENTAL|unique arm|"* At V0: 1500 will be screened~* At V1: 1000 subjects will be performed following samples: blood, nasal swab,stool. 500 subjects among 1000 will be performed one additional sample (Skin Biopsy)~* At V2: only the 500 subjects having performing the skin biopsy at V1 will come at V2 to perform blood, nasal swab and stool samples"
62083564|NCT02563834|EXPERIMENTAL|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
62083565|NCT02563834|EXPERIMENTAL|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
62083566|NCT05472220|EXPERIMENTAL|Phase 1: Dose Escalation|Patients with advanced solid tumors will be adminsitered Alpelisib and Carboplatin in 21 day cycles until unacceptable toxicity, disease progression or death. At baseline, patients will undergo cross-sectional imaging of the abdomen with HP13C. Participants will wear a glucose monitor for the first two treatment cycles.
62083567|NCT05472220|EXPERIMENTAL|Phase 2: Dose Expansion|Patients with HPV+ squamous cell carcinoma will be administered the recommended phase 2 dose of Alpelisib and Carboplatin in 21 day cycles until unacceptable toxicity, disease progression or death. At baseline, patients will undergo cross-sectional imaging of the abdomen with HP13C. Participants will wear a glucose monitor for the first two treatment cycles
62083568|NCT03988374|ACTIVE_COMPARATOR|0% Baking Soda Dentifrice|
62083569|NCT03988374|ACTIVE_COMPARATOR|20% Baking Soda Dentifrice|
62083570|NCT03988374|ACTIVE_COMPARATOR|35% Baking Soda Dentifrice|
62083571|NCT05208281|EXPERIMENTAL|Adult: GNR-055|GNR-055: 1.0-2.0-3.0 mg/kg
62083572|NCT05208281|EXPERIMENTAL|Paediatric: GNR-055 2.0 mg/kg|GNR-055 2.0 mg/kg
62083573|NCT05208281|EXPERIMENTAL|Paediatric: GNR-055 3.0 mg/kg|GNR-055 3.0 mg/kg
62083574|NCT06073028|EXPERIMENTAL|Rhythmic auditory cueing|"The rhythmic auditory cueing (RAC) is a constant stimulation (bip signal) delivered by a numeric metronome, which is adjusted on 110% of the patient's own cadence."
62083575|NCT06073028|EXPERIMENTAL|Adaptive spatial auditory cueing|"Adaptive spatial auditory cueing (ASAC) is a verbal instruction stimulation delivered by an application when the stride length of the patient is less than a predetermined threshold, during two consecutive strides. The instruction is given in the patient's native language, which is French: allongez le pas (i.e. lengthen the step). The predetermined threshold is 110% of the patient's own stride length."
62282822|NCT02793362||Post stroke patients without sarcopenia(by sarcopenia index)|patients who do not satisfy the value of DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
62459264|NCT05933005|SHAM_COMPARATOR|Sham group|"The sham group will watch an educational animation video on a mobile tablet device at least 5 times a week for 30 minutes each session, for a duration of 12 weeks.~The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.~The educational animations are original animations created by DOBAIN Inc.."
62459265|NCT01287013|OTHER|Cone Beam CT|Procedure performed with Xperguide cone-beam Computed Tomography (CT) navigation
62650482|NCT04596904|PLACEBO_COMPARATOR|Distilled water group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
62650483|NCT06150261|EXPERIMENTAL|AvailOm|Availom capsules will be administered orally in a dose of 5 capsules/day per individum for a total of 6 months.
62650484|NCT06150261|PLACEBO_COMPARATOR|Placebo|Placebo capsules matching AvailOm will be administered orally in a dose of 5 capsules/day per individum for a total of 6 months.
62650485|NCT03453294|EXPERIMENTAL|Apnoeic oxygenation using THRIVE|Oxygenation by apnoea oxygenation using THRIVE
62282823|NCT02793362||Post stroke patients with sarcopenia(by lean body mass)|Existence of sarcopenia will be determined by DEXA scan where appendicular lean mass less than \<19.75 kg in men, and \<15.02 kg in women are considered sarcopenia.
62282824|NCT02793362||Post stroke patients without sarcopenia(by lean body mass)|patienst who do not satisfy the value of DEXA scan where appendicular lean mass less than \<19.75 kg in men, and \<15.02 kg in women are considered sarcopenia.
62282825|NCT00122135|NO_INTERVENTION|Patients without Values Inventory (VI)|Clinic encounter w/physician \& patient and/or surrogate - Patients who did not receive the VI prior to their physician clinic encounter
62083576|NCT06358469|ACTIVE_COMPARATOR|Sub-Study A: Active Surveillance|If the laboratory test results show vulvar cancer is caused by HPV
62282826|NCT00122135|EXPERIMENTAL|Patients with Values Inventory (VI)|Clinic encounter w/physician \& patient and/or surrogate - Patients who completed the VI prior to their physician clinic encounter
62282827|NCT03845387|EXPERIMENTAL|KDT-3594|
62083577|NCT06358469|ACTIVE_COMPARATOR|Sub-Study B: Re-excision|If the laboratory test results show vulvar cancer is not caused by HPV
62083578|NCT06358469|ACTIVE_COMPARATOR|Sub-Study B: Active Surveillance|If the laboratory test results show vulvar cancer is not caused by HPV
62282828|NCT03845387|OTHER|Pramipexole|Reference drug
62083579|NCT03260361|EXPERIMENTAL|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
62282829|NCT04737473|EXPERIMENTAL|Opiod Free Anesthesia (OFA) group|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium 0.6mg/kg. Anesthesia will be maintained using isofluorane through volume controlled ventilation, and a mixture of magnesium sulfate 40mg/kg (without exceeding 2.5g/24h), lidocaine 1.5mg/kg, ketamine 25mg, and clonidine 1ug/kg in an electric pump syringe at 10 - 15 ml/h.
61978532|NCT03064191|ACTIVE_COMPARATOR|calcium hydroxide chlorhexidine|intervention: calcium hydroxide chlorhexidine combination an intra-canal medication composed of calcium hydroxide powder and chlorhexidine solution as a combination to be administered as intra-canal paste for decreasing postoperative symptoms
61978533|NCT03064191|ACTIVE_COMPARATOR|calcium hydroxide|intervention: calcium hydroxide an intra-canal medicament composed of calcium hydroxide paste for decreasing postoperative symptoms and signs .
61978534|NCT05974033|EXPERIMENTAL|Intervention group|Stenting plus medical therapy
62083580|NCT03260361|OTHER|usual practice|physiopathology and treatments
62083581|NCT04365140||positive ACD to nickel|Patients with positive epicutaneous patch test to nickel
62083582|NCT04365140||negative ACD to nickel|Patients with negative epicutaneous patch test to nickel
62282830|NCT04737473|ACTIVE_COMPARATOR|General anesthesia (GA) group|The GA protocol described in the intervention arm
62282831|NCT01196559|EXPERIMENTAL|Vinorelbine and Gemcitabine|Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks
62282832|NCT06375304|OTHER|Antiretroviral Speed Access Program Switch|HIV (type 1) infected adults born outside of Canada (migrants) and recently moved to province of Quebec (less than 2 years), ART-experienced, newly referred at the study sites.
62282833|NCT01957137|OTHER|Continuous|The device parameter will be continuous.
62282834|NCT01957137|OTHER|Cycling Parameter #1|The device parameter will be cyclic program #1.
62282835|NCT01957137|OTHER|Cycling Parameter #2|The device parameter will be cyclic program #2.
61978535|NCT05974033|ACTIVE_COMPARATOR|Control group|Medical therapy alone
61978536|NCT05060159|NO_INTERVENTION|Hemodialysis|Conventional hemodialysis
61978537|NCT05060159|EXPERIMENTAL|Hemofiltration|Postdilutional hemofiltration
62083583|NCT02717013|PLACEBO_COMPARATOR|Placebo Diet Restriction|
62083584|NCT02717013|PLACEBO_COMPARATOR|Placebo No Diet Restriction|
62083585|NCT02717013|ACTIVE_COMPARATOR|HMB Diet Restriction|
62083586|NCT02717013|ACTIVE_COMPARATOR|HMB No Diet Restriction|
62083587|NCT00999401|EXPERIMENTAL|sapacitabine and seliciclib|Sequential or concomitant administration of sapacitabine and seliciclib
62282836|NCT01957137|OTHER|Cycling Parameter #3|The device parameter will be cyclic program #3.
62282837|NCT01957137|OTHER|No Stimulation|Following the randomized portion of the study, an assessment was conducted to estimate the effect of a month of no stimulation on incontinence.
62282838|NCT02659592|EXPERIMENTAL|infertile cancer survivors|infertile cancer survivors who seek to conceive and had frozen ovarian tissue when diagnosed years before
62459266|NCT01287013|OTHER|Conventional CT|Procedure performed with Conventional Computed Tomography (CT) image guidance
62459267|NCT03909659|NO_INTERVENTION|Control|Normal salt
62459268|NCT03909659|EXPERIMENTAL|Reduced-sodium added-potassium salt substitute|salt substitute
62650486|NCT03453294|ACTIVE_COMPARATOR|Endotracheal intubation and mechanical ventilation|Ventilation and oxygenation by an endotracheal tub and mechanical ventilation
61978538|NCT03327415||Age groups|Eleven age groups that took into account the previous surveys and the key stages of child development were defined: 15 days to 3 months, 4, 5, 6, 7, 8-9, 10-11, 12- 17, 18-23, 24-29, and 30-35 months.
62459269|NCT02582541|ACTIVE_COMPARATOR|SEMS alone|Endoscopic retrograde cholangiopancreatography (ERCP) was performed under standard operating conditions with a duodenoscope (TJF 260V, Olympus, Tokyo, Japan) to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) (Wallstent, Boston Scientific, USA) would be placed across the biliary stricture.
62459270|NCT02582541|EXPERIMENTAL|SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The Habib EndoHBP catheter (Emcision, London, United Kingdom) was placed through the biliary stricture under fluoroscopic guidance. The RFA energy can be delivered repetitively at different tumor sites within one procedure, according to the stricture size. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
62459271|NCT02886468|EXPERIMENTAL|ultrasound images|ultrasound images of the anterolateral aspect of the mid-right thigh
62083588|NCT02986737|EXPERIMENTAL|ACURATE neo™ and ACURATE TA™ LP|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System
62282839|NCT05182346|EXPERIMENTAL|Acupressure of classical acupoints|Acupressure is applied on four acupoints: Pressure was applied to large intestine 10 (LI10) (large intestine meridians): It is located on the dorsal radial side of the forearm, 2 Cun below the transverse cubital crease. Hegu (large intestine meridians, LI 4): It is in the middle of the 2nd metacarpal bone on the radial side. TE5 (Triple energizer): It is located 2 cun proximal to the dorsal wrist crease between the radius and the ulna. SI3 (small intestine meridians): It is located at the ulnar end of the distal palmar crease proximal to the 5th metacarpal phalangeal joint. These acupoints are commonly used in the treatment of cervical myofascial pain syndrome.
62650487|NCT05279872|EXPERIMENTAL|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
62650488|NCT02491762||bilateral|bilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
62282840|NCT05182346|EXPERIMENTAL|Ischemic compression release of myofascial trigger points|Ischemic compression was gradually applied pressure to the trigger point with your thumb. The patient will likely feel referred pain in a question mark pattern (along the back of the neck, around the side of the head, and then a focused pain right behind the eye). Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points will be treated. Then apply a few effleurage strokes to flush out the area and follow up with a passive stretch to the muscle.
62650489|NCT02491762||unilateral|unilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
61978539|NCT00770276||Bariatric surgery|Bariatric surgery
62083589|NCT04776941|EXPERIMENTAL|Arm I (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief positive messages and write essays about their experiences over 30 minutes (non-stop) QW for 3 weeks.
62083590|NCT04776941|ACTIVE_COMPARATOR|Arm II (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief neutral messages and write essays about neutral topics over 30 minutes (non-stop) QW for 3 weeks.
62459272|NCT05064319|EXPERIMENTAL|Group A - Gabapentin|
62459273|NCT05064319|PLACEBO_COMPARATOR|Group B - Placebo|
62459274|NCT01570699||2: patients included in METHADOSE study|includes opiate-dependent patients substituted by methadone
62650490|NCT03336125|EXPERIMENTAL|Vitamin D group|Intervention is vitamin D supplement
62650491|NCT03336125|PLACEBO_COMPARATOR|Control group|Placebo capsule contains olive oil
61978540|NCT00770276||conservative Therapie|diet and exercise
61978541|NCT04962633|EXPERIMENTAL|Probiotic Pasta Group|Subjects in the Probiotic Pasta group will consume 80 g per day of a probiotic pasta for 4 weeks
61978542|NCT04962633|ACTIVE_COMPARATOR|Control Pasta Group|Control Pasta Subjects in the Control Pasta group will consume 80 g per day of conventional pasta for 4 weeks.
62650492|NCT02164916|ACTIVE_COMPARATOR|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
61978543|NCT04843423|EXPERIMENTAL|Cariprazine treatment|
61978544|NCT03406351||Asthma|
61978545|NCT03406351||Healthy|Matched controls
62083591|NCT06373588|NO_INTERVENTION|Usual Care|Participants will receive care usually provided within their clinics and a standard package with healthcare resources. In keeping with the pragmatic design, there will be variation in the support provided for navigation and care coordination, referral patterns to health and social services, as well as community resources. However, we will document these differences to provide context about potential differences in effects which may occur between sites.
62083592|NCT06373588|EXPERIMENTAL|Patient Navigator|Participants will be paired with a patient navigator. The patient navigator will contact participants: 1) Within 7 days of randomization; 2) At least once every 3 months up to 12 months; 3) As needed to follow-up on tasks identified in previous visits; and 4) As initiated by the participant. Contacts will occur during in-person clinic visits (prioritized for first encounter, if possible), or over video, telephone, SMS, and/or emails. The navigator will tailor the topics addressed during these interactions according to the needs of the participant and compile a care plan with input from the patient, family, and clinicians. In addition, to assess intervention fidelity, patient navigators will document all participant contacts on standardized forms, including topics addressed, services and coordination provided, written care plan provided, and concurrent resources/interventions accessed (e.g., social worker, funding/housing applications, support from community organizations).
62083593|NCT04149262|ACTIVE_COMPARATOR|Fiasp/Novorapid|4 weeks on Fiasp® then crossover to 4 weeks on NovoRapid® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
62282841|NCT01694004|EXPERIMENTAL|Benzocaine Infusion into Duodenum|The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.
62282842|NCT01001702|EXPERIMENTAL|Oral Aripiprazole|Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
62282843|NCT03336502|EXPERIMENTAL|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
62282844|NCT02389270||Healthy children|Healthy children without lower urinary tract diseases, history of urinary tract infection, chronic diseases, anomalies of urinary or genital tract, and remarkable clinical examination.
62282845|NCT04297462|EXPERIMENTAL|3-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during three consecutive days after the contact with influenza
62282846|NCT04297462|ACTIVE_COMPARATOR|7-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during seven consecutive days after the contact with influenza
62282847|NCT06075225|EXPERIMENTAL|Ruxolitinib|Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
62282848|NCT06075225|NO_INTERVENTION|Control|Patients assigned to the control group are treated based on symptom-triggered aGvHD therapy.
62459275|NCT01570699||1: opiate-non dependent patients|Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse
62459276|NCT00620763|EXPERIMENTAL|A|Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
62459277|NCT00620763|EXPERIMENTAL|B|Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet
62459278|NCT00012857|OTHER|Arm 1|
62459279|NCT00365300|ACTIVE_COMPARATOR|Pantoprazole|
62459280|NCT00365300|PLACEBO_COMPARATOR|Placebo|
62459281|NCT01581970|EXPERIMENTAL|Cetuximab/low dose Cyclophosphamide|Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
61978546|NCT03121547|PLACEBO_COMPARATOR|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
61978547|NCT03121547|EXPERIMENTAL|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
62650493|NCT02164916|EXPERIMENTAL|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62083594|NCT04149262|ACTIVE_COMPARATOR|Novorapid/Fiasp|4 weeks on NovoRapid® then crossover to 4 weeks on Fiasp® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
62083595|NCT02005614|EXPERIMENTAL|Gamma Knife Radiosurgery|"Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort."
62083596|NCT04686643|EXPERIMENTAL|Treatment|AGSAVI
62083597|NCT04686643|ACTIVE_COMPARATOR|Reference|AGLS
62083598|NCT04934319|EXPERIMENTAL|Balance training|A single training group
62083599|NCT04218370|ACTIVE_COMPARATOR|Conventional|Thrice-weekly intermittent dialysis until pre-specified criteria for recovery are met
62083600|NCT04218370|EXPERIMENTAL|Conservative|Conservative dialysis strategy--dialysis prescribed only when specific metabolic or clinical indications are met. These indications are: blood urea nitrogen \>112 mg/dL (40 mmol/L; blood potassium concentration \>6 mmol/L; blood potassium concentration \>5.5 mmol/L despite medical treatment; arterial blood gas pH \<7.15, or in the absence of an available blood gas, serum bicarbonate \<12 mmol/L, acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min or equivalent via face mask/tracheostomy mask to maintain SpO2 \>95% or requiring FiO2 \>50% in patients with tracheostomy already on invasive or non-invasive mechanical ventilation and despite diuretic therapy; clinician judgement
62083601|NCT05912530||male|All of the participants were Al jouf University students between the ages of 20 and 35. A BMI between 18 and 30 as well as a normal ROM at the time of the test were inclusion criteria. Additionally, participants had been excluded if they were taking any medications, showed a musculoskeletal injury to the leg, had a cognitive impairment, had a history of surgery, had a cardiovascular condition, or had any other health issue that would have an impact on their physical ability. There was no incentive for the individuals to participate. Prior to data collection, every single participant were informed that being involved in the investigation was voluntary and private, and they provided signed informed consent.
62083602|NCT05912530||female|All of the participants were Al jouf University students between the ages of 20 and 35. A BMI between 18 and 30 as well as a normal ROM at the time of the test were inclusion criteria. Additionally, participants had been excluded if they were taking any medications, showed a musculoskeletal injury to the leg, had a cognitive impairment, had a history of surgery, had a cardiovascular condition, or had any other health issue that would have an impact on their physical ability. There was no incentive for the individuals to participate. Prior to data collection, every single participant were informed that being involved in the investigation was voluntary and private, and they provided signed informed consent.
62282849|NCT01046695|ACTIVE_COMPARATOR|TENS Unit|"This arm will be adding the use of the TENS unit for 48 hours in addition to standard care for their post operative pain control.~Patient's primary area of postoperative pain was determined by nursing personnel. Four electrodes were placed on or around the area of maximum pain. The TENS unit was turned on, 1 of 5 frequency patterns selected and the impulse turned up until the patient could feel the impulse. The location of the electrodes, the pattern, and/or the intensity of the TENS unit were adjusted until the patient achieved maximum comfort with the sensation."
62282850|NCT01046695|NO_INTERVENTION|Control Arm|This arm will have standard care for their post operative pain control.
62282851|NCT06270979||Leiehome vzw|Participant recruitment entails including persons aged 65 years or older living in an assisted housing or a nursing home.
62282852|NCT06270979||University Hospital Antwerp/University of Antwerp|Participant recruitment entails including persons aged 65 years or older undergoing rehabilitation at University Hospital Antwerp.
62459282|NCT03618953|EXPERIMENTAL|Arm 1 (Intravenous dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
62282853|NCT02654002|EXPERIMENTAL|Cohort 1: Cilofexor 10 mg|Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
62282854|NCT02654002|EXPERIMENTAL|Cohort 2: Cilofexor 30 mg|Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.
62459283|NCT03618953|EXPERIMENTAL|Arm 2 (Intravenous and Intra-tumoral injection dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 \& 29.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
62459284|NCT02057848|ACTIVE_COMPARATOR|low amount of carbohydrates|2 x 10 g carbohydrates (muesli bars)
62459285|NCT02057848|ACTIVE_COMPARATOR|high amount of carbohydrates|2 x 20 g carbohydrates (muesli bars)
62459286|NCT02057848|OTHER|Rapid-acting carbohydrates|30 g rapidly absorbable carboh. + 20 g muesli bar
62459287|NCT03482063|EXPERIMENTAL|Swisse Ultiboost Memory + Focus|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
62650494|NCT00635505|EXPERIMENTAL|T|albuterol HFA 180 mcg QID
62650495|NCT00635505|ACTIVE_COMPARATOR|R|180 mcg QID 12 weeks
62650496|NCT00635505|PLACEBO_COMPARATOR|P|2 actuations QID 12 weeks or until use of rescue drug
62282855|NCT02654002|EXPERIMENTAL|Cohort 3: Cilofexor 100 mg|Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.
62282856|NCT02654002|EXPERIMENTAL|Cohort 4: Cilofexor 300 mg|Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.
62282857|NCT02654002|EXPERIMENTAL|Cohort 5: Cilofexor 100 mg|Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.
62282858|NCT02654002|EXPERIMENTAL|Cohort 6: Cilofexor 50 mg|Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.
62282859|NCT02654002|EXPERIMENTAL|Cohort 7: Cilofexor 15 mg|Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.
62282860|NCT02654002|EXPERIMENTAL|Cohort 8: Cilofexor 10 mg|Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
62282861|NCT02654002|EXPERIMENTAL|Cohort 9: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
62282862|NCT02654002|EXPERIMENTAL|Cohort 10: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
62282863|NCT01984255|ACTIVE_COMPARATOR|A- Bavituximab plus Ipilimumab|Arm A-Interventions Drug: Bavituximab Dose:3mg/kg IV over 90 minutes weekly x 2 followed by Bavituximab 3mg/kg IV over 90 minutes weekly Duration-x 12 weeks plus Drug :Ipilimumab 3mg/kg IV over 90 minutes every 3 weeks Duration-x 4.weeks
62282864|NCT01984255|EXPERIMENTAL|Arm B Ipilimumab|Arm B-Interventions Drug- I3mg/kg IV over 90 minutes day 1 followed three weeks later by Drug: Ipilimumab every 3 weeks x 3weeks. Total number of treated patients will be 8.
61978548|NCT03121547|EXPERIMENTAL|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
62459288|NCT03482063|PLACEBO_COMPARATOR|Placebo|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
62459289|NCT03619005|PLACEBO_COMPARATOR|Placebo|
62459290|NCT03619005|ACTIVE_COMPARATOR|Prasterone|
62459291|NCT03482440|PLACEBO_COMPARATOR|Placebo|
62083603|NCT06063369|EXPERIMENTAL|Palmitoylethanolamide 1200 mg|"Dose: PEA 1200 mg given in 300 mg capsules (2 capsules twice daily) Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
62282865|NCT01722513|EXPERIMENTAL|Alprostadil, Control|Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography
62282866|NCT03194984|OTHER|Young Patient|With 18-25 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
62282867|NCT03194984|OTHER|Adult Patient|With 40-65 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
62282868|NCT05971966|ACTIVE_COMPARATOR|Virtual Reality technique|Virtual reality technique+ Conventional PT
62282869|NCT05971966|EXPERIMENTAL|Muscle energy technique|Muscle energy technique + Conventional PT
62282870|NCT03509220|EXPERIMENTAL|PBK-1701TC|2-Day Split-Dosing Regimen
62282871|NCT03509220|ACTIVE_COMPARATOR|Standard oral preparation|2-Day Split-Dosing Regimen
62282872|NCT03248726|EXPERIMENTAL|Polyethylene glycol and bisacodyl|In order to decrease the dose and frequency of polyethylene glycol, we added bisacodyl at the night before examination to facilitate the action of polyethylene glycol given solely in the morning of examination.
62459292|NCT03482440|EXPERIMENTAL|Salsalate|
62459293|NCT06233409||lenticules group|Morphology of cornea and intra-ocular pressure were obtained by optical coherence tomography, Non-contact tonometer, Slit-lamp photography
62459294|NCT06233409||Penetrating keratoplasty group|Morphology of cornea and intra-ocular pressure were obtained by optical coherence tomography, Non-contact tonometer, Slit-lamp photography
62459295|NCT04069637||Early onset Scoliosis|Patients with early onset scoliosis treated with growth-sparing instrumentation (TGR, MCGR, and, VEPTR).
62459296|NCT04069637||Control group|Patients with operative fractures.
62459297|NCT03746093|PLACEBO_COMPARATOR|Control Group|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
62459298|NCT03746093|EXPERIMENTAL|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
62459299|NCT06263348|EXPERIMENTAL|Dorzagliatin group|Dorzagliatin tablet (75 mg, BID) treatment for 52 weeks
62459300|NCT03897088|EXPERIMENTAL|Tildrakizumab|
62282873|NCT03248726|ACTIVE_COMPARATOR|Split-dose polyethylene glycol|The standard regimen of polyethylene glycol was used in this group. The participant of this arm receives polyethylene glycol in the evening before examination and the morning of examination .
62083604|NCT06063369|PLACEBO_COMPARATOR|Matching placebo|"2 capsules twice daily identical to study arm. Route of administration: oral Duration and frequency: pills will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
62083605|NCT06449235|EXPERIMENTAL|Omarigliptin|Arm A will include patients receiving omarigliptin. However, the decision to initiate omarigliptin will be at the treating physician's discretion. The dose of omarigliptin will be 12.5 mg or 25 mg, oral tablet, once weekly decided by the respective physician.
62083606|NCT06449235|ACTIVE_COMPARATOR|Sulphonylureas|This Arm will include patients receiving Sulphonylureas (Gliclazide/ Glipizide/ Glimepiride/ Tolbutamide) according to the physician's choice.
62083607|NCT06449235|ACTIVE_COMPARATOR|Metformin|This Arm will include patients receiving Metformin according to the physician's choice.
62083608|NCT06449235|ACTIVE_COMPARATOR|DPP-4i|This Arm will include patients receiving DPP-4i other than sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin etc.
62459301|NCT03897088|PLACEBO_COMPARATOR|Placebo|
62083609|NCT06449235|ACTIVE_COMPARATOR|Thiazolidinediones|This Arm will include patients receiving Thiazolidinediones (Glitazones, pioglitazone, rosiglitazones)
62083610|NCT06449235|ACTIVE_COMPARATOR|Alpha-Glucosidase Inhibitor|This Arm will include patients receiving Alpha-Glucosidase Inhibitor (Acarbose, Miglitol, etc.)
62083611|NCT06449235|ACTIVE_COMPARATOR|Glucagon-Like Peptide-1|This Arm will include patients receiving Glucagon-Like Peptide-1
62083612|NCT06449235|ACTIVE_COMPARATOR|Receptor Agonists (GLP1RA)|This Arm will include patients receiving Exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide etc.
62083613|NCT06449235|ACTIVE_COMPARATOR|SGLT2 inhibitors|This Arm will include patients receiving Empagliflozin, Ertugliflozin, Canagliflozin, Dapagliflozin
62083614|NCT01062906|PLACEBO_COMPARATOR|Control|The control group receives intravenous fentanyl at the induction of anesthesia followed by a continuous infusion of lidocaine during the surgery.
62282874|NCT05325320|EXPERIMENTAL|Stigma Reduction Intervention|Participants randomized to the experimental condition will receive the SMI/SIA Stigma Reduction Intervention.
62282875|NCT05325320|OTHER|Disaster Preparedness Course|Participants randomized to the control condition will receive a Disaster Preparedness Course, addressing the basics of natural disaster preparedness.
62282876|NCT05730179|ACTIVE_COMPARATOR|Mechanical stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 5/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
62282877|NCT05730179|ACTIVE_COMPARATOR|Repeated mechanical stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 2/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be performed for 2 minutes 4 times with 1 minute rest."
62282878|NCT05730179|ACTIVE_COMPARATOR|Repeated mechanical stimulation at different locations|"Mechanical compression is applied with the thumb. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 2/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. Stimulation will be performed for 2 minutes, 4 times, at four different sites (left and right upper trapezius and left and right lumbar paravertebral) with 1 minute of rest."
62459302|NCT03897088|NO_INTERVENTION|PART 3: Observational Safety Follow-up|The subjects will not receive study treatment during the follow-up period
62459303|NCT02025465|EXPERIMENTAL|Metoprolol|"Metoprolol 2.5 to 5.0 mg IV bolus over two minutes~Repeat every five minutes up to a total dose of 15 mg as long as tolerated (Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\\Hg systolic and the patient is not dizzy))~If rate inadequate the physician has option of:~1. Further doses of metoprolol IV or PO~2. Intravenous amiodarone~3. IV diltiazem~4. Observation"
62083615|NCT01062906|ACTIVE_COMPARATOR|Lidocaine|The Lidocaine group will receive lidocaine as bolus at the induction of anesthesia followed by a continuous infusion of lidocaine until the end of surgery
62083616|NCT04770818|ACTIVE_COMPARATOR|Modified Brostrum procedure|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL (anterior talo-fibular ligament), CFL (calcanealfibular ligament), lateral ankle capsule and extensor retinaculum.
62083617|NCT04770818|ACTIVE_COMPARATOR|Modified Brostrum procedure with InternalBrace ligament augmentation|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL, CFL, lateral ankle capsule and extensor retinaculum with InternalBrace fixation using a 4.75mm BioComposite SwiveLock.
62282879|NCT03280979|EXPERIMENTAL|study group1|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
62282880|NCT03280979|EXPERIMENTAL|study group2|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
62282881|NCT00855660|ACTIVE_COMPARATOR|Riociguat|Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
62282882|NCT00855660|PLACEBO_COMPARATOR|Placebo|Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
62459304|NCT02025465|ACTIVE_COMPARATOR|Diltiazem|"Bolus 0.25 Mg/Kg over two minutes (average adult dose 20 mg).~If after 15 minutes~1. The first dose is tolerated, and~2. Ventricular rate is over 100 beats a minute AND~3. Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\\Hg systolic and the patient is not dizzy)~Give diltiazem 0.35 Mg/Kg over two minutes (average adult dose 25 mg).~After initial bolus', start infusion 5 to 15 Mg/hour to maintain rate control as long as:~1. BP over 100 mm/Hg or between 90 and 100 mm/Hg and the patient is not dizzy.~If rate inadequate the physician has an option of:~1. Metoprolol PO (by mouth) or IV (intravenous)~2. Digoxin PO or IV~3. Intravenous amiodarone~4. Observation"
62282883|NCT01289496|EXPERIMENTAL|Peg-interferon alpha-2a, Ribavirin|"Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).~This is a pilot study with no control group."
62459305|NCT02977026|NO_INTERVENTION|Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
62459306|NCT02977026|EXPERIMENTAL|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to provide personalized normative feedback aimed at motivating reductions in drinking"
62459307|NCT02977026|EXPERIMENTAL|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding drinking."
62461797|NCT00262964|NO_INTERVENTION|Control|Subjects were found to have intrahepatic triglyceride levels below the threshold for Non-Alcoholic Fatty Liver Disease (NAFLD). For this study that threshold was set at 10% intrahepatic triglyceride content as determined by magnetic resonance spectroscopy. These control subjects did not participate in any intervention. Only baseline features were characterized for this arm.
62282884|NCT00424970|PLACEBO_COMPARATOR|acetazolamide|acetazolamide 250mg /day oral administration, for 6 months
62461798|NCT00262964|EXPERIMENTAL|NAFLD-fenofibrate|Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
62650497|NCT05790590|ACTIVE_COMPARATOR|Standard dose CT|Standard dose protocol CT using standard radiation dose (120 kVp) and standard dose of contrast media, and reconstructed with commercially available reconstruction algorithm of the CT scanner.
62282885|NCT01833130|EXPERIMENTAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
62282886|NCT01833130|PLACEBO_COMPARATOR|Placebo (Normal saline)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
62282887|NCT04817501||Breast cancer|At least eighty five subjects with breast cancer
62282888|NCT04817501||Ovarian cancer|At least 32 subjects with ovarian cancer
62650498|NCT05790590|EXPERIMENTAL|Double low dose CT|Double low dose protocol CT using low radiation dose (120 kVp \& 70% of reference mAs of standard dose CT) and low dose of contrast media, and reconstructed with commercially available vendor-agonistic AI-based software.
62650499|NCT03528941||Lamivudine|Patients who received lamivudine
62650500|NCT03528941||No prophylaxis|Patients who did not receive any prophylaxis
62282889|NCT04817501||Endometrial Cancer|At least 33 subjects with endometrial cancer
62282890|NCT04817501||Healthy control|30 healthy volunteers
62282891|NCT04817501||Suspected malignant tumor non-verified|Patients with suspected malignant tumor, which was not verified by biopsy. Nubmber of patients to be defined
62282892|NCT05224544|EXPERIMENTAL|Test Catheter|Healthy volunteers to test the investigational intermittent catheter.
62282893|NCT05224544|ACTIVE_COMPARATOR|Comparator Catheter|Healthy volunteers to test the comparator.
62083618|NCT01221181|EXPERIMENTAL|Eculizumab|Patients will receive Eculizumab and be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitides vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
62083619|NCT01843452|EXPERIMENTAL|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
62083620|NCT06004752|EXPERIMENTAL|treatment group|"Cyclosporine: 3mg/kg/d 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml;~Avatrombopag: The dosage was 40\~60mg orally, once a day, and the dosage was adjusted according to the subject's platelet count. The drug was administered for 24 weeks (6 months)."
62282894|NCT04271332|EXPERIMENTAL|Arbaclofen|Arbaclofen will be dosed flexibly, with maximum permissible dose depending on age.
62282895|NCT04271332|PLACEBO_COMPARATOR|Placebo|The placebo tablet is manufactured to match arbaclofen in shape, size, color, and taste, and will be administered in the same manner as arbaclofen.
62282896|NCT00639080||Entire study population|All study subjects.
62282897|NCT06087757|EXPERIMENTAL|Open Label|
62282898|NCT06087757|EXPERIMENTAL|Blinded randomize withdrawal|
62282899|NCT02998723|EXPERIMENTAL|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
62282900|NCT02998723|ACTIVE_COMPARATOR|Late booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
62282901|NCT02998723|NO_INTERVENTION|Control group|The control group will receive no booster at all.
62282902|NCT05753956|EXPERIMENTAL|Cohort A: Dose A single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
62282903|NCT05753956|EXPERIMENTAL|Cohort B: Dose B single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
62282904|NCT05753956|EXPERIMENTAL|Cohort C: Dose C single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
62282905|NCT05753956|EXPERIMENTAL|Cohort D: Dose D single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
62282906|NCT05753956|EXPERIMENTAL|Cohort E: Dose E single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
62282907|NCT05753956|EXPERIMENTAL|Cohort F: Dose F single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
62282908|NCT05753956|EXPERIMENTAL|Cohort G: Dose G single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
62282909|NCT05753956|EXPERIMENTAL|Cohort J: Individualized Dosing Regimen|Administration of up to 3 doses of GH002 within a single day (doses to be confirmed following review of data from single-dose part)
62282910|NCT04150380|EXPERIMENTAL|Supplement|8 weeks of dietary augmentation with oral LGG 1.0 x 1010 colony forming units (CFU) once daily (delivered in a size 1 capsule)
62282911|NCT04150380|PLACEBO_COMPARATOR|Placebo|8 weeks of dietary augmentation with placebo once daily (delivered in a size 1 capsule)
62282912|NCT02452372|ACTIVE_COMPARATOR|givosiran (ALN-AS1)|
62282913|NCT02452372|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62650501|NCT05580016||Soluble Urokinase Plasminogen Activation Receptor measurement|
62650502|NCT04568655||COVID-19 patients need noninvasive ventilation|
62083621|NCT04288362|EXPERIMENTAL|Intervention Group|
62282914|NCT05699720|EXPERIMENTAL|Magnesium Sulphate|Conventional treatment and 250mg of MgSO4 through nebulizer four times a day. 1 vial of injection MgSO4 was taken which contains 1gm of MgSO4 (each vial contains 10ml). It was divided into 4 equal parts, each contained 250mg MgSO4 i.e., 2.5 ml solution, which were used for nebulization 4 times a day.
62282915|NCT05699720|NO_INTERVENTION|Conventional|conventional treatment in the form of oxygen inhalation, anti-cholinergic and beta-2 agonist nebulization, intravenous steroids, as well as intravenous antibiotics.
62282916|NCT03931278|OTHER|persons with Multiple Sclerosis (MS)|
62282917|NCT03931278|OTHER|Healthy controls|
62083622|NCT04288362|ACTIVE_COMPARATOR|Control Group|
62282918|NCT00560755|EXPERIMENTAL|ProQuad®|Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.
62282919|NCT06312891||Conventional anti-inflammatory treatment (control group).|
62282920|NCT06312891||Conventional ttt PLUS Carvedilol.|
62282921|NCT06312891||Conventional ttt PLUS Ivabradine.|
62083623|NCT02011958|EXPERIMENTAL|Liposomal Amphotericin B / Miltefosine|"Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11~Miltefosine: orally taken every day during 28 days~* 1 x 50 mg capsule per day if patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg"
62282922|NCT02199899|EXPERIMENTAL|BIIF 1149 BS - single rising doses|BIIF 1149 BS oral drinking solution and a BIIF 1149 BS tablet
62282923|NCT02199899|PLACEBO_COMPARATOR|Placebo|
62282924|NCT05729893|ACTIVE_COMPARATOR|resin group|obturated with resin sealer
62461799|NCT00262964|PLACEBO_COMPARATOR|NAFLD-placebo|These subjects were diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) and received an 8 week course of a placebo pill. Their baseline characteristics were averaged into the overall NAFLD baseline characteristics along with the baseline data for the two intervention groups.
62461800|NCT00894283|ACTIVE_COMPARATOR|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
62083624|NCT02011958|EXPERIMENTAL|Liposomal Amphotericin B|Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24
62083625|NCT03293485|EXPERIMENTAL|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
62282925|NCT05729893|ACTIVE_COMPARATOR|bio ceramic group|obturated with bioceramic sealer
62282926|NCT01361347|PLACEBO_COMPARATOR|placebo|"rice/soy/oat milkdrink, masked"
62282927|NCT01361347|EXPERIMENTAL|milk|cow's milk
62282928|NCT05394038||CPC Cohort|A patient with chest tightness and pain during the Covid-19 outbreak.
62282929|NCT01201473||Measure impact of research participation|
62282930|NCT01799057|EXPERIMENTAL|Metformin|Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e. maximum of 2000mg per day).
62282931|NCT01799057|PLACEBO_COMPARATOR|Placebo|Matching placebo twice daily for 16-18 weeks.
62282932|NCT03410511|EXPERIMENTAL|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
62650503|NCT00934375|EXPERIMENTAL|1|
62083626|NCT04104672|EXPERIMENTAL|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The dose expansion dose level will be determined in this part with escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose (RP2D) and the standard nab-paclitaxel and gemcitabine chemotherapy regimen in participants with advanced pancreatic cancer.
62083627|NCT04104672|EXPERIMENTAL|Dose Expansion(AB680+Zimberelimab+nab-paclitaxel(NP) & gemcitabine (Gem):Cohort A1 (front-line/1L)|Participants with advance pancreatic cancer, naïve to any prior treatment will receive AB680 (at the RP2D identified during dose escalation) combined with Zimberelimab and the standard nab-paclitaxel (NP) and gemcitabine (Gem) (NP/Gem) chemotherapy regimen
62083628|NCT04104672|EXPERIMENTAL|Dose Expansion (AB680 + NP/Gem): Cohort A2 (front-line/1L)|Participants with advance pancreatic cancer who are naïve to any prior treatment will receive AB680 (at the RP2D identified during dose escalation) and the standard NP/Gem chemotherapy regimen.
62083629|NCT04104672|EXPERIMENTAL|Dose Expansion (AB680 + Zimberelimab + NP/Gem): Cohort B (second-line/2L)|Participants with advance pancreatic cancer who have received 1 prior line of treatment will receive AB680 (at the RP2D identified during dose escalation) combined with Zimberelimab and NP-Gem chemotherapy regimen.
62083630|NCT04104672|EXPERIMENTAL|Dose Expansion (AB680 + Zimberelimab + NP/Gem): Cohort C (front-line/1L)|Participants with advance pancreatic cancer naïve to any prior treatment will receive AB680 combined with Zimberelimab and NP-Gem chemotherapy regimen.
62083631|NCT04104672|EXPERIMENTAL|Dose Expansion (AB680 + NP/Gem): Cohort D (front-line/1L)|Participants with advance pancreatic cancer naïve to any prior treatment will receive AB680 combined with NP-Gem chemotherapy regimen.
62083632|NCT00003288|EXPERIMENTAL|Arm I|See arm description.
62083633|NCT01125774|EXPERIMENTAL|Telcagepant|Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
62282933|NCT03410511|EXPERIMENTAL|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol/nicotine (mix 50:50) intake.
62282934|NCT03410511|EXPERIMENTAL|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
62282935|NCT02183519|EXPERIMENTAL|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
62282936|NCT02183519|EXPERIMENTAL|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
62282937|NCT01072409|OTHER|Single Arm|Single arm design
62282938|NCT04255667||Study group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing with hemostat at start of surgery
62282939|NCT04255667||Control group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing without hemostat
62650504|NCT00934375|PLACEBO_COMPARATOR|2|
62083634|NCT01125774|PLACEBO_COMPARATOR|Placebo|Placebo was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
62282940|NCT00805740|EXPERIMENTAL|Anidulafungin arm|
62282941|NCT00805740|EXPERIMENTAL|Caspofungin arm|
62282942|NCT00440726|EXPERIMENTAL|Ph 1 Dose Escalation|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
62650505|NCT05468320|EXPERIMENTAL|Caplacizumab & immunosuppressive therapy without 1st-line TPE|All participants will receive open label caplacizumab daily and immunosuppressive therapy (corticosteroid +/-anti-CD20 therapy antibody \[rituximab or biosimilar\]) without first line TPE
62083635|NCT05159505||"the before group"|40 teenagers after scoliosis surgery before interdisciplinary program implementation
62083636|NCT05159505||"the after group 1"|40 teenagers after scoliosis surgery after ERAS program implementation
62083637|NCT05159505||"the after group 2"|40 teenagers after scoliosis surgery after ERAS and educational program implementation
62282943|NCT00440726|EXPERIMENTAL|Ph 2 Efficacy and Safety|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
62282944|NCT03711604|EXPERIMENTAL|Tenalisib|Participants receive Tenalisib (RP6530) BID Orally
62650506|NCT03470922|EXPERIMENTAL|Arm A: Relatlimab + Nivolumab|Combination
62650507|NCT03470922|EXPERIMENTAL|Arm B: Nivolumab|Monotherapy
62650508|NCT03891225|EXPERIMENTAL|Amniotic Membrane implantation Arm|All consecutive patients undergone pancreaticoduodenectomy with high FRS will be treated with implantation of AM, by overlapping it over the pancreo-jejunal anastomosis.
62650509|NCT00481663|EXPERIMENTAL|Sitagliptin 25 mg once daily|Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
62650510|NCT00481663|EXPERIMENTAL|Sitagliptin 50 mg once daily|Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
62282945|NCT02376465|EXPERIMENTAL|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
62282946|NCT02376465|EXPERIMENTAL|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
62282947|NCT02376465|ACTIVE_COMPARATOR|PEG based below preparation|Oral bowel preparation for colonoscopy
62282948|NCT02019654||1|Mild or moderate TBI within the past 30 days
62650511|NCT00481663|EXPERIMENTAL|Sitaglipin 100 mg once daily|Sitagliptin, 100 mg, once daily for 158 weeks, orally
62083638|NCT05970289|EXPERIMENTAL|Cohort 1|Participants will receive multiple doses of PEG-IFNα for 48 weeks.
62282949|NCT03591081|OTHER|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
62282950|NCT02159144|EXPERIMENTAL|healthy adults|
62282951|NCT06439030|EXPERIMENTAL|Recovery group|This is the group to which the interventions in the recovery program are applied.
62282952|NCT06439030|NO_INTERVENTION|Control Group|
62650512|NCT00481663|EXPERIMENTAL|Sitagliptin 50 mg twice daily|Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
62282953|NCT02268435|EXPERIMENTAL|Dovitinib plus Imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
62282954|NCT06462014||Relugolix patients|Patients who have initiated relugolix
62282955|NCT04176185|EXPERIMENTAL|Active|HDM SLIT-tablet once daily for approximately 24 weeks
62282956|NCT04176185|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily for approximately 24 weeks
62282957|NCT01779284|ACTIVE_COMPARATOR|Travoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
62282958|NCT01779284|ACTIVE_COMPARATOR|Latanoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
62282959|NCT05708001|EXPERIMENTAL|Transcranial alternating current stimulation (tACS)|The randomized, sham-controlled, parallel-arm, double-blind clinical trial will include 12 weeks of daily, home-based stimulation sessions. MCI patients will be randomly assigned to the active or sham group.
62461801|NCT00894283|ACTIVE_COMPARATOR|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
62461802|NCT03109132|ACTIVE_COMPARATOR|Model 1|Device - O2/CO2 Oral/Nasal cannula sample line - Oridion smart CapnoLine® H Plus with Wedge cannula
62461803|NCT03109132|ACTIVE_COMPARATOR|Model 2|Device -O2/CO2 Oral/Nasal cannula sample line- Oridion smart CapnoLine® Plus with Non-Wedge cannula
62461804|NCT03109132|ACTIVE_COMPARATOR|Model 3|Device - Experimental sample line Model 3
62461805|NCT03109132|ACTIVE_COMPARATOR|Model 4|Device - Experimental sample line Model 4
62282960|NCT05708001|EXPERIMENTAL|neurophysiological (hdEEG)|At the baseline, after the first 4 weeks, and at the end of 12 weeks, MCI patients will be evaluated in the laboratory using hdEEG.
62282961|NCT05708001|EXPERIMENTAL|clinical measures (MoCA)|At the baseline, after the first 4 weeks, and at the end of 12 weeks, MCI patients will be evaluated in the laboratory using MoCA.
62282962|NCT01160601|EXPERIMENTAL|paclitaxel/carboplatin plus bavituximab|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles, in combination with 3 mg/kg bavituximab administered weekly.
62461806|NCT03109132|ACTIVE_COMPARATOR|Model 5|Device - Experimental sample line Model 5
62083639|NCT05970289|EXPERIMENTAL|Cohort 2|Participants will receive multiple doses of higher dose level of BRII-835 + PEG-IFNα for 48 weeks.
62282963|NCT01160601|ACTIVE_COMPARATOR|paclitaxel/carboplatin|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
62282964|NCT05329077|OTHER|Home Ultrasound users|Single Arm home ultrasound in pregnant women users
62282965|NCT01137240||Children with mitochondrial disorders|suffering from gastrointestinal dysfunction
62282966|NCT00080782|EXPERIMENTAL|Arm I: Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
62282967|NCT00080782|EXPERIMENTAL|Arm II: No Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.
62650513|NCT00481663|PLACEBO_COMPARATOR|Placebo to Sitagliptin → Metformin|Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
62083640|NCT05970289|EXPERIMENTAL|Cohort 3|Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks.
62083641|NCT05970289|EXPERIMENTAL|Cohort 4|Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks (participants who received BRII-179 in a previous study will roll over into this cohort).
62083642|NCT02585791|EXPERIMENTAL|vape NFEC containing 100% PG|Subjects will then be instructed how to use the NFEC (eGo-T® with light emitting diode (LED) display) for 1 week of regularly vaping NFEC containing 100% Propylene Glycol . Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to \~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
62282968|NCT00697671|OTHER|Strata A|Patients with ALL, CML, JMML, MDS, or NHL with bone marrow relapse after stem cell transplant.
62282969|NCT00697671|OTHER|Strata B|Patients with ALL, CML, JMML , MDS, or NHL with primary induction failure and persistent disease; or participants with relapsed ALL, CML, JMML, MDS, or NHL with persistent disease after re-induction
62282970|NCT01859247|ACTIVE_COMPARATOR|Dorsal Premotor rTMS|0.2 Hz rTMS for 15 minutes
62083643|NCT02585791|EXPERIMENTAL|vape 100% vegetable glycerin -VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 100% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to \~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
62282971|NCT01859247|ACTIVE_COMPARATOR|Primary motor cortex rTMS|0.2 Hz rTMS for 15 minutes
62282972|NCT01859247|ACTIVE_COMPARATOR|Supplemental Motor Area rTMS|0.2 Hz rTMS for 15 minutes
62282973|NCT01859247|ACTIVE_COMPARATOR|Anterior Cingulate rTMS|0.2 Hz rTMS for 15 minutes
62282974|NCT01859247|SHAM_COMPARATOR|Sham rTMS|0.2 Hz rTMS for 15 minutes
62282975|NCT06127641|ACTIVE_COMPARATOR|Control|Participants will receive standard care (SC)
62282976|NCT06127641|EXPERIMENTAL|Intervention|Participants will receive the standard care (SC) plus pulmonary rehabilitation (PR)
62083644|NCT02585791|EXPERIMENTAL|vape PG+VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 50% PG and 50% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 milliamp hours (mAh) battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to \~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
62083645|NCT06203444|EXPERIMENTAL|Treatment Arm|Eligible subjects will be enrolled to receive the study drug
62282977|NCT00892554|EXPERIMENTAL|DHA supplementation|
62282978|NCT00892554|PLACEBO_COMPARATOR|corn/soy capsule, no DHA|
62282979|NCT03163654|ACTIVE_COMPARATOR|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
62282980|NCT03163654|ACTIVE_COMPARATOR|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
62282981|NCT03329456|OTHER|Ropivacaine|Single arm intervention
62282982|NCT02642978|EXPERIMENTAL|RSRCLM|robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).Three different liver resection procedures were chose to personalized patients. Generally, when the size of liver metastasis was ≤ 3 cm, a wedge resection was chose without Hilar vessels blocking. The segmentectomy was performed using the Glissonian approach when tumor size was among 3-5 cm, and Hilar vessels was blocked, if necessary. For resection of Couinaud's segments II and III, left lateral sectionectomy (LLS) was performed commonly. Intraoperative ultrasound can help us find intrahepatic pedicles and follow the proper resection line. When liver tumor size was more than 5 cm or more than 3 tumors with the size over 3cm, hemicolectomy was applied usually.
62282983|NCT02642978|ACTIVE_COMPARATOR|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis. The DFS and safety event were evaluated.
62282984|NCT04640766|EXPERIMENTAL|Participants with ADHD|
62282985|NCT01301430|EXPERIMENTAL|H-1 parvovirus (H-1PV)|
62461807|NCT03109132|ACTIVE_COMPARATOR|Model 6|Device - O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
62650514|NCT04866576|EXPERIMENTAL|Q CAN PLUS POWDER|QCAN PLUS POWDER: 2 pouches per day, each pouch contains (12-15 gms of fermented soy powder)
62650515|NCT04866576|PLACEBO_COMPARATOR|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
62083646|NCT03531463|ACTIVE_COMPARATOR|Operative treatment|"Operative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles.~Rehabilitation with standardized physiotherapy guideline and self exercise protocol"
62083647|NCT03531463|NO_INTERVENTION|Non-Operative treatment|Rehabilitation with standardized physiotherapy guideline and self exercise protocol
62083648|NCT01940653|OTHER|Progesterone|Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International). On the 5th (group A) of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
62083649|NCT01940653|ACTIVE_COMPARATOR|progesterone 3 days|Group B receives 3 days of micronized progesterone vaginally. On the 3rd day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
62083650|NCT00003509|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62083651|NCT03524274|EXPERIMENTAL|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
62083652|NCT03524274|ACTIVE_COMPARATOR|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
62083653|NCT03524274|NO_INTERVENTION|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62083654|NCT05597683|EXPERIMENTAL|QL block group|Bilateral transmuscular QL block will be performed under ultrasound-guidance. Twenty mililiter of 0.375% ropivacaine will be injected to each side.
62083655|NCT05597683|NO_INTERVENTION|Control group|QL block will be not performed.
62083656|NCT00507026|EXPERIMENTAL|A|DIC075V (IV diclofenac)
62650516|NCT06115460|ACTIVE_COMPARATOR|Oral sitagliptin 50 mg supplementation for three months|Intervention group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system receiving oral sitagliptin 50 mg for three months on a daily basis
62083657|NCT00507026|ACTIVE_COMPARATOR|B|IV Ketorolac
62083658|NCT00507026|PLACEBO_COMPARATOR|C|Placebo
62083659|NCT05631990|EXPERIMENTAL|Experimental 1|AD-209, AD-209-1 placebo
62083660|NCT05631990|EXPERIMENTAL|Experimental 2|AD-209-1A, AD-209 placebo
62083661|NCT05631990|EXPERIMENTAL|Experimental 3|AD-209-1B, AD-209 placebo
62083662|NCT05631990|EXPERIMENTAL|Experimental 4|AD-209-1C, AD-209 placebo
62083663|NCT01107730|ACTIVE_COMPARATOR|L-Carnitine|L-Carnitine intravenously (2 gr/day \[1grX2\] for 2 days prior to surgery, and postoperatively for 4 days
62083664|NCT01107730|ACTIVE_COMPARATOR|Vitamin C|VitC intravenously (2g/day \[500mgX4\] for 2 days prior to surgery, and postoperatively for 4 days
62083665|NCT01107730|ACTIVE_COMPARATOR|Placebo|
62083666|NCT04377022|NO_INTERVENTION|Conventional Therapy|In this group, Patients receive Conventional Therapy for 40 minutes daily and 5 days in a week. The training period was 5 week after the recruitment of patients.
62083667|NCT04377022|EXPERIMENTAL|Combined Therapy|In this group, Patients receive Aerobic exercise training in addition to conventional Physical Therapy. Patients undergoes Aerobic exercise training for 25 minutes and 3 days in a week. A total of 15 session of aerobic exercise training session was given to patient.
62083668|NCT03095599|EXPERIMENTAL|Vaccine|Received one dose of IVACFLU-S vaccine intramuscularly.
62083669|NCT03095599|PLACEBO_COMPARATOR|Placebo|Received one dose of placebo intramuscularly.
62083670|NCT06504576|EXPERIMENTAL|Cilostazol treatment with conventional treatment|The drug treatment group will receive two consecutive weeks of Cilostazol two days after admission and receive conventional treatment as well.
62083671|NCT06504576|PLACEBO_COMPARATOR|Conventional treatment only|The conventional treatment group will receive conventional internal medicine treatment only.
62650517|NCT06115460|NO_INTERVENTION|Control group ( No intake of oral sitagliptin 50 mg supplementation for three months)|Control group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system who did not take oral sitagliptin 50 mg for three months on a daily basis
62650518|NCT02262117|PLACEBO_COMPARATOR|standard care|No specific treatment (standard care)
62083672|NCT00721331|EXPERIMENTAL|CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)|
62083673|NCT00721331|EXPERIMENTAL|CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)|
62650519|NCT02262117|EXPERIMENTAL|specific treatment|As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
62083674|NCT00721331|EXPERIMENTAL|0.1% nortriptyline HCl|
62083675|NCT00721331|ACTIVE_COMPARATOR|0.1% mometasone furoate|
62282986|NCT05961033||study|Individuals in the first group to be included in the study group will be included in a virtual reality-based exercise program for half an hour a day, 5 days a week for a total of 4 weeks, in addition to routine electrotherapy programs for half an hour a day, 5 days a week for a total of 4 weeks. These individuals will be able to play the games saved in the Oculus Quest 2 SG system in the virtual environment, thanks to the three-dimensional glasses and handpiece that can be worn on the head.
62282987|NCT05961033||control|Individuals who receive traditional electrotherapy and exercise program
62282988|NCT02225548|EXPERIMENTAL|Selegiline and Tadalafil|Tadalafil 2.5mg for 4 weeks then oral selegiline 5mg daily for 2 weeks then increased to 5mg twice daily for 2 more weeks
62282989|NCT04389242|EXPERIMENTAL|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
62282990|NCT04389242|EXPERIMENTAL|app-based cognitive behavioral intervention|"Application-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
62282991|NCT04389242|OTHER|Wait-list control group|No intervention will be provided when the experimental groups are receiving services, but the access to the App-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
62282992|NCT04629677||Cohort A (questionnaire, medical record review)|Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.
62282993|NCT04629677||Cohort B (medical record review)|Patients' medical records are reviewed retrospectively.
62282994|NCT02548026|EXPERIMENTAL|High Eating Frequency (High EF)|8 Eating Occasions
62282995|NCT02548026|EXPERIMENTAL|Low Eating Frequency (High EF)|3 Eating Occasions
62282996|NCT02080793|OTHER|Patients phase pilote|
62459308|NCT05261464|ACTIVE_COMPARATOR|Metoprolol protocol|"1. Metoprolol tartrate 50 mg will be given if patient's HR is more than 60 bpm.~2. Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~3. If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 50-mg metoprolol will be given.~4. If patient can not reach targeted HR at next 30 minutes, then third dose of 50-mg metoprolol will be given.~5. If patient can not reach targeted HR at next 30 minutes, then fourth dose of 50-mg metoprolol will be given.~6. If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 200 mg metoprolol tartrate, then total time will be recorded and patient will proceed to CCTA.~7. If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
62650520|NCT03183817|EXPERIMENTAL|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
62650521|NCT03183817|NO_INTERVENTION|Usual Care|Evidence-based care
62650522|NCT04694469||Group Day|operated at 07:30 AM - 06:30 PM
62083676|NCT00721331|PLACEBO_COMPARATOR|Active ingredient free vehicle cream of CRx-197|
62083677|NCT03450421|EXPERIMENTAL|Actamax™Adhesion Barrier|Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
62083678|NCT03450421|NO_INTERVENTION|Surgical Control|Myomectomy will be performed with no adhesion barrier application.
62083679|NCT02945293||Study Procedures|Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.
62083680|NCT04173663|EXPERIMENTAL|ASSIST intervention group|This group will attend the 12 sessions of the ASSIST training program (one 2-hour session per week for 12 weeks).
62282997|NCT02080793|OTHER|Patients phase réelle|
62650523|NCT04694469||Group Night|operated at 06:30 PM - 07:30 AM
62650524|NCT05291507|EXPERIMENTAL|Muse MRgFUS System|Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standard of care.
62083681|NCT04173663|OTHER|Control: Written materials only group|"This informational control group will receive the ASSIST binder and all written materials developed for the program on the same schedule as the treatment group but will not attend the group sessions.~After the treatment group is treated and follow up data is collected for comparison between treatment and control, the control group will have the option to take the ASSIST training program."
62083682|NCT05136196|EXPERIMENTAL|Treatment (nivolumab and cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cabozantinib PO daily. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans and collection of blood samples throughout the trial. Patients undergo a tumor biopsy during screening and optionally during follow-up.
62083683|NCT04592614|EXPERIMENTAL|High dose|CTM-NS participants receiving monthly virtual group meetings for 2 years (24 meetings total)
62282998|NCT03592160|EXPERIMENTAL|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
62282999|NCT03592160|NO_INTERVENTION|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
62283000|NCT01471080|EXPERIMENTAL|RFA group|using RFA to treat cavernous hemangiomas
62283001|NCT01471080|ACTIVE_COMPARATOR|hepatectomy group|using laparoscopic hepatectomy to treat cavernous hemangiomas of the liver
62283002|NCT02320487|EXPERIMENTAL|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
62283003|NCT00802685|EXPERIMENTAL|early ibuprofen|"Drug: Early ibuprofen~IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to early treatment will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV."
62461808|NCT04182152|EXPERIMENTAL|Bronchoscopic ICG localization|The nodule will be located preoperatively by ENB-Guided bronchoscopic ICG injection; During the VATS operation, a near-infrared fluorescence thoracoscopy will be used to identify ICG distribution in the visceral pleura to guide an accurate surgical resection.
62461809|NCT04182152|ACTIVE_COMPARATOR|percutaneous hook-wire localization|The nodule will be located preoperatively by percutaneous placement of hook wire; During the VATS operation, the resection scope is determined by the location relationship between hook wire and the nodule under CT scan.
62461810|NCT03963206|OTHER|Cabozantinib group|patients will receive Cabozantinib (within the framework of its MA) (an ECG is added)
62650525|NCT05354297|EXPERIMENTAL|Cecelia Health|Access to live Cecelia health coach on the telephone for 1 year plus access to Cecelia health coach by text messaging (via the OneTouch Reveal mobile diabetes app). Subjects will be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) diabetes app.
62083684|NCT04592614|EXPERIMENTAL|Low dose|CTM-NS participants receiving quarterly virtual group meetings for 2 years (8 meetings total)
62083685|NCT05574075||group of preterm and term children|group 1: preterm children group 2: term children
62083686|NCT05574075||group of different ages of preschool children|group 1: children with age of 25 months-36 months group 2: children with age of 37 months-48 months group 3: children with age of 49 months-60 months
62459309|NCT05261464|EXPERIMENTAL|Ivabradine protocol|"1. Ivabradine 5 mg will be given if patient's HR is more than 60 bpm.~2. Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~3. If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 5-mg Ivabradine will be given.~4. If patient can not reach targeted HR at next 30 minutes, then third dose of 5-mg Ivabradine will be given.~5. If patient can not reach targeted HR at next 30 minutes, then placebo will be given.~6. If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 15 mg ivabradine with 1 dose of placebo, then total time will be recorded and patient will proceed to CCTA.~7. If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
62083687|NCT01567163|EXPERIMENTAL|ramucirumab (IMC-1121B) and docetaxel|"Cycle 1: docetaxel administered on Day 1 of 3-week cycle~Cycle 2: ramucirumab and docetaxel administered on Day 1 of 3-week cycle~Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle~Extension Phase: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
62283004|NCT00802685|OTHER|Late Ibuprofen expectant group (placebo)|"Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to late expectant group will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, late ibuprofen or expectant)."
62459310|NCT05261464|EXPERIMENTAL|Diltiazem protocol|"1. Diltiazem immediate release (IR) 30 mg will be given if patient's HR is more than 60 bpm.~2. Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~3. If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 30-mg diltiazem will be given.~4. If patient can not reach targeted HR at next 30 minutes, then third dose of 30-mg diltiazem will be given.~5. If patient can not reach targeted HR at next 30 minutes, then fourth dose of 30-mg diltiazem will be given.~6. If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 120 mg 30-mg diltiazem IR, then total time will be recorded and patient will proceed to CCTA.~7. If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
62459311|NCT02012920|EXPERIMENTAL|Single Failure of Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28 day cycles
62283005|NCT03555266|EXPERIMENTAL|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
62083688|NCT05825729|ACTIVE_COMPARATOR|ABC|"The arms of the study are just the order of the interventions are performed~1. º Dry suction technique~2. º Slow pull technique~3. º Wet suction technique"
62083689|NCT05825729|ACTIVE_COMPARATOR|ACB|"The arms of the study are just the order of the interventions are performed~1. º Dry suction technique~2. º Wet suction technique~3. º Slow pull technique"
62083690|NCT05825729|ACTIVE_COMPARATOR|BAC|"The arms of the study are just the order of the interventions are performed 2º Slow pull technique~1º Dry suction technique 3º Wet suction technique"
62283006|NCT03555266|SHAM_COMPARATOR|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
62283007|NCT03718845||Peer Counselors|Mind-Body Medicine Curriculum
62283008|NCT01976559|EXPERIMENTAL|Hydrocephalus / Shunt Malfunction|Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.
62283009|NCT06391398|EXPERIMENTAL|Stoma care belt group|In addition to routine treatment and care, patients in the intervention stoma care belt group will receive education with the Stoma Care Training Belt during the preoperative period.
62283010|NCT06391398|NO_INTERVENTION|Control group|Patients in the control group will not undergo any additional intervention beyond routine treatment and care.
62283011|NCT01717469|ACTIVE_COMPARATOR|RV Pacing|Right ventricular pacing
62283012|NCT01717469|EXPERIMENTAL|LV Pacing|Left ventricular pacing through coronary sinus tributaries
62459312|NCT02012920|EXPERIMENTAL|Double Failure of Abiraterone and Enzalutimide|Seviteronel: given orally once daily in 28 day cycles
62650526|NCT05354297|EXPERIMENTAL|Fitbit|Fitbit Inspire 2 wearable plus 1 year subscription to premium Fitbit application. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
62650527|NCT05354297|EXPERIMENTAL|Noom|Noom behavioural weight loss program subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
62650528|NCT05354297|EXPERIMENTAL|Welldoc|Multi-condition support program from Welldoc subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter.
62650529|NCT03261193|SHAM_COMPARATOR|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
62459313|NCT04804800|NO_INTERVENTION|Control group|The patients benefit from the care recommended by the HAS. They benefit from psychological interviews, psychiatric follow-up, dietetic follow-up, family interviews and therapy. Body therapies (physiotherapy, massage, fascia therapy, psychomotor skills, dance therapy, etc.) may also take place. Patients will also benefit from relaxation and body scan.
62650530|NCT03261193|EXPERIMENTAL|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
62650531|NCT02410629|EXPERIMENTAL|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
62650532|NCT02410629|ACTIVE_COMPARATOR|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
62650533|NCT00944554|PLACEBO_COMPARATOR|Placebo|Group given placebo.
62283013|NCT01260103|ACTIVE_COMPARATOR|Temozolomide (TMZ)|Study subjects receive TMZ for 13 cycles
62650534|NCT00944554|EXPERIMENTAL|Varenicline|Experimental group given varenicline dosing.
62650535|NCT03966066|EXPERIMENTAL|low dose erythromycin group|Erythromycin 3-5mg/kg.d orally for 6 months
62283014|NCT01260103|EXPERIMENTAL|ANP Therapy|Escalating doses of ANP therapy are given daily for 52 weeks.
62459314|NCT04804800|EXPERIMENTAL|Experimental group 1 : Virtual Reality|The patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan (1 hour).
62650536|NCT03966066|NO_INTERVENTION|Non-erythromycin treatment group|systemic treatment
62650537|NCT00764114|ACTIVE_COMPARATOR|1|- group A : during 6 weeks after the inclusion
62650538|NCT00764114|ACTIVE_COMPARATOR|2|-group B : during 12 weeks after the inclusion
62283015|NCT01798576||Pegylated interferon alfa-2a|Participants with chronic hepatitis C with previous treatment failure received combination therapy with pegylated interferon alfa-2a plus ribavirin or treatment regimens containing direct-acting anti-viral (DAAs)
62283016|NCT02999490|NO_INTERVENTION|Controls|The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
62283017|NCT02999490|EXPERIMENTAL|Patients|The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
62650539|NCT01299584||Remifentanil|Patients administrated remifentanil at the site
62650540|NCT00880841||no treatment|phase 1a study for healthy normals
62650541|NCT03797352|NO_INTERVENTION|Control|Receive healthy ageing advice every 3 months for the duration of 12 months
62650542|NCT03797352|EXPERIMENTAL|Intervention|To participate in supervised Multicomponent exercise (combined exercise and cognitive activity) up to three times a week for 6 months and receive healthy ageing advice
62650543|NCT03695081|EXPERIMENTAL|Patient Pathway Pharmacist intervention|"1. Medication reconciliation at admission to hospital~2. Medication review post surgery~3. Optimised list of drugs in the discharge summary, in accordance with hospital procedures~4. Medication reconciliation, six weeks after discharge~5. Medication review, six weeks after discharge"
62650544|NCT03695081|NO_INTERVENTION|No intervention|Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
62650545|NCT02117518||no treatment|T1D patients at ages 0-25
62650546|NCT00112749|EXPERIMENTAL|Study Arm|Please see intervention description
62650547|NCT00128128|ACTIVE_COMPARATOR|Arm 1|Cranberry Juice Cocktail- 4 ounces
62283018|NCT01150084|EXPERIMENTAL|lunchtime walking|
62283019|NCT01150084|OTHER|waiting-list control|
62459315|NCT04804800|EXPERIMENTAL|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|The patients benefit from the care recommended by the HAS, the virtual reality and the multisensory remediation programs, and also the body scan.
62459316|NCT00733330|OTHER|Conventional TKR arm|Patients to receive treatment with either a P.F.C. Sigma or L.C.S. knee using the conventional manual surgical technique
62459317|NCT00733330|ACTIVE_COMPARATOR|MiTKR CAS arm|Patients to receive treatment with either a P.F.C. or L.C.S. knees in chronological order into the CAS group which will use minimally invasive surgery and computer navigation
62459318|NCT03707379||common care group|diabetic patients under common care group
62459319|NCT02430870|EXPERIMENTAL|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
62650548|NCT00128128|ACTIVE_COMPARATOR|Arm 2|Cranberry Juice Cocktail-8 ounces
62650549|NCT00128128|PLACEBO_COMPARATOR|Arm 3|Placebo- 4 ounces
62650550|NCT00128128|PLACEBO_COMPARATOR|Arm 4|Placebo- 8 ounces
62650551|NCT02653820|EXPERIMENTAL|Chemotherapy patients|Chemotherapy patients will receive reflexology treatment
62650552|NCT01781897|ACTIVE_COMPARATOR|mosapride|mosapride
62650553|NCT01781897|EXPERIMENTAL|Electro-acupuncture|Electro-acupuncture
62283020|NCT02113670|EXPERIMENTAL|SUI 1|Patients will perform urodynamic study before and after instillation of 50 ml of air
62650554|NCT01781897|SHAM_COMPARATOR|mosapride + sham acupuncture|mosapride + sham acupuncture
62650555|NCT00322322|EXPERIMENTAL|1|L-Carnitine
62650556|NCT01277029||lower urinary tract symptoms|
62650557|NCT05971589|EXPERIMENTAL|Intravenous of LM103|≥5×10\^9 cells (LM103) will be infused i.v. to patients after non-myeloablative lymphodepletion treatment with Cyclophosphamide for Injection and Fludarabine Phosphate for Injection.
62650558|NCT05816941|OTHER|Control Arm|Conventional Periodontal Treatment: Complete Oral Disinfection.
62650559|NCT05816941|EXPERIMENTAL|Experimental Arm|Conventional Periodontal Treatment (Complete Oral Disinfection) and Adjunctive Photodynamic Therapy in periodontal pockets with PPD ≥ 5 mm.
62283021|NCT05317494||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
62283022|NCT02965235||non-POCD|Patients who don't develop POCD after surgery.
62283023|NCT02965235||POCD|Patients who develop POCD after surgery.
62283024|NCT01515228|ACTIVE_COMPARATOR|Xience Prime stent|everolimus eluting stent
62459320|NCT02430870|EXPERIMENTAL|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
62459321|NCT02430870|PLACEBO_COMPARATOR|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
62459322|NCT02430870|EXPERIMENTAL|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
62459323|NCT02430870|EXPERIMENTAL|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
62461811|NCT05506462|EXPERIMENTAL|Ketamine|50-60 minutes intravenous infusion of 60mg ketamine
62650560|NCT01014234|EXPERIMENTAL|Rapamycin|Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
62650561|NCT01014234|ACTIVE_COMPARATOR|cyclosporine|Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
62650562|NCT01356420|EXPERIMENTAL|Cholesterol supplementation|All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
62283025|NCT01515228|EXPERIMENTAL|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent
62283026|NCT02328066|EXPERIMENTAL|NBI used by trained endoscopists|Assessment with NICE classification and NBI technology of colonic lesions (Paris classification type 0) greater than 1 cm found in a routine colonoscopy. This assessment was performed by previously trained endoscopists.
62283027|NCT00653861|EXPERIMENTAL|Juvederm with Lidocaine|Subjects receive Juvederm with Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in one nasolabial fold.
62283028|NCT00653861|ACTIVE_COMPARATOR|Juvederm|Subjects receive Juvederm without Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in the other nasolabial fold.
62283029|NCT01044186|EXPERIMENTAL|ICL670|
62283030|NCT04033419|EXPERIMENTAL|Memantine|Subjects receive memantin
62650563|NCT02308046|ACTIVE_COMPARATOR|Terconazole vaginal gel|One applicator full at bedtime
62650564|NCT02308046|PLACEBO_COMPARATOR|Gel vehicle|One applicator full at bedtime
62650565|NCT03130413|EXPERIMENTAL|Ambu Aura Gain|Ambu Aura Gain supraglottic airway size 2 or 2.5 will be inserted once patients are paralyzed
62650566|NCT03130413|ACTIVE_COMPARATOR|Air-Q|Air-Q supraglottic airway size 1.5 and 2.0will be inserted once the patients are paralyzed
62650567|NCT06283017|EXPERIMENTAL|Hypoglossal nerve stimulation|Device-mediated stimulation of the hypoglossal nerve
62650568|NCT03874611|EXPERIMENTAL|electrophysiological data from DBS|
62459324|NCT02430870|EXPERIMENTAL|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
62459325|NCT02430870|EXPERIMENTAL|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
62650569|NCT04186156|EXPERIMENTAL|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
62283031|NCT02977104|OTHER|Patients in afib or flutter|Maestro ECG
62650570|NCT01384656|EXPERIMENTAL|GIK group|
62650571|NCT01384656|PLACEBO_COMPARATOR|Control group|
62650572|NCT03228082|EXPERIMENTAL|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
62650573|NCT03228082|NO_INTERVENTION|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
62083691|NCT05825729|ACTIVE_COMPARATOR|BCA|"The arms of the study are just the order of the interventions are performed~1. º Slow pull technique~2. º Wet suction technique~3. º Dry suction technique"
62283032|NCT02977104|OTHER|Patients in sinus rhythm|Maestro ECG
62283033|NCT05941819|EXPERIMENTAL|All participants|All participants will be provided with the ARC-IM Thoracic System (implantable and non-implantable parts)
62083692|NCT05825729|ACTIVE_COMPARATOR|CAB|"The arms of the study are just the order of the interventions are performed~1. º Wet suction technique~2. º Dry suction technique~3. º Slow pull technique"
62283034|NCT06233695||The Female Group|Patients with an apparent gender of female.
62283035|NCT06233695||The Male Group|Patients with an apparent gender of male.
62283036|NCT01697930|EXPERIMENTAL|[18F] 4-L-Fluoroglutamine (2S,4R)|This pilot, first in-human microdose PET trial of the positron-emitting agent \[18F\] 4-L-Fluoroglutamine (2S,4R) will be an open-label study. The \[18F\] 4-L-Fluoroglutamine (2S,4R) agent will be administered by bolus intravenous injection. In all study patients, the pharmacokinetics, metabolism, and biodistribution of \[18F\] 4-L-Fluoroglutamine (2S,4R) will be evaluated by non-invasive blood- and PET-based assays, at multiple time points (see Table 1,) during one day. Eligible patients optionally can participate in the study twice, on a separate date, receiving a second radiotracer microdose of \[18F\] 4-L-Fluoroglutamine (2S,4R), followed by non-invasive blood- and PET-based assays. At the discretion of the investigator, scan 3 can be waived.
62283037|NCT05644171|OTHER|Patients with motor complete chronic spinal cord injury|
62283038|NCT03163381|EXPERIMENTAL|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
62283039|NCT04507087|EXPERIMENTAL|Intervention|See detailed preregistration: https://osf.io/xrckh/registrations
62083693|NCT05825729|ACTIVE_COMPARATOR|CBA|"The arms of the study are just the order of the interventions are performed~1. º Wet suction technique~2. º Slow pull technique~3. º Dry suction technique"
62283040|NCT04507087|SHAM_COMPARATOR|Control|See detailed preregistration: https://osf.io/xrckh/registrations
62283041|NCT02155933||Hyperandrogenemia|Peripubertal girls with hyperandrogenemia
62283042|NCT02155933||Controls|Peripubertal girls without hyperandrogenemia
62283043|NCT04628546|EXPERIMENTAL|Intervention|
62283044|NCT04628546|NO_INTERVENTION|Assessment Only|
62283045|NCT05242783|ACTIVE_COMPARATOR|intramyometrial Terlipressin injection|"intramyometrial Terlipressin injection in women undergoing open myomectomy procedure using haemostatic tourniquets.~(After the uterus has been reached, the Foley's urethral catheter will be adapted as a uterine tourniquet and will be applied at the base of the uterus before enucleating the fibroid masses. intramural Terlipressin will be injected, and then the uterine incision is done and the surgeon can now separate out the fibroids with ease and then amount of blood loss is calculated)"
62283046|NCT05242783|ACTIVE_COMPARATOR|intramyometrial Carbetocin injection|"intramyometrial Carbetocin injection in women undergoing open myomectomy procedure using haemostatic tourniquets.~(After the uterus has been reached, the Foley's urethral catheter will be adapted as a uterine tourniquet and will be applied at the base of the uterus before enucleating the fibroid masses. intramural carbitocin will be injected, and the uterine incision is done and the surgeon can now separate out the fibroids with ease and then amount of blood loss is calculated)"
62083694|NCT02153021|PLACEBO_COMPARATOR|Lifestyle counseling|alimentation information: a nutritionist provides nutritional orientation; exercise training: 3 days by week the patients will have specific sessions of resistance training (30 minutes) and aerobic training (30 minutes); phototherapy: all patients will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. In Sham group,the equipment will be off.
62083695|NCT02153021|ACTIVE_COMPARATOR|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
62083696|NCT00004189|EXPERIMENTAL|Arm I|See detailed description.
62283047|NCT05242783|PLACEBO_COMPARATOR|intramyometrial saline injection|"intramyometrial saline injection in women undergoing open myomectomy procedure using haemostatic tourniquets.~After the uterus has been reached, the Foley's urethral catheter will be adapted as a uterine tourniquet and will be applied at the base of the uterus before enucleating the fibroid masses. intramural saline as a aplacebo will be injected, and the uterine incision is done and the surgeon can now separate out the fibroids with ease and then amount of blood loss is calculated) and amount of blood loss and operative time is compared between all arms"
62283048|NCT02244242|EXPERIMENTAL|Tamsulosin hydrochloride|modified release capsules
62283049|NCT01726088|ACTIVE_COMPARATOR|modafinil|Study participants randomized to the active arm of the study will take modafinil 100mg capsules orally each day for 4 weeks.
62650574|NCT03359746|EXPERIMENTAL|Treatment Group|This is a prospective, interventional, case-control study at King Faisal Specialist Hospital \& Research Centre in post-renal transplant patients who are receiving Grazoprevir/Elbasvir combination. Data will be compared with matched historical controls, which will be selected according to the following matching criteria: age, time from transplant to initiation of therapy. Only patients who completed at least 48 weeks of pegylated Interferon + Ribavirin therapy in the control group and 12 weeks of therapy on the case group will be enrolled. Any patient who received at least one dose of Grazoprevir/Elbasvir combination will be included in the safety analysis.
62650575|NCT03847402|EXPERIMENTAL|GDD intervention|The early integrated intervention for GDD
62650576|NCT03847402|ACTIVE_COMPARATOR|GDD non-intervention|Community intervention for GDD
62650577|NCT03847402|EXPERIMENTAL|ASD intervention|The early integrated intervention for ASD
62650578|NCT03847402|ACTIVE_COMPARATOR|ASD non-intervention|Community intervention for ASD
62650579|NCT03847402|EXPERIMENTAL|ADHD intervention|The early integrated intervention for ADHD
62650580|NCT03847402|ACTIVE_COMPARATOR|ADHD non-intervention|Community intervention for ADHD
62650581|NCT03882632|EXPERIMENTAL|Patients with Fecal Incontinence|Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
62650582|NCT04744623|EXPERIMENTAL|effect of large dose corticosteroids with intra-lestional injection in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I)
62459326|NCT02430870|PLACEBO_COMPARATOR|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
62650583|NCT04744623|EXPERIMENTAL|effect of of (MMF), dapsone and cortisone in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
62650584|NCT03451071|EXPERIMENTAL|Gardasil9|
62650585|NCT06320392||metastatic|44 female BC patients, volunteered in the study, diagnosed with metastatic BC. Patients were enrolled randomly from the Clinical Oncology Department, Faculty of Medicine, Mansoura University Hospitals, Mansoura University, Mansoura, Egypt, after signing the IC.
62650586|NCT06320392||non-metastatic|46 female BC patients, volunteered in the study, diagnosed with primary naive (non-metastatic) invasive BC . Patients were enrolled randomly from the Clinical Oncology Department, Faculty of Medicine, Mansoura University Hospitals, Mansoura University, Mansoura, Egypt, after signing the IC.
62650587|NCT04556747|OTHER|VR - Distraction|
62650588|NCT04556747|OTHER|VR - Biofeedback|
62650589|NCT00776256|ACTIVE_COMPARATOR|1|effect of beta-glucan
62650590|NCT00776256|ACTIVE_COMPARATOR|2|effect of fructo-oligosaccharide
62650591|NCT00776256|ACTIVE_COMPARATOR|3|effect of beta-glucan and fructooligosaccharide
62083697|NCT01349010|PLACEBO_COMPARATOR|Placebo|Placebo Arm: Placebo 1 tablet bid. p.o
62083698|NCT01349010|ACTIVE_COMPARATOR|Probucol|Probucol Arm: Imported Probucol 250 mg (1 tablet) bid. p.o
62083699|NCT03692988|EXPERIMENTAL|Interventiongroup|Dignity Therapy. Patients receive dignity-therapy-Intervention after randomization
62650592|NCT00776256|PLACEBO_COMPARATOR|4|no beta-glucan nor fructooligosaccharide
62650593|NCT02645890|ACTIVE_COMPARATOR|CKD-397|Tadalafil/ Tamsulosin Fixed dose combination
62650594|NCT02645890|EXPERIMENTAL|TD+TM|Tadalafil/ Tamsulosin Coadministration
62650595|NCT03310567|EXPERIMENTAL|Epacadostat + pembrolizumab|
62650596|NCT01233765||Control volunteers with periodontal health|Control volunteers with periodontal health
62650597|NCT01233765||Patient volunteers with chronic periodontitis|Patient volunteers with chronic periodontitis
62650598|NCT01924598|EXPERIMENTAL|DBS surgery|
62650599|NCT03779555||Patients taking lenalidomide for multiple myeloma|-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)
62083700|NCT03692988|NO_INTERVENTION|Waitinggroup|Patients receive dignity-therapy-Intervention after a waiting time of 3 months post randomization
62083701|NCT04133428||Sacubitril-Valsartan cohort|Patients with severe systolic disfunction (left ventricle ejection fraction\<40%) heart failure that remain functional class II, III or IV after at least 3 months of optimal treatment and after being evaluated by the cardiologist by doing an echocardiography, blood test and clinical evaluation, start Sacubitril-Valsartan treatment.
62083702|NCT04261361|EXPERIMENTAL|CBCBT intervention|"1. Adherence counseling~2. Psycho-education package~3. The intervention program consists of three components: 1) eight weekly sessions of face-to-face interventions, 2) four weekly consolidation individual telephone calls and 3) three monthly individual follow-up phone calls."
62083703|NCT04261361|ACTIVE_COMPARATOR|enhanced treatment as usual (ETAU)|"1. Adherence counseling;~2. Psycho-education package;~3. To maintain some control over the contact time, we will give them 4 bi-weekly individual phone calls of about 10 minutes each while the CBCBT intervention group is having their 8 weeks of face-to-face group sessions."
62083704|NCT05539391|EXPERIMENTAL|Treatment group|Combination rapid sequence intubation (RSI) with use of rocuronium and the bag-mask ventilation between induction and Gum Elastic Bougie GEB will be systematically used at the first attempt to facilitate intubation.
62083705|NCT05539391|ACTIVE_COMPARATOR|Control Group|Physicians will be reminded of the current recommendations for emergency intubation: Rapid sequence intubation (RSI) using succinylcholine and use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
62083706|NCT01179542||first trimester|first trimester
62083707|NCT01179542||third trimester|third trimester
62459327|NCT01737190|EXPERIMENTAL|PEEP guided by Esophageal pressure + Recruitment maneuver.|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
62083708|NCT01179542||prgnancies complicated with IUGR|prgnancies complicated with IUGR
62459328|NCT05270005||Asymptomatic carotid artery stenosis|Patients with an asymptomatic carotid artery stenosis, defined by 30% to 69% narrowing of the carotid artery according to conventional duplex measurements in the absence of ipsilateral retinal or cerebral ischemia in the preceding 6 months.
62083709|NCT01179542||preeclampsia|preeclampsia
62459329|NCT01398384|ACTIVE_COMPARATOR|Nitric Oxide|nitric oxide for inhalation
62459330|NCT01398384|PLACEBO_COMPARATOR|Placebo|inhalation gas
62650600|NCT03347591||Patients with rare bleeding disorders|All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V \& VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
62083710|NCT02333929||VTE prevention|Prophylaxis of VTE in patients undergoing knee or hip replacement surgery (10 mg OD): orthopaedic department of the hospital will be in charge of the sample collection.
62283050|NCT01726088|PLACEBO_COMPARATOR|Sugar Pill|Study participants randomized to the placebo arm of the study will take matching capsules orally each day for 4 weeks.
62283051|NCT00570102|ACTIVE_COMPARATOR|A highly hydrolyzed casein formula|
62650601|NCT03332342|EXPERIMENTAL|Daily rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed daily.
62650602|NCT03332342|ACTIVE_COMPARATOR|Weekly rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed weekly.
62283052|NCT00570102|PLACEBO_COMPARATOR|A conventiona cow's milk based formula|
62650603|NCT03332342|EXPERIMENTAL|Occasional rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed on two separate occasions
62083711|NCT02333929||DVT/PE treatment|Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and risk reduction of DVT and PE recurrence; (15 mg BID for 3 weeks then 20 mg OD): different departments of the hospital will be in charge of the sample collection (samples can come e.g., from emergency room, vascular lab or cancer unit).
62083712|NCT02333929||SPAF|Stroke prevention and reduction of systemic embolism in non-valvular patients with atrial fibrillation (SPAF) (20 mg OD): cardiology department of the hospital will be in charge of the sample collection.
62283053|NCT00501982|NO_INTERVENTION|1|N Cpap in delivery room and than rescue curosurf in case of need
62283054|NCT00501982|EXPERIMENTAL|2|Poractant alfa (Curosurf) + N Cpap in delivery room
62283055|NCT01679041|EXPERIMENTAL|Single Arm|Conditioning regimens with Alemtuzumab, Fludarabine, and Cyclophosphamide will be used for all patients.
62283056|NCT03198130|EXPERIMENTAL|REGN2810|REGN2810 administered IV over a 30 minute infusion
62283057|NCT01793402||Preterm infants born at or less than 32 weeks gestation|
62283058|NCT04881123|EXPERIMENTAL|SER150|Randomized participants will receive SER150, 15 mg, orally, BID (except on Day 168 where participants will only receive a 15 mg single dose (QD) in the morning)
62283059|NCT04881123|PLACEBO_COMPARATOR|Placebo|Randomized participants will receive matching placebo, orally, BID (except on Day 168 where participants will only receive a 15 mg single dose (QD) in the morning)
62283060|NCT00165958|EXPERIMENTAL|Punch excision|
62283061|NCT00165958|ACTIVE_COMPARATOR|Traditional excision|
62459331|NCT05096780|ACTIVE_COMPARATOR|Beverage 1|Free caffeine 160 mg
62283062|NCT01682850|ACTIVE_COMPARATOR|Intervention|The Intervention Arm will receive 10 sessions of Mindfulness Based Pulmonary Rehabilitation prior to lung surgery
62283063|NCT01682850|PLACEBO_COMPARATOR|Usual Care|The Usual Care Arm will receive the normal care that a patient with severe COPD having a lung surgery would receive.
62283064|NCT05768490|EXPERIMENTAL|early intervention group of brain radiotherapy|the brain radiotherapy started within 1 month of almonertinib the brain radiotherapy here specifically refers to stereotactic radiotherapy
62283065|NCT05768490|ACTIVE_COMPARATOR|late intervention group of brain radiotherapy|Brain radiotherapy was given within 3 months after brain progression during almonertinib treatment
62459332|NCT05096780|EXPERIMENTAL|Beverage 2|Encapsulated caffeine 160 mg
62459333|NCT05096780|ACTIVE_COMPARATOR|Beverage 3|Free caffeine 250 mg
62083713|NCT03416504|EXPERIMENTAL|Gradual Exposure Group|The gradual exposure group received the Gradual Exposure (EXP-G) Intervention.
62083714|NCT03416504|EXPERIMENTAL|Variable Exposure Group|The variable exposure group received the Variable Exposure (EXP-V) Intervention.
62083715|NCT01988519|ACTIVE_COMPARATOR|Closed suction drain|Two closed suctions drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
62083716|NCT01988519|ACTIVE_COMPARATOR|Closed gravity drain|Two closed gravity drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
62083717|NCT00131911|EXPERIMENTAL|Group A (patients with carcinoid tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
62083718|NCT00131911|EXPERIMENTAL|Group B (islet cell and other neuroendocrine tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
62083719|NCT01112150|ACTIVE_COMPARATOR|Pumping group|Patients in this arm will get a pumping session 2-3 times a day .
62083720|NCT01112150|ACTIVE_COMPARATOR|No pumping|These patients will not receive pumping but only classical treatment clinically indicated (diuretics, oxygen, Digoxin, Nitrates, ACE inhibitors etc, as necessary)
62083721|NCT03092960|ACTIVE_COMPARATOR|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
62083722|NCT03092960|EXPERIMENTAL|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
62283066|NCT01734317|EXPERIMENTAL|Dressing|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
62459334|NCT05096780|EXPERIMENTAL|Beverage 4|Encapsulated caffeine 250 mg
62650604|NCT03332615|ACTIVE_COMPARATOR|Clinicians with MI coaching|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
62083723|NCT06425705|EXPERIMENTAL|Group Silymarin|Received 140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
62083724|NCT06425705|PLACEBO_COMPARATOR|Group Placebo|Received placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
62083725|NCT05486208|EXPERIMENTAL|LY3844583 (Part A)|Single doses of LY3844583 administered subcutaneously (SC) and/or intravenously (IV).
62083726|NCT05486208|EXPERIMENTAL|LY3844583 (Part B)|Multiple doses of LY3844583 administered SC and/or IV.
62083727|NCT05486208|EXPERIMENTAL|LY3844583 (Part C)|Repeat doses of LY3844583 administered SC and/or IV.
62083728|NCT05486208|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC and/or IV.
62083729|NCT05486208|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC and/or IV.
62083730|NCT05486208|PLACEBO_COMPARATOR|Placebo (Part C)|Placebo administered SC and/or IV.
62083731|NCT04039802||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery
62083732|NCT04039802||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures
62083733|NCT00492804|OTHER|Neurectomy|
62083734|NCT00492804|OTHER|Nerve preservation|
62283067|NCT00814814||Cardiopulmonary arrest|
62083735|NCT00585559|PLACEBO_COMPARATOR|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
62083736|NCT00585559|ACTIVE_COMPARATOR|Acetaminophen and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
62083737|NCT00585559|ACTIVE_COMPARATOR|N-acetylcysteine and acetaminophen|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
62083738|NCT00585559|ACTIVE_COMPARATOR|Acetaminophen 1 Gram and N-acetylcysteine|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
62459335|NCT02230007|EXPERIMENTAL|MEOPA|ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
62459336|NCT02230007|NO_INTERVENTION|Without MEOPA|Physiotherapit care without MEOPA
62083739|NCT00585559|ACTIVE_COMPARATOR|Acetaminophen 1.5 Gram and N-acetylcysteine|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
62083740|NCT05551429||Patients with Acute Coronary Syndrome|The study sample will comprise acute coronary syndrome patients admitted to Gazi University Faculty of Medicine, Cardiology Department, Coronary Intensive Care Unit because of one or more of the diagnoses of acute ST-elevation myocardial infarction (MI), acute non-ST elevation MI and unstable angina pectoris. Patients who are hemodynamically stable and have no signs of residual ischemia after acute care will be informed by the cardiologist about the study. After the inclusion process, patients will be evaluated in terms of clinical characteristics, muscle strength, quality of life, and health literacy. They will be given detailed information about CR and an appointment will be made four weeks later for starting the exercise program. In the follow-up, the Cardiac Rehabilitation Barriers Scale-Turkish Version will be applied to those who do not participate in the initial exercise program.
62083741|NCT05810948|EXPERIMENTAL|efgartigimod IV|Patients receiving intravenous (IV) infusions of efgartigimod
62083742|NCT05810948|PLACEBO_COMPARATOR|Placebo|Patients receiving intravenous (IV) infusions of placebo
62083743|NCT00884520|EXPERIMENTAL|VM4-037|Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head \& neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
62083744|NCT03347864|EXPERIMENTAL|68Ga-NOTA-RM26 PET/CT|The patients were injected with 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 30-45 min later
62083745|NCT01694992|EXPERIMENTAL|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after stroke, five times per week for 30 plus a time spent out of bed (sitting).
62083746|NCT01694992|NO_INTERVENTION|Control|The Control Group will follow within the routines of the hospital as is usually done.
62283068|NCT01273545||001|PRILIGY (dapoxetine hydrochloride) The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists and in Italy by urologists
62283069|NCT00666926|EXPERIMENTAL|1|
62083747|NCT03646045||Transpyloric feed|Preterm infant receiving transpyloric feeding.
62283070|NCT00666926|EXPERIMENTAL|2|
62283071|NCT00666926|EXPERIMENTAL|3|
62283072|NCT00666926|EXPERIMENTAL|4|
62650605|NCT03332615|PLACEBO_COMPARATOR|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
62650606|NCT03424278|ACTIVE_COMPARATOR|Motor Control|
62650607|NCT03424278|EXPERIMENTAL|Resistance Training|
62650608|NCT01294813|EXPERIMENTAL|Bronchoscopy-EIT|Patients who routinely undergo bronchoscopy will be measured by EIT directly before, directly after and 10, 30, 60 minutes after bronchoscopy with a rubber belt which is placed around their chest. The EIT measurements will take 1-2 minutes; the total examination will last 1.5 hours.
62650609|NCT03276208|EXPERIMENTAL|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
62083748|NCT03646045||Control|Preterm infants receiving gastric feeding
62083749|NCT04632290|EXPERIMENTAL|All participants|All participants receive the same intervention.
62283073|NCT04849572|ACTIVE_COMPARATOR|Sleep Education|Also referred to as Arm 1. Arm 1 receives sleep education initially.
62283074|NCT04849572|ACTIVE_COMPARATOR|Delayed Sleep Education|Also referred to Arm 2. Arm 2 receives no initial sleep education.
62283075|NCT00097357|EXPERIMENTAL|A1|"Apixaban: 2.5 mg, BID~PLUS~Enoxaparin Placebo"
62283076|NCT00097357|EXPERIMENTAL|A2|"Apixaban: 5 mg, BID~PLUS~Enoxaparin Placebo"
62283077|NCT00097357|EXPERIMENTAL|A3|"Apixaban: 10 mg, BID~PLUS~Enoxaparin Placebo"
62283078|NCT00097357|EXPERIMENTAL|A4|"Apixaban: 5 mg, QD~PLUS~Enoxaparin Placebo"
62283079|NCT00097357|EXPERIMENTAL|A5|"Apixaban: 10 mg, QD~PLUS~Enoxaparin Placebo"
62283080|NCT00097357|EXPERIMENTAL|A6|"Apixaban: 20 mg, QD~PLUS~Enoxaparin Placebo"
62283081|NCT00097357|ACTIVE_COMPARATOR|E1|"Enoxaparin: 30 mg~PLUS~Apixaban Placebo"
62283082|NCT00097357|ACTIVE_COMPARATOR|W1|Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0
62283083|NCT03961711|EXPERIMENTAL|Telemedicine encounter|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
62283084|NCT03961711|ACTIVE_COMPARATOR|In-person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
62083750|NCT02005003|ACTIVE_COMPARATOR|Probiotic|Probiotic pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
62650610|NCT03276208|ACTIVE_COMPARATOR|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
62283085|NCT01902732|OTHER|Implantation of valves (IBV)|Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
62283086|NCT02883244|EXPERIMENTAL|Soft-Picks Advanced|Device: Curved Soft-Picks
62283087|NCT02883244|ACTIVE_COMPARATOR|Floss|Device: Waxed tape floss
62083751|NCT02005003|PLACEBO_COMPARATOR|Placebo|Placebo pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
62083752|NCT02027363|EXPERIMENTAL|Observation group|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation.
62083753|NCT02027363|EXPERIMENTAL|Capecitabine group|"Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy could continue to receive oral capecitabine as maintenance therapy, capecitabine, 1000mg/m2 bid d1-14, every 3 week.~The maintenance treatment was continued until progression, unacceptable toxicity, or patient withdrawal."
62283088|NCT04304131|EXPERIMENTAL|Colorectal cancer|Confirmed colorectal cancer under colonoscopy
62283089|NCT04304131|EXPERIMENTAL|Colon polyp|Confirmed colorectal polyp under colonoscopy
62283090|NCT04304131|ACTIVE_COMPARATOR|Healthy|Confirmed no cancer nor polyp under colonoscopy
62283091|NCT04635306|EXPERIMENTAL|Low Nitrogen GEBT test meal|GEBT test meal containing low %N content (below 7%)
62283092|NCT05693415||Control Group|No treatment
62283093|NCT05693415||Trial Group|"Non drug and none surgical treatment of contracted Lumber Spine~Other Names:~Contracture Correction Therapy"
62283094|NCT04082663|EXPERIMENTAL|Dental Mouthpiece|Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans.
62283095|NCT01386333|EXPERIMENTAL|Oxytocin 24IU|Oxytocin 24 IU administered intranasally twice daily for 1 week
62283096|NCT01386333|EXPERIMENTAL|Oxytocin 48 IU|48 IU of intranasal oxytocin administered twice daily for 1 week
62283097|NCT01386333|EXPERIMENTAL|72 IU oxytocin|72 IU of intranasal oxytocin administered twice daily for 1 week
62283098|NCT01386333|PLACEBO_COMPARATOR|Saline nasal spray|
62283099|NCT04357457|EXPERIMENTAL|Almitrine|
62283100|NCT04357457|PLACEBO_COMPARATOR|Placebo|
62650611|NCT02060409||spliceosome|patient who have available data for spliceosome mutation status
62283101|NCT01912209|EXPERIMENTAL|My Everyday Health Group|Subjects in this group will be randomized to a web based diet and weight modification program (MyEveryday Health) and provided personal access codes. They will also continue to have access to the WebMD website provided as part of their employment with Baptist Health South Florida.
62283102|NCT01912209|NO_INTERVENTION|WebMD Group|This group will continue to have access to a website that is available for use of all employees (WebMD) at Baptist Health South Florida. This is the care-as-usual arm.
62283103|NCT02514967|EXPERIMENTAL|Blisibimod|
62283104|NCT02514967|PLACEBO_COMPARATOR|Placebo|
62283105|NCT00331500|EXPERIMENTAL|Olopatadine Hydrochloride 0.2%|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks
62283106|NCT00331500|PLACEBO_COMPARATOR|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks
62459337|NCT02968186|EXPERIMENTAL|Implementation program|Health professionals will receive a training and support implementation program
62650612|NCT03622450|EXPERIMENTAL|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
62650613|NCT03622450|ACTIVE_COMPARATOR|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
62083754|NCT02175160|EXPERIMENTAL|Braking and functionality with right knee osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right knee osteoarthritis
62283107|NCT00132730|EXPERIMENTAL|MK-0873 2.5 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
62283108|NCT00132730|EXPERIMENTAL|MK-0873 1.25 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
62283109|NCT00132730|EXPERIMENTAL|MK-0873 0.75 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
62283110|NCT00132730|PLACEBO_COMPARATOR|Placebo|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)
62283111|NCT00132730|EXPERIMENTAL|MK-0873 2.5 mg + Usual Care|Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
62283112|NCT00132730|ACTIVE_COMPARATOR|Usual Care|Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
62283113|NCT06496672|ACTIVE_COMPARATOR|Traditional|Participants in this group receive the existing treatment, which is a cast that terminates at the palmar bar.
62283114|NCT06496672|EXPERIMENTAL|Modified|Participants in this group receive the experimental treatment, a cast that terminates at the wrist.
62283115|NCT00781157|EXPERIMENTAL|1|
62283116|NCT01975922|EXPERIMENTAL|Enhanced Milieu Teaching|"Parents receive 28 intervention sessions in which they learn to use language support strategies with their children.~Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline."
62283117|NCT01975922|NO_INTERVENTION|Community Services|Children receive speech-language services in the community. Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline.
62283118|NCT02917967|EXPERIMENTAL|BTX injection group|Botulinum toxin injection group
62283119|NCT02776241|NO_INTERVENTION|water restriction|20 patients will be subjected to 3 hours of water restriction following MR scan of the kidneys.
62283120|NCT02776241|ACTIVE_COMPARATOR|high water intake|20 patients will be subjected to 1 hour of high water intake (20 ml/kg) following MR scan of the kidneys.
62083755|NCT02175160|EXPERIMENTAL|Braking and functionality with right knee arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right total knee arthroplasty
62083756|NCT04178200||1.5 ml Dose|For retrobulbar anesthesia, 1.5 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
62083757|NCT04178200||3 ml Dose|For retrobulbar anesthesia, 3 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
62083758|NCT00401921|PLACEBO_COMPARATOR|Minocycline arm|Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
62283121|NCT03064672|EXPERIMENTAL|induction by transcervical Balloon Catheters insertion|
62283122|NCT03064672|NO_INTERVENTION|induction without transcervical Balloon Catheters|
62283123|NCT01533675|EXPERIMENTAL|Hydrogen peroxide|
62283124|NCT01533675|ACTIVE_COMPARATOR|Saline|
62283125|NCT03064490|OTHER|Single arm interventional study|Single arm, non randomized, open label study. Subjects will receive three doses of neoadjuvant pembrolizumab (200 mg administered as an intravenous infusion over 30 minutes every 3 weeks). Pembrolizumab will be administered with weekly standard of care Carboplatin/Paclitaxel concurrent chemo-radiation therapy in the neo-adjuvant setting. Postoperatively, three additional cycles of pembrolizumab (200 mg every 3 weeks) will be administered as adjuvant therapy.
62083759|NCT00401921|PLACEBO_COMPARATOR|Placebo arm|Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
62083760|NCT05259943|PLACEBO_COMPARATOR|Blinded Placebo|In this condition participants will receive an inert placebo once weekly for 4 weeks, but they will not know whether they receive placebo or psilocybin.
62083761|NCT05259943|EXPERIMENTAL|Blinded Psilocybin|In this condition participants will receive psilocybin once weekly for 4 weeks, but they will not know whether they receive placebo or psilocybin.
62083762|NCT05259943|EXPERIMENTAL|Open Label|In this condition participants will receive psilocybin once weekly for 4 weeks, and will be told that they are receiving psilocybin.
62083763|NCT02802683|EXPERIMENTAL|"BUPI,P"|patients who received hyperbaric bupivacaine and continous infusion of phenylephrine
62083764|NCT02802683|PLACEBO_COMPARATOR|"BUPI,N"|patients who received hyperbaric bupivacaine and continous infusion of normal saline
62283126|NCT06375343|EXPERIMENTAL|PRO-240|"* Propylene glycol 0.3% - Polyethylene glycol 400 0.5% - Glycerin 0.2%. Ophthalmic solution.~* Dosage: 1 drop QID \[4\] (four times per day) for 7 days in both eyes.~* Route of administration: Ophthalmic"
62283127|NCT06375343|ACTIVE_COMPARATOR|Optive®|"* Carboxymethylcellulose 0.5%; Glycerin 0.9%. Ophthalmic solution.~* Dosage: 1 drop QID \[4\] (four times per day) for 7 days in both eyes.~* Route of administration: Ophthalmic"
62459338|NCT02968186|NO_INTERVENTION|Waiting list|Health professionals will be assigned to a waiting list to receive the implementation program
62283128|NCT02986594|EXPERIMENTAL|aspirin group|low dose aspirin, 75-100mg, bid, after pregnancy
62283129|NCT02986594|EXPERIMENTAL|low molecular weight heparin group|low molecular weight heparin, 4100u, qd, after pregnancy
62283130|NCT02986594|EXPERIMENTAL|combination group|low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid. After pregnancy
62283131|NCT02313129||Rheumatoid Arthritis|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history and detailed menstrual history. They will also have a physical exam and blood tests.
62283132|NCT02313129||Healthy Controls|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history detailed menstrual history, and blood tests.
62283133|NCT03834532|EXPERIMENTAL|Intervention|Participants randomized to the intervention group will receive a breast reconstruction decision aid. Participants will be provided instructions on how to access and navigate the decision aid. Participants will access the decision aid through a website link that is emailed to them or on a tablet at the study site.
62283134|NCT03834532|ACTIVE_COMPARATOR|Control|Participants randomized to the control group will receive two website pages on healthy living with breast cancer from an educational website. Participants will be provided instructions on how to access and navigate the website pages. Participants will access the website pages through a link that is emailed to them or on a tablet at the study site.
62459339|NCT05284890|EXPERIMENTAL|CC-99677|
62459340|NCT03365726|EXPERIMENTAL|DST (dobutamine-stress-test)|dobutamine stress echocardiography performed to patients undergoing major surgery
62459341|NCT03365726|NO_INTERVENTION|NDST (no-dobutamine-stress-test)|patients refused the dobutamine stress test and transesophageal echocardiography measured the troponin level in first 24 hours after surgery
62083765|NCT02802683|EXPERIMENTAL|"LEVO,P"|patients who received isobaric levobupivacaine and continous infusion of phenylephrine
62083766|NCT02802683|ACTIVE_COMPARATOR|"LEVO,N"|patients who received isobaric levobupivacaine and continous infusion of normal saline
62083767|NCT01238783|EXPERIMENTAL|AL-15469A 0.5% and AL-65150.3% Ophthalmic Suspension|
62083768|NCT01238783|EXPERIMENTAL|AL-15469A 0.5%|
62083769|NCT01238783|EXPERIMENTAL|AL-6515 0.3%|
62283135|NCT03118596|ACTIVE_COMPARATOR|I-gel|Fibreoptic guided tracheal intubation through I-gel
62459342|NCT04908332|EXPERIMENTAL|Kangaroo baby Massage|The mother will apply the massage. The baby kangaroo will be exposed to the KBM for 10 minutes once a day during the time that the infant need to stay in kangaroo position at home. If the baby wakes up and wants to eat the KBM will be interrupted immediately and the baby will be fed, The temperature will be measured before and after the intervention. The massage will begin 60 minutes after the feed.
62650614|NCT01067391|ACTIVE_COMPARATOR|tadalafil 20 mg|Oral study medication to be administered once to each participant
62083770|NCT01238783|PLACEBO_COMPARATOR|Vehicle|
62083771|NCT01645332|PLACEBO_COMPARATOR|Treatment I (control)|Placebo of DLBS3233 once daily for 12 weeks + lifestyle modification
62083772|NCT01645332|EXPERIMENTAL|Treatment II|100 mg DLBS3233 once daily for 12 weeks + lifestyle modification
62083773|NCT00826917||Objective 1: XI VOCALTM in 3D fetal volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
62283136|NCT03118596|ACTIVE_COMPARATOR|LMA Protector|Fibreoptic guided tracheal intubation through Protector
62283137|NCT02132351||Hepatologists|Doctors working as hepatologists
62283138|NCT01940666||Controls|patients who have all androgens (TT, A4, FAI, and DHEA-S) lower than their cut-off values
62283139|NCT01940666||Total Testosterone >= 2.39|Patients who have only total testosterone higher than its cut-off value; (TT) \>=2.39
62650615|NCT01067391|PLACEBO_COMPARATOR|placebo|oral study medication to be administered once to each study participant
62083774|NCT00826917||Objective 2: XI VOCALTM in 3D placental volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
62083775|NCT00826917||Objective 3: Comparison between 2 ultrasound machine|"1. intramachine reliability for (i)fetal, (ii)gestational sac and (iii)placenta volumetry measurement for (a)multiplanar and (b)VOCALTM:- group 1:Accuvix; group 2:Voluson 730~2. intermachine reliability for fetal, gestational sac and placenta volumetry measurement for (a)multiplanar and (b)VOCALTM for Accuvix and Voluson 730"
62083776|NCT00826917||Objective 4:3D volumetry in fetuses at risk of Hb Bart's|Measurement of fetal, gestational sac and placenta volume per CRL quotient using multiplanar technique:- group 1: affected; group 2: unaffected
62083777|NCT04772157||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
62083778|NCT04395768|EXPERIMENTAL|Vitamin C|"Participants will receive vitamin C in addition to active comparator treatment:~Inpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;~Plus Active Comparator treatment:~Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days"
62083779|NCT04395768|ACTIVE_COMPARATOR|Control|Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days
62459343|NCT04908332|ACTIVE_COMPARATOR|Kangaroo position|The infant must be in Kangaroo position with the mother semi sitting on bed with elevation of at least 30 degrees during 10 minutes every day until the infant doesn´t need to stay in kangaroo position at home.The temperature will be measured 60 minutes after the feed and 10 minutes after KP. If the baby wakes up and wants to eat the KP will be interrupted immediately and the baby will be fed, then the KP will be completed of time ( 10 minutes) to measure the temperature.
62459344|NCT03354104|EXPERIMENTAL|Recession coverage with connective tissue graft + Emdogain®|A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with 24% EDTA (PrefGel®, Straumann, Basel, Switzerland) for 2 minutes and then washed with saline. Subsequently, EMD (Emdogain®, Straumann, Basel, Switzerland) is applied on root surfaces. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
62459345|NCT03354104|ACTIVE_COMPARATOR|Recession coverage with connective tissue graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
62459346|NCT03748082|PLACEBO_COMPARATOR|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
62459347|NCT03748082|EXPERIMENTAL|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
62083780|NCT02589925|SHAM_COMPARATOR|sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
62083781|NCT02589925|ACTIVE_COMPARATOR|NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
62083782|NCT03684187|EXPERIMENTAL|Stress in Control for Healthy Liver (SynC-HL) Intervention:|This mindfulness based intervention to target healthy liver focuses on teaching skills of mindfulness, yoga and self-control to improve lifestyle choices and decision making.
62283140|NCT01940666||Androstenedione >= 2.99|Patients who have only androstenedione higher than its cut-off value; (A4) \>=2.99
62283141|NCT01940666||Free Androgen Index >= 6.53|Patients who have only free androgen index higher than its cut-off value; (FAI) \>=6.53
62283142|NCT01940666||DHEAs >= 181.55|Patients who have only dehyroepiandrosterone sulfate higher than its cut-off value; (DHEA-S)\>=181.55
62283143|NCT01790048|EXPERIMENTAL|Whey permeate RUSF|75 kcal/kg/day (314 k Joules (kJ)/kg/day) of whey RUSF. Whey RUSF contains whey permeate, Whey Permeate (WPC) 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier. Whey permeate RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
62283144|NCT01790048|ACTIVE_COMPARATOR|Soy Protein RUSF|75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources. Soy RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
62459348|NCT06143722|EXPERIMENTAL|Simultaneous radiotherapy group|
62459349|NCT06143722|ACTIVE_COMPARATOR|Sequential radiotherapy group|
62459350|NCT02082353||Retrospective CGD Cohort|Longitudinal analysis
62459351|NCT02082353||Prospective CGD Cohort|Longitudinal analysis
62459352|NCT02082353||HCT CGD Cohort|Cross-sectional analysis
62083783|NCT00141687|EXPERIMENTAL|Early External Cephalic Version Group|Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation
62083784|NCT00141687|ACTIVE_COMPARATOR|Delayed External Cephalic Version Group|Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation
62459353|NCT02082353||Conventional Non-Transplant CGD Cohort|Longitudinal analysis
62459354|NCT05829122|EXPERIMENTAL|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|
62650616|NCT04366674|ACTIVE_COMPARATOR|Langerbeck's repair|Langerbeck's repair of cleft palate,without specific restoration of levator veli palatini or tensor veli palatini. Incisions along the margins of the cleft at the junction of oral and nasal mucosa. Lateral relaxing incisions were performed and the mucoperiosteal flap of hard palate were elevated on both sides except the ones with only soft palate cleft. The anterior end of the mucoperiosteal flap may be cut off for the purpose of tension relieving and would be resutured to the anterior area during closing. In the soft palate, the division was made between the oral mucous layer and the palatal musculature layer. Hamulus were broken for closing the cleft without tension. Closing was done by two seperated layers, one layer of nasal mucosa-palatal muscle, and one layer of oral mucosa.
62650617|NCT04366674|ACTIVE_COMPARATOR|restoration of levator veli palatini|The incision was made similar to Langerbeck's repair. During disection, the levator veli palatini was identified after the elevation of flap. The levator veli palatini was separate from the oral and nasal mucosa. During closing, the anterior end of levator veli palatini was rotated towards the midline and the two muscle bundle from the two sides were sutured in the midline. In this process, the tensor veli palatini was not intentionally identified or dissected.
62083785|NCT05459220|EXPERIMENTAL|Treatment group A|SHR0410 Injection（Low Dose）
62083786|NCT05459220|EXPERIMENTAL|Treatment group B|SHR0410 Injection（High Dose）
62459355|NCT02645526|EXPERIMENTAL|KMC with woolen cap|In this group, the head of the patients will be covered with a woolen cap during KMC.
62083787|NCT05459220|PLACEBO_COMPARATOR|Treatment group C|Placebo for SHR0410 Injection.
62459356|NCT02645526|NO_INTERVENTION|KMC without woolen cap|In this group, the head of the patients will be uncovered during KMC.
62459357|NCT02475083|EXPERIMENTAL|Virtual Reality Group|Rehabilitation with virtual reality using games with balance training goal.
62459358|NCT02475083|ACTIVE_COMPARATOR|Conventional Group|Conventional physiotherapy with exercises for balance training.
62083788|NCT02985333|EXPERIMENTAL|Intervention|paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.
62283145|NCT02847754|EXPERIMENTAL|A|A patients in arm A carry out daily physical Training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home. exercise tailored isometric physical exercise
62283146|NCT02847754|NO_INTERVENTION|B|Patients in arm B (control group) receive 10 daily sessions of 15 min progressive muscle relaxation starting from day one of radiotherapy.
62283147|NCT03454854|EXPERIMENTAL|APP-assisted anti-thrombotic therapy|Intelligent response system:real-time receiving data or events that doctor or patient terminal upload,then spontaneously evaluate the thrombosis and bleeding risk based on code of point built-in,respectively send messages to doctor and patient after this, then doctors direct the patients to adjust treatment schedule.Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal APP, establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
62283148|NCT05533892|EXPERIMENTAL|Nocardia rubra cell wall skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab|N-CWS 400μg hypodermic injected every week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected Q4W. Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Tislelizumab 200mg intravenously every 3 weeks.
62283149|NCT04342728|ACTIVE_COMPARATOR|Ascorbic Acid|8000 mg of ascorbic acid divided into 2-3 doses/day with food.
62283150|NCT04342728|ACTIVE_COMPARATOR|Zinc Gluconate|50 mg of zinc gluconate to be taken daily at bedtime
62459359|NCT01210456|ACTIVE_COMPARATOR|Physiological Saline and N-Acetylcysteine|
62459360|NCT01210456|ACTIVE_COMPARATOR|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|
62459361|NCT05887297|EXPERIMENTAL|Cognitive behavioural therapy for insomnia|Following randomisation, participants in the intervention group will receive the CBT-I intervention, delivered over 4 weeks.
62459362|NCT05887297|NO_INTERVENTION|Waitlist control|Participants in the waitlist condition will complete all measures at the same timepoints as the intervention group. They will receive the CBT-I intervention after completing the 12-week follow-up assessment. This will then be used as a baseline measure for these participants to compare to their post-intervention and follow-up after receiving the treatment.
62459363|NCT01444443|EXPERIMENTAL|Closed-loop glucose control|Blood glucose controlled by control algorithm.
62459364|NCT01444443|ACTIVE_COMPARATOR|Open-loop glucose control|Blood glucose controlled by patient
62459365|NCT05919966||chlorhexidine group|Patients were bathed one day involving the use of wipes soaked in a 2% chlorhexidine gluconate (CHG) solution and the next day using a towel soaked with water and soap during the MICU stays.
62459366|NCT05919966||usual care group|Patients were bathed with towels soaked in water and soap on a daily basis during the MICU stays.
62459367|NCT03338972|EXPERIMENTAL|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 1|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 1 contains patients treated as dose level 1 (50 x 10\^6 EGFRt cells)"
62459368|NCT03338972|EXPERIMENTAL|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 2|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 2 contains patients treated as dose level 2 (150 x 10\^6 EGFRt cells)"
62083789|NCT00832143|NO_INTERVENTION|1|Usual Care
62083790|NCT00832143|EXPERIMENTAL|2|Referral Card with one-to-one counseling
62083791|NCT02702258|EXPERIMENTAL|MB-BP|This is the primary intervention tested in this single arm trial.
62083792|NCT03013361|ACTIVE_COMPARATOR|Group B (n=20)|Group B (n=20): The patients in this group were infiltrated with 3 mL of 0.5% bupivacaine.
62083793|NCT03013361|ACTIVE_COMPARATOR|Group R (n=20):|Group R (n=20): The patients in this group were infiltrated with 3 mL of 0.5% ropivacaine.
62083794|NCT03013361|PLACEBO_COMPARATOR|Group S (n=20, Control):|Group S (n=20, Control): The patients in this group were infiltrated with 3 mL of normal saline.
62283151|NCT04342728|ACTIVE_COMPARATOR|Ascorbic Acid and Zinc Gluconate|8000 mg of ascorbic acid divided into 2-3 doses/day with food and 50 mg of zinc gluconate to be taken daily at bedtime.
62283152|NCT04342728|OTHER|Standard of Care|Standard of care medications only as prescribed by patient's physician.
62283153|NCT04846361|EXPERIMENTAL|Hygiene wash plus metronidazole|Hygiene wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
62083795|NCT04957940|EXPERIMENTAL|SMOF lipid 20% IV infusion|Intravenous fish-oil-based lipid (SMOF lipid 20%) emulsion supplementation to standard enteral nutrition.
62283154|NCT04846361|PLACEBO_COMPARATOR|placebo wash plus metronidazole|Placebo wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
62283155|NCT04846361|NO_INTERVENTION|Healthy control|Asymptomatic healthy women with BV negative test
62283156|NCT00962026|EXPERIMENTAL|Rilonacept|
62283157|NCT01743638|EXPERIMENTAL|MR-Guided Laser Ablation|
62283158|NCT05490797|EXPERIMENTAL|app based training with conventional therapy|In experimental group app based training will be performed along with conventional hand fine motor skills and dexterity therapy.
62283159|NCT05490797|ACTIVE_COMPARATOR|conventional therapy|The control group will receive conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
62283160|NCT01348373||GENOUS EPC-coated stent|Patients treated with GENOUS EPC-coated stent
62283161|NCT01027533||Restor +3|patients will be implanted bilaterally with Restor + 3
62283162|NCT01027533||restor +4|Patients will be implanted bilaterally with Restor +4
62283163|NCT05361629|ACTIVE_COMPARATOR|NON-SURGERY GROUP|Group 1: Patients whose serum cortisol level was observed before starting the treatment, who were injected with 40 mg of prednol at 4 weeks intervals for 3 months for each lesion. The total monthly dose will not exceed 120 mg, and the total 3-month dose will not exceed 200 mg. In this group of patients, the serum cortisol level should have reappeared on the 2nd or 3rd day following each intralesional administration. In this group of patients, low-dose oral prednol (\<30 mg/day) and/or topical prednol cream can be applied twice a day during the treatment.
62283164|NCT05361629|ACTIVE_COMPARATOR|SURGERY GROUP|"In patients included in Group 2, serum cortisol levels should have been observed before starting treatment. Then the patients should be operated and the mass(s) should be excised. Intraoperatively, not less than 40 mg of prednol should be injected into each mass cavity (it may vary according to the cavity diameter), and the amount applied to all cavities should not exceed 200 mg in total. The amount of prednol administered for each cavity should be recorded. In this group of patients, prednol may have been administered to the cavity walls (Group 2a) or inside the cavity (Group 2b). Serum cortisol levels should be seen in patients 7 to 10 days after the procedure.~Group 2a: 4 Quadrants 40 mg predmol per cavity wall (for \< 2cm lesion and an additional 20 mg for each additional 1 cm) Group 2b: 40 mg predmol into the cavity (for \< 2 cm lesion and an additional 20 mg for each additional 1 cm)"
62283165|NCT06176157|ACTIVE_COMPARATOR|oral vitamin D2 group|
62283166|NCT06176157|ACTIVE_COMPARATOR|oral vitamin D3 group|
62459369|NCT03338972|EXPERIMENTAL|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 3|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 3 contains patients treated as dose level 3 (300 x 10\^6 EGFRt cells)"
62083796|NCT04957940|PLACEBO_COMPARATOR|Saline placebo IV infusion|Intravenous 0.9% saline supplementation to standard enteral nutrition.
62283167|NCT06176157|ACTIVE_COMPARATOR|Parenteral vitamin D2 group|
62283168|NCT06176157|ACTIVE_COMPARATOR|Parenteral vitamin D3 group|
62283169|NCT01931059|EXPERIMENTAL|Risperidone then Placebo|This group will receive 2 mg (\>200lbs), 1.5mg (150-200lbs.) or 1 mg (\< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
62283170|NCT01931059|EXPERIMENTAL|Placebo then Risperidone|This group will receive a placebo on the first day and 2mg (\> 200lbs.), 1.5mg (150-200lbs), or 1 mg (\<150lbs.) of risperidone oral solution on the second day
62283171|NCT06089447|EXPERIMENTAL|Control Group|Participants will receive the intervention immediately
62283172|NCT06089447|ACTIVE_COMPARATOR|Waitlist Group|Participants will be allocated to a waitlist group and will receive the intervention aft 6 months.
62283173|NCT02312947|ACTIVE_COMPARATOR|coblation|coblation adenoidectomy
62283174|NCT02312947|ACTIVE_COMPARATOR|cold dissection|cold dissection adenoidectomy
62283175|NCT05529563||obesity without AN (OB group) and obesity with AN (AN group)|LSG
62083797|NCT00663117|PLACEBO_COMPARATOR|Placebo, Sugar pill|placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
62083798|NCT00663117|ACTIVE_COMPARATOR|Naltrexone-HCl|Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.
62083799|NCT05929456|EXPERIMENTAL|Glioblastoma group|This study will consist of 1 group and therefore 1 arm
62083800|NCT01238796|EXPERIMENTAL|Normal renal function|Subjects with normal renal function
62083801|NCT01238796|EXPERIMENTAL|Severe renal impairment|Subjects with severe renal impairment
62283176|NCT01305863|ACTIVE_COMPARATOR|Propaten graft|Untreated Propaten vascular graft
62283177|NCT01305863|EXPERIMENTAL|ASC-Coated ePTFE graft|ASC Coated BARD IMPRA® ePTFE Vascular Graft
62283178|NCT04462198|EXPERIMENTAL|PIPE-505|
62283179|NCT04462198|PLACEBO_COMPARATOR|Placebo|
62461812|NCT04177368||assess nutrition with regular dialysis|This study aims to assess the growth and the nutritional status in children with end-stage kidney disease on regular hemodialysis to define the degree of malnutrition , predict and quantify the risk for complications deriving from impaired nutritional status .Giving them theragran 60ml ,twice daily for 3 month.
62083802|NCT01238796|EXPERIMENTAL|End stage renal disease|Subjects with end stage renal disease
62083803|NCT03661229|EXPERIMENTAL|CVInsight Monitoring|Single group arm: All participants receive the same intervention/treatment CVInsight non-contact device and CVInsight contact device application.
62283180|NCT01869647|ACTIVE_COMPARATOR|"high likelihood of stone group"|"Subjects in the high likelihood of stone group will be eligible to get either ULDCT or expectant management. The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan."
62283181|NCT01869647|ACTIVE_COMPARATOR|"moderate likelihood of stone group"|"Subjects in the moderate likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan."
62459370|NCT03338972|EXPERIMENTAL|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 4|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 4 contains patients treated as dose level 4 (450 x 10\^6 EGFRt cells)"
62459371|NCT06028607|OTHER|Study Population|"Participants will be recruited and consented as part of routine care. All will trial supplement initially and have standard and additional measures taken. they will be followed up at month 1 and 2 collecting the primary outcomes (acceptability/palatability and dietary intake) and all initial measures repeated at month 3.~Each participant will receive 3 months supply of gels to consume 2 per day."
62283182|NCT01869647|ACTIVE_COMPARATOR|"low likelihood of stone group"|"In the low likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging."
62283183|NCT03336255|NO_INTERVENTION|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
62083804|NCT06497660|EXPERIMENTAL|Anthracene ring drug α group|choosing anthracycline drugs in neoadjuvant chemotherapy for breast cancer and using the intervention of deoxyadrenaline in this study.
62083805|NCT06497660|EXPERIMENTAL|Carboplatin drug α group|choosing carboplatin drugs in neoadjuvant chemotherapy for breast cancer and using the intervention of deoxyadrenaline in this study.
62083806|NCT06497660|EXPERIMENTAL|Combined use α group|choosing anthracycline and carboplatin drugs in neoadjuvant chemotherapy for breast cancer and using the intervention of deoxyadrenaline in this study.
62083807|NCT06497660|PLACEBO_COMPARATOR|control α group|Group without neoadjuvant chemotherapy during the treatment of breast cancer,and using the intervention of deoxyadrenaline in this study.
62283184|NCT03336255|EXPERIMENTAL|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
62283185|NCT02624492|EXPERIMENTAL|BI 836826-GemOx|
62283186|NCT02624492|ACTIVE_COMPARATOR|R-GemOx|
62283187|NCT03905863|NO_INTERVENTION|Standard of care arm|SOC was defined to include wound cleansing with sterile water or saline solution, and gentle irrigation of the study ulcer with warm tap water; sharp debridement using a standardised protocol based on TIME principles for wound bed preparation; offloading with a TCC twice in the first week and weekly thereafter (all exceptions had to be agreed by the lead investigator; a fixed ankle walker boot or similar device was acceptable as an alternative, but shoe inserts were not deemed to provide sufficient offloading); moisture balance was provided using a hydrofibre or alginate dressing. In addition, patients were instructed on adherence to the protocol and given instructions to call their clinic if they suspected any signs of an infection.
62283188|NCT03905863|ACTIVE_COMPARATOR|Intervention arm|Same protocol as SOC only but were also provided with a Natrox® Oxygen Wound Therapy System, consisting of two elements: the Natrox® OG and the Natrox® ODS. The OG is a multi-use battery powered device which generates oxygen though water electrolysis at a rate of 15mL/hr. The ODS is a sterile, single use device that allows wound exudate to pass through to the secondary dressing while allowing the diffusion of oxygen across the wound bed. It connects directly to the OG via a thin flexible fine-bore tube. While the ODS can remain in situ for 7 days, it should be changed at each dressing change, based on exudate level or clinical judgement. This is a battery-operated system with a 30-hour battery life; the kit includes two interchangeable, rechargeable batteries. Each participant was advised to charge one battery while the other was in use, as the battery required changing daily. The oxygen generator is worn in a holster so that patients can remain ambulatory.
62650618|NCT04366674|EXPERIMENTAL|mordified restoration of tensor veli palatini|Incision was made similar to Langerbeck's repair. During disection, the tensor veli palatini was identified after flap elevation. Its tendinous fibers was released from but still connected to the pterygoid process without breaking the hamulus or cutting off the tendinous fibers. If the tension is too strong during suturing, the tensor tendon could be partly dissected laterally meanwhile be kept continuity medially so that the tensor veli palatini could be rotated more medially. The levator veli palatini, tensor veli palatini, together with the palatine aponeurosis and the nasal mucosa from two sides were sutured in the middle line. The tensor veli palatini may not be jointed to the contralateral one directly.
62083808|NCT06497660|EXPERIMENTAL|Anthracene ring drug β group|choosing anthracycline drugs in neoadjuvant chemotherapy for breast cancer and using an equal amount of physiological saline with α group in this study.
62083809|NCT06497660|EXPERIMENTAL|Carboplatin drug β group|choosing carboplatin drugs in neoadjuvant chemotherapy for breast cancer and using an equal amount of physiological saline with α group in this study.
62083810|NCT06497660|EXPERIMENTAL|Combined use β group|choosing anthracycline and carboplatin drugs in neoadjuvant chemotherapy for breast cancer and using an equal amount of physiological saline with α group in this study.
62083811|NCT06497660|PLACEBO_COMPARATOR|control β group|Group without neoadjuvant chemotherapy during the treatment of breast cancer,and using an equal amount of physiological saline with α group in this study.
62083812|NCT02465333|OTHER|Pathway A|"Screening visit followed by heel fat grafting procedure with local anesthetic and visits at:~1 week Post op study visit 2 (1 month) Post op study visit 3 (2 month) Post op study visit 4 (6 month) Post op study visit 5 (12 month) Crossover to standard podiatry visits Study visit 6 (18 months) Study visit 7 (24 months)"
62283189|NCT03396094|EXPERIMENTAL|Intervention|High-flow nasal cannula oxygenation at 60L/min for pre-oxygenation and apnoeic oxygenation
62283190|NCT03396094|ACTIVE_COMPARATOR|Control|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
62459372|NCT02590185|EXPERIMENTAL|cocktail probe drugs|"* A capsule of omeprazole ABBOTT® 10mg~* 10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~* 1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~* A tablet of fexofenadine Zentiva® 120mg"
62459373|NCT06004726|EXPERIMENTAL|Experimental and control|Experimental group will get 4 module of intervention
62283191|NCT03797105|NO_INTERVENTION|Control, 0 days|control group, no intervention
62283192|NCT03797105|EXPERIMENTAL|1 day|received the intervention 1 day/week
62283193|NCT03797105|EXPERIMENTAL|3 days|received the intervention 3 days/week
62283194|NCT03797105|EXPERIMENTAL|5 days|received the intervention 5 days/week
62283195|NCT04515966|ACTIVE_COMPARATOR|Ultrasound-guided steroid injection|Participants with CTS who meet the inclusion criteria are randomized to two groups. One group (or arm) will receive an ultrasound-guided steroid injection in the vicinity of the median nerve within the carpal tunnel. A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine is injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
62650619|NCT00523432|EXPERIMENTAL|A|Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
62650620|NCT00523432|EXPERIMENTAL|B|Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
62650621|NCT05088356|EXPERIMENTAL|Arm A1: Matched related/matched unrelated donor transplantation (closed)|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:.~* Fludarabine (160 mg/m2)~* Melphalan (50 mg/m2)~* TBI (4Gy)~All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus."
62650622|NCT05088356|EXPERIMENTAL|Arm B: Haploidentical transplantation (closed)|"Subjects without an identified matched related or matched unrelated donor will receive a haploidentical transplantation with reduced intensity preparative conditioning:~-. Fludarabine (160 mg/m2)~* Melphalan (100 mg/m2~* TBI (4Gy)~Patients will receive GVHD prophylaxis with post-transplant cyclophosphamide and tacrolimus."
62083813|NCT02465333|OTHER|Pathway B|"Screening visit followed by:~Study visit 1 (6 months) Study Visit 2 (12 months) Crossover to Pathway A~Heel fat grafting procedure and local anesthetic and visits at:~1 week Post op study visit 2 (1 month post procedure) Post op study visit 3 (2 month post procedure) Post op study visit 4 (6 month post procedure) Post op study visit 5 (12 month post procedure)"
62083814|NCT02577835||Hypertensive patients|No intervention. Patients will be sumbitted to standard tests required for hypertension management, including ambulatory blood pressure monitoring, and pharmacologically treated according to recommendations of international guidelines. The registry will include data from subjects fulfilling the inclusion criteria and whose data are contained in existing databases collected by the participating centers and who are regularly followed-up at the center. New subjects can be enrolled for this project, but they must be submitted to ambualtory blood pressure monitoring because it is required for evaluating their hypertension status, according to current recommendations.
62083815|NCT01728038|EXPERIMENTAL|Cessation Counseling|Parental smokers will be given a brief cessation intervention consisting of counseling, nicotine replacement therapy and Quitline connection.
62083816|NCT04861207|EXPERIMENTAL|Cladribine|
62083817|NCT03295006||Previous Therasphere treatment|Patients who had received TheraSphere yttrium-90 microspheres
62083818|NCT04102540|EXPERIMENTAL|Infographic intervention group|Participants in the infographic intervention group will receive health education using infographics during a study visit scheduled immediately following their regularly scheduled clinic visits.
62083819|NCT06047873|EXPERIMENTAL|cases|
62083820|NCT02448836|EXPERIMENTAL|Active dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of dTMS active treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
62083821|NCT02448836|SHAM_COMPARATOR|Sham dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
62283196|NCT04515966|ACTIVE_COMPARATOR|Wrist splint|Participants in this arm are treated with a wrist splint.
62283197|NCT02690623|EXPERIMENTAL|Pediatric hospitalist program|As currently planned, hospitalist services will involve an in-house hospitalist at all hours. The attending hospitalist on each hospitalist service will make morning rounds on weekdays and be present supervising the residents or providing care throughout the day. A different hospitalist will cover at night. On weekends, one hospitalist will cover up to 2 services each day. None will work for more than 25 hours at a stretch.
62459374|NCT06004726|NO_INTERVENTION|Control|control group will not get intervention ,Information Booklet and video assisted teaching will be given after posttest
62459375|NCT01091090|EXPERIMENTAL|Cognitive behavioral|Subjects with receive a cognitive behavioral intervention for smoking cessation
62459376|NCT01091090|ACTIVE_COMPARATOR|Control|Treatment as usual
62459377|NCT00643578|ACTIVE_COMPARATOR|2|a single dose of 24 mcg of formoterol
62459378|NCT00643578|ACTIVE_COMPARATOR|1|a single dose of 12 mcg of formoterol
62459379|NCT04038060|EXPERIMENTAL|WhatsApp Group|Participants will be assigned to participate in a WhatsApp Group
62459380|NCT04038060|EXPERIMENTAL|2-way SMS|Participants will be assigned to receive weekly 2-way SMS initiated by the study team
62459381|NCT04038060|EXPERIMENTAL|2-way SMS and monthly counseling sessions|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and monthly counseling sessions
62461813|NCT02038608|EXPERIMENTAL|PET|
62283198|NCT02690623|ACTIVE_COMPARATOR|General Pediatric Inpatient Services|The attending pediatrician on each service conducts daily morning rounds on weekdays, supervises the students and house staff and is available to the residents by phone or in person during the day. On some afternoons the attending physician may be responsible for supervising care in a pediatric clinic. On weeknights, an on-call pediatrician is available to the residents by phone. On weekends two on-call pediatricians make rounds, supervise the residents, and take call from home for the 4 services. Each service usually maintains 10-20 patients at a time and generally accepts 8-12 new admissions per admitting day. This approach on the General Pediatric Services will not be changed materially as hospitalists assume responsibility for one or more of the 4 services.
62083822|NCT01708187|EXPERIMENTAL|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
62083823|NCT01708187|NO_INTERVENTION|Control arm without Clarix™1k graft|Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
62083824|NCT01862211|EXPERIMENTAL|members of family of children with a DA1AT|
62083825|NCT01862211|EXPERIMENTAL|children with a DA1AT|
62083826|NCT02266329|ACTIVE_COMPARATOR|prazosin|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
62283199|NCT00510185|EXPERIMENTAL|1|Coronary angiography within 72h and revascularization as clinical indicated
62283200|NCT00510185|SHAM_COMPARATOR|2|Initially conservative treatment with coronary angiography only for recurrent ischemia
62283201|NCT05091320|ACTIVE_COMPARATOR|Mechanical thrombectomy|this arm will include all patient underwent mechanical thrombectomy, either alone or after failure of medical treatment.
62283202|NCT05091320|ACTIVE_COMPARATOR|medical managemnet|this arm will include all patients who received medical treatment only, either anti-platelet or alteplase.
62459382|NCT04038060|EXPERIMENTAL|2-way SMS and drug level feedback|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and drug level feedback
62459383|NCT04038060|EXPERIMENTAL|WhatsApp Group and monthly counseling sessions|Participants will be assigned to participate in a WhatsApp Group and monthly counseling sessions
62459384|NCT04038060|EXPERIMENTAL|WhatsApp Group and drug level feedback|Participants will be assigned to participate in a WhatsApp Group and drug level feedback
62650623|NCT05088356|EXPERIMENTAL|Arm A2: Fully matched (8/8) related/unrelated donor transplantation|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~* Fludarabine (160 mg/m2)~* Thiotepa (10 mg/kg)~* TBI (4Gy)~All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus."
62283203|NCT03980366|EXPERIMENTAL|ECT to treat self-injurious behaviors in adults with ASD|After initial exams and pre-screening, participants will receive bilateral Electroconvulsive Therapy (ECT) for 12 treatments sessions over the course of 4 weeks, plus non-ECT follow-up sessions at 1, 2, 6, and 12 months post-ECT treatment.
62283204|NCT00782548|ACTIVE_COMPARATOR|1|Test product A (1 x 30 mg KADIAN)
62083827|NCT02266329|PLACEBO_COMPARATOR|placebo|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
62083828|NCT06054620|ACTIVE_COMPARATOR|Collagen and Vitamin C|
62083829|NCT06054620|PLACEBO_COMPARATOR|Carbohydrate Placebo|
62083830|NCT01734382|EXPERIMENTAL|Part 1: Tocilizumab (TCZ) Q2W|Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants \< 30 kg; 8 mg/kg for participants \>/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.
62459385|NCT04842045|EXPERIMENTAL|Single Arm|Medically and psychiatrically healthy adults ages 21 to 65 years will receive a single 25 mg dose of psilocybin combined with repeated boluses of midazolam administered in a clinically supportive setting.
62459386|NCT04762056||COVID-19 patients after ICU discharge|Patients who suffered COVID-19 pneumonia and stayed in ICU and discharged
62459387|NCT00936260|EXPERIMENTAL|alendronate 6 years|
62459388|NCT00936260|EXPERIMENTAL|alendronate 5 years|No treatment during year 6th
62459389|NCT00936260|EXPERIMENTAL|alendronate 5 years, not continued|No treatment during year 5th
62083831|NCT01734382|EXPERIMENTAL|Part 2: TCZ IV 12 mg/kg Q3W/Q4W|Participants with weight \< 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.
62083832|NCT01734382|EXPERIMENTAL|Part 2: TCZ IV 8 mg/kg Q3W/Q4W|Participants with weight \>/= 30 kg will receive tocilizumab IV infusions of 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 8 mg/kg Q4W up to Week 52 in Part 2 of the study.
62083833|NCT03242044|EXPERIMENTAL|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
62083834|NCT00684983|ACTIVE_COMPARATOR|Arm A (lapatinib ditosylate, capecitabine)|Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62083835|NCT00684983|EXPERIMENTAL|Arm B (cixutumumab, lapatinib ditosylate, capecitabine)|Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also receive cixutumumab IV over 1 hour on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62083836|NCT02059343||age less than or equal to 2 years|
62083837|NCT05139979|EXPERIMENTAL|Webinar-Based Intervention|Breathing and Wellness Webinar: two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
62283205|NCT00782548|ACTIVE_COMPARATOR|2|Reference product B (1 x 30 mg Avinza)
62459390|NCT00936260|EXPERIMENTAL|alendronate 4 years|No treatment during year 5th and 6th
62459391|NCT00936260|EXPERIMENTAL|alendronate 5 years, uncontinued|No treatment during year 4th
62459392|NCT00936260|EXPERIMENTAL|alendronate 4 years, not continued|No treatment during year 4th and 6th
62459393|NCT00936260|EXPERIMENTAL|alendronate 4 years, uncontinued|No treatment during year 4th and 5th
62459394|NCT00936260|EXPERIMENTAL|Alendronato 3 years|No treatment during the last 3 years
62459395|NCT02304588|EXPERIMENTAL|Mesenchymal stem cells|Maximal amount of MSC cells injected: 10-20\*10\^6 cells (up to volume of 20mL, depending on the wound size \& patient weight).
62459396|NCT03200067|EXPERIMENTAL|Personalized rehabilitation service group|Breast cancer patients who use mobile healthcare service application and receive personal feedback from clinician
62459397|NCT03200067|NO_INTERVENTION|Conventional group|Breast cancer patients with conventional care
62459398|NCT05008822|EXPERIMENTAL|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
62459399|NCT05008822|ACTIVE_COMPARATOR|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
62283206|NCT01172015|EXPERIMENTAL|PTI patients|Study NK cells functions, phenotypic changes and transcripts from ITP patients
62283207|NCT01172015|OTHER|healthy volunteers|Study NK cells functions, phenotypic changes and transcripts from healthy volunteers
62283208|NCT02794220|EXPERIMENTAL|CN Electronic cigarette 10 mg|"10 mg strength~- Administration once every hour for a total of 4 hours."
62283209|NCT02794220|EXPERIMENTAL|CN Electronic cigarette 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
62459400|NCT01014728|ACTIVE_COMPARATOR|Intravenous anesthesia|Intravenous anesthesia with propofol for endoscopic sinus surgery
62459401|NCT01014728|ACTIVE_COMPARATOR|Inhalation anesthesia|Inhalation anesthesia with sevoflurane for endoscopic sinus surgery
62459402|NCT01938482|EXPERIMENTAL|Part 1|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm\^2 (0.3%), 400 cm\^2 (1%) or 1200 cm\^2 (1%), respectively, in each of three sequential cohorts
62283210|NCT02794220|ACTIVE_COMPARATOR|Nicorette Inhalator 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
62459403|NCT01938482|EXPERIMENTAL|Part 2|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm\^2 (0.3%), 400 cm\^2 (1%) or 1200 cm\^2 (1%), respectively, in each of three sequential cohorts
62459404|NCT02834611|EXPERIMENTAL|Ceramide NanoLiposome|Dose escalation of Ceramide NanoLiposome
62283211|NCT02794220|ACTIVE_COMPARATOR|Cigarette|"Subjects will all smoke the same brand.~- Administration once every hour for a total of 4 hours."
62459405|NCT05324735|EXPERIMENTAL|Pentoxifylline|Pentoxifylline (tablet): 400 mg twice a day for 12 weeks
62459406|NCT05324735|PLACEBO_COMPARATOR|Control group|Placebo (tablet): twice a day for 12 weeks
62650624|NCT05088356|EXPERIMENTAL|Arm A3: Fully (8/8) matched related/unrelated donor transplantation|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~* Fludarabine (160 mg/m2)~* Thiotepa (5 mg/kg)~* TBI (2-3 Gy).~All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus."
62283212|NCT02000141||Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
62283213|NCT04687501|EXPERIMENTAL|VR-group|"The participants randomised into this group can choose for an immersive guided relaxation VR experience or an interactive VR experience. The VR intervention is additional to the standard postoperative care management, the standard pain protocol is explained below.~The VR-intervention will be given using the Oculus Go Virtual Reality glasses with touchpad."
62083838|NCT05139979|PLACEBO_COMPARATOR|Control|This group will be asked to wait for 3 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
62283214|NCT04687501|NO_INTERVENTION|Standard care-group|"The participants randomized into the standard care- group will receive the usual standard pre-and postoperative management.~Standard pain protocol:~1. Preoperative (arrival day-care unit) start with 1000mg paracetamol orally administered.~2. Postoperative Meloxicam 15mg orally administered, or when oral medication is not possible (due to nausea e.g.) than diclofenac supp 100mg or diclofenac i.v. 75mg.~3. On recovery ward, when necessary depending on pain score (NRS\>4): dipidolor 2.5-5mg i.v. and 10-15mg i.m. after consulting the anesthesiologist.~4. Postoperative at home 4dd1000mg paracetamol will be continued, in combination with meloxicam 1dd15mg during 3 days. Also tramadol 50mg with a maximum of 4dd will be prescribed."
62283215|NCT05596019|EXPERIMENTAL|neurodynamics specific exercise group|"The experimental group will perform a multimodal therapeutic physical exercise program. The components of balance, walking, cardiovascular endurance, strength and flexibility will be worked globally, in addition to including respiratory exercises.~Specific neurodynamic exercises oriented to the treatment of the main nerves of the brachial plexus will be included as part of the exercise sessions. The specific neurodynamic program will consist of the following exercises:~1. Opening of the cervical conjunction holes with cranio-cervical and cervical flexion movements, cervical lateroflexions and lateral vertebral sliding self-mobilizations.~2. Opening of the thoracic passages of the brachial plexus with stretching of the scalene muscles, opening of the costoclavicular space and stretching of the pectoralis minor muscles.~3. Specific exercises of neurodynamic sliding of the nerves of the upper limb: median, radial and ulnar nerves."
62459407|NCT04428541|EXPERIMENTAL|Questionnaire|Description : 18 items questionnaire, filled by the parents of the child
62459408|NCT01695551||Ventricular Tachycardia|Participants in cohort will have implantable defibrillators in-situ and are undergoing ablation procedure for ventricular tachycardia.
62650625|NCT05088356|EXPERIMENTAL|Arm C1:7/8 mismatched related/unrelated donor transplantation (closed)|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~* Fludarabine (160 mg/m2)~* Thiotepa (10 mg/kg)~* TBI (4 Gy) All enrolled subjects will receive GVHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF)."
62083839|NCT01426906|EXPERIMENTAL|Study A|
62083840|NCT01426906|EXPERIMENTAL|Study B|
62083841|NCT06304311|ACTIVE_COMPARATOR|Routine Obstetrics care (Control)|Participants in the control arm received routine obstetrics care, which typically includes standard prenatal care, monitoring during labor, and delivery management according to established hospital protocols. There were no additional interventions or techniques implemented beyond standard practice for managing labor and delivery.
62083842|NCT06304311|EXPERIMENTAL|Routine Obstetrics care & Lamaze breathing techniques and backside massage (Interventional group)|Participants in the experimental arm received routine obstetrics care, similar to the control group, along with additional interventions of Lamaze breathing techniques and backside massage. Lamaze breathing techniques were taught to participants during antenatal classes or individual sessions, focusing on deep breathing, relaxation, and pain management strategies during labor. Backside massage was administered by trained personnel using gentle, rhythmic strokes on the lower back to alleviate discomfort and promote relaxation during labor. These interventions were integrated into the labor and delivery process alongside routine obstetrics care.
62083843|NCT04929119||Before wearing the Orthokeratology|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
62083844|NCT04929119||Wear Orthokeratology for a week|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
62083845|NCT04929119||Wear Orthokeratology for a month|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
62083846|NCT04929119||Wear Orthokeratology for three months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
62083847|NCT04929119||Wear Orthokeratology for six months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
62083848|NCT01103986|NO_INTERVENTION|Control Group|
62283216|NCT05596019|ACTIVE_COMPARATOR|The nonspecific exercise group|The nonspecific exercise group performed balance, cardiovascular endurance, stability, upper and lower limb strength, flexibility, and breathing exercises.
62283217|NCT02337803|EXPERIMENTAL|Strength Training Group|Participants will meet three times a week for one hour strength training sessions for twelve weeks.
62459409|NCT04529746|EXPERIMENTAL|EVERYbody Project: Professional facilitator version|"The EVERYbody Project is a dissonance body image intervention created from focus group feedback (Ciao, Ohls, \& Pringle, 2017) and through an iterative process of student-driven feedback. The Body Project manual (Stice et al., 2006) was adapted to retain key dissonance activities while expanding the gender focus, adding an exploration of the diversity characteristics within appearance ideals, and adjusting activities to be inclusive of diversity characteristics. Several adapted versions of the intervention were piloted with groups of college students and further adapted based on feedback.~Facilitators received 16 hours of training on the EVERYbody Project manual and facilitation guidelines."
62459410|NCT04529746|NO_INTERVENTION|Waitlist control group|Participants allocated to the waitlist completed assessments at time points parallel to those in the EVERYbody Project condition and were offered the EVERYbody Project upon completing the one-month follow-up assessment.
62083849|NCT01103986|EXPERIMENTAL|motivational/ health literacy education|
62283218|NCT02337803|ACTIVE_COMPARATOR|Usual Care|Participants will be given access to the strength training program after the twelve week study ends.
62283219|NCT03015805|EXPERIMENTAL|Contingency Management|This group will receive regular probation services but will also receive the Contingency Management program for substance abuse from their juvenile probation officer during regular meetings.
62283220|NCT03015805|ACTIVE_COMPARATOR|Probation as Usual|This group will receive regular services that are usually provided by juvenile probation officers.
62459411|NCT00406848|EXPERIMENTAL|Duloxetine|
62459412|NCT00406848|PLACEBO_COMPARATOR|Placebo|
62283221|NCT01815541|EXPERIMENTAL|teicoplanin|this group receive the teicoplanin
62283222|NCT05635890|EXPERIMENTAL|Group I|received conventional vestibular rehabilitation along with the Cawthorne Cooksey exercise protocol
62283223|NCT05635890|ACTIVE_COMPARATOR|Group II|received conventional vestibular rehabilitation only
62459413|NCT00699322|EXPERIMENTAL|1|Sitagliptin
62283224|NCT04523532|EXPERIMENTAL|Group 1: Folate + hazelnut oil|Group 1 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of vegetables rich in folate - 191µg and additionally received 01 capsule containing 25 mg hazelnut oil per day.
62283225|NCT04523532|PLACEBO_COMPARATOR|Group 2: Folate|Group 2 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of folate-rich vegetables - 191 µg and 01 placebo capsule.
62459414|NCT00699322|ACTIVE_COMPARATOR|2|Glimepiride
62459415|NCT05376683|NO_INTERVENTION|Control|
62459416|NCT05376683|ACTIVE_COMPARATOR|Telemonitoring group|
62459417|NCT05376683|ACTIVE_COMPARATOR|AI. + Telemonitoring group|
62083850|NCT06476587||IBV patients|Persons with bilateral vestibulopathy
62283226|NCT04523532|EXPERIMENTAL|Group 3: Moderate folate + hazelnut oil|Group 3 = in this group, individuals received, during the period of 08 weeks daily, with 300 g of vegetables containing 94 µg of folate and 01 capsule containing 25 mg of hazelnut oil per day.
62283227|NCT04523532|NO_INTERVENTION|Group 4: Control|Group 4 = in this group, individuals received weekly visits during the 08 week period to maintain their eating habits.
62283228|NCT05927883|EXPERIMENTAL|Intervention group|Adolescents who scored high on IGD-SF-9. The group will be given IACBTGA
62459418|NCT02268799||DC Cardioversion|Patients undergoing DC cardioversion
62459419|NCT03299907||COPD|Subject with FEV1/FVC post BD \< 0.7 or LLN
62459420|NCT03299907||Non COPD|Subject with FEV1/FVC post BD \>= 0.7 or LLN
62459421|NCT03487107|EXPERIMENTAL|SOF 400 mg+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks.
62459422|NCT01675557|ACTIVE_COMPARATOR|Vitamin D2|a single oral dose of vitamin D2
62083851|NCT06476587||Controls|Healthy volunteers matched with patients with respect to their age, sex and level of education
62083852|NCT06441019|EXPERIMENTAL|HAIC combined with TQB2868 and Ramucirumab|
62083853|NCT01175538|EXPERIMENTAL|Lactulose|
62083854|NCT01144221|EXPERIMENTAL|Stem cell treatment|Patients treated via stem cell injection
62083855|NCT05594355|EXPERIMENTAL|Arm 1|Treatment with EGb 761® (TEBOFORTAN 240 mg) during 24 months.
62083856|NCT05594355|NO_INTERVENTION|Arm 2|No Treatment during 12 months and treatment with EGb 761® (TEBOFORTAN 240 mg) for the next 12 months.
62459423|NCT01675557|PLACEBO_COMPARATOR|Placebo|a single oral dose of a placebo
62459424|NCT01675557|EXPERIMENTAL|Vitamin D3|A single oral dose of vitamin D3
62459425|NCT05756530||Cases|Right-handed women diagnosed with restricting type or binge-eating/purging type AN, according to the Diagnostic and Statistical Manual of Mental Disorders (5th Edition)'s criteria (DSM, American Psychiatric Association, 2013), will be consecutively recruited during their rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders will be the exclusion criteria, as well as the evidence of any skin-related condition possibly affecting sensitivity on the participants' forearm (e.g., eczema, scars)
62459426|NCT05756530||Controls|Age-matched, right-handed, healthy women (i.e., with no history of eating disorders) will be recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
62650626|NCT05088356|EXPERIMENTAL|Arm C2: 7/8 mismatched related/unrelated donor transplantation|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~* Fludarabine (160 mg/m2)~* Thiotepa (5 mg/kg)~* TBI (2-3 Gy)~All enrolled subjects will receive GVHD prophylaxis with tacrolimus and ruxolitinib."
62650627|NCT03979066|ACTIVE_COMPARATOR|Atezolizumab|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
62283229|NCT05927883|ACTIVE_COMPARATOR|Intervention group with Parental Psycho-education|Adolescents who scored high on IGD-SF-9, parents of adolescents will also be added in intervention and CBT based psycho-education will be provided to parents and adolescents will be provided IACBTGA.
62650628|NCT03979066|EXPERIMENTAL|Atezolizumab in combination with PEGPH20|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery in combination with PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
62283230|NCT05927883|NO_INTERVENTION|Control|This group will not be given no intervention
62459427|NCT00319358|ACTIVE_COMPARATOR|Antioxidants|Intervention was done with antioxidants
62650629|NCT00667511|ACTIVE_COMPARATOR|Home Short Daily Hemodialysis|Intervention: Patients perform short daily hemodialysis (2 to 4 hour treatments) in the home setting using the NxStage System One.
62650630|NCT00667511|EXPERIMENTAL|Home Nocturnal Hemodialysis|Intervention: Patients perform nocturnal hemodialysis (6 to 10 hour treatments) in the home setting using the NxStage System One.
62650631|NCT03798236|EXPERIMENTAL|PBF-1650 40mg|
62650632|NCT03798236|EXPERIMENTAL|PBF-1650 80mg|
62650633|NCT03798236|EXPERIMENTAL|PBF-1650 120mg|
62083857|NCT05802550|OTHER|Longitudinal cohort study in cataract patients|Longitudinal, open-label, single-center cohort study in cataract patients.
62083858|NCT01959945|EXPERIMENTAL|Study Group 1, Flublok|Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
62083859|NCT01959945|ACTIVE_COMPARATOR|Study Group 2, Fluarix|Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
62283231|NCT01420484||different blood pressure intervals|
62283232|NCT03545256|OTHER|T1-N0 or T2-N0 cancers of the oral cavity|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
62283233|NCT01360645|EXPERIMENTAL|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
62283234|NCT01360645|PLACEBO_COMPARATOR|Phase A|Intervention: Drug: Placebo + ADT
62283235|NCT02460211|ACTIVE_COMPARATOR|Treatment|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
62283236|NCT02460211|PLACEBO_COMPARATOR|Placebo/Control Arm|Those randomized to the control arm will receive three oral placebo doses.
62283237|NCT02000804|EXPERIMENTAL|darapladib 160mg|drug
62283238|NCT01493180|EXPERIMENTAL|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
62283239|NCT01493180|ACTIVE_COMPARATOR|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution
62459428|NCT00319358|PLACEBO_COMPARATOR|Placebo|
62459429|NCT06459388|EXPERIMENTAL|Stabilizing Reversals and Rhythmic Stabilization|This group will receive stabilizing reversals and rhythmic reversals technique. The patient will perform 3 sets with 15 repetitions in each session, 5 days per week for 8 weeks
62650634|NCT03798236|EXPERIMENTAL|PBF-1650 240mg|
62650635|NCT03798236|PLACEBO_COMPARATOR|Placebo|
62650636|NCT00933153|ACTIVE_COMPARATOR|Meals on Wheels|Participants will receive two meals daily from Meals on Wheels.
62650637|NCT00933153|EXPERIMENTAL|Meals on Wheels + Ensure Plus supplement|Participants will receive two meals from Meals on Wheels daily plus Ensure Plus supplements with meals.
62653064|NCT05205356||Clinicians|Following focus groups at each of the participating sites to assess the feasibility \& needs of each site, the care teams will receive basic training in genomics and how to disclose GS results with VIGOR support. Study orientation will be completed as part of the training. Focus groups will be conducted within 1 year post implementation \& again between year 4 \& the completion of the study, to assess feasibility \& appropriateness of VIGOR. We will administer brief surveys to the care providers before \& after receipt of genomic education to assess their baseline knowledge \& comfort with genomic medicine in newborns. Surveys will be repeated within a week of disclosure to families regarding feedback on the process \& satisfaction with VIGOR. After approximately 3-5 disclosure events, study staff will approach the clinical care team members to participate in a qualitative interview to assess their perspectives in more depth.
62653065|NCT01786291||CPAP compliant|CPAP (continuous positive airway pressure) compliant patients
62653066|NCT01786291||CPAP non-compliant|patients who did not use CPAP therapy
62459430|NCT06459388|EXPERIMENTAL|Pelvic Proprioceptive Neuromuscular Facilitation|This group will receive Pelvic PNF protocol. The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
62650638|NCT04968704||patients undergoing facial reconstructive surgery|Patients with facial cancer or disfigurement who require reconstructive surgery will be offered participation in this study.
62083860|NCT01959945|EXPERIMENTAL|Study Group 3, Flublok|Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
62083861|NCT01959945|ACTIVE_COMPARATOR|Study Group 4, Fluarix|Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
62083862|NCT01284777||patients|
62083863|NCT04123860|EXPERIMENTAL|buccal fat pad|will undergo sinus lifting using intralift technique then placement of buccal fat pad followed by immediate implant placement.
62459431|NCT04524065|EXPERIMENTAL|Early intervention group|The 14 early rehabilitation sessions(10 physical therapy sessions; 15minutes per session, 4 occupational therapy sessions; 20minutes per session) occurred per week until discharge.
62083864|NCT04123860|ACTIVE_COMPARATOR|prf|will undergo sinus lifting using intralift technique the prpration of PRF and immediate implant placement.
62083865|NCT00413608|EXPERIMENTAL|1|Clopidogrel
62283240|NCT01983787||Pharmacokinetics Piperacillin|Patients with cystic fibrosis , treated with Piperacillin/Tazobactam, given as continuous infusion for a period of two weeks.
62459432|NCT04524065|NO_INTERVENTION|Control group|The control group received 2 sessions(physical therapy) per week over a 2-week period for 10 minutes each.
62459433|NCT04860219|NO_INTERVENTION|Control Group|None of the participants in the Control Group received lactoferrin
62459434|NCT04860219|ACTIVE_COMPARATOR|200 mg lactoferrin orally once daily Group|received 200 mg lactoferrin orally once daily
62083866|NCT00413608|EXPERIMENTAL|2|Clopidogrel
62459435|NCT04860219|ACTIVE_COMPARATOR|200 mg lactoferrin orally twice daily Group|received 200 mg lactoferrin orally twice daily
62650639|NCT02576470|EXPERIMENTAL|Videofluoroscopy (VF) and Barium|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium to provide biofeedback for targeted dysphagia swallowing maneuver.
62459436|NCT02298322|EXPERIMENTAL|CoolSculpting Treatment|The intervention is the CoolSculpting System.
62459437|NCT06361498|OTHER|Ultrasound Imaging|This study consists of one group/ All participants will receive ultrasound imaging prior to the standard of care fluoroscopic imaging.
62459438|NCT00881270|EXPERIMENTAL|Dermacyd infantile (Lactic Acid)|treatment duration 21 consecutive days
62459439|NCT02539485|OTHER|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
62283241|NCT02641535|EXPERIMENTAL|research arm|"12 healthy volunteers from the border guard of the police forces will participate in this study. The subjects will undergo 4 experiment days:~1. Recruitment , medical examination and VO2max test.~2. Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3.2 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~1. Protective garment in current use + NBC mask.~2. The new BC membrane protective garment + NBC mask"
62283242|NCT02452762|EXPERIMENTAL|Enteral Loading Arm|Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)
62283243|NCT02452762|PLACEBO_COMPARATOR|Placebo Arm|Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.
62650640|NCT02576470|ACTIVE_COMPARATOR|Surface Electromyography (sEMG)|This group will receive the following types of procedures during visits. sEMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
62650641|NCT02576470|ACTIVE_COMPARATOR|Mixed VF and sEMG|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium, and EMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
62283244|NCT01822002|ACTIVE_COMPARATOR|Canalith repositionig maneuver; Epley maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver.
62650642|NCT02576470|EXPERIMENTAL|VF with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
62650643|NCT02576470|EXPERIMENTAL|sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with anodal transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
62650644|NCT02576470|EXPERIMENTAL|Mixed VF, sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
62083867|NCT00559910|EXPERIMENTAL|PH-797804|PH-797804 at four dose levels
62083868|NCT00559910|PLACEBO_COMPARATOR|Placebo|Placebo
62083869|NCT04344834||Health care workers|Egyptian health care workers
62283245|NCT01822002|ACTIVE_COMPARATOR|Canalith repositioning maneuver : Semont maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver group.
62283246|NCT06348563|OTHER|Health controls|Diagnostic assessment
62283247|NCT06348563|OTHER|NAFLD|"Diagnostic assessment. confirmation of diagnosis from liver biopsy is required.~* NASH Diagnosis is on histological assessment from NASH CRN score:~  * NASH CRN score of ≤ 3 is classified as steatosis.~ * NASH CRN score of ≥ 5 is classified as NASH.~* Participant samples can be subsequently diagnosed with CAP or MRI-PDFF to rule out NASH (or in rule in simple steatosis) but cannot be used to rule in NASH (as biopsy is required for confirmation).~* All diagnostic criteria for participant at time of visit is requested."
62283248|NCT06348563|OTHER|Liver Fibrosis|"Diagnostic assessment, For fibrosis diagnosis and analysis, diagnostic tools can constitute zero or mild fibrosis (F0-F1), significant fibrosis (F2), and advanced fibrosis (F3-F4) in the presence or absence of NASH.~* Participant samples can be diagnosed through non-invasive modalities such as but not limited to FIB4, ELF, PROC3, and/or imaging modalities such as but not limited to vibration controlled transient elastography (VCTE), magnetic resonance elastography (MRE), acoustic radiation force impulse (AFRI) or multiparameter imaging assessments.~* All diagnostic criteria for participant at time of visit is requested."
62283249|NCT02052557|ACTIVE_COMPARATOR|Bupivacaine|30 milliliters (ml) of 0.5% marcaine with epinephrine
62283250|NCT02052557|ACTIVE_COMPARATOR|Bupivacaine liposome suspension|exparel 20ml, diluted with 10ml sterile saline for total of 30ml
62283251|NCT01208090|EXPERIMENTAL|Investigational drug - Dose 1|
62283252|NCT01208090|EXPERIMENTAL|Investigational drug - Dose 2|
62283253|NCT01208090|PLACEBO_COMPARATOR|Matching placebo|
62283254|NCT05859477|EXPERIMENTAL|Nivolumab in combination with chemotherapy|Nivolumab 360 mg with CAPOX (capecitabine and oxaliplatin) every 3 weeks
62283255|NCT02174718|EXPERIMENTAL|Daily 4000IU transdermal D patch|Only in the stage 2, Efficacy Study
62283256|NCT02174718|ACTIVE_COMPARATOR|Daily placebo patch plus oral placebo|Only in the stage 3, non-inferiority Study
62653067|NCT01981252|EXPERIMENTAL|Ulthera® System Treatment|Ulthera® System treatment of the peri-orbital and peri-oral regions.
62083870|NCT04344834||General population|Any Egyptian personnel
62083871|NCT04344834||Recovered fromCOVID-19|Patients recovered from COVID-19
62083872|NCT00680303|EXPERIMENTAL|1|The child will receive the Lidcombe Program 2x per week
62083873|NCT00680303|EXPERIMENTAL|2|The child will receive the Lidcombe Program once every 2 weeks (fortnightly visits)
62083874|NCT00680303|OTHER|3|The child will receive the standard Lidcombe Program once per week (control)
62083875|NCT00949962|ACTIVE_COMPARATOR|Arm I|Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
62283257|NCT02174718|ACTIVE_COMPARATOR|Daily placebo patch plus oral vitamin D|Only in the stage 3 Non-inferiority Study
62283258|NCT02174718|ACTIVE_COMPARATOR|Daily 4000IU topical patch plus oral placebo|Only for the 3rd Stage of the study, Non-inferiority Study
62283259|NCT02174718|PLACEBO_COMPARATOR|Daily transdermal placebo patch|Only in the stage 2, Efficacy Study
62283260|NCT04110041|EXPERIMENTAL|Moderate Intensity|Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
62283261|NCT04110041|EXPERIMENTAL|High Intensity|Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
62283262|NCT04634266|EXPERIMENTAL|Experimental intervention|Transcatheter tricuspid valve treatment (TTVT) plus optimal medical therapy (OMT)
62283263|NCT04634266|NO_INTERVENTION|Control intervention|OMT for severe tricuspid regurgitation in right-sided heart failure
62283264|NCT03728205|EXPERIMENTAL|Observational|All 10 pilot subjects will be taking yoga
62283265|NCT06542146|ACTIVE_COMPARATOR|group A|patients will follow usual diet
62650645|NCT02576470|SHAM_COMPARATOR|VF with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images without the transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
62650646|NCT02576470|SHAM_COMPARATOR|sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images without the transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
62083876|NCT00949962|EXPERIMENTAL|Arm II|Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.
62083877|NCT01799772|EXPERIMENTAL|Comprehensive behavioral intervention|"It will involve regular contacts over 6 month period. It will include 2 weekly contacts for weeks 1-6, weekly contacts for weeks 7-8, bi-weekly contact for months 3-4, and monthly contact for months 5-6. There is a combination of 20 individual and group-based sessions.~It is a combination of 4 components: a) Evidence-based exercise program, b) Physical activity promotion, c) Healthy nutrition guidance, and d) Self-management."
62283266|NCT06542146|ACTIVE_COMPARATOR|group B|Patients will follow Mediterranean die
62283267|NCT04036669||RA patients|RA patients ( N=80; BMI= 26.4± 3.96 ) Eighty patients diagnosed with Rheumatoid arthritis according to American Rheumatology Association criteria and radiographic analysis for at least 10 years previously were randomly involved in this study
62283268|NCT04036669||Healthy control|A healthy control group ( N=80; BMI=22.3± 1.85) eighty age and sex-matched healthy controls were included in the study following the assignment of informed consent.
62283269|NCT03597165|EXPERIMENTAL|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
62283270|NCT03597165|ACTIVE_COMPARATOR|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
62283271|NCT04696640|EXPERIMENTAL|Remote Patient Monitoring|All participants who have successfully established remote data-sharing from their glucose monitors to the research team's Glooko account by conclusion of the one-month baseline period will advance to the six-month intervention period.
62283272|NCT01560273||Aspen Spinous Process Fixation Device|The Aspen device provides supplemental posterior fixation for fusion
62283273|NCT05655377|EXPERIMENTAL|At home exercise therapy with FitMi PD|Participants will be instructed to use FitMi PD exercise system for three hours per week over 3-week period.
62459440|NCT01994525|EXPERIMENTAL|Cohort 1: PfRAS-infected|"5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.~Challenge occurs 3 weeks after final immunization."
62650647|NCT02576470|SHAM_COMPARATOR|Mixed VF, sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images without transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
62650648|NCT02576470|EXPERIMENTAL|VF with reward|This group will receive the following the procedure outlined below for biofeedback. The biofeedback is based on the videofluoroscopy (VF) and Barium with financial reward.
62650649|NCT02576470|EXPERIMENTAL|sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3-days.
62283274|NCT04167475|EXPERIMENTAL|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
62650650|NCT02576470|EXPERIMENTAL|Mixed VF, sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3 days.
62283275|NCT04167475|PLACEBO_COMPARATOR|Placebo capsule|The participants consume one placebo capsule a day for 8 weeks
62459441|NCT01994525|PLACEBO_COMPARATOR|Cohort 1: Noninfected|"Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.~Challenge occurs 3 weeks after final immunization."
62083878|NCT01799772|ACTIVE_COMPARATOR|Standard of Care Exercise Program (SCE)|The SCE will be delivered by a physical therapist. It represents the typical rehabilitation after TKA surgery. It is expected to provide small and short-lived functional improvement. Subjects will participate in 12 supervised sessions (2 x/week, for 6 weeks). The SCE consists of: a) lower extremity range of motion and stretching exercises, b) lower extremity strengthening exercises of moderate intensity, and d) endurance exercises using treadmill.
62083879|NCT03587987|ACTIVE_COMPARATOR|Neopuff|neopuff
62083880|NCT03587987|EXPERIMENTAL|r PAP|rPap device
62083881|NCT04239365|EXPERIMENTAL|Group A: WLE followed by NBI|EMR scar is interrogated using WLE followed by NBI
62083882|NCT04239365|ACTIVE_COMPARATOR|Group B: NBI followed by WLE|EMR scar is interrogated using NBI followed by WLE
62083883|NCT02492217|EXPERIMENTAL|Adalimumab|Adalimumab will be provided to trial participants as 0.8 ml single dose pre-filled syringes containing 40mg adalimumab each. A kit will be dispensed to he subject every two weeks, each kit containing one syringe.
62083884|NCT05783674|EXPERIMENTAL|BrainBreaks for people without mental health problems|BrainBreaks for people without mental health problems
62083885|NCT05783674|EXPERIMENTAL|BrainBreaks for people with mental health problems|BrainBreaks for people with mental health problems
62083886|NCT01820468|EXPERIMENTAL|Adapted critical time intervention team|Community-based team will help facilitate early inpatient discharge and re-entry into the community.
62083887|NCT01820468|NO_INTERVENTION|Regular inpatient care|
62083888|NCT04082182|EXPERIMENTAL|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIX4-LUNG autologous DC vaccine
62283276|NCT01668654|EXPERIMENTAL|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
62283277|NCT00243997|ACTIVE_COMPARATOR|1|Subjects receiving the Becoming Parents Program
62283278|NCT00243997|PLACEBO_COMPARATOR|2|Subjects not receiving the Becoming Parents Program
62283279|NCT05589285|EXPERIMENTAL|Treatment group|Chronic plantar fasciitis patients who will receive autologous whole blood injection.
62283280|NCT05589285|SHAM_COMPARATOR|Control group|Chronic plantar fasciitis patients who will receive normal saline injection.
62283281|NCT02256930|EXPERIMENTAL|M518101|M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
62283282|NCT02256930|PLACEBO_COMPARATOR|M518101 Vehicle|M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
62283283|NCT02256930|ACTIVE_COMPARATOR|Sodium lauryl sulfate|The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
62650651|NCT05994742|ACTIVE_COMPARATOR|Arm 1: Standard-of-care (control)|Children in the control arm will receive Ready to Use Therapeutic Food (RUTF) for at least 2 weeks, plus all standard care. Children with HIV will receive long-term Cotrimoxazole prophylaxis and antiretroviral therapy, as per current guidelines.
62650652|NCT05994742|EXPERIMENTAL|Arm 2: Antimicrobial package|Children will receive a bundle of azithromycin (3 days every month), isoniazid (daily), rifampicin (daily) and pyridoxine (daily) for 12 weeks.
62083889|NCT00463541|EXPERIMENTAL|1|
62083890|NCT02514564||2x/wk|This group will be consisted of patients that will perform exercise two times a week.
62083891|NCT02514564||3x/wk|This group will be consisted of patients that will perform exercise three times a week.
62083892|NCT02514564||Control|This group will not perform exercise.
62083893|NCT02496858||Early-onset CAD|The anticipated 2000 young CAD patients who aged ≤45years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
62083894|NCT02496858||Late-onset CAD|The anticipated 2000 old CAD patients aged≥65years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
62083895|NCT02496858||Age-matched controls|The anticipated 2000 control subjects without obvious coronary stenosis aged≤45years or ≥65years will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
62283284|NCT02256930|SHAM_COMPARATOR|Saline|The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
62283285|NCT02250209|EXPERIMENTAL|Trastuzumab,Capecitabine,Oxaliplatin|"Patients receive eight 3-week cycles of oral capecitabine (800-1000 mg/m2 twice daily on days 1-14 of each cycle) ,intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) plus intravenous Trastuzumab (440mg on day 0 of each cycle).~Number of cycle:capecitabine and oxaliplatin --8 cycles; Trastuzumab--14-16 cycles."
62650653|NCT05994742|EXPERIMENTAL|Arm 3: Reformulated RUTF|Children will receive a reformulated RUTF, with increased medium-chain triglycerides (MCTs), higher hydrolysed protein content and a more bioavailable form of selenium (selenium yeast). Children will receive RUTF for at least 2 weeks.
62653068|NCT05203185|EXPERIMENTAL|Intervention Site|Full time employed Emergency Department providers will use the new CDS tool, Pulmonary Embolism Risk Kalculator (PERK), which includes nudges to improve use and will be integrated into the electronic medical record and will be accessible for 6 months
62653069|NCT05203185|NO_INTERVENTION|No Intervention Site|Full time employed Emergency Department providers used a CDS tool, Pulmonary Embolism Calculator (PE CALC), without nudges to improve use, to reduce unnecessary imaging in the diagnosis of pulmonary embolism (PE) in the emergency department (ED).
62653070|NCT03652896|EXPERIMENTAL|anatomical liver resection|resect the tumor located liver segment or lobe
62283286|NCT02816879|EXPERIMENTAL|Screening (anal cytology collection)|Patients undergo anal cytology collection using 2 NF swabs and 1 Dacron swab for analysis via Pap staining, HPV genotyping, and PCR.
62283287|NCT00772447|EXPERIMENTAL|AZ drug|Daptomycin
62083896|NCT05540691|EXPERIMENTAL|group 1|Intraoperative intervention with noise-canceling earphones was performed to isolate the noise
62283288|NCT00772447|ACTIVE_COMPARATOR|Comparator|Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin
62283289|NCT01481896||Metal-on-Metal Total Hip Arthroplasties|Consecutive series of patients who had metal-on-metal primary total hip arthroplasty performed with DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium alloy femoral heads.
62283290|NCT06548659|EXPERIMENTAL|intervention group|"Students who agreed to participate in the study and met the inclusion criteria were divided into two groups, intervention and control groups, using a computer-based randomized program. 8 people who did not attend the lecture were not included in the continuation of the study. Randomization occurred among 198 individuals. The intervention group was trained in groups of 10 people with screen-based simulation in the computer laboratory. A pilot study was conducted with the first group. No negative feedback was received. Pilot study group data were also included in the study.~20 days after the training they received through simulation, the Student Satisfaction and Learning Self-Confidence Scale used in Simulation Training and the Self-Efficacy Scale in Drug Administration in Children were re-administered to Nursing Students. It was applied to both groups through face-to-face interview technique and survey."
62650654|NCT05994742|EXPERIMENTAL|Arm 4: Psychosocial package|"Caregiver-child pairs will receive a low-cost, co-designed intervention to strengthen caregiver support, enhance income generation and promote child play. This is delivered over 12 weeks and comprises:~i) The Friendship Bench, developed as a low-cost psychological intervention utilising problem-solving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders.~ii) Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities in a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards.~iii) Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma, HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours."
62650655|NCT05994742|EXPERIMENTAL|Arm 5: Antimicrobial package + reformulated RUTF + psychosocial package|A combination of all interventions from arms 2, 3 and 4, plus standard care delivered for 12 weeks.
62650656|NCT03356093||Patients with head and neck cancer|No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
62653071|NCT03652896|EXPERIMENTAL|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
62459442|NCT01994525|OTHER|Cohort 1: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
62459443|NCT01994525|EXPERIMENTAL|Cohort 2: PfRAS-infected|"3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
62459444|NCT01994525|PLACEBO_COMPARATOR|Cohort 2: Noninfected|"Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
62459445|NCT01994525|OTHER|Cohort 2: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
62459446|NCT01994525|EXPERIMENTAL|Hyperimmunity PfRAS-infected|"Cohort 1 sub-cohort~3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.~Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)"
62653072|NCT00388999|OTHER|0 mg/kg|
62653073|NCT00388999|OTHER|0.5 mg/kg|
62653074|NCT00388999|OTHER|1.0 mg/kg|
62283291|NCT06548659|NO_INTERVENTION|control group|"The subject of drug administration in children was explained to all participating students using the traditional narrative method.~Students who agreed to participate in the study and met the inclusion criteria were divided into two groups, intervention and control groups, using a randomized program. Randomization occurred among 198 individuals. The control group was not given training via simulation at this stage of the study and ended with the training that both groups received in step 2.~Student Satisfaction and Self-Confidence in Learning Scale and Nursing Students Self-Efficacy Scale for Medication Administration in Children were re-administered to both groups and the results were obtained. analyzed. After the data collection process was completed, the control group was also given medication administration training to children through simulation."
62283292|NCT03883737|EXPERIMENTAL|Group 1: PNM in pain knee|participants in whom PNM will be applied to the femoral nerve of the pain knee
62459447|NCT04452734|ACTIVE_COMPARATOR|Control Group|
62650657|NCT01799889|EXPERIMENTAL|CLL, Entospletinib MM/SDD|Participants with CLL, receive original formulation (mono-mesylate \[MM\]) of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib (spray dried dispersion \[SDD\]) 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62083897|NCT05540691|NO_INTERVENTION|group 2|After general anesthesia, the intervention of wearing noise-canceling earphones was not given
62083898|NCT02415218|EXPERIMENTAL|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
62083899|NCT00682695||1|"Participants who have had a hemorrhagic stroke at University of Maryland, University of Cincinnati, Massachusetts General Hospital, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of the patient or legal representative to provide informed consent. Racial/ethnic category meets one of the following: African American, Caucasian or Hispanic.~Healthy volunteers who are matched to the study cases with hemorrhagic stroke within +/- 5 years of age, same gender and same race."
62083900|NCT04047069|OTHER|Control|Awareness Training
62083901|NCT04047069|EXPERIMENTAL|Intervention group|"* Awareness Training~* Person-Centered Occupational Therapy Intervention"
62083902|NCT01914367|ACTIVE_COMPARATOR|Cervarix group|One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme.
62083903|NCT01914367|ACTIVE_COMPARATOR|Gardasil Group|One sib of each twin pair will be given Gardasil according to the 0, 1, 6 month vaccination scheme.
62083904|NCT04253197|OTHER|Morbidly adherent placenta|This arm was given stage according to ultrasound features.
62083905|NCT00553111|EXPERIMENTAL|1|pre survey, intervention, post test survey
62083906|NCT00553111|NO_INTERVENTION|2|pre test survey and post test survey
62083907|NCT00553111|EXPERIMENTAL|3|video intervention and post test survey
62083908|NCT00553111|NO_INTERVENTION|4|post test survey
62083909|NCT06352515||Group I|Patients with newly diagnosed, active, untreated ulcerative colitis
62083910|NCT06352515||Group II|Ulcerative colitis patients on non-biologic immunosuppressive drugs.
62083911|NCT06352515||Group III|Ulcerative colitis patients on established biological treatment.
62083912|NCT06352515||Group IV|Age- and sex-matched healthy controls.
62083913|NCT00508339||1|Patients with a diagnosis of soft tissue sarcoma.
62083914|NCT04427891||Group I|"Patients undergoing emergency surgery due to perforated diverticulitis with peritonitis.~No intervention, samples from abdominal fluid, blood, tissue, feces"
62283293|NCT03883737|EXPERIMENTAL|Group 2: PNM in non-pain knee|participants in whom PNM will be applied to the femoral nerve of the non-pain knee
62459448|NCT04452734|EXPERIMENTAL|Study Group|
62459449|NCT04448678|EXPERIMENTAL|HIEP intervention|Participants will be randomized to receive the insurance navigation intervention from patient navigators, which includes four, one hour long, educational learning sessions. Randomization will be done by age at diagnosis and site.
62083915|NCT04427891||Group II|Patients with colorectal cancer undergoing elective surgery. No intervention. Samples as for Group I
62083916|NCT04427891||Group III|Patients with mild diverticulitis, not undergoing surgery. No intervention. Samples from blood and feces.
62083917|NCT06292624|EXPERIMENTAL|Intermittent vacuum therapy + Cycling exercise|Participants received 12 IVT sessions of 30 minutes combined with 20 minutes of cycling exercise during the 6-week period.
62083918|NCT02739243|EXPERIMENTAL|Tailored group intervention|"Participants take part in the tailored group intervention which consists of five 90-minute group sessions over eight weeks. The sessions are in the form of structured group talk/discussions following specific themes:~Session 1 - Coping and acceptance: identification of common themes from participants' feedback, provision of information about support services, mindfulness practices~Session 2 - Distress: introduction of the distress model, identification of resources, breathing practices~Session 3 - Handling of stressful situations: individual identification in tandems, discussion of common pitfalls in the group~Session 4 - Self-care: inspection of individual daily routines, group collects positive experiences with windows for self-care~Session 5 - Feedback and outlook: stabilisation, retrospective reflection on the group experience and its benefits and, if applicable, potential adverse events"
62083919|NCT02739243|ACTIVE_COMPARATOR|Treatment as usual|Participants are provided with brief information in a leaflet, about the possibilities for individual counselling including referral to the local outpatient cancer counselling centre providing client-centred counselling and financial social work.
62083920|NCT05552690|OTHER|Thalassemia screening positive|In this study only 1 group of participants. No comparative. Only description
62083921|NCT01314781|EXPERIMENTAL|solifenacin 5mg, PFMT and WBVT|Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
62083922|NCT01314781|ACTIVE_COMPARATOR|solifenacin 5mg|Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
62083923|NCT04079283||Monotherapy|Patients who has received mono-therapy of immune checkpoint inhibitor.
62083924|NCT04079283||Combined therapy|Patients who has received immune checkpoint inhibitor combining chemotherapy.
62083925|NCT02033460|EXPERIMENTAL|Manual therapy, education and Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added an exercise protocol :~In the fifth session we explained the patients to perform :~* Five sets of isometric contraction of the deep neck flexors for 8-10 seconds.~* Five sets of isometric contraction of the neck extensors for 6-8 seconds~* Neural self-mobilization and stretching held for 10 - 12 seconds for the levator scapulae and the trapezius muscle.~In the sixth session the patient repeat all the exercises from the previous session and also with the help of a theraband made :~• Isotonic contraction of the head, performing 3-4 sets of 8-10 repetitions."
62083926|NCT02033460|ACTIVE_COMPARATOR|Manual Therapy and Education|"The protocol used for therapeutic education consisted of two approaches:~Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective."
62459450|NCT04448678|ACTIVE_COMPARATOR|Usual Care|"Participants will be randomized to receive standard navigation provided by patient navigators (usual care)."
62459451|NCT02664584||Cross-sectional cohort|Cohort who took part in the cross-sectional study (n=5186)
62083927|NCT02033460|ACTIVE_COMPARATOR|Manual Therapy|Manual therapy will consist on Traction oscillatory, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
62283294|NCT00620243|EXPERIMENTAL|1|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
62283295|NCT04105777||Standard Low Glucose Parenteral Nutrition using Eurotubes®|Patients receive standard PN reduced in glucose in Eurotubes®.
62283296|NCT04105777||Standard Parenteral Nutrition using Eurotubes®.|Patients receive standard PN in Eurotubes®.
62283297|NCT04105777||Standard Parenteral Nutrition using 2/3-chamber bags|Patients receive PN according to the routine used by the participating site.
62283298|NCT02892266||Adolescent Transplant Recipients|"1. Questionnaire battery at enrollment (Participants and their parents/guardians)~2. Clinical data from patient's chart (6 months of retrospective data \& 6 months of prospective tacrolimus trough level data)"
62083928|NCT05742776||Patient Group|CTS Patients
62083929|NCT05742776||Control Group|Healthy Individuals
62283299|NCT00200850|ACTIVE_COMPARATOR|Low dose SLIT|Low dose SLIT
62083930|NCT03740074|EXPERIMENTAL|PAI|Participants will utilize a MIO Slice wearable device to generate a PAI score, which will be utilized to provide feedback and incentive for physical activity.
62083931|NCT01835561|EXPERIMENTAL|Part 1: Severe liver disease and healthy volunteer match|Subjects with severe liver disease (Group 2) and healthy volunteer subjects (Group 1) matched to the subjects with liver disease
62083932|NCT01835561|EXPERIMENTAL|Part 2: Mild and moderate Liver disease|Subjects with moderate (Group 3) and/or mild (Group 4) liver disease
62283300|NCT00200850|ACTIVE_COMPARATOR|High dose SLIT|High dose SLIT
62283301|NCT00200850|PLACEBO_COMPARATOR|Placebo|Placebo
62283302|NCT02796105|EXPERIMENTAL|Progevera|Progevera 10 mg
62283303|NCT02796105|ACTIVE_COMPARATOR|Orgalutran|Orgalutran 0.25 mg
62283304|NCT02567929|ACTIVE_COMPARATOR|propofol group|The patient who anesthetized by using propofol.
62283305|NCT02567929|ACTIVE_COMPARATOR|sevoflurane group|The patient who anesthetized by using propofol
62283306|NCT03542058|EXPERIMENTAL|Treatment Group|Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
62283307|NCT03542058|NO_INTERVENTION|Control Group|Study participant will not receive any cardiac medication, apart from standard cancer care.
62283308|NCT05883280|EXPERIMENTAL|Binaural beats group|Starting 30 minutes before the end of the surgery, a continuous pure tone binaural beat is delivered through headphones to the pediatric patient, with a frequency of 432 Hz in the left ear and 420 Hz in the right ear.
62283309|NCT05883280|NO_INTERVENTION|Silence group|The headphones are placed on the pediatric patient, but there is no sound in the audio file being played.
62283310|NCT03442634|EXPERIMENTAL|Early Hydration Group|this study group will get 200 ml of sugar free water within 1 hour after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Early Oral Hydration
62283311|NCT03442634|ACTIVE_COMPARATOR|Traditional Hydration Group|this study group will get 200 ml of sugar free water after 6 hours after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Traditional Oral Hydration
62283312|NCT01187537|EXPERIMENTAL|Continuous Femoral Nerve Block|
62283313|NCT01187537|ACTIVE_COMPARATOR|Single-Inj Nerve Block with IV PCA|
62283314|NCT01187537|ACTIVE_COMPARATOR|IV PCA|
62459452|NCT02664584||Cross-sectional cohort + follow-up|Cohort who took part in both the cross-sectional and follow-up study (planned n=500 (on-going))
62459453|NCT06485375||Patients|Patients requiring orthopedic/orthodontic
62459454|NCT05015348|EXPERIMENTAL|O3A arm|participants of this arm will be provided with omega-3 PUFA
62459455|NCT05015348|PLACEBO_COMPARATOR|placebo arm|participants of this arm will be provided with same amount of palm oil as placebo
62459456|NCT01551095|EXPERIMENTAL|PEGJ|Patients in this arm will receive self-propelled balloon PEGJ tube.
62459457|NCT01452451|PLACEBO_COMPARATOR|Placebo|Placebo
62083933|NCT05700799|EXPERIMENTAL|Intervention|This is a single arm pilot intervention.
62459458|NCT01452451|ACTIVE_COMPARATOR|HM11260C|HM11260C
62459459|NCT00515645|EXPERIMENTAL|1|
62459460|NCT01376843||Health care workers|health care workers who performed TST or Quantiferon-TB Gold In tube assay before
62459461|NCT01386047|EXPERIMENTAL|iCPR randomized providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. The iCPR tool will automatically trigger for providers randomized into the iCPR intervention arm when they initiated an encounter for a patient that meets the criteria for possible evaluation of Strep Pharyngitis or Pneumonia.
62283315|NCT02583334|EXPERIMENTAL|Verum Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).
62283316|NCT02583334|SHAM_COMPARATOR|Sham Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture (Device: Streitberger device) three times a week, for 4 weeks (12 treatment in total).
62283317|NCT05233657|EXPERIMENTAL|JX11502MA 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received JX11502MA capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water.
62283318|NCT05233657|PLACEBO_COMPARATOR|Placebo 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received placebo capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water..
62283319|NCT01239355|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62083934|NCT04015882|ACTIVE_COMPARATOR|exercise|the exercise group will applied virtual reality exercises by Nintendo Wii Fit Plus System Game Console.
62083935|NCT04015882|NO_INTERVENTION|control|No exercise applied the control group.
62083936|NCT05398497|EXPERIMENTAL|Early stage breast cancer up to 2.5 cm|Patients treated with Cryocare SL followed by traditional surgery, radiotherapy and adjuvant systemic therapy.
62083937|NCT00026637|ACTIVE_COMPARATOR|Sertraline|
62083938|NCT00026637|ACTIVE_COMPARATOR|CBT|
62459462|NCT01386047|NO_INTERVENTION|Control providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. These providers will conduct visits for Strep Pharyngitis and Pneumonia in their manner (usual care).
62459463|NCT01451762|PLACEBO_COMPARATOR|Placebo|.9 normal saline IV
62459464|NCT01451762|ACTIVE_COMPARATOR|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
62459465|NCT01451762|ACTIVE_COMPARATOR|50 mg diphenhydramine IV|50 mg diphenhydramine IV administered before surgery
62459466|NCT02352298|EXPERIMENTAL|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
62459467|NCT02352298|ACTIVE_COMPARATOR|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
62083939|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
62083940|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
62283320|NCT01484782|EXPERIMENTAL|Interactive Voice Response (IVR) calls|Weekly automated telephone assessment and behavior change calls focused on blood pressure management. The experimental group will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
62283321|NCT01484782|NO_INTERVENTION|Usual care|This group received results of blood pressure readings. PCP referrals. Educational materials about hypertension and self-management. At follow-up, patients received home blood pressure monitoring cuffs.
62283322|NCT02581254|EXPERIMENTAL|Thin Wire Snare Arm|Use of Thin Wire Snare to resect polyp \<10mm
62283323|NCT02581254|EXPERIMENTAL|Thick Wire Snare Arm|Use of Thick Wire Snare to resect polyp \<10mm
62283324|NCT04275115|EXPERIMENTAL|Foliglurax|Foliglurax, iv midazolam and cocktail of CYP450 probe substrates
62283325|NCT02298933|EXPERIMENTAL|Eculizumab|1200 mg IV infusion over 30-40 min
62283326|NCT01056445|ACTIVE_COMPARATOR|carotid stenting and hemodynamic instability|27 patients undergone carotid stenting
62283327|NCT01056445|ACTIVE_COMPARATOR|carotid stenting without hemodynamic instability|no hemodynamic instability after carotid stenting
62283328|NCT01567098|EXPERIMENTAL|SILS appendectomy|Single incision laparoscopic appendectomy
62283329|NCT01567098|ACTIVE_COMPARATOR|3 Ports appendectomy|performing appendectomy through conventional 3 incisions on the abdomen
62283330|NCT02173119||HCC patients having MRI post-TACE|HCC patients who have undergone conventional lipiodol based chemoembolization.
62083941|NCT06493500|EXPERIMENTAL|Eggshell derived Nano-hydroxyapatite (n-HAp) with Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
62283331|NCT01836679|EXPERIMENTAL|Arm 1|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
62283332|NCT01836679|PLACEBO_COMPARATOR|Arm 2|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
62283333|NCT03728946|EXPERIMENTAL|Liposomal Bupivacaine Interscalene Block|Liposomal bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
62083942|NCT06493500|EXPERIMENTAL|Eggshell derived Nano-hydroxyapatite (n-HAp) without Fluoride containing toothpaste|patients would be instructed totreat their teeth for 5 min twice a day with the provided toothpaste.
62283334|NCT03728946|NO_INTERVENTION|Bupivacaine Interscalene Block|Bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
62283335|NCT03452566|EXPERIMENTAL|ingenol mebutate gel|Phase 1/2, always 3 consecutive days, with 24 hours interval, dosage from 5 mg/cm2 to 18 mg/cm2 in a 3+3 design.
62283336|NCT00652353|EXPERIMENTAL|Intervention|Participants will be given a standardized information sheet providing a mnemonics to help remember the Ottawa Ankle and foot Rules.
62283337|NCT00652353|PLACEBO_COMPARATOR|0|control group
62083943|NCT06493500|ACTIVE_COMPARATOR|Commercially available Fluoride containing toothpaste (Sensodyne Rapid Relief)|patients would be instructed totreat their teeth for 5 min twice a day with the provided toothpaste.
62083944|NCT04323644||Cohort 1|Patients with COVID-19 infection undergoing surgery
62283338|NCT01744132|EXPERIMENTAL|Aim 3: Contract|Half of patients screened in the pharmacy are selected to a contract group, which encourages patients to review the results of the screen, share the results with their PCP, and schedule and attend a follow-up appointment with an ophthalmologist if the results are abnormal.
62283339|NCT01744132|NO_INTERVENTION|Aim 3: Control|No contract is signed for half of the patients screened in Aim 3.
62083945|NCT04968028|EXPERIMENTAL|ACAF|Participants underwent anterior decompression of Anterior Controllable Antedisplacement and Fusion
62459468|NCT02101541|EXPERIMENTAL|FIRM ablation|"The first part of this within-patient trial investigate the efficacy of focal impulse and rotor modulation in 20 patients with paroxysmal atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring.~The second part consists of 20 patients with persistent or longstanding persistent atrial fibrillation following the same scheme."
62650658|NCT01799889|EXPERIMENTAL|FL, Entospletinib MM/SDD|Participants with FL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62083946|NCT04968028|EXPERIMENTAL|Laminoplasty|Participants underwent posterior decompression of Laminoplasty
62083947|NCT00995358|EXPERIMENTAL|vaccination|
62083948|NCT04916262||TSH < 30uIU/mL group|Clinical information was collected from patients with TSH \< 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
62083949|NCT04916262||TSH ≥ 30uIU/mL group|Clinical information was collected from patients with TSH ≥ 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
62283340|NCT02762513|EXPERIMENTAL|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
62283341|NCT03604185|EXPERIMENTAL|Choir Singing Group|Choir participants will take part in weekly two-hour group choral sessions over the course of fourteen weeks, during which time they will receive pitch training and vocal direction. In addition to the weekly group choir sessions, participants will be offered optional individual online musical and vocal training exercises (up to one hour weekly).
62283342|NCT03604185|ACTIVE_COMPARATOR|Music Appreciation Group|Participants assigned to the music appreciation class will take part in a fourteen week course which will emphasize analytic listening to musical excerpts, which will match the choir class in terms of duration, homework demands, and instructor - both classes will be taught by the same person.
62650659|NCT01799889|EXPERIMENTAL|DLBCL, Entospletinib MM/SDD|Participants with DLBCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62283343|NCT03604185|NO_INTERVENTION|Do-Nothing Control Group|The do-nothing control group will not receive any active training.
62083950|NCT05851989||Neurosurgical treatment|This cohort contains the patients with aneurysmal subarachnoid hemorrhage who received the neurosurgical clipping treatment.
62283344|NCT05977647|ACTIVE_COMPARATOR|Tamsulosin|Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on tamsulosin 0.4 mg once daily, therapy will be given for a maximum of 4 weeks.
62283345|NCT05977647|ACTIVE_COMPARATOR|Silodosin|Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on Silodosin 8 mg once daily. Therapy will be given for a maximum of 4 weeks.
62283346|NCT02596659|EXPERIMENTAL|The experimental group|Participants in the experimental group received radial extracorporeal shock wave therapy (rESWT) plus physical therapy for 3 weeks.
62283347|NCT02596659|SHAM_COMPARATOR|The control group|Participants in the control group received sham shockwave therapy plus physical therapy for 3 weeks.
62283348|NCT02128126|EXPERIMENTAL|ISA101/ISA101b|The maximum total treatment duration for a patient is six cycles (1 cycle is 21 days) for a total of 18 weeks. On day 15 of cycles 2, 3 and 4 patients are to receive the vaccination scheme of ISA101/ISA101b. Patients will be vaccinated with a fixed dose of ISA101/ISA101b every three weeks for a total of three rounds of vaccination. Four dose levels of ISA101 have been tested. ISA101b will be tested in bridging cohorts.
62459469|NCT01704742||No treatment|
62283349|NCT03169426|EXPERIMENTAL|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.~Intervention: taking beta-blocker"
62283350|NCT03169426|NO_INTERVENTION|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
62459470|NCT01754025||Cancer patients with T790M|Have a diagnosis of cancer of any type. Have an EGFR T790M mutation identified on either genotyping of their cancer at diagnosis OR on quantitative plasma genotyping with evidence of high level (\>40% allelic fraction) EGFR T790M. OR another EGFR mutation previously reported as germline detected on tumor genotyping of their cancer.
62459471|NCT01754025||Relatives of Carriers|Have a relative known to carry a germline EGFR mutation (either T790M or other novel germline EGFR mutation)
62459472|NCT01754025||Individuals known to be carriers|Have a known germline EGFR mutation (either T790M or other novel germline EGFR mutation)
62459473|NCT03830164|EXPERIMENTAL|Treatment (atorvastatin, vitamin E, pentoxifylline)|Patients receive atorvastatin PO QD for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning week 7, patients receive atorvastatin PO QD, vitamin E PO QD, and pentoxifylline PO TID for up to 12 months in the absence of disease progression or unacceptable toxicity.
62459474|NCT02745522|EXPERIMENTAL|Oxytocin|Oxytocin nasal spray
62459475|NCT02745522|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
62459476|NCT03190486|EXPERIMENTAL|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
62283351|NCT00481845|EXPERIMENTAL|Vandetanib + Anastrozole|Vandetanib and Anastrozole as neoadjuvant therapy
62459477|NCT03190486|EXPERIMENTAL|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
62459478|NCT03190486|EXPERIMENTAL|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
62459479|NCT03190486|EXPERIMENTAL|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
62459480|NCT00524758|EXPERIMENTAL|Ologen in Trabeculectomy|Ologen in Trabeculectomy
62459481|NCT00524758|ACTIVE_COMPARATOR|MMC in Trabeculectomy|MMC in Trabeculectomy
62459482|NCT00149500|EXPERIMENTAL|Coaching group for lifestyle changes|Patients received monthly phone calls with coaching for lifestyle changes over 2 years.
62459483|NCT00149500|NO_INTERVENTION|Routine pediatric care|This group receives routine care with their pediatrician.
62459484|NCT05891990|EXPERIMENTAL|Intervention group|"sticky tooth preparation:~* patient's venous blood will be collected using a 21 g needle with a butterfly handle.~* The blood in the test tubes will be centrifuged at 700 rpm for 3 min for women and 4 min for men because of a different hematocrit.~* The liquid PRF fraction will be collected using a sterile syringe. It gently will be mixed with the demineralized dentin granules and allowed for five-ten minutes for polymerization in order to produce a sticky tooth."
62459485|NCT05891990|ACTIVE_COMPARATOR|Control group|"Autogenous demineralized dentin graft preparation~* Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present), using a high-speed fine finishing stone and saline irrigation.~* The pulp will be removed, using a root canal instrument. Subsequently, the remaining dentin will be cut into pieces. These pieces of dentin will be ground using a bone mill to produce dentin particles.~* The sorted particles will be immersed in 70% ethanol and 4% H2O2 in a sterile container to remove any soft tissue remnants, bacteria, and smear layer.~* Tooth particles will be demineralized using 0.6N HCl for 30 minutes to expose the dentine organic matrix.~* After demineralization, the materials will be washed with phosphate-buffered saline (PBS) and dried with sterile gauze."
62459486|NCT01774123||Healthy|Healthy controls
62459487|NCT01774123||MS-ON|Multiple sclerosis with optic neuritis
62459488|NCT01774123||MS-NON|Multiple sclerosis without optic neuritis
62459489|NCT05128981|OTHER|MI-CBT via the Internet|The MI-specific CBT will consist of 8 modules delivered via the Internet with home assignments that can be reviewed and reported in the research groups secure platform.
62459490|NCT05104983|EXPERIMENTAL|Sirolimus|Sirolimus
62459491|NCT05104983|PLACEBO_COMPARATOR|Placebo|Placebo
62459492|NCT04382937|EXPERIMENTAL|P1101 + Ribavirin|P1101 400 µg SC Q2W
62083951|NCT05851989||Endovascular treatment|This cohort contains the patients with neurysmal subarachnoid hemorrhage who received the endovascular coiling treatment. Other endovascular treatments which will be included as well are flow diverter procedures, Woven EndoBridge (WEB) devices and stent assisted coiling.
62459493|NCT04382937|ACTIVE_COMPARATOR|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W
62283352|NCT00481845|ACTIVE_COMPARATOR|Anastrozole|Anastrozole as neoadjuvant therapy
62283353|NCT00888238|EXPERIMENTAL|Sitagliptin/Sitagliptin/Placebo|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
62283354|NCT00888238|EXPERIMENTAL|Sitagliptin/Placebo/Sitaglipitin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
62283355|NCT00888238|EXPERIMENTAL|Placebo/Sitagliptin/Sitagliptin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
62283356|NCT00757731|EXPERIMENTAL|Minalcipran 100 mg|
62650660|NCT01799889|EXPERIMENTAL|MCL, Entospletinib MM/SDD|Participants with MCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62283357|NCT00757731|EXPERIMENTAL|Minalcipran 150 mg|
62283358|NCT00757731|EXPERIMENTAL|Minalcipran 200 mg|
62283359|NCT03324360|EXPERIMENTAL|Control Participants Part I|A MRI with injection of hyperpolarized 13C pyruvate.
62283360|NCT03324360|EXPERIMENTAL|Intracranial Metastasis Part II|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
62459494|NCT04848948|EXPERIMENTAL|F.X.Mayr & Biofeedback|two weeks of F.X. Mayr diet and biofeedback
62459495|NCT04848948|ACTIVE_COMPARATOR|F.X.Mayr|two weeks of F.X. Mayr diet
62459496|NCT04848948|EXPERIMENTAL|VLCD & Biofeedback|two weeks of very low calorie diet and biofeedback
62459497|NCT04848948|ACTIVE_COMPARATOR|VLCD|two weeks of very low calorie diet
62459498|NCT00002725|EXPERIMENTAL|Arm I|Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
62083952|NCT02899598|EXPERIMENTAL|Pregnant women|
62650661|NCT01799889|EXPERIMENTAL|non-FL iNHL, Entospletinib MM/SDD|Participants with non-FL iNHL (ie, participants with LPL/WM, SLL, or MZL), receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62083953|NCT02210910|SHAM_COMPARATOR|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
62083954|NCT02210910|ACTIVE_COMPARATOR|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair, and placement of the InSpace™ system.
62083955|NCT00585702||1|Pregnant women with bipolar disorder
62083956|NCT00585702||2|Pregnant women without bipolar disorder
62083957|NCT04421378|EXPERIMENTAL|Phase 1: Arm A: Selinexor+Radiation Therapy|Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.
62283361|NCT03324360|EXPERIMENTAL|Intracranial Metastasis Part III|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate1-5 days following radiation treatment.
62283362|NCT01821300||Down syndrome|No intervention occurred as this was a cross sectional observational study.
62283363|NCT01821300||Control|No intervention occurred as this was a cross sectional observational study.
62283364|NCT04663178|EXPERIMENTAL|Warm Salt Water Foot Bath Group|"In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale (PFS) were applied to the patients. A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to patients.~Each patient received iodine salt and a liquid thermometer to measure the temperature of the water. The patients were asked 1 day after the treatment to apply warm salt water bath of 41-42ºC once a day for 20 minutes for 7 days.~Subsequently, the fatigue level of the patients was evaluated 30 minutes after having a warm saltwater foot bath and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. In the last interview PFS was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
62459499|NCT00482521|EXPERIMENTAL|CC-4047|
62459500|NCT00929500|EXPERIMENTAL|MAST program|Mixed Aerobic and Strength Training program (MAST): Each exercise session consisted of 10 minutes of warm-up, 15-30 minutes of interval aerobic training by cycle ergometer according to the program, 20 minutes of strength training exercises, and 10 minutes of cool-down by stretching.
62459501|NCT00929500|NO_INTERVENTION|UC|Usual Care (UC) with Educational Lectures: No exercise sessions.
62650662|NCT01799889|EXPERIMENTAL|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 100 mg|Participants with CLL, who are prior B-cell receptor (BCR) inhibitor naive, receive new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62459502|NCT00528242|EXPERIMENTAL|1|SLx-2101
62459503|NCT00528242|PLACEBO_COMPARATOR|2|Matching Placebo Dose
62083958|NCT04421378|ACTIVE_COMPARATOR|Arm A Control: Temozolomide+Radiation Therapy|Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m\^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.
62083959|NCT04421378|EXPERIMENTAL|Phase 1: Arm B: Selinexor+Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m\^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period. Participants will continue selinexor weekly per dose level assigned until PD.
62459504|NCT02962297|EXPERIMENTAL|treatment group|Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
62459505|NCT02962297|PLACEBO_COMPARATOR|placebo group|A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
62459506|NCT01578694|OTHER|Patient Group|The patient group has been diagnosed by the surgeon as having femoro-acetabular impingement (FAI) of the hip and will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
62459507|NCT01578694|OTHER|Control healthy volunteers|The control group has not been diagnosed with any hip problems, but will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
62461814|NCT03411330|ACTIVE_COMPARATOR|Group H (Hyaluronidase added to local anaesthetics)|"group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve"
62650663|NCT01799889|EXPERIMENTAL|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 200 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 200 mg (1 × 200 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62083960|NCT04421378|ACTIVE_COMPARATOR|Arm B Control: Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 75 mg/m\^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.
62083961|NCT04421378|EXPERIMENTAL|Arm C: Selinexor+Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m\^2 of lomustine or 150-200 mg/m\^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
62083962|NCT04421378|ACTIVE_COMPARATOR|Arm C Control: Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 110 mg/m\^2 of lomustine or 200 mg/m\^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
62083963|NCT04421378|EXPERIMENTAL|Arm D: Selinexor+Bevacizumab|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.
62083964|NCT04421378|EXPERIMENTAL|Arm E: Selinexor+TTField|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
62650664|NCT01799889|EXPERIMENTAL|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 400 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62650665|NCT01799889|EXPERIMENTAL|CLL (Non-Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to Bruton tyrosine kinase (BTK) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62650666|NCT01799889|EXPERIMENTAL|CLL (Non-Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to phosphatidylinositol 3-kinase (PI3K) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62083965|NCT00743743|EXPERIMENTAL|1|receive 1 Longevinex brand capsule daily containing 215 mg of resveratrol active ingredient
62083966|NCT00743743|PLACEBO_COMPARATOR|2|Receive 1 capsule daily for 52 weeks containing placebo for comparison to experimental arm
62083967|NCT05924490|EXPERIMENTAL|Real-time strategy-based videogame training|Participants played a real-time strategy-based videogame in laboratory setting, Rise of Nations, for 2 hours a day, two days per week, for 5 weeks.
62283365|NCT04663178|NO_INTERVENTION|Control Group|"A training booklet about chemotherapy-induced fatigue~In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale were applied to the patients.~A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to experimental group.~Subsequently, the fatigue level of the patients was evaluated and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. The patients were evaluated in the evening. In the last interview conducted with the patient on the 7th day, Piper's Fatigue Scale was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
62283366|NCT04173741||Leg Rise Position - 3 Minutes|Patients who stayed in passive leg rise position for 3 minutes
62083968|NCT05924490|ACTIVE_COMPARATOR|Crystallized intelligence training|Participants completed a series of crossword puzzles each week, for 5-6 weeks. Training sessions were completed at the participants' home or area of preference. Participant received a periodic phone call (2 times per week) from research staff to update any notes or details regarding participants' study progress.
62283367|NCT04173741||Leg Rise Position - 1 Minute|Patients who stayed in passive leg rise position for 1 minute
62283368|NCT03903380|ACTIVE_COMPARATOR|MT treatment + Usual care exercise|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where usual care exercise protocol will be introduced.~The manual therapy protocol that will be used is the one proposed by Beltrán-Alacreu et al. (2015). The mentioned protocol consist of specific passive movements in the facet cervical joints, global mobilization of the cervical spine and high-velocity technique in the thoracic región."
62459508|NCT03914066|EXPERIMENTAL|Group treatment in primary care|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
62459509|NCT05901948||Asherman Patients|Patients diagnosed with Asherman syndrome based on patient complaint of hypomenorrhea or amenorrhea and hysterosalpingography.
62459510|NCT00620490|EXPERIMENTAL|1|Ropivacaine 0.5% 0.1 ml/kg per hour
62650667|NCT01799889|EXPERIMENTAL|CLL (Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to BTK inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62650668|NCT01799889|EXPERIMENTAL|CLL (Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to PI3K inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
62650669|NCT01005381|EXPERIMENTAL|Small Particle Size Calcium Carbonate|Subjects are given small particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
62650670|NCT01005381|ACTIVE_COMPARATOR|Large Particle Size Calcium Carbonate|Subjects are given a large particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
62650671|NCT01005381|PLACEBO_COMPARATOR|Calcium Placebo|Subjects are given two placebo tablets daily, which are identical to the large and small particle size calcium carbonate supplements.
62650672|NCT01005381|ACTIVE_COMPARATOR|No Vitamin D supplement|Subjects are given calcium carbonate supplement once daily (325 mg/d from supplement).
62650673|NCT01005381|EXPERIMENTAL|Vitamin D supplement|Subjects are given a calcium supplement once daily (325 mg/d from supplement) with 1000 IU/d vitamin D supplement.
62650674|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
62650675|NCT04894058|ACTIVE_COMPARATOR|10 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 10 ° reverse Trendelenburg position
62459511|NCT00620490|PLACEBO_COMPARATOR|2|
62459512|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
62283369|NCT03903380|EXPERIMENTAL|MT treatment + Augmented reality (AR) exercises|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where AR will be applied as an exercise method.~The same manual therapy protocol will be used for both groups.~For this group, the Microsoft HoloLens Development Edition device will be used, which is a holographic device that allows us to interact with high definition holograms in its environment. The application that will be used will be the Roboraid software, this app is a shooter, which requires the cervical movement to move the pointer and be able to play."
62283370|NCT02072473||Unsuccessful right-sided AVNRT ablation|Patients with unsuccessful right-sided slow pathway ablation attempt, will be candidates for Coronary sinus / left-sided slow pathway ablation.
62083969|NCT00219141|EXPERIMENTAL|Aliskiren 300 mg|Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan placebo. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan placebo. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
62083970|NCT00219141|ACTIVE_COMPARATOR|Losartan 100 mg|Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
62083971|NCT00219141|EXPERIMENTAL|Aliskiren/losartan 300/100 mg|Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
62083972|NCT06268639|EXPERIMENTAL|Osseodensification in Dental Implant Surgery|The arm involves participants undergoing dental implant surgery with the use of osseodensification drills. This technique is intended to enhance bone density and improve the primary stability of the implants by compacting bone rather than removing it during the osteotomy process. The study aims to assess the impact of osseodensification on bone density at the implant sites, comparing pre-operative and post-operative bone density measurements to evaluate the effectiveness of this intervention.
62083973|NCT03391713|NO_INTERVENTION|Control|No exposure to waiting room posters
62083974|NCT03391713|ACTIVE_COMPARATOR|Intervention|During the second half of the study (two weeks), there will be an education poster in the waiting room of the clinic, fashioned after the Face, Arms, Speech, Time (FAST) poster developed by the American Heart Association (AHA), but in Malay.
62083975|NCT01327937|ACTIVE_COMPARATOR|Apligraf Group|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
62083976|NCT01327937|PLACEBO_COMPARATOR|Standard of Care Dressing Group|Standard of care dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
62083977|NCT00232843|EXPERIMENTAL|1|Cordis SMART™ nitinol self-expanding stent.
62083978|NCT00232843|ACTIVE_COMPARATOR|2|balloon angioplasty
62083979|NCT01007552|EXPERIMENTAL|Gemcitabine, Capecitabine and Bevacizumab|Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
62283371|NCT02935309|EXPERIMENTAL|Pre-Surgery Chemotherapy/Radiotherapy|Pre-surgery chemotherapy and external radiation therapy. Dose escalation of Lenvatinib; fixed dose Capecitabine; Radiotherapy. Lenvatinib and capecitabine will be started on day 1 with radiation and will be discontinued on the last day of radiation. Surgical resection should occur between 6 - 10 weeks after the participant completes preoperative lenvatinib, capecitabine, and radiation therapy. Postoperative chemotherapy after surgery will be given at investigator's discretion.
62283372|NCT06028633|EXPERIMENTAL|Arm I|Participants will receive pembrolizumab IV 200 mg D1 every 3 weeks, lenvatinib 8 mg orally every day, albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks,until disease progression, intolerable toxicity, investigator decision, or completion of 35 cycles(for pembrolizumab) and 4-6 cycles(for albumin-bound paclitaxel).
62283373|NCT01893333|EXPERIMENTAL|Nerve sparing radical hysterectomy group|"1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
62283374|NCT01893333|ACTIVE_COMPARATOR|Radical hysterectomy group|Conventional radical hysterectomy
62283375|NCT03932552|ACTIVE_COMPARATOR|Control|Personalized nutritional therapy
62283376|NCT03932552|EXPERIMENTAL|Exercise|Aerobic exercise + Personalized nutritional therapy
62283377|NCT03897738|EXPERIMENTAL|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
62283378|NCT03897738|PLACEBO_COMPARATOR|Placebo|"Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~Placebo capsules are identical to Amberen and Smart B capsules."
62459513|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
62283379|NCT05130307|EXPERIMENTAL|Treatment Order 1|Treatment order 1: Low Tech (less interactive) Virtual Reality for 1st pain stimulus+ High Tech for 2nd pain stimulus
62283380|NCT05130307|ACTIVE_COMPARATOR|Treatment Order 2|Treatment order 2: High Tech VR (more interactive) for 1st pain stimulus + Low Tech for 2nd pain stimulus.
62283381|NCT02940067|EXPERIMENTAL|MedEx|This group will receive nutritional supplementation (based on components of the MEDiterranean diet) and supervised EXercise training for four weeks - hence the trial name, MedEx.
62283382|NCT02940067|NO_INTERVENTION|Standard Care|This group will follow current standard preoperative care before scheduled pancreatic resection.
62283383|NCT02056158||HIV Negative Early COPD Smokers|HIV Negative Early COPD Smokers
62283384|NCT02056158||HIV Negative COPD Smokers|HIV Negative COPD Smokers
62283385|NCT02056158||HIV Negative Nonsmokers|HIV Negative Nonsmokers
62283386|NCT02056158||HIV Negative Smokers|HIV Negative Smokers
62283387|NCT02056158||HIV Positive Smokers|HIV Positive Smokers
62283388|NCT02056158||HIV Positive Nonsmokers|HIV Positive Nonsmokers
62283389|NCT02056158||HIV Positive COPD Smokers|HIV Positive COPD Smokers
62283390|NCT02056158||HIV Positive Early COPD Smokers|HIV Positive Early COPD Smokers
62283391|NCT06215833||Group ( p )|This group will undergo anesthesia via total intravenous anesthesia using Propofol in induction and maintenance
62283392|NCT06215833||Group ( s )|This group undergo anesthesia via total inhalational anesthesia using sevoflurane in induction and maintenance
62283393|NCT04360356|EXPERIMENTAL|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
62283394|NCT04360356|ACTIVE_COMPARATOR|Standard care|Oxygen via ventilators
62283395|NCT02912273||Fall Risk Assessment Group|-Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
62283396|NCT01284114|ACTIVE_COMPARATOR|Aliskiren|
62283397|NCT02346188|EXPERIMENTAL|Ferrous fumarate|Tablet formulated as ferrous fumarate, 30 mg. Given once daily for 6 months.
62283398|NCT02346188|EXPERIMENTAL|Zinc oxide|Tablet formulated as zinc oxide, 30 mg. Given once daily by mouth for 6 months.
62283399|NCT02346188|EXPERIMENTAL|Ferrous fumarate and zinc oxide|Tablet, formulated as ferrous fumarate 30 mg plus zinc oxide 30 mg. Given once daily by mouth for 6 months.
62083980|NCT04118985|ACTIVE_COMPARATOR|Self-implementation|Individuals randomized to this group will be given all the materials about cognitive compensations techniques and brain health behavior guidelines and encouraged to implement those on their own.
62283400|NCT02346188|PLACEBO_COMPARATOR|Placebo|Sugar tablet formulated to look like the experimental arms of the study. Given daily by mouth for 6 months.
62283401|NCT03728387|EXPERIMENTAL|osteoarthritis and clinical pilates exercise|34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section.
62283402|NCT06527365|EXPERIMENTAL|VDPHL01 Tablet|
62283403|NCT00814957|EXPERIMENTAL|Open-label|D3 receptor antagonist
62283404|NCT02276586|ACTIVE_COMPARATOR|Group 1|Horizontal Tooth preparation
62283405|NCT02276586|EXPERIMENTAL|Group 2|Vertical tooth preparation
62283406|NCT02029287|EXPERIMENTAL|Subjects with CHF follow-up|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.
62283407|NCT02029287|ACTIVE_COMPARATOR|Subjects with CHF conventional clinic visit|Subjects with standardized treatment according to latest guidelines via conventional visit.
62283408|NCT06405672|OTHER|Endotracheal tube with stylet|The obese patients who will be intubated with stylet in laparoscopic sleeve gastrectomy
62283409|NCT06405672|OTHER|Endotracheal tube alone|The obese patients who will be intubated without stylet in laparoscopic sleeve gastrectomy
62283410|NCT04799561|EXPERIMENTAL|Teleprehabilitation cohort|Patients in this single-arm study will receive multimodal teleprehabilitation.
62283411|NCT00553046||family burden|chronich respiratory failure home ventilated patients
62283412|NCT01970163|EXPERIMENTAL|DermACELL|DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).
62459514|NCT01351688|EXPERIMENTAL|AZD3514|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
62459515|NCT01747603|NO_INTERVENTION|Current management of LPTB|The current pragmatic, but non-systematic, pattern of management of LPTB infants. Growth measurements, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, and basic developmental milestones (as itemized in the Rourke Developmental screening tool) will be recorded by families and primary health care providers as itemized in the Memory Book at the assessments made at the discretion of the health care providers.
62459516|NCT01747603|EXPERIMENTAL|Specialized LPTB Clinic|Additional 6 specialized LPTB follow-up clinic visits attended by pediatricians and neonatologists. Detailed findings from physical examination, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, basic developmental milestones (as itemized in the Rourke Developmental screening tool) and physician recommendations will be recorded at each appointment. These will be compared to those obtained from families and primary health care providers as itemized in the Memory Book.
62459517|NCT04508998|EXPERIMENTAL|Patients with microvascular angina|Patients with clinical features of microvascular angina screened for the main PRIZE trial however not possessing the PHACTR1 GG minor allele single nucleotide polymorphism
62459518|NCT03676738||In-patient spine surgery|Scheduled for an in-patient, elective spine surgery where subject will receive general anesthesia
62459519|NCT03676738||Non-surgical spine care|Presenting to spine clinic and undergoing conservative, non-surgical management of spine disorder
62459520|NCT01327963|EXPERIMENTAL|Transoral Incisionless Fundoplication|"Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0).~With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GastroEsophageal Junction (GEJ) below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications."
62650676|NCT04894058|ACTIVE_COMPARATOR|20 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 20 ° reverse Trendelenburg position
62650677|NCT04894058|SHAM_COMPARATOR|Standard lithotomy|Patients who underwent ureteroscopic lithotripsy in standard lithotomy position
62650678|NCT03139539|ACTIVE_COMPARATOR|Ioban|In this arm patients will be operated using Ioban as incisional drape.
62083981|NCT04118985|EXPERIMENTAL|Health-behavior intervention|Individuals randomized to this group will attend 10 weekly classes designed to provide information about cognitive compensation techniques and brain health behaviors as well as interventional support to implement those recommendations with homework and follow-up classes.
62283413|NCT01970163|PLACEBO_COMPARATOR|Conventional care dressings|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.
62283414|NCT01970163|ACTIVE_COMPARATOR|GraftJacket|GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.
62283415|NCT04942392|EXPERIMENTAL|digital dance for PD|
62283416|NCT06459947|ACTIVE_COMPARATOR|Group 1 (Control group)|After FGG is taken from the palatal area, the sponge is placed in the wound area.
62283417|NCT06459947|ACTIVE_COMPARATOR|Group 2 (Cyanoacrylate group)|After the FGG is taken from the palatal area, a cyanoacrylate tissue adhesive is placed in the wound area.
62283418|NCT06459947|ACTIVE_COMPARATOR|Group 3 (Concentrated Growth Factor group)|After the FGG is taken from the palatal area, concentrated growth factor (CGF) group is placed in the wound area. CGF is obtained by centrifuging blood in four different cycles and times.
62283419|NCT01130987|EXPERIMENTAL|Comprehensive Handoff Program|Introduction of Computerized tool plus team training
62650679|NCT03139539|NO_INTERVENTION|Control|In this arm patients will be operated using no incisional drape.
62650680|NCT04975139||IDH-mutant astrocytoma or oligodendroglioma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
62083982|NCT05757895||Hemiparetic SP|The Level of Gross Motor Function Classification System (GMFCS), Trunk Affect Level ( Trunk Impairment Scale- TIS), Activity Level ( Gross Motor Function Criterion- GMFM-88), Participation Level ( Pediatric Data Collection Tool- PODCI) and Quality of Life Level (Cerebral Palsy Questionnaire for Children Cerebral Palsy Module- PedsQL) will be evaluated.
62283420|NCT02971124||Healthy Elderly|
62283421|NCT02971124||Mild Cognitive Impaired Elderly|
62283422|NCT05156541|EXPERIMENTAL|Interferon|After a cryodestruction session, therapy with Ingaron 100,000 IU once a day every other day. The course of treatment consisted of 5 injections.
62283423|NCT05156541|NO_INTERVENTION|Control|Cryodestruction session only.
62283424|NCT00510809|ACTIVE_COMPARATOR|1|Policosanol 20mg daily
62459521|NCT05593965|EXPERIMENTAL|TMS to lateral prefrontal cortex followed by TMS to medial prefrontal cortex|Participants will receive TMS while performing a reward-based decision-making task. In the first stimulation session, the TMS coil will be placed over the lateral prefrontal cortex on the scalp. In the second session, the TMS coil will be placed over the medial prefrontal cortex on the scalp. during every session, subjects receive Delta-beta patterned TMS, Theta-gamma patterned TMS, and Arrhythmic TMS.
62083983|NCT05757895||Diparetic SP|The Level of Gross Motor Function Classification System (GMFCS), Trunk Affect Level ( Trunk Impairment Scale- TIS), Activity Level ( Gross Motor Function Criterion- GMFM-88), Participation Level ( Pediatric Data Collection Tool- PODCI) and Quality of Life Level (Cerebral Palsy Questionnaire for Children Cerebral Palsy Module- PedsQL) will be evaluated.
62283425|NCT00510809|PLACEBO_COMPARATOR|2|
62283426|NCT00510809|ACTIVE_COMPARATOR|3|Policosanol 20mg daily Plus Statin Therapy Already In Use
62283427|NCT02100904||Women undergoing radiofrequency ablation.|Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).
62283428|NCT02100904||Women undergoing myomectomy|About 25% of women in the trial will be in the group who receive treatment with myomectomy.
62283429|NCT02093442|EXPERIMENTAL|Endometrial injury|Women allocated to this group will be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
62283430|NCT02093442|NO_INTERVENTION|Control|Women allocated to this group will NOT be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
62283431|NCT02592889|NO_INTERVENTION|CONTROL|OPTIMIZED MEDICAL TREATMENT
62283432|NCT02592889|ACTIVE_COMPARATOR|DEVICE|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM + OPTIMIZED MEDICAL TREATMENT
62283433|NCT03568877|PLACEBO_COMPARATOR|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks
62283434|NCT03568877|EXPERIMENTAL|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks
62083984|NCT04531072|EXPERIMENTAL|ATVr-arm|10 participants living with HIV and having uncomplicated Falciparum malaria were administered: Atazanavir-ritonavir (300/100 mg) one tablet once daily continuously + tenofovir-lamivudine (300/300 mg) one tablet once daily continuously and artemether-lumefantrine (80/480 mg) one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
62083985|NCT04531072|ACTIVE_COMPARATOR|AL-arm (Control)|10 participants who were HIV negative but having uncomplicated Falciparum malaria were administered: Artemether-lumefantrine 80/480 mg, one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
62283435|NCT03934788|EXPERIMENTAL|Oxysoft|olifilcon C, daily disposable soft contact lens, 1 month
62283436|NCT03934788|ACTIVE_COMPARATOR|SiHy|olifilcon B, dialy disposable soft contact lens, 1 month
62083986|NCT04537338||Active / Recovered Cases|"Active Cases:~Diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.~Most of the cases of Covid-19 are treated at CCSS hospitals or clnics.~Recovered cases:~Are subjects previously diagnosed with Covid-19 via a positive PCR test who were considered recovered because they had two consecutive negative PCR tests."
62283437|NCT01397578|EXPERIMENTAL|Part 1: Subcutaneous cohort exp|
62283438|NCT01397578|EXPERIMENTAL|Part 2: Intravenous cohort exp|
62283439|NCT01397578|PLACEBO_COMPARATOR|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
62283440|NCT01397578|PLACEBO_COMPARATOR|Part 2: Intravenous cohort|Repeating intravenous injection
62283441|NCT00400400|EXPERIMENTAL|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium tablets taken orally twice a day (in the morning and in the evening) at a dose equimolar to the dose of mycophenolate mofetil the participant was taking prior to start of the study + Placebo to mycophenolate mofetil capsules taken orally twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
62283442|NCT00400400|ACTIVE_COMPARATOR|Mycophenolate mofetil|Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
62459522|NCT05593965|EXPERIMENTAL|TMS to medial prefrontal cortex followed by TMS to lateral prefrontal cortex|Participants will receive TMS while performing a reward-based decision-making task. In the first stimulation session, the TMS coil will be placed over the medial prefrontal cortex on the scalp. In the second session, the TMS coil will be placed over the lateral prefrontal cortex on the scalp. during every session, subjects receive Delta-beta patterned TMS, Theta-gamma patterned TMS, and Arrhythmic TMS.
62459523|NCT01498848|ACTIVE_COMPARATOR|Soybean oil|Families were given soybean oil for cooking during 4 weeks
62459524|NCT01498848|ACTIVE_COMPARATOR|Sunflower oil|Families were given sunflower oil for cooking during 4 weeks
62083987|NCT04537338||Community control group|The community control group will be frequency-matched on age, sex and area of residence. Two controls per case will be selected as follows
62459525|NCT03913806|EXPERIMENTAL|Treatment group|Bevacizumab-IRDye800CW
62459526|NCT00376922|NO_INTERVENTION|usual care|
62083988|NCT04537338||Household survey|"Are a household contact of a person diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.~A household will be defined as a group of persons living together who share a kitchen. To be considered eligible for inclusion a contact must have spent at least one night per week in the living area since onset in the index case."
62459527|NCT00376922|EXPERIMENTAL|Music therapy|
62459528|NCT00803920||Exenatide|
62459529|NCT00803920||Exenatide LAR|
62083989|NCT03133468|EXPERIMENTAL|Part 1: AJM347|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
62459530|NCT02216071|ACTIVE_COMPARATOR|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
62459531|NCT02216071|EXPERIMENTAL|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
62459532|NCT01631565|NO_INTERVENTION|Standard care|Usual care given to the patients. Treatment, follow-up.
62459533|NCT01631565|EXPERIMENTAL|Early Palliative Care|"Intervention: Early allocation to palliative care. Intervention: Nutritional counseling. Intervention: patient and care-taker psychoeducation, depression and anxiety evaluation.~Standard of care: Oncological treatment according to stage of disease (IIIb/IV).~Treatment: Chemotherapy (platins, taxans, TKIs) Baseline: BMI, and anthropometric characteristics (weight, height). Follow-up: During 6 chemotherapy circles with: Quality of Life (EORTC qlq-c30), HADS, ESAS and ZARIT."
62459534|NCT00740493|ACTIVE_COMPARATOR|1|18 months of active warfarin therapy
62459535|NCT00740493|PLACEBO_COMPARATOR|2|18 months of placebo of warfarin
62459536|NCT00469586|EXPERIMENTAL|A|
62459537|NCT00469586|EXPERIMENTAL|B|
62459538|NCT00469586|ACTIVE_COMPARATOR|C|
62461815|NCT03411330|ACTIVE_COMPARATOR|Group A (local anaesthetics alone)|"Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve"
62083990|NCT03133468|PLACEBO_COMPARATOR|Part 1: Placebo|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
62083991|NCT03133468|EXPERIMENTAL|Part 2: Low-dose AJM347|"Caucasian and Japanese participants will receive a low dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods."
62083992|NCT03133468|EXPERIMENTAL|Part 2: High-dose AJM347|"Caucasian and Japanese participants will receive a high dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups)."
62283443|NCT03404999|EXPERIMENTAL|clinical decision support activated|"TWO MED ASSIST ALERTS~1. Enter height (when missing)~2. Repeat BP (when high)~ONE PROVIDER ALERT~1. BP high \& prior BP/BP%s~2. Defines elev. BP, HTN stage 1-2 with button to enter diagnosis~3. Link to tailored ordersets~TAILORED ORDERSETS~1. Elevated BP~   1. Button to schedule f-up \<6 m~  2. Button for diet/lifestyle counseling/check-out instructions~2. HTN stage 1~   1. Buttons to order labs/studies pre-checked for stage 1 recs~  2. Button for nephrology referral~  3. Button to schedule f-up in 1-2 wk/\<1 m~  4. Button for diet/lifestyle counseling/check-out instructions~3. HTN stage 2~   1. Buttons to order labs/studies for stage 2~  2. Button for nephrology referral (pre-checked)~  3. Button to f-up 1 wk~  4. Button for diet/lifestyle counseling/check-out instruction"
62283444|NCT03806127|EXPERIMENTAL|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 12 weeks.
62283445|NCT03806127|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally once daily for 12 weeks.
62283446|NCT05773404|EXPERIMENTAL|passive manual therapy|The physiotherapist performs passive techniques on the hamstring muscles of the footballers.
62283447|NCT05773404|EXPERIMENTAL|active therapy (exercise)|The physiotherapist does not perform passive techniques and it is the player who performs active techniques on the hamstring muscles.
62283448|NCT05773404|ACTIVE_COMPARATOR|combined therapy|The physiotherapist performs passive techniques and in addition the player performs active techniques on the hamstring muscles.
62283449|NCT05504161||Endometrial cancer group|Patients pathologically diagnosed with endometrial cancer
62283450|NCT05504161||Control group|Patients with benign endometrial pathology and interepithelial neoplasia
62283451|NCT05606926|OTHER|Group I|15 Children with spastic diplegia in this group will a designed physical therapy program for 60 minutes per session in addition to WBV for 10 minutes, three times a week, for three consecutive months.
62283452|NCT05606926|EXPERIMENTAL|Experimental group|15 Children with spastic diplegia in this group will receive the same designed physical therapy program while WBV will be conducted while wearing a weighted vest.
62283453|NCT06076629|EXPERIMENTAL|Low temperature (16#) group|Subjects in exposure group will be exposed to low temperature (16#) for about 2 hours in a chamber.
62283454|NCT06076629|SHAM_COMPARATOR|Moderate temperature (22#) group|Subjects in exposure group will be exposed to moderate temperature (22#) for about 2 hours in a chamber.
62283455|NCT06416163||Retrospective|All participants will be in one group which is the collection of retrospective data
62283456|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
62461816|NCT05165680|EXPERIMENTAL|experimental group, group A|Thirty patients in this group will perform aerobic exercise in the form of walking on electric treadmill three times/ week day after day and low caloric diet rich in iron, vitamin C and folate and iron supplement for 12 weeks.
62083993|NCT03133468|EXPERIMENTAL|Part 3: AJM347|Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
62283457|NCT06194357|EXPERIMENTAL|Intervention group|Intervention group will receive training on Qigong exercise and mindfulness.
62283458|NCT06194357|NO_INTERVENTION|Control group|Control group will not receive intervention.
62283459|NCT05809531|EXPERIMENTAL|Pegcetacoplan administered subcutaneously|Pegcetacoplan administered subcutaneously twice weekly according to protocol defined dosing regimen
62283460|NCT05112887|EXPERIMENTAL|OMT Group|"The OMT protocol treatment sequence was performed in the following order:~1. Rib raising from a seated position 2. Suboccipital Release from a supine position 3. Thoracic Inlet Release 4. Miller Lymphatic Pump 5. Pedal Pump 6. Suboccipital Release 7. Cranial Sinus Effleurage~1. Engaging the sagittal midline of occiput with pressure until release of the tissue is palpated~2. Direct pressure along the external region of the transverse sinus until release of the tissue is palpated.~3. Pressure on sagittal suture with transverse traction until release of the tissue is palpated~4. Pressure on metopic suture with transverse traction in a pulsatile manner~5. Vault hold~1. Appreciate cranial respiratory motion 2. Diagnose cranial strain pattern 3. Place cranial strain pattern into position of ease"
62283461|NCT05112887|PLACEBO_COMPARATOR|Placebo/Light Touch/Sham Group|Participants in the sham/placebo group were lightly touched in equivalent positions to the OMT treatments. First, sham participants were lightly touched on the thoracic cage while seated, followed by light touch of the neck, chest, feet, and cranium while supine. The length of light touch was modeled after the approximate time needed for the OMT matching each treatment region. Each treatment sequence lasted about 20 minutes in total.
62283462|NCT00816374|OTHER|1|Group I
62283463|NCT00816374|OTHER|2|Group II
62283464|NCT04624425|EXPERIMENTAL|Segmental breathing exercises|Segmental breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
62083994|NCT03133468|PLACEBO_COMPARATOR|Part 3: Placebo|Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
62083995|NCT03439696|EXPERIMENTAL|Needlescopic-assisted|Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
62459539|NCT02017964|EXPERIMENTAL|Treatment (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on days 1, 15, and 29; cyclophosphamide IV over 1 hour on days 1-3; methotrexate IV over 24 hours on days 15 and 29; etoposide IV over 60-120 minutes on days 43-45; and carboplatin IV over 1 hour on days 43-45. Treatment repeats every 63 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CONTINUATION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on day 1, cyclophosphamide IV over 1 hour on days 1-3, etoposide IV over 60-120 minutes on days 21-23, and carboplatin IV over 1 hour on days 21-23. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity."
62083996|NCT03439696|ACTIVE_COMPARATOR|Uniportal|Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
62083997|NCT02026973|EXPERIMENTAL|IM Placebo/Oral Placebo|IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
62083998|NCT02026973|EXPERIMENTAL|IM Placebo/PO Anastrozole|IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
62083999|NCT02026973|EXPERIMENTAL|IM Fulvestrant/PO Placebo|IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
62084000|NCT02026973|EXPERIMENTAL|IM Fulvestrant/IM Anastrozole|IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
62084001|NCT01339494|ACTIVE_COMPARATOR|arginine supplementation|Oral L-arginine supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Arginine will be given every 4 hours.
62084002|NCT01339494|ACTIVE_COMPARATOR|citrulline supplementation|Oral L-citrulline supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Citrulline will be given every 4 hours
62283465|NCT04624425|ACTIVE_COMPARATOR|Buteyko breathing exercises|Buteyko breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
62283466|NCT03014856||OB-NMR|overweight and obese children and adolescents
62283467|NCT03014856||NMR-C|normal-weight children and adolescents
62084003|NCT02487446|EXPERIMENTAL|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
62283468|NCT03508492|ACTIVE_COMPARATOR|Knee surgeons|Four knee surgeons
62459540|NCT01492400|EXPERIMENTAL|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
62459541|NCT01492400|ACTIVE_COMPARATOR|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
62084004|NCT02487446|EXPERIMENTAL|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
62084005|NCT04974879|EXPERIMENTAL|study drug|osimertinib oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
62084006|NCT05557383|EXPERIMENTAL|use peanut ball|Registered nurses were educated by the investigators on the study protocol, and standard care was given to both the intervention and control groups.The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
62084007|NCT05557383|NO_INTERVENTION|usual care|usual nursing care.
62084008|NCT01934699|ACTIVE_COMPARATOR|MRI-Arm|Myocardial vitality determination based on MRI diagnostics.
62084009|NCT01934699|EXPERIMENTAL|Echo-Arm|Myocardial vitality determination using echocardiography in combination with 2D-Strain Analysis.
62084010|NCT01403389|EXPERIMENTAL|Eculizumab|
62283469|NCT03508492|ACTIVE_COMPARATOR|Hip surgeons|Six hip surgeons
62283470|NCT03508492|ACTIVE_COMPARATOR|Cardiac surgeons|6 cardiac surgeons
62283471|NCT03508492|ACTIVE_COMPARATOR|Colon surgeons|6 colon surgeons
62084011|NCT01403389|PLACEBO_COMPARATOR|0.9% Sodium Chloride|
62650681|NCT04975139||IDH-wildtype astrocytoma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
62650682|NCT04975139||Benign Brain Tumor|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
62650683|NCT06522113|ACTIVE_COMPARATOR|aspirin with clopidogrel|aspirin 100mg with clopidogrel 75mg for 21 days
62650684|NCT06522113|EXPERIMENTAL|aspirin with cilostazol|aspirin 100mg with cilostazol 200 mg for 21 days
62650685|NCT04103840||Severe alcohol- associated hepatitis|Severe alcohol associated hepatitis as defined by probable/ conformed National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria
62650686|NCT04103840||Control|Apparently healthy Family controls
62650687|NCT00443859||PPHN|Infants with persistent pulmonary hypertension (PPHN)
62650688|NCT03039075|ACTIVE_COMPARATOR|Metformin SR Tablet|Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD
62650689|NCT03039075|ACTIVE_COMPARATOR|Glucophage|The original drug of metformin
62650690|NCT01734720||common bile duct stone|Patients undergoing cholecystectomy
62650691|NCT05227248|EXPERIMENTAL|Main study arm|Patients received intervention 1 and then intervention 2 after 7 weeks
62084012|NCT05187598|EXPERIMENTAL|Effective communication training in perinatal patient safety|Nursing department students will be given training on effective communication training in perinatal patient safety.
62084013|NCT05187598|NO_INTERVENTION|Control group|There is no intervention for this group
62650692|NCT02425553||Faculty and Delegates of Ascona II Meeting|
62650693|NCT04968496|NO_INTERVENTION|Food Insecure Group|Children randomized to the naturally-occurring Food Insecure group will receive a weekly newsletter with information on available area-specific food programs. The weekly newsletter will be sent in two ways: 1) a paper copy will be mailed and 2) a link to an electronic version will be sent via Ilumivu to families to remove any barriers to engagement with the information. In the absence of school meal programs, children from low-income households are at increased risk for food insecurity during the summer.37-39 Given low engagement in summer food programs, it is not expected that this newsletter will impact food security in this group.
62650694|NCT04968496|EXPERIMENTAL|Food Secure Group|Children randomized to the Food Secure group will receive breakfast and lunch meals for eight weeks throughout the summer. Weekly meals will be delivered to each participant's home by Yumble, a company that prepares meals for children ages 3 to 12 years and ships them fresh in insulated, food safe packaging to the home. The meals have similar nutrition standards to those offered via the National School Lunch Program and include fruits, vegetables, whole grains, and lean/ vegetarian proteins. To accommodate cultural preferences or dietary constraints, Yumble offers 20 different breakfast, lunch and dinner meals each week. Families will choose their weekly menus to improve adherence. Participants who have siblings in their home will be provided a family meal kit, which provides 24 meals each week. Additional meals will help to prevent household food insecurity and ensure that the child enrolled in the study consumes the meals each week.
62650695|NCT02931461|EXPERIMENTAL|needle Procore ®|
62650696|NCT02931461|ACTIVE_COMPARATOR|needle Cook®|
62650697|NCT06389461|EXPERIMENTAL|4th Ventricular Compression Technique|The technique was preformed by the investigator during 5 minutes.
62650698|NCT06389461|PLACEBO_COMPARATOR|"Sham Therapy"|The technique was preformed by the investigator during 5 minutes.
62650699|NCT00941343|EXPERIMENTAL|1|XATRAL 10mg OD
62650700|NCT06436768|EXPERIMENTAL|Sugammadex group (S group)|After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.
62650701|NCT06436768|ACTIVE_COMPARATOR|Neostigmine group (N group)|After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine plus atropine 0.02 mg/kg was administered.
62650702|NCT04168242|EXPERIMENTAL|Experimental arm|Patients have scalp cooling during the chemotherapy period
62650703|NCT04168242|PLACEBO_COMPARATOR|Control arm|Patients do not have scalp cooling during the chemotherapy period
62650704|NCT00644059|EXPERIMENTAL|TIV-adj|Adjuvanted trivalent inactivated subunit influenza vaccine
62650705|NCT00644059|ACTIVE_COMPARATOR|Flu-control|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
62650706|NCT00644059|SHAM_COMPARATOR|Non-flu Control|Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
62650707|NCT06351176||Individuals with type 1 diabetes|
62650708|NCT06351176||Healthy controls|
62650709|NCT01865019||volume controlled|volume ontrolled ventilation
62084014|NCT05162807|EXPERIMENTAL|Palliative Care Education|The intervention arm will view a psychoeducational video on palliative care.
62084015|NCT05162807|PLACEBO_COMPARATOR|Attention Control|The control arm will view an educational video on nutrition as an attention control.
62084016|NCT01599416|ACTIVE_COMPARATOR|U-relax Group|Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
62084017|NCT01599416|PLACEBO_COMPARATOR|Placebo Group|Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep
62084018|NCT05266196|EXPERIMENTAL|Single agent|Single agent seclidemstat, as assigned per parent protocol
62084019|NCT05266196|EXPERIMENTAL|TC Combination|Combination of seclidemstat with topotecan and cyclophosphamide, as assigned per parent protocol
62084020|NCT05711238|EXPERIMENTAL|Robot Assisted Therapy Group|"Investigators planned to apply robotic rehabilitation therapy with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 40 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience for the hands on the affected side of the children in the Robot Assisted Therapy Group group.~Amadeo (Tyromotion, Graz, Austria) is an end-effector device designed for the hand. It is a groove-shaped device attached to the forearm using magnets using bandages on the fingers."
62283472|NCT05370573||Patients with central nervous system infections admitted to intensive care|
62283473|NCT01389115||Liver Cirrhosis|Patient with liver cirrhosis undergoing liver transplant
62283474|NCT01389115||Liver donors|Subjects eligible for organ explant
62283475|NCT01389115||Healthy controls|
62283476|NCT01412957|EXPERIMENTAL|Panitumumab + BSC|Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.
62283477|NCT01412957|OTHER|BSC Alone|Participants received best supportive care until disease progression, withdrawal of consent, or death.
62084021|NCT05711238|ACTIVE_COMPARATOR|Conventional Therapy Group|"Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.~A total of 30 sessions of treatment were planned for both groups, 5 days a week. It will be recommended that they continue with the same dose of the medical treatment they have been using during the treatment program. Children will be evaluated by a physiatrist blinded to groups before and after treatment."
62084022|NCT01581879|EXPERIMENTAL|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
62084023|NCT01581879|EXPERIMENTAL|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
62084024|NCT03048110|EXPERIMENTAL|ODM-201|All subjects will receive a single dose of BAY1841788 (ODM-201) (600 mg) in the first treatment period of the study, then all subjects will receive twice daily 200 mg itraconazole on 1 day and once daily 200 mg itraconazole for the following 6 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the second treatment period, then all subjects will receive once a day 600 mg rifampicin for 10 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the third treatment period
62084025|NCT03472287|EXPERIMENTAL|Cohort 1 (Adolescents, Adults)|Adolescent and adult subjects with EB (aged 12 years and older) received diacerein 1% ointment daily for 10 days.
62084026|NCT03472287|EXPERIMENTAL|Cohort 2 (Children)|Children with EB (aged 4 to 11 years, inclusive) received diacerein 1% ointment daily for 10 days.
62084027|NCT05835193||Study Group|Pre-school students in Alexandroupolis, Greece
62084028|NCT00725010||Patients|Participants with newly diagnosed Glioblastoma multiforme who were prescribed temozolomide and radiotherapy as standard care.
62084029|NCT04996069|EXPERIMENTAL|All Participants|This is a single arm study. All subjects enrolled will be apart of the experimental group. Subjects in this group will use Crest Whitening Emulsions on their teeth up to 4 times a day for 7 days in order for the study team to evaluate if the study intervention product increases saliva production in this Xerostomic population.
62283478|NCT04067830|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive usual care consisting of physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
62283479|NCT04067830|EXPERIMENTAL|Arm II (RMT + usual care)|Patients use a power lung device to complete 3 sets of 15 RMT exercises over 30 minutes 6 days per week over 2-4 weeks for a minimum of 12 sessions prior to surgery. Patients also receive usual care consisting of attending physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
62283480|NCT02388568|ACTIVE_COMPARATOR|Lorcaserin plus Lifestyle Modification|
62283481|NCT02388568|PLACEBO_COMPARATOR|Placebo plus Lifestyle Modification|
62283482|NCT06501703|EXPERIMENTAL|XP Endo finisher|technique used for final irrigation in vertical lengthwise movement to the full working length for 1 minute in each canal.
62650710|NCT01865019||pressure controlled|pressure controlled ventilation
62084030|NCT01691443|EXPERIMENTAL|Use of the glove|The subject wear the glove for the time of the trial
62461817|NCT05165680|ACTIVE_COMPARATOR|healthy diet|ow caloric diet rich in iron, vitamin C and folate and iron supplement for 12 weeks.
62084031|NCT05767047|EXPERIMENTAL|Apremilast|Participants with a weight between ≥ 12 kg to \< 20 kg will receive apremilast 10 mg BID (twice a day), participants with a weight between ≥ 20 kg to \< 50 kg will receive 20 mg BID, and participants with a weight ≥ 50 kg will receive apremilast 30 mg BID.
62283483|NCT06501703|EXPERIMENTAL|Passive Ultrasonic Irrigation|technique used for final irrigation in vertical strokes reaching 2 mm short from the full working length for 1 minute in each canal.
62084032|NCT01648179|EXPERIMENTAL|GSK1322322 IV formulation|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via IV formulation
62084033|NCT01648179|EXPERIMENTAL|GSK1322322 Wet milled Tablet (Fasted)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fasted)
62084034|NCT01648179|EXPERIMENTAL|GSK1322322 Oral mesylate salt solution|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Oral mesylate salt solution
62084035|NCT01648179|EXPERIMENTAL|GSK1322322 Wet milled Tablet (Fed)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fed)
62283484|NCT06501703|EXPERIMENTAL|Fanta AF max file|technique used for final irrigation in vertical lengthwise movement to the full working length for 1 minute in each canal.
62084036|NCT06423586|EXPERIMENTAL|PCIBS Group|Participants with post-acute COVID-19 irritable bowel syndrome (PCIBS) supplemented with lecithin-based formulations of Curcuma longa (Meriva™) and Boswellia serrata (Casperome™) extracts.
62283485|NCT06501703|ACTIVE_COMPARATOR|Manual Dynamic agitation|technique used for final irrigation in Intermittent manual activation for 1 min in up-and-down motion using master gutta percha cone was performed.
62650711|NCT02347709||Group 1/Diabetic Foot Ulcer|Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
62650712|NCT02347709||Group 2/Diabetic Neuropathy|Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
62650713|NCT02347709||Group 3/Type 2 Diabetes|Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
62650714|NCT00619840|ACTIVE_COMPARATOR|1|
62650715|NCT00619840|PLACEBO_COMPARATOR|2|
62084037|NCT06423586|ACTIVE_COMPARATOR|IBS Control Group|Participants with irritable bowel syndrome (IBS) without prior COVID-19 infection supplemented with lecithin-based formulations of Curcuma longa (Meriva™) and Boswellia serrata (Casperome™) extracts.
62084038|NCT04745858|EXPERIMENTAL|Bowen's Technique|Sequence of short gentle moves are applied over Hamstrings.Skin slack is taken to lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are be given for 4 weeks. The treatment time for each session is 20 minutes.
62283486|NCT01539980|EXPERIMENTAL|Sericin scaffold|
62283487|NCT01158339|ACTIVE_COMPARATOR|Arm 1: CBGT|Cognitive Behavioural Group Therapy (CBGT)
62283488|NCT01158339|EXPERIMENTAL|Arm 2: CBGT-ISE|Cognitive Behavioural Group Therapy, with in-Session Exposure (CBGT-ISE).
62283489|NCT01099202|EXPERIMENTAL|Procrit|Starting dose 40,000 units subcutaneously once a week with chemotherapy.
62283490|NCT01099202|NO_INTERVENTION|No Procrit|No intervention.
62650716|NCT01077492||Suspected mediastianl lymph nodes|Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
62650717|NCT01553851|EXPERIMENTAL|GSK1120212|GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
62650718|NCT03044418||anesthesia with laser tube|The special endotracheal (ET) laser tube is tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
62650719|NCT04547816|EXPERIMENTAL|biofeedback and tibial neuromodulation (BFB+TNM)|
62650720|NCT04547816|EXPERIMENTAL|BFB+TNM + pelvic floor muscles training (PFMT)|
62650721|NCT04547816|EXPERIMENTAL|BFB+TNM+PFMT+diet modification|
62650722|NCT02997163|EXPERIMENTAL|Group A (control, normal renal function)|
62650723|NCT02997163|EXPERIMENTAL|Group B (mild renal impairment)|
62650724|NCT02997163|EXPERIMENTAL|Group C (moderate renal impairment)|
62650725|NCT02997163|EXPERIMENTAL|Group D (severe renal impairment)|
62650726|NCT04343144|EXPERIMENTAL|Nivolumab|
62650727|NCT04343144|NO_INTERVENTION|Standard of Card|
62650728|NCT00384631|SHAM_COMPARATOR|2|
62650729|NCT00384631|EXPERIMENTAL|1|
62650730|NCT05412277|OTHER|VIA Disc NP|HCT/P: VIA Disc Nucleus Pulposus Allograft
62650731|NCT00639184|EXPERIMENTAL|1|Home intervention program
62650732|NCT00639184|ACTIVE_COMPARATOR|2|health education counseling
62650733|NCT05623527||Ischemic stroke group|"1. Ischemic stroke secondary to patients receiving cardiac electronic implants~2. Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed by cranial CT/MRI scan."
62459542|NCT02395822|EXPERIMENTAL|Preparative Regimen and SubQ rHuIL-15|"Preparative Regimen of Fludarabine and Cyclophosphamide~IL-15 Activation of Donor NK Cells:~IL-15 to Facilitate NK Cell Survival and Expansion"
62650734|NCT05623527||Transient ischemic attack group|"1. Transient ischemic attack secondary to patients receiving cardiac electronic implants~2. Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed negative of new onset of infarction by cranial CT/MRI scan."
62650735|NCT05623527||Cerebral hemorrhage group|"1. Cerebral hemorrhage secondary to patients receiving cardiac electronic implants~2. Cerebral hemorrhage met the diagnostic criteria of the 2021 Chinese Guidelines for the Diagnosis and Treatment of cerebral hemorrhage and was confirmed by head CT/MRI."
62650736|NCT05069467|EXPERIMENTAL|Acupuncture|Licensed acupuncturists with more than 5 years of experience will be responsible for administering interventions three times per week for 6 weeks. The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling. Acupuncture was defined as targeting the 10 bilateral acupuncture points: Xinshu (BL15), Shenshu (BL23), Zhongliao (BL33), Sanyinjiao (SP6), Yinlingquan (SP9). The needle will be left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.
62650737|NCT05069467|SHAM_COMPARATOR|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
62650738|NCT05069467|NO_INTERVENTION|Usual Care|Patients receiving usual care received neither acupuncture nor sham acupuncture. After the 6-week assessment, patients will be offered the option to receive acupuncture treatment as the acupuncture group.
62650739|NCT04903301|EXPERIMENTAL|Study Group|Contoura Vision LASIK using Phorcides Analytic Software
62459543|NCT05602688|EXPERIMENTAL|Supplement Group|This arm will receive oral 200 mg Lemon Balm supplement tablet two times a day for three-weeks.
62459544|NCT05602688|ACTIVE_COMPARATOR|Control group|This arm will receive an oral matched placebo tablet two times a day for three-weeks.
62650740|NCT01903226|EXPERIMENTAL|High intensity training|Patients in this group will perform high aerobic intensity training, in 30 minutes, twice a week, in a 12 week period.
62650741|NCT01903226|EXPERIMENTAL|Moderate intensity training|Patients in this group will perform moderate aerobic intensity training, in 45 minutes, three times a week, in a 12 week period.
62650742|NCT01903226|NO_INTERVENTION|controll|Patients in this group will perform no (additional) training.
62650743|NCT06135038|ACTIVE_COMPARATOR|Suprascapular nerve block with physical therapy|"Suprascapular Nerve Block was applied to Group I before physical therapy program.~After the nerve block, a physical therapy program including standard procedure was applied to the patients in Group 1."
62650744|NCT06135038|ACTIVE_COMPARATOR|Only physical therapy|Patients in group 2 were applied only a physical therapy program that included the same standard procedure as group 1.
62650745|NCT03848663|EXPERIMENTAL|Patients with scotoma|No remapping (control condition), traditional remapping, personalized remapping
62650746|NCT03848663|ACTIVE_COMPARATOR|Normally sighted with artificial scotoma|No remapping (control condition), traditional remapping, personalized remapping
62650747|NCT02870868|EXPERIMENTAL|Slow breathing with exhale greater than inhale|Participants randomized to slow breathing with prolonged exhale to inhale ratio received progressive increases in expiration relative to inspiration based on initial assessment until they reached a goal breath length or longest comfortable breath. Prior to performing the breathing practice, subjects in this exhale\>inhale condition performed the same yoga movements as the exhale-inhale group.
62653075|NCT03636256|EXPERIMENTAL|Non-Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75, 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL and additional Induction (6 weekly NanoDoce intravesical instillations, followed by 6 weeks of rest) and Maintenance (3 weekly NanoDoce intravesical instillations, followed by 9 weeks of rest) instillations at 2.0 or 3.0 mg/mL.
62653076|NCT03636256|EXPERIMENTAL|Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75, 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL. Subjects will then go on to receive institutional standard of care.
62459545|NCT05039502|EXPERIMENTAL|Retreatment system using in rotational motion|Previous root canal filling materials were removed with D1-D2-D3 retreatment files with using an endodontic motor in rotational motion
62459546|NCT05039502|EXPERIMENTAL|Retreatment system using in reciprocal motion|Previous root canal filling materials were removed with Reciproc 25 file with using an endodontic motor in reciprocal motion
62650748|NCT02870868|EXPERIMENTAL|Slow breathing with exhale equal to inhale|Participants randomized to slow breathing with equal inspiration and expiration received progressive increases in both inspiration and expiration over 4 weeks until they reach a goal breath length or longest comfortable breath. Goal breaths were assigned based on initial breath assessment. Prior to performing the breathing practice, participants performed a few standardized yoga movements. The purpose of movements was to prepare the subject to sit and focus on breathing. Subjects randomized to exhale=inhale will receive progressive increases in both inspiration and expiration until they reach a goal breath length. Goal breaths will be assigned based on initial breath assessment. Prior to performing the breathing practice, subjects will perform a set of standardized breathing practices. The purpose of these few breathing practices is to prepare the subject to sit and focus on breathing.
62650749|NCT00109343|EXPERIMENTAL|1|Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)
62650750|NCT00109343|EXPERIMENTAL|2|Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)
62283491|NCT04055103|ACTIVE_COMPARATOR|Intervention Group|Half of the participating hospitals will be in the intervention group for the first 6 months. The intervention will switch to the control group after the 6 months.
62283492|NCT04055103|NO_INTERVENTION|Control Group|Half of the participating hospitals will be in the control group for the first 6 months. The control group will undergo the intervention in the second 6 months.
62283493|NCT03922854||Mobile Monitor Group|Participants are recruited to this study if they have been monitored during their labour with a monica AN 24 monitor
62283494|NCT06466330|EXPERIMENTAL|Embolization|The genicular artery embolisation procedure identifies abnormal blood vessels in the knee via angiography. Through groin access and puncture of the femoral artery through a microcatheter, microspheres (Embozene) will be injected into this area.
62459547|NCT05039502|EXPERIMENTAL|Retreatment system using in additional rotational motion|Previous root canal filling materials were removed with XP-endo finisher r file with using an endodontic motor in rotational motion
62459548|NCT03133195|EXPERIMENTAL|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
62459549|NCT03133195|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous once daily for 12 weeks
62459550|NCT02606565|EXPERIMENTAL|Intervention arm: 4% chlorhexidine|Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
62650751|NCT00109343|EXPERIMENTAL|3|Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)
62650752|NCT06399159||Cohort with Lymph Node Metastasis|Depending on the pathological findings, it is classified as the presence of lymph node metastases.
62650753|NCT06399159||Cohort without Lymph Node Metastasis|Depending on the pathological findings, it is classified as the absence of lymph node metastases.
62084039|NCT04745858|ACTIVE_COMPARATOR|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
62084040|NCT02832765|EXPERIMENTAL|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions
62084041|NCT02832765|EXPERIMENTAL|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis
62283495|NCT06466330|SHAM_COMPARATOR|Placebo|In the control (sham) arm patients will undergo angiography but there will be injection of saline.
62459551|NCT02606565|NO_INTERVENTION|Control arm: Dry cord care|Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
62459552|NCT05400148||low volume|This cohort will include the patients to whom an analgesic PENG block was administered with a bupivacaine solution volume of up to 20 ml in a dose of 2.5mg/kg-1. This cohort is anticipated to have 56 participants.
62459553|NCT05400148||high volume|This cohort will include the patients to whom an analgesic PENG block was administered with a bupivacaine solution volume more than 20 ml in a dose of 2.5mg/kg-1. This cohort is anticipated to have 56 participants.
62459554|NCT05224895||General Anesthesia in Trendelenburg position for robotic prostatectomy|
62461818|NCT04513964||Control|Patient not suffering from COVID-19
62459555|NCT03150602|EXPERIMENTAL|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
62084042|NCT02832765|EXPERIMENTAL|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions
62283496|NCT01764633|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
62283497|NCT01764633|EXPERIMENTAL|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.
62459556|NCT00473356|ACTIVE_COMPARATOR|1|to receive amino acid supplement
62459557|NCT00473356|NO_INTERVENTION|2|no amino acid supplement
62459558|NCT03664908|EXPERIMENTAL|serum samples of SLE patients without LN|100 serum samples coming from systemic lupus erythematosus (SLE) patients without lupus nephritis (LN).
62459559|NCT03664908|EXPERIMENTAL|serum samples of Lupus nephritis (LN) patients|100 serum samples coming from systemic lupus erythematosus(SLE) patients with lupus nephritis (LN)
62459560|NCT03664908|EXPERIMENTAL|healthy voluntary blood donors (control group)|100 serum sample coming from 100 healthy voluntary blood donors (provided by Regional blood center of Reims). This arm will be our control group.
62459561|NCT02632136|ACTIVE_COMPARATOR|TAP block group|"This group will receive 30 ml of 0.25% Bupivacine given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine.~They will also receive normal saline injections at port sites, which will be injected before the ports are inserted. 15 ml of normal saline will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports."
62084043|NCT02832765|EXPERIMENTAL|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis
62084044|NCT00925028|EXPERIMENTAL|Group A|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. After four months the groups will switch to the alternate management strategy.
62283498|NCT05057455||ICU patients diagnosed with sepsis or septic shock|compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
62283499|NCT01889849|EXPERIMENTAL|BIP48|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
62283500|NCT01889849|ACTIVE_COMPARATOR|Pegasys|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
62459562|NCT02632136|PLACEBO_COMPARATOR|Peri-Portal block Group|"They will receive 0.5% Bupivacaine injections at port sites, which will be injected before the ports are inserted. 15 ml of 0.5% Bupivacaine will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports.~This group will also receive 30 ml of Normal Saline Injection given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine."
62084045|NCT00925028|EXPERIMENTAL|Group B|Patients of group B will continue to be managed by their physician. After four months the groups will switch to the alternate management strategy.
62084046|NCT00002708|EXPERIMENTAL|Arm 1|Whole brain radiation therapy (WBRT) to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week followed by radiosurgery to all metastases
62283501|NCT04676048|EXPERIMENTAL|ASC618|Experimental Arm
62283502|NCT02630953|ACTIVE_COMPARATOR|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
62283503|NCT02630953|EXPERIMENTAL|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
62283504|NCT04227756|EXPERIMENTAL|LSD-100|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
62283505|NCT04227756|ACTIVE_COMPARATOR|Psilocybin-20|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
62283506|NCT04227756|ACTIVE_COMPARATOR|Mescaline-300/500|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
62283507|NCT04227756|PLACEBO_COMPARATOR|Placebo|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
62283508|NCT02420769||Threatened abortion|Pregnant patients \> 8 weeks gestation coming to the ANC clinic with mild vaginal bleeding but healthy viable intrauterine pregnancy. Vaginal color doppler for uterine artery and corpus luteum together with serum progesterone and CA125 will be assessed.
62283509|NCT01165957||Mobile bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is designed to slide or rotate on the metal baseplate.
62283510|NCT01165957||Fixed bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is locked to the metal baseplate.
62459563|NCT04506866|OTHER|Overactive Bladder Cohort|Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
62459564|NCT04506866|OTHER|Fecal Incontinence Cohort|Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.
62459565|NCT04506866|OTHER|Non-Obstructive Urinary Retention Cohort|Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
62459566|NCT01934673||Subjects with diabetes (type 2)|
62459567|NCT03097120|ACTIVE_COMPARATOR|unopposed estrogen|0.625 mg of conjugated equine estrogen
62459568|NCT03097120|ACTIVE_COMPARATOR|estrogen-plus-medroxyprogesterone|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
62459569|NCT03097120|PLACEBO_COMPARATOR|placebo|placebo
62459570|NCT03695926|EXPERIMENTAL|[18F]MNI-1054|To measure blood metabolites, dynamic uptake, and washout of \[18F\]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.
62459571|NCT03576846|EXPERIMENTAL|Intervention|Stretching and Spinal Manipulative Therapy
62459572|NCT03576846|ACTIVE_COMPARATOR|Comparator|Stretching
62459573|NCT05166265|EXPERIMENTAL|Sentio system|Prospective, open label, single-arm multi-centre investigation following clinical practice for bone conduction devices.
62459574|NCT02178722|EXPERIMENTAL|Phase 1: MK-3475 + INCB024360|Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
62459575|NCT02178722|EXPERIMENTAL|Phase 2: MK-3475 + INCB024360|(recommended phase 2 dose)
62459576|NCT03815981||Allergic|Collection of blood, stool, urin samples
62459577|NCT03815981||Sensitized|Collection of blood, stool, urin samples
62459578|NCT03815981||Non-Allergic|Collection of blood, stool, urin samples
62459579|NCT04981938||Lobectomy with angioplasty|81 patients who underwent lobectomy with pulmonary artery reconstruction during oncologic lung resection from January 2001 to December 2020
62084047|NCT00002708|ACTIVE_COMPARATOR|Arm 2|WBRT to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week
62084048|NCT02438462||Group with PE|"The criteria for confirmation of PE are:~* PE on spiral computed tomography (CT)~* proximal deep vein thrombosis on ultrasound (US)~* thromboembolic events objectively confirmed during the follow up"
62283511|NCT05423405|NO_INTERVENTION|control|Treatment as usual with pharmacotherapy and other complementary therapies
62283512|NCT05423405|SHAM_COMPARATOR|Sham|No actual acupoint pressed but same settings as in acupressure therapy
62459580|NCT02287545||Glaucoma, primary|Glaucoma patients undergoing trabeculectomy
62459581|NCT02027909||Therapy group one|Lower rate of 60 bpm and out of the box rate response settings of an ADL Rate of 95 bpm and rate profile optimization on with the only change being adjusting the activity threshold from med/low to low.
62459582|NCT02027909||Therapy group two|Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
62459583|NCT02027909||Therapy group three|Lower rate of 60 bpm and the ADL rate based upon 220- age x 55%. Activity threshold is programmed to low. Rate Profile Optimization will be turned ON.
62459584|NCT02613156||laparoscopic group|patients in the laparoscopic group underwent laparoscopic resection of recurrent HCC
62459585|NCT02613156||control group|patients in the control group underwent conventional open surgery
62459586|NCT00813293|EXPERIMENTAL|Sorafenib|Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
62459587|NCT00813293|PLACEBO_COMPARATOR|Placebo|Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
62283513|NCT05423405|EXPERIMENTAL|Intervention|Treatment as usual plus acupressure intervention with selected acupoints pressure
62283514|NCT02504281||RM|Women 18-43 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (miscarriage occurred earlier than 22 weeks of gestation for equal or greater than 3 times) in our IVF institute.
62283515|NCT02504281||Control|Normal females who are visiting Shanghai JIAI genetics and IVF institute for IVF/ICSI because of only male factor.
62459588|NCT02771548||Anterior Cruciate Ligament Reconstruction|Those who have undergone unilateral anterior cruciate ligament reconstructive surgery in the Sports Surgery Clinic.
62459589|NCT02771548||Control|Healthy volunteers with no previous knee injury, no current lower limb injuries and take part in regular multidirectional team sports.
62459590|NCT04589910|OTHER|Ultra-sound arm|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
62459591|NCT05809765|OTHER|Group 1 dialysis on Mondays, Wednesdays, and Fridays|8-week breath training by using a disposable, flow-oriented, Triflow three-ball incentive spirometer.
62459592|NCT05809765|OTHER|Group 2 dialysis on Tuesdays, Thursdays, and Saturdays|8-week breath training by using a disposable, flow-oriented, Triflow three-ball incentive spirometer.
62459593|NCT05293249|EXPERIMENTAL|Cohort A1 - 1x 0.5 mg|Participants (n=3) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, for a total dose of 0.5 mg of each plasmid.
62459594|NCT05293249|EXPERIMENTAL|Cohort A2 - 1x 1 mg|Participants (n=3) will be administered 1 mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, for a total dose of 1 mg of each plasmid.
62459595|NCT05293249|EXPERIMENTAL|Cohort B - 2x 0.5 mg|Participants (n=6) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 1 mg of each plasmid.
62459596|NCT05293249|EXPERIMENTAL|Cohort C - 2x 1 mg|Participants (n=6) will be administered 1mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 2 mg of each plasmid.
62459597|NCT05293249|EXPERIMENTAL|Cohort D - 2x 0.25 mg|Participants (n=6) will be administered 1 mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 2 mg of each plasmid.
62459598|NCT05293249|EXPERIMENTAL|Cohort E - 2x 2 mg|Participants (n=5) will be administered 2 mg of dMAb AZD5396 and 2 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 4 mg of each plasmid.
62283516|NCT01864616|EXPERIMENTAL|Group 3|Vitamin D3, 10,000 IU daily
62283517|NCT01864616|EXPERIMENTAL|Group 2|Vitamin D3 2,000 IU daily
62283518|NCT01864616|EXPERIMENTAL|Group 1|Vitamin D3 600 IU daily (Control group, RDA level)
62283519|NCT01681329|EXPERIMENTAL|Cognitive-behavioral therapy with interpretation training|14 sessions of cognitive-behavioral therapy combined with computerized interpretation modification training
62283520|NCT01681329|ACTIVE_COMPARATOR|Cognitive-behavioral therapy with non-active training|14 sessions of cognitive-behavioral therapy combined with computerized non-active training
62283521|NCT04147468|ACTIVE_COMPARATOR|Virtual Reality Gaming Intervention|A newly developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child, will be used. The research team will loan the system to the family. The child will be asked to move their arms to 'pop' as many virtual objects as possible with the focus on outwards, upwards, and across midline.
62283522|NCT04147468|EXPERIMENTAL|Functional Strength Training|Children will receive repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises which are designed to move their arms.
62283523|NCT04113915||Group 1|Group of ITP patients received triple therapy
62459599|NCT05293249|EXPERIMENTAL|Cohort F - 2x 0.5 mg|Participants (n=5) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0070 parameter on D0 and D3, for a total dose of 1 mg of each plasmid.
62459600|NCT05293249|EXPERIMENTAL|Cohort G - 4x 0.5 mg|Participants (n=5) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, D3, D28 and D31, for a total dose of 2 mg of each plasmid.
62459601|NCT02272764|OTHER|Itraconazole|Itraconazole or placebo
62459602|NCT02272764|EXPERIMENTAL|ALKS 5461|ALKS 5461 or placebo Sublingual tablet
62459603|NCT00982553|EXPERIMENTAL|Phase 1_ribavirin|Treatment with Single dose ribavirin (800 mg) administered on day 1
62283524|NCT04113915||Group 2|Group of ITP patients received steroids
62283525|NCT04113915||Group 3|Normal control group
62459604|NCT00982553|EXPERIMENTAL|Phase2_raltegravir|Treatment with Raltegravir (400 mg twice daily) administered from days 15-19
62459605|NCT00982553|EXPERIMENTAL|Phase3_ribavirin+raltegravir|Treatment with Ribavirin (800 mg) and Raltegravir (400 mg) administered day 20
62459606|NCT00710229|ACTIVE_COMPARATOR|A|Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
62459607|NCT00710229|ACTIVE_COMPARATOR|B|Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
62283526|NCT03778086||cataractous eyes|eyes of children with unilateral or bilateral cataract
62283527|NCT03778086||fellow eyes|fellow eyes of children with unilateral cataract
62283528|NCT02870231|EXPERIMENTAL|NNC9204-0530 / Placebo and Liraglutide 1.8|
62283529|NCT02870231|ACTIVE_COMPARATOR|NNC9204-0530 /Placebo and Liraglutide 3.0|
62459608|NCT01302496|EXPERIMENTAL|TriMix-DC and Ipilimumab|
62459609|NCT04205201|EXPERIMENTAL|Group A|Latanoprost
62459610|NCT04205201|OTHER|Group B|Brimonidine
62459611|NCT03512405|EXPERIMENTAL|Treatment (pembrolizumab, blinatumomab)|Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62283530|NCT06244797|PLACEBO_COMPARATOR|CONTROL GROUP|Patient group in which no material is placed in the extraction socket after impacted tooth extraction. There will be 25 patients in this group.
62459612|NCT06381609|EXPERIMENTAL|Peer support Group|"313 patients will be recruited over 3 years in the peer support group. Patients will be accompanied by an addiction peer support specialist, as part of an add-on follow-up compared with conventional follow-up (same management as in the control group)."
62283531|NCT06244797|ACTIVE_COMPARATOR|L-PRF (leukocyte-platelet rich fibrin):|The patient group in which L-PRF will be placed in the extraction socket after impacted tooth extraction. There will be 25 patients in this group. Device information to be used: Electromag M815P centrifuge device.
62459613|NCT06381609|ACTIVE_COMPARATOR|Control Group|"313 patients will be recruited over 3 years in the control group. Patients will receive as usual outpatient abstinence-maintenance follow-up, with consultations of all kinds (medical, psychological, nursing, group, etc.)"
62459614|NCT05106166|EXPERIMENTAL|Experimental group: occupational therapy program + the usual special education program (USEP)|"The practitioner used the less-to-more orientation to get the child to respond to the offer of joint attention. For example, if the child did not respond to the joint attention offer within 5-10 seconds, practitioner first directed the child, used exaggerated gestures, gave a moving hint if he still did not respond, and physically slowly directed the child's head towards the target if he still did not respond. In addition, the practitioner gave a verbal command (practitioner said: look at how his arms are waving, pointing to the toy, now look at me). When the child looked at the toy and reacted, he again gave enthusiastic and activity-appropriate feedback (e.g. he tickled the child, saying, Isn't it weird, is there ever such a long arm?). The child's interest and leadership in the activities were followed, including what the child did and said. Positive feedback was then provided."
62459615|NCT05106166|ACTIVE_COMPARATOR|Control group: the usual special education program (USEP)|The USEP studied was including gross motor skills, communication skills, preschool preparation skills, and self-care skills. The control group of the study consisted of children attending the USEP.
62459616|NCT03107468|EXPERIMENTAL|Mokhuri intensive treatment group|Patients in this arm will be treated with 35-week of Mokhuri intensive treatment program which compromise 10 sessions of acupuncture, Chuna and patient consultation during 5 weeks.
62283532|NCT06244797|ACTIVE_COMPARATOR|H-PRF (horizontal-platelet rich fibrin)|The patient group in which H-PRF will be placed in the extraction socket after impacted tooth extraction. There will be 25 patients in this group. Device information to be used: Electromag M815A2 centrifuge device.
62283533|NCT03661320|ACTIVE_COMPARATOR|Arm A: Gemcitabine/Cisplatin (GC) Chemotherapy|
62283534|NCT03661320|EXPERIMENTAL|Arm B: Nivolumab + GC Chemotherapy|
62283535|NCT03365778|ACTIVE_COMPARATOR|Patient Educational Intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
62283536|NCT03365778|PLACEBO_COMPARATOR|Usual care group|Patients receive standard of care.
62084049|NCT02438462||Group without PE|"The criteria for exclusion of PE are:~* low or moderate clinical probability and D-dimer ELISA \<0.50 µg/mL or \<10xage in patients older than 50 years and negative follow up~* low and moderate clinical probability and negative CT and negative follow up~* high clinical probability and negative CT, US and follow up."
62084050|NCT00918749|ACTIVE_COMPARATOR|150 mg|150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
62084051|NCT00918749|EXPERIMENTAL|75 mg|75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
62650754|NCT02935920|EXPERIMENTAL|Individual, tailored follow-up|Patient symptoms are evaluated by the use of PRO-data to uncover the needs of a consultation. The outcome of the questionnaire is used to customize the follow-up program to the individual patient.
62650755|NCT02935920|NO_INTERVENTION|Standard follow-up|Scheduled clinical examination every six months throughout the course of adjuvant treatment. Performed by a doctor or nurse.
62650756|NCT06057064|PLACEBO_COMPARATOR|Placebo|Single dose of Placebo IM (0.9% sodium chloride)
62650757|NCT06057064|EXPERIMENTAL|AZD3152|Single dose of 300 mg IM
62650758|NCT00945243|OTHER|Treatment|Treatment of cervical DDD with the Zero-P device
62084052|NCT00918749|EXPERIMENTAL|100 mg|100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
62084053|NCT01919463|NO_INTERVENTION|Control Group|Colonoscopy is completed without abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process.
62084054|NCT01919463|EXPERIMENTAL|Experimental Group 2 (Monitoring)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression by his subjective judgement.
62283537|NCT03365778|OTHER|Ophthalmologist Educational Intervention group|General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database receive online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT).
62459617|NCT03107468|ACTIVE_COMPARATOR|Non-surgical conventional treatment group|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment during 5 weeks.
62459618|NCT03341481|EXPERIMENTAL|Femaltiker|7.7 g of Femaltiker twice a day for 14 days of the trial.
62650759|NCT02254746|EXPERIMENTAL|Phase I (dose escalation)/ Phase II|"Phase I~* Prostate tumor: starting dose 9 Gy per fraction in 5 fractions (total 45 Gy) and subsequent dose escalation up to 10 Gy.~* Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions (no dose escalation). Total 36.25 Gy.~Phase II~Additional patients will be treated at either the maximum tolerated dose (MTD) or at the highest dose level as determined by the investigators from the Phase I portion of the study."
62650760|NCT05423418|ACTIVE_COMPARATOR|A244/B.63521 + 200 μg of ALFQ adjuvant|Arm 1: An injection containing 300 μg A244 plus 300 μg B.63521 with 200 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
62283538|NCT05079490|NO_INTERVENTION|Baseline|All children will receive outcome measures.
62459619|NCT03341481|PLACEBO_COMPARATOR|placebo|7.7 g placebo 14 days of the trial.
62459620|NCT00041509|EXPERIMENTAL|SB424323, 500 mg BID|
62650761|NCT05423418|ACTIVE_COMPARATOR|A244/B.63521 + 100 μg of ALFQ adjuvant|Arm 2: An injection containing 300 μg A244 plus 300 μg B.63521 with 100 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
62650762|NCT05423418|ACTIVE_COMPARATOR|A244/B.63521 + 50 μg of ALFQ adjuvant|Arm 3: An injection containing 300 μg of A244 plus 300 μg B.63521 with 50 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
62650763|NCT03869099||Sindh|
62650764|NCT03869099||KPK|
62650765|NCT03869099||Punjab|
62650766|NCT03869099||Balochistan|
62650767|NCT05645198|EXPERIMENTAL|Oozfix|Arm with oozfix after gastrectomy
62650768|NCT05645198|ACTIVE_COMPARATOR|Greenplast|Arm with greenplast after gastrectomy
62650769|NCT02371616|EXPERIMENTAL|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
62650770|NCT02371616|ACTIVE_COMPARATOR|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
62653077|NCT03823144|EXPERIMENTAL|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.
62283539|NCT05079490|EXPERIMENTAL|Intervention phase|Children in the experimental group will receive intervention for 12 weeks while children in the control group remain their regular activities.
62283540|NCT05079490|NO_INTERVENTION|Follow up phase|All children will be followed after the end of intervention phase and receive outcome measures at 3- and 6-month after the completion of intervention.
62650771|NCT06027515|EXPERIMENTAL|Prehabilitation Program|"30 participants will be enrolled and will complete study procedures as follows:~* Enrollment at least 4 weeks prior to esophageal cancer surgery.~* In-person clinic visit with dietitian and physical therapist for assessments, and completion of baseline questionnaires with study coordinator.~* Adherence to daily physical function, dietary, and sleep recommendations and consumption of 5-day immunonutrition supplement.~* Regular electronic/phone-call check-ins with study staff.~* Telehealth appointment with physical therapist and dietitian prior to surgery.~* After surgery and during hospital admission, final visit with dietitian and physical therapist for assessments, and completion of questionnaires.~* 6-month follow-up period."
62084055|NCT01919463|EXPERIMENTAL|Experimental Group 1 (Guiding)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown both to investigators for study and to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression according to the guidance of magnetic endoscopic imaging system.
62084056|NCT03029780|EXPERIMENTAL|Co-Administration|Nivolumab and Ipilimumab Co-Administration
62084057|NCT03029780|EXPERIMENTAL|Sequential Administration|Nivolumab and Ipilimumab Sequential Administration
62650772|NCT05808179|EXPERIMENTAL|Light + Cognitive Behavioral Therapy (CBT)|1 hour of light flashes (typical wake time - 75 min → typical wake time - 15 min) and cognitive behavioral therapy
62084058|NCT03772743|OTHER|Culprit-only revascularization|All patients randomized to culprit only revascularization must not undergo percutaneous coronary intervention (PCI) any lesion except from the culprit lesion already treated at the moment of the randomization. Staged procedures are considered protocol violation.
62084059|NCT03772743|OTHER|Complete functionally-guided revascularization|Patients who are randomized to this strategy will receive revascularization of the culprit lesion and guided by functional assessment on all non-culprit lesions. Functional evaluation is mandatory for all stenosis with diameter stenosis % between 50 and 90% at visual estimation. Revascularization must be guided by functional assessment on all vessels. The system utilized to obtain functional evaluation is left to Operator's discretion. PCI is allowed only if functional evaluation is positive according to the threshold of the chosen functional system. It is suggested to achieve functional complete revascularization within the index procedure, while it is mandatory to obtain it within the index hospitalization.
62084060|NCT00804869||1|PalmScan biometric group
62084061|NCT00804869||2|A-mode ultrasonography biometric group
62084062|NCT01621282|EXPERIMENTAL|Education|Departments passed 6-month interactive educational course
62283541|NCT03206723|ACTIVE_COMPARATOR|Group 1|1. Standard care
62283542|NCT03206723|ACTIVE_COMPARATOR|Group 2|"1. Standard care~2. Bandage contact lens"
62084063|NCT01621282|NO_INTERVENTION|No Education|Departments not passed 6-month interactive educational course
62283543|NCT00545701|EXPERIMENTAL|1|
62650773|NCT05808179|ACTIVE_COMPARATOR|Sham light + CBT|1 hour of sham light flashes (one flash) and cognitive behavioral therapy
62084064|NCT03506217||mitral valve prolaps|Hemodynamic recovery and anesthesia revealed by invasive arterial cardiac output (CO) measurement (Vigileo Flo-trac device) in 13 cases who underwent mitral valve (MV) repair with the transapical off-pump minimally invasive method in our clinic.
62283544|NCT04822545|OTHER|Intervention Arm|"-Adult (≥ 18 years of age) hospitalized patients who have obesity (BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 if Asian/South Asian), as recorded in the medical chart, who have decision-making capacity and whose acute medical condition has been stabilized.~we will exclude patients who are enrolling in hospice/comfort care and the patients who are already enrolled in the CWM clinic. Non-English speaking patients. Patients who have opted out of research in their Epic EHR will be excluded from consideration for participation."
62283545|NCT01662440|ACTIVE_COMPARATOR|R/JE - Conv|Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
62283546|NCT01662440|EXPERIMENTAL|R/JE - Acc|Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
62084065|NCT04814485|EXPERIMENTAL|SHR-1020 combined with albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel
62084066|NCT03208400|OTHER|virtual reality exposure|one-session exposure conveyed via virtual reality technology
62650774|NCT02192788|EXPERIMENTAL|SBRT|Stereotactic Body Radiation Therapy for Oligometastases (SBRT)
62084067|NCT06451744|EXPERIMENTAL|Oral lichen planus erosive|"Human biological samples :~* blood samples collection at visit 1 and 2 (6 month after first visit)~* brushing on skin or mucous membrane lesions at visit 1~* skin or mucous membrane biopsy at visit 1 and 2"
62084068|NCT06451744|EXPERIMENTAL|mucosal pemphigoid with oral lesions|"Human biological samples :~* blood samples collection at visit 1~* brushing on skin or mucous membrane lesions at visit 1"
62084069|NCT06451744|EXPERIMENTAL|lichen planus with scalp involvement|"Human biological samples :~* blood samples collection at visit 1~* brushing on skin or mucous membrane lesions at visit 1"
62084070|NCT06451744|EXPERIMENTAL|Pseudopelade of Brocq|"Human biological samples :~* blood samples collection at visit 1~* brushing on skin or mucous membrane lesions at visit 1~* skin or mucous membrane biopsy at visit 1"
62084071|NCT06451744|EXPERIMENTAL|lichen planus with nail involvement|"Human biological samples :~* blood samples collection at visit 1~* brushing on skin or mucous membrane lesions at visit 1"
62084072|NCT06451744|EXPERIMENTAL|psoriasis and specific nail involvement|"Human biological samples :~* blood samples collection at visit 1~* brushing on skin or mucous membrane lesions at visit 1"
62084073|NCT06451744|EXPERIMENTAL|Lichenoid graft-versus-host disease|"Human biological samples :~* blood samples collection at visit 1~* brushing on skin or mucous membrane lesions at visit 1"
62084074|NCT04326985|EXPERIMENTAL|Autologous Mesenchymal Stem Cells Treatment (MSCs)|"The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.~The treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.~T0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
62084075|NCT04326985|ACTIVE_COMPARATOR|Hyaluronic acid (HA)|"The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.~T0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
62084076|NCT02786043|EXPERIMENTAL|Single arm|
62084077|NCT06196645|EXPERIMENTAL|Intervention Group-1|Participants in this arm of the experimental group will participate in a school-based intervention program that is based on the theory of planned behavior and includes behavior change techniques. These participants will participate in the intervention plan only in physical education and sports classes at their schools.
62084078|NCT06196645|EXPERIMENTAL|Intervention Group-2|Participants in this arm of the experimental group will participate in a school-based intervention program based on the theory of planned behavior and including behavior change techniques, and at least one of the parents of these participants will also participate in this application. Adolescent female participants will participate in the intervention plan only in physical education and sports classes at their schools. Parents will be invited to physical education and sports classes or participate in the application online, depending on their time availability.
62084079|NCT06196645|NO_INTERVENTION|Control Group|This group will not be involved in any implementation until the end of the research. Ethically, after the research is completed, the proposal to repeat the most effective intervention arm for this group will be presented to the participants in this group.
62084080|NCT02262611||Hypertension patients - Pneumology|
62084081|NCT02262611||Hypertension patients - Cardiology|
62084082|NCT02262611||Hypertension patients - Nephrology|
62084083|NCT02262611||Hypertension patients - Diabetology|
62084084|NCT05449574||people with MS|People with MS with relapsing-remitting form
62283547|NCT01662440|ACTIVE_COMPARATOR|R - Conv|Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
62084085|NCT05449574||healthy people|people from the age of 30-45 years old
62084086|NCT00938119||Diabetes patients with PCI|this is single group
62283548|NCT01662440|ACTIVE_COMPARATOR|JE - Conv|Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.
62283549|NCT01885000|EXPERIMENTAL|Brimonidine tartrate 0.5% gel|Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
62084087|NCT03020095|EXPERIMENTAL|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
62084088|NCT01517841||Chronic kidney disease|Patients with chronic kidney disease (20% or less kidney function remaining. Patients with end stage renal disease who are currently receiving dialysis.
62084089|NCT04130906|ACTIVE_COMPARATOR|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
62084090|NCT04130906|SHAM_COMPARATOR|Sham Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
62084091|NCT00955903|EXPERIMENTAL|Weight Loss|Participants receive Exercise and Reduced Calorie Diet Interventions
62084092|NCT00955903|ACTIVE_COMPARATOR|Control|Participants receive Exercise Intervention
62084093|NCT00955903|ACTIVE_COMPARATOR|Weight Maintenance|Participants receive Exercise and a Weight Maintenance Diet Interventions
62283550|NCT01885000|PLACEBO_COMPARATOR|Vehicle|Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.
62283551|NCT04241965|EXPERIMENTAL|Intervention 1|Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
62283552|NCT04241965|PLACEBO_COMPARATOR|Placebo|Single dose; potential for a matching OPC-214870 dose to be administered.
62283553|NCT01936389|EXPERIMENTAL|0.5%|0.5% Rho-Kinase Inhibitor
62283554|NCT01936389|EXPERIMENTAL|0.7%|0.7% Rho-Kinase Inhibitor
62459621|NCT00041509|EXPERIMENTAL|SB424323, 125 mg BID|
62084094|NCT06442813|EXPERIMENTAL|EXPERİMENTAL GROUP|"First Stage: Determining the groups by randomization method and filling out the data collection forms for the groups (pre-test).~Second Stage: Training pregnant women in the control group on the management of standard hyperemesis gravidarum (training content will be prepared and opinions will be obtained from 3 experts in the field).~For the intervention group, pregnant women were given a session with EFT (Average: 40-60 minutes) and a program was created for the pregnant woman to do affirmations in between depending on her condition (Positiveness with EFT strokes 3 times a day).~Third Stage: After 15 days, it is planned to conduct post-tests for both groups and complete the study. In the final stage, pregnant women\&amp;#39;s questions will be answered, counseling will continue where deemed necessary, and prepared training booklets will be given to pregnant women"
62084095|NCT06442813|NO_INTERVENTION|CONTROL GROUP|Pregnant women diagnosed with hyperemesis gravidarum (HG) who meet the inclusion criteria for the study will constitute the control group. Providing training to the control group only for HG management (training content will be prepared and opinions will be obtained from 3 experts in the field).
62084096|NCT00778063|PLACEBO_COMPARATOR|saline|intranasal saline will be given 30 minutes prior to surgery
62084097|NCT00778063|EXPERIMENTAL|dexmedetomidine|2 mcg/kg dexmedetomidine will be given intranasally 30 minutes prior to surgery
62084098|NCT04602494|EXPERIMENTAL|Varenicline|Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
62084099|NCT04602494|PLACEBO_COMPARATOR|Placebo|Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
62084100|NCT04602494|NO_INTERVENTION|Monitoring only|Participants will attend weekly and monthly sessions that will only consist of assessments. No study medication, no behavioral or texting support.
62283555|NCT01308411|EXPERIMENTAL|50% reduction in ICS dose|All patients will reduce their inhaled corticosteroid dose by 50%
62283556|NCT05825066|EXPERIMENTAL|Neoadjuvant Chemotherapy (Gemcitabine and nab-Paclitaxel and mFOLFIRNIOX)|"* Gemcitabine (1000 mg/m2 weekly, on day 1,8 and 15 OR 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab-paclitaxel infusion.~* nab-Paclitaxel (125 mg/m2 weekly, on days 1,8, and 15 OR on days 1 and 15 as a 30-40 minute infusion administered first) for one month and then transition to mFOLFIRNIOX for one month~  1 Cycle = 4 weeks: Day 1,8,15 in a 28 day cycle; 3 consecutive weeks (weeks 1, 2, and 3) of chemotherapy with 1 week off, OR~  1 Cycle = 4 weeks: Day 1, 15 in a 28 day cycle; Every other week (weeks 1 and 3) of chemotherapy with 2nd and 4th week off~* mFOLFIRINOX: Oxaliplatin, 85 mg/m² IV once every two weeks over 2 hours on Day 1 Irinotecan, 150 mg/m² IV once every two weeks over 90 minutes on Day 1 5-FU, 2,400 mg/m² IV once every two weeks over 46-48 hours administered via infusion Leucovorin, 400 mg/m2 IV every two weeks over 90 minutes on Day 1~  1. Cycle = 4 weeks, administration on Day 1 and Day 15 of each mFOLIRINOX cycle"
62283557|NCT04573387|ACTIVE_COMPARATOR|Fixed-time drainage|Drainage will be removed after 48 hours.
62283558|NCT04573387|EXPERIMENTAL|Exhaustive drainage|Drainage will be removed when postoperative hematoma volume is minimized with repeated urokinase injection into hematoma cavity through catheter.
62459622|NCT00041509|PLACEBO_COMPARATOR|Placebo|
62459623|NCT04431947||Youth|Youth, between the ages of 2 and 17, with type 1 diabetes
62459624|NCT04431947||Parent|Parents of youth with type 1 diabetes
62650775|NCT01094288|EXPERIMENTAL|Alisertib + Docetaxel|"Alisertib in escalating dose (10-40 mg), enteric-coated tablets (ECT), orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 along with docetaxel 60-75 mg/m\^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable adverse events (AEs) or withdrawal of consent.~The starting alisertib dose is 10 mg, orally, twice daily (total 20 mg/day)."
62650776|NCT01822444||Intent-to-treat population with aCRC or mCRC|Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria
62459625|NCT06329947|EXPERIMENTAL|Experimental group|Surufatinib in combination with Camrelizumab and mFOLFOX6
62459626|NCT00679965|EXPERIMENTAL|Group 1|AN2690 Solution, 2.5%
62459627|NCT00679965|EXPERIMENTAL|Group 2|AN2690 Solution: 5%
62459628|NCT00679965|EXPERIMENTAL|Group 3|AN2690 Solution, 7.5%
62459629|NCT00679965|PLACEBO_COMPARATOR|Group 4|AN2690 Solution Vehicle
62459630|NCT01273181|EXPERIMENTAL|Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10\^9-3x10\^10, and greater than 3x10\^10-1x10\^11 in a standard phase I dose escalation fashion using a 3+3 design."
62461819|NCT04513964||COVID-19|Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology
62461820|NCT05266430||Case Group|Patients with primary Choroidal Melanoma and Indeterminate Lesions who have received belzupacap sarotalocan (bel-sar; AU-011) in a previous Aura sponsored clinical trial
62283559|NCT03942315||Liver transplant in Hereditary Hemorrhagic Telangiectasia|Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
62283560|NCT02213874|OTHER|Questionnaire|A questionnaire will be administered during the early stages of prenatal care \& again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy \& collect information about demographics, contraceptive \& reproductive history, future pregnancy intentions, \& baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy \& contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, \& the type of counseling received.
62283561|NCT04931953|ACTIVE_COMPARATOR|Group 1|iTBS intervention lasting 30 minutes, given 4 days a week, for 1 week
62283562|NCT04931953|ACTIVE_COMPARATOR|Group 2|iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks
62283563|NCT04931953|ACTIVE_COMPARATOR|Group 3|iTBS intervention lasting 30 minutes, given 4 days a week, for 4 weeks
62283564|NCT04931953|SHAM_COMPARATOR|Group 4|Sham iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks.
62283565|NCT01557829|ACTIVE_COMPARATOR|PEEK interbody cage|Posterior fusion with an interbody spacer (cage) made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is filled with local bone or bone harvested from the iliac crest.
62283566|NCT01557829|EXPERIMENTAL|Valeo OL ceramic cage|Posterior fusion with the Valeo OL cage, a silicon nitride ceramic interbody spacer. The center area of the cage is filled with autograft local bone or bone harvested from the iliac crest.
62283567|NCT06314464|EXPERIMENTAL|Praxis|Fifteen SMs with post-acute mTBI and residual dizziness/imbalance complaints from the Center for the Intrepid's Special Operations Performance and Recovery (SPaR) Program will receive 4 weeks of Praxis intervention (45 minutes, 5 days per week)
62459631|NCT01273181|EXPERIMENTAL|Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10\^9-3x10\^10, and greater than 3x10\^10-1x10\^11 in a standard phase I dose escalation fashion using a 3+3 design."
62459632|NCT01273181|EXPERIMENTAL|Ph II:Anti-MAGE TCR PBL MTD+HD IL-2|"Phase II:Anti-MAGE A3/12 TCR PBL MTD + HD IL-2, Melanoma, RCC~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
62650777|NCT01673386|EXPERIMENTAL|Tivozanib Hydrochloride|1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks.
62283568|NCT06314464|ACTIVE_COMPARATOR|Control|Fifteen SMs without dizziness/imbalance complaints from the Center for the Intrepid's Special Operations Performance and Recovery (SPaR) Program will receive 4 weeks of supervised cardiovascular activity (45 minutes, 5 days per week)
62283569|NCT01966770|ACTIVE_COMPARATOR|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
62283570|NCT01966770|ACTIVE_COMPARATOR|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
62283571|NCT01966770|ACTIVE_COMPARATOR|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
62283572|NCT01966770|ACTIVE_COMPARATOR|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
62283573|NCT01966770|ACTIVE_COMPARATOR|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
62283574|NCT01966770|ACTIVE_COMPARATOR|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
62283575|NCT05513014||Secukinumab: Overall Cohort|Patients with Psoriasis who initiated Secukinumab
62283576|NCT05513014||Biologic Experienced|Patients who had the history of use of ≥1 biologic medication for the treatment of PsO at the time of SEC initiation
62283577|NCT05513014||Biologic Naive|Patients who had no history of use of biologic medication for the treatment of PsO at the time of SEC initiation
62283578|NCT06124131|EXPERIMENTAL|Full financial incentives|$50/service patient financial incentive for completion of: COVID-19 shot, flu shot, colorectal cancer screening
62283579|NCT06124131|ACTIVE_COMPARATOR|Partial financial incentives|$50/service patient financial incentive for completion of: COVID-19 shot, flu shot
62283580|NCT03603002|EXPERIMENTAL|Stage I NSCLC with SABR Therapy|Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
62084101|NCT03654053|EXPERIMENTAL|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
62084102|NCT03654053|PLACEBO_COMPARATOR|Placebo|Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
62084103|NCT02544737|EXPERIMENTAL|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
62084104|NCT01984710|EXPERIMENTAL|DBS for Treatment Resistant Depression|"DBS for TRD: Exploration of LFP with the Medtronic Activa PC+S Brain Radio system"
62084105|NCT01844193|NO_INTERVENTION|Standard Therapy|This arm of the study will follow the standard therapy course after total knee arthroplasty.
62084106|NCT01844193|EXPERIMENTAL|Standard Therapy + NMES|This arm will follow the standard course of therapy but also incorporate daily neuromuscular electrical stimulation into the daily therapy regimen after total knee arthroplasty through use of the Compex Rehab device.
62084107|NCT00900627|EXPERIMENTAL|1|AZD8931 plus Paclitaxel
62283581|NCT01901094|OTHER|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
62459633|NCT01273181|EXPERIMENTAL|Ph II:Anti-MAGE A3/12 TCR PBL MTD|"Phase II: Anti-MAGE A3/12 TCR PBL MTD + HD-IL2 Other Cancer~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
62459634|NCT03536624|EXPERIMENTAL|Experimental group|"Participants will be involved in a short-term spa residential program of 6 days combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.~After the program, participants will be followed for 12 months."
62459635|NCT04599699|EXPERIMENTAL|1|"Simultaneously integrated boost or sequential integrated boost~* Simultaneously integrated boost Prostate tumor: starting dose 8.7 Gy per fraction in 5 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy.~* Sequential integrated boost Prostate tumor: starting dose 7.25 Gy per fraction in 6 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy."
62459636|NCT00762086|ACTIVE_COMPARATOR|Treatment Group|AngioPress Intermittent pneumatic compression (IPC) Device
62459637|NCT00762086|OTHER|Control Group|Aspirin/Clopidegrol and Standard walking exercises
62459638|NCT04338126|EXPERIMENTAL|Tranexamic Acid Treatment|Oral dosing of tranexamic acid at dose of 1300 mg p.o. three times per day x 5 days; alternative dosing intravenously with loading dose of 10 mg/kg followed by 1 mg/kg/hr infusion x 5 days
62459639|NCT04338126|PLACEBO_COMPARATOR|Placebo Treatment|2 tablets of placebo three times per day x 5 days; alternative dosing intravenous normal saline at volumes similar to those use for experimental arm
62459640|NCT06485258|EXPERIMENTAL|3.75 µg CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM)|20 healthy adults will be administered via IM injection a single dose of IRV at days 1, 29 and 57
62650778|NCT01673386|ACTIVE_COMPARATOR|Sunitinib|50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks.
62650779|NCT02957201|OTHER|Blood samples|Blood samples taken at baseline, day 1-2, day 3-4 and day 7-8 for Endothelial Progenitor Analysis with flow cytometer
62650780|NCT02332603|ACTIVE_COMPARATOR|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
62084108|NCT00900627|PLACEBO_COMPARATOR|2|Placebo plus Paclitaxel
62084109|NCT04141579|EXPERIMENTAL|Treatment arm|Evolocumab (140mg) will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of 140 mg/mL Evolocumab.
62084110|NCT04141579|PLACEBO_COMPARATOR|Comparator arm|Placebo will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of placebo.
62084111|NCT04707391|EXPERIMENTAL|ABCWY Group|Participants received 2 doses of the MenABCWY vaccine on Day 1 and Day 181 (0,6-month schedule) and 1 dose of placebo on Day 211.
62084112|NCT04707391|ACTIVE_COMPARATOR|ACWY Group|Participants received 1 dose of MenACWY vaccine on Day 1 and 2 doses of MenB vaccine on Day 181 and Day 211.
62084113|NCT06058871|EXPERIMENTAL|EMI intervention group|Participants in the intervention group will receive instant messaging (i.e., an EMI delivery platform). Our multidisciplinary team, including an obstetrician, midwife, lactation consultant, biostatistician, and social psychologist, will develop a message library and protocol for EMI delivery.
62084114|NCT06058871|NO_INTERVENTION|Control group|Participants in the control group will receive text messages containing general information on breastfeeding from the Hospital Authority, which is open to the public and includes reminder text messages of important follow-up surveys. Messages will not be personalised, and nurse-led real-time support messages will not be available.
62084115|NCT03757169|ACTIVE_COMPARATOR|Control group|Verbal informations about the disease, and exercise behavior, and nutrition.
62459641|NCT06485258|EXPERIMENTAL|7.5 µg CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM)|20 healthy adults will be administered via IM injection a single dose of IRV at days 1, 29 and 57
62459642|NCT01417078|EXPERIMENTAL|Diazepam Nasal Spray|
62459643|NCT01751152|EXPERIMENTAL|NNC0114-0006|
62459644|NCT01751152|PLACEBO_COMPARATOR|Placebo|
62459645|NCT02328443|EXPERIMENTAL|midazolam alone|midazolam administration alone
62084116|NCT03757169|ACTIVE_COMPARATOR|Hand grip group|Three supervised sessions por week: 4 series (2 at each arm) of two minutes of isometric hand grip contraction at 30% of maximal voluntary contraction. Between series there will be two minutes to rest.
62084117|NCT05280470|EXPERIMENTAL|Ifinatamab Deruxtecan (8 mg/kg)|Participants will be randomized to receive I-DXd at 8 mg/kg.
62084118|NCT05280470|EXPERIMENTAL|Ifinatamab Deruxtecan (12 mg/kg)|"Participants will be randomized to receive I-DXd at 12 mg/kg.~In Part 2, all participants will receive I-DXd 12 mg/kg."
62084119|NCT00824174||Questionnaire|1 questionnaire, about 15-20 minutes.
62084120|NCT02911337|EXPERIMENTAL|Lifestyle modification|Lifestyle modification
62084121|NCT00763932|EXPERIMENTAL|1|
62084122|NCT01190033|ACTIVE_COMPARATOR|Neurolysis|In this intervention the neurotome will be connected
62084123|NCT01190033|PLACEBO_COMPARATOR|Neurotome OFF|neurotome not raised
62084124|NCT06261944|OTHER|All participants|All individuals will be screened for their diabetes risk / status (if previously undiagnosed)
62084125|NCT01443429|EXPERIMENTAL|subjects with normal renal function|
62459646|NCT02328443|EXPERIMENTAL|midazolam and itraconazole|Itraconazole 200 mg PO twice; midazolam iv single administration
62084126|NCT01443429|EXPERIMENTAL|patients with mild renal impairment|
62084127|NCT01443429|EXPERIMENTAL|patients with moderate renal impairment|
62459647|NCT02328443|EXPERIMENTAL|midazolam and rifampicin|rifampicin 150 mg PO for 9 days administration, midazolam iv single administration
62459648|NCT00302705|ACTIVE_COMPARATOR|Valsartan|160 mg/day on awakening
62459649|NCT00302705|ACTIVE_COMPARATOR|Enalapril|10-20 mg/day on awakening
62084128|NCT01443429|EXPERIMENTAL|patients with severe renal impairment|
62084129|NCT04814017|EXPERIMENTAL|Radial shock-wave group|Group I (15 subjects) received radial shock-wave application one times a week for six weeks and home based stretching exercises.
62459650|NCT00811668|EXPERIMENTAL|CPAP before SOMNOVentCR|started with CPAP and continued with SOMNOvent CR
62650781|NCT02332603|PLACEBO_COMPARATOR|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
62650782|NCT04117022|EXPERIMENTAL|supplemented arm|Each subject will receive DVS formula, 2 softgels per day for 6 months.
62084130|NCT04814017|EXPERIMENTAL|Control|Group II (15 subjects) received home based stretching exercises for six weeks.
62283582|NCT01901094|OTHER|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
62283583|NCT01291017|EXPERIMENTAL|PD0332991|PD0332991 125 mg PO days 1 - 21
62084131|NCT01591161|EXPERIMENTAL|Mapracorat|Mapracorat ophthalmic suspension, 3%,
62084132|NCT01591161|PLACEBO_COMPARATOR|Vehicle|The vehicle of the mapracorat ophthalmic suspension
62084133|NCT04276818|ACTIVE_COMPARATOR|PRP group|Second-degree superficial burn group treated with PRP
62084134|NCT04276818|ACTIVE_COMPARATOR|conventional treatment group|second-degree superficial burn group treated with cream containing silver sulfadiazine
62084135|NCT01773538|ACTIVE_COMPARATOR|Anti cHE treatment arm|Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
62084136|NCT01773538|PLACEBO_COMPARATOR|Placebo arm|The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
62084137|NCT04381702||Patients with an open approach|Patients requiring pancreatoduodenectomy and operated with an open approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology before the first laparoscopic pancreaticoduodenectomy.
62283584|NCT05000346|EXPERIMENTAL|Experimental AQ001S 0.125 mg/mL quarter in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation 4 times a day
62084138|NCT04381702||Patients with a laparoscopic approach|Patients requiring pancreatoduodenectomy and operated with a laparoscopic approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology operated with a laparoscopic approach.
62084139|NCT00598481|EXPERIMENTAL|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
62084140|NCT04932720|EXPERIMENTAL|experimental group|Experimental group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
62283585|NCT05000346|EXPERIMENTAL|Experimental AQ001S 0.125 mg/mL bis in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation twice a day + placebo by inhalation twice a day
62283586|NCT05000346|PLACEBO_COMPARATOR|Comparator: placebo|No active drug - administered by inhalation 4 times a day
62283587|NCT04982640|EXPERIMENTAL|Yoga|12-week program, 60 minutes, twice weekly group-delivered Iyengar yoga
62283588|NCT04982640|ACTIVE_COMPARATOR|Standard Exercise|12-week, 60 minutes, twice weekly group-delivered aerobic exercise (e.g., walking) program
62283589|NCT01482078||Receive MgSO4 infusion|Parturients who present to the hospital at less than 34 weeks gestational age with potential pre-term labor, pre-term rupture of membranes or intrauterine growth restriction
62459651|NCT00811668|EXPERIMENTAL|SOMNOVentCR before CPAP|began with SOMNOvent CR and ended with CPAP
62459652|NCT03946501||clinical research visit|
62459653|NCT03970122|EXPERIMENTAL|GFB-887 SAD active|GFB-887 single dose active
62459654|NCT03970122|PLACEBO_COMPARATOR|GFB-887 SAD placebo|GFB-887 single dose placebo
62459655|NCT03831451|EXPERIMENTAL|Stroke Preparedness Intervention|The stroke preparedness educational intervention was designed with input from the community where it is being tested. It will be delivered in-person by a research team member. The intervention focuses on recognizing stroke symptoms and the importance of calling 911.
62461821|NCT05266430||Control Group|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
62459656|NCT03831451|ACTIVE_COMPARATOR|Healthy lifestyle intervention|The Healthy lifestyle stroke risk reduction educational intervention is based on patient materials from the American Heart Association. It will be delivered in-person by a research team member. The intervention focuses on stroke risk reduction.
62459657|NCT04745962||Procedural group|
62459658|NCT02016612|ACTIVE_COMPARATOR|Reduction, Mastopexy No Implant, No Seri|Patients undergoing reduction or mastopexy but no implant is used and no Seri Surgical Scaffold support is used
62084141|NCT04932720|NO_INTERVENTION|control group|Also the control group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
62283590|NCT01482078||Do not receive MgSO4 infusion|"We will approach a control group of subjects: i.e. parturients undergoing cesarean section (elective or emergency) with neuraxial anesthesia.~We will seek to ensure that the control group is similar to the study group with respect to the following parameters:~* Number of singleton or multiple pregnancy~* Parity of parturients~* Anesthetic technique (spinal or epidural)~* Time of cesarean section (08:00-19:59 or 20:00 to 07:59) Once informed consent is obtained these subjects will be treated identically to the study group in terms of anesthetic management and data collection."
62283591|NCT02146287|ACTIVE_COMPARATOR|Early Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 28 weeks PMA
62283592|NCT02146287|ACTIVE_COMPARATOR|Late Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 36 weeks PMA
62283593|NCT05501093||Diabetic patients|Diabetic patients who plan to undergo bariatric surgery
62459659|NCT02016612|ACTIVE_COMPARATOR|Mastopexy, Implant no Seri Scaffold|Mastopexy with implant, No Seri Surgical Scaffold support is used
62650783|NCT03668106|ACTIVE_COMPARATOR|swim up method|Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
62653078|NCT03963440|EXPERIMENTAL|Cohorte 1|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
62653079|NCT01457794|OTHER|NewNordicDiet first|Intervention with NND for 3 mo then no intervention for 3 mo
62084142|NCT01093300|EXPERIMENTAL|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion
62283594|NCT05501093||Normo-glycemic (non-diabetic) patients|Non-diabetic patients who plan to undergo bariatric surgery
62283595|NCT00464204|EXPERIMENTAL|Voluven® Arm|
62283596|NCT00464204|ACTIVE_COMPARATOR|0.9 % NaCl|
62283597|NCT06237517|EXPERIMENTAL|Progressive acclimation of healthy individuals with Idiopathic Chilblains|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes, the temperature was maintained at 10°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test for 15 minutes, and an occlusion foot test (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase, and 5 minutes ''release'' phase) was performed to observe any hemodynamic changes in the foot. Participants provided blood and urine samples before and following the trial.
62459660|NCT02016612|ACTIVE_COMPARATOR|Breast Reduction with Seri Support|Patients undergoing breast reduction with the use of Seri Surgical scaffold support
62459661|NCT02016612|ACTIVE_COMPARATOR|Augmentation Mastopexy, Implant and Seri|Augmentation Mastopexy patients where Seri Surgical scaffold is used
62459662|NCT01483352|EXPERIMENTAL|Single Arm|Participants were implanted with Accu-Chek DiaPort with Infusion Set connected to an Accu-Chek Insulin Pump to perform continuous intraperitoneal insulin delivery.
62459663|NCT03948347|ACTIVE_COMPARATOR|active|Active patients will receive liraglutide injections
62459664|NCT03948347|NO_INTERVENTION|standard care/no intervention|standard care for stroke as per hospital protocol
62461822|NCT02524197|ACTIVE_COMPARATOR|CR845 0.25 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
62084143|NCT01093300|ACTIVE_COMPARATOR|Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion
62084144|NCT02206152|PLACEBO_COMPARATOR|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
62084145|NCT02206152|EXPERIMENTAL|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
62650784|NCT03668106|ACTIVE_COMPARATOR|sperm gradient centrifugation|"PureSperm gradients 40 % and 80 % were used for the experiment. All procedures were conducted under sterile conditions. Using a sterile pipette, 2.0 mL of the lower layer (80% PureSperm gradient) was transferred into a conical centrifuge tube.~Using a new sterile pipette, 2.0 mL of the upper layer (40% PureSperm gradient) was gently dispensed on top of the lower layer. A liquefied semen sample was then placed on top of the upper layer and the tube was centrifuged for 20 minutes at 300g. The upper and lower layers were carefully aspirated without disturbing the pellet. Using a transfer pipette, 2-3 mL of Ham's F10 +10% HAS was added to the pellet and the resuspended pellet was centrifuged for 7 minutes at 300g. The supernatant was then removed and the pellet was suspended in a volume of 0.5 mL of Ham's F10 + FCS 10%. Aliquots of the detached sperm were dealt with like previous arm"
62653080|NCT01457794|OTHER|NewNordicDiet last|No intervention for 3 mo and then intervention with NND for 3 mo
62653081|NCT02524938|EXPERIMENTAL|Treatment group|Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
62653082|NCT02524938|SHAM_COMPARATOR|Control group|Conventional coffee (habitual diet)
62653083|NCT05299749|EXPERIMENTAL|stg-rt-fMRI|will receive feedback from the STG
62283598|NCT06237517|EXPERIMENTAL|Progressive acclimation of healthy individuals with Idiopathic Chilblains (Rewarming Phase)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24 °C and 40-50% relative humidity for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes (the chamber's temperature was 10°C and 40-50%), a radiator heater was placed in front of the participants to increase the temperature of their extremities. Simultaneously, the investigators increased the temperature of the chamber to 22-24 °C and 40-55% relative humidity, and the participants remained in the same sitting position for 20 minutes. Following this period, an occlusion foot test was performed to observe any hemodynamic changes in the foot. The test consisted of a 5-minute ''baseline'' phase, a 5-minute ''occlusion'' phase, and a 5-minute ''release'' phase. Before and after the trial, participants provided blood and urine samples.
62283599|NCT06237517|ACTIVE_COMPARATOR|Progressive acclimation of healthy individuals without Idiopathic Chilblains|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes, the temperature was maintained at 10°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test for 15 minutes, and an occlusion foot test (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase, and 5 minutes ''release'' phase) was performed to observe any hemodynamic changes in the foot. Participants provided blood and urine samples before and following the trial.
62283600|NCT06237517|ACTIVE_COMPARATOR|Progressive acclimation of healthy individuals without Idiopathic Chilblains (Rewarming Phase)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24 °C and 40-50% relative humidity for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes (the chamber's temperature was 10°C and 40-50%), a radiator heater was placed placed in front of the participants to raise the temperature of their extremities. Simultaneously, the investigators increased the chamber temperature to 22-24 °C and 40-55% relative humidity, and the participants remained in the same sitting position for 20 minutes. Following this period, an occlusion foot test was performed to observe any hemodynamic changes in the foot. The test consisted of a 5-minute ''baseline'' phase, a 5-minute ''occlusion'' phase, and a 5-minute ''release'' phase. Before and after the trial, participants provided blood and urine samples.
62461823|NCT02524197|ACTIVE_COMPARATOR|CR845 0.50 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
62461824|NCT02524197|ACTIVE_COMPARATOR|CR845 1 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
62084146|NCT03962452|OTHER|Mitochondrial disease|Unresolved index patients with suspected mitochondrial disease
62084147|NCT04033211||Novosyn® CHD|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using Novosyn® CHD suture for fascia and skin closure of trocar wounds.
62653084|NCT05299749|SHAM_COMPARATOR|sham-rt-fMRI|will receive feedback from the motor cortex
62653085|NCT01243281|ACTIVE_COMPARATOR|drug combination|
62653086|NCT02805023|PLACEBO_COMPARATOR|Placebo|Intramuscular injection of control medium only
62084148|NCT04033211||Novosyn®|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using either Novosyn® suture for fascia and skin closure of trocar wounds.
62084149|NCT01490515|ACTIVE_COMPARATOR|Morphology embryo evaluation|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
62084150|NCT01490515|EXPERIMENTAL|non-invasive metabolomic profiling|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
62084151|NCT05552729|ACTIVE_COMPARATOR|High dose group|A 2000IU vitamin D3 supplement was started the next day after surgery.
62084152|NCT05552729|ACTIVE_COMPARATOR|Low dose group|A 400IU vitamin D3 supplement was started the next day after surgery.
62084153|NCT05552729|NO_INTERVENTION|The control group.|No vitamin D3 supplement was started the next day after surgery.
62084154|NCT05445596|EXPERIMENTAL|FCT Evaluation|This study uses single case experimental design in which participants will serve as their own control. Each participant will receive the treatment (functional communication training) and will participate in comparison conditions to evaluate the effects of the treatment. We will evaluate the effects of functional communication training during three treatment phases: initial implementation, schedule thinning, and generalization.
62084155|NCT05064124||CADDIE|Participants will have a colonoscopy with the assistance of the CADDIE device characterisation AI system
62084156|NCT05064124||Control group|Participants will have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system
62084157|NCT06250166|EXPERIMENTAL|Intervention group|Receive iPLANT diet plan and diet counselling by a qualified dietitian in oncology setting.
62084158|NCT06250166|ACTIVE_COMPARATOR|Control group|Receive usual diet counselling only
62084159|NCT06463457|EXPERIMENTAL|Cohort 1 Short Pharmacokinetics (PK)|"Enrolled participants will complete study procedures as follows:~* Cycle 1:~  * Day 1 of 28 Day Cycle: Predetermined dose of Relugolix 1x daily. First dose will be administered in-clinic.~ * Day 1 of 28 Day Cycle: Predetermined dose of Darolutamide 2x daily. First dose will be administered in-clinic.~* Cycle 2 through End of Treatment:~  * Predetermined dose of Relugolix 1x daily.~ * Predetermined dose of Darolutamide 2x daily.~* End of Treatment visit.~* Follow Up: every 3 months for 18 months."
62084160|NCT06463457|EXPERIMENTAL|Cohort 2 Long Pharmacokinetics (PK)|"Enrolled participants will complete study procedures as follows:~* Cycle 1:~  * Days 1, 2, 8 of 28 Day Cycle: Predetermined dose of Relugolix 1x daily. First dose will be administered in-clinic.~ * Days 1, 2, 8 of 28 Day Cycle: Predetermined dose of Darolutamide 2x daily. First dose will be administered in-clinic.~* Cycle 2:~  * Day 1 of 28 Day Cycle: Predetermined dose of Relugolix 1x daily. First dose will be administered in-clinic.~ * Day 1 of 28 Day Cycle: Predetermined dose of Darolutamide 2x daily. First dose will be administered in-clinic.~* Cycle 3 through End of Treatment:~  * Predetermined dose of Relugolix 1x daily.~ * Predetermined dose of Darolutamide 2x daily.~* End of Treatment visit.~* Follow Up: every 3 months for 18 months."
62084161|NCT05531903|EXPERIMENTAL|Patients with atrioventricular node reentrant tachycardia|Patient with documented AVNRT and fragmented/slow conduction zones observed in a 3D high density mapping
62084162|NCT05771194|EXPERIMENTAL|group A|Group A received conventional preoperative and postoperative anti-infective therapy.
62084163|NCT05771194|ACTIVE_COMPARATOR|group B|On the basis of group A,Group B was given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery, and one cleaning, hot compresses and massage of the meibomian gland.
62084164|NCT00322374|EXPERIMENTAL|25 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 25 mg/m\^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m\^2 epirubicin every 21 days.
62084165|NCT00322374|EXPERIMENTAL|30 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 30 mg/m\^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m\^2 epirubicin every 21 days.
62084166|NCT00322374|EXPERIMENTAL|35 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 35 mg/m\^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m\^2 epirubicin every 21 days.
62084167|NCT03259971|PLACEBO_COMPARATOR|Placebo (for tic disorder)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
62084168|NCT03259971|ACTIVE_COMPARATOR|PS128 (tic disorder)|The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10\^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
62084169|NCT03259971|PLACEBO_COMPARATOR|Placebo (for Rett syndrome)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
62084170|NCT03259971|ACTIVE_COMPARATOR|PS128 (Rett syndrome)|The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10\^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
62459665|NCT06374615|EXPERIMENTAL|Serological test for Tick-borne Patogens|"A baseline visit (T0) will be scheduled within 7-10 days of the tick bite. T0 visit will include: signature of ICF, data collection, blood sampling. Signature of a specific consent will be sought for storage of the leftover samples at -80°.~12 weeks apart from the bite (T1), subjects will be invited to a clinical and serological follow-up visit.~Participants will be taught to contact the study investigators in case of emergence of compatible signs/symptoms. In this case, one of the study members will call the participant to schedule an additional visit (T unscheduled, TU). At this time a blood sample will be collected. Timing for molecular and serological tests will be performed in relation to the emergence of patient's symptoms. In case of TBDs caused by TBEV, Rickettsia spp, Borrelia spp, Ehrlichia, Anaplasma spp. and Babesia spp the patient will be treated according to standard clinical practice."
62459666|NCT03577626|EXPERIMENTAL|Hemay005 Fast|
62084171|NCT05474443|EXPERIMENTAL|Myofascial gun with Conventional therapy|• Myofascial gun was applied over the Upper Trapezius muscle for 5 minutes. In the first two sessions frequency was set to 1-2 then increased to next two sessions 3-4 and so on.
62084172|NCT05474443|ACTIVE_COMPARATOR|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool moved over the skin on upper trapezius muscle from its origin to insertion at 45 degree. conventional therapy applied with Thermotherapy, upper trapezius, levator scapulae and pectoralis major stretching and cryotherapy at the end
62084173|NCT01924403|EXPERIMENTAL|Staple Closure|Staple closure will be one technique employed to close the wound in primary total knee arthroplasty.
62459667|NCT03577626|EXPERIMENTAL|Hemay005 Fed|
62650785|NCT03668106|ACTIVE_COMPARATOR|zeta method|"sperm samples were diluted 5 million in 1 ml. To induce a positive charge, the tube was placed inside a latex glove up to the cap and grasping the cap, the tube was rotated two or three turns and rapidly pulled out. Each tube was kept at room temperature for 1 minute to allow adherence of the charged sperm to the wall of the centrifuge tube.~Tubes were hold by the cap to avoid grounding of the tube. After 1 minute the tubes were centrifuged at 200g for 5 minutes. Then, the medium and pellet were discarded in order to discard non adhering sperm and other cells. The surface of tube was washed by 0.2ml of Ham's F10+ FCS 10% in order to neutralize the charge on the wall of the tube and detach the adhering sperm.~The collected medium at the bottom of each tube was repipetted and used to rinse the wall of the same tube several times to increase the number of recovered sperm . Aliquots of the detached sperm were dealt with like previous arm"
62650786|NCT05643235|OTHER|Patients initiated on Bruton tyrosine kinase inhibitors, consenting to installment of ILR|Patients free of documented arrhythmia initiating treatment with a BTK inhibitor who consent to monitoring using the Medtronic LINQ-2 implanted cardiac monitoring device (ILR) prior to initiating BTK inhibitor therapy.
62650787|NCT05016960|EXPERIMENTAL|Sleep-SMART|Sleep-SMART intervention
62650788|NCT04457856|EXPERIMENTAL|TJ003234|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
62653087|NCT02805023|EXPERIMENTAL|BGC101|Intramuscular injection of BGC101 (autologous EnEPC preparation)
62084174|NCT01924403|EXPERIMENTAL|Running Subcuticular Closure|Running subcuticular closure will be one technique employed to close the wound in primary total knee arthroplasty.
62084175|NCT01924403|EXPERIMENTAL|Vertical Mattress Closure|Vertical mattress closure will be one technique employed to close the wound in primary total knee arthroplasty.
62084176|NCT02451904||Severe/Cerebral Malaria|Intensive monitoring
62084177|NCT02451904||Uncomplicated Malaria|Intensive monitoring
62459668|NCT04453202|EXPERIMENTAL|Cohort 1 Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an Ad26-based RSV vaccine on Day 1.
62084178|NCT02451904||Sepsis|Intensive monitoring
62084179|NCT02451904||Acidosis|Intensive monitoring
62459669|NCT04453202|EXPERIMENTAL|Cohort 1 Group 2: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 1) on Day 1.
62283601|NCT06237517|EXPERIMENTAL|Thermoneutral environment healthy participants with Idiopathic Chilblains (Baseline)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After 20 minutes, the temperature was maintained at 22°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test was conducted (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase, and 5 minutes ''release'' phase), to observe any hemodynamic changes in the foot.
62283602|NCT06237517|ACTIVE_COMPARATOR|Thermoneutral environment healthy participants without Idiopathic Chilblains (Baseline)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After 20 minutes, the temperature was maintained at 22°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test was conducted (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase and 5 minutes ''release'' phase), to observe any hemodynamic changes in the foot.
62283603|NCT02481505|EXPERIMENTAL|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
62283604|NCT02481505|EXPERIMENTAL|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
62283605|NCT02481505|EXPERIMENTAL|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
62283606|NCT03430986|EXPERIMENTAL|JUVÉDERM® VOLUMA® with Lidocaine|Participants were treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel during the 24-week Control Period. Participants were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable. Follow-up continued in the 24-week Post-Control period.
62283607|NCT03430986|EXPERIMENTAL|No-treatment Control|Participants received no treatment during the 24-week Control Period. After 24 weeks, participants had the option of treatment with JUVÉDERM® VOLUMA® with Lidocaine Injectable Gel in the nose area during the 24-week Post-Control period and were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable.
62283608|NCT01877564|EXPERIMENTAL|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
62459670|NCT04453202|EXPERIMENTAL|Cohort 1 Group 3: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 2) on Day 1.
62653088|NCT01426529|EXPERIMENTAL|major allele homozygous|we will compare this arm with the minor allele carrier arm
62283609|NCT01877564|NO_INTERVENTION|Group 2 - No treatment|
62283610|NCT04172883|NO_INTERVENTION|Control arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the standard device setting or MINERVA setting ( control arm)
62084180|NCT02451904||Encephalitis|Intensive monitoring
62283611|NCT04172883|ACTIVE_COMPARATOR|Treatment arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the reduced sequence programming ( treatment arm)
62283612|NCT03682120|EXPERIMENTAL|Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
62283613|NCT03682120|EXPERIMENTAL|Arm 2|7.5 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
62459671|NCT04453202|EXPERIMENTAL|Cohort 1 Group 4: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 3) on Day 1.
62459672|NCT04453202|PLACEBO_COMPARATOR|Cohort 1 Group 5: Placebo|Participants will receive IM injection of placebo on Day 1.
62459673|NCT04453202|EXPERIMENTAL|Cohort 2 Group 6: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
62459674|NCT04453202|EXPERIMENTAL|Cohort 2 Group 7: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 1) on Day 1.
62459675|NCT04453202|PLACEBO_COMPARATOR|Cohort 2 Group 8: Placebo|Participants will receive IM injection of placebo on Day 1.
62459676|NCT04453202|EXPERIMENTAL|Cohort 3 Group 9: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
62459677|NCT04453202|EXPERIMENTAL|Cohort 3 Group 10: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 2) on Day 1.
62459678|NCT04453202|EXPERIMENTAL|Cohort 3 Group 11: Placebo|Participants will receive IM injection of placebo on Day 1.
62459679|NCT04617769|PLACEBO_COMPARATOR|Psychoeducation alone (PSYED)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors.
62459680|NCT04617769|ACTIVE_COMPARATOR|Psychoeducation followed by exposure (PSYED+EXP)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated.
62459681|NCT04617769|EXPERIMENTAL|Psychoeducation & exposure/Antagonistic Actions (PSYED+EXP+AA)|"The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated. Antagonistic action strategies during exposure to the trauma-videoclips will include (a) adopting an open posture; (b) eating a palatable snack; (c) smiling; and (d) wishing on high levels of emotional distress (e.g., come on distress hit me with your best shot). The participant will engage in all of the four antagonistic actions for the six exposure trials."
62459682|NCT05806203|ACTIVE_COMPARATOR|Low Intensity plus PT|Participants receive active low intensity shockwave treatment from plus typical physical therapy.
62459683|NCT05806203|SHAM_COMPARATOR|Sham Shockwave Treatment plus PT|Participant receives sham shockwave treatment plus typical physical therapy.
62459684|NCT00156247|EXPERIMENTAL|etanercept with acitretin|open-label
62459685|NCT02292745|EXPERIMENTAL|Stereotactic radiotherapy|Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy
62650789|NCT04457856|PLACEBO_COMPARATOR|Placebo|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
62283614|NCT03682120|EXPERIMENTAL|Arm 3|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
62283615|NCT03682120|EXPERIMENTAL|Arm 4|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) unadjuvanted administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=53
62283616|NCT00741156|EXPERIMENTAL|Enalaprilat|enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose
62283617|NCT00624455|ACTIVE_COMPARATOR|1|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
62283618|NCT00624455|PLACEBO_COMPARATOR|2|Placebo
62283619|NCT03221894||Conventional therapy with herbs|Patients were treated with conventional therapy with Chinese herbal medicine (GRAPE granules).
62283620|NCT03221894||Conventional therapy alone|In conventional therapy group, donepezil was the commonly used ChEI(cholinesterase inhibitor) to treat mild to severe AD patients. Memantine, a NMDA(N-methyl-D-aspartate ) antagonist, was given to moderate and severe AD patients. The dose of donepezil ranged from 5 to 10 mg once a day according to patients.
62283621|NCT06095388|EXPERIMENTAL|JR-441 low dose|
62283622|NCT06095388|EXPERIMENTAL|JR-441 high dose|
62283623|NCT03129308||HIV infected patients|4.5 ml of blood will be collected during a routine medical check-up.
62283624|NCT03129308||HIV negative control patients|4.5 ml of blood will be collected during a routine medical check-up.
62283625|NCT00760981|EXPERIMENTAL|Imatinib|200 mg orally daily and 400 mg orally daily for 4 weeks.
62283626|NCT02557178|EXPERIMENTAL|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen. Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
62283627|NCT02557178|NO_INTERVENTION|Control|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.
62283628|NCT00984672||Bone morphogenetic protein within an interbody cage|Transforaminal Lumbar Interbody Fusion with the use of BMP
62283629|NCT00984672||Other bone grafting techniques within cage (non-BMP)|Use of iliac crest autograft, allograft, or local autogenous bone grafting within the cage during Transforaminal Lumbar Interbody Fusion.
62283630|NCT00518479|EXPERIMENTAL|1|Neurohormonal stimulatory arm
62283631|NCT00518479|EXPERIMENTAL|2|Neurohormonal inhibitory arm
62283632|NCT02147873|ACTIVE_COMPARATOR|azacitidine with birinapant|Azacitidine 75 mg/m2 IV on days 1-5, 8 \& 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 \& 4) for 3 out of 4 weeks
62283633|NCT02147873|PLACEBO_COMPARATOR|Azacitidine and placebo|Azacitidine 75mg/m2 IV days 1-5, 8 \& 9 OR days 1-7 and placebo IV twice a week (days 1 \& 4) for 3 out of 4 weeks
62283634|NCT02436460|EXPERIMENTAL|AbGn-168H|AbGn-168H will be administered once weekly for four weeks via intravenous infusion.
62283635|NCT05306132|EXPERIMENTAL|ASKC202|Participants received ASKC2020 50mg\~600mg orally
62283636|NCT05545956|ACTIVE_COMPARATOR|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
62283637|NCT05545956|EXPERIMENTAL|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
62283638|NCT02435602|ACTIVE_COMPARATOR|NBI endoscopy|"* GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy~* Biopsy at the visually abnormal lesions~* Pathologic examination of all biopsy tissue specimens~* Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
62283639|NCT02435602|ACTIVE_COMPARATOR|lugol chromoendoscopy|"* GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy~* Biopsy at the unstained lesions \>= 5 mm diameter~* Pathologic examination of all biopsy tissue specimens~* Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
62459686|NCT04177290|EXPERIMENTAL|sintilimab (M1b) 200mg|
62283640|NCT03633084|EXPERIMENTAL|RBM-007 Injectable Solution - 0.2 mg|No additional information.
62283641|NCT03633084|EXPERIMENTAL|RBM-007 Injectable Solution - 1.0 mg|No additional information.
62459687|NCT04177290|ACTIVE_COMPARATOR|sintilimab (approved) 200mg|
62459688|NCT02441478|EXPERIMENTAL|Patients|
62459689|NCT02441478|ACTIVE_COMPARATOR|Controls|
62283642|NCT03633084|EXPERIMENTAL|RBM-007 Injectable Solution - 2.0 mg|No additional information.
62459690|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
62084181|NCT02451904||Healthy Individuals|Monitoring
62084182|NCT04537949|EXPERIMENTAL|Part A participants aged 18 to 55 years|Escalating dose levels
62084183|NCT04537949|EXPERIMENTAL|Part A participants aged 56 to 85 years (optional)|Escalating dose levels
62084184|NCT01615861|EXPERIMENTAL|IOL implantation|Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
62084185|NCT03069794|OTHER|Use of stable force platform|Ennrollment of every patient programmed for spinal surgery in orthopaedic service
62084186|NCT06328920|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
62084187|NCT06328920|ACTIVE_COMPARATOR|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
62084188|NCT04899505||Evaluation on appearance of unpleasant body odors|Incidence of the development of unpleasant body odors in AYA oncology patients
62084189|NCT00890643|EXPERIMENTAL|Arm 1|Persons with PTSD
62084190|NCT00890643|PLACEBO_COMPARATOR|Arm 2|Persons with PTSD
62084191|NCT00792428|ACTIVE_COMPARATOR|Real-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with real transcranial direct current stimulation (tDCS) over the motor region for up to 30 min.
62084192|NCT00792428|SHAM_COMPARATOR|Sham-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with sham (pretend) tDCS for up to 30 min. over the motor region.
62084193|NCT03268590|EXPERIMENTAL|All Study Participants|Breathing 21% oxygen via non-rebreather face mask followed by breathing 100% oxygen via non-rebreather face mask
62459691|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
62084194|NCT04071470|ACTIVE_COMPARATOR|Standard of Care|Standard of care for pregnant women at risk of HIV seroconversion includes couples counseling and access to PrEP (women) and ART (men)
62084195|NCT04071470|EXPERIMENTAL|Storytelling Intervention|Participants in this group will receive the same services as those in the SOC but will also be provided three storytelling sessions for themselves and their families as a way to educate and de-stigmatize PrEP services.
62084196|NCT03732703|EXPERIMENTAL|Sub-Protocol A1|Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
62084197|NCT03732703|EXPERIMENTAL|Sub-Protocol B1|Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
62084198|NCT03732703|EXPERIMENTAL|Sub-Protocol C1|Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
62084199|NCT03732703|EXPERIMENTAL|Sub-Protocol D1|Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
62084200|NCT03732703|EXPERIMENTAL|Sub-Protocol E1|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
62084201|NCT03732703|EXPERIMENTAL|Sub-Protocol Y1|Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)
62084202|NCT03732703|EXPERIMENTAL|Sub-Protocol Y2|Patients with Non-Actionable Genetic Abnormality receive Belantamab mafodotin in combination with ixazomib, pomalidomide and dexamethasone (IPd)
62084203|NCT03732703|EXPERIMENTAL|Sub-Protocol Y3|Patients with Non-Actionable Genetic Abnormality receive Selinexor in combination with ixazomib, pomalidomide and dexamethasone (IPd)
62283643|NCT01178866||Clinical course|complicated course group (death within 30 days after surgery or ICU stay \> 4 days) and uncomplicated course group (ICU stay ≤ 4 days).
62459692|NCT05745805||Mild COVID-19 group|Confirmed diagnosis of mild Covid-19 (WHO criteria)
62084204|NCT03682822|EXPERIMENTAL|Early artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
62459693|NCT05745805||Moderate COVID-19 group|Confirmed diagnosis of moderate Covid-19 (WHO criteria)
62084205|NCT03682822|ACTIVE_COMPARATOR|Delayed artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
62283644|NCT01758510|EXPERIMENTAL|HYNR-CS-Allo|HYNR-CS-Allo inj. 2 times by intrathecal administration with 28 days interval.
62283645|NCT01145937|EXPERIMENTAL|PET|"Partial endothelial trepanation in addition to anterior lamellar keratoplasty.~The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature."
62283646|NCT01145937|ACTIVE_COMPARATOR|DALK|Conventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.
62283647|NCT03176316|EXPERIMENTAL|Naloxone|1 mg/ml oral solution administered enterally every eight hours for 48 hours
62283648|NCT00167245|EXPERIMENTAL|Topiramate|topiramate capsules dose titrated up to 300 mg daily
62283649|NCT00167245|PLACEBO_COMPARATOR|Placebo|placebo capsules identical in appearance to the topiramate capsules
62084206|NCT01632332|EXPERIMENTAL|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
62084207|NCT06062823|EXPERIMENTAL|Afatinib|Afatinib given as monotherapy daily in a 28-days cycle.
62084208|NCT04054895|EXPERIMENTAL|Physiological pacing|"Pacing the his-purkinje system.~Crossover to biventricular CRT will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (\>3.5V / 1ms); no shortening of QRS (shortening \<20%) or failure to meet non-selective HBP criteria \[Europace. 2019 Oct 9. doi: 10.1093/europace/euz275\]."
62084209|NCT04054895|ACTIVE_COMPARATOR|Biventricular resynchronization therapy|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.~Crossover from biventricular CRT to physiological pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
62084210|NCT06615141|EXPERIMENTAL|Conventional Therapy + Immersive Virtual Reality Therapy|15 minutes of conventional therapy followed by 45 minutes of immersive virtual reality therapy will be administered to this group referred to as Group 1.
62459694|NCT05745805||Uninfected Healthy controls|Healthy people who have not had COVID-19
62084211|NCT06615141|EXPERIMENTAL|Conventional Therapy + Non Immersive Virtual Reality Therapy|15 minutes of conventional therapy followed by 45 minutes of non-immersive virtual reality therapy will be administered to this group referred to as Group 2
62084212|NCT01950260|EXPERIMENTAL|Levothyroxine|In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation.
62084213|NCT01950260|PLACEBO_COMPARATOR|Placebo|In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks.
62084214|NCT02936154|EXPERIMENTAL|300 mg|
62084215|NCT02936154|PLACEBO_COMPARATOR|placebo|
62084216|NCT01620359|EXPERIMENTAL|ExAblate|
62084217|NCT01560377|EXPERIMENTAL|Subjects Imaged with PINPOINT|Colonic tissue perfusion assessed with PINPOINT for laparoscopic left colectomy in the lower tract.
62459695|NCT01238237|EXPERIMENTAL|Cetuximab|
62084218|NCT04641624||Premature ovarian insufficiency (POI)|"POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotrophins and low estradiol.~The study population will be consisted of 45 women with POI as study group."
62084219|NCT04641624||Control group|45 patients with normal healthy women as control group.
62084220|NCT02696226|EXPERIMENTAL|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
62084221|NCT02696226|EXPERIMENTAL|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
62084222|NCT02696226|EXPERIMENTAL|SAVR Aspirin Arm|Aspirin arm (81mg/day)
62084223|NCT02696226|EXPERIMENTAL|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
62084224|NCT04079374|EXPERIMENTAL|Etanercept|Patients receive Etanercept in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
62084225|NCT04079374|ACTIVE_COMPARATOR|Enbrel|Patients receive Enbrel in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
62084226|NCT05232149|EXPERIMENTAL|Lower Dose|Orelabrutinib is a white, round, uncoated tablet
62084227|NCT05232149|EXPERIMENTAL|Higher Dose|Orelabrutinib is a white, round, uncoated tablet
62084228|NCT01828307|ACTIVE_COMPARATOR|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
62084229|NCT01828307|EXPERIMENTAL|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
62084230|NCT00892268|EXPERIMENTAL|Arm I|Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
62459696|NCT02446626|ACTIVE_COMPARATOR|Cohort #1: Patients with Lyme disease, post-therapy|Participants with Lyme disease, post-therapy had 25-30 clean laboratory-reared larval ticks applied as close as possible to the previous site of Lyme disease manifestation. Ticks were secured under a retention dressing and allowed to attach to the research participant. Ticks were removed 3 - 6 days after the placement.
62459697|NCT02446626|ACTIVE_COMPARATOR|Cohort #2: Patients with post-Lyme disease symptoms (PTLDs)|Participants with post-treatment Lyme disease symptoms (PTLDS) at least 12-months from initial treatment had 25-30 clean laboratory-reared larval ticks applied as close as possible to the previous site of Lyme disease manifestation. Ticks were secured under a retention dressing and allowed to attach to the research participant. Ticks were removed 3 - 6 days after the placement.
62084231|NCT00892268|ACTIVE_COMPARATOR|Arm II|Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.
62084232|NCT01670227|EXPERIMENTAL|PARENTCORPS|ParentCorps is a school-based, family-focused universal intervention designed to attenuate the multiple risks associated with urban poverty, on children's health and development
62084233|NCT01670227|OTHER|Control Condition|No intervention
62084234|NCT04112264|EXPERIMENTAL|Monopolar radiofrequency ablation|Patients will receive ultrasound-guided monopolar radiofrequency ablation
62084235|NCT04112264|ACTIVE_COMPARATOR|Bipolar radiofrequency ablation|Patients will receive ultrasound-guided bipolar radiofrequency ablation
62283650|NCT03705585|EXPERIMENTAL|Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine prior to routine endoscopic examination. During endoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings might also be obtained.
62283651|NCT03705585|EXPERIMENTAL|Endoscopy, Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine after initial endoscopic exam and specimen collection and prior to a routine follow up endoscopic examination during which additional specimens will be collected.
62283652|NCT03705585|NO_INTERVENTION|Endoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during endoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum if colonoscopy performed, duodenum if EGD performed).
62283653|NCT00565331|ACTIVE_COMPARATOR|1|Rituximab
62459698|NCT02446626|ACTIVE_COMPARATOR|Cohort #3: New Acute Erythema Migrans|"Participant with new onset of acute erythema migrans had 25-30 clean laboratory-reared larval ticks applied as close as possible to the site of Lyme disease manifestation. Ticks were secured under a retention dressing and allowed to attach to the research participant. Ticks were removed 3 - 6 days after the placement.~Acute erythema migrans participant (possible positive control)"
62459699|NCT02446626|ACTIVE_COMPARATOR|Cohort #4: Untreated Lyme Arthritis|"Participant with untreated Lyme arthritis had 25-30 clean laboratory-reared larval ticks applied as close as possible to the site of Lyme disease manifestation. Ticks were secured under a retention dressing and allowed to attach to the research participant. Ticks were removed 3 - 6 days after the placement.~Lyme Arthritis participant (possible positive control)"
62459700|NCT02446626|ACTIVE_COMPARATOR|Cohort #5: Healthy Volunteers|"Healthy volunteers with no history of Lyme disease had 25-30 clean laboratory-reared larval ticks applied to a body site that was comfortable for participant. Ticks were secured under a retention dressing and allowed to attach to the research participant. Ticks were removed 3 - 6 days after the placement.~Healthy Volunteers (negative control)"
62459701|NCT00162123|EXPERIMENTAL|First reinduction: Ipilimumab, 0.3 to 10 mg/kg|Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
62084236|NCT03057158||1|Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
62084237|NCT03057158||2|Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
62084238|NCT03057158||3|Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
62283654|NCT00565331|PLACEBO_COMPARATOR|2|Placebo
62084239|NCT03057158||4|Healthy Volunteers
62084240|NCT01668433|ACTIVE_COMPARATOR|G6PD Normal|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
62084241|NCT01668433|EXPERIMENTAL|G6PD deficiency|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
62084242|NCT04974125|EXPERIMENTAL|Arm A :Aspiration of peritoneal gas through a drain|"Patients in experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out by a drain.~Then, patients will be followed-up during 7 days after surgery."
62084243|NCT04974125|ACTIVE_COMPARATOR|Arm B : Manual evacuation of the peritoneal gas, via the trocar|"Laparoscopic or robotised laparoscopic surgery + Trocar~Patient in this experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out carried out manually using the trocar (standard of care).Then, patient will be followed-up during 7 days after surgery."
62283655|NCT03501966|ACTIVE_COMPARATOR|Acetazolamide including Diet|"Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet."
62283656|NCT03501966|ACTIVE_COMPARATOR|Optic Nerve Sheath Fenestration|"Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria."
62459702|NCT00162123|EXPERIMENTAL|First reinduction: Ipilimumab, 3 to 10 mg/kg|Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
62650790|NCT05001620|EXPERIMENTAL|Palliative Care Consultation in Post-Acute Care|Subjects will receive usual care plus a telehealth palliative care consultation by specialty providers who will document their findings in the Electronic Health Record (EHR), and communicate their findings and recommendations to the clinical team.
62653089|NCT01426529|EXPERIMENTAL|minor allele carriers|we will compare this arm with the major allele homozygous arm
62084244|NCT05471193||Instability|
62459703|NCT00162123|EXPERIMENTAL|First reinduction: Ipilimumab, 10 to 10 mg/kg|Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
62459704|NCT00162123|EXPERIMENTAL|Extended maintenance: Ipilimumab, 0.3 mg/kg|Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
62459705|NCT00162123|EXPERIMENTAL|Extended maintenance: Ipilimumab, 3 mg/kg|Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
62459706|NCT00162123|EXPERIMENTAL|Extended maintenance: Ipilimumab, 10 mg|Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
62459707|NCT00162123|NO_INTERVENTION|Follow-up|Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
62084245|NCT05471193||No Instability|
62283657|NCT03501966|ACTIVE_COMPARATOR|Ventriculoperitoneal CSF Shunting|"Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity."
62283658|NCT01610635|EXPERIMENTAL|Male - 8 weeks|Male donors assigned to an 8 week donation interval frequency
62283659|NCT01610635|EXPERIMENTAL|Male - 10 weeks|Male donors assigned to 10 week donation interval frequency
62283660|NCT01610635|NO_INTERVENTION|Male - 12 weeks|Male donors assigned to 12 week donation interval frequency
62283661|NCT01610635|EXPERIMENTAL|Female - 12 weeks|Female donors assigned to 12 week donation interval frequency
62283662|NCT01610635|EXPERIMENTAL|Female - 14 weeks|Female donors assigned to 14 week donation interval frequency
62283663|NCT01610635|NO_INTERVENTION|Female - 16 weeks|Female donors assigned to 16 week donation interval frequency
62459708|NCT00455351|EXPERIMENTAL|A I|Study drug
62459709|NCT05885165|EXPERIMENTAL|Supervised team-based exercise|In this arm, participants will receive guided training by an instructor in teams of 10 on the online platform Zoom.
62283664|NCT01758757|ACTIVE_COMPARATOR|Proliferative diabetic retinopathy|
62283665|NCT04635865|EXPERIMENTAL|3D-printed patient-specific plate group|3D-printed patient-specific plate will be used for reconstruction in this patient group
62283666|NCT04635865|ACTIVE_COMPARATOR|Conventional plate group|conventional commercial plates will be used for reconstruction in this patient group
62283667|NCT03629483|EXPERIMENTAL|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
62283668|NCT03629483|PLACEBO_COMPARATOR|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
62283669|NCT05866107|EXPERIMENTAL|Block 1|50 patients with schizophrenia and 50 patients with bipolar disorder
62283670|NCT05866107|EXPERIMENTAL|Block 2|50 patients with schizophrenia and 50 patients with bipolar disorder
62283671|NCT03665363|EXPERIMENTAL|SCOPE|Participants allocated to SCOPE, will receive an internet-based psychoeducation intervention, eight weeks of ASD-theme modules with coaching.
62283672|NCT03665363|ACTIVE_COMPARATOR|Self-study|Participants allocated to self-study will receive eight weekly emails containing informative and relevant websites about ASD. The emails are accessed on the same platform as the experimental condition (SCOPE), no active contact with the coaches is available.
62283673|NCT03665363|NO_INTERVENTION|Wait-list controls/Treatment as usual|Participants allocated to wait-list will receive prompts to answer outcome measures but otherwise no other contact with the study coordinators or coaches. Participants may receive treatment as usual.
62283674|NCT00132041|OTHER|All Patients|patients with cirrhosis undergoing solitary or repetitive percutaneous RFA treatment sessions for the treatment of HCC.
62283675|NCT04401592||disease and control|
62283676|NCT03891147|EXPERIMENTAL|Electro-acupunture (EA) group|"Patients will receive the treatment of electro-acupuncture with acupoints (i) Riyue (GB-24) ; (2) Danshu (B19) ; (3) Ganshu (B18) ; (4) Qimen (LR14) ; (5) Yanglingquan (GB34)~The EA will be conducted by using disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length). The needles are inserted at a depth of 10-30 mm vertically or obliquely into acupoints, on which electrical stimulation with continuous waves with 2 Hz and 100 Hz are delivered for 15 min for each frequency through an electrical acupuncture treatment instrument (Hwarto, SDZ-II). The intensities of stimulation are adjusted to a level at which patients feel most comfortable. Each session lasts for 30 minutes."
62283677|NCT03891147|NO_INTERVENTION|Usual care group|Participants randomized to usual care will continue regular follow up arranged by their visiting physicians in public or private sectors. Current usual care of these patients is limited to symptomatic treatment and dietary advice only during the follow-up session in out-patient clinic until the end of observation period (week 10).
62283678|NCT04954807|ACTIVE_COMPARATOR|Human Milk Fortifier|human milk fortifier which contains protein, lipid, carbohydrate and micronutrients
62283679|NCT04954807|PLACEBO_COMPARATOR|placebo|Placebo is made of polysaccharides (0.9 g/1 g placebo) and maltose (0.1 g/1 g placebo) and minerals.
62283680|NCT02024516|EXPERIMENTAL|50 gr concentrated pomegranate juice|
62283681|NCT05095142||Experimental group:|patients with idiopathic osteoarthritis of the knee
62283682|NCT05095142||Control group|patients without idiopathic osteoarthritis of the knee
62459710|NCT05885165|ACTIVE_COMPARATOR|Unsupervised exercise|In this arm, participants will perform the training individually with the exercises provided on the platform Exorlive, which is a one-way communication platform. However, the first two weeks (5 training sessions) will be conducted in teams of 10 participants with the presence of an instructor who will introduce, demonstrate, and supervise correct form and technique and ensure understanding of the exercise concept.
62650791|NCT05001620|NO_INTERVENTION|Stakeholder Engagement|We will engage stakeholders in a stakeholder engagement plan that include Palliative Care providers; Social Work (SW) NH champions; post-acute care unit nursing staff and providers (including medial directors); NH leadership, information technology staff; and a PLWD and their care partners in focus groups and one on one semi structured interviews via phone or videoconference.
62084246|NCT01555021||Treatment as Usual (TAU)|"This group will provide blood samples to be analyzed at a later date for genotyping to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications.Treatment will be initiated based on the attending clinicians decision making absent genotyping results.~All subjects in the group will receive the following assessment instruments for diagnosis: SCID-I/P and the Mini International Neuropsychiatric Interview (MINI)~All subjects in the group will have the severity of their depression measured by the HAM D-17 (physician rating scale), the QIDS-SR-16 (patient rating). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the UKU. ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the TAU group will provide saliva samples for future GWAS analysis."
62084247|NCT01555021||Assay Guided Treatment (AGT)|"This group will provide blood samples for genotyping test to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications . This test result will be available within 3-5 days available to guide clinicians in their choice and dosing of antidepressant medications.~All subjects in the group will have the severity of their depression measured by the Hamilton Depression Rating Scale-17 (physician rating scale), the QIDS-SR-16 (patient rating scale). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the Udvalg for Kliniske Undersogelser (UKU). ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the AGT group will provide saliva samples for future GWAS analysis."
62084248|NCT06234137|EXPERIMENTAL|treatment arm|
62283683|NCT02809833||Tocilizumab for RA in Routine Practice|Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.
62283684|NCT02591719|EXPERIMENTAL|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS with language task: Perilesional Broca's area
62283685|NCT02591719|SHAM_COMPARATOR|MagPro magnetic stimulator (sham)|Most activated area from fNIRS with language task: Perilesional Broca's area
62283686|NCT02591719|ACTIVE_COMPARATOR|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
62459711|NCT01768806|EXPERIMENTAL|P.L.A.Y. Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
62459712|NCT01768806|ACTIVE_COMPARATOR|Special Education Pre-school|Special education pre-school services include 10-12 hours per week of special education preschool, occupational therapy, and speech and language therapy. No intensive intervention is provided.
62459713|NCT04629404|EXPERIMENTAL|LY03003|
62459714|NCT04629404|PLACEBO_COMPARATOR|Placebo|
62650792|NCT05124015||Patients with pulmonary arterial hypertension|Exercise capacity using six minute walk test, respiratory muscle strength using mouth pressure device, pulmonary function using spirometry, dyspnea using Modified Borg scale physical activity using multi-sensor activity monitor.
62084249|NCT02107443|EXPERIMENTAL|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
62283687|NCT04385173|EXPERIMENTAL|B7-H3 CAR-T|Patients will received regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval. 3 infusions of B7-H3 CAR-T with 1-2 weeks of interval will be used in between cycles of Temozolomide treatment. Temozolomide treatment during B7-H3 CAR-T infusions will be stopped and resumed after CAR-T infusion.
62283688|NCT04557384|EXPERIMENTAL|Ramucirumab|Participants received starting dose of 700 milligram (mg) ramucirumab loading dose (LD) subcutaneously (SC) followed, a week later, by 350 mg ramucirumab maintenance dose (MD) administered SC once a week.
62283689|NCT02111564|EXPERIMENTAL|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
62283690|NCT02111564|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
62283691|NCT04430179|ACTIVE_COMPARATOR|Active drug|Dupilumab 300 mg every other week for 24 weeks
62283692|NCT04430179|PLACEBO_COMPARATOR|Placebo|Placebo
62283693|NCT00828282|EXPERIMENTAL|1|
62283694|NCT05882786|ACTIVE_COMPARATOR|The corticosteroid (Triamcinolone Acetonide) injection group|Participants in this group will receive a single subacromial injection of 40mg triamcinolone acetonide.
62283695|NCT05882786|ACTIVE_COMPARATOR|Tendon dry needling group|Participants in this group will receive a total of 3 sessions of dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscle tendons.
62459715|NCT01223365|EXPERIMENTAL|Hydrocodone ER|Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
62459716|NCT00799656|EXPERIMENTAL|1|First period: Ataciguat - Second period: Placebo
62084250|NCT02107443|ACTIVE_COMPARATOR|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
62084251|NCT04622644|EXPERIMENTAL|Single Arm|All patients perform StrokeWave exam, after NCCT and before CTA acquisition.
62084252|NCT01460680||Fibromyalgia patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR 1990 criteria
62283696|NCT00741819|EXPERIMENTAL|Inhaled treprostinil|Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.
62283697|NCT01488253|EXPERIMENTAL|acute GVHD prevention by sirolimus based regimen|The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.
62283698|NCT00356642|EXPERIMENTAL|Single dose 1 cohort|Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
62283699|NCT00356642|EXPERIMENTAL|Repeat dose 1 cohort|Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1
62283700|NCT00356642|EXPERIMENTAL|Repeat dose 2 cohort|Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1
62283701|NCT00356642|EXPERIMENTAL|Repeat dose 3 cohort|Subjects with BSA disease involvement \>=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1
62283702|NCT02981836|EXPERIMENTAL|Experimental Group|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~* Intervention: investigational live attenuated varicella vaccine;"
62283703|NCT02981836|SHAM_COMPARATOR|Control Group|"* Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~* Intervention: diluent of lyophilized vaccine;"
62283704|NCT02480452||CVI|All children consulting at the CVI clinic (with suspicion of CVI) receiving a diagnosis of CVI
62283705|NCT02480452||no CVI|All children consulting at the CVI clinic (with suspicion of CVI) not receiving a diagnosis of CVI
62283706|NCT04982081|EXPERIMENTAL|hiPSC-CM therapy low dosage|
62283707|NCT04982081|EXPERIMENTAL|hiPSC-CM therapy high dosage|
62283708|NCT01334398||Initial Treatment Group|
62084253|NCT01460680||SLE patients|Patients diagnosed as suffering from Systemic Lupus Erythematosus by the ACR criteria
62283709|NCT01334398||Deferred Treatment Group|
62283710|NCT05660304|EXPERIMENTAL|ccPAS group|Patients under this group will receive ccPAS followed by speech-language therapy.
62283711|NCT05660304|SHAM_COMPARATOR|Sham ccPAS group|Patients under this group will receive sham ccPAS followed by speech-language therapy.
62283712|NCT02688647|EXPERIMENTAL|Belumosudil-R|"Subjects receive two 200 mg tablets of belumosudil (400 mg) PO QD for 24 weeks. Subjects may also continue treatment with belumosudil 400 mg PO QD after 24 weeks.~No subject may receive more than 96 weeks of treatment with belumosudil"
62283713|NCT02688647|ACTIVE_COMPARATOR|BSC-R|Subjects receive best supportive care as determined by the physician. Subjects may later crossover to treatment with belumosudil 400 mg PO QD. No subject may receive more than 96 weeks of treatment with belumosudil.
62283714|NCT03691415||BELKYRA Inj.|Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.
62283715|NCT02492633|ACTIVE_COMPARATOR|Standard|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study.
62283716|NCT02492633|EXPERIMENTAL|Enhanced|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing.
62283717|NCT02363478|EXPERIMENTAL|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
62283718|NCT05398198|EXPERIMENTAL|GSK3923868|All participants in this arm will receive GSK3923868
62283719|NCT05398198|PLACEBO_COMPARATOR|Placebo|All participants in this arm will receive matching placebo
62084254|NCT01460680||Healthy controls|Healthy controls
62283720|NCT01826708|NO_INTERVENTION|Psychomotor retardation syndromic|Psychomotor retardation syndromic by Identification of breakpoints
62283721|NCT05572463|EXPERIMENTAL|Treatment Arm 1|Sintilimab is a recombinant fully human anti-programmed cell death protein 1 (PD-1) monoclonal antibody, and IBI110 is a recombinant fully human anti-lymphocyte activation gene 3 (LAG3) monoclonal antibody. Sintilimab (IBI308) will be administered intravenously (IV) in combination with IBI110 administered intravenously (IV) every 3-weeks (Q3W).
62283722|NCT04610658|EXPERIMENTAL|Phase 1 Dose Level 1: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 1: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 1.5 mg/m\^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 1 every 3 weeks.
62283723|NCT04610658|EXPERIMENTAL|Phase 1 Dose Level 2: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 2: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 2.6 mg/m\^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 2 every 3 weeks.
62283724|NCT04610658|EXPERIMENTAL|Phase 1 Dose Level 3: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 3: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 3.2 mg/m\^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 3 every 3 weeks.
62283725|NCT02906072|EXPERIMENTAL|Low fat plant-based diet|Low fat plant-based diet with conventional meals and supplemented with plant-based meal replacements and participants attend the lectures on health effects of a low fat plant-based diet.
62283726|NCT02906072|OTHER|Control group|Control participants attend the lectures on health effects of a low fat plant-based diet.
62283727|NCT00759070|ACTIVE_COMPARATOR|1|Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)
62084255|NCT03213015|EXPERIMENTAL|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
62459717|NCT00799656|EXPERIMENTAL|2|First period: Placebo - Second period: Ataciguat
62459718|NCT02458482|ACTIVE_COMPARATOR|Standard Nebulizer Mask Group|"Patients randomized to this Control or standard therapy group are to receive current institutional standard therapy for moderate asthma exacerbation which includes 10 mg Albuterol combined with 1.5mg Ipratropium nebulized therapy over one hour."
62084256|NCT03447379|EXPERIMENTAL|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
62283728|NCT00759070|ACTIVE_COMPARATOR|2|Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)
62283729|NCT04856657||Session 1: tACS at IAPF + 2 Hz|Participants in this arm will undergo tACS at a frequency 2 Hz above their IAPF during stimulation session 1. They will undergo tACS at a frequency 2 Hz below their IAPF during stimulation session 2.
62283730|NCT04856657||Session 1: tACS at IAPF - 2 Hz|Participants in this arm will undergo tACS at a frequency 2 Hz below their IAPF during stimulation session 1. They will undergo tACS at a frequency 2 Hz above their IAPF during stimulation session 2.
62459719|NCT02458482|EXPERIMENTAL|AccuPAP Group|"Patients randomized to this group must also have moderate asthma exacerbation and will use an investigational device called AccuPAP to receive three allotments of Albuterol and Ipratropium in nebulized form."
62459720|NCT03476460|EXPERIMENTAL|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
62459721|NCT03476460|ACTIVE_COMPARATOR|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
62459722|NCT03362437|EXPERIMENTAL|Treatment A|Receive 200 mg BMS-986177 Form A without food
62459723|NCT03362437|EXPERIMENTAL|Treatment B|Receive 200 mg BMS-986177 Form B without food
62459724|NCT03362437|EXPERIMENTAL|Treatment C|Receive 200 mg BMS-986177 Form B with food
62459725|NCT02319148|EXPERIMENTAL|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
62459726|NCT02319148|EXPERIMENTAL|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
62084257|NCT03447379|ACTIVE_COMPARATOR|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
62084258|NCT02543723|ACTIVE_COMPARATOR|Nurse Coach Intervention|The nurse coach conducted an initial assessment with the participant and identified specific adherence strategies tailored to the participant's needs. The educational strategies include information about the patient's cancer treatment and expected outcomes; clear instructions about medication dosing schedule; what to do if a dose is missed or delayed; medication side effects and/or potential drug interactions; and review of cancer health literacy infographics. The behavioral skills and affective support strategies include coping strategies for side effects, skills for fitting medication regimen into daily routine, identifying a support network, communication skills for interacting with providers, and facilitating a positive perception for effective self-management experience. Patients received weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period.
62084259|NCT02543723|NO_INTERVENTION|Control|Patients received standard of care.
62084260|NCT02668406||Burkholderia pseudomallei|Patients for whom blood cultures grew Burkholderia pseudomallei
62084261|NCT02668406||No pathogen|Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis
62084262|NCT02668406||Another pathogen|Patients for whom blood cultures grew another pathogen
62084263|NCT03619174|ACTIVE_COMPARATOR|Active Treatment|Treatment dose
62084264|NCT03619174|PLACEBO_COMPARATOR|Sham Treatment|Sub-therapeutic dose
62084265|NCT05812703||Behavioral Group Treatment (Cognitive Behavioral Therapy CBT + Movement)|Cognitive Behavioral Therapy Group led by a psychologist to learn pain coping skills, with gentle movement component of duration from 45 minutes to 60 minutes under a licensed Healthcare provider (PT or OT).
62283731|NCT04251364|EXPERIMENTAL|Acetazolamide|Oral acetazolamide (250 mg/day) intake for 9 months
62283732|NCT04251364|EXPERIMENTAL|Atorvastatin|Oral atorvastatin (40 mg/day) intake for 9 months
62283733|NCT04251364|PLACEBO_COMPARATOR|Placebo|Oral placebo pill (daily) intake for 9 months
62283734|NCT01914952|ACTIVE_COMPARATOR|CaHMB Capsule|
62283735|NCT01914952|ACTIVE_COMPARATOR|HMB free acid gelcap|
62283736|NCT01914952|ACTIVE_COMPARATOR|HMB free acid in water|
62283737|NCT01914952|ACTIVE_COMPARATOR|CaHMB powder in water|
62283738|NCT01914952|ACTIVE_COMPARATOR|HMB free acid (oral not in gelcap or water)|
62283739|NCT01601899|ACTIVE_COMPARATOR|ARM A|Stavudine (d4T) 30 mg po BD if wt \< 60kg, or 40 mg po BD if wt \> 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
62283740|NCT01601899|ACTIVE_COMPARATOR|ARM B|Stavudine (d4T) 20 mg po BD if wt \< 60kg, or 30 mg po BD if wt \> 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
62084266|NCT05812703||Behavioral Group Treatment (ACT) only|Acceptance and Commitment Therapy Group led by a psychologist to learn skills to change their relationship with pain to decrease pain's impact on their life.
62084267|NCT05812703||Behavioral Group Treatment (ACT + Movement)- Back in ACTion|Acceptance and Commitment Therapy Group led by a psychologist to learn skills to change their relationship with pain to decrease pain's impact on their life and improve willingness to engage in valued activities. Movement component to last from with intense and gentle movement sessions with a total movement time of 90 minutes - 2 hours led by licensed health care provider a PT or OT.
62084268|NCT02253524|ACTIVE_COMPARATOR|Dimenhydrinate|50 mg Dimenhydrinate with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
62084269|NCT02253524|ACTIVE_COMPARATOR|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
62084270|NCT01046747|ACTIVE_COMPARATOR|Pre-drill|These pins will be pre-drilled
62084271|NCT01046747|ACTIVE_COMPARATOR|No pre-drill|these pins will not be pre-drilled, but will rely on the self drilling function of the pin for insertion
62084272|NCT00230815|EXPERIMENTAL|Follitropin alfa injected by Pen device|
62084273|NCT04633083|OTHER|Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbosacral level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbosacral level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
62084274|NCT04633083|OTHER|No Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbar level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbar level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
62084275|NCT04424290|EXPERIMENTAL|Single-rising dose part - low dose BI 764524|Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of low dose BI 764524.
62283741|NCT01601899|ACTIVE_COMPARATOR|ARM C|TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
62283742|NCT00217165|PLACEBO_COMPARATOR|placebo|cellulose
62283743|NCT00217165|ACTIVE_COMPARATOR|active drug|taurine
62283744|NCT04415866|EXPERIMENTAL|Effects of PASAT on Sensory Testing|After baseline evaluation of light and pain sensitivity FM subjects and controls will undergo the PASAT task. This task consists of responding to a rapid presentation of numbers by ear phones. Subjects are asked to add each 2 consecutive numbers and provide a response each time the sum is equal to 13. This test will last several minutes and delivered at increasing speed.
62283745|NCT01621685|EXPERIMENTAL|Spirometry, auscultation, questionnaire|\>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score \>4
62459727|NCT02319148|EXPERIMENTAL|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
62459728|NCT05978479|EXPERIMENTAL|Teach-Back Method|The intervention group will be trained using the Teach Back Method in 3 sessions on every other day that will last 45-60 minutes. Training topics are hemodialysis treatment, end stage renal failure, fluid and diet restrictions and their importance, medication adherence and its importance and lifestyle rules. At the same time, patients will take education booklets.
62459729|NCT05978479|NO_INTERVENTION|Control group|No intervention will be given to the patients in the control group.
62283746|NCT05698173|EXPERIMENTAL|Systemic Lupus Erythematosus|Diagnosis of systemic lupus erythematosus according to American College of Rheumatology (ACR) or SLICC criteria
62283747|NCT05698173|OTHER|Controls|Healthy controls
62283748|NCT03287180|EXPERIMENTAL|Experimental group|Participants in the experimental group will attend one individual assessment with the study physician for combination of buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
62283749|NCT03287180|ACTIVE_COMPARATOR|Control group|Participants in the control condition will attend weekly individual medical management sessions with the MD who will also provide a prescription for a combination of buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
62283750|NCT03850184||Mental Health Professionals|Psychiatrists, Psychologists, Nurses working with patients with mental disorders
62459730|NCT01078025||transvaginal hybrid cholecystectomy|
62459731|NCT01078025||laparoscopic cholecystectomy|
62459732|NCT03110003|ACTIVE_COMPARATOR|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
62459733|NCT03110003|ACTIVE_COMPARATOR|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
62084276|NCT04424290|EXPERIMENTAL|Single-rising dose part - medium dose BI 764524|Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of medium dose BI 764524.
62084277|NCT04424290|EXPERIMENTAL|Single-rising dose part - high dose BI 764524|Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of high dose BI 764524.
62459734|NCT01638988|EXPERIMENTAL|Metformin|
62084278|NCT04424290|SHAM_COMPARATOR|Multiple dosing part - Sham|Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three sham intravitreal injections, each separated by 4 weeks.
62283751|NCT01810679|EXPERIMENTAL|Perceval S Aortic Heart Valve|Treatment with the Perceval S Aortic Heart Valve
62459735|NCT01638988|ACTIVE_COMPARATOR|Clomiphene Citrate|
62459736|NCT02066922|EXPERIMENTAL|DAILIES TOTAL1|Delefilcon A contact lens randomly assigned to one eye, with narafilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
62283752|NCT00859365|EXPERIMENTAL|Acupuncture|Real Acupuncture
62283753|NCT00859365|PLACEBO_COMPARATOR|2 Placebo acupuncture|
62283754|NCT00859365|NO_INTERVENTION|3 No treatment|No treatment performed
62084279|NCT04424290|EXPERIMENTAL|Multiple dosing part - high dose BI 764524|Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three intravitreal injections of high dose BI 764524, each separated by 4 weeks.
62084280|NCT05355753|EXPERIMENTAL|Dose Escalation Phase 1/Part1: CFT8634|Up to approximately 40 subjects ≥18 years of age or between ≥16 and \<18 years of age and weighing ≥50 kg with locally advanced or metastatic SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors, having received ≥ 1 prior anticancer therapy
62084281|NCT05355753|EXPERIMENTAL|Dose Escalation Phase 1/Part 2: CFT8634|Up to approximately 6-12 subjects ≥12 and \<16 years of age and weighing ≥40 kg or ≥16 and \<18 years of age and weighing ≥40 kg and \<50 kg with locally advanced or metastatic SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors
62084282|NCT05355753|EXPERIMENTAL|Phase 2 - Arm A: CFT8634|Approximately 30 subjects with locally advanced or metastatic synovial sarcoma at the recommended phase 2 dose (RP2D) having received 1-2 prior anticancer therapies
62084283|NCT05355753|EXPERIMENTAL|Phase 2 - Arm B: CFT8634|Approximately 20 subjects with locally advanced or metastatic SMARCB1-null tumors at the RP2D having received ≥1 prior anticancer therapy
62084284|NCT02247999||Cohort|HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, andBelgaum in India.
62084285|NCT03855111|EXPERIMENTAL|Standard (fixed) protocol Acu/Moxa - Active|"Standard (Fixed) Acupuncture / Moxibustion Active Protocol~Subjects receive active standard Acu/Moxa protocol aimed at reducing neuropathic pain/discomfort."
62084286|NCT03855111|EXPERIMENTAL|Individualized (tailored) protocol Acu/Moxa - Active|"Individualized (Tailored) Active Acupuncture / Moxibustion Protocol~Subjects receive active individualized Acu/Moxa protocol based on traditional Chinese medicine assessment aimed reducing neuropathic pain/discomfort."
62084287|NCT03855111|NO_INTERVENTION|Sham Acu/Placebo Moxa (Control)|"Sham Acu/Placebo Moxa (Control)~Note. All subjects randomized to the Control will be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
62084288|NCT03855111|NO_INTERVENTION|WaitList (Control)|"WaitList (Control) No treatment. Subjects receive all aspects of study participation with the exception of exposure to Acupuncture / Moxibustion.~Note. All subjects randomized to the Control will then be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
62084289|NCT01703533|EXPERIMENTAL|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
62084290|NCT01703533|PLACEBO_COMPARATOR|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
62084291|NCT01024751|EXPERIMENTAL|Bausch & Lomb Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
62084292|NCT01024751|ACTIVE_COMPARATOR|Ciba's Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
62084293|NCT03376555|ACTIVE_COMPARATOR|Baseline|Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
62084294|NCT03376555|EXPERIMENTAL|Low Sodium, No Cheese|"Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
62084295|NCT03376555|EXPERIMENTAL|Low Sodium, Cheese|"Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
62084296|NCT03376555|EXPERIMENTAL|High Sodium, No Cheese|"Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
62084297|NCT03376555|EXPERIMENTAL|High Sodium, Cheese|"Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
62084298|NCT01012973|EXPERIMENTAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
62084299|NCT01012973|SHAM_COMPARATOR|Sham treatment|Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.
62084300|NCT00231894|ACTIVE_COMPARATOR|Pioglitazone and life-style group|Pioglitazone (30-45 mg/daily) plus life-style diet group
62084301|NCT00231894|PLACEBO_COMPARATOR|Placebo and life style group|Placebo capsules daily plus life-style diet group
62084302|NCT05832580|EXPERIMENTAL|Etidronate|Daily dosis of 20mg/kg of etidronate in a cyclical regimen of 2 weeks on and 10 weeks off, for a total of 24 months.
62459737|NCT02066922|ACTIVE_COMPARATOR|TRUEYE|Narafilcon A contact lens randomly assigned to one eye, with delefilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
62650793|NCT05124015||Healthy controls|Exercise capacity using six minute walk test, respiratory muscle strength using mouth pressure device, pulmonary function using spirometry, dyspnea using Modified Borg scale physical activity using multi-sensor activity monitor.
62084303|NCT05832580|PLACEBO_COMPARATOR|Placebo|Daily dosis of placebo in a cyclical regimen of 2 weeks on and 10 weeks off, for a total of 24 months.
62084304|NCT00743132||1|Postoperative no renal dysfunction
62084305|NCT00743132||2|Postoperative renal dysfunction
62084306|NCT02601729||RT-CGM population|Prospective data collection during standardized clinical follow-up and from filled out questionnaires.
62084307|NCT02601729||Pump only population|Retrospective data collection on demographic and clinical characteristics.
62084308|NCT01722136|EXPERIMENTAL|Low Dosage|Exercise dose of 8kcal/kg/week
62084309|NCT01722136|EXPERIMENTAL|High Dosage|Exercise dose 14kcal/kg/week
62084310|NCT01508143|EXPERIMENTAL|400 microgram misoprostol|400 micrograms misoprostol each 6 hours for 8 dose
62084311|NCT01508143|ACTIVE_COMPARATOR|800 micrograms misoprostol|800 micrograms misoprostol each 12 hours for 4 dose
62084312|NCT04016051|EXPERIMENTAL|Clarithromycin DST|"Participants received oral administration of Clarithromycin DST twice a day:~* 125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years).~* 187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years).~* 250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years).~For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw."
62084313|NCT04016051|ACTIVE_COMPARATOR|Clarithromycin Syrup|"Participants received oral administration of Clarithromycin Syrup twice a day:~* 2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years).~* 3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years).~* 5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years)."
62084314|NCT01120171|EXPERIMENTAL|1|Cyclofosfamide/Liposomal-encapsulated doxorubicin
62084315|NCT05335772|EXPERIMENTAL|VR-AOT|Experimental group, observing actions in virtual reality
62084316|NCT05335772|OTHER|VR-LO|Control group, observing a matched dose of videos depicting landscapes in virtual reality
62084317|NCT02391285|EXPERIMENTAL|pelvic floor dynamometry|
62084318|NCT00650221|EXPERIMENTAL|1|
62283755|NCT03432728||S-ECC|Children in their fifth year of life with severe early childhood caries Children selected will require complete dental rehabilitation under general anesthesia All enrolled children will receive treatment of all dental carious lesions under general anesthesia
62459738|NCT03920137|ACTIVE_COMPARATOR|Active- UP-ST|The intervention will be the UP-ST therapy sessions. Treatment will be delivered using the new UP-ST protocol that will be developed in Phase I by integrating components of smoking cessation treatments (e.g. using the nicotine patch) with the theoretical model and treatment components of the existing UP treatment protocol, which includes both a therapist14 and patient12 manual. The UP-ST will maintain the same focus on transdiagnostic mechanisms of change as in the original UP, but will be adapted to integrate the smoking cessation focus and concurrent use of NRT. Thus, the investigators can successfully adapt and develop the new UP-ST to be delivered in eight 90-minute sessions and will be able to incorporate content from each of the 8 modules of the UP in the new UP-ST protocol.
62084319|NCT00650221|ACTIVE_COMPARATOR|2|
62084320|NCT01050075|EXPERIMENTAL|Arm I|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
62084321|NCT01050075|EXPERIMENTAL|Arm II|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.
62084322|NCT05175482|EXPERIMENTAL|Education received group|Health belief model based education on HPV infection and vaccination
62084323|NCT05175482|NO_INTERVENTION|Control Group|No virtual education
62084324|NCT01549691|EXPERIMENTAL|zopiclone|zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
62084325|NCT01549691|EXPERIMENTAL|alprazolam|given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
62084326|NCT01549691|PLACEBO_COMPARATOR|placebo|Placebo given night before operation and the morning of operation
62084327|NCT04695015||Melanoma and Nevus|Patients diagnosed with melanoma or/and nevus on the skin around the eye before surgery.
62084328|NCT04695015||Basal cell carcinoma;Squamous cell carcinoma;Sebaceous gland carcinoma|Patients diagnosed with basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma before surgery.
62650794|NCT00133796|EXPERIMENTAL|Heceptin|Herceptin administered to enrolled subjects
62650795|NCT06243302||Treatment Arm|VAAFT followed by OTSC clip inserted to close the inner opening of the anal fistula
62084329|NCT00857376|PLACEBO_COMPARATOR|placebo|Placebo 2 tabs three times daily
62283756|NCT03432728||Control|Children age and sex matched with the S-ECC group who are free of dental caries
62283757|NCT02642926|ACTIVE_COMPARATOR|Monopolar endoscopic endometrial ablation|
62283758|NCT02642926|EXPERIMENTAL|Bipolar endoscopic endometrial ablation|
62283759|NCT05597293|ACTIVE_COMPARATOR|FreeStyle Libe 2|Participants in this group will wear the FreeStyle Libre 2 device
62283760|NCT05597293|ACTIVE_COMPARATOR|FreeStyle Libre pro iQ|Participants in this arm will wear the FreeStyle Libre pro iQ device
62084330|NCT00857376|EXPERIMENTAL|Alpha lipoic acid 1|Alpha lipoic acid 600 mg daily
62084331|NCT00857376|EXPERIMENTAL|Alpha lipoic acid 2|Alpha Lipoic acid 1200 mg daily
62084332|NCT00857376|EXPERIMENTAL|Alpha lipoic acid 3|Alpha lipoic acid 1800 mg daily
62084333|NCT01340482|EXPERIMENTAL|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)
62650796|NCT06517199|PLACEBO_COMPARATOR|placebo|placebo 1 tablet/day for 28 days
62650797|NCT06517199|ACTIVE_COMPARATOR|olanzapine 2.5|olanzapine 2.5 mg/day for 28 days
62650798|NCT06517199|ACTIVE_COMPARATOR|olanzapine 5|olanzapine 5 mg/day for 28 days
62084334|NCT00136812|NO_INTERVENTION|enhanced usual care control|NRT during hospitalization with brief advice to stay quit once discharged
62084335|NCT00136812|EXPERIMENTAL|stage-tailored intervention|NRT during hospitalization with brief advice to stay quit once discharged plus a computer-delivered stage-tailored smoking cessation intervention with manual and counseling plus 10-weeks of nicotine patch available post-hospitalization
62084336|NCT04184024|ACTIVE_COMPARATOR|Massage group|Patients in this group were applied to massage plus neck stabilization exercise.
62084337|NCT04184024|ACTIVE_COMPARATOR|Kinesio taping group|Patients in this group were applied to Kinesio taping plus neck stabilization exercise.
62084338|NCT04394546|EXPERIMENTAL|Device Group|Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
62084339|NCT04394546|ACTIVE_COMPARATOR|Control Group|Randomized to non-vitamin K oral anticoagulant (NOAC)
62084340|NCT02370290||Observational (QIM)|Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.
62084341|NCT05181943|EXPERIMENTAL|Laser irradiation (Test group)|laser irradiation over lesion
62084342|NCT05181943|ACTIVE_COMPARATOR|Conventional treatment (Control group|
62084343|NCT06052033|EXPERIMENTAL|ALA-PDT Group|PDT involves cervical gel application and 25-minute laser light exposure. The procedure is repeated three times.
62084344|NCT06052033|OTHER|CO2 Laser Group|CO2 laser therapy ablates cervical lesions with a depth of 7-10mm and a width of 3-5mm in a single session.
62084345|NCT02971891|EXPERIMENTAL|CLS006 (Furosemide)|CLS006 (Furosemide) Topical Gel, 0.125%
62084346|NCT02971891|PLACEBO_COMPARATOR|Vehicle|Vehicle Topical Gel
62084347|NCT05018429||nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
62084348|NCT05018429||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles) during the operation.
62084349|NCT01629654|EXPERIMENTAL|Lifestyle counseling|Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
62084350|NCT05794919|EXPERIMENTAL|Calcium Hydroxybenzene Sulphonate Dispersible Tablets|The healthy subjects will be administered a single dose of Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g under fast or fed conditions.
62084351|NCT05794919|ACTIVE_COMPARATOR|Doxium®|The healthy subjects will be administered a single dose of Doxium® 250mg under fast or fed conditions.
62084352|NCT05753449|ACTIVE_COMPARATOR|Standard of care programming|Standard of care DBS electrical stimulation
62084353|NCT05753449|EXPERIMENTAL|Experimental/Burst-type programming|Burst-type DBS electrical stimulation
62084354|NCT06275932|EXPERIMENTAL|Interventional group|All the enrolled newborns will make the skin-to-skin contact with the use of a thermal blanket after birth.
62084355|NCT06275932|ACTIVE_COMPARATOR|Standard of care group|All the enrolled newborns will make the skin-to-skin contact according to local procedure after birth.
62283761|NCT00709956|EXPERIMENTAL|Active / placebo|Single dose of iloprost (5 µg) on study day 2 followed by single dose of placebo on study day 3
62283762|NCT00709956|PLACEBO_COMPARATOR|Placebo / active|Single dose of placebo on study day 2 followed by single dose of iloprost (5 µg) on study day 3
62283763|NCT05734729|EXPERIMENTAL|Pleural Arm|Patient's maximum volume is 1 litre per hour, not to exceed total 4 litres over 4 hours
62459739|NCT03920137|EXPERIMENTAL|Control- Standard|The Intervention will be the standard therapy sessions. Participants will receive a standard smoking cessation treatment based on the most recent clinical practice guideline from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence19. The investigative team has considerable expertise in developing and evaluating behavioral and pharmacological treatments for smoking cessation. Treatment will be delivered in eight, 90-minute sessions over an eight-week period.
62084356|NCT02168920|EXPERIMENTAL|Aripiprazole, 2 mg/day|
62084357|NCT02168920|EXPERIMENTAL|Aripiprazole, 3 mg/day|
62084358|NCT02168920|EXPERIMENTAL|Aripiprazole, 6 mg/day|
62084359|NCT02168920|PLACEBO_COMPARATOR|Placebo|
62084360|NCT00201474||brief depressive periods|brief depressive periods together with other fluctuating psychiatric symptoms
62084361|NCT00201474||major depressive disorder|
62084362|NCT01383993|EXPERIMENTAL|1.0|Immunocompromised children aged 2 to \<15 and 12 to \<15 years weighing \<50 kg who are at high risk for systemic fungal infection.
62084363|NCT01383993|EXPERIMENTAL|2.0|Immunocompromised children aged 12 to \<15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
62084364|NCT04128033|EXPERIMENTAL|puncture of the RP6 point|The acupuncturist midwife, who does not perform the delivery herself, punctures the RP6 point at the time of the expulsive efforts.
62084365|NCT04128033|PLACEBO_COMPARATOR|puncture of the placebo point|The acupuncturist midwife, who does not perform the delivery herself, punctures the placebo point at the time of the expulsive efforts.
62084366|NCT02643979|EXPERIMENTAL|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
62084367|NCT02643979|ACTIVE_COMPARATOR|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
62459740|NCT03923179|EXPERIMENTAL|pyrotinib+Etoposide|
62084368|NCT01037205|ACTIVE_COMPARATOR|DAS181 High Dose|DAS181 Dry Powder 10 mg qd x 3 days
62084369|NCT01037205|ACTIVE_COMPARATOR|DAS181 Low Dose|DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
62084370|NCT01037205|PLACEBO_COMPARATOR|Lactose Placebo|Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
62084371|NCT05747625|EXPERIMENTAL|Diagnostic (89Zr panitumumab PET/CT)|Patients receive panitumumab IV, 89Zr panitumumab IV, and undergo PET/CT on study
62283764|NCT05734729|EXPERIMENTAL|Ascites arm|Patient's maximum volume is 3 litre per hour, not to exceed total 15 litres over 5 hours
62283765|NCT03668574|EXPERIMENTAL|Aerobic exercise group|Patients will firstly warm up for 5 minutes and begin training on the treadmill. There will be two weekly sessions, lasting 40 minutes, for 6 weeks, reaching a total of 12 sessions. The exercise intensity will vary from 60 to 90% of the maximum heart rate (HRmax) predicted by the percentage formula HR = HR rep + percentage (HRmax - HR rep), where HRmax = 220-age (years) and HR rep = HR obtained for five minutes of rest. Heart rate and level of subjective perception of the effort will be monitored during all sessions. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
62650799|NCT02294266|EXPERIMENTAL|Mephedrone and alcohol|"Mephedrone 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
62084372|NCT05278923|NO_INTERVENTION|clean airway|CPR and endotracheal intubation in an airway without regurgitation
62084373|NCT05278923|EXPERIMENTAL|regurgitation airway|CPR and endotracheal intubation in an airway with regurgitation
62084374|NCT06257264|EXPERIMENTAL|Part 1 Part A: Dose Escalation and Safety Expansion (BG-68501 Monotherapy)|Sequential cohorts of increasing dose levels of BG-68501 will be evaluated as monotherapy.
62084375|NCT06257264|EXPERIMENTAL|Part 1 Part B: Dose Escalation (BG-68501 + Fulvestrant)|Sequential cohorts of increasing dose levels of BG-68501 will be evaluated in combination with fulvestrant.
62084376|NCT06257264|EXPERIMENTAL|Part 1 Part C: Dose Escalation and Safety Expansion (BG-68501 + Fulvestrant + BGB-43395)|Sequential cohorts of increasing dose levels of BG-68501 will be evaluated in combination with fulvestrant and BGB-43395.
62084377|NCT06257264|EXPERIMENTAL|Part 2: Dose Expansion|The RFDE for BG-68501 (as monotherapy and in combination with fulvestrant and BGB-43395) from Part 1 will be evaluated in selected tumor cohorts.
62084378|NCT01683994|EXPERIMENTAL|combination of cabozantinib, docetaxel and prednisone|combination of cabozantinib, docetaxel and prednisone
62084379|NCT01683994|ACTIVE_COMPARATOR|PII/ Arm 1-docetaxel + prednisone only|docetaxel + prednisone only
62084380|NCT01683994|ACTIVE_COMPARATOR|PII/Arm 2 -docetaxel+ prednisone + cabozantinib|docetaxel+ prednisone + cabozantinib
62084381|NCT00771875|ACTIVE_COMPARATOR|Rabbit Antithymocyte Globulin (RATG)|Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels \> 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
62084382|NCT00771875|EXPERIMENTAL|RATG/Rituximab|Rabbit Antithymocyte Globulin (RATG) + Rituximab Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels \> 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
62283766|NCT03668574|PLACEBO_COMPARATOR|Placebo Group|Patients will received a detuned pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes, twice weekly for 6 weeks. The devices will be used with disconnected internal cables to obtain the placebo effect; however, it will be possible to manipulate the devices and adjust the doses and alarms as if they were connected, in order to simulate the pragmatism of clinical practice as well as to increase the credibility of the use of these devices in patients. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
62283767|NCT05374707|EXPERIMENTAL|The motivational interviewing group|"The data of the study were collected through online questionnaires. An motivational interviewing lasting 30 minutes on average, both online and face-to-face, was carried out with the experimental group. Four reminder text messages were sent to the experimental group in a one-month period.~One month after the interview was carried out and Questionnaire on Smoking Urges and Smoking Cessation Success Prediction Scale were completed as a pretest for the experimental group, the scales were completed again as a post-test."
62084383|NCT00771875|EXPERIMENTAL|RATG/Bortezomib|Rabbit Antithymocyte Globulin (RATG) + Bortezomib -Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels \> 25 cells/mm3). Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Bortezomib will be given at a dose of 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Methylprednisolone will be administered prior to each bortezomib dose. On days 2 and 5, administer methylprednisolone 100 mg intravenous push (IVP). On days 9 and 12, administer methylprednisolone 50 mg intravenous push (IVP). If thymoglobulin is administered the same day as bortezomib, the order of administration is- methylprednisolone, then bortezomib, then thymoglobulin.
62283768|NCT05374707|NO_INTERVENTION|The group in which no motivational interviews were conducted|The control group, on the other hand, were asked to fill in Questionnaire on Smoking Urges and Smoking Cessation Success Prediction Scale as a pretest, and again a month later as a post-test.
62283769|NCT00660894|EXPERIMENTAL|tegafur-gimeracil-oteracil potassium|Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
62459741|NCT02665143|EXPERIMENTAL|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
62459742|NCT01690494|EXPERIMENTAL|PACT + TAU|4-session PACT delivered to both partners together + standard treatment of care services (TAU) delivered to the male participant
62283770|NCT00660894|ACTIVE_COMPARATOR|tegafur-uracil and folinate calcium|Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.
62283771|NCT05554627|EXPERIMENTAL|Esketamine|Intranasal spray of esketamine. Administered twice weekly for first 4 weeks, reduced to once weekly until week 12, then dosage will be determined by response and treating prescriber.
62283772|NCT05554627|ACTIVE_COMPARATOR|Aripiprazole|Participants will be randomized in a 1:1 ratio of equal allocation to either adjunctive ARI (n=470) or adjunctive IN ESK (n=470), stratified by participating site.
62283773|NCT02292771|EXPERIMENTAL|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
62283774|NCT02292771|ACTIVE_COMPARATOR|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
62283775|NCT05631912|EXPERIMENTAL|Autologous TRAC locus-inserted CD19-targeting STAR-T cells|"A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous targeting CD19 synthetic T-cell receptor antigen receptor T cells.~Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control."
62283776|NCT06159075|EXPERIMENTAL|Video with Childhood Maltreatment-Related Content|Participants will view a video of an actor describing the story of an individual who experienced childhood maltreatment and how they overcame its effects on their life.
62459743|NCT01690494|ACTIVE_COMPARATOR|TAU|TAU control condition delivered to the male participant
62459744|NCT02983110||Cohort B|Group B will be HIV Infected post-menopausal women who are not receiving hormonal therapy to provide tissue, blood, and cells
62459745|NCT02983110||Cohort C|Group C will be HIV infected transgendered women receiving hormone therapy to provide tissue and blood
62459746|NCT02983110||Cohort E|Group E will be HIV infected men
62459747|NCT02717390|EXPERIMENTAL|Bright By Three (BB3) Intervention|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years
62459748|NCT02717390|ACTIVE_COMPARATOR|Texts for Child Safety (TCS) Intervention|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety \[TCS\]) among participants in the injury prevention arm with those randomized to the BB3 arm.
62459749|NCT01372579|EXPERIMENTAL|Treatment (neoadjuvant chemotherapy)|Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62459750|NCT01390337|EXPERIMENTAL|AC220|
62459751|NCT01799798|EXPERIMENTAL|Denosumab subcutaneously|
62459752|NCT02707978|EXPERIMENTAL|Experimental F 18 T807|
62084384|NCT02320721|EXPERIMENTAL|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
62084385|NCT02320721|ACTIVE_COMPARATOR|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
62084386|NCT03055832|EXPERIMENTAL|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
62084387|NCT03055832|ACTIVE_COMPARATOR|LipiFlow Thermal Pulsation System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
62084388|NCT02564055|EXPERIMENTAL|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram \[mg/g\]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
62084389|NCT02564055|EXPERIMENTAL|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
62084390|NCT02564055|EXPERIMENTAL|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
62084391|NCT02564055|EXPERIMENTAL|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
62459753|NCT01987271|EXPERIMENTAL|With noninvasive ventilation|When patients do the six minute walk test with the noninvasive ventilation.
62084392|NCT02564055|PLACEBO_COMPARATOR|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
62084393|NCT02564055|PLACEBO_COMPARATOR|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
62084394|NCT05482880||head-neck cutaneous Squamous cell carcinomas|Patients with high risk cutaneous squamous cell carcinoma of the head-neck area receiving regular, multidisciplinary care.
62084395|NCT01300559|EXPERIMENTAL|Treatment Group|Tissuelink device plus Unipolar electrocautery will be used in this arm of the study.
62084396|NCT01300559|NO_INTERVENTION|No treatment|Unipolar electrocautery without Tissuelink device will be used in this arm of the study.
62084397|NCT03868319|EXPERIMENTAL|control group|nonprotective ventilation with a tidal volume of 9 ml kg-1 PBW with ZEEP
62084398|NCT03868319|EXPERIMENTAL|LPV group|a tidal volume of 6 ml kg-1 PBW with a 7 cmH2O level PEEP
62084399|NCT04672746|EXPERIMENTAL|Brief MI interaction via instant communication|The interaction communication using brief motivational interviewing will be applied via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
62084400|NCT04672746|PLACEBO_COMPARATOR|General health information|"The subjects will receive general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
62084401|NCT05737667|EXPERIMENTAL|YRI+Mobile Supervision|Youth Readiness Intervention delivered by teachers receiving mobile-based supervision
62459754|NCT01987271|NO_INTERVENTION|Without noninvasive ventilation|When patients do the six minute walk test without noninvasive ventilation.
62459755|NCT02749513|EXPERIMENTAL|Itraconazole|Itraconazole 300 mg po bid for 14-17 days
62459756|NCT00812734||surgery|
62084402|NCT05737667|ACTIVE_COMPARATOR|YRI+Standard Supervision|Youth Readiness Intervention delivered by teachers receiving standard supervision
62084403|NCT05737667|NO_INTERVENTION|Control|Wait listed control
62084404|NCT03950219||Intervention, Centre for Diabetes or local setting|Group-based course in diabetes education including 6 sessions of approximately 3 hours. Sessions are constructed around themes such as; diabetes knowledge and complication, mental health, diet, physical activity, Ramadan, medicine and include practical exercises such as blood sugar measurements, walking etc.
62084405|NCT03950219||Usual care|Usual care in 5 municipalities in the west area of Copenhagen
62283777|NCT06159075|NO_INTERVENTION|Control Video|Participants in this arm will view a same-length video with the same actor, but without a personal narrative of CM experience.
62283778|NCT00991679||Normal control subjects|Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
62459757|NCT04493723||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
62283779|NCT00991679||dry eye patients|Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (\<10 mm), low tear clearance rate (\<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
62283780|NCT03871855|EXPERIMENTAL|A:SHR-1702 Dose Escalation|SHR-1702 given intravenously (IV).
62283781|NCT03871855|EXPERIMENTAL|B:SHR-1702 Dose Expansion|SHR-1702 given intravenously (IV).
62283782|NCT03871855|EXPERIMENTAL|C:SHR-1702 and Camrelizumab Dose Escalation|SHR-1702 and Camrelizumab given intravenously (IV).
62283783|NCT03871855|EXPERIMENTAL|D:SHR-1702 and Camrelizumab Dose Expansion|SHR-1702 and Camrelizumab given intravenously (IV).
62459758|NCT04709809|EXPERIMENTAL|Experimental arm|Measurement RVA / IOP / with ECG gating
62283784|NCT01256216|OTHER|Signature Custom Cutting Guides|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Signature Cutting Guides Surgical Technique.
62283785|NCT01256216|OTHER|CAS (Computer Assisted Surgery)|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Computer Assisted Surgery Technique.
62459759|NCT03187002|EXPERIMENTAL|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
62084406|NCT02774343|EXPERIMENTAL|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
62084407|NCT02774343|PLACEBO_COMPARATOR|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
62084408|NCT05194917|EXPERIMENTAL|Older Smoker Motivational Intervention|Message package focused on the link between smoking and dementia
62084409|NCT05194917|ACTIVE_COMPARATOR|Control Motivational Message 1|CDC TIPS from former smokers campaign
62084410|NCT05194917|NO_INTERVENTION|Control Treatment as Usual|No intervention
62084411|NCT05194917|ACTIVE_COMPARATOR|Control Motivational Message 2|American Lung Association campaign
62084412|NCT01866241|EXPERIMENTAL|Arm A: sublingual misoprostol 600µg|Misoprostol is a uteretonic drug
62084413|NCT01866241|PLACEBO_COMPARATOR|Arm B: 10 IU Oxytocin|Oytocin is a standard of care treatment for PPH
62084414|NCT01140022||Female Patients 18-25 yo|Female patients aged 18-25 who have come to one of the ED or urgent care sites for care, regardless of the presence of CT symptoms.
62084415|NCT01189253|ACTIVE_COMPARATOR|Doxorubicin 75 mg/m² every 3 weeks|Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles
62084416|NCT01189253|EXPERIMENTAL|Trabectedin IV 3 hours|Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression
62084417|NCT01189253|EXPERIMENTAL|Trabectedin IV 24 hours every 3 weeks|Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression
62084418|NCT05181813|EXPERIMENTAL|Group 1: Ginge-Cal group:|primary molars were filled by creamy mixture pulpectomy paste of Gingerols and Calcium Hydroxide.
62084419|NCT05181813|ACTIVE_COMPARATOR|Group 2: Metapex group|primary molars were filled by a ready-made injectable creamy mixture pulpectomy paste of Metapex
62084420|NCT04616274||Venetoclax|Adult CLL patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025.
62084421|NCT01940094|EXPERIMENTAL|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
62084422|NCT01940094|EXPERIMENTAL|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
62650800|NCT02294266|ACTIVE_COMPARATOR|Mephedrone|"Mephedrone 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
62650801|NCT02294266|ACTIVE_COMPARATOR|Alcohol|"Lactose 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
62650802|NCT02294266|PLACEBO_COMPARATOR|Placebo|"Lactose 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
62650803|NCT02424825|EXPERIMENTAL|Rouxbe|Subjects will attend a one-month online cooking course, and be followed before, during, and after their participation for quality-of-life, fatigue, and blood biomarker changes.
62650804|NCT05947331|ACTIVE_COMPARATOR|Group I (Graded Anderson procedure)|patients with idiopathic infantile nystagmus related head turn corrected by graded Anderson procedure.
62650805|NCT05947331|ACTIVE_COMPARATOR|Group II (Kestenbaum procedure)|patients with idiopathic infantile nystagmus related head turn corrected by Kestenbaum procedure.
62650806|NCT05662969||Low/mid-volume liver transplant centres|
62650807|NCT05662969||High-volume liver transplant centres|
62084423|NCT04506580|EXPERIMENTAL|Dermabond group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using DERMABOND™ PRINEO™
62650808|NCT01977833|EXPERIMENTAL|High Calorie Breakfast (BTdiet)|High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
62650809|NCT01977833|ACTIVE_COMPARATOR|High Calorie Dinner (DTdiet)|High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
62650810|NCT03034967|EXPERIMENTAL|Danirixin 5 mg|Eligible participants will receive danirixin 5 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
62650811|NCT03034967|EXPERIMENTAL|Danirixin 10 mg|Eligible participants will receive danirixin 10 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
62650812|NCT03034967|EXPERIMENTAL|Danirixin 25 mg|Eligible participants will receive danirixin 25 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
62650813|NCT03034967|EXPERIMENTAL|Danirixin 35 mg|Eligible participants will receive danirixin 35 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
62650814|NCT03034967|EXPERIMENTAL|Danirixin 50 mg|Eligible participants will receive danirixin 50 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
62650815|NCT03034967|PLACEBO_COMPARATOR|Placebo|Eligible participants will receive placebo tablet with food twice daily along with standard care of treatment for 24 weeks.
62650816|NCT02652793|EXPERIMENTAL|Experimental|All participants will switch their current antiretroviral regimen to a boosted atazanavir and lamivudine once daily.
62283786|NCT02628860|EXPERIMENTAL|Ferinject|"Ferinject to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50 Kg .~Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® must be diluted only in sterile 0.9% sodium chloride.~Strength/Packaging: 10 mL vials containing 500 mg iron as iron per vial."
62283787|NCT03799510|EXPERIMENTAL|Group 1|Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
62459760|NCT03187002|ACTIVE_COMPARATOR|Moderate IV Sedation|Fentanyl, versed
62459761|NCT01382719|PLACEBO_COMPARATOR|Placebo|Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
62650817|NCT01803438|ACTIVE_COMPARATOR|AADs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
62650818|NCT01803438|EXPERIMENTAL|Cryoablation procedure|electrical pulmonary veins isolation performed with cryoballoon ablation system
62650819|NCT03927092||Multiple Sclerosis patients|Patients that attended an annual patient education seminar at the investigators' university hospital were asked to fill out the Turkish version of the Multiple Sclerosis Knowledge Questionnaire
62283788|NCT03799510|EXPERIMENTAL|Group 2|School children with an infectious history of S. haematobium and-or S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
62459762|NCT01382719|EXPERIMENTAL|bremelanotide arm 1|Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
62459763|NCT01382719|EXPERIMENTAL|bremelanotide arm 2|Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
62459764|NCT01382719|EXPERIMENTAL|bremelanotide arm 3|High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
62459765|NCT05703048|EXPERIMENTAL|dexmedetomidine group|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
62084424|NCT04506580|NO_INTERVENTION|Subcuticular group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using 3-0 Dermalon with subcuticular suture method
62084425|NCT04845438|ACTIVE_COMPARATOR|hand-sewn gastroenteroanastomosis|
62283789|NCT03799510|NO_INTERVENTION|Group 3|School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
62283790|NCT05049603|EXPERIMENTAL|Atorvastatin|Atorvastatin 20 mg/day (the experimental treatment), one tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks, associated with intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks
62650820|NCT05295407||Men 40-69 years old|Men with moderately-elevated PSA (2.5-10 ng/mL) undergoing prostate biopsy for detecting prostate cancer at NorthShore University HealthSystem, Northwestern University, or Johns Hopkins Hospital. The trial will not alter any clinical practice for diagnostic biopsy that includes state-of-the-art procedures (transperineal fusion biopsy, multiparametric MRI, and novel biomarkers).
62650821|NCT01803386||ALS Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. The ALSFRS-R will also be administered. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
62459766|NCT05703048|ACTIVE_COMPARATOR|Esmolol group|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
62650822|NCT01803386||Healthy Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
62084426|NCT04845438|ACTIVE_COMPARATOR|stapler gastroenteroanastomosis|
62084427|NCT00988585|PLACEBO_COMPARATOR|Olive Oil|Olive Oil 600 mg/day
62084428|NCT00988585|ACTIVE_COMPARATOR|EPA 1800|1800 mg/day
62084429|NCT00988585|ACTIVE_COMPARATOR|DHA|DHA 600 mg/day
62084430|NCT00988585|ACTIVE_COMPARATOR|EPA 600|EPA 600 mg/day
62283791|NCT05049603|PLACEBO_COMPARATOR|Placebo|Intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks, and placebo (one tablet/day, given approximately at 10 pm, after dinner and before going to bed) for 24 weeks
62283792|NCT04956900|EXPERIMENTAL|Aurase wound gel X0|Cohort 1: Aurase wound gel x0 dose concentration
62650823|NCT04140448||UWFA-RVO-ME|Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab
62650824|NCT02016326|EXPERIMENTAL|HD Colon|High Definition White Light modality will be used by the endoscopist for the entire procedure.
62084431|NCT03518164|OTHER|Allograft|Bone graft
62084432|NCT03518164|OTHER|Autograft|Bone from iliac crest
62084433|NCT00737984|NO_INTERVENTION|1|Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
62084434|NCT00737984|ACTIVE_COMPARATOR|2|Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
62084435|NCT00416923|EXPERIMENTAL|intrathecal rituximab|3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg
62084436|NCT03717259|ACTIVE_COMPARATOR|Open nephrectomy|These patients will undergo an open nephrectomy.
62283793|NCT04956900|EXPERIMENTAL|Aurase wound gel X1|Cohort 2: Aurase wound gel x1 dose concentration
62283794|NCT04956900|EXPERIMENTAL|Aurase wound gel X1.8|Cohort 3: Aurase wound gel X1.8 dose concentration
62650825|NCT02016326|EXPERIMENTAL|I-Scan 1|I-scan 1 modality will be used by the endoscopist for the entire procedure.
62650826|NCT02016326|EXPERIMENTAL|I-Scan 2|I-Scan 2 modality will be used by the endoscopist through out the procedure.
62650827|NCT04197440|EXPERIMENTAL|Bam8-22|
62650828|NCT04197440|EXPERIMENTAL|SPT pricks|
62650829|NCT01627132|EXPERIMENTAL|dasatinib|
62650830|NCT06294470|EXPERIMENTAL|Experimental|Altomare Score score ≥3pts and Agachan Wexner Score ≥12pts
62650831|NCT06294470|ACTIVE_COMPARATOR|Control|Altomare Score score \<3pts and Agachan Wexner Score \<12pts
62650832|NCT02431429||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
62650833|NCT02387086|EXPERIMENTAL|A:gefitinib and thalidomide/aspirin|intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
62650834|NCT02387086|PLACEBO_COMPARATOR|B:Placebo|intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
62650835|NCT02597413||Before group|Women in this group are included before the implementation of a strategy of systematic catheterization (they will not be catheterized).
62650836|NCT02597413||After group|"Women in this group are included after the implementation of a department-wide strategy of systematic catheterization.~Intervention: catheterization"
62650837|NCT02149134|EXPERIMENTAL|New extensively hydrolyzed casein formula|Subjects with cow's milk allergy treated with a new formula
62650838|NCT03028441|EXPERIMENTAL|Group 1- low dose|30 Subjects: 5 x 10\^4 TCID50 MV-CHIK at Day1 and at Day 29 for 25 subjects, placebo for 5 subjects
62650839|NCT03028441|EXPERIMENTAL|Group 2-low dose|30 Subjects: 5 x 10\^4 TCID50 MV-CHIK at Day 1 and at Day 85 for 25 subjects, placebo for 5 subjects
62650840|NCT03028441|EXPERIMENTAL|Group 3-low dose|30 Subjects: 5 x 10\^4 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
62650841|NCT03028441|EXPERIMENTAL|Group 4 -high dose|30 Subjects: 5 x 10\^5 TCID50 MV-CHIK at Day 1 and at Day 29 for 25 subjects, placebo for 5 subjects
62650842|NCT03028441|EXPERIMENTAL|Group 5-high dose|30 Subjects: 5 x 10\^5 TCID50 MV-CHIK at Day 1and at Day 85 for 25 subjects, placebo for 5 subjects
62650843|NCT03028441|EXPERIMENTAL|Group 6-dose-High Dose|30 Subjects: 5 x 10\^5 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
62459767|NCT05961930||Surgeons estimate of postoperative infection|All surgeons will be asked to fill in a questionnaire, containing 5 questions, pertaining to the estimated risk of postoperative infection (within 30days). Thus there is a single arm and no comparison.
62650844|NCT03164642|EXPERIMENTAL|LENA with Feedback|Mothers who will run the LENA system with their young children, AND who will receive feedback from their service providers on how to enhance the language the home language environment.
62283795|NCT04956900|EXPERIMENTAL|Aurase wound gel X5|Cohort 4: Aurase wound gel X5 dose concentration
62283796|NCT04956900|EXPERIMENTAL|Aurase wound gel X9|Cohort 5: Aurase wound gel X9 dose concentration
62283797|NCT03792074|EXPERIMENTAL|SCT510 combined paclitaxel and carboplatin|SCT510 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
62283798|NCT03792074|ACTIVE_COMPARATOR|Bevacizumab combined paclitaxel and carboplatin|Bevacizumab 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
62283799|NCT03881969|EXPERIMENTAL|Financial incentive offered|Patient offered £100 incentive payment in initial trial invitation letter.
62283800|NCT03881969|EXPERIMENTAL|No incentive. Payment not offered|Patient sent standard trial invitation letter with no offer of incentive payment.
62283801|NCT04988100|EXPERIMENTAL|Patients who undergo Splenic artery ligation|If inclusion criteria are met, these group of patients will undergo splenic artery ligation .
62459768|NCT02372630|PLACEBO_COMPARATOR|Placebo|Patients will be treated for 12 weeks with placebo once daily
62650845|NCT03164642|PLACEBO_COMPARATOR|LENA no feedback|Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.
62650846|NCT06447636|EXPERIMENTAL|Surufatinib，sintilimab and SOX chemotherapy|Surufatinib: 250mg qd，d1-21, q3w; Surufatinib: 200mg, ivdrip, d1, q3w; SOX: Oxaliplatin+S-1 S-1:40\~60mg Bid, d1\~14, q3w; Oxaliplatin: 130mg/m2, ivdrip,d1, q3w; Neoadjuvant therapy for 2-4 cycles, adjuvant therapy for 3-5 cycles. After 6 cycles of SOX chemotherapy, Surufatinib + Surufatinib was taken orally until one year.
62650847|NCT02678819|EXPERIMENTAL|Digital Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid during anesthesia and intensive care crises management.
62650848|NCT02678819|NO_INTERVENTION|No digital aid|Anesthesia and intensive care crises managed without any cognitive aid.
62650849|NCT06045117|EXPERIMENTAL|Study Group|"The study group will use the CardioPulmonary Management (CPM) device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI (Analog Devices, Inc) triaging team will monitor the CPM device data and call the patient as indicated by the data.~The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website."
62650850|NCT06045117|NO_INTERVENTION|Control Group|The control group will not receive a device and will continue their normal standard of care.
62650851|NCT02005796|EXPERIMENTAL|Blue-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
62650852|NCT02005796|EXPERIMENTAL|Yellow-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
62650853|NCT02005796|EXPERIMENTAL|Bilberries and potato starch|Intervention: A gel boiled with bilberries and potato starch
62650854|NCT03496740|ACTIVE_COMPARATOR|Penile Block|"Ultrasound guided dorsal penile nerve block will be administered after general anesthesia.~0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks"
62283802|NCT04988100|ACTIVE_COMPARATOR|No splenic artery ligation|If inclusion criteria are met, these group of patients will not undergo splenic artery ligation.
62084437|NCT03717259|ACTIVE_COMPARATOR|Hand-assisted laparoscopic nephrectomy|These patients will undergo a hand-assisted nephrectomy.
62084438|NCT03717259|ACTIVE_COMPARATOR|Laparoscopic nephrectomy|These patients will undergo a pure laparoscopic nephrectomy.
62084439|NCT06411288|EXPERIMENTAL|Del-desiran|Del-desiran (AOC 1001) will be administered seven times
62084440|NCT06411288|PLACEBO_COMPARATOR|Placebo|Saline will be administered seven times
62459769|NCT02372630|ACTIVE_COMPARATOR|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
62650855|NCT03496740|ACTIVE_COMPARATOR|Pudendal Block|Nerve stimulator-guided pudendal block. 0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks
62084441|NCT00927628||Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were \>40-years-of-age.
62084442|NCT02209636|EXPERIMENTAL|Lanthanum carbonate|Eligible subjects who are randomly assigned to the experimental arm will receive lanthanum carbonate (1500-4500 mg/day in divided doses) titrated to serum phosphorus levels.
62084443|NCT02209636|PLACEBO_COMPARATOR|placebo|Eligible subjects who are randomly assigned to the placebo arm will receive placebo tablets (identical to the active lanthanum carbonate tablets) to be taken 3 times daily and titrated to serum phosphorus levels.
62084444|NCT03508128||Micra subjects|Surgical procedure
62084445|NCT06218836|ACTIVE_COMPARATOR|Intubation with pre-inflated ETT|Patient's trachea will be intubated using pre- inflated endotracheal tube (ETT)
62084446|NCT06218836|ACTIVE_COMPARATOR|Intubation with non-inflated ETT|Patient's trachea will be intubated using non-inflated ETT
62084447|NCT06439290|EXPERIMENTAL|Experimental group: phonosurgery|Group undergoing phonosurgery (glottoplasty, cricothyroid approximation, thyroplasty or chondrolaryngoplasty)
62283803|NCT03609619|EXPERIMENTAL|AEVI-001|
62459770|NCT01900730|PLACEBO_COMPARATOR|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
62650856|NCT06326957|EXPERIMENTAL|SELF-BREATHE (Intervention)|SELF-BREATHE + usual NHS care (Intervention)
62650857|NCT06326957|NO_INTERVENTION|Usual NHS care (Control)|Participants randomised to the control group continue with usual NHS care, as was available to them prior to entry into the trial
62084448|NCT06439290|ACTIVE_COMPARATOR|Control group: other surgery|Control group: age matched TGD PFAB/PMAB undergoing mastectomy or breast augmentation surgery with the same in- and exclusion criteria.
62084449|NCT05967260|EXPERIMENTAL|Intervention|Participants will use the DailyDose Smart Snack smart phone application which contains an AI-based model that predicts the likelihood of overnight low glucose at bedtime every night and will recommend a personalized snack to help avoid nocturnal hypoglycemia. The nutritional content of the snack (carbohydrate, protein, fat, etc.) will be dependent on the predicted overnight minimum glucose and the predicted time of the minimum overnight glucose level. During this arm, participants will also be asked to wear a smart watch overnight, weigh themselves weekly, and answer a one-item sleep quality scale survey weekly.
62084450|NCT05967260|ACTIVE_COMPARATOR|Control|Participants will wear Dexcom G6 CGM and will manage their glucose as usual. Participants will be asked to wear a smart watch overnight to collect sleep metrics, weigh themselves weekly in the morning before eating, and answer a one-item sleep quality scale survey weekly.
62084451|NCT04823897|EXPERIMENTAL|Dose Escalation and Expansion|"Dose escalation phase: CCI-001 will be administered at the starting dose to a cohort of patients with recurrent and/or metastatic solid tumours. The dose will be escalated sequentially in subsequent cohorts to determine the maximum tolerated dose, or recommended dose for the dose expansion cohort.~Dose expansion phase: patients with the following tumour types will be permitted to enroll: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined during the dose escalation phase."
62084452|NCT02642718|PLACEBO_COMPARATOR|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision
62283804|NCT03609619|PLACEBO_COMPARATOR|Placebo|
62283805|NCT05445973|EXPERIMENTAL|Real-Time Contrast-Enhanced Ultrasonography-CT/MRI Fusion Guidance|To investigate whether CEUS-CT/MRI fusion imaging improved the visualization of small (≤ 3 cm) primary and secondary malignant liver tumors that were inconspicuous on B-mode US for percutaneous RFA.
62283806|NCT00701714|EXPERIMENTAL|1|HX575, EPO HEXAL
62283807|NCT00701714|ACTIVE_COMPARATOR|2|ERYPO
62283808|NCT02758457|ACTIVE_COMPARATOR|metal-based restorations|single crown with a metal framework and pressed ceramic
62650858|NCT03953716|EXPERIMENTAL|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
62650859|NCT03953716|PLACEBO_COMPARATOR|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
62084453|NCT02642718|EXPERIMENTAL|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision. (a single dose).
62283809|NCT02758457|EXPERIMENTAL|zirconia-based restorations|single crown with a zirconia framework and pressed ceramic
62283810|NCT01742260|EXPERIMENTAL|Repair of cranial defect|Repair of cranial defects by tissue engineering
62084454|NCT01011790|EXPERIMENTAL|Stress Management Tool|All subjects will use the Healing Rhythms™ meditation program for 4 weeks.
62084455|NCT04376411||patients with Behcet disease|Flow-cytometric assay Detailed 2 Di mention Echocardiographic analysis Two-Dimensional speckle tracking echocardiography
62084456|NCT04376411||Healthy control subjects|Flow-cytometric assay
62084457|NCT03785340|EXPERIMENTAL|OCU-310|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks
62084458|NCT03785340|PLACEBO_COMPARATOR|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks
62084459|NCT01716208|EXPERIMENTAL|Ofatumumab + Fresh Frozen Plasma|Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).
62084460|NCT04786561||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years or older were invited to participate in HUNT 4 70+. HUNT4 refers to the fourth wave of the HUNT-study (HelseUndersøkelse i Nord-Trøndelag or health survey in northern part of Trøndelag community in Middle of Norway) and 70+ refers to the part of the survey directed to participants aged seventy years and older.
62459771|NCT01900730|EXPERIMENTAL|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
62459772|NCT03463278||0-4 blastocysts|group A: cumulative pregnancy rate of 0-4 blastocysts vitrified
62084461|NCT04786561||HUNT4 70+ Trondheim|All inhabitants of one district in Trondheim 70 years or older were invited to participate in HUNT 4 70+
62084462|NCT04454762|EXPERIMENTAL|Cabozantinib|40 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 20 mg daily.
62084463|NCT01874574|EXPERIMENTAL|Single shot Hylan G-F 20 (Synvisc)|Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)
62283811|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
62459773|NCT03463278||5-7 blastocysts|group B: cumulative pregnancy rate of 5-7 blastocysts vitrified
62084464|NCT01874574|ACTIVE_COMPARATOR|Corticosteroid (Triamcinolone acetonide)|Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot
62084465|NCT04408001||Symptomatic individuals|"Hospital staff identified by the COVID-19 case census cell :~* who have been infected (confirmed by a positive RT-PCR result on a nasopharyngeal swab)~* OR who have displayed clinical signs compatible with COVID-19 despite a negative RT-PCR result."
62084466|NCT04408001||Asymptomatic individuals|Hospital staff who have not been identified by the COVID-19 case census cell.
62084467|NCT01608438|EXPERIMENTAL|SCI Static|SCI group that practices with a static body-machine map
62084468|NCT01608438|EXPERIMENTAL|SCI Machine Learning|Spinal Cord Injury patients who practice with a body-machine map that is adapted using machine learning
62084469|NCT06220201|EXPERIMENTAL|Administration of CC-97540 (RMS arm)|
62084470|NCT06220201|EXPERIMENTAL|Administration of CC-97540 (PMS arm)|
62084471|NCT06126822|EXPERIMENTAL|Zabdeno/Mvabea® vaccinated - Zabdeno® booster|Participants previously vaccinated with the Zabdeno/Mvabea® vaccination schedule, will receive a single intramuscular Zabdeno® booster vaccine (0,5 ml) = homologous vaccination scheme.
62084472|NCT06126822|EXPERIMENTAL|Zabdeno/Mvabea® vaccinated - Ervebo® booster|Participants previously vaccinated with the Zabdeno/Mvabea® vaccination schedule, will receive a single intramuscular Ervebo® booster vaccine (1 ml) = heterologous vaccination scheme.
62283812|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
62283813|NCT04415073|ACTIVE_COMPARATOR|Axatilimab (SNDX-6352)|Axatilimab on Days 1 and 15, IV + SOC
62283814|NCT04415073|PLACEBO_COMPARATOR|Placebo|Matching placebo on Days 1 and 15, IV + SOC
62084473|NCT06126822|EXPERIMENTAL|Ervebo® vaccinated - Ervebo® booster|Participants previously vaccinated with Ervebo®, will receive a single intramuscular Ervebo® booster vaccine (1 ml) = homologous vaccination scheme.
62084474|NCT06126822|EXPERIMENTAL|Ervebo® vaccinated - Zabdeno® booster|Participants previously vaccinated with Ervebo®, will receive a single intramuscular Zabdeno® booster vaccine (0,5 ml) = heterologous vaccination scheme.
62084475|NCT02347449|EXPERIMENTAL|Early stage breast cancer|"Women with node positive (1-3 nodes), ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.~Study subjects will have ONCOTYPE Dx assay performed on their breast tumors, and will complete study questionnaires."
62283815|NCT00257010|EXPERIMENTAL|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
62283816|NCT02127255|ACTIVE_COMPARATOR|A (Acupuncturist 1)|Manual acupuncture implemented by acupuncturist 1 (clinical experience \>15 years)
62283817|NCT02127255|ACTIVE_COMPARATOR|B (Acupuncturist 2)|Manual acupuncture implemented by acupuncturist 2 (clinical experience \< 5 years)
62084476|NCT03781011|EXPERIMENTAL|Vegetarian diet intervention|Patients identified as high-TMAO producers through the oral carnitine challenge test will be invited to participate in a two-month vegetarian diet intervention, supervised by a registered dietitian.
62283818|NCT05873348|EXPERIMENTAL|FMTgroup|
62283819|NCT05873348|NO_INTERVENTION|control gtoup|
62283820|NCT05738577||1|patients with type 1 diabetes aged 20-30 years
62283821|NCT05738577||2|healthy people serve as controls of the same age group
62283822|NCT05521737|SHAM_COMPARATOR|Sham group|Sham acupuncture will be administered in a total of 32 sessions within five months.
62283823|NCT05521737|EXPERIMENTAL|Interventional group|Electroacupuncture will be administered in a total of 32 sessions within five months.
62283824|NCT06538766|ACTIVE_COMPARATOR|Internal Focus Condition|In the internal focus condition the participant is instructed to realize seated calf raises by focusing on contracting the plantar-flexors. In clinical applications the internal focus is the most commonly used instruction. It is not possible to have a neutral focus condition, as participants always have to receive instructions and will always be focusing on something. Therefore, the internal focus condition is used as an active comparator.
62283825|NCT06538766|EXPERIMENTAL|Proprioceptive External Focus Condition|In the proprioceptive external focus condition the participant is instructed to realize seated calf raises by focusing on lifting the machine's bar.
62283826|NCT06538766|EXPERIMENTAL|Visual External Focus Condition|In the visual external focus condition the participant is instructed to realize seated calf raises by focusing on a line representing the displacement of the bar projected on a screen.
62283827|NCT00841737|EXPERIMENTAL|Psychoeducational group intervention|Psychoeducational group received weekly a psychoeducational intervention during a period of 12 weeks run by a nurses.
62283828|NCT00841737|ACTIVE_COMPARATOR|Control group|Individual conventional care
62283829|NCT03899701|EXPERIMENTAL|PEC I and PEC II block|Ultrasound guided nerve block group.
62283830|NCT03194815|ACTIVE_COMPARATOR|Intravenous immunoglobulin and Rituximab|One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
62459774|NCT03463278||>7 blastocysts|group C: cumulative pregnancy rate of \>7 blastocysts vitrified
62084477|NCT03423459||CT Cohort|"1. Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.~2. Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.~3. Determine how the Evolut PRO conforms to LVOT calcification.~4. Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.~5. Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.~6. Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR."
62084478|NCT03423459||Non-CT Cohort|"1. Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.~2. Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.~3. Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation."
62084479|NCT00605371|EXPERIMENTAL|Subjects receiving regimen A|Eligible subjects will receive regimen A containing lamotrigine extended release tablet of 200 milligrams plus 50 milligrams in fasted state
62283831|NCT03194815|PLACEBO_COMPARATOR|Placebo|One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
62283832|NCT03538743|PLACEBO_COMPARATOR|Placebo|
62283833|NCT03538743|EXPERIMENTAL|PF-06882961 30 mg|
62650860|NCT03953716|EXPERIMENTAL|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
62650861|NCT03953716|ACTIVE_COMPARATOR|Marvelon|1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
62084480|NCT00605371|EXPERIMENTAL|Subjects receiving regimen B|Eligible subjects will receive regimen B containing lamotrigine extended release caplet of 250 milligrams in fasted state.
62084481|NCT00605371|EXPERIMENTAL|Subjects receiving regimen C|Eligible subjects will receive regimen C containing lamotrigine extended release caplet of 250 milligrams in fed state.
62283834|NCT03538743|EXPERIMENTAL|PF-06882961 100 mg|
62283835|NCT03538743|EXPERIMENTAL|PF-06882961 300 mg|
62283836|NCT03538743|EXPERIMENTAL|PF-06882961 600 mg|
62283837|NCT03538743|EXPERIMENTAL|PF-06882961 dose TBD Cohort 5|
62283838|NCT03538743|EXPERIMENTAL|PF-06882961 dose TBD Cohort 6|
62283839|NCT03538743|EXPERIMENTAL|PF-06882961 dose TBD Cohort 7|
62283840|NCT03538743|EXPERIMENTAL|PF-06882961 dose TBD Cohort 8|
62283841|NCT03791333||multi trauma patients group|
62283842|NCT03838224|EXPERIMENTAL|Dry needling|Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves.
62459775|NCT03973177|EXPERIMENTAL|Treatment Group: Phenol injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target sites
62650862|NCT03893786|EXPERIMENTAL|Robotic Treatment|"Fifteen patients with Parkinson's Disease will perform ten 45-minutes training sessions of the upper limb using the Armeo®Spring applied bilaterally, an electromedical device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upper limb training and it is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
62650863|NCT03893786|ACTIVE_COMPARATOR|Conventional Treatment|Fifteen patients with Parkinson's Disease will undergo ten 45-minutes training sessions of the upper limb with a traditional approach, performing the same excercises of the experimental group, i.e. flexo-extension of the wrist, prono-supination of the forearm, etcc.
62650864|NCT01795443|ACTIVE_COMPARATOR|Healthy volunteers 1|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
62653090|NCT01963468|EXPERIMENTAL|Early language intervention|"Children will receive 6 months of weekly parent-implemented intervention sessions.~Children will be assessed monthly via audio recordings and language checklists to monitor language development more closely."
62084482|NCT05948462|EXPERIMENTAL|Lorlatinib and Platinum and Pemetrexed|Lorlatinib will be administered by mouth daily plus Pemetrexed by IV infusion every 3 weeks until progression or intolerable toxicity. Platinum-based standard of care chemotherapy by IV infusion will also be given every 3 weeks for the first 4 cycles; carboplatin or cisplatin are the platinum agents that may be selected based on physician discretion. One cycle is defined as 3 weeks.
62084483|NCT01610973|EXPERIMENTAL|Manual preparation|Manual preparation of the graft
62084484|NCT01610973|ACTIVE_COMPARATOR|Automatized preparation|Automatized preparation of the graft with microkeratoma
62084485|NCT04971616||Group 1: Patients with shoulder, neck and lower back discomfort|Patients with shoulder, neck and lower back discomfort.
62084486|NCT03513198||Non-resectable pancreatic cancer|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months.~Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included.~Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment"
62283843|NCT03838224|SHAM_COMPARATOR|sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
62283844|NCT06002503|EXPERIMENTAL|1: Intramuscular|Route (device): Intramuscular (PharmaJet Stratis Needle-free Injection System) Vaccine dose schedule (week): 0, 4, 8 Saline dose schedule (week): 26
62283845|NCT06002503|EXPERIMENTAL|2: Intramuscular|Route (device): Intramuscular (PharmaJet Stratis Needle-free Injection System) Vaccine dose schedule (week): 0, 8, 26 Saline dose schedule (week): 4
62283846|NCT06002503|EXPERIMENTAL|3: Intradermal|Route (device): Intradermal (PharmaJet Tropis Needle-free Injection System) Vaccine dose schedule (week): 0, 4, 8 Saline dose schedule (week): 26
62283847|NCT06002503|EXPERIMENTAL|4: Intradermal|Route (device): Intradermal (PharmaJet Tropis Needle-free Injection System) Vaccine dose schedule (week): 0, 8, 26 Saline dose schedule (week): 4
62283848|NCT05466214|EXPERIMENTAL|CBC Treatment Group|For this group, school staff who work with families and teachers to address student emotional and behavioral concerns will use the CBC model to do so.
62459776|NCT03973177|OTHER|Control Group: Methylprednisolone injection|Methylprednisolone acetate 10 mg with 2 mL preservative free saline and 0.5 mL iopamidol 300 will be injected at each of the target site
62459777|NCT00376623|EXPERIMENTAL|200 milligram (mg) of BI 2536|Day 1
62459778|NCT00376623|EXPERIMENTAL|50 milligram (mg) of BI 2536|Day 1, 2, and 3
62459779|NCT00376623|EXPERIMENTAL|60 milligram (mg) of BI 2536|Day 1, 2, and 3
62459780|NCT04233320|EXPERIMENTAL|silicone cream containing Allium Cepa extract|Silicone cream containing Allium Cepa extract will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
62084487|NCT02682498|ACTIVE_COMPARATOR|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
62084488|NCT02682498|ACTIVE_COMPARATOR|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
62084489|NCT02965209|EXPERIMENTAL|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
62084490|NCT04731103|ACTIVE_COMPARATOR|Abacavir (ABC)|Participants receive Abacavir (ABC) for 6 weeks and 4 weeks of washout.
62084491|NCT04731103|ACTIVE_COMPARATOR|Lamivudine (3TC)|Participants receive Lamivudine (3TC) for 6 weeks and 4 weeks of washout.
62084492|NCT04731103|ACTIVE_COMPARATOR|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Participants receive Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) for 6 weeks and 4 weeks of washout.
62084493|NCT01396928||"J pouch"|"Anastomosis coloanal wiht j pouch reservoir"
62084494|NCT01396928||Transverse coloplasty pouch|Coloanal anastomosis with transverse coloplasty pouch reservoir
62084495|NCT03395938|PLACEBO_COMPARATOR|Current practice|"Intervention A depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation."
62084496|NCT03395938|ACTIVE_COMPARATOR|Proactive engagement|"Intervention B involves a series of proactive engagements in hope to spur patients into contacting their siblings and improve their receptiveness towards colorectal cancer screening."
62084497|NCT05773040|EXPERIMENTAL|Part 1 (dose escalation)|Part 1, the dose of JV-213 participants receive will depend on when you join this study. Up to 3 dose levels of JV-213 will be tested. About 3-6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level of JV-213. Each new group will receive a higher dose of JV-213 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of JV-213 is found.
62084498|NCT05773040|EXPERIMENTAL|Part 2 (dose expansion)|Participants will receive JV-213 at the recommended dose that was found in Part 1.
62084499|NCT01484509||Intermittent claudication|
62084500|NCT05321914|NO_INTERVENTION|Control|Habitual physical activity
62459781|NCT04233320|ACTIVE_COMPARATOR|commercial scar gel|Commercial scar gel will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
62653091|NCT01963468|NO_INTERVENTION|Monthly language check-ups|Children will be assessed monthly via home observations and parents will complete a language checklist to monitor language development more closely.
62653092|NCT02941640|EXPERIMENTAL|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
62084501|NCT05321914|EXPERIMENTAL|Morning exercise|Exercise training in the morning (6:00-10:00am)
62084502|NCT05321914|EXPERIMENTAL|Evening exercise|Exercise training in the evening (4:00-8:00pm)
62084503|NCT01242943|EXPERIMENTAL|L19SIP I131|"Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I."
62084504|NCT00580229|EXPERIMENTAL|prednisone|Prednisone 40mg by mouth 30-60 minutes prior to rituximab.
62283849|NCT05466214|NO_INTERVENTION|Control Group|For this group, school staff who work with families and teachers to address student emotional and behavioral concerns will engage in business as usual.
62459782|NCT05702424|EXPERIMENTAL|IGM-7354 Single-Agent Dose Escalation|IGM-7354 will be administered intravenously as a single agent.
62459783|NCT05702424|EXPERIMENTAL|IGM-7354 Single-Agent Dose Expansion Serial Biopsy|IGM-7354 will be administered intravenously as a single agent and patients will undergo pre-treatment and on-treatment biopsies.
62459784|NCT05290194|EXPERIMENTAL|Oligometastatic nasopharyngeal carcinoma|Patients included are going to receive radiotherapy, chemotherapy and immunotherapy. Radiotherapy includes IMRT and SBRT. IMRT is applied for primary sites and cervical lymph nodes，and SBRT following is applied for oligometastatic sites. PD-1 inhibitors: during the whole trial, intravenous, Q3W; Capecitabine: 650mg, po, bid, following the radiotherapy for a year.
62459785|NCT04067102|EXPERIMENTAL|Nab-paclitaxel Based Regimens|
62459786|NCT04067102|ACTIVE_COMPARATOR|Paclitaxel Based Regimens|
62650865|NCT01795443|ACTIVE_COMPARATOR|Healthy volunteers 2|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
62283850|NCT04319900|EXPERIMENTAL|favipiravir tablets+chloroquine phosphatetablets tablets group|favipiravir tablets+chloroquine phosphatetablets tablets
62283851|NCT04319900|EXPERIMENTAL|favipiravir tablets group|favipiravir tablets
62084505|NCT00338715|EXPERIMENTAL|A|Prophylactic Pulmonary Vein Isolation in Addition to CABG for the prevention of postoperative Atrial Fibrillation
62283852|NCT04319900|PLACEBO_COMPARATOR|placebo treatment group|placebo
62650866|NCT01795443|ACTIVE_COMPARATOR|Healthy volunteers 3|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
62459787|NCT01845363|OTHER|Cefazolin|"Cefazolin used in antimicrobial prophylaxis~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
62084506|NCT01210235|EXPERIMENTAL|FLU-FIT Arm|In this arm, eligible patients aged 50-75 will be offered a FIT kit
62084507|NCT01210235|NO_INTERVENTION|FLU-Only Arm|In this arm, patients will receive flu shots as usual, without the FLU-FIT intervention.
62084508|NCT04227340|EXPERIMENTAL|Photobiomodulation Therapy (PBM)|The PBM will be administered extra-oral and intra-oral.
62283853|NCT06536452||Observational|Patients undergo blood sample collection and bone marrow aspiration and biopsy and have their medical records reviewed on study.
62650867|NCT01795443|ACTIVE_COMPARATOR|Healthy volunteers 4|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
62650868|NCT01795443|ACTIVE_COMPARATOR|Healthy volunteers 5|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
62650869|NCT01795443|ACTIVE_COMPARATOR|Healthy volunteers 6|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
62650870|NCT01795443|EXPERIMENTAL|Back pain patients 1|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
62650871|NCT01795443|EXPERIMENTAL|Back pain patients 2|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
62653093|NCT02941640|EXPERIMENTAL|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
62283854|NCT03446885|EXPERIMENTAL|Lab visit 1|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
62653094|NCT02941640|EXPERIMENTAL|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
62084509|NCT01719146||UofL Subjects|Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY
62084510|NCT01719146||Duke Subjects|Subjects undergoing Specimen Collection at Duke University, Durham, NC
62084511|NCT01719146||WNERTA Subjects|Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA
62084512|NCT02626403|ACTIVE_COMPARATOR|anodal tDCS|Patients will receive anodal tDCS (bilateral fronto-parietal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
62084513|NCT02626403|SHAM_COMPARATOR|sham tDCS|Patients will receive sham tDCS (15 second of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
62084514|NCT04058821|EXPERIMENTAL|Adults with traumatic brachial plexus injuries|Participants will have two MRI scans before surgery (to find out the best time to scan), then two after surgery (at 6 and 12 months).
62084515|NCT06071975|EXPERIMENTAL|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
62084516|NCT06071975|EXPERIMENTAL|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
62084517|NCT03949751|NO_INTERVENTION|Control group|The participants of the control group will not get the local therapy in the investigator's preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative.
62084518|NCT03949751|EXPERIMENTAL|Therapy group|30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae.
62084519|NCT05447247|EXPERIMENTAL|Acupuncturing Ba Liao point under ultrasound guidance|
62084520|NCT05447247|EXPERIMENTAL|Conventional acupuncture|
62459788|NCT06496542|EXPERIMENTAL|Daily Caloric Restriction|The daily caloric restriction group will participate in a 2-year, group-based, behavioral weight loss intervention based on a 30% reduction in caloric intake and increased physical activity.
62084521|NCT03390036|EXPERIMENTAL|Cingal|Cingal is a combination product consisting of 88 milligrams of crosslinked HA (hyaluronic acid) with 18 milligrams of TH (triamcinolone hexacetonide) in a 4 milliliter (mL) intra-articular injection.
62650872|NCT01795443|EXPERIMENTAL|Back pain patients 3|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
62650873|NCT01795443|EXPERIMENTAL|Back pain patients 4|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
62650874|NCT01795443|EXPERIMENTAL|Back pain patients 5|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
62084522|NCT03390036|ACTIVE_COMPARATOR|Monovisc|Monovisc is a device that consists of 88 milligrams of cross-linked HA (hyaluronic acid) in a 4 milliliter (mL) intra-articular injection.
62084523|NCT03390036|ACTIVE_COMPARATOR|Triamcinolone Hexacetonide (TH)|Triamcinolone hexacetonide (TH) is a corticosteroid supplied in a 20 milligram per 1 milliliter (20 mg/mL) intra-articular injection.
62084524|NCT06191731|EXPERIMENTAL|excretion kinetics of gadolinium contrast agents in patients|urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
62084525|NCT06354621|NO_INTERVENTION|Group-A (Control Group)|Participants receiving standard antenatal care without having any vitamin-D supplementation/intervention
62084526|NCT06354621|EXPERIMENTAL|Group-B (2000IU/day)|Participants receiving 2000IU/day of Vitamin-D supplementation, in addition to having standard antenatal care
62084527|NCT06354621|EXPERIMENTAL|Group-C (4000IU/day)|Participants receiving 4000IU/day of Vitamin-D supplementation, in addition to having standard antenatal care
62650875|NCT01795443|EXPERIMENTAL|Back pain patients 6|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
62650876|NCT01580631||BE with dysplasia.|Patients having Barrett's esophagus with dysplasia.
62650877|NCT01580631||BE without dysplasia.|Patients having Barrett's esophagus without dysplasia.
62653095|NCT02941640|EXPERIMENTAL|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
62084528|NCT05887804|EXPERIMENTAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|"UC-MSC was collected in 50 mL of transport medium, which contained alpha minimal essential medium (αMEM \[GIBCO 12000-0221\]), penicillin/streptomycin (final concentration 300u/mL \[GIBCO 15140-122\]) and amphotericin B (final concentration 7500ng /mL \[JR Scientific 50701\]), and processed in less than 8 hours after collection.~Group 1 was given UC-MSC 2 million cells/mL/cm3"
62084529|NCT05887804|EXPERIMENTAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|group 2 was given UC-CM 1 mL/cm3
62084530|NCT05887804|ACTIVE_COMPARATOR|triamcinolone acetonide|group 3 was given TA 40 mg/mL/cm3
62084531|NCT05212493|ACTIVE_COMPARATOR|Seach CBD:THC 20:1 cannabis oil|cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Seach LTD and oil manufactured by Nextar Pharma LTD.
62084532|NCT05212493|ACTIVE_COMPARATOR|Candoc CBD:THC 20:1 cannabis oil|cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Candoc LTD and oil manufactured by Panaxia LTD.
62650878|NCT01099644|EXPERIMENTAL|131 I-8H9|This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.
62650879|NCT03012646|EXPERIMENTAL|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
62650880|NCT01118299|EXPERIMENTAL|Device|AMPLATZER Cardiac Plug
62650881|NCT01118299|ACTIVE_COMPARATOR|Optimal Medical Therapy (control)|Warfarin Dabigatran
62650882|NCT05024448|ACTIVE_COMPARATOR|Prednisone|Prednisone, 60mg/d, for 10 days
62650883|NCT05024448|PLACEBO_COMPARATOR|Placebo|
62650884|NCT05321537|EXPERIMENTAL|Somatosensory training|It consists of head relocation exercises, eye tracking, gaze stability and eye-head coordination. It requires the use of special material, the pupillary glasses allow the gaze to be fixed by restricting peripheral vision and the laser pointer provides visual feedback on the positioning of the head.
62650885|NCT05321537|EXPERIMENTAL|Endurance-strength training|It consists of low-load training of the craniocervical flexor muscles. This exercise is specific for the deep cervical flexor muscles, while seeking minimal activation of the superficial flexor muscles. This training consists of 5 phases, starting with a pressure of 20 mmHg, progressively increasing 2 mmHg in each phase.
62650886|NCT03746496||pre-hospital emergency patients|Patient in a need of an IO-access. Patient in a need of point-of-care laboratory analysis. Over 18 years. Alive (no Cardiac arrest.)
62084533|NCT01510613|EXPERIMENTAL|Pomalidomide and Dexamethasone|
62283855|NCT03446885|EXPERIMENTAL|Lab visit 2|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
62650887|NCT05600959||Lymphoma group|Patients with histopathologically confirmed lymphoma who did not receive systemic chemotherapy before enrollment.
62650888|NCT05600959||Lymphoma-associated HLH group|Patients with histopathologically confirmed lymphoma who meet HLH-04 diagnostic criteria, and did not receive systemic chemotherapy before enrollment.
62650889|NCT04529694|ACTIVE_COMPARATOR|Cognitive-only Intervention|This condition includes cognitive interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, \& Emery (1979).
62650890|NCT04529694|ACTIVE_COMPARATOR|Behavioral-only Intervention|The condition includes behavioral interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, \& Emery (1979).
62650891|NCT01481493|EXPERIMENTAL|Active Treatment|BT061 monoclonal antibody (subcutaneous)
62650892|NCT01481493|PLACEBO_COMPARATOR|Placebo|subcutaneous injection of placebo
62650893|NCT02915835|ACTIVE_COMPARATOR|riociguat|Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
62650894|NCT02915835|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
62650895|NCT05859698|EXPERIMENTAL|Valbenazine|Valbenazine administered once daily for 24 weeks.
62650896|NCT05893238||In Vitro Fertilisation (IVF)-Patients without hormonal stimulation (Natural cycle IVF)|Natural cycle IVF
62650897|NCT05893238||In Vitro Fertilisation (IVF)-Patients with hormonal stimulation (conventional IVF)|conventional IVF
62650898|NCT02663700|EXPERIMENTAL|1.8x10^6 sporozoites 2 doses|To be completed after safety data from Cohorts 1 and 2 are reviewed. Vaccination with 1.8x10\^6 sporozoites on study weeks 3 and 11. n=8
62084534|NCT04131868|EXPERIMENTAL|Extended sleep opportunity|
62084535|NCT04131868|ACTIVE_COMPARATOR|Typical sleep opportunity|
62084536|NCT00948012||Patients without pulmonary hypertension|Patients with sickle cell with normal response of pulmonary artery pressure to exercise
62084537|NCT00948012||Exercise-induced pulmonary hypertension|Patients with sickle-cell anemia with exercise-induced pulmonary hypertension.
62650899|NCT02663700|EXPERIMENTAL|2.7x10^6 sporozoites 2 doses|To be completed after safety data from Cohort 3 is reviewed. Vaccination with 1.8x10\^6 sporozoites on study weeks 5 and 13. n=8
62650900|NCT02663700|EXPERIMENTAL|2.7x10^6 sporozoites 3 doses|Subjects to be assigned 1:1 to either PfSPZ vaccine (pending safety data from cohort 4) or placebo. Subjects will be administered the intervention on a 0, 8, and 16 week schedule (study days 1, 57, and 113). n=80
62084538|NCT02451813|EXPERIMENTAL|Intervention|"A 22 GA 5 cm nerve block needle will be advanced to the following conditions:~1. Needle tip slightly indenting the fascia iliaca~2. Needle tip advanced through fascia iliaca~3. Needle tip slightly indenting the anterior surface of the femoral nerve~4. Needle tip withdrawn 1 mm from nerve.~At each of these conditions, 1 ml of dextrose solution will be injected and spread of injectate observed sonographically. A blinded observer will measure injection pressure. If opening pressure reaches 15 psi, this investigator will halt the injection. In addition, minimum threshold current required to elicit a motor response will be recorded for conditions 3 and 4."
62084539|NCT01857323|EXPERIMENTAL|Albuterol Spiromax®|The approximate 50-day treatment period consisted of 180 mcg (90 mcg/dose cycle, 2 dose cycles) twice daily study medication administration with Albuterol Spiromax with dose-counter.
62084540|NCT05748782||BASKA GROUP|the BASKA mask will be inserted, and its size will be chosen according to the manufacturer's weight-based recommendations.
62084541|NCT05748782||ETT GROUP|Patients in this group will be anesthetized using an endotracheal tube of appropriate size.
62084542|NCT01553786|EXPERIMENTAL|lenalidomide|lenalidomide + CHOP
62084543|NCT01628510|ACTIVE_COMPARATOR|Traditional NICU Positioning|Methods of positioning in the NICU have been used for several decades. These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper® The continued use of these methods of positioning is the control group in the current study.
62650901|NCT02663700|EXPERIMENTAL|4.5x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 4.5x10\^5 sporozoites on study weeks 1 and 9. n=8
62650902|NCT02663700|EXPERIMENTAL|9x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 9x10\^5 sporozoites on study weeks 1 and 9. n=8
62650903|NCT03774108|EXPERIMENTAL|Metformin Experimental Arm|Metformin 850mg/12 hours, oral, 8 weeks
62650904|NCT03774108|PLACEBO_COMPARATOR|Placebo Comparator Arm|Placebo pills/12hours, oral, 8 weeks
62650905|NCT03599960|EXPERIMENTAL|Chemotherapy|
62084544|NCT01628510|EXPERIMENTAL|Dandle Roo/Dandle Wrap|The new Dandle Roo and Dandle Wrap were developed by NICU professionals to support the neurodevelopment of the preterm infant, and this device is produced by Dandle Lion Medical. The Dandle Roo/Wrap provides all around contact, containment, and proprioceptive input, (which more closely mimics the uterine environment) and can decrease excitability and promote self-regulation, while also allowing for movement with recoil back to flexion.
62084545|NCT06386146|EXPERIMENTAL|Dose escalation phase|Multiple dose levels of JAB-30355 will be explored to determine the maximum tolerated dose (MTD)
62084546|NCT06386146|EXPERIMENTAL|Dose expansion phase|Dose Expansion Phase will explore JAB-30355's clinical benefit and optimal tolerability in selected dose level.
62650906|NCT05788263|EXPERIMENTAL|Craniovertebral angle assesment|Craniovertebral angle is the most widely used measurement to assess Forward head posture. Craniovertebral angle is described as the acute angle formed between a horizontal line passing through the spinous process of the seventh cervical vertebra (C7) and the line connecting the midpoint of the tragus to the spinous process of C7.
62653096|NCT04796857|EXPERIMENTAL|Tislelizumab in Combination With Lenalidomide|On the day of tislelizumab infusion, lenalidomide should be taken 30 minutes after the end of tislelizumab infusion
62650907|NCT05788263|EXPERIMENTAL|Spatio-temporal gait analyz (LEGSystm)|The gait performance of the cases was evaluated with a spatio-temporal gait analysis device named LEGSystm developed by BioSensicstm. The device consists of two sensors. The sensors are placed 3-5 cm above the ankle of the subject to be tested with the help of velcro. The device is controlled from the computer with its own software and instantly sends the raw data it collects to the computer via Bluetooth. The software analyzes the raw data it receives from the device and turns it into results.The Modified Get Up and Go Test (MKYT), which is also supported by the legsyst, was used for assesment. The test was repeated 2 times and the average time was recorded. Legsystm provides information on double stride length, duration and speed of walking, as well as standing, turning, sitting times and total time
62650908|NCT05788263|EXPERIMENTAL|Neck Disabilty Index|It is a questionnaire created to determine the level of disability caused by chronic neck pain in daily life.
62650909|NCT05313139||Unvaccinated participants|Participants who did received the rVSV-ZEBOV vaccine nor had any prior close contact with EBOV patients nor presenting a travel history to East DRC
62650910|NCT05313139||Primary vaccinated participants|Participants who received a first rVSV-ZEBOV vaccine dose as part of the WHO vaccination campaign organized in Goma region (end of 2021), of which vaccination date and brand is known
62650911|NCT05313139||Participants vaccinated < 1 year ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose less than a year prior to inclusion of which vaccination date and brand is known
62650912|NCT05313139||Participants vaccinated 1-2 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose between 1-2 years prior to inclusion of which vaccination date and brand is known
62650913|NCT05313139||Participants vaccinated 2-3 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose between 2-3 years prior to inclusion of which vaccination date and brand is known
62650914|NCT05313139||Participants vaccinated > 3 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose \> 3 years prior to inclusion of which vaccination date and brand is known
62084547|NCT01531140|ACTIVE_COMPARATOR|Polyethylene glycol|Polyethylene glycol p.o.(Fortrans):60 ml/kg for 2 days
62084548|NCT01531140|EXPERIMENTAL|PEG + Bisacodyl|Polyethylene glycol p.o.(Fortrans): 30 ml/kg for 2 days + Bisacodyl p.o.: 10-15 mg/day
62283856|NCT01301989|PLACEBO_COMPARATOR|Sleep Education Control|"The control group receives a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers (in English and Spanish)."
62283857|NCT01301989|EXPERIMENTAL|Sleep Counselor Intervention|"The sleep counselor visits are to assess the family's understanding of their child's sleep problems; help parents recognize the child's sleep deficiency; discuss how sleep problems affect behavior, learning, and health; and reassure parents that the sleep counselor can help them with these problems.~Additionally, sleep counselors: review parent's sleep goals to monitor changes to the child's bedtime routine and sleep environment; help them solve problems with implementation; provide positive feedback to help the parent recognize success; and help parents set additional goals for improving sleep."
62283858|NCT05729009||heart transplantation|
62084549|NCT01531140|EXPERIMENTAL|Sennosides|Sennosides: 1tbl/8kg/day for 2 days (1 tbl=8,6 mg sennosides B)
62283859|NCT02894840|ACTIVE_COMPARATOR|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine \[A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains\] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
62283860|NCT02894840|PLACEBO_COMPARATOR|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
62283861|NCT03804385|OTHER|intercostal tube|insertion of intercostal tube is surgical operation used in pneumothorax
62650915|NCT04270877|EXPERIMENTAL|Naltrexone|"Low Dose Naltrexone (LDN) is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets once daily in the evening."
62650916|NCT04270877|PLACEBO_COMPARATOR|Placebo|"LDN-placebo is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets (similar in size, shape and taste to the active medication), once daily in the evening."
62650917|NCT02996383|ACTIVE_COMPARATOR|Cemented hemiarthroplasty|Treatment of the fracture by a replacement arthroplasty with a cemented CPT hemiarthroplasty (manafactured by Zimmer company, Warsaw IN, USA) inserted via an anteriolateral approach to the hip
62650918|NCT02996383|ACTIVE_COMPARATOR|Internal fixation|Internal fixation of the fracture with a screw and plate device (Targon FN plate, Aesculap cooperation, Tuttingham, Germany)
62283862|NCT05825872|NO_INTERVENTION|control group|patients will undergo a thoracoscopic surgery under general anesthesia with double-lumen bronchial intubation without any special treatment.
62283863|NCT05825872|ACTIVE_COMPARATOR|experimental group|patients will receive US-guided iSLN block bilaterally with 2 ml of ( 0.5 ml of 2%lidocaine and 1,5 ml of 0.5% bupivacaine) on either side immediate after the operation concomitant with GA in order to undergo thoracoscopic surgery
62283864|NCT04684420|EXPERIMENTAL|First Reference GXR (Fasting), Then Test GXR RM (Fasting)|Participants received a single oral dose of 500 milligram (mg) of reference GXR (Glucophage® Extended Release) tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg test GXR RM (Reduced Mass) tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
62650919|NCT04329260||Pediatric population|"Children between 3 to 18 years old with severe (BMI\> IOTF-30) and early (before the age of 6) obesity.~A Saliva sample for screening of the deletion Δ6-8 of LEPR gene will be performed for each child."
62650920|NCT04329260||Adult member family|The screening of the same deletion according the same procedure will be proposed to the adult family member if the child presents the deletion Δ6-8 of LEPR gene.
62650921|NCT01086488|EXPERIMENTAL|Nasopharyngeal Carcinoma|A: Experimental B: Active Comparator
62650922|NCT01685437|EXPERIMENTAL|AA4500|collagenase clostridium histolyticum
62650923|NCT03023501|EXPERIMENTAL|Gabapentin|Gabapentin 1200mg capsule was administered orally 2 hours before surgery
62283865|NCT04684420|EXPERIMENTAL|First Test GXR RM (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
62283866|NCT04684420|EXPERIMENTAL|First Reference GXR (Fed), Then Test GXR RM (Fed)|Participants received a single oral dose of 500 milligrams (mg) of reference GXR tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of test GXR RM tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
62283867|NCT04684420|EXPERIMENTAL|First Test GXR RM (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
62283868|NCT05585034|EXPERIMENTAL|Dose Escalation and Expansion XmAb®808 administered in combination with pembrolizumab|XmAb®808 in combination with pembrolizumab
62084550|NCT00047710|EXPERIMENTAL|Bevacizumab|Radiation, Bevacizumab, and Capecitabine
62650924|NCT03023501|PLACEBO_COMPARATOR|Placebo|Placebo capsule was prepared by hospital pharmacy and was administered orally 2 hours before surgery.
62650925|NCT01341704|EXPERIMENTAL|MSP3-LSP/AlOH|Synthetic polyprotein of 96 amino acids (186-276 in 3D7 strain) manufactured by solid-phase synthesis by SYNPROSIS, France; lyophilized product was formulated extemporaneously with aluminum hydroxide (Reheis). 30 microgram per dose; three dose schedule on study day 0, 28 and 56 for primary series
62650926|NCT01341704|PLACEBO_COMPARATOR|Control|Primary series: Verorab Rabies vaccine; Secondary/Booster series: 0.9% NaCL/Normal Saline
62650927|NCT02759458|EXPERIMENTAL|Healicoil|Patients that met the inclusion criteria who were randomly selected to receive the Healicoil anchor for their rotator cuff repair.
62650928|NCT02759458|ACTIVE_COMPARATOR|Twinfix|Patients that met the inclusion criteria who were randomly selected to not receive the Healicoil anchor for their rotator cuff repair.
62283869|NCT03986255|EXPERIMENTAL|Lumbar Puncture|Participants will undergo Lumbar puncture procedure
62283870|NCT06387680|EXPERIMENTAL|Peanut Ball Group|When the cervical dilation reached 4 cm, the peanut ball was first applied to the pregnant women in the side-lying position (right side/left side) for 20 minutes, and then the pregnant women were allowed to rest for 10 minutes. Second, the semi-seated position was applied for 20 minutes and the pregnant women were allowed to rest for 10 minutes. Third, the supine position was applied for 20 minutes followed by 10 minutes of rest. Fourth, the hand-knee position was applied for 20 minutes and rested for 10 minutes. Finally, the squatting position was practiced for 20 minutes and then the pregnant women rested for 10 minutes. Each position was practiced with the peanut ball for 20 minutes and rested for 10 minutes. Each position was performed once during the procedure. A pregnant woman who wished to remain in a position longer was allowed an additional 10 minutes without interrupting the flow of the intervention and then rested for 10 minutes.
62283871|NCT06387680|NO_INTERVENTION|Control Group|Control Group (CG) No intervention other than routine intrapartum midwifery care was provided to primiparous pregnant women in the control group. After admission to the hospital for delivery, the pregnant women in the control group were informed about the study, written informed consent was obtained, routine practices and care in the delivery room were performed (taking history, taking vital signs, demonstrating correct breathing techniques, ensuring freedom of movement), vaginal examination and cervical changes were recorded on the partograph, EFM (electronic fetal monitoring) was performed when the time came according to the doctor's order, fetal heart rate (FHR) was listened to every half hour and recorded on the partograph.
62283872|NCT01274247|ACTIVE_COMPARATOR|Topical Benzocaine|For infants treated with topical benzocaine prior to the procedure
62650929|NCT02265523|NO_INTERVENTION|Standard Post-op Exercise Group|The standard post-operative exercises are already currently recommended to patients. Briefly, they include deep breathing and coughing, ankle pumping, buttock contractions, and static quadriceps strengthening. These are performed on a daily basis , 2-3 times per day, 30 repetitions.
62650930|NCT02265523|EXPERIMENTAL|Viscus Group|The Viscus (intervention) group will complete the standard post-operative exercises and will also have access to a Viscus V1.5 cycle ergometer 24 hours per day in their recovery room to use at their leisure.
62650931|NCT02978469|EXPERIMENTAL|Life style changing: reducing sedentary behavior|Meetings with social worker and physical therapist.
62650932|NCT02978469|ACTIVE_COMPARATOR|Physical exercise group|Physical therapy exercise training in group, strengthening and stretching muscles.
62650933|NCT06099535|EXPERIMENTAL|LNK01001 Dose A|Participants will receive LNK01001 Dose A orally BID for up to 24 weeks.
62650934|NCT06099535|EXPERIMENTAL|LNK01001 Dose B|Participants will receive LNK01001 Dose B orally BID for up to 24 weeks.
62650935|NCT06099535|PLACEBO_COMPARATOR|placebo/LNK01001 Dose A|Participants will receive a placebo orally BID for 12 weeks in Period 1. Participants will be re-randomized at Week 13 in a 1:1 ratio to receive LNK01001 Dose A orally BID for up to 24 weeks.
62084551|NCT00959803|EXPERIMENTAL|Single dose|3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.
62283873|NCT01274247|NO_INTERVENTION|no benzocaine|No benzocaine applied
62283874|NCT05205408|EXPERIMENTAL|Oncolytic Virus Injection(RT-01)|Intratumoral administration of RT-01 as single agent for patients with advanced solid tumors. Dose cohorts: 1×10\^8 TCID50/mL and 7×10\^8 TCID50/ mL
62283875|NCT03440359|OTHER|# 1- no progesterone therapy|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is \>17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase
62283876|NCT03440359|ACTIVE_COMPARATOR|# 2 - Progesterone Vaginal Gel 8%|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7. Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is \>17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination.Crinone 8% (progesterone) vaginal therapy was provided in luteal phase for 14 days .Administration was started the second day after intrauterine insemination or timed intercourse.
62283877|NCT03502720||Control Patients|"Data obtained retrospectively from Scaphoid fixation surgeries performed at our center using the standard procedure (no device for guide wire positioning).~This control group should have registered al parameters and variables to be studied."
62283878|NCT03502720||Case Patients|Prospective series of ten patients on which the external 3D guide system will be used.
62283879|NCT01641120|EXPERIMENTAL|30 gauge|Subjects used a 30 gauge needle for intramuscular injection of Avonex.
62283880|NCT01641120|EXPERIMENTAL|25 gauge|Subjects used a 25 gauge needle for intramuscular injection of Avonex.
62283881|NCT01415635|EXPERIMENTAL|Nutritional intervention|"The study will compare standard nutritional care (control group) with tailored nutritional care (the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)(intervention group)."
62283882|NCT03176082|EXPERIMENTAL|Intervention Group|"Intervention group will receive:~1. A reminder letter indicating need for screening~2. A FIT kit with completion instructions~3. A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)~4. A pre-paid return mailer for FIT Kit"
62283883|NCT03176082|ACTIVE_COMPARATOR|Comparison Group|"Comparison group will receive:~1. A reminder letter indicating need for screening~2. Instructions for obtaining a FIT kit~3. A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
62283884|NCT04478825|EXPERIMENTAL|BBT-401-1S|BBT-401-1S, rectal administration
62283885|NCT03337256|EXPERIMENTAL|GI bleeding score|Early endoscopy in emergency department + other clinical parameters
62283886|NCT01324557|EXPERIMENTAL|CSII|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII)
62283887|NCT01324557|NO_INTERVENTION|MDI|MDI: Control Optimized subcutaneous insulin by multiple daily injections (MDI)
62283888|NCT02141893|ACTIVE_COMPARATOR|CALMA|Participants only received a family education intervention (previously tested) known as CALMA
62283889|NCT02141893|EXPERIMENTAL|Calma plus|Participants in Arm 2 received the CALMA family education intervention and physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs.
62283890|NCT04047901|NO_INTERVENTION|control group|"A group of patients who will not be trained will be evaluated at baseline (pre) and after 16 weeks.~They are oriented to maintain lifestyle changes"
62283891|NCT04047901|EXPERIMENTAL|Training group|Patients will complete 16 weeks of training including 40 minutes of aerobic training, 15 minutes of resistive exercise and 5 minutes of relaxation.
62283892|NCT06273254|EXPERIMENTAL|Test Product|Sacubitril and Valsartan Tablets 49mg/51mg to be orally administered
62283893|NCT06273254|ACTIVE_COMPARATOR|Reference product|Entresto® (48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex) to be orally administered
62283894|NCT03725410|ACTIVE_COMPARATOR|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
62283895|NCT03725410|PLACEBO_COMPARATOR|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
62283896|NCT05990855|EXPERIMENTAL|eCBTi-obj|In the experimental condition, participants will complete a 5-week eCBTi program delivered via a mobile application while wearing an EEG headband (Muse S) during sleep. As part of the sleep restriction therapy component of CBTi, participants will be asked to follow an individualized sleep window (i.e., bed and wake schedule) which will be adjusted each week based on objective sleep data derived from their EEG recordings from the previous week. Participants will also receive a weekly sleep report based on this data.
62650936|NCT06099535|PLACEBO_COMPARATOR|placebo/LNK01001 Dose B|Participants will receive a placebo orally BID for 12 weeks in Period 1. Participants will be re-randomized at Week 13 in a 1:1 ratio to receive LNK01001 Dose B orally BID for up to 24 weeks.
62650937|NCT01667588||Pre-Dialysis|
62459789|NCT06496542|OTHER|Other: Standard Advice Control|The standard advice control group will receive an initial consultation with a registered dietician regarding current clinical recommendations for ADPKD without subsequent counseling sessions.
62084552|NCT00959803|EXPERIMENTAL|Multiple dose|3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.
62084553|NCT05107778|EXPERIMENTAL|Queue ASC42 10mg|ASC42 10mg, ih PEG-IFN α-2a and ETV for 12 weeks.
62283897|NCT05990855|ACTIVE_COMPARATOR|eCBTi-subj|In the active comparator condition, participants will complete the same 5-week eCBTi program, but will not be wearing an EEG headband during the intervention. As part of the sleep restriction therapy component of CBTi, participants will be asked to follow an individualized sleep window (i.e., bed and wake schedule) which will be adjusted each week based on the subjective sleep data derived from their sleep diary of the previous week, as is typically done during classical CBTi. Participants will not receive any EEG-based sleep report during the intervention.
62283898|NCT02657135|EXPERIMENTAL|History of Traumatic Brain Injury|All participants have a history of TBI. At study outcome participants are provided treatment recommendations that are the result of a consensus meeting of all physician investigators. Follow up care is not provided by this clinical trial.
62283899|NCT00769145|EXPERIMENTAL|Ranibizumab|Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally
62283900|NCT02899858|EXPERIMENTAL|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
62283901|NCT02343484|ACTIVE_COMPARATOR|Gelified ethanol|Gelified ethanol (Discogel) is a sterile, implantable medical solution containing ethyl alcohol, cellulose derivative product and an opaque agent (tungsten). The implant is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. The implant causes migration of fluid (by hydrophilic and osmotic phenomena) from the periphery towards the center, causing disk reinforcement. Filling of the annulus fibrosus tears interrupts the outflow of inflammatory factors towards dorsal root ganglions, dura and posterior longitudinal ligament.
62283902|NCT02343484|ACTIVE_COMPARATOR|Gelified ethanol combined to pulsed radiofrequency|Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain.Intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
62283903|NCT03657719|EXPERIMENTAL|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
62084554|NCT05107778|EXPERIMENTAL|Queue ASC42 15mg|ASC42 15mg , ih PEG-IFN α-2a and ETV for 12 weeks.
62283904|NCT03657719|ACTIVE_COMPARATOR|Active Comparator: GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
62650938|NCT01667588||Dialysis|
62650939|NCT06181149|EXPERIMENTAL|Group 1|
62283905|NCT03093155|ACTIVE_COMPARATOR|Ixabepilone|Ixabepilone 20 mg/m2 days 1, 8, 15 Q 28 days
62283906|NCT03093155|EXPERIMENTAL|Ixabepilone + Bevacizumab|"Ixabepilone 20 mg/m2 days 1, 8, 15~+ Bevacizumab 10 mg/kg days 1, 15 Q 28 days"
62459790|NCT06430437|EXPERIMENTAL|SHR-A1811|
62459791|NCT06430437|ACTIVE_COMPARATOR|Standard of Care（Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin）|
62650940|NCT06181149|EXPERIMENTAL|Group 2|
62650941|NCT06181149|EXPERIMENTAL|Group 3|
62650942|NCT06181149|EXPERIMENTAL|Group 4|
62650943|NCT04273490||Hereditary hypophosphatemia|Adult persons with genetically or biochemically verified hereditary hypophosphatemia.
62650944|NCT04273490||Control|Adult control persons without disturbances in calcium, vitamin D or phosphate homeostasis matched on age, gender and menopausal status.
62084555|NCT05107778|PLACEBO_COMPARATOR|Queue Placebo|Placebo, ih PEG-IFN α-2a and ETV for 12 weeks.
62084556|NCT02929342|EXPERIMENTAL|Pitolisant|Pitolisant, oral single dose administration, from Day1 to Day7.
62084557|NCT02929342|EXPERIMENTAL|[14C]-Pitolisant|\[14C\]-Pitolisant, oral single dose administration at Day8.
62084558|NCT01041508|EXPERIMENTAL|Related Donor Arm|Patients with related stem cell donors. Patients will receive Clofarabine in combination with 2Gy total body irradiation (TBI) as a preparative regimen for stem cell transplantation, in turn followed by cyclosporine and Mycophenolate Mofetil as GVHD prophylaxis.
62084559|NCT01041508|EXPERIMENTAL|Unrelated Donor Arm|Patients with unrelated stem cell donors. Patients will receive Clofarabine in combination with 2Gy total body irradiation (TBI) as a preparative regimen for stem cell transplantation, in turn followed by cyclosporine and Mycophenolate Mofetil as GVHD prophylaxis.
62084560|NCT04420780|EXPERIMENTAL|Xyl Group|Children will receive sugar-free gums containing 100% Xylitol as sweetener
62084561|NCT04420780|ACTIVE_COMPARATOR|Pol Group|Children will receive sugar-free gums containing a polyols mixture plus a low amount of Xylitol (22%).
62459792|NCT03414749|EXPERIMENTAL|Lower Extremity First (LEF)|The treatment was a non-specific long-axis distraction to the ankle, knee, and hip provided was at the discretion of the clinic doctor (over 25 years experience).
62459793|NCT03414749|EXPERIMENTAL|Upper Extremity First (UEF)|The treatment was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
62459794|NCT00924326|EXPERIMENTAL|1x10^9-1x10^10+ high dose Interleukin-2|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + cryopreserved anti-CD19-CAR PBL
62459795|NCT00924326|EXPERIMENTAL|1x10^9-1x10^10 + high dose Retreat|
62650945|NCT02790177|EXPERIMENTAL|HiB|This group will receive the compound for the reduction of adhesions
62650946|NCT02790177|PLACEBO_COMPARATOR|Normal saline|This group will just receive normal saline to ensure blinding.
62650947|NCT02530541|EXPERIMENTAL|CHG 1 min|1 min application time
62084562|NCT01117142||CLL/SLL|Chronic lymphocytic leukemia/small lymphocytic lymphoma
62084563|NCT01117142||Healthy Volunteers|Healthy Volunteers
62650948|NCT02530541|EXPERIMENTAL|CHG 2 min|2 min application time
62650949|NCT02530541|ACTIVE_COMPARATOR|Comparator CHG|Marketed CHG
62650950|NCT03426345|PLACEBO_COMPARATOR|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
62084564|NCT01117142||MBL|Monoclonal B-cell lymphocytosis
62084565|NCT01117142||MCL|Mantle Cell Lymphoma
62283907|NCT03634800|EXPERIMENTAL|nivolumab/radiotherapy|"All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy (6 Gy x 5 fractions) to a targetable lesion.~* Nivolumab 240 mg IV starts with the first radiotherapy fraction 240 mg IV every 2 weeks from first radiotherapy fraction until disease prograssion or dose limiting toxicity is reached~* Radiotherapy Dose of 6 Gy x 5 days will be given (patients will receive 1 fraction over 5 days for a total of 5 fractions) during the first week of starting Nivolumab"
62283908|NCT04707755|EXPERIMENTAL|Motor imagery technique|Motor Imagery technique Plus Conventional Physical therapy
62283909|NCT04707755|ACTIVE_COMPARATOR|Conventional Physical therapy|passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
62283910|NCT05539846|EXPERIMENTAL|test group|
62084566|NCT03577145|EXPERIMENTAL|Tomato, onion & lovage soup with inulin|One dose of tomato (300g), onion (100g) \& lovage (20g) with 10g inulin will be given to subjects in the form of a soup
62459796|NCT00924326|EXPERIMENTAL|0.5x10^7 cells/kg|
62084567|NCT03577145|EXPERIMENTAL|Tomato, onion & lovage soup|One dose of tomato (300g), onion (100g) \& lovage (20g) will be given to subjects in the form of a soup
62650951|NCT03426345|EXPERIMENTAL|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 12 weeks.
62084568|NCT03577145|EXPERIMENTAL|Inulin|One dose of 10g inulin will be given to subjects in the form of a drink
62084569|NCT02444143|ACTIVE_COMPARATOR|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
62084570|NCT02444143|EXPERIMENTAL|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
62084571|NCT04019561|EXPERIMENTAL|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
62283911|NCT05539846|NO_INTERVENTION|control group|
62283912|NCT04689776|EXPERIMENTAL|High Frequency Dual-Task Training (HF)|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-120 minutes of training.
62084572|NCT04019561|PLACEBO_COMPARATOR|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
62084573|NCT04019561|EXPERIMENTAL|MEDI0382 low dose|MEDI0382 low dose administered subcutaneoously
62084574|NCT04019561|PLACEBO_COMPARATOR|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
62084575|NCT05323214|OTHER|Control group|Normal saline 2 ml will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
62084576|NCT05323214|OTHER|Fentanyl group|Fentanyl 2 ml (100 μg) will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
62084577|NCT05323214|OTHER|Dexmedetomidine group|Dexmedetomidine 1 ml (100 μg) plus 1 ml normal saline will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
62084578|NCT01160991|ACTIVE_COMPARATOR|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
62084579|NCT01160991|EXPERIMENTAL|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
62084580|NCT01160991|PLACEBO_COMPARATOR|Placebo|Placebo capsules are given at 8:00 a.m. Procedures are performed as described above.
62084581|NCT02431728|ACTIVE_COMPARATOR|Melatonin|capsule containing 5mg melatonin plus cellulose
62084582|NCT02431728|PLACEBO_COMPARATOR|Matched Placebo|capsule containing cellulose
62084583|NCT03496025|EXPERIMENTAL|Electrical stimulation|
62084584|NCT00928460||Regular preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to current protocol, including routine preoperative ECG.
62084585|NCT00928460||New preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to a new protocol, in which a routine preoperative ECG is no longer provided.
62283913|NCT04689776|EXPERIMENTAL|Low Frequency Dual-Task Training (LF)|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-120 minutes of training.
62283914|NCT02629562|EXPERIMENTAL|Arm 1|first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously
62283915|NCT02629562|EXPERIMENTAL|Arm 2|first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously
62283916|NCT03539445|EXPERIMENTAL|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
62283917|NCT03539445|PLACEBO_COMPARATOR|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
62283918|NCT02314507|EXPERIMENTAL|Gua sha|Paritcipants in this group will receive a single treatment of Gua sha conducted by a well-trained nurse or Chinese practitioner
62283919|NCT02314507|ACTIVE_COMPARATOR|Hot Pack Therapy|Participants in this group will receive a single treatment of Hot Pack conducted by a well-trained nurse or Physiotherapist
62459797|NCT00924326|EXPERIMENTAL|2.5x10^6 cells/kg|
62459798|NCT00924326|EXPERIMENTAL|1.0x10^6 cells/kg|
62459799|NCT00924326|EXPERIMENTAL|1.0x10^6 cells/kg (Reduced chemo)|
62459800|NCT00924326|EXPERIMENTAL|2.0x10^6 cells/kg (Reduced chemo)|
62459801|NCT00924326|EXPERIMENTAL|6.0x10^6 cells/kg (Reduced chemo)|
62459802|NCT00924326|EXPERIMENTAL|2.0x10^6 cells/kg (Moderate chemo)|
62459803|NCT00924326|EXPERIMENTAL|2.0x10^6 cells/kg (9-12 days culture)|
62650952|NCT01621061||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension
62650953|NCT01621061||High altitude control|Healthy highlanders
62650954|NCT01621061||Low altitude control|Healthy lowlanders
62650955|NCT03532763|EXPERIMENTAL|Tocotrienol-rich fraction|
62650956|NCT03532763|PLACEBO_COMPARATOR|Placebo|
62650957|NCT01469871|ACTIVE_COMPARATOR|Hypafix Transparent dressing|The Hypafix Transparent dressing, a stretchable dressing, will be used to treat the patients in this group
62283920|NCT02058147|EXPERIMENTAL|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
62283921|NCT02058147|ACTIVE_COMPARATOR|Insulin Glargine|Insulin glargine QD for 30 weeks. Dose individually adjusted.
62283922|NCT02058147|ACTIVE_COMPARATOR|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
62650958|NCT01469871|ACTIVE_COMPARATOR|Mepore Pro dressing|The Mepore Pro dressing, a self-adhesive perforated dressing, will be used to treat the patients in this group
62650959|NCT01469871|ACTIVE_COMPARATOR|Mepilex Border dressing|The Mepilex Border dressing, a self-adherent soft silicone dressing, will be used to treat the patients in this group
62650960|NCT03043053|EXPERIMENTAL|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
62650961|NCT03043053|PLACEBO_COMPARATOR|placebo|placebo nasal spray (4 times per day for 8 weeks)
62650962|NCT00729742|EXPERIMENTAL|Part 1|erlotinib
62283923|NCT05728879|EXPERIMENTAL|CTCL participants|Visits will include screening, pre-treatment (week 0), weeks 4 and 8.
62283924|NCT02338687|ACTIVE_COMPARATOR|Education|Educational sessions
62283925|NCT02338687|EXPERIMENTAL|Education plus supplement|Educational sessions and 500 mg calcium per day
62650963|NCT00729742|EXPERIMENTAL|Part 2|erlotinib + dalotuzumab
62283926|NCT00643994|EXPERIMENTAL|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction in patients with low and intermediate risk prostate cancer.
62283927|NCT01171651|EXPERIMENTAL|JX-594 followed by sorafenib|1e9 pfu (plaque-forming units) total JX-594 dose on each of up to four (4) JX-594 treatment days. Sorafenib is initiated after 3 JX-594 treatments and briefly interrupted if an optional 4th JX-594 treatment is given.
62283928|NCT01740180||CLIPPERS patients|"The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).~Intervention: Data entry"
62283929|NCT05673538|EXPERIMENTAL|TT-00973-MS Tablets|TT-00973-MS tablets will be administered at the starting dose of 2mg. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design.
62650964|NCT01183923|EXPERIMENTAL|Broccoli Sprouts, then Alfalfa Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by alfalfa sprouts after washout.
62650965|NCT01183923|EXPERIMENTAL|Alfalfa Sprouts, then Broccoli Sprouts|Alfalfa Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by broccoli sprouts after washout.
62650966|NCT02251847|ACTIVE_COMPARATOR|R5|Rosuvastatin 5mg
62650967|NCT02251847|ACTIVE_COMPARATOR|R10|Rosuvastatin 10mg
62650968|NCT02251847|ACTIVE_COMPARATOR|R20|Rosuvastatin 20mg
62650969|NCT02251847|EXPERIMENTAL|R5/E10|Rosuvastatin 5mg/ezetimibe 10mg
62650970|NCT02251847|EXPERIMENTAL|R10/E10|Rosuvastatin 10mg/ezetimibe 10mg
62084586|NCT01345643|EXPERIMENTAL|Hemoglobin level based on WCPTS|According to WCPTS, the patient's hemoglobin level will be maintained not less than 7,8,9,or 10g/dL. Determination of whether a patient need red blood cells transfusion is based on WCPT Score.
62084587|NCT01345643|ACTIVE_COMPARATOR|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
62084588|NCT00432575|PLACEBO_COMPARATOR|1|
62084589|NCT00432575|ACTIVE_COMPARATOR|2|surinabant 2,5 mg/day
62459804|NCT01787708|ACTIVE_COMPARATOR|Low intensity red laser|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
62650971|NCT02251847|EXPERIMENTAL|R20/E10|Rosuvastatin 20mg/ezetimibe 10mg
62650972|NCT03444584|EXPERIMENTAL|MEDI0382|Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.
62084590|NCT00432575|ACTIVE_COMPARATOR|3|surinabant 5 mg/day
62084591|NCT00432575|ACTIVE_COMPARATOR|4|surinabant 10 mg/day
62084592|NCT01043536|EXPERIMENTAL|radiotherapy + temozolomide|"Radiotherapy:~dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3~dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3~Chemotherapy:~temozolomide given at the dose of 75mg/m2"
62084593|NCT04791228|EXPERIMENTAL|All Patients|LTLD 50 mg/m2 will be administered intravenously over 30 minutes on day 1 of every 21-day cycle. MR-HIFU hyperthermia will follow infusion (+/- 30 minutes) for one hour to a target area with a target temperature of 40-45°C followed by ablation therapy (\>55°C). The HIFU hyperthermia regimen will have a duration of at least 60 minutes and will then be followed by ablation therapy. Patients may receive up to a total of 6 cycles. Subsequent treatment cycles may treat alternative target lesions. Disease status will be evaluated using standard imaging techniques (CT/MR) post each cycle.
62650973|NCT03444584|PLACEBO_COMPARATOR|Placebo|Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period
62650974|NCT05259631|EXPERIMENTAL|Inhalational sedation|
62650975|NCT05259631|ACTIVE_COMPARATOR|Intravenous sedation|
62084594|NCT03864133|OTHER|Omidria|Phenylephrine/Ketorolac (1%/0.3%) will be administered to all participants enrolled into the study.
62283930|NCT00179387|ACTIVE_COMPARATOR|1|Psycho-educational / Stress Management group
62650976|NCT04116333|EXPERIMENTAL|ML + ETI|Intubation with using endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
62650977|NCT04116333|ACTIVE_COMPARATOR|ML|Intubation with using the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
62084595|NCT01424163|EXPERIMENTAL|Treatment 1 (Part A)|Dexpramipexole single dose (reduced dose)
62084596|NCT01424163|EXPERIMENTAL|Treatment 2 (Part A)|Dexpramipexole single dose (Standard dose)
62283931|NCT00179387|ACTIVE_COMPARATOR|2|Spiritual-Existential Support Group
62084597|NCT01424163|EXPERIMENTAL|Treatment 3 (Part A)|Dexpramipexole multiple dosing
62084598|NCT01424163|EXPERIMENTAL|Treatment for Part B|Dexpramipexole multiple dosing
62084599|NCT06093191|ACTIVE_COMPARATOR|Combination group|Participants will receive inhaled 300mg of tobramycin solution twice daily for 12 weeks and oral 750mg of ciprofloxacin twice daily for 2 weeks
62283932|NCT04741269||Lack of knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
62283933|NCT04741269||Full knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion. Patients in group 2 don't have any asymmetric full knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
62283934|NCT04183985|EXPERIMENTAL|Anatomically aligned total knee arthroplasty|Use anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith \& Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
62283935|NCT04183985|ACTIVE_COMPARATOR|Conventaional total knee arthroplasty|Use conventional total knee arthroplasty implant (Legion total knee system, Smith \& Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
62283936|NCT02266030|EXPERIMENTAL|Cilostazol|Cilostazol 100-200 mg qd
62283937|NCT02266030|ACTIVE_COMPARATOR|Aspirin|Asprin 100mg qd for active comparator
62283938|NCT05486403|EXPERIMENTAL|Intervention|Preschool Educators deliver the Appetite Toolbox programme directly to children over a period of six weeks after the pre-test and before the post-test effectiveness measures.
62283939|NCT05486403|OTHER|Waitlist Control|Preschool Educators continue to deliver their usual preschool curriculum over a period of six weeks after the pre-test and before the post-test effectiveness measures. They will deliver the Appetite Toolbox programme directly to children after the post-test measures.
62283940|NCT02135731|NO_INTERVENTION|Paper|Usual care -medication review on paper
62283941|NCT02135731|EXPERIMENTAL|Computer|Medication review software with pictures
62283942|NCT03658369|ACTIVE_COMPARATOR|Lanconone®|Lanconone®: 2 Capsules once a day after breakfast
62283943|NCT03658369|PLACEBO_COMPARATOR|Methyl Crystalline Cellulose|2 Capsules once a day after breakfast
62283944|NCT02640963|EXPERIMENTAL|Intervention: the GrACE programme|The programme included several weight-bearing exercises (using body weight and dumbbells) and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. While developed for respite care older adults, the GrACE programme was slightly modified for the RAC setting; using reduced range of motion and resistance, and an extended conditioning/familiarisation phase. The conditioning phase lasted for three weeks and focus on the development of correct technique. After concluding the conditioning phase, participants started to use light dumbbells. Participants performed the exercises twice per week for 12 weeks. Training sessions lasted approximately 45 minutes, were separated by at least 48 hours and were delivered by an experienced allied health professional.
62650978|NCT05805449|SHAM_COMPARATOR|Surgery|Control patients will receive usual standard of care surgical repair of their complex fistula by The ligation of intersphincteric tract (LIFT) or advancement flap technique without any biologic adjunct.
62650979|NCT05805449|EXPERIMENTAL|Surgery plus platelet-rich plasma (PRP)|
62650980|NCT05805449|EXPERIMENTAL|Surgery plus matrix|
62650981|NCT05805449|EXPERIMENTAL|Surgery plus PRP plus matrix material|
62084600|NCT06093191|ACTIVE_COMPARATOR|Tobramycin inhalation solution alone group|Participants will receive inhaled 300mg of tobramycin twice daily for 12 weeks and oral ciprofloxacin placebo twice daily for 2 weeks
62084601|NCT06093191|ACTIVE_COMPARATOR|Oral ciprofloxacin alone group|Participants will receive oral 750mg of ciprofloxacin twice daily for 2 weeks and inhaled saline twice daily for 12 weeks
62650982|NCT03667521||non-nerve-sparing laparaoscopic sacrocolpopexy.|
62650983|NCT03667521||nerve-sparing laparaoscopic sacrocolpopexy.|
62084602|NCT06093191|PLACEBO_COMPARATOR|Placebo group|Participants will receive inhaled saline twice daily for 12 weeks and oral ciprofloxacin placebo twice daily for 2 weeks
62084603|NCT01233635|EXPERIMENTAL|A Group 1 no drug|Patients who have not taken ACE/ARB, randomized to no drug.
62084604|NCT01233635|EXPERIMENTAL|A Group 2|Patients who have not taken ACE/ARB, randomized to take cozaar.
62084605|NCT01233635|EXPERIMENTAL|B|Patients currently taking ACE/ARB will have their prescription changed to cozaar.
62283945|NCT02640963|PLACEBO_COMPARATOR|Control Group|All subjects assigned to the control group were given the option to engage in other activities that were offered by the facility during the 12-week intervention period. Activities were facility specific, and included Zumba aerobic exercise and walking, however no specific resistance exercises were offered.
62283946|NCT04986787|EXPERIMENTAL|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - within-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS on a visual working memory task in aged HV
62283947|NCT04986787|EXPERIMENTAL|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - cross-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized cross-frequency fronto-parietal tACS stimulation on a visual WM task in aged HV
62283948|NCT04986787|EXPERIMENTAL|Cerebellar rTMS to modify the effects of cortico-cortical, fronto-parietal tACS in HV|double-blind, randomized, sham-controlled, cross-over trial assessing the effects of cerebellar stimulation on individualized fronto-parietal tACS stimulation during a visual WM task in aged HV
62283949|NCT04986787|EXPERIMENTAL|Neuromodulation protocol in MCI patients (precise protocol to be chosen on results of previous arms)|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized striatal TIS combined with cereberal TMS on a visual working memory task in MCI patients
62283950|NCT05892887|EXPERIMENTAL|Erector 10|Received 10ml of preoperative bilateral ultrasound guided ESPB by bupivacaine 0.25% on each side
62283951|NCT05892887|EXPERIMENTAL|Erector 15|Received 15ml of preoperative bilateral ultrasound guided ESPB by bupivacaine 0.25% on each side
62283952|NCT05892887|EXPERIMENTAL|Erector 20|Received 20ml of preoperative bilateral ultrasound guided ESPB by bupivacaine 0.25% on each side
62650984|NCT01973751|NO_INTERVENTION|Healthy controls|Healthy controls who will be studied at baseline and serve as a control group for the bronchoscopy, induced sputum and peripheral blood collection.
62650985|NCT01973751|ACTIVE_COMPARATOR|Asthmatics (treatment)|Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
62650986|NCT01973751|NO_INTERVENTION|Asthmatics (no treatment)|Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
62650987|NCT00322036|EXPERIMENTAL|1|Oral 800 mg BID dosing
62650988|NCT00322036|PLACEBO_COMPARATOR|2|Oral BID dosing
62084606|NCT01474408|EXPERIMENTAL|interval training|4 x 4 minutes exercise at 90 - 95 % of peak heart rate separated with 3 minutes at 70 % of peaks heart rate
62084607|NCT01474408|ACTIVE_COMPARATOR|moderate exercise|moderate continuous exercise at 70 % of peak heart rate on venous function.
62084608|NCT01474408|OTHER|control|routine measurements, no exercise
62084609|NCT03606096|EXPERIMENTAL|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
62084610|NCT03606096|EXPERIMENTAL|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
62084611|NCT03606096|ACTIVE_COMPARATOR|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
62084612|NCT03606096|ACTIVE_COMPARATOR|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
62283953|NCT03543410|EXPERIMENTAL|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
62283954|NCT03543410|EXPERIMENTAL|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets)
62283955|NCT03543410|PLACEBO_COMPARATOR|Placebo|Placebo (supplied in two tablets/day
62650989|NCT04192149|EXPERIMENTAL|Patients receiving Craniotomy|Patients receiving an awake or asleep craniotomy for brain tumors and/or epilepsy will undergo a brain mapping procedure using electrical stimulation as a part of their normal care. The research procedures will duplicate this mapping with an invasive Focused Ultrasound mapping.
62650990|NCT04192149|EXPERIMENTAL|Epilepsy Patients|Patients undergoing long term monitoring for epilepsy will receive a non-invasive form of Focused Ultrasound stimulation which will be measured by their EEG cap and intracranial electrodes which are a part of their normal care.
62650991|NCT04192149|EXPERIMENTAL|Tremor Patients receiving FUS|Patients undergoing high intensity FUS treatment for tremor will be asked to wear a research provided EEG cap while undergoing a non-invasive low intensity Focused Ultrasound research procedure and changes in their tremor will be monitored.
62084613|NCT03826433|EXPERIMENTAL|Treatment Group|Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6\*10\^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 \* 10 \^ 7 (30 ml)
62084614|NCT03826433|NO_INTERVENTION|Control Group|Control Group: Using basic contrast .
62084615|NCT03867474|EXPERIMENTAL|Intervention (MBSR)|Mindfulness-Based Stress Reduction (MBSR) - Intervention Arm
62084616|NCT03867474|NO_INTERVENTION|Control - Usual Care|Control
62084617|NCT04351750|EXPERIMENTAL|high-intensity group|The participants will receive high-intensity general exercise and pelvic floor muscle training in high-intensity group. The intensity of aerobic exercise is 60 \~ 89% of heart rate reserve (HRR) or oxygen uptake reserve (VO2R), which is equivalent to the vigorous intensity exercise proposed in the American College of Sports Medicine (ACSM). The intensity of resistance exercise is 60\~80% of 1 repetition maximum (RM), which is equivalent to the moderate-to-vigorous intensity exercise proposed in ACSM. After finishing the general exercise, participants will receive pelvic floor muscle training.
62084618|NCT04351750|EXPERIMENTAL|low-intensity group|The participants will receive low-intensity general exercise and pelvic floor muscle training in low-intensity group. The intensity of aerobic exercise is 40\~59% of HRR or VO2R, which is equivalent to the moderate intensity exercise proposed in ACSM. The intensity of resistance exercise is 40\~50% of 1RM, which is equivalent to the very light-to-light intensity exercise proposed in ACSM. After finishing the general exercise, participants will receive pelvic floor muscle training.
62084619|NCT04351750|ACTIVE_COMPARATOR|control group|The participants will only receive pelvic floor muscle training in control group.
62084620|NCT00980109|PLACEBO_COMPARATOR|placebo oseltamivir|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
62084621|NCT00980109|ACTIVE_COMPARATOR|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
62084622|NCT00980109|PLACEBO_COMPARATOR|placebo inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
62084623|NCT00980109|ACTIVE_COMPARATOR|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
62084624|NCT06228664|ACTIVE_COMPARATOR|foam rolling|foam rolling along with conventional physical therapy treatment
62084625|NCT06228664|EXPERIMENTAL|bowen therapy|bowen therapy along with conventional physical therapy treatment
62283956|NCT06157385|EXPERIMENTAL|Culinary Medicine|The participants in this group will receive culinary medicine in the form of videos that will include cooking demonstrations and nutrition education based on lean beef to enhance protein intake.
62283957|NCT06157385|OTHER|Control|This group will only receive recipes based on lean beef to enhance protein intake.
62650992|NCT04192149|EXPERIMENTAL|Tremor Patients receiving DBS|Patients undergoing Deep Brain Stimulation (DBS) treatment for tremor will receive a non-invasive Focused Ultrasound stimulation observed through their newly implanted electrode.
62650993|NCT04192149|EXPERIMENTAL|Patients receiving Spinal Surgery|Patients receiving a spinal surgery will undergo a spinal stimulation using electrical stimulation as a part of their normal care. The research procedures will duplicate this with an invasive Focused Ultrasound stimulation.
62084626|NCT02809274||Patients with PV, not newly diagnosed|"Patients with clinically overt PV treated with watchful waiting (with or without aspirin), Phlebotomy (PHL), Hydrea or any other treatment.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
62084627|NCT02809274||Newly diagnosed patients with PV|"Patients with clinically overt PV, newly diagnosed, before any treatment and before phlebotomy initiation.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
62084628|NCT00588003|EXPERIMENTAL|1|This is an exploratory study utilizing micro-array technology and immunohistochemistry to test the hypothesis that changes in gene expression occur as an early event in response to endocrine therapy and that these changes can be correlated with changes in surrogate biological markers.
62084629|NCT00588003|PLACEBO_COMPARATOR|2|no medication before surgery
62084630|NCT03728153|EXPERIMENTAL|20mg dose|Fluoxetine 20 MG Oral Tablet
62084631|NCT06256068||study group|"Study group: 144 children children \>1 year and \<5 years from a cancer treatment completion involving cardiotoxicity risk factors and are now in the follow-up observation.~Participants' examination is going to compromise:~* exercise capacity test (CPET) to examine the exercise capacity,~* extended ALPHA (Assessing Levels of Physical Activity) health-related fitness test battery to assess physical function,~* echocardiography to examine cardiac function,~* questionnaires: Pediatric Quality of Life Inventory (PedsQL) to assess quality of life, Physical Activity and Leisure Motivation Scale (PALMS) to assess motivation to physical activity and original questionnarie to asses lifestyle, socio-demographic, self-efficacy, anthropogenic factors,~* examination with the use of ActiGraph GT3X Accelerometer - a wearable tool on the elastic belt to measure physical activity level, measurement for 14 days."
62084632|NCT06256068||control group|"The control: 144 children who are \>1 year and \<5 years from a cancer treatment completion without cardiotoxicity risk factors and are now in the follow-up observation.~Participants' examination is going to compromise:~* exercise capacity test (CPET) to examine the exercise capacity,~* extended ALPHA (Assessing Levels of Physical Activity) health-related fitness test battery to assess physical function,~* echocardiography to examine cardiac function,~* questionnaires: Pediatric Quality of Life Inventory (PedsQL) to assess quality of life, Physical Activity and Leisure Motivation Scale (PALMS) to assess motivation to physical activity and original questionnarie to asses lifestyle, socio-demographic, self-efficacy, anthropogenic factors,~* examination with the use of ActiGraph GT3X Accelerometer - a wearable tool on the elastic belt to measure physical activity level, measurement for 14 days."
62084633|NCT01935960|EXPERIMENTAL|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
62084634|NCT01935960|PLACEBO_COMPARATOR|Arm II (placebo)|Participants receive a placebo PO QD on days 1 and 8-36.
62084635|NCT00333788|EXPERIMENTAL|Certolizumab pegol 400 mg|400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
62084636|NCT04006366|OTHER|Intervention|To test the effects of a 10-hour time restricted eating intervention before and after the 12 weeks of treatment on weight (primary), caloric and macronutrient intake, and a variety of psychosocial measures, including sleep, physical activity, blood pressure and eating behaviors (all secondary).
62084637|NCT03085121|EXPERIMENTAL|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
62084638|NCT03085121|EXPERIMENTAL|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
62084639|NCT03085121|ACTIVE_COMPARATOR|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
62084640|NCT03085121|ACTIVE_COMPARATOR|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
62084641|NCT03658811|EXPERIMENTAL|Upper eyelid meibomian gland dysfunction|Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments
62084642|NCT00187317|EXPERIMENTAL|PERT|Perturbation-based balance training.
62084643|NCT00187317|PLACEBO_COMPARATOR|CON|Flexibility and relaxation training.
62084644|NCT04961216|EXPERIMENTAL|OPTIMISE intervention|"After a baseline week of self-monitoring their meat consumption, participants will receive health and environmental feedback on their consumption and will be prompted to think about how they could reduce their intake. They will be asked to pre-select strategies from a list of meat consumption reduction actions and set themselves a meat reduction goal.~During the following four weeks (weeks 2-5), participants will be asked every morning to log their meat consumption of the previous day, plan one of their chosen actions and formulate an if-then plan. Participants will receive weekly feedback on their achieved meat reduction in comparison to week 1.~After the completion of the fifth week (follow-up 1), participants will be asked to continue performing the actions they found useful for the next four weeks (weeks 6-9). During the ninth week (follow-up 2) participants will be invited back to log their meat intake."
62650994|NCT00930020|PLACEBO_COMPARATOR|matching placebo pill|matching placebo
62084645|NCT04961216|NO_INTERVENTION|Control|After a baseline week of self-monitoring their meat consumption participants will be asked to try and reduce their meat consumption over the next eight weeks, with no further guidance. They will be invited back to complete log their meat consumption of the previous day during weeks five and nine (follow-up 1 and 2).
62084646|NCT01114620|EXPERIMENTAL|Arepanrix Group|Healthy Japanese male and female adults, 65 years of age or older, who received one dose of the study vaccine Arepanrix™, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
62650995|NCT00930020|ACTIVE_COMPARATOR|Oral minocycline|Minocycline 200mg
62650996|NCT02226770|OTHER|ICD|Implantation of an Implantable Cardioverter Defibrillator (ICD) in patients with heart failure
62650997|NCT05884593|OTHER|Arm 1|Single Arm. All participants undergoing posterior thoracolumbar arthrodesis procedures betweenT2-S1 in which preplanning is done using the Mazor X robotic system.
62650998|NCT03601676|ACTIVE_COMPARATOR|Intervention|
62650999|NCT03601676|NO_INTERVENTION|Control|
62651000|NCT01383278|EXPERIMENTAL|Computer-directed 5 A's intervention for smoking|
62651001|NCT01383278|ACTIVE_COMPARATOR|Screening and resource provision|
62651002|NCT05187221||Control Group|The participants will respond to CVS-F4 questionnaire online via SurveyMonkey to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. This group will contains participants with no CVS complains.
62084647|NCT00339625|EXPERIMENTAL|1|low fat, high fiber, high fruit and vegetable eating plan
62084648|NCT00339625|NO_INTERVENTION|2|Usual Diet
62084649|NCT05075655|EXPERIMENTAL|EBUS-MFB and EBUS-TBNA|patient will have both TBNA and MFB in the same operating time
62084650|NCT03709875|EXPERIMENTAL|TR Treatment|TR will be delivered by means of an advanced video-conferencing system, and patients will be provided with low-cost monitoring devices, able to collect data about the health status and QoL. All treatments from remote are based on scheduled videoconferences between the patient's home and the Clinical Units, and therapists can control and modify the exercises. A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech and cognitive exercises will be delivered from the two Research Institutes to the patient's home.
62084651|NCT03709875|OTHER|Conventional Treatment|"In this group patients will be treated with conventional physiotherapy and speech training, adjusted in reason of the clinical needs, as usually. Treatments for motor limbs activity will be focused on functional active-assistive and active exercises. Conventional paper and pencil training will be used to improve cognitive function."
62084652|NCT05251064|ACTIVE_COMPARATOR|Suture|Standard suture wound closure
62283958|NCT06205056|EXPERIMENTAL|Arm 1: Co-administration: Ad26.Mos4.HIV and CH505 TF chTrimer + ALFQ|"• Arm 1: Dose-consistent injections (5x10\^10 vp/0.5 mL) of Ad26.Mos4.HIV in a 0.5 mL injection volume and dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume (20 participants)~OR a 0.5 mL injection and a 1.1 mL injection of Placebo on Study Days 1, 57, and 169 (5 participants)"
62651003|NCT00909870|EXPERIMENTAL|1|Weekly applications of Dermagraft and compression dressings, in combination with systematic surgical wound debridement.
62651004|NCT00909870|ACTIVE_COMPARATOR|2|Weekly application of compression dressings only, in combination with systematic surgical wound debridement.
62084653|NCT05251064|ACTIVE_COMPARATOR|Adhesive wound closure device|Clozex wound closure device
62084654|NCT05251064|ACTIVE_COMPARATOR|Adhesive wound closure device with zip ties|Zipline wound closure device
62084655|NCT05133479|EXPERIMENTAL|Intervention|Participants receive the Let's Know! intervention in small groups as provided by research staff
62084656|NCT05133479|NO_INTERVENTION|Business-As-Usual|Participants continue to receive only their typical classroom instruction (i.e., no small groups)
62084657|NCT00039182|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62084658|NCT01236027||HIV-negative women|HIV-negative women who agree to have specimens collected for validation of laboratory procedures
62084659|NCT03565770|EXPERIMENTAL|standard care + coaching|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving individual coaching and usual standard care
62084660|NCT03565770|SHAM_COMPARATOR|Standard care|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving usual standard care only.
62084661|NCT02327910|NO_INTERVENTION|Conventional group|Conventional group:The patients of conventional group were extubated when standard criteria were met;
62084662|NCT02327910|EXPERIMENTAL|TOF group|TOF group: patients had a TOF ratio of greater than 0.90 as an additional extubation criterion;
62084663|NCT02327910|EXPERIMENTAL|TOF unit TcPCO2 group|Qualitative TOF and transcutaneous partial pressure of carbon dioxide monitoring(Unite group):the patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
62651005|NCT02337764|EXPERIMENTAL|TVP-1012 1mg|TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet for 52 weeks as treatment period after 2 weeks of run-in period.
62651006|NCT03369782|PLACEBO_COMPARATOR|Placebo|Placebo alternative for rocuronium and for sugammadex
62651007|NCT03369782|ACTIVE_COMPARATOR|Rocuronium|Rocuronium as bolus and in syringe pump Sugammadex just before reduction of the joint
62651008|NCT06380569|EXPERIMENTAL|Treatment Group|In this arm, participants would participate in in an intervention program that uses character strengths to improve job maintenance skills in young adults.
62651009|NCT06380569|NO_INTERVENTION|Control Group|In this arm, participants are services as usual and will participate in their regular activities.
62084664|NCT00962663|EXPERIMENTAL|ICA-105665|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
62459805|NCT01787708|ACTIVE_COMPARATOR|High intensity red light|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
62459806|NCT01787708|NO_INTERVENTION|No treatment1 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
62651010|NCT01130844|EXPERIMENTAL|MMX Mesalamine (30mg/kg)|
62084665|NCT00962663|ACTIVE_COMPARATOR|Ibuprofen|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
62084666|NCT00962663|PLACEBO_COMPARATOR|Placebo|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
62084667|NCT01743274|NO_INTERVENTION|Control Group|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups. In the Control Group, the angioplasty procedure will be guided by traditional fluoroscopy alone.~In both groups, fractional flow reserve (FFR) will be measured at the end of the procedure, once the operator considers the result of the angioplasty to be optimal. The average of three consecutive FFR measures will be recorded."
62651011|NCT01130844|EXPERIMENTAL|MMX Mesalamine (60 mg/kg)|
62084668|NCT01743274|EXPERIMENTAL|Optical Coherence Tomography|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups.~In the OCT group, OCT will be performed to optimise the results of angioplasty. The procedure will be performed according to usual practice, with or without pre-dilation before implantation of one or more stents (drug-eluting or bare metal). In the OCT group, OCT will be performed after initial coronary angiography and at the end of the procedure and the operator will have the possibility to change procedural strategy according to the data immediately available on the OCT images, with the possibility of additional interventions (additional balloon inflations, addition stent implantation, use of GPIIb/IIIa inhibitors and/or thromboaspiration and/or rotational atherectomy)."
62084669|NCT05604287|EXPERIMENTAL|SAD: ID119031166M|
62084670|NCT05604287|EXPERIMENTAL|MAD: ID119031166M|
62651012|NCT01130844|EXPERIMENTAL|MMX Mesalamine (100 mg/kg)|
62651013|NCT04280549||Healthy Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
62651014|NCT04280549||Type 2 Diabetic Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
62651015|NCT00650962|ACTIVE_COMPARATOR|CPR first|Compression First (CF)
62651016|NCT00650962|ACTIVE_COMPARATOR|Analysis First|Rhythm analysis first
62651017|NCT01032928|EXPERIMENTAL|Respiratory Phase Training|Chronically dysphagic, medically stable patients at least 6 months post treatment for head and neck cancer with non-optimal respiratory-swallowing patterns participated in up to 8 sessions of respiratory phase training to learn an optimal respiratory - swallow phase pattern
62651018|NCT02850835|EXPERIMENTAL|Video Decision Aid|This group will be shown a video decision aid along with their standard of care.
62651019|NCT02850835|NO_INTERVENTION|Standard Care|This group will not see the video decision aid and will only receive standard of care.
62651020|NCT02225418|SHAM_COMPARATOR|Placebo TQL block|30 ml single shot TQL block with saline 0,9%
61978549|NCT05107687||Assisted Smoking Cessation|"Subject participates in a structured smoking cessation program hosted at Virtua Health which may be either smoking cessation group sessions or individual sessions and/or both. All participants will be provided with a list of smoking cessation resources.~Description of Group Smoking Education and Support: These sessions are led by a Tobacco Treatment Specialist and include 2-3 sessions in-person or virtually and cover the following topics: Biological changes caused by nicotine, addiction, tips to quit smoking, health benefits to quitting smoking, types of nicotine replacement therapy, e-cigarettes and devices, aromatherapy, meditation and various resources. In addition, access to nicotine replacement therapies is optional."
62084671|NCT05604287|PLACEBO_COMPARATOR|SAD: Placebo|
62084672|NCT05604287|PLACEBO_COMPARATOR|MAD: Placebo|
62084673|NCT00113698|PLACEBO_COMPARATOR|1|
62084674|NCT00113698|ACTIVE_COMPARATOR|2|Ace inhibition (enalapril)
62651021|NCT02225418|ACTIVE_COMPARATOR|Active TQL block|30 ml single shot TQL block with ropivacaine 0,75%
62084675|NCT02927821|EXPERIMENTAL|ADS Plus|Families in settings assigned to intervention will receive Adult Day Services (ADS) as usual in addition to ADS Plus. ADS Plus has 5 key components: care management, referral/linkage; disease education; counseling/emotional support/stress reduction, and care skills managing daily challenges and behavioral disturbances. The intervention begins with 2 face-to-face sessions with the site interventionist to conduct a needs assessment to identify concerns and needs and develop an agreed upon care plan. The interventionist then meets with caregivers face-to-face at convenient times to implement the care plan, every other week for the first 3 months, and then for monthly reassessments for newly emerging care concerns thereafter. Contact occurs about a minimum of 1 hour per month over 12 months.
62651022|NCT05216575||Almitrine treated patients|Administration of Almitrine in spontaneoulsy breathing COVID-19 patients with moderate to severe ARDS treated by high-flow nasal canula oxygen therapy as first-line ventilatory support with persitent severe hypoxemia after awake prone positioning.
62651023|NCT05188105|EXPERIMENTAL|real tACS|Single session of alpha tACS (12 Hz) at 3 mA over the occipital cortex.
62084676|NCT02927821|NO_INTERVENTION|ADS Usual Care|Caregivers in the 15 sites assigned to serve as the usual care control group will receive Adult Day Services (ADS) as usual. Near completion of the study (project year 05), control group sites will have the option of receiving training in ADS Plus for their setting.
62084677|NCT05978648|EXPERIMENTAL|Cohort A: Triple-negative Breast Cancer|Cohort A Administered Trilaciclib in Combination with Chemotherapy(EC-wP)
62084678|NCT05978648|EXPERIMENTAL|Cohort B: ER-negative PR-negative Her2-positive Breast Cancer|Cohort B Administered Trilaciclib in Combination with Chemotherapy(TCbH±P)
62651024|NCT05188105|PLACEBO_COMPARATOR|sham tACS|Single session of sham tACS over the occipital cortex.
62651025|NCT02676804|EXPERIMENTAL|High-intensity aerobic exercise|Subjects will participate in a 16 week high-intensity aerobic exercise program.
62651026|NCT01096940|EXPERIMENTAL|1|AZD1656
62651027|NCT01096940|EXPERIMENTAL|2|Simvastatin
62651028|NCT01096940|EXPERIMENTAL|3|AZD1656 + simvastatin
62651029|NCT03257267|EXPERIMENTAL|Experimental Therapy|Cemiplimab
62084679|NCT01958177|OTHER|BMMNC|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
62084680|NCT01757080|EXPERIMENTAL|Diabetic-hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
62084681|NCT01757080|ACTIVE_COMPARATOR|Hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
62084682|NCT05456815|OTHER|Standardized diet|Standardized food products/meals will be tested
62084683|NCT06310590|EXPERIMENTAL|NRT6003 Injection|"Patients will be administered a single dose of NRT6003 Injection, and then they will be assessed by SPECT-CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.~Nine Patients will be tested for the radioactivity of Yttrium-90 in blood, urine, and feces (if available)."
62084684|NCT04717063|ACTIVE_COMPARATOR|Peroxyl|"Drug: Peroxyl Mouthwash Mouthwash~Other Names:~• 1.5% HP"
62651030|NCT03257267|ACTIVE_COMPARATOR|Control Therapy|Investigator choice (IC) chemotherapy
62651031|NCT03592628|PLACEBO_COMPARATOR|Standard Instructions|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care.
62651032|NCT03592628|EXPERIMENTAL|Enhanced Instruction|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care AND they received an additional printed visual diagram.
62651033|NCT01631942|EXPERIMENTAL|Low dose (healthy subjects)|
62651034|NCT01631942|EXPERIMENTAL|Medium dose (subjects with haemophilia)|
62651035|NCT01631942|EXPERIMENTAL|High dose (subjects with haemophilia)|
62651036|NCT04793568|EXPERIMENTAL|Recombinant Interferon gamma 1b (IMUKIN®)|
62084685|NCT04717063|PLACEBO_COMPARATOR|placebo mouthwash|"Drug: Placebo Mouthwash Mouthwash~Other Names:~• 0.0% HP Mouthwash"
62084686|NCT05656638|EXPERIMENTAL|Brain-injured participants|Participants with post-stroke fluent or non-fluent chronic aphasia
62084687|NCT02344303|EXPERIMENTAL|Part A|Fixed sequence, open label
62084688|NCT02344303|EXPERIMENTAL|Part B|4 way cross over, double blind
62084689|NCT02996708||Group with teleconsultation - before period|
62084690|NCT02996708||Group without teleconsultation - before period|
62084691|NCT02996708||Group with teleconsultation - after period|
62084692|NCT02996708||Group without teleconsultation - after period|
62084693|NCT01439711|EXPERIMENTAL|letrozole + MRI + surgery|Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.
62084694|NCT00555204|EXPERIMENTAL|A|
62084695|NCT00555204|EXPERIMENTAL|B|
62084696|NCT00555204|EXPERIMENTAL|C|
62084697|NCT00555204|EXPERIMENTAL|D|
62084698|NCT00555204|EXPERIMENTAL|E|
62084699|NCT00555204|EXPERIMENTAL|F|
62084700|NCT00555204|PLACEBO_COMPARATOR|G|
62651037|NCT04793568|PLACEBO_COMPARATOR|Recombinant Interferon gamma 1b placebo|
62084701|NCT01907412|NO_INTERVENTION|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
62084702|NCT01907412|EXPERIMENTAL|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
62459807|NCT01787708|NO_INTERVENTION|No treatment2 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
62459808|NCT05777707|EXPERIMENTAL|Neoadjuvant PD-1 Blockade Plus Chemotherapy|PD-1 blockade, 200 mg, IV., every 3 weeks, 2-3 cycles； Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles； Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
62651038|NCT01715246|PLACEBO_COMPARATOR|Starter infant formula without HMO|Volumes of feed depend on age, weight and appetite.
62651039|NCT01715246|ACTIVE_COMPARATOR|Starter infant formula with 2 HMOs|Volumes of feeds depend on age, weight and appetite
62651040|NCT01715246|NO_INTERVENTION|Breasfed reference group|
62651041|NCT05426174|EXPERIMENTAL|Group 1 mRNA NA: Low dose Level|Participants will receive a low dose of mRNA vaccine
62651042|NCT05426174|EXPERIMENTAL|Group 2 mRNA NA: Medium dose level|Participants will receive a medium dose of mRNA vaccine
62651043|NCT05426174|EXPERIMENTAL|Group 3 mRNA NA: High dose level|Participants will receive a high dose of mRNA vaccine
62651044|NCT05426174|ACTIVE_COMPARATOR|Group 4: QIV-HD|Participants will receive QIV-HD (high dose quadrivalent influenza) vaccine
62651045|NCT03881436|EXPERIMENTAL|Pelvic MRI|"This arm involves patients undergoing a pelvic MRI.~At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
62084703|NCT06140160|EXPERIMENTAL|Patient with an indication for Doppler ultrasound of the supra-aortic trunks|
62651046|NCT03881436|EXPERIMENTAL|Pelvic surgery|"This arm involves patients undergoing a pelvic surgery and coming for a postoperative MRI. An additional MRI is performed before the surgery and additional sequences are added to the planned postoperative MRI, at the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
62651047|NCT01597986|EXPERIMENTAL|Isavuconazole and oral contraceptive|Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.
62651048|NCT03662412|EXPERIMENTAL|Sirolimus treatment|Oral solution of sirolimus, 2mg, once a day. The trial will be terminated when a serious adverse reaction occurred, or the tumor progressed rapidly twice in a row, or when the patient did not want to continue.
62651049|NCT02266524|EXPERIMENTAL|Tamsulosin hydrochloride, very low dose|
62651050|NCT02266524|EXPERIMENTAL|Tamsulosin hydrochloride, low dose|
62651051|NCT02266524|EXPERIMENTAL|Tamsulosin hydrochloride, medium dose|
62651052|NCT02266524|EXPERIMENTAL|Tamsulosin hydrochloride, high dose|
62651053|NCT04980404|EXPERIMENTAL|Dose Escalation Inqovi|"Study will follow a standard '3+3' dose escalation design:~* Initial group of 3 participants will receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 42 day cycle/dose-limiting toxicity (DLT) period.~* Additional enrollment, dosage and study cyles will be determined by number of dose-limiting toxicity (DLT) that occur in initial group"
62651054|NCT04980404|EXPERIMENTAL|Recommended Phase 2 Dose Expansion (RP2S) Inqovi|Once the Recommended Phase 2 Dose Expansion (RP2S) is established, 10 additional participants will be enrolled and receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 28 day study cycle.
62651055|NCT01308515|OTHER|Posterior Stabilized|Patients who received a PS (Posterior Stabilized) Tibial Bearing.
62651056|NCT01308515|OTHER|Anterior Stablized|Patients who received an AS (Anterior Stabilized) Tibial Bearing
62651057|NCT00310544|EXPERIMENTAL|Arm 2|
62651058|NCT00310544|EXPERIMENTAL|Arm 1|
62651059|NCT02339688|OTHER|convential MS rehabilitation|Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility
62651060|NCT02078544||All cancer|
62651061|NCT02890017|EXPERIMENTAL|Hotel-Ambu|Outpatient surgery with a patient-hotel night
62084704|NCT02529865|EXPERIMENTAL|ADRCs and Adipose tissue|Periurethral injection of autologous adipose derived regenerative cells and adipose tissue
62084705|NCT03706911|EXPERIMENTAL|VM-1500A-LAI 150mg|VM-1500A-LAI 150mg IM single dose
62651062|NCT02890017|OTHER|conventional hospitalization|conventional hospitalization
62084706|NCT03706911|EXPERIMENTAL|VM-1500A-LAI 300mg|VM-1500A-LAI 300mg IM single dose
62084707|NCT03706911|EXPERIMENTAL|VM-1500A-LAI 600mg|VM-1500A-LAI 600mg IM single dose
62084708|NCT03706911|EXPERIMENTAL|VM-1500A-LAI 1200mg|VM-1500A-LAI 1200mg IM single dose
62084709|NCT03706911|EXPERIMENTAL|VM-1500A-LAI 600 mg Multiple|VM-1500A-LAI Multiple dose (2 injections every 4 weeks)
62459809|NCT02193880|OTHER|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
62459810|NCT05652725|PLACEBO_COMPARATOR|Placebo Control 1|Clarity Product Form 1 - control
62459811|NCT05652725|PLACEBO_COMPARATOR|Placebo Control 2|Clarity Product Form 2 - control
62459812|NCT05652725|PLACEBO_COMPARATOR|Placebo Control 3|Clarity Product Form 3 - control
62459813|NCT05652725|PLACEBO_COMPARATOR|Placebo Control 4|Clarity Product Form 4 - control
62459814|NCT05652725|EXPERIMENTAL|Active Product 1.1|Clarity Product Form 1 - active product 1
62459815|NCT05652725|EXPERIMENTAL|Active Product 2.1|Clarity Product Form 2 - active product 1
62653097|NCT02603900|EXPERIMENTAL|Adductor Canal Catheter|This group will receive ropivacaine 0.5% 15 ml for the adductor canal block under ultrasound guided nerve block. A multi-orifice catheter will be placed in the adductor canal and an infusion of ropivacaine 0.2% at 10 ml/hr will be continued for 72 hours.
62084710|NCT01818700|OTHER|Single arm-Norspan patch (Buprenorphine)|This trial is single arm with Norspan patch. Treatment with NORSPAN Ò will be started from 5 μg/h (1 patch a week) for 2 weeks, and proper titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4) according to the investigator's decision. The up-titration will be considered by investigator's judgement as follows; (1) if the rescue medication was used more than 2 times per day, on average or (2) based on the daily average NRS(Numeric Rating Scale), if the NRS was changed to worsen since the previous visit, (3) Investigator's judgement by considering any titration needed situation (e.g. dose, frequency of rescue medication).
62459816|NCT05652725|EXPERIMENTAL|Active Product 3.1|Clarity Product Form 3 - active product 1
62459817|NCT05652725|EXPERIMENTAL|Active Product 4.1|Clarity Product Form 4 - active product 1
62459818|NCT05652725|EXPERIMENTAL|Active Product 4.2|Clarity Product Form 4 - active product 2
62651063|NCT05513547|OTHER|resting subgroup|Will be allowed to engage in activities that do not require self-luminous displays (e.g., study/read, play boardgames, listen to podcasts) during the three scheduled 7-hour light exposure (LE) conditions. For 'resting' participants, the time they spend under the open sky, in the shade or half-shade, will be matched to what the 'hikers' experience.
62084711|NCT03990077|EXPERIMENTAL|dose escalation of HL-085 plus Docetaxel|"HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects."
62084712|NCT05878925|EXPERIMENTAL|Aroma|Preterm infants on CPAP support will be exposed to either vanilla or strawberry aroma. A pen with and without vanilla or strawberry aroma will be used to apply the aroma to the inner surface of the CPAP mask.
62084713|NCT05878925|PLACEBO_COMPARATOR|Control|Preterm infants on CPAP support will be exposed to placebo. The placebo pen will contain the carrier solution and natural coloring agents but no aroma.
62084714|NCT06307483||Taichi group|Participants in the Tai chi group were regular Tai chi practitioners who had practiced Tai chi for at least 3 months, at least three times a week for at least 30 minutes each time.
62283959|NCT06205056|EXPERIMENTAL|Arm 2: Rapidvax: Ad26.Mos4.HIV and CH505 TF chTrimer + ALFQ|"• Arm 2: A lower dose of Ad26.Mos4.HIV (2.5x10\^10 vp/0.25 mL) in a 0.25 mL injection volume and a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS-21) in a 0.5 mL injection volume on Study Day 1; followed by rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume); followed by dose consistent injections of Ad26.Mos4.HIV (5x1010 vp/0.5 mL) in a 0.5 mL injection volume and CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Days 57 and 169 (20 participants);~OR a 0.25 mL injection and a 0.5 mL injection of Placebo on Study Day 1; followed by 0.5 mL, 0.5 mL, and 0.9 mL injections of Placebo on Study Days 4, 8, and 15, respectively; followed by a 0.5 mL injection and a 1.1 mL injection of Placebo on Study Days 57 and 169 (5 participants)"
62283960|NCT01725750|EXPERIMENTAL|Bright White Light (BWL)|"Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box."
62283961|NCT01725750|ACTIVE_COMPARATOR|Dim Red Light (DRL)|Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
62283962|NCT02697942|NO_INTERVENTION|Standard of care|Participants randomized to the standard of care arm will not receive any intervention.
62283963|NCT02697942|EXPERIMENTAL|Cognitive training (CT)|"Participants randomized to the CT arm will be given a tablet with connection to Lumosity®, which is a web-based brain game. Participants will use the tablets to play brain games at each dialysis session."
62459819|NCT05652725|EXPERIMENTAL|Active Product 4.3|Clarity Product Form 4 - active product 3
62459820|NCT05652725|PLACEBO_COMPARATOR|Placebo Control 5|Clarity Product Form 5 - control
62651064|NCT05513547|OTHER|hiking subgroup|Will have 4 hours of scheduled moderate physical activity (average approx. 70-75% of maximum heart rate during each LE starting 3h after waking up to meet the circadian time when the most pronounced phase-advance is expected. The scheduled 4-hour activity will be a hike in the greater Basel area, which will cover about 12-14 km and a gain in elevation of less than 500 metres. Participants will be instructed to walk at their own speed. During protocol 1, which will take place in the lab, participants in the 'hiking' group will walk on a tiltable treadmill.
62651065|NCT02737137|OTHER|Manual measurement by the anesthetist|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic : Group 1
62459821|NCT05652725|EXPERIMENTAL|Active Product 5.1|Clarity Product Form 5 - active product 1
62459822|NCT05652725|EXPERIMENTAL|Active Product 5.2|Clarity Product Form 5 - active product 2
62459823|NCT03272048|EXPERIMENTAL|Low-Fear/Not-Temporary|
62459824|NCT03272048|EXPERIMENTAL|Low-Fear/Temporary|
62459825|NCT03272048|EXPERIMENTAL|High-Fear/Not-Temporary|
62459826|NCT03272048|EXPERIMENTAL|High-Fear/Temporary|
62084715|NCT06307483||Exercise group|The subjects in the exercise group had regular exercise habits, and insisted on non-Tai chi exercise for at least 3 months, at least three times a week, at least 30 minutes each time.
62459827|NCT03129425|EXPERIMENTAL|Intervention group|Sessions in groups
62459828|NCT03129425|SHAM_COMPARATOR|Control group|Sessions in groups
62084716|NCT06307483||Control group|The subjects in the control group were people without long-term exercise habits.
62084717|NCT05263453|EXPERIMENTAL|HL-085+Vemurafenib|HL-085 12mg BID+Vemurafenib 720mg BID combination therapy
62084718|NCT01976611||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
62459829|NCT06344624|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy Group|In the first sessions, less time was allotted to the introductory phase because it was anticipated that students would face similar issues in terms of age, gender, and academic standing, and that their depressive symptoms would be milder than those of clinical patient groups. Additionally, more intensive short-term cognitive behavioral therapy (b-CBT) was preferred. Six sessions, two per week for three weeks, lasting sixty minutes each, were planned, with four groups of eight to twelve students based on course schedules. A researcher with a doctorate in mental health nursing and certification in CBT will oversee CBT. The program aims to enhance students' mindful awareness. Key CBT techniques will include breath-body awareness, coping methods for emotional and physical depression symptoms (breathing and attention exercises), recognizing thought-emotion-behavior interactions, cognitive restructuring, and future planning.
62459830|NCT06344624|ACTIVE_COMPARATOR|Laughter Yoga Therapy Group|There will be a certified researcher leading the laughter yoga sessions. Laughter yoga will ideally allow participants to sit comfortably in front of each other's eyes. Six sessions, two per week for three weeks, lasting sixty minutes each, were planned, with four groups of eight to twelve students based on course schedules. Laughter yoga consists of four parts: deep breathing exercises, warm-up exercises, playful activities, and laughter exercises.
62651066|NCT02737137|EXPERIMENTAL|Measurement by a pressure gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the injection pressure of the local anesthetic : Group 2
62084719|NCT03373474|EXPERIMENTAL|local distribution points association|Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
62084720|NCT03373474|EXPERIMENTAL|local-distal points association|Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
62084721|NCT03373474|NO_INTERVENTION|waiting-list|Patients in the waiting-list group will not receive any acupuncture treatment during the study. However, for ethical consideration, 20 free acupuncture treatments will be offered after the study is completed.
62084722|NCT00109928|EXPERIMENTAL|PEGS Treatment|VP-16 (Etoposide) 40 mg/m2 IV Days 1-4 Methyl Prednisolone 250 mg IV Days 1-4 Cisplatin 25 mg/m2 IV Days 1-4 Gemcitabine 1,000 mg/m2 IV Day 1
62084723|NCT00252928|PLACEBO_COMPARATOR|A|Placebo group does not receive Aquatabs.
62084724|NCT00252928|EXPERIMENTAL|B|Intervention arms receives Aquatabs.
62084725|NCT03844516|OTHER|Peak oxygen uptake test with pacing|Peak oxygen uptake test with pacing
62084726|NCT03844516|SHAM_COMPARATOR|Peak oxygen uptake test without pacing|Peak VO2 test without pacing
62084727|NCT01406561|EXPERIMENTAL|OMS103HP-S|OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
62084728|NCT01406561|PLACEBO_COMPARATOR|Vehicle Irrigation Solution|Vehicle Irrigation Solution
62084729|NCT06139484|ACTIVE_COMPARATOR|SNT Group|Patients will be treated with neuronavigated transcranial magnetic stimulation. The treatment protocol is 90% motor threshold (RMT) stimulation intensity for 60 cycles of 10 triplet pulses each at a frequency of 50 Hz, in 2-second stimulation sequences (5 Hz) with 8-second intervals. Stimulation treatments were performed hourly. Ten treatments per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses total).
62084730|NCT06139484|OTHER|rTMS Group|Patients will be treated with the normal non-neuronavigated transcranial magnetic stimulation. The treatment protocol is 90%-100% RMT stimulation intensity; 10 Hz frequency for 4 seconds with 26 seconds of rest; 4,000 pulses per session; total duration 50 minutes, twice daily (8,000 pulses/day) for 5 days (40,000 pulses total).
62459831|NCT05250245|ACTIVE_COMPARATOR|CPAP only group|Patients who are going to receive only CPAP treatment for their moderate-to-severe obstructive sleep apnea syndrome (OSAS)
62459832|NCT05250245|ACTIVE_COMPARATOR|Combined use of CPAP and tolterodine|Patients who are going to receive combined use of CPAP and tolterodine 4mg a day treatment for their OSAS
62459833|NCT03694665|OTHER|Morbidly anesthetized obese|Morbidly obese patients undergoing bariatric surgery (single-arm study) will receive a Lung recruitment maneuver to treat atelectasis..
62651067|NCT01612195|EXPERIMENTAL|Anal fistula plug|
62651068|NCT05442658||Food hypersensitivity, Food allergy|"younger children undergo complete screening of the fecal microbiota and determination of total serum IgE and specific IgE levels.~The specific IgE antibodies that were measured included those for the following food allergens: egg white, cow milk, wheat, peanut, soy, and gluten. Subjects with FH were defined as those with a total IgE level of over 100 IU/ml and a level of at least one specific IgE of greater than 0.35 IU/ml."
62084731|NCT04025190||Allogeneic Transplant|All patients seen in the UNC Bone Marrow Transplant clinic who are candidates for allogeneic transplantation attending their pre-admission visit were approached to offer study participation. Study participation included completion of surveys over a time period up to 60 days after their transplant.
62084732|NCT00386308|EXPERIMENTAL|1|
62084733|NCT00386308|PLACEBO_COMPARATOR|2|
62084734|NCT01298180|EXPERIMENTAL|SPW|Children presenting a Prader-Willi Syndrome
62084735|NCT01298180|EXPERIMENTAL|GHD|Patient deficient in Growth Hormone
62084736|NCT01298180|EXPERIMENTAL|SPW-B|Patient with Prader-Willi Syndrome who has Biopsy
62084737|NCT01298180|EXPERIMENTAL|T|Patient Control
62084738|NCT01298180|EXPERIMENTAL|SPW-GH-B|Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
62084739|NCT02256774|EXPERIMENTAL|Combivir® plus BILR 355/Ritonavir|
62084740|NCT02256774|EXPERIMENTAL|BILR 355/Ritonavir|
62084741|NCT01859156||Carbon Monoxide Exposure|
62459834|NCT01320696|EXPERIMENTAL|Cohort 1|50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
62459835|NCT01320696|EXPERIMENTAL|Cohort 2|After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
62459836|NCT06048146|EXPERIMENTAL|FOLFOXIRI and Lateral lymph node dissection|"Participants will~* receive three cycles of chemotherapy with FOLFOXIRI regimen, and the specific dose was: irinotecan 150mg/m2, d1, Oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, continuously pumped for 46 hours, repeated for 14 days.~* After 3 cycles of chemotherapy, rectal MRI reexamination was performed, and the efficacy was evaluated using the RECIST method.~* For cCR or cPR, another 2 cycles of chemotherapy will be performed, and CT and rectal MRI evaluations will be performed again after treatment. Radical rectal cancer surgery and LLND were performed 4-6 weeks after the last administration (unilateral or bilateral LLND was determined based on the metastasis of LLN before treatment)."
62459837|NCT06048146|ACTIVE_COMPARATOR|Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection|All patients received preoperative long-term concurrent chemoradiotherapy: radiotherapy for five weeks, five days a week (pelvic 2 Gy/ time, GT50 Gy), during which capecitabine (1650mg/m2/ day, orally divided twice). Intensity modulated radiotherapy was used. CT and rectal MRI were evaluated again 8-12 weeks after radiotherapy, followed by radical resection of rectal cancer plus LLND (unilateral or bilateral LLND was performed according to LLN metastasis before treatment).
62459838|NCT00757406||1|Test group - Lymphedema sufferers
62651069|NCT05442658||Healthy control|The control children came from an age-matched cohort and did not exhibit allergic manifestations or increased total or specific IgE levels.
62084742|NCT04592536|EXPERIMENTAL|CVL-865|High dose CVL-865 (25mg) Low dose CVL-865 (7.5mg)
62084743|NCT04592536|ACTIVE_COMPARATOR|Alprazolam|Active Comparator Alprazolam with extended release oral tablets; 1 tablet BID
62084744|NCT04592536|PLACEBO_COMPARATOR|Placebo|Placebo Comparator matching oral tablets for CVL-865, capsule for Alprazolam
62084745|NCT00688506|EXPERIMENTAL|1|Combined sono-electro-magnetic therapy
62084746|NCT00688506|PLACEBO_COMPARATOR|2|placebo therapy
62084747|NCT02688920||With T2DM|Subjects with type 2 diabetes.
62084748|NCT02688920||Without T2DM|Subjects without type 2 diabetes
62283964|NCT02697942|ACTIVE_COMPARATOR|Exercise training (ET)|Participants randomized to ET arm will be given a stationary foot peddler. This foot peddler will be situated at a comfortable distance from the dialysis chair so that the patient can comfortably reach the peddler. Participants will use the foot peddlers at each dialysis session.
62459839|NCT00757406||2|Control group - healthy volunteers
62459840|NCT05335408|EXPERIMENTAL|Vario-group|Patients in this group recieve the Acunex Vario IOL bilaterally during the cataract surgery.
62459841|NCT05335408|ACTIVE_COMPARATOR|Vivity-group|Patients in this group recieve the Alcon Acrysof IQ Vivity IOL bilaterally during the cataract surgery.
62459842|NCT01488149||Recipients of intrapartum epidural analgesia|
62084749|NCT02593032|EXPERIMENTAL|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
62084750|NCT02593032|NO_INTERVENTION|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
62084751|NCT04636697|PLACEBO_COMPARATOR|Placebo|Placebo (0.5 mL)
62459843|NCT01488149||Non-recipients of intrapartum epidural analgesia|
62459844|NCT00366509||1|Lung Disease
62459845|NCT00366509||2|Healthy volunteer
62283965|NCT00684190|EXPERIMENTAL|1|AZD3355 150 mg
62084752|NCT04636697|EXPERIMENTAL|3.75 µg of CoVLP Vaccine adjuvanted|3.75 µg of CoVLP adjuvanted vaccine with AS03 adjuvant (0.5 mL)
62084753|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
62084754|NCT02382510|EXPERIMENTAL|TRN-157|
62084755|NCT02382510|PLACEBO_COMPARATOR|Placebo|
62084756|NCT02382510|ACTIVE_COMPARATOR|Tiotropium|
62084757|NCT00548275|EXPERIMENTAL|1|Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
62283966|NCT00684190|EXPERIMENTAL|2|Esomeprazole 40mg
62283967|NCT00684190|EXPERIMENTAL|3|AZD3355 150mg/Esomeprazole 40mg
62283968|NCT06485128|OTHER|Chronic kidney disease|
62283969|NCT06485128|OTHER|Diastolic heart failure|
62283970|NCT06485128|OTHER|Neuronal small vessel disease|
62283971|NCT06485128|OTHER|Glaucoma|
62283972|NCT06485128|OTHER|Healthy patients|
62283973|NCT01345500|EXPERIMENTAL|Higher Carbohydrate/Lower Fat Diet|
62283974|NCT01345500|EXPERIMENTAL|Lower Carbohydrate/Higher Fat Diet|
62283975|NCT01345500|ACTIVE_COMPARATOR|Individualized Counseling|
62283976|NCT03651947|EXPERIMENTAL|QL1206|QL1206 injection (120mg) by subcutaneous injection once on the first day.
62459846|NCT03416647|EXPERIMENTAL|SMAS patients|
62459847|NCT01522664|EXPERIMENTAL|Single group|
62084758|NCT00548275|ACTIVE_COMPARATOR|2|Standard Sexual Risk Management (SSRM): In SSRM, patients will attend two 10-minute gender non-specific individual educational sessions about HIV/AIDS provided by one of the study physicians who will be trained in HIV testing and risk counseling. Session 1 will coincide with the physician visit at the time of randomization. The patient will receive pre-test counseling at this time and undergo HIV antibody testing. Session 2 will take place 7 days later when the patient returns to receive their HIV test results and post-test counseling. In addition, subjects will receive didactic prevention messages about HIV relevant to their reported risks and will be asked if they have questions regarding this information.
62084759|NCT01801384|EXPERIMENTAL|Original contingent vouchers schedule|Women will receive an abstinence-contingent voucher-based incentives intervention (Contingency Management) for smoking cessation and relapse prevention.
62084760|NCT01801384|EXPERIMENTAL|Revised contingent vouchers schedule|Women receive abstinence-contingent voucher-based incentives (Contingency Management) intervention designed to further increase cessation and relapse prevention rates.
62084761|NCT01801384|SHAM_COMPARATOR|Non-contingent vouchers schedule|This serves as a control condition wherein women earn incentives independent of smoking status.
62084762|NCT06201013|PLACEBO_COMPARATOR|Standard Urotherapy|Participants were asked to undergo a 30-minute course every 6 weeks at follow-up, including (1) education to dispel doubts about the disease and understand the benefits of curing dysfunction to facilitate better treatment outcomes for children, (2) regular urination to establish good urination habits, (3) dietary guidance to avoid constipation, and (4) how to accurately record symptoms of OAB
62084763|NCT06201013|ACTIVE_COMPARATOR|Standard Urotherapy Combined with Solifenacin Drug Treatment|Standard Urotherapy plus Solinasine succinate 5mg once daily with a maximum dose of 10mg/day
62084764|NCT06201013|EXPERIMENTAL|Standard Urotherapy Combined with Vitamin D supplementation|Standard Urotherapy plus high dose vitamin D supplement 2400iu/d
62459848|NCT03006419|ACTIVE_COMPARATOR|Group A (Basiliximab group)|Basiliximab (Simulect) induction therapy: 20 mg IV at day of transplant (to be administered 2 hours prior to transplant and up to 4 hours after transplant) and second dosage (20 mg) at fourth day after kidney transplantation.
62459849|NCT03006419|EXPERIMENTAL|B (Low-dose Thymoglobulin group)|Thymoglobulin induction therapy (1 mg/kg rounded by 25 mg increments) at day of transplant followed by same dosage (1 mg/kg rounded by 25 mg increments) during day 1 and day 2 after transplant in order to complete 3 mg/kg accumulated dose.
62651070|NCT01060371||Spinocerebellar Ataxia 1|"If you decide to participate in this study, the following study procedures will be performed:~* blood collection for DNA testing, analysis (genetic modifier study) and banking~* Medical history~* Physical exam~* Scale for Assessment and Rating of Ataxia (SARA)~* Timed measure of your hand dexterity and walking (25 ft)~* Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~* Disease stage estimation by the clinician.~* Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~* Review of your medical records"
62651071|NCT01060371||Spinocerebellar Ataxia 2|"If you decide to participate in this study, the following study procedures will be performed:~* blood collection for DNA testing, analysis (genetic modifier study) and banking~* Medical history~* Physical exam~* Scale for Assessment and Rating of Ataxia (SARA)~* Timed measure of your hand dexterity and walking (25 ft)~* Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~* Disease stage estimation by the clinician.~* Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~* Review of your medical records"
62084765|NCT03615625|NO_INTERVENTION|Control session|Control session without any exercise. The participants remained in seated rest throughout 40 min
62084766|NCT03615625|EXPERIMENTAL|Power Training Session|The power training session lasted 40 min, in which the participants performed a resistance exercise session using high velocity contractions during the exercises characterizing a power training session
62459850|NCT06451861|EXPERIMENTAL|ABC-14 regimen|AZA,Venetoclax,Chidamide
62459851|NCT06451861|ACTIVE_COMPARATOR|3+7 chemotherapy regimen|Daunorubicin/idarubicin/mitoxantrone and cytarabine
62459852|NCT06451861|ACTIVE_COMPARATOR|AB-14 regimen|AZA,Venetoclax
62459853|NCT00832377|EXPERIMENTAL|Timolol/Dorzolamide|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
62459854|NCT03637582|ACTIVE_COMPARATOR|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 4% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 4% lidocaine gel. The subject will then perform the second uroflow study.~Complex urodynamics with the use of lidocaine hydrochloride 4% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
62084767|NCT00577720|ACTIVE_COMPARATOR|35 mg IRBB|35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
62084768|NCT00577720|EXPERIMENTAL|35 mg DRFB|35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
62651072|NCT01060371||Spinocerebellar Ataxia 3|"If you decide to participate in this study, the following study procedures will be performed:~* blood collection for DNA testing, analysis (genetic modifier study) and banking~* Medical history~* Physical exam~* Scale for Assessment and Rating of Ataxia (SARA)~* Timed measure of your hand dexterity and walking (25 ft)~* Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~* Disease stage estimation by the clinician.~* Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~* Review of your medical records"
62651073|NCT01060371||Spinocerebellar Ataxia 6|"If you decide to participate in this study, the following study procedures will be performed:~* blood collection for DNA testing, analysis (genetic modifier study) and banking~* Medical history~* Physical exam~* Scale for Assessment and Rating of Ataxia (SARA)~* Timed measure of your hand dexterity and walking (25 ft)~* Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~* Disease stage estimation by the clinician.~* Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~* Review of your medical records"
62651074|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
62084769|NCT00577720|EXPERIMENTAL|50 mg DRFB|50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
62084770|NCT00577720|EXPERIMENTAL|50 mg DRBB|50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
62651075|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
62283977|NCT03651947|ACTIVE_COMPARATOR|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day.
62084771|NCT03658629|EXPERIMENTAL|Dose A|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; in-clinic mix with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
62084772|NCT03658629|EXPERIMENTAL|Dose B|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; co-formulated with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
62651076|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
62651077|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
62651078|NCT04166214|EXPERIMENTAL|Dental Providers|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
62651079|NCT04166214|EXPERIMENTAL|Dental Patients|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
62651080|NCT00601081||1|Very low birth weight and preterm infants who will likely receive fortification of breast milk with HMF
62084773|NCT03658629|EXPERIMENTAL|Dose C|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; co-formulated with 75 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
62084774|NCT03658629|EXPERIMENTAL|Dose D|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and 90 µg HA per B strain; co-formulated with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
62283978|NCT02796755|EXPERIMENTAL|Riluzole Arm|Participants will take a daily oral dose of 100 mg of riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
62283979|NCT02796755|PLACEBO_COMPARATOR|Placebo Arm|Participants will take a daily oral dose of 100 mg of a placebo that appears identical to riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
62283980|NCT01671345|ACTIVE_COMPARATOR|Intervention|Patients randomized to the intervention will view the intervention video
62084775|NCT03658629|EXPERIMENTAL|Dose E|Alternating deltoid injections of Quad-NIV (60 µg HA per A and B strain without adjuvant) on Day 0 and Licensed 2018-2019 Influenza vaccine on Day 28.
62283981|NCT01671345|PLACEBO_COMPARATOR|Control|Patients randomized to control will view an informative video about nutrition and exercise of similar length
62283982|NCT03729778|ACTIVE_COMPARATOR|HIV+|One time administration of Prevnar-13 vaccine to HIV+ participants
62283983|NCT03729778|ACTIVE_COMPARATOR|HIV Negative Controls|One time administration of Prevnar-13 vaccine to HIV Negative Control participants
62084776|NCT03658629|EXPERIMENTAL|Dose F|Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine on Day 0 and Placebo on Day 28.
62084777|NCT03658629|EXPERIMENTAL|Dose G|Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine on Day 0 and Placebo on Day 28.
62084778|NCT01804673|EXPERIMENTAL|Fentanyl-ITS|
62283984|NCT01651780|EXPERIMENTAL|Bivalirudin|Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram \[mg/kg\]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.
62283985|NCT01651780|ACTIVE_COMPARATOR|Unfractionated heparin (UFH)|The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.
62283986|NCT06496373|EXPERIMENTAL|Personalized neoantigen vaccine + PD-1|Personalised mRNA vaccine combined with PD-1 inhibitor treatment every 3 weeks, 3 weeks as a treatment cycle, a total of 13 cycles.
62283987|NCT00809328|EXPERIMENTAL|Azithromycin|Azithromycin switch therapy (switch from intravenous to oral)
62283988|NCT02246257|OTHER|Intervention|"In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.~Hyperlipidaemia: LDL \> 2.5 is treated with 40 mg Simvastatin; Hypertension: BT \> 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT \> 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio \> 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
62283989|NCT02246257|OTHER|Control|"In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.~Hyperlipidaemia: LDL \> 2.5 is treated with 40 mg Simvastatin; Hypertension: BT \> 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT \> 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio \> 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
62283990|NCT03550560||EUS-Guided drainage|Cancer patients in terminal phase with refractory malignant ascites
62459855|NCT03637582|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
62459856|NCT01221376|EXPERIMENTAL|Imatinib Mesylate|
62459857|NCT00854100|PLACEBO_COMPARATOR|Placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo
62459858|NCT00854100|EXPERIMENTAL|Cariprazine 0.1 - 0.3 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose
62459859|NCT00854100|EXPERIMENTAL|Cariprazine 1.0 - 2.0 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose
62459860|NCT00595166||B|Speculum Sheath group. Participants all received the speculum sheath.
62459861|NCT01876706|EXPERIMENTAL|UroLift® System|Single-arm of qualified subjects receiving UroLift® System intervention.
62084779|NCT04783324|EXPERIMENTAL|Experimental Group|Pregnant women in the intervention group will use the e-mobile health application developed by the researcher.
62084780|NCT04783324|NO_INTERVENTION|Control Group|Pregnant women in the control group will not be intervened and standard care will be applied.
62084781|NCT04572490||Narrow platform implant|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
62084782|NCT04572490||Regular platform implants|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
62084783|NCT03413605|EXPERIMENTAL|a multilevel CBPR intervention|The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
62084784|NCT03413605|NO_INTERVENTION|control group|the standard CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) will be provided to control groups.
62084785|NCT04223154|EXPERIMENTAL|Real TBS to the dlPFC|One session of real intermittent Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
62084786|NCT04223154|SHAM_COMPARATOR|Sham TBS to the dlPFC|One session of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
62084787|NCT02308501|ACTIVE_COMPARATOR|Lastacaft ®|One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
62651081|NCT04009616|EXPERIMENTAL|Aloe Vera mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving aloe vera mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying aloe vera mouthwash for 5 days rinsing phase."
62651082|NCT04009616|EXPERIMENTAL|Chlorhexidine mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving chlorhexidine mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying chlorhexidine mouthwash for 5 days rinsing phase."
62651083|NCT04009616|PLACEBO_COMPARATOR|Placebo mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving placebo mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying placebo mouthwash for 5 days rinsing phase."
62084788|NCT02308501|PLACEBO_COMPARATOR|Tears Naturale ®|One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
62084789|NCT02019030||BPH on anticoagulation|Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication
62084790|NCT05039775|EXPERIMENTAL|Study group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal and will use EROS-CTD Clitoral Therapy Device in addition to psychosexual support sessions and will be closely followed for three months.
62084791|NCT05039775|OTHER|Control group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal will receive psychosexual support sessions and will be closely followed after 3 months.
62084792|NCT03034317|ACTIVE_COMPARATOR|NeuRx DPS|Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).
62084793|NCT03034317|NO_INTERVENTION|No DPS|Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.
62651084|NCT02730962|EXPERIMENTAL|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
62084794|NCT05950048|EXPERIMENTAL|Web-based breastfeeding counseling/experimental group|The web-based breastfeeding counseling/experimental group (n =33) will be given the web-based breastfeeding counseling.
62651085|NCT02730962|PLACEBO_COMPARATOR|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
62651086|NCT04939467|EXPERIMENTAL|Pirfenidone & BLD-0409|Following an overnight fast, subjects will be administered IP in a fixed sequence.
62651087|NCT04939467|EXPERIMENTAL|Nintedanib & BLD-0409|Following an overnight fast, subjects will be administered IP in a fixed sequence.
62651088|NCT02160626|PLACEBO_COMPARATOR|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
62084795|NCT05950048|NO_INTERVENTION|Control group|It will only take routine treatment and midwifery care.
62084796|NCT02178774||parturients|tissue oxymetry
62084797|NCT03504865|EXPERIMENTAL|Liposomal bupivacaine|"If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a field-effect encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement."
62084798|NCT03504865|ACTIVE_COMPARATOR|Standard bupivacaine|Patients randomized to the SB arm will receive weight-based dosing of bupivacaine, administered in the same manner as the LB arm.
62459862|NCT06389409||Patient with testicular cancer|"* subjects suffering from suspected neoplastic testicular pathology candidates for testicle removal surgery~* patients suffering from neoplastic testicular pathology requiring removal of the retroperitoneal lymph nodes"
62651089|NCT02160626|ACTIVE_COMPARATOR|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
62651090|NCT02160626|ACTIVE_COMPARATOR|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
61978550|NCT05107687||Unassisted Smoking Cessation|The subject receives no professional support but is provided with a list of smoking cessation resources, in this cohort the subject engages in smoking cessation with no assistance from a provider.
62283991|NCT02505282||Orthostatic Hypotension|\>20mmHg systolic BP drop or \>10mmHg diastolic BP drop on standing, and syncopal symptoms on standing
62283992|NCT02505282||Control|No fall in BP or \<20mmHg systolic BP drop and \<10mmHg diastolic BP drop on standing, and no syncopal symptoms on standing
62651091|NCT03705325|EXPERIMENTAL|Spirobank smart spirometer with VitalFlo mobile app|In this single arm study, all participants will be receive the spirometer and an iPhone 5S (without SIM card) loaded with the VitalFlo app.
62651092|NCT06403943|EXPERIMENTAL|Experimental group|BaidiZiyin Wan and ShenqiYifei Wan are traditional Chinese medicines. Used as an adjuvant therapy for pulmonary tuberculosis. It is mainly used to improve the symptoms of tuberculosis (including fever, cough, expectoration, blood sputum or hemoptysis, anorexia, chest pain, emaciation, night sweats).
62651093|NCT06403943|ACTIVE_COMPARATOR|Control group|2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
62651094|NCT01458626|ACTIVE_COMPARATOR|Add-on therapy|mirtazapine 30mg QD and paroxetine 20mg QD
62651095|NCT01458626|ACTIVE_COMPARATOR|mirtazapine monotherapy|mirtazapine 30mg QD
62651096|NCT01458626|ACTIVE_COMPARATOR|paroxetine monotherapy|paroxetine 20mg QD
62651097|NCT02144766|EXPERIMENTAL|Ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
62651098|NCT02144766|PLACEBO_COMPARATOR|saline|caudal block with 1 ml/kg of saline
62651099|NCT04111835|NO_INTERVENTION|Conventional exfoliative cytology/LBC|"According to current Polish guidelines:~ASC-US: repeat Pap testing in 6 months - current standard protocol~LSIL - repeat Pap testing in 6 months or refer for colposcopy (by the decision of cytologist) - current standard protocol~ASC-H and higher and all glandular lesions - refer for colposcopy - current standard protocol~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~If screening cytology is negative -\> rescreening after 3 years."
62459863|NCT02977520|EXPERIMENTAL|Interventional group|Obtain the CTA data of cerebral aneurysms and built the 3D printing models. Combined with the 3D model, the neurosurgeon can complete the discussion of preoperative prediction of aneurysms and recognize the adjacent bone, blood vessels, aneurysm directions and so on. In addition, the model can also be used to the young doctor's training, and the patient and their families can be convenient and intuitive understanding of the disease, so as to form a good communication between doctors and patients.
62084799|NCT03504865|PLACEBO_COMPARATOR|Placebo|Patients who are in the placebo arm will have a similar volume of saline injected into the operative site.
62084800|NCT04616118|EXPERIMENTAL|Phone|Participants randomized to this arm will receive usual care via telephone only
62084801|NCT04616118|EXPERIMENTAL|Video|Participants randomized to this arm will receive usual care via video call
62084802|NCT05405387|EXPERIMENTAL|Run-In Phase|Budesonide EC 3 mg three times a day, oral
62084803|NCT05405387|EXPERIMENTAL|Arm 1: Treatment|Budesonide EC 3 mg three times a day, oral
62084804|NCT05405387|PLACEBO_COMPARATOR|Arm 2: Placebo|Placebo 3 mg three times a day, oral
62084805|NCT05773898||person close to the deceased|Relatives will be invited to participate in two semi-structured research interviews in the form of a storytelling interview with an interviewer. All interviews will be conducted after obtaining the participants' non-objection. The interviews will be recorded and, once transcribed, will be analysed.
62084806|NCT02666586|PLACEBO_COMPARATOR|Control smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
62084807|NCT02666586|EXPERIMENTAL|Faba Bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder.
62084808|NCT02666586|EXPERIMENTAL|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
62084809|NCT02666586|EXPERIMENTAL|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
62459864|NCT02977520|NO_INTERVENTION|general group|Obtain the CTA data of cerebral aneurysms, the neurosurgeon complete the discussion of preoperative prediction of aneurysms.
62283993|NCT04869800|EXPERIMENTAL|Sequence 1|"1. Period 1: Reference drug(CKD-501, D745)~2. Period 2: Test drug(CKD-398)"
62459865|NCT00755196|ACTIVE_COMPARATOR|1|AN2728 Ointment, 5%
62459866|NCT00755196|PLACEBO_COMPARATOR|2|AN2728 Ointment vehicle
62084810|NCT02666586|EXPERIMENTAL|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
62084811|NCT02550275|OTHER|presymptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) \< 5
62084812|NCT02550275|OTHER|symptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) \> 5
62084813|NCT02550275|OTHER|controls|unaffected patient with Huntington's disease
62084814|NCT04995835|EXPERIMENTAL|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.
62084815|NCT06256887||Infants at risk of Cerebral Palsy|N= 20, Infants at risk of Unilateral Cerebral Palsy (UCP); N= 20, Infants at risk of Bilateral Cerebral Palsy (BCP).
62084816|NCT06256887||Infants with diagnosis of SMA1|N=20, Infants with a diagnosis of SMA type 1.
62084817|NCT06256887||Infants at very low neurodevelopmental risk (control group)|N=20, Infants born preterm or at term in absence of perinatal neurological complications, therefore a very low neurodevelopmental risk.
62084818|NCT01167179|NO_INTERVENTION|comparison group|Usual care Participants in the comparison group receive the usual care which consists of a 5 year medical routine control schedule based on the national guidelines, and - if appropriate - involvement of the dietician and the speech language therapist.During years one to five the routine control appointments are planned at a minimum of every 2, 3, 4, 6 and 12 months respectively. Most patients who undergo a total laryngectomy have additional contact with an oncology nurse during their 6-8 weekly medical control visits at the outpatient clinic for approximately the first year of follow-up. All other head and neck cancer patients have no structured follow-up contact with an oncology nurse.
62283994|NCT04869800|EXPERIMENTAL|Sequence 2|"1. Period 1: Test drug(CKD-398)~2. Period 2: Reference drug(CKD-501, D745)"
62283995|NCT05745935|EXPERIMENTAL|Group A|About 50 Patients Will receive 20 units of local oxytocin infiltration before skin closure . 10 units of oxytocin will be infiltrated at the upper skin edge and 10 units of oxytocin will be infilterated at the lower skin edges at equal intervals of 2 cm in between infiltration points.
62459867|NCT03729297|EXPERIMENTAL|cabozantinib|cabozantinib 60 mg tablets OD
62459868|NCT05853484|EXPERIMENTAL|Home based prehabilitation|Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
62283996|NCT05745935|EXPERIMENTAL|Group B|About 50 Patients Will receive the 10 units of local oxytocin infiltration before skin closure . 5 units will be infiltrated at the upper skin edge and 5 units will be infiltrated at the lower skin edge at equal intervals of approximately 2 cm in between infiltration points.
62283997|NCT05827757|EXPERIMENTAL|MSC transplantation|Transplant 100 million MSCs
62283998|NCT03006809|EXPERIMENTAL|1|pretreatment antibiotics + FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
62283999|NCT03006809|EXPERIMENTAL|2|no antibiotics, FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
62651100|NCT04111835|EXPERIMENTAL|hrHPV molecular testing|"hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -\> colposcopy~Normal reflex LBC -\> repeat LBC in 6 months~Positive - colposcopy~Negative -\> The CINtec PLUS Cytology and The QIASURE methylation test~The CINtec PLUS Cytology Positive -\> colposcopy Negative -\> rescreen in 3 years~The QIASURE methylation test Positive -\> colposcopy Negative -\> rescreen in 3 years~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~HPV-negative - rescreen in 5 years"
62084819|NCT01167179|EXPERIMENTAL|nurse-led consultation|"Interventional care Year 1 follow-up: 2-monthly medical control visit + 30 minute nursing consultation, to a minimum of 6 in year 1. No restrictions with regard to cancer stage, site or treatment modality.~Intervention consist of standardised nursing consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. Goals: helping patients (and their partners) cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship."
62084820|NCT00697021|ACTIVE_COMPARATOR|1|Patients who suffered acute STEMI and were treated by PPCI and by Aspirin 100mg and Plavix 75mg and showed on treatment platelet over-reactivity observed by TEG system on the 5th day after admission to ICCU
62084821|NCT00697021|OTHER|2|Patients who suffered acute STEMI and were treated by PPCI and recieved by Aspirin 100mg and Plavix 75mg and showed platelet inhibition observed by TEG system on the 5th day after admission to ICCU
62284000|NCT03006809|EXPERIMENTAL|3|pretreatment antibiotics + FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
62284001|NCT03006809|EXPERIMENTAL|4|no antibiotics, FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
62284002|NCT05818865|OTHER|device (CLG)|"The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity."
62284003|NCT06340009|EXPERIMENTAL|Mime therapy group|Mime therapy focuses on improving facial symmetry and muscle control through self-massage, breathing exercises, eye and lip closure exercises, letter and word exercises, and expression exercises in front of mirror
62284004|NCT06340009|ACTIVE_COMPARATOR|motor imagery group|Motor imagery technique involves mental rehearsal of motor activities, activating similar brain regions as actual movements, which enhances neuroplasticity.
62651101|NCT05189002|EXPERIMENTAL|Group 1a|Patients from groups 1a took the study product once a day in doses 40 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
62651102|NCT05189002|EXPERIMENTAL|Group 1b|Patients from groups 1b took the study product once a day in doses 60 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
62651103|NCT05189002|ACTIVE_COMPARATOR|Group 2|Patients from the control group (group 2) were received Fragmin in accordance with the instruction for medical use (5000 IU s/c once a day with 24-hour interval) and six Placebo tablets masked as study product Dimolegin - DD217 once a day.
62651104|NCT01946503||Short bowel syndrome|Patients followed in a clinic for short bowel syndrome
62651105|NCT01946503||Healthy controls|Patients seen in a general pediatric clinic without chronic or acute diseases
62651106|NCT06405893|EXPERIMENTAL|Mindful Breathing|10 minute mindful breathing exercise
62084822|NCT01293526|EXPERIMENTAL|Experimental 1|Patients who respond will have their leads placed based on study measurements.
62084823|NCT01293526|EXPERIMENTAL|Control|Leads will be placed using standard procedures.
62284005|NCT01692678|EXPERIMENTAL|Trabectedin (Part 1 and Part 2)|Trabectedin will be administered at a dose of 1.5, 1.2 or 1.0 mg/m2 as a 24-hour intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
62284006|NCT01692678|ACTIVE_COMPARATOR|Dacarbazine (Part 2)|Dacarbazine will be administered at a dose of 1 g/m2 as a longer than 30-minute intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
62284007|NCT00525577|EXPERIMENTAL|1:A|Placebo
62284008|NCT00525577|EXPERIMENTAL|2:B|AGI-1067 75 mg
62284009|NCT00525577|EXPERIMENTAL|3:C|AGI-1067 150 mg
62284010|NCT03902080|EXPERIMENTAL|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 24 weeks.
62284011|NCT03902080|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally once daily for 24 weeks.
62284012|NCT04951076|EXPERIMENTAL|BNC210|
62284013|NCT04951076|PLACEBO_COMPARATOR|Placebo|
62284014|NCT00569894||2|TIV
62284015|NCT00569894||1|FluMist
62284016|NCT00569894||3|Unvaccinated
62284017|NCT04182867|EXPERIMENTAL|UK dietary guideline diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). The experimental diet will meet UK dietary guidelines for fiber, salt, sugar, saturated fat, fruit and vegetable intake. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant. The diet will be consumed across 3 consecutive night shifts.
62459869|NCT02625454|EXPERIMENTAL|Intravenous Acetaminophen|Subjects will receive 1000 mg of intravenous Acetaminophen q 6 hours, up to two doses and an oral placebo resembling oral acetaminophen
62459870|NCT02625454|ACTIVE_COMPARATOR|Oral Acetaminophen|Subjects will receive 1000 mg of oral Acetaminophen q 6 hours, up to two doses and an intravenous placebo resembling intravenous acetaminophen
62459871|NCT05340010|EXPERIMENTAL|HCG group|n Group 1 (hCG): participants will receive endometrial preparation with estrogen and an intramuscular hCG injection will before progesterone supplementation
62084824|NCT01293526|EXPERIMENTAL|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
62084825|NCT02459509|ACTIVE_COMPARATOR|Dexmedetomidine 2 mcg/kg|2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
62084826|NCT02459509|ACTIVE_COMPARATOR|Dexmedetomidine 4 mcg/kg|4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
62084827|NCT04230980|EXPERIMENTAL|Gabapentin|Participants receive Gabapentin 600mg tablet taken pre-operatively and 300mg taken three times a day for 3 days.
62084828|NCT04230980|PLACEBO_COMPARATOR|Placebo|Participants receive Placebo tablet taken pre-operatively and three times a day for 3 days
62084829|NCT01330043|ACTIVE_COMPARATOR|Non-extended treatment|"* 26 weeks of CBT~* 10 weeks of combination bupropion plus nicotine patch~* Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks"
62084830|NCT01330043|EXPERIMENTAL|Extended treatment|"* 26 weeks of CBT~* 10 weeks of combination bupropion plus nicotine patch~* Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks~* 24 additional weeks of CBT"
62084831|NCT05952115|EXPERIMENTAL|lumbar motor control exercises|patients will receive lumbar motor control and cervical stabilization exercises three times a week for four weeks
62084832|NCT05952115|ACTIVE_COMPARATOR|cervical stabilization exercises|the patients will receive cervical stabilization exercises three times a week for four weeks
62084833|NCT05765435|OTHER|Control|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program. There will be no stimulation.
62084834|NCT05765435|EXPERIMENTAL|NMES|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program and receive stimulation assistance during the exercise sessions.
62284018|NCT04182867|OTHER|Shift worker diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). Typical 'shift diet' based on previous research investigating what UK night workers eat. The 'shift diet' will contain \~15% energy from added sugar, 15g fiber, 2.5 portions fruit/vegetable, no whole grains. Required energy intake (calories) for each day to maintain their current body weight. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.The diet will be consumed across 3 consecutive night shifts.
62084835|NCT05765435|EXPERIMENTAL|NMES and FES|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program and receive stimulation assistance during the exercise and walking sessions.
62084836|NCT03758924|EXPERIMENTAL|Active arm|Week 0-7: Take 1 ml orally of the product daily (solution of ANAVEX2-73)
62651107|NCT06405893|SHAM_COMPARATOR|Control|10 minute recorded info about mindfulness
62084837|NCT03758924|PLACEBO_COMPARATOR|Placebo arm|Week 0-7: Take 1 ml orally of the product daily (placebo)
62084838|NCT04192942|EXPERIMENTAL|intensive care management|Administration of childern with major burn in intensive care to improve out comes
62084839|NCT03900312|EXPERIMENTAL|Intervention|The program consists of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices.
62084840|NCT01980979|EXPERIMENTAL|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
62084841|NCT00299689|EXPERIMENTAL|Intervention|Single-arm: Ontak
62084842|NCT03478423|EXPERIMENTAL|Codeine|"Patients will be provided with 30mg tablets of codeine, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
62084843|NCT03478423|EXPERIMENTAL|Oxycodone|"Patients will be provided with 5mg tablets of oxycodone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
62084844|NCT03478423|EXPERIMENTAL|Hydromorphone|"Patients will be provided with 1mg tablets of hydromorphone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
62651108|NCT06514300||MASLD patients|patients presenting with liver steatosis and at least one cardiometabolic criteria.
62651109|NCT06514300||ALD patients|patients presenting with liver steatosis secondary to an excessive consumption of alcoholic beverages and with no cardiometabolic criteria.
62651110|NCT06514300||MetALD patients|patients presenting with liver steatosis, at least one cardiometabolic criteria and an excessive consumption of alcohol beverages.
62651111|NCT05098769||Acute pulmonary embolism|an age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
62084845|NCT03848091||Antibiotic pretreatment|patients having had an antibiotic pretreatment before a one-step exchange arthroplasty
62084846|NCT04877704|EXPERIMENTAL|Symprove|Symprove probiotic
62084847|NCT04877704|PLACEBO_COMPARATOR|Placebo|Matched placebo provided by Symprove. Identical in appearance to Symprove probiotic.
62084848|NCT03870503|ACTIVE_COMPARATOR|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
62084849|NCT03870503|ACTIVE_COMPARATOR|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mc sublingual misoprostol
62084850|NCT03870503|ACTIVE_COMPARATOR|Carbetocin|The patient will be received Carbetocin 100 mic gm IV
62084851|NCT06279754|EXPERIMENTAL|recombinant human endostatin Group|Recombinant human endostatin and enrolizumab injection combined with Synchronal Radiochemotherapy
62651112|NCT00769418|EXPERIMENTAL|1|odanacatib (MK0822)
62651113|NCT00769418|PLACEBO_COMPARATOR|2|placebo to odanacatib (MK0822)
62651114|NCT02765165|EXPERIMENTAL|Dose-Escalation USL311, Solid Tumor, Part 1a|USL311, intravenous, once per week, starting at 60 mg/m˄2
62651115|NCT02765165|EXPERIMENTAL|Dose-Escalation USL311, Solid Tumor, Part 1b|USL311, oral, daily, starting at 40 mg
62651116|NCT02765165|EXPERIMENTAL|Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2|USL311, oral, daily, starting at dose as determined in Part 1b, in combination with lomustine 90 mg/m˄2, oral, once every 6 weeks
62651117|NCT02765165|EXPERIMENTAL|Dose-Expansion, USL311, GBM, Part 3|USL311, oral, daily, starting at dose determined in Part 1b
62084852|NCT02524054|EXPERIMENTAL|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
62084853|NCT02524054|EXPERIMENTAL|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
62084854|NCT02524054|EXPERIMENTAL|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
62084855|NCT03133143|EXPERIMENTAL|Cognifit|Participants are instructed to play CogniFit 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
62084856|NCT03133143|ACTIVE_COMPARATOR|SIMS 4 (Maxis, Inc)|Participants are instructed to play SIMS 4 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
62084857|NCT03133143|NO_INTERVENTION|Treatment as usual|No specific intervention will be offered to those who receive treatment as usual according to their treatment schedule. The participants are encouraged not to play video games during the study period.
62084858|NCT04004208|EXPERIMENTAL|Aflibercept arm|Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.
62084859|NCT04004208|ACTIVE_COMPARATOR|Laser photocoagulation arm|Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.
62084860|NCT03041454|EXPERIMENTAL|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers. Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
62084861|NCT03041454|NO_INTERVENTION|Traditional systematic review format|Control participants will be asked to read and answer questions using a traditional systematic review format.
62084862|NCT04780438|ACTIVE_COMPARATOR|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following catheter ablation.
62084863|NCT04780438|PLACEBO_COMPARATOR|Placebo|Patients who will be randomized to receive placebo following catheter ablation.
62084864|NCT03671720|EXPERIMENTAL|personalized vaccine|
62084865|NCT04668989|EXPERIMENTAL|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week then cross-over to the control lenses for one week.
62084866|NCT04668989|ACTIVE_COMPARATOR|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week then cross-over to the test lenses for one week.
62084867|NCT02649400||Diastolic Heart Failure|Women with diastolic heart failure and previous coronary artery disease
62084868|NCT04049201|EXPERIMENTAL|Group tablet|group T will receive interactive Tablet containing many cartoon's videos 20 minutes before parental separation until the anesthesia induction
62284019|NCT05587283|EXPERIMENTAL|Low dose LABTHERA-001 capsule|Low dose LABTHERA-001 capsule (0.2 x 10\^9 CFU), administered intravaginally once a day for 7 consecutive days.
62084869|NCT04049201|ACTIVE_COMPARATOR|Group Midazolam|group Midazolam will receive oral midazolam 0.5 mg/kg (max 20 mg) 20 minutes before the parental separation
62284020|NCT05587283|EXPERIMENTAL|Medium dose LABTHERA-001 capsule|Medium dose LABTHERA-001 capsule (1 x 10\^9 CFU), administered intravaginally once a day for 7 consecutive days.
62284021|NCT05587283|EXPERIMENTAL|High dose LABTHERA-001 capsule|High dose LABTHERA-001 capsule (5 x 10\^9 CFU), administered intravaginally once a day for 7 consecutive days.
62459872|NCT05340010|NO_INTERVENTION|control group|Group 2 (control): participants will receive the conventional endometrial preparation with estrogen followed by progesterone supplementation
62459873|NCT04062409||Sickle cell patients|
62084870|NCT01868789|EXPERIMENTAL|Weightbearing CT (AAFD group)|Weightbearing CT scan of affected foot
62651118|NCT02765165|EXPERIMENTAL|Dose-Expansion, USL311 with Lomustine, GBM, Part 4|USL311, oral, daily, in combination with lomustine, oral, once every 6 weeks, at dose(s) as determined in part 2
62651119|NCT02596295||Mothers for term infants|Lactating mothers
62651120|NCT02596295||Mothers for preterm infants|Lactating mothers
62651121|NCT05583630||Ligament tension measurement group|All participants will receive ligament tension measurement by the tension device during operation
62651122|NCT04578366|EXPERIMENTAL|Shockwavetherapy Group/Experimental group|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
62084871|NCT01868789|ACTIVE_COMPARATOR|Weightbearing CT (control group)|Weightbearing CT scan of normal foot
62084872|NCT04126473|EXPERIMENTAL|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
62084873|NCT06363955|EXPERIMENTAL|Carbamide Peroxide Mouthwash|A mouthwash containing carbamide proxide/hydrogen peroxide as active ingredient
62084874|NCT06363955|PLACEBO_COMPARATOR|Placebo|A mouthwash that looks, smells and tastes like the experinmental mouthwash without active ingredients
62284022|NCT05587283|PLACEBO_COMPARATOR|Low dose Placebo capsule|Low dose Placebo (excipients of the study drug) capsule administered intravaginally once a day for 7 consecutive days.
62651123|NCT04578366|ACTIVE_COMPARATOR|Conventional Group|Conventional therapy hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
62651124|NCT02667639|ACTIVE_COMPARATOR|Treatment|A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
62651125|NCT02667639|PLACEBO_COMPARATOR|Placebo|A single 0.9% sodium chloride injection will be administered subcutaneously.
62651126|NCT04242849||IDH1/2 mutated patients|Patients harboring mutations in IDH1 or IDH2 genes
62284023|NCT05587283|PLACEBO_COMPARATOR|Medium dose Placebo capsule|Medium dose Placebo capsule (excipients of the study drug) administered intravaginally once a day for 7 consecutive days.
62284024|NCT05587283|PLACEBO_COMPARATOR|High dose Placebo capsule|High dose Placebo capsule (excipients of the study drug) administered intravaginally once a day for 7 consecutive days.
62284025|NCT03683784||Males|Male diabetics or male subjects proved to be diabetics
62284026|NCT03683784||Female|Female diabetics or male subjects proved to be diabetics
62284027|NCT03074929|EXPERIMENTAL|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
62284028|NCT03074929|NO_INTERVENTION|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
62284029|NCT01267448|ACTIVE_COMPARATOR|Saxagliptin + Metformin XR|Saxagliptin 5 mg + Metformin XR 1000 mg will be automatically titrated weekly in 2 weeks to Saxagliptin 5 mg + Metformin XR 2000 daily for a total duration of 12 weeks.
62284030|NCT01267448|ACTIVE_COMPARATOR|the Control goup Glipizide XL|The control group will receive Sulphonylurea (Glipizide XL 10mg orally) for a total duration of 12 weeks.
62284031|NCT01019785|ACTIVE_COMPARATOR|High dose Vitamin D|
62084875|NCT04532151|OTHER|Early SSc group|"Patients with SSc according to the criteria ACR / EULAR 2013, without scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements.~Patients will be reassessed at M24. The participation of each subject will be 24 months, with two visits of one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
62459874|NCT04062409||Asmathic patients|
62459875|NCT02216903||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
62651127|NCT04242849||Patients without IDH1/2 mutations|Patients that don´t present any mutation in IDH1/2 genes
62084876|NCT04532151|OTHER|Established SSc group|"Patients with SSc according to criteria ACR / EULAR 2013 with scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
62084877|NCT04532151|OTHER|Control group:|"Patient without systemic sclerosis Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
62084878|NCT02080520|ACTIVE_COMPARATOR|Nattokinase|Oral nattokinase 2,000 fibrinolytic units daily
62084879|NCT02080520|PLACEBO_COMPARATOR|Placebo|Matched placebo daily
62084880|NCT04894578|ACTIVE_COMPARATOR|Group A|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a reverse distal metatarsal minimal-invasive osteotomy
62084881|NCT04894578|ACTIVE_COMPARATOR|Group B|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a fusion of one or more midfoot (tarsometatarsal) joints
62084882|NCT03470285|OTHER|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
62084883|NCT03911193|EXPERIMENTAL|Cabozantinib|Elegible NSCLC patients with MET exon 14 skipping mutations or MET amplification will be treated with open label orally cabozantinib 60 mg/daily, cycles each 28 days.
62084884|NCT01564082|EXPERIMENTAL|ETT first|Patients will have the endotracheal tube (ETT) introduced into the pharynx prior to GlideScope insertion, and then advanced under GlideScope guidance into the trachea.
62084885|NCT01564082|NO_INTERVENTION|Control Group|Patients will have the GlideScope introduced into the pharynx. The endotracheal tube (ETT) will then be advanced under direct vision into the mouth/pharynx. The ETT will then be advanced into the trachea under GlideScope guidance.
62084886|NCT03393299|EXPERIMENTAL|STOPP/START|Use of STOPP/START criteria during medication reconciliation
62084887|NCT03393299|NO_INTERVENTION|CONTROL|Medication reconciliation done as usual, without the consideration of the STOPP/START criteria
62084888|NCT03215121|ACTIVE_COMPARATOR|One handed mask airway, switch to two hands|Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec
62084889|NCT03215121|ACTIVE_COMPARATOR|Two handed mask airway + jaw thrust|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec
62284032|NCT01019785|SHAM_COMPARATOR|Low dose Vitamin D|
62459876|NCT00759928|EXPERIMENTAL|Erlotinib/Sorafenib|Patients will receive erlotinib 150 mg once daily by mouth and sorafenib 400 mg twice daily by mouth. The study will begin with a 2-week run-in period (which will begin on Day 14 of the study, and continue through Day 1 of the study), in which erlotinib will be dosed alone at 150 mg once daily. Patients will continue taking erlotinib as a single agent at 150 mg once daily through Day 1. After the 2-week run-in period, patients will receive continuous dosing of both agents (erlotinib 150 mg once daily and sorafenib 400 mg twice daily) in cycles of 28 days each. Toxicity will be assessed every cycle (every 4 weeks) for all patients. Because this is not an efficacy study, restaging tumor measurements will be at the discretion of the physician every 8 weeks during treatment. Patients with objective response or stable disease will continue therapy; patients with disease progression or unacceptable toxicity will be discontinued from the study.
62459877|NCT03846388|OTHER|Patients with unexplained infertility|
62284033|NCT05422066|EXPERIMENTAL|Selinexor-R-CHOP|Selinexor po 60mg once weekly, Rituximab iv 375 mg/sqm on day 1, Cyclophosphamide iv 750 mg/sqm on day 1, Doxorubicin iv 50 mg/sqm on day 1, Vincristine iv 0.5 mg/kg on day 1, Prednisone po 100mg on days 1-5 in a 21 days per cycle.
62651128|NCT03000153|EXPERIMENTAL|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
62651129|NCT03000153|NO_INTERVENTION|therapy as usual|In this arm, clients will have therapy as usual.
62084890|NCT03215121|ACTIVE_COMPARATOR|Two handed mask airway, switch to one hand|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 20 sec and then switch to one hand + chin lift - 20 sec
62284034|NCT04679831|EXPERIMENTAL|Ujiplus® porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
62459878|NCT03846388|OTHER|patients with tubal, male factor or polycystic ovary syndrome|
62459879|NCT02503943|EXPERIMENTAL|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide(50mg, 3/d)"
62459880|NCT02503943|ACTIVE_COMPARATOR|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
62084891|NCT01785641|EXPERIMENTAL|ceftazidime+ciprofloxacin|2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
62084892|NCT01785641|ACTIVE_COMPARATOR|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
62084893|NCT01785641|EXPERIMENTAL|cefazolin+gentamicin|cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
62084894|NCT01785641|ACTIVE_COMPARATOR|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
62084895|NCT03375814|EXPERIMENTAL|Experimental group|The group that takes the main drug. They received the conventional treatment group and crocin.
62084896|NCT03375814|PLACEBO_COMPARATOR|Placebo group|The group that takes the Placebo.
62459881|NCT02503943|ACTIVE_COMPARATOR|"Mitiglinide"|"Mitiglinide(50mg, 3/d)"
62459882|NCT00048126|EXPERIMENTAL|1|
62459883|NCT01790581|ACTIVE_COMPARATOR|Balance Training|
62651130|NCT04871464|EXPERIMENTAL|Probiotics|Bifidobacterium triple viable capsules（BIFICO），containing Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis(each ≥ 1.0×10\^7 CFU/capsule)，Day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
62459884|NCT01790581|EXPERIMENTAL|Balance Training w/ STARS|
62651131|NCT04871464|PLACEBO_COMPARATOR|Placebo|Placebo，day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
62651132|NCT04871464|NO_INTERVENTION|Healthy control|Healthy subjects without constipation matched for age and sex to PD subjects
62651133|NCT05719961|EXPERIMENTAL|INS062|
62651134|NCT05719961|ACTIVE_COMPARATOR|NovoRapid ®|
62284035|NCT04679831|ACTIVE_COMPARATOR|Praziquantel 400mg|Arm receiving the approved Praziquantel treatment of 400mg once with plain porridge daily (without papaya seeds)
62284036|NCT04167345|PLACEBO_COMPARATOR|Parts A1, A2 and B Combined: Placebo|Participants received placebo matched to VX-814 in the treatment period for 28 days.
62651135|NCT05719961|EXPERIMENTAL|HR20014|
62284037|NCT04167345|EXPERIMENTAL|Part A1: VX-814 100 milligrams (mg)|Participants received VX-814 100 mg every 12 hours (q12h) in the treatment period for 28 days.
62284038|NCT04167345|EXPERIMENTAL|Part A1: VX-814 200 mg|Participants received VX-814 200 mg q12h in the treatment period for 28 days.
62284039|NCT04167345|EXPERIMENTAL|Parts A1 and A2 Combined: VX-814 400 mg|Participants received VX-814 400 mg q12h in the treatment period for 28 days.
62284040|NCT04167345|EXPERIMENTAL|Part B: VX-814 600 mg|Participants received VX-814 600 mg q12h in the treatment period for 28 days.
62284041|NCT05489445||Patients undergoing EP|Patients already clinically indicated for undergoing catheter-based eletrophysiological intervention, in which the FDA approved medical device KODEX-EPD system will be used.
62284042|NCT02413437|EXPERIMENTAL|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided
62459885|NCT01472601||FOLFOX_6|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, first 6 cycles, then Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, 6 cycles
62651136|NCT05719961|ACTIVE_COMPARATOR|BIAsp 30|
62651137|NCT02909062||Electronic Activity Monitoring (EAM)|This is a prospective, observational study. The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy. Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
62651138|NCT00486044|EXPERIMENTAL|simvastatin|simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months
62284043|NCT02413437|OTHER|US guided biopsy|Biopsy was operated under conventional ultrasound-guided
62284044|NCT00874302|EXPERIMENTAL|25 mg|25 mg Proellex
62284045|NCT00874302|EXPERIMENTAL|50 mg|50 mg Proellex
62284046|NCT01618292||Robotic-assisted sacrocolpopexy patients|Patients who underwent robotic-assisted laparoscopic sacrocolpopexy between January 2007 and August 2011.
62284047|NCT04873466|EXPERIMENTAL|Enzyme-rich malt extract|Enzyme-rich malt extract (15 ml b.i.d with food)
62284048|NCT00630331|EXPERIMENTAL|CCI|Subjects received one dose of cell culture-derived influenza vaccine.
62284049|NCT00630331|EXPERIMENTAL|IVV|Subjects received one dose of the trivalent egg-derived influenza vaccine.
62284050|NCT00630331|PLACEBO_COMPARATOR|Placebo|Subjects received one dose of phosphate buffered solution (PBS).
62284051|NCT04456829|EXPERIMENTAL|Resveratrol drink|
62284052|NCT04456829|PLACEBO_COMPARATOR|Placebo drink|
62651139|NCT00486044|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet nightly for 9 months
62651140|NCT02382939|EXPERIMENTAL|somapacitan|
62651141|NCT02382939|ACTIVE_COMPARATOR|hGH (somatropin)|
62651142|NCT03998735|EXPERIMENTAL|Group 1 (N=15)|160 µg/g herbal snuff, median level found in commercial moist snuff
62284053|NCT04653493|EXPERIMENTAL|CD19 CAR-T cells|Pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukemia (R/R B-ALL)
62284054|NCT04228848|ACTIVE_COMPARATOR|Healthy adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
62284055|NCT04228848|EXPERIMENTAL|ACL adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
62284056|NCT04228848|ACTIVE_COMPARATOR|Healthy adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
62651143|NCT03998735|EXPERIMENTAL|Group 2 (N=15)|70 µg/g herbal snuff, lowest level found in commercial moist snuff (rounded)
62651144|NCT03998735|EXPERIMENTAL|Group 3 (N=15)|3.5 µg/g herbal snuff, 5% of the lowest level found in commercial moist snuff
62651145|NCT03998735|ACTIVE_COMPARATOR|Group 4(N=10)|0 µg/g herbal snuff, control group will use unmodified herbal snuff
62084897|NCT03076658|OTHER|asymptomatic EOS Imaging|patients that qualify for study and EOS imaging to analyze spino-pelvic parameters
62084898|NCT04640571|EXPERIMENTAL|placebo, then metformin, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
62084899|NCT04640571|EXPERIMENTAL|metformin, then polysorbate 80, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
62084900|NCT04640571|EXPERIMENTAL|polysorbate 80, then placebo, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
62084901|NCT04640571|EXPERIMENTAL|polysorbate 80, then metformin, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
62084902|NCT04640571|EXPERIMENTAL|placebo, then polysorbate 80, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
62084903|NCT04640571|EXPERIMENTAL|metformin, then placebo, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
62084904|NCT02838225|EXPERIMENTAL|DA|docetaxel 75 mg/m², iv, day 1, doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1, every 3 weeks for 6 cycles
62084905|NCT02838225|ACTIVE_COMPARATOR|DAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
62284057|NCT04228848|EXPERIMENTAL|ACL adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video.Legs muscle strength will be assessed using hand held dynamometer
62284058|NCT04381442|EXPERIMENTAL|Buccal &palatal low level laser therapy|In group I,low level laser therapy was delivered at 10 points; 5 from buccal and 5 from palatal aspects with a total dose of 8 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
62651146|NCT06524115|EXPERIMENTAL|Photorefraction prototype device|- Photoretinoscopic images without cycloplegia
62084906|NCT03406442|OTHER|patients|The patient who have lesions affecting pterygopalatine fossa, lateral recess of the sphenoid sinus, petrous apex, Meckel's cave, cavernous sinus, infratemporal fossa and lateral nasopharynx and can be treated by endonasal endoscopic transptergoid approaches
62084907|NCT01270997|EXPERIMENTAL|HD203|Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
62084908|NCT01270997|ACTIVE_COMPARATOR|Enbrel|Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.
62084909|NCT03824938|EXPERIMENTAL|Aspirin|Aspirin 650 mg capsule by mouth, single dose
62084910|NCT03824938|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 650 mg capsule by mouth, single dose
62084911|NCT03824938|PLACEBO_COMPARATOR|Placebo|Placebo 650 mg capsule by mouth, single dose
62084912|NCT05244187|EXPERIMENTAL|OrthoCor Active System|OrthoCor Active System used for pain relief
62084913|NCT05244187|NO_INTERVENTION|Standard of care|standard of care: over-the-counter pain medication
62084914|NCT06529562|ACTIVE_COMPARATOR|surgery plus target reduction Chemoradiotherapy|"Surgery:~Endoscopic Nasopharyngectomy:Radical Reaction of the Primary Lesion Using Nasal Endoscopy.~Retropharyngeal lymphadenectomy: Radical retropharyngeal LNs reaction using nasal endoscopy.~Neck lymph node dissection Selection of region where the possitive lymph nodes are located.~Intensity modulated radiotherapy with GTV and CTV1 Reduction:~CTV2:50.00Gy/25Fr/2.00Gy. Chemotherapy: cisplatin-based regimens."
62084915|NCT06529562|EXPERIMENTAL|surgery plus dose reduction Chemoradiotherapy|"Surgery:~Endoscopic Nasopharyngectomy: Radical Reaction of the Primary Lesion Using Nasal Endoscopy.~Retropharyngeal lymphadenectomy: Radical retropharyngeal LNs reaction using nasal endoscopy.~Neck lymph node dissection Selection of region where the possitive lymph nodes are located.~Intensity modulated radiotherapy with CTV1 and CTV2 dose Reduction:~CTV1：48.00-50.00Gy/20Fr/2.40-2.50Gy； CTV2：40.00Gy/20Fr/2.00Gy. Chemotherapy: cisplatin-based regimens."
62284059|NCT04381442|ACTIVE_COMPARATOR|Buccal low level laser therapy|In group II, low level laser therapy was delivered at 5 points; from buccal palatal aspects only with a total dose of 4 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
62651147|NCT05109715|ACTIVE_COMPARATOR|Control group|"Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure.~Blood will be drawn:~* At baseline: before general anaesthesia~* After start of heart-lung machine~* After clamping the aorta~* Before unclamping the aorta~* After the operation~* 5 h after clamping the aorta~* 12 hours after clamping the aorta~* 24 hours after aortic clamping~* 48h after clamping the aorta~* 72 hours after clamping the aorta"
62284060|NCT04222751|EXPERIMENTAL|Stretch Group|Subjects assigned to this group will be instructed on how to wear the device to produce the appropriate amount of dorsiflexion (stretch). Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
62459886|NCT01472601||FOLFOX_12|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, total of 12 cycles
62651148|NCT05109715|EXPERIMENTAL|Ventilation group|"Ventilation is continued from going on CPB until clamping of the ascending aorta.~Blood will be drawn:~* At baseline: before general anaesthesia~* After start of heart-lung machine~* After clamping the aorta~* Before unclamping the aorta~* After the operation~* 5 h after clamping the aorta~* 12 hours after clamping the aorta~* 24 hours after aortic clamping~* 48h after clamping the aorta~* 72 hours after clamping the aorta"
62651149|NCT01464138|EXPERIMENTAL|Fosmidomycin-Clindamycin|Single arm study. Co-administration of Fosmidomycin and Clindamycin.
62651150|NCT01147822|EXPERIMENTAL|Pazopanib|800 mg administered once daily orally continuous dosing
62651151|NCT01147822|ACTIVE_COMPARATOR|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
62084916|NCT03510858|EXPERIMENTAL|Intervention group|
62459887|NCT02520505|OTHER|Expectant Management: Timed Intercourse|Patients randomized to expectant management will be counseled on timed intercourse and the window in which intercourse should be performed during the randomization phone call. Patients will be encouraged to contact their fertility doctor and the primary investigator if they become pregnant and an estimated date of confinement will be calculated based upon the patient's last menstrual period. Patients will also be notified that they will be contacted at the end of the six month timeframe to inquire as to whether or not they became pregnant.
62459888|NCT02520505|ACTIVE_COMPARATOR|Supraovulation + IUI|Women randomized to super ovulation (SO) will be treated according to a standard protocol under the care of their staff physician and fertility nurses. The patient will be treated with 100mg/day of clomiphene citrate starting on day 3 of the menstrual cycle and ending on day 7. Intrauterine insemination will be performed 36 hours after the hCG surge (follicle rupture) by inserting a catheter through the cervix of the patient in dorsal lithotomy position.
62459889|NCT06496646|EXPERIMENTAL|Reminders Alone|This group will receive 12 weeks of personalized daily text reminders without financial incentives.
62459890|NCT06496646|EXPERIMENTAL|Reminders and Incentives|This group will receive 12 weeks of personalized daily text reminders paired with 6 weeks of financial incentives.
62459891|NCT06496646|NO_INTERVENTION|Usual Care|The usual care group will receive no text reminders or financial incentives.
62459892|NCT04774757|EXPERIMENTAL|Systemic therapy sequenced PALND|All received systemtic therapy (at most two lines).
62459893|NCT05842109||ABO HDN|positive in diagnosis of ABO-HDN
62651152|NCT06519058|EXPERIMENTAL|self-myofascial stretching group|
62084917|NCT03510858|OTHER|Control group with crossover|Participants in the control group will receive the intervention after 12 months, cross-over design
62651153|NCT06519058|SHAM_COMPARATOR|conventional physical therapy group|
62651154|NCT05037630|EXPERIMENTAL|Self-guided Digital Tool for Problematic Alcohol Use|Self-guided Digital Tool for Problematic Alcohol Use during 8 weeks with clinical telephone interviews pre ant post intervention.
62651155|NCT01482832|EXPERIMENTAL|Experimental|Behavioral: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
62651156|NCT01482832|ACTIVE_COMPARATOR|Control|Behavioral: Standard care Participants assigned to receive standard care will focus on prenatal education including issues associated with pregnancy and postpartum. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
62459894|NCT05842109||non ABO HDN|negative in diagnosis of ABO-HDN
62084918|NCT04565314|EXPERIMENTAL|Plumpy'Mum|Mother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area.
62084919|NCT00972543|ACTIVE_COMPARATOR|Raptiva|Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
62084920|NCT00972543|PLACEBO_COMPARATOR|Placebo|Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
62084921|NCT04716140|NO_INTERVENTION|MTP1 joint with no cartillage laesion or grade I|Patients in whom no treatment of the cartilage lesions is performed: these patients have no cartilage lesion or a grade I cartilage lesion at the MTP I joint that has been found peroperatively. The degree of the cartilage lesions will be determined on the basis of the ICRS scale and an MS Hololens.
62084922|NCT04716140|NO_INTERVENTION|MTP1 joint with cartillage laesion > grade I - non treatment|Patients in whom a cartilage lesion\> grade 1 is found during surgery randomised in the no treatment group
62284061|NCT04222751|PLACEBO_COMPARATOR|No Stretch Group|Subjects assigned to this group will wear the splints but instructed to wear the device in a position that produces no stretch. Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
62284062|NCT03170752|EXPERIMENTAL|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:~1. Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);~2. Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);~3. Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
62284063|NCT03170752|NO_INTERVENTION|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
62084923|NCT04716140|EXPERIMENTAL|MTP1 joint with cartillage laesion > grade I - treatment|Patients in whom a cartilage lesion\> grade 1 is found during surgery randomised in the treatment group. They will be treated through debridement of the lesion and microfracture.
62084924|NCT04126525|EXPERIMENTAL|neoadjuvant pyrotinib|pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m\^2, d1, 8, 15, 22 cisplatin 25mg/m\^2, d1, 8, 15 every 28 days
62084925|NCT04456738|EXPERIMENTAL|Parent Training|16 weeks of parent training in a group context with 5 to 10 relative and non-relative foster caregivers
62084926|NCT04456738|NO_INTERVENTION|Services as Usual|Foster care services as usual
62084927|NCT01220141||A|
62084928|NCT06418035|EXPERIMENTAL|Experimental group: treatment with technological tool|The intervention will be structured according to Applied Behavioral Analysis. The target activities to be performed are shown on the iPad through video-modeling. The child, using iPad, scans QR codes placed in various stations of the HomeLab, near the place where the target autonomy will be carried out. HomeLab is a room that simulates a real apartment with various domestic areas and allows the child to feel as comfortable as at home.
62084929|NCT06418035|OTHER|Control group: traditional treatment without technological tool|The intervention will be structured according to Applied Behavioral Analysis. The target activities to be performed within HomeLab are shown, live, by an operator who acts as a model.
62084930|NCT05255263|ACTIVE_COMPARATOR|Programmed Intermittent Epidural Bolus|Intermittent epidural bolus as the first line labor epidural analgesia maintenance infusion
62084931|NCT05255263|ACTIVE_COMPARATOR|Continuous Epidural Infusion|Continuous epidural infusion as the first line labor epidural analgesia maintenance infusion
62459895|NCT04662996|EXPERIMENTAL|1- Chemotherapy|Intervention : one blood sample is done before beginning chemotherapy as a first treatment line for a metastatic castration resistant prostate cancer
62459896|NCT04662996|EXPERIMENTAL|2- Novel Hormonal Agent|Intervention : one blood sample is done before beginning a novel hormonal agent (abiraterone, enzalutamide) as a first treatment line for a metastatic castration resistant prostate cancer
62651157|NCT05115396|EXPERIMENTAL|Mirror therapy|"To perform mirror therapy, the participant shall be seated in a chair with a table in front of him/her. On the table there will be a mirror in the sagittal plane between the two upper limbs. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the intervention, participants will be instructed to concentrate on the hand reflected in the mirror.~During MT, they will perform an exercise protocol based on previous studies and the American College of Sports Medicine guidelines. The duration will be 30 minutes."
62651158|NCT05115396|ACTIVE_COMPARATOR|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
62651159|NCT00717886|EXPERIMENTAL|1|Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity approximately 3 hours before surgery.
62651160|NCT01494558|ACTIVE_COMPARATOR|PE concurrent chemotherapy|Radiotherapy concurrently with PE chemotherapy
62651161|NCT01494558|ACTIVE_COMPARATOR|PC concurrent chemotherapy|Radiotherapy concurrently with PC chemotherapy
62651162|NCT02435134||Healthy participants|
62651163|NCT03334175|EXPERIMENTAL|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
62651164|NCT03334175|NO_INTERVENTION|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
62651165|NCT04812158|ACTIVE_COMPARATOR|Control group|participants in the control group receive gold standard physiotherapy intervention 5 times a week for 6 weeks
62651166|NCT04812158|EXPERIMENTAL|Experimental group|3 min video-aided mindful deep breathing (VAMDB) or visual guiding on deep breathing with 6 deep breath per minute along with standard physiotherapy (SP) protocol and the control group was given standard physiotherapy (SP) protocol 5 times a week for 6 weeks
62459897|NCT02779543|ACTIVE_COMPARATOR|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
62651167|NCT04812158|NO_INTERVENTION|Healthy control|Active healthy participants who engaged in regular collegial sports
62651168|NCT04239924|EXPERIMENTAL|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program
62084932|NCT02541539|ACTIVE_COMPARATOR|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
62084933|NCT02541539|PLACEBO_COMPARATOR|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
62084934|NCT04367142||positive SARS-Cov2|100 patients with a positive diagnosis of SARS-CoV-2
62651169|NCT06464029||Control|40 healthy older adults and 40 young adults. Potential volunteers for the study will be recruited from a list of volunteers at the University of Minnesota or study information pamphlets distributed people who express an interest in participating (e.g. at research events, support group meetings, or to colleagues of participants tested). Interested individuals will self-identify and contact our research staff for further information.
62651170|NCT06464029||Experimental|40 people with Parkinson's disease. Potential volunteers will be recruited from the Movement Disorders Clinic at the University of Minnesota Medical Center. Patients that are referred to this center for standard-of-care evaluations will be seen by a movement disorders neurologist. Patients will be evaluated as per standard of care, regardless of whether they are interested in participating in research protocols.
62651171|NCT03968809||Standard Coronary Artery Disease Screening|All patients presenting for standard coronary artery disease screening will undergo additional imaging with CardioFlux MCG. These patients will be followed longitudinally for short and long term MACE.
62651172|NCT03702699||KOA group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
62651173|NCT03702699||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
62651174|NCT01749371|EXPERIMENTAL|Early Vitamin E|Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.
62651175|NCT01749371|EXPERIMENTAL|Delayed Vitamin E|Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.
62651176|NCT03614000|EXPERIMENTAL|positive screenings|
62651177|NCT05724290|EXPERIMENTAL|immunohistochemistry|Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry
62651178|NCT05724290|EXPERIMENTAL|WestBlot|Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.
62084935|NCT04367142||negative SARS-Cov2|100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
62084936|NCT00061360|EXPERIMENTAL|ATG+CsA|ATG+CsA for 6 months followed by a slow CsA taper in the subsequent 18 months
62084937|NCT00061360|EXPERIMENTAL|ATG+CsA+RA|ATG+CsA+RAPA for 6 months
62084938|NCT03323151|EXPERIMENTAL|Phase I: Ixazomib & Ibrutinib|Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
62284064|NCT03828487|EXPERIMENTAL|Neonatal Test group|Subjects will receive a Masimo O3 Neonatal sensors as well as a 510(k) cleared sensor.
62284065|NCT03904797|EXPERIMENTAL|e-PRO|EI service coordinators participated in a 90-minute training on the study protocol, to gain clearance to recruit families when they were being contacted to schedule their annual reviews of progress. The recruitment protocol was later modified in response to low enrollment, such that a designated EI staff member was paired with research staff to recruit participants. Eligible and interested caregivers visited the project website to create an account, confirmed study eligibility, provided informed consent and HIPAA authorization for abstracting select EI service use data, and completed a demographic questionnaire and the Young Children's Participation and Environment Measure (YC-PEM) e-PRO. Caregivers received immediate access to an online report summarizing their e-PRO responses to share with their child's EI team
62284066|NCT04405960|EXPERIMENTAL|Intervention group|Individuals in intervention group were given oral Vitamin D supplements (Alphacalcidol 1 µg) once daily
62284067|NCT04405960|PLACEBO_COMPARATOR|Control Group|Individuals in control group were given placebo once daily
62459898|NCT02779543|ACTIVE_COMPARATOR|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
62461825|NCT02524197|ACTIVE_COMPARATOR|CR845 5 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
62651179|NCT02456896|NO_INTERVENTION|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
62084939|NCT03323151|EXPERIMENTAL|Phase II: Ixazomib & BTK-Naive|Patients who are BTK-Naive will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
62084940|NCT03323151|EXPERIMENTAL|Phase II: Ixazomib & BTK Pre-Treated (Closed 8/7/2020)|Patients previously treated with a BTK will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
62084941|NCT00896454|EXPERIMENTAL|denosumab|Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
62084942|NCT05843175|EXPERIMENTAL|Pregnant women with type 1 diabetes|Participants will undergo 3 experimental conditions in random order at week of gestation 16 and 35 (experimental phases 1 and 2): pre-meal exercise, post-meal exercise, and non-exercise meal.
62084943|NCT05843175|EXPERIMENTAL|Non-pregnant women with type 1 diabetes|Participants will undergo 3 experimental conditions in random order after recruitment (experimental phase 1): pre-meal exercise, post-meal exercise, and non-exercise meal.
62084944|NCT01577030|EXPERIMENTAL|Dairy|Add 4 daily servings of non-fat dairy to diet for a period of 4 weeks
62084945|NCT01577030|ACTIVE_COMPARATOR|Fruit|Add 4 daily servings of fruit to diet, remove all dairy from diet for a period of 4 weeks
62084946|NCT03976310|OTHER|The study population|The study population corresponds to severe eosinophilic asthma patients (see eligibility criteria).
62084947|NCT00649480|EXPERIMENTAL|1|BALSALAZIDE DISODIUM CAPSULES, 750 MG
62084948|NCT00649480|ACTIVE_COMPARATOR|2|COLAZAL® Capsules 750 mg
62084949|NCT05476211|EXPERIMENTAL|Reduction of wrinkles|
62084950|NCT00255567|ACTIVE_COMPARATOR|1|Sodium Stibogluconate (30 days)
62084951|NCT00255567|EXPERIMENTAL|2|Paromomycin Sulphate (21 days)
62284068|NCT00808743|ACTIVE_COMPARATOR|Group 1|Patients receive oral celecoxib twice daily and oral placebo twice daily
62284069|NCT00808743|EXPERIMENTAL|Group 2|Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily
62084952|NCT00255567|EXPERIMENTAL|3|Sodium Stibogluconate + Paromomycin Sulphate (17 days)
62284070|NCT02554929|EXPERIMENTAL|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
62284071|NCT02554929|ACTIVE_COMPARATOR|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
62284072|NCT00967278||Off-Pump|Patients with coronary artery disease undergoing elective off-pump CABG
62284073|NCT00805896|EXPERIMENTAL|1|Songyou Granule
62284074|NCT00805896|PLACEBO_COMPARATOR|2|
62284075|NCT01301846||Wheelchair users|People who have a wheelchair for home and community use.
62284076|NCT05220267|OTHER|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle) .Sintilimab was administered intravenously (200mg once every 3weeks).
62651180|NCT02456896|EXPERIMENTAL|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
62651181|NCT01154660|EXPERIMENTAL|Neutral|
62651182|NCT01154660|ACTIVE_COMPARATOR|Trendelenberg|
62284077|NCT01186393|EXPERIMENTAL|Control|Arm includes dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). Control diet will be prescribed for weight maintenance.
62284078|NCT01186393|EXPERIMENTAL|Low Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
62459899|NCT02779543|ACTIVE_COMPARATOR|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
62459900|NCT06325189|NO_INTERVENTION|Medication alone|Participants in this arm will not receive any specific intervention. They will only receive standard care medications after angioplasty. No additional treatments or therapies will be administered.
62651183|NCT02251275|EXPERIMENTAL|Tolvaptan|"Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:~* Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.~* Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.~* Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability."
62284079|NCT01186393|EXPERIMENTAL|High Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on High Glycemic Index foods.
62284080|NCT02700178|EXPERIMENTAL|Biofeedback|Participants will be asked to participate in all or a subset of daily activities for wheelchair users. The intervention will consist of visual and/or auditory cues to guide their movement while performing the tasks during one to two sessions.
62284081|NCT01750814|ACTIVE_COMPARATOR|GC FLU inj.|Influneza vaccine, single-dose vial
62284082|NCT01750814|EXPERIMENTAL|GC3102C|Influneza vaccine, multi-dose vial
62284083|NCT04293016|ACTIVE_COMPARATOR|Support as usual|
62284084|NCT04293016|EXPERIMENTAL|Problem Solving therapy|
62284085|NCT04293016|EXPERIMENTAL|ICU diary|
62084953|NCT04436081|ACTIVE_COMPARATOR|Hemp-based CBD oil Gelcaps|The intervention consists of 6 weeks oral administration of CBD oil Gelcaps, starting at a dosage of 15 mg twice per day with up titration to 45 mg twice per day. At any given dose, if participants develop side effects, the dosage will be reduced to the previous dose.
62284086|NCT05769660|EXPERIMENTAL|BEY1107 + Temozolomide|Administer BEY1107 in combination with Temozolomide, 4-weeks as 1 cycle.
62284087|NCT03313050|EXPERIMENTAL|Stage 1 multivalent (ages 50-64 years)|multivalent
62651184|NCT06262984|EXPERIMENTAL|Therapeutic Play Group|The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
62651185|NCT06262984|NO_INTERVENTION|Control Group|Children who choose the control group will be explained the nasopharyngeal swab procedure as routinely performed in the outpatient clinic.The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
62651186|NCT05884216|EXPERIMENTAL|Entarik|Entarik FT System guided placement
62651187|NCT05884216|ACTIVE_COMPARATOR|Control|Entarik Ft placement placement not guided with monitor
62651188|NCT05336539||Positive group|subjects received colorectal cancer polygene methylation test at baseline, and all positive results were included in the positive group. They will undergo further FIT testing, blood carcinoembryonic antigen testing and colonoscopy within three months of colorectal cancer polymethylation testing.
62651189|NCT02002663|EXPERIMENTAL|ropivacaine + methylprednisolone|Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
62651190|NCT02002663|PLACEBO_COMPARATOR|saline|Continuous infusion of saline through intralesional catheter for 24 hs
62651191|NCT03988660||Healthy controls|Healthy individuals
62651192|NCT03988660||Histologically confirmed appendicitis|Patients who have diagnosis of appendicitis on histology
62651193|NCT03988660||Histologically normal appendix|Patients who have diagnosis of a normal appendix on histology
62651194|NCT03988660||Alternative diagnosis group|Patients who diagnosed with a condition other than appendicitis
62084954|NCT04436081|PLACEBO_COMPARATOR|Oral placebo Gelcaps|Participants in the control group will receive oral placebo Gelcaps that are identical in appearance to the CBD oil Gelcaps. Dosing will be identical to the intervention arm.
62651195|NCT03699748|EXPERIMENTAL|Intervention Group Arm|"Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice).~The intervention arm will also receive usual care as provided by Unite Here Health and their local oncologists."
62651196|NCT03699748|ACTIVE_COMPARATOR|Control Group Arm|The control group arm will receive usual care as provided by Unite Here Health and their local oncologists.
62084955|NCT04636203||General population|A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate.
62084956|NCT04636203||Healthcare workers (HCWs)|All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects.
62084957|NCT05076370|ACTIVE_COMPARATOR|CBD 400mg|CBD 400mg
62284088|NCT03313050|ACTIVE_COMPARATOR|Stage 1 Tdap (ages 50-64 years)|Tdap
62651197|NCT00513214|ACTIVE_COMPARATOR|XOMA 052|
62651198|NCT00513214|PLACEBO_COMPARATOR|Placebo|
62284089|NCT03313050|EXPERIMENTAL|Stage 2 multivalent (ages 65-85 years)|multivalent
62284090|NCT03313050|ACTIVE_COMPARATOR|Stage 2 polysaccharide (ages 65-85 years)|polysaccharide
62284091|NCT02690194|PLACEBO_COMPARATOR|Placebo Group|"1. Pre-Placebo therapy~   * Blood pressure, pulse, and respiration rate~  * State-Trait Anxiety Inventory~2. PLACEBO THERAPY SESSION~3. Post-Placebo therapy/Pre-procedure~   * Blood pressure, pulse, and respiration rate~  * State-Trait Anxiety Inventory~4. PROCEDURE~5. Post-procedure -Rate pain level of procedure"
62284092|NCT02690194|EXPERIMENTAL|Experimental (Buddhify) Group|"1. Pre-Buddhify therapy~   * Blood pressure, pulse, and respiration rate~  * State-Trait Anxiety Inventory~2. BUDDHIFY THERAPY SESSION~3. Post-Buddhify therapy/Pre-procedure~   * Blood pressure, pulse, and respiration rate~  * State-Trait Anxiety Inventory~4. PROCEDURE~5. Post-procedure -Rate pain level of procedure"
62284093|NCT02690194|NO_INTERVENTION|Control Group|"1. Pre-Procedure~   * Blood pressure, pulse, and respiration rate~  * State-Trait Anxiety Inventory~2. PROCEDURE~3. Post-procedure -Rate pain level of procedure"
62284094|NCT00176293|EXPERIMENTAL|1|dexamethasone
62651199|NCT05278897|EXPERIMENTAL|Soft Tissue Adapted Biocompatible Hyaluronic Acid|Soft Tissue Adapted Biocompatible Hyaluronic Acid is a clear solution of sterile 1% sodium hyaluronate (10 mg/mL) contained in a 1.2 mL pre-filled syringe. Patients will receive two injections, spaced 2 to 3 days apart (for ankle sprains) or 7 days apart (for elbow injections).
62651200|NCT00560716|EXPERIMENTAL|CYC116|CYC116 dose escalation first-in-human evaluation
62651201|NCT03722576|EXPERIMENTAL|Vidofludimus Calcium (VC)|Daily dosing of VC over 6 months
62459901|NCT06325189|EXPERIMENTAL|Aerobic Interval Training and medication|In this arm, participants will receive the intervention. The intervention consists of aerobic interval training in addition to medication.
62651202|NCT06332482|ACTIVE_COMPARATOR|Group 1|Patients who will use surgical stent in recording the digital Jaw relation
62651203|NCT06332482|ACTIVE_COMPARATOR|Group 2|Patients who will use acrylic complete denture in recording the digital Jaw relation
62651204|NCT06332482|ACTIVE_COMPARATOR|Group 3|Patients who will use mandibular stent in recording the digital Jaw relation
62651205|NCT05107375|EXPERIMENTAL|Population Ⅰ|One dose of influenza virus split vaccine and one dose of recombinant Novel coronavirus vaccine (CHO cells) were given in the contralateral arm on day 0, the second dose of recombinant Novel coronavirus vaccine (CHO cells) on day 30 and the third dose of recombinant Novel coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
62651206|NCT05107375|EXPERIMENTAL|Population Ⅱ|The first dose of recombinant Novel Coronavirus vaccine (CHO cells) was given on day 0, the second dose of recombinant Coronavirus vaccine (CHO cells) on day 30, the first dose of influenza virus lysate vaccine on day 44, and the third dose of recombinant Coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
62084958|NCT05076370|ACTIVE_COMPARATOR|CBD 800mg|CBD 800mg
62084959|NCT05076370|ACTIVE_COMPARATOR|CBD 1200mg|CBD 1200mg
62284095|NCT00176293|NO_INTERVENTION|2|
62284096|NCT04528121|EXPERIMENTAL|study group|(CoDuSe) exercise inform of core stability, dual tasking, and sensory strategies the conventional selected exercise program inform of static and dynamic balance training exercises
62284097|NCT04528121|EXPERIMENTAL|control group|the conventional selected exercise program inform of static and dynamic balance training exercises
62284098|NCT00898365||Ancillary-correlative (renal tumor classification, biology)|Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)
62284099|NCT04299100|NO_INTERVENTION|Control Group|Participants randomized to the Control Group will receive usual care from their pain physician.
62284100|NCT04299100|EXPERIMENTAL|Sleep Health Program - Suspected No/mild sleep apnea|Participants randomized to the Sleep Health Program with no/mild sleep apnea.
62651207|NCT03409965|EXPERIMENTAL|Lutronic Systems Combination Treatment|Combination treatment of the face and/or neck using the Lutronic Infini System and Lutronic LaseMD System.
62651208|NCT02026297|PLACEBO_COMPARATOR|Control, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
62651209|NCT02026297|EXPERIMENTAL|Treated, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
62651210|NCT01626170||Correlative (laboratory biomarker analysis)|Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).
62651211|NCT01620424|EXPERIMENTAL|Dosing visit 1|
62651212|NCT01620424|EXPERIMENTAL|Dosing visit 2|
62651213|NCT02282462|EXPERIMENTAL|Reg pressure, Active suction (Dig)|Regulated pleural pressure with active suction
62651214|NCT02282462|EXPERIMENTAL|Reg pressure, Passive drainage (Dig)|Regulated pleural pressure with passive drainage
62084960|NCT01015573|EXPERIMENTAL|healthy subjects|
62284101|NCT04299100|EXPERIMENTAL|Sleep Health Program - Suspected Moderate/severe sleep apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea.
62284102|NCT04276207|EXPERIMENTAL|100 U/mL LY900014|100 units per milliliter (U/mL) LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
62284103|NCT04276207|ACTIVE_COMPARATOR|100 U/mL Insulin Lispro (Humalog)|100 U/mL Insulin Lispro (Humalog) administered by CSII in one of two study periods.
62459902|NCT03741348|ACTIVE_COMPARATOR|ES|Erector Spinae Plane Block
62459903|NCT03741348|PLACEBO_COMPARATOR|control|the control group will not receive block
62459904|NCT05328804|EXPERIMENTAL|rhTPO|rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days.
62459905|NCT05328804|EXPERIMENTAL|Herombopag|Herombopag will be taken orally at 5 mg daily for 28 days.
62459906|NCT05328804|EXPERIMENTAL|Herombopag in combination of rhTPO|Herombopag will be taken orally at 5 mg daily for 28 days，while rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days
62651215|NCT02282462|EXPERIMENTAL|Unreg pressure, Active suction (Trad)|Unregulated pleural pressure with active suction
62651216|NCT02282462|EXPERIMENTAL|Unreg pressure, Passive drainage (Trad)|Unregulated pleural pressure with passive drainage
62651217|NCT01118676|EXPERIMENTAL|Cilengitide with standard radiochemotherapy|Cilengitide (4 dose levels are defined :12, 18, 27 et 40 mg /hour) concomitant with radiotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction) and cisplatin and vinorelbine based chemotherapy.
62651218|NCT05319717|ACTIVE_COMPARATOR|Ready-to-use therapeutic food, no rice bran (control/comparator)|Randomized participants will receive a locally produced ready-to-use therapeutic food to be consumed daily.
62651219|NCT05319717|EXPERIMENTAL|Ready-to-use therapeutic food, with heat stabilized rice bran (Experimental)|Randomized participants will receive a locally produced ready-to-use therapeutic food with 5% heat stabilized rice bran to be consumed daily.
62651220|NCT02517749|ACTIVE_COMPARATOR|Usual Care Group|Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc
62084961|NCT02619708|NO_INTERVENTION|Standard Preoperative Experience|The preoperative visit will be performed, as it would be normally. Patients will be given a description of the preoperative experience, they will be told what to expect, they will be given brochures detailing what will happen on the day of the surgery, and will be given the opportunity to ask questions. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
62084962|NCT02619708|EXPERIMENTAL|Immersive Preoperative Experience|The preoperative visit will be performed, as it would be normally, with the only addition of a 5-minute video for the patients randomized to the intervention group. Patients will be given a few minutes to watch the video, and will have the chance to ask questions. The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
62084963|NCT04368195|NO_INTERVENTION|Control group|This group will not receive any regional block
62084964|NCT04368195|EXPERIMENTAL|Erector spinae block group|This group will receive erector spinae block
62084965|NCT00657111|EXPERIMENTAL|A1|Subjects 01-08; 5 mg CS-8958
62084966|NCT00657111|PLACEBO_COMPARATOR|A2|Subjects 01-08; placebo
62084967|NCT00657111|EXPERIMENTAL|B1|Subjects 09-16; 10 mg CS-8958
62084968|NCT00657111|PLACEBO_COMPARATOR|B2|Subjects 09-16; placebo
62084969|NCT00657111|EXPERIMENTAL|C1|Subjects 17-24; 20 mg CS-8958
62084970|NCT00657111|PLACEBO_COMPARATOR|C2|Subjects 17-24; placebo
62084971|NCT00657111|EXPERIMENTAL|D1|Subjects 25-32; 40mg CS-8958
62084972|NCT00657111|PLACEBO_COMPARATOR|D2|Subjects 25-32; placebo
62084973|NCT01966536|EXPERIMENTAL|Poor ovarian reserve|Autologous transplantation of CD133+ cells into ovarian artery
62084974|NCT01064583|EXPERIMENTAL|flavanol rich cocoa drink (596mg)|dissolved in water, twice daily intervention
62084975|NCT01064583|EXPERIMENTAL|flavanol poor cocoa drink ( 13mg)|dissolved in water, twice daily intervention
62084976|NCT03174795|EXPERIMENTAL|RO7079901 and Meropenem|Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.
62084977|NCT02636881|ACTIVE_COMPARATOR|Autologous Chondrocyte Implantation|A diagnostic arthroscopy of the knee joint.The lesion is stabilized down to the subchondral bone, but not through it. Cartilage biopsy is taken from the medial femoral notch. The harvested cartilage is transported to the cell culture Laboratory and cultured for two weeks. The chondrocyte implantation: A mini-open arthrotomy is performed and the lesion is curetted down to subchondral bone, avoiding bleeding. The lesion is measured and a template of sterile aluminum foil is used to cut out a matching piece of collagen sheet which is used to contain the cells in the defect. The flap is sutured to the lesion and sealed with fibrin glue, leaving and opening at the upper part for injection of the cells. The last opening is then closed with a last stitch and fibrin glue.
62084978|NCT02636881|SHAM_COMPARATOR|Arthroscopic Debridement|"The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. Lose bodies are removed, any meniscal pathology is addressed. Inflamed synovium is debrided. The lesion is stabilized by debridement around the edges and down to the subchondral bone using a ring curette, but not through it. Microfracture or any other cartilage treatment will not be performed.~No intra-articular local anesthetics will be used due to the possible harmful effect on cartilage \[41-43\].~All the operating surgeons will receive proper training in the operative procedure before study start."
62084979|NCT02358460|ACTIVE_COMPARATOR|Pressure-limited ventilation|
62284104|NCT06540950|EXPERIMENTAL|Oral vinorelbine concurrent radiotherapy group|All patients with unresectable stage III non-small cell lung cancer who received neoadjuvant chemo-immunotherapy received oral vinorelbine (60mg per square meter of body-surface area every 2 weeks before radiotherapy, and 30mg per square meter of body-surface area per week during radiotherapy) as radical concurrent chemoratherapy.
62651221|NCT02517749|ACTIVE_COMPARATOR|Indwelling Pleural Catheter Group|Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc
62651222|NCT01366391|OTHER|Metformin|study parallel with one arm only.
62084980|NCT02358460|ACTIVE_COMPARATOR|Volume-targeted ventilation|
62084981|NCT01913964|EXPERIMENTAL|Acetyl-L-carnitine|2 g daily for 12 months
62084982|NCT01913964|PLACEBO_COMPARATOR|placebo|
62084983|NCT00131560|OTHER|A|
62459907|NCT02597998|EXPERIMENTAL|14C-BI 409306 - 25 mg|14C-BI 409306 oral solution
62651223|NCT00771108|NO_INTERVENTION|control|Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
62651224|NCT00771108|EXPERIMENTAL|Exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
62651225|NCT00988182|EXPERIMENTAL|whey protein, 5g|
62651226|NCT00988182|EXPERIMENTAL|whey protein, 10g|
62651227|NCT00988182|EXPERIMENTAL|whey protein, 20g|
62651228|NCT00988182|EXPERIMENTAL|whey protein, 40g|
62084984|NCT04488172|EXPERIMENTAL|Epilepsy subjects|Receiving multi-vitamins supplementation (B6, B9, D, E, Q10) for 6 months trial
62084985|NCT02912429|OTHER|Inlay|specific technical type of patellofemoral arthroplasty
62284105|NCT03696680|EXPERIMENTAL|FSRT Stereotactic radiation therapy|Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
62284106|NCT02672085|EXPERIMENTAL|PRP infiltration|Supraspinatus interstitial lesion needling and infiltration with PRP
62284107|NCT02672085|ACTIVE_COMPARATOR|Needling|Supraspinatus interstitial lesion needling and infiltration with NaCl
62459908|NCT06006364||1.Group|Nomophobia Level:none
62459909|NCT06006364||2.Group|Nomophobia Level: mild
62459910|NCT06006364||3.Group|Nomophobia Level: medium
62651229|NCT00988182|EXPERIMENTAL|water control|
62084986|NCT02912429|OTHER|Onlay|specific technical type of patellofemoral arthroplasty
62084987|NCT04271384|EXPERIMENTAL|SABR + Nivolumab|"Pre-operative treatment with standard SABR (3 x 18 Gy or 5 x 10 Gy or 8 x 7.5 Gy) concomitant with nivolumab at 360 mg every 21 days x3 doses.~Standard-of-care surgery to be performed after 12 weeks from D1 of treatment."
62284108|NCT02538484|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
62284109|NCT02538484|ACTIVE_COMPARATOR|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
62459911|NCT06006364||4.Group|Nomophobia Level: extreme
62459912|NCT00425672|EXPERIMENTAL|Arm I|Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62459913|NCT02830022|EXPERIMENTAL|Patients|Children from 8 to 18 years with autism without without intellectual disabilities (IQ \> 70), verbals and responding to classification CIM 10-DSM IV.
62651230|NCT02900716|EXPERIMENTAL|Phase Ia|DTRMWXHS-12: oral capsules, daily x 21 days every 28 days
62084988|NCT01196104|EXPERIMENTAL|Technosphere® Insulin Inhalation Powder (TI)|Insulin Glargine and Technosphere® Insulin Inhalation Powder
62084989|NCT01196104|ACTIVE_COMPARATOR|Comparator|Insulin Glargine and Insulin Aspart
62284110|NCT02538484|ACTIVE_COMPARATOR|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
62284111|NCT04805086|EXPERIMENTAL|MON002|Minimum of 1x10\~7 cells to maximum of 2x10\~6 cells/kg. Single infusion.
62284112|NCT00374244|PLACEBO_COMPARATOR|1|placebo pimozide
62284113|NCT00374244|ACTIVE_COMPARATOR|2|active pimozide
62459914|NCT02830022|EXPERIMENTAL|Healthy volunteers|Paired for age, gender, IQ and and the practice of a physical activity strictly within the school context.
62459915|NCT03998865|EXPERIMENTAL|PEEK Provisional Abutment|The provisional crown will be fixed onto a PEEK abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
62651231|NCT02900716|EXPERIMENTAL|Phase Ib, DTRM-505|DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days
62651232|NCT02900716|EXPERIMENTAL|Phase Ib, DTRM-555|"DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:~daily x 21 days every 28 days"
62651233|NCT00980876|ACTIVE_COMPARATOR|Cipro HC|Reference product
62651234|NCT00980876|EXPERIMENTAL|Ciprofloxacin HCl and Hydrocortisone|Test product
62084990|NCT01521949|EXPERIMENTAL|Acai Juice|2 ounces of Acai Juice Product by mouth twice daily.
62084991|NCT02447679|EXPERIMENTAL|thalidomine|"1. Thalidomide 400mg/day for 1 year~2. tegafur-uracil 2 tables for 1 year."
62084992|NCT05040061|EXPERIMENTAL|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
62084993|NCT05040061|ACTIVE_COMPARATOR|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI consisted of similar activities, but they all omitted savoring practices. These activities included attending to any current thoughts and feelings, planning everyday activities, remembering and recording daily events, and anticipating important events.
62084994|NCT04141111|EXPERIMENTAL|CGM intervention|Underwent intervention defined by the intermittent use of a continuous glucose monitoring (CGM) device.
62284114|NCT03077932|OTHER|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
62284115|NCT02274337|EXPERIMENTAL|AC0010|patients receiving avitinib treatment Qd, at different dose stages
62284116|NCT01979497|ACTIVE_COMPARATOR|Suture with Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then steri-strips for the adhesive stripped half of the scar is applied.
62284117|NCT01979497|ACTIVE_COMPARATOR|Suture without Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then no closure material for the half of the scar is applied.
62651235|NCT01860196|ACTIVE_COMPARATOR|Treatment-Placebo Group|Treatment on 0 day Placebo at 5th week
62651236|NCT01860196|ACTIVE_COMPARATOR|Placebo-Treatment Group|Placebo on 0 day Treatment at 5th week
62084995|NCT01418092|PLACEBO_COMPARATOR|Placebo|Capsules for oral administration
62084996|NCT01418092|EXPERIMENTAL|ALKS 37|Capsules for oral administration
62084997|NCT03930966|EXPERIMENTAL|PDEQ, PCL-5 and demographic survey|State of the patient evaluated with questionnaires to make the connection between peri-traumatic dissociation and the occurrence of post-traumatic stress disorder
62084998|NCT05084261|EXPERIMENTAL|BT051 200 mg|Participants will receive oral BT051 200 mg once daily for 28 days.
62084999|NCT05084261|EXPERIMENTAL|BT051 800 mg|Participants will receive oral BT051 800 mg once daily for 28 days.
62085000|NCT05084261|EXPERIMENTAL|BT051 3200 mg|Participants will receive oral BT051 3200 mg once daily for 28 days.
62085001|NCT05084261|PLACEBO_COMPARATOR|Placebo|Participants will receive oral Placebo to match BT051 once daily for 28 days.
62085002|NCT02359968|ACTIVE_COMPARATOR|FOLFOX|"* Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days~* Oxaliplatin 85 mg/m², 2-hr IV infusion on day 1~* Folinic acid 200 mg/m² 2-hr IV infusion on day 1~* 3 cycles, q14"
62284118|NCT00617877|EXPERIMENTAL|1|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
62284119|NCT03005626|EXPERIMENTAL|Therapeutic education|Structured therapeutic education programs
62284120|NCT03005626|ACTIVE_COMPARATOR|Control group|standard outpatient follow-up
62284121|NCT00706030|EXPERIMENTAL|neratinib 160 mg + vinorelbine|neratinib 160 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle
62459916|NCT03998865|ACTIVE_COMPARATOR|Titanium Provisional Abutment|The provisional crown will be fixed onto a titanium abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
62651237|NCT01548963|EXPERIMENTAL|Perioperative glycemia control|Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
62085003|NCT02359968|EXPERIMENTAL|CarboP-pacliT|"* Carboplatin (carboP) AUC=2, given by intravenous infusion~* Paclitaxel (pacliT) 50 mg/m², given by intravenous infusion~* on days 1, 8, 15, 22 and 29"
62085004|NCT01513967|EXPERIMENTAL|Part A, SAD Treatment 1|RPh201 single dose (SAD Low Dose )
62085005|NCT01513967|PLACEBO_COMPARATOR|Part A, SAD Placebo 1|Placebo single dose (SAD Low Dose )
62085006|NCT01513967|EXPERIMENTAL|Part A, SAD Treatment 2|RPh201 single dose (SAD Mid Dose )
62085007|NCT01513967|PLACEBO_COMPARATOR|Part A, SAD Placebo 2|Placebo single dose (SAD Mid Dose )
62085008|NCT01513967|EXPERIMENTAL|Part A, SAD Treatment 3|RPh201 single dose (SAD High Dose )
62085009|NCT01513967|PLACEBO_COMPARATOR|Part A, SAD Placebo 3|Placebo single dose (SAD High Dose )
62085010|NCT01513967|EXPERIMENTAL|Part B, MAD Treatment 1|RPh201 multiple dose (MAD Low Dose )
62459917|NCT00694551|EXPERIMENTAL|A. Level 100 mcg Peptide Vaccine|Peptide vaccine dose level 100 mcg + Poly IC-LC
62459918|NCT00694551|EXPERIMENTAL|B. Level 300 mcg Peptide Vaccine|Peptide vaccine dose level 300 mcg + Poly IC-LC
62085011|NCT01513967|PLACEBO_COMPARATOR|Part B, MAD Placebo 1|Placebo multiple dose (MAD Low Dose )
62085012|NCT01513967|EXPERIMENTAL|Part B, MAD Treatment 2|RPh201 multiple dose (MAD Mid Dose )
62085013|NCT01513967|PLACEBO_COMPARATOR|Part B, MAD Placebo 2|Placebo multiple dose (MAD Mid Dose )
62085014|NCT01513967|EXPERIMENTAL|Part B, MAD Treatment 3|RPh201 multiple dose (MAD High Dose )
62085015|NCT01513967|PLACEBO_COMPARATOR|Part B, MAD Placebo 3|Placebo multiple dose (MAD High Dose )
62085016|NCT06318390|EXPERIMENTAL|Keto5 XOGenius Beverage|Keto5 XOGenius Beverage contains natural ingredients that are high in the Ketone β-OHB content and has anti-inflammatory and antioxidant properties
62085017|NCT01454713||Veritas|Breast reconstruction with Veritas
62085018|NCT01850966||Iguratimod|
62085019|NCT06109259|EXPERIMENTAL|DWJ1567|DWJ1567
62085020|NCT06109259|ACTIVE_COMPARATOR|DWC202312|DWC202312
62085021|NCT05608733|EXPERIMENTAL|Epidural catheter|Epidural catheter infusion of bupivacaine 0.1% (4-6 cc/h) at level L3-L4
62459919|NCT00694551|EXPERIMENTAL|C. Level 1 mg Peptide Vaccine|Peptide vaccine dose level 1 mg + Poly IC-LC
62085022|NCT05608733|ACTIVE_COMPARATOR|Continuous sciatic nerve block|Continuous sciatic catheter infusion of bupivacaine 0.1% (6-10 cc/h)
62085023|NCT05023317|EXPERIMENTAL|Strengths-based linkage to alcohol care (SLAC)|SLAC is a behavioral intervention designed to link persons with substance use/misuse to a care or help option
62284122|NCT00706030|EXPERIMENTAL|neratinib 240 mg + vinorelbine|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle
62284123|NCT00706030|EXPERIMENTAL|neratinib 240 mg + vinorelbine, No Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle
62284124|NCT00706030|EXPERIMENTAL|neratinib 240 mg + vinorelbine, Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle
62284125|NCT01275222|EXPERIMENTAL|Phase l: RAD001 20mg/week|RAD001 20 mg was given once a week.
62284126|NCT01275222|EXPERIMENTAL|Phase l: RAD001 2.5mg/day + Glivec 600mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 600mg/day.
62284127|NCT01275222|EXPERIMENTAL|Phase l: RAD001 5mg/day + Glivec 600mg/day|RAD001 5 mg was given in combination with Glivec/Gleevec 600mg/day.
62284128|NCT01275222|EXPERIMENTAL|Phase l: RAD001 2.5mg/day + Glivec 800mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 800mg/day.
62284129|NCT01275222|EXPERIMENTAL|Phase ll - Stratum l (first-line resistant/refractory): RAD001 2.5mg/day + Glivec 600mg/day|All first-line resistant/refractory patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day.
62459920|NCT01084460||EUS-suspected gastric GISTs|In this retrospective study, 50 patients with EUS-suspected gastric GISTs, less than 3 cm were enrolled and had EUS follow-up at least two times over a period of more than 24 months.
62284130|NCT01275222|EXPERIMENTAL|Phase ll - Stratum ll: (post second-line therapy): RAD001 2.5mg/day + Glivec 600mg/day|All post-second-line patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day
62284131|NCT00934076|EXPERIMENTAL|AT-101 plus Erlotinib|"Subjects will begin study treatment at 150 mg of erlotinib taken once daily in a continuous regimen expressed in 3 week cycles.~Subjects will begin treatment with oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
62085024|NCT05023317|ACTIVE_COMPARATOR|Usual care|Usual care consists of brief intervention in primary care and/or standard referral to more intensive alcohol care (e.g., outpatient/inpatient, pharmacotherapy)
62085025|NCT02263144||histologically-verified <10mm polyps|histologically-verified \<10mm polyps, analyzed by virtual chromo-endoscopy using FICE Fujifilm Technology
62284132|NCT04201080|EXPERIMENTAL|Part A: TRV250 for SC injection|2 SC injections of (10 mg/ml per injection)
62284133|NCT04201080|PLACEBO_COMPARATOR|Part A: Placebo for SC injection|2 SC injections (identical to the TRV250)
62284134|NCT04201080|EXPERIMENTAL|Part B: TRV250 dose 1 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
62459921|NCT01521988|ACTIVE_COMPARATOR|Atrial flutter ablation|RF atrial flutter ablation
62459922|NCT01521988|EXPERIMENTAL|Atrial flutter ablation and pulmonary vein isolation|RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
62085026|NCT01134211|OTHER|nelfilcon A / filcon II 3|Nelfilcon A contact lenses worn first, with filcon II 3 contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
62085027|NCT01134211|OTHER|filcon II 3 / nelfilcon A|Filcon II 3 contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
62085028|NCT04033991||Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic)
62284135|NCT04201080|EXPERIMENTAL|Part B: TRV250 dose 2 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
62284136|NCT04201080|EXPERIMENTAL|Part B: TRV250 dose 3 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
62459923|NCT06202196|EXPERIMENTAL|Experimental group|"Patients of the experimental group will have therapeutic patient education sessions that include one Recognizing and Managing the Risks of Epilepsy workshop."
62085029|NCT05128292|EXPERIMENTAL|CoQ10 plus selenium|"Nutraceutical intervention:~400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks"
62284137|NCT04201080|PLACEBO_COMPARATOR|Part B: Placebo for SC injection|Placebo (using syringes identical to the TRV250 arms)
62459924|NCT06202196|OTHER|"Control group Usual management"|"Patients of the control group will have the usual therapeutic patient education sessions."
62459925|NCT04095871||Patients included|"Patients over 18 years old performed CISC for more than 1 month, exclusive or not, are included.~At home, patients have to complete one diary on the specific duration of a 24-hour CISC and the next day a second diary on the total duration of CISC.~The specific time of CISC described by the timed duration from the moment when the circumstances of care are combined to carry it out : isolated place, nearby equipment.~The total time of CISC described by the timed duration from the moment of the intention to self-catheter until the return to the initial activity."
62459926|NCT04882670||hip fracture|
62459927|NCT05733715|EXPERIMENTAL|A: Pembrolizumab + Lenvatinib|Subjects will receive Pembrolizumab + Lenvatinib. Pembrolizumab 200 mg or 400 mg will be administered as a 30-minute IV infusion every 3 weeks. Lenvatinib 20 mg daily will be self-administered PO by subject for 28 consecutive days, beginning Day -7.
62284138|NCT05019105|PLACEBO_COMPARATOR|Placebo|Placebo administered orally
62284139|NCT05019105|ACTIVE_COMPARATOR|ALKS 1140|Up to 8 single ascending doses of ALKS 1140 and 4 multiple ascending doses administered orally
62284140|NCT00578643|EXPERIMENTAL|Allogeneic unrelated transplant|Conditioning from Day -9 to Day -1. Stem cells given on Day 0. Busulfan, alemtuzumab, cyclophosphamide, fludarabine, cyclosporine, stem cell infusion.
62284141|NCT06385704|EXPERIMENTAL|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
62284142|NCT03246828|EXPERIMENTAL|Omission of gliclazide|
62459928|NCT05733715|EXPERIMENTAL|B: Pembrolizumab|Subject will receive Pembrolizumab 200 mg or 400 mg will be administered as a 30-minute IV infusion every 3 weeks.
62459929|NCT00995553|EXPERIMENTAL|Cognitive Remediation|A 48-session working memory focused cognitive remediation program is conducted. Training tasks have been selected from 3 software programs, PSS CogRehab, BrainTrain, and custom made N-back tasks.
62459930|NCT00995553|PLACEBO_COMPARATOR|Computer Skills|This is a 48-session, time matched comparison group in which participants practice keyboarding skills and the fundamentals of Microsoft Office Word, Powerpoint, and Excel programs.
62459931|NCT05427656|EXPERIMENTAL|185 MBq [18F] TRACK|Each participant will receive a single scan with 185 MBq \[18F\] TRACK
62284143|NCT03603652|EXPERIMENTAL|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
62459932|NCT00604500|EXPERIMENTAL|MF/F MDI 100/10 mcg BID with dose counter|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
62459933|NCT04175548||surgery for a pertrochanteric fracture|Patients having had surgery for a pertrochanteric fracture at the CHU Brugmann Hospital between January 2013 and May 2019.
62459934|NCT05283005|ACTIVE_COMPARATOR|alveolar cleft patients will be treated by conventional technique|Reconstruction of alveolar cleft by autogenous cancellous bone from the anterior iliac crest (gold standard technique).
62459935|NCT05283005|EXPERIMENTAL|alveolar cleft patients will be treated by double cortex technique|Reconstruction of alveolar cleft by autogenous double iliac cortico-cancellous bone blocks from the anterior iliac crest.
62085030|NCT02400307|EXPERIMENTAL|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
62085031|NCT02400307|EXPERIMENTAL|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
62284144|NCT02058901|EXPERIMENTAL|Sunitinib high dose, weekly schedule|Initial dose of sunitinib is set at 200 mg once weekly. Three patients are treated at the current dose level. If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
62085032|NCT02400307|EXPERIMENTAL|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
62085033|NCT05493904|ACTIVE_COMPARATOR|OCT-guided PCI arm|Use of OCT will be strongly recommended at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT evaluation after stent implantation will be mandatory. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
62085034|NCT05493904|ACTIVE_COMPARATOR|Angiography-guided PCI arm|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
62085035|NCT04746430|EXPERIMENTAL|Intervention|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
62085036|NCT04746430|NO_INTERVENTION|Control|Only remote monitoring
62085037|NCT04207684|EXPERIMENTAL|Testosterone|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration (6 fractions: 0-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h post-administration).
62085038|NCT04288973||Typical development children|Control sample
62085039|NCT04288973||Children with developmental disability|Clinical sample
62085040|NCT00977028|EXPERIMENTAL|Tumescent Lidocaine with liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
62085041|NCT00977028|EXPERIMENTAL|Tumescent Lidocaine No Liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
62085042|NCT04342299||Responders|"Responders are participants who show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
62085043|NCT04342299||Non-responders|"Non-responders are participants who do not show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
62085044|NCT05153850||Cases|Patients diagnosed with inflammatory bowel disease with the complete vaccination regimen.
62085045|NCT05806424||pelvic muscle awareness|
62284145|NCT02058901|EXPERIMENTAL|Sunitinib high dose, biweekly schedule|When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
62284146|NCT01267630||Surgical ICU|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48 hours .
62085046|NCT05806424||not pelvic muscle awareness|
62284147|NCT02921451|OTHER|Restorelle Smartmesh|Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
62284148|NCT01625325||extremely obese|BMI ≥35kg/m2
62284149|NCT01625325||obese|BMI 30-34.9kg/m2
62085047|NCT02381860|PLACEBO_COMPARATOR|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
62085048|NCT02381860|ACTIVE_COMPARATOR|60mL of cherry concentrate with 100ml water|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol \< 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
62085049|NCT03046303|EXPERIMENTAL|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
62085050|NCT03046303|NO_INTERVENTION|conventional pathway group|The conventional pathway group received conventional care.
62085051|NCT01150851|ACTIVE_COMPARATOR|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
62085052|NCT01150851|ACTIVE_COMPARATOR|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
62085053|NCT01150851|ACTIVE_COMPARATOR|caloric restriction and aerobic exercise|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration, and supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
62085054|NCT01150851|NO_INTERVENTION|usual diet and usual activity|usual diet and usual activity
62085055|NCT05900453||Usual Care TKA rehabilitation|This cohort of patients received Usual Care TKA rehabilitation at two outpatient physical therapy clinics in the Greenville, South Carolina, USA area. These patients received treatment guided by their clinician's professional judgment and the clinic's best practice guidelines for TKA.
62284150|NCT05405647|EXPERIMENTAL|shock wave therapy|received a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session, and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
62085056|NCT05900453||CDS tool TKA rehabilitation|This cohort of patients received TKA rehabilitation at the same two outpatient physical therapy clinics in the Greenville, South Carolina, USA area. These patients also received treatment guided by their clinician's professional judgement and the clinic's best practice guidelines. Additionally, this cohort of patients was exposed to the CDS tool (i.e., clinicians used the tool to view personalized information about the patient at least once during the patient's episode of care).
62085057|NCT00773071|EXPERIMENTAL|A|"Single photon emission computed tomography/computed tomography (SPECT/CT) guided lymphatic mapping and sentinel lymphadenectomy (LM/SL) vs. complete lymph node dissection (CLND)~All cervical cancer and vulvar cancer patients will undergo CLND according to the standard of care in gynecologic cancers as recommended by the International Federation of Gynecology and Obstetrics (FIGO).~Patients with FIGO IA2 and IB1 cervical cancers will be scheduled for radical hysterectomy and pelvic lymph node dissection.~Patients with FIGO IB and II vulvar cancers and those of patients with FIGO III with clinically negative regional lymph nodes will be scheduled for vulvectomy and inguinal lymph node dissection."
62284151|NCT05405647|EXPERIMENTAL|kinesio tape|kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6 weeks.
62085058|NCT04012814|EXPERIMENTAL|Subject treatment group|Treatment group receiving 3 diode treatments and 3 RF/PEMF treatments at Week 0, 8 and 16 with a follow-up at Week 24.
62284152|NCT02120755|ACTIVE_COMPARATOR|AmnioClear™|AmnioClear™ Human Allograft Amniotic Membrane
62284153|NCT02120755|NO_INTERVENTION|Standard of Care|Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)
62284154|NCT04378283|EXPERIMENTAL|LET as topical anesthetic for wound repair.|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%) is a topical anesthetic that is routinely used before laceration repair.
62284155|NCT04378283|ACTIVE_COMPARATOR|EMLA plus infiltration as anesthetic for wound repair.|"EMLA (eutectic mixture of local anesthetics) with subsequent lidocaine infiltration. EMLA is a mixture of lidocaine (2.5%) and prilocaine (2.5%) in a cream base."
62284156|NCT05124223||Post-COVID-19|From May 2020 to May 2021, we retrospectively examined 104 clinical cardiac magnetic resonance (CMR) examinations performed in patients with suspected cardiac involvement post COVID-19. The mean time from first positive PCR to CMR was 112 +- 76 days. During their COVID-19 disease, 21% of patients required hospitalization, 17% supplemental oxygen and 7% mechanical ventilation.
62284157|NCT05124223||Post-COVID-19-Vaccination|Between May 2021 and August 2021, we examined 27 patients with suspected cardiac disease after COVID-19 vaccination.
62284158|NCT00814242|ACTIVE_COMPARATOR|hepatectomy|Patients with HCC adjacent to major blood vessels recieved radical resection.
62284159|NCT00814242|EXPERIMENTAL|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation
62459936|NCT06486610|NO_INTERVENTION|Control Group: Routine clinical practice|Fear, Emotional Indicators and Physiological Parameters in Children
62459937|NCT06486610|EXPERIMENTAL|Therapeutic play: Fish-shaped nebulizer and fish-shaped toy|Fear, Emotional Indicators and Physiological Parameters in Children
62459938|NCT06486610|EXPERIMENTAL|silent nebulizer|Fear, Emotional Indicators and Physiological Parameters in Children
62085059|NCT05465421|ACTIVE_COMPARATOR|socket preservation with platelet rich fibrin PRF alone the implant placement 3 months after|after extraction socket preservation will be done by using PRF only in the socket and closed the socket by flap advancement.
62085060|NCT05465421|EXPERIMENTAL|socket preservation with BMMNCs of bone marrow aspirated of maxillary tuberosity|after extraction socket preservation will be done by using bone marrow mononuclear cell layer seeded on PRF in the socket and close the socket by flap advancement
62085061|NCT01375894|ACTIVE_COMPARATOR|depresive patients|30 patients suffering from depression
62085062|NCT01375894|EXPERIMENTAL|Schizophrenia patients|30 Schizophrenia patients
62085063|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
62085064|NCT02478359|NO_INTERVENTION|Standard Care|Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
62085065|NCT02478359|EXPERIMENTAL|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
62085066|NCT02328456|OTHER|SMS and free eye drops group|the patient after trabeculectomy surgery in the SMS associated with free eye drops group will receive free eye drops and a SMS reminder message about the revisit time.
62085067|NCT02328456|NO_INTERVENTION|the control group|the patient after trabeculectomy surgery in the control group won't get any free eye drop and reminder message before the appointment.
62085068|NCT03406234||A group of participants|
62085069|NCT02900911|EXPERIMENTAL|Early rehabilitation|Early intervention consisting in standard swallow therapy and instructions to train respiratory muscles starting 2 weeks before Radiotherapy during 6 months
62085070|NCT02900911|ACTIVE_COMPARATOR|Later rehabilitation|Late intervention consists of standard swallow therapy and instructions to train respiratory muscles starting after completing Radiotherapy
62284160|NCT01120665|EXPERIMENTAL|PLACEBO-CONTROL|PLACEBO + CONTROL TO EXERCISE
62085071|NCT01058863|EXPERIMENTAL|Albuterol Spiromax® 90 mcg|A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
62085072|NCT01058863|EXPERIMENTAL|Albuterol Spiromax® 180 mcg|A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
62085073|NCT01058863|ACTIVE_COMPARATOR|ProAir® HFA 90 mcg|A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
62085074|NCT01058863|ACTIVE_COMPARATOR|ProAir® HFA 180 mcg|A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
62085075|NCT01058863|PLACEBO_COMPARATOR|Placebo Inhaler|Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
62085076|NCT02839681|EXPERIMENTAL|1/Safety Run-in Arm|Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
62284161|NCT01120665|EXPERIMENTAL|ESTROGEN THERAPY + CONTROL|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + CONTROL TO EXERCISE
62284162|NCT01120665|EXPERIMENTAL|PLACEBO+AEROBIC TRAINING|PLACEBO + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
62284163|NCT01120665|EXPERIMENTAL|ESTROGEN THERAPY + AEROBIC TRAINING|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
62284164|NCT00331006|EXPERIMENTAL|Rituximab|Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks
62459939|NCT02513797|EXPERIMENTAL|LARIAT + PVI Treatment Group|Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
62284165|NCT00899093||Ancillary-Correlative (serum collection for YKL-40 and CA125)|Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
62284166|NCT02012556|EXPERIMENTAL|Tesamorelin|
62284167|NCT02146339|EXPERIMENTAL|Unfortified-3g-5g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
62459940|NCT02513797|ACTIVE_COMPARATOR|PVI Catheter Ablation Group|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
62459941|NCT05554809|EXPERIMENTAL|Dynamic stretching|
62459942|NCT05554809|EXPERIMENTAL|Static stretching|
62459943|NCT05554809|ACTIVE_COMPARATOR|Controll|
62459944|NCT03119480||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
62459945|NCT04154033|NO_INTERVENTION|Arm A: Circadian Rhythm of Itch|For the study arm A, to evaluate circadian rhythm of itching, patients will record for 7 days 6 times daily in a booklet the itch intensity on a visual analog scale (VAS) scale. These time points for itch intensity recording will be hours after time of awakening (AW), so they will be AW+2h, AW+4h, AW+6h, AW+8h, AW+10h, AW+12h. Patients are to document all their pruritus attacks at these time points. On day 8 the investigators will collect suction blisters (4-5 10mm blisters) at these 6 time points from unaffected skin on the trunk. For this purpose, the investigators will use the commercially available 47mm orifice plate (Electronic Diversities, Finksburg MD, USA) with 4-5 x10mm openings for each time point and use the 4-5 1mm blister roofs for harvesting.
62459946|NCT04154033|EXPERIMENTAL|Arm B: Topical Naltrexone Cream|Patients will start with placebo in week 2 and move on to naltrexone treatment in week 3. There will be a wash-in phase during week 1. Following week 2 and week 3, at visits 3 and 4, patients will be asked for the area where they are experiencing most intense itch and the investigators will take suction blisters from that area before any treatment. They will be told to bring the medication they have been using and they will apply this topically. After an hour, another suction blister will be taken from the same area. This will ensure the study is still blinded as neither the physician or the participant will know whether the medication was a placebo or not. Participants may apply their topical treatment as often as he wishes.
62459947|NCT04154033|PLACEBO_COMPARATOR|Arm C: Placebo Cream|Patients will start with naltrexone treatment in week 2 and move on to placebo treatment in week 3. Other than this, all procedures will be the same as in study arm B.
62651238|NCT01548963|ACTIVE_COMPARATOR|Postoperative glycemia control|Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
62085077|NCT02839681|EXPERIMENTAL|2/Phase 2 Arm|Subjects will be dosed with anetumab ravtansine at the recommended phase 2 dose (dose level 1 if no more than 1 dose limiting toxicity (DLT) occurred in the safety run-in arm, or at dose level -1 otherwise)
62085078|NCT05248464||Rheumatic diseases patients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences
62085079|NCT01071265|PLACEBO_COMPARATOR|Sham RIPC|Inflation of thigh pneumatic tourniquet to \<15 mmHg
62284168|NCT02146339|EXPERIMENTAL|Unfortified-5g-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
62284169|NCT02146339|EXPERIMENTAL|3g-5g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
62459948|NCT06261892|EXPERIMENTAL|Collect HPV DNA from urine|
62459949|NCT02853279|EXPERIMENTAL|Interval exercise training|Supervised exercise training undertaking interval exercise twice per week for 30 min each visit over 12 weeks.
62459950|NCT02853279|ACTIVE_COMPARATOR|Continuous exercise training|Supervised exercise training undertaking continuous exercise twice per week for 30 min each visit over 12 weeks.
62459951|NCT02067793|PLACEBO_COMPARATOR|Placebo|Placebo
62459952|NCT02067793|EXPERIMENTAL|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
62459953|NCT02067793|EXPERIMENTAL|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
62459954|NCT02067793|EXPERIMENTAL|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
62459955|NCT03904303|EXPERIMENTAL|Geloprep|Novel and patented Polyethylene glycol 3350 mixture
62651239|NCT01657617|EXPERIMENTAL|Radiation Therapy|Boost Stereotactic Body Radiation Therapy (SBRT)
62651240|NCT03890575|EXPERIMENTAL|Airway Stent for Malignant Stricture|Patients with malignant stricture were implanted with covered metallic segmented stent modified with 3D printing.
62651241|NCT01922453|EXPERIMENTAL|Music and Sound|Music and Sound applied to maternal abdomen through a special device for pregnant women.
62651242|NCT01922453|NO_INTERVENTION|no music and sound|
62651243|NCT04936893|EXPERIMENTAL|HeadSpace Mobile App|Mindfulness practice
62651244|NCT04936893|ACTIVE_COMPARATOR|Lumosity Mobile App|Cognitive games
62085080|NCT01071265|ACTIVE_COMPARATOR|Active RIPC|300 mmHg inflation of thigh pneumatic tourniquet for three cycles of 5 minutes each with 5 minutes of no inflation between cycles.
62085081|NCT02689856|PLACEBO_COMPARATOR|Vehicle cream|Placebo control base cream
62085082|NCT02689856|EXPERIMENTAL|3% hydrocortisone|3% Hydrocortisone acetate cream
62085083|NCT02689856|EXPERIMENTAL|0.5% hydrocortisone|0.5% Hydrocortisone acetate cream
62085084|NCT02689856|EXPERIMENTAL|5% lidocaine|5% Lidocaine hydrochloride cream
62085085|NCT02689856|EXPERIMENTAL|1% lidocaine|1% Lidocaine hydrochloride cream
62085086|NCT02689856|EXPERIMENTAL|3% Hydro 5% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 3% and 5% cream
62085087|NCT02689856|EXPERIMENTAL|0.5% Hydro 1% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 0.5% and 1% cream
62085088|NCT00432861|ACTIVE_COMPARATOR|1|Pancrecarb(R) MS-16 Capsules
62085089|NCT00432861|PLACEBO_COMPARATOR|2|
62085090|NCT03094897|EXPERIMENTAL|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
62085091|NCT05994599|EXPERIMENTAL|EVE119 vaginal ring|EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
62085092|NCT05994599|ACTIVE_COMPARATOR|Nuvaring vaginal ring|Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
62284170|NCT02146339|OTHER|3g-Unfortified-5g milk polar lipid fortified cheese product|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
62284171|NCT02146339|EXPERIMENTAL|5g-unfortified-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
62284172|NCT02146339|OTHER|5g-3g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
62284173|NCT03644628|ACTIVE_COMPARATOR|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
62284174|NCT03644628|EXPERIMENTAL|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
62284175|NCT01087541|NO_INTERVENTION|Control|Usual clinical health care
62284176|NCT01087541|EXPERIMENTAL|Intervention|Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )
62284177|NCT05023031|EXPERIMENTAL|NVP-2102|NVP-2102
62284178|NCT05023031|ACTIVE_COMPARATOR|NVP-2102-R|NVP-2102-R
62284179|NCT05762328|NO_INTERVENTION|Standard of care|Patients allocated in hospitals randomized to non-interventional arm. Observational analysis of patients treated by clinicians with standard of care.
62284180|NCT05762328|OTHER|Interventional|Patients allocated in hospitals randomized to interventional arm. Intervention: automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
62284181|NCT00035451|PLACEBO_COMPARATOR|1|placebo tablets
62284182|NCT00035451|ACTIVE_COMPARATOR|2|Sotalol
62284183|NCT00035451|EXPERIMENTAL|3|azimilide
62284184|NCT04202640|EXPERIMENTAL|Arm A - Mechanical Stimulation|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, mechanical stimulation
62085093|NCT03557983|EXPERIMENTAL|fenofibrate|Fenofibrate should be topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
62085094|NCT03557983|PLACEBO_COMPARATOR|Saline|Saline is topically spread three times per day for one week.
62085095|NCT01888562|EXPERIMENTAL|Ponatinib|Ponatinib 45mg po daily for 4 weeks (4 weeks equal 1 cycle).
62085096|NCT04736940||Patients|Patients followed or currently treated for a solid or haematological neoplasia
62085097|NCT04736940||Doctors|Medical oncologist or haematologist
62085098|NCT04736940||Paramedical staff|Nurses or assistant nurses
62085099|NCT04736940||Oncopsychologist|Psychologist specialised in the care of patients with cancer
62085100|NCT02694614|EXPERIMENTAL|smartphone-assisted dietary coaching|
62085101|NCT05466474|EXPERIMENTAL|Tislelizumab combined with dacarbazine|Tislelizumab combined with dacarbazine in the treatment of advanced melanoma.
62085102|NCT01833117|EXPERIMENTAL|FID 119515A|FID 119515A, 1 drop instilled in the study eye, single dose
62085103|NCT01833117|ACTIVE_COMPARATOR|Blink|Blink® Tears, 1 drop instilled in the study eye, single dose
62085104|NCT00388362|EXPERIMENTAL|Sirolimus Therapy|Administration of Sirolimus and Prednisone
62284185|NCT04202640|SHAM_COMPARATOR|Arm B - Massages|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, massages.
62284186|NCT04959331|ACTIVE_COMPARATOR|Short-course fosfomycin|3 g of fosfomycin once daily for two days (sachets)
62284187|NCT04959331|ACTIVE_COMPARATOR|Short-course nitrofurantoin|Five-day nitrofurantoin 100 mg t.i.d. (pills)
62284188|NCT04959331|ACTIVE_COMPARATOR|Short-course pivmecillinam|Three-day pivmecillinam 400 mg. t.i.d. (pills)
62284189|NCT04959331|ACTIVE_COMPARATOR|Single-dose fosfomycin|Single 3 g dose of fosfomycin (sachet)
62284190|NCT01564836|EXPERIMENTAL|Imatinib treatment discontinuing|
62284191|NCT01638728||Endotracheal tube|
62284192|NCT02911766|ACTIVE_COMPARATOR|Corsodyl, 0.2% mouthrinse|"The comparator solution was Corsodyl, 0.2% Chlorhexidine mouthrinse,~Intervention Rinsing 60 sec with Comparator solution twice daily for 21 days"
62459956|NCT03904303|ACTIVE_COMPARATOR|Moviprep|Standard of care Polyethylene glycol 3350 mixture
62284193|NCT02911766|EXPERIMENTAL|FluxProKlorhexidine 0.12% mouthrinse|"The experimental solution was FluxProChlorhexidine 0.12% mouthrinse~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
62284194|NCT02911766|EXPERIMENTAL|Corsodaily 0.06% mouthrinse|"The second experimental solution was Corsodaily, 0.06% chlorhexidine mouthrinse.~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
62284195|NCT05783700||DIABETIC|"PERFORMANCE OF BIOIMPEDANCIOMETRY WITH DETERMINATION OF:~* Daily calorie intake~* Body fat mass and percentage~* Segmental body fat percentage~* Resting Heart Rate~* Lean Mass~* Risk of sarcopenia~* Proteins~* Extra Cellular Water~* Intracellular Water~* Phase Angle~* Visceral fat~* Muscle mass~* Segmental muscle mass~* Muscle quality score~* Total body water (%)~* Metabolic age"
62284196|NCT04162210|EXPERIMENTAL|Participants receiving Belantamab mafodotin|Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W
62085105|NCT01151982|EXPERIMENTAL|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
62085106|NCT01151982|NO_INTERVENTION|Usual Care|The kind of care that general practitioners usually provide when not knowing the level and risk profile of depression of the patients
62284197|NCT04162210|ACTIVE_COMPARATOR|Participants receiving pom/dex|Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.
62284198|NCT05590520|EXPERIMENTAL|Botulinum group|The internal anal sphincter to be palpated and injected with a 27-gauge needle while the patient lying on his or her left side. Each patient will receive 0.4 ml of solution containing botulinum toxin (for a total of 20 U), administered as two injections of equal volume (0.2 ml), one on each side of the anterior midline of the internal anal sphincter. No sedation or local anesthesia to be used during the procedure)
62284199|NCT05590520|ACTIVE_COMPARATOR|GTN group|0.2 percent nitroglycerin ointment applied twice daily for six weeks.
62651245|NCT02638792|EXPERIMENTAL|Internet-based exposure therapy|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
62651246|NCT02638792|ACTIVE_COMPARATOR|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
62284200|NCT02369081|ACTIVE_COMPARATOR|Spironolactone|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase.
62284201|NCT02369081|PLACEBO_COMPARATOR|Placebo|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
62284202|NCT02369081|ACTIVE_COMPARATOR|Doxazosin|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
62284203|NCT02369081|ACTIVE_COMPARATOR|Bisoprolol|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
62284204|NCT00946309|EXPERIMENTAL|High Sulforaphane Extract|
62284205|NCT00946309|PLACEBO_COMPARATOR|Placebo|
62284206|NCT05772637|EXPERIMENTAL|MS Patient with Bladder disorders|
62651247|NCT02638792|NO_INTERVENTION|Waitlist|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, and 4, 12 months later using the same questionnaires as the treatment group. The participants will be able to choose which treatment they receive i.e. no randomization.
62284207|NCT01234155|NO_INTERVENTION|Control|
62651248|NCT05844540|OTHER|harvesting and augmentation of bone block|autogenous bone block was harvested from the symphysis, trimmed to L-shape and used to augment the anterior maxilla or mandible horizontally and vertically.
62651249|NCT04931615|PLACEBO_COMPARATOR|without ARTISS|Surgery performed without active comparative
62651250|NCT04931615|ACTIVE_COMPARATOR|with ARTISS|Surgery performed with active comparative
62085107|NCT01227343||Female Smokers|Healthy females who smoke 10-30 cigarettes per day for the past 2 years and meet criteria for nicotine dependence.
62085108|NCT01227343||Female Non-smokers|Healthy females who do not currently smoke cigarettes.
62085109|NCT01227343||Male Smokers|Healthy males who smoke 10-30 cigarettes per day for the past 2 years and who meet criteria for nicotine dependence.
62085110|NCT01227343||Male - Non-Smokers CLOSED|WE ARE NO LONGER RECRUITING MALE NON-SMOKERS
62085111|NCT03351361|EXPERIMENTAL|Nivolumab + Ipilimumab|
62085112|NCT03351361|ACTIVE_COMPARATOR|Chemotherapy|carboplatin and pemetrexed or carboplatin and paclitaxel
62085113|NCT05397938|EXPERIMENTAL|JMT103 60 mg group|Patients will be administrated with JMT103 60 mg subcutaneously every 6 months (Q6W) and alendronate sodium tablet placebo once every week (QW).
62085114|NCT05397938|EXPERIMENTAL|JMT103 90 mg group|Patients will be administrated with JMT103 90 mg subcutaneously every 6 months (Q6W) and alendronate sodium tablet placebo once every week (QW).
62085115|NCT05397938|ACTIVE_COMPARATOR|Alendronate sodium group|Patients will be administrated with alendronate sodium tablet orally 70 mg weekly (QW) and JMT103 placebo subcutaneously every 6 months (Q6W).
62085116|NCT03389893|EXPERIMENTAL|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
62085117|NCT03389893|PLACEBO_COMPARATOR|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
62085118|NCT04142463|NO_INTERVENTION|Before-group|This arm comprises patients who are recruited in phase 3 of the study, i.e. before the implementation of the care pathway. It is intended that patients included in phase 3 serve as a control-group for patients included in phase 6.
62085119|NCT04142463|EXPERIMENTAL|After-group|This arm comprises patients who are recruited in phase 6 of the study, i.e. after the implementation of the care pathway.
62085120|NCT03157102|EXPERIMENTAL|HFNC group|
62085121|NCT03157102|OTHER|Standard Oxygen Therapy group (STO group)|
62085122|NCT01959880|OTHER|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
62085123|NCT01959880|OTHER|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
62085124|NCT01959880|OTHER|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
62284208|NCT01234155|EXPERIMENTAL|Exercise - Continuous Walking|
62284209|NCT01234155|EXPERIMENTAL|Exercise - Interval Walking|
62284210|NCT02361645|NO_INTERVENTION|Control Group|No NSAIDs were administered prior to surgery
62284211|NCT02361645|EXPERIMENTAL|Ketorolac eyedrops|Ketorolac 0.5% eyedrops were administered prior to surgery
62284212|NCT02361645|EXPERIMENTAL|Indomethacin eyedrops|Indomethacin 0.5% eyedrops were administered prior to surgery
62284213|NCT02361645|EXPERIMENTAL|Nepafenac eyedrops|Nepafenac 0.1% eyedrops were administered prior to surgery
62284214|NCT02361645|EXPERIMENTAL|Bromfenac eyedrops|Bromfenac 0.09% eyedrops were administered prior to surgery
62284215|NCT02797119|EXPERIMENTAL|tranexamic acid 1 g (TA1)|"To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration"
62085125|NCT01959880|OTHER|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
62459957|NCT04351516|EXPERIMENTAL|hydroxychloroquine|
62459958|NCT04351516|PLACEBO_COMPARATOR|Placebo|
62459959|NCT04792944||No treatment|Those are the patients that do not receive any treatment for the aneurysm, neither endovascular nor surgical
62085126|NCT05993871||Patients with diabetic small fiber neuropathy|Diabetic Patients presented with pure small fiber neuropathy.
62085127|NCT05993871||Patients with diabetic mixed small and large fiber neuropathy|Diabetic Patients presented with mixed small and large fiber neuropathy
62085128|NCT05993871||Subjects without neuropathy|Healthy subjects without any symptoms and/or signs suggesting neuropathy, and within average IENFD on skin biopsy.
62085129|NCT03405662|ACTIVE_COMPARATOR|Acitve PBM|This arm will receive active photobiomodulation (PBM), delivered with the Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
62085130|NCT03405662|SHAM_COMPARATOR|Sham PBM|This arm will not receive active photobiomodulation (PBM). Instead, they will use a sham Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
62085131|NCT02372175|EXPERIMENTAL|Low dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single low dose (0.5 mL of 6.5 x 10\^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
62085132|NCT02372175|EXPERIMENTAL|Medium dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single medium dose (0.5 mL of 6.5 x 10\^4 PFU/mL) inoculated subcutaneously
62085133|NCT02372175|EXPERIMENTAL|High dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single high dose (0.5 mL of 6.5 x 10\^5 PFU/mL) inoculated subcutaneously
62085134|NCT06048874|EXPERIMENTAL|FNB|sono-guided injection with 20ml ropivacaine
62085135|NCT06048874|PLACEBO_COMPARATOR|no FNB|sono-guided injection with 20ml 0.9% saline
62085136|NCT03437434||BunnyLens and Gore-Tex suture|All patients Underwent 4 point PC-IOL scleral fixation with Gore-Tex sutures
62085137|NCT00747981|EXPERIMENTAL|A|Thoracic CT Scan
62085138|NCT04675242|EXPERIMENTAL|NCX 4251|NCX 4251 Ophthalmic Suspension
62085139|NCT04675242|PLACEBO_COMPARATOR|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension
62085140|NCT01426620|EXPERIMENTAL|Blueberry powder|This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
62085141|NCT03927872||cardioembolic stroke|
62085142|NCT03927872||non cardioembolic stroke|
62085143|NCT00906295|ACTIVE_COMPARATOR|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
62085144|NCT00906295|EXPERIMENTAL|Allowed drop in hemoglobin to 5.6-6.5 mmol/L|Transfusion with red blood cells to level between 5.6-6.5 mmol/L
62085145|NCT03187561|EXPERIMENTAL|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
62085146|NCT03187561|EXPERIMENTAL|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
62284216|NCT02797119|EXPERIMENTAL|tranexamic acid 0.5 g (TA1/2)|To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
62085147|NCT03187561|OTHER|Control|Participants in this arm will not receive either intervention.
62085148|NCT00129675|EXPERIMENTAL|[123I]ß CIT|To assess \[123I\]ß CIT and SPECT imaging
62085149|NCT04268836|EXPERIMENTAL|Treatment arm|Patients will be treated by the Optimal Acuity Clear-K Low Vision Aid System.
62085150|NCT05381428|ACTIVE_COMPARATOR|Indomethacin Group (Control Arm)|Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
62085151|NCT05381428|EXPERIMENTAL|Indomethacin and Lactated Ringer Group (Intervention Arm)|Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
62085152|NCT05353738||Patients with severe neuromuscular disease|Patient with severe neuromuscular disease and having received vaccination with the Moderna vaccine
62085153|NCT05353738||Patients groupe témoins négatif|Patient having had a blood sample taken as part of the treatment for virological analysis before anti-COVID 19 vaccination
62085154|NCT05353738||Patients groupe témoins positif|Patient having had a blood sample taken as part of the treatment for virological analysis following infection with the omicron variant.
62284217|NCT02797119|PLACEBO_COMPARATOR|Saline Solution (TA0)|To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
62284218|NCT02797119|NO_INTERVENTION|NH|To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section
62284219|NCT04148274||Patients|Patients with Ulcerative Colitis diagnosis
62651251|NCT04078386|EXPERIMENTAL|RC18 240mg|
62651252|NCT04078386|EXPERIMENTAL|RC18 160 mg|
62651253|NCT04078386|PLACEBO_COMPARATOR|Placebo|
62085155|NCT06082128|NO_INTERVENTION|Usual care|Dyads in the control group will receive usual care only. Usual advanced cancer care is known to be heterogeneous. It is expected usual care to include care from specialists, doctors, nurses or other health care professionals that patients usually engage with.
62651254|NCT00223821|ACTIVE_COMPARATOR|Drug Therapy Aone|Oxybutynin chloride, extended-release, individually-titrated
62651255|NCT00223821|EXPERIMENTAL|Drug Therapy + Behavioral Training|Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
62651256|NCT04059952||Unipolar Depression|Patients diagnosed with Major Depressive Disorder.
62284220|NCT01642745|EXPERIMENTAL|Methacholine (Provocholine) with deep inhalation|
62284221|NCT01642745|EXPERIMENTAL|Mannitol (Aridol)|
62284222|NCT01642745|ACTIVE_COMPARATOR|Methacholine (Provocholine) tidal breathing|
62284223|NCT05141305|EXPERIMENTAL|tenecteplase ( 0.25 mg/kg, Max 25 mg )|Tenecteplase (0.25 mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.
62284224|NCT05141305|ACTIVE_COMPARATOR|standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of local investigators.
62284225|NCT01556984||DSA group|
62284226|NCT01556984||control group|
62284227|NCT06547983|NO_INTERVENTION|Control group|
62284228|NCT06547983|EXPERIMENTAL|Intervention group|
62284229|NCT06547983|EXPERIMENTAL|Intervention plus group|
62284230|NCT01691469|EXPERIMENTAL|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
62284231|NCT01691469|ACTIVE_COMPARATOR|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp \& Dohme Ltd., USA
62284232|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.~No interventions."
62651257|NCT04059952||Bipolar Depression|Patients diagnosed with Bipolar I or II.
62651258|NCT04059952||Healthy Control|Patients without psychiatric diagnoses.
62651259|NCT00726245|EXPERIMENTAL|1|PRGF
62651260|NCT00726245|PLACEBO_COMPARATOR|2|physiological saline
62651261|NCT05230836|EXPERIMENTAL|30 kilohertz|Alternating current stimulation at 30 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
62651262|NCT05230836|EXPERIMENTAL|40 kilohertz|Alternating current stimulation at 40 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
62651263|NCT05230836|EXPERIMENTAL|50 kilohertz|Alternating current stimulation at 50 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
62284233|NCT00135304|EXPERIMENTAL|Cinacalcet and low-dose Vitamin D|Cinacalcet and low-dose IV Vitamin D
62284234|NCT00135304|ACTIVE_COMPARATOR|Vitamin D alone|Escalating doses of IV Vitamin D alone
62284235|NCT00760409||Radiation Injury|Radiation Injury Recurrent symptoms after radiation therapy of a brain tumor are not always the result of tumor recurrence but may represent radiation necrosis of the brain.
62284236|NCT00760409||Tumor Recurrence|Symptoms are the result of actual tumor recurrence
62284237|NCT02720757||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
62651264|NCT05230836|SHAM_COMPARATOR|Sham stimulation|Sham stimulation via transcutaneous, 15 minutes each intervention, following the same procedures as 30, 40 and 50kHz HFAC groups.
62651265|NCT04772443|EXPERIMENTAL|DWJ1506|
62651266|NCT04772443|EXPERIMENTAL|DWJ1507|
62651267|NCT04772443|ACTIVE_COMPARATOR|DWC202011|
62651268|NCT04772443|ACTIVE_COMPARATOR|DWJ1177|
62651269|NCT02696616|EXPERIMENTAL|BI 655088|
62651270|NCT02696616|PLACEBO_COMPARATOR|Placebo|
62651271|NCT00091078|EXPERIMENTAL|Treatment (oblimersen sodium and imatinib mesylate)|Patients receive oblimersen IV continuously on days 1-14. Patients also receive oral imatinib mesylate on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62651272|NCT00587665|EXPERIMENTAL|1|Low dose ketamine given
62651273|NCT00587665|PLACEBO_COMPARATOR|2|Saline given as control
62651274|NCT01391806||Breast cancer|Patients selected for breast-conserving surgery based on conventional radiological methods, following the criteria recommended by the Norwegian Breast Cancer Group
62284238|NCT05610371|EXPERIMENTAL|Lidocaine The study group|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml.
62284239|NCT05610371|PLACEBO_COMPARATOR|Saline The control group|The control group underwent hysteroscopy using a saline distension medium.
62284240|NCT05764967|EXPERIMENTAL|Low Dye Taping|One Arm will be given Low Dye taping. The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive will be used for all of the taping procedures. Prior to application of the tape, any hair in the region will be shaved and the foot and leg will be washed with soap and warm water to remove any dirt or oils that might decrease the adhesion of the tape. The Transverse Tibial Rotation (TTR) measurements will be repeated following application of tape.
62284241|NCT05764967|ACTIVE_COMPARATOR|Temporary Felt Insoles|other will be given temporary shoe insoles. A temporary orthosis will be fabricated from 7-mm orthopedic felt. The orthosis consist of two parts, a medial longitudinal buttress and a navicular/sustentaculum tali pad. The medial longitudinal buttress will extend from the posterior calcaneus to the first metatarsal head and from the medial border of the foot to the bisection of the calcaneus and calcaneal recess will be cut out. A navicular/sustentaculum tali pad will extend from the sustentaculum tali to the cuneiform.
62284242|NCT02758535|EXPERIMENTAL|Core needle biopsy with coaxial method|The patients undergo renal biopsy with a coaxial Tru-Cut needle
62284243|NCT02758535|EXPERIMENTAL|Core needle biopsy with noncoaxial method|The patients undergo renal biopsy with a noncoaxial Tru-Cut needle
62284244|NCT03881007|EXPERIMENTAL|LCM, then placebo|Mouthwash with LCM for 3 months followed by mouthwash with placebo for 3 months.
62284245|NCT03881007|EXPERIMENTAL|Placebo, then LCM|Mouthwash with placebo for 3 months followed by mouthwash with LCM for 3 months
62284246|NCT01931761|EXPERIMENTAL|[C14] selumetinib 75mg single dose|\[C14\] selumetinib 75mg single dose
62284247|NCT01214044|EXPERIMENTAL|Study Drug|Subjects will have a total of 12 visits to Oregon Clinical \& Translational Research Institute at Oregon Health \& Science University over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.
62284248|NCT00809731||Observational Group|All commercially available 2nd-generation antipsychotic with an indication of treating schizophrenia will be prescribed by the physician according to normal practices
62284249|NCT00713219|EXPERIMENTAL|1|CHEMORADIATION
62284250|NCT02549716|EXPERIMENTAL|IV acetaminophen + oral placebo|Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
62284251|NCT02549716|EXPERIMENTAL|Oral acetaminophen + IV placebo|Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.
62085156|NCT06082128|EXPERIMENTAL|FOCUSau|Dyads in the FOCUSau arm will receive the web-based FOCUSau program in addition to usual care.
62085157|NCT00510796||High Risk Group|Colon and/or Endometrial Cancer
62085158|NCT05188365|ACTIVE_COMPARATOR|group A|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
62651275|NCT03934775||Patients with acute illness|Patients admitted to the acute medical/emergency department and/or Cardiology department at Bispebjerg Hospital.
62651276|NCT05407883|EXPERIMENTAL|Intervention-School traffic warden programme|"The intervention will address multiple risk factors related to behaviour through placing traffic wardens at school crossing points. The assumption is that school traffic wardens situated at safe crossing points will increase yield rates of drivers to pedestrians and reduce the risk of pedestrian motor-vehicle collision. They will be placed at safe locations. Visibility and safety at pedestrian crossings will be enhanced by one trained school traffic warden placed a designated safe crossing point. The school traffic warden will assist pupils in crossing at all times during peak hours i.e. 6:00am-8:00am; 01:00pm-02:00pm; 03:00-07:00pm. In total, 11 school traffic wardens will under-go a 3 day road safety training prior to the start of the study. A similar follow up training will be conducted after 3 months and these will be motivated with non-monetary incentives e.g. high visibility jackets and a lollipop stop sign."
62651277|NCT05407883|NO_INTERVENTION|Control-road safety manuals|The control schools will receive road safety manuals and leaflets developed by the Uganda Red Cross Society and the Uganda National Curriculum Development Centre.
62085159|NCT05188365|SHAM_COMPARATOR|Group B|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days.
62651278|NCT00519350||I|Liver surgery
62651279|NCT00519350||II|Colon surgery
62651280|NCT00519350||III|Femur Fracture
62651281|NCT06524258|OTHER|tese positive|micro tese positive
62651282|NCT06524258|OTHER|tese negative|micro tese negative
62651283|NCT02767531|EXPERIMENTAL|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
62651284|NCT02767531|NO_INTERVENTION|Off drug|Standard therapy will be given for three months
62651285|NCT02057341|EXPERIMENTAL|ARRY-371797 (Dose 1)|
62651286|NCT02057341|EXPERIMENTAL|ARRY-371797 (Dose 2)|
62284252|NCT02932787|EXPERIMENTAL|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
62284253|NCT02932787|NO_INTERVENTION|Control|
62651287|NCT05184855|EXPERIMENTAL|Blueberry|26 g freeze-dried blueberry powder per day or approximately one cup fresh blueberries equivalent; two weeks intake.
62284254|NCT02185937|NO_INTERVENTION|water|imatinib intake with water
62284255|NCT02185937|ACTIVE_COMPARATOR|cola|imatinib intake with cola
62284256|NCT02118376|EXPERIMENTAL|exenatide|exenatide, 5ug, bid, 3months
62284257|NCT05772897|EXPERIMENTAL|Circle of Security Parenting (COSP) group|This group of mothers will be assigned to begin the parenting skills intervention (COSP) group soon after enrollment, and data collection (developmental testing, buccal swabs, play-based assessment, questionnaires) will proceed as planned. COSP groups will be conducted remotely via Zoom.
62284258|NCT05772897|NO_INTERVENTION|Waitlist Control Group|This group of mothers will be assigned to a waitlist control group and will be scheduled to begin the parenting skills group at a later time. In order to serve as a no-intervention control, they will be administered assessments while on the waiting list. These assessments will be given concurrently with mid-point assessment of the intervention group.
62284259|NCT01656772|ACTIVE_COMPARATOR|Manual Lasso navigation|Use of conventional manual navigation techniques with the Lasso catheter
62284260|NCT01656772|EXPERIMENTAL|Vdrive Lasso navigation|Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter
62284261|NCT01417845|EXPERIMENTAL|High Intensity Exercise|High intensity resistance and aerobic training
62284262|NCT01417845|ACTIVE_COMPARATOR|Moderate Intensity Exercise|Moderate intensity resistance and aerobic training
62284263|NCT06217120|ACTIVE_COMPARATOR|COLCHICINE|
62284264|NCT06217120|PLACEBO_COMPARATOR|PLACEBO|
62284265|NCT00705263||Patients with chronic hepatitis C|Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
62651288|NCT05184855|PLACEBO_COMPARATOR|Placebo|26 g placebo powder per day matched for color, taste, aroma; two weeks intake.
62651289|NCT05127460|EXPERIMENTAL|Intervention|Patients randomized to intervention will have access to the screening tool.
62651290|NCT05127460|NO_INTERVENTION|Control|Patients randomized to control will continue routine practice.
62651291|NCT05503498||AFIBRINOGENEMIA, CIRRHOSIS, TRAUMATICS|PATIENTS WITH CONGENIAL AFIBRINOGENEMIA:RECORD OF PLASMA FIBRINOGEN LEVEL PATIENTS WITH ADQUIRED CRONIC HIPOFIBRINOGENEMIA AND END STAGE OF THE LIVER DISEASE: RECORD OF PLASMA FIBRINOGEN LEVEL PATIENTS WITH ADQUIRED ACUTE HIPOFIBRINOGENEMIA AND ACUTE TRAUMA: RECORD OF PLASMA FIBRINOGEN LEVEL
62284266|NCT02656628||Fractures of humerus femur tibia|Dynamic Locking Screw 3.7mm and 5.0mm
62651292|NCT03913247||Group with different size measures|Each patient included in the study will have different measure of size.
62651293|NCT06525792|ACTIVE_COMPARATOR|Control group|Standard treatment
62651294|NCT06525792|EXPERIMENTAL|Experimental group 1|
62651295|NCT06525792|EXPERIMENTAL|Experimental group 2|
62651296|NCT03786640||Single Arm|Patients implanted with an SJM Tendril STS 2088 or Isoflex 1944/1948 lead, together with an Assurity MRI or Endurity MRI pacemaker, and who will undergo a 3T MRI scan are eligible to participate in this study.
62651297|NCT00407511|EXPERIMENTAL|Pregabalin|
62284267|NCT04259853|EXPERIMENTAL|QFR-guided PCI group|QFR-guided revascularization on non-culprit vessels in patients with STEMI
62284268|NCT04259853|ACTIVE_COMPARATOR|CAG-guided PCI group|CAG-guided revascularization on non-culprit vessels in patients with STEMI
62284269|NCT04786067|EXPERIMENTAL|Immunosuppression Taper|Patients included in this arm are kidney transplant recipients with stable kidney function currently on or are converting to a Belatacept based immunosuppression regimen. Eligible patients who are deemed immune quiescent after a 3 month monitoring period will undergo sequential withdrawal of immunosuppression medications over a 12 month period from a three drug regimen to a Belatacept only immunosuppression regimen. During the total 15 month period patients will be monitored with monthly clinic visits, blood draws for routine monitoring as well as donor derived cell free DNA and genetic testing through KidneyCare to monitor immune suppression.
62284270|NCT02920788|EXPERIMENTAL|Veteran Mild TBI Group - GOALS Intervention|Veterans ages 18+ with chronic mild TBI, to undergo GOALS cognitive training as an intervention.
62284271|NCT02920788|ACTIVE_COMPARATOR|Veteran Mild TBI - Treatment as Usual|Veterans ages 18+ with chronic mild TBI, matched by demographic and clinical criteria to the GOALS group, to receive the standard clinical care.
62284272|NCT02920788|NO_INTERVENTION|Veteran Non TBI - No Treatment|Veterans ages 18+ with no history of TBI, to undergo Neuropsychologic evaluation and MR Imaging with no intervention.
62284273|NCT00332709|EXPERIMENTAL|Letrozole|Letrozole orally 2.5 mg/day for 3 years
62284274|NCT00332709|EXPERIMENTAL|Letrozole + Zoledronic Acid|Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
62284275|NCT00997009|EXPERIMENTAL|Arm A|chemotherapy plus cetuximab
62284276|NCT00997009|ACTIVE_COMPARATOR|Arm B|chemotherapy
62284277|NCT02382133|OTHER|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
62651298|NCT05413044||Abatacept Group|Participants with established RA or PsA and receiving abatacept.
62651299|NCT05413044||Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group|Participants with established RA or PsA and not previously treated with any targeted DMARDs and who start treatment with a non-targeted DMARD.
62651300|NCT05413044||Targeted DMARD Group|Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs.
62651301|NCT04394325|EXPERIMENTAL|Group A) Intervention group|Group A) an intervention group (n=80) who will receive the standard care and information (oral and written) + the digital information tool.
62651302|NCT04394325|NO_INTERVENTION|Group B) Control group|Group B) a control group (n=80) who will receive standard care and information (oral and written).
62085160|NCT06314191|EXPERIMENTAL|arthrose group|
62284278|NCT04074772||Healthy Controls|This group will consist of healthy controls between the ages of 18 and 70-years-old. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be used to train a neural network to identify points of interest in a generalized patient population.
62651303|NCT04443192|ACTIVE_COMPARATOR|Part A Cohort 1 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 1
62651304|NCT04443192|PLACEBO_COMPARATOR|Part A - Placebo to ZF874 - Single Dose|Single oral dose of placebo by mouth in the fasted state
62651305|NCT04443192|ACTIVE_COMPARATOR|Part A Cohort 2 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 2
62284279|NCT04074772||Movement Disorder Patients|This group will consist of movement disorder clinic patients between the ages of 18 and 70-years-old with a diagnosed or putative movement disorder. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
62085161|NCT06314191|ACTIVE_COMPARATOR|controle group|
62085162|NCT04669080|OTHER|Cost navigation training intervention|
62085163|NCT00876122|EXPERIMENTAL|1|
62085164|NCT04179994|EXPERIMENTAL|Miswak extract-containing toothpaste group|Test group.
62085165|NCT04179994|ACTIVE_COMPARATOR|Toothpaste containing Potassium Nitrates|Positive control.
62085166|NCT04179994|PLACEBO_COMPARATOR|Placebo group|Toothpaste contains same ingredients of test group except for the active ingredient as negative control.
62085167|NCT03890120|EXPERIMENTAL|Cilofexor 100 mg (Blinded Phase)|Participants received cilofexor 100 mg tablet, orally, once daily for up to 100.3 weeks.
62284280|NCT04074772||Age-Matched Controls|This group will consist of relatives of movement disorder clinic patients that are visiting with them to serve as age-matched controls (within 10 years of patient's age). Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
62651306|NCT04443192|ACTIVE_COMPARATOR|Part A Cohort 3 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 3
62085168|NCT03890120|PLACEBO_COMPARATOR|Placebo (Blinded Phase)|Participants received placebo to match cilofexor 100 mg tablet, orally, once daily for up to 98.1 weeks.
62085169|NCT03890120|EXPERIMENTAL|Cilofexor From Cilofexor 100 mg (OLE Phase)|Participants who received cilofexor in blinded phase and had entered the open-label extension (OLE) phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 44.7 weeks.
62085170|NCT03890120|EXPERIMENTAL|Cilofexor From Placebo (OLE Phase)|Participants who received placebo in blinded phase and had entered the OLE phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 45.0 weeks.
62085171|NCT03699046|ACTIVE_COMPARATOR|Subchondroplasty and Knee Arthroscopy|Patients randomized to the Subchondroplasty and Knee Arthroscopy group will receive the subchondroplasty procedure before or after knee arthroscopy that will be completed based on current standard of care guidelines.
62284281|NCT00565994||Hemodialysis patients|Male and female patients undergoing hemodialysis therapy as outpatients
62085172|NCT03699046|SHAM_COMPARATOR|Knee Arthroscopy Alone|Patients randomized to the Knee Arthroscopy Alone group will receive the knee arthroscopy that will be completed based on current standard of care guidelines.
62284282|NCT00565994||Control|Male and female healthy volunteers
62284283|NCT00565994||Pre-dialysis patients|Male and female patients with Stage 3, 4, or 5 chronic kidney disease, but not yet on dialysis
62284284|NCT04399083|EXPERIMENTAL|Single Arm|
62284285|NCT02468648|EXPERIMENTAL|Combination of sofosbuvir and GS-5816|Combination of sofosbuvir and GS-5816 agent into a single pill will be used.
62284286|NCT03830216|EXPERIMENTAL|Treatment Arm|Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
62284287|NCT03830216|SHAM_COMPARATOR|Control Arm|Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.
62651307|NCT04443192|ACTIVE_COMPARATOR|Part A Cohort 4 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 4
62651308|NCT04443192|PLACEBO_COMPARATOR|Part A - Placebo to ZF874 - Two Doses|Two doses of placebo (12 h apart) by mouth in the fasted state
62651309|NCT04443192|ACTIVE_COMPARATOR|Part A Cohort 5 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 5
62085173|NCT02145481|NO_INTERVENTION|Survey development|Patients with coronary artery disease will be given a survey to complete assessing their knowledge, communication with physicians, involvement, and treatment preferences after completing the treatment decision-making process.
62085174|NCT02145481|EXPERIMENTAL|Decision Aid|Patients with stable coronary artery disease will be given a decision aid to review prior to making a treatment decision.
62085175|NCT02145481|ACTIVE_COMPARATOR|CAD Education|Patient with coronary artery disease will be given a general educational handout on coronary artery disease.
62085176|NCT03386760|EXPERIMENTAL|A- Ultra-Speed Picosecond laser|Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
62085177|NCT03386760|ACTIVE_COMPARATOR|B- Nanosecond laser|Utilisation of Nanosecond laser for tattoo depigmentation
62651310|NCT04443192|ACTIVE_COMPARATOR|Part A Cohort 6 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 6
62085178|NCT01203241|ACTIVE_COMPARATOR|Conventional ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
62085179|NCT01203241|ACTIVE_COMPARATOR|Conventional ablation plus left atrial roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
62085180|NCT03688789|EXPERIMENTAL|Hydrocortisone supplementation|
62085181|NCT02460471|EXPERIMENTAL|palliative radiation therapy|25 Gy in 5 daily fractions
62085182|NCT06479473|ACTIVE_COMPARATOR|Chemoimmunotherapy group|Patients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of standard chemoimmunotherapy followed by immunotherapy maintenance to 2 years.
62085183|NCT06479473|EXPERIMENTAL|Chemoimmunotherapy with radiotherapy group|Patients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of standard chemoimmunotherapy followed by radiotherapy to all residual lesions and immunotherapy maintenance to 2 years.
62085184|NCT04793464|EXPERIMENTAL|Promotores|The Promotores de Salud intervention involves specified outreach and psychoeducation on SARS-CoV-2 health related behaviors.
62085185|NCT04793464|ACTIVE_COMPARATOR|Control|Services as usual includes outreach as usual strategies and pamphlets on site at events.
62085186|NCT04562506|ACTIVE_COMPARATOR|Real rTMS stimulation|real deep excitatory, high frequency rTMS with H-coil stimulation
62085187|NCT04562506|SHAM_COMPARATOR|Sham rTMS stimulation|sham high frequency H-coil stimulation
62651311|NCT04443192|ACTIVE_COMPARATOR|Part A Cohort 7 - ZF874 - Single Dose|Single oral dose of ZF874 by mouth after consuming a high-fat breakfast. Dose Level 3
62085188|NCT01762163|EXPERIMENTAL|Qizhitongluo Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.~intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks."
62085189|NCT01762163|ACTIVE_COMPARATOR|Naoxintong Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.~intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks."
62085190|NCT01762163|PLACEBO_COMPARATOR|Placebo|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.~intervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks."
62085191|NCT02435511|NO_INTERVENTION|Control arm|The control group will receive usual care, no HealtheRx.
62085192|NCT02435511|EXPERIMENTAL|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
62085193|NCT05721339|EXPERIMENTAL|Acceptance and commitment therapy|Intern nurses will participate in acceptance and commitment therapy through virtual group-based eight sessions twice weekly with homework assignments between sessions and skills demonstration.
62085194|NCT05721339|NO_INTERVENTION|control group|Intern nurses who will not participate in acceptance and commitment therapy. And they are undergoing the pre-and post-tests and the post-test follow-up test.
62085195|NCT01637493|EXPERIMENTAL|Pegfilgrastim, 30mcg/kg|
62085196|NCT01637493|EXPERIMENTAL|Pegfilgrastim, 60mcg/kg|
62085197|NCT01637493|EXPERIMENTAL|Pegfilgrastim, 100mcg/kg|
62085198|NCT01637493|EXPERIMENTAL|Pegfilgrastim, 200mcg/kg|
62085199|NCT04378634|EXPERIMENTAL|ME/CFS Exercise|Patients undergoing the physical stress test (aerobic power index)
62085200|NCT04378634|EXPERIMENTAL|Patients Stress|Patients undergoing the mental stress task (MIST)
62085201|NCT04378634|ACTIVE_COMPARATOR|Healthy Exercise|Healthy controls undergoing the physical stress test (aerobic power index)
62085202|NCT04378634|ACTIVE_COMPARATOR|Healthy Stress|Healthy controls undergoing the mental stress task (MIST)
62085203|NCT03717675|EXPERIMENTAL|Interventional|Interventional arm, where the NovaCross™ CTO micro-catheter will be placed in study subjects during the Total Occlusion opening procedure.
62459960|NCT04792944||External ventricular drain only with neither embolization nor clipping|These patients will be treated with an external ventricular drain only with neither embolization nor clipping
62085204|NCT03434535|EXPERIMENTAL|Intervention|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months. They will also receive an activity sensor and weight scale. Health state data from this group will be generated over a 3-6 month period and remotely monitored. These data will be used to provide personalized feedback regarding the participant's progress towards established goals.
62085205|NCT03434535|NO_INTERVENTION|Control|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months.
62085206|NCT02959138|EXPERIMENTAL|Moderate Renal Impairment (Cohort 1)|Participants with moderate renal impairment and matched healthy controls will receive a single dose of lanraplenib
62085207|NCT02959138|EXPERIMENTAL|Severe Renal Impairment (Adaptive Cohort 2)|Participants with severe renal impairment and matched healthy controls will receive a single dose of lanraplenib
62085208|NCT02959138|EXPERIMENTAL|Mild Renal Impairment (Adaptive Cohort 3)|Participants with mild renal impairment and matched healthy controls will receive a single dose of lanraplenib
62085209|NCT04997967|EXPERIMENTAL|Ketofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Will receive Ketofol (ketamine: propofol concentration 1:4) prepared in 50 ml syringe containing dextrose 5% (each ml contained 8 mg propofol and 2 mg ketamine), administered as following; 5 ml of ketofol as loading then infusion titrated till targeted RSS score.
62085210|NCT04997967|ACTIVE_COMPARATOR|Propofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
62085211|NCT03088137|EXPERIMENTAL|Primapur (Follitropin alfa)|
62459961|NCT04792944||Embolization|These patients will be treated endovascularly
62459962|NCT04792944||Programmed surgical clipping|These patients will be treated no on an emergency basis with surgical clipping of an aneurysm that has bled
62459963|NCT04792944||Emergency surgical clipping with cisternal urokinase administration|These patients with undergo emergency surgical clipping with cisternal urokinase administration
62459964|NCT04792944||Patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping|This group will include patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping
62284288|NCT04957381||low to moderate CRF with low MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and low muscular fitness (MF).
62284289|NCT04957381||low to moderate CRF with moderate MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and moderate muscular fitness (MF).
62284290|NCT04957381||low to moderate CRF with high MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and high muscular fitness (MF).
62284291|NCT04957381||high CRF with low to moderate MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and low to moderate muscular fitness (MF).
62284292|NCT04957381||high CRF and high MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and high muscular fitness (MF).
62284293|NCT00783393|EXPERIMENTAL|Single arm|"The study consists of two steps:~* Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and~* Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1."
62085212|NCT03088137|ACTIVE_COMPARATOR|Gonal-f (Follitropin alfa)|
62085213|NCT02342587|EXPERIMENTAL|single arm|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
62284294|NCT05100641|EXPERIMENTAL|AV-GBM-1|Autologous dendritic cells loaded with autologous tumor antigens cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
62284295|NCT05100641|PLACEBO_COMPARATOR|Autologous monocyte control (MC)|Autologous monocytes cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
62284296|NCT04947527|EXPERIMENTAL|Test Varnish|Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.
62284297|NCT04947527|ACTIVE_COMPARATOR|Control Varnish|Control Varnish. 5% (w/v) Sodium Fluoride .
62284298|NCT01037673|EXPERIMENTAL|PT progressive exercises|A progressive program of movement and strength exercises for the rotator cuff and scapular muscles combined with mobilisation of the joint capsule when needed
62284299|NCT01037673|ACTIVE_COMPARATOR|Movement exercises neck and shoulder|General movements for the neck and shoulder,
62284300|NCT01543347|EXPERIMENTAL|Temocillin|Treatment group
62284301|NCT01535079|PLACEBO_COMPARATOR|Placebo|
62284302|NCT01535079|EXPERIMENTAL|V0498TA01A 15 mg|
62284303|NCT01535079|EXPERIMENTAL|V0498TA01A 25 mg|
62284304|NCT01535079|EXPERIMENTAL|V0498TA01A 35 mg|
62284305|NCT01535079|OTHER|Strefen|Positive control
62284306|NCT06341673|ACTIVE_COMPARATOR|Active arm: Transcutaneous Electrical Nerve Stimulation- Transcutaneous Tibial Nerve Stimulation|Participants will useTENS to stimulate tibial nerve on the medial side of the foot for 6 weeks, a total of 18 sessions, three times weekly for 30 minutes per session. All TENS units will be programmed and locked by principal investigator to ensure fixed stimulation parameters are used among participants throughout the study intervention. The stimulation frequency will be set at 10 Hz with a pulse duration 200 μs. Participants will be advised to apply the stimulation in a supine position or supported sitting with extended legs to avoid compression of nerve roots at the knee joint. Participants will place the stimulation electrode, the negative electrode, between 5 and 10 cm above the medial malleolus and the positive electrode behind the left medial malleolus.
62284307|NCT06341673|SHAM_COMPARATOR|Sham arm: Transcutaneous Electrical Nerve Stimulation|Participants randomized to the sham group, will place the TENS on the lateral side of the foot, the negative electrode on the top of the foot just above the small toe for conduction and the positive electrode on the bottom of below the smallest toe to avoid the tibial nerve and relevant cutaneous nerves. The location of conduction electrode was chosen since this location is proved to be away from bladder, pelvic, or major organ nerve acupuncture pathway. Participants will be instructed to raise up the intensity until the first and slight tingling sensation on the sole of the foot or toe. The stimulation will be used for 6 weeks, a total of 18 sessions, three times weekly for 30 minutes per session.
62284308|NCT02078531||Chemotherapy and anti-hormonal therapy|"1. cognitive assessment using CANTAB~2. Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
62284309|NCT02078531||chemotherapy only and healthy control group|"1. cognitive assessment using CANTAB~2. Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
62284310|NCT01961479|EXPERIMENTAL|Internet-based CBT for patients with PMS|The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
62284311|NCT01961479|OTHER|waiting list|During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
62284312|NCT04373460|EXPERIMENTAL|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
62284313|NCT04373460|ACTIVE_COMPARATOR|Standard Control plasma|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
62284314|NCT04999579|ACTIVE_COMPARATOR|Complete denture|Conventional complete denture without supporting devices
62284315|NCT04999579|EXPERIMENTAL|Ultra suction retained complete denture|Conventional complete denture with ultra suction device
62284316|NCT02808390|EXPERIMENTAL|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
62284317|NCT02808390|EXPERIMENTAL|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
62284318|NCT02808390|EXPERIMENTAL|Placebo|Placebo BID for 8 Weeks
62459965|NCT05589415|EXPERIMENTAL|High Definition tDCS and rehabilitation|"10 sessions (2 hours/session) will be completed with high definition tDCS and upper limb rehabilitation.~Two times prior and two times after rehabilitation, upper limb weakness and neurophysiology will be assessed."
62651312|NCT04443192|ACTIVE_COMPARATOR|Part B Cohort 1 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
62651313|NCT04443192|PLACEBO_COMPARATOR|Part B Cohort 1 - Placebo to ZF874|Two doses of placebo (12 h apart) by mouth daily for 28 days.
62085214|NCT05174650|EXPERIMENTAL|Combined treatment with Atezolizumab and Derazantinib|Treatment with Atezolizumab 1200 mg i.v. every 3 weeks and Derazantinib 300 mp p.o. once daily for a maximum of 60 weeks or until disease progression or unacceptable toxicity or study termination
62085215|NCT04647019|EXPERIMENTAL|Blueberry powder|
62085216|NCT04647019|EXPERIMENTAL|Placebo powder|
62085217|NCT05587387||Cohort 1|Without Nal-IRI/FL; From Jan. 2012 to Jan. 2018 (Before launch of nal-IRI)
62085218|NCT05587387||Cohort 2|With Nal-IRI/FL; From Jan. 2018 to Dec. 2021 (After launch of nal-IRI)
62085219|NCT02873299|NO_INTERVENTION|Treatment as usual|Treatment as usual, wait list control group
62085220|NCT02873299|ACTIVE_COMPARATOR|rTMS at 10Hz|10 Hz rTMS of the right dorsolateral prefrontal cortex
62085221|NCT02873299|ACTIVE_COMPARATOR|rTMS at 20Hz|20 Hz rTMS of the right dorsolateral prefrontal cortex
62085222|NCT00884286|EXPERIMENTAL|Arm One|Aplidin® given as a 1-hour weekly IV infusion
62085223|NCT05424861|ACTIVE_COMPARATOR|Acupressure group|Postpartum 6-24 days in the acupressure group. Acupressure will be applied 1 time just before breastfeeding between hours. The visual analog scale, in which the introductory information form is filled by the researcher and the pain score is evaluated, will be marked by the participant once before breastfeeding, once at the 10th minute of breastfeeding, and once at the 20th minute, in total 3 times.
62085224|NCT05424861|ACTIVE_COMPARATOR|Control group|Postpartum 6-24 days in the control group. Introductory information form will be filled by the researcher between hours. The visual analog scale, in which the pain score is evaluated, will be marked by the participant for a total of 3 times, once just before breastfeeding, once at the 10th minute of breastfeeding, and once at the 20th minute.
62085225|NCT02420327|EXPERIMENTAL|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
62085226|NCT02420327|EXPERIMENTAL|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
62085227|NCT02420327|EXPERIMENTAL|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
62085228|NCT02420327|EXPERIMENTAL|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
62085229|NCT03903146|EXPERIMENTAL|Intervention Group|This group of participants was assigned to receive the intervention by the bicultural/bilingual team of Peer counselor and Lactation Consultant. An intensive support intervention (1 prenatal visit, 1 in-hospital visit, 1 home postpartum visit, and free phone calls) were conducted individually to mothers participating until 6 months after the birth of the infant.
62085230|NCT03903146|NO_INTERVENTION|Control Group|All participants in this group received traditional prenatal care in the clinic and received the usual educational material (in their proficient language) about breastfeeding during prenatal care provided by the Special Supplemental Nutritional for Women, Infants, and Children (WIC) program implemented in the clinics. Women were also able to receive one breastfeeding consultation during their hospital stay in the birthing center as part of the actual protocol established in the UK Chandler Hospital (Baby-friendly Hospital that includes support of breastfeeding during hospital stay). Women in the usual care group did not have any contact with the study IBCLC/PC.
62461826|NCT05267236|EXPERIMENTAL|Treatment-On Demand Format|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
62651314|NCT04443192|ACTIVE_COMPARATOR|Part B Cohort 2 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
62085231|NCT01307852|EXPERIMENTAL|In Vivo Dosimetry|Modified endorectal device capable of real-time dose measurement during prostate radiation therapy
62284319|NCT05042427||primigravida women|Weight management health literacy of primigravida women.
62651315|NCT04443192|ACTIVE_COMPARATOR|Part B Cohort 3 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
62651316|NCT04443192|ACTIVE_COMPARATOR|Part B Cohort 4 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
62284320|NCT05281263|EXPERIMENTAL|Group 1, young adult cohort (age 18-59)|BLB-201 administered as a single dose of 10\^7.5 PFU by intranasal route on Day 1
62284321|NCT05281263|EXPERIMENTAL|Group 2, older adult cohort (age 60-75)|BLB-201 administered as a single dose of 10\^7.5 PFU by intranasal route on Day 1
62284322|NCT05300945|NO_INTERVENTION|Control|
62284323|NCT05300945|EXPERIMENTAL|HIPEC|
62284324|NCT00483860|EXPERIMENTAL|Topotecan|once a day
62651317|NCT04447729|EXPERIMENTAL|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
62459966|NCT05589415|ACTIVE_COMPARATOR|Conventional tDCS and rehabilitation|"10 sessions (2 hours/session) will be completed with conventional tDCS and upper limb rehabilitation.~Two times prior and two times after rehabilitation, upper limb weakness and neurophysiology will be assessed."
62085232|NCT04179461|EXPERIMENTAL|Personalized Treatment|"Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention."
62284325|NCT05281874|PLACEBO_COMPARATOR|Control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
62085233|NCT04437771||Subjects with Fanconi Anaemia Subtype A (FA-A)|Subjects treated with ex vivo lentiviral gene therapy product in FANCOLEN-I trial and agree to participate in this long-term follow-up (LTFU) study
62085234|NCT00531011|ACTIVE_COMPARATOR|XIENCE V|Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)
62284326|NCT05281874|EXPERIMENTAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
62284327|NCT05281874|EXPERIMENTAL|Positive Change (+Change) Plus Booster|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation. It is provided at baseline and a booster at 6 months.
62651318|NCT05822466|ACTIVE_COMPARATOR|Virtual tai ji quan|Participants participating are intervened with practice and drills of tai ji quan forms and associated movements. Training focuses on lower-extremity strength, postural control, and mobility, with an emphasis on weight bearing and weight shifting, extending and controlling the body's center of mass over its base of support; self-induced movement perturbation; gait preparation, initiation, locomotion, and termination; and sensory integration. The exercise training also emphasizes connecting tai ji quan forms to transitional movements that are associated with performing daily activities. Each session includes brief movement-based warm-ups and light breathing cool-down exercises.
62085235|NCT00531011|ACTIVE_COMPARATOR|TAXUS® Liberté™|Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
62085236|NCT04822636|EXPERIMENTAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
62085237|NCT01667120|PLACEBO_COMPARATOR|Placebo|Postoperative surgical neonates will receive an equivalent volume of 0.9% normal saline as placebo.
62284328|NCT04861220|EXPERIMENTAL|Pre-habilitation group + neoadjuvant treatment|The patients in the Pre-habilitation group + neoadjuvant treatment (Group A), will undergo neoadjuvant cancer therapy and be instructed to practice physical exercises at home 03 times a week, during neoadjuvant therapy, until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
62284329|NCT04861220|EXPERIMENTAL|Prehabilitation Program + immediate surgical treatment|The patients in the Pre-habilitation group + immediate surgical treatment (Group B), will be instructed to practice physical exercises at home 03 times a week until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
62459967|NCT05642494|EXPERIMENTAL|SDF+NaF|Silver Diamine fluoride 38% (Applied biannually)+ Sodium Fluoride Varnish 5% (Applied every 3 months)
62459968|NCT05642494|ACTIVE_COMPARATOR|SDF|Silver Diamine fluoride 38% (Applied biannually)
62459969|NCT05552781|EXPERIMENTAL|20 mg QD, oral|H002 20mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62459970|NCT05552781|EXPERIMENTAL|40 mg QD, oral|H002 40mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62085238|NCT01667120|EXPERIMENTAL|Ketorolac|Postoperative ketorolac 0.5mg/kg intravenously every 8 hrs for 72hrs will be administered.
62085239|NCT00951860||Newborn|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the hospital neonatal unit at the time of registration (after 37 weeks corrected for prematurity) or in the maternity
62085240|NCT02781506|EXPERIMENTAL|Nivolumab and SABR|Nivolumab alone: IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity. SABR, dose variable, in 1-3 fractions.
62085241|NCT05122754|EXPERIMENTAL|B/F/TAF group|Bictegravir/emtricitabine/tenofovir alafenamide for 48 weeks.
62085242|NCT05122754|ACTIVE_COMPARATOR|TDF-based triple ART regimen switching to B/F/TAF|TDF-based triple ART regimen for 24 weeks, and all switch to bictegravir/emtricitabine/tenofovir alafenamide for the later 24 weeks.
62085243|NCT03169179|EXPERIMENTAL|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
62653098|NCT02603900|EXPERIMENTAL|Local Infiltration of Analgesia|Local infiltration using 20 ml of free bupivacaine solution (Marcaine 0.25% with epinephrine 1:200000, ) diluted with 40 ml of normal saline following implantation of the knee prosthesis, the solution will be injected into the vastus medialis (5 ml), medial retinaculum (5 ml), origin of MCL (5 ml) and LCL (5 ml), lateral portion of quadriceps tendon (5 ml), vastus lateralis (5 ml), and subcutaneous tissues especially along saphenous nerve distribution (30 ml). Postoperatively, a sham adductor canal catheter will be placed as in the ACC arm following stabilization in the PACU to infuse only normal saline with an initial bolus of 15 ml saline and infusion of saline at 10ml/hr for 72 hours.
62085244|NCT01207934|PLACEBO_COMPARATOR|placebo|saline placebo for fourteen days
62085245|NCT01207934|EXPERIMENTAL|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
62085246|NCT01207934|EXPERIMENTAL|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
62085247|NCT05125692|OTHER|women with symptomatic post cesarean Istmocele|vaginal surgical repair of post cesarean symptomatic isthmocele using conventional low cost surgical techniques
62085248|NCT05500027||Pancreatic cancer|All TNM stages of pancreatic cancer, before/after surgery, before/after chemotherapy, before/after bile drainage
62085249|NCT05500027||Low malignant grade of pancreatic neoplasms|IPMN, MCN, PNEN, and SPN
62085250|NCT05500027||Pancreatitis|acute, chronic, and auto-immune pancreatitis
62085251|NCT05500027||Auto-immune diseases|SLE, RA, et al
62284330|NCT04861220|NO_INTERVENTION|Usual activities + neoadjuvant treatment|Patients allocated to this group (Group C) will not participate in the pre-habilitation program and will be instructed to continue their usual activities during the neoadjuvant cancer therapy, until the date of surgery.
62284331|NCT04861220|NO_INTERVENTION|Usual activities + immediate surgical treatment|Patients allocated to this group (Group D) will not participate in the pre-habilitation program and will be instructed to continue their usual activities until the date of surgery.
62284332|NCT03981432|EXPERIMENTAL|Constitutional leanness|Constitutional leanness
62459971|NCT05552781|EXPERIMENTAL|80 mg QD, oral|H002 80mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62459972|NCT05552781|EXPERIMENTAL|150 mg QD, ora|H002 150mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62085252|NCT05500027||Pancreatic-biliary infections|cholecystitis, cholangitis, et al
62085253|NCT03772106|EXPERIMENTAL|Group P|Group P : Propolipid 1% dose : variable to keep BIS between 40 and 60
62085254|NCT03772106|EXPERIMENTAL|Group S|Group S : Sevoflurane dose : variable to keep BIS between 40 and 60
62085255|NCT01800344|ACTIVE_COMPARATOR|The laryngeal mask airway-ClassicTM (LMA)|The LMA is a large foreign body that exerts pressure on the pharyngeal mucosa. High LMA intracuff pressures may reduce pharyngeal mucosal perfusion and lead to throat discomfort.
62085256|NCT01800344|ACTIVE_COMPARATOR|The AES Ultra CPVTM LMA (Ultra)|Ultra is a new supraglottic airway with anatomical features and insertion technique virtually identical to the LMA-ClassicTM. The cuff and the shaft are made of silicone with a built-in CPV pilot balloon valve which provides continuous monitoring of the intracuff pressure. The CPV cuff pressure indicator has 3 zones indicated by color: yellow corresponds to pressure \< 50 cm H2O; green 60 cm H2O; and red \>70 cm H2O
62085257|NCT03164733||<40|patients younger than 40 years
62459973|NCT05552781|EXPERIMENTAL|250 mg QD, oral|H002 250mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62459974|NCT05552781|EXPERIMENTAL|350 mg QD, oral|H002 350mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62461827|NCT05267236|EXPERIMENTAL|Control-Virtual or In-Person Format|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
62461828|NCT01056965|EXPERIMENTAL|davunetide (Al-108, NAP) nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with either davunetide 15 mg or placebo. Davunetide and placebo will be administered intranasally with a multi-dispensing, metered nasal spray pump device.
62461829|NCT01056965|PLACEBO_COMPARATOR|Placebo nasal spray|
62653099|NCT04730011|EXPERIMENTAL|Treatment Group|Patients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week.
62085258|NCT03164733||40-60|patients younger than 60 years and not older than 40 years
62085259|NCT03164733||60-80|patients younger than 80 years and not older than 80 years
62085260|NCT03164733||>80|patients older than 80 years
62085261|NCT03666065|ACTIVE_COMPARATOR|Aspart-U100 Insulin|Standard Concentration Rapid Acting Insulin
62085262|NCT03666065|EXPERIMENTAL|Aspart-U25 Insulin|Diluted Concentration of Rapid Acting Insulin
62085263|NCT03427086|ACTIVE_COMPARATOR|Interventional|Patient will received high dose of biotin (300 mg/day)
62085264|NCT03427086|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo
62085265|NCT05441358||Patients undergoing open heart surgery|"Subjects scheduled for elective cardiothoracic surgery requiring a sternotomy.~* Coronary artery bypass grafting (CABG)~* Combined CABG and valve surgery~* On-pump double or triple valve procedures~* Aortic surgery or redo surgery~* Off pump CABG as part of a hybrid revascularization approach"
62284333|NCT03981432|EXPERIMENTAL|Normal weight|Normal weight women
62284334|NCT03981432|EXPERIMENTAL|Anorexia nevrosa|women presenting Anorexia nevrosa
62085266|NCT05573919|EXPERIMENTAL|VivAer Patients|These patients will undergo the VivAer procedure, which involves the use of a stylus to deliver radiofrequency heating to the nasal sidewall to reshape the tissue. This will be done to resolve the patients' nasal obstruction. They will have PNIF measurements taken and will complete symptom assessment questionnaires before and after the VivAer procedure.
62085267|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
62085268|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
62085269|NCT01630031||Control group|Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.
62085270|NCT01630031||CF group|Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.
62085271|NCT01822028|PLACEBO_COMPARATOR|Treatment A|"Treatment A: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
62284335|NCT00110942|ACTIVE_COMPARATOR|Minor sub-study AMG 108|N = 15
62085272|NCT01822028|EXPERIMENTAL|Treatment B|"Treatment B: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
62085273|NCT03908281|EXPERIMENTAL|Fasted Exercise|Exercise training will be performed in the fasted state (i.e., before breakfast).
62085274|NCT03908281|ACTIVE_COMPARATOR|Postprandial Exercise|Exercise will be performed in the postprandial period (i.e., after breakfast)
62085275|NCT01283217|EXPERIMENTAL|DS(Docetaxel with S-1)|Docetaxel with S-1
62085276|NCT01283217|ACTIVE_COMPARATOR|SP(S-1 with cisplatin)|S-1 with cisplatin
62085277|NCT01912820|EXPERIMENTAL|Arm I (quercetin, green tea extract)|Patients receive GT extract PO BID and quercetin PO BID for 3-6 weeks before undergoing prostatectomy.
62653100|NCT06530810|EXPERIMENTAL|HS-10382+Flumatinib|"Subjects with resistant or intolerant CML CP/AP will be enrolled in dose-escalation stage.Dose escalation of HS-10382 combined flumatinib will be done to determine maximum tolerated dose(Part 1).~Depending on data obtained from the dose-escalation stage,dose expansion may proceed with in subjects with newly diagnosed CML-CP.The safety and efficacy will be evaluated at the target dose.(Part 2)"
62085278|NCT01912820|PLACEBO_COMPARATOR|Arm II (GT extract, placebo)|Patients receive GT extract PO BID and placebo PO BID for 3-6 weeks before undergoing prostatectomy.
62085279|NCT01632358|EXPERIMENTAL|TAP311 capsules|Patients will receive TAP311 capsule orally once daily for 14 days.
62085280|NCT01632358|PLACEBO_COMPARATOR|Placebo of TAP311 capsules|Matching placebo to TAP311 capsule, once daily for 14 days
62085281|NCT03041714||Normal volunteers|people who are healthy and without tremor
62085282|NCT03041714||Essential tremor|Patients with essential tremor
62085283|NCT03041714||Dystonic tremor|patient with tremor who also have dystonia
62085284|NCT02522338|OTHER|iohexol plasma clearance|patients had received iohexol for measuring GFR
62085285|NCT05175443|EXPERIMENTAL|Exercise Intervention|"1. Wall Angels:Stretching tight anterior shoulder musculature Participants will assume this position and slide their arms up and down the wall for 2 minutes.~2. Cervical Spine Mobility: will be accomplished by having the participant stabilize their shoulders and side bend their head in various positions to stretch each side of their next for 2 minutes with 10-15 second holds in each position.~3. Posterior shoulder strengthening: will be performed with shoulder externally rotating and squeezing the scapular with 5 second holds for 2 minutes.~4. Thoracic Spinal mobility: to improve thoracic extension participants will use a strap or tennis ball and perform thoracic extension with 10 second holds for 2 minutes."
62085286|NCT03390361|ACTIVE_COMPARATOR|LCS|Laser cataract surgery will be performed. 5-minutes after LCS aqueous humour will be collected and frozen in -80° celsius.
62085287|NCT03390361|PLACEBO_COMPARATOR|MCS|Manual cataract surgery will be performed. Aqueous humour will be collected and frozen in -80° celsius before MCS starts.
62085288|NCT00068666|EXPERIMENTAL|radiation + temozolomide|"Patients receive concurrent chemoradiotherapy comprising whole brain radiotherapy daily on days 1-5, 8-13, and 16-21 and oral temozolomide daily on days 1-5. Subsequent treatment with temozolomide repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months."
62085289|NCT06357546|ACTIVE_COMPARATOR|Arm A: Intraoperative bladder catheterization|Patients will have spontaneous urination in the hour preceding the caesarean section and will have a systematic intraoperative bladder catheterization.
62085290|NCT06357546|EXPERIMENTAL|Arm B: Absence of intraoperative bladder catheterization|Patients will have spontaneous urination in the hour preceding the caesarean section but will not have intraoperative bladder catheterization.
62085291|NCT04592133||Scoliosis Patients|
62085292|NCT04592133||Control Group|
62085293|NCT01767129|EXPERIMENTAL|AVP-923-45|AVP-923-45 twice daily for 14 days
62085294|NCT01767129|PLACEBO_COMPARATOR|Placebo|Placebo twice a day for 14 days
62284336|NCT00110942|PLACEBO_COMPARATOR|Minor sub-study placebo|N = 15
62284337|NCT00110942|ACTIVE_COMPARATOR|Main sub-study AMG 108|N = 73
62284338|NCT00110942|PLACEBO_COMPARATOR|Main sub-study placebo|N = 73
62284339|NCT01497262|EXPERIMENTAL|Fingolimod|Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
62284340|NCT01140009|PLACEBO_COMPARATOR|Group 1|FLuviral 2010/11Tri-valent Seasonal Influenza Vaccine (TIV)1st; saline placebo 10 days later
62284341|NCT01140009|PLACEBO_COMPARATOR|Group 2|Saline placebo 1st; Fluviral 2010/11 Tri-valent Seasonal Influenza Vaccine (TIV)10 days later
62085295|NCT06193759|EXPERIMENTAL|Embryonal brain tumors|These patients are young children (\<5 years of age) with newly diagnosed high-risk embryonal CNS malignancies and are expected to have a modest male predominance reflecting the sex-based incidence of pediatric brain tumors. Patients will have a Lansky performance status of ≥60.
62085296|NCT06392516|NO_INTERVENTION|control|patient who undergo hemodialysis two times a week
62085297|NCT06392516|EXPERIMENTAL|intervention|will be given parenteral ketoacid analogues intradialytics two times a week
62085298|NCT03524820|EXPERIMENTAL|Metastatic colorectal cancer patients|Metastatic colorectal cancer patients receiving third line cetuximab treatment
62284342|NCT02373111|ACTIVE_COMPARATOR|Isoflavone and Astaxanthin|Each subject takes one active tablet per day for 24 weeks. Each tablet contains isoflavone 27mg and astaxanthin 4mg.
62284343|NCT02373111|PLACEBO_COMPARATOR|Placebo|Each subject takes one placebo tablet per day for 24 weeks.
62085299|NCT02696720|EXPERIMENTAL|Lidocaine|During a period of six weeks, a lidocaine patch will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
62085300|NCT02696720|SHAM_COMPARATOR|Sham|During a period of six weeks, a visually identical patch (sham) will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
62284344|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + ASV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
62284345|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + SMV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
62284346|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + ASV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
62284347|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + SMV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
62284348|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + ASV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \> 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
62284349|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + SMV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \> 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
62284350|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + ASV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
62284351|NCT02583685|EXPERIMENTAL|PR4 + LDV/SOF + SMV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA \<2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
62284352|NCT05366283|EXPERIMENTAL|Cohort 1 (Part 1)|Single dose of 250 microgram (mcg) sargramostim IV over 2 hours
62284353|NCT05366283|EXPERIMENTAL|Cohort 2 (Part 1)|Single dose of 25 mcg sargramostim SC
62284354|NCT05366283|EXPERIMENTAL|Cohort 3 (Part 1)|Single dose of 125 mcg sargramostim SC
62284355|NCT05366283|EXPERIMENTAL|Cohort 4 (Part 1)|Single dose of 250 mcg sargramostim SC
62284356|NCT05366283|EXPERIMENTAL|Cohort 5 (Part 1)|Single dose of 500 mcg sargramostim SC
62284357|NCT05366283|EXPERIMENTAL|Cohort 6 (Part 1)|Single dose of 250 mcg sargramostim IH
62284358|NCT05366283|EXPERIMENTAL|Cohort 7 (Part 2)|Two doses of 500 mg sargramostim SC, weekly
62284359|NCT04409184||Convalescent subjects|Convalescent, now asymptomatic, subjects with documented prior COVID-19 due to SARS-CoV-2 infection
62284360|NCT04409184||Healthy controls|
62284361|NCT05147480|ACTIVE_COMPARATOR|yoga group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers intervention: 6-week, once a week internet-based mother and baby yoga
62284362|NCT05147480|NO_INTERVENTION|control group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers the standardized follow-up without intervention
62653101|NCT01578291|NO_INTERVENTION|No intervention|Parents given routine information by the medical staff.
62653102|NCT01578291|ACTIVE_COMPARATOR|Parental information|Parents are provided with an educational brochure of the study and the expectations of the discomfort.
62284363|NCT05268406|EXPERIMENTAL|Single arm|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
62284364|NCT02262169|ACTIVE_COMPARATOR|Treatment I|2 Omeprazole capsules 20 mg once daily and 1 placebo caplet of DLBS2411, twice daily
62284365|NCT02262169|EXPERIMENTAL|Treatment II|1 DLBS2411 caplet 250 mg twice daily and 2 placebo capsules of Omeprazole once daily
62284366|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
62284367|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
62284368|NCT02115230|EXPERIMENTAL|Renal denervation + medical therapy|Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
62284369|NCT02115230|NO_INTERVENTION|Medical therapy|Standard optimized medical therapy for diastolic heart failure
62284370|NCT04172558|ACTIVE_COMPARATOR|BTX100 group|ICI of Botox 100 U
62284371|NCT04172558|ACTIVE_COMPARATOR|Trimix group|ICI of Trimix
62284372|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
62284373|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
62284374|NCT06491134|EXPERIMENTAL|liposomal irinotecan|liposomal irinotecan With Cisplatin and Concurrent Radiotherapy
62284375|NCT01171820|ACTIVE_COMPARATOR|TAXUS® Liberté™|
62284376|NCT01171820|ACTIVE_COMPARATOR|XIENCE V® EECSS|
62653103|NCT01578291|ACTIVE_COMPARATOR|Play Therapy|Child and the parents will spend time in the office with the child life therapist undergoing play therapy.
62653104|NCT03409380|EXPERIMENTAL|Arginine|Arginine drink provided 1 time. There is about 10 g of arginine in the product.
62653105|NCT03409380|PLACEBO_COMPARATOR|Placebo|Placebo drink provided 1 time.
62653106|NCT05639036|ACTIVE_COMPARATOR|Control-Free Hand External Ventricular Drain Placement|This group will receive an external ventricular drain placed using the standard free-hand technique
62085301|NCT02408549|EXPERIMENTAL|Lacosamide|"Start dose~SP0982 completers at V1:~* LCM 10 mg/kg/day for pediatric subjects weighing \<30 kg~* LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to \<50 kg~* LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~SP0982 Baseline failures at V1:~* LCM 2 mg/kg/day for pediatric subjects weighing \<50 kg~* LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~Oral solution (pediatric subjects \<50 kg):~* Minimum LCM dose: 4 mg/kg/day~* Maximum LCM dose: 12 mg/kg/day~Tablets (pediatric subjects ≥50kg):~* Minimum LCM dose: 200 mg/day~* Minimum LCM dose: 600 mg/day~Tablets (adult subjects):~* Minimum LCM dose: 200 mg/day~* Maximum LCM dose: 800 mg/day"
62085302|NCT06464679|EXPERIMENTAL|CD19 CAR NK cells|
62651319|NCT05822466|ACTIVE_COMPARATOR|Virtual multimodal exercise|Participants participating are intervened with a multicomponent exercise program that involves light walking, strength, postural control, and flexibility exercises. Walking exercises include amble forward and backward walk, long strides, heel-toe walking, narrow- and wide-base walking, and sidestepping. Strength training includes single- and multi-joint exercises such as semi-squats, lunging forward and sideways, and toe stands that involve exercising ankle dorsiflexors, knee extensors, and hip abductors. Balance training involves semi-tandem foot-standing, heel-toe and line walking, single-leg standing, alternation of the base of support, weight transfers, toe and heel movements, and various reaching and stretching movements away from the center of the base of support. Flexibility exercises include a static stretching routine of major upper and lower body muscle groups. Each session includes brief movement-based warm-ups and light breathing cool-down exercises.
62651320|NCT05090644||Experimental group:|Patients with schizophrenia
62651321|NCT05090644||Control group|Patients without schizophrenia
62085303|NCT03262337||Elderly Travelers|approximately 135 travelers with an age \>= 60 years will be enrolled
62085304|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
62085305|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
62085306|NCT01077024|EXPERIMENTAL|Smoking-cessation treatment + substance treatment as usual|
62085307|NCT01077024|NO_INTERVENTION|Substance-treatment as usual|Treatment as usual is outpatient stimulant-dependence treatment as typically provided by the participating site.
62085308|NCT01874327|ACTIVE_COMPARATOR|Baby JASPER|This classroom will spend the majority of the time focusing on social-communication goals
62284377|NCT01784835|OTHER|control|patients under standard medical care
62284378|NCT01784835|EXPERIMENTAL|OMT|patients under usual medical care plus osteopathic treatment
62284379|NCT01692808|NO_INTERVENTION|Exclusive Enteral Nutrition|This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.
62284380|NCT01692808|EXPERIMENTAL|EEN + Vitamin D3 3000 UI daily|Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.
62284381|NCT01692808|NO_INTERVENTION|Corticosteroïd|Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month
62284382|NCT01692808|EXPERIMENTAL|Corticosteroids + Vitamin D3 4000 UI|Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month
62459975|NCT05853328|ACTIVE_COMPARATOR|Epley Maneuver|"The SOC therapy for this patient population is Physical Therapy. No medication or medical device therapy was included. In addition to SOC, patients in this arm were allocated to Epley Maneuver. The first treatment maneuver was performed once by a physician according to the assigned treatment group. The patient simultaneously received verbal instructions on how to perform the maneuver. Fifteen minutes after the first diagnostic maneuver, a second diagnostic maneuver was carried out in order to evaluate the effect of a single maneuver.~For the self-maneuvers, patients received written instructions with figures on how to perform the EM independently in a home environment. For the self-maneuver at home, the modified Epley self-maneuver was done by the patient with a pillow under the shoulders.~The frequency at home was three times in the morning, three times at noon, and three times in the evening, i.e., nine times per day."
62459976|NCT05853328|ACTIVE_COMPARATOR|SemontPLUS Maneuver|"The SOC therapy for this patient population is Physical Therapy. No medication or medical device therapy was included. In addition to SOC, patients in this arm were allocated to the SemontPLUS Maneuver. The first treatment maneuver was performed once by a physician according to the assigned treatment group. For the SM+, the angle of the 60° overextended head and body was measured by an inclinometer application. The patient simultaneously received verbal instructions on how to perform the maneuver. Fifteen minutes after the first diagnostic maneuver, a second diagnostic maneuver was carried out in order to evaluate the effect of a single maneuver.~For the self-maneuvers, patients received written instructions with figures on how to perform the SM+ independently in a home environment.~The frequency at home was three times in the morning, three times at noon, and three times in the evening, i.e., nine times per day."
62459977|NCT05513742|EXPERIMENTAL|CTX-009 Treatment|
62459978|NCT02510547|ACTIVE_COMPARATOR|CrossBoss Catheter|Crossing the CTO with upfront use of the CrossBoss catheter
62085309|NCT01874327|ACTIVE_COMPARATOR|Standard Baby Classroom|This classroom will focus more heavily on developing motor and cognitive skills
62284383|NCT01692808|EXPERIMENTAL|Vitamin D3 4000 UI|Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.
62284384|NCT06156865|EXPERIMENTAL|Intervention to address late talking|half the participants receive an intervention program addressing late talking. The intervention is comprised of adult learning (to teach parents) and direct support for children who are late talkers. The intervention occurs over 6 to 8 weeks and is designed to improve grammar, vocabulary, and functional communication
62284385|NCT06156865|NO_INTERVENTION|Waitlist controls|half the participants are waitlist controls who receive intervention at a later date, after the study has ended
62284386|NCT02714478|EXPERIMENTAL|treatment|"3 Equistasi devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
62284387|NCT02714478|PLACEBO_COMPARATOR|controls|"3 placebo devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
62284388|NCT06064344|EXPERIMENTAL|Intralesional Rituximab Injection|
62284389|NCT06064344|ACTIVE_COMPARATOR|Involved Site Radiation Therapy|
62284390|NCT03669315|ACTIVE_COMPARATOR|Active cTBS treatment|Active cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. TBS consists of bursts of 3 pulses separated by 20ms (i.e. 50 Hz), with each triplet being repeated every 200 ms (i.e. 5 Hz). Stimulus intensities will be set at 80% of AMT. The investigators will use 2 trains of 600 pulses each separated by 1 minute (a total of 1200 pulses).
62284391|NCT03669315|SHAM_COMPARATOR|Sham cTBS treatment|Sham cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same active cTBS configuration will be used.
62284392|NCT06406348|EXPERIMENTAL|Active|Single Ascending Dose (SAD) cohorts
62284393|NCT06406348|PLACEBO_COMPARATOR|Placebo|Single Ascending Dose (SAD) cohorts
62284394|NCT05653778|EXPERIMENTAL|Scrambler therapy|"Scrambler Therapy is a non-invasive neuromodulation approach using superficial electrocardiogram (ECG) electrodes in paired channels on the involved dermatomes to send non-pain information along the existing nerve pathways, which can modify peripheral and central sensitization."
62653107|NCT05639036|EXPERIMENTAL|Intervention - Image Guided External Ventricular Drain Placement Using the NAV3 System|This group will receive an external ventricular drain placed using the assistance of the Stryker NAV3 image guidance system
62085310|NCT04318964|EXPERIMENTAL|TAEST16001 cells treat tumor antigen NY-ESO-1|"The dose escalation was carried out according to the principle of 3 + 3 increase. Four dose levels (calculated by the number of tcr-t positive cells) were set up: the dose level was 1: 5 × 108 ± 30%; the dose level was 2: 2 × 109 ± 30%; the dose level was 3: 5 × 109 ± 30%; the dose level was 4: 1.2 × 1010 ± 30%. Three patients in the first group, if there is no DLT, they will be enrolled in the next higher dose group; if one of the three patients in a certain dose group has DLT, three patients in the group will be supplemented with the same dose and method. If DLT occurred in 1 or more of the 3 cases, the dose increase was stopped. The former dose was defined as MTD; if DLT did not occur in 3 cases, the dose increased to the next group. Dose escalation is not allowed for the same patient."
62085311|NCT00799071|EXPERIMENTAL|posaconazole|posaconazole as antifungal prophylaxis
62459979|NCT02510547|ACTIVE_COMPARATOR|Antegrade Wire Escalation Strategy|Crossing the CTO with upfront antegrade wire escalation strategy
62459980|NCT03533465|EXPERIMENTAL|Complicated Grief Treatment (CGT)|10 adults with CG who successfully completed Aim 1 and will also participate in open complicated grief treatment (CGT), during which they will complete additional subjective and objective sleep assessments.
62651322|NCT03133013|EXPERIMENTAL|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
62651323|NCT03133013|OTHER|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
62284395|NCT05653778|ACTIVE_COMPARATOR|TENS treatment|Transcutaneous electrical nerve stimulation (TENS) is a battery-powered device which delivers low-voltage electrical current through superficial electrocardiogram (ECG) electrodes placed on the surface of the skin to provide pain relief.
62651324|NCT01853865|NO_INTERVENTION|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
62085312|NCT01182922|ACTIVE_COMPARATOR|Doctor's Information Invitation|Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
62284396|NCT02840851||Healthy young women|Healthy young women between the age of 20-34 years.
62284397|NCT02840851||Healthy young men|Healthy young men between the age of 20-34 years.
62284398|NCT02840851||Healthy older women|Healthy older women between the age of 50-64 years.
62284399|NCT02840851||Healthy older men|Healthy older men between the age of 50-64 years.
62651325|NCT01853865|EXPERIMENTAL|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
62085313|NCT01182922|ACTIVE_COMPARATOR|Gender Preference Invitation|Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
62284400|NCT01602055|EXPERIMENTAL|Azivol|
62284401|NCT01602055|ACTIVE_COMPARATOR|Zithromax|
62459981|NCT03983564||All patients|Patients in this group will serve to validate the cutoff of the combination of the DES-OSA and BOSTON scores derived in the retrospective group.
62459982|NCT02463695|EXPERIMENTAL|vestibular deficit|"* Initial clinical assessment including otoneurological examination, pure tone audiometry, tympanometry vestibular screening tests and Magnetic Resonance Imaging as clinically indicated.~* The cortical vestibular evoked potentials will add approximately add an extra 30 minutes to the test sequence but is minimally invasive and will not cause any pain or discomfort. It will be conducted on both the affected and non-affected ears."
62284402|NCT02324166|ACTIVE_COMPARATOR|Cefazolin|For the control group, cefazolin will be drawn into a 1 mL syringe and 0.5 mL will be injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery.
62459983|NCT02463695|ACTIVE_COMPARATOR|otologically normal controll|Normative data will be collected from 36 normal ears from subjects that have no history of audiovestibular symptoms and are not being investigated for any balance disorders. The cortical vestibular evoked potentials will be recorded from both ears
62459984|NCT06123520|ACTIVE_COMPARATOR|Ho-YAG Laser internal urethrotomy|consists of those who will undergo Ho-YAG laser internal urethrotomy only.
62651326|NCT06452342|EXPERIMENTAL|Tranexamic acid|Tranexamic acid (Cyclokapron®) 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period.
62651327|NCT06452342|OTHER|No tranexamic acid|Routine clinical care without Tranexamic acid
62284403|NCT02324166|ACTIVE_COMPARATOR|Cefazolin + Lidocaine|For the comparator group, the cefazolin and 0.2 mL lidocaine 2% will be mixed together in the same 1 mL syringe and 0.5 mL of the mixed solution injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery surgery.
62284404|NCT05438667|EXPERIMENTAL|TCR-T treatment group|Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T infusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 will be injected intravenously for 14 days .After 3 months of treatment, the patient's condition was evaluated. If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed .
62284405|NCT03757988|EXPERIMENTAL|Single Arm Experimental Walking Group|This is a pilot project with one single group that will be evaluated on the adherence to a walking protocol (Exercise Intervention- PACE-Life). Subjects will be walking two times a week under the supervision of the psychiatric clinic. In addition, subjects will be encouraged to add walking on their own on the days when subjects are not exercising under the supervision of the clinic. This pilot will be used to inform the final design of the subsequent randomized clinical trial that will be implemented following this pilot.
62284406|NCT00796588|NO_INTERVENTION|Control group|Patients undergoing liver surgery without the designated intervention
62284407|NCT00796588|OTHER|RIPC|application of pneumatic tourniquet in patients undergoing liver surgery
62284408|NCT02538172|EXPERIMENTAL|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
62284409|NCT02538172|OTHER|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
62284410|NCT01390909||Medicaid patients with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
62085314|NCT01182922|ACTIVE_COMPARATOR|Standard Invitation|Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
62085315|NCT02403531|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
62284411|NCT01390909||Medicaid patients with well-controlled epilepsy|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
62284412|NCT01390909||Medicaid patients with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
62284413|NCT01390909||Patients in a private health plan with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
62284414|NCT01390909||Patients in a private health plan with well-controlled epileps|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
62284415|NCT01390909||Patients in a private health plan with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
62284416|NCT04361201||Ligament plastic surgery ankle|Patient treated priorly by ligament plastic surgery of lateral ankle plane under arthroscopy
62284417|NCT04361201||Control group|Controlateral ankle
62284418|NCT01823068|EXPERIMENTAL|Vandetanib treatment arm|Vandetanib 300 mg once daily orally
62284419|NCT04856241|EXPERIMENTAL|Supported Implementation (Intervention)|Our supported implementation approach is designed to improve uptake of Prep-to-Play. The Prep-to-Play program consists of four components: dynamic warm-up, strength training, football fundamentals, and education. At the start of the intervention period, Prep-to-Play Physiotherapists will conduct a 3-hour workshop for coaches and influential players. Ongoing support will be provided via a range of strategies. Prep-to-Play Physiotherapists will attend training (two times) during and immediately post implementation to provide coaches with support (feedback on missing components, player technique, questions). Monthly Coaches Shed; Online drop-in session with education component to meet other coaches (peer support \& networking) and ask questions. Refresher workshops will be run in pre-season 2022 for the teams who have received the intervention in 2021.
62284420|NCT04856241|ACTIVE_COMPARATOR|Unsupported implementation (Control)|"The unsupported implementation arm will be usual care. Access to the Prep-to-Play resources, including videos, downloadable manuals and posters, are freely available to coaches online. The online resources incorporate the same four concepts as described in the supported implementation - dynamic warm-up, strength exercises, football fundamentals, and education. In the control arm, no additional resources, education, or support will be provided."
62284421|NCT04955275|EXPERIMENTAL|Parkinson's Disease Patients receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will undergo 10 weeks of Brain HQ training, 2 times a week an hour at a time. Also patients pre- and post-intervention RBANS and PDQ-39 scores.
62284422|NCT04955275|NO_INTERVENTION|Parkinson's Disease Patients not receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will receive no intervention, but still undergo pre- and post-intervention RBANS and PDQ-39 scores.
62085316|NCT02403531|EXPERIMENTAL|Induction chemotherapy plus chemoradiotherapy|Patients assigned to this Arm first received two cycles of 3-weekly schedule of IC before definitive chemoradiotherapy, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
62085317|NCT03263351|EXPERIMENTAL|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
62459985|NCT06123520|EXPERIMENTAL|Ho-YAG Laser internal urethrotomy + Paclitaxel injection|those who will undergo Ho-YAG laser internal urethrotomy with circumferential submucosal paclitaxel injection at the stricture site.
62651328|NCT01414244|ACTIVE_COMPARATOR|Glutamine supplementation|Glutamine
62085318|NCT03263351|ACTIVE_COMPARATOR|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
62085319|NCT00059254|EXPERIMENTAL|Oleic acid (OA)|
62284423|NCT04282031|EXPERIMENTAL|phase 1 (dose escalation study, dose expansion study and PK trail)|Participants will first receive single dose BPI-1178 orally at dose levels of 25mg, 75mg, 150mg, 250mg, 400mg and 500mg followed by a 7-day washout period , and then start receiving the 28 days/cycle continuous treatment until disease progression or unacceptable toxicity. After the 500 mg dose escalation trial is completed, the PK study will be conducted for the 400 mg dose group, the 300 mg dose group and the 200 mg dose group.
62284424|NCT04282031|EXPERIMENTAL|phase 2a cohort A|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with fulvestrant for 3 consecutive weeks, followed by 1 week drug withdrawal or continuous dosing for 28 days, in each 28-day treatment cycle, until disease progression or unacceptable toxicity.
62085320|NCT00059254|EXPERIMENTAL|Palmitic acid (PA)|
62284425|NCT04282031|EXPERIMENTAL|phase 2a cohort B|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with letrozole for 3 consecutive weeks, followed by 1 week drug withdrawal or continuous dosing for 28 days, in each 28-day treatment cycle, until disease progression or unacceptable toxicity.
62284426|NCT06270680|EXPERIMENTAL|Supplement Group|The group receiving the carotenoid supplement.
62284427|NCT06270680|PLACEBO_COMPARATOR|Placebo Group|The group receiving the placebo.
62284428|NCT01175005||Fever and a central venous catheter|
62284429|NCT06451965|NO_INTERVENTION|Baseline Phase|During this phase, participants are randomly allocated to either 2, 3 or 4 weeks of the baseline phase. No intervention will be delivered while in this stage. Participants will be asked to complete the visual analogue scale daily.
62284430|NCT06451965|EXPERIMENTAL|Treatment Phase|After the baseline phase, participants will enter the treatment phase. This phase will consist of 6 weekly and hourly therapy sessions to deliver the wisdom enhancement timeline intervention.
62284431|NCT05855512|NO_INTERVENTION|Controlled group|No intervention was given, only the material was provided in the form of a booklet
62284432|NCT05855512|EXPERIMENTAL|Interventional Group|The nursing educational intervention sessions were conducted, and the material was provided in the form of a booklet
62085321|NCT06157775||Healthy Individuals|
62085322|NCT03554161|EXPERIMENTAL|Tocilizumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
62284433|NCT05431296|EXPERIMENTAL|Real time CGM post acute myocardial infarct|Real time Dexcom ONE CGM system to be applied for 26 weeks post acute myocardial infarct. Option for participants in this group to continue using rCGM in an open label observational extension phase for a total of 3 years.
62284434|NCT05431296|NO_INTERVENTION|Blinded CGM post acute myocardial infarct|Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment, and then at days 17-23, week 10 and week 24. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. CGM measurements will be blinded until the end of the study. Management of diabetes in this cohort as per usual standards of care.
62284435|NCT05431296|NO_INTERVENTION|Blinded CGM historical acute myocardial infarct (>6 months and <10 years ago)|Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. Management of diabetes in this cohort as per usual standards of care.
62284436|NCT05431296|NO_INTERVENTION|Cardiovascular outcomes control group|Age and sex-matched controls from the NIHR Cardiovascular Health Informatics Collaborative.
62284437|NCT02182349|EXPERIMENTAL|BI 201335 NA|multiple doses of BI 201335 NA soft gelatin capsule on days 1-8 and 11-15 and one single dose of \[14C\]-BI 201335 NA radiolabelled drug on day 9
62284438|NCT02676830|EXPERIMENTAL|K-312|
62651329|NCT01414244|PLACEBO_COMPARATOR|Placebo|Whey protein powder
62085323|NCT01907152|EXPERIMENTAL|Protein enriched yoghurt drink and bread|Yoghurt drink enriched with Whey Protein Concentrate Whole wheat bread enriched with cereal protein and soy
62085324|NCT01907152|NO_INTERVENTION|Regular yoghurt drink and bread|Commercially available yoghurt drink and whole wheat bread
62085325|NCT02129569|EXPERIMENTAL|Arm I (psychoeducational and behavioral interventions)|Participants meet with a nurse in-person for approximately 30 minutes to receive information about strategies for cognitive self-management of distress and an individualized walking prescription to gradually increase their walking to 30 minutes per day, 5 times per week. Participants wear a pedometer for at least 3 consecutive days during weeks 1, 6, and 12. Participants are also contacted by the nurse via telephone at 1 and 3 weeks for supplemental counseling support.
62085326|NCT02129569|ACTIVE_COMPARATOR|Arm II (control)|Participants meet with a nurse in-person for approximately 20 minutes to receive NCI educational booklets and a link to the ACS website. Participants are also contacted by the nurse via telephone at 1 and 3 weeks but the calls are primarily social in nature and do not include counseling support.
62459986|NCT05252130|EXPERIMENTAL|Auscultation with a newly developed electronic stethoscope: NoaScope|Identification of abnormal heart and lung sounds in study participants
62459987|NCT00886171|EXPERIMENTAL|Social Skills Training|
62284439|NCT05640401|EXPERIMENTAL|Endoscopy procedure + mixed reality|This group is comprised by expert gastrointestinal endoscopists designated to perform diagnostic procedures. The procedure will be performed without physical surgical monitors, and through the guidance of Mixed Reality by using the HXtend™ application holographic monitors.
62284440|NCT03952260|ACTIVE_COMPARATOR|Fasting clear fluid for 1 hour prior to anaesthesia|Fasting clear fluid for 1 hour prior to anaesthesia
62459988|NCT00886171|EXPERIMENTAL|Physical Activity Training|
62459989|NCT02096510|EXPERIMENTAL|continuous subcutaneous hydrocortisone|continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate
62459990|NCT02096510|ACTIVE_COMPARATOR|cortef tablets|the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.
62459991|NCT02096510|EXPERIMENTAL|ultradian subcutaneous hydrocortisone|ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate
62459992|NCT00620048|EXPERIMENTAL|Low dose of autologous CD34-positive cells (stem cells)|
62459993|NCT00620048|EXPERIMENTAL|High dose of autologous CD34-positive cells (stem cells)|
62459994|NCT02936856|EXPERIMENTAL|After Hepatic Arteriography|
62459995|NCT02936856|ACTIVE_COMPARATOR|Before Hepatic Arteriography|
62459996|NCT03021538||Cardiopulmonary Bypass|There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
62651330|NCT02866643|EXPERIMENTAL|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
62284441|NCT03952260|NO_INTERVENTION|Fasting clear fluid for 2 hours prior to anaesthesia|Fasting clear fluid for 2 hours prior to anaesthesia
62284442|NCT04388501|EXPERIMENTAL|Treatment Sequence ABC|Participants will receive milvexian capsule once daily (qd) for 5 days (Treatment A) in Period 1 followed by Atorvastatin tablets qd for 5 days (Treatment B) in Period 2 followed by milvexian capsules qd and atorvastatin tablets qd for 5 days (Treatment C) in Period 3. Each period is separated by a washout period of 7 days.
62284443|NCT04388501|EXPERIMENTAL|Treatment Sequence BCA|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
62284444|NCT04388501|EXPERIMENTAL|Treatment Sequence CAB|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
62284445|NCT04388501|EXPERIMENTAL|Treatment Sequence CBA|Participants will receive Treatment C in Period 1 followed by Treatment B in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
62284446|NCT04388501|EXPERIMENTAL|Treatment Sequence ACB|Participants will receive Treatment A in Period 1 followed by Treatment C in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
62284447|NCT04388501|EXPERIMENTAL|Treatment Sequence BAC|Participants will receive Treatment B in Period 1 followed by Treatment A in Period 2 and Treatment C in Period 3. Each Period is separated by a washout period of 7 days.
62459997|NCT03021538||Extracorporeal Membrane Oxygenation|There will be 40 patients placed on ECMO during lung transplantation.
62459998|NCT02652026|EXPERIMENTAL|Treatment Group|The Treatment Group (TG) received full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron, Acteon, Merignac, France) and Gracey curettes (Hu- Friedy, Chicago, USA).Also received Oral Hygienic Instructions
62459999|NCT02652026|ACTIVE_COMPARATOR|Control Group|The Control Group (CG) received periodontal prophylaxis at baseline, by removal of supragingival deposits (plaque and calculus) with ultrasonic scaler. Also received Oral Hygienic Instructions
62460000|NCT04988984||Suspected TB|Patient suspected of TB undergoing diagnostic testing.
62460001|NCT01415700|EXPERIMENTAL|Stimulator|
62460002|NCT01415700|ACTIVE_COMPARATOR|Orthosis|
62460003|NCT06354504|EXPERIMENTAL|Healty|Non-surgical periodontal treatment
62460004|NCT02719223|EXPERIMENTAL|High Flux Hemodialysis|
62460005|NCT02719223|EXPERIMENTAL|OL-HDF|
62460006|NCT01094067|EXPERIMENTAL|1|Placebo at visit 1, tezosentan at visit 2
62460007|NCT01094067|EXPERIMENTAL|2|Tezosentan at visit 1, placebo at visit 2
62460008|NCT04732195|EXPERIMENTAL|Pilocarpine microneedle patch|Participants will receive in their left forearm the microneedle patch. Upon application to skin, the MNs penetrate into the skin's upper layers and dissolve in the interstitial fluid to release the loaded drugs. MN patches are painless and can be administered with little or no training.
62460009|NCT04732195|ACTIVE_COMPARATOR|Pilocarpine Iontophoresis|Participants will receive in their right forearm the pilocarpine iontophoresis. Uses a gel disc containing Pilocarpine that drives the medication into the skin with a small electric current (iontophoresis) followed a 30-minute period of sweat collection.
62460010|NCT05061290|EXPERIMENTAL|Control Porridge|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
62460011|NCT05061290|EXPERIMENTAL|Reference Porride A|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Ascorbic acid, Corn starch
62651331|NCT02866643|ACTIVE_COMPARATOR|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
62651332|NCT04224467|EXPERIMENTAL|Indocyanine Green Fluorescent Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then, a NIR imaging systems included the NIR (800-900 nm) and white-light (400-650nm) dual-channel will be used to detect In situ lesions, metastatic lesions, lymph nodes, obturator nerve, pelvic autonomic nerve, etc during surgery according to disease and clinical needs.
62284448|NCT04773405|OTHER|Selective Trunk Block|Selective trunk block will be done under ultrasound guidance to patients scheduled for upper extremities surgeries. Local anaesthetic agents (a 1:1 mixture of 2% lidocaine with 5ug/ml of epinephrine and 0.5% levobupivacaine) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anaesthetize the whole upper limb.
62284449|NCT01119235|ACTIVE_COMPARATOR|Cohort 1: PF-04531083|
62284450|NCT01119235|ACTIVE_COMPARATOR|Cohort 2: PF-04531083|
62284451|NCT05429567|EXPERIMENTAL|fentanyl infusion Group|According to the body weight, 2 ug/kg fentanyl was diluted to 100 ml with normal saline. with rate of 2 mL/h infusions, 10 min lockout time and Initial PCIA analgesia regimen consisting of a 0.5 mL bolus was commenced to be given to the patients postoperative with evaluation the pain
62085327|NCT04689022|OTHER|Group І received general anesthesia (n=53)|"The sedation with constant rate infusion of 1% propofol, 1-4mg/kg/h, guided by Bispectral analysis (60-70 - for regional anesthesia and 40-60 - for the general one). 0.005% fentanyl analgesia was injected, 3-10 mkg/kg or 0.05-0.2 mkg/kg/min during induction; and 2-10 mkg/kg/h for maintaining analgesia, by periodic bolus injection 25-100 mkg or by permanent infusion.~The postoperative pain management of the I group patients was provided according to the local clinical protocol: paracetamol+/-non-steroid anti-inflammatory drugs +/-opioids.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
62085328|NCT04689022|OTHER|Group II received regional anesthesia: peripheral block was performed (n=73)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
62284452|NCT05429567|EXPERIMENTAL|NO fentanyl infusion Group|All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine only
62460012|NCT05061290|EXPERIMENTAL|Test Porridge B|Wholegrain maize flour, Moringa leaf powder, Mango powder, Carrot powder, Corn starch
62460013|NCT05061290|EXPERIMENTAL|Test Porridge C|Wholegrain maize flour, Baobab fruit powder, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
62284453|NCT01385735|PLACEBO_COMPARATOR|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
62284454|NCT01385735|ACTIVE_COMPARATOR|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
62284455|NCT06332898|PLACEBO_COMPARATOR|Placebo|Maltodextrin + Flavoring
62284456|NCT06332898|EXPERIMENTAL|AG1 - Nutritional Supplement|AG1, a foundational nutritional supplement
62460014|NCT05061290|EXPERIMENTAL|Test Porridge D|Wholegrain maize flour, Baobab fruit powder, Moringa leaf powder, Mango powder, Carrot powder
62460015|NCT04179045|EXPERIMENTAL|Bioheart|Subjects have CAD with one or two de novo native coronary artery lesions and will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System. There will be only one arm in this study.
62460016|NCT01705769|EXPERIMENTAL|RUTF-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company
62460017|NCT01705769|EXPERIMENTAL|RUTF-Locally produced|Ready to Use Therapeutic Food-Locally produced by the study team at each study site
62460018|NCT01705769|ACTIVE_COMPARATOR|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
62460019|NCT00006734|EXPERIMENTAL|Regimen A|Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
62460020|NCT00006734|EXPERIMENTAL|Regimen B|Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.
62460021|NCT03947242|EXPERIMENTAL|Pyrotinib + trastuzumab +Vinorelbine|Pyrotinib in Combination With Trastuzumab Plus Vinorelbine
62460022|NCT01287923||DLBCL|DLBCL patients included 075-GOELAMS trial or 075-like patient.
62085329|NCT04689022|OTHER|Group III received regional anesthesia with sedation (n=92)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
62460023|NCT01287923||Healthy controls|Blood donors from the EFS (French Blood Bank) of Rennes.
62460024|NCT01287923||Septic patients|septic patients included at the Rennes University Hospital.
62085330|NCT00442286|EXPERIMENTAL|On|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
62460025|NCT01287923||DLBCL in completed remission|DLBCL patients from the 075 GOELAMS study in completed remission.
62461830|NCT00615069|EXPERIMENTAL|31 mm GORE EXCLUDER® Test Subjects|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
62460026|NCT01479738|EXPERIMENTAL|Capitate bone grafting|18 patients with PIP joint defects were included in the study. There were 13 male and 5 female patients with a mean age of 31 years (range, 18-47 years). The injury occurred in the right hand in 11 patients and on the left hand in 7. The injured PIP joints were in the index finger (n=7), long finger (n=9), and ring finger (n=2).
62284457|NCT01726179|EXPERIMENTAL|Resin infiltration|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Control. Teeth in this arm are treated by the resin infiltration technique using Icon (DMG, Germany) according to manufactures´ instructions. In addition patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
62460027|NCT03787680|EXPERIMENTAL|Cohort 1 (DRPro)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
62460028|NCT03787680|EXPERIMENTAL|Cohort 2 (DRDef)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).
62460029|NCT03725605|EXPERIMENTAL|LTX-315 plus TIL infusion|LTX-315 intratumoural injection, TILs expansion and infusion.
62085331|NCT00442286|EXPERIMENTAL|Off|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
62460030|NCT04999709|ACTIVE_COMPARATOR|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
62460031|NCT04999709|SHAM_COMPARATOR|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
62460032|NCT03597334||critical ill patients|critical ill patients who admit to ICU
62460033|NCT04978649|ACTIVE_COMPARATOR|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
62085332|NCT00780442|EXPERIMENTAL|DCS|D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
62085333|NCT00780442|PLACEBO_COMPARATOR|Placebo|Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
62085334|NCT01609153|ACTIVE_COMPARATOR|Olanzapine or Placebo|
62085335|NCT01609153|ACTIVE_COMPARATOR|Amisulpride or Placebo|
62085336|NCT01609153|ACTIVE_COMPARATOR|Olanzapine and Amisulpride|
62085337|NCT05269511|EXPERIMENTAL|Treatment group|Chinese Herbal Medicine
62085338|NCT05269511|NO_INTERVENTION|Control group|usual care
62085339|NCT00926965|EXPERIMENTAL|Olanzapine group|randomized to Olanzapine group with dose range of 2.5-30mg/day
62085340|NCT00926965|EXPERIMENTAL|Amisulpiride group|the subjects were randomized to the amisulpiride group with dose range of 100 to 800mg/day
62085341|NCT00926965|ACTIVE_COMPARATOR|FGA group|The subjects were randomized to maintain the conventional antipsychotics
62085342|NCT05956977|EXPERIMENTAL|prospective arm|Use of 3D ultrasound intraoperative before intraoperative MRI
62085343|NCT05956977|NO_INTERVENTION|retrospective matched pair arm|no use of intraoperative ultrasound before intraoperative MRI
62085344|NCT02100618|EXPERIMENTAL|HPV Group 1|Subjects who were aged 9-14 years at study entry and received two doses of the HPV-16/18 vaccine according to a 0,6-months schedule in the study HPV-048 PRI (NCT00541970).
62085345|NCT02100618|ACTIVE_COMPARATOR|HPV Group 2|Subjects who were aged 15-25 years at study entry and received three doses of the HPV 16/18 vaccine according to a 0,1,6-months schedule in the study HPV-048 PRI (NCT00541970).
62085346|NCT03254693|ACTIVE_COMPARATOR|1-step self-etch approach (SE)|According to the manufacturer's instructions.
62085347|NCT03254693|ACTIVE_COMPARATOR|selective enamel etching (SEE)|According to the manufacturer's instructions.
62085348|NCT03254693|EXPERIMENTAL|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
62085349|NCT03254693|EXPERIMENTAL|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
62284458|NCT01726179|OTHER|Control|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Resin infiltration. Teeth randomized into this arm do not recieve any special treatment except general oral nonivasiv treatment (flossing and brushing). Patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
62085350|NCT04573231|EXPERIMENTAL|18F-DCFPyL PSMA-based PET/CT|"* 18F-DCFPyL whole body PET/CT scan~* Review of relevant imaging and medical record information~* Blood draw for circulating tumor cells (CTCs)~* Analysis of diagnostic tissue specimens"
62085351|NCT01780493|OTHER|Direct Nipple Ureteroneocystostomy|
62085352|NCT02873286|EXPERIMENTAL|Group 1 - Single Low Dose / Booster|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
62085353|NCT02873286|EXPERIMENTAL|Group 2 - Two Low Doses|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
62284459|NCT05836233||Enrolled patients - LVAD candidates|"Inclusion criteria~* Age over 18 years old.~* Diagnosis of advanced heart failure with an indication for LVAD implantation.~* Mean Arterial Pressure (MAP) \> 60 mmHg; Mean Pulmonary Arterial Pressure (mPAP) \> 20 mmHg; Pulmonary Artery Wedge Pressure \>15 mmHg.~* Vasodilator Challenge performed through NTP infusion.~Exclusion criteria~* State of pregnancy.~* Inability to perform vasodilator challenge~* Need for extracorporeal membrane oxygenator or short-term right ventricular assist devices.~* Planned right ventricular assist device implantation in the peri-procedural setting."
62284460|NCT02848833||JARDIANCE|T2DM with JARDIANCE
62284461|NCT02313831|EXPERIMENTAL|Exercise training|Patients of this group will be submitted to an interval training
62284462|NCT02039739||Orsiro™ Drug Eluting Stent|
62460034|NCT04978649|PLACEBO_COMPARATOR|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
62460035|NCT04400123|EXPERIMENTAL|Treatment group TR|Intervention: Drug: famitinib malate, new formulation; Intervention: Drug: famitinib malate, old formulation.
62085354|NCT02873286|EXPERIMENTAL|Group 3 - Single High Dose / Booster|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
62085355|NCT02873286|EXPERIMENTAL|Group 4 - Two High Doses|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
62085356|NCT02873286|EXPERIMENTAL|Group 5 - Placebo|First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)
62085357|NCT04796935|EXPERIMENTAL|Experimental Group 1: Tactile Imaging (VerTouch)|VerTouch used to identify and mark, or begin placement of a needle, at an insertion site.
62085358|NCT04796935|ACTIVE_COMPARATOR|Group 2: Control (palpation)|Palpation used to identify and mark an insertion site.
62085359|NCT06012838|EXPERIMENTAL|cause classification of OHCA protocol|The cause classification of OHCA protocol was developed by an expert cardiac arrest committee. A lecture concerning the Utstein's template, the epidemiology of cardiac arrest and the CCCA protocol was addressed to the participants.
62085360|NCT04849728|EXPERIMENTAL|Lanifibranor (IVA 337) (800 mg/day)|2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --\> once a day (quaque die, QD)
62085361|NCT04849728|EXPERIMENTAL|Lanifibranor (IVA 337) (1200 mg/day)|3 Lanifibranor tablets 400mg with food --\> once a day (quaque die, QD)
62085362|NCT04849728|PLACEBO_COMPARATOR|Matching placebo|3 Placebo to match tablets with food --\> once a day (quaque die, QD)
62085363|NCT00739635|EXPERIMENTAL|1|
62085364|NCT00739635|PLACEBO_COMPARATOR|2|
62085365|NCT02093143|EXPERIMENTAL|Remifentanil|"The general anesthesia during the diagnostic panendoscopy of the upper airway will associate the target controlled infusion of propofol (pharmacologic model of Schnider et al.) and of remifentanil (pharmacologic model of Minto et al.) in the remifentanil group.~The arm will be randomized prior to the beginning of the surgical procedure and blinded to the investigator and to the practitioner in charge of the patient.~Two milligrams of remifentanil will be diluted in 40 cc of sodium chloride 0,9% in a 50 ml syringe."
62085366|NCT02093143|PLACEBO_COMPARATOR|Placebo|"The general anesthesia during the diagnostic panendoscopy of the upper airway will consist in the target controlled infusion of propofol alone (pharmacologic model of Schnider et al.) in the placebo group.~The placebo is a 40 ml sodium chloride 0,9% solution in a 50 ml syringe. No one can distinguish the syringe of placebo from the syringe of remifentanil."
62085367|NCT05731375||Study population|Patients with large B-cell lymphoma or T-cell lymphoma scheduled for 6 full-dose cycles of 1st line immunochemotherapy with (R-)CHOP
62085368|NCT03501238|EXPERIMENTAL|BSG|Participant receives bovine milk, then milk substitute, then milk substitute treated with gelatin
62085369|NCT03501238|EXPERIMENTAL|BGS|Participant receives bovine milk, then milk substitute with gelatin, then milk substitute
62085370|NCT03501238|EXPERIMENTAL|SBG|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin.
62284463|NCT01824979|EXPERIMENTAL|Pilairo mask|Pilairo nasal pillows mask during CPAP titration
62284464|NCT01824979|ACTIVE_COMPARATOR|Other CPAP mask|Other CPAP mask during CPAP titration
62284465|NCT03360760|EXPERIMENTAL|Pre surgical Chemotherapy|Immediate pre surgical chemotherapy treated with four drugs including doxorubicin, cisplatin, high-dose methotrexate (MTX) and ifosfamide in eleven weeks, and then definitive surgery followed by adjuvant chemotherapy according to chemotherapy regimen in Peking University People's Hospital(PKUPH).
62085371|NCT03501238|EXPERIMENTAL|SGB|Participant receives milk substitute, then milk substitute with gelatin, then bovine milk
62085372|NCT03501238|EXPERIMENTAL|GSB|Participant receives milk substitute with gelatin, then milk substitute, then bovine milk.
62085373|NCT03501238|EXPERIMENTAL|GBS|Participant receives milk substitute with gelatin, then bovine milk, then milk substitute.
62085374|NCT02676063||neonatal Hypoxic Ischemic encephalopathy|moderate or severe HIE among term and late preterm newborn
62085375|NCT02694003|EXPERIMENTAL|Intervention|The intervention arm will receive access to the BNBD-NDD Intervention.
62085376|NCT02694003|NO_INTERVENTION|Usual Care|The usual care arm does not receive the BNBD-NDD intervention. This arm is free to access other resources while enrolled in the study. After the 8-month follow up time point, the usual care arm will be able to access the intervention.
62085377|NCT01033396|EXPERIMENTAL|PF-03654764 + Allegra|
62085378|NCT01033396|EXPERIMENTAL|PF-03654764|
62085379|NCT01033396|ACTIVE_COMPARATOR|Allegra-D|
62085380|NCT01033396|PLACEBO_COMPARATOR|Placebo|
62284466|NCT03360760|OTHER|Immediate Surgery|Immediate definitive surgery, and then post operative chemotherapy based on doxorubicin, cisplatin, high-dose MTX and ifosfamide according to chemotherapy regimen in PKUPH.
62284467|NCT05152940|ACTIVE_COMPARATOR|Ertugliflozin then Placebo|Treatment with Ertugliflozin for one month, washout period for one month, and then with Placebo for one month
62284468|NCT05152940|ACTIVE_COMPARATOR|Placebo|Treatment with matching placebo for one month, washout period for one month, and then Ertugliflozin for one month
62085381|NCT02239653|EXPERIMENTAL|Physician communication|"The Milk. Water. Period intervention comprises brochures, posters, and key talking points for use by primary pediatricians to use in discussion with the parent about the child's beverages consumption."
62085382|NCT02239653|NO_INTERVENTION|Usual care|
62085383|NCT04349111|OTHER|Experimental: Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
62085384|NCT03100838|EXPERIMENTAL|Nifedipine (Generic)|1 x 60 mg Nifedipine extended-release tablet
62085385|NCT03100838|ACTIVE_COMPARATOR|Nifedipine (Brand)|1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet
62085386|NCT03100838|ACTIVE_COMPARATOR|Nifedipine (Generic) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg Nifedipine extended-release tablet on day 7
62085387|NCT03100838|ACTIVE_COMPARATOR|Nifedipine (brand) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet on day 7
62460036|NCT04400123|EXPERIMENTAL|Treatment group RT|Intervention: Drug: famitinib malate, old formulation; Intervention: Drug: famitinib malate, new formulation.
62460037|NCT00667524||I|
62085388|NCT01987375|EXPERIMENTAL|Cetuximab-IRDye800 Participants|Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
62085389|NCT00958529|EXPERIMENTAL|inulin|0, 5, 10 g inulin
62085390|NCT03693261||Coronary Artery Disease (CAD)|Patients with clinically and angiographically established coronary artery disease (CAD) who require CABG, as part of the standard medical care.
62085391|NCT03693261||controls|Control group will be formed by subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography).
62085392|NCT05030935|EXPERIMENTAL|Intervention Group|This group will be able to use the mHealth App.
62460038|NCT01888081|EXPERIMENTAL|A-dmDT390-bisFv(UCHT1) with Ionizing Radiation|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation
62085393|NCT05030935|NO_INTERVENTION|Control group|The Instructions Manual consists of a hard copy of the mHealth App bibliographical content. In addition, a calendar that can be used as a reminder for patient position switching is present and a hard copy explanation of the scale which can be used by the caregiver and through handwriting, determine the need for support surfaces.
62085394|NCT03013699|ACTIVE_COMPARATOR|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
62284469|NCT04928261|EXPERIMENTAL|De-escalated HER2 targeted treatment|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery.
62284470|NCT03352531|EXPERIMENTAL|AK-105|Single-arm
62284471|NCT02078219|EXPERIMENTAL|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
62284472|NCT02078219|EXPERIMENTAL|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
62284473|NCT02078219|EXPERIMENTAL|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
62284474|NCT02078219|PLACEBO_COMPARATOR|RDEA3170 4|RDEA3170 Placebo
62284475|NCT02078219|OTHER|Allopurinol|Allopurinol 200mg
62284476|NCT04009941|EXPERIMENTAL|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
62284477|NCT05014477||Patients experiencing device embolization after left atrial appendage occlusion|Device embolization following either surgical or interventional left atrial appendage occlusion
62284478|NCT02926326|OTHER|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - BCT 197 14mg on Day 1 and Azithromycin 500mg on Day 1,2 and 3"
62085395|NCT03013699|EXPERIMENTAL|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
62085396|NCT05290103|EXPERIMENTAL|Game intervention|Participants in this arm will receive the game intervention including 15-30 minutes of digital health game playing at school and 2 weeks of free usage of the game during free time and a 30-minute debriefing session with a researcher.
62085397|NCT05290103|NO_INTERVENTION|No intervention|The participants in this arm will receive no intervention.
62460039|NCT03119935|EXPERIMENTAL|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
62460040|NCT03119935|EXPERIMENTAL|Ambu bag ventilation|Ordinary method (ambu bag ventilation
62461831|NCT04559347|EXPERIMENTAL|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine for erector spinae block as local anesthetic
62284479|NCT01570244|EXPERIMENTAL|Reference|multiple doses of Microgynon
62284480|NCT01570244|ACTIVE_COMPARATOR|Test|multiple doses of Microgynon + BI 201335
62284481|NCT05800587|EXPERIMENTAL|Platinum doublet plus immunotherapy (IO)|
62284482|NCT05800587|EXPERIMENTAL|Platinum doublet with or without a VEGFi|
62284483|NCT05800587|EXPERIMENTAL|Single agent chemotherapy with or without a VEGFi|
62284484|NCT06017154|EXPERIMENTAL|Physically active females|Healthy active females between 18 and 25
62284485|NCT03889041||Caregivers of children with EA-TEF|Caregivers of children with esophageal atresia and tracheoesophageal fistula will be included in the study.
62284486|NCT06184347||Screening group|All participants will receive an HBsAg finger blood test and a questionnaire gathering their personal information and medical history concerning viral hepatitis, cirrhosis, and hepatocellular carcinoma. Individuals positive for HBsAg will undergo further clinical detections to distinguish dormant liver diseases and HCC.
62284487|NCT06184347||Control group|All subjects in this arm will be followed by linkage to the Guangdong Provincial Center for Disease Control and Prevention, Cancer Registry, and Population Registry.
62284488|NCT03670355|EXPERIMENTAL|Tenofovir (TFV) Intravaginal Ring (IVR)|The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
62461832|NCT04559347|ACTIVE_COMPARATOR|Continuous catheter infusion ropivacaine|Ropivacaine (0.5% bolus followed by 0.2% infusion) using a continuous catheter for erector spinae plane block as local anesthetic
62651333|NCT03093181|PLACEBO_COMPARATOR|No treatment and Standard cleanser|Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
62085398|NCT05398354|EXPERIMENTAL|Active Retirement - intervention|The duration of the program is 24-weeks, 2-times a week, for up to 50 minutes per session. The sessions will be divided into three phases: the initial phase (10 minutes) will consist of a 5-minute walk followed by a joint warm-up; fundamental phase (25 minutes) will work in an exercise circuit, this circuit will consist of 4 cycles, with 8 exercises each, with a duration of 50 seconds and a rest of 15 seconds, for the exchange of exercise; and return to calm (10 minutes), where we will perform muscle stretching.
62085399|NCT05398354|NO_INTERVENTION|Active Retirement - control|The control group will only carry out the assessments and will be offered the same intervention as the intervention group at the end of the intervention.
62085400|NCT04017741|ACTIVE_COMPARATOR|Active group|The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.
62085401|NCT04017741|PLACEBO_COMPARATOR|Placebo group|The placebo group will be administered 4mls of 0.9% saline.
62085402|NCT05468671|EXPERIMENTAL|Remazolam general anesthesia group (R group)|Remazolam 0.4 mg/kg, oxycodone 0.2 mg/kg and rocuronium 0.9 mg/kg were given for anesthesia induction.Group R was given remazolam 1mg/kg/h and remifentanil 6-8ug/kg/h for maintenance.
62085403|NCT05468671|ACTIVE_COMPARATOR|Propofol general anesthesia control group (P group)|Propofol 1.5mg/kg, oxycodone 0.2mg/kg and rocuronium 0.9mg/kg were given for induction of anesthesia.Group P was given propofol 4-8 mg/kg/h and remifentanil 6-8ug/kg/h for anesthesia maintenance.
62085404|NCT00217100|ACTIVE_COMPARATOR|Multi Vitamin Formulation|
62085405|NCT00217100|PLACEBO_COMPARATOR|Sugar pill|
62085406|NCT06270290||RBD group|Participants with a diagnosis of REM sleep behaviour disorder
62085407|NCT06270290||Control group|Participants without a diagnosis of REM sleep behaviour disorder
62085408|NCT01719120|EXPERIMENTAL|Self-help CBT with tel. consultation|Self-help CBT with tel. consultation (SHTC)group will receive telephone consultation provided by the investigator in addition to self-help cognitive-behavioral therapy once per week for 6 consecutive weeks.During the consultation, the investigator will answer questions about the treatment content, monitor whether the subjects read the assigned materials and comply with the tasks and procedures, and provide encouragement and support.
62085409|NCT01719120|EXPERIMENTAL|Self-help CBT|The subjects will receive self-help cognitive-behavioral therapy (SH)once per week for 6 consecutive weeks.
62085410|NCT01719120|NO_INTERVENTION|Waiting-list control (WL)|Subjects in this group will not receive any kind of treatment during the waiting period. They will receive the treatment identical to the self-help group within 3 months from the baseline.
62085411|NCT00739193|PLACEBO_COMPARATOR|Placebo|Placebo Control
62085412|NCT00739193|EXPERIMENTAL|PM101|PM101
62085413|NCT00739193|ACTIVE_COMPARATOR|Amiodarone IV|Amiodarone IV
62284489|NCT03670355|PLACEBO_COMPARATOR|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
62460041|NCT04797130|NO_INTERVENTION|Control group|All subjects eligible for inclusion in this study receive usual care physiotherapy as prescribed by the physician. The number of treatment sessions and content of physiotherapy treatment sessions will depend on the diagnosis and needs of the individual patient. This study will not interfere with the content of the usual care physiotherapy treatment. Patients in the control group will receive an accelerometer, measuring PA, which is applied by the physiotherapist during the first treatment. They receive no other additional intervention. Usual care physiotherapy sessions will take approximately 20-30 minutes per session.
62460042|NCT04797130|EXPERIMENTAL|Intervention group|Patients in the intervention group will receive usual care physiotherapy and use Hospital Fit 2.0 (HF) additionally. After the last treatment session (max. 7 days), the therapist will remove the accelerometer and participation in the study will end.
62284490|NCT02063035|EXPERIMENTAL|Tranexamic acid|Participants undergoing spinal surgery will receive a single, topical dose of tranexamic acid. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
62460043|NCT05483153|EXPERIMENTAL|Infant-Directed Singing Coaching Group|At-risk mothers and infants will receive four, 30-minute sessions of an infant-directed singing coaching intervention.
62085414|NCT04640480|EXPERIMENTAL|Cohort 1|SNB-101 5/8mg/m2 Q2W IV
62085415|NCT04640480|EXPERIMENTAL|Cohort 2|SNB-101 10/16mg/m2 Q2W IV
62085416|NCT04640480|EXPERIMENTAL|Cohort 3|SNB-101 20/32mg/m2 Q2W IV
62284491|NCT02063035|PLACEBO_COMPARATOR|Placebo|Participants undergoing spinal surgery will receive a single, topical dose of matching placebo. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
62284492|NCT06449586|EXPERIMENTAL|CMI-F|Letemovir prophylaxis stops when CMV-FlowSpot \>1.5.
62460044|NCT04349592|EXPERIMENTAL|Combination therapy group|hydroxychloroquine 200mg TID for 7 days plus Azithromycin 500mg OD 1st day and 250 from day 2 to 5
62460045|NCT04349592|ACTIVE_COMPARATOR|Monotherapy therapy group|hydroxychloroquine 200mg TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
62460046|NCT04349592|PLACEBO_COMPARATOR|Control group|Placebo Cap TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
62085417|NCT04640480|EXPERIMENTAL|Cohort 4|SNB-101 30/48mg/m2 Q2W IV
62085418|NCT04640480|EXPERIMENTAL|Cohort 5|SNB-101 40/64mg/m2 Q2W IV
62085419|NCT04640480|EXPERIMENTAL|Cohort 6|SNB-101 45/72mg/m2 Q2W IV
62284493|NCT06449586|OTHER|CMI-N|Letemovir prophylaxis stopos in the first 100 days after allo-HSCT.
62284494|NCT02562326|EXPERIMENTAL|BioChaperone insulin lispro|
62284495|NCT02562326|ACTIVE_COMPARATOR|Humalog®|
62284496|NCT01019018|ACTIVE_COMPARATOR|Stevens cannula|Subtenon with stevens cannula
62284497|NCT01019018|EXPERIMENTAL|Olive tip|Olive tip group
62284498|NCT00799305||COPD patients|
62284499|NCT02633371|EXPERIMENTAL|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
62085420|NCT04640480|EXPERIMENTAL|Cohort 7|SNB-101 50/80mg/m2 Q2W IV
62085421|NCT05498766|EXPERIMENTAL|Huaier group|The participants volunteering to take Huaier granule will be assigned to the Huaier group.
62085422|NCT05498766|ACTIVE_COMPARATOR|Control group|The participants volunteering to take SOX will be assigned to the control group.
62460047|NCT05267366|EXPERIMENTAL|Chemothreapy with PD-1 inhibitor and bevacizumab|PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Carboplatin 5 AUC /cisplatin 75 mg/m2, iv day 1 Pemtrexed 500 mg/m2, iv day 1 Bevacizumab 15 mg/m2, iv day 1 as induction therapy every 21 days a cycle for 4 cycles, PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Bevacizumab 15mg/m2, iv day 1 every 21 days a cycles as maintenance treatment for 31 cycles or 2 years.
62284500|NCT01811147|EXPERIMENTAL|High Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant.
62284501|NCT01811147|EXPERIMENTAL|Low Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant..
62284502|NCT01811147|NO_INTERVENTION|Healthy Control|There is no intervention, but rather phone follow ups conducted as check ins to determine the continued eligibility of the healthy control participant.
62284503|NCT01811147|NO_INTERVENTION|Bipolar|Bipolar participants are checked in with via phone conversations every three months, and have the opportunity to be scheduled for non-study visits to manage their symptoms.
62284504|NCT01886521|EXPERIMENTAL|Lumbar drain group|Lumbar drain
62284505|NCT01886521|ACTIVE_COMPARATOR|Ventricular drain|Ventricular drain
62284506|NCT03484715|EXPERIMENTAL|Physical Activity Intervention|Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
62284507|NCT03484715|NO_INTERVENTION|Usual Care Control|The participants in the control arm will receive usual care, which will be guided by current nursing and medical care plans.
62284508|NCT01780155||1|Parents and premature newborns with a birth weight less than or equal to1250 g from member institutions of the hospital network will be invited to participate in this study.
62284509|NCT02027740|EXPERIMENTAL|almond|almonds are substituted for visible fat and carbohydrates
62284510|NCT05458336|EXPERIMENTAL|Cases|Subjects who have been given nasal lavages
62284511|NCT05458336|NO_INTERVENTION|Controls|Subjects who haven't been given nasal lavages
62284512|NCT02363075|EXPERIMENTAL|Dexamfetamine sulphate|Dexamfetamine Sulphate 5 mg Tablets
62460048|NCT05267366|ACTIVE_COMPARATOR|Chemothreapy with PD-1 inhibitor|PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Carboplatin 5 AUC /cisplatin 75 mg/m2, iv day 1 Pemtrexed 500 mg/m2, iv day 1 as induction therapy every 21 days a cycle for 4 cycles, PD-1 inhibitor (pembrolizumab) 200mg iv day 1 every 21 days a cycles as maintenance treatment for 31 cycles or 2 years.
62284513|NCT02363075|PLACEBO_COMPARATOR|placebo|Aspect tablets identical to the active
62284514|NCT05700474|EXPERIMENTAL|Intervention Arm|There is one arm of the study and this involves participating in holistic behavioral health treatment for people living with HIV and the LGBTQ+ community for a 6 month period. Specific services include individual and group therapy, case management, peer support, and behavioral health education and awareness
62284515|NCT01790503|EXPERIMENTAL|Phase 1b dose escalation - 600mg/day PLX3397 cohort|600mg/day PLX3397, Radiation Therapy, and Temozolomide
62460049|NCT00605709|EXPERIMENTAL|1|Active Cream 3% ; AM \& PM
62284516|NCT01790503|EXPERIMENTAL|Phase 1b dose escalation - 800mg/day PLX3397|800mg/day PLX3397, Radiation Therapy, and Temozolomide
62085423|NCT01330121|ACTIVE_COMPARATOR|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic \& non-glycemic goal levels Explaining the importance of compliance with medications \& appointments Educating on the basics of nutrition and physical activity"
62460050|NCT00605709|ACTIVE_COMPARATOR|2|Placebo Cream AM; 3% Active Cream PM
62085424|NCT01330121|NO_INTERVENTION|Standard therapy|Standard therapy: Nurses distribute a education pamphlet on diabetes
62460051|NCT00605709|ACTIVE_COMPARATOR|3|Placebo Cream AM; 1.5% Active Cream PM
62651334|NCT03093181|EXPERIMENTAL|Test product and Standard cleanser|Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.
62651335|NCT03093181|ACTIVE_COMPARATOR|Positive control and positive cleanser|Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
62085425|NCT01198925|ACTIVE_COMPARATOR|extended infusion|
62085426|NCT01198925|EXPERIMENTAL|continuous infusion|
62085427|NCT03756402||Healthy Subjects|All subjects underwent protein loading test and IRRIV test on the same day. The renal resistive index (RRI) measurements were performed by one trained sonographer using a multi-frequency convex probe through a manual RRI calculations. The RRIs were measured on three interlobular arteries (superior, middle and inferior) in each kidney, and expressed as a mean value. RFR was measured using an oral protein loading test and was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Urinary creatinine and sCr were measured by the enzymatic method (IL testTM Instrumentation(R), Laboratory SpA, Milano, Italy) and by ILab650 (Instrumentation Laboratory, Werfen Group, Barcelona, Spain).
62460052|NCT00605709|PLACEBO_COMPARATOR|4|Placebo Cream AM \& PM
62651336|NCT05974761|EXPERIMENTAL|Side lying muscle massage|The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, after that, the tendon was found to be induration with elbow tip probing, and the tendon was plucked 3-5 times vertically along the vertical direction.
62651337|NCT05974761|OTHER|Traditional Chinese massage|Through the point, massage, bone-setting treatment
62284517|NCT01790503|EXPERIMENTAL|Phase 1b dose escalation - 1000 mg/day PLX3397 cohort|1000 mg/day PLX3397, Radiation Therapy, and Temozolomide
62284518|NCT01790503|EXPERIMENTAL|Phase 2 - Recommended phase 2 dose of PLX3397|Recommended phase 2 dose of PLX3397 (800mg/day), Radiation therapy, and Temozolomide
62460053|NCT02417636|EXPERIMENTAL|Nurse-initiated and monitored ART|This is an experimental task shifting of ART initiation and monitoring from a clinician-led model to a nurse-led model. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
62284519|NCT04799041|ACTIVE_COMPARATOR|GTX 2/3|Dose level administered of GTX 2/3 was 80 mcg. Dose was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of GTX 2/3 was injected. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 40 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
62284520|NCT04799041|PLACEBO_COMPARATOR|Placebo|Placebo was of identical appearance to the IMP, and was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of placebo was injected.
62284521|NCT04871503|EXPERIMENTAL|HIFEM+RF (HR)|The HR group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with mild heating of the muscles.
62284522|NCT04871503|EXPERIMENTAL|HIFEM (H)|The H group will receive a treatment with the intensities of the magnetic field just below the patient's tolerance threshold without the use of radiofrequency.
62651338|NCT06185296|EXPERIMENTAL|Intelligent telemonitoring|The subjects will be telemonitored using the intelligent telemonitoring system. All subjects will use a CGM, a Fitbit, and a smart pen during the trial period. Staff at the endocrinology clinic will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject) using the intelligent telemonitoring system with embedded decision support to facilitate treatment evaluation and adjustments. The subjects will have access to a smartphone app that is able to provide a risk for nocturnal hypoglycemia before bed.
62284523|NCT01809548|EXPERIMENTAL|Early complementary feeding group|"Early intervention group:~Introduction of early complementary feedings between the 10th -12th week of gestation corrected for prematurity"
62284524|NCT01809548|EXPERIMENTAL|Late complementary feeding group:|"Late intervention group:~Introduction of late complementary feedings between the 16th and 18th week of life corrected for prematurity"
62284525|NCT02594488|ACTIVE_COMPARATOR|Remote monitoring|Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor
62284526|NCT02594488|NO_INTERVENTION|Control arm|Follow-up at the same frequency, but with no implantable cardiac monitor
62284527|NCT03820557|EXPERIMENTAL|Decision Counseling|Patients undergo participation in the DCP prior to an audio-recorded oncology appointment.
62284528|NCT03633500|PLACEBO_COMPARATOR|Sterile water|Sterile water: Started by six hours of age, In the control arm, 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
62284529|NCT03633500|EXPERIMENTAL|Breastmilk|Breastmilk. This is started at 6 hours of age at the earliest; breast milk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
62284530|NCT03966326|PLACEBO_COMPARATOR|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
62284531|NCT03966326|ACTIVE_COMPARATOR|PECS II group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
62284532|NCT05247788|EXPERIMENTAL|Intoxicated risk awareness training session|Participants will complete an intoxicated risk awareness training session in which they receive a controlled alcohol dose with structured feedback and training to accurately appraise the impairing effects of alcohol and estimate their blood alcohol concentration (BAC).
62284533|NCT05247788|ACTIVE_COMPARATOR|Alcohol exposure only|Participants assigned to the alcohol-exposure-only condition undergo the same alcohol dose exposures over the session but receive a general body scan and do not receive feedback concerning BAC or performance.
62460054|NCT02417636|ACTIVE_COMPARATOR|Clinician - initiated and monitored ART|This is Standard of Care for the Uganda Ministry of Health to compared with the experimental task shifting. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Clinicians (Clinical Officer or Medical Officer) and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually.
62651339|NCT06185296|ACTIVE_COMPARATOR|Telemonitoring|The subjects will be telemonitored. All subjects will use a CGM, a Fitbit, and a smart pen during the entire trial period. Staff at the endocrinology clinic will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject)
62651340|NCT06185296|NO_INTERVENTION|Usual care|The subjects will wear a blinded CGM the first 20 days after inclusion, 20 days before the second visit to the trial site, and the final 20 days of the trial. The subjects will use a blinded smart pen throughout the trial period. Hence, the subjects cannot see their measured data during the trial and will not be monitored.
62651341|NCT01760902|EXPERIMENTAL|Diet and Physical Activity|Participants convene weekly for 12 consecutive weeks and then once per month for 9 months. Each sessions is 90 minutes
62284534|NCT01709188|EXPERIMENTAL|Musical Dual Task Training|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the Musical Dual Task Training session, participant will be asked to sing familiar songs, play simple percussive musical instruments such as paddle drums and shakers, sing while walking, and play instruments while walking.
62284535|NCT01709188|ACTIVE_COMPARATOR|Walking and Talking|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the walking and talking session, participant will be asked to read a newspaper article prior to a walk and have a conversation with the music therapist based on the content of the news while walking.
62284536|NCT01467492|EXPERIMENTAL|Black|Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing \<75 kilograms \[kg\]) or 1200 mg/day (for participants weighing \>=75 kg) for 24 or 48 weeks.
62284537|NCT01467492|EXPERIMENTAL|Non-Black|Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing \<75 kg) or 1200 mg/day (for participants weighing \>=75 kg) for 24 or 48 weeks.
62284538|NCT03396770|ACTIVE_COMPARATOR|Control group|Standard clinical routine
62284539|NCT03396770|EXPERIMENTAL|Nephrocheck group|Nephrocheck test
62461833|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
62284540|NCT02266433|ACTIVE_COMPARATOR|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
62651342|NCT02968810|EXPERIMENTAL|Group I (simvastatin)|Patients receive simvastatin PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood on study and CT/MRI throughout the trial.
62284541|NCT02266433|EXPERIMENTAL|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
62284542|NCT03325179|EXPERIMENTAL|participants received treatment|100 participants who are diagnosed as simple obesity under the standards of... are planned to enrolled in the trial. Each will receive Thread-embedding therapy.
62284543|NCT05410548|OTHER|Standard-of-Care|Patient participants will receive routine standardized prosthetic follow-up care by a certified prosthetist, including evaluation of prosthesis use, prosthesis-enabled mobility, socket comfort and sock ply usage, falls, body anthropometrics, and functional mobility.
62284544|NCT05410548|EXPERIMENTAL|Standard-of-Care + Clinical Screening|In addition to routine, standardized prosthetic follow-up care, patient participants will receive comorbidity screening for contralateral limb peripheral arterial disease, peripheral neuropathy, major depression, and greater than low risk for persistent low back pain. Participants will be educated on clinical screening findings, provided a copy of their screening results to share with their medical providers, and their results will be securely sent to their primary care provider.
62284545|NCT06198725|EXPERIMENTAL|High fiber intervention group|Participants in the high fiber intervention group take high fiber dietary products (28g dietary fiber per day) for 12 weeks, and at the same time, follow the doctor's advice to use subcutaneous insulin injection for treatment.
62284546|NCT06198725|NO_INTERVENTION|Usual treatment group|Participants in the usual treatment group received routine diet education for diabetes and were treated with subcutaneous insulin injection according to the doctor's advice
62651343|NCT02968810|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood on study and CT/MRI throughout the trial.
62651344|NCT02923869|ACTIVE_COMPARATOR|Group L|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
62651345|NCT02923869|ACTIVE_COMPARATOR|Group B|Children will receive 0.15 ml/kg of 0.2% Bupivacaine
62651346|NCT03920956|EXPERIMENTAL|Experimental: 24-hour ABPM by Pharmacists|Patients will meet with the pharmacist to be equipped with a 24-hour ambulatory blood pressure monitor (ABPM). Patients will return the monitor for the pharmacists to download the results to send to their medical provider.
62651347|NCT00405769|PLACEBO_COMPARATOR|1|placebo control
62085428|NCT00467142|EXPERIMENTAL|Folfiri and Bevacizumab|"* Premedication = Dexchlorpheniramine, 5 mg in slow Direct IntraVeinous (DIV) on D1.~* FOLFIRI (simplified LV5FU2 + irinotecan):~* Irinotecan (Campto®): 180 mg/m² on D1 by IV infusion in 250 mL of 0.9% saline over 90 minutes.~* LV5FU2, in its so-called simplified version, will be administered as follows L-folinic acid, as a 2-hour intravenous infusion, at a dose of 200 mg/m², on Day 1, in 500 mL of 5% glucose solution, concomitantly with the irinotecan infusion via a Y-tube, followed by 5 Fluorouracil (5 FU), intravenous bolus, at a dose of 400 mg/m² on D1, followed by 5 Fluorouracil (5 FU) as a 46-hour continuous infusion at a dose of 2400 mg/m² from D1 to D3, either in 1000 mL of 5% glucose solution, or in an electric syringe or pump dispenser~* Bevacizumab (Avastin®): 5 mg/kg IV infusion in 100 mL of 0.9% saline over 90 minutes for the first infusion, then 60 minutes for the second infusion if tolerated, and 30 minutes for subsequent infusions if tolerated."
62085429|NCT04155684||HIV + with COPD|COPD will be defined as Subjects with FEV1/FVC\<0.70 or FEV1 and DLco \< 80% predicted
62284547|NCT05285501|EXPERIMENTAL|Virtual Therapeutic Garden|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of VRTierOne therapy (20 minutes each)"
62284548|NCT05285501|ACTIVE_COMPARATOR|Control|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of group relaxation and psychoeducation (20 minutes each)"
62085430|NCT04155684||HIV+ normal|Normal PFT's
62085431|NCT03403933|EXPERIMENTAL|cardiopathic patients in hypovitaminosis|Didrogyl 10 ml: 10 drops a day to obtain levels of vitamin D \> 30 ng /ml. Once these values are obtained lower the dose to 4-5 drops a day, with the aim, however, of keeping the plasma values between 30 and 60 ng/ml during 6 months of the study
62085432|NCT03565861|PLACEBO_COMPARATOR|Placebo|Placebo intravenous 30 minute infusion on day 1
62085433|NCT03565861|EXPERIMENTAL|NP10679 5 mg|NP10679 5 mg intravenous infusion on day 1
62085434|NCT03565861|EXPERIMENTAL|NP10679 15 mg|NP10679 15 mg intravenous infusion on day 1
62085435|NCT03565861|EXPERIMENTAL|NP10679 50 mg|NP10679 50 mg intravenous infusion on day 1
62085436|NCT03565861|EXPERIMENTAL|NP10679 100 mg|NP10679 100 mg intravenous infusion on day 1
62284549|NCT05000515|EXPERIMENTAL|High-resistance inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
62651348|NCT00405769|ACTIVE_COMPARATOR|2|red yeast rice
62460055|NCT02186730|EXPERIMENTAL|Stressbsuters|"Computerised Cognitive Behaviour package consisting of eight 30-45 minute sessions of CBT designed for 12-18 year olds. Each Stressbusters session is an interactive presentation featuring narration synchronised with videos, animations, graphics and printouts.~The programme has a narrator guiding individuals through each of the eight sessions in a linear progression. Each session builds on the knowledge gained in previous sessions and on tasks carried out at home. Sessions contain flexible add-ons such as written fact sheets (for example about bullying, sleep problems) which can be printed out and taken away together with home practice related handouts from the programme (for example mood diary sheets). Session topics include getting activated, relapse prevention, challenging negative thoughts and problem solving"
62085437|NCT03565861|EXPERIMENTAL|NP10679 200 mg|NP10679 200 mg intravenous infusion on day 1
62085438|NCT03565861|EXPERIMENTAL|NP10679 300 mg|NP10679 300 mg intravenous infusion on day 1
62284550|NCT05000515|ACTIVE_COMPARATOR|Aerobic exercise|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
62085439|NCT01593735|EXPERIMENTAL|Panel A: GT1, low dose|Participants with genotype 1 (GT1) Hepatitis C Virus (HCV) will receive low dose MK-2748 daily for 7 days.
62085440|NCT01593735|EXPERIMENTAL|Panel B: GT1, lower dose|Participants with GT1 HCV will receive lower dose MK-2748 daily for 7 days.
62284551|NCT03603041|NO_INTERVENTION|Control|These participants will maintain their daily food and exercise routine and will receive no intervention.
62085441|NCT01593735|EXPERIMENTAL|Panel C: GT1, dose based on Panels A+B|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose) and B (lower dose).
62085442|NCT01593735|EXPERIMENTAL|Panel G: GT1, dose based on Panels A+B+C|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), and C.
62085443|NCT01593735|EXPERIMENTAL|Panel H: GT1, dose based on Panels A+B+C+G|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), C, and G.
62085444|NCT01593735|EXPERIMENTAL|Panel D: GT3, low dose (Omitted)|Participants with genotype 3 (GT3) HCV were to receive low dose MK-2748 daily for 7 days. Panel D was omitted from the study design and participants were not enrolled in this panel.
62085445|NCT01593735|EXPERIMENTAL|Panel E: GT3, high dose|Participants with genotype 3 (GT3) HCV will receive high dose MK-2748 daily for 7 days.
62085446|NCT01593735|EXPERIMENTAL|Panel F: GT3, dose based on Panel E|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panel E (high dose).
62460056|NCT02186730|ACTIVE_COMPARATOR|Websites|Any individuals randomised to arm 2 of the trial will spend the equivalent time accessing currently available self help websites that provide information about low mood/depression. These four websites will be the same as those used in our initial feasibility study of which, based on our preliminary data, there is evidence for their usefulness.
62085447|NCT01593735|EXPERIMENTAL|Panel I: GT3, dose based on Panels E+F|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose) and F.
62085448|NCT01593735|EXPERIMENTAL|Panel J: GT3, dose based on Panels E+F+I|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose), F, and I.
62085449|NCT00107380|EXPERIMENTAL|R-CHOP x 8 with I-131 Tositumomab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 cycles~Unlabeled Anti-B1 Antibody 450 mg IV Day 170 Dosimetric dose 35 mg IV Day 170~Unlabeled Anti-B1 Antibody 450 mg IV Day 177 Therapeutic dose 35 mg IV Day 177"
62085450|NCT05489029||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
62085451|NCT05489029||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
62085452|NCT04137510|EXPERIMENTAL|Orsiro|
62085453|NCT04137510|ACTIVE_COMPARATOR|Resolute Onyx|
62085454|NCT02764775|EXPERIMENTAL|Headed utilization|Use of Headpod for 6 months duration; 3 x per day for a minimum of 15 minutes each time;
62085455|NCT01723553|EXPERIMENTAL|PiB positron emission tomography (PET)|All subjects will receive PET imaging with C-11 PiB on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
62085456|NCT04436003|EXPERIMENTAL|Muscle and Articulation chains GDS method treatment|"Participants in the intervention Group are examined and treated according to the principles of Muscle and Articulation Chains GDS Method. They receive GDS treatment individually, up to 8 sessions of 1 hour."
62284552|NCT03603041|EXPERIMENTAL|Whey Protein Supplementation|Participants will receive protein supplementation daily for 16 weeks.
62284553|NCT03603041|EXPERIMENTAL|Omega-3 Fatty Acids (O3FA)|Participants will receive O3FA supplementation daily for 16 weeks.
62085457|NCT04436003|NO_INTERVENTION|Control (treatment as usual)|The Control Group receives standard treatment from their RGP/ doctor. Some are prescribed physiotherapy or chiropractor treatment, or they choose their own alternatives.
62085458|NCT01290094|EXPERIMENTAL|Single Arm|
62085459|NCT05640739|NO_INTERVENTION|Control group patients|Data will be collected from the patients in the control group without any application and their ability to use MDI will be evaluated.
62085460|NCT05640739|EXPERIMENTAL|Demonstration group patients|Patients in the demonstration group will be given inhaler training (practically) by the researcher. The training will include steps compatible with the video. After the training, the patients will be asked to use inhaler drugs again, and their skill scores will be re-evaluated and the mistakes made by the patients will be shown by the researcher in the demonstration group. On the 7th day of the study, the patients will be called by the researcher with a video call, and the patients will be asked to use their MDI drugs again, and the MDI use skill chart will be filled again.
62085461|NCT05640739|EXPERIMENTAL|Video group patients|The patients in the video group will be shown the video of using MDI prepared by the researchers. The training will be completed by watching the MDI usage video prepared by the researchers in the patients in the video group. After the training, the patients will be asked to use the inhaler again and their skill scores will be re-evaluated. Their mistakes will be shown by making them watch it again from the video. On the 7th day of the study, the patients will be called by the researcher with a video call, and the patients will be asked to use their MDI drugs again, and the MDI use skill chart will be filled again.
62085462|NCT05157685|EXPERIMENTAL|Azithromycin oral tablet|Azithromycin 250 mg once daily morning or evening (with or without meals)
62085463|NCT05157685|PLACEBO_COMPARATOR|Placebo|Placebo once daily morning or evening (with or without meals)
62085464|NCT02155582|EXPERIMENTAL|Arm 1|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients
62085465|NCT02155582|EXPERIMENTAL|Arm 2|45 mg and 60 mg for the diabetic patients
62085466|NCT01782326|EXPERIMENTAL|QVA149|QVA149 (110/50 μg) once daily
62085467|NCT01782326|ACTIVE_COMPARATOR|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone (50/500μg) b.i.d
62085468|NCT02727868|OTHER|exclusive breast irradiation group|to assess the impact of irradiation areas
62085469|NCT02727868|OTHER|breast and sternal irradiation group|to assess the impact of irradiation areas
62085470|NCT05973890|EXPERIMENTAL|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
62085471|NCT05973890|EXPERIMENTAL|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
62085472|NCT05973890|NO_INTERVENTION|control|standard of care for repeat blood donation
62085473|NCT04544007|EXPERIMENTAL|Administer Poly-ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
62085474|NCT06115278||nurses|Our inclusion criteria for the nurses are the following: (1) 18 years old or older; (2) currently employed as a licensed nurse; and (3) current employment duties include routinely assessing the musculoskeletal pain of cognitively intact, adult outpatients. Our exclusion criteria for the nurses are the following: (1) currently managing a painful musculoskeletal condition; and (2) has ever felt musculoskeletal pain on most days for 3 months or longer.
62284554|NCT03603041|EXPERIMENTAL|Whey Protein and O3FA|Participants will receive protein and O3FA supplementation daily for 16 weeks.
62085475|NCT06115278||patients|"Our inclusion criteria for the patients are the following: (1) 18 years old or older; (2) currently being treated by a health care provider for a painful musculoskeletal condition; (3) has felt a usual musculoskeletal pain intensity rating of 2 or higher on a 0 to 10 scale over the last 24 hours; (4) has felt extreme pain that completely disappeared; (5) has felt musculoskeletal pain on most days of the last 3 months; (6) chronic musculoskeletal pain has increased and decreased during the last 3 months; and (6) has felt musculoskeletal pain in more than one location on most days of the last 3 months. Our exclusion criterion for the patients is ever employed as a licensed health care provider."
62085476|NCT04218136||patient with head and neck cancer|Patients treated by standard treatment and have a minimum of 4 blood samples.
62460057|NCT03356821|EXPERIMENTAL|Mesenchymal Stem Cells|All (near-)term newborns ≥36 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study.
62651349|NCT05711368|ACTIVE_COMPARATOR|interventional group|Nursing students who participated in distress tolerance training session
62284555|NCT03603041|PLACEBO_COMPARATOR|Whey Protein and Placebo Fat Source|Participants will receive protein and placebo fat source supplementation daily for 16 weeks.
62284556|NCT01592201|EXPERIMENTAL|Paliperidone ER|Immediate initiation of Paliperidone ER for a total of 12 weeks
62651350|NCT05711368|NO_INTERVENTION|control group|Nursing students not participating in distress tolerance training session
62085477|NCT02139982|OTHER|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
62085478|NCT02139982|OTHER|group UL( phase 1)|specific nerve block:ulnar nerve block
62085479|NCT02139982|OTHER|group RA (phase 1)|specific nerve block:radial nerve block
62085480|NCT02139982|OTHER|group ME (phase 1)|specific nerve block:median nerve block
62284557|NCT01592201|EXPERIMENTAL|Antipsychotics and paliperidone ER|Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
62284558|NCT02300766||Posterior fossa tumor patients|Children (0-18 years) with a tumour in the posterior fossa (cerebellum/4th ventricle/brainstem ) requiring surgery or open biopsy at one of the participating centres.
62460058|NCT04999670|ACTIVE_COMPARATOR|Single suture, knot above fascia|Fascia sutured with #1 polysorb braided absorbable suture, with the knot being superficial to the fascia, starting at the left angle of the fascial incision and closed in a continuous fashion. The contralateral angle is grasped with a kocher clamp and the suture is then tied behind the angle ensuring adequate closure.
62651351|NCT00924898|EXPERIMENTAL|Acute HIV Treatment Group|Single arm, open label study in which all participants received the same study treatment with efavirenz, emtricitabine, and tenofovir DF
62085481|NCT02139982|EXPERIMENTAL|group A(phase 2)|30ml ropivacaine 0.125%
62085482|NCT02139982|EXPERIMENTAL|group B(phase 2)|30ml ropivacaine 0.2%
62085483|NCT02139982|EXPERIMENTAL|group C(phase 2)|30ml ropivacaine 0.25%
62085484|NCT02139982|EXPERIMENTAL|group D(phase 2)|30ml ropivacaine 0.375%
62085485|NCT02139982|EXPERIMENTAL|group E(phase 2)|30ml ropivacaine 0.5%
62085486|NCT02139982|EXPERIMENTAL|group F(phase 2)|30ml ropivacaine 0.75%
62085487|NCT02025205|EXPERIMENTAL|ELVR with Endobronchial Valves|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
62085488|NCT02025205|NO_INTERVENTION|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice.
62085489|NCT00506285|EXPERIMENTAL|A|This arm was 4 weeks long. Subjects were treated using Methylphenidate Transdermal System. Patients were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone contact. MTS was initiated using a 12.5 cm patch. The dose was increased during the first 2 weeks based on treatment response and side effects to the largest tolerated dose/patch size. It was held steady the last 2 weeks.
62085490|NCT00506285|PLACEBO_COMPARATOR|B|This arm was 4 weeks long. Placebo patch was initiated using a 12.5 cm patch and then increased to the largest tolerated patch size during the first 2 weeks and held steady the last two weeks. Subjects were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone visit.
62284559|NCT02803164|OTHER|Vacuum-assisted dressing|Eligible subjects will receive negative pressure wound therapy during surgery.
62284560|NCT02803164|OTHER|Historical control group for comparison|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
62284561|NCT06140979|EXPERIMENTAL|Test Group|The patients in the test group will be given a visual focus game to play, and the treatment will be required at least 5 times per week for 2 weeks, with each session lasting 30 minutes.
62085491|NCT00946647|EXPERIMENTAL|Panobinostat + 5-Azacytidine|"In phase I: Panobinostat : Escalating doses starting with 20 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In both phases, dose of 5-Azacytidine was 75 mg/m\^2, subcutaneously Daily for Day 1 to Day 7."
62085492|NCT00946647|ACTIVE_COMPARATOR|5-Azacytidine|"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.~Dose of 5-Azacytidine : 75 mg/m\^2 subcutaneously daily from Day 1 to Day 7."
62085493|NCT02555007|EXPERIMENTAL|Oral Vinorelbine|
62085494|NCT01759875|ACTIVE_COMPARATOR|Ritonavir-boosted Atazanavir|
62085495|NCT01759875|EXPERIMENTAL|Ritonavir-boosted Atazanavir plus Rabeprazole|
62085496|NCT01759875|EXPERIMENTAL|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl|
62460059|NCT04999670|ACTIVE_COMPARATOR|Two sutures, knot above fascia|Fascia sutured using #1 polysorb braided absorbable suture with a superficial knot, starting at the left angle and closed in a continuous fashion until the suture is above the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is tied behind the right angle with a superficial knot and run across in a continuous fashion to meet the opposing suture which are then tied together.
62651352|NCT01047319|EXPERIMENTAL|Experimental: Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
62651353|NCT00769301||1|Not hospitalized cancer patients under active treatment
62651354|NCT00769301||2|Caregivers of these cancer patients
62651355|NCT04623710|EXPERIMENTAL|Cohort 1: Severe Impaired Renal Function|Participants will receive ALXN2050.
62085497|NCT04896892||Total Knee Arthroplasty|Patients in this group will be undergoing total knee arthroplasty.
62085498|NCT04896892||Total Hip Arthroplasty|Patients in this group will be undergoing total hip arthroplasty.
62085499|NCT00870025|ACTIVE_COMPARATOR|hCG|200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH
62085500|NCT00870025|PLACEBO_COMPARATOR|placebo|similar injection at same time points with similar diluent but no hCG
62085501|NCT00743522||Control|PROVE Trial settings
62085502|NCT00743522||Experimental|Pre-selected settings
62085503|NCT02410161|EXPERIMENTAL|4 week ALA treatment|Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
62085504|NCT03913728|EXPERIMENTAL|Outcome of blood test provided|These patients are given the results of their drug level blood tests and treatment can be altered/ further advice can be provided as a result of this.
62085505|NCT03913728|NO_INTERVENTION|Outcome of blood test not provided|The blood results for these people are not fed back to the patient or the clinical site.
62085506|NCT03913728|EXPERIMENTAL|Patients have a telephone interview|All patients are randomised for a second time; 20% (10) of them will have a semi-structured phone interview
62085507|NCT03913728|NO_INTERVENTION|No telephone interview|All patients are randomised for a second time; 80% won't have a phone call and this will be as per standard care.
62651356|NCT04623710|EXPERIMENTAL|Cohort 2: Moderate Impaired Renal Function|Participants will receive ALXN2050.
62651357|NCT04623710|EXPERIMENTAL|Cohort 3: Mild Impaired Renal Function|Participants will receive ALXN2050.
62085508|NCT00097370|EXPERIMENTAL|mepolizumab|750mg Intravenous, monthly and individual dosing schedule
62085509|NCT03327675|EXPERIMENTAL|68Ga-PSMA PET/MR|Hybrid 68Ga-PSMA PET/MR scan
62085510|NCT00790829|EXPERIMENTAL|A, B|Group B received a seven-milligram transdermal patch and Group A received a placebo patch.
62085511|NCT05115656|EXPERIMENTAL|Online group intervention 1|Participants in group 1 meet weekly online for a 2-hour group sessions for 10 weeks where the instructor will provide leadership in discussions, which will include practice of basic routines. Participants will also be asked to do 20-30 minutes of daily activities/exercises, where they will be asked to practice mental exercises.
62085512|NCT05115656|ACTIVE_COMPARATOR|Online group intervention 2|Similar to group 1, participants will meet weekly online or in person for 2-hour group sessions for 10 weeks where the instructor will provide leadership in discussions, which will include practice of basic routines. Participants will also be asked to do 20-30 minutes of daily activities/exercises, where they will be asked to practice mental exercises.
62085513|NCT02916082||Prolonged pregnancy|Pregnancies with 41 weeks or more of gestation determined by a reliable last menstrual period or early fetal ultrasound.
62085514|NCT00939796|EXPERIMENTAL|Tympanostomy Tube Delivery System (TTDS)|Tympanostomy tube placement with Acclarent tube delivery system
62085515|NCT00518505|OTHER|I|This is a single arm study. All patients will be asked to complete questionnaires and have their medical charts reviewed.
62085516|NCT01442974|EXPERIMENTAL|Gemcitabine plus nab-paclitaxel|This is a single arm study.
62284562|NCT06140979|SHAM_COMPARATOR|Control Group|The patients in the control group were given an animated video of the game that had no therapeutic effect, and the video will be required at least 5 times per week for 2 weeks, with each session lasting 30 minutes.
62085517|NCT01480635||Incomplete Colonoscopy|
62085518|NCT02006043|EXPERIMENTAL|Erlotinib 150mg/day taken orally|Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities
62284563|NCT06348082|EXPERIMENTAL|MBTI|Participants randomized to MBTI group.
62284564|NCT06348082|NO_INTERVENTION|Control|Participants randomized to waitlist control group.
62651358|NCT04623710|EXPERIMENTAL|Cohort 4: Healthy Control|Participants will receive ALXN2050.
62284565|NCT04416802|EXPERIMENTAL|PRP and Li-ESWT treatment|Participants diagnosed with erectile dysfunction will receive the combined treatment of platelet-rich plasma and low-intensity extracorporeal shockwave therapy.
62284566|NCT05784207||IPF/UIP_CT based|patients with an ILD and a pathological UIP pattern and a final diagnosis of IPF
62284567|NCT05784207||IPF/UIP_Biopsy based|patients with a final diagnosis of IPF but a less typical HRCT pattern( lung biopsy required for the diagnosis)
62284568|NCT05784207||ILD but not IPF and prove by biopsy not UIP|patients with an ILD and a pathological non-UIP pattern
62284569|NCT05784207||Normal|Normal healthy patients
62284570|NCT01069445|ACTIVE_COMPARATOR|Diet advices|will receive the Optimal Diet for Elderly
62284571|NCT01069445|EXPERIMENTAL|Diet advices + VSL-3|will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
62284572|NCT01069445|EXPERIMENTAL|Diet advices + 5203-L|will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
62284573|NCT01069445|EXPERIMENTAL|Diet advices + Argan oil|will receive the Optimal Diet for Elderly + Argan oil
62284574|NCT03675867||Obese teenagers|
62284575|NCT04095169||axSpA|Patients with low back pain ≥three months who a) fulfilled the ASAS definition for a positive MRI scan of sacroiliac joints (definite inflammation) or b) were HLA-B27 positive with at least one concomitant clinical spondyloarthritis feature.
62284576|NCT04095169||non-axSpA|Patients with a) positive MRI according to the ASAS definition, but no additional clinical spondyloarthritis features, or b) positive HLA-B27 and one clinical spondyloarthritis feature.
62284577|NCT04095169||Controls|Patients with non-specific low back pain without spondyloarthritis-related features and negative MRI SIJ.
62284578|NCT02567526|NO_INTERVENTION|Usual Care Control Group|Eligible, consented residents continued to receive usual care from nursing home staff and were monitored by trained research staff.
62651359|NCT03845894|ACTIVE_COMPARATOR|Liposomal Bupivacaine Interscalene brachial plexus (ISB)|
62284579|NCT02567526|EXPERIMENTAL|Between-meal Intervention Group|Non-nursing staff trained as Feeding Assistants were utilized to deliver supplements and snacks twice per day, between meals for 24 study weeks.
62460060|NCT04999670|ACTIVE_COMPARATOR|Two sutures, buried knots below fascia|Fascia sutured using #1 polysorb braided absorbable suture with a buried knot below the fascia starting at the left angle and closed in a continuous fashion until the suture overlies the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is then tied behind the right angle with a buried knot below the fascia and run across in a continuous fashion to meet the opposing suture which are then tied together.
62460061|NCT05629884|EXPERIMENTAL|Experimental arm|This group will perform the rehabilitation from home or from the gym following online instructions in the COPERIA platform.
62284580|NCT04172285|EXPERIMENTAL|Physical activity group|
62284581|NCT04172285|EXPERIMENTAL|Physical activity and supplementation group|
62284582|NCT04172285|EXPERIMENTAL|Control group|
62284583|NCT00962845|EXPERIMENTAL|Hydroxychloroquine|Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patients will undergo resection of their tumors. HCQ will be given to the patients up to the day of the operation but not resumed postoperatively.
62284584|NCT04870671|EXPERIMENTAL|High Adherence|TDF/FTC (300/200 mg), 7 pills/week. Total of 14 pills
62651360|NCT03845894|ACTIVE_COMPARATOR|Bupivacaine with adjuvants ISB|
62651361|NCT01413997||Chronic Low Back Pain|
62651362|NCT01413997||No Low Back Pain|
62460062|NCT05629884|NO_INTERVENTION|Control arm|This control arm will train at the rehabilitation service or at home following the instructions provided by the rehabilitation service.
62460063|NCT05872178|PLACEBO_COMPARATOR|Omegia® Softgel -A|Take Omegia® Softgel -A once a day for 12 weeks
62460064|NCT05872178|EXPERIMENTAL|Omegia® Softgel -B|Take Omegia® Softgel-B once a day for 12 weeks
62460065|NCT00607230|EXPERIMENTAL|E|BCG vaccination
62284585|NCT04870671|EXPERIMENTAL|Low Adherence|TDF/FTC (300/2200 mg), 3 pills/week. Total of 6 pills
62460066|NCT00607230|PLACEBO_COMPARATOR|P|Saline vaccination
62460067|NCT06360913|EXPERIMENTAL|Metabolomics evaluation|LC-MS-qTOF analysis of DBS and urine using a combination of methods
62284586|NCT04285333|ACTIVE_COMPARATOR|fascial iliaca|: A linear high frequency ultrasound probe (10-15MHz) was placed in a transverse direction over the anterior thigh below the inguinal ligament. We identified the femoral artery and the iliacus muscle lateral to it, covered by the fascia iliaca. The needle was inserted in plane and a 22 gauge, 50 mm needle was advanced until the tips placed underneath the fascia iliaca. Following negative aspiration, the local anesthetic solution was injected in 5mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine
62284587|NCT04285333|EXPERIMENTAL|Percapsular nerve group block|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine.
62284588|NCT05163288|EXPERIMENTAL|N-acetyl-L-leucine (IB1001)|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients \<13 will receive weight-tiered doses.
62651363|NCT05902676||no anticholinergic burden|Patients with a score of 0 were considered to have not used anticholinergic medications. Short-term use of medications, daily dosages of medications, and topical, ophthalmic, otologic, or inhalation medications were excluded from scoring.
62085519|NCT02353117|ACTIVE_COMPARATOR|Intervention|Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
62085520|NCT02353117|NO_INTERVENTION|Control|Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
62284589|NCT05163288|PLACEBO_COMPARATOR|Placebo comparator|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients \<13 will receive weight-tiered doses.
62284590|NCT02431416|ACTIVE_COMPARATOR|Gonadotropin releasing hormone (GnRH)|A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
62284591|NCT02431416|PLACEBO_COMPARATOR|Sodium chloride|A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
62085521|NCT02150044|EXPERIMENTAL|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
62085522|NCT02116140|EXPERIMENTAL|[C11]Acetate HED PET|"AMEND is a single centre substudy of the ADVENT-HF trial. This substudy is a clinical physiologic proposal designed to determine the effects of long-term (6 months) ASV on cardiac energetics and SN function in patients with chronic stable HF and sleep apnea extending our previous evaluation of short-term CPAP in patients with OSA and HF.~All subjects consenting to the ADVENT primary trial will be eligible to participate in the substudy.~Substudy consenting patients will have \[11C\]acetate and \[11C\]HED PET imaging; HR variability; plasma norepinephrine (NE) levels, urine normetanephrine levels within 2 weeks of the sleep study. Baseline measurements will be repeated after 6 months in all patients."
62085523|NCT05351736|EXPERIMENTAL|Recent-onset schizophrenia|Patients diagnosed with schizophrenia with onset in the last 5 years that will be started on lurasidone or that have been on treatment with lurasidone for less than two weeks at the time of enrollment.
62284592|NCT01200784|EXPERIMENTAL|250 mg/d modified release Nicotinamide|
62284593|NCT01200784|EXPERIMENTAL|500 mg/d modified release Nicotinamide|
62284594|NCT01200784|EXPERIMENTAL|750 mg/d modified release Nicotinamide|
62284595|NCT01200784|EXPERIMENTAL|1000 mg/d modified release Nicotinamide|
62284596|NCT01200784|ACTIVE_COMPARATOR|1000 mg/d immidiate release Nicotinamide|
62651364|NCT05902676||anticholinergic burden|Patients with a score of 1 or higher were considered to have used anticholinergic medication. Short-term use of medications, daily dosages of medications, and topical, ophthalmic, otologic, or inhalation medications were excluded from scoring.
62085524|NCT01942655|EXPERIMENTAL|Patients with recto-colic biopsies prescribed|45 patients
62085525|NCT04055506|EXPERIMENTAL|Combination Therapy|
62085526|NCT00000783||1|Sexually active HIV-infected concordant couples
62085527|NCT00000783||2|Sexually active HIV-infected discordant couples
62085528|NCT05914428||sepsis|We selected blood samples from sepsis patients from the biological bank of Qilu hospital.The ALDH2 genotype (rs671) was detected in these septic patients and divided into ALDH2 wild-type ,ALDH2 rs671 mutation.
62085529|NCT01545362||Staged bilateral total knee arthroplasty|Patients that have bilateral total knee arthroplasty staged within one week
62085530|NCT06242197|EXPERIMENTAL|written advice|written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
62085531|NCT06242197|ACTIVE_COMPARATOR|standard verbal advice|verbal advice about cancer risk and screening methods was given to CRC patients to pass on to their first degree relatives
62085532|NCT02064725|EXPERIMENTAL|Sodium cridanimod|Sodium cridanimod in combination with megestrol acetate or medroxyprogesterone acetate. Treatment period is 12 months; patients will be followed for another 12 month period or to disease progression whichever occurs first.
62085533|NCT04463615|EXPERIMENTAL|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
62085534|NCT06160713|ACTIVE_COMPARATOR|Standard care|Standard care of bronchiectasis
62085535|NCT06160713|EXPERIMENTAL|Itraconazole arm|Supra-bioavailable- Itraconazole capsule 65 mg
62085536|NCT02887560|EXPERIMENTAL|All patient|Only one arm has been specified for the protocol. This arm included all study patient (33) for which the intervention is to be administered
62085537|NCT04218643|ACTIVE_COMPARATOR|Standard technique|Intravenous catheter inserted via standard technique
62085538|NCT04218643|EXPERIMENTAL|Ultrasound-guided technique|Intravenous catheter inserted via ultrasound guidance
62085539|NCT05677867|EXPERIMENTAL|Formulation A (Reference) followed by Formulation B (Test)|
62284597|NCT01262976|EXPERIMENTAL|HIV(+)-HA/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
62284598|NCT01262976|PLACEBO_COMPARATOR|HIV(+)-HA/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
62284599|NCT01262976|EXPERIMENTAL|HIV(+)-TN/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
62085540|NCT05677867|EXPERIMENTAL|Formulation B (Test) followed by Formulation A (Reference)|
62085541|NCT05530954|ACTIVE_COMPARATOR|Mineral trioxide aggregate (MTA)|"* where the pulp tissue is exposed during final caries removal, hemostasis will be achieved by cavity irrigation with sterile saline solution for up to 4 minutes till control of bleeding~* Teeth with pulp exposure less than 1mm in diameter surrounded by sound dentin will be candidates for direct pulp capping~* Following the removal of the saline, the exposed pulp will be irrigated with 17% EDTA solution (Prevest Direct, India) for 1 minute~* According to site of exposure, the groups will be further subdivided into Group A (n=13) with exposure in pulpal floor and Group B (n=13) with exposure in axial wall of the cavity.~* Exposed pulp will be covered with fast set MTA paste after cavity dryness with sterile cotton pellet then the tooth will be restored with Self-cured glass ionomer restorative material (SDI Riva self-cure, Australia) and tooth will be covered by stainless steel crown"
62085542|NCT05530954|ACTIVE_COMPARATOR|Hard setting Calcium Hydroxide (Dycal)|"* where the pulp tissue is exposed during final caries removal, hemostasis will be achieved by cavity irrigation with sterile saline solution for up to 4 minutes till control of bleeding~* Teeth with pulp exposure less than 1mm in diameter surrounded by sound dentin will be candidates for direct pulp capping~* Following the removal of the saline, the exposed pulp will be irrigated with 17% EDTA solution (Prevest Direct, India) for 1 minute~* According to site of exposure, the groups will be further subdivided into Group A (n=13) with exposure in pulpal floor and Group B (n=13) with exposure in axial wall of the cavity.~* Exposed pulp will be covered with Dycal paste after cavity dryness with sterile cotton pellet then the tooth will be restored with Self-cured glass ionomer restorative material (SDI Riva self-cure, Australia) and tooth will be covered by stainless steel crown"
62085543|NCT03044093|ACTIVE_COMPARATOR|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
62085544|NCT03044093|EXPERIMENTAL|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.~Mifepristone"
62085545|NCT05791461||Intervention cohort|Patients with work-related stress (F43.2/8/9 or Z56.3 (ICD-0)) who received the stress management intervention between 2011-2018 (N\>400). The intervention is based on cognitive behavioral therapy, delivered by a trained psychologist in groups of 8-10 patients. The intervention consists of 8 sessions in 3 months, with a booster session 3 months after the intervention has ended.
62284600|NCT01262976|PLACEBO_COMPARATOR|HIV(+)-TN/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
62460068|NCT01419106|NO_INTERVENTION|Control|This arm of the study will NOT receive point of care ultrasound. They will receive all other standard care implemented during their visit to the ED (currently, ultrasound is NOT standard of care). The same blood tests will be done in both groups, as this will offer a means of comparing physiological changes between the two arms.
62651365|NCT02033863||Cohort A|Varicocele arising from the spermatic vein(s) and pampiniform plexus, with or without concomitant diagnosis of infertility or subfertility
62284601|NCT01262976|EXPERIMENTAL|HIV(-)/GSK692342|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
62651366|NCT02033863||Cohort B|Pelvic varices in females for the treatment of pelvic congestion syndrome (e.g., pelvic venous incompetence).
62651367|NCT06473805|ACTIVE_COMPARATOR|• Group I (3D printed PMMA implant spacer):|10 patients with a gummy smile caused by excessive gingival display ≥ 4 mm due to subnasal depression will perform minimally invasive vestibular incision subperiosteal tunnel access (VISTA) and 3D printed PMMA implants.
62460069|NCT01419106|EXPERIMENTAL|Ultrasound|This group WILL receive point of care ultrasound. The protocol they will receive is the ACES protocol (described above).
62460070|NCT01437501|EXPERIMENTAL|Broccoli Sprout Extract Beverage|
62284602|NCT01262976|PLACEBO_COMPARATOR|HIV(-)/Placebo|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
62460071|NCT01437501|PLACEBO_COMPARATOR|Placebo beverage|
62284603|NCT02534636|EXPERIMENTAL|Part A: Single ascending dose|BMS-986165 or Placebo specified dose on specified days
62284604|NCT02534636|EXPERIMENTAL|Part B: Multiple ascending dose|BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
62284605|NCT02534636|EXPERIMENTAL|Part C: Multiple ascending dose|BMS-986165 or Placebo specified dose on specified days
62284606|NCT02534636|EXPERIMENTAL|Part D: Relative Bioavailability|BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days
62284607|NCT02828072|EXPERIMENTAL|Sky|Sky treatment foe 15 days
62284608|NCT02828072|SHAM_COMPARATOR|control|standard medical therapy
62460072|NCT03963063|ACTIVE_COMPARATOR|Non Goal-directed Care Group|
62460073|NCT03963063|EXPERIMENTAL|Goal-directed Care Group|
62460074|NCT00920764|ACTIVE_COMPARATOR|A|
62460075|NCT00920764|ACTIVE_COMPARATOR|B|
62460076|NCT00920764|ACTIVE_COMPARATOR|C|
62460077|NCT00920764|PLACEBO_COMPARATOR|D|
62651368|NCT06473805|ACTIVE_COMPARATOR|• Group II (3D printed PEEk implant spacer):|10 patients with a gummy smile caused by excessive gingival display ≥ 4 mm due to subnasal depression will perform minimally invasive vestibular incision subperiosteal tunnel access (VISTA) and 3D printed PEEK implants.
62651369|NCT00822471|OTHER|Diabetes Self-Management Education|Education intervention with historic self-controls.
62284609|NCT06503445|EXPERIMENTAL|Interventional group|The experimental group with cardiac implantable electronic devices will receive cardiac rehabilitation health education video intervention.
62284610|NCT06503445|SHAM_COMPARATOR|Control group|The control group with cardiac implantable electronic devices will receive only health education video intervention.
62284611|NCT04620486|EXPERIMENTAL|Active Best Practice Alert|Care providers taking care of these patients will receive a Best Practice Alert (BPA) in the electronic medical record (EMR) one hour before an antibiotic expires with no subsequent doses ordered. The BPA will prompt the care provider to re-order the antibiotic and give information on recommended dosage and frequency based on indication and patient characteristics.
62284612|NCT04620486|NO_INTERVENTION|Inactive Best Practice Alert|The Best Practice Alert described in the Experimental Arm will not be active for patients in this arm. Care providers will proceed with usual care.
62284613|NCT01193400|EXPERIMENTAL|Clofarabine-Cytarabine|Induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine
62284614|NCT00536172|EXPERIMENTAL|Escitalopram|Participants will receive treatment with escitalopram
62284615|NCT00536172|PLACEBO_COMPARATOR|Placebo|Participants will receive treatment with placebo
62460078|NCT00270764||Full cohort|Adult ART patients at 3 treatment facilities in South Africa
62460079|NCT04480073|OTHER|edentulous patients with atrophic jaws|patients presenting with severely atrophic edentulous sites in the upper and lower jaw, and requesting implant-supported prosthetic restorations, will be enrolled in this study.
62460080|NCT01123681||Ventilator associated pneumonia|
62460081|NCT01123681||No pneumonia|
62460082|NCT02107300|EXPERIMENTAL|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
62460083|NCT02107300|PLACEBO_COMPARATOR|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
62460084|NCT00950625|ACTIVE_COMPARATOR|intraperitoneal lignocaine|Intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine for pain control after laparoscopic cholecystectomy
62460085|NCT00950625|ACTIVE_COMPARATOR|intraperitoneal bupevacaine|intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine after laparoscopic cholecystectomy
62460086|NCT00005856|EXPERIMENTAL|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.
62460087|NCT05000840||HbA1c <7.5%|For participants with HbA1c ≥ 7.5%, Community Scientists will offer enrollment in existing SDRI diabetes education programs and will schedule a follow-up contact for 3 and 6 months later for repeat testing. Study participation for each participant will end upon completion of 6 month follow up.
62460088|NCT05000840||HbA1c ≥7.5%|For participants with HbA1c \< 7.5%, Community Scientists will schedule a follow-up contact 6 months later. Study participation for each participant will end upon completion of 6 month follow up.
62460089|NCT02293668|ACTIVE_COMPARATOR|Combined 450|Recombinant FSH 225IU/day and human menopausal gonadotropin (hMG) 225IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
62460090|NCT02293668|ACTIVE_COMPARATOR|Combined 300|Recombinant FSH 150IU/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
62085546|NCT05791461||Comparison cohort|Patients with work-related stress (diagnoses F43.2/8/9 or Z56.3 (ICD-10)) who was seen at a consultation at Department of Occupational and Environmental Health in Odense (DOEM) in 2011-2012, but did not receive the intervention because it was not yet offered. The patients were offered advice and support by a psychologist (usual care). The intervention was introduced at DOEM in 2011 for a limited number of patients due to introducing the intervention and establishing the capacity of psychologists involved. In 2013 the intervention was implemented at full scale to include every eligible patient.
62085547|NCT03613779|EXPERIMENTAL|LUS-guided therapy group|"LUS-guided therapy group. Patients randomly allocated to this arm will receive standard of care + LUS examination accessible to treating physician in every visit. Depending on the results of LUS examination, a low dose or high dose of diuretics will be administered.~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
62085548|NCT03613779|ACTIVE_COMPARATOR|Control group.|"Control group. Patients randomly allocated to this arm will receive standard of care + LUS examination blinded to the treating physician in every visit. Diuretic titration will be based on standard practice (physical examination, symptoms and lab results).~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
62085549|NCT04777188|EXPERIMENTAL|Hypertrophic Obstructive Cardiomyopathy|Left ventricular systolic function by speckle tracking echocardiography before and after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy.
62085550|NCT04607915|EXPERIMENTAL|Intervention for TECC Model|
62085551|NCT00649129|EXPERIMENTAL|1|Oxybutynin Chloride ER Tablets 10 mg
62460091|NCT02293668|ACTIVE_COMPARATOR|Letrozole and hMG|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
62085552|NCT00649129|ACTIVE_COMPARATOR|2|Ditropan XL® Tablets 10 mg
62085553|NCT04746274|EXPERIMENTAL|Online large-group one-session multicomponent positive psychological intervention|
62085554|NCT04746274|ACTIVE_COMPARATOR|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|
62085555|NCT04746274|NO_INTERVENTION|Waitlist Control Group|
62085556|NCT05127161|EXPERIMENTAL|Early Intervention|The early intervention arm will begin receiving the intervention in study period 1.
62085557|NCT05127161|OTHER|Delayed Intervention (Control)|The delayed intervention (control) arm will begin receiving the intervention in study period 2. They will receive no intervention during period 1.
62085558|NCT02359253|EXPERIMENTAL|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
62085559|NCT02359253|EXPERIMENTAL|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
62085560|NCT02359253|EXPERIMENTAL|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
62085561|NCT02359253|EXPERIMENTAL|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
62284616|NCT02613455|ACTIVE_COMPARATOR|Kenalog (triamcinolone )|Patients assigned to the corticosteroid arm will receive an intratendinous injection of 1cc Kenalog-40 (triamcinolone-40mg) + 2cc lidocaine 1% by an attending orthopaedic hand surgeon in clinic. They will be provided a home stretching regimen for lateral epicondylitis. They will be discouraged from using nonsteroidal anti-inflammatory drugs . No additional physical or occupational therapy will prescribed.
62460092|NCT06318702|NO_INTERVENTION|KETEM|This group was given a three-week standard gynecological cancer education program by the Cancer Early Diagnosis, Screening and Education Centers (KETEM) unit.
62460093|NCT06318702|EXPERIMENTAL|constructivist model group|Gynecologic cancer education was given to the intervention group for 3 weeks based on the constructivist education model, taking into account the assimilation, adaptation and balancing stages of education.
62460094|NCT01218165|NO_INTERVENTION|Control Group|without intervention
62460095|NCT01218165|EXPERIMENTAL|Intervention Group|This group receives a probiotic drink daily for 6 week.
62460096|NCT02359981|ACTIVE_COMPARATOR|Generic suggestions|Control group participants received suggestions generated by the a nutritionist and exercise trainer. These suggestions didn't relate to user's life or their past behavior.
62085562|NCT00429793|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62085563|NCT00590070|ACTIVE_COMPARATOR|1|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
62085564|NCT00590070|ACTIVE_COMPARATOR|2|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
62085565|NCT00590070|PLACEBO_COMPARATOR|3|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered
62085566|NCT05158257|ACTIVE_COMPARATOR|Intervention: balloon and Stents|plain balloon and Stents group
62085567|NCT05158257|EXPERIMENTAL|Intervention: debulking and drug coated balloon|debulking and drug coated balloon group
62085568|NCT05540717|EXPERIMENTAL|PQ Grass|6 subcutaneous injections of active treatment (900, 2700, 6000, 6000, 6000 and 6000 SU sequentially) to achieve a cumulative nominal dose of 27600 SU
62085569|NCT05540717|PLACEBO_COMPARATOR|Placebo|6 subcutaneous injections of placebo
62085570|NCT00179010|EXPERIMENTAL|Adenosine then Adenosine Mono Phosphate (AMP)|Intrarterial infusion of adenosine then same subject switch to AMP one month apart.
62085571|NCT00179010|EXPERIMENTAL|Adenosine Mono Phosphate (AMP) then adenosine|Intrarterial infusion of AMP then same subject switch to Adenosine one month apart.
62085572|NCT00917228||Feedback|Subjects of this group are equipped with the biofeedback system
62284617|NCT02613455|ACTIVE_COMPARATOR|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either Walter Reed National Military Medical Center (WRNMMC) or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24 kilovolts, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
62085573|NCT00917228||Control|Subjects of this group are not equipped with the biofeedback system
62085574|NCT03623412|EXPERIMENTAL|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
62085575|NCT03623412|ACTIVE_COMPARATOR|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
62085576|NCT04745104|EXPERIMENTAL|SHR-1707 Dose level 1|SHR-1707 or placebo is administered intravenous to young healthy subjects
62284618|NCT05848661|EXPERIMENTAL|AUDISSEE-verbal, AUDISSE-non-verbal, Placebo, Placebo|"In this arm, the group will perform first the AUDISSEE therapy starting with the verbal sub-training then the non-verbal sub-training. Then it will perform the placebo training for 10 weeks.~The AUDISSEE therapy takes place over 10 weeks with 3 sessions of 20 minutes per week. It is divided into two parts (5 weeks for each part):~* verbal training exercises in noise that are specifically aimed at improving patients' intelligibility in noise~* non-verbal training exercises using environmental sounds and musical sounds, which are specifically aimed at improving non-verbal auditory perception"
62085577|NCT04745104|EXPERIMENTAL|SHR-1707 Dose level 2|SHR-1707 or placebo is administered intravenous to young healthy subjects
62085578|NCT04745104|EXPERIMENTAL|SHR-1707 Dose level 3|SHR-1707 or placebo is administered intravenous to young healthy subjects
62085579|NCT04745104|EXPERIMENTAL|SHR-1707 Dose level 4|SHR-1707 or placebo is administered intravenous to young healthy subjects
62460097|NCT02359981|EXPERIMENTAL|MyBehavior|Experiment group participants received personalized suggestions from MyBehavior that relates their life and past behavior.
62460098|NCT00893256|EXPERIMENTAL|Risperidone and citalopram|24 patients were randomized to receive add-on citalopram (20 mg/day) in a double-blind fashion to open-label risperidone (4-8 mg/day)
62460099|NCT00893256|PLACEBO_COMPARATOR|Risperidone and placebo|24 patients were randomized to receive add-on placebo in a double-blind fashion to open-label treatment with risperidone (4-8 mg/day)
62085580|NCT04745104|EXPERIMENTAL|SHR-1707 Dose level 5|SHR-1707 or placebo is administered intravenous to young healthy subjects
62085581|NCT04745104|EXPERIMENTAL|SHR-1707 Dose level 3 (Elderly subjects)|SHR-1707 or placebo is administered intravenous to Elderly subjects
62085582|NCT06483412|EXPERIMENTAL|Stanford REACH Lab Healthy Futures Curriculum|At the start of Year 1, schools will be randomized in a 1:1 ratio to either receive 'Stanford REACH Lab's Healthy Futures: Alternative-to-Suspension Curriculum' or 'delay-in-treatment (standard of care)'. Students in these schools who are found using tobacco/nicotine or who want to quit these products will be administered the Healthy Futures: Alternative-to-Suspension curriculum for 3 years.
62085583|NCT06483412|EXPERIMENTAL|Delay In Treatment|At the start of Year 1, schools will be randomized in a 1:1 ratio to either receive 'Stanford REACH Lab's Healthy Futures: Alternative-to-Suspension Curriculum' or 'delay-in-treatment (standard of care).' Schools in this arm will receive a standard of care for one year. After year 1, the delay-in-treatment group will crossover to receive 'Stanford REACH Lab's Healthy Futures: Alternative-to-Suspension Curriculum until year 3 (receive intervention for years 2 and 3).
62085584|NCT03135548|EXPERIMENTAL|Spesolimab (low dose)|
62085585|NCT03135548|EXPERIMENTAL|Spesolimab (high dose)|
62085586|NCT03135548|PLACEBO_COMPARATOR|Placebo|
62085587|NCT04316767|EXPERIMENTAL|App Intervention|Participants will download a mobile self-care app on their smartphones. The app guides users through exercises based on cognitive behavioral therapy principles. Participants will be able to use the app as frequently as desired throughout the course of the study.
62085588|NCT04316767|NO_INTERVENTION|Control|Participants will receive usual supportive care provided to family members of ICU patients.
62085589|NCT02986828|EXPERIMENTAL|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
62085590|NCT02986828|ACTIVE_COMPARATOR|Normal saline|Normal saline for ultrasound-guided hydrodissection
62085591|NCT05079880|EXPERIMENTAL|GC group|received 300 mg of caffeine citrate infusion
62284619|NCT05848661|EXPERIMENTAL|AUDISSE-non-verbal, AUDISSEE-verbal, Placebo, Placebo|In this arm, the group will perform first the AUDISSEE therapy starting with the non-verbal sub-training then the verbal sub-training. Then it will perform the placebo training for 10 weeks.
62284620|NCT05848661|PLACEBO_COMPARATOR|Placebo, Placebo, AUDISSEE-verbal, AUDISSE-non-verbal|"In this arm, the group will perform first placebo training for 10 weeks. Then, it will perform the AUDISSEE therapy starting with the verbal sub-training then the non-verbal sub-training.~At each session of the placebo therapy, the patient will listen to an excerpt from an audio-book or podcast of similar length to the duration of the training exercises (20 min).~This therapy engages the patient in a similar manner than the AUDISSEE therapy in terms of time spent (same session frequency, same session duration), but does not specifically train auditory perception networks."
62284621|NCT05848661|PLACEBO_COMPARATOR|Placebo, Placebo, AUDISSE-non-verbal, AUDISSEE-verbal|In this arm, the group will perform first placebo training for 10 weeks. Then, it will perform the AUDISSEE therapy starting with the non-verbal sub-training then the verbal sub-training.
62284622|NCT01598376|ACTIVE_COMPARATOR|5/0 gauge vicryl suture|Patients randomly assigned to 5/0 gauge test everting suture
62284623|NCT01598376|ACTIVE_COMPARATOR|7/0 gauge vicryl suture|Patients randomly assigned to 7/0 gauge test everting suture
62085592|NCT05079880|PLACEBO_COMPARATOR|GS group|Equivalent saline infusion
62284624|NCT01361763|EXPERIMENTAL|Dabigatran|
62284625|NCT01361763|ACTIVE_COMPARATOR|Antiplatelets|
62284626|NCT04945798|NO_INTERVENTION|No OMT|The STAI (Y2), DASS and Scale of Body Connection administered to this cohort at baseline (T1), after two treatments (T3), and after four treatments (T4).
62085593|NCT05556746|EXPERIMENTAL|BCZD|Bedaquiline 200 mg for 12 weeks + pyrazinamide 1000 - 2000 mg (according to weight) for 12 weeks + clofazimine 300 mg for 2 weeks, followed by 100 mg for 10 weeks + delamanid 200 mg for 12 weeks, all given once daily.
62085594|NCT05556746|ACTIVE_COMPARATOR|Standard TB Treatment|Rifampin, isoniazid, ethambutol and pyrazinamide for 8 weeks, followed by rifampin and isoniazid for 18 weeks; given daily in fixed dose combinations at standard weight-based doses.
62085595|NCT01611103|SHAM_COMPARATOR|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS
62085596|NCT01611103|EXPERIMENTAL|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
62085597|NCT02268396|EXPERIMENTAL|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
62085598|NCT03413371|EXPERIMENTAL|0,5 % bupivacaine with of 2% lidocaine|in group BL patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
62085599|NCT03413371|EXPERIMENTAL|0,5 % bupivacaine|in group B patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
62284627|NCT04945798|ACTIVE_COMPARATOR|OMT|"OMT: direct myofascial release for the triplanar diagnonosis to the OA, thoracic outlet, respiratory diaphragm and pelvic diaphragm concluding with a pedal pump for 120 seconds.~The STAI (Y2), DASS and Scale of Body Connection administered to this cohort at baseline (T1), after two treatments (T3), and after four treatments (T4)."
62284628|NCT03924401|EXPERIMENTAL|Participants Receiving Abatacept|Pediatric participants who are undergoing URD HSCT for serious NMHD will receive 8 doses of abatacept in addition to conventional GVHD prophylaxis.
62284629|NCT01902979|EXPERIMENTAL|Lifestyle intervention|In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
62284630|NCT01902979|NO_INTERVENTION|Usual Care|
62284631|NCT00434525|EXPERIMENTAL|1 Sleeve gastrectomy with omentectomy|
62085600|NCT03413371|EXPERIMENTAL|1 % ropivacaine with of 2% lidocaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
62085601|NCT03413371|EXPERIMENTAL|1 % ropivacaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (5 ml)
62085602|NCT03413371|EXPERIMENTAL|paracetamol|in P group patients will receive preemptive analgesia using 1 gram of paracetamol before induction of general anaesthesia
62085603|NCT03325621|ACTIVE_COMPARATOR|PRS-080#022-DP|Experimental: PRS-080#022-DP Hepcidin antagonist, repeated administrations, ascending doses
62085604|NCT03325621|PLACEBO_COMPARATOR|PRS-080-Placebo#001|Experimental: PRS-080-Placebo#001 Comparator treatment, repeated administrations
62085605|NCT05183009|EXPERIMENTAL|Therapy|Neuromuscular electrical stimulation
62085606|NCT05183009|NO_INTERVENTION|No Therapy|Under the care of the referring physician, with no therapy applied
62085607|NCT02748564|EXPERIMENTAL|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks and aldesleukin IV every 8 hours for up to 14 doses at weeks 4, 7, 16, 19, 28, and 31 in the absence of disease progression or unacceptable toxicity.
62085608|NCT01406860|EXPERIMENTAL|Droperidol|
62085609|NCT01406860|ACTIVE_COMPARATOR|Metoclopramide + Diphenhydramine|
62085610|NCT00677456|ACTIVE_COMPARATOR|1|Patients will receive R-Y reconstruction after total gastrectomy as intervention
62085611|NCT00677456|ACTIVE_COMPARATOR|2|Patients will receive P-Y reconstruction after total gastrectomy as intervention
62085612|NCT00677456|ACTIVE_COMPARATOR|3|Patients will receive Pouch reconstruction after total gastrectomy as intervention.
62085613|NCT00677456|ACTIVE_COMPARATOR|4|Patients will receive P-I reconstruction after total gastrectomy as intervention.
62085614|NCT04882020||AHI ≤ 5|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≤ 5 events / hour; prior blood collection between 7-9 am and questionnaires.
62085615|NCT04882020||AHI ≥ 30|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≥ 30 events / hour; prior blood collection between 7-9 am and questionnaires.
62085616|NCT03753880|EXPERIMENTAL|Hemopatch|Hemopatch used to cover the resection surface after LR
62085617|NCT04583319||SARS-CoV-2 Positive|patients tested positive for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
62085618|NCT04583319||SARS-CoV-2 Negative|participants tested negative for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
62284632|NCT00434525|ACTIVE_COMPARATOR|2 Sleeve gastrectomy|
62284633|NCT06545357|ACTIVE_COMPARATOR|The intervention group|36 participants received upright shoulder X-rays before intervention to evaluate shoulder subluxation. Participants of the intervention group were received modified acupuncture to improve the biceps brachii muscle, supraspinatus muscle and deltoid muscle; The degree of shoulder subluxation will be evaluated by X-ray of the shoulder joint after 4 weeks of intervention.
62284634|NCT06545357|SHAM_COMPARATOR|The control group|36 participants received upright shoulder X-rays before intervention to evaluate shoulder subluxation. Participants of the control group were received conventional electroacupuncture according to The Stomach Channel -Yangming; The degree of shoulder subluxation will be evaluated by X-ray of the shoulder joint after 4 weeks of intervention.
62284635|NCT01041248|EXPERIMENTAL|Tocilizumab|Single arm open label study. In this arm patient will receive 8mg/kg of Tocilizumab q 2 weeks iv.
62460100|NCT03322709||Robotic-assisted kidney transplant|Adult patients undergoing robotic kidney transplantation. The transplant operation will be undertaken using the da Vinci systems robot in minimally invasive fashion.
62460101|NCT03322709||Open kidney transplant|Adult patients undergoing kidney transplantation via an open approach.
62085619|NCT02418299|EXPERIMENTAL|IncontiLase Er:YAG laser treatment|Er:YAG laser treatment for stress and mixed urinary incontinence
62085620|NCT01667315|EXPERIMENTAL|Bupivacaine|Bupivacaine 0,375%
62284636|NCT05911100||Main|Patients 18 years of age and older who have undergone COVID-19 and who are scheduled for the second stage of rehabilitation at the Federal Research Center for Fundamental and Translational Medicine
62085621|NCT03358212||denosumab used postoperatively|the postoperative denosumab group, including patients receiving denosumab after piecemeal intralesional curettage aided by digital subtraction angiography(DSA) and balloon occlusion of abdominal aorta;
62085622|NCT01686594|ACTIVE_COMPARATOR|PUVA maintenance treatment|Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
62085623|NCT01686594|NO_INTERVENTION|No maintenance treatment|observation
62085624|NCT06455761|EXPERIMENTAL|68Ga-DOTA-NI-FAPI04 PET/ CT|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
62460102|NCT03322709||Donor nephrectomy|Adult patients undergoing donor nephrectomy will have a scan of their abdominal wound to compare wound healing.
62460103|NCT06295653|ACTIVE_COMPARATOR|Autogenous Subepithelial Connective Tissue Graft plus dental implants|implant placement and augment Subepithelial Connective Tissue Graft and suture implant site
62460104|NCT06295653|ACTIVE_COMPARATOR|Amniotic Chorion Membrane plus dental implant|implant placement and augment Amniotic Chorion Membrane and suture implant site
62284637|NCT00576979|EXPERIMENTAL|Level 1: 1200cGy|150cGy BID x Days 1-4. Total dose 1200cGy.
62284638|NCT00576979|EXPERIMENTAL|Level 2: 1350cGy|150cGy BID Day 1-4 then 150 cGy QD Day 5. Total dose 1350cGy.
62284639|NCT00576979|EXPERIMENTAL|Level 3: 1500cGy limited dose to ribs, sternum, liver, brain 1200cGy|150cGy BID Day 1-5. Total dose 1500Gy.
62284640|NCT00576979|EXPERIMENTAL|Level 4: 1500cGy limited dose to liver, brain 1200cGy|150cGy BID Day 1-5. Total dose 1500Gy.
62460105|NCT01400022|ACTIVE_COMPARATOR|Cortisone|
62460106|NCT01400022|EXPERIMENTAL|UVA1 phototherapy|
62460107|NCT00483899|EXPERIMENTAL|Cohort 1: Part A|Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.
62460108|NCT00483899|EXPERIMENTAL|Cohort 2: Part A|Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.
62460109|NCT00483899|EXPERIMENTAL|Part B|Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.
62460110|NCT05116670||Qinghai Red Cross Hospital|
62460111|NCT05116670||Shenzhen Baoan Women's and Children's Hospital|
62460112|NCT01215409||Group 1|
62460113|NCT01901666|EXPERIMENTAL|Growth hormone deficient group|0.3mg/kg/week GH in seven divided doses will be given subcutaneously for one year.
62460114|NCT01424839|OTHER|Germinoma metastatic|"• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol~Radiotherapy~* Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)~* Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)"
62460115|NCT01424839|OTHER|germinoma non-metastatic|"Chemotherapy:~• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination~Radiotherapy~* Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~* Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~* Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
62460116|NCT01424839|OTHER|Non-germinoma non-metastatic standard risk|"Chemotherapy:~• Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions"
62085625|NCT06455761|EXPERIMENTAL|68Ga-FAPI/18F-FDG PET/ CT|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18FFDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
62085626|NCT04729283||Sigmoidectomy for sigmoid cancer|Sigmoid resection surgery for patients who suffer from sigmoid cancer
62085627|NCT04729283||Sigmoidectomy for diverticulitis|Sigmoid resection surgery for patients who suffer from symptomatic diverticulitis
62284641|NCT00576979|EXPERIMENTAL|Level 5: 1600cGy limited dose to liver, porta-hepatic, brain 1200cGy|160cGy BID Day 1-5. Total dose 1600Gy.
62284642|NCT00576979|EXPERIMENTAL|Level 6: 1700cGy limited dose to liver, porta-hepatic, brain 1200cGy|170cGy BID Day 1-5. Total dose 1700Gy.
62284643|NCT00576979|EXPERIMENTAL|Level 7: 1800cGy limited dose to liver, porta-hepatic, brain 1200cGy|180cGy BID Day 1-5. Total dose 1800Gy.
62284644|NCT00576979|EXPERIMENTAL|Level 8: 1900cGy limited dose to liver, porta-hepatic, brain 1200cGy|190cGy BID Day 1-5. Total dose 1900Gy.
62284645|NCT00576979|EXPERIMENTAL|Level 9: 2000cGy limited dose to liver, porta-hepatic, brain 1200cGy|200cGy BID Day 1-5. Total dose 2000Gy.
62284646|NCT04763330|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Active comparator (EUC only).
62284647|NCT04763330|EXPERIMENTAL|Active treatment plus EUC|Veterans randomized to this condition received the treatment plus EUC.
62284648|NCT01656902|EXPERIMENTAL|N3D plus|NOVOCART® 3D plus (Autologous Chondrocyte Transplantation System)
62085628|NCT05121675|EXPERIMENTAL|App with behavioral economics + financial incentives|NeuroFlow uses behavioral economics reminders, gamification, and fun, motivating messages to encourage use. It also includes financial incentives so users can earn redeemable points accrued for activity completion for gift cards at popular outlets (e.g., 1000 points which is the maximum per month = $10 gift card).
62085629|NCT05121675|ACTIVE_COMPARATOR|App with behavioral economics incentives only|NeuroFlow uses behavioral economics reminders, gamification, and fun, motivating messages to encourage use. including points accrued for activity completion. This version of the app does not have financial incentives.
62085630|NCT01720797|EXPERIMENTAL|Micro-osteoperforation|Minimally invasive micro-osteoperforation (PROPEL™) procedure used to achieve rapid orthodontic tooth movement. Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice. Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice, will take place. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
62085631|NCT01720797|OTHER|Non Micro-osteoperforation|Prior to intervention a swish of 5cc of chlorhexidine for one minute, twice, will take place. Chlorhexidine rinses are to begin twice a day for a week.
62085632|NCT01270763||The Look AHEAD Study|The Look AHEAD Study includes intensive lifestyle intervention treatment, focusing on caloric intake and physical activity, and a treatment arm focused on diabetes support and education.
62085633|NCT06320275|EXPERIMENTAL|Storytelling Intervention|The Storytelling video intervention created is approximately 20 minutes long.
62085634|NCT06320275|ACTIVE_COMPARATOR|control group|Routine hospital protocol was applied to the women in this group. Storytelling fertility awareness video intervention was also given to the control group after the study.
62651370|NCT03567096|ACTIVE_COMPARATOR|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 \& LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
62085635|NCT02451423|EXPERIMENTAL|Cohort A1: Atezolizumab (Single dose)|Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 1 cycle (1200mg x 1 dose)
62085636|NCT02451423|EXPERIMENTAL|Cohort A2: Atezolizumab Monotherapy (2 doses)|Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 2 cycles (1200 mg x 2 doses)
62085637|NCT02451423|EXPERIMENTAL|Cohort A3: Atezolizumab Monotherapy (3 doses)|Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 3 cycles (1200 mg x 3 doses)
62085638|NCT05543421|ACTIVE_COMPARATOR|rTMS active|
62085639|NCT05543421|SHAM_COMPARATOR|rTMS sham|
62085640|NCT05543421|EXPERIMENTAL|iTBS active|
62085641|NCT05543421|SHAM_COMPARATOR|iTBS sham|
62085642|NCT05350085|EXPERIMENTAL|Remimazolam Group|Use remimazolam as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
62651371|NCT03567096|EXPERIMENTAL|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 \& LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
62651372|NCT05217030|EXPERIMENTAL|Animal Assisted Therapy|This group of patients with traumatic brain injury received AAT throughout the acute care hospitalization
62085643|NCT05350085|ACTIVE_COMPARATOR|Midazolam Group|Use midazolam as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
62085644|NCT05902403||Elevated Initial Mean Airway Pressure|Patients recieving invasive mechanical ventilation with mean airway pressure no less than 10 centimeter of water within the first 24 hours on ICU admission.
62085645|NCT02958761|EXPERIMENTAL|Platelet-rich plasma|Patients in the intervention group will receive three autologous PRP plus calcium gluconate (as activator) intraarticular injections at 4-week intervals. Briefly, at the Immunohaematology and Transfusion Service, on each scheduled visit 20 ml of autologous whole blood will be sampled from each patient, 2 ml ACD-A will be added directly the syringe as anticoagulant; finally the vial will be gently centrifuged at 900rpm for 7 minutes. Platelet-rich plasma was collected. The PRP vials plus activator will be immediately shipped to the rehabilitation unit, where intraarticular injection will be performed by an experienced physiatrist.
62085646|NCT02958761|ACTIVE_COMPARATOR|hyaluronic acid|Patients in the control group will receive three intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals, by the same study staff.
62085647|NCT03124680|ACTIVE_COMPARATOR|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
62085648|NCT03124680|PLACEBO_COMPARATOR|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
62085649|NCT04027335|EXPERIMENTAL|Leva Arm|Subjects will undergo training in the use of a vaginal device and its associated app, to be used twice daily to perform pelvic floor muscle exercises guided by the device/app for 10 weeks.
62085650|NCT05507489|EXPERIMENTAL|treatment group|Jinzhen oral liquid(for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day)
62085651|NCT05507489|ACTIVE_COMPARATOR|control group|The usage and dosage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition and recorded truthfully
62284649|NCT01656902|ACTIVE_COMPARATOR|Microfracture|Microfracture is the standard care surgery.
62284650|NCT03346408||Patients|data collection obtained from patient (self-questionnaire) and algologist physician (questionnaire).
62284651|NCT01926925||1|Overweight Hispanic children/adolescents
62284652|NCT01926925||2|Lean Hispanic children/adolescents
62284653|NCT01163786|EXPERIMENTAL|Bortezomib|Patients will Receive 2 4week cycles of Bortezomib. Each cycle will consist of weekly bortezomib with a 2 week interval between cycles.
62284654|NCT00214461|PLACEBO_COMPARATOR|Placebo Vaccine Group|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28 and 56, respectively.
62085652|NCT05655481|EXPERIMENTAL|Telerehabilitation|"AEROBIC TRAINING~2 training sessions per week for a period of 8 weeks~Connection platform: WhatsApp~The research participant will use a 20 cm step on which he will have to go up and down until he reaches the predicted training heart rate.~Intensity: 60-80% of the maximum heart rate reached at the peak of the incremental step test~5 minutes warm-up: 60% of maximum heart rate~20 minutes of Training: 60 to 80% of the maximum heart rate reached at the peak of the incremental step test~5 minute cool down: 60% of maximum heart rate~Duration 30 minutes~RESISTANCE TRAINING~Devices: Anklet (variable load), these devices will be made available to the research participant~Exercises for upper limbs, shoulder flexion, elbow flexion and shoulder abduction, and for lower limbs hip flexion and extension.~Intensity: 70% of the maximum starting load of a 1RM repetition~3 sets of 8 repetitions~Duration: 30 minutes"
62085653|NCT05655481|EXPERIMENTAL|Telehealth|"Guidelines leaflet with health education proposals Explanations about your disease, what it is, psychopathological diagnoses and pharmacological and non-pharmacological treatment), information about the importance of physical activity in your daily life, such as walking, stretching or some daily physical activity according to your preference .~This group will not receive aerobic or resistance training.~You will receive telemonitoring twice a week over a period of 8 weeks as a form of teleconsultation in health with the physiotherapist for monitoring throughout the research.~After this period it will be reassessed."
62085654|NCT04728711|EXPERIMENTAL|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week|
62085655|NCT04728711|PLACEBO_COMPARATOR|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week|
62085656|NCT00608361|EXPERIMENTAL|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62085657|NCT02013687|EXPERIMENTAL|2 µg + Alhydrogel|vaccine
62085658|NCT02013687|EXPERIMENTAL|10 µg + Alhydrogel|vaccine
62085659|NCT02013687|EXPERIMENTAL|30 µg + Alhydrogel|vaccine
62085660|NCT02013687|EXPERIMENTAL|100 µg + Alhydrogel|vaccine
62085661|NCT01946243|EXPERIMENTAL|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.
62085662|NCT06387498|EXPERIMENTAL|Testicular Tissue Cryopreservation|Enrolled participants will undergo a testicular tissue biopsy. The method and amount of tissue procurement will be at the discretion of the surgeon.
62085663|NCT00178256|EXPERIMENTAL|1st dose cohort 15mg/m2 taxol plus RT|"15 mg/m2 Paclitaxel On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.~On Monday, Tuesday, Wednesday, Thursday, Friday Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible"
62460117|NCT01424839|OTHER|Non-Germinoma metastatic standard risk|Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
62284655|NCT00214461|EXPERIMENTAL|Low Dose Vaccine Group|Participants will receive a dose of vaccine containing of 2 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
62284656|NCT00214461|EXPERIMENTAL|Medium dose vaccine group|Participants will receive a dose of vaccine containing of 10 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
62085664|NCT00178256|EXPERIMENTAL|2nd dose cohort20 mg/m2 taxol plus daily RT|
62284657|NCT00214461|EXPERIMENTAL|High dose vaccine group|Participants will receive a dose of vaccine containing of 50 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
62460118|NCT01424839|OTHER|Non-germinoma non-metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
62651373|NCT05217030|NO_INTERVENTION|Control|This group of patients with traumatic brain injury did not receive AAT throughout the acute care hospitalization
62085665|NCT00178256|EXPERIMENTAL|3rd Dose Cohort --25mg/m2 taxol plus RT|
62085666|NCT00178256|EXPERIMENTAL|Phase II Arm --20mg/m2 taxol plus RT|
62085667|NCT00807222|ACTIVE_COMPARATOR|lisdexamfetamine dimesylate|30, 50, or 70 mg
62085668|NCT00807222|PLACEBO_COMPARATOR|placebo|
62085669|NCT01356030|ACTIVE_COMPARATOR|EUS-FNA|
62085670|NCT01356030|ACTIVE_COMPARATOR|ERCP Brushing and Biopsy|
62284658|NCT03765645|ACTIVE_COMPARATOR|3 doses on intra venous antibiotics|Patients will receive 3 doses of intra venous antibiotics. (1 dose preoperative, 1 intra operative and 1 post-operative)
62284659|NCT03765645|ACTIVE_COMPARATOR|9 doses of intra venous antibiotics|Patients will receive 9 doses of intra venous antibiotics. (1 dose preoperative, rest 8 doses at equal intervals)
62284660|NCT03075163|EXPERIMENTAL|Acupressure|Manual pressure will be applied on the wrists bilaterally.
62284661|NCT03075163|ACTIVE_COMPARATOR|Ondansetron|Ondansetron (Zofran) is used for the treatment of nausea and vomiting.
62085671|NCT04554485|EXPERIMENTAL|Blinatumomab followed by high-dose chemotherapy|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
62085672|NCT05819060|EXPERIMENTAL|Fuzuloparib Combination with Bevacizumab|Fuzuloparib 150mg/bid ; Bevacizumab 7.5mg/kg，d1，Q3W
62284662|NCT04107727|EXPERIMENTAL|Quizartinib|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days"
62085673|NCT05275270|ACTIVE_COMPARATOR|Group A|patients were treated with an active gel containing oxytocin
62651374|NCT02783066|EXPERIMENTAL|"PulseFlow group"|Eligible subjects will try a new offloading boot for 4 weeks
62085674|NCT05275270|PLACEBO_COMPARATOR|Group B|patients were treated with placebo gel without oxytocin
62284663|NCT04107727|PLACEBO_COMPARATOR|Placebo|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
62284664|NCT06327646|ACTIVE_COMPARATOR|IFA-180 (Blister)|
62284665|NCT06327646|EXPERIMENTAL|MMS-180 (Blister)|
62284666|NCT06327646|EXPERIMENTAL|MMS-180 (Bottle)|
62284667|NCT04555941|EXPERIMENTAL|active iTBS|The patient is treated with iTBS stimulation according to protocol with an active coil.
62284668|NCT04555941|SHAM_COMPARATOR|Sham iTBS|The patient is treated with Sham-iTBS stimulation according to protocol with an inactive coil.
62284669|NCT02276859|EXPERIMENTAL|Normal/ Dual-wave|"On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
62284670|NCT02276859|EXPERIMENTAL|Dual-wave/Normal|"On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
62284671|NCT05097586|EXPERIMENTAL|active tDCS|2mA of direct current delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
62284672|NCT05097586|SHAM_COMPARATOR|control|Sham stimulation where the current is turned off after 30 seconds in a slow ramp down, delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
62284673|NCT01455103|EXPERIMENTAL|Arm 1: BMS-936559 (1mg/kg)|
62651375|NCT02242617|ACTIVE_COMPARATOR|MAS-PAP|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
62085675|NCT00147043|EXPERIMENTAL|Autologous Stem Cells|
62085676|NCT02687503|OTHER|Daily dose of probiotic|All children enrolled into the study will receive a daily dose of probiotic
62085677|NCT05995340|EXPERIMENTAL|ELAPR002f Injectable Gel|Participants will receive 3 treatments of ELAPR002f injectable gel into the cheek area on each side of the face.
62085678|NCT05995340|OTHER|Saline Active Control|Participants will receive 3 treatments of Saline Active Control into the cheek area on each side of the face.
62085679|NCT02923219|EXPERIMENTAL|Stem cells separation|Stem cells separation: The adipose-derived stem cells are separated from vacuumed fat obtained through liposuction of abdomen, hip, thigh and so on. It was confirmed the adipose-derived stem cells can be induced differentiation into fat cells under the special condition in the current literature.Stem cells are used to treat wrinkles and facial rejuvenation.
62085680|NCT05451511|ACTIVE_COMPARATOR|Door-In-The-Face Technique|Using sequential request strategies, participants randomized to the Door-In-The-Face Technique group will be asked if they would like vaccination support (if not already vaccinated) and if they say no, they will be asked if they'd like to try a COVID-19 self-test at home.
62284674|NCT01455103|EXPERIMENTAL|Arm 2: BMS-936559 (3mg/kg)|
62284675|NCT01455103|EXPERIMENTAL|Arm 3: BMS-936559 (10mg/kg)|
62284676|NCT01916980|EXPERIMENTAL|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
62284677|NCT01916980|EXPERIMENTAL|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
62284678|NCT01008345|EXPERIMENTAL|ezetimibe|will receive the active treatment with ezetimibe and statin
62651376|NCT02242617|ACTIVE_COMPARATOR|PAP-MAS|Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
62651377|NCT00433836|EXPERIMENTAL|Valsartan 80 mg|
62651378|NCT00433836|EXPERIMENTAL|Valsartan 160 mg|
62085681|NCT05451511|ACTIVE_COMPARATOR|Foot-In-The-Door Technique|Using sequential request strategies, participants randomized to the Foot-In-The-Door Technique group will be first asked if they are interested in trying an at-home COVID-19 test and then asked if they are interested in vaccination support (if not already vaccinated).
62085682|NCT06387732|EXPERIMENTAL|Aerobic exercise|Participants will be randomised to eight weeks of 45 min aerobic exercise of moderate-to-vigorous activity (experimental group: three times per week, N=125).
62085683|NCT06387732|ACTIVE_COMPARATOR|Stretching and relaxation|Participants will be randomised to eight weeks of 45 min aerobic exercise of stretching and relaxation (control group: three times per week, N=125).
62085684|NCT02430636|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Stomach Neoplasms
62284679|NCT01008345|PLACEBO_COMPARATOR|placebo|
62284680|NCT03136107|EXPERIMENTAL|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
62284681|NCT03136107|ACTIVE_COMPARATOR|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
62284682|NCT03136107|NO_INTERVENTION|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
62284683|NCT01619215||Bariatric Surgery|As the number of patients dropping out during follow-up, we had difficulty achieving our secondary outcomes, and so the team decided to continue the recruitment until all our outcomes are reached. Main part of the primary outcomes is finalised and published The effects of bariatric surgeries on nonalcoholic fatty liver disease. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. Surg Endosc. 2016 Jul 12
62284684|NCT03120832|EXPERIMENTAL|PAN-301-1 (SNS-301) Vaccine|PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
62284685|NCT01437241||etravirine|Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)
62651379|NCT00433836|EXPERIMENTAL|Valsartan 320 mg|
62651380|NCT00433836|ACTIVE_COMPARATOR|Enalapril 10 mg|
62085685|NCT02430636|NO_INTERVENTION|Control|The patients without treatment
62284686|NCT03950973|EXPERIMENTAL|CareAvenue|Participants receive access to CareAvenue, an e-health tool, and receive one weekly automated telephone call and 4-5 text messages per week for 52 weeks.
62651381|NCT00433836|ACTIVE_COMPARATOR|Enalapril 20 mg|
62651382|NCT00433836|ACTIVE_COMPARATOR|Enalapril 40 mg|
62651383|NCT04898881|ACTIVE_COMPARATOR|Breast Milk|2 ml of Breast milk given one time, two minutes prior to the heel lance
62651384|NCT04898881|OTHER|24 %Sucrose|0.5 ml sucrose to be given once, two minutes prior to the heel lance
62651385|NCT03094156|EXPERIMENTAL|Placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
62651386|NCT03094156|EXPERIMENTAL|BIA 6-512 25 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
62085686|NCT02006303|ACTIVE_COMPARATOR|Green light PVP|The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
62085687|NCT02006303|ACTIVE_COMPARATOR|Prostatic Artery Embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
62085688|NCT05415059|OTHER|Main Cohort|Cohort of healthy volunteers to have device affixed
62085689|NCT00156338|EXPERIMENTAL|1|volume and sodium restriction
62085690|NCT00156338|ACTIVE_COMPARATOR|2|volume restriction
62085691|NCT00156338|ACTIVE_COMPARATOR|3|liberal fluid management
62085692|NCT04643249|EXPERIMENTAL|Active|Daily treatment
62085693|NCT00189176|EXPERIMENTAL|Tetrathiomolybdate|
62085694|NCT06471647|PLACEBO_COMPARATOR|placebo|Dextrose capsules
62085695|NCT06471647|EXPERIMENTAL|5 mg delta-9-tetrahydrocannabinol (THC)|Marinol (dronabinol)
62085696|NCT06471647|EXPERIMENTAL|10 mg delta-9-tetrahydrocannabinol (THC)|Marinol (dronabinol)
62085697|NCT05092360|EXPERIMENTAL|Nemvaleukin and Pembrolizumab Combination|
62085698|NCT05092360|EXPERIMENTAL|Pembrolizumab (enrollment completed)|
62284687|NCT03950973|ACTIVE_COMPARATOR|Guest Assistance Program|Participants receive information about the Guest Assistance Program (GAP) and receive 3-4 text messages per week related to diabetes management and resources for 52 weeks.
62284688|NCT02098954|EXPERIMENTAL|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
62284689|NCT01642641|ACTIVE_COMPARATOR|Non-surgical subgingival debridement|
62284690|NCT01642641|ACTIVE_COMPARATOR|Simplified Papilla Preservation Flap|
62085699|NCT05092360|EXPERIMENTAL|Nemvaleukin (enrollment completed)|
62284691|NCT01642641|ACTIVE_COMPARATOR|Resective Flap with Osseous Recontouring|
62284692|NCT04674566|EXPERIMENTAL|Cohort 1|COR-101 low dose
62284693|NCT04674566|EXPERIMENTAL|Cohort 2|COR-101 mid dose 1
62085700|NCT05092360|ACTIVE_COMPARATOR|Investigator's Choice|Options for protocol-specific Investigator's choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine. The Investigator will pre-select the Investigator's choice treatment before the randomization of each patient.
62085701|NCT02273505|EXPERIMENTAL|Asasantin (ER)|
62085702|NCT02273505|ACTIVE_COMPARATOR|Combination of Persantin and ASA|
62085703|NCT03264196|ACTIVE_COMPARATOR|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
62284694|NCT04674566|EXPERIMENTAL|Cohort 3|COR-101 mid dose 2
62284695|NCT04674566|EXPERIMENTAL|Cohort 4|COR-101 high dose
62284696|NCT04615637|EXPERIMENTAL|Sensors|All subjects will follow the same experimental procedure: a recording using classical MEG followed by a recording in the same condition with the OPM He4 prototype.
62284697|NCT04596345||University students|"This group will include all those participants who declare to be attending a study program to get a higher education degree.~No intervention will be applied."
62284698|NCT04596345||Non-university-attending peers|"This group will include all those participants who are not attending a study program to get a higher education degree.~No intervention will be applied."
62284699|NCT04417829||Only one arm (intervention=TAVI)|There is not control group/arm for comparison.
62284700|NCT01933841||Days 1-30|Adult surgery patients whose operations occurred during Days 1-30 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
62284701|NCT01933841||Days 31-60|Adult surgery patients whose operations occurred during Days 31-60 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
62284702|NCT01933841||Days 61-90|Adult surgery patients whose operations occurred during Days 61-90 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
62085704|NCT03264196|NO_INTERVENTION|Conservative|Non-operatively managed Condylar Head Fracture
62085705|NCT03487003|ACTIVE_COMPARATOR|MR group|When the patients asleep, 0.3 mg/kg rocuronium is administered.
62284703|NCT01933841||Days 91-120|Adult surgery patients whose operations occurred during Days 91-120 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
62085706|NCT03487003|EXPERIMENTAL|NMR group|When the patients asleep, 0.3 mg/kg saline is administered.
62085707|NCT04766502|EXPERIMENTAL|Blood sample (20ml) and Quality of Life Survey|
62085708|NCT01498913||Repaglinide|
62085709|NCT03113162|EXPERIMENTAL|Autologous Hematopoietic Stem Cell with BEAM Regimen|Autologous HSCT following Reduced-Intensity BEAM Regimen
62284704|NCT03033745|EXPERIMENTAL|IgPro20 (Pump-Assisted Volume Cohort)|Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
62460119|NCT01424839|OTHER|Non-Germinoma metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
62460120|NCT01424839|NO_INTERVENTION|Teratoma|collection of information on surgery, applied treatment and outcome
62460121|NCT00076050|EXPERIMENTAL|1|Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.
62085710|NCT03724461|ACTIVE_COMPARATOR|High intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg is established as control.
62284705|NCT03033745|EXPERIMENTAL|IgPro20 (Pump Assisted Flow Rate Cohort)|Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
62284706|NCT03033745|EXPERIMENTAL|IgPro20 (Manual Push Flow Rate Cohort)|Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
62284707|NCT05701865|EXPERIMENTAL|Alcohol Intoxication|Participant will receive alcohol, the dose of which will be administered to result in a breath alcohol concentration of .08%.
62284708|NCT05701865|ACTIVE_COMPARATOR|No-Alcohol Control|Participant will receive a no alcohol control beverage, therefore their breath alcohol concentration will be .00%.
62284709|NCT04207047|EXPERIMENTAL|Group A|Group A (up to n=5): Genius exposure 1-3 hours before tissue resection
62460122|NCT00076050|PLACEBO_COMPARATOR|2|Participants will receive placebo daily over 2 years.
62460123|NCT02072538||Pre-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
62460124|NCT02072538||Post-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
62460125|NCT06246474|NO_INTERVENTION|control group (A)|Adolescents in control group (A) will received a designed physical therapy program for the treatment of thoracic kyphosis
62460126|NCT06246474|EXPERIMENTAL|group (B)|Adolescents in study group (B) will received the same designed physical therapy program for the control group in addition to Kinesio taping.
62651387|NCT03094156|EXPERIMENTAL|BIA 6-512 50 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
62085711|NCT03724461|ACTIVE_COMPARATOR|Light intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes light-moderate intensity resistance training (12 weeks) and the other leg is established as control.
62460127|NCT05954325|EXPERIMENTAL|Immunoadsorption|5 immunoadsorption treatments
62460128|NCT05954325|SHAM_COMPARATOR|Sham immunoadsorption|5 sham immunoadsorption treatments
62085712|NCT03724461|EXPERIMENTAL|High vs Light intensity (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg undergoes light-moderate intensity resistance training.
62085713|NCT03724461|EXPERIMENTAL|High intensity (Acute)|Analysis of the effects of one High Intensity resistance training session, with a crossover design.
62284710|NCT04207047|EXPERIMENTAL|Group B|Group B (up to n=5): Genius exposure 30+7 days, 14+3 days, and 7+3 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
62284711|NCT04207047|EXPERIMENTAL|Group C|Group C (up to n=5): Genius exposure 90+14 days, 60+10 days, and 30+7 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
62460129|NCT04462406|EXPERIMENTAL|Arm A (active surveillance)|Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance.
62460130|NCT04462406|ACTIVE_COMPARATOR|Arm B (nivolumab, pembrolizumab, ipilimumab)|Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity.
62460131|NCT04462406|OTHER|Standard of Care (nivolumab, pembrolizumab, ipilimumab)|Patients continue their standard of care anti-PD-1 therapy. Treatment may consist of the following regimens: 1) nivolumab IV over 30 minutes Q2W or Q4W; 2) pembrolizumab IV over 30 minutes Q3W or Q6W; 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity.
62460132|NCT01876576|ACTIVE_COMPARATOR|clear liquids|Clear liquids the day of bowel preparation up to 2.5 hrs before colonoscopy
62284712|NCT04207047|EXPERIMENTAL|Group D|Group D (up to n=10): Genius, LaseMD, LaseMD FLEX, eCO2 and/or PicoPlus exposure 14+3 days, 7+3 days, and 1-3 hours before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
62460133|NCT01876576|ACTIVE_COMPARATOR|low residue diet|Low residue breakfast and lunch up to 1pm; clear liquids thereafter up to 2.5 hrs before colonoscopy
62460134|NCT03018834|EXPERIMENTAL|A: ANAKINRA|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
62460135|NCT03018834|PLACEBO_COMPARATOR|B: Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
62460136|NCT01353469|EXPERIMENTAL|Insuman Comb 25|Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.
62460137|NCT01353469|ACTIVE_COMPARATOR|Novolin® 30R|Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R
62460138|NCT00630305|OTHER|Session A|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session A only contains senofilcon A toric and alphafilcon A toric lenses.
62460139|NCT00630305|OTHER|Session B|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session B only contains senofilcon A toric and alphafilcon A toric lenses.
62284713|NCT01888614||Sickle Cell Patients|Patients with Sickle Cell, over 18 years of age
62284714|NCT00360399|ACTIVE_COMPARATOR|Escitalopram|Participants will receive treatment with escitalopram for 12 weeks
62284715|NCT00360399|ACTIVE_COMPARATOR|Duloxetine|Participants will receive treatment with duloxetine for 12 weeks
62284716|NCT00360399|ACTIVE_COMPARATOR|CBT|Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks
62284717|NCT02307916|EXPERIMENTAL|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
62284718|NCT02307916|PLACEBO_COMPARATOR|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
62284719|NCT05061303||Group Omperazole|Patients will receive p.o. the standard, most commonly used triple immunosuppression regimen: tacrolimus, mycophenolate mofetil, prednisone and p.o. omeprazole 20 mg (group Omeprazole).
62284720|NCT05061303||Group Famotidine|Patients will receive p.o. the standard, most commonly used triple immunosuppression regimen: tacrolimus, mycophenolate mofetil, prednisone and p.o. famotidine 20 mg (group Famotidine).
62460140|NCT00630305|OTHER|Session C|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
62085714|NCT03724461|EXPERIMENTAL|Light intensity (Acute)|Analysis of the effects of one Light-moderate Intensity resistance training session, with a crossover design.
62085715|NCT03807505|ACTIVE_COMPARATOR|Interscalene nerve block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot interscalene brachial plexus nerve block or an interscalene brachial plexus nerve catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
62085716|NCT03807505|ACTIVE_COMPARATOR|Erector Spinae Plane block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot erector spinae plane block or receive erector spinae plane catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
62085717|NCT02209207|ACTIVE_COMPARATOR|Continuous walking training|n=10 patients with COPD Walking intensity 60 percent of 6-minute walking test speed
62085718|NCT02209207|ACTIVE_COMPARATOR|Interval walking training|n=10 patients with COPD Walking intensity 120 percent of 6-minute walking test speed for 1 minute alternating with 1 minute of rest
62651388|NCT03094156|EXPERIMENTAL|BIA 6-512 75 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
62085719|NCT02004860|EXPERIMENTAL|Protopic Arm|Protopic® 0.1% ointment - 2 applications per week for 6 months
62284721|NCT02327091|PLACEBO_COMPARATOR|white rice flour capsule|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo for 12 weeks
62284722|NCT02327091|ACTIVE_COMPARATOR|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
62284723|NCT04681404|ACTIVE_COMPARATOR|Total Knee Arthroplasty (TKA)|Patients intended to undergo surgery for total knee arthroplasty
62284724|NCT04681404|ACTIVE_COMPARATOR|Unicompartmental Knee Arthroplasty (UKA)|Patients intended to undergo surgery for unicompartmental knee arthroplasty
62651389|NCT03094156|EXPERIMENTAL|BIA 6-512 100 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
62085720|NCT02004860|ACTIVE_COMPARATOR|Mycoster Arm|2 applications per week for 6 months
62085721|NCT04005547|EXPERIMENTAL|Program+survey|
62085722|NCT04005547|NO_INTERVENTION|Survey-only|
62085723|NCT01084928|EXPERIMENTAL|Intervention Arm (Diet and Exercise)|The lifestyle intervention will include a 16-week intervention period, followed by an 8 week, less intensive maintenance period.
62085724|NCT02419755|EXPERIMENTAL|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
62085725|NCT02419755|EXPERIMENTAL|Stratum 2: ALL and MLM|Participants in Stratum 2 \[Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)\] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
62085726|NCT03494374|EXPERIMENTAL|treatment group|Treatment with UCBL and exercise therapy
62284725|NCT04681404|NO_INTERVENTION|Healthy Control|
62284726|NCT00685594|EXPERIMENTAL|1|Cholecalciferol 20.000 IU per week for 5 years
62284727|NCT00685594|PLACEBO_COMPARATOR|2|
62284728|NCT01808612|EXPERIMENTAL|20 mg Fluoxetine|20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
62284729|NCT01808612|EXPERIMENTAL|40 mg Fluoxetine|40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
62284730|NCT01808612|PLACEBO_COMPARATOR|Placebo|Placebo (capsules) administered orally, once daily, for 6 weeks
62284731|NCT01528787|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
62284732|NCT01528787|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
62284733|NCT01528787|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.04%|1 drop to study eye once daily
62284734|NCT01528787|PLACEBO_COMPARATOR|AR-13324 Ophthalmic Solution Vehicle|1 drop to study eye once daily
62284735|NCT04965740||North American First Responders|Spread directly to union representatives for email and messaging to those interested in taking the survey
62284736|NCT04965740||Oceana and European first responders|First responder unions and groups that are located outside of North America - particularly Australia, New Zealand, United Kingdom, other commonwealth nations.
62284737|NCT02542072|ACTIVE_COMPARATOR|comfilcon A|Participants were randomized to wear the comfilcon A lens pair for one month during the cross over study.
62284738|NCT02542072|ACTIVE_COMPARATOR|samfilcon A|Participants were randomized to wear the samfilcon A lens pair for one month during the cross over study.
62085727|NCT05627089||Patients with Rheumatoid Arthritis and/or Myositis|"All patients 18 years or older who have been diagnosed with Rheumatoid Arthritis according to the 2010 ACR/EULAR Classification Criteria.~All patients 18 years or older who have been diagnosed with Myositis according to the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies Classification Criteria."
62651390|NCT03350919|EXPERIMENTAL|Training in the blind field|Training in the blind field using software
62085728|NCT00885495|ACTIVE_COMPARATOR|B|Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days
62085729|NCT00885495|ACTIVE_COMPARATOR|A|Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days
62085730|NCT02746536|EXPERIMENTAL|Slow chest compression|Patients will receive the slow chest compression for one minute, immediately after 6MST.
62085731|NCT02746536|PLACEBO_COMPARATOR|No slow chest compression|Immediately after 6MST, the patient will not receive the SCC and will remain seated at rest for one minute, without any intervention.
62085732|NCT03385057|ACTIVE_COMPARATOR|Ibuprofen Arm|
62085733|NCT03385057|ACTIVE_COMPARATOR|Acetaminophen|
62085734|NCT06384443||Inappropriate use of PPI|PPI is prescribed without approved indication or used for a prolonged period beyond the recommended duration.
62284739|NCT01273064|EXPERIMENTAL|CTS-1027 60 mg + ribavirin + peglyated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
62284740|NCT01273064|EXPERIMENTAL|CTS-1027 30 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
62284741|NCT01273064|EXPERIMENTAL|CTS-1027 15 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
62284742|NCT01273064|ACTIVE_COMPARATOR|placebo + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.
62651391|NCT03350919|EXPERIMENTAL|Training in the intact field|Training in the intact field using software
62460141|NCT00630305|OTHER|Session D|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
62460142|NCT03994432|EXPERIMENTAL|Intervention group|"patients with symptomatic endometriosis in therapy with estro-progestins or progestins, who will be asked to follow a mediterranean diet and to practice an aerobic physical exercise according to the 7-minutes workout model"
62651392|NCT05105685|PLACEBO_COMPARATOR|Group A|Subjects were randomly divided into two different groups. Group A began with placebo while group B with rhGH. Randomisation of the treatment order (i.e., starting with rhGH or placebo) was done through a permuted four-block designed by the physician, who was the only one not blinded for treatment allocation.
62651393|NCT05105685|EXPERIMENTAL|Group B|Subjects were randomly divided into two different groups. Group A began with placebo while group B with rhGH. Randomisation of the treatment order (i.e., starting with rhGH or placebo) was done through a permuted four-block designed by the physician, who was the only one not blinded for treatment allocation.
62651394|NCT00982345|OTHER|Open label Quetiapine|Open-label Quetiapine XL 50 - 400 mg daily treatment 8 weeks
62651395|NCT02855255|ACTIVE_COMPARATOR|NHS smoking cessation|NHS 1-1 smoking cessation programme. One thirty minute session followed by up to five shorter sessions (approx.10/15minutes) comprising Cognitive Behavioural Therapy/Motivational Interviewing to assist with smoking cessation.
62651396|NCT02855255|ACTIVE_COMPARATOR|Allen Carr's Easyway smoking cessation|Group smoking cessation programme. One 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) comprising of Allen Carr's Easyway method being delivered in a spoken form.
62651397|NCT01502553|EXPERIMENTAL|Blood Pressure, Heart Rate, Monitor|"Device Comparison Test DUT: Transtek Blood Pressure Monitor, LS-802 Refrence Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Groups/Cohorts: Blood Pressure \& Heart Rate Monitor"
62460143|NCT03994432|NO_INTERVENTION|Control group|patients with symptomatic endometriosis in therapy with estro-progestins or progestins.
62651398|NCT04472702|EXPERIMENTAL|Subjects with knee OA using ultrasound for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to ultrasound (N=45) cRFA treatment arm.
62085735|NCT06384443||Appropriate use of PPI|PPI is prescribed for the approved indication and used within the recommended duration.
62085736|NCT01625338|EXPERIMENTAL|SOF+RBV 12 Weeks|SOF+RBV for 12 weeks
62085737|NCT01625338|EXPERIMENTAL|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
62085738|NCT01625338|EXPERIMENTAL|SOF+RBV+Peg-IFN 12 Weeks|SOF+RBV+Peg-IFN for 12 weeks
62085739|NCT06096636||Study participants|Participants will complete survey and dietary assessment.
62460144|NCT04494867|EXPERIMENTAL|Core warming|Patients receive the Attune Medical Esophageal Heat Transfer Device (EnsoETM) and undergo core warming
62085740|NCT03670147|EXPERIMENTAL|Pain Returns|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
62085741|NCT03670147|EXPERIMENTAL|No Pain|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
62085742|NCT00581256|EXPERIMENTAL|1|Best Delivery-optimized radiotherapy technique (IMRT)
62085743|NCT00581256|ACTIVE_COMPARATOR|2|Best 3-dimensional standard PWTF technique
62085744|NCT02647047|EXPERIMENTAL|Spinal|Patients will receive spinal analgesia (morphine 0.2 mg) before general anesthesia for minor laparotomic liver resection.
62085745|NCT02647047|ACTIVE_COMPARATOR|Epidural|Patients will receive epidural analgesia (bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL) before general anesthesia for minor laparotomic liver resection.
62085746|NCT03404869|OTHER|Treatment with ORL-1M - D-mannose|
62284743|NCT02969902|EXPERIMENTAL|Buzzy® device|The Buzzy® device is applied just above the selected site of the venipuncture; an ice pack is attached under the device; the device is turned on and after 15 second the venipuncture is made.
62284744|NCT02969902|ACTIVE_COMPARATOR|Hand-held computer|Using an hand-held computer, children start to play with an age-appropriate videogame three minutes before the procedure. They continue to play during the venipuncture.
62460145|NCT04494867|ACTIVE_COMPARATOR|Standard of Care|Patients receive standard temperature management and treatment
62460146|NCT01866449|EXPERIMENTAL|Cabazitaxel|Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
62460147|NCT01459874||Cardiac Implantable Device recipients|
62460148|NCT02091882|EXPERIMENTAL|Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System|"Participants were placed a patch by the clinical staff prior to each ingestible event marker (IEM) tablet ingestion. Participants received one IEM tablet approximately every 2 hours, for a total of 4 ingestions on Day 1 at 0, 2, 4 and 6 hours.~Following placement of the patch by clinic staff, participants ingested one 10 mg aripiprazole-embedded IEM tablet without food at Hour 0, one placebo-embedded IEM tablet without food at approximately Hour 2, one placebo-embedded IEM tablet with a high fat meal at approximately Hour 4, and one placebo-embedded IEM tablet without food at approximately Hour 6. Clinic staff recorded the time of each ingestion of an IEM and the time detected by MIND1 System."
62284745|NCT01495494|ACTIVE_COMPARATOR|Marketed nasal strip|Marketed nasal strip
62284746|NCT01495494|EXPERIMENTAL|Prototype nasal dilator|Prototype nasal dilator
62460149|NCT00575406|ACTIVE_COMPARATOR|R-CHOP|Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone
62460150|NCT00575406|EXPERIMENTAL|R-COMP|Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone
62460151|NCT05385068|EXPERIMENTAL|Niraparib combined with Anlotinib|Participants received Niraparib 200mg or 300mg QD PO continually and Anlotinib 10mg QD PO on Days 1-14 (21 days/cycle) .
62460152|NCT00973193|EXPERIMENTAL|panitumumab|
62460153|NCT01203878|EXPERIMENTAL|Imiquimod & photodynamic therapy|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
62460154|NCT01203878|ACTIVE_COMPARATOR|Imiquimod|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation
62460155|NCT00679367|EXPERIMENTAL|Melphalan Revlimid and Dexamethasone|Melphalan Lenalidomide Dexamethasone
62460156|NCT03450070|EXPERIMENTAL|Test Panel|Light Therapy Mask Cream
62460157|NCT04453462|ACTIVE_COMPARATOR|Local direct median nerve block|The local anesthetic technique is proposed by Wood SH and Logan AM in 1999 by using the plastic catheter to inject the anesthetic 4 cm proximally to the incision site direct over the median and ulna nerve
62651399|NCT04472702|EXPERIMENTAL|Subjects with knee OA using fluoroscopy for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to fluoroscopic (N=45) cRFA treatment arm.
62651400|NCT04553419|EXPERIMENTAL|Cephalexin|Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
62651401|NCT04553419|PLACEBO_COMPARATOR|Placebo|The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks
62651402|NCT05733910|EXPERIMENTAL|carbon ion radiotherapy|simultaneous integrated boost with carbon ion radiotherapy
62085747|NCT01316146|EXPERIMENTAL|CAR.CD30 T cells|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection (IV) according to the dosing schedules: starting with the lowest cell dose (2×10\^7 cells/m2) and then escalate the cell dose to the highest cell dose (2×10\^8/m2) as per study design.
62085748|NCT00911924|EXPERIMENTAL|iStent|
62085749|NCT03007589|OTHER|Location|Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters
62460158|NCT04453462|ACTIVE_COMPARATOR|Brachial plexus block|The brachial plexus block technique is axillary block performed under ultrasound-guided by the well-trained anesthesiologist.
62460159|NCT04328532|EXPERIMENTAL|Pregnancy with risk factors for PPA|
62460160|NCT02735174|EXPERIMENTAL|Single arm asthma self-management|"Interventions include:~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
62460161|NCT05577845|EXPERIMENTAL|Ramosetron|
62460162|NCT05577845|ACTIVE_COMPARATOR|Loperamide|
62460163|NCT01408199|EXPERIMENTAL|Lenalidomide Group|
62085750|NCT03007589|OTHER|Single Duration or SPF Test|Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters
62284747|NCT02493569||Epidemiology breast cancer patients|Observe the features of clinical diagnosis and treatment for female breast cancer patients
62085751|NCT01013480|ACTIVE_COMPARATOR|STX209|
62284748|NCT03017573|EXPERIMENTAL|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
62284749|NCT02556567|OTHER|Intervention|Participants will wear the Fitbit® Charge Heart Rate (HR) wristband for eight weeks.
62284750|NCT02984592||Group 1|The participants in group 1 will state that they participate regular exercise programs in the previous 6 months
62284751|NCT02984592||Group 2|The participants in group 2 will state that they do not perform any regular exercise in previous 6 months.
62284752|NCT03739528|EXPERIMENTAL|Levofloxacin + Dexamethasone followed by dexamethasone|Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
62284753|NCT03739528|ACTIVE_COMPARATOR|Tobramycin + dexamethasone|Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
62284754|NCT00786877|EXPERIMENTAL|Improved biomass cookstove with exterior ventilation|"In phase 1, installation of an improved cookstove with ventilation to exterior is the active arm.~In phase 2, this improved biomass cookstove is the control arm."
62284755|NCT00786877|NO_INTERVENTION|Traditional cookstove|In phase 1, the control arm is the traditional standard open burning cookstove in house.
62651403|NCT03620162|ACTIVE_COMPARATOR|Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™|Participants will receive a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
62651404|NCT03620162|EXPERIMENTAL|Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
62651405|NCT03620162|EXPERIMENTAL|Group 3: Prevnar 13™-Prevnar 13™-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
62085752|NCT03615482|EXPERIMENTAL|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
62085753|NCT03615482|EXPERIMENTAL|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
62085754|NCT03073005|NO_INTERVENTION|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
62284756|NCT00786877|EXPERIMENTAL|Phase 2 invervention arm (LPG stove)|In phase 2 of this project, households are individually randomized to either continuation of the improved biomass stove from phase 1, or a new LPG stove and gas for 12 months.
62284757|NCT01852084|EXPERIMENTAL|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
62284758|NCT01852084|EXPERIMENTAL|enVista control lens|Spherical control lens
62085755|NCT03073005|EXPERIMENTAL|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
62085756|NCT04357002|EXPERIMENTAL|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
62085757|NCT04357002|ACTIVE_COMPARATOR|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
62284759|NCT03609372|EXPERIMENTAL|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
62284760|NCT03562663|EXPERIMENTAL|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
62284761|NCT03562663|SHAM_COMPARATOR|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
62284762|NCT05102526|EXPERIMENTAL|"Young Millie prevention program, active teachers"|"The Young Mili program will be delivered to teens ages 10-12, over 3 months. The program contains nine 90-minute weekly sessions focusing on media literacy, self-esteem, self-esteem and physical self-esteem. Teachers will also participate by delivering planned activities to their students in addition to each week's theme, in parallel with an externally delivered program. All participants will complete a self-report questionnaire at the beginning of the study, after the end of the program and three months after the end of the program."
62284763|NCT05102526|ACTIVE_COMPARATOR|"Young Mili prevention program, passive teachers"|"The Young Mili program will be delivered to teens ages 10-12, over 3 months. The program contains nine 90-minute weekly sessions focusing on media literacy, self-esteem, self-esteem and body image. Teachers will not participate in the program, they will be present in class only during the program on transfer abroad. All participants will complete a self-report questionnaire at the beginning of the study, after the end of the program and three months after the end of the program."
62284764|NCT06334588|EXPERIMENTAL|Suspected or confirmed Autism Spectrum Disorders (ASD)|Patient with ASD or suspected ASD for whom an MRI is requested by the clinician as part of care
62651406|NCT03620162|EXPERIMENTAL|Group 4: Prevnar 13™-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
62651407|NCT03620162|EXPERIMENTAL|Group 5: V114-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
62651408|NCT03627676|EXPERIMENTAL|Intervention|
62085758|NCT04357002|PLACEBO_COMPARATOR|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
62085759|NCT05666102|OTHER|Focus Groups|Focus groups will occur during the course of the study period.
62085760|NCT02278796|EXPERIMENTAL|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
62085761|NCT02278796|ACTIVE_COMPARATOR|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
62085762|NCT04192812|EXPERIMENTAL|GnRHa|3,75 MG LEUPROLIDE ACETATE FOR EVERY 4 WEEKS THROUGHOUT 3 MONTHS BEFORE SURGERY
62085763|NCT04192812|PLACEBO_COMPARATOR|no GnRHa|NO TREATMENT
62085764|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 5.000 subcutaneous|5.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
62085765|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 10.000 subcutaneous|10.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
62085766|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 30.000 subcutaneous|30.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
62284765|NCT06334588|EXPERIMENTAL|Healthy volunteers over 3 years of age|Healthy Control Children will be recruited specifically for the research
62651409|NCT06215742|EXPERIMENTAL|the experimental group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
62085767|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 50.000 subcutaneous|50.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
62085768|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 5.000 sublingual|5.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
62085769|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 10.000 sublingual|10.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
62085770|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 30.000 sublingual|30.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
62284766|NCT06334588|NO_INTERVENTION|Healthy volunteers under 5 years of age|Children who have already undergone an MRI for various medical reasons and whose MRI was normal.
62284767|NCT05497726|EXPERIMENTAL|Sentinel lymph node detection using intravenous bevacizumab-800CW|Sentinel lymph node detection using intravenous bevacizumab-800CW
62085771|NCT02661854|EXPERIMENTAL|MM09 Mannosylated 50.000 sublingual|50.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
62460164|NCT02852980||gestational diabetes women|Women who had childbirth in the Hospital center Rene Dubos and who had gestational diabetes.
62460165|NCT00118547|OTHER|1|
62085772|NCT02661854|PLACEBO_COMPARATOR|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
62085773|NCT02716597|EXPERIMENTAL|25% Albumin|25% albumin 75 grams IV over 1 hour once.
62085774|NCT02716597|PLACEBO_COMPARATOR|Placebo|0.9% normal saline 200mL IV over 1 hour once.
62284768|NCT03022942|EXPERIMENTAL|Costal mobilization & Diaphragm Release|Costal mobilization. Lying: two sets of ten deep respiratory cycles with one minute interval between sets. Sitting: two series with interval of one minute between them. Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
62284769|NCT03022942|ACTIVE_COMPARATOR|Manual Diaphragm Release|Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
62284770|NCT01609595|EXPERIMENTAL|Treatment|Study drug treatment
62284771|NCT02451787|EXPERIMENTAL|Active|vitamin D supplementation group (2500 IU day for 3 months)
62460166|NCT04729660|ACTIVE_COMPARATOR|Study group|Evaluate of the Kinesio tex gold tape that applied to anterior neck localised.
62460167|NCT04729660|SHAM_COMPARATOR|Sham group|Evaluate of the Kinesio tex gold tape that applied to different neck localised as no-stretched.
62085775|NCT01324804||CABG - subjects|only one group
62085776|NCT05935280|PLACEBO_COMPARATOR|Room temperature injection|Pain induced by intradermal injection of fluid with room temperature.
62085777|NCT05935280|PLACEBO_COMPARATOR|Cold temperature injection 1|Pain induced by intradermal injection of increasingly cold fluid down to 3°C.
62460168|NCT05247658|ACTIVE_COMPARATOR|Therapeutic lens alone|
62284772|NCT02451787|PLACEBO_COMPARATOR|Control|no vitamin D supplementation
62651410|NCT06215742|ACTIVE_COMPARATOR|the control group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
62651411|NCT02779985|EXPERIMENTAL|Lycium Barbarum mixed meal|Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
62651412|NCT02779985|ACTIVE_COMPARATOR|Control mixed meal|Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
62085778|NCT05935280|ACTIVE_COMPARATOR|Cold temperature injection with lidocain|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including lidocain (unspecific sodium channel blocker).
62085779|NCT05935280|PLACEBO_COMPARATOR|Cold temperature injection 2|Pain induced by intradermal injection of increasingly cold fluid down to 3°C.
62460169|NCT05247658|EXPERIMENTAL|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|
62651413|NCT03136198|EXPERIMENTAL|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
62651414|NCT03136198|PLACEBO_COMPARATOR|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
62085780|NCT05935280|EXPERIMENTAL|Cold temperature injection with PF-05105679|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05105679 (specific TRPM8 antagonist).
62085781|NCT05935280|EXPERIMENTAL|Cold temperature injection with A-967079|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including A-967079 (specific TRPA1 antagonist).
62085782|NCT05935280|EXPERIMENTAL|Cold temperature injection with PF-05089771|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05089771 (specific Nav1.7 antagonist).
62085783|NCT05935280|EXPERIMENTAL|Cold temperature injection with PF-06305591|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-06305591 (specific Nav1.8 antagonist).
62284773|NCT06438679|EXPERIMENTAL|3T therapy arm|This is a single arm experiment
62284774|NCT02492438|ACTIVE_COMPARATOR|PPV23 naive, PPV23 vaccination|vaccination with PPV-23 in 40 PPV-23 naive patients
62284775|NCT02492438|EXPERIMENTAL|PPV23 naive, PCV13 vaccination|vaccination with PCV-13 in 40 PPV-23 naive patients
62284776|NCT02492438|EXPERIMENTAL|PPV23 > 4 years ago, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 more than 4 years ago
62284777|NCT02492438|EXPERIMENTAL|PPV23 < 4 years, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 less than 4 years ago
62284778|NCT00482118||Cases|Non smoking women with lung cancer
62284779|NCT00482118||Controls|Non smoking women without lung cancer
62460170|NCT04349735|EXPERIMENTAL|Adults with asthma or COPD|Assessment of inhalation technique by three methods in all patients
62460171|NCT05091385||Severe asthma patients treated with mepolizumab|Patients having received mepolizumab 100 mg SC every 4 weeks for at least 12 months in six severe-asthma clinics in Poland between December 2017 and December 2019
62651415|NCT03603613|EXPERIMENTAL|EPP: Entrepreneurship Programme|EPP: Entrepreneurship Programme: Youth randomized into the EPP-only arm will receive GIZ's employment programming within two weeks after the completion of the baseline assessments. The GIZ-supported EPP program includes six training modules. The modules include skills related to entrepreneurship, financial literacy, and skills building.
62085784|NCT05935280|EXPERIMENTAL|Cold temperature injection with PF-05105679, A-967079, PF-05089771, PF-06305591|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05105679 (TRPM8)-, A-967079 (TRPA1)-, PF-05089771 (Nav1.7)-, PF-06305591 (Nav1.8)- antagonist.
62284780|NCT06549010|OTHER|Healthy subjects|30 healthy subjects
62284781|NCT06549010|OTHER|Glaucoma subjects|30 glaucoma patients, 10 mild, 10 moderate, 10 severe
62284782|NCT04015830|EXPERIMENTAL|Older Adults with HIV (N = 60)|African Americans and Whites age 50 and older
62284783|NCT04887402||clomiphene citrate sensitive|"Based on the ovulation pattern, these patients will be divided into two groups, one who ovulated with CC maximum 150 mg and others who did not ovulate considered as CC resistant. The patients who ovulated will be further classified into three subgroups based on whether they ovulated with 50 mg or 100 mg or 150 mg of CC.~The various parameters will be compared between the CC-resistant and CC-sensitive groups."
62284784|NCT04887402||clomiphene citrate resistent|"Based on the ovulation pattern, these patients will be divided into two groups, one who ovulated with CC maximum 150 mg and others who did not ovulate considered as CC resistant. The patients who ovulated will be further classified into three subgroups based on whether they ovulated with 50 mg or 100 mg or 150 mg of CC.~The various parameters will be compared between the CC-resistant and CC-sensitive groups."
62284785|NCT06147557|EXPERIMENTAL|Heat therapy|14 heat sessions of whole-body immersed in a 45°C water bath for 5 minutes.
62284786|NCT01354028|EXPERIMENTAL|Massage therapy|Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
62284787|NCT01354028|NO_INTERVENTION|No massage therapy|This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.
62284788|NCT04959357||coronary microvascular dysfunction group|
62085785|NCT01177202|EXPERIMENTAL|Group A|HAC1 Dose = 15ug; Alum Dose = 0
62284789|NCT04959357||obstructive coronary artery disease|
62284790|NCT04959357||control group|
62284791|NCT02312570|EXPERIMENTAL|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
62284792|NCT02312570|OTHER|Usual and Customary Practice|Usual and customary practice for non-healing pressure wounds
62284793|NCT04868552|EXPERIMENTAL|Naloxone education|These participants will receive a pre-hospital naloxone education module during their pre-operative joint class
62284794|NCT04868552|NO_INTERVENTION|Standard Education|These participants will receive the standard pre-hospital education including pain management and opioid safety, but will not specifically be given the new naloxone-education module in the pre-hospital setting
62284795|NCT01526421|EXPERIMENTAL|monetary reinforcer|
62284796|NCT01526421|NO_INTERVENTION|no reinforcer|
62284797|NCT05357131|EXPERIMENTAL|Healthy Volunteers - Hypnosis without VR (HYP )|Cross-over and within-participant control design: Participants will receive recorded hypnosis without VR.
62284798|NCT05357131|EXPERIMENTAL|Healthy Volunteers - Hypnosis with VR (VRH)|Cross-over and within-participant control design: Participants will receive hypnosis with VR.
62284799|NCT02999087|ACTIVE_COMPARATOR|Arm A Patient FIT|"Lead-in phase (Day-8) : no treatment~Concomitant radiotherapy phase : Radiotherapy by IMRT + cisplatin 100mg/m2~Maintenance phase : no treatment until follow-up phase"
62284800|NCT02999087|EXPERIMENTAL|Arm B Patient FIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase : Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
62284801|NCT02999087|EXPERIMENTAL|Arm C Patient UNFIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
62284802|NCT02999087|ACTIVE_COMPARATOR|Arm D Patient UNFIT|"Lead-in phase (Day-8): Cetuximab 400mg/m2~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2~Maintenance phase : no treatment until follow-up phase"
62284803|NCT04713761|EXPERIMENTAL|Toripalimab|
62284804|NCT02070107|OTHER|no arms|no arms, sponsor withdrew
62085786|NCT01177202|EXPERIMENTAL|Group B|HAC1 Dose = 15ug; Alum Dose = 0.75mg
62085787|NCT01177202|EXPERIMENTAL|Group C|HAC1 Dose = 45ug; Alum Dose = 0
62085788|NCT01177202|EXPERIMENTAL|Group D|HAC1 Dose = 45ug; Alum Dose = 0.75mg
62085789|NCT01177202|EXPERIMENTAL|Group E|HAC1 Dose = 90ug; Alum Dose = 0
62085790|NCT01177202|EXPERIMENTAL|Group F|HAC1 Dose = 90ug; Alum Dose = 0.75mg
62085791|NCT01177202|PLACEBO_COMPARATOR|Group G|Saline
62085792|NCT01177202|ACTIVE_COMPARATOR|Group H|H1N1
62284805|NCT04161287||SBRT with TACE|
62284806|NCT04161287||SBRT alone|
62284807|NCT01283932|EXPERIMENTAL|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
62284808|NCT01283932|ACTIVE_COMPARATOR|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
62284809|NCT01988389|EXPERIMENTAL|whole apples|Subjects are asked to consume 2 apples a day for 8 weeks in addition to their habitual diet
62284810|NCT01988389|OTHER|apple juice squash|Subjects are asked to consume 100 ml of apple juice squash (recommended dilution with water up to 500 ml) for 8 weeks in addition to their habitual diet. The apple juice is used as a sugar matched control.
62284811|NCT02276092||intervention|exposure to antimicrobial stewardship intervention
62284812|NCT02276092||control|usual care with no exposure to antimicrobial stewardship
62460172|NCT04661878|EXPERIMENTAL|MASI|Participants randomized to the intervention condition will receive access to MASI, the smartphone app customized for this study. MASI is an adapted version of HealthMpowerment, a theory-based smartphone app with features including an anonymous interactive discussion forum, a medication and adherence tracker, a platform to ask questions to an expert, a section with engaging activities (including quizzes, self-assessments, and goal-setting activities), and a multi-media resource center.
62460173|NCT04661878|ACTIVE_COMPARATOR|Information-only version of MASI|Participants randomized to the control condition will an information-only version of MASI which will include the Resources feature and the home page.
62085793|NCT06143020|EXPERIMENTAL|Erector spinae plane block group|"Before surgery, an ultrasound-guided ESPB was performed. 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle.~Ropivacaine is produced by AstraZeneca AB under the trade name of Naropin, and the specifications are 75 mg / 10 ml. Dexmedetomidine is produced by HengRui medical China and the specifications are 100μg / 1 ml。"
62085794|NCT06143020|NO_INTERVENTION|Control group|Control groups do not receive additional analgesia.
62284813|NCT00734669||1|Type 2 diabetic patients on glibenclamide at individual dosage up to 7 mg/day for more than one year prone to hypoglycemic events
62284814|NCT00510276|EXPERIMENTAL|Atomoxetine|
62284815|NCT00510276|PLACEBO_COMPARATOR|Placebo|
62284816|NCT02786823|EXPERIMENTAL|Folic acid|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents \[Metformin +/- Sulfonylurea\] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
62284817|NCT02786823|EXPERIMENTAL|Vitamin B12|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents \[Metformin +/- Sulfonylurea\] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
62284818|NCT02786823|EXPERIMENTAL|"Folic acid and Vitamin B12"|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents \[Metformin +/- Sulfonylurea\] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
62460174|NCT00386009|PLACEBO_COMPARATOR|1|Placebo
62651416|NCT03603613|EXPERIMENTAL|EPP+YRI|EPP+YRI: Youth randomized into the EPP+YRI arm will begin the Entrepreneurship programme within two weeks of baseline assessments. The entrepreneurship modules will occur for 15 days for 5 hours each day, 5 days per week. Immediately following the EPP, youth will begin receiving the YRI. The YRI curriculum (12 modules), will be delivered twice weekly over the course of 6 weeks. Each session lasts approximately 90-minutes, with additional time taken as needed. These sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention quantitative assessment.
62651417|NCT03603613|NO_INTERVENTION|Control|Control: Youth randomized into the control arm will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline and post-intervention). Due to access to funding and feasibility, youth in the control arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. The list of youth from the control group will be provided to GIZ so they can participate in the future phases. Youth will also be compensated for their participation in our quantitative assessments.
62651418|NCT04053582|ACTIVE_COMPARATOR|Augmented Mindfulness Training (AMT)|Participants will receive real-time neurofeedback from the PCC during mindfulness practice in the MRI
62085795|NCT01375959|EXPERIMENTAL|Resveratrol|resveratrol 500 mg capsules, 3 each day for 6 weeks
62284819|NCT02786823|ACTIVE_COMPARATOR|Control|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents \[Metformin +/- Sulfonylurea\] will be recruited and receive no additional supplementation
62284820|NCT03018886|OTHER|healthy control subjects|126 healthy controls underwent the GHRH plus arginine stimulations test
62284821|NCT03018886|EXPERIMENTAL|patients with suspected GH deficiency|34 patients with pituitary disease and suspicion of GH deficiency underwent the GHRH plus arginine test
62284822|NCT04360967|EXPERIMENTAL|Randomized Standard Formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
62284823|NCT04360967|EXPERIMENTAL|Randomized Nutrient-enriched formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
62460175|NCT00386009|ACTIVE_COMPARATOR|2|tadalafil
62085796|NCT01375959|PLACEBO_COMPARATOR|Placebo|matching placebo capsule containing lactose, 3 each day for 6 weeks
62085797|NCT05760729||Inflammatory bowel disease patients|It is mandatory to have a certain diagnosis of IBD before the inclusion.
62085798|NCT05760729||Healthy controls|Patients who have never had the diagnosis of inflammatory bowel disease
62284824|NCT04360967|NO_INTERVENTION|Non-randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
62284825|NCT04360967|NO_INTERVENTION|Non-Randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
62284826|NCT04219228||Students in urban counties|All first-grade students in urban counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
62284827|NCT04219228||Students in rural counties|All first-grade students in rural counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
62284828|NCT01902615||Cohort|
62284829|NCT05546619|EXPERIMENTAL|Treating with a Design Protocol|
62284830|NCT02303431|EXPERIMENTAL|Cohort 1a|12 to \< 18 years of age: edoxaban low dose group
62284831|NCT02303431|EXPERIMENTAL|Cohort 1b|12 to \< 18 years of age: edoxaban high dose group
62284832|NCT02303431|EXPERIMENTAL|Cohort 2a|6 to \< 12 years of age: edoxaban low dose group
62284833|NCT02303431|EXPERIMENTAL|Cohort 2b|6 to \< 12 years of age: edoxaban high dose group
62284834|NCT02303431|EXPERIMENTAL|Cohort 3a|2 to \< 6 years of age: edoxaban low dose group
62460176|NCT03741595|EXPERIMENTAL|Single Arm|
62085799|NCT01781611|EXPERIMENTAL|extended release dipyridamole/aspirin|extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
62284835|NCT02303431|EXPERIMENTAL|Cohort 3b|2 to \< 6 years of age: edoxaban high dose group
62284836|NCT02303431|EXPERIMENTAL|Cohort 4a|6 months to \<2 years of age: edoxaban low dose group
62284837|NCT02303431|EXPERIMENTAL|Cohort 4b|6 months to \<2 years of age: edoxaban high dose group
62284838|NCT02303431|EXPERIMENTAL|Cohort 5a|0 to 6 months of age: edoxaban low dose group
62284839|NCT02303431|EXPERIMENTAL|Cohort 5b|0 to 6 months: edoxaban high dose group
62460177|NCT03688126|EXPERIMENTAL|Self-Guided Lifestyle Intervention|Lifestyle modification program that is developed by the participant to meet his/her specific needs.
62651419|NCT04053582|ACTIVE_COMPARATOR|Sham|Participants will receive an artificial neurofeedback signal during mindfulness practice in the MRI
62085800|NCT01781611|ACTIVE_COMPARATOR|aspirin|half a tablet of a 81mg aspirin twice daily for 24 weeks
62284840|NCT02435914|EXPERIMENTAL|AGN-223575 Dose A|1 drop of AGN-223575 Dose A ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose A ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
62284841|NCT02435914|EXPERIMENTAL|AGN-223575 Dose B|1 drop of AGN-223575 Dose B ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose B ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
62284842|NCT02435914|EXPERIMENTAL|AGN-223575 Dose C|1 drop of AGN-223575 Dose C ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose C ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
62085801|NCT02158650|EXPERIMENTAL|Video Group|Patients randomized to Group II will be emailed the educational video, pre- and post- knowledge assessments, and patient satisfaction survey with instructions on what order to fill them out. Group II patients will report to the treatment visit and undergo discussion of options and treatment as per standard of care. An additional knowledge assessment survey will be administered to Group II patients after discussion with treating physician.
62284843|NCT02435914|PLACEBO_COMPARATOR|AGN-223575 Vehicle|1 drop of Vehicle to AGN-223575 ophthalmic solution administered in each eye twice daily for 14 day followed by 1 drop of vehicle to AGN-223575 ophthalmic solution in each eye once daily for 7 days.
62284844|NCT02953145|EXPERIMENTAL|Tisseel applied|In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty
62284845|NCT02953145|NO_INTERVENTION|No fibrin sealant|In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.
62284846|NCT06419283|EXPERIMENTAL|stenting group|Middle Cerebral Artery Stent Implantation
62284847|NCT06419283|PLACEBO_COMPARATOR|control group|standard treatment with aspirin.
62284848|NCT01288560|ACTIVE_COMPARATOR|Advanced cardiac imaging (PET/CT or CMR)|Patients will undergo cardiac imaging as evaluation of heart failure using 1 of the following alternate/advanced imaging modalities: Positron Emission Tomography (PET/CT), Cardiac Magnetic Resonance (CMR)
62460178|NCT03688126|EXPERIMENTAL|Structured Lifestyle Intervention|Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.
62460179|NCT05442866|EXPERIMENTAL|Virtual reality (VR) dosing arm|All participants will proceed in this single arm, in which each participant will complete baseline measures, then receive 1 week of VR daily for 10 minutes per session, then 1 week of VR twice a day for 10 minutes per session, then 1 week of VR use as desired by the participant.
62460180|NCT01829308|EXPERIMENTAL|Specialist|The brief interventions are delivered by behavioral health counselors.
62460181|NCT01829308|ACTIVE_COMPARATOR|Generalist|The brief interventions are delivered by the primary care provider.
62651420|NCT02265835||Cases of anastomotic airway complication|Cases of anastomotic airway complication
62651421|NCT02265835||Patients with normal anastomotic healing|Patients with normal anastomotic healing
62651422|NCT05453721|EXPERIMENTAL|Indocyanine green fluorescence imaging method group|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
62651423|NCT05453721|ACTIVE_COMPARATOR|Modified inflation-deflation method group|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
62460182|NCT03663803|EXPERIMENTAL|Intervention|Participants in the intervention group received the offer of four 2h group sessions during five weeks, and two further sessions after one and six months. The attendance rates of the sessions were 95%, 88%, 87%, 73%, 67% and 51%, respectively. The course was delivered by health care staff in the Holstebro Health Care Centre, including a dietitian and an occupational therapist, both with health pedagogic competences. It was delivered to seven intervention groups, which varied in size from 5 to 15 participants.
62085802|NCT02158650|NO_INTERVENTION|Control Group|Patients randomized to Group I will be come to the clinic for the treatment visit and discuss options and treatment as per standard of care. Pre- and post- discussion knowledge assessments and satisfaction surveys will be administered at the time of the treatment visit.
62284849|NCT01288560|ACTIVE_COMPARATOR|Standard cardiac imaging (SPECT)|Patients will undergo standard cardiac imaging procedures for evaluation of heart failure such as single photon emission computed tomography (SPECT).
62284850|NCT01260155|EXPERIMENTAL|Treatment A Fasted|
62460183|NCT03663803|NO_INTERVENTION|Control|Usual practice
62460184|NCT04175964|EXPERIMENTAL|Group 1|PCO patients that will receive ketogenic diet only
62460185|NCT04175964|EXPERIMENTAL|Group 2|PCO patients that will receive caloric diet with Metformin
62651424|NCT06069388|EXPERIMENTAL|Diaphragm technique|The continuity between the diaphragm and the lumbar spine demonstrates the existence of an anatomical and functional connection between them. Changes in the mobility of the diaphragmatic domes in addition to improvement in spirometric parameters when carrying out a diaphragm stretching technique. This makes us think that the mobility of the lumbar spine may be compromised by diaphragm dysfunction.
62651425|NCT06069388|ACTIVE_COMPARATOR|conventional physiotherapy|"Application of the tetrapolar transcutaneous electrical neurostimulation (TENS) device with the I-tech Mio-care equipment in the analgesia program with an intensity of between 10-20 milliamps, according to the patient's tolerance, with an application time of 15 minutes in the lumbar paravertebral area on both sides. 250w infrared lamp at a distance of 1m from the patient, with an application time of 10 minutes. Ultrasound on the quadratus lumborum muscle area with a frequency of 1Mhz, at an intensity of 1.2w/cm2 and with an application time of 10 minutes. Ischemic compression and analytical stretching of the quadratus lumborum, multifidus and iliocostalis muscles, constant pressure with the thumb on each muscular trigger point (MTrP) for between 30 s and 2 min the intensity of the pressure will be adjusted to a level at which each subject reports comfortable pain, that is, between the pain threshold and the maximum tolerable pain"
62651426|NCT03629288|PLACEBO_COMPARATOR|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and one tablet containing lactose once a day for three days immediately after the scaling and root planning.
62460186|NCT04175964|EXPERIMENTAL|Group 3|PCO patients that will receive caloric diet only
62085803|NCT00632762|ACTIVE_COMPARATOR|1|Amantadine MANTADIX
62085804|NCT00632762|PLACEBO_COMPARATOR|2|placebo
62284851|NCT01260155|EXPERIMENTAL|Treatment B Fasted|
62284852|NCT01260155|EXPERIMENTAL|Treatment C Food Effect|
62284853|NCT05850845||CTX group in remission|The patients with idiopathic membranous nephropathy were divided into two groups: the group in remission and the group without remission after the application of cyclophosphamide. The pathological sections of the kidneys of the two groups were observed by microhyperspectral imaging system, and the differences between the two groups of patients under the spectrum were analyzed.
62284854|NCT05850845||CTX group without remission|The patients with idiopathic membranous nephropathy were divided into two groups: the group in remission and the group without remission after the application of cyclophosphamide. The pathological sections of the kidneys of the two groups were observed by microhyperspectral imaging system, and the differences between the two groups of patients under the spectrum were analyzed.
62284855|NCT03357393|ACTIVE_COMPARATOR|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
62460187|NCT03261323|ACTIVE_COMPARATOR|Immediate breast reconstruction|The surgical schedule will follow unaltered standard protocol for immediate reconstruction right after the patient's mastectomy. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and at different time points during the follow up. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
62651427|NCT03629288|EXPERIMENTAL|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500 milligrams (mg) of Azithromycin once a day for three days immediately after the scaling and root planning.
62284856|NCT03357393|EXPERIMENTAL|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
62284857|NCT03357393|EXPERIMENTAL|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
62284858|NCT04878367|EXPERIMENTAL|COPD_E|COPD patients with intervention
62284859|NCT04878367|NO_INTERVENTION|COPD_C|COPD patients without intervention
62284860|NCT00364182|EXPERIMENTAL|A|
62284861|NCT00364182|EXPERIMENTAL|B|
62284862|NCT04095767|EXPERIMENTAL|Treatment arm|The thrombectomy in eligible patients will be carried out by making use of the device under investigation.
62284863|NCT02211261|EXPERIMENTAL|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
62284864|NCT02211261|EXPERIMENTAL|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
62284865|NCT02211261|EXPERIMENTAL|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
62284866|NCT02211261|EXPERIMENTAL|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
62284867|NCT02211261|EXPERIMENTAL|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
62284868|NCT02211261|EXPERIMENTAL|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
62085805|NCT03116451|EXPERIMENTAL|Foot Health Promoting Program|The experimental group will receive an electronic intervention (Foot Health Promotion Program, FHPP) for 8 weeks consisting of foot self-care guidance (skin and nail self-care), foot exercises, foot stretching and professional footwear guidance. Each topic includes lectures (delivered via Adobe Presenter) and self-directed learning where participant will go through a list of links to websites and watch videos about foot self-care. In addition, the learning will be evaluated using four individual tasks related to foot self-care.
62085806|NCT03116451|NO_INTERVENTION|Comparison group|The comparison group will not receive any instructions or guidance for foot self-care but participant in the comparison group will complete the same measurement points than experimental group. After the study, the comparison group will also receive the same intervention than experimental group (if effective).
62085807|NCT02778282|NO_INTERVENTION|Standard Care|Standard Care through office-based opioid treatment with buprenorphine/naloxone and weekly urine toxicology screening
62085808|NCT02778282|EXPERIMENTAL|Standard Care + MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents Standard Care plus MySafeRx™.
62085809|NCT01076088|EXPERIMENTAL|Sitagliptin 50 mg + metformin 500 mg|Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
62284869|NCT02211261|EXPERIMENTAL|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
62460188|NCT03261323|EXPERIMENTAL|Delayed breast reconstruction|Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
62284870|NCT02211261|EXPERIMENTAL|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
62460189|NCT05901922|EXPERIMENTAL|intervention group|Social skills training will be applied to this group. social skills training will be applied for 10 sessions. Sessions will be 2 sessions per week. Session duration will be 1 hour.
62460190|NCT05901922|NO_INTERVENTION|control group|No intervention.
62460191|NCT02985593|EXPERIMENTAL|KHK4083|IV/SC administration
62085810|NCT01076088|EXPERIMENTAL|Sitagliptin 50 mg + metformin 850 mg|Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
62085811|NCT01076088|ACTIVE_COMPARATOR|Metformin 500 mg|Metformin 500 mg twice daily for 24 weeks.
62085812|NCT01076088|ACTIVE_COMPARATOR|Metformin 850 mg|Metformin 850 mg twice daily for 24 weeks.
62085813|NCT01076088|EXPERIMENTAL|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
62085814|NCT01076088|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets for 24 weeks.
62284871|NCT02211261|EXPERIMENTAL|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
62284872|NCT01091571|PLACEBO_COMPARATOR|Endotoxemia placebo|Endotoxin combined with placebo
62284873|NCT01091571|EXPERIMENTAL|Endotoxemia Dipyridamole|Endotoxin combined with Dipyridamol treatment
62284874|NCT04642742||Plant sterol chewable|
62284875|NCT01323478|EXPERIMENTAL|Vortioxetine|
62284876|NCT02498873|ACTIVE_COMPARATOR|Linear Periodization|Linear Periodization Running (Crossover Design)
62284877|NCT02498873|ACTIVE_COMPARATOR|Non Linear Periodization|Non Linear Periodization Running (Crossover Design)
62460192|NCT02985593|PLACEBO_COMPARATOR|Placebo|IV/SC administration
62460193|NCT05380271|EXPERIMENTAL|sequential DEB-BACE and Arotinib and Tirelizumab|"1. First treatment. Only infusion chemotherapy (THP + Nedaplatin + Letitrexed), THP 20 \~ 30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusion chemotherapy, Callispheres microspheres is used for embolization: Callispheres microspheres (300-500 μ m) 1tube was loaded and adsorbed THP (40 \~ 600mg/m2) End point of embolization: stagnation of blood flow in tumor feeding artery.~3. The third treatment. Arotinib, 8-12mg, oral (stop oral for 1W every 3W).Tirelizumab, 200mg, intravenous drip (every 3W)."
62651428|NCT03783065|EXPERIMENTAL|Experimental group|Procedure: Laparoscopic splenectomy and pericardial devascularization Drug: Propranolol
62651429|NCT03783065|ACTIVE_COMPARATOR|Control group|Procedure: Endoscopic therapy Drug: Propranolol
62651430|NCT05250232|EXPERIMENTAL|onlays conservative|conservative onlays preparation with partial cusp coverage only defective cusps
62085815|NCT01153854|EXPERIMENTAL|ORS-Raceca In hospital Group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
62085816|NCT01153854|PLACEBO_COMPARATOR|ORS-Placebo in hospital group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and placebo in double blind assigned.
62085817|NCT01153854|PLACEBO_COMPARATOR|ORS-Placebo ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and placebo in double blind assigned and ambulatory (in home) bases.
62085818|NCT01153854|EXPERIMENTAL|ORS-Raceca ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
62284878|NCT05574257|ACTIVE_COMPARATOR|Group P|The group received propofol injection at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery).
62284879|NCT05574257|EXPERIMENTAL|Group R|The group received remimazolam injection at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery).
62284880|NCT03143803|ACTIVE_COMPARATOR|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
62284881|NCT03143803|PLACEBO_COMPARATOR|Placebo|Placebo will contain an inert substance
62284882|NCT03152240||Women patients|Women patients
62284883|NCT03152240||Men patients|Men patients
62284884|NCT05436548|EXPERIMENTAL|Brief and frequent Work-life check-ins between clinic supervisors and each staff member|Primary care clinics assigned to the intervention will conduct frequent (every 8 weeks) supervisor-employee brief (30 min) check-ins to identify work stressors. Supervisors at such clinics will complete training on how to use the check-ins to address work stressors.
62284885|NCT05436548|EXPERIMENTAL|Usual practice, waitlist controls|Primary care clinics randomly assigned to the control condition will continue as usual practice. If the check-is are effective in reducing burnout, then supervisor-level training will become available to supervisors at the end of the study
62284886|NCT06271525|EXPERIMENTAL|cupping therapy|patients with cervical spondylosis will receive cupping therapy one time per month for three months
62460194|NCT05380271|ACTIVE_COMPARATOR|DEB-BACE alone|"1. First treatment. Only infusion chemotherapy (THP + Nedaplatin + Letitrexed), THP 20 \~ 30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusion chemotherapy, Callispheres microspheres is used for embolization: Callispheres microspheres (300-500 μ m) 1tube was loaded and adsorbed THP (40 \~ 600mg/m2) End point of embolization: stagnation of blood flow in tumor feeding artery."
62460195|NCT05723809|EXPERIMENTAL|Percussive Therapy Device|Participants will be going to physical therapy - 1 session per week for 6 weeks and will use a percussive therapy device daily for 3-7 minutes
62651431|NCT05250232|ACTIVE_COMPARATOR|onlays conventional|onlays preparation design conventional as all cusps covered with shoulder finish line preparation
62651432|NCT00434434|EXPERIMENTAL|1|
62085819|NCT01628874|EXPERIMENTAL|Lidocaine Injection|0.5 mL (5mg) of 1% lidocaine injection given with the J-Tip
62085820|NCT01628874|ACTIVE_COMPARATOR|lidocaine 2.5% and prilocaine 2.5% (EMLA) Cream|Patients in this arm will receive 1g EMLA cream if they are in the younger age group and 10g EMLA cream if they are in the older age group. This will be placed for a minimum of 30 minutes.
62284887|NCT00235079|EXPERIMENTAL|Colchicine|Colchicine 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months
62284888|NCT00235079|PLACEBO_COMPARATOR|Placebo|Placebo 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months
62284889|NCT00408967|EXPERIMENTAL|Tucotuzumab celmoleukin (EMD 273066)|
62651433|NCT00434434|EXPERIMENTAL|2|
62651434|NCT00434434|PLACEBO_COMPARATOR|3|
62651435|NCT05150574|EXPERIMENTAL|Condition 1|Core Health platform only
62651436|NCT05150574|EXPERIMENTAL|Condition 2|Core Health platform plus Practice with feedback coaching
62085821|NCT06251726||Cohort of patients with stage T1 CRC treated by primary endoscopic resection.|Secondary surgery is performed in patients with pejorative histopathologic feature(s) of the tumor.
62460196|NCT05723809|ACTIVE_COMPARATOR|Control group|Participants will be going to physical therapy - 1 session per week for 6 weeks
62085822|NCT05608941|EXPERIMENTAL|Experimental Group|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
62284890|NCT00983411||Healthy and OHS subjects|10 healthy subjects: 20 to 60 years old 10 patients with Obesity hypoventilation syndrome: 20 to 70 years old treated with nocturnal non invasive ventilation for at least three months.
62284891|NCT01677247|EXPERIMENTAL|Group I (Test)|Test : glimepiride 4 mg tablet of PT Dexa Medica
62284892|NCT01677247|ACTIVE_COMPARATOR|Group II (Reference)|Reference : glimepiride (Amaryl) 4 mg tablet of PT Sanofi-Aventis, Indonesia
62284893|NCT06549179||Patients evaluated by AMSE|Adult patients seeking ASD diagnostic evaluation in an expert center.
62284894|NCT03929887||KORNERSTONE|"Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy (IgAN)~Participants enrolled in KORNERSTONE with a biopsy proven GN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
62284895|NCT03926676|EXPERIMENTAL|Grandio blocks|Nano hybrid composite blocks
62460197|NCT01149629|ACTIVE_COMPARATOR|Fed Dosing|Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules
62460198|NCT01149629|ACTIVE_COMPARATOR|Fasted Dosing|Subjects fasted prior to receiving 3 x 100mg capsules
62651437|NCT05150574|EXPERIMENTAL|Condition 3|Core Health platform plus behavioural initiation coaching
62284896|NCT03926676|ACTIVE_COMPARATOR|E max|ceramic blocks
62284897|NCT02137967|EXPERIMENTAL|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medication
62284898|NCT02137967|ACTIVE_COMPARATOR|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament
62284899|NCT01208129|EXPERIMENTAL|Active drug|
62284900|NCT01208129|PLACEBO_COMPARATOR|Vehicle alone|
62284901|NCT01796951|EXPERIMENTAL|Celecoxib, aspirin, followed by aspirin/celecoxib|Celecoxib 200 mg twice daily x3 days, aspirin 325 mg daily x10 days, celecoxib 200 mb twice daily + aspirin 325 mg daily x 3 days
62284902|NCT02765282|EXPERIMENTAL|DBS-Expert Programming First|These patients will be undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) first and then be programmed by a clinician within five days.
62284903|NCT02765282|EXPERIMENTAL|Traditional Programming First|These patients will be programmed by a clinician first and then undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) within five days.
62284904|NCT01483430|PLACEBO_COMPARATOR|Placebo|
62284905|NCT01483430|EXPERIMENTAL|Ginseol Kg1, high dose|
62284906|NCT01483430|EXPERIMENTAL|Ginseol Kg1, low dose|
62284907|NCT00715975|EXPERIMENTAL|1|The patients will be treated with halobetasol once a day for 15 days.
62284908|NCT00715975|EXPERIMENTAL|2|The patients will be treated with clobetasol once a day for 15 days.
62460199|NCT01149629|ACTIVE_COMPARATOR|Bioequivalence|Subjects fasted prior to receiving 1x 300mg capsule
62460200|NCT01149629|ACTIVE_COMPARATOR|TID Dosing|Droxidopa 300 mg given TID
62460201|NCT01027780|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction|Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
62651438|NCT05150574|EXPERIMENTAL|Condition 4|Core Health platform plus Practice with feedback coaching and behavioural initiation coaching
62651439|NCT05150574|EXPERIMENTAL|Condition 5|Core Health platform plus Momentary HRV feedback
62651440|NCT05150574|EXPERIMENTAL|Condition 6|Core Health platform plus Momentary HRV feedback and Practice with feedback coaching
62085823|NCT05608941|SHAM_COMPARATOR|Control Group|The control group will also perform the exercises using the Orygen Dual Valve device. A sham intervention will be implemented: the initial resistance of the device will be 0cmH2O, and will be maintained throughout the intervention period - there will be no load progression. All procedures adopted with experimental group, including the weekly home visit, will also be performed with individuals in the control group. However, there will be no real change in the training load. All devices will be wrapped with an opaque material so that the load or possible respiratory training load is not visualized.
62085824|NCT06381635|EXPERIMENTAL|intervention group|patients will be given 20 mL of Manuka honey with aloe vera gel, 15 min before and after the radiotherapy. They were instructed to swallow slowly to smear the layer of honey on the oral and pharyngeal mucosa. Patients were also advised to take 20 mL of Manuka honey before sleeping in the night. This treatment protocol was followed from day 1 of radiation till 6 weeks.
62085825|NCT06381635|PLACEBO_COMPARATOR|Control group|patients will be given 20 mL of 0.9% of saline 15 min before and after radiotherapy \[54\]. They will be advised to rinse saline. They will be instructed to keep saline for at least 5 min duration and then to spit it out. They will be advised to rinse 20 mL of saline in the same manner before sleeping. This treatment protocol was followed from day 1 of radiation till 6 weeks.
62085826|NCT06221735|EXPERIMENTAL|Cy-TB test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
62085827|NCT06221735|EXPERIMENTAL|STANDARD F TB-Feron FIA test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
62085828|NCT06221735|ACTIVE_COMPARATOR|QuantiFERON-TB Gold Plus assay|The QuantiFERON-TB Gold Plus assay will be used as the study's reference standard
62085829|NCT01050101|PLACEBO_COMPARATOR|High GI low fiber meal|No fiber control meal
62085830|NCT01050101|ACTIVE_COMPARATOR|Low GI high fiber viscous meal|80:20 ratio of viscous polysaccharide fiber to insoluble non-viscous producing fiber
62085831|NCT01050101|ACTIVE_COMPARATOR|Low GI high fiber non-viscous meal|20:80 ratio of viscous polysaccharide fiber source to insoluble non-viscous producing fiber
62284909|NCT00732745|EXPERIMENTAL|Phase II arm I|Patients receive docetaxel IV over 1 hour on days 1 and 8, oxaliplatin IV over 2 hours on day 1, and oral vandetanib (at the maximum tolerated dose determined in phase I) once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
62284910|NCT00732745|ACTIVE_COMPARATOR|Phase II arm II|Patients receive docetaxel and oxaliplatin as in arm I. Patients also receive an oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
62460202|NCT01027780|NO_INTERVENTION|Wait-list control|Wait-list control participants were offered MBSR training after completion of their primary assessments periods.
62085832|NCT06385912||lymphadenectomy group|Patients received lymphadenectomy during IDS
62284911|NCT03446456|PLACEBO_COMPARATOR|Saline|"Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.~Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril."
62651441|NCT05150574|EXPERIMENTAL|Condition 7|Core Health platform plus Momentary HRV feedback and behavioural initiation coaching
62460203|NCT03760211|EXPERIMENTAL|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Battle Viro on their mobile phones, an electronic pill monitoring device, and, for 24 weeks, game-related text messages guided by medication adherence data (collected from an electronic pill monitoring device).
62460204|NCT03760211|ACTIVE_COMPARATOR|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game and an electronic pill monitoring device.
62460205|NCT02627209|ACTIVE_COMPARATOR|serum angiotensin converting enzyme|spectrophotometric assay
62460206|NCT02627209|ACTIVE_COMPARATOR|serum lysozyme|radial immunodiffusion
62460207|NCT00907998|EXPERIMENTAL|APL180 (first dose level)|
62651442|NCT05150574|EXPERIMENTAL|Condition 8|Core Health platform plus Momentary HRV feedback, behavioural initiation coaching, and Practice with feedback coaching
62651443|NCT05150574|EXPERIMENTAL|Condition 9|Core Health platform plus Daily resting HRV
62460208|NCT00907998|EXPERIMENTAL|APL180 (second dose level)|
62085833|NCT06385912||no lymphadenectomy group|Patients did not receive lymphadenectomy during IDS
62284912|NCT03446456|EXPERIMENTAL|Arginine vasopressin|Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).
62284913|NCT01872338|ACTIVE_COMPARATOR|Mindfulness-Based Cognitive Therapy + Treatment As Usual|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
62085834|NCT03630081|EXPERIMENTAL|WCK 4282 (FEP-TAZ) 4 g|WCK 4282 (FEP-TAZ) Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
62085835|NCT03630081|ACTIVE_COMPARATOR|Meropenem|Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min
62085836|NCT02201563|EXPERIMENTAL|Minocycline|oral Minocycline 100 mg twice a day for 3 months.
62460209|NCT00907998|PLACEBO_COMPARATOR|Placebo|
62085837|NCT05528887|EXPERIMENTAL|Autologous CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CAR-T cells. CAR-T cells targeted CD19/BCMA/CD123/CD7 are autologous genetically modified T cells.
62085838|NCT04762173|EXPERIMENTAL|Online self-help intervention|Participants are provided access to two online self-help programs provided by SilverCloud Health. One program is designed to support general stress resilience using principles and techniques from positive psychology and cognitive-behavioral therapy. The other program is designed to support coping with pandemic-related stressors using psychoeducation and cognitive-behavioral therapy and grief therapy principles. Participants have access to both programs and can proceed through them in the order and pace of their choosing. The online self-help intervention is fully self-guided.
62085839|NCT04762173|NO_INTERVENTION|Care as usual|Participants are provided information about how to contact the counseling center at their college and/or in the local community using the phone number and website of their counseling center (if available), as well as the Substance Abuse and Mental Health Services Administration treatment locator.
62284914|NCT01872338|OTHER|Treatment As Usual|VA standard care for suicide prevention
62284915|NCT01130571||Non-Small Cell Lung Cancer|
62284916|NCT03312569||Intracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an intracorporeal anastomosis due to begin or malignant Right Colon Disease.
62284917|NCT03312569||Extracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an extracorporeal anastomosis due to begin or malignant Right Colon Disease.
62284918|NCT01096147|ACTIVE_COMPARATOR|SCS|patients receiving SCS for chronic leg and/or back pain.
62460210|NCT01820923|EXPERIMENTAL|Brain stimulation|"Brain stimulation will consist of 4 types of intervention:~* real transcranial direct current stimulation (two weeks, five days a week)~* a week of wash-out~* Sham transcranial direct current stimulation (two weeks, five days a week)~* two weeks of wash-out~* real repetitive transcranial magnetic stimulation (two weeks, four days a week)~* a week of wash-out~* Sham repetitive transcranial magnetic stimulation (two weeks, three days a week)~Stimulations will be counterbalanced between patients."
62460211|NCT02410928|EXPERIMENTAL|fiberoptic nasal laringoscopy|the vocal cords ill be visualized with fiberoptic nasal laringoscopy
62284919|NCT04258579|EXPERIMENTAL|Video PROTECT|Participants will receive PROTECT therapy once a week for 9 weeks.
62284920|NCT01819519|NO_INTERVENTION|Standard Prenatal Care|Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.
62460212|NCT02410928|EXPERIMENTAL|ultrasonography|the vocal cords ill be visualized with ultrasonography
62460213|NCT02410928|ACTIVE_COMPARATOR|Direct laringoscopy|the vocal cords ill be visualized with direct laringoscopy
62460214|NCT03365037|EXPERIMENTAL|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
62460215|NCT03365037|ACTIVE_COMPARATOR|Fracture healing film|Patients with acute soft tissue injury treated with fracture healing film
62460216|NCT03210636|EXPERIMENTAL|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
62284921|NCT01819519|EXPERIMENTAL|Educational Intervention|This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
62284922|NCT05713864|EXPERIMENTAL|BTL-899 Treatments|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
62284923|NCT05713864|EXPERIMENTAL|HPM-6000UF Treatments|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
62085840|NCT02147860|PLACEBO_COMPARATOR|Sensor Augmented Pump Therapy|Each camp participant will be randomized to full day and night CLC or sensor augmented pump therapy for up to 7 days/6 nights. The subject will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
62085841|NCT02147860|EXPERIMENTAL|Diabetes Assistant (DiAs) with USS Virginia|"With the use of the UVA Artificial Pancreas (DiAs), the study will assess safety and feasibility and are not powered for statistical significance. These studies are intended to train staff on system function and obtain data regarding safe and feasible system use.~Camp participants will be randomized to either closed-loop control using the DiAs or sensor-augmented pump therapy only. These studies would generate up to 120 days of closed-loop data and 120 comparable days of open-loop data."
62085842|NCT04184102|EXPERIMENTAL|Intervention exercise|The experimental group received education and exercise training before a mastectomy.
62085843|NCT04184102|NO_INTERVENTION|Control|Received routine hospital care which did not include any exercise education
62284924|NCT00167635|EXPERIMENTAL|1|Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
62284925|NCT00167635|EXPERIMENTAL|2|Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
62284926|NCT00167635|NO_INTERVENTION|3|Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
62284927|NCT02463955|EXPERIMENTAL|Thoracoscopy|"1. experimental intervention (flexible video endoscope)~2. reference procedure (video-rigid thoracoscope)"
62284928|NCT03437239|EXPERIMENTAL|Occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy to include occlusion training.
62284929|NCT03437239|NO_INTERVENTION|Non-occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy without occlusion training (standard of care).
62284930|NCT05296590||Positive Blood Culture/ Monocyte Distribution Width Normal|"No intervention Monocyte Distribution Width considered normal (MDW less than 20 IU) in Emergency Department patients with Positive Blood Cultures.~We will evaluate associated factors with this observation."
62284931|NCT05296590||Positive Blood Culture/ Monocyte Distribution Width Abnormal|"No intervention Monocyte Distribution Width considered abnormal (MDW equal or greater than 20 IU) in Emergency Department patients with Positive Blood Cultures.~We will evaluate associated factors with this observation."
62284932|NCT05296590||Negative Blood Culture/ Monocyte Distribution Width Normal|"No intervention Monocyte Distribution Width considered normal (MDW less than 20 IU) in Emergency Department patients with negative Blood Cultures.~We will evaluate associated factors with this observation."
62284933|NCT05296590||Negative Blood Culture/ Monocyte Distribution Width Abnormal|"No intervention Monocyte Distribution Width considered abnormal (MDW equal or greater than 20 IU) in Emergency Department patients with negative Blood Cultures.~We will evaluate associated factors with this observation."
62284934|NCT04869267|EXPERIMENTAL|ACT group|Participants in the intervention group will receive ACT intervention, consisting of four individual sessions (First session by face to face, the last three sessions by Wechat) of 60-90 min each (once/week), in addition to usual care.
62284935|NCT04869267|OTHER|Usual care group|Participants randomized to the control group will receive usual care, including treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge.
62284936|NCT06014944|EXPERIMENTAL|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|Radiotherapy 5 \* 5 Gy, once a day, 5 Gy each time, for 5 days.Two weeks after the end of radiotherapy, the patients were treated with furoquintinib combined with slurimab, furoquintinib 5 mg / time / day, d1-14, Q3 W ; combined with 300 mg of brucella, intravenous injection, d1, Q3W ; a total of 4 cycles of treatment.
62085844|NCT04433793|EXPERIMENTAL|Yoga group|Patients in the yoga group will receive yoga therapy, one hour every week for eight weeks.
62085845|NCT04433793|NO_INTERVENTION|Waitlist-control group|Patients in the waitlist-control group will receive no intervention at first, but nine weeks after IG, they will get the opportunity to also receive yoga therapy for 8 weeks.
62085846|NCT05768295|OTHER|Axiom BL X3|Dental implant Axiom BL X3
62085847|NCT02334319|EXPERIMENTAL|Treatment (ganetespib, surgery)|Patients receive ganetespib IV over 1 hour twice weekly for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery the day after the last dose of ganetespib.
62085848|NCT00209027|EXPERIMENTAL|schizophrenia subjects|Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
62085849|NCT05267834||Positive high-risk HPV|Women with adenocarcinoma of the uterine cervix and positive for high-risk HPV (genotype16/18/31/33/35/39/45/51/52/56/58/59/68).
62085850|NCT05267834||Negative high-risk HPV|Women with adenocarcinoma of the uterine cervix and negative for high-risk HPV (genotype16/18/31/33/35/39/45/51/52/56/58/59/68).
62085851|NCT05114590|EXPERIMENTAL|iGlarLixi|iGlarLixi (i.e., insulin glargine 100 Units/ml /lixisenatide 33 μg/mL) once daily for 16 weeks.
62085852|NCT03896230|ACTIVE_COMPARATOR|Arm 1: 0.1 mg/kg ketamine|0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
62085853|NCT03896230|ACTIVE_COMPARATOR|Arm 1: 0.2 mg/kg ketamine|0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
62085854|NCT03896230|ACTIVE_COMPARATOR|Arm 1: 0.3 mg/kg ketamine|0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
62085855|NCT06469073|EXPERIMENTAL|Transversus thoracic muscle plane block (T) group|
62284937|NCT01724437|ACTIVE_COMPARATOR|Loss of pace capture|"Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved~catheter based pulmonary vein isolation"
62284938|NCT01724437|ACTIVE_COMPARATOR|Conventional|"Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.~catheter based pulmonary vein isolation"
62085856|NCT06469073|EXPERIMENTAL|Erector spinal plane block (E) group|
62284939|NCT00933036|EXPERIMENTAL|Treatment arm|Crosstrees Pod System for PVA.
62284940|NCT00631137|PLACEBO_COMPARATOR|Arm 1: Control Group|whey protein powder
62284941|NCT00631137|ACTIVE_COMPARATOR|ARM 2 : Treatment Group|Testosterone Gel (10g pouch/day) applied to skin
62284942|NCT01795547|EXPERIMENTAL|Aripiprazole and aripiprazole once-monthly|
62284943|NCT01795547|ACTIVE_COMPARATOR|Paliperidone and paliperidone palmitate|
62284944|NCT01977885|EXPERIMENTAL|High Protien Diet + Exercise|All participants will participate in both interventions (High Protein Diet and Exercise).
62284945|NCT05520528|EXPERIMENTAL|Reading Group|All participants in this group will receive language intervention within weekly group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia.
62460217|NCT02869646|EXPERIMENTAL|Verum acupuncture|Traditional Chinese Medicine (TCM) based acupuncture at prescribed sites
62460218|NCT02869646|SHAM_COMPARATOR|Minimal needling|shallow and non-acupoint needles at same number of sites
62460219|NCT04513379|EXPERIMENTAL|Trial|EFV 400mg
62460220|NCT04513379|ACTIVE_COMPARATOR|Control|EFV 600mg
62460221|NCT05383222|EXPERIMENTAL|ICU clinicians- technical first|Staff working on the Great Ormond Street ICUs Completing technical task first
62085857|NCT06469073|NO_INTERVENTION|General anesthesia only (G) group|
62085858|NCT02615756|EXPERIMENTAL|Physical exercise|
62085859|NCT02131714|ACTIVE_COMPARATOR|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
62085860|NCT02131714|PLACEBO_COMPARATOR|lifestyle counseling|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character.
62284946|NCT02006992|ACTIVE_COMPARATOR|RTF Infant Formula 1|a ready to feed (RTF) extensively hydrolyzed infant formula fed ad lib.
62284947|NCT02006992|EXPERIMENTAL|Powder Infant Formula 2|a powdered extensively hydrolyzed infant formula fed ad lib.
62284948|NCT03983551|EXPERIMENTAL|Dipeptidyl peptidase 4 inhibitors|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
62284949|NCT03983551|ACTIVE_COMPARATOR|Sulfonylureas|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
62284950|NCT04792710|EXPERIMENTAL|Intervention arm|This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose
62284951|NCT04792710|PLACEBO_COMPARATOR|Control arm|This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose
62284952|NCT01896960|ACTIVE_COMPARATOR|2 ml Bupivacaine|2 ml Bupivacaine with 15 micrograms of fentanyl
62284953|NCT01896960|ACTIVE_COMPARATOR|1.5 ml Bupivacaine|1.5 ml Bupivacaine with 15 micrograms of fentanyl
62284954|NCT01271621|ACTIVE_COMPARATOR|Macintoch group|Intubation with Macintoch Laryngoscope
62284955|NCT01271621|EXPERIMENTAL|Glidescope|Inubation by Glidescope
62284956|NCT02684721|NO_INTERVENTION|Control group|Patients in the control group receive usual care as a minimum. This includes 3-5 days of hospitalisation where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
62460222|NCT05383222|EXPERIMENTAL|ICU clinicians- administrative first|Staff working on the Great Ormond Street ICUs Completing administrative task first
62085861|NCT06500520|ACTIVE_COMPARATOR|Resisted Exercise group|Participants underwent resistance training for 8 weeks, focusing on trunk, upper, and lower body segments with 10-12 reps per exercise at 30-65% intensity. Sessions lasted 50-60 minutes, 3 times weekly
62085862|NCT06500520|ACTIVE_COMPARATOR|Stretching Exercise group|The participants were made to perform stretching exercises, selected by reviewing the literature, under supervision 3 days a week for 8 weeks, and they were asked not to do any other exercises during this intervention period.
62085863|NCT06500520|NO_INTERVENTION|control group|No treatment was applied to the control group; they were allowed to use painkillers and continued their normal daily lives.
62085864|NCT02089971||Young Chinese adults|cross-sectional, observational study of community dwelling young Chinese adults
62460223|NCT03553823|EXPERIMENTAL|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
62460224|NCT03553823|ACTIVE_COMPARATOR|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
62460225|NCT02589171|EXPERIMENTAL|Neo Close Abdominal Closure|
62460226|NCT02589171|ACTIVE_COMPARATOR|Carter Thomason Device|
62460227|NCT03943433|ACTIVE_COMPARATOR|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration at specific time points.
62460228|NCT03943433|EXPERIMENTAL|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration at specific time points.
62460229|NCT06261229|EXPERIMENTAL|Intermittent fasting|The participant will consume food about/ within 8 hours per day
62085865|NCT03706729|EXPERIMENTAL|Spraino intervention group|Participants will use Spraino® as a measure to prevent future lateral ankle sprains during all training sessions and games.
62085866|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
62085867|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
62085868|NCT06285760||Hospitalized heart failure patients|Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied.
62651444|NCT05150574|EXPERIMENTAL|Condition 10|Core Health platform plus Daily resting HRV feedback and Practice with feedback coaching
62651445|NCT05150574|EXPERIMENTAL|Condition 11|Core Health platform plus Daily resting HRV feedback and Behavioural initiation coaching
62085869|NCT03299374|ACTIVE_COMPARATOR|Falls Group|Falls prevention intervention
62085870|NCT03299374|EXPERIMENTAL|Pilates Group|Pilates intervention
62085871|NCT01859650||NSCLC patients undergoing RT|
62085872|NCT03079115|ACTIVE_COMPARATOR|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
62085873|NCT03079115|OTHER|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
62651446|NCT05150574|EXPERIMENTAL|Condition 12|Core Health platform plus Daily resting HRV feedback, Behavioural initiation coaching, and Practice with feedback coaching
62085874|NCT00401817|EXPERIMENTAL|Study Treatment Arm|Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1, and standard dose R-CHOP on day 3, for six 21-day cycles
62085875|NCT02784652|EXPERIMENTAL|RT & Zoledronic acid|Radiotherapy: 5 days/ week, 3 Gy \* 10-13 fractions or 4 Gy \* 5 fractions, Zoleronic acid: every 4 weeks, 6 times, 4.0 mg iv
62085876|NCT03544528|EXPERIMENTAL|Regeneration|This treatment aims to regenerate pulp-like tissue within the root canal space after inducing an influx of stem cells from the apical papilla that results in reestablishment of pulp protective functions.
62085877|NCT03544528|NO_INTERVENTION|Apexification|Traditional method. The application of Mineral Trioxide Aggregate (MTA) as an artificial apical barrier; also refer as the MTA apical plug method.
62085878|NCT06500182|EXPERIMENTAL|hippotherapy sessions|Patients will benefit from the hippotherapy sessions in additional to continuing to receive traditional care ,To evaluate any differences between the initial visit and the evaluation following 6 weeks in PDQ8 scores, which contain 8 items given a score between 0 (never) and 4 (always)
62085879|NCT03662893|SHAM_COMPARATOR|Behavioural therapy with written guideline|Patients were instructed to apply only written guideline forms of behavioural therapy which were the same as those in the checklist over six-month period.
62085880|NCT03662893|ACTIVE_COMPARATOR|Behavioural therapy with checklist|Patients were instructed to apply behavioural therapy with a written checklist for patients to fully complete over six-month period.
62085881|NCT03662893|ACTIVE_COMPARATOR|antimuscarinic drug plus verbal behavioural therapy|Patients received medical treatment (once or twice per day) plus behavioural therapy without checklist over six-month period.
62651447|NCT05150574|EXPERIMENTAL|Condition 13|Core Health platform plus Daily resting HRV feedback and Momentary HRV feedback
62651448|NCT05150574|EXPERIMENTAL|Condition 14|Core Health platform plus Daily resting HRV feedback, Momentary HRV feedback, and Practice with feedback coaching
62651449|NCT05150574|EXPERIMENTAL|Condition 15|Core Health platform plus Daily resting HRV feedback, Momentary HRV feedback, and Behavioural initiation coaching
62651450|NCT05150574|EXPERIMENTAL|Condition 16|Core Health platform plus Daily resting HRV feedback, Momentary HRV feedback, Behavioural initiation coaching, and Practice with feedback coaching
62651451|NCT05265572|EXPERIMENTAL|Intervention group|The group that will receive the intervention to apply
62651452|NCT05265572|NO_INTERVENTION|Control group|The group that will not receive the intervention
62651453|NCT00815152|EXPERIMENTAL|1|Twenty five caregivers will randomly be assigned to receive active coping skills training and 25 caregivers will randomly receive usual care at The Preston Robert Tisch Brain Tumor Center at Duke.
62651454|NCT00815152|PLACEBO_COMPARATOR|2|Caregivers that will receive ususal care.
62651455|NCT04597437|EXPERIMENTAL|Zanamivir|In the treatment group, participants weighing less than 50 kg will receive 12 mg/kg and those weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function.
62085882|NCT03662893|ACTIVE_COMPARATOR|antimuscarinics plus checklist|Patients received medical treatment (once or twice per day) with a written checklist to fully complete over six-month period.
62085883|NCT01071889|OTHER|Brotizolam|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo
62085884|NCT01071889|OTHER|Zolpidem|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo.
62085885|NCT04778384|EXPERIMENTAL|Intervention Group|30 patients receive micro-training based on a checklist \& targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire)
62085886|NCT04778384|SHAM_COMPARATOR|Control Group|30 patients receive a sham intervention: an unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
62085887|NCT01703442||Ovarian cancer patients|Perioperative primary epithelial ovarian cancer patients
62651456|NCT04597437|PLACEBO_COMPARATOR|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
62651457|NCT01979432|OTHER|Cardiovascular evaluation|Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure
62651458|NCT06354608|EXPERIMENTAL|Audio Book Group|Audiobooks are stories with illustrated stories, and these stories are voiced. Audiobooks are visual and auditory distractions. The researcher will introduce this audio book to both children and parents before the procedure. The child will be allowed to examine the book. Before starting the IM injection procedure, the researcher will show the pages of the book and start the story. The story will be supported by showing the pictures in the book to attract the child's attention. After the child concentrates on the story, the child's leg area where the vastus lateralis muscle is located will be hygienized before the IM injection. During the entire IM injection procedure, the audiobook will continue until the end of the procedure.
62651459|NCT06354608|EXPERIMENTAL|Local Vibration Group|A local vibration device, an electric vibration device, will be used. During the application, the device must be in full contact with the skin. Local vibration application reduces perceived pain by stimulating nerve fibres according to Melzack and Wall's Gate Control Theory. In the local vibration group, local vibration is applied to the leg area of the child where the vastus lateralis muscle is located for 30 seconds before the IM injection is applied with the vibrating Dolphin massage device. Then, the leg area will be hygienized, and the device will be placed 3-5 cm above the injection area during the procedure, and IM injection will be performed. The device must be in full contact with the skin during the application.
62651460|NCT06354608|NO_INTERVENTION|Control Group|Children in the control group will be received standard care. Control group children will not receive any distraction techniques.
62651461|NCT01824017|OTHER|Blood Draw|Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting
62085888|NCT03202875|EXPERIMENTAL|Test (T)|SAR341402: single dose injection
62085889|NCT03202875|ACTIVE_COMPARATOR|Reference 1 (R1)|NovoRapid®: single dose injection
62085890|NCT03202875|ACTIVE_COMPARATOR|Reference 2 (R2)|NovoLog®: single dose injection
62085891|NCT04946448|EXPERIMENTAL|FIT group|Patients treated with biological treatment and the FIT diet
62085892|NCT04946448|NO_INTERVENTION|Control group|Patients treated with biological treatment and the standard diet
62085893|NCT04298684|EXPERIMENTAL|Metformin|In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control.
62085894|NCT04298684|PLACEBO_COMPARATOR|Sitagliptin|In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months.
62085895|NCT06058143|EXPERIMENTAL|Group 1|Patients who received CLIF-LP treatment
62085896|NCT06058143|ACTIVE_COMPARATOR|Group 2|Patients who received TLIF treatment
62085897|NCT06022874||Patient's Diagnosed with Atopic Dermatitis|Patient's Diagnosed with Atopic Dermatitis
62651462|NCT02690727|EXPERIMENTAL|RP6530 in fast condition|A single dose of RP6530 following fast condition
62651463|NCT02690727|EXPERIMENTAL|RP6530 in fed condition|A single dose of RP6530 following fed condition
62460230|NCT06261229|EXPERIMENTAL|Intermittent fasting + Behavioral economic|The participant will consume food about/ within 8-hour per day. They will be rewarded as money when they achieve their weight loss goal or/and successfully do intermittent fasting 5 days/week.
62085898|NCT03866057||1 study group|All patients hospitalized in 4 intensive rehabilitation Structures of Don Gnocchi Foundation during the enrollment period, suffering from acute (within 30 days) ischemic or emorragic stroke
62460231|NCT06261229|EXPERIMENTAL|Intensive Lifestyle Modification|Advice about nutrition knowledge, healthy eating diet, diet prescription, and exercise
62085899|NCT03093311|EXPERIMENTAL|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
62460232|NCT05532332|EXPERIMENTAL|Test Product (T)|subjects were administered a single hard gelatin capsule of 10 mg Fluoxetine with approximately 240 ml water after an overnight fast of 10 hours
62085900|NCT03093311|NO_INTERVENTION|Arm B|Brain tissue oxygenation is not measured.
62085901|NCT02332681||With insufficiency fracture|Patients with acute pain that sustained a knee insufficiency fracture
62460233|NCT05532332|ACTIVE_COMPARATOR|Reference Product (R)|subjects were administered a single hard gelatin capsule of 10 mg Fluoxetine with approximately 240 ml water after an overnight fast of 10 hours
62085902|NCT02332681||Without insufficiency fracture|Patients with acute pain that did not sustained a knee insufficiency fracture
62085903|NCT03881540|ACTIVE_COMPARATOR|tDNA-MI group|Follow tDNA intervention and motivational interviewing counselling
62085904|NCT03881540|ACTIVE_COMPARATOR|tDNA-CC group|Follow tDNA intervention and conventional counselling
62085905|NCT03881540|OTHER|UC group|Follow a conventional diet with standard diabetes support and lifestyle education
62085906|NCT05652764|EXPERIMENTAL|Immuno-SelfCare|
62085907|NCT05652764|NO_INTERVENTION|Control Group|
62085908|NCT03590743|ACTIVE_COMPARATOR|Apixaban|Apixaban 5mg (10 mg twice daily for 7 days followed by 5 mg twice daily for 3 months).
62085909|NCT03590743|PLACEBO_COMPARATOR|Placebo|Patients will receive matching placebo.
62085910|NCT06478875|OTHER|[68Ga]Ga-PentixaFor; single injection|\[68Ga\]Ga-PentixaFor; 150 (± 50) MBq intravenous injection over 30 seconds; single injection
62085911|NCT04068727|NO_INTERVENTION|Control|
62284957|NCT02684721|EXPERIMENTAL|Exercise group|8-week home-base exercise programme: Patients in the intervention group receive the same usual care as patients in the control group. In addition the patients participate in an 8 week home-based exercise programme, including follow-up telephone calls with the physiotherapist after 1 week, 2 weeks and 4 weeks. Briefly put, the patients are required to exercise for a minimum of 3 times per week for 30-60 minutes, and with 3-4 intervals of approximately 1 minute at a high intensity level. Total exercise time and intervals increase during the 8 week programme. The patients can choose whatever type of exercise they prefer, and they are generally encouraged to choose something they already do, or something that they have previously had positive experiences doing.
62284958|NCT02950792|EXPERIMENTAL|ViewRay MRI-IGART|"ViewRay MRI-Image-Guided Adaptive Radiation Therapy (IGART):~* Daily MRI on ViewRay 5 days per week for 4 weeks in combination with weekly standard of care chemo-radiation.~* Daily MRI on ViewRay during Week 5 in combination with Stereotactic Body Radiation Therapy boost for daily for up to 1 week.~* Continued standard of care consolidation chemotherapy every 21 days for 3 cycles, beginning 4 - 6 weeks after completion radiation therapy, ."
62085912|NCT04068727|EXPERIMENTAL|Clinical Pharmacist Intervention|
62085913|NCT06372990||HBV|"* 150 HBV patients under NUC treatment~* 50 HBV patients with inactive carrier profile, treatment naive"
62085914|NCT06372990||HBV/HDV|"* 70 HDV patients treated with Bulevirtide~* 30 HDV patients treatment naive"
62284959|NCT03285256|EXPERIMENTAL|Experimental Memory Training|Experimental memory training program
62284960|NCT03285256|ACTIVE_COMPARATOR|Comparator Memory Training 1|Comparator memory training program
62284961|NCT03285256|ACTIVE_COMPARATOR|Comparator Memory Training 2|Alternative comparator memory training program
62284962|NCT01505829||Biological validation cohort 1|
62284963|NCT01505829||Response assessment cohort 2|
62085915|NCT03184714|NO_INTERVENTION|Control|
62085916|NCT03184714|EXPERIMENTAL|Interventional group|NIPPV as treatment of OS
62085917|NCT01653847|ACTIVE_COMPARATOR|Group 1: Tacrolimus with MMF.|This group will receive a standard dose Tacrolimus and MMF. This will follow standard of care protocol at Northwestern Memorial Hospital's Comprehensive Transplant Center.
62085918|NCT01653847|ACTIVE_COMPARATOR|Group 2: Tacrolimus with Everolimus|This group will receive a low dose Tacrolimus with concentration controlled Everolimus
62085919|NCT01653847|NO_INTERVENTION|Donors|One time blood samples will be collected from kidney donors to recipients in this study
62085920|NCT05814874|PLACEBO_COMPARATOR|meat-based diet; placebo|
62085921|NCT05814874|ACTIVE_COMPARATOR|meat-based diet; selenium supplement|
62085922|NCT05814874|ACTIVE_COMPARATOR|meat-based diet; Brazil nut|
62085923|NCT05814874|PLACEBO_COMPARATOR|vegan diet; placebo|
62085924|NCT05814874|ACTIVE_COMPARATOR|vegan diet; selenium supplement|
62085925|NCT05814874|ACTIVE_COMPARATOR|vegan diet; Brazil nut|
62085926|NCT05125120|OTHER|Attention Deficit and Hyperactivity Disorder|Attention Deficit and Hyperactivity Disorder (CO-OP Group) Attention Deficit and Hyperactivity Disorder (Control Group)
62085927|NCT01457040|EXPERIMENTAL|Complete Remission (CR)|CR Cohort: high-risk ALL in CR and standard-risk ALL in the status of ≥CR2
62085928|NCT01457040|EXPERIMENTAL|Non-Remission (NR)|NR Cohort: ALL in non-remission
62085929|NCT02703961|EXPERIMENTAL|experimental|"concurrent and adjuvant chemotherapy with cisplatin and docetaxel combined radical radiotherapy.~During external beam radiotherapy: cisplatin 60mg/m2, d1,d22; docetaxel 60mg/m2, d1,d22.~After external beam radiotherapy: cisplatin 75mg/m2, d43,d64;~The patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.~docetaxel 75mg/m2, d43,d64."
62085930|NCT02703961|OTHER|control|"standard chemoradiotherapy with weekly cisplatin.~Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29.~Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy."
62085931|NCT00605319|OTHER|Toviaz (Fesoterodine)|Toviaz 4mg to 8mg
62085932|NCT02675140|EXPERIMENTAL|ZENTEL|Children in intervention group 1 was received 400 mg single-dose albendazole administration, by mouth, for once.
62085933|NCT02675140|EXPERIMENTAL|ZENTEL and Vitamin A Soft Capsules|Children in intervention group 2 was received a 200,000 IU vitamin A capsule combined 400 mg single-dose albendazole once initially, by mouth.
62085934|NCT02675140|NO_INTERVENTION|No drug adminitrated|Children in this Group were received no intervention as control group
62651464|NCT05342571|EXPERIMENTAL|Supportive care (ABC session, surveys, biospecimen collection)|Phase 1 of the intervention (10 weeks) will follow the following agenda: 1) Overview and progressive muscle relaxation, 2) Seeking and asking for disease-related and treatment-related information, 3) Problem solving skills, 4) Breathing techniques and sleep hygiene, 5) Assertive communication skills, 6) Identifying social network, 7) Asking for support, 8) Further information on social support, 9) Physical activity, and 10) Review of major topics, transition. Phase 2 of the intervention (4 weeks) which will be completed only by patients who do not experience remission in depressive symptoms by the end of phase 1, will follow the following agenda: 1) Identifying negative thoughts and problematic thinking patterns, 2) Generating alternative thoughts, 3) Behavioral activation, and 4) Review and wrap-up, transition to optional maintenance. Each session in Phase 1 and Phase 2 occurs once per week, for 60 minutes each. Maintenance sessions occur monthly, 60 minutes each.
62284964|NCT04457960|EXPERIMENTAL|JNJ-66525433|Participants will receive JNJ-66525433 in increasing dose level 1 to dose level 4 in Parts 1, 2, and dose level 3 in part 3.
62284965|NCT04457960|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo in Parts 1, 2 and 3.
62284966|NCT05836454|EXPERIMENTAL|Progressive Muscle Relaxation Group:|Progressive Muscle Relaxation technique will be applied to this group. Technique will be applied 3 days a week for 2 menstrual cycles.
62284967|NCT05836454|EXPERIMENTAL|Myofascial Release Technique Group|Myofascial Release Technique will be applied to this group. Technique will be applied 3 days a week for 2 menstrual cycles.
62284968|NCT05836454|NO_INTERVENTION|Control Group|The control group will be asked to continue their normal lives.
62085935|NCT02173535|EXPERIMENTAL|etafilcon test contact lens Variant AP|
62085936|NCT02173535|EXPERIMENTAL|etafilcon test contact lens Variant JG|
62085937|NCT02173535|EXPERIMENTAL|etafilcon test contact lens Variant CS|
62284969|NCT02817672|ACTIVE_COMPARATOR|PRIME 1.0|8 weeks use of PRIME 1.0 (current version). Mobile application designed to improve psychosocial functioning and motivational deficits.
62284970|NCT02817672|EXPERIMENTAL|PRIME 2.0|8 weeks use of PRIME 2.0 (version with the NLP-powered dashboard). Mobile application designed to improve psychosocial functioning and motivational deficits.
62284971|NCT02881034||Hepatitis C patients|Hepatitis C virus (HCV) infected patients with a previous non-response to pegylated-interferon/ribavirin therapy and re-treated with pegylated-interferon/ribavirin and telaprevir
62284972|NCT00697957|NO_INTERVENTION|2|Control group
62284973|NCT00697957|EXPERIMENTAL|1|Exercise
62284974|NCT06192173||Closure group|Migraine patients with PFO who managed with percutaneous PFO closure.
62284975|NCT06192173||Drug group|Migraine patients with PFO who treated with medicion.
62284976|NCT02056509||Out of hospital cardiac arrest|Out of hospital cardiac arrest of non-traumatic cause
62085938|NCT02173535|EXPERIMENTAL|etafilcon test contact lens Variant VC|
62085939|NCT02173535|EXPERIMENTAL|etafilcon test contact lens Variant LA|
62085940|NCT01807078|ACTIVE_COMPARATOR|Ezetimibe|Patients will receive for 6 months ezetimibe (10 mg/day)
62284977|NCT02056509||Unexpected in-hospital cardiac arrest|Unexpected cardiac arrest during emergency department stay
62284978|NCT04345445|EXPERIMENTAL|Tocilizumab|Tocilizumab is given at 8 mg/kg (body weight) once and administered as an intravenous infusion within no less than 60 minutes.
62085941|NCT01807078|ACTIVE_COMPARATOR|Nutraceuticals|Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
62085942|NCT06179589|EXPERIMENTAL|VS002A|Advanced Amino acid-based ORS: VS002A Traditional oral rehydration solutions (ORS) contain sugars which stimulate intestinal sodium and water absorption through a variety of mechanisms. However, it has been under-appreciated that traditional ORS possess no anti-diarrheal functions and may exacerbate infectious diarrheal secretions.
62085943|NCT06179589|ACTIVE_COMPARATOR|WHO-ORS|WHO-ORS usually used worldwide in the treatment of diarrhoea.
62085944|NCT05188391|OTHER|Positive Group (Rupture and Gap Sign are both positive)|Rupture and Gap Sign are both positive
62284979|NCT04345445|ACTIVE_COMPARATOR|Methylprednisolone|Reconstituted methylprednisolone is infused over 30 minutes and administered at a dose of 120mg/day for 3 days
62284980|NCT04295070|PLACEBO_COMPARATOR|Placebo|Saline (0.9%) delivered intranasally via dropper
62284981|NCT04295070|EXPERIMENTAL|Low dose cohort|CodaVax-RSV delivered intranasally via dropper
62284982|NCT04295070|EXPERIMENTAL|High dose cohort|CodaVax-RSV delivered intranasally via dropper
62284983|NCT05223595|EXPERIMENTAL|dose escalation|Gentuximab at a dose of 8 mg/kg or 12 mg/kg based on body weight + Almonertinib at a dose of 110mg for one 28-day cycle
62284984|NCT00983190|OTHER|Single Group Assignment|
62460234|NCT06547944|EXPERIMENTAL|ZGR regimen|"Dose Escalation lenalidomide combined with Zanubrutinib and Obinutuzumab (Dose escalation will occur using a 3+3 design)~Recommended phase II dose (RP2D) lenalidomide combined with Zanubrutinib and Obinutuzumab"
62460235|NCT02087371||Included patients|Patients with end-stage liver failure and registered on transplantation list.
62085945|NCT05188391|OTHER|Rupture Positive Group (Rupture positive but Gap Sign is negative)|Rupture positive but Gap Sign is negative
62085946|NCT05188391|OTHER|Gap Sign Positive Group (No rupture exists but Gap Sign is positive)|No rupture exists but Gap Sign is positive
62085947|NCT05188391|OTHER|Negative Group (Rupture and Gap sign are both negative)|Rupture and Gap sign are both negative
62651465|NCT05841511|EXPERIMENTAL|Immediate treatment group|"The immediate treatment group will receive the intervention in the first time period, while the wait-list control group will receive the intervention program during the second time period. Baseline and outcome evaluation will be accessed at three-time points: baseline assessment (1st week), assessment 1-midway (5th week), and assessment 2-final (10th week) in this study.~To establish and develop an efficient program, several theories were implemented into the intervention design to address handwriting problems in children with ASD, including psycho-geometric theory, motor learning theory, and cognitive training theories. The intervention will be delivered in thirty-six activities for visual perceptual, fine motor, and visual motor integration skill training integrated with the unique properties of the Chinese writing system. A total of 12 hours of intervention program will be conducted in eight sessions within four weeks."
62284985|NCT06496412|EXPERIMENTAL|fecal microbiota transplantation|On the basis of baseline medication, high-dose fecal microbiota transplantation (FMT) will be administered, with subjects taking 50 fecal microbiota capsules. Subsequently, maintenance doses will be administered at week 2, 4, 8, 12, and 20, with 10 capsules taken each time. Fasting is required 4 hours before and 1 hour after capsule ingestion, and subjects are instructed to maintain a stable diet and physical activity pattern throughout the 24-week study period. Capsules will be transported on ice and warmed for 10 minutes at 37°C before FMT administration.
62085948|NCT05919667|EXPERIMENTAL|Dairy-based Product 1|2% Cow's milk (Neilson, St-Laurent, Quebec)
62284986|NCT06496412|PLACEBO_COMPARATOR|placebo|Different from the experimental group, the control group will receive placebo capsules that have the same appearance as the fecal microbiota capsules, while other procedures remain the same as those in the experimental group.
62085949|NCT05919667|EXPERIMENTAL|Dairy-based Product 2|Regular fat cheddar cheese (Armstrong, St-Laurent, Québec)
62284987|NCT01501903|ACTIVE_COMPARATOR|Standard|Biopsy using standard technique of FNA
62284988|NCT01501903|OTHER|Fanning|Biopsy using fanning technique
62284989|NCT03760497|EXPERIMENTAL|CIV Group|Temporary Restoration with Glass Ionomer (Equia Forte® - GC Corporation, Tokyo, Japan) for 30 days + Restoration in Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA).
62284990|NCT03760497|EXPERIMENTAL|Composite Resin Group|Restoration with Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, United States).
62284991|NCT03760497|EXPERIMENTAL|Composite Resin Group + Laser|Composite Resin Restoration (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA) + Application of Diode Laser.
62284992|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
62284993|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
62284994|NCT00188630|ACTIVE_COMPARATOR|N-Acetylcysteine|IV NAC as a 100mg/kg bolus at the start of the surgical procedure (prior to the initiation of CPB), followed by a 10 mg/kg/hr infusion until 4 hours after completion of surgery
62284995|NCT00188630|PLACEBO_COMPARATOR|Placebo|The control arm will instead receive placebo (5% dextrose solution), both as a bolus and infusion.
62460236|NCT03100305||Extremely preterm infants|
62460237|NCT03100305||Very preterm infants|
62460238|NCT03100305||Moderately preterm infants|
62460239|NCT03100305||Late preterm infants|
62085950|NCT05919667|EXPERIMENTAL|Plant-based Product 3:|Vanilla Soy Beverage (Silk, Broomfield, Colorado)
62085951|NCT05919667|EXPERIMENTAL|Plant-based Product 4|Vanilla Almond Beverage (Earth's Own, Vancouver, British Columbia)
62085952|NCT05919667|EXPERIMENTAL|Plant-based Product 5|Plant-based Cheddar-Style Block (President' Choice, Brampton, Ontario)
62085953|NCT06220786|ACTIVE_COMPARATOR|Low-level laser therapy|Laser pen with low-level laser therapy.
62460240|NCT02869425|EXPERIMENTAL|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
62460241|NCT02869425|PLACEBO_COMPARATOR|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
62085954|NCT06220786|SHAM_COMPARATOR|Sham no low-level laser therapy|Identical laser pen without the low-level laser production.
62460242|NCT03056781|EXPERIMENTAL|social interaction|Participants will engage in a social interaction with another person
62284996|NCT06177366||Adults with MPN who need a bone marrow biopsy during the management of the disease|
62284997|NCT04041856|ACTIVE_COMPARATOR|EKC patients|Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
62284998|NCT04041856|NO_INTERVENTION|Control group|All patients will undergo observational treatments including artificial tear drop and improving hygiene level
62284999|NCT03951636|SHAM_COMPARATOR|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
62460243|NCT03056781|EXPERIMENTAL|food consumption|Participants will be offered food stuffs to eat/drink
62285000|NCT03951636|EXPERIMENTAL|Er:YAG laser|Er:YAG laser treatment will be provided on the implant/abutment surface.
62285001|NCT03951636|ACTIVE_COMPARATOR|Air Powder|an Air-Powder treatment will be provided on the implant/abutment surface.
62285002|NCT04870437|EXPERIMENTAL|Extracorporeal phototherapy|
62285003|NCT01951677|ACTIVE_COMPARATOR|HBsAg + alum adjuvant|HBsAg + standard alum adjuvant
62285004|NCT01951677|EXPERIMENTAL|HBsAg + Advax-1(TM)|HBsAg + Advax-1
62285005|NCT01951677|EXPERIMENTAL|HBsAg + Advax-2(TM)|HBsAg + Advax-2
62085955|NCT05249764|ACTIVE_COMPARATOR|Exercise|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
62085956|NCT05249764|ACTIVE_COMPARATOR|Control|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
62285006|NCT01951677|EXPERIMENTAL|HBsAg + Advax-3(TM)|HBsAg + Advax-3
62285007|NCT01951677|ACTIVE_COMPARATOR|preS HBsAg + alum adjuvant|preS HBsAg + alum adjuvant
62285008|NCT01951677|EXPERIMENTAL|preS HBsAg + Advax-1(TM)|preS HBsAg + Advax-1
62285009|NCT01951677|EXPERIMENTAL|preS HBsAg + Advax-2(TM)|preS HBsAg + Advax-2
62285010|NCT01951677|EXPERIMENTAL|preS HBsAg + Advax-3(TM)|preS HBsAg + Advax-3
62653108|NCT05042492|NO_INTERVENTION|Group 1: SC (moveUP)|In group 1: moveUP (class 1, CE-marked, medical device) is being used as the rehabilitation solution after TKA. It has become a valid digital rehabilitation solution and is recognised by the Belgian government as mobile health application in rehabilitation of hip and knee arthroplasty surgeries. It's a full service with daily personalized and individualized follow up by certified physical therapists and certified health care providers. The use of tele-rehabilitation for TKA patients has been internationally recognized with the 2018 John N. Insall Award during the American Knee Society Meeting
62460244|NCT02918994|EXPERIMENTAL|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
62460245|NCT04697498|ACTIVE_COMPARATOR|The Control Group|The control group will include patients who will undergo surgery under general anesthesia.
62460246|NCT04697498|EXPERIMENTAL|The Study Group|The study group will include patients who will undergo surgery under general anesthesia using a bilateral bi-level Erector spine plane block.
62460247|NCT03587649|EXPERIMENTAL|[18F]MNI-1126|To measure the dynamic uptake and washout of \[18F\]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
62460248|NCT03472365|EXPERIMENTAL|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m\^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd if there is no PD.
62085957|NCT04345211|ACTIVE_COMPARATOR|Group1 (G1): walking group|"All walks will be done immediately after the MT and TB intervention, as this has been shown to improve the synergistic effect of combining the two interventions. The walking sessions will be organized twice a week. The walking sessions will begin with a 10-minute warm-up. After warming up, you will take a continuous walk for 10-20 min, at a target intensity of 13 (somewhat difficult) on the Borg scale. Using the Borg scale, which ranges from 6 to 20, participants will be asked to walk at an intensity of 13 (perception of somewhat difficult activity). Each session will be completed with a 10 minute cool down period. The objectives of Walinking will be individualized according to the level of physical condition of each participant. The walking group will include a weekly walking goal of 75 minutes."
62285011|NCT01951677|ACTIVE_COMPARATOR|high dose preS HBsAg + alum adjuvant|high dose preS HBsAg + alum adjuvant
62285012|NCT01951677|EXPERIMENTAL|high dose preS HBsAg + Advax-1(TM)|high dose preS HBsAg + Advax-1
62460249|NCT03472365|EXPERIMENTAL|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continuous oral administration of each 3-week cycle.
62460250|NCT02962570|EXPERIMENTAL|Only Arm|"Two minutes: Intervention: Device: On Demand Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Two minutes intervention: Device: Traditional, Always-On, Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Repeat until the end of the surgical procedure"
62285013|NCT01951677|EXPERIMENTAL|high dose preS HBsAg + Advax-2(TM)|high dose preS HBsAg + Advax-2(TM)
62460251|NCT03784664|ACTIVE_COMPARATOR|Arterial blood gas|
62460252|NCT03784664|EXPERIMENTAL|Veinous blood gas|
62653109|NCT05042492|EXPERIMENTAL|Group 2: SC (moveUP) with 10 days of geko|In group 2: Next to SC (moveUP), the application of a single gekoTM device is used on the operated leg after surgery (day 0). This device will be worn for 24 hours and at least 8 hours from day 1 until day 10.
62653110|NCT01214122|EXPERIMENTAL|Treatment A|AZD9668 - 2 x30mg tablets
62653111|NCT01214122|EXPERIMENTAL|Treatment B|Warfarin - 10 x2.5 mg tablets
62285014|NCT01951677|EXPERIMENTAL|high dose preS HBsAg + Advax-3(TM)|high dose preS HBsAg + Advax-3
62460253|NCT05552001|EXPERIMENTAL|Single arm receiving sacituzumab govitecan|
62085958|NCT04345211|ACTIVE_COMPARATOR|Group 2 (G2): walking plus manual therapy|"Walking as previously described plus a self-administered manual chest therapy:~- Neurolymphatic points pressure: Participants will be placed in a neutral position and their arms next to their bodies. They are asked to take a conscious breath. The physical therapist will apply firm, direct rotary pressure through the thumb or fingertip for 1 minute from the T1 transverse processes to the T12 transverse processes. Suboccipital decompression / mobilization, slippage of the cervical vertebral joints (anterior / posterior), myofascial release of sternocleidomastoid and trapezius, slippage of the sternoclavicular joint (anterior / posterior direction), myofascial release of intercostal muscles and paravertebral muscles (anterior rib mobilization, posterior, lateral), mobilization of the scapulothoracic joint, diaphragmatic release."
62085959|NCT04345211|ACTIVE_COMPARATOR|Group 3 (G3): walking plus thorax exercises with Theraband.|Walking as previously described plus a self-administered exercises with elastic-band. The exercises will include chest and arms exercises in sitting position.
62085960|NCT04345211|NO_INTERVENTION|Group 4 (G4): control group|Control group will do usual life and assessments as the rest of the groups.
62085961|NCT05687617|EXPERIMENTAL|Gastric cancer with ICG|Patient to receive IV ICG during diagnostic laparoscopy.
62085962|NCT00372060|EXPERIMENTAL|1|MK0431 + pioglitazone
62085963|NCT00372060|PLACEBO_COMPARATOR|2|Placebo/MK0431 + pioglitazone
62653112|NCT00566826|EXPERIMENTAL|1|Patient support treatment sessions
62085964|NCT04522921|NO_INTERVENTION|Control Group (CG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and regular follow-up.
62085965|NCT04522921|EXPERIMENTAL|Follow-up group (FUG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and increased follow-up.
62085966|NCT04522921|EXPERIMENTAL|Intervention group (IG)|A higher protein diet (25E%/day) for the 10 weeks they attend the camp and increased follow-up.
62285015|NCT03607773|ACTIVE_COMPARATOR|Mindfulness Behavioural Intervention (MBI) group|10 one-hour mindfulness sessions
62285016|NCT03607773|NO_INTERVENTION|Control group|Standard of care.
62285017|NCT06364995|EXPERIMENTAL|Volleyball specialised physical education|Volleyball specialised physical education intervention in weeks 1-10 of the experiment
62285018|NCT06364995|ACTIVE_COMPARATOR|Traditional Physical Education|This arm is the control group receiving a traditional Physical Education program， Over 10 weeks, participants will engage in regular physical education sessions that include volleyball training
62285019|NCT01471665|EXPERIMENTAL|GSK2190915 100mg|This is a crossover study so patients will receive 100mg of GSK2190915 once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the placebo arm of the study.
62285020|NCT01471665|PLACEBO_COMPARATOR|Placebo|This is a crossover study so patients will receive placebo once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the GSK2190915 100mg arm of the study.
62653113|NCT00566826|ACTIVE_COMPARATOR|2|Treatment as usual
62653114|NCT03057418|EXPERIMENTAL|Aurixim|"Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.~Mode of administration: intravenous."
62085967|NCT06458387|EXPERIMENTAL|Active protein supplementation|The participants in active nutritional supplementation arm received nutritional support targeting specific protein (over 1.5 g/kg/day), with consultation from the nutritional support team and the initiation of nutritional supplementation on the same day as intensive care unit admission.
62085968|NCT06458387|EXPERIMENTAL|Conventional protein supplementation|The participants in conventional protein supplementation arm underwent conventional nutrition management without specific protein targets, but less than 1.5 g/kg/day.
62085969|NCT03178305|EXPERIMENTAL|Intervention|"Besides the behavior change programme (Do Something Different)~1. All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~2. patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~3. Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
62085970|NCT03178305|NO_INTERVENTION|Care as usual|Patients in this arm will receive care as usual with no restrictions.
62085971|NCT02079207|EXPERIMENTAL|NBP606|Participants aged over 50 years are given a 0.5mL dose of 13-valent peumococcal conjugate vaccine administered on day 0.
62285021|NCT05176912|EXPERIMENTAL|Experimental Exercise Group|Reformer Pilates exercises will given for 8 weeks, 3 days in a week.
62285022|NCT05176912|NO_INTERVENTION|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
62285023|NCT04019366|EXPERIMENTAL|Group I|The experimental group was treated with Balance Training on Biodex Stability System along with traditional exercises.
62285024|NCT04019366|ACTIVE_COMPARATOR|Group II|The Control group was treated with Traditional exercises only for Symptomatic knee osteoarthritis.
62460254|NCT04155281||suspicion of intoxication|New Psychoactive Substances research in urine
62460255|NCT00720265|ACTIVE_COMPARATOR|1|
62460256|NCT00720265|EXPERIMENTAL|2|
62460257|NCT04933825|EXPERIMENTAL|"Four escalating dose-levels of ET-02 will be evaluated using a 3+3 design."|
62460258|NCT04332302|EXPERIMENTAL|Power training group|Participants will be enrolled in a resistance training program.
62460259|NCT04332302|NO_INTERVENTION|Control group|Participants will be doing their normal life.
62460260|NCT04538170||ORC|Group orchidectomy following cancer
62460261|NCT04538170||GAC|Group sex reassignment surgery
62460262|NCT01671514|EXPERIMENTAL|Sedentary|The sedentary arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
62460263|NCT01671514|EXPERIMENTAL|Heart failure/diabetes|The heart failure/diabetes arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
62085972|NCT02079207|ACTIVE_COMPARATOR|Prodiax-23|Participants aged over 50 years are given a 0.5mL dose of 23-valent pneumococcal polysaccharide vaccine administered on day 0.
62085973|NCT03188328|EXPERIMENTAL|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
62085974|NCT04201496|EXPERIMENTAL|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)
62085975|NCT04201496|EXPERIMENTAL|Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks|Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)
62085976|NCT04201496|ACTIVE_COMPARATOR|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)
62085977|NCT04201496|ACTIVE_COMPARATOR|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)
62085978|NCT01739387||Breath actuated inhaler (BAI)|Placebo. Two to nine puffs on one day only
62085979|NCT01739387||Flutiform® pMDI|Placebo. Two to nine puffs on one day only
62085980|NCT02300779|EXPERIMENTAL|Low-residue diet|Subjects will follow a low-residue diet for 4 days. Their usual treatment for diabetes will be adjusted to the degree of glycemic control.
62460264|NCT00527423|EXPERIMENTAL|Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)|
62653115|NCT04491799||Nosocomial diarrhea|Patients who are hospitalized and develop diarrhea after 72 hours of hospitalization.
62653116|NCT02106481|ACTIVE_COMPARATOR|Femoral Nerve Catheters|Patients will receive a Single Shot Femoral Nerve Block along with a conventional continuous femoral nerve catheter
62085981|NCT02300779|ACTIVE_COMPARATOR|Usual care|Subjects will follow a low-residue diet for 3 days (from 4 to 2 days before the procedure) and a liquid diet on the following day (the one before the procedure). No changes in their treatment for diabetes will be made
62460265|NCT01206257||Group 1|
62653117|NCT02106481|ACTIVE_COMPARATOR|Single Shot Femoral Nerve Blocks|Patients will receive a Single Shot Femoral Nerve Block and a sham catheter post op.
62653118|NCT04445168|NO_INTERVENTION|Usual Care|Participants assigned to usual care may receive advice from their primary care physician to increase their physical activity. They will receive handouts about every 6 weeks on general health topics.
62085982|NCT00809432|EXPERIMENTAL|Visit 1|2 hour city centre kerbside walk in Beijing China
62085983|NCT00809432|EXPERIMENTAL|Visit 2|2 hour city centre kerbside walk in Beijing China
62085984|NCT04847479|EXPERIMENTAL|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to their close contacts.
62085985|NCT04847479|ACTIVE_COMPARATOR|Test referral distribution|Participants in the test referral arm receive text messages providing testing information to send to their close contacts.
62085986|NCT06150677|EXPERIMENTAL|Static apnea at High Lung Volume|Participants will remain at rest in the supine position for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
62085987|NCT06150677|NO_INTERVENTION|Static at normal breathing|Participants will remain at rest in the supine position for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes
62460266|NCT04569942|ACTIVE_COMPARATOR|Vasopressor|a restricted fluids and early vasopressor strategy
62460267|NCT04569942|ACTIVE_COMPARATOR|Fluids|a larger intravenous (IV) fluid volume and later vasopressor strategy
62460268|NCT00543686|ACTIVE_COMPARATOR|1|Montelukast
62460269|NCT00543686|ACTIVE_COMPARATOR|2|Fluticasone
62460270|NCT04303364||Subjects without T2DM and without HF|
62460271|NCT04303364||Patients without T2DM and with HFpEF|
62460272|NCT04303364||Patients with T2DM and without HFpEF|
62460273|NCT04303364||Patients with T2DM and HFpEF|
62460274|NCT04303364||Patients without T2DM and with hypertrophic cardiomyopathy|
62460275|NCT04303364||Patients with T2DM and with hypertrophic cardiomyopathy|
62460276|NCT01674530|EXPERIMENTAL|Lubiprostone|Manufactured by Dr Reddy's Laboratories Ltd( 24 mcg administered for 7 days )
62460277|NCT01674530|ACTIVE_COMPARATOR|AMITIZA®|Manufactured by Sucampo Pharmaceuticals(24 mcg administered for 7 days)
62085988|NCT04112472|EXPERIMENTAL|Examination of participants|Examination of participants by means of the investigational device as well as the comparative devices.
62085989|NCT05554250||Obese patients|The population of the study consisted of individuals who applied to the Diet Polyclinic of a hospital, and the sample consisted of 500 individuals who applied to the Diet Polyclinic and met the research criteria.
62085990|NCT02041364||Control: patients without fatigue|Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
62085991|NCT02041364||Patients with fatighe|Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue
62285025|NCT02844998|ACTIVE_COMPARATOR|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
62285026|NCT02844998|EXPERIMENTAL|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
62460278|NCT01674530|PLACEBO_COMPARATOR|Placebo|Manufactured by Dr Reddy's Laboratories Ltd ( 24 mcg adminstered for 7 days )
62653119|NCT04445168|EXPERIMENTAL|Intervention|Participants assigned to the intervention arm will receive telephone-based motivational interviews with trained interventionists to encourage increases in physical activity.
62460279|NCT00731926|EXPERIMENTAL|1|
62460280|NCT00731926|ACTIVE_COMPARATOR|2|
62085992|NCT03529903|NO_INTERVENTION|Control Group|\*Complete an online survey and intake appointment with a trained Health Coach (HC), who will measure their height, weight, and blood pressure, assess their current health habits (sleep, nutrition, exercise) and work with they to set realistic, achievable health goals. \*Wear a Fitbit device daily to track physical activity and weight (members of the MyLife study team can access their data during throughout the program and de-identified, anonymous, data will be shared with Fitbit as part of a research partnership). \*Complete another online survey and telephone check-in with their HC at the halfway point to monitor their progress toward reaching their goals. \*Complete a final online survey and outtake appointment with their HC to re-check their measurements and discuss their progress.
62651466|NCT05841511|EXPERIMENTAL|Wait-list control group|"The immediate treatment group will receive the intervention in the first time period, while the wait-list control group will receive the intervention program during the second time period. Baseline and outcome evaluation will be accessed at three-time points: baseline assessment (1st week), assessment 1-midway (5th week), and assessment 2-final (10th week) in this study.~To establish and develop an efficient program, several theories were implemented into the intervention design to address handwriting problems in children with ASD, including psycho-geometric theory, motor learning theory, and cognitive training theories. The intervention will be delivered in thirty-six activities for visual perceptual, fine motor, and visual motor integration skill training integrated with the unique properties of the Chinese writing system. A total of 12 hours of intervention program will be conducted in eight sessions within four weeks."
62651467|NCT05987800|OTHER|Preterm infants on non-invasive respiratory support|All infants on non-invasive respiratory support will be studied. Only infants on less than 32 weeks of gestation at birth, will undergo an intervention.
62651468|NCT04337632|EXPERIMENTAL|PP|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, day 1, intravenous drip, repeated every three weeks.
62285027|NCT02844998|SHAM_COMPARATOR|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
62460281|NCT00731926|PLACEBO_COMPARATOR|3|
62460282|NCT00242866|EXPERIMENTAL|Arm 1|GW274150 - 5mg or 30mg
62651469|NCT04337632|ACTIVE_COMPARATOR|TP|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
62653120|NCT05513911|EXPERIMENTAL|Acute intermittent Hypoxia Therapy|This group will receive the acute intermittent hypoxia therapy (9% O2) for 30 minutes. Before and after the intervention the participant will perform flexion of the elbow at various levels of intensity
62460283|NCT00242866|PLACEBO_COMPARATOR|Arm 2|Placebo to match GW274150
62460284|NCT03940001|EXPERIMENTAL|arm|"Biological: Sintilimab For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1~Drug: Paclitaxel 50 mg/m\^2 IV Q3W day 1, day 8 and day 15~Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15~Radiotherapy:~1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy"
62460285|NCT04586088|EXPERIMENTAL|Apatinib plus Camrelizumab arm|Subjects receive apatinib plus camrelizumab
62460286|NCT01075711||NIS in-house doctors|This group will be assigned to general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months. Three subjects are expected per in-house doctor therefore altogether, 1000 in-house doctors will be obtained or appointed for the observation study.
62460287|NCT01075711||NIS specialists|This group will be assigned to specialists (rheumatologist) with an observation period of 9 months. Ten subjects per rheumatologist are expected therefore altogether, 500 rheumatologists will be obtained or appointed for the observation study.
62651470|NCT05899361|EXPERIMENTAL|Electromagnetic Guided Laparoscopy + Ultrasound|"This trial will investigate the use of the novel imaging protocol patients who have a confirmed cancer diagnosis in any of the following urologic regions or organs: Bladder, Prostate, Testicle, Ureter, Kidney, Urethra, Penis, and Scrotum.~- This research study involves the use of a standard of care laparoscope and ultrasound probe. The laparoscope and ultrasound probe will have an electromagnetic sensor attached which will assist in the tracking of lymph nodes of interest or organs of interest. It is expected that the entire time to record the data will be less than 10 minutes. standard of care laparoscope and ultrasound probe"
62651471|NCT02517281|EXPERIMENTAL|Patients having received targeted therapies|Patients treated using targeted therapies
62651472|NCT04529564||EAP patients|The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in Taiwan during 2018 to 2019.
62651473|NCT05462574||Participants with Pulmonary Arterial Hypertension (PAH)|Participants with heritable, idiopathic, and scleroderma associated PAH.
62651474|NCT02576899|ACTIVE_COMPARATOR|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program \[FFS\]. This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
62651475|NCT02576899|PLACEBO_COMPARATOR|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
62651476|NCT03693196|OTHER|Straumann®|Titanium implants the surfaces of which were roughened with SLA (sandblasted and acid-etched titanium surface) (Straumann®, Basel, Sweden). Immunological parameters (PICF, Perio-paper®) , microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
62460288|NCT03267745|EXPERIMENTAL|Amino Acid|Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
62460289|NCT03267745|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 23.7g of excipient-matched placebo in water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
62085993|NCT03529903|EXPERIMENTAL|Experimental Group|\*Complete survey/ intake appointment with a HC, who will measure their height, weight, and blood pressure, assess their health habits and set achievable health goals. \*Wear a Fitbit to track their daily physical activity and weight \*Set a weekly active minutes goal and record their weight weekly. \*Receive motivational text messages 4x per week, one will ask for their weekly active minutes goal and weight and another will ask for goal progression.\*Complete photo food diaries biweekly (send pictures of everything they eat/drink to their HC). \*Complete surveys/telephone check-ins with their HC every 2 weeks to monitor their progress toward reaching their goals. \*Complete final survey/outtake appointment with their HC to for final measurements and to discuss goal progression (about 2 hours).
62460290|NCT00983710|EXPERIMENTAL|1|Participants will receive a new patient education program designed to help men manage side-effects related to treatment for localized prostate cancer. The intervention will be targeted to low health literacy men.
62085994|NCT05943483||All subjects|Subjects who filled out our modified CCMQ questionnaire
62085995|NCT04782310|EXPERIMENTAL|Group Pregabalin|Patients will receive oral Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
62460291|NCT00983710|ACTIVE_COMPARATOR|2|Usual care, including a booklet on coping with localized prostate cancer. After the 6-month primary outcome data are collected, control group men will be offered the opportunity to cross-over and receive the new educational intervention.
62460292|NCT01436032|EXPERIMENTAL|N1539 15 mg|
62651477|NCT03693196|OTHER|Astra Tech, OsseoSpeed™|Implants the surfaces of which were roughened by modifying with fluorine (Astra Tech, OsseoSpeed™, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
62653121|NCT04628624|PLACEBO_COMPARATOR|Placebo group|Placebo - capsulated, colour matched potato starch (\~450mg per capsule) - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
62085996|NCT04782310|EXPERIMENTAL|Group Duloxetine|Patients will receive oral duloxetine 30mg two hour preoperatively ...will be continued for one week once per day after breakfast .
62285028|NCT06339398||Extensive Rehabilitation Group|PD patients of Extensive Group will perform a 45-minutes daily session of low-intensity aerobic exercise of 2-3 METs (37%-45% VO 2max ; 57-63% HR max) twice a week, for a 4-weeks period. Exercise volume: 180 METs-minutes/week
62285029|NCT06339398||Intensive Rehabilitation Group|PD patients of Intensive Rehabilitation Group will exercise for 45 minutes daily at high-intensity aerobic training of 6-8.8 METs (46-91% VO2max ; 76-95% HRmax), five days per week, for 4-weeks period. Exercise volume:1350 METs-minutes/week
62285030|NCT01385020|EXPERIMENTAL|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects
62285031|NCT02400255|EXPERIMENTAL|Cohort A|Cohort A will include patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) while in first or second complete remission with count recovery. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 42 days but no later than 90 days after allogeneic HSCT.
62285032|NCT02400255|EXPERIMENTAL|Cohort B|Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 42 days but no later than 90 days after allogeneic HSCT.
62285033|NCT03094000|EXPERIMENTAL|Experimental group (CBTE-MIND)|Adding a mindfulness skills intervention to group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008)
62285034|NCT03094000|ACTIVE_COMPARATOR|Control group (CBTE)|Group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008), without a mindfulness skills intervention
62460293|NCT01436032|EXPERIMENTAL|N1539 30 mg|
62460294|NCT01436032|ACTIVE_COMPARATOR|Ketorolac|IV
62460295|NCT01436032|PLACEBO_COMPARATOR|Placebo|IV
62460296|NCT01436032|EXPERIMENTAL|N1539 7.5mg|
62460297|NCT02845895||Neuroscience pole|Patient hospitalized in the department of medicine-surgery-obstetric of the neuroscience pole department
62460298|NCT02845895||Respiratory tracts pole|Patient hospitalized in the department of medicine-surgery-obstetric of the respiratory tracts pole department
62460299|NCT04348162|ACTIVE_COMPARATOR|Cocoa Flavanols|Cocoa is taken every day for 10-12 weeks.
62460300|NCT04348162|ACTIVE_COMPARATOR|Berries anthocyanins|Red-berries are taken every day for 10-12 weeks.
62460301|NCT04348162|ACTIVE_COMPARATOR|Cocoa flavanols plus berries anthocyanins|Cooa and red-berries are taken every day for 10-12 weeks.
62460302|NCT04348162|NO_INTERVENTION|Control|Normal diet for 10-12 weeks
62460303|NCT03716141|ACTIVE_COMPARATOR|Autologous Platelets Rich Plasma|In this group we will be managing diabetic wounds with platelet rich plasma treatment.
62460304|NCT03716141|ACTIVE_COMPARATOR|Conventional Saline dressing|In this group we will be managing diabetic wounds with normal saline dressing.
62085997|NCT04782310|EXPERIMENTAL|Group Pregabalin& Duloxetine|Patients will receive single dose of Pregabalin 75mg + duloxetine 30mg two hour preoperatively, 75mg pregabalin 12 hour postoperative and then will continue pregabalin twice per day +duloxetine once after breakfast for one week.
62085998|NCT01458275|ACTIVE_COMPARATOR|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
62285035|NCT06056752|EXPERIMENTAL|Patients with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia|A conditional chemotherapy regimen of fludarabine and cyclophosphamide will be administered, followed by investigational therapy, QH103 Cells
62285036|NCT03696992|EXPERIMENTAL|NBI|Tandem colonoscopy with NBI follow by WL
62285037|NCT03696992|ACTIVE_COMPARATOR|BLI|Tandem colonoscopy with BLI follow by WLI
62285038|NCT03696992|EXPERIMENTAL|WLI|Tandem colonoscopy with WLI follow by WL
62285039|NCT04451330|EXPERIMENTAL|Trifarotene Cream + Doxycycline|Participants were applied with Trifarotene (CD5789) 50 micrograms per gram (mcg/g) cream topically on the face once daily in the evening for 12 weeks and received doxycycline 120 milligrams (mg) tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
62285040|NCT04451330|PLACEBO_COMPARATOR|Trifarotene Vehicle + Doxycycline Placebo|Participants were applied with vehicle CD5789 topically on the face once daily in the evening for 12 weeks and received doxycycline matching placebo tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
62285041|NCT02238535|ACTIVE_COMPARATOR|Ventavis + Warfarin|Patients in this group will receive drug treatment - ventavis (2,0 ml - 6 time per day - during 5 days). Warfarin - INR=2,0-3,0
62651478|NCT03693196|OTHER|Nobel Biocare, Replace®|Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
62651479|NCT01951716|EXPERIMENTAL|Truncal Vagotomy|Healthy participants without diabetes who have undergone a complete truncal vagotomy
62085999|NCT01458275|ACTIVE_COMPARATOR|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
62086000|NCT01458275|PLACEBO_COMPARATOR|Placebo|
62285042|NCT02238535|ACTIVE_COMPARATOR|Warfarin|Patients in this group will receive drug treatment according to up-to-date guidelines (Warfarin - INR=2,0-3,0)
62086001|NCT00349102|ACTIVE_COMPARATOR|A|Free breathing during conformal radiation
62086002|NCT00349102|EXPERIMENTAL|B|Breath holding during conformal radiation
62086003|NCT02325726||Renal Resistive Index/Nephrocheck test|Patients undergoing elective cardiac surgery with extracorporeal circulation and who are at risk to develop postoperative Acute Kidney Injury.
62285043|NCT06265844|EXPERIMENTAL|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
62285044|NCT06265844|ACTIVE_COMPARATOR|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
62285045|NCT01438008|EXPERIMENTAL|Sucrose 24% po|"24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution"
62651480|NCT01951716|EXPERIMENTAL|No Vagotomy|Healthy participants without diabetes who have not had a complete truncal vagotomy
62651481|NCT04900311|EXPERIMENTAL|pyrotinib + trastuzumab + nab-paclitaxel|
62651482|NCT04900311|ACTIVE_COMPARATOR|pertuzumab + trastuzumab + nab-paclitaxel|
62651483|NCT06369480||Cholangiocarcinoma|Patients with diagnosis of Cholangiocarcinoma confirmed by MDT
62651484|NCT03699592|NO_INTERVENTION|Control|
62651485|NCT03699592|EXPERIMENTAL|Reach Home and Read|This arm will receive the Reach Home and Read early literacy intervention
62651486|NCT03587636|EXPERIMENTAL|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
62285046|NCT01438008|PLACEBO_COMPARATOR|Placebo po|"The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings"
62285047|NCT02117726|EXPERIMENTAL|Dexmedetomidine,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02\~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2\~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02\~0.1mg/kg/h, until the target level is reached.
62285048|NCT02117726|ACTIVE_COMPARATOR|Propofol,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02\~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3\~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02\~0.1mg/kg/h, until the target level is reached.
62285049|NCT03867045|EXPERIMENTAL|mRCC treated with cabozantinib|Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
62460305|NCT04251390||trexo Home intervention|Participants family is renting a trexo Home from trexo. The decision to use the device was separate from this research, and the decision to do research on its use was secondary. The proposed procedures may be modified to adapt to the child and family's interest and needs. Participant will use the trexo Home in their home, school, and community.
62460306|NCT02757248|EXPERIMENTAL|Cohort 1|Volasertib 75mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
62651487|NCT03587636|ACTIVE_COMPARATOR|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
62651488|NCT02394756|EXPERIMENTAL|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
62651489|NCT02394756|ACTIVE_COMPARATOR|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
62651490|NCT02394756|ACTIVE_COMPARATOR|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
62460307|NCT02757248|EXPERIMENTAL|Cohort 2|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
62460308|NCT02757248|EXPERIMENTAL|Cohort 3|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
62651491|NCT03906864|NO_INTERVENTION|Control group|Usual care consisted of 2 half hourly therapy sessions per day from Monday to Friday and medical ward rounds 3 times a week. Multidisciplinary rounds were conducted every 2 weeks. Any specific goals or interventions were at the discretion of the managing team.
62651492|NCT03906864|EXPERIMENTAL|Intervention group|Intervention group had structured assessments and checklists (as part of the integrated care pathway) in addition to usual care.
62651493|NCT04219189|EXPERIMENTAL|Vaping to Control Group|Participants in this arm will undergo the vaping condition during the first visit and the control condition during the second visit.
62651494|NCT04219189|EXPERIMENTAL|Control to Vaping Group|Participants in this arm will undergo the control condition during the first visit and the vaping condition during the second visit.
62651495|NCT01706328|EXPERIMENTAL|FF/VI Inhalation Powder NDPI|Subjects randomized to the FF/VI 100/25 arm will take an active inhalation of study medication during their morning dosing from their NDPI and will have an inhalation of dummy medication (placebo) as their morning ACCUHALER/DISKUS dose and as their evening dose.
62651496|NCT01706328|ACTIVE_COMPARATOR|Fluticasone Propionate/Salmeterol Inhalation Powder|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg arm will have an active dose of medication during both their morning and evening treatments from the ACCUHALER/DISKUS and a dummy placebo dose in the morning from their NDPI.
62651497|NCT04524156|ACTIVE_COMPARATOR|COVIS 19 positive|
62651498|NCT04524156|SHAM_COMPARATOR|COVID 19 negative|
62651499|NCT00922584|EXPERIMENTAL|sorafenib|Patients with stage IIIB/IV NSCLC who failed EGFR-TKI therapy will receive oral sorafenib 400 mg twice daily until disease progression or unacceptable toxicity.
62460309|NCT02757248|EXPERIMENTAL|Cohort 4|Volasertib 150mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
62651500|NCT02178865||translocation carrier|balanced translocation carriers who have undergone IVF
62651501|NCT04287348|OTHER|Beovu (Brolucizumab)|Prospective, one-treatment-arm, monocentre study
62651502|NCT01100788|PLACEBO_COMPARATOR|Placebo|No treatment
62651503|NCT01100788|EXPERIMENTAL|scFOS 5 g|5 g scFOS
62086004|NCT01923389|PLACEBO_COMPARATOR|Placebo|
62086005|NCT01923389|EXPERIMENTAL|100 mg PF-05231023|
62086006|NCT02426385||1POD26PFT|Patients implanted with the POD 26% FineVision Toric
62086007|NCT02426385||2POD26PT|Patients implanted with the POD 26% Toric
62086008|NCT01930643|EXPERIMENTAL|Electric muscle stimulation(EMS)|EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
62086009|NCT01930643|NO_INTERVENTION|Control|Patients with routine passive rehabilitation program.
62086010|NCT00543218|ACTIVE_COMPARATOR|A|teriparatide 20 micrograms/day subcutaneous
62086011|NCT00543218|ACTIVE_COMPARATOR|B|
62086012|NCT01220440|EXPERIMENTAL|Methylphenidate, Dexamphetamine, Placebo|The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
62285050|NCT00584233|EXPERIMENTAL|Breast CT and Breast MRI|Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
62285051|NCT01119547|EXPERIMENTAL|Home exercise|The patients is training at home during 6 v. with an individual exercise program.
62460310|NCT02757248|EXPERIMENTAL|Cohort -1|Volasertib 50mg/m2 on days 1 and 8 Romidepsin 10mg/m2 on days 1, 8 and 15
62651504|NCT01100788|EXPERIMENTAL|scFOS 8 g|8 g scFOS
62651505|NCT01104168||Nursing home residents with diabetes|
62651506|NCT05627596|ACTIVE_COMPARATOR|Electric Toothbrush|Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and an electric toothbrush.
62086013|NCT06263361||Included patients|Adult patients (\>18 years) candidates to stereotactic biopsy for histopathological diagnosis of intra-axial lesions suspected for primary central nervous system lymphoma (PCNSLs).
62086014|NCT03037229||STEMI|"Subjects in which a STEMI protocol has been initiated.~* An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~* If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~* If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~* Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
62086015|NCT03037229||Chest Pain|"Subjects presenting at the emergency department with chest pain.~* An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~* If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~* If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~* Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
62086016|NCT02298543||coronary spasm|
62086017|NCT02364453|EXPERIMENTAL|Placebo to PACAP38|Pre-treatment with placebo. PACAP38 8pmol/kg/min
62285052|NCT01119547|EXPERIMENTAL|Exercise in group|The patients is doing their individual exercise program in a group.
62285053|NCT04698967|EXPERIMENTAL|CCD-V Group|Veterans in this arm will receive treatment as usual, which is transitional work experience intervention, as well as the CCD-V intervention
62285054|NCT04698967|ACTIVE_COMPARATOR|Treatment as Usual|Veterans in this arm will receive treatment as usual, which is transitional work experience intervention.
62285055|NCT03092050|ACTIVE_COMPARATOR|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
62460311|NCT01284205|EXPERIMENTAL|MCC|Intravesical Administration of Mycobacterial Cell-Wall DNA Complex
62460312|NCT01284205|ACTIVE_COMPARATOR|BCG|Intravesical Administration of Bacillus Calmette-Guerin
62460313|NCT05285085||Secondary prevention|Individuals with previous myocardial infarction and/or stroke
62651507|NCT05627596|EXPERIMENTAL|Nicotine Replacement Therapy|Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and a two week supply of 14mg nicotine patches and 4mg lozenges.
62651508|NCT04096690|EXPERIMENTAL|Anti-PD-1 antibody plus pegaspargase|Participants will receive induction treatment for six cycles of Anti-PD-1 antibody plus pegaspargase (21-day cycle) and Anti-PD-1 antibody monotherapy maintenance treatment for about 2 years (21-cycle)
62086018|NCT02364453|EXPERIMENTAL|Clemastin 1 mg/ml to PACAP38 8pmol/kg/min|Pre-treatment with Clemastin 1 mg/ml PACAP38 8 pmol/kg/min
62086019|NCT02682563|EXPERIMENTAL|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
62285056|NCT03092050|EXPERIMENTAL|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
62285057|NCT03685773|EXPERIMENTAL|MRI: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
62285058|NCT03685773|PLACEBO_COMPARATOR|MRI: Non-diabetic transplant (Placebo)|Taste-matched placebo for diazoxide
62285059|NCT03685773|EXPERIMENTAL|MRI: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
62285060|NCT03685773|PLACEBO_COMPARATOR|MRI: T2D transplant (Placebo)|Taste-matched placebo for diazoxide
62285061|NCT03685773|EXPERIMENTAL|Clamp: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
62285062|NCT03685773|PLACEBO_COMPARATOR|Clamp: Non-diabetic transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
62285063|NCT03685773|EXPERIMENTAL|Clamp: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
62285064|NCT03685773|PLACEBO_COMPARATOR|Clamp: T2D transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
62651509|NCT04642222|EXPERIMENTAL|APOLO-Teens Intervention Group (APOLO-Teens group)|In addition to the Treatment As Usual for pediatric obesity offered in Portuguese public hospitals, participants in this group receive the APOLO-Teens web-based intervention. It comprises three key components: 1) a manualized psychoeducational intervention implemented via Facebook® private groups, including cognitive-behavioral therapy strategies; 2) A weekly self-monitoring system (the APOLO-Teens web application) with automatic feedback messages assessing hours of physical activity, sedentary time, and consumption of fruits and vegetables; and 3) Monthly chat sessions.
62651510|NCT04642222|ACTIVE_COMPARATOR|Treatment As Usual (TAU) Control Group (TAU control group)|Treatment As Usual control group receives the standard intervention for pediatric obesity offered in Portuguese public hospitals. It comprises pediatric or/and nutritional appointments, usually a 30-minute appointment every 3 months. These appointments usually include a physical examination (weight, height) and personalized dietary/lifestyle recommendations. The Treatment As Usual intervention is common to the APOLO-Teens group and TAU control groups.
62086020|NCT02682563|ACTIVE_COMPARATOR|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
62086021|NCT00678444|NO_INTERVENTION|Arm 1: Non-educational video self-cath|Randomized to not watching educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
62086022|NCT00678444|EXPERIMENTAL|Arm 2: Educational Video Self-cath|Randomized to watch educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
62086023|NCT02514980|ACTIVE_COMPARATOR|Bupivacaine group|Infraorbital nerve block using bupivacaine 0.25% on each side.
62086024|NCT02514980|ACTIVE_COMPARATOR|Bupivacaine-Ketamine group.|Infraorbital nerve block using bupivacaine 0.25% combined with 0.5mg/kg ketamine on each side.
62086025|NCT03403569|EXPERIMENTAL|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
62086026|NCT03403569|PLACEBO_COMPARATOR|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
62285065|NCT03685773|EXPERIMENTAL|Clamp: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg) before pancreatic clamp study
62285066|NCT03685773|EXPERIMENTAL|Clamp: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide) before pancreatic clamp study
62460314|NCT05285085||Primary prevention|Individuals with hypertension, diabetes and/or dyslipidemia
62285067|NCT03685773|EXPERIMENTAL|MRI: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg)
62460315|NCT05285085||Unknown diagnosis|Individuals without a previous myocardial infarction and/or stroke or a diagnosis of hypertension, diabetes and/or dyslipidemia
62460316|NCT00144625|EXPERIMENTAL|1|
62460317|NCT06025448|ACTIVE_COMPARATOR|BIO-RSA|
62086027|NCT00513019|ACTIVE_COMPARATOR|1|Lamictal (lamotrigine)
62086028|NCT00513019|PLACEBO_COMPARATOR|2|Placebo
62086029|NCT02196493|EXPERIMENTAL|Azithromycin|250mg azithromycin three times weekly for 12 weeks
62086030|NCT05666700|EXPERIMENTAL|Cilta-cel|
62086031|NCT01018823|EXPERIMENTAL|Ertugliflozin 1 mg|Ertugliflozin 1 mg, oral, once daily for 14 days
62086032|NCT01018823|EXPERIMENTAL|Ertugliflozin up to 5 mg|Ertugliflozin up to 5 mg, oral, once daily for 14 days
62285068|NCT03685773|EXPERIMENTAL|MRI: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide)
62285069|NCT00947401||elective post surgery patients|
62086033|NCT01018823|EXPERIMENTAL|Ertugliflozin up to 25 mg|Ertugliflozin up to 25 mg, oral, once daily for 14 days
62086034|NCT01018823|EXPERIMENTAL|Ertugliflozin up to 100 mg|Ertugliflozin up to 100 mg, once daily for 14 days
62285070|NCT01840046|EXPERIMENTAL|Interleukin 2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5."
62285071|NCT02118792|EXPERIMENTAL|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
62285072|NCT02118792|PLACEBO_COMPARATOR|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
62460318|NCT06025448|EXPERIMENTAL|MIO-RSA|
62460319|NCT01674582|OTHER|MRI, Neuropsychological testing|
62460320|NCT01340430|EXPERIMENTAL|FEC-paclitaxel-trastuzumab|fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks
62086035|NCT01018823|PLACEBO_COMPARATOR|Placebo|Placebo to Ertugliflozin once daily for 14 days
62086036|NCT02337361|EXPERIMENTAL|e-SBI|Single session, Electronic SBI for risky alcohol use
62086037|NCT02337361|NO_INTERVENTION|Control|Treatment as usual with only assessment
62086038|NCT02935855|ACTIVE_COMPARATOR|Nondiabetics (group 1)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
62086039|NCT02935855|ACTIVE_COMPARATOR|Diabetics (group 1)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
62285073|NCT02023658|EXPERIMENTAL|Systems analysis and improvement|pMTCT systems analysis and improvement
62285074|NCT02023658|NO_INTERVENTION|Control|No systems analysis and improvement intervention for prevention of mother to child HIV transmission services in place.
62285075|NCT04553107|EXPERIMENTAL|Deprescribing Intervention|
62285076|NCT04553107|ACTIVE_COMPARATOR|Usual Care|
62285077|NCT06310746|EXPERIMENTAL|HLX6018|
62285078|NCT06310746|PLACEBO_COMPARATOR|Placebo|
62285079|NCT03871478|ACTIVE_COMPARATOR|Lidocaine|Buffered lidocaine 1% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
62460321|NCT00995410|EXPERIMENTAL|PA32540 tablet|325 mg enteric coated (EC) ASA and 40 mg omeprazole to be taken by mouth once daily
62460322|NCT06025838|EXPERIMENTAL|positive feedback|Participants receive positive feedback and reward for their decisions taken during a small game similar to a normal person's life. For example, they are encouraged to exercise, make food, and interact with friends.
62460323|NCT06025838|NO_INTERVENTION|no feedback|Participants receive no feedback. While they may undertake the same decisions during a small game similar to a normal person's life, they receive no encouragement and are not given reward or positive feedback.
62460324|NCT01674556|EXPERIMENTAL|Contrast-enhanced ultrasound (CEUS)|
62460325|NCT04692610|PLACEBO_COMPARATOR|Group A|Postoperative Education Group received stoma education and stoma care after surgery beginning from the postoperative day-1. In the preoperative period they were informed about stoma and stoma sites were marked.
62460326|NCT04692610|ACTIVE_COMPARATOR|Group B|Pre- and Postoperative Education Group received stoma education both before surgery and on the postoperative day-1. They received stoma care postoperatively as usual. In the preoperative period they were also informed about stoma and stoma sites were marked.
62086040|NCT02935855|ACTIVE_COMPARATOR|Nondiabetics (group 2)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
62460327|NCT04692610|EXPERIMENTAL|Group C|Prehabilitation Group received the same protocol as Group B, however in addition they were prehabilitated with a water-filled stoma pouch (250 ml) 48 hours before surgery. These pouches were not removed until surgery, and EST nurse preoperatively taught the patients how to manage the stoma pouch with similar standards as the usual postoperative stoma-care.
62460328|NCT01313416|EXPERIMENTAL|Single arm|Combination CT-011 and Gemcitabine
62460329|NCT00003666|EXPERIMENTAL|HMAF|treatment of refractory or relapsed NSCLC with HMAF
62460330|NCT04234256|EXPERIMENTAL|Static exercise|The experimental group doing static exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
62460331|NCT04234256|EXPERIMENTAL|Dynamic exercise|This group doing dynamic exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
62460332|NCT04234256|NO_INTERVENTION|Control group|Control group doing not the stretching exercise
62460333|NCT06496035|EXPERIMENTAL|Blood flow restriction training|Patients will perform exercises as directed by a Doctor of Physical Therapy with the use of blood flow restriction device
62460334|NCT06496035|ACTIVE_COMPARATOR|Traditional physical therapy|Patients perform physical therapy exercises guided by a Doctor of Physical Therapy without the use of a blood flow restriction device, as is current standard practice.
62460335|NCT01064349||Breast cancer patients with brain metastases|Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
62460336|NCT01200043|EXPERIMENTAL|fructose restriction|Isocaloric fructose restricted diet for 10 days
62651511|NCT01955811|OTHER|Platelet concentrate transfusion and Human Fibrinogen|Blood samples will be collected directly before the start of transfusion and 1 hour after the end of transfusion. These samples will be spiked with Human Fibrinogen and clotting tests will be performed. After 24 h after end of transfusion a clotting test will be performed again.
62086041|NCT02935855|ACTIVE_COMPARATOR|Diabetics (group 2)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
62086042|NCT01693939|OTHER|FS200 Femtosecond Laser|The LASIK flap will be created using the FS200 Femtosecond Laser
62086043|NCT02325232|EXPERIMENTAL|Enteroscopy|Capsule endoscopy, double balloon enteroscopy sequential use
62086044|NCT00720005||Aspheric Acrysof ResTOR Lens|Implantation of Aspheric Acrysof ResTOR
62086045|NCT02930122|EXPERIMENTAL|Anakinra|Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury
62086046|NCT02930122|PLACEBO_COMPARATOR|Placebo Control|Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury
62285080|NCT03871478|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine 0.5% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
62285081|NCT03871478|ACTIVE_COMPARATOR|Lidocaine and Bupivacaine|"Buffered lidocaine 1% with epinephrine 1:200,000 and bupivacaine 0.5% with epinephrine 1:200,000 injected sequentially.~Injected at the start of every Mohs excision stage"
62285082|NCT02500004|ACTIVE_COMPARATOR|Cachectic pancreatic cancer|"Cachectic patients with pancreatic cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
62285083|NCT02500004|ACTIVE_COMPARATOR|Cachectic NSCLC|"Cachectic patients with non-small cell lung cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
62460337|NCT03971825|EXPERIMENTAL|Administration of CC-92252 and Placebo in Healthy Subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.
62460338|NCT03971825|EXPERIMENTAL|Administration of CC-92252 and Placebo in Psoriasis subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.
62460339|NCT05353452|EXPERIMENTAL|Collaborative Care|Participants in this arm will receive 24 weeks of neurology based collaborative care.
62460340|NCT05353452|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants in this arm will receive provider-recommended clinic visits, prescriptions, testing, and referrals.
62460341|NCT01148095|EXPERIMENTAL|1|AZD2516 (dose escalating)
62460342|NCT01148095|PLACEBO_COMPARATOR|2|Placebo
62460343|NCT00860223|EXPERIMENTAL|1|Digoxin alone
62460344|NCT00860223|EXPERIMENTAL|2|Digoxin plus neratinib
62460345|NCT04578158|ACTIVE_COMPARATOR|Standard of care|This arm will receive the standard COVID-19 care as per the hospital physician guidelines.
62086047|NCT02216422|EXPERIMENTAL|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
62086048|NCT03963479|ACTIVE_COMPARATOR|Magnesium-Vitamin B6|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
62086049|NCT03963479|PLACEBO_COMPARATOR|Placebo|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
62086050|NCT04710693|OTHER|CAD polyp-detection system|In this arm, a CAD polyp detection system will be used during the colonoscopy.
62086051|NCT04710693|NO_INTERVENTION|Standard (no CAD polyp-detection system)|In this arm, a CAD polyp detection system will not be used during the colonoscopy.
62086052|NCT00487422|ACTIVE_COMPARATOR|1|Prucalopride
62086053|NCT00487422|ACTIVE_COMPARATOR|2|Prucalopride
62086054|NCT00487422|PLACEBO_COMPARATOR|3|Placebo
62086055|NCT02766673|ACTIVE_COMPARATOR|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
62086056|NCT02766673|ACTIVE_COMPARATOR|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
62086057|NCT02766673|PLACEBO_COMPARATOR|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
62086058|NCT04245046|EXPERIMENTAL|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:~* Age: 18-49 years~* Weight: 55-105 kg~* Height: 163-188 cm~* BMI 18.5-29.9 kg/m²"
62086059|NCT02949518|EXPERIMENTAL|Enhanced Recovery Pathway for Spine|
62086060|NCT02949518|NO_INTERVENTION|Usual Care|
62285084|NCT02500004|ACTIVE_COMPARATOR|Cachectic COPD|"Cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
62285085|NCT02500004|ACTIVE_COMPARATOR|Non-cachectic COPD|"Non-cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
62460346|NCT04578158|EXPERIMENTAL|Quercetin Phytosome|This arm will receive standard COVID-19 care + Quercetin Phytosome
62460347|NCT01985893|OTHER|Lapatinib plus trastuzumab|Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
62285086|NCT02500004|OTHER|Healthy individuals|"BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
62460348|NCT01985893|OTHER|Lapatinib plus Capecitabine|Drug intervention: Lapatinib and Capecitabine on prescription. Lapatinib 1250 mg p.o. once daily. Capecitabine 2000 mg/m2 p.o. in two divided doses on days 1 to 14 of a 21 day cycle.
62285087|NCT01110252|ACTIVE_COMPARATOR|pre-procedure|emphysema patients evaluated prior to the stem cells infusion
62285088|NCT01110252|EXPERIMENTAL|post-procedure|emphysema patients evaluated 30 days after the stem cells infusion
62285089|NCT01154647|EXPERIMENTAL|selective serotonin reuptake inhibitor|intravenous, acute, 20mg/ml
62285090|NCT01154647|PLACEBO_COMPARATOR|1 ml 0.9 % NaCl|
62285091|NCT00254410|EXPERIMENTAL|FCM-R + Pegylated Filgrastim|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6. Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6. Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6. Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6. Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
62460349|NCT05760872||Placement of an esophageal catheter|In this group we will assess the influence of placing an esophageal catheter on the cortisol levels in HV
62460350|NCT03389438|EXPERIMENTAL|Experimental arm|Participants who were treated with autologous Tcm cells immunotherapy.
62460351|NCT03389438|NO_INTERVENTION|No intervention arm|Participants who were treated with no autologous Tcm cells immunotherapy.
62086061|NCT02294162|EXPERIMENTAL|0.5 mg/kg body weight Ketamin|Patients allocated to this arm will receive an iv dose of 0.5 mg/kg body weight ketamine.
62086062|NCT02294162|PLACEBO_COMPARATOR|5 ml normal saline as placebo|Patients allocated to this arm will receive an iv dose of 5ml saline as placebo.
62086063|NCT04679883|EXPERIMENTAL|GLH8NDE 5% and GLH8NDE Placebo|Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo
62086064|NCT04679883|EXPERIMENTAL|GLH8NDE 5%|Total 6 times 1 drop of GLH8NDE 5%
62086065|NCT04679883|PLACEBO_COMPARATOR|GLH8NDE Placebo|Total 6 times 1 drop of GLH8NDE Placebo
62086066|NCT04746547|OTHER|Twice Daily DTG|Twice daily Dolutegravir (50mg) with Rifampicin containing TB treatment / Twice daily Dolutegravir (10mg) dispersible
62086067|NCT00315211|OTHER|Arm A|Weekly intravenous topotecan with intravenous docetaxel
62086068|NCT00479674|EXPERIMENTAL|Abraxane, Carboplatin, Bevacizumab|Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
62285092|NCT00173862|EXPERIMENTAL|A|
62285093|NCT01502904|ACTIVE_COMPARATOR|Cypher group|
62460352|NCT01471093|EXPERIMENTAL|Solution|A single dose of OPC-12759 Ophthalmic solution for two-day treatment
62460353|NCT01471093|ACTIVE_COMPARATOR|Suspension|A single dose of OPC-12759 Ophthalmic suspension for two-day treatment
62086069|NCT01250249|ACTIVE_COMPARATOR|BCG Vaccine - Intradermal injection|"Subjects must be in the age group of 0 - 14 years of age.~2. Subject's parent should be able to understand and have to sign the informed consent form after being explained by the investigator. They must be aware of the experimental nature of the therapy, its potential benefits, side effects and risks.~3. Ability to comply with the schedule of treatment and follow-up.~4. Absence of BCG scar~5. Tuberculin negative~6. No evidence of any other infection~7. No evidence of skin disease~Skin testing with tuberculin is not generally carried out before giving BCG but when performed, those who are found to be positive reactors need not to be immunized"
62086070|NCT04003311||Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
62285094|NCT01502904|EXPERIMENTAL|Nobori group|
62285095|NCT01502904|ACTIVE_COMPARATOR|Pravastatin group|
62285096|NCT01502904|ACTIVE_COMPARATOR|Pitivastatin group|
62460354|NCT00301769|EXPERIMENTAL|Arm I|Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
62460355|NCT01094197||Transfused microchimeric subject|Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
62460356|NCT02589223|ACTIVE_COMPARATOR|Multisensory Stimulation Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
62086071|NCT04003311||Comprehensive Anatomic Versa-Dial Titanium Humeral Heads|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral Heads to repair shoulder malfunction/disease.
62086072|NCT00264043|EXPERIMENTAL|1|AngioGuard™ device and Bx Velocity™ stent
62086073|NCT01899495|EXPERIMENTAL|High sodium diet and low sodium diet|Each subject experiences both a high sodium and a low sodium diet.
62086074|NCT01456858|PLACEBO_COMPARATOR|Child UPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Untreated plastic sheeting (interior wall and ceiling lining)
62086075|NCT01456858|EXPERIMENTAL|Child ITPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Insecticide treated plastic sheeting (interior wall and ceiling lining)
62086076|NCT01456858|PLACEBO_COMPARATOR|Child UPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Untreated plastic sheeting (ceiling and interior roof lining)
62086077|NCT01456858|EXPERIMENTAL|Child ITPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Insecticide treated plastic sheeting (ceiling and interior roof lining)
62086078|NCT04600401|EXPERIMENTAL|Participants integrate the Mentis Plus+ program|Mentis Plus+ Program was developed based in The Multifactorial Model of Positive Mental Health and its construction resulted from a systematic literature review and validation through focus group. The duration of the Mentis Plus+ program depends on the number of the six factors to be worked on. The Mentis Plus+ lasts at least 7 weeks (1 session per week, lasting 1 hour) and can work individually or in groups (2-12 people). There will be 2 initial sessions of 1 hour each and 3 sessions for each factor to work with duration of 1 hour. Still, a final session and a follow-up session (3-6 months after the program) will be held.
62086079|NCT04600401|NO_INTERVENTION|Participants on a waiting list (Control Group)|Participants in the control group were told they were on a waiting list for 3-6 months, as a minimum, before they integrate the Mentis Plus+ program. Given the preventive nature of this study, a waiting list control group won't bring risks or damages to participants
62285097|NCT01502904|ACTIVE_COMPARATOR|Non-ARB group|
62285098|NCT01502904|EXPERIMENTAL|ARB group|
62285099|NCT05206448|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 in first study treatment cycle. Participants who ovulate and do not become pregnant will repeat the same treatment protocol for their next study cycle. Participants who do not ovulate will repeat the protocol with Letrozole dose increase of 2.5 mg daily in the next treatment cycle, to a maximum dose of 7.5 mg in the 3rd cycle.
62285100|NCT05206448|EXPERIMENTAL|Letrozole + Clomiphene Citrate|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomiphene Citrate 50 mg orally for 5 days on cycle days 3-7. Participants who ovulate and do not become pregnant will repeat the same treatment protocol for their next study cycle. Participants who do not ovulate will repeat the protocol with Letrozole dose increase of 2.5mg daily in the next treatment cycle to a maximum dose of 7.5 mg in the 3rd cycle, while maintaining the same dose of Clomiphene Citrate.
62285101|NCT04534777||Consciousness disorder patients|"The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches.~Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years."
62285102|NCT06335615|EXPERIMENTAL|Intervention|The intervention group follows a one-hour in-person intervention focused on acceptance of stress. Each participant follows this intervention individually.
62285103|NCT06335615|ACTIVE_COMPARATOR|Control|The control group follows a 20-minute online psychoeducation at home. Each participant follows this intervention individually.
62285104|NCT04764552|EXPERIMENTAL|Yeahhh Baby Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
62651512|NCT02750995|EXPERIMENTAL|Vaccination|Azacitidine + NPMW-peptide vaccine
62651513|NCT06055374|EXPERIMENTAL|BxC-I17e|"* Subcutaneous (SC) injection of 50, or 100 ug BxC-I17e~* Treatment on Day 1, 15, 29, and 43 for a total 4 biweekly doses"
62651514|NCT06055374|PLACEBO_COMPARATOR|Placebo|"* Subcutaneous (SC) injection of the matching placebo~* Treatment on Day 1, 15, 29, and 43 for a total 4 biweekly doses"
62086080|NCT00936013|EXPERIMENTAL|oseltamivir|single antiviral treatment
62086081|NCT00936013|EXPERIMENTAL|oseltimivir and chinese medicinal herbs|combination treatment
62086082|NCT02406014|ACTIVE_COMPARATOR|Treatment Group A|Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
62086083|NCT02406014|ACTIVE_COMPARATOR|Treatment Group B|Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.
62086084|NCT05209087||Children with Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy who are between Levels 1-4 (continuing ambulation) according to Brooke Lower Extremity Functional Classification will be included in the study. This classification method was designed on the basis of the classification method to determine the functional status of the lower and upper extremities in the clinical evaluation of Duchenne Muscular Dystrophy.
62086085|NCT00994487|EXPERIMENTAL|Breastfed child|Female, normal weight, 3 to 5 year old children, exclusively breastfed from birth to 3 months of age
62086086|NCT00994487|ACTIVE_COMPARATOR|Bottle Fed Child|Female, normal weight, 3 to 5 year old children, exclusively bottle fed from birth to 3 months of age
62285105|NCT04764552|PLACEBO_COMPARATOR|Placebo Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
62460357|NCT02589223|PLACEBO_COMPARATOR|Control Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
62651515|NCT03473990|ACTIVE_COMPARATOR|Laboratory HIT|Supervised (Laboratory HIT) exercise in the lab up to 4 times per week for 4 weeks
62086087|NCT04537351|EXPERIMENTAL|CYP-001|The investigational medicinal product used in this study is known as CYP-001. The active agent in CYP-001 is Cymerus™ MSCs. CYP-001 is supplied as 100 million Cymerus MSCs formulated in 20 mL cryoprotectant medium. On D1 and D3, each participant randomised to receive CYP-001 will receive an IV infusion of 2 million Cymerus MSCs/kg of body weight (up to a maximum of 200 million cells per infusion).
62086088|NCT04537351|NO_INTERVENTION|Standard of care|Control participants will be randomised to received standard of care treatment.
62285106|NCT05187832|EXPERIMENTAL|AND019 single dose escalation and expansion|Subjects will be administrated with AND019 capsule PO QD from 20 mg to 400 mg during Part 1, and 2 dose groups will be selected for dose expansion study
62285107|NCT00756938|EXPERIMENTAL|Losartan potassium 0.1 to 1.4 mg/kg|Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
62285108|NCT00756938|EXPERIMENTAL|Losartan potassium 0.3 to 1.4 mg/kg|Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
62285109|NCT00756938|EXPERIMENTAL|Losartan potassium 0.7 to 1.4 mg/kg|Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
62285110|NCT01351441|OTHER|Age 65 years or over AND at least 5 chronic medications|
62651516|NCT03473990|ACTIVE_COMPARATOR|Home HIT|Unsupervised (Home HIT) exercise at home up to 4 times per week for 4 weeks
62651517|NCT03473990|NO_INTERVENTION|Control Group|No intervention
62086089|NCT03989713|EXPERIMENTAL|MRD-triggered arm|"1. Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~   (Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~2. Consolidation therapy: Patients receive one cycle of HAM and are further allocated based on the MRD-results assessed by flow cytometry with a cut of level of 0.1%: if the MRD is negative they remain in the MRD-triggered arm, whereas MRD positive patients cross over to the prophylactic arm.~   (Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~3. Observation: No treatment will be given in the MRD-triggered arm. (Duration: 48 weeks in total.)~4. Safety follow-up and observational follow-up"
62086090|NCT03989713|EXPERIMENTAL|Prophylactic Arm|"1. Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~   (Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~2. Consolidation therapy: Patients may receive up to two cycle of Q-HAM. (Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~3. Maintenance therapy: Quizartinib will be given as single-agent therapy. The dose of quizartinib is aimed to be increased during maintenance therapy. (Up to 12 cycles. Duration: four times three cycles á 28 days, 48 weeks in total.)~4. Safety follow-up and observational follow-up"
62086091|NCT06401928|ACTIVE_COMPARATOR|active tDCS group|The patients in this group receive 10 daily sessions of 1.5-mA transcranial direct current stimulation (tDCS) targeting the left lateral prefrontal cortex and right orbitofrontal cortex with anodal and cathodal stimulation respectively.
62086092|NCT06401928|EXPERIMENTAL|tDCS with cognitive rehabilitation group|The patients in this group receive 10 daily sessions of 1.5-mA transcranial direct current stimulation (tDCS) followed by a 30-minute cognitive training intervention.
62086093|NCT06401928|SHAM_COMPARATOR|sham tDCS group|The patients in this group receive 10 daily sessions of 1.5-mA sham transcranial direct current stimulation (tDCS).
62086094|NCT02434952|EXPERIMENTAL|DHA PP plus primaquine, G6PD deficiency|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children \<18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (\<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
62086095|NCT02434952|ACTIVE_COMPARATOR|DHA PP plus primaquine, G6PD normal|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children \<18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (\<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
62086096|NCT02434952|ACTIVE_COMPARATOR|DHA PP alone, G6PD deficiency|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
62086097|NCT02434952|ACTIVE_COMPARATOR|DHA PP alone, G6PD normal|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (\<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
62086098|NCT00972946|EXPERIMENTAL|Administration of labelled cells|MRI scanning before and after administration of iron-labelled cells
62086099|NCT00972946|EXPERIMENTAL|Administration of Endorem|MRI scanning before and after intravenous administration of Endorem
62086100|NCT02659644|EXPERIMENTAL|Oral citrulline|
62651518|NCT03485586||Group:Traditional ultrasonic biological|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use traditional ultrasonic biological combined with cornea curvimeter to measure the ocular parameter.
62086101|NCT05331820|NO_INTERVENTION|standard care group|this group of participants will be used to compare to the intervention group. normal and professional instructions and motivation will be given to them but they will not receive weekly reminders about the importance of adherence to instructions
62285111|NCT04439955|EXPERIMENTAL|CBD|At the end of the one month run-in period, all trial subjects will continue on individual Standard of case plus increasing doses of CBD during the first six weeks of the study. Dosage of CBD will start at 25 mg twice a day and will be increased once every 14 days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day CBD respectively. Treatment will be given with food. If the 300 mg CBD dose level is deemed safe for two weeks patients will continue receiving 300 mg CBD +for an additional follow-up period of three months
62460358|NCT03548389|EXPERIMENTAL|Mother and newborn skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
62460359|NCT03548389|NO_INTERVENTION|Conventional care|In the routine care group, the infant was delivered from the mother by a midwife, wrapped in blankets, taken to be routinely cared under a warmer, and then dried quickly. Afterwards, the Apgar score was determined immediately after the umbilical cord was cut. The infants were provided with all routine care by the midwife working in the delivery room. After the infants were weighed, dressed, and measured, they were handed to their mothers who were encouraged to begin breastfeeding.
62460360|NCT03206866||patients with HCC|
62086102|NCT05331820|EXPERIMENTAL|weekly reminder group|this group of participants will receive a weekly reminder about the importance of oral hygiene, appliance care, and adherence to recommendations from the dentist.
62460361|NCT03206866||patients with hepatitis C Ab positive|
62460362|NCT03206866||patients with hepatitis C Ab negative|
62460363|NCT02857088|EXPERIMENTAL|depressed patients|patient with a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
62460364|NCT02857088|EXPERIMENTAL|non depressed subject|subject without a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
62086103|NCT03230955|EXPERIMENTAL|Psychological and psycho-educational support|The intervention group (IG) \[that will receive telephone-based assistance to quit (including psychological and psycho-educational support and pharmacological treatment advice, if required) provided by trained nurses who will proactively call at one week, 15 day, a month, 3, 6 and 12 months after discharge, plus the calls made by the patients during the process\]
62460365|NCT02303548|EXPERIMENTAL|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
62086104|NCT03230955|ACTIVE_COMPARATOR|Control Group|The control group (CG) \[that will receive only a brief counselling session after discharge\]
62086105|NCT03053492|EXPERIMENTAL|Duck Duck Punch|Subjects in this arm will engage in Duck Duck Punch Play, a custom designed computer game developed for stroke rehabilitation for 6 weeks.
62285112|NCT00047346|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62285113|NCT00775489|ACTIVE_COMPARATOR|1|Steroid nasal spray (beclomethasone)
62460366|NCT02303548|PLACEBO_COMPARATOR|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
62460367|NCT00419770|EXPERIMENTAL|B|Deferasirox
62460368|NCT00419770|PLACEBO_COMPARATOR|A|
62460369|NCT00822926|EXPERIMENTAL|Placebo then Botox|Injection 1: Saline- Subcutaneous injection of saline into scar tissue Injection 2: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
62651519|NCT03485586||Group:Lenstar|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use lenstar to measure the ocular parameter.
62086106|NCT03053492|ACTIVE_COMPARATOR|Commercially Available Game|Subjects in this arm will engage in a Commercially Available Game Play off-the-shelf computer game for 6 weeks.
62086107|NCT02445885|EXPERIMENTAL|Acute PCI|Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours
62086108|NCT02445885|ACTIVE_COMPARATOR|Subacute PCI|Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours
62285114|NCT00775489|PLACEBO_COMPARATOR|2|Normal saline nasal spray
62460370|NCT00822926|EXPERIMENTAL|Botox then Placebo|Injection 1: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue Injection 2: Saline- Subcutaneous injection of saline into scar tissue
62460371|NCT04107974|EXPERIMENTAL|Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. Two T-fasteners are inserted into the stomach approximately 4cm apart. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate. The gastropexy/T-fastener sutures are cut after one week.
62285115|NCT06548802|EXPERIMENTAL|Standard treatment plus Baricitinib|On standard treatment, Baricitinib was given 4mg once daily, with the first dose taken within 24 hours of the appearance of lung injury and continued for 14 days.
62086109|NCT01896011|ACTIVE_COMPARATOR|Teriparatide 20 mcg daily|Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
62086110|NCT01896011|PLACEBO_COMPARATOR|Placebo|Placebo injection pen identical to active drug injection pen
62086111|NCT05991050|ACTIVE_COMPARATOR|Diet regimen group|an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.
62086112|NCT05991050|ACTIVE_COMPARATOR|whole body vibration group|"For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion squats with 90° knee angle, semi-squats with 120° knee angle and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions."
62086113|NCT03909581|ACTIVE_COMPARATOR|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization
62086114|NCT03909581|ACTIVE_COMPARATOR|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator
62086115|NCT02462785|ACTIVE_COMPARATOR|In-Class Instruction|This group of adolescents will receive carbohydrate counting instruction through an in-person, in class session led by a registered dietician. This represents the usual standard of care at the Diabetes Clinic at The Hospital for Sick Children (SickKids).
62086116|NCT02462785|EXPERIMENTAL|Internet-Based Teaching|This group of adolescents will receive carbohydrate counting instruction through an online teaching tutorial.
62086117|NCT01048203|EXPERIMENTAL|ABR-215050|
62086118|NCT00956540|EXPERIMENTAL|Deflating|Deflating tracheal cuff (total air suction under negative pressure using a syringe) during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support. During ventilatory support the tracheal cuff remain pressurized (30 mmHg).
62086119|NCT00956540|NO_INTERVENTION|Not deflating|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support
62086120|NCT00956540|EXPERIMENTAL|Deflating 2|Deflating tracheal cuff during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
62285116|NCT06548802|NO_INTERVENTION|Standard treatment|Given standard treatment.
62285117|NCT04480281|ACTIVE_COMPARATOR|Lidocaine Group|Bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
62285118|NCT04480281|PLACEBO_COMPARATOR|Placebo Group|Equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
62285119|NCT03543085|EXPERIMENTAL|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
62285120|NCT04133584|EXPERIMENTAL|Group 1 EV71 +SIV|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV) simultaneously with 28 days apart
62285121|NCT04133584|ACTIVE_COMPARATOR|Group 2 EV71|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) with 28 days apart
62285122|NCT04133584|ACTIVE_COMPARATOR|Group 3 SIV|Give 2 doses of seasonal influenza vaccine(SIV) simultaneously with 28 days apart
62651520|NCT05233813|EXPERIMENTAL|ABM intervention group|The intervention group received three, 45-min group exercise lessons for 12 weeks. The group exercise lessons were taught by two experienced instructors.. Each participant in the intervention group received a Fitbit (Model InspireHR) activity tracker to self-monitor their daily PA, 5 days per week for 12 weeks.
62651521|NCT05233813|NO_INTERVENTION|Comparison group|The comparison group continued their usual activities.
62086121|NCT00956540|NO_INTERVENTION|Not deflating 2|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
62086122|NCT02059772|EXPERIMENTAL|Control Group|Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC
62086123|NCT02059772|EXPERIMENTAL|Treatment Group|Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment
62086124|NCT03505411|EXPERIMENTAL|melatonin, submaximal effort|1 arm 5 mg melatonin 1 hr before bedtime for 30 days
62086125|NCT02938741|EXPERIMENTAL|r-ATG Immunosuppressive agents|"Rabbit Anti-human Thymoglobulin (r-ATG 2.5 mg/kg×4 days) were extra used in the treatment group.~The conditioning include of Busulfex 3.2mg/kg\*4d,CTX 60mg/kg \*4d."
62086126|NCT02938741|PLACEBO_COMPARATOR|placebo|"Rabbit Anti-human Thymoglobulin (r-ATG) were not used as intervention in the treatment group.~The conditioning include of Busulfex 3.2mg/kg\*4d,CTX 60mg/kg \*4d."
62285123|NCT03868943|EXPERIMENTAL|Solriamfetol|Given orally daily
62285124|NCT00693199|EXPERIMENTAL|1|
62285125|NCT00693199|ACTIVE_COMPARATOR|2|
62285126|NCT00693199|EXPERIMENTAL|3|
62285127|NCT03653520|ACTIVE_COMPARATOR|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
62285128|NCT03653520|ACTIVE_COMPARATOR|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
62285129|NCT03653520|EXPERIMENTAL|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
62651522|NCT02815371|EXPERIMENTAL|Needle Acupuncture|Sterile, disposable needles were inserted into specific acupoints until Deqi sensation was elicited. The needles were retained for 25 minutes before and after embryo transfer.
62651523|NCT02815371|EXPERIMENTAL|Laser Acupuncture|Each point was stimulated with a laser (Luminex Laser Therapy System: Medical Laser Systems, Branford, CT) set at 5 joules/cm2 (J/cm2) in continuous mode for 0.10 seconds. Based on various studies, a minimum of 4 J/cm2 produces an improved circulatory effect.
62285130|NCT02168595|EXPERIMENTAL|Cohort 1|2 mg/kg GMI-1271 or matching placebo
62285131|NCT02168595|EXPERIMENTAL|Cohort 2|5 mg/kg GMI-1271 or matching placebo
62285132|NCT02168595|EXPERIMENTAL|Cohort 3|10 mg/kg GMI-1271 or matching placebo
62285133|NCT00212147|EXPERIMENTAL|General anesthesia with nitrous oxide|
62285134|NCT00212147|ACTIVE_COMPARATOR|General anesthesia without nitrous oxide|
62651524|NCT02815371|SHAM_COMPARATOR|Sham Laser Acupuncture|However, support staff uninvolved in the design of the trial or analysis of the data disarmed the machine, such that no laser irradiation was emitted. This system created an illusion for both the patient and the acupuncturist, and allowed for a truly double blinded control group.
62086127|NCT02552849||Overall study|Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
62086128|NCT03045120||dasatinib cohort|Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
62086129|NCT03045120||imatinib cohort|Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
62086130|NCT03045120||nilotinib cohort|Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
62651525|NCT02815371|NO_INTERVENTION|No Treatment|This control group was not exposed to any additional physical contact or acupuncture related protocol. They were only exposed to dim light and calming music before and after embryo transfer, mimicking the natural waiting room and procedure room setting for all patients undergoing embryo transfer.
62651526|NCT06101498|EXPERIMENTAL|Conventional fluid therapy|Patients who received conventional fluid therapy
62651527|NCT06101498|EXPERIMENTAL|Non invaziv goal directed therapy|Patients who received non invaziv goal directed therapy
62086131|NCT03045120||bosutinib cohort|Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
62086132|NCT02360774|EXPERIMENTAL|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
62086133|NCT02360774|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
62086134|NCT01273649|EXPERIMENTAL|ice, rate of force development|to monitor the long term effect of cryotherapy in rate of force development.
62086135|NCT02176928|ACTIVE_COMPARATOR|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
62285135|NCT01827631|EXPERIMENTAL|GSK1605786 500 mg once daily|GSK1605786 500 mg is given once daily in the morning
62285136|NCT01827631|EXPERIMENTAL|GSK1605786 500 mg twice daily|GSK1605786 500 mg is given twice daily in the morning and in the evening
62285137|NCT02238847|ACTIVE_COMPARATOR|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
62285138|NCT02238847|ACTIVE_COMPARATOR|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
62285139|NCT06300515|ACTIVE_COMPARATOR|Control|During the intervention phase (hospitalization for hematopoietic stem cell transplantation (HSCT) and subsequent 8-week outpatient phase following discharge), the control group will participate in a Health Counseling Program (1 time/week) on aspects related to a healthy lifestyle such as reducing sedentary lifestyle, acquiring healthy nutritional habits, the importance sleep, screen use, and how to address barriers related to clinical status. We will adapt the program to the needs and timing of the patient's treatment, providing the content in one session/week orally (e.g. using presentations) and in writing (e.g. through brochures).
62285140|NCT06300515|EXPERIMENTAL|Exercise|During the intervention phase (hospitalization for hematopoietic stem cell transplantation (HSCT) and subsequent 8-week outpatient phase following discharge), the intervention group will participate in exactly the same Health Counseling Program as the Control group. Additionally, this group will perform an exercise program combining aerobic and muscle strength exercises
62285141|NCT03004807|EXPERIMENTAL|Multivitamin|Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
62651528|NCT06101498|EXPERIMENTAL|Minimal invaziv goal directed therapy|Patients who received minimal invaziv goal directed therapy
62086136|NCT02176928|SHAM_COMPARATOR|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
62285142|NCT03004807|PLACEBO_COMPARATOR|Control|Matching tablet to active multivitamin arm: 1/day
62285143|NCT02702648|EXPERIMENTAL|AC-082, Single Ascending Dose|Subjects receive AC-082 at different single dose levels in a sequential manner, starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each subject can participate in only one dose level
62285144|NCT02702648|PLACEBO_COMPARATOR|Placebo, Single Ascending Dose|Subjects receive a single dose of the matched placebo
62285145|NCT02702648|EXPERIMENTAL|AC-082, Multiple Ascending Dose|Subjects receive AC-082 at different dose levels for 4 consecutive days in a sequential manner (dose levels and duration to be adapted according to the results of the single ascending dose cohorts). Each subject can participate in only one dose level
62285146|NCT02702648|PLACEBO_COMPARATOR|Placebo, Multiple Ascending Dose|Subjects receive the matched placebo for 4 days
62285147|NCT05137561|ACTIVE_COMPARATOR|PSMA PET/CT guided biopsy arm|PSMA PET/CT guided biopsy will be done from PSMA avid lesion of the prostate after reviewing the whole body PSMA PET/CT scan.
62285148|NCT05137561|ACTIVE_COMPARATOR|MRI directed TRUS guided biopsy|The MRI-directed transrectal ultrasound-guided per-rectal prostate biopsy will be done by cognitive fusion.
62285149|NCT03644563||Follow-up|Those subjects with oncogenic oral HPV infection and/or HPV oncogene serum antibodies from screening.
62285150|NCT06199245|EXPERIMENTAL|emotional freedom technique experimental group|Emotional Freedom Technique was applied to the participants in the experimental group, who had a cesarean section on the first postpartum day and agreed to participate in the study, and their breastfeeding self-efficacy and breastfeeding success were evaluated.
62285151|NCT06199245|NO_INTERVENTION|control group|Participants in the control group were selected from the same sample group, but no intervention was applied. Breastfeeding self-efficacy and breastfeeding success were evaluated after a routine hospital procedure.
62285152|NCT04915040|EXPERIMENTAL|Behavioral Activation for Depression|
62285153|NCT06452264|EXPERIMENTAL|Experimental|pre-specified computer tasks using an Internet-based cognitive training portal, to be completed 3x per week for 60 minutes each session for 12 weeks total
62285154|NCT06452264|PLACEBO_COMPARATOR|Placebo Control|pre-specified computer tasks using an Internet-based cognitive training portal, to be completed 3x per week for 60 minutes each session for 12 weeks total
62285155|NCT05420389|EXPERIMENTAL|breast massage|The mothers who were included in the breast massage group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day state anxiety scale (SATI-I). Milk amounts are measured in ml.
62460372|NCT04107974|EXPERIMENTAL|Non-Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate.
62460373|NCT04988061|EXPERIMENTAL|Counselling arm|Educating and Counselling are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
62651529|NCT01455519|PLACEBO_COMPARATOR|Sugar pill|Subjects may receive a pill with no medicine.
62651530|NCT01455519|ACTIVE_COMPARATOR|Hydromorphone ER|Subjects received study drug: Hydromorphone ER
62651531|NCT03312738|EXPERIMENTAL|Everolimus + Exemestane|Participants received everolimus as a continuous oral daily dose of 10 mg and exemestane as a continuous oral daily dose of 25 mg
62651532|NCT03312738|ACTIVE_COMPARATOR|Placebo + Exemestane|Participants received placebo as a continuous oral daily dose and exemestane as a continuous oral daily dose of 25 mg
62651533|NCT02258672|EXPERIMENTAL|Prehabilitation program|Participants will be physically trained before undergoing surgery
62285156|NCT05420389|EXPERIMENTAL|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the state anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
62460374|NCT04988061|NO_INTERVENTION|standard arm|The information about hearing screening results and an appointment date are provided as a routine by either nurses or nurse assistances who perform the screening test.
62460375|NCT04949698||No TMA|parturients without thrombotic microangiopathies
62651534|NCT02258672|NO_INTERVENTION|Control|Patients will follow the normal course of care provided by the hospital
62651535|NCT02471339|EXPERIMENTAL|1/Acceptance and Commitment Therapy (ACT) Group|2 Acceptance and Commitment Therapy (ACT) Training Sessions followed by weekly emails and video chats.
62086137|NCT02522546||nasopharyngeal swab|Children ages 1-5 years and their household contacts
62086138|NCT03712098|EXPERIMENTAL|Smoking Cessation Counseling & Liraglutide|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of the medication liraglutide. Liraglutide comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which follows FDA guidelines and is documented to be safe and well-tolerated in prior clinical studies, will begin at 0.6 mg and increase weekly by 0.6 mg until the recommended dose of 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
62086139|NCT03712098|ACTIVE_COMPARATOR|Smoking Cessation Counseling & Placebo|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of placebo. The placebo comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which is the same as the liraglutide regimen, will begin at 0.6 mg and increase weekly by 0.6 mg until 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
62086140|NCT05852769|EXPERIMENTAL|BMS-986196 and/or Cocktail Probe Substrate Drugs|
62086141|NCT02200393|EXPERIMENTAL|Abdominal FES|Participants in the Abdominal Functional Electrical Stimulation (AFES) group will receive AFES 5 times per week (20 to 40 mins per day), on four alternate weeks.
62086142|NCT03591861|EXPERIMENTAL|Ketogenic Diet|"* Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)~* Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months~* Laboratory studies prior to hospital admission and then at each follow-up visit~* Hospital admission (3-5 day) to start the ketogenic diet~* Standard of care chemotherapy with BCNU for up to 2 years~* Ketogenic diet can continue for up to 2 years"
62086143|NCT06185023|ACTIVE_COMPARATOR|Low-intensity physical exercise|The participants will participate in a low-intensity non-aerobic exercise program for 2 weeks.
62086144|NCT06185023|EXPERIMENTAL|High-intensity physical exercise|The participants will take part in a high-intensity Aphasia Physical EXercise (APEX) intervention designed specifically for individuals with chronic post-stroke aphasia for 8 weeks.
62086145|NCT03391349||Group I|GROUP I: 35 generalized severe chronic periodontitis subjects without type II diabetes mellitus and systemically healthy.
62086146|NCT03391349||Group II|GROUP II: 35 generalized severe chronic periodontitis subjects diagnosed with type II diabetes mellitus.
62086147|NCT02332330|EXPERIMENTAL|VEST|
62086148|NCT02517333|OTHER|Proof-of-principle (PoP)|"Proof-of-principle phase of the study. All participants undergo the exercise intervention as part of the feasibility.~1. Screen within Year 9 Class~2. Targeted recruitment for those scoring in bottom 5th percentile~3. Invite students to take part in 6-week intervention~4. Enroll students participating~5. Pre-intervention assessment~6. Start 6-week Epic Club gym intervention (1-2 times weekly for 45-60 mins) consisting of 30 min cardiovascular exercise and 25-30 min strength/resistance and weight training~7. Post-intervention assessment~8. Exit to longer-term sport/physical activity"
62460376|NCT04949698||TMA with plasma exchange|parturients with thrombotic microangiopathies, and treated with plasma exchange
62460377|NCT04949698||TMA without plasma exchange|parturients with thrombotic microangiopathies, but not treated with plasma exchange
62460378|NCT00910364|EXPERIMENTAL|Exercise testing|Feasibility study; all participants receive intervention
62460379|NCT05687630|EXPERIMENTAL|Video-assisted group|
62460380|NCT05687630|ACTIVE_COMPARATOR|Traditional group|
62651536|NCT02471339|ACTIVE_COMPARATOR|2/Waitlist (WL) Group|Waitlist group - no intervention for first 8 weeks (then will receive Acceptance and Commitment Therapy (ACT) intervention as Arm 1)
62086149|NCT01786746|EXPERIMENTAL|Psychotherapy|Psychotherapy arm that consists of a randomization into 12 session manualized cognitive behavioral therapy or culturally adapted cognitive behavioral therapy for Chinese Americans.
62086150|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
62086151|NCT06448468||dry group|
62086152|NCT06448468||Non dry eye group|
62086153|NCT04563442||covid 19|complications and comorbidities
62086154|NCT05044793||Cohort A|Pre-operative washout of ocular hypotensive medications with post-washout DIOP of 21-36mmHg
62086155|NCT05044793||Cohort B|Pre-operative washout of ocular hypotensive medications with pre-operative medicated IOP ≥18 mmHg and on 1 to 5 hypotensive medications
62086156|NCT02470624||treatment following current guideline|
62086157|NCT02425683|EXPERIMENTAL|Regorafenib|Regorafenib 120 or 160 mg by mouth every day for the first 21 days of each 28-day cycle. If the dose is tolerated during the first 2 cycles in the 120 mg group, in Cycle 3 the 120 mg dose will be increased to 160 mg by mouth each day for the first 21 days of each 28-day cycle for 4 more cycles for a total of 6 cycles or 6 months of therapy.
62086158|NCT02425683|NO_INTERVENTION|Standard of Care (No Treatment)|No study drug (which is the standard care for Stage IIIC colorectal cancer patients after they've received FOLFOX chemotherapy).
62086159|NCT02366208|EXPERIMENTAL|PEG-Tα1|PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
62086160|NCT02366208|PLACEBO_COMPARATOR|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
62285157|NCT05420389|EXPERIMENTAL|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
62285158|NCT05420389|NO_INTERVENTION|control group|The mothers who were included in the control group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were told by the researcher how to fill out the breast milk follow-up form for 4 days as long as they were in the hospital. Milk amounts are measured in ml. On the last day, the state anxiety scale has been filled.
62285159|NCT05916404|EXPERIMENTAL|Training Group|The training group will receive upper extremity high-intensity interval aerobic exercise training on an arm ergometer accompanied by a physiotherapist for 6 weeks.
62651537|NCT03816358|EXPERIMENTAL|Arm I (anetumab ravtansine, nivolumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
62651538|NCT03816358|EXPERIMENTAL|Arm II (anetumab ravtansine, nivolumab, ipilimumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive ipilimumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of cycles 2-4. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
62086161|NCT05522920|EXPERIMENTAL|Therapy|Conventional physical therapy will be used with and without spinal cord stimulation to investigate improvement of upper limb function.
62086162|NCT01110720|EXPERIMENTAL|Davunetide 30 mg BID|
62086163|NCT01110720|PLACEBO_COMPARATOR|Placebo|
62086164|NCT03523871|EXPERIMENTAL|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
62086165|NCT00479037|ACTIVE_COMPARATOR|PTH(1-84)|
62086166|NCT00479037|ACTIVE_COMPARATOR|Strontium Ranelate|
62086167|NCT06040463|EXPERIMENTAL|Remote Glucose Monitoring > Remote Glucose Monitoring (RGM->RGM)|Participant will be randomized into the RGM study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a responder (A1c improved by at least 1 percentage point), patient will remain in the RGM group.
62086168|NCT06040463|EXPERIMENTAL|Remote Glucose Monitoring > Remote Glucose Monitoring+Community Health Worker (RGM->RGM+CHW)|Participant will be randomized into the RGM study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being a continuation of RGM, with the addition of a CHW to provide tailored support.
62086169|NCT06040463|EXPERIMENTAL|Remote Glucose Monitoring > Diabetes Self-Management Training (RGM->DSMT)|Participant will be randomized into the RGM study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being diabetes self-management training (DSMT).
62086170|NCT06040463|EXPERIMENTAL|Diabetes Self-Management Training > Standard of Care (DSMT->SOC)|Participant will be randomized into the DSMT study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a responder (A1c improved by at least 1 percentage point), patient will be directed back to standard of care.
62086171|NCT06040463|EXPERIMENTAL|Diabetes Self-Management Training > Community Health Worker (DSMT->CHW)|Participant will be randomized into the DSMT study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being a CHW to provide tailored support.
62086172|NCT06040463|EXPERIMENTAL|Diabetes Self-Management Training > Remote Glucose Monitoring (DSMT->RGM)|Participant will be randomized into the DSMT study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being RGM.
62086173|NCT06325943|ACTIVE_COMPARATOR|Treatment arm|"Rituximab~Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6"
62086174|NCT06325943|PLACEBO_COMPARATOR|Placebo arm|"Placebo~Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6"
62285160|NCT05916404|SHAM_COMPARATOR|Control Group|The control group will not be given any training for 6 weeks during the study period.
62285161|NCT03983395|EXPERIMENTAL|Part 1: Cohort 101 - ISB 1302 250 ng/kg|Cohort 101, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
62285162|NCT03983395|EXPERIMENTAL|Part 1: Cohort 201 - ISB 1302 325 ng/kg|Cohort 201, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
62285163|NCT03983395|EXPERIMENTAL|Part 1:Cohort 301- ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Cohort 301, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
62285164|NCT03983395|EXPERIMENTAL|Part 1:Cohort 401- ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Cohort 401, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
62651539|NCT03816358|EXPERIMENTAL|Arm III (anetumab ravtansine, nivolumab, gemcitabine)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive gemcitabine hydrochloride over 30-40 minutes on days 1 and 8. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
62651540|NCT04707937|EXPERIMENTAL|Online education|Participants will gain access to the online education modules in addition to receiving current standard of care education (pamphlets and one on one teaching with health care provider)
62651541|NCT04707937|ACTIVE_COMPARATOR|Regular standard of care education|Participants only receive current standard of care education (pamphlets and one on one teaching with health care provider)
62651542|NCT06380283|EXPERIMENTAL|Pediatric dental treatment using VR|At the beginning of the dental visit, subjects enrolled in the virtual reality (VR) group (n=64) will receive instructions about how to operate the VR system. The research team will then properly fit VR headset onto the child's head and ensure that there are no discomforts. Then, the research team will monitor the intervention using the tablet interface, allowing them to start, pause, and stop the VR intervention. The child will be given 5 minutes to get used to the device. During this time, any adjustments to the headset will be made. The VR intervention will last the duration of the dental procedure, unless told otherwise by the patient, their parent/legal-guardian, or the research team. The entire VR intervention will be closely monitored for any adverse events. Time of play and the patients' compliance of using VR will be noted.
62086175|NCT03119571|EXPERIMENTAL|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
62285165|NCT03983395|EXPERIMENTAL|Part1Cohort501-ISB1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Cohort 501, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
62086176|NCT03119571|ACTIVE_COMPARATOR|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
62086177|NCT05797311|EXPERIMENTAL|PNF Group|"After classical physiotherapy consisting of 40 minutes of hot pack, TENS, US and Exercise (a set of stretching exercises including Wand and Codman pendulum exercises) was applied by an experienced Physiotherapist, additional PNF exercises were performed once a day, 5 times a week by the same Physiotherapist in the cases in the PNF group. It will be applied for a total of 3 weeks (Total of 15 sessions).~1. PNF contract-relax to subscapularis and internal rotators (7 Sec of contraction and 15 Sec of relaxation in external rotation, 5 repetitions) Followed by facilitation of D2 Flexion patterns for 5 repetitions.~2. PNF all scapular patterns with Rhythmic initiation and repeated contractions Technique ."
62086178|NCT05797311|OTHER|Stabilization Group|"After classical physiotherapy consisting of 40 minutes of hot pack, TENS, US and Exercise (a set of stretching exercises including Wand and Codman pendulum exercises) was applied by an experienced Physiotherapist, stabilization exercises were performed by the same Physiotherapist once a day, 5 times a week, for a total of 5 times a week. It will be applied for 3 weeks (Total of 15 sessions).~1. scapular stabilization exercises~2. stabilization exercise for the shoulder joints.~In all the exercises, the subjects maintained the position for 10 seconds, and they took a rest for 3 seconds. Ten repetitions was considered one set, and the subjects conducted three sets. A break of 3 minutes was given between each set."
62086179|NCT00262743|EXPERIMENTAL|polyphenon E|Designed to assess toxicity, treatment response, and pertinent laboratory measurements in patients with previously untreated, asymptomatic, Rai Stage 0-II CLL.
62086180|NCT00646867|EXPERIMENTAL|1|Experimental
62086181|NCT00646867|PLACEBO_COMPARATOR|2|Placebo
62086182|NCT02981784||Ponatinib (PACE trial)|"PACE trial : Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL), NCT01207440"
62285166|NCT03983395|EXPERIMENTAL|Part1Cohort601-ISB1302 325ng/kgD1;550 ng/kg D8;900 ng/kgD15,22|Cohort 601, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
62285167|NCT03983395|EXPERIMENTAL|Part 1 Cohort 701- ISB 1302 escalating doses,1200 ng/kg D15,22|Cohort 701, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
62285168|NCT03983395|EXPERIMENTAL|Part 2 (Dose Expansion) -ISB 1302 at the MTD and/or RP2D dose|Subjects treated with ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
62285169|NCT03746561||spinal stenosis|Spinal stenosis is a narrowing of the spaces within your spine, which can put pressure on the nerves that travel through the spine. Spinal stenosis occurs most often in the lower back and the neck.
62285170|NCT02004002|ACTIVE_COMPARATOR|Weight maintenance with normal protein intake|Control group will consume 1.4 g protein/kg body wt/d; consistent with the average protein intake in the US population.
62285171|NCT02004002|EXPERIMENTAL|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
62086183|NCT02981784||Allogenis stem cell transplantation (EBMT registry)|EBMT : European Group for Blood and Marrow Transplantation
62086184|NCT00280293|PLACEBO_COMPARATOR|1|Placebo
62651543|NCT06380283|NO_INTERVENTION|Control group|Subjects enrolled in the control group (n=64) will receive their dental care using the behavior management techniques recommended by the American Academy of Pediatric Dentistry (i.e., tell-show-so, communicative guidance, distraction through stories and positive reinforcement).
62086185|NCT00280293|ACTIVE_COMPARATOR|2|LAmotrigine
62285172|NCT04525963|EXPERIMENTAL|Experimental: Intervention Arm|":In the experimental group,the operating room nurse, who is given intervention training , will be provided to visit the patient before surgery. After the verbal training of the operating room nurse, a printed booklet will be left for the patient to read.~Assigned Interventions The level of anxiety experienced by the patients increases the postoperative perception and analgesic need, increasing the sequence and anesthetic substance. For these reasons, there is a need for studies to reduce pain distribution and severity by directly dealing with pre- and postoperative anxiety and anxiety levels. Similarly, the role of the operating room nurse in reducing patient anxiety is increasingly recognized. It is observed that the pre-operative visit and education reduce the pre-operative anxiety level in patients undergoing surgical intervention, and the pre-operative visit of the operating room nurse is on the agenda."
62285173|NCT04525963|NO_INTERVENTION|No Intervention|There will be no intervention in the control group. The procedures of the institution will be applied before and after the operation.
62460381|NCT03843593||Melanoma patients|This is a pilot prospective study to identify the factors patients consider in deciding whether or not to undergo adjuvant therapy. Patients are eligible regardless of whether they decide to accept adjuvant therapy. If the researcher plans to treat the participant with pembrolizumab instead of nivolumab, it should be known that although the video discusses nivolumab, the risks and benefits are the same.
62086186|NCT02839135|EXPERIMENTAL|Reformulated scopolamine patch|Participants will receive reformulated scopolamine Transdermal Delivery System (TDS) patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
62086187|NCT02839135|ACTIVE_COMPARATOR|Marketed scopolamine patch|Participants will receive currently marketed scopolamine TDS patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area, with delivery of approximately 1.0 mg over 72 hours.
62285174|NCT00832897|SHAM_COMPARATOR|Eyedrop|
62285175|NCT00832897|ACTIVE_COMPARATOR|Crosslinking|The patients will be submitted to corneal collagen crosslinking, by use riboflavin eyedrop with UVA light.
62460382|NCT01054534|OTHER|Placement of interstim lead|Placement of interstim lead using US image fusion technology
62086188|NCT03024242|EXPERIMENTAL|Tight vaginoscope|The vaginoscope was extracted and loaded inside a thick rubber ring before its reinsertion inside the vagina again. To avoid leakage from the center of the thick rubber ring, the vaginoscopy is inserted through a premade central cruciate incision.
62086189|NCT04962893|EXPERIMENTAL|VLP-Wuhan group (Group V1)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
62086190|NCT04962893|EXPERIMENTAL|VLP-Alpha (British) variant group (Group V2)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
62086191|NCT04962893|EXPERIMENTAL|VLP-Wuhan+Alpha group (Group V3)|"110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan and Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.~Initial vaccination with Wuhan followed by a booster of Alpha variant."
62086192|NCT00933062|ACTIVE_COMPARATOR|SRT2104|Subjects will receive a dose of 2.0 g SRT2104 (administered as eight 250 mg capsules) on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
62086193|NCT00933062|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
62086194|NCT01773668|EXPERIMENTAL|Integrated sensor and infusion set|
62285176|NCT01868360|EXPERIMENTAL|Group A subconjunctival aflibercept|"Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as \>1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period."
62285177|NCT01868360|PLACEBO_COMPARATOR|Group B: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
62285178|NCT04620330|EXPERIMENTAL|Arm 1: avutometinib (VS-6766) monotherapy|in patients with NSCLC KRAS-G12V tumor
62285179|NCT04620330|EXPERIMENTAL|Arm 2: avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC KRAS-G12V tumor
62285180|NCT04620330|EXPERIMENTAL|Arm 3: avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC KRAS-other (non-G12V) tumor
62460383|NCT01366508|OTHER|Visit B|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.
62086195|NCT03110328|EXPERIMENTAL|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
62086196|NCT03891459|EXPERIMENTAL|spray+ group|"In spray+ condition, participants learned oxytocin materials on a self-paced basis and then intranasally administered with saline (but it was told as oxytocin). Participants were instructed to refrain from smoking or drinking (except water) for 2 h before the experiment. The spray was administered to each participant three times, and each administration consisted of one inhalation into each nostril. Participants took a rest (they were told it was a time period waiting for treatment to produce effects) for 10min and then performed the experimental tasks."
62285181|NCT04620330|EXPERIMENTAL|Arm 4: avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC BRAF-V600E tumor
62285182|NCT04620330|EXPERIMENTAL|Arm 5:avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC BRAF-non-V600E tumor
62285183|NCT00848120|EXPERIMENTAL|1|
62285184|NCT01569984|EXPERIMENTAL|Avastin, SBRT|2 treatments of avastin followed by 6 treatments of SBRT every other day.
62460384|NCT01366508|OTHER|Visit A|At approximately 13:00 the subject will be given a standard high calorie lunch that the subject is required to finish
62460385|NCT05904730|EXPERIMENTAL|Axitinib is 5 mg BID administered orally|The starting dose of Axitinib 5 mg BID administered orally with food.
62651544|NCT04765787||Painful musculoskeletal disorders in random order|Nuberol Forte® (Paracetamol 650 mg + Orphenadrine 50 mg) for the symptomatic management of the painful musculoskeletal disorders one tablet three times a day or as per physician discretion or as per severity of pain and treatment duration is 7-10 days
62651545|NCT01967199|ACTIVE_COMPARATOR|Drug Eluting Stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
62285185|NCT05568589||Preoperative Interpectoral - Pectoserratus Plane Block|The block will be done by the Anesthesiologist.
62285186|NCT05568589||Intraoperative Interpectoral - Pectoserratus Plane Block|The block will be made by the surgeon.
62086197|NCT03891459|PLACEBO_COMPARATOR|control group|"In control condition, the materials and procedure were same with the spray+ condition except the nasal spray was told as saline instead. Oxytocin materials used in current experiments were adopted from previous study"
62460386|NCT00414466|PLACEBO_COMPARATOR|Placebo (0mg/day)|Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
62460387|NCT00414466|ACTIVE_COMPARATOR|Gabapentin Low (1mg/day)|Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
62086198|NCT00802737|EXPERIMENTAL|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
62285187|NCT05568589||Non Block|will not be blocked.
62285188|NCT01774422|EXPERIMENTAL|noninvasive ventilation alone|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~* Noninvasive ventilation alone~* Noninvasive ventilation associated with the DECAP CO2 device"
62086199|NCT04280471|EXPERIMENTAL|Treatment (OpenBiome FMT capsule DE)|Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.
62086200|NCT01840761|EXPERIMENTAL|herbal drug|Traditional Chinese herbal drug
62086201|NCT01840761|PLACEBO_COMPARATOR|Placebo|
62086202|NCT05027750|EXPERIMENTAL|Intervention|The selected womens were associated with obesity risk factors about obesity (overweight) or obese and between 18-49 years old) and randomly assigned to the experimental group. Obesity training consisting of a total of five sessions structured according to Theory of Planned Behavior was scheduled for the intervention group. Each session lasted for approximately 30 minutes.
62086203|NCT05027750|NO_INTERVENTION|Control|The control group of the Randomized Controlled Trial (RCT) was composed of 39 womens (between 18-49 years old) randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between ≥30.0 according to the risk rating scales. A standard obesity training consisting of a single session was scheduled for the control group.
62086204|NCT04435730||Group 1|45 patients with cutaneous psoriasis with no musculoskeletal manifestations.
62086205|NCT04435730||Group 2|45 patients with psoriatic arthritis fulfilling CASPAR criteria of PsA
62086206|NCT04435730||Group 3|45 patients with subclinical psoriatic arthritis (patients with cutaneous psoriasis and musculoskeletal manifestations but not fulfilling CASPARcriteria of PsA).
62086207|NCT04435730||Group 4|45 sex and age matched healthy controls
62460388|NCT00414466|ACTIVE_COMPARATOR|Gabapentin Medium (6mg/day)|Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
62460389|NCT00414466|ACTIVE_COMPARATOR|Gabapentin High (30mg/day)|Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
62460390|NCT02609464|ACTIVE_COMPARATOR|Inturrupted Knotte Sutures|
62460391|NCT02609464|ACTIVE_COMPARATOR|Barbed Sutures|
62460392|NCT03802370|OTHER|single am|single arm , superiority trial , tunneling technique in connective tissue graft around dental implants
62460393|NCT05583318||Part 1: Patients diagnosed with non-Hodgkin's lymphoma|Diagnosis period 2010-2018, from the hematological malignancy registries of Côte-d'Or, Gironde, Basse-Normandie
62460394|NCT05583318||Part 2: Patients diagnosed with live non-Hodgkin's lymphoma after vital status update|Update of vital status in December 2022
62460395|NCT02012244|EXPERIMENTAL|fentanyl-based analgesia|fentanyl intravenous patient-controlled analgesia + additional pethidine
62460396|NCT02012244|EXPERIMENTAL|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
62460397|NCT04317066|EXPERIMENTAL|Pembrolizumab in Participants with rrPMBCL|Participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months.
62460398|NCT04091971|EXPERIMENTAL|Depressed adults with current MDD|Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.
62086208|NCT03722212|OTHER|Prospective patients|The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.
62086209|NCT03722212|OTHER|Retrospective patients|Patients with confirmed Glut1DS diagnosis Already diagnosed patients are included retrospectively as well as patients with pending diagnosis at inclusion (inconsistent biological or genetic data).
62086210|NCT04467840|EXPERIMENTAL|Opaganib|In addition to standard of care, opaganib will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. When required this may be made into a suspension form and may be administered by nasogastric tube.
62086211|NCT04467840|PLACEBO_COMPARATOR|Placebo|In addition to standard of care, a matching placebo will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. Where required this may be made into a suspension form and may be administered by nasogastric tube.
62086212|NCT06018597||percent age difference < -6.6%|"The percentage age difference in the negative direction represents patients whose metabolic age is greater than their chronological age.~When we analyze the ROC analysis in the negative direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percentage age difference is -6,6%.~This group refers to those whose percentage age difference is less than -6.6%"
62086213|NCT06018597||percent age difference -6.6% to 11.7% those between|"When we analyze the ROC analysis in the negative direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percentage age difference is -6,6%. When we analyze the ROC analysis in the positive direction, the cut-off value of the percent age difference is 11.7%.~This group refers to those whose percentage age difference between -6.6% and 11.7%"
62086214|NCT06018597||percent age difference > 11.7%|"the percent age difference in the positive direction represents patients whose metabolic age is less than their chronological age.~When we analyze the ROC analysis in the positive direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percent age difference is 11.7%.~This group refers to those whose percentage age difference is more than 11.7%"
62086215|NCT05926856|ACTIVE_COMPARATOR|1 day before surgery|0.25mg/kg Indocyanine Green will be administered 1 day before surgery
62086216|NCT05926856|EXPERIMENTAL|45 min before surgery|0.05mg Indocyanine Green will be administered 45minutes before surgery
62086217|NCT05701943|EXPERIMENTAL|Sprint Interval Training|The SIT consisted of a combination of aerobic, resistance, balance, and flexibility exercises. Exercise started with 5 min of warm-up followed by bouts of 5-10 min of exercise consisting of 5-20 s all-out sprints followed by 15-45 s of low cadence recovery (1:3-1:2 work-rest ratio). The duration of the sprints and active recovery were modified throughout the program. To ensure that participants exercised at the appropriate intensity, the OMNI scale 8-10 (Stanish \& Aucoin, 2007) was applied during the home intervention, and an HR chest band (H10 Polar, Electro, Kempele, Finland) was used during the gym intervention.
62285189|NCT01774422|OTHER|noninvasive ventilation associated with the DECAP CO2 device|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~* Noninvasive ventilation alone~* Noninvasive ventilation associated with the DECAP CO2 device"
62285190|NCT06361641|EXPERIMENTAL|Phemop Cohort|
62285191|NCT00664248|EXPERIMENTAL|1|
62285192|NCT00664248|ACTIVE_COMPARATOR|2|
62285193|NCT00664248|ACTIVE_COMPARATOR|3|
62285194|NCT00664248|PLACEBO_COMPARATOR|4|
62285195|NCT06100575|EXPERIMENTAL|Website (www.mee-leven.be)|Participants in this group (all participants) are asked to complete a questionnaire and then receive access to the website during three days, after which they were asked to complete another questionnaire.
62285196|NCT00508573||Lynch Syndrome Registry|Patient that has or is at risk for Lynch Syndrome.
62285197|NCT01865331|EXPERIMENTAL|Low dose, insulin degludec|
62285198|NCT01865331|EXPERIMENTAL|Medium dose, insulin degludec|
62285199|NCT01865331|EXPERIMENTAL|High dose, insulin degludec|
62285200|NCT01865331|EXPERIMENTAL|IDegAsp 50|
62285201|NCT03382509|EXPERIMENTAL|Single Dose Group|
62285202|NCT03382509|EXPERIMENTAL|Multiple Dose Group|
62285203|NCT02290314|OTHER|minimally invasive MID-line Lumbar Fusion (MIDLF)|MIDLF surgery involves a minimally invasive midline laminectomy posterior approach to the lumbar spine. An incision that is smaller than the standard incision is made in the midline of the low back directly over the spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed as described in the PLIF procedure.
62285204|NCT02290314|OTHER|posterior lumbar interbody fusion (PLIF)|PLIF surgery involves a standard incision in the midline of the low back directly over the involved spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed in between the vertebral bodies where the disc usually lies. This will allow bone fusion (healing) to occur from one vertebral body to the other.
62285205|NCT05313542|EXPERIMENTAL|Physical Activity Group (PA group)|The PA group will receive a 6-week home-based self-defence training programme consisting of 120 min video training (including daily practice time) per week. Self-report questionnaires will be collected at baseline, immediate post-intervention, and 4-week follow up assessments.
62285206|NCT05313542|OTHER|Waitlist Group (WL group)|The waitlist group will receive access to the programme at the end of study.
62285207|NCT05689333|EXPERIMENTAL|27 GA Vista Ophthalmics vitrector|The vitrectomy will be performed through the pars plana using the 27 GA Vista Ophthalmics vitrector.
62285208|NCT00457496|ACTIVE_COMPARATOR|A|
62285209|NCT00478491||1|Persons with a parent with Alzheimer's disease
62285210|NCT00478491||2|Persons whose parents survived to old age without memory problems
62285211|NCT00478491||3|Persons with diagnosed mild cognitive impairment
62285212|NCT00478491||4|Persons without memory problems
62285213|NCT05888688||patients with Heart Failure with Preserved Ejection Fraction (HFpEF)|"Heart Failure (HF) Patients: Stage A/B HFpEF~1. Established clinical diagnosis of HFpEF (EF\>50%)~2. Clinically stable for ≥ 3 months (no admissions to hospital)~3. Age ≥65~4. Willing to provide written consent for participation in the study."
62285214|NCT05888688||patients with Heart Failure with Reduced Ejection Fraction (HFrEF)|"HF Patients: Stage C/D HFpEF and HFrEF~1. Established clinical diagnosis of HFpEF (EF\>50%) OR HFrEF (EF\<40%)~2. Clinically stable for ≥ 3 months (no admissions to hospital)~3. Age ≥65~4. Willing to provide written consent for participation in the study."
62285215|NCT05888688||Asymptomatic T2D|"1. Male or female, aged ≥18 and ≤75 years.~2. Diagnosis of stable T2D (determined by i) formal diagnosis in primary care physician case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level ≥6.5%)."
62285216|NCT05888688||Healthy Volunteers|"1. Age \>18~2. Able to provide written informed consent"
62285217|NCT01067131|EXPERIMENTAL|PEV7C1, intravaginal|Vaccine containing virosomes intravaginally applied
62285218|NCT01067131|PLACEBO_COMPARATOR|PEV7C9, placebo, intravaginal|Placebo vaccine (excipient only) intravaginally applied
62285219|NCT01067131|EXPERIMENTAL|PEV7B2, intramuscular low dose|Intramuscular vaccine low dose of antigen
62285220|NCT01067131|EXPERIMENTAL|PEV7B1, intramuscular high dose|Intramuscular vaccine, high dose of antigen
62285221|NCT02709278|OTHER|Group 1A: low dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10\^3 cfu by the aerosol inhaled route, followed by bronchoscopy.
62285222|NCT02709278|OTHER|Group 1B: medium dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10\^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
62285223|NCT02709278|EXPERIMENTAL|Group 1C: standard dose aerosol BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10\^5 cfu by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
62285224|NCT02709278|EXPERIMENTAL|Group 1D: standard dose intradermal BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10\^5 cfu by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
62285225|NCT02709278|OTHER|Group 2A: lower than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10\^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
62285226|NCT02709278|OTHER|Group 2B: close to the standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10\^5 cfu by the aerosol route, followed by bronchoscopy.
62285227|NCT02709278|OTHER|Group 2C: higher than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10\^6 cfu by the aerosol inhaled route, followed by bronchoscopy.
62285228|NCT02709278|EXPERIMENTAL|Group 2D: close to or higher than standard aerosol BCG|3 volunteers receiving 1 x 10\^7 cfu aerosol inhaled BCG Bulgaria (InterVax), followed by bronchoscopy 14 days later
62086218|NCT05701943|ACTIVE_COMPARATOR|Continuous Aerobic Exercise Training|CAET was based on a combination of aerobic, resistance, balance, and flexibility exercises. The exercise on the cycle ergometer started with 5-min of warm-up followed by 3 bouts of continuous cycling at a steady-state intensity. The duration of the bouts (5-10 min) and the intensity (55-85% HRR) were progressively increased throughout each phase. To ensure that the participants exercised at the appropriate intensity, the OMNI scale 4-6 (Stanish \& Aucoin, 2007) was used during the home-based intervention, and an HR chest band (H10 Polar, Electro, Kempele, Finland) was worn during the gym-based intervention.
62086219|NCT04859049|EXPERIMENTAL|Group 1|Infra- medial injection of local anesthesia mixture
62086220|NCT04859049|EXPERIMENTAL|Group 2|medial canthus injection of the local anesthesia mixture
62086221|NCT02136485|EXPERIMENTAL|MBSR|8 weekly sessions each lasting 2.5 hours
62086222|NCT02136485|OTHER|Control|Control arm - waiting list control, once the intervention group has completed MBSR the control group will be invited to participate in MBSR
62086223|NCT02818608|ACTIVE_COMPARATOR|Functional electrical stimulation (FES)|Chronic stroke patients submitted to functional electrical stimulation (FES).
62086224|NCT02818608|EXPERIMENTAL|Combination of transcranial direct current stimulation and FES|Chronic stroke patients submitted to transcranial direct current stimulation (tDCS) and functional and to functional electrical stimulation (FES).
62086225|NCT05305937|EXPERIMENTAL|One arm - all patients|
62086226|NCT01766583|EXPERIMENTAL|CC-292 + lenalidomide|Combination of CC-292 + lenalidomide
62086227|NCT02696278|EXPERIMENTAL|Hummus and vegetables|Children will receive a lesson about vegetables and hummus and vegetables as part of their daily snack.
62086228|NCT02696278|EXPERIMENTAL|Vegetables only|Children will receive a lesson about vegetables and vegetables as part of their daily snack.
62086229|NCT03089372|ACTIVE_COMPARATOR|Group A|Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
62086230|NCT03089372|ACTIVE_COMPARATOR|Group B|Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
62086231|NCT05034510|ACTIVE_COMPARATOR|Low frequency 80 Hz then short pulse width 30 usec stimulation|Each participant will undergo to low frequency stimulation for 4 weeks, then will switch to short pulse width stimulation paradigm for 4 weeks according to the crossover design.
62285229|NCT02709278|EXPERIMENTAL|Group 2E: close to or higher than standard intradermal BCG|9 volunteers receiving the optimal dose of aerosol inhaled BCG Bulgaria (InterVax) identified from preliminary results obtained from Groups 2C and 2D, and ID saline placebo, followed by bronchoscopy 14 days later
62086232|NCT05034510|ACTIVE_COMPARATOR|Short pulse width 30 usec then low frequency 80 Hz stimulation|Each participant will undergo to short pulse width stimulation paradigm for 4 weeks, then will switch to low frequency for 4 weeks according to the crossover design.
62086233|NCT06169436||Experimental|Patients with upper urinary tract urothelial cancer who underwent nephroureterectomy surgery
62086234|NCT05565222|EXPERIMENTAL|Piperacillin/tazobactam or temocillin|Piperacillin/tazobactam, 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure). Piperacillin/tazobactam will be infused over 4 hours. Duration of treatment will be adjusted according to the site of infection Temocillin, 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure). Temocillin will be infused continuously. Duration of treatment will be adjusted according to the site of infection
62086235|NCT05565222|ACTIVE_COMPARATOR|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure). Meropenem will be infused over 2 hours. Duration of treatment will be adjusted according to the site of infection
62086236|NCT05655065|ACTIVE_COMPARATOR|Increase of MAP at low target 65-70 mmHg (with catecholamines or volemic expansion)|Target of mean arterial pressure (MAP) at 65-70 mmHg The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations.
62285230|NCT02709278|EXPERIMENTAL|Group 2F: 1 log lower than Group 2E|12 volunteers will receive aerosol inhaled saline placebo and intradermal BCG Bulgaria (InterVax), at a dose a log lower than 2E then bronchoscopy and punch biopsy
62285231|NCT06068387|EXPERIMENTAL|experimental group|locally advanced cervical cancer treated with surgical staging
62285232|NCT04040361|EXPERIMENTAL|Pembrolizumab+Ramucirumab+Surgery|Pembrolizumab and Ramucirumab will be administered simultaneously for non small cell lung cancer patients for 2 cycles before surgery.
62086237|NCT05655065|EXPERIMENTAL|Increase of MAP at high target 80-85 mmHg (with catecholamines or volemic expansion)|Target of mean arterial pressure (MAP) at 80-85 mmHg The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations.
62460399|NCT04766281|ACTIVE_COMPARATOR|MLC901 (NeuroAiD II)|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
62285233|NCT05429879|EXPERIMENTAL|Preferred Music Arm|This arm will allow patients to listen to their preferred music choice during their cystoscopy.
62285234|NCT05429879|EXPERIMENTAL|Classical Music Arm|Patients will listen to a standard playlist of copyright free classical music.
62285235|NCT05429879|NO_INTERVENTION|No music Arm|Patients will not listen to music during cystoscopy.
62285236|NCT03704129|EXPERIMENTAL|"Tutor group"|"After a theoretical part through the administration of a video-tutorial, a 10-point questionnaire will be administered to evaluate the level of learning for each participant. Every single participant will pass the test if he/she correctly answer to \>70% of the questions. Those passing the test, will be randomized to two groups.~The interventional group will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself."
62285237|NCT03704129|NO_INTERVENTION|"No tutor group"|This control group will directly perform the ultrasound examination of the diaphragm. The expert tutor will only show the learners how to use the various functions of the ultrasound, the linear and convex probes both in two-dimensional and in M-mode.
62460400|NCT04766281|PLACEBO_COMPARATOR|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
62460401|NCT06096740|EXPERIMENTAL|Immediate Treatment|Those individuals randomized to immediate treatment will commence individual cognitive processing therapy (CPT) with an assigned study therapist, following the completion of baseline procedures.
62460402|NCT06096740|PLACEBO_COMPARATOR|Delayed Treatment|Individuals randomized to the delayed treatment condition will be informed after randomization that their treatment will start in 6-8 weeks (the approximate period it will take for individuals in the immediate treatment arm to complete CPT and post-treatment assessments).
62460403|NCT00909402|EXPERIMENTAL|All Subjects|
62285238|NCT02476318|EXPERIMENTAL|ArterX Vascular Sealant|
62460404|NCT05523271|NO_INTERVENTION|Patients undergoing White Light Endoscopy (standard of care)|All subjects in Experimental Arm A will undergo SOC (white-light endoscopy).
62460405|NCT05523271|EXPERIMENTAL|Patients undergoing CAD EYE endoscopy|All subjects in Experimental Arm B will undergo CADEYE endoscopy.
62460406|NCT02353169|EXPERIMENTAL|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
62460407|NCT02353169|EXPERIMENTAL|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
62460408|NCT02353169|EXPERIMENTAL|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
62460409|NCT02353169|SHAM_COMPARATOR|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
62460410|NCT03021720|ACTIVE_COMPARATOR|Femoral arterial access|Femoral arterial puncture for the uterine fibroid embolization procedure
62460411|NCT03021720|EXPERIMENTAL|Radial arterial access|Radial arterial puncture for the uterine fibroid embolization procedure
62460412|NCT05561426|EXPERIMENTAL|Fast UPF meals|Meals consisting of UPF with textures that are consumed fast
62460413|NCT05561426|EXPERIMENTAL|Slow UPF meals|Meals consisting of UPF with textures that are consumed slow
62651546|NCT01967199|EXPERIMENTAL|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
62651547|NCT05300282|EXPERIMENTAL|phase I|patients will receive the BEGEV regimen plus Atezolizumab in order to determine MTD of the last one drug.
62651548|NCT05300282|ACTIVE_COMPARATOR|phase IIb - arm A|patients will receive the BEGEV regimen followed by ASCT for patients achieving CR.
62086238|NCT01613820|EXPERIMENTAL|Ketamine plus placebo|Subjects assigned to this paradigm will receive a 15 minute infusion of normal saline (placebo) followed by IV ketamine at 0.25mg/kg over 45 minutes twice a week for 3 weeks.
62086239|NCT01613820|EXPERIMENTAL|Scopolamine plus placebo|Subjects will receive a 15 minute infusion of IV scopolamine 2ug/kg followed by a 45 minute infusion of normal saline (placebo).
62086240|NCT01613820|EXPERIMENTAL|Ketamine plus scopolamine|Subject will receive an IV scopolamine infusion at a dose of 2ug/kg over 15 minutes, followed by an IV infusion of ketamine at a dose of 0.25mg/kg over 45 minutes.
62086241|NCT02503462|EXPERIMENTAL|darunavir/ritonavir vs cobicistat|All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.
62285239|NCT06369493||Thin Gingival Phenotype|Thin phenotype group: Gingival thickness ≤1 mm
62285240|NCT06369493||Thick Phenotype|Thick phenotype group: Gingival thickness \> 1 mm
62285241|NCT01112709|EXPERIMENTAL|SCT|This arm is a long-term, Social Cognitive Theory (SCT)-based intervention, emphasizing self-regulation and other SCT strategies to optimize training, with faded contact.
62285242|NCT01112709|ACTIVE_COMPARATOR|Control|"This arm will be the control condition; a Standard intervention with minimal contact."
62285243|NCT02663739||Aortic Dissection|Treating patients with acute complicated Stanford Type B aortic dissection with the Zenith® TXD
62285244|NCT01745757||Cohort|first line treatment for metastatic breast cancer
62285245|NCT03902678|EXPERIMENTAL|EUS - FNA for benign PVT by imaging|Intervention: Procedure/Surgery: EUS guided fine needle aspiration of portal vein thrombus
62285246|NCT02805205|EXPERIMENTAL|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
62285247|NCT01629615|EXPERIMENTAL|BKM120|
62285248|NCT02071433|EXPERIMENTAL|Saphenous nerve blockade|Experimental treatment 15 mL of levobupivacaine 0.5%
62285249|NCT02071433|ACTIVE_COMPARATOR|Femoral nerve blockade|Standard treatment 15 mL of levobupivacaine 0.5%
62285250|NCT01324284|EXPERIMENTAL|Lubiprostone|Lubiprostone with PEG solution versus Placebo with PEG solution
62651549|NCT05300282|EXPERIMENTAL|phase IIb - arm B|patients will receive combination treatment with Atezolizumab (at dose obtained from phase I) and BEGEV regimen followed for patients reaching CR by ASCT plus a consolidation with 6 doses of atezolizumab at 1200 mg every 4 weeks.
62651550|NCT00183430|EXPERIMENTAL|1|Participants will receive treatment with prazosin plus psychotherapy
62651551|NCT00183430|PLACEBO_COMPARATOR|2|Participants will receive treatment with placebo plus psychotherapy
62651552|NCT02783911|EXPERIMENTAL|Mineral Trioxide Aggregate|Subject with pulpotomy treated with MTA MTA paste (\< 1gm) will be placed on pulp orifice once for the life of the primary teeth
62651553|NCT02783911|EXPERIMENTAL|Ferric Sulfate|Subject with pulpotomy treated with FS FS paste (\<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth
62086242|NCT04794621|NO_INTERVENTION|Standard of Care Only|This will be group 1
62086243|NCT04794621|EXPERIMENTAL|SOC and PED-10 +Procellera|In group 2, in addition to SoC, the patients will apply the EDThi dressing (PED-10) on the wound(s) for the first 3 weeks following enrollment followed by Procellera® or EDTlo for additional 3 weeks. The use of dressings will be discontinued anytime if complete wound closure is achieved.
62086244|NCT05814861||patients presented with GIT symptoms|Fresh Stool samples will be collected in clean sterile cups from patients suffering from gastrointestinal symptoms attending Assiut University Hospitals and examined for detection of Blastocystis hominis
62285251|NCT01324284|PLACEBO_COMPARATOR|lubiprostone versus placebo|
62285252|NCT00000815|EXPERIMENTAL|1|Participants who receive vaccination at 6 and 12 months of age
62285253|NCT00000815|EXPERIMENTAL|2|Participants who receive vaccination only at 12 months of age
62285254|NCT05310214|EXPERIMENTAL|Acupuncture treatment (ACP)|The experimental group will be treated with acupuncture
62285255|NCT05310214|ACTIVE_COMPARATOR|Laser acupuncture treatment (LACP)|The active comparator group will be treated with laser acupuncture
62285256|NCT00903279|PLACEBO_COMPARATOR|Placebo|
62285257|NCT00903279|EXPERIMENTAL|Altabax|
62285258|NCT03737162|EXPERIMENTAL|Covered stent group|Covered stent
62285259|NCT03737162|ACTIVE_COMPARATOR|Bare-metal stent group|Bare-metal stent
62285260|NCT04217564|EXPERIMENTAL|Intervention group|The intervention group will receive a counselling session then instructed on the subsequent follow up dates and final assessment by the end of the study.
62285261|NCT04217564|NO_INTERVENTION|Control group|The control group will not receive nutritional counselling during the study period but will be instructed to attend for final assessment by the end of the study.
62285262|NCT02324270|ACTIVE_COMPARATOR|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
62285263|NCT02324270|EXPERIMENTAL|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
62285264|NCT02324270|PLACEBO_COMPARATOR|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
62285265|NCT06504277|ACTIVE_COMPARATOR|Standard Pressure|Patient undergoing laparosocpy at standard pressure (15 mm HG)
62285266|NCT06504277|EXPERIMENTAL|Low Pressure|Patient undergoing experimental intervention of low pressure pneumoperitoneum (10 mmHg)
62651554|NCT01124253|EXPERIMENTAL|NP plus recombinant human endostatin|
62651555|NCT01124253|NO_INTERVENTION|vinorelbine plus cisplatin|
62651556|NCT03272152||Inflamed CD group|Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
62651557|NCT03272152||Non-inflamed CD group|Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
62651558|NCT03272152||Control group|Control ileal mucosa was obtained from healthy patients
62086245|NCT05814861||clinically free persons undergo routine stool analysis for any reasons other than GIT complaint|Fresh Stool samples will be collected in clean sterile cups from clinically free persons under go routine stool examination for any cause other than GIT troubles and examined for detection of Blastocystis hominis
62086246|NCT04945343|OTHER|Children who had growing rods instrumentation for correction of Early Onset Scoliosis|Growing spine profiler instrumentation
62086247|NCT05722171|EXPERIMENTAL|gdT cell injection targeting B7-H3 chimeric atigen receptor|UTAA06 injection
62086248|NCT02677103|EXPERIMENTAL|RSWT group|The RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder. RSWT will be performed once per week, and will be continued for 3 weeks.
62086249|NCT02677103|EXPERIMENTAL|USNP group|All needle punctures will be guided by ultrasound (US). The puncture needle is a 3.8cm 22# needle attached on a 5ml syringe. Before puncture, the skin of the puncture site will be sterilized with better iodine, and the transducer will be covered with a sterilized plastic bag. After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed. The needle tract will be monitored by ultrasound to make sure the needle penetrated through the calcific plaque, but does not penetrate the rotator cuff.
62086250|NCT02677103|EXPERIMENTAL|RSWT plus USNP|In this group, each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs
62086251|NCT02095600|EXPERIMENTAL|Radiosurgical thalamotomy|
62086252|NCT04676828|EXPERIMENTAL|SPECT functional avoidance treatment|SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.
62086253|NCT04676828|NO_INTERVENTION|Standard treatment|CT-based radiation therapy given over 5- 6.5 weeks.
62086254|NCT01917734||IM-SAM|Children 6-59 months with bilateral pitting edema, and/or WHZ \< - 3 and/or MUAC \< 115 mm.
62086255|NCT00750893||Rotarix Group|Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
62086256|NCT00777803|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin®/Bocouture®)|IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
62086257|NCT00777803|ACTIVE_COMPARATOR|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.
62086258|NCT01639274|OTHER|COPD|
62086259|NCT04212481|EXPERIMENTAL|single port group|Uniport video-assisted thoracoscopic surgery for NSCLC
62086260|NCT04212481|ACTIVE_COMPARATOR|two ports group|video-assisted thoracoscopic surgery for NSCLC using two ports
62086261|NCT04212481|ACTIVE_COMPARATOR|three ports group|video-assisted thoracoscopic surgery for NSCLC using three ports
62086262|NCT04701437|EXPERIMENTAL|Peer-enhanced intervention|Those randomized to the peer-enhanced intervention group will be contacted by a peer mentor within 72 hours of enrollment to discuss the early release period, readiness for HCV treatment, and identify ancillary needs. Individuals randomized to this arm will be provided a study cell phone.
62086263|NCT04701437|PLACEBO_COMPARATOR|Standard of care|If randomized to the standard of care intervention, the participant will only receive passive referral to HCV-care.
62651559|NCT00247234|EXPERIMENTAL|schema therapy|
62086264|NCT03676036|EXPERIMENTAL|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 28 days: DS107E taken topically twice a day
62086265|NCT03676036|PLACEBO_COMPARATOR|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and Vehicle taken once a day Next 28 days: Vehicle taken topically twice a day
62086266|NCT02117544|OTHER|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
62086267|NCT02117544|OTHER|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
62086268|NCT06273189|EXPERIMENTAL|Lindeman|BSSO were performed with Lindeman and round bur
62086269|NCT06273189|ACTIVE_COMPARATOR|Bone scalpel|BSSO were performed unilaterally using an ultrasonic bone scalpel
62086270|NCT05050487|EXPERIMENTAL|treatment|patient will recieve pericapsular nerve group block
62086271|NCT05050487|EXPERIMENTAL|treatement|patient will receive lumbar erector spinae plane block
62086272|NCT03681821|EXPERIMENTAL|The intervention group|Patients in the intervention group receiving the follow-up TTM-based intervention sessions.
62086273|NCT03681821|NO_INTERVENTION|The control group|No interventions except conventional care were performed for the control group.
62086274|NCT01469793|EXPERIMENTAL|DMOT4039A Q3W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with 0.2 milligrams per kilogram (mg/kg), as intravenous infusion every 3 weeks (Q3W) to determine the maximum tolerated dose (MTD) of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
62086275|NCT01469793|EXPERIMENTAL|DMOT4039A Q3W: Dose Expansion|Participants will receive DMOT4039A at recommended phase 2 dose (RP2D) for Q3W dosing schedule as intravenous infusion Q3W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
62086276|NCT01469793|EXPERIMENTAL|DMOT4039A Q1W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with a dose 33% of MTD for Q3W dosing schedule, as intravenous infusion every week (Q1W) to determine the MTD of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
62086277|NCT01469793|EXPERIMENTAL|DMOT4039A Q1W: Dose Expansion|Participants will receive DMOT4039A at RP2D for Q1W dosing schedule as intravenous infusion Q1W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
62651560|NCT00247234|ACTIVE_COMPARATOR|standard care|standard psychiatric out-patient care
62651561|NCT00670059|ACTIVE_COMPARATOR|A|group: single embryo transfer without aneuploidy screening
62651562|NCT00670059|EXPERIMENTAL|B|group: single embryo transfer with aneuploidy screening
62460414|NCT03006965||Hemophilia A patients|"Group of patients in prophylactic treatment with Advate® (octocog alfa) or Adynovi® (rurioctocog alfa pegol), or patients using already myPKFit®.~Patients will be given a dose of octocog alfa or rurioctocog alfa pegol according to usual clinical practice, and two blood samples will be taken in case of octocog alfa: one sample will be extracted 3-4h postdose (+/- 30 minutes), and the second sample will be extracted 24-32h postdose (+/- 60 minutes). In case of rurioctocog alfa pegol, the first sample is taken in the same conditions than octocog alfa, and the second sample will be extracted 48h postdose (+/- 120 minutes), and other sample post 72h(+/- 120 minutes) optional."
62651563|NCT02011178|ACTIVE_COMPARATOR|Optimal medical treatment and surgery|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
62086278|NCT02920593|EXPERIMENTAL|Vitamin D Prophylaxis|Participants will be provided Vitamin D 3000 IU daily or Vitamin D 4000 IU daily with and without concurrent use of prenatal vitamins, respectively.
62086279|NCT02920593|NO_INTERVENTION|No Vitamin D Prophylaxis|Participants will not receive additional Vitamin D in the pregnancy.
62086280|NCT03832725|ACTIVE_COMPARATOR|High protein (HP) weight loss diet|A weight loss high protein (HP) (30% Kcal protein, 40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
62086281|NCT03832725|ACTIVE_COMPARATOR|High carbohydrate (HC) weight loss diet|"A weight loss high carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.~Intervention with the HC diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
62086282|NCT02921022|EXPERIMENTAL|Patients without a prior thromboembolic event (TE)|Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
62086283|NCT02921022|EXPERIMENTAL|Patients with a prior thromboembolic event (TE)|Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
62086284|NCT00021398|EXPERIMENTAL|Radiation Therapy, Chemotherapy and Surgery|
62086285|NCT03148080||Observational|Participants complete a Current Medical Conditions Form, the CogState web-based cognitive assessment, and a Self-Report Questionnaire administration over 45-60 minutes containing measures of work ability and other work-related measures, cognitive, physical, and psychosocial symptoms, and characteristics of workplace environment. Self-report measures of individual and family characteristics, resources, and demands are also included.
62086286|NCT01305057|EXPERIMENTAL|Evaluation of P-IP on hydration and barrier function|Effects of P-IP on improvement of skin hydration and TEWL were examined.
62086287|NCT06432699|NO_INTERVENTION|Control|Participants in this arm will receive no MOP treatment
62086288|NCT06432699|EXPERIMENTAL|Experimental|participants in this arm will receive MOPS intervention
62086289|NCT03507829|ACTIVE_COMPARATOR|Basal insulin|NPH Insulin Titration Regimen : Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) \> 240 mg/dl 14 Increase by 4 \> 180 mg/dl 12 Increase by 4 \> 140 mg/dl 10 Increase by 4 \> 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - \<100 mg/dl 0 Decrease by 4 60 - \<80 mg/dl 0 Decrease by 8 \< 60 mg/dl 0 Give ½ of previous dose
62086290|NCT03507829|ACTIVE_COMPARATOR|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
62285267|NCT02504788|EXPERIMENTAL|Hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) if the role of RT was considered either adjuvant following craniotomy with tumor removal or therapeutic for treating oligometastatic brain disease.
62460415|NCT01087970|EXPERIMENTAL|Triplet Combination Therapy|"Cycle 1:~Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1"
62651564|NCT02011178|OTHER|Optimal medical treatment|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
62651565|NCT04337788|EXPERIMENTAL|gerontological telemonitoring action|"Nurses answer a daily resident-reported questionnaire (e.g. temperature, dyspnea, pain), edited by French health authorities. From D0 to D20, data are transmitted to the NHSP. Warning algorithms specially developed for older persons identify signs that are monitored by the NHSP geriatrician coordinator. A feedback is provided to the general physician for specific actions required and appropriate support.~A last questionnaire is completed at D30 by the nurse in order to stop monitoring and know event occurred between D20 to D30."
62651566|NCT04337788|NO_INTERVENTION|routine care without gerontological telemonitoring|routine care
62651567|NCT01080261|EXPERIMENTAL|PROMUS Element|everolimus-eluting coronary stent
62086291|NCT03507829|ACTIVE_COMPARATOR|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
62086292|NCT03897166|EXPERIMENTAL|Trimodality Imaging|Positron Emission Tomography coupled with Computed Tomography computed coupled with Magnetic Resonance Imaging and whole-body Biphoton Absorptiometry
62285268|NCT01303055|EXPERIMENTAL|Alogliptin|Alogliptin 25 mg
62285269|NCT01303055|ACTIVE_COMPARATOR|Metformin|Metformin 750 mg
62285270|NCT05916586|EXPERIMENTAL|Prednisone + usual care|Prednisone tablets, 40 mg once a day orally, for 7 days plus usual treatment for acute heart failure
62285271|NCT05916586|NO_INTERVENTION|Usual care|Usual treatment for acute heart failure
62086293|NCT00658697|EXPERIMENTAL|Docetaxel, Bevacizumab, and ADT|"Docetaxel:~Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles~Bevacizumab:~Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles~ADT or Luteinizing hormone-releasing hormone agonist (LHRH):~Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)~Bicalutamide:~Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)"
62086294|NCT01861782|EXPERIMENTAL|Dead Sea Solar and Water Treatment|Dead Sea Solar and Water Treatment
62086295|NCT01861782|EXPERIMENTAL|Sulfur Pool & Medicinal Mud|Sulfur Pool \& Medicinal Mud
62086296|NCT03937050|EXPERIMENTAL|Intervention|A package of three interconnected educational/behavioural film-based interventions will developed for delivery at the cluster (clinic) level. The aim of the three components will be as follows: a) improving knowledge of GDM guidelines and skills among health providers involved in GDM management, b) raising awareness of GDM and the importance of screening among pregnant women and their family members, and c) improving confidence and skills in self-management of GDM among women diagnosed.
62086297|NCT03937050|NO_INTERVENTION|Control|Usual care practices.
62086298|NCT01305356|EXPERIMENTAL|Augment® Injectable Bone Graft|Standard rigid fixation + Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
62086299|NCT01305356|ACTIVE_COMPARATOR|Autologous bone graft|Standard Rigid Fixation + Autologous bone graft
62086300|NCT00305760|EXPERIMENTAL|Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab|
62086301|NCT03062150|PLACEBO_COMPARATOR|Placebo+Placebo|Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
62086302|NCT03062150|ACTIVE_COMPARATOR|Fludrocortisone+Placebo|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH."
62086303|NCT03062150|ACTIVE_COMPARATOR|Placebo+D-Cycloserine|"Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
62086304|NCT03062150|ACTIVE_COMPARATOR|Fludrocortison+D-Cycloserine|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
62086305|NCT05520190|EXPERIMENTAL|All Participants|
62285272|NCT01823419||7-9 year olds|Typically developing 7- to 9-year-olds will be enrolled and tested.
62086306|NCT03268486||Triple monitoring|Pregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, \> 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.
62086307|NCT05313685||Mayo Clinic hiccup educational materials|
62285273|NCT01653119|ACTIVE_COMPARATOR|High loading dose of rosuvastatin|rosuvastatin 20mg/d×1w
62285274|NCT01653119|ACTIVE_COMPARATOR|Routine rosuvastatin therapy|rosuvastatin 10mg/d×1w
62086308|NCT05313685||Mayo Clinic hiccup educational materials + updated supplementary content|
62086309|NCT01651403|EXPERIMENTAL|Tenofovir DF (Blinded Randomized Treatment)|Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
62285275|NCT05508555|ACTIVE_COMPARATOR|HITHOC group|the group that will receive HITHOC after pleurectomy decortication
62285276|NCT05508555|NO_INTERVENTION|pleurectomy decortication without HITOC|the group who received pleurectomy decortication without HITHOC
62651568|NCT02188550|EXPERIMENTAL|Single|This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
62460416|NCT06023147|EXPERIMENTAL|E-TACE|Procedure: The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at one milliliter/two milliliter (1mL/2mL), and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
62285277|NCT04436276|EXPERIMENTAL|Cohort 1a|Participants (healthy adults aged greater than or equal to (\>=)18 to less than or equal to (\<=) 55 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received coronavirus disease-2019 (COVID-19) vaccination (as primary regimen or additional dose) if the last vaccination was \>=6 months ago, will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
62285278|NCT04436276|EXPERIMENTAL|Cohort 1b|Participants (healthy adults aged \>=18 to \<= 55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was \>=6 months ago will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
62086310|NCT01651403|PLACEBO_COMPARATOR|Placebo to match TDF (Blinded Randomized Treatment)|Participants will receive TDF placebo for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
62086311|NCT01651403|EXPERIMENTAL|Tenofovir DF (Open-label Treatment)|Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).
62086312|NCT01651403|EXPERIMENTAL|Tenofovir DF (Open-label Extension Phase)|Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in participants of their age and weight.
62651569|NCT05741697||Patient need NIV ventillation|Patients will be eligible for enrolment if they are diagnosed with bronchiectasis and admitted to the respiratory intensive care unit (RICU); requiring ventilator support without invasive mechanical ventilation and will need NIV
62651570|NCT05741697||patient need HFNC|Patients will be eligible for enrolment if they are diagnosed with bronchiectasis and admitted to the respiratory intensive care unit (RICU); requiring ventilator support without invasive mechanical ventilation and will need HFNC
62651571|NCT00844311|ACTIVE_COMPARATOR|Control arm|150 iu/day of rFSH alone
62651572|NCT00844311|EXPERIMENTAL|hCG low dose|150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1
62651573|NCT00844311|EXPERIMENTAL|hCG medium dose|150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1
62651574|NCT00844311|EXPERIMENTAL|hCG high dose|150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1
62651575|NCT03406663|EXPERIMENTAL|Group 1|"In group 1, the dose of Gla-300 will be titrated by the patients by 1 unit per day until achieving a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (INSIGHT algorithm).~Titration algorithms:~Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~1. ≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose~2. \> 4.4 and ≤ 5.6 mmol/L, no change~3. \< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
62653122|NCT04628624|EXPERIMENTAL|Green tea 1|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
62086313|NCT01170975|OTHER|Treatment sequence 1|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
62086314|NCT01170975|OTHER|Treatment sequence 2|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
62086315|NCT05485974|EXPERIMENTAL|Dose Escalation and Expansion|HBI-2438 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6-8 patients will then be enrolled in the expansion cohort at the recommended dose.
62086316|NCT02471508|EXPERIMENTAL|Tank top with biofeedback system|"The design of biofeedback tank-top will incorporate sensors to record and monitor the posture of the wearer in real time basis. Alerts will be emitted to the wearer once poor posture is detected. The tank-top will be designed to fit the wearer's body and allow the sensor to be placed securely at the targeted position along the spine to minimize the noise from other factors than the wearers' posture and yet comfortable for long-term wearing."
62086317|NCT01394328||Persons with Dementia|Persons with Dementia are identified by the Modified Blessed Dementia Rating Scale and the IQCODE
62086318|NCT05810675|EXPERIMENTAL|Telehealth Early Intervention Program (TEIP) group|The TEIP group will also receive a 16-week telehealth intervention with guidance, digital learning platform, teaching parents to learn intervention skills to improve children's attention and play ability, social communication, cognition, perceptual movement, and improve parents' management of children's behavior problems.
62086319|NCT05810675|NO_INTERVENTION|Telephone group|The telephone group will receive 16-weeks of care and child development counseling through phone calls.
62086320|NCT05205993|EXPERIMENTAL|Intrauterine infusion of antibiotics|Thirty women will receive only intrauterine infusion of antibiotics for 30 days.
62285279|NCT04436276|EXPERIMENTAL|Cohort 2a|Participants (healthy adults aged \>=18 to \<=55 years) will receive Ad26.COV2.S as single vaccination in the primary regimen or matching Placebo on Day 1, followed by booster vaccination at 6 or 12 months with same dose or matching Placebo. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was \>= 6 months ago, will be offered to receive a single ad hoc booster dose of Ad26.COV2.S and who are not willing to receive single ad hoc booster dose of Ad26.COV2.S or are not eligible to receive the ad hoc booster dose will continue to receive booster vaccination.
62285280|NCT04436276|EXPERIMENTAL|Cohort 2b|Participants(healthy adults aged \>=18 to \<=55 years)will receive Ad26.COV2.S in primary regimen or matching Placebo on Day 1 and 57,followed by booster vaccination at 8 or 14 months (that is, 6 or 12 months after completion of primary regimen)with same dose or matching Placebo.At unblinding visit,post EUA,conditional licensure,or approval for single dose regimen of Ad26.COV2.S vaccine,participants initially receiving placebo will be offered to receive single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination.All eligible participants who have previously received any COVID-19 vaccination(as primary regimen or additional dose)if last vaccination was \>= 6 months ago,will be offered to receive single ad hoc booster dose of Ad26.COV2.S and who are not willing to receive single ad hoc booster dose of Ad26.COV2.S or are not eligible for ad hoc booster dose will continue to receive booster vaccination.
62285281|NCT04436276|EXPERIMENTAL|Cohort 3|Participants (good or stable health adults aged \>=65 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was \>=6 months ago will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose or if they are not eligible for ad-hoc booster dose, then they will be asked to continue to be followed in this study.
62285282|NCT04989608|OTHER|patients having suffered to transient ischemic accident|
62285283|NCT04989608|OTHER|healthy volunteers|
62285284|NCT00003454|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62285285|NCT00622895|EXPERIMENTAL|Treatment: allogeneic UCB after reduced intensity conditioning|Patients receive fludarabine phosphate IV on days -4, -3 and -2, cyclophosphamide IV over 1-2 hours on days -6, -5, 3, and 4, and undergo low-dose TBI on day -1. Patients receive hematopoietic cell transplantation on day 0.
62285286|NCT05731804|EXPERIMENTAL|Cohort 1 of Part A|Subjects with mild renal impairment(SIM0417 600 mg; Ritonavir100 mg )
62285287|NCT05731804|EXPERIMENTAL|Cohort 2 of Part A|Subjects with moderate renal impairment(SIM0417 375 mg; Ritonavir100 mg )
62285288|NCT05731804|EXPERIMENTAL|Cohort 3 of Part A|Subjects with normal renal function(SIM0417 600 mg; Ritonavir100 mg )
62460417|NCT03256942|EXPERIMENTAL|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.~Single injection session, injections into the lips."
62460418|NCT03256942|NO_INTERVENTION|No Treatment|
62086321|NCT05205993|EXPERIMENTAL|Combination of intrauterine infusion and oral administration of antibiotics|Thirty women will receive a combination of intrauterine infusion and oral administration of antibiotics for 30 days.
62086322|NCT05205993|ACTIVE_COMPARATOR|Oral administration of antibiotics|Thirty women will receive only oral administration of antibiotics for 30 days.
62086323|NCT00563992|EXPERIMENTAL|1|Participants will take lithium for 12 months
62086324|NCT00563992|EXPERIMENTAL|2|Participants will take valproate for 12 months
62086325|NCT05746520|EXPERIMENTAL|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care (SOC) with complicated (gangrenous or perforated) appendicitis will receive 24 hours of SOC post-operative antibiotics."
62285289|NCT05731804|EXPERIMENTAL|Cohort 4 of Part A|Subjects with normal renal function(SIM0417 375 mg; Ritonavir100 mg )
62086326|NCT05746520|OTHER|Restricted Duration of SOC Antibiotic Use|Use of Standard of Care Antibiotics, type as determined by the clinician, will be restricted to none or 24 hours of post-operatively.
62460419|NCT04826809|EXPERIMENTAL|Health care workers|Health care workers will complete a fit test while wearing the Nordell Single E-100 layer + (cotton layer) mask, Nordell Double E-100 layer mask and an N95 mask
62460420|NCT04329208||Cerebral vasospasm|13 patients developed symptomatic cerebral vasospasm detected by CT angiography and TCD
62460421|NCT04329208||Non Vasospasm|27 patients without cerebral vasospasm
62460422|NCT01828996|ACTIVE_COMPARATOR|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
62285290|NCT05731804|EXPERIMENTAL|Cohort 5 of Part B|Subjects with moderate hepatic impairment (SIM0417 750 mg; Ritonavir100 mg )
62285291|NCT05731804|EXPERIMENTAL|Cohort 6 of Part B|Subjects with normal hepatic function(SIM0417 750 mg; Ritonavir100 mg )
62460423|NCT01828996|PLACEBO_COMPARATOR|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
62651576|NCT03406663|ACTIVE_COMPARATOR|Group 2|"In group 2, the dose of Gla-300 will be titrated by the patients based on the SMPG values of the last 3 days at least weekly, but no more often than every 3 days to achieve a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (EDITION algorithm).~Fasting SMPG (median of the last 3 days including current day) in the range of~1. ≥ 7.8 mmol/L, increase 6 units of Gla-300 dose~2. \> 5.6 and \< 7.8 mmol/L, increase 3 units of Gla-300 dose~3. \> 4.4 and ≤ 5.6 mmol/L, no change~4. ≥ 3.3 and \< 4.4 mmol/L, reduce 3 units of Gla-300 dose~5. \< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
62651577|NCT03889392||polycystic kidney disease|Adult autosomal dominant polycystic kidney disease patients who received kidney transplantation at Asan Medical Center between 1994 and 2018
62651578|NCT01131273|ACTIVE_COMPARATOR|Methadone maintenance for 12 weeks|Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
62651579|NCT01131273|ACTIVE_COMPARATOR|buprenorphine-naloxone (Suboxone)|12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling
62460424|NCT01851577|EXPERIMENTAL|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
62460425|NCT01851577|ACTIVE_COMPARATOR|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
62651580|NCT03794596|EXPERIMENTAL|(Arm A) Avelumab + PPI|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
62086327|NCT05746520|ACTIVE_COMPARATOR|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will receive 24 hours of post-operative antibiotics.~Participants undergoing standard of care (SOC) with complicated (gangrenous or perforated) appendicitis will receive 4 days of SOC post-operative antibiotics."
62086328|NCT05746520|OTHER|Liberal Duration of SOC Antibiotic Use|Use of Standard of Care Antibiotics, type as determined by the clinician, will be permitted for 24 hours or 4 days of post-operatively.
62086329|NCT00923039||Exposed/ Not exposed|
62086330|NCT05090982||Patients with Atopic dermatitis|150 patients with Atopic dermatitis
62086331|NCT02230579|EXPERIMENTAL|Cohort SAD1 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
62086332|NCT02230579|EXPERIMENTAL|Cohort SAD2 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
62285292|NCT00792298|EXPERIMENTAL|Suvorexant 10 mg → Placebo|After an \~1- to 2-week single-blind placebo run-in period, participants received 10 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
62285293|NCT00792298|EXPERIMENTAL|Placebo → Suvorexant 10 mg|After an \~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 10 mg suvorexant daily prior to bedtime during Treatment Period 2.
62285294|NCT00792298|EXPERIMENTAL|Suvorexant 20 mg → Placebo|After an \~1- to 2-week single-blind placebo run-in period, participants received 20 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
62460426|NCT03649048|ACTIVE_COMPARATOR|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
62460427|NCT03649048|ACTIVE_COMPARATOR|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
62460428|NCT05614570||Baseline|This cohort contains individuals tested at baseline, usually in the pre-season of their sporting season
62460429|NCT05614570||Concussed|This cohort contains individuals who have had a concussion, diagnosed by a doctor.
62651581|NCT03794596|EXPERIMENTAL|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
62651582|NCT04913922|EXPERIMENTAL|Combination therapy|"5-azacitidine 75 mg/m2 body surface area s.c. for 7 days nivolumab 480mg i.v. day 1 relatlimab 80-160mg i.v. day 1~repeat day 28"
62651583|NCT01470170|EXPERIMENTAL|Group1|Alfentanil 2.5μg/kg before propofol
62651584|NCT01470170|EXPERIMENTAL|Group2|Alfentanil 5μg/kg before propofol
62651585|NCT01470170|EXPERIMENTAL|Group 3|Alfentanil 2.5μg/kg two minutes before propofol
62651586|NCT01470170|EXPERIMENTAL|Group 4|Alfentanil 5μg/kg two minutes before propofol
62651587|NCT01470170|PLACEBO_COMPARATOR|Group 5 Control|propofol alone
62651588|NCT04642989|SHAM_COMPARATOR|Healthy Control + Sham Treatment|Healthy participants who received the sham treatment
62651589|NCT04642989|ACTIVE_COMPARATOR|Healthy Control + Facial Effleurage|Healthy participants who received the Facial Effleurage treatment
62086333|NCT02230579|EXPERIMENTAL|Cohort SAD3 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
62086334|NCT02230579|EXPERIMENTAL|Cohort SAD4 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
62651590|NCT04642989|ACTIVE_COMPARATOR|Acute Rhinosinusitis + Antibiotics|Sick participants who received the recommended antibiotics
62086335|NCT02230579|EXPERIMENTAL|Cohort SAD5 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
62086336|NCT02230579|EXPERIMENTAL|Cohort SAD6 Fed|Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
62086337|NCT03795805|OTHER|TKA and Tourniquet|Total knee arthroplasty and use of tourniquet limb cuff at 270 mmHg
62086338|NCT03795805|EXPERIMENTAL|Intraarticular lidocain|Total knee arthroplasty with Intaarticular lidocain
62086339|NCT00311155|EXPERIMENTAL|1|"Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks"
62086340|NCT04598880|EXPERIMENTAL|Pleinvue|Subjects receive polyethylene glycol + ascorbate (PEG1A) as laxative treatment for colonoscopy preparation.
62651591|NCT04642989|SHAM_COMPARATOR|Acute Rhinosinusitis + Sham Treatment|Sick participants who received the sham treatment
62651592|NCT04642989|EXPERIMENTAL|Acute Rhinosinusitis + Facial Effleurage|Sick participants who received the Facial Effleurage treatment
62651593|NCT04642989|SHAM_COMPARATOR|Acute Rhinosinusitis + Sham Treatment + Antibiotics|Sick participants who received the recommended antibiotics and the sham treatment
62651594|NCT04642989|EXPERIMENTAL|Acute Rhinosinusitis + Facial Effleurage + Antibiotics|Sick participants who received the recommended antibiotics and the Facial Effleurage treatment
62651595|NCT01175057||Group A|10 patients who undergo home monitoring with the MeDiNa Homebox for 4 weeks and then 4 weeks without the MeDina Homebox
62651596|NCT01175057||Group B|Group B starts without the MeDiNa Homebox for 4 weeks and then undergo Homemonitoring with the MeDiNa Homebox for 4 weeks.
62651597|NCT04716985|ACTIVE_COMPARATOR|TREATMENT GROUP|"Water saturated with molecular hydrogen at the rate of 2 times 250 mL / day for 21 days.~80 mg of Mg metal, and safe excipients (dextrose, malic acid, L-tartaric acid, adipic acid)."
62651598|NCT04716985|PLACEBO_COMPARATOR|PLACEBO GROUP|Water saturated with magnesium at the rate of 2 times 250 mL / day for 21 days. 80 mg of Mg, but in ionic form.
62086341|NCT04598880|EXPERIMENTAL|Citrafleet|Subjects receive sodium picosulfate + magnesium citrate (PSCM) as laxative treatment for colonoscopy preparation.
62086342|NCT04252703|ACTIVE_COMPARATOR|Minimalist|The 'Minimalist' strategy is PCI treatment of the culprit lesion only. Other coronary stenoses are to be managed medically. It is recognized that there may be multiple culprit lesions in such patients, though there are no data on how frequently this might be expected. Operators may elect to treat multiple putative culprit lesions in this case.
62086343|NCT04252703|EXPERIMENTAL|More complete|The 'More complete' strategy is PCI of the culprit lesion and fractional flow reserve (FFR)- or instantaneous wave-free ratio (iFR)-guided treatment of other angiographically significant (\> 50% diameter) stenoses amenable to coronary stenting in vessels with reference diameters ≥2.5mm. Physiological assessment is strongly encouraged but not mandatory for lesions of ≥90% angiographic stenosis. PCI of chronic total occlusions will not be attempted as part of the study.
62086344|NCT02075983|EXPERIMENTAL|Group 3 (IM+EP)|Group 3 will receive 12.0mg of vaccine over 12 weeks administered with EP using the Trigid Ichor device. We expect to see the greatest proportion of individuals making T cell and antigen specific antibody responses responses in this group. Depending on the magnitude of the effects, the differences between group 3 and the other groups may be statistically significant.
62086345|NCT02075983|EXPERIMENTAL|Group 2 (IM+TC)|Group 2 will also receive 13.2mg of vaccine over 12 weeks, with 12.0mg given IM and 1.2mg TC. We are interested in the impact of TC relative to ID vaccination on the ratio between HIV-specific T-cell responses, and whether or not CD8+ Tcells are favoured by this route.
62651599|NCT00772837|EXPERIMENTAL|1.H.Pylori Eradication Group|The eradication group will receive triple therapy (omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BID and Amoxycillin 1g BID) for 1 week for the eradication of H. pylori
62651600|NCT00772837|PLACEBO_COMPARATOR|2.Control Placebo Group|The control group will receive omeprazole 20 mg BID for 1 week along with placebo antibiotics for 1 week
62651601|NCT04452864|EXPERIMENTAL|Study Intervention|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by AD. This training will be performed for three months (each day for 20 minutes). After three months this group will continue the training at home for six months and meet monthly for group sessions (i.e. booster sessions) on site.
62651602|NCT04452864|ACTIVE_COMPARATOR|Active Control Group|This control study arm will watch documentaries at home for three months (each day for 20 minutes) , instead of performing the CCT and serve as active control group. This group will also train with the CCT tasks after these three months.
62651603|NCT04452864|OTHER|Wait-List Control|This control study arm will start with the CCT with a delay of three months and serve as wait-list control group.
62651604|NCT01654276|EXPERIMENTAL|Febuxostat|Adult patients (age \> 21 years) with gout and hyperuricemia (serum uric acid \> 7.0 mg/dl in men and \>6.0 mg/dl in women) requiring uric acid lowering therapy.
62651605|NCT05029531|EXPERIMENTAL|intervention/treatment|
62651606|NCT06305481|OTHER|Imaging Device|Various scans will be captured
62651607|NCT00411320|ACTIVE_COMPARATOR|Group 1|Smokers with asthma
62651608|NCT00411320|ACTIVE_COMPARATOR|Group 2|Ex-smokers with asthma
62651609|NCT00411320|ACTIVE_COMPARATOR|Group 3|Non-smokers with asthma
62651610|NCT00411320|NO_INTERVENTION|Group 4|Non smokers without asthma
62651611|NCT00411320|NO_INTERVENTION|Group 5|Smokers without asthma or COPD
62285295|NCT00792298|EXPERIMENTAL|Placebo → Suvorexant 20 mg|After an \~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 20 mg suvorexant daily prior to bedtime during Treatment Period 2.
62460430|NCT03931642|EXPERIMENTAL|R-CHOP- blinatumomab|"Patients will first undergo a prior debulking therapy including 2 cycles of R-CHOP.~At Day1 (D1) : Rituximab 375 mg/m² Intravenous (IV) + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² Per Os (PO). Patients with CR and no measurable lesion left will not be treated further in the setting of the present trial. All the remaining patients will be continuing and treating on study with a single cycle of blinatumomab induction therapy : Blinatumomab at 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/d from day 15-56.~Patients who achieve an objective response after induction are eligible to receive one further optional cycle of blinatumomab consolidation : blinatumomab 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/day IV from day 15-28."
62460431|NCT01278056|EXPERIMENTAL|Exjade|
62285296|NCT00792298|EXPERIMENTAL|Suvorexant 40 mg → Placebo|After an \~1- to 2-week single-blind placebo run-in period, participants received 40 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
62285297|NCT00792298|EXPERIMENTAL|Placebo → Suvorexant 40 mg|After an \~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 40 mg suvorexant daily prior to bedtime during Treatment Period 2.
62460432|NCT04751448||Observational|All patients going on study will be put in the observational grouping for blood and tissue collection with option for stool collection.
62460433|NCT00378690|ACTIVE_COMPARATOR|Continuous Androgen Deprivation (CAD)|
62651612|NCT04092478||Traditional Sitting Position|We are going to use the Traditional Sitting Position on each patients.
62651613|NCT04092478||Lateral Decubitis Position|We are going to use the Lateral Decubitis Position on each patients.
62651614|NCT04092478||Abdominal Crunch Position|We are going to use the Abdominal Crunch Position on each patients.
62651615|NCT02764736|EXPERIMENTAL|atorvastatin|Patients in this arm will receive 20mg atorvastatin PO daily for 12 weeks followed by 40mg atorvastatin PO daily for 12 weeks.
62086346|NCT02075983|ACTIVE_COMPARATOR|Group 1 (IM+ID)|"Group 1 will serve as the reference arm and this group will receive a total dose of 13.2mg vaccine over 12 weeks with 12.0mg given IM and 1.2mg ID. This is 7.2mg more than has been given previously to healthy individuals and 6.2 mg more than given to those HIV-infected but similar doses of HIV DNA vaccines have been given in other trials with no serious consequences."
62086347|NCT01470378|ACTIVE_COMPARATOR|Control Group|This group will not be undergoing to manual lymphatic drainage
62285298|NCT00792298|EXPERIMENTAL|Suvorexant 80 mg → Placebo|After an \~1- to 2-week single-blind placebo run-in period, participants received 80 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
62460434|NCT00378690|EXPERIMENTAL|Intermittent Androgen Deprivation (IAD)|
62460435|NCT06362486||Cohort A N=1000|neurodevelopment assessment by pediatrician, need to refer to neurodevelopmental assessment by specialized team. m-chat. autism diagnosis.
62460436|NCT06362486||Cohort B N=500|Mental health assessment
62460437|NCT06362486||Cohort C N=100|biological
62460438|NCT00486837|EXPERIMENTAL|Group 1|Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
62460439|NCT00486837|EXPERIMENTAL|Group 2|Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
62460440|NCT05293847|EXPERIMENTAL|Telerehabilitation exercises|Exercises about postural structures on the cervical and thoracal region. Bilateral pectoral stretching, chin tack exercises, cervical isotonic exercises, stretching of the upper trapezius and longus Colli, scapular region strengthening, shoulder capsular stretching, Wand exercises for 12 weeks and 3 times a week.
62651616|NCT00912366||Group A|VATS
62651617|NCT00912366||Group B|Open Surgery
62651618|NCT01502891|ACTIVE_COMPARATOR|Decision aid|DEPRESSION CHOICE decision aid is provided to clinician to share with patient
62651619|NCT01502891|NO_INTERVENTION|Normal care|
62651620|NCT01885065|EXPERIMENTAL|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
62651621|NCT05877989|ACTIVE_COMPARATOR|Standard care|Patients will receive usual care in Intensive Care Unit (prescription of a standard nutrition formula (at approximately 20 -25 kcal/ kg/day and protein intake 1.2 g/kg/day) once patients are hemodynamically stable.
62086348|NCT01470378|ACTIVE_COMPARATOR|Study Group|This group will be undergoing to manual lymphatic drainage
62086349|NCT03548311|PLACEBO_COMPARATOR|Placebo|intramuscular injection of saline solution
62086350|NCT03548311|ACTIVE_COMPARATOR|methylcobalamin|intramuscular injection of methylcobalamin
62285299|NCT00792298|EXPERIMENTAL|Placebo → Suvorexant 80 mg|After an \~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 80 mg suvorexant daily prior to bedtime during Treatment Period 2.
62460441|NCT00625443|EXPERIMENTAL|Placebo (double-blind)|
62651622|NCT05877989|ACTIVE_COMPARATOR|Protein and exercise group|patients will receive the amino acid intervention that is provided in addition to 'usual care' enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day. The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient). The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
62460442|NCT00625443|EXPERIMENTAL|Avatrombopag tablets (open-label)|
62651623|NCT01788514|OTHER|Videogame|Subject will play educational videogame
62651624|NCT01814540|PLACEBO_COMPARATOR|Placebo Control, Glucose polymer|Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.
62086351|NCT03787290|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab followed by whole-body hyperthermia
62086352|NCT03787290|ACTIVE_COMPARATOR|Placebo|Participants will receive a placebo followed by whole-body hyperthermia
62086353|NCT03847636|ACTIVE_COMPARATOR|Familial Adenomatous Polyposis (FAP)|Individuals with duodenal adenomas (DAs) and FAP with Spigelman class 2,3 or 4, treated with cryoballoon ablation (intervention)
62086354|NCT03847636|ACTIVE_COMPARATOR|Sporadic duodenal adenomas|Individuals with at least 1 sporadic duodenal adenoma (DA) between 1-5 cm in maximum diameter, treated with cryoballoon ablation (intervention)
62086355|NCT01096732|EXPERIMENTAL|GDC-0449|Study drug.
62086356|NCT05822297|EXPERIMENTAL|All participants|Each participant will undergo the same procedures and intervention, consisting of a baseline phase, intervention phase and follow-up phase. The length of the baseline phase will be randomized 3, 4, 5 or 6 weeks.
62086357|NCT03374345|EXPERIMENTAL|SDT group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
62086358|NCT03374345|PLACEBO_COMPARATOR|Placebo group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
62285300|NCT05095025|EXPERIMENTAL|Bupivacaine dose finding|Sequential up and down dose modification based on the outcome of the intervention in the preceding participant
62285301|NCT03057366|EXPERIMENTAL|[14C]-Pevonedistat 25 mg/m^2|\[14C\]-pevonedistat (containing approximately 60-98 mCi \[approximately 2.22-3.626 MBq\] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m\^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m\^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m\^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m\^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m\^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles. Based on investigator and sponsor discretion, participants deriving benefits will continue to receive current combination therapy or pevonedistat alone beyond 12 cycles.
62651625|NCT01814540|EXPERIMENTAL|Treatment 2: Low-Dose BMO|"Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
62651626|NCT01814540|EXPERIMENTAL|Treatment 3: High-Dose BMO|"Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
62651627|NCT04493762||PSO/PSA|Patients diagnosed with psoriasis or psoriatic arthritis
62651628|NCT04493762||RA|Patients diagnosed with rheumatoid arthritis
62651629|NCT01399996|PLACEBO_COMPARATOR|Yogurt smoothie without probiotic.|
62651630|NCT01399996|EXPERIMENTAL|Probiotic added post fermentation.|
62651631|NCT01399996|EXPERIMENTAL|Probiotic added pre-fermentation.|
62651632|NCT01399996|EXPERIMENTAL|A capsule containing the probiotic.|
62086359|NCT03840837|NO_INTERVENTION|Arm 1: baseline only (cross-sectional)|At baseline, all participants will undergo instrumented gait/balance testing, using a wearable sensor (Dynaport MT), and cognitive testing, using a computerized cognitive test battery (NeuroTrax Mild Cognitive Impairment \& Early Dementia Battery by MindStreams). In other words, all participants will be part of arm 1.
62086360|NCT03840837|EXPERIMENTAL|Arm 2: rivastigmine (longitudinal)|As study intervention, a subgroup of participants will then be treated with transdermal rivastigmine patch for 12 weeks, with dose increases every 4 weeks and titration up to 13.3 mg/24h, if tolerated. For the arm 2 subgroup of participants, the same assessment that was performed at baseline (quantitative gait testing and NeuroTrax computerized cognitive test battery) will be repeated after 12 weeks, with the patient on a stable dose of transdermal rivastigmine.
62086361|NCT02617420||Intervention|All patients will be enrolled in one arm. These patients will have monitoring devices placed on their asthma controller and rescue medication, with data transmitted both to their smartphones and a dashboard accessed by their primary pediatric pulmonary provider.
62086362|NCT04468243|EXPERIMENTAL|Nurse-led|Nurse-led (group A). Patients randomized to group A will be taken to an available consultation room within the clinic and provided brief diabetes education which includes understanding what it means to have diabetes, healthy eating, and physical activity. Patients will also receive instructions on how to use a glucometer and how to take Metformin.
62285302|NCT00882141|EXPERIMENTAL|1|Weight loss
62285303|NCT00882141|EXPERIMENTAL|2|Exercise plus weight loss
62460443|NCT00625443|EXPERIMENTAL|Avatrombopag tablets (double-blind)|
62460444|NCT03043547|EXPERIMENTAL|Nal-IRI + 5-FU + leucovorin (Arm A)|nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion), 5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
62460445|NCT03043547|OTHER|5-FU + leucovorin (Arm B)|Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
62651633|NCT03246178|OTHER|MSD-HSCT|This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
62651634|NCT03246178|EXPERIMENTAL|HFD-HSCT|This group received treatment of haploid family donor - hematopoietic stem cell transplantation (HFD-HSCT).
62651635|NCT00997893|EXPERIMENTAL|Estradiol/Medroxyprogesterone Acetate|1 mg/d oral Estradiol pill and 0 mg/d oral placebo pill for 12 weeks, followed by 10 mg/d oral medroxyprogesterone acetate (MPA) pill, for 10 days.
62651636|NCT00997893|EXPERIMENTAL|Soy Phytoestrogen|55 mg/twice daily oral Novasoy®/Soy Phytoestrogen pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
62086363|NCT04468243|NO_INTERVENTION|Usual Care|Usual Care (Control; group B). Patients randomized to usual care will be informed of their HbA1c value, will continue to receive usual cancer care, and will be encouraged to follow-up with their PCP for T2D management. The RA will ensure that oncology visit clinic notes and the results of the HbA1c testing are relayed to the patient's PCP office. Patients who do not have a PCP identified will be referred to an appropriate provider.
62086364|NCT06480669|EXPERIMENTAL|Time Restricted Feeding (TRF)|8 participants who followed a 12/12 Time Restricted Feeding (12 consecutive hours of fasting, from 20:30 to approximately 8:30 the following day).
62086365|NCT06480669|ACTIVE_COMPARATOR|Mediterranean diet|A control group consisting of 9 participants who followed a standard Mediterranean diet.
62086366|NCT02718417|ACTIVE_COMPARATOR|Arm A|Chemotherapy followed by observation
62086367|NCT02718417|EXPERIMENTAL|Arm B|Chemotherapy followed by avelumab in maintenance
62086368|NCT02718417|EXPERIMENTAL|Arm C|Chemotherapy in combination with avelumab followed by avelumab in maintenance
62086369|NCT05205486|EXPERIMENTAL|Cefazolin 3gm Injection|Study drug will be administrated as an infusion over 30 minutes starting approximately 0.5 hours before surgery begins and following institutional guidelines on Day 1 (day of surgery). All subjects will have five (5) individual whole blood samples (4 mL each) collected for the estimation of cefazolin concentration in plasma at the following times after the start of the infusion: 0.5 (+/-10 min) end of infusion, 1 h (+/-15 min), 2 h (+/-15 min), 4 h (+/-15 min), and 8 h (+/-15 min).
62086370|NCT03886675|EXPERIMENTAL|carbon-dioxide|Flushing of stent-grafts in TEVAR with carbon-dioxide
62086371|NCT03886675|ACTIVE_COMPARATOR|Saline|Flushing of stent-grafts with saline
62285304|NCT02190019|ACTIVE_COMPARATOR|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
62285305|NCT02190019|SHAM_COMPARATOR|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 10 treatments identical in duration will be administered over a two week period.
62285306|NCT05774340|EXPERIMENTAL|CM326 Low Dose|CM326 220 mg/2 mL, subcutaneous at low dose
62651637|NCT00997893|PLACEBO_COMPARATOR|Placebo|0 mg tablet/twice daily oral placebo pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
62086372|NCT01705470|EXPERIMENTAL|arm1|will receive 60 mg (6 ml) of intra-venous furosemide before administration of the blood transfusion (250-300 ml of packed cells).
62086373|NCT01705470|EXPERIMENTAL|arm2|will receive 6 ml of normal saline (NaCl 0.9%) before administration of the blood transfusion (250-300 ml of packed cells).
62086374|NCT03127592|EXPERIMENTAL|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
62086375|NCT03127592|ACTIVE_COMPARATOR|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
62086376|NCT03127592|ACTIVE_COMPARATOR|Group 3|1 active treatment (Etodolac) + 2 placebos
62285307|NCT05774340|EXPERIMENTAL|CM326 High Dose|CM326 220mg/2mL, subcutaneous at high dose
62285308|NCT05774340|PLACEBO_COMPARATOR|Placebo|Placebo 2mL, subcutaneous
62651638|NCT02313402|EXPERIMENTAL|EOL (Eye On Line)|training program allowing a gradual acquisition of the eye-writing
62651639|NCT02265510|EXPERIMENTAL|Phase 1a: INCB052793 Monotherapy|
62086377|NCT01458249|EXPERIMENTAL|eribulin mesylate 1.4 mg/m^2|
62285309|NCT02385279|EXPERIMENTAL|MiStent®|Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
62651640|NCT02265510|EXPERIMENTAL|Phase 1b: INCB052793 Combination Therapy|
62086378|NCT00525694|OTHER|1|glucose tolerance test solution
62086379|NCT00525694|OTHER|2|Diet Coke
62086380|NCT00525694|OTHER|3.|Coke Zero
62086381|NCT02622139|EXPERIMENTAL|Multispectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography (MSOT) for the evaluation of disease activity in inflammatory bowel diseases (IBD)
62086382|NCT05226845|EXPERIMENTAL|exercise to improve the neck strength in neck pain chosen by the therapist|
62086383|NCT05226845|EXPERIMENTAL|exercise to improve the neck strength in neck pain chosen by the patient|
62285310|NCT02385279|ACTIVE_COMPARATOR|XIENCE EES|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
62285311|NCT05512871|EXPERIMENTAL|Group 1 (Intervention group)|Group 1 (Intervention group) :Oura ring with Oura App + HealthifySG App (receive lifestyle interventions via HealthifySG App)
62460446|NCT04088773||Aim 1 Crohn Disease participants (B2 phenotype)|Crohn's Disease participants scheduled for ileal small bowel resection; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
62460447|NCT04088773||Aim 2 Crohn Disease participants (B1 phenotype)|Crohn's Disease participants with uncomplicated small bowel disease; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
62651641|NCT02265510|EXPERIMENTAL|Phase 2: INCB052793 and itacitinib Combination Therapy|
62651642|NCT00129636|OTHER|Patient attending hospital clinic|patients were sent a letter especially dictated for them and a copy of the letter written by the hospital consultant to their GP to review
62651643|NCT01841372|ACTIVE_COMPARATOR|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
62086384|NCT01148043|PLACEBO_COMPARATOR|Placebo|
62086385|NCT01148043|EXPERIMENTAL|Hydroxychloroquine|
62086386|NCT04084743|EXPERIMENTAL|Virtual reality training and Dual task intervention|Cognitive and motor Dual-task intervention and virtual reality training intervention in patients with Parkinson's disease
62086387|NCT04084743|ACTIVE_COMPARATOR|Conventional physiotherapy and Dual task intervention|The dual-task intervention without virtual reality training intervention in patients with Parkinson's disease
62086388|NCT03883685|EXPERIMENTAL|experimental group|40 subjects will be randomly allocated to receive probiotics pills for consecutive 8 weeks.
62086389|NCT03883685|PLACEBO_COMPARATOR|Control group|40 subjects will be randomly allocated to receive placebo pills for consecutive 8 weeks.
62086390|NCT02271282|EXPERIMENTAL|Oral Toremifene/Oral Placebo|"Oral toremifene will be given once on Day 1 and continue daily x10 days. A single combined IV injection of growth hormone releasing hormone (GHRH)/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral placebo on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
62460448|NCT04088773||Aim 2 Healthy Controls|No intervention; observational only; collection of blood, stool, and completion of Gastrointestinal Symptoms Rating Scale
62460449|NCT05975853|EXPERIMENTAL|Binaural beat music group (BBM group)|20 minutes of music thrice a week (Monday, Wednesday, and Friday) for two weeks (total of 12 times)
62460450|NCT05975853|SHAM_COMPARATOR|Control group|20 minutes of music thrice a week (Monday, Wednesday, and Friday) for two weeks (total of 12 times)
62086391|NCT02271282|EXPERIMENTAL|Oral Placebo/Oral Toremifene|"Oral placebo will be given once on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral toremifene on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
62086392|NCT04279028|ACTIVE_COMPARATOR|Standard CBT|Standard CBT, 12 sessions each lasting 45 minutes
62086393|NCT04279028|EXPERIMENTAL|Adapted CBT|Adapted CBT, 12 sessions each lasting 45 minutes
62086394|NCT04896658|EXPERIMENTAL|Arm A|"1. Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.~2. Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 3 weeks cycles."
62086395|NCT04896658|EXPERIMENTAL|Arm B|"1. Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.~2. Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 6 weeks cycles."
62285312|NCT05512871|OTHER|Group 2 (Control group)|Group 2 (Control group) : Oura ring with Oura App alone (without lifestyle interventions)
62285313|NCT05039060|ACTIVE_COMPARATOR|Group 1|Group 1: Modified MAC diet (first 3-weeks) followed by conventional diet (second 3-weeks)
62285314|NCT05039060|PLACEBO_COMPARATOR|Group 2|Group 2: Conventional diet (first 3-weeks) followed by modified MAC diet (second 3-weeks)
62460451|NCT05699005|EXPERIMENTAL|Individulised transfusion strategy group|Patients will recieve red blood cells transfusion in case of a drop of ScVO2 \<65% after an assessment for the optimisation of SaO2 normalisation (SaO2\>94%), volume optimisation, ECMO output increase, Fever (body temperature 38°3 C°), Anxiety and Pain
62651644|NCT01841372|EXPERIMENTAL|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
62651645|NCT02980315|EXPERIMENTAL|CAR-T cells|the group treat with CAR-T cells
62651646|NCT02980315|NO_INTERVENTION|placebo|the group treat with CAR-T cells
62653123|NCT04628624|EXPERIMENTAL|Green tea 2|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG + 150mg quercitin and 150mg alpha lipoic acid - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
62285315|NCT05315609|EXPERIMENTAL|Intervention: Virtual Reality Mindfulness Group|The intervention will be 4-weeks, twice per week, 15-minute/session VR-mindfulness intervention group.
62285316|NCT05315609|NO_INTERVENTION|No intervention: Waitlist Control Group|These participants will be on a waitlist to receive the VR guided meditation program after data collection has been completed (after the 4 weeks)
62285317|NCT06498934|EXPERIMENTAL|real DN-DBS + rehabilitation|Study treatment is deep brain stimulation of the dentate nucleus (DN-DBS) delivered during 6-month rehabilitation period.
62285318|NCT06498934|ACTIVE_COMPARATOR|sham DN-DBS + rehabilitation|Active control treatment is rehabilitation (standard-of-care treatment) with sham DN-DBS (electrode implanted but won't turn on the device).
62086396|NCT03912480|EXPERIMENTAL|Stem cells from human exfoliated teeth|"Basic treatment:~The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia).~Stem cell therapy:~Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight .~Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment.~Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed."
62086397|NCT00389974|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
62086398|NCT04860700|EXPERIMENTAL|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62086399|NCT00793143||Sleeve|
62086400|NCT00793143||Bypass|
62086401|NCT01561690|EXPERIMENTAL|ARRY-502|
62086402|NCT01561690|PLACEBO_COMPARATOR|Placebo|
62086403|NCT06167382|EXPERIMENTAL|Healthy Female and Male Adults|Demographic Survey Form,the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+),Digital Dynamometer Measurement,ROM Measurements, Muscle Strength Tests, Grip Strength Measurement, Hand Skill and Function Tests, Arm Ergometer,Modified Borg Scale, Pulseoximeter will be applied to the participants.
62285319|NCT03436173|EXPERIMENTAL|Fluoxetine|Fluoxetine 10 mg/2.5 ml
62285320|NCT03436173|PLACEBO_COMPARATOR|Placebo|Peppermint syrup measured to equivalent volume
62460452|NCT05699005|ACTIVE_COMPARATOR|Conventionnal transfusion strategy group|Transfusion will be performed in case of a hemoglobin drop \<9 g/dL
62460453|NCT04450043|EXPERIMENTAL|Run In|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
62651647|NCT04716543||ILI Investigation|The suspected ILI cases will be first identified using the WHO clinical case definition of ILI and Covid 19 as either with:Acute onset of fever (\> 37.5˚C axillary temperature or \> 38˚C tympanic temperature) AND cough; OR Acute onset of ANY ONE OR MORE of the following signs or symptoms: Fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anosmia (loss of smell) or ageusia (loss of taste); with symptoms with onset within the last 10 days.
62651648|NCT02937376|EXPERIMENTAL|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
62086404|NCT03810079|ACTIVE_COMPARATOR|Anodal tDCS High Vigilance|Patients will undergo continuous 20 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined high level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
62086405|NCT03810079|ACTIVE_COMPARATOR|Anodal tDCS Low Vigilance|Patients will undergo continuous 20 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined low level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
62086406|NCT03810079|SHAM_COMPARATOR|Anodal tDCS Random Vigilance|Patients will undergo continuous 20 channels EEG and receive tDCS (bilateral prefrontal stimulation) at a random level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
62285321|NCT04724473|EXPERIMENTAL|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
62285322|NCT04724473|ACTIVE_COMPARATOR|RETIN-A® (Tretinoin) Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
62651649|NCT02937376|PLACEBO_COMPARATOR|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
62285323|NCT04724473|PLACEBO_COMPARATOR|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
62651650|NCT05441007|EXPERIMENTAL|Hypoxic|Participants inhale ambient air, the hypoxic gas mixture, and ambient air.
62651651|NCT05441007|EXPERIMENTAL|Hypercapnic|Participants inhale ambient air, the hypercapnic gas mixture, and ambient air.
62653124|NCT01088087|PLACEBO_COMPARATOR|Colostrum|
62285324|NCT03977246|EXPERIMENTAL|Open-placebo|The open-placebo intervention session
62285325|NCT03977246|PLACEBO_COMPARATOR|Control|The control session
62086407|NCT04447781|EXPERIMENTAL|Group 1 (Part A)|"* Number of Subjects: 20 subjects~* ID Injection of INO-4800 1mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
62086408|NCT04447781|EXPERIMENTAL|Group 2 (Part A)|"* Number of Subjects: 20 subjects~* ID Injection of INO-4800 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
62086409|NCT04447781|EXPERIMENTAL|Group 3 (Part B)|"* Number of Subjects: 90 subjects~* ID Injection of INO-4800 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
62086410|NCT04447781|PLACEBO_COMPARATOR|Group 4 (Part B, Placebo)|"* Number of Subjects: 30 subjects~* ID Injection of Placebo (SSC) 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
62086411|NCT00280475|ACTIVE_COMPARATOR|1|Device: Whole brain radiation therapy arm
62086412|NCT00280475|EXPERIMENTAL|2|Device: Salvage stereotactic radiosurgery arm
62086413|NCT02106221|EXPERIMENTAL|Intervention|Financial incentives will be provided based on performance in areas determined to be of high-value.
62086414|NCT02106221|ACTIVE_COMPARATOR|Control|Financial incentives are a flat rate which can be reduced if an appropriate amount of effort or improvement is not met
62086415|NCT01489020|EXPERIMENTAL|Group A active|"6 administrations and 5 weeks duration~1. Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~2. Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
62086416|NCT01489020|PLACEBO_COMPARATOR|Group A placebo|"6 administrations and 5 weeks duration~1. Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~2. Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
62285326|NCT04345666|EXPERIMENTAL|Testosterone group|20 patients will receive a 200 mg testosterone cyprionate intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
62285327|NCT04345666|PLACEBO_COMPARATOR|Placebo group|20 patients will receive a sterile saline intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
62086417|NCT01489020|EXPERIMENTAL|group B active|"8 administrations and 7 weeks duration~1. Vial 1: 0.2 ml at 1 week intervals~2. Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~3. Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
62285328|NCT06469463|PLACEBO_COMPARATOR|Control group|Control group of healthy subjects
62285329|NCT06469463|ACTIVE_COMPARATOR|Patients group|Patients group of post-stroke with upper-limb deficits on one side
62285330|NCT00412776|EXPERIMENTAL|1|Proxinium plus Best Supportive Care
62285331|NCT00412776|NO_INTERVENTION|2|Best Supportive Care
62285332|NCT02770521|EXPERIMENTAL|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
62285333|NCT02770521|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered as a single SC bolus injection.
62651652|NCT05441007|EXPERIMENTAL|Hypoxic and Hypercapnic|Participants inhale ambient air, the hypoxic and hypercapnic gas mixture, and ambient air.
62086418|NCT01489020|PLACEBO_COMPARATOR|Group B placebo|"8 administrations and 7 weeks duration~1. Vial 1: 0.2 ml at 1 week intervals~2. Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~3. Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
62086419|NCT01489020|EXPERIMENTAL|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~1. Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~2. Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~3. Week 3: vial 3 - 2 doses of 0.1 ml with 30 minute interval~4. Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
62086420|NCT01489020|PLACEBO_COMPARATOR|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~1. Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~2. Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~3. Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~4. Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
62086421|NCT01531192|EXPERIMENTAL|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
62086422|NCT01531192|ACTIVE_COMPARATOR|Nystatin|50000 unit/3 times a day
62086423|NCT04458389|EXPERIMENTAL|TY101|"Dose escalation：Humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg (fix dose) until disease progresses or unacceptable tolerability occurs.~Dose expansion：After completion of the DLT observation, the sponsor and principal investigator will select a possible dose（RP2D）for dose expansion to further confirm the efficacy and safety of RP2D."
62285334|NCT02770521|EXPERIMENTAL|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
62285335|NCT02770521|ACTIVE_COMPARATOR|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
62285336|NCT01126255|ACTIVE_COMPARATOR|1|Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
62285337|NCT01126255|EXPERIMENTAL|2|Progesterone 8%, topical application, once daily about 2 g, during 12 weeks
62285338|NCT06024525|EXPERIMENTAL|Paclitaxel-Coated Coronary Balloon Catheters|receiving the treatment with Swide®DCB in small vessel cohort
62285339|NCT06024525|ACTIVE_COMPARATOR|Paclitaxel-Releasing Coronary Balloon Catheter|receiving the treatment with SeQuent® please Neo in small vessel cohort
62285340|NCT00766805|ACTIVE_COMPARATOR|EVL + Drugs|Patients randomized to the EVL plus drugs therapy received EVL plus beta-blocker (propranolol) and nitrate (ISMN).
62285341|NCT00766805|PLACEBO_COMPARATOR|EVL alone|Patients assigned to the EVL group underwent variceal band ligation alone till variceal obliteration.
62651653|NCT02457091|ACTIVE_COMPARATOR|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
62653125|NCT01088087|NO_INTERVENTION|Sugar pill|
62285342|NCT04657432|EXPERIMENTAL|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62086424|NCT01754779|EXPERIMENTAL|Placebo, then Citric Acid, then Potassium Citrate|Participants will receive at random, First intervention (1 week), then experience a washout period (1 week) and then receive Second Intervention (1 week) followed by another washout period of 1 week to finally receive the Third Intervention (1 week)
62086425|NCT01754779|EXPERIMENTAL|Placebo, then Potassium Citrate, then Citric Acid|Participants will receive at random, First intervention (1 week), then experience a washout period (1 week) and then receive Second Intervention (1 week) followed by another washout period of 1 week to finally receive the Third Intervention (1 week)
62086426|NCT01754779|EXPERIMENTAL|Potassium Citrate, then Placebo, then Citric Acid|Participants will receive at random, First intervention (1 week), then experience a washout period (1 week) and then receive Second Intervention (1 week) followed by another washout period of 1 week to finally receive the Third Intervention (1 week)
62086427|NCT01754779|EXPERIMENTAL|Potassium Citrate, then Citric Acid, then Placebo|Participants will receive at random, First intervention (1 week), then experience a washout period (1 week) and then receive Second Intervention (1 week) followed by another washout period of 1 week to finally receive the Third Intervention (1 week)
62086428|NCT01754779|EXPERIMENTAL|Citric Acid, then Potassium Citrate, then Placebo|Participants will receive at random, First intervention (1 week), then experience a washout period (1 week) and then receive Second Intervention (1 week) followed by another washout period of 1 week to finally receive the Third Intervention (1 week)
62086429|NCT01754779|EXPERIMENTAL|Citric Acid, then Placebo, then Potassium Citrate|Participants will receive at random, First intervention (1 week), then experience a washout period (1 week) and then receive Second Intervention (1 week) followed by another washout period of 1 week to finally receive the Third Intervention (1 week)
62086430|NCT02595229|ACTIVE_COMPARATOR|PQ (Pronator quadraus) repair|Following volar plate osteosynthesis the pronator quadratus muscle is sutured with 3 to 5 U-shaped stitches using a polyfilament absorbable synthetic suture.
62086431|NCT02595229|NO_INTERVENTION|No PQ repair|Following volar plate osteosynthesis the pronator quadratus muscle is placed in its anatomical position without suture repair.
62086432|NCT05370339||Adolescents|Adolescents with type 1 diabetes between the ages of 11 and 17 years.
62086433|NCT02478086|EXPERIMENTAL|use amine acids parenteral 3.5g|"Amino acids parenteral (Levamin Nomo 10% ®) Group A with an initial doses of amino acids until reaching 3.5 g/kg/day during 28 days.For the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
62086434|NCT02478086|EXPERIMENTAL|use amine acids parenteral 4g|"Group B with an initial doses of 2.5 g/kg/day with daily increments of 0.5 g/kg/day until reaching 4 g/kg/day during 34 days.Weight, urea, creatinine and blood urea nitrogen (BUN) were measured weeklyFor the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
62086435|NCT01177813|EXPERIMENTAL|BI 10773 low dose|Patients receive BI 10773 low dose tablets once daily
62086436|NCT01177813|EXPERIMENTAL|BI 10773 high dose|Patients receive BI 10773 high dose tablets once daily
62285343|NCT04657432|EXPERIMENTAL|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285344|NCT04657432|EXPERIMENTAL|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285345|NCT04657432|EXPERIMENTAL|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62086437|NCT01177813|PLACEBO_COMPARATOR|Placebo|Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
62086438|NCT01177813|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Patients receive Sitagliptin 100 mg tablets once daily
62086439|NCT01177813|EXPERIMENTAL|BI 10773 high dose open label|Patients receive BI 10773 high dose tablets open label once daily
62460454|NCT04450043|EXPERIMENTAL|Intervention|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
62285346|NCT04657432|EXPERIMENTAL|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285347|NCT04657432|EXPERIMENTAL|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285348|NCT04657432|EXPERIMENTAL|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285349|NCT04657432|EXPERIMENTAL|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285350|NCT04657432|EXPERIMENTAL|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285351|NCT04657432|EXPERIMENTAL|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285352|NCT04657432|EXPERIMENTAL|Study 2: 10 Active Doses|All participants will be assigned to 10 sessions (per treatment day) of accelerated rTMS for 5 treatment days. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 active sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
62285353|NCT04749381|EXPERIMENTAL|TCM group|Rectal cancer patients randomized to this group will have acupoint application with traditional Chinese medicine.
62285354|NCT04749381|PLACEBO_COMPARATOR|Control group|Rectal cancer patients randomized to this group will have acupoint application with placebo .
62285355|NCT02249702|EXPERIMENTAL|Trabectedin|Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
62285356|NCT02249702|ACTIVE_COMPARATOR|gemcitabine + docetaxel|Gemcitabine 900 mg/m2 will be administered via a central venous catheter on days one and eight over 90 min, followed by docetaxel 75 mg/m2 on day eight iv over 1 h. Gemcitabine+docetaxel treatment is planned for six cycles, unless there is evidence of disease progression, unacceptable toxicity or patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician. Patients with continued response after six cycles can receive two additional cycles of combination therapy or continue with Gemcitabine alone.
62285357|NCT02149810|EXPERIMENTAL|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
62285358|NCT02149810|NO_INTERVENTION|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
62285359|NCT01587742||Patients with a diagnosis of any cancer type|All patients of the study population with a diagnosis of any cancer type based on Read codes and ICD-10 codes
62285360|NCT01587742||Patients with a diagnosis of breast cancer|All patients of the study population with a diagnosis of breast cancer based on Read codes and ICD-10 codes
62285361|NCT01587742||Patients with a diagnosis of prostate cancer|All patients of the study population with a diagnosis of prostate cancer based on Read codes and ICD-10 codes
62285362|NCT01587742||Patients with a diagnosis of colon cancer|All patients of the study population with a diagnosis of colon cancer based on Read codes and ICD-10 codes
62285363|NCT01587742||Patients without a diagnosis of any cancer type|All patients of the study population without a diagnosis of any cancer type
62285364|NCT02648386|SHAM_COMPARATOR|Laparoscopic surgery|Patients receive no interventions after rectal cancer treatment.
62285365|NCT02648386|EXPERIMENTAL|NeuroRegen scaffold transplantation|Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.
62285366|NCT02648386|EXPERIMENTAL|NeuroRegen scaffold/BMMCs transplantation|Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
62285367|NCT02648386|EXPERIMENTAL|NeuroRegen scaffold/HUC-MSCs transplantation|Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
62086440|NCT00402883|EXPERIMENTAL|Intervention|Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy.
62086441|NCT02409875||Risk groups|"For families that both parents have BMI\>=24 or at least one of them BMI\>=28, then calculated as high-risk group.~For families that both parents have BMI\<24 or one parents with BMI\<24 and one with 24\<=BMI\<28, then grouped as low-risk group."
62086442|NCT01015261|EXPERIMENTAL|Bone Marrow Transplantation|
62086443|NCT01015261|ACTIVE_COMPARATOR|Chemotherapy|
62086444|NCT01349829|EXPERIMENTAL|HAVpur|
62086445|NCT01349829|ACTIVE_COMPARATOR|Havrix|
62086446|NCT06269549|OTHER|The effect of dietary supplements added to physical exercise intervention|This study arm will include two groups of participants, one receiving 12 weeks physical exercise intervention together with real dietary supplements (Active Joint, and Collagen Powder Blend), while the other group receiving exercise intervention with placebo dietary supplements (placebo Active Joint and placebo Collagen Powder Blend).
62086447|NCT06269549|OTHER|The effect of physical exercise added to dietary supplement intervention|This study arm will include two groups of participants, one receiving 12 weeks real dietary supplements alone (Active Joint, and Collagen Powder Blend), while the other group receiving real dietary supplements (Active Joint and Collagen Powder Blend) with physical exercise.
62086448|NCT00583180||A|Capsaicin treated patients
62086449|NCT00583180||P|Placebo treated patients
62086450|NCT03259698|EXPERIMENTAL|ARM 1 = TEXT MESSAGING SUPPORT|"PEP will be delivered by ID physician and participants will receive weekly text message check-ins and optional automated text appointment reminders via the WelTel system."
62086451|NCT03259698|EXPERIMENTAL|ARM 2 = NO TEXT MESSAGING SUPPORT|"PEP will be delivered according to the standard of care by an infectious diseases physician. Participants will not receive text message reminders or check-in."
62086452|NCT03259698|EXPERIMENTAL|ARM 3 = NURSE-LED nPEP|PEP will be delivered by a sexual health clinic nurse operating under a medical directive.
62086453|NCT03259698|ACTIVE_COMPARATOR|ARM 4 = ID PHYSICIAN-LED nPEP,|PEP will be delivered according to the standard of care by an infectious diseases physician.
62086454|NCT04925921|EXPERIMENTAL|Treatment|Treatment with the SR-1 Laser
62086455|NCT05725187||Low risk group for paroxysmal atrial fibrillation|Subject patients are above 20 in age who are hospitalized in our hospital or outpatients with arrhythmia symptoms after the clinical research approval. The sinus rhythm electrocardiogram at the time of the patient's participation in the study is put into the artificial intelligence prediction algorithm, and the risk stratification results are blinded and are not informed to both the research director and the subjects. For the low-risk group, after attaching the wearable electrocardiogram to the subject, the electrocardiogram recorded a week later is analyzed to confirm the occurrence of atrial fibrillation.
62086456|NCT05725187||High risk group for paroxysmal atrial fibrillation|Subject patients are above 20 in age who are hospitalized in our hospital or outpatients with arrhythmia symptoms after the clinical research approval. The sinus rhythm electrocardiogram at the time of the patient's participation in the study is put into the artificial intelligence prediction algorithm, and the risk stratification results are blinded and are not informed to both the research director and the subjects. For the highrisk group, after attaching the wearable electrocardiogram to the subject, the electrocardiogram recorded a week later is analyzed to confirm the occurrence of atrial fibrillation.
62086457|NCT02440906|EXPERIMENTAL|Intervention|A person-centered wellness intervention that includes a patient-directed wellness account. Enrollees meet with a patient Navigator to develop a wellness plan. The enrollee can then use the flexible wellness account to make purchases that are consistent with the goals of the wellness plan. Health Navigators have monthly phone contact with enrollees and meet quarterly with them to discuss goals and spending with the express goal of improving self-management, use of preventive services, satisfaction with care, healthcare utilization and expenditures and quality of care.
62086458|NCT02440906|NO_INTERVENTION|Control|Control group participants receive a monthly mailing requesting updated contact information. They can send this card via mail, or by calling the toll free number.
62086459|NCT02440906|NO_INTERVENTION|Comparison|These are STAR+PLUS enrollees who meet the same enrollment criteria as the intervention and control but reside outside of the Harris Service Area. The purpose of the comparison group is to follow them and their outcomes. This group will help us to better compare the outcomes we see with those enrolled in the WIN Project to a comparable group for whom we already house data.
62086460|NCT00447330|EXPERIMENTAL|1|
62086461|NCT05873257|OTHER|main arm|Non comparative - One armed - open labelled Intervention - subjects will wear the test dressing in a four weeks period with planned dressing changes once pr. week.
62285368|NCT00591695|ACTIVE_COMPARATOR|A|positioning in emergency of a prosthetic metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
62086462|NCT03867708||patients with residual shunt|patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
62086463|NCT03867708||patients without residual shunt|patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
62651654|NCT02457091|EXPERIMENTAL|Resistance exercise|The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
62086464|NCT00803140|ACTIVE_COMPARATOR|Cautery Arm|Cautery to make skin incision
62086465|NCT00803140|ACTIVE_COMPARATOR|Scalpel Incision|Scalpel to make skin incision
62086466|NCT05829941|EXPERIMENTAL|HabitAware condition|This group will receive the device which messages the participant after a passively detected binge-eating episode with CBT strategies.
62086467|NCT05829941|PLACEBO_COMPARATOR|Reminder Condition|This group will receive a device that vibrates randomly throughout the day as a reminder not to binge eat.
62086468|NCT02319447|NO_INTERVENTION|Usual Care|After randomization, these study participants will receive the Usual Care received by all listed kidney transplant candidates at our center.
62285369|NCT00591695|ACTIVE_COMPARATOR|B|emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
62285370|NCT04753892|EXPERIMENTAL|Arm 1|The 3Sm peptide is conjugated to a mutant diphtheria carrier protein (CRM197) and the resulting challenge agent (3SM2-G-CRM197) will be mixed with a squalene adjuvant before intramuscular administration at Months 0, 1, 2 and 4, at a dosage of 32 micrograms of 3SM2-G-CRM197 and 9.7 micrograms of adjuvant.
62285371|NCT04513483|EXPERIMENTAL|CPAP treatment for 12 months|CPAP treatment for 12 months
62285372|NCT04513483|PLACEBO_COMPARATOR|Placebo|observation
62285373|NCT05587751|EXPERIMENTAL|Pulmonary Function in Transgender and Gender Diverse Patients|Transgender and gender diverse (TGD) patients undergoing masculinizing or feminizing hormone therapies will have breathing tests to evaluate their lung function
62285374|NCT06526936|EXPERIMENTAL|Experimental group|Training will be provided on diabetic foot care.
62285375|NCT06526936|NO_INTERVENTION|Control group|Since it is a control group, no application will be made.
62285376|NCT06236347|EXPERIMENTAL|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
62285377|NCT06236347|ACTIVE_COMPARATOR|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
62285378|NCT00576238|EXPERIMENTAL|1:1|Part 1 - eczema treatment
62285379|NCT00576238|ACTIVE_COMPARATOR|1:2|Part 1 - eczema treatment
62285380|NCT00576238|EXPERIMENTAL|2:1|Part 2 - maintenance treatment
62285381|NCT00576238|NO_INTERVENTION|2:2|Part 2 - maintenance treatment
62651655|NCT01118078||Biomarker (DNA methylation, gene expression, RT-PCR)|Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
62651656|NCT03150043|OTHER|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
62651657|NCT03174639|EXPERIMENTAL|Inverted and free ILM insertion|Both inverted and free ILM flaps were inserted into the macular hole
62086469|NCT02319447|EXPERIMENTAL|Additional education|These study participants will be invited to attend a 60-90 minute educational seminar, entitled Destination: Transplant, delivered in a group setting. They will also receive monthly mailings for 9 months and a follow-up phone call from a transplant educator.
62086470|NCT00050414|EXPERIMENTAL|Trabectedin|Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
62285382|NCT02061735||oral propranolol|Dosage of 1 mg/kg per day divided 2 times daily. Blood pressure, heart rate and oxygen saturation are monitored after propranolol initiation. Treatment is continued with a gradual increase to 2 mg/kg per day divided 2 times daily. Treatment is continued until the hemangioma no longer changes in the characteristics judged by the physicians, including, color, size, temperature and deformability.
62285383|NCT02061735||timolol maleate 0.5% gel|One drop of of timolol maleate 0.5% gel is topically applied and massaged into the hemangioma twice per day . This dosage provides an estimated 0.5 mg of timolol per day. The treatment is continued until it is considered to be no longer effective as judged by the physicians.
62651658|NCT00116181|EXPERIMENTAL|continuous therapy|Subjects will receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24.
62285384|NCT02061735||No treatment, observation only|No oral or topical treatment will be given as recommended by the treating physicians and elected by the parents. Patients will be evaluated periodically to determine what changes in treatment are warranted. If this occurs, the patients will be included in the appropriate study group.
62651659|NCT00116181|ACTIVE_COMPARATOR|intermittent therapy|Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
62285385|NCT02644226||Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
62285386|NCT02644226||Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
62651660|NCT03427411|EXPERIMENTAL|1/Arm 1-M7824 1,200 mg intravenous (IV) once every 2 weeks|M7824 at a flat dose of 1,200 mg intravenous (IV) once every 2 weeks
62651661|NCT04495621|EXPERIMENTAL|MEN1611|MEN1611 + Cetuximab
62651662|NCT05340699|EXPERIMENTAL|experimental group|A group of children wearing Xingyouxue Defocus Distributed Multi-point lens
62651663|NCT05340699|ACTIVE_COMPARATOR|control group|A group of children wearing single vision lens
62086471|NCT05909293|EXPERIMENTAL|Venclexta|"During the consolidation phase, which occurs within 2 months after the completion of consolidation therapy, the BCL-2 inhibitor maintenance treatment will consist of 12 cycles, with each cycle lasting 28 days.~The specific regimen for the Venclexta is as follows:~Venclexta: 400mg/day, orally, from day 1 to day 14 of each cycle."
62285387|NCT03135912|EXPERIMENTAL|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
62285388|NCT03135912|PLACEBO_COMPARATOR|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
62651664|NCT03834350|OTHER|At-Home Breathes Program|Participants will participate in the at-home BREATHES program which will consist of a video education module and using a hand-held spirometry device, SpiroPD.
62651665|NCT01858961|EXPERIMENTAL|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
62651666|NCT01858961|EXPERIMENTAL|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
62086472|NCT01602952|EXPERIMENTAL|Radotinib|"Phase 1 : 200mg/kg or 1200mg/m\^2~Phase 2 : 400mg Bid"
62086473|NCT04864496|ACTIVE_COMPARATOR|Prescribe N-acetylcysteine tablets|
62086474|NCT04864496|PLACEBO_COMPARATOR|Prescribe placebo tablets|
62086475|NCT03790930||thin layer CT|Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm.
62460455|NCT04450043|ACTIVE_COMPARATOR|Control|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
62460456|NCT01449630|EXPERIMENTAL|LY3031207|Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally.
62460457|NCT01449630|PLACEBO_COMPARATOR|Placebo|Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.
62086476|NCT02181894||Orally intubated infants|Subjects will be \<72 hours of age and orally intubated. Following consent, four measures will be reported (i.e. body weight, nasal to tragus length, suprasternal notch to xyphoid process and shoulder to elbow length). Measures will be compared against a chest x-ray and placement of ETT at the subjects lip to identify the most accurate method to place endotracheal tubes in the newborn.
62086477|NCT00591357|ACTIVE_COMPARATOR|A|Loperamide
62460458|NCT01449630|ACTIVE_COMPARATOR|Celecoxib|Single 400mg dose of celecoxib administered orally on one occasion.
62086478|NCT00591357|PLACEBO_COMPARATOR|B|Placebo
62285389|NCT03135912|ACTIVE_COMPARATOR|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
62285390|NCT00074958|EXPERIMENTAL|Fabrazyme|1.0 mg/kg of Fabrazyme given to the patients every 2 weeks
62285391|NCT02652039||cancer patients|
62460459|NCT02522806|EXPERIMENTAL|Group A|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle.
62460460|NCT02522806|NO_INTERVENTION|Group B|none endometrial biopsy
62460461|NCT02770963|EXPERIMENTAL|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~Huatuo Brand needle (0.3\*75 mm) will be used for BL25 and Huatuo Brand needle (0.3\*40mm) will be used for BL23, BL40 and BL57."
62460462|NCT02770963|SHAM_COMPARATOR|Sham acupuncture|The acupoints will be the same as the acupuncture group. Specially designed sham needles (0.3\*25 mm) will be used . The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).
62460463|NCT05339802|EXPERIMENTAL|Cohort 1|9MW1411 injection , single administration, intravenous infusion, infusion time 2H (120 ± 15min);
62460464|NCT05339802|EXPERIMENTAL|Cohort 2|9MW1411 injection , single administration, intravenous infusion, infusion time 2H (120 ± 15min);
62086479|NCT00927381||Severe envenomation|Patients with a calculated severity score of 5 or 6 were included in this group.
62086480|NCT00927381||Minimal/Moderate Envenomation|Severity Score less than 5
62086481|NCT05724524||Profile 2|People living with HIV with immune activation profile 2: inflammatory profile - high level of sTNFRI
62086482|NCT05724524||Other profiles|People living with HIV with immune activation profiles1 + 3-5: T8, NK, T4 and monocyte profiles
62285392|NCT02909894|EXPERIMENTAL|Prolonged Sitting|
62285393|NCT02909894|ACTIVE_COMPARATOR|Light intensity arm ergometry breaks|
62285394|NCT04935983|ACTIVE_COMPARATOR|High CHO|High CHO diet for 36 h
62285395|NCT04935983|EXPERIMENTAL|Low CHO|Low CHO diet for 36 h
62285396|NCT03163420|PLACEBO_COMPARATOR|Placebo|placebo
62285397|NCT03163420|EXPERIMENTAL|Diclofenac potassium|Diclofenac potassium 50 mg
62285398|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
62460465|NCT05339802|PLACEBO_COMPARATOR|Placebo|9MW1411 injection placebo, single administration, intravenous infusion, infusion time: 2h (120 ± 15min)
62460466|NCT04234100|EXPERIMENTAL|Orange juice rich in hesperidin and narirutin|The consumption of the orange juice will be made in a single dose of 500 ml. The juice is presented in a concentrated and frozen format, packed in opaque cans of 500 mL, for which it must be thawed and diluted with mineral water up to 1.5 L before its ingestion.
62651667|NCT06094036|OTHER|weekly physical activity volume performed above 600 MET·minutes/week|Exercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.
62086483|NCT03964025|EXPERIMENTAL|Cardioskin™ and 3-lead Holter recorder|This is single-arm study. All subjects will receive the investigational device (Cardioskin™) and comparator device (3-lead Holter recorder).The subject will be wearing both the Cardioskin™ and 3-lead Holter recorder for a period of 24 hours, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
62086484|NCT00929305|PLACEBO_COMPARATOR|Placebo laser|inactive laser light
62285399|NCT04121845|ACTIVE_COMPARATOR|Treatment group|Coronary sinus reducer implantation through right internal jugular vein.
62285400|NCT04121845|SHAM_COMPARATOR|Sham group|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
62460467|NCT06305416|EXPERIMENTAL|Ranibizumab 10mg/ml Injection (Proposed Ranibizumab Biosimilar)|Test Group of 35 adult patient with DME will get Ranibizumab (Proposed Ranibizumab Biosimilar)
62086485|NCT00929305|ACTIVE_COMPARATOR|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 milliWatt (mW) of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
62285401|NCT03706703|EXPERIMENTAL|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with docetaxel/carboplatin or pemetrexed/carboplatin
62285402|NCT00483886|ACTIVE_COMPARATOR|1|Prucalopride 2 mg
62460468|NCT06305416|ACTIVE_COMPARATOR|Lucentis (Ranibizumab)|Comparator Group of 35 adult patient with DME will get Lucentis
62285403|NCT00483886|PLACEBO_COMPARATOR|3|Placebo
62285404|NCT00483886|ACTIVE_COMPARATOR|2|Prucalopride 4 mg
62285405|NCT04571255|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive a minimum of 3 and a maximum of 6 music therapy sessions (i.e. Music-Assisted Relaxation) during a two weeks time frame.
62285406|NCT04571255|NO_INTERVENTION|Control Group|Treatment as usual.
62460469|NCT03761290||Pseudphypoparathyroidism type 1A (PHP1A)|Case
62651668|NCT06094036|OTHER|weekly physical activity volume performed below 600 MET·minutes/week|Exercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.
62651669|NCT00964782|ACTIVE_COMPARATOR|Sildenafil crossover to placebo|Sildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.
62285407|NCT05398614|EXPERIMENTAL|CD7 CAR-T|SENL101
62285408|NCT03869255||Hospitalized patients|Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
62285409|NCT03869255||Community patients|"People coming to donate blood in Etablissement Français du Sang will be included and a nasal swab will be performed"
62285410|NCT00508391|EXPERIMENTAL|Simultaneous 1st, Optimized 2nd|Lumax HF-T device programmed to simultaneous biventricular pacing first for 30 days, followed by optimized biventricular pacing for 30 days.
62285411|NCT00508391|EXPERIMENTAL|Optimized 1st, Simultaneous 2nd|Lumax HF-T device programmed to optimized biventricular pacing first for 30 days, followed by simultaneous biventricular pacing for 30 days.
62285412|NCT02000947|EXPERIMENTAL|Dose Escalation|MEDI4736 and tremelimumab received by intravenous infusion.
62285413|NCT02000947|EXPERIMENTAL|Arm A|Medi4736 and tremelimumab received by intravenous infusion
62285414|NCT02000947|EXPERIMENTAL|Arm B|MEDI4736 and tremelimumab received by intravenous infusion
62285415|NCT02000947|EXPERIMENTAL|Arm C|MEDI4736 and tremelimumab received by intravenous infursion
62285416|NCT02753010||Acute hip fracture|Women preoperatively with acute hip fracture with gastric emptying of carbohydrate-rich beverage
62285417|NCT02753010||Elective hip replacement|Women on waiting list for elective hip replacement with gastric emptying of carbohydrate-rich beverage
62285418|NCT02753010||Healthy volunteers|Healthy female volunteers with gastric emptying of carbohydrate-rich beverage
62285419|NCT05030727|OTHER|Evaluation of intraoperative NGAL levels in terms of acute kidney injury in geriatric patients|only one group
62285420|NCT03247621|EXPERIMENTAL|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
62285421|NCT03247621|PLACEBO_COMPARATOR|Article|Participants will read a neutral article on their smartphones during the taste test
62285422|NCT03247621|ACTIVE_COMPARATOR|No Phone|Participants will not use their phones during the taste test
62285423|NCT00975247|ACTIVE_COMPARATOR|Received Booklet|Patients who have received colonoscopy preparation booklet
62285424|NCT00975247|NO_INTERVENTION|Did not receive booklet|Patients who did not receive colonoscopy preparation booklet
62285425|NCT06111989||Stroke patients|Patients who suffered ischemic or hemorrhagic stroke.
62285426|NCT00888511|EXPERIMENTAL|1|
62285427|NCT01292278||aSAH|consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
62285428|NCT01292278||control group|no neurological disease but spinal anesthesia
62285429|NCT00382031|ACTIVE_COMPARATOR|zalutumumab|Zalutumumab in combination with Best Supportive Care
62285430|NCT00382031|OTHER|Control|Best Supportive Care
62460470|NCT03761290||Pseudopseudohypoparathyroidism (PPHP)|Case
62460471|NCT03761290||Controls|Matched control group
62460472|NCT03123237|PLACEBO_COMPARATOR|Control|"control will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
62460473|NCT03123237|ACTIVE_COMPARATOR|Diabetic|"diabetic cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
62460474|NCT03123237|ACTIVE_COMPARATOR|Hypertensive|"hypertesive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
62460475|NCT03123237|ACTIVE_COMPARATOR|Diabetic & Hypertensive|"Diabetic \& Hypertensive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
62460476|NCT03985670|EXPERIMENTAL|treatment group|teripalimab 240mg d1 paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1
62086486|NCT02580682|EXPERIMENTAL|Sanfu herbal patch|one kind of acupoint application which used in hot dog days of summer,The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba asarum), Bai Jie Zi (Semen Sinapis Albae), and Rou Gui (Cortex Cinnamomi) at a ratio of 2:2:1:1:2:1.The bilateral Feishu (BL13), Pishu (BL20), Shenshu (BL23), Neiguan (PC6), and Guanyuan (CV4) acupoints were selected for treatment
62285431|NCT06261671|ACTIVE_COMPARATOR|Group 1: antioxidants-enriched culture medium (Gx)|Blastocyst exposed to antioxidants-enriched culture medium (Gx) in continuous culture conditions, without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
62285432|NCT06261671|ACTIVE_COMPARATOR|Group 2: Global total one step media (GT)|Blastocyst exposed to Global total one step media (GT) in continuous culture conditions, without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
62285433|NCT01837693|NO_INTERVENTION|one year follow up|A random sample of HPV positive women with negative cytology will be invited to repeat HPV DNA test and biomarkers after a year, as recommended by the current screening protocols based on HPV DNA
62285434|NCT01837693|EXPERIMENTAL|direct sending in colposcopy|Experimental: immediate colposcopy. A random sample of HPV positive women with negative cytology will be sent to immediate colposcopy
62285435|NCT04901156|EXPERIMENTAL|Multi-modality aphasia therapy plus 1Hz rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
62285436|NCT04901156|SHAM_COMPARATOR|Multi-modality aphasia therapy plus sham rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
62086487|NCT02580682|EXPERIMENTAL|Sanfu moxibustion|use moxibustion in hot dog days of summer,and adopting the indirect moxibustion box method at the bilateral BL13, BL20, and BL23 acupoints
62086488|NCT02580682|EXPERIMENTAL|Sanfu herbal patch and Sanfu moxibustion|use herbal patch and moxibustion together in hot dog days
62285437|NCT03529747|EXPERIMENTAL|Online self-help|A website providing information and psycho-education aimed at parents and carers of children with food allergies.
62285438|NCT03529747|NO_INTERVENTION|Wait list control|A waiting list control group, who will receive access to the online self-help once the RCT is complete.
62086489|NCT02580682|NO_INTERVENTION|controlled|patients in this group will not accept herbal patch or moxibustion therapy in these 3 years. After the 3-year experimental period they will be offered corresponding treatments for free as well, so they are in our wait list.
62285439|NCT05073848||BfitBwell Participants|Individuals in the BfitBwell Cancer Exercise Program complete a FACIT-Fatigue questionnaire at their baseline assessment. This will be screened for all incoming BfitBwell participants and those meeting the inclusion criteria of a score of 48 or less will be approached for interest in participating. The primary research activities beyond recruitment, screening, and informed consent are the collection of EMA fatigue assessments via smartphone application and PA assessment via actigraphy.
62285440|NCT06062446|EXPERIMENTAL|Modified Lumbar Puncture|
62285441|NCT00590421||1|145 individuals treated by irradiation in their childhood
62285442|NCT00590421||2|150 matched control subjects with no history of irradiation
62285443|NCT05523700|EXPERIMENTAL|Interventional Arm|Use of Mobile Application
62285444|NCT05523700|NO_INTERVENTION|Control Arm|Routine care and symptom management
62086490|NCT02236923||Group A: Single procedure|Group A consists of patients recorded as having only had an ascending aortic dissection repair procedure.
62285445|NCT03749395|ACTIVE_COMPARATOR|Erector Spinae Plane Block group|"* The Erector Spinae Plane block will be done as follow,the patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.~* All patients will receive general anesthesia as described in conventional group"
62285446|NCT03749395|NO_INTERVENTION|Conventional group|"* Nothing will be injected~* All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCo2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC), 0.5μg/kg fentanyl will be given intraoperative when either heart rate or Non Invasive Blood Pressure report an increase by more than 20% of the basal records. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria."
62651670|NCT00964782|PLACEBO_COMPARATOR|Placebo crossover to sidenafil|Patient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.
62285447|NCT02266108|EXPERIMENTAL|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
62086491|NCT02236923||Group B: Multiple procedures|Group B consists of patients who had an ascending aortic dissection repair procedure together with any other surgical intervention.
62285448|NCT02266108|OTHER|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
62285449|NCT05285137|EXPERIMENTAL|Cohort 1A (sentinel)|Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
62285450|NCT05285137|EXPERIMENTAL|Cohort 1A (main)|Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
62285451|NCT05285137|EXPERIMENTAL|Cohort 1B (sentinel)|Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
62285452|NCT05285137|EXPERIMENTAL|Cohort 1B (main)|Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
62285453|NCT05285137|EXPERIMENTAL|Cohort 2A (sentinel)|Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62285454|NCT05285137|EXPERIMENTAL|Cohort 2A (main)|Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62460477|NCT03985670|ACTIVE_COMPARATOR|chemotherapy followed by immunotherapy|paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1 teripalimab 240mg d3
62653126|NCT05869474|EXPERIMENTAL|I125-AG|Participants will receive the implantation of radioactive seeds under EUS guide. 48h after implantation, chemotherapy with Gemcitabine 1000mg/m2 plus albumin paclitaxel 125mg/m2 given on days 1 and 8 of each 21-day cycle will be conducted.
62086492|NCT03870087||Robotic PCI|All subjects treated with CorPath GRX during the PCI procedure.
62086493|NCT00862511|EXPERIMENTAL|Coated Total Knee Arthroplasty|allergy coated TKA
62086494|NCT00862511|ACTIVE_COMPARATOR|Standard Total Knee Arthroplasty|normal TKA
62086495|NCT03584685|EXPERIMENTAL|With Mask|Use of the surgical mask in one routine wound treatment appointment.
62086496|NCT03584685|ACTIVE_COMPARATOR|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
62086497|NCT03432039|PLACEBO_COMPARATOR|Psychoeducation arm|This arm will provide information about admission procedures, story telling and a follow-up phone call
62086498|NCT03432039|EXPERIMENTAL|Behavioral intervention|This arm will provide information about what invasive procedures maybe given to the child, the emotional and behavioral reactions of the child while on the ward, games and stories that the child can engage with the mother and a follow-up phone call
62086499|NCT02322775|EXPERIMENTAL|Arm A|Benralizumab administered subcutaneously every 4 weeks
62086500|NCT02322775|EXPERIMENTAL|Arm B|Placebo administered subcutaneously every 4 weeks
62086501|NCT01680120|EXPERIMENTAL|Continuous spinal anaesthesia|
62086502|NCT02460900|ACTIVE_COMPARATOR|Varenicline and Standard of Care|Participants will receive varenicline and standard of care
62086503|NCT02460900|PLACEBO_COMPARATOR|Placebo and Standard of Care|Participants will receive placebo and standard of care
62651671|NCT05475639|EXPERIMENTAL|"axillary diclophenac phonophoresis ( diclophen gel voltaren gel)"|the subject in the axillary diclophenac phonophoresis group will receive axillary diclophenac phonophoresis using ultrasound 1 MHz to increases the absorbtion. Diclofenac phonophoresis will be applied beside conventional therapy program ,Apply the diclophen gel (voltaren gel) on the head of the US in the axillary pouch of the capsule at 1.5 W\\cm2 for 10 minutes as pulsed U.S. the group will be treated for 4weeks, 3 sessions per week and all patients will be assessed pre and post intervention.
62086504|NCT02460900|ACTIVE_COMPARATOR|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
62086505|NCT02460900|ACTIVE_COMPARATOR|Positively Smoke Free and Varenicline|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
62086506|NCT04858789|EXPERIMENTAL|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|The experimental group will receive an 8-session CA-CBI in an online group format.
62086507|NCT04858789|NO_INTERVENTION|Control|The control (care as usual) group will receive the information about freely available psychological support options. After all the measurements are completed, the control group will be able to receive CA-CBI, too.
62086508|NCT05188079|ACTIVE_COMPARATOR|Beetroot Juice|140 ml of beetroot juice (high nitrate dietary supplement)
62086509|NCT05188079|PLACEBO_COMPARATOR|Placebo|Placebo drink looks and tastes like the beetroot juice but has the nitrate removed from the juice.
62086510|NCT04650347|EXPERIMENTAL|internal urethrotomy using Holmium laser representing group|In group 1, a three hundred micron laser fiber was used to conduct the laser energy. holmium laser pulse energy of approximately 1 joule was used that was generated from a Holmium laser Quanta device and total power of 15 watts. the laser fiber was aimed directly to the midline at 12 o'clock position to start the procedure and cut the fibrous tissue till access to a wide lumen.
62285455|NCT05285137|EXPERIMENTAL|Cohort 2B (sentinel)|Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62285456|NCT05285137|EXPERIMENTAL|Cohort 2B (main)|Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62285457|NCT05285137|EXPERIMENTAL|Cohort 3A (sentinel)|High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62460478|NCT01295853|ACTIVE_COMPARATOR|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
62086511|NCT04650347|ACTIVE_COMPARATOR|internal urethrotomy with Sachs cold knife|In group B, Sache cold knife internal urethrotomy was used with the same technique as Holmium laser internal urethrotomy at the same site to mechanically cut instead of the laser fiber.
62653127|NCT05869474|ACTIVE_COMPARATOR|AG|Participants receive chemotherapy alone. Gemcitabine 1000mg/m2 plus albumin paclitaxel 125mg/m2 given on days 1 and 8 of each 21-day cycle.
62086512|NCT02999971|EXPERIMENTAL|circuit class therapy in water|CCT on water. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
62086513|NCT02999971|EXPERIMENTAL|circuit class therapy on land|CCT on land. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
62653128|NCT01870596|EXPERIMENTAL|Arm A (cytarabine, Chk1 inhibitor SCH 900776)|Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
62086514|NCT02662361||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
62086515|NCT02662361||peri-implant disease|The subjects who suffered from peri-implant disease.
62086516|NCT00971516|ACTIVE_COMPARATOR|Diabetes|compare cytokines between diabetes and non diabetes patients
62086517|NCT00971516|ACTIVE_COMPARATOR|Implants|Compare implant healing phases
62086518|NCT00831246|EXPERIMENTAL|1|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
62086519|NCT00831246|SHAM_COMPARATOR|2|Patients are given standard post-op care with clear liquid diet as tolerated .
62086520|NCT06148714|EXPERIMENTAL|Provitalize Probiotic|Participants will take 2 capsules every morning on an empty stomach before their first meal of the day.
62086521|NCT06148714|PLACEBO_COMPARATOR|Placebo|Participants will take 2 capsules every morning on an empty stomach before their first meal of the day.
62086522|NCT03379233|ACTIVE_COMPARATOR|Usual Care|Concept2 inhaler
62086523|NCT03379233|EXPERIMENTAL|Telehealth|Concept2 inhaler with patient application
62086524|NCT00749619|EXPERIMENTAL|A|
62086525|NCT00749619|EXPERIMENTAL|B|
62086526|NCT00749619|NO_INTERVENTION|C|
62086527|NCT01235325|PLACEBO_COMPARATOR|Placebo oil capsule|Banner Pharmacaps Europe
62460479|NCT01295853|ACTIVE_COMPARATOR|t4 sypathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
62086528|NCT01235325|EXPERIMENTAL|phylloquinone (1000 mcg)|Banner Pharmacaps Europe
62086529|NCT02346487|EXPERIMENTAL|LPV/RTV pellets and AZT/3TC or ABC/3TC|Only 1 arm. No comparator
62086530|NCT01184768||participants in the 6th tromsø study|
62086531|NCT06429371||Individuals with Shoulder Pain|Individuals with shoulder pain that is at least 3/10 within the past 24 hours.
62086532|NCT01052662|EXPERIMENTAL|Memantine 30mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
62086533|NCT01052662|EXPERIMENTAL|Memantine 15mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
62086534|NCT01052662|PLACEBO_COMPARATOR|Memantine 0mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Matching placebo capsule was started on week 2. The placebo capsules were given on a twice a day schedule until week 12 and then discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
62651672|NCT05475639|EXPERIMENTAL|Post isometric Facilitation Techniques.|the subject in the Post isometric Facilitation Techniques group will be treated by applying isometric contraction followed by isometric relaxation followed by stretching to the target muscle .when performing isometric facilitation with the shoulder in flexion , the patient was seated with his\\her back supported and the therapist standing facing the patient's painful shoulder .the patient's shoulder joint was flexed to the maximum available range with the elbow completely flexed .the patient performed isometric contraction of the shoulder extensors against maximum resistance provided by the therapist .this contraction will last for 10 seconds followed by relaxation for 5 seconds .this contraction will allow the shortened shoulder extensors to relax and permit easier stretching.the group will be treated for 4weeks, 3 sessions per week and all patients will be assessed pre and post intervention.
62651673|NCT05475639|ACTIVE_COMPARATOR|traditional physiotherapy (infrared, supervised exercise program, home exercise program)|"The traditional physical therapy program, which includes Infrared (IR) lambs apply heat to deep joints such as shoulder joint. Avoid deltoid muscle; apply over thin, bony areas for maximum penetration.~supervised exercise program are self-exercise included: 1-Codmans or pendulum exercise (circumduction): It should be done 5 times daily in 5 to 10 minute sessions Passive stretching exercise (for shoulder extensors, abductors, and internal rotator) home exercise program includes the same exercise as in supervised exercise program. The participant will instruct to perform exercises1-2 times/day within pain -free ROM.~the group will be 4weeks, 3 sessions per week and all patients will be assessed pre and post intervention."
62086535|NCT03739385|EXPERIMENTAL|Intergenerational Group|Pre-school children and residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
62086536|NCT03739385|ACTIVE_COMPARATOR|Peer Group Children|Pre-school children will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
62285458|NCT05285137|EXPERIMENTAL|Cohort 3A (main)|High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62460480|NCT02507427|EXPERIMENTAL|Nerve monitoring arm|They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.
62460481|NCT05045118|EXPERIMENTAL|Intervention arm|Single-arm prospective, multiple assessment intervention study. Participants will receive a digital structured patient education material
62651674|NCT05222867|EXPERIMENTAL|Intervention|pregnant women undergoing lower back massage
62651675|NCT05222867|NO_INTERVENTION|control group|pregnant women given routine care
62086537|NCT03739385|ACTIVE_COMPARATOR|Peer Group Seniors|Residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
62653129|NCT01870596|ACTIVE_COMPARATOR|Arm B (cytarabine)|Patients receive cytarabine as in Arm A.
62086538|NCT03739385|NO_INTERVENTION|Control Group Children|Pre-School children will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
62086539|NCT03739385|NO_INTERVENTION|Control Group Seniors|Residential seniors will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
62086540|NCT06242496||Patients with brain abscesses after transplantation|
62086541|NCT02297503|EXPERIMENTAL|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
62086542|NCT02297503|EXPERIMENTAL|Filler alone as single treatment|HA filler alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
62460482|NCT00868010|EXPERIMENTAL|1: donepezil|Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
62651676|NCT05655871|EXPERIMENTAL|Enterprise Group|"Elderly individuals were divided into 5 groups according to the stages of change in the TTM scale. According to the change phase, those in the non-thinking phase are at 10:00 on Mondays, Wednesdays and Fridays, those in the thinking phase are at 13:00 on Mondays, Wednesdays and Fridays, and those in the preparatory phase are at 15:00 on Mondays, Wednesdays and Fridays of the week. They were asked to come to the seminar hall at 00:00. It was explained that a training video about physical activity would be watched. Those in the preparation phase were asked to come to the activity hall at 10:00 on Tuesdays, Thursdays and Saturdays of the week, and at 14:00 on Tuesdays, Thursdays and Saturdays of the week, while wearing their comfortable clothes. It was said that a training and motivational video about physical activity would be watched and the exercises would be done under the supervision of the researcher with the show-and-make technique."
62651677|NCT05655871|EXPERIMENTAL|Control Group|"Data collection forms were applied to the control group in the pre-test. These forms are; Personal Information Form, Tinetti Balance and Gait Test, Exercise Change Stages Scale, Exercise Change Process Scale, Exercise Decision-Making Scale, Exercise Self-Efficacy Scale. In order to avoid an ethical dilemma between the individuals in the control and intervention groups, the videos will be watched by the individuals in the control group at the end of the study."
62651678|NCT01211171||Group 1|
62651679|NCT01726166|ACTIVE_COMPARATOR|Suprapubic Aspiration|A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
62460483|NCT00868010|PLACEBO_COMPARATOR|2. placebo|Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
62460484|NCT05020925|EXPERIMENTAL|SHR-1701 plus Famitinib|SHR-1701+Famitinib for R/M NPC failure after platinum-based chemotherapy and anti PD-1/PD-L1 antibody therapy
62285459|NCT05285137|EXPERIMENTAL|Cohort 3B (sentinel)|High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62285460|NCT05285137|EXPERIMENTAL|Cohort 3B (main)|High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
62460485|NCT02321384|EXPERIMENTAL|A: SAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 6 planned SAD cohorts to receive single dose of RO6889678/matching placebo in fasted state as per anticipated dose escalation sequence (30 milligrams \[mg\], 100 mg, 300 mg, 600 mg, 1000 mg and 1500 mg). Cohort 1 will be split in 2 groups: 2 participants will be dosed 1 day (1 on RO6889678 and 1 on matching placebo) and 3 participants (2 on RO6889678 and 1 on matching placebo) will be dosed at least 24 hours afterward following satisfactory safety assessment for first 2 participants. Cohort 2 \& beyond will include 8 healthy participants with 6 participants randomly assigned to RO6889678 \& 2 randomly assigned to placebo. Participants who will tolerate fasted dose and agree to continue in food-effect SAD cohort, will receive single dose (dose level, either 300 mg or 600 mg, decided based on PK and safety data of first 2 SAD cohorts) of RO6889678/matching placebo with US FDA recommended high-fat and high-calorie breakfast on Day 16.
62460486|NCT02321384|EXPERIMENTAL|B: MAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 4 planned MAD cohorts to receive RO6889678 or matching placebo (at a dose that will be decided as per the safety, tolerability and PK data from SAD 4 cohort) twice daily (BID) for 14 days except for Day 14, where only one dose in the morning will be given. Each of the MAD cohorts will include 8 healthy participants with 6 participants randomly assigned to RO6889678 and 2 participants randomly assigned to placebo. All participants enrolled to the MAD cohorts will receive an oral microdose of midazolam (100 micrograms \[mcg\]) before (Day -1) and after (Day 14) the repeat treatment with RO6889678 or matching placebo.
62460487|NCT02321384|EXPERIMENTAL|C:RTV-Boosted SAD & MAD Cohorts-RO6889678/Matching Placebo+RTV|Healthy participants will be enrolled in up to 3 SAD cohorts (2 compulsory and 1 optional) and up to 3 MAD cohorts (1 compulsory and 2 optional) to receive RO6889678 in combination with RTV in fed state. Participants of the first 2 RTV-boosted SAD cohorts will receive 100 mg RO6889678 + 100 mg RTV and 300 mg RO6889678 + 100 mg RTV respectively. Based on the PK and safety evaluation of the first 2 RTV-boosted SAD cohorts, another SAD cohort may be enrolled to receive a different dose of RO6889678 in combination with RTV. MAD RTV-boosted cohort will start based on the safety, tolerability and PK data of the RTV-boosted SAD cohorts. All participants enrolled to the RTV-boosted MAD cohorts will receive RO6889678 or placebo together with RTV on BID schedule for 14 days, and additionally an oral microdose of midazolam (100 mcg) before (Day -1) and after (Day 14) the treatment.
62460488|NCT03931876|PLACEBO_COMPARATOR|Placebo|placebo
62460489|NCT03931876|ACTIVE_COMPARATOR|Active|AV-006
62460490|NCT04659421|EXPERIMENTAL|Low-grade gliomas|Treated with Recombinant human endostatin, Carboplatin, and Vincristine
62460491|NCT00330447||Studygroup|Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy
62460492|NCT00330447||Control group|Children from the general population
62285461|NCT05285137|EXPERIMENTAL|Cohort 4B (sentinel)|Highest dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection
62285462|NCT05285137|EXPERIMENTAL|Cohort 4B (main)|Highest dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection
62285463|NCT05643079||metal/Bio-Tenodesis group|"medializing calcaneal osteotomy, debridement of the tibialis posterior tendon, and/or transfer of the flexor digitorum longus (FDL) tendon with the following screws:~Metal-/Bio-Tenodesis screw (Arthrex, Naples, Florida, USA)~Metal-Screw:~ø 6,7 mm length: 40-60 mm~Bio-Tenodesis screw:~ø 4,00 mm, length: 10 mm ø 4,75 mm, length: 15 mm ø 5,50 mm, length: 15 mm"
62086543|NCT04719013|EXPERIMENTAL|treatment|Treatment areas include face, under chin (submental)
62460493|NCT01257009|OTHER|1|Arm 1: cessation of any statin therapy for at least 6 weeks, then the first sympathetic activity measurement will be done.Subsequently, atorvastatin 20mg is added for 6 weeks. Then the second sympathetic measurement will be performed.
62460494|NCT01257009|OTHER|2|Patients will receive atorvastatin for 6 weeks, then the first sympathetic measurement will be done. Then atorvastatin will be stopped and 6 weeks the second measurement will be done
62285464|NCT05643079||human, allogeneic cortical bone screw (Shark Screw®)|"medializing calcaneal osteotomy, debridement of the tibialis posterior tendon, and/or transfer of the flexor digitorum longus (FDL) tendon with the following screws:~Shark Screw® (Surgebright-GmbH, 4040 Lichtenberg, Austria)~Versions used:~Shark Screw® diver ø: 5,0 mm, length: 35 mm Shark Screw® diver ø: 5,0 mm, length: 45 mm Shark Screw® tendon ø: 5,0 mm, length: 15 mm"
62285465|NCT00849667|ACTIVE_COMPARATOR|Farletuzumab (1.25 mg/kg)|Participants will receive farletuzumab 1.25 milligram per kilogram (mg/kg) administer as an intravenous (IV) infusion weekly, followed by taxane (paclitaxel \[175 milligram per meter square {mg/m\^2}\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain area under curve \[AUC\] 5-6 milligram per milliliter per minute \[mg/mL/minute\]), administer as IV infusion, every three weeks, on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 1.25 mg/kg, administer as IV infusion, weekly is given until disease progression.
62285466|NCT00849667|ACTIVE_COMPARATOR|Farletuzumab (2.5 mg/kg)|Participants will receive farletuzumab 2.5 mg/kg administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 2.5 mg/kg, administer as IV infusion, weekly is given until disease progression.
62460495|NCT00552669|EXPERIMENTAL|A--Oral Rapamycin plus BMS|Oral sirolimus plus bare metal stent implantation
62460496|NCT00552669|ACTIVE_COMPARATOR|B -- Drug Eluting Stent|Drug Eluting Stents
62460497|NCT04109222|EXPERIMENTAL|Group 1: Fluzone Quadrivalent Influenza vaccine: 6 to < 36 Months|Participants aged 6 to \<36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
62460498|NCT04109222|EXPERIMENTAL|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to < 9 years|Participants aged 3 to 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
62460499|NCT04109222|EXPERIMENTAL|Group 3: Fluzone High-Dose Influenza Vaccine: >= 65 years|Participants aged \>=65 years received a of 0.5-mL dose of Fluzone high-dose vaccine, intramuscularly, at Day 0.
62460500|NCT01121276|EXPERIMENTAL|NN1218, formulation A|
62460501|NCT01121276|EXPERIMENTAL|NN1218, formulation B|
62460502|NCT01121276|EXPERIMENTAL|NN1218, formulation C|
62651680|NCT01726166|ACTIVE_COMPARATOR|Urinary Catheterization|"The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat)."
62651681|NCT02742207||Observational|All comers with Atrial fibrillation
62651682|NCT00276302|EXPERIMENTAL|1|Schedule A: Doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration.
62651683|NCT00276302|EXPERIMENTAL|2|Schedule B: Doses occur on Days 1, 4, 8, 11, 15, and 18 (twice weekly for 3 weeks continuously).
62460503|NCT01121276|EXPERIMENTAL|NN1218, formulation D|
62460504|NCT01121276|ACTIVE_COMPARATOR|insulin aspart|
62460505|NCT02702817|ACTIVE_COMPARATOR|naproxen|naproxen sodium tablets 220 mg twice daily for two years
62460506|NCT02702817|PLACEBO_COMPARATOR|placebo|tablets identical in appearance to naproxen tablets twice daily for two years
62460507|NCT04892511|NO_INTERVENTION|Standard treatment|"Post-thrombectomy patients will have their blood pressure measured every hour for the first 24 hours after thrombectomy, and every 6 hours from 24 to 72 hours. The target blood pressure is not predefined by the study, but in patients who have received previous treatment with rt-PA, it is advisable to keep it below 180/110 mmHg. If the patient has not received rt-PA, there is no limitation, although the guidelines recommend keeping the pressure below 200/120 mmHg.~The hypotensive or hypertensive treatments used will be noted."
62651684|NCT00581191|EXPERIMENTAL|1|0.5 mg SLV-351 (fasted)
62651685|NCT00581191|EXPERIMENTAL|2|1 mg SLV-351 (fasted)
62651686|NCT00581191|EXPERIMENTAL|3|2.5 mg SLV-351 (fasted)
62651687|NCT00581191|EXPERIMENTAL|4|5 mg SLV-351 (fasted)
62651688|NCT00581191|EXPERIMENTAL|5|10 mg SLV-351 (fasted)
62651689|NCT00581191|EXPERIMENTAL|6|15 mg SLV-351 (fasted)
62651690|NCT00581191|EXPERIMENTAL|7|20 mg SLV-351 (fasted)
62460508|NCT04892511|EXPERIMENTAL|Optimized hemodynamic treatment|"Post-thrombectomy patients will have their blood pressure measured every 30 minutes for the first 24 hours after thrombectomy, and every 1 hour from 24 to 72 hours. Blood pressure objectives will depend on the degree of recanalization achieved after thrombectomy (see intervention section).~The hypotensive or hypertensive treatments used will be noted."
62651691|NCT00581191|EXPERIMENTAL|8|30 mg SLV-351 (fasted)
62651692|NCT00581191|EXPERIMENTAL|9|xx mg SLV-351 (fasted and fed)
62285467|NCT00849667|PLACEBO_COMPARATOR|Placebo|Participants will receive farletuzumab-matched placebo (0.9 percent \[%\] saline) administer as an IV infusion weekly, followed by taxane (paclitaxel \[175 mg/m\^2\] or docetaxel \[75 mg/m\^2\]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab-matched placebo (0.9% saline), administer as IV infusion, weekly is given until disease progression.
62285468|NCT02229734|EXPERIMENTAL|Radiation plus Androgen Supression|Radiation plus Androgen Suppression give as stereotactic radiation 7gray (Gy) per week x 5 weeks and leuprolide 45mg every 6 months for 18 months
62285469|NCT03412409|EXPERIMENTAL|RIC regimen|"Old patients or those have high comorbidity burden without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
62285470|NCT00787787|EXPERIMENTAL|Treatment (sunitinib malate and capecitabine)|Patients receive sunitinib malate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence or disease progression or unacceptable toxicity.
62285471|NCT05136963|EXPERIMENTAL|volunteers|"48 volunteers will be included according to the following demographic characteristics (corresponding to the demographic profile of kidney donors according to the national data of the Biomedicine Agency):~* aged between 20 and 35 years old: 4 women, 3 men~* aged between 35 and 50 years old: 7 women, 5 men~* aged between 50 and 65: 11 women, 8 men~* \> 65 years old: 6 women, 4 men"
62285472|NCT04999189|EXPERIMENTAL|Patients using mobile applications|Patients diagnosed with type 2 diabetes will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
62285473|NCT04999189|NO_INTERVENTION|Control group|Patients will receive treatment from medical staff (as usual).
62285474|NCT02469571|ACTIVE_COMPARATOR|Probiotic|5 g of Winclove-607 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24 at a concentration of 1.1 x 109 cfu/g twice daily for the 4 weeks
62285475|NCT02469571|PLACEBO_COMPARATOR|Placebo|a similar looking and tasting placebo without bacteria once daily for 4 weeks
62285476|NCT00851604||1|Patients with malignant neuroendocrine tumors
62285477|NCT02393391|ACTIVE_COMPARATOR|NIBS tDCS/tACS stimulation|Each patient will undergo initial diagnosis with NIBS algorithm utilizing EEG measurements combined with TMS. Initial diagnosis will last 10 minutes in which EEG measurement will be recorded 5 minutes and then in combination with TMS for another 5 minutes with no more than 500 TMS stimuli applied to cortex at low frequency of up to 5Hz. EEG recording will be analyzed by NIBS algorithm which will propose a course of treatment with the following limitations: stimulation of 2mA (32, 33) current after 30 seconds ramp up of 0.1mA increments, 20 min for each session, twice a week
62460509|NCT01194492|OTHER|Albumin kinetics|
62651693|NCT05598736|EXPERIMENTAL|Investigational device|FlowOx 2.0 (-40mmHg intermittent negative pressure)
62651694|NCT02977351|EXPERIMENTAL|Atherosclerosis|Patients with atherosclerosis and chronic periodontitis
62651695|NCT02977351|ACTIVE_COMPARATOR|Systemically healthy|Patients with Systemically healthy and chronic periodontitis.
62651696|NCT01131936|EXPERIMENTAL|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
62651697|NCT01131936|ACTIVE_COMPARATOR|Norvasc Tablets, 10 mg|
62651698|NCT04330872|ACTIVE_COMPARATOR|Enteric coated Aspirin|"EC aspirin loading dose 300mg followed by 100 mg (2 days).~The study's total duration is 3 days."
62086544|NCT04289987|EXPERIMENTAL|CVI-HBV-002|"* CVI-HBV-002 1.0mL(20ug/dose)~* Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
62651699|NCT04330872|PLACEBO_COMPARATOR|Plain Aspirin|"Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days)~The study's total duration is 3 days."
62086545|NCT04289987|PLACEBO_COMPARATOR|Normal Saline|"* Normal Saline Choonwae Inj. 1.0 mL~* Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
62086546|NCT01177345||Terminal Disease|Terminal cervical cancer- not treatable
62086547|NCT01177345||Early Disease|Early cervical cancer = meaning treatable with hysterectomy.
62086548|NCT01177345||Advanced Disease|Advanced cervical cancer- treatable with chemotherapy and/or radiation.
62086549|NCT04305236|EXPERIMENTAL|Abemaciclib and Fulvestrant|Abemaciclib will be administered orally at the dose of 150 mg twice daily. Fulvestrant will be administered intramuscularly at an initial loading dose of 500mg on days 1 and 15 of the first cycle and then 500 mg intramuscularly every first day of each subsequent cycle. One cycle is 28 days.
62651700|NCT02422758|EXPERIMENTAL|Active Prewarming 3M™ BairHugger™Blanket|Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative \& Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
62651701|NCT02422758|PLACEBO_COMPARATOR|Passive Prewarming|Passive prewarming with a cotton sheet and blanket for 20 minutes. Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
62651702|NCT03754920|EXPERIMENTAL|prolonged fasting|Participants fast for five days, without any food, except unlimited mineral water, and do some fitness regimen(such as meditation and mild physical exercise ).
62086550|NCT02662595|NO_INTERVENTION|Control|
62086551|NCT02662595|ACTIVE_COMPARATOR|Text message|Subjects in this arm will receive a text message reminder in due time for measles vaccination.
62086552|NCT02662595|ACTIVE_COMPARATOR|Text message and voice call|Subjects in this arm will receive a voice call in addition to a text message reminder in due time for measles vaccination.
62086553|NCT02162693|EXPERIMENTAL|Mesenchymal progenitor cells|Administrated for intra-articular use of Mesenchymal progenitor cells
62086554|NCT02162693|ACTIVE_COMPARATOR|Sodium Hyaluronate|Administrated for intra-articular use of Sodium Hyaluronate.
62086555|NCT02395705|EXPERIMENTAL|Neo-adjuvant chemotherapy group|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~1. Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~2. Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~3. Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy~1. Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~2. Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
62285478|NCT02393391|PLACEBO_COMPARATOR|inactive electrodes|diagnosis and monitoring will be performed as in active treatment, but during treatment anodal/cathodal/alternate stimulation will begin and automatically stop after 30 seconds leaving subject with an inactive electrodes in place for the remainder of treatment duration
62285479|NCT05191160|ACTIVE_COMPARATOR|2% Soy Milk|Participants will be asked to substitute their regular sugar sweetened beverage with the 2% soy milk (up to a maximum of 6 servings/day)
62651703|NCT05347628|EXPERIMENTAL|PLB1004|PLB1004 given alone as monotherapy.
62651704|NCT02598674||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
62285480|NCT05191160|ACTIVE_COMPARATOR|2% Cow's Milk|Participants will be asked to substitute their regular sugar sweetened beverage with the 2% cow's milk (up to a maximum of 6 servings/day)
62285481|NCT05191160|ACTIVE_COMPARATOR|Usual Sugar Sweetened Beverage|Participants will be asked to continue drinking their regular sugar sweetened beverage
62285482|NCT06388902|EXPERIMENTAL|BR115|
62651705|NCT02598674||Control|This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
62651706|NCT04641806||Lymphoma cases|Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. Past history of B-cell NHL in remission, active surveillance or during first-line or second-line treatment Affiliated with a social security, consenting to the study
62651707|NCT04641806||Controls|"Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. No past history of lymphoma .~Affiliated with a social security, consenting to the study"
62651708|NCT05644496|EXPERIMENTAL|Intervention|In addition to the standard-of-care arm description, single administration of Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release in the surgical site before complete wound closure.
62086556|NCT02395705|NO_INTERVENTION|Surgery alone group|"Surgery:~2-3weeks after Neo-adjuvant chemotherapy~1. Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~2. Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
62086557|NCT02412761|ACTIVE_COMPARATOR|Amlodipine, then HCTZ, then Lisinopril|Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
62285483|NCT05236998|EXPERIMENTAL|Sequence A|Period 1: Dapagliflozin and Sitagliptin / Period 2: SID1903 (FDC)
62285484|NCT05236998|EXPERIMENTAL|Sequence B|Period 1: SID1903 (FDC) / Period 2: Dapagliflozin and Sitagliptin
62285485|NCT06158503||AID initiation|"The participants will be selected on the basis that they are planning to start using one of the commercially available AID.~They will start treatment after the initial measurements (baseline), then repeat the measurements at 2 and 4 months post-AID."
62651709|NCT05644496|NO_INTERVENTION|Standard-of-care|Usual standard of care procedure for knee replacement and pain management before, during and immediately following surgery.
62086558|NCT02412761|ACTIVE_COMPARATOR|Amlodipine, then Lisinopril, then HCTZ|Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
62086559|NCT02412761|ACTIVE_COMPARATOR|HCTZ, then Amlodipine, then Lisinopril|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
62086560|NCT02412761|ACTIVE_COMPARATOR|HCTZ, then Lisinopril, then Amlodipine|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
62086561|NCT02412761|ACTIVE_COMPARATOR|Lisinopril, then Amlodipine, then HCTZ|Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
62086562|NCT02412761|ACTIVE_COMPARATOR|Lisinopril, then HCTZ, then Amlodipine|Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
62086563|NCT03750773|ACTIVE_COMPARATOR|Subjects receiving gabapentin drug|Administration of Gabapentin 600mg orally every 8 hours. Women will receive gabapentin for a total of 48 hours after cesarean
62086564|NCT03750773|PLACEBO_COMPARATOR|Subjects receiving placebo oral capsule|Administration of identical placebo capsule orally every 8 hours. Women will receive placebo for 48 hours after cesarean
62285486|NCT06307704|EXPERIMENTAL|US - PEEP group|Lung Ultrasound - guided Positive End Expiratory Pressure group
62285487|NCT06307704|ACTIVE_COMPARATOR|Standard group|Standard Ventilation group
62460510|NCT01613911||Epileptics having invasive monitoring|People between 10 and 65 years of age with epilepsy and who are coming in to have invasive electrophysiological monitoring.
62460511|NCT03830125|EXPERIMENTAL|Single Ascending Doses|
62651710|NCT00761098|ACTIVE_COMPARATOR|1|Standard Care (albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
62651711|NCT00761098|EXPERIMENTAL|2|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
62086565|NCT01140659|OTHER|Objective measurement of sweat|"We selected 40 patients from February 2007 to May 2009. All participants were randomized into two groups of 20 patients (G3 and G4) and underwent the sympathectomy, being followed for 12 months. We used an objective method for measuring sweat, checking the TEWL (transepidermal water loss) measured by the VapoMeter, and evaluated the quality of life before and after the operation. Also studied were: incidence and intensity of the compensatory hyperhidrosis."
62086566|NCT05315219|EXPERIMENTAL|Endoscopic Thyroidectomy Bilateral Areola Approach|
62086567|NCT05315219|NO_INTERVENTION|Open Thyroidectomy|
62086568|NCT01676220|EXPERIMENTAL|HOE901-U300|
62086569|NCT01676220|ACTIVE_COMPARATOR|Lantus|
62285488|NCT03118440|EXPERIMENTAL|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
62460512|NCT03830125|EXPERIMENTAL|Multiple Ascending Doses|
62651712|NCT03798314|EXPERIMENTAL|Treatment (nivolumab and pomalidomide)|Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
62651713|NCT04061785|ACTIVE_COMPARATOR|Participants in 12 week Judo Inspired Exercise program|"The subjects will participate in a 12 week judo inspired training program (45 minute sessions once a week) with the specific aim to increase physical qualities related to falls and injuries during falls.~The subjects will be tested before and after the 12 week period"
62086570|NCT03252678|EXPERIMENTAL|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
62086571|NCT03252678|ACTIVE_COMPARATOR|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
62086572|NCT05215262|EXPERIMENTAL|T.A.K.E. Steps Motivational Interviewing Intervention|Four MI intervention sessions, 1:1 with participant and health coach.
62086573|NCT05215262|ACTIVE_COMPARATOR|Standard of Care|Standard of Care control visit with primary care physician (PCP)
62086574|NCT05942404|NO_INTERVENTION|Group of no bowel preparation|none mechanical bowel preparation
62086575|NCT05942404|ACTIVE_COMPARATOR|Group of bowel preparation|mechanical bowel preparation
62086576|NCT05441475|EXPERIMENTAL|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w.|During part a, all subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w). After the first subject (sentinel subject) in each dose cohort completed the first combined medication, follow-up subjects were administered at least 7 days later
62086577|NCT01476579|OTHER|Non-invasive CT coronary angiography|This study is evaluating diagnostic accuracy of non-invasive CT coronary angiography with invasive coronary angiography.
62086578|NCT03018106|EXPERIMENTAL|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
62086579|NCT03018106|ACTIVE_COMPARATOR|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
62086580|NCT05683041|EXPERIMENTAL|intrauterine gel application|Application of Hyalobarrier intrauterine after myomectomy.
62086581|NCT05683041|NO_INTERVENTION|no intra-uterine gel application|No application of Halobarrier intrauterine after myomectomy.
62086582|NCT02967211|EXPERIMENTAL|Toujeo|Toujeo will be administered once daily in addition to non-insulin antidiabetic agents
62086583|NCT02967211|ACTIVE_COMPARATOR|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents
62086584|NCT02628847|EXPERIMENTAL|Drug|Sildenafil citrate 25mg once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
62086585|NCT02628847|PLACEBO_COMPARATOR|control|placebo capsule once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
62086586|NCT06380595||Infective Native Abdominal Aortic Aneurysms (INAA)|"Infective native aortic aneurysms (INAA) are rare but highly morbid conditions that pose unique diagnostic and therapeutic challenges to the vascular surgeon.~Patients with confirmed NAA who were treated with complex endovascular techniques at participating centers will be included in the registry."
62086587|NCT06380595||Inflammatory aortic aneurysms (IAA)|"Inflammatory aortic aneurysms (IAA) are rare but highly morbid conditions that pose unique diagnostic and therapeutic challenges to the vascular surgeon.~Patients with confirmed IAA who were treated with complex endovascular techniques at participating centers will be included in the registry."
62086588|NCT01607411|PLACEBO_COMPARATOR|Fluoride free toothpaste|toothpaste with no fluoride
62086589|NCT01607411|EXPERIMENTAL|1426ppm Fluoride Toothpaste|Experimental toothpaste containing 1426 ppm Fluoride
62086590|NCT01607411|EXPERIMENTAL|1000 ppm Fluoride Toothpaste|Experimental toothpaste containing 1000 ppm Fluoride
62086591|NCT01607411|EXPERIMENTAL|500 ppm Toothpaste|Experimental toothpaste containing 500 ppm Fluoride
62651714|NCT04061785|NO_INTERVENTION|Control Group|The subjects will go about their normal life for 12 weeks without any intervention. The persons will be tested before and after the 12 week period.
62086592|NCT05390892|ACTIVE_COMPARATOR|Sodium-glucose cotransporter-2 inhibitor (SGLT2i)|Therapy with an SGLT2i with proven cardiovascular benefit. This means either canagliflozin, dapagliflozin, or empagliflozin
62086593|NCT05390892|ACTIVE_COMPARATOR|Glucagon-like peptide-1 receptor agonist (GLP-1 RA)|Therapy with a GLP-1 RA with proven cardiovascular benefit. This means either dulaglutide, liraglutide, or semaglutide.
62285489|NCT03118440|ACTIVE_COMPARATOR|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
62086594|NCT01888718|EXPERIMENTAL|Fexofenadine Hydrochloride Orally Disintegrating|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd
62086595|NCT01888718|ACTIVE_COMPARATOR|ALLEGRA|ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis
62086596|NCT03023332|EXPERIMENTAL|Self-management need|SM-need (i.e. need for bipolar education or resourcefulness training or HRV-focused biofeedback training or no need for any)
62086597|NCT03023332|EXPERIMENTAL|Self-management preference|SM-preference (i.e. preference for bipolar education or resourcefulness training or HRV-focused biofeedback training or no intervention)
62086598|NCT03023332|NO_INTERVENTION|Control|No intervention or treatment
62086599|NCT03023332|ACTIVE_COMPARATOR|Usual care|Bipolar education
62285490|NCT06415721|EXPERIMENTAL|Active fMRI-guided TMS|
62285491|NCT06415721|SHAM_COMPARATOR|Sham fMRI-guided TMS|
62285492|NCT01075386||Grade 2|Patients with Endometrial cancer of Grade 1 differentiation
62285493|NCT01075386||Benign|Patients without endometrial cancer
62285494|NCT01075386||Grade 1|Patients with Endometrial cancer of Grade 2 differentiation
62285495|NCT01075386||Grade 3|Patients with Endometrial cancer of Grade 3 differentiation
62285496|NCT00763009|OTHER|All subjects receive dipyridamole|Compare to baseline
62285497|NCT03618056|EXPERIMENTAL|AIDSVAX® B/E|Participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.
62285498|NCT02777528|OTHER|Zone 0/1 Aortic aneurysm|Zone 0/1 Aortic aneurysm
62651715|NCT06079294|EXPERIMENTAL|FDG PET|
62651716|NCT03353077|EXPERIMENTAL|Alpha DaRT|Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.
62086600|NCT06526208|ACTIVE_COMPARATOR|MB-IMP Group|Participants in this group will receive the MB-IMP, an oil-based solution that will contain CBD and THC (23:1 ratio, respectively) and be taken orally. Participants or study partners will dispense the daily dose with an eye dropper according to instructions from the Principal Investigator or delegated study coordinator. Dosing will start at 0.25 ml per day (50 mg of CBD and 2.18 mg of THC). The dose will gradually increase to 1.0 ml per day (200 mg of CBD, and 8.7 mg of TCH) by week 4. Weeks 5 through 8 will be at the maximum dose, 2 ml per day (400 mg of CBD and 17.4 mg of THC). With the exception of week 1 at the lowest dose (0.25 ml), participants will dose in the morning and evening to reach the maximum dose for that time period.
62086601|NCT06526208|PLACEBO_COMPARATOR|Placebo Group|Participants will follow the same dosing instructions for the MB-IMP group, but will take only MCT oil.
62086602|NCT05599880|EXPERIMENTAL|Treatment|Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
62086603|NCT06016374|EXPERIMENTAL|telerehabilitation for post stroke patient|During the study, the patient will be asked to use the TeleRé programme on the devices on a regular, daily basis, either in a hospital room or at home. They will also be asked to evaluate the programme via various questionnaires and assessments.
62460513|NCT05504603|EXPERIMENTAL|zanubrutinib(80mg), rituximab(100mg), ASCT|"1. Phase I(Combined Immunotherapy Phase):~   Part A(Induction Immunotherapy Phase): Patients receive zanubrutinib on days 1-28 and rituximab on day 1,8,15,22.~   Part B(Consolidation Immunotherapy Phase): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for 4 cycles.~2. Phase II(ASCT): BEAM pretreatment. Patients receive semustine on day1, etoposide on days 2-5, cytarabine on days 2-5 and melphalan on day 6.~3. Phase III(maintenance): Zanubrutinib"
62460514|NCT04574648|EXPERIMENTAL|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the non-adherence information such that community pharmacists can view the information prior to dispensing medications.
62460515|NCT04574648|NO_INTERVENTION|Standard care (ADE information retained locally)|Patients in the control arm will have their information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their information will not be visible to other providers via PharmaNet.
62460516|NCT02853162|EXPERIMENTAL|ARREST-study|SBRT renal cell carcinoma 5 times 7Gy
62651717|NCT04211376||Anxiety|Patients with anxiety
62651718|NCT03502824|ACTIVE_COMPARATOR|PuraPly® AM plus Standard of Care|
62651719|NCT03502824|ACTIVE_COMPARATOR|Standard of Care (SOC) for Pressure Ulcers|
62651720|NCT00374868|EXPERIMENTAL|Pemetrexed + Cisplatin|
62651721|NCT00166699|NO_INTERVENTION|Palpation|Use of palpation to guide the the insertion site of combined spinal epidural needle in obese parturients
62651722|NCT00166699|EXPERIMENTAL|ultrasound|The use of ultrasound to guide the insertion of a combined spinal epidural needle
62086604|NCT04838093||Patient cohort:|all patients with vascular disorders consecutively admitted at our tertiary care hospital from March 16 to December 07, 2020
62086605|NCT04838093||Control cohort:|data of two nationwide PCR-based studies conducted in a representative random sample, from April 1-6, and November 12-14, 2020, collected by the Austrian Ministry of Science and the Austrian Red Cross to estimate the spread of SARS-CoV-2 infection among the non-hospitalized Austrian population.
62086606|NCT04838093||HCP cohort:|HCP worker data, including nurses, nurse technicians, physicians, surgical personal, physical therapists, nurse practitioners, environmental service workers, administrative staff, and dietitians, working in close proximity to admitted patients at our tertiary care hospital from March 16 to December 07, 2020.
62460517|NCT00064753|EXPERIMENTAL|High Dose Multivitamin|Multivitamin with increased folic acid, vitamin B6 and vitamin B12
62460518|NCT00064753|ACTIVE_COMPARATOR|Low Dose Multivitamin|Multivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
62285499|NCT02777528|OTHER|Zone 0/1 Non-aneurysm aortic lesions|Includes dissection and other isolated lesion types
62285500|NCT05611957|EXPERIMENTAL|LY3437943 (Control)|LY3437943 administered subcutaneous (SC) to participants with normal renal function
62460519|NCT03289156|ACTIVE_COMPARATOR|Arousal Reappraisal|Brief educational intervention about the stress response and arousal reappraisal
62460520|NCT03289156|ACTIVE_COMPARATOR|Exercise|Three 5-minute bouts of aerobic exercise at increasing intensities
62460521|NCT03289156|EXPERIMENTAL|Arousal Reappraisal + Exercise|Brief educational intervention about the stress response and arousal reappraisal followed by three 5-minute bouts of aerobic exercise at increasing intensities with practice applying the arousal reappraisal learned earlier.
62460522|NCT03289156|NO_INTERVENTION|Control|Time-matched rest
62460523|NCT04810416|EXPERIMENTAL|Texting- 10 minutes|Assigned participants will do texting for 10 minutes.
62285501|NCT05611957|EXPERIMENTAL|LY3437943 (Severe Renal Impairment)|LY3437943 administered SC to participants with severe renal impairment
62285502|NCT05611957|EXPERIMENTAL|LY3437943 (End-Stage Renal Disease)|LY3437943 administered SC to participants with end-stage renal disease
62460524|NCT04810416|EXPERIMENTAL|Writing- 10 minutes|Assigned participants will do writing for 10 minutes.
62460525|NCT04810416|EXPERIMENTAL|Texting- 15 minutes|Assigned participants will do texting for 15 minutes.
62285503|NCT06546982|EXPERIMENTAL|Healthy|The serum samples of healthy patients will be measured.
62285504|NCT06546982|EXPERIMENTAL|Early-stage typhoid fever|The serum samples of early-stage typhoid fever patients will be measured.
62285505|NCT06546982|EXPERIMENTAL|Consolidated-stage typhoid fever|The serum samples of consolidated-stage typhoid fever patients will be measured.
62285506|NCT02070861|EXPERIMENTAL|Comparing cardiac output changes|"Explore the relationship between changes in cardiac output measured with eosophagal Doppler, the volume-clamp-method and exhaled CO2 during ventricular pacing and passive leg raise.~Measurements with the volume-clamp-method were aborted due to technological difficulties."
62285507|NCT04024501|EXPERIMENTAL|Treatment 1|During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.
62285508|NCT04024501|EXPERIMENTAL|Treatment 2|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.
62460526|NCT04810416|EXPERIMENTAL|Writing-15 minutes|Assigned participants will do writing for 15 minutes.
62460527|NCT04810416|NO_INTERVENTION|Control group|No hand activities.
62460528|NCT00169195|EXPERIMENTAL|R-GEMOX|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
62460529|NCT03178500|EXPERIMENTAL|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
62651723|NCT04905992|EXPERIMENTAL|Single daily session (Hypertonic saline + airway clearance techniques)|The experimental group will perform a daily session at home including nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
62285509|NCT04024501|EXPERIMENTAL|Treatment 3|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.
62285510|NCT04024501|EXPERIMENTAL|Treatment 4|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.
62285511|NCT04024501|EXPERIMENTAL|Treatment 5|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.
62460530|NCT03178500|EXPERIMENTAL|Stair step protocol|If there is no response (no follicle \>10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
62460531|NCT02730078|ACTIVE_COMPARATOR|Attention-meetings (AG)|Attention-control
62460532|NCT02730078|EXPERIMENTAL|VEMOFIT (VG)|Personal value exploration, disease education, emotional skills and goal setting.
62460533|NCT01949194|EXPERIMENTAL|Regorafenib|Single-agent regorafenib
62460534|NCT05697471|EXPERIMENTAL|Dienogest|
62460535|NCT05697471|ACTIVE_COMPARATOR|Danazol|
62460536|NCT01670695||IgG4-RD|Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
62460537|NCT03463369|EXPERIMENTAL|Placebo + Nucleos(t)ide Analogs (NA)|Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
62086607|NCT02710006|EXPERIMENTAL|SonoHysteroAVC|Three-dimensional sonohysterography is the first point for uterine cavity volume estimation, and it is going to be performed in all participants. The investigators are going to fill the uterine cavity twice by saline solution during single sonohysterography procedure, and acquise the volumetric datasets of uterus for offline analysis. The 3D dataset containing the entire uterine cavity will by analyzed using a personal computer and/or the ultrasound machine with specific softwere.
62086608|NCT04342962|EXPERIMENTAL|Experimental arm|"12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cycles of therapy; each cycle is 21 days.~Patients will receive the study drug until disease progression or in case of toxicity."
62086609|NCT03093363|OTHER|Intervention group|Asthmatic patients with the pharmacist's intervention
62460538|NCT03463369|EXPERIMENTAL|JNJ-64300535 + NA|Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
62460539|NCT03959878|EXPERIMENTAL|Gastrostomy Tube|Non-hospitalized outpatients undergoing placement of a gastrointestinal gastrostomy tube (GIG tube) or GI jejunostomy tube (GIJ tube) will receive the usual Standards of Care related to the placement of a GIG or GIJ tube and the Constant Pressure Skin Disk.
62460540|NCT04470791|EXPERIMENTAL|F(ab')2 antivenom plus local cryotherapy.|Group A: patients with a Crotalus snakebite, and grade II envenomation received F(ab')2 antivenom therapy and application of local cryotherapy.
62460541|NCT04470791|ACTIVE_COMPARATOR|F(ab')2 antivenom.|Group B: patients who received only F(ab')2 antivenom therapy.
62460542|NCT06148480||Mother-Infant Dyads|Women and their neonates admitted to the postpartum floor will be enrolled after being screened for the exclusion criteria
62460543|NCT02892500|EXPERIMENTAL|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
62651724|NCT04905992|ACTIVE_COMPARATOR|Twice daily session (Hypertonic saline + airway clearance techniques)|The control group will perform two daily sessions at home involving nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
62651725|NCT02375503|EXPERIMENTAL|Calcium/Vitamin D|Dietary supplement distributed and consumed as one calcium and vitamin D fortified snack bar per day
62651726|NCT02375503|PLACEBO_COMPARATOR|Placebo|Placebo distributed and consumed as one isocaloric, unfortified snack bar per day
62651727|NCT03483428|EXPERIMENTAL|Parent Coaches|"Parent coaches will complete interventionist training and supervision in the Family Check-Up, an evidence-based behavioral parent training (BPT) program, including in the adaptations for families with DHH children. Each parent coach will deliver the intervention to 5 parent-child dyads."
62651728|NCT03483428|EXPERIMENTAL|Parent-Child Dyads|"Parents and children will receive the adapted Family Check-Up behavioral parent training (BPT) intervention delivered by parent coaches."
62086610|NCT03093363|OTHER|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
62086611|NCT03701425|EXPERIMENTAL|Mediterranean diet and exercise plan|"Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the distribution of macronutrients: Protein contribution 0.8-1.2 gram, Carbon Hydrates 45-50% Lipids 30% An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
62086612|NCT03701425|EXPERIMENTAL|Mediterranean diet|Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the following distribution of macro nutrients: Protein contribution 0.8-1.2 gram Carbon Hydrates 45-50% Lipids 30%
62086613|NCT03701425|ACTIVE_COMPARATOR|Only exercise|"An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
62086614|NCT03701425|ACTIVE_COMPARATOR|Low standard low fat diet|Random assignment, through software, to 4 groups of treatment: consume the low standard low fat diet: according to the definition, with the following distribution of macro nutrients:Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 20%
62086615|NCT03415490|ACTIVE_COMPARATOR|Classic technique of self-adherent wrap|"1. over 16 years old~2. free of any symptoms in the eyes~3. classic technique of self-adherent wrap after surgery"
62285512|NCT01506882|EXPERIMENTAL|Levetiracetam 1000 mg/day to 2000 mg/day group|"Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
62285513|NCT01506882|EXPERIMENTAL|Levetiracetam 3000 mg/day group|"Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period.~They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
62285514|NCT01275209|EXPERIMENTAL|HCD122|
62285515|NCT02862314|EXPERIMENTAL|procalcitonin group|The procalcitonin concentration is measured at inclusion.
62285516|NCT02862314|NO_INTERVENTION|control group|Concentrations of procalcitonin are not measured. .
62285517|NCT02321293|EXPERIMENTAL|1|"CurcuVIVA™ (NPN 80027414) at a single dose of 80 mg PO daily without any dose escalation to be taken in conjunction with an EGFR-TKI therapy.~CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)~Tyrosine Kinase Inhibitors:~1. Gefitinib is a targeted therapy, given in a capsule form once daily. The daily dose is 250 mg .~2. Erlotinib is a targeted therapy, given in a capsule form once daily. The daily dose is 150 mg .~Study intervention is 8 weeks, following which the patients will continue taking their EGFR-TKI without curcumin until progression. The side effects of curcumin will be followed for another 8 weeks from the date of stopping curcumin."
62285518|NCT03219073|SHAM_COMPARATOR|SHAM tDCS|SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
62285519|NCT03219073|ACTIVE_COMPARATOR|Active tDCS with a tDCS device|Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
62285520|NCT01672931||BMI over 30|Women undergoing IVF with BMI over 30
62285521|NCT01672931||BMI 20-25|Women undergoing IVF treatments with BMI between 20-25
62285522|NCT05679362|EXPERIMENTAL|immediate individual treatment (A)|5 online individual sessions
62651729|NCT05841420|ACTIVE_COMPARATOR|"A: Full dose single agent strategy"|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks
62651730|NCT05841420|EXPERIMENTAL|"B: Reduced dose (80%) combination-therapy strategy"|Nab-Paclitaxel: 100mg/m2 plus gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
62651731|NCT02406820||No Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is not clinically indicated and who are registered to twice daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
62086616|NCT03415490|EXPERIMENTAL|Folded technique of self-adherent wrap|"1. over 16 years old~2. free of any symptoms in the eyes~3. folded technique of self-adherent wrap after surgery"
62651732|NCT02406820||Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to three times daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
62460544|NCT02892500|ACTIVE_COMPARATOR|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
62285523|NCT05679362|EXPERIMENTAL|immediate group treatment (B)|5 online group sessions with other women with PCOS
62285524|NCT05679362|NO_INTERVENTION|care as usual (cau)|The CAU group receives standard treatment for depressive symptoms from their general practitioner (GP).
62285525|NCT03327233|EXPERIMENTAL|Intervention group|Implementing the Connecare system to support integrated care for complex patients with an unplanned admission to Assuta Ashdod who are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community by a Maccabi integrated care nurse for a period of 3 months post discharge.
62285526|NCT03327233|NO_INTERVENTION|Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
62285527|NCT02557061|EXPERIMENTAL|Patient with colorectal cancer|Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer
62285528|NCT04455711|PLACEBO_COMPARATOR|Remifentanil group|Emerge with continuous infusion of remifentanil 1.5 ng/ml
62285529|NCT04455711|EXPERIMENTAL|Lidocaine group|Emerge with continuous infusion of remifentanil 1.5 ng/ml with IV bolus of lidocaine 1.5 mg/kg
62460545|NCT05687864|EXPERIMENTAL|Polysaccharide superparamagnetic ferric oxide injection|Participants will receive one single dose of 1mg/kg or 2mg/kg or 3mg/kg or 4mg/kg or 5mg/kg of Polysaccharide superparamagnetic ferric oxide injection on Day 1.
62460546|NCT04168788|OTHER|Nephrobalstoma or ALL|Pateints treated for a nephrobalstoma or ALL in childhood or adolescence
62285530|NCT03285932|EXPERIMENTAL|Post-operative SRS of resection cavity|"High-resolution contrast-enhanced post-operative MRI imaging in preparation for Cyberknife SRS. Cyberknife SRS of the resection cavity and all potential additional metastases diagnosed in the treatment planning MRI (up to 10 lesions)~Resection cavity:~7 x 5 Gy @ 95%-isodose~Potential additional brain metastases:~20 Gy @ 70%-isodose (lesions \< 2 cm max. diameter) 18 Gy @ 70%-isodose (lesions 2 - 3 cm max. diameter) 6 x 5 Gy @ 70%-isodose (lesions \> 3 cm max. diameter)"
62285531|NCT03285932|OTHER|Post-operative WBRT|Post-operative WBRT will be performed according to the following dose regimen: 10 x 3 Gy
62285532|NCT01567644|EXPERIMENTAL|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
62285533|NCT02630160|ACTIVE_COMPARATOR|Intraarticular Catheter with anesthesic|Intraarticular infusion with Bupivacaine Hydrochloride
62460547|NCT04283084|EXPERIMENTAL|Study group|Number of participants in this group is anticipated to be 25. Participants in this group will be receiving 10 minutes of exercise with the virtual reality based balance and coordination training system (MARBES). In the MARBES system two exercises (1. Balance exercise, 2. Coordination exercise) will be played for 5 minutes each.
62086617|NCT01587729||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
62460548|NCT02462330|PLACEBO_COMPARATOR|Placebo comparator|injection of human albumin 4%
62460549|NCT02462330|EXPERIMENTAL|Autologous MSC from bone marrow|intramyocardial injection of 6.10e7 stem cells
62460550|NCT04341740|EXPERIMENTAL|Renal Cell Carcinoma or Urothelial Carcinoma Patients|Patients in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate and 75 ml of peripheral blood sample.
62460551|NCT04887077|EXPERIMENTAL|Kiplin intervention|Kiplin intervention composed of the access to a mobile app and to telecoaching sessions. The number of teleocaching sessions per week will decrease over 3 months.
62651733|NCT02406820||No Indwelling PAC, No Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to no daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
62086618|NCT01587729||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
62285534|NCT02630160|PLACEBO_COMPARATOR|Intraarticular Physiological Saline|Infusion of Physiological Saline \[Flebobag Salina Fisiologica Grifols 0.9%\] Sterile Solution by intraarticular catheter
62285535|NCT02630160|ACTIVE_COMPARATOR|Perifascial Catheter with anesthesic|Perifascial infusion with Bupivacaine Hydrochloride
62460552|NCT04887077|ACTIVE_COMPARATOR|face-to-face supervised PA (usual care at the University Hospital of Clermont-Ferrand, France)|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
62460553|NCT04882332||metformin usage index and vitamin B12 level|Samples for correlation between metformin usage index and vitamin B1 level will be withdrawn from 108 type 2 diabetes patients
62460554|NCT02456714|EXPERIMENTAL|Progressive cholangiocarcinoma, second line treatment|FOLFIRINOX
62460555|NCT06126848|OTHER|Observation Cohort|
62460556|NCT02077270|EXPERIMENTAL|electroacupuncture|patients in whom precolonoscopic electroacupuncture is preformed
62285536|NCT02630160|PLACEBO_COMPARATOR|Perifascial Physiological Saline|Infusion of Physiological Saline \[Flebobag Salina Fisiologica Grifols 0.9%\] Sterile Solution by Perifascial catheter
62460557|NCT02077270|PLACEBO_COMPARATOR|Sham electroacupuncture|sham electroacupuncture
62460558|NCT02077270|SHAM_COMPARATOR|No intervantion|no intervantion
62460559|NCT05723588|EXPERIMENTAL|active rTMS|Participants assigned to this group will receive active repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.
62460560|NCT05723588|SHAM_COMPARATOR|sham rTMS|Participants assigned to this group will receive sham repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.
62285537|NCT04909905|EXPERIMENTAL|Group EN (standard enteral nutrition)|Patients receive standard enteral nutrition according to ICU nutrition protocol during 7days from admission
62285538|NCT04909905|EXPERIMENTAL|Group GN (glutamine supplemented enteral nutrition)|Patients receive intravenous glutamine supplementation to enteral nutrition in a dose of glutamine of 0.4 g/kg/day during 7 days from admission.
62460561|NCT01566318|EXPERIMENTAL|Problem solving therapy (PST)|6-8 sessions of PST, with booster, delivered over 8 weeks
62460562|NCT01566318|NO_INTERVENTION|Usual care|Usual agency care, monitored for mental health services
62460563|NCT00828048||Pancreatic Cyst|Pancreatic Cyst
62285539|NCT00700804|EXPERIMENTAL|High Calcium Diet|
62285540|NCT00700804|EXPERIMENTAL|Low Calcium Diet|
62285541|NCT01256177|EXPERIMENTAL|1|
62285542|NCT01256177|PLACEBO_COMPARATOR|2|
62460564|NCT00429364|ACTIVE_COMPARATOR|Atenolol|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.
62460565|NCT00429364|ACTIVE_COMPARATOR|Losartan|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).
62460566|NCT02139553|EXPERIMENTAL|Rhythmic rehabilitation|Patients undergo a first evaluation, and a second evaluation one month later to determine their natural evolution. The following month, patients get 12 sessions of rhythmic therapy. A third evaluation is organized straight after this month and a fourth evaluation, 3 months after to assess the after-effects of the therapy.
62460567|NCT05155306|EXPERIMENTAL|Tfasted|T: Test Treatment fasted: under fasted conditions
62460568|NCT05155306|EXPERIMENTAL|Tfed|T: Test Treatment fed: under fed conditions
62460569|NCT05155306|EXPERIMENTAL|Rfasted|R: Reference Treatment fasted: under fasted conditions
62460570|NCT05155306|EXPERIMENTAL|Rfed|R: Reference Treatment fed: under fed conditions
62460571|NCT00979732|ACTIVE_COMPARATOR|GSE beverage active|grape seed extract beverage 150 mg/BID
62086619|NCT03887741|EXPERIMENTAL|Plasmapheresis|3 patients will have monthly plasmapheresis for 6 months and followed for a total of 12 months
62086620|NCT03887741|EXPERIMENTAL|Plasma infusion|3 patients will have biweekly plasma infusion for 6 months and followed for 12 months
62086621|NCT03887741|NO_INTERVENTION|Control group|3 patients will be followed for 12 months
62086622|NCT00948259|EXPERIMENTAL|NP031112|Patients will receive 400 mg of NP031112 for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this dose will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for dose escalation will remain on the tolerated dose for the remainder of the study.
62285543|NCT02419976|EXPERIMENTAL|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
62285544|NCT06225284|EXPERIMENTAL|Arm A|"After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 3 days of randomization and during neoadjuvant chemotherapy treatment. The protocol-defined chemotherapy will be given 7 to 14 days after GnRH agonist injection. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.~* Anthracycline/cyclophosphamide combination or dose-dense schedule: anthracycline/cyclophosphamide combination (Use of dose-dense schedule or not will be stratified.)~* Taxane (docetaxel or paclitaxel) ± optional platinum (Use of platinum or not will be stratified.)"
62285545|NCT06225284|NO_INTERVENTION|Arm B|"* Anthracycline/cyclophosphamide combination or dose-dense schedule: anthracycline/cyclophosphamide combination (Use of dose-dense schedule or not will be stratified.)~* Taxane (docetaxel or paclitaxel) ± optional platinum (Use of platinum or not will be stratified.)"
62285546|NCT05323422||Group 1|COVID-19 positive and pre-induction low-dose intravenous ketamine (0.5 mg/kg) will administering
62285547|NCT05323422||Group 2|COVID-19 positive and without intravenous ketamine (0.5 mg/kg)
62285548|NCT05323422||Group -3|COVID-19 negative and pre-induction low-dose intravenous ketamine (0.5 mg/kg) will administering
62285549|NCT05323422||Group4|COVID-19 negative and without intravenous ketamine (0.5 mg/kg)
62285550|NCT02701673|EXPERIMENTAL|Belinostat/Gem/Bu/Mel + AutoSCT|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1.~Caphosol oral rinses 30 mL four times a day used from Day -8. Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.~Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1. Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2. Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2. Participants with cluster of differentiation antigen 20 (CD20+) tumors receive Rituximab 375 mg/m2 by vein on Day -9.~Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.~Melphalan 60 mg/m2/d by vein on Day -2. Stem cell transplant by vein given on Day 0."
62285551|NCT04127201|EXPERIMENTAL|Online intervention, en_línea|Participants will be provided with a username and a password to acess to a website. en_línea program is an online adaptation of the LEARN program. The five treatment areas are: Lifestyle, Exercise, Attitudes, Relationships and Nutrition. We have designed and developed a website (www.programaenlinea.org) with 17 weekly treatment sessions and an exclusive mobile application for self-recording.
62285552|NCT04127201|ACTIVE_COMPARATOR|Standard group therapy|Participants in this arm will received a 10 sessions of standard primary care group therapy. Sessions 1 and 2 will be weekly and sessions from 3 to 10 will be biweekly. Sessions, between 8 and 10 participants, will be conducted by a specialized psychologist and they will last 90 minutes. Treatment areas will be the same as en_línea, beginning with nutrition and exercise and a progressive incorporation of the other topics. Material to work at home and self-recording will be provided in paper.
62285553|NCT04127201|NO_INTERVENTION|Control group|Participants in the control group only will receive a biweekly newsletter by email without feedback. They will be provided with material and instructions to self-record their daily meals and exercise. The newsletter only will content basic information about nutrition and exercise.
62285554|NCT06550167|EXPERIMENTAL|Nano-PSO|Nano-PSO or Pomegranate seed oil with nanotechnology, capsules with a net content of 640mg with a dosage indicated by sponsor of 2 capsules in fast
62285555|NCT06550167|PLACEBO_COMPARATOR|PLACEBO|Placebo physically identical to Nano-PSO capsules Soft gelatin capsules 640 mg edible oil for PLACEBO being the following information: oil edible, oval shape, 640 mg
62285556|NCT05464745|EXPERIMENTAL|PERINDOPRES® DUO (Test)|A single oral dose of the test product PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets.
62285557|NCT05464745|ACTIVE_COMPARATOR|Noliterax® 10 mg/2.5 mg (Reference)|A single oral dose of the reference product Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets.
62285558|NCT01959165|EXPERIMENTAL|MEDI7183 dose 1|Double blinded
62651734|NCT04546841|EXPERIMENTAL|Vaccination|"A single vaccination with the IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides, XS15 emulsified in Montanide ISA 51 VG) (500 µl) will be applied subcutaneously (s.c.) to the abdominal skin.~1. Part I: Age 18-55 at the time of screening, n=12~2. Part II: Age 56-74 years at the time of screening, n=12~3. Part III: Age ≥ 75 years at the time of screening, n=12"
62086623|NCT00948259|PLACEBO_COMPARATOR|Placebo|Patients will receive 400 mg for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for escalation will remain on the tolerated dose for the remainder of the study.
62285559|NCT01959165|EXPERIMENTAL|MEDI7183 dose 2|Double blinded
62285560|NCT01959165|EXPERIMENTAL|MEDI7183 dose 3|Double blinded
62285561|NCT01959165|PLACEBO_COMPARATOR|Placebo|Double blinded
62285562|NCT02257580|EXPERIMENTAL|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
62285563|NCT02257580|PLACEBO_COMPARATOR|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
62285564|NCT02723201|EXPERIMENTAL|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
62285565|NCT02723201|EXPERIMENTAL|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
62460572|NCT00979732|PLACEBO_COMPARATOR|GSE beverage placebo|grape seed extract placebo beverage 150 mg/BID
62086624|NCT01327547|EXPERIMENTAL|1.0|
62086625|NCT01327547|PLACEBO_COMPARATOR|2|
62086626|NCT00801593||Children with JIA|
62086627|NCT03883958|ACTIVE_COMPARATOR|TPVB|
62086628|NCT03883958|EXPERIMENTAL|ESPB|
62086629|NCT01034111|EXPERIMENTAL|Sitagliptin|Sitagliptin as add-on therapy to a stable dose of metformin
62086630|NCT05898737||Parturients|Parturients on labour requiring an epidural
62086631|NCT02653274|ACTIVE_COMPARATOR|OATS PORRIDGE|Oats breakfast porridge
62086632|NCT02653274|ACTIVE_COMPARATOR|RYE PORRIDGE|Rye breakfast porridge
62086633|NCT02653274|ACTIVE_COMPARATOR|FINGER (RAGI) MILLET PORRIDGE|Finger (ragi) millet breakfast porridge
62086634|NCT02653274|ACTIVE_COMPARATOR|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge
62086635|NCT00373295|EXPERIMENTAL|Baclofen 60 mg, Placebo, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
62086636|NCT00373295|EXPERIMENTAL|Baclofen 90 mg, Placebo, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
62086637|NCT00373295|EXPERIMENTAL|Baclofen 60 mg, Baclofen 90 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
62086638|NCT00373295|EXPERIMENTAL|Baclofen 90 mg, Baclofen 60 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
62460573|NCT00454909|EXPERIMENTAL|Group A|Subjects aged 10 years (\< 11 years) vaccinated with meningococcal vaccine GSK134612.
62086639|NCT00373295|EXPERIMENTAL|Placebo, Baclofen 90 mg, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
62460574|NCT00454909|EXPERIMENTAL|Group B|Subjects aged 11 to 25 years vaccinated with meningococcal vaccine GSK134612.
62651735|NCT06550323|EXPERIMENTAL|Group using virtual reality glasses|Virtual reality application will be applied to this group and virtual reality glasses will be put on 5 minutes before the procedure and the video will be started to be watched during the process.
62086640|NCT00373295|EXPERIMENTAL|Placebo, Baclofen 60 mg, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
62086641|NCT03265379||patients with an isolated recurrence in the chest wall|
62086642|NCT03265379||distant metastatic disease is present but who undergo FTCWR|
62086643|NCT03265379||patient with primary tumor, no distant ds, failed conventional|
62086644|NCT03265379||patients refusing to undergo surgery|
62086645|NCT02044198|ACTIVE_COMPARATOR|Group 1 - FMP2.1/AS01B vaccine|"FMP2.1/AS01B vaccine administered at days 0, 28 and 56.~Blood-stage controlled human malaria infection (CHMI) at day 70."
62086646|NCT02044198|NO_INTERVENTION|Group 2 - control|"Group 2 is an infectivity-control group for the malaria infection challenge procedures; these volunteers will not be vaccinated.~Blood-stage controlled human malaria infection (CHMI) at day 70."
62285566|NCT02723201|EXPERIMENTAL|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
62285567|NCT02723201|EXPERIMENTAL|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
62285568|NCT02723201|EXPERIMENTAL|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
62285569|NCT02723201|EXPERIMENTAL|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
62285570|NCT02723201|EXPERIMENTAL|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
62285571|NCT04719351|EXPERIMENTAL|Condition 1: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62285572|NCT04719351|EXPERIMENTAL|Condition 2: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62285573|NCT04719351|EXPERIMENTAL|Condition 3: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62285574|NCT04719351|EXPERIMENTAL|Condition 4: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62086647|NCT01090037|EXPERIMENTAL|TRK-100STP|
62460575|NCT00454909|ACTIVE_COMPARATOR|Group C|Subjects aged 11 to 25 years vaccinated with Menactra®.
62651736|NCT06550323|NO_INTERVENTION|Group not using virtual reality glasses|Standard protocols will be applied to this group and no action will be taken.
62086648|NCT01090037|PLACEBO_COMPARATOR|Placebo|
62086649|NCT04147260|EXPERIMENTAL|BI 730357 low dose|
62086650|NCT04147260|ACTIVE_COMPARATOR|Ciprofloxacin|
62086651|NCT04147260|EXPERIMENTAL|BI 730357 high dose|
62086652|NCT04147260|PLACEBO_COMPARATOR|Placebo|
62086653|NCT06169761||Healthy adults|Healthy adults of 18 years and older will fill out the STOP-BANG Questionnaire and undergo protrusive motor skills measurements.
62086654|NCT00905060|EXPERIMENTAL|Protein Peptide-Complex (HSPPC-96)|Patients will receive 4 weekly injections of HSPPC-96 followed by a 5th vaccine injection on the same day of the start of maintenance temozolomide administered 2 weeks (+ 4 days) following vaccine administration #4 on the same day of the start of maintenance temozolomide (Day 36). Monthly vaccine injections will then begin on day 21 (+/- 7 days) of the first 28 day temozolomide cycle (Day 56 of the study), 3 weeks following vaccine administration #5 and will continue every 28 days until depletion of vaccine or progression.
62460576|NCT02024087|EXPERIMENTAL|Dalantercept 0.6 mg/kg plus sorafenib 400 mg|Cohort 1: Participants received dalantercept 0.6 mg/kg by subcutaneous (SC) injection once every 3 weeks plus sorafenib 400 mg orally (PO) once daily
62460577|NCT02024087|EXPERIMENTAL|Dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 2: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
62651737|NCT05968378|ACTIVE_COMPARATOR|Standard healthy eating advice|Subjects in this group will be counselled according to the Irish National Healthy Eating Guidelines.
62651738|NCT05968378|EXPERIMENTAL|eTRE plus Mediterranean diet|Subjects in this group will be asked to restrict their eating to 8-hours daily (8am - 4pm) and to adhere to a Mediterranean style diet.
62086655|NCT04963062|EXPERIMENTAL|Participants treated with Holmium laser with the Moses laser|
62460578|NCT02024087|EXPERIMENTAL|Expansion cohort - dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 3: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
62086656|NCT04963062|EXPERIMENTAL|Participants treated with Holmium laser with the thulium laser|
62285575|NCT04719351|EXPERIMENTAL|Condition 5: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62285576|NCT04719351|EXPERIMENTAL|Condition 6: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62285577|NCT04719351|EXPERIMENTAL|Condition 7: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62285578|NCT04719351|EXPERIMENTAL|Condition 8: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: not included;"
62285579|NCT04719351|EXPERIMENTAL|Condition 9: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285580|NCT04719351|EXPERIMENTAL|Condition 10: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285581|NCT04719351|EXPERIMENTAL|Condition 11: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285582|NCT04719351|EXPERIMENTAL|Condition 12: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285583|NCT04719351|EXPERIMENTAL|Condition 13: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285584|NCT04719351|EXPERIMENTAL|Condition 14: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285585|NCT04719351|EXPERIMENTAL|Condition 15: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285586|NCT04719351|EXPERIMENTAL|Condition 16: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: not included;"
62285587|NCT04719351|EXPERIMENTAL|Condition 17: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62460579|NCT04334590||Cleft Lip/Nose Repair without PSIO|Participants who will undergo cleft lip/nose repair prior to addition of PSIO as part of standard of care in Hopkins.
62086657|NCT03550729|EXPERIMENTAL|Training|12-weeks of supervised endurance training program.
62086658|NCT00649974|EXPERIMENTAL|1|Valacyclovir Hydrochloride Tablets 1000 mg
62086659|NCT00649974|ACTIVE_COMPARATOR|2|Valtrex® Tablets 1000 mg
62086660|NCT06305273|EXPERIMENTAL|Supine|Participant will be ventilated with facemask while in supine position.
62086661|NCT06305273|EXPERIMENTAL|Head elevated|Participant will be ventilated with facemask while in head elevated position.
62086662|NCT00541957|OTHER|2|Medication prescribed by PCP
62086663|NCT00541957|EXPERIMENTAL|1|Medication prescribed by PCP + behavior therapy
62086664|NCT01373853|EXPERIMENTAL|Femtec Groupe A|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery
62086665|NCT01373853|ACTIVE_COMPARATOR|Manual Group B|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
62460580|NCT04334590||Presurgical Infant Orthopedic Therapy|Participants who will undergo cleft lip/nose repair after addition of PSIO as part of standard of care in Hopkins.
62651739|NCT00473083|EXPERIMENTAL|Arm 1: Prophylactic Treatment|Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
62285588|NCT04719351|EXPERIMENTAL|Condition 18: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62651740|NCT00473083|EXPERIMENTAL|Arm 2: Reactive Treatment|"Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:~Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade~Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.~Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.~Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln."
62651741|NCT00473083|EXPERIMENTAL|Arm 3: No Treatment Unless Severe (Grade 3)|This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
62651742|NCT02974504|EXPERIMENTAL|evogliptin|evogliptin 5mg qd
62285589|NCT04719351|EXPERIMENTAL|Condition 19: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62285590|NCT04719351|EXPERIMENTAL|Condition 20: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62285591|NCT04719351|EXPERIMENTAL|Condition 21: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62285592|NCT04719351|EXPERIMENTAL|Condition 22: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62285593|NCT04719351|EXPERIMENTAL|Condition 23: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62460581|NCT00946803|EXPERIMENTAL|PC-CB Intervention|Patient-Controlled Cognitive-Behavioral Intervention
62460582|NCT00946803|NO_INTERVENTION|Wait list|Wait list control group. Offered PC-CB Intervention after the study.
62460583|NCT03388307|EXPERIMENTAL|unilateral laminotomy|patients with lumbar canal stenosis who undergo unilateral laminotomy for bilateral decompression
62460584|NCT03388307|EXPERIMENTAL|decompressive laminectomy|patients with lumbar canal stenosis who undergo decompressive laminectomy
62460585|NCT03202914|ACTIVE_COMPARATOR|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
62460586|NCT03202914|ACTIVE_COMPARATOR|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
62460587|NCT03202914|EXPERIMENTAL|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
62460588|NCT00984295|EXPERIMENTAL|1|ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
62460589|NCT00984295|EXPERIMENTAL|2|ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
62086666|NCT00123513|EXPERIMENTAL|1|Worksite intervention for obesity prevention
62285594|NCT04719351|EXPERIMENTAL|Condition 24: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: not included;~5. Behavioral prompts: included;"
62285595|NCT04719351|EXPERIMENTAL|Condition 25: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285596|NCT04719351|EXPERIMENTAL|Condition 26: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285597|NCT04719351|EXPERIMENTAL|Condition 27: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285598|NCT04719351|EXPERIMENTAL|Condition 28: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: not included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285599|NCT04719351|EXPERIMENTAL|Condition 29: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285600|NCT04719351|EXPERIMENTAL|Condition 30: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: not included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285601|NCT04719351|EXPERIMENTAL|Condition 31: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: not included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285602|NCT04719351|EXPERIMENTAL|Condition 32: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~1. Questions about positive emotions: included;~2. Questions about workload/work environment: included;~3. Questions about controllability: included;~4. Questions with open answers: included;~5. Behavioral prompts: included;"
62285603|NCT04750460|EXPERIMENTAL|Teriparatide group (11 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, who will receive subcutaneous injections ot recombinant parathyroid hormone (Teriparatide) after surgery in addition to the standard local protocol for hypocalcemia treatment.
62285604|NCT04750460|NO_INTERVENTION|Control group (9 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, receiving standard local protocol for hypocalcemia treatment (2 micrograms of alphacalcidol plus 4 grams of oral calcium daily).
62285605|NCT03372239|EXPERIMENTAL|Part 1: Bioavailability and Food Effect|"Subjects will be randomized to receive the following 3 regimens in randomized sequence:~1. Single dose of Indoximod base formulation under fasting conditions~2. Single dose of Indoximod HCL (salt) formulation under fed conditions~3. Single dose of Indoximod HCL (salt) formulation under fasting conditions"
62285606|NCT03372239|EXPERIMENTAL|Part 2: Single Ascending Dose|
62285607|NCT02235506|EXPERIMENTAL|epidural infusion|In epidural infusion group, a lumbar epidural catheter was placed at the L3-4 level using loss-ofresistance procedure. ropivacaine 0.2% and fentayl 2mcg/ml were infused at a rate of 5ml/hr from the end of operation,
62086667|NCT00123513|NO_INTERVENTION|2|Control group
62285608|NCT02235506|EXPERIMENTAL|femoral sciatic|In femoral sciatic group, the femoral and sciatic nerve are located using ultrasound and 0.2% ropivacain is injected. A catheter is inserted to femoral nerve. From the end of operation, 0.2% ropivacaine was infused through the femoral catheter at a rate of 5ml/hr.
62285609|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
62285610|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
62285611|NCT05442710|EXPERIMENTAL|ARTICE Treatment Group|Subjects with septic shock treated with immune cell extracorporeal therapy on top of standard of care
62651743|NCT02974504|ACTIVE_COMPARATOR|linagliptin|linagliptin 5mg qd
62651744|NCT03028246|EXPERIMENTAL|ExAblate 4000 System|MR-Guided Focused Ultrasound
62086668|NCT00914017|EXPERIMENTAL|Atorvastatin|40 mg of Lipitor (atorvastatin) daily for 1 year
62086669|NCT00914017|PLACEBO_COMPARATOR|Sugar Pill|Sugar pill daily for 1 year
62086670|NCT04481516||Yoga|Single group study representing cohort of NHS health care workers with possible Covid-19 related stress and anxiety disorder. Participants act as their own controls pre and post regular practice of yoga technique.
62086671|NCT05475769||Nummular headache patients|Patients that fulfill the International Classification of Headache Disorders, 3rd edition, for Nummular Headache.
62086672|NCT00671593|EXPERIMENTAL|Experimental inhaled dust mite|All subjects receive the same experimental inhaled challenge interventions
62086673|NCT03312803|ACTIVE_COMPARATOR|Mini autogenous skin grafts|we take the autogenous skin graft from the same patient then cut it into small pieces then we spread it over the burn wound on one limb then cover these small pieces with homogenous skin graft taken from another person.
62285612|NCT05442710|NO_INTERVENTION|Control Group|Subjects with septic shock receiving standard of care
62285613|NCT02551120||Patients|Patients with idiopathic hypoparathyroidism, autosomal dominant hypocalcaemia and pseudohypoparathyroidism.
62285614|NCT06500754||Celiac Disease patients|
62651745|NCT01860209|EXPERIMENTAL|Group A|the first polysomnography (PSG) is performed before hemodialysis (HD), followed by a post-HD PSG on the subsequent night
62285615|NCT02130713|ACTIVE_COMPARATOR|Group A, antibiotics|Prulifloxacin 600 mg
62285616|NCT02130713|ACTIVE_COMPARATOR|Group B, antibiotics plus nutraceuticals|Prulifoxacin plus Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg
62285617|NCT05758883||IC-8 Apthera intraocular lens (IOL) Group|Patients previously enrolled in the IC-8 Apthera IOL Investigational Device Exemption (IDE) study (G180075) and implanted with the IC-8 Apthera IOL.
62285618|NCT01291602|EXPERIMENTAL|NXL104|Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
62285619|NCT01291602|PLACEBO_COMPARATOR|Placebo|Three Japanese subjects to receive placebo IV doses
62285620|NCT01291602|EXPERIMENTAL|Ceftazidime NXL104 (CAZ104)|Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
62285621|NCT05074108|EXPERIMENTAL|Pilot study|Adapt and pilot a nutrition-based intervention. The program will take a holistic approach to educate participants about basic nutrition and cooking skills, sleep, and mindfulness strategies to enhance mental health.
62285622|NCT05384041|ACTIVE_COMPARATOR|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The Fisher Wallace Stimulator provides cranial electrotherapy stimulation and is an active device.
62285623|NCT05384041|PLACEBO_COMPARATOR|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
62285624|NCT05222074||CVP ≥ 12|central venous pressure ≥12 mmHg
62285625|NCT05222074||CVP ≥ 16|central venous pressure ≥16 mmHg
62285626|NCT05222074||CVP ≥ 20|central venous pressure ≥20 mmHg
62285627|NCT05222074||MAP ≤ 55 mmHg|mean arterial pressure ≤55 mmHg
62285628|NCT05222074||MAP ≤ 65 mmHg|mean arterial pressure ≤65 mmHg
62285629|NCT05222074||MAP ≤ 75 mmHg|mean arterial pressure ≤75 mmHg
62285630|NCT06487546|EXPERIMENTAL|Ergothioneine|Ergothioneine (range 5 mg to 25 mg) oral daily for up to 16 weeks
62285631|NCT01811511|EXPERIMENTAL|Chungkookjang|Chungkookjang(35g/day)
62285632|NCT01811511|PLACEBO_COMPARATOR|Placebo|Placebo(35g/day)
62285633|NCT04878133|EXPERIMENTAL|Exsperimental Arm|
62651746|NCT01860209|EXPERIMENTAL|Group B|the first PSG is performed after hemodialysis (HD), followed by a pre-HD PSG, on the subsequent night
62651747|NCT01220284|EXPERIMENTAL|Satraplatin in combo with vinorelbine|"Escalating doses of satraplatin and oral vinorelbine in subsequent cohorts of 3-6 patients according to the type and severity grade of acute toxicities observed during cycle 1.~The dose escalation process will be discontinued once the MTD is achieved."
62086674|NCT03312803|ACTIVE_COMPARATOR|Autogenous skin graft|we take the regular autogenous one piece skin graft from the same patient and cover the burn wound on the other limb then we make a comparison between both limbs
62285634|NCT04878133|NO_INTERVENTION|Control Arm|
62285635|NCT03012373|EXPERIMENTAL|Ear acupressure & Electroacupuncture (A)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
62285636|NCT03012373|EXPERIMENTAL|Ear acupressure & Electroacupuncture (B)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
62285637|NCT00721487||Fluconazole|30 evaluable patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy.
62285638|NCT01953744|EXPERIMENTAL|Fluconazole|Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
62285639|NCT01953744|ACTIVE_COMPARATOR|Meglumine Antimoniate|Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.
62285640|NCT01671280||Azithromycin IV|Subjects who are treated with Azithromycin IV
62285641|NCT05222633||Neovascular age-related macular edema|Patients with new-onset and recurrent Neovascular age-related macular edema.
62086675|NCT01620411|EXPERIMENTAL|Comprehensive Medical Management (CMM)|This arm will receive standard of care treatment for injuries sustained while on active duty. Non-Invasive.
62086676|NCT01620411|EXPERIMENTAL|CMM + Spinal Cord Stimulator (SCS)|This arm will combine comprehensive medical management with placement of a spinal cord stimulator.
62086677|NCT06530901||Elderly patients undergoing elective noncardiac surgery under general anesthesia|
62285642|NCT05222633||Diabetic macula edema|Patients with new-onset and recurrent diabetic macula edema
62285643|NCT05222633||Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy|Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
62285644|NCT05222633||Retinal vein occlusions|Patients with new-onset and recurrent retinal vein occlusions
62285645|NCT05222633||Choroidal neovascularization|Patients with new-onset and recurrent choroidal neovascularization
62285646|NCT01848145|EXPERIMENTAL|Ofatumumab|Rapid Infusion of Ofatumumab
62460590|NCT00984295|ACTIVE_COMPARATOR|3|Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)
62285647|NCT04485585|EXPERIMENTAL|Sequence T/M/T+M|"A total of 36 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(T, M, T+M) assigned to on sequence group in Period 1, Period 2, and Period 3.~* Period 1(T): BR9006-1 (Tamsulosin HCL 0.2mg) - 1 capsule QD, five-day repeated-dose~* Period 2(M): BR9006-2 (Mirabegron 50mg) - 1 tablet QD, eleven-day repeated-dose~* Period 3(T+M): BR9006-1 (Tamsulosin HCL 0.2mg) 1 capsule + BR9006-2 (Mirabegron 50mg) 1 tablet QD, five-day repeated-dose~* Washout period between Period 1 and Period 2: five days~* Washout period between Period 2 and Period 3: none"
62285648|NCT03635931|ACTIVE_COMPARATOR|Concentrated Growth Factor|plaque control, scaling and root planing if required, surgical application of CGF
62285649|NCT03635931|NO_INTERVENTION|Control Group|plaque control, scaling and root planing if required
62086678|NCT00860561||1|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options.
62086679|NCT02809638||DVT of the lower limbs|patients with first suspected episode of unprovoked DVT of the lower limbs and patients with episode of unprovoked DVT of the lower limbs at third month of follow-up
62285650|NCT05215366||children with febrile seizures|
62285651|NCT05215366||febrile children without seizures|
62285652|NCT05215366||healthy control children|
62285653|NCT00463476|EXPERIMENTAL|2-year olds|Healthy children 2 years of age (±3 months) who had previously received all vaccinations recommended under the Sri Lankan childhood immunization schedule according to their age. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12 and 13 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
62285654|NCT00463476|EXPERIMENTAL|5-year olds|Healthy children 5 years of age (±3 months) that met all other eligibility criteria. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12, 13, and 24 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
62285655|NCT00378326|EXPERIMENTAL|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
62285656|NCT05086042||Psoriatic arthritis patients|
62285657|NCT05086042||healthy volunteers|
62460591|NCT03861065|EXPERIMENTAL|Tertiary Wound Closure|In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
62086680|NCT04329052|EXPERIMENTAL|Experimental group|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
62086681|NCT04329052|NO_INTERVENTION|Control group|Participants would have their usual activity without any intervention.
62086682|NCT03606135||The Pneumonia Group|Subjects with chest images (x-ray or CT scan) indicating pneumonia.
62285658|NCT01132105||Normal subjects|Adults normal hearing and vestibular function subjects
62285659|NCT03567148|ACTIVE_COMPARATOR|PRF group|Four layers of PRF membranes were placed in the palatal wound and sutured with 5/0 resorbable sutures
62285660|NCT03567148|ACTIVE_COMPARATOR|Essix retainer group|An impression of palatal region was taken and the Essix retainer was prepared before the patients underwent surgery.
62086683|NCT03606135||The Control Group|Healthy subjects
62285661|NCT03567148|ACTIVE_COMPARATOR|Ozone therapy group|Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
62285662|NCT03567148|ACTIVE_COMPARATOR|LLLT group|Irradiation was performed at the same points described above using a diode laser (λ=970±15 nm, 14-W source power) (SIROLaser Xtend; Sirona Dental Systems GmbH, Bensheim, Germany) that continuously emitted a wavelength with 320µm fiberoptic; the power was 2W and the tissue dose was 35 J/cm2. Total irradiation time was 30 seconds. The applications were performed immediately after surgery, and on the 1st, 3rd and 7th, days following the operation.
62460592|NCT03861065|ACTIVE_COMPARATOR|Historical Wound Closure|"The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure)."
62651748|NCT03789721||Adrenoleukodystrophy|All patients living in the United States diagnosed with adrenoleukodystrophy, either by newborn screen, based on family history or otherwise, are eligible to participate in this study.
62651749|NCT05232721||Fecal Immunochemical Test|People in this group will detect hemoglobin in stool before colonoscopy by the new instrument
62651750|NCT05161390|EXPERIMENTAL|LM-302 Dose Escalation at different dose levels|LM-302 Dose Escalation. 6 dose levels were pre-defined, and the initial accelerated titration followed by the i3+3 design was adopted during phase I.
62651751|NCT05161390|EXPERIMENTAL|LM-302(RP2D) Dose Expansion|LM-302 Dose Expansion, RP2D will be selected for dose expansion, with the aim to further evaluate the preliminary anti-tumor activity, safety and tolerability, etc.
62651752|NCT03314480||Midfacial fracture suspected patients|Patients who are suspected of maxillofacial fracture
62651753|NCT03314480||Mandibular fracture suspected patients|Patients who are suspected of a mandibular fracture
62651754|NCT03002402|EXPERIMENTAL|Internet-based CBT-I|"Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of cognitive-behavioral treatment for insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is allocated out over time through 6 Cores. Users obtain access to a new Core based on a time and event-based schedule (e.g., 7 days after completion of previous Core). SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window)."
62086684|NCT01463774|EXPERIMENTAL|Treatment Sequence AB|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
62086685|NCT01463774|EXPERIMENTAL|Treatment Sequence BA|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
62086686|NCT01111591|NO_INTERVENTION|2. Bile duct cancer - control|Bile duct cancer patients do not administration of COX inhibitor
62086687|NCT01111591|EXPERIMENTAL|3. Pancreas cancer - experimental|Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
62285663|NCT03567148|ACTIVE_COMPARATOR|Collagen fleece group|Collagen fleece (BEGO Collagen Fleece, Bremen, Germany) was sutured with 5/0 resorbable sutures (Pegesorb, Istanbul, Turkey) on the open wound with the aid of vertical mattress sutures.
62086688|NCT01111591|NO_INTERVENTION|4. Pancreas cancer - control|Pancreas cancer patients do not administration of COX inhibitor
62285664|NCT03567148|NO_INTERVENTION|Control group|Palatal wounds were left for spontaneous healing
62285665|NCT01424735|EXPERIMENTAL|Mw.|Administration of immunomodulator Mw.
62651755|NCT01512888|EXPERIMENTAL|Treatment|Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT
62086689|NCT01111591|EXPERIMENTAL|Bile duct cancer - experimental|Bile duct cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
62086690|NCT04129632|OTHER|IEPF intervention|Survey respondent voluntary decides to do a 4 weeks mindfulness intervention
62285666|NCT06098638|ACTIVE_COMPARATOR|control group|Group (A) included 27 overweight breastfeeding woman who received nutritional recommendation and faradic current stimulation on the abdominal surface for 12 weeks, while group
62086691|NCT00807027|NO_INTERVENTION|Control Group|The study subjects randomly assigned to the control group is given Temozolomide chemotherapy and radiation therapy for 6 weeks according to the clinical test plans, and then administers Temozolomide only for 6 weeks.
62086692|NCT00807027|EXPERIMENTAL|Test Group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after surgery by administering Temozolomide chemotherapy and radiation therapy same as control group with Immuncell-LC (14 times).
62086693|NCT01473420|EXPERIMENTAL|Epoetin Hospira|Epoetin Hospira
62086694|NCT01473420|ACTIVE_COMPARATOR|Epogen (Amgen)|Epogen (Amgen)
62086695|NCT05793762||Healthy participants|30 right handed healthy participants aged between 18 and 60.
62086696|NCT04166695|EXPERIMENTAL|Monolithic / facially veneered zirconia|Participants receive one monolithic / facially veneered zirconia fixed partial denture.
62086697|NCT04166695|OTHER|Completely veneered CoCr|Control group. Participants receive one completely veneered metal ceramic fixed partial denture.
62086698|NCT05180747|OTHER|Burst group|Patients received two physical therapy sessions weekly for 6 weeks.
62086699|NCT05180747|OTHER|Spaced Group|Patients received one physical therapy sessions every 2 weeks for 6 months.
62086700|NCT00574678|NO_INTERVENTION|1|
62285667|NCT06098638|EXPERIMENTAL|exercise group|Group (B) 27 overweight breastfeeding women, who received the same nutritional recommendation and faradic current stimulation on the abdominal surface plus exercise training (aerobic + resisted) for 12 weeks.
62285668|NCT01554501||Community sample|
62285669|NCT06112041|EXPERIMENTAL|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
62086701|NCT06077825|EXPERIMENTAL|experimental group|30 patients who underwent total hip arthroplasty surgery took part in the experimental group.
62086702|NCT00530179|ACTIVE_COMPARATOR|Arm A|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)~Assigned interventions: Drug: R-CHOP (Rituximab, Cyclophosphamide, Etoposide, Cisplatin, Mesna, G-CSF 6 - 21 DAY Cycles of R-CHOP"
62086703|NCT00530179|ACTIVE_COMPARATOR|Arm B|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.~Assigned Interventions: Procedure/Surgery: Autologous Blood Stem Transplantation 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION"
62086704|NCT01827410||patients with a ventral hernia repair|All patients with a ventral hernia repair performed in Region Zealand and registered in The Danish Ventral Hernia Database during October 1st 2010 to October 1st 2011
62086705|NCT03833700|EXPERIMENTAL|Dose Escalation Part: E7386|Participants will receive E7386 10, 15, 20 mg (milligram) or more, tablets, orally, twice daily, in 28-days treatment cycle until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
62086706|NCT03833700|EXPERIMENTAL|Expansion Part 1|Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The highest dose of E7386 which is deemed tolerable, or the optimal dose based on PK or PD analysis in dose escalation part will be used for Expansion Part 1.
62086707|NCT03833700|EXPERIMENTAL|Expansion Part 2|Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The dose of Expansion Part 2 will be based on the available safety data from Dose Escalation and Expansion Part 1 of the study.
62086708|NCT01359098|ACTIVE_COMPARATOR|Ciprodex Otic Suspension|Ciprodex Sterile Otic Solution (Alcon, Inc.)
62086709|NCT01359098|EXPERIMENTAL|Ciprodexa Otic Foam|Ciprodexa Otic Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone otic foam)
62086710|NCT01047943|EXPERIMENTAL|Psoriasis therapy|
62086711|NCT03896269|EXPERIMENTAL|Treatment (liposome-encapsulated daunorubicin-cytarabine)|"INDUCTION THERAPY: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. After 2-5 weeks, patients who do not achieve a CR/CRi/CRp, have acceptable or no toxicity, and have stable disease and no disease progression may receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients who achieve at least a HI response, receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 5-8 weeks, patients who do not show clinically significant disease progression or unacceptable toxicity may receive liposome-encapsulated daunorubicin-cytarabine for up to 12 additional cycles."
62086712|NCT01222832|EXPERIMENTAL|Bacitracin|Nasopore sponge soaked in Bacitracin, no oral antibiotics
62086713|NCT01222832|NO_INTERVENTION|Saline|Nasopore sponge soaked in saline, routine oral antibiotics
62086714|NCT03247062|OTHER|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.~The entire ICU population will be observed before and after intervention."
62086715|NCT02246374|EXPERIMENTAL|ExAblate Treated Arm|ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
62086716|NCT02246374|SHAM_COMPARATOR|ExAblate Sham Treated Arm|ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
62086717|NCT06308393|EXPERIMENTAL|Treatment group 1|Single dose in healthy subjects
62086718|NCT06308393|EXPERIMENTAL|Treatment group 2|Multiple dose in healthy subjects
62086719|NCT06308393|EXPERIMENTAL|Treatment group 3|Multiple dose in patients
62086720|NCT05515679|EXPERIMENTAL|Treatment|BRAIN Intervention
62086721|NCT06304844||diabetic without MAFLD|patients with type 2 DM but has no evidence of MAFLD
62285670|NCT01470235||Ovarian Cancer|"Women treated for ovarian cancer at the departments of obstetrics and gynecology, Aarhus University Hospital and Rigshospitalet, Copenhagen.~Expected recruitment: 200"
62651756|NCT03243396|EXPERIMENTAL|Health-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in a community setting from Community Health Volunteers.
62651757|NCT03243396|EXPERIMENTAL|Education-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in their school setting from teachers employed by their school.
62651758|NCT02081807||Dabigatran|
62651759|NCT02081807||Warfarin|
62086722|NCT06304844||diabetic with MAFLD (high hepatic involvement)|patients with type 2 DM and have evidence of MAFLD (according to abdominal ultrasonography) and have high controlled attenuation parameter and liver stiffness measurement in Fibroscan
62285671|NCT01470235||Control patients|"Women referred to the departments of obstetrics and gynecology in Aarhus University Hospital and Rigshospitalet, Copenhagen on benign indication.~Expected recruitment: 200."
62651760|NCT02943213|EXPERIMENTAL|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
62651761|NCT02943213|EXPERIMENTAL|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
62651762|NCT05815966|EXPERIMENTAL|Experimental: emotion recognition and empathy focused training program|A suitable hall for children will be determined by the school administration. Education days and hours for the children in the experimental group will be determined by negotiating with the 4th grade teachers. In this study, a 50-minute training program consisting of 2 sessions per week, lasting 5 weeks, will be applied to the experimental group.
62651763|NCT05815966|NO_INTERVENTION|Control group|Standard care group
62651764|NCT04056169|ACTIVE_COMPARATOR|Rosuvastatin|rosuvastatin 20 mg once a day for 6 months
62651765|NCT04056169|EXPERIMENTAL|ezetimibe/rosuvastatin|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
62651766|NCT01569022|ACTIVE_COMPARATOR|CPAP First, MAD|"CPAP treatment for sleep apnea~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks"
62651767|NCT01569022|EXPERIMENTAL|MAD First, CPAP|"MAD treatment for sleep apnea~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks"
62086723|NCT06304844||diabetic with MAFLD (low hepatic involvement)|patients with type 2 DM and have evidence of MAFLD (according to abdominal ultrasonography) and have low controlled attenuation parameter and liver stffiness measurement in Fibroscan
62086724|NCT02998528|ACTIVE_COMPARATOR|Platinum doublet chemotherapy|Specified dose on specified days
62086725|NCT02998528|EXPERIMENTAL|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
62086726|NCT02998528|EXPERIMENTAL|Nivolumab plus Ipilimumab|Specified dose on specified days
62086727|NCT01113463|EXPERIMENTAL|TPI 287|TPI 287 Starting dose 160 mg/m\^2 intravenous (IV) every 3 weeks
62086728|NCT04319003|NO_INTERVENTION|Control School|This school did not receive intervention (until after the study was completed)
62651768|NCT01740232|ACTIVE_COMPARATOR|Trephination|A 1 x 10 mm pricker are used for the trephination of the meniscus before normal meniscal repair.
62651769|NCT01740232|PLACEBO_COMPARATOR|Normal meniscal repair|standard operation. Normal meniscalrepair.
62651770|NCT02667899|ACTIVE_COMPARATOR|DBS group|Besides routine treatment, Doc patients in this group will accepted deep brain stimulation treatment.
62651771|NCT02667899|ACTIVE_COMPARATOR|TMS group|Besides routine treatment, Doc patients in this group will accepted transcranial magnetic stimulation treatment.
62651772|NCT02667899|PLACEBO_COMPARATOR|Control group|This Doc patients will accepted routine treatment.
62460593|NCT04008498|EXPERIMENTAL|AEEG monitoring|"Babies whose families consent to involvement will have their head cleaned, EEG leads attached, the monitor set up, and observations.~Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, the investigators will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.~Before being discharged home, the babies will have additional follow-up. They will receive magnetic resonance imaging (MRI) of the brain on a 1.5T scanner at the University of Sheffield. They will also have a standardised examination of their neurological system performed by a physiotherapist (The Hammersmith Neonatal Neurological Examination)."
62651773|NCT04664205|EXPERIMENTAL|High intensity interval training, Moderate Intensity Continuous Training, Control|Participants randomly assigned to this arm will first receive high intensity interval training and then randomly assigned to both moderate intensity continuous training and control session, on different days.
62086729|NCT04319003|EXPERIMENTAL|Intervention School|This school received a one-week sugar-reduction intervention
62651774|NCT04664205|EXPERIMENTAL|Moderate Intensity Continuous Training, High Intensity Training, Control|Participants randomly assigned to this arm will first receive moderate intensity continuous training then randomly assigned to both high intensity interval training and a control session, on different days.
62651775|NCT04664205|EXPERIMENTAL|Control session, High intensity interval training, moderate intensity continuous training|Participants randomly assigned to this arm will first complete a control session (no exercise) and then randomly assigned to both by a high intensity interval training and moderate intensity continuous training session, on different days.
62651776|NCT03415178|EXPERIMENTAL|Auto-Injector Device (AI)|Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
62285672|NCT01470235||HBOC/HNPCC|"Patients registered in the large Danish Register of HBOC( hereditary breast and ovarian cancer) and HNPCC (hereditary nonpolyposis colorectal cancer).~Expected recruitment: 200."
62285673|NCT00486447|EXPERIMENTAL|Imaging|General imaging subjects receiving CT exams
62285674|NCT00004183|EXPERIMENTAL|capecitabine|Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
62285675|NCT02129673|EXPERIMENTAL|VS101 Insert Dose A|VS101 Insert Dose A placed under the conjunctiva
62285676|NCT02129673|EXPERIMENTAL|VS101 Insert Dose B|VS101 Insert Dose B placed under the conjunctiva
62285677|NCT02129673|EXPERIMENTAL|VS101 Insert Dose C|VS101 Insert Dose C placed under the conjunctiva
62285678|NCT02129673|ACTIVE_COMPARATOR|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
62285679|NCT01777763|EXPERIMENTAL|Posaconazole 200 mg|Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
62285680|NCT01777763|EXPERIMENTAL|Posaconazole 300 mg|Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days
62086730|NCT04378504||ACS|All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
62285681|NCT00843908|ACTIVE_COMPARATOR|TVT|Women in this arm will undergo the Tension Free Vaginal Tape procedure
62285682|NCT00843908|EXPERIMENTAL|Miniarc|Women in this group will undergo the Miniarc suburethral sling procedure
62086731|NCT01364961|PLACEBO_COMPARATOR|Cellulose capsules|
62086732|NCT01364961|EXPERIMENTAL|Resveratrol capsules|
62460594|NCT02468739|EXPERIMENTAL|Ganglioside-monosialic acid arm|"Patients will receive treatment of adjuvant chemotherapy. Ganglioside-monosialic acid(GM1, 80mg per day) will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 \*4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 \*4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
62460595|NCT02468739|PLACEBO_COMPARATOR|placebo arm|"Patients will receive treatment of adjuvant chemotherapy. Placebo will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 \*4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 \*4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
62460596|NCT04351204|OTHER|MRL|radiotherapy on MR linac
62460597|NCT01917838|EXPERIMENTAL|MFG plus MyMFG|"MFG plus MyMFG will be tested and the aim is:~1. Greater quality of the Design and Do process rated by therapists, parents, and independent coders.~2. Greater quantity and quality of HW assignments rated by therapists and parents.~3. Greater quality of the Review process as rated by therapists, parents, and independent coders.~4. Greater satisfaction with treatment as rated by the parent, target child, and therapists."
62460598|NCT00939653|EXPERIMENTAL|Single Arm - Clofarabine with Chemo|All patients receive the same treatment regimen consisting of clofarabine, etoposide, cyclophosphamide, cytarabine, and filgrastim. Up to 4 courses of therapy may be given.
62460599|NCT05184842|EXPERIMENTAL|Decitabine/Venetoclax (Single Arm)|Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitaboine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).
62460600|NCT04504396|EXPERIMENTAL|PB-119 once-weekly-subcutaneous injection|PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150μg once-weekly subcutaneously to patients in active drug group for 24 weeks.
62460601|NCT04504396|PLACEBO_COMPARATOR|Placebo once-weekly-subcutaneous injection|PB-119 150μg matched placebo which will be used in placebo group for 24 weeks.
62086733|NCT01477749|EXPERIMENTAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
62086734|NCT01381744|EXPERIMENTAL|Group 3: 6 mcg Flagellin/F1/V|12 subjects will receive 6 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
62086735|NCT01381744|EXPERIMENTAL|Group 4: 10 mcg Flagellin/F1V|12 subjects will receive 10 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
62086736|NCT01381744|EXPERIMENTAL|Group 2: 3 mcg Flagellin/F1/V|12 subjects will receive 3 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
62086737|NCT01381744|EXPERIMENTAL|Group 1: 1 mcg Flagellin/F1/V|12 subjects will receive 1 microgram (mcg) of Flagellin/F1/V or placebo on Day 0 and Day 28.
62086738|NCT04288466|ACTIVE_COMPARATOR|Adults|Adults \< 60 years-old maltodextrin solution 450ml
62460602|NCT03571048|ACTIVE_COMPARATOR|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
62460603|NCT03571048|EXPERIMENTAL|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
62460604|NCT04980001|EXPERIMENTAL|FOCUS TIC-COM arm|"Health care providers will be trained in FOCUS TIC-COM through professional development and from this group the investigators plan to recruit participants for the surveys about the training, intervention feasibility and acceptability. Health care providers will be encouraged to implement FOCUS TIC-COM will all of their pediatric patients who are overweight/obese.~Parents / Caregivers of children who are overweight or obese will be recruited into the study after exposure to the intervention. Only those exposed to the intervention will be recruited to participate in the study which includes one survey and focus groups."
62651777|NCT03415178|EXPERIMENTAL|New Auto-injector Device (SYDNEY)|Alirocumab 300 mg SC injection on Week 0 (Day 1), self-administered using new auto-injector device (SYDNEY), on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, same treatment (Alirocumab 300 mg) with the same device (SYDNEY) was self-administered, (unsupervised) Q4W until Week 16 in the single arm treatment period added to LMT. Duration of single arm treatment period was 12 weeks, i.e. from Week 4 to 16.
62086739|NCT04288466|ACTIVE_COMPARATOR|Elders|Elders 65 or more years-old maltodextrin solution 450ml
62086740|NCT05665764||Veterans|Veterans will be the primary cohort for this study. Veterans who will be enrolled with have current insomnia and a history of traumatic brain injury.
62651778|NCT05223127|EXPERIMENTAL|Experimental group|Aloe vera
62086741|NCT05665764||Caregivers|Caregivers of enrolled veterans will be an optional cohort for this study. If applicable and willing to participate, caregivers of enrolled Veterans will be asked to provide collateral information regarding the Veteran's experience with the study.
62086742|NCT05981729|EXPERIMENTAL|Technology enhanced stroke rehabilitation|Supported use of stroke rehabilitation technology
62086743|NCT03841344|ACTIVE_COMPARATOR|Healthy volunteers|MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
62086744|NCT03841344|ACTIVE_COMPARATOR|Treatment naive patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH initiating PAH therapy for the first time"
62086745|NCT03841344|ACTIVE_COMPARATOR|Treatment change patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH, currently on PAH therapy who are undergoing an escalation of PAH therapy"
62086746|NCT03841344|ACTIVE_COMPARATOR|Stable patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients with PAH who are NOT undergoing changes in their treatment regime"
62086747|NCT03254069|EXPERIMENTAL|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
62086748|NCT03254069|NO_INTERVENTION|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
62086749|NCT05609019|EXPERIMENTAL|SYHX2005|"Stage1 dose-escalation: Patients with advanced solid tumors will receive escalating doses of SYHX2005 as monotherapy.~Stage2 dose-expansion: Patients with advanced solid tumors will receive SYHX2005 monotherapy at recommended dose (1 or 2 ) in Stage 1 (dose escalation) to evaluate the preliminary antitumor activity of SYHX2005."
62086750|NCT00908856|PLACEBO_COMPARATOR|Placebo|Placebo
62086751|NCT00908856|ACTIVE_COMPARATOR|autologous mononuclear cells|a single intravenous autologous bone marrow mononuclear cell transfusion
62086752|NCT00908856|ACTIVE_COMPARATOR|autologous marrow stromal cells|a single intravenous autologous marrow stromal cell transfusion
62086753|NCT03971695|EXPERIMENTAL|BI 706321|
62460605|NCT00849459|EXPERIMENTAL|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
62086754|NCT03971695|PLACEBO_COMPARATOR|Placebo|
62086755|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
62285683|NCT03436784|NO_INTERVENTION|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
33813088|NCT06625476|EXPERIMENTAL|Part A: Cohort 1|Healthy participants will be randomized to receive GSK4771261 Dose 1.
33813089|NCT06625476|EXPERIMENTAL|Part A: Cohort 2|Healthy participants will be randomized to receive GSK4771261 Dose 2.
62285684|NCT03436784|EXPERIMENTAL|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
33813090|NCT06625476|EXPERIMENTAL|Part A: Cohort 3|Healthy participants will be randomized to receive GSK4771261 Dose 3.
33813091|NCT06625476|EXPERIMENTAL|Part A: Cohort 4|Healthy participants will be randomized to receive GSK4771261 Dose 4.
33813092|NCT06625476|EXPERIMENTAL|Part A: Cohort 5|Healthy participants will be randomized to receive GSK4771261 Dose 5.
33813093|NCT06625476|EXPERIMENTAL|Part A: Cohort 6|Healthy participants will be randomized to receive GSK4771261 Dose 6.
33813094|NCT06625476|EXPERIMENTAL|Part A: Cohort 7 (optional)|Healthy participants will be randomized to receive GSK4771261 Dose 7 as the recommendation of Dose escalation committee (DEC).
62460606|NCT01507857|EXPERIMENTAL|400U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
62460607|NCT01507857|PLACEBO_COMPARATOR|0/0.5ml placebo in infants|0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28
62460608|NCT03708835|EXPERIMENTAL|Transitional Care Model is applied|Types of interventions that are applied to stroke caregivers and patient based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training. Multiple interventions including at least three face-to-face interviews at the hospital, distance education via Web and telephone communication for three months,and one home visit within seven days after discharge will be performed in order to increase health literacy levels and caregiving competence of the caregivers and to reduce burnout. In pre-tests and post-tests to be applied to the caregivers. Rate of return to the hospital, risk of pressure sore, and time of access to home health services will be assessed in stroke patients
62460609|NCT03708835|NO_INTERVENTION|Routine hospital schedule|In the first interview after the admission to the hospital, the pretest will be applied to intervention and control groups and the posttest would be applied to the groups at the end of three months after discharge. After taking the posttest, the website will be made available to the control group.
62460610|NCT03884166||stroke|
62460611|NCT03884166||control|
62285685|NCT00594217|EXPERIMENTAL|Progesterone|oral micronized progesterone suspension, single 100 mg oral dose
62285686|NCT00594217|PLACEBO_COMPARATOR|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
62285687|NCT01748604|ACTIVE_COMPARATOR|Standard trimodality therapy with MLD|Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
62460612|NCT05987371|EXPERIMENTAL|TQC3721 Suspension for Inhalation (Twice a day)+ Salbutamol|TQC3721 suspension for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
62460613|NCT05987371|EXPERIMENTAL|TQC3721 Suspension for Inhalation (Once a day)+ Salbutamol|TQC3721 suspension for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
62460614|NCT05987371|PLACEBO_COMPARATOR|TQC3721 matching placebo for inhalation (Twice a day)+ Salbutamol|TQC3721 suspension placebo for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
62460615|NCT05987371|PLACEBO_COMPARATOR|TQC3721 matching placebo for inhalation (once a day)+ Salbutamol|TQC3721 suspension placebo for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
62460616|NCT05865353||Diabetes|Ten Diabetic participants at risk of DFU/ in this cross-sectional study, participants will be asked to use the smart insole and complete sitting, standing and walking task
62460617|NCT05865353||Healthy control|Ten healthy participants without movement disorder or Diabetes. The same tasks (sitting, standing and walking) while wearing the smart insole will be repeated for the control group
62460618|NCT04699149|ACTIVE_COMPARATOR|real stimulation|The PD patients randomized in the experimental group will receive VBT each time preceded by a real rTMS stimulation.
62460619|NCT04699149|SHAM_COMPARATOR|sham stimulation|The PD patients randomized in the control group will receive VBT each time preceded by a sham TMS.
62285688|NCT01748604|EXPERIMENTAL|Trimodality therapy with LPD|Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
62460620|NCT02351024|EXPERIMENTAL|OXP005|
62460621|NCT02351024|ACTIVE_COMPARATOR|Naproxen|
62460622|NCT01719406|EXPERIMENTAL|Intervention, behavioral lifestyle education|Pregnant women will participate in 20 educational sessions designed to promote daily exercise, vegetable and fruit intake, maintain a diet that is relatively lower in fat and rich in whole grains.
62460623|NCT01719406|NO_INTERVENTION|Control|Standard medical care
62285689|NCT01748604|EXPERIMENTAL|Bimodality therapy without MLD|intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
62460624|NCT00987181||Angiography high risk|Patients with multiple risk factors, positive non-invasive test, or known pre-existing coronary artery/vascular disease. Patients with diabetes mellitus will be identified, and subject to a sub-group analysis.
62651779|NCT05223127|NO_INTERVENTION|Control group|routine care (dressing with dry gauze)
33813095|NCT06625476|EXPERIMENTAL|Part A: Cohort 8 (optional)|Healthy participants will be randomized to receive GSK4771261 Dose 8, as per the recommendation from DEC.
33813096|NCT06625476|EXPERIMENTAL|Part B: Cohort 1|Participant with Autosomal dominant polycystic kidney disease (ADPKD) will be randomized to receive GSK4771261 Dose 9.
33813097|NCT06625476|EXPERIMENTAL|Part B: Cohort 2|Participant with ADPKD will be randomized to receive GSK4771261 Dose 10.
62285690|NCT00249574|EXPERIMENTAL|pegInterferon|Open label, observational trial to determine the safety of HCV treatment in active IDUs stabilized on buprenorphine/naloxone
62285691|NCT03502850|EXPERIMENTAL|ASK120067|patients take ASK120067 orally once per day at different dose
62285692|NCT02365623|EXPERIMENTAL|TMC207 (bedaquiline) + Background Regimen (BR)|Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4\*100 mg tablets once daily 2 weeks (14 days). From Week 3, participants will receive 200 mg (2 tablets) TMC207 (bedaquiline) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase. After TMC207 is stopped, the BR will be continued up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
62651780|NCT02218463|ACTIVE_COMPARATOR|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
33813098|NCT06625476|EXPERIMENTAL|Part B: Cohort 3|Participant with ADPKD will be randomized to receive GSK4771261 Dose 11.
33813099|NCT06625476|EXPERIMENTAL|Part B: Cohort 4 (optional)|Participant with ADPKD will be randomized to receive GSK4771261 Dose 12 as the recommendation from DEC.
33813100|NCT06625476|EXPERIMENTAL|Part B: Cohort 5 (optional)|Participant with ADPKD will be randomized to receive GSK4771261 Dose 13, as per the recommendation from DEC.
33813101|NCT06625476|EXPERIMENTAL|Part A and B: Placebo|Healthy participant and participants with ADPKD will be randomized to receive matching Placebo.
62086756|NCT05951699||minimally invasive preoperative image-guided vacuum-assisted biopsy|"cT1-cT2-cT3 cN0-cN1 breast cancer patients, either with clinical/radiological complete response, or with \<1 cm residual breast disease after systemic primary treatment, undergo preoperative image-guided breast VAB with 9-gauge needle.~Patients who are cN1 before systemic primary treatment undergo removal of the tagged axillary nodes.~In both cases the aim is to identify any residual disease. Conservative breast surgery or mastectomy will be performed in all patients after multidisciplinary clinical evaluation.~Surgically confirmed residual tumor will be compared to VAB result."
62086757|NCT05349396|EXPERIMENTAL|Eszopiclone Test Product T-1|Participants will receive one tablet of the Test T-1 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
62086758|NCT05349396|EXPERIMENTAL|Eszopiclone Test Product T-2|Participants will receive one tablet of the Test T-2 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
62086759|NCT05349396|ACTIVE_COMPARATOR|Eszopiclone Referent Product|Participants will receive one tablet of the marketed reference formulation containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
62086760|NCT02019433||Structan®|
62086761|NCT04807829|EXPERIMENTAL|Nabilone|Patients in the treatment group will be administered oral Nabilone 2 mg once daily for 3 days in addition to treatment as usual according to current clinical guidelines and standard of care.
62086762|NCT04807829|PLACEBO_COMPARATOR|Placebo Comparator|Patients in the Placebo Comparator group will receive placebo once daily for 3 days plus treatment as usual.
62460625|NCT00987181||Angiography Low Risk|Patients with chest pain symptoms, minimal risk factors, and inconclusive evidence of myocardial ischaemia on non-invasive testing.
62086763|NCT06127160|ACTIVE_COMPARATOR|Standard Duration Treatment|
62086764|NCT06127160|EXPERIMENTAL|Patient-directed antimicrobial duration (PDAD)|
62086765|NCT01579578|EXPERIMENTAL|1|
62086766|NCT01579578|PLACEBO_COMPARATOR|2|
62086767|NCT00989170|EXPERIMENTAL|Family Program for the Prevention of Weight Gain|Use of an enhanced Family Program on the prevention of weight gain in families with overweight children.
62086768|NCT00989170|ACTIVE_COMPARATOR|No enhanced Family Program|
62285693|NCT03372941|ACTIVE_COMPARATOR|Alternative treatment strategy|Patient will receive a single dose of dalbavancin administered in the BJH ED or ED observation unit for ABSSSI followed by discharge w/ close Infectious Disease outpatient clinic follow-up.
62285694|NCT03372941|NO_INTERVENTION|Usual care|"Patients will receive usual care (i.e., hospital admission for intravenous antibiotics - typically, vancomycin) - antibiotic and doses to be determined at the discretion of the treating clinician (both in the BJH ED and on the BJH inpatient ward)."
62086769|NCT01272596||Multiple Sclerosis Patients|Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
62086770|NCT03754738|EXPERIMENTAL|Balloon guide catheter group|mechanical thrombectomy with a balloon guide catheter group
62086771|NCT03754738|ACTIVE_COMPARATOR|Non-balloon guide catheter group|mechanical thrombectomy with a non-balloon guide catheter group
62086772|NCT03101592|NO_INTERVENTION|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
62086773|NCT03101592|EXPERIMENTAL|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
62460626|NCT00086762|EXPERIMENTAL|MR Therapy|Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. A CD with the mindfulness relaxation technique recorded on it will be given to participant. Participant to listen to the recording for about 30 minutes before receiving chemotherapy and during the time they are receiving chemotherapy. In addition to the mindfulness relaxation technique, they will also receive general information about how to manage symptoms that develop due to the chemotherapy they are receiving.
62086774|NCT03101592|EXPERIMENTAL|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
62086775|NCT04129411|EXPERIMENTAL|RFA Group|
62086776|NCT00724334|EXPERIMENTAL|1|
62086777|NCT03891680|EXPERIMENTAL|Botox injection|
62086778|NCT03891680|ACTIVE_COMPARATOR|Genicular Radio frequency|
62285695|NCT05862792||TORS + Liposomal Bupivacaine + Postoperative Antipyretics and Opioids Group|"Per standard of care, at the conclusion of the TORS procedure, liposomal bupivacaine will be injected into the surgical bed- (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\], intramuscular) in this group. Possible injection sites include the base of tongue and/or tonsil. Total dose injected will be 3-4 mL. Subjects will also be given a pain regimen including:~1. Tylenol 650 mg every 4 hours as needed for mild pain~2. Oxycodone 5 mg every 4 hours as needed for moderate pain~3. Morphine 2mg every 3 hours as needed for breakthrough pain~The treatment type (TORS +/- Liposomal Bupivacaine + Postoperative Antipyretics and Opioids) is determined by the subject's surgeon based on his standard practice."
62285696|NCT05862792||TORS + Postoperative Antipyretics and Opioids Group|"Per standard of care, subjects in this group will only be given a pain regimen including:~1. Tylenol 650 mg every 4 hours as needed for mild pain~2. Oxycodone 5 mg every 4 hours as needed for moderate pain~3. Morphine 2mg every 3 hours as needed for breakthrough pain~The treatment type (TORS +/- Liposomal Bupivacaine + Postoperative Antipyretics and Opioids) is determined by the subject's surgeon based on his standard practice."
62285697|NCT01726647||No product is tested|No intervention
62285698|NCT03498820|EXPERIMENTAL|Analgesia Nociception Index|Intraoperative remifentanil administration guided by the Analgesia Nociception Index
62285699|NCT03498820|ACTIVE_COMPARATOR|Usual practice|Intraoperative remifentanil administration managed in standard practice
62651781|NCT02218463|ACTIVE_COMPARATOR|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
62086779|NCT04592328||Patients planned for elective open cardiac surgery|
62086780|NCT03640689|EXPERIMENTAL|Intervention Group|Endovenous ablation + iliac US +/- iliac stenting
62086781|NCT03640689|ACTIVE_COMPARATOR|Control Group|Endovenous ablation of Great Saphenous Vein
62651782|NCT02629302|EXPERIMENTAL|animal assisted therapy|"Standard therapy (speech therapy, occupational therapy and physiotherapy) that is done in the presence and with Integration of an animal."
62651783|NCT02629302|ACTIVE_COMPARATOR|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
62460627|NCT00086762|EXPERIMENTAL|Relaxing Music (RM) Therapy|Arm II: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment.
62285700|NCT00419471|EXPERIMENTAL|Escitalopram|
62651784|NCT02404142|PLACEBO_COMPARATOR|Control group (saline isotonic solution)|saline isotonic solution
62651785|NCT02404142|EXPERIMENTAL|Curar (Atracurium) group|Curar (Atracurium)
62285701|NCT00419471|PLACEBO_COMPARATOR|Placebo pill|
62285702|NCT04909684|NO_INTERVENTION|Standard of care|100% pembrolizumab
62285703|NCT04909684|EXPERIMENTAL|Intervention|75% pembrolizumab
62285704|NCT05994937|EXPERIMENTAL|Active Portable Air Cleaner (PAC) Filtration|High Efficiency Particulate Air (HEPA) filter will be left intact in the PAC for 4 weeks.
62460628|NCT00086762|ACTIVE_COMPARATOR|Standard Symptom Management|Arm III: Participants receive standard symptom management education.
62086782|NCT02311192|EXPERIMENTAL|Ultrasonography B-scan|Patients of uveitis who are included in the study will be imaged using ultrasound B-scan
62460629|NCT03420300|EXPERIMENTAL|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
62651786|NCT01130272|EXPERIMENTAL|Eluxadoline 5 mg|Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks.
62651787|NCT01130272|EXPERIMENTAL|Eluxadoline 25 mg|Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
62651788|NCT01130272|EXPERIMENTAL|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks.
62651789|NCT01130272|EXPERIMENTAL|Eluxadoline 200 mg|Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks.
62651790|NCT01130272|PLACEBO_COMPARATOR|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks.
62651791|NCT04156698|EXPERIMENTAL|Camrelizumab (PD-1 inhibitor) group|"Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total:~Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1;~Radical radiotherapy plus concurrent immunotherapy (CR or PR):~Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction)；CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22;~Maintenance period:~After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy)."
62651792|NCT01584934|EXPERIMENTAL|Sodium oxybate|Patient group receives sodium oxybate as treatment.
62651793|NCT01584934|PLACEBO_COMPARATOR|Placebo|Patient group receives placebo as treatment.
62651794|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
62651795|NCT04260165|EXPERIMENTAL|Proximal Row Carpectomy|
62651796|NCT04260165|ACTIVE_COMPARATOR|Four-corner fusion|
62086783|NCT03250598|EXPERIMENTAL|Cohort A|
62285705|NCT05994937|SHAM_COMPARATOR|Sham Portable Air Cleaner (PAC) Filtration|High Efficiency Particulate Air (HEPA) filter will be removed from the PAC for 4 weeks.
62285706|NCT01011348|OTHER|Placebo vs Q10 100mg vs Q10 300mg|
62285707|NCT01011348|OTHER|Q10 100mg vs Placebo vs Q10 300mg|
62285708|NCT01011348|OTHER|Placebo vs. Q10 300mg vs. Q10 100mg|
62285709|NCT01011348|OTHER|Q10 300mg vs. Placebo vs. Q10 100mg|
62285710|NCT00427856|EXPERIMENTAL|Obatoclax mesylate 40mg|40 mg over 3 hrs q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
62285711|NCT00427856|EXPERIMENTAL|Obatoclax mesylate 60mg|60 mg obatoclax mesylate over 24 hours, q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
62460630|NCT01706471|EXPERIMENTAL|Everolimus + Low dose CsA +PD|
62460631|NCT01706471|ACTIVE_COMPARATOR|Myfortic+ Standard CsA + PD|
62651797|NCT01116557|OTHER|THERMOCOOL® group|Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
62651798|NCT01116557|ACTIVE_COMPARATOR|PVAC® group|Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®
62086784|NCT03250598|EXPERIMENTAL|Cohort B|
62460632|NCT05192330|EXPERIMENTAL|Virtual Reality Glasses|"After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale(pain and nursing satisfaction) scoring scale will apply to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were applied, the nurse gave Virtual Reality Glasses for 30 minutes.~Glasses will be given put on before the process starts and training will be given to continue watching the video while wearing the glasses.The women include in the Virtual reality application group will be shown a video with a nature view during the procedure.~Every woman will be shown the same video."
62086785|NCT03250598|EXPERIMENTAL|Cohort C|
62285712|NCT02899156|ACTIVE_COMPARATOR|Flumazenil Infusion|The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
62285713|NCT02899156|PLACEBO_COMPARATOR|Placebo Infusion|The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
62460633|NCT05192330|EXPERIMENTAL|Therapeutic Touch|"Applied therapeutic touch intervention on their hands for 30 minutes to help patients feel comfortable during the procedure.The researcher started the application by taking an appropriate hand of the patient between his hands and held it for 30 minutes. The researcher's fingers are closed, not clasped, and his hand is placed on the participant's hand.~The researcher held her hand steady without touching or rubbing it. In addition, the researcher is not use gloves."
62460634|NCT05192330|NO_INTERVENTION|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (virtual reality or Therapeutic Touch) was performed. Both groups were re-evaluated using the same scales after the intrauterine insemination. Within 5 minutes of completing the procedure, participants will asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale, anxiety scale and satisfaction scale.
62460635|NCT03077516||Mobi-C|Prior recipient of Mobi-C Disc in IDE/Post Approval Study
62460636|NCT03077516||ACDF|Prior control subject in IDE/Post Approval Study
62460637|NCT03675828|EXPERIMENTAL|Virtual Visit|In this arm, the 7-day post discharge visit will be completed by a scheduled virtual visit with a member of the study team using the Cleveland Clinic Online Express Care application on a computer or a tablet/phone.
62086786|NCT02886728|EXPERIMENTAL|Filgotinib 200 mg + MTX|Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
62460638|NCT03675828|NO_INTERVENTION|Outpatient Clinic|In this arm, the 7-day post discharge visit will be completed by a standard-of-care, in-person outpatient visit with a member of the study team in the heart failure clinic.
62651799|NCT05507450|EXPERIMENTAL|V181 High-Potency Level Group|Participants will receive a single 0.5mL subcutaneous (SC) dose of V181 High-Potency vaccine.
62086787|NCT02886728|EXPERIMENTAL|Filgotinib 100 mg + MTX|Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg
62285714|NCT01018355|EXPERIMENTAL|Device closure of PFO|Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
62086788|NCT02886728|EXPERIMENTAL|Filgotinib 200 mg Monotherapy|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX
62086789|NCT02886728|ACTIVE_COMPARATOR|MTX Monotherapy|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
62086790|NCT02594696|EXPERIMENTAL|Proactive Psychiatry Consultation (PPC)|"The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention.~* Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline)~* Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)"
62285715|NCT01018355|ACTIVE_COMPARATOR|Medical anticoagulative treatment|Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
62460639|NCT04088760|EXPERIMENTAL|TCRαβ+/CD19+ depleted HSCT|
62460640|NCT04318665|EXPERIMENTAL|CT Perfusion|Severe TBI patients will be undergoing CT perfusion test
62460641|NCT03043924|OTHER|PCOS women|26 PCOS women who receive consultation for hyperandrogenism needing treatment with Cyproterone Acetate + estradiol will be recruited.
62460642|NCT03043924|OTHER|Healthy volunteers|26 Healthy volunteers subjects who receive consultation contemplating oral contraceptives (Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet ) will be recruited.
62651800|NCT05507450|EXPERIMENTAL|V181 Mid-Potency Level Group|Participants will receive a single 0.5mL SC dose of V181 Mid-Potency vaccine.
62086791|NCT05348824|EXPERIMENTAL|Moringa oleifera|
62086792|NCT05348824|ACTIVE_COMPARATOR|Sodium hypochlorite|
62651801|NCT05507450|EXPERIMENTAL|V181 Low-Potency Level Group|Participants will receive a single 0.5mL SC dose of V181 Low-Potency vaccine.
62651802|NCT05507450|PLACEBO_COMPARATOR|Placebo|Participants will receive a single SC 0.5 mL dose of placebo.
62086793|NCT03655496|NO_INTERVENTION|Control group|Subject to standard care.
62086794|NCT03655496|EXPERIMENTAL|Intervention group|Exposed to the home-based tool.
62086795|NCT06010485|ACTIVE_COMPARATOR|Serial Casting|The serial casting group received intermittent serial casting once every three days for three weeks.
62285716|NCT05606237|EXPERIMENTAL|Low Level Red Light Treatment Arm|On top of wearing single vision spectacles, subjects in the intervention group will receive low-level red light treatment twice a day from Monday to Friday, with each treatment lasting for 3 minutes at a minimal interval of 4 hours.
62285717|NCT05606237|NO_INTERVENTION|Control Treatment Arm|Subjects in the control group will wear single vision spectacles.
62285718|NCT04761796||Professional flight members|
62651803|NCT03504553|EXPERIMENTAL|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
62651804|NCT03504553|NO_INTERVENTION|Control|Normal operating room environment.
62651805|NCT05308914||Resilience Study Cohort|Observational, descriptive longitudinal cohort design. See inclusion and exclusion criteria for more information
62651806|NCT04808102|EXPERIMENTAL|IER serious game|A serious game training interpersonal emotion regulation strategies.
62460643|NCT06090149|EXPERIMENTAL|CPAP/APAP INTERVENTION WITH AND WITHOUT OXYGEN SUPPORT|Patients in this group will be selected from the Sleep Disorder Center database for printing data on hypoxemia below 90% during the night and for treatment received (CPAP/APAP and/or oxygen therapy). And from available data in PSCUH data systems on patient diagnoses, previous results of studies (results of blood gas tests), and recommended treatments on hospital and outpatient disease cards, which will include indications of possible chronic hypoxemia. The selected patients will be called (telephone visit) and, if agreed, will be scheduled for study time. Consequently, if the consent questionnaire was signed, a study will be launched following an evaluation of the inclusion and exclusion criteria.
62460644|NCT02879682|ACTIVE_COMPARATOR|nTMS|presurgical motor mapping by nTMS and fusion with intraoperative neuronavigation
62460645|NCT02879682|SHAM_COMPARATOR|non-nTMS|presurgical motor mapping by nTMS without access of the surgeon to these data
62460646|NCT05427383|EXPERIMENTAL|KN026 + Paclitaxel/ Docetaxel/ Irinotecan|IV KN026 at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W
62460647|NCT05427383|EXPERIMENTAL|Placebo + Paclitaxel/ Docetaxel/ Irinotecan|IV Placebo at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W
62460648|NCT01459328|ACTIVE_COMPARATOR|Arm A: Conventional Long Course Chemo-Radiation|Conventional long course chemo-radiation
62651807|NCT04808102|SHAM_COMPARATOR|control game|A control puzzle game without psychoeducational content.
62651808|NCT02279953|EXPERIMENTAL|Vortioxetine 10-20 mg|daily, encapsulated, orally
62651809|NCT02279953|EXPERIMENTAL|Vortioxetine 10-20 mg + SSRI|daily, encapsulated, orally
62651810|NCT02279953|EXPERIMENTAL|SSRI|licensed doses, encapsulated, orally
62651811|NCT03243149|SHAM_COMPARATOR|False Feedback|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. False feedback (sham) shows a thermometer that indicates false feedback consisting of noise.
62651812|NCT03243149|ACTIVE_COMPARATOR|View Condition|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. View condition shows a thermometer that indicates true activation of ventromedial PFC minus amygdala but the participant is asked not to attempt neuroregulation.
62651813|NCT03243149|EXPERIMENTAL|Free Regulate|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. Free regulate shows a thermometer that indicates true activation of ventromedial PFC minus amygdala while the participant attempts neuroregulation.
62651814|NCT06551545|EXPERIMENTAL|Experimental: Tryptophan in healthy young adults (18-45 years)|Tryptophan intake levels, up to 5 levels, will be tested in a random order in all subjects
62086796|NCT06010485|ACTIVE_COMPARATOR|Exercise|The physical therapy group underwent three sessions per week for three weeks, consisting of stretching exercises, strengthening exercises, balance training, proprioception exercises, and walking on heels.
62086797|NCT06010485|NO_INTERVENTION|Control Group|This group consists of the patients on the waitlist.
62086798|NCT01537354|ACTIVE_COMPARATOR|Survanta®|Survanta® (Beractant, Abbot Laboratories, Columbus, OH) Surfactant will be administered by respiratory therapist not involved in patient's care.
62086799|NCT01537354|ACTIVE_COMPARATOR|Curosurf®|Curosurf® (Cornerstone Therapeutics, Inc., Cary, NC Surfactant will be administered by respiratory therapist not involved in patient's care.
62460649|NCT01459328|EXPERIMENTAL|Arm B: Short Course Radiation Followed by Chemotherapy|Experimental short course radiation followed by chemotherapy.
62460650|NCT03809026||Study group|Couples where the men have Klinefelter's syndrome, maturation stop in the spermatogenesis or failed retrieval of testicular sperm by conventional techniques with needle or TruCut, and where testicular sperm could be obtained by micro-TESE.
62460651|NCT03809026||Control group|Couples as in the study group, but where testicular sperm could not be obtained by micro-TESE. The oocytes therefore must be fertilized using donor sperm.
62460652|NCT05316922|EXPERIMENTAL|TSH suppression during irradiation|"From 14 days beforehand and throughout their RT, patients in the experimental arm will receive L-thyroxine in the morning, starting with 1-2 μg/kg, and adjusting the dose every 3 days to ensure TSH \< 0.3 μIU/mL before RT beginning. The 0.3 μIU/mL threshold is just below normal range not causing hyperthyroidism, and is defined as mild TSH suppression. Based on hormone status, L-thyroxine doses will be gradually increased to patients' individual minimum TSH-suppressive dose before starting RT, maintained throughout the treatment, then rapidly tapered off and stopped. During radiation treatment course will be checked twice a week for serum FT3, FT4, TSH assays in order to maintain TSH \< 0.3 μIU/mL, possibly without exceeding normal levels of FT3 and FT4. Once a week patients will also have a full visit and any other blood examination according to protocol in use and Institutional practice."
62651815|NCT04786769|EXPERIMENTAL|Iron supplementation|"Intravenous ferric carboxymaltose will be administered according to weight and hemoglobin values at randomization as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention (if determined by dose calculation, otherwise placebo) 12 weeks after valve intervention (if iron deficiency persists, otherwise placebo)"
62086800|NCT04404257|EXPERIMENTAL|ControlRad System|Participant will undergo Cardiac catheterization or electrophysiology implant procedures with the ControlRad system installed in Cath lab room 5
62651816|NCT04786769|PLACEBO_COMPARATOR|Placebo|"Intravenous 0.9% NaCl (placebo) will be administered as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention 12 weeks after valve intervention"
62086801|NCT04404257|ACTIVE_COMPARATOR|Without ControlRad System|Participant will undergo the cardiac catheterization or electrophysiology implant procedures per standard of care. Meaning, without the ControlRad system installed in Cath lab room 5.
62086802|NCT02086799|EXPERIMENTAL|IV thyroxin|IV thyroxin
62086803|NCT02086799|PLACEBO_COMPARATOR|control IV saline|Placebo
62086804|NCT05931705||High risk|
62651817|NCT04996030|EXPERIMENTAL|Single-Dose PK Module: Sequence 1|Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fed state on Day 8, and SY-210 in a fasted state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
62651818|NCT04996030|EXPERIMENTAL|Single-Dose PK Module: Sequence 2|Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fasted state on Day 8, and SY-2101 in a fed state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
62651819|NCT04996030|EXPERIMENTAL|Single-Dose PK Comparability Module|Participants will receive two single-dose treatments of SY-2101, with separated from one another by approximately 1 week and separated from any preceding IV ATO dose by at least 72 hours.
62651820|NCT04996030|EXPERIMENTAL|Multiple-Dose IV Module|Participants will receive IV ATO, once daily (QD), 5 days/week for 28 days as a part of at least one cycle (Weeks 1 through 4) of SOC treatment consolidation.
62651821|NCT04996030|EXPERIMENTAL|Multiple-Dose Oral Module|Participants will receive SY-2101, QD, 5 days/week for 28 days as a part of one cycle (Cycle 4; Weeks 1 through 4) of SOC treatment consolidation.
62651822|NCT05627687|PLACEBO_COMPARATOR|Music Listening Control|Music listening control (MLC) will consist of listening to selected music tracks of choice using either the Pandora or Spotify app (with coaching to download app and play, and log listening time in diary), specifically choosing a neutral channel, Coffeehouse Playlist. For both interventions, FCG will be asked to practice/listen 10-minutes at a time with their AD patient (sharing as much or as little as is possible/preferred) for at least 4-5 days/week, and asked to complete diary/checklists to show times practicing/listening.
62651823|NCT05627687|ACTIVE_COMPARATOR|Heart Rate Variability Biofeedback|"Participants will receive coaching in a practice that is guided using an Inner Balance app with a device that senses pulse and provides feedback to help achieve a rhythm of heart rate variability called resonant frequency, or coherence. They will be guided first in slowed heart-focused breathing and positively-focused emotions and then will connect to the app to receives visual feedback to achieve a favorable HRV."
62086805|NCT01880515|EXPERIMENTAL|Tetracycline|Patients will receive tetracycline 250mg every 12 hours for 1 month plus general dermatological recommendations (sunscreen and emollient cream)
62285719|NCT05891665|EXPERIMENTAL|Patients treated with the acceleration method|Patients will be treated using fixed orthodontic appliances assisted by minimally-invasive corticotomy (osteoperforations and piezocision) to accelerate impacted canines' traction after levelling and aligning the upper dental arch and opening an appropriate distance.
62460653|NCT05316922|NO_INTERVENTION|Any TSH suppression during irradiation|Patient in the standard arm will perform radiotherapy treatment without any TSH suppression. At the end of radiation they will do serum FT3, FT4, TSH assay and then, after one year from RT, thyroid ultrasound + serum FT3, FT4, TSH assay.
62460654|NCT05734222|ACTIVE_COMPARATOR|Control Group|The control group is retrospective. It will include patients who have been operated on for POVG in the surgical department No. 1 of the KPH during the last 3 years (25-35) and 5-10 patients who will be operated on within the next 6-8 months.
62086806|NCT01880515|NO_INTERVENTION|No Tetracycline|This arm only with general dermatologic recommendations. Patients in this arm can receive tetracycline after week 4 of assessment only if rash grade 3-4 occur
62086807|NCT01953510|ACTIVE_COMPARATOR|A: 3+1 PCV10|PCV10 administered at 2, 3, 4 and 9 months of age
62086808|NCT01953510|EXPERIMENTAL|B: 3+0 PCV10|PCV10 administered at 2, 3 and 4 months of age
62460655|NCT05734222|EXPERIMENTAL|Established group|The established group - patients who will be operated on in the surgical department No. 1 of the KPH over the next 1.5 - 2 years, using the developed techniques.
62460656|NCT03729310|OTHER|Propel Implant|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
62086809|NCT01953510|EXPERIMENTAL|C: 2+1 PCV10|PCV10 administered at 2, 4 and 9 months of age
62086810|NCT01953510|EXPERIMENTAL|D: 1+1 PCV10|PCV10 administered at 2 and 6 months of age
62086811|NCT01953510|EXPERIMENTAL|E: 2+1 PCV13|PCV13 administered at 2, 4 and 9 months of age
62086812|NCT01953510|NO_INTERVENTION|F: control|No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
62086813|NCT01953510|NO_INTERVENTION|G: control|Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age
62086814|NCT02213419|EXPERIMENTAL|ethanol double lavage|Endoscopic ultrasonography-guided double ethanol lavage
62086815|NCT02907697|EXPERIMENTAL|LifeSteps-Drug Use|The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
62086816|NCT02907697|ACTIVE_COMPARATOR|Health Education|The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
62651824|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
62086817|NCT06098807|EXPERIMENTAL|Familiy Based Treatment|;one session per week during a period of four weeks with high quality content. The sessions will be performed at CAP location in Lund. The treatment will be performed by a clinician at CAP who could be a doctor, psychologist or health counselor - all with cognitive behavioral therapy competence. The sessions will be in group settings, separately for children and parents. In that sense, children will be included in a group with other children and parents will be included in a group with other parents. Each group will have 1-2 therapists leading the program. The theme of the week will be the same for both parent and child group, although the delivery will potentially differ. We expect that a session will last approximately 90 min with a 15-minute coffee break included.
62086818|NCT05530967|EXPERIMENTAL|Triaging Tool|
62285720|NCT05891665|ACTIVE_COMPARATOR|Patients treated with the traditional traction technique|Patients will be treated using the fixed orthodontic appliances to track the palatally impacted canines after levelling and aligning the upper dental arch and opening an appropriate space to receive the impacted canine.
62285721|NCT03038347|EXPERIMENTAL|Training|In the training group, participants work six weeks on the training program, one module per week. The modules contain PDF-files with text-based information, video files, case studies with associated questions as well as practical exercises that participants perform independently. The main purpose of this intervention is the improvement of cross-cultural competencies in psychotherapists
62285722|NCT03038347|ACTIVE_COMPARATOR|Education only|In the education only group, participants work six weeks on a slimmed down version of the training program. The modules only contain text-based information without any exercises. After completion, participants receive access to the practical exercises, case studies and video files as well. Main purpose of the education only group is to determine whether the practical part of the training program can offer additional benefit.
62285723|NCT03038347|NO_INTERVENTION|Waiting control|Initially, participants do not receive any training contents. After a six week waiting period, they can participate in the training program as well. Modules are equivalent to those of the training group. Purpose of this group is to determine whether the training program is effective.
62651825|NCT02934594||Group A|Motor function intact group: received palliative decompression
62651826|NCT02934594||Group B1|motor deficit group: received palliative decompression within 48 hours after symptoms occured
62086819|NCT05530967|EXPERIMENTAL|Video Education|
62086820|NCT05879640|NO_INTERVENTION|Before- standard care|
62086821|NCT05879640|OTHER|After- intervention|Patients studied in this arm receive the new educational intervention delivered in conjunction with standard care
62086822|NCT04555629|EXPERIMENTAL|Advanced Cognitive Stimulation Therapy Hong Kong|"Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. It has also been translated and adapted for the Hong Kong Chinese population.~ACST-HK will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee, or care home staff."
62285724|NCT02911688|PLACEBO_COMPARATOR|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
62651827|NCT02934594||Group B2|motor deficit group: received palliative decompression 48 hours after symptoms occured
62651828|NCT05761847|NO_INTERVENTION|Usual Care|The usual care group will receive standard-of-care medication management practices delivered during the course of a routine clinical visit.
62651829|NCT05761847|EXPERIMENTAL|Intervention|The intervention group will receive the pMTM study intervention before a routine clinical visit.
62651830|NCT02437292|EXPERIMENTAL|Ischemic compression with stretching|The participants will receive the ischemic compression with stretching onto the trapezius muscle
62651831|NCT02437292|NO_INTERVENTION|Control|Rest on the bed
62651832|NCT05899998|EXPERIMENTAL|Bright IDEAS|
62651833|NCT05899998|NO_INTERVENTION|Standard of Care|
62086823|NCT04555629|NO_INTERVENTION|Treatment as usual|Standard care in care homes
62086824|NCT00615602|EXPERIMENTAL|1|FEC -\> TXT+H 12m
62285725|NCT02911688|ACTIVE_COMPARATOR|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
62285726|NCT03244657|EXPERIMENTAL|Q12W group|
62285727|NCT03244657|EXPERIMENTAL|TAE group|
62285728|NCT03779438|ACTIVE_COMPARATOR|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
62460657|NCT03729310|OTHER|Nasopore soaked with triamcinolone|"This packing' is a sponge-like material which dissolves while releasing triamcinolone, which is another type of steroid. Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA."
62285729|NCT03779438|PLACEBO_COMPARATOR|placebo to 17-OHPC|patients received weekly placebo to 17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
62285730|NCT04869241|EXPERIMENTAL|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
62285731|NCT00150098|EXPERIMENTAL|lifestyle counselling|Education
62285732|NCT03012074|EXPERIMENTAL|Patients with Type II Diabetes|Patients with Type II Diabetes
62460658|NCT02550574|EXPERIMENTAL|Wound closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
62086825|NCT00615602|EXPERIMENTAL|2|FEC -\> TXT+H 6m
62086826|NCT01351610|EXPERIMENTAL|Group B|
62086827|NCT01351610|EXPERIMENTAL|Group A|
62086828|NCT02034084|EXPERIMENTAL|Right radial approach|Coronary diagnostic procedures performed through right radial approach
62086829|NCT02034084|EXPERIMENTAL|Left radial approach|Coronary diagnostic procedures performed through left radial approach
62285733|NCT04940234|EXPERIMENTAL|Black Expert|Survey respondents are exposed to a Black person wearing expert attire.
62285734|NCT04940234|EXPERIMENTAL|Black Layperson|Survey respondents are exposed to a Black person wearing layperson's attire.
62285735|NCT04940234|EXPERIMENTAL|White Expert|Survey respondents are exposed to a white person wearing expert attire.
62285736|NCT04940234|EXPERIMENTAL|White Layperson|Survey respondents are exposed to a white person wearing layperson's attire.
62460659|NCT02550574|ACTIVE_COMPARATOR|Wound closure with 5-0 vicryl sutures|One side of the patient's wound defect will be assigned to wound closure with 5-0 vicryl sutures.
62460660|NCT06484647||T-stenting And Minimal Protrusion|"Percutaneous coronary intervention is performing according to current coronary Revascularization guidelines (ACC/ESC).~The vascular access is chosing according patients characteristics and operator preferences and require radial or femoral insertion of the sheath.~Antiplatelets strategy is a discretion of the operator and is depending on clinical presentation of the patients and respect the current guidelines (i.e Clopidogrel 600 mg load dose following 75 mg/daily, Ticagrelor 180 mg load dose following 180 mg/daily, Prasugrel 60 mg load dose following 10 mg/daily).~The procedural steps of the technique are described below:~* MV stenting~* Distal rewiring towards SB~* Kissing Balloon for opening distal struts towards SB~* SB stent implantation~* Final Kissing Balloon"
62460661|NCT06484647||External Minicrush|"Percutaneous coronary intervention is performing according to current coronary Revascularization guidelines (ACC/ESC).~The vascular access is chosing according patients characteristics and operator preferences and require radial or femoral insertion of the sheath.~Antiplatelets strategy is a discretion of the operator and is depending on clinical presentation of the patients and respect the current guidelines (i.e Clopidogrel 600 mg load dose following 75 mg/daily, Ticagrelor 180 mg load dose following 180 mg/daily, Prasugrel 60 mg load dose following 10 mg/daily).~The procedural steps of the technique are described below:~* SB stent deployment with protrusion into MB~* Crush the SB stent with a balloon inflating into MB (\>0.5 mm of the SB stent)~* MB stent deployment~* Rewiring~  * POT~ * KBI~ * Final POT technique"
62460662|NCT04085107||243 PwMCI|
62086830|NCT04223921||Patients who will be discharged from hospital (acute geriatric|Patients who will be discharged from hospital (acute geriatric care unit) between January and March 2020
62086831|NCT06697743||Patient undergo bariatric surgery|"1. Inclusion criteria:~   1. Age more than 18 years old undergo bariatric surgery .~  2. BMI ≥30 : ( BMI = weight in kg / height in m²)~2. Exclusion criteria:~   1. previous kidney diseases(AKI , CKD) .~  2. patients unfit for surgery e.g ( comorbidities : CHD , LCF ) 3. Drugs : (ACE-I , ARBs, and NSAIDS)"
62086832|NCT00463151|PLACEBO_COMPARATOR|1|0mg rebamipide
62086833|NCT00463151|EXPERIMENTAL|2|60mg rebamipide
62086834|NCT00463151|EXPERIMENTAL|3|150mg rebamipide
62086835|NCT00463151|EXPERIMENTAL|4|300mg rebamipide
62086836|NCT03498755|EXPERIMENTAL|Multi-sectoral anemia behavior change|Address multiple behavioral determinants of anemia by promoting the identification, knowledge, valuation and practice of four behavioral domains: 1) consumption of micronutrient-rich animal-source foods; 2) malaria and soil-transmitted helminth infection control practices; 3) water, sanitation and hygiene (WASH) best practices; and 4) women's autonomy in decision-making and control of the use of earned income.
62285737|NCT02681666|ACTIVE_COMPARATOR|FODMAPs CONTROL arm|Dietary intervention in this cohort with irritable bowel syndrome will be administered a low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols diet by a dietician.
62460663|NCT02458638|EXPERIMENTAL|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
62460664|NCT00115882|EXPERIMENTAL|1|proactive smoking-cessation telephone counseling
62285738|NCT02681666|EXPERIMENTAL|MB-IBS-EAT INTERVENTION STUDY arm|Irritable Bowel Syndrome eating awareness training intervention will be started in a comprehensive 8 weekly sessions of Mindfulness eating training.
62285739|NCT01390792||Subjects prescribed zanamivir|Subjects prescribed zanamivir during study period
62285740|NCT00559273|EXPERIMENTAL|Mircera|Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
62285741|NCT00559273|ACTIVE_COMPARATOR|Darbepoetin Alfa|Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
62285742|NCT05619458|EXPERIMENTAL|Mindfulness intervention|The intervention will consist of 6 one-hour sessions delivered once per week in a classroom at an alternative high school during normal school hours.
62285743|NCT04774939|ACTIVE_COMPARATOR|EVLA only|Only main trunk/trunks with venous reflux will be treated
62285744|NCT04774939|ACTIVE_COMPARATOR|EVLA and sclerotherapy of tributaries|Main trunk/trunks with venous reflux will be treated combined with foam sclerotherapy
62285745|NCT05749757|EXPERIMENTAL|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 40 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.
62285746|NCT05749757|SHAM_COMPARATOR|Sham Acupuncture|Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session sham acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.
62285747|NCT01777672|ACTIVE_COMPARATOR|Dietary and oral hygiene recommendations|Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.
62285748|NCT01777672|EXPERIMENTAL|oral TRPV1 agonist|Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.
62285749|NCT01777672|EXPERIMENTAL|pharyngeal electrical stimulation|Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.
62285750|NCT01777672|EXPERIMENTAL|transcutaneous electrical stimulation|Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
62460665|NCT00115882|NO_INTERVENTION|2|no-intervention control
62460666|NCT02149888|EXPERIMENTAL|Tenofovir/emtricitabine|MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis
62460667|NCT01453556|EXPERIMENTAL|Intracorpopreal anastomosis|Intracorporeal mechanical anastomosis
62285751|NCT05402826|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pills.
62285752|NCT05402826|ACTIVE_COMPARATOR|Zinc+vitamin E supplements|Patients will receive zinc tablets plus alpha-tocopherol.
62285753|NCT05679206||Preeclampsia and obstetric Antiphospholipid Syndrome|Women in this group wil be followed during 3 years. Echocardiography images, 24-hour ambulatory blood pressure monitoring will be collected.
62285754|NCT05679206||Preeclampsia without obstetric Antiphospholipid Syndrome|Women in this group wil be followed during 3 years. Echocardiography images, 24-hour ambulatory blood pressure monitoring will be collected.
62285755|NCT05050760|EXPERIMENTAL|The experimental group|Drug：DCF+Camrelizumab Camrelizumab:200mg/time,IV,Q3W
62285756|NCT01772667|NO_INTERVENTION|Usual care|Usual care during the whole study period without pulmonary rehabilitation. The patients will perform their normal daily life.
62460668|NCT01453556|ACTIVE_COMPARATOR|Extracorporeal anastomosis|Extracorporeal mechanical anastomosis
62460669|NCT04671888|EXPERIMENTAL|COPD patients|
62460670|NCT01097408|EXPERIMENTAL|AZD7295|
62460671|NCT01097408|PLACEBO_COMPARATOR|Matched placebo|
62460672|NCT04220151||Hepatocellular carcinoma|Sixty patients with HCC
62460673|NCT04220151||Hepatic cirrhosis|Thirty patients with hepatic cirrhosis
62460674|NCT04220151||Healthy controls|Ten healthy controls.
62086837|NCT03498755|EXPERIMENTAL|Strengthening market engagement of fish processors|Assist women in overcoming limited access to credit, inadequate storage facilities, and insufficient information about market prices, which constrain the timeliness and amount of market-ready product available for sale, through a three-pronged approach that includes: 1) a conditional cash transfer; 2) entrepreneurship training; and 3) enhanced access to market price information.
62086838|NCT03498755|EXPERIMENTAL|Improving fish smoking technology and practices|Introduce and promote a recently developed fish smoking oven known as the Ahotor, which was explicitly designed to reduce emission from biomass fuel combustion, decrease polycyclic aromatic hydrocarbon (PAH) levels of smoked fish, and increase fuel efficiency. Use of this oven will reduce workload, increase earnings, and reduce harmful occupational exposures. Introduction of this improved fish smoking oven will be combined with behavior change education focused on promoting optimal fish smoking and handling practices.
62086839|NCT06085560|ACTIVE_COMPARATOR|Usual Care Message|"Participants selecting a colorectal cancer screening will receive usual care from the FQHC."
62086840|NCT06085560|ACTIVE_COMPARATOR|Implementation Intention Intervention: Standard Message|"Participants selecting a colorectal cancer screening will receive implementation intention messages in addition to the usual care from the FQHC."
62285757|NCT01772667|ACTIVE_COMPARATOR|Inpatient Rehabilitation|3-week inpatient multimodal pulmonary rehabilitation program, including daily exercise training, breathing therapy, medical treatment and psychological support. In the following 3 month, the patients will perform their normal daily life.
62285758|NCT01698957||UA Doppler Velocimetry|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
62285759|NCT05546892|EXPERIMENTAL|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery~Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Natrium sulfate - 7,5 g Natrium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Natrii ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 Macrogol-3350 - 100 g Natrium sulfate - 7,5 g Natrium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Natrii ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
62285760|NCT05546892|ACTIVE_COMPARATOR|No bowel preparation|No bowel preparation (enema of not more then 500 ml is allowed prior or during surgery)
62651834|NCT02582489|EXPERIMENTAL|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
62651835|NCT02582489|PLACEBO_COMPARATOR|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
62285761|NCT00983567|EXPERIMENTAL|Teen web|Main web - with all components
62285762|NCT00983567|ACTIVE_COMPARATOR|Minimal teen web|Teen web minus behavioral components
62285763|NCT04007315|EXPERIMENTAL|SaeboGlove Therapy + usual care|Use for 6 weeks - given an individualised self-management training programme involving repetitive grasping and releasing movements.
62285764|NCT04007315|ACTIVE_COMPARATOR|Usual care|Usual NHS rehabilitation care based on National Clinical Guidelines for 6 weeks + 2 study visits and one study phone call
62651836|NCT00431418|ACTIVE_COMPARATOR|1|Sildenafil oral solution.
62285765|NCT01449708|NO_INTERVENTION|Balanced Anesthesia|Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
62285766|NCT01449708|ACTIVE_COMPARATOR|NoNarc TIVA|Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine
62651837|NCT00431418|PLACEBO_COMPARATOR|2|Placebo oral solution.
62285767|NCT03752645|EXPERIMENTAL|intervention|Transverse Many Channels Laser Instrument
62285768|NCT03752645|NO_INTERVENTION|control|
62285769|NCT05480319|EXPERIMENTAL|EDICARS|
62285770|NCT05480319|ACTIVE_COMPARATOR|Usual care|
62460675|NCT03339856|EXPERIMENTAL|Treatment arm|Patients received selective retina therapy
62460676|NCT02020707|EXPERIMENTAL|Treatment (AB-complex)|Patients receive nab-paclitaxel/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may receive paclitaxel if supply of nab-paclitaxel is exhausted.
62460677|NCT02472184|ACTIVE_COMPARATOR|Office Hysteroscopy|Group of patients in which office hysteroscopy will be performed prior to endometrial biopsy
62651838|NCT03829176|NO_INTERVENTION|Standard-of-Care|Participants who are randomized to not have whole genome sequencing performed on their sample. These participants will have standard-of-care genetic testing only (ordered by their clinical provider) and will not receive genetic results as part of this study.
62086841|NCT06085560|EXPERIMENTAL|Implementation Intention Intervention: Culturally-Targeted Message|"Participants selecting a colorectal cancer screening will receive culturally-targeted implementation intention messages in addition to the usual care from the FQHC."
62086842|NCT03670797||controlled diabetic patients|
62086843|NCT03670797||uncontrolled diabetic patients|
62651839|NCT03829176|EXPERIMENTAL|Whole Genome Sequencing|Participants who are randomized to have their genome sequenced and receive a whole genome sequencing report. Results disclosure sessions will include a discussion of the whole genome sequencing report, how the results compare to their standard-of-care genetic testing report, and any potential relevant recommendations. Participants in this arm will receive a copy of their whole genome sequencing report accompanied by a summary letter written by a study genetic counselor.
62086844|NCT01013220|EXPERIMENTAL|Depression Product Detailing|Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org
62651840|NCT03151369|OTHER|Morphine|patients with the visual analog scale over 3 will receive morphine
62651841|NCT00976365|EXPERIMENTAL|THL-P|Solution for study only.
62460678|NCT02472184|ACTIVE_COMPARATOR|Endometrial biopsy|Group of patients in which endometrial biopsy will be performed prior to office hysteroscopy
62651842|NCT00976365|PLACEBO_COMPARATOR|Sugar pill|THL-p
62651843|NCT01391611|EXPERIMENTAL|Pazopanib arm|
62651844|NCT04518696|EXPERIMENTAL|suprachoroidal buckling treatment group|suprachoroidal buckling for therapy of rhegmatogenous retinal detachment
62651845|NCT05244200|NO_INTERVENTION|Non-Intervention Group|Patients in the non-intervention group will be followed for the therapeutic outcomes and detection of DTPs without tempting to resolve them
62651846|NCT05244200|EXPERIMENTAL|Intervention Group|A strict protocol developed by IDC for insulin prescription is going to be implement and patients will be assessed for the therapeutic outcomes along with the detection and resolution of drug therapy problems throughout the course
62651847|NCT02636621|ACTIVE_COMPARATOR|Brazilian Dental Appliance|The device increases the volume of the airway by mandibular traction.
62651848|NCT02636621|PLACEBO_COMPARATOR|Placebo|Oral device that does not change the volume of the airway
62651849|NCT02438579|EXPERIMENTAL|Nasal Irrigation & Gargling|"Videos on how to collect nasal swabs, prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) are shown. A nasal swab is collected. Participant chooses the highest concentration of hypertonic saline he/she is comfortable with (from 1.5, 2.0, 2.5 and 3.0%) and performs HSNIG under observation. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
62651850|NCT02438579|NO_INTERVENTION|Control|"The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
62285771|NCT05730387||mother and newborn dyads|We will recruit 6700 mother and newborn dyads from the two participating hospitals. We will continue to follow-up with all patients enrolled in the study until 6 weeks (42 days) post delivery.
62651851|NCT01366716|EXPERIMENTAL|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
62651852|NCT01366716|EXPERIMENTAL|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
62651853|NCT01366716|NO_INTERVENTION|Non-CM Control|Participants in the non-CM control condition will provide urine specimens during the 12-week period as do the two experimental conditions, but will receive no contingent rewards other than praise from the RAs.
62651854|NCT03329885|EXPERIMENTAL|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
62651855|NCT03329885|EXPERIMENTAL|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
62651856|NCT03329885|EXPERIMENTAL|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
62651857|NCT05551416||EPIGASTRIC|Patients with GC.
62651858|NCT05551416||EDGAR 1|Symptomatic patients subjected to a diagnostic gastroscopy to study the prevalence of premalignant gastric lesions.
62651859|NCT05551416||EDGAR 2|Patients with premalignant gastric lesions and early gastric neoplasias treated by endoscopy resection.
62651860|NCT05551416||Negative control|"Patients from EDGAR 1 without gastric pathology or familial history of this neoplasia."
62651861|NCT04260633|NO_INTERVENTION|Group 1|22-hour tray wear time, DM assisted aligner change frequency
62651862|NCT04260633|ACTIVE_COMPARATOR|Group 2|22-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
62651863|NCT04260633|SHAM_COMPARATOR|Group 3|22-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
62651864|NCT04260633|ACTIVE_COMPARATOR|Group 4|12-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
62651865|NCT04260633|SHAM_COMPARATOR|Group 5|12-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
62651866|NCT02245711|EXPERIMENTAL|Stem Cell|
62651867|NCT00504400|EXPERIMENTAL|A|
62651868|NCT02574091|EXPERIMENTAL|Cohort 1-Experimental|"4 healthy adult participants will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
62651869|NCT02574091|PLACEBO_COMPARATOR|Cohort 1-Placebo|"2 healthy adult participants will be randomized to receive placebo (blank cream), applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
62651870|NCT02574091|EXPERIMENTAL|Cohort 2-Experimental|"4 healthy adult participants will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
62086845|NCT01013220|PLACEBO_COMPARATOR|Depression HEDIS Detailing|Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive
62086846|NCT02761629|EXPERIMENTAL|Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
62086847|NCT02761629|ACTIVE_COMPARATOR|Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
62651871|NCT02574091|PLACEBO_COMPARATOR|Cohort 2-Placebo|"2 healthy adult participants will be randomized to receive matching placebo, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
62651872|NCT02574091|EXPERIMENTAL|Cohort 3-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
62086848|NCT05143242|ACTIVE_COMPARATOR|Guided bone regeneration: Control|Deproteinized bovine derived xenograft (Geistlich Bio-Oss® 0.25 - 1 mm, Geistlich Pharma AG, Wolhusen, Switzerland)
62651873|NCT02574091|PLACEBO_COMPARATOR|Cohort 3-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
62086849|NCT05143242|ACTIVE_COMPARATOR|Connective tissue graft: Test|Connective tissue graft harvested from the palate
62086850|NCT03317210|OTHER|iron therapy with good response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. The maximum total iron dose was 1,600 mg, therefore therapy was stopped if the maximal iron sucrose dose was administered, or target Hb \> 10.5 g/dL was achieved.
62460679|NCT03905486|ACTIVE_COMPARATOR|G1: patients will receive pregabalin|pregabalin as a mono-therapy will be administered in increment doses for 3 months
62651874|NCT02574091|EXPERIMENTAL|Cohort 4-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
62651875|NCT02574091|PLACEBO_COMPARATOR|Cohort 4-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
62651876|NCT02497469|EXPERIMENTAL|Vedolizumab IV 300 mg|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
62651877|NCT02497469|ACTIVE_COMPARATOR|Adalimumab SC 160/80/40 mg|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
62651878|NCT01516216|ACTIVE_COMPARATOR|Chemotherapy + Standard Dose Vitamin D|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 400 IU vitamin D3 orally once daily~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
62651879|NCT01516216|ACTIVE_COMPARATOR|Chemotherapy + Higher Dose|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 8000 IU daily x 2 weeks as loading dose, followed by 4000 IU daily as maintenance dose.~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
62651880|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
62651881|NCT01477567|EXPERIMENTAL|0.3 mg LY3009385|LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
62651882|NCT01477567|EXPERIMENTAL|1 mg LY3009385|LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
62651883|NCT01477567|EXPERIMENTAL|3 mg LY3009385|LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
62651884|NCT01477567|EXPERIMENTAL|9 mg LY3009385|LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
62651885|NCT01477567|EXPERIMENTAL|22 mg LY3009385|LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
62651886|NCT01477567|EXPERIMENTAL|54 mg LY3009385|LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
62651887|NCT01477567|PLACEBO_COMPARATOR|Placebo|Placebo: saline, subcutaneous (SC) injection, single dose on Day 1
62651888|NCT00193635|ACTIVE_COMPARATOR|1|oral MMF
62651889|NCT01323556|EXPERIMENTAL|Exposure with fear augmentation|exposure-based CBT, including interoceptive exposure and in-vivo exposure with fear augmentation by interoceptive exercises (e.g. hyperventilation)
62651890|NCT01323556|EXPERIMENTAL|Exposure without fear augmentation|exposure-based CBT, including interoceptive and in-vivo exposure without fear augmentation during in-vivo exposure
62651891|NCT05227716|EXPERIMENTAL|Magnesium sulphate|"Administration of intravenous MgSO4 as an adjunct to anesthesia.~Dose: 30 mg / kg of MgSO4 IV 15 minutes before induction of anesthesia and 10 mg / kg / h in continuous IV infusion during the operation"
62651892|NCT05227716|PLACEBO_COMPARATOR|Placebo|"Administration of intravenous physiological solution (NaCl 0.9%) as a complement to anesthesia.~Dose: equivalent to that administered in the MgSO4 group"
62651893|NCT05152121|OTHER|carb counting|Patients using insulin infusion pumps will be placed CGMS for 2 days before starting the study to check whether they are within the target blood glucose levels and normoglycemia will be provided. The content of the first day of the study; The test meal, which is 80 g carbohydrate (29.3%), 70.2 g fat (57.9%), 34.7 g protein (12.7%), will be consumed in the evening meal and normal bolus insulin will be given according to carbohydrate counting. On the second day of the study, instead of the normal bolus for the test meal, the additional insulin for fat-protein by dual wave bolus that.The data obtained will be analyzed by evaluating the CGMS data of all patients by a pediatric endocrinologist experienced in diabetes, CGMS and insulin infusion pump therapy.
62651894|NCT00723827||All Participants|Participants with newly diagnosed glioblastoma multiforme (treat with temozolomide \& radiotherapy) or participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy (treat with temozolomide).
62651895|NCT01926691||Acute First-ever Stroke|Patients over 50 years and without pre-stroke dementia, displaying an ischemic first-ever stroke or transient ischemic attack (TIA), onset within the last 72 hours, Israeli residents.
62651896|NCT01416038|EXPERIMENTAL|Vaccine|Cohort A: 0.5 mL of DPX-Survivac (injection)
62651897|NCT01416038|EXPERIMENTAL|Vaccine + low dose cyclophosphamide|Cohort B: 0.1 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
62651898|NCT01416038|EXPERIMENTAL|Vaccine + low dose cyclophosphamide.|Cohort C: 0.5 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
62651899|NCT02613130|EXPERIMENTAL|Two-Step stannous fluoride toothpaste|Two-Step stannous fluoride toothpaste
62651900|NCT02613130|ACTIVE_COMPARATOR|Potassium nitrate toothpaste|Potassium nitrate toothpaste
62651901|NCT00299858|ACTIVE_COMPARATOR|Study Group|Patients will be given theophylline, titrated to optimal blood levels, for a period of 4 weeks.
62651902|NCT00299858|PLACEBO_COMPARATOR|Placebo group|Patients will receive placebo pills for a period of 4 weeks.
62651903|NCT04732793|EXPERIMENTAL|Hyruan ONE®|
62651904|NCT04732793|ACTIVE_COMPARATOR|Durolane®|
62651905|NCT05047900|EXPERIMENTAL|Rapid antigen testing kit use once weekly|"Community will use rapid antigen testing kit once weekly every Monday and will be asked to conduct a weekly self-test for 3 weeks.~This research use COVID-19 Saliva Antigen Rapid Test from Tigsun COVID-19 Speichel Antigen-Schnelltest from Beijing Tigsun Diagnostics"
62651906|NCT05047900|EXPERIMENTAL|Rapid antigen testing kit use twice weekly|Community will use rapid antigen testing kit twice weekly every Monday and Thursday and will be asked to conduct a twice-weekly self-test for 3 weeks This research use COVID-19 Saliva Antigen Rapid Test from Tigsun COVID-19 Speichel Antigen-Schnelltest from Beijing Tigsun Diagnostics
62651907|NCT05047900|NO_INTERVENTION|Control|Did not routinely use Rapid antigen testing kit
62460680|NCT03905486|ACTIVE_COMPARATOR|G2: patients will receive pregabalin and milnacipran|pregabalin and milancipran as a combination therapy will be administered in increment doses for 3 months
62460681|NCT06360627|OTHER|Low Dose|Standard Low Dose CT
62460682|NCT06360627|OTHER|Ultra Low Dose|Ultra Low Dose CT
62086851|NCT03317210|OTHER|iron therapy with poor response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. If response to therapy with iron sucrose was poor (i.e. Hb increase \<0.7 g/dl after 2 weeks), patients additionally received recombinant human erythropoietin (10,000 U EPREX®, Janssen-Cilag, Baar, Switzerland).
62086852|NCT03317210|OTHER|iron therapy and erythropoietin|Patients with an Hb between 8.0 and 8.9 g/dl received 200mg iron sucrose and recombinant human erythropoietin intravenously twice weekly.
62086853|NCT02011243||Professional players, men|This group includes professional, male, handball players meeting study inclusion criteria.
62285772|NCT02561936|EXPERIMENTAL|Panel 1: Group 1|Participants will receive Treatment A (25 milligram \[mg\] rilpivirine \[RPV\] formulated as the oral tablet under fed condition \[standardized breakfast\]) followed by Treatment D (25 mg RPV formulated as granules formulation G002 \[10 g of 2.5 mg/g granules, dispersed in water\] under fed \[standardized breakfast\]) followed by Treatment B (25 mg RPV formulated as dispersible tablet formulation G007 \[10\*2.5 mg tablets, dispersed in water\] under fed condition) followed by Treatment C (25 mg RPV formulated as dispersible tablet formulation G009-01 \[10\*2.5 mg tablets, dispersed in water\] under fed condition).
62285773|NCT02561936|EXPERIMENTAL|Panel 1: Group 2|Participants will receive treatment B followed by treatment A then treatment C followed by treatment D.
62460683|NCT02208492|EXPERIMENTAL|Levetiracetam|
62460684|NCT02208492|ACTIVE_COMPARATOR|Carabamazepine|
62086854|NCT02011243||Professional players, women|This group includes professional, female, handball players meeting study inclusion criteria.
62460685|NCT01050647|ACTIVE_COMPARATOR|17-hydroxyprogesterone caproate|Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
62460686|NCT01050647|PLACEBO_COMPARATOR|Castor oil injections|Weekly injections of Caster Oil (placebo)
62460687|NCT01212874|ACTIVE_COMPARATOR|Nitroglycerin|nitroglycerin titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
62460688|NCT01212874|ACTIVE_COMPARATOR|Esmolol|esmolol titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
62460689|NCT01980862||Heart Failure patients|No interventions for this study. Blood draw provided by patients.
62460690|NCT04165148|EXPERIMENTAL|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the Intelligent Flow System (iFS) AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
62460691|NCT04165148|ACTIVE_COMPARATOR|conventional laparoscopy|conventional laparoscopy
62460692|NCT05406349|OTHER|Electrophysiological recordings in participants with intracranially implanted electrodes|All participants will perform behavioral tasks that test their spatial navigation and memory performance in self-navigation and observation tasks.
62460693|NCT01740219|EXPERIMENTAL|Capacity Enhancement|
62460694|NCT01740219|ACTIVE_COMPARATOR|Standard Dissemination|
62460695|NCT03947138|EXPERIMENTAL|GC3107_Part1|Part 1 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
62460696|NCT03947138|EXPERIMENTAL|GC3107_Part2|Part 2 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
62651908|NCT01038765|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
62086855|NCT02011243||Junior players, men|This group includes junior, male, handball players meeting study inclusion criteria.
62086856|NCT02011243||Junior players, women|This group includes junior, female, handball players meeting study inclusion criteria.
62086857|NCT01091285|ACTIVE_COMPARATOR|Single Balloon Catheter|Cervix Ripening is achieved by a single balloon catheter. Further induction by cytotec or/amniotomy and pitocin
62651909|NCT01038765|NO_INTERVENTION|Waiting list control group|3-month waiting list group
62651910|NCT05622006|EXPERIMENTAL|Control condition|Control condition: Sitting from 8 am until 3pm.
62086858|NCT01091285|ACTIVE_COMPARATOR|Double balloon catheter|Cervix Ripening is achieved by a double balloon catheter. Further induction by cytotec or/amniotomy and pitocin
62651911|NCT05622006|EXPERIMENTAL|Condition 1|Condition 1: 35 minutes of treadmill walking followed by sitting until hour 7 is reached
62651912|NCT05622006|EXPERIMENTAL|Condition 2|Condition 2: 2.5 minutes of treadmill walking for every 30 minutes until hour 7 is reached.
62651913|NCT05622006|EXPERIMENTAL|Condition 3|Condition 3: 5 minutes of treadmill walking every 60 minutes, until hour 7 is reached.
62086859|NCT00862875|EXPERIMENTAL|1:Insulin detemir|Insulin detemir (Levemir® - Novolin® 4 pen)
62086860|NCT00862875|ACTIVE_COMPARATOR|2:Insulin Glargin|Insulin glargine (Lantus® - Solostar®)
62086861|NCT05674084||Study group|Critically ill patients undergoing any vasopressor treatment. CRT will be measured over the course of hospitalization. Maximal number of CRT measurements from a single patient is limited to 5.
62086862|NCT03374111|EXPERIMENTAL|Experimental group|15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd) ， taken once daily for 8 weeks
62285774|NCT02561936|EXPERIMENTAL|Panel 1: Group 3|Participants will receive treatment C followed by treatment B then treatment D followed by treatment A.
62285775|NCT02561936|EXPERIMENTAL|Panel 1: Group 4|Participants will receive treatment D followed by treatment C then treatment A followed by treatment B.
62285776|NCT02561936|EXPERIMENTAL|Panel 2: Group 1|Participants will receive Treatment E (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 \[10\*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water\] under fed \[standardized breakfast\] condition) followed by Treatment H (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 \[10\*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water\] under fed \[yoghurt\] condition) followed by Treatment F (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 \[10\*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water\] under fasted condition) followed by Treatment G (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 \[10\*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water\] under fed \[standardized breakfast\] condition).
62460697|NCT03947138|ACTIVE_COMPARATOR|BCG SSI_Part1|Part 1 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
62460698|NCT03947138|ACTIVE_COMPARATOR|BCG SSI_Part2|Part 2 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
62460699|NCT05536518|OTHER|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|
62086863|NCT03374111|PLACEBO_COMPARATOR|Control group|a Simulate Agent of Colla corii asini granule， similar in size, shape，color and taste to Colla corii asini granule, taken once daily for 8 weeks
62086864|NCT03677375|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00026.
62086865|NCT05608720|EXPERIMENTAL|study group|Information Booklet prior to the dental visit
62086866|NCT05608720|NO_INTERVENTION|control group|no information prior to the dental visit
62086867|NCT00285090|EXPERIMENTAL|Early Treatment|
62651914|NCT02130999|EXPERIMENTAL|Sequence A|"* Single oral dose of tasimelteon 20 mg on Day 1~* Single I.V. dose of tasimelteon 2 mg on Day 6"
62651915|NCT02130999|EXPERIMENTAL|Sequence B|"* Single I.V. dose of tasimelteon 2 mg on Day 1~* Single oral dose of tasimelteon 20 mg on Day 6"
62086868|NCT00285090|EXPERIMENTAL|LateTreatment|
62086869|NCT00285090|EXPERIMENTAL|Total Treatment|
62086870|NCT00285090|PLACEBO_COMPARATOR|No Treatment|
62086871|NCT01491529|EXPERIMENTAL|AFQ056 150 mg|Patients randomized to the AFQ056 150 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 150 mg twice daily.
62086872|NCT01491529|EXPERIMENTAL|AFQ056 200 mg|"Patients randomized to the AFQ056 200 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 200 mg twice daily.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
62285777|NCT02561936|EXPERIMENTAL|Panel 2: Group 2|Participants will receive Treatment F followed by Treatment E then Treatment G followed by Treatment H.
62285778|NCT02561936|EXPERIMENTAL|Panel 2: Group 3|Participants will receive Treatment G followed by Treatment F then Treatment H followed by Treatment E.
62285779|NCT02561936|EXPERIMENTAL|Panel 2: Group 4|Participants will receive Treatment H followed by Treatment G then Treatment E followed by Treatment F.
62285780|NCT04391725|EXPERIMENTAL|Periapical surgery with guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and the defect is filled with mixture of iPRF and type 1 collagen granules before flap closure.
62460700|NCT01320306||Subarachnoid hemorrhage|A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
62086873|NCT01491529|PLACEBO_COMPARATOR|Placebo|Patients randomized to the Placebo arm will receive oral AFQ056 Placebo twice daily
62086874|NCT01461993|ACTIVE_COMPARATOR|Group 1|rLP2086 + Gardasil
62285781|NCT04391725|ACTIVE_COMPARATOR|Periapical surgery without any guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and flap closure done.
62285782|NCT02856984||ZIKV infected women|The study will prospectively enroll pregnant women up to 17 weeks and 6 days gestation and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.
62285783|NCT02856984||Control (uninfected women)|The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.
62285784|NCT02117687|ACTIVE_COMPARATOR|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
62285785|NCT02117687|ACTIVE_COMPARATOR|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
62460701|NCT01320306||Prophylactic surgical treatment of un-ruptured aneurysms|A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
62460702|NCT01320306||Conservative treatment|A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
62460703|NCT01320306||Control group of healthy subjects|Control group of healthy subjects
62460704|NCT04127045||IMN-Group|Patients treated with intramedullary nailing
62460705|NCT04127045||HA-Group|Patients treated with Hemiarthroplasty
62460706|NCT01050803|EXPERIMENTAL|FDSME group|In the FDSME group, sessions will be held interactive; and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
62460707|NCT01050803|ACTIVE_COMPARATOR|Control group|
62460708|NCT02161848||Patients|Patients with verified singe large-scale mtDNA deletions and chronic progressive external ophthalmoplegia.
62651916|NCT02706574||Isolated Traumatic Brain Injury|This group will present to our Level 1 Trauma Center with a Traumatic Brain Injury and no other associated injuries. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
62086875|NCT01461993|PLACEBO_COMPARATOR|Group 2|rLP2086 and saline
62086876|NCT01461993|ACTIVE_COMPARATOR|Group 3|Saline + Gardasil
62086877|NCT05380739|ACTIVE_COMPARATOR|In-Person, MCI|Participants diagnosed with MCI will undergo 10 sessions of WM training in person.
62651917|NCT02706574||Isolated Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient with no injury to their head. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
62086878|NCT05380739|ACTIVE_COMPARATOR|Online, MCI|Participants diagnosed with MCI will undergo 10 sessions of WM training online.
62086879|NCT05380739|ACTIVE_COMPARATOR|Online, Healthy|Cognitively intact older adults will undergo 10 sessions of WM training online.
62285786|NCT02688348|OTHER|Ancillary-Correlative (late toxicity and QOL)|Patients complete the EORTC QLQ-BLM-C30 at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.
62651918|NCT02706574||Combined Traumatic Brain Injury and Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient that had injuries to both their head and body. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
62651919|NCT02706574||Healthy, Uninjured Controls|This group will consist of subjects that have not been exposed to any major trauma in the previous 12 months. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
62086880|NCT00159510|NO_INTERVENTION|Control|The control group with neither nitric oxide nor methylene blue used
62086881|NCT00159510|ACTIVE_COMPARATOR|MB alone|Single methylene blue used
62086882|NCT00159510|ACTIVE_COMPARATOR|NO alone|Nitric oxide alone used
62086883|NCT00159510|ACTIVE_COMPARATOR|MB+NO|Both nitric oxide and methylene blue used
62086884|NCT00253903|EXPERIMENTAL|1|5 mg/day
62086885|NCT00253903|PLACEBO_COMPARATOR|2|
62086886|NCT03548636|EXPERIMENTAL|Single-Arm Feasibility Study|Participant determined 6-month physical activity program
62086887|NCT02877953|NO_INTERVENTION|Control group|The conventional care was performed for the patients of control group
62086888|NCT02877953|EXPERIMENTAL|Intervention group|the prevention of complications post-TIPS
62651920|NCT04050033|EXPERIMENTAL|Treatment Arm|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments (Tx.1, Tx.2 and Tx.3).
62086889|NCT02165124|EXPERIMENTAL|Intervention/Bariatric Embolization|
62086890|NCT04548154|EXPERIMENTAL|Proximal Resistance Training|Participants will receive 6 one-on-one supervised intervention visits and 8 telerehabilitation visits over 10 weeks. For the first 4 weeks intervention frequency will start with 1x/ week in clinic and 1x/ week via telerehabilitation, and the participant will be asked to perform exercises 2x/ week independently. For the final 6 weeks there will be 1x week supervised visits (weeks 6 and 8 in person, and weeks 5,7, 9, and 10 via telerehabilitation) and the participant will be asked to perform exercises 3x/ week independently.
62086891|NCT02854306|ACTIVE_COMPARATOR|Surgery|Obese patient without mindfulness program in parallel.
62086892|NCT02854306|ACTIVE_COMPARATOR|Surgery with mindfulness program|Obese patient following a mindfulness program in parallel.
62086893|NCT02333396|EXPERIMENTAL|PICU Supports|Participants will receive the PICU Supports intervention.
62086894|NCT02333396|ACTIVE_COMPARATOR|Educational Brochure|Participants will receive an educational brochure about the pediatric intensive care unit.
62285787|NCT03226626|ACTIVE_COMPARATOR|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
62285788|NCT03226626|EXPERIMENTAL|TAAD + IVAD|Both subcutaneous tumescent anesthesia \& antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
62285789|NCT02667145|EXPERIMENTAL|Intervention|Self care program focusing on the assistive device, For 4 weeks (1 to week lasting 90 minutes).
62285790|NCT02667145|NO_INTERVENTION|Control group|receive only a brochure with orientations of joint protection.
62285791|NCT00524056|EXPERIMENTAL|001|Carisbamate two 100 mg tablets twice per day
62285792|NCT00524056|PLACEBO_COMPARATOR|002|Placebo two placebo tablets twice per day
62086895|NCT05646485|EXPERIMENTAL|BCa Early Screening Group|"All participants undergo Urinalysis testing every 6 months for 2 years. Based on the RBC count, each participant will go through each of the screening procedures : \[cystoscopy + Upper tract imaging\] or \[urine marker cancer testing with Cxbladder triage + Upper tract imaging\] or \[Repeat urinalysis\]~Patients with suspicious findings on cystoscopy or imaging will get treatment as per standard of care.~Their outcomes will be compared to a historical control (bladder cancer detected by standard of care using SEER registries)."
62086896|NCT05646485|NO_INTERVENTION|Historical Control Group|This will include historical control (bladder cancer detected in patients by standard of care) using SEER registries).
62285793|NCT00283556|EXPERIMENTAL|Cohort #1|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
62285794|NCT00283556|EXPERIMENTAL|Cohort #2|"Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
62285795|NCT00283556|EXPERIMENTAL|Cohort #3|"Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
62285796|NCT03653390|EXPERIMENTAL|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
62285797|NCT03653390|ACTIVE_COMPARATOR|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
62285798|NCT03653390|NO_INTERVENTION|Control|Participant continues with their lives as they normally would.
62460709|NCT02161848||Controls|Healthy controls matched for age and gender.
62651921|NCT01576614||Nurse-Physician Rounding by Phone|"The SICU's practice involves daily morning team rounding at the bedside. The team includes the critical care attending physician (AP), surgical resident physician, and critical care nurse. The AP is physically present in the SICU during these rounds and for the hours between approximately 7am and 7pm. During off-shift hours (7pm-7am), the AP is available by phone as the on-call attending physician. In addition to this on-call availability, the standard of practice in SICU for years has been that the on-call physician proactively places a telephone call to the SICU at least once every evening to perform telephone rounds with the resident physician aeach SICU patient."
62285799|NCT04025645||PATIENTS WITH CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITH CHOLELITHIASIS
62285800|NCT04025645||PATIENTS WITHOUT CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITHOUT CHOLELITHIASIS
62460710|NCT02161848||Patient group as Controls|Patients with mitochondrial DNA 3243A\>G mutations
62460711|NCT05299047|ACTIVE_COMPARATOR|Group US-guided|will receive superior hypogastric plexus neurolysis by the US-guided anterior approach
62285801|NCT02538302|EXPERIMENTAL|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
62285802|NCT02538302|ACTIVE_COMPARATOR|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
62285803|NCT06068972||MolecuLight cohort|The MolecuLight bacterial imaging procedure was used in combination with standard of care clinical wound assessment.
62285804|NCT06068972||Standard of Care cohort|Standard of care clinical wound assessment.
62285805|NCT03417271|ACTIVE_COMPARATOR|30us stimulation then 60us stimulation|All patients will receive both types of stimulation in a randomised crossover design. This arm will receive 30us stimulation for 4 weeks then will be switched to 60us stimulation for 4 weeks.
62460712|NCT05299047|ACTIVE_COMPARATOR|- Group fluoroscopy-guided|will receive superior hypogastric plexus neurolysis by the fluoroscopy-guided anterior approach
62285806|NCT03417271|ACTIVE_COMPARATOR|60us stimulation then 30us stimulation|All patients will receive both types of stimulation in a randomised crossover design.This arm will receive 60us stimulation for 4 weeks then will be switched to 30us stimulation for 4 weeks.
62460713|NCT01052116|ACTIVE_COMPARATOR|Soy Isoflavone|Oral isoflavone supplement (100 mg/day)
62086897|NCT05461560|SHAM_COMPARATOR|Control: Sucrose solution|Participants will consume 50g of sucrose dissolved in 500 ml of tap water
62086898|NCT05461560|EXPERIMENTAL|Experimental: Seaweed extract in sucrose solution|Participants will consume 50g of sucrose and 1g of seaweed extract dissolved in 500 ml of tap water
62086899|NCT05915871|EXPERIMENTAL|Tegoprazan, Bismuth, Amoxicillin and Clarithromycin|"Oral administration of Tegoprazan 50 mg twice daily on Days 1 to 7. Oral administration of Bismuth 600 mg twice daily, Amoxicilli 1000 mg twice daily and Clarithromycin 500 mg twice daily on Days 14 to 20.~Oral administration of Tegoprazan 50 mg twice daily, Bismuth 600 mg twice daily, Amoxicilli 1000 mg twice daily and Clarithromycin 500mg twice daily on Days 21 to 27."
62086900|NCT00619151|ACTIVE_COMPARATOR|1|CarboMedics Supra-annular Top Hat Valve
62285807|NCT00236080|EXPERIMENTAL|1|PROVIGIL 200 mg/day
62285808|NCT00236080|EXPERIMENTAL|2|Armodafinil 250 mg/day
62285809|NCT00236080|EXPERIMENTAL|3|Armodafinil 200 mg/day
62285810|NCT00236080|EXPERIMENTAL|4|Armodafinil 150 mg/day
62285811|NCT00236080|PLACEBO_COMPARATOR|5|Placebo
62285812|NCT04138160|EXPERIMENTAL|5:2 intermittent energy restriction|The 5:2 intermittent energy restriction (IER) of 70% restriction (\~600 kcal) delivered for two non-consecutive days/week and no restriction (so sufficient energy to meet the requirement of participants) on the other 5 days/week.
62460714|NCT01052116|PLACEBO_COMPARATOR|Placebo|Matching placebo
62460715|NCT05655832|EXPERIMENTAL|COPD cohort|
62460716|NCT05655832|EXPERIMENTAL|Calibration participants cohort|
62460717|NCT05915403||Patient|female patient with fibromyalgia
62086901|NCT00619151|ACTIVE_COMPARATOR|2|St. Jude Medical Regent Valve
62086902|NCT01506492|NO_INTERVENTION|Usual Care|Usual care includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed.
62285813|NCT04138160|OTHER|Continuous energy restriction|The continuous energy restriction (CER) of 20% restriction below the estimated requirement of participants (\~1600 kcal) 7 days/week.
62285814|NCT01773421|EXPERIMENTAL|Part A|
62460718|NCT05915403||healthy controls|women
62460719|NCT05124184||PAD Cohort|Patient was treated for peripheral arterial disease or peripheral arterial aneurysm requiring bypass treated with GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
62460720|NCT05124184||AAA Cohort|Patient underwent simultaneous or staged aortic aneurysm repair (open surgical AAA or TAAA) involving a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft
62460721|NCT05124184||Dialysis Access Cohort|Patient required the creation of a vascular access graft for hemodialysis secondary to a diagnosis of End-Stage Renal Disease using a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
62086903|NCT01506492|EXPERIMENTAL|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
62460722|NCT00305045|ACTIVE_COMPARATOR|High-frequency Left (HFL)|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 29 - 5 second trains with 30 second inter-train interval."
62460723|NCT00305045|ACTIVE_COMPARATOR|Bilateral|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: i) low-frequency right: 4 trains of 100 second duration and one train of 65 second duration, with a 30 second inter-train interval, followed by ii) HFL: 15 - 5 second trains with 30 second inter-train interval."
62460724|NCT00305045|SHAM_COMPARATOR|Sham Stimulation|Stimulation will occur over the site of active treatment, but with only the side-edge resting on the scalp. It will be administered as HFL for 17 minutes, with the coil angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
62086904|NCT05204784|EXPERIMENTAL|Arm 1|2 Rheopheresis treatments per week x 2, followed by 8 weeks without treatment, 8 overall treatments
62086905|NCT05204784|EXPERIMENTAL|Arm 2|2 Rheopheresis treatments in week 1, followed by 1 treatment every 2 weeks, 8 overall treatments
62086906|NCT05204784|ACTIVE_COMPARATOR|Control Group|Standard of care treatment with intravenous iloprost
62086907|NCT06337539||SSRI treatment|"The subjects who will participate in this study will be outpatients seen in the Psychiatry Outpatient Clinics of the Germans Trias i Pujol University Hospital (Badalona, Spain) clinically diagnosed with major depression and eligible to receive antidepressant treatment with SSRIs.~The control group will be made up of healthy subjects, using the same inclusion and exclusion criteria except for the psychiatric diagnosis."
62285815|NCT01773421|EXPERIMENTAL|Part B|
62285816|NCT03045003|OTHER|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
62285817|NCT03045003|OTHER|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
62285818|NCT03817203|EXPERIMENTAL|Kinesio tape group|Kinesio tape application and pelvic floor exercise have been applied
62285819|NCT03817203|SHAM_COMPARATOR|Control group|Sham kinesio tape application and pelvic floor exercise have been applied
62285820|NCT06549751|EXPERIMENTAL|Escalation|Cohort -1 / 100 million cells / 3-6 patients Cohort 1 / 200 million cells / 3-6 patients Cohort 1 / 400 million cells / 3-6 patients
62086908|NCT03199716|EXPERIMENTAL|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
62086909|NCT03199716|NO_INTERVENTION|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
62086910|NCT00680056|ACTIVE_COMPARATOR|1|Formoterol plus Placebo (Tiotropium)
62086911|NCT00680056|EXPERIMENTAL|2|Formoterol plus Tiotropium
62086912|NCT06104865|EXPERIMENTAL|Tinnitus Sound Therapy|Resound Tinnitus Application, different sounds will be presented over a six months period of time on the speaker of the mobile handset in the background for 30 mins twice a day at least, loudness near but less than the tinnitus intensity itself.
62086913|NCT04042662||Meropenem Failure ( Treatment failure)|
62086914|NCT04042662||Meropenem Success ( Treatment Success)|
62086915|NCT01326585|EXPERIMENTAL|Dexamethasone|Subjects receive intravenous intraoperative dexamethasone
62285821|NCT06549751|EXPERIMENTAL|Expansion|The Dose Expansion portion will begin after completion of the Dose Escalation portion and focus on the efficacy of MT-601 as add-on to front-line chemotherapy. The dose level for the expansion portion of the study will be selected based on totality of the data. The primary objective is to evaluate clinical efficacy for the dose expansion. A total of 20 to 25 patients are planned to be enrolled.
62285822|NCT05351307||POAG patients|OCT angiography will be performed
62285823|NCT05351307||Normal participants|OCT angiography will be performed
62460725|NCT02194998|EXPERIMENTAL|Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
62086916|NCT01326585|PLACEBO_COMPARATOR|Saline solution|Subjects receive intravenous intraoperative normal saline solution
62086917|NCT02025348|EXPERIMENTAL|Treatment A metoprolol 50mg|IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
62086918|NCT02025348|EXPERIMENTAL|Treatment B metoprolol 50mg|IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
62086919|NCT02025348|EXPERIMENTAL|Treatment C metoprolol 50mg|IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
62086920|NCT02025348|EXPERIMENTAL|Treatment D metorpolol 50mg|metoprolol oral solution 1 mg/mL (dose 50 mg).
62086921|NCT03757611|EXPERIMENTAL|tabetri|Tabetri capsule will be administered orally twice daily for 12 weeks
62086922|NCT03757611|PLACEBO_COMPARATOR|Placebo|Placebo capsule will be administered orally twice daily for 12 weeks
62086923|NCT00461565|ACTIVE_COMPARATOR|Part A1|
62086924|NCT00461565|PLACEBO_COMPARATOR|Part A2|
62086925|NCT00461565|EXPERIMENTAL|Part B1|
62086926|NCT00461565|PLACEBO_COMPARATOR|Part B2|
62086927|NCT04958187|EXPERIMENTAL|ANG-3777|Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).
62285824|NCT01211808|EXPERIMENTAL|Treatment A (BMS-914832)|
62285825|NCT01211808|EXPERIMENTAL|Treatment B (BMS-914832 + diltiazem)|
62285826|NCT02617238|ACTIVE_COMPARATOR|PWV group|"Cardiovascular risk management based on PWV will include altogether~1. the implementation of international guidelines,~2. the normalisation of blood pressure, and~3. the normalisation of arterial stiffness"
62285827|NCT02617238|NO_INTERVENTION|Conventional group|These patients will be treated according to the 2007 (and then 2013) ESH-ESC Guidelines for the management of hypertension
62285828|NCT04082208|EXPERIMENTAL|Intervention Group|High Flow nasal cannula (HF)
62285829|NCT04082208|ACTIVE_COMPARATOR|Standar Care Group|Standar Care: low flow device (LF)
62285830|NCT02971202|OTHER|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 milliunit (mU)/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
62285831|NCT02971202|OTHER|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
62285832|NCT02971202|OTHER|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
62285833|NCT05055232|EXPERIMENTAL|XZP-3621|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
62285834|NCT04703569|EXPERIMENTAL|Monolayer high compression elastic bandage|An elastic bandage of cotton, viscose, nylon and elastane
62285835|NCT04703569|ACTIVE_COMPARATOR|Unna boot|A wet bandage with zinc oxide
62285836|NCT02077933|EXPERIMENTAL|alpelisib and everolimus|alpelisib and everolimus administered once a day
62285837|NCT02077933|EXPERIMENTAL|alpelisib, everolimus and exemestane|alpelisib, everolimus and exemestane administered once a day
62285838|NCT02077933|EXPERIMENTAL|alpelisib and exemestane|alpelisib and exemestane administered once a day
62285839|NCT00638937|EXPERIMENTAL|Treatment (saracatinib)|Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
62285840|NCT03162640||P|for cannabis
62285841|NCT03162640||C|for the control group
62285842|NCT05007353|EXPERIMENTAL|Structured Lifestyle Intervention|Structured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation.
62460726|NCT02194998|EXPERIMENTAL|Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
62460727|NCT02194998|EXPERIMENTAL|Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
62460728|NCT02194998|EXPERIMENTAL|Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
62460729|NCT04280757||Arm 1|Biopsied ICSI embryos
62460730|NCT04280757||Arm 2|Non biopsied ICSI embryos
62460731|NCT04280757||Arm 3|Natural pregnancy embryos
62285843|NCT05007353|EXPERIMENTAL|Self-Guided Intervention|General health information provided to participants.
62460732|NCT06196801||Triple Combination therapy|
62460733|NCT00912353|EXPERIMENTAL|AZD7268|
62460734|NCT00912353|PLACEBO_COMPARATOR|Placebo|
62460735|NCT01406795|EXPERIMENTAL|Venous Stent Arm|The study is a single treatment arm study and the venous stent will be placed in all eligible participants.
62460736|NCT05330754||Control group|No caffeine intake
62460737|NCT05330754||Safe level Group|Caffeine daily intake ≤200 mg/day
62460738|NCT05330754||Unsafe level group:|Caffeine daily intake \>200 mg/day
62460739|NCT01931033|EXPERIMENTAL|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
62460740|NCT04963309||OR-EX|the group with endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
62460741|NCT04963309||NOR-EX|the group without endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
62460742|NCT02820922||Orthopedic emergency surgery|Patients of all ages who have undergone emergency orthopedic surgery The analysis of medical data with regard to age, sex, the American Society of Anesthesiologists (ASA) score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
62460743|NCT00487500|EXPERIMENTAL|Ultrabrief, Right Unilateral ECT|Right unilateral ECT administered with an ultrabrief pulse width (0.3 ms), at a dose 6 times the initial seizure threshold
62460744|NCT00487500|EXPERIMENTAL|Ultrabrief, Bilateral ECT (2.5 X ST)|Bilateral (frontotemporal) ECT with an ultrabrief pulse width with dosage 2.5 times the initial seizure threshold
62460745|NCT00487500|ACTIVE_COMPARATOR|Brief Pulse, Right Unilateral ECT|Right unilateral ECT, with a standard brief pulse (1.5 ms), with dosage 6 times the initial seizure threshold
62460746|NCT00487500|ACTIVE_COMPARATOR|Brief Pulse, Bilateral ECT|Bilateral (frontotemporal) ECT with a standard brief pulse (1.5 ms), with dosage 2.5 times the initial seizure threshold
62460747|NCT04734665|EXPERIMENTAL|experimental|Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous
62460748|NCT01358565|ACTIVE_COMPARATOR|Mild and Moderate Hepatic Dysfunction|Patients with mild and moderate hepatic dysfunction
62460749|NCT01358565|ACTIVE_COMPARATOR|Healthy Volunteers|Healthy volunteers
62460750|NCT00565448|EXPERIMENTAL|Docetaxel/Cisplatin/5-FU (TCF)|"* Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks~* Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks~* 5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
62285844|NCT00505947|ACTIVE_COMPARATOR|A|"Infliximab 5 mg/Kg body weight by intravenous infusion on visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, arm A will receive placebo at visits 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
62285845|NCT00505947|PLACEBO_COMPARATOR|B|"Arm B will receive placebo at visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, group B will receive infliximab 5 mg/Kg body weight by intravenous infusion at visit 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
62460751|NCT00565448|ACTIVE_COMPARATOR|Cisplatin/5-FU (CF)|"* Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks~* 5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy.~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
62460752|NCT01001208|EXPERIMENTAL|Etanercept Plus Methotrexate|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received active methotrexate titrated as follows: 7.5 mg per week (3 capsules) for weeks 1 and 2, 10 mg per week (4 capsules) for weeks 3 and 4, and then up to 15 mg per week (6 capsules) or the maximum tolerated dose for the remainder of the 24-week treatment period.
62460753|NCT01001208|ACTIVE_COMPARATOR|Etanercept Plus Placebo|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received oral placebo that was the same number of capsules per week as the methotrexate dosing regimen.
62460754|NCT04420923|EXPERIMENTAL|Observe-and-Plan|Patients will follow the same protocol as described by dr. Mantel et al. (2014) in the first Observe-and-Plan study conducted in Lausanne.
62460755|NCT04420923|ACTIVE_COMPARATOR|Treat-and-Extend|Patients will follow the standard treatment protocol for Treat-and-Extend, used for several years in the participating clinics.
62460756|NCT01926548|EXPERIMENTAL|CJ Imatinib 200mg|1 tablet(200mg) a day,PO,QD
62460757|NCT01926548|ACTIVE_COMPARATOR|Gleevec 100mg|2 tablet(100mg) a day,PO,QD
62460758|NCT00411203|ACTIVE_COMPARATOR|Tamoxifen Citrate|
62460759|NCT00411203|PLACEBO_COMPARATOR|Placebo|
62460760|NCT04305145|EXPERIMENTAL|Infliximab|"Patients randomized to this arm will receive IV infliximab regardless of whether they are hospitalized due to their colitis.~* Infliximab: Predetermined dose of intravenous infliximab, up to 3 times over 7 weeks~* Crossover for inadequate response: Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm (corticosteroids) at full initial dosing."
62086928|NCT01306708|ACTIVE_COMPARATOR|nimesulide|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral non-steroidal anti-inflammatory (nimesulide 100 mg, twice per day, for 14 days);
62086929|NCT06388070|EXPERIMENTAL|HUC3-053|"Participants received HUC3-053 drops in each eye five to six times a day for 12 weeks."
62086930|NCT06388070|ACTIVE_COMPARATOR|Hyalein Mini Drops|"Participants received Hyalein Mini Drops in each eye five to six times a day for 12 weeks."
62460761|NCT04305145|EXPERIMENTAL|Corticosteroids|"Patients randomized to this arm will receive IV steroids or oral steroids depending on whether the severity of their colitis requires hospitalization (inpatient).~* Inpatient: Predetermined intravenous dose of methylprednisolone, 2x daily up until patients can safely be transitioned to an oral prednisone taper~* Outpatient: Predetermined oral dose of predisone, daily over 7 weeks~Crossover for inadequate response: Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm (infliximab) at full initial dosing."
62460762|NCT03988270|EXPERIMENTAL|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
62460763|NCT03988270|NO_INTERVENTION|Control|Participants in the control group will not receive any pre-surgical instructions for exercise in the access arm
62460764|NCT05556590||QFR-Low Group|Based on preoperative CAG, QFR analysis will be conducted for vessels bypassed with RA grafts. The RA-grafted vessels with QFR below the best cut-off value (0.50-0.55 assumed) will be allocated to QFR-Low group.
62460765|NCT05556590||QFR-High Group|Based on preoperative CAG, QFR analysis will be conducted for vessels bypassed with RA grafts. The RA-grafted vessels with QFR over the best cut-off value (0.50-0.55 assumed) will be allocated to QFR-High group.
62460766|NCT03474510|EXPERIMENTAL|EXPAREL|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
62651922|NCT01576614||Nurse-Physican rounding by R T P|"Remote Telepresence Robotics (RTP) is a form of telemedicine that enables a fast and direct face-to-face response by a physician, located remotely, and may sometime utilize a mobile robot.~RTP provides the physician the ability to teleconference with patients and other healthcare providers using two way audio visual technology. The sophistication of these devices varies and can range from simple video conferencing to remote robotic control devices with audio visual conferencing capabilities. The robotic capabilities refer to ability of the physician to remotely direct or drive the device from one location to another.~The technology allows clinical experts to provide the right care at the right time and has become an accepted standard of care when used under appropriate circumstances."
62651923|NCT02983123||1 hour-troponin|1-hour troponin collected of all recruited patients in addition to the daily routine with serial troponins collected at 0- and 4/6 hours.
62651924|NCT02585440|EXPERIMENTAL|Group A|CMX157, tablet, 5 mg, QD, 14 days versus CMX157 placebo, 5 mg, tablet, QD, 14 days
62651925|NCT02585440|EXPERIMENTAL|Group B|CMX157, tablet, 10 mg, QD, 14 days versus CMX157, placebo tablet, 10 mg, QD, 14 days
62651926|NCT02585440|EXPERIMENTAL|Group C|CMX157, tablet, 25 mg, QD, 14 days versus placebo CMX157, placebo tablet, 25 mg, QD, 14 days
62651927|NCT02585440|EXPERIMENTAL|Group D|CMX157, tablet, 50 mg, QD, 14 days versus CMX157, placebo tablet, 50 mg, QD, 14 days
62651928|NCT02585440|EXPERIMENTAL|Group E|CMX157, tablet, 100 mg, QD, 14 days versus CMX157, placebo tablet, 100 mg, QD, 14 days
62651929|NCT05231356||2|group 1 with positive signs group 2 with negative signs
62651930|NCT00647478||1|AD
62651931|NCT00647478||2|Control elderly subjects with normal cognitive function
62651932|NCT00647478||3|MCI
62651933|NCT01248455|EXPERIMENTAL|anti-KIR in Smoldering Multiple Myeloma Patients|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
62651934|NCT06270134|ACTIVE_COMPARATOR|Lower dialysate bicarbonate concentration (32 versus mmol/L)|Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of 32 mmol/L.
62651935|NCT06270134|ACTIVE_COMPARATOR|Higher dialysate bicarbonate concentration (38 mmol/L)|Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of 38 mmol/L.
62086931|NCT03564054|EXPERIMENTAL|Photodynamic Therapy|Photodynamic therapy (PDT) uses activation of a photosensitizer by light of a specific wavelength to generate reactive oxygen species and singlet oxygen that causes direct cell damage and death, apoptosis, tumor vasculature damage and thrombosis, and inflammation leading to an immunological response.Following randomization, subjects will undergo treatment with either PDT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment
62086932|NCT03564054|EXPERIMENTAL|Argon Plasma Coagulation|Argon plasma coagulation (APC) is a noncontact form of electrocautery. Following randomization, subjects will undergo treatment with either DPT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment.
62651936|NCT03517904|EXPERIMENTAL|IVUS-guided group|Intravascular ultrasound-guided intervention group
62651937|NCT03517904|ACTIVE_COMPARATOR|Angiography-guided group|Angiography-guided intervention group
62086933|NCT03220737|EXPERIMENTAL|Cohort 1 (active, 12-17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.
62086934|NCT03220737|PLACEBO_COMPARATOR|Cohort 1 (placebo, 12 - 17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
62086935|NCT03220737|EXPERIMENTAL|Cohort 2 (active, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
62086936|NCT03220737|PLACEBO_COMPARATOR|Cohort 2 (placebo, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
62285846|NCT05182047|EXPERIMENTAL|Treatment Sequence AB|Participant will receive a single oral dose of butamirate citrate syrup 1.5 milligrams per milliliter (mg/mL) (Treatment A \[investigational product\]) on Day 1 in Treatment Period 1, followed by a single oral dose of sinecod syrup (vanilla) 1.5 mg/mL (Treatment B \[Reference product\]) on Day 11 in Treatment Period 2. A wash-out period of at least 10 days will be maintained between each treatment period.
62285847|NCT05182047|EXPERIMENTAL|Treatment Sequence BA|Participants will receive Treatment B on Day 1 in Treatment Period 1, followed by Treatment A on Day 11 in Treatment Period 2. A wash-out period of at least 10 days will be maintained between each treatment period.
62285848|NCT01799876|EXPERIMENTAL|Autologous Cell|Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.
62285849|NCT01799876|SHAM_COMPARATOR|Control|Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).
62285850|NCT05835414|EXPERIMENTAL|Adjunctive eTMS treatment (no delay)|6 weeks (30 sessions) of daily eTMS as an adjunct to standard of care TSRD treatment
62285851|NCT01084551|EXPERIMENTAL|SPM 962 4.5|started at 2.25 mg/day to 4.5 mg/day for 13 weeks
62285852|NCT01084551|EXPERIMENTAL|SPM 962 6.75|started at 2.25 mg/day to 6.75 mg/day for 13 weeks
62651938|NCT03294915|ACTIVE_COMPARATOR|Resistant Starch|Green banana flour
62651939|NCT03294915|PLACEBO_COMPARATOR|Placebo|Maltodextrin, cellulose and guar gum
62651940|NCT00911911|EXPERIMENTAL|FEC 100 + TAXOTERE|"FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE~TAXOTERE 100 mg/m²/cycle~1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100"
62651941|NCT05005598||pediatric population|pediatric population of CHU of Nancy, France.
62651942|NCT02517619|EXPERIMENTAL|Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate ophthalmic solution (40 mg/mL)
62651943|NCT02517619|ACTIVE_COMPARATOR|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate Ophthalmic (1%)
62651944|NCT00660452|ACTIVE_COMPARATOR|1|360 active patients with house dust mites related asthma with or without allergic rhinitis
62651945|NCT00660452|PLACEBO_COMPARATOR|2|180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.
62086937|NCT03220737|EXPERIMENTAL|Cohort 3 (active, 2 - 5 yrs)|Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
62086938|NCT03220737|PLACEBO_COMPARATOR|Cohort 3 (placebo, 2 - 5 yrs)|Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
62086939|NCT03220737|OTHER|Historical Control: Adult Bridging Population|This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
62086940|NCT02472314|EXPERIMENTAL|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
62086941|NCT02472314|ACTIVE_COMPARATOR|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
62086942|NCT02472314|EXPERIMENTAL|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
62086943|NCT02472314|ACTIVE_COMPARATOR|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
62086944|NCT01628328||Stenting|patient who received colonic stenting for obstructive colorectal cancer
62086945|NCT01628328||Control|patients who had only colonoscopy without obstruction and without stenting
62086946|NCT02344836|ACTIVE_COMPARATOR|Theory-based podcast|"Receive a 3-month weight loss intervention delivered via theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method).~Intervention: podcast + mobile diet app"
62285853|NCT01084551|PLACEBO_COMPARATOR|placebo|for 13 weeks
62285854|NCT00183690|EXPERIMENTAL|1|Participants receiving prolonged exposure therapy
62285855|NCT00183690|ACTIVE_COMPARATOR|2|Participants receiving active psychotherapy
62285856|NCT02336477|EXPERIMENTAL|1|Mexiletine / Placebo
62651946|NCT06068959|EXPERIMENTAL|Photobiomodulation|Photobiomodulation using a LED cluster
62285857|NCT02336477|EXPERIMENTAL|2|Placebo / Mexiletine
62285858|NCT06543433|EXPERIMENTAL|Skincubator|This is the only arm. All babies in trial will receive the intervention.
62651947|NCT06068959|PLACEBO_COMPARATOR|Placebo Photobiomodulation|Placebo Photobiomodulation with the equipment turned off
62651948|NCT00959257||Asthma|Asthma patients on inhaled corticosteroids
62651949|NCT00959257||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
62086947|NCT02344836|EXPERIMENTAL|Theory-based podcast + Social POD|"Receive a 3-month weight loss intervention delivered via Theory-based Podcast (TBP) plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).~Intervention: podcast + theory-based mobile diet app"
62086948|NCT03685279|EXPERIMENTAL|NHA Group|"Six-week, online intervention with weekly, sequential, content knowledge and skills practice. Each week included recorded, slide presentations (narrated by the developer of the NHA, Howard Glasser); readings from The Transforming the Intense Child Workbook by Howard Glasser with Melissa Lowenstein; participants' skills practice, web postings, and live sessions with Howard Glasser and Advanced NHA Trainers."
62651950|NCT02008656|EXPERIMENTAL|INCT|Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 5 cycles of CapeOX over a period of approximately 15-16 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine.
62086949|NCT03685279|OTHER|Control Group|The Control Group received the same intervention after the collection of NHA Group post-intervention surveys.
62086950|NCT06581536|EXPERIMENTAL|Yes and Know curriculum|Youth will receive the Yes and Know curriculum.
62651951|NCT02008656|EXPERIMENTAL|CNCT|Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX.
62651952|NCT05661032||Covid Positive|Nasopharyngeal Swab
62086951|NCT06581536|ACTIVE_COMPARATOR|Nutrition Education for Adolescents|Youth will receive education about adolescent nutrition.
62086952|NCT04850144|EXPERIMENTAL|Tiotropium Easyhaler Product variant D|
62086953|NCT04850144|EXPERIMENTAL|Tiotropium Easyhaler Product variant E|
62086954|NCT04850144|EXPERIMENTAL|Tiotropium Easyhaler Product variant F|
62460767|NCT03474510|ACTIVE_COMPARATOR|interscalene nerve block|Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
62651953|NCT05661032||Covid Negative|Nasopharyngeal Swab
62651954|NCT04318197|ACTIVE_COMPARATOR|Global rehabilitation|2 hours of daily rehabilitation, 3 days per week during 4 weeks
62086955|NCT04850144|EXPERIMENTAL|Tiotropium Easyhaler Product variant G|
62086956|NCT04850144|EXPERIMENTAL|Tiotropium Easyhaler Product variant H|
62086957|NCT04850144|ACTIVE_COMPARATOR|Spiriva HandiHaler|
62086958|NCT04850144|EXPERIMENTAL|Tiotropium Easyhaler Product variant F administered with oral activated charcoal|
62086959|NCT04868474|ACTIVE_COMPARATOR|Usual care training|A refresher training course will be the equivalent of 'enhanced' usual care. Enhanced because the course will likely augment short-term knowledge of smoking cessation treatments, and participation in the study could trigger more discussions about smoking cessation than routine practice. However, it will be impossible to have any blinding between groups without at least some training.
62086960|NCT04868474|EXPERIMENTAL|Intervention training|The training course and decision aid aim to make treatment of tobacco use the default choice
62086961|NCT00081471|EXPERIMENTAL|1|
62086962|NCT00081471|ACTIVE_COMPARATOR|2|
62086963|NCT01581047||Amoxicillin/Clavulanic Acid|Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
62086964|NCT01581047||Cefuroxime|Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
62460768|NCT04426799|NO_INTERVENTION|Control group|no application
62460769|NCT04426799|EXPERIMENTAL|Experimental group|application is done
62651955|NCT04318197|EXPERIMENTAL|Personalized rehabilitation|2 hours of daily rehabilitation including at least 2 times 20 minutes of electrostimulation on atrophied muscles, 3 days per week during 4 weeks
62086965|NCT05203939|EXPERIMENTAL|Cohort 1 (Low Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation or RHO mutations subgroup
62086966|NCT05203939|EXPERIMENTAL|Cohort 2 (Mid Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation or RHO mutations subgroup
62086967|NCT05203939|EXPERIMENTAL|Cohort 3 (High Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation, RHO mutations subgroup and LCA patients with CEP290
62086968|NCT05203939|EXPERIMENTAL|Pediatric Arm|Pediatric subjects will receive the medium dose concentration and will have subjects with RP and LCA
62086969|NCT05203939|NO_INTERVENTION|Natural History Study (OCU400-104)|"A Prospective and Retrospective Natural History Study of RP and LCA:~This is an observatory study for the prospective natural history of RP and LCA in adult and pediatric subjects. The study will also collect and review retrospective data and ophthalmology examination of natural history and progression of disease for all subjects starting with earliest timepoint on or after the date of their diagnosis of RP or LCA.~Subjects will be seen up to a total of four times during the 12 months of the Observational Period, at baseline, 3 months, 6 months and 12 months.~A total of up to 100 subjects will be enrolled in the study, including:~Approximately 76 newly enrolled subjects consisting of 50 adult RP subjects 6 adult LCA subjects 20 pediatric RP/LCA subjects. Up to 24 subjects that reconsent from the OCU400-101 study (subjects from OCU400-101 will provide data on their untreated eye)"
62086970|NCT05203939|EXPERIMENTAL|Adult Arm|Following DSMB confirmation, adult LCA subjects with CEP290 mutation will receive a medium dose concentration of OCU400.
62460770|NCT05210738||Single incision sling group|The patient will receive Altis mini-incision sling for treatment of occult SUI
62460771|NCT05210738||Urethral bulking group|The patient will receive Bulkamid urethral bulking agent for treatment of SUI
62651956|NCT04318197|NO_INTERVENTION|Classic rehabilitation|40 minutes of rehabilitation, once a week during 4 weeks.
62460772|NCT03727568|EXPERIMENTAL|Cryobiopsy: longer freezing time|Group nº1: A total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and a freezing time from ≥5 seconds for the following biopsies.
62460773|NCT03727568|EXPERIMENTAL|Cryobiopsy: shorter freezing time|Group nº 2: A total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and a freezing time from \<5 seconds for the following biopsies.
62086971|NCT03943303|EXPERIMENTAL|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. The natural gamma radiation doses of the monazite sands will be monitored, the radiation measurements gamma will be associated with the atmospheric and climatic measurements of each group. It is understood here as atmospheric measurements, level of solar radiation, spectrum of sunlight at the time of exposure, humidity, wind speed, ultraviolet radiation level, amount of ions present in the air and measurements of the magnetic field in the place.
62086972|NCT03943303|PLACEBO_COMPARATOR|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. To ensure the absence of radiation, mesuaraments of possible radiation will be monitored.
62285859|NCT05537545|ACTIVE_COMPARATOR|Immediate soft tissue grafting|A connective tissue graft is immediately harvested and inserted in the buccal mucosa at the moment of implant placement
62285860|NCT05537545|EXPERIMENTAL|Delayed soft tissue grafting|Three months after implant placement, a connective tissue graft is harvested and inserted in the buccal mucosa
62285861|NCT01904981|EXPERIMENTAL|Atenolol|Atenolol group
62285862|NCT01904981|EXPERIMENTAL|Valsartan|Valsartan group
62460774|NCT00591630|ACTIVE_COMPARATOR|Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
62460775|NCT00591630|ACTIVE_COMPARATOR|Zevalin + BEAM + Rituximab +Stem Cell Transplant|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant
62285863|NCT05360667|EXPERIMENTAL|Intervention group|The intervention in this group is standard care plus plus exergame-based multicomponent training program
62285864|NCT05360667|SHAM_COMPARATOR|Control group|The control group receives usual care in the LTCFs.
62460776|NCT00591630|ACTIVE_COMPARATOR|BEAM + Rituximab + Stem Cell Transplant + Rituximab|BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
62460777|NCT00591630|ACTIVE_COMPARATOR|BEAM + Rituximab + Stem Cell Transplant|BEAM + Rituximab Followed by Stem Cell Transplant
62460778|NCT01652001|EXPERIMENTAL|Malic Acid 1%|"Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).~Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A."
62460779|NCT01652001|PLACEBO_COMPARATOR|Control|Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
62460780|NCT05425381|EXPERIMENTAL|Enhanced version of Interconnected Systems Framework (ISFE)|The ISFE addresses limitations of positive behavioral interventions and supports (PBIS) and school mental health (SMH) and improves the quality of services within the three tiers of multi-tiered systems of support (MTSS) by providing specific guidance on their systematic interconnection. Meaningful interconnection requires effective interdisciplinary collaboration, well-functioning teams, data-based decision making, and effective selection and implementation of evidence-based practices. The original interconnected systems framework (ISF) capitalizes on PBIS' strong implementation infrastructure and universal prevention strategies and combines these elements with SMH enhancements to Tiers 2 and 3 to achieve a comprehensive continuum of evidence-based practices. The ISFE leverages the strengths of PBIS and SMH to create one integrated system of care that achieves synergy and economies of scale.
62086973|NCT02475044|NO_INTERVENTION|Treatment as usual (TAU)|Participants recive Psycho-education and neuro-psycological diagnosis.
62086974|NCT02475044|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT)|Participants recive 16 sessions of CBT in addition to arm TAU treatment.
62285865|NCT02244151|EXPERIMENTAL|DECAPEPTYL® diario|Group 1: DECAPEPTYL® diario,OPU 24 hours after GnRHa administration.
62285866|NCT02244151|EXPERIMENTAL|Decapeptyl® diaro|Group 2:Decapeptyl® diario OPU 30 hours after GnRHa administration.
62285867|NCT02244151|EXPERIMENTAL|Decapeptyl® diario.|Group 3: Decapeptyl® diario, OPU 40 hours after GnRHa administration.
62285868|NCT02244151|ACTIVE_COMPARATOR|Decapeptyl® daily|Group 4: Decapeptyl® daily OPU 36 hrs after GnRH administration
62285869|NCT01438697|EXPERIMENTAL|Internet Intervention|Assigned to Sleep Healthy Using the Internet (SHUTi)
62285870|NCT01438697|ACTIVE_COMPARATOR|Patient Education Website|Assigned to Patient Insomnia Educational Website
62285871|NCT04861337|EXPERIMENTAL|Remimazolam Group|Remimazolam infusion is initiated after induction of general anesthesia at a rate of 0.25 mg/kg/h and stopped 15 minutes before the end of surgery.
62651957|NCT04600349|EXPERIMENTAL|Identity Oriented Psychotrauma Therapy (IOPT)|35 participants will be randomly allocated to the IOPT group. They will attend 10 groups of IOPT every two weeks and they will work 10 Intentions. The groups will be conducted by clinicians or psychotherapists specialized in IOPT. IOPT represents a group treatment developed by Franz Ruppert 20 years ago. It is an effective therapeutic intervention, offering access to less conscious aspects of our psyche, with the help of other persons, named 'representatives.' The method is based on the theory of multigenerational psychotraumatology developed by Ruppert. Although it is very often and widely used all over the world, it has not previously been the subject of randomized controlled trials (RCT), and therefore, its potential efficacy is unknown. In the current study, we want to test this new intervention model on autoimmune thyroiditis.
62651958|NCT04600349|ACTIVE_COMPARATOR|Treatment as Usual|35 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
62651959|NCT03621956|ACTIVE_COMPARATOR|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
62651960|NCT03621956|ACTIVE_COMPARATOR|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
62651961|NCT04174742||A|Subjects 45 years of age or younger
62651962|NCT04174742||B|Subjects over 45 years of age
62651963|NCT02240329|OTHER|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
62651964|NCT04283318|OTHER|Healthy|Age \>18 years; BMI 20-27 kg/m2; Fasting plasma Glucose \<110 mg/dL
62651965|NCT04283318|OTHER|Obese people|Age \>18 years; BMI \>30 kg/m2; Fasting Plasma Glucose \<110 mg/dL
62651966|NCT04283318|OTHER|Type 2 Diabetes|Age \>18 years; Diagnosed Type 2 Diabetes mellitus (diet or a monotherapy or combination of metformin, DPP-4-inhibitors or sulfonylurea)
62651967|NCT04283318|OTHER|Type 1 Diabetes|Age \>18 years; Diagnosed Type 1 Diabetes mellitus \>12 months; Treated with multiple daily Insulin injections (MDII) or continuous subcutaneous Insulin Infusion (CSII); Stable Insulin therapy as clinically assessed by the study physician C-Peptide negative defined as 0.3 nmol/L; No diabetic ketoacidosis within the last 12 months; No severe hypoglycaemia requiring external assistance within the last 12 months; Running on the FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System (iCGM) as Standard of care for Glucose monitoring
62651968|NCT02066571|OTHER|droxidopa, then sugar pill|Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
61904042|NCT05278351|EXPERIMENTAL|A|Tislelizumab 200mg, D1, D15, intravenous drip, Q4W and Cetuximab 500mg/m2, D1, D15, intravenous drip, Q4W and Irinotecan 180mg/m2, D1, D15, intravenous drip, Q4W
61904043|NCT05278351|ACTIVE_COMPARATOR|B|Fruquinitinib 5mg QD D1-21, oral, Q4W or Regorafenib 160mg QD D1-21 oral, Q4W or Trifluridine Tipiracil Tablets 35mg/m2 BID D1-D5, D8-D12 oral, Q4W
62086975|NCT02229903|ACTIVE_COMPARATOR|Active DTMS Treatment|Active DTMS Treatment constitutes the Deep Transcranial Magnetci Stimulation (DTMS) which is a new form of TMS which allows direct stimulation of deeper neruonal pathways than the standard TMS. The DTMS coil is designed to allow deeper brain stimulation without significant increase of electric fields included in superficial cortical regions.
62285872|NCT04861337|PLACEBO_COMPARATOR|Placebo Group|Placebo (0.9% saline) infusion is initiated after induction of general anesthesia at the same rate as in the remimazolam group and stopped 15 minutes before the end of surgery.
62285873|NCT02495948|OTHER|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
62285874|NCT02495948|OTHER|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
62285875|NCT05773677|EXPERIMENTAL|Case Group: with diet|Prescription of specific diet in pregnancy
61904044|NCT00228176|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily
61904045|NCT00228176|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily.
61904046|NCT01412489|EXPERIMENTAL|1|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
62285876|NCT05773677|NO_INTERVENTION|Control Group: no diet|Retrospective group with no diet
62285877|NCT02575209||Women schiz.|Women with recent diagnosis of schizophrenia
61904047|NCT01294098|NO_INTERVENTION|PCA only|this group will only get a pain control anesthesia pump to use for post-operative pain
61904048|NCT01294098|EXPERIMENTAL|PCA and femoral nerve block|this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
61904049|NCT01294098|EXPERIMENTAL|PCA + hematoma block|patient will receive hematoma block during surgery
61904050|NCT04947852|EXPERIMENTAL|Investigation Mask|Bi Level CPAP Mask
61904051|NCT04947852|ACTIVE_COMPARATOR|Comparator Mask|Bi Level CPAP Mask
61904052|NCT00637949|EXPERIMENTAL|1|
61904053|NCT00637949|ACTIVE_COMPARATOR|2|
61904054|NCT00545272|EXPERIMENTAL|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
61904055|NCT00545272|EXPERIMENTAL|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62285878|NCT02575209||Men schiz.|Men with recent diagnosis of schizophrenia
62651969|NCT02066571|OTHER|sugar pill, then droxidopa|Subject will be be on sugar pill for 5 weeks (4 weeks of placebo treatment and one week of wash-out or sugar pills). Then, droxidopa will be titrated over 2 week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks.
62651970|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
62651971|NCT01357772|EXPERIMENTAL|Tamoxifen|tamoxifen at daily dose of 5 mg for a total treatment time of 3 years
62651972|NCT01357772|PLACEBO_COMPARATOR|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
61904056|NCT00545272|EXPERIMENTAL|indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62651973|NCT02542527|EXPERIMENTAL|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
62651974|NCT02837588|ACTIVE_COMPARATOR|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
62651975|NCT02837588|NO_INTERVENTION|CONTROL|No intervention with radiofrequency treatment, only evaluation to usual drug treatment
62651976|NCT05482334|EXPERIMENTAL|Sargramostim|Sargramostim 250 μg/m2/day subcutaneously (5 days per week)
62651977|NCT05482334|PLACEBO_COMPARATOR|Placebo Control - Saline|Placebo equivalent volume subcutaneously (5 days per week)
62651978|NCT01262586|EXPERIMENTAL|Vildagliptin|
62651979|NCT01262586|ACTIVE_COMPARATOR|Glimepiride|
62651980|NCT02606812|EXPERIMENTAL|Traditional-food|During the 3 months, a dish containing traditional food will be provided 5 days per week. The food will contain an average of 600 Kcal, ≤ 50 mg of cholesterol, ≥ 10 g of fiber, ≥ 130 g of vegetables, and ≤ de 200 mg of sodium. Each dish will be accompanied with 3 standard-sized corn tortillas.
62651981|NCT02606812|NO_INTERVENTION|Control|Is the group who will intake the cafeteria fast food. The control group will receive habitually consumed fast food provided by the cafeteria of the campus at a similar caloric proportion.
62651982|NCT04210518|EXPERIMENTAL|Neuromuscular training|"Neuromuscular training consisting of:~* Single limb balance task.~* Balance training on an unstable surface.~* Hop drills."
62651983|NCT04210518|EXPERIMENTAL|Stroboscopic glasses group|"This group performed the same neuromuscular training with the addition of stroboscopic glasses during the training performance.~* Single limb balance task.~* Balance training on unstable surfaces.~* Hop drills."
62651984|NCT04210518|NO_INTERVENTION|Control group|This group received no intervention
62651985|NCT03594006|OTHER|Cancer patients on active therapy|
62651986|NCT01279746||ultrasond compression of deep veins|
62651987|NCT06265311|EXPERIMENTAL|IDUS examination during ERCP|CBD stones cases with high recurrence risks apply IDUS during ERCP
62651988|NCT06265311|NO_INTERVENTION|Control|CBD stones cases with high recurrence risks don't apply IDUS during ERCP
61904057|NCT00545272|EXPERIMENTAL|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
61904058|NCT00545272|ACTIVE_COMPARATOR|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
61904059|NCT00545272|PLACEBO_COMPARATOR|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
61904060|NCT03776006||TPLA|
62285879|NCT02575209||Women healthy|Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
62651989|NCT03885973|EXPERIMENTAL|Lactobacillus plantarum|1 bottle of fermented milk (100 g) containing probiotic Lactobacillus plantarum IS-10506 1.0x10\^8 CFU will be given daily for three weeks.
61904061|NCT05090800|EXPERIMENTAL|Definity contrast agent|
61904062|NCT01343641|EXPERIMENTAL|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.
62285880|NCT02575209||Men healthy|Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
61904063|NCT01343641|PLACEBO_COMPARATOR|Placebo|Inactive Pill used as a comparator
62651990|NCT03885973|PLACEBO_COMPARATOR|Placebo|1 bottle of fermented milk (100 g) containing placebo will be given daily for three weeks.
62651991|NCT02170714||ASC|Consecutive children hospitalized for an episode of acute ASC, defined as a PUCAI \> 65. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI\>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms. A follow-up of 2 years for the colectomy risk was evaluated for all patients.
62651992|NCT01044524|EXPERIMENTAL|1|SLV 334
62285881|NCT00618748|EXPERIMENTAL|Pre-Olanzapine|Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
62651993|NCT02698293|EXPERIMENTAL|Cohort 1|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~Total duration of drug product administration (including any open-label lead-in, if applicable).~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
62651994|NCT02698293|EXPERIMENTAL|Cohort 2|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
62651995|NCT02698293|EXPERIMENTAL|Cohort 3|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
62651996|NCT05424341|EXPERIMENTAL|Group A|This group will receive muscle energy technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
62651997|NCT05424341|ACTIVE_COMPARATOR|Group B|This group will receive counterstrain technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
62651998|NCT00833755|ACTIVE_COMPARATOR|Opioid - Ketamine|This group consists of 16 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
61904064|NCT04257188||minimally invasive vitrectomy under subtenon anaesthesia|
61904065|NCT04257188||minimally invasive vitrectomy under general anaesthesia|
62086976|NCT02229903|SHAM_COMPARATOR|Sham Treatment|The Sham Treatment consists of an electrical field which cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
62285882|NCT00618748|EXPERIMENTAL|Pre-Placebo|Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
62285883|NCT00618748|EXPERIMENTAL|New Olanzapine|Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
62651999|NCT00833755|ACTIVE_COMPARATOR|Non-opioid - Ketamine|This group consists of 22 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
62652000|NCT00833755|PLACEBO_COMPARATOR|Opioid - Placebos|This group consists of 18 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
62652001|NCT00833755|PLACEBO_COMPARATOR|Non-opioid - Placebos|This group consists of 23 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
62086977|NCT05490069|EXPERIMENTAL|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
62285884|NCT06332508|EXPERIMENTAL|PEMFs prior to surgery|During the study period, subjects will receive local magnetic therapy (PEMFs). The study aims to enrol subjects in 4 groups - in dose level 1 and 2 (subjects who do not need chemotherapy prior to surgery), PEMF will be administered prior to surgery;
62285885|NCT06332508|EXPERIMENTAL|PEMFs prior to chemotherapy|In dose level 3 and 4 (subjects who require chemotherapy), PEMF will be administered prior to chemotherapy.
62285886|NCT05589792|PLACEBO_COMPARATOR|Placebo|Placebo capsule before bedtime for 3 nights before the studies (inclusive)
62285887|NCT05589792|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide 250 mg before bedtime 3 nights before the study, Acetazolamide 500 mg before bedtime for 2 nights before the study (inclusive)
62285888|NCT02347904|EXPERIMENTAL|Adjuvant S-1 and Oxaliplatin|Adjuvant treatment with s-1 and oxaliplatin after neoadjuvant chemoradiation and esophagectomy in patients with resectable esophageal cancer
62652002|NCT02654678|EXPERIMENTAL|Enalapril Orodispersible Minitablets|Individually adapted dose of enalapril consisting of 1 to maximum 4 enalapril ODMTs of 0.25 mg and/or 1 mg and/or other prescribed treatment of heart failure.
62652003|NCT06515990|EXPERIMENTAL|Dose Level 1|0.5mg/kg
62652004|NCT06515990|EXPERIMENTAL|Dose Level 2|≤1 mg/kg
62086978|NCT05490069|NO_INTERVENTION|Control group|Receive general mental health information through instant message.
62285889|NCT04285775||Insertion of Dialysis Catheter|Hospital inpatients planned for dialysis catheter insertion, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
62285890|NCT04285775||Removal of Dialysis Catheter|Hospital inpatients planned for dialysis catheter removal, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
62285891|NCT02762487|EXPERIMENTAL|LINX arm|Previous LSG patient will be treated with the LINX device and serve as their own control
62285892|NCT01295060|EXPERIMENTAL|Octreotide Implant|
62285893|NCT04865965|EXPERIMENTAL|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
62652005|NCT06515990|EXPERIMENTAL|Dose Level 3|≤2 mg/kg
62285894|NCT04865965|NO_INTERVENTION|No Exercise|No Exercise Session
62285895|NCT02485080|EXPERIMENTAL|Simeprevir + sofosbuvir daily, 24 weeks|Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.
62285896|NCT05303129|OTHER|Blood tests|"Realization of 4 blood tests for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts ), during CDK4/6 treatment :~* before initiation of CDK4/6 treatment~* At 3 mois after initiation of CDK4/6 treatment~* At 6 mois after initiation of CDK4/6 treatment~* At 12 mois after initiation of CDK4/6 treatment or at early end of study"
62652006|NCT06515990|EXPERIMENTAL|Dose Level 4|≤4 mg/kg
62652007|NCT06515990|EXPERIMENTAL|Dose Level 5|≤6 mg/kg
62285897|NCT01817790|EXPERIMENTAL|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
62652008|NCT06515990|EXPERIMENTAL|Dose Level 6|≤8 mg/kg
62652009|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
62652010|NCT03057574|EXPERIMENTAL|Treatment|Follitropin Alfa (Gonapure)
62652011|NCT04550299|ACTIVE_COMPARATOR|Group A|single bundle technique with the use of bioabsorbable implants
62086979|NCT05360758||Patients diagnosed with CLL with treatment criteria, first line or relapsed/refractory.|
62086980|NCT04575805|EXPERIMENTAL|Internet-delivered Combined Cognitive Bias Modification|CBM Version 1 is the combination of internet-delivered Cognitive Bias Modification-Interpretation and internet-delivered Cognitive Bias Modification-Attention interventions taking place over 4 weeks (eight sessions, twice per week).
62652012|NCT04550299|ACTIVE_COMPARATOR|Group B|single bundle technique with the use of Bio-Intrafix
62652013|NCT04550299|ACTIVE_COMPARATOR|Group C|double bundle technique with the use of bioabsorbable implants
62652014|NCT04550299|ACTIVE_COMPARATOR|Group D|double bundle technique with the use of Bio-Intrafix
62652015|NCT06317012|EXPERIMENTAL|Le Fort I osteotomy|
62652016|NCT01721798|ACTIVE_COMPARATOR|Copper T-380a Intrauterine Device (C-IUD)|Copper T-380A Intrauterine Device with approximately 380 mm2 exposed copper. Devices used were those included as part of the South African public sector health formulary.
62652017|NCT01721798|ACTIVE_COMPARATOR|Levonorgestrel IUD (LNG-IUD)|Levonorgestrel IUD containing 52 mg levonorgestrel registered for contraceptive use in South Africa at the time of the trial.
62652018|NCT03229499|EXPERIMENTAL|Anastrozole|1mg (1 tablet)taken by mouth once a day for one year
62652019|NCT03229499|PLACEBO_COMPARATOR|Placebo|1 tablet taken by mouth once a day for one year
62652020|NCT02832713|EXPERIMENTAL|Intra-articular injection of botulinum toxin A|
62086981|NCT04575805|EXPERIMENTAL|Internet-delivered Cognitive Bias Modification-Interpretation|CBM Version 2 is an internet-delivered Cognitive Bias Modification-Interpretation intervention taking place over 4 weeks (eight sessions, twice per week).
62086982|NCT04575805|EXPERIMENTAL|Internet-delivered Cognitive Bias Modification-Attention|CBM Version 3 is an internet-delivered Cognitive Bias Modification-Attention intervention taking place over 4 weeks (eight sessions, twice per week).
61904066|NCT03133884|EXPERIMENTAL|Acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 20 seconds.
62652021|NCT02832713|ACTIVE_COMPARATOR|Intra-articular injection of hyaluronic acid|
62652022|NCT06169722|ACTIVE_COMPARATOR|200mg|200mg oral once a day
62285898|NCT01817790|PLACEBO_COMPARATOR|Placebo nasal spray|Two sprays of placebo per nostril to be administered in morning.
62285899|NCT05779709|EXPERIMENTAL|Urotherapy group|The purpose of urotherapy education was to teach children to empty the bladder regularly and completely. The standardized urotherapy which included instructions on daily fluid intake of at least 1,200 ml evenly distributed daily as described and voiding at 2-hour intervals until bedtime in which the voiding and defecation positions were taught not to perform avoidance maneuvers. In this training, families were given basic information about the anatomy and physiology of the lower urinary tract (LUT) and anorectum, normal voiding and defecation, fluid consumption and voiding habits of children. The children were allowed to pee whenever they wanted occasionally at any time. Children were also asked to report the number of wet days during 8 weeks
62285900|NCT05779709|EXPERIMENTAL|Reformer pilates group|The basic pilates principles were explained to the children. The diaphragmatic breathing, neutral position of the pelvis, centering and pelvic floor control were teached with appropriate language for their age. Verbal help were given to maintain centering during each movement. The exercises (30 min) were started by doing 10 repetitions in combination with diaphragm breathing, and progressed 12 repetitions after 3 weeks, 15 repetitions after 6 weeks (frog series, leg circles series, hundred series, box series, side splits series).İndividual reformer pilates training consisting of 30 minutes two days a week was given to the exercise group by an expert physiotherapist for 8 weeks.
62285901|NCT01089660|EXPERIMENTAL|Study Group 1|Swine-origin A/H1N1 Vaccine Low-dose
62285902|NCT01089660|EXPERIMENTAL|Study Group 2|Swine-origin A/H1N1 Vaccine High-dose
62285903|NCT02043925||psychiatric patients treated with QT-prolonging drugs|
62285904|NCT06068114||Diabetic patients|Either type I or type II diabetes mellitus, possibly also suffering from functional dyspepsia or gastroparesis
62285905|NCT06068114||Healthy controls|
62285906|NCT03955094|EXPERIMENTAL|AMBU® AURAGAIN™ device|Assess feasibility of AMBU® AURAGAIN™ as an intubating device in paediatrics
62652023|NCT06169722|ACTIVE_COMPARATOR|400mg|400mg oral once a day
61904067|NCT03133884|OTHER|Superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
61904068|NCT01566084|OTHER|Normal sodium|Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
62652024|NCT06169722|ACTIVE_COMPARATOR|200mg or 400mg|200mg or 400mg oral once a day
62652025|NCT04970940|EXPERIMENTAL|Sequence 1|"* Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days)~* Wash-out for 7 days~* Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days)~* Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)"
62086983|NCT04575805|NO_INTERVENTION|Wait-List Control|This arm is wait-list control group which will also receive internet-delivered Combined Cognitive Bias Modification intervention after the follow-up assessment
62086984|NCT01225042|EXPERIMENTAL|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
62086985|NCT01225042|PLACEBO_COMPARATOR|placebo|Carrier material powder of identical appearance
62086986|NCT00848211|PLACEBO_COMPARATOR|Placebo|
62086987|NCT00848211|EXPERIMENTAL|TUTI-16 0.03 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
62086988|NCT00848211|EXPERIMENTAL|TUTI-16 0.1 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
62086989|NCT00848211|EXPERIMENTAL|TUTI-16 0.6 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
62285907|NCT03787589|EXPERIMENTAL|Exercise Intervention|Participants in this arm will receive standard of care along with the exercise prescription intervention
62285908|NCT03787589|NO_INTERVENTION|Standard of Care|This group will receive standard of care treatment including regular verbal encouragement to exercise (monthly) by dialysis unit staff.
62285909|NCT04990921|EXPERIMENTAL|Palliative Radiation in Combination with Pembrolizumab|"Stereotactic radiation therapy will be delivered using either linac-based SBRT using 10x flattening filter-free (FFF) photons or Cyberknife Pencil Beam Technology utilizing 6X photons. Treatment will be delivered in 1-5 fractions. Fractionation and total dose (1500 - 3000 cGy) will depend on the site of disease, previous radiation treatment, and patient symptomatology.~Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for intravenous infusion. Pembrolizumab at a dose of 200 mg will be administered intravenously every 3 weeks (± 3 days)."
62285910|NCT03450928|ACTIVE_COMPARATOR|Short POEM|Patients in the Short POEM-group will undergo a Peroral Endoscopic Myotomy (POEM) extended for a total of 7 cm (including 4 cm above the esophago-gastric junction and 3cm on the stomach).
62652026|NCT01517217|OTHER|No girdle postoperative|patients undergoing major abdominal surgery will get NO individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
62652027|NCT01517217|OTHER|Girdle postoperative|patients undergoing major abdominal surgery will get an individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
62086990|NCT00628069||Group 1|performers who will participate in the training sessions.
62652028|NCT04942067|EXPERIMENTAL|APG-2575 +Pd or LD|APG-2575+ Pomalidomide 4mg QD x 21 days + dexamethasone
62652029|NCT04942067|EXPERIMENTAL|APG-2575+LD|APG-2575+ Lenalidomide +Dexa Days 1 through 21 of each 28-day cycle,
62652030|NCT00637013|ACTIVE_COMPARATOR|Acromioplasty|Acromioplasty + physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
62285911|NCT03450928|ACTIVE_COMPARATOR|Long POEM|Patients in the Long POEM-group will receive a 12cm-long Peroral Endoscopic Myotomy (POEM), including 9 cm on the esophagus and 3cm on the gastric wall
62652031|NCT00637013|ACTIVE_COMPARATOR|Physiotherapy|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
62652032|NCT05863442|ACTIVE_COMPARATOR|Soliris|
62652033|NCT05863442|EXPERIMENTAL|TUR03|
62652034|NCT01637168|EXPERIMENTAL|Test Group|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
62086991|NCT00628069||Assistants|Assisants-paired with the performers and will be allowed to assists only, without the opportunity to practice the technical skills related to the task.
62086992|NCT01316497|EXPERIMENTAL|Remote ischemic preconditioning (RIPC)|See intervention description
62285912|NCT00094757|EXPERIMENTAL|Sitagliptin 100 mg|Sitagliptin 100 mg
62285913|NCT00094757|EXPERIMENTAL|Sitagliptin 200 mg|Sitagliptin 200 mg
62285914|NCT00094757|PLACEBO_COMPARATOR|Placebo/Pioglitazone|Placebo/Pioglitazone
62285915|NCT04025593|ACTIVE_COMPARATOR|RCHOP|
62285916|NCT04025593|EXPERIMENTAL|RCHOPX|
62285917|NCT01894126|EXPERIMENTAL|Two-way SMS dialogue|Women will receive SMS messages with prompts to reply. They will have the ability to text back to the system and both respond to and initiate SMS dialogue
62285918|NCT01894126|EXPERIMENTAL|One-way SMS Messaging|Women will receive scheduled one-way SMS messages
62652035|NCT01637168|ACTIVE_COMPARATOR|Comparator Group|Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
62086993|NCT01316497|PLACEBO_COMPARATOR|Control|
62086994|NCT04119245|EXPERIMENTAL|study group|"after induction of general anesthesia, a proper size of Igel will be inserted after compelete muscle relaxation. In order to confirm proper positioning of the I-gel,a fiberoptic bronchoscope will be pass through the device and pushed forward up to1 cm proximal to it to obtain a glottic view, leak airway pressure test will be done.~Afterwards the same patient will be placed in the lateral decubitus position ,confirmation of I-gel position using fiberoptic bronchoscope will be done and recorded.The leak air way pressure test will be done as previously done in supine position and recorded.~The patient will be returned to supine position."
62086995|NCT05805540|EXPERIMENTAL|Cold-water immersion|Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times.
62086996|NCT05805540|EXPERIMENTAL|Protein-carbohydrates supplementation|Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water.
62086997|NCT05805540|EXPERIMENTAL|Active recovery|Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax).
62086998|NCT05805540|PLACEBO_COMPARATOR|Placebo|Subjects drank a water-based drink and sweetener. Both the PLA and SUPPL group sat for 25 minutes until all recovery methods were completed.
62086999|NCT01336062|EXPERIMENTAL|Nanoparticle Albumin-Bound Paclitaxel|The study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
62087000|NCT00642928|PLACEBO_COMPARATOR|Placebo|
62087001|NCT00642928|EXPERIMENTAL|BF 2.649-5 mg|
62087002|NCT00642928|EXPERIMENTAL|BF 2.649 10 mg|
62087003|NCT00642928|EXPERIMENTAL|BF 2.649 20 mg|
62087004|NCT00642928|EXPERIMENTAL|BF 2.649 40 mg|
62087005|NCT00283309|ACTIVE_COMPARATOR|Memantine|Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
62652036|NCT06532305|EXPERIMENTAL|Empowerment classes|"Content:~Mental Health and Stress Management: Techniques and strategies for managing stress, mindfulness practices, and mental health awareness.~Dementia Care Skills: Training on dementia care, communication with dementia patients, and specific caregiving techniques.~Language and Communication Skills: Improving proficiency in local languages and enhancing communication skills relevant to caregiving.~Follow-up: After completing the empowerment classes, participants will switch to the social gatherings intervention."
62087006|NCT00283309|PLACEBO_COMPARATOR|Placebo|Inactive ingredient matching the active medication in appearance
62087007|NCT00283309|ACTIVE_COMPARATOR|Riluzole|Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.
62087008|NCT04351490|EXPERIMENTAL|Group supplementation|
62087009|NCT04351490|NO_INTERVENTION|Group usual treatment|
62087010|NCT03819569|ACTIVE_COMPARATOR|Biopsy|Subjects receive a renal cell biopsy prior to making a decision about treatment
62087011|NCT03819569|SHAM_COMPARATOR|No Biopsy|Subjects do not receive a renal cell biopsy prior to making a decision about treatment
62087012|NCT04506671|EXPERIMENTAL|Cryoablation group|Patients with T1b renal tumor and ECOQ\>20
62087013|NCT04506671|ACTIVE_COMPARATOR|Partial nephrectomy group|Patients with T1b renal tumor
62087014|NCT03070314|EXPERIMENTAL|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
62087015|NCT03696979|ACTIVE_COMPARATOR|myofascial induction|Twice a week for 8 weeks. Lumbar interfacial field stroke application, Lumbar interfacial field to deep application, Lumbar region cross-hands induction technique, Hip flexor region induction.
62652037|NCT06532305|ACTIVE_COMPARATOR|Social gatherings|"Content:~Social Interaction: Regular gatherings to promote social bonding and peer support among care workers.~Recreational Activities: Group activities designed to foster relaxation and social engagement.~Informal Discussions: Opportunities for care workers to share experiences and coping strategies in an informal setting.~Follow-up: After completing the social gatherings, participants will switch to the empowerment classes intervention."
62285919|NCT01894126|NO_INTERVENTION|Control|
62652038|NCT00299039|ACTIVE_COMPARATOR|1|
62652039|NCT00299039|ACTIVE_COMPARATOR|2|
62652040|NCT05220488||Asthma Group|Asthma Group
62652041|NCT05220488||Healthy Group|Healthy Group
62652042|NCT02785211|EXPERIMENTAL|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
62652043|NCT02785211|PLACEBO_COMPARATOR|control group|"For the control group, participants will receive regular physical examinations and education by village doctors weekly during the 8 week intervention.The weekly visits for every old people whose age above 65 by country doctors are not arranged by our study, it is the country doctors routine work by government health policy. This study was permitted by the local community health center, the director with specific responsibility will inform all country doctors to support our study."
61904069|NCT01566084|OTHER|Low sodium|Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
61904070|NCT03718091|EXPERIMENTAL|Cohort T1: ATRX-mutant Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904071|NCT03718091|EXPERIMENTAL|Cohort T2: Truncating ATM Mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904072|NCT03718091|EXPERIMENTAL|Cohort T3: Other HR Gene Mutations|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904073|NCT03718091|EXPERIMENTAL|Cohort 1A: Osteosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904074|NCT03718091|EXPERIMENTAL|Cohort 1B: Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904075|NCT03718091|EXPERIMENTAL|Cohort 2: Truncating ATM mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904076|NCT03718091|EXPERIMENTAL|Cohort 3A: Germline BRCA mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904077|NCT03718091|EXPERIMENTAL|Cohort 3B: Other HR Alteration|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904078|NCT03718091|EXPERIMENTAL|Cohort 4A: MYC amplification, FBXW7 mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904079|NCT03718091|EXPERIMENTAL|Cohort 4B: Cyclin E amplification|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904080|NCT03718091|EXPERIMENTAL|Cohort 5: ARID1A mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904081|NCT03718091|EXPERIMENTAL|Cohort T4: SDH-Mutant GIST|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
61904082|NCT05103852|EXPERIMENTAL|Patients with right cardiac catheterization|
62087016|NCT03696979|ACTIVE_COMPARATOR|Therapeutic Pain education|Pain education,twice a week for 8 weeks. The mechanism of pain,Pain processing in the center, How sensitive the central nervous system is in chronic pain, Pain becomes chronic with the contribution of factors, Problems related to fear of pain will be explained in detail.
62087017|NCT06160921||2|
62087018|NCT03055845|EXPERIMENTAL|STA363 dose 1|
62652044|NCT00806065|EXPERIMENTAL|ENMD-2076|Oral capsules, once daily in 28-day cycles
62087019|NCT03055845|EXPERIMENTAL|STA363 dose 2|
62652045|NCT00937339|ACTIVE_COMPARATOR|Control|The control group will perform the same exercises on the vibration platform, as in the experimental group. However, the vibration device will be turned off during the exercises.
62652046|NCT00937339|EXPERIMENTAL|Whole body vibration|Subjects in the experimental group will undergo whole body vibration (1 session per day, 3 sessions per week) for 8 weeks. The vibration loading will be carried out using the Jet-Vibe System (Danil SMC Co., Ltd., Seoul, Korea). The vibration protocol used in this study will be 30Hz. While standing on the vibration platform, patients will be instructed to repeat the following set of light exercises: (1) light squatting,(2)deep squatting , (3) side-to-side weight-shift, (4) Forward and backward weight-shift, (5) forward lunge, (6) marching on the spot. The total duration of exposure of whole body vibration per session will be about 10 minutes.
62285920|NCT01526525|PLACEBO_COMPARATOR|TK|In TK group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point in both hands, the needles were not inserted in the skin but they were put atop the skin and were secured by adhesive tape. For 30min in the E/A stimulator ITO ES-160 the indicator light was on but no electrical current was applied. Thereafter the E/A device deactivated and after the awakening of the patients, it was connected in ST36 and LI4 points for 30min with the same technique. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36. The patients were told that they may or may not feel electrical current because of its very high frequency.
62460781|NCT05425381|ACTIVE_COMPARATOR|Positive Behavioral Interventions and Supports with Co-located School Mental Health (PBIS+SMH)|Mental health clinicians will be assigned and can work with MTSS teams (or not). Otherwise, there will be no special guidance. We expect this condition to mimic typical practices in schools, where PBIS and SMH efforts are co-located, but not meaningfully interconnected. In other words, we expect parallel functioning (Splett et al., 2014).
62652047|NCT02072200|EXPERIMENTAL|Modified release prednisone|Single arm / Lodotra
62652048|NCT06353061|EXPERIMENTAL|The group treated with metformin in combination with synchronous chemoradiotherapy|After the group allocation is determined, patients in the experimental group will undergo CA-IX PET/CT scans. Subsequently, they will commence taking metformin at a dose of 850 mg per tablet, once daily, for three consecutive days. One week later, a second CA-IX PET/CT scan will be performed. Following this, synchronous chemoradiotherapy will be initiated, with patients taking metformin twice daily during the course of radiotherapy, at a dosage of one tablet per administration.
62652049|NCT06353061|ACTIVE_COMPARATOR|The group undergoing chemoradiotherapy alone.|Patients in the control group will undergo the first CA-IX PET/CT scan after the group allocation. One week later, they will undergo the second PET/CT scan. Subsequently, they will commence synchronous chemoradiotherapy.
61904083|NCT04571671||Study group|Women with Müllerian anomalies who have received an oocyte donation. The diagnosis of Müllerian anomalies is established when a cavity is demonstrated uterine abnormality with any of the defects described in the American classifications or European in transvaginal ultrasound, hysteroscopy or hysterosalpingography (HSG). The differential diagnosis in case of doubts is established with 3D ultrasound, MRI or hystero / laparoscopy. All the septa have been resected prior to performing the OVODON cycle.
61904084|NCT04571671||Control group|Patients who receive donated oocytes and who do not present Müllerian anomalies. An absence of AM, a transvaginal ultrasound, an HSG or a normal hysteroscopy with a uterine cavity with a normal shape and absence of intracavitary images is considered
61904085|NCT02720172|EXPERIMENTAL|Early Home Exercise Program|The early home exercise program is an exercise-based self-management program for patients immediately after cervical spine surgery.
62087020|NCT03055845|EXPERIMENTAL|STA363 dose 3|
62087021|NCT03055845|PLACEBO_COMPARATOR|Placebo|
62087022|NCT06200038|EXPERIMENTAL|Mulligan group (MG)|Individuals underwent 11 sessions (every day for the first week, every other day for the next two weeks).Hot pack was applied to the neck and upper trapezius area for 20 minutes.2 channels and 4 electrodes in the neck area; Conventional transcutaneous electrical nerve stimulation (TENS) was applied to the patient for 20 minutes with current transition time: 50-100 microseconds, frequency: 60-120 Hz and mild tingling without causing discomfort.US application was performed at a frequency of 1.5 W/cm2 and 1 Mhz for 8 minutes.Stretching exercises were applied to the trapezius upper part and levator scapula muscles for 15-30 seconds with 10 repetitions under the supervision of a physiotherapist.In addition to physiotherapy applications in MG, Mulligan natural apophyseal reversal technique was applied to the upper thoracic segments. Mulligan mobilization was performed with 3 sets of 10 repetitions and 15-20 seconds of rest between sets.
62460782|NCT04792749|EXPERIMENTAL|Metformin treatment|Patients who receive metformin in addition to progestin therapy
62460783|NCT04792749|NO_INTERVENTION|Conventional treatment|Patients who receive progestin therapy only
62460784|NCT06398678||Patients who had undergone cytoreductive surgery.|
62460785|NCT01051570|EXPERIMENTAL|Carboplatin, RAD 001 & Prednisone|"Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)\*IV over 30-60 min, Day 1 of a 21 day cycle~RAD 001: 5 mg Orally daily, starting from Day 2 continuously~Prednisone 5 mg Orally twice daily, continuously"
62460786|NCT01168505|NO_INTERVENTION|no iron supplentation|
62460787|NCT01168505|EXPERIMENTAL|iron supplement|
62652050|NCT00314145|EXPERIMENTAL|ChimeriVax™-JE|Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
62652051|NCT00314145|ACTIVE_COMPARATOR|JE-VAX®|Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.
62652052|NCT03430739||Babies; Usage time of Helmet between 15-18 hours a day|Babies who worn the helmet for 15-18 hours a day
62652053|NCT03430739||Babies; Usage time of Helmet between 19-23 hours a day|Babies who worn the helmet for 19-23 hours a day
62087023|NCT06200038|SHAM_COMPARATOR|Sham (different in the direction and amplitude of mobilization) group|Individuals underwent 11 sessions (every day for the first week, every other day for the next two weeks).Hot pack was applied to the neck and upper trapezius area for 20 minutes.2 channels and 4 electrodes in the neck area; Conventional TENS was applied to the patient for 20 minutes with current transition time: 50-100 microseconds, frequency: 60-120 Hz and mild tingling without causing discomfort.US application was performed at a frequency of 1.5 W/cm2 and 1 Mhz for 8 minutes.Stretching exercises were applied to the trapezius upper part and levator scapula muscles for 15-30 seconds with 10 repetitions under the supervision of a physiotherapist.Sham mobilization was applied to the segments where Mulligan mobilization was carried out in Sham group, in which the direction of thrust and thrust were different.
62460788|NCT06486480|EXPERIMENTAL|Robot assisted endoscopy group|Using robot assisted endoscopy to clear intraventricular hemorrhage
62460789|NCT06486480|ACTIVE_COMPARATOR|External ventricular drainage group|Using External ventricular drainage to clear intraventricular hemorrhage
62652054|NCT05545150|EXPERIMENTAL|Diagnostic (Volumetric Specimen Imager Device)|Patients undergo breast conservation surgery (lumpectomy or partial mastectomy) per standard care, and VSI intraoperative imaging is captured on the day of surgery.
62652055|NCT04325997|EXPERIMENTAL|an ordinary laryngos with mouth opener|
61904086|NCT02720172|OTHER|Usual Care|Usual postoperative care.
62460790|NCT05227820|EXPERIMENTAL|Experimental Arm: NE3107|All participants will take 200mg BID (12 hours apart) of NE3107 for 3 months.
62460791|NCT05371444|EXPERIMENTAL|Controlled DoF|The treatment that this gruop will receive consist in a training with the exoskeleton that will restrict the DoF of the arm and trunk
62652056|NCT04325997|NO_INTERVENTION|Video laryngoscopy intubation|
62652057|NCT04325997|EXPERIMENTAL|Video laryngoscope with mouth opener|
62652058|NCT06232096|EXPERIMENTAL|MBS314|
62652059|NCT02360332|EXPERIMENTAL|PS-ASD|Treatment Condition, participants assigned to this condition will receive the treatment, one school year (9 months) of Project SEARCH plus ASD Supports
61904087|NCT04583059|EXPERIMENTAL|Taping Group|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lower end of the shank. Second step involved application of the stirrup. During this step, the foot was held in neutral, and the tape applied to pass from the medial side of the ankle, under the foot just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. The second step was repeated to apply the second stirrup. Both ends of the stirrups were firmly attached to the anchor tape applied during the first step and this attachment was reinforced with a locking tape during the third and final step by once again applying the tape circumferentially just above the malleolar level at the lower end of the shank. Taping was applied by a physical therapist according to the health association requirements
62460792|NCT05371444|ACTIVE_COMPARATOR|Non controlled DoF|The treatment that this gruop will receive consist in a training with out the exoskeleton and without restriction of the DoF
62460793|NCT05386589|EXPERIMENTAL|Moderate Hepatic Impairment|Participants with moderate hepatic impairment received a single oral dose of molnupiravir 800 mg on Day 1.
62460794|NCT05386589|EXPERIMENTAL|Healthy-Matched Control Group|Healthy matched participants received a single oral dose of molnupiravir 800 mg on Day 1.
62087024|NCT06200038|OTHER|Physiotherapy group|Individuals underwent 11 sessions (every day for the first week, every other day for the next two weeks).Hot pack was applied to the neck and upper trapezius area for 20 minutes.2 channels and 4 electrodes in the neck area; Conventional TENS was applied to the patient for 20 minutes with current transition time: 50-100 microseconds, frequency: 60-120 Hz and mild tingling without causing discomfort.US application was performed at a frequency of 1.5 W/cm2 and 1 Mhz for 8 minutes.Stretching exercises were applied to the trapezius upper part and levator scapula muscles for 15-30 seconds with 10 repetitions under the supervision of a physiotherapist.
62087025|NCT04529538|EXPERIMENTAL|Group1: nOPV1 (IPV History)|Healthy adults fully vaccinated against polio exclusively by IPV were administered 1 vaccination of novel OPV type 1 (nOPV1) containing 10\^6.5 cell culture infectious dose 50% (CCID50) on Day 1.
62087026|NCT04529538|ACTIVE_COMPARATOR|Group 2: mOPV1 (IPV History)|Healthy adults fully vaccinated against polio exclusively by IPV were administered 1 vaccination of mOPV1 containing 10\^6.0 CCID50 on Day 1.
62087027|NCT04529538|EXPERIMENTAL|Group 3: nOPV1 (OPV History)|Healthy adults fully vaccinated against polio with an OPV-containing vaccine history were administered 2 vaccinations of nOPV1 containing 10\^6.5 CCID50/dose, given 28 days apart.
62087028|NCT04529538|ACTIVE_COMPARATOR|Group 4: mOPV1 (OPV History)|Healthy adults fully vaccinated against polio with an OPV-containing vaccine history were administered 2 doses of mOPV1 containing ≥ 10\^6.0 CCID50/dose, given 28 days apart.
62285921|NCT01526525|ACTIVE_COMPARATOR|TKE|In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
62460795|NCT02300090||Intervention group|This group of patients (n=250) will receive the digital service (smart phone application and bluetooth inhaler device) in addition to current best care from their healthcare professional.
62460796|NCT02300090||Control group|This group of patients (n=250) will receive current best care alone. Control patients will not have access to the digital service.
62460797|NCT02465567|EXPERIMENTAL|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler \[MDI\])
61904088|NCT04583059|EXPERIMENTAL|Bandaging Group|Standard 10 cm width elastic bandage was used. The elastic bandage was wrapped around the ankle joint to form an 8-figure shape starting from the forefoot. Then, the bandage was taken diagonally upwards, steeply enough to go well above the heel. Then, the bandage was taken around the lower calf area to form an anchor. Then its diagonally taken down across the midfoot. Again the bandage was wrapped around the forefoot and going diagonally up to finish off around the lower calf, leaving the heel open. During the bandage application process, the therapiest didn't stretch the bandage, because bandage does note need to be stretched during the application, as the bandage becomes naturally tight when its layers wraped over each others. the participant was asked to wear his/her sport shoes over the bandage during the measurement procedures.
61904089|NCT01080781||Group 1|normal pressures in right auricle (\<10 mmHg) /and or pulmonary artery (\<35 mmHg)
61904090|NCT01080781||Group 2|high pressures in right auricle (\> 10 mmHg) /and or pulmonary artery (\>35 mmHg)
61904091|NCT01102998||Brain Tumor Survivors|Brain tumor survivors ages 8 to 18 years who are at least 5 years post diagnosis and at least 2 years post active therapy or observation and their parents/guardians will be approached to participate during clinic visits.
62460798|NCT02465567|EXPERIMENTAL|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler \[MDI\])
62285922|NCT01189383|EXPERIMENTAL|IL15-DC Vaccine|Approximately 9 x 10\^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12.At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
61904092|NCT04432727|EXPERIMENTAL|ACTIVE FT-CC|Text message reminders will be sent if subject does not use the device for 2 consecutive days.
61904093|NCT04432727|EXPERIMENTAL|PASSIVE FT-CC|Text message reminders will not be sent to subjects.
62087029|NCT04529538|EXPERIMENTAL|Group 5: nOPV3 (IPV History)|Healthy adults fully vaccinated against polio exclusively by IPV were administered 1 vaccination of nOPV3 containing 10\^6.5 CCID50 on Day 1.
62285923|NCT04208425|EXPERIMENTAL|Project Personality|The web-based growth mindset intervention, called Project Personality, is delivered entirely via Qualtrics and takes approximately 30 minutes to complete. All intervention activities are self-administered by youth and delivered in a web-based format, including illustrations and audio-recordings of text. Intervention content is designed to maximize relevance for youths experiencing symptoms of depression, including excessive sadness and hopelessness.
62285924|NCT04208425|ACTIVE_COMPARATOR|Sharing Feelings Intervention|The Sharing Feelings Intervention is delivered entirely via Qualtrics, is self-administered by youth, and takes approximately 30 minutes to complete. It is structurally similar to the growth mindset intervention, but it is designed to mimic supportive therapy (ST). The goals of the ST intervention is to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions.
62285925|NCT02020044|OTHER|Endothelial Keratoplasty|Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK
62285926|NCT00445302|ACTIVE_COMPARATOR|Normal renal function|Participants with normal renal function (creatinine clearance (CLcr) \> 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
62285927|NCT00445302|EXPERIMENTAL|Mild renal impairment|Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
61904094|NCT05167695|EXPERIMENTAL|Habit-based Sleep Health Intervention (HABITs)|"Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x30-minute weekly sessions.~Participants in this group will not receive the texts discussed below."
62285928|NCT00445302|EXPERIMENTAL|Moderate renal impairment|Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
62285929|NCT00445302|EXPERIMENTAL|Severe renal impairment|Participants have severe renal impairment (creatinine clearance (CLcr) \< 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
62285930|NCT01926626|EXPERIMENTAL|Nicotine Patch+Moclobemide|After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
61904095|NCT05167695|EXPERIMENTAL|Habit-based Sleep Health Intervention plus text messages (HABITs+texts)|"Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x30-minute weekly sessions.~Additionally, participants in this group will receive the text messaging intervention."
61904096|NCT04125953|EXPERIMENTAL|Intervention|A 3 week intervention with Andullation will be performed, 3 times a week for 20 minutes after completion of the radiotherapy session
61904097|NCT04125953|PLACEBO_COMPARATOR|Control|This group will follow the same intervention protocol, but without the application of the Andullation technology
61904098|NCT04513626|OTHER|Delayed switch|the maintaining of their current ART followed by a switch to doravirine/raltegravir at W48 (delayed switch group).
61904099|NCT04513626|EXPERIMENTAL|Immediate switch|Immediate switch to doravirine/raltegravir
61904100|NCT02093052|EXPERIMENTAL|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up - 10 session intervention to enhance nurturance and following the lead
61904101|NCT02093052|ACTIVE_COMPARATOR|Developmental Education for Families|Developmental Education for Families - 10 session intervention that targets cognitive development
61904102|NCT02093052|NO_INTERVENTION|Low-risk|Low-risk comparison group
62087030|NCT04529538|ACTIVE_COMPARATOR|Group 6: mOPV3 (IPV History)|Healthy adults fully vaccinated against polio by exclusively IPV were administered 1 vaccination of mOPV3 containing ≥ 10\^5.8 CCID50 on Day 1.
62087031|NCT04529538|EXPERIMENTAL|Group 7: nOPV3 (OPV History)|Healthy adults fully vaccinated against polio with an OPV-containing vaccine history were administered 2 vaccinations of nOPV3 in a dose of 10\^6.5 CCID50/dose, given 28 days apart.
62285931|NCT00544869|EXPERIMENTAL|1|
62285932|NCT02411747|EXPERIMENTAL|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
62285933|NCT02411747|ACTIVE_COMPARATOR|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
62285934|NCT01261559|NO_INTERVENTION|Standard CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
62652060|NCT02360332|NO_INTERVENTION|High School As Usual|Control Condition, Participants assigned to this condition will have no interaction or intervention with the research team with the exception of data collection at the specified time points.
62652061|NCT01631214|ACTIVE_COMPARATOR|Alendronate/Alendronate|Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
62652062|NCT01631214|EXPERIMENTAL|Romosozumab/Alendronate|Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
62652063|NCT00352183|EXPERIMENTAL|1|
62652064|NCT00352183|ACTIVE_COMPARATOR|2|
62652065|NCT02721784|OTHER|Pre- and Post- Radiotherapy MRI|"mpMRI/VERDICT sequences to be preformed pre- and post- EBRT (external beam radiotherapy) according to the following schedule:~Pre-Androgen Deprivation Therapy 3 weeks before radiotherapy 6 week after starting radiotherapy 6 Months after starting radiotherapy~External Beam Radiotherapy to be given after 3 months of androgen deprivation"
62652066|NCT05338463|EXPERIMENTAL|Fespixon Cream|"A single arm of Fespixon Cream for DFU (TEXAS 1A, 2A) in dialysis patients~Test drug :~1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks"
62652067|NCT06516224|EXPERIMENTAL|Group 1|dermocosmetic regimen consisting in Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream (all Vichy Laboratoires, France) for 6 months + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+
62652068|NCT06516224|ACTIVE_COMPARATOR|Group 2|hydroquinone 4% (HQ4%, Hydroquinona 40 mg/g, Germed, Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
62652069|NCT06516224|ACTIVE_COMPARATOR|Group 3|Combination of hydroquinone, resorcinol corticosteroid (Kligman Trio, Vitacid Plus Cream, Claredor Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
62652070|NCT01757132|OTHER|Implantable Miniature Telescope|Post approval study
62652071|NCT02030600|EXPERIMENTAL|IDeg OD ± OADs followed by IGlar OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
61904103|NCT02070198|EXPERIMENTAL|Long acting FSH and GnrH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
61904104|NCT02070198|EXPERIMENTAL|daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
62285935|NCT01261559|EXPERIMENTAL|Chrysalis CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.
62285936|NCT04736667||Subjects fail screening for TMVI|Subjects with symptomatic mitral valve disease who after referral for TMVI, are deemed not to be candidates for TMVI.
62285937|NCT01934569|EXPERIMENTAL|Active tratment|Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771
62285938|NCT02550028|EXPERIMENTAL|Oral levetiracetam|Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
62460799|NCT02465567|EXPERIMENTAL|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT009)
62460800|NCT02465567|EXPERIMENTAL|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT003)
62460801|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
62460802|NCT00709553|EXPERIMENTAL|1|midazolam, one single dose of 705mg
62652072|NCT02030600|ACTIVE_COMPARATOR|IGlar OD ± OADs followed by IDeg OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
62652073|NCT01299909|ACTIVE_COMPARATOR|Mindfulness Training for Smokers|MTS participants will receive 8 classes of training in mindfulness meditation, access to the MTS website, and 2 weeks of nicotine patches.
61904105|NCT02070198|EXPERIMENTAL|Triptorelin and recombinant FSH|Women in triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day until the day of HCG administration.
61904106|NCT03568188|EXPERIMENTAL|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
61904107|NCT03006861|EXPERIMENTAL|Oral creatine supplementation|21 g/d oral creatine for 7 days
61904108|NCT03006861|PLACEBO_COMPARATOR|Oral placebo supplementation|21 g/d oral placebo for 7 days
61904109|NCT02520089|ACTIVE_COMPARATOR|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
62087032|NCT04529538|ACTIVE_COMPARATOR|Group 8: mOPV3 (OPV History)|Healthy adults fully vaccinated against polio with an OPV-containing vaccine history were administered 2 vaccinations of mOPV3 containing ≥ 10\^5.8 CCID50/dose, given 28 days apart.
62087033|NCT02420275|PLACEBO_COMPARATOR|Severe brain injury patient|Severe brain injury patients with placebo
62087034|NCT02420275|EXPERIMENTAL|Severe brain injury patient with device|"Severe brain injury patients withe with Luminette,Lucimed Belgium"
62460803|NCT00709553|EXPERIMENTAL|2|ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )
62460804|NCT04677764|EXPERIMENTAL|Wii Fit Group|Received Standard of care and Wii Fit protocol consisted of strength, balance, and aerobic programs that were performed on the Wii Fit balance board (Nintendo Inc., Kyoto, Japan). For muscle strengthening exercise, lunges, single-leg extensions, sideways leg lifts, single leg twists, and rowing squats were performed. For exercise that enhances balancing sense, the soccer heading, ski slalom, penguin, table tilt, and balance bubble games were used. Aerobic games as hula hoop, super hula hoop and basic step.
62087035|NCT02059161|EXPERIMENTAL|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of \>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
62087036|NCT02059161|ACTIVE_COMPARATOR|Lantus|Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of \>70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
61904110|NCT02520089|EXPERIMENTAL|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
62087037|NCT02914106||Control group|Sixty-90 year-old subjects were randomly selected and distributed in two experimental groups: 1) a control group, involving subjects without physical or psychiatric illness, and 2) an Acute Ischemic Stroke group (AIS group).
61904111|NCT02429180|EXPERIMENTAL|Rehabilitation training|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
62087038|NCT02914106||Acute Ischemic Stroke group|Patients with diagnosis of AIS within the 24 hours of their neurovascular event.
62652074|NCT01299909|ACTIVE_COMPARATOR|Integrated Training for Smokers|ITS participants will receive 8 classes of training in smoking cessation strategies, access to the Freedom From Smoking online program, and 2 weeks of nicotine patches.
62087039|NCT06213012|ACTIVE_COMPARATOR|Transcutaneous Spinal Stimulation (TSS)|Spinal Stimulation delivered over the skin using a research stimulator with conventional surface electrodes during research visits.
62285939|NCT02550028|ACTIVE_COMPARATOR|Intravenous phenobarbital|Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance
62285940|NCT04688203|ACTIVE_COMPARATOR|Magnesium sulfate infudsion|patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
62285941|NCT04688203|ACTIVE_COMPARATOR|Labetalol infusion|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
62285942|NCT00716469|EXPERIMENTAL|LS11 Administration|"Treatment will be given with a standard 3+3 light dose escalation. The Treatment Period will be 28 days. The LS11 dose will be 30mg/m2. The initial light dose will be 50 J/cm. If criteria for dose escalation are met, then the light dose will be escalated to 100J/cm, 150J/cm and 200J/cm. Once the maximum light dose is determined, up to 6 additional patients will be treated at that level to gain further experience with this modality prior to phase II testing. In particular, at least 3 subjects \<12 years of age will be enrolled at the maximum tolerable dose (MTD) to allow for further evaluation of safety in younger children. If grade 3 or 4 toxicities are noted at light dose level #1, the LS11 dose will be decreased to 20mg/m2 (2/3 of the standard dose)."
62285943|NCT04642846|EXPERIMENTAL|one application of SDF|
62285944|NCT04642846|EXPERIMENTAL|two application of SDF one month apart|
62285945|NCT01707030|EXPERIMENTAL|BAI Arm|Receiving a web-based brief intervention for alcohol problems
62285946|NCT01707030|ACTIVE_COMPARATOR|Usual Care|In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
62285947|NCT01007214|EXPERIMENTAL|Prostate cancer|A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
62285948|NCT03655834|EXPERIMENTAL|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
62652075|NCT01299909|OTHER|Quitline|Quitline participants will consist of participants who elect not to participate in the high-intensity treatments (Mindfulness Training for Smokers; Integrated Training for Smokers. This Quitline group is a Non-Randomized, Treatment as Usual group.
62652076|NCT03024567|ACTIVE_COMPARATOR|Salt|6 grams sodium chloride per day for 14 days
62652077|NCT03024567|PLACEBO_COMPARATOR|Placebo|6 grams gelatine per day for 14 days
62652078|NCT02659735|EXPERIMENTAL|Panel 1: Treatment ADBC|Participants will receive Treatment A (600 milligram \[mg\] JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fed conditions) in Period 1; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 \[test 3\] under fed conditions) in Period 2; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 \[test 1\] under fed conditions) in Period 3; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 \[test 2\] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
61904112|NCT02429180|NO_INTERVENTION|Control|Control: treatment as usual plus receipt of a UK Stroke Association booklet on exercise after stroke.
61904113|NCT02365233|ACTIVE_COMPARATOR|Thiazolidinedione|(Pioglitazone, 15 mg/day)
61904114|NCT02365233|ACTIVE_COMPARATOR|Lantus Insulin|0.35 U per kg body weight once daily
61904115|NCT02365233|ACTIVE_COMPARATOR|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
61904116|NCT00074698|EXPERIMENTAL|FG-3019 Low Dose|Participants will receive a single intravenous (IV) infusion of FG-3019 low dose on Day 0.
61904117|NCT00074698|EXPERIMENTAL|FG-3019 Medium Dose|Participants will receive a single IV infusion of FG-3019 medium dose on Day 0.
61904118|NCT00074698|EXPERIMENTAL|FG-3019 High Dose|Participants will receive a single IV infusion of FG-3019 high dose on Day 0.
62285949|NCT05479903|EXPERIMENTAL|acupuncture stroke group|
62285950|NCT05479903|SHAM_COMPARATOR|sham acupuncture stroke group|
62285951|NCT05479903|PLACEBO_COMPARATOR|no acupuncture stroke group|
62285952|NCT05479903|PLACEBO_COMPARATOR|acupuncture healthy group|
62285953|NCT05479903|EXPERIMENTAL|computerized cognitive training group|
62285954|NCT05479903|PLACEBO_COMPARATOR|tranditional cognitive training group|
62460805|NCT04677764|OTHER|Standard of care group|On discharge from the hospital, patients in the SOC group were given instructions on how to perform physical therapy and occupational therapy exercises after discharge. After education, patients could perform the physical therapy and occupational therapy exercises either at their own home or a gym.
62087040|NCT06213012|SHAM_COMPARATOR|Sham|Sham Stimulation delivered over the skin using a research stimulator with conventional surface electrodes during research visits. Sham stimulation will be delivered using the intensity of stimulation set as during active sessions of ESS, but then gradually decreased down to zero in approximately 30 s. There will be 5-10 minute breaks interspersed between intervals of stimulation, and will vary according to the individual's tolerance and fatigue levels
62087041|NCT06213012|EXPERIMENTAL|Epidural Spinal Stimulation (ESS)|Stimulation delivered internally using an implanted device operated by an external control (only used during research visits).
62087042|NCT03198260|EXPERIMENTAL|Fascial Manipulation|fascial manipulation is a manual therapy technique were to apply deep frictional massage to the deep fascial structure or point to increase its pliability
62460806|NCT02107690|EXPERIMENTAL|low temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
62460807|NCT02107690|EXPERIMENTAL|room temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
62087043|NCT03198260|ACTIVE_COMPARATOR|Running kinematics|the change in a range of joint angles during different phases of running
62652079|NCT02659735|EXPERIMENTAL|Panel 1: Treatment BACD|Participants will receive Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 \[test 1\] under fed conditions) in Period 1; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fed conditions) in Period 2; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 \[test 2\] under fed conditions) in Period 3; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 \[test 3\] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
62087044|NCT05054829|EXPERIMENTAL|PEERS|
62087045|NCT05054829|OTHER|Controls|
62460808|NCT02107690|EXPERIMENTAL|body temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
62652080|NCT02659735|EXPERIMENTAL|Panel I: Treatment CBDA|Participants will receive Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 \[test 2\] under fed conditions) in Period 1; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 \[test 1\] under fed conditions) in Period 2; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 \[test 3\] under fed conditions) in Period 3; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
62652081|NCT02659735|EXPERIMENTAL|Panel I: Treatment DCAB|Participants will receive Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 \[test 3\] under fed conditions) in Period 1; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 \[test 2\] under fed conditions) in Period 2; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fed conditions) in Period 3; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 \[test 1\] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
62087046|NCT01062815|EXPERIMENTAL|Cycling Parenteral Nutrition|Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
62087047|NCT01062815|ACTIVE_COMPARATOR|Continuous Parenteral Nutrition|Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.
62460809|NCT03595657|EXPERIMENTAL|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
62460810|NCT05324436||Cohort 1|Participants with unresectable advanced/recurrent malignant pleural mesothelioma (MPM)
62087048|NCT00830986||1|Computer Assisted Total Knee Arthroplasty
62087049|NCT00830986||2|Conventional Instrumented Total Knee Arthroplasty
62087050|NCT04724174||Pancreaticogastrostomy (PG) group|Patients underwent pancreatoduodenectomy with the PG technique
62087051|NCT04724174||Pancreaticojejunostomy (PJ) group|Patients underwent pancreatoduodenectomy with the PJ technique
62087052|NCT04106687|ACTIVE_COMPARATOR|Caudal Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided caudal block wil performe with bupivacaine 1 ml/kg as 0.25%.
62087053|NCT04106687|ACTIVE_COMPARATOR|Sacral Erector Spinae Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided sacral erector spinae block wil performe with bupivacaine 1 ml/kg as 0.25%.
62087054|NCT02501811|EXPERIMENTAL|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
62087055|NCT02501811|EXPERIMENTAL|c-kit+ cells|Target dose of 5 million c-kit+ cells
62087056|NCT02501811|EXPERIMENTAL|Combination Cells (MSC and c-kit+ cells)|Target dose of 150 million MSCs and 5 million c-kit+ cells
62087057|NCT02501811|PLACEBO_COMPARATOR|Placebo (Plasmalyte A)|Plasmalyte A
62087058|NCT02775747|EXPERIMENTAL|platelet rich plasma gel|Injection of Platelet rich plasma (PRP) gel in 64 cases at time of wound closure in women undergoing cesarean section for improving wound healing after fullfit to all the inclusion and exclusion craiteria
62087059|NCT02775747|PLACEBO_COMPARATOR|Saline|64 Controlled Women with recurrent cesarean section and fullfit to all the inclusion and exclusion craiteria will reseve saline injection at time of wound closure
62087060|NCT01277237|ACTIVE_COMPARATOR|Omacor|
62087061|NCT01277237|PLACEBO_COMPARATOR|Lactose tablet|
62087062|NCT01889160|EXPERIMENTAL|Part A Active|AZD4721 Solution
62087063|NCT01889160|PLACEBO_COMPARATOR|Part A Placebo|Placebo for AZD4721
62285955|NCT05479903|EXPERIMENTAL|aerobics group|
62285956|NCT05140148|PLACEBO_COMPARATOR|Placebo|placebo pill, twice daily
62285957|NCT05140148|ACTIVE_COMPARATOR|Amantadine|100 mg amantadine twice daily, or if 65 years or older once daily
62652082|NCT02659735|EXPERIMENTAL|Panel 2: Treatment EFG|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fasted conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 4\] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 5\] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
62285958|NCT00603135|EXPERIMENTAL|A|
62460811|NCT05083598||Adult patients undergoing major surgery|Patients aged 70 or older undergoing major non cardiac surgery, with expected surgical duration \> 2 hours.
62652083|NCT02659735|EXPERIMENTAL|Panel 2: Treatment FGE|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 4\] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 5\] under fed conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
62652084|NCT02659735|EXPERIMENTAL|Panel 2: Treatment GEF|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 5\] under fed conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fasted conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 4\] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
62652085|NCT02659735|EXPERIMENTAL|Panel 2: Treatment GFE|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 5\] under fed conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 4\] under fasted conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
62652086|NCT02659735|EXPERIMENTAL|Panel 2: Treatment FEG|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 4\] under fasted conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 5\] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
62087064|NCT01889160|EXPERIMENTAL|Part B solution|AZD4721 Solution
62087065|NCT01889160|ACTIVE_COMPARATOR|Part B Suspension|AZD4721 Suspension
62087066|NCT00816140|ACTIVE_COMPARATOR|Klaricid, triple therapy|Klaricid based triple therapy
62087067|NCT00816140|EXPERIMENTAL|Cravit, triple therapy|Cravit based triple therapy
62087068|NCT01269398|NO_INTERVENTION|GO-LIF procedure, posetrior facets fusion|
62087069|NCT01269398|OTHER|solid fusion, GO-LIF procedure|ability to achieve solid fusion, comibing the GO-LIF procedure for spinal fixation and stabilization with percutaneous posetrior facets fusion
62087070|NCT04466332|EXPERIMENTAL|Saline ECG with Pilot Tip Location System|PICC insertion using electrocardiographic guidance Pilot Tip Location System (TLS), ECG signal transmission is with saline water
62087071|NCT04466332|EXPERIMENTAL|Guidewire ECG with Sherlock Tip Confirmation System|PICC insertion using electrocardiographic guidance Sherlock 3CG Tip Confirmation System (TCS), ECG signal transmission is with guidewire
62285959|NCT00605267|ACTIVE_COMPARATOR|1|Tamoxifen
62285960|NCT00605267|EXPERIMENTAL|2|Anastrazole (Arimidex)
62285961|NCT04447885|EXPERIMENTAL|Experimental blanket|This blanket is the weight being tested which cannot be disclosed without unblinding participants.
62285962|NCT04447885|ACTIVE_COMPARATOR|Control blanket|This blanket is the control weight which cannot be disclosed without unblinding participants.
62087072|NCT06229470|EXPERIMENTAL|ECAP-Controlled, Closed-Loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude.
62087073|NCT06492941|EXPERIMENTAL|Docetaxel for Injection (Albumin Bound) in combination with best supportive care|Docetaxel for Injection (Albumin Bound) ：i.v., q3w,100mg/m\^2； Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care
62285963|NCT01262625|EXPERIMENTAL|Group A: CCTA Diagnostic|Participants randomized to diagnostic evaluation using coronary computed tomographic angiography (CCTA) to determine therapeutic course of action.
62285964|NCT01262625|ACTIVE_COMPARATOR|Group B: SPECT MPI/ICA Diagnostic|Standard-of-care diagnostic assessment using single photon emission computed tomography myocardial perfusion imaging (SPECT MPI), possibly followed by diagnostic invasive coronary angiography (ICA) dependent on SPECT MPI results.
62285965|NCT03711903|EXPERIMENTAL|Treatment arm|The study drug, CN-105, will be administered at 1.0 mg/kg every 6 +/- 1 hour. The calculated volumes of study agent will be removed from the vials and transferred to 250 mL of normal saline (0.9% sodium chloride injection, USP). The recorded weight at baseline will be used to determine the appropriate amount of CN-105 drug product to administer. Estimated weight may be used if recorded weight is not available. Each dose of CN-105 or placebo will be administered as a slow IV bolus over 30 minutes.
62285966|NCT03711903|PLACEBO_COMPARATOR|Placebo arm|The Placebo arm will be given 0.9% NaCL
62460812|NCT02366949|EXPERIMENTAL|Arm 1|Experimental Treatment (combination of BAY1217389 with paclitaxel in an intermittent dosing schedule) Expansion Cohort - Maximum tolerated dose of BAY1217389 and Paclitaxel
62460813|NCT02366949|PLACEBO_COMPARATOR|Arm 2|Standard Treatment (Single-agent Paclitaxel )
62087074|NCT06492941|PLACEBO_COMPARATOR|Placebo in combination with best supportive care|Placebo ：i.v., q3w； Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care
62087075|NCT04123873|EXPERIMENTAL|Group A|"Paracetamol 1000 mg + Ibuprofen 400 mg administered orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus placebo (matching DXM) IV administered after induction of anaesthesia"
62652087|NCT02659735|EXPERIMENTAL|Panel 2: Treatment EGF|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet \[reference\] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 5\] under fed conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 \[test 4\] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
62652088|NCT01075776|EXPERIMENTAL|CNP|Infusion of CNP prior to IR injury
62087076|NCT04123873|EXPERIMENTAL|Group B|"Paracetamol 1000 mg and placebo (matching ibuprofen) orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
62087077|NCT04123873|EXPERIMENTAL|Group C|"Placebo (matching paracetamol) + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
62652089|NCT01075776|PLACEBO_COMPARATOR|Saline|Effect of saline infusion prior to IR injury
62087078|NCT04123873|EXPERIMENTAL|Group D|"Paracetamol 1000 mg + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
62285967|NCT04569838|EXPERIMENTAL|Bendamustine hydrochloride injection|Bendamustine hydrochloride injection 120 mg/m² or 100 mg/m² intravenously (IV) on Day 1 and Day 2 of 21-day cycle (6-8 cycles maximum) for non-hodgkin's lymphomas or chronic lymphocytic leukemia. After 6-8 cycles, the course of treatment could be added based on patient's benefit and investigator's determination.
62285968|NCT05944536|ACTIVE_COMPARATOR|Balance Exercise (BE)|Balance exercises; static standing on flat ground for 30 seconds, standing in tandem position for 30 seconds, standing on one foot for 30 seconds, standing on tiptoe for 30 seconds, looking left and right with one foot in the air, backward rotation with one foot in the air, rotation, squatting slightly in knee flexion with one foot in the air, squatting slightly in knee extension with one foot in the air, going on tiptoe and turning with the heel, multi-directional stretches on the balance board Each exercise will be performed with 10 repetitions for both lower extremities.
62285969|NCT05944536|EXPERIMENTAL|BE+Dual Task|"Cognitive and motor secondary tasks were given along with balance exercises. Cognitive tasks: color discrimination, counting city names, counting fruit and vegetable names, saying 3 numbers between 50-100, talking on a mobile phone, subtracting 3 and 7 in series, saying male names, counting backwards out loud, asking for a series of addition and subtraction operations.~Motor tasks: carrying a glass of water, carrying a glass on a tray, carrying an object, pressing a button, transferring money from hand to hand, rhythmic clapping"
62285970|NCT04120155|OTHER|Dissecting the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary dessection during the upper lobe thoractomy.
62285971|NCT04120155|OTHER|Preserving the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary preservation during the upper lobe thoractomy.
62285972|NCT00804687|EXPERIMENTAL|JNJ-39220675 then Pseudoephedrine then Placebo|Single-dose of JNJ-39220675 will be administered as 1 milliliter (ml) of 10 milligram/milliliter (mg/ml) solution orally along with placebo tablet in first treatment period; after that in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 milligram (mg) pseudoephedrine tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
62652090|NCT01327768|EXPERIMENTAL|OECs, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.
62652091|NCT00908934|EXPERIMENTAL|1|50 or 400 mg AZD9056, Test formulation
62652092|NCT00908934|EXPERIMENTAL|2|50 or 400 mg AZD9056, Reference formulation
62652093|NCT02786303|OTHER|arm whole-body MRI|
62652094|NCT06477978|OTHER|End stage kidney disease patient on maintenance hemodialysis|All patient that have been recruited with have the lean body mass index measured sing the Bio-impedance analysis ( BIA )
62087079|NCT02156882||TB patients and Tb suspects|Patients with confirmed tuberculosis who are treated by the National TB Programme
62087080|NCT02880449|EXPERIMENTAL|Intervention|The intervention will be conducted in pre-existing older women's groups based in community centres. The intervention will consist of three educational sessions, encouragement to enlist the support of a partner or 'buddy' (e.g. a spouse, partner or friend), an information pack (containing information on the local area, walking routes, points of interest) and the option of weekly telephone contact. Participants will be given the opportunity to discuss their progress and share feedback with the rest of the group at weekly meetings.
62087081|NCT02880449|NO_INTERVENTION|Control|Due to the stepped wedge design of the study, one group in each centre will not receive the intervention procedure detailed above until week seven. The control groups shall be given information about the study at baseline and informed that they will receive the intervention 6 weeks later.
62652095|NCT06034496|ACTIVE_COMPARATOR|Active CES|Active Cranial Electrotherapy Stimulation (CES)
62652096|NCT06034496|SHAM_COMPARATOR|Sham CES|Sham Cranial Electrotherapy Stimulation (CES)
62652097|NCT00902863|EXPERIMENTAL|YOGA patients|Patients assessed for chronic pain at our Pain Management Centre
62652098|NCT05066477|ACTIVE_COMPARATOR|CalGo (Salmon bone meal)|4 capsules daily of CalGo (salmon bone meal enriched with Vitamin D3) is taken per orally. Each capsule contains \~500 mg of salmon bone meal (380 mg calcium, 200 mg phosphorus, 500 mg native collagen type 2), and 10 micrograms of vitamin D3 (400 IU). Once daily dosing. Duration: 2 years.
62652099|NCT05066477|PLACEBO_COMPARATOR|Maltodextrin|4 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once daily dosing. Duration: 2 years.
62652100|NCT03340883|EXPERIMENTAL|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
62652101|NCT03143023|EXPERIMENTAL|arginine toothpaste|
62285973|NCT00804687|EXPERIMENTAL|JNJ-39220675 then Placebo then Pseudoephedrine|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
62087082|NCT02800811|EXPERIMENTAL|Part 1: Cohort A, Group 1, FR104|Dose: single 0.005 mg/kg.
62285974|NCT00804687|EXPERIMENTAL|Placebo then JNJ-39220675 then Pseudoephedrine|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
62285975|NCT00804687|EXPERIMENTAL|Placebo then Pseudoephedrine then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
62460814|NCT00167505|EXPERIMENTAL|Risk Avoidance|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
62460815|NCT00167505|EXPERIMENTAL|Risk Reduction|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
62460816|NCT01412580||observational followup|This was an observational follow-up to a larger study in which treatment group was given 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid
62460817|NCT04625114|EXPERIMENTAL|Camostat|camostat 100mg 3 tablets 3x/day D1-\>D5 (+ possible extension D6-\>D10)
62652102|NCT03143023|ACTIVE_COMPARATOR|fluoride toothpaste|
62087083|NCT02800811|EXPERIMENTAL|Part 1: Cohort A, Group 2, FR104|Dose: single 0.05 mg/kg.
62087084|NCT02800811|EXPERIMENTAL|Part 1: Cohort A, Group 3, FR104|Dose: single 0.2 mg/kg.
62087085|NCT02800811|EXPERIMENTAL|Part 1: Cohort A, Group 4, FR104|Dose: single 0.5 mg/kg.
62087086|NCT02800811|PLACEBO_COMPARATOR|Part 1: Cohort A, placebo|Placebo, single administration, double blind (1/4 healthy subject in group 1, 1/4 in group 2, 2/5 in group 3 and 2/5 in group 4).
62087087|NCT02800811|EXPERIMENTAL|Part 1: Cohort B, Group 7, FR104|Dose: single 0.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
62087088|NCT02800811|EXPERIMENTAL|Part 1: Cohort B, Group 8, FR104|Dose: single 0.2 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
62087089|NCT02800811|EXPERIMENTAL|Part 1: Cohort B, Group 9, FR104|Dose: single 1.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
62652103|NCT03966989|EXPERIMENTAL|Performance Feedback|Feedback offline either via email or text
62652104|NCT03966989|NO_INTERVENTION|Control|Standard practice control
62087090|NCT02800811|EXPERIMENTAL|Part 1: Cohort B, Group 9 bis, FR104|Dose: single 0.02 mg/kg group. Healthy subject naïve to KLH and that will receive a KLH challenge.
62087091|NCT02800811|PLACEBO_COMPARATOR|Part 1: Cohort B, placebo|placebo, single administration, double-blind: healthy subjects naïve to KLH and that will receive a KLH challenge (2/5 in each group of cohort B)
62087092|NCT02800811|EXPERIMENTAL|Part 2: Group 10, FR104|Dose: repeat, 0.2 mg/kg. Two administrations separated by an interval of 28 days.
62087093|NCT02800811|EXPERIMENTAL|Part 2: Group 11, FR104|Dose: repeat, 0.5 mg/kg. Two administrations separated by an interval of 28 days.
62087094|NCT02800811|PLACEBO_COMPARATOR|Part 2: placebo|placebo, repeat, double-blind: 2/5 subjects in each group of Part 2. Two administrations separated by an interval of 28 days.
62087095|NCT01575782|EXPERIMENTAL|Chloroquine|
62087096|NCT03195582|EXPERIMENTAL|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
62285976|NCT00804687|EXPERIMENTAL|Pseudoephedrine then JNJ-39220675 then Placebo|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
62285977|NCT00804687|EXPERIMENTAL|Pseudoephedrine then Placebo then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
62285978|NCT05034900|ACTIVE_COMPARATOR|Chest Physiotherapy Group|Patients in this group will perform comprehensive chest physiotherapy program two times a day, 7 days a week for 8 weeks at their homes.
62285979|NCT05034900|EXPERIMENTAL|OPEP device + Chest Physiotherapy Group|In addition to the same physiotherapy program applied to the controls, patients in this group will also use OPEP device two times a day, 7 days a week for 8 weeks at their homes.
62285980|NCT04664348|EXPERIMENTAL|Experimental: Posteroanterior lumbar mobilization (extension of the lumbar spine)|
62285981|NCT04664348|EXPERIMENTAL|Experimental: Posteroanterior lumbar mobilization (lumbar spine in neutral positioning)|
62285982|NCT02804763|PLACEBO_COMPARATOR|Placebo|Placebo in a specified sequence for a total of 24 weeks
62285983|NCT02804763|EXPERIMENTAL|DZP dose 1|Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
62652105|NCT00383526|EXPERIMENTAL|Study Group 1|
62652106|NCT00383526|ACTIVE_COMPARATOR|Study Group 2|
62087097|NCT03195582|NO_INTERVENTION|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
62087098|NCT03082209|EXPERIMENTAL|Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab|Participants with KRAS-mutant CRC are administered with ABBV-621 in combination with bevacizumab plus FOLFIRI
62087099|NCT03082209|EXPERIMENTAL|Chemotherapy combination: ABBV-621+FOLFIRI|Participants with RAS-mutant CRC who have received one prior line of therapy will be administered ABBV-621 in combination FOLFIRI.
62087100|NCT03082209|EXPERIMENTAL|Dose Optimization: ABBV-621 + Venetoclax for AML|Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.
62087101|NCT03082209|EXPERIMENTAL|Dose Optimization: ABBV-621 Monotherapy for AML|Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.
62285984|NCT02804763|EXPERIMENTAL|DZP dose 2|Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
62285985|NCT02804763|EXPERIMENTAL|DZP dose 3|Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
62652107|NCT01277861|ACTIVE_COMPARATOR|FENTANYL|FENTANYL
62087102|NCT03082209|EXPERIMENTAL|Dose Optimization: ABBV-621 + Venetoclax for DLBCL|Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.
62087103|NCT03082209|EXPERIMENTAL|Dose Optimization for Pancreatic Cancer|Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).
62652108|NCT01277861|PLACEBO_COMPARATOR|SALINE|SALINE
62652109|NCT03537833||"PPI-positive or test group"|Patients treated with PPI
62652110|NCT03537833||"PPI-negative or control group"|Patients not treated with PPI
62652111|NCT05662813|EXPERIMENTAL|Almonertinib|Almonertinib 110 mg，orally once a day. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
62652112|NCT04980729|EXPERIMENTAL|the template-guided group|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction using a modular hemipelvic prosthesis.
62652113|NCT04980729|ACTIVE_COMPARATOR|the traditional operation group|In the traditional operation group (n = 14), acetabulum was manually reconstructed using a modular hemipelvic prosthesis by the surgeon's experience.
62652114|NCT04980729|SHAM_COMPARATOR|the validation group|In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without acetabulum reconstruction.
61904119|NCT01980589|EXPERIMENTAL|Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)|Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
61904120|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
62087104|NCT03082209|EXPERIMENTAL|Dose Optimization for KRAS-mutant CRC|Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.
62285986|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (\< 50% by NASCET criteria for men, \<70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
62285987|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
62652115|NCT01125930|PLACEBO_COMPARATOR|Vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
62652116|NCT01125930|ACTIVE_COMPARATOR|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
61904121|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
62087105|NCT03082209|EXPERIMENTAL|Dose Escalation|ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).
62285988|NCT05408260|EXPERIMENTAL|Screening (automated breast ultrasound, handheld ultrasound)|Participants undergo HHUS and ABUS in no required order over 1 hour.
62285989|NCT05073055|ACTIVE_COMPARATOR|Group SA|Group 1 (SE) (n = 35): patients undergoing spinal anesthesia of patients in our hospital to do unilateral inguinal hernia operation. Block application and the times when the sensory block reaches the T10 level are recorded. Surgery is allowed in patients who develop sensory block at the T10 level. During our study, no changes will be made to the procedure described above, which is standardized during our study, only patient data will be recorded observationally. Patients who do not have sufficient sensory block to start the procedure despite waiting 10 minutes will be registered and excluded from the study and additional anesthesia will be applied.
62285990|NCT05073055|ACTIVE_COMPARATOR|Group ESP+TA|Group 2 (Errector spina block + TA) (n = 35): 2% lidocaine hydrochloride (10 mg / ml) 15 ml, 0.5% bupivacaine hydrochloride (20 mg / ml) 15 ml, serum 8.4% Sodium Bicarbonate 5 ml to be used for each patient before the operation in order to apply the erectile spina block block with tumescent anesthesia. Adding adrenaline tartrate (5 μg / mL) to 5 ml with saline, a total of 40 ml of mixture was prepared. Hydrodissection was achieved using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle on the Transverse Process of L1. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
62460818|NCT04625114|PLACEBO_COMPARATOR|Placebo|Placebo 3 tablets 3x/day D1-\>D5 (+ possible extension D6-\>D10)
62652117|NCT02532400|EXPERIMENTAL|Neoadjuvant endocrine therapy|Six months of exemestane or anastrozole plus goserelin.
62652118|NCT02532400|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).
62652119|NCT05237141|EXPERIMENTAL|Main cohort|Insertion of etonogestrel contraceptive implant prior to LH surge
62652120|NCT01070680|ACTIVE_COMPARATOR|dexmedetomidine|sedative medicine
61904122|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
62087106|NCT05854940||Eligible participants for early diagnosis of prostate cancer|According to the 2014 edition of China Prostate Cancer Diagnosis and Treatment Guidelines, patients need to undergo prostate biopsy
62087107|NCT04716595|EXPERIMENTAL|morning administration|K-877 ER 0.2 mg/day morning administration (once daily)
62087108|NCT04716595|EXPERIMENTAL|evening administration|K-877 ER 0.2 mg/day evening administration (once daily)
62285991|NCT01357811|ACTIVE_COMPARATOR|digoxin|
62460819|NCT05452226|EXPERIMENTAL|Pilot Study Cohort|Every participant in this small prospective cohort study will receive the study intervention.
62460820|NCT03246100|NO_INTERVENTION|Control|These patients will receive no reminders from the health department and will receive usual care.
62460821|NCT03246100|EXPERIMENTAL|Autodialer R/R|Autodialer calls (up to 3 reminders)- with brief education message + practice name + practice phone #
62460822|NCT03246100|EXPERIMENTAL|Mail R/R|Mailed reminder (up to 3 reminders)-- with brief education message + practice name + practice phone #
62652121|NCT01070680|PLACEBO_COMPARATOR|sodium chloride 0,9%|
62460823|NCT04064632|EXPERIMENTAL|RPV +DRV/cobi|The experimental receives rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day) since randomization.
61904123|NCT01736761|EXPERIMENTAL|Darunavir, Ritonavir, Rilpivirine|Darunavir 800 mg once daily, Ritonavir 100 mg once daily and Rilpivirine 25 mg once daily
61904124|NCT04554836|EXPERIMENTAL|FOLFIRI + cetuximab|"Patients in Arm A will receive FOLFIRI + cetuximab until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first. The recurrence of RAS-mutation without PD to switch back to FOLFIRI. In case of repeated conversion to RAS wild-type without PD, treatment will shift to FOLFIRI + cetuximab again, and so on. Switches of treatment will proceed until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.~\[FOLFIRI = Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)\]"
62460824|NCT04064632|ACTIVE_COMPARATOR|baseline therapy (CAR)|The control arm continues the baseline therapy (CAR) based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day).
62087109|NCT04974320||MINOCA|All patients diagnosed with MINOCA in precision cohort (NCT04044066) will be included.
62087110|NCT04974320||acute myocardial infarction (AMI）|All patients diagnosed with acute myocardial infarction（AMI）in precision cohort (NCT04044066) will be included.
62087111|NCT04974320||unstable angina (UA)|The patients diagnosed with unstable angina（UA) in precision cohort (NCT04044066) will be selected according to the matching method.
62087112|NCT04974320||MINOCA （multi-center）|The patients diagnosed with MINOCA in multi-center cohort will be included.
62087113|NCT01233102|ACTIVE_COMPARATOR|Conserved Therapy|Conserved Therapy
62087114|NCT01233102|EXPERIMENTAL|Interventional Therapy|"Patients with liver cirrhosis will be randomly divided into three groups.~1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
62087115|NCT00008502||18 years of age or older|without keloids
62285992|NCT01357811|EXPERIMENTAL|eliglustat with digoxin|
62285993|NCT00862095|PLACEBO_COMPARATOR|Placebo|Placebo group
62285994|NCT00862095|EXPERIMENTAL|Propranolol|Propranolol (target dose 80 mg a day)
62285995|NCT00862095|EXPERIMENTAL|Topiramate|Topiramate (target dose 100 mg a day)
62285996|NCT00862095|EXPERIMENTAL|Amitriptyline|Amitriptyline (target dose 50 mg a day)
62285997|NCT01384682|NO_INTERVENTION|No change|continue their current cART regimen
62285998|NCT01384682|ACTIVE_COMPARATOR|Replace N(t)RTI drugs with Maraviroc|Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
62652122|NCT03711721|EXPERIMENTAL|Food basket|
62652123|NCT03711721|EXPERIMENTAL|Ready-to-Use Therapeutic Food|
62652124|NCT06180057|EXPERIMENTAL|Chenodeoxycholic acid capsules|Chenodeoxycholic acid capsules (250mg chenodeoxycholic acid)
62652125|NCT06180057|ACTIVE_COMPARATOR|Chenodeoxycholic acid leadiant hard capsules|Chenodeoxycholic acid leadiant hard capsules (250mg chenodeoxycholic acid)
62652126|NCT01089712||Patients undergoing cardiac surgery|The patient population for this study consists of all patients undergoing cardiac surgical interventions. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.
62652127|NCT05019677|EXPERIMENTAL|GP+PD-1+Tight|"Experimental: Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
62087116|NCT00008502||family members over 12 years of age|who have either classic or non-classic keloids
62087117|NCT00008502||Probands|original participants who have had a classic (butterfly-shaped or wound-overflowing) keloidfor at least one year
62087118|NCT01004419|EXPERIMENTAL|Vandetanib plus fulvestrant|vandetanib by mouth once daily for 28 days plus fulvestrant intra-muscular injection each cycle
62087119|NCT02830789|EXPERIMENTAL|Calcium Carbonate|1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3
62087120|NCT02830789|EXPERIMENTAL|Calcium Citrate|2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3
62087121|NCT03391167|SHAM_COMPARATOR|Control|Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
62087122|NCT03391167|EXPERIMENTAL|ESP Block|In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
62087123|NCT01154803|EXPERIMENTAL|Ready to Use Therapeutic Food (RUTF)|500 kcal /day for 2 weeks
62285999|NCT01384682|ACTIVE_COMPARATOR|Replace PI/r drugs with Maraviroc|Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.
62286000|NCT02002702|EXPERIMENTAL|Serelaxin 10 mcg/kg/Day|Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
62286001|NCT02002702|EXPERIMENTAL|Serelaxin 30 mcg/kg/Day|Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
62286002|NCT02002702|PLACEBO_COMPARATOR|Placebo|Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.
62286003|NCT04678648|EXPERIMENTAL|RSC-1255 Treatment|Single Arm Study. All study participants receive RSC-1255.
62652128|NCT04705090|EXPERIMENTAL|YY-20394 treatment|YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.
62652129|NCT02914327|EXPERIMENTAL|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
62652130|NCT06002204||Diagnosed with Mood Disorder|Individuals with a lifetime or a current diagnosis of a mood disorder (based upon a semi-structured diagnostic interview)
62652131|NCT06002204||At-risk for Developing Mood Disorder|Individuals at risk for developing mood disorders (has history of anxiety disorder, substance use disorder, trauma, or mood disorder that does not meet criteria for MDD or Bipolar Disorder or a first-degree relative with a history of mood disorders)
62460825|NCT03422211||Sports orthopaedic surgery|Patients that recently underwent orthopaedic sports surgery performed by two separate surgeons
62460826|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
62460827|NCT05094713|OTHER|Flossing - control|Control group where flossing wrapping pressure is between 20 and 30 mmHg
61904125|NCT04554836|OTHER|FOLFIRI|Patients in Arm B will continue therapy with FOLFIRI until PD, unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.
61904126|NCT02489422|EXPERIMENTAL|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
61904127|NCT02489422|ACTIVE_COMPARATOR|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
61904128|NCT02558647|EXPERIMENTAL|CBT for insomnia (CBT-I)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) comprises a fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention
61904129|NCT02558647|ACTIVE_COMPARATOR|Psychoeducation about Sleep (PE)|The PE intervention gives participants access to a website with information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
61904130|NCT03531632|EXPERIMENTAL|MGD007 + MGA012|MGD007 is a gpA33 x CD3 bi-specific DART antibody; MGA012 is an anti-PD-1 monoclonal antibody.
62460828|NCT05094713|EXPERIMENTAL|Flossing with medium wrapping pressure|A flossing band will be applied over tight musculature with medium wrapping pressure
62460829|NCT03423225|EXPERIMENTAL|ADVAGRAF®|One arm: Treatment conversion will take placefrom twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
62460830|NCT05526118||AHORA group|All 50 prospective subjects are enrolled into a single cohort, all subjects must meet inclusion/exclusion criteria
62460831|NCT00921648||Mr Q, 40 years old|Dementia, sensory aphasia, irritability, hallucination MRI showed cortical lesion, mesial temporal lobe atrophy.
62460832|NCT00921648||Mr Guo,35 years old|Dementia, sensory aphasia, tremor, gait disturbance MRI showed cortical lesion, enlarged ventricle, white matter lesion, cerebral atrophy
62460833|NCT00921648||Mr Zhang,40 years old|Dementia, apraxia of speech, gatism , irritability, insomnia, gait disturbance MRI showed white matter lesion, cerebral atrophy.
62087124|NCT01154803|EXPERIMENTAL|Micronutrient Powder (MNP)|2 x 1 g sachets micronutrients /day for 2 weeks
62087125|NCT01154803|NO_INTERVENTION|no supplement|no supplementation
62087126|NCT01020565|EXPERIMENTAL|Entecavir (0.1 mg)|
62087127|NCT01020565|EXPERIMENTAL|Entecavir (0.5 mg)|
61904131|NCT02463890|EXPERIMENTAL|Training|"In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
62087128|NCT00235495|ACTIVE_COMPARATOR|Albumin (ALB)|Albumin (human albumin, 25% solution, 2.0 g/kg), infused intravenously over a period of 2 hours
62087129|NCT00235495|PLACEBO_COMPARATOR|Saline|Saline (isotonic solution), 8 ml/kg, infused intravenously over a 2-hour period
62087130|NCT02264392|ACTIVE_COMPARATOR|Ultrasound Guided|Ultrasound Guided Incision and Drainage- Patients will undergo ultrasound guided drainage of the abscess using bedside ultrasound
62087131|NCT02264392|ACTIVE_COMPARATOR|Blind I&D|Blind Incision and Drainage- Patients will undergo drainage of the abscess using physical exam.
62087132|NCT03492996|EXPERIMENTAL|LCB01-0371 dose with a [14C]-LCB01-0371-tracer|A mass balance study to investigate the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose in healthy male subjects
62087133|NCT02556723|EXPERIMENTAL|Ziv-aflibercept IV|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks.
62087134|NCT00980707|EXPERIMENTAL|inhaled corticosteroid|All asthmatics will start inhaled corticosteroids.
62087135|NCT06696794|EXPERIMENTAL|Neoadjuvant intravesical instillation mitomycin C combined with en-bloc surgery|
62087136|NCT06696794|PLACEBO_COMPARATOR|Neoadjuvant intravesical instillation normal saline combined with en-bloc surgery|
62087137|NCT05987150||Type A|Type A was defined as a round/oval spinal cord shape with visible cerebrospinal fluid (CSF) between the cord and the apical vertebrae.
62087138|NCT05987150||Type B|Type B was defined as a round/oval spinal cord shape with no CSF between the apical vertebrae and spinal cord.
62087139|NCT05987150||Type C|Type C cord was defined as a spinal cord that is fattened/deformed by the vertebral body, with no visible CSF between the apex and the cord.
62087140|NCT03302533||Primary arthroplasty|All patients who received TEA for an acute trauma with fracture of the distal humerus.
62087141|NCT03302533||Secondary arthroplasty|All patients who received TEA due to a failed reconstruction or non-operative treatment after a distal humerus fracture.
62460834|NCT00921648||Mr Liu,40 years old|Dementia, apraxia of speech, irritability, insomnia MRI showed normal.
61904132|NCT02463890|OTHER|Control|In this group, patients will receive only diets and physical activity counselling
61904133|NCT03881761|EXPERIMENTAL|experimental arm|CAR-T cell group
62087142|NCT05299489|EXPERIMENTAL|Direct composite in hypomineraliztion molars.|
62087143|NCT05299489|OTHER|Indirect composite in hypomineraliztion molars.|
62460835|NCT00921648||Mr Zhang,54 years old|Dementia, apraxia of speech MRI showed white matter lesion, cerebral atrophy.
61904134|NCT04608903|EXPERIMENTAL|Sulforaphane Group|Administration of 4g L-sulforaphane per day, for 2 months and after the washout period (2 months) the groups will be crossed and will receive the same amount of placebo as the other group for 2 months.
61904135|NCT04608903|PLACEBO_COMPARATOR|Placebo Group|Administration of 4g of corn starch colored with chlorophyll, per day, for 2 months and then after the washout period (2 months) the groups will be crossed and will receive the same amount of sulfarophane as the treatment group.
62087144|NCT00182663|EXPERIMENTAL|Treatment (immunomodulator, antiangiogenesis, steroid therapy)|Patients receive thalidomide PO QD dexamethasone PO once weekly, and clarithromycin PO BID. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity.
62087145|NCT02182882|EXPERIMENTAL|GINSANA|
62087146|NCT02182882|PLACEBO_COMPARATOR|Placebo|
62087147|NCT00904241||Ancillary-Correlative (cytology specimen collection)|Patients undergo collection of blood, tissue, and bone marrow samples for analysis via RT-PCR, quantitative PCR, flow cytometry, and FISH.
62087148|NCT00701311|EXPERIMENTAL|Study Drug CC-10004|Study drug CC-10004 20mg taken orally twice a day.
62087149|NCT05164536|EXPERIMENTAL|[18F]Florbetapir|Participants will undergo amyloid PET imaging with an approved amyloid radiotracer (ie, \[18F\]Florbetapir (Amyvid™)) to assess β-amyloid neuritic plaque density.
62087150|NCT05963425|EXPERIMENTAL|Physical activity: basic physical training (BPT)|"Exercises will target the large muscle groups, with a component/emphasis on the eccentric phase of concentration. The kBox4 Platform (Exxentric AB), a device designed to maximize performance and training outcomes, will be used to enhance the eccentric phase of the exercises.~kBox4 is controlled by a specific program, Kmeter, which records and stores all the information (duration, intensity, repetitions, etc.) of each movement. Exxentric kBox4 will be adapted with special harnesses, insurances on the wall and in front of support bars, according to the needs of the patients. In addition to the major muscle groups, specific attention will be given to the key muscles involved in the gait cycle, such as the tibialis anterior, medial gastrocnemius, rectus femoris, and hamstrings, from a biomechanical perspective."
62460836|NCT03733509|EXPERIMENTAL|Intraoperative Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of Bupivacaine 0.25%.~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml of saline solution (NaCl 0.9%)."
62087151|NCT05963425|EXPERIMENTAL|Physical activity: BPT combined with functional exercises|In addition to the BPT program (which includes the transverse focus on strength and resistance exercises), this intervention group will incorporate functional exercises that involve dual task training. The dual task training can encompass both motor-motor and motor-cognitive activities. This means that coordinated exercises will be performed, with cognitive activities introduced at the extremes of the movement. This approach ensures engagement of both physical and cognitive abilities during the PA sessions.
62087152|NCT05963425|ACTIVE_COMPARATOR|Control|Participants in the control group will maintain their regular daily routines throughout the study period.
62087153|NCT00996086||CRT device-recipients|
62087154|NCT01871285|EXPERIMENTAL|MSE Dose Group 1|Morning and evening dose of buprenorphine HCl buccal film (300 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
62087155|NCT01871285|EXPERIMENTAL|MSE Dose Group 2|Morning and evening dose of buprenorphine HCl buccal film (450 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
62087156|NCT04012320||Pamidronate therapy|
62087157|NCT04012320||Zoledronate therapy|
62652132|NCT06002204||Healthy Control|Healthy individuals who do not have a psychiatric diagnosis (including no history of mood disorders and no first-degree relative with a history of mood disorders)
62652133|NCT04468711|ACTIVE_COMPARATOR|treatment group|vitamin D plus topical 1% hydrocortisone cream twice daily
62652134|NCT04468711|PLACEBO_COMPARATOR|placebo group|placebo plus plus topical 1% hydrocortisone cream twice daily
62652135|NCT02679976|EXPERIMENTAL|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
61904136|NCT01242813|EXPERIMENTAL|Canakinumab|This was an open-label, single treatment arm, multicenter study of monthly canakinumab 150 mg (2 mg/kg for patient ≤ 40 kg) subcutaneous injections in patients with active recurrent or chronic TRAPS.
62652136|NCT04663516|EXPERIMENTAL|experimental|exercise through video game (Wii)
62652137|NCT04663516|NO_INTERVENTION|control|children in this group will be given advice about the importance of exercising
62652138|NCT05919134|EXPERIMENTAL|Group 1 - probiotic|"The use of Streptococcus salivarius M18 containing tablets (Dentoblis, registration number: AM.01.06.01.003.R.000061.07.20; 15.07.2020, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: basic active ingredients - Streptococcus salivarius M18 (≥5×108 CFU in 1 tablet), Vitamin D (320 IU (8 mcg) in 1 tablet); excipients - isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
61904137|NCT03457064|NO_INTERVENTION|Physical Activity (PA)|Physical activity (PA) involved a program of physical exercise alone.
61904138|NCT03457064|ACTIVE_COMPARATOR|PA+Social Adherence Intervention(PASAI)|PA+Social Adherence Intervention(PASAI) involved a program of physical exercise combined with a social adherence intervention.
61904139|NCT03246997|OTHER|Autumn Group|Intervention Group
61904140|NCT03246997|OTHER|Spring Group|Delayed Intervention
61904141|NCT04620213|EXPERIMENTAL|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
61904142|NCT04620213|PLACEBO_COMPARATOR|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
61904143|NCT02711241|ACTIVE_COMPARATOR|Dipyrone|
61904144|NCT02711241|ACTIVE_COMPARATOR|Papaverine|
62087158|NCT05847790|EXPERIMENTAL|Remote NST|
62087159|NCT05847790|ACTIVE_COMPARATOR|In-clinic NST - Standard of Care|
62087160|NCT02490384|ACTIVE_COMPARATOR|Physical exam indicated cerclage|Cerclage
62087161|NCT02490384|NO_INTERVENTION|Expectant management|No cerclage
62087162|NCT05525208|EXPERIMENTAL|Primary dose of inactivated (Sinovac®) vaccine (1)|Subject who had received a complete primary dose of inactivated (Sinovac®) vaccine
62087163|NCT05525208|EXPERIMENTAL|Primary dose of mRNA (Pfizer®) vaccine (1)|Subject who had received a complete primary dose of mRNA (Pfizer®) vaccine
62087164|NCT05525208|EXPERIMENTAL|Primary dose of Viral Vector (AstraZeneca®) vaccine (1)|Subject who had received a complete primary dose of viral vector (AstraZeneca®) vaccine
62087165|NCT05525208|EXPERIMENTAL|Primary dose of inactivated (Sinovac®) vaccine (2)|Subject who had received a complete primary dose of inactivated (Sinovac®) vaccine
62087166|NCT05525208|EXPERIMENTAL|Primary dose of mRNA (Pfizer®) vaccine (2)|Subject who had received a complete primary dose of mRNA (Pfizer®) vaccine
62087167|NCT05525208|EXPERIMENTAL|Primary dose of Viral Vector (AstraZeneca®) vaccine (2)|Subject who had received a complete primary dose of viral vector (AstraZeneca®) vaccine
62087168|NCT04349761|EXPERIMENTAL|Cohort 1 - 5mg MyMD1|8 subjects randomized to receive either 5mg MyMD1 (6 subjects) or Placebo (2 subjects)
62087169|NCT04349761|EXPERIMENTAL|Cohort 2 - 10mg MyMD1|8 subjects randomized to receive either 10mg MyMD1 (6 subjects) or Placebo (2 subjects)
62087170|NCT04349761|EXPERIMENTAL|Cohort 3 - 15mg MyMD1|8 subjects randomized to receive either 15mg MyMD1 (6 subjects) or Placebo (2 subjects)
62652139|NCT05919134|PLACEBO_COMPARATOR|Group 2 - placebo|"The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
62652140|NCT03087240|EXPERIMENTAL|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
62652141|NCT03087240|OTHER|Control|Wait \& Control Study Design: Dental Prophylaxis after 3 months (T2) only
61904145|NCT03060122|NO_INTERVENTION|Standard Care|Patient's randomized to this arm will receive standard post operative/post immobilization physical therapy or occupational therapy rehabilitation care without the use of NIN or CES.
62087171|NCT04349761|EXPERIMENTAL|Cohort 4 - 20mg MyMD1|8 subjects randomized to receive either 20mg MyMD1 (6 subjects) or Placebo (2 subjects)
62087172|NCT04349761|EXPERIMENTAL|Cohort 5 - 25mg MyMD1 or Placebo|8 subjects randomized to receive either 25mg MyMD1 (6 subjects) or Placebo (2 subjects)
62087173|NCT00647348|ACTIVE_COMPARATOR|1|Simvastatin 80mg OD
62087174|NCT00647348|PLACEBO_COMPARATOR|2|Placebo
62087175|NCT06120062||1st experimental group|swaddled
62087176|NCT06120062||2nd experimental group|inhale the mother's breast milk odour
62087177|NCT06120062||3rd experimental group|both swaddled and made to inhale the mother's breast milk odour
62087178|NCT06120062||the control group|no procedure
62652142|NCT03475238||Cohort for nursing care|Patients in ICU under oxygen and/or mechanical ventilation and/or vasoactive drugs and/or non-invasive ventilation
62087179|NCT00329719|EXPERIMENTAL|Group I (sorafenib tosylate, temsirolimus)|Patients receive sorafenib tosylate and temsirolimus as in Phase I.
62652143|NCT04272229|ACTIVE_COMPARATOR|Control Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
62652144|NCT04272229|EXPERIMENTAL|Migrain Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
62087180|NCT00329719|EXPERIMENTAL|Group II (sorafenib tosylate, temsirolimus, surgery)|Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
62087181|NCT00329719|EXPERIMENTAL|Group III (sorafenib tosylate, temsirolimus, anti-VEGF)|Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
62087182|NCT00636584|EXPERIMENTAL|1|arm1: sodium nitroprusside group
62087183|NCT00636584|PLACEBO_COMPARATOR|2|arm2: control group,saline infused instead of sodium nitroprusside
62087184|NCT01635894|EXPERIMENTAL|nurse specialist|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
62286004|NCT06166628|ACTIVE_COMPARATOR|Genicular artery embolization|Genicular artery embolization will be performed by board certified Interventional Radiologists in the interventional radiology angiography suite at Kingston General Hospital. Patients will be blinded to which procedure they have been randomized too, careful language will be used by the clinical and research team throughout the procedure to not compromise the blinding. Patients will be positioned supine on the procedure table. The affected knee will be prepped and draped using standard sterile technique and 1-2cc of 1% lidocaine will be administered to the area for local anesthetic. A drape will be placed such that the patient is unable to see the affected knee during the procedure. Geniculate artery embolization will be performed via an intraarterial access and use of embolization microspheres injected into the hypervascular arteries feeding the knee joint.
62286005|NCT06166628|ACTIVE_COMPARATOR|Genicular nerve phenol nerve ablation|Genicular nerve phenol nerve ablation All procedures will be performed by a fellowship trained interventional pain physician in a fluoroscopy suite in Hotel Dieu Hospital using sterile precautions. Patients will be blinded to which procedure they have been randomized too, careful language will be used by the clinical and research team throughout the procedure to not compromise the blinding. IV access and saline lock obtained per our usual clinic protocol. Patients will be positioned supine on the procedure table. The affected knee will be prepped and draped using standard sterile technique and 1-2cc of 1% lidocaine will be administered to the area for local anesthetic. Phenol nerve ablation will be performed via ultrasound guidance.
62652145|NCT06370793||Patients with Schizophrenia|
62652146|NCT01253161|EXPERIMENTAL|Pasireotide LAR Treatment|The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.
62652147|NCT03630393|EXPERIMENTAL|Pressure 6 mmHg|Pneumoperitoneum Pressure 6 mmHg
62652148|NCT03630393|ACTIVE_COMPARATOR|Pressure 15 mmHg|Pneumoperitoneum Pressure 15 mmHg
62460837|NCT03733509|ACTIVE_COMPARATOR|Ultrasound Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of of saline solution (NaCl 0.9%).~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml Bupivacaine 0.25%."
62652149|NCT03651804|ACTIVE_COMPARATOR|Control Group|"The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks."
62652150|NCT03651804|ACTIVE_COMPARATOR|Treatment Group|The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
62652151|NCT03651804|ACTIVE_COMPARATOR|Crossover Group|This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.
61904146|NCT03060122|EXPERIMENTAL|NIN (InterX) and CES (Alpha-Stim)|"The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area. Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
61904147|NCT03060122|ACTIVE_COMPARATOR|NIN (InterX) and sham CES|"The Alpha-Stim Cranial Electrical Stimulation device intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level that serves as a sham treatment.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
61904148|NCT05194371||Definitive (chemo)radiotherapy|
62087185|NCT01635894|EXPERIMENTAL|practice nurse|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
62652152|NCT06248606|EXPERIMENTAL|Adagrasib + SRS (Stereotactic Radiosurgery)|All patients will receive oral adagrasib 600mg twice daily for every cycle and SRS which will be administered as standard of care. Initiation of adagrasib and treatment with SRS will occur within 3 weeks of each other, in whichever order. Patients may have received SRS prior to study enrollment. Cycle 1 Day 1 will begin on the first day of adagrasib dosing. Adagrasib should be held the day before and the day of SRS. There is no maximum duration of treatment.
62087186|NCT01635894|NO_INTERVENTION|Control|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment (but no training given) and were followed-up for their final assessment at 3 months."
62087187|NCT04625855|EXPERIMENTAL|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr
62286006|NCT06166628|SHAM_COMPARATOR|Sham procedure|The sham procedure will be performed by a fellowship trained interventional pain physician in a fluoroscopy suite in Hotel Dieu Hospital using sterile precautions. Patients will be blinded to which procedure they have been randomized too, careful language will be used by the clinical and research team throughout the procedure to not compromise the blinding. IV access and saline lock obtained per our usual clinic protocol. The patient will be placed supine, and the appropriate knee prepped and draped using appropriate sterile technique . A drape will be placed such that the patient is unable to see the affected knee during the procedure.
62286007|NCT04880005|EXPERIMENTAL|The intervention group|The three core elements of the intervention are: 1) individualized data-driven recommendations to GPs on how to treat each individual T2D patient, as well as 2) individualized digital coaching of T2D patients, and 3) on-line presentation of patient registered outcomes (PRO) to GPs.
62286008|NCT04880005|NO_INTERVENTION|Control group|Usual care
62286009|NCT03630055|EXPERIMENTAL|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
62286010|NCT03630055|NO_INTERVENTION|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
62652153|NCT01704261|EXPERIMENTAL|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose \>=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose \>=1500 mg per day).
62652154|NCT01704261|PLACEBO_COMPARATOR|Placebo|Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose \>=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose \>=1500 mg per day).
62286011|NCT00905957|ACTIVE_COMPARATOR|Transversus abdominis plane (TAP) Group|Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia
62652155|NCT01259245|EXPERIMENTAL|Tai chi + PRP|Tai chi elements in incorporated into the exercise component of standard pulmonary rehabilitation program. The exercise content was totally identical to the PRP group except 15 minutes of Tai Chi exercises was substituted to 15 minutes of relaxation exercise. The 5 forms of Sun Style of Tai Chi were taught.
62652156|NCT01259245|ACTIVE_COMPARATOR|PRP|PRP is a formal pulmonary rehabilitation program consisted of physical training including warm up and cool down exercise and aerobic exercises in addition to breathing control exercises, safety precautions for physical training, Thera-Band strengthening exercises and overview of COPD management.
62286012|NCT00905957|PLACEBO_COMPARATOR|Control Group|Patients will receive a TAP block using a placebo after induction of anaesthesia
62286013|NCT05319236|OTHER|Gabi System|Subjects will wear the Gabi system each time they go to sleep or are resting, to measure and record their SpO2, pulse rate, respiratory rate and movements.
62286014|NCT05368545|ACTIVE_COMPARATOR|usual care lipid lowering|Usual care: atorvastatin 40 mg
62286015|NCT05368545|EXPERIMENTAL|Intensive lipid lowering|Intensive: rosuvastatin 40 mg + ezetimibe 10 mg
62286016|NCT00332956|ACTIVE_COMPARATOR|Group 1|Volunteers will be vaccinated with 80 mcg rF1V vaccine on Study Days 0 , 28, 182
62286017|NCT00332956|ACTIVE_COMPARATOR|Group 2|Volunteers will be vaccinated with 80 mcg of rF1V vaccine at Study Days 0, 56, 182
62286018|NCT00332956|ACTIVE_COMPARATOR|Group 3|Volunteers will be vaccinated with 160 mcg rF1V vaccine given on Study Days 0, 28, 182
61904149|NCT02029300|OTHER|Nasal Route|The nasal route will be when the airway is acquired and secured with a fiberoptic bronchoscope through one of the nares.
61904150|NCT02029300|OTHER|Oral Route|The oral route will be when the airway is acquired and secured with a fiberoptic bronchoscope through the patient's mouth.
61904151|NCT01697280|EXPERIMENTAL|Educational messages only|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization
61904152|NCT01697280|EXPERIMENTAL|Immunization status verification only|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
62087188|NCT03672864|EXPERIMENTAL|Immediate Group|The intervention is intensive exercise, delivered over 12 weeks beginning on admission to the study. The group will then be followed for 9 months post intervention.
62087189|NCT03672864|NO_INTERVENTION|Delay Group|The group will be followed for 6 months with no intervention. After 6 months the group will be given the opportunity to receive the same intensive exercise intervention as the Immediate group. The group will be followed for 3 months following the intervention.
62087190|NCT04843319|EXPERIMENTAL|VERU-100 at various doses|2 ml, 2.5 ml, 3 ml, 3.5 ml of VERU-100
62286019|NCT00332956|ACTIVE_COMPARATOR|Group 4|Volunteers will be vaccinated with 160 mcg rf1V vaccine on Study Days 0, 56, 182
62460838|NCT04864548|EXPERIMENTAL|Group 1A: Low dose challenge|"Intranasal viral challenge with 1 x 10\^1 TCID_50 in previously infected volunteers~N= 6-8 participants"
62460839|NCT04864548|EXPERIMENTAL|Group 1B: Medium dose #1 challenge|"Intranasal viral challenge with 1 x 10\^2 TCID_50 in previously infected volunteers~N= 6-8 participants"
62087191|NCT01852955|ACTIVE_COMPARATOR|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
62286020|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
62286021|NCT02062567||Acute Achilles tendon rupture|
62286022|NCT02022449|NO_INTERVENTION|Control|participants only complete assessments
62286023|NCT02022449|EXPERIMENTAL|Stress management|Cognitive Behavioral Stress management Coping enhancement strategies Progressive muscle relaxation Guided imagery relaxation skills Deep breathing relaxation skills Social support
62286024|NCT04278807|EXPERIMENTAL|PENG-group|Ultrasound-guided PENG-block - 30 patients
62460840|NCT04864548|EXPERIMENTAL|Group 1C: Medium dose #2 challenge|"Intranasal viral challenge with 1 x 10\^3 TCID_50 in previously infected volunteers~N= 6-8 participants"
62460841|NCT04864548|EXPERIMENTAL|Group 1D: Medium dose #3 challenge|"Intranasal viral challenge with 1 x 10\^4 TCID_50 in previously infected volunteers~N= 4-8 participants"
62460842|NCT04864548|EXPERIMENTAL|Group 1E: High dose challenge|"Intranasal viral challenge with 1 x 10\^5 TCID_50 in previously infected volunteers~N= 4-8 participants"
62460843|NCT04864548|EXPERIMENTAL|Group 2: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 1a-e (1x10\^1, 1x10\^2, 1x10\^3, 1x10\^4, or 1x10\^5 TCID_50)~N=10-30 participants"
62460844|NCT04864548|EXPERIMENTAL|Group 3a: Medium dose #1 challenge|"Intranasal viral challenge with 1 x 10\^2 TCID_50 in previously uninfected, vaccinated volunteers~N=6-8 participants"
62460845|NCT04864548|EXPERIMENTAL|Group 3b: Medium dose #2 challenge|"Intranasal viral challenge with 1 x 10\^3 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
62460846|NCT04864548|EXPERIMENTAL|Group 3c: Medium dose #3 challenge|"Intranasal viral challenge with 1 x 10\^4 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
62460847|NCT04864548|EXPERIMENTAL|Group 3d: High dose challenge|"Intranasal viral challenge with 1 x 10\^5 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
62652157|NCT05733338|ACTIVE_COMPARATOR|IH group|Participants will receive 10 times intermittent hypoxia (oxygen concentration: 13%) intervention before exposure to acute hypoxia environment.
61904153|NCT01697280|EXPERIMENTAL|Education and vaccine verification|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization, identify and record details of un/under-vaccinated children in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
61904154|NCT01697280|NO_INTERVENTION|Status quo|No interventional activity will take place in this group. Therefore, the status quo (routine services) will be maintained during Polio NID
61904155|NCT01558128|OTHER|Amiodarone with cardioversion|If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.
61904156|NCT01583829|EXPERIMENTAL|Neurofeedback|
61904157|NCT01583829|EXPERIMENTAL|Cognitive Training|
61904158|NCT01583829|ACTIVE_COMPARATOR|Waitlist Control|
61904159|NCT02168036||Patients with lung disease|General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.
61904160|NCT04478344|EXPERIMENTAL|Ultrasound guided hydrodissection to superior cluneal nerve|Patients with superior cluneal nerve enttrappment given by ultrasound guided perineural injection with a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline to superior cluneal nerve of affected side.
61904161|NCT04478344|NO_INTERVENTION|Control arm|Patients without superior cluneal nerve entrappment
61904162|NCT01395524|EXPERIMENTAL|NKTR-118 12.5mg|
61904163|NCT01395524|EXPERIMENTAL|NKTR-118 25mg|
62087192|NCT01852955|PLACEBO_COMPARATOR|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
62286025|NCT04278807|EXPERIMENTAL|FIB-group|Ultrasound-guided Fascia Iliaca block - 30 patients
62286026|NCT03540186|EXPERIMENTAL|Epigenorm Antivir and acupuncture arm|Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.
62460848|NCT04864548|EXPERIMENTAL|Group 4: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 3a-d (1x10\^2, 1x10\^3, 1x10\^4 or 1x10\^5 TCID_50)~N=10-30 participants"
62460849|NCT04751578|EXPERIMENTAL|Intervention|
61904164|NCT01395524|PLACEBO_COMPARATOR|Placebo|
61904165|NCT04723264|EXPERIMENTAL|Eating behavior activities|
61904166|NCT05867589|EXPERIMENTAL|68Ga/18F-FAPI-04|For the injection, subjects will receive a target dose of 0.1\~0.15mCi/Kg 68Ga/18F-FAPI-04 as a bolus injection.
61904167|NCT03954340|ACTIVE_COMPARATOR|1 iRemember Treatment|Subjects randomized to this arm of the study will undergo 20 EEG NFB treatments with the iRemember System for the treatment of MCI
61904168|NCT03954340|SHAM_COMPARATOR|2 Sham Treatment|Subjects randomized to this arm of the study will undergo 20 SHAM treatments
61904169|NCT00824837|EXPERIMENTAL|A|New larger pore membrane
62087193|NCT01668979||new system to detect Near Falls|the new system comprises of a treadmill and a virtual reality simulation that will be used to induce Near Falls in healthy older adults with a history of falls.
62286027|NCT02427048|NO_INTERVENTION|Pre-Intervention|Delayed feedback and peer comparison
62286028|NCT02427048|EXPERIMENTAL|Feedback with Peer Comparison|Individualized adherence feedback with peer comparison
62087194|NCT05162118|EXPERIMENTAL|Single Arm|"1. Intratumoral injection of VG161 - 1.5\*10\^8 on D1 + Nivolumab on D8, D22~2. Intratumoral injection of VG161 - 1.0\*10\^8 on D1, D2 + Nivolumab on D8, D22~3. Intratumoral injection of VG161 - 1.0\*10\^8 on D1, D2, D3 + Nivolumab on D8, D22"
62087195|NCT01992198|EXPERIMENTAL|cefoperazone + metronidazole|cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition
62087196|NCT01992198|ACTIVE_COMPARATOR|meropenem|Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition
62087197|NCT01625910|EXPERIMENTAL|behavioral counseling|Receive counseling via motivational interviewing seeking to encourage health eating habits and increased physical activity
62087198|NCT01625910|PLACEBO_COMPARATOR|Instructions in school readiness and performance|Parents receive instructions in school readiness and performance
62460850|NCT06307925|EXPERIMENTAL|dose-escalation phase|HC010 0.15mg/kg to 20mg/kg Q2w/28d intravenous infusion
62460851|NCT06307925|EXPERIMENTAL|dose expansion phase|Fixed dose of HC010 Q2w/28d intravenous infusion
62460852|NCT06138184|ACTIVE_COMPARATOR|Standard Care|Standard Educational process
62087199|NCT01831492|ACTIVE_COMPARATOR|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
62087200|NCT01831492|PLACEBO_COMPARATOR|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
62087201|NCT02990221|ACTIVE_COMPARATOR|Ingenol mebutate|application of ingenol mebutate for 3 consecutive days on an area of face/scalp of 25 cm2
62087202|NCT02990221|ACTIVE_COMPARATOR|cryotherapy|application of criotherapy on actinic keratosis present in an area of face/scalp of 25 cm2 different from the ingenol mebutate area
62286029|NCT01722838|EXPERIMENTAL|B-ME intervention|Men will receive behavioral HIV prevention intervention, B-ME.
62460853|NCT06138184|EXPERIMENTAL|Education Intervention|New educational intervention
62087203|NCT01813422|PLACEBO_COMPARATOR|Placebo|Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
62087204|NCT01813422|EXPERIMENTAL|Evolocumab|Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
62460854|NCT01135927|EXPERIMENTAL|A|
62460855|NCT01135927|ACTIVE_COMPARATOR|B|
62652158|NCT05733338|SHAM_COMPARATOR|Control group|Participants will receive 10 times sham-hypoxia (oxygen concentration: 21%) intervention in 5 days before exposure to acute hypoxia environment.
61904170|NCT00824837|ACTIVE_COMPARATOR|B|Standard haemodialysis membrane
61904171|NCT00848562|EXPERIMENTAL|Nicorandil|
62087205|NCT03342911|EXPERIMENTAL|Treatment (nivolumab, paclitaxel, carboplatin)|Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62286030|NCT01722838|NO_INTERVENTION|Control Arm|Men in this arm will receive monthly text or telephone voice messages relaying general health messages.
62460856|NCT05216081|EXPERIMENTAL|Elder adults in emergency department setting with cognitive impairment|Elder mistreatment in an Emergency Department setting with cognitive impairment.
62460857|NCT00822874|EXPERIMENTAL|in-vitro maturation of oocytes|
62286031|NCT01658267|EXPERIMENTAL|Nutritional Supplement|Instructions and techniques to improve the quality of the diet to meet the child's daily nutritional requirements will be provided.
62286032|NCT02553135|EXPERIMENTAL|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
62286033|NCT05158855|EXPERIMENTAL|neutralizing antibody booster for vaccinated participants|participants after 6-month vaccinated with COVID-19 vaccine received 1 capsule of B. subtilis spore extract
62286034|NCT03780829|EXPERIMENTAL|hypoxia plus training|combined hypoxia treatment with exercise training
62286035|NCT03780829|SHAM_COMPARATOR|sham hypoxia plus training|combined sham hypoxia treatment with exercise training
62460858|NCT01767428|EXPERIMENTAL|Experimental Paracetamol Tablet|Experimental paracetamol tablet (500 milligrams \[mg\]) administered with 240 milliliters (mL) of water.
62460859|NCT01767428|ACTIVE_COMPARATOR|Standard Paracetamol Tablet (500 mg)|Standard paracetamol tablet (500 mg) administered with 240 mL of water.
62460860|NCT04768179|NO_INTERVENTION|Arm1 (Control group)|standard of care
62460861|NCT04768179|EXPERIMENTAL|Arm 2|Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
62460862|NCT04768179|EXPERIMENTAL|Arm 3|3-day Ivermectin 600 mcg/kg/day/14-day 75mgASA/day + standard of care (Intervention 2)
62652159|NCT04111302|EXPERIMENTAL|IV-PCA|use IV-PCA for postoperative pain
62652160|NCT04111302|EXPERIMENTAL|IV-dezocine|use IV-dezocine for postoperative pain
61904172|NCT05468073|EXPERIMENTAL|Treatment|Patient will be treated with low dose of Interleukin 2 (PROLEUKIN ®)
61904173|NCT05468073|PLACEBO_COMPARATOR|Placebo|Patient will receive sodium chloride solution (NaCl)
61904174|NCT05908565|ACTIVE_COMPARATOR|Aim 1|To examine the impact of demographic matching and supervision intensity on treatment engagement, treatment satisfaction, symptoms, and functioning for students receiving digital therapy. Hypothesis for Main Effect 1: Participants who are matched with Latinx peer coaches will show greater treatment engagement, satisfaction, and improvements in symptom and functioning relative to participants who are not. Hypothesis for Main Effect 2: Participants assigned to peer coaches in standard supervision will show greater treatment engagement, satisfaction, and improvements in symptom and functioning relative to those assigned to coaches in reduced supervision. Hypothesis for Interaction Effect: Students assigned to coaches who are demographically matched and receiving standard supervision will show greater treatment engagement, satisfaction, and improvements in symptom and functioning relative to those in all other conditions.
62652161|NCT04111302|EXPERIMENTAL|IV-PCA+AA|use IV-PCA and AA for postoperative pain
62652162|NCT04111302|EXPERIMENTAL|IV-dezocine+AA|use IV-dezocine and AA for postoperative pain
62652163|NCT02472353|ACTIVE_COMPARATOR|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
62652164|NCT02472353|EXPERIMENTAL|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
62652165|NCT02450643|ACTIVE_COMPARATOR|Test then Control|Subjects will perform a DBPCFC with the Test formula followed by the Control formula
62652166|NCT02450643|ACTIVE_COMPARATOR|Control then Test|Subjects will perform a DBPCFC with the Control formula followed by the Test formula
61904175|NCT05908565|NO_INTERVENTION|Aim 2|To examine explanatory/intervening variables impacting treatment engagement, treatment satisfaction, symptoms and functioning for students receiving digital therapy. Hypothesis 2: Evidence of mediation will be observed for the following five explanatory/intervening variables: 1) quality of the relationship between the participant and peer coach, 2) the participants' perception of cultural similarity with their coach, 3) the participants' treatment expectancy and treatment credibility, 4) the participants' perception of their peer coach's cultural competence, and 5) the peer coaches' fidelity to the treatment model.
62087206|NCT02903784|OTHER|grade 2 glioma|Patient with grade 2 glioma use a neuropsychological examination and brain imaging (fMRI and tractography)
62087207|NCT02903784|OTHER|healthy volunteers|healthy volunteers use a neuropsychological examination and brain imaging (fMRI and tractography)
62087208|NCT00072163|EXPERIMENTAL|Treatment (temozolomide, thalidomide)|Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
62087209|NCT01899248||Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
62286036|NCT03780829|EXPERIMENTAL|hypoxia plus training plus NMDA agonist|combined hypoxia treatment with exercise training and with NMDA agonist treatment
62286037|NCT03780829|PLACEBO_COMPARATOR|hypoxia plus training plus sham NMDA agonist|combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
62286038|NCT05752929|ACTIVE_COMPARATOR|Umpierrez|The Umpierrez sensitive correction scheme correction
62286039|NCT05752929|EXPERIMENTAL|Davidson|Davidson correction factor
62286040|NCT00483327|EXPERIMENTAL|Megestrol Acetate|80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
62087210|NCT01899248||Desflurane|Performing liver transplantation under general anesthesia using desflurane
62286041|NCT04158063|EXPERIMENTAL|Dual Task Training (DTT)|
62286042|NCT04158063|ACTIVE_COMPARATOR|Single Mobility Training (SMT)|
62286043|NCT03155646|ACTIVE_COMPARATOR|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
62286044|NCT03155646|ACTIVE_COMPARATOR|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
62087211|NCT01171365|ACTIVE_COMPARATOR|Ciclesonide|Ciclesonide 320 microgrammes twice daily
62087212|NCT01171365|PLACEBO_COMPARATOR|Placebo|Placebo 2 inhalations twice daily
62087213|NCT04595695|EXPERIMENTAL|Transparent Mask|Surgeons will be provided a transparent mask for use during in-person clinic visits with a new patient. Otherwise, visits will be conducted as per usual and the patient will be surveyed immediately after the visit.
62087214|NCT04595695|ACTIVE_COMPARATOR|Covered Mask|Surgeons will be instructed to wear a typical, covered mask for the in-person clinic visit with a new patient. The visit will be conducted as it typically would, and the patient will be surveyed immediately after the visit.
62087215|NCT05676398||Ambulatory rhythm monitoring|Ambulatory rhythm monitoring by use of patch-type device.
62286045|NCT03155646|ACTIVE_COMPARATOR|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
62286046|NCT03082001|ACTIVE_COMPARATOR|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
62286047|NCT03082001|EXPERIMENTAL|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A \& B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
62286048|NCT03158220|EXPERIMENTAL|Adult Women 27- to 45-years Old|Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
62652167|NCT01687439|EXPERIMENTAL|Treatment|Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment.
62652168|NCT06472921|EXPERIMENTAL|Early initiation group|Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days.
62652169|NCT06472921|OTHER|Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml|Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days.
62652170|NCT01402232||coronary angiography|We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
62087216|NCT05886075|EXPERIMENTAL|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors
62286049|NCT03158220|ACTIVE_COMPARATOR|Young Adult Women 16- to 26-years Old|Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
62286050|NCT05874388|EXPERIMENTAL|open-label, comparative study|"The study will involve two groups: a group of adolescents and adults symptomatic with FA with a confirmed molecular diagnosis, followed in the genetics department of the Necker Hospital, and a control group comprising subjects free of any motor or cognitive impairment, recruited from healthy relatives of patients (siblings, cousins, spouses).~The study will take place in a single session, during a health care consultation, during which the previously selected patients will take the tests included in the battery on a computer dedicated for the study. The total duration of the test is 45 minutes. No further visits will be necessary.~The validation of the results obtained will be determined by the correlation indices between the cognitive test scores used and the demographic variables and disease parameters considered, in particular the number of GAA triplet repeats in the allele of the FXN gene that contains the fewest repeats."
62286051|NCT04582838||Spontaneous breathing ICU non-COVID|"Spontaneously breathing non-COVID-19 critically ill patients with sinus rhythm.~Inclusion and exclusion criterion are listed elsewhere."
62286052|NCT04582838||Spontaneous breathing ICU COVID|"Spontaneously breathing COVID-19 critically ill patients with sinus rhythm.~Inclusion and exclusion criterion are listed elsewhere."
62286053|NCT03266835|OTHER|SoundBite™ Crossing System - Peripheral|This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
62286054|NCT02813122||with x-ray|patients underwent bariatric surgery and underwent x-ray
62286055|NCT02813122||without x-ray|patients underwent bariatric surgery and did not underwent x-ray
62286056|NCT04376437|EXPERIMENTAL|medical cannabis|All patients will start with 250mcg cannabis flos BID and will follow the titration plan of dose modification according to CIPN relief and adverse events. Maximum dose of 2,000mcg per day is prescribed at the end of titration period, which is continuous for 15 days (about 2 weeks).On 10 weeks visit all patients will be discontinued from the treatment. In case of worsening of neuropathy at any point during the 4 weeks of FU, patients might be able to restart with inhaled MC treatment for no more than 4 weeks. Total treatment in this study will be for no more than 14 weeks.
62286057|NCT05886062|EXPERIMENTAL|Experimental Group|In addition to routine basketball technical-tactical training, the athletes in the experimental group will be given motor imagery training to facilitate sensorimotor relearning.
62286058|NCT05886062|ACTIVE_COMPARATOR|Control Group|Individuals in the control group will only continue their routine basketball technical-tactical training.
62286059|NCT06499818|EXPERIMENTAL|STABLE-SR|
62286060|NCT06499818|EXPERIMENTAL|STABLE-AF|
62652171|NCT02146183|PLACEBO_COMPARATOR|placebo / Corn starch|Carbohydrate-containing composition that comprises 2 g carbohydrate per kg of body weight. This composition will be 500 mg placebo starch corn.
62652172|NCT02146183|ACTIVE_COMPARATOR|Carbohydrate steviol glycosides|500 mg steviol glycosides.
62652173|NCT03764605|EXPERIMENTAL|Metformin|"Patients will take metformin starting from 500 mg a day. They will up-titrate every week, if tolerating IMP, adding one 500 mg dose 8 hours after the former, till reaching 500 mg thrice a day.~The minimum tolerated dose requested in order to be admitted to the study is 500 mg twice a day.~Those reaching eGFR\<45 ml/min will reduce the dose by one third. Those reaching eGFR\<30 will drop out the study."
62652174|NCT03764605|ACTIVE_COMPARATOR|Tolvaptan|Patient will start Tolvaptan in a split dose regimen 45 mg as first dose, followed by 15 mg 8 hours later. Those tolerating this dose will uptitrate to 60/30 mg and then to 90/30 mg a day. Those not tolerating 45/15 mg a day will drop out.
62652175|NCT04105608|EXPERIMENTAL|HFV meal|A vegetarian meal high in dietary carbohydrate and fiber
61904176|NCT05908565|NO_INTERVENTION|Aim 3|To examine the cost-effectiveness of providing standard supervision. Hypothesis 3: Cost-effectiveness analyses will demonstrate that the increased costs incurred by standard supervision relative to reduced supervision will be justified by participants assigned to peer coaches receiving standard supervision experiencing greater improvements in symptoms than those assigned to peer coaches receiving reduced supervision.
61904177|NCT02691585|EXPERIMENTAL|Music intervention group 1|Raga 1 will be given
62286061|NCT06499818|ACTIVE_COMPARATOR|CPVI alone|
62652176|NCT04105608|ACTIVE_COMPARATOR|MED meal|A Mediterranean-like meal
62652177|NCT01276834|EXPERIMENTAL|everolimus-based immunosuppression|immunosuppression with everolimus, prednisone and mycophenolate
62652178|NCT01276834|ACTIVE_COMPARATOR|standard immunosuppression|immunosuppression with tacrolimus, prednisone and mycophenolate
61904178|NCT02691585|EXPERIMENTAL|Music intervention group 2|Raga 2 will be given
61904179|NCT02691585|EXPERIMENTAL|Music intervention group 3|Raga 3 will be given
62286062|NCT03611439|ACTIVE_COMPARATOR|ReBuilder Actives|Subjects take one 650 mg capsule by mouth twice a day for 12 months.
62652179|NCT01141608|EXPERIMENTAL|Vigorous Intensity High Dose Exercise|Usual Care Augmented with Vigorous Intensity High Dose Exercise
62652180|NCT01141608|EXPERIMENTAL|Health Education Intervention|Health Education Intervention
62652181|NCT00487188|EXPERIMENTAL|ENF + HAART|Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
61904180|NCT02691585|NO_INTERVENTION|Control Group 4|No raga. Just collection of electrophysiological parameters will be done.
61904181|NCT02447237|EXPERIMENTAL|liquid food|dietary counselling in fulfilling need of protein and energy through liquid food
61904182|NCT02447237|OTHER|solid food|dietary counselling in fulfilling need of protein and energy through solid food
61904183|NCT06085456||EOC group|Patients diagnosed with epithelial ovarian cancer
61904184|NCT06085456||Control group|Patients diagnosed with benign gynecological diseases, including ovarian cysts, uterine fibroids and uterine prolapse.
61904185|NCT01806701|EXPERIMENTAL|Psychotherapy|Trauma-focused Cognitive Behavioral Therapy
61904186|NCT03730402|ACTIVE_COMPARATOR|bupivacaine block|laparoscopic assisted plane block of standardized dose of bupivacaine plain
62087217|NCT02306395|EXPERIMENTAL|Endometrial local injury|Endometrial local injury is carried in the first 3-5 days after menstrual period at the same time of hysteroscopy.
62652182|NCT00487188|ACTIVE_COMPARATOR|HAART|Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.
62087218|NCT02306395|NO_INTERVENTION|The blank group|Any processing does not carry on the endometrium in the first 3-5 days after menstrual period except hysteroscopy.
62087219|NCT00942240|EXPERIMENTAL|ACU-4429 tablet|
62087220|NCT00942240|PLACEBO_COMPARATOR|matching placebo tablet|
62087221|NCT02372448|OTHER|ALK-positive|ALK positive analysis on CTCs detected by ISET
62087222|NCT02372448|OTHER|ALK-negative|ALK negative analysis on CTCs detected by ISET
62087223|NCT01454336|EXPERIMENTAL|Cirrhotic Patients|3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy
62087224|NCT03807193|EXPERIMENTAL|Fixed treatment, weekly support|Receives a predetermined treatment program and have weekly support.
62087225|NCT03807193|EXPERIMENTAL|Fixed treatment, support on demand|Receives a predetermined treatment program and have access to support on demand.
62286063|NCT03611439|PLACEBO_COMPARATOR|ReBuilder Placebo|Subjects take one placebo capsule by mouth twice a day for 12 months.
62652183|NCT05368649|EXPERIMENTAL|Healthy Volunteers|Short-wave diathermy
62652184|NCT05368649|NO_INTERVENTION|Shoulder Pain|Volunteers with unilateral shoulder pain
62652185|NCT06443008|NO_INTERVENTION|control group|Comprehensive rehabilitation treatment in control group
62652186|NCT06443008|EXPERIMENTAL|Observation Group|The observation group carried out myoelectric biofeedback therapy on the basis of the control group
62652187|NCT00600522||1|Patients selected for hepatectomy because carriers of hepatocellular carcinoma or colorectal cancer liver metastases invading the middle hepatic vein at caval confluence (last 4 cm).
62652188|NCT02224417|OTHER|Diabetes Educational Program (DEP) only|Participants will receive the Diabetes Educational Program, as required, which is part of usual care at the Polyclinic. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one).
62652189|NCT02224417|OTHER|DEP + Process Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified process goals.
62652190|NCT02224417|OTHER|DEP + Outcome Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified outcome goals.
62652191|NCT02043977|EXPERIMENTAL|propofol infusion|Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.
62652192|NCT00350545|EXPERIMENTAL|rituximab + prednisone arm|Rituximab will be given as an IV fusion as initial treatment, followed by predisone (given during registration) which will be continued through-out trial and tapered off by physician. Cyclosporine A and tacrolimus will be used if chances of new diagnosis of chronic GVHD occur. Both drugs have no interaction with Rituxan, but will be tapered off after predisone is completely tapered.
62652193|NCT02005107|EXPERIMENTAL|venlafaxine|Venlafaxine IR and XR, single dosages of each separated by a wash-out period
62087226|NCT03807193|EXPERIMENTAL|Selected treatment, weekly support|Select their own treatment material and have weekly support.
62087227|NCT03807193|EXPERIMENTAL|Selected treatment, support on demand|Select their own treatment material and have access to support on demand.
62087228|NCT04920461|EXPERIMENTAL|Additional MRI sequences|
62087229|NCT01925170|EXPERIMENTAL|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
62087230|NCT00921297|ACTIVE_COMPARATOR|Immediate Cataract Surgery|Subjects randomly selected into the Immediate Surgery group will have their cataract surgery scheduled one month from the time their initial study visits are completed. The subjects will be followed monthly for a period of 6 months for surgical and non-surgical adverse events. At the 6-month point, subjects will receive a final comprehensive eye exam and neuropsychological testing. The research partners will complete final activities of daily living and resource utilization questionnaires.
62087231|NCT00921297|NO_INTERVENTION|Delayed Cataract Surgery|Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.
62087232|NCT05719636|ACTIVE_COMPARATOR|Conventional treatment|
62087233|NCT05719636|EXPERIMENTAL|Progressive resistance exercise|
62087234|NCT00242463|EXPERIMENTAL|nandrolone|Patients receive weekly injections of nandrolone
62087235|NCT00242463|PLACEBO_COMPARATOR|Placebo|
62087236|NCT03029338|EXPERIMENTAL|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
62087237|NCT01646320|EXPERIMENTAL|Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR|
62087238|NCT01646320|EXPERIMENTAL|Arm 2: Placebo + Saxagliptin + Metformin IR|
62087239|NCT03774992|EXPERIMENTAL|Orthokeratology|Subjects randomized to OKL in the CONTROL-study
62286064|NCT01405092|PLACEBO_COMPARATOR|Standard volume management|patients on this arm will receive usual care volume management during continuous renal replacement therapy
62286065|NCT01405092|ACTIVE_COMPARATOR|continuous volume management|use of Critline, Hemametrics USA, in conjunction with continuous renal replacment therapy to determine volume removal
62286066|NCT06103747|EXPERIMENTAL|First group of healthy volunteers|The first group of healthy volunteers, defined by randomization
62652194|NCT02005107|OTHER|Venlafaxine XR and Venlafaxine IR|Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
62087240|NCT03774992|EXPERIMENTAL|Cross over|Subjects randomized to SVS in the CONTROL-study
62087241|NCT01656759|NO_INTERVENTION|Control Group|Control group. Will not receive the fibrin spray.
62286067|NCT06103747|ACTIVE_COMPARATOR|Second group of healthy volunteers|The second group of healthy volunteers, defined by randomization
62087242|NCT01656759|ACTIVE_COMPARATOR|Treatment Group--Evicel Fibrin Spray|"Patient will receive the fibrin spray after implantation of device but before the wound is closed.~Patients will be randomized to receive spray or not and postop parameters measured."
62652195|NCT01092767|EXPERIMENTAL|Valiant Thoracic Stent Graft with the Captivia Delivery System|Valiant Thoracic Stent Graft with the Captivia Delivery System
62652196|NCT05563324||clinical sample|adolescents with nonsuicidal self-injury
62087243|NCT01988987||Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
62286068|NCT01561651|EXPERIMENTAL|Left Atrial Appendage Occlusion Group|Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.
62286069|NCT01561651|NO_INTERVENTION|No Left Atrial Appendage Occlusion Group|Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.
62286070|NCT05255380|EXPERIMENTAL|Mindful Activity group|Participants complete mindfulness and compassion-based practices via the study app.
62286071|NCT05255380|SHAM_COMPARATOR|Mindful Awareness group|Participants monitor and report their thoughts and feelings via the study app.
62286072|NCT01618760|EXPERIMENTAL|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
62652197|NCT05563324||original control group|adolescents with no history of nonsuicidal self-injury
62652198|NCT05563324||general control group|adolescents from the general population
62652199|NCT04227834|ACTIVE_COMPARATOR|Single education|Single health hygiene education
62652200|NCT04227834|EXPERIMENTAL|Repeated education|Four-monthly health hygiene education
61904187|NCT03730402|ACTIVE_COMPARATOR|liposomal bupivacaine block (Exparel 266 milligram Per 20 ML)|laparoscopic assisted plane block of standardized dose of bupivacaine plain
61904188|NCT03730402|PLACEBO_COMPARATOR|saline block|laparoscopic assisted plane block with placebo saline injection
61904189|NCT00612105|EXPERIMENTAL|1|Retigabine
61904190|NCT00612105|PLACEBO_COMPARATOR|2|Placebo
61904191|NCT05634993||MS Group|
61904192|NCT04592718|EXPERIMENTAL|Slow deep breathing plus breath counting|Participants in this group will do a daily 5-min slow deep breathing exercise (6 breaths/minute) and will also count their breaths
61904193|NCT04592718|ACTIVE_COMPARATOR|Normal-paced breathing plus breath counting|Participants in this group will do a daily 5-min normal-paced breathing (15 breaths/minute) and will also count their breaths
62087244|NCT02467959||Ultrasound|Ultrasound evaluation
62087245|NCT01067495|EXPERIMENTAL|Exercise|
62087246|NCT02018315|EXPERIMENTAL|Triheptanoin|Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.
62087247|NCT05573113|ACTIVE_COMPARATOR|AXR Arm 1|Abdomen Radiograph
62087248|NCT05573113|ACTIVE_COMPARATOR|AXR + BUS Arm 2|Abdomen Radiograph + Bowel Ultrasound
62087249|NCT04696848|EXPERIMENTAL|CKD-516 plus Durvalumab|Stage 1 : dose escalation durvalumab (1500 mg Q4W) plus CKD-516 at dose levels (9, 11, or 13 mg/m2) Stage 2 : durvalumab (1500 mg Q4W) plus CKD-516 at recommended phase 2 dose
62286073|NCT01618760|ACTIVE_COMPARATOR|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
62286074|NCT03529409|EXPERIMENTAL|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
62286075|NCT03529409|NO_INTERVENTION|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
62286076|NCT04043000|EXPERIMENTAL|Super 13 Pro & Prebiotics|"Super 13 Pro \& Prebiotics was given three times a day for four weeks."
62286077|NCT04043000|PLACEBO_COMPARATOR|Placebo|" The placebo without Super 13 Pro \& Prebiotics was given three times a day for four weeks."
62286078|NCT05918380|OTHER|Low CVD risk|PAL2
62286079|NCT05918380|OTHER|High CVD risk|Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA)
62286080|NCT05242692|EXPERIMENTAL|S-ketamine|S-ketamine (50 mg, 2 ml) is diluted to 50 ml (1 mg/ml) with 48 ml normal saline;
62286081|NCT05242692|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine (200 ug, 2 ml) is diluted to 100 ml (2 ug/ml) with 98 ml normal saline;
62652201|NCT05856968|ACTIVE_COMPARATOR|continuous subcutaneous tissue closure|continuous subcutaneous tissue closure
62652202|NCT05856968|ACTIVE_COMPARATOR|Interrupted subcutaneous tissue closure|Interrupted subcutaneous tissue closure
62652203|NCT01300403|EXPERIMENTAL|FLUTTER|Since this was a crossover study, all patients performed all interventions in a randomized order.
62652204|NCT01300403|EXPERIMENTAL|ELTGOL|Since this was a crossover study, all patients performed all interventions in a randomized order.
62652205|NCT01300403|ACTIVE_COMPARATOR|CONTROL|Since this was a crossover study, all patients performed all interventions in a randomized order.
62652206|NCT02323074|EXPERIMENTAL|fBCI-robot|focalized BCI-robot hand training
62652207|NCT02323074|EXPERIMENTAL|gBCI-robot|generalized BCI-robot hand training
61904194|NCT04592718|NO_INTERVENTION|Control|Participants in this group will serve as a control and will not do any breathing exercises or breath counting.
62087250|NCT02187822|EXPERIMENTAL|Dose Escalation + Dose Expansion|"Dose Escalation followed by Dose Expansion.~Dose Escalation Phase: The maximum tolerated dose (MTD) for TPI 287 given concurrently with Fractionated Stereotactic Radiotherapy (FSRT) will be determined using the standard 3+3 study design.~Dose Expansion Phase: Participants will be treated with TPI 287 at MTD given concurrently with FSRT to further assess toxicity and tumor response."
62286082|NCT05242692|PLACEBO_COMPARATOR|Normal saline|Control group only contains 50 ml normal saline in light of blindness
62286083|NCT01551693|EXPERIMENTAL|STA-9090 Cohort A|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
62286084|NCT01551693|EXPERIMENTAL|STA-9090 Cohort B|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort B patients received STA-9090 150 mg/m2 twice weekly (d1, 4, 8, 11, 15, 18 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
62286085|NCT00818259|EXPERIMENTAL|Part IA-fosaprepitant 115 mg/aprepitant|Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
62286086|NCT00818259|EXPERIMENTAL|Part IB-fosaprepitant 150 mg|Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
62286087|NCT00818259|EXPERIMENTAL|Part IIA-aprepitant 80 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to \<12 years of age - 47 mg/m\^2; 4 months to \<6 months of age - 2.0 mg/kg; 1 month to \<4 months of age - 1.0 mg/kg; birth to \<1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
62286088|NCT00818259|EXPERIMENTAL|Part IIB-aprepitant 125 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to \<12 years of age - 74 mg/m\^2; 6 months to \<2 years of age - 1.3 mg/kg; 4 months to \<6 months of age - 3.0 mg/kg; 1 month to \<4 months of age - 1.5 mg/kg; birth to \<1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
62286089|NCT00818259|ACTIVE_COMPARATOR|Part III-ondansetron|Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to \<12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.
62286090|NCT00818259|EXPERIMENTAL|Part IV-aprepitant regimen|Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to \<12 years of age - 3.0 mg/kg; 1 month to \<4 months of age - 1.5 mg/kg; Birth to \<1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to \<12 years of age - 2.0 mg/kg; 1 month to \<4 months of age - 1.0 mg/kg; Birth to \<1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.
62286091|NCT00818259|EXPERIMENTAL|Part V-fosaprepitant regimen|Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to \<12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
62286092|NCT00927641|ACTIVE_COMPARATOR|Ketoprofen Patch (HKT-500)|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
62286093|NCT00927641|PLACEBO_COMPARATOR|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
61904195|NCT03049241||knee extensors|
61904196|NCT03049241||ankle plantar|
61904197|NCT00294619|EXPERIMENTAL|LB03002|
61904198|NCT00294619|PLACEBO_COMPARATOR|Placebo|
61904199|NCT00096356|ACTIVE_COMPARATOR|Arm 1 - CoQ10 & Vitamin E|CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.
61904200|NCT00096356|PLACEBO_COMPARATOR|Arm 2 - Placebo & Vitamin E|Placebo-Vitamin E 100 mg/day in 3 doses
61904201|NCT06293976|EXPERIMENTAL|Patients under mechanical ventilation|Patients intubated for more than 12 hours, on assist-control ventilation, not triggering the ventilator with or without reverse triggering, exposed to sedation for at least 6 hours, with a sedation-agitation score ≤ 4.
61904202|NCT02852187|ACTIVE_COMPARATOR|MOBIS PEEK|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS PEEK Cage
62087251|NCT00625274|EXPERIMENTAL|1|Oral
62087252|NCT00625274|EXPERIMENTAL|2|Oral
62286094|NCT03720457|EXPERIMENTAL|Human CD19 targeted T Cells Injection|
62286095|NCT05585749|EXPERIMENTAL|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
62652208|NCT02323074|SHAM_COMPARATOR|sham-BCI|Sham BCI
61904203|NCT02852187|ACTIVE_COMPARATOR|MOBIS II ST|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS II ST Cage
61904204|NCT02888496||PMR patients|Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
61904205|NCT02888496||Healthy controls|Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease
61904206|NCT04207541|EXPERIMENTAL|Control group and Intervention group|For control group, participants will be treated with usual care. For intervention group, participants will be provided a session of education regarding insulin initiation with brief motivation interviewing.
62087253|NCT00625274|EXPERIMENTAL|3|Oral
62087254|NCT00218985|EXPERIMENTAL|exercise training|
62087255|NCT00218985|NO_INTERVENTION|physician's advice|patients follow their physician's advice in regard to physical activity.
62087256|NCT00052559|EXPERIMENTAL|Treatment (bevacizumab, fluorouracil, radiation therapy)|"Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery 7 weeks after completion of chemoradiotherapy.~Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD."
62286096|NCT05585749|NO_INTERVENTION|Control group|Routine maintenance will be applied.
62652209|NCT05689437||ILD Silent Mode|The ILD model will be run on patients undergoing routine treatment planning imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
62652210|NCT05689437||ILD Prospective Mode|Following successful silent mode, the ILD model will be run on patients undergoing routine treatment planning imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
62286097|NCT04206826|EXPERIMENTAL|PREDELFI Film|
62286098|NCT04206826|PLACEBO_COMPARATOR|CONTROL Film|
62286099|NCT04915287|EXPERIMENTAL|Avatrombopag|Oral administration of Avatrombopag Maleate Tablets to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whose mean baseline platelet count is less than 50 × 10\^9/L. RhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc., are prohibited during the trial.
62286100|NCT04915287|EXPERIMENTAL|Conventional treatment|Conventional treatment (platelet transfusion if needed or rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.) to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whoes mean baseline platelet count is less than 50 × 10\^9/L.
62652211|NCT05689437||SGR Silent Mode|The SGR model will be run on patients undergoing routine treatment planning imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
62286101|NCT02059876|EXPERIMENTAL|carboplatin and paclitaxel ± trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer.
62286102|NCT02269722|EXPERIMENTAL|Short Clamp time|Radial clamp applied at full pressure for 20 minutes. At the end of 20 minutes, the clamp will be loosened ¼ turn every 5 minutes over 20 minutes and then removed.
62286103|NCT02269722|EXPERIMENTAL|Long Clamp Time|Radial clamp applied at full pressure for 60 minutes. At the end of 60 minutes, the clamp is to be loosened and removed under the same instruction as those patients in arm one.
62286104|NCT02953717|ACTIVE_COMPARATOR|Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery
62286105|NCT02953717|ACTIVE_COMPARATOR|Whole Brain Radiation Therapy (WBRT)|Whole Brain Radiation Therapy
62652212|NCT05689437||SGR Prospective Mode|Following successful silent mode, the SGR model will be run on patients undergoing routine treatment planning imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
62652213|NCT05689437||CBCT Silent Mode|The CBCT model will be run on patients receiving routine on-treatment imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
62652214|NCT05689437||CBCT Prospective Mode|Following successful silent mode, The CBCT model will be run on patients receiving routine on-treatment imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
62652215|NCT01985178|EXPERIMENTAL|Omega-3 Fatty Acid Supplement|
62652216|NCT04259333|EXPERIMENTAL|Test Arm|celecoxib 200 mg tablet by mouth every 12 hours for 7 days postoperatively prn pain
61904213|NCT01606865||elective and acute non-cardiac surgery|
62087257|NCT04114396||Severe asthma|Untreated by anti-IL5 treatment for severe asthma at point of recruitment. To be prescribed anti-IL5 as part of their treatment following consent. Note: Anti-IL5 treatment is prescribed as per agreed multidisciplinary team meeting, outside of the decision to enrol the patient on the study, and is administered by the clinical team as part of the patient's clinical care outside of the research study.
62087258|NCT04114396||Healthy control|Control group without respiratory condition
62087259|NCT05080621|EXPERIMENTAL|Escalation|"Escalation Phase: Increasing doses of ripretinib in combination with increase doses of binimetinib in patients with advanced GIST who have progressed on at least imatinib or are intolerant to imatinib and are ripretinib naïve in repeated 28-day cycles.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
62087260|NCT05080621|EXPERIMENTAL|Expansion|"Ripretinib in combination with binimetinib at the recommended Phase 2 dose (RP2D) in patients with advanced GIST who have progressed on imatinib or are intolerant to imatinib and are naïve.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
62087261|NCT02355704|ACTIVE_COMPARATOR|Atorvastatin|22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
62087262|NCT02355704|PLACEBO_COMPARATOR|Placebo|22 patients received oral placebo 40 mg 1 time for day for 4 weeks
62286106|NCT03692416|ACTIVE_COMPARATOR|Ibuprofen|"Patients in this group will receive:~Ibuprofen~* Oral~* At a dosage of 30 to 40 mg/kg/day, divided into 3 or 4 doses/day, max 2400 mg/day, given with food, in the form of suspension or tablets.~* Duration of therapy: 4 - 6 weeks."
62286107|NCT03692416|ACTIVE_COMPARATOR|Prednisone Oral or Methylprednisolone IV|"Steroids:~1. Pednisone (for mild/moderate cases):~   * Oral~  * Single daily morning dosage of 0.05-2.0 mg/kg/day, or in 2 - 4 divided doses, max 80 mg/d.~  * Duration: 4 - 6 weeks, with gradual tapering to the lowest effective dose.~2. Methylprednisolone (for severe/acute cases):~   * IV~  * 10-30 mg/kg/dose (max 1 g), over 1 hr daily for 1-5 days, followed by oral prednisone, with gradual tapering to the lowest effective dose.~  * The duration is variable according to the condition of the patient."
62286108|NCT03692416|ACTIVE_COMPARATOR|Methotrexate|"Patients in this group will receive:~Methotrexate~* Oral~* At a dosage of 10 to 20 mg/m2/wk (0.35 to 0.65 mg/kg/wk), max dose 25 mg/wk.~* Duration of therapy: 6 - 12 weeks."
62286109|NCT01290887|EXPERIMENTAL|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.
62286110|NCT04275713|EXPERIMENTAL|Standard Chemoradiotherapy +/- metformin|Metformin will be given orally at doses of 850 mg twice a day. Metformin will be started one week prior to the start of standard cisplatin-based chemoradiotherapy, and will be continued throughout the entire radiation treatment
62286111|NCT04275713|ACTIVE_COMPARATOR|Standard chemoradiotherapy|"Standard chemoradiotherapy is given as a combination of EBRT and IGT:~* 45 Gy in 1.8 Gy/fraction to the pelvis/abdomen, 5 fractions/week~* 55-57.5 Gy in 2.2-2.3 Gy/fraction to pathological lymph nodes as a simultaneously integrated boost (SIB)~* 4 fractions of brachytherapy, 7.8 Gy/fraction, to the cervix~* Concomitant Cisplatin weekly during the external beam radiotherapy (EBRT)"
62286112|NCT04673097|EXPERIMENTAL|Group 1|
62286113|NCT04673097|ACTIVE_COMPARATOR|Group 2|
62286114|NCT04673097|ACTIVE_COMPARATOR|Group 3|
62087263|NCT02682017|PLACEBO_COMPARATOR|Treatment 1|Pork meat from pigs feed with a standard feed
62087264|NCT02682017|EXPERIMENTAL|Treatment 2|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
62087265|NCT04658719|EXPERIMENTAL|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
62087266|NCT04658719|ACTIVE_COMPARATOR|Standard Care|Foley catheter, uncoated
62087267|NCT04340674|EXPERIMENTAL|Telerehabilitation based on aerobic exercise|Aerobic low-impact exercise guided by audiovisual material. The intensity of exercise is adapted to each participant and is established according to the perceived effort after each session, according to the modified Borg perceived effort scale.
62087268|NCT04340674|NO_INTERVENTION|Control group|Group that maintain the same medical treatment and not receive additional intervention.
62286115|NCT04230447||sepsis associated encephalopathy (SAE)|This study is an observational study without drug and other interventions The SAE was defined as the Glasgow Coma Scale (GCS) score of less than 15
62286116|NCT04230447||Non-SAE|This study is an observational study without drug and other interventions Non-SAE group GCS = 15
62286117|NCT04230447||Control|This study is an observational study without drug and other interventions The control group was the emergency department patients with acute disease strikes, including heart attack, infraction, and healthy control.
62286118|NCT02704598|ACTIVE_COMPARATOR|Rivaroxaban|Patients with deep venous thrombosis using Rivaroxaban for 6 months, and then will be evaluated with DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
62652217|NCT04259333|ACTIVE_COMPARATOR|Control Arm|codeine 30mg-acetaminophen 300mg-caffeine 15 mg tabelt by mouth every 4 hours for 7 days postoperatively prn pain
62652218|NCT01398241|EXPERIMENTAL|Active|
62652219|NCT01398241|PLACEBO_COMPARATOR|Placebo|
62087269|NCT06028256|EXPERIMENTAL|Norepinephrine|The interventional group will receive a continuous infusion of norepinephrine 5 minutes (0.01μg/kg\*min) before anesthesia induction until skin incision.
62087270|NCT06028256|PLACEBO_COMPARATOR|Placebo|the placebo group will receive a continuous infusion of normal saline (10 ml/h) 5 minutes before anesthesia induction until skin incision.
62087271|NCT04576871|EXPERIMENTAL|Heavily Exposed|
62087272|NCT04576871|EXPERIMENTAL|Moderately Exposed|
62087273|NCT05556005|EXPERIMENTAL|Group 1|Patients will receive 35 mg of Trimetazidine modified release tablet twice daily in addition to their standard treatment for three months.
62087274|NCT05556005|PLACEBO_COMPARATOR|Group 2|Patients will receive Placebo tablet twice daily in addition to their standard treatment for three months.
62286119|NCT02704598|ACTIVE_COMPARATOR|Warfarin|Patients with deep venous thrombosis using Warfarin for 6 months, and then will be evaluated wiht DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
62286120|NCT00578357|EXPERIMENTAL|1|immediate intervention
62286121|NCT00578357|NO_INTERVENTION|2|note: participants in this arm will receive the intervention after the 6-month follow-up (serving as control during the trial)
62286122|NCT03329378|ACTIVE_COMPARATOR|ddACTHP|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Pegfilgrastim 6mg SC, day 2 of AC~Cycled every 14 days for 4 cycles, followed by, Paclitaxel 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15 Trastuzumab 8 mg/kg IV day 1, followed by 6mg/kg Pertuzumab loading dose 840 mg IV followed by 420 mg IV every 3 weeks~Cycled every 21 days for 4 cycles, followed by, Trastuzumab 6mg/kg every 21 days to complete 1 year"
62652220|NCT03427892|EXPERIMENTAL|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
62652221|NCT03200223|EXPERIMENTAL|Personalized lifestyle intervention group|Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician
62652222|NCT03200223|NO_INTERVENTION|Conventional group|Patients with conventional care
61904224|NCT00744302|EXPERIMENTAL|PCD|Physiological calcium (1.25 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
61904225|NCT00744302|ACTIVE_COMPARATOR|NCD|Normal calcium (1.5 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
61904226|NCT03816540|EXPERIMENTAL|FXTAS-affected|FXTAS-affected participants will receive HRV and respiratory coherence biofeedback training for 20 sessions.
62087275|NCT00955656||primary care providers|"Primary care providers who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors (ARIA#53054)"
62087276|NCT04501458|EXPERIMENTAL|Functional community health units|Community health units with active community health workers.
62087277|NCT04501458|NO_INTERVENTION|Non functional community health units|Community health units without active community health workers.
62087278|NCT04501458|EXPERIMENTAL|Health facilities with oxygen capacity|Health facility with regular oxygen capacity.
62087279|NCT04501458|NO_INTERVENTION|Health facilities without oxygen capacity|
61904227|NCT03816540|ACTIVE_COMPARATOR|FXTAS-unaffected|FXTAS-unaffected participants will be assessed to compare the effects of biofeedback based on FXTAS status. This arm will receive HRV and respiratory coherence biofeedback training for 20 sessions.
62087280|NCT01591395|ACTIVE_COMPARATOR|Multiport TEP|Adult inguinal hernia patients who randomized to receive multiport endoscopic TEP repair
62087281|NCT01591395|ACTIVE_COMPARATOR|LESS TEP|Adult inguinal hernia patients who randomized to receive laparoendoscopic single-site TEP repair
62087282|NCT00669695|PLACEBO_COMPARATOR|Stat/CPAP|Atorvastatin and CPAP treatments
62087283|NCT00669695|PLACEBO_COMPARATOR|Stat/sham CPAP|Atorvastatin and sham CPAP treatments
62087284|NCT00669695|SHAM_COMPARATOR|Placebo/CPAP|Placebo and CPAP treatments
62652223|NCT01653691|ACTIVE_COMPARATOR|Pulse Dye Laser, burn scars|A scar will be located on the study subject's torso or thigh and divided in half. Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side. Each side will be evaluated during outpatient visits. 12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
62652224|NCT01653691|SHAM_COMPARATOR|No treatment to half of scar|A scar on the child's torso or thigh will be divided in half. One side will receive laser treatment and the other half will receive laser or sham treatment.
62286123|NCT03329378|ACTIVE_COMPARATOR|TCHP|TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim ) institutional practice is to titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
62652225|NCT01543165|EXPERIMENTAL|Group 1|Sequential intravenous administration of ketorolac and nefopam
62652226|NCT01543165|ACTIVE_COMPARATOR|Group 2|Sequential intravenous administration of ketorolac and morphine
62652227|NCT01543165|PLACEBO_COMPARATOR|Group 3|Intravenous administration of ketorolac
62652228|NCT05029284|EXPERIMENTAL|teleABLE|Participants will complete 12 teleABLE sessions via videoconferencing, guided by an intervention therapist and participant workbook.
62652229|NCT00003858|EXPERIMENTAL|Mitoxantrone|Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 3 years, and then every 6 months for the next 3 years or until disease progression.
62652230|NCT00726453|EXPERIMENTAL|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
62652231|NCT00005676||VA-HIT and FOS|VA-HIT cohort: men with established CHD and low HDL-C FOS cohort: men without CHD
62652232|NCT04541121|EXPERIMENTAL|3D printed model|Mother is given 3D printed model of fetus' face
62652233|NCT04541121|PLACEBO_COMPARATOR|Placebo|Mother is given printed picture of 3D ultrasound of fetus
62652234|NCT03401957||RAS wild-type colorectal cancer|RAS mutation of patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be evaluated using liquid biopsy during cetuximab treatment.
62652235|NCT01273363||1|Male and female over 18. Patients with asthma diagnosed in accordance with the Global Initiative for Asthma within 6 months before inclusion into the study and without changes in treatment for 2 months before inclusion
61904236|NCT02631473|ACTIVE_COMPARATOR|1st Stage-Group A|"1. Day 1: 50 mg NANO-efavirenz single dose~2. Days 4-21: 50 mg NANO-efavirenz OD (once daily)"
61904237|NCT02631473|ACTIVE_COMPARATOR|1st Stage-Group B|"1. Days 1-7: 400mg NANO-lopinavir BID (twice daily)~2. Days 8-21: Wash-out period~3. Days: 22-28: 200mg NANO-lopinavir BID plus 100mg Ritonavir (Norvir) BID"
61904238|NCT02631473|ACTIVE_COMPARATOR|2nd Stage-Group A-Group 1-Dose level 1|"1. 21 Days: 300mg NANO-efavirenz OD~2. 4 weeks: Wash-out period~3. 21 days: 600mg Sustiva OD"
61904239|NCT02631473|ACTIVE_COMPARATOR|2nd Stage-Group A-Group 2-Dose level 2|"1. 21 Days: 200mg NANO-efavirenz OD~2. 4 weeks: Wash-out period~3. 21 days: 400mg Sustiva OD"
62286124|NCT00004160|EXPERIMENTAL|Dose 1 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
62286125|NCT00004160|EXPERIMENTAL|Dose 2 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
62652236|NCT02164617|EXPERIMENTAL|Wheelchair-bound Senior Elastic Band|Wheelchair-bound Senior Elastic Band (WSEB) exercise program has three phases: 1) warm-up: 6 movements to loosen up the body and elevate the energy for a safe transition to the next phase, 2) aerobic motions: 6 low-to-medium speed exercises to enhance the cardiovascular-respiratory workout, and 3) static stretching: 6 low-speed, gentle stretching exercises to build up muscle power/endurance and increase range of motion and flexibility. It is conducted three times per week, 40 minutes per practice.
62652237|NCT02164617|NO_INTERVENTION|control|routine care
62652238|NCT05853263|OTHER|morphine|Standard care, continuous morphine IV.
62652239|NCT05853263|ACTIVE_COMPARATOR|paracetamol|intervention group, intermittent paracetamol IV
62652240|NCT00730184|ACTIVE_COMPARATOR|1|Participants receive potassium bicarbonate in dosage of 90 mmol/d. This compound has no other name.
62652241|NCT00730184|PLACEBO_COMPARATOR|2|Participants receive placebo as microcrystalline cellulose. This compound has no other name.
62652242|NCT02141932|EXPERIMENTAL|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries and the heart. All participants will then be examined by reference imaging in specific ultrasound laboratories and when appropriate computer tomography or magnetic resonance imaging.
62652243|NCT03170310|EXPERIMENTAL|Apatinib|
62652244|NCT02171455|EXPERIMENTAL|Dabigatran etexilate low dose|
62652245|NCT02171455|EXPERIMENTAL|Dabigatran etexilate medium dose|
62652246|NCT02171455|EXPERIMENTAL|Dabigatran etexilate high dose|
62652247|NCT06491498||Group R in the right upper limb.|Group R (30) will receive 15 mL of 0.5% bupivacaine with dexametomidine by dose 1 μg / kg in the right upper limb.
62652248|NCT06491498||Groub L in the left upper limb.|Groub L (30) will receive 15 mL of 0.5% bupivacaine with dexametomidine by dose 1 μg / kg in the left upper limb.
62652249|NCT06314269||Perioperative cerebrovascular stroke patients|all Patients admitted to General surgery, cardiothorasic surgery and vascular surgery Depatments in assuit university hospitals during one year that will going to operation
62652250|NCT00942643|NO_INTERVENTION|no treatment|being observed at 4 weeks and 12 weeks
62652251|NCT00942643|ACTIVE_COMPARATOR|CPAP treatment|a machine delivers positive airway pressure into the upper airway via nasal mask
62652252|NCT03229603|OTHER|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
62652253|NCT00012909|OTHER|Arm 1|
62652254|NCT00424242|EXPERIMENTAL|Escalating doses of Pemetrexed|Escalating doses of Pemetrexed beginning at 500 mg/m2
62652255|NCT02349386|EXPERIMENTAL|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
62652256|NCT02349386|EXPERIMENTAL|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
62652257|NCT02349386|EXPERIMENTAL|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
62652258|NCT02349386|PLACEBO_COMPARATOR|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
62652259|NCT03101020|EXPERIMENTAL|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
62652260|NCT03101020|PLACEBO_COMPARATOR|Control Group|The participants will receive standard care physiotherapy plus placebo visceral manipulation
62652261|NCT05993104||Retrospective observational|Retrospective observational arm recruiting \>50 participants, utilising data already collected as part of standard clinical care.
62652262|NCT05993104||Prospective single-arm|Prospective single-arm recruiting 20 participants undergoing AcQMap guided ablation.
62652263|NCT05993104||Feasibility study|Feasibility study recruiting 10 participants.
62087285|NCT00669695|ACTIVE_COMPARATOR|Placebo/sham CPAP|Placebo and sham CPAP treatments
62087286|NCT02104856||Alair System (Bronchial Thermoplasty)|Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.
62652264|NCT02500251|EXPERIMENTAL|Group A (5 subjects)|Subjects will receive bortezomib and plasmapheresis.
62652265|NCT02500251|EXPERIMENTAL|Group B (5 subjects)|Subjects will receive belimumab, bortezomib, and plasmapheresis.
62652266|NCT02500251|EXPERIMENTAL|Group C (5 subjects)|Subjects will receive belimumab, bortezomib, rituximab, and plasmapheresis.
62652267|NCT02552940||Rheumatoid Arthritis participants treated with Tocilizumab SC|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
62652268|NCT04490408|ACTIVE_COMPARATOR|long surgical bypass|long surgical bypass for multilevel lower limb ischemia
62652269|NCT04490408|EXPERIMENTAL|Hybrid approach|surgical bypass and endovascular treatment for multilevel lower limb ischemia
62652270|NCT05807282|EXPERIMENTAL|Intervention group|40 farmworkers will be randomized to receive the workplace- and individual-level interventions developed in collaboration with study partners (e.g., provision of hydration packs to participants). Participants will receive the intervention at the workplace and will be monitored for five weeks after the intervention to evaluate the efficacy in reducing perceived and physiological heat stress.
62652271|NCT05807282|NO_INTERVENTION|Control group|40 farmworkers will be randomized to receive no intervention, and will continue their work as normal. These farmworkers will be monitored for the same period as the intervention group to assess perceived and physiological heat stress.
62652272|NCT05652777||Pregnant women|Pregnant women attending antenatal care clinic during routine community outreach activities in Lusaka, Zambia.
61904240|NCT02631473|ACTIVE_COMPARATOR|2nd Stage-Group B-Arm 1|"1. 7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD~2. 2 weeks: Wash-out period~3. 7 days: NANO-lopinavir (200mg +/- ritonavir®)"
61904241|NCT02631473|ACTIVE_COMPARATOR|2nd Stage-Group B-Arm 2|"1. 7 days: NANO-lopinavir (200mg +/- ritonavir Norvir)~2. 2 weeks: Wash-out period~3. 7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD"
61904242|NCT01865552|EXPERIMENTAL|SB4 and EU sourced Enbrel in Part A|SB4 followed by EU sourced Enbrel
61904243|NCT01865552|EXPERIMENTAL|EU sourced Enbrel and SB4 in Part A|EU sourced Enbrel followed by SB4
61904244|NCT01865552|EXPERIMENTAL|SB4 and US sourced Enbrel in Part B|SB4 followed by US sourced Enbrel
62087287|NCT04531150|EXPERIMENTAL|Cohort 1|Subjects will be randomized to receive either placebo or 20 mg INV-101
62087288|NCT04531150|EXPERIMENTAL|Cohort 2|Subjects will be randomized to receive either placebo or 80 mg INV-101
62652273|NCT05067855|EXPERIMENTAL|Pilates exercise program group|The pilates exercise program group will perform five exercises
62652274|NCT06144372|OTHER|Electroconductive Type|Sonolith i-move® shockwave lithotripter (EDAP, Lyon, France)
62652275|NCT06144372|OTHER|Electrohydraulic Type|Rifle lithotripter (HNT Medical, Seoul, Korea)
62652276|NCT01729195|EXPERIMENTAL|Single-arm|The syndesmosis injury of the patients will be fixed with a ciprofloxacin containing bioabsorbable PLGA bone screw or a stainless steel metal screw
62652277|NCT05359484|EXPERIMENTAL|detrusor underactivity|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.
62652278|NCT05359484|EXPERIMENTAL|bladder out flow obstruction|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.
62652279|NCT00300729|ACTIVE_COMPARATOR|Celecoxib|Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
62652280|NCT00300729|PLACEBO_COMPARATOR|Placebo|Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
62652281|NCT03980678|ACTIVE_COMPARATOR|Mineral Rich Algae with orange flavoring|Participants will consume the Aquamin Soluble (Mineral Rich Algae) equivalent of 1000mg Calcium in 250 ml of orange flavoured water.
62652282|NCT03980678|PLACEBO_COMPARATOR|Water with orange flavoring|Participants will consume a placebo of maltodextrin in 250 ml of orange flavoured water (40mg Calcium).
62087289|NCT04531150|EXPERIMENTAL|Cohort 3|Subjects will be randomized to receive either placebo or 160 mg INV-101
62087290|NCT04531150|EXPERIMENTAL|Cohort 4|Subjects will be randomized to receive either placebo or 320 mg INV-101
62087291|NCT04531150|EXPERIMENTAL|Cohort 5|Subjects will be randomized to receive either placebo or 500 mg INV-101
62087292|NCT03248440|EXPERIMENTAL|SUN-131 1.5% TDS|
62087293|NCT03248440|PLACEBO_COMPARATOR|Placebo TDS|
62460863|NCT03509103|EXPERIMENTAL|Electronic partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
62460864|NCT03509103|ACTIVE_COMPARATOR|Paper Partograph|An standard training on how to use and fill out partograph was conducted
62286126|NCT00004160|EXPERIMENTAL|Dose 3 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
62286127|NCT00004160|EXPERIMENTAL|Dose 4 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
62286128|NCT00004160|EXPERIMENTAL|Dose 5 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
62460865|NCT01449071|PLACEBO_COMPARATOR|Placebo Group|
62460866|NCT01449071|EXPERIMENTAL|Epratuzumab 600 mg Group|
62460867|NCT01449071|EXPERIMENTAL|Epratuzumab 100 mg Group|
62460868|NCT01449071|EXPERIMENTAL|Epratuzumab 400 mg Group|
62460869|NCT01449071|EXPERIMENTAL|Epratuzumab 1200 mg Group|
62460870|NCT03732443||Critical Ill Patients|Critically ill patients with a RASS ≥ 3. FAM-CAM and CAM-ICU will be administered.
62460871|NCT05287438|ACTIVE_COMPARATOR|Group A - Culture|Following local standard of care, treatment will be based on standard culture
62460872|NCT05287438|EXPERIMENTAL|Group B - NGS|Treatment will be based on NGS results reviewed by an infectious disease doctor
61904245|NCT01865552|EXPERIMENTAL|US sourced Enbrel and SB4 in Part B|US sourced Enbrel followed by SB4
62087294|NCT05410535|EXPERIMENTAL|Patients who received UDCA 600mg|Patients who participated in PEGASUS-D clinical trial and received UDCA 600mg
62460873|NCT04066166||Subjects|Healthy
62460874|NCT03317548||fresh embryo transfer|patients with fresh day 3 embryo transfer after oocyte pick up, the hormone including FSH, LH, E2 and progesterone was test before embryo transfer for analysis. The clinical outcomes including implantation and pregnancy were checked and recorded.
62460875|NCT03317548||frozen embryo transfer|"freeze-all embryo was performed after oocyte fertilization, the hormone including FSH, LH, E2 and progesterone was test before oocyte pick up and embryo transfer for analysis.~vitrification of pronuclear stage embryo (zygote) and frozen embryo transfer"
62460876|NCT03986177|EXPERIMENTAL|Intervention|The intervention arm will receive a multi-faceted self-management intervention package.
62460877|NCT03986177|NO_INTERVENTION|Enhanced care|The control arm will receive usual care plus basic asthma education from a trained nurse educator.
61904246|NCT01865552|OTHER|EU and US sourced Enbrel in Part C|EU sourced Enbrel followed by US sourced Enbrel
62286129|NCT05636631||Patients with Pneumonia (1)|Patients presented with symptoms suggestive of pneumonia as fever, tachypnea, cough with sputum. These patients will receive IV fluids \& antibiotics with follow up of sepsis parameters
62460878|NCT04643938||Two spontaneous abortions|No intervention
62460879|NCT04643938||three spontaneous abortions|No intervention
62460880|NCT04643938||Four or more spontaneous abortions|No intervention
62460881|NCT03836066|EXPERIMENTAL|Experimental: Atezolizumab plus Bevacizumab arm|1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.
62460882|NCT03500861|EXPERIMENTAL|Dry Needling|While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.
62460883|NCT03500861|SHAM_COMPARATOR|Sham Dry Needling|In the Sham Dry Needling (SDN) group, three times a week for 2 weeks, the SDN procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
62460884|NCT02808065||Tacrolimus + Mycophenolate mofetil|
62460885|NCT02262377|EXPERIMENTAL|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
62460886|NCT02262377|NO_INTERVENTION|Standard of Care|primary care visits, which include medications and advice
62460887|NCT03079271|OTHER|open label|
62460888|NCT03029936||Obesity Group|
62460889|NCT03029936||Asthma Group|
61904247|NCT01865552|OTHER|US and EU sourced Enbrel in Part C|US sourced Enbrel followed by EU sourced Enbrel
62087295|NCT05410535|EXPERIMENTAL|Patients who received UDCA 300mg|Patients who participated in PEGASUS-D clinical trial and received UDCA 300mg
62460890|NCT03029936||Obesity-Asthma Group|
62460891|NCT03029936||Control|
62652283|NCT06173284|EXPERIMENTAL|611|Induction treatment period : subcutaneous injection, 611 600mg (loading dose, week 0) + 300mg Q2W (from Week 2 to Week 14, 7 cycles) Maintenance treatment period : subcutaneous injection, 611 300mg Q2W or Q4W
61904250|NCT02771496||Patients with OCD|Patients with diagnosis of OCD as confirmed by x-ray or MRI. Surveys collected from patients at 2 years, 5 years, 10 years, and 25 years.
62286130|NCT05636631||Patients with decongestive heart failure (2)|Patients presented with symptoms suggestive of acute congestive heart failure as dyspnea, orthopnea, bilateral lower limb edema. These patients will receive anti-failure treatment as diuretics, ACE inhibitors \& Beta blockers with follow up of resolving signs of decompensated heart failure
62286131|NCT06091839|ACTIVE_COMPARATOR|anchor technique|In the anchor technique , the suture was secured first at the heel region after entering the artery and the vein in an inside-out fashion, and a surgical knot was tied, after which the suture was run continuously across the lateral margins of anastomosis, entering the vein outside-in and the artery inside-out, from heel (proximal end of arteriotomy) to toe (distal end). Then the suture was run to complete suturing the medial margins from heel to toe, entering the artery outside-in and the vein inside-out, and final knots were taken.
62460892|NCT01474564||Pts with Pancreatic Adenocarcinoma|This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
62460893|NCT04744909|EXPERIMENTAL|Percutaneous tracheotomy using a new device|
62460894|NCT01563965|ACTIVE_COMPARATOR|Conventional preoperative fast|Patients underwent surgery after 8h fast
62460895|NCT01563965|EXPERIMENTAL|Carbohydrate plus protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil).All the patients fasted for solids at least 8 hours from the operation
62652284|NCT06173284|PLACEBO_COMPARATOR|Placebo|Induction treatment period : subcutaneous injection, placebo Q2W (from Week 0 to Week 14, 7 cycles) Maintenance treatment period : subcutaneous injection, 611 600mg (loading dose, week 16) + 300mg Q2W or Q4W
62652285|NCT05545917|EXPERIMENTAL|APP care|The experimental arm will receive advanced practice physiotherapy care.
62652286|NCT05545917|ACTIVE_COMPARATOR|Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician.
62652287|NCT03055936|EXPERIMENTAL|A1|levodopa 50 mg, carbidopa 12.5 mg
61904251|NCT04411563||Group I-Mild|The patients who have these mild symptoms are low-grade fever (not more than 38 degrees celsius), dry cough, fatigue, sore throat, headache, the new loss of taste, and smell. Patients with normal or mild pneumonia findings of radiological imaging and blood lymphocyte count ≥800 / µl and serum CRP≤40 mg /l, ferritin ≤500ng/ml, D-Dimer ≤1000 ng/ml will be included in group I.
61904252|NCT04411563||Group II-Moderate|The patients who have these moderate symptoms are fever of about 38,5-39 degrees celsius, chills, deep cough, fatigue and body aches, muscle pain, the general feeling of being unwell. Patients with bilateral diffuse pneumonia findings of radiological imaging or blood lymphocyte count \<800 / µl or serum CRP\> 40 mg / l or ferritin\> 500ng / ml or D-Dimer\> 1000 ng / ml will be included in group II.
61904253|NCT04411563||Group III-Severe|The patients who have these severe symptoms are all the common symptoms mentioned above along with shortness of breath, chest discomfort, confusion/unresponsiveness, bluish face/lips, possible gastrointestinal issues, like diarrhea or nausea. Patients with ICU (intensive care unit) admission criteria, such as confusion or tachycardia (\> 125 / min) or respiratory distress or tachypnea (\> 22 / min) or hypotension \<90/60 mmHg or SPO2 \<93%will be included in group III. Also, patients with the central nervous system and heart involvement will be directly included in the severe case group
61904254|NCT03425474|EXPERIMENTAL|Remimazolam Tosilate|Remimazolam Tosilate at 5mg for initial dose
61904255|NCT03425474|ACTIVE_COMPARATOR|Propofol|Propofol at 1.5mg/kg for initial dose
61904256|NCT04305067|EXPERIMENTAL|Supervised aerobic and resistance exercise|16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
61904257|NCT05750199|EXPERIMENTAL|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
61904258|NCT05750199|EXPERIMENTAL|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course.
62087296|NCT05410535|PLACEBO_COMPARATOR|Patients who received Placebo|Patients who participated in PEGASUS-D clinical trial and received Placebo
62087297|NCT01492517|SHAM_COMPARATOR|Clean air exposure|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to clean air for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC.
62652288|NCT03055936|EXPERIMENTAL|B1|levodopa 50 mg, carbidopa 65 mg
62652289|NCT03055936|EXPERIMENTAL|C1|levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg
62652290|NCT03055936|EXPERIMENTAL|D1|levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
62652291|NCT03055936|EXPERIMENTAL|A2|levodopa 100 mg, carbidopa 25 mg
62087298|NCT01492517|OTHER|Ozone exposure|Exposure to 0.3ppm ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
62087299|NCT01492517|OTHER|Diesel exhaust exposure|Exposure to diesel exhaust will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to diesel exhaust (up to 300 ug/m3). Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. The DE will be generated from a diesel generator used to power a load bank that is located outside the Human Studies Facility, and subsequently introduced into the exposure chamber after different dilutions with clean HEPA and charcoal filtered and humidified air to give a chamber concentration of up to 300 μg/m3.
62087300|NCT01492517|OTHER|18Ozone|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O). Exposure to 0.3ppm 18O will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
62087301|NCT05830461|EXPERIMENTAL|Experimental group|The experimental group will receive the self-applied intervention through a digital platform. The intervention consists of three stages, depending on the situation of the patient: 1) Patients who undergo screening and obtain negative results for malignancy, 2) patients with suspicion and undergo a biopsy, 3) Patients with positive results for breast cancer.
62087302|NCT05830461|ACTIVE_COMPARATOR|Control group|The experimental group will receive the self-applied intervention through written visual material that will be given to them. The content of the material will be the same as the experimental group.
62087303|NCT05551962|ACTIVE_COMPARATOR|First group|The patients undergo implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuber region on the maxilla or palate.
62087304|NCT05551962|EXPERIMENTAL|Second group|"The patients undergo implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibro-Gide"
62087305|NCT00372528|EXPERIMENTAL|pregabalin|open label treatment
62087306|NCT01332240|EXPERIMENTAL|Endosonography|Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
62087307|NCT00965484|EXPERIMENTAL|Genotropin pen|All subjects will receive genotropin pen to use for 2 months.
62087308|NCT02819479|EXPERIMENTAL|Low-dose Intra-arterial Bevacizumab|A single intra-arterial targeted dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
62087309|NCT03479060|ACTIVE_COMPARATOR|Continue WCT Application|From the 3rd month to the 12th month Wet cupping applied as an intervention MIDAS was applied at the end of the 6th and 12th months.
62087310|NCT03479060|NO_INTERVENTION|Discontinue WCT Application|No intervention in this arm.Only MIDAS applied
62087311|NCT01448174|ACTIVE_COMPARATOR|atorvastatin|"The prospective, randomized, double-blind, placebo-controlled study:~* will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)~* 130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.~Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).~The prospective, observational study:~- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia"
62460896|NCT04784598|EXPERIMENTAL|Experimental group|Group 1- The intervention group I will receive a customized strip slipper with a 3mm EVA horseshoe piece (Shore A 32). And 2.5mm EVA cover (Shore A 28).
62460897|NCT04784598|SHAM_COMPARATOR|Sham group|Group 2- The control group will receive a slipper with a 2.5mm EVA cover (Shore A 32) identical to the one used by the intervention group, but without corrective par
62652292|NCT03055936|EXPERIMENTAL|B2|levodopa 100 mg, carbidopa 65 mg
62652293|NCT03055936|EXPERIMENTAL|C2|levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg
62652294|NCT03055936|EXPERIMENTAL|D2|levodopa 100 mg, carbidopa 37,5 mg
62652295|NCT03055936|EXPERIMENTAL|A3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
62652296|NCT03055936|EXPERIMENTAL|B3|levodopa 150 mg, carbidopa 65 mg
62652297|NCT03055936|EXPERIMENTAL|C3|levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg
62652298|NCT03055936|EXPERIMENTAL|D3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
62652299|NCT03055936|EXPERIMENTAL|A4|levodopa IR 100 mg (Sinemet), carbidopa 25 mg
62652300|NCT03055936|EXPERIMENTAL|B4|levodopa 100 mg, carbidopa 65 mg
62652301|NCT03055936|EXPERIMENTAL|C4|levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg
62652302|NCT03055936|EXPERIMENTAL|D4|levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
62286132|NCT06091839|ACTIVE_COMPARATOR|parachute technique|In the parachute technique, suture was first secured at 11 o'clock position entering both vessels in an inside-out fashion, then continuous suturing was commenced towards 5 o'clock position across the heel, entering the vein outside-in and the artery inside-out, without approximating the vessels. Then, gentle traction was applied on the sutures to allow even distribution of tension along the suture-line and 'parachuting' or approximation of vessel walls together. The suture was then run in a continuous fashion across the proximal margin (toward surgeon) and across the toe region, and finally, surgical knots were applied at midway on the distal margin.
62460898|NCT05627141|EXPERIMENTAL|Photobiomodulation|10 participants will receive active photobiomodulation immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session
62460899|NCT05627141|SHAM_COMPARATOR|Sham Photobiomodulation|10 participants will receive sham photobiomodulation immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session
62286133|NCT03142698|EXPERIMENTAL|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
62286134|NCT04535219|EXPERIMENTAL|Group A|Participants will have vascular function assessed following total sleep deprivation
62460900|NCT05627141|EXPERIMENTAL|Active Cryotherapy|10 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression on the lower limbs, or sham (25°C for 20 min) damage and fatigue induction protocol. muscle.
62460901|NCT05627141|SHAM_COMPARATOR|Sham Cryotherapy|10 participants will receive sham cryotherapy (25°C for 20 min) combined with light compression on the lower limbs immediately after the damage and fatigue induction protocol. muscle.
62460902|NCT05627141|EXPERIMENTAL|Massage|10 participants will receive the effective massage immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session.
62460903|NCT05627141|SHAM_COMPARATOR|Sham Massage|10 participants will receive the sham massage immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session.
62460904|NCT03559023|ACTIVE_COMPARATOR|Ultrasound Only|Ultrasound assisted epidural placement
62460905|NCT03559023|ACTIVE_COMPARATOR|Manometry Only|Manometry confirmation in epidural placement
62460906|NCT03559023|ACTIVE_COMPARATOR|Ultrasound Plus Manometry|Ultrasound Plus Manometry confirmation in epidural placement
62460907|NCT03559023|SHAM_COMPARATOR|Usual Care/Management|Usual epidural technique placement
62460908|NCT00359164|ACTIVE_COMPARATOR|1|Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.
62460909|NCT00359164|ACTIVE_COMPARATOR|2|Bevacizumab with verteporfin at Very Low Photodynamic Therapy.
62652303|NCT03607318|EXPERIMENTAL|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
62286135|NCT04535219|NO_INTERVENTION|Group B|Participants will have vascular function assessed following a full night of sleep
62286136|NCT04535219|EXPERIMENTAL|Group C|Participants will have vascular function assessed following total sleep deprivation preceded by exercise
62286137|NCT04535219|NO_INTERVENTION|Group D|Participants will have vascular function assessed following a full night of sleep
62286138|NCT06230354|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection
62286139|NCT06230354|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection
62286140|NCT06040294|EXPERIMENTAL|dementia and disability simulation program (DDS)|DDS program consists of dementia virtual reality and disability simulation of activity design for seniors
62286141|NCT06040294|ACTIVE_COMPARATOR|dementia course with no DDS|Regular dementia course and group discussions of activity design for seniors with no DDS
62286142|NCT05973136|EXPERIMENTAL|Intervention group|Group of participant receiving the hybrid telerehabilitation intervention
62286143|NCT00455117|PLACEBO_COMPARATOR|1|placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
62286144|NCT00455117|ACTIVE_COMPARATOR|2|parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy
62460910|NCT00359164|SHAM_COMPARATOR|3|Bevacizumab with verteporfin with Sham Photodynamic Therapy.
62460911|NCT01460797|OTHER|High Glycemic Index|Hypocaloric diet with predominating high glycemic index foods
62460912|NCT01460797|OTHER|Low Glycemic Index|Hypocaloric diet with predominant low glycemic index foods
62460913|NCT01460797|OTHER|Low Glycemic Index plus Metformin|Hypocaloric diet with predominant low glycemic index foods plus Metformin (1g/d)
62460914|NCT02598479||IPTLD and nutrition therapy|Patients presenting to the Arizona Center for Advanced Medicine for the treatment of cancer using Insulin Potentiation Low Dose Chemotherapy and Nutrition Therapy
62460915|NCT04170309||With medical condition of interest|"Participants treated with ceftobiprole with at least one of the following conditions:~* Renal Insufficiency~* Hepatic Insufficiency~* Immunosuppression"
62460916|NCT04170309||Without medical condition of interest|"Patients treated with ceftobiprole without any of the following conditions:~* Renal Insufficiency~* Hepatic Insufficiency~* Immunosuppression"
62460917|NCT03804359|NO_INTERVENTION|GEMRITUX protocol|6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains \> 3.5 g/g and albuminemia \< 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.
62652304|NCT03607318|ACTIVE_COMPARATOR|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
62652305|NCT04934358|EXPERIMENTAL|Physical activity program and motivational intervention|Physical activity program agreed with the patient / family and according to functional status (based on the 6-minute walk test) and motivational intervention. In addition to the care provided in usual care, a progressive physical exercise program based on basal functional capacity is prescribed. The exercise will be developed at home.
62087312|NCT01448174|NO_INTERVENTION|Lifestyle counseling|"Protocol of the prospective study in obese persons:~* after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity~* follow-up for 30 weeks (measurement of body weight every week)."
62286145|NCT02926703||GTCS patients|Patients with generalized tonic-clonic seizures (GTCS) and whose serum lactate and creatine kinase (CK) concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers
62286146|NCT02926703||Syncope patients|Patients with syncope and whose serum lactate and CK concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers.
62286147|NCT03201055|EXPERIMENTAL|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
62286148|NCT04934930|EXPERIMENTAL|Reduced number of bendamustine cycles in patients with mid-induction MRD negativity|Patients with follicular lymphoma treated with obinutuzumab bendamustine \& achieving MRD negativity as well as complete metabolic response on PET-CT at mid-induction would continue obinutuzumab treatment while omitting bendamustin after 4 cycles.
62460918|NCT03804359|EXPERIMENTAL|Personalized treatment|"* restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)~* restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains \> 3.5 g/g and albuminemia \< 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;~* Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains \> 3.5 g/g and albuminemia \< 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6."
62652306|NCT04934358|ACTIVE_COMPARATOR|Treatment as usual|Multidisciplinary rehabilitation provided by professionals in the hospital and primary care settings, according to the individual needs of patients at different times of their recovery and the accessibility and availability of services in the different care settings.
62652307|NCT00419705|EXPERIMENTAL|Transcranial Laser Therapy|
62652308|NCT00419705|SHAM_COMPARATOR|Sham control procedure|
62652309|NCT01540617||Persons with low back pain|
62286149|NCT02111733|EXPERIMENTAL|Hs-TnT|Hs-TNT dosage
62286150|NCT06439420|EXPERIMENTAL|Telehealth Cognitive Behavioral Therapy for Insomnia|
62286151|NCT06439420|NO_INTERVENTION|Enhanced Treatment as Usual|
62286152|NCT06395493|EXPERIMENTAL|Pilates Intervention Group|The Pilates intervention group will consist of a twice weekly sessions for a duration of 1 hour each for a period of 12 weeks. These sessions will be conducted at the Physiotherapy Department at St Luke's Hospital and the physiotherapist, who is the main researcher will be leading the Pilates sessions.
62286153|NCT06395493|EXPERIMENTAL|Exercise Intervention Group|The exercise group will also receive a twice weekly session, each lasting 1 hour for a duration of 12 weeks. This group will be assigned general exercises for the low back, which will also be supervised and directed by the primary researcher.
62087313|NCT01448174|NO_INTERVENTION|The controls (healthy volunteers)|
62087314|NCT03548545|EXPERIMENTAL|CBT combined with active tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with active tDCS over the dorsolateral prefrontal cortex.
62087315|NCT03548545|SHAM_COMPARATOR|CBT combined with sham tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with sham tDCS over the dorsolateral prefrontal cortex.
62460919|NCT04539197||IgG4-RD group|300 IgG4-RD were enrolled and followed up for more than 6 months. Peripheral blood of all patients were collected at baseline, disease remission and relpase for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline, each follow up were collected.
62087316|NCT03174093|EXPERIMENTAL|MATCh AFib|Participants assigned to the intervention group will have the support of the MATCh AFib application during the consultations with their physician and receive individual text messaging targeting knowledge about atrial fibrillation, medication adherence and monitoring during months 1-3.
62286154|NCT06395493|EXPERIMENTAL|Control Group|The control group, on the other hand will include patients who either opt not to do the exercises or are on the waiting list for physiotherapy treatment. However, after completing the 12 weeks of no intervention, they will be asked whether they would like to receive physiotherapy treatment.
62286155|NCT05666557|EXPERIMENTAL|manual erector spinae myofascial realease|Myofascial release is performed by a therapist. The patient prone and using two pillows, one on the head and the other under the abdomen, flexing the lumbar spine maximally under the abdomen with the erector spinae in extension. The therapist will then perform 3 sets of 15 reps with a 1-minute rest between sets with myofascial loosening using standard massage techniques.
62286156|NCT05666557|EXPERIMENTAL|self-myofascial release technique|Use a roller (roller) to release fascia. The subject stand beside the wall and roll back and forth 15 times as a group, rest for one minute in between, and do a total of 3 groups.
62286157|NCT00045032|NO_INTERVENTION|Observation Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
62286158|NCT00045032|EXPERIMENTAL|Herceptin 1-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
62460920|NCT04539197||other autoimmune disease group|200 patients( RA, SLE, pSS, BD, et al) were enrolled in this study. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
62460921|NCT04539197||IgG4-RD mimicker group|60 IgG4-RD mimickers (pancreatic cancer, cholangiocarcinoma, vasculitis, lymphoproliferative diseases, inflammatory bowel disease, kimura disease) were collected. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
62087317|NCT03174093|NO_INTERVENTION|Standard Care|Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment, INR monitoring and consultations with their physician without mHealth support)
62087318|NCT05293535||Klotho|"Evaluate the expression of Klotho in gastric adenocarcinoma via immunohistochemistry, find the association between the expression of Klotho in gastric adenocarcinoma and demographic patient data, and clinicopathologic parameters of the patients and investigate the effect of Klotho expression on the prognosis of gastric adenocarcinoma.~Correlate between the Klotho and LRP-6 protein expression."
62460922|NCT04539197||healthy control group|100 healthy controls were collected. Peripheral blood of healthy controls were collected at baseline for plasmablast/plasma cells detection. Demographic features of healthy controls were collected.
62652310|NCT01540617||Healthy persons|
62652311|NCT05817123||OSAS patients|Patients with Obstructive Sleep Apnea Syndrome
62286159|NCT00045032|EXPERIMENTAL|Herceptin 2-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
62286160|NCT02666326|NO_INTERVENTION|Conventional diagnostic strategy|"Standard Diagnostics for suspected myocardial infarction, including standard biochemical analysis: min. two measurements of high sensitive troponin T with an interval of minimum 3 hours.~A normal value of high sensitive cardiac troponin-T in both blood samples rules out AMI and the patients can be discharged immediately if no other conditions are suspected."
62286161|NCT02666326|EXPERIMENTAL|Accelerated diagnostic strategy|'Accelerated, combined biomarker rule-out strategy for MI'. Copeptin measurement in a prehospital blood sample combined with high sensitive cardiac troponin T measurement in the first blood sample upon hospital admission, A normal value of both copeptin and cardiac troponin rules out AMI and the patients can be discharged immediately if no other conditions are suspected.
62286162|NCT04434352|ACTIVE_COMPARATOR|Baseline Erectile Dysfunction|The first arm of the study will be those men with erectile dysfunction as defined by IIEF score. These men will either have PDE5i refractory or responsive erectile dysfunction. Subjects will receive either Sham treatment (no ultrasound energy delivered via a Sham probe) or LiSWT for erectile dysfunction. Follow up will occur at 1 month, 3 months, and 6 months following the end of treatment. Effectiveness will be measured by change in IIEF/SHIM score and EHS score. Each questionnaire is described in the trial description with a higher score indicating improved function.
62286163|NCT04434352|ACTIVE_COMPARATOR|Erectile Dysfunction-Penile Rehabilitation|The second population of patients will be those who are planning to undergo treatment for prostate cancer. In a similar manner, men will be randomized to either the Sham or active treatment groups. Men will be treated prior to undergoing definitive treatment for prostate cancer to assess the effectiveness in LiSWT as a means of erectile preservation prior to prostate cancer treatment.
62652312|NCT05817123||Partners|Partners of OSAS patients
62652313|NCT06513299||VT1 - low tidal volume|Patients mechanically ventilated with tidal volume between 6.0 and 8.0 ml/kg PBW, until weaning conditions are satisfied. When weaning criteria are met, extubation may be attempted, it may either fail or not, or any other mechanical ventilation regime may be chosen, according to clinical practice.
62652314|NCT06513299||VT2 - high tidal volume|Patients mechanically ventilated with tidal volume between 8.0 and 10.0 ml/kg PBW, until weaning conditions are satisfied. When weaning criteria are met, extubation may be attempted, it may either fail or not, or any other mechanical ventilation regime may be chosen, according to clinical practice.
62652315|NCT06513299||∆P1 - low driving pressure|Patients mechanically ventilated with driving pressure between 7.0 and 12.0 cmH2O, until weaning conditions are satisfied. When weaning criteria are met, extubation may be attempted, it may either fail or not, or any other mechanical ventilation regime may be chosen, according to clinical practice.
62652316|NCT06513299||∆P2 - high driving pressure|Patients mechanically ventilated with driving pressure between 12.0 and 18.0 cmH2O, until weaning conditions are satisfied. When weaning criteria are met, extubation may be attempted, it may either fail or not, or any other mechanical ventilation regime may be chosen, according to clinical practice.
62652317|NCT00080262|EXPERIMENTAL|1|
62652318|NCT01077557||No HIV infection|Subjects without HIV infection (Group 1) are adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. A 3:1 match of subjects without HIV infection to a subject with HIV infection will occur. Each member of the comparator group without HIV infection will be matched on gender, month/year of IHCIS enrolment, and duration of enrollment to the respective study subject with HIV infection.
62652319|NCT01077557||HIV infection with no antiretroviral (ARV) drug exposure|HIV infection with no ARV drug exposure (Group 2) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have no pharmacy dispensing for ARV drugs.
62652320|NCT01077557||HIV infection with ARV drug exposure|HIV infection with ARV drug exposure (Group 3) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have at least one pharmacy dispensing for an HIV antiretroviral drug.
62087319|NCT05293535||LRP-6|"Evaluate the expression of LRP-6 protein in gastric adenocarcinoma via immunohistochemistry, find the association between the expression of LRP-6 protein in gastric adenocarcinoma and demographic patient data, and clinicopathologic parameters of the patients and investigate the effect of LRP-6 protein expression on the prognosis of gastric adenocarcinoma.~Correlate between the Klotho and LRP-6 protein expression."
62087320|NCT04635787||Healthy Adults|Adults 18 years or older
62460923|NCT05732766|EXPERIMENTAL|Group-I (Age: ≥18)|Group-I (Age: ≥18) In this group, a total of 600 participants aged ≥18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
62460924|NCT05732766|EXPERIMENTAL|Group-II (Age: ≥5 to <18)|Group-II (Age: ≥5 to \<18): In this group, a total of 600 participants aged ≥5 to \<18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
62460925|NCT05732766|EXPERIMENTAL|Group-III (Age: ≥1 to <5)|Group-III (Age: ≥1 to \<5): In this group, a total of 600 participants aged ≥1 to \<5 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14
62460926|NCT01223612|EXPERIMENTAL|Ranibizumab|Intravitreal injection of ranibizumab
62460927|NCT01223612|ACTIVE_COMPARATOR|Laser|Modified ETDRS laser
62087321|NCT04635787||COVID19|Adults 18 years or older diagnosed with COVID 19
62087322|NCT03508102|EXPERIMENTAL|Remifentanil 1 μg kg-1 (R1)|Received remifentanil 1μg/kg when induction of general anesthesia
62286164|NCT04434352|ACTIVE_COMPARATOR|Erectile Dysfunction Post-Prostate Cancer Treatment|The third population of patients will be those who have undergone treatment for prostate cancer. The investigators will compare IIEF scores and EHS scores in men who have undergone prostatectomy or radiation therapy. Again, there will be a sham and treatment group.
62652321|NCT05923996|EXPERIMENTAL|Microbotox injection|21 Egyptian patients with wide facial pores will be treated in a split-face manner. In this side of the face will received single session of microbotox injection contains 20 units of botulinum toxin A.
62652322|NCT05923996|EXPERIMENTAL|Fractional carbon dioxide laser in second side of the face|21 Egyptian patients with wide facial pores will be treated in a split-face manner. In this side will be treated by Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals.
62652323|NCT05500937|ACTIVE_COMPARATOR|UDCA 500mg per day|This group of participants receive UDCA 500mg per day.
62087323|NCT03508102|EXPERIMENTAL|Remifentanil 0.5 μg kg-1 (R0.5),|Received remifentanil 0.5μg/kg when induction of general anesthesia
62087324|NCT03508102|NO_INTERVENTION|saline (control)|Injected the equal volume normal saline when induction of general anesthesia
62087325|NCT00122161|OTHER|Arm 1|
62286165|NCT00927563|EXPERIMENTAL|Tolcapone|Tolcapone 100-300mg/day
62286166|NCT02159027|PLACEBO_COMPARATOR|placebo|placebo identical in appearance to maraviroc 150 and 300 mg tablets will be added to each subjects antiretroviral regimen at doses as recommended by the package insert
62286167|NCT02159027|EXPERIMENTAL|maraviroc|Maraviroc Tablets are available as 150 mg and 300 mg tablets. Each subject will add maraviroc to their current antiretroviral regimen with dosage based on recommendations as per maraviroc package insert
62286168|NCT01172756|EXPERIMENTAL|Arm 1|
62286169|NCT01172756|EXPERIMENTAL|Arm 2|
62286170|NCT01172756|EXPERIMENTAL|Arm 3|
62460928|NCT02766075|EXPERIMENTAL|Supervised TAVR Exercise Program (STEP)|Subjects in the experimental arm will participate in an individualized 4-week STEP prior to undergoing TAVR. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
62460929|NCT02766075|NO_INTERVENTION|Standard of Care|Subjects in the no intervention arm will proceed with their TAVR after a minimum 4 weeks without an exercise intervention. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
62460930|NCT04764565|EXPERIMENTAL|Nuun Instant|2 servings of Nuun instant in 1 liter water
62460931|NCT04764565|PLACEBO_COMPARATOR|Control|1 liter of water
62460932|NCT04764565|EXPERIMENTAL|Nuun Electrolyte|2.1 servings of Nuun Electrolyte in 1 liter water
62087326|NCT03383185||Non-hormonal contraceptive|Users of non- hormonal intrauterine device during the 5 years follow-up
62087327|NCT03383185||Hormonal contraceptives|Users of combined oral contraceptive, progestin-only pills, depot-medroxyprogestereone acetate during 5 years follow-up
62087328|NCT05484258|NO_INTERVENTION|Standard Care|On baseline screen, would be screened for depression, alcohol use, and loneliness. Loneliness screen will be checked every 3 months.
62087329|NCT05484258|ACTIVE_COMPARATOR|Group Medical VIsits|For this arm, patients will have three visits of a shared medical visit, wherein a physician/APP will partner with a social worker to give a discussion about topics relevant to the high need population, including managing multiple medications, managing stress, and also palliative care.
62087330|NCT04127305||VA ECMO|Patients will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
62286171|NCT01172756|PLACEBO_COMPARATOR|Arm 4|
62087331|NCT04127305||VA EMCO + RRT|Patients with RRT will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
62286172|NCT02975830||0-2 years|Children aged from birth to 24 months Three dimensional CT based images
62460933|NCT01041456||complicated and/or failed BPD|
62460934|NCT03657979|EXPERIMENTAL|Ropivacaine|Conventional PCA morphine +TAP-block ropivacaine 0.2%
62652324|NCT05500937|PLACEBO_COMPARATOR|Placebo|This group of participants receive placebo.
62652325|NCT01922999|ACTIVE_COMPARATOR|Placebo controlled|comparison of placebo controlled to 1mg melatonin or 3mg melatonin
62652326|NCT01922999|ACTIVE_COMPARATOR|Melatonin|comparison of melatonin 1mg or melatonin 3mg
62652327|NCT00357942|EXPERIMENTAL|C group I|Morphine mouthwash and placebo i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
62286173|NCT02975830||2-4 Years|Children aged from 25-48 months Three dimensional CT based images
62286174|NCT02975830||4-6 Years|Children aged from 49-72 Three dimensional CT based images
62286175|NCT02975830||6-8 years|Children aged from 73-96 months Three dimensional CT based images
62286176|NCT05658224|ACTIVE_COMPARATOR|Short education|Individuals receiving a short (1-minute) educational session on exercise-induced hypoalgesia
62286177|NCT05658224|ACTIVE_COMPARATOR|Long education|Individuals receiving long (10-15 minutes) educational session on exercise-induced hypoalgesia
62286178|NCT02009878|OTHER|tolvaptan 3.75 mg|tolvaptan 3.75 mg
62286179|NCT02009878|OTHER|tolvaptan 7.5 mg|tolvaptan 7.5 mg
62286180|NCT02009878|OTHER|tolvaptan 15 mg|tolvaptan 15 mg
62286181|NCT04273048|ACTIVE_COMPARATOR|Diet and Exercise|Group 1 = Diet Intervention group: They will be asked to follow a personalized diet during study period and record what they eat. The meal plan for this study is Mediterranean style and nutritionally complete for 8 to 12 weeks or until oocyte retrieval procedure. Exercise Intervention: Exercise 3 times/week at a gym of their choice or at home for 8 to 12 weeks or until oocyte retrieval procedure. Exercises will be light intensity and short duration at first and will gradually increase to moderate intensity and longer duration during the first 3 weeks. They will also be encouraged to walk an average 10,000 steps per day and wear a pedometer to monitor progress.
62460935|NCT03657979|PLACEBO_COMPARATOR|TAP-block with placebo|Conventional PCA morphine treatment with TAP-block with placebo
62286182|NCT04273048|NO_INTERVENTION|Standard Care|Group 2 = Standard: They will receive standard care from the Little Rock Fertility Center.
62460936|NCT02473640|EXPERIMENTAL|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
62460937|NCT03165058||Inflammatory Bowel Disease|Patients undergoing standard of care colonoscopy for inflammatory bowel disease (IBD) surveillance will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
62460938|NCT03165058||control|Patients undergoing standard of care colonoscopy for age appropriate screening will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
62460939|NCT00519142|PLACEBO_COMPARATOR|1|metformin + placebo for mitiglinide
62460940|NCT00519142|EXPERIMENTAL|2|metformin + mitiglinide three times a day with meals
62460941|NCT00519142|EXPERIMENTAL|3|metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal
62460942|NCT04712422||Healthy participants|At least 25 healthy participants aged from 18 to 50 years old. Participants will be excluded if pregnant.
62087332|NCT04127305||VV ECMO|Patients will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
62087333|NCT04127305||VV ECMO + RRT|Patients with RRT will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
62087334|NCT04127305||Control|Patients will be included within 24-48h after start of an antiinfective therapy
62087335|NCT03625011|PLACEBO_COMPARATOR|Placebo Group|Participants will be randomized to either Control Group or Gabapentin Group
62087336|NCT03625011|ACTIVE_COMPARATOR|Gabapentin Group|Participants will be randomized to either Control Group or Gabapentin Group
62087337|NCT04525274|PLACEBO_COMPARATOR|control group|patient will receive 40 ml bupivacaine 0.25% + 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
62460943|NCT04712422||Pathologic group|At least 22 participants with diagnosis of Myotonic Dystrophy 1.
62460944|NCT01042886|EXPERIMENTAL|Family plus community focused intervention|
62087338|NCT04525274|ACTIVE_COMPARATOR|dexmedetomidine group|patient will receive 40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
62087339|NCT04525274|ACTIVE_COMPARATOR|ketamine group|patient will receive 40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
62286183|NCT00085280|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment."
62286184|NCT01703000|EXPERIMENTAL|NG PROMUS stent|Single-arm treatment group receiving interventional NG PROMUS study stent
62286185|NCT05157126|EXPERIMENTAL|Gentamicin|The intervention consists of 80mg of liquid gentamicin diluted in 5 mL normal saline (16mg/mL). The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
62286186|NCT05157126|PLACEBO_COMPARATOR|Saline|The control consists of 5 mL normal saline injected immediately after wound closure at the open fracture site. The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
62286187|NCT03168815|EXPERIMENTAL|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
62652328|NCT00357942|ACTIVE_COMPARATOR|C group II|Placebo mouthwash and morphine i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
62652329|NCT00357942|PLACEBO_COMPARATOR|C group III|Placebo mouthwash and placebo i.v. (24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
62087340|NCT04576195|EXPERIMENTAL|Real PENS|One single session of PENS
62087341|NCT04576195|SHAM_COMPARATOR|Sham PENS|One single session of Sham-PENS
62460945|NCT01042886|ACTIVE_COMPARATOR|Standard Behavioral Weight Loss Maintenance Intervention|
62460946|NCT01724502|EXPERIMENTAL|Obese Non-Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
62460947|NCT01724502|EXPERIMENTAL|Type 2 Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
62087342|NCT01448837|ACTIVE_COMPARATOR|Bimatoprost/Timolol drops|The patients will be treated with bimatoprost/timolol fixed combination therapy
62460948|NCT01724502|EXPERIMENTAL|Healthy Control Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
62652330|NCT02537496|EXPERIMENTAL|Alzheimer's disease rTMS|The intervention procedure done in this group is repetitive Transcranial Magnetic Stimulation.
62652331|NCT02537496|SHAM_COMPARATOR|Alzheimer's disease rTMS Sham|The intervention procedure done in this group is Repetitive Transcranial Magnetic Stimulation - Sham
62652332|NCT02537496|NO_INTERVENTION|Healthy Control|Healthy control group will only participate in baseline assessments which include baseline neuropsychological testing and baseline measurement of neuroplasticity. This will be used to standardize neuropsychological test scores and to compare the baseline neuroplasticity between healthy participants and Alzheimer's disease (AD) participants. Healthy control group will not get rTMS intervention.
62652333|NCT01533259|EXPERIMENTAL|Stribild|Participants will switch to Stribild for 48 weeks.
62087343|NCT01448837|ACTIVE_COMPARATOR|Latanoprost drops|The patients will be crossed over to therapy with latanoprost
62087344|NCT02342314|EXPERIMENTAL|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
62286188|NCT03168815|ACTIVE_COMPARATOR|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
62286189|NCT00947284|EXPERIMENTAL|Women|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm.
62286190|NCT00947284|EXPERIMENTAL|Men|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm
62286191|NCT02766660|OTHER|Thyroid ophthalmopathy|Thyroid associated ophthalmopathy patients were measured by optical coherence tomography.
62286192|NCT02766660|OTHER|Control|Control group was consisted by age and sex- macthed healthy people adn they were measured by optical coherence tomography.
62460949|NCT05564247|EXPERIMENTAL|Experimental Group (WSTP)|Participants will complete 12, 45-minute weekly sessions of WSTP delivered by clinicians with \>5 years of experience working with children who use MWC. Trainers will customize each session based on the age group (child or adolescent) and training goals of each child as determined in session one. Subsequent sessions will begin with a 5-minute review of progress and socializing, followed by a 10-minute warm-up (random practice of the previously learned skills); 20 minutes of attempting new skills (training on each skill will be carried to next session until the skills are learned or until the trainer and participant mutually agree that training should be abandoned; the trainer will periodically ask the participant to practice newly learned skills to incorporate variability of practice); 10 minute cool-down, during which the participant will practice skills in a self-controlled environment. Age-appropriate considerations are incorporated into training materials
62460950|NCT05564247|NO_INTERVENTION|Control Group (Attention)|Participants will be attention-matched to mimic time and contacts ‬of‭ ‬the‭ experimental‭ ‬group. The control group will receive 12, 45-minute weekly sessions of 'Games and Activities' facilitated by healthcare professionals (e.g., occupational therapy/rehabilitation students) who will not be involved in the intervention or any other aspect of the study. The control group facilitator will mimic the same type of attention as the training at each site (i.e., sessions will be held at healthcare facilities and in the community (e.g., libraries, shopping centres, museums, parks). Facilitators will be equipped with current popular games and activities (according to social media and websites of popular children's stores) kits that include various board and card games, hand-eye coordination games, active games, cognitive activities, and arts and crafts suitable for children and adolescents to ensure interest and acceptability for all participants.
62286193|NCT04120558||Through knee amputees|Community dwelling individuals with through knee amputation of all mobility levels.
62460951|NCT04829227|EXPERIMENTAL|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
62286194|NCT04120558||Above knee amputees|Community dwelling individuals with above knee amputation of all mobility levels.
62286195|NCT04938440||Prescribers of Instanyl®|Healthcare professionals (Oncologists, oncoradiologists, anaesthesiologists, pain management prescribers, palliative care prescribers, internal medicine prescribers, general practitioners and other specialties) who are current and potential prescribers of Instanyl® will be assessed before and after the distribution of the updated EMs via web-based survey questionnaire.
62460952|NCT04829227|EXPERIMENTAL|"off the face areas"|"off the face areas: abdomen, or arms or thighs or Décolleté."
62652334|NCT03658980|EXPERIMENTAL|Health Education Intervention|Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
62652335|NCT03658980|NO_INTERVENTION|Control Group|No Intervention will be conducted in this control group
62652336|NCT05127720||patients with severe sleep apnea|defined by a pacemaker-derived mean RDI ≥ 20/h in the first 12 months after enrollment
62652337|NCT05127720||patients with autonomic imbalance|defined by PRD ≥ 5.75deg2 assessed within the first 12 months of enrollment
62652338|NCT05127720||patients with a sedentary lifestyle|defined by a pacemaker-derived mean daily physical activity level \< 2h in the first 12 months after enrollment
62286196|NCT04274296||Control|Control-cohort in which no change in care is needed
62460953|NCT02748161|ACTIVE_COMPARATOR|DEB-TACE: Standard Endhole Catheter|Subjects will undergo DEB-TACE using a standard endhole catheter.
62460954|NCT02748161|ACTIVE_COMPARATOR|DEB-TACE: Surefire Infusion System|Subjects will undergo DEB-TACE using the Surefire Infusion System.
62460955|NCT02942953||Diaphragmatic Pacer|Patient that have been proposed to diaphragmatic pacer placement at our institution.
62460956|NCT06304701|EXPERIMENTAL|Experimental arm : Adults with autism spectrum disorder|All of the interventions described below
62460957|NCT06304701|ACTIVE_COMPARATOR|Control arm : Adults with typical development|All of the interventions described below
62460958|NCT04719000|EXPERIMENTAL|rhFSH+rhLH|Ovarian Stimulation with rhFSH+rhLH
62460959|NCT04719000|ACTIVE_COMPARATOR|rhFSH|Ovarian Stimulation with rhFSH
62460960|NCT04191980||Patients with a MRI on a 3 Tesla (T) unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 3T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
62460961|NCT04191980||Patients with a MRI on a 1.5 Tesla unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 1.5T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
62460962|NCT06431906||transdermal fentanyl|Subjects receiving a transdermal fentanyl patch for postoperative pain control will be included here.
62286197|NCT04274296||Advisory|Cohort in which advisory is activated
62286198|NCT03294551|NO_INTERVENTION|Standard of Care Control|Usual source of care
62286199|NCT03294551|EXPERIMENTAL|HPV Vaccine Reminder Recall - Autodialer|HPV Vaccine Reminder Recall - Autodialer: Receive up to 4 reminders via telephone (live call or voicemail) - includes brief educational message + providers name + providers telephone number
62286200|NCT03294551|EXPERIMENTAL|HPV Vaccine Reminder Recall - Texting|HPV Vaccine Reminder Recall - Texting: Receive up to 4 reminders via text message - includes brief educational message + providers name + providers telephone number
62286201|NCT02274285|EXPERIMENTAL|Group A (SP0204)|Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
62286202|NCT02274285|ACTIVE_COMPARATOR|Group B (control)|Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
62286203|NCT02274285|EXPERIMENTAL|Group C|Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly
62286204|NCT03135405|NO_INTERVENTION|Usual care|
62286205|NCT03135405|EXPERIMENTAL|Intervention|
62286206|NCT02293122||Observational|Observational group exposure to three test devices and one comparative device. The test Konan Non-con Robo Pachy F\&A Specular Microscope.
62286207|NCT06173999|EXPERIMENTAL|Treatment group A|
62286208|NCT06173999|EXPERIMENTAL|Treatment group B|
62460963|NCT06431906||morphine PCA|Subjects receiving a morphine PCA for postoperative pain control will be included here.
62460964|NCT00503152|EXPERIMENTAL|benazepril|
62460965|NCT00503152|EXPERIMENTAL|valsartan|
62460966|NCT00503152|EXPERIMENTAL|benazepril/valsartan|
62460967|NCT04926883|ACTIVE_COMPARATOR|Sonic fill|
62460968|NCT04926883|ACTIVE_COMPARATOR|X-tra fill|
62460969|NCT02631629|PLACEBO_COMPARATOR|Non-fortified foods SA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of South Asian (SA) origin
62460970|NCT02631629|PLACEBO_COMPARATOR|Non-fortified foods CA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of Caucasian (CA) origin
62460971|NCT02631629|ACTIVE_COMPARATOR|Vitamin D fortified foods SA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of South Asian (SA) origin
62460972|NCT02631629|ACTIVE_COMPARATOR|Vitamin D fortified foods CA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of Caucasian (CA) origin
62460973|NCT02445300|ACTIVE_COMPARATOR|AQUACEL® Ag Surgical dressing|AQUACEL® Ag Surgical dressing is used to cover the surgical wound in the OR. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer.
62460974|NCT02445300|ACTIVE_COMPARATOR|Sofra-Tulla® dressing|The Sofra-Tulle® dressing was used in the OR and routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine.
62286209|NCT04146922|ACTIVE_COMPARATOR|IV Group|Eligible patients randomized to complete their antimicrobial therapy course through intravenous (IV) administration.
62286210|NCT04146922|EXPERIMENTAL|Oral Group|Eligible patients randomized to step down to oral antimicrobial therapy for the remainder of their treatment course.
62286211|NCT03286673|EXPERIMENTAL|calcium phosphate|Pentacalcium hydroxy-triphosphate (Ca5(PO4)3OH) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
62286212|NCT03286673|EXPERIMENTAL|Tricalcium Phosphate|β-tricalcium phosphate (Ca3(PO4)2) as incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
62286213|NCT03286673|EXPERIMENTAL|Calcium carbonate|Calcium carbonate (CaCO3) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
62286214|NCT03286673|ACTIVE_COMPARATOR|Placebo|Wholemeal and crispy wafer bread without additional calcium additive.
62087345|NCT02342314|EXPERIMENTAL|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
62087346|NCT02342314|PLACEBO_COMPARATOR|Placebo (Part A)|Single SC injection of normal saline on Day 1
62286215|NCT06500377|EXPERIMENTAL|Arm I (breathing only meditation)|Patients learn breathing only meditation with an instructor over 60 minutes for 3 sessions within 6 weeks. Patients also practice meditation at home and undergo saliva sample collection on study.
62286216|NCT06500377|EXPERIMENTAL|Arm I (focused attention only meditation)|Patients learn focused attention only meditation with an instructor over 60 minutes for 3 sessions within 6 weeks. Patients also practice meditation at home and undergo saliva sample collection on study.
62286217|NCT06500377|EXPERIMENTAL|Arm III (mindfulness only meditation)|Patients learn mindfulness only meditation with an instructor over 60 minutes for 3 sessions within 6 weeks. Patients also practice meditation at home and undergo saliva sample collection on study.
62286218|NCT06500377|EXPERIMENTAL|Arm IV (combined meditation)|Patients learn breathing, focused attention, and mindfulness combined meditation with an instructor over 60 minutes for 3 sessions within 6 weeks. Patients also practice meditation at home and undergo saliva sample collection on study.
62286219|NCT00046228|EXPERIMENTAL|001|Abciximab; reteplase; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
62286220|NCT00046228|EXPERIMENTAL|002|abciximab; reteplase placebo; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
62286221|NCT00046228|EXPERIMENTAL|003|abciximab placebo; reteplase placebo, abciximab, abciximab placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
62286222|NCT01647737|ACTIVE_COMPARATOR|MighTeaFlow|4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
62286223|NCT01647737|ACTIVE_COMPARATOR|Xylitol|4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
62286224|NCT05322213|ACTIVE_COMPARATOR|Active THC|Daily, inhaled, flexible dose of cannabis product with THC.
62286225|NCT05322213|PLACEBO_COMPARATOR|Placebo Cannabis|Daily, inhaled, flexible dose of cannabis product without THC.
62286226|NCT05533749|EXPERIMENTAL|GILL eHealth module|Patients will perform the GILL eHealth. This eHealth contains two modules focusing on systematic somatic screening and lifestyle behaviors.
62286227|NCT05533749|NO_INTERVENTION|Care as usual|Patients will receive usual care and have unrestricted access to mental care and treatment.
62286228|NCT02084446|ACTIVE_COMPARATOR|Mycophenolate + Low Tacrolimus|"Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
62286229|NCT02084446|EXPERIMENTAL|Everolimus + Very Low Tacrolimus|"Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
62286230|NCT04588103|NO_INTERVENTION|Control|Participants will be asked to maintain their regular physical activity habits for the duration of the 8-week intervention period.
62286231|NCT04588103|EXPERIMENTAL|Heat therapy|Participants will be asked to undergo 45 minutes of lower limb hot water immersion (42 degrees C) 3 times per week for 8 weeks.
62460975|NCT04995822||EUROSTEM femoral stem|All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)
62460976|NCT05813548|EXPERIMENTAL|Treatment|FASTer Way Application-Based Lifestyle Program
62087347|NCT02342314|ACTIVE_COMPARATOR|rGlucagon (Part B)|Single SC injection on Day 1
62087348|NCT02342314|PLACEBO_COMPARATOR|Placebo (Part B)|Single SC injection of normal saline on Day 1
62087349|NCT06277128|EXPERIMENTAL|WS016 3g|
62087350|NCT06277128|EXPERIMENTAL|WS016 6g|
62087351|NCT06277128|EXPERIMENTAL|WS016 12g|
62087352|NCT06277128|PLACEBO_COMPARATOR|Matching Placebo|
62087353|NCT06494423|EXPERIMENTAL|Work Support Intervention|This is a single arm proof-of-concept trial with up to 35 HSCT recipients reporting employment concerns. We will refine and preliminarily evaluate a Work Support (WorkS) self-management intervention designed to catalyze return-to-work self-efficacy.
62087354|NCT00632528|EXPERIMENTAL|1|Administration of MEOPA gaz during postoperative physical therapy
62652339|NCT05094375|EXPERIMENTAL|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
62087355|NCT00632528|PLACEBO_COMPARATOR|2|Administration of medical air during postoperative physical therapy
62087356|NCT03285711|EXPERIMENTAL|Lanraplenib 30 mg|"Participants receive lanraplenib 30 mg tablet + filgotinib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
62286232|NCT04588103|EXPERIMENTAL|Exercise training|Participants will be asked to undergo 45 minutes of moderate-intensity cycling exercise (\~40-59% VO2 reserve) 3 times per week for 8 weeks.
62087357|NCT03285711|EXPERIMENTAL|Filgotinib 200 mg|"Participants receive filgotinib 200 mg tablet + lanraplenib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
62087358|NCT03285711|EXPERIMENTAL|Lanraplenib 30 mg to Filgotinib 200 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive filgotinib 200 mg + lanraplenib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
62286233|NCT04588103|EXPERIMENTAL|Combined training|Participants will be asked to undergo 90 minutes of moderate-intensity cycling exercise and lower limb hot water immersion sequentially 3 times per week for 8 weeks.
62286234|NCT05901467|EXPERIMENTAL|kisspeptin, GnRH|IV administration of kisspeptin 112-121; one bolus. IV administration of GnRH; one bolus.
62286235|NCT00870337|EXPERIMENTAL|Single arm|
62286236|NCT04351139||gynecological cancer|Patients over 18 with gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned during the period of COVID-19 pandemic during 2020
62286237|NCT04351139||control group|Patients over 18 with gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned outside the period of COVID-19 pandemic, on the end of the year 2019
62286238|NCT02009241|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|The intervention group will perform a 12 week pulmonary rehabilitation program consisting of 30 minutes of treadmill aerobic exercise training and 30 minutes of muscle strength training.
62286239|NCT02009241|NO_INTERVENTION|Control|
62286240|NCT02519881|EXPERIMENTAL|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of ankle
62652340|NCT05094375|ACTIVE_COMPARATOR|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
62087359|NCT03285711|EXPERIMENTAL|Filgotinib 200 mg to Lanraplenib 30 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive lanraplenib 30 mg + filgotinib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
62087360|NCT06386224|EXPERIMENTAL|Internet-delivered pain self-management (CBT Condition)|Participants randomized to the CBT condition will receive access to a pain self-management program, available through any internet-enabled device. The design and treatment content follow a cognitive-behavioral framework in which participants receive information to understand their CP pain, learn a range of cognitive and behavioral skills to manage their symptoms and difficulties, and practice and adopt the skills taught in the program. The program consists of 5 online lessons, which are in the form of a slide show, and 5 downloadable lesson summaries, which provide homework assignments to assist participants in learning and applying the skills described in the lessons. These materials are released over the course of eight weeks and include a combination of didactic information and narrative examples. Several detailed case stories and real-world examples of individuals with CP pain are integrated throughout the course.
62087361|NCT06386224|PLACEBO_COMPARATOR|Education Program|Participants randomized to the education program will receive access to a website with information about pancreatitis pain from publicly available educational websites (e.g., National Pancreas Foundation). Participants assigned to the education program will complete five modules released over the same time interval as the CBT group.
62286241|NCT02519881|ACTIVE_COMPARATOR|microfracture|simple microfracture for cartilage defect of ankle
62652341|NCT02254655|EXPERIMENTAL|Puerarin injection 400 mg|Patients were administrated with 400 mg intravenously infused puerarin injection once a day. Puerarin injection was prepared in 250 mL 0.9% sodium chloride injection before the use. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
62652342|NCT02254655|SHAM_COMPARATOR|Control|Patients receive routine anti-rheumatic care only. Patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
62652343|NCT00981617|EXPERIMENTAL|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
62286242|NCT00771784||1|Short term endotracheal intubation.
62652344|NCT00981617|EXPERIMENTAL|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
62652345|NCT00981617|EXPERIMENTAL|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
62652346|NCT00981617|PLACEBO_COMPARATOR|Placebo|Matching placebo (capsules without active study drug) provided for daily oral administration
62652347|NCT03505346|EXPERIMENTAL|percutanous coronary intervention(PCI)|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention
62652348|NCT03505346|EXPERIMENTAL|Coronary artery bypass-graft(CABG)|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention
62286243|NCT00771784||2|Long term endotracheal intubation.
62652349|NCT03408899|EXPERIMENTAL|PC-1005|All participants will receive 3 single escalating doses of PC-1005 gel during Visits 3, 5, and 7, with a 2-to-6-week washout period between dosing visits. Each participant will be on study for approximately 3 to 5 months.
62652350|NCT01587313|EXPERIMENTAL|Group 1|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 am
62286244|NCT06206096|EXPERIMENTAL|CAPOX+BEV+PD-1|
62286245|NCT03110588|EXPERIMENTAL|PACE with Cabazitaxel @ 15 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
62652351|NCT01587313|EXPERIMENTAL|Group 2|ISDN/HYD 2 SR caps crossover to 1 IR cap at 5 pm
62652352|NCT01587313|EXPERIMENTAL|Group 3|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 pm
62286246|NCT03110588|EXPERIMENTAL|PACE with Cabazitaxel @ 20 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
62286247|NCT05888350|EXPERIMENTAL|Foster treatment group|Participant inhales Foster (Inhaled Beclometasone Dipropionate and Formoterol Inhalation Aerosol) 1 puff bid for 4 weeks.
62652353|NCT01587313|ACTIVE_COMPARATOR|Group 4|ISDN/HYD 1 IR cap and two SR caps at 8 am crossover to Day 8: BiDil Tablet tid
62652354|NCT02542969|OTHER|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
62460977|NCT05813548|ACTIVE_COMPARATOR|Control|General health and dietary guidelines
62087362|NCT05836662|ACTIVE_COMPARATOR|2D Concussion Education|During their in person study visit, participants will complete a brief ( \~5 minute) pre-survey before viewing the CrashCourse and Brain Fly-Through concussion educations. Participants in this group will receive both of these educations in 2D (via a video on a laptop). Participants will then be asked to complete a brief ( \~2 minute) survey to assess their knowledge, self-efficacy, and empathy surrounding concussions.
62087363|NCT05836662|EXPERIMENTAL|3D Concussion Education|During their in person study visit, participants will complete a brief ( \~5 minute) pre-survey before viewing the CrashCourse and Brain Fly-Through concussion educations. Participants in this group will receive both of these educations in 3D (via a Virtual Reality headset). Participants will then be asked to complete a brief ( \~2 minute) survey to assess their knowledge, self-efficacy, and empathy surrounding concussions.
62087364|NCT04473859|EXPERIMENTAL|FSR Peptide 20 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
62087365|NCT04473859|EXPERIMENTAL|FSR peptide 50 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
62087366|NCT04473859|EXPERIMENTAL|FSR peptide 100 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
62087367|NCT04473859|EXPERIMENTAL|FSR peptide 200 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
62286248|NCT05888350|PLACEBO_COMPARATOR|Placebo controlled group|Participant inhales matched placebo 1 puff bid for 4 weeks.
62286249|NCT02917460|EXPERIMENTAL|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic Biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
62286250|NCT03147469|NO_INTERVENTION|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
62286251|NCT03147469|EXPERIMENTAL|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
62286252|NCT03147469|EXPERIMENTAL|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
62286253|NCT03147469|EXPERIMENTAL|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
62286254|NCT06384092|EXPERIMENTAL|Site T1|Test Product A - Test Sun Protection Cream Dosage Form - Cream Route of Administration - Topical Mode of Usage - Apply directly on the designated site till absorbed. Dosage - 0.2 mL/site
62286255|NCT06384092|ACTIVE_COMPARATOR|Site T2|Test Product B - Benchmark (Sun Protection Cream) Dosage Form - Cream Route of Administration - Topical Mode of Usage - Apply directly on the designated site till absorbed. Dosage - 0.2 mL/site
62286256|NCT06384092|NO_INTERVENTION|Site U1-4|Test Product : No test product applied.
62286257|NCT04947644|ACTIVE_COMPARATOR|Thoracic epidural analgesia group|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
62460978|NCT03596190|OTHER|Assessment arm|
62460979|NCT00826930|EXPERIMENTAL|1A|0.5 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
62460980|NCT00826930|EXPERIMENTAL|2A|0.75 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
62460981|NCT00826930|EXPERIMENTAL|3A|1.0 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
62460982|NCT00826930|EXPERIMENTAL|4A|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - phenytoin only or none
62460983|NCT00826930|EXPERIMENTAL|1B|0.5 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
62460984|NCT00826930|EXPERIMENTAL|2B|0.75 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
62460985|NCT00826930|EXPERIMENTAL|3B|1.0 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
62460986|NCT00826930|EXPERIMENTAL|4B|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - any except phenytoin-only or none
62087368|NCT04473859|PLACEBO_COMPARATOR|Placebo only|Each subject will have two punch biopsies. Placebo will be applied to both punch biopsies.
62087369|NCT01158378|ACTIVE_COMPARATOR|DuraSeal Dural Sealant System|
62087370|NCT01158378|EXPERIMENTAL|Adherus Dural Sealant System|
62087371|NCT02269618|ACTIVE_COMPARATOR|Control group (Group A)|The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed
62460987|NCT01396278|EXPERIMENTAL|BI 54903 low dose|patient to receive Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoroalkane (HFA) metered dose inhaler (MDI)
62460988|NCT01396278|EXPERIMENTAL|BI 54903 medium dose|Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI
62087372|NCT02269618|OTHER|Intervention group (Group B)|"Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be:~1. Home-based telehealth program~2. Home-based rehabilitation"
62087373|NCT05732675|OTHER|Immediate Intervention|Participants immediately enter the intervention upon enrollment
62087374|NCT05732675|OTHER|Waitlist|Participants enter a waitlist for 4-weeks prior to participating in the intervention
62087375|NCT00915070|ACTIVE_COMPARATOR|BQ-123|
62087376|NCT00915070|PLACEBO_COMPARATOR|Physiological saline solution|
62460989|NCT01396278|EXPERIMENTAL|BI 54903 high dose|Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI
62460990|NCT01396278|ACTIVE_COMPARATOR|Fluticasone propionate 440 mcg BID|Fluticasone HFA MDI containing 440 mcg ICS plus placebo matching Respimat inhaler
62087377|NCT01625039|EXPERIMENTAL|Intervention|Participated in weekly educational workshops
62087378|NCT01625039|ACTIVE_COMPARATOR|Control group|Received once off educational session and materials
62087379|NCT00651469|EXPERIMENTAL|Arm 1|
62087380|NCT00651469|PLACEBO_COMPARATOR|Arm 2|
62087381|NCT04044079|EXPERIMENTAL|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
62087382|NCT04044079|ACTIVE_COMPARATOR|misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
62087383|NCT04044079|PLACEBO_COMPARATOR|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
62087384|NCT04519775|EXPERIMENTAL|HOBSCOTCH-V (virtual)|"Participants will receive the HOBSCOTCH intervention consisting of 1:1 sessions delivered once per week, including:~* 1 pre-HOBSCOTCH Session (on webcam)~* 1 educational session (on webcam)~* 6 telephone sessions~* 1 wrap-up session (webcam or telephone)~Participants will also receive 3 booster sessions, via webcam or telephone, once per month."
62087385|NCT04519775|OTHER|Control|Participants will be wait listed and will receive HOBSCOTCH-V (above) following a 6 month wait period.
62460991|NCT01396278|ACTIVE_COMPARATOR|Fluticasone propionate 88 mcg BID|Fluticasone HFA MDI containing 88 mcg ICS plus placebo matching Respimat inhaler
62460992|NCT06150326|EXPERIMENTAL|medical honey|the patients randomised to this arm will have honey (Activon® Advancis Medical.)
62460993|NCT06150326|ACTIVE_COMPARATOR|standard of care|the patients randomised to this arm will have standard of care recommanded by HAS (french organisation)
62460994|NCT01922648||2-4 months|Infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
62460995|NCT01922648||6 - 12 months|Infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
62460996|NCT01922648||3 - 6 years|Children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
62652355|NCT01828658|NO_INTERVENTION|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
62652356|NCT01828658|ACTIVE_COMPARATOR|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
62460997|NCT01918800|EXPERIMENTAL|Fatigue: Take Control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
62460998|NCT01918800|ACTIVE_COMPARATOR|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
62652357|NCT03048786|ACTIVE_COMPARATOR|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
62652358|NCT03048786|EXPERIMENTAL|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
62652359|NCT06261723||Control Group without obesity|Control Group with periodontitis and without obesity
62652360|NCT06261723||Obesity Group|Obesity Group with periodontitis
62652361|NCT02695407|EXPERIMENTAL|3 days cannulation|radial artery cannula removed after 3 days
62652362|NCT02695407|EXPERIMENTAL|5 days cannulation|radial artery cannula removed after 5 days
62652363|NCT03036267|EXPERIMENTAL|BREATHE|7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach
62652364|NCT03036267|ACTIVE_COMPARATOR|Attention Control Condition|7-minute diet and exercise discussion
62652365|NCT05989425|EXPERIMENTAL|surufatinib|Surufatinib 300mg will be taken orally once daily continuously through a 28-day cycle of study treatment. After treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination. Patients with high risk of postoperative recurrence will receive 131I treatment. After 131I treatment, maintenance treatment with surufatinib will be determined according to the recurrence risk stratification.
62652366|NCT06437756|EXPERIMENTAL|Theraband resistance training|
62652367|NCT06437756|ACTIVE_COMPARATOR|Conventional Resistance Training|
62652368|NCT05553717|ACTIVE_COMPARATOR|group 1|33 patients who will receive aspirin 150mg + carvedilol 12.5mg twice daily plus other traditional therapy of ischemia for three months.
62652369|NCT05553717|NO_INTERVENTION|group 2 control|33 patients who will receive aspirin 150mg + Captopril 12.5mg twice daily plus other traditional therapy of ischemia for three months.
62460999|NCT05542108|EXPERIMENTAL|Multisensory Stimulation and Family Education Group (MSG)|"Parents of the MSG will be asked to carry out up to two treatment sessions per day with their child, until they reach the 8th post-term week. Sessions will initially be carried out together with a therapist who will have the task of transmitting the necessary skills to parents/caregivers.~In addition, all families will receive the evidence-based program of Family Education which is based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~The family education group sessions involve about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalization in the NIC directly at the child's bed between the operator and one or both parents. Each meeting involves the discussion of one of the following topics."
62461000|NCT05542108|ACTIVE_COMPARATOR|Family Education Only Group (FEG)|"Parents of the FEG group infants will be asked to participate in an evidence based program for parents of NICU infants that includes 6-8 visits with a a trained healthcare provider operator.~This evidence-based program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~The program takes its conceptual basis from the Mother Infant Transaction Program (MITP).~It involves about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalization in the NICU directly at the child's bed between the operator and one or both parents."
62461001|NCT06088420|ACTIVE_COMPARATOR|Intrathcal Morphine Group|Intrathecal morphine administration for post operative pain relief after cesarean section
62652370|NCT05806970|EXPERIMENTAL|Intervention - Email Nudge|The intervention will include contacting UCLA Health Cardiology clinic managers with a list of all HFrEF patients eligible for an MRA who are cared for by a provider randomized to the intervention arm. Clinic managers will be asked to make an appointment in the next 60 days for these patients with the specific indication: GDMT initiation - consider MRA. If an appointment is already present in the next 60 days, the indication will be changed to: GDMT initiation - consider MRA.
62652371|NCT05806970|NO_INTERVENTION|No Intervention - Control Group|Providers randomized to the control arm will perform clinical duties as usual. Their patients will receive routine clinical care.
62652372|NCT00522834|ACTIVE_COMPARATOR|1|Elesclomol (STA-4783) in Combination With Paclitaxel
62087386|NCT02590133|EXPERIMENTAL|Nedaplatin+5-Fu+Endostar|Drug: Recombinant Human Endostatin Injection (Endostar) Endostar, 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
62087387|NCT02590133|ACTIVE_COMPARATOR|Nedaplatin+5-Fu|Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
62087388|NCT04496167|EXPERIMENTAL|EN3835|EN3835 up to 1.74 mg
62087389|NCT04496167|PLACEBO_COMPARATOR|Placebo|Placebo
62087390|NCT05031936|ACTIVE_COMPARATOR|Touhy needle group|cervical medial branch block using touhy needle
62087391|NCT05031936|PLACEBO_COMPARATOR|Quincke needle group|cervical medial branch block using quincke needle
62087392|NCT05211830|EXPERIMENTAL|SXR1096 cream|The active treatment will be the specific small molecule inhibitor of KLK5, 7 and 14 in a proprietary skin cream formulation.
62087393|NCT05211830|PLACEBO_COMPARATOR|Placebo cream|The placebo control will be the proprietary skin cream formulation without the active substance.
62286258|NCT04947644|EXPERIMENTAL|Ultrasound guided continuous erector spinae plane block group|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
62286259|NCT01431092|EXPERIMENTAL|Melatonin|
62286260|NCT01431092|PLACEBO_COMPARATOR|Placebo|
62286261|NCT04577963|EXPERIMENTAL|Part 1|Approximately 6-12 patients with locally advanced or metastatic solid tumors will be enrolled to receive fruquintinib in combination with tislelizumab and assessed for DLTs during the 28-day DLT observation period
62652373|NCT00522834|OTHER|2|Paclitaxel alone
62652374|NCT02136693|PLACEBO_COMPARATOR|Placebo|3.5 g /day of inert compound for 180 days after STARR
62652375|NCT02136693|EXPERIMENTAL|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
62652376|NCT00877968|PLACEBO_COMPARATOR|Whole wheat banana bread|Banana bread made with whole wheat flour
62652377|NCT00877968|ACTIVE_COMPARATOR|Whole pea flour banana bread|Banana bread made with whole pea flour
62652378|NCT00877968|PLACEBO_COMPARATOR|Whole wheat biscotti|Biscotti made with whole wheat flour
62652379|NCT00877968|ACTIVE_COMPARATOR|Whole pea biscotti|Biscotti made with whole pea flour
62652380|NCT00877968|PLACEBO_COMPARATOR|Whole wheat pasta|Pasta made with whole wheat durum
62087394|NCT00795418|EXPERIMENTAL|CAD106|
62087395|NCT00795418|PLACEBO_COMPARATOR|Placebo|
62087396|NCT01152554|EXPERIMENTAL|SSRI/Serotonin/SNRI + TC-5214 1-4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
62087397|NCT01152554|PLACEBO_COMPARATOR|SSRI/Serotonin/SNRI + placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
62087398|NCT02283099|EXPERIMENTAL|rVSVΔ-ZEBOV-GP (BPSC1001)|Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.
62286262|NCT04577963|EXPERIMENTAL|Part 2|"Patients will be enrolled to one of the following expansion cohorts:~* Cohort A: TNBC (immuno-oncology \[IO\]-treated in the metastatic setting)~* Cohort B: TNBC (IO-Naïve in the metastatic setting)~* Cohort C: EC~* Cohort D: MSS CRC"
62461002|NCT06088420|ACTIVE_COMPARATOR|Quadratus Lumborum nerve block group|Quadratus Lumborum nerve block administration for post operative pain relief after cesarean section
62461003|NCT06088420|ACTIVE_COMPARATOR|Erector Spinae nerve block group|Erector Spinae nerve block administraion for post operative pain relief after cesarean section
62461004|NCT03144700||Compensated Cirrhosis|
62652381|NCT00877968|ACTIVE_COMPARATOR|Whole pea flour|Pasta made with 30% whole pea flour and 70% white wheat durum
62652382|NCT00877968|PLACEBO_COMPARATOR|White bread|
62652383|NCT00877968|PLACEBO_COMPARATOR|Boiled yellow peas|
62652384|NCT06269783|EXPERIMENTAL|sipIT|Participants will receive an educational handout about physical activity, a connected water bottle with its companion mobile application. For months 1-3, participants will receive lapse-contingent reminders to drink delivered by text message.
62652385|NCT03513419|EXPERIMENTAL|AMOR Method|The AMOR Method: The parent resilience training involves a series of eight weekly 90-minute group sessions, as well as three individual sessions. Group session content includes training in mindfulness, grief and loss processing, acceptance and committed actions, optimistic thinking, and resilience through the use of didactic training, group discussions, and homework assignments. Individual session content will center on additional and individualized training in grief and loss processing, optimistic thinking, and maintaining resilience over time.
62652386|NCT03513419|NO_INTERVENTION|Wait List|Participants assigned to the waitlist will continue stable treatments and will be offered the opportunity to participate in the treatment after completion of the 8-week trial.
62652387|NCT06243445||Patients underwent cardiac surgery with need for a central venous catheter|Patients underwent cardiac surgery with need for a central venous catheter and indication to intraoperative trans esophageal echocardiography
62652388|NCT05916209||PENG + LFCN Block|group in which PENG + LFCN Block was performed
62461005|NCT02587962|EXPERIMENTAL|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
62652389|NCT05916209||FIC Block|group in which FIC Block was performed
62652390|NCT04297592|ACTIVE_COMPARATOR|Additional Antibiotic Group|Patients will receive an oral antibiotic to be started after completion of standard perioperative antibiotics following primary hip or knee arthroplasty. Oral antibiotic will either be a first-generation cephalosporin (Cefadroxil or Cephalexin) or Doxycycline based upon patient allergies, kidney function and result of nasal colonization testing for MRSA.
62652391|NCT04297592|NO_INTERVENTION|Control Group - No Additional Antibiotic|Patients will receive standard perioperative antibiotics following primary hip or knee arthroplasty and no additional antibiotics.
62652392|NCT03442452|OTHER|Electronic Decision Aid|For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
62652393|NCT02243748|ACTIVE_COMPARATOR|Phase I (usual care)|Participants receive usual care. This phase will aid in identifying usual care patterns in each site and provide an audit of system utilization as well as finalization of the educational materials for Phase II.
62087399|NCT03244592|ACTIVE_COMPARATOR|Minocycline|200 mg/day
62087400|NCT03244592|PLACEBO_COMPARATOR|Sugar Pill|Matched placebo
62087401|NCT02332317|NO_INTERVENTION|Control arm|150 patients will receive standard oncology treatment.
62087402|NCT02332317|ACTIVE_COMPARATOR|Intervention arm|150 patients will receive standard oncology treatment alongside a 12-week specialized palliative rehabilitation program
62087403|NCT02114281|EXPERIMENTAL|Care|Patient with dental care
62087404|NCT02114281|ACTIVE_COMPARATOR|Not care|Patient with not dental care
62087405|NCT01804543||Angina, Heart Disease|ranolazine 500 mg twice daily for 1 week, then 1000 mg twice daily for 3 weeks
62286263|NCT01054079|EXPERIMENTAL|Treatment (cinacalcet hydrochloride)|Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
62286264|NCT02439580|EXPERIMENTAL|Annona muricata extract|Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
62286265|NCT02439580|PLACEBO_COMPARATOR|Placebo|Maltose capsule, 300 mg/day, for eight weeks
62461006|NCT02024321||Tumor patients, TPN, surgery|This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital.
62461007|NCT01316445|EXPERIMENTAL|nasal Midazolam|3 mg of the standard IV solution of midazolam (5 mg/mL) was given via a metered-dose nasal sprayer (6 sprays × 0.1 ml/spray, or 6 × 0.5 mg/spray) divided between the two nostrils within 1-2 min. During the EEG, vital signs (blood oxygen saturation, blood pressure, pulse and respiratory rate) were monitored and a nurse and a physician were available at all times. Subjects were monitored for 2 hours after administration of midazolam to ensure adequate recovery from sedation.
62461008|NCT03841188|OTHER|Nutritional Orientation|The patients received a nutritional orientation with emphasis in food rich in calcium
62461009|NCT03807141|EXPERIMENTAL|Diet arm|"Modified Atkins diet will be administered with carbohydrate restriction to 10 grams per day. Proteins will be allowed unrestricted and fats will be actively encouraged.~The ongoing antiepileptic medication will be continued unchanged"
62461010|NCT03807141|NO_INTERVENTION|Control|The control group will continue their anti-epileptic medication unchanged with no additional dietary input
62286266|NCT03416231|EXPERIMENTAL|apatinib plus docetaxel|apatinib combine with docetaxel， 4\~6 cycles
62286267|NCT01176916|EXPERIMENTAL|A|
62286268|NCT01191112|EXPERIMENTAL|Peptide Based enteral formula|
62286269|NCT06548139|EXPERIMENTAL|Experimental group 1|Natural full human monoclonal antibody CBB 1 injection：Each dose (2.5ml) contained 0.5 mg / natural monoclonal antibody ml CBB 1 Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection Character: colorless to pale green and yellow liquid Specification: 1.25 mg (2.5 ml) / bottle Mode of administration: intramuscular injection of the vastus lateralis muscle. Usage and dosage: The injection dose was calculated according to the group and body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site, and at least 2.5 cm apart.
62286270|NCT06548139|EXPERIMENTAL|Experimental group 2|Natural full human monoclonal antibody CBB 1 injection：Each dose (2.5ml) contained 0.5 mg / natural monoclonal antibody ml CBB 1 Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection Character: colorless to pale green and yellow liquid Specification: 1.25 mg (2.5 ml) / bottle Mode of administration: intramuscular injection of the vastus lateralis muscle. Usage and dosage: The injection dose was calculated according to the group and body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site, and at least 2.5 cm apart.
62286271|NCT06548139|ACTIVE_COMPARATOR|Positive control group|"Rabies Human Immunoglobulin (HRIG) Active ingredient: Rabid human immunoglobulin Specification: 200 IU / 2 ml / bottle Administration mode: intramuscular injection of the vastus lateral muscle group.~Usage and dosage: the injection dose was calculated according to the body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site and at least 2.5 cm apart"
62286272|NCT04159883|EXPERIMENTAL|app|For the App group, we installed the app from the store in their smart phone or tablets, made their account using the same email they use in their smart phone store. the participant was informed if they cannot follow the animated image in the app, they can re-launch the program and start to follow.
62286273|NCT04159883|ACTIVE_COMPARATOR|paper|For the paper group, the participants were provided with a hard copy of the exercise program; we gave one paper of all nine exercises.
62286274|NCT00861159||1|
62286275|NCT06228612|ACTIVE_COMPARATOR|group I:vacuum therapy|group I:vacuum therapy VT:patients who were diagnosed with TMJ osteoarthritis. The patients received Isolated vacuum therapy VT
62087406|NCT01244763|EXPERIMENTAL|Cohort A: Roxadustat Tiered, Weight Based Dosing TIW|Participants will receive roxadustat capsules, administered orally 3 times weekly (TIW) for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight \[45 to 60 kilograms (kg)\], medium-weight \[\>60 to 90 kg\], and heavy-weight \[\>90 to 140 kg\] participants will receive 60, 100, and 140 milligrams \[mg\] roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL.
62087407|NCT01244763|EXPERIMENTAL|Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW|Participants will receive roxadustat capsules orally for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight \[45 to 60 kg\], medium-weight \[\>60 to 90 kg\], and heavy-weight \[\>90 to 140 kg\] participants will receive 60, 100, and 140 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to 2 times a week (BIW) at the time of the initial Hb response.
62087408|NCT01244763|EXPERIMENTAL|Cohort C: Roxadustat at 50 mg TIW|Participants will receive roxadustat capsules at 50 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
62286276|NCT06228612|ACTIVE_COMPARATOR|group II: maxillary stabilization splint (MSS)|group II, patients who were diagnosed with TMJ osteoarthritis. The patients received stabilization splint therapy (STT)
62286277|NCT06228612|ACTIVE_COMPARATOR|group III: vacuum therapy VT and maxillary stabilization splint (MSS)|group III: patients who were diagnosed with TMJ osteoarthritis. The patients received combined VT and SST.
62286278|NCT01307033|ACTIVE_COMPARATOR|MK-954H (L50/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)
62286279|NCT01307033|EXPERIMENTAL|MK-0954A (L100/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension
62286280|NCT04041336|EXPERIMENTAL|All participants|All participants will have measurements taken. There are no comparators or controls in this feasibility study
62286281|NCT02437136|EXPERIMENTAL|Ph 2 NSCLC (squamous or adeno)|Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
62286282|NCT02437136|EXPERIMENTAL|Ph 2 NSCLC pre-treated PD-1/LD-L1|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
62286283|NCT02437136|EXPERIMENTAL|Ph 2 Melanoma pre-treated PD-1/PD-L1|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
62461011|NCT06215079|ACTIVE_COMPARATOR|active transcranial magnetic stimulation in stroke patients with complex regional pain syndrome|The intermittent theta-burst stimulation (iTBS) intensity for patients, applied under doctor supervision for a total of 5 days over one week (from Monday to Friday), will be set at 70% of the resting motor threshold. Stimulation will consist of bursts at a frequency of 50 Hz, with 3 bursts every 10 seconds, each burst lasting 2 seconds, totaling 600 bursts. Subsequently, the resting motor threshold will be adjusted to 80%, and a total of 2000 bursts will be delivered at a frequency of 10 Hz, repeated every 30 seconds, each lasting 10 seconds.
62461012|NCT06215079|SHAM_COMPARATOR|sham transcranial magnetic stimulation in stroke patients with complex regional pain syndrome|Similar protocol will be applied and sham transcranial magnetic stimulation treatment will be given with a sham coil to the sham group.
62087409|NCT01244763|EXPERIMENTAL|Cohort D: Roxadustat at 100 mg TIW|Participants will receive roxadustat capsules at 100 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
62461013|NCT06215079|PLACEBO_COMPARATOR|conventional rehabilitation program in stroke patients with complex regional pain syndrome|Only a conventional rehabilitation program consisting of discontinuous ultrasound, transcutaneous electrical nerve stimulation (TENS), and contrast bath, formed by 5 sessions, will be applied to this group.
62087410|NCT01244763|EXPERIMENTAL|Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW|Participants will receive roxadustat capsules for 24 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight \[45 to 60 kg\], medium-weight \[\>60 to 90 kg\], and heavy-weight \[\>90 to 140 kg\] participants will receive 70, 100, and 150 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from BIW to 1 time a week (QW) at the time of the initial Hb response.
62286284|NCT02437136|EXPERIMENTAL|Ph 2 Mismatch Repair-Proficient CRC|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
62286285|NCT02685917|EXPERIMENTAL|Microfracture with Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
62286286|NCT02685917|ACTIVE_COMPARATOR|Microfracture without Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
62286287|NCT00491179|EXPERIMENTAL|Pegylated IFN + RBV for HCV genotype 1|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks for HCV genotype 1
62286288|NCT00491179|EXPERIMENTAL|Pegylated IFN + RBV for HCV genotype 2|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks for HCV genotype 2
62286289|NCT01590173|EXPERIMENTAL|Prednisolone and Heparin during COH for IVF|
62286290|NCT01590173|ACTIVE_COMPARATOR|COH for IVF|
62286291|NCT03706053|PLACEBO_COMPARATOR|Placebo|Investigational pharmacy formulated placebo. In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group)
62286292|NCT03706053|EXPERIMENTAL|Midodrine Hydrochloride 10 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
62286293|NCT03706053|EXPERIMENTAL|Midodrine Hydrochloride 20 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
62286294|NCT01983644|EXPERIMENTAL|RECO thrombectomy|IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
62286295|NCT01983644|ACTIVE_COMPARATOR|Solitaire FR thrombectomy|IA thrombectomy is executed by Solitaire FR flow restoration device
62286296|NCT02761967|EXPERIMENTAL|Physical activity|"The women in the EG (Exercise Group) performed moderate physical exercise in water, following the SWEP method (Study of Water-based Exercise during Pregnancy). It consists of performing moderate physical exercise in an aquatic environment from weeks 20 to 37 of gestation. The sessions take place three times weekly, with a duration of 60 minutes each (45 minutes of activity followed by 15 minutes of relaxation). The sessions are composed of three phases: a) warm-up; b) the main phase, divided into aerobic exercise and strength-endurance exercises, designed specifically for pregnant women; c) stretching and relaxation.~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
62087411|NCT01244763|EXPERIMENTAL|Cohort F: Roxadustat at 70 mg BIW then QW|Participants will receive roxadustat capsules at 70 mg for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to BIW at the time of the initial Hb response. Then after \>8 weeks of stable Hb, dose frequency will be reduced from BIW to QW.
62087412|NCT01477645||Leaded ammunition|
62087413|NCT01477645||Non-leaded ammunition|
62087414|NCT01477645||Modified non-leaded ammunition|
62286297|NCT02761967|NO_INTERVENTION|No exercise|"The CG (Control Group) received the standard recommendations during pregnancy, including guidelines from the midwife on the positive effects of physical exercise. These participants received the usual visits from healthcare providers (midwives, obstetricians and family doctor) during pregnancy, as did those in the EG.~After the postpartum period, the women in the control group did not perform regulated physical activity."
62286298|NCT05903287||Software diagnosis|Software diagnosis with gold standard of 3 specialist physicians' interpretation.
62087415|NCT05015777|EXPERIMENTAL|Intervention Group|Participated in the exercise programme
62087416|NCT05015777|NO_INTERVENTION|Control Group|Were advised not to change anything about their current lifestyle, and in particular not to undertake any new structured physical activity.
62286299|NCT05695326|EXPERIMENTAL|Effects of a 3D Printing Technology Learning Program|
62286300|NCT02662790|EXPERIMENTAL|Preterm|
62286301|NCT01072344|EXPERIMENTAL|Chamomile Extract|Pharmaceutical grade oral chamomile extract.
62286302|NCT01072344|PLACEBO_COMPARATOR|Placebo|Pharmaceutical grade lactose monohydrate.
62286303|NCT05088408|ACTIVE_COMPARATOR|Control|Bowel preparation as usual. Colonoscopy.
62286304|NCT05088408|EXPERIMENTAL|Dietary supplement|"Bowel preparation as usual plus two bottles of the dietary supplement Resource® Energy Apricot.~Colonoscopy."
62286305|NCT06420232|EXPERIMENTAL|Weighted Blanket|
62286306|NCT02381379|ACTIVE_COMPARATOR|Peginterferon-α-2a (Pegasys®)|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year
62286307|NCT02381379|NO_INTERVENTION|Observation|Stop tyrosine kinase inhibitor that was on and no active medication that might affect CML, for example any immune-modulatory agents, traditional herbs or medications, chemotherapeutic agents, growth factors, or colony stimulating factors is allowed during the trial period.
62286308|NCT03987204|EXPERIMENTAL|Ivabradine|Patients with permanent atrial fibrillation and previously implanted pacemakers who will be started on ivabradine.
62286309|NCT01338467|EXPERIMENTAL|EYEOP Treatment|Open label, all subject treated by the EYEOP device
62461014|NCT04520386|EXPERIMENTAL|Open label single arm|1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval
62461015|NCT05999006|EXPERIMENTAL|ELIOS Procedure|ELIOS Procedure
62087417|NCT01949675|EXPERIMENTAL|Study Group 1|Participants aged 1 through 4 years at enrollment
62087418|NCT01949675|EXPERIMENTAL|Study Group 2|Participants aged 5 through 14 years at enrollment
62087419|NCT01949675|EXPERIMENTAL|Study Group 3|Participants aged 15 years and above at enrollment
62087420|NCT03847168|EXPERIMENTAL|KN026|Patient will be intravenously administrated with one dose of KN026. Dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
62286310|NCT04281199|EXPERIMENTAL|Treatment (TBI, IMRT)|Patients undergo TBI using IMRT with VMAT or tomotherapy BID on days -7 to -4 then undergo stem cell transplantation on day 0.
62286311|NCT05721066||POST-COVID|Patients hospitalized due to acute COVID-19 pneumonia and discharged home. No residual symptoms after recovery. Contacted by phone and invited to an in-person interview about their health conditions and a blood withdrawal for the assessment of the coagulation profile (both in standard laboratory and point-of-care device ClotPro).
62286312|NCT05721066||LONG-COVID|"Patients hospitalized due to acute COVID-19 pneumonia and discharged home. Presence of residual symptoms after recovery or new symptoms appeared after discharge not otherwise explained.~Contacted by phone and invited to an in-person interview about their health conditions and a blood withdrawal for the assessment of the coagulation profile (both in standard laboratory and point-of-care device ClotPro)."
62461016|NCT02379247|EXPERIMENTAL|Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 250mg daily on day 1-28~Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
62087421|NCT03862482|ACTIVE_COMPARATOR|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at one site
62461017|NCT02379247|EXPERIMENTAL|Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 300mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
62087422|NCT03862482|EXPERIMENTAL|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Device placement: B (Brånemark® dental implant) placed at one site, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at two sites
62087423|NCT03862482|EXPERIMENTAL|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at one site, SC (Screw-Vent® dental implant) placed at two sites
62087424|NCT00864565|EXPERIMENTAL|A|Fentanyl 25 μg/h transdermal system, single application
62087425|NCT00864565|ACTIVE_COMPARATOR|B|Duragesic 25 μg/h transdermal system single application
62286313|NCT04530162||Emergency Medicine Herpes Zoster Patients|Emergency Medicine adult patients with herpes zoster pain onset within 30 days of characteristic dermatomal herpes zoster rash who receive nerve block using bupivacaine and dexamethasone. The patient will be then started on Acyclovir 800 mg five times daily for seven days. For mild to moderate breakthrough pain, the patient will be prescribed a 5-day course of Tylenol 650 mg and Ibuprofen 400 mg taken up to every 8 hours together. For severe breakthrough pain, the patients will be prescribed a two-day course of 7.5 mg morphine sulfate immediate release to be taken up to every 6 hours. The location of the nerve block and dosage of injected medications will depend on the distribution of the affected dermatome.
62286314|NCT04577040||1|Tadalafil in moderate puts
62286315|NCT04577040||2|Tadalafil in severe puts
62286316|NCT04577040||3|Tadalafil with sildosin in moderate luts
62286317|NCT04577040||4|Tadalafil with sildosin in severe luts
62461018|NCT02379247|EXPERIMENTAL|Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 350mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
62087426|NCT02687386|EXPERIMENTAL|Mitoxantrone packaged EDV|Mitoxantrone packaged EDV (EnGeneIC Dream Vector)
62087427|NCT04937959||Arm 1: MCI amyloid positive|"* Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62087428|NCT04937959||Arm 2: MCI amyloid negative|"* Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62087429|NCT04937959||Arm 3: CN amyloid positive|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62087430|NCT04937959||Arm 4: CN amyloid negative|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62087431|NCT03348826|EXPERIMENTAL|Alteplase then Sodium Bicarbonate|Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered.
62087432|NCT03348826|EXPERIMENTAL|Sodium Bicarbonate then Alteplase|Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered.
62286318|NCT05697133|EXPERIMENTAL|SEMSTOP|It is the group to which the initiatives will be applied.
62286319|NCT05697133|ACTIVE_COMPARATOR|Control|It is the group to be compared to which the interventions will not be applied.
62461019|NCT02379247|EXPERIMENTAL|BYL-719 (alpelisib) Dose Expansion|"BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
62087433|NCT05279027|EXPERIMENTAL|PET imaging|This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma.
62461020|NCT00844948||Young adults (18-25 years old)|Young adults (18-25 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C \& QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
62461021|NCT00844948||Elderly (60-80 years old)|Elderly (60-80 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C \& QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
62652394|NCT02243748|EXPERIMENTAL|Phase II (individualized palliative care)|Participants receive individualized palliative care comprised of tailored educational sessions designed for each patient and FCG that have been modified based on patterns observed in Phase I. The first patient teaching session will cover physical and psychological areas and the second will cover social and spiritual areas. These sessions will be completed within 2 weeks of accrual. A third teaching session is held with the FCG alone to give the FCG the opportunity to discuss their perspectives and focus on their needs. Patients will be asked to identify topics they want included and which if any should be omitted which provides for tailoring of the content to the patient's needs and preferences.
62286320|NCT01728779|EXPERIMENTAL|Nelfinavir w/Stereotactic Body Radiation Therapy (SBRT)|Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
62286321|NCT02384811|EXPERIMENTAL|Radiation group|Radiation therapy
62286322|NCT05571683||recovered from covid-19, 2 l/min oxygen support|20 patients, who recovered from COVID-19 will be supported with 2 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
62461022|NCT00844948||Chinese speakers|Chinese speakers (Mandarin or Cantonese). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C \& QIDS-IVR, will have recently started or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
62461023|NCT03382548|ACTIVE_COMPARATOR|Short antibiotic treatment duration for VAP (7 days or less)|
62461024|NCT03382548|ACTIVE_COMPARATOR|Long antibiotic treatment duration for VAP ( 8 days or more)|
62652395|NCT05449665|EXPERIMENTAL|Control - High Fibre - Low Fibre (CTRL - HF - LF)|"* Phase 1 - CTRL: Control diet with moderate fibre consumption for 13days.~* Phase 2 - HF: ad libitum consumption of HF meals for 13days.~* Phase 3 - LF: ad libitum consumption of LF meals for 13days."
62652396|NCT04425317|OTHER|Diagnostic arm|Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells
62652397|NCT04040439||Dexmedetomidine Hydrochloride|"Pediatric patients (45 weeks corrected gestational age to \<18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation during and after mechanical ventilation in the intensive care setting"
62652398|NCT04689542|EXPERIMENTAL|Surgical Facemask|The surgical facemask will be worn during the sit-to-stand test
62087434|NCT00163215|EXPERIMENTAL|Somatropin|
62087435|NCT05443399|NO_INTERVENTION|3D-3D|All items presented in 3D form.
62087436|NCT05443399|EXPERIMENTAL|3D-2D|Initial exposure to items in 3D, generalization in 2D
62087437|NCT05443399|EXPERIMENTAL|2D-3D|Initial exposure to items in 2D, generalization in 3D
62087438|NCT05443399|EXPERIMENTAL|2D-2D|Initial exposure to items in 2D, generalization in 2D
62087439|NCT03748537|EXPERIMENTAL|Hydrocortisone|Hydrocortisone will be administered intravenously at 200 mg every 24 hours for 5 days, then tapered to a 50 mg intravenous bolus every 12 hours for days 6 to 8 and 50 mg every 24 hours for days 9 to 11, and then stopped.
62087440|NCT03748537|NO_INTERVENTION|No Hydrocortisone|In control group, patient will not receive any corticosteroids for seven day after inclusion.
62087441|NCT02728921|ACTIVE_COMPARATOR|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.
62652399|NCT04689542|NO_INTERVENTION|Control|No facemask will be worn during the sit-to-stand test
62652400|NCT05721391||Non Frail Group|The patients in no frail group did not have any component of Frailty criteria
62652401|NCT05721391||Pre Frail Group|The patients in prefrail Group had 1-2 component of Frailty criteria.
62652402|NCT05721391||Frail Group|The patients in Frail Group had 3-5 component of Frailty criteria.
62286323|NCT05571683||no covid anamnese, 2 l/min oxygen support|20 patients with no COVID-19 anamnese will be supported with 2 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
62286324|NCT05571683||recovered from covid-19, 4 l/min oxygen support|20 patients, who recovered from COVID-19 will be supported with 4 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
62286325|NCT05571683||no covid anamnese, 4 l/min oxygen support|20 patients with no COVID-19 anamnese will be supported with 4 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
62286326|NCT01597102||Liver transplantation|Patients with liver failure and liver transplantation
62286327|NCT00930059|EXPERIMENTAL|PF-04447943|
62286328|NCT00930059|PLACEBO_COMPARATOR|Placebo|
62286329|NCT04334382|EXPERIMENTAL|Hydroxychloroquine|
62286330|NCT04334382|ACTIVE_COMPARATOR|Azithromycin|
62286331|NCT02492945|EXPERIMENTAL|PDRN group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. PDRN group take ultrasonography-guided 3ml-Rejuvinex injection for the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks.
62286332|NCT02492945|ACTIVE_COMPARATOR|Dextrose group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
62286333|NCT05033392|EXPERIMENTAL|Toripalimab group|Toripalimab is administrated with160mg and repeated every 2 weeks.
62286334|NCT02909621|ACTIVE_COMPARATOR|Group A|Group A: FLEXOFYTOL® high dosage
62652403|NCT00524498|EXPERIMENTAL|A|FAIT
62087442|NCT02728921|EXPERIMENTAL|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight
62087443|NCT03580720|EXPERIMENTAL|Intervention|Intervention group, receiving Inspiratory threshold loading protocol.
62286335|NCT02909621|ACTIVE_COMPARATOR|Group B|Group B: FLEXOFYTOL® low dosage
62286336|NCT02909621|PLACEBO_COMPARATOR|Group C|Group C: PLACEBO
62286337|NCT01233206|EXPERIMENTAL|Experimental group|Patients receiving metformin pretreatment and co-administration
62652404|NCT00524498|ACTIVE_COMPARATOR|B|BST
62652405|NCT06436716||Control, SCI-1, SCI-2, SCI-3|Control: No spinal cord injury
62652406|NCT06436716||SCI-1|SCI-1: spinal cord injury and ASIA Grade A and B
62652407|NCT06436716||SCI-2|SCI-2: spinal cord injury and ASIA Grade C
62286338|NCT01233206|PLACEBO_COMPARATOR|Control group|Placebo
62286339|NCT03480802|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
62286340|NCT03480802|ACTIVE_COMPARATOR|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
62652408|NCT06436716||SCI-3|SCI-3: spinal cord injury and ASIA Grade D
62652409|NCT02427867|EXPERIMENTAL|remote ischemic preconditioning|Three cycles of 5 minutes ischemia will be applied to the upper left arm (or right arm or legs if the left arm will not be deemed suitable by the attending physician), achieved by inflation of a blood-pressure cuff to 200 mm Hg, followed by 5 minutes reperfusion while the cuff will be deflated.
62652410|NCT02427867|PLACEBO_COMPARATOR|no ischemic preconditioning|The cuff will be placed around the arm but not inflated.
62652411|NCT00255892||Part A - Provider Interviews|The provider interviews will be comprised of participants who are clinical providers, mental health providers, and case managers with at least 1 year of experience working with HIV-positive youth; one from each category from all 15 ATN sites will be targeted for a total of 45 participants.
62652412|NCT00255892||Part B - Youth Focus Groups|"The focus groups will be comprised of 6-8 participants per group who are between the ages of 16 and 24, diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive services at three selected ATN sites or their community partners for a total of 36-48 participants.~For the purposes of this study, youth who acquired HIV perinatally will be excluded from participation in this study."
62652413|NCT00701363|EXPERIMENTAL|Lanreotide Autogel 120 mg|
62652414|NCT05157373||Group 1|Patients with any type of endometrial cancer
62087444|NCT06458660|ACTIVE_COMPARATOR|Control Arm: LinkPositively|Women assigned to the LinkPositively arm will have access to all four components of the LinkPositively app. Women will be scheduled for a session with staff to inform them of their assigned virtual Peer Navigator (PN). Staff will train participants on how to download the app, explain the five components, using each component, and contacting their PN. Within the first week after, virtual PNs will complete a one-on-one, in-person or phone intake session with the participant, based on the participant's preference. During this intake session, the PN will conduct a participant needs assessment to connect her to HIV medical care via local health clinics and identify other areas of need, services of need, and assisted referrals (domestic violence services, mental health care, substance abuse treatment, housing and legal support, etc.). PNs will provide trauma-informed emotional and informational support, including guidance on accessing information about referred services.
62286341|NCT01052857|EXPERIMENTAL|1|acupuncture daily fo 7 days
62286342|NCT01052857|NO_INTERVENTION|2|observation
62652415|NCT05157373||Group 2|Patients with hyperplastic endometrial lesion (all type of endometrial hyperplasia and endometrial polyps). In this group will be included the breast cancer survivors under tamoxifen.
62652416|NCT05157373||Control group|A random sample of women without any endometrial pathology.
62652417|NCT05541705|EXPERIMENTAL|TOW|Treadmill Oscillation Walking training
62652418|NCT02414061|EXPERIMENTAL|Breakfast - Carbohydrate + Whey Protein|Addition of whey protein isolate (20 g dissolved in flavoured water) to breakfast meal composition
62652419|NCT02414061|PLACEBO_COMPARATOR|Breakfast - Carbohydrate|Only flavoured water consumed with breakfast meal
62652420|NCT02414061|NO_INTERVENTION|No Breakfast|Only water consumed at breakfast time point
62286343|NCT01571063|EXPERIMENTAL|Vitamin D3|
62286344|NCT01571063|PLACEBO_COMPARATOR|Placebo|
62286345|NCT02972320|EXPERIMENTAL|temozolomide maintain therapeutic|Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.
62286346|NCT04278885|EXPERIMENTAL|Lanadelumab|
62286347|NCT03568890|ACTIVE_COMPARATOR|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 60 days.
62286348|NCT03568890|ACTIVE_COMPARATOR|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 60 days.
62652421|NCT03336346||DTG group|Reproductive-aged HIV-infected women taking dolutegravir-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
62652422|NCT03336346||No ART group|Reproductive-aged HIV-uninfected women using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
62652423|NCT03336346||EFV group|Reproductive-aged HIV-infected women taking efavirenz-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
62652424|NCT05716464|EXPERIMENTAL|Lifestyle medicine intervention (LM)|Participants in the LM group will receive a 6-week group-based lifestyle medicine intervention.
62652425|NCT05716464|EXPERIMENTAL|Cognitive-behavioral therapy for depression (CBT-D)|Participants in the CBT-D group will receive a 6-week group-based cognitive-behavioral therapy for depression.
62087445|NCT06458660|EXPERIMENTAL|Intervention Arm: LinkPositively+|Women assigned to the LPP+ arm will receive all components of the LP arm plus access to mindfulness videos via the app, in addition to participating in a virtual 6-session weekly, PN led mindfulness meditation enhanced intervention. The sessions will be delivered in real time, by PNs and will involve 1 on 1 discussions on a) the principles and health benefits of mindfulness meditation, b) lived experiences of women living with HIV and intersectional identities of being Black, and doubling identifying as women, c) experiencing trauma in personal relationships, d) ethnic pride, e) sex/gender pride, and f) positive self-affirmations. Sessions will be conducted online, in-app, and include culturally congruent video clips, role playing, and skills building activities that enhance self-pride and coping during stressful situations.
62087446|NCT01594658||Foam sclerotherapy|This arm corresponds to ultrasound-guided foam sclerotherapy of superficial venous reflux plus conservative management
62286349|NCT00348621|ACTIVE_COMPARATOR|Visual impairment intervention program|enhanced access to eye care services
62652426|NCT00478959|EXPERIMENTAL|Lenalidomide|Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma.
62652427|NCT03208153|EXPERIMENTAL|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
62652428|NCT03208153|ACTIVE_COMPARATOR|Conservative|In-hospital coronary angiogram only if poor clinical course
62652429|NCT03251417|EXPERIMENTAL|Combination treatment|Combination treatment of irinotecan and apatinib.
62652430|NCT02550795|PLACEBO_COMPARATOR|Control|administration of 0.9% normal saline 10ml
62286350|NCT00348621|NO_INTERVENTION|Usual care|family and nursing home was apprised of ocular exam results; eye care services left to family/nursing home arrangements
62286351|NCT02848079|EXPERIMENTAL|combined TAS-102 and oxaliplatin|"Combination treatment with TAS-102 and oxaliplatin. Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional 3+3 design. The subjects in Part 2 were treated with dose level 3.~Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle."
62652431|NCT02550795|ACTIVE_COMPARATOR|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
62652432|NCT02550795|ACTIVE_COMPARATOR|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
62652433|NCT05259917|PLACEBO_COMPARATOR|Placebo|
62652434|NCT05259917|EXPERIMENTAL|KVD900 600 mg|
62652435|NCT05259917|EXPERIMENTAL|KVD900 300 mg|
62652436|NCT01675609|PLACEBO_COMPARATOR|Placebo|
62652437|NCT01675609|EXPERIMENTAL|Brimonidine Tartrate 0.025%|
62652438|NCT00774475|PLACEBO_COMPARATOR|1: standard therapy|clopidogrel 75 mg/day
62652439|NCT00774475|ACTIVE_COMPARATOR|2: doubled therapy|clopidogrel 150 mg/day
62652440|NCT06402019|ACTIVE_COMPARATOR|Intervention Group|
62652441|NCT06402019|PLACEBO_COMPARATOR|Control Group|
62087447|NCT01594658||Conservative|This arm only has medical standard handling (healings performed by the nurse group)
62087448|NCT01040780|EXPERIMENTAL|Icotinib|125 mg three times daily (375 mg per day) by mouth
62087449|NCT01040780|ACTIVE_COMPARATOR|Gefitinib|250 mg every 24 hours by mouth
62087450|NCT02986724||Vedolizumab|Bio-naïve participants with UC or CD will be treated with vedolizumab as per local prescriptions from physician in routine medical practice for up to 52 Week. Participants who fail on vedolizumab may be switched during the study to another biologic treatment as prescribed by the physician during routine medical practice for up to 52 Weeks.
62087451|NCT00504348|EXPERIMENTAL|Prospective investigation group|Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
62087452|NCT00281944|EXPERIMENTAL|Treatment (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62087453|NCT00180674|EXPERIMENTAL|Warfarin anticoagulation|Anticoagulated with warfarin to maintain an INR of 2-3 between 8 and 16 weeks (treatment period).
62087454|NCT03354988|ACTIVE_COMPARATOR|physical exercise group|For the exercise group, Intervention by doing physical exercise. systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital.
62087455|NCT03354988|OTHER|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
62087456|NCT03560141|OTHER|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
62087457|NCT03560141|OTHER|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
62087458|NCT01603940|ACTIVE_COMPARATOR|Losartan|This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
62652442|NCT01092377|EXPERIMENTAL|DHA/EPA capsules and iron tablet|
62087459|NCT01603940|ACTIVE_COMPARATOR|Benazepril|This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
62087460|NCT03928561|EXPERIMENTAL|1 - Active air cleaner then Placebo|Exposure to cat allergen in the presence of active air cleaners then placebo. 3-week wash-out period between the two exposures.
62087461|NCT03928561|EXPERIMENTAL|2 - Placebo then active air cleaner|Exposure to cat allergen in the presence of placebo then active air cleaners. 3-week wash-out period between the two exposures.
62087462|NCT03327506|EXPERIMENTAL|hypnosis group|Intervention: hypnosis session the eve of the surgery
62087463|NCT03327506|ACTIVE_COMPARATOR|premedication|alprazolam 0,5 mg the eve and the morning of the surgery
62087464|NCT02031744|PLACEBO_COMPARATOR|erlotinib [Tarceva] + placebo|
62087465|NCT02031744|EXPERIMENTAL|erlotinib [Tarceva] + onartuzumab [MetMAb]|
62087466|NCT00604929|EXPERIMENTAL|1|
62087467|NCT00620165|EXPERIMENTAL|1|
62087468|NCT00620165|PLACEBO_COMPARATOR|2|
62087469|NCT04558099|EXPERIMENTAL|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
62087470|NCT04558099|NO_INTERVENTION|Wait-list control|Usual practice
62087471|NCT06026787|EXPERIMENTAL|Dapagliflozin Arm|During the study duration of 6 months, this cohort will be administered a daily dose of 10 mg dapagliflozin in conjunction with the standard of care for primary nephrotic syndrome based on the KDIGO 2021 guidelines. The conventional treatment regimen may encompass immunosuppressive medications, agents that block the renin-angiotensin-aldosterone system (RAAS), statins, and diuretics as deemed necessary.
62286352|NCT02522767|EXPERIMENTAL|Mesalamine|4 g extended release granules (sachet)
62652443|NCT01092377|EXPERIMENTAL|DHA/EPA and placebo tablet|
62652444|NCT01092377|PLACEBO_COMPARATOR|placebo capsules & placebo tablet|
62652445|NCT01092377|EXPERIMENTAL|iron tablet and placebo capsules|
62652446|NCT06155435|EXPERIMENTAL|experimental group|"Firstly, the Pregnant Information Form, Traumatic Birth Perception Scale and Vaginal Birth Self-Efficacy Scale forms will be applied.Solution-oriented approach training; It is indicated for pregnant women one by one and in the form of at least 4 entries. A recording will take approximately 30-35 minutes.15-21 days after the solution-oriented approach training is completed the traumatic birth perception and vaginal birth self-efficacy scale form will be applied again.The traumatic birth perception form will be applied again 15-21 days after birth. The woman's birth type will be learned and recorded.~40 pregnant women will be followed in the experimental group."
62652447|NCT06155435|NO_INTERVENTION|control group|Firstly, the Pregnant Information Form, Traumatic Birth Perception Scale and Vaginal Birth Self-Efficacy Scale forms will be applied. will be no intervention on the pregnant women in the control group, and the 15-21st week after the prenatal care given to the pregnant women by the Ministry of Health is completed. Traumatic birth perception and vaginal birth self-efficacy scale form will be filled in on these days. The traumatic birth perception form will be applied again 15-21 days after birth. The woman's birth type will be learned and recorded. 40 pregnant women will be followed in the control group.
62286353|NCT02522767|PLACEBO_COMPARATOR|Placebo|Matching placebo
62286354|NCT03773302|EXPERIMENTAL|Infigratinib (BGJ398) 125 mg|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
62286355|NCT03773302|ACTIVE_COMPARATOR|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.
62286356|NCT03625440|OTHER|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.~The Digit span test and PASAT with waterpipe smoking"
62286357|NCT03625440|OTHER|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.~The Digit span test and PASAT without waterpipe smoking"
62286358|NCT01578031|ACTIVE_COMPARATOR|Obese Patients with Obstructive Sleep Apnea|Obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
62286359|NCT01578031|ACTIVE_COMPARATOR|Non-obese Patients with Obstructive Sleep Apnea|Non-obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
62286360|NCT01578031|OTHER|Obese subjects without OSA|Control.
62286361|NCT01578031|OTHER|Non-obese subjects without OSA|Control.
62286362|NCT01374061|ACTIVE_COMPARATOR|1: Classical intubation|
62286363|NCT01374061|EXPERIMENTAL|2: Glidescope intubation|
62286364|NCT01361581||ACD (acid-citrate-dextrose)|
62286365|NCT01361581||4% trisodium citrate|
62286366|NCT01361581||unfractionated heparin (UFH)|
62286367|NCT02808104|EXPERIMENTAL|Mazindol Controlled Release|Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.
62286368|NCT02808104|PLACEBO_COMPARATOR|Placebo|Matching placebo
62286369|NCT01484964|EXPERIMENTAL|Treatment A|ASP015K Formulation 1 with moderate-fat meal
62286370|NCT01484964|EXPERIMENTAL|Treatment B|ASP015K Formulation 2 under fasting conditions
62286371|NCT01484964|EXPERIMENTAL|Treatment C|ASP015K Formulation 2 with moderate-fat meal
62286372|NCT03229720|ACTIVE_COMPARATOR|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
62286373|NCT03229720|NO_INTERVENTION|Normal Dental Environment Group|Normal Dental Environment without any distractions.
62286374|NCT02542267|OTHER|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
62286375|NCT01111305|ACTIVE_COMPARATOR|Reslizumab + DEC|Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
62286376|NCT01111305|PLACEBO_COMPARATOR|Placebo + DEC|Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
62286377|NCT05574179|EXPERIMENTAL|midazola.|Inj.midazolam
62286378|NCT05574179|EXPERIMENTAL|Dexnedetomidine|inj.dexmedetomidine
62286379|NCT04884789|EXPERIMENTAL|Post-Burn Face scar|Use of 3d printed TFO with silicone interface (COFIS 3D)
62286380|NCT04760145|EXPERIMENTAL|Intervention Group|Multicomponent exercise with blood flow restriction
62286381|NCT04760145|ACTIVE_COMPARATOR|Control Group|Multicomponent exercise without blood flow restriction
62286382|NCT04009928|EXPERIMENTAL|Active followed by sham stimulation|2 weeks of active stimulation of the medial forebrain bundle or subcallosal cingulate at the optimized stimulation settings derived during the open-label phase. After 1 week of washout period (with no stimulation), subjects undergo 2 weeks of sham stimulation
62286383|NCT04009928|SHAM_COMPARATOR|Sham followed by active stimulation|"2 weeks of sham-stimulation, followed by 2 weeks of active stimulation, separated with 1 week washout period.~This is a crossover study, patients will undergo both arms, the order of which they do is randomized."
62286384|NCT01583179|NO_INTERVENTION|Control group|will get only local anesthetic and epinephrine in block. no additive in block
62286385|NCT01583179|EXPERIMENTAL|buprenorphine|will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block
62286386|NCT02921386|OTHER|Breakfast A - Fasting|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
62286387|NCT02921386|OTHER|Breakfast B - 15 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
62286388|NCT02921386|OTHER|Breakfast C - 30 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
62087472|NCT06026787|NO_INTERVENTION|Control Arm|This cohort will exclusively be subjected to the standard of care tailored for primary nephrotic syndrome. This could encompass administration of immunosuppressive drugs, agents targeting the renin-angiotensin-aldosterone system (RAAS), statins, and diuretics as warranted by individual needs.
62087473|NCT04242875||PanOptix|Participants will receive the PanOptix intraocular lens.
62087474|NCT04487028||Thoracic Surgical Patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
62087475|NCT05767138||Bamako Participants|301 male and female participants. Teenagers and adults. Living in two urban regions of Bamako.
62087476|NCT03430128|EXPERIMENTAL|Oral IMPACT|"Perioperative immunonutrition will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.~The recommended dose for IMPACT immunotherapy is one packet, to be taken three times a day."
62087477|NCT03430128|ACTIVE_COMPARATOR|Standard Nutrition (ENSURE)|Standard nutritional supplementation will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
62087478|NCT03749382|EXPERIMENTAL|Intervention Neutral instructions|Appearance based intervention group delivered with neutral instructions from the investigator alongside general stop smoking intervention leaflet.
62087479|NCT03749382|EXPERIMENTAL|Intervention Additional instructions|Appearance based intervention group delivered with neutral instructions with additional reassuring messages from the investigator alongside general stop smoking intervention leaflet.
62286389|NCT02921386|OTHER|Breakfast D - 45 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
62286390|NCT02921386|OTHER|Breakfast E - High Fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
62286391|NCT04112680|EXPERIMENTAL|Intervention group 1|Audio messages in this group are focussed on providing a Plausible Alternative to the misinformation
62286392|NCT04112680|EXPERIMENTAL|Intervention group 2|Audio messages in this group focus on Avoiding the Misinformation and instead only provide the correct information
62286393|NCT04112680|PLACEBO_COMPARATOR|Control group|Audio messages in this control group are on a different topic
62286394|NCT02005120|EXPERIMENTAL|Arm A|Bevacizumab
62286395|NCT02005120|EXPERIMENTAL|Arm B|recombinant human endostatin
62286396|NCT04722185|EXPERIMENTAL|Evaluation of the Veriton SPECT/CT system|To determine if the Veriton system can achieve equal or better image quality than a standard SPECT/CT system.
62652448|NCT03632824|EXPERIMENTAL|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
62652449|NCT03632824|PLACEBO_COMPARATOR|comparative group|expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected
62652450|NCT02745106|EXPERIMENTAL|PADN treatment|"Procedure/Surgery: Right heart catheterization, Radiofrequency pulmonary artery denervation using following devices:~1. Ablation catheter~2. Carto 3, Carto RMT, Stereotaxis~3. Swan-Ganz catheter"
62652451|NCT02745106|SHAM_COMPARATOR|Control (Sham)|"Procedure: Right heart catheterization~Using following device:~- Swan-Ganz catheter"
62652452|NCT06342232|EXPERIMENTAL|Neurofeedback Mindfulness|The participants received 8 weeks of intervention (10 min/day) including a neurofeedback mindfulness exercise via a portable EEG headband.
62087480|NCT03749382|NO_INTERVENTION|Control|Neutral task plus the general stop smoking intervention in the form of a leaflet, administered by the investigator.
62087481|NCT04664335||endometriosis cases|endometriosis laparoscopically removed / child wish
62087482|NCT04664335||controls|endometriosis laparoscopically excluded / child wish
62087483|NCT06176456|ACTIVE_COMPARATOR|10 sessions with a frequency of 1 Hz|10 sessions with a frequency of 1 Hz with an amplitude of 120% of the evoked motor response in the projection of the left Dorsolateral prefrontal cortex 1600 pulses per session with total duration of procedure \~ 20 minutes
62087484|NCT06176456|ACTIVE_COMPARATOR|10 sessions with a frequency of 20 Hz|10 sessions with a frequency of 20 Hz with an amplitude of 120% of the evoked motor response in the projection of Dorsolateral prefrontal cortex (1600 pulses per session with total duration of the procedure \~ 20 minutes)
62461025|NCT02777060|EXPERIMENTAL|Exergame|inertial sensor based system (wearable sensors, LEGSys, Biosensics LLC) will be used for balance training with computerized feedback. The balance training program is focused on lower extremities including ankle joint exercise and virtual obstacle crossing tasks.
62652453|NCT06342232|ACTIVE_COMPARATOR|Simple Attention Task|In the control group, the participants used the portable EEG headband for the same duration of intervention (8 weeks of practice, 10 min/day), but only listened to an audiobook without realtime access to their EEG recordings.
62286397|NCT06448065||Children and adults with cerebral palsy|Children and adults with cerebral palsy who attented the gait lab for a gait analysis are included in this study.
62286398|NCT05074758||non-COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) unrelated to COVID-19
62286399|NCT05074758||COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) linked to COVID-19
62286400|NCT06312787|EXPERIMENTAL|Sequence 1|Participants will receive a single dose of VX-118 as a suspension in the fasted state in dosing period 1, followed by a single dose of VX-118 as tablets in the fasted state in dosing period 2, followed by a single dose of VX-118 as tablets in the fed state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods.
62087485|NCT06176456|PLACEBO_COMPARATOR|10 placebo sessions|The coil emits sound and tactile artifacts indistinguishable from therapeutic ones, but without a magnetic pulses.
62286401|NCT06312787|EXPERIMENTAL|Sequence 2|Participants will receive a single dose of VX-118 as tablets in the fasted state in dosing period 1, followed by a single dose of VX-118 as tablets in the fed state in dosing period 2, followed by a single dose of VX-118 as a suspension in the fasted state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods.
62087486|NCT03985722|EXPERIMENTAL|Unlimited cycles of Olaratumab and Trabectedin|"The study is a phase I, non-randomised, one-armed, multicenter trial, open-label,.~The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin."
62087487|NCT02156791|EXPERIMENTAL|gpASIT+TM|
62652454|NCT03937778|EXPERIMENTAL|Tourniquet block to left upper arm|Participants underwent \~10 minutes of baseline testing followed by a tourniquet placement to left upper arm and inflated to 80-100 mmHG above systolic blood pressure. Participants repeatedly rated a variety of sensory stimuli after tourniquet was placed. Participants rated intensity and pleasantness of slow brushing and deep pressure on both hands/forearms at baseline and after loss of A-beta sensation.
62652455|NCT03256578|EXPERIMENTAL|RFM visible|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
62087488|NCT04055285|EXPERIMENTAL|Sympathetic Renal Denervation|Sympathetic Renal Denervation
62087489|NCT04055285|ACTIVE_COMPARATOR|Conventional treatment with drug therapy|Conventional drug therapy of resistant hypertension
62286402|NCT06312787|EXPERIMENTAL|Sequence 3|Participants will receive a single dose of VX-118 as tablets in the fed state in dosing period 1, followed by a single dose of VX-118 as a suspension in the fasted state in dosing period 2, followed by a single dose of VX-118 as tablets in the fasted state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods.
62286403|NCT01370967||Study formula-fed only|
62286404|NCT01370967||Human milk-fed only|
62286405|NCT01370967||Mixed-fed using study formula only|
62286406|NCT05853471|ACTIVE_COMPARATOR|Alzheimer's disease|Patients diagnosed with Alzheimer's disease
62286407|NCT05853471|ACTIVE_COMPARATOR|Mild Cognitive Impairment|Patients diagnosed with Mild Cognitive Impairment
62286408|NCT05853471|ACTIVE_COMPARATOR|Parkinson's disease|Patients diagnosed with Parkinson's disease
62286409|NCT02487992|EXPERIMENTAL|CIK plus S-1 and Bevacizumab|"Cytokine-Induced Killer Cells are used to treat advanced colorectal cancer patients with S-1 and Bevacizumab.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress.~Cytokine-induced killer cells 3 cycles,every 1 year. Continue until the disease progress."
62652456|NCT03256578|NO_INTERVENTION|RFM masked|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
62652457|NCT06192732|EXPERIMENTAL|More plant-based diet|Participants receive the dietary counselling focused on a more plant-based diet during weight loss
62087490|NCT04361630|EXPERIMENTAL|Main treatment group|Collagen membranes incorporating 10ng/ml human recombinant basic fibroblast growth factor (FGF-2/bFGF) will be placed in the sites.
62087491|NCT02874846|EXPERIMENTAL|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
62087492|NCT02874846|PLACEBO_COMPARATOR|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
62087493|NCT03862443|EXPERIMENTAL|Fixed Incentive|Eligible to earn a weekly payment during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will win $5; high adherence threshold (brushing twice per day for 14 days in a week) will win $10.
62087494|NCT03862443|EXPERIMENTAL|Drawing Incentive|Eligible to earn a weekly drawing entry with different winning probabilities during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
62286410|NCT02487992|NO_INTERVENTION|S-1 and Bevacizumab|"S-1 is an oral anticancer agent, is a derivative of fluorouracil. Bevacizumab (Avastin) is a recombinant human monoclonal IgG1 antibody, which plays a role in the biological activity of human vascular endothelial growth factor. Bevacizumab is mainly used in the treatment of advanced colorectal cancer.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress."
62286411|NCT01864785|OTHER|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
62286412|NCT01864785|OTHER|Fixation Combined With Fusion|Posterior Fixation Combined With Articular Process Fusion in thoracolumbar Fracture.
62652458|NCT02528032|OTHER|Echocardiographic evaluation|Echocardiographic evaluation of heart function with new processing tools
62652459|NCT03184740|EXPERIMENTAL|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
62461026|NCT02777060|ACTIVE_COMPARATOR|Home based balance training|The control group will ask to perform a home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback. Exercises include postural balance tasks, such as backward and forward weight shifting, as well as dynamic balance exercises, such as marching in place (comparable to virtual obstacle crossing in experimental group).
62461027|NCT01619800|EXPERIMENTAL|Blended Sensor Optimization (BSO)|Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
62461028|NCT01619800|SHAM_COMPARATOR|Accelerometer Alone (AA)|Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active
62652460|NCT03184740|SHAM_COMPARATOR|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
62652461|NCT00512434|ACTIVE_COMPARATOR|Control in arm fields|Standard treatment Intervention no'Osteosynthesis'
62652462|NCT00512434|EXPERIMENTAL|IMOCA|Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
62652463|NCT02961842|EXPERIMENTAL|Combination|500 mL colloid preload and 500 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
62652464|NCT02961842|ACTIVE_COMPARATOR|Coload|1000 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
62652465|NCT05462600||BMI>24.9 kg/m2|
62652466|NCT05462600||BMI 18-24.9 kg/m2|
62087495|NCT03862443|NO_INTERVENTION|Control - Delayed Incentive|No rewards during the first 2-months, but information on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app. After the Month 2 follow-up visit, may opt to participate in a delayed 2-month open label extension to earn the same monetary rewards the fixed incentive intervention group could earn Baseline through Month 2. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
62087496|NCT03064893|ACTIVE_COMPARATOR|Dermacell|Device for immediate implant based breast reconstruction
62461029|NCT02865408|ACTIVE_COMPARATOR|Group 1: Peptamen 1.5% via enteral only|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard EN Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d
62652467|NCT05394948|EXPERIMENTAL|Group receiving dietary recommendations including experimental nutraceutic.|Experimental group will consume experimental nutraceutic instead of the habitual breakfast during 3 weeks and within a dietary recommendations.
62087497|NCT03064893|ACTIVE_COMPARATOR|Alloderm|Device for immediate implant based breast reconstruction
62087498|NCT01423903|EXPERIMENTAL|OPDC-51602|Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
62087499|NCT01223859|EXPERIMENTAL|intervention|Interstitial soft palate RF surgery
62087500|NCT03024320|EXPERIMENTAL|M2M|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability.
62461030|NCT02865408|ACTIVE_COMPARATOR|Group 2: Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive the same enteral feeding as group 1 (Peptamen 1.5) but in addition will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/d
62461031|NCT02865408|ACTIVE_COMPARATOR|Group 3: Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids (Prosol 20%) in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/day.
62461032|NCT01128686||CHB patients who started LAM as an initial antiviral treatment|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation
62461033|NCT01387737|EXPERIMENTAL|TA-7284-Low|
62461034|NCT01387737|EXPERIMENTAL|TA-7284-High|
62461035|NCT00095212|ACTIVE_COMPARATOR|1 Transdermal Testosterone (Patch)|300 micrograms applied twice a week
62652468|NCT05394948|ACTIVE_COMPARATOR|Group receiving dietary recommendations including control nutraceutic.|Experimental group will consume control nutraceutic instead of the habitual breakfast during 3 weeks and within a dietary recommendations.
62461036|NCT00095212|PLACEBO_COMPARATOR|2 Placebo Patch (identical in appearance)|placebo patch (0 micrograms of testosterone)applied twice a week
62461037|NCT01130025|EXPERIMENTAL|Innohep®|Long-term treatment with Innohep® only.
62461038|NCT01130025|ACTIVE_COMPARATOR|Warfarin|Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.
62461039|NCT02788448|EXPERIMENTAL|VIVASURE CLOSURE DEVICE|Large hole closure device
62461040|NCT00048581|ACTIVE_COMPARATOR|Abatacept|Short Term Portion of Study
62461041|NCT00048581|PLACEBO_COMPARATOR|Placebo|Short Term Portion of Study
62461042|NCT00048581|ACTIVE_COMPARATOR|Abatacept (Long Term)|"Long Term Portion of Study:~All participants receive Active Drug"
62461043|NCT02544594|ACTIVE_COMPARATOR|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
62461044|NCT02544594|NO_INTERVENTION|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
62461045|NCT01399736|ACTIVE_COMPARATOR|FFR-guided revascularisation strategy|In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of \>0.80 will not be treated.
62652469|NCT03715062|EXPERIMENTAL|Intervention group|Receives education in diagnosing urinary tract infection and use of observation, reflection and communication tool.
62461046|NCT01399736|PLACEBO_COMPARATOR|randomised to guidelines group|In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
62461047|NCT04840251|EXPERIMENTAL|Intervention|The treatment group will have a physiotherapy well-being review and be referred for rehabilitation. They will be seen after 6 months for follow-up
62461048|NCT04840251|NO_INTERVENTION|Control|The control group will have initial assessments then receive brief advice on exercise. They will also be followed up after 6 months
62461049|NCT04840251|OTHER|Qualitative|to understand how it feels to take part in the well-being review, we will interview some participants who have already had this kind of treatment and ask questions about their experiences of it and how it was for them. We are also interested to know what differences they felt it made so that we can help to decide about the things we want to measure as outcomes in the interventional of the study.
62461050|NCT03025594|EXPERIMENTAL|Gonyautoxin|Gonyautoxin 40mcg
62652470|NCT03715062|NO_INTERVENTION|Control group|No intervention
62652471|NCT00361985|EXPERIMENTAL|1|Nexium group
62652472|NCT05298241|EXPERIMENTAL|Hand-grip Strength Game|Participants will receive a hand-grip strength game for 5-20 minutes twice a day for consecutive three days.
62461051|NCT03025594|ACTIVE_COMPARATOR|Control|Mix of chirocaine 0,2%, ketorolac and epinephrine..
62461052|NCT00376948|EXPERIMENTAL|Novasoy®, Gemcitabine & Erlotinib|Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, \& 15; Erlotinib 150 mg day 1 until day 28
62461053|NCT01706536|PLACEBO_COMPARATOR|EP-101 Placebo|EP-101 Placebo AM + EP-101 Placebo PM
62461054|NCT01706536|EXPERIMENTAL|EP 101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
62461055|NCT01706536|EXPERIMENTAL|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
62461056|NCT01706536|EXPERIMENTAL|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
62461057|NCT01706536|EXPERIMENTAL|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
62652473|NCT05298241|NO_INTERVENTION|routine care|The control group will not involve hand-grip strength game at night.
62652474|NCT05554835||Mitochondrial patients|Patients with a suspected or confirmed mitochondrial disease.
62652475|NCT01943604|EXPERIMENTAL|Experimental|"Nutella Breakfast~Waffle Breakfast"
62652476|NCT00193453|EXPERIMENTAL|Intervention|Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d).
62652477|NCT01541306||achondroplasia or hypochondroplasia|Children or adults with achondroplasia or hypochondroplasia
62286413|NCT00786045|EXPERIMENTAL|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
62286414|NCT00786045|NO_INTERVENTION|Control|The investigators have devised a series of mobility-related tasks that can be easily and safely carried out at home without ongoing professional supervision
62286415|NCT01929057||Acne patients|This group consists of patients who have at least moderate to severe acne on their back
62286416|NCT01929057||Healthy Controls|This group contains participants who do not have any active acne lesions on their back
62286417|NCT00988247|EXPERIMENTAL|BDP HFA 320 µg/day|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
62087501|NCT03024320|EXPERIMENTAL|M2Mplus|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability. This arm also includes a social networking platform where participants will be able to interact and encourage one another through the program, as well as group-based tele-coaching session.
62087502|NCT03024320|ACTIVE_COMPARATOR|Attention Control|Participants receive health-focused articles and infographics throughout 48 weeks and receive a Fitbit.
62286418|NCT00988247|PLACEBO_COMPARATOR|Placebo|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
62286419|NCT00299988|EXPERIMENTAL|IVIG|ivig
62652478|NCT05149339|NO_INTERVENTION|Case subgroup with deficient Vitamin D|Group with deficient Vitamin D \< 20 ng/mL No treatment for the Vitamin D deficiency
62286420|NCT00299988|PLACEBO_COMPARATOR|Placebo|
62286421|NCT03782454||intensive care patients with sepsis|Adult patients with verified or suspected sepsis admitted to the intensive care department from the emergency department
62286422|NCT04793399|EXPERIMENTAL|Bosutinib-Atezolizumab Combination|"Drugs to be administered:~Bosutinib 400 milligram (mg)/day Oral Tablet \[Bosulif 100mg oral tablets\] for 1 year Atezolizumab 1680 mg/28 days \[Tecentriq 840 MG in 14 ML Injection\] for 1 year"
62286423|NCT04008732|EXPERIMENTAL|MED2005 (0.6 mg)|MED2005 (0.2% GTN) gel to be used topically in Part 1 of the study
62286424|NCT04008732|EXPERIMENTAL|MED2005 (1.2 mg)|MED2005 (0.4% GTN) gel to be used topically in Part 1 of the study
62286425|NCT04008732|EXPERIMENTAL|MED2005 (1.8 mg)|MED2005 (0.6% GTN) gel to be used topically in Part 1 of the study
62286426|NCT04008732|ACTIVE_COMPARATOR|Nitrostat (1.8 mg) - Treatment Period 1|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
62286427|NCT04008732|ACTIVE_COMPARATOR|Nitrostat (1.8 mg) - Treatment Period 2|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
62286428|NCT04008732|EXPERIMENTAL|MED2005 (2.4 mg)- Part 1|MED2005 (0.8% GTN) gel to be used topically in Part 1 of the study
62652479|NCT05149339|EXPERIMENTAL|Case subgroup with deficient Vitamin D + Vitamin D supplementation|Group with deficient Vitamin D + Daily oral dose of Cholecalciferol for 28 days for correcting the deficiency
62652480|NCT05149339|NO_INTERVENTION|Case subgroup with normal Vitamin D|Group with normal Vitamin D level \> 20 ng/mL
62652481|NCT04638062|EXPERIMENTAL|Post Isometric Relaxation|"This study ARM will receive following therapies~1. Post isometric relaxation (Upper Trapezius and Levator Scapulae muscles)~2. Isometric neck strengthening exercises~3. Cryotherapy"
62286429|NCT04008732|ACTIVE_COMPARATOR|Intravenous (I.V.) dose of GTN (0.3 mg)|GTN solution for infusion (1 mg/ml) to be used intravenously in Part 2 of the study
62652482|NCT04638062|EXPERIMENTAL|Myofascial Release Therapy|"This study ARM will receive following therapies~1. Myofascial release therapy (Upper Trapezius and Levator Scapulae muscles~2. Isometric neck strengthening exercises~3. Cryotherapy"
62652483|NCT06054711|OTHER|Joint Fluid Aspiration|all included patients reporting prothesis complication will undergo a joint fluid aspiration
62286430|NCT04008732|EXPERIMENTAL|MED2005 (2.4 mg)- Part 2|MED2005 (0.8% GTN) gel to be used topically in Part 2 of the study
62286431|NCT06050135|EXPERIMENTAL|Web-based decision support (Roadmap to Parenthood)|Patients will receive access to the Roadmap to Parenthood tool (website). The goal of the Roadmap tool is to encourage young adult females (YA-Fs) to be informed about family-building options, set realistic expectations about potential difficulties, and plan ahead to avoid or mitigate barriers, while also inspiring hope and confidence that parenthood may be achieved, despite their cancer histories.
62286432|NCT06050135|ACTIVE_COMPARATOR|Informational booklet|Patients will receive the web-based Livestrong 'Planning for Life After Cancer: A Guide to Survivorship for Teens and Young Adults' informational booklet, covering many topics (e.g., physical symptoms, emotional concerns, day-to-day needs).
62286433|NCT00552110|EXPERIMENTAL|Combination1|Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily
62286434|NCT00552110|EXPERIMENTAL|Combination3|MFNS with OXY 3 sprays once daily
62286435|NCT00552110|ACTIVE_COMPARATOR|Mometasone|MFNS once daily
62286436|NCT00552110|ACTIVE_COMPARATOR|Oxymetazoline|OXY twice daily
62286437|NCT00552110|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
62286438|NCT02704247|EXPERIMENTAL|Testing CARDIOSPACE System|Healthy volunteers have to test CARDIOSPACE System
62652484|NCT01911741|EXPERIMENTAL|Treatment A|Single dose of 4 liquid-filled capsules of MDV3100 reference formulation
62652485|NCT01911741|EXPERIMENTAL|Treatment B|Single dose of 2 tablets of MDV3100 formulation tablet B
62652486|NCT01911741|EXPERIMENTAL|Treatment C|Single dose of 2 tablets of MDV3100 formulation tablet C
62652487|NCT01739335|EXPERIMENTAL|Mifepristone|'Mifepristone Oral Tablet \[Korlym\] (2 x 300mg =600 mg total, once daily, at bedtime) for 7 days
62652488|NCT01739335|PLACEBO_COMPARATOR|Placebo|Placebo Oral tablet (2 sugar pills, once daily, at bedtime) for 7 days
62652489|NCT06147271|ACTIVE_COMPARATOR|intervention|All adult patients undergoing a heart transplant between January 2017 and December 2023 at Hospital de Messejana randomized to SGLT2i intervention
62652490|NCT06147271|NO_INTERVENTION|no intervention|All adult patients undergoing a heart transplant between January 2017 and December 2023 at Hospital de Messejana randomized to routine surveillance
62652491|NCT02750631|EXPERIMENTAL|Triple Therapy|Combined Wake Therapy (one night of missed sleep), early morning bright light and sleep phase advance
62652492|NCT01528371|ACTIVE_COMPARATOR|Midazolam|Intravenous administration of midazolam at dose of 0.02mg/kg
62286439|NCT05179616||Heart Failure Patients|Patients suffering from symptoms of right heart failure due to high-grade tricuspid regurgitation
62286440|NCT04022382|EXPERIMENTAL|Restylane Defyne recipient|
62286441|NCT05249946|EXPERIMENTAL|Intervention group|"* increasing provision of vegetables and sustainable fish in food offered in early childhood education and care (ECEC) and adjusting intake of meat and milk to reasonable levels to meet recommendations~* advancing food education, reducing food waste and assessing the climate and financial impacts of the shift towards a more plant-based diet"
62286442|NCT05249946|NO_INTERVENTION|Control group|Food supply and food education continue as usual.
62286443|NCT06526780|EXPERIMENTAL|Study group|Critical ill children with airway diseases
62286444|NCT04313972|EXPERIMENTAL|Low-dose naltrexone|2mg low-dose naltrexone capsules
62286445|NCT04313972|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62286446|NCT03016780|ACTIVE_COMPARATOR|Treatment in part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with ulcerative colitis in part 1.
62652493|NCT01528371|PLACEBO_COMPARATOR|NSS|Intravenous administration of saline solution at dose of 0.004ml/kg as a placebo drug
62652494|NCT03588338|ACTIVE_COMPARATOR|Perfalgan|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
62652495|NCT03588338|OTHER|Control|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
62652496|NCT03747471|EXPERIMENTAL|Experimental Arm|Intervention: Diabetic Conversation Map x 4 Sessions
62652497|NCT03747471|NO_INTERVENTION|Control Arm|No intervention
62652498|NCT01147796|ACTIVE_COMPARATOR|Thrombus|patients with positive TEE (thrombus)
62652499|NCT01147796|PLACEBO_COMPARATOR|No thrombus|patients with negative TEE (no thrombus)
62652500|NCT01610518|EXPERIMENTAL|250 mL medium viscosity|250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
62652501|NCT01610518|EXPERIMENTAL|600 mL low viscosity|600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
62652502|NCT01610518|EXPERIMENTAL|250 mL high viscosity|250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
62087503|NCT01995942||Group 1|Patients with mrEMVI positive rectal cancer
62087504|NCT01995942||Group 2|Patients with mrEMVI negative rectal cancer
62087505|NCT01515956|EXPERIMENTAL|BMN 110 Weekly|
62087506|NCT01882062|EXPERIMENTAL|Triheptanoin 1g/kg/day|All patients received Triheptanoin oil at 1g/kg/day during 1 month
62286447|NCT03016780|PLACEBO_COMPARATOR|Placebo in part 2|The traditional treatments and normal saline will be used in patients with ulcerative colitis in part 2 according to associated guidelines.
62087507|NCT03553940|EXPERIMENTAL|Arm 1|A single dose of monovalent live attenuated influenza H3N2 M2SR vaccine (M2SR) administered intranasally on Day 1, and a single dose of licensed quadrivalent influenza vaccine (QIV) administered intramuscularly on Day 92. N=25
62087508|NCT03553940|PLACEBO_COMPARATOR|Arm 2|A single dose of Placebo administered intranasally on Day 1, and a single dose of licensed QIV administered intramuscularly on Day 92. N=25
62087509|NCT02127684|ACTIVE_COMPARATOR|Standard Dosing Group|Standard Dosing Group will receive intravitreal injections of 0.3mg. ranibizumab at baseline, week 4 and 8 )sham injections at week 2 and 6). After week 8 retreatment will be given monthly if edema is greater than 290um or ETDRS visual acuity score \<83
62087510|NCT02127684|EXPERIMENTAL|Frequent dosing group|Frequent dosing subjects will be evaluated and treated every two weeks through week 8 with intravitreal injection of 0.3mg ranibizumab. Subjects will then be evaluated monthly through week 24 and will receive treatment with ranibiumab based on residual edema and visual acuity
62087511|NCT02900781|ACTIVE_COMPARATOR|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
62087512|NCT02900781|PLACEBO_COMPARATOR|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
62087513|NCT00440674|EXPERIMENTAL|1|Direct stenting technique
62087514|NCT00440674|EXPERIMENTAL|2|Conventional stenting with pre-dilatation strategy
62286448|NCT01973309|EXPERIMENTAL|Vantictumab combined with paclitaxel|Drug: vantictumab combined with paclitaxel - administered intravenously
62652503|NCT01610518|EXPERIMENTAL|600 mL medium viscosity|600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
62652504|NCT01610518|PLACEBO_COMPARATOR|250mL control|250 mL beverage containing 50g glucose
62652505|NCT01610518|PLACEBO_COMPARATOR|600mL control|600mL beverage containing 50g glucose
62652506|NCT04113603|EXPERIMENTAL|A_Single bolus|Single bolus computed tomography urography (CTU)
62652507|NCT04113603|EXPERIMENTAL|B_Split bolus|Split bolus computed tomography urography (CTU)
62652508|NCT04357795|EXPERIMENTAL|CequaTM (Cyclosporine 0.09%) ophthalmic solution|
62652509|NCT04240873|EXPERIMENTAL|MASTER cell|Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10\^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis
62652510|NCT04240873|PLACEBO_COMPARATOR|Saline|Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis
62652511|NCT02349412|EXPERIMENTAL|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
62652512|NCT02349412|EXPERIMENTAL|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
62652513|NCT04115813|EXPERIMENTAL|Intervention Arm|The intervention arm participants received the Project YES! intervention for the first phase and then after midline data collection went into a maintenance phase.
62652514|NCT04115813|OTHER|Comparison Arm|The comparison arm was a usual care arm during the first phase (and primary analysis). After midline data collection the comparison arm began receiving the Project YES! intervention.
62652515|NCT05766241|EXPERIMENTAL|Program group|Participants in this group will receive five weekly sessions of Sensory Strategies Training (SST), facilitated by a trained clinician or graduate/post-graduate student in a health-related field.
62652516|NCT05766241|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will not receive SST or any other PTSD or sensory-processing treatments for the duration of the study.
62652517|NCT00177411|EXPERIMENTAL|PTHrP group|Subjects receiving PTHrP in varying doses.
62286449|NCT02407093|EXPERIMENTAL|High-Intensity Functional Training|CrossFit will be the HIFT intervention framework with training elements, exercise programming, and scheduling set by CrossFit staff. Workouts will be comprised of one or more of three exercise modalities: aerobic/monostructural (e.g., running), gymnastics (e.g., pullups), and weightlifting/resistance training with workouts designed to maximize use of equipment available in deployed environments (e.g.,vehicle tires). All workouts will be individually scaled to each soldier's current level of fitness by a certified trainer. Sessions will be standardized across the 6 months of intervention so that each cluster will receive exactly the same training.
62461058|NCT04549844|ACTIVE_COMPARATOR|the intervention group (G A)|Group general anaesthesia plus peribulbar block : Total 35 cases who will receive general anesthesia with peribulbar block (bupivacaine 0.5 % xylocaine 2% hyaluronidase with total volume 0.06 mg \\kg (bupivacaine : (xylocaine :hyaluronidase ) 1:1) Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
62652518|NCT04413045||C Group|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
62652519|NCT05883982|EXPERIMENTAL|I-PRF|Patients receiving I-PRF injections into temporomandibular joints.
62087515|NCT06091566|EXPERIMENTAL|Electrical stimulation|Electrical stimulation to the dorsal genital nerve.
62087516|NCT00623415|ACTIVE_COMPARATOR|Verum|flupirtine + interferon beta 1b
62087517|NCT00623415|PLACEBO_COMPARATOR|Placebo|placebo + interferon beta 1b
62087518|NCT01603121|EXPERIMENTAL|Lisofylline subcutaneous|Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
62286450|NCT02407093|ACTIVE_COMPARATOR|Army Physical Readiness Training|"The APRT program has combat readiness as the primary focus and is mandated for active duty personnel. For this study, APRT sessions have been standardized across the 6 months of the intervention according to FM 7-22 Army Physical Readiness Training manual so each cluster will receive the same training program using the Reset Phase. Sessions will consist of preparation, activities and recovery and will include strength, endurance, and mobility exercises that involve on-ground (e.g., running), off-ground (e.g., climbing), and combatives (e.g., striking and grappling) training, with supervision by a certified trainer."
62286451|NCT05607628|ACTIVE_COMPARATOR|Low-Calorie Control Group|"The control group will receive 2x calorie-restricted balanced meals per day, each consisting of a portion of animal proteins (\~20g), a portion of vegetables, and a portion of starch (rice/ noodles) per meal. The group will also receive a mid-morning beverage in the form of a malted drink (\~150 kcal and \~5g protein). The third meal of the day and any additional snacks will be left to the free choice of the participants, with calorie advice provided by study dietitian. Calorie restriction aims to reduce body weight of individual participants by \~5 - 10%.~The group will also be asked to undergo a supervised mixed exercise regime three days per week, 1 hour per day. The mixed exercise regime will consist of 2 sessions of resistance training and 1 session of aerobic training."
62286452|NCT05607628|ACTIVE_COMPARATOR|Low-Calorie Treatment Group|"The treatment group will receive 2x calorie-restricted balanced meals per day, each consisting of a portion of plant proteins (\~25g), a portion of vegetables, and a portion of starch (rice/noodles) per meal. The group will also receive a mid-morning beverage, in the form of a soy-based, plant protein beverage (\~120 kcal and 13g protein). The third meal of the day and any additional snacks will be left to the free choice of the participants, with calorie advice provided by study dietitian. Calorie restriction aims to reduce body weight of participants by \~5 - 10%.~The group will also be asked to undergo a supervised mixed exercise regime three days per week, 1 hour per day. The mixed exercise regime will consist of 2 sessions of resistance training and 1 session of aerobic training."
62286453|NCT03705416||Endoscopic sleeve gastroplasty|All obese patients who will be undergoing an endoscopic sleeve gastroplasty (ESG). As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the endoscopic sleeve gastroplasty patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
62087519|NCT01603121|EXPERIMENTAL|Lisofylline intravenous|Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
62087520|NCT03289546|EXPERIMENTAL|Mindfulness training only|1 mindfulness training class (1 hour) every week for 8 weeks.
62087521|NCT03289546|EXPERIMENTAL|Aerobic training only|3 aerobic training sessions (1 hour) per week for 12 weeks.
62087522|NCT03289546|EXPERIMENTAL|mindfulness + aerobic training|2 aerobic training sessions + 1 mindfulness training class every week for 8 weeks, then continue with 3 aerobic training sessions/ week for 4 additional weeks.
62087523|NCT03289546|NO_INTERVENTION|Usual care|
62087524|NCT05705050|EXPERIMENTAL|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
62087525|NCT05705050|PLACEBO_COMPARATOR|Control group|Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
62087526|NCT04538807||Lumbar disc herniation|Patients are complaining of lower extremity radiating pain due to lumbar disc herniation.
62087527|NCT06031662|EXPERIMENTAL|Treatment|
62087528|NCT06031662|SHAM_COMPARATOR|Sham|
62286454|NCT03705416||Surgery (VSG or RYGBP)|All obese patients who will be undergoing either a vertical sleeve gastrectomy or a Roux-en-Y gastric bypass. As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the surgical procedure patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
62461059|NCT04549844|PLACEBO_COMPARATOR|the control group (G B )|"General group: Total 35 cases who will receive general anesthesia only, i.e., without peribulbar block. (Fentanyl 1µg\\kg, atracurium 0.5 mg\\kg and propofol 2mg \\kg.~After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane."
62461060|NCT01938586||Surgical excision|
62461061|NCT04010331|EXPERIMENTAL|Nokyong Mixture Extract(CME-PI) group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 1 g/day)
62652520|NCT05378503|EXPERIMENTAL|Active|"1. Administration of Qsymia 3.75mg/23mg once a daily for 2-week(W2), and then administration of Qsymia 7.5mg/46mg once a daily for 12-week(W14).~2-1. At W14, if the weight loss rate is 3% or more, administration of Qsymia 7.5mg/46mg once a daily by the end of visit(W56).~2-2. At W14, if the weight loss rate is NOT 3% or more, administration of Qsymia 11.25mg/69mg once a daily for 2-week(W16), and then administration of Qsymia 15mg/92mg once a daily by the end of visit(W56)."
62652521|NCT05378503|PLACEBO_COMPARATOR|Placebo|Administration of Qsymia placebo once a daily by the end of visit(W56).
62652522|NCT06033469||IBD group|Pediatric patients with IBD
62652523|NCT02530385|EXPERIMENTAL|FMT|Active FMT capsules
62461062|NCT04010331|PLACEBO_COMPARATOR|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 0 g/day)
62461063|NCT00023309|EXPERIMENTAL|Lamivudine and adefovir|
62461064|NCT00023309|ACTIVE_COMPARATOR|Adefovir|
62087529|NCT04039880|EXPERIMENTAL|Cohort A (mass balance)|evaluation of mass balance and metabolite profiling
62087530|NCT04039880|EXPERIMENTAL|Cohort B (biliary evaluation)|evaluation of biliary elimination
62087531|NCT01264263||1|
62087532|NCT06529211|ACTIVE_COMPARATOR|Low caloric diet group|low-caloric diet of 1500 kcal/day.
62087533|NCT06529211|EXPERIMENTAL|ultrasound cavitation group|The participants will be treated by ultrasound cavitation, in addition to the low-caloric diet of 1500 kcal/day.
62087534|NCT06529211|EXPERIMENTAL|whole-body vibration group|The participants will be treated by whole body vibration, in addition to the low-caloric diet of 1500 kcal/day.
62087535|NCT01481935|EXPERIMENTAL|Enhanced Cleaning|Rooms in the Enhanced Cleaning arm will receive cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
62087536|NCT01481935|SHAM_COMPARATOR|Sham Enhanced Cleaning|Rooms in the Sham Enhanced Cleaning arm will receive a sham cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
62087537|NCT06440382||screening invitees|eligible women in Scotland invited to cervical screening
62087538|NCT06440382||interview study|50 women from diverse ethnic groups
62286455|NCT05064657|EXPERIMENTAL|Experimental Group|"Experimental Group (ball squeezing) The group were used a ball squeezing method during the blood collection process.~The children were given a ball during the blood draw and told to tighten and loosen it."
62461065|NCT03756857|EXPERIMENTAL|Afterload transfer|First, an empty catheter passes to the level of the lower uterine segment under ultrasound guidance to a point where the inner catheter enters the endometrial cavity. The inner sheath is removed slowly, leaving the outer sheath just beyond the internal os. After verifying the catheter's position on the TA ultrasound scan, the physician gives the signal to the embryologist to start the embryo loading. The embryologist brings the loaded inner catheter and inserts it into the outer sheath, which is maintained in its position by the physician.
62652524|NCT02530385|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62652525|NCT04596293|EXPERIMENTAL|BBT-401-1S (800mg)|"* Induction Phase: BBT-401 800mg for 8 weeks~* Extension Phase: After 8 weeks,~  * Participants who achieved clinical remission in the induction phase will continue the same treatment for 8 weeks~ * Participants who did not achieve clinical remission in the induction phase will receive BBT-401 1600mg for 8 weeks"
62652526|NCT04596293|EXPERIMENTAL|BBT-401-1S (1,600mg)|"* Induction Phase: BBT-401 1600mg for 8 weeks~* Extension Phase: After 8 weeks, Participants will continue the same treatment for 8 weeks"
62286456|NCT05064657|ACTIVE_COMPARATOR|Active Comparator|Active Comparator ( bubble blowing) The group were used a bubble blowing method during the blood collection process. During the blood collection process, the children were asked to blow bubbles by giving the apparatus inside the foam bubble to their free arm.
62286457|NCT05064657|NO_INTERVENTION|Control Group|No intervention
61978551|NCT02366845|ACTIVE_COMPARATOR|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.~INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
62087539|NCT03654586|ACTIVE_COMPARATOR|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
62087540|NCT03654586|EXPERIMENTAL|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
62087541|NCT03654586|EXPERIMENTAL|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
62087542|NCT03654586|EXPERIMENTAL|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
62087543|NCT02521519|OTHER|One side of the patient's back|medial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
62087544|NCT02521519|OTHER|Other side of the patient's back|These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
62087545|NCT04535739|EXPERIMENTAL|PCI group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy and prophylactic cranial irradiation。
62087546|NCT04535739|OTHER|control group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy。
62087547|NCT05466708|EXPERIMENTAL|Esketamine combined with dexmedetomidine|Esketamine will be administered at 1mg/kg, IVP, then intravenously pumped at 0.25-1.5mg/kg/h in combination with dexmedetomidine 1μg/kg for 20 min, followed by continuous intravenously pumped at 0.2-0.7mg/kg/h, maintaining a RASS score of -2-0.
62286458|NCT04633590|EXPERIMENTAL|home-based exergaming|The home-based exergame intervention will take place in an unsupervised place of the participant's choosing. Participants will be provided with all of the equipment (including a television if required) and receive instructions on how to use the system. Participants will be provided with a stepped training plan with exergame session durations of 19 minutes (4x 3-minutes 45-seconds of exercise interspersed with 1 minute of rest) in weeks 1 and 2; 24-minutes (4x 5-minutes of exercise interspersed with 1 minute of rest) in week 3 and 4; and 30-minutes (5x 5-minutes of exercise interspersed with 1 minute of rest) in week 5 and 6. Sessions will be set at a vigorous intensity (≥80% heart rate maximum) and participants will be provided with individualised heart rate zones to achieve in line with heart rate maximum determined during a maximal exercise test in Visit 2. Participants will be asked to train 3 times per week.
62087548|NCT05466708|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine will be administered at 1μg/kg for 20 min, followed by continuous intravenous pumping at 0.2-0.7mg/kg/h to maintain a RASS score of -2-0
62087549|NCT02038283||Low-risk Colorectal Polyps|≤2 adenomas or 3-4 adenomas all of which are \<1cm
62087550|NCT02038283||High-risk Colorectal Polyps|≥5 adenomas or ≥3 adenomas at least one of which is ≥1cm
62286459|NCT03006614|EXPERIMENTAL|PERS:NVB,DDP,GEM,CAP,H etc.|vinorelbine 25mg/m2 d1,d8 iv,q3w cisplatin 70mg/m2 d1，q3w gemcitabine 1000mg/m2 d1,d8,q3w capecitabine 1000mg/m2,bid,d1-14,q3w Trastuzumab
62461066|NCT03756857|EXPERIMENTAL|Trial Followed by Transfer|First a trial transfer is performed using both the inner catheter and outer sheath connected together in standard configuration, just before the actual embryo transfer. It is passed up to and just through the the internal os. When it appears that the actual transfer will be possible without great difficulty ,the trial catheter is withdrawn. An embryo transfer catheter is loaded and the actual transfer is performed
62461067|NCT00148304||Group 1|
62286460|NCT03006614|ACTIVE_COMPARATOR|EPI+CTX-T+/-H|Epirubicin 90mg/m2 d1+ CTX 600mg/m2 d1 q2w, Docetaxel 75mg/m2 +/-herceptin d1,q3w
62286461|NCT05782829|EXPERIMENTAL|L-Tyrosine|
62286462|NCT05782829|PLACEBO_COMPARATOR|Placebo|
62461068|NCT04473170|EXPERIMENTAL|Group A|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.
62461069|NCT04473170|ACTIVE_COMPARATOR|Group B|COVID-19 Standard care.
62461070|NCT00996320|EXPERIMENTAL|Intervention Schedule|Interns on the intervention schedule work the a modified ICU schedule averaging about 60 hours per week over 4 weeks, with maximum scheduled shift length 16 hours.
62652527|NCT04596293|PLACEBO_COMPARATOR|Placebo|"* Induction Phase: Placebo for 8 weeks~* Extension Phase: After 8 weeks,~  * Participants who achieved clinical remission in the induction phase will continue the same treatment for 8 weeks~ * Participants who did not achieve clinical remission in the induction phase will receive BBT-401 800mg for 8 weeks"
62286463|NCT03695913|EXPERIMENTAL|Normal Diet + CGM then low carb + CGM|"Phase I (part 1) - regular diet:~Patients will wear a CGM sensor (with no real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings.~Phase II (part 2) - low carb diet:~Patients will wear a CGM sensor (with real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings; document their blood sugar before and two hours after eating (as well as before breakfast and before going to bed)."
62286464|NCT06126991|EXPERIMENTAL|The Modified Sedation and Analgesia Regimen Group|midazolam, fentanyl, cetirizine
62286465|NCT06126991|ACTIVE_COMPARATOR|The Sedation and Analgesia Regimen Group|midazolam, fentanyl
62286466|NCT04524845|EXPERIMENTAL|Rebel Reliever|Rebel Reliever (RR) (Thuasne, Levallois Perret, France) with bilateral rigid frames and two hinges. The valgus correction was set by adjusting the medial and lateral frame lengths to a difference of two or three points as dictated by the participant's feeling and comfort. Six straps maintained the brace in place
62087551|NCT02038283||Stage I CRC|at least six months since diagnosis of Stage I CRC
62286467|NCT04524845|EXPERIMENTAL|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France) made mainly from textile. Upper and lower straps were adjusted to the participant's feeling and comfort.
62286468|NCT04524845|ACTIVE_COMPARATOR|Unloader One|Unloader One (UO) (Össur, Reykjavik, Iceland), with unilateral frame and one hinge. Upper and lower straps were adjusted to the setting recommended by the fitting instructions and confirmed by the participant's sensation.
62286469|NCT04524845|NO_INTERVENTION|No orthosis|Control condition without brace
62286470|NCT03120169|ACTIVE_COMPARATOR|treadmill endurance training|
62286471|NCT03120169|ACTIVE_COMPARATOR|cycling endurance training|
62286472|NCT05166707|EXPERIMENTAL|BIXINK OC Free|A 6 week ERP-based intervention
62461071|NCT00996320|NO_INTERVENTION|Traditional Schedule|Interns on the traditional schedule work the usual ICU schedule averaging about 80 hours per week over 4 weeks, with maximum shift length 30 hours.
62461072|NCT04759248|EXPERIMENTAL|Atezolizumab in combination with Trastuzumab and Vinorelbine|
62461073|NCT05585866||Sevoflurane|The group of patients which received sevoflurane as randomized anesthetic modality.
62087552|NCT02038283||Stage II CRC|at least six months since diagnosis of Stage II CRC
62087553|NCT02038283||Stage III CRC|at least six months since diagnosis of Stage III CRC
62087554|NCT02038283||Stage IV CRC|at least six months since diagnosis of Stage IV CRC
62087555|NCT04850365|OTHER|Abdominal sacral hysteropexy|The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.
62087556|NCT04850365|OTHER|Vaginal sacrospinous hysteropexy|"This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.~The outcomes will be obtained as follow;"
62087557|NCT03839563|EXPERIMENTAL|Conventional exercise|This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months. Each session will last 60 min.
62087558|NCT03839563|EXPERIMENTAL|Tai chi chuan|The 8-form Yang-style tai chi chuan intervention will take place at a subject's residence or in the neighborhood once a week for 6 months, and each session will last 60 min.
62286473|NCT05025566||Psychotic disorders|
62286474|NCT05025566||Depressive disorders|
62286475|NCT05025566||Bipolar disorders|
62286476|NCT05025566||Anxiety disorders|
62286477|NCT05025566||Autism spectrum disorders|
62286478|NCT05025566||Eating disorders|
62286479|NCT05025566||Healthy volunteers|
62286480|NCT06070948|EXPERIMENTAL|Regimen A|Participants will receive venetoclax dose A commercial formulation following a high-fat meal.
62286481|NCT06070948|EXPERIMENTAL|Regimen B|Participants will receive venetoclax dose B new formulation following a high-fat meal.
62286482|NCT06070948|EXPERIMENTAL|Regimen C|Participants will receive venetoclax dose A new formulation following a high-fat meal.
62286483|NCT06070948|EXPERIMENTAL|Regimen D|Participants will receive venetoclax dose B new formulation under fasted conditions.
62286484|NCT04586829|ACTIVE_COMPARATOR|Conventional diet|Conventional diet. (50% carbohydrate, 30% lipids, 20% protein). Current dietary recommendations from official guidelines will be reinforced.
62286485|NCT04586829|EXPERIMENTAL|Ketogenic diet|Tailored ketogenic diet. Participants will be allowed to chose their meals as long as they consume less than 50gr of carbohydrates per day.
62286486|NCT02682680|EXPERIMENTAL|Colesevelam|Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks
62286487|NCT02682680|ACTIVE_COMPARATOR|Ezetimibe|Ezetimibe 10 mg once daily for 24 weeks
62286488|NCT02269358|EXPERIMENTAL|Addition of methotrexate|Addition SC methotrexate at 15 mg/m2, not to exceed 25 mg/m2 . Patients in remission after 4 weeks will reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
62286489|NCT00936988|EXPERIMENTAL|cinacalcet|
62461074|NCT05585866||Propofol|The group of patients which received propofol as randomized anesthetic modality.
62461075|NCT02268032|EXPERIMENTAL|Vaginal ring 1 (VRD)|20 women using DHEA (VRD) for 2 menstrual cycles
62461076|NCT02268032|EXPERIMENTAL|Vaginal ring 2 (VRaA)|20 women using another androgenic agent (VRaA) for 2 menstrual cycles
62461077|NCT02268032|EXPERIMENTAL|Vaginal ring 3 (VR2A)|20 women using fixed combination of 2 androgenic agents (VR2A) for 2 menstrual cycles
62652528|NCT05989581|EXPERIMENTAL|BP goal <130/80mmHg|
62652529|NCT05989581|NO_INTERVENTION|BP goal <140/90 (usual care)|
62652530|NCT04830280|ACTIVE_COMPARATOR|Posterior quadratus lumborum block|
62652531|NCT04830280|SHAM_COMPARATOR|control group|
62286490|NCT02317757||cancer patients receiving chemotherapy|Patients who are older than 70 years old receiving chemotherapy
62286491|NCT05025215|EXPERIMENTAL|Group A： Precise|The experimental group accepts improved precise aerosol inhalation nursing program，which was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc. This group is planned to enroll 100 patients.
62286492|NCT05025215|EXPERIMENTAL|Group B：Traditional|The control group accepts traditional aerosol inhalation nursing method. This group is planned to enroll 100 patients.
62286493|NCT03709927|EXPERIMENTAL|Therapeutic ZTI-01 6 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g
62286494|NCT03709927|EXPERIMENTAL|Supra-therapeutic ZTI-01 12 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g
62652532|NCT05375916|EXPERIMENTAL|Sustained-release opioid|3mg of sustained-release hydromorphone three times a day
62652533|NCT05375916|ACTIVE_COMPARATOR|Short-acting opioid|1-4 mg of short-acting hydromorphone 2-4 times a day as needed
62652534|NCT05623800|EXPERIMENTAL|PREM-Kit group|
62652535|NCT05623800|NO_INTERVENTION|Control group|
62652536|NCT02239289|EXPERIMENTAL|Biofeedback|Subjects will be provided with four sessions of supervised biofeedback training
62652537|NCT06352606|EXPERIMENTAL|Spinal Anesthesia|Oxygen supply will be done via nasal prong (2 L/min) when necessary. The local anesthetic used will be bupivacaine 0.6 mg/kg.
62286495|NCT03709927|ACTIVE_COMPARATOR|moxifloxacin 400 mg PO|oral moxifloxacin 400mg film coated tablets - Avelox(TM)
62461078|NCT01357278|EXPERIMENTAL|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
62461079|NCT01357278|NO_INTERVENTION|Patient education|Patient education will be offered every eight week.
62461080|NCT03622138|EXPERIMENTAL|Naive EBP Providers|Naive Providers (providers with no prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
62286496|NCT03709927|PLACEBO_COMPARATOR|Placebo IV|IV 0.9% normal saline solution
62286497|NCT04639323||Overall eligible participants|Eligible participants whose varix size will be measured by endoscopists and endoscopic ruler will receive standard esophagogastroduodenoscopy
62286498|NCT01029730|EXPERIMENTAL|Bendamustine/Bortezomib/Rituximab|Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
62286499|NCT01573910|EXPERIMENTAL|Moxifloxacin|Moxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
62652538|NCT06352606|ACTIVE_COMPARATOR|General Anesthesia|Patients will receive sevoflurane for induction and maintenance in an air/oxygen mixture along. Endotracheal tube will be inserted. No opioids or nitrous oxide was used intraoperatively.
62652539|NCT06525168|EXPERIMENTAL|DA414 Granules|The trial plans to conduct studies with five dosage groups. The 12.5 mg dosage group will include 2 subjects, both receiving DA414 granules. The 25 mg, 50 mg, and 100 mg dosage groups will each include 10 subjects randomly assigned in a 8:2 ratio (8 receiving the investigational drug and 2 receiving placebo). The 200 mg dosage group will include 8 subjects, randomly assigned in a 6:2 ratio (6 receiving the investigational drug and 2 receiving placebo).
62652540|NCT06525168|PLACEBO_COMPARATOR|DA414 Placebo|The trial plans to conduct studies with five dosage groups. The 12.5 mg dosage group will include 2 subjects, both receiving DA414 granules. The 25 mg, 50 mg, and 100 mg dosage groups will each include 10 subjects randomly assigned in a 8:2 ratio (8 receiving the investigational drug and 2 receiving placebo). The 200 mg dosage group will include 8 subjects, randomly assigned in a 6:2 ratio (6 receiving the investigational drug and 2 receiving placebo).
62652541|NCT03179384|EXPERIMENTAL|ceftriaxone treatment|
62652542|NCT01669239|EXPERIMENTAL|Liposomal Doxorubicin|"Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
62652543|NCT02748772|ACTIVE_COMPARATOR|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
62652544|NCT02748772|PLACEBO_COMPARATOR|Pure chemotherapy（Xelox）|chemotherapy alone for the patients of Advanced Colorectal Cancer
62652545|NCT00021242|EXPERIMENTAL|Relapsed or Refractory ALL, AML|Docetaxel 60 mg/m\^2 per dose weekly (Days 1,8,15) for 3 weeks followed by 1 week of rest.
62652546|NCT03915743|EXPERIMENTAL|Palliative care|Specialized palliative care arm in a newly formed COPD outpatient clinic
62652547|NCT03915743|NO_INTERVENTION|Usual care|Usual care in a standard pulmonary out-patient clinic. Treatment as described in national standards.
62652548|NCT01199549||Lycopene group|Mixed age and gender group of healthy volunteers for testing bio-availability of Lycopene containing supplement
62087559|NCT03839563|NO_INTERVENTION|Health education/usual physical activity|After the baseline, the case manager will visit subjects in this group once for comparability with the other two intervention groups and instruct them to maintain their usual physical activity.
62652549|NCT01199549||Resveratrol group|Mixed age and gender group of healthy volunteers for testing bio-availability of Resveratrol containing supplement
62652550|NCT01199549||Laflavon group|Mixed age and gender group of healthy volunteers for testing bio-availability of Soy Isoflavones containing supplement
62652551|NCT00623181|EXPERIMENTAL|Fluzone Intradermal First, Then Fluzone Intramuscular|
62652552|NCT00623181|EXPERIMENTAL|Fluzone Intramuscular First, Then Fluzone Intradermal|
62652553|NCT05916170|EXPERIMENTAL|Intervention - Health Warnings|Cafes will display text-only warning signs
62652554|NCT05916170|EXPERIMENTAL|Control - No Warnings|No warnings posted in the hookah café
62652555|NCT05458778||Women who are trying to conceive|
62652556|NCT02372461|PLACEBO_COMPARATOR|Experimental|Placebo
62652557|NCT02372461|ACTIVE_COMPARATOR|Control|Amoxicillin Liquid
62652558|NCT03153657|EXPERIMENTAL|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
62652559|NCT03153657|PLACEBO_COMPARATOR|Placebo|Intervention: Drug Placebo
62652560|NCT00300599|ACTIVE_COMPARATOR|A|Continue positive airway pressure
62652561|NCT00300599|PLACEBO_COMPARATOR|B|Placebo
62652562|NCT04164238|EXPERIMENTAL|Arm A|Toripalimab 240mg IV, every 3 weeks;
62652563|NCT04164238|EXPERIMENTAL|Arm B|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m\^2, IV, Q3W; Carboplatin AUC 5, IV, Q3W
62652564|NCT04164238|EXPERIMENTAL|Arm C|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m\^2, IV, Q3W; Cisplatin 25mg/m\^2 IV,d1-d3, Q3W; 5-FU 3000mg/m\^2 CIV 72h, Q3W
62652565|NCT04635839|ACTIVE_COMPARATOR|Standard Dosing|Standard dose of unfractionated heparin
62652566|NCT04635839|ACTIVE_COMPARATOR|Gestational Age-Based Dosing|Dose of unfractionated heparin based on trimester of pregnancy
62652567|NCT03206359||Patients|Patients with SLE
62652568|NCT03206359||Healthy subjects|
62461081|NCT03622138|EXPERIMENTAL|Experienced EBP Providers|Experienced EBP Providers (providers with prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
62087560|NCT02726555|EXPERIMENTAL|Red yeast rice and atorvastatin|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 300mg of red yeast rice and 2 10mg of atorvastatin.
62286500|NCT01573910|ACTIVE_COMPARATOR|Ofloxacin|Ofloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
62286501|NCT03655444|EXPERIMENTAL|Phase I: Abemaciclib + Nivolumab|"* Abemaciclib (150 mg) will be administered orally twice per day (with or without food) on Days 1 through 28 of every 4-week cycle~* Nivolumab 480 mg will be given intravenously (IV) over 30 minutes on Day 1 of every 4-week cycle."
62286502|NCT03655444|EXPERIMENTAL|Phase II: Abemaciclib + Nivolumab|"* Phase II Lead-in: Patients will be treated with abemaciclib monotherapy at the recommended phase II dose (150 mg) on Day -7 through Day -1 prior to starting Cycle 1 with the combination of abemaciclib and nivolumab. Patients will proceed directly from Day -1 to Cycle 1 Day 1 of combination abemaciclib + nivolumab, there is not a Day 0.~* Patients will be treated with abemaciclib at the RP2D (150 mg) (Days 1 through 28) + nivolumab (480 mg, Day 1) of each 4-week cycle."
62286503|NCT00789633|EXPERIMENTAL|Masitinib & gemcitabine|Participants receive masitinib (9 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
62286504|NCT00789633|PLACEBO_COMPARATOR|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
62286505|NCT04977206|NO_INTERVENTION|No Intervention|Patients receiving usual care
62286506|NCT04977206|EXPERIMENTAL|Intervention|Patient's receiving care following nurse education on mutual goal-setting
62286507|NCT05708742|SHAM_COMPARATOR|Control group|The control group underwent US-guided sham block at L4 vertebrae level with 20 ml of saline 0.9%. At the level of L4 and after skin sterilization, sham block was administered in a sitting position. Hydro dissection of the interfascial plane between the erector spinae muscle and TP was confirmed by visualizing the local anesthetic spreading in a linear pattern between the muscle and the bony acoustic shadows of the TP. Then, up to 20 ml Saline 0.9% was injected.
62461082|NCT03182322|EXPERIMENTAL|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
62461083|NCT03182322|PLACEBO_COMPARATOR|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
62652569|NCT04762186|EXPERIMENTAL|Dose escalation|SARS CoV-2 infected participants will receive a single infusion over 15 to 30 minutes
62087561|NCT02726555|ACTIVE_COMPARATOR|Atorvastatin alone|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 placebo and 2 10mg of atorvastatin.
62087562|NCT02351895||Copper linens|One ward during each period (23 weeks each) used copper impregnated linen on the bed and as patient gowns. The second ward used regular linen on the bed and as patient gowns
62652570|NCT01294046|EXPERIMENTAL|Deep brain stimulation of SPG for migraine|Electrical SPG for Treatment of Migraine
62652571|NCT06072638|EXPERIMENTAL|Eating in the Absence of Hunger (single arm)|The researchers will enroll 120 children from the long-term observational study, NCT06039878.
62087563|NCT00635843|EXPERIMENTAL|MAVERICK™ Disc|
62087564|NCT00635843|ACTIVE_COMPARATOR|Fusion|
62087565|NCT02157415|EXPERIMENTAL|Long-term catherized patients|Uro-Tainer Polihexanide 0.02% 100ml rinsing solution
62087566|NCT03572829|EXPERIMENTAL|Aprepitant|Aprepitant combined with ondansetron and dexamethasone
62087567|NCT05653180|EXPERIMENTAL|IBI310+ sintilimab|All Subjects will be treated with : Sintilimab 200mg IV Q3W continuously and IBI310 2mg/kg IV single dose, 3 weeks later, IBI310 maintenance dose is 1mg/kg IV Q6W until progression (treatment duration up to 24 months).
62087568|NCT03499600|EXPERIMENTAL|Clinical Assessment and CFI|CA and CFI families will receive the Cultural Formulation Interview prior to their standard Clinical Assessment during their intake.
62087569|NCT03499600|ACTIVE_COMPARATOR|Clinical Assessment Only|CA families will receive a standard Clinical Assessment during intake.
62087570|NCT02875678|EXPERIMENTAL|ABX-1431|ABX-1431, capsules, 40 mg, single dose
62087571|NCT02875678|PLACEBO_COMPARATOR|Placebo|Placebo, capsules, single dose
62087572|NCT03311854|EXPERIMENTAL|Emapalumab|
62461084|NCT06001034|EXPERIMENTAL|Group 1: Aerobic exercise plus occlusive tool.|Performing low-impact aerobic exercise with an occlusive tool 2 days per week.
62652572|NCT03976908|EXPERIMENTAL|ON-OFF|Patients receive the same baseline, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
62652573|NCT03976908|EXPERIMENTAL|OFF-ON|Patients receive the same baseline, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
62652574|NCT00115388|OTHER|Deferred screening control group|Samples from women in the control group were stored and tested at the end of the trial
62652575|NCT03740464|EXPERIMENTAL|Study group|Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
62652576|NCT03740464|ACTIVE_COMPARATOR|Control group|Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
62652577|NCT01988324|EXPERIMENTAL|FES/FDHT-PET|
62652578|NCT02623192||ARDS|
62087573|NCT02448719|EXPERIMENTAL|Cohort 1-active|Single oral administration of TAK-792 30 milligram (mg) in Japanese participants
62461085|NCT06001034|NO_INTERVENTION|Group 2: Aerobic exercise without occlusive tool.|Performing low-impact aerobic exercise without an occlusive tool 2 days per week.
62652579|NCT04556266|EXPERIMENTAL|Cohort -1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10\^4 cells/kg"
62652580|NCT04556266|EXPERIMENTAL|Cohort 1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10\^5 cells/kg"
62652581|NCT04556266|EXPERIMENTAL|Cohort II|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 2 x 10\^5 cells/kg"
62652582|NCT04556266|EXPERIMENTAL|Cohort III|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 4 x 10\^5 cells/kg"
62652583|NCT05197738||High risk OSA|"Cohort of individuals found to sleep have scores categorized as High risk, on the Berlin questionnaire."
62652584|NCT05197738||Low risk OSA|"Cohort of individuals found to sleep have scores categorized as Low risk, on the Berlin questionnaire."
62652585|NCT05197738||Short sleepers|Cohort of individuals found to have average sleep duration of \< 7 hours per night. Individuals who sleep on average less than 6 hours per night will further be sub-categorized as very short sleeprs.
62652586|NCT05197738||Long sleepers|Cohort of individuals found to have average sleep duration of \>9 hours per night.
62652587|NCT05197738||Average lengths leepers|Cohort of individuals found to have an average sleep duration between 7 and 9 hours per night
62652588|NCT05197738||Regular sleepers|Cohort of individuals whose standard deviation of sleep duration falls within 1 standard deviation of their mean sleep duration.
62652589|NCT05197738||Irregular sleepers|Cohort of individuals whose standard deviation of sleep duration falls greater than 1 standard deviation of their mean sleep duration
62652590|NCT05197738||Severe insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as severe
62652591|NCT05197738||Moderate insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as moderate
62652592|NCT05197738||No insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as low
62652593|NCT05197738||Increased social jet lag|Individuals who are more than 1 hour less or more of sleep on weekdays compared to average weekend sleep.
62652594|NCT02774889|ACTIVE_COMPARATOR|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.~1. Fall prevention tips~2. Fall prevention exercise videos noting technique and safety~3. Guest expert videos and communication with expert~4. Tools to set exercise goals, reminders and track progress~5. Fall prevention specialist for feedback and group activities~6. Discussion and messaging (1:1, small and large group)~7. Fall prevention resources."
62087574|NCT02448719|PLACEBO_COMPARATOR|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
62087575|NCT02448719|EXPERIMENTAL|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
62087576|NCT02448719|PLACEBO_COMPARATOR|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
62087577|NCT02448719|EXPERIMENTAL|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
62087578|NCT02448719|PLACEBO_COMPARATOR|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
62087579|NCT02448719|EXPERIMENTAL|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
62087580|NCT02448719|PLACEBO_COMPARATOR|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
62087581|NCT02448719|EXPERIMENTAL|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
62087582|NCT02448719|PLACEBO_COMPARATOR|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
62087583|NCT02448719|EXPERIMENTAL|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
62087584|NCT02448719|PLACEBO_COMPARATOR|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
62286508|NCT05708742|EXPERIMENTAL|ESP group|The ESP group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%. After skin sterilization, ESP block was administered in a sitting position. A linear US transducer was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between. Next, 2-3 ml of 2% lidocaine was infiltrated. Hydro dissection of the interfascial plane between the erector spinae muscle and TP was confirmed by visualizing the local anesthetic spreading in a linear pattern between the muscle and the bony acoustic shadows of the TP.
62286509|NCT03556215|EXPERIMENTAL|Effusion, Eustachian tube dilatation device and myringotomy|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy
62087585|NCT00125775|ACTIVE_COMPARATOR|1|Engerix-B 40 mcg dose
62087586|NCT00125775|ACTIVE_COMPARATOR|2|Engerix-B 80 mcg dose
62087587|NCT04629144|EXPERIMENTAL|Belimumab|Belimumab administered subcutaneously 200mg weekly from week 1 to week 24.
62087588|NCT04629144|PLACEBO_COMPARATOR|Placebo|Placebo of Belimumab administered subcutaneously weekly from week 1 to week 24.
62087589|NCT05270382|ACTIVE_COMPARATOR|Cetylpyridinium chloride/pH adjuster 1|A mouthwash contains cetylpyridinium chloride and pH adjuster 1.
62087590|NCT05270382|PLACEBO_COMPARATOR|Placebo 1|A mouthwash without cetylpyridinium chloride and pH adjuster 1
62087591|NCT05270382|ACTIVE_COMPARATOR|Cetylpyridinium chloride/pH adjuster 2|A mouthwash contains cetylpyridinium chloride and pH adjuster 2.
62087592|NCT05270382|PLACEBO_COMPARATOR|Placebo 2|A mouthwash without cetylpyridinium chloride and pH adjuster 2
62087593|NCT04643730|EXPERIMENTAL|Reflexology Group|Foot Reflexology was applied to the babies before heel lancing
62087594|NCT04643730|EXPERIMENTAL|Acupressure Group|Acupressure was applied to the babies before heel lancing
62087595|NCT04643730|ACTIVE_COMPARATOR|Control Group|No pre-application was made to the babies in the control group as a routine procedure
62087596|NCT05516628|EXPERIMENTAL|Surgery followed by Adjuvant Atezolizumab-Bevacizumab Therapy every 3-weekly|Patient will receive adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following surgery.
62087597|NCT05661760||chronic pain osteoarthritis|Patients with chronic pain and disability with osteoarthritis
62087598|NCT01241578|EXPERIMENTAL|Mobile Phone Intervention|Participants receive a behavioral intervention via mobile phone and brief in-person counseling sessions.
62461086|NCT04403880||Group 1|"Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~* 1A: Persons with asymptomatic infection, ages 18 through 55, inclusive~* 1B: Persons with asymptomatic infection, age \> 55~* 1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55~* 1D: Persons with symptomatic infection (ie, COVID-19), age \> 55"
62087599|NCT05641077|EXPERIMENTAL|Virtual Visit|Patients randomized to the experimental arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
62087600|NCT05641077|ACTIVE_COMPARATOR|Office Visit|Patients randomized to the active comparator arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
62087601|NCT05118087|ACTIVE_COMPARATOR|Coaptation Splint|
62087602|NCT05118087|ACTIVE_COMPARATOR|Sarmiento Brace|
62087603|NCT03700606|ACTIVE_COMPARATOR|Nasal CPAP - Period 1|"Eligible infants stable on high flow nasal cannula (nCPAP) therapy of 5-7 cm H20 achieved with a ventilator, an underwater bubble system, or a variable-flow device will be enrolled. A data acquisition cart will be placed at the subject's bedside to collect hemodynamic and respiratory parameters measured including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices. A neonatal chest belt, sized to the infant's chest circumference (nipple level) using warmed ultrasound gel applied to the belt beforehand, will collect regional lung volume measurements using electrical impedance tomography (EIT). Subject video recording will capture apnea events and the interventions used to resolve them such as positive pressure ventilation, repositioning, or stimulation. Data will be collected for 15 minutes on nCPAP."
62461087|NCT04403880||Group 2|"Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~* 2A: Persons 18 through 55 years of age~* 2B: Persons \> 55 years of age"
62652595|NCT02774889|NO_INTERVENTION|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
62652596|NCT04577508|EXPERIMENTAL|Functional Remediation|Functional Remediation
62087604|NCT03700606|ACTIVE_COMPARATOR|High Flow Nasal Cannula (HFNC) - Period 2 & 3|Respiratory support will be crossed over to a HFNC Optiflow Jr 2 (Fisher \& Paykel Healthcare, Auckland, New Zealand) at a flow rate of 8 LPM. The size of the nasal cannula will be determined according to the manufacturer's instructions in order to maintain a leak at the nares. Identical data collection will occur for two 15 minute periods on HFNC, at the beginning and end of the six hour Study period.
62087605|NCT03700606|ACTIVE_COMPARATOR|Nasal CPAP - Period 4|After 6 hours of HFNC of 8 LPM, or sooner if the infant meets failure criteria, the infant will then be crossed back to the nCPAP device and at the settings previously utilized in Study Period 1. The infant will remain on the nCPAP device with identical data collection for 15 minutes. The total duration of the study and data collection will be 8 hours. The infant's body position will be similar for each lung volume measurement during the study periods.
62087606|NCT02427646|EXPERIMENTAL|ET BoNT-A treatment|ET participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
62286510|NCT03556215|EXPERIMENTAL|Effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)
62286511|NCT03556215|EXPERIMENTAL|No effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy
62087607|NCT02427646|EXPERIMENTAL|PD tremor BoNT-A treatment|PD participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
62087608|NCT06351267|EXPERIMENTAL|Core Stability Exercises and Back Strengthening exercises group:|we will ask the patient to perform a combined exercise program of core stability exercises program with a back strengthening exercises program. 5 sessions per week and post-intervention assessment after 4 weeks follow-up
62087609|NCT06351267|ACTIVE_COMPARATOR|Core Stability Exercise group|In this group, patients will only perform the Core Stability Exercises program. 5 sessions per week and post-intervention assessment after 4 weeks follow-up
62286512|NCT03599700||myeloproliferative neoplasms|"* history taking~* physical examination~* laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
62461088|NCT04403880||Group 3|Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)
62286513|NCT00130286|EXPERIMENTAL|rhGH + rosi|Recombinant human growth hormone + rosiglitazone
62286514|NCT00130286|EXPERIMENTAL|rhGH placebo + rosi|Placebo for recombinant human growth hormone + rosiglitazone
62286515|NCT00130286|EXPERIMENTAL|rhGH + rosi placebo|Recombinant human growth hormone + placebo for rosiglitazone
62286516|NCT00130286|PLACEBO_COMPARATOR|Double placebo|Placebo for recombinant human growth hormone + placebo for rosiglitazone
62286517|NCT00650858|ACTIVE_COMPARATOR|0.3 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
62461089|NCT01174680|EXPERIMENTAL|patients with stable angina pectoris|stable patients, who have been admitted to one of the participating centres for an elective coronary angiography
62461090|NCT02828709|EXPERIMENTAL|Irreversible electroporation (IRE)|"IRE is based on high current electric pulses, transferred between two or more placed needle electrodes. Charging the cell membrane causes holes in the cell membrane called nanopores, resulting in increased permeability of the cell and subsequent cell death."
62461091|NCT03026270|OTHER|seven layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
62461092|NCT03026270|OTHER|ten layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
62652597|NCT04577508|OTHER|Control|Treatment as usual
62461093|NCT02738242|EXPERIMENTAL|Novus system users|Sixteen (16) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be recruit for this study and will receive the Novus system for daily use.
62087610|NCT01880554|OTHER|Contrast-enhanced intraoperative ultrasound|Contrast-enhanced intraoperative ultrasound
62087611|NCT03929302|ACTIVE_COMPARATOR|Cognitively normal adults group|A group of cognitively normal adults will be included to investigate whether MyTAP oral airway management with a mouth shield improves sleep and cognition.
62087612|NCT03929302|ACTIVE_COMPARATOR|Mild Cognitive Impairment (MCI) group|A group of MCI will be included to investigate whether MyTAP oral airway management with a mouth shield improves sleep and cognition.
62087613|NCT03929302|ACTIVE_COMPARATOR|Alzheimer's Disease group|A group of AD will be included to investigate whether MyTAP oral airway management with a mouth shield improves sleep and cognition.
62286518|NCT00650858|ACTIVE_COMPARATOR|1.0 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
62286519|NCT00650858|EXPERIMENTAL|1.0 mg Rt-PA q8h|In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
62286520|NCT04505683|EXPERIMENTAL|test drug arm|Benapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
62286521|NCT04505683|ACTIVE_COMPARATOR|active control arm|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
62286522|NCT03690310|EXPERIMENTAL|Anti-CD19 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19 CAR NK cells will be administered at day0
62286523|NCT00495157|EXPERIMENTAL|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
62286524|NCT00495157|EXPERIMENTAL|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
62286525|NCT00495157|EXPERIMENTAL|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
62286526|NCT05628922|EXPERIMENTAL|Early Responders|those with undetectable plasma EBV DNA after first cycle of induction chemotherapy (GP regimen)
62461094|NCT03432897|EXPERIMENTAL|Treatment|"Olaparib 300 mg BID q 4 weeks for up to 3 cycles. The 3rd cycle will not be given if patient is found to progress post cycle 2.~Between 22-42 days post Olaparib, patients will undergo a prostatectomy."
62461095|NCT02665013|EXPERIMENTAL|Tailored|Participants will complete surveys at each intervention time point. Based on survey responses, they will receive vaccine information on the study website tailored to their vaccine concerns and values
62461096|NCT02665013|PLACEBO_COMPARATOR|Untailored|Participants will complete surveys at each intervention time point and receive vaccine information on the study website. The vaccine information will NOT be tailored to their concerns and values.
62461097|NCT02665013|NO_INTERVENTION|Usual Care|Participants will complete surveys at each intervention time point. They will receive vaccine information sheets that are provided in the well child visits at enrollment in the study.
62461098|NCT02774928||Chronic Obstructive Pulmonary Disease|Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world.COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.Spirometry is required to make a clinical diagnosis of COPD; the presence of a post-bronchodilator FEV1/FVC \< 0.70 confirms the presence of persistent airflow limitation and thus of COPD .
62461099|NCT02774928||Interstitial lung diseases|Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
62087614|NCT04769882|ACTIVE_COMPARATOR|Er:YAG laser therapy group|The removal of caries was performed with Er:YAG laser (Doctor Smile, Lambda SRL,Italy) with BOOST handpiece to cut the enamel and open the cavity, and 90° handpiece to remove the carious dentin with tips of 800 µ in diameter and 8 mm or 12 mm in length, in relation to the depth and distance of the lesion.
62087615|NCT04769882|NO_INTERVENTION|Traditional therapy group|The removal of caries was performed with manual and rotating instruments, such as dentin spoon (ASA Dental S.p.a.), turbine (NSK Dental Italy S.r.l.) with diamond burs (Kerr Dental Italia S.r.l.) to cut the enamel and open the cavity and drill handpiece (KaVo Dental Italia S.r.l.) with tungsten carbide burs (Kerr Dental Italia S.r.l.) to remove the infected dentin.
62286527|NCT05628922|EXPERIMENTAL|Intermediate Responders|those with detectable plasma EBV DNA after first cycle of induction chemotherapy (GP regimen), and undetectable plasma EBV DNA at completion of induction chemotherapy
62286528|NCT05628922|EXPERIMENTAL|Late Responders|those with detectable plasma EBV DNA after first cycle and at completion of induction chemotherapy (GP regimen)
62286529|NCT03449264|EXPERIMENTAL|Biological collection|"samples of different natures:~* Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~* Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.~In parallel to this biological collection, standardized clinical data will be entered into a database"
62652598|NCT01142336|EXPERIMENTAL|Simvastatin|Simvastatin 40mg qHS for 1 year
62652599|NCT01142336|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet qHS for 1 year
62652600|NCT04630353|EXPERIMENTAL|HB-201 Intravenously on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx or unknown primary cancer site.
62652601|NCT04630353|EXPERIMENTAL|HB-201 Intravenously 7 to 14 days before chemoradiation|Patients with newly diagnosed HPV 16+ genotype advanced cervical cancer, clinical stages IB to IVB with plan for initial treatment of definitive chemoradiation.
62087616|NCT04243161|EXPERIMENTAL|Group 1|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.
62286530|NCT04157387|EXPERIMENTAL|Cyriax inferior capsular stretching + Manual Therapy|"Cyriax inferior capsular stretching~+ Electrotherapy Manual therapy : Kaltenborn grade 1 and 2 Mobilization~Active ROM exercises :~Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction"
62286531|NCT04157387|ACTIVE_COMPARATOR|Manual Therapy|Analgesic short-wave diathermy Manual Therapy: Kalternbon grade 1 and 2 Mobilization :, Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction.
62286532|NCT00927368|ACTIVE_COMPARATOR|Ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
62461100|NCT02774928||Obstructive sleep apnea (OSA)|"Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.~These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.~OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome-also referred to as obstructive sleep apnea-hypopnea syndrome."
62461101|NCT01079988|EXPERIMENTAL|Cyclosporin|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
62461102|NCT01079988|EXPERIMENTAL|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
62461103|NCT01079988|EXPERIMENTAL|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
62652602|NCT04877600||gender difference|dual task performance
62652603|NCT02547740||Early Glaucomatous Damage|Patients with early functional glaucomatous damage.
62652604|NCT02547740||Ophthalmologically Healthy|Healthy subjects that are ophthalmologically normal
62652605|NCT05348434||patients with maxillofacial deformities|10 patients with maxillofacial deformities (trauma patients, war injuries, patients with pre-existing maxillofacial tumours, and meucrmycotic patients)
62087617|NCT04243161|ACTIVE_COMPARATOR|Group 2|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.
62087618|NCT00105885|EXPERIMENTAL|Arm 1|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
62286533|NCT00927368|ACTIVE_COMPARATOR|Ultrasound guidance needle stimulation|For the ultrasound guidance and needle stimulation arm, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation
62286534|NCT00927368|ACTIVE_COMPARATOR|Ultrasound guidance+catheter stimulation|For the ultrasound guidance and catheter stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
62652606|NCT05675670|EXPERIMENTAL|Intervention|Patients randomized to intervention will have access to the screening tool
62652607|NCT05675670|NO_INTERVENTION|Control|Patients randomized to control will continue routine practice.
62087619|NCT00105885|NO_INTERVENTION|Arm 2|Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval.
62652608|NCT05395442|EXPERIMENTAL|Experimental Group|Web-supported diabetic foot care training based on health belief model
62652609|NCT05395442|NO_INTERVENTION|Control Group|No action will be taken.
62652610|NCT01344135|PLACEBO_COMPARATOR|Group 1 (placebo control)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
62652611|NCT01344135|EXPERIMENTAL|Group 2 (nutritional intervention)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
62087620|NCT06166511|EXPERIMENTAL|Group undergo laparoscopic liver resection|Any patient from 18 to 65 and has localized liver pathology and underwent laparoscopic non anatomical resection of this pathology
62087621|NCT00565682|EXPERIMENTAL|A|Etoricoxib 120 mg
62652612|NCT00651209|EXPERIMENTAL|1|Sub-group 1- continue telbivudine if HBV DNA non-detectable at week 24 Sub-group 2- tenofovir added to telbivudine in patients if HBV DNA detectable at week 24
62652613|NCT00626145|PLACEBO_COMPARATOR|1|Patients receive intracoronary injections of saline 7 days after PCI.
62652614|NCT00626145|EXPERIMENTAL|2|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
62087622|NCT06164353|ACTIVE_COMPARATOR|bovine xenograft covered with a collagen membrane|"The same procedure of implant placement will be performed but xenograft will be used for augmentation.~In both groups, the placed graft will be covered with a collagen membrane. Finally, tension free wound closure will be attained after periosteal releasing incision and suturing using 5/0 proline interrupted sutures.~An immediate postoperative CBCT scan will be done following the surgical procedure."
62087623|NCT06164353|EXPERIMENTAL|Partially demineralized dentin graft covered with a collagen membrane|The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
62087624|NCT02838004|EXPERIMENTAL|Single arm receiving Mini WELL Ready IOL|IOL implantation for cataract
62087625|NCT02856919|OTHER|Mirvaso® gel|Mirvaso® gel (5 mg/g brimonidine tartrate)
62087626|NCT01845636|EXPERIMENTAL|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
62286535|NCT03048955|ACTIVE_COMPARATOR|Indirect Decompression System|Superion® IDS surgical procedure
62286536|NCT03048955|ACTIVE_COMPARATOR|Direct decompression Surgery|Open, direct decompression surgical procedure
62286537|NCT00389155|EXPERIMENTAL|vinflunine and gemcitabine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
62286538|NCT00389155|PLACEBO_COMPARATOR|placebo and gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
62286539|NCT00217919|EXPERIMENTAL|1|Health-Counselor Mediated Telephone Counseling Intervention
62286540|NCT00217919|NO_INTERVENTION|2|Usual care
62652615|NCT03143452|ACTIVE_COMPARATOR|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
62652616|NCT03143452|ACTIVE_COMPARATOR|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
62652617|NCT04215835|EXPERIMENTAL|study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
62652618|NCT04215835|PLACEBO_COMPARATOR|control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
62087627|NCT06021119|ACTIVE_COMPARATOR|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors with Iftar meal
62652619|NCT02832037|EXPERIMENTAL|BI 425809 dose 1|
62652620|NCT02832037|EXPERIMENTAL|BI 425809 dose 2|
62652621|NCT02832037|EXPERIMENTAL|BI 425809 dose 3|
62652622|NCT02832037|EXPERIMENTAL|BI 425809 dose 4|
62652623|NCT02832037|PLACEBO_COMPARATOR|Placebo|
62652624|NCT06472648|EXPERIMENTAL|GID group|GID: Global Instability Device. Out of the total sample, 10 subjects were randomly assigned to each group. The GID group consisted of 10 amateur soccer players, both men and women, who performed the intervention using the BOSU.
62652625|NCT06472648|EXPERIMENTAL|SID group|SID: Specific Instability Device. Out of the total sample, 10 subjects were randomly assigned to each group. The SID group consisted of 10 amateur soccer players, both men and women, who performed the intervention using the Blackboard.
62087628|NCT06021119|NO_INTERVENTION|Control group|No Dipeptidyl peptidase-4 inhibitors intake with Iftar meal
62087629|NCT02977975|EXPERIMENTAL|Raw sauerkraut|75 grams of raw, traditionally produced, lacto-fermented sauerkraut, each day for 6 weeks.
62087630|NCT02977975|OTHER|Pasteurized sauerkraut|75 grams of pasteurized sauerkraut, each day for 6 weeks.
62087631|NCT05797753|EXPERIMENTAL|Part-A, Period-1|Single dose of SAR443820 tablet on Day 1
62087632|NCT05797753|EXPERIMENTAL|Part-A, Period-2|Single dose of SAR443820 tablet on Day 6, and erythromycin ethyl succinate (EES) three-time a day (TID) from Day 1 to Day 9
62286541|NCT01958645|EXPERIMENTAL|A|MEDI8111
62286542|NCT01958645|PLACEBO_COMPARATOR|B|Placebo for MEDI8111
62286543|NCT05926427|EXPERIMENTAL|OR-chemo|Drug: Orelabrutinib, Rituximab and recommended chemotherapy according to histopathologic type
62286544|NCT03776656|EXPERIMENTAL|Allopurinol|Oral administration of Allopurinol (Zyloric®) for 12 months without exceeding 400 mg / day in children and 900 mg / day in adults, with dosage adjustment in case of renal failure
62286545|NCT03470181||Participants with Diagnosed CVS|This cohort will consist of 15 current patients previously diagnosed with Cyclic Vomiting Syndrome.
62286546|NCT03470181||Healthy Volunteers|This cohort will consist of 15 healthy volunteers, with no history of Cyclic Vomiting.
62286547|NCT01575795|ACTIVE_COMPARATOR|Ticagrelor 180mg loading dose|Ticagrelor 180mg loading dose
62286548|NCT01575795|EXPERIMENTAL|Ticagrelor 360mg loading dose|Ticagrelor 360mg loading dose
62286549|NCT06151561|EXPERIMENTAL|Dose 1|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1.
62286550|NCT06151561|EXPERIMENTAL|Dose 2|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1.
62286551|NCT06151561|EXPERIMENTAL|Dose 3|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1.
62286552|NCT06151561|PLACEBO_COMPARATOR|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1.
62286553|NCT03209219|EXPERIMENTAL|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10\^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
62286554|NCT03209219|ACTIVE_COMPARATOR|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
62286555|NCT02342834|NO_INTERVENTION|Control|"During the control study, each subject ingest 500 ml of water 30 minutes before a standard 75 g Oral Glucose Tolerance Test"
62286556|NCT02342834|EXPERIMENTAL|Small mixed protein and lipid meal|"During the preload study, each subject ingest a small mixed meal 30 minutes before a standard 75 g Oral Glucose Tolerance Test. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
62286557|NCT05891067|EXPERIMENTAL|SterkWerk|SterkWerk is a classroom-based approach (throughout the school year) for primary school groups 5-8 (children aged 8-12 years old) in which children are given specific roles to actively work on responsibility, ownership and prosocial behavior. SterkWerk consists of three main components: meaningful roles, classroom meeting and compliments.
62652626|NCT04329065|EXPERIMENTAL|Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab)|Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62652627|NCT00477685||OculusGen Collagen Matrix|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
62652628|NCT02474186|EXPERIMENTAL|Radiation therapy|"Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol"
62652629|NCT01838876|EXPERIMENTAL|Cariprazine + ADT|Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.
62286558|NCT05891067|ACTIVE_COMPARATOR|Treatment-as-usual|Schools in the control group do not receive the intervention (do not receive material or training), and function as normal (treatment-as-usual). Control schools are requested to not start any social-emotional program during the school year 2023/2024.
62652630|NCT01104649|EXPERIMENTAL|Riluzole|Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
62286559|NCT05612919|EXPERIMENTAL|Patients exclusively transfused with UCB-RBC|Interventional group infants arm will receive UCB-RBC bag when RBC transfusion is indicated as per standard practice, and when UCB-RBC is available within the first 6 hours of the request.
62286560|NCT05612919|ACTIVE_COMPARATOR|Patients exclusively transfused with AB-RBC|Standard treatment group infants arm will receive AB-RBC when RBC transfusion is indicated as per standard practice, and compatible UCB-RBC bag is not available.
62286561|NCT05612919|NO_INTERVENTION|Non transfused patients|Patients with no indications for RBC transfusion. Their clinical management will be the usual in our neonatal unit.
62461104|NCT01079988|EXPERIMENTAL|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
62461105|NCT01079988|EXPERIMENTAL|Systemic corticosteroids/methotrexate|"Corticosteroid starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%.~Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks."
62461106|NCT03992066|EXPERIMENTAL|Vadadustat 600 mg|Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.
62652631|NCT01104649|PLACEBO_COMPARATOR|Placebo comparator|Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
62652632|NCT01138735|ACTIVE_COMPARATOR|adapalene/benzoyl peroxide|Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
62652633|NCT01138735|PLACEBO_COMPARATOR|Topical Gel Vehicle|Topical Gel Vehicle applied topically once daily for 12 weeks
62652634|NCT03282864|ACTIVE_COMPARATOR|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
62652635|NCT03282864|PLACEBO_COMPARATOR|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
62652636|NCT01963611|EXPERIMENTAL|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
62652637|NCT01963611|EXPERIMENTAL|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
62652638|NCT01963611|EXPERIMENTAL|Plovamer acetate 10 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
62286562|NCT05662267||Islet-after-kidney group|"Patients with type 1 diabetes with a kidney transplant received or not an islet transplantation after kidney transplantation. As soon as they received an islet transplantation, they belong to the Islet-after-kidney group."
62286563|NCT05662267||Kidney alone group|"Patients with type 1 diabetes with a kidney transplant who did not receive an islet transplantation belong to the  Kidney alone group ."
62286564|NCT06074952|OTHER|Group A- Control group|Control group will use distilled water as a control medium
62286565|NCT06074952|OTHER|Group B- Study group|In this group, 4 sub-groups will be made in which acrylic teeth of Welbite brand will be immersed in tea, coke, turmeric, and honey solutions.
62286566|NCT06074952|OTHER|Group C- Study group|In this group, 4 sub-groups will be made in which acrylic teeth of the Huge Kaili brand will be immersed in tea, coke, turmeric, and honey solutions.
62286567|NCT03530384|EXPERIMENTAL|Cognitive training|Computerized cognitive training program targeting inhibitory control
62286568|NCT03530384|SHAM_COMPARATOR|Control Training|A sensorial program with similar conditions, but targeting visual acuity, considered as neutral in the addiction field
62286569|NCT05641532|EXPERIMENTAL|Capability-Opportunity-Motivation-Behavior (COM-B) based physical activity behavioral intervention|This is a 1-arm study with an intervention condition based on the COM-B model
62286570|NCT02021409|EXPERIMENTAL|BAY85-3934 (25mg)|Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
62461107|NCT03992066|EXPERIMENTAL|Vadadustat 750 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.
62461108|NCT03992066|EXPERIMENTAL|Vadadustat 900 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.
62461109|NCT03992066|OTHER|Erythropoiesis-stimulating agent|Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.
62461110|NCT03365375|ACTIVE_COMPARATOR|Usual Care Referral|Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.
62652639|NCT01963611|EXPERIMENTAL|Plovamer acetate 20 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
62652640|NCT01963611|ACTIVE_COMPARATOR|Copaxone 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
62087633|NCT05797753|EXPERIMENTAL|Part-B, Period-1|Single dose of SAR443820 capsule on Day 1
62087634|NCT05797753|EXPERIMENTAL|Part-B, Period-2|Single dose of SAR443820 capsule on Day 6, and Itraconazole once daily (QD) from Day 1 to Day 11
62087635|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
62087636|NCT01153256|EXPERIMENTAL|group M|
62286571|NCT02021409|EXPERIMENTAL|BAY85-3934 (50mg)|Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
62286572|NCT02021409|EXPERIMENTAL|BAY85-3934 (75mg)|Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
62286573|NCT02021409|ACTIVE_COMPARATOR|Darbepoetin alfa|Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.
62286574|NCT02611401|EXPERIMENTAL|Mindulness Based Intervention|intervention with group-based Mindfulness Based Intervention
62286575|NCT02611401|ACTIVE_COMPARATOR|Active Control|intervention with group-based Psychoeducation and Relaxation
62286576|NCT02784093|EXPERIMENTAL|Exposure Group|Participants were allocated to receive 100 mL of Gastrograﬁn orally once daily for 6 consecutive days.
62286577|NCT02784093|PLACEBO_COMPARATOR|Control Group|Participants were allocated to receive enemas twice daily for 6 consecutive days.
62461111|NCT03365375|EXPERIMENTAL|MBSR Referral|Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.
62286578|NCT05231083|EXPERIMENTAL|Arm A - 20Hz Stimulation|Transcutaneous stimulation of the genital nerves at 20Hz
62087637|NCT01153256|PLACEBO_COMPARATOR|Group R-0.6|
62087638|NCT01153256|PLACEBO_COMPARATOR|Group R-0.9|
62087639|NCT04159116|EXPERIMENTAL|Suctioned Prior to Endoscope|This group will be suctioned prophylactically after sedation but prior to introduction of endoscope.
62087640|NCT04159116|OTHER|Standard of Care|This group will be suctioned by anesthesia providers when clinically indicated by copious secretions, coughing, choking or desaturation.
62087641|NCT01421043|EXPERIMENTAL|triazolam liquid oral drops|
62087642|NCT01421043|ACTIVE_COMPARATOR|triazolam tablets|
62087643|NCT06488729|EXPERIMENTAL|Foot massage|Foot massage was applied to the patients in the foot massage group.
62286579|NCT05231083|EXPERIMENTAL|Arm B - 60Hz Stimulation|Transcutaneous stimulation of the genital nerves at 60Hz
62087644|NCT06488729|NO_INTERVENTION|Control|No procedures were applied to the control group other than clinical standard protocols.
62286580|NCT04280432||Cesarean|Women hospitalized for cesarean section
62286581|NCT00392184|EXPERIMENTAL|APBI|Accelerated Partial Breast Irradiation with interstitial Brachytherapy
62286582|NCT00611494|ACTIVE_COMPARATOR|A|MMF
62286583|NCT00611494|ACTIVE_COMPARATOR|B|EC-MPS
62286584|NCT01446939||Parkinson's disease|Patients with primary Parkinson's disease
62286585|NCT01446939||Essential tremor|Patients with essential tremor
62286586|NCT01446939||Healthy volunteers|Healthy volunteers
62286587|NCT04067765|EXPERIMENTAL|Alcohol Cue|Alcohol cue exposure in scanner
62461112|NCT05462561|EXPERIMENTAL|Treatment (VCBA)|Patients undergo robotic VCBA transplantation.
62087645|NCT01973465|EXPERIMENTAL|Fecal Microbiota Therapy|
62087646|NCT05625841|EXPERIMENTAL|Honey|Each pack of 10 grams of honey after three meals a day.
62087647|NCT05625841|EXPERIMENTAL|Honey and propolis|Each pack contains 0.7ml of propolis + 9.3g of honey after three meals a day.
62286588|NCT04067765|ACTIVE_COMPARATOR|Neutral Cue|Neutral cue exposure in scanner
62286589|NCT05686109||Monitoring device Biobeat®|"Biobeat® non-invasive monitoring devices can be used in an out-of-hospital perioperative setting to observe patients' vital signs up to 5 days postoperatively.~The Biobeat® portable adhesive device will be installed after the surgery, in the recovery room. All patients will be equipped with a portable single-use Biobeat® Bluetooth device that will be positioned at chest level and connected via Bluetooth to the patient's cell phone. These patches have been FDA approved since 2019 (new approval in 2022) for non-invasive (systolic, diastolic, and mean) blood pressure measurement without a cuff. The following other parameters will also be recorded: peripheral oxygen saturation, heart rate, respiratory rate and body temperature based on the analysis of the plethysmography wave. This data will be recorded as soon as the patches are installed."
62087648|NCT05625841|PLACEBO_COMPARATOR|Usual care|General routine oral care.
62087649|NCT06343961|EXPERIMENTAL|targeted retinal photocoagulation(TRP)|TRP is a laser technology aimed at the peripheral non-perfusion and ischemic areas of the retina, and the laser area is determined according to the degree and progression ofthe patient's retinopathy.TRP can speciﬁcally act on unperfused retinal capillaries and retinal intermediate ischemic areas, reduce damage to tissue perfusion areas and panretinal photocoagulation (PRP) complications or adverse events.
62286590|NCT00325078|EXPERIMENTAL|Treatment|Study drug (TNFa inhibitor-infliximab or adalimumab) treated group.
62286591|NCT00325078|NO_INTERVENTION|Observation|Subjects with IBD without TNFa inhibitor treatment
62461113|NCT01297036|ACTIVE_COMPARATOR|Reference arm|Treated with Reference (Aricept, 10 mg donepezil tablet)
62461114|NCT01297036|EXPERIMENTAL|Test arm|Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)
62461115|NCT02686333|EXPERIMENTAL|Meditation Intervention Arm|10-15 minute meditation practices (brief silent meditations, guided meditations, body scans, gentle arm movement exercises). Before each session, the interventionist will perform a brief check in, and may discuss the patient's experience with them for 1-2 minutes after the intervention. Patients will be encouraged to practice the techniques at home between sessions. Patients will also be offered literature on mental health promotion.
62461116|NCT02686333|NO_INTERVENTION|Control Group (No Meditation Exposure)|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as Usual in the dialysis setting.
62461117|NCT05515926|EXPERIMENTAL|Cranial OMT|The experimental group received the three cranial osteopathic manipulative techniques, occipital-atlantal decompression (OAD), occipital-mastoid decompression (OMD), and compression of the fourth ventricle (CV4), consecutively applied.
62461118|NCT05515926|SHAM_COMPARATOR|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
62286592|NCT03281785|ACTIVE_COMPARATOR|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
62286593|NCT03281785|ACTIVE_COMPARATOR|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
62286594|NCT03281785|ACTIVE_COMPARATOR|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
62286595|NCT03871114||OLP patients|fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks
62461119|NCT05515926|NO_INTERVENTION|Non touch group|The control group whose members did not receive any manipulations.
62461120|NCT05830019|EXPERIMENTAL|carbon ion radiotherapy|carbon ion radiotherapy
62461121|NCT01416766|NO_INTERVENTION|Control|Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
62461122|NCT01416766|EXPERIMENTAL|Intervention|Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
62461123|NCT00017953|EXPERIMENTAL|Lifestyle Intervention|Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.
62461124|NCT00017953|ACTIVE_COMPARATOR|Diabetes Support and Education|The diabetes support and education arm provides group sessions on diabetes management and social support.
62461125|NCT03469297|EXPERIMENTAL|Brown Glaucoma Implant|
62652641|NCT00775879|EXPERIMENTAL|A|2.5% target concentration
62652642|NCT00775879|ACTIVE_COMPARATOR|B|2.5% manually selected
62286596|NCT03871114||Control group|
62286597|NCT01268254||red wine|red wine usual consumer versus abstemious
62286598|NCT06461910|EXPERIMENTAL|Anti-PD-1 Combined with Thymosin and SOX|
62286599|NCT00470080|EXPERIMENTAL|1|venepuncture
62286600|NCT03980314|ACTIVE_COMPARATOR|Arm A (Process C)|
62461126|NCT04772105|EXPERIMENTAL|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route of administration: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: once every 4 weeks, 6 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
62461127|NCT04772105|EXPERIMENTAL|4mg of BAT5906|Specification: 16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4mg/eye/time, 50μl; medication duration: once every 4 weeks, 3 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
62286601|NCT03980314|EXPERIMENTAL|Arm B (Process D)|
62461128|NCT05512026|EXPERIMENTAL|Feasibility Assessment|The Poseidon System is investigational and indicated to provide a pathway to control waste fluid during irrigation of the colon. All consented patients will receive the Device use during their colonoscopy procedure.
62461129|NCT00500487|EXPERIMENTAL|1|
62461130|NCT00500487|ACTIVE_COMPARATOR|2|
62461131|NCT00500487|ACTIVE_COMPARATOR|3|
62461132|NCT05367388|EXPERIMENTAL|Treatment Sequence A/P|Subject will receive a single oral dose (200mg) of Treatment A on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment P.
62652643|NCT01258374||Single arm with dual therapy|Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD
62652644|NCT05186480|ACTIVE_COMPARATOR|test group|they receive the immune enhancing formula
62652645|NCT05186480|NO_INTERVENTION|control group|they receive the conventional formula
62652646|NCT05968235||Vitiligo|Patients diagnosed with vitiligo
62652647|NCT05968235||Healthy|Healthy volunteers with sex- and age-matched with vitiligo patients
62286602|NCT02508805|EXPERIMENTAL|Neuromultivit +Voltaren+Sirdalud|"Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days.~Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days."
62286603|NCT02508805|ACTIVE_COMPARATOR|Voltaren+Sirdalud alone|Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days
62286604|NCT02497001|EXPERIMENTAL|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
62286605|NCT02497001|EXPERIMENTAL|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
62286606|NCT02497001|EXPERIMENTAL|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
62286607|NCT02497001|ACTIVE_COMPARATOR|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
62286608|NCT05307458||Buprenorphine Microdosing|Participants transitioning to buprenorphine from methadone using a microdosing protocol.
62286609|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
62087650|NCT06343961|EXPERIMENTAL|panretinal photocoagulation(PRP)|The scope oftraditional PRP is mainly distributed in the middle and peripheral part of the retina, 1.5-2 optic disc diameters (DD) posteriorly from the optic disc and 2 DD temporally from the fovea,bounded by the superior and inferior vascular arches; forward to the ampulla of the vortex vein (or equator). Currently, PRP is the gold standard for the treatment of extensive areas of non-perfusion , as well as the main method for the treatment of severe nonproliferative diabetic retinopathy (NPDR) and PDR. However, due to the photochemical damage of the laser,panretinal laser photocoagulation causes more damage to the ocular tissue, and its side effects include hemorrhage, choroidal detachment, acute angle-closure glaucoma, etc. The occurrence of these complications is closely related to laser parameters such as increased duration and power and intensive treatment in a single session, which all lead to increased diffusion of thermal energy within the retina and choroid .
62461133|NCT05367388|EXPERIMENTAL|Treatment Sequence P/A|Subject will receive a single oral dose (200mg) of Treatment P on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment A.
62461134|NCT03117569|OTHER|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
62461135|NCT03117569|EXPERIMENTAL|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
62652648|NCT00995878|ACTIVE_COMPARATOR|Focused Ultrasound (MRgFUS)|
62652649|NCT00995878|ACTIVE_COMPARATOR|Uterine Artery Embolization (UAE)|
62652650|NCT01117870|PLACEBO_COMPARATOR|Placebo|The needle will be continuously stimulated at a low voltage to give a sensation of PRF treatment.
62652651|NCT01117870|EXPERIMENTAL|Pulsed Radiofrequency|PRF will be applied for 120 seconds at 42 degrees celsius.
62652652|NCT04587713|EXPERIMENTAL|Part A, Sequence 1|"Part A, Sequence 1 = Treatment (Tx) C, Tx A, Tx C, Tx A~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout between treatments"
62652653|NCT04587713|EXPERIMENTAL|Part A, Sequence 2|"Part A, Sequence 2: Tx D, Tx B, Tx D, Tx B~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
62652654|NCT04587713|EXPERIMENTAL|Part A, Sequence 3|"Part A, Sequence 3: Tx C, Tx A, Tx D, Tx B~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
62652655|NCT04587713|EXPERIMENTAL|Part A, Sequence 4|"Part A, Sequence 4: Tx D, Tx B, Tx C, Tx A~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
62652656|NCT04587713|EXPERIMENTAL|Part A, Sequence 5|"Part A, Sequence 5: Tx A, Tx C, Tx A, Tx C~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
62652657|NCT04587713|EXPERIMENTAL|Part A, Sequence 6|"Part A, Sequence 6: Tx B, Tx D, Tx B, Tx D~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
62087651|NCT02726243||IBD without CRC|
62087652|NCT02726243||IBD with CRC|
62461136|NCT05532527|EXPERIMENTAL|Study group|Microwave ablation combined with Camrelizumab and chemotherapy
62461137|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
62461138|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
62461139|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
62461140|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
62087653|NCT02726243||IBD with dysplasia|
62087654|NCT02726243||non IBD without CRC|
62652658|NCT04587713|EXPERIMENTAL|Part A, Sequence 7|"Part A, Sequence 7: Tx A, Tx C, Tx B, Tx D~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
62286610|NCT01831128||Control|No ASV treatment
62286611|NCT04093596|EXPERIMENTAL|ALLO-647, ALLO-715, Nirogacestat|
62286612|NCT02153502|EXPERIMENTAL|AVP-786|
62652659|NCT04587713|EXPERIMENTAL|Part A, Sequence 8|"Part A, Sequence 8: Tx B, Tx D, Tx A, Tx C~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
62652660|NCT04587713|EXPERIMENTAL|Part B,Treatment A|Single oral dose of Treatment A on Day 1
62652661|NCT04264741|EXPERIMENTAL|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 4 weeks.
62652662|NCT04264741|SHAM_COMPARATOR|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday. Treatment will lasted for 4 weeks.
62652663|NCT06284473|EXPERIMENTAL|Intranasal Ketamine|Participants assigned to this arm will receive intranasal ketamine administered at 0.7mg/kg along with normal lidocaine local sedation
62652664|NCT06284473|PLACEBO_COMPARATOR|Placebo|Participants assigned to this arm will receive volume-based dose of intranasal saline administered along with normal lidocaine local sedation
62087655|NCT02726243||non IBD with CRC|
62087656|NCT02726243||IBD-PSC without CRC|
62087657|NCT02726243||IBD-PSC with CRC|
62652665|NCT01789268||Full-Term Healthy Infants (> /=37 weeks gestational age)|130 male and female term infants born at a gestational age of 37 0/7 to 41 6/7 weeks (Healthy comparator) will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
62087658|NCT02726243||IBD-PSC with dysplasia or healthy subjects|IBD-PSC with dysplasia or healthy subjects for whom a colonoscopy is scheduled
62087659|NCT05836155|EXPERIMENTAL|Intervention|The study product contains Lactobacillus acidophilus W53, Lactobacillus acidophilus W55, Lactobacillus casei W56, Lactobacillus plantarum W1, Lactobacillus plantarum W21, Lactobacillus rhamnosus W71, and Pediococcus acidilactici W143.
62087660|NCT01712789|EXPERIMENTAL|Pomalidomide plus Dexamethasone|Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
62286613|NCT02153502|PLACEBO_COMPARATOR|Placebo|
62286614|NCT01052441||CT Scan|Subjects with typical or atypical chest pain suspected of coronary artery disease and referred for an elective invasive coronary angiography (ICA), and scheduled to undergo CCTA before ICA or after ICA, if no intervention has been performed.
62286615|NCT05559567|OTHER|Orthokeratology|Orthokeratology is fitting of a contact lens for overnight wear to flatten the cornea and correct myopia temporarily during the day. This procedure has also been shown to slow down the axial length growth in children.
62286616|NCT04038944||Subjects with new onset atrial fibrillation|Subjects with new onset atrial fibrillation who may or may not require electrical cardioversion
62286617|NCT01468311|EXPERIMENTAL|Yttrium-90-labeled Daclizumab + Chemotherapy|Yttrium-90-labeled Daclizumab + BCNU, etoposide, cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)
62286618|NCT05812677|EXPERIMENTAL|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or Intraperitioneal in patients with relapsed/refractory cervical and endometrial Cancer.
62286619|NCT01232478|EXPERIMENTAL|Comprehensive Adherence Program (CAP)|The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
62652666|NCT01789268||Preterm Infants (<36 weeks gestational age)|150 male and female preterm infants born at gestational age 23 0/7 to 35 6/7 weeks will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
62652667|NCT00623675|EXPERIMENTAL|A|
62652668|NCT00838851|EXPERIMENTAL|CCRE|
62652669|NCT04194632|EXPERIMENTAL|Single Arm|All patients will undergo hemodynamic measurements at baseline, with the intervention, and post-intervention thus serving as their own control.
62652670|NCT05861908|EXPERIMENTAL|Body Bulk-Fill|20 cavity class II restored with Body bulk-fill Resin composite
62652671|NCT05861908|EXPERIMENTAL|preheated Bulk-Fill|20 cavity class II restored with preheated bulk-fill Resin composite
62652672|NCT05861908|EXPERIMENTAL|Injectable Bulk-Fill|20 cavity class II restored with injectable bulk-fill Resin composite
62652673|NCT05861908|EXPERIMENTAL|Sonic-Fill|20 cavity class II restored with sonic-fill bulk-fill Resin composite
62286620|NCT01232478|EXPERIMENTAL|Standard Care (SC)|Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
62286621|NCT01403909|EXPERIMENTAL|With compression|The patients randomized to this group will have intermittent pneumatic venous compression of the lower limbs during surgery.
62286622|NCT01403909|ACTIVE_COMPARATOR|Without compression|The patients randomized to this group will not have intermittent pneumatic venous compression of the lower limbs during surgery. (Standard care)
62286623|NCT05202626||Sun Yat-Sen University Cancer Center|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Sun Yat-Sen University Cancer Center. The physicians in Sun Yat-Sen University Cancer Center consider it necessary to perform an endoscopic image-guided biopsy.
62087661|NCT02940769|EXPERIMENTAL|light glasses|Study subjects will wear light glasses
62286624|NCT05202626||Guangdong Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Guangdong Provincial People's Hospital. The physicians in Guangdong Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
62286625|NCT05202626||Nanfang Hospital, Southern Medical University|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Nanfang Hospital. The physicians in Nanfang Hospital consider it necessary to perform an endoscopic image-guided biopsy.
62087662|NCT02940769|SHAM_COMPARATOR|sham glasses (placebo)|Study subjects will wear sham glasses
62652674|NCT02130609|EXPERIMENTAL|Skintel|
62652675|NCT02807922|ACTIVE_COMPARATOR|Zopiclone|Zopiclone six nights
62087663|NCT01561079|EXPERIMENTAL|Maternal buprenorphine treatment|Buprenorphine maintenance during pregnancy
62087664|NCT03162965|ACTIVE_COMPARATOR|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
62087665|NCT03162965|ACTIVE_COMPARATOR|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
62087666|NCT06410911|ACTIVE_COMPARATOR|Group A|subcostal transversus abdominis plane block will be performed 50 patients undergoing open cholecystectomy surgery
62087667|NCT06410911|ACTIVE_COMPARATOR|Group B|Ultrasound-guided Erector spinae block will be performed 50 patients undergoing open cholecystectomy surgery
62652676|NCT02807922|PLACEBO_COMPARATOR|Placebo|Placebo six nights
62461141|NCT04517019|EXPERIMENTAL|Arm A (Tracker/daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients phyiscal activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
62652677|NCT00808340|ACTIVE_COMPARATOR|senofilA test/senofilA prod/balafilconA|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, senofilcon A production worn second, and balafilcon A worn third.
62652678|NCT00808340|ACTIVE_COMPARATOR|senofilcon A test/balafilcon A/senofilcon A prod|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, balafilcon A worn second, and senofilcon A production worn third.
62652679|NCT00808340|ACTIVE_COMPARATOR|senofilcon A prod/senofilcon A test/balafilcon A|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, senofilcon A test worn second, and balafilcon A worn third.
62652680|NCT00808340|ACTIVE_COMPARATOR|senofilcon A prod/ balifilcon A/ senofilcon A test|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, balafilcon A worn second, and senofilcon A test worn third.
62652681|NCT00808340|ACTIVE_COMPARATOR|balafilcon A/senofilcon A test/senofilcon A prod|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A test worn second, and senofilcon A production worn third.
62652682|NCT00808340|ACTIVE_COMPARATOR|balafilcon A/senofilcon A prod/senofilcon A test|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A production worn second, senofilcon A test worn third.
62286626|NCT05202626||Fujian Provincial Cancer Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Fujian Provincial Cancer Hospital. The physicians in Fujian Provincial Cancer Hospital consider it necessary to perform an endoscopic image-guided biopsy.
62652683|NCT03356717|EXPERIMENTAL|educational intervention - observer tool|"Participants in this arm will be given the observer tool (OT) before the scenario and will be explained how to use it, i.e. observe all details of the scenario on the screen and tick on the OT all actions which are done by active participants.The observer tool will also be used to engage observers during the debriefing session.~The scenario will then be observed in a screen (i.e. the scenario is played by active participants in an adjacent room using direct video-recording and transmission."
62652684|NCT03356717|ACTIVE_COMPARATOR|without observer tool|Participants in this arm will not be given the observer tool (OT) before the scenario but will be asked to observe all details of the scenario on the screen.The observers will also be asked to participate during the debriefing session.
62652685|NCT01794468|EXPERIMENTAL|study group-Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor
62652686|NCT02939352|EXPERIMENTAL|Cocaine Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
62652687|NCT02939352|EXPERIMENTAL|Alcohol Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
62652688|NCT04009837|EXPERIMENTAL|Hip-focused|Hip-focused rehabilitation intervention
62652689|NCT04009837|ACTIVE_COMPARATOR|Spine-focused|Spine-focused rehabilitation intervention
62652690|NCT02156258||Diagnostic Cases|Collection of cases that were scheduled for biopsy (BI-RADS 4 or 5) using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
62652691|NCT02156258||Recall Cases|Collection of Imaging Recall Cases (were scheduled for additional imaging due an assessment of BI-RADS 0) using FFDM Mammography and DBT Mammography
62652692|NCT02156258||Screening Cases|Collection of cases who underwent routine screening mammography using FFDM Mammography and DBT Mammography
62652693|NCT02926014|EXPERIMENTAL|Lingual Tonsil Hypertrophy participants|"The research group consisted of 50 consecutive adult outpatients suffering from swallowing disorders, examined by otorhinolaryngologist at the Hospital of Lithuanian University of Health Sciences.~Lingual Tonsil Hypertrophy was diagnosed using videolaryngoscopy."
62652694|NCT02926014|OTHER|Control participants|The control group consisted of 50 healthy adult participants, who were examined using videolaryngoscopy and no pharyngeal pathologies were diagnosed, including lingual tonsil hypertrophy.
62652695|NCT02655874|EXPERIMENTAL|Six-monthly influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
62652696|NCT02655874|ACTIVE_COMPARATOR|Annual influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180
62652697|NCT03315260||Bone metastatic CRPC patients|Japanese patients who are designated to undertake Ra-223/Xofigo therapy based on physician judgement
62087668|NCT02071095|EXPERIMENTAL|Arm A: Poly-ICLC|Arm A (N=15): Patients will receive an injection of 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir) subcutaneously on day 1 and day 2.
62087669|NCT02071095|PLACEBO_COMPARATOR|Arm B: Normal Saline|Arm B: (N=5): Patients will receive an injection of normal saline subcutaneously on day 1 and day 2.
62286627|NCT05202626||Hainan Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Hainan Provincial People's Hospital. The physicians in Hainan Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
62652698|NCT03271697|EXPERIMENTAL|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
62652699|NCT03271697|PLACEBO_COMPARATOR|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
62652700|NCT03423771|EXPERIMENTAL|NPF-08 Low dose （1-day treatment）|
62652701|NCT03423771|EXPERIMENTAL|NPF-08 Medium dose （2-day split dose）|
62652702|NCT03423771|EXPERIMENTAL|NPF-08 High dose （2-day split dose）|
62652703|NCT03423771|EXPERIMENTAL|NPF-08 Medium dose （1-day treatment）|
62652704|NCT03423771|EXPERIMENTAL|NPF-08 High dose （1-day treatment）|
62652705|NCT03423771|EXPERIMENTAL|NPF-08 Low～High dose （1-day treatment）|
62286628|NCT03633188|EXPERIMENTAL|Patients treated by antibiotherapy|35 Patients treated by antibiotherapy for acute and subacute post-operative implant-associated BJI infections and among them 10 patients with Staphylococcus. aureus treated with antibiotics as part of their standard treatment procedure for metagenomic procedure.
62286629|NCT00542997|EXPERIMENTAL|IgPro20|
62286630|NCT05885581|EXPERIMENTAL|Group A|Grow Well and will receive the adapted Healthy Beginnings Curriculum (n= 15 mother-infant-caregiver triad) determine the feasibility, acceptability, and preliminary efficacy of the adapted intervention. The intervention will be on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.
62652706|NCT03423771|EXPERIMENTAL|NPF-08 Medium～High dose （2-day split dose）|
62652707|NCT01022606|OTHER|Patients with walking limitation|Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording
62652708|NCT05201937|EXPERIMENTAL|Arm A: Panel 1 (JNJ-64281802 High Dose Regimen)|Participants will receive Loading Dose (LD) 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by maintenance Dose (MD) 1 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
62652709|NCT05201937|EXPERIMENTAL|Arm A: Panel 2 (JNJ-64281802 High Dose Regimen)|Participants will receive LD 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 2 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
62087670|NCT04860154|EXPERIMENTAL|PDT with stent|Before photodynamic therapy, candidate patients undergoing biliary biopsy and biliary duct drainage. If pathology shows a bile duct malignancy, PDT therapy will carry out until total bilirubin drops below 100 μmol/L.Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or metal stent will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
62286631|NCT05885581|ACTIVE_COMPARATOR|Group B:|Group B will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
62286632|NCT03131102||Patients with epithelial ovarian cancer (EOC)|Patients undergoing cytoreductive surgery due to epithelial ovarian cancer
62286633|NCT03131102||Subgroup - Metabolomics in EOC patients without ascites|In a subgroup (n=10), patients without preoperative ascites will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
62286634|NCT03131102||Subgroup - Metabolomics in EOC patients with ascites >500ml|In a subgroup (n=10), patients with preoperative ascites \>500ml will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
62286635|NCT06542562|EXPERIMENTAL|Group 1 will undergo fully guided dental implant surgery|Group 1 will undergo fully guided dental implant surgery
62286636|NCT06542562|EXPERIMENTAL|Group 2 will undergo half guided dental implant surgery|Group 2 will undergo half guided dental implant surgery. Where the implant will be placed after removal of the guide
62461142|NCT04517019|EXPERIMENTAL|Arm B (Tracker/no daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
62461143|NCT04517019|NO_INTERVENTION|Arm C (no activity tracker)|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
62652710|NCT05201937|EXPERIMENTAL|Arm B: Panel 3 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 3 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
62286637|NCT03406871|EXPERIMENTAL|Nivolumab + Regorafenib|Nivolumab and Regorafenib
62286638|NCT04297358|EXPERIMENTAL|Stroke patients|40 consecutive sessions of hyperbaric oxygen will be administered at a pressure of 2 absolute atmosphere (ATA) to 10 patients. If there are drop outs, recruitment will be continued until a total of 10 patients with at least 30 sessions.
62286639|NCT02736903|ACTIVE_COMPARATOR|Individual intervention|Behavioral: PennFit mobile individual intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their own daily steps and the minutes for vigorous, moderate, and muscle-strengthening exercises that they completed for each day. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening.
62652711|NCT05201937|EXPERIMENTAL|Arm B: Panel 4 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 4 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
62652712|NCT05201937|EXPERIMENTAL|Arm C: Panel 5 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
62461144|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
62461145|NCT06424145|EXPERIMENTAL|Superior group of radial artery|Injection of 1% lidocaine 1 ml above the artery
62461146|NCT06424145|EXPERIMENTAL|Right radial artery group|Injection of 1% lidocaine 1 ml to the right side of the artery
62461147|NCT04223440|EXPERIMENTAL|Postero-superior Rotator Cuff Tear|MRI, ultrasonographic explorations
62652713|NCT05201937|EXPERIMENTAL|Arm C: Panel 6 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
62652714|NCT02849028||TBI Patients with sleep disorder|All the patients should be diagnosed by polysomnographic (PSG)
62652715|NCT02849028||health people|The people have a normal sleep
62087671|NCT04860154|NO_INTERVENTION|ERCP stent|After obtaining bile duct biopsy, the candidates were placed with biliary plastic stents or metal stents directly.
62087672|NCT02303340||Study Group|Any patient who enrolled and signed informed consent will be sent to bone mineral density DEXA Scan, and for blood testing for PTH, Phosphor, Calcium ,Vitamin D and Creatinine levels. Density measurements will be done in specific sites on the CBCT's of the jaws.
62087673|NCT01367587|EXPERIMENTAL|Arm 1|
62286640|NCT02736903|EXPERIMENTAL|Online network intervention|Behavioral: PennFit mobile online network intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their exercises. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening. Participants were randomly assigned to 4-person online networks in the PennFit app. Participants in the online networks could see both their own information and the profiles and activity logs of the three other people assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
62286641|NCT00773279|EXPERIMENTAL|PDS290 --> FlexPen®|Subjects will receive trial drug with PDS290 for 12 weeks (treatment sequence 1) followed by FlexPen® for 12 weeks (treatment sequence 2)
62652716|NCT04694092|EXPERIMENTAL|Intensive rate control with landiolol|Intensive heart rate control using landiolol with the goal to achieve HR\<115 during the first 2 hours.
62652717|NCT04694092|ACTIVE_COMPARATOR|Standard therapy|Standard heart rate control with therapy other than landiolol
62286642|NCT00773279|EXPERIMENTAL|FlexPen® --> PDS290|Subjects will receive trial drug with FlexPen® for 12 weeks (treatment sequence 1) followed by PDS290 for 12 weeks (treatment sequence 2)
62652718|NCT05964062|EXPERIMENTAL|active rTMS treatment|10 sessions of active rTMS would be delivered to the right preSMA daily, with a session of 1800 pulse.
62652719|NCT05964062|SHAM_COMPARATOR|sham rTMS treatment|5 sessions of sham rTMS would be delivered to the right preSMA daily, with a session of 1800 pulse.
62652720|NCT01324297||Healthy Control|Caucasian males and females between 19 and 30 years of age.
62087674|NCT04329143|ACTIVE_COMPARATOR|open completion cholecystectomy|open completion cholecystectomy for cystic duct stump stone
62286643|NCT05617521|EXPERIMENTAL|Abdominal Binder Intervention Group|Patients randomized to the Abdominal Binder Intervention Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy.
62652721|NCT01324297||First Episode Psychosis|Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.
62286644|NCT05617521|SHAM_COMPARATOR|Sham Group|Sham Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure.
62286645|NCT01664793|EXPERIMENTAL|Intervention Group Year 1|The 4 Pillars Immunization Toolkit along with donated vaccines for early season vaccination, staff education and support.
62087675|NCT04329143|ACTIVE_COMPARATOR|laparoscopic completion cholecystectomy|lap completion cholecystectomy for cystic duct stump stone
62087676|NCT04969744|EXPERIMENTAL|Intermittent Cold Exposure (ICE)|Stage 1- healthy volunteers aged 16-26 years will receive ICE for one day. stage 2a - controls aged 8-16 will receive ICE for one day. Stage 2b- NAFLD patients aged 8-16 years will receive ICE for one day or choose to continue for 5 days.
62087677|NCT03208309|ACTIVE_COMPARATOR|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
62087678|NCT03208309|PLACEBO_COMPARATOR|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
62087679|NCT06227325|EXPERIMENTAL|treatment group|Neoadjuvant therapy:RC48 combined with Sintilimab and XELOX repeat every 2 weeks or every 3 weeks for a total of 3 cycles Adjuvant therapy: RC48 combined with Sintilimab and XELOX repeat every 2 weeks or every 3 weeks for a total of 5 cycles
62652722|NCT02106507|EXPERIMENTAL|Progressive Metastatic Castration-Resistant Prostate Cancer|This is a single-institution Phase 1b dose-escalation study in which eligible patients with progressive mCRPC will receive oral doses of apalutamide in combination with everolimus.
62087680|NCT01968161|OTHER|Asenapine|Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)
62461148|NCT04223440|OTHER|Healthy Postero-superior Rotator Cuff|MRI, ultrasonographic explorations
62652723|NCT00570947|ACTIVE_COMPARATOR|Class|The control group will be advised to take a traditional CPR class and be offered a list of local classes.
62652724|NCT06018090||Acute Ischemic Stroke Patients with Atrial Fibrillation|
62652725|NCT04410393||sacrocolpopexy patients|Patients who underwent sacrocolpopexy for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
62652726|NCT04410393||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
62087681|NCT06104774|EXPERIMENTAL|Tai Chi group|After recruitment, participants will receive Tai Chi Exercise teaching. In the acupressure group, participants will receive acupressure treatment.
62652727|NCT00325416|EXPERIMENTAL|Age Group A - Melphalan and Topotecan plus Stem Cell Rescue|Participants 18 - 60 years of age. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
62087682|NCT06104774|NO_INTERVENTION|Control group|conventional treatment
62286646|NCT01664793|NO_INTERVENTION|Control Group Year 1|Control sites will not receive assistance with increasing influenza vaccination in Year 1, they will follow guidelines for usual care.
62652728|NCT00325416|ACTIVE_COMPARATOR|Age Group B - Melphalan and Topotecan plus Stem Cell Rescue|Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
62652729|NCT04585997|ACTIVE_COMPARATOR|Mepolizumab|Mepolizumab
62652730|NCT04585997|ACTIVE_COMPARATOR|Omalizumab|Omalizumab
62652731|NCT03076463|EXPERIMENTAL|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
62652732|NCT03076463|NO_INTERVENTION|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
62652733|NCT01962675|EXPERIMENTAL|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
62652734|NCT01962675|SHAM_COMPARATOR|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
62652735|NCT03051711|EXPERIMENTAL|GBT440 Dose 1|Dose 1
62652736|NCT03051711|EXPERIMENTAL|GBT440 Dose 2|Dose 2
62652737|NCT05828342||Pediatric Patients|Patients under the age of 18 who were operated under general anesthesia and intubated with a cuffed endotracheal tube between 15 July 2022 and 15 October 2022 in the pediatric operating room.
62652738|NCT05441189||training cohort|30 patients undergoing resection between March 2015 and December 2016 at Chinese PLA General Hospital in Beijing, China
62087683|NCT04644497||Transphyseal drilling technique|
62087684|NCT04644497||Physeal sparing drilling technique|
62652739|NCT05441189||validation cohort|40 patients from The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga)
62652740|NCT03069989|EXPERIMENTAL|Cohort 1 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62087685|NCT02472561|EXPERIMENTAL|Mobile Health Application Group 1|"Participants will wear a Fitbit Physical Activity Monitor to objectively quantify physical activity patterns. Once a week (± 3 days) during the 12 week mHealth intervention patients will measure and download their blood pressure and blood glucose (if diabetic) by means of a mHealth blood pressure cuff and mHealth glucometer. Medication adherence will be measured at baseline and 12-weeks by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Each participant will be provided with a electronic version of the book titled, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease; patients will be asked to read approximately one chapter per week for educational purposes."
62286647|NCT03396991||Study Group|In the study Group the investigators enrolled 26 patients scheduled for hallux valgus surgery and treated with a new analgesici approach. After sub-gluteal sciatic nerve block with short acting local anesthetic (mepivacaine 2%, 15 ml), each patient received an ultrasound-guided Posterior Tibial Nerve Block (PTNB) with levobupivacaine 0,5% (7-8 ml). The investigators measured: the intensity of pain at the baseline (before the surgery) and at 3, 6, 12 and 24 hours (h) using a Visual Analogue Scale (VAS); the consumption of oxycodone in the first 24 hours after surgical treatment and the motor recovery using modified Bromage score.
62461149|NCT01727271|ACTIVE_COMPARATOR|Tenofovir Monotherapy|Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)
62461150|NCT01727271|EXPERIMENTAL|PegIFN-2b/Tenofovir Sequential Therapy|Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
62461151|NCT01727271|EXPERIMENTAL|Peg-IFN-2b + Tenofovir Combination Therapy|Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
62461152|NCT02177981|ACTIVE_COMPARATOR|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
62461153|NCT02177981|SHAM_COMPARATOR|Control|The cuff will be placed around the arm but not inflated.
62087686|NCT02472561|NO_INTERVENTION|Usual Care Group 2|"Participants will follow standard care as ordered by their individual, treating physician. Each participant will be given a paperback copy of the book, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments."
62087687|NCT00447915|EXPERIMENTAL|1|
62087688|NCT00447915|EXPERIMENTAL|2|
62087689|NCT00447915|ACTIVE_COMPARATOR|3|
62087690|NCT06478771|EXPERIMENTAL|Patient choice-essix retainer|The group in which the patient chooses the retention appliance, essix retainer
62286648|NCT03396991||Control group|The investigators compared the study group with a control group of 26 patients previously scheduled for the same surgery and treated with another post-operative analgesia technique more frequently used in our hospital: local infiltration (Local Infiltration Anesthesia, LIA) with levobupivacaine 0, 5% (15 ml) performed by the surgeon directly on the operative site.
62286649|NCT00663741|EXPERIMENTAL|Arm 1|
62286650|NCT00663741|EXPERIMENTAL|Arm 2|
62286651|NCT00663741|EXPERIMENTAL|Arm 3|
62286652|NCT02978482|EXPERIMENTAL|durvalumab|durvalumab alone
62286653|NCT02978482|EXPERIMENTAL|durvalumab+tremelimumab|durvalumab plus tremelimumab
62461154|NCT06301698|EXPERIMENTAL|Comprehensive rehabilitation+Stellate ganglion block|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62286654|NCT04326634|EXPERIMENTAL|Controlled exercises Group|
62461155|NCT06301698|ACTIVE_COMPARATOR|Comprehensive rehabilitation|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
62461156|NCT01002638|EXPERIMENTAL|Occlusive Dressing|
62461157|NCT01002638|ACTIVE_COMPARATOR|Surgery|
62461158|NCT02175706|ACTIVE_COMPARATOR|Resolute Integrity®|The coating of Resolute Integrity consists of zotarolimus as antiproliferative agent and the BioLinx® polymer system. This polymer system consists of a blend of three different polymers: (1) the hydrophobic C10 polymer, which aids in the control of drug release; (2) the hydrophilic C19 polymer, which supports biocompatibility; and (3) polyvinyl pyrro-lidinone, which increases the initial drug burst and enhances the elution rate.
62461159|NCT02175706|ACTIVE_COMPARATOR|Promus Element®|"Promus Element utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation.~Promus Element is composed of the Element platform, a thin fluoropolymer coating, and Everolimus."
62286655|NCT04326634|EXPERIMENTAL|Non controlled exercises Group|
62461160|NCT04549883|EXPERIMENTAL|Performing after session|LB control during hip extension after intervention
62652741|NCT03069989|PLACEBO_COMPARATOR|Cohort 1 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62087691|NCT06478771|EXPERIMENTAL|Patient choice-lingual retainer|The group in which the patient chooses the retention appliance, lingual retainer
62087692|NCT06478771|ACTIVE_COMPARATOR|Clinician choice-essix retainer|The group from which the orthodontist chooses the retention appliance, essix retainer
62087693|NCT06478771|ACTIVE_COMPARATOR|Clinician choice-lingual retainer|The group from which the orthodontist chooses the retention appliance, lingual retainer
62087694|NCT02050789|NO_INTERVENTION|Usual Care Arm|Programs will continue adhering to current ACGME requirements.
62087695|NCT02050789|EXPERIMENTAL|Intervention Arm|The intent of the intervention arm is to allow flexibility in surgical resident duty hours and improve continuity of care.
62087696|NCT03660722|OTHER|Blood and urinary sample|Blood and urinary sample in HIV 1 positive adults initiating treatment
62286656|NCT05032950|ACTIVE_COMPARATOR|Treatment A|Midazolam orally
62286657|NCT05032950|EXPERIMENTAL|Treatment B|PF-07321332/ritonavir orally + Midazolam orally
62286658|NCT05032950|ACTIVE_COMPARATOR|Treatment C|Ritonavir orally + Midazolam orally
62286659|NCT04590001|EXPERIMENTAL|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD device.
62286660|NCT06120257|ACTIVE_COMPARATOR|Group A :Flexible ureteroscope group|Flexible ureteroscope (F-URS) group underwent holmium laser lithotripsy using flexible ureteroscopy (Boston® scientific (lithovue)
62286661|NCT06120257|ACTIVE_COMPARATOR|Group B : extracorporeal shock wave lithotripsy (ESWL) group|extracorporeal shock wave lithotripsy (ESWL) group underwent electromagnetic extracorporeal shock wave lithotripsy (STORZ® MEDICAL Modulith SLX-F2 FD21, Germany)
62286662|NCT06120257|ACTIVE_COMPARATOR|Group C : Mini perc group|Mini perc group underwent holmium laser lithotripsy using Karl® Storz MIP set.
62286663|NCT05777733|EXPERIMENTAL|N_acetylcystein as antioxidant on iron and frequency of blood transfusion in thalassemia major|N_acetylcystein administration on single oral dose 10mg /kg for 6 months and it's effect on iron and frequency of blood transfusion before and after its use.
62461161|NCT03902496|EXPERIMENTAL|Avulux Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
62461162|NCT03902496|SHAM_COMPARATOR|Sham Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
62286664|NCT00388050|EXPERIMENTAL|Diabetes Medication Choice decision aid|Patients in this arm will discuss diabetes medication for glucose control with the help of a decision aid that covers five commonly prescribed anti-hyperglycemic medications.
62286665|NCT00388050|OTHER|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
62286666|NCT05340205|ACTIVE_COMPARATOR|Tranexamic acid group|Patients will receive 1 gm (10 ml) tranexamic acid diluted in 20 ml of Glucose 5% (administered as IV infusion over 5 minutes, at least 15 minutes prior to skin incision). Following the delivery of the baby, patients will additionally receive a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).
62286667|NCT05340205|ACTIVE_COMPARATOR|Misoprostol group|Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and swabbing the uterine cavity. Patients will additionally receive a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).
62286668|NCT05340205|ACTIVE_COMPARATOR|Oxytocin only (control) group|Patients will receive only an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
62286669|NCT05671380|ACTIVE_COMPARATOR|Enhanced Usual Care: Ask-Advice-Connect (AAC)|AAC participants will receive care through their primary care provider as usual (with the caveat that providers in the clinics will be trained to provide AAC). AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.
62286670|NCT05671380|EXPERIMENTAL|AAC + Longitudinal Proactive Outreach (LPO)|AAC+LPO participants will receive AAC plus an MI tailored outreach call at baseline and at 3, 6, and 9 months post-enrollment. AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.
62652742|NCT03069989|EXPERIMENTAL|Cohort 2 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62652743|NCT03069989|PLACEBO_COMPARATOR|Cohort 2 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
62286671|NCT00177515|EXPERIMENTAL|1|Computerized counseling about Emergency Contraception
62286672|NCT00177515|ACTIVE_COMPARATOR|2|Computerized counseling about peri-conception folate
62286673|NCT00441792|EXPERIMENTAL|Etomidate|
62286674|NCT00441792|EXPERIMENTAL|midazolam|
62286675|NCT04401033||Endoscopic cohort|Endoscopic examinations: They will be carried out according to the recommendations of the Spanish society for digestive endoscopy (SEED). In summary, the patient will perform a hand wash with hydroalcoholic solution before entering the endoscopy room, and will put on a surgical mask and gloves. Personnel close to the patient will wear an FFP2 mask, exceptionally a surgical mask, a gown (waterproof in high-risk examinations as established in the SEED guidelines), a cap, nitrile gloves and face shield or safety glasses (reusable) and shoe covers. The examinations will be performed by endoscopist-guided sedation in accordance with current clinical guidelines.
62652744|NCT02445469|OTHER|Parkinson's disease|MRI exam of the brain
62652745|NCT02445469|OTHER|Multiple System Atrophy|MRI exam of the brain
62652746|NCT02445469|OTHER|Progressive Supranuclear Palsy|MRI exam of the brain
62652747|NCT02445469|OTHER|Vascular parkinsonism|MRI exam of the brain
62286676|NCT04401033||Ultrasonography cohort|Abdominal ultrasound: They will be carried out according to international clinical guidelines (12). The explorer will wear an FFP2 mask, exceptionally a surgical mask, a gown, a hat, nitrile gloves, and a face shield or safety glasses (reusable) and shoe covers. The gel bottle, transducer, and stretcher will be washed prior to each scan with low-level disinfectant
62286677|NCT04401033||Telephonic cohort|The patient will be telephonically contacted for a medical visit.
62286678|NCT01705704||Cohort|
62286679|NCT01325103|EXPERIMENTAL|Stem Cell Transplantation|Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation.
62652748|NCT02445469|OTHER|Healthy volunteers|MRI exam of the brain
62652749|NCT04260113|EXPERIMENTAL|Apatinib Arm|
62652750|NCT01434511|EXPERIMENTAL|OBI-1|
62652751|NCT01855269|ACTIVE_COMPARATOR|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
62652752|NCT01855269|ACTIVE_COMPARATOR|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
62652753|NCT01855269|PLACEBO_COMPARATOR|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
62652754|NCT00677222|EXPERIMENTAL|1|Treatment arm
62652755|NCT00677222|NO_INTERVENTION|2|Registry Arm -standard of care
62652756|NCT05555680||PCOS patients with clinical or biochemical hyperandrogenism|Clinical hyperandrogenism consists of patients with one of the following conditions: Acne, Hirsutism (using modified Ferriman-Gallwey (FG) score) or Androgenic alopecia Biochemical hyperandrogenism consists of elevated serum level of at least one of the following hormones: Total testosterone, free testosterone, DHEAS, androstenedione using the cut-offs adopted by the laboratory.
62652757|NCT05555680||PCOS patients with no clinical or biochemical hyperandrogenism|In this cohort, women have not be affected by either clinical of biochemical hyperandrogenism. The PCOS diagnosis will be based on oligo-anovulation and on polycystic ovaries during an ultrasound
62652758|NCT04301050|EXPERIMENTAL|Yoga Intervention|Participants will complete 8-week course (75-minute, weekly yoga classes) delivered online via videoconferencing software. Participants will complete patient-reported outcomes at baseline (prior to class 1) and post-intervention (after class 8), as well as post-intervention measures of feasibility/acceptability.
62652759|NCT05203315|EXPERIMENTAL|Treatment Group A|Subjects whose baseline Itch and/or Burning/Stinging Score is less than 2 (moderate), one tube of Duobrii along with one jar of CeraVe cream, will be dispensed to the subject at the Baseline visit. The study participant will be instructed to apply the CeraVe cream to the treatment area twice daily and advised to apply a thin layer of the Duobrii only to the affected skin once daily in the evening.
62087697|NCT03038074|EXPERIMENTAL|Test Group|The subjects will be enrolled in the test group and will receive Pulse Oximeter with respiration rate sensor to examine the respiration rate.
62087698|NCT00972985|EXPERIMENTAL|modafinil|All healthy control subjects receive modafinil in this crossover design
62461163|NCT03171493|EXPERIMENTAL|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
62286680|NCT06249750|EXPERIMENTAL|Immuno-targeted therapy group|ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d; RTK inhibitor regimen: Anlotinib, 12mg (at an initial dose of 12mg, later adjusted according to the instructions), po., d1\~14, q21d.
62286681|NCT06249750|EXPERIMENTAL|Hyperthermia-immuno-targeted therapy group|ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h. ICI regimen: Tislelizumab, 200mg, ivgtt., d2, q21d; RTK inhibitor regimen: Anlotinib, 12mg (at an initial dose of 12mg, later adjusted according to the instructions), po., d2\~15, q21d.
62286682|NCT02731742|EXPERIMENTAL|Dose A MK-1966 + Dose A SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
62286683|NCT02731742|EXPERIMENTAL|Dose A MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
62461164|NCT06287905|NO_INTERVENTION|group of antivenom only|Dose of antivenom 1-1 ampoule intramuscular and/ or, 2-1 to 5 Polyvalent anti-scorpion serum ampoules produced by the vaccine \& serum institution (VACSERA)in Egypt according to the severity of the case on 200 to 500 ml glucose 5% infusion and assess the patient clinically to repeat the dose after 4 to 6 hours. (Shoreit et al., 2019)
62461165|NCT06287905|EXPERIMENTAL|group of adding prazosin plus standard treatment|1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
62461166|NCT02768064|EXPERIMENTAL|Flexible screwed electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a flexible screwed electrode.
62461167|NCT02768064|ACTIVE_COMPARATOR|Stiff standard electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a stiff standard temporary electrode
62461168|NCT02543671|ACTIVE_COMPARATOR|vitamin D3 enriched cheese|vitamin D3 enriched, reduced-fat yellow cheese
62461169|NCT02543671|PLACEBO_COMPARATOR|plain cheese|plain (non-fortified) reduced-fat yellow cheese
62652760|NCT05203315|EXPERIMENTAL|Treatment Group B|Subjects whose baseline Itch and/or Burning/Stinging Score is greater than or equal to 2 (moderate), in addition to one tube of Duobrii along with one jar of CeraVe cream, the participant will be given a tube of hydrocortisone 1% cream and instructed to apply to the treatment area twice daily for 5 days, along with CeraVe cream. Starting at day 6 and ongoing, subjects will be instructed to discontinue the hydrocortisone cream and initiate Duobrii application every night, while continuing the CeraVe cream twice daily.
62652761|NCT01029756|ACTIVE_COMPARATOR|Macintosh Laryngoscope|
62652762|NCT01029756|ACTIVE_COMPARATOR|Pentax AWS Videolaryngoscope|
62652763|NCT06372561|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|is a powder that consist of Calcium oxide, silicone dioxide, aluminum oxide, bismuth oxide, purified water. It is a bactericidal dressing material, promotes pulp healing, and does so without producing inflammation and promotes dentin bridge formation.
62087699|NCT00972985|EXPERIMENTAL|methylphenidate|All healthy control subjects receive methylphenidate in this crossover design
62087700|NCT00972985|EXPERIMENTAL|lorazepam|All healthy control subjects receive lorazepam in this crossover design
62087701|NCT00972985|PLACEBO_COMPARATOR|placebo|All healthy control subjects receive placebo in this crossover design
62087702|NCT03190863|EXPERIMENTAL|Motor imagery combined with neurofeedback (MINF)|
62286684|NCT02731742|EXPERIMENTAL|Dose B MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
62461170|NCT01925092|EXPERIMENTAL|mifepristone|Daily doses of mifepristone over 84 days.
62087703|NCT03190863|ACTIVE_COMPARATOR|Motor imagery (MI)|
62087704|NCT03190863|SHAM_COMPARATOR|Control (C)|
62087705|NCT01867853||successful weaning|the SUCCESS of SBT or not need for reintubation or noninvasive ventilation within 48 h following extubation
62087706|NCT01867853||failed weaning|the failure of SBT or the need for reintubation or noninvasive ventilation within 48 h following extubation
62087707|NCT05804864|EXPERIMENTAL|KM501-1001|
62087708|NCT04315038||All patients|Spinal anesthesia
62087709|NCT02065921||COPD patients|establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.
62652764|NCT06372561|EXPERIMENTAL|Melatonin|(N-acetyl-5-methoxy-tryptamine) is a pleiotropic hormone synthesized in the pineal gland that has important chronobiotic properties. there is a Melatonin drug (powder) that proved to play an essential role in the regulation of bone growth (bone regeneration) and it may promote osteoblast differentiation, and stimulates mineralized matrix formation
62087710|NCT02011308|ACTIVE_COMPARATOR|Green Light Laser|
62087711|NCT02011308|ACTIVE_COMPARATOR|TURP|Transurethral Resection of the Prostate
62087712|NCT00258713|ACTIVE_COMPARATOR|1|
62087713|NCT00258713|ACTIVE_COMPARATOR|2|
62087714|NCT00258713|ACTIVE_COMPARATOR|3|
62087715|NCT01579617|EXPERIMENTAL|BUtiful|Intervention arm, 'BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved', has 8 website sessions focused on pregnancy and STI prevention
62087716|NCT01579617|OTHER|DIVAS|Attention control arm, 'DIVAS. Diversity, Individuality, Vitality, Activity and Strong', has 8 website sessions focused on general health and nutrition
62652765|NCT06372561|EXPERIMENTAL|Mineral Trioxide and Melatonin|Mixture of the two materials' powders.
62087717|NCT01318811|ACTIVE_COMPARATOR|Dilute heparin|Arm A will receive dilute heparin delivered as an intravenous infusion proximal to the dialysis filter.
62087718|NCT01318811|ACTIVE_COMPARATOR|Standard concentrated heparin|Arm B will receive standard concentrated heparin and will be delivered as an intravenous infusion proximal to the dialysis filter.
62087719|NCT01195064||COPD+ OSAS- patients|Patients with chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
62087720|NCT01195064||COPD- OSAS+ patients|Patients with obstructive sleep apnea syndrome (OSAS) and without chronic obstructive pulmonary disease (COPD), before planned cardiovascular surgery
62087721|NCT01195064||COPD+ OSAS+ patients|Patients with chronic obstructive pulmonary disease (COPD) and with obstructive sleep apnea syndrome (OSAS), with planned cardiovascular surgery
62087722|NCT01195064||COPD- OSAS- patients|Patients without chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
62652766|NCT01898416|EXPERIMENTAL|5-AminoLevulinicc Acid|consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.
62652767|NCT01258049|EXPERIMENTAL|ArTiMist|
62652768|NCT01258049|ACTIVE_COMPARATOR|Quinine|
62087723|NCT00739583|ACTIVE_COMPARATOR|1|Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)
62087724|NCT00739583|ACTIVE_COMPARATOR|2|Skin preparation for hip replacement with an Iodine based skin preparation solution, Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA.
62087725|NCT06614335||Retrospective analysis group|A retrospective analysis was performed on 220 patients who underwent IE surgery, followed up to 4 years of age, and the risk factors affecting the success rate of stereoscopic establishment were analyzed, such as strabismus, age of surgery, MRI brain features, concomitant symptoms of strabismus, etiology, refractive status, etc. The optimal timing of IE surgery and the imaging evidence related to the selection of the optimal timing were determined according to the operative orthostatic rate and the success rate of stereoscopic establishment, and the prediction model of the success rate of binocular stereoscopic establishment after surgery at different time points was constructed.
62087726|NCT06614335||External validation cohort of patients undergoing surgery|An externally validated retrospective analysis of 60-80 patients undergoing IE surgery was conducted to construct a prediction model for the success rate of binocular stereovision establishment after surgery at different time points.
62087727|NCT01349907|EXPERIMENTAL|Asenapine/Asenapine|Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
62087728|NCT01349907|EXPERIMENTAL|Placebo/Asenapine|Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
62087729|NCT00652574|EXPERIMENTAL|Dasatinib|Dasatinib = BMS-354825, Sprycel
62087730|NCT04018781||MR group|Patients who benefit from a full process of medication reconciliation (entrance and discharge) before being discharged to home.
62652769|NCT03255187|EXPERIMENTAL|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
62652770|NCT03255187|PLACEBO_COMPARATOR|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
62286685|NCT02731742|EXPERIMENTAL|Dose C MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
62286686|NCT02731742|EXPERIMENTAL|Part B Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
62286687|NCT02731742|EXPERIMENTAL|Part C Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
62087731|NCT04018781||Control group|Patients who benefitted from a medication reconciliation at entrance only before being discharged to home.
62087732|NCT06505850|EXPERIMENTAL|Tapered-shaped cuff ETT group|A tapered-shaped cuff tube was used to intubate for general anesthesia
62087733|NCT06505850|ACTIVE_COMPARATOR|Cylindrical-shaped cuff ETT group|A cylindrical-shaped cuff tube was used to intubate for general anesthesia
62087734|NCT03132714|ACTIVE_COMPARATOR|PD + (AMX + MET)|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg
62087735|NCT03132714|ACTIVE_COMPARATOR|PD + CLM|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg
62087736|NCT03132714|ACTIVE_COMPARATOR|PD + (AMX + MET) + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT
62652771|NCT04794907||DR|Patients with diabetes
62652772|NCT04794907||AMD|Patients age 55 and older
62652773|NCT06048224|EXPERIMENTAL|HS628|Subjects will receive 8mg/kg intravenous(IV) HS628 at Week 0,Week 4, Week 8, Week 12, Week 16, Week 20,Week 24
62652774|NCT06048224|ACTIVE_COMPARATOR|Actemra|Subjects will receive 8mg/kg intravenous(IV) ACTEMRA® at Week 0,Week 4, Week 8, Week 12, Week 16, Week 20,Week 24
62286688|NCT02834949|EXPERIMENTAL|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS will be described to participants as the College Adjustment Session and the session will be conducted using an MI plus personalized feedback approach."
62652775|NCT05280990|EXPERIMENTAL|Future Liver Remnant Function (FLRF)|Preoperative FLRF risk assessment via 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS)
62286689|NCT02834949|ACTIVE_COMPARATOR|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
62286690|NCT02834949|NO_INTERVENTION|Assessment|Participants will fill out a battery of measures and receive no intervention.
62652776|NCT05280990|ACTIVE_COMPARATOR|Future Liver Remnant Volume (FLRV)|Preoperative FLRV assessment by CT/MRI volumetry
62652777|NCT03171090|ACTIVE_COMPARATOR|sphenopalatine block using local anasthetic|
62652778|NCT03171090|PLACEBO_COMPARATOR|sphenopalatine block using saline|
62286691|NCT01501591|OTHER|Hydroxyzine|This group will receive a first generation H-1 receptor antagonist, hydroxyzine (25 mg) twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
62286692|NCT01501591|OTHER|Placebo|This group will receive a placebo twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
62286693|NCT01501591|OTHER|Hydroxyzine/placebo|This group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design.
62652779|NCT01114724|EXPERIMENTAL|Valiant Thoracic Stent Graft with the Captivia Delivery System|
62652780|NCT01513655|EXPERIMENTAL|LTNIV group|"LTNIV group is discharged with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.~Furthermore, the patients are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
62652781|NCT01513655|NO_INTERVENTION|Control group|"Patients in the control group are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
62652782|NCT00732914|ACTIVE_COMPARATOR|1|Sunitinib (first-line) followed by Sorafenib (second-line)
62652783|NCT00732914|EXPERIMENTAL|2|Sorafenib (first-line) followed by Sunitinib (second-line)
62087737|NCT03132714|ACTIVE_COMPARATOR|PD + CLM + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT
62087738|NCT03132714|ACTIVE_COMPARATOR|PD + (AMX + MET) + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT
62087739|NCT03132714|ACTIVE_COMPARATOR|PD + CLM + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT
62087740|NCT02169830|ACTIVE_COMPARATOR|nortriptyline|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
62087741|NCT02169830|ACTIVE_COMPARATOR|topiramate|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
62087742|NCT02169830|OTHER|diet modification|Participants will begin with diet modification for four (4) weeks.
62087743|NCT03575442|OTHER|"3 session program of art therapy"|Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
62087744|NCT04563052|EXPERIMENTAL|Education|Air pollution educational module exposure.
62087745|NCT01429714|EXPERIMENTAL|Intervention: individually tailored ECS|Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
62087746|NCT01429714|ACTIVE_COMPARATOR|Control: ECS 24 months|Elastic compression therapy with a standard duration of 24 months
62087747|NCT03756649||Control Group|Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
62087748|NCT03756649||Inflammatory bowel disease (IBD)|Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
62087749|NCT06478823|EXPERIMENTAL|Healthy volunteers for stool donation|
62087750|NCT06614452|EXPERIMENTAL|EUS-FNB|"Consecutive patients diagnosed with biliary strictures in absence of a pancreatic or abdominal mass will be assessed for eligibility.~Patients with jaundice requiring decompression, will undergo ERCP with tissue sampling (brushing and/or biopsy) and biliary drainage, preferably in the same session immediately after EUS-FNB."
62087751|NCT02059317||Group 1|"Six groups are created in order to randomized the order of interventions. In group 1, the order of interventions is as follows:~1. Flexion-extension in the sagittal plane~2. Rotation in a transverse plane~3. Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 \& 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
62087752|NCT02059317||Group 2|"Six groups are created in order to randomized the order of interventions. In group 2, the order of interventions is as follows:~1. Flexion-extension in the sagittal plane~2. Complex movement in three dimensions~3. Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 \& 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
62286694|NCT02409511||Type 1 diabetic, retinopathy, non cardiovascular disease|Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease
62286695|NCT02409511||Non-diabetic, hipertension|Non-diabetic patients with hypertension and microalbuminuria
62286696|NCT02409511||Type 2 diabetic, non diabetic retinopathy|Type 2 diabetic patients without diabetic retinopathy and microalbuminuria
62087753|NCT02059317||Group 3|"Six groups are created in order to randomized the order of interventions. In group 3, the order of interventions is as follows:~1. Rotation in a transverse plane~2. Flexion-extension in the sagittal plane~3. Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 \& 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
62087754|NCT02059317||Group 4|"Six groups are created in order to randomized the order of interventions. In group 4, the order of interventions is as follows:~1. Rotation in a transverse plane~2. Complex movement in three dimensions~3. Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 \& 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
62087755|NCT02059317||Group 5|"Six groups are created in order to randomized the order of interventions. In group 5, the order of interventions is as follows:~1. Complex movement in three dimensions~2. Flexion-extension in the sagittal plane~3. Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 \& 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
62286697|NCT02409511||Type 2 diabetic with diabetic retinopathy|Type 2 diabetic patients with diabetic retinopathy and microalbuminuria
62286698|NCT02409511||Type 2 diabetic, with proven nephropathy|Type 2 diabetic patients with biopsy proven diabetic nephropathy.
62652784|NCT05540431|OTHER|Activated charcoal|"1st group~Oral activated charcoal~20 to 25 patient with CKD will receive standard care plus Activated charcoal capsule (charconut) three times dialy for six weeks."
62652785|NCT05540431|OTHER|Probiotic|"2nd group~Oral probiotic~20 to 25 patient with CKD will receive standard care plus Probiotic tablet twice dialy for six weeks."
62652786|NCT05540431|OTHER|Control group|"3rd group~Control group~20 to 25 patient with CKD will receive standard care only for six weeks."
62286699|NCT02949830|EXPERIMENTAL|Givosiran|At the beginning of this study, participants received either givosiran 2.5 mg/kg subcutaneous (SC) injection once monthly(QM), givosiran 5.0 mg/kg SC injection QM, or givosiran 5.0 mg/kg SC injection once every 3 months (Q3M). Within a year, all participants were transitioned to givosiran 2.5 mg/kg SC injection QM.
62286700|NCT02085291|EXPERIMENTAL|Resp-FL|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one. The target MAP was maintain MAP within 10% of the reference value.
62286701|NCT02085291|EXPERIMENTAL|Resp-NE|In Resp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
62286702|NCT02085291|EXPERIMENTAL|Nonresp-NE|In Nonresp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
62286703|NCT02356809|EXPERIMENTAL|pl-vegf165|Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
62286704|NCT02356809|NO_INTERVENTION|standard care|Patients of this group will receive standard therapy accepted in a clinical centre
62286705|NCT01944085|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen was administered 1 hour prior to pin removal (weight dependent dose)
62087756|NCT02059317||Group 6|"Six groups are created in order to randomized the order of interventions. In group 6, the order of interventions is as follows:~1. Complex movement in three dimensions~2. Rotation in a transverse plane~3. Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 \& 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
62087757|NCT04928989|ACTIVE_COMPARATOR|Convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
62652787|NCT00139529|EXPERIMENTAL|1|Participants will receive an educational intervention during pregnancy combined with a motivational interviewing program using telephone counseling to prevent postpartum relapse to tobacco use.
62087758|NCT04928989|EXPERIMENTAL|Neck-specific exercise in addition to convergence dialogue meeting|Neck-specific exercise with digital web-based support and four visits to a physiotherapist. Neck-specific exercise will be performed based on a well-structured framework of neck-specific exercise for facilitation of deep neck muscles, increased muscle coordination, improved neck posture and increased neck muscle endurance. Plus additional convergence dialogue meeting as treatment arm no 1.
62087759|NCT00414869|EXPERIMENTAL|NCX-1000|Experimental drug under evaluation
62087760|NCT00414869|PLACEBO_COMPARATOR|Placebo|Placebo powder
62286706|NCT01944085|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen was administered 1 hour prior to pin removal (weight dependent dose)
62286707|NCT01944085|PLACEBO_COMPARATOR|Vitamin C (Placebo)|Vitamin C was administered 1 hour prior to pin removal (weight dependent dose)
62286708|NCT00887861|EXPERIMENTAL|BGG492|
62286709|NCT00887861|PLACEBO_COMPARATOR|Placebo|
62286710|NCT00706017||A|
62652788|NCT00139529|ACTIVE_COMPARATOR|2|Participants will receive an educational intervention during pregnancy.
62652789|NCT03211507||Case|Males with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
62286711|NCT03931304||Cases group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
62286712|NCT03931304||Control group|Cytoreductive surgery alone
62286713|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
62286714|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
62286715|NCT00546975|EXPERIMENTAL|1|Resource Support® Novartis
62286716|NCT00546975|ACTIVE_COMPARATOR|2|Resource Protein®, Novartis
62286717|NCT00546975|PLACEBO_COMPARATOR|3|
62286718|NCT00006227|EXPERIMENTAL|Treatment (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
62286719|NCT02603744|EXPERIMENTAL|5 million MSC|The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.
62286720|NCT02603744|EXPERIMENTAL|10 million MSC|The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.
62286721|NCT02603744|EXPERIMENTAL|15 million MSC|The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells.
62286722|NCT05207228|NO_INTERVENTION|Treatment as usual|After completing the inpatient care (at discharge of inpatient care), patients randomized to TAU will receive day-care / outpatient treatment.
62286723|NCT05207228|EXPERIMENTAL|Treatment as usual + CBT4CBT|After completing the inpatient care (at discharge), the patients randomly assigned to the experimental condition will receive the TAU + CBT4CBT a web-based treatment which has been tested on individuals with cocaine use disorder in America by the team of Dr. K.M. Carroll.
62652790|NCT03211507||Controls|Males with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
62087761|NCT06373692||Traditional Chinese Medical cohort|The standardized use of TCM treatment regimen was regarded as an exposure factor, and the treatment methods of the enrolled patients were defined and grouped: patients who took medication continuously for more than 3 months per year, or who took medication intermittently for more than 6 months in the total time of the year, were in the exposure group.
62087762|NCT06373692||Non Traditional Chinese Medical cohort|Those who used conventional Western medicine treatment without using standardized Chinese medicine treatment regimen were in the non-exposure group.
62087763|NCT01529762||Osseotite Certain Tapered|Dental implant Osseotite Certain Tapered design
62087764|NCT00534911|EXPERIMENTAL|Cognitive Behavioral Therapy|Primary \& Secondary Control Enhancement Training (PASCET)
62286724|NCT02844387|EXPERIMENTAL|Arginine|In the Arginine arm patients will receive 10 mg of L-arginine hydrochloride solution oral supplementation (in 200 ml of flavoured drinking water solution) administered twice a day prior to the radiation therapy fraction
62286725|NCT02844387|PLACEBO_COMPARATOR|Placebo|In the Placebo arm patients will receive 200 ml of flavoured drinking water oral solution administered twice a day prior to the radiation therapy fraction
62286726|NCT02088385|EXPERIMENTAL|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
62286727|NCT02088385|ACTIVE_COMPARATOR|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
62286728|NCT04926935||Patients hospitalized in the ICU during the study period.|Patients hospitalized in the ICU during the study period with clinically suspected infection.
62286729|NCT05193565|EXPERIMENTAL|RaparoBell Tablet|RaparoBell Tablet
62286730|NCT05193565|ACTIVE_COMPARATOR|Mycophenolate Mofetil Tablet/Capsule|Myrept Tablet/Capsule
62286731|NCT06007989||Basic science study, no intervention.|Basic science study, no intervention.
62286732|NCT04282005|EXPERIMENTAL|surgery group|Fourteen patients who meet study criteria will be assigned to the study group and will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
62286733|NCT04282005|ACTIVE_COMPARATOR|lifestyle and diet|Fourteen patients matched to the surgery group for age, gender, BMI, diabetes status, and NALFD score will undergo additional lifestyle interventions, dietary counselling and or meal replacement by a dietician aimed at inducing at least a 5-7% weight reduction, prior to their surgery (while on the waiting list for surgery).
62461171|NCT02015390|ACTIVE_COMPARATOR|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects that involves the induction of a biomembrane about a poly(methylmethacrylate)(PMMA) cement spacer within the defect and, following cement removal, autogenous bone grafting (harvested using Reamer-Irrigator-Aspirator) or allogeneic bone graft is used to pack the defect while preserving the biomembrane. The typical time interval between the two stages is 6-8 weeks. The biomembrane not only assists in retaining the bone graft, but serves as a rich source of vascular supply and growth factors which constitute an excellent biological milieu for the graft to consolidate and heal the defect.
62652791|NCT00300053|EXPERIMENTAL|CLBS14: Low-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight
62087765|NCT00534911|ACTIVE_COMPARATOR|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy
62087766|NCT03464643|OTHER|Single embryo culture|Embryo is cultured individually in 25 ul media
62286734|NCT05756725|OTHER|All Pilot Sites|All community health centers participating in the study will implement the new population health management tools utilizing tailored implementation strategies
62286735|NCT01859377|OTHER|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
62286736|NCT01859377|OTHER|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
62286737|NCT05488860|ACTIVE_COMPARATOR|Traditional injection|Intralesional injection of drug by traditional injection needle. This is the traditional approach for drug delivery recommended by international guidelines for each skin diseases.
62286738|NCT05488860|EXPERIMENTAL|Piezoelectric drived microneedling|Intralesional injection of drug by piezoelectric drived microneedles.
62286739|NCT03992144|EXPERIMENTAL|amoxicillin|single preoperative oral 500 mg dose of Amoxicillin before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
62286740|NCT03992144|EXPERIMENTAL|metronidazole|single preoperative oral 400 mg dose of metronidazol before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
62087767|NCT03464643|OTHER|Group embryo culture|2-3 Embryos are group cultured in 50 ul media
62087768|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
62087769|NCT02521259||normal BIS group|BIS range from 40 to 60
62087770|NCT04846205||Patients who underwent a systematic etiological|Patients who underwent a systematic etiological assessment in the context of their cryptogenic ischemic stroke between 2015 and 2020. A collect data in medical record will be realized.
62286741|NCT03992144|ACTIVE_COMPARATOR|conventional group|conventional therapy for prevention of dry socket post operative; 400mg metrinidazol 3 times a day for 5 days 500mg of amooxicillin 2 times a day for 5 days painkiller 48 hours after extraction then sos
62286742|NCT01568203|EXPERIMENTAL|AMG 579|
62286743|NCT01568203|PLACEBO_COMPARATOR|Placebo|
62652792|NCT00300053|EXPERIMENTAL|CLBS14: High-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight
62652793|NCT00300053|PLACEBO_COMPARATOR|Placebo injection|10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma
62652794|NCT03706846|OTHER|Fasting 2 hours|Fasting 2 hours
62652795|NCT03706846|OTHER|Fasting 6 hours|Fasting 6 hours
62652796|NCT01654887|EXPERIMENTAL|Lung Ultrasound|LUS first with the option of obtaining CXR second
62087771|NCT01800409|EXPERIMENTAL|AFES training|Participants will take part in AFES training sessions five times per week (Mon-Fri) for a total of 8 weeks During these sessions participants will receive AFES for 40 minutes. Training sessions are designed to strengthen the participants abdominal muscles in order to improve respiratory function
62087772|NCT01800409|NO_INTERVENTION|Control period|Four week control period. The order of the control and training periods will be randomised for each participant.
62087773|NCT00610883|EXPERIMENTAL|1 - LSA4|
62087774|NCT01854333|OTHER|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
62087775|NCT01110564||1|COPD patients
62087776|NCT02034721|EXPERIMENTAL|Protein supplementation|60 grams protein before, during, after eccentric exercise
62286744|NCT05202145|EXPERIMENTAL|Part 1 - Cyclosporine|"Participants will receive ALXN2050 and cyclosporine in a fixed sequence over 3 periods.~Period 1: Participants will receive multiple doses of ALXN2050.~Period 2: Participants will receive multiple doses of cyclosporine.~Period 3: Participants will receive multiple doses of ALXN2050 co-administered with multiple doses of cyclosporine.~There will be a washout period between the last dose of ALXN2050 in Period 1 and the first dose of cyclosporine in Period 2 and between the last dose of cyclosporine in Period 2 and the first dosing in Period 3."
62087777|NCT02034721|PLACEBO_COMPARATOR|Placebo|60 grams placebo before, during, after eccentric exercise
62286745|NCT05202145|EXPERIMENTAL|Part 2 - Tacrolimus|"Participants will receive tacrolimus and ALXN2050 in a fixed sequence over 2 periods.~Period 1: Participants will receive a single dose of tacrolimus.~Period 2: Participants will receive multiple doses of ALXN2050 alone and co-administered with a single dose of tacrolimus.~There will be a washout period between the dose of tacrolimus in Period 1 and the first dose of ALXN2050 in Period 2."
62286746|NCT05202145|EXPERIMENTAL|Part 3 - MMF|"Participants will receive MMF and ALXN2050 in a fixed sequence over 2 periods.~Period 1: Participants will receive a single dose of MMF.~Period 2: Participants will receive multiple doses of ALXN2050 alone and co-administered with a single dose of MMF.~There will be a washout period between the dose of MMF in Period 1 and the first dose of ALXN2050 in Period 2."
62087778|NCT01300429||patients with Non Small Cell Lung cancer|This is a protocol to obtain and/or analyze tissue specimens of patients with NSCLC harboring an activating ALK inversion or translocation that have had a previous clinical response to tyrosine kinase inhibitor therapy and subsequently experience progressive disease. The tissue will be used to identify changes in the ALK gene that are acquired during treatment with an ALK TKI and may account for acquired resistance.
62087779|NCT04271592|EXPERIMENTAL|Part 1: SAD Cohorts 1-7 ABI-H3733 Liquid Form|A single dose of ABI-H3733 liquid oral dosage form administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
62087780|NCT04271592|PLACEBO_COMPARATOR|Part 1: SAD Cohorts 1-7 Placebo Liquid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
62087781|NCT04271592|EXPERIMENTAL|Part 1: MAD Cohorts 8-10 ABI-H3733 Liquid Form|Once-daily doses of ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
62286747|NCT02367521|EXPERIMENTAL|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
62286748|NCT02367521|PLACEBO_COMPARATOR|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
62286749|NCT00935389|EXPERIMENTAL|immunosuppressor|TW 30mg,q.d.\*3 months and reduced into 20mg b.i.d
62286750|NCT05949307|EXPERIMENTAL|Acupuncture group|receive acupuncture treatment
62286751|NCT05949307|EXPERIMENTAL|Laser acupuncture group|receive laser acupuncture treatment
62286752|NCT05949307|SHAM_COMPARATOR|Sham laser acupuncture group|receive sham-laser acupuncture treatment
62286753|NCT03239431||Asthma group|Patients with asthma
62286754|NCT05708807||Observational - all|All included stroke patients.
62286755|NCT01445535|EXPERIMENTAL|siplizumab + EPOCH (combo chemo) + rituximab|siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
62286756|NCT04905745||Facial palsy|Adulthood facial palsy patients group who receive Korean integrative medicine.
62286757|NCT03623919|EXPERIMENTAL|Exercise group|"Group games, including two teams of seniors aged 50 years or older. The FallSensing games software include 3 mini-games to be played by two teams with up to 3 players each will compete against each other alternately.~The players will perform an initial evaluation with FallSensing screening tool, 16 sessions of group games (2 times a week/8weeks) with FallSensing multiplayer games and a final evaluation also with FallSensing screening tool.~Both initial and final evaluation include six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for Exercise."
62461172|NCT02015390|ACTIVE_COMPARATOR|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. It involves the implantation of a fenestrated cylindrical titanium mesh cage packed with autogenous bone graft (harvested using Reamer-Irrigator-Aspirator) or with allogeneic bone graft.
62652797|NCT01654887|ACTIVE_COMPARATOR|Chest X-Ray|CXR first followed by LUS second
62087782|NCT04271592|PLACEBO_COMPARATOR|Part 1: MAD Cohorts 8-10 Placebo Liquid Form|Once-daily doses of placebo matching ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
62087783|NCT04271592|EXPERIMENTAL|Part 2: Single Dose Fasted Cohort 11 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
62087784|NCT04271592|PLACEBO_COMPARATOR|Part 2: Single Dose Fasted Cohort 11 Placebo Solid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
62087785|NCT04271592|EXPERIMENTAL|Part 2: Single Dose Fed Cohort 12 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
62087786|NCT04271592|PLACEBO_COMPARATOR|Part 2: Single Dose Fed Cohort 12 Placebo Solid Form|A single dose of placebo matching ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
62087787|NCT00738530|EXPERIMENTAL|Bevacizumab + IFN-Alfa-2A|Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
62286758|NCT02292212|EXPERIMENTAL|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
62286759|NCT06484894||Hypermetrope|Effect of hypermetropia on central corneal thickness by using pentacam and IOL master
62286760|NCT06484894||Emmetrope|Effect of emmetropia on central corneal thickness by using pentacam and IOL master
62286761|NCT06484894||Myopia|Effect of myopia on central corneal thickness by using pentacam and IOL master
62286762|NCT04941196|EXPERIMENTAL|Test Group|Oral administration of Anplag® 90mg (Ticagrelor) whole Tablet, manufactured by PharmEvo Private Laboratories (Pak) Ltd., after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
62286763|NCT04941196|ACTIVE_COMPARATOR|Reference Group|Oral administration of Brilinta® 90mg (Ticagrelor) Whole Tablet, manufactured by AstraZeneca Pharmaceuticals., after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
62286764|NCT05925205|EXPERIMENTAL|Group A|Experimental group 1.
62286765|NCT05925205|EXPERIMENTAL|Group B|Experimental group 2.
62461173|NCT00219830|EXPERIMENTAL|1 - home-based walking program|Based on medical record held in general practice, patients who had not attended a formal cardiac rehabilitation program after myocardial infarction and were enrolled in home-based walking programme
62652798|NCT00668616|ACTIVE_COMPARATOR|1|
62652799|NCT00668616|EXPERIMENTAL|2|
62652800|NCT02173613|EXPERIMENTAL|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
62652801|NCT02173613|NO_INTERVENTION|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
62652802|NCT05664516|PLACEBO_COMPARATOR|Placebo Arm|Solution without oxytocin
62286766|NCT05925205|EXPERIMENTAL|Group C|Experimental group 3.
62286767|NCT00599417|EXPERIMENTAL|1|
62286768|NCT00599417|PLACEBO_COMPARATOR|2|
62652803|NCT05664516|EXPERIMENTAL|TNX-1900|Solution with oxytocin
62652804|NCT03257579|EXPERIMENTAL|90 Day Supply|Intervention: At Hamilton Health Sciences a policy change implementing a standardized discharge prescription form of a 90-day supply with 3 repeats for all cardiac medications available on all wards where MI patients are managed.
62652805|NCT03257579|EXPERIMENTAL|Education Alone|At St. Joseph's Hospital and Niagara Health System education regarding the benefits of lengthening prescriptions to a 90 day supply with 3 repeats for all cardiac medications will be implemented.
62652806|NCT03257579|NO_INTERVENTION|Control|Remaining Ontario cardiac sites will receive usual care and act as concurrent control group.
62286769|NCT06250140||Internal hemorrhoid ligation group|Endoscopic internal hemorrhoid ligation
62286770|NCT06250140||Hemorrhoids injection group|Endoscopic hemorrhoid injection was performed
62286771|NCT06250140||Internal hemorrhoids combined treatment group|Lines of endoscopic hemorrhoids and internal ligation under endoscope to injection
62087788|NCT00738530|PLACEBO_COMPARATOR|Placebo + IFN-Alfa-2A|Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
62652807|NCT01160302|EXPERIMENTAL|Microgranular Curcumin|Consume 4g microgranular curcumin (Curcumin C3 Complex) twice per day
62652808|NCT04056468|EXPERIMENTAL|Moderate HI (Child-Pugh B): Mobocertinib 40 mg|Mobocertinib 40 milligram (mg), capsule, orally, a single dose on Day 1.
62087789|NCT04100161|EXPERIMENTAL|Protein supplementation|20g protein supplementation twice daily for 3 months
62652809|NCT04056468|EXPERIMENTAL|Severe HI (Child-Pugh C): Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
62652810|NCT04056468|EXPERIMENTAL|Normal Hepatic Function: Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
62652811|NCT04100213|EXPERIMENTAL|TSST|
62652812|NCT02728336|ACTIVE_COMPARATOR|Heart Failure Patients|patients who are scheduled to undergo clinically ordered CRT for heart failure complicated by dyssynchrony
62652813|NCT02728336|ACTIVE_COMPARATOR|Control|20 matched control subjects
62652814|NCT00067080|EXPERIMENTAL|ICL670 + deferoxamine|
62087790|NCT04100161|ACTIVE_COMPARATOR|Carbohydrate supplementation|20g maltodextrin supplementation twice daily for 3 months
62652815|NCT06069102|ACTIVE_COMPARATOR|Usual Care Group|Standard of care BP medication will usually be started if a subject's BP consistently exceeds 150/100 mmHg at any point.
62652816|NCT06069102|EXPERIMENTAL|Intervention (Tight Blood Pressure Control) Group|BP medication will be started if a subject's hospital BP consistently exceeds 140/90 mmHg or her home BP consistently exceeds 135/85 mmHg.
62652817|NCT04583501|EXPERIMENTAL|Omalizumab|Ex vivo exposure of excised human surgical polyp tissue to omalizumab.
62652818|NCT05229913|PLACEBO_COMPARATOR|The control group （Esketamine is not added）|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
62652819|NCT05229913|EXPERIMENTAL|Esketamine experimental group(E0.2)|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
62087791|NCT01656603|EXPERIMENTAL|unlicensed CBU|The Principal Investigators will be the transplant physicians at participating US transplant centers
62087792|NCT06010121|EXPERIMENTAL|Liposomal Vitamin D|Daily oral dose of liposomal vitamin D for 4 weeks
62087793|NCT06010121|ACTIVE_COMPARATOR|Traditional Vitamin D|Daily oral dose of traditional vitamin D for 4 weeks
62087794|NCT01166087|EXPERIMENTAL|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
62087795|NCT01166087|ACTIVE_COMPARATOR|Prozac ® weekly|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
62087796|NCT06697938|EXPERIMENTAL|Neoadjuvant Chemoradiotherapy Group|Preoperative umor SBRT and surgery after Neoadjuvant Chemotherapy
62087797|NCT06697938|NO_INTERVENTION|Neoadjuvant Chemotherapy Group|Surgery after Neoadjuvant Chemotherapy
62087798|NCT01446029|NO_INTERVENTION|Usual Care|
62087799|NCT01446029|ACTIVE_COMPARATOR|Intervention Device|
62652820|NCT05229913|EXPERIMENTAL|Esketamine experimental group (E0.4)|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
62652821|NCT05229913|EXPERIMENTAL|Esketamine experimental group (E0.6)|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
62461174|NCT00219830|NO_INTERVENTION|2 - cardiac rehabilitation|Based on medical record held in general practice, patients who are identified as having attended a Cardiac Rehabilitation program following myocardial infarction - 'usual care'
62087800|NCT04182607||hand-assisted kidney transplant|Kidney donors and recipients who underwent a hand-assisted kidney transplant
62087801|NCT04182607||robotic kidney transplant|Kidney donors and recipients who underwent a robotic kidney transplant
62087802|NCT04313387||Control group - Normal eyes (CG)|"• Control group - Normal eyes (CG): 351 eyes without KC of 351 patients who underwent LASIK or photorefractive keratectomy (PRK), stable after at least 18 months of follow-up, without any changes in the posterior elevation at the 18-month Pentacam in relation to the preoperative exam (surgeries performed in 2012-2018). Our objective topographic criteria were: both eyes with a KISA% index of less than 60%, Kmax of 47.2 D or less, and I-S difference of less than 1.45 D. Because no truly established tomographic parameter(s)/cut-off(s) for differentiating normal from keratoconus suspect eyes exist, we adapted our classification for normal eyes to the recent publication by Ambrósio et al. by adding the criterion of overall subjective normal topography and tomography examinations based on the evaluation of experienced refractive surgeon (GCAJ). Only one eye was randomly selected for further statistical analysis."
62087803|NCT04313387||Very assimetric ectasia with normal topography|• Very assimetric ectasia with normal topography group (VAE-NT G): 88 eyes of 88 patients with very asymmetric ectasia with normal topography (VAE-NT) in one eye and frank ectasia (VAE-E) in the fellow eye. The inclusion criteria followed previous studies (28, 32, 33) Eyes in this group with insufficient topographic findings to meet diagnostic criteria for keratoconus, and following features normal-appearing cornea on slit-lamp biomicroscopy, keratometry, retinoscopy. These cases were the less affected eye (fellow eye) of a keratoconic patient was included if the following criteria were met: KISA% index of less than 60%, I-S difference of less than 1.45 D, and Kmax of 47.2 D or less (ie, same topographic criteria as in normal eyes, except than in normal eyes, both eyes of the patient met the criteria). These patients can be considered with corneas highly susceptible to ectasia.
62087804|NCT04313387||Keratoconus group (KCG)|• Keratoconus group (KCG): 148 patients (one eye each) with bilateral clinical KC. The KCG included one eye randomly selected from 148 patients with keratoconus; one eye was randomly included per patient to avoid selection bias related to the use of both eyes from the same patient. The inclusion criteria were the same as for VAE-E, except that both eyes of the patient met the ectasia criteria.
62087805|NCT03354403||Patients|Up to 50 mothers of sons of all ages diagnosed with XLRS are eligible to participate in this study. Up to 50 fathers of sons of all ages with XLRS are also eligible to participate and will serve as a comparison group.
62087806|NCT02341534|OTHER|BioMonitor arm|BioMonitor group (implantation with investigational device + transfer of information via Home Monitoring)
62087807|NCT02341534|NO_INTERVENTION|Control arm|Control group (standard of care)
62087808|NCT05728983|EXPERIMENTAL|Treatment group|Participants randomly assigned to the treatment group arm experience both a well-rested and sleep-restricted week during the study
62286772|NCT04725279|EXPERIMENTAL|Type of rehabilitation treatment|Depending on whether the cervical pain associated with vertigo in the patients associated pain radiating to the arms or not, treatment with conventional physiotherapy or electrotherapy was prescribed. In addition, both groups had a control group that performed exercises at home prescribed by a physician.
62286773|NCT04390867|EXPERIMENTAL|TOPS1 DBS|Participants receive TOPS1 for one week if it meets screening criteria, followed by one week each of TOPS2, TOPS3, and Standard in random order.
62461175|NCT02426710|EXPERIMENTAL|Flutter ablation with intracardiac echocardiography|Atrial flutter ablation will be done using intracardiac echocardiography.
62461176|NCT02426710|ACTIVE_COMPARATOR|Flutter ablation without intracardiac echocardiography|Atrial flutter ablation will be done without intracardiac echocardiography.
62461177|NCT00748228|EXPERIMENTAL|A|10 mEq/day dietary sodium
62461178|NCT00748228|EXPERIMENTAL|B|150 mEq/day dietary sodium
62461179|NCT00748228|EXPERIMENTAL|C|300 mEq/day dietary sodium
62461180|NCT00005006|ACTIVE_COMPARATOR|1|Alendronate alone
62461181|NCT00005006|ACTIVE_COMPARATOR|2|Teriparatide daily plus alendronate
62461182|NCT00005006|ACTIVE_COMPARATOR|3|Teriparatide cyclically plus alendronate
62461183|NCT00866593|EXPERIMENTAL|1|Generic Escitalopram Oxalate Tablets
62286774|NCT04390867|EXPERIMENTAL|TOPS2 DBS|Participants receive TOPS2 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS3, and Standard in random order.
62286775|NCT04390867|EXPERIMENTAL|TOPS3 DBS|Participants receive TOPS3 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS2, and Standard in random order.
62286776|NCT04390867|ACTIVE_COMPARATOR|Standard DBS|Participants receive Standard for one week, followed by one week each of TOPS1, TOPS2, and TOPS3 in random order.
62286777|NCT02152345|EXPERIMENTAL|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
62461184|NCT00866593|ACTIVE_COMPARATOR|2|Innovator Escitalopram(Lexapro®)
62087809|NCT05728983|PLACEBO_COMPARATOR|Control group|Participants randomly assigned to the treatment group arm experience two well-rested weeks during the study (and they still have an ad lib sleep week in between the two well-rested weeks)
62087810|NCT01214564|EXPERIMENTAL|1|Up to three days of treatment
62087811|NCT04066855||Chronic Kidney Disease (CKD)|patients diagnosed as CKD
62286778|NCT02152345|ACTIVE_COMPARATOR|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
62461185|NCT02702960|EXPERIMENTAL|part. liver transplant and BMT|"Patients receive living related donor partial liver transplantation performed according to standard practices. Patients will be maintained on tacrolimus, MMF, and prednisone after liver transplantation.~Upon recovery, patient must undergo eligibility screening for bone marrow transplantation (BMT).~If eligible, patients will begin:~Antithymocyte globulin (ATG): Day -16 to Day -14; fludarabine: Days -6 to Day -2 low-dose cyclophosphamide: Day -6 and -5. Tacrolimus, mycophenolate mofetil (MMF), and prednisone: day -7 and day -6. Total body irradiation on Day -1 Bone marrow infusion on Day 0. High dose cyclophosphamide plus MESNA: Day 3 and 4th Filgrastim, tacrolimus,MMF, and prednisone: Day 5 until neutrophil counts recover.~Patients followed up through post transplant day 60, then weekly following discharge."
62461186|NCT03661047|ACTIVE_COMPARATOR|Omega-3 treatment|Daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent ethyl)
62461187|NCT03661047|PLACEBO_COMPARATOR|Placebo|Identical placebo
62461188|NCT01188837|ACTIVE_COMPARATOR|Full Kinetic Chain Manipulative Therapy|
62461189|NCT01188837|ACTIVE_COMPARATOR|Full Kinetic Chain Rehabilitation|
62461190|NCT01188837|ACTIVE_COMPARATOR|Full Kinetic Chain Manipulative Therapy with Rehabilitation|
62087812|NCT04066855||Renal transplant|recipients of renal transplantation
62087813|NCT03688542|EXPERIMENTAL|Intervention|Nursing Homes allocated to the Intervention arm will enact the Quality Circle Deprescribing Module and create a local deprescribing consensus and implementation strategy.
62286779|NCT01206855|ACTIVE_COMPARATOR|SOC Treated Side of Incision|One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
62286780|NCT01206855|ACTIVE_COMPARATOR|MIST Treated Side of Incision|One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
62286781|NCT05116774|EXPERIMENTAL|BCX9930 monotherapy|"In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor~In Part 2, all subjects receive BCX9930 monotherapy"
62286782|NCT05116774|ACTIVE_COMPARATOR|Continued C5 inhibitor therapy|In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor
62286783|NCT03665038|EXPERIMENTAL|Brexanolone|Participants will receive a 60-hour single continuous IV infusion of brexanolone, at 30 mcg/kg/hour (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.
62087814|NCT03688542|NO_INTERVENTION|Control|Nursing Homes allocated to the Control arm will not enact the intervention.
62087815|NCT03386695|OTHER|Education by Pamphlets|Half of the women in each group will be provided an information pamphlet on the risk factors, methods of early detection, prevention, signs and symptoms of cervical cancer and how to use the self samplers at home.
62286784|NCT01217541|OTHER|Education and supervision|Personnel in nursing home units get intervention in form of education and supervision
62286785|NCT01217541|NO_INTERVENTION|Control|Only registering of patient and personnel data in the beginning and the end of the study without any form of intervention.
62286786|NCT04214847|EXPERIMENTAL|polypropylene plate of Ahmed Glaucoma Valve|polypropylene plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The polypropylene plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
62461191|NCT02835261|NO_INTERVENTION|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
62461192|NCT02835261|EXPERIMENTAL|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
62461193|NCT04842162|EXPERIMENTAL|Patients with head and neck cancer|
62461194|NCT03608878|ACTIVE_COMPARATOR|TACE alone arm|TACE (Transarterial Chemoembolization)
62461195|NCT03608878|EXPERIMENTAL|adagloxad simolenin arm|TACE plus adagloxad simolenin/OBI-821 adjuvant therapy
62461196|NCT01781286|ACTIVE_COMPARATOR|High Protein|Higher Protein Soy-based Snacks
62087816|NCT03386695|OTHER|Health education programme|Half of the women in each group will be invited to specially organised camps in their neighbourhood for Health Education and distribution of self samplers.
62087817|NCT01017120|EXPERIMENTAL|1|Tazarotene foam, 0.1%
62087818|NCT01017120|PLACEBO_COMPARATOR|2|Vehicle Foam
62461197|NCT01781286|ACTIVE_COMPARATOR|Low Protein|Typical, Low Protein Snacks
62461198|NCT01781286|NO_INTERVENTION|No Snack|No Snack
62461199|NCT05354232|EXPERIMENTAL|2mA transcranial direct current stimulation|
62461200|NCT05354232|EXPERIMENTAL|1mA transcranial direct current stimulation|
62087819|NCT00004074|EXPERIMENTAL|Treatment (IL12 and trastuzumab)|Patients receive an initial loading dose of trastuzumab IV over 90 minutes on day 1 of the first week and a maintenance dose of trastuzumab IV over 30-90 minutes on day 1 of each subsequent week. Patients receive IL-12 IV on days 2 and 5 beginning on week 3. Treatment with maintenance trastuzumab and IL-12 repeats weekly for 14 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease continue treatment for up to 38 additional weeks.
62087820|NCT04294979|EXPERIMENTAL|Rehabilitation|Conventional Physical Therapy
62087821|NCT02208323|EXPERIMENTAL|Bubble CPAP|Bubble CPAP for 28 days
62286787|NCT04214847|ACTIVE_COMPARATOR|silicone plate of Ahmed Glaucoma Valve|silicone plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The silicone plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
62286788|NCT01361516|EXPERIMENTAL|Intravenous sedation, General anaesthesia|IV sedation-ESWL under spontaneous respiration GA - ESWL under controlled respiration
62286789|NCT04758962|EXPERIMENTAL|1 µg CoV2 SAM (LNP) Group|Participants aged 18-50 years, allocated in the 1 µg COV2 SAM (LNP) Group receive 2 doses of 1 µg CoV2 SAM (LNP) vaccine 30 days apart, at day 1 and day 31 and are followed up until the study end.
62286790|NCT01032148|EXPERIMENTAL|LBH589|LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
62286791|NCT01231555|EXPERIMENTAL|GSK2248761 100 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
62087822|NCT03330119|EXPERIMENTAL|Alternate Management|
62087823|NCT03330119|PLACEBO_COMPARATOR|Control|The regular Lankenau cesarean section order set.
62087824|NCT04587531|ACTIVE_COMPARATOR|Active CES Therapy|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
62087825|NCT04587531|SHAM_COMPARATOR|Sham CES Therapy|Group receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
62286792|NCT01231555|EXPERIMENTAL|GSK2248761 200 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
62286793|NCT01231555|ACTIVE_COMPARATOR|Efavirenz 600 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
62286794|NCT00844233|EXPERIMENTAL|1|Irinotecan Bead
62286795|NCT05429086|ACTIVE_COMPARATOR|group remimazolam|"The initial dose of remimazolam was 0.2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score ≤3), the gastroscopy will begin; If MOAA/S score \> 3 point, additional administration of remimazoalm will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was \>3 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after gastroscopy: In order to maintain a certain degree of sedation after gastroscopy , the evaluator decides when to administer additional drugs.~remimazolam supplemental administration: the supplemental dose was 2.5 mg , bolus"
62286796|NCT05429086|ACTIVE_COMPARATOR|group propofol|"The initial dose of propofol was 2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score ≤3), the gastroscopy will commence. If subjects' MOAA/S score \> 3 point, additional administration of propofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was \>3 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after gastroscopy: In order to maintain a certain degree of sedation after gastroscopy , the evaluator decides when to administer additional drugs.~Propofol supplemental administration: the supplemental dose was 0.5mg/kg, bolus."
62286797|NCT05429086|EXPERIMENTAL|group remimazolam combined propofol|"The initial dose of remimazolam was 0.1 mg/kg, combined propofol 0.5mg/kg, and the infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score ≤3), the gastroscopy will begin. If subjects' MOAA/S score \> 3, additional administration of propofol will be allowed. If the MOAA/S score was \>3 after 3 consecutive times of addition, sedation was failure, and the study was recorded and quit. Maintenance of sedation after gastroscopy: In order to maintain a certain degree of sedation after gastroscopy, the evaluator decides when to administer additional drugs.~supplemental administration: the supplemental dose was remimazolam 2.5 mg,single dose, bolus. There is no permission to use propofol , unless the MOAA/S score still \> 3 after five consecutive dosing supplement"
62286798|NCT00354601|EXPERIMENTAL|Weekly Docetaxel and Capecitabine|Weekly Docetaxel and Capecitabine
62286799|NCT02908100|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
62286800|NCT02908100|EXPERIMENTAL|GDC-0853 (150mg) QD|Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
62286801|NCT02908100|EXPERIMENTAL|GDC-0853 (200mg) BID|Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
62461201|NCT05354232|SHAM_COMPARATOR|Sham transcranial direct current stimulation|
62087826|NCT03956576|ACTIVE_COMPARATOR|Chronic Kidney Disease patients|"Forearm blood flow studies~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and \[Pyr1\]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.~Renal clearance studies~* Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.~* Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.~* \[\[Pyr1\]apelin-13 infusions: 1nmol/min and 30nmol/min for 30 minutes each."
62087827|NCT03956576|ACTIVE_COMPARATOR|Healthy volunteers|"Forearm blood flow studies~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and \[Pyr1\]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.~Renal clearance studies~* Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.~* Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.~* \[Pyr1\]apelin-13 infusions: 1nmol/min and 30nmol/min for 30 minutes each."
62087828|NCT02318225|ACTIVE_COMPARATOR|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
62087829|NCT02318225|PLACEBO_COMPARATOR|Placebo|Placebo is administered vaginally 12 hours before office hysteroscopy
62087830|NCT01154036|EXPERIMENTAL|Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg|Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
62087831|NCT01154036|ACTIVE_COMPARATOR|Phase I: Atorvastatin 20 mg|Atorvastatin 20 mg tablet once daily for 6 weeks
62087832|NCT01154036|ACTIVE_COMPARATOR|Phase I: Rosuvastatin 10 mg|Rosuvastatin 10 mg tablet once daily for 6 weeks
62087833|NCT01154036|EXPERIMENTAL|Phase II: EZ 10mg+Atorva 10mg|Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
62087834|NCT01154036|EXPERIMENTAL|Phase II: EZ 10mg + Atorva 20mg [A]|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
62087835|NCT01154036|ACTIVE_COMPARATOR|Phase II: Atorva 40mg|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
62087836|NCT01154036|EXPERIMENTAL|Phase II: EZ 10mg + Atorva 20mg [R]|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
62087837|NCT01154036|ACTIVE_COMPARATOR|Phase II: Rosuvastatin 20mg|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase
62087838|NCT03645486|EXPERIMENTAL|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
62087839|NCT04153513|EXPERIMENTAL|Lanolin|
62461202|NCT00448097|OTHER|Data not available PI relocated|No verifiable data available, PI relocated
62087840|NCT04153513|ACTIVE_COMPARATOR|Mother's milk|
62087841|NCT06498674|OTHER|Concordant Group|Patients in whom the detection and diagnostic results of thyroid nodules and lymph nodes are consistent between traditional two-dimensional ultrasound and AI-assisted ultrasound.
62087842|NCT06498674|OTHER|Discordant Group|Patients in whom the detection and diagnostic results of thyroid nodules and lymph nodes differ between traditional two-dimensional ultrasound and AI-assisted ultrasound.
62461203|NCT05570084|ACTIVE_COMPARATOR|Tamsulosin|0.4mg daily for 4 weeks
62461204|NCT05570084|EXPERIMENTAL|Silodosin|8mg daily for 4 weeks
62461205|NCT01493752|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|Six weeks once daily dose of nitrate rich beetroot juice
62087843|NCT03943186||Ectoin Lozenges Honey Lemon|application of 1 Lozenge every three hours or as often as required, not more than 10 lozenges per day
62087844|NCT03943186||Hyaluronic acid/Icelandic moss Lozenges|application as often as required, not more than 6 lozenges per day
62461206|NCT01493752|PLACEBO_COMPARATOR|Nitrate deplete beetroot juice|six weeks daily dose beetroot juice (nitrate deplete)
62652822|NCT05229913|EXPERIMENTAL|Esketamine experimental group (E0.8)|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
62087845|NCT03282175|EXPERIMENTAL|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
62087846|NCT03282175|EXPERIMENTAL|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
62087847|NCT03282175|ACTIVE_COMPARATOR|Control group|Participants allocated to control group did not receive any placebo or treatment.
62087848|NCT05190549|EXPERIMENTAL|CAV Regimen Bridging to HSCT|
62087849|NCT03664167|EXPERIMENTAL|intervention|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
62087850|NCT03664167|NO_INTERVENTION|control|usual care
62087851|NCT03635138|EXPERIMENTAL|Adhesives Cu/Zn nanoparticles doped|Adhesive dopped with Zn Oxide + Cu nanoparticles in a ( 5% / 0.2% concentration )
62087852|NCT03635138|ACTIVE_COMPARATOR|Adhesive control|Adhesive conventional
62087853|NCT02810808|EXPERIMENTAL|Ranibizumab 0.5 mg 1+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 11 month treatment period Intervention: Drug: Ranibizumab
62087854|NCT02810808|ACTIVE_COMPARATOR|Ranibizumab 0.5 mg 3+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization after three Monthly intravitreal injections of the same dose.
62087855|NCT04754061|EXPERIMENTAL|Psilocybin Microdosing|Participants will receive a 4-week psilocybin microdosing intervention (1-3mg/day, Monday-Friday for up to 4 weeks; start at 1mg with opportunity to increase dose each week)
62087856|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
62087857|NCT00192283|EXPERIMENTAL|1|CAIV-T
62087858|NCT00192283|PLACEBO_COMPARATOR|2|Placebo
62087859|NCT05123131|EXPERIMENTAL|Isa-RVD|"Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.~Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32. Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance \[CrCl\] ≥30 to \<60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.~Dexamethasone (IV on the days of Isatuximab and PO on other days):~20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33.~If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32."
62087860|NCT00655395|EXPERIMENTAL|1|"1. Laromustine 300 mg/m2 (cohort 1) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
62087861|NCT00655395|EXPERIMENTAL|2|"1. Laromustine 400 mg/m2 (cohort 2) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
62087862|NCT00655395|EXPERIMENTAL|3|"1. Laromustine 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
62087863|NCT00655395|EXPERIMENTAL|5|"1. Laromustine will be administered at the recommended phase II dose on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
62087864|NCT00655395|EXPERIMENTAL|4|"1. Laromustine 600 mg/m2 (cohort 4) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
62087865|NCT05153278||Control group|Patients that received standard treatment (packed red blood cells) for iron deficiency anemia
62087866|NCT05153278||Experimental group|Patients that received intravenous iron instead of standard treatment (packed red blood cells) for iron deficiency anemia
62087867|NCT03572010|PLACEBO_COMPARATOR|FeFum fortified maize test meal|
62087868|NCT03572010|PLACEBO_COMPARATOR|FeSO4 fortified LNS|
62087869|NCT03572010|PLACEBO_COMPARATOR|FeSO4 supplement|
62087870|NCT03572010|PLACEBO_COMPARATOR|FeSO4 fortified fruit juice|
62087871|NCT00377741|EXPERIMENTAL|1|
62461207|NCT05558891|EXPERIMENTAL|Experimental: THRIVE + Usual Care|Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk
62087872|NCT02717598|EXPERIMENTAL|CSP|Cold snare polypectomy is an easy-to-apply technique and has been the most popular technique esprcially for small and diminutive polyps. Briefly, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp, until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
62461208|NCT05558891|ACTIVE_COMPARATOR|Usual Care|Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk
62652823|NCT00301834|EXPERIMENTAL|Single arm - conditioning and transplant|Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m\*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m\*2 on day +1, 10 mg/m\*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.
62652824|NCT00216372|EXPERIMENTAL|1|
62652825|NCT00216372|PLACEBO_COMPARATOR|2|
62461209|NCT02465697|EXPERIMENTAL|BPD Emotion Regulation Training|Guided practice in reappraisal
62461210|NCT02465697|NO_INTERVENTION|BPD Control|no training in reappraisal
62461211|NCT02465697|EXPERIMENTAL|APD Emotion Regulation Training|Guided practice in reappraisal
62461212|NCT02465697|NO_INTERVENTION|APD Controls|no training in reappraisal
62461213|NCT02465697|EXPERIMENTAL|Healthy Controls Emotion Regulation Training|Guided practice in reappraisal
62461214|NCT02465697|NO_INTERVENTION|Healthy Controls|no training in reappraisal
62461215|NCT02157220|EXPERIMENTAL|Randomised group 1|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
62461216|NCT02157220|EXPERIMENTAL|Randomised group 2|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
62461217|NCT04232605|ACTIVE_COMPARATOR|GLP-1|Receive intravenous infusion of GLP-1.
62461218|NCT04232605|PLACEBO_COMPARATOR|Placebo|Receive intravenous infusion of saline.
62461219|NCT02166216||Healty subjects|Healthy subjects that participate in a high intensity, endurance bicycle race.
62461220|NCT04125706|EXPERIMENTAL|Mincycline hydrochloride 2% oral gel|Minocycline will be delivered locally in the periodontal pocket.
62461221|NCT04125706|EXPERIMENTAL|Metronidazole hylcate 0.75 % oral gel|Metronidazole gel will be delivered locally in the periodontal pocket.
62461222|NCT03437356|ACTIVE_COMPARATOR|ADT ON Group|'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.
62461223|NCT03437356|ACTIVE_COMPARATOR|ADT OFF Group|'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation
62461224|NCT02123979|PLACEBO_COMPARATOR|placebo patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
62652826|NCT02924155|EXPERIMENTAL|SJP002|9 subjects received single dose of SJP002 and then received multiple dose of SJP002
62652827|NCT02924155|PLACEBO_COMPARATOR|Placebo|3 subjects received single dose of placebo and then received multiple dose of placebo
62652828|NCT06216496|EXPERIMENTAL|Dynamic test|
62652829|NCT03118180|EXPERIMENTAL|CART19 group|All patients were included for CART19 therapy
62652830|NCT03116230|EXPERIMENTAL|Experimental Treatment A then B|Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
62461225|NCT02123979|EXPERIMENTAL|Neupro® transdermal patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
62461226|NCT05533502|ACTIVE_COMPARATOR|Dietary Supplement: Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Fava-Bean Protein Concentrate and Aquamin F
62461227|NCT05533502|PLACEBO_COMPARATOR|Placebo Control|Placebo Control
62461228|NCT04392271|EXPERIMENTAL|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by \[18F\]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later.
62461229|NCT05332015|ACTIVE_COMPARATOR|Oral hydration with normal water|Oral hydration with drinkable normal water daily additional 2 liters for 5 days
62461230|NCT05332015|ACTIVE_COMPARATOR|Oral hydration with distilled water|Oral hydration with distilled water daily 2 liters for 5 days
62461231|NCT02989688|ACTIVE_COMPARATOR|modified carbohydrate drink|Dietary Supplement - renal specific slow release carbohydrate ONS (220 ml Nepro HP (Abbott Nutrition)
62461232|NCT02989688|ACTIVE_COMPARATOR|macronutrient matched drink|Dietary Supplement - 125 ml Fortisip Compact Protein (Nutricia) plus 20ml Calogen (Nutricia)
62461233|NCT02989688|ACTIVE_COMPARATOR|standard drink|Dietary Supplement - 125 ml Fortisip compact (Nutricia)
62087873|NCT02717598|EXPERIMENTAL|HSP|Hot snare polypectomy, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp,then use Electrocoagulation until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
62087874|NCT00290082|ACTIVE_COMPARATOR|loxapine|agitated patients were randomly assigned either to loxapine, either to midazolam group
62087875|NCT00290082|ACTIVE_COMPARATOR|midazolam|midazolam is compared to loxapine in terms of efficacy and tolerance
62461234|NCT00205049|EXPERIMENTAL|Pentoxifylline/Placebo|All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
62087876|NCT00443469|EXPERIMENTAL|Magnetic Stimulation|
62087877|NCT00443469|PLACEBO_COMPARATOR|Magnetic Stimulation with tilted coil|Magnetic Stimulation with tilted coil
62087878|NCT02635061|EXPERIMENTAL|ACY-241 in combination with nivolumab|
62286802|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in five Latin American cities (Barretos, Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
62286803|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
62286804|NCT03118947|EXPERIMENTAL|Pimavanserin 20 mg OR 34 mg per day|
62286805|NCT01277640|PLACEBO_COMPARATOR|matched placebo|
62286806|NCT01277640|PLACEBO_COMPARATOR|universal placebo|
62286807|NCT01277640|ACTIVE_COMPARATOR|dapivirine|
62461235|NCT02246478|PLACEBO_COMPARATOR|Placebo|
62652831|NCT03116230|EXPERIMENTAL|Experimental Treatment B then A|Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.
62087879|NCT04816994|EXPERIMENTAL|High dose cannabis oil|Single-dose 20.0 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic.
62087880|NCT04816994|EXPERIMENTAL|Low dose cannabis oil|Single-dose 10 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
62087881|NCT04816994|PLACEBO_COMPARATOR|Control|Single-dose Olive oil that is similar in appearance and taste to cannabis oil
62087882|NCT00360555|EXPERIMENTAL|flibanserin|flibanserin 25 mg b.i.d
62087883|NCT00360555|EXPERIMENTAL|flibanserin 50mg|flibanserin 50mg qhs/b.i.d
62087884|NCT00360555|EXPERIMENTAL|flibanserin 100mg|flibanserin 50mg b.i.d./100mg qhs
62087885|NCT00360555|PLACEBO_COMPARATOR|placebo|placebo comparator
62087886|NCT02507219|PLACEBO_COMPARATOR|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
62087887|NCT02507219|ACTIVE_COMPARATOR|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
62087888|NCT02507219|ACTIVE_COMPARATOR|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
62087889|NCT05762393|EXPERIMENTAL|Cohort A|Cohort A will receive the low-dose antigen formulation(10 μg Sm-p80 + 5 μg GLA-SE) or placebo. Cohort will include 20 participants randomized to receive either Sm-p80 product or placebo in a 3:1 ratio. All participants will receive three intramuscular injections of 0.5 mL of the designated study product / placebo, on Days 0, 28, and 56 (28 days apart).
62087890|NCT05762393|EXPERIMENTAL|Cohort B|Cohort B will receive the low-dose antigen formulation(30 μg Sm-p80 + 5 μg GLA-SE) or placebo. Cohort will include 20 participants randomized to receive either Sm-p80 product or placebo in a 3:1 ratio. All participants will receive three intramuscular injections of 0.5 mL of the designated study product / placebo, on Days 0, 28, and 56 (28 days apart).
62286808|NCT00529737|EXPERIMENTAL|Group 1|Post Procedure Mammogram Projection View A -- (view same projection as used in the biopsy procedure), then View B (view orthogonal projection to the first view).
62286809|NCT00529737|EXPERIMENTAL|Group 2|Post Procedure Mammogram Projection View B than View A
62286810|NCT05845359|EXPERIMENTAL|Methadone group|Patients in this group will receive intraoperative methadone.
62461236|NCT02246478|ACTIVE_COMPARATOR|TAS-205 low dose|
62461237|NCT02246478|ACTIVE_COMPARATOR|TAS-205 middle dose|
62461238|NCT02246478|ACTIVE_COMPARATOR|TAS-205 high dose|
62461239|NCT02301676|ACTIVE_COMPARATOR|General anesthesia & Control|"After the surgery, the patients are discharged from the hospital, investigators will check the postoperative cognitive function 4 times: 1weak, 3months, 6months, 1 year later using the intervention Korean version of telephone interview for cognitive status (TICS). The test will be administered to spouse simultaneously by telephone."
62087891|NCT05762393|EXPERIMENTAL|Cohort C|Cohort C will receive the low-dose antigen formulation(100 μg Sm-p80 + 5 μg GLA-SE) or placebo. Cohort will include 20 participants randomized to receive either Sm-p80 product or placebo in a 3:1 ratio. All participants will receive three intramuscular injections of 0.5 mL of the designated study product / placebo, on Days 0, 28, and 56 (28 days apart).
62087892|NCT05170035|EXPERIMENTAL|MMS + Autologous patch|Mohs micrographic surgery + Autologus patch formed from 18 ml venous blood sample collected from the patient + polymycin-terramycin B ointment and a Jelonet applied on top of the patch.
62087893|NCT05170035|ACTIVE_COMPARATOR|MMS + Secondary intention healing|Mohs micropgraphic surgery + Polymycin-terramycin B ointment + dry wound dressing
62087894|NCT01200719|EXPERIMENTAL|tACS group|
62087895|NCT01200719|NO_INTERVENTION|Control group|Patients in the control group followed exactly the same protocol but without receiving the transcranial alternating current stimulation .
62087896|NCT00136916|EXPERIMENTAL|Inhaled Insulin|Inhalable short-acting insulin
62087897|NCT00136916|ACTIVE_COMPARATOR|Subcutaneous insulin|
62087898|NCT03791528|ACTIVE_COMPARATOR|Kinesio-taping Treatment Group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the sacroiliac joint (SIJ), and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
62087899|NCT03791528|NO_INTERVENTION|Control Group|Without Kinesio-taping treatment evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
62087900|NCT01853254|EXPERIMENTAL|Peginterferon alfa-2a monotherapy or combined with ribavirin|The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
62087901|NCT04725409||Epilepsy patients|All participants will be patients with medically refractory epilepsy undergoing depth electrode placement for seizure localization. For this study participants will complete psychiatric questionnaires measuring depression, anxiety, obsessive compulsive disorder, and impulsivity, and EEG recordings will be collected from the depth electrodes while subjects rest quietly. Some subjects will also participate in neuro cognitive tasks while neural recordings/stimulation are performed.
62286811|NCT05845359|NO_INTERVENTION|Control group|Patients in this group will receive saline (placebo), instead of methadone
62461240|NCT02301676|ACTIVE_COMPARATOR|Sevoflurane & Propofol & Dexmedetomidine|The anesthetic methods are divided into the following 3 kinds: Sevoflurane, Propofol, Dexmedetomidine. These anesthetic drugs are used in general anesthesia generally.
62087902|NCT02861495|EXPERIMENTAL|humeral nail|Surgical fixation with a humeral compression/distraction nail.
62087903|NCT02722941|ACTIVE_COMPARATOR|Cohort A: Maintenance Therapy|Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.
62087904|NCT02722941|ACTIVE_COMPARATOR|Cohort B: Maintenance Therapy|Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.
62286812|NCT00956943|ACTIVE_COMPARATOR|21mg transdermal nicotine + placebo patch|21mg transdermal nicotine + placebo patch
62286813|NCT00956943|EXPERIMENTAL|42mg transdermal nicotine|42mg transdermal nicotine
62286814|NCT02222714|ACTIVE_COMPARATOR|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
62286815|NCT02222714|ACTIVE_COMPARATOR|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
62286816|NCT02222714|ACTIVE_COMPARATOR|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
62286817|NCT02222714|ACTIVE_COMPARATOR|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
62461241|NCT02947243|ACTIVE_COMPARATOR|Standard pharmacological treatment|Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
62652832|NCT01408472|EXPERIMENTAL|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye.
62652833|NCT01189448|ACTIVE_COMPARATOR|Pyrimethamine/Sulfadiazine|Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
62286818|NCT02222714|PLACEBO_COMPARATOR|Placebo|Matching placebo, q12h for up to 5 doses
62286819|NCT05357378|EXPERIMENTAL|Experimental Arm - HIT Reverse HRS|Subjects in the Experimental Arm will receive the HIT Reverse HRS Investigational Device. Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
62286820|NCT05357378|ACTIVE_COMPARATOR|Control Arm|Subjects in the Control Arm will receive one of the already-marketed semi- constrained uncemented hip systems using a metal-on-highly-cross-linked polyethylene (XLPE) or ceramic-on-XLPE bearing combination.
62286821|NCT00963950|EXPERIMENTAL|Intervention group|transvaginal cholecystectomy
62286822|NCT00963950|ACTIVE_COMPARATOR|laparoscopic cholecystectomy|Laparoscopic cholecystectomy (4 port)
62475156|NCT00824291|EXPERIMENTAL|2|
62653226|NCT03720561||Group: Ibrutinib Treatment|Participants will not receive any intervention as a part of this study. This study will collect retrospective and prospective real-world data to describe retention rates for participants of chronic lymphocytic leukemia (CLL) receiving ibrutinib in routine Italian clinical practice over a 2-year follow-up period. Participants with CLL who have started ibrutinib treatment within 3 months before enrollment visit or in case ibrutinib was prescribed before or on the enrollment day as per routine clinical practice within the 30 days after enrollment visit will be included in the study. The primary data source for this observational study will be the medical records of each enrolled participant, as well as questionnaires concerning quality of life and treatment adherence. Data will be collected every 3 months for the first year and every 6 months for the second year during prospective period.
62653227|NCT04399681|OTHER|Suspected COVID-19 Group|Patients who admitted to emergency department with suspicion of COVID 19 pneumonia will be evaluated with POCUS/ bedside lung ultrasound.
62475157|NCT01067833|PLACEBO_COMPARATOR|Placebo|Placebo
62475158|NCT01067833|EXPERIMENTAL|Dose 1|K201
62653228|NCT02225587|EXPERIMENTAL|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
62653229|NCT02225587|PLACEBO_COMPARATOR|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
62653230|NCT01380366|OTHER|Patients consent to rHGH study|Patients consent to be given growth hormone (rHGH) for their short bowel syndrome.
62653231|NCT01922583|EXPERIMENTAL|Vial|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
62653232|NCT03413735|PLACEBO_COMPARATOR|Placebo Confection|Confection without green tea extract consumed daily for 4 weeks
62653233|NCT03413735|EXPERIMENTAL|Green Tea Extract-Confection|Confection with green tea extract consumed daily for 4 weeks
62653234|NCT02576600|EXPERIMENTAL|PUPILLO|Videopupillometer Algiscan peroperative remifentanil target concentration adapted every five minutes to pupillary diameter in patients under propofol and remifentanil TCI
62653235|NCT02576600|SHAM_COMPARATOR|STANDARD|peroperative remifentanil target concentration as standard practice in patients under propofol and remifentanil TCI
62653236|NCT06314815||1|Patients that received the ilioinguinal-iliohypogastric nerve block \[IINB\] were chosen by the anesthetists prior to surgery based on patient suitability, consultation with patients, and availability of time and resources. The Ilioinguinal-iliohypogastric nerve block contained one of 0.5% Bupivacaine and 2% Lidocaine, 0.5% Marcaine and 2% Lidocaine, 0.25% Marcaine with Epinephrine, 0.25% or 0.1% Bupivacaine 2ith 2% Lidocaine (mixtures such as: 0.5% Bupivacaine (also called Marcaine) and 2% Lidocaine, with or without Epinephrine mix).
62653237|NCT06314815||2|Matched patients in terms of biometric and peroperative data, who did not receive an Ilioinguinal-iliohypogastric nerve block.
61919749|NCT04228575|EXPERIMENTAL|8 Week ICBT no Booster|In the standard condition, clients will receive 8 weeks of therapist support. They will not be given the option to extend their treatment and support to 12 weeks. The booster course will not be offered in this condition.
62475159|NCT01067833|EXPERIMENTAL|Dose 2|K201
62475160|NCT01067833|EXPERIMENTAL|Dose 3|K201
62653238|NCT02699164|EXPERIMENTAL|combine group|"Conventional physiotherapy applied 15 sessions of treatment. In addition to conventional physiotherapy non-surgical spinal decompression therapy applied.~First 10 sessions of treatment non-surgical decompression therapy applied and last 5 sessions spinal stabilization exercise applied."
62653239|NCT02699164|EXPERIMENTAL|conventional physiotherapy|conventional physiotherapy applied 15 sessions of treatment. Conventional physiotherapy consisted hotpack, Transcutaneal Electric Nerve Stimulation(TENS) and Ultrasound Currents. Spinal stabilization exercises applied last five sessions of therapy.
62653240|NCT05668273|EXPERIMENTAL|education with simulated patient|Participants will be given training on auscultation skills with a simulated patient.
62653241|NCT05668273|EXPERIMENTAL|education with simulator|Participants will be given training on auscultation skills with a simulation.
61919750|NCT04228575|EXPERIMENTAL|Extended Contact with Booster|"Clients in the Extended Contact condition will receive an email at the 6 week mark letting them know that they if they like they can extend their treatment and receive up to 12 weeks of support. At week 6, clients will answer questions on the website about whether they would like this additional support or not and what they would like to focus on during this time. Clients who indicate they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks.~They will also be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks."
61919751|NCT04228575|EXPERIMENTAL|8 week ICBT with Booster|Clients in the booster condition will be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks.
61919752|NCT03905109|EXPERIMENTAL|ABX464 dose A|Dose A QD
61919753|NCT03905109|EXPERIMENTAL|ABX464 Dose B|Dose B QD
61919754|NCT03905109|PLACEBO_COMPARATOR|Placebo|Matching dose
61919755|NCT02937974|EXPERIMENTAL|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
61919756|NCT02937974|PLACEBO_COMPARATOR|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
61919757|NCT04025671|EXPERIMENTAL|Nasal Spray Naloxone|This arm will be randomized to administer a nasal spray naloxone device in a simulated overdose setting.
62120130|NCT04135989|OTHER|Cre8 AES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
62461834|NCT02027714||Women's Focus Group Discussions|"6-8 focus groups of approximately 6-12 pregnant or recently postpartum women will be conducted. Focus group discussions will be organized according to HIV serostatus to allow for open dialogue and participant comfort. All group discussions will be conducted in Sesotho. Each group discussion will be facilitated, preferably, by a female study-staff member. All group discussions will be held in a private space either within a study site or another speciﬁed location within the community. All study activities will take approximately two hours to complete.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding male circumcision will be asked."
62461835|NCT02027714||Male Interviews|"30 in-depth individual interviews with men. In-depth semi structured interviews consisting of open-ended questions will be conducted in either English or Sesotho depending on the participant's preference will be conducted. Interview activities will be conducted in a private space either within or around the clinic building.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding traditional and medical male circumcision will be asked.~Following the completion of the interview, the same facilitator will administer a brief survey to the study participant."
62653242|NCT05668273|ACTIVE_COMPARATOR|control group|Participants will be given training on auscultation skills with their peer students.
62461836|NCT04053348|EXPERIMENTAL|Intervention|Participants allocated to the intervention group will receive their home-based rehabilitation program using mobile app installed in the mobile device.
62461837|NCT04053348|ACTIVE_COMPARATOR|Control|Those assigned to the control group will receive the same home-based rehabilitation program but with information and instructions delivered through the use of paper-based handouts.
62461838|NCT03657160|PLACEBO_COMPARATOR|Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).
62461839|NCT03657160|EXPERIMENTAL|Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once on Day -1 along with background GvHD prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).
62461840|NCT04764916|EXPERIMENTAL|Exparel/Intervention group|Will receive 10mL of standard 0.5% bupivacaine followed by 10mL of liposomal bupivacaine as adductor canal field block preoperatively
62461841|NCT04764916|ACTIVE_COMPARATOR|Standard of Care group|Will receive 20mL of standard 0.5% bupivacaine as adductor canal field block preoperatively
62461842|NCT04061005|ACTIVE_COMPARATOR|Hot snare polypectomy (HSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). According to the randomized group, patients with HSP group were treated with HSP to excise 5-15 mm colorectal polyps. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopist carefully observed the edge of the resection to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
62475161|NCT01339247|ACTIVE_COMPARATOR|Paxil CR Reference|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
62653243|NCT03287765||Experimental 18F-AV-1451|
62653244|NCT00758888|EXPERIMENTAL|Treatment|Place the blocks under the pelvis for 2 minutes
62653245|NCT00758888|ACTIVE_COMPARATOR|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
62653246|NCT00758888|SHAM_COMPARATOR|Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
62653247|NCT02130440|ACTIVE_COMPARATOR|Resveratrol nasal spray|2 sprays per nostril 3 times a day for a period of two months
62653248|NCT02130440|PLACEBO_COMPARATOR|Placebo|2 sprays per nostril 3 times a day for a period of two months
62653249|NCT01969526|EXPERIMENTAL|Multifactorial Intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication.
62653250|NCT01969526|NO_INTERVENTION|No intervention|Usual care
61919758|NCT04025671|ACTIVE_COMPARATOR|Intramuscular|This arm will be randomized to administer a intramuscular naloxone device in a simulated overdose setting.
61919759|NCT04025671|ACTIVE_COMPARATOR|Improvised Nasal Atomizer|This arm will be randomized to administer an improvised nasal atomizer naloxone device in a simulated overdose setting.
61919760|NCT04351061|EXPERIMENTAL|Acetazolamide Arm|Participants in this arm will receive the Acetazolamide intervention for 7 consecutive days post standard of care endoscopic skull base surgery.
61919761|NCT02825407|EXPERIMENTAL|main study|
61919762|NCT03325751||Healthy subjects|
61919763|NCT03325751||Glaucoma subjects|Patients with primary open-angle-, pseudoexfoliation- or primary angle-closure glaucoma
61919764|NCT03813823||Phobic|Adults aged 18-40 exhibiting high levels of self-reported phobic symptoms to spiders
61919765|NCT03813823||Nonphobic|Adults aged 18-40 exhibiting low levels of self-reported phobic symptoms to spiders
62653251|NCT02646085|EXPERIMENTAL|Intervention|C11 Methionine positron emission tomography (PET/CT) studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 10 millicuries of C11 Methionine will be injected intravenously. Approximately 60 minutes following tracer injection, the patient will be positioned on a Siemens Biograph PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first with while the patient is free breathing. PET will be acquired at 3 minutes per bed position using the 3D mode, approximately 6-7 bed positions. C11 Methionine PET/CT imaging will take less than 60 minutes.
62653252|NCT01113099|EXPERIMENTAL|Academic detailing of physicians|
62088440|NCT05274776|NO_INTERVENTION|NVK Guidelines|The NVK guidelines use 8 maternal and 15 neonatal risk factors, each categorized as either red flag or non-red flag. These criteria guide clinicians on the management in case of suspected EOS. Briefly, antibiotic treatment is recommended if at least one red flag and, or, two or more non-red flags are present. An observation period of at least 12 hours is recommended if one non-red flag is present. Antibiotics are recommended when an infection is suspected during this observation. Newborns without EOS risk factors, with a good clinical condition, and a gestational age of more than 36 weeks will be discharged. If the guidelines recommend an observation period, the newborn with a good clinical condition is discharged after repeating physical examination. In case antibiotic treatment is started, discharge depends on the duration of treatment and the clinical course. At discharge, parents are instructed to call the hospital in case of signs of infection within the first 14 days of life.
62088441|NCT05274776|EXPERIMENTAL|EOS Calculator|Using the EOS calculator application between 0-24 hours after birth, maternal EOS risk factors combined with the physical examination of the newborn are used to assign a risk category and accompanying clinical recommendation based on estimated EOS incidence for each newborn at-risk for an infection. The EOS calculator results are used to guide clinical management on performing either a diagnostic work-up and start of antibiotics for (suspected) EOS, or a conservative approach with routine controls of vital parameters every 3 hours. In case of routine controls, re-evaluation of physical appearance by a pediatric resident or pediatrician will take place within 24 hours postpartum. Newborns will be observed for at least 24 hours. In case antibiotics are started, the need for further treatment is depending on blood culture results, infection parameters, and clinical condition of the newborn. Discontinuation of antibiotics and discharge is at the discretion of the treating physician.
62088442|NCT05574374|EXPERIMENTAL|Cohort 1|"* Treatment A: DWC202202 1 tablet qd for 7days~* Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days~* Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days"
62088443|NCT05574374|EXPERIMENTAL|Cohort 2|"* Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days~* Treatment A: DWC202202 1 tablet qd for 7days~* Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days"
62088444|NCT05574374|EXPERIMENTAL|Cohort 3|"* Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days~* Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days~* Treatment A: DWC202202 1 tablet qd for 7days"
62653253|NCT01113099|NO_INTERVENTION|Usual care|
62653254|NCT06163859|EXPERIMENTAL|Intervention Group|Female Community Health Volunteers (FHPC) implementation strategy
62088445|NCT04262154|EXPERIMENTAL|Metastatic Prostate Cancer|Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
62088446|NCT01336335|EXPERIMENTAL|CPAP|OSA treatment with CPAP
62088447|NCT01336335|NO_INTERVENTION|control|no intervention
62088448|NCT02083640|OTHER|Treatment A (Reference)|
62088449|NCT02083640|OTHER|Treatment B (Test)|
62088450|NCT02083640|OTHER|Treatment C (Test)|
62287187|NCT05222321|EXPERIMENTAL|SenPlay Intervention Group|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through activities such as pushing, pulling, climbing, jumping, and crashing. These activities are designed to facilitate changes in the child's arousal by providing sensory input and are used at random during the 15 minute window and are facilitated and monitored to ensure the child is reaching a threshold of moderate to vigorous physical activity. All participants will wear the ActiGraph accelerometer to measure the intensity of physical activity during the SenPlay intervention. Intervention sessions will occur at three time points, one per week for three weeks. Following the SenPlay intervention, participants will engage in 10 minutes of developmentally appropriate tasks (DAT) lead by the same investigator. DAT will be videotaped and coded for off task behaviors using Momentary Time Sampling (MTS).
62653255|NCT06163859|NO_INTERVENTION|Control Arm|Routine hypertension care
62653256|NCT05232617||Rheumatological rehabilitation training|
62653257|NCT02313051|EXPERIMENTAL|Everolimus arm|Everolimus+letrozole
62653258|NCT02313051|ACTIVE_COMPARATOR|Controll arm|letrozole alone, and when progress, followed by everolimus
62653259|NCT00992888|EXPERIMENTAL|albumin liver dialysis|
62653260|NCT00992888|NO_INTERVENTION|Standard medial care without dialysis|
62653261|NCT01700582||Patients with advanced lung cancer|Patients with advanced lung cancer
62287188|NCT05222321|PLACEBO_COMPARATOR|Free play Control Group|The control group will engage in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes, prior to the assessment of off-task behaviors during 10 minutes of developmentally appropriate tasks (DAT). All participants will wear the ActiGraph accelerometer to measure the intensity of physical activity reached during spontaneous, free play. Participants in the control group will participate in three sessions, one per week for three weeks. Intervention sessions will occur at three time points, one per week for three weeks. Following the spontaneous play, participants will engage in 10 minutes of developmentally appropriate tasks (DAT) lead by the same investigator. DAT will be videotaped and coded for off task behaviors using Momentary Time Sampling (MTS).
62287189|NCT01437787|PLACEBO_COMPARATOR|Placebo comparator|once daily X 28 days, orally, empty stomach, approximately same time each day
62287190|NCT01437787|EXPERIMENTAL|SAR302503 400 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
62287191|NCT01437787|EXPERIMENTAL|SAR302503 500 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
62287192|NCT00955773|EXPERIMENTAL|Group I|20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.
62287193|NCT00955773|EXPERIMENTAL|Group II|20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
62287194|NCT00955773|EXPERIMENTAL|Group III|Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
62287195|NCT00891995|EXPERIMENTAL|Intensive Treatment|closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
62287196|NCT00891995|ACTIVE_COMPARATOR|Standard Treatment|home glucose monitoring (2 years)
62287197|NCT01442181|ACTIVE_COMPARATOR|Minimally Invasive Surgery|Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
62287198|NCT01442181|ACTIVE_COMPARATOR|Medical Therapy|Patients are treated with rhythm and rate control medications.
62287199|NCT02429856|ACTIVE_COMPARATOR|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
62287200|NCT02429856|ACTIVE_COMPARATOR|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
62287201|NCT05623891|EXPERIMENTAL|177Lu-Anti-ED-B mAbs|Patients will receive a tracer (5 mg, IV) dose of 177Lu (10 mCi) labeled anti-ED-B mAbs(177Lu-B5-IgG4)
62287202|NCT05077696||Patients with progressive motor neuron disease without definite diagnosis|Patients with progressive motor neuron disease without definite diagnosis
62287203|NCT03125278||Medication indication on the label|Patients discharged from Regions Hospital (St. Paul, MN) where we have implemented a standard process of printing the indication for all new medications on the prescription bottle.
62461843|NCT04061005|EXPERIMENTAL|Cold snare polypectomy (CSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). After randomization, patients in the CSP group will be treated with CSP to remove colorectal polyps of 10-15 mm size. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopic surgeon carefully observed the resection margin to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
62461844|NCT05859386|EXPERIMENTAL|Mindfulness maintenance program|Participants receive: (1) Four-week course to strengthen and extend skills learned in 8-week MBCT course, (2) Monthly 1.5 hour meeting session, and (3) Monthly check-in survey.
62287204|NCT03125278||No medication indication given|Patients discharged from Brigham and Women's Hospital (Boston, MA) where there is no requirement for providing information on medication indications to patients at discharge.
62287205|NCT05859035|EXPERIMENTAL|KIOS Informational App evaluation|"Study participants will use the app at least three times per week. The app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
62287206|NCT03433781|EXPERIMENTAL|Vitamin C 50 g|Patients will receive Vitamin C as a continuous intravenous infusion (CIVI) of 50 grams (g) daily over 24 hours for 5 days for total of 250 grams over 5 days up.
62287207|NCT03433781|EXPERIMENTAL|Vitamin C 75 g|Patients will receive Vitamin C as a continuous intravenous infusion (CIVI) of 75 grams (g) daily over 24 hours for 5 days for total of 375 grams over 5 days.
62287208|NCT03433781|EXPERIMENTAL|Vitamin C 100 g|Patients will receive Vitamin C as a continuous intravenous infusion (CIVI) of 100 grams (g) daily over 24 hours for 5 days for total of 500 grams over 5 days.
62287209|NCT00655928|EXPERIMENTAL|N-acetylcysteine|Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
62461845|NCT05859386|NO_INTERVENTION|Wait-list|Participants receive follow-up measures but no intervention until the end of the wait-list period.
62461846|NCT01384838|OTHER|Counseling|Patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
62461847|NCT01384838|EXPERIMENTAL|Controlled physical activity|"All patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.~Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable, unobserved exercise program at home."
62287210|NCT00655928|PLACEBO_COMPARATOR|Placebo|Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively
62287211|NCT06501859|ACTIVE_COMPARATOR|Standard of care physical therapy|Control group and will not use the shoulder pacemaker, but will participate in a standardized physical therapy protocol for 3 months.
62653262|NCT01508312|EXPERIMENTAL|FDG-PET abnormal|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
62653263|NCT01508312|EXPERIMENTAL|FDG-PET normalization|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
62088451|NCT05461963||breastfeeding pregnants( n:76)|pregnants in early weeks of pregnancy who practice breastfeeding
62088452|NCT05461963||control group ( n:76)|pregnants in early weeks of pregnancy who not practice breastfeeding
62088453|NCT02628522|EXPERIMENTAL|ADRCs therapy|"Infiltration with 20mL Lidocaine 2% and Epinephrine 1:100 000. Liposuction will be done from the abdomen using Tulip cannulas. Fat will be processed with Celution system.~Isolated ADRCs will be administered in chronic anal fissures."
62088454|NCT03799705||History of VACTERL or congenital malformations|1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.
62088455|NCT04053283|EXPERIMENTAL|Intravenous|"Phase 1a dose escalation: one cycle of treatment.~Phase 1a dose optimisation: up to 8 cycles of treatment"
62088456|NCT04328376|EXPERIMENTAL|Prospective FEMQT Group|Propositus patients with genetically proven LQTS and their relatives
62088457|NCT01528709|EXPERIMENTAL|High-dose statin therapy|Atorvastatin 80 mg daily
62088458|NCT01528709|ACTIVE_COMPARATOR|Moderate-dose statin therapy|Atorvastatin 10 mg daily
62287212|NCT06501859|EXPERIMENTAL|Shoulder pacemaker with physical therapy|Include a standardized physical therapy protocol with utilization of the Shoulder Pacemaker device 3 times per week over a 3-month period starting at 6 weeks post-operatively.
62287213|NCT01425385||Autoregulation monitoring|Patients will be grouped into Meld Score
62287214|NCT03346174|EXPERIMENTAL|AAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage. By modulating manually the functional breathing level within the vital capacity, optimal airflow will be obtained at the targeted airway generations, where secretions have been identified. A gentle increase of manual pressure on the chest during each inspiration is performed to guide the breathing of the patient towards the desired lung volume level. During expiration the breathing movement of the patient is followed gently.
62653264|NCT00599001|EXPERIMENTAL|Escalating Dose of SD-101|
62088459|NCT04751513|EXPERIMENTAL|Experimental group|The experimental group will receive acupressure on six auricular points.
62088460|NCT04751513|NO_INTERVENTION|Control group|The control group will receive no intervention.
62088461|NCT03750279|ACTIVE_COMPARATOR|Exercise therapy + LLLT|"* Exercise therapy 3 times per week for 8 weeks from baseline.~* LLLT applied to the knee 3 times per week for 3 weeks from baseline."
62088462|NCT03750279|PLACEBO_COMPARATOR|Exercise therapy + sham LLLT|"* Exercise therapy 3 times per week for 8 weeks from baseline.~* Sham LLLT applied to the knee 3 times per week for 3 weeks from baseline."
62088463|NCT06529783|ACTIVE_COMPARATOR|Shockwave Therapy + Therapeutic Exercises|Patients on this group receive two interventions based on Shockwave Therapy and Therapeutic Exercises
62088464|NCT06529783|EXPERIMENTAL|Shockwave Therapy + Therapeutic Exercises + US-Guided percutaneous neuromodulation|Patients on this group receive both interventions previously described and ultrasound-guided percuteneous neuromodulation is added.
62119886|NCT06676852|EXPERIMENTAL|Sentinel, primary palliative care intervention|"All participants will receive Sentinel, a primary palliative care intervention, in this single-arm feasibility trial. Participants will complete patient-reported assessments at the following time points:~* Baseline (prior to HCT admission)~* Week-2 of HCT hospitalization (+/- 3 business days)~* 1 month post-HCT (+/- 7 business days)~* 3 months post-HCT (+/- 7 business days)"
62119887|NCT06199648|EXPERIMENTAL|Arm A: web-based documentation and advice|
62119888|NCT06199648|NO_INTERVENTION|Arm B: Standard of care|
62287215|NCT03346174|EXPERIMENTAL|BAAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage .AAD sometimes leads to crying or resistance against therapy.Bouncing (at low amplitude:6-8 cm) in a stable upright position is a gentle up-and-down movement on a physio ball. It is not an ACT, but used to maximize the relaxation of the infant, avoiding resistance against or crying during treatment. Due to the relaxing effect of bouncing, infants appear to tolerate better AAD, increasing the effectiveness of the treatment.
62461848|NCT01962337|EXPERIMENTAL|1-FPA008/Placebo Randomize DoseLevels1-4|Single infusion at 4 different dose levels
62461849|NCT01962337|EXPERIMENTAL|2-FPA008/Placebo Randomize DoseLevels1-2|Dual Infusions at 2 different dose levels
62119889|NCT06677294||Control|while those who did not undergo such interventions were placed in the control group
62088465|NCT01804634|EXPERIMENTAL|Reduced intensity conditioning|Fludarabine IV infusion over 30 minutes on D-7 to D-3. The dose will be 30 mg/m2/dose (adjusted for renal function). Melphalan: IV infusion over 30-60 minutes, depending on volume, on D-2. The dose will be 100mg/m2.Total body irradiation: 200 cGy AP/PA with 4MV or 6MV photons at 8 12 cGy/min at the point of prescription (average separation of measurements at mediastinum, abdomen, and hips) will be administered in a single fraction on day -1. Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant. Tacrolimus begins on Day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 3 hours every 12 hours. Mycophenolic acid mofetil (MMF) F will be given at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).
62088466|NCT05690022|NO_INTERVENTION|Before sleeve gastrectomy|Gastroesophageal Reflux Disease (GERD) will be evaluated before surgery. EndoFlip, gastroscopy, pH-study and GERD-Health-Related Quality of Life Questionnaire will be realized for all patients.
62088467|NCT05690022|EXPERIMENTAL|Sleeve gastrectomy|After the surgical intervention, new onset or worsening of GERD will be evaluated.
62088468|NCT01700504|EXPERIMENTAL|Gentamicin lavage|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
62088469|NCT01700504|ACTIVE_COMPARATOR|Normal saline lavage|Patients undergoing 2 axillary lavages with 500ml of normal saline
62088470|NCT02772250|ACTIVE_COMPARATOR|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by a investigator at 15:00-17:00 on the day before colonoscopy.
62088471|NCT02772250|EXPERIMENTAL|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
62088472|NCT04889781|EXPERIMENTAL|Rotatory Instruments without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy without Intramuscular Dexamethasone injection
62287216|NCT03892837|ACTIVE_COMPARATOR|Control group|Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
62307906|NCT05090345||Biorepository trial of children and adolescents/young adults (AYA)|undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
62653265|NCT00599001|PLACEBO_COMPARATOR|Placebo|
62088473|NCT04889781|EXPERIMENTAL|Rotatory Instruments with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
62088474|NCT04889781|EXPERIMENTAL|Piezosurgery technique without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique without Intramuscular Dexamethasone injection
62088475|NCT04889781|EXPERIMENTAL|Piezosurgery technique with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
62088476|NCT00787943|EXPERIMENTAL|Left side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to left side of the face.
62088477|NCT00787943|EXPERIMENTAL|Right side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to right side of the face.
62088478|NCT02834715|EXPERIMENTAL|Stevia|Once-daily oral intake of 240 mg of Stevia liquid extract for 30 days as food supplement.
62287217|NCT03892837|EXPERIMENTAL|PRP group|Procedure/Surgery: PRP PRP treatment following the conventional treatment Slow spray / inject autogenous PRP to cover the wound of stenosis. Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
62088479|NCT02834715|NO_INTERVENTION|Control|No intervention, similar follow up as experimental arm to control for trial effect
62120131|NCT04135989|OTHER|Synergy EES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
62120132|NCT04135989|OTHER|Synergy EES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
61904704|NCT00641511|EXPERIMENTAL|1 (Medication arm - SYN117 aka Nepicastat)|"Veterans will be receiving the study medication Nepicastat initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily; During the 8 weeks (weeks: 7-14) extension phase, those from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed for an additional 8 weeks. Those who have a prior defined positive clinical response to the study medication, Nepicastat, will be continued on open label Nepicastat at 120mg once daily, in order to assess further improvement and safety; those who do not have a positive clinical response during the 6 weeks RCT will be offered the addition of the standard first-line PTSD pharmacotherapy, Paroxetine. Paroxetine is an allowed concomitant medication (i.e. rescue medication) and is not considered a research medication or subject of a research question during the 8 weeks extension phase."
62088480|NCT06425978|EXPERIMENTAL|Cellular Matrix / A-CP-HA Kit|(a combination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid) is a sterile tube designed for use in the preparation of a mixture of PRP and hyaluronic acid, tube is under vacuum allowing the withdrawal of 6 ml of blood and contains: 2 ml of hyaluronic acid gel (20mg/ml, 40 mg per tube) in phosphate buffer. Not crosslinked, hyaluronic acid is obtained from bacterial fermentation, 3 g of inert cell-selector gel, and 0.6 ml of anticoagulant (sodium citrate 4%). Centrifuged at 1,500 g, 3,000 rpm for 5 min. Platelet recovery of more than 70%, granulocyte depletion of 94.3% and red blood cells of 99.5% are achieved.
62287218|NCT05374473|EXPERIMENTAL|Intervention|Intervention-tailored program with information regarding modifiable lifestyle related risk factors implicated in disease progression.
62287219|NCT05374473|OTHER|Standard-care|containing general health information sourced from standard MS websites.
62653266|NCT03612219|EXPERIMENTAL|IMRT with CC+Adjuvant Apatinib|Treat with Apatinib mesylate tablet for adjuvant treatment(the dose was 250 mg,orally,qd,28 days for an observation period,Six cycles)of local advanced nasopharyngeal carcinoma after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
62088481|NCT06425978|ACTIVE_COMPARATOR|Local estrogen therapy|Blissel, estriol 50 micrograms/g vaginal gel
62088482|NCT01296529||HIV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HIV antibodies and/or HIV viral RNA, and a negative antibody test for HCV
62088483|NCT01296529||HCV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HCV antibodies and HCV viral RNA, and a negative antibody test for HIV
62088484|NCT01296529||HIV and HCV coinfection|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, and positive tests for HCV antibodies and HCV RNA.
62088485|NCT01296529||HIV/HCV coinfection with HCV clearance|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, a positive tests for HCV antibodies, and undetectable HCV RNA without hepatitis C treatment (spontaneous clearance) or \>6 months after hepatitis therapy (sustained virologic response)
62088486|NCT00260156|EXPERIMENTAL|vildagliptin|
62088487|NCT00260156|PLACEBO_COMPARATOR|Placebo|
62088488|NCT03136250|ACTIVE_COMPARATOR|Group A (Control Group - Static Stretching)|(Control Group - Static Stretching + Standard Treatment)
62088489|NCT03136250|EXPERIMENTAL|Group B (Autogenic Inhibition MET)|(Autogenic Inhibition - PIR + Standard treatment)
62088490|NCT03136250|EXPERIMENTAL|Group C (Reciprocal Inhibition MET)|(Reciprocal Inhibition - RI + Standard treatment)
62088491|NCT02029703|SHAM_COMPARATOR|Sham injection|Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
62088492|NCT02029703|ACTIVE_COMPARATOR|Synvisc-One Injection|Subjects randomized into the Synvisc-One group will receive a single 6 mL intra-articular injection of Synvisc-One under sterile conditions. The unblinded treating physician will prepare the treatment site according to his/her standard practice guidelines (i.e. after cutaneous numbing with a vasocoolant spray and / or local lidocaine injection), an 18 gauge needle will be advanced into one of three compartments of the knee using the injectors' technique of choice. Subjects will be monitored for a minimum 5 minutes post injection to evaluate for adverse events.
62088493|NCT06698211||Posaconazole tablet|Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of IFD, after which the Posaconazole plasma concentration on day 5 will be examined.
62088494|NCT01612364|EXPERIMENTAL|thoracic sympathetic block|Sympathetic block of upper limb via thoracic vertebra T3
62088495|NCT01612364|ACTIVE_COMPARATOR|control block|Same medication used in experimental group, but in dorsal subcutaneous
62088496|NCT02912195|EXPERIMENTAL|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if \<50kg, 100 mg if 50 - 100 kg, and 150 mg if \>100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if \<50kg, 100 mg if 50 - 100 kg, and 150 mg if \>100 kg) in a 100 mL normal saline minibag.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
62088497|NCT02912195|ACTIVE_COMPARATOR|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
62287220|NCT06548321|EXPERIMENTAL|Extracorporeal Shockwave Therapy|
62287221|NCT01983995||Actigraphy|Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.
62287222|NCT05980884|EXPERIMENTAL|L-Carnitine supplementation|Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days. During the intervention, participants are asked to collect urine sample and dietary record each day. Blood and fecal samples will be collected before and after the intervention. Each participant needs to complete a food frequency questionnaire.
62287223|NCT03524573|EXPERIMENTAL|Delayed Appendectomy|Patients will undergo appendectomy the morning following the decision to operate. This group will have an anticipated delay between 3 - 14 hours from the decision to operate, with a surgical start time between 0530 - 0900.
62088498|NCT02153294|EXPERIMENTAL|Ventilation with lower tidal volumes|Use of low tidal volume (4 to 6 ml/kg PBW) after intubation and during all mechanical ventilation
62461850|NCT01962337|EXPERIMENTAL|3-FPA008 Open-Label DoseLevels 1-3|Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels
62653267|NCT03612219|ACTIVE_COMPARATOR|IMRT with CC|Only obeservation after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
62088499|NCT02153294|OTHER|Ventilation with higher tidal volumes|Use of high tidal volume (8 to 10 ml/kg PBW) after intubation and during all mechanical ventilation
62088500|NCT04479098|EXPERIMENTAL|Exercise training|Postmenopausal breast cancer survivors undergoing tamoxifen treatment, who will do the evaluations before the beginning and after 12 weeks of exercise training and subsequently 12 weeks of detraining.
62287224|NCT03524573|ACTIVE_COMPARATOR|Immediate Appendectomy|Patients will undergo appendectomy within 6 hours of the decision to operate. Surgery will take place between 2000 - 0400.
62287225|NCT03889587|EXPERIMENTAL|Innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibula bone flaps. In simultaneous innervated group, neurorrhaphy between the ilioinguinal nerve or fibula flap nerve with inferior alveolar nerve or great auricular nerve will be performed.~Intervention: Procedure: Innervation"
62287226|NCT03889587|ACTIVE_COMPARATOR|Non-innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibular bone flaps. In traditional noninnervated group, neurorrhaphy will not be performed.~Intervention: Procedure: Non-innervation"
62287227|NCT01917786||Dexmedetomidine patients|Surgical patients receiving dexmedetomidine.
62287228|NCT01917786||Control patients|Surgical patients not receiving dexmedetomidine.
62287229|NCT02977923|ACTIVE_COMPARATOR|Standard pharmacological treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
62307907|NCT05573685|ACTIVE_COMPARATOR|DiNaMo Study App|Randomization ratio as 3 DiNaMo Study Apps: 1 Digital Control App
62307908|NCT05573685|PLACEBO_COMPARATOR|Digital Control App|Randomization ratio as 3 DiNaMo Study Apps: 1 Digital Control App
62307909|NCT01380093|PLACEBO_COMPARATOR|Placebo|
62307910|NCT01380093|ACTIVE_COMPARATOR|MS Contin (morphine sulfate, controlled release)|
62088501|NCT03773055|ACTIVE_COMPARATOR|NPC-06 (High dosage)|18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage
62088502|NCT03773055|ACTIVE_COMPARATOR|NPC-06 (Low dosage)|15 mg (iv) in Day 1 as an induction dosage and 6 mg (iv) in Day 2 - 7 as a maintenance dosage
62088503|NCT03773055|PLACEBO_COMPARATOR|Placebo|Saline will be administered intravenously
62088504|NCT03674840|OTHER|control group|Subjects in this group will go through a cataract surgery with SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
62307911|NCT01380093|EXPERIMENTAL|EMBEDA (morphine sulfate / naltrexone hydrochloride)|
62088505|NCT03674840|EXPERIMENTAL|design group|Subjects in this group will go through a cataract surgery with SBL-3 implantation based on kappa angle(described by Pentacam HR preoperatively) guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
62120133|NCT02845063|EXPERIMENTAL|concentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
62120134|NCT02845063|EXPERIMENTAL|eccentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
62653268|NCT06515275|EXPERIMENTAL|Experimental Group|Participants will complete a demographic and treatment-related questionnaire. Prior to starting ovulation induction, they will complete the SCREENIVF, STAI, and FertiQol scales. On the first day of ovulation induction, participants will receive face-to-face and video-assisted education on prescribed medications, covering purpose, dose, administration, injection technique, timing, effects, and side effects. After follicle tracking confirms readiness for egg retrieval, participants will receive individual education on the ovulation-triggering medication, followed by QR code-linked educational videos specific to this medication. Post-oocyte aspiration, once sedation effects wear off, participants will complete the SCREENIVF, STAI, and FertiQol scales, along with an Education Satisfaction Evaluation Form.
62653269|NCT06515275|NO_INTERVENTION|Control Group|Participants will complete a demographic and treatment-related questionnaire. Before starting ovulation induction, they will complete the SCREENIVF, STAI, and FertiQol scales. On the first day of ovulation induction, participants will receive face-to-face education on medication use, covering purpose, dose, administration, injection technique, timing, effects, and side effects. After ovulation induction, follicle tracking will occur. Upon readiness for egg retrieval, participants will receive individual education on the medication to trigger ovulation. After oocyte aspiration and recovery from sedation, participants will complete the SCREENIVF, STAI, and FertiQol scales, plus an Education Satisfaction Evaluation Form. Control group participants seeking continued treatment after a failed cycle will receive post-study access to video-assisted medication education via QR codes.
62461851|NCT03328936|EXPERIMENTAL|Arm I (melphalan hydrochloride for 3-day severe neutropenia)|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for for predicted 3-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
62653270|NCT00712504|EXPERIMENTAL|1|SU011248 in combination with docetaxel
62653271|NCT01041911|ACTIVE_COMPARATOR|Euphorbia 50 mg|This arm subjects will be given 50 mg Euphorbia prostrata
62653272|NCT01041911|ACTIVE_COMPARATOR|Euphorbia 100 mg|In this arm subjects will be given 100 mg Euphorbia
62653273|NCT01041911|ACTIVE_COMPARATOR|Euphorbia 200 mg|In this arm subject will be given 200 mg Euphorbia tablets
62653274|NCT01041911|PLACEBO_COMPARATOR|Placebo|In this arm subjects will be given placebo tablets
62653275|NCT04582799|ACTIVE_COMPARATOR|Standard of Care (NIV)|Patients in the control group will be treated with non-invasive ventilation only.
62653276|NCT04582799|EXPERIMENTAL|Extracorporeal CO2 Removal (NIV+ECCO2R)|Patients in the treatment group will be treated with non-invasive ventilation combined with Extracorporeal CO2 Removal.
62653277|NCT04121143|ACTIVE_COMPARATOR|Treatment group A|SHR-1314 low dose short intervals of subcutaneous injection
61904705|NCT00641511|PLACEBO_COMPARATOR|2 (Placebo arm)|During the 6 weeks ( weeks: 1-6) double- blind, randomized clinical trial (RCT) phase, the veterans who have been randomized to the placebo treatment group will be receiving placebo pills. During the 8 weeks (weeks: 7-14) extension phase, all veterans from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed by the study team for an additional 8 weeks. The veterans on the placebo during the RCT will receive the study medication at end of the study week 6, the medication will be initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily for 8 weeks until the end of the study.
62653278|NCT04121143|ACTIVE_COMPARATOR|Treatment group B|SHR-1314 high dose long intervals of subcutaneous injection
62653279|NCT04121143|ACTIVE_COMPARATOR|Treatment group C|SHR-1314 high dose short intervals of subcutaneous injection
62653280|NCT04121143|PLACEBO_COMPARATOR|Placebo group|Placebo was subcutaneously injected into the 16 weeks turnover SHR-1314 subcutaneous injection
62653281|NCT00984867|ACTIVE_COMPARATOR|1|Dapagliflozin 10 mg tablet
62653282|NCT00984867|PLACEBO_COMPARATOR|2|Matching placebo tablet
62461852|NCT03328936|EXPERIMENTAL|Arm II (melphalan hydrochloride or 5-day severe neutropenia))|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for predicted 5-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
62461853|NCT04365309|NO_INTERVENTION|the NCP standard treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment).
62653283|NCT01200641|ACTIVE_COMPARATOR|melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
62653284|NCT01200641|ACTIVE_COMPARATOR|gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
61904706|NCT01423188|EXPERIMENTAL|RVX000222, 200 mg daily|
61904707|NCT01423188|PLACEBO_COMPARATOR|Placebo|
61904708|NCT02551796|EXPERIMENTAL|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
62653285|NCT01200641|PLACEBO_COMPARATOR|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
62088506|NCT01710293|EXPERIMENTAL|Communication of Patients Lost to Follow-up to Providers|This intervention will consist of two related, continuous steps over at least a 12-month period. In the first step, the investigators will query the VA's Corporate Data Warehouse (CDW, a repository of near real-time patient data from all VA medical centers) weekly to identify possible lost to follow-up events in a pre-specified time period and for a random sample of about half of the providers at the investigators' study sites. These identified patient charts will be reviewed by Facility Recipients/Cancer Trackers at each site who will then communicate patients truly found to be lost to follow-up to the appropriate provider/care team.
62088507|NCT01710293|NO_INTERVENTION|Usual Care|In the usual care group, providers will continue to use the existing notification system to receive abnormal test results in accordance with institutional norms, policies, and procedures. There are no formal patient-tracking programs currently at our study sites for all abnormal test results. The investigators will apply our computerized surveillance tools in the usual care arm only when the investigators are ready to conduct the final chart reviews on intervention patients and identify these patients in similar time periods as in the intervention arm. If persistent delays are found, the investigators will inform the patients' primary care providers.
62088508|NCT04571762|EXPERIMENTAL|Single arm|Patients with low-risk, intermediate-risk and low-volume metastatic prostate cancer eligible for stereotactic body radiotherapy will be recruited.
62088509|NCT06460012|EXPERIMENTAL|Experimental Group|Care partners start the STELLA-R Curriculum immediately after enrollment.
62307912|NCT03285529|ACTIVE_COMPARATOR|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
62461854|NCT04365309|EXPERIMENTAL|the NCP aspirin treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). Patients in the NCP aspirin group were given aspirin 100 mg/d orally after admission and aspirin for 14 days after discharge.
61904709|NCT02551796|EXPERIMENTAL|laser in situ keratomileusis|The patients in this group chose to receive the laser in situ keratomileusis surgery.
62088510|NCT06460012|ACTIVE_COMPARATOR|Waitlist Control Group|Care partners start the STELLA-R Curriculum 8 weeks after enrollment.
62088511|NCT03325335|ACTIVE_COMPARATOR|Midazolam premedication group (Group P)|Patients of group P were premedicated with intramuscular midazolam 0.05 mg/kg 30 minutes before surgery.
62088512|NCT03325335|OTHER|Control group (Group N)|Patients of group N were not premedicated with midazolam (Do not use placebo). \[Treatment of Glycopyrrolate (0.2 mg, IM) 30 minutes prior to surgery is not intervention because it is a routine practice of this center. (-\> removed from interventions)\]
62120135|NCT02845063|ACTIVE_COMPARATOR|concentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
62120136|NCT02845063|ACTIVE_COMPARATOR|eccentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
62120137|NCT00971711|EXPERIMENTAL|Probiotic|To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).
62120138|NCT04563156||Severe Covid-19 Survivors|Severe Covid-19 survivors previously admitted in the hospital
62120139|NCT00869323|EXPERIMENTAL|Treated Patients|This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).
62120140|NCT04725305|EXPERIMENTAL|BiZact|A bipolar electrosurgical device that employs radiofrequency(RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger
62120141|NCT04725305|ACTIVE_COMPARATOR|Standard of care|In electrocautery tonsillectomy (or diathermy) electric current from a radiofrequency generator is passed through the tissue between two electrodes. The resulting high temperature (400º-600ºC) cuts the tissue and simultaneously seals the blood vessels
62120142|NCT01152970||drug-using youth with violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for an acute violent injury
62653286|NCT00754741|NO_INTERVENTION|Usual care|All Physicians are given limited training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software when they see patients assigned to this arm
62653287|NCT00754741|ACTIVE_COMPARATOR|Adherence|
62653288|NCT00754741|ACTIVE_COMPARATOR|Adherence Plus|
62653289|NCT01512654|OTHER|algorithm DIAdvisor activated|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
62653290|NCT01512654|OTHER|algorithm of DIAdvisor disactivated|Glucosepredictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
62653291|NCT05668559|EXPERIMENTAL|Active rTMS Group|A stimulation set will be administered to each participant in the rTMS group with 15 sessions stimulation for total five days after surgery.
62653292|NCT05668559|SHAM_COMPARATOR|Sham Stimulation Group|Patients randomly assigned to sham group will receive 15 sessions sham stimulation for total five days after surgery.
62653293|NCT04031170|EXPERIMENTAL|Intervention|Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic \& Advanced Parent Training Program. It consists of twelve (12) 2-hour classes led by Dean Coffey, a senior psychologist and certified peer coach in the Incredible Years Parent Training Series.
62653294|NCT04031170|OTHER|Control|Parents assigned to the control arm will be emailed and mailed written parent education materials from the American Academy of Pediatrics called the Bright Futures handouts. The control group is offered the Incredible Years® School Age Basic \& Advanced Parent Training Program after a 3-month wait list period.
62653295|NCT05363774|EXPERIMENTAL|Single ascending dose (SAD) part|Participants will receive up to six dose levels of subcutaneous NNC0519-0130 or matching placebo in a sequential manner with the dose increasing between cohorts.
62653296|NCT05363774|EXPERIMENTAL|Multiple ascending dose (MAD) QD part|MAD QD part comprises two cohorts in participants with overweight or obesity and a cohort in participants with type 2 diabetes (T2D). The participants in first cohort will receive NNC0519-0130 or matching placebo subcutaneously up to 5 dose levels, and the participants in the second MAD QD cohort will receive NNC0519-0130 or matching placebo orally up to 5 dose levels.
62653297|NCT05363774|EXPERIMENTAL|Type 2 diabetes (T2D) part|Participants will receive NNC0519-0130 or matching placebo up to 2 dose levels with dose escalation within the cohort.
62653298|NCT05363774|EXPERIMENTAL|MAD QW part|MAD QW part comprises two cohorts in participants with overweight or obesity and who are otherwise generally healthy. The participants in first cohort will receive NNC0519-0130 and 2nd cohort will receive matching placebo subcutaneously up to 6 dose levels.
62653299|NCT01066234|EXPERIMENTAL|concurrent chemoradiotherapy|
62653300|NCT01066234|ACTIVE_COMPARATOR|chemotherapy only|
62653301|NCT01694680|ACTIVE_COMPARATOR|Lutein-enriched-egg beverage|Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
62653302|NCT01694680|PLACEBO_COMPARATOR|Placebo|Powder in sachet to prepare beverage
62653303|NCT02232867|EXPERIMENTAL|Arm and Leg Cycling Exercise Program|Multiple baseline test sessions will be used for the same participant to establish a meaningful baseline thus confirming consistency of all outcome measures prior to the intervention.
61904710|NCT02551796|EXPERIMENTAL|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the FS assisted laser in situ keratomileusis surgery.
61904711|NCT04101838|ACTIVE_COMPARATOR|Fluzone Younger|10 adults 18-50 years old, will receive a single dose of the Fluzone influenza vaccine each year for two sequential years
62653304|NCT02820662|EXPERIMENTAL|RETCAM|
61904712|NCT04101838|ACTIVE_COMPARATOR|Flucelvax|10 adults 18-50 years old, will receive a single dose of the Flucelvax influenza vaccine each year for two sequential years
62287230|NCT02977923|EXPERIMENTAL|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
62287231|NCT00684177|EXPERIMENTAL|Retapamulin Ointment, 1%|
62287232|NCT00684177|PLACEBO_COMPARATOR|Placebo Ointment|
62287233|NCT01921998||Biomarker and health economics|Biomarkers will be taken throughout cycle 1. Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
62653305|NCT03188822|EXPERIMENTAL|Bioabsorbable steroid releasing sinus implant & nasal dressing impregnated with steroid|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
62653306|NCT03316105|ACTIVE_COMPARATOR|Transcutaneous electrical nerve stimulation (TENS) stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
62287234|NCT02700984|EXPERIMENTAL|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
62653307|NCT03316105|SHAM_COMPARATOR|No TENS stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
62287235|NCT02700984|ACTIVE_COMPARATOR|Cataract Surgery Only|Cataract Surgery (COMPASS trial) with no CyPass Micro-Stent implantation
62287236|NCT04754789|ACTIVE_COMPARATOR|group for loading with statin before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive two 80-mg loading doses of atorvastatin, the first loading dose will be administered in the Emergency Room before transfer to Cath Lab, the second dose of 80-mg atorvastatin will be administered 24 hours afterthe first dose."
62287237|NCT04754789|PLACEBO_COMPARATOR|group receive the routine guidelines management before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive only the routine management."
62287238|NCT05464537|ACTIVE_COMPARATOR|Unipolar Polarity Switch Left and CAI-OPR-LAAP Right|
62287239|NCT05464537|ACTIVE_COMPARATOR|CAI-OPR-LAAP Left and Unipolar Polarity Switch Right|
62287240|NCT00968422|EXPERIMENTAL|Low dose ABT-384|
61904713|NCT04101838|ACTIVE_COMPARATOR|Fluzone Older|10 adults 65-80 years old, will receive a single dose of the Fluzone influenza vaccine
61904714|NCT04101838|ACTIVE_COMPARATOR|Fluzone High Dose|10 adults 65-80 years old, will receive a single dose of the Fluzone High-Dose influenza vaccine
61904715|NCT04101838|ACTIVE_COMPARATOR|Fluad|10 adults 65-80 years old, will receive a single dose of the Fluad influenza vaccine
62287241|NCT00968422|EXPERIMENTAL|Mid dose ABT-384|
62287242|NCT00968422|EXPERIMENTAL|High dose ABT-384|
62287243|NCT00968422|PLACEBO_COMPARATOR|Placebo|
62287244|NCT04041115|ACTIVE_COMPARATOR|Control|personalized nutritional therapy + aerobic exercise
62287245|NCT04041115|ACTIVE_COMPARATOR|Non-alcoholic Beer|non-alcoholic beer + personalized nutritional therapy + aerobic exercise
62287246|NCT04305015|ACTIVE_COMPARATOR|Routine opioid management|Clinicians will be blinded to NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when
62287247|NCT04305015|EXPERIMENTAL|NOL-guided opioid administration|Clinicians will titrate fentanyl to keep NOL under 25 - always using good clinical judgement for individual patients
62287248|NCT01468987|ACTIVE_COMPARATOR|Insulin Glargine + Insulin Lispro|"Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks."
62287249|NCT01468987|EXPERIMENTAL|LY2605541 + Insulin Lispro|"Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks."
62653308|NCT01346098|EXPERIMENTAL|GROUP B|At the time of surgery the surgeon will directly assess pancreatic consistency and the pancreatic duct size. In the presence of a soft pancreas and a small duct (diameter \<3 mm), the patient will be randomly assigned to receive either a pancreaticoduodenectomy with pancreatic anastomosis (group A) or a total pancreatectomy with IAT (group B).
62287250|NCT01322022|EXPERIMENTAL|Parent Training|Behavioral Intervention
62653309|NCT01346098|ACTIVE_COMPARATOR|GROUP A|
62287251|NCT01322022|ACTIVE_COMPARATOR|Parent Education|5 Sessions of individual parent education
62287252|NCT06265142|OTHER|Catheterization|Group A: is the control group, participant will undergo bladder catheterization. (The standard practice)
62653310|NCT01978756||Outpatient clinic|All patients treated for breast cancer with curative intent in MAASTRO clinic in 2002-2003 who are still alive, who respond to our invitation letter and are willing to participate to visit the outpatient clinic. These patients will be sent a questionnaire with both basic and more detailed questions on their disease-status and on quality of life related outcome. In addition they will be asked to come to MAASTRO clinic for a more detailed evaluation of late side effects of the treatment. Patients are seen by a physician or a physician assistant at the outpatient clinic.
62653311|NCT03163628|EXPERIMENTAL|7 biomarkers combination|
62653312|NCT04553718|EXPERIMENTAL|experiemental group|Experimental group was the mHealth app to improved their gestational weight gain and physical activity during pregnancy.
62653313|NCT04553718|NO_INTERVENTION|control group|standard prenatal care and without mHealth app
62653314|NCT04010305|PLACEBO_COMPARATOR|Placebo|Sublingual Film with no active drug; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
62287253|NCT06265142|EXPERIMENTAL|Clean Catch|Group B: is the experimental group, participant will undergo clean catch urine via bladder massage technique.
62287254|NCT01501279|EXPERIMENTAL|pudendal nerve block|USG guided pudendal nerve block performed under general anesthesia
62653315|NCT04010305|EXPERIMENTAL|20 micrograms|Sublingual Film containing 20 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
62653316|NCT04010305|EXPERIMENTAL|60 micrograms|Sublingual Film containing 60 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
62653317|NCT04010305|EXPERIMENTAL|120 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501; single administration of 2 films with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
62653318|NCT04010305|EXPERIMENTAL|180 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501.
62653319|NCT06550648||Idiopathic Pulmonary Arterial Hypertension|Patients with Idiopathic PAH excluding all other causes Right Heart Catheterization will be done as routine as well as blood samples for IgG and IgM and EBV PCR
62653320|NCT06550648||Pulmonary Arterial Hypertension associated with Connective Tissue Disease|Proved CTD Right Heart Catheterization will be done as routine as well as blood samples for IgG and IgM and EBV PCR
62653321|NCT06550648||Control group ( Normal Individuals )|Healthy Individuals ( only Blood samples withdrawn)
62653322|NCT01592955|EXPERIMENTAL|EYEOP1 device|cyclocoagulation HIFU
62653323|NCT01206764|EXPERIMENTAL|RAD001|
62653324|NCT00295802|EXPERIMENTAL|HIFU|Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
62653325|NCT00295802|ACTIVE_COMPARATOR|Cryotherapy|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
61904716|NCT01643785|EXPERIMENTAL|with Endonase|Second-line quadruple therapy \[PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID\] plus 20,000 units of pronase (endonase), BID for 7 days
61904717|NCT01643785|NO_INTERVENTION|without Endonase|Second-line quadruple therapy \[PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID\] for 7 days
62287255|NCT01501279|NO_INTERVENTION|no nerve block|Control group without nerve block
62653326|NCT00410163|ACTIVE_COMPARATOR|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
62653327|NCT00410163|ACTIVE_COMPARATOR|Active Comparator 2|Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg
62653328|NCT03657732||Familial Alzheimer's disease group|Familial Alzheimer's disease with the known mutation presenilin1 (PSEN1), presenilin2 (PSEN2) and amyloid precursor protein (APP) including mutation carriers and noncarriers, presymptomatic and symptomatic.
62653329|NCT03657732||Normal control group|Normal cognitive control people
62287256|NCT00891826|PLACEBO_COMPARATOR|Corn oil|
62287257|NCT00891826|EXPERIMENTAL|Omega-3 fatty acids|
62287258|NCT00788645|EXPERIMENTAL|Forecast|COPD patients receiving advice and poor weather warning
62287259|NCT00788645|EXPERIMENTAL|No Forecast|COPD patients receiving advice and poor weather warning
62287260|NCT00788645|NO_INTERVENTION|Control|Age matched non - COPD subjects
62287261|NCT05328570|EXPERIMENTAL|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
62287262|NCT01451645|OTHER|placebo|daily placebo dosing for 16 weeks with background allopurinol therapy
62653330|NCT04400994|ACTIVE_COMPARATOR|Rituximab only|"* Rituximab infusion 375mg/m2 body surface area (BSA) weekly for 4 weeks from baseline (week 0, 1, 2, 3)~* Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 24 (week 24, 25, 26, 27)~* Rituximab infusion 375mg/m2 BSA weekly for 2 weeks at week 52 (week 52, 53)~* Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 76 (week 76, 77)~* A total of 12 doses of rituximab will be given in 55 weeks"
62653331|NCT04400994|EXPERIMENTAL|Rituximab and IVIG|"* Rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 1, 2, 3);~* Week 4: Rituximab + IVIG 2g per kg~* Week 5, 6, 7: Above treatment repeated for 2nd cycle, infusion of rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 5, 6, 7);~* Week 8: Rituximab + IVIG 2g/kg~* In months 3, 4, 5, 6, patients received a single infusion of rituximab (375 mg/m2 BSA) plus infusion of 2g/kg IVIG~* Thus in 6-month period patients received a total of 12 infusions of rituximab and 7 infusions of IVIG~* If a patient was clinically free of disease at end of 6 months, additional infusions of IVIG will be given at week 30, 38, 48, 60 and 76~* A total of 12 doses of rituximab and 12 cycles of IVIG will be given"
62653332|NCT01409473|EXPERIMENTAL|Prostate SBRT|Prostate SBRT with concurrent boost to intraprostatic lesion (IPL) will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
62653333|NCT01092468|PLACEBO_COMPARATOR|Diathermy|Perforator flap elevation using conventional diathermy technique
62653334|NCT01092468|ACTIVE_COMPARATOR|Harmonic Scalpel|Perforator flap elevation using Harmonic Scalpel
62088513|NCT05218564|EXPERIMENTAL|Group 1, consisting of participants with COPD and usually using O2|In this group, in addition to the standard care, the participant undergoes the 6 Minute Walking Test (6MWT) using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The same, then, in addition to the standard care, is subjected to the execution of the 6 Minute Walking Test (6MWT), thanks to the use of cylinders of Oxygen (O2), believing that inside the cylinder there is Oxygen (O2). The sequence of this group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen).
62287263|NCT01451645|ACTIVE_COMPARATOR|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks with background allopurinol therapy
62461855|NCT06311942|EXPERIMENTAL|Triple adjuvant therapy group|Patients in the triple adjuvant therapy group received HAIC in combination with PD-1 inhibitors and lenvatinib adjuvant therapy.
62461856|NCT06311942|ACTIVE_COMPARATOR|Dual adjuvant therapy group|Patients in the Dual adjuvant therapy group received PD-1 inhibitors combined lenvatinib adjuvant therapy.
62088514|NCT05218564|PLACEBO_COMPARATOR|Group 2, consisting of participants with COPD and usually not using O2|In this group, in addition to standard care, the participant is given the 6 Minute Walking Test (6MWT) using oxygen (O2) cylinders, believing that there is oxygen (O2) inside the cylinder. Next, the participant undergoes the 6 Minute Walking Test (6MWT), using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The sequence of this group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
62088515|NCT03567083|EXPERIMENTAL|E-CAU with Problem Management Plus (PM+)|30 participants will be randomly assigned to E-CAU with PM+ group. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
62120143|NCT01152970||drug-using youth with non-violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for non-violence related care
62120144|NCT05865314|EXPERIMENTAL|Interventional group|
62120145|NCT05865314|ACTIVE_COMPARATOR|Control group|
62461857|NCT04235881|EXPERIMENTAL|MBSR group|Enforcement of the standardized program Mindfulness-Based Stress Reduction
62461858|NCT04235881|EXPERIMENTAL|App group.|Enforcement of the emotional regulation program based on mindfulness (ERM) through the mobile phone application REM volver a casa
62461859|NCT04235881|NO_INTERVENTION|Control group|Usual care
62461860|NCT04341285|ACTIVE_COMPARATOR|Early ECMO|Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
62653335|NCT00426270|EXPERIMENTAL|Octagam 10% 1 g/kg/day|Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.
62653336|NCT00879190|ACTIVE_COMPARATOR|Unasyn (ampicillin/sulbactam)|
62120146|NCT06101992|ACTIVE_COMPARATOR|Mesoglycan|According to randomization, patients will take mesoglycan mg 50 (heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine) 4 capsules/day for 5 days and 2 capsules/day for 35 days
62120147|NCT06101992|PLACEBO_COMPARATOR|Placebo|According to randomization, patients will take placebo (lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate) 4 capsules/day for 5 days and 2 capsules/day for 35 days
62120148|NCT03264846||Group 1|PCOS participants with periodontitis
62120149|NCT03264846||Group 2|PCOS participants with periodontally healthy
62653337|NCT00879190|ACTIVE_COMPARATOR|Ampicillin/gentamicin|
62653338|NCT00835926|EXPERIMENTAL|Fluzone® Vaccine Group 1|Participants aged 18 to 59 years at enrollment - Fluzone® Group
62653339|NCT00835926|EXPERIMENTAL|Fluzone® Vaccine Group 2|Participants aged 60 years and older at enrollment - Fluzone® Group
62653340|NCT04992247|EXPERIMENTAL|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
62653341|NCT04992247|PLACEBO_COMPARATOR|Placebo|Excipient
62120150|NCT03264846||Group 3|systemically healthy participants with periodontitis
62120151|NCT03264846||Group 4|systemically and periodontally healthy participants
62120152|NCT01102049|EXPERIMENTAL|self-administered food intake|self-administered food intake according to dietary protocol
62653342|NCT01464567|ACTIVE_COMPARATOR|"T Tube Spontaneous Breathing Trial"|"Spontaneous Breathing Trial wuth T Tube for 30 minutes."
62653343|NCT01464567|EXPERIMENTAL|Pressure Support Ventilation|Spontaneous Breathing Trial wuth Ventilation on Pressure-Support mode set at 10cmH2O for 30 minutes
62653344|NCT02354118|ACTIVE_COMPARATOR|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
62653345|NCT02354118|EXPERIMENTAL|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
62653346|NCT05248789|EXPERIMENTAL|OH2|OH2 dosage: 1x10e7 CCID50/mL Administration：intratumoral injection Frequency：once two weeks
62653347|NCT02327455|EXPERIMENTAL|Stress Dobutamine Echocardiographic 4DE Image System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
62653348|NCT06264713|EXPERIMENTAL|Experimental Immersive Virtual Reality|Patients will undergo nine sessions of 20 minutes for three sessions/week, for a total of three weeks of treatment. The training consists of 3 different virtual reality tasks specifically designed for neglect training.
62653349|NCT06264713|ACTIVE_COMPARATOR|Sham Immersive Virtual Reality|Patients will undergo nine sessions of 20 minutes for three sessions/week, for a total of three weeks of treatment. The training consists of 3 different virtual reality tasks specifically designed for neglect training.
62653350|NCT00547339|EXPERIMENTAL|Phase 1: Stereotactic Body Radiation Therapy (SBRT) 45 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated - 45 Gy
62653351|NCT00547339|EXPERIMENTAL|Phase 1: Stereotactic Body Radiation Therapy (SBRT)- 47.5 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated- 47.5 Gy
62088516|NCT03567083|NO_INTERVENTION|Enhanced care as usual (E-CAU) only|30 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a referral document), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
62653352|NCT00547339|EXPERIMENTAL|Phase 1: Stereotactic Body Radiation Therapy (SBRT)- 50 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated- 50 Gy
62653353|NCT00547339|EXPERIMENTAL|Phase 2: Stereotactic Body Radiation Therapy (SBRT)- 50 Gy|The dose of SBRT is escalated - 50 Gy in Phase 2
62653354|NCT01526980|EXPERIMENTAL|Treatment period 1|
62653355|NCT01526980|ACTIVE_COMPARATOR|Treatment period 2|
62653356|NCT03259893|ACTIVE_COMPARATOR|Standard of care group 1|Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
62653357|NCT03259893|EXPERIMENTAL|Intervention group 2|The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
62653358|NCT02057770|EXPERIMENTAL|Treatment (preparative regimen, transplant, cyclophosphamide)|"BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.~OR~FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.~AND~DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.~AND~POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4."
62653359|NCT02057770|EXPERIMENTAL|CRS preventive regimen|The final \~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.
62653360|NCT03907345|EXPERIMENTAL|Exposure|Participants of this arm receive one 120-minute session of exposure treatment for spider fear.
62653361|NCT03907345|NO_INTERVENTION|No Exposure|Participants of this arm receive no exposure or other adequate treatment.
62653362|NCT01180062|ACTIVE_COMPARATOR|Arm 1|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
62653363|NCT01180062|ACTIVE_COMPARATOR|Active Comparator - Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
62653364|NCT01180062|ACTIVE_COMPARATOR|Active Comparator - Arm 3|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
62653365|NCT01327794||Group 1|Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25\[OH\]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
62653366|NCT03394937|EXPERIMENTAL|Cohort 1 600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006
62653367|NCT03394937|EXPERIMENTAL|Cohort 1 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006
62653368|NCT03394937|EXPERIMENTAL|Cohort 2 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006
62653369|NCT03394937|EXPERIMENTAL|Cohort 2 3600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006
62287264|NCT01656720|PLACEBO_COMPARATOR|Placebo|Placebo 2g Suppository
62287265|NCT01656720|ACTIVE_COMPARATOR|NRL001 5mg|5mg NRL001 in a 2g suppository
62653370|NCT01800253|EXPERIMENTAL|Total sleep deprivation|Participants will be required to stay up for the entire night before 'Blood Samples' and 'Tissue samples' will be taken and the 'Portion Size Task' and 'Inhibitory task' will be performed. This will then be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
62653371|NCT01800253|EXPERIMENTAL|Sleep|Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
62653372|NCT05466058|OTHER|cases|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
62653373|NCT05466058|OTHER|control|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
62653374|NCT01204242|PLACEBO_COMPARATOR|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
62653375|NCT01204242|EXPERIMENTAL|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
62653376|NCT01790399|EXPERIMENTAL|Identification of sentinel node(s)|
62653377|NCT03343314||Hospitalized patients due to a severe, symptomatic aortic sten|Patients who agreed to participate in the study, aged ≥75 years, with severe and symptomatic aortic stenosis, and hospitalized in one of the medical and surgical centers participating in the study
62653378|NCT01738958|ACTIVE_COMPARATOR|Probiotic lactobacilli|L. reuteri, two times a day for 6 weeks
62653379|NCT01738958|PLACEBO_COMPARATOR|Placebo|Placebo tablets, two times a day for 6 weeks
62653380|NCT00703534|EXPERIMENTAL|AZD3355|
62653381|NCT00703534|PLACEBO_COMPARATOR|Placebo|
62653382|NCT00408499|EXPERIMENTAL|Erlotinib + Cetuximab|Daily erlotinib combined with weekly cetuximab
62653383|NCT01375101|ACTIVE_COMPARATOR|quercetin|quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
62653384|NCT01375101|PLACEBO_COMPARATOR|placebo|placebo capsul is produced with lactose for using in placebo/ control group.
62653385|NCT03962361||Sudden cardiac death of ischemic cause|Patients admitted to the Coronary Care Unit for sudden cardiac death of ischemic cause and remain comatose (GCS \< 8 points).
62653386|NCT01409668|EXPERIMENTAL|L. Amylovorus|
61904719|NCT01410357|EXPERIMENTAL|Targeted Training in Illness Management (TTIM)|Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
62653387|NCT01409668|EXPERIMENTAL|L. Fermentum|
61904720|NCT01410357|NO_INTERVENTION|Treatment As Usual (TAU)|Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.
61919766|NCT00847119|EXPERIMENTAL|Bevacizumab & capecitabine & radiotheraphy|"Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period."
61919767|NCT04562272|ACTIVE_COMPARATOR|Mechanical unloading|Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment
62287266|NCT01656720|ACTIVE_COMPARATOR|NRL001 7.5mg|7.5mg NRL001 in a 2g suppository
62287267|NCT01656720|ACTIVE_COMPARATOR|NRL001 10mg|10mg NRL001 in a 2g suppository
62287268|NCT00067756|EXPERIMENTAL|4-PBA|The study will involve a 4-PBA dose escalation and pharmacokinetics component The study group will be comprised of a total of at least 10 AAT-deficient,(phenotype ZZ referred to as PiZZ) patients. These patients will be divided into two groups: with and without clinical evidence of mild to moderate hepatocellular injury.
62653388|NCT01141101||MRSA-exposed|The MRSA-exposed group will include 100 MRSA-colonized mothers and their babies
62653389|NCT01141101||MRSA-unexposed|The MRSA-unexposed group will include 100 MRSA-negative mothers and their babies.
62653390|NCT03883386|EXPERIMENTAL|Loratadine first|Take treatment daily for 7 days.
62653391|NCT03883386|PLACEBO_COMPARATOR|Placebo first|Take placebo daily for 7 days.
62653392|NCT05298657||Poor IVF Treatment Responders|
62653393|NCT05298657||Hyper IVF Treatment Responders|
62653394|NCT05298657||Normal responders/ Control group|
62653395|NCT05264116|EXPERIMENTAL|Healthy adult participants|All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors.
62653396|NCT04049461||PDAC Group|Radical operations were performed through central abdominal incisions. The postoperative pathology was pancreatic ductal adenocarcinoma.
62653397|NCT04049461||Benign Group|The abdominal midline incision was performed and the postoperative pathology was benign.
62653398|NCT00318396|EXPERIMENTAL|Compaction|The bone is pressed very hard together before implantation of femoral component.
62653399|NCT00318396|ACTIVE_COMPARATOR|Conventional technique|The bone is broached before implantation of femoral component.
62461861|NCT04341285|ACTIVE_COMPARATOR|Late ECMO|Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.
62653400|NCT02346864|EXPERIMENTAL|Three-stair-position group|The infants in the study group (n=72) received three-stair-position (TSP) intervention (head up 15°) for a week.
62653401|NCT02346864|OTHER|head elevated tilt position group|The control group(n=72)received head elevated tilt position (HETP) intervention (head up 15°) for a week．
62653402|NCT03707002|ACTIVE_COMPARATOR|scFOS|scFOS consumed at 5g/day for 6 weeks
62653403|NCT03707002|PLACEBO_COMPARATOR|Placebo|maltodextrin consumed at 5g/day for 6 weeks
62653404|NCT06381232||Healthy Control|
62653405|NCT06381232||Cases (Various Phenotypes)|
62653406|NCT04861792|NO_INTERVENTION|Usual Care|Patients seen before the intervention launch date.
62653407|NCT04861792|EXPERIMENTAL|Quality Improvement Intervention|Patients seen after the intervention launch date.
62653408|NCT04673773|EXPERIMENTAL|Feasibility / A massive open course|"1. The online MOOC contains eight units which cover the following topics (Understanding low back pain (LBP), Physical activity and exercise in relation to LBP, Psychological factors, Sleep / nutrition, Management of LBP at the workplace, Communication with health care, Other issues related to LBP). Each unit will include short factual texts, short videos (2-5mins) with older workers (aged 55+ years) with low back pain and professional experts, as well as knowledge tests. The complete MOOC will take 2-3 hours to complete. It would be possible to complete the MOOC at one time however users will be recommended to complete two units per week over a month period.~2. The mobile game is designed to encourage participation with the MOOC by providing feedback on engagement with the MOOC, presentation of quizzes to test knowledge gained on the MOOC, as well as feedback on clinical markers of their condition e.g. Mood, pain, physical activity levels."
62653409|NCT03913039||transperineal protocol|"1. Transperineal biopsy approach with avoidance of rectal flora~2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~4. Multi-antibiotic prophylaxis~5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
62653410|NCT03913039||Traditional biopsy|"1. Transrectal approach~2. Standard 12-core template~3. Surgeon-specific antibiotic prophylaxis~4. Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
62653411|NCT01381120|EXPERIMENTAL|VESIcare + Narcotic Painkiller|VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
62653412|NCT01381120|ACTIVE_COMPARATOR|Narcotic Painkiller|Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
61919768|NCT04562272|NO_INTERVENTION|Standard care|Standard treatment of AMI after PCI according to guidelines.
62088517|NCT03790293|EXPERIMENTAL|Rituximab|Rituximab in combination with reduced corticosteroids is administrated
62088518|NCT03790293|ACTIVE_COMPARATOR|Standard corticosteroid|Standard corticosteroid is administrated
62088519|NCT06418295||Unilateral thoracotomy|Unilateral thoracotomy to proceed according to standard of care guidelines.
62088520|NCT06443671|ACTIVE_COMPARATOR|CapeOX group|"Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
62088521|NCT06443671|EXPERIMENTAL|Fruquintinib and Tislelizumab combined with mCapeOX|"Receiving Fruquintinib plus Tislelizumab combined with mCapeOX treatment for up to four cycles before surgery:~Fruquintinib: 3mg/d, QD, PO, Use for 2 weeks, stop for 1 week, Q3W; Tislelizumab: 200mg, D1, Intravenous infusion, Q3W; Capecitabine: 825mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 100 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
62088522|NCT04122053|EXPERIMENTAL|study group|group will receive dietary advice and genotype information
62088523|NCT04122053|ACTIVE_COMPARATOR|Control group|group will receive dietary advice
62088524|NCT04319094|EXPERIMENTAL|PEERS|Peer mentors who have experience of depression are trained and supervised to deliver depression care. Peers will meet with depressed older adults for 8 weekly meeting lasting approximately 45 minutes. Peer mentors will provide social support defined as emotional, informational and appraisal support that includes coping strategies. Peers will be supervised by a mental health professional.
62088525|NCT04319094|ACTIVE_COMPARATOR|Social interaction|A study staff member will provide eight weekly social interaction visits and phone calls to the depressed older adult.
62088526|NCT00519987|EXPERIMENTAL|Treatment A|intranasal ketamine
62088527|NCT03808441|NO_INTERVENTION|Standard Arm|"Dabrafenib + Trametinib~Switch to N+I at first progression"
62088528|NCT03808441|ACTIVE_COMPARATOR|ctDNA Guided Switch|"Dabrafenib + Trametinib~Switch to N+I when ctDNA levels in the blood have dropped by ≥80%."
62461862|NCT01395030|EXPERIMENTAL|18F-fluoromethylcholine PET/CT|Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.
62653413|NCT00398229|ACTIVE_COMPARATOR|A|receiving hCG injection
62653414|NCT00398229|PLACEBO_COMPARATOR|B|
62653415|NCT05246995|EXPERIMENTAL|IBI325 and Sintilimab combination does-escalation|
62653416|NCT06514235||Primary vaginal cancer|Adult patients with vaginal cancer treated with curative intent by primary radio(chemo)therapy and MRI based image-guided adaptive brachytherapy according to the protocol target concept.
62653417|NCT03931564|ACTIVE_COMPARATOR|PRESERFLO Microshunt (formerly InnFocus Microshunt (IMS))|The intervention group will undergo PRESERFLO (formerly InnFocus) Microshunt implantation (IMS).
62287269|NCT04355988|ACTIVE_COMPARATOR|Well controlled diabetics|Nonsurgical root canal treatment
62287270|NCT04355988|ACTIVE_COMPARATOR|Poorly controlled diabetics|Nonsurgical root canal treatment
62287271|NCT04355988|ACTIVE_COMPARATOR|Healthy control group|Nonsurgical root canal treatment
62287272|NCT02481635|EXPERIMENTAL|Gemcitabine/Nab-paclitaxel, Radiation and Surgery|"Gemcitabine (neoadjuvant and adjuvant), intravenously, at a dose of 1000 mg/m2 given over 30-40 minutes, on Day 1 of every 28 day cycle for 2 cycles.~Nab-paclitaxel, intravenously, at a dose of 125 mg/m2 given over 30-40 minutes, on Days 1, 8, and 15 of every 28 day cycle for 2 cycles.~Radiation Therapy: 50.4 Gy in 28 fractions (1.8 Gy/fraction)~Surgery: Tumor resection and arterial resection/reconstruction"
62287273|NCT06321692|OTHER|Evaluation of blood levels of biomarkers of cardiac damage|Evaluation of blood levels of biomarkers of cardiac damage (ultra-sensitive troponin I), hemodynamic impairment (BNP, NT-proBNP), and cardiac fibrosis (ST2) in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
62287274|NCT03394560|EXPERIMENTAL|high-frequency rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
62287275|NCT03394560|SHAM_COMPARATOR|sham rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
62287276|NCT05145621|ACTIVE_COMPARATOR|Test|Fingolimod 0.5 mg capsules - (administered as 3 x Fingolimod 0.5 mg capsules)
62287277|NCT05145621|ACTIVE_COMPARATOR|Reference|Fingolimod 0.5 mg capsules -(administered as 3 x Fingolimod 0.5 mg capsules)
62287278|NCT02008825|EXPERIMENTAL|ViSiGi|Utilization of ViSiGi calibration tube
62287279|NCT02008825|ACTIVE_COMPARATOR|Usual standard of care|Usual non suction Bougie
62461863|NCT02581748|EXPERIMENTAL|safety|Assessment of safety of HLX02 at different doses
62461864|NCT02581748|ACTIVE_COMPARATOR|PK comparative|Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin®(U.S. and German)
62653418|NCT03931564|ACTIVE_COMPARATOR|Trabeculectomy|The usual care/control group will undergo a standard trabeculectomy.
62653419|NCT00142415|EXPERIMENTAL|Cohort 1, 30 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 30 mCi/m\^2 of 177-Lu.
62653420|NCT00142415|EXPERIMENTAL|Cohort 2, 40 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 40 mCi/m\^2 of 177-Lu.
61919769|NCT00841373|ACTIVE_COMPARATOR|1|Panretinal Photocoagulation
61919770|NCT00841373|ACTIVE_COMPARATOR|2|Ranibizumab Supplementing Panretinal Laser Photocoagulation
61919771|NCT05466448|EXPERIMENTAL|RZL-012 50mg/ml|small synthetic molecule for submental fat reduction
62287280|NCT05850208|NO_INTERVENTION|Routine treatment group|No special measures were taken and routine treatment was adopted
62287281|NCT05850208|EXPERIMENTAL|BMSCs group|BMSCs were transplanted on the basis of routine treatment: the transplanted cells were injected intravenously and transplanted in two times at a dose of 1 × 106/kg body weight, each volume was 80ml ± 5ml, and the time interval between two transplants was 1 week
62287282|NCT01992822|EXPERIMENTAL|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm
62287283|NCT03359135||group1|hEDS treated with rehabilitation only
62287284|NCT03359135||group 2|hEDS treated with rehabilitation associated to compression garments wearing
62287285|NCT01508741|ACTIVE_COMPARATOR|5-Aminolevulinic Acid (5-ALA)|Active component 50 mg. capsules of 5-Aminolevulinic Acid (5-ALA)
62287286|NCT01508741|PLACEBO_COMPARATOR|Placebo capsule|Non-active component capsules
62287287|NCT02257424|OTHER|Phase 1/2|
62287288|NCT01255774|EXPERIMENTAL|Ranibizumab|Open Label use of Ranibizumab for wet age related macular degeneration
62287289|NCT02399306|EXPERIMENTAL|Arm A|chemoradiotherapy with Enteral Nutrition intervention
62287290|NCT02399306|PLACEBO_COMPARATOR|Arm B|chemoradiotherapy
62287291|NCT00768898||2.5 microliters lissamine green|
62287292|NCT00768898||5.0 microliters lissamine green|
62287293|NCT00768898||10.0 microliters lissamine green|
62287294|NCT03777449||Vertical bone loss|Infra-osseous defects
62287295|NCT03777449||Horizontal bone loss|Supra-osseous defects
62287296|NCT03777449||Combined bone loss|Combined supra-osseous and infra-osseous defects
62287297|NCT04828044||Microwave Ablation/ Coagulation Arm|These patients will receive microwave ablation using MedWaves Microwave Ablation/ Coagulation System.
62287298|NCT00369031|EXPERIMENTAL|1|Human Immunodeficiency Virus glycoprotein 140 (vaccine)
62287299|NCT00369031|ACTIVE_COMPARATOR|2|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant
62287300|NCT00369031|ACTIVE_COMPARATOR|3|Labile Toxin mutant LTK63 adjuvant
62461865|NCT01743326|EXPERIMENTAL|RFD-group|Radio Frequency Denervation
62461866|NCT01743326|ACTIVE_COMPARATOR|Local Anesthesia-group|Local Anesthesia-group
62461867|NCT01174134|PLACEBO_COMPARATOR|Milk-based beverage w/out DHA|
62461868|NCT01174134|EXPERIMENTAL|Milk-based beverage with DHA|
62461869|NCT01174134|EXPERIMENTAL|Milk-based beverage containing DHA at a higher level|
62653421|NCT00142415|EXPERIMENTAL|Cohort 3, 50 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 50 mCi/m\^2 of 177-Lu.
62653422|NCT00142415|EXPERIMENTAL|Cohort 4, 60 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 60 mCi/m\^2 of 177-Lu.
62653423|NCT00142415|EXPERIMENTAL|Cohort 5, 70 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 70 mCi/m\^2 of 177-Lu.
62653424|NCT00142415|EXPERIMENTAL|Cohort 6, 65 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 65 mCi/m\^2 of 177-Lu.
62653425|NCT02188160|ACTIVE_COMPARATOR|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
62653426|NCT02188160|PLACEBO_COMPARATOR|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
62653427|NCT04440488|EXPERIMENTAL|ARALAST NP 120 mg/kg|Participants will receive 120 mg/kg BW of ARALAST NP intravenous (IV) infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
62653428|NCT04440488|EXPERIMENTAL|ARALAST NP 60 mg/kg|Participants will receive 60 mg/kg BW of ARALAST NP IV infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
62653429|NCT02745288|EXPERIMENTAL|Nerve block|This arm will receive inferior alveolar nerve block
62653430|NCT02745288|NO_INTERVENTION|control|Control arm will not receive inferior alveolar block
62653431|NCT05338632|EXPERIMENTAL|Intravenous fentanyl year 1|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
62653432|NCT05338632|EXPERIMENTAL|Intravenous sufentanil year 1|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
62653433|NCT05338632|EXPERIMENTAL|Intravenous sufentanil year 2|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
62653434|NCT05338632|EXPERIMENTAL|Intravenous fentanyl year 2|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
62653435|NCT04546646|EXPERIMENTAL|GROUP A (Elastic Band Exercises)|Warm up: for 10 min, Exercise: Lower limb exercises using elastic band for 30 min. Cool down: Self-stretches 5 min.
62653436|NCT04546646|NO_INTERVENTION|GROUP - B (No Intervention)|Routine activities of daily living
62653437|NCT00613795|ACTIVE_COMPARATOR|1|Lactobacillus
62653438|NCT00613795|PLACEBO_COMPARATOR|2|placebo
62653439|NCT03884764|EXPERIMENTAL|PRF on S3 + ganglion impar denervation|patients will receive pulsed radiofrequency on sacral root number 3 in conjunction with ganglion impar denervation by alcohol
62653440|NCT03884764|ACTIVE_COMPARATOR|ganglion impar denervation|patients will receive ganglion impar denervation by alcohol
62653441|NCT03897335|ACTIVE_COMPARATOR|Aminophylline pre CPB & immediately post CPB|
62653442|NCT03897335|PLACEBO_COMPARATOR|Placebo|
62653443|NCT01693952|EXPERIMENTAL|blood samples|
62653444|NCT04151459|EXPERIMENTAL|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy on severe obesity PCOS patients
61919772|NCT06134271|EXPERIMENTAL|Rezvilutamide cohort|Rezvilutamide 240 mg orally once a day. Patients should also receive androgen deprivation therapy, which includes both gonadotropin releasing hormone analogue (GnRHa) castration treatment or bilateral orchiectomy.
62120153|NCT01168154|ACTIVE_COMPARATOR|Lactobacillus Reuterii|
62653445|NCT05545501|PLACEBO_COMPARATOR|No Salt, No β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
62653446|NCT05545501|ACTIVE_COMPARATOR|High Salt, No β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
62653447|NCT05545501|EXPERIMENTAL|High Salt, High β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
62653448|NCT02209064|OTHER|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
62088529|NCT01720017|ACTIVE_COMPARATOR|Inservice Training Only|Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
62120154|NCT01168154|PLACEBO_COMPARATOR|Placebo|
62120155|NCT05919446|EXPERIMENTAL|Older people with ACT intervention|4 week ACT plus back exercise group
62120156|NCT05919446|OTHER|Older people without ACT intervention|4-week back exercise control group
62287301|NCT05087615|NO_INTERVENTION|Control|Patients who did not receive any antiemetic during hospitalization (NA).
62287302|NCT05087615|EXPERIMENTAL|MA|Patients receiving metoclopramide alone (MA).
62120157|NCT01282346|EXPERIMENTAL|SOLX Gold Shunt|
62120158|NCT00839241|EXPERIMENTAL|Autologous Blood Transfusion|
62120159|NCT00839241|ACTIVE_COMPARATOR|Allogenic Blood Transfusion|
62120160|NCT04779892|EXPERIMENTAL|CMAB008|
62120161|NCT04779892|ACTIVE_COMPARATOR|Remicade|
62461870|NCT06403930|ACTIVE_COMPARATOR|Group I|PMMA bulbs on metal frameworks
62088530|NCT01720017|EXPERIMENTAL|Inservice and Manikin Training|Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.
62088531|NCT04422821|EXPERIMENTAL|FreeStyle Libre™|FreeStyle Libre™ will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will receive subcutaneous sensor for glucose monitoring (FreeStyle Libre™; Abbott Diabetes Care, Alameda, CA) for 4 weeks.
62088532|NCT04422821|ACTIVE_COMPARATOR|iXell®|iXell® will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will monitor glycemia through use of standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) for 4 weeks.
62088533|NCT06581640|EXPERIMENTAL|CAR-T|
62088534|NCT05353569|EXPERIMENTAL|Children's Wisconsin Urgent Care Clinics|Subjects will receive a standard-of-care otoscopy examination, followed by a research-only examination using an OCT device (PCT).
62088535|NCT05353569|NO_INTERVENTION|Children's Wisconsin (Effusion in 0 or 1 ear)|Subjects will only receive a standard-of-care otoscopy examination.
62088536|NCT05353569|EXPERIMENTAL|Children's Wisconsin (Effusion in 2 ears)|Subjects will receive standard-of-care ear and hearing examinations (otoscopy and audiometry/tympanometry), followed by research-only examinations using two OCT devices (UIUC OCT and PCT).
62088537|NCT05926661|OTHER|Parent/Caregiver of high-risk children with heart disease|"The parent/caregivers of high-risk children with heart disease coming to the Nemours Cardiac Center for care will be offered a support tool and will be asked for it's acceptance and feasibility through their experience."
62088538|NCT02078310|EXPERIMENTAL|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
62088539|NCT02078310|PLACEBO_COMPARATOR|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
62287303|NCT05087615|EXPERIMENTAL|OA|Patients who received ondansetron only (OA).
62287304|NCT05087615|EXPERIMENTAL|MO|Patients receiving a combination of metoclopramide and ondansetron (MO).
62287305|NCT05087615|EXPERIMENTAL|GA|Patients who received granisetron alone (GA).
62461871|NCT06403930|EXPERIMENTAL|Group II|Injection-molded PMMA obturators.
62461872|NCT02992093||obese with PCOS|all the indicators
62461873|NCT02992093||nonobese with PCOS|all the indicators
62461874|NCT02992093||PCOS with IGT|all the indicators
62653449|NCT04663113|OTHER|Control group|Standard physiotherapy (1st Group): It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
62287306|NCT05422131||Patients Prescribed Clozapine|
62287307|NCT01183273|ACTIVE_COMPARATOR|Micro-laparoscopic bypass|
62461875|NCT02992093||PCOS with T2DM|all the indicators
62461876|NCT02992093||Healthy volunteers|all the indicators
62461877|NCT05956678|EXPERIMENTAL|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
62461878|NCT05956678|EXPERIMENTAL|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions and is comprised of 4 cross-cutting interventions featured in every session, 5 modules that apply to the vast majority of patients, and 1 optional module used less commonly, depending on the presentation.
62461879|NCT04019678|EXPERIMENTAL|Group 1: experimental|patients with micro metastatic sentinel lymph node and/or parasentinella lymph node (ypN1mi). Axillary dissection is not performed.
62088540|NCT02078310|EXPERIMENTAL|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
62653450|NCT04663113|EXPERIMENTAL|Aerobic Exercises group|Aerobic exercise will be given with bicycle ergometer in addition to Standard physiotherapy (It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises)
62653451|NCT04663113|EXPERIMENTAL|the group in which the exercise protocol to be developed was applied|Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.
62653452|NCT04168957|EXPERIMENTAL|Oraxol|Subjects in KX-ORAX-008 will begin treatment at the last oral paclitaxel dose they received in Study KX-ORAX-007.
62653453|NCT03777241|ACTIVE_COMPARATOR|Behavioral Intervention Team|The participants in this arm will receive the Behavioral Intervention Team.
62653454|NCT03777241|ACTIVE_COMPARATOR|Standard of Care|The participants in this arm will receive the standard of care.
62653455|NCT01632319|EXPERIMENTAL|MI + CBT|Motivational Interviewing (MI) and cognitive behavioral therapy (CBT). In this course of therapy students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms.
62653456|NCT01632319|ACTIVE_COMPARATOR|CBT|Cognitive behavior therapy (CBT)
62653457|NCT06082739|EXPERIMENTAL|Exercise group|Patients perform stretching exercises daily.
62653458|NCT05107115|EXPERIMENTAL|Rilzabrutinib dose A|dose A
62088541|NCT02078310|PLACEBO_COMPARATOR|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
62088542|NCT04545619|EXPERIMENTAL|Paroxysmal and Early Persistent AFIB|
62088543|NCT00147979|EXPERIMENTAL|1|PTFE with bounded heparin
62088544|NCT00147979|ACTIVE_COMPARATOR|2|PTFE without bounded heparin
62287308|NCT01183273|ACTIVE_COMPARATOR|Laparoscopic gastric bypass|
62653459|NCT05107115|EXPERIMENTAL|Rilzabrutinib dose B|dose B
62653460|NCT05107115|EXPERIMENTAL|Rilzabrutinib dose C|dose C
62653461|NCT05107115|PLACEBO_COMPARATOR|Placebo|Matching placebo
62653462|NCT04636723||HNC Patients w/ CSS|HNC survivor patients presenting high chronic systemic symptoms
62653463|NCT04636723||Healthy Controls|Non-clinical controls
62653464|NCT04636723||HNC Patients wo/ CSS|Patient Control - HNC survivor patients presenting no/low chronic systemic symptoms
62653465|NCT00851149||1/10|Abdominal aortic surgery patients
62088545|NCT02166086||Endoscopic imaging|Any patient who has undergone advanced imaging procedures for diagnosis and/or treatment of a pancreatico-biliary disorder.
62287309|NCT04810702||patients with von Willebrand disease|
62287310|NCT04810702||case control|
62287311|NCT04217265|EXPERIMENTAL|study group|2 tablets of Letrozole 2.5 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
62653466|NCT00851149||2/10|Total hip replacement patients
62653467|NCT05085145|EXPERIMENTAL|Coronavirus vaccination|Patients in the experimental need to accept the coronavirus vaccination
62653468|NCT03327974|OTHER|depressed patients|"All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits.~All patients are depressed patients."
62653469|NCT06157476|EXPERIMENTAL|SSC-Ex group|Children in this group received the SSC-Ex program
62653470|NCT06157476|ACTIVE_COMPARATOR|Control group|Children in this group received the standard exercise program.
62653471|NCT06060470|EXPERIMENTAL|Virtual reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 10 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The first six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song. The first 6 weeks are conducted in the laboratory. The next four weeks are conducted in the participants home via telerehabilitation. The four week sessions consisted of 3 sessions/week."
62653472|NCT06060470|ACTIVE_COMPARATOR|Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
62088546|NCT03729206|EXPERIMENTAL|Sublingual microscopy|
62088547|NCT02055911|EXPERIMENTAL|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
62088548|NCT04967248||alpelisib in combination with fulvestrant|Patients treated with alpelisib in combination with fulvestrant
62287312|NCT04217265|PLACEBO_COMPARATOR|control group|2 tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum three doses
62653473|NCT02856958|EXPERIMENTAL|Operative|Peroneal nerve decompression
62653474|NCT02856958|ACTIVE_COMPARATOR|Non-operative|Physical therapy
62653475|NCT01107210||stroke patients|50 patients recruited in the stroke rehabilitation unit in the University Hospital, Leuven, Belgium will be included
62653476|NCT05502029|ACTIVE_COMPARATOR|Control|Translator in preoperative area
62653477|NCT05502029|EXPERIMENTAL|Intervention|Translator in preoperative area, continued through transport to the operating room, and in the operating room until the patient is under general anesthesia
62088549|NCT01062984|ACTIVE_COMPARATOR|Continuous Venovenous Hemofiltration|
62653478|NCT03885063|EXPERIMENTAL|Benjamin Rose Institute Care Consultation (BRI-CC)|
62653479|NCT03885063|NO_INTERVENTION|No intervention|
62653480|NCT01635088|OTHER|Mometasone furoate 220 vs. Mometasone furoate 440|
62653481|NCT01635088|ACTIVE_COMPARATOR|Mometasone 220 mcg vs. 440 mcg|Inhaled steroid
62653482|NCT06140134||Intrahepatic cholangiocarcinoma listed for liver transplant|Listed patients enrolled with diagnosis of intrahepatic cholangiocarcinoma will be enrolled on an intent to treat basis with comparison between patients receiving transplant versus those who expire or are removed from the waitlist.
62653483|NCT04019639|EXPERIMENTAL|CG Paste+EasyFoam|"The subjects assigned to the test group through random assignment will receive the wound treatment by applying CG Paste and EasyFoam. CG Paste is a medical device currently marketed in CGBio.It is a free-flowing, acellular allogeneic dermis processed from human tissue skin, and then granulated and homogenized. This increases the water content and viscosity of the micronized ADM particles mixed with the gelatin sol carrier to protect the wound area and maintain the wet environment by applying to the desired wound area.It contains collagen, elastin and various growth factors in the dermis and has excellent tissue compatibility compared to the heterogeneous or synthetic material, so that the immune rejection is hardly observed in the graft site.~It also contains collagen, elastin, fibronectin, laminin, and proteoglycans, which are components of the human skin, to help the interaction between normal cells and extracellular matrix."
62653484|NCT04019639|ACTIVE_COMPARATOR|EasyFoam|"Subjects randomly assigned to the control group receive EasyFoam treatment for wound healing.~The foam has excellent moisture permeability, absorbs a large amount of exudates, and prevents scar formation to minimize scar formation."
62653485|NCT05767385|EXPERIMENTAL|Single Arm|Maternal Hyperoxia (MH) will be administered to pregnant patients after their standard of care fetal echocardiogram has been performed at their scheduled fetal cardiology visit at ³28 weeks gestation. The evaluation at ³28 weeks was chosen since gestational age impacts both the cardiovascular and cerebrovascular response to MH.31 The evaluation will extend the duration of the visit by approximately 30 minutes but additional evaluations or visits for the study will not be required.
62088550|NCT01062984|ACTIVE_COMPARATOR|Continuous Venovenouos Hemodialysis|
62653486|NCT01353534|EXPERIMENTAL|Group 1|3.8 mcg with AS03 adjuvant at D0 and 21
62287313|NCT01187992|EXPERIMENTAL|Full-dose atorovastatin (80 mg/d)|For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
62287314|NCT01187992|NO_INTERVENTION|Conventional medical treatment|For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels \<100 mg/dL (2.5 mmol/L).
62088551|NCT06268353|EXPERIMENTAL|pregnancy|Non-pregnant and pregnant women are compared
62088552|NCT04266743|EXPERIMENTAL|Hemiparetic patient|patients who had a stroke at least 6 months before inclusion
62287315|NCT03482869|EXPERIMENTAL|Diabetic patients|Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images
62653487|NCT01353534|EXPERIMENTAL|Group 2|15 mcg at D0 and 21
62653488|NCT01353534|EXPERIMENTAL|Group 3|15 mcg + 50 mcg VEP at D0 and 21
62653489|NCT01353534|EXPERIMENTAL|Group 4|30 mcg + 50 mcg VEP at D0
62088553|NCT02184897|ACTIVE_COMPARATOR|AM group|Lenograstim is administered at 8 am and apheresis is started at 10 am on D4.
62088554|NCT02184897|EXPERIMENTAL|PM group|Lenograstim is administered at 6 pm and apheresis is started at 8 am on D5
62653490|NCT05901220|EXPERIMENTAL|Students of a school in the Campania region|
62653491|NCT01799941|OTHER|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
62088555|NCT02821390|ACTIVE_COMPARATOR|Nepafenac 0.1% Eye Drops|One drop of Nepafenac 0.1% Eye Drops will be instilled to the eye's cul de sac prior to the intravitreal injection.
62653492|NCT05998967|EXPERIMENTAL|Self-directed MRP|Self-directed instruction in MRP via Internet
62653493|NCT05998967|ACTIVE_COMPARATOR|Supported MRP|Supported instruction in MRP via Internet
62653494|NCT03163732|OTHER|Large molecular profiling panel|This panel is FOne Panel with a 324 cancer-related gene.
62653495|NCT03163732|OTHER|Limited molecular profiling panel|This panel is CONTROL Panel with a 87 cancer-related gene.
62653496|NCT03299985|EXPERIMENTAL|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
62653497|NCT03299985|SHAM_COMPARATOR|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
62653498|NCT01292902|ACTIVE_COMPARATOR|healthy volunteers|
62653499|NCT01292902|OTHER|chronic heart failure|
62653500|NCT05397418|EXPERIMENTAL|Intervention group|Supervised exercise program week 1-12, unsupervised exercise week 13-24.
62653501|NCT05397418|SHAM_COMPARATOR|Control group|Maintain habitual activity week 1-12, unsupervised exercise week 13-24.
62653502|NCT04523376|EXPERIMENTAL|Sickle Cell Disease|Patients with Sickle Cell Disease (SCD) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
62653503|NCT04523376|EXPERIMENTAL|Beta Thalassemias Major|Patients with Beta Thalassemias Major (BTM) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
62088556|NCT02821390|PLACEBO_COMPARATOR|Artificial Tears|One drop of Artificial Tears will be instilled to the eye's cul de sac prior to the intravitreal injection.
62287316|NCT04140214|EXPERIMENTAL|Standard Care and HTS|Standard care and twice-daily nebulised HTS (MucoClear 6%, PARI Pharma). Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser and eTrack controller (PARI Pharma).
62653504|NCT04969289|EXPERIMENTAL|Dr. Eric Digital Health Intervention|"Participants will interact with an ED-based iPad and the Dr. Eric app for a recorded period of time. After completion, an animated video will explain the ERIC texting program and live office hours. The participant enters his phone number and then receives a welcome text. Weekly texts are sent directly to the participant phone via short message service (SMS)."
62653505|NCT04969289|NO_INTERVENTION|Standard of Care|Participants randomized to the SC arm will receive standard medical care as determined by the ED provider, which is typically referral to a primary care or adolescent provider. Mobile telephone numbers will be collected for follow up purposes.
62653506|NCT01493622|PLACEBO_COMPARATOR|placebo|Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
62653507|NCT01493622|ACTIVE_COMPARATOR|minocycline|Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
62678898|NCT06686732|EXPERIMENTAL|Multimodal group|Experimental group included cold pack over lateral epicondyle, Passive stretching exercises in cervical spine and upper limb. Eccentric exercise of the extensor muscles associated with mobilization with movement.Neuromusclar Rehabilitation Excersise. Inhibition of points of tension in the belly of the extensor region. Early mobilization with movement with the wrist in extension. Lateral sustained glide.
62088557|NCT06129825||Healthy Adult Volunteers|Healthy Adults Volunteers \>/= 18yrs of age without acute or chronic illness.
62088558|NCT05149079|PLACEBO_COMPARATOR|Placebo (whey protein supplement)|Participants will consume 18 g of the placebo whey protein supplement each day for 12 weeks.
61904728|NCT06329193|EXPERIMENTAL|Training Group|The 3-week mid-season camp period loading at sea level, including daily gym and field-based exercise interventions, five days a week, will be applied to the participants in the sports club's gym and soccer field.
61919773|NCT06134271|EXPERIMENTAL|Rezvilutamide plus abiraterone cohort|Rezvilutamide 240 mg orally once a day. Simultaneously, take orally 1000 mg of Abiraterone tablets and 5 mg of prednisone once a day. Patients should also receive androgen deprivation therapy simultaneously, that is, they should also receive gonadotropin releasing hormone analogue (GnRHa) castration treatment or have undergone bilateral orchiectomy.
62088559|NCT05149079|ACTIVE_COMPARATOR|Cod protein hydrolysate supplement|Participants will consume 18 g of the cod protein supplement each day for 12 weeks.
62088560|NCT02092987|EXPERIMENTAL|NYU Caregiver Intervention|The New York University (NYU) caregiver intervention arm received the NYU caregiver intervention in addition to social work support and educational materials.
62653508|NCT05096715|EXPERIMENTAL|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Study will begin with a safety lead of 6 participants to determine the maximum tolerated dose (MTD) of Stereotactic beam radiation therapy (SBRT) with atezolizumab and bevacizumab followed by study expansion to 14 more participants after maximum tolerated dose (MTD) is established.~Safety Lead-In: 6 cycles/18 weeks (study cycle is 3 weeks/21 days)~* Cycle 1: Atezolizumab + Bevacizumab (1x) with Stereotactic beam radiation therapy (SBRT) every 1-3 days~* Cycles 2-6: Atezolizumab + Bevacizumab (1x) every 3 weeks~Expanded Study:~* Cycle 1: Atezolizumab + Bevacizumab (1x) with Stereotactic beam radiation therapy (SBRT) every 1-3 days~* Cycles 2-End:Atezolizumab + Bevacizumab (1x) every cycle"
62653509|NCT04393727|EXPERIMENTAL|Intervention|Patients in the intervention group will receive 200 cc of convalescent plasma
62653510|NCT04393727|NO_INTERVENTION|Control|Patients will continue to receive standard therapy
62653511|NCT00900562|EXPERIMENTAL|Arm 1|Zalypsis (PM00104)
62653512|NCT05812404|EXPERIMENTAL|Cohort 1|"* Treatment A: DWC202201 40 mg qd for 7 days~* Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days~* Treatment C: DWP14012 40 mg qd for 14 days"
61919774|NCT06134271|EXPERIMENTAL|Continue previous treatment cohort|Continue using the previous treatment regimen for treatment.
62088561|NCT02092987|ACTIVE_COMPARATOR|REACH OUT|The Resources for Enhancing Caregiver Health Offering Useful Treatments (REACH OUT) intervention arm received the REACH OUT caregiver intervention in addition to social work support and educational materials.
62088562|NCT02414828|PLACEBO_COMPARATOR|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
62088563|NCT02414828|EXPERIMENTAL|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10\^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
62287317|NCT04140214|EXPERIMENTAL|Standard Care and Carbocisteine|Standard care and carbocisteine (750 mg three-times-per-day until visit 3, reducing to 750 mg two times per day) over 52 weeks.
62653513|NCT05812404|EXPERIMENTAL|Cohort 2|"* Treatment C: DWP14012 40 mg qd for 14 days~* Treatment A: DWC202201 40 mg qd for 7 days~* Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days"
62088564|NCT02414828|EXPERIMENTAL|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10\^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
62088565|NCT02414828|EXPERIMENTAL|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10\^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
62307913|NCT03285529|PLACEBO_COMPARATOR|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
62088566|NCT01244009|EXPERIMENTAL|MK-4827|All Participants
62088567|NCT03002987|ACTIVE_COMPARATOR|Intervention, education|Education of leaders (3 hours) in how to implement Active Pregnancy policy at their departements/workplaces
62653514|NCT05812404|EXPERIMENTAL|Cohort 3|"* Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days~* Treatment C: DWP14012 40 mg qd for 14 days~* Treatment A: DWC202201 40 mg qd for 7 days"
62088568|NCT03002987|NO_INTERVENTION|control|as usual
62653515|NCT03625128|EXPERIMENTAL|F-18 PMPBB3|F-18 PMPBB3 imaging
62653516|NCT01793506||PID|Any subject having testing done to evaluate the immune system is eligible for this study. This will include patients with known PIDs as well as patients evaluated for a suspected immunodeficiency.
62653517|NCT04704050|ACTIVE_COMPARATOR|Treatment Group|Dronedarone 400 mg orally, twice per day (BID)
62653518|NCT04704050|PLACEBO_COMPARATOR|Control Group|Placebo tablet orally, twice per day (BID)
62653519|NCT04753515|ACTIVE_COMPARATOR|Group DMR|dexmedetomidine combined with midazolam and remifentanil.
62653520|NCT04753515|ACTIVE_COMPARATOR|Group PMR|propofol combined with midazolam and remifentanil.
62653521|NCT00515996||2|paroxetine treatment group vs. normal control group
62653522|NCT05778565|EXPERIMENTAL|Extraocular muscle stretching arm|
62088569|NCT03230487|EXPERIMENTAL|BI 1015550|
62307914|NCT03679494|EXPERIMENTAL|SDM intervention group|Using shared decision making support tool for intervention
62653523|NCT03962829|PLACEBO_COMPARATOR|Placebo condition|Participants receive placebo capsule
62461880|NCT04019678|ACTIVE_COMPARATOR|Group 2: standard|patients with negative sentinel lymph node (ypN0) or with ITC finding (ypN0 / YpN0 (i +)). Axillary dissection is not performed as standard treatment.
62461881|NCT02272777|ACTIVE_COMPARATOR|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.
61904731|NCT02659774|EXPERIMENTAL|Group A|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
61904732|NCT02659774|PLACEBO_COMPARATOR|Group B|Face to Face counseling (Motivational intervention) + Booklet + SMS
61904733|NCT02659774|PLACEBO_COMPARATOR|Group C|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
61904734|NCT02659774|PLACEBO_COMPARATOR|Group D|Phone counseling (Motivational intervention) + booklet + SMS
62088570|NCT03230487|PLACEBO_COMPARATOR|Placebo|
62307915|NCT03679494|NO_INTERVENTION|Usual care group|No intervention, just continue using usual care
62461882|NCT02272777|EXPERIMENTAL|Nilotinib|Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.
62461883|NCT02342054|EXPERIMENTAL|MRI-TRUS fusion guided Single Frac HDR|Patients treated with a Single Fraction Real-Time High-Dose-Rate (HDR 19Gy)
61904735|NCT00970385|ACTIVE_COMPARATOR|CHOP 21|"Induction therapy CHOP every 21 days:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5."
61919775|NCT05363943|ACTIVE_COMPARATOR|Fixation|open reduction and internal fixation by using lateral and medial plates.
62088571|NCT02817490||Patients with hypermobility type Ehlers-Danlos Syndrome|Patients with hypermobility type Ehlers-Danlos Syndrome participating to one out of the three patient education sessions included in the study.
62088572|NCT02817490||Caregivers|Caregivers participating to one out of the three patient education sessions included in the study.
62088573|NCT04222647|EXPERIMENTAL|WO533|Formulation containing WO533 for intravaginal application
62287318|NCT04140214|EXPERIMENTAL|Standard Care and Combination of HTS and Carbocisteine|Standard care and combination of twice-daily nebulised HTS (MucoClear 6%, PARI Pharma) and carbocisteine. Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser eFlow rapid nebuliser and eTrack controller (PARI Pharma). They will also be given carbocisteine (750 mg of three times per day until visit 3, reducing to 750 mg twice per day) over 52 weeks.
62461884|NCT03900624|NO_INTERVENTION|Methylprednisolone Arm|Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
62461885|NCT03900624|EXPERIMENTAL|Dexamethasone Arm|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
62461886|NCT05452447|EXPERIMENTAL|Spatial Repellent|Transfluthrin
62461887|NCT05452447|PLACEBO_COMPARATOR|Placebo|Inert ingredients
62461888|NCT01190293|EXPERIMENTAL|All subjects|All Subjects will receive the same intervention.
62461889|NCT01821144|OTHER|Control|No salt awareness education
62461890|NCT01821144|EXPERIMENTAL|Salt reduction|Salt reduction
61919776|NCT05363943|EXPERIMENTAL|Replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
62461891|NCT02011204||People with ALS|"People diagnosed with early ALS (possible, probable, probable-laboratory supported or definite ALS according to El Escorial criteria)~Intervention: Electrical Impedance Myography (EIM)."
62461892|NCT02011204||Other Neurological Diseases|People with a diagnosis of a disease that mimics ALS
62461893|NCT02011204||Healthy Controls|Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.
62461894|NCT00320112|EXPERIMENTAL|Reciprocal Diabetes Peer Support program|peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
62461895|NCT00320112|OTHER|Nurse Case Management|patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.
62461896|NCT06011122||Zimmer Biomet|Patients who were operated with a Zimmer Biomet plate
62461897|NCT06011122||Newclip Technics|Patients who were operated with a Newclip Technics plate
62461898|NCT06011122||Stryker|Patients who were operated with a Stryker plate
62461899|NCT06011122||Medartis|Patients who were operated with a Medartis plate
62461900|NCT06011122||Medartis Footprint|Patients who were operated with a Medartis Footprint plate
62653524|NCT03962829|ACTIVE_COMPARATOR|mCPP condition|Participants receive active (mCPP) capsule
62653525|NCT00695019|EXPERIMENTAL|500 IU qd|500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day
61904736|NCT00970385|EXPERIMENTAL|VIP/ABVD arm|"VIP cycle:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD cycle:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD)."
62287319|NCT04140214|NO_INTERVENTION|Standard Care Only|Standard care over 52 weeks. Patients in the standard care group will use airway clearance techniques in the management of their BE.
61904738|NCT03923244|EXPERIMENTAL|cohorte 1|"Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
62088574|NCT04032457|ACTIVE_COMPARATOR|A1 - SiHyDD to Moist|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
62287320|NCT01736904|ACTIVE_COMPARATOR|FOLFIRI|FOLFIRI regimen
61904741|NCT04135170|EXPERIMENTAL|Plain bone cement|
62287321|NCT01736904|EXPERIMENTAL|wXELIRI regimen|wXELIRI
62287322|NCT03497845|EXPERIMENTAL|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
62287323|NCT03497845|EXPERIMENTAL|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
62287324|NCT03497845|EXPERIMENTAL|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
62287325|NCT03497845|EXPERIMENTAL|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
62287326|NCT03497845|EXPERIMENTAL|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
62287327|NCT03497845|EXPERIMENTAL|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
62287328|NCT03497845|EXPERIMENTAL|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
62461901|NCT06011122||Synthes|Patients who were operated with a Synthes plate
62461902|NCT05047003||Patients under evaluation for Suspected Concussion|Device: EyeBOX Model EBX-4 (Portable version)
62461903|NCT04250662|EXPERIMENTAL|Active tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
62653526|NCT00695019|EXPERIMENTAL|500 IU tid|500 IU interferon-alpha lozenge taken 3 times per day
62287329|NCT03497845|EXPERIMENTAL|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
62287330|NCT03497845|EXPERIMENTAL|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
62287331|NCT03497845|EXPERIMENTAL|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
62461904|NCT04250662|EXPERIMENTAL|Active tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes while remaining seated, no guided imagery will be provided.
62653527|NCT00695019|PLACEBO_COMPARATOR|placebo|placebo lozenges taken 3 times per day
62653528|NCT03451045|EXPERIMENTAL|Lenabasum 20 mg BID|
62653529|NCT03451045|EXPERIMENTAL|Lenabasum 5 mg BID|
62653530|NCT03451045|PLACEBO_COMPARATOR|Placebo BID|
62653531|NCT03371550|EXPERIMENTAL|Radiochemotherapy|Induction chemotherapy with docetaxel and cisplatine and concomitant radiotherapy
61904742|NCT04135170|ACTIVE_COMPARATOR|Antibiotic loaded bone cement|
62088575|NCT04032457|ACTIVE_COMPARATOR|A2 - Moist to SiHyDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
62088576|NCT04032457|ACTIVE_COMPARATOR|A3 - SiHyDD to OASDD|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of ACUVUE® OASYS 1-Day contact lenses.
62287332|NCT03497845|EXPERIMENTAL|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
61904743|NCT01905787||Group 2 - Dana group|50 patients will be included in the study.
62088577|NCT04032457|ACTIVE_COMPARATOR|A4 - OASDD to SiHyDD|1 week of ACUVUE® OASYS 1-Day contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
62088578|NCT04032457|ACTIVE_COMPARATOR|A5 - SiHyDD to DT1|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of Alcon DAILIES TOTAL 1® contact lenses.
62088579|NCT04032457|ACTIVE_COMPARATOR|A6 - DT1 to SiHyDD|1 week of Alcon DAILIES TOTAL 1® contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
62088580|NCT04032457|ACTIVE_COMPARATOR|B1 - HydDD to Moist|1 week of Test HydDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
62088581|NCT04032457|ACTIVE_COMPARATOR|B2 - Moist to HydDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
62088582|NCT04032457|ACTIVE_COMPARATOR|B3 - HydDD to BioTrue|1 week of Test HydDD contact lenses followed by cross over to 1 week of BIOTRUE ONEday® contact lenses.
62461905|NCT04250662|SHAM_COMPARATOR|Sham tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
62653532|NCT00706563|EXPERIMENTAL|Fluarix Adult Group|Subjects who are 18-40 years of age received one dose of Fluarix™.
62653533|NCT00706563|EXPERIMENTAL|Fluarix Elderly Group|Subjects who are ≥ 60 years of age received one dose of Fluarix™.
62088583|NCT04032457|ACTIVE_COMPARATOR|B4 - BioTrue to HydDD|1 week of BIOTRUE ONEday® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
62088584|NCT04032457|ACTIVE_COMPARATOR|B5 - HydDD to AqCom+|1 week of Test HydDD contact lenses followed by cross over to 1 week of DAILIES® AquaComfort PLUS® contact lenses.
62088585|NCT04032457|ACTIVE_COMPARATOR|B6 - AqCom+ to HydDD|1 week of DAILIES® AquaComfort PLUS® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
62088586|NCT05552053|ACTIVE_COMPARATOR|Maternal Wellness Self Help (MWSH) Application|The Maternal Wellness Self Help (MWSH) app was created to help individuals to identify and manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
62088587|NCT05552053|EXPERIMENTAL|MWSH plus Candlelit Care|Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.
62088588|NCT05352529|EXPERIMENTAL|Experimental condition|This condition implemented the assistive technology in question: the MapHabit System (MHS). The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application was made available to families through compatible tablets.
62287333|NCT03497845|EXPERIMENTAL|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
62287334|NCT05459532|EXPERIMENTAL|Monulpiravir|Eligible participants will be randomised in a 1:1 manner to receive either molnupiravir 800 mg orally approximately 12-hourly for five days or a placebo for the equivalent amount of time.
62653534|NCT03578042|ACTIVE_COMPARATOR|LosanetAMplus|Patients taking the fixed triple combination
62653535|NCT03578042|OTHER|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
62653536|NCT05408364|PLACEBO_COMPARATOR|Natural yoghurt|SRP+nature yogurt (Danone® yogurt, Luleburgaz, Türkiye)
62653537|NCT05408364|EXPERIMENTAL|Probiotic yoghurt|SRP+probiotic containing yogurt (Danone Activia® Plain, Luleburgaz, Türkiye)
62653538|NCT05518721|ACTIVE_COMPARATOR|Synthetic Cartilage Implant|
62653539|NCT05518721|ACTIVE_COMPARATOR|Dermal Interposition Arthroplasty|
62461906|NCT04250662|SHAM_COMPARATOR|Sham tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject will remain seated, no guided imagery will be provided.
61904744|NCT01905787||Group 3 - Schneider group|50 patients will be included in the study
61904745|NCT01905787||Group 4 - Detroit group|100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
61904746|NCT01905787||Group 1 - Emek group|100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).
61904747|NCT02886208|EXPERIMENTAL|Intervention|This study has a single arm. All participants in a summer employment program at an urban farm in Indianapolis, IN are invited to participate.
61904749|NCT04242667|EXPERIMENTAL|Actionable gene result for cancer risk|
61904750|NCT04242667|EXPERIMENTAL|Actionable gene result for cardiovascular disease risk|
61904751|NCT01128621|OTHER|Part A|Part A is open label, in T2DM subjects on established metformin monotherapy. Subjects will receive a single dose of GSK1292263 with food. This will permit a comparison of GSK1292263 exposures in this cohort with those observed in study GPR111598 in which T2DM subjects were drug naïve or washed off prior anti-diabetic medications.
62088589|NCT05352529|ACTIVE_COMPARATOR|Control condition|The control condition acted as the active comparator to the experimental condition. This condition implemented educational videos focused on Alzheimer's disease, dementia care, and caregiver support. The videos were made available to caregivers through compatible tablets.
62088590|NCT00376480|EXPERIMENTAL|administration of adoptive donor lymphocyte infusion|administration of donor lymphocytes made using costimulatory blockade ex vivo
62287335|NCT05459532|PLACEBO_COMPARATOR|Placebo|Eligible participants will be randomised in a 1:1 manner to receive either molnupiravir 800 mg orally approximately 12-hourly for five days or a placebo for the equivalent amount of time.
62461907|NCT03444116||Cases (+FDO)|Patients who underwent an FDO
62461908|NCT03444116||Controls (-FDO)|Same as cases but did not undergo an FDO
62461909|NCT02109042|EXPERIMENTAL|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
62461910|NCT02127281|ACTIVE_COMPARATOR|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
62461911|NCT02127281|NO_INTERVENTION|Control|A standard of care sterile wound dressing will be placed.
62461912|NCT03272022||women|never-pregnant women
62461913|NCT03272022||pregnant women|pregnant
62461914|NCT05867576|ACTIVE_COMPARATOR|Allocated to treatment|Patients randomly allocated to this arm will receive treatment immediately. They will receive 6-12 sessions of ACT while patients allocated to the waitlist control arm do no receive any treatment.
62461915|NCT05867576|NO_INTERVENTION|Allocated to waitlist control|Patients randomly allocated to this arm will receive a delay in the treatment they receive. After a 12-week wait they will receive 6-12 sessions of ACT, while patients allocated to the immediate treatment arm receive no treatment for an equal duration.
62461916|NCT01889836|EXPERIMENTAL|MenCC-Bio|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
62461917|NCT01889836|ACTIVE_COMPARATOR|MENJUGATE®|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE®.
62461918|NCT04062890|ACTIVE_COMPARATOR|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 1-7), 1000 mg twice daily for 7 days (days 8-14), 1500 mg twice daily for 10 days (days 15-24), 1000 mg twice daily for 7 days (days 25-31), 500 mg twice daily for 7 days (days 32-38).
62461919|NCT04062890|PLACEBO_COMPARATOR|Placebo|Placebo - Pill, 1 pill twice daily for 7 days (days 1-7), 2 pills twice daily for 7 days (days 8-14), 3 pills twice daily for 10 days (days 15-24), 2 pills twice daily for 7 days (days 25-31), 1 pill twice daily for 7 days (days 32-38).
62461920|NCT02491346|ACTIVE_COMPARATOR|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
62461921|NCT02491346|EXPERIMENTAL|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
62088591|NCT06345209|EXPERIMENTAL|Test Group|Sirolimus-coated Coronary Balloon Dilatation Catheter
62287336|NCT00877292||Down syndrome|Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.
62461922|NCT02865564|ACTIVE_COMPARATOR|Intervention group|The intervention group will receive 5 drops, a minimum of 100 million live Lactobacillus reuteri DSM 17938 a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
62461923|NCT02865564|PLACEBO_COMPARATOR|Placebo group|Placebo group will receive 5 drops of maltodextrin in the some oil suspension a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
62088592|NCT06345209|ACTIVE_COMPARATOR|Control Group|Drug Eluting Balloon Catheter
62088593|NCT00333138|EXPERIMENTAL|Fingolimod (FTY720) 1.25 mg/day|Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
62287337|NCT04625777|NO_INTERVENTION|Waitlist control|In this waitlist control condition, participants will not receive any programming intervention. They will know that they have access to stress reduction programming after a certain date. They will also provide survey data at 3 time points and heart rate variability data at 2 time points while waiting. The survey questions will include a wide variety of stress items.
62287338|NCT04625777|EXPERIMENTAL|One of three stress reduction interventions|There are three stress reduction interventions: Mindfulness Based Stress Reduction, Daily Examen, and stress inoculation.
62461924|NCT01311804|EXPERIMENTAL|periarticular parecoxib sodium|patients will be given periarticular parecoxib sodium injection
62088594|NCT00333138|PLACEBO_COMPARATOR|Placebo/Fingolimod (FTY720)|Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
62287339|NCT05503355|EXPERIMENTAL|Treatment|BSR-236 + venetoclax
62461925|NCT01311804|ACTIVE_COMPARATOR|intravenous parecoxib sodium|intravenous parecoxib sodium will be given during total knee arthroplasty
62461926|NCT01504698|EXPERIMENTAL|Treatment with manipulation|
62461927|NCT01504698|ACTIVE_COMPARATOR|Treatment without manipulation|
62461928|NCT05369247|EXPERIMENTAL|1st Exercise session|Participants completed either the HIIT or MICT session.
62461929|NCT05369247|EXPERIMENTAL|2nd Exercise session|Participants completed the subsequent exercise protocol (i.e. HIIT or MICT)
62461930|NCT01330498||Tysabri (natalizumab) infusing|Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).
62461931|NCT02552342|ACTIVE_COMPARATOR|methylprednisolone|This group was entitled to receive methylprednisolone 80mg/day for 3 days，then 40mg/day for 3 days
62653540|NCT04941989|EXPERIMENTAL|Part 1 Single Ascending Dose|Eight subjects in up to 7 cohorts will be dosed. One or more subcutaneous injections of HTL0022562 will be administered. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
62287340|NCT02680353|ACTIVE_COMPARATOR|Study group|Patients received bilateral superficial cervical plexus block before operation
62461932|NCT02552342|PLACEBO_COMPARATOR|Placebo|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug
62461933|NCT00693966|EXPERIMENTAL|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
62461934|NCT00693966|EXPERIMENTAL|Group B|Formulation 2 of the vaccine
62461935|NCT00693966|EXPERIMENTAL|Group C|Formulation 3 of the vaccine
62461936|NCT00693966|EXPERIMENTAL|Group D|Formulation 4 of the vaccine \[with Al(OH)3\]
62461937|NCT00816504|EXPERIMENTAL|1|Galactose
62461938|NCT01472393|EXPERIMENTAL|Creatine supplementation|
62461939|NCT01472393|PLACEBO_COMPARATOR|Placebo|
62461940|NCT01336660|EXPERIMENTAL|Equine F(ab')2 antivenom|Intensive care support and Equine F(ab')2 antivenom
62461941|NCT01336660|PLACEBO_COMPARATOR|Placebo|Intensive care support plus placebo
62461942|NCT02997098||Patients undergoing hepatectomy|Patients undergoing hepatectomy, or liver resection, for a non-transplant indication.
62461943|NCT02348983|EXPERIMENTAL|Interventional Arm|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
62461944|NCT05989893|EXPERIMENTAL|Neural recordings and stimulation during language tasks|
62461945|NCT05763238|EXPERIMENTAL|Interventional Group|Preoperative Exercise therapy Patient Education, and post-operative conventional protocol.
62461946|NCT05763238|ACTIVE_COMPARATOR|Control group|Patient Education, and post-operative conventional protocol.
62461947|NCT00999050|EXPERIMENTAL|diabetic pts <35BMI|All patients will be in a single arm receiving bypass surgery to assist with diabetes management
62461948|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index \<3% on pH-metry. Antacid therapy will be discontinued.
62653541|NCT04941989|EXPERIMENTAL|Part 2 Multiple Ascending Dose|Eight subjects in up to 4 cohorts will be dosed, following safety, tolerability and PK review of completed dose of Single Ascending Dose Cohort 5. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
62653542|NCT05776992|EXPERIMENTAL|balance games|virtual reality games
62653543|NCT05776992|ACTIVE_COMPARATOR|balance training|Biodex balance training
62653544|NCT04643886|EXPERIMENTAL|Cohort with Genetic Profile A|"Subjects will have Genetic Profile A.~Intervention: Biological: GEM103."
62088595|NCT00333138|EXPERIMENTAL|Fingolimod (FTY720) 5.0 mg/day|Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
62088596|NCT01109303|ACTIVE_COMPARATOR|TightRope System|Patients are operated on using the TightRope implant by Arthrex.
62088597|NCT01109303|ACTIVE_COMPARATOR|Screw fixation implant|Patients are operated on using the rigid four-cortices 3,5 mm screw fixation by Synthes.
62088598|NCT00671541|ACTIVE_COMPARATOR|Merogel stent vs. Nasopore Stent|This study has two arms consiting of 50 subjects each (100 total) Arm 1 will recieve the standard stent (merogel)in their right sinus and a nasopore stent in their left sinus.
62653545|NCT04643886|EXPERIMENTAL|Cohort with Genetic Profile B|"Subjects will have Genetic Profile B.~Intervention: Biological: GEM103"
62088599|NCT00671541|EXPERIMENTAL|bacitracin vs. gentamicin treated stent|The second arm will consist of 50 new subjects. These 50 subjects will have a nasopore stent placed in the left sinus. The first 25 subjects will have nasopore stent placed postoperatively with a bacitracin soaked nasopore in right sinus the second 25 will have a gentamycin soaked nasopore stent in right sinus.
62088600|NCT02763540|OTHER|Lung cryobiopsy|
62088601|NCT03116763|EXPERIMENTAL|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
62088602|NCT03116763|ACTIVE_COMPARATOR|Control Group|The control group will receive standard care but without the iPeer2Peer program.
62088603|NCT04001114|OTHER|Smokers with schizophrenia|This is a diagnostic group, defined independently from this study.
62088604|NCT04001114|OTHER|Smokers without schizophrenia|This is a diagnostic group (i.e., no diagnosis of schizophrenia), defined independently from this study.
62653546|NCT00931424|EXPERIMENTAL|reconstruction|patients in this group will have both valve reconstruction and superficial vein surgery
62088605|NCT00176865|ACTIVE_COMPARATOR|Arm 1 - Matched sibling donor|Stem Cell Transplant: human leukocyte antigen (HLA) genotypic matched sibling donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
62287341|NCT02680353|NO_INTERVENTION|Control group|Patients received no intervention before operation
62653547|NCT00931424|NO_INTERVENTION|unreconstruction|patients in this group will only have superficial vein surgery
62653548|NCT02035124|EXPERIMENTAL|BKM120 and Cabazitaxel|"BKM 120 orally once daily;~Cabazitaxel 25 mg/m2 IV every 3 weeks"
62653549|NCT06274827|EXPERIMENTAL|Superficial electromyography|Electrode placement was performed on the participants' dominant side UT, MT, LT, and SA muscles. Following this, superficial electromyography measurements were performed during maximal voluntary isometric contraction tests and six different upper extremity closed kinetic chain exercises.
62653550|NCT04400318|EXPERIMENTAL|Dupilumab|Participants received a loading dose of dupilumab 600 mg as 2 subcutaneous (SC) injections on Day 1, followed by a single dupilumab 300 mg SC injection Q2W for 24 weeks along with a stable dose of medium to high ICS dose in combination with a second controller medication +/- a third controller.
61904752|NCT01128621|PLACEBO_COMPARATOR|Part B - PLA|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
61904753|NCT01128621|ACTIVE_COMPARATOR|Part B - Active|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
62088606|NCT00176865|ACTIVE_COMPARATOR|Arm 2 - Matched unrelated donor|Stem Cell Transplant: HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
62088607|NCT00176865|ACTIVE_COMPARATOR|Arm 3 - Mismatched double cord donors|Stem Cell Transplant: two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord) and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
62287342|NCT01960855|PLACEBO_COMPARATOR|Placebo BID|Placebo twice daily (BID) for 12 weeks.
62287343|NCT01960855|EXPERIMENTAL|ABT-494 3 mg BID|ABT-494 3 mg twice daily (BID) for 12 weeks.
62287344|NCT01960855|EXPERIMENTAL|ABT-494 6 mg BID|ABT-494 6 mg twice daily (BID) for 12 weeks.
62287345|NCT01960855|EXPERIMENTAL|ABT-494 12 mg BID|ABT-494 12 mg twice daily (BID) for 12 weeks.
62287346|NCT01960855|EXPERIMENTAL|ABT-494 18 mg BID|ABT-494 18 mg twice daily (BID) for 12 weeks.
62287347|NCT05183919|EXPERIMENTAL|AKL-T01|Digital treatment
62287348|NCT04252599||Control group|
62287349|NCT04252599||Multiple sclerosis group|
62287350|NCT04252599||Multiple sclerosis trunk impairment|
62287351|NCT04274348|OTHER|Skin biopsies and blood samples|
62287352|NCT01081756|EXPERIMENTAL|Subjects treated with r-hCG|Subjects treated with r-hCG
62287353|NCT01081756|ACTIVE_COMPARATOR|Subjects treated with urinary hCG|Subjects treated with urinary hCG
62287354|NCT04619394|NO_INTERVENTION|Control Group (CG)|Control Group (CG): Formed by those pregnant women who do not perform any physical exercise, only the basic and instrumental activities of daily life (ABVD and AIVD respectively) and intensity of the physical labor load of very light to moderate. The period from 10-12 SG to 37-41 SG.
62287355|NCT04619394|ACTIVE_COMPARATOR|Experimental Group 1 (GE1)|Experimental Group 1 (GE1): Created for pregnant women who carry out their own program of each monitor in the different sports centers and public and private swimming pools in the South of the Autonomous Community of Galicia. These own programs will all have the same format: initial warm-up phase, main part of indicated and personalized exercises for pregnancies and final phase with a return to calm.
62287356|NCT04619394|ACTIVE_COMPARATOR|Experimental Group 2 (GE2)|Experimental Group 2 (GE2): In this third and last group, we incorporated the AIPAP program into the exclusive programs of each monitor in the various public and private sports centers and swimming pools in the South of the Autonomous Community of Galicia. The researcher trained in this method, together with the monitors who voluntarily wish to do so, will translate said format and program into their sessions.
62287357|NCT00620061|EXPERIMENTAL|All Participants|Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks
62287358|NCT03403192|ACTIVE_COMPARATOR|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
62287359|NCT03403192|ACTIVE_COMPARATOR|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
62287360|NCT03403192|ACTIVE_COMPARATOR|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
62653551|NCT04400318|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to dupilumab as 2 x 2 mL SC injections on Day 1, followed by a single SC injection Q2W for 24 weeks along with a stable dose of medium to high ICS dose in combination with a second controller medication +/- a third controller.
62088608|NCT04919681|EXPERIMENTAL|Stretching|Static stretching of the knee flexors
62088609|NCT03951376|EXPERIMENTAL|Intervention|"The schools in this arm will implement the UPRIGHT programme (18 skills related to Mindfulness, Coping, Efficacy and Social and emotional learning) during a minimum of 18 sessions and a maximum of 24 in a period of 6 months, which will be conducted by teachers to adolescents of 1st grade (12-14 years of age).~Teachers will be trained by the UPRIGHT team at the beginning of the school year (3 months) and families will have a combination of face to face training and online training throughout the UPRIGHT platform."
62088610|NCT03951376|NO_INTERVENTION|Control|Schools in the control arm have their usual curricula and are not provided of any intervention resources or support, apart from those in the common daily activities.
62653552|NCT01668797|PLACEBO_COMPARATOR|Placebo|Placebo comparator for 52 weeks
62653553|NCT01668797|EXPERIMENTAL|Brexpiprazole (OPC-34712)|Brexpiprazole (OPC-34712) for 52 weeks
62653554|NCT05494528|EXPERIMENTAL|Ropeginterferon alfa-2b monotherapy|Subjects will be treated with 450 µg of Ropeginterferon alfa-2b every two weeks
62653555|NCT05494528|ACTIVE_COMPARATOR|Entecavir monotherapy|Subjects will be treated with 0.5 mg of Entecavir monotherapy once per day
62653556|NCT03153670|EXPERIMENTAL|fMRI-based programming|DBS patients will undergo fMRI scanning while on different stimulation settings. The results will be fed to the programming clinician (movement disorder neurologist) to aid the conventional programming process at the clinician's discretion.
62653557|NCT01162200|OTHER|Stereotactic Body Radiation Therapy|SBRT dose per fraction
62653558|NCT00990886|EXPERIMENTAL|001|Oxybutynin chloride 15 mg once daily for 12 weeks
62653559|NCT00990886|PLACEBO_COMPARATOR|002|Placebo Once daily for 12 weeks
62653560|NCT01613833||Primary OA Group|Subjects who are to undergo primary total knee arthroplasty due to primary OA which may include but is not limited to bilateral or peripheral involvement with no significant history of overuse or trauma to the joint.
62653561|NCT01613833||Secondary/Post-traumatic OA Group|Subjects who are to undergo primary total knee arthroplasty due to osteoarthritis of the knee that is secondary to injury or overuse of the joint.
62653562|NCT02346747|ACTIVE_COMPARATOR|Group A|Vigil immunotherapy will be administered at a concentration of 1.0 x 10e7 cells/dose given via intradermal injection every 4 weeks for a minimum of 4 and a maximum of 6 administrations as determined by the number of doses manufactured and as long as the subject is clinically stable and recurrence free.
62653563|NCT02346747|PLACEBO_COMPARATOR|Group B|Placebo will be administered via intradermal injection every 4 weeks for a minimum of 4 and a maximum of 6 administrations as determined by the number of doses manufactured and as long as the subject is clinically stable and recurrence free.
62653564|NCT01612013|ACTIVE_COMPARATOR|Intravenous NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
62653565|NCT01612013|ACTIVE_COMPARATOR|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
62461949|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index \> 3% on pH-metry.~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
61919777|NCT02008578|EXPERIMENTAL|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.
62287361|NCT03403192|ACTIVE_COMPARATOR|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
62461950|NCT02528760|EXPERIMENTAL|Metaclopromide group|
62653566|NCT01612013|ACTIVE_COMPARATOR|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
62653567|NCT01612013|PLACEBO_COMPARATOR|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
62653568|NCT03768375|EXPERIMENTAL|target therap|The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
62653569|NCT03768375|EXPERIMENTAL|FORFIRINOX|The patients wil receive conventional chemotherapy(FORFIRINOX)
62653570|NCT05986110|EXPERIMENTAL|Intervention Group|
62653571|NCT05986110|NO_INTERVENTION|Control Group|
62088611|NCT06161649|NO_INTERVENTION|traditional outpatient care group|After confirming that the diagnosis of heart failure is met, the patient will receive 10-15 minutes of disease care education from a nurse when the patient receives the case. At the same time, the patient will receive a personal disease self-care education manual, and will get the contact number of the case manager in case the patients encounter emergencies or disease care needs at home (the patient can call for consultation on home care for diseases if the patient want).
62120162|NCT05254769|EXPERIMENTAL|Neurofeedback Intervention in children with Autism Spectrum Disorder|Neurofeedback therapy will be provided to 35 children with Autism Spectrum Disorder 30 sessions each and cognitive domains will be assessed before and after intervention.
62120163|NCT02425917|EXPERIMENTAL|geko|
62120164|NCT02425917|ACTIVE_COMPARATOR|ipc-calf|intermittent pneumatic compression of the calf
62287362|NCT01633957|EXPERIMENTAL|Genotype-based Warfarin Initiation|
62287363|NCT01633957|ACTIVE_COMPARATOR|clinical factor-based warfarin initiation|
62287364|NCT05600075|ACTIVE_COMPARATOR|Glycolic acid 35% group|will be subjected to microneedling with topical glycolic acid 35%.
62287365|NCT05600075|ACTIVE_COMPARATOR|topical insulin group|will be subjected to microneedling with topical human insulin solution.
62307916|NCT02024464|EXPERIMENTAL|Hydrus Microstent|Cataract removal and intraocular lens (IOL) implantation, followed by insertion of the Hydrus Microstent in one eye (study eye)
62307917|NCT02024464|ACTIVE_COMPARATOR|iStent|Cataract removal and intraocular lens (IOL) implantation, followed by insertion of the iStent Trabecular Micro Bypass in one eye (study eye)
62461951|NCT02528760|EXPERIMENTAL|Erythromycin group|
62461952|NCT02528760|PLACEBO_COMPARATOR|Placebo group|
62653572|NCT00122603|EXPERIMENTAL|Group 1|Atazanavir + Fosamprenavir + ritonavir
62653573|NCT00122603|EXPERIMENTAL|group 2|Atazanavir + saquinavir + ritonavir
62653574|NCT06550596|ACTIVE_COMPARATOR|Standard of Care|Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.
62653575|NCT06550596|EXPERIMENTAL|Axolotl DualGraft + SOC|Axolotl DualGraft is a dehydrated human amnion membrane.
62120165|NCT03949855|EXPERIMENTAL|Part A: Low Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.~Participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~Low proteinuria classification: The excretion of ≥4 to \<8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
62120166|NCT03949855|EXPERIMENTAL|Part A :High Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.~Participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
62120167|NCT03949855|EXPERIMENTAL|Part B: Belimumab and Rituximab|"Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.~At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):~* Anti-PLA2R level is ≥ 25% of baseline~* Proteinuria is ≥ 50% of baseline~* Serum albumin is \< 2.8 g/dL"
62120168|NCT03949855|PLACEBO_COMPARATOR|Part B: Placebo and Rituximab|"Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab placebo 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.~At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):~* Anti-PLA2R level is ≥ 25% of baseline~* Proteinuria is ≥ 50% of baseline~* Serum albumin is \< 2.8 g/dL"
61904754|NCT01128621|ACTIVE_COMPARATOR|Part B - Sitagliptin|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
61904755|NCT02044107|EXPERIMENTAL|Co-packaging and counseling messages|"Current standard care at public health center ( zinc ORS for treatment of diarrhea and antibiotics for treatment of of pneumonia).~The intervention consists of health center level co-packaging and visual counseling messages (zinc \& ORS packaged at health center for diarrhea, and zinc \& antibiotics co-packaged at health center for pneumonia) Co-packaging is done in a plastic bag, which is covered with pre-tested zinc treatment messages - a distinct packaging has been designed for diarrhea and for pneumonia"
62088612|NCT06161649|EXPERIMENTAL|automated mobile education system group|"Intervention group (accepting the operation process of automated intelligent education software system):~1. Execute registration and qualification review~2. Automated smart education interaction~At the same time, the patient will receive a personal disease self-care education manual, and will get the contact number of the case manager in case the patients encounter emergencies or disease care needs at home (the patient can call for consultation on home care for diseases if the patient want)."
62461953|NCT04200417|EXPERIMENTAL|Lung, Endobronchial, Mediastinal or Pleural Metastases|Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy
61904756|NCT02044107|NO_INTERVENTION|Control group|Current standard care at public health center (zinc \& ORS for treatment of diarrhea and zinc \& antibiotics for treatment of of pneumonia).
61904757|NCT06297772|ACTIVE_COMPARATOR|Flu-Bu4|Preconditioning with Flu-Bu4 without decitabine for patients with AML-MR
62461954|NCT04751734||Vaccinations|SARS-CoV-2 vaccination
62461955|NCT01729377||Suicidal older persons and their families|Suicidal older persons and their families will be interviewed
62461956|NCT00659464||1|Children who present to the heart center exercise stress lab for investigation of syncope
62461957|NCT01087476|EXPERIMENTAL|doxycycline hyclate|Patients will be randomly assigned to receive either a sub-microbial dose of doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
62461958|NCT00863746|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
62461959|NCT00863746|PLACEBO_COMPARATOR|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
62461960|NCT00077948|EXPERIMENTAL|active enoximone plus active ER metoprolol|
62461961|NCT00077948|ACTIVE_COMPARATOR|placebo enoximone plus active ER metoprolol|
62461962|NCT00077948|PLACEBO_COMPARATOR|placebo enoximone plus placebo ER metoprolol|
62461963|NCT01417390|EXPERIMENTAL|Concurrent chemoradiotherapy|Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy
62461964|NCT01417390|EXPERIMENTAL|Inductive and concurrent|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
62461965|NCT01059903|EXPERIMENTAL|Rotigotine PR2.2.1 first|Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
62461966|NCT01059903|EXPERIMENTAL|Rotigotine PR2.1.1 first|Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
62461967|NCT05573620|EXPERIMENTAL|ACT+In vivo exposure|5 individual weekly sessions which included ACT methods + in vivo exposure
62461968|NCT05573620|EXPERIMENTAL|ACT+Virtual reality|5 individual weekly sessions which included ACT methods + virtual reality
62461969|NCT05573620|NO_INTERVENTION|Waiting list|Participants assigned to Waiting List arm waited for 5 weeks before receiving treatment (i.e., after completing the measures they continued in the study and then were randomly assigned to ACT+in vivo exposure or ACT+virtual reality arms).
62461970|NCT02291562|EXPERIMENTAL|Tetrahydrocannabinol|10 mg of Tetrahydrocannabinol as capsule (once)
62461971|NCT02291562|EXPERIMENTAL|Cannabidiol|600 mg Cannabidiol capsule (once)
62461972|NCT02291562|PLACEBO_COMPARATOR|placebo|placebo capsule (once)
62461973|NCT05847205|EXPERIMENTAL|r-Hirudin|Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
61904758|NCT06297772|EXPERIMENTAL|Dec-Flu-Bu4|Preconditioning with Flu-Bu4 and decitabine for patients with AML-MR
62287366|NCT03822481|EXPERIMENTAL|Experimental|Participants in this arm were given the MCD. The MCD is a mindful eating intervention aimed at facilitating weight loss and cultivating a present centred awareness. The MCD consists of ten questions that an individual must consider while eating. Participants were required to consider the questions while eating (no writing required). Participants were asked to use the MCD at their three main meals (breakfast, lunch, dinner). The
61919778|NCT02008578|PLACEBO_COMPARATOR|Placebo|Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).
61919779|NCT01796496|EXPERIMENTAL|Manipulative Therapy Techniques|Manipulative Therapy Techniques involve three techniques on lumbar and sacral areas. This protocol will be administered one a week for 3 weeks.
62088613|NCT05837975|EXPERIMENTAL|FREE Walk Exoskeleton vs Traditional Rehabilitation for Stroke Patients|Participants in this arm will receive one month of traditional rehabilitation followed by one month of using the exoskeleton at home.
62287367|NCT03822481|NO_INTERVENTION|Control|Participants in this arm were required to eat as normal and were not given the MCD until the study was complete.
62461974|NCT03396523|EXPERIMENTAL|Losartan group|
62461975|NCT03396523|PLACEBO_COMPARATOR|Placebo group|
62461976|NCT04606420|EXPERIMENTAL|Experimental (Intervention) Group|These patients will receive the comprehensive lifestyle medicine intervention from day 1 through the end of the study. They will be tested at baseline, after 20 weeks, and after 40 weeks.
62461977|NCT04606420|NO_INTERVENTION|Control (Non-Intervention) Group|"These patients will be asked to continue their current diet and lifestyle without making any changes for 20 weeks. They will be tested at baseline and after 20 weeks. Then, they will cross over and receive the same lifestyle medicine intervention for 20 weeks and will be tested again after 20 weeks of the intervention and also after 40 weeks of the intervention. After 20 weeks in the randomized control group, patients who no longer meet these eligibility criteria (e.g, a MoCA score \<18) will not cross over and will not receive the lifestyle intervention; their data during the first 20 weeks in the control group (when they met the entry criteria) will be used."
62461978|NCT04949620|EXPERIMENTAL|REThink game, then responder monitoring|Participants in this group will have access to the REThink game for four weeks; based on their response to the intervention, they will be monitored for an additional period of four weeks.
62461979|NCT04949620|EXPERIMENTAL|REThink game, then online parent intervention for non-responders|Participants who are allocated to the REThink game and do not respond to the four-week intervention will be allocated to the online
62461980|NCT04949620|NO_INTERVENTION|Monitoring|Participants in this arm will be monitored for a total of eight weeks, for comparison with the REThink game intervention (after four weeks) and the online parenting program (after an additional four weeks).
62461981|NCT02674477|EXPERIMENTAL|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using participant's specific login information. Participants can use it as much or as little as participants like. Participants will continue with treatment as usual during and after hospitalization, as well.
62461982|NCT02674477|OTHER|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual \[TAU\]) provided to patients on the service.
62461983|NCT02222155|ACTIVE_COMPARATOR|CCX168 low dose plus standard of care|Capsule, 10 mg, twice daily + standard of care for 12 weeks
62461984|NCT02222155|ACTIVE_COMPARATOR|CCX168 high dose plus standard of care|Capsule, 30 mg, twice daily + standard of care for 12 weeks
62461985|NCT02222155|PLACEBO_COMPARATOR|Placebo, twice daily + standard of care|Capsule, placebo, twice daily + standard of care for 12 weeks
62461986|NCT00992771|EXPERIMENTAL|Varneicline|
62461987|NCT00992771|PLACEBO_COMPARATOR|Placebo|
62461988|NCT03382756|EXPERIMENTAL|Group A|"Period 1: 1 capsule of test drug(CKD-337) administered under fasting condition~Period 2: 1 capsule of test drug(CKD-337) under high fat diet condition"
62461989|NCT03382756|EXPERIMENTAL|Group B|"Period 1: 1 capsule of test drug(CKD-337) under high fat diet fed condition~Period 2: 1 capsule of test drug (CKD-337) administered under fasting condition"
62461990|NCT00931099||Low risk pregnant women|300 women in the third trimester of a singleton uncomplicated pregnancy, who attend a low risk obstetric surveillance
62461991|NCT00931099||High risk pregnant women|100 women hospitalized at the Antenatal department due to pregnancy related hypertensive disorder, IUGR, diabetes mellitus or premature labor
62287368|NCT05799014|EXPERIMENTAL|Traditional CT-guided percutaneous lung biopsy group|
62287369|NCT05799014|EXPERIMENTAL|Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology group|
62287370|NCT04313556|OTHER|Lateral patellar release|Arthroscopic lateral patellar retinacular release
62287371|NCT02803333||Data Capture Participants|This is a prospective observational cohort study of advanced non-small cell lung cancer patients (stage 3b/4) receiving treatment at the Moffitt Cancer Center (MCC) or The Ohio State Comprehensive Cancer Center (OSUCCC) to assess treatment impact at monthly intervals from baseline to 6 months post-enrollment.
62287372|NCT03939182|EXPERIMENTAL|Abexinostat and Ibrutinib|The investigational agents to be used in this study are ibrutinib and abexinostat. Ibrutinib will be administered once daily on a 28-day cycle. Abexinostat will be administered orally twice daily (approximately 4-6 hours apart) for 7 days a week given every other week on a 28-day cycle.
62287373|NCT03857789|OTHER|Regular care|Participant will be received by Healthcare professional (HCP). The HCP will administer a questionnaire. The HCP will discuss the results.
62287374|NCT03857789|EXPERIMENTAL|New care|Participant will be received by Healthcare professional (HCP). The social robot will administer a questionnaire. The HCP will discuss the results.
62307918|NCT05978895|EXPERIMENTAL|Intervention group|22 adults with autism spectrum disorder (grade 1-2 or 3), admitted to the daycare service of Sacra Famiglia Onlus Foundation in Cesano Boscone (Milan, Italy)
62307919|NCT00887042|EXPERIMENTAL|Fludarabine|
61904759|NCT02968537|EXPERIMENTAL|Alc-IT (50/50) (morning)|Alc-IT (50/50) (morning): This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
61904760|NCT02968537|EXPERIMENTAL|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
62287375|NCT06395844|EXPERIMENTAL|METR-NK cell（metabolic remodeling nature killer cells）|Intraperitoneal allogeneic METR-NK cells infusion ： Dilute 200 mL of METR-NK cells in 1500 mL of 0.9% saline solution at 37°C. The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells per kilogram. Continuous infusion for 2 days constitutes one course, with 4 courses, with 13-day interval between each course
62287376|NCT05140057|EXPERIMENTAL|Protocol 1|1L of Moviprep® solution the night before the procedure
62287377|NCT05140057|EXPERIMENTAL|Protocol 2|1L of Moviprep® solution up to 2h before the procedure
62287378|NCT05140057|EXPERIMENTAL|Protocol 3|0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum
62461992|NCT00931099||Pregnant women in labor|200 women of a singleton uncomplicated full term pregnancy will be recruited during labor at the delivery room
62461993|NCT00931099||Newborns|400 newborns belong to women in first two groups
62461994|NCT05417100|ACTIVE_COMPARATOR|Methadone bolus during surgery|Patients will be administered methadone 0.2 mg/kg (max 20 mg).
62461995|NCT05417100|NO_INTERVENTION|No Methadone during surgery|No Methadone during surgery
62461996|NCT05436509|EXPERIMENTAL|bi-4SCAR-CD19/79b T Cell Therapy for CD19 and/or CD79b positive B cell malignancies|
62461997|NCT05909124||healthy weight people (18.5≤BMI<25)|18.5≤BMI\<25
62653576|NCT02819453||prior corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) by two clinicians on the first day of hospital admission (not receiving corticosteroids yet)
61904761|NCT02968537|PLACEBO_COMPARATOR|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
62088614|NCT05837975|EXPERIMENTAL|Traditional Rehabilitation vs FREE Walk Exoskeleton for Stroke Patients|Arm Description: Participants in this arm will receive one month of using the exoskeleton at home followed by one month of traditional rehabilitation.
62088615|NCT02407509|EXPERIMENTAL|Part I - Twice weekly (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours.
62088616|NCT02407509|EXPERIMENTAL|Part I - Three times weekly (COMPLETED)|VS-6766 will be administered three times weekly in 4 week cycles in patients with solid tumours.
62287379|NCT05140057|EXPERIMENTAL|Protocol 4|1L of Moviprep® solution after the capsule had reached the duodenum
62287380|NCT02268461|ACTIVE_COMPARATOR|rTMS|repetitive Transcranial Magnetic Stimulation (rTMS)
62461998|NCT05909124||obese people (BMI≥30)|BMI≥30
62461999|NCT01122485|EXPERIMENTAL|Low dose group|two tablets per dose (one tablet of investigational drug and one tablet of placebo)
62462000|NCT01122485|EXPERIMENTAL|High dose group|two tablets per dose (two tablets of investigational drug)
62462001|NCT01122485|PLACEBO_COMPARATOR|Control group|two tablets per dose (two tablets of placebo)
62462002|NCT01228409|OTHER|Low dose Acitretin (17.5 mg)|
62653577|NCT02819453||after corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) after corticosteroids treatment
62653578|NCT00300196|EXPERIMENTAL|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
62653579|NCT00300196|PLACEBO_COMPARATOR|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
62653580|NCT01458587|EXPERIMENTAL|ALA|
62653581|NCT01458587|PLACEBO_COMPARATOR|Vehicle|
62088617|NCT02407509|EXPERIMENTAL|Part IIA (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway.
62287381|NCT02268461|SHAM_COMPARATOR|Sham rTMS|Sham repetitive Transcranial Magnetic Stimulation (Sham rTMS)
62287382|NCT01929135|EXPERIMENTAL|Medicated 2% atorvastatin dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a medicated 2% atorvastatin dentifrice 2 times a day for two minutes each time, for 30 days.
62653582|NCT01867775|ACTIVE_COMPARATOR|Mirtazapine|Mirtazapine, 15 mg once a day, at night for 14 days
62653583|NCT01867775|PLACEBO_COMPARATOR|Placebo|Placebo 15 mg, once a day at night for 14 days
62653584|NCT05031767|ACTIVE_COMPARATOR|Usual care|Conventional current follow-up strategy
62653585|NCT05031767|EXPERIMENTAL|Remote monitoring|Remote monitoring by health professionals at the hospital
62653586|NCT05031767|EXPERIMENTAL|Patient-initiated care|No pre-scheduled visits or remote monitoring.
62088618|NCT02407509|EXPERIMENTAL|Part IIB (CLOSED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with multiple myeloma with a mutation in KRAS, NRAS or BRAF. In order to accommodate steroid use for patients with multiple myeloma, patients will be administered for 3 weeks followed by a week interruption.
62462003|NCT01884090|EXPERIMENTAL|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
62088619|NCT02407509|EXPERIMENTAL|Part IIC (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. Upon occurrence of specified G2 toxicity, dosing intensity will be reduced to 3 weeks followed by a week interruption in a 4 week cycle.
62088620|NCT02407509|EXPERIMENTAL|Part IID - Once weekly dose confirmation (COMPLETED)|VS-6766 and everolimus will be administered once weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
62462004|NCT01884090|ACTIVE_COMPARATOR|Standard After School Programming|Youth in the comparison arm of the study will participate in standard after-school programming administered by Flint Community Schools and Genesee Intermediate School District. The standard program is the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009)
62462005|NCT01762709|ACTIVE_COMPARATOR|The VT 4 ml/kg group|Use of tidal volume of 4 ml/kg during one lung ventilation
62462006|NCT01762709|ACTIVE_COMPARATOR|The VT 6 ml/kg group|Use of tidal volume of 6 ml/kg during one lung ventilation
62462007|NCT01762709|EXPERIMENTAL|The VT 8 ml/kg group|Use of tidal volume of 8 ml/kg during one lung ventilation
62462008|NCT00949312||Stage II unresected Colon Cancer|
62462009|NCT05306470|EXPERIMENTAL|Ethyl chloride|Pre cooling done by the application of single spray ethyl chloride on a cotton pellet and placed for 30 seconds at the injection site for numbing effect
62462010|NCT05306470|EXPERIMENTAL|5% lidocaine gel|5% lidocaine gel 2ml applied on a cotton pallet for 30 seconds on the oral mucosa at the site of injection for the numbing effect
62462011|NCT05306470|NO_INTERVENTION|control|Local anesthesia infiltration is administrated without using any numbing agent
62462012|NCT05221242|EXPERIMENTAL|Patients with PLV|All patients will receive ceramic partial laminate veneers as treatment. As this is a split mouth design, one side of the mouth will receive partial laminate veneers bonded with a conventional light-curing resin cement and the other side of the mouth with a pre-heated resin composite.
62462013|NCT05128812|PLACEBO_COMPARATOR|CONTROL GROUP|Nutraceutical placebo intake group
62462014|NCT05128812|EXPERIMENTAL|PLX400mg GROUP|Intake of natural herbal dietary supplement composed of lemon verbena extract (Lippia citriodora).
62653587|NCT00003723|EXPERIMENTAL|Gemcitabine/Cisplatin|Gemcitabine 1000 mg/m\^2 days 1, 8 15 (q 28 days) cisplatin 30 mg/m\^2 days 1, 8, 15 (q 28 days)
62462015|NCT03967730|EXPERIMENTAL|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
62462016|NCT03088670|EXPERIMENTAL|Gosogliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
62462017|NCT03088670|ACTIVE_COMPARATOR|Vildagliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
62462018|NCT02895048||Chronic heart failure|
62462019|NCT02895048||CCM treatment|Subjects with heart failure receiving OPTIMIZER system implant
62462020|NCT02393482|ACTIVE_COMPARATOR|Balanced estroprogestins|Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
62462021|NCT02393482|ACTIVE_COMPARATOR|GnRHa|Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
62462022|NCT03996109|EXPERIMENTAL|Aim2Be|Youth-parent dyads randomized to Aim2Be
62462023|NCT03996109|ACTIVE_COMPARATOR|BnLt|Youth-parent dyads randomized to BnLt
62462024|NCT05266521|EXPERIMENTAL|zLock Facet Locking Implant System|Device: zLOCK Facet Stabilization System zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
62653588|NCT04424602|EXPERIMENTAL|cyclophosphamide|participants will receive intra venous cyclophosphamide 500mg once every two weeks for 6months.
62653589|NCT04424602|ACTIVE_COMPARATOR|mycophenolate|participants will receive oral mycophenolat 2 to 3mg/kg for 6 months.
62653590|NCT02908334|NO_INTERVENTION|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
62287383|NCT01929135|PLACEBO_COMPARATOR|Non-medicated dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a non-medicated dentifrice as placebo 2 times a day for two minutes each time, for 30 days.
62653591|NCT02908334|EXPERIMENTAL|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
62088621|NCT02407509|EXPERIMENTAL|Part IID - Twice weekly dose confirmation (COMPLETED)|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
62088622|NCT02407509|EXPERIMENTAL|Part IID - Dose expansion|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with KRAS-mutant lung cancer. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
62088623|NCT02407509|EXPERIMENTAL|Part IIE- Biopsy Cohort|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with documented RAS or RAF mutant solid tumours All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
62287384|NCT06018779|EXPERIMENTAL|Group A|Group A will include patients who will receive a rehabilitation treatment consisting of: cryo-ultrasound therapy and high-intensity laser therapy
62462025|NCT01975207|NO_INTERVENTION|Group 1|"Patients will have information collected on their quality of life (QOL) at baseline (EuroQual 5-item measure - EQ-5D). Patients will be followed up at week 12 for a repeated measure of QOL and a score on the depression rating scale being used in this study (Patient Health Questionnaire-9 item version - PHQ-9). Individuals will also be asked on their health care access frequency (HCAF) at baseline and follow up."
62653592|NCT03998072|EXPERIMENTAL|Intervention|
62653593|NCT03998072|NO_INTERVENTION|Treatment as usual (waiting list control)|
62653594|NCT05385406|EXPERIMENTAL|Triage by genotyping|The study intervention will consist in applying HPV genotyping as a triage method of HPV-positive women for cervical cancer screening. After primary screening with the Xpert HPV test, positive women will be sorted according to two groups of genotypes: group 1 (HPV types 16,18,45, 31, 33, 35, 52 and/or 58 obtained from channels 1, 2 and 3) and group 2 (HPV types 51, 59, 39,56, 66 and/or 68 obtained from channels 4 and 5). Women of group 1 will immediately treated, while those of group 2 will not receive immediate treatment and will be followed-up at 12 months. An exception will be made for participants with lesions suspicious of invasive cancer upon examination, which will be referred for further investigations regardless of the HPV type.
62653595|NCT05385406|ACTIVE_COMPARATOR|Triage by visual inspection after application of acetic acid (VIA)|The control arm will consist in triage of HPV-positive women by VIA, as currently recommended by the WHO. Women with a positive VIA will be treated immediately, while VIA-negative women will not be treated and will be followed-up at 12 months.
62653596|NCT05684770|EXPERIMENTAL|4G Tablet|
62653597|NCT03727282|OTHER|Liberal strategy|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician
62653598|NCT03727282|EXPERIMENTAL|ejection volume index|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index
62653599|NCT01574963||CAD Patients|Patients suffering from CAD requiring coronary artery bypass grafting
62653600|NCT01574963||Control Patients|Patients without CAD
62462026|NCT01975207|EXPERIMENTAL|Group 2|"Group #2. Screening for depression followed by treatment as usual: Patients will complete baseline measurements of their score on the PHQ-9, self-reported HCAF and QOL (EQ-5D) score.~The PHQ-9 score will be given to the clinic staff who will then follow up with treatment as usual. Patients will be followed up at week 12 for self-reported HCAF,PHQ-9 and QOL scores."
62653601|NCT04562376|EXPERIMENTAL|Group A|The program consists of high-intensity resistance training for 60 minutes twice a week for group A during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group A will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
62653602|NCT04562376|ACTIVE_COMPARATOR|Group B|The program consists of high-intensity resistance training for 60 minutes once a week for group B during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group B will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
62653603|NCT00293592|ACTIVE_COMPARATOR|Dexamethasone|
62653604|NCT00293592|PLACEBO_COMPARATOR|Placebo|
62653605|NCT05784675|EXPERIMENTAL|MOBI-CPR|Participants use MOBI-CPR game at home environment.
62653606|NCT05784675|NO_INTERVENTION|No MOBI-CPR|Participants do not use MOBI-CPR game at home environment.
62653607|NCT04698434|ACTIVE_COMPARATOR|0.5mg/kg esketamine group|0.5mg/kg esketamine group will be given a single intravenous 0.5mg/kg esketamine
62653608|NCT04698434|ACTIVE_COMPARATOR|.75mg/kg esketamine group|0.75mg/kg esketamine groupwill be given a single intravenous 0.75mg/kg esketamine
62653609|NCT04698434|ACTIVE_COMPARATOR|1.0mg/kg esketamine group|1.0mg/kg esketamine group will be given a single intravenous 1.5mg/kg esketamine
62287385|NCT06018779|PLACEBO_COMPARATOR|Group B|Group B will include patients who will receive a rehabilitation treatment consisting of: cryo-ultrasound therapy and diathermy
62287386|NCT03038308|EXPERIMENTAL|ROP Intervention|Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study
62287387|NCT02243228|EXPERIMENTAL|GM-CSF, nebulizer|After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.
61904762|NCT02968537|EXPERIMENTAL|Alc-IT (50/50) (afternoon)|"Alc-IT (50/50) (afternoon): As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
61904763|NCT02968537|EXPERIMENTAL|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
62287388|NCT00110994|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine|Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m\^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
62287389|NCT00110994|ACTIVE_COMPARATOR|Placebo + Dacarbazine|Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m\^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
62653610|NCT01082471|EXPERIMENTAL|M6G|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
62653611|NCT01082471|ACTIVE_COMPARATOR|Morphine|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
62653612|NCT06551857||Cisplatin|50 patients receiving cisplatin as the standard care for their underlying malignancy
62653613|NCT06551857||Cisplatin-based chemoradion therapy in the head and neck region|50 patients receiving cisplatin-based chemoradiation therapy in the head and neck region as the standard care for their underlying malignancy
62653614|NCT06551857||Head and neck region radiation therapy|50 patient receiving head and neck region radiation therapy as the standard care for their underlying malignancy
62653615|NCT06551857||Oxaliplatin|50 patients receiving oxaliplatin as the standard care for their underlying malignancy
62653616|NCT06551857||Control|50 healthy volunteers who have never received any ototoxic medications
61904764|NCT02968537|PLACEBO_COMPARATOR|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
61904765|NCT05350956|EXPERIMENTAL|Herombopag monotherapy|
61904766|NCT05350956|EXPERIMENTAL|Herombopag is treated in combination with rhTPO(Recombinant human thrombopoietin)|
62287390|NCT02789813|EXPERIMENTAL|Valproic Acid and fear reactivation|This group will receive once a combination of 500mg Valproic Acid (oral solution) and fear reactivation before exposure therapy.
62287391|NCT02789813|ACTIVE_COMPARATOR|Valproic Acid and no fear reactivation|This group will receive once 500mg Valproic Acid (oral solution) before exposure therapy.
62653617|NCT06208397||Experimental: Diagnostic (MRE)|Patients undergo a preoperative routine MRI scan and MRE the day before their scheduled surgery to assess OSS and NOSS. After surgery, the HGP of tumor will be assessed by H\&E-stained sections.
62653618|NCT00187551|EXPERIMENTAL|interruption of enfuvirtide|enfuvirtide interruption
62653619|NCT05604417|EXPERIMENTAL|PHASE 1: ZANDELISIB + TAZEMETOSTAT|"Phase 1 study (3+3 design), followed by a phase 2 expansion component~* For phase 1 portion, which follows the same dosing schedule as Arm A, there will not be any randomization.~* Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles~* Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles. There will be 2 dose levels of tazemetostat."
62653620|NCT05604417|EXPERIMENTAL|Arm A: COMBINATION ZANDELISIB + TAZEMETOSTAT|"Participants randomized into Arm A of the phase 2 component will receive~* Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles~* Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles"
62653621|NCT05604417|EXPERIMENTAL|Arm B: Zandelisib and Tazemetostat|"Participants randomized into Arm B of the phase 2 component will receive~* Zandelisib oral, daily on predetermined days (Cycles 1-2) and predetermined days of cycle 3 and onwards up to 14 cycles.~* Tazemetostat, oral, twice daily on predetermined days of each cycle. This will begin on cycle 3 and will continue for up to 12 cycles."
62653622|NCT02255747|ACTIVE_COMPARATOR|anal dilatation|
62653623|NCT02255747|ACTIVE_COMPARATOR|Oral Lactulose|
62653624|NCT03173339|ACTIVE_COMPARATOR|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
62653625|NCT03173339|EXPERIMENTAL|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
61904769|NCT01033149|OTHER|N-acetylcysteine|open label N-acetylcysteine, flexible dose
62287392|NCT02789813|PLACEBO_COMPARATOR|Placebo and fear reactivation|This group will receive once a combination of Placebo (oral solution) and fear reactivation before exposure therapy.
62287393|NCT02789813|PLACEBO_COMPARATOR|Placebo and no fear reactivation|This group will receive once Placebo (oral solution) before exposure therapy.
62653626|NCT00737048|EXPERIMENTAL|Tramadol plus Acetaminophen and Placebo|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (\>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
62653627|NCT00737048|EXPERIMENTAL|Tramadol and Placebo|Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
62653628|NCT00737048|EXPERIMENTAL|Acetaminophen and Placebo|Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
62653629|NCT04156659|EXPERIMENTAL|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel will receive a single dose of tisagenlecleucel.~For subjects ≤ 50 kg, tisagenlecleucel will be administered as a single infusion of 0.2 to 5.0 x 10\^6 CAR positive viable T cells per kg body weight.~For subjects \> 50 kg, tisagenlecleucel will be administered as a single infusion of 0.1 to 2.5 x 10\^8 CAR positive viable T cells."
62653630|NCT05530005|ACTIVE_COMPARATOR|Hands on|Patients with shoulder impingement syndrome. Age 18-50 years. Shoulder pain lasting from 3 months to 1 year, No surgery and injection intervention in the shoulder joint and surrounding area in the history of the disease. - Ailments in scales I and II according to Neer.
62653631|NCT05530005|NO_INTERVENTION|Hands off|Patients with shoulder impingement syndrome. Age 18-50 years. Shoulder pain lasting from 3 months to 1 year, No surgery and injection intervention in the shoulder joint and surrounding area in the history of the disease. - Ailments in scales I and II according to Neer.
62653632|NCT03733964|EXPERIMENTAL|Manual therapy|A group of 50 people using manual therapy as a treatment method.
62653633|NCT03733964|EXPERIMENTAL|PNF|A group of 50 people using PNF (Proprioceptive Neuromuscular Facilitation) as a treatment method.
62653634|NCT03733964|EXPERIMENTAL|Manual therapy + PNF|A group of 50 people using combination therapy - manual therapy and PNF.
62653635|NCT03733964|EXPERIMENTAL|Kinesiotherapy|A group of 50 people using traditional kinesiotherapy (exercises) as a treatment method.
62653636|NCT03413696||Not referred for HCV therapy|
62653637|NCT03413696||Referred for HCV therapy,did not show up|
62653638|NCT03413696||Referred,attended HCV therapy evaluation|
62653639|NCT02014623|ACTIVE_COMPARATOR|Grass pollen sublingual immunotherapy tablet|A sublingual allergen immunotherapy tablet (Oralair) containing: 300 index of reactivity (IR) of 5 grass pollen allergen extracts:perennial ryegrass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum) in an open label fashion administered for 4 months prior to the pollen season.
62653640|NCT02014623|OTHER|Control|Standard medical therapy: oral antihistamines AND/OR nasal steroids AND/OR nasal antihistamines
62653641|NCT00522665|ACTIVE_COMPARATOR|Arm A: Irinotecan + Cetuximab +/- RAD001|
62653642|NCT00522665|ACTIVE_COMPARATOR|Arm B: Ironotecan + Cetuximab|
62653643|NCT03184246|EXPERIMENTAL|GlideScope|intubation with GlideScope
61904770|NCT05860270|ACTIVE_COMPARATOR|Treatment group|Patients will be given Cholecalciferol (produced by Xymogen Company) 4000 U (2 capsules) per day
61904771|NCT05860270|PLACEBO_COMPARATOR|Control group|Patients will receive placebo, 2 capsules per day.
62653644|NCT03184246|ACTIVE_COMPARATOR|Direct laryngoscopy|intubation with laryngoscope
61904773|NCT04368078|EXPERIMENTAL|Toripalimab plus Lenvatinib|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.~Toripalimab is a recombinant anti-human PD-1 monoclonal antibody."
62287394|NCT01098890|PLACEBO_COMPARATOR|Placebo|Placebo will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
62287395|NCT01098890|ACTIVE_COMPARATOR|tPA (tissue plaminogen activator)|Intraventricular TPA will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
62287396|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
62287397|NCT01182038|EXPERIMENTAL|Birth seat group|Randomized to birth on a midwife designed birth seat
62287398|NCT01182038|NO_INTERVENTION|Non-birth seat group|Randomized to birth in any other position except on the midwife designed birth seat.
62287399|NCT02769598||ANI Index for Hospitalized children|"Each child will be registered upon arrival in the service and for a period of 24 hours. Registration will finish at the end of 24 hours or when the patient is discharged from the service. A FLACC scale (Face, Legs, Activity, Cry, Consolability scale) will be performed at the patient's input and then once every 4 hours corresponding to the patient's baseline. A FLACC scale will then be performed at each painful episode of the patient and 30 minutes after the end of production of analgesic treatment corresponding to the post-treatment painful condition of the patient.~A measurement of blood pressure will be performed at each pain rating by the patient assisted by the nurse."
62287400|NCT03544580|EXPERIMENTAL|immediate implant with dentin chips|using the tooth structure presented in socket either as remaining root or as unrestorable tooth structure remove all periodontal ligaments \& scraping all enamel \& cementum using a stone also to cut it into slices then putting it in acid to demineralize the dentine ; then using a bone mill to transform dentine into small particles or chips to be used in jumping gap between implant \& thin buccal bone
62287401|NCT03544580|ACTIVE_COMPARATOR|immediate implant with xenograft|after surgical removal of entire badly decayed tooth we immediately put implant and in jumping gap we use xenograft
62287402|NCT01667263|EXPERIMENTAL|All-trans retinoic acid ＆Danazol|Danazol 400mg po and ATRA 10mg bid po
62287403|NCT01667263|ACTIVE_COMPARATOR|Danazol|Danazol 400mg po
62287404|NCT04765605|EXPERIMENTAL|WeFlow-Tbranch Stent Graft System|Participants will be treated with WeFlow-Tbranch Stent Graft System
62287405|NCT06020794|ACTIVE_COMPARATOR|Control Group|First group (14 people): 4-weeks home exercise program will be given to control group. The exercise program includes quadriceps isometric exercises (holding for 10 seconds, 20 reps), straight leg raises (20 reps holding for 6 seconds), and semi-squatting exercises (20 reps), hip flexors, hamstring and iliotibial band stretching exercises (20-repetitions), strengthening exercises for hip abductors and adductors (holding for 6 seconds with 20 repetitions). These exercises were said to be performed for 30 minutes, once a day, every day for 4 weeks.
62287406|NCT06020794|ACTIVE_COMPARATOR|LP-PRP Group|Second group (14 people): LP-PRP injection and 4-week exercise program will be applied by targeting the suprapatellar bursa. The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
62287407|NCT03064763|EXPERIMENTAL|Talimogene laherparepvec|"Participants will receive talimogene laherparepvec administered by intralesional injection only into injectable cutaneous, subcutaneous, and nodal tumors, with or without image ultrasound guidance.~On Day 1 (Week 0), the initial dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 Plaque forming units per millilitre (PFU/mL). Subsequent doses of talimogene laherparepvec will be up to 4.0 mL of 10\^8 or 10\^7 PFU/mL. The second dose is to be administered 3 weeks (+ 5 days) after the initial dose, and subsequent doses were to be given every 2 weeks (+ 3 days)."
62287408|NCT01199666|EXPERIMENTAL|Text message reminders|
62678899|NCT06686732|ACTIVE_COMPARATOR|Conventional physiotherapy|Control group included Cold pack, Extensor carpi radialis brevis stretching. Active ROM of wrist flexion and extension. Active ROM of elbow flexion, extension, supination and pronation. Manually resisting wrist extensors. Maitland elbow joint mobilization with 1 min of rest between sets.
61919780|NCT01796496|ACTIVE_COMPARATOR|Functional Technique|Manipulative Therapy Technique involves one technique on lumbar area. This protocol will be administered one a week for 3 weeks.
62287409|NCT01199666|ACTIVE_COMPARATOR|standard of care for MMR, letter reminder for Hep A|MMR: automated phone call appointment reminder Hep A: recall letter, automated phone call appointment reminder
62287410|NCT05888974||patients with shock (MAP < 65 mmHg) requiring vascular filling|The study population consisted of patients with shock (MAP \< 65 mmHg) requiring vascular filling indicated by the referring physician physician, recruited consecutively in the emergency department of the CHU of Nîmes and Montpellier.
62287411|NCT00891202|EXPERIMENTAL|Active|Eliglustat
62287412|NCT00891202|PLACEBO_COMPARATOR|Placebo|Placebo
62287413|NCT01800942|PLACEBO_COMPARATOR|Placebo|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
62462027|NCT01975207|EXPERIMENTAL|Group 3|Group #3 is Internet intervention: At baseline patients will complete QOL (EQ-5D), PHQ-9 scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered a guided internet-based intervention for the treatment of depression by the study staff. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL scores.
62462028|NCT01975207|EXPERIMENTAL|Group 4|Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.
62462029|NCT06368037|EXPERIMENTAL|The treament of DragonFire Transcatheter myocardial ablation system|If drug therapy does not work or drug side effects are not tolerated, transaortic interventional surgery can be evaluated
62462030|NCT05420805|ACTIVE_COMPARATOR|Pre- and post-biotic (ALAC, inulin, FOS, and sodium butyrate)|The product (ALAC+butyrate+inulin+fructo oligosaccharides FOS) is a powder for oral suspension. Dosage is dependent on weight. For participants weighing \<50 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥50 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.
62475162|NCT01339247|ACTIVE_COMPARATOR|Paxil CR Test|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2
61919781|NCT01064245|EXPERIMENTAL|Cough Variant Asthma|Those diagnosed with cough variant asthma.
62287414|NCT01800942|EXPERIMENTAL|Azithromycin|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
62287415|NCT06325501|ACTIVE_COMPARATOR|misoprostol|receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery
61904777|NCT03757390|EXPERIMENTAL|Sequence 1|"* period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg~* period 2: receive CJ-30060 5/160/10mg"
62287416|NCT06325501|ACTIVE_COMPARATOR|oxytocin|After the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
62287417|NCT02048345|EXPERIMENTAL|Suspension, fasted state|Suspension Noxafil will be administered in the fasted state to the volunteers.
62287418|NCT02048345|EXPERIMENTAL|Suspension, with sugar (delay gastric emptying)|Suspension will be co-administered with glucose to delay the gastric emptying time
62287419|NCT02048345|EXPERIMENTAL|Solution, fasted state|A solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.
62287420|NCT02048345|EXPERIMENTAL|Solution, with sugar (delaying gastric emptying)|A solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.
62287421|NCT03479047|EXPERIMENTAL|Ventilated patients|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
62287422|NCT01350089|PLACEBO_COMPARATOR|Placebo|
62287423|NCT01350089|ACTIVE_COMPARATOR|Comparator 1 (with alcohol)|
62287424|NCT01350089|ACTIVE_COMPARATOR|Comparator 2 (with alcohol and coffeine)|
62287425|NCT01350089|EXPERIMENTAL|Comparator 3 (with alcohol and energy drink)|
62287426|NCT06056947|EXPERIMENTAL|fenticonazole + tinidazole + lidocaine vaginal ovule (EVEGYN A)|EVEGYN A is a fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule.
62653645|NCT02600260|OTHER|enoxaparin|A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
62287427|NCT06056947|EXPERIMENTAL|fenticonazole + tinidazole + lidocaine vaginal ovule (EVEGYN B)|EVEGYN B is a fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule.
62287428|NCT06056947|ACTIVE_COMPARATOR|Gynomax® XL Vaginal Ovule|Gynomax® XL is a fixed-dose combination of 300 mg tinidazole + 200 mg tioconazole nitrate + 100 mg lidocaine
62287429|NCT01650987||Col 1|Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
62287430|NCT01650987||Col 2|Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
62287431|NCT01650987||Col 3|patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
62287432|NCT01650987||Endometrial 4|patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
62287433|NCT01650987||endometrial 5|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
62287434|NCT01650987||endometrial 6|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
62287435|NCT05119803||Parkinson's patients|"The cognitive status of the participants will be evaluated using the 'Standardized Mini Mental Test'.~The 'Unified Parkinson's Disease Assessment Scale Part 3' will be used to evaluate the motor function of Parkinson's patients.~Spinal posture will be assessed using the IDIAG M360 (IDIAG, Fehraltorf, Switzerland) Spinal Mouse. This device is an electronic computer aided measuring device that measures the range of motion of the spine and evaluates the angle and shape of the spine in the sagittal and frontal planes.~The upper extremity functions of Parkinson's patients will be evaluated with the '9-Hole Peg Test'.~A short version of PDQ-39, called the 8-item Parkinson's Disease Questionnaire (PDQ-8), will be applied to determine the quality of life of Parkinson's patients. The PDQ-8 consists of eight items that belong to each of the eight dimensions in the original PDQ-39."
62475163|NCT00695162|OTHER|1|hearing impaired inpatients
61904778|NCT03757390|EXPERIMENTAL|Sequence 2|"* period 1: receive CJ-30060 5/160/10mg~* period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg"
61904779|NCT03085849|EXPERIMENTAL|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.~1. Dose escalation phase: 6-12 patients~2. MTD expansion cohort: 10 patients"
61919782|NCT01064245|EXPERIMENTAL|Asthma|Those with diagnosed asthma.
62475164|NCT00695162|OTHER|2|Non-hearing-impaired inpatients
62653646|NCT02600260|OTHER|no intervention|Pregnant women admitted in hospital for clinical treatment and/or delivery and that does not score for thromboprophylaxis.
62462031|NCT05420805|ACTIVE_COMPARATOR|Post-biotic (sodium butyrate and zinc oxide)|The product (sodium butyrate+ zinc oxide) is in the form of tablets. Dosage is dependent on weight. For participants weighing \<25 kg, one 380 mg tablet is intended to be administered orally twice a day . For participants weighing 25 to 40 kg, three 380 mg tablet dose is intended to be administered orally according to the 2+1 tablets per day schedule (12h interval). For participants weighing ≥40 kg, four 380 mg tablet dose is intended to be administered orally according to the 2+2 tablets per day schedule (12h interval).
62462032|NCT03110302|ACTIVE_COMPARATOR|Office-based telehealth (OBT)|Veterans come to a VA clinic and meet with a therapist via telehealth, using videoconferencing technology
62653647|NCT01122173|EXPERIMENTAL|Robotic catheter manipulation, Ablation|To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
62653648|NCT05055765|EXPERIMENTAL|TEST GROUP I|Thin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
62653649|NCT05055765|ACTIVE_COMPARATOR|TEST GROUP II|Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
62653650|NCT00941551||Group A|receiving levothyroxine postoperatively
62653651|NCT00941551||Group B|not-receiving levothyroxine postoperatively
62653652|NCT00207740|EXPERIMENTAL|CNTO 148 (golimumab)|
62653653|NCT00207740|PLACEBO_COMPARATOR|Placebo|
62287436|NCT05119803||Healthy control group|"The cognitive status of the participants will be evaluated using the 'Standardized Mini Mental Test'. This scale is frequently used for the general determination of the cognitive status of individuals rather than for the purpose of diagnosis.~The upper extremity functions of healty control group will be evaluated with the '9-Hole Peg Test'.~Spinal posture will be assessed using the IDIAG M360 (IDIAG, Fehraltorf, Switzerland) Spinal Mouse. This device is an electronic computer aided measuring device that measures the range of motion of the spine and evaluates the angle and shape of the spine in the sagittal and frontal planes."
62287437|NCT01737931|EXPERIMENTAL|Topical Steroid|Topical medication of steroid (Dexamethasone) to the application sites after the patch removal
62287438|NCT01737931|EXPERIMENTAL|Topical antihistamine|Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal
62287439|NCT01737931|NO_INTERVENTION|No-treatment|No treatment to the application sites after the patch removal
62287440|NCT03835741|EXPERIMENTAL|Automated Oxygen titration|In this arm, an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
62287441|NCT03835741|OTHER|Manual Oxygen titration|In this arm, a manual adjustment of oxygen during patient hospitalisation by hospital staff
62287442|NCT05146557||Group Obese adolescents|BMI above the 97th percentile + 2.17 to+2.18 SDS
62287443|NCT05146557||Group Normal weight adolescents|BMI between the 10th and 90th percentile -1.64 to +1.64 SDS
62462033|NCT03110302|ACTIVE_COMPARATOR|Home-based telehealth (HBT)|Veterans stay at home and meet with the therapist via telehealth, using videoconferencing technology
62462034|NCT03110302|EXPERIMENTAL|In home, in person (IHIP)|Therapist goes to the Veterans' homes to provide the psychotherapy
62462035|NCT01848301|EXPERIMENTAL|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
62462036|NCT02958111|EXPERIMENTAL|Adjuvant capecitabine|Adjuvant chemotherapy with single-agent capecitabine
62653654|NCT06430489|PLACEBO_COMPARATOR|Medical air administration|
62653655|NCT06430489|EXPERIMENTAL|Nitrous oxide administration|
62653656|NCT04611815|ACTIVE_COMPARATOR|Robotic-assisted total knee arthroplasty|Patients undergoing robotic-assisted total knee arthroplasty with use of Journey II BCS implants
62653657|NCT04611815|ACTIVE_COMPARATOR|Conventional total knee arthroplasty|Patients undergoing conventional total knee arthroplasty with use of Journey II BCS implants
62653658|NCT02610010|EXPERIMENTAL|IMRT alone|Intensity-modulated radiotherapy without cisplatin-based concurrent chemotherapy
62287444|NCT02597062|EXPERIMENTAL|Carfilzomib plus cyclophosphamide plus dexamethasone|20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (\< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg
62287445|NCT03644290|EXPERIMENTAL|Cognitive training|Semantic categorization training sessions
62287446|NCT03644290|ACTIVE_COMPARATOR|Control condition|Five sessions of behavioral control condition with information and education
62287447|NCT06381193|EXPERIMENTAL|Group A|
62653659|NCT02610010|ACTIVE_COMPARATOR|IMRT plus concurrent chemotherapy|Intensity-modulated radiotherapy with cisplatin-based concurrent chemotherapy
62653660|NCT06069089||Controlled beta thalassemia major|Controlled beta thalassemia major Hb\>9g/dl , serum ferritin \<500ng/ml
62653661|NCT06069089||Uncontrolled beta thalassemia major|Uncontrolled beta thalassemia major Hb\<9g/dl , serum ferritin \>500ng/ml
62653662|NCT00248053|OTHER|Lower GI|
62287448|NCT06381193|EXPERIMENTAL|Group B|
62287449|NCT06381193|EXPERIMENTAL|Group C|
62287450|NCT06381193|PLACEBO_COMPARATOR|Group D|
62307920|NCT02897908||liver fibrosis and steatosis|measurements of liver fibrosis and steatosis will be obtained using Vibration controlled transient elastography FDA approved device- FibroScan for the purpose of building a data base of potential subjects for future research.
62653663|NCT05673122|EXPERIMENTAL|Implant intact with shield|Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, the implant is in contact with the shield.
62653664|NCT05673122|EXPERIMENTAL|Implant not intact with shield|Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, there was a jumping gap more than 2mm between the shield and the implant, in which the gap was grafted with Xenograft.
62653665|NCT04632485||Aim 1: Ultrasound Only|Approximately 280 asymptomatic participants will participate in ultrasound (US) studies and blood work.
62678900|NCT06019832|ACTIVE_COMPARATOR|Group A: Stemmed Tibial Implant|This study group will receive a stemmed tibial implant as part of their TKA.
62462037|NCT02958111|NO_INTERVENTION|Observation|Clinical follow-up and surveillance only
61904780|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
61904781|NCT06466408|EXPERIMENTAL|enzyme group|enzyme group consumed 30 mL of vegetable and fruit enzymes (The contents include needle-leaf cherries, cherries, apples, cranberries, blackberries, black currants, blueberries, beets, broccoli, cabbage, carrots, Concord grapes, cranberries, elderberries, kale, oranges, peaches, papayas, parsley, pineapples, raspberries, red currants, spinach, and tomatoes, etc.)(Enzyme Village, Chiayi, Taiwan) mixed with 150 mL of water twice a day (at breakfast and dinner) for 14 consecutive days.
61904782|NCT06466408|PLACEBO_COMPARATOR|placebo group|The placebo group followed the same protocol but consumed malt syrup (Amazon, USA) mixed with 150 mL of water twice a day (at breakfast and dinner) for 14 consecutive days.
61904783|NCT03460509|PLACEBO_COMPARATOR|Sugammadex 0 mg/kg|Placebo NaCl 0,9%
61904784|NCT03460509|ACTIVE_COMPARATOR|Sugammadex 0,25 mg/kg|Sugammadex 0.25 mg/kg IBW
62462038|NCT03097900|ACTIVE_COMPARATOR|Treatment (Caffeine Citrate) group|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
62462039|NCT03097900|PLACEBO_COMPARATOR|Placebo (Water) group|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
62462040|NCT03923465|ACTIVE_COMPARATOR|EPP with EMD+BS|Using minimally invasive surgery, entire papilla preservation technique with the adjunctive use of amelogenins and bone substitutes
62462041|NCT03923465|OTHER|EPP without EMD+BS|Using minimally invasive surgery, entire papilla preservation technique without the adjunctive use of amelogenins and bone substitutes
62462042|NCT01790204|EXPERIMENTAL|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
62462043|NCT05065229|EXPERIMENTAL|A|Right foot no.520 Left foot no.521
62462044|NCT05065229|EXPERIMENTAL|B|Right foot no.521 Left foot no.520
62462045|NCT04828720|ACTIVE_COMPARATOR|PRF group|"The PRF was prepared according to Choukroun et al. \[5\] immediately before surgery, a 10 ml blood sample was taken by venipuncture of the antecubital vein without anticoagulant. The tubes were centrifuged immediately by a dedicated centrifuge at 3,000 rpm for 10 minutes.~A structured fibrin clot was produced by such preparation protocol in the middle of the tube, with the erythrocytes at the bottom and acellular plasma at the top. Following elimination of acellular plasma, a sterile scissors was used to separate the PRF from the erythrocytes. A membrane of PRF was formed by squeezing it gently between two pieces of gauze. Folding of the membrane was performed to achieve the required thickness (1.0 mm) with accurate trimming to match the palatal wound. The obtained membrane was then placed at the palatal donor site and compressed with gauze. Then, it was secured with 3-0 black plaited silk and a stent was placed."
62462046|NCT04828720|PLACEBO_COMPARATOR|Control group|the palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in control group used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
62462047|NCT04828720|EXPERIMENTAL|ozonated group|the palatal wound in ozanaited group will be painted by ozainated oil 2ml daily for 1 week, Patients used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
62462048|NCT06035445|EXPERIMENTAL|In-person adolescent-friendly service (iPAS) intervention:|Adolescents at study clinics who score low or intermediate on transition readiness during screening will be invited to enroll in the study. Adolescents attending clinics randomized to the in-person supported adolescent friendly services will attend their clinic after school hours on a designated day or on weekends dedicated for adolescent care monthly for 9 months.
62462049|NCT06035445|EXPERIMENTAL|mHealth (InTSHA) intervention|Adolescents at study clinics who score low or intermediate on transition readiness during screening will be invited to enroll in the study. Adolescents attending clinics randomized to the mHealth intervention will receive the InTSHA intervention based in the Got Transition elements and the SMART model for 9 months.
62475165|NCT02003833|EXPERIMENTAL|Poly-L-lactic acid|Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
61904785|NCT03460509|ACTIVE_COMPARATOR|Sugammadex 0,5 mg/kg|Sugammadex 0.50 mg/kg IBW
62088624|NCT02407509|EXPERIMENTAL|Part IIF- LGSOC Cohort|"VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with LGSOC who have previously been treated with the combination of VS-6766 and defactinib within 24 months of trial entry. Additionally, all patients must have displayed anti-tumour activity on the VS-6766 and defactinib combination, defined as follows:~• Experienced a response - confirmed partial response (PR) or complete response (CR) - according to RECIST 1.1.~Or~• Experienced stable disease (SD) according to RECIST 1.1 (Appendix 3) AND patient received VS-6766 and defactinib treatment for a minimum of 12 months.~All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle."
62088625|NCT04501328|EXPERIMENTAL|CIC+VA-CRAFT|Coaching Into Care plus VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
62088626|NCT04501328|ACTIVE_COMPARATOR|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
62088627|NCT02303574|EXPERIMENTAL|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
62653666|NCT04632485||Aim 2: Ultrasound and MRI|A sub-group of 40 at risk volunteers determined from the clinical ultrasound scans and bloodwork from Aim 1 will be asked to participate in a longitudinal US and MRI study. Participants will be selected from a population of individuals that do not have significant atherosclerosis, but present with increased risk due to the presence of soft, lipid rich plaque that are hypoechogenic or echolucent on ultrasound B-mode images. These participants may also satisfy the current clinical guidelines of increased vessel diameter and decreased blood flow velocity with ultrasound that may result in plaque deposition for being in the at risk population. Participants will receive US, strain and shear wave imaging every 2 years after the first scan in Aim 1 and MRI Imaging in Year 1 and Year 5: separated by 4 years
62653667|NCT03889288|NO_INTERVENTION|conventional management of postoperative pain|Patients who have had an aortic valve replacement surgery have a conventional management of pain after surgery. The pain is treated by morphine using a patient-controlled analgesia for the administration. Patients are recruiting prospectively or possibly retrospectively. The management is usual, nothing from the conventional care of patients change, only data will be collected.
62287451|NCT06157671||Patients at increased risk for developing pancreatic cancer|Patients being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes) and are undergoing other imaging diagnostic tests to determine if they have pancreatic cancer
62653668|NCT03889288|EXPERIMENTAL|Medical device - electronic-pain killer|In addition to the conventional management of postoperative pain, patients benefit from perioperative treatment sessions with medical device. Patients are recruiting prospectively.
62653669|NCT05111717||group 1|Peripheral venous blood samples will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). DNA will be obtained from blood samples , and global DNA methylation analysis will be done.
62653670|NCT00255580|EXPERIMENTAL|1|Active cannabis (1-8% THC by weight)
62653671|NCT00255580|PLACEBO_COMPARATOR|2|Placebo cannabis
62653672|NCT04657913|EXPERIMENTAL|cold water spray group|application of cold water in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
62653673|NCT04657913|EXPERIMENTAL|cold saline spray group|application of cold 0.9% SF (saline) in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
62653674|NCT04657913|NO_INTERVENTION|control group|no intervention
62287452|NCT00555087|EXPERIMENTAL|A= Nebido|It is and intervention study with 1 arm
62287453|NCT02527707|EXPERIMENTAL|lonafarnib/ritonavir|Lonafarnib starting at 50 mg BID in combination with ritonavir 100 mg BID and escalating to lonafarnib 75 mg BID and then 100 mg BID as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
62653675|NCT01767337|EXPERIMENTAL|injection of 0.1 mL saline|deliver from FluGen 101.2 device
62653676|NCT01767337|EXPERIMENTAL|injection of 0.25 mL saline|deliver from FluGen 101.2 device
62653677|NCT01767337|EXPERIMENTAL|Injection of 0.5 mL saline|deliver from FluGen 101.2 device
62653678|NCT03160950|EXPERIMENTAL|LuxaCrown|
62653679|NCT05650502||ISC (ISAMIMA children group-Cobly)|"This group included children from 6 to 59 months living in Cobly and receiving the SMC treatment. The treatment is administered for three consecutives days for 4 months (from july to october).~For children under 12 months: one dose of SP 250/12.5mg on day 1 AQ 75mg once daily for 3 days For children from 12 to 59 months: one dose of SP 500/25mg on day 1 AQ 150 mg once daily for 3 days A monthly visit was planned for monitoring during the follow up. Sample was collected in jun, september, january and April."
62653680|NCT05650502||IST (ISAMIMA children group-Tchaourou)|"This group included children from 6 to 59 months living inTchaourou and who did not receiving the SMC treatment.~A monthly visit was planned for monitoring during the follow up. Sample was collected in jun, september, january and April."
62653681|NCT03658525|EXPERIMENTAL|MR LINAC RADIOTHERAPY|RADIOTHERAPY DELIVERED ON MR LINAC
62653682|NCT00478621|EXPERIMENTAL|Group A|
62088628|NCT02303574|PLACEBO_COMPARATOR|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
62088629|NCT05727995|EXPERIMENTAL|Experimental group|The dressing is a polyurethane film with acrylic adhesive that adheres the dressing to the skin surrounding the incision and a polyurethane shell that encapsulates the foam bolster and interface layer, providing a closed system. The PICO pump maintains negative pressure wound therapy (NPWT) at 80mmHg (nominal) +/- 20mmHg to the wound surface. Exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film. PICO is intended for use in wound sizes (surface area x depth) up to 400 cm3, which are considered to be low to moderately exuding. The kit is intended to be used for 7 days on low-exuding wounds and 6 days on moderately exuding wounds. The therapy duration of the kit may be less than indicated if a clinical practice or other factors, such as wound type, wound size, rate or volume of exudate, orientation of the dressing or environmental conditions, result in more frequent dressing changes.
62088630|NCT05727995|SHAM_COMPARATOR|Control group|Patients in the control arm will receive a usual care dressing using absorbent cotton pads placed in contact with the wound. Dressings will be applied directly to the wound surface to protect the wound surface environment and the wound bed. Dressing chances are scheduled every 48h.
62088631|NCT06051539|EXPERIMENTAL|Cohort A: Restart Intervention|Participants in Cohort A will perform active walking for 30 minutes at a time with MR-001, at least 3 times a week, for 12 weeks in their home/community environment.
62088632|NCT06051539|NO_INTERVENTION|Cohort B: Continued Washout|Participants in Cohort B will continue their washout period for another 24 weeks.
62653683|NCT00478621|EXPERIMENTAL|Group B|
62653684|NCT00478621|EXPERIMENTAL|Group C|
62653685|NCT00478621|EXPERIMENTAL|Group D|
62653686|NCT00478621|EXPERIMENTAL|Group E|
62653687|NCT00478621|ACTIVE_COMPARATOR|Group F|
62653688|NCT01989832||Biological and clinical Data collected|
62653689|NCT01496742|EXPERIMENTAL|Bevacizumab+MetMAb|
61904786|NCT03460509|ACTIVE_COMPARATOR|Sugammadex 1mg/kg|Sugammadex 1.0 mg/kg IBW
62653690|NCT01496742|ACTIVE_COMPARATOR|Bevacizumab+Placebo|
62653691|NCT01496742|EXPERIMENTAL|Pemetrexed+MetMAb|
62653692|NCT01496742|ACTIVE_COMPARATOR|Pemetrexed+Placebo|
62653693|NCT04749199|EXPERIMENTAL|Enhanced mirror therapy group|Participants in this group will perform complex and randomized finger opposition and reposition movements based on the training protocol, along with enhanced complexity and altered clarity of the displayed image.
62653694|NCT04749199|SHAM_COMPARATOR|Standard mirror therapy group|Participants in this group will perform simple and sequential finger opposition and reposition movements, along with a clear image showing the exercising hand of the participants.
62653695|NCT01389778|EXPERIMENTAL|Metformin|Subjects treated with metformin.
62678901|NCT06019832|ACTIVE_COMPARATOR|Group B: Non-Stemmed Tibial implant|This study group will receive a non-stemmed tibial implant as part of their TKA.
62462050|NCT06035445|ACTIVE_COMPARATOR|Standard of Care/Delayed Intervention|Adolescents at study clinics who score low or intermediate on transition readiness during screening will be invited to enroll in the study. Adolescents attending clinics randomized to deliver the standard of care before transitioning to adult care in their standard local adult clinic. Participants will be invited to receive the intervention the clinic is randomized to deliver when the 9 month period of administering the standard of care is complete.
62088633|NCT01714089|EXPERIMENTAL|RNS60 125 ml|125 ml of RNS60 administered weekly by IV infusion
62088634|NCT01714089|EXPERIMENTAL|RNS60 250 ml|250 ml of RNS60 administered weekly by IV infusion
62088635|NCT01714089|ACTIVE_COMPARATOR|Interferon beta-1a|Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.
62088636|NCT01010893|EXPERIMENTAL|Influenza vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose).
62088637|NCT01010893|EXPERIMENTAL|Influenza vaccination and co-vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
62088638|NCT00001230||1|Patients that have, or are suspected of having, one of the filarial infections affecting humans
62088639|NCT03194776|EXPERIMENTAL|LLG783|Patients will receive LLG783 i.v. infusion every 4 weeks for 12 weeks.
62088640|NCT03194776|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
62088641|NCT03073629|ACTIVE_COMPARATOR|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
62287454|NCT06318845|EXPERIMENTAL|Sequence A|DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days
62462051|NCT06035445|NO_INTERVENTION|Healthcare Providers|Healthcare providers working at one of study clinics, administering the study intervention selected for that clinic.
62088642|NCT03073629|NO_INTERVENTION|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
62088643|NCT02379117||Crohn's Disease Patients|Patients with a diagnosis of Crohn's disease fitting the studies inclusion \& exclusion criteria.
62088644|NCT02379117||Healthy Volunteers|For healthy volunteers the studies exclusion criteria apply.
62287455|NCT06318845|EXPERIMENTAL|Seqeunce B|DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days
62088645|NCT01839825|EXPERIMENTAL|QuietCare|QuieCare system installed
62088646|NCT01839825|NO_INTERVENTION|control|no system installed
62088647|NCT03985098|EXPERIMENTAL|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
62088648|NCT03985098|NO_INTERVENTION|Control|usual care
62088649|NCT04936490|EXPERIMENTAL|Crocin|
62088650|NCT04936490|PLACEBO_COMPARATOR|Placebo|
62088651|NCT01861301|EXPERIMENTAL|Treatment (tivantinib)|Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
62088652|NCT02816333||Type B aortic dissection|Patients with Type B aortic dissection requiring TEVAR
62088653|NCT04990440|EXPERIMENTAL|Part A: Bermekimab Dose 1|Participants will receive bermekimab Dose 1 or placebo as an intravenous (IV) infusion weekly from Week 0 to Week 15.
62475166|NCT02003833|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
62088654|NCT04990440|EXPERIMENTAL|Part B: Bermekimab Dose 2|Participants will receive bermekimab Dose 2 or placebo as an IV infusion weekly from Week 0 to Week 15.
62287456|NCT06318845|EXPERIMENTAL|Sequence C|DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days
62462052|NCT06035445|NO_INTERVENTION|Observational cohort|Adolescents at study clinics who score high on transition readiness during screening will not be invited to enroll in the study but will be asked for their consent to have their clinic records reviewed for medical records, retention data and transition readiness data. They will also complete a questionnaire at Months 9, 18, and 24.
62462053|NCT05371665|EXPERIMENTAL|Culturally Adapted Compass for Courage|All youth will receive the culturally adapted Compass for Courage from Native American providers in the school setting.
62462054|NCT00902109||perimetry, HRT, OCT|perimetry, HRT, OCT
62462055|NCT05706337|ACTIVE_COMPARATOR|propofol group|According to grouping，patients were premeditated with injection of Propofol 1-2mg / kg IV . If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is \>60, propofol 0.5mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil.
62462056|NCT05706337|EXPERIMENTAL|ciprofol group|According to grouping，patients were premeditated with injection of ciprofol 0.2-0.5mg/kg IV. If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is \>60, ciprofol 0.1mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil in both groups.
62462057|NCT01085825|ACTIVE_COMPARATOR|Manual Vacuum Aspiration|
62462058|NCT01085825|ACTIVE_COMPARATOR|Electric Vacuum Aspiration|
62462059|NCT04526210|EXPERIMENTAL|Treatment A|Participants will receive bupropion.
61904787|NCT03460509|ACTIVE_COMPARATOR|Sugammadex 2mg/kg|Sugammadex 2 mg/kg IBW
61904788|NCT00629967|ACTIVE_COMPARATOR|A|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A \& B)
61904789|NCT00629967|ACTIVE_COMPARATOR|B|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A \& B)
62287457|NCT06318845|EXPERIMENTAL|Sequence D|DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days
62307921|NCT04786210|EXPERIMENTAL|Site A of keloid scar|One half of keloid scarring on a single subject
62462060|NCT04526210|EXPERIMENTAL|Treatment B|Participants will receive bupropion with ALXN1840.
62088655|NCT04990440|EXPERIMENTAL|Part C: Bermekimab Dose 3|Participants will receive bermekimab or placebo at a higher or lower dose (not less than \[\<\] Dose 1) than Part B, but with a maximum dose of Dose 3 IV weekly based on pharmacokinetic (PK), pharmacodynamic (PD), efficacy, and safety analysis.
62462061|NCT03283254|EXPERIMENTAL|Practical Resources for Effective Postpartum (PREPP)|A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
61904790|NCT01452100|EXPERIMENTAL|prednisone|• Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
62088656|NCT03505359|EXPERIMENTAL|Experimental group|Group treated by the new protocol with partial knee immobilization
62088657|NCT03505359|ACTIVE_COMPARATOR|Control group|Group treated by a standard protocol for ACL reconstruction.
62088658|NCT04288193||Trinity Health LIFE New Jersey PACE|Participants enrolled in Trinity Health LIFE New Jersey PACE facility who received an antipsychotic medication for the treatment of BPSD or insomnia
62088659|NCT01306565|ACTIVE_COMPARATOR|High dose atorvastatin|Three 80mg daily doses of atorvastatin
62088660|NCT01306565|EXPERIMENTAL|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
62462062|NCT03283254|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
62462063|NCT03705897|OTHER|Screening|Employ innovative methods for assessing personalized guideline-based screening in the clinic setting to evaluate guideline-based, over- and under-screening. Interventions include Computerized Risk Stratification Tool, Algorithmic Risk Stratification Tool, and Step completion assessment.
62462064|NCT00206583|EXPERIMENTAL|EV/DNG (Qlaira, BAY86-5027)|Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
61919783|NCT00633867|ACTIVE_COMPARATOR|Intubation c McGrath videolaryngoscope|Tracheal Intubation using McGrath video-laryngoscope
62088661|NCT00671463|EXPERIMENTAL|1|Pre-operative pancreatic duct stenting
62462065|NCT04697745|ACTIVE_COMPARATOR|dexamethasone intrathecal|
62462066|NCT04697745|ACTIVE_COMPARATOR|dexmedetomidine intrathecal|
62088662|NCT00671463|NO_INTERVENTION|2|Control group, no endoscopy and no stent pre-operatively
62088663|NCT01839643|EXPERIMENTAL|2.4 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
62088664|NCT01839643|EXPERIMENTAL|3.0 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
62088665|NCT01333943|EXPERIMENTAL|Experimental|Saphenous (Adductor Canal) Nerve Block
62088666|NCT01333943|ACTIVE_COMPARATOR|Control|Femoral Nerve Block
62088667|NCT05247879|ACTIVE_COMPARATOR|Commercial reduced-osmolarity oral rehydration solution (ORS|
62088668|NCT05247879|EXPERIMENTAL|VS011, new children's ORS, a sugar-free blend of amino acids and electrolytes|
62088669|NCT05594563|ACTIVE_COMPARATOR|Treatment Arm|Difluoromethylornithine (DFMO) pill ,1000mg/m2/day, for 6 months
62462067|NCT03494322|EXPERIMENTAL|Avelumab + cetuximab|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab + cetuximab combination therapy:~Cycle 1~* Day 1: Cetuximab 500\* mg/m2 given IV over approx 3 hrs~* Day 15: Cetuximab 500\* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~All other cycles:~- Days 1 and 15: Cetuximab 500\* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~\*Cetuximab dose will be dependent on outcome of safety run-in.~There must be a 60 minute break between the administration of cetuximab and avelumab."
62462068|NCT03494322|OTHER|Avelumab monotherapy|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab monotherapy will be given as follows:~All cycles Avelumab 10 mg/kg on days 1 and 15 given IV over approximately 1 hour"
62462069|NCT04107454|ACTIVE_COMPARATOR|Active group|The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
61919784|NCT00633867|ACTIVE_COMPARATOR|Intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
62088670|NCT05594563|PLACEBO_COMPARATOR|Placebo Arm|Placebo pill taken twice a day orally for 6 months
62088671|NCT05013164|EXPERIMENTAL|Folinic Acid + Behavioral Therapy|Children receiving folinic acid and behavioral therapy. Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks.
62088672|NCT05013164|NO_INTERVENTION|Behavioral Therapy|Children received only behavioral therapy for 12 weeks.
62088673|NCT02703285|EXPERIMENTAL|questionnaire|task of the participants in the study to determine the chest sound based on specific sounds
62088674|NCT03344614|EXPERIMENTAL|raltitrexed combined with apatinib|therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.
62088675|NCT04469842|EXPERIMENTAL|Immunosuppression with Extended-Release Tacrolimus|"LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
62088676|NCT04469842|ACTIVE_COMPARATOR|Immunosuppression with Intermediate Release Tacrolimus|"IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
62088677|NCT05729815|EXPERIMENTAL|Relaxation group|Relaxation program sessions had 3 phases: initial dialogue (2 min); a main section (25 min); final ritual (3 min). During the main section, participants listened and observed the therapist, who described and demonstrated all the exercises of the session, which were focused on Jacques Choque Method (Choque, 1994).
62088678|NCT05729815|EXPERIMENTAL|Loose parts play group|Loose Parts Play program sessions had 3 phases: initial dialogue (2 min); main section (25 min); final ritual (3 min). During the main section, participants were allowed to play freely with any materials (loose parts) available in the playground.
62462070|NCT04107454|PLACEBO_COMPARATOR|Placebo group|Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
62088679|NCT05729815|EXPERIMENTAL|Combined group|In the combined program, the sessions had 4 phases: initial dialogue (3 min); loose parts play moment (20 min); relaxation exercises moment (5 min); final ritual (2 min).
62088680|NCT05729815|NO_INTERVENTION|Control group|No intervention. Maintained their usual routines.
62088681|NCT05835492||Setting 1 - Hospital Readmission Reduction|North Bristol NHS Trust and University Hospitals Bristol and Weston NHS Foundation Trust (hospital readmissions reduction): Using myCOPD to support high risk patients with a primary focus on acute hospital admission discharge bundle following AECOPD. Patients who have been discharged from hospital following an AECOPD diagnosis and assessed in a follow-up clinic, including virtual wards, within 6 weeks can be included.
62088682|NCT05835492||Setting 2 - Pulmonary Rehabilitation|Cornwall Partnership NHS Foundation Trust (increasing community care provision of PR): Using myCOPD to support delivery of PR and self-management in the community.
62088683|NCT06053593||Testing of Ketostix by Persons with Diabetes.|Each PWD will test Ketostix in their self-collected urine, complete a labeling evaluation, and test four urine control solutions.
62088684|NCT06053593||Testing of Keto-Diastix by Persons with Diabetes.|Each PWD will test Keto-Diastix in their self-collected urine, complete a labeling evaluation, and test four urine control solutions.
62088685|NCT00830947|EXPERIMENTAL|OrthoAccel Device|Device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
62462071|NCT05451446|EXPERIMENTAL|proprietary water|Participants in this group will consume a proprietary water blend for 5-free living days and then throughout their heat stress environment day.
62287458|NCT06318845|EXPERIMENTAL|Seqeunce E|DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days
62287459|NCT06318845|EXPERIMENTAL|Seqeunce F|DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days
62287460|NCT03957967||acute pain|Patient with acute pain
62287461|NCT00777179|EXPERIMENTAL|Vandetanib|
62462072|NCT05451446|ACTIVE_COMPARATOR|carbohydrate-electrolyte drink|Participants in this group will consume a commercial carbohydrate-electrolyte drink for 5-free living days and then throughout their heat stress environment day.
61904791|NCT01452100|PLACEBO_COMPARATOR|placebo|Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
62287462|NCT00777179|PLACEBO_COMPARATOR|Placebo|
62287463|NCT04825054|EXPERIMENTAL|A 60-min trial ventilated with NAVA|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
62287464|NCT04825054|EXPERIMENTAL|A 60-min trial ventilated with PCV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
62287465|NCT04825054|EXPERIMENTAL|A 60-min trial ventilated with PSV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
62307922|NCT04786210|EXPERIMENTAL|Site B of keloid scar|One half of keloid scarring on a single subject
62462073|NCT05451446|PLACEBO_COMPARATOR|distilled water|Participants in this group will consume distilled water for 5-free living days and then throughout their heat stress environment day.
62462074|NCT02841488|ACTIVE_COMPARATOR|Continuous nerve block|Continuous peripheral sciatic nerve block through popliteal perineural catheter with ropivacaine
62462075|NCT02841488|ACTIVE_COMPARATOR|Systemic analgesia|Intravenous fentanyl patient controlled analgesia device
62462076|NCT05325047|EXPERIMENTAL|Speech rehabilitation|
62462077|NCT05856903||Severe hemophiliac patients under emicizumab|
62462078|NCT05856903||Healthy volunteers|
62462079|NCT00581646||1|gynecologic cancer survivors
62462080|NCT00581646||2|survivors of any type of malignancy with history of BMT/SCT
62462081|NCT00581646||3|non-cancer infertile women awaiting third party reproduction
61904792|NCT05724693|EXPERIMENTAL|Group 1 -Mild Hepatic Impairment|Drug: single dose Bemnifosbuvir (BEM)
62462082|NCT00488748|EXPERIMENTAL|MST|Magnetic Seizure Therapy (MST)
62462083|NCT00488748|ACTIVE_COMPARATOR|ECT|Electroconvulsive Therapy (ECT)
62462084|NCT04549584||metaplastic breast cancer|Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.
62462085|NCT04549584||non-metaplastic breast cancer|Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer
62462086|NCT03415997|ACTIVE_COMPARATOR|Total Body Weight|
62653696|NCT04131972|EXPERIMENTAL|Single arm 1|Each patient will be planned to perform 7 study visits and at the second visit excision / lumpectomy and REGENERA implant will be performed during the same surgical intervention.
61904793|NCT05724693|EXPERIMENTAL|Group 2-Moderate Hepatic Impairment|Drug: single dose Bemnifosbuvir (BEM)
62088686|NCT00830947|SHAM_COMPARATOR|Sham Device (inactive device)|Sham device will look identical to active devices but will not deliver vibration to the patient.
62088687|NCT01435408|ACTIVE_COMPARATOR|Conventional treatment.|Conventional primary PCI in STEMI.
62088688|NCT01435408|EXPERIMENTAL|IPost|Ischemic postconditioning in STEMI.
62462087|NCT03415997|ACTIVE_COMPARATOR|Lean Body Weight|
62653697|NCT05284175|EXPERIMENTAL|Orelabrutinib, orally, 50 mg QD|Orelabrutinib, orally, 50 mg QD
62653698|NCT03986099|NO_INTERVENTION|Standard of care|SOC viral load
62653699|NCT03986099|ACTIVE_COMPARATOR|Near point of care|POC viral load
62653700|NCT04487548|NO_INTERVENTION|Control group|The control group will have their preadmission clinic telephone call as normal and may be given advice to quit smoking and information about available smoking cessation resources over the phone.
62653701|NCT04487548|EXPERIMENTAL|Intervention group|The intervention group will be emailed (or postal mailed) the smoking cessation bundle with educational video, brochure, referral to the Smokers' Helpline and direct referral to an online pharmacy for nicotine replacement.
61904794|NCT05724693|EXPERIMENTAL|Group 3 - Healthy Subjects matching mild and moderate impairment groups|Drug: single dose Bemnifosbuvir (BEM)
62287466|NCT01097772|OTHER|Ovation Abdominal Stent Graft System|Implant of Ovation Abdominal Stent Graft System
62653702|NCT03575169||Patients with TBI|Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
62653703|NCT06514859|ACTIVE_COMPARATOR|Laparoscopic repair of inguinal hernia|
62653704|NCT06514859|ACTIVE_COMPARATOR|Open repair of inguinal hernia|
62653705|NCT06466239|EXPERIMENTAL|PNF Stretching Group|The PNF stretching method for each muscle was applied to the athlete in the form of self-stretching by the participant, with the direct treatment concept of hold and relax technique, with the training of a specialist physiotherapist. The muscle to be stretched (the antagonist muscle for the pattern - the muscle that causes the limitation) was first brought to the position where it could be extended, and at that point, the stretched muscle was contracted submaximally (65% of the intensity determined according to the Stretch Intensity Scale) for 5 seconds, causing isometric contraction. Then, the athlete was given 5 relax commands for the tense muscle. Then, the stretched muscle was stretched as far as it could go, and the muscle that needed to be stretched was passively stretched for 20 seconds (1 set). After a 5-second rest interval, the method was repeated and 8 sets (lasting 4 minutes) were performed for 1 muscle. Stretching was done on the hamstring muscle.
62653706|NCT06466239|OTHER|Static Stretching Group|Classical static stretching was applied to the hamstring muscle in the same position for 30 seconds each, 8 repetitions, a total of 4 minutes for one leg and 8 minutes for both legs, in the stance position of PNF stretching.
62653707|NCT03857256|PLACEBO_COMPARATOR|Placebo|matching placebo for 12 weeks.
62653708|NCT03857256|ACTIVE_COMPARATOR|Oat beta-glucan 1.5g|CP105F (Oat beta-glucan) 1.5g (1 tablet of 0.5g TID) for 12 weeks.
62653709|NCT03857256|ACTIVE_COMPARATOR|Oat beta-glucan 3g.|CP105F (Oat beta-glucan) 3g (2 tablets of 0.5g TID) for 12 weeks.
62653710|NCT03857256|ACTIVE_COMPARATOR|Oat beta-glucan 6g.|CP105F (Oat beta-glucan) 6g (4 tablets of 0.5g TID) for 12 weeks.
62653711|NCT01756703|EXPERIMENTAL|MT-3995 Low group|
62653712|NCT01756703|EXPERIMENTAL|MT-3995 High group|
62653713|NCT01756703|PLACEBO_COMPARATOR|Placebo group|
62653714|NCT02305264|EXPERIMENTAL|PET -18F-DPA-714 and 18F-FDG|"18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mCi(185MBq), will be injected via an arm intravenous catheter."
62653715|NCT01266343||Experimental Group|
62653716|NCT01266343||Control Group|
62653717|NCT01555775|EXPERIMENTAL|P-CHO supplement|This group will drink the P-CHO supplement in the first trial and the fruit milk shake in the second.
62653718|NCT01555775|EXPERIMENTAL|Fruit Milk Sake|This group will drink the fruit milk shake in the first trial and the P-CHO supplement in the second.
62653719|NCT03668210||Patients with contralateral ACL after Ligamentoplasty|"Athletic patients who have consulted in Sports Medicine Department at the Rennes University Hospital, victims of an ACL rupture during sports activity and who declared a contralateral ACL after the ligamentoplasty.~Isokinetic evaluation."
62653720|NCT03668210||Patients without contralateral ACL rupture|"Athletic patients who have consulted in Sports Medicine Department at Rennes University Hospital, without ACL rupture.~Isokinetic evaluation."
61904795|NCT05724693|EXPERIMENTAL|Group 4 - Severe Hepatic Impairment|Drug: single dose Bemnifosbuvir (BEM)
61904796|NCT05724693|EXPERIMENTAL|Group 5 - Normal hepatic function matching severe impairment group|Drug: single dose Bemnifosbuvir (BEM)
61904797|NCT01528267|ACTIVE_COMPARATOR|Autologous blood|Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
61904798|NCT01528267|SHAM_COMPARATOR|Saline|Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
62088689|NCT01435408|EXPERIMENTAL|Deferred primary PCI.|Deferred strategy in STEMI.
62088690|NCT04004858|ACTIVE_COMPARATOR|Standard margin|Patient cohort planned with the current standard PTV margin
62287467|NCT00308763|ACTIVE_COMPARATOR|1|Nicotine patch plus placebo sustained-release bupropion
62287468|NCT00308763|ACTIVE_COMPARATOR|2|Placebo nicotine patch plus sustained-release bupropion
62287469|NCT00308763|ACTIVE_COMPARATOR|3|Nicotine patch plus sustained-release bupropion
62287470|NCT04298762|PLACEBO_COMPARATOR|Comparison Group|Physicians in the control group did not receive peer comparison emails.
61904799|NCT01425580|EXPERIMENTAL|liraglutide|The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
62088691|NCT04004858|EXPERIMENTAL|Reduced margin|Patient cohort planned with the reduced margin validated from the retrospective study
62088692|NCT03816527||AUD patients|Individuals with alcohol use disorder
62088693|NCT03816527||Healthy controls|Healthy controls
62088694|NCT06285916|EXPERIMENTAL|NORA520 Tablets Dose 1|NORA520 Tablets Dose 1
62287471|NCT04298762|EXPERIMENTAL|Intervention Group|Physicians in the intervention group received peer comparison emails.
62462088|NCT03094312|EXPERIMENTAL|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
62287472|NCT05903521||Control group|BMI ≥ 35 kg/m2 without previous bariatric surgery
62462089|NCT04138732|EXPERIMENTAL|Intervention treatment group|This arm will receive the intervention treatment aimed to help improve their health behaviors. Interventions will include nutrition workshops and personal consultation for employees at risk, environmental intervention that includes brief exercise session prior to weekly meetings, placement of sports equipment in the department, and pedometer program, and stress reduction workshops. Healthy options will be demarcated in the hospital cafeteria.
62462090|NCT04138732|OTHER|Control group|This arm will be the control group and not receive the intervention treatment aimed to help improve their health behaviors.Once completing their time as the control group, they will continue into another phase of the trial and receive the intervention treatment.
62462091|NCT01822548|EXPERIMENTAL|Vildagliptin & metformin|Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
62462092|NCT01822548|ACTIVE_COMPARATOR|Glibenclamide & metformin|Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
62462093|NCT01798212|OTHER|full thickness gastroplication|
62462094|NCT04752462|NO_INTERVENTION|Standard of Care with provider|Participant will continue follow up for sleep apnea with provider.
62462095|NCT04752462|EXPERIMENTAL|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
62462096|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
62462097|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
62462098|NCT00735904|EXPERIMENTAL|AG-013736/Cisplatin/Gemcitabine|
62462099|NCT03938922|EXPERIMENTAL|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
62462100|NCT03546842|EXPERIMENTAL|9vHPV vaccine|Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6
62287473|NCT05903521||Treatment group|Having had Sleeve Gastrectomy or Roux-en-Y Gastric Bypass more than 12 months ago and without a weight regain of ≥ 15% of nadir weight
62287474|NCT01987908|EXPERIMENTAL|Cohort A (Drug)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
62287475|NCT01987908|PLACEBO_COMPARATOR|Cohort A (Placebo)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
62462101|NCT04048369|EXPERIMENTAL|Point-of-care testing arm|for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7.
62462102|NCT04048369|ACTIVE_COMPARATOR|Core Lab testing arm|for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday)
62462103|NCT02376348|NO_INTERVENTION|Control|Individuals receiving the standard Ministry of Health Package
62462104|NCT02376348|EXPERIMENTAL|Intervention|Individuals receiving the targeted demand creation strategy to increase adult men taking up VMMC
62462105|NCT02011776||Group 1|using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops
62088695|NCT06285916|EXPERIMENTAL|NORA520 Tablets Dose 2|NORA520 Tablets Dose 2
62088696|NCT06285916|PLACEBO_COMPARATOR|Placebo Tablets|Placebo Tablets
62307923|NCT01079923|ACTIVE_COMPARATOR|Single High Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects .
62307924|NCT01079923|ACTIVE_COMPARATOR|Daily Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects.
62653721|NCT05645991|PLACEBO_COMPARATOR|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
62287476|NCT01987908|EXPERIMENTAL|Cohort B (Drug)|In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
62287477|NCT01987908|PLACEBO_COMPARATOR|Cohort B (Placebo)|The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
62287478|NCT00454779|EXPERIMENTAL|Arm 1|Panitumumab + Docetaxel + Cisplatin
62287479|NCT00454779|OTHER|Arm 2|control
62287480|NCT04523974||Preemptive and Precise Intervention|Preemptive surgical intervention will be performed on enrolled CKD-SHPT patients. Safety and efficacy of this intervention will be evaluated during peri-operative period, and long-term outcomes will be analyzed during 1-year follow-up.
62653722|NCT05645991|EXPERIMENTAL|Coconut Sap Powder|Capsules containing coconut sap powder (CSP; 1.5 g/day) were taken orally once daily for 8 weeks.
62653723|NCT02105090|PLACEBO_COMPARATOR|Sodium chloride 0.9%|Sodium chloride 0.9% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
62653724|NCT02105090|EXPERIMENTAL|Articaine hydrochloride 1%|Articaine hydrochloride 1% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
62653725|NCT02105090|EXPERIMENTAL|Articaine hydrochloride 2%|Articaine hydrochloride 2% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
62653726|NCT02992717||Patients undergoing elective general anaesthesia|Male and female adult patients undergoing elective general anaesthesia.
62653727|NCT04262219|EXPERIMENTAL|iShare|Participants will be asked to listen to a podcast intervention.
62653728|NCT04605081|EXPERIMENTAL|Naltrexone+Bupropion Medication|
62653729|NCT04605081|PLACEBO_COMPARATOR|Placebo|
62653730|NCT04748718|EXPERIMENTAL|Injury Prevention Arm|exercise-based neuromuscular training injury prevention program
61904800|NCT01425580|ACTIVE_COMPARATOR|glimepiride|4 mg p.o. (QD)
61904801|NCT06023836|ACTIVE_COMPARATOR|group 1: ESWT treatment|Participants in this group will only receive ESWT treatment
62287481|NCT03689192|EXPERIMENTAL|ARG1-18,19,20 peptide vaccine|One ARG1-vaccine every third week for 45 weeks.
62287482|NCT04206878||HIV-exposed infants (HEI) eligible for birth testing|All HEI live births born at, or presenting to, one of the 3 study sites, within 3 days of birth.
62653731|NCT00872742|EXPERIMENTAL|1|Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
62653732|NCT00872742|ACTIVE_COMPARATOR|2|Participants will receive psychoeducation and supportive therapy (PST) for TTM.
62678902|NCT06337097|EXPERIMENTAL|Troponin Surveillance|Participants in Group 1, will have blood tests performed prior to each immune checkpoint inhibitor infusion for 12 weeks.
62678903|NCT06337097|EXPERIMENTAL|Standard of Care|Participants in Group 2, will have standard of care testing for any heart-related side effects of immune checkpoint inhibitors.
61904802|NCT06023836|ACTIVE_COMPARATOR|Dry needling|Participants in this group will only receive Dry needling treatment
61904803|NCT00340899||Pregnant women|Pregnant women with gestational age between 6 and 22 weeks
61904804|NCT00966914|PLACEBO_COMPARATOR|Placebo|Placebo in combination with cisplatin and either paclitaxel or docetaxel
62653733|NCT02054780|ACTIVE_COMPARATOR|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling (PC) was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH. PC is considered an enhanced model of a Psychosocial Support program for OVC."
62653734|NCT02054780|EXPERIMENTAL|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Recent trials have provided direct evidence that CBT may be effective in HIV prevention. TF-CBT has eight components including: Psychoeducation, Relaxation, Affective Modulation, Cognitive Coping, Trauma Narrative, In-vivo Exposure (if needed), Conjoint parent-child session, and Enhancing Safety Skills. This cognitive behavioral therapy teaches skills such as how to think about situations differently in order to feel better. It also includes helping a child face the fear and anxiety of the traumatic situations, rather than avoid them. Based on earlier pilot projects, the MoH has endorsed TF-CBT in Zambia.
62653735|NCT02933814|NO_INTERVENTION|Control Group|Patients in Group 1 (Plain Bupivacaine) will be treated intra-operatively with injections of 0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.
62653736|NCT02933814|EXPERIMENTAL|Experimental Group|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
62653737|NCT05167071|EXPERIMENTAL|HBM4003 and Toripalimab|HBM4003 combined with Toripalimab in patients with advanced NEN and other solid tumors
62653738|NCT01390506|ACTIVE_COMPARATOR|Sodium-selenite infusion|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
62653739|NCT01390506|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride
62653740|NCT05192642||Larotrectinib clinical trial cohort|
62653741|NCT05192642||RW external comparator cohort|
62653742|NCT05853900|EXPERIMENTAL|Arm A|Mobile application A as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults.
62653743|NCT05853900|EXPERIMENTAL|Arm B|Mobile application B is an investigational digital therapeutic that is being studied for the preventative treatment of episodic migraine.
62653744|NCT04738383|EXPERIMENTAL|Version 1: Paramedic|Physician is replaced by a paramedic, but the physician still acts as a supervisor.
62653745|NCT04738383|EXPERIMENTAL|Version 2: Physician-on-call|Physician is not present, but is on call.
62653746|NCT04738383|EXPERIMENTAL|Version 3: Trained instructor|Physician acts as a supervisor, but is not constantly present. The instructor received a special training preparing for emergency cases.
62653747|NCT04738383|NO_INTERVENTION|Control group|The sessions take place in the usual way, meaning that a physician is present in every session.
62653748|NCT05411237|ACTIVE_COMPARATOR|Pegylated Liposomal Doxorubicin|Participants will receive a single intravenous dose of PLD 20 mg/m2 once every 3 weeks for a total of 18 weeks.
62653749|NCT05411237|ACTIVE_COMPARATOR|Paclitaxel|Participants will receive a single intravenous dose of PTX 100 mg/m2 once every 3 weeks for a total of 18 weeks.
62653750|NCT01675778|OTHER|Hydromorphone|Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
62653751|NCT05072288|EXPERIMENTAL|Remote activity program|Activity program based on objective evaluation. Possibility of 35 different programs primarily targeting impairments (lower limb, upper limb or balanced)
62653752|NCT01740206|ACTIVE_COMPARATOR|Amphetamine and/or methylphenidate|Patients who took their amphetamine and/or methylphenidate the morning of surgery.
61904805|NCT00966914|ACTIVE_COMPARATOR|Tavocept (BNP7787)|Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
61904806|NCT05176457|NO_INTERVENTION|BEFORE PICT'REA introduction|Patients will have the usual communication tools (pen and paper, hands gestures...)
62653753|NCT01740206|EXPERIMENTAL|Hold stimulant medication|Patients who did not take their stimulant medication the morning of surgery.
62653754|NCT03991533||affected|patients with a histologically confirmed head and neck tumour
61904807|NCT05176457|EXPERIMENTAL|AFTER PICT'REA introduction|Patients will be given a tablet to communicate with the caregivers whenever needed
62462106|NCT02011776||Group 2|using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops
62462107|NCT04737200|EXPERIMENTAL|Nighttime cycled enteral feeds first|Patients will start nighttime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start daytime cycled enteral feeds for 12 hours.
62462108|NCT04737200|EXPERIMENTAL|Daytime cycled enteral feeds first|Patients will start daytime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start nighttime cycled enteral feeds for 12 hours.
62462109|NCT06222749|EXPERIMENTAL|NC follicular|Naturally cycling, healthy women in the follicular menstrual cycle phase.
62462110|NCT06222749|EXPERIMENTAL|NC luteal|Naturally cycling, healthy women in the luteal menstrual cycle phase.
62462111|NCT06222749|EXPERIMENTAL|OC combined|Healthy women taking combined oral hormonal contraceptives.
62462112|NCT06222749|EXPERIMENTAL|OC progestogen-only|Healthy women taking progestogen-only oral hormonal contraceptives.
62462113|NCT02192047|EXPERIMENTAL|palm olein margarine|8 weeks
62462114|NCT02192047|EXPERIMENTAL|IE palm olein margarine|8 weeks
62462115|NCT02192047|EXPERIMENTAL|IE soybean oil-based margarine|8 weeks
62462116|NCT03482427|EXPERIMENTAL|Intervention|After completion of the Healthy Hear Score assessment, participants will receive a lifestyle intervention based on the Healthy Heart Score results for 12-weeks by trained dietetic interns on-site. Participants will receive a check-in email or phone 6 weeks after the initial visit. A Registered Dietitian is also available to speak with patients. The intervention will consist on educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors
62462117|NCT03482427|NO_INTERVENTION|Control|Participants in the control group will follow their usual care protocol after taking the Healthy Heart Score assessment. Researchers will provide the Healthy Heart Score survey results, but will not discuss or interpret the results with them. Participants can discuss any concern they have with their usual physician if they choose. After the follow-up visit and upon completion of the study, all participants in the control group may also receive the educational handouts and will be granted access to the Healthy Heart Score application if they wish.
62462118|NCT01374919|OTHER|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
62462119|NCT02539589|EXPERIMENTAL|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
62462120|NCT02539589|ACTIVE_COMPARATOR|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
62462121|NCT01264120|EXPERIMENTAL|Health Psychology Intervention|A 50 minute health psychology behavioural intervention with sessions pre-surgery, post-surgery and at 3 month follow up.
62462122|NCT01264120|NO_INTERVENTION|Control Group|The control group receive usual care through the bariatric surgery process.
62462123|NCT03608215|EXPERIMENTAL|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
62462124|NCT03608215|SHAM_COMPARATOR|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
62462125|NCT01220076|EXPERIMENTAL|Tamoxifene|
62462126|NCT04721652||Hemodialysis Patients (nondiabetic)|Nondiabetic adult hemodialysis patients
62462127|NCT01434121|ACTIVE_COMPARATOR|High Dose Ascorbic Acid|Subject receives a high dose of infused Vitamin C
62462128|NCT01434121|ACTIVE_COMPARATOR|Low Dose Ascorbic Acid|Subject receives a low dose of infused Vitamin C
62462129|NCT01434121|PLACEBO_COMPARATOR|Placebo|Subject receives an infusion of saline
61904808|NCT03554694|EXPERIMENTAL|Start with prebiotics|Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
62462130|NCT05193279|EXPERIMENTAL|SCB-2019/SCB-2019/placebo, 12 to < 18 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
62462131|NCT05193279|EXPERIMENTAL|Placebo/SCB-2019/SCB-2019, 12 to < 18 years|Day 1: placebo, Day 22 and 43: SCB-2019
62462132|NCT05193279|EXPERIMENTAL|SCB-2019/placebo/SCB-2019, 12 to < 18 years|Day 1 and 43: SCB-2019, Day 22: placebo
62462133|NCT05193279|EXPERIMENTAL|Low dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
62462134|NCT05193279|EXPERIMENTAL|Mid dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
62462135|NCT05193279|EXPERIMENTAL|High dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
62462136|NCT05193279|EXPERIMENTAL|SCB-2019/SCB-2019/placebo, 5 to < 12 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
62462137|NCT05193279|EXPERIMENTAL|Placebo/SCB-2019/SCB-2019, 5 to < 12 years|Day 1: placebo, Day 22 and 43: SCB-2019
62462138|NCT05193279|EXPERIMENTAL|SCB-2019/placebo/SCB-2019, 5 to < 12 years|Day 1 and 43: SCB-2019, Day 22: placebo
62462139|NCT05193279|EXPERIMENTAL|Low dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
62462140|NCT05193279|EXPERIMENTAL|Mid dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
62462141|NCT05193279|EXPERIMENTAL|High dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
62462142|NCT05193279|EXPERIMENTAL|SCB-2019/SCB-2019/placebo, 2 to < 5 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
62462143|NCT05193279|EXPERIMENTAL|Placebo/SCB-2019/SCB-2019, 2 to < 5 years|Day 1: placebo, Day 22 and 43: SCB-2019
62462144|NCT05193279|EXPERIMENTAL|SCB-2019/placebo/SCB-2019, 2 to < 5 years|Day 1 and 43: SCB-2019, Day 22: placebo
61904809|NCT03554694|EXPERIMENTAL|Start with placebo|Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.
61904810|NCT00065429|EXPERIMENTAL|BB-10901, 5mg/m2 - Phase I|
61904811|NCT00065429|EXPERIMENTAL|BB-10901, 10 mg/m2 - Phase I|
61904812|NCT00065429|EXPERIMENTAL|BB-10901, 20 mg/m2 - Phase I|
61904813|NCT00065429|EXPERIMENTAL|BB-10901, 40 mg/m2 - Phase I|
61904814|NCT00065429|EXPERIMENTAL|BB-10901, 60 mg/m2 - Phase I & Phase II|Phase I and Phase II were consecutive and sequential. Different patients received the 60mg/m2 dose in Phase I and in Phase II.
61904815|NCT00065429|EXPERIMENTAL|BB-10901, 67.5 mg/m2 - Phase I|
61904816|NCT00065429|EXPERIMENTAL|BB-10901, 75 mg/m2 - Phase I|
61904817|NCT02630901|EXPERIMENTAL|PRX003|
61904818|NCT02630901|PLACEBO_COMPARATOR|Placebo|
61904819|NCT02855541|EXPERIMENTAL|Cycling intervention|Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
61904823|NCT04546984|EXPERIMENTAL|Single dose of HEC96719 （Part 1，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC96719 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
61904824|NCT04546984|EXPERIMENTAL|Mulltiple doses HEC96719（ Part 2, Cohort 1）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
61904825|NCT04546984|EXPERIMENTAL|Mulltiple doses HEC96719（ Part 2, Cohort 2）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
61904826|NCT04546984|EXPERIMENTAL|Mulltiple doses HEC96719（ Part 2, Cohort 3）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
61904827|NCT04546984|EXPERIMENTAL|Mulltiple doses HEC96719（ Part 2, Cohort 4）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
61904828|NCT04546984|EXPERIMENTAL|Mulltiple doses HEC96719（ Part 2, Cohort 5）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
61904829|NCT05966337|ACTIVE_COMPARATOR|Control group 1 (usual care)|Patients undergo physiotherapy treatment twice daily, transitioning from the ICU to the ward. The treatment plan spans several days, starting on the first postoperative day after ICU discharge. In the ICU, Day 1 includes diaphragmatic breathing exercises, coughing stimulus, upper limb exercises (shoulder flexion/extension, abduction), and lower limb exercises (thigh flexion, dorsiflexion/plantarflexion). Day 2 involves diaphragmatic breathing, coughing stimulus, upper limb exercises, lower limb exercises, cycling for 3 minutes, and respiratory device exercises. Upon moving to the ward on Day 3, patients perform diaphragmatic breathing, coughing stimulus, upper limb exercises, lower limb exercises, and a 5-minute walk. Day 4 focuses on diaphragmatic breathing, coughing stimulus, and a 10-minute walk. Finally, on Day 5, patients engage in diaphragmatic breathing, coughing stimulus, and a 15-minute walk.
61904830|NCT05966337|EXPERIMENTAL|Intervention group 2 (CPAP)|They will be submitted to the same care as the control group, adding NIV with nasal CPAP 10cmH2O for 1 hour using device and brand approved by ANVISA, during the 5 days of hospitalization, both in the ICU and in the ward. The frequency of the sessions will be two (2) per day, in the morning and in the afternoon. Flexibility of time for carrying out the procedure is also planned, since in a hospital environment the patient can often undergo exams, other behaviors that may make it difficult to apply the protocol at the initially scheduled time. After the fifth day, the patient will be reassessed with the same instruments reported.
61904831|NCT05966337|EXPERIMENTAL|Intervention group 2 (BIPAP):|They will undergo the same care as the control group, adding NIV with nasal BIPAP with IPAP of 13cmH2O and EPAP 8 cmH2O for 1 hour, using equipment and brand approved by ANVISA, during the 5 days of hospitalization, both in the ICU and in the ward . The frequency of the sessions will be two (2) per day, in the morning and in the afternoon. Flexibility of time for carrying out the procedure is also planned, since in a hospital environment the patient can often undergo exams, other behaviors that may make it difficult to apply the protocol at the initially scheduled time. After the fifth day, the patient will be reassessed with the same instruments reported.
61904832|NCT03117439|NO_INTERVENTION|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
61904833|NCT03117439|EXPERIMENTAL|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
62462145|NCT05193279|EXPERIMENTAL|Low dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
62462146|NCT05193279|EXPERIMENTAL|Mid dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
62462147|NCT05193279|EXPERIMENTAL|High dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
62462148|NCT05193279|EXPERIMENTAL|SCB-2019/SCB-2019/placebo, birth to < 2 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
62462149|NCT05193279|EXPERIMENTAL|Placebo/SCB-2019/SCB-2019, birth to < 2 years|Day 1: placebo, Day 22 and 43: SCB-2019
62462150|NCT05193279|EXPERIMENTAL|SCB-2019/placebo/SCB-2019, birth to < 2 years|Day 1 and 43: SCB-2019, Day 22: placebo
62287483|NCT02139956||stress urinary incontinence|group 1 women with stress urinary incontinence by ultrasonography
62287484|NCT02139956||continent group|group 2 women without stress urinary incontinence by ultrasonography
62287485|NCT03091504|EXPERIMENTAL|Albuterol via High flow nasal cannula|Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.
62287486|NCT01857921|ACTIVE_COMPARATOR|Pravastatin group|
62462151|NCT02602925|EXPERIMENTAL|Dose decrease|Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
62462152|NCT02602925|OTHER|Usual care|Patients will continue treatment with the normal dose and treatment regimens will be based on usual daily practice care. Treatment decisions are made at the discretion of the treating physician.
62462153|NCT04675580|EXPERIMENTAL|Tele Toy Talk|Caregivers of child participants receive 1-hour of telemedicine featuring parent-mediated naturalistic developmental behavioral intervention weekly for 10 weeks.
62462154|NCT04675580|NO_INTERVENTION|Multiple Baseline|Prior to receiving the intervention, participants will be randomized into one of three baseline conditions: a three-, four-, or five-week baseline period. At each weekly baseline session, caregivers will record the Tele-BOSCC (see Outcomes Measures section).
62462155|NCT02492568|EXPERIMENTAL|SBRT + Pembrolizumab|Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
62653755|NCT03991533||control|histologically confirmed Whartin tumour or pleomorphic adenoma of the parotid gland, without malignant transformation
62653756|NCT00795340|EXPERIMENTAL|Arm I Cediranib|Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
62287487|NCT01857921|EXPERIMENTAL|Combination of Atorvastatin and trimetazidine group|
62462156|NCT02492568|ACTIVE_COMPARATOR|Pembrolizumab alone|Dose of pembrolizumab is 200 mg, every 3 weeks.Patients can continue the pembrolizumab treatment for maximal 2 years.
62462157|NCT01450085|ACTIVE_COMPARATOR|GeneXpert|Point of care GeneXpert
62462158|NCT01450085|ACTIVE_COMPARATOR|LED Microscopy|Point of care LED Microscopy
62653757|NCT00795340|PLACEBO_COMPARATOR|Arm II Placebo|Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
62653758|NCT04802434|EXPERIMENTAL|Strengthening Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member, or friend) will attend weekly 3 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach cognitive compensation and mindfulness-based emotion regulation skills. Strategies from the PEERS Social Skills Program will also be taught. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
62653759|NCT04802434|ACTIVE_COMPARATOR|PEERS Social Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member or friend) will attend weekly 1.5 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach skills for improving social relationships and handling social rejection. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
62653760|NCT04802434|NO_INTERVENTION|Delayed Treatment Control Group|Participants in the delayed treatment control group will participate in a 10-month wait period, during which they will complete data collection procedures at three time points (Baseline, Post, and 6-month follow-up).
62287488|NCT04234737|EXPERIMENTAL|Hypnotherapy|
62287489|NCT04234737|NO_INTERVENTION|Control|
62287490|NCT04481022|OTHER|group will receive proximal control exercises|
62287491|NCT00880360|EXPERIMENTAL|Ontak|Administration of Ontak IV for treatment of epithelial ovarian cancer
62287492|NCT01818726|EXPERIMENTAL|Serum ferritin level ≥ 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin ≥ 1000 mg/L on programmed immune suppressive treatment with cyclosporine A who were receiving chelation with Exjade (deferasirox) during the study
62287493|NCT01818726|EXPERIMENTAL|Serum ferritin level < 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin \< 1,000 mg/L on programmed immune suppressive treatment with cyclosporine A who were not receiving the investigational product
62475167|NCT06267703||Participants with chronic atrophic gastritis|Corpus-dominant chronic atrophic gastritis was characterized by a PGI/PGII ratio of less than 3.
62462159|NCT04509180|EXPERIMENTAL|Catheter ablation group|Patients undergoing catheter procedure will be put under conscious sedation and local anesthesia. Pulmonary vein isolation and posterior wall isolation will be performed with a radiofrequency ablation catheter (20-45W, open-tip irrigation). Ablation index will be used for the lesion formation guidance (450-500 on anterior aspects; 350-400 on the posterior aspects). A wide antral circumferential ablation will be performed for pulmonary veins and a box lesion set for the posterior left atrial wall. Voltage mapping and signal analysis performed by the operator will be used to assess electrical isolation of the pulmonary veins and posterior wall and to identify gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
62462160|NCT04509180|ACTIVE_COMPARATOR|Convergent group|Patients undergoing convergent procedure will be put under general anesthesia. A minimally invasive epicardial radiofrequency ablation (30W, 90s) of posterior wall will be performed through a subxiphoid window. Monitoring of the esophageal temperature will be performed with an esophageal temperature probe set at 38°C. Next, an endocardial radiofrequency ablation (20-40W, open-tip irrigation; ablation index 450-500 anteriorly and 350-400 posteriorly) of pulmonary veins in a wide antral circumferential fashion will be performed. Voltage mapping and signal analysis performed by the operator will be used to assess the electrical isolation of the pulmonary veins and posterior wall and to identify the gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
62475168|NCT06267703||Healthy participants|Healthy participants in the TwinGene cohort were included.
62475169|NCT01850173|EXPERIMENTAL|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
62653761|NCT02837159|EXPERIMENTAL|mHealth application|The assessment of the end points will be made at three moments: at baseline, at 8 weeks (at the end of the program) and at 12 months of follow-up. The intervention will consist in: 1)Feedback daily or weekly of physical exercise and diet through the application (notice) according to the records of diet and exercise and following recommendations of International Organizations 2) Participation in three sessions of seminars (1 hour each every 15 days) on habits of life healthy and cancer and the self-regulation through measurements performed by the application 3) Calls weekly to the patients of way individual to comment possible errors or doubts about the application, of 10 min of duration (8 calls).
62475170|NCT01850173|NO_INTERVENTION|Control group|general recommendations about physical activity and lifestyle
62475171|NCT06485531|ACTIVE_COMPARATOR|Pranayama|Nadi Shothana Pranayama was applied to the patients for 15 minutes before the surgery and for 7 days after the surgery. After the application, FVC, FEV1, and FEV1/FVC values were measured with a spirometer (Contec Spirometer SP70B, Contec Medical Systems Co,. Ltd., China) and recorded in the Patient Follow-up Form. In cases where the patient did not perform well, the measurement was repeated at least three times and the best data was taken. Systolic and diastolic blood pressure, heart rate, respiratory rate, and peripheral oxygen saturation, which were thought to affect the results of FVC, FEV1, and FEV1/FVC values, were also measured and recorded. In addition, hematocrit level, analgesia dose, and amounts used during the day were recorded daily and in the Patient Follow-up Form. Pain levels were evaluated 4 times daily (10:00-14:00-22:00-06:00) during the 0th to 6th days after surgery and recorded on the Visual Analog Scale Form.
62653762|NCT02837159|NO_INTERVENTION|Usual care|Usual care
62653763|NCT05676658|EXPERIMENTAL|Coherent breathing|
62653764|NCT05676658|PLACEBO_COMPARATOR|Placebo coherent breathing|
62653765|NCT00720759|EXPERIMENTAL|Arm 1|D-cycloserine + distributed treatment
62287494|NCT01136343|EXPERIMENTAL|lifestyle modified project|education, counseling
62653766|NCT00720759|SHAM_COMPARATOR|Arm 2|D-cycloserine + condensed treatment
62653767|NCT00720759|PLACEBO_COMPARATOR|Arm 3|Placebo + distributed treatment
62653768|NCT00720759|PLACEBO_COMPARATOR|Arm 4|Placebo + condensed treatment
62653769|NCT01267032|EXPERIMENTAL|Arm 1|Integrated Care + Cognitive-Behavioral Treatment for Insomnia
62653770|NCT01267032|SHAM_COMPARATOR|Arm 2|Integrated Care + Desensitization Treatment for Insomnia
62287495|NCT01136343|NO_INTERVENTION|control|waiting list control
62287496|NCT00152867|ACTIVE_COMPARATOR|1|Dexamethasone
62287497|NCT00152867|PLACEBO_COMPARATOR|2|Placebo
62653771|NCT03003117|EXPERIMENTAL|Intervention Program|Experimental: Intervention Program
62653772|NCT03003117|ACTIVE_COMPARATOR|Usual Care|Active comparator: Usual Care
62653773|NCT03530293|EXPERIMENTAL|Pre-randomization Valbenazine|Participants received valbenazine once daily for up to 12 weeks, depending on if and when randomization occured. The starting dose was 20 mg for participants \<50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for participants \<50 kg and 80 mg for participants ≥50 kg to achieve an optimal dose of valbenazine for each participant.
62287498|NCT02186184|EXPERIMENTAL|Orthokeratology in the first year|The participants would wear orthokeratology in the first year and then switch to spectacle in the second year
62462161|NCT01806805|EXPERIMENTAL|Zonegran|Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
62462162|NCT01806805|PLACEBO_COMPARATOR|placebo|Placebo /Experimental Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
62462163|NCT04109521|EXPERIMENTAL|Trained vendors|"The intervention consists of a Training, Certification and Marketing scheme for dairy vendors operating in the informal sector. This scheme includes a 12hr training offered at the beginning of the study, followed by 2 quarterly visits where milk will be tested for microbiological quality and results will be discussed with participants.~The training will include three main components: (i) milk hygiene and quality; (ii) business skills; (iii) milk marketing.~Trainings will be offered free of charge. The trainings will be given by business development service (BDS) providers, who will be trained through a training of trainers ahead of the intervention. Quarterly visits will involve the collection of a milk sample from each participant in the experimental arm in an unannounced visit and results on the microbiological quality of the milk reported back individually and explained to each vendor."
62653774|NCT03530293|PLACEBO_COMPARATOR|Randomized Placebo|Participants received placebo (matching valbenazine) once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.
62653775|NCT03530293|EXPERIMENTAL|Randomized Valbenazine|Participants received their optimized dose of valbenazine once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.
62653776|NCT02597270||Cohort 1|Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.
62653777|NCT01923558|EXPERIMENTAL|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
62653778|NCT01923558|ACTIVE_COMPARATOR|Aricept|Aricept® 23 mg tablet of Eisai Inc
62653779|NCT02049632|EXPERIMENTAL|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
62653780|NCT00544414|EXPERIMENTAL|Treatment|"Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.~Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.~Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy."
62653781|NCT01484340|EXPERIMENTAL|Counseling only|Participants in this arm will receive advice to quit smoking and self-help materials from the study interventionist in a standardized fashion (intensive anti-smoking counseling).
62653782|NCT01484340|EXPERIMENTAL|Nicotine Replacement Therapy +counseling|Participants in this arm will receive the nicotine patch in addition to the intensive anti-smoking counseling. Participants will receive instruction on proper use of the nicotine patch (i.e., placement, use of one patch a day, importance of not smoking while using the patch, and tapering of patches).
62653783|NCT03133676|EXPERIMENTAL|KA34 Active Drug|KA34 active drug in the dose range of 50 - 400 ug per knee
62287499|NCT02186184|ACTIVE_COMPARATOR|Spectacle in the first year|The participants would wear spectacle in the first year and then changed to orthokeratology in the second year
62653784|NCT03133676|PLACEBO_COMPARATOR|Placebo|Placebo is the formulation for KA34.
62653785|NCT03095287|EXPERIMENTAL|Alphanate|Participants were to receive alphanate 100 International Units (IU/kg/day) for up to 33 months in Immune tolerance induction (ITI) Treatment Phase. The dose could be increased up to 200 IU/kg/day based on Investigator's discretion. Following ITI Treatment Phase, participants were to enter the Prophylactic Phase where alphanate dose was to be tapered down in a step wise manner to reach a final prophylactic dose of 50 IU/kg every other day or 3 times per week, at the investigator's discretion.
62653786|NCT04200300||Nurses working with patients with mental disorders|Nurses in Germany currently working with patients with mental disorders
62462164|NCT04109521|NO_INTERVENTION|Untrained vendors|Participants in the no-intervention arm will receive the same unannounced quarterly visits, where milk will be sampled and tested for microbiological quality, but results will not be shared with the participants. The participants in this arm will only receive the training upon completion of the endline survey (i.e. when the study is finished).
62462165|NCT01823965|EXPERIMENTAL|ranibizumab|
62462166|NCT04271826|EXPERIMENTAL|cases with normal CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
62653787|NCT06062056|EXPERIMENTAL|Intervention|Behavioral health clinicians will use motivational interviewing with eligible patients to address vaccine hesitancy
62088697|NCT00813488|EXPERIMENTAL|Fentanyl buccal tablet first then immediate release oxycodone|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
62653788|NCT06062056|NO_INTERVENTION|Control|Control sites will adhere to standard practice in behavioral health sessions (i.e., no discussions about vaccination)
61904834|NCT02123914|EXPERIMENTAL|Aerobic exercise with Vit. C & Aerobic exercise|
62287500|NCT02494596|EXPERIMENTAL|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m\^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
62462167|NCT04271826|EXPERIMENTAL|cases with proven appendicitis on CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
62462168|NCT03142360|EXPERIMENTAL|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
62653789|NCT04816344||Group MP (n=35)|"The patients were separated into four groups according to the anaesthetic agents given.~Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage."
62653790|NCT04816344||Group MK (n=35)|Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg ketofol (10% ketamine + 10% propofol) iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg iv ketofol was given as additional dosage.
61904835|NCT02123914|ACTIVE_COMPARATOR|exercise without vit. c supplement & no exercise|
62653791|NCT04816344||Group DP (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage.
62653792|NCT04816344||Group DK (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg ketofol iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg ketofol iv was given as an additional dosage.
62653793|NCT01655901|EXPERIMENTAL|Active video gaming|Playing Kinect
61904836|NCT01849744|EXPERIMENTAL|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
62653794|NCT01655901|EXPERIMENTAL|Passive video gaming|Playing Xbox 360
62653795|NCT01655901|EXPERIMENTAL|Resting|Stay seated on a comfortable chair
62653796|NCT04926168||Adjuvant TMZ (Treatment group):|"Adjuvant TMZ (temozolomide) will be given to patients as standard of Care (SOC) treatment is administered on an outpatient basis.~Patients will be provided with medication diaries and instructed in their use. TMZ will be dispensed as SOC."
61904837|NCT04267900|EXPERIMENTAL|99mTc-HPArk2 SPECT/CT|The patients were injected with 11.1 (MBq) per kilogram body weight of 99mTc-HPArk2 in one dose intravenously and underwent SPECT/CT scan 30-60 min later.
61904838|NCT03338322|EXPERIMENTAL|Twisted file adaptive|Files that are used in root canal preparation in adaptive motion
62653797|NCT04926168||Delay TMZ (Observation group):|"Patients in this cohort will have their TMZ in the adjuvant setting delayed and they will be observed with SOC procedures. Once the patient recurs, will be off observation and will be able to either have TMZ prescribed or something other."
62653798|NCT05232890|EXPERIMENTAL|Datterino tomato purée from hydroponic technology|100% Italian datterino tomato purée deriving from hydroponic technology (soilless) with particular characteristics such as nickel free and zero residue.
61904839|NCT03338322|ACTIVE_COMPARATOR|Reciproc|Reciproc files are used in root canal preparation with reciprocation motion
61904840|NCT06492499||SVC Approach Group|This group includes patients who underwent zero-fluoroscopy radiofrequency catheter ablation (RFCA) for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) approach. The catheter was inserted through the median cubital vein or basilic vein, navigating through the axillary vein, subclavian vein, and brachiocephalic vein to reach the SVC. The ablation procedure was performed under conscious sedation and local infiltration anesthesia, with a large-tip electrode catheter used for mapping and ablation guided by the EnSite NavX system. The ablation parameters were set at 40 W power and 50°C temperature.
61919785|NCT05030961|EXPERIMENTAL|Pediatric Cochlear Implant Candidate Group|Participants who are in the process of receiving standard of care cochlear implant evaluation. Participants will receive a virtual team-based clinic as a part of the candidacy evaluation process for one year.
62287501|NCT02494596|EXPERIMENTAL|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m\^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
62287502|NCT02494596|EXPERIMENTAL|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m\^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m\^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
62287503|NCT04513470|EXPERIMENTAL|COVID-19|Five subjects, male or female \> 18 and \< 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
62287504|NCT04005794|ACTIVE_COMPARATOR|VR Social Skills Training|Participants will undergo a virtual reality social skills training program for 10 sessions. Each session takes about an hour. Participants visit the lab twice a week. Therefore, the training duration is 5 weeks.
62287505|NCT04005794|OTHER|Cognitive training game|If there is a significant improvement in social skills for the active treatment condition, the reason might be that the participants were exposed to social environment by coming to the lab and interacting with the research staff twice a week for 5 weeks and/or they used a computerized training tool twice a week for 5 weeks. In order to control for these potential confounds, we included a cognitive training arm. Participants will undergo a commercially available cognitive training program for ten 1-hour sessions (twice a week for 5 weeks).
62287506|NCT04005794|NO_INTERVENTION|Healthy Controls|Healthy controls are recruited to yield comparison data. They do not undergo training.
62287507|NCT00778973|EXPERIMENTAL|1|sertraline 100 mg tablets of Ranbaxy
62287508|NCT00778973|ACTIVE_COMPARATOR|2|Zoloft® 100 mg tablets
62462169|NCT03142360|NO_INTERVENTION|Non-Treatment group|On the other hand, the control group does not take anything.
62462170|NCT04489264||ASCT group|patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy
62462171|NCT04489264||Observation group|patients who achieved CR or PR after 6-8 cycles first-line therapy finish their therapy and go into follow-up
62462172|NCT02171793|EXPERIMENTAL|BI 1744 CL|
62462173|NCT02171793|PLACEBO_COMPARATOR|Placebo|
62462174|NCT04949932|EXPERIMENTAL|Intervention Arm|Poly herbal powder (PHP)
62462175|NCT04949932|PLACEBO_COMPARATOR|Placebo Arm|Powder of Cicer arietinum
62462176|NCT03310190||Participants receiving venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
62462177|NCT03480425|EXPERIMENTAL|Esophageal then tracheal intubated patient|Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to \>30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to \>30cm water pressure, and force of extubation recorded.
62462178|NCT02183688|EXPERIMENTAL|ASA + paracetamol + caffeine|
62462179|NCT02183688|ACTIVE_COMPARATOR|ASA + paracetamol|
62462180|NCT02183688|ACTIVE_COMPARATOR|ASA|
62462181|NCT02183688|ACTIVE_COMPARATOR|Paracetamol|
62462182|NCT02183688|ACTIVE_COMPARATOR|Caffeine|
62462183|NCT02183688|PLACEBO_COMPARATOR|Placebo|
62462184|NCT04901962|EXPERIMENTAL|JOBST® Confidence compression garments|The CE-marked class I medical devices JOBST® Confidence compression garments for lower and upper extremities will be tested under routine conditions according to their selected intended use. Subjects will be treated with either thigh-high compression stockings (AG) or arm compression garments without hand part (CG1), depending on their indication.
62462185|NCT06077526|EXPERIMENTAL|Experimental - P.E.A.K. Rx|Group A intervention, P.E.A.K. Rx, will be supervised and directed by healthcare clinicians, known as Pain Coaches. P.E.A.K. Rx will involve 2 meetings per week of pain education + physical activity.
62462186|NCT06077526|ACTIVE_COMPARATOR|Control - Usual Care|Group B will receive the community hospital's usual care.
62462187|NCT04659798||Participants with MM|Participants diagnosed with MM who have received treatment within 12 months preceding the enrollment will be observed prospectively. Data will be collected from the participants medical charts and via electronic case report forms (eCRFs).
62653799|NCT05232890|ACTIVE_COMPARATOR|Datterino tomato purée from conventional cultivation|100% Italian datterino tomato purée deriving from conventional cultivation.
62653800|NCT00843349|ACTIVE_COMPARATOR|900 mg Phosphate Diet-LC|dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
62653801|NCT00843349|ACTIVE_COMPARATOR|Ad Libitum Diet-LC|no dietary intervention + phosphorus binder (Lanthanum Carbonate)
62088698|NCT00813488|EXPERIMENTAL|Immediate Release Oxycodone first then FBT|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
62088699|NCT02046538|EXPERIMENTAL|Postoperative Chemo WITH Zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
62088700|NCT02046538|ACTIVE_COMPARATOR|Postoperative chemo WITHOUT zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
62088701|NCT01192490|EXPERIMENTAL|Lidocaine Arm|This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.
62088702|NCT01192490|PLACEBO_COMPARATOR|Lubricant|Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.
62462188|NCT04659798||Participants with AL Amyloidosis|Participants diagnosed with AL Amyloidosis who have received treatment within 12 months preceding the enrollment will be observed prospectively. Data will be collected from the participants medical charts and via eCRFs.
62653802|NCT00843349|ACTIVE_COMPARATOR|900 mg Phosphate Diet-LC Placebo|dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
62653803|NCT00843349|PLACEBO_COMPARATOR|Ad Libitum Diet-LC Placebo|no dietary intervention + placebo
62653804|NCT04711005|EXPERIMENTAL|SAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.1 mg/kg via slow IV infusion (40 minutes)
62287509|NCT02629731|EXPERIMENTAL|ankle OA|inclusion criteria: 1) diagnosis of ankle OA or PTTD \[non-control subjects only\], 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m) with the primary impediment to pain-free ambulation being ankle OA or PTTD
62287510|NCT02629731|EXPERIMENTAL|flat foot|inclusion criteria: 1) diagnosis of flat foot, 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m)
62653805|NCT04711005|EXPERIMENTAL|SAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 0.25 mg/kg via slow IV infusion (40 minutes)
62653806|NCT04711005|EXPERIMENTAL|SAD Cohort 3|(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes)
62088703|NCT01971307|EXPERIMENTAL|SGE-PsyScan|The SGE-PsyScan is an internet application to which the General Practitioner (GP) refers the patient, which includes the distress screener, the 4-Dimensional Symptom Questionnaire (4DSQ) and a series of additional questions for differentiating between stress, depressive, anxious and somatization symptoms. Based on the 4DSQ patients and GPs receive advices for possible treatments.
62088704|NCT01971307|NO_INTERVENTION|Usual care|Usual care for persons with psychosocial symptoms and disorders in Dutch primary care includes all usual care procedures; preventive, screening, diagnostic, (non-)pharmacological or therapeutic procedures which are routinely used in everyday care.
62653807|NCT04711005|EXPERIMENTAL|SAD Cohort 4|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes)
62653808|NCT04711005|EXPERIMENTAL|SAD Cohort 5|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes)
62653809|NCT04711005|EXPERIMENTAL|SAD Cohort 6|(2R,6R)-Hydroxynorketamine @ 4.0 mg/kg via slow IV infusion (40 minutes)
62653810|NCT04711005|EXPERIMENTAL|MAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
62653811|NCT04711005|EXPERIMENTAL|MAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
62653812|NCT04711005|PLACEBO_COMPARATOR|Placebo|Control product (placebo) will be sterile saline also administered via slow IV infusion (40 minutes).
62653813|NCT04711005|EXPERIMENTAL|CSF Capture Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.25 mg/kg via slow IV infusion (40 minutes)
62653814|NCT01490411|PLACEBO_COMPARATOR|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV.
62653815|NCT01490411|EXPERIMENTAL|20 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
62088705|NCT03431805|EXPERIMENTAL|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
62088706|NCT03431805|PLACEBO_COMPARATOR|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
62088707|NCT05584657|EXPERIMENTAL|Sulopenem etzadroxil/probenecid|Sulopenem etzadroxil/probenecid 500 mg/500 mg PO twice daily for 5 days
62088708|NCT05584657|ACTIVE_COMPARATOR|Amoxicillin/clavulanate|Amoxicillin/clavulanate PO twice daily for 5 days
62088709|NCT05616182||LARS ligament and bone prosthesis replacement was performed|To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
62088710|NCT04861922|EXPERIMENTAL|Unfractionated Heparin|A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour), which last 5 days or until the death or discharge.
62088711|NCT04861922|PLACEBO_COMPARATOR|Normal saline|The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.
62088712|NCT04883346|EXPERIMENTAL|Liraglutide|Treated with Liraglutide
62088713|NCT06696937|EXPERIMENTAL|Tai chi|Tai chi is a practice that involves a series of slow gentle movements and physical postures, a meditative state of mind, and controlled breathing. Tai chi originated as an ancient martial art in China. Over the years, it has become more focused on health promotion and rehabilitation.
62088714|NCT06696937|EXPERIMENTAL|Full body vibrator|Advocates say that as little as 15 minutes a day of whole-body vibration three times a week may aid weight loss, burn fat, improve flexibility, enhance blood flow, reduce muscle soreness after exercise, build strength and decrease the stress hormone cortisol.
62088715|NCT05414929|EXPERIMENTAL|HPV self-sampling group|
62088716|NCT03449459|EXPERIMENTAL|oral probiotics|
62088717|NCT03449459|EXPERIMENTAL|aerosol inhaled amikacin|
62088718|NCT03449459|EXPERIMENTAL|combined vaccination|
62088719|NCT03449459|NO_INTERVENTION|conventional therapy (blank control)|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.
62287511|NCT02629731|NO_INTERVENTION|control|inclusion criteria: 1) between 18 and 80 years of age, and 2) ambulatory (able to walk at least 15 m)
62088720|NCT04081545|ACTIVE_COMPARATOR|Control Goup A- Opioid-based regimen|"Preop - Multimodals unless contraindicated~Induction~* Fentanyl (50mcg IV)~* Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)~* Propofol 2-3mg/kg IV bolus~* Neuromuscular blockade per Anesthesiology team discretion~Maintenance~* Sevoflurane~* Neuromuscular blockade at discretion of anesthesiology team~* May use fentanyl to treat SBP or HR \> 20% of baseline~Emergence~* Neuromuscular reversal, dosed according to Virginia Mason protocol~* May titrate fentanyl per anesthesiology team throughout the case.~* Patient extubated and brought to PACU~PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
62088721|NCT04081545|EXPERIMENTAL|Experimental Group B- Opioid-free regimen|"Preop - Multimodals unless contraindicated~Induction~* Dexmedetomidine 1mcg/kg IV bolus over 10 minutes using IBW~* Lidocaine 1.5mg/kg IV bolus using IBW~* Propofol 2-3mg/kg IV bolus~* Neuromuscular blockade per Anesthesiology team discretion~* Ketamine 0.5mg/kg IV bolus (based on IBW)~Maintenance~* Sevoflurane~* Dexmedetomidine 0.4 mcg/kg/hr IV infusion using IBW (may titrate based on patient response between 0.3-0.5mcg/kg/hr)~* Lidocaine 2mg/kg/hr IV infusion using IBW~* May use esmolol as needed to treat SBP or HR \> 20% of baseline~* Neuromuscular blockade at the discretion of anesthesiology team~Emergence~* Dexmedetomidine infusion turned off during laparoscopic desufflation~* Lidocaine infusion turned off at skin closure~* Neuromuscular reversal, dosed according to VM protocol~* Pt extubated and brought to PACU~* PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
62287512|NCT01845714|ACTIVE_COMPARATOR|Cross Linking Group (CxL group)|Patients that received CXL
62088722|NCT04101864|EXPERIMENTAL|Electromagnetic navigation|In the study group acetabular components in total hip arthroplasty will be placed with the help of electromagnetic image-less navigation system. Reference plane will be anterior pelvic plane.
62088723|NCT04101864|ACTIVE_COMPARATOR|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
62287513|NCT01845714|ACTIVE_COMPARATOR|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
62287514|NCT06170970|EXPERIMENTAL|solriamfetol then placebo first|Four weeks of treatment with solriamfetol followed by one week of washout and four weeks of treatment with placebo
62287515|NCT06170970|EXPERIMENTAL|placebo then solriamfetol first|Four weeks of treatment with placebo followed by one week of washout and four weeks of treatment with solriamfetol
62307925|NCT05227846|EXPERIMENTAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Standard of care (SOC) plus a dose-escalation with 4 cohorts with 3-6 subjects/cohort who receive doses of 5, 10，15 and 20 ×10E7 cells. Proceed from lower dose to next higher dose if no safety concerns for each cohort.
62653816|NCT01490411|EXPERIMENTAL|80 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
62653817|NCT01490411|EXPERIMENTAL|160 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
62088724|NCT01863966|EXPERIMENTAL|Hot water drinking therapy|Hot water drinking before,after meal and before sleep
62088725|NCT01863966|ACTIVE_COMPARATOR|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation
62287516|NCT06303661|EXPERIMENTAL|RF and SWT|The treatment will be carried out through the application of monopolar non-ablative radiofrequency (IBRAMED, Amparo, São Paulo, Brazil - model Neartek) associated with electromagnetic low-intensity shock wave therapy (IBRAMED, Amparo, São Paulo, Brazil - model THOOR) on the fibrotic plaque in the penis, 2 to 5 times a week, according to the patient's availability, totaling 24 sessions.
62287517|NCT00652184|PLACEBO_COMPARATOR|1|Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
62287518|NCT00652184|ACTIVE_COMPARATOR|2|Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10
62287519|NCT00652184|EXPERIMENTAL|3|Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
62287520|NCT00652184|OTHER|4|Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10
61904841|NCT06492499||IVC Approach Group|This group includes patients who underwent zero-fluoroscopy radiofrequency catheter ablation (RFCA) for atrioventricular nodal reentrant tachycardia (AVNRT) using the inferior vena cava (IVC) approach. The catheter was inserted through the femoral vein, extending through the iliac vein to the IVC. The ablation procedure was performed under conscious sedation and local infiltration anesthesia, with a large-tip electrode catheter used for mapping and ablation guided by the EnSite NavX system. The ablation parameters were set at 40 W power and 50°C temperature.
61904842|NCT00458029|EXPERIMENTAL|School based intervention|Integration of activities, events, and programs affecting total school food service environment, physical education class, behavior change, promotion, and communications
61904843|NCT00458029|NO_INTERVENTION|Control|Observational control
62287521|NCT03871686|EXPERIMENTAL|Experimental Group|Participants will be asked to complete a brief online program over a 4 to 8-week period. Each week participants will be asked to complete one session of the program online. There are four sessions.
62462189|NCT04836000|PLACEBO_COMPARATOR|Placebo Group|In addition to the conservative treatment of the control group, low-level laser therapy (turned off) will be applied for 6 weeks. In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions.
61904844|NCT04873232|EXPERIMENTAL|Engensis|Patients who have received Engensis in protocol VMDN-003-2
61904845|NCT04873232|PLACEBO_COMPARATOR|Placebo|Patients who have received Placebo in protocol VMDN-003-2
61904846|NCT00742664|EXPERIMENTAL|1|Will receive 12 sessions of twice weekly psychotherapy targeting obsessive-compulsive symptoms.
62462190|NCT04836000|EXPERIMENTAL|Experimental Group|In addition to the conservative treatment of the control group, low-level laser therapy will be applied for 6 weeks.
61904847|NCT00742664|PLACEBO_COMPARATOR|2|
62287522|NCT03871686|NO_INTERVENTION|Control Group|Participants will receive no intervention from the investigators. Participants may continue services as usual as provided by Children's Brain Tumor Foundation.
62462191|NCT04836000|ACTIVE_COMPARATOR|Control Group|For 6 weeks, all three groups will receive five sessions per week of a protocolised treatment based on therapeutic exercises, analgesic electrotherapy and cryotherapy.
61904848|NCT04782206|ACTIVE_COMPARATOR|group 1|superior hypogastric plexus block
62287523|NCT03030963|EXPERIMENTAL|Equal-ratio ventilation(ERV) group|ventilator inspiration to expiration ratio will be set 1:1.
62287524|NCT03030963|ACTIVE_COMPARATOR|Control group|ventilator inspiration to expiration ratio will be set 1:2.
61904849|NCT04782206|ACTIVE_COMPARATOR|group 2|pulsed radiofrequency at S3 nerve root + superior hypogastric plexus block
62088726|NCT03511989|ACTIVE_COMPARATOR|Bone Borne distractor|The device being investigated, Boneborne distraction appliance
62462192|NCT04142970|ACTIVE_COMPARATOR|Mild renal impairment|Mild renal impairment (eGFR: 60-89 mL/min/1.73 m\^2)
62088727|NCT03511989|OTHER|Tooth borne distractor|The control device Toothborne distraction appliance
62088728|NCT03511989|NO_INTERVENTION|Segmental LF1 osteotomy group 1|Control Group, no stabilization of palatal vault
62088729|NCT03511989|ACTIVE_COMPARATOR|Segmental LF1 osteotomy group 2|Testgroup, biodegradable plate at osteotomy site in palate
62088730|NCT03511989|ACTIVE_COMPARATOR|Segmental LF1 osteotomy group 3|Testgroup, autologous bonegraft at palatal osteotomy site
62088731|NCT03673098|EXPERIMENTAL|Intervention Group: Adapted 3RP|The intervention condition will consist of the 10-week adapted 3RP intervention.
62088732|NCT03673098|NO_INTERVENTION|Control Group: Supportive Psychotherapy|The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
62088733|NCT05560516|EXPERIMENTAL|Patients with chemotherapy-induced peripheral neuropathy who receive Qutenza|
62088734|NCT05560516|ACTIVE_COMPARATOR|Patients with chemotherapy-induced peripheral neuropathy who receive Duloxetine|
62088735|NCT02613897|ACTIVE_COMPARATOR|DAPA/SAXA (dapagliflozin plus saxagliptin)|Dapagliflozin 10mg + Saxagliptin 5mg (plus standard of care treatment of metformin or metformin plus sulfonylurea).
62088736|NCT02613897|ACTIVE_COMPARATOR|DAPA (Dapagliflozin plus placebo)|Dapagliflozin 10mg + Placebo (plus standard of care treatment of metformin or metformin plus sulfonylurea).
62088737|NCT02613897|PLACEBO_COMPARATOR|PCB (Placebo plus placebo)|Placebo (for dapagliflozin) + placebo (for saxagliptin) (plus standard of care treatment of metformin or metformin plus sulfonylurea).
62088738|NCT02058342|EXPERIMENTAL|Active Play at Home Intervention|Participant parents in the intervention arm will receive: 1) Active Play at Home curriculum and equipment, 2) Training session on Active Play at Home curriculum, 3) counseling on physical activity scheduling, identification of barriers, motivational strategies, 4) phone calls to check on compliance and issues with doing the program at home
62462193|NCT04142970|ACTIVE_COMPARATOR|Moderate renal impairment|Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m\^2)
62653818|NCT01490411|EXPERIMENTAL|320 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
62653819|NCT03571789|EXPERIMENTAL|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
62653820|NCT03761316||FBSS patients|patients with Failed Back Surgery Syndrome, eligible for SCS
62653821|NCT03984929|EXPERIMENTAL|Localized Information Resource Intervention|
62653822|NCT03984929|ACTIVE_COMPARATOR|Generic Information Resource Intervention|
62653823|NCT00265434|ACTIVE_COMPARATOR|Dornase alfa|DBPC-cross over trial
62653824|NCT00265434|PLACEBO_COMPARATOR|isotonic saline|
62653825|NCT02506920|ACTIVE_COMPARATOR|Pack butter|Oral fat tolerance test contains: Cream, lactic acid culture, salt. Fat contents in grams: Saturated fat (SFA) 52, monounsaturated fat (MUFA) 19.1, polyunsaturated fat (PUFA) 1.6
62653826|NCT02506920|ACTIVE_COMPARATOR|Kjaergaarden blend butter|Oral fat tolerance test contains:Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 37.4, MUFA 27.3, PUFA 1.8
61904850|NCT03931135|ACTIVE_COMPARATOR|Dexamethasone|
62088739|NCT02058342|NO_INTERVENTION|Wait-listed control|Participants will attend the baseline visit to do baseline measurements but will not receive any materials related to the Active Play at Home curriculum and will also not be contacted by phone during the control 24 weeks. After they serve as control group, they will be provided with the opportunity to receive the intervention.
62307926|NCT06365333||FGAR-treated|Patients diagnosed with idiopathic intussusception, admitted to the National Children's Hospital between January 2016 and December 2017, exhibiting clinical signs and symptoms consistent with intussusception, and confirmed via ultrasound examination
62462194|NCT04142970|ACTIVE_COMPARATOR|Subjects with normal renal functions|Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m\^2)
62653827|NCT02506920|ACTIVE_COMPARATOR|Blend butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 23.7, MUFA 23.2, PUFA 7.8
62653828|NCT02506920|ACTIVE_COMPARATOR|Fish oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, fish oil, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 0.7
62287525|NCT02208245|ACTIVE_COMPARATOR|Ultrasound: Axillary block|For the axillary group, the ultrasound probe will be placed upright in the armpit to obtain a cross section of this region. After visualization of the nerves form the brachial plexus by ultrasound, 5 mL of ropivacaine 0.5% will be injected around each nerve to be blocked (median, ulnar, radial and musculocutaneous). If resistance to the injection of the solution is present or the patient complains of severe pain, the needle will be immediately repositioned.
62287526|NCT02208245|ACTIVE_COMPARATOR|Ultrasound: Infraclavicular block|For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
62088740|NCT04239287||Preterm|Children age 8-16 years born at \<32 weeks gestation.
62088741|NCT04239287||Control|Children age 8-16 years born at \>37 weeks gestation
62287527|NCT01679002|EXPERIMENTAL|Group A|"BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period~BIA 2-093 450 mg od - BIA 2-093 450 mg bid - OXC 900 mg bid"
62287528|NCT01679002|EXPERIMENTAL|Group B|"BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period~BIA 2-093 450 mg bid - OXC 450 mg bid - BIA 2-093 900 mg od"
62653829|NCT02506920|ACTIVE_COMPARATOR|Olive oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, olive oil, lactic acid culture, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 5.7
61904851|NCT03931135|ACTIVE_COMPARATOR|Cyclizine|
62287529|NCT01679002|EXPERIMENTAL|Group C|"oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period~OXC 450 mg bid - BIA 2-093 900 mg od - BIA 2-093 450 mg bid"
62653830|NCT02506920|ACTIVE_COMPARATOR|Low saturated fat butter|Oral fat tolerance test contains: Butter, lactic acid culture, salt. Fat contents in grams: SFA14.9, MUFA16, PUFA 5.6
62653831|NCT02078258|EXPERIMENTAL|Attentional bias modification training|"Attention bias modification training (ABMT) is a a variation of attention tasks to modify attentional biases, in which a probe always appears in the location of relatively positive stimuli after the two stimuli, one neutral and one emotional, were simultaneously presented.~Participants complete 8 sessions (320 trials each with 20 minutes) over two weeks of neutral ABMT to shift attention toward neutral, in which a probe appeared in the location of neutral with 90% probability, and sadness-related with 10% probality. At a 9-week follow-up, participants completed 4 more sessions (480 trials each with 30 minutes)over two weeks of positive ABMT to shift attention toward positive words,in which a probe appeared in the location of 67% positive or 33% neutral."
62653832|NCT02078258|ACTIVE_COMPARATOR|Placebo control|The placebo ABMT was identical to the active ABMT, but shifted toward neutral (50%) or sad (50%) stimuli equally often (i.e., 50/50 training).
62653833|NCT02515474|ACTIVE_COMPARATOR|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
62287530|NCT02903004|EXPERIMENTAL|Trabectedin|Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)
62287531|NCT02903004|OTHER|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
62287532|NCT05855304|EXPERIMENTAL|manual therapy|
62287533|NCT05855304|EXPERIMENTAL|Kinesiology taping|
62287534|NCT02686294|EXPERIMENTAL|T-R|First period : administration of test drug Second period : administration of reference drug
62287535|NCT02686294|EXPERIMENTAL|R-T|First period : administration of reference drug Second period : administration of test drug
62287536|NCT01446809|EXPERIMENTAL|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
62287537|NCT01446809|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
62287538|NCT06031233|EXPERIMENTAL|Nivolumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
62287539|NCT06031233|EXPERIMENTAL|Pembrolizumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
62287540|NCT06031233|EXPERIMENTAL|ipilimumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
62287541|NCT06031233|EXPERIMENTAL|Durvalumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
62287542|NCT06031233|EXPERIMENTAL|Atezolizumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
61904853|NCT00081094|OTHER|PET scan (FDG-PET & 11C-acetate-PET)|Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
62088742|NCT03466840|EXPERIMENTAL|The Coronally Advanced Lingual Flap|"On the lingual side of mandible, a full-thickness muco-periosteal flap is elevated until reaching mylohyoid line. Using a blunt instrument, a connective tissue band is localized continuing with the epimysium of the mylohyoid muscle and is inserted into the inner part of the lingual flap . The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe the amount of advancement is measured."
62088743|NCT03466840|ACTIVE_COMPARATOR|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured"
62088744|NCT06325397||High Intraocular Pressure (IOP)|Eyes in this arm will maintain an Intraocular Pressure (IOP) of 65 millimeters of mercury (mmHg) throughout the cataract surgery.
62088745|NCT06325397||Low Intraocular Pressure (IOP)|Eyes in this arm will maintain an Intraocular Pressure (IOP) of 24 millimeters of mercury (mmHg) throughout the cataract surgery.
62462195|NCT01598701|EXPERIMENTAL|Intravenous Acetaminophen|Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
61904854|NCT02161692|EXPERIMENTAL|High dose chemotherapy|"Characterized by the following sequence:~High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin~1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue"
61904855|NCT02161692|ACTIVE_COMPARATOR|Conventional dose chemotherapy|Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles
61904856|NCT04381182|OTHER|Biostrap/Apollo Device Use|Participants wear a Biostrap wearable device which measures steps, heart rate, heart rate variability, sleep metrics, and quantitative data in typical day-to-day activities of residents. Participants then again wear Biostrap except now also with the Apollo device which is worn around the ankle and is suggested to modulate heart rate variability and perceived stress of participants.
61904857|NCT05354453|EXPERIMENTAL|SRD Part|Single-rising dose (SRD)
61904858|NCT05354453|PLACEBO_COMPARATOR|SRD Part: Placebo|
61904859|NCT05354453|EXPERIMENTAL|Skin Challenge Part|
61904860|NCT05354453|PLACEBO_COMPARATOR|Skin Challenge Part: Placebo|
61904861|NCT04010578|EXPERIMENTAL|MK-7 and vitamin D3 supplementation|Patients will receive a daily MK-7 and vitamin D3 supplementation for 3 months.
61904862|NCT04010578|PLACEBO_COMPARATOR|Placebo|Patients will receive a daily placebo for 3 months.
61904863|NCT03595618|EXPERIMENTAL|GLPG1972 75 mg|Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
61904864|NCT03595618|EXPERIMENTAL|GLPG1972 150 mg|Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
61904865|NCT03595618|EXPERIMENTAL|GLPG1972 300 mg|Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.
61904866|NCT03595618|PLACEBO_COMPARATOR|Placebo|Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.
61904871|NCT05747040|OTHER|48-h monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~* t0: baseline~* t1: pre-treatment~* t2: post-treatment~* t3: follow-up"
61904872|NCT00913458|EXPERIMENTAL|1|etanercept + methotrexate; etanercept + methotrexate
61904873|NCT05239429|EXPERIMENTAL|Transcendental Meditation Technique|Participants are trained on the use of the Transcendental Meditation Technique. They will perform the technique twice a day for 20-minutes per session.
61904874|NCT05239429|NO_INTERVENTION|Lifestyle-as-usual (control)|There is no change to the participants daily schedule and lifestyle.
62287543|NCT06031233|EXPERIMENTAL|bevacizumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
62462196|NCT01598701|PLACEBO_COMPARATOR|Placebo|Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
62462197|NCT02456779||Erosive Esophagitis|"Patients diagnosed with GERD with erosive esophagitis present on routine endoscopy during the previous 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
62287544|NCT06031233|EXPERIMENTAL|Trastuzumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
62287545|NCT04067518|EXPERIMENTAL|SHP674|"Part 1: Participants with ALL who were stratified into the standard risk (SR) or intermediate risk (IR) groups received total 3 doses of SHP674 in the 36-week treatment period and who were stratified into the high risk (HR) group received total 8 doses of SHP674 in the 45-week treatment period.~Part 2: Participants with ALL who were stratified into the SR or IR groups received total 3 doses of SHP674 in the 41-week treatment period and who were stratified into the HR group received total 8 doses of SHP674 in the 45-week treatment period."
62287546|NCT04427254|EXPERIMENTAL|Neurological biological samples|
62287547|NCT05883098|EXPERIMENTAL|SUPRA SDRM|"The subject will receive wound standard of care that will include Supra SDRM as an active synthetic wound closure matrix, covered with a non-adherent dressing plus an appropriate outer dressing to maintain moisture balance, then wrapped with stretch gauze and self-adherent wrap. Supra SDRM will be applied weekly, and the exterior dressings will be redressed as necessary.~Supra SDRM is FDA-cleared (K090160, K170213) for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. It is commercialized as a single dermal substitute matrix for wound management. No preparation of SUPRA SDRM matrix is necessary. When applied to the wound SUPRA SDRM adheres well to the wound bed without the need for direct fixation. SUPRA SDRM becomes translucent after the application allowing healthcare professionals to easily assess the wound healing. SUPRA SDRM® is available in multiple sizes and can be trimmed to meet the patient's needs."
62287548|NCT05883098|ACTIVE_COMPARATOR|Fibracol Plus|"The subject will receive wound standard of care that will include Fibracol Plus collagen dressing as an active synthetic wound closure matrix, covered with a non-adherent dressing plus an appropriate outer dressing to maintain moisture balance, then wrapped with stretch gauze and self-adherent wrap. Fibracol Plus collagen dressing will be applied weekly, and the exterior dressings will be redressed as necessary.~FIBRACOL™ Plus Collagen Wound Dressing with Alginate dressing contains more than just pure collagen. It's a soft, absorbent, and conformable wound dressing, composed of 90% collagen and 10% calcium alginate. In the presence of wound fluid, FIBRACOL™ Plus Dressing helps maintain a physiologically moist microenvironment at the wound surface. This environment supports granulation tissue formation, epithelialization and rapid wound healing."
62287549|NCT03897751|EXPERIMENTAL|ABT12 Multi-Purpose Solution|Participants will use ABT12 Multi-Purpose Solution to clean their contact lenses daily for 3 months. Participants will use Sensitive Eyes Rewetting Drops as needed during the study.
62287550|NCT03897751|ACTIVE_COMPARATOR|COMPLETE Multi-Purpose Solution|Participants will use COMPLETE Multi-Purpose Solution to clean their contact lenses daily for 3 months. Participants will use Sensitive Eyes Rewetting Drops as needed during the study.
62307927|NCT02420652|EXPERIMENTAL|Arm I (metformin hydrochloride, aspirin)|Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
61904877|NCT03517345|EXPERIMENTAL|Prebiotic group|Given a prebiotic product (inulin + oligofructose; 5 g) mixed with conventional yogurt (100 g) which given as snack, twice a day.
62088746|NCT03012880|EXPERIMENTAL|Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)|"INDUCTION PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-21. Patients receive daratumumab IV over 3-7 hours on days 1, 8, 15, and 22 of courses 1 and 2, on days 1 and 15 of courses 3, 4, and 5, and on day 1 of courses 7 and beyond. Patients also receive dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and daratumumab IV over 3-7 hours on day 1. Courses repeat every 28 days for up to 36 months from registration in the absence of disease progression or unacceptable toxicity."
62088747|NCT02490930|EXPERIMENTAL|Experimental|Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy. Fingolimod will be administered at 0.5 mg every day for the first two weeks. Beginning the third week, they will take fingolimod on Monday, Wednesday and Friday until the end of radiotherapy or until the 28th dose, whichever comes first.
62462198|NCT02456779||non erosive reflux disease|"Patients diagnosed with GERD with erosive esophagitis not present on routine endoscopy during the last 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
62462199|NCT02456779||healthy controls|"No GERD symptoms RDQ = 0 RSI = 0-9~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire intervention: questionnaire"
62462200|NCT00073060||NIH Platelepheresis Donors|75, Apheresis Study Group - donation procedures use same devices as leukapheresis donors, also requiring citrate infusion
62307928|NCT02420652|PLACEBO_COMPARATOR|Arm II (metformin hydrochloride placebo, aspirin placebo)|Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
62462201|NCT00073060||NIH Research Leukapheresis Donors|75, Apheresis Study Group - donation procedures use same devices as plateletpheresis donors, also requiring citrate infusion; citrate administered may be twice as great as during plateletpheresis.
62462202|NCT00073060||NIH Whole Blood Donors|150 age, gender, race-matched donors - CONTROL GROUP
61904878|NCT03517345|EXPERIMENTAL|Control group|Given conventional yogurt (100 g) which given as snack, twice a day.
62462203|NCT01239121|EXPERIMENTAL|HIE-Enhanced Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
62653834|NCT02515474|ACTIVE_COMPARATOR|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
62088748|NCT00445692|EXPERIMENTAL|Treatment (clarithromycin, dexamethasone, lenalidomide)|"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.~NOTE: \*After one year of treatment, dexamethasone is tapered for an additional 4 weeks."
62088749|NCT00752570|PLACEBO_COMPARATOR|2|AMG 386 placebo QW, FOLFIRI Q2W
62088750|NCT00752570|ACTIVE_COMPARATOR|1|Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W
62287551|NCT00553462|EXPERIMENTAL|paclitaxel + carboplatin + radiation + erlotinib|"Patients receive paclitaxel IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease progression outside of the chest after induction therapy are removed from study.~Patients with intrathoracic disease progression within the potential radiation field may continue protocol therapy at the discretion of the Study Chair. Patients with no disease progression outside the planned radiation field (either regional or distant) proceed to concurrent erlotinib hydrochloride and radiotherapy.~Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily. Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions) in the absence of rapid disease progression outside of the chest or unacceptable toxicity.~After completion of study therapy, patients are followed every 3 months for 1 year, and then every 6 months for up to 2 years"
62287552|NCT02507804|EXPERIMENTAL|Arm A diary arm|Patients in Arm A are required to complete a patient diary. This will be reviewed by an Investigator at every visit in order to gain Adverse Event and Concomitant Medication information.
62287553|NCT02507804|ACTIVE_COMPARATOR|Arm B standard of care|Patients will be asked to recall Adverse Events and Concomitant Medication information as standard of care practice would dictate.
62287554|NCT00823641|EXPERIMENTAL|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
62287555|NCT03728881|EXPERIMENTAL|Group I (Cervarix)|Participants 9-14 years old receive Cervarix IM at baseline.
62287556|NCT03728881|ACTIVE_COMPARATOR|Group II (Gardasil)|Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
62287557|NCT04850560|EXPERIMENTAL|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|
62287558|NCT06213662|EXPERIMENTAL|experimental group|"Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) 100U, diluted with~1 ml.9% sodium chloride solution for reserve use.Each patient was injected with 90U"
62287559|NCT02487186|ACTIVE_COMPARATOR|Test group: DB+DOX|Test group: DB (full mouth debridment) +DOX (doxicicline) - 45 minutes of full-mouth debridement + subgingival application of PLGA microspheres loading doxycycline 10%.
62653835|NCT04804137||Group|adult patients with adenocarcinoma type non-small cell lung cancer
62287560|NCT02487186|ACTIVE_COMPARATOR|Control group: DB alone|"Control group: DB alone (Full-mouth debridment)~Intervention: 45 minutes of full-mouth debridement + subgingival application of void PLGA microspheres."
62287561|NCT03604731||Uncomplicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures
62287562|NCT03604731||Complicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures complicated by multiorgan failure
62287563|NCT05284201|EXPERIMENTAL|Functional task practice and ARC Therapy|FTP and ARC Therapy with the LIFT System at home for 1 month.
62462204|NCT01239121|ACTIVE_COMPARATOR|Optimal Medication Reconciliation without HIE|Optimal Medication Reconciliation without Health Information Exchange (HIE) for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
62462205|NCT01239121|OTHER|Pilot HIE-Enhanced Outpatient Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans seen as outpatients in Geriatrics Primary care clinic
62653836|NCT01467752|EXPERIMENTAL|MCP joint|reconstruction of metacarpophalangeal (MCP) joint
62653837|NCT02297126|NO_INTERVENTION|Control Arm|4,000 patients receiving a new prescription for targeted medication(s) randomized into the control arm receive standard care (no intervention affecting drug selection, dosage, dosage form, frequency and duration of therapy). Healthcare costs and adverse events data collected and analyzed for 12 months from time of entry into study. List of targeted medications: codeine, amitriptyline, aripiprazole, atazanavir, atomoxetine, azathioprine, citalopram, clopidogrel, cyclophosphamide, doxepin, efavirenz, escitalopram, esomeprazole, fluconazole, simvastatin, fluorouracil, phenytoin, quetiapine, glyburide, lansoprazole, mercaptopurine, methadone, methotrexate, nortriptyline, omeprazole, pantoprazole, rasburicase, tacrolimus, thioguanine, tramadol, venlafaxine, voriconazole and warfarin
62287564|NCT01247857|ACTIVE_COMPARATOR|Preoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity before surgery
62287565|NCT01247857|ACTIVE_COMPARATOR|Postoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity after surgery
62287566|NCT01247857|PLACEBO_COMPARATOR|Control|Nebulization of normal saline 3 ml before and after surgery
62287567|NCT00947531|EXPERIMENTAL|Cerebrolysin|
62653838|NCT02297126|EXPERIMENTAL|Pharmacogenetic Intervention Arm|2,000 patients receiving new prescription for targeted medication(s) identified in the control arm will be randomized to the intervention arm, consented and a tests will be performed from a blood sample. The treating physicians will be provided with the pharmacogenetic information and will determine if intervention is appropriate. Physician may elect to stay the course of therapy or alter drug selection, dosage, dosage form, frequency or duration of therapy based on the pharmacogenetic test results and input from clinical pharmacology consultations (if requested). Patients in the intervention arm will have their overall healthcare costs and clinical outcomes (specifically adverse events) followed and analyzed for a 1 year period from the time that they are entered into the study
62653839|NCT00632294||Retrieved Allograft|Patients that require the retrieval of a bone allograft (transplant).
61904879|NCT04792242|ACTIVE_COMPARATOR|goal directed therapy|svo2,haematocrite value,urine output,mean arterial pressure and central venous pressure
62088751|NCT02846662|EXPERIMENTAL|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an applicative for smartphones (CONEMO), which encourages them to be more active and to incorporate more activities in their everyday life.~Primary care nurses will train participants to use the CONEMO app, monitor patients' adherence to CONEMO, calling patients when they are non-adherent, and give technical support when necessary. They will be supervised by clinical psychologists.~Primary care teams are informed of participants' depression level and deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication."
62088752|NCT02846662|NO_INTERVENTION|ENHANCED USUAL CARE|The primary care teams are informed of the participants' depression level and can deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication. This is considered enhanced usual care because the teams are notified about participants' level of depressive symptomatology, which otherwise might go undetected, and then decide about the best way to handle with patients' needs related to their depressive symptomatology.
62088753|NCT06697210|ACTIVE_COMPARATOR|• Dental Floss (Vitis®, Dentaid, Barcelona, Spain).|dental floss is used as interproximal hygiene device. The intervention includes thorough instruction on the correct flossing technique around dental implants to ensure effective removal of plaque and debris. Participants will be supplied with dental floss and given detailed guidance on integrating flossing into their daily oral hygiene regimen. The effectiveness of this method will be evaluated by measuring plaque levels before and after the intervention.
62088754|NCT06697210|ACTIVE_COMPARATOR|• Superfloss (Oral B®, Procter & Gamble, USA)|superfloss is used as the primary interproximal hygiene device. Superfloss is designed to clean around dental implants, bridges, and wide spaces between teeth. Participants will receive instructions on how to effectively use superfloss, which includes its unique combination of foam, regular floss, and spongy material to remove plaque and debris. The intervention will focus on demonstrating the proper technique to ensure optimal cleaning. The effectiveness of this method will be evaluated by comparing plaque levels before and after the intervention.
62088755|NCT06697210|ACTIVE_COMPARATOR|• Oral irrigator (Waterpick®, Water Pik, Inc., CO., USA)|oral irrigator used as the primary interproximal hygiene device. The oral irrigator delivers a stream of pulsating water to help remove plaque and food particles from around dental implants and between teeth. Participants will receive guidance on how to properly use the oral irrigator, including the appropriate pressure settings and angles for effective cleaning. The intervention aims to enhance oral hygiene by providing a thorough rinse of the interproximal areas. The effectiveness of this method will be assessed by comparing plaque levels before and after the intervention.
62088756|NCT06697210|ACTIVE_COMPARATOR|• Interproximal brushes (Interprox®, Vitis, Dentaid, Spain)|interproximal brush is used as the primary interproximal hygiene device. The interproximal brush is specifically designed to clean between teeth and around dental implants, effectively removing plaque and debris in areas that traditional toothbrushes may miss. Participants will receive instructions on how to select the appropriate brush size and how to use it effectively to ensure optimal cleaning. The intervention will emphasize the importance of thorough brushing technique for maintaining oral health. The effectiveness of this method will be evaluated by comparing plaque levels before and after the intervention.
62287568|NCT00947531|PLACEBO_COMPARATOR|0.9% Saline Solution|
62287569|NCT00437216||1|Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®
62287570|NCT00437216||2|Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment
62287571|NCT01857609|EXPERIMENTAL|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
62287572|NCT01857609|EXPERIMENTAL|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
62287573|NCT01857609|EXPERIMENTAL|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
62287574|NCT03806426|EXPERIMENTAL|Treatment Group A|Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
62287575|NCT03806426|PLACEBO_COMPARATOR|Treatment Group B|Placebo 500mg
62287576|NCT03710447|EXPERIMENTAL|HIIT + WB-EMS|High-intensity interval training (HIIT) combined with whole-body electromyostimulation (WB-EMS) Sequence of application: HIIT - WB-EMS
62287577|NCT03710447|EXPERIMENTAL|WB-EMS + HIIT|Whole-body electromyostimulation (WB-EMS) combined with High-intensity interval training (HIIT) Sequence of application: WB-EMS - HIIT
62287578|NCT03710447|EXPERIMENTAL|HIIT + CST|High-intensity interval training (HIIT) combined with conventional low-volume strength training (CST) Sequence of application: HIIT - CST
62287579|NCT03710447|EXPERIMENTAL|CST + HIIT|Conventional low-volume strength training (CST) combined with high-intensity interval training (HIIT) Sequence of application: CST - HIIT
62287580|NCT01597063||low risk pregnancies|
61904880|NCT04792242|ACTIVE_COMPARATOR|PCO2 gap algorithm|PCO2 gap,haematocrite value,Spo2,cardiac index
62088757|NCT05761080|EXPERIMENTAL|Experimental branch|"Patients will be included in the study during the anesthetic surgery evaluation.~The patient will be randomized at the time of informed consent to know the postoperative guideline to be used.~Randomization of patients on postoperative day 3.~If patient belong to the Fast Track group:~Application of discharge criteria in the experimental branch at 72 hours post-surgery, and administration of oral antibiotic therapy: Amoxicillin - clavulanic acid, dose: 100mg/Kg/day every 8 hours for a total of 5 days.~There will be a follow-up at 5, 7 and 30 days after discharge. In addition, there will be a face-to-face visit 2 weeks after the intervention."
62088758|NCT05761080|ACTIVE_COMPARATOR|Control branch|"Patients will be included in the study during the anesthetic surgery evaluation.~The patient will be randomized at the time of informed consent to know the postoperative guideline to be used.~Randomization of patients on postoperative day 3.~If patient belongs to the control group:~Application of discharge criteria in control branch 5 days postoperative, according to current clinic guidelines. Administration of Amoxicillin - clavulanic acid, dose: 100mg/Kg/day every 8 hours, intravenous during 5 days~There will be a follow-up at 5, 7 and 30 days after discharge. In addition, there will be a face-to-face visit 2 weeks after the intervention."
62088759|NCT06039891|EXPERIMENTAL|Nimotuzumab, Tislelizumab group|Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication
62088760|NCT06436547|EXPERIMENTAL|subiculum-DBS group|participants will undergo subiculum-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
62088761|NCT04428086|EXPERIMENTAL|Assess PK effects of Apatinib on Rosuvastatin|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 7 and Apatinib at a dose of 250 mg once daily from Day 4 until Day 9.
62088762|NCT04428086|EXPERIMENTAL|Assess PK effects of Apatinib on Metformin|Participant will be administered a single oral dose of metformin 500 milligram (mg) on Day 1 and Day 6 and Apatinib at a dose of 250 mg once daily from Day 3 until Day 7.
62088763|NCT04549077||Cystic Fibrosis Patients|Patients with Cystic Fibrosis.
62088764|NCT04549077||Historical Controls|Patients diagnosed with solid tumors, who have had a normal chest CT scan during screening for possible metastasis
62088765|NCT06084429|EXPERIMENTAL|pre and post test|School adolescents studying in 8th grade.
62088766|NCT06103474|ACTIVE_COMPARATOR|Standard of Care Report|The subject will receive standard of care imaging report.
62088767|NCT06103474|ACTIVE_COMPARATOR|Clinical Report|The subject will receive a technical report that avoids language that may cause catastrophizing or evoke the nocebo effect.
62088768|NCT01760681|EXPERIMENTAL|H coil DTMS|20 daily deep TMS treatments
62088769|NCT01760681|SHAM_COMPARATOR|inactive stimulation|20 daily sham deep TMS treatments
62287581|NCT01474590|EXPERIMENTAL|Epiduo/Tactuo + doxycycline 200mg|
62287582|NCT01474590|ACTIVE_COMPARATOR|Isotretinoin + vehicle gel|
62287583|NCT01203657|EXPERIMENTAL|Tai Chi|Tai Chi instruction, 2x week in a community senior center setting
62287584|NCT01203657|NO_INTERVENTION|Wait List Control|This is a wait list control group. There is no active or placebo intervention.
61904881|NCT04849702||Postoperative complication after colorectal resection|Documentation of all postoperative complications after colorectal resections
61904882|NCT03905044||CC|eyes with congenital cataracts
61904883|NCT02292914|EXPERIMENTAL|Robot-Assisted Surgery|patients undergoing robot assisted surgery for the treatment of cancer
62088770|NCT04534855|EXPERIMENTAL|Treprilimab treatment group|Treprilimab 240mg ivdrip Q3W until progression or unacceptable toxicity
62088771|NCT05752578||Subjects with HIV infection|Both male and female subjects, over 18 years of age, on antiretroviral therapy, native speakers of Italian
62287585|NCT01786317||Fecal incontience|Patient with fecal incotinence who will be explored using high resoltuion manometry
62287586|NCT01786317||Healthy controls|Healthy volunteers who will be explored using high resoltuion manometry
62287587|NCT02198833|EXPERIMENTAL|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
62287588|NCT02198833|ACTIVE_COMPARATOR|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
62287589|NCT01693172|ACTIVE_COMPARATOR|early postoperative mobilization|Early postoperative supervised aerobic exercise, resistance and flexibility training
62287590|NCT01693172|NO_INTERVENTION|Standard|Standard rehabilitation care
62287591|NCT04266535||TCI|Patients receiving Target Controlled Infusion (TCI) Anesthesia
62287592|NCT04266535||MCI|Patients receiving Manually Controlled Infusion (MCI) Anesthesia
62653840|NCT00666770|EXPERIMENTAL|Gabapentin 250 mg|
62653841|NCT00666770|EXPERIMENTAL|Gabapentin 500 mg|
62653842|NCT00666770|PLACEBO_COMPARATOR|Placebo|
62088772|NCT05752578||Healthy control subjects|Both male and female subjects, over the age of 18 years, no neurological or psychiatric conditions that would alter test performance, native speakers of Italian
62287593|NCT01261819|EXPERIMENTAL|transurethral laparoscope|These patients had cystoscopy performed with the transurethral laparoscope.
62653843|NCT05595226|EXPERIMENTAL|RT3D-TEE-guided mitral valve repair|Two experienced surgeons and two experienced echocardiography technicians jointly formulated the plan for the TEE-guided mitral valve repair.
62653844|NCT05595226|NO_INTERVENTION|Control|
62653845|NCT04198168||ICU patients|ICU patients who are assessed by their attending physician as having need for fluid therapy and are planned to receive IV crystalloid fluid due to oliguria and/or to improve GFR.
61904884|NCT02292914|ACTIVE_COMPARATOR|Conventional Surgery|patients undergoing conventional surgery for the treatment of cancer
62088773|NCT00688961|NO_INTERVENTION|1|Baseline
62653846|NCT01946867|EXPERIMENTAL|NBTXR3 IntraTumoral injection (IT)|Single intratumor injection
62653847|NCT02497066|PLACEBO_COMPARATOR|Neuropathic Pain|Subjects with neuropathic pain will receive a neuropathic pain cream combined of Ketamine 10%/Gabapentin 6%/Clonidine 0.2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
61904885|NCT04549402|EXPERIMENTAL|Mirror Therapy group|The intervention will consist of the visualization of movement through the Mirror Therapy VR® application, broadcast on a mobile device and visualized with virtual reality glasses. The knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (walking and feeding, respectively).
61904886|NCT04549402|ACTIVE_COMPARATOR|Video group|The intervention will consist of the visualization of movement through the reproduction of an immersive 360º video broadcast on a mobile device and viewed with virtual reality glasses. Knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively).
61904887|NCT04549402|NO_INTERVENTION|Control group|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
61904888|NCT04385693|EXPERIMENTAL|Pulpotomy|Group A: The patient will benefit from an experimental treatment: a Pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
61904889|NCT04385693|ACTIVE_COMPARATOR|Control Group|Group B: Extracted teeth will serve as controls, and information regarding the need or not of space maintenance, and the impact on the occlusion and eruption of the succedaneous permanent tooth will be noted.
61904890|NCT03350269|EXPERIMENTAL|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
61904891|NCT03350269|NO_INTERVENTION|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
61904892|NCT01096628|EXPERIMENTAL|Chiropractic + Exercise|
61904893|NCT01096628|ACTIVE_COMPARATOR|Exercise|
61904894|NCT00877123|EXPERIMENTAL|Vitamin D|Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
61904895|NCT00877123|PLACEBO_COMPARATOR|Placebo|
61904896|NCT06426459||Natural menstrual cycle|Adolescent girls who have a natural menstrual cycle and have not used any kind of hormonal contraception for at least 6 months.
61904897|NCT06426459||Oral contraceptive|Adolescent girls who use combined oral contraceptives for at least 4 months.
62088774|NCT00688961|EXPERIMENTAL|2|Aspirin (1 day after a single, 625 mg dose)
62088775|NCT00688961|EXPERIMENTAL|3|Omacor
62287594|NCT01261819|ACTIVE_COMPARATOR|Traditional cystoscopy|"These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard."
62088776|NCT00688961|EXPERIMENTAL|4|Omacor plus aspirin
62088777|NCT05281393|NO_INTERVENTION|Control|Access to mobile health platform for resources and information about PrEP
62287595|NCT05112510||event group|The patients with nasopharyngeal carcinoma developed distant metastasis or recurrence after standard treatment.
62287596|NCT05112510||non-event group|The patients with nasopharyngeal carcinoma did not develop distant metastasis or recurrence after standard treatment.
62287597|NCT04489979||Analgetics only|Children with epididymitis / orchitis treated by analgetics only.
62287598|NCT04489979||Analgetics and antibiotics|Children with epididymitis / orchitis treated by analgetics and antibiotics.
62653848|NCT02497066|PLACEBO_COMPARATOR|Nociceptive pain|Subjects with nociceptive pain will receive a nociceptive pain cream combined of Ketoprofen 10%/Baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
62678904|NCT03731585|EXPERIMENTAL|Group I (psychological intervention)|Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
62088778|NCT05281393|EXPERIMENTAL|Experimental|Access to mobile health platform for resources and information about PrEP plus sessions with peer health support navigator, social app interactions, goal setting capabilities
62088779|NCT05151133|EXPERIMENTAL|Low dose UCMSCs|
62088780|NCT05151133|EXPERIMENTAL|Moderate dose UCMSCs|
62088781|NCT05151133|EXPERIMENTAL|High dose UCMSCs|
61919786|NCT05030961|EXPERIMENTAL|Established Cochlear Implant Recipient Group|Participants who are established cochlear implant recipients. Participants will receive a virtual team-based clinic, including remote cochlear implant programming, for one year.
62088782|NCT05950906|EXPERIMENTAL|Part 1 SAD SC PDM608|Single ascending dose, subcutaneous administration of PDM608
62088783|NCT05950906|PLACEBO_COMPARATOR|Part 1 SAD SC Placebo|Single ascending dose, subcutaneous administration of matching placebo
62088784|NCT05950906|EXPERIMENTAL|Part 2 MAD SC PDM608|Multiple ascending dose, subcutaneous administration of PDM608 once weekly for 4 weeks.
61919787|NCT03191578|EXPERIMENTAL|RUTI® injection|
62088785|NCT05950906|PLACEBO_COMPARATOR|Part 2 MAD SC Placebo|Multiple ascending dose, subcutaneous administration of placebo once weekly for 4 weeks.
62088786|NCT04871373|EXPERIMENTAL|Experimental group|A trained periodontist delivered oral hygiene instructions and motivational interviewing sessions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
62088787|NCT04871373|ACTIVE_COMPARATOR|Control group|A trained periodontist delivered only oral hygiene instructions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
62088788|NCT06432543||polyethylene containing Vitamin E|polyethylene containing Vitamin E
62088789|NCT06432543||conventional polyethylene (no highly cross-linking)|conventional polyethylene (no highly cross-linking)
62088790|NCT06432543||conventional polyethylene (with highly cross-linking)|conventional polyethylene (with highly cross-linking)
62088791|NCT01984125|EXPERIMENTAL|Point-of-Care Prompt|A prompt, either electronically or by a nurse, will notify a provider if an adolescent is due for a vaccination. This prompt will appear at any type of visit where the patient is seen by a health provider.
62088792|NCT01984125|NO_INTERVENTION|Control|
62088793|NCT02240680|EXPERIMENTAL|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
62462206|NCT02360462|EXPERIMENTAL|Active tDCS|Active tDCS will be applied in the head of the patients in 20 minute sessions, twice. First session will be applied in the night before and the second session, in the morning before the surgical procedure. The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current
62462207|NCT02360462|SHAM_COMPARATOR|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
62462208|NCT02683967|ACTIVE_COMPARATOR|Acupuncture|These patients received acupuncture during the follicular development phase and on the day of egg collection.
62462209|NCT02683967|NO_INTERVENTION|Control|Patients received standard care, no acupuncture.
62462210|NCT05979779|EXPERIMENTAL|Active Treatment: HU6 Planned doses of HU6|
62462211|NCT05979779|PLACEBO_COMPARATOR|Placebo Comparator Non-active study drug|
62462212|NCT04583852|EXPERIMENTAL|brightening micro-needle patch|apply brightening micro-needle patch to one of the two assigned spots on the face according to the instructions on the package
62462213|NCT04583852|PLACEBO_COMPARATOR|Placebo|apply placebo micro-needle patch to another one of the two assigned spots on the face according to the instructions on the package
62653849|NCT02497066|PLACEBO_COMPARATOR|Mixed pain|Subjects who have a mixed (nociceptive and neuropathic) pain conditions will receive a mixed pain cream combined of Ketamine 10%/Gabapentin 6%/Diclofenac 3%/baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
62678905|NCT03731585|EXPERIMENTAL|Group II (educational intervention)|Patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. Patients also complete questionnaires and participate in group sessions as in group I.
62088794|NCT02240680|PLACEBO_COMPARATOR|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
62088795|NCT00887731||Part 1 group|Observational study with a convenience sample of ten (10) patients. PART 1 will end when at least 3 of 4 consecutive patients achieve the goal of less than six (6) operator required interruptions per hour for oxygen saturation deviations from study guidelines, or at ten (10) patients.
62088796|NCT00887731||Part 2 group|(After successful completion of PART 1) Within patient cross-over study with a randomized cross-over sequence. Sequential data analysis methods will be used to help minimize the patient sample size which will be no more than twenty (20) patients plus up to a maximum of seven (7) who might be eligible from PART 1.
62088797|NCT00887731||Part 3 Group|(After successful completion of PART 2) Within patient cross-over study with a randomized cross-over sequence. Studies will last 4 to 12 hours divided in two (2) equal time blocks with one cross-over to either automatic or manual control modes.
62088798|NCT02954718|EXPERIMENTAL|1|patient-centered task oriented activity training in real life
62088799|NCT02954718|EXPERIMENTAL|2|patient-centered video-based task oriented activity training
62088800|NCT05058586|ACTIVE_COMPARATOR|Conventional theraphy group|13 patients received twenty sessions of conventional therapy for four weeks
62088801|NCT05058586|ACTIVE_COMPARATOR|Anti gravity treadmill training|13 patients received twenty sessions of conventional therapy for four weeks and Alter-G training was performed 3 days/week for 4 weeks, with up to 30 min. of training per session.
62653850|NCT03742596|EXPERIMENTAL|Probiotic Formula Capsule|In this intervention arm the patients will receive oral viable capsules of probiotic contain (1\*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
62088802|NCT05058586|ACTIVE_COMPARATOR|Underwater walking therapy group|13 patients received twenty sessions of conventional therapy for four weeks and three sessions of aerobic exercise treatment of 45 minutes per week underwater
62088803|NCT02110927|EXPERIMENTAL|Transcutaneous microcurrent|This group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 milliampere (mA). Every 20 minutes changed from 25 hertz (Hz) to 10 Hz
62287599|NCT04993625|EXPERIMENTAL|Avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|
62287600|NCT06411093|EXPERIMENTAL|A combination of Kinesiology tape wrapping and conventional treatment|Patients in the intervention arm will receive Kinesiology tape wrapping to separate the nail plate from the inflamed periungual tissue in addition to conventional treatment. This intervention will be applied at outpatient visits or during hospitalization. If the Kinesiology tape falls off, patients can either replace it themselves or leave it off until the next outpatient visit or unexpected hospitalization.
62287601|NCT06411093|ACTIVE_COMPARATOR|Conventional treatment|Patients in this arm will receive management according to routine clinical practice, including chemical cauterization with silver nitrate, with or without topical antiseptics, topical steroids, topical beta-blockers, systemic steroids, and systemic antibiotics. The above treatment will be applied at outpatient visits or during hospitalization.
62287602|NCT03290950|EXPERIMENTAL|Cohort 1|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
62287603|NCT03290950|EXPERIMENTAL|Cohort 2|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
62287604|NCT03656965|EXPERIMENTAL|Antiviral Drug with Chemoradiotherapy|Antiviral therapy Acyclovir 800 mg per day during the whole course of treatment.
62653851|NCT03742596|OTHER|Control|In this intervention arm, the control arm will receive normal treatment without any probiotic
62653852|NCT04676204||Cladribine|Participants with MS commencing cladribine disease modifying treatment as clinically prescribed.
62653853|NCT04676204||Dimethyl Fumarate|Participants with MS commencing dimethyl fumarate disease modifying treatment as clinically prescribed.
62653854|NCT04676204||Fingolimod|Participants with MS commencing fingolimod disease modifying treatment as clinically prescribed.
62653855|NCT04676204||Teriflunomide|Participants with MS commencing teriflunomide disease modifying treatment as clinically prescribed.
62653856|NCT04676204||Ozanimod|Participants with MS commencing Ozanimod disease modifying treatment as clinically prescribed.
61904900|NCT01757145|EXPERIMENTAL|Eltrombopag|"Eltrombopag will be given orally as a single daily dose. From day +1 after cord blood transplantation, start eltrombopag 100 mg/d. If primary end point not reached on day +14,then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d (maximal dose). If dose not tolerated, return to last tolerated dose.~Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.~In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks.~After 4 weeks we will re-attempt to hold the drug."
61919788|NCT03191578|PLACEBO_COMPARATOR|Sodium Chloride 0.9% injection|
62088804|NCT02110927|PLACEBO_COMPARATOR|Control group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
62088805|NCT05095155||Experimental group:|children with B-cell leukemia and lymphoma of Kazakhstani nationality
62088806|NCT05095155||Control group|children without B-cell leukemia and lymphoma of Kazakhstani nationality
62088807|NCT05564299|NO_INTERVENTION|Standard of Care|Point-of-care gram stain
62088808|NCT05564299|EXPERIMENTAL|Rapid STI Test|
62287605|NCT03656965|OTHER|Chemoradiotherapy|Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
62287606|NCT03038646|EXPERIMENTAL|Regimen A|32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state
62287607|NCT03038646|EXPERIMENTAL|Regimen B|32 mg MIN-101 MR administered in the fasted state
62653857|NCT04676204||Diroximel Fumarate|Participants with MS commencing diroximel fumarate disease modifying treatment as clinically prescribed.
62653858|NCT05601336|ACTIVE_COMPARATOR|metformin monotherapy|Glucophage 1000 once daily
62653859|NCT05601336|ACTIVE_COMPARATOR|Dapagliflozin monotherapy .|Farxiga once per day
62653860|NCT05601336|ACTIVE_COMPARATOR|metformin and dapagliflozin combined therapy|Xigduo once daily
62653861|NCT05601336|NO_INTERVENTION|control group.|placebo
62653862|NCT01866254|EXPERIMENTAL|Hydromorphone|100 mg, intrathecal administration
62653863|NCT01866254|ACTIVE_COMPARATOR|Morphine|200 mg, intrathecal administration
62653864|NCT04054297|EXPERIMENTAL|High GI/SFA diet|Subjects will adhere to a two-week high GI and high SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
62653865|NCT04054297|EXPERIMENTAL|Low GI/SFA diet|Subjects will adhere to a two-week low GI and low SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
62653866|NCT02314546|PLACEBO_COMPARATOR|Saline placebo|saline placebo
62653867|NCT02314546|ACTIVE_COMPARATOR|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
61904903|NCT03279289|EXPERIMENTAL|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
61904904|NCT03279289|ACTIVE_COMPARATOR|Group B|FOLFIRI + aflibercept
61904905|NCT00375401|EXPERIMENTAL|CP-945,598 Treatment A|
61904906|NCT00375401|EXPERIMENTAL|CP-945,598 Treatment B|
61904907|NCT00375401|PLACEBO_COMPARATOR|Placebo|
61904908|NCT03741387|EXPERIMENTAL|Gain-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you save his life? Donors in this group will answer the questions about attitude of saving patients' lives."
61904909|NCT03741387|EXPERIMENTAL|Loss-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you prevent him from death? Donors in this group will answer the questions about the attitude of preventing patients from death."
62653868|NCT02314546|ACTIVE_COMPARATOR|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
62653869|NCT05991375|ACTIVE_COMPARATOR|BUPIvacaine 0.25%|(Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) making a total volume of local anaesthetic solution equal to 30 mL
62653870|NCT05991375|EXPERIMENTAL|Bupivacaine0.25%+DEX|Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml) making a total volume of local anaesthetic solution equal to 30 mL
62653871|NCT05023980|EXPERIMENTAL|Arm A (Pirtobrutinib)|Pirtobrutinib administered orally
62653872|NCT05023980|ACTIVE_COMPARATOR|Arm B (BR)|Bendamustine plus rituximab administered intravenously (IV)
62653873|NCT02378311||Cases|Those satisfying the inclusion \& exclusion criteria whose injury involved impact with the handlebar end who have sustained an injury more severe than a skin or subcutaneous tissue contusion from an end-on handlebar impact
62653874|NCT02378311||Controls|Those satisfying the inclusion \& exclusion criteria in whom the handlebars were not implicated in the mechanism of injury
62653875|NCT01520753|EXPERIMENTAL|BIAsp 70|
62653876|NCT01520753|EXPERIMENTAL|BIAsp 70 + BIAsp 50|
61904910|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
61904911|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
61904912|NCT00798278|EXPERIMENTAL|Urokinase|urokinase infusion for 3 days
62653877|NCT01949545|EXPERIMENTAL|Normal Hepatic Function|Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
62653878|NCT01949545|EXPERIMENTAL|Mild Hepatic Impairment|Participants with mild hepatic impairment (bilirubin \> 1-1.5 x ULN or AST \> ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
62653879|NCT01949545|EXPERIMENTAL|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (bilirubin \> 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
61904913|NCT00798278|ACTIVE_COMPARATOR|Thoracoscopic|Video-Assisted Thoracoscopic
61904914|NCT06277843|EXPERIMENTAL|Thermal Jacket|
61904915|NCT04909476||Severe COVID pneumonia with ET|Severe COVID 19 pneumonia undergoing endotracheal intubation
62287608|NCT03038646|EXPERIMENTAL|Regimen C|32 mg MIN-101 MR administered in the fasted state
61904916|NCT05771883|EXPERIMENTAL|DLBCL and other B-NHL patients such as FL, MZL, MCL, etc.|"In this study, lenalidomide was administered at a fixed dose, in which 25 mg was used for DLBCL patients,and 20mg was used for other B-NHL patients such as FL, MZL, MCL, etc. and daily oral therapy with IMM0306 was used on the 1\~21st day of each repeat 28-day cycle.~The RP2D of the IMM0306 monotherapy trial was administered once a week (7 days ± 1 day) for intravenous infusion every 4 weeks"
62287609|NCT03038646|EXPERIMENTAL|Part 2 selected dose|32 mg MIN-101 of MR administered in the fed state
61904917|NCT01875198|EXPERIMENTAL|RAMPS|Radical Antegrade Modular Pancreatectomy with Splenectomy
61904918|NCT01875198|ACTIVE_COMPARATOR|RAMP|Radical Antegrade Modular Pancreatectomy without splenectomy
61904919|NCT01550653|EXPERIMENTAL|Liraglutide|"See Intervention"
61904920|NCT01550653|PLACEBO_COMPARATOR|Placebo|"See Intervention"
62287610|NCT01244256|EXPERIMENTAL|Treatment with Clotrimazole + Gentamicin + Beclomethasone|
62287611|NCT01244256|ACTIVE_COMPARATOR|Treatment with Clotrimazole + Gentamicin|
62287612|NCT05449457|NO_INTERVENTION|Layered Closure|One half of the wound will have a cutaneous layer of sutures (2 layers), as is standard of care, while the other half of the wound will have an additional layer of 2-octyl cyanoacrylate (3 layers).
62287613|NCT05449457|EXPERIMENTAL|Layered Closure with 2-Octyl Cyanoacrylate|One half of the wound will have a cutaneous layer of sutures (2 layers), as is standard of care, while the other half of the wound will have an additional layer of 2-octyl cyanoacrylate (3 layers).
62462214|NCT05286593|OTHER|Normal volunteers|Normal participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
61904921|NCT00086268|EXPERIMENTAL|Zometa®|4mg monthly for 12 months from date of first chemotherapy dose
61904922|NCT00086268|NO_INTERVENTION|no further treatment|Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
62462215|NCT05286593|OTHER|Clinical patients|Clinical patients participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
62462216|NCT05286593|OTHER|Infarcts|Infarct participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
62462217|NCT05470556||Overweight adolescents|This group will consist of 20 overweight adolescents (Body mass index (BMI) percentile value is 85.-95)
62653880|NCT01949545|EXPERIMENTAL|Severe Hepatic Impairment|(Bilirubin \> 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin \> 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
62653881|NCT04734613|EXPERIMENTAL|Tai Chi intervention|Tai Chi exercise intervention provided twice a week for one hour for 12 weeks
62653882|NCT04734613|ACTIVE_COMPARATOR|self management|self management program provided 6 sessions (one hour per session) for 12 weeks
62653883|NCT05141773|EXPERIMENTAL|Computed adenoma detection system (CADe) and Endocuff|CADe system can detect in the screen suspicion areas of adenomatous polyps. This is an additional help for the endoscopist for the detection of lesions. Endocuff increases the colonic surface examinated
62653884|NCT05141773|ACTIVE_COMPARATOR|Control group (Endocuff)|Endocuff increases the colonic surface examinated
62653885|NCT04222049|EXPERIMENTAL|spastic Tongue Dysarthria|The purpose of gadget is to transmit the mechanical vibration waves to the brain of the subjects.
62653886|NCT04938336||expert healthcare professionals|Delphi Procedure
61904927|NCT05676918|EXPERIMENTAL|Positive Psychology Intervention|Ten weekly sessions. Session duration: 90 minutes.
61904928|NCT05676918|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|Ten weekly sessions. Session duration: 90 minutes.
62462218|NCT05470556||Obese adolescents|This group will consist of 20 obese adolescents (BMI percentile value is above the 95th)
62462219|NCT05470556||normal weight|This group will consist of 20 normal-weight adolescents (BMI percentile value is 5th-85th.)
62653887|NCT04938336||healthcare professionals, patients and informal carers|interviews
62653888|NCT03103958|ACTIVE_COMPARATOR|probiotic|Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
61904929|NCT06304467|NO_INTERVENTION|Treatment As Usual (TAU)|Study Subjects randomized to treatment as usual (TAU) will not receive an intervention. They will continue with follow-up visits in the outpatient clinic as part of standard of care. .
61919789|NCT03203278|EXPERIMENTAL|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
61919790|NCT03203278|NO_INTERVENTION|Control group|Usual care
62653889|NCT03103958|PLACEBO_COMPARATOR|Placebo|Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
62653890|NCT00319124||Case|Patients with hip Osteoarthritis
62653891|NCT00319124||Control|Healthy controls without hip osteoarthritis
62653892|NCT05282784|EXPERIMENTAL|Hyperthermia group|Hyperthermia Radiotherapy
62653893|NCT05282784|ACTIVE_COMPARATOR|Control|Radiotherapy
62653894|NCT03482024|EXPERIMENTAL|Tirzepatide - Control|Group 1 - Tirzepatide 5 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.
62653895|NCT03482024|EXPERIMENTAL|Tirzepatide - Mild Renal Impairment|Group 2 - Tirzepatide 5mg administered SC to participants with mild renal impairment.
62653896|NCT03482024|EXPERIMENTAL|Tirzepatide - Moderate Renal Impairment|Group 3 - Tirzepatide 5mg administered SC to participants with moderate renal impairment.
62287614|NCT04953871|EXPERIMENTAL|Spondyloarthritis|Spondyloarthritis patients who was initiated TNF alfa blocker
62287615|NCT04942886|EXPERIMENTAL|Treatment group|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation. The intervention group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months.
62287616|NCT04942886|NO_INTERVENTION|delayed treatment group|The delayed treatment group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months. If the patient in the delayed treatment group shows HBV reactivation (positive HBsAg or HBV DNA ≥10 IU/mL), entecavir treatment is started.
62462220|NCT05240222|EXPERIMENTAL|Theory-informed pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and subsequent follow-up consultation. The content of SC-PIES was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
62462221|NCT05240222|SHAM_COMPARATOR|Active control|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
62462222|NCT04443660||Group A|without medical history or risk factors, with a normal pregnancy
62653897|NCT03482024|EXPERIMENTAL|Tirzepatide - Severe Renal Impairment|Group 4 - Tirzepatide 5mg administered SC to participants with severe renal impairment.
62653898|NCT03482024|EXPERIMENTAL|Tirzepatide - End Stage Renal Disease (ESRD)|Group 5 - Tirzepatide 5mg administered SC to participants with ESRD.
62653899|NCT05397652|EXPERIMENTAL|Tranexamic acid injectable product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously
62653900|NCT05397652|PLACEBO_COMPARATOR|Placebo|Patients from the control group will receive 10 minutes before the procedure 100 ml sterile saline intravenously
62653901|NCT04777513||Standard of care: FFR, ICA, CCTA|Patients with medical history for ischaemic heart disease will take part in non-invasive determination of haemodynamic parameters in coronary arteries with Cardiolens FFR-CT Pro technology.
62462223|NCT04443660||Group B|without medical history or risk factors, developing a pregnancy complication
62653902|NCT00355719|EXPERIMENTAL|Nevirapine-atazanavir|Atazanavir/ritonavir 300/100 mg once daily for ≥2 weeks. Nevirapine was added at a dose of 200 mg once daily from days 0 to 14, and 200 mg twice daily from days 14 to 28.
61904930|NCT06304467|EXPERIMENTAL|Contingency Management (CM)|Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
61904931|NCT06086197|EXPERIMENTAL|A+RGEMOX|"A-RGEMOX regimen (21 days per cycle, A total of 6 cycles) :~Allotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1"
61904932|NCT03343353|EXPERIMENTAL|LED red group (630nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
61904933|NCT03343353|EXPERIMENTAL|LED infrared group (940nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
61904934|NCT03343353|SHAM_COMPARATOR|Group Sham|This group will not receive irradiation by led light. You will only receive the routine care of the hospital unit to which you are hospitalized. These patients will be evaluated in the same way as the other two intervention groups, and also by a blind evaluator.
61904935|NCT02661763||Schoolchildren in Zambia|Schoolchildren in grades 7-12 in fifteen randomly selected schools in Lusaka area
61904936|NCT02522624|EXPERIMENTAL|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
61904937|NCT02522624|NO_INTERVENTION|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
62287617|NCT00059202|PLACEBO_COMPARATOR|Placebo|Placebo tablet that is identical (size, color, etc) to experimental ursodeoxycholic acid tablet.
62287618|NCT00059202|EXPERIMENTAL|Ursodeoxycholic acid|Ursodeoxycholic acid 28-30 mg/kg/day
62287619|NCT02125214|EXPERIMENTAL|ASA 1-2|ASA 1-2 patients 20-40 yr
62287620|NCT06229392|EXPERIMENTAL|Intratumoral influenza vaccine|
62287621|NCT04052581||POEM-TIF|All participants will undergo the POEM-TIF in the same session.
62287622|NCT05210504|EXPERIMENTAL|Participants administered oral lysine|participants will be administered 5g oral lysine
62462224|NCT04443660||Group C|with risk of complication, having a normal pregnancy
62462225|NCT04443660||Group D|with a risk of complication, developing a pregnancy complication
62462226|NCT00172055|EXPERIMENTAL|ZOL446 (zoledronic acid)|
62653903|NCT06036095|ACTIVE_COMPARATOR|Inhalational Anesthesia|Inhalational maintenance of anesthesia group using sevoflurane
62653904|NCT06036095|ACTIVE_COMPARATOR|Intravenous Anesthesia|Intravenous maintenance of anesthesia group using propofol
62653905|NCT01707524|EXPERIMENTAL|Trans-radial approach|Randomized left versus right radial artery approach
62653906|NCT01707524|NO_INTERVENTION|Trans-femoral approach|Observational
62653907|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
62287623|NCT02667184|EXPERIMENTAL|Low FODMAP Oral Nutrition Supplement 1|Low FODMAP Oral Nutrition Supplement
62287624|NCT02667184|EXPERIMENTAL|Low FODMAP Oral Nutrition Supplement 2|Low FODMAP Oral Nutrition Supplement
62088809|NCT02413788|EXPERIMENTAL|combined group (treadmill and resisted)|- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
62088810|NCT02413788|ACTIVE_COMPARATOR|aerobic group (treadmill)|10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
62287625|NCT02667184|EXPERIMENTAL|Low FODMAP Oral Nutrition Supplement 3|Low FODMAP Oral Nutrition Supplement
62653908|NCT00691275|PLACEBO_COMPARATOR|2|Saline
62653909|NCT00691275|ACTIVE_COMPARATOR|1|Zofran
62653910|NCT05258552|EXPERIMENTAL|Enema group|
62653911|NCT05258552|NO_INTERVENTION|Control group|
62653912|NCT00863122|EXPERIMENTAL|lapatinib|Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
62653913|NCT00863122|NO_INTERVENTION|control|Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
62653914|NCT03222726|ACTIVE_COMPARATOR|exercise group|6000 steps/day or 40,000 steps/week
62653915|NCT03222726|OTHER|less-exercise group|less than 6000 steps/day or 40,000 steps/week
62088811|NCT04171726|EXPERIMENTAL|Edoxaban|treatment with edoxaban
62088812|NCT01246843||metastatic Renal Cell Carcinoma without treatment|patients with metastasized RCC who did not receive treatment
62088813|NCT01246843||mRCC with treatment|"patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for~≥ 8 weeks"
62287626|NCT02667184|EXPERIMENTAL|FOS Supplement|Supplement containing fructooligosaccharides
62653916|NCT03366753|EXPERIMENTAL|Acute normovolemic hemodilution|acute normovolemic hemodilution by using hydroxyethyl starch
62653917|NCT03366753|EXPERIMENTAL|In-vitro hemodilution|adding additional hydroxyethyl starch for achieving further 30% dilution of whole blood sample which already underwent ANH of 4-6 ml/kg.
62653918|NCT03323762|EXPERIMENTAL|RIC|"RIC treatment arm The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes.~The treatment will be carried out on the morning of day 2 to day 7 by the participants themselves at their home."
62653919|NCT06255743|EXPERIMENTAL|case|cases diagnosed systemic lupus erythematosus we measure degree of depression and anxiety and relation to (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies)
62653920|NCT01114555|EXPERIMENTAL|Bevacizumab, Irinotecan and Temozolomide|This is a phase II study of the combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.
62653921|NCT00834184|EXPERIMENTAL|A|nikkomycin Z 250 mg BID versus placebo BID x 14 days
62653922|NCT00834184|EXPERIMENTAL|B|nikkomycin Z 500 mg BID versus placebo BID x 14 days
62653923|NCT00834184|EXPERIMENTAL|C|nikkomycin Z 750 mg BID versus placebo BID x 14 days
62653924|NCT00834184|EXPERIMENTAL|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
62653925|NCT02875457|EXPERIMENTAL|Arm A|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and apatinib 250mg/d , repeated every 21 days, a total of 6 cycles, and then continue to take apatinib 250mg/d until progressive Disease(PD).
62653926|NCT02875457|PLACEBO_COMPARATOR|Arm B|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and placebo, repeated every 21 days, a total of 6 cycles, and then continue to take placebo until PD.
62088814|NCT03735810|EXPERIMENTAL|SAD - Cohort 1|50 mg LBS-008 or placebo
62088815|NCT03735810|EXPERIMENTAL|SAD - Cohort 2|100 mg LBS-008 or placebo
62088816|NCT03735810|EXPERIMENTAL|SAD - Cohort 3|200 mg LBS-008 or placebo
62088817|NCT03735810|EXPERIMENTAL|SAD - Cohort 4|400 mg LBS-008 or placebo
62088818|NCT03735810|EXPERIMENTAL|SAD - Cohort 5|25 mg LBS-008 or placebo
62088819|NCT03735810|EXPERIMENTAL|MAD - Cohort 1|10 mg LBS-008 or placebo
62088820|NCT03735810|EXPERIMENTAL|MAD - Cohort 2|25 mg LBS-008 or placebo
62088821|NCT03735810|EXPERIMENTAL|MAD - Cohort 3|5 mg LBS-008 or placebo
62088822|NCT03735810|EXPERIMENTAL|MAD - Cohort 4|12 mg LBS-008 or placebo
62088823|NCT06615648|EXPERIMENTAL|PMT Information|The participant will watch the PMT-video and then complete the associated questionnaires.
62088824|NCT06615648|ACTIVE_COMPARATOR|Non-contact Control|The participant will watch a non-specific video about coffee and then complete the associated questionnaires.
62088825|NCT02702934|EXPERIMENTAL|High-amylose rusks|Test meal with 100g of carbohydrates coming from high-amylose rusks
62287627|NCT05244239|EXPERIMENTAL|Treatment (lurbinectedin and palliative radiation therapy)|Patients undergo palliative RT over 5 or 10 treatment fractions at the discretion of the treating physician daily for 21 days. Patients also receive lurbinectedin IV over 1 hour on day 1 of each cycle. Cycles of lurbinectedin repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62287628|NCT01246206|EXPERIMENTAL|Tacrolimus and Thymoglobulin|Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis
62653927|NCT00656617|EXPERIMENTAL|Idarubicin + Ara-C + Vorinostat|Idarubicin 12 mg/m\^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m\^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
62678906|NCT03346746|EXPERIMENTAL|Low GI diet|This diet contained three Low GI meals. This was the Low Glycaemic Diet intervention.
62678907|NCT03346746|EXPERIMENTAL|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
62088826|NCT02702934|ACTIVE_COMPARATOR|Control rusks|Test meal with 100g of carbohydrates coming from regular rusks used as control
62088827|NCT03413774||Abortion group|910 women attended Fayoum University hospital outpatient gynecology clinic with recent first trimesteric spontaneous miscarriage
62088828|NCT03413774||Control group|940 women attended Fayoum University hospitalpresented for any other gynecological complaint
62088829|NCT05876936|OTHER|contact lens sensor Triggerfish® in patients selected for deep sclerectomy with collagen implant|The contact lens sensor (CLS) SENSIMED Triggerfish® in will be placed on the study eye as selected for deep sclerectomy with collagen implant (DSCI)
62088830|NCT00257816|EXPERIMENTAL|Topotecan|Adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
62088831|NCT03354299|EXPERIMENTAL|Group I|Group I patients received 25 gram of sugar (pudding) and 50 cc of coconut milk as late night snack for a month
62287629|NCT02282787|EXPERIMENTAL|5 micron dex arm|
62088832|NCT03354299|ACTIVE_COMPARATOR|Group II|Group II patients received 50 gram of sugar (25 gram pudding and 25 gram syrup) as late night snack for a month
62088833|NCT03055585|EXPERIMENTAL|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
62088834|NCT03055585|OTHER|Comparison arm|Standard practice dengue control activities
62088835|NCT05575843|OTHER|Group A|First neurologist, second nurse
62088836|NCT05575843|OTHER|Group B|First nurse, second neurologist
62088837|NCT04750408|ACTIVE_COMPARATOR|Oxygen use|Patients will use standard oxygen via face mask of nasal prongs as usual care.
62088838|NCT04750408|EXPERIMENTAL|NHF use|Patients will use NHF instead of oxygen. Oxygen will be supplemented via the NHF flow.
62088839|NCT05435183|EXPERIMENTAL|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the non-invasive bi-level positive pressure mode, and the high-frequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
62088840|NCT05435183|ACTIVE_COMPARATOR|Bilevel positive pressure ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
62088841|NCT02662738|ACTIVE_COMPARATOR|A wheat product|A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
62287630|NCT02282787|EXPERIMENTAL|10 micron dex arm|
62287631|NCT03712826|EXPERIMENTAL|anti TNF|Crohn patient with antiTNF treatment
62287632|NCT03712826|EXPERIMENTAL|Ustekinumab|Crohn disease with ustekinumab treatment
62462227|NCT01809171|EXPERIMENTAL|vitamin D3|1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
62462228|NCT01809171|PLACEBO_COMPARATOR|Placebo|1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months
62462229|NCT05354648|ACTIVE_COMPARATOR|Hypoxic-hyperoxic preconditioning (HHP)|HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, and at the last stage, a period of breathing with atmospheric air until the cardio-pulmonary bypass is connected. The anaerobic threshold was determined 72 hours before surgery to establish a safe oxygen concentration in the respiratory gas mixture during the hypoxic phase of preconditioning.
62088842|NCT02662738|PLACEBO_COMPARATOR|Control|A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
62088843|NCT02662738|OTHER|Glucose solution|A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.
62088844|NCT02788136|EXPERIMENTAL|Klinefelter syndrome|13 men with diagnosis of Klinefelter syndrome were stimulated with human chorionic gonadotropin (hCG)
62088845|NCT02788136|ACTIVE_COMPARATOR|Control|12 healthy age-related men were stimulated with human chorionic gonadotropin (hCG)
62088846|NCT02081365|EXPERIMENTAL|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
62088847|NCT02081365|NO_INTERVENTION|High Anxiety Wailist Control|
62287633|NCT00699179||A|
62088848|NCT01066156|EXPERIMENTAL|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
62287634|NCT04972994|ACTIVE_COMPARATOR|laparoscopic intracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic intracorporeal versus for right and left hemicolectomies in management of colonic cancers
62287635|NCT04972994|ACTIVE_COMPARATOR|laparoscopic extracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
62287636|NCT02835430|EXPERIMENTAL|Coronally advanced flap and PRF with DFDBA|Coronally advanced flap and platelet-rich fibrin membrane with demineralized freeze-dried bone allograft.
62653928|NCT04377867||LRBA deficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
62653929|NCT04377867||CTLA4 haploinsufficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
62653930|NCT04377867||Control group|Age matched healthy control group will be used during the study to determine the reference values of the immunological assays.
62287637|NCT02835430|ACTIVE_COMPARATOR|Coronally advanced flap and PRF without DFDBA|Coronally advanced flap and Platelet-rich fibrin membrane without demineralized freeze-dried bone allograft.
62287638|NCT03030287|EXPERIMENTAL|OMP-305B83 plus paclitaxel|
62653931|NCT04909723|PLACEBO_COMPARATOR|Stage 1 placebo arm|
62653932|NCT04909723|EXPERIMENTAL|Stage 1 NB1000S 10^9 CFU one time on Day 1|
62653933|NCT04909723|EXPERIMENTAL|Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 0.5g/day|
62287639|NCT02168686|EXPERIMENTAL|Part A: Dose 1|ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
62287640|NCT02168686|EXPERIMENTAL|Part A: Dose 2|ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
62287641|NCT02168686|EXPERIMENTAL|Part A: Dose 3|ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
62287642|NCT02168686|EXPERIMENTAL|Part A: Dose 4|ADVM-043 administered at a dose that will be determined
62287643|NCT02168686|EXPERIMENTAL|Part B (optional): Intrapleural administration|ADVM-043 administered intrapleurally at a dose that will be determined
62287644|NCT02835885|EXPERIMENTAL|Active tVNS Stimulation|Stimulating electrode will be placed on left tragus of subject. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied.The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
62307929|NCT03489291|EXPERIMENTAL|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
62462230|NCT05354648|PLACEBO_COMPARATOR|Control|The anaerobic threshold was determined, however, patients in the control group were not preconditioned. Mechanical ventilation was carried out with individual settings maintaining the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively), until the cardio-pulmonary bypass was connected.
62653934|NCT04909723|EXPERIMENTAL|Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 10g/day|
61904938|NCT03354143|ACTIVE_COMPARATOR|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
62088849|NCT01870817|ACTIVE_COMPARATOR|Home jejunostomy feeding|Six weeks of post hospital discharge home enteral feeding
62653935|NCT04909723|EXPERIMENTAL|(Optional) Stage 1 variable doses of NB1000S and NB2000P at varying dosing regimens.|Adaptive trial design supports the enrollment of additional arms with variable doses of NB1000S, NB2000P, at varying frequencies of NB1000S and NB2000P administrations.
62653936|NCT04909723|EXPERIMENTAL|Stage 1 NB2000P at a dose to be determined|
62653937|NCT04909723|EXPERIMENTAL|Stage 2 NOV-001 at dose determined in Stage 1|In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive NOV-001 (consisting of NB1000S and NB2000P at a dose and regimen determined in Stage 1) for 28 days.
62653938|NCT04909723|PLACEBO_COMPARATOR|Stage 2 placebo arm|In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive placebo for 28 days.
62653939|NCT00658528|EXPERIMENTAL|1|
62653940|NCT00658528|ACTIVE_COMPARATOR|2|
62653941|NCT05883111|OTHER|Trans men and non-binary people with a cervix|Participants will have a clinician-collected cervical screening sample and then collect the following self-samples for research: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection.
62678908|NCT02738398|EXPERIMENTAL|PET imaging|PET imaging
62653942|NCT05883111|EXPERIMENTAL|Trans women and non-binary people|Participants will collect the following self-samples for research in the clinic: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection. Participants will collect the following self-samples for research at home: Vaginal swab, Anal swab, and Oral rinse sample for the detection of HPV detection.
62653943|NCT04502277|EXPERIMENTAL|Flucanazole|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
62653944|NCT04502277|ACTIVE_COMPARATOR|Diflucan|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
62653945|NCT04023578|EXPERIMENTAL|Rheo Knee XC|Amputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
62653946|NCT05499286|ACTIVE_COMPARATOR|Mindfulness Program|Participants will attend an online mindfulness program known as the Mindful Awareness and Resilience Skills for Adolescents (MARS-A) program.
62653947|NCT05499286|NO_INTERVENTION|Online Peer Support Program|Participants will attend an online peer support program where they will engage with each other by sharing experiences while providing advice and emotional support.
62653948|NCT01812187|EXPERIMENTAL|SHIFT Cognitive Behavioral Therapy|Service to Home for Individually-Focused Therapy (SHIFT), a Cognitive Behavioral Treatment for Substance Use Disorders
62653949|NCT05322785|OTHER|Single Visit breath collection|"Following informed consent, exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask. Exhaled breath will be diverted into a collection device, which may include a bag, tube, or other device with minimal resistance. The collection process, including completing forms, will not exceed 30 minutes.~At no time will the patients be breathing anything other than ambient air with or without oxygen enrichment as clinically indicated. Inhaled air will not be manipulated."
62653950|NCT04139135|EXPERIMENTAL|HLX10|HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase
62653951|NCT04139135|PLACEBO_COMPARATOR|Placebo|Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
62088850|NCT01870817|NO_INTERVENTION|Control|Standard care
62287645|NCT02835885|SHAM_COMPARATOR|Sham tVNS Stimulation|Stimulating electrode will be placed on left ear lobe of subject for sham tVNS stimulation condition. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied. The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
62287646|NCT06190457||Experimental group|"From May 2015 to December 2020, 16 children with NHL who were diagnosed in the Department of Pediatric Oncology of Sun Yat-sen Memorial Hospital of Sun Yat-sen University agreed to receive RTX intrathecal therapy and signed an informed consent form. Among them, there were 13 males and 3 females, with a male-to-female ratio of 4.33:1.00, an age of 5.1-13.1 years, and an average age of onset of 8.5 years.~1.2 Diagnosis All children are diagnosed according to WHO lymphoma typing criteria by pathomorphological classification and immunotyping of tissue or bone marrow .~Exclusion Criteria Patients with severe organic diseases such as heart, liver and kidney, allergic to rituximab."
62287647|NCT04598490|EXPERIMENTAL|Healed extraction site|Old Extraction Space
62287648|NCT04598490|EXPERIMENTAL|unhealed extraction site|Recent Extraction space
62287649|NCT02914509|EXPERIMENTAL|OTX-TP (sustained release travoprost) Intracanalicular Depot|OTX-TP (sustained release travoprost) Intracanalicular Depot
62287650|NCT02914509|PLACEBO_COMPARATOR|PV (Placebo Vehicle) Intracanalicular Depot|PV (Placebo Vehicle) Intracanalicular Depot
62287651|NCT01062360|EXPERIMENTAL|Arm 1|
62653952|NCT04213261|EXPERIMENTAL|FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts|Intra-subject randomized (paired wounds in each subject receive experimental treatment, FCX-007, or remain untreated). Up to three target wound pairs will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (FCX-007 is administered) or control wound. Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1 and the second at Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month 9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.
62653953|NCT05414604||PV group|Patients who had a spine CT
62653954|NCT00443300||Protective environment|Participants in a Protective environment
61904939|NCT03354143|EXPERIMENTAL|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
62653955|NCT00443300||Not a protective environment|Participants not in a protective environment
62088851|NCT04079036||Underweight Adult Male|Male patients with Underweight BMI classification and more than 20 years old https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
62287652|NCT01062360|ACTIVE_COMPARATOR|Arm 2|
62287653|NCT01062360|ACTIVE_COMPARATOR|Arm 3|
62653956|NCT05902624|OTHER|Group intralesional injection of HBV vaccine|Group 1: will include 20 patients with multiple cutaneous warts. They will be treated by intralesional injection of HBV vaccine into the largest wart by an insulin syringe every 2-weeks until complete clearance or for a maximum of 5 sessions.
62088852|NCT04079036||Healthy Weight Adult Male|Male patients with Healthy Weight BMI classification and more than 20 years old
62287654|NCT01062360|PLACEBO_COMPARATOR|Arm 4|
62287655|NCT05796986|EXPERIMENTAL|Wide neck saccular cerebral aneurysms patients|
62287656|NCT01956851||Normal Healthy|Normal Healthy: includes healthy patients eligible for enrolment,
62287657|NCT01956851||Diabetics on Oral Hypoglycemic Agents|Diabetics on Oral Hypoglycemic Agents: includes diabetic patients on oral diabetic drug therapy with all eligibility criterion fulfilled,
62462231|NCT04231084|ACTIVE_COMPARATOR|Inhaled Nitric Oxide|Vasodilator testing will be performed with inhaled nitric oxide
62653957|NCT05902624|OTHER|Group cryotherapy|Group 2: will include 20 patients with multiple cutaneous warts. They will be treated by cryotherapy every 2-weeks until complete clearance or for a maximum of 5 sessions.
62653958|NCT05902624|OTHER|Group cryotherapy with intralesional injection of HBV vaccine|Group 3: will include 20 patients with multiple cutaneous warts. They will be treated by cryotherapy with intralesional injection of HBV vaccine into the largest wart by an insulin syringe every 2-weeks until complete clearance or for a maximum of 5 sessions.
62653959|NCT01443884|EXPERIMENTAL|Group 1|After a 1 week baseline, volunteers will consume two packets of grape powder stirred into water for three weeks. Each packet will contain the equivalent of approximately 2 servings of fresh grapes (46 grams of powder). Following a two week washout period, volunteers will cross-over to a placebo powder.
62653960|NCT01443884|EXPERIMENTAL|Group 2|After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
62653961|NCT06232876|SHAM_COMPARATOR|Blinded continuous monitoring|Continuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators.
62653962|NCT06232876|EXPERIMENTAL|Unblinded continuous monitoring|Continuous ward monitoring with vital signs available to patients, clinicians, and investigators.
62653963|NCT06112145|EXPERIMENTAL|group I|Flexor tendon zon II rupture patients
62653964|NCT06112145|EXPERIMENTAL|group II|Flexor tendon other zon rupture patients
62653965|NCT06091514|OTHER|Cohort group|"Patients will be followed during a period ranging from 3 to 12 months depending on his period at risk of AF. This period will be defined at the inclusion visit. During this period, the patient will be followed as part of usual care, considering the medical informations given by the ILR device already implanted.~During this period, the patient will have to wear the watch permanently outside charging time. Moreover, he will have to realize ECG measurement when the Medical Watch will indicate it. The patient could also trigger an ECG measurement if he feels the need."
62653966|NCT00410358|EXPERIMENTAL|LBQ707|
61904940|NCT02809716||Ancillary-Correlative (blood and tumor tissue collection)|Patients undergo collection of blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo and tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including, whole-genome CNV profiles, protein expression, and cell morphology.
62088853|NCT04079036||Overweight Adult Male|Male patients with OverWeight or Obese BMI classification and more than 20 years old
62088854|NCT04079036||Underweight Adult Female|Female patients with Underweight BMI classification and more than 20 years old
62088855|NCT04079036||Healthy Weight Adult Female|Female patients with Healthy Weight BMI classification and more than 20 years old
62088856|NCT04079036||Overweight Adult Female|Female patients with Overweight or Obese BMI classification and more than 20 years old
62088857|NCT04079036||Underweight children Male|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
62088858|NCT04079036||Healthy Weight children Male|Male patients less than 20 year old, and with Healthy Weight BMI classification
62088859|NCT04079036||Overweight children Male|Male patients less than 20 year old, and with Overweight or Obese BMI classification
62287658|NCT01956851||Diabetics on Insulin Therapy|Diabetics on Insulin Therapy: includes diabetic patients on insulin therapy with all eligibility criterion fulfilled
62462232|NCT04231084|EXPERIMENTAL|Inhaled Epoprostenol|Vasodilator testing will be performed with inhaled epoprostenol
62653967|NCT03509441||South Asians with Insulin Resistance|125 patients (anticipated)
62653968|NCT03509441||South Asians without Insulin Resistance|125 patients (anticipated)
62287659|NCT04390087|EXPERIMENTAL|Exercise|Upper-body rowing performed up to 30 min, 3 times per week with moderate-to-vigorous intensity
62287660|NCT04390087|NO_INTERVENTION|Control|The participants allocated to the control group will be asked to maintain their normal lifestyle throughout the intervention period
62287661|NCT01806467||critically ill patients|patients admitted to the medical-surgical ICU
62287662|NCT01806467||post-cardiac surgical patients|patients admitted to the post-cardiac surgical ICU
62287663|NCT00893516|EXPERIMENTAL|1|CHOP chemo therapy + CD4 therapy
62287664|NCT00893516|ACTIVE_COMPARATOR|2|CHOP chemotherapy
62462233|NCT03663478|ACTIVE_COMPARATOR|Intervention|Ropivacaine
62462234|NCT03663478|PLACEBO_COMPARATOR|Control|Isotonic saline
62653969|NCT02746861|EXPERIMENTAL|Diabetes Self-Management Support (DSMS)|Patient receives 6-months of DSMS while receiving support from a trained peer mentor (Peer-supported DSMS).
62653970|NCT02746861|NO_INTERVENTION|Usual Care|Patient continues to receive usual care.
62088860|NCT04079036||Underweight children Female|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
62088861|NCT04079036||Healthy Weight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
62088862|NCT04079036||Overweight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
62287665|NCT01344967|EXPERIMENTAL|Zometa, Bone Suppression, Active Ingredient|
62287666|NCT05203250||Brain tumors, skull base tumors, spinal cord tumors|NEUROPARTICLE
62287667|NCT05203250||Ocular melanomas|
62287668|NCT05203250||Head and Neck tumors|
62287669|NCT05203250||Tumors of thorax and/or abdomen|GI-Particle
62462235|NCT04603209||IORT|All participants who plan to undergo partial mastectomy for treatment of early stage breast cancer will be considered for eligibility for IORT. Patient with single breast cancer less than 3cm in disease span, clinical negative axillary node will be offered the option of having IORT. If IORT is delivered following surgical resection of the tumor they will be followed in this registry for short and long term outcomes.
62653971|NCT04925401|EXPERIMENTAL|Information brochure Arm|The experimental group will receive an information brochure on fever in children and how to deal with a febrile episode and usual medical management.
62653972|NCT04925401|NO_INTERVENTION|Habitual care|The control group will receive the usual medical management
62653973|NCT04128553|EXPERIMENTAL|Intervention motivational interview group|"Face-to-face motivational interviews lasted for an average of 30 minutes. After the MI, the exercise information guideline prepared by the researcher and the TTM-based MI guideline according to the stages were given to the older adults. During the MI, a form prepared by the researcher was used to note the content of the interview. At the end of MI, the next appointment was planned. In addition, the older adults were given a chart prepared by the researcher to note their walk.~On the other hand, the phone-based motivation interviews lasted an average of five to seven minutes. Before the telephone interview, it was determined which stage of change the older adult was in. Then a motivational interview was held according to the stage."
62653974|NCT04128553|NO_INTERVENTION|Control|The Control Group (CG) was only followed up at the beginning and end of the study, no intervention was made. The CG received standard care. Although the family health staff do not give routine and standard training about the benefits of exercising in the FHC to the elderly, they give information when necessary.
62653975|NCT02619201|EXPERIMENTAL|ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
62653976|NCT02619201|ACTIVE_COMPARATOR|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
62653977|NCT03329989|EXPERIMENTAL|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
62653978|NCT02598908||NHS staff volunteer donors|Interested staff working within the Pathology Department at SWBH NHS Trust will be provided with written information regarding the proposed EQA scheme and the sample collection procedure. A consent form will be given to staff members, who will be asked to return the signed form within 1 week if they wish to participate. Each participating staff member will be assigned a unique patient identifier to allow for sample results to be anonymised.
62678909|NCT03927846|ACTIVE_COMPARATOR|Telephone Contact (Nurse)|6 regular telephone contacts by nurses who will use a motivational interviewing technique
62678910|NCT03927846|ACTIVE_COMPARATOR|E-mail contact|6 computer generated email reminders (control arm) over an 8-week period.
62088863|NCT02842879|EXPERIMENTAL|Outpatient Foley cervix priming|Patients randomized to outpatient cervix priming will have the insertion of the catheter in the same conditions defined by the Department protocol for inpatient cervix priming. They will be discharged after a reassuring cardiotocogram following the introduction of the Foley catheter. When discharged, the patients will be instructed to apply manual traction to the catheter every 6 hours and they will be given a written document with all the information that should bring them back to hospital.
62088864|NCT02842879|NO_INTERVENTION|Inpatient Foley cervix priming|The introduction of a deflated catheter (Foley catheter nº 16F) through the outer cervix orifice is preceded by iodine disinfection of the cervix. The intracervical catheter is distended with 40mL of a saline solution. The end of the catheter is taped to the medial portion of the thigh and manual traction is applied to the catheter every 6 hours. If it is not spontaneously extruded it is removed after 24h. Cervix priming occurs in an inpatient setting.
62287670|NCT05203250||Pelvic tumors|GYN-Particle
62287671|NCT05203250||Sarcomas and tumors of limbs|SarTAP-Particle
62287672|NCT05203250||Pediatric tumors|
62287673|NCT05203250||Mobile spine and sacral tumors|
62287674|NCT01714986|ACTIVE_COMPARATOR|Affect School|Psychological group education intervention
62287675|NCT01714986|ACTIVE_COMPARATOR|Body Awareness Therapy|Physiotherapeutic psychosomatic intervention
62287676|NCT04406870|EXPERIMENTAL|Intervention|patients with propranolol-resistant IHHE are given propranolol combined with sirolimus
62287677|NCT02487108|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to TV46763 (hydrocodone bitartrate/acetaminophen) immediate release (IR) tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
62307930|NCT06021743||Sepsis|Patients hospitalized due to the sepsis
62653979|NCT02598908||SWBH outpatient donors|A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer system (Telepath). Those with a TPMT activity of interest, measured in the past five years, will be contacted with the agreement of their hospital consultant. Information and consent forms will be sent to the patient either through the post or via their hospital consultant. Each participating patient will be assigned a unique patient identifier to allow for sample results to be anonymised.
62653980|NCT02100787|EXPERIMENTAL|TheraTears lubricating drops|TheraTears lubricating eye drops to be used 1 drop in both eyes four times a day (QID)
62653981|NCT03955549|EXPERIMENTAL|Insight Enhancement Program (IEP)|The insight enhancement program is a dynamo-cognitive therapeutic modality with the main target of improving insight in psychotic patients as a means of improving their overall outcome.
61904941|NCT05033405|EXPERIMENTAL|Experimental:Neuro Linguistic Programming|One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field.
62088865|NCT06585020|EXPERIMENTAL|ARIKAYCE|Experimental arm = ARIKAYCE® during 6 months in addition to standard treatment (duration determined with date of sputum conversion)
62287678|NCT02487108|EXPERIMENTAL|TV-46763 5.0 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 5.0 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
62287679|NCT02487108|EXPERIMENTAL|TV-46763 7.5 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 7.5 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
62287680|NCT02487108|EXPERIMENTAL|TV-46763 10.0 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 10.0 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
62287681|NCT05812664|EXPERIMENTAL|bolus feeding group|bolus feeding method;The amount of food to be given for 24 hours calculated for the patient was given as 4 equal amounts for 40 minutes at 4 different times. Starting with 150 cc, the target calorie was reached by increasing 100 cc according to the intolerance before the next feeding hour.
62287682|NCT05812664|EXPERIMENTAL|intermittent feeding group|The formula was started as 40 cc/h continuous infusion. It was interrupted after 5 hours. 30 minutes after the break, PGD was measured and intolerance was checked, and if the residue was negative, it was increased by 40 cc. The amount was increased until reaching the amount of formula that should be given for 24 hours calculated for the patient. This cycle was repeated 3 times in 24 hours. At 24:00, it was stopped and feeding was interrupted between 24:00 and 06:00.
62287683|NCT05812664|ACTIVE_COMPARATOR|continous feeding group|The same method was applied as in Group 2. However, after 24:00, feeding was not interrupted and continued as the 4th cycle.
62287684|NCT03575026|EXPERIMENTAL|Intervention|Subjects will receive 12-week music-with-movement intervention at home by their trained caregivers for 12 weeks, at least 3 sessions per week and 30 minutes for each session.
62287685|NCT03575026|PLACEBO_COMPARATOR|Wait-list control|Subjects will receive 12-week usual care (social activity) at home. Dose is similar to intervention arm. After the completion of 12-week usual care, subjects will receive the same music intervention as intervention arm.
62287686|NCT04424563||Group A|Patients of group A include 40 patients, received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
62307931|NCT06067113||Obese|Obese patients with an indication for bariatric surgery
62307932|NCT06067113||Controls|Age and sex-matched controls
62653982|NCT03955549|EXPERIMENTAL|Metacognitive Training for Psychosis (MCT)|The metacognitive training program, developed by Moritz et al. (Moritz \& Woodward, 2007) targets cognitive biases putatively involved in the formation and maintenance of psychotic symptoms.
62653983|NCT03955549|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|"Treatment as usual will be used as a control condition to assure ethicality of our procedure.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
62653984|NCT01101178|EXPERIMENTAL|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
61904942|NCT05033405|NO_INTERVENTION|control group|No NLP was applied on the control group patients.
62088866|NCT06585020|ACTIVE_COMPARATOR|Standard treatment|Control arm = standard treatment Standard treatment = Rifampicin, ethambutol and clarithromycin
62462236|NCT04344847|OTHER|coincidental GIST during LSG patients|With institutional review board approval from Zagazig University Hospitals 338. A double-centre prospective study was conducted on prospectively collected data of all morbidly. 17 patients in Zagazig University Hospitals, Faculty of Medicine, Egypt and 321 patients done in bariatric surgery excellence unit in a tertiary hospital in Riyadh-KSA.
62462237|NCT06114251||First Affiliated Hospital, Zhejiang University School of Medicine|
62088867|NCT05678595|ACTIVE_COMPARATOR|A hot laser derived from a Nd: YAG laser|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
62088868|NCT05678595|SHAM_COMPARATOR|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
62088869|NCT03019458|EXPERIMENTAL|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
62287687|NCT04424563||Group B|While patients of group B include 40 patients, received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed.
62287688|NCT02393911|ACTIVE_COMPARATOR|Study A - with diet|Patients with LPV, treated by Low Oxalate Diet for three months.
62287689|NCT02393911|ACTIVE_COMPARATOR|Study B- no diet|Patients with LPV, not treated by Low Oxalate Diet for three months.
62287690|NCT02393911|ACTIVE_COMPARATOR|Control|Healthy women without LPV, not treated by Low Oxalate Diet
62287691|NCT02553694|EXPERIMENTAL|Enhanced education and Enhanced follow up|Subjects will watch a short video and will be contacted by an MD by phone
62287692|NCT02553694|ACTIVE_COMPARATOR|Usual education and Usual follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and will be contacted by a sleep center staff member by phone
62287693|NCT02553694|EXPERIMENTAL|Enhanced education and Usual follow up|Subjects will watch a short video immediately prior to the initiation of the in-laboratory polysomnogram and will be contacted by sleep center non-MD staff member by phone
62462238|NCT06114251||Shulan (Hangzhou) Hospital|
62462239|NCT02226185|EXPERIMENTAL|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
62462240|NCT02226185|PLACEBO_COMPARATOR|placebo|identical-appearing placebo supplements for 2-3 years
62653985|NCT01101178|ACTIVE_COMPARATOR|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
62088870|NCT03019458|NO_INTERVENTION|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
62088871|NCT02518932|EXPERIMENTAL|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
62462241|NCT02970656|EXPERIMENTAL|Teens.Connect|The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes. Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist.
62462242|NCT02970656|NO_INTERVENTION|Control|Wait listing will serve as the control condition. Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service. Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
62653986|NCT05764499||Children|Patients under the age of 18
62653987|NCT05764499||Adults|Patients 18 years old and above
62653988|NCT04772976||Patient group|Patients with Ankylosing Spondylitis
62088872|NCT02518932|PLACEBO_COMPARATOR|Placebo|To examine the effect of saline on glucose uptake
62088873|NCT05159882|EXPERIMENTAL|THR-1442 20mg|Each subject will receive THR-1442 20 mg and Dapagliflozin placebo, once daily for the duration of the study.
62088874|NCT05159882|ACTIVE_COMPARATOR|Dapagliflozin10mg|Each subject will receive Dapagliflozin 10 mg and THR-1442 placebo, once daily for the duration of the study.
62287694|NCT02553694|EXPERIMENTAL|Usual education with Enhanced follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and contacted by an MD by phone
62287695|NCT04519996|EXPERIMENTAL|US Internal Jugular Vein Collapsibility Index|The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility.
62287696|NCT04519996|EXPERIMENTAL|US Inferior Vena Cava Collapsibility Index|The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration.
62287697|NCT05527457|PLACEBO_COMPARATOR|Placebo|Placebo (saline) nasal spray, taken before bedtime. Dosage is taken on one instance for one night only.
62287698|NCT05527457|EXPERIMENTAL|BAY2586116 (oro-nasal breathing night)|BAY2586116 nasal spray, taken before bedtime. Dosage is taken on one instance for one night only for the oro-nasal breathing night.
62653989|NCT04772976||Healthy controls|Healthy controls
62653990|NCT02396667||pregnant women with macrosomia|Pregnant wo.en between 37 and 42 weeks with fetal macrosomia as suspected by clinical estimation and 2D ultrasound.
62653991|NCT05658068|EXPERIMENTAL|SAFE Spaces training and coaching|Staff in facilities assigned to this arm are offered the SAFE Spaces training and coaching model.
62462243|NCT04770883|EXPERIMENTAL|Internet based cognitive behavioral therapy group|80 patients will be randomized to receive iCBT. Psychological therapy is effective in IBS patients. The treatment takes 10 weeks and is divided into five successive steps. Patients have to report that they have worked through a treatment step to get access to the next. The patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half of the treatment on step 5, in which exposure exercises are introduced. A psychologist/CBT therapist will manage the online therapeutic contact with the patients.
62462244|NCT04770883|EXPERIMENTAL|Low FODMAP group|80 patients will then be randomized to receive Low FODMAP diet. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) are poorly absorbed short-chain carbohydrates including fructose (in excess of glucose), lactose, polyols, fructans and galacto-oligosaccharides. The concept of considering all these molecules collectively as a treatment for IBS is relatively new. Understanding of FODMAPs comprises mechanisms of action such as luminal distension from their osmotic effect and rapid fermentation to hydrogen. These findings have led to increased application of the low FODMAP diet to manage IBS symptoms. Treatment will undergo 10 weeks supervised monotherapy with low FODMAP diet. This will be done with the help of professional dieticians in Örebro region, who will meet the patients and inform them how this diet works as well as follow up.
62462245|NCT04770883|ACTIVE_COMPARATOR|Control group|The control Group (40 patients) will wait for 10 weeks before being randomised to treatment with either iCBT or low FODMAP diet.
62462246|NCT02704182|ACTIVE_COMPARATOR|Real tDCS|Direct current stimulation using anodal electrode, 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
62462247|NCT02704182|SHAM_COMPARATOR|Sham tDCS|Sham direct current stimulation, 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
62653992|NCT05658068|NO_INTERVENTION|Training as Usual|Staff in facilities assigned to this arm receive training as usual.
62653993|NCT02768987|EXPERIMENTAL|Overweight|Sedentary adolescents with T1D and overweight
62653994|NCT02768987|EXPERIMENTAL|Normal Weight|Sedentary adolescents with T1D and normal weight
62653995|NCT05413772||Temocillin received empirically|Temocillin received in probabilistic , in curative context or in preventive use (prophylaxis)
62653996|NCT05413772||Temocillin received on second line of treatment|Temocillin received second-line therapy in curative context or in preventive use (prophylaxis)
61904945|NCT00740935|OTHER|1|Cohort of vaccinated infants against rotavirus
62088875|NCT02278575|OTHER|Consisting of treatment with Atenativ|During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin
62088876|NCT00901056|ACTIVE_COMPARATOR|Treated Group|This group will receive actual shockwave treatment
62088877|NCT06367062||Multiple anesthesia group|Children who underwent more than one general anesthesia procedure between the ages of 0-3 years.
62088878|NCT06367062||Single anesthesia group|Children who underwent only one general anesthesia procedure between the ages of 0-3 years.
62287699|NCT05527457|EXPERIMENTAL|BAY2586116 (nasal breathing only night)|BAY2586116 nasal spray, taken before bedtime. Dosage is taken on one instance for one night only for the nasal only breathing night.
62287700|NCT01967290|EXPERIMENTAL|Hand-to-mouth task - vibratory feedback|Hand-to-mouth task under vibratory feedback and 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis and provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed a vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
62287701|NCT01967290|ACTIVE_COMPARATOR|Hand-to-mouth task - no vibratory feedback|Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
62287702|NCT01869348|NO_INTERVENTION|Wait list control|This group will receive no intervention until after data collection for the randomized trial is completed. Then, they will receive the monitor intervention.
62653997|NCT04763512|EXPERIMENTAL|Intact Cow's Milk Protein Formula Group (CMFG)|All enrolled subjects will be fed Stage 1 CMF libitum for 4 months. Thereafter, they will discontinue study formula and complete the study.
62287703|NCT01869348|EXPERIMENTAL|Monitor intervention|This arm will receive the monitor intervention, including provision of a wristband activity monitor and mini-tablet as well as weekly counseling phone calls
62287704|NCT05275569|EXPERIMENTAL|True acupuncture + standard antiemetic treatment|
62287705|NCT05275569|PLACEBO_COMPARATOR|Sham acupuncture + standard antiemetic treatment|
62287706|NCT00997516|EXPERIMENTAL|SILS appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
62307933|NCT03863496|OTHER|Neuromuscular scoliosis|Efficacy of Surgical Treatment by Different Pedicle Screw Systems in Pediatric Neuromuscular Spinal Deformity
62307934|NCT05561621||Patients with relapsing MS|
62462248|NCT01985347|ACTIVE_COMPARATOR|Obstructive Sleep Apnoea|Patients with newly diagnosed obstructive sleep apnoea and who have anxiety and depression would be given continuous positive airway pressure (CPAP) treatment.
62462249|NCT01985347|NO_INTERVENTION|Chronic obstructive pulmonary disease and western population|(For this group no intervention needed).Patients with COPD, who have anxiety and depression \& normal population in Western Adelaide who also have anxiety and depression their prevalence would be compare with patients of Obstructive sleep apnoea.
62653998|NCT04763512|EXPERIMENTAL|Partially Hydrolysed Whey Formula Group (pHFG)|All enrolled subjects will be fed Stage 1 pHF libitum for 4 months. Thereafter, they will switch to Stage 2 pHF at age 6 months (Study Month 4) and to Stage 3 pHF at age 12 months (Study Month 9) and continue until age 18 months (Study Month 15). Thereafter, they will discontinue study formula and complete the study.
62088879|NCT06367062||Control group|Children who underwent no general anesthesia procedure between the ages of 0-3 years.
62287707|NCT00997516|ACTIVE_COMPARATOR|Conventional laparoscopic appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
62287708|NCT05242770|PLACEBO_COMPARATOR|Control Arm|Educational pamphlet with resources for sexual dysfunction
62287709|NCT05242770|EXPERIMENTAL|Physical Therapy Arm|Physical therapy for sexual dysfunction.
62287710|NCT03882424|EXPERIMENTAL|TRS003|Proposed biosimilar of bevacizumab，Intravenous administration
62736367|NCT05087368|EXPERIMENTAL|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 8|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 8: (N=100) Day 1 (boost) -SCB-2019;"
62088880|NCT01034475|EXPERIMENTAL|CPI-613|CPI-240 mg/m2
62088881|NCT03950401|ACTIVE_COMPARATOR|Monocryl|Closure of the skin at the completion of surgery by interrupted subcuticular technique with absorbable Monocryl suture.
62088882|NCT03950401|ACTIVE_COMPARATOR|Nylon|Closure of the skin at the completion of surgery by interrupted technique on top of the skin with non-absorbable Nylon suture. These will be removed at the first postoperative visit.
62088883|NCT04755868|EXPERIMENTAL|Maintenance therapy with talazoparib|Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
62088884|NCT04755868|ACTIVE_COMPARATOR|Maintenance therapy with placebo|Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
62287711|NCT03882424|ACTIVE_COMPARATOR|China-approved Bevacizumab|Intravenous administration
62287712|NCT03882424|ACTIVE_COMPARATOR|US-licensed Avastin|Intravenous administration
62287713|NCT00004054|EXPERIMENTAL|Hormones and RT|Androgen suppression (AS) (Luteinizing hormone releasing hormone agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]). AS will continue for a total of 24 months from initiation of all treatment. Oral anti-androgen will be discontinued at the end of radiation therapy (RT).
62462250|NCT06447883|EXPERIMENTAL|Lifestyle modification program|The LMP included 12 treatment modules which was administered by the occupational therapist with a national occupational therapist license and a certification from the USC Lifestyle Redesign® course in 2001. The experimental group engaged in 24 weekly group sessions, each lasting approximately 2 hours. Each session started with stretching, followed by knowledge sharing, group discussion, and activities participation which aligned with the session's themes and discussion topics. The four strategies, including didactic presentation, peer exchange, direct experience, and personal exploration, were employed to deliver the treatment module content. Following these strategies, the primary researcher emphasized the connection between participants' personal meanings, individual contexts, and occupations. Afterward, participants were encouraged to formulate a personalized action plan and integrate what they had learnt into their daily routine.
62088885|NCT05799924|EXPERIMENTAL|Women with dysmenorrhea treated with TEAS|The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 \~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.
62088886|NCT05799924|ACTIVE_COMPARATOR|Women with dysmenorrhea receiving medication|Take NSAIDs or birth control pills every six hours during your period when you feel unbearable pain.
62088887|NCT04708184|EXPERIMENTAL|GLPG3970 solution|Single oral dose of GLPG3970 in fasted conditions
62088888|NCT04708184|EXPERIMENTAL|GLPG3970 tablet fasted|Single oral dose of GLPG3970 in fasted conditions
62088889|NCT04708184|EXPERIMENTAL|GLPG3970 tablet fed|Single oral dose of GLPG3970 in fed conditions
62088890|NCT02719197|EXPERIMENTAL|AC-083, Single Ascending Dose|AC-083 administered at different single dose levels in a sequential manner, and in a maximum of 9 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
62088891|NCT02719197|PLACEBO_COMPARATOR|Placebo, Single Ascending Dose|Matched placebo administered as single ascending doses in parallel to AC-083
62307935|NCT05561621||Healthy controls|
62307936|NCT04436913|EXPERIMENTAL|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care)."
62088892|NCT00799461|EXPERIMENTAL|Arm I (full website access w/ PST; first study only)|Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
62088893|NCT00799461|EXPERIMENTAL|Arm II (full website access without PST)|Patients receive full access to INSPIRE website for 6 months as in arm I.
62088894|NCT00799461|SHAM_COMPARATOR|Arm III (delayed website access)|Patients do not have access to INSPIRE website for 6 months. After 6 months, patients receive full access to INSPIRE website for 3 months.
62088895|NCT00070629|EXPERIMENTAL|1|Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection
62088896|NCT00070629|ACTIVE_COMPARATOR|2|Chemotherapy (a taxane and a platinum compound)
62088897|NCT02554175|EXPERIMENTAL|the target propofol concentration|patients were allocated to 1 of 6 groups of predefined propofol target Ce for induction, namely, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 µg.mL-1.Propofol was administered to achieve target propofol Ce.
62287714|NCT00004054|EXPERIMENTAL|Hormones and RT plus Chemotherapy|AS (LHRH agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]) and estramustine phosphate sodium, etoposide, paclitaxel, and warfarin \[Coumadin®\]. AS will continue for a total of 24 months from initiation all treatment. Oral antiandrogen will be discontinued at the end of RT.
62287715|NCT05861505|ACTIVE_COMPARATOR|Upfront repeat local treatment|
62653999|NCT02312843|ACTIVE_COMPARATOR|High-Intensity Program-aerobic exercises|This exercise program will consist of walking or running on a treadmill or elliptical trainer, or spinning on a stationary bicycle. The goal of the program will be for participants to exercise at a moderate to high level of intensity, defined as 70-80% (American College of Sports Medicine guidelines) of heart rate reserve (HRR), for 45-60 minutes 4 days per week. At the start of each training session and following a 5-minute warm-up, subjects will exercise at 50% HRR (0.5\[HRmax-HRrest\] +HRrest) and intensity will gradually be increased to the individualized target heart rate training zone. Exercise facilitators will use a pre-specified computerized program. This program provides guidelines for the individualized progression of exercise based on age and resting heart rate. Subjects will wear a digital heart rate monitoring device for the duration of the training session to ensure they are exercising safely at the specified level of intensity.
62654000|NCT02312843|PLACEBO_COMPARATOR|Low-intensity Program-Stretching|The low-intensity activity program will consist of an individualized and organized series of stretching and balance activities for the whole body, specifically designed for older adults. Consistent with the high-intensity protocol, subjects will complete the prescribed 45-60 minute stretching routine 4 days per week at the exercise facility. All stretching routines will include warm-up and cool-down activities, and will be within each subject's range of motion. Each stretch will be held for 20-30 s and repeated 5-10 times. Subjects will wear a digital heart rate monitoring device to ensure they are stretching safely and at an intensity below 35% HRR. The activity log completed during each stretching session will include HR, stretching duration, and mean HR during stretching. Subjects will also have the option to participate in structured pre-approved (by the exercise facilitator) stretching classes at the exercise facility when available.
62654001|NCT04057092|EXPERIMENTAL|Intervention group|Eligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total.
62654002|NCT02934685|EXPERIMENTAL|hypofraction|70 Gy in 28 fractions over 5.6 weeks
62654003|NCT02934685|ACTIVE_COMPARATOR|convention|80Gy in 40 fractions over 8 weeks
62654004|NCT00362232|EXPERIMENTAL|Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
62088898|NCT03033121|ACTIVE_COMPARATOR|group A|Sixteen growth hormone (GH) deficiency children were assigned to receive daily growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
62287716|NCT05861505|EXPERIMENTAL|Neoadjuvant systemic therapy followed by repeat local treatment|
62088899|NCT03033121|ACTIVE_COMPARATOR|group B|Sixteen growth hormone (GH) deficiency children were assigned to receive three time weekly growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
62088900|NCT05830695|EXPERIMENTAL|human treated dentin matrix|study group
62654005|NCT00362232|ACTIVE_COMPARATOR|Enoxaparin 30 mg twice a day (bid)|Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
62654006|NCT02348333|ACTIVE_COMPARATOR|FYU-981|
62654007|NCT02348333|PLACEBO_COMPARATOR|Placebo|
62088901|NCT05830695|EXPERIMENTAL|mineral tri oxide aggregate|control group
62088902|NCT05101109|EXPERIMENTAL|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation.
62088903|NCT04813146|EXPERIMENTAL|Synchronized Lifestyle Modification Program (SLP)|Synchronized Lifestyle Modification Program ( Synchronization of dietary intake with the natural circadian rhythm of the body)
62088904|NCT04813146|EXPERIMENTAL|Synchronized Lifestyle Modification Program along with Physiotherapy|Synchronized Lifestyle Modification Program along with Physiotherapy (Synchronization of dietary intake and Physiotherapy including aerobic, resistance, flexibility and balance exercises)
62088905|NCT04813146|EXPERIMENTAL|Physiotherapy|Physiotherapy (aerobics, resistance, flexibility and balance exercises)
62088906|NCT04813146|NO_INTERVENTION|Control Group|No Intervention will be given to this group ( conventional medicine will be given to these patient )
62088907|NCT04302090|EXPERIMENTAL|pain level changes according to the use of the Winner flow|"each included patient will experience :~* a period of consecutive spontaneous uterine contractions without using the regulated expiration mouthpiece~* a period of consecutive uterine contractions managed by the regulated expiration method using the Winner flow"
62088908|NCT00595283|EXPERIMENTAL|1|Participants assigned to Parent-Child Interaction Therapy-Emotional Development
62088909|NCT00595283|ACTIVE_COMPARATOR|2|Participants assigned to Developmental Education Parenting Intervention
62654008|NCT00802971|EXPERIMENTAL|1: FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
62654009|NCT00802971|NO_INTERVENTION|2: Control|
62088910|NCT00107185|EXPERIMENTAL|Vaccine|
62088911|NCT00811889|PLACEBO_COMPARATOR|Placebo|
62088912|NCT00811889|EXPERIMENTAL|Bardoxolone Methyl (RTA 402): 75mg|
62088913|NCT00811889|EXPERIMENTAL|Bardoxolone Methyl (RTA 402): 150mg|
62654010|NCT01932385|EXPERIMENTAL|sorafenib|sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
62654011|NCT01932385|ACTIVE_COMPARATOR|Best Supportive Care|treatment mainly on nutrition and symptoms control
62654012|NCT04753801|EXPERIMENTAL|Best Possible Self (writing only)|Participants are asked to think and write about their best possible future self (15 min).
62654013|NCT04753801|EXPERIMENTAL|Best Possible Self (writing+imagining)|Participants are asked to think and write about their best possible future self (15 min) and, then to imagine their positive future (5 min).
62654014|NCT04753801|EXPERIMENTAL|Best Possible Self (writing+mindfulness)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief mindfulness sequence (5 min).
62654015|NCT04753801|EXPERIMENTAL|Best Possible Self (writing+recall)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief recall imagination task about the past two days (5 min).
62088914|NCT00811889|EXPERIMENTAL|Bardoxolone Methyl (RTA 402): 25mg|
62088915|NCT06200155|EXPERIMENTAL|Arm A|Participants will receive psilocybin (25 mg).
62088916|NCT06200155|PLACEBO_COMPARATOR|Arm B|Participants will receive the placebo (100 mg of Niacin).
62088917|NCT03415087|ACTIVE_COMPARATOR|sequential intrathecal injection of fentanyl and bupivacaine|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially
62088918|NCT03415087|EXPERIMENTAL|rapid sequential intrathecal injection of fentanyl and bupiva|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.
62088919|NCT03871881||Atrial septal defect|Patients with an open atrial septal defect, diagnosed in childhood
62088920|NCT03871881||Ventricular septal defect|Patients who had surgical closure of a ventricular septal defect in childhood
62654016|NCT04753801|ACTIVE_COMPARATOR|Writing about the past|Participants are asked to think and write about activities of the past two days (15 min).
62654017|NCT03349307|EXPERIMENTAL|No Intervention|
62088921|NCT03871881||Healthy control|Healthy, young adults matched on age, gender and education
62119890|NCT06677294||Case|In the study, women who underwent intrauterine interventions during the third stage of labor for placental removal were included in the case group (n=32), while those who did not undergo such interventions were placed in the control group (n=32). Manual placental removal (hallas) and the cleaning of the uterine cavity using the hand or gauze/sponge (wrapped around the hand or using an over-clamp) after placental expulsion were considered intrauterine interventions
62119891|NCT06176716|EXPERIMENTAL|participants with mild hepatic impairment (Child-Pugh A)|
62088922|NCT01661881|EXPERIMENTAL|RB/RC|"Patients received 3 cycles of outpatient RB (rituximab 375 mg/m2 day 1, bendamustine 90 mg/m2 days 1 and 2 of a 4-week cycle), followed by interim CT restaging. Patients with progressive disease (PD) went off study. Those with stable disease (SD) or better went on to receive three cycles of inpatient RC (rituximab 375 mg/m2 day 1, cytarabine 3 g/m2 every 12 h for 4 doses). The cytarabine was dose reduced to:~1. 2 g/m2 for age \>60 years old, creatinine 114.9-176.8 lmol/l (for patients ≤60 years old), and pre-existing neurotoxicity;~2. 1.5 g/m2 for age \>60 years old AND creatinine 114.9-176.8 lmol/l, or for age \>60 years old AND pre-existing neurotoxicity;~3. 1 g/m2 for age \> 60 years old AND creatinine 114.9-176.8 lmol/l AND pre-existing neurotoxicity.~Stem cell mobilization and collection, ASCT and post-transplantation supportive care were performed per institutional standard and not as part of this study."
62119892|NCT06176716|EXPERIMENTAL|participants with moderate hepatic impairment (Child-Pugh B)|
62287717|NCT05518604|EXPERIMENTAL|Intervention Arm 1|Women in this arm will undergone dietary counseling in the first year postpartum in addition to close supervision of diet, exercise, and sleep.
62287718|NCT05518604|EXPERIMENTAL|Intervention Arm 2|Women in this arm will not have dietary counseling but will have close supervision of diet, exercise and sleep.
62654018|NCT05236530|EXPERIMENTAL|Cohort 1|Each participant will receive a single oral dose of the 4-probe substrate cocktail consisting of midazolam, repaglinide, dextromethorphan and metformin in the morning of Day 1 of Period 1. In Period 2, participants will receive ganaplacide and lumefantrine combination orally once daily (q.d.) in the morning on Days 1 through 3, with a single oral dose of the 4-probe substrate cocktail co-administered on Day 3.
62654019|NCT05236530|EXPERIMENTAL|Cohort 2|Each participant will receive a single oral dose of the 2 probe substrate cocktail consisting of rosuvastatin and dolutegravir in the morning on Day 1 of Period 1. In Period 2, participants will receive ganaplacide and lumefantrine combination orally q.d. in the morning on Days 1 through 3, with a single oral dose of the 2 probe substrate cocktail co-administered on Day 3.
61904946|NCT01774656|EXPERIMENTAL|HeartMate II plus Pharmacological Treat|"The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.~The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily."
61904947|NCT00842907|ACTIVE_COMPARATOR|oral isotretinoin|Twelve subjects will be treated with oral isotretinoin 20.0 mg, once a day, every other day, for 24 weeks.
61904948|NCT00842907|ACTIVE_COMPARATOR|tretinoin|Twelve patients will be treated with 0,05% tretinoin cream applied on face and forearms at night and moisturizer broad-spectrum sunscreen twice a day.
61904949|NCT03976804|EXPERIMENTAL|atherosclerotic cardiovascular event associated with tobacco|
61904950|NCT05788289|EXPERIMENTAL|Participants with Mantle Cell Lymphoma|Participants have a diagnosis of Mantle Cell Lymphoma have previously failed or could not tolerate Bruton's tyrosine kinase inhibitors/BTKi
61904951|NCT04921813|EXPERIMENTAL|Schroth method + brace|3-dimensional scoliosis exercise program according to Schroth method + brace.
61904952|NCT04921813|EXPERIMENTAL|Schroth + balance-coordination exercises + brace.|3-dimensional scoliosis exercise program according to Schroth + balance-coordination exercises + brace.
61904953|NCT04921813|EXPERIMENTAL|Brace|Only brace treatment.
61904954|NCT04921813|NO_INTERVENTION|healthy individuals|Age-matched control group
61904957|NCT02825797|EXPERIMENTAL|Group 1A|HIV-infected individuals, on ART with HIV-1 RNA \< 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
61904958|NCT02825797|EXPERIMENTAL|Group 1B|HIV-infected individuals, on ART with HIV-1 RNA \< 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.
61904959|NCT02825797|EXPERIMENTAL|Group 1C|HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.
61904960|NCT02825797|EXPERIMENTAL|Group 2|HIV-infected individuals, on ART with HIV-1 RNA \< 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.
61904961|NCT02825797|EXPERIMENTAL|Group 3|HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.
61904962|NCT00912236||1|BMI 20-25 kg/m2
61904963|NCT00912236||2|BMI \> 30 kg/m2 with low TG (\<150) and normal HDL (\>50 for females, \>40 for males)
61904964|NCT00912236||3|BMI \> 30 kg/m2 with high TG (\>150) and low HDL (\<50 for females, \<40 for males)
62119893|NCT06176716|EXPERIMENTAL|Normal hepatic function|
62119894|NCT06552325|EXPERIMENTAL|Single Session Narrative Therapy Intervention|A single narrative therapy session with a trained licensed behavioral health provider will be offered to patients at \[Blinded\] low-barrier clinics.
62119895|NCT05523674|EXPERIMENTAL|warm-up performed at 30% VO2max|The warm-up exercise will be performed on an ergometric treadmill, through a protocol of 15 minutes duration, with the first 5 minutes of acceleration, until reaching 30% of VO2max, the following 5 minutes of maintenance and the remaining 5 minutes being of slowdown.
61904965|NCT05371847|ACTIVE_COMPARATOR|breast cancer patients|Women and men in the prospective cohort study will be invited to participate in this additional validity and/or reliability testing
61904966|NCT05371847|ACTIVE_COMPARATOR|healthy volunteers|age- and gender-matched
61904967|NCT04523727|EXPERIMENTAL|Ferric citrate|Participants aged 6 to \< 17 years will receive ferric citrate for 36 weeks at a starting dose based on body weight categories.
62088923|NCT01932996|ACTIVE_COMPARATOR|Integrated Intensive Smoking + Alcohol|IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
62088924|NCT01932996|PLACEBO_COMPARATOR|Usual Care|UC: 12-week treatment with nicotine patch plus nicotine gum/lozenge along with a one time brief smoking cessation and brief alcohol counseling both based on the USPHS's Guidelines
62088925|NCT02543593|EXPERIMENTAL|Intervention|Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
62088926|NCT02543593|SHAM_COMPARATOR|Placebo|Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
62287719|NCT05518604|NO_INTERVENTION|Control|Women in this arm will undergo routine postpartum care.
62287720|NCT03547557|EXPERIMENTAL|ExAblate MRgFUS|
62287721|NCT03062657|EXPERIMENTAL|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
62462251|NCT06447883|NO_INTERVENTION|Control group|The control group participants were selected from the same community as the experimental group but did not receive the LMP.
62654020|NCT03176485|EXPERIMENTAL|ArmA: With Solar Simulated Light Exposure|
62088927|NCT06474117||Post-Stroke Patients|Patients will undergo gait analysis coupled with ultrasound to measure the lengths of the Achilles tendon and gastrocnemius medialis muscle. They will also have their force/length profile of the GM measured on an isokinetic dynamometer with simultaneous ultrasound
62088928|NCT06474117||Post-Spinal Cord Injury Patients|Similar to the post-stroke group, these patients will undergo gait analysis coupled with ultrasound to measure the lengths of the Achilles tendon and gastrocnemius medialis muscle. The force/length profile of the GM will also be measured on an isokinetic dynamometer with simultaneous ultrasound.
62088929|NCT06474117||Healthy controls|The healthy control group will undergo the same gait analysis and ultrasound measurements as the patient groups. Their force/length profile of the GM will also be measured on an isokinetic dynamometer with simultaneous ultrasound for comparison with the post-stroke and post-spinal cord injury groups.
62088930|NCT06619912|EXPERIMENTAL|Dexmedetomidine group|The Dexmedetomidine group will receive dexmedetomidine infusion at a rate of 0.1ug/kg/h. The intervention will commence immediately after induction and will persist until 8 am on the next day.
62287722|NCT00687791|EXPERIMENTAL|1|20 enrolled patients will be chosen according to the enrollment acceptance criteria. The evidence for the determination of enrolled patients shall be recorded, reviewed and approved. 2\> Phacotrabeculectomy is performed.3\> After completing phacotrabeculectomy, implant/place ologen™ Collagen Matrix on top of the scleral flap under the conjunctiva. For every inspection and observation, the detailed description and/or inspection data shall be recorded. If any unwanted adverse event is observed during inspection and observation, it shall be recorded and be reported to the investigation conductor.
62287723|NCT01911858|EXPERIMENTAL|Askina Calgitrol Paste|
62287724|NCT02886299|ACTIVE_COMPARATOR|Fenofibrate group|Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).
62287725|NCT02886299|ACTIVE_COMPARATOR|Simvastatin group|Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).
62287726|NCT01694043|EXPERIMENTAL|Non-Food Related Commercials|Participants will watch a 30-minute Saturday Night Live television show with non-food related commercials embedded.
62287727|NCT01694043|EXPERIMENTAL|Healthy Food Commercials|Participants will watch a 30-minute Saturday Night Live television show with healthy food commercials embedded.
62287728|NCT01694043|EXPERIMENTAL|Unhealthy Food Commericlas|Participants will watch a 30-minute Saturday Night Live television show with unhealthy food commercials imbedded.
62462252|NCT00994669||healthy control male|
62462253|NCT00994669||lung cancer male|
62462254|NCT01175616|EXPERIMENTAL|Creatine|Open-Label Active Treatment with Creatine 5 grams daily for 8 weeks.
62462255|NCT06157710|EXPERIMENTAL|Procrastinate digital programme|"8-week unternet-based CBT for procrastination~* Behavioural Module: Introduction~* Behavioural Module: Goal setting techniques~* Behavioural Module: Motivation~* Behavioural Module: Barriers to action~* Behavioural Module: Managing maladaptive thoughts and beliefs~* Behavioural Module: Value clarification~* Behavioural Module: Moving forward"
62654021|NCT03176485|EXPERIMENTAL|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
62287729|NCT05068609||Cohort 1|Participants with squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab
62287730|NCT04214652|EXPERIMENTAL|IDP-126 Gel|
62287731|NCT04214652|PLACEBO_COMPARATOR|IDP-126 Vehicle Gel|
62307937|NCT04436913|EXPERIMENTAL|preventive regimen using Fluoride based toothpaste (Signal).|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride)
62654022|NCT03176485|NO_INTERVENTION|ArmC: Without Solar Simulated Light Exposure|
62088931|NCT06619912|NO_INTERVENTION|Control group|In the control group, the treatment is sodium chloride 0.9% administered with electric syringe. Infusion follows the same rules as in the experimental group.
62088932|NCT00675961|EXPERIMENTAL|1|Behavioral Counseling Intervention (BCI) plus treatment as usual (TAU) (i.e. standard referral to and management by an addictions specialist)
62088933|NCT00675961|EXPERIMENTAL|2|Naltrexone/ Brief Behavioral Compliance Enhancement Treatment (BBCET) plus TAU
62088934|NCT00675961|EXPERIMENTAL|3|BCI + Naltrexone/BBCET plus TAU
62088935|NCT00675961|ACTIVE_COMPARATOR|4|Treatment as Usual (TAU)
62088936|NCT04164160|EXPERIMENTAL|integrated-care-model benefiting group|Chronic patients whose clinical and social data will be added in the integrated care model application software.
62088937|NCT04774185|EXPERIMENTAL|New hearing aid loudspeaker|The new hearing aid loudspeaker is a loudspeaker system with a modified acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
62088938|NCT04774185|ACTIVE_COMPARATOR|Standard hearing aid loudspeaker|The hearing aid loudspeaker is a loudspeaker system with the existing acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
62088939|NCT01924143|EXPERIMENTAL|TD-9855|
62088940|NCT05059574|EXPERIMENTAL|Experimental group|Mothers in this group will begin their baby's first breastfeeding by crawling to the breast.
62088941|NCT05059574|NO_INTERVENTION|Control group|Mothers in this group will begin their baby's first breastfeeding with biological breastfeeding.
62088942|NCT02194218|EXPERIMENTAL|Nevirapine XR 4 doses|
62088943|NCT02194218|ACTIVE_COMPARATOR|Nevirapine XR 2 doses|
62088944|NCT05761925|EXPERIMENTAL|Intervention|Caregivers will participate in 6 30-minute skills sessions. A clinical psychologist will deliver all of the sessions. The main intervention goal is to provide dyads with resiliency skills to reduce emotional distress and prevent chronic distress.
62088945|NCT02800928|EXPERIMENTAL|CERC-501|Administered orally once daily, 10mg daily, 8 days
62088946|NCT02800928|PLACEBO_COMPARATOR|Placebo|Administered orally daily, 8 days
62462256|NCT06157710|NO_INTERVENTION|Waitlist control|"Wait-list control group. They do not receive the weekly modules though they are asked to complete 4-week and 8-week online surveys.~They will be allowed to revive the intervention after 8 weeks."
62088947|NCT02453230|ACTIVE_COMPARATOR|light on|BPP done with lights on
62088948|NCT02453230|NO_INTERVENTION|light off|Biophysical profile examinations done with the light off
62088949|NCT05992155|EXPERIMENTAL|Cohort 1, Severe RI: TAK-279 50 mg|Participants with severe RI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study.
62088950|NCT05992155|EXPERIMENTAL|Cohort 2, Normal Renal Function: TAK-279 50 mg|Participants with normal renal function will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study.
62088951|NCT05992155|EXPERIMENTAL|Cohort 3, Moderate RI: TAK-279 50 mg|Participants with moderate RI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part B of the study.
62088952|NCT03503994|OTHER|Drug|"Patients receiving inhaled beclomethasone diproprionate in four escalating doses:~1. 200 mcg bid~2. 400 mcg bid~3. 600 mcg bid~4. 800 mcg bid"
62088953|NCT05010382|EXPERIMENTAL|Test group|Hybrid surface dental implant
62088954|NCT05010382|EXPERIMENTAL|Control group|moderately rough surface implant
62088955|NCT06696495||Pregnancy women|Each participant will undergo various tests to assess morphofunctional and baropodometric changes in the foot and ankle. These tests will include measuring the size and width of the foot using a 3D scanner, assessing the height of the plantar arch using a podoscope, and applying functional scales such as the AOFAS (Ankle and Foot Outcome Score), the FPI (Foot Posture Index) and the FFI (Foot Function Index). In addition, plantar pressure distribution and centre of pressure (COP) will be analysed to identify variations in stability and balance during pregnancy.
62088956|NCT04266990|EXPERIMENTAL|Epilepsy patients|Epilepsy patients admitted for clinical purposes in the EEG monitoring units at the UZ
62088957|NCT04266990|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers recruited from among colleagues from the department and hospital staff
62088958|NCT00963703|EXPERIMENTAL|Rituximab|
62088959|NCT02713997|NO_INTERVENTION|Standard Care|Patients in the standard care arm will undergo the usual procedure of TPIAT with no ancillary therapies provided.
62462257|NCT01929122|PLACEBO_COMPARATOR|Placebo-Control|Randomized participants consume 1 meal and 1 snack per day that does not include either rice bran or navy bean powder for 28 days.
62287732|NCT03649152|EXPERIMENTAL|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
62287733|NCT03649152|EXPERIMENTAL|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
62307938|NCT04436913|ACTIVE_COMPARATOR|Fluoride toothpaste and fluoride varnish|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride) and fluoride varnish
62088960|NCT02713997|EXPERIMENTAL|etanercept|Patients in the etanercept arm will undergo the usual procedure of TPIAT with additional therapy of etanercept.
62088961|NCT02713997|EXPERIMENTAL|alpha-1 antitrypsin|Patients in the alpha-1 antitrypsin arm will undergo the usual procedure of TPIAT with additional therapy of alpha-1 antitrypsin (Aralast NP)
62462258|NCT01929122|EXPERIMENTAL|Cooked Navy Bean Powder|Randomized participants consume 1 meal and 1 snack per day containing cooked navy bean powder (35 g/day) for 28 days.
62462259|NCT01929122|EXPERIMENTAL|Rice Bran|Randomized participants consume 1 meal and 1 snack per day containing rice bran (30 g/day) for 28 days.
62462260|NCT05926479||physiotherapy patient|
62462261|NCT04745546|EXPERIMENTAL|WeFlow-JAAA Stent Graft System|Participants will be treated with WeFlow-JAAA Stent Graft System
62088962|NCT00124605|EXPERIMENTAL|Treatment (pamidronate disodium and arsenic trioxide)|Patients receive pamidronate IV and over 2 hours on days 1 and 15 and arsenic trioxide IV over 2 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62287734|NCT02519660|EXPERIMENTAL|Lidocaine/Tetracaine patch (Ralydan)|Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure
62287735|NCT02519660|ACTIVE_COMPARATOR|Lidocaine/Prilocaine cream (EMLA)|EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure
62462262|NCT01716793|OTHER|Risk-adapted postremission treatment|Ara-C, autologous transplantation, Allogeneic HLA-identical sibling transplantation depending on risk factors (cytogenetics, courses to CR)and availability of an HLA-identical sibling, CD34+ selection.
62462263|NCT04074174|EXPERIMENTAL|NNC0174-0833 treatment-free period; NNC0174-0833 treatment|During the NNC0174-0833 treatment-free period participants will receive OC tablets and acetaminophen. During the NNC0174-0833 treatment period participants will receive OC tablets and acetaminophen in addition to NNC0174-0833.
62287736|NCT01652924|EXPERIMENTAL|Mechanical ventilation|1: Active Comparator Children 1 month-14 years of age Intervention:Mechanical ventilation with facial mask during anesthetic induction
62287737|NCT01652924|ACTIVE_COMPARATOR|Manual ventilation|2: Active Comparator Children 1 month-14 years of age Intervention: Manual ventilation with facial mask during anesthetic induction
62287738|NCT04819906|EXPERIMENTAL|T-ST-P-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62287739|NCT04819906|EXPERIMENTAL|ST-M-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62462264|NCT02059746||Vaginal birth|"Patients in the group give birth vaginally.~Intervention: Questionnaires sent by mail"
62462265|NCT02059746||Cesaren section|"Patients in this group give birth via cesarean section.~Intervention: Questionnaires sent by mail"
62462266|NCT06158516|EXPERIMENTAL|Surufatinib|
62462267|NCT06158516|PLACEBO_COMPARATOR|Placebo|
62462268|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
62462269|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
62462270|NCT01654783||5-ASA|Patient's treated with oral 5-ASA
62462271|NCT00921622|ACTIVE_COMPARATOR|Vitamin D|1000 IU twice daily for up to 10 days
61919791|NCT06331845|EXPERIMENTAL|intermittent systematic chemotherapy group|Patients diagnosed with wmNPC (more than five metastatic lesions) by histopathology are assigned to receive ISC following SC. Typically, SC(GP) was administered once every three weeks, with a maximum of six courses. Following this, ISC (TS1) was administered to extend the chemotherapy interval, once every 6-8 weeks, until widely progressive disease (WPD: defined as more than five progressive lesions), treatment intolerance, or patient refusal.
62462272|NCT00921622|ACTIVE_COMPARATOR|Vitamin C|500 mg twice daily for up to 10 days
62462273|NCT04046211|EXPERIMENTAL|Hydrogen exposure|The first two patients will be exposed to 2.4% hydrogen gas in medical air via HFNC for 24 hours. The second two patients will be exposed to the same gas for 48 hours. The final 4 patients will be exposed to the same gas for 72 hours.
62462274|NCT06367400||PSQ-cohort|Patients recruited from Akademiska Sjukhuset, Örebro, Västra Götaland, Skåne, Stockholm and Umeå.
62462275|NCT02144753|EXPERIMENTAL|NTX-1|NTX-1 (18 g)
62462276|NCT02144753|ACTIVE_COMPARATOR|Psyllium|psyllium (15 g)
62088963|NCT05053308|ACTIVE_COMPARATOR|IV PCA (proportional dosage)|Breakthrough pain control by bolus based IV patient-controlled anagesia Fentanyl bolus = MME \* 15%
62088964|NCT05053308|EXPERIMENTAL|SL-FTN (equivalent dose for PCA bolus)|Breakthrough pain control by sublingual fentanyl Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
62088965|NCT01375712|ACTIVE_COMPARATOR|Fermented milk|Fermented milk containing Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
62088966|NCT01375712|PLACEBO_COMPARATOR|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
62462277|NCT02812732|OTHER|Intervention|Providers at each clinic will receive the intervention (DOSE HPV) on a rolling basis. Vaccination rates will be compared pre- and post-intervention at each clinic, and changes in rates will be compared across clinics.
62462278|NCT03815669||Arthroscopic subacromial decompression|Patients referred to arthroscopic subacromial decompression
62462279|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
62462280|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
62654023|NCT01687660|EXPERIMENTAL|acupoint-meridian group|Apply traditional acupuncture to prevent the migraine attack according to TCM theory
62654024|NCT01687660|OTHER|sham-acupoint group|sham-acupoint will be penetrated for migraine prophylaxis.
62654025|NCT01687660|NO_INTERVENTION|waiting list|No acupuncture nor other methods will be conducted in this group.
62088967|NCT03660605|EXPERIMENTAL|Rhythmic Auditory Stimulation|Participants will walk on treadmill to metronome set at 85% of typical cadence, followed by overground walking with metronome set at 115% of typical cadence.
62654026|NCT01012050|EXPERIMENTAL|NV Group|Performed nebulization coupled with noninvasive ventilation
62654027|NCT01012050|ACTIVE_COMPARATOR|NEB group|Performed nebulization alone.
62654028|NCT00067340|EXPERIMENTAL|Intervention group|Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
62088968|NCT04934553|EXPERIMENTAL|Amplification of Positivity for Alcohol Use Disorders (AMP-A; 12 sessions)|
62088969|NCT04934553|ACTIVE_COMPARATOR|Cognitive-behavioral Therapy (CBT; 12 sessions)|
62287740|NCT04819906|EXPERIMENTAL|P-T-M-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62088970|NCT01577732|EXPERIMENTAL|Infanrix-IPV+Hib Group|Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
62088971|NCT06697509||Patients with suspected or established myocardial disease referred for CMR|Consenting adult patients with suspected or established myocardial disease referred for cardiovascular magnetic resonance (CMR) imaging with gadolinium contrast at Akershus University Hospital
62088972|NCT02949674|EXPERIMENTAL|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
62287741|NCT04819906|EXPERIMENTAL|M-P-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62287742|NCT04819906|EXPERIMENTAL|ST-P-T-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62287743|NCT04819906|EXPERIMENTAL|P-M-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62088973|NCT02949674|EXPERIMENTAL|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
62287744|NCT04819906|EXPERIMENTAL|T-ST-M-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62654029|NCT00067340|PLACEBO_COMPARATOR|Control|Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse
62088974|NCT02949674|NO_INTERVENTION|Control|No application of anesthetic
62088975|NCT02555371|EXPERIMENTAL|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
62654030|NCT01997580|EXPERIMENTAL|Escitalopram|depressed patients receiving escitalopram treatment
62654031|NCT01997580|NO_INTERVENTION|Control|healthy controls matched for age, gender, and BMI
62654032|NCT04925635||experimental group|The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group.
62654033|NCT04925635||control group|Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given.
62654034|NCT02470741|EXPERIMENTAL|Letrozole|Oral letrozole 2.5mg/day
62462281|NCT04734145||Participants with an Undiagnosed Pulmonary Nodule|One hundred evaluable individuals aged 21 to 85 years with a single undiagnosed pulmonary nodule measuring \<3 cm, clinically staged as cT1N0M0 (eighth edition of the TNM staging manual) by CT and PET scans, will be enrolled in this diagnostic study and will undergo e-nose testing. These patients must have a risk assessment profile that, according to institutional guidelines, identifies them as candidates for subsequent surgical resection of the pulmonary nodule, which will confirm the results of the breathprinting analysis.
62654035|NCT02470741|PLACEBO_COMPARATOR|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
62654036|NCT02145390|EXPERIMENTAL|TURBT, NAC and Chemoradiation|"* Transurethral Resection of the Bladder Tumor \& Cystoscopy (TURBT);~* Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;~* For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;~* For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;~* Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);~* International Prostate Symptom Score (IPSS)."
62119896|NCT05523674|EXPERIMENTAL|warm-up performed at 80% VO2max|The warm-up exercise will be performed on an ergometric treadmill, through a protocol of 15 minutes duration, with the first 5 minutes of acceleration, until reaching 80% of VO2max, the following 5 minutes of maintenance and the remaining 5 minutes being of slowdown.
62462282|NCT04047147||Enrollment in the Million Hearts CVD Risk Reduction Model|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to participate in the Million Hearts CVD Risk Reduction Model intervention.
62654037|NCT03631641|EXPERIMENTAL|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
62119897|NCT05523674|EXPERIMENTAL|warm-up performed at 30% VO2max with Blood Flow Restriction|The warm-up exercise will be performed on an ergometric treadmill, through a protocol of 15 minutes of duration, with the first 5 minutes of acceleration, until reaching 30% of VO2max, the following 5 minutes of maintenance and the remaining 5 minutes being of slowdown. During the warm-up exercise, a pressure cuff will be used on each leg, with the blood flow restriction technique (80% of arterial occlusion pressure).
62119898|NCT03848234|EXPERIMENTAL|A Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
62119899|NCT03848234|PLACEBO_COMPARATOR|B Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
62119900|NCT00530517|EXPERIMENTAL|1|
62119901|NCT01091831|ACTIVE_COMPARATOR|CRD|Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
62119902|NCT01091831|ACTIVE_COMPARATOR|MEL200|High dose Melphalan therapy (200 mg/m2) followed by stem cell support for 2 cycles every 4 months (for 1 cycle if at least VGPR was achieved after the 1st MEL200)
62119903|NCT03694288|ACTIVE_COMPARATOR|Removal Group|The implant removal group will have surgery scheduled 6 months after their initial surgical fixation.
62119904|NCT03694288|NO_INTERVENTION|Retention Group|The implant retention group will retain their implant for a minimum of 2 years from the time of their initial surgery.
62088976|NCT02555371|PLACEBO_COMPARATOR|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
62088977|NCT00742885|EXPERIMENTAL|Influenza A (H5N1) 20-40 Years Group|Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
62119905|NCT06280950|EXPERIMENTAL|Interventional Group 1|Participants in this group will slowly reduce their dose of tacrolimus and continue everolimus as their only immunosuppression medication.
62654038|NCT01192815|EXPERIMENTAL|Arm I|Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62654039|NCT03957993|EXPERIMENTAL|Occupational Therapy via Telehealth|Participants in the telehealth-based model will undergo occupational therapy treatment via a telehealth-based video chat platform for the entire episode of care (generally 10-12 weeks in duration). The patient will use the video chat client to connect to his/her occupational therapist, and the therapist will conduct the session over this virtual connection.
62654040|NCT03957993|ACTIVE_COMPARATOR|Standard of Care Occupational Therapy|Participants in the standard of care model will undergo occupational therapy treatment via traditional in- person encounters in an outpatient clinic setting for the entire episode of care (generally 10-12 weeks). These children will receive routine occupational treatment via in-person sessions with an occupational therapist conducted in an outpatient clinic setting.
62654041|NCT04224116|EXPERIMENTAL|Group TA|receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
62654042|NCT04224116|PLACEBO_COMPARATOR|Group SSI|Serum saline isotonic (SSI) group: placebo with isotonic saline serum.
62654043|NCT03950882|EXPERIMENTAL|PXL770|PXL770 500 mg once daily (QD) for 4 weeks
62654044|NCT03950882|PLACEBO_COMPARATOR|Placebo|placebo once daily (QD) for 4 weeks
62654045|NCT01919853|EXPERIMENTAL|Mindfulness-Based Stress Reduction|The MBSR intervention is an 8-week course meeting 2 hours weekly. The curriculum is based on MBSR manuals with a brief CRF education component incorporated into the first and second class sessions, drawing from information from the National Comprehensive Cancer Network clinical practice guidelines for CRF. In general, the MBSR class includes guided meditation practice; mindful, gentle movement (hatha yoga); didactic material on self-regulatory responses to stress; and group discussion that includes the participants' growing incorporation of mindfulness in adapting to life experiences. Along with class time, each participant is asked to commit 20 minutes per day, six days per week to formal meditation practice using compact disk recordings of the teacher's voice.
62119906|NCT06280950|EXPERIMENTAL|Interventional Group 2|Participants in this group will continue to take reduced Tacrolimus and Everolimus IS regimen.
62119907|NCT06280950|NO_INTERVENTION|Observational Group|"Participants in this group could not tolerate the addition of everolimus. These participants will not be randomized.~* Participants in this group will stop taking everolimus.~* Participants in this group will resume taking their tacrolimus +/- mycophenolate compound and prednisone immunosuppression regimen."
62119908|NCT01041365||Healthy adolescents|Healthy adolescent African American and Caucasian females, ages 14-18
62462283|NCT04047147||Enrollment in control provider organizations|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to the control group.
62287745|NCT04819906|EXPERIMENTAL|M-T-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62287746|NCT04819906|EXPERIMENTAL|P-T-ST-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62462284|NCT03104101|ACTIVE_COMPARATOR|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
62287747|NCT04819906|EXPERIMENTAL|T-M-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62287748|NCT04819906|EXPERIMENTAL|ST-P-M-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62462285|NCT03104101|ACTIVE_COMPARATOR|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
62462286|NCT02767310|EXPERIMENTAL|Test Product|Rosuvastatin 20 mg film-coated tablets
62462287|NCT02767310|ACTIVE_COMPARATOR|Reference product|Crestor 20 mg film-coated tablets
62462288|NCT05986448|EXPERIMENTAL|Tai-chi group|Basic care measures and Tai-chi exercise
62462289|NCT05986448|NO_INTERVENTION|control group|Basic care measures
62462290|NCT03806803|ACTIVE_COMPARATOR|LFMT|Lyophilized fecal microbiota transplant capsules
62462291|NCT03806803|EXPERIMENTAL|LSFF|Lyophilized sterile fecal filtrate capsules
62462292|NCT02654912|EXPERIMENTAL|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
62462293|NCT02654912|NO_INTERVENTION|Reactive Focal Test and Treat|This is the current standard of care in Southern Province and is described by a reactive response to passively detected index case of malaria. The reactive response consists of testing all individuals within a defined radius of each RDT-confirmed incident malaria case with an RDT and treating all positive individuals with artemether-lumefantrine (AL).
62462294|NCT01627457|EXPERIMENTAL|GEx Training|CAD Patients in cardiac rehabilitation phase II (inpatient) and phase III (at home)in order to analyze data for quality of heart rate measurement and data acquisition by device as well as for practicability and technical problems at home.
62462295|NCT06191939|EXPERIMENTAL|Mindful Self-Compassion for Lung Cancer (MSC-LC)|Group-based psychosocial intervention adapted from Mindful Self-Compassion that focuses on the development of mindfulness and self-compassion skills to reduce lung cancer stigma.
62462296|NCT06191939|ACTIVE_COMPARATOR|Enhanced standard of care with waitlist|Control group that will receive a list of mental health resources and will complete questionnaire assessments during a parallel timeframe as participants in the intervention condition and be placed on a waiting list to receive the MSC-LC intervention after study completion.
62462297|NCT03100630|ACTIVE_COMPARATOR|Treatment A: RO7239361|RO7239361 subcutaneous injections on specified days; abdomen
62462298|NCT03100630|ACTIVE_COMPARATOR|Treatment B: RO7239361|RO7239361 subcutaneous injections on specified days; arm
62462299|NCT03100630|ACTIVE_COMPARATOR|Treatment C: RO7239361|RO7239361 subcutaneous injections on specified days; thigh
62654046|NCT01919853|ACTIVE_COMPARATOR|Attention Control|"The attention control is an 8-week class meeting 2 hours weekly. The group sessions are supportive in tone, focus on pre-designated topics relevant to fatigue management (e.g., sleep hygiene, nutrition, exercise, emotional regulation), and involve weekly readings and open group discussion about session topics. This condition contains non-specific factors similar to MBSR (e.g., facilitator offering participants compassionate attention, empathy, genuine caring, and an opportunity to discuss what is important to them in a supportive environment); however, mindfulness is not presented/practiced in the group."
62088978|NCT00742885|EXPERIMENTAL|Influenza A (H5N1) 41-64 Years Group|Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
62287749|NCT04819906|EXPERIMENTAL|M-ST-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
62462300|NCT02392897|EXPERIMENTAL|High Eating Frequency|6 Eating Occasions
62462301|NCT02392897|EXPERIMENTAL|Low Eating Frequency|3 Eating Occasions
62462302|NCT05050448|EXPERIMENTAL|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62462303|NCT05050448|EXPERIMENTAL|SAM2 Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wireless SAM Ultrasonic Diathermy Device for 1 hour at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62462304|NCT05050448|PLACEBO_COMPARATOR|Topical Pain-Relief Gel|Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
62462305|NCT05087693|EXPERIMENTAL|Exercising in ozone following salbutamol inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling 200ug of salbutamol.
62287750|NCT02505529|EXPERIMENTAL|Resistance Exercise Training|12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
62287751|NCT02505529|EXPERIMENTAL|Mental Imagery|6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
62462306|NCT05087693|ACTIVE_COMPARATOR|Exercising in filtered air following salbutamol inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered air after inhaling 200ug of salbutamol.
62654047|NCT00989300|EXPERIMENTAL|Treatment group|patients received clopidogrel 75 mg with rabeprazole 20 mg, omeprazole 20 mg, or placebo in a crossover manner
61904968|NCT04269083|EXPERIMENTAL|experimental arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
61904969|NCT04269083|ACTIVE_COMPARATOR|control arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
61904973|NCT00659347|ACTIVE_COMPARATOR|1|
61904974|NCT00659347|PLACEBO_COMPARATOR|2|
61904975|NCT03772288|EXPERIMENTAL|Dose Escalation: TAK-659 + NKTR-214|TAK-659 tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 in a 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participant. The dose escalation phase will determine the MTD or RP2D of TAK-659. Dose escalation of TAK-659 will be based on available safety and tolerability data.
62088979|NCT00865475|NO_INTERVENTION|TZV (Trizivir)|Keeping on TZV in patients with viral suppression
62462307|NCT05087693|PLACEBO_COMPARATOR|Exercising in ozone following placebo inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling placebo medication.
62654048|NCT00989300|PLACEBO_COMPARATOR|Placebo group|
62654049|NCT04956809|ACTIVE_COMPARATOR|Dapagliflozin 10mg|Active arm will be 6 weeks in duration, separated by a 2-week wash-out period.
62654050|NCT04956809|PLACEBO_COMPARATOR|Placebo|Placebo arm will be 6 weeks in duration, separated by a 2-week wash-out period.
62287752|NCT02505529|NO_INTERVENTION|Control Group|6-weeks of no change in lifestyle.
62654051|NCT04910464|EXPERIMENTAL|Tranexamic acid|Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.
62654052|NCT04910464|PLACEBO_COMPARATOR|Saline placebo|Give the same volume (100 ml normal saline) and same duration (first three days).
62654053|NCT03320811||"group celiac disease"|
62654054|NCT03320811||"group no celiac disease"|
62654055|NCT01141816|EXPERIMENTAL|Contrast-Enhanced Ultrasound|
62654056|NCT05096377||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
62654057|NCT04868032|EXPERIMENTAL|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
62654058|NCT04868032|ACTIVE_COMPARATOR|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
62654059|NCT04616534|EXPERIMENTAL|Treatment (gemcitabine, elimusertib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and elimusertib QD or PO BID on days 2-3 and 9-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. All patients also undergo medical imaging scans after cycle 2 and then every 9 weeks throughout the trial and collection of blood samples during screening and on days 1, 2, and 9-10 of cycle 1. Patients in the dose-expansion portion of the trial also undergo biopsies during screening and on day 9 of cycle 1.
62654060|NCT00774917|EXPERIMENTAL|Numen|
62654061|NCT02423408|EXPERIMENTAL|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
62654062|NCT02423408|PLACEBO_COMPARATOR|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
62654063|NCT01946490||Radiotherapy in 2001|
62654064|NCT01946490||Radiotherapy in 2004|
62654065|NCT01946490||Radiotherapy in 2006|
62654066|NCT01946490||Radiotherapy in 2010|
61904976|NCT03772288|EXPERIMENTAL|Safety Expansion: TAK-659 + NKTR-214|TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
61904977|NCT04211220|EXPERIMENTAL|Type 1 diabetes|
61904978|NCT06531434|EXPERIMENTAL|Induction chemotherapy followed by chemoradiotherapy|This is a single-arm study. All patients will be assigned to receive Induction chemotherapy followed by concurrent chemoradiotherapy.
62287753|NCT02181933|EXPERIMENTAL|Nevirapine|Mother: two doses, Infant: one dose
62287754|NCT02181933|ACTIVE_COMPARATOR|Zidovudine (ZDV) + Lamivudine (3TC)|
62287755|NCT03705481|OTHER|Remote treatment of PCI.|5 sequential subjects presenting for remote PCI who have signed informed consent.
62287756|NCT01716481|EXPERIMENTAL|Mesenchymal stem cell treatment|
62287757|NCT01716481|NO_INTERVENTION|Standard treatment|
62287758|NCT04119570|NO_INTERVENTION|No intervention|Participants will have their clinic visit as per usual care.
62287759|NCT04119570|ACTIVE_COMPARATOR|CKD Report Card|Participants will receive the CKD Report Card prior to the clinic visit.
62654067|NCT00537277|EXPERIMENTAL|BIAsp 30|Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).
62654068|NCT05991817||Adults 30-50 years|
62654069|NCT03199690|EXPERIMENTAL|Single arm|"Single arm trial design based on the dosing regimen below:~Day 1 - 7~- Dolutegravir 50 mg once daily with food~Day 8 - 14 - Dolutegravir 100 mg once daily with food~Day 15 - 28~- Rifampicin 600 mg once daily~Day 29 - 35 - Rifampicin 600 mg once daily \& Dolutegravir 50 mg once daily~Day 36 - 42~- Rifampicin 600 mg once daily \& Dolutegravir 100 mg once daily"
62088980|NCT00865475|EXPERIMENTAL|2|Switching to LPV/r monotherapy
62088981|NCT02953548|EXPERIMENTAL|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
62088982|NCT02037061|PLACEBO_COMPARATOR|normal saline|Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.
62088983|NCT02037061|ACTIVE_COMPARATOR|bupivacaine|Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.
62654070|NCT05203653|EXPERIMENTAL|All participants|All participants will undergo two separate testing sessions
62654071|NCT04269616|EXPERIMENTAL|Numerical survival, followed by disability information|Participants in this arm were presented with a pictograph displaying numerical survival information, followed by a pictograph displaying disability information.
62088984|NCT05567666|EXPERIMENTAL|Treatment|Optilume Catheter System
62088985|NCT04752657|EXPERIMENTAL|Experimental Group|The experimental group will receive the physical function survey at weeks 2, 10, 18, and 26; the physical activity survey at weeks 2, 14, and 26; the events survey at weeks 2, 6, 10, 14, 18, 22, and 26. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
62088986|NCT04752657|ACTIVE_COMPARATOR|Control Group|The control group will receive the physical function survey at weeks 0, 8, 16, and 24; the physical activity survey at weeks 0, 12, and 24; the events survey at weeks 0, 4, 8, 12, 16, 20, and 24. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
62119909|NCT03324035|EXPERIMENTAL|Treatment|Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
62119910|NCT03324035|PLACEBO_COMPARATOR|Placebo|Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
62119911|NCT05241847|EXPERIMENTAL|Pediatric liver transplant recipients|"As this is a single arm trial, all eligible liver transplant recipients and their caregivers will be enrolled in this arm.~Eligible participants are children who received a liver transplant at least 1 year prior to enrollment at a participating SNEPT center and continue to receive their post-transplant care at that center."
62088987|NCT04880915|EXPERIMENTAL|SMOKE PROTECTION|Pre- and post-operative blood and urine samples of the surgical team (surgeon, surgical resident, anaesthesiologist, scrub nurse, circulating nurse, support staff and researcher), who worked in the standard practice, and the use of four different preventive measures that may affect the surgical smoke exposure during total mastectomy surgery in the operating room of the General Surgery Department of a University HospitaL. The surgical resident, anaesthesiologist, anaesthesia technician and support staff included in the study did not consist of the same people due to the change in the work schedules. Blood and urine samples were collected from a team of seven people before and after surgery \[7 volunteers × 2 (blood and urine before and after surgery) = 14 (14 blood analysis + 14 urine analysis) 14 × 5 surgery = 70 (70 blood analysis + 70 urine analysis)\].
62088988|NCT00604721|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive a single dose of selumetinib on day 1 and undergo blood collection for PK sampling pre-dose (within 30 min of dosing), 15 and 30 minutes and 1, 2, 4, 8, 12, 24 and 48 hours post-dose. Beginning 48 hours after the initial dose and continuing until day 21, patients receive oral selumetinib twice daily. Patients also undergo blood collection for PK sampling on day 15 of course 1. In all subsequent courses, patients receive selumetinib on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62088989|NCT06613555||patients with systemic vascular disease|"* patients with either:~* systemic vascular pathology~* high cardiovascular risk~* inflammatory vascular pathology~* preeclampsia during pregnancy"
62088990|NCT06613555||healthy controls|patients with no systemic or vascular inflammatory pathology and no high cardiovascular risk
62088991|NCT05468567||Military person with acoustic trauma (experimental group)|Active or reserve military member, diagnosed with acoustic trauma for at least one month. Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup.
62088992|NCT05468567||Normal hearing volunteers (control group)|Person without known hearing loss.
62088993|NCT00940134|PLACEBO_COMPARATOR|placebo|Study participants will receive a 3 hour IV infusion of saline while fasting.
62088994|NCT00940134|EXPERIMENTAL|PYY3-36 + GLP-1|Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.
62287760|NCT01880411|EXPERIMENTAL|PEK Fusion Protein Vaccine|PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals
62287761|NCT03743831|OTHER|orotracheal intubation direct|
62287762|NCT03743831|OTHER|orotracheal intubation indirect|
62088995|NCT00940134|ACTIVE_COMPARATOR|GLP-1|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
62088996|NCT00940134|ACTIVE_COMPARATOR|PYY3-36|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
62287763|NCT01825902|EXPERIMENTAL|Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)|Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
62287764|NCT05957887|ACTIVE_COMPARATOR|Dapagliflozin use in diabetic patients with anterior STEMI|
62287765|NCT05957887|NO_INTERVENTION|diabetic patients with anterior STEMI without Dapagliflozin|
62287766|NCT05957887|ACTIVE_COMPARATOR|Dapagliflozin use in non-diabetic patients with anterior STEMI|
62287767|NCT05957887|NO_INTERVENTION|Non-diabetic patients with anterior STEMI without Dapagliflozin|
62287768|NCT02970929|EXPERIMENTAL|SEP-363856|SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
62287769|NCT00403260|EXPERIMENTAL|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
62287770|NCT00403260|ACTIVE_COMPARATOR|Mefloquine plus artesunate|Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
62287771|NCT02953808|EXPERIMENTAL|Cohort 1 Group A|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, GSK2315698 20 mg/hr, and Placebo, respectively, as intravenous infusion over 1 hour.
62088997|NCT01258387|PLACEBO_COMPARATOR|GGF2|Seven dosing cohorts: 2 patients randomized to receive 1 GGF2, 1 placebo; if no drug-related dose-limiting toxicities in GGF2-treated patient, other 4 patients in cohort will be randomized (3:1) and dosed
62088998|NCT01194505|ACTIVE_COMPARATOR|ACL, sciatic, femoral, obturator|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
62287772|NCT02953808|EXPERIMENTAL|Cohort 1 Group B|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, Placebo, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
62287773|NCT02953808|EXPERIMENTAL|Cohort 1 Group C|In dosing sessions 1, 2, and 3, subjects will receive Placebo, GSK2315698 20 mg/hr, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
62287774|NCT02953808|EXPERIMENTAL|Cohort 2 Group D|In a single dosing session, subjects will receive GSK2315698 20 mg/hr as intravenous infusion over 15 hours.
62462308|NCT05087693|PLACEBO_COMPARATOR|Exercising in filtered air following placebo inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered after inhaling placebo medication.
62654072|NCT04269616|EXPERIMENTAL|Survival with description, followed by disability information|Participants in this arm were presented with a pictograph displaying survival information including the average course of stay in the NICU, followed by a pictograph displaying disability information.
62654073|NCT04269616|EXPERIMENTAL|Disability information, followed by numerical survival|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying numerical survival.
62654074|NCT04269616|EXPERIMENTAL|Disability information, followed by survival with description|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying survival information including the average course of stay in the NICU.
61904983|NCT04414735|NO_INTERVENTION|1- Control group (Standard immunosuppression)|1- Control group (n=15): Standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate), according to the clinical protocol of the Nephrology and Kidney Transplant Department.
62088999|NCT01194505|ACTIVE_COMPARATOR|ACL, sciatic nerve block, posterior lumbar plexus block|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
62089000|NCT01894958|EXPERIMENTAL|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
62287775|NCT02953808|PLACEBO_COMPARATOR|Cohort 2 Group E|In a single dosing session, subjects will receive Placebo as an intravenous infusion over 15 hours.
62287776|NCT03623789|ACTIVE_COMPARATOR|Group I|Primary total hip replacement with application of Floseal hemostatic matrix on potential bleeding sites after prosthesis implantation, and intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
62287777|NCT03623789|ACTIVE_COMPARATOR|Group II|Primary total hip replacement with intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
62287778|NCT03623789|PLACEBO_COMPARATOR|Group III|Control group, neither TXA nor Floseal® will be used. Equivalent volume of normal saline injection pre- and post-operatively
62654075|NCT02668003|EXPERIMENTAL|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
62089001|NCT01894958|PLACEBO_COMPARATOR|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water
62654076|NCT02668003|NO_INTERVENTION|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
62654077|NCT05803460|EXPERIMENTAL|Stage 1 Experimental A group: Actual experience of nature environment|actual natural environment
62654078|NCT05803460|EXPERIMENTAL|Stage 1 Experimental B group: virtual reality experience of nature environment|virtual reality experience of nature environment
61904984|NCT04414735|EXPERIMENTAL|2- Treatment group (ECP+Standard immunosuppression)|2- Treatment group (n=15): Extracorporeal photopheresis in combination with standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate) according to the clinical protocol of the Nephrology and Kidney Transplant Department
62089002|NCT00044590||Cases|Patients with Parkinson's Disease
62089003|NCT00044590||Controls|Controls, subjects without Parkinson's Disease
62287779|NCT01834404|EXPERIMENTAL|Phentermine-Topiramate ER|Qualifying participants were assigned to the Phentermine-Topiramate ER for a minimum of 5 days. The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
62654079|NCT05803460|ACTIVE_COMPARATOR|Stage 1 Control group: actual experience of city|actual experience of city
62654080|NCT05803460|OTHER|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
62287780|NCT01834404|PLACEBO_COMPARATOR|Placebo|Qualifying participants were assigned to placebo for a minimum of 5 days. Placebo pills matched the study drug in appearance for the 2 dose levels.
62287781|NCT03805126|EXPERIMENTAL|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
62287782|NCT03805126|ACTIVE_COMPARATOR|Usual Care|Usual care includes consultation with a social worker and a community health worker.
62462309|NCT06039982||cervical cancer treated with surgery|The inclusion criteria were: (1) pathologically confirmed CC; (2) FIGO stage IB-IIA according to the result of physical examination and imaging; (3) abdominal MRI was performed within three weeks before surgery. Exclusion criteria were: (1) accompanied with other tumors. (2) with chronic infectious disease. (3) incomplete clinical data.
62462310|NCT02120443|EXPERIMENTAL|Non-Infiltrated Tissue|The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.
62654081|NCT05803460|EXPERIMENTAL|Stage 3 Experimental group|virtual reality experience of nature environment
61904985|NCT04107389|ACTIVE_COMPARATOR|Intervention Group|Receives Art Therapy assessment and intervention
61904986|NCT04107389|ACTIVE_COMPARATOR|Wait List Control Group|Added to wait list to receive intervention at a later date, participant is made aware of this
61904987|NCT04284462|PLACEBO_COMPARATOR|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
61904988|NCT04284462|PLACEBO_COMPARATOR|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
61904989|NCT04284462|ACTIVE_COMPARATOR|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
62287783|NCT05768373|EXPERIMENTAL|3M™ Clinpro™ Fluoride Aqueous Solution|Investigational product.
62287784|NCT05768373|ACTIVE_COMPARATOR|3M™ Vanish™|Commercialized product
62287785|NCT02034045|ACTIVE_COMPARATOR|Usual Care|Patients randomized to the control group will continue to receive usual care from their Family Health Care Team. Usual care includes physician assessment and treatment and periodic augmentation of care in the community (CCAC or case manager, nurse practitioner) at the discretion of the treating physician.
62287786|NCT02034045|EXPERIMENTAL|Community Paramedicine|The intervention will consist of an initial visit and 3 follow-up visits at 3 month intervals over one year by a paramedic who has received additional training in chronic disease management, in addition to routine usual care and any additional visits prompted by the patient, the paramedic or the Family Health Care Team.
61904990|NCT04284462|ACTIVE_COMPARATOR|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
62462311|NCT01852435|ACTIVE_COMPARATOR|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
61904991|NCT04284462|ACTIVE_COMPARATOR|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
62462312|NCT01852435|EXPERIMENTAL|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
62462313|NCT01852435|EXPERIMENTAL|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
62462314|NCT02435745||Ehlers-Danlos Syndrome|Patients with the diagnosis of Ehlers-Danlos syndrome
62462315|NCT02435745||Controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
62462316|NCT06347042|EXPERIMENTAL|study group|receive qigong exercise + routine medical treatment +Anti-inflammatory diet
62654082|NCT05803460|ACTIVE_COMPARATOR|Stage 3 Control group|routine care
62654083|NCT01521741||Breast Cancer|
62654084|NCT03962699||Obese patients selected for bariatric surgery|Normospermic obese patients ((BMI\>40), aged 20-50 years) who will undergo Bariatric surgery.
62654085|NCT03962699||Control Group: Non obese volunteers|Normospermic obese patients ((BMI\>40), aged 20-50 years
62654086|NCT05662995|EXPERIMENTAL|Lung- and cardiac ultrasound, as well as optic nerve sheath diameter.|An ultrasound examination (approximately 25-30 minutes in duration) will be performed at the time of venous blood sampling on admission. The examination will consist of an assessment of systolic and diastolic function, lung ultrasound, and measurement of the optic nerve sheath diameter
62654087|NCT02023827|EXPERIMENTAL|RAYS intervention|In addition to standard care, participants receive three monthly online RAYS sessions, each followed by a one-on-one discussion with the probation officer
61919792|NCT05275660|EXPERIMENTAL|HFB30132A|Participants will receive HFB30132A administered across 2 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
62089004|NCT05347537|EXPERIMENTAL|Mulligan mobilization|Group A will be treated with only mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
62287787|NCT02780076|EXPERIMENTAL|Functional training group|Participation in a functional training program in addition to usual care. The functional training program is initiated by the nurses and consists of walking, sit-to-stands, balance training, weight transfer training, knee squats. The program is performed 4 times a day for 3 weeks while at short-term stays.
61904992|NCT04284462|ACTIVE_COMPARATOR|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
62287788|NCT02780076|NO_INTERVENTION|Control group|Usual care only. No participation in the functional training program while at short-term stays.
62287789|NCT05446493|ACTIVE_COMPARATOR|Tadalafil group|Each patient will be treated by tadalafil 5mg daily for 3months
62287790|NCT05446493|NO_INTERVENTION|control group|Estimation of serum YKL-40, platelet indices and serum total testosterone in healthy individuals in camparing with tadalafil group
62287791|NCT01743833|ACTIVE_COMPARATOR|Thoracic HVLAMT, Postive Message|Thoracic HVLAMT with a positive message given prior to the intervention.
62462317|NCT06347042|PLACEBO_COMPARATOR|control group|receive medical treatment + Anti-inflammatory diet
62462318|NCT02087904|EXPERIMENTAL|ABT-981 low dose|25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
62462319|NCT02087904|EXPERIMENTAL|ABT-981 medium dose|100 mg ABT-981 SC E2W
62654088|NCT02023827|NO_INTERVENTION|Standard care|Participants receive standard care from the probation officer
62654089|NCT02650752|EXPERIMENTAL|Lapatinib in Tandem With Capecitabine|A minimum of one patient at each dose level will be enrolled. Patients will receive a 4 week treatment cycle consisting of lapatinib 3 day on/11 day off in tandem with capecitabine 7 day on/7 day off with lapatinib. Both drugs will be administered orally as outpatient. Safety, toxicity, and DLT will be assessed weekly during the cycle 1 (first 4 weeks). Each patient will be monitored during cycle 1 prior to enrolling the next patient to the next higher dose level. Dose escalation will take place if no DLT or less than two occurrences of grade 2 toxicity (except those listed below) is observed within a given patient. In the event that a second instance of separate grade 2 toxicity (except those listed below) is noted, the cohort will be expanded to 3 patients at the same dose level and the study will revert to the standard 3+3 design with 3 patients per cohort. There will be no intra-patient dose escalation.
61904995|NCT02560506|EXPERIMENTAL|Elastic assisted treadmill walking|Participants will participate in treadmill training with a low cost pulley system device made of rubber bands (Theraband(R)), which will assist therapists in advancing limbs while gait training.
61904996|NCT02850471|EXPERIMENTAL|TEAS group|Before anesthesia, patients in this group treated with Transcutaneous Electric Acupoint Stimulation (TEAS) which is an electroacupuncture on Feishu, Hegu, Chize half an hour before the surgery, using the device Hua Tuo SDZ-II Acupoint Stimulator. The stimulus parameters set as 2/100Hz, 2V, 30min.
61904997|NCT02850471|NO_INTERVENTION|controlled group|Patients in controlled group treated without TEAS or other placebo.
61904998|NCT00322972|OTHER|A|Annual mass treatment
61904999|NCT00322972|OTHER|B|Biannual mass treatment
61905000|NCT00322972|EXPERIMENTAL|C|Mass administration of antibiotic; treatment of children (1-10 years of age) only
61905001|NCT00322972|NO_INTERVENTION|D|Delayed initiation of mass administration of antibiotic
61905002|NCT00322972|OTHER|F|One-time mass administration only
62089005|NCT05347537|ACTIVE_COMPARATOR|Mulligan mobilization with clamshell exercise|Group B will be treated with mulligan's mobilization with movement and clamshell exercises.
62089006|NCT03753321|EXPERIMENTAL|Whey protein|Whey protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
62287792|NCT01743833|ACTIVE_COMPARATOR|Thoracic HVLATM, Neutral Message|Thoracic HVLAMT with a neutral message given prior to the intervention.
62287793|NCT01743833|ACTIVE_COMPARATOR|Scapular HVLATM, Positive Message|Scapular HVLAMT with a positive message given prior to the intervention.
62462320|NCT02087904|EXPERIMENTAL|ABT-981 high dose|200 mg ABT-981 SC E2W
62462321|NCT02087904|PLACEBO_COMPARATOR|Placebo|Placebo
62089007|NCT03753321|EXPERIMENTAL|Soy protein|Soy protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
62089008|NCT03753321|PLACEBO_COMPARATOR|Placebo (maltodextrin)|Isoenergetic, maltodextrin (7 day pre-loading phase and 3 day training phase)
62089009|NCT05407363|EXPERIMENTAL|ABB and ATG with simultaneous implant placement|Using ABB with ATG to fill the gap around simultaneously placed dental implants
62089010|NCT05407363|EXPERIMENTAL|XBB and ATG with simultaneous implant placement|Using XBB with ATG to fill the gap around simultaneously placed dental implants
62089011|NCT05407363|ACTIVE_COMPARATOR|ABB and ABG with immediate implant|Using ABB with ABG to fill the gap around immediately placed dental implants
62089012|NCT05402579||Cases|Patients with type 2 diabetes mellitus who were hospitalized with SGLT2 inhibitor-associated DKA (60 cases).
62089013|NCT05402579||Controls|There are two sources for controls. \[1\] Patients hospitalized at one of the participating hospitals who were on an SGLT2i and do not have DKA. \[2\] Population controls using publicly available data from the Canadian Longitudinal Study on Aging (CLSA) database (1000 controls via CLSA).
62089014|NCT02747264|EXPERIMENTAL|eRAPID intervention|Participants in the intervention arm will receive training in using the eRAPID system to report their symptoms and side effects (at least on a weekly basis) from home via the internet whilst they are receiving treatment online and weekly for 6 weeks post treatment (a total of 12 weeks) and then at 18 \& 24 weeks. Hospital staff will be able to review eRAPID reports and use the information during the consultation in clinic, when attending radiotherapy or answering phone calls. Alerts will also be sent to the relevant clinical team when severe symptoms are reported by patients.
62654090|NCT06522204|EXPERIMENTAL|Grup Underweight|Experimental: Underweight pediatric patient Underweight children aged 6-14 years, under 5% percentile, fasted for the night before planned surgery.
62654091|NCT06522204|ACTIVE_COMPARATOR|Group Normal weight|Active Comparator: Normal weight pediatric patient Normal weight children aged 6-14 years, between 5-85% percentile, fasted for the night before planned surgery.
62089015|NCT02747264|NO_INTERVENTION|Usual care|The Usual care patients act as a comparison to the patients using eRAPID. They complete a paper-based quality of life questionnaire at baseline and then 6, 12 and 24 weeks after. The researchers will also collect clinical process measures for this group including number of hospital contacts and admissions.
62089016|NCT02096081|EXPERIMENTAL|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
62089017|NCT02096081|ACTIVE_COMPARATOR|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
62089018|NCT03941938|EXPERIMENTAL|Cyanoacrylate|the anastomotic reinforcement with nebulized cyanoacrylate glue using the special short catheter device for open surgery or the laparoscopic catheter.
62654092|NCT05031351|EXPERIMENTAL|High dosage Withania somnifera|544mg oral twice a day
62654093|NCT05031351|EXPERIMENTAL|Medium dosage Withania somnifera|272mg oral twice a day
62654094|NCT05031351|PLACEBO_COMPARATOR|Placebo|Matched capsules twice a day
61905003|NCT00322972|EXPERIMENTAL|G|One-time mass administration of antibiotics, plus intensive latrine construction
61905004|NCT02338232|EXPERIMENTAL|160 mg Telmisartan|60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days
62089019|NCT03941938|ACTIVE_COMPARATOR|No reinforcement|No reinforcement will be applied on the anastomosis line
62089020|NCT02093585|EXPERIMENTAL|Tenofovir to abacavir|Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)
62089021|NCT02093585|EXPERIMENTAL|Abacavir to tenofovir|Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)
62089022|NCT06613711|EXPERIMENTAL|Magnet System, DI Biofragmentable|GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System)
62287794|NCT01743833|ACTIVE_COMPARATOR|Scapular HVLATM, Neutral Message|Scapular HVLAMT with a neutral message given prior to the intervention.
62287795|NCT04802473|EXPERIMENTAL|Gingival recession treatment|Gingival recession treatment by means of tunnel technique and OrACell dermal matrix.
62287796|NCT03204630|ACTIVE_COMPARATOR|Bifido|Infant formula containing Bifidobacterium breve CECT7263
62287797|NCT03204630|ACTIVE_COMPARATOR|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
62287798|NCT03204630|PLACEBO_COMPARATOR|Control|Standard infant formula
61905005|NCT05844475|ACTIVE_COMPARATOR|Free gingival graft (FGG)|Conventional free gingival graft, involving the harvesting of an epithelialized graft from the hard palate, which is then stabilized/sutured to the recipient site (implant).
61905006|NCT05844475|EXPERIMENTAL|Buccal Strip Graft + Collagen matrix (bSG + CM)|Strip graft obtained from the buccal mucosa of a site showing abundant keratinized gingiva, combined with a collagen matrix. The bSG + CM graft is stabilized/sutured to the recipient site (implant).
62089023|NCT04254679|EXPERIMENTAL|Opioid analgesia|
62089024|NCT04254679|ACTIVE_COMPARATOR|Opioid-free analgesia|
62089025|NCT06168656|EXPERIMENTAL|Experimental|The experimental group will use a mobile application intervention developed for expectant fathers.
62089026|NCT06168656|NO_INTERVENTION|No Intervention|Control group receive routine care.
62089027|NCT06109532||DENGUE INFECTED PATIENTS. YEAR 2016|We conducted a prospective cohort study in patients with newly diagnosed dengue infection at Hospital Posadas in Argentina, between January 1, 2016, and december 31, 2016. Diagnosis was confirmed by IgM serology or PCR. Hyponatremia was defined as serum sodium concentration ≤135 mEq/L.
62089028|NCT06109532||DENGUE INFECTED PATIENTS. YEAR 2020|We conducted a prospective cohort study in patients with newly diagnosed dengue infection at Hospital Posadas in Argentina, between January 1, 2020, and december 31, 2020. Diagnosis was confirmed by IgM serology or PCR. Hyponatremia was defined as serum sodium concentration ≤135 mEq/L.
62089029|NCT06109532||DENGUE INFECTED PATIENTS. YEAR 2023|We conducted a prospective cohort study in patients with newly diagnosed dengue infection at Hospital Posadas in Argentina, between January 1, 2023, and november 1, 2023. Diagnosis was confirmed by IgM serology or PCR. Hyponatremia was defined as serum sodium concentration ≤135 mEq/L.
62287799|NCT06018701|EXPERIMENTAL|Maxillary Anterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on maxillary anterior region.
62089030|NCT05700721|EXPERIMENTAL|Monotherapy|
62089031|NCT01907399|OTHER|obese patients|(BMI\> 30 kg/m2) androids (waist circumference\> 102 cm in men and\> 88 cm in woman)
62089032|NCT01907399|OTHER|obese patients with type 2 diabetes|(BMI\> 30 kg/m2) androids (waist circumference\> 102 cm in men and\> 88 cm in woman)with diabetes
62089033|NCT01907399|OTHER|healthy volunteers|free of disease inflammatory or infectious and will have a BMI \<25 Kg/m2et fasting glucose \<1g / L
62287800|NCT06018701|EXPERIMENTAL|Maxillary Posterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on maxillary posterior region.
62287801|NCT06018701|EXPERIMENTAL|Mandibular Anterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on mandibular anterior region.
62287802|NCT06018701|EXPERIMENTAL|Mandibular Posterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on mandibular posterior region.
62287803|NCT01730248|EXPERIMENTAL|JAK Inhibitor Naive|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period ( 6 or more cycles of 28 days, with visits every 28days for 6 cycles and then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine maximum tolerated dose (MTD) / Recommended Phase II dose (RPIID) \& an Expansion Phase
62287804|NCT01730248|EXPERIMENTAL|Prior JAK Inhibitor|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period (6 or more cycles of 28 days, with visits every 28 days for 6 cycles then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine MTD / RPIID \& an Expansion Phase
61919793|NCT05275660|PLACEBO_COMPARATOR|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
61919794|NCT06450951|ACTIVE_COMPARATOR|Educational Intervention|The educational intervention arm includes EDC testing and personalized report-back, a self-directed online interactive curriculum of EDC material, access to live coaches, and an online forum.
61919795|NCT06450951|ACTIVE_COMPARATOR|Test Only|The test-only arm includes EDC testing and report-back.
62089034|NCT03432221||MDD|Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
62089035|NCT03432221||Healthy Controls|Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited
62287805|NCT00237679|ACTIVE_COMPARATOR|Neuromuscular Electrical Stimulation|Subjects will receice Neuromuscular Electrical Stimulation (NMES)-stimulated swallowing combined with exercise therapy.
62654095|NCT05664906|ACTIVE_COMPARATOR|Intervention Group: Chinese Medicine Oral Rinse and Standard Care|"* Prescription and oral rinsing with Chinese Medicine Oral Rinse Formula-I (CMORF-I) which mainly consists of the Nong's concentrated CM granules of Wu Wei Xiao Du Yin and other ingredients.~* Standard care will be following the indications provided by patient's western medical doctor.~* Patients should not take any other TCM and non-prescribed medication and nutritional supplements during the intervention period."
61905007|NCT05307198|EXPERIMENTAL|Rectal Artery Infusion Chemotherapy|Patients receive 2 cycles of Capecitabine and Oxaliplatin (CapeOx) chemotherapy and evaluated with rectum Magnetic Resonance Imaging (MRI). Patients with more than 20% regression of maximum diameter of rectal tumor in MRI image will entry into next step of rectal artery infusion of Oxaliplatin and oral Capecitabine（1000mg/㎡）with anti-PD1 antibody（200mg）every 3 weeks for 2 cycles.Then those patients will receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME.
62089036|NCT05646069|EXPERIMENTAL|Storz Flex-XC1 disposable flexible ureteroscope|A patient is randomized to the experimental arm using the Storz Flex-XC1 disposable flexible ureteroscope.
62089037|NCT05646069|NO_INTERVENTION|Analogue scope|A patient is not randomized to the experimental arm using the Storz Flex-XC1 disposable flexible ureteroscope.
62089038|NCT05646069|EXPERIMENTAL|Digital ureteroscope|A patient is randomized to the experimental arm using a Digital ureteroscope.
62089039|NCT06140420|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|24 randomized patients will take placebo daily for 8 weeks.
62089040|NCT06140420|ACTIVE_COMPARATOR|Active Comparator: Naltrexone|24 randomized patients will take naltrexone daily for 8 weeks
62089041|NCT04027790||Group 1 - Cancer Patients|Subjects with known colorectal cancer (i.e. AJCC/UICC stages 0, I, II, and III) who provide plasma at least 7 days after diagnosis by colonoscopy, but prior to surgery or treatment
62089042|NCT04027790||Group 2 - Screening Subjects|Prospectively enrolled subjects reporting for screening colonoscopy who provide a blood sample up to 2 weeks prior to bowel prep and prior to colonoscopy. We accept all subjects who meet the institutional criteria as average risk subjects referred for a screening colonoscopy for colorectal cancer, including subjects undergoing a colonoscopy as a follow-up to a positive (non-colonoscopic) test
62287806|NCT00237679|SHAM_COMPARATOR|Unstimulated|Subjects will receive sham (unstimulated) swallow therapy combined with exercise therapy.
62089043|NCT00527085|EXPERIMENTAL|AMG 073|
62089044|NCT00527085|PLACEBO_COMPARATOR|Placebo|
61919796|NCT03400982|EXPERIMENTAL|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
61919797|NCT00588952|EXPERIMENTAL|Family History Positive|Subjects with a positive family history of alcoholism
61919798|NCT00588952|EXPERIMENTAL|Family History Negative|Subjects with a negative family history of alcoholism
62089045|NCT01693146|ACTIVE_COMPARATOR|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
62089046|NCT01693146|ACTIVE_COMPARATOR|Nasal oxygen insufflation with a TNI® 20 oxy device|Device: TNI®20 oxy Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
62089047|NCT02269436|EXPERIMENTAL|sNN0029 infusion solution|
62089048|NCT03931005|EXPERIMENTAL|Decision-Support|An electronic copy of a collaboration decision-support guide.
62089049|NCT00481754||Females with ovarian cancer|Recruited from Magee Women's Hospital
62287807|NCT01891071|EXPERIMENTAL|Lung volume recruitment|Lung volume recruitment twice daily for 9 months
62089050|NCT05911074||The SD Biosensor COVID-19 Ag test kit|This is one of the Investigational product or medical device(s) intended to be used with a study participant according to the study protocol
62089051|NCT03314337|NO_INTERVENTION|Distal Pancreatectomy without pancreatic stent|
62089052|NCT03314337|EXPERIMENTAL|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
62089053|NCT04610203|PLACEBO_COMPARATOR|Glucose|Glucose - 50 g
62089054|NCT04610203|EXPERIMENTAL|Nutralys S85 Plus 25 g|Nutralys S85 Plus Pea Protein 25 g + 50 g Glucose
62089055|NCT04610203|EXPERIMENTAL|Nutralys S85 Plus 50 g|Nutralys S85 Plus Pea Protein 50 g + 50 g Glucose
62089056|NCT06065007||Swedish cohort of persons with Systemic Mastocytosis|We aim to include all individuals with a diagnosis of SM in Sweden, by identification via either one the two centers of excellence of mastocytosis or by a regional representative for the mastocytosis group in Sweden.
62089057|NCT01951365||Growing schwannoma|Overall volumetric growth rate more over than 10%
61905010|NCT02998632|EXPERIMENTAL|Interventional|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution.~Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
62089058|NCT01951365||Stable schwannoma|Overall volumetric growth rate less than 10%
62089059|NCT00813111|EXPERIMENTAL|SKY0402|A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
62089060|NCT00813111|ACTIVE_COMPARATOR|Bupivacaine HCl|A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
62089061|NCT06265649||Surgical Group (SG)|Patients with ALCD undergoing NOM admitted to the surgical ward
62089062|NCT06265649||Non-Surgical Group (NSG)|Patients with ALCD undergoing NOM admitted to the medical ward
62089063|NCT01387646|OTHER|Control Group|Participants in the control arm will be interviewed at baseline, be given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and will receive abuse and enhanced clinical counseling
61905011|NCT02998632|ACTIVE_COMPARATOR|Comparator|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane.~Osstell instrument will be used to measure and record fixture primary stability in ISQ units.~Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
62089064|NCT06040892|EXPERIMENTAL|Group A|bilateral cochlear implant children with rehabilitation including 8 sessions with a spatialized sensory index
62089065|NCT06040892|EXPERIMENTAL|Group B|bilateral cochlear implant children with rehabilitation including initially 4 sessions without spatialized sensory cue followed by 4 sessions with spatialized sensory cue
62089066|NCT06040892|ACTIVE_COMPARATOR|Normal hearing volunteers|Children without known hearing loss
62089067|NCT00184028|EXPERIMENTAL|Arm 1|On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days.
62089068|NCT06497634|ACTIVE_COMPARATOR|Group 25w (25 gauge Whitacre needle)|Spinal anesthesia will be performed with 25 G pencil point needle (Whitacre)
62089069|NCT06497634|ACTIVE_COMPARATOR|Group 25q (25 gauge Quincke needle)|Spinal anesthesia will be performed with 25 G sharp edge needle (Quincke)
62089070|NCT06497634|ACTIVE_COMPARATOR|Group 27q (27 gauge Quincke needle)|Spinal anesthesia will be performed with 27 G sharp edge needle (Quincke)
62089071|NCT04355676|EXPERIMENTAL|Selinexor 40mg|Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
62089072|NCT04355676|EXPERIMENTAL|Selinexor 20mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
62089073|NCT04209127|EXPERIMENTAL|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment for adenomyosis
62089074|NCT04209127|ACTIVE_COMPARATOR|Control|Uterine artery embolization; percutaneous application of a catheter into the femoral artery or branches thereof
62287808|NCT01891071|NO_INTERVENTION|Standard care|Standard care
62287809|NCT03527576|ACTIVE_COMPARATOR|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
62089075|NCT06391034|EXPERIMENTAL|Part 1: Image Optimization Group|Participants will undergo Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea imaging as part of a multi-parametric magnetic resonance imaging (mpMRI) exam, with the primary objective of optimizing imaging sequences and techniques to maximize signal-to-noise ratio of imaging modality.
62089076|NCT06391034|EXPERIMENTAL|Part 2A: Prospective imaging (Stereotactic body radiotherapy (SBRT) Participants)|Participants with pre-planned, non-interventional stereotactic body radiotherapy (SBRT) will undergo an HP Pyruvate +/-Urea mpMRI exam at baseline, at 3 months post-SBRT treatment and at 1yr post-treatment.
62089077|NCT06391034|EXPERIMENTAL|Part 2B: Prospective imaging (High-risk localized prostate cancer)|Participants with with high-risk localized prostate cancer and have pre-planned, non-interventional primary radiation therapy (RT) with concurrent, systemic, non-interventional hormone therapy will undergo HP Pyruvate+/-Urea mpMRI at baseline prior to the start of systemic hormone therapy, 4-12 weeks after the initiation of systemic hormone therapy (prior to radiation therapy), at 3 months post-radiation therapy, and at +1yr post-radiation therapy.
62089078|NCT06391034|EXPERIMENTAL|Part 3: SBRT participants at time of biochemical recurrence (BCR)|Evaluable SBRT participants who undergo HP Pyruvate +/-Urea mpMRI at time of biochemical failure, followed by magnetic resonance (MR) / ultrasound (US) fusion-guided prostate biopsy within 12 weeks following baseline MR exam. Participants in this group have the option of undergoing a follow up HP Pyruvate +/-Urea MR exam 6-15 months following the baseline scan, to evaluate for any interval change.
62089079|NCT03904628|EXPERIMENTAL|150 mg, BIW in every 28d|TG02 capsules were given orally at 150 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
62089080|NCT03904628|EXPERIMENTAL|200 mg, BIW in every 28d|TG02 capsules were given orally at 200 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
62089081|NCT03904628|EXPERIMENTAL|250 mg, BIW in every 28d|TG02 capsules were given orally at 250 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
62287810|NCT03527576|PLACEBO_COMPARATOR|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
62287811|NCT03168516|EXPERIMENTAL|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
62462322|NCT02185690|OTHER|Binimetinib efficacy/safety|"This is a Phase I/Ib, open-label, dose-escalation, multi-center, non-randomized study designed to evaluate the safety and tolerability of oral Binimetinib in combination with carboplatin and pemetrexed.~Phase I part A standard 3+3 dose-escalation will be used to determine the maximum administered dose (MAD) and the RP2D for the combination in subjects with advanced non-squamous lung carcinoma.~Phase Ib part Once RP2D has been identified, an expansion cohort will be accrued; these patients will be stratified by KRAS genotype.~The RP2D will be expanded by enrolling additional patients, stratified by KRAS genotype, to a total of 30 patients eligible for the safety set (including those treated at the same dose combination in the dose-escalation phase of the study who are eligible for the safety set) to be evaluated for safety, tolerability, pharmacokinetics and biologic activity of MEK162."
62654096|NCT05664906|PLACEBO_COMPARATOR|Control Group: Placebo and Standard Care|"* Placebo: The placebo consists of an inert substance, made of starch filler, flavor and colorings. It is also manufactured under GMP standard. To ensure blinding, the CMORF-I formula and placebo will be indistinguishable in appearance, smell and favour.~* Standard care will be following the indications provided by patient's western medical doctor.~* Patients should not take any other TCM and non-prescribed medication and nutritional supplements during the intervention period."
62654097|NCT03309618|EXPERIMENTAL|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
61905014|NCT05423353|ACTIVE_COMPARATOR|Paraffin Bath Therapy|Paraffin bath therapy is a physical therapy method that can create a temperature increase of 7.5 °C in the joint capsule and 4.5 °C in the muscle.
61905015|NCT05423353|ACTIVE_COMPARATOR|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
61905016|NCT01136187|EXPERIMENTAL|Radial approach|Primary percutaneous coronary intervention from the radial approach
62654098|NCT03309618|PLACEBO_COMPARATOR|Control group|16 participants received placebo per orally once daily for 30 days.
62654099|NCT05672563|EXPERIMENTAL|women with previous CSP|experimental: women with previous cesarean scar pregnancy that are invited to our unit for sonographic evaluation.
62654100|NCT02214654||ticagrelor，clopidogrel，antiplatelet drugs|
61905017|NCT01136187|ACTIVE_COMPARATOR|Femoral approach|Primary percutaneous coronary intervention from the femoral approach
62654101|NCT00742352||Breast cancer patients|
62654102|NCT00742352||Lung cancer patients|
62654103|NCT05666024||Parturients|Maternity about to give birth
61905018|NCT03796520||Patients suspected for epilepsy|The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.
62654104|NCT06129214|EXPERIMENTAL|Synovium removal group|
62654105|NCT06129214|NO_INTERVENTION|Synovium sustain group|
62654106|NCT01692574|EXPERIMENTAL|Combined|Group cognitive-behavior therapy for depression combined with behavior modification for weight loss
62654107|NCT01692574|ACTIVE_COMPARATOR|GCBT-ND|Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss
62654108|NCT01692574|ACTIVE_COMPARATOR|DSE|Behavior modification for weight loss combined with depression support and education.
62654109|NCT06013566||Baseline|This cohort contains individuals tested at baseline, usually in the pre-season of their sporting season
62654110|NCT06013566||Concussed|This cohort contains individuals who have had a concussion, diagnosed by a doctor.
62089082|NCT04846062|ACTIVE_COMPARATOR|Intervention|Intervention arm will receive nutrition behavior Children's mothers/caregivers will receive explanatory education and behavior about micronutrient essentiality and utilization. Also, dietary diversification and demonstration in the process of enriching child complimentary food will be given for participants every month for the consecutive six months. Posters and video shows will be used.
62287812|NCT03168516|NO_INTERVENTION|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
62654111|NCT06013566||Suspected Concussion|This cohort contains individuals suspected of having a concussion, but were cleared by a medical professional and do not have a concussion.
61905019|NCT01630278|NO_INTERVENTION|Small ductus|
61905020|NCT01630278|EXPERIMENTAL|Large ductus ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
61905021|NCT01630278|PLACEBO_COMPARATOR|Large ductus placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
61905022|NCT05411627|EXPERIMENTAL|Treatment Group|Pilot group of all 8 anticipated participants
62089083|NCT04846062|ACTIVE_COMPARATOR|control|Control arm will not receive nutrition behavior
62287813|NCT06443658|OTHER|ELTGOL group|Control group. Patients will do twice-daily ELTGOL technique
62287814|NCT06443658|PLACEBO_COMPARATOR|ELTGOL + isotonic saline solution (0,9%)|Placebo group. Patients will do twice-daily ELTGOL technique and will receive 5ml of 0.9% saline before performing the ELTGOL technique in the morning
61905023|NCT04356261|PLACEBO_COMPARATOR|Control PNF|Personalized Normative Feedback on non-alcohol/health related topics delivered in all weekly rounds (active control)
61905024|NCT04356261|ACTIVE_COMPARATOR|Light Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 33% of weekly rounds
61905025|NCT04356261|ACTIVE_COMPARATOR|Heavy Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 67% of weekly rounds
61905026|NCT05423223|ACTIVE_COMPARATOR|Paraffin Bath Therapy|Paraffin bath therapy is a physical therapy method that can create a temperature increase of 7.5 °C in the joint capsule and 4.5 °C in the muscle.
62089084|NCT04832477|OTHER|Stigma Counseling for PrEP Access|Behavioral counseling
62089085|NCT06615271||Patients who have undergone neurosurgery form more than 3 hours.|The ones who perform the selection criteria determined for this study will be chosen consecutively, and a follow-up will be carried out from the immediate preoperative moment until 72 hours once the surgery has finished.
62287815|NCT06443658|EXPERIMENTAL|ELTGOL + hypertonic saline solution (7%)|Experimental group. Patients will do twice-daily ELTGOL technique and will receive 5ml of 7% saline before performing the ELTGOL technique in the morning
62287816|NCT01061931|ACTIVE_COMPARATOR|Arctic Front® catheter|
62287817|NCT01061931|ACTIVE_COMPARATOR|HD Mesh Ablator® catheter|
62089086|NCT01725867|EXPERIMENTAL|PT program|manual myofascial release for craniomandibular system for 30\~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
62089087|NCT01725867|ACTIVE_COMPARATOR|Splint group|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
62089088|NCT03640013|EXPERIMENTAL|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
62089089|NCT03640013|OTHER|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
62089090|NCT00791531|EXPERIMENTAL|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
62089091|NCT03050281|EXPERIMENTAL|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
62089092|NCT03050281|PLACEBO_COMPARATOR|Didactic Workshop|Lectures
62089093|NCT00742274|EXPERIMENTAL|1|TAG+BMT
62089094|NCT00742274|ACTIVE_COMPARATOR|2|BMT alone
62654112|NCT02475369|OTHER|PES, Then Placebo|Participants first received Pancreatic Enzyme Supplementation (PES) for 10 days. PES taken 6 times daily with gluten free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received placebo tablets (matching PES treatment) 6 times daily for 10 days.
62654113|NCT02475369|OTHER|Placebo, Then PES|Participants first received placebo tablets (matching PES) for 10 days. Placebo was taken 6 times daily with gluten-free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received PES tablets six times daily for 10 days.
62089095|NCT04125511|EXPERIMENTAL|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62089096|NCT06352190|EXPERIMENTAL|SY-5007|Single oral dose of 160 mg SY-5007 suspension (containing approximately 120 μCi \[14C\] SY-5007)
62089097|NCT06309303||KD with SARS-COV-2|Subjects with Kawasaki Disease and presence of concomitant SARS-COV-2 infection
62089098|NCT06309303||KD without SARS-COV-2|Subjects with Kawasaki Disease and absence of concomitant SARS-COV-2 infection
62462323|NCT05233163|EXPERIMENTAL|Study Drug Arm|Subjects will take empagliflozin 10 mg oral daily for 12 weeks.
62462324|NCT04753437|EXPERIMENTAL|Clarithromycin + Amoxicillin + Bismuth + Vonoprazan|Clarithromycin 500 milligram (mg), tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and vonoprazan 20 mg, tablets, orally, BID on Days 1 to 14.
62462325|NCT04753437|ACTIVE_COMPARATOR|Clarithromycin + Amoxicillin + Bismuth + Esomeprazole|Clarithromycin 500 mg, tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and esomeprazole 20 mg, tablets, orally, BID on Days 1 to 14.
62654114|NCT00747604||Increlex patients|Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
62654115|NCT05755126|EXPERIMENTAL|Iatrosedation|
62654116|NCT05755126|EXPERIMENTAL|Musical Therapy|
62089099|NCT05329389|EXPERIMENTAL|StoneMD|"Patients will receive standard recommendations of keeping diuresis at the level of 2.5 l/day and to use the StoneMD application on their smartphones after the surgery. Patients will use the section Water balance and follow the instructions during the 12 month after the surgery."
62089100|NCT05329389|EXPERIMENTAL|StoneMD & Schools of Patients|"Patients will receive standard recommendations of keeping diuresis at the level of 2.5 l/day and and recommendations to use the StoneMD application on their smartphones after the surgery. Patients will use the section Water balance and follow the instructions during the 12 month after the surgery. Additionally, patients will visit schools during a following year. Patients receive 4 consultations (one per 3 month)."
62089101|NCT05329389|ACTIVE_COMPARATOR|Recommendations only|Only fluid balance recommendations given at the day of discharge. Patients will receive recommendations of keeping diuresis at the level of 2.5 l/day after the surgery
62089102|NCT05650294|ACTIVE_COMPARATOR|Active group|This group will receive a single dose of the PL+ omega 3 fatty acids capsules first, then receive a single dose of the standard FO EE omega 3 fatty acids capsules. Wash-out period is 2 weeks between treatments.
62089103|NCT05650294|PLACEBO_COMPARATOR|Placebo group|This group will receive a single dose of the standard FO EE omega 3 fatty acids capsules first, then receive a single dose of the PL+ omega 3 fatty acids capsules. Wash-out period is 2 weeks between treatments.
62089104|NCT05539404|EXPERIMENTAL|Experimental Strategy Group|endovascular treatment in addition to best medical treatment
62089105|NCT05539404|NO_INTERVENTION|Control Strategy Group|best medical treatment
62089106|NCT05481034|EXPERIMENTAL|Simplified carbohydrate estimation first, exact carbohydrate estimation second|"In the first study period, participants will use the CamAPS FX system and adopt the simplified meal announcement (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit. In the second study period, Participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals."
62654117|NCT05755126|NO_INTERVENTION|Control|
62654118|NCT02663986|EXPERIMENTAL|Organizational Skills Training (OST) Intervention|"To improve children's organizational functioning, OST focuses on four key skills.~* Tracking Assignments~* Managing Materials~* Time Management~* Task Planning"
62654119|NCT02415946|ACTIVE_COMPARATOR|Sinus floor augmentation (lateral)|Maxillary sinus floor elevation using a lateral approach
62287818|NCT00700856|EXPERIMENTAL|1|metformin 2000 mg + pioglitazone 15-45 mg
62287819|NCT00700856|ACTIVE_COMPARATOR|2|metformin 2000 mg + glibenclamide 5-15 mg or metformin 2000 mg + gliclazide 30-120 mg or metformin 2000 mg + glimepiride 2-6 mg
62287820|NCT01044563|EXPERIMENTAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
62089107|NCT05481034|EXPERIMENTAL|Exact carbohydrate estimation first, simplified carbohydrate estimation second.|"In the first study period, participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals. In the second study period, participants will use the CamAPS FX system and adopt the simplified meal announcement (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit."
62089108|NCT03377075||Healthy subjects|
62089109|NCT01627847|EXPERIMENTAL|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
62287821|NCT01044563|ACTIVE_COMPARATOR|Stress management|Cognitive reconstructive strategies for stress management
62654120|NCT02415946|EXPERIMENTAL|Sinus floor augmentation (transcrestal)|Maxillary sinus floor elevation using a transcrestal approach (Smart Lift technique; Trombelli et al. 2008)
62654121|NCT05603247||Acute myocardial infarction (AMI) and acute heart failure (AHF)|"All patients identified with the respective International Statistical Classification of Diseases and Related Health Problems (ICD) 10th revision codes for AMI and/or the phenotype of AHF will undergo detailed medical review to verify patients' diagnosis of AMI and/or AHF according to current European Society of Cardiology (ESC) guidelines that are reflected in the subsequent inclusion criteria."
61905027|NCT05423223|ACTIVE_COMPARATOR|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
61905028|NCT04039100|EXPERIMENTAL|Family Caregiver Ambassador Support|Intervention group: caregivers of newly diagnosed patients (n=30), former family caregivers as ambassadors (n=20)
61919799|NCT01484938|EXPERIMENTAL|OPTI-FREE|OPTI-FREE PureMoist multi-purpose contact lens solution used for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses, per protocol-specified regimen
62089110|NCT01627847|ACTIVE_COMPARATOR|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
62089111|NCT03356743|EXPERIMENTAL|Ex-Vivo|
62089112|NCT00792129||Control|Posterior unilateral interbody fusion using an open approach midline incision (TLIF)
62089113|NCT00792129||Experimental|MiLIF procedure with specialized Atavi instrumentation and minimally invasive visualization capabilities
62287822|NCT00923429|ACTIVE_COMPARATOR|S-A|
62287823|NCT00923429|ACTIVE_COMPARATOR|S-A+stretch|
62089114|NCT04542447|ACTIVE_COMPARATOR|Nuvastatic + standard treatment|5 patients, dosage: 3000 mg of Nuvastatic™ (C5OSEW5050ESA) each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
62287824|NCT00923429|EXPERIMENTAL|S-A+stretch+manther|
62287825|NCT00923429|EXPERIMENTAL|S-A+stretch+manther+sterinject|
62287826|NCT01231165|EXPERIMENTAL|Amiloride,nitrates,clopidogrel,aspirin,statins|Comparative Efficacious Research
62287827|NCT01231165|ACTIVE_COMPARATOR|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
62287828|NCT03015103|EXPERIMENTAL|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
62287829|NCT02550158|EXPERIMENTAL|Educated Group|"Training of patients by the educational program EDU-MICI"
62089115|NCT04542447|PLACEBO_COMPARATOR|Placebo|5 patients, dosage: 3000 mg of placebo each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
62287830|NCT02550158|OTHER|Control group|"During the first 6 months : no training of patients by the educational program EDU-MICI. Then, a crossover allowed uneducated patients to benefit from the educational program the next 6 months."
62089116|NCT06143761||neoadjuvant chemoimmunotherapy+surgery|Patients who underwent neoadjuvant chemoimmunotherapy before surgery
62089117|NCT06143761||surgery|Patients who accepted the surgery alone
62089118|NCT01506921|ACTIVE_COMPARATOR|Racemic ketamine|
62089119|NCT01506921|ACTIVE_COMPARATOR|S-ketamine|All subjects receive both study drugs in a cross- over design. Equipotent doses are used. 0,6 mg/kg racemic ketamine equals 0,3 mg/kg s-ketamine
62089120|NCT03398356|OTHER|group A|metformin dose 3 x 500 mg
62654122|NCT03185000|EXPERIMENTAL|Immediate ATIMP (AP)|Patients will receive Treg immunotherapy (TR004) infusion at Week 0.
62287831|NCT02619851|EXPERIMENTAL|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
62287832|NCT02619851|ACTIVE_COMPARATOR|Conventional Therapy|Typical therapy conducted for burn injury patients
62287833|NCT02932267|EXPERIMENTAL|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
62654123|NCT01559168|EXPERIMENTAL|Prolapse patients recieving UpHold LITE|Non-pregnant female patients \>= 50 years who are not considering future pregnancies, who are diagnosed with uterine or vault prolapse with ICS POP-Q score of stage 2 or greater, who are receiving the UpholdTM LITE mesh kit and who agree to be in the study.
62287834|NCT05061407||Paediatric surgical patients|All patients \< 18 years old, admitted to participating hospitals during the study period who undergo elective and non-elective surgery
62287835|NCT01276184|NO_INTERVENTION|Usual Care|Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
62287836|NCT01276184|EXPERIMENTAL|SMS Text Message|Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.
62287837|NCT01552681|EXPERIMENTAL|Baminercept|Subcutaneous injections of 100 mg every week for 24 weeks
62287838|NCT01552681|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of matched placebo every week for 24 weeks
62287839|NCT02690909|EXPERIMENTAL|Redy™ Renal Denervation System|Renal Denervation System
62287840|NCT03288246|NO_INTERVENTION|Standard-of-care|Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.
62287841|NCT03288246|EXPERIMENTAL|Point-of-care|Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.
62287842|NCT04500704|ACTIVE_COMPARATOR|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
62287843|NCT04500704|EXPERIMENTAL|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
62654124|NCT02631057||Non-Valvular Atrial Fibrillation|
62654125|NCT02631057||acute ischemic stroke|
61919800|NCT06233760||Patients with rheumatic diseases|All the rheumatic diseases outpatients from the National Institute of Medical Sciences
62089121|NCT03398356|OTHER|group B|metformin dose 3 x 1000 mg
62089122|NCT03398356|NO_INTERVENTION|group C|healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study
62089123|NCT03806049|EXPERIMENTAL|A: triplet|chemotherapy-free combination of niraprib + bevacizumab + Dostarlimab
62089124|NCT03806049|EXPERIMENTAL|B: Doublet|chemotherapy-free combination of niraparib + bevacizumab
62089125|NCT03806049|ACTIVE_COMPARATOR|C: standard of care|Standard of care chemotherapy: Carboplatin + paclitaxel
62089126|NCT01106976||Group 1 Parkinson disease subjects|Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.
62089127|NCT06505265|EXPERIMENTAL|Povorcitinib|Povorcitinib will be administered at the protocol defined dose.
62089128|NCT06483984|ACTIVE_COMPARATOR|Facemask 'Nivairo'|Oronasal mask for noninvasive ventilation
62089129|NCT06483984|EXPERIMENTAL|Bridge-free facemask 'Visairo'|Bridge-free facemask for noninvasive ventilation. This Bridge-Free NIV contacts the patient's nose only on the nostrils
62089130|NCT06483984|EXPERIMENTAL|Facemask 'Optiniv'|Facemask for noninvasive ventilation favoring carbon dioxide washout
62089131|NCT01698671|OTHER|InterGard Synergy Vascular Graft|
62089132|NCT02621567|EXPERIMENTAL|Bright Light Therapy Group|Participants in this group will receive bright light therapy lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
62089133|NCT02621567|PLACEBO_COMPARATOR|Dim Light Group|Participants in this group will receive modified dim lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
62089134|NCT02008266||Patients with Rheumatoid Arthritis|
62089135|NCT03059836|EXPERIMENTAL|n3 PUFA|Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
62654126|NCT02316925|PLACEBO_COMPARATOR|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
62654127|NCT02316925|EXPERIMENTAL|Glutathione supplement|500 mg/day Setria glutathione supplement
61905029|NCT02773784||invasive breast cancer|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
62089136|NCT03059836|PLACEBO_COMPARATOR|Placebo|Intervention: Organic Sunflower Oil 5000mg per day
61905030|NCT04740645||NOCDURNA cohort|
62287844|NCT05641701|EXPERIMENTAL|Deep Brain Simulation (DBS) System|The DBS device will be turned on to compare stutter to when the device was off (which would be the control).
62287845|NCT06126640|EXPERIMENTAL|SHR-A1811|
62287846|NCT06126640|ACTIVE_COMPARATOR|Trastuzumab Emtansine (T-DM1)|
62287847|NCT05912933||Cohort|New users of palbociclib for inoperable or recurrent breast cancer divided into 4 groups based on severity levels of hepatic impairment
62287848|NCT04426695|EXPERIMENTAL|On Low-Flow Oxygen|Cohort 1 (C1): O2 saturation \>93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
62287849|NCT04426695|EXPERIMENTAL|With COVID-19 symptoms but not requiring supplemental O2|Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
62287850|NCT04426695|EXPERIMENTAL|High O2 No Mechanical Ventilation|Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
62287851|NCT04426695|EXPERIMENTAL|On Mechanical Ventilation|Cohort 3 (C3): On mechanical ventilation
62654128|NCT05115929|ACTIVE_COMPARATOR|Decompressive Craniectomy Group|participants with severe TBI randomly assigned as described in the study protocol
61905031|NCT04740645||Lower urinary tract symptoms (LUTS) Cohort|
62089137|NCT06058689|EXPERIMENTAL|Pomalidomide Test|Pomalidomide 4 MG Oral Capsule per os,1 capsule per period
62089138|NCT06058689|EXPERIMENTAL|Pomalidomide Reference|Pomalidomide 4 MG Oral Capsule (Pomalyst) per os,1 capsule per period
62089139|NCT02696252||CGM Users|
62089140|NCT01303185||Experimental Group|
62089141|NCT01303185||Control Group|
62089142|NCT04035759|EXPERIMENTAL|APPEAL Program|Participants receive the APPEAL program, consisting of three one-on-one sessions, each lasting approximately one hour, and spaced one month apart. Sessions are designed to promote positive affect. Participants receive optional weekly check-ins to support behavior change efforts. All participants continue to receive standard of care.
62287852|NCT04093648|EXPERIMENTAL|TEGAR T cells + Fludarabine and Cytoxan|GPC3-CAR (TEGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
62287853|NCT01196442|EXPERIMENTAL|Arm I electric stimulation pain therapy|Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
62287854|NCT03475212|EXPERIMENTAL|Virus specific T cell lines (VSTs) against three viruses|The study will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, activated using overlapping peptide libraries spanning immunogenic antigens from CMV, adenovirus and EBV, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy.
62287855|NCT04495699||Observation|Patients who elect to have observation of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
62654129|NCT05115929|ACTIVE_COMPARATOR|Decompressive Laparotomy Group|participants with severe TBI randomly assigned as described in the study protocol
62654130|NCT00084630|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with documented tumor progression and no serious side effects may continue therapy at a higher dose for another 6 courses.
62089143|NCT04035759|NO_INTERVENTION|Standard of care|Participants receive standard of care.
62287856|NCT04495699||Stone treated|Patients who elect to have intervention of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
62287857|NCT05152381|EXPERIMENTAL|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
62287858|NCT04452890|EXPERIMENTAL|Sonourethrography|Ultrasound of the urethra (Sonourethrography - SUG): In this procedure, a Foley catheter is inserted into the top of the urethra and physiological serum is instilled into the urethra while a linear 7.5 MHz ultrasound probe is placed sagitally on the course of the urethra to detect a narrowing of the urethra.
62287859|NCT03148730|NO_INTERVENTION|manual group|This group will have a standard of care anesthesia. All the drugs, fluid and adjustement of ventilation settings will be done manually by the supervising anesthesiologist using the same drugs and fluids as the closed-loop group
62287860|NCT03148730|EXPERIMENTAL|automated closed-loop group|This group will have a fully automated anesthesia, analgesia , ventilation and fluid management using 3 indenpendent closed-loop systems same drugs used in both groups ( propofol and remifentanil, Plasmalyte and /or Voluven)
62089144|NCT06115122||Pre-eclampsia risk group|Approximately 300 women will be enrolled into a risk group according to a pre-eclampsia risk calculator.
62089145|NCT06115122||PCOS group|Women enrolled into study who fulfill ≥2 Rotterdam criteria. Women with PCOS may be included in risk- or control groups.
62089146|NCT06115122||Control group|Approximately 300 women in low risk for pre-eclampsia according to a pre-eclampsia risk calculator.
62089147|NCT06115122||Follow up group|Approximately 2100 women who are not enrolled into risk-, control- or PCOS groups.
62089148|NCT06115122||Children|Mothers and fathers will be asked for permission to follow the child's health information from national registers until the age of 15 years. Approximately 300 children will be recruited to PEPPI-offspring follow up study (including also PCOS offspring).
62089149|NCT06115122||Fathers|The role of fathers in the development of pregnancy complications and on the health of the offspring.
62089150|NCT06491381||Elective Cesarean Delivery|This group will consist of 110 patients who are scheduled for planned cesarean deliveries at El-hussien Hospital. These patients will have non-emergency indications for cesarean section, such as previous cesarean delivery, breech presentation, maternal request, or other medical indications that allow for scheduled surgery. Participants in this group will undergo standard pre-operative preparation and receive routine post-operative care as per hospital protocols. Their surgical site will be monitored for signs of infection during their hospital stay and follow-up period.
62089151|NCT06491381||Emergency Cesarean Delivery|This group will consist of 110 patients who undergo unplanned, emergency cesarean deliveries at the Emergency Unit of El-hussien Hospital. Indications for emergency cesarean section may include, but are not limited to, fetal distress, placental abruption, cord prolapse, failed induction of labor, or arrest of labor progression. Patients with premature rupture of membranes will be excluded from this group due to their increased risk of infection. Participants in this group will receive urgent pre-operative preparation and post-operative care as per hospital emergency protocols. Their surgical sites will be monitored for signs of infection during their hospital stay and follow-up period, similar to the elective group.
62287861|NCT04244370|EXPERIMENTAL|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
62287862|NCT00887458|ACTIVE_COMPARATOR|Low Dose|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
62287863|NCT00887458|ACTIVE_COMPARATOR|High Dose|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
62089152|NCT04308174|EXPERIMENTAL|Durvalumab + Gem/Cis|"\<Investigational arm: preoperative phase (up to 4 cycles)\> Durvalumab 1,500 mg IV on Day 1, every 3 weeks (preop period) 1,500 mg IV Day 1, every 4 weeks (postop period) Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks~\<Postoperative therapy for all patients (up to 6 cycles)\> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
62287864|NCT04311658|EXPERIMENTAL|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG-IUD insertion
62287865|NCT04311658|PLACEBO_COMPARATOR|placebo|one tablet of placebo vaginally 3 hours prior to LNG- IUD insertion
62287866|NCT04248205|ACTIVE_COMPARATOR|Intraoperative ketamine infusion|Subjects in this group will receive standard anesthesia during surgery and a dose of ketamine at 0.3 mg/kg IV bolus prior to surgical incision. If the procedure lasts more than 1 hour, an additional bolus dose will be given.
62287867|NCT04248205|NO_INTERVENTION|Control group|This group will only receive the standard anesthesia during surgery with no ketamine.
62287868|NCT04859413||the young group|healthy participants age between 20 and 40
62089153|NCT04308174|ACTIVE_COMPARATOR|Gem/Cis|"\<Control arm: preoperative phase (up to 4 cycles)\> Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks~\<Postoperative therapy for all patients (up to 6 cycles)\> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
62287869|NCT04859413||the elder group|healthy participants age over 60
62462326|NCT04119349|EXPERIMENTAL|Counseling|Women are given extra 15-minute counseling on the pros and cons of all different methods for prenatal testing including no testing at all
62462327|NCT04119349|NO_INTERVENTION|Standard care|Women receiving standard care by means of counseling
62462328|NCT02226952|EXPERIMENTAL|Group 1|BILN 2061 W, medium dose, in patients with genotype 1, minimal fibrosis
62462329|NCT02226952|EXPERIMENTAL|Group 2|BILN 2061 W, high dose, in patients with genotype 1, minimal fibrosis
62462330|NCT02226952|EXPERIMENTAL|Group 3|BILN 2061 W, high dose, in non-genotype 1 patients, minimal fibrosis
62287870|NCT02273245||thoracic aortgram CTs|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult (age\>18) patients presenting with symptoms of AAS.
62287871|NCT05011487|EXPERIMENTAL|osimertinib plus chemotherapy|Osimertinib (80mg/qd) po. for 60 days with two cycles of Pemetrexed (500 mg/m2) to be administered with cisplatin (75mg/m2) on Day 1 of every 3-week cycle for 2 cycles
62462331|NCT02226952|EXPERIMENTAL|Group 4|BILN 2061 W, low dose, in patients with genotype 1, minimal fibrosis
62462332|NCT02226952|EXPERIMENTAL|Group 5|BILN 2061 W, medium dose, in patients with genotype 1, advanced fibrosis
62462333|NCT02226952|PLACEBO_COMPARATOR|Placebo|
62462334|NCT01758276||Non smokers|Women who did not report smoking in pregnancy
62462335|NCT01758276||Smokers in pregnancy|Women who report smoking in pregnancy
62462336|NCT00493142|ACTIVE_COMPARATOR|Usual care|Usual care
62462337|NCT00493142|EXPERIMENTAL|Exercise|Exercise
62462338|NCT01388465|EXPERIMENTAL|Mobile phone text message Intervention|Daily assessments with feedback about (1) filling prescription and (2) number of doses taken
62089154|NCT06233955|EXPERIMENTAL|Group A|Group A received LLLT and Maitland mobilization technique along with conventional physical therapy,
62462339|NCT01388465|NO_INTERVENTION|Control|No TM queries or feedback
62089155|NCT06233955|EXPERIMENTAL|Group B|received LLLT and conventional physical therapy
62089156|NCT06233955|EXPERIMENTAL|Group C|received Maitland mobilization and conventional physical therapy.
62287872|NCT03624257|EXPERIMENTAL|Scaling and root planning + Laser treatment|
62287873|NCT03624257|ACTIVE_COMPARATOR|Mucosal flap surgery|
62462340|NCT05922449|EXPERIMENTAL|Paravertebral block group (PV group)|This group of patients will undergo ultrasound-guided thoracic paravertebral nerve block in T4 and T7 thoracic paravertebral spaces before general anesthesia.
62462341|NCT05922449|NO_INTERVENTION|Control group (C group)|This group of patients did not undergo any nerve block procedures before general anesthesia.
62089157|NCT05891613|ACTIVE_COMPARATOR|Control Breast Treatment Group: Bupivacaine Hydrochloride|Subjects undergoing breast reduction surgery will receive standard 0.25% Bupivacaine Hydrochloride in one breast.
62462342|NCT03164772|EXPERIMENTAL|Arm A: BI 1361849 mRNA Vaccine + durvalumab|"The BI 1361849 mRNA vaccine comprises 6 drug product components (F2408 coding for MUC1, F2409 coding for survivin, F2410 coding for NY-ESO-1, F2624 coding for 5T4, F2625 coding for MAGE-C2, and F2626 coding for MAGE-C1), which were provided and administered separately; each component was administered twice, thus there were 12 intradermal administrations of 100 µL (80 µg) each for each dose. The PharmaJet Tropis® device was used for the administration of the BI 1361849 components.~Durvalumab 1500 mg was to be administered as an intravenous (IV) infusion every 4 weeks for 12 cycles; BI 1361849 was to be administered as 14 doses over the 12 cycles."
62654131|NCT01550926|ACTIVE_COMPARATOR|Arm 1|60 mg orlistat
62287874|NCT00623571|EXPERIMENTAL|1|Patients treated by hospital-at-home service (GHHS)
62287875|NCT00623571|ACTIVE_COMPARATOR|2|Patients treated in a general medical ward (GMW)
62654132|NCT01550926|ACTIVE_COMPARATOR|Arm 2|120 mg orlistat (2 X 60 mg capsules)
62654133|NCT01550926|EXPERIMENTAL|Arm 3|orlistat experimental formulation
61919801|NCT05648071|EXPERIMENTAL|Sintilimab Plus Bevacizumab and Platinum-Based Doublet Chemotherapy|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus bevacizumab until disease progression or intolerable toxicity.
62089158|NCT05891613|EXPERIMENTAL|Treatment Breast Treatment Group: Liposomal (Exparel) Bupivacaine|Subjects undergoing breast reduction surgery will receive a mixture of liposomal (Exparel) bupivacaine with plain 0.25% bupivacaine hydrochloride in contralateral breast.
62089159|NCT05168865|EXPERIMENTAL|PCOS women will receive letrozole ovarian stimulation.|Polycystic ovarian disease (PCOS) women undergoing frozen embryo transfer (FER) will use Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
62089160|NCT05168865|ACTIVE_COMPARATOR|PCOS women will receive Estradiol and Progesterone (hormonal endometrial preparation).|PCOS women will use daily Cetorelix acetate 0.25 mg injections for 5 days from day 1-3 of the menstrual follow or after progesterone (P4) withdrawal bleeding. They will commence daily oral Estradiol Valerate (E2) 2 mg twice daily for 5 days starting from day 3 of the menstrual flow or after P4 withdrawal bleeding, then-after three times daily. When endometrial thickness reaches 7 mm or more, the dose of E2 will be reduced to 4 mg/ day. Women will start using vaginal micronized P4 100 mg three times daily starting from 8PM. After 48 hours of starting the vaginal P4, oral Dydrogesterone 10 mg three times daily will commence.
62089161|NCT05010772|EXPERIMENTAL|Arm A (decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
62287876|NCT01590342|ACTIVE_COMPARATOR|Diclofenac|
62287877|NCT01590342|PLACEBO_COMPARATOR|Placebo|
62287878|NCT05974982|EXPERIMENTAL|Platelet-rich plasma|Under aseptic precautions 20 ml of venous blood was drawn and added to a test tube containing acid citrate dextrose in a ratio of 9:1 (blood: Acid citrate dextrose), centrifuged at 5000 rpm for 15 min to separate the red blood cells from the platelets and plasma. Then the supernatant and the buffy coat composed of platelets and plasma were collected and centrifuged again at 2000 rpm for 5-10 min. The bottom layer about 1.5 ml was taken and 10% calcium chloride was added (0.3 ml for 1 ml of PRP). Then the activated PRP was applied to the wound after proper surgical debridement and was dressed with a non-absorbent dressing (paraffin gauze). This process was repeated once weekly for 6 weeks.
62287879|NCT05974982|ACTIVE_COMPARATOR|Conventional therapy|These patients were treated conservatively by compression using graduated elastic stockings below the knee and dressing using saline and vaseline gauze weekly for 6 weeks.
62287880|NCT01275014|PLACEBO_COMPARATOR|Placebo|
62654134|NCT06492213||PRP+PRF|PRF procedure will be performed at first. Puncture point will be identified at the surface projection point of the infraorbital foramen on the affected side, and after reach the infraorbital foramen under the guidance of thin-slice CT (2 mm/layer, Somaton, Siemens Company, Munich, Germany). The radiofrequency electrode needle (PMK-21-100; Baylis Medical Inc.) will be inserted into the trocar after removal of the the stylet and confirmation of no bleeding or air when withdrawal using a syringe. The standard PRF mode will be initially set at 42℃, then the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the treatment will be continued for 360 seconds. After PRF, the PRF electrode needle will be removed and 2 milliliter PRP will be injected into the same puncture site through the trocar needle.
62654135|NCT06492213||PRF alone|Puncture point will be identified at the surface projection point of the infraorbital foramen on the affected side, and after reach the infraorbital foramen under the guidance of thin-slice CT (2 mm/layer, Somaton, Siemens Company, Munich, Germany). The radiofrequency electrode needle (PMK-21-100; Baylis Medical Inc.) will be inserted into the trocar after removal of the the stylet and confirmation of no bleeding or air when withdrawal using a syringe. The standard PRF mode will be initially set at 42℃, then the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the treatment will be continued for 360 seconds.
62089162|NCT05010772|EXPERIMENTAL|Arm B (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62089163|NCT05010772|EXPERIMENTAL|Arm C (decitabine and cedazuridine, gilteritinib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62089164|NCT05010772|EXPERIMENTAL|Arm D (decitabine and cedazuridine, enasidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62089165|NCT05010772|EXPERIMENTAL|Arm E (decitabine and cedazuridine, ivosidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62089166|NCT04615858|ACTIVE_COMPARATOR|Genepro Generation 3|1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
62089167|NCT04615858|ACTIVE_COMPARATOR|Whey Protein|1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
62089168|NCT05454137|EXPERIMENTAL|participate in shared medical appointment|The POTS shared medical appointment will occur once monthly for four months. Each visit will last 1.5 hours. The group will meet in our clinic group space and lifestyle management therapies will be taught by a physician and another provider ie occupational therapist, dietician etc
62089169|NCT05454137|NO_INTERVENTION|Do not participate in shared medical appointment|participants will only have one-on-one traditional visit with the physician
62089170|NCT02375763|EXPERIMENTAL|Sortware suggestions|Children will fill a questionnaire regarding their dietary habits. Afterwards a dietary analysis will be performed using a computer software, and dietary instructions will be given to the children.
62089171|NCT02375763|PLACEBO_COMPARATOR|Traditional suggestions|
62089172|NCT04367194|EXPERIMENTAL|BPPV intervention|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
62089173|NCT04367194|EXPERIMENTAL|BPPV Epley|Only Epley training.
62654136|NCT00888836|ACTIVE_COMPARATOR|GBP|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo gastric bypass
62654137|NCT00888836|ACTIVE_COMPARATOR|BPD 2|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo bilio-pancreatic diversion
62654138|NCT00888836|ACTIVE_COMPARATOR|Med Ter3|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 yearsundergo medical therapy
62287881|NCT01275014|EXPERIMENTAL|Dexamethasone|
62287882|NCT05389449|EXPERIMENTAL|Danicopan|Participants will receive their last dose of danicopan from the parent study the night prior to Day 1 of this LTE study and will continue daily treatment with danicopan together with their background C5i therapy.
62654139|NCT02324153|EXPERIMENTAL|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
62654140|NCT02324153|PLACEBO_COMPARATOR|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
62654141|NCT05170113|ACTIVE_COMPARATOR|Alpinia galanga formulation|Alpinia galanga formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
62654142|NCT05170113|ACTIVE_COMPARATOR|Theacrine formulation|Theacrine formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
62654143|NCT05170113|ACTIVE_COMPARATOR|Caffeine formulation.|Caffeine formulation capsule: Take one (1) capsules once daily at noon with 8 oz.(240 ml) of water for a 14-day dosing period
62654144|NCT05170113|PLACEBO_COMPARATOR|Placebo|Placebo capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
62654145|NCT01240382|EXPERIMENTAL|3% DE-089|
62654146|NCT01240382|ACTIVE_COMPARATOR|0.1% HA|
62089174|NCT04367194|EXPERIMENTAL|BPPV Optocinetic|Only Optocinetic training.
62089175|NCT05808647|ACTIVE_COMPARATOR|Energy balanced metabolic diet (5-days)|45 kcals/kg of fat free mass \[FFM\]/day; 28% fat, 15% protein, 57% carbohydrate
62089176|NCT05808647|EXPERIMENTAL|Low energy availability metabolic diet (5-days)|20 kcal/kg of FFM/day; 28% fat, 15% protein, 57% carbohydrate
62089177|NCT01443143|EXPERIMENTAL|Commercial diet|Commercially available diet program (i.e., Nutrisystem D) that includes pre-packaged low-glycemic index portion-controlled entrees and snacks that are supplemented with grocery items in accordance with a structured meal plan.
62462343|NCT03164772|EXPERIMENTAL|Arm B: BI 1361849 mRNA Vaccine + durvalumab + tremelimumab|"The BI 1361849 mRNA vaccine comprises 6 drug product components (F2408 coding for MUC1, F2409 coding for survivin, F2410 coding for NY-ESO-1, F2624 coding for 5T4, F2625 coding for MAGE-C2, and F2626 coding for MAGE-C1), which were provided and administered separately; each component was administered twice, thus there were 12 intradermal administrations of 100 µL (80 µg) each for each dose. The PharmaJet Tropis® device was used for the administration of the BI 1361849 components.~Durvalumab 1500 mg was to be administered as an intravenous (IV) infusion every 4 weeks for 12 cycles; tremelimumab 75 mg was to be administered as an intravenous (IV) infusion every 4 weeks for the first 4 cycles (Arm B only); BI 1361849 was to be administered as 14 doses over the 12 cycles."
62089178|NCT01443143|NO_INTERVENTION|Usual Diet|Participants' usual consumption of food and beverages.
62089179|NCT05491005|EXPERIMENTAL|eHealth|
62089180|NCT05491005|EXPERIMENTAL|Face-to-face|
62462344|NCT02992678|EXPERIMENTAL|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
62462345|NCT02992678|PLACEBO_COMPARATOR|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
62462346|NCT02751398|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg/day
62462347|NCT02751398|PLACEBO_COMPARATOR|Placebo|
62654147|NCT00671060|ACTIVE_COMPARATOR|2|Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
62089181|NCT05491005|NO_INTERVENTION|Healthy control group|
62089182|NCT02479529|EXPERIMENTAL|administration of norepinephrine by dynamic elastance|The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
62287883|NCT01107444|EXPERIMENTAL|LY2181308 + Docetaxel|"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.~Docetaxel: 75 milligrams/square meter (mg/m\^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."
62287884|NCT01107444|ACTIVE_COMPARATOR|Docetaxel|Docetaxel: 75 milligrams/square meter (mg/m\^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.
62287885|NCT05977907|EXPERIMENTAL|Single Cohort|"Neoadjuvant Pembrolizumab ( 400mg IV infusion x1) + IO102-103 ( Subcutaneous injection weekly x6)~Adjuvant Pembrolizumab ( 400 mg IV infusion Every 6 weeks x8) + IO102-103 ( Subcutaneous injection every 3 week x6 then every 6 weeks x5)"
62462348|NCT04525781||1|
62462349|NCT02924038|EXPERIMENTAL|IMA950/poly-ICLC subcutaneous (subQ) + Varlilumab IV|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously followed immediately by a Varlilumab 3mg/kg infusion (intravenously) -23±2 days (about 3 weeks) before the date of scheduled standard-of-care surgery to remove the WHO grade II glioma. Patients will continue receiving IMA950/poly-ICLC subcutaneous injections every week leading up to surgery (Days -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). After surgery, patients will continue receiving a Varlilumab infusion every 6 weeks immediately following the IMA950/poly-ICLC injection (Weeks A1, A7, A13, and A19).
62089183|NCT02479529|OTHER|control administration of norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
62089184|NCT05657067|EXPERIMENTAL|Emotionally Focused Family Therapy (EFFT)|For this pilot study we aim for 15-20 included families who will be treated by three to five family therapists.
62089185|NCT01093261|EXPERIMENTAL|Hydrocortisone and fludrocortisone|Patients with glucocorticoid insufficiency
62089186|NCT01093261|PLACEBO_COMPARATOR|Placebo|Patients with glucocorticoid insufficiency
62089187|NCT01093261|NO_INTERVENTION|Controlled|Adapted glucocorticoid function
62089188|NCT01273090|EXPERIMENTAL|Treatment|
62089189|NCT02667691|EXPERIMENTAL|SODB Dimpless-caloric restriction|This arm receives daily two capsules of SODB Dimpless 40mg containing 480 UI of superoxide dismutase (SOD), associated with a moderate caloric restriction.
62089190|NCT02667691|PLACEBO_COMPARATOR|Placebo-caloric restriction|This arm receives daily two capsules Placebo containing excipients only, associated with a moderate caloric restriction.
62089191|NCT03888885|EXPERIMENTAL|Sport Education Group|Participants participated in the required physical education lessons which were delivered in a season of sport education model for 10 lessons.
62462350|NCT02924038|EXPERIMENTAL|IMA950/poly-ICLC subQ only|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
62089192|NCT03888885|NO_INTERVENTION|Control Group|Participants received no intervention treatment. They were asked to attend in normal physical education classes for the same period of time.
62089193|NCT01026779||Cases of rotavirus gastroenteritis|Patients will be eligible as cases if they have been identified by the investigator's ongoing rotavirus surveillance studies as having been hospitalized with laboratory-confirmed rotavirus gastroenteritis between January 1, 2007 and June 31, 2009. To be eligible as a case, the child must meet the following criteria: 1) immunocompetent; 2) born after April 15, 2006 (to select a population that would have been in the age group eligible for at least 1 dose of RV5 (RotaTeq); and 3) \> 2 months of age on the day of admission.
62462351|NCT01333150|EXPERIMENTAL|Propranolol|
62462352|NCT01333150|EXPERIMENTAL|Placebo|
62654148|NCT00671060|PLACEBO_COMPARATOR|1|Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
62654149|NCT01344928|EXPERIMENTAL|HIT training|
62654150|NCT01344928|ACTIVE_COMPARATOR|Aerobic exercise training|
62654151|NCT03847493||Patients with suspected sepsis|Patients admitted in the ICU with the clinical suspicion of infection/sepsis.
62654152|NCT03847493||Non-sepsis Patients (control group)|Patients admitted in the ICU with other conditions apart from infection/sepsis.
62654153|NCT04571489|EXPERIMENTAL|Gimatecan group|All patients will receive gimatecan (0.8mg/m2, on days 1 to 5, PO, every 4 weeks) until progressive disease (PD).
62654154|NCT04571489|PLACEBO_COMPARATOR|placebo group|All patients will receive tegafur, gimeracil and oteracil potassium (40-60mg, twice daily, on days 1 to 14 , PO, every 3 weeks) or gemcitabine (1000mg/m2, on days 1、8, IV, every 3 weeks) until progressive disease (PD).
62654155|NCT01902667||Curative intent surgery alone|Patients with retroperitoneal sarcoma randomised into surgery alone arm.
62654156|NCT01902667||Pre-operative radiotherapy plus surgery|Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.
62654157|NCT01152671|EXPERIMENTAL|Arm 1|
62654158|NCT01152671|PLACEBO_COMPARATOR|Arm 2|
62654159|NCT04992533|ACTIVE_COMPARATOR|Long-duration tourniquet|Tourniquets inflated before arthroscopic exploration and deflated after high tibial osteotomy
62654160|NCT04992533|EXPERIMENTAL|Short-duration tourniquet|Tourniquet should be inflated before arthroscopic exploration and deflated immediately after the exploration
62654161|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
62654162|NCT03679793|ACTIVE_COMPARATOR|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger.
62654163|NCT03679793|EXPERIMENTAL|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
62654164|NCT01395719|NO_INTERVENTION|Non remote ischemic conditionin(non-rIC)|Patients receiving kidney transplantation from a deceased donor. This group does not receive remote ischemic conditioning, but has a tourniquet on the leg (not inflated).
62654165|NCT01395719|EXPERIMENTAL|Remote ischemic conditioning (rIC)|Patients receiving kidney transplantation from a deceased donor. This group receives remote ischemic conditioning by inflating a tourniquet on the leg during surgery, before reperfusion of the kidney.
62654166|NCT02608619||PET Imaging|This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.
62654167|NCT01510639|EXPERIMENTAL|Cuff repair PRP|Cuff repair Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the cuff repair group
62462353|NCT02218411|EXPERIMENTAL|Exercise|Exercises routine based on the Otago exercise programme
62462354|NCT02994615||hypertrophic cardiomyopathy|
62654168|NCT01510639|NO_INTERVENTION|Cuff repair Control|No intervention
62654169|NCT01510639|EXPERIMENTAL|NEER PRP|Neer Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the NEER surgery group
62654170|NCT01510639|NO_INTERVENTION|NEER Control|No intervention
62654171|NCT03708224|EXPERIMENTAL|Atezolizumab Monotherapy|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery.
62654172|NCT03708224|EXPERIMENTAL|Atezolizumab (Adjuvant)|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery. The first 9 participants in Arm A (atezolizumab monotherapy) will also receive adjuvant atezolizumab 16 weeks after standard of care surgery and radiation, or chemoradiation therapy, at a fixed dose of 1200 mg IV every 3 weeks for an additional 12 cycles.
62654173|NCT03708224|EXPERIMENTAL|Atezolizumab + Tiragolumab|Participants will receive 840 mg of atezolizumab IV and 600 mg of Tiragolumab during the 15-day neoadjuvant period prior to definitive surgery.
62654174|NCT03708224|EXPERIMENTAL|Atezolizumab + Tocilizumab|Participants will receive 840 mg of atezolizumab IV and 6 mg/kg of Tocilizumab during the 15-day neoadjuvant period prior to definitive surgery.
62654175|NCT00375752|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment
62654176|NCT00375752|EXPERIMENTAL|Zolendronic Acid + Letrozole|2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
62654177|NCT00914069|EXPERIMENTAL|RIVS vascular access|RIVS vascular access
62654178|NCT00914069|ACTIVE_COMPARATOR|Conventional vascular access|Conventional vascular access
62287886|NCT01524991|EXPERIMENTAL|Treatment|Gemcitabine 1000 mg/m2 Days 1 \& 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 (start cycle 3)
62462355|NCT02994615||Control|
62462356|NCT03157856||Experimental: fluorescence assessment|Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.
62462357|NCT03105830|EXPERIMENTAL|intervention and data collection|pain management by iv paracetamol
62462358|NCT01911520|EXPERIMENTAL|BMI < 50, Total Body Weight (TBW), 2mg/kg|Patients with a BMI \< 50, who will be dosed according to total body weight.
62462359|NCT01911520|EXPERIMENTAL|BMI < 50, TBW, 4 mg/kg|Patients with a BMI \< 50, who will be dosed according to total body weight.
62654179|NCT01010763|EXPERIMENTAL|M2a Magnum|Total HIp Arthroplasty using with the M2a Magnum Large Metal Articulation is an ultra-high performance metal-on-metal articulation with a big ball (greater than or equal to 38mm) in acetabulums as small as 44mm.
62654180|NCT01010763|ACTIVE_COMPARATOR|M2a Taper|Total Hip Arthroplasty using with the M2a Taper Acetabular System consists of a titanium outer shell with cobalt chromium (Co-Cr-Mo) metallic liner, which articulates with with a cobalt chromium (Co-Cr-Mo) modular femoral head.
62089194|NCT01026779||Control Subjects|Three controls for each case will be identified using KIDSNET, the state child health registry. Controls will be matched to cases by age and county of residence at birth.
62654181|NCT03871556|EXPERIMENTAL|Experimental Group|
62654182|NCT01065012|EXPERIMENTAL|Udenafil 50 mg|50 mg Udenafil
62654183|NCT01065012|EXPERIMENTAL|Udenafil 100 mg|100 mg Udenafil
62654184|NCT01065012|EXPERIMENTAL|Udenafil 150 mg|150 mg Udenafil
62654185|NCT01065012|PLACEBO_COMPARATOR|Placebo|Placebo Tablets matching Udenafil tablets
62654186|NCT01951300|OTHER|Gallium-68 citrate|Intravenous bolus injection of 200 MBq of Gallium-68 citrate
62654187|NCT03307135|EXPERIMENTAL|Simple Assessment group|Intervention is a single evaluation with the MSPMI by two evaluators.
62654188|NCT03307135|EXPERIMENTAL|Hospitalization group|Evaluation with the MSPMI by two evaluators on two consultations separate by a 7 days interval.
62654189|NCT03307135|EXPERIMENTAL|Treatment group|Evaluation with the MSPMI by two evaluators before and after specific therapies proposed on our usual practices (Selective tibial neurotomy, anesthetic block or botulinum toxin intramuscular injection).
62654190|NCT03767478|SHAM_COMPARATOR|Control group|Best Medical Therapy + Sham Revitive Medic Coach (Sham Neuromuscular Electrical Stimulation Device) for 6 months
62654191|NCT03767478|ACTIVE_COMPARATOR|Intervention group|Best Medical Therapy + Revitive Medic Coach (Neuromuscular Electrical Stimulation Device) for 6 months
62654192|NCT04686032|EXPERIMENTAL|Advanced Rehab Group|The experimental group will receive early physical therapy interventions including patient education, ambulation, in-bed exercises, deep breathing exercises, connective tissue manipulation and TENS during the first 3 post-operative days following abdominal hysterectomy
62654193|NCT04686032|ACTIVE_COMPARATOR|Early ambulation Group|Participants of this group will receive patient education and early ambulation during the first 3 post-operative days following abdominal hysterectomy
62654194|NCT03069664|ACTIVE_COMPARATOR|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
62654195|NCT03069664|NO_INTERVENTION|Control group|control group
62654196|NCT06252792||daratumumab, pomalidomide, and dexamethasone (Dara-PD)|the first relapse of patients who received daratumumab, pomalidomide, and dexamethasone (Dara-PD) treatment
62654197|NCT06252792||other regimens in the same period (including Dara-KPD, VPd, KPd, IPd, Pd)|the first relapse of patients who received other regimens in the same period (including Dara-KPD, VPd, KPd, IPd, Pd) treatment
62654198|NCT02110251|EXPERIMENTAL|Supervised exercise therapy|Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.
62654199|NCT02110251|NO_INTERVENTION|Walking advice|Standard care and a oral walking advice.
62654200|NCT01621074|ACTIVE_COMPARATOR|Sodium bicarbonate|
62654201|NCT01621074|PLACEBO_COMPARATOR|Placebo|
62654202|NCT05985759|NO_INTERVENTION|970nm diode laser|
62462360|NCT01911520|EXPERIMENTAL|BMI < 50, Ideal Body Weight (IBW), 2 mg/kg|Patients with a BMI \< 50, who will be dosed according to ideal body weight.
62654203|NCT05985759|EXPERIMENTAL|N acetyle cystiene|
62089195|NCT00737308|EXPERIMENTAL|A|crown for clasp
62654204|NCT05985759|NO_INTERVENTION|calcium hydroxide|
62654205|NCT06252480|EXPERIMENTAL|Intensities of tDCS and dual task cognitive functions|We have done in a one arm type. The participants are divided into different intensity group (0.5 mA, 1.0 mA, 1.5 mA and 2.0 mA).
62654206|NCT05624541||preterm Infant|30 premature infants with a gestational age of 37 weeks and below and a history of stay in the neonatal intensive care unit will be evaluated.
62462361|NCT01911520|EXPERIMENTAL|BMI < 50, IBW, 4 mg/kg|Patients with a BMI \< 50, who will be dosed according to ideal body weight.
62654207|NCT02136381|EXPERIMENTAL|LEAP intervention|A newly developed internet-based lifestyle programme (Living, Eating, Activity and Planning through retirement (LEAP)) will promote three key health and social behaviours; healthy eating following a Mediterranean diet, increasing physical activity and improve social connectedness.
62654208|NCT02136381|OTHER|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~This website contains general information on improving life style and health."
62654209|NCT05286346|EXPERIMENTAL|Experimental group|Tenolid Tab
62654210|NCT05286346|ACTIVE_COMPARATOR|Control group|Viread Tab
62654211|NCT04159376|EXPERIMENTAL|Bone Metastases Patients|
62654212|NCT04521296|EXPERIMENTAL|DWJ1248|Camostat mesylate
62089196|NCT06696885|EXPERIMENTAL|Group A|Group A received mobile based video games along with task based training.
62089197|NCT06696885|NO_INTERVENTION|Group B|Group B received conventional physical therapy plan.
62089198|NCT04562779|EXPERIMENTAL|XR Naltrexone|Participants will receive a single dose of extended-release, injectable naltrexone prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
62462362|NCT01911520|EXPERIMENTAL|BMI > 50, TBW, 2mg/kg|Patients with a BMI \> 50, who will be dosed according to total body weight.
62654213|NCT04521296|PLACEBO_COMPARATOR|Placebo|Placebo
62654214|NCT01642381|ACTIVE_COMPARATOR|Psychotherapy|
62654215|NCT01642381|NO_INTERVENTION|"Self-Change Control (SCC)"|SCC participants will be told that they should attempt to reduce their drinking over the course of 8 weeks. (If unsuccessful, they will be offered Full Motivational Interviewing therapy sessions.)
62654216|NCT05395585|NO_INTERVENTION|Spontaneous separation|
62654217|NCT05395585|EXPERIMENTAL|Manual separation|
62654218|NCT05751551|EXPERIMENTAL|Intervention group|"The intervention group will conduct a motor-cognitive training program added to usual care. The intervention starts with a familiarization period in rehabilitation centers (face-to-face supervision) for 2 weeks before participants of the intervention group continue it at home (under remote supervision) for 10 weeks with 3 training sessions per week for about 20-30 minutes.~Besides, participants of the intervention group will participate in 3 assessment sessions: (1) T1 (baseline assessments), (2) T2 (pre-intervention, after familiarization period, before starting the home-based training), (3) T3 (post-intervention assessment)."
62654219|NCT05751551|NO_INTERVENTION|Control group|The control group will continue with their usual care. Apart from that, they will only attend 3 assessment sessions: (1) T1 (baseline assessments), (2) T2 (pre-intervention, after familiarization period, before starting the home-based training), (3) T3 (post-intervention assessment).
62089199|NCT04562779|EXPERIMENTAL|IV Ketamine|Participants will receive a single dose of intravenous ketamine (0.5mg/kg over 40 minutes) prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
62654220|NCT04732234|ACTIVE_COMPARATOR|( Group A)|ultrasound guided superior hypogastric plexus block using 20 ml Bupivacaine 0.5% before skin incision.
62089200|NCT04562779|ACTIVE_COMPARATOR|Linkage|Participants will receive no single-dose addiction medication prior to hospital discharge, but will receive enhanced linkage to follow-up addiction care.
62089201|NCT02223182|EXPERIMENTAL|Viaskin Milk 150 mcg|One Viaskin epicutaneous delivery system (patch) containing 150µg of cow's milk proteins applied each day for 12 months.
62307939|NCT04819672|EXPERIMENTAL|Low Intensity Training associated with Partial Blood Flow|In the experimental group, a cuff with compression at 60% of the pressure required for total arterial occlusion will be placed, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff with partial blood flow restriction will be used during knee extension and squat exercises.
62462363|NCT01911520|EXPERIMENTAL|BMI > 50, TBW, 4mg/kg|Patients with a BMI \> 50, who will be dosed according to total body weight.
62654221|NCT04732234|PLACEBO_COMPARATOR|(Group B)|ultrasound guided superior hypogastric plexus block using 20 ml normal saline 0.9% instead of bupivacaine.
62654222|NCT06520163|EXPERIMENTAL|EAP regimen group|66 subjects will be enrolled into the EAP regimen group. EAP regimen is the etoposide, cytarabine, and PEG-rhG-CSF combination therapy.
62654223|NCT06520163|ACTIVE_COMPARATOR|Disease-specific chemotherapy mobilization regimens group|33 subjects will be enrolled into the disease-specific chemotherapy mobilization regimens group. The disease-specific chemotherapy mobilization regimens include but not limited to: CHOP, Hyper-CVAD, ID-MTX+Ara-C.
62654224|NCT06307379||Bronchoscopy under local anesthesia|Bronchoscopy under local anesthesia
62654225|NCT06307379||Bronchoscopy under anxiolysis|Bronchoscopy under anxiolysis
62089202|NCT02223182|EXPERIMENTAL|Viaskin Milk 300 mcg|One Viaskin epicutaneous delivery system (patch) containing 300µg of cow's milk proteins applied each day for 12 months.
62089203|NCT02223182|EXPERIMENTAL|Viaskin Milk 500 mcg|One Viaskin epicutaneous delivery system (patch) containing 500µg of cow's milk proteins applied each day for 12 months.
62462364|NCT01911520|EXPERIMENTAL|BMI >50, IBW, 2 mg/kg|Patients with a BMI \> 50, who will be dosed according to ideal body weight.
61919802|NCT04831788||Adults|Adults older than 50 years of age, residing in the city of Novi Sad, Serbia and providing oropharyngeal and nasopharyngeal swab specimen upon signing informed consent
62089204|NCT02223182|PLACEBO_COMPARATOR|Viaskin Placebo|One Viaskin epicutaneous delivery system (patch) containing placebo applied each day for 12 months.
62089205|NCT05392985||FES+-|MBC patients with both FES positive(+) and negative(-) lesions.
62089206|NCT05463211|EXPERIMENTAL|Trexo Plus Pediatric Exoskeleton|Experimental lower-limb wearable pediatric exoskeleton used biweekly in clinical and school settings.
62089207|NCT01155999|EXPERIMENTAL|T1225|
62654226|NCT06307379||Bronchoscopy under conscious sedation|Bronchoscopy under conscious sedation
62654227|NCT06307379||Bronchoscopy under general anesthesia|Bronchoscopy under general anesthesia
62654228|NCT05226429|EXPERIMENTAL|UNAIR Inactivated COVID-19 Vaccine 3 microgram|
62654229|NCT05226429|EXPERIMENTAL|UNAIR Inactivated COVID-19 Vaccine 5 microgram|
62462365|NCT01911520|EXPERIMENTAL|BMI >50, IBW, 4 mg/kg|Patients with a BMI \> 50, who will be dosed according to ideal body weight.
62089208|NCT01155999|ACTIVE_COMPARATOR|Tobramycin|
62287887|NCT01957956|EXPERIMENTAL|Treatment (vaccine therapy and temozolomide)|"COURSE 1: Patients receive temozolomide PO daily on days 1-5.~COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5.~COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62462366|NCT04680715|EXPERIMENTAL|Per-Operative Radiotherapy technique by Papillon +TM|Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM
62462367|NCT00540501|EXPERIMENTAL|Oseltamivir 150mg and zanamivir 50mg/hour|Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours
62462368|NCT00540501|EXPERIMENTAL|Zanamivir IV 50mg/hour|Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)
62462369|NCT00540501|EXPERIMENTAL|Oseltamivir 150mg and zanamivir 600mg|Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h
62462370|NCT00540501|ACTIVE_COMPARATOR|Oseltamivir 150mg|Oseltamivir 150mg PO q12h for 3 days
62462371|NCT01884740|EXPERIMENTAL|SIACI of Erbitux and Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Erbitux (200 mg/m\^2) and Bevacizumab (15 mg/kg)
62462372|NCT06157749||3D Computerized Gait Analysis|The gait analysis will be conducted through 3D computerized gait analysis.
62462373|NCT06157749||Gait-Analyzer|The gait analysis will be performed using a smartphone application called Gait-Analyzer.
62462374|NCT06305897|EXPERIMENTAL|Condition 1:|Sequence of cryogenic gas (EC14_4osc)
62462375|NCT06305897|EXPERIMENTAL|Condition 2:|Sequence of cryogenic gas (EC+05_1osc)
62462376|NCT06305897|EXPERIMENTAL|Condition 3:|Sequence of cryogenic gas (EC+05_2osc)
62462377|NCT02923388|ACTIVE_COMPARATOR|Experimental|"Intervention: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks."
62462378|NCT02923388|PLACEBO_COMPARATOR|Placebo|"Intervention: Injection normal saline (1 ml) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Oral placebo pill 2 tablets thrice daily for 5 weeks."
62462379|NCT05108571|EXPERIMENTAL|Sequence A|
62089209|NCT02276547|EXPERIMENTAL|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
62089210|NCT06569290|ACTIVE_COMPARATOR|Arm 1|Post card; control letter; 2 calls
62089211|NCT06569290|ACTIVE_COMPARATOR|Arm 2|Post card; control letter; 4 calls
62287888|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
62089212|NCT06569290|ACTIVE_COMPARATOR|Arm 3|Post card; behavioral letter; 2 calls
62287889|NCT05910229|NO_INTERVENTION|Patient with standard care|Consultation with the onco radiotherapeutic and submission of the recommendations to follow before the simulation CT Scan before the radiotherapy
62287890|NCT05910229|EXPERIMENTAL|Patient with personalized support|Consultation with the onco radiotherapeutic and submission of the recommendations to follow before the simulation CT Scan before the radiotherapy and a phone call by a radiotherapy technician
62287891|NCT00931164|EXPERIMENTAL|Sodium oxybate|"* The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.~* Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy."
62287892|NCT02096094|EXPERIMENTAL|Chlorhexidine bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes impregnated with 2% chlorhexidine and with shampoo with 0.15% chlorhexidine.
62287893|NCT02096094|PLACEBO_COMPARATOR|Control bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes and shampoo without chlorhexidine.
62287894|NCT05136833|EXPERIMENTAL|Group A (RUTI)|Subjets will receive one inoculation of the RUTI® vaccine at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 mL
62287895|NCT05136833|PLACEBO_COMPARATOR|Group B (Placebo)|Subjets will receive one inoculation of normal saline at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region.
62462380|NCT05108571|EXPERIMENTAL|Sequence B|
62462381|NCT06032533|EXPERIMENTAL|Remote Ischemic Conditioning|After randomization a large thigh blood pressure cuff will be placed on the lower limb. The cuff will be inflated to a pressure 30 mm Hg greater than the systolic arterial blood pressure measured by the patient's arterial line or upper limb blood pressure cuff. The adequate level of inflation will be confirmed by the absence of pulse in the ipsilateral pedal artery detected by palpation. If the pulse signal is still present, the cuff will be inflated further until it disappears. The cuff will remain inflated for 5 minutes. Then the cuff will be deflated and the limb allowed to re-perfuse for 5 minutes. The procedure will be repeated five times followed by reperfusion. The first session will be performed 24-72 hours after the initial hemorrhage, within the first 24 hours after treatment of aneurysm, and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14.
62462382|NCT06032533|SHAM_COMPARATOR|Sham-RIC|"After randomization a large leg blood pressure cuff will be placed on the lower limb.~This cuff will be inflated to 50 mm Hg only. The device will the be operated by trained staff. The cuff will remain inflated for 5 minutes, then the cuff will be deflated for 5 minutes. The procedure will be repeated for five cycles. The first session will be performed 48-72 hours after the initial hemorrhage, at least 24 hours after treatment of aneurysm and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14."
62462383|NCT02978586||[Ga-68]PSMA PET/MR|Up to 3 experimental PET/MRI scans will be performed to determine the level of \[Ga-68\]PSMA tumor uptake
62654230|NCT05226429|ACTIVE_COMPARATOR|CoronaVac Biofarma COVID-19 Vaccine|
62654231|NCT02934646|EXPERIMENTAL|Subacute stroke patients|Elbow passive/active robotic treatment provided by NEUROExos Elbow Module
62462384|NCT03133364|ACTIVE_COMPARATOR|Sensory optimized meals|"Intervention group is receiving:~Popular dishes selected from hospital and meal service menus optimized by sensory experts. Optimization is done with respect to taste, texture and appereance and on nutritional composition of the meals with focus on protein content."
62089213|NCT06569290|ACTIVE_COMPARATOR|Arm 4|Post card; behavioral letter; 4 calls
62089214|NCT06569290|ACTIVE_COMPARATOR|Arm 5|No post card; control letter; 2 calls
62287896|NCT02908516|EXPERIMENTAL|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
62462385|NCT03133364|PLACEBO_COMPARATOR|Control|"Control group is receiving:~Popular dishes selected from hospital and meal service menus, NOT optimized by sensory experts."
62462386|NCT00929565||Lung cancer|Comparison between individuals with and without pulmonary malignancy
62462387|NCT06063005|EXPERIMENTAL|Translocation|
62654232|NCT04320667||Active ANCA glomerulonephritis|Patients with ANCA related disease (Microscopic Polyangiitis, Granulomatosis with Polyangiitis or Churg-Strauss Syndrome) and active renal involvement
62654233|NCT04320667||Control|Patients with ANCA related disease (MPA, GPA, CSS) without renal involvement or complete remission
62654234|NCT04377568|EXPERIMENTAL|Convalescent Plasma + Standard of Care (C19-CP + SoC)|Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.
62654235|NCT04377568|NO_INTERVENTION|Standard of Care (SoC)|Participants will receive standard of care while being hospitalized for COVID-19.
62654236|NCT05974332|ACTIVE_COMPARATOR|Ulcerative colitis Patients|45 Patients with UC. The diagnosis of UC will be based on endoscopic finding and histopathological finding
62654237|NCT05974332|ACTIVE_COMPARATOR|Control|45 apparently healthy subjects as controls who were not UC
62654238|NCT02456311|OTHER|Harmonic Ace+7|Pulmonary ARtery sealing with Harmonic Ace+7 in open lobectomy
61905034|NCT02372734||Sepsis with acute kidney injury (AKI)|Prior admission for sepsis with a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
62089215|NCT06569290|ACTIVE_COMPARATOR|Arm 6|No post card; control letter; 4 calls
62089216|NCT06569290|ACTIVE_COMPARATOR|Arm 7|No post card; behavioral letter; 2 calls
62089217|NCT06569290|ACTIVE_COMPARATOR|Arm 8|No post card; behavioral letter; 4 calls
62287897|NCT02908516|PLACEBO_COMPARATOR|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
62654239|NCT03979417||Liver fibrosis F0-F1|Blood draw and liver resection at the liver surgery
62654240|NCT03979417||Liver fibrosis F2-F3|Blood draw and liver resection at the liver surgery
62654241|NCT03979417||Liver Fibrosis F4|Blood draw and liver resection at the liver surgery
62089218|NCT05391828|EXPERIMENTAL|Total Knee Arthroplasty (TKA) performed using a medial congruent articular bearing surface design|
62089219|NCT05391828|ACTIVE_COMPARATOR|Total Knee Arthroplasty (TKA) performed using a posterior stabilized bearing design|
62089220|NCT04438551|ACTIVE_COMPARATOR|Standard dietary counseling|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection.
62654242|NCT03184272|EXPERIMENTAL|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
62462388|NCT06063005|ACTIVE_COMPARATOR|Peeling|
62462389|NCT03607032|EXPERIMENTAL|RespinPad and usual treatment|
62462390|NCT03607032|ACTIVE_COMPARATOR|only usual treatment|
62462391|NCT04148391|PLACEBO_COMPARATOR|Placebo|Matching placebo Capsules
62462392|NCT04148391|EXPERIMENTAL|NYX-458 30 mg|Single oral dose taken daily for 12 weeks.
62462393|NCT03301285||Children with osteoporosis associated to multiple disabilities|Treated with zoledronic acid
62462394|NCT01861262|EXPERIMENTAL|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
62287898|NCT00733525|EXPERIMENTAL|Stepped Care|Participants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
62287899|NCT00733525|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Participants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.
61905035|NCT02372734||Sepsis without acute kidney injury (AKI)|Prior admission for sepsis without a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
62287900|NCT05554120||Non-smoking adolescents|Non-smoking youth aged 12-17 years old. As the investigators monitor the cohort, it is possible that some of the cohort will become smokers.
62287901|NCT05554120||Smoking adults from disadvantaged neighbourhoods|Smoking adults aged 18 years and older from disadvantaged neighbourhoods. The investigators distinguish between disadvantaged and non-disadvantaged neighborhoods by using data from CBS Statistics Netherlands (CBS).
62287902|NCT05554120||Smoking adults from non-disadvantaged neighbourhoods|Smoking adults aged 18 years and older from non-disadvantaged neighbourhoods. The investigators distinguish between disadvantaged and non-disadvantaged neighborhoods by using data from CBS Statistics Netherlands (CBS).
61905036|NCT01543581|ACTIVE_COMPARATOR|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
61905037|NCT01543581|PLACEBO_COMPARATOR|Inactive placebo|Those to whom the inactive placebo is given.
61905038|NCT00974584|EXPERIMENTAL|GDC-0941+Paclitaxel+Carboplatin|Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941
61905039|NCT00974584|EXPERIMENTAL|GDC-0941+Paclitaxel+Carboplatin+Bevacizumab|Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.
61905040|NCT00974584|EXPERIMENTAL|GDC-0941+Pemetrexed+Cisplatin|Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\\n
62654243|NCT06214884|EXPERIMENTAL|Mindfulness for All (MFA) Group|"This intervention program named MINDFULNESS FOR ALL (MFA) developed on the conceptual basis of traditional mindfulness programs. Its formal structure resembles the traditional mindfulness programs, but it has been tailored to meet the needs and demands of employees.The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session.~The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material."
62287903|NCT02770157|EXPERIMENTAL|DA-3002|1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
62287904|NCT02770157|ACTIVE_COMPARATOR|Genotropin®|1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
62287905|NCT02770157|OTHER|Non-treatment control group|After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
62287906|NCT03969875|ACTIVE_COMPARATOR|Interscalene catheter|Interscalene catheter 0.5 % bupivacaine 15cc with rescue catheters attached to a PCA pump with bupivacaine infusion at 6cc /hour.
62287907|NCT03969875|EXPERIMENTAL|Interscalene single shot with liposomal bupivacaine|Liposomal bupivacaine 10cc of exparel with 0.5% bupivacaine 5cc, total 15cc with rescue catheter attached to a PCA pump with normal saline at 6cc/hour infusion.
62287908|NCT03969875|EXPERIMENTAL|Interscalene with bupivacaine and dexamethasone|Interscalene single shot with bupivacaine and dexamethasone as adjuvant 0.5% bupivacaine 14cc with 1 cc of 4mg dexamethasone, total 15cc with rescue catheter attached to a PCA pump with normal saline at 6cc/hour infusion.
62287909|NCT04691102||Stroke group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
61905041|NCT00974584|EXPERIMENTAL|GDC-0941+Pemetrexed+Cisplatin+Bevacizumab|Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\\n
61905042|NCT00486811|PLACEBO_COMPARATOR|Matching Placebo (twice daily)|The starting dose of placebo was matched with the active treatment arms taken twice daily for the first 3 days. The dose was then increased to match the active treatments for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days as in the active treatment arms. Dose decreases were allowed without time restrictions.
61905043|NCT00486811|EXPERIMENTAL|Tapentadol ER (100 to 250 mg twice daily)|The starting dose was tapentadol ER 50 mg twice daily for 3 days. The dose was then increased to 100 mg tapentadol ER twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
61905044|NCT00486811|ACTIVE_COMPARATOR|Oxycodone CR (20 to 50 mg twice daily)|The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
62654244|NCT06214884|ACTIVE_COMPARATOR|Wait-list control group|The wait-list control group will receive their training two weeks after interventional group complete their training. There will be a 90-minute online training session aimed at introducing participants to mindfulness in general and encouraging them to practice mindfulness by teaching several techniques. There will be no potential harm occurs among the subjects in the wait-list control group.
62654245|NCT00063453|EXPERIMENTAL|Vitamin E and selenium placebo|Vitamin E alone
62089221|NCT04438551|EXPERIMENTAL|Standard dietary counseling plus mobile app|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection. Subjects will use a mobile app to build their shopping lists prior to grocery shopping.
62654246|NCT00063453|EXPERIMENTAL|Selenium and vitamin E placebo|Selenium alone
62462395|NCT03827863||ARDS WITH ACP|"1. Diagnostic criteria for ARDS ARDS defined as within 1 week of a known clinical insult or new or worsening respiratory symptoms. ARDS was classified as mild (200 mmHg \< PaO2/FIO2≤300 mmHg), moderate (100 mmHg \< PaO2/FIO2≤200 mmHg) and severe (PaO2/FIO2≤100 mmHg) according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.~2. Ultrasound diagnostic criteria for ACP The specific diagnostic parameters are as follows: TR\>2.8m/s; RVEDA/LVEDA\>0.6 or Right ventricle/left ventricle basal diameter ratio\>1.0 or systolic D sign; IVC \>2cm with decreased inspiratory collapse; Pulmonary Regurgitation Velocity \>2.2m/s."
62089222|NCT01803932|EXPERIMENTAL|Behavioral intervention|Male-focused group violence prevention intervention
62089223|NCT01803932|NO_INTERVENTION|Control communities|Communities in which male-focused group prevention activities will not be conducted
62654247|NCT00063453|EXPERIMENTAL|Vitamin E and selenium|Vitamin E and selenium combined
62654248|NCT00063453|PLACEBO_COMPARATOR|vitamin E Placebo and Selenium placebo|Double placebo
62654249|NCT06042517|EXPERIMENTAL|Cohort 1: Ultrasound during a hyperinsulinemic euglycemic clamp (HEC).|Hepatic ultrasound during a hyperinsulinemic euglycemic clamp (HEC).
62654250|NCT06042517|EXPERIMENTAL|Cohort 2: Ultrasound then NMR with unlabeled glucose.|Hepatic ultrasound and subsequent NMR measurement of glycogen with unlabeled glucose.
62654251|NCT06042517|EXPERIMENTAL|Cohort 3: Ultrasound then NMR with carbon13 labeled glucose.|Hepatic ultrasound and subsequent NMR measurement of glycogen with carbon13 labeled glucose.
62654252|NCT06042517|EXPERIMENTAL|Cohort 4: Dual site ultrasound stimulation followed by CGM glucose recording alone.|Hepatoportal plexus + superior mesenteric plexus dual site ultrasound stimulation followed by CGM glucose recording alone.
62654253|NCT00525356|ACTIVE_COMPARATOR|1|Anti-hypertensive medical treatment
62654254|NCT03979313|EXPERIMENTAL|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
62654255|NCT03979313|PLACEBO_COMPARATOR|Placebo|Commercially available 0.9% (w/v) saline
62654256|NCT06486701|EXPERIMENTAL|Experimental|Singing
62654257|NCT06486701|NO_INTERVENTION|No intervention|Control
62654258|NCT05222308|OTHER|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
62654259|NCT00392223|EXPERIMENTAL|Treatment Group A|
62654260|NCT00392223|EXPERIMENTAL|Treatment Group B|
62654261|NCT01471626|EXPERIMENTAL|telematic attended polysomnography|
61905049|NCT04924439|EXPERIMENTAL|experimental group (foot reflexology group)|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other.~Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks."
62119912|NCT03703297|EXPERIMENTAL|Durvalumab + Placebo|Durvalumab monotherapy: Durvalumab (1500 mg intravenous \[IV\]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.
62119913|NCT03703297|EXPERIMENTAL|Durvalumab + Tremelimumab|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.
62119914|NCT03703297|PLACEBO_COMPARATOR|Placebo + Placebo|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
62654262|NCT04491058||Carpal tunnel syndrome patients|Subjects with unilateral or bilateral carpal tunnel syndrome
62654263|NCT04491058||Healthy|Subjects without carpal tunnel syndrome
62654264|NCT01772082|ACTIVE_COMPARATOR|Pedometer alone|pedometer
62654265|NCT01772082|EXPERIMENTAL|Pedometer plus website|pedometer and website
62654266|NCT00761319|EXPERIMENTAL|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
62654267|NCT00761319|ACTIVE_COMPARATOR|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
62654268|NCT00764218|EXPERIMENTAL|SAS+HTA+|Obstructive sleep apnea syndrome and hypertension
62654269|NCT00764218|EXPERIMENTAL|SAS+HTA-|non hypertensive patients with obstructive sleep apnea syndrome
62287910|NCT04691102||Traumatic Brain Injury group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
62654270|NCT00764218|EXPERIMENTAL|SAS-HTA+|hypertensive patients without obstructive sleep apnea syndrome
62654271|NCT00764218|EXPERIMENTAL|SAS-HTA-|non hypertensive patients without obstructive sleep apnea syndrome
62654272|NCT02642900|EXPERIMENTAL|Nystatin 100.000 units|Patients were treated with a topical antifungal nystatin oral suspension(1000.000 units) 5mL every six hours/14 days. Patients were instructed to rinse the solution for 5 minutes and then to spit the solution out. Samples were collected on days 7, 14 and 30 after the end of treatment (follow-up).
62654273|NCT02642900|ACTIVE_COMPARATOR|Photodynamic Therapy|Patients used mouthwash with methylene blue 0.005% for 20 minutes (pre-irradiation time). The palatal mucosa was irradiated using a low level laser with the following settings: wavelength of 660 nm, energy density of 120 J/cm ², output power of 40 milliwatt, 2 minutes per point. PDT was performed in two sessions (one session per week). Samples were collected immediately after each clinical procedure and 30 days after the second procedure (follow-up).
62287911|NCT04691102||Mild Cognitive Impairment group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
62462396|NCT03827863||ARDS WITHOUT ACP|Diagnosis as ARDS but no ultrasound evidence of ACP.
62462397|NCT03820466|ACTIVE_COMPARATOR|Aspirin|Aspirin 100 mg once daily and Placebo Atorvastatin once daily
62462398|NCT03820466|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 20 mg once daily and Placebo Aspirin once daily
62654274|NCT04207671|OTHER|Omission of chest tube|After wedge resection and the air-leak test, patients will receive complete omission of chest tube and directly close the incision.
62654275|NCT04207671|EXPERIMENTAL|Improved drainage strategy|After wedge resection and the air-leak test, patients willreceive a two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-removal.
62654276|NCT03989544|EXPERIMENTAL|Tezepelumab via Vial-and-syringe|Participants will be randomized to a single dose of tezepelumab via SC administration with Vial-and-syringe
62119915|NCT05095051|EXPERIMENTAL|Healthy subjects|To assess safety and tolerability of limb cryocompression, as well as to determine the optimal temperature and pressure to be used. The occurrence or lack of core hypothermia will be studied.
62119916|NCT05095051|EXPERIMENTAL|Cancer patients|Once the optimal temperature and pressure of limb cryocompression is established in healthy subjects, a group of cancer patients will undergo limb cryocompression over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
62119917|NCT00000251|PLACEBO_COMPARATOR|Placebo|Subjects inhale 100% oxygen
62119918|NCT00000251|ACTIVE_COMPARATOR|30% N2O|Subjects inhale 30% N2O
62307940|NCT04819672|SHAM_COMPARATOR|Low Intensity Training associated with Partial Blood Flow-Sham|In the sham group, the cuff will be placed, but there will be no arterial occlusion pressure, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff without partial blood flow restriction will be used during knee extension and squat exercises.
62462399|NCT03820466|EXPERIMENTAL|Aspirin-Atorvastatin|Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
62462400|NCT03820466|PLACEBO_COMPARATOR|Placebo|Placebo Aspirin once daily and Placebo Atorvastatin once daily
62462401|NCT01914497|EXPERIMENTAL|Acutus Medical System|Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.
62462402|NCT00839605||Dexmedetomidine|Those requiring thoracic surgery and receiving dex
62654277|NCT03989544|EXPERIMENTAL|Tezepelumab via APFS|Participants will be randomized to a single dose of tezepelumab via SC administration with APFS
62654278|NCT03989544|EXPERIMENTAL|Tezepelumab via AI|Participants will be randomized to a single dose of tezepelumab via SC administration with AI
62462403|NCT00839605||placebo|Group having thoracic surgery and not receiving dex drug
62462404|NCT04309422||Overexpression of PDL1|Overexpression of PDL1
62462405|NCT04309422||Absence of overexpression of PDL1|Absence of overexpression of PDL1
62462406|NCT05288127|EXPERIMENTAL|Talazoparib Single Agent|"The study will have 1 treatment group. Patients will receive a single oral dose of talazoparib (Talzenna®) 1mg/day daily for 28-day cycles until progressive disease, limiting toxicities, intercurrent medical issues, patient withdrawal of consent, death, or end of trial whichever occurs first. Treatment will be administered on an outpatient basis. Talazoparib should be taken orally once daily (i.e., continuous daily dosing) at approximately the same time each day (preferably in the morning). Talazoparib will be swallowed whole and may be taken with or without food. If a subject vomits a dose, the subject should not take a second dose that calendar day. The subject should resume daily dosing the next day.~Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered if the evidence of response or clinical benefit to talazoparib is noted."
61905050|NCT04924439|NO_INTERVENTION|control group|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
61905051|NCT05457621|EXPERIMENTAL|Effaclar serum|Participants are asked to apply Effaclar serum once daily in the evening on the whole face avoiding contact with eyes for 2 months.
61905052|NCT01596062|ACTIVE_COMPARATOR|Simulect 40mg + Neoral + Myfortic + steroids|A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
62089224|NCT03709784||Cohort 1|This is a prospective, longitudinal, multi-center, observational study designed to evaluate the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) in ambulatory and non-ambulatory adult patients with SMA. Subjects with SMA II/III that are 18 years to 70 years of age who are planning to initiate treatment with SPINRAZA® (nusinersen) as part of their clinical care plan will be enrolled in this study. This study does not provide SPINRAZA® (nusinersen) or cover costs associated with standard clinical care.These patients will be treated by their respective physicians according to standard clinical practice. Study visits, some of which including standardized assessments of strength and function, will occur at baseline, day 15 after treatment initiation, day 30, day 60, and then 4-month intervals through month 30.
62307941|NCT03685656|EXPERIMENTAL|ANACA3|ANACA3 slimming gel
62089225|NCT03709784||Cohort 2|The cohort 2 is a one time survey to gain a better understanding of this adult population and their treatment preferences.
62089226|NCT03190083|EXPERIMENTAL|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
62119919|NCT00000251|ACTIVE_COMPARATOR|0.2% isoflurane|Subjects inhale 0.2% isoflurane
62119920|NCT00000251|ACTIVE_COMPARATOR|0.4% isoflurane|Subjects inhale 0.4% isoflurane
62119921|NCT00000251|ACTIVE_COMPARATOR|0.2% isoflurane + 30% N2O|Subjects will inhale a combination of 0.2% isoflurane and 30% N2O
62462407|NCT00723528|PLACEBO_COMPARATOR|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
62462408|NCT00723528|ACTIVE_COMPARATOR|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
62462409|NCT00723528|ACTIVE_COMPARATOR|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
62462410|NCT00723528|PLACEBO_COMPARATOR|Placebo A (After CP)|After the controlled period (that is \[i.e.\], during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
62462411|NCT00723528|PLACEBO_COMPARATOR|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
62462412|NCT00723528|ACTIVE_COMPARATOR|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
62462413|NCT00723528|ACTIVE_COMPARATOR|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
62462414|NCT04206410|EXPERIMENTAL|Probiotic|Multistrain probiotic mixture consisting of two Lactobacillus strains (L. rhamnosus and L. acidophilus) and three Bifidobacterium strains (B. longum, B. bifidum and B. lactis) administered for 8 weeks in a dose 1,0E+10/day, 2x sachets/day (5,0E+9/cfu per sachet)
62462415|NCT04206410|PLACEBO_COMPARATOR|Maltodextrin|Placebo - Maltodextrin manufactured with an appearance, taste and packaging (sachets) identical to the probiotic mixture administarted for 8 weeks 2x sachets/day
62462416|NCT06370221||Group A: Cases Group|About 100 patient females suffering from Psoriatic arthritis and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients
62462417|NCT06370221||Group B: Control Group|About 80 healthy control females
62462418|NCT03267628|SHAM_COMPARATOR|Saline intrathecal as well as saline in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
62462419|NCT03267628|ACTIVE_COMPARATOR|Saline intrathecal as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
62462420|NCT03267628|ACTIVE_COMPARATOR|Intrathecal morphine as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
62462421|NCT03267628|ACTIVE_COMPARATOR|Intrathecal morphine as well as saline in Block|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
62119922|NCT00000251|ACTIVE_COMPARATOR|0.4% isoflurane + 30% N2O|Subjects will inhale a combination of 0.4% isoflurane and 30% N2O
62119923|NCT06504368|EXPERIMENTAL|DCR-PDL1|Participants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.
62119924|NCT00012740|OTHER|Arm 1|
62462422|NCT06199297||ABTH|Atezolizumab plus bevacizumab combined with TACE-HAIC
62462423|NCT06199297||SBTH|Sintilimab plus bevacizumab combined with TACE-HAIC
62462424|NCT03169205||preexisting Diabetes mellitus type 1|
62462425|NCT03169205||preexisting Diabetes mellitus type 2|
62462426|NCT03169205||Gestational Diabetes mellitus|
62462427|NCT05297032|EXPERIMENTAL|Quercetin Phytosome|All participants will receive Quercetin Phytosome
62462428|NCT00213421||1|
62462429|NCT00213421||2|
61905053|NCT01596062|EXPERIMENTAL|Simulect 80mg + Neoral + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
61905054|NCT01596062|EXPERIMENTAL|Simulect 80mg + Certican + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
62307942|NCT03685656|PLACEBO_COMPARATOR|Placebo|Slimming gel contening no active ingredient
62462430|NCT03310697|EXPERIMENTAL|Children with afebrile seizure|"For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.~Intervention : Collection of blood and urine samples, and Clinical examination"
62462431|NCT01974648|ACTIVE_COMPARATOR|propofol|In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
62654279|NCT02684929|EXPERIMENTAL|vegan|Vegan subjects interveinted with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
62089227|NCT02787538|EXPERIMENTAL|US-ANSWER-2 decision aid|The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
62462432|NCT01974648|EXPERIMENTAL|propofol and remifentanil|In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.
62462433|NCT04885296|EXPERIMENTAL|Test/Control|Eligible subjects will be randomized into one of two possible lens wear sequences, Test/Control.
62462434|NCT04885296|EXPERIMENTAL|Control/Test|Eligible subjects will be randomized into one of two possible lens wear sequences, Control/Test.
62654280|NCT02684929|ACTIVE_COMPARATOR|omnivor|Omnivorous subjects iterveined with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
62654281|NCT01774643||Pancreatic cancer with liver metastases|Tumor tissue biopsy, blood samples
62654282|NCT05162456||participants willing to receive a 3-dose vaccination schedule|participants willing to receive a 3-dose vaccination schedule
62307943|NCT04655586|EXPERIMENTAL|rNAPc2 Higher Dose|loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5
62462435|NCT01459003|EXPERIMENTAL|experimental|
62654283|NCT05162456||participants unwilling to receive a 3rd dose of vaccination|participants who received a 2-dose vaccination schedule, unwilling to receive a 3rd dose
62654284|NCT01027949|EXPERIMENTAL|Oral Treprostinil|Subjects from previous studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405), TDE-PH-301 (NCT00325442), TDE-PH-302 (NCT00325403), or TDE PH-308 (NCT00887978). Subjects were instructed to take the appropriate amount of 0.125, 0.25, 0.5, 1, and/or 2.5 mg tablets based upon their prescribed dose. Investigators were instructed to increase the dose of oral treprostinil in the absence of dose limiting drug-related AEs to ensure each subject received the optimal clinical dose throughout the study
61905055|NCT04370340|NO_INTERVENTION|control|
61905056|NCT04370340|ACTIVE_COMPARATOR|intervention|
62307944|NCT04655586|EXPERIMENTAL|rNAPc2 Lower Dose|loading dose of 5 ug/kg SC on Day 1 followed by 3 ug/kg SC on Days 3 and 5
62307945|NCT04655586|ACTIVE_COMPARATOR|Heparin|heparin at either prophylactic or therapeutic doses per Standard of Care at Institution
62462436|NCT01459003|NO_INTERVENTION|control|
62462437|NCT01288131|ACTIVE_COMPARATOR|CSA+MMF|Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
62462438|NCT01288131|ACTIVE_COMPARATOR|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day
62462439|NCT05727137|EXPERIMENTAL|Single shot adductor canal block|
62462440|NCT05727137|ACTIVE_COMPARATOR|Continuous adductor canal block|
62462441|NCT05411926||The group that receiving PD-1 / PD-L1 inhibitor before liver transplantation|
62307946|NCT01868269|OTHER|Dexamethasone Cyclophosphamide Rituximab|
62307947|NCT00043225||Cystic Fibrosis|Cystic Fibrosis patients
62462442|NCT05411926||The group without receiving PD-1 / PD-L1 inhibitor before liver transplantation|
62462443|NCT05908864||IV Magnesium Sulfate|
62462444|NCT05908864||Inhaled Magnesium Sulfate|
62462445|NCT05908864||Control group|
62462446|NCT00743548|ACTIVE_COMPARATOR|1|Interdental brush (IB), the intervention is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
62654285|NCT06026397|EXPERIMENTAL|Cohort 1|Participants will receive dose A of SK10 (n=6) or placebo (n=2)
62089228|NCT02787538|ACTIVE_COMPARATOR|Control group (Online medication guide)|The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.
62089229|NCT02803840|OTHER|Experimental|DLBCL patients with indication for palliative radiotherapy
62089230|NCT06685107|ACTIVE_COMPARATOR|Standard of Care (SOC)|Analgesia as determined by the treating physician
62089231|NCT06685107|ACTIVE_COMPARATOR|Virtual Reality (VR) + Standard of Care (SOC)|Analgesia as determined by the treating physician and Virtual Reality experience that will use a geriatric-focused VR platform that has age appropriate VR content and will run for approximately 5-10 minutes
62089232|NCT06080217|EXPERIMENTAL|study group|"The patients were lying in the lithotomy position with the streTched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average."
62089233|NCT06080217|SHAM_COMPARATOR|placebo group|"The patients were lying in the lithotomy position with the streched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe) . A capacitive probe in the free treatment / power control program was used, with NO electricity was released to the bladder for 20 minutes"
62287912|NCT04691102||Parkinson Disease group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
62287913|NCT04691102||Multiple Sclerosis group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
62287914|NCT04691102||Healthy subjects groups|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
62287915|NCT01050114|OTHER|ARM 1: onaBoNT-A injection + placebo|onaBoNT-A 200 U (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and placebo oral capsule daily
62287916|NCT01050114|OTHER|ARM 2: Placebo injection + oxybutynin ER|Placebo injection (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and oxybutynin ER 10 mg capsule daily
62307948|NCT01215318|EXPERIMENTAL|Modified vaginal tampons|Patients using modified vaginal tampons during FDG PET/CT
62307949|NCT01215318|PLACEBO_COMPARATOR|Unmodified vaginal tampons|Patients using unmodified vaginal tampons during FDG PET/CT
62307950|NCT00677781||F64|We investigate a cohort of 20 consecutive patients undergoing hepatic or pancreatic surgery (Pilot study)
62654286|NCT06026397|EXPERIMENTAL|Cohort 2|Participants will receive dose B of SK10 (n=6) or placebo (n=2)
62654287|NCT06026397|EXPERIMENTAL|Cohort 3|Participants will receive dose C of SK10 (n=6) or placebo (n=2)
62654288|NCT04009382|EXPERIMENTAL|Baduanjin|This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
62654289|NCT04009382|ACTIVE_COMPARATOR|Cognitive Fitness Program|This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
62654290|NCT03980223|EXPERIMENTAL|Doxy PEP|Doxycycline 200mg in addition to standard of care STI testing and treatment
62654291|NCT03980223|NO_INTERVENTION|Control|The control arm will consist of standard of care STI testing and treatment
62654292|NCT00676884|EXPERIMENTAL|1|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
62654293|NCT00676884|PLACEBO_COMPARATOR|2|placebo control
62654294|NCT04781062|EXPERIMENTAL|Breast Cancer Stage T1 Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed T1 breast cancer, patients will undergo a second peripheral blood and urine collection after primary breast cancer surgery."
62287917|NCT06091644|OTHER|Evaluation of device performances in normal and difficult airway management|"Each endotracheal intubation (ETI) attempt could enhance the participant's experience in the next attempt. Hence, the order of use of ETI devices was randomized to avoid experience-based bias. Six subgroups were needed to determine the order in which the SMSS would use the devices based on a permutation of three because three ETI devices were planned to be used in total. Accordingly, participants were randomized into six groups using the Random Team Generator.~Six experiment stations were set up. Normal airway manikins (NAMs) were used in the first three stations, and difficult airway manikins (DAMs) were used in the subsequent three. The interventions were to be conducted by the participants using NAMs first, followed by DAMs in the predetermined randomization order. Participants were assisted by an experienced assistant researcher in ETI during their attempts to extend the ETT, who also check the intubation accuracy with a bag valve mask (BVM) at the end of the intervention."
62654295|NCT04781062|ACTIVE_COMPARATOR|Benign Breast Lesion Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed benign lesion, no other samples will be collected."
62089234|NCT04512742|OTHER|Leishmania infected-Phlebotomus duboscqi human challenge|There is no clear indication in the medical literature to determine which of the major sand fly vectors of Leishmania major - Phlebotomus papatasi or Phlebotomus duboscqi, will be most effective at transmitting infection to a human host. Both species have a similar mode of feeding and can support L. major development. In our previous study, FLYBITE, no significant difference in biting rates on humans was observed. Based on pre-clinical data , Phlebotomus duboscqi was determined to be the lead candidate for use in this study. If all the 6 participants have developed lesions within the 6-month follow up after Leishmania challenge, the challenge phase of the study is completed. If only 5 participants have developed lesions, then a further 6 participants will undergo Leishmania challenge by P. duboscqi. If only 4 or less subjects in the first cohort develop lesions, then the investigators will switch vector to P. papatasi and a further 6 subjects will undergo Leishmania challenge.
62089235|NCT04921995|EXPERIMENTAL|Experimental|"Main group: Patients will be given first line tislelizumab plus investigator's choice chemotherapy, with re-irradiation postponed or omitted.~Subgroup: For patients that progressed after exposure to another PD-1 antibody, tislelizumab rechallenge combined with either low dose SBRT or low dose gemcitabine and metronomic capecitabine is accepted as a second subgroup."
62089236|NCT04435886|EXPERIMENTAL|Probiotic group|A multi-strain probiotic
62089237|NCT04435886|PLACEBO_COMPARATOR|Placebo group|Identical placebo
62089238|NCT05761444|EXPERIMENTAL|Eze/Ato: Ezetimibe/Atorvastatin|Participants will receive ezetimibe/atorvastatin 10/40 mg QD from Visit 2 (Day 1) to Visit 3 (Week 6). If the LDL-C target is reached (LDL-C \< 55 mg/dL) at Visit 3, maintain the dose to Visit 4 (Week 12). If the LDL-C target level is not reached at Visit 3, dose is increased to ezetimibe/atorvastatin 10/80 mg QD from Visit 3 to Visit 4.
62287918|NCT02195492||Synvisc®|
62462447|NCT00743548|PLACEBO_COMPARATOR|2|Dental floss (DF), the positive control, is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
62462448|NCT03446248|ACTIVE_COMPARATOR|Fetal Acoustic Stimulator|Participants in this group will receive fetal vibroacoustic stimulation with the Corometrics-146 device first, followed by the mobile phone application second.
62462449|NCT03446248|EXPERIMENTAL|Mobile Phone Application|Participants in this group will receive fetal vibroacoustic stimulation with the mobile phone application first, followed by the Corometrics-146 device second.
62462450|NCT04257474||Assessing Health Services Utilization Model (HSUM)|150 women with a high lifetime breast cancer risk will be recruited from mammography and primary care clinics. Researchers will assess HSUM factors influencing screening breast MRI utilization. Results will identify participant-level HSUM factors significantly associated with screening outcomes.
62287919|NCT00748748|EXPERIMENTAL|1|Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
62287920|NCT06202573|ACTIVE_COMPARATOR|group1A|patients who have a step counter and we do not motivate them to walk
62654296|NCT04745351|EXPERIMENTAL|Remdesivir (RDV)|Participants will receive continued Standard of Care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg from Day 2 up to Day 5.
62089239|NCT05761444|ACTIVE_COMPARATOR|Ato: Atorvastatin|Participants will receive atorvastatin 40 mg QD from Visit 2 (Day 1) to Visit 3 (Week 6). If the LDL-C target is reached (LDL-C \< 55 mg/dL) at Visit 3, maintain the dose to Visit 4 (Week 12). If the LDL-C target is not reached at Visit 3, dose is increased to atorvastatin 80 mg QD from Visit 3 to Visit 4.
62089240|NCT02253238|OTHER|Standard of Care Group|Surveys administered in person or by telephone interview and are audio-recorded.
62287921|NCT06202573|ACTIVE_COMPARATOR|Group 1B|patients who have a step counter, who do not motivate us to walk, and who will apply ice only on the 1st day after surgery
62462451|NCT04257474||Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi-structured qualitive interviews exploring factors impacting utilization of screening breast MRI
62462452|NCT01653353|EXPERIMENTAL|Entire group|A peer-applied guideline will be applied to the physicians.
62462453|NCT01055899|EXPERIMENTAL|Dose 1|First dose of SC REGN88
62462454|NCT01055899|EXPERIMENTAL|Dose 2|Second dose of SC REGN88
62462455|NCT01055899|EXPERIMENTAL|Dose 3|Third dose of SC REGN88
62654297|NCT04745351|PLACEBO_COMPARATOR|Placebo|Participants will receive continued SOC therapy together with RDV matching placebo on Day 1 followed by RDV matching placebo from Day 2 up to Day 5.
62654298|NCT04932109||Healthy Group|
62654299|NCT04932109||Hand Injuries Group|
62654300|NCT04932109||Healthcare professional|Clinical healthcare professionals who specialized in orthopedic, rehabilitation, hand anatomy, musculoskeletal ultrasound and so on
62654301|NCT03955315|EXPERIMENTAL|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells)
62654302|NCT03955315|EXPERIMENTAL|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
62654303|NCT03955315|SHAM_COMPARATOR|Sham|Sham needle puncture (outside disc)
62654304|NCT04184141|EXPERIMENTAL|alprazolam|
62654305|NCT04184141|EXPERIMENTAL|hydroxyzine|
62089241|NCT02253238|EXPERIMENTAL|CYCORE Group + Standard of Care|"Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer).~Surveys administered in person or by telephone interview and are audio-recorded."
62089242|NCT03795779|EXPERIMENTAL|CLL1-CD33 cCAR T cells|CLL1-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs
62089243|NCT00514072|EXPERIMENTAL|Arm I|Patients receive ONY-P1 vaccine with BCG intradermally on days 1 and 15. Patients then receive ONY-P1 vaccine alone on day 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
62089244|NCT00514072|PLACEBO_COMPARATOR|Arm II|Patients receive placebo vaccine intradermally on days 1, 15, and 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
62654306|NCT04184141|PLACEBO_COMPARATOR|control|
62654307|NCT05181072|EXPERIMENTAL|Enhanced in-person peer-motivation|This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
62654308|NCT05181072|EXPERIMENTAL|Virtual peer-motivation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual.
61905057|NCT02036151|EXPERIMENTAL|Experimental, control|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
62089245|NCT01379235|EXPERIMENTAL|Intervention group|Intervention group: will receive 12 weeks of pilatis exercise 3 times a week.
62089246|NCT01379235|OTHER|control group|The control group will be offered the same intervention (pilatis exercise) at the end of the study period.
62462456|NCT05527678||5 years ICU survivors|Survivors 5 years after ICU and who participated in the Promorea1 study will be contacted to assess their quality of life.
62462457|NCT03635359||positive for fetal aneuploidy|
62462458|NCT03635359||negative for fetal aneuploidy|
62089247|NCT02130492|EXPERIMENTAL|FDG arm|Patients will receive increasing doses of FDG.
62089248|NCT01837043|EXPERIMENTAL|Belatacept|Subjects will be converted from standard of care CNI therapy to Belatacept 10 mg/kg IV on post renal transplant Day 7 (+/- 3 days). As suggested in the package insert for de novo dosing, further dosing of belatacept will be given as 10 mg/kg IV at weeks 2, 4, 8 and 12 then 5 mg/kg at week 16 and then every 4 weeks (+/- 5 days) through week 52. CNI will be stopped during the first belatacept infusion.
62089249|NCT01837043|ACTIVE_COMPARATOR|Calcineurin Inhibitor|Patients randomized to this arm will remain on the current CNI as prescribed by post-transplant standard of care therapy.
62089250|NCT00514007|EXPERIMENTAL|OSI-906 QD|Once per day
62089251|NCT00514007|EXPERIMENTAL|OSI-906 BID|Twice per day
62119925|NCT04795544|EXPERIMENTAL|cuff inflation by the residual volume|"LMA will be inserted with the initial inflating volume correspondent to residual volume group (RV group):~volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 mL syringe without plunger is connected to the laryngeal cuff for 5 minutes"
62119926|NCT04795544|EXPERIMENTAL|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group)
62119927|NCT04795544|PLACEBO_COMPARATOR|unchanged cuff inflation volume|LMA will be inserted unchanged (NV group): LMA is unpacked and used without inflating or deflating the cuff.
62287922|NCT06202573|ACTIVE_COMPARATOR|group 2|without step counter (only photos will be requested)
62462459|NCT02648880|EXPERIMENTAL|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
62654309|NCT05181072|NO_INTERVENTION|Self-help/Control|The participants in the control group will receive the services already in place, including a brief motivation enhancement session.
62654310|NCT03747003||HIV-infected male patients|Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided
62654311|NCT05262101|EXPERIMENTAL|TQB2858 injection|TQB2858 injection (1800mg intravenous(iv), on day 1 of every 3 weeks)
62654312|NCT00712920|PLACEBO_COMPARATOR|1|Placebo
62654313|NCT00712920|EXPERIMENTAL|2|0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
62119928|NCT01505881|EXPERIMENTAL|Dabigatran etexilate|Patient dose determined by dose allocated in 1160.113 and CrCl levels
62654314|NCT00712920|EXPERIMENTAL|3|0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks
62654315|NCT03815513|EXPERIMENTAL|cases|Patient with spontaneous intracerebral hemorrhage
62654316|NCT03815513|EXPERIMENTAL|controls|Healthy control without history of symptomatic cerebrovascular diseases
62654317|NCT04068532|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to BIIB104 on Days 1-4 in treatment periods 1 or 2.
62654318|NCT04068532|EXPERIMENTAL|BIIB104|Participants will receive BIIB104 on Days 1-4 in treatment periods 1 or 2.
62654319|NCT05604313|EXPERIMENTAL|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC)
62654320|NCT05604313|NO_INTERVENTION|Do-as-usual|On the test day (crossover study), participants will play with the usual preferred chin and shoulder rest.
62654321|NCT03749200|EXPERIMENTAL|Obemat2.0 Intervention Group|Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
62654322|NCT03749200|ACTIVE_COMPARATOR|Control Group|Control Intervention: regular practise in primary care (11 individual monthly visits) Duration: 12 months (+3 months). Setting: Primary care centers. Providers: standard pediatritians and nurses Children and their families receive the usual recommendations conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity. At visits, the family receive explanations about carrying out a balanced diet, divided into 5 meals, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports regular practise is recommended. Monthly visits are organized in which weight and height are measured and compliance with advice is reviewed.
62654323|NCT01813175|ACTIVE_COMPARATOR|Intervention Group I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
62654324|NCT01813175|ACTIVE_COMPARATOR|Interventional Group II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
62654325|NCT01813175|PLACEBO_COMPARATOR|Control Group|Regular non-hydrolysed cow's milk based infant formula
62654326|NCT01813175|NO_INTERVENTION|Reference Group|Exclusively breast-fed infants
62654327|NCT05567341|EXPERIMENTAL|RIC|On the right upper extremity a blood pressure cuff is inflated to 200mmHg for 4x5min at the beginning of the surgery
62654328|NCT05567341|SHAM_COMPARATOR|Control|On the right upper extremity a blood pressure cuff is inflated to 0mmHg for 4x5min at the beginning of the surgery
62654329|NCT01140906|PLACEBO_COMPARATOR|Placebo|
62654330|NCT01140906|EXPERIMENTAL|Vortioxetine: 15 mg|
61905058|NCT02036151|ACTIVE_COMPARATOR|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
62462460|NCT02648880|ACTIVE_COMPARATOR|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
62654331|NCT01140906|EXPERIMENTAL|Vortioxetine: 20 mg|
62654332|NCT01140906|OTHER|Duloxetine: 60 mg|Active Reference
62654333|NCT05884580|EXPERIMENTAL|Participants receiving treatment with the Neuflo BPH Treatment System.|
62654334|NCT02948400|EXPERIMENTAL|Google Cardboard virtual environment|pedestrian safety training using the Google Cardboard device and delivery of a pedestrian virtual environment by mobile smartphone. Note that children in this arm will be trained using an immersive virtual environment delivered by smartphone, which is different from the other arm that is trained using a semi-immersive virtual environment delivered in a kiosk. The intervention is pedestrian safety training for both arms.
61905059|NCT04303728|EXPERIMENTAL|Muscle ultrasound|Muscle ultrasound will be performed for the patient on admission and at 1-2 months from inpatient rehabilitation.
61905060|NCT02553252|EXPERIMENTAL|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
62119929|NCT01505881|ACTIVE_COMPARATOR|warfarin|warfarin doses to maintain INR levels
62654335|NCT02948400|ACTIVE_COMPARATOR|semi-immersive virtual environment|pedestrian safety training using a semi-immersive virtual pedestrian environment kiosk. Note that children in this arm will be trained using a semi-immersive virtual environment delivered in a kiosk, which is different from the other arm that is trained using an immersive virtual environment delivered by smartphone. The intervention is pedestrian safety training for both arms.
62654336|NCT04013464|EXPERIMENTAL|MDD and Health Control|MDD in open label
62654337|NCT04800627|EXPERIMENTAL|Treatment (pevonedistat, pembrolizumab)|Patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62654338|NCT05922332|EXPERIMENTAL|Rich medium chain fatty acid milk powder group|This group will be fed milk powder rich in medium-chain fatty acids. The MCT content of formula milk is 39%, and the total energy is 68kcal/100ml.
62654339|NCT05922332|ACTIVE_COMPARATOR|Regular milk powder group|This group will be fed regular milk powder.The MCT content of formula milk is less than 30%, and the total energy is 67kcal/100ml.
62119930|NCT06554769|EXPERIMENTAL|Non-Rigid connection|side received a non-rigid 0.014-inch St.St ligature ligating the upper second premolar to the miniscrew.
62089252|NCT03190174|EXPERIMENTAL|Arm 1|"This is an open label, dose-seeking phase 1b study using a defined dose of nivolumab and escalating doses of Nab-Rapamycin (ABI-009) given intravenously.~I. Dose Escalation Phase 1 Part of Study: The study will employ the standard cohort of three design. No intra-patient dose escalation will take place.~II. Expansion Phase 1b Part of Study: Following dose escalation, an additional 22-28 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs."
62654340|NCT02321527|EXPERIMENTAL|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™). Ultrasound images and videos of tumor and lymph nodes in underarm area taken. Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery. Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
62654341|NCT04161196|ACTIVE_COMPARATOR|patients with post - tonsillectomy suturing tonsil pillars|
62654342|NCT04161196|PLACEBO_COMPARATOR|patients without post - tonsillectomy suturing tonsil pillars|
62654343|NCT04398472|ACTIVE_COMPARATOR|Challenge|"Participants in the challenge will be asked to complete four activities over the next four weeks to address loneliness and social isolation in their communities.~The activities will involve doing an activity with people in their neighbourhood. These activities have been selected based on being positive, engaging and feasible to the average individuals. An example of the type of activities is having a conversation with a neighbour on the phone or via video chat and safely checking in on someone who is elderly or living alone. All activities will adhere to the relevant country or states health department's safety recommendations and laws during COVID-19.~Hypothesis 1 (H1). There will be a reduction in the primary outcome, loneliness in participants assigned to the Nextdoor KIND Challenge groups compared to the waitlist control group post the 4-week intervention"
62654344|NCT04398472|NO_INTERVENTION|Waitlist|
62654345|NCT01773369|EXPERIMENTAL|Early treatment group|These children will undergo the intervention (i.e., early leg training) shortly after recruitment. Measures will be taken before, during and after the intervention.
62654346|NCT01773369|EXPERIMENTAL|Delayed treatment group|These children will undergo the intervention (delayed leg training) after a delay of \~3 months, during which outcome measures will be taken so that they can serve as a control for the early treatment group. Their intervention is identical to the Immediate treatment group.
62654347|NCT01773369|NO_INTERVENTION|Control group|These children will be recruited close to the age of 4 years old, and will only undergo gait analysis and GMFM-66 scoring.
62654348|NCT01773369|EXPERIMENTAL|Parent training group|These children will undergo the intervention (i.e., parent leg training) shortly after recruitment. Parents will be trained to provide the intervention instead of a physical therapist. Measures will be taken before, during and after the intervention.
62654349|NCT01555593|EXPERIMENTAL|COPD FEV1<70%pred feNO Cardioline Exp'air|COPD subjects with FEV1\<70% of predicted value and Forced Expiratory Volume Forced to Forced Vital Capacity ratio (FEV1/FVC) less than 88% (males)or less than 89% (females) of Low Levels of Normality (LLN) entering the respiratory rehabilitation unit will undergo multiflow feNo measure with Cardioline Exp'air by Medi-soft - Sorinnes (B)
62654350|NCT01361737||preeclampsia|"* Control group: 86 healthy women not developing preeclampsia (PE)~* Case group: 43 women developing PE"
62654351|NCT01820832|EXPERIMENTAL|Calcitriol|General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
62654352|NCT01820832|NO_INTERVENTION|Control|General treatments.
62089253|NCT06037252|EXPERIMENTAL|Tirzepatide High Dose 1|Participants will receive tirzepatide subcutaneously (SC).
62089254|NCT06037252|EXPERIMENTAL|Tirzepatide High Dose 2|Participants will receive tirzepatide SC.
62654353|NCT00638430||1|low myopic group
62654354|NCT00638430||2|moderate myopic group
62654355|NCT04800497||Patients resected for hepatocellular carcinoma|Surgical resection, peripheral blood sampling
62654356|NCT04800497||Patients who underwent surgery for benign diseases|Surgical resection, peripheral blood sampling
62654357|NCT06197490||Patient with cystic fibrosis, eligible for KAFTRIO therapy|Patient with cystic fibrosis, eligible for KATRIO, over 18 years old.
62654358|NCT00789165|EXPERIMENTAL|Quinidine|Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.
62089255|NCT06037252|ACTIVE_COMPARATOR|Tirzepatide|Participants will receive tirzepatide SC.
62089256|NCT06037252|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62089257|NCT04636086|EXPERIMENTAL|Test treatment|Test Treatment: Ampoule for enteral use containing 25,000 IU/mL of cholecalciferol taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
62654359|NCT00789165|ACTIVE_COMPARATOR|no therapy|Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
62654360|NCT00193648|ACTIVE_COMPARATOR|1|Avandia (rosiglitazone)
62089258|NCT04636086|PLACEBO_COMPARATOR|Placebo treatment|Placebo Treatment: Ampoule of placebo for enteral use containing excipient only taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
62654361|NCT00193648|ACTIVE_COMPARATOR|2|Humira (adalimumab)
62654362|NCT01543854|EXPERIMENTAL|RLX030|RLX030 as intravenous infusion for 20 hours
62654363|NCT01543854|PLACEBO_COMPARATOR|Placebo|Matching placebo as intravenous infusion for 20 hours.
62654364|NCT01703468|ACTIVE_COMPARATOR|Oxcarbazepine then Trileptal|600 mg suspension
62654365|NCT01703468|ACTIVE_COMPARATOR|Trileptal then Oxcarbazepine|600 mg suspension
62462461|NCT04192006|ACTIVE_COMPARATOR|Conventional|Jig-based procedure
62089259|NCT03801720|NO_INTERVENTION|Control Group|Utilize standard practice for obtaining a CCU in pre-continent children; this consists of cleaning the GU area with betadine and waiting 5 minutes for micturition to occur.
62089260|NCT03801720|EXPERIMENTAL|Experimental Group|Consists of cleaning the GU area with betadine followed by using an ultrasound probe to apply cool ultrasound gel and subprapubic pressure to the patient to induce micturition.
62736368|NCT05087368|EXPERIMENTAL|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 9|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 9: (N=50) Day 1 (boost) - ChAdOx1-S;"
62089261|NCT06398457|EXPERIMENTAL|Daratumumab-SC followed by standard of care DSA desensitization and alloBMT|Darzalex Faspro (Daratumumab and hyaluronidase-fihj) will be administered subcutaneously (SC) weekly (every 7 day +/- 1 day) for a total of four doses followed by standard desensitization regimen and allogeneic stem cell transplant.
62089262|NCT02015533|EXPERIMENTAL|CR8020|
62089263|NCT02015533|PLACEBO_COMPARATOR|Placebo|
62089264|NCT03256266||healthy controls|healthy controls
62089265|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
62089266|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
62089267|NCT05960279||Training group|The head CT findings from this patient group will be used to teach the MD100 how to interpret its scan of the patients.
62089268|NCT05960279||Testing group|Once sufficient training data has been obtained, subsequent head CT findings from patients enrolled into the study will be used to test the accuracy of the MD100
62089269|NCT01744496|EXPERIMENTAL|Rotigotine|Rotigotine Transdermal Patches
62089270|NCT01744496|PLACEBO_COMPARATOR|Placebo|Placebo Transdermal Patches
62089271|NCT03423264|EXPERIMENTAL|Gabapentin|Participants randomized to this arm will receive gabapentin beginning on evening of the first day of radiation treatment at a dose of 600 mg. Gabapentin will continue to be taken twice a day (morning and evening) for the next 4 days of radiation treatment at increasing doses (up to 900 mg). Participants will continue to receive standard best supportive care medications as per their treating physician's recommendation.
62287923|NCT06202573|ACTIVE_COMPARATOR|group 3|patients with step counters whom we motivate to take at least 5000 steps
61905061|NCT02553252|NO_INTERVENTION|wait list control (WLC)|Participants will receive training in SKY after 12 weeks have passed since the baseline assessment.
62089272|NCT03423264|NO_INTERVENTION|Supportive Care Only|Participants will receive standard best supportive care medications as per their treating physician's recommendation.
62089273|NCT01004263|EXPERIMENTAL|Rizatriptan|Rizatriptan benzoate
62287924|NCT06202573|ACTIVE_COMPARATOR|group 4|patients with step counters whom we motivated to take at least 10000 steps
62287925|NCT03646448|EXPERIMENTAL|Intervention group|Counseling based on Motivational Interviewing and elements of Cognitive Behavioral Therapy
62287926|NCT03646448|NO_INTERVENTION|Control group|Control group receiving a booklet on problematic Internet use
62089274|NCT00983619|EXPERIMENTAL|Part A-MEDI-551 0.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62287927|NCT05869006|NO_INTERVENTION|Control Group|"No attempt was made. Measurement tools were applied simultaneously with the placebo control group and intervention group before, after and during the follow-up.~* pretest~* final test~* Evaluated by follow-up measurements."
62462462|NCT04192006|EXPERIMENTAL|Robotic arm-assist|Mako robotic-arm assist based procedure
62462463|NCT04929457||Individuals screened for Familial Hypercholesterolemia|Individuals participating in diagnostic activities in the digiphysical health care screening program for Familial Hypercholesterolemia and have provided informed consent are included in the cohort.
62462464|NCT00719316|EXPERIMENTAL|Group 1|Patients receive Aliskiren 300mg for 6 weeks
62462465|NCT00719316|NO_INTERVENTION|Group 2|4 weeks no antihypertensive medication
61905062|NCT03371888|EXPERIMENTAL|PRP injections|Intramuscular injection of Platelet-Rich Plasma into the masseter and temporalis muscle
62287928|NCT05869006|PLACEBO_COMPARATOR|Placebo Control Group|"A symbolic intervention consisting of six sessions, which was different from the content of the sessions applied to the intervention group, did not have any curative and active content, and was carried out simultaneously with the intervention group as the application time, was applied.~Sessions lasted approximately one hour. It was carried out once a week. It was completed in six weeks. In the sessions, the problems faced by nursing students due to distance education during the Covid-19 pandemic, professional difficulties, experiences, and issues related to their professional goals were discussed.~The effectiveness of the semi-structured sessions;~* pretest~* symbolic group work~* final test~* evaluated by follow-up measurements."
62462466|NCT01393678|EXPERIMENTAL|PENNEL|2cap T.I.D
62736369|NCT05087368|EXPERIMENTAL|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 10|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 10: (N=50) Day 1 (boost) - CoronaVac."
61905063|NCT03371888|PLACEBO_COMPARATOR|0,9% NaCl injections|Intramuscular injection of 0,9% NaCl into the masseter and temporalis muscle
61905064|NCT04229732|EXPERIMENTAL|ClearMate Intervention|Participants undergo passive isocapnic hyperventilation via the ClearMateTM device and have regular venous blood samples obtained to measure ethanol clearance kinetics.
61905065|NCT04229732|NO_INTERVENTION|Supportive Management|Participants receive standard of care, supportive management, for alcohol intoxication, having regular venous blood samples obtained to measure ethanol clearance kinetics.
61905066|NCT00514852|EXPERIMENTAL|1|Carboxymethylcellulose and Glycerin based artificial tear
62462467|NCT01393678|ACTIVE_COMPARATOR|NISSEL|"NISSEL~BDD (biphenylmethyl dicarboxylate) ................25mg~2cap T.I.D"
62462468|NCT01700621|EXPERIMENTAL|measles-rubella and rotavirus vaccines|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
62462469|NCT01700621|ACTIVE_COMPARATOR|measles-rubella vaccine|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age
62462470|NCT02274129|EXPERIMENTAL|Use of Healing cap II|Single arm study using a new healing cap as intervention
62462471|NCT05414760|ACTIVE_COMPARATOR|Womed Leaf group|Womed Leaf is inserted immediately after completion of the endometrial ablation.
62462472|NCT05414760|NO_INTERVENTION|No adhesion prevention group|Standard of care: no IUA prevention, no placebo after ablation
62462473|NCT00259012|ACTIVE_COMPARATOR|Low dose|
62462474|NCT00259012|ACTIVE_COMPARATOR|High dose|
62462475|NCT04840264|EXPERIMENTAL|A (First-Line Therapy)|Docetaxel 25 mg/square metre, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85 mg/square metre, ivdrip 180 min, D1, D15; 5Fu 1200 mg/square metre, civ 24 hours, D1, D8, D15; Repeat every 4 weeks.
62462476|NCT04840264|EXPERIMENTAL|B (Second-Line Therapy)|Docetaxel 25 mg/square metre, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85 mg/square metre, ivdrip 180 min, D1, D15; 5Fu 1200 mg/square metre, civ 24 hours, D1, D8, D15; Repeat every 4 weeks.
62462477|NCT04840264|EXPERIMENTAL|C (Third- or Later-Line Therapy)|Docetaxel 25 mg/square metre, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85 mg/square metre, ivdrip 180 min, D1, D15; 5Fu 1200 mg/square metre, civ 24 hours, D1, D8, D15; Repeat every 4 weeks.
62462478|NCT00803764|ACTIVE_COMPARATOR|Test Product|
62462479|NCT00803764|ACTIVE_COMPARATOR|Reference Product|
62462480|NCT00817193|EXPERIMENTAL|Physical Activity|Participants will begin to participate in walking sessions and strength building classes that will be offered at each location. Participants will be asked to attend a minimum of 1 strength class per week, with a target of doing 150 minutes of moderate exercise each week. The exercise classes will include stretching and counseling to help participants understand and address the barriers to becoming and staying involved in regular exercise.
62462481|NCT00817193|ACTIVE_COMPARATOR|Wellness|Participants will begin to participate in a wellness program that will meet at each site twice per month. The first meeting will involve a lecture or presentation on a wellness-related topic. The second meeting will follow-up on concepts that were introduced in the first meeting, and will also to provide participants an opportunity to share experiences. Participants will be asked to attend both wellness sessions each month for whole year that the program is running.
62462482|NCT02830386||LVIS stents group|The patients with ruptured intracranial saccular aneurysm wil be treated with a LVIS stent without coils.
61905067|NCT00514852|ACTIVE_COMPARATOR|2|Carboxymethylcellulose
61905068|NCT06095648|ACTIVE_COMPARATOR|Usual treatment arm|Babies who are randomized to this arm will receive the usual treatment of 15ml/kg platelets when they are getting a platelet transfusion
62462483|NCT00893464|EXPERIMENTAL|IXAZOMIB|
62462484|NCT01722877|EXPERIMENTAL|JetStream Atherectomy|Jetstream NAVITUS System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic disease and thrombus in peripheral vasculature.
62462485|NCT01492894|ACTIVE_COMPARATOR|50% decrease in calcineurin inhibitor|
62462486|NCT01492894|ACTIVE_COMPARATOR|Rapamune|
62462487|NCT04952558||Cross sectional observational study|"Cross sectional observational study will be conducted among 700 patients of Egyptian inflammatory bowel diseased patients for different regions~Detailed history will be taken from all included patients focus on~* age ,sex , special habit ,residence .~* education level -socioeconomic status~* type of the inflammatory bowel disease~* lag time for reaching the proper diagnosis of inflammatory bowel disease which definite as time from the first symptoms presentation to reaching definite diagnosis~* symptoms that causing patients seeking medical advice~* number of Inflammatory bowel diseased patients referred for first time from surgeons~* number of patients have perianal symptoms~* number of patients have previous history of appendicectomy"
62462488|NCT05480657|EXPERIMENTAL|Single Arm AT-1501|Single-arm, open-label trial
62736370|NCT03802630|EXPERIMENTAL|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
62287929|NCT05869006|EXPERIMENTAL|Intervention Group|"A semi-structured group study consisting of six sessions based on interpersonal relations supported by the designed SIA instrument was applied. Sessions lasted approximately one hour. One session per week was administered. It was completed in six weeks. The initiatives applied in the sessions were implemented based on Peplau's theory of Interpersonal Relations. Group work was supported by the SIA instrument and music therapy techniques were used. In addition, positive psychology and psychological well-being literature were examined in the creation of initiatives. The effectiveness of semi-structured sessions;~* pretest~* group interaction study consisting of six sessions~* final test~* evaluated by follow-up measurements."
62287930|NCT04629560|EXPERIMENTAL|Miracle Fruit Arm|Patient will be randomly assigned, by a computer generated randomization, to receive one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures.
61905069|NCT06095648|EXPERIMENTAL|Intervention arm|Babies who are randomized to this arm will receive the experimental treatment of 5ml/kg platelets when they are getting a platelet transfusion
62287931|NCT04629560|NO_INTERVENTION|Control Arm (supportive measures only)|standard of care supportive measures
62462489|NCT05621265|EXPERIMENTAL|Intervention|Automated Text messaging for sleep behavior change
62462490|NCT05621265|NO_INTERVENTION|Control|Control, Traditional physical therapy only
62462491|NCT01855932|EXPERIMENTAL|Technology Supported|
62462492|NCT01244126|ACTIVE_COMPARATOR|IM morphine|0.1 mg/kg morphine IM
62462493|NCT01244126|ACTIVE_COMPARATOR|IV morphine|0.1 mg/kg morphine IV
62462494|NCT01244126|ACTIVE_COMPARATOR|fentanyl IN|Intranasal fentanyl 2 mcg/kg IN
62462495|NCT04865952|EXPERIMENTAL|HA application (treatment group - HA)|periodontal surgery + HA application + buccal attached gingival (G) biopsies 24 hr after surgical procedure
62462496|NCT04865952|OTHER|NO HA application (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
62462497|NCT01454544|EXPERIMENTAL|ALK house dust mite tablet 6 DU|
62462498|NCT01454544|EXPERIMENTAL|ALK house dust mite tablet 12 DU|
62462499|NCT01454544|PLACEBO_COMPARATOR|Placebo|
62462500|NCT06031792|EXPERIMENTAL|Piezo endodontic surgery|Experimental: Piezo endodontic surgery The osteotomy will be applied under magnification with a surgical operating microscope (at the apical third of the root. Osteotomy will be done with the Piezosurgery touch
62462501|NCT06031792|EXPERIMENTAL|Conventional endodontic surgery|Experimental: Conventional endodontic surgery The osteotomy will be applied under magnification with a surgical operating microscope at the apical third of the root. Osteotomy will be done with air motor high speed hand-piece and round bur with copious irrigation
62462502|NCT00812266|EXPERIMENTAL|A|Topotecan + cisplatin
62462503|NCT00812266|ACTIVE_COMPARATOR|B|Etoposide + carboplatin
62462504|NCT04439396|PLACEBO_COMPARATOR|Control|Saline injection administered during surgical procedure
62462505|NCT04439396|EXPERIMENTAL|Low Dose (15mg) Toradol|15mg ketorolac (toradol) administered during surgery
62462506|NCT04439396|EXPERIMENTAL|High Dose (30mg) Toradol|30mg ketorolac (toradol) administered during surgery
62462507|NCT04227639|ACTIVE_COMPARATOR|T-piece trial|In patients assigned to control group all spontaneous breathing trials will be performed using T-piece trial.
62462508|NCT04227639|EXPERIMENTAL|Pressure-Support trial|In patients assigned to experimental group all spontaneous breathing trials will be performed with a pressure-support level of 8 cm H2O without positive end-expiratory pressure.
62462509|NCT06115369|EXPERIMENTAL|Medically Tailored Meals|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice daily prepared medically tailored meals (MTM). Study participants will be able to select choices for these from a large selection of health options. The study team will work with Season Health to create customizations to allow for the incorporation of patient dietary preferences. Study team members will assist patients in setting up their Season Health accounts.
62462510|NCT06115369|EXPERIMENTAL|Fresh Produce|We will work with Season Health, our food intervention partner to provide participants with weekly deliveries of a large box full of fresh produce and pantry staples. The study participants will be able to select choices for these from a large selection of health options. The study team will work with Season Health to create customizations to allow for the incorporation of patient dietary preferences. Study team members will assist patients in setting up their Season Health accounts.
62462511|NCT06115369|NO_INTERVENTION|Control arm|This control arm will receive dietary education only.
62462512|NCT05142995||Behcet disease|Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale SF36 questionnaire Epworth sleepiness scale Pittsburgh sleep quality index
62462513|NCT05142995||control|Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale SF36 questionnaire Epworth sleepiness scale Pittsburgh sleep quality index
62462514|NCT02193178|EXPERIMENTAL|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
62462515|NCT01083277|EXPERIMENTAL|variable ventilation|A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
61905071|NCT05811234||CAL/BDP PAD Cream:|Participants who have been prescribed CAL/BDP PAD cream treatment to manage plaque psoriasis of the scalp according to summary of product characteristic (SmPC) in routine clinical practice settings will be observed prospectively for up to 8-12 weeks.
61905072|NCT01714791|ACTIVE_COMPARATOR|Usual care|Patients following the outpatient cardiac rehabilitation program.
62287932|NCT01417754|OTHER|Toremifene|
61905073|NCT01714791|EXPERIMENTAL|Usual care and Osteopathic treatment|Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.
61905074|NCT04812847||Gram negative infection, MDR present|Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
62287933|NCT01576640|OTHER|Replapse Prevention Therapy|
62287934|NCT00363831|EXPERIMENTAL|1|Oxaliplatin
62287935|NCT03227367|EXPERIMENTAL|Test group|Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
62287936|NCT03227367|OTHER|control group|Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
62287937|NCT04929990|EXPERIMENTAL|Inpiratory and expiratory muscle training|The initial intensity of training was set on 30% of the MIP and MEP for inspiratory and expiratory muscle training, respectively. The intensity was adjusted to add 5% of resistance each week
62287938|NCT04929990|ACTIVE_COMPARATOR|Inspiratory muscle training|The initial resistance of the breathing trainer was also set on 30% of MIP, and the following adjustments were also in accordance to the protocol of the experimental group
62287939|NCT01873755|EXPERIMENTAL|asthma physical activity intervention|two schools will receive intervention
62462516|NCT01083277|OTHER|conventional ventilation|This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
62462517|NCT01139437|EXPERIMENTAL|Adults|Adults ages 18 to 49 years of age. Open label.
62462518|NCT01139437|EXPERIMENTAL|Seropositive children - vaccine|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving the HPIV2 vaccine.
62462519|NCT01139437|EXPERIMENTAL|Seronegative infants and children - low dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of the HPIV2 vaccine.
62462520|NCT01139437|EXPERIMENTAL|Seronegative infants and children - standard dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of the HPIV2 vaccine.
62462521|NCT01139437|PLACEBO_COMPARATOR|Seropositive children - placebo|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving a placebo.
62462522|NCT01139437|PLACEBO_COMPARATOR|Seronegative infants and children - low dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of placebo.
62462523|NCT01139437|PLACEBO_COMPARATOR|Seronegative infants and children - standard dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of placebo.
62462524|NCT04680364|EXPERIMENTAL|participants|to analyze the effects of 6-month ballroom dance (3 times/wk) on physical fitness and reaction time in twenty-four experienced older adults
62462525|NCT00915096||High Tumor Burden Follicular Lymphoma|
62462526|NCT02008565|PLACEBO_COMPARATOR|Placebo - Exercise plus Biofeedback|"Placebo and biofeedback intervention. Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
62462527|NCT02008565|EXPERIMENTAL|Loperamide - Exercise plus Biofeedback|"Loperamide and biofeedback intervention. Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
62462528|NCT02008565|PLACEBO_COMPARATOR|Placebo - Education Only|"Placebo and education (usual care). Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
62462529|NCT02008565|EXPERIMENTAL|Loperamide - Education Only|"Loperamide and education (usual care). Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
62089275|NCT00983619|EXPERIMENTAL|Part A-MEDI-551 1 mg/kg|Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62089276|NCT00983619|EXPERIMENTAL|Part A-MEDI-551 2 mg/kg|Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62089277|NCT00983619|EXPERIMENTAL|Part A-MEDI-551 4 mg/kg|Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62287940|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
62287941|NCT03047525|NO_INTERVENTION|control group|patients will just regularly chemotherapy
62287942|NCT03047525|EXPERIMENTAL|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
62287943|NCT04566367|ACTIVE_COMPARATOR|Standard White Light Imaging|In this group the participants will be examined by white light endoscopy first and secondly with blue laser imaging technique during the same gastroscopy.
62287944|NCT04566367|EXPERIMENTAL|Blue Light Imaging|In this group the participants will be examined by blue laser imaging technique first and secondly with standard white light during the same gastroscopy.
62089278|NCT00983619|EXPERIMENTAL|Part A-MEDI-551 8 mg/kg|Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62089279|NCT00983619|EXPERIMENTAL|Part A-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62089280|NCT00983619|EXPERIMENTAL|Part B-MEDI-551 6 mg/kg|Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62089281|NCT00983619|EXPERIMENTAL|Part B-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62287945|NCT05740774|EXPERIMENTAL|Tongue tumor resection|
62287946|NCT05755815|ACTIVE_COMPARATOR|Group A (RLB block)|Ultrasound-guided RLB block will be performed under strict aseptic precautions with patient turned to the lateral position.
62287947|NCT05755815|ACTIVE_COMPARATOR|Group B (Peritoneal block)|Peritoneal block will be performed under strict aseptic precautions before giving an incision for the ports, and at the end of surgery and before the removal of trocars
62287948|NCT04548557|NO_INTERVENTION|Control|They will not receive any intervention
62287949|NCT04548557|EXPERIMENTAL|IVIG group|They will reveive intravenous immunoglobulin therapy
62287950|NCT03996772|EXPERIMENTAL|Direct Oral Anticoagulant|"If the patient is randomized in this arm, a direct oral anticoagulant (DOAC) included:~* Direct thrombin inhibitor: Dabigatran~* Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban will be prescribed to the patient. Choice and dose of DOAC treatment as well as the use of concomitant medication during the study treatment will be at the Principal Investigator´s discretion within the spectrum of licensed doses labelled for stroke prevention in atrial fibrillation patients in Europe following the Summary of Product Characteristics."
62287951|NCT03996772|NO_INTERVENTION|No Anticoagulant|If the patient is randomized in this arm investigators will use their best judgment to decide upon the prescription of an antiplatelet drug of their choice or no such therapy
62287952|NCT01713192||Cardiac surgery|
62736371|NCT03802630|ACTIVE_COMPARATOR|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
62089282|NCT00983619|EXPERIMENTAL|Part B-MEDI-551 24 mg/kg|Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
62287953|NCT04420130|EXPERIMENTAL|Camrelizumab combined with ablation and chemotherapy|First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.
62287954|NCT04460755|ACTIVE_COMPARATOR|Control group|A group of participants that will be using toothpaste without tooth whitening ingredients.
62287955|NCT04460755|EXPERIMENTAL|Whitening toothpaste 1|A group of participants that will be using urea peroxide whitening toothpastes.
62462530|NCT06188091|ACTIVE_COMPARATOR|Intervention with active exercises for knee joint 2 times a day|Intervention group A does 1 active exercise to improve flexion and 1 active exercise to improve extension 2 times a day, 18 days in a row
62089283|NCT00983619|EXPERIMENTAL|Part C-MEDI-551 8 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
62089284|NCT00983619|EXPERIMENTAL|Part C-MEDI-551 12 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
62089285|NCT00983619|EXPERIMENTAL|Part D-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.
62089286|NCT06611722||intra-articular hip pain group|
62089287|NCT06611722||extra-articular hip pain group|
62089288|NCT06611722||intra-articular combined extra-articular hip pain group|
62089289|NCT04878172|EXPERIMENTAL|TempSure Firm Day 0 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 0 (within 24 hours after treatment).
62089290|NCT04878172|EXPERIMENTAL|TempSure Firm Day 10 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 10 (+/- 3 days) after treatment.
62089291|NCT04878172|EXPERIMENTAL|TempSure Firm Day 20 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 20 (+/- 3 days) after treatment.
62089292|NCT04878172|EXPERIMENTAL|TempSure Firm Day 30 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 30 (+/- 7 days) after treatment.
62287956|NCT04460755|EXPERIMENTAL|Whitening toothpaste 2|A group of participants that will be using hydrogen peroxide whitening toothpastes.
62089293|NCT04279964|EXPERIMENTAL|Boot Camp Translation|Intervention practices will undergo the Boot Camp Translation process.
62089294|NCT04279964|ACTIVE_COMPARATOR|Control|Control practice will behave as usual.
62089295|NCT06379893|EXPERIMENTAL|Voltaren Gel|Participants will use Voltaren Gel 1 percent (%) (in the US) or Voltaren Gel 1.16% or Voltaren Gel 2.32% (in the EU) topically, applied daily as per label and leaflet instructions for up to 21 days. Participants will be instructed to wear Actigraph device on the wrist as per label, leaflet or site-specific instructions post training throughout the day for up to 21 days.
62089296|NCT06487650|EXPERIMENTAL|sleep intervention|Participants in the intervention group will receive both the standardized usual care and the sleep intervention. The intervention consists of sleep education, health professional support, and counseling. The intervention will be delivered from pregnancy to postpartum for mothers and fathers.
62089297|NCT06487650|ACTIVE_COMPARATOR|Control|Participants in the control group will receive a perinatal health booklet in addition to the standardized usual care.
62089298|NCT04722224|EXPERIMENTAL|Intervention: Home-based pulmonary rehabilitation|Patients will be treated for 12 weeks. The intervention consists in a strategic mixture of home visits and phone calls. The program includes exercise training and the self-management educational program Living Well with COPD.
62089299|NCT05324982|PLACEBO_COMPARATOR|Placebo|Single acute administration of oral Placebo liquid (MCT oil).
62089300|NCT05324982|EXPERIMENTAL|Oral administration of 25mg CBG|Single acute administration of 25mg CBG suspended in MCT oil.
62089301|NCT05324982|EXPERIMENTAL|Oral administration of 50mg CBG|Single acute administration of 50mg CBG suspended in MCT oil.
62089302|NCT05324982|EXPERIMENTAL|Oral administration of 100mg CBG|Single acute administration of 100mg CBG suspended in MCT oil.
62287957|NCT04460755|EXPERIMENTAL|Whitening toothpaste 3|A group of participants that will be using whitening toothpastes that contain abrasive ingredients.
62287958|NCT04460755|EXPERIMENTAL|Whitening toothpaste 4|A group of participants that will be using whitening toothpastes that contain enzymes as whitening ingredients.
62287959|NCT04460755|EXPERIMENTAL|Whitening toothpaste 5|A group of participants that will be using toothpastes that contain an activated charcoal.
62287960|NCT03103893|EXPERIMENTAL|Rapamycin|Rapamycin
62287961|NCT04320524|EXPERIMENTAL|All subjects|
62287962|NCT05953636|OTHER|pre-dialytic|40 patients will receive oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 8 weeks 1 hour before the start of the session (pre-dialytic).
62089303|NCT05324982|EXPERIMENTAL|Oral administration of 200mg CBG|Single acute administration of 200mg CBG suspended in MCT oil.
62089304|NCT06330831|EXPERIMENTAL|Intensive, Group Based CIMT|The intensive, group based CIMT program lasted for 3 hours/day x 5 days/week x 4 weeks. Children wore a cast on their non-affected arm for 24 hours/day for 3 weeks. During the last week, the cast was removed to focus on bimanual skills. Occupational therapists ran and were present for every hour of the program. Both physical therapy and speech language pathology cotreated for 1 1/2 hours two times per week and either music, art, or adaptive martial arts occurred 1 hour per week. Interns and volunteers served as intervention assistants to maintain a 2:1 or 1:1 child to therapist/interventionist ratio. The same theme-based lesson plans were used for the 2-3-year-old program and the 4-6-year-old program. Each age group program offered spots for 3-6 children to attend per year except for 2020 when the programs were suspended due to COVID 19 pandemic.
62089305|NCT04212169|EXPERIMENTAL|MEDI3506 at dose level 1|Participant will receive multiple doses of MEDI3506 at dose level 1.
62089306|NCT04212169|EXPERIMENTAL|MEDI3506 at dose level 2|Participant will receive multiple doses of MEDI3506 at dose level 2.
62089307|NCT04212169|EXPERIMENTAL|MEDI3506 at dose level 3|Participant will receive multiple doses of MEDI3506 at dose level 3.
62287963|NCT05953636|OTHER|intra-dialytic|40 patients will receive oral protein nutritional supplement (ONS) for 8 weeks 2 hours after the start of the session (intra-dialytic).
62462531|NCT06188091|ACTIVE_COMPARATOR|Intervention with active exercises for knee joint 8 times a day|Intervention group B does 1 active exercise to improve flexion and 1 active exercise to improve extension 8 times a day, 18 days in a row
62089308|NCT04212169|PLACEBO_COMPARATOR|Placebo|Participant will receive multiple doses of Placebo
62287964|NCT05953636|OTHER|inter-dialytic|40 patients will receive oral protein nutritional supplement (ONS) for 8 weeks in non-dialysis days (inter-dialytic).
62287965|NCT00424398|EXPERIMENTAL|Bepreve|Bepotastine Besilate Ophthalmic Solution 1.5%
62287966|NCT00424398|PLACEBO_COMPARATOR|Placebo|sterile ophthalmic solution
62462532|NCT03347032|EXPERIMENTAL|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
62089309|NCT06693037||Trastuzumab combined with pertuzumab|The postoperative adjuvant regimen was trastuzumab combined with pertuzumab, and the planned treatment duration was 1 year
62089310|NCT06693037||T-DM1|The postoperative adjuvant regimen was T-DM1, and the planned treatment duration was 1 year
62287967|NCT00424398|EXPERIMENTAL|Bepotastine Besilate|sterile ophthalmic solution 1.0%
62287968|NCT02825121|EXPERIMENTAL|Monitoring Neuromuscular Blockade|Monitoring Neuromuscular Blockade the Flexor Hallucis and adductor of the thumb.
62287969|NCT05358132||ARM-ED group 1 - Acute toxicity group|Patients attending the Emergency Department with acute sedating drug toxicity
62287970|NCT05358132||ARM-ED group 2 - PSA group|Patients undergoing procedural sedation and analgaesia in the Emergency Department
62287971|NCT04061135|EXPERIMENTAL|Treatment|Parkinson's Disease Patients receiving DBS electrodes
62287972|NCT04061135|NO_INTERVENTION|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
62287973|NCT04610476|NO_INTERVENTION|Control group|Individual previous stable glucocorticoid/DMARD therapy is continued
62287974|NCT04610476|EXPERIMENTAL|Reduction group|Individual previous stable dosage of glucocorticoids/DMARDs will be stepwise reduced according to a predefined algorithm
62462533|NCT03347032|SHAM_COMPARATOR|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
61905075|NCT04812847||Gram negative infection, MDR absent|Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
61905077|NCT04693052||Mental Health patients starting pre-COVID|Patients receiving mental health care prior to and during the COVID-19 pandemic
62089311|NCT05925270|EXPERIMENTAL|mhGAP-Remote|mhGAP-Remote was developed specifically by our team. It involves the same intervention components described in mhGAP-Standard. However, in mhGAP-Remote the intervention is delivered mostly through standardized SMSs. There is one in-person session with the interventionist, where the participant learns the core skills of mhGAP. This is followed by standardized SMSs to reinforce intervention content learned in the first session. Study interventionists will be able to provide brief telephonic support to participants if participants struggle to implement the skills learned.
62089312|NCT05925270|ACTIVE_COMPARATOR|mhGAP-Standard|"mhGAP-Standard refers to the existing evidence-based intervention guide that was developed by the WHO to help non-specialist providers in LMIC settings provide treatment for alcohol use, among other mental health and neurological conditions. For the current study, the intervention will focus on mhGAP's psychosocial interventions, which involve psychoeducation, brief motivational interviewing, and providing strategies to reduce and/or stop use. The intervention uses a harm reduction approach, meaning that participants do not need to stop using alcohol altogether. Interventionists will deliver 4 sessions, approximately 45-60 mins each, to participants in person. Sessions are designed to be delivered approximately weekly. Providers have the option to deliver up to 2 additional booster sessions to participants who may benefit from additional care."
62089313|NCT03174964|EXPERIMENTAL|Treatment group|IVIg group
62089314|NCT03174964|NO_INTERVENTION|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
62089315|NCT01235273|EXPERIMENTAL|GH replacement therapy|
62089316|NCT01235273|PLACEBO_COMPARATOR|Placebo|
62089317|NCT03059030|EXPERIMENTAL|Subjects with thrombocytopenia secondary to cirrhosis|Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
62089318|NCT02284464|ACTIVE_COMPARATOR|Steroids, tacrolimus and mycophenolate|Normal treatment arm
62089319|NCT02284464|EXPERIMENTAL|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
62089320|NCT04520958|EXPERIMENTAL|Mindfulness of Breath|
62089321|NCT04520958|EXPERIMENTAL|Mindfulness of Pain|
62089322|NCT04520958|ACTIVE_COMPARATOR|Cognitive-Behaviorally Based Pain Psychoeducation|
62462534|NCT04362891|EXPERIMENTAL|Juvéderm®|Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
61905083|NCT01541397|NO_INTERVENTION|Non-Kuvan treated|Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.
61905084|NCT01541397|EXPERIMENTAL|Kuvan treated|Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
62089323|NCT04521205|EXPERIMENTAL|Standardized FMT|The patients will receive standardized FMT. The FMT was given by capsule. It was given three times a week.
62089324|NCT04521205|PLACEBO_COMPARATOR|Without FMT|The patients will receive FMT with blank capsule.
62089325|NCT01790945||No treatment Study|Population of subjects will have been diagnosed with mild NPDR, Moderate NPDR, Severe NPDR, PDR and DME
62089326|NCT05400720|EXPERIMENTAL|Mentee|Participants will be approached by a mentor, exchange experiences and invite the prospective mentee to the program. Those interested to continue will undergo matching based on their desired criteria.
62089327|NCT05282342||Transplanted with low levels of physical activity (TPL)|
62089328|NCT05282342||Transplanted with moderate levels of physical activity (TPM)|
62654366|NCT03715647||Sepsis|"The puerperal / postpartum women who evolved with sepsis, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
62654367|NCT03715647||HELLP Syndrome|"The puerperal / postpartum women who evolved with HELLP syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
62654368|NCT03715647||Respiratory Distress Syndrome, Adult|"The puerperal / postpartum women who evolved with Adult Respiratory Distress Syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
62654369|NCT01311791|EXPERIMENTAL|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure.
62654370|NCT01311791|ACTIVE_COMPARATOR|Standard Medical Therapy|as per protocol
62654371|NCT01724268|EXPERIMENTAL|Pred + Meth|"Prednisolone : 10 mg daily~+ Methotrexate : 25 mg/ day~ARM 1 Treatment Arm"
62654372|NCT01724268|ACTIVE_COMPARATOR|Anti TNF + Meth|"Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg~+ Methotrexate 25 mg per day Control Arm"
62654373|NCT00977145|EXPERIMENTAL|intratumoral IFN-gamma plus MELITAC 12.1,|intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1, an emulsion of a mixture of 12 class I MHC-restricted melanoma-derived peptides (12-MP) and a class II MHC-restricted tetanus toxoid-derived helper peptide (Peptide-tet).
62654374|NCT01993966||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients
62654375|NCT01993966||normal|specimens come from normal bladder urothelial carcinoma patients
62654376|NCT01993966||non-tumoral|specimens come from non-tumoral patients
61905091|NCT02968056|EXPERIMENTAL|Hybrid group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation followed by catheterized radiofrequency ablation within the same procedure
61905092|NCT02968056|ACTIVE_COMPARATOR|MIS group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation only
62089329|NCT05282342||Transplanted with high levels of physical activity (TPH)|
62089330|NCT05282342||Healthy sedentary individuals (S)|
62089331|NCT06110143|OTHER|PrePROBE|Periodontal treament during pregnancy
62089332|NCT06110143|OTHER|PostPROBE|Peridontal treatment postpartum
62089333|NCT03849872|EXPERIMENTAL|Part 1 Absolute Bioavailability|Single oral dose of 10 mg ONO-5788 capsule followed by iv infusion 100 μg/ 41 kBq (1.1 μCi) \[14C\]-ONO-5788 in 6 healthy male subjects.
62462535|NCT04362891|EXPERIMENTAL|Restylane®|Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
62654377|NCT00916578|EXPERIMENTAL|Radiation Therapy + Capecitabine|"Capecitabine 825 mg/m2 twice a day. One of the two daily doses of capecitabine should be taken approximately 2 hours before receiving radiotherapy. The first day of Capecitabine is same day that radiotherapy is started, and last day that Capecitabine is given is last day of radiotherapy. Capecitabine administered only on days patient receives radiation therapy.~Radiation therapy dose 50-57 Gy to initial clinical target volume (CTV, gross disease + tissue at risk for micrometastatic disease including margin around gross disease and draining regional lymphatics)."
61905096|NCT03069729||Control group|non-diabetic; no intervention
61905097|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
61905098|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
62089334|NCT03849872|EXPERIMENTAL|Part 2 Mass Balance|Single oral dose of 10 mg \[14C\]-ONO-5788 capsule containing 4.1 MBq (111 μCi) \[14C\]-radioactivity in 6 healthy male subjects.
62089335|NCT00322868|EXPERIMENTAL|Pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda
62089336|NCT02510066|EXPERIMENTAL|Acupuncture|Acupuncture participants would receive electroacupuncture on Jiaji (Ex-B2) points for 3 times in a week.
62089337|NCT02510066|PLACEBO_COMPARATOR|Placebo acupuncture|Placebo acupuncture participants would receive placebo acupuncture on non-point points for the same period.
62089338|NCT04280328|EXPERIMENTAL|Ciforadenant in combination with daratumumab|Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg.
62287975|NCT05027386|EXPERIMENTAL|Apatinib Mesylate combined with IT Regimen|"The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.~Combination therapy phase: Apatinib (orally once daily continuously in a 21-day cycle) was combined with IT regimen (repeated every 3 weeks) for up to 6 courses of treatment.~Apatinib:~\<25Kg：0.25g，po，qd； 25Kg≤wight\<40Kg：0.425g，po，qd； 40Kg≤wight\<50Kg：0.5g，po，qd.~IT regimen:~Temozolomde：150mg/m2，iv 90min，d1-5，（1h before irinotecan）； Irinotecan: 50mg/m2，iv 90min，d1-5.~Monotherapy maintenance phase: Apatinib is administered as a monotherapy until tumor progression, patient withdrawal, or toxicity becomes intolerable."
61905103|NCT03478293|EXPERIMENTAL|iStent inject surgery|Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
61905104|NCT04064125|EXPERIMENTAL|FMX-101|
62287976|NCT01708057|EXPERIMENTAL|1|Single dose of AZD8683 50 µg
62287977|NCT01708057|EXPERIMENTAL|2|Single dose of AZD8683 150 µg
62287978|NCT01708057|EXPERIMENTAL|3|Single dose of AZD8683 300 µg
62287979|NCT01708057|EXPERIMENTAL|4|Single dose of AZD8683 900 µg
61905107|NCT00554281|NO_INTERVENTION|A|Run in period
61905108|NCT00554281|EXPERIMENTAL|B|
61905109|NCT05728099|EXPERIMENTAL|Expiratory muscle strength training + SpiroGym application|The experimental arm will undergo 24 weeks of expiratory muscle strength training coupled with SpiroGym app.
61905110|NCT05728099|ACTIVE_COMPARATOR|Expiratory muscle strength training|The experimental arm will undergo 24 weeks of expiratory muscle strength training.
62089339|NCT06428253|EXPERIMENTAL|HMM1-022|Participants will receive injections into the wrinkles at the corners of each eye, up to 1 mL each, four times at two-week intervals.
62089340|NCT06428253|ACTIVE_COMPARATOR|REJURAN®|Participants will receive injections into the wrinkles at the corners of each eye, up to 1 mL each, four times at two-week intervals.
62089341|NCT02362113||Isfahani adults|GI/GL
62089342|NCT03459820|EXPERIMENTAL|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
62089343|NCT03300089|ACTIVE_COMPARATOR|General Anaesthesia|General Anaesthesia during surgery
62089344|NCT03300089|EXPERIMENTAL|Regional Anaesthesia|Regional Anaesthesia during surgery
62089345|NCT03927365|ACTIVE_COMPARATOR|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
62287980|NCT01708057|PLACEBO_COMPARATOR|5|Single dose of placebo
62287981|NCT01708057|ACTIVE_COMPARATOR|6|Single dose of tiotropium 18 µg
61905115|NCT01323855|EXPERIMENTAL|Part 1: Severe Renal Impairment|Participants with severe CRI, defined as creatinine clearance of \<30 mL/min/1.73 m\^2, were treated with a single tablet of 5 mg preladenant, administered orally
61905116|NCT01323855|EXPERIMENTAL|Part 2: Moderate Renal Impairment|Participants with moderate CRI defined as creatinine clearance of ≥30 and \<50 mL/min/1.73 m\^2, were treated with a single tablet of 5 mg preladenant, administered orally
61905117|NCT01323855|EXPERIMENTAL|Part 2: Mild Renal Impairment|Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m\^2, were treated with a single tablet of 5 mg preladenant, administered orally
61905118|NCT01323855|EXPERIMENTAL|Part 1: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of \>80 mL/min/1.73 m\^2, were treated with a single tablet of 5 mg preladenant, administered orally
61905119|NCT01323855|EXPERIMENTAL|Part 2: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of \>80 mL/min/1.73 m\^2, were treated with a single tablet of 5 mg preladenant, administered orally
61905120|NCT04734197|EXPERIMENTAL|SURF-100 (a combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
61905121|NCT04734197|EXPERIMENTAL|Mycophenolic Acid 0.1%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
61905122|NCT04734197|EXPERIMENTAL|Mycophenolic Acid 0.3%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
62089346|NCT03927365|PLACEBO_COMPARATOR|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
62089347|NCT01861756|EXPERIMENTAL|Diabetes Medication Choice Decision Aid|
62089348|NCT01861756|NO_INTERVENTION|Standard care|
62089349|NCT02501733|OTHER|Medacta GMK Sphere® Knee Prosthesis|All subjects enrolled will receive the Medacta GMK Sphere® Medial Knee Prosthesis
62287982|NCT04660188|EXPERIMENTAL|Multidisciplinary collaborative care arm|Post-treatment clinical follow-up visits will be staggered between the oncologist and a dedicated PCP. A patient navigator will be assigned to each study participant to conduct follow-up sessions over the phone regularly at an approximate interval of 3 months.
61905123|NCT04734197|EXPERIMENTAL|Betamethasone Sodium Phosphate 0.01%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
61905124|NCT04734197|PLACEBO_COMPARATOR|Vehicle|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
62089350|NCT00950053|ACTIVE_COMPARATOR|Achilles decompression & debridement|
62089351|NCT00950053|ACTIVE_COMPARATOR|Achilles decompression,debride&FHLtransf|Achilles tendon decompression and debridement augmented with FHL transfer. The preferred skin incision will be followed by central-splitting Achilles debridement, resection of a Haglund's lesion if present and pathologic, followed by FHL harvest for patients in group 2. The fixation technique in group 2 will utilize an interference screw for the FHL. For all patients, the Achilles will be reattached with lateral and medial suture anchors (just distal to interference screw in FHL patients).
62089352|NCT02424331|EXPERIMENTAL|Quiet Breathing or Pursed Lips Breathing|Free or natural breathing for six minutes.
62089353|NCT01723826|EXPERIMENTAL|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
62089354|NCT05976594||HE group|Subjects who has been diagnosed as HE.
62089355|NCT05976594||Control group|Subjects who didn't meet the diagnosis criteria of HE.
62287983|NCT04660188|NO_INTERVENTION|Attentional control arm|BCS will receive follow-up care by their oncologists and any other healthcare providers under existing usual care practices at NCCS.
62287984|NCT04371367|EXPERIMENTAL|avdoralimab|"Biological/Vaccine: avdoralimab intravenous administration of avdoralimab~Other Names:~• IPH5401"
62654378|NCT01452256|EXPERIMENTAL|Desflurane|Desflurane for pharmacological conditioning
62654379|NCT01452256|EXPERIMENTAL|Propofol|
61905125|NCT04734197|ACTIVE_COMPARATOR|Cyclosporine 0.05% Ophthalmic Emulsion|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
61905126|NCT04734197|ACTIVE_COMPARATOR|Lifitegrast 5% Ophthalmic Solution|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
61905127|NCT04578652|ACTIVE_COMPARATOR|MET|MET (850 mg po bid - standard of care) + Fiber placebo daily
61905128|NCT04578652|ACTIVE_COMPARATOR|FIBER|Fiber supplementation \[35g fiber daily\] + MET placebo po bid
61905129|NCT04578652|EXPERIMENTAL|FIBER + MET|Fiber supplementation \[35g fiber daily\] + MET 850 mg po bid
61905132|NCT03977740|EXPERIMENTAL|chest PNF|"participants received conventional chest physiotherapy along with chest PNF technique 5 days for 1 week.~Chest PNF technique includes oblique downward pressure at the sternum, diagonal pressure at lower rib cage at the supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on the elbow."
62089356|NCT06085196|EXPERIMENTAL|Mindful walking|Complete a 24-session outdoor mindful walking intervention over 3 months
62089357|NCT06085196|OTHER|Delayed mindful walking group|Option to complete a delayed 24-session mindful walking
62089358|NCT01636440|OTHER|Reliability|The same testing procedure is repeated after a delay of 7 days to test the reliability of the measure
62089359|NCT02377765|ACTIVE_COMPARATOR|Percutaneus Stimulation|PTNS performed bilaterally every 4 weeks within the Physiotherapy Department.
62089360|NCT02377765|EXPERIMENTAL|Transcutaneous Stimulation|TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg at least 3 times per week.
62089361|NCT00503048||1|foster care children
62462536|NCT04362891|EXPERIMENTAL|Belotero®|Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
62462537|NCT04362891|EXPERIMENTAL|Stylage®|Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
62654380|NCT00961064|EXPERIMENTAL|Eltrombopag in Low to Int-2 Risk Myelodysplastic Syndrome (MDS)|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety in participants with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
62654381|NCT02295059|EXPERIMENTAL|Omega 3 fatty acids - high dose|\~5 g EPA+DHA in 5 capsules per day
62287985|NCT04371367|PLACEBO_COMPARATOR|Placebo|intravenous administration of Placebo
61905133|NCT03977740|ACTIVE_COMPARATOR|Conventional|participants received conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
61905134|NCT00717236|EXPERIMENTAL|Certolizumab pegol (CZP)|
61905135|NCT00717236|PLACEBO_COMPARATOR|Placebo|
61905140|NCT04605991|EXPERIMENTAL|LY900014|LY900014 (100 units/milliliter (U/mL)) is a mealtime insulin administered subcutaneously (SC) 0-2 minutes prior to each meal in combination with insulin glargine (100 U/mL) SC as long-acting insulin. Mealtime (bolus) and long-acting (basal) insulin doses were titrated to achieve glucose targets during the study.
61905141|NCT04643145|ACTIVE_COMPARATOR|Ureteral catheter|This group will receive ureteral catheter for 2 days after the procedure
62089362|NCT00503048||2|reference children (living with families)
62089363|NCT00935792|EXPERIMENTAL|Arm I|Patients receive oral everolimus thrice weekly for 9 weeks and alemtuzumab subcutaneously thrice weekly for 8 weeks.
62089364|NCT04058314|EXPERIMENTAL|Study Eye|Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction
62089365|NCT04058314|ACTIVE_COMPARATOR|Control Eye|control eyes will received an approved monofocal or toric IOL after cataract extraction
62462538|NCT03581448|EXPERIMENTAL|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.~The intervention Sensory Restoration During Prosthesis Control will be used."
62654382|NCT02295059|EXPERIMENTAL|Omega 3 fatty acids - low dose|\~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
62089366|NCT03746444|ACTIVE_COMPARATOR|General Anesthesia|"The patients in this group will undergo unilateral total knee arthroplasty under general anesthesia. Following vascular access and monitorization (non-invasive blood pressure, saturation, electrocardiography).~Epidural chateterisation will be performed and test dose will be applied. Induction will be carried out using propofol (3mg/kg), fentanyl (1cmg/kg) and rocuronium (0.6 mg/kg). Maintenance will be carried out using sevoflurane (%2-3) and 50-50% mixture of nitrous oxide and oxygen. Epidural analgesia will be initiated after the end surgery."
62089367|NCT03746444|ACTIVE_COMPARATOR|Regional Anesthesia|The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
62089368|NCT04596761|EXPERIMENTAL|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
62089369|NCT04596761|EXPERIMENTAL|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
62119931|NCT06554769|ACTIVE_COMPARATOR|Rigid Connection|rigid wire 19 x 25 inch stst wire was place between upper first molar and the miniscrew placed between the first molar and second premolar
62654383|NCT04782141|EXPERIMENTAL|Positioning the trunk and upper limb to improve the coordination the hand.|The study investigated the effects of the trunk and upper limb positioning on improving wrist and hand coordination.
62654384|NCT01757548|EXPERIMENTAL|open operation|high ligation of spermatic vein by open operation
61905142|NCT04643145|ACTIVE_COMPARATOR|Indwelling double J stent|This group will receive indwelling double J stent for 2-4 weeks after the procedure
61905147|NCT01764139||Knee pain patients with minimal knee changes|Male \& no pregnant female age between 18-40 yrs.
62089370|NCT02754609|EXPERIMENTAL|Necator americanus-hookworm larvae L3-10|A total of 40 participants week 0 and week 8 will have low dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 10 L3 in 200 microliter (uL) of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
62089371|NCT02754609|PLACEBO_COMPARATOR|Tabasco® Sauce|A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing. Tabasco® Sauce is an ideal placebo as the sensation to the skin is similar to a hookworm. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge.
62089372|NCT02754609|EXPERIMENTAL|Necator americanus-hookworm larvae L3-20|A total of 10 participants at week 0 and week 8 will have medium dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 20 L3 in 200 uL of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
62089373|NCT06669871|EXPERIMENTAL|BMI-Normal|Participants with BMI 18.50-24.50 will be included
62089374|NCT06669871|EXPERIMENTAL|BMI greater than 25|Participants with BMI 25 and above will be included
62089375|NCT06614738||Patients with genetically proven familial adenomatous polyposis undergoing surgery|Patients with familial adenomatous polyposis hospitalized for regular endoscopic follow-up by upper and lower digestive endoscopy at Hôpital Edouard Herriot, Lyon, France or Hôpital de la Croix-Rousse, Lyon, France
62089376|NCT02821598|EXPERIMENTAL|Upper limb pattern|Upper Limb pattern with flexion - abduction - external rotation
62089377|NCT02821598|EXPERIMENTAL|Lower limb pattern 1|Lower Limb pattern with flexion - adduction - external rotation with knee flexion;
62089378|NCT02821598|EXPERIMENTAL|Lower limb pattern 2|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion;
62089379|NCT02821598|EXPERIMENTAL|Lifting to the right|
62089380|NCT02821598|ACTIVE_COMPARATOR|Sit to Stand|Sit to Stand task
62089381|NCT01403987|ACTIVE_COMPARATOR|Control Arm|Control group will receive standard teaching by the Residency Program regarding management of ascites and performance of paracentesis.
62089382|NCT01403987|EXPERIMENTAL|Intermediate Education Arm|In addition to the teaching provided by the residency program, the intermediate education group will receive a dedicated lecture by a gastroenterology fellow designed to teach consensus guidelines and their rationale in management of ascites. They will also receive a pocket card noting specific indications for paracentesis, and a brief summary of guidelines.
62089383|NCT01403987|EXPERIMENTAL|"Intensive Education Arm (Pager Arm)"|This group will receive the residency teaching, the specialist lecture, the pocket card, and have access to a pager carried by a gastroenterology fellow for personal assistance in performing paracentesis.
62089384|NCT02433093|EXPERIMENTAL|Basimglurant: Healthy Cohort (1)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
62089385|NCT02433093|EXPERIMENTAL|Basimglurant: Healthy Cohort (2)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.
62462539|NCT05805657|EXPERIMENTAL|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
62089386|NCT02433093|EXPERIMENTAL|Basimglurant: Healthy Cohort (3)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
62089387|NCT02433093|EXPERIMENTAL|Basimglurant: Healthy Cohort (4)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.
62089388|NCT02433093|EXPERIMENTAL|Basimglurant: MDD Cohort (5)|Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.
62089389|NCT02433093|PLACEBO_COMPARATOR|Placebo: Healthy Cohorts (1 to 4)|Healthy participants will receive a 22-day regimen of matching placebo capsules.
62287986|NCT02749214||Parkinson's Disease (PD)|Participant's with Parkinson's Disease will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
62287987|NCT02749214||Healthy Control|Age and gender-matched healthy controls will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
62654385|NCT01757548|EXPERIMENTAL|microsurgery|high ligation of spermatic vein by microsurgery
62654386|NCT04127474||Group I|25 Generalized chronic periodontitis subjects without coronary heart disease.
61905150|NCT00910299|EXPERIMENTAL|Prasugrel|
61905151|NCT00910299|ACTIVE_COMPARATOR|Clopidogrel|
61905152|NCT05576545|EXPERIMENTAL|general routine care and the Breast Cancer Self-Care App|
61905153|NCT05576545|NO_INTERVENTION|general routine care|
61905154|NCT04120311|EXPERIMENTAL|Phase I open label study|"Drug: Episcleral Dexamethasone Sequestered Transscleral, Controlled-Release Dexamethasone~Other Names:~• Sustained Release Transscleral Dexamethasone"
62287988|NCT03455673||Atrial fibrillation|ATE score will be determined for patients hospitalized for ablation of atrial fibrillation or symptomatic left atrial tachycardia
61905161|NCT05006742|ACTIVE_COMPARATOR|CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
61905162|NCT05006742|ACTIVE_COMPARATOR|FB-CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
62287989|NCT00976144|EXPERIMENTAL|GSK573719, GW642444, GSK573719+GW642444, placebo|This is a four-way cross-over study. Subjects, healthy volunteers, will receive a single dose of GSK573719 (500ug), GW642444 (50ug), GSK573719 (500ug)+GW642444 (50ug) administered concurrently, or placebo at each of the four treatment periods. There is a minimum wash-out period of seven days between doses. On enrolment into the study, subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start.
62287990|NCT02968017||MCA-PI|Measurement Middle cerebral artery pulsatility index
62462540|NCT05805657|EXPERIMENTAL|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions.
62462541|NCT05805657|ACTIVE_COMPARATOR|UC-DT|Usual Care Delayed Treatment. Usual care in the partner CMHCs starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
62462542|NCT02745925|EXPERIMENTAL|normal-weight|normal-weight women
62462543|NCT02745925|EXPERIMENTAL|obesity|obese women
62462544|NCT04164745|EXPERIMENTAL|Experimental: Anlotinib plus Pembrolizumab|
62462545|NCT05506280||Pregnant women|pregnant women infected by Covid-19
62462546|NCT00366899|EXPERIMENTAL|1|13-valent pneumococcal conjugate vaccine
61905165|NCT04653467|EXPERIMENTAL|GLPG4399 SAD|Single doses of GLPG4399 at up to 6 dose levels in ascending order
61905166|NCT04653467|PLACEBO_COMPARATOR|Placebo SAD|Single doses of placebo
61905167|NCT04653467|EXPERIMENTAL|GLPG4399 MAD|Multiple ascending doses of GLPG4399
61905168|NCT04653467|PLACEBO_COMPARATOR|Placebo MAD|Multiple doses of placebo
61905169|NCT04653467|EXPERIMENTAL|GLPG4399 FE-rBA|Single dose of GLPG4399 in fed and fasted state
61905170|NCT04653467|EXPERIMENTAL|GLPG4399 FE|Single dose of GLPG4399 in fed and fasted state
62089390|NCT02433093|PLACEBO_COMPARATOR|Placebo: MDD Cohort (5)|Participants with MDD will receive a 22-day regimen of matching placebo capsules.
62089391|NCT02431533|EXPERIMENTAL|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
62089392|NCT02431533|PLACEBO_COMPARATOR|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
62089393|NCT04105985|EXPERIMENTAL|Kovanaze Nasal Spray (endodontics)|Adults (\>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
62462547|NCT00366899|ACTIVE_COMPARATOR|2|7-valent pneumococcal conjugate vaccine
62462548|NCT04157348|EXPERIMENTAL|Benralizumab arm|1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
62462549|NCT04157348|ACTIVE_COMPARATOR|Mepolizumab arm|3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
62462550|NCT05451030|EXPERIMENTAL|remote ischemic preconditioning|
62462551|NCT05451030|SHAM_COMPARATOR|control group|
62462552|NCT03049488|EXPERIMENTAL|Group 1: DS-Cav1 (50 mcg)|"DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
62462553|NCT03049488|EXPERIMENTAL|Group 2: DS-Cav1 (50 mcg) + alum|"DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
61905172|NCT05884749|EXPERIMENTAL|P2C Intervention|Participants in this condition will receive the P2C model.
61905173|NCT05884749|ACTIVE_COMPARATOR|Care as Usual|Participants in this group will receive care as usual supports, and will be waitlisted to receive P2C model supports after 6 months.
61905178|NCT05923216|EXPERIMENTAL|High dose|20 patients Intervention: Dietary Supplement: High dose OIT
61905179|NCT05923216|ACTIVE_COMPARATOR|Low dose|20 patients Intervention: Dietary Supplement: Low dose OIT
61905180|NCT02462642|EXPERIMENTAL|Brahmi - 36 subjects|36 subjects both male and female will consume 2 capsules of Brahmi for 84 days.
61905181|NCT02462642|PLACEBO_COMPARATOR|Placebo- 36 subjects|36 subjects male and female who will take 2 capsules of placebo every day
61905182|NCT02462642|EXPERIMENTAL|Brahmi - 8 Subjects|For PK part of the study 8 male subjects will be taken for treatment arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
61905183|NCT02462642|PLACEBO_COMPARATOR|Placebo- 4 subjects|4 male subjects in PK part will be in the placebo arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
61905185|NCT01473680||Patients who will receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
62089394|NCT04105985|ACTIVE_COMPARATOR|Articaine Injections (endodontics)|Adults (\>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
62089395|NCT05879211|NO_INTERVENTION|Control|Usual care
62089396|NCT05879211|EXPERIMENTAL|Intervention|Feedback to provider regarding frequency and quality of communication
61905186|NCT01473680||Patients who will not receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
61905187|NCT01473680||Healthy Controls|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
61905188|NCT02537795||Deep Brain Stimulation Patients|Patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
61905189|NCT02537795||Deep Brain Stimulation Family Members|Family members of patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
61905190|NCT02537795||Anterior Capsulotomy Patients|Patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
61905191|NCT02537795||Anterior Capsulotomy Family Members|Family members of patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
61905193|NCT03140059|ACTIVE_COMPARATOR|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
61905194|NCT03140059|ACTIVE_COMPARATOR|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
62089397|NCT04578028|EXPERIMENTAL|ONO-2808 Part A - Fasted|Single ascending doses of ONO-2808 or placebo orally under fasted conditions. Additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.
62089398|NCT04578028|PLACEBO_COMPARATOR|ONO-2808 Placebo Part A- Fasted|Single ascending doses of ONO-2808 or placebo orally under fasted conditions
62089399|NCT04578028|EXPERIMENTAL|ONO-2808 Part A - Fed|Single ascending doses of ONO-2808 or placebo orally under fed conditions
62287991|NCT01766947|EXPERIMENTAL|Triggerfish|Device : Sensimed Triggerfish
62089400|NCT04578028|PLACEBO_COMPARATOR|ONO-2808 Placebo Part A - Fed|Single ascending doses of ONO-2808 or placebo orally under fed conditions
62089401|NCT04578028|EXPERIMENTAL|ONO-2808 Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers .
62089402|NCT04578028|PLACEBO_COMPARATOR|ONO-2808 Placebo Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers
62089403|NCT04578028|EXPERIMENTAL|ONO-2808 Part C|Multiple ascending doses of ONO-2808 or placebo orally
62089404|NCT04578028|PLACEBO_COMPARATOR|ONO-2808 Placebo Part C|Multiple ascending doses of ONO-2808 or placebo orally
62089405|NCT06051942|EXPERIMENTAL|Aquablation|
62089406|NCT04677465|EXPERIMENTAL|RheOx Treatment|
62089407|NCT04677465|SHAM_COMPARATOR|Sham Procedure|
62089408|NCT03026569|EXPERIMENTAL|Orange juice|Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.
62089409|NCT03026569|NO_INTERVENTION|Control|Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.
62287992|NCT02266173||Pertuzumab|Participants for whom the treating physician has decided to administer pertuzumab according to standard of care and in line with the current summary of product characteristics (SmPC)/local labeling, will be observed.
62287993|NCT04822532|EXPERIMENTAL|Pharmacogenetic based-model (GSTA1)|
62654387|NCT04127474||Group II|25 Generalized chronic periodontitis subjects diagnosed with coronary heart disease.
61905196|NCT05307913|EXPERIMENTAL|EIT-guided PEEP|PEEP titration by EIT
61905197|NCT05307913|ACTIVE_COMPARATOR|Table-guided PEEP|PEEP selection by the lower PEEP/FiO2 table
62654388|NCT04127474||Group III|25 Periodontally healthy subjects diagnosed with coronary heart disease.
62654389|NCT00747877|EXPERIMENTAL|Arm I|Patients receive high-dose melphalan IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.
62089410|NCT04632966|EXPERIMENTAL|PTP-001 - Low Dose (100 mg)|intra-articular injection of 100 mg PTP-001 resuspended with 4 mL of normal saline
62089411|NCT04632966|EXPERIMENTAL|PTP-001 - High Dose (200 mg)|intra-articular injection of 200 mg PTP-001 resuspended with 4 mL of normal saline
62287994|NCT04822532|ACTIVE_COMPARATOR|The most performing method based on age and weight - McCune's model|
62287995|NCT01137357|EXPERIMENTAL|Yoghurt with Lactobacillus strain (L.plantarum WCFS1)|
62287996|NCT01137357|EXPERIMENTAL|Yoghurt with Lactobacillus strain (L.plantarum NIZO3400)|
62287997|NCT01137357|EXPERIMENTAL|Yoghurt with Lactobacillus strain (L. plantarum NIZO2877)|
62287998|NCT01137357|EXPERIMENTAL|Yoghurt with Lactobacillus strain (L.plantarum CBS125632)|
62287999|NCT01137357|ACTIVE_COMPARATOR|Yoghurt with Lactobacillus casei Shirota|
62654390|NCT00747877|EXPERIMENTAL|Arm II|Patients receive low-dose cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.
62654391|NCT03854500|ACTIVE_COMPARATOR|Tenecteplase|Tenecteplase
62654392|NCT03854500|ACTIVE_COMPARATOR|Alteplase|Alteplase
62288000|NCT01137357|PLACEBO_COMPARATOR|Placebo Yoghurt|
62288001|NCT00732173|EXPERIMENTAL|Arm I|"Patients receive a lifestyle intervention, Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED), on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact."
62288002|NCT00732173|ACTIVE_COMPARATOR|Arm II|Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
62288003|NCT01487369||Insulin Aspart|
62288004|NCT04226313|ACTIVE_COMPARATOR|Self-sampling device sent at home|Women randomly selected from a commercial vendor database (both attenders and non-attenders) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked (Conformité Européenne, In Vitro Diagnostics) HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
62654393|NCT05020353|EXPERIMENTAL|Investigational Device|Observed self-test of oral fluid with the OraQuick HIV Self-Test
62288005|NCT04226313|EXPERIMENTAL|Self-sampling device sent by gynecologist(s)|Women selected from databases of cooperating gynecologists (non-attenders for at least 3 years) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
62462554|NCT03049488|EXPERIMENTAL|Group 3: DS-Cav1 (150 mcg)|"DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose."
62654394|NCT04658355|ACTIVE_COMPARATOR|Povidone-Iodine|Povidone-iodine to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
62654395|NCT04658355|EXPERIMENTAL|Chlorhexidine Gluconate|Chlorhexidine gluconate to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
62654396|NCT02320175|NO_INTERVENTION|Pre-intervention|Before implementation of Patient and Family Centered I-PASS.
62654397|NCT02320175|EXPERIMENTAL|Post-intervention|After implementation of Patient and Family Centered I-PASS.
62654398|NCT01765322|EXPERIMENTAL|Assisted hatching group (AH group)|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
62089412|NCT05140174|EXPERIMENTAL|RHIS Informed Psychotherapy|Therapists will be trained in Radical Healing and Internalized Stigma (RHIS) and meet with their clients as part of their usual care for 15 tele-psychotherapy sessions
62089413|NCT00558324|EXPERIMENTAL|I|Corneal flaps were created with mechanical microkeratome (Hansatome 160μm (Chiron Vision Corp, Claremont, Calif)
62089414|NCT00558324|EXPERIMENTAL|II|Corneal flaps were created with mechanical microkeratome K3000 130μm ( BD Ophthalmic Systems, Waltham, Mass) .
62089415|NCT00558324|EXPERIMENTAL|III|Corneal flaps were created with microkeratome femtoseconds laser (Intralase Corp, Irvine, Calif.)
62089416|NCT04061161|ACTIVE_COMPARATOR|Tiotropium respimat|Tiotropium respimat 2.5mcg two actuations once daily
62089417|NCT04061161|PLACEBO_COMPARATOR|Placebo respimat|Placebo respimat two actuations once daily
62089418|NCT01474512|EXPERIMENTAL|80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)|Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 \[every 2 weeks (Q2W)\] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 \[every 4 weeks (Q4W)\] or Dosing Regimen 3 \[every 12 weeks Q12W)\].
62089419|NCT01474512|EXPERIMENTAL|80 mg Ixekizumab Dosing Regimen 2 (Q4W)|Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
62089420|NCT01474512|EXPERIMENTAL|80 mg Ixekizumab Dosing Regimen 3 (Q12W)|Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
62288006|NCT04226313|EXPERIMENTAL|Self-sampling device obtained from general practitioner(s)|Women selected from databases of cooperating general practitioners (non-attenders for at least 3 years) receive a self-sampling device. Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
62654399|NCT01765322|NO_INTERVENTION|Control group|The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
62654400|NCT02422654|EXPERIMENTAL|Concentration 1 eliglustat in vehicle A|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
62654401|NCT02422654|EXPERIMENTAL|Concentration 1 eliglustat in vehicle B|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
62654402|NCT02422654|EXPERIMENTAL|Concentration 1 eliglustat in vehicle C|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
62089421|NCT01474512|PLACEBO_COMPARATOR|Placebo|Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
62654403|NCT02422654|EXPERIMENTAL|Concentration 1 eliglustat in vehicle D|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
62654404|NCT02422654|EXPERIMENTAL|Concentration 1 eliglustat in vehicle E|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
61905206|NCT01293071|ACTIVE_COMPARATOR|Mixing arm|Antibiotic rotation, each consecutive initiated antibiotic treatment a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems)
61905207|NCT01293071|ACTIVE_COMPARATOR|Cycling|Antibiotic rotation, every 1.5 month a different preferred antibiotic treatment from a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems) is used for empiric treatment.
62089422|NCT03490890|EXPERIMENTAL|Microwave ablation in the GGO|Patients with GGO were treated with microwave ablation.
62089423|NCT05039203||Intervention group|Inpatients with an indwelling urinary catheter (IUC) at admission to a rehabilitation clinic for persons ≥65 years in Sweden. Intervention is removal of the IUC.
62089424|NCT05039203||Control group|Inpatients without an IUC at admission to a rehabilitation clinic for persons ≥65 years in Sweden
62089425|NCT04150835|EXPERIMENTAL|Xingnaojing|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
62089426|NCT04150835|PLACEBO_COMPARATOR|Placebo|Subjects will receive intravenously administered Xingnaojing placebo, combined with guidelines-based standard care.
62089427|NCT00712855|EXPERIMENTAL|A|mapatumumab and sorafenib
62089428|NCT01998282||Household water filter and improved cook stove|Vestergaard-Frandsen LifeStraw Family 2.0 filter and Ecozoom stove
62089429|NCT01998282||Control|Traditional water management practices and cooking stoves
62089430|NCT04132284|EXPERIMENTAL|DBT IOP plus DBT PI|Standard Dialectical Behavior Therapy (DBT) delivered in the context of an intensive outpatient program (DBT IOP) for adolescents plus an 8-10 session DBT-based parenting intervention (DBT PI)
62089431|NCT04132284|ACTIVE_COMPARATOR|DBT IOP alone|No parenting intervention provided beyond what is part of the DBT IOP treatment as usual.
62089432|NCT04575675|EXPERIMENTAL|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
62089433|NCT04575675|PLACEBO_COMPARATOR|Standard of care|Standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
62288007|NCT06224114|EXPERIMENTAL|Coloured light 1 group|Coloured light 1 group will be provided with a coloured-light torch and instructed to apply it to their study eye for 3 minutes at home each morning between 8 - 10 am for 28 days.
62462555|NCT03049488|EXPERIMENTAL|Group 4: DS-Cav1 (150 mcg) + alum|"DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
62462556|NCT03049488|EXPERIMENTAL|Group 5: DS-Cav1 (500 mcg)|"DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
62462557|NCT03049488|EXPERIMENTAL|Group 6:DS-Cav1 (500 mcg) + alum|"DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
61905210|NCT03598114|EXPERIMENTAL|Program Sustainability Training|"* Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.~* The intervention group will receive a follow-up survey inviting them to evaluate the training and their progress on executing their sustainability plan. The intervention group will also receive a follow-up survey inviting them to evaluate the technical assistance they have received from the research team. Responses on neither follow-up survey impact participants standing in the study"
62089434|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
62089435|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
62089436|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
62089437|NCT05112874||Prospective Cross-Reactive Cohort|"Ages 18-89, Exhibiting symptoms compatible with a viral upper respiratory tract infection at the time of screening.~Lab test confirming~1. Negative for SARS-CoV-2 (by Polymerase Chain Reaction (PCR) or Antibody detection test)~2. Respiratory Panel positive for the common seasonal coronaviruses: NL63, 229E, OC43, and HKU1"
62089438|NCT01373047|EXPERIMENTAL|Intrahepatic anti-CEA designer T cells|
62089439|NCT00576602|EXPERIMENTAL|1|
62089440|NCT00576602|ACTIVE_COMPARATOR|2|
62089441|NCT06204523||Popolation|
62089442|NCT01615627|EXPERIMENTAL|Hypotonic Treprostinil Solution|Hypotonic Treprostinil Solution
62089443|NCT01615627|ACTIVE_COMPARATOR|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
62089444|NCT06137755|EXPERIMENTAL|Group 1|Recombinant Herpes Zoster Vaccine(CVI-VZV-001) 0.37 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
62462558|NCT03265080|EXPERIMENTAL|Part A|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.~Two dose levels of ADXS-NEO will be explored: 1 x 10\^9 and 1 x 10\^8 colony forming unit (CFU)."
62462559|NCT03265080|EXPERIMENTAL|Part B|Two dose levels of ADXS-NEO will be explored (i.e., 1 x 10\^8 and 5 x 10\^8 CFU) in combination with 200 mg of pembrolizumab.
62462560|NCT03265080|EXPERIMENTAL|Part C|ADXS-NEO will be explored at 1 x 10\^8 CFU in combination with 200 mg of pembrolizumab in an expansion cohort.
62089445|NCT06137755|EXPERIMENTAL|Group 2|Recombinant Herpes Zoster Vaccine(CVI-VZV-001) 0.50 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
62462561|NCT06218680|EXPERIMENTAL|group P|Receive 0.5 mg/kg of propofol intravenously at end of sevoflurane anesthesia
62462562|NCT06218680|PLACEBO_COMPARATOR|group S|Receive saline intravenously at end of sevoflurane anesthesia
62462563|NCT01449266|OTHER|Dotarem®-injected patients|Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
62089446|NCT06137755|EXPERIMENTAL|Group 3|Recombinant Herpes Zoster Vaccine(CVI-VZV-001) 0.75 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
62089447|NCT06137755|ACTIVE_COMPARATOR|Active Control|Shingrix 0.50 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
62089448|NCT04924582|EXPERIMENTAL|Capacity Coaching|Participants randomized to the Capacity Coaching arm will receive three months of coaching with a Health and Wellness coach. They will receive one one-hour session and five half-hour sessions approximately two weeks apart.
62089449|NCT04924582|NO_INTERVENTION|No Capacity Coaching|Participants randomized to the No Capacity Coaching arm will receive usual care.
62089450|NCT06697067|EXPERIMENTAL|Patient undergoing emergent laparotomy due to hollow viscus perforation|
62089451|NCT06697067|EXPERIMENTAL|patient undergoing emergent laparotomy|patient undergoing emergent laparotomy for hollow viscus perforation
62089452|NCT00664521|EXPERIMENTAL|Rituximab Plus Atacicept|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
62089453|NCT00664521|PLACEBO_COMPARATOR|Rituximab Plus Placebo|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
62089454|NCT04638699|NO_INTERVENTION|Phase 1 Survey of the actual state|
62089455|NCT04638699|OTHER|Phase 2 Survey after the OptiScreen training|
62089456|NCT06614153|EXPERIMENTAL|Group A，Subjects will receive HRG2010(I)|administered orally
62089457|NCT06614153|EXPERIMENTAL|Group B，Subjects will receive HRG2010(II)|administered orally
62089458|NCT06614153|ACTIVE_COMPARATOR|Group C，Subjects will receive Sustained-release|Carbidopa/Levodopa administered orally
62288008|NCT06224114|PLACEBO_COMPARATOR|Coloured light 2 group|Coloured light 2 group will be provided with a different coloured-light torch and instructed to apply it to their study eye for 3 minutes at home each morning between 8 - 10 am for 28 days.
62288009|NCT04086732|EXPERIMENTAL|Temporomandibular disorder|
62288010|NCT04086732|EXPERIMENTAL|Healthy control|
62288011|NCT02700451|PLACEBO_COMPARATOR|Intravenous (IV) Placebo|IV Placebo arm
62462564|NCT04354558||survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
62462565|NCT04354558||non-survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
62288012|NCT02700451|EXPERIMENTAL|IV Ketorolac|IV Ketorolac arm
62089459|NCT03835520|EXPERIMENTAL|MOLECULAR TARGETED THERAPIES|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
62089460|NCT03835520|EXPERIMENTAL|IMMUNOTHERAPY|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
62089461|NCT02184884||MACE group|the patients with MACE after OPCAB
62089462|NCT02184884||no MACE group|the patients without MACE after OPCAB
62089463|NCT06267274|EXPERIMENTAL|Bimatoprost Ophthalmic Solution, 0.01%|Test Product: Bimatoprost Ophthalmic Solution, 0.01%
62089464|NCT06267274|ACTIVE_COMPARATOR|LUMIGAN® (bimatoprost ophthalmic solution) 0.01%|Reference Product: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
62089465|NCT05531825||Normal control group|Patients with no disease in the main organs, with well-developed body shape, and with good physiological functions, physical activity abilities and labor abilities.
62089466|NCT05531825||Newly established arteriovenous fistula group|Chronic kidney disease stage 5 (CKD5) non-dialysis patients planning to undergo internal arteriovenous fistula surgery.
62089467|NCT05531825||reconstructed arteriovenous fistula group|Patients with maintenance hemodialysis who need to reconstruct the internal arteriovenous fistula on account of dissatisfaction with blood flow.
62089468|NCT05531825||Long-term maintenance hemodialysis group|Patients undergoing hemodialysis with long-term fixed internal arteriovenous fistula.
62089469|NCT04069910|EXPERIMENTAL|Arm A (SRS/SRT, surgery)|Patients undergo 1, 5, or 10 fraction of SRS/SRT radiation. Surgery is performed within 72 hours of radiation therapy.
62089470|NCT04069910|ACTIVE_COMPARATOR|Arm B (surgery, SRS/SRT)|Within 2-5 weeks after standard of care surgery, patients undergo 1, 5, or 10 fraction of SRS/SRT.
62288013|NCT02700451|EXPERIMENTAL|IV Acetaminophen|IV Acetaminophen arm
62288014|NCT04997239|EXPERIMENTAL|Experimental Group ：Vaccine-unprimed subjects with two doses|200 vaccine-unprimed children will receive two doses of quadrivalent influenza vaccine on the immunization schedule of day 0,28.
62462566|NCT02268422|EXPERIMENTAL|7 day patch|Buprenorphine transdermal system (BTDS) 2nd generation
62462567|NCT02268422|ACTIVE_COMPARATOR|7 Day Patch|1st Generation BTDS: Butrans
62288015|NCT04997239|EXPERIMENTAL|Experimental Group ：Vaccine-unprimed subjects with one dose|200 vaccine-unprimed children will receive one dose of quadrivalent influenza vaccine.
62288016|NCT04997239|EXPERIMENTAL|Experimental Group：Vaccine-primed subjects with one dose|200 vaccine-primed children will receive one dose of quadrivalent influenza vaccine.
62462568|NCT00983684|EXPERIMENTAL|Intra-operative radiotherapy|A single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
62288017|NCT06353776|EXPERIMENTAL|MP-TLT + conjunctival biopsy|Participants underwent MicroPulse transscleral laser therapy, followed by conjunctival biopsies for the analysis of inflammation and fibrosis.
62089471|NCT05634057|EXPERIMENTAL|Anisodamine hydrobromide combined with heparin|Anisodamine hydrobromide injection + low molecular weight heparin + basic treatment: The dosage of scopolamine butylbromide is 2.0mg/(kg\*d), administered via a micro-pump at a constant rate, continuously for 3 days. The dosage range for low molecular weight heparin is limited to 3000-6000U, administered subcutaneously once daily, continuously for 3 days.
62089472|NCT05634057|NO_INTERVENTION|conventional therapy|Conventional treatment includes shock treatment, eliminating the cause of the condition, actively treating the primary disease, replenishing blood volume, correcting acid-base imbalances, using vasoactive drugs to maintain blood pressure, and advanced life support as needed, such as the use of a ventilator and bedside blood filtration for organ support.
62462569|NCT00983684|ACTIVE_COMPARATOR|Post-operative radiotherapy|Standard post-operative radiotherapy.
62462570|NCT03930498|EXPERIMENTAL|PD-1 antibody plus chemoradiotherapy|
62462571|NCT04622657|EXPERIMENTAL|parkinson disease|Assessment
62462572|NCT04221425|EXPERIMENTAL|VRRS GROUP|Home rehabilitation program is provided through a virtual reality based telerehabilitation system
62089473|NCT05353530|EXPERIMENTAL|8R-70CAR T cells|Cohort 1 will receive 1 x 10\^6 cells/kg. Cohort 2 will receive 1 x 10\^7 cells/kg. Cohort 3 will receive 1 x 10\^8 cells/kg. Cohort 4 will receive Cy/Flu + CAR T cells at established maximum tolerated dose.
62089474|NCT06393322|EXPERIMENTAL|Depression e-Learning A|
62089475|NCT06393322|EXPERIMENTAL|Anxiety e-Learning A|
62288018|NCT01366248||IO Clinic Breast Cancer Patients|Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
62089476|NCT06393322|EXPERIMENTAL|Depression e-Learning B|
62462573|NCT04221425|ACTIVE_COMPARATOR|CONTROL GROUP|Home rehabilitation program is provided through illustrative booklet containing characteristics of exercises and indications for recovery
62462574|NCT03412357|EXPERIMENTAL|pleurectomy/decortication|
62089477|NCT06393322|EXPERIMENTAL|Anxiety e-Learning B|
62089478|NCT02402764|EXPERIMENTAL|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
62089479|NCT04958031|EXPERIMENTAL|CVL-871 1.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 1.0 milligrams (mg) until Day 85 during the treatment period.
62089480|NCT04958031|EXPERIMENTAL|CVL-871 3.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 3.0 milligrams (mg) until Day 85 during the treatment period.
62288019|NCT01366248||CSS Match-Control Patients|For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
62288020|NCT00245271|EXPERIMENTAL|1|OMS103 Irrigation Solution
62288021|NCT00245271|PLACEBO_COMPARATOR|2|Balanced Salt Solution (BSS)
62288022|NCT03592979|EXPERIMENTAL|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62288023|NCT03592979|EXPERIMENTAL|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
62462575|NCT03412357|EXPERIMENTAL|indwelling pleural catheter|
62462576|NCT01020734|EXPERIMENTAL|transplantation|perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
62462577|NCT00976664|ACTIVE_COMPARATOR|Orthotic group|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
62462578|NCT00976664|OTHER|Shoe Orthotic Wait group|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.
62462579|NCT05317078|EXPERIMENTAL|Part 1: AMG 794 Monotherapy Dose Exploration|Participants with claudin 6 (CLDN6)-positive advanced/metastatic non-squamous non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), or other solid tumor indications will be treated in up to 11 multiple ascending cohorts with additional participants optionally enrolled in dose exploration cohorts with target dose levels that have previously been shown to be safe and tolerable.
62462580|NCT05317078|EXPERIMENTAL|Part 2: AMG 794 Monotherapy Dose Expansion|Participants with CLDN6-positive advanced/metastatic NSCLC, EOC, or other solid tumor indications will be treated with the OBD of AMG 794 identified in Part 1.
62462581|NCT02506309|EXPERIMENTAL|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
62462582|NCT02506309|ACTIVE_COMPARATOR|TOT trans obturator tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
62462583|NCT05137483||With cognitive impairment|Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.
62462584|NCT05137483||without cognitive impairment|Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.
62462585|NCT03639311|EXPERIMENTAL|CAB LA + RPV LA Q2M|Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 milligrams (mg) plus RPV 25 mg and who successfully completed Week 300 received their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections were administered 1 month after initial loading dose, with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants continued to receive the treatment until the study intervention was locally approved and commercially available. Participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason entered a 52-week long-term follow-up (LTFU) Phase.
62462586|NCT03639311|EXPERIMENTAL|DTG + RPV|Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 mg plus RPV 25 mg and who successfully completed Week 300 received their first dose of the Dolutegravir (DTG) 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12 in the current study. These participants were not eligible for the LTFU phase.
62089481|NCT04958031|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo matched to CVL-871 tablets orally QD until Day 85 during the treatment period.
62089482|NCT01256476|EXPERIMENTAL|pitavastatin 4 mg once daily (QD)|
62089483|NCT01256476|ACTIVE_COMPARATOR|pravastatin 40 mg once daily (QD)|
62288024|NCT03541421|EXPERIMENTAL|Intervention|The patients administers own drugs during hospital stay.
62462587|NCT03639311|EXPERIMENTAL|LTFU: CAB LA+RPV LA Q2M Group|This group included the participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason before end of Maintenance Period. The participants entered a 52-week LTFU period.
62462588|NCT04944537||ICU management for patients with severe trauma|Group to investigate the current status of ICU management for patients with severe trauma
62462589|NCT02359617|EXPERIMENTAL|glucose sensing and insulin delivery|"Subcutaneous insulin delivery with an insulin pump plus glucose sensing with a continuous glucose sensor placed at the site of subcutaneous insulin delivery.~In parallel, capillary glucose determinations using a conventional glucose meter as well as glucose sensing in subcutaneous, insulin-unexposed tissue using a continuous glucose sensor."
62462590|NCT03560544|EXPERIMENTAL|Breaking up sitting time|A behaviour-change intervention to break up prolonged sitting in the workplace
62462591|NCT03560544|NO_INTERVENTION|Control|The participants in the control group will continue their daily activities as normal without any form of information about the intervention.
62654405|NCT02422654|EXPERIMENTAL|Concentration 2 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62654406|NCT02422654|EXPERIMENTAL|Concentration 2 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62654407|NCT02422654|EXPERIMENTAL|Concentration 2 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62089484|NCT02890056|EXPERIMENTAL|H2GO! intervention|H2GO! is a community-based behavioral intervention to reduce sugar-sweetened beverage consumption and promote water intake among school-age youth and parents.The intervention consists of 6 weekly group-based sessions (1-hour sessions twice a week) that target beverage knowledge, attitudes, and behaviors through interactive activities, youth-produced narratives, and parent-child activities. The intervention is delivered through a youth-based community setting (Boys and Girls Clubs of America) by trained Boys and Girls Club staff.
62089485|NCT02890056|NO_INTERVENTION|Comparison|Usual care will take place at the comparison site (standard programming at the Boys and Girls Club comparison site).
62089486|NCT02219828|PLACEBO_COMPARATOR|Placebo|placebo sc
62089487|NCT02219828|ACTIVE_COMPARATOR|Anakinra|Anakinra 2mg/Kg up to 100mg (maximum dose)
62089488|NCT04307602|EXPERIMENTAL|Children with cerebral palsy GMFCS IV-V|Exercise intervention in the waling aide Innowalk
62089489|NCT04307602|ACTIVE_COMPARATOR|Children with cerebral palsy GMFCS I-II|Exercise intervention on spinning bikes
62288025|NCT03541421|NO_INTERVENTION|Control|The patients receive medications from the medicine room dispensed by a nurse (standard care). No intervention
62288026|NCT04711096||Group A|TAB group formed of 65 patients
62288027|NCT04711096||Group B|"Group B : The Infiltration Group formed of 65 patients.~• This group will B wills provided with single-shot local anesthetic wound infiltration with 20 ml of 0.25% bupivacaine injected subcutaneously above and below skin incision before closure of skin."
62288028|NCT04711096||Group C|"Group C : Narcotics only group formed of 20 patients~• routine analgesic was taken only without any intervention"
62288029|NCT04103866|EXPERIMENTAL|Pressure Offloading Innersole System|Use of Juvederm Voluma in the foot for fat pad restoration
62288030|NCT01589484|EXPERIMENTAL|Shockwave lithotripsy (SWL)|All patients will be submitted to a noncontrast computed tomography before to shockwave lithotripsy (SWL). Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
62288031|NCT01247311|ACTIVE_COMPARATOR|1.|"1,25 Vitamin D (0.50ug \*3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
62288032|NCT01247311|ACTIVE_COMPARATOR|2.|"25 Vitamin D (5000IU \* 3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
62462592|NCT05486637|EXPERIMENTAL|Vocal emotion communication by children and adults with cochlear implants or normal hearing|Participants will be native speakers of American English and include pediatric cochlear implant recipients with unilateral or bilateral devices aged 6-19 years, children with normal hearing aged 6-19 years, postlingually deaf adults with cochlear implants, and adults with normal hearing. In Aim 1 participants will listen to emotional speech sounds and identify the talker's intended emotion. In Aim 2 participants will be invited to produce emotional speech by reading out scripted materials or in a more naturalistic conversational setting.
62462593|NCT01026077||Fibromyalgia/prospective pregnancies|Women taking Savella during pregnancy. Register prospectively, provide verbal consent.
62462594|NCT02234050|EXPERIMENTAL|Trabectedin|Patient will be treated with trabectedin
62462595|NCT02234050|OTHER|Local standard of care|Treatment in the control arm is left to the discretion of the investigator, according to the local standard of care.
62462596|NCT04590300|OTHER|Schizophrenia|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
62462597|NCT04590300|OTHER|Bipolar disorder|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
62288033|NCT01247311|PLACEBO_COMPARATOR|3.|Placebo given orally 3xweek for six months
62654408|NCT02422654|EXPERIMENTAL|Concentration 2 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62288034|NCT06206889||Nurse|Nurses working in tertiary intensive care
62288035|NCT02058732|ACTIVE_COMPARATOR|ALS patients receivng stem cells|Amyotrophic lateral sclerosis(ALS)subjects, who will be receiving stem cells, will undergo a brief clinical evaluation and questionnaire that will last approximately 20 to 30 min. Subjects will be asked to undergo magnetic resonance imaging(MRI)scans of the cervical spine and brain that will last approximately 60 minutes.
62288036|NCT02058732|ACTIVE_COMPARATOR|ALS patients not receiving stem cells|Amyotrophic lateral sclerosis(ALS)patient who will not be receiving stem cells, will have an MRI that lasts approximately 60 minutes. This MRI will be repeated at three different time points. Subjects will have an initial MRI, then another at both 6 and 12 months after the initial magnetic resonance imaging(MRI)scan. Subjects will also complete a clinical examination which will take approximately 30 minutes for each MRI. The follow-up magnetic resonance imaging(MRI)scans done for ALS patients who do not receive stem cells are part of routine clinical studies and therefore subjects will not be billed.
62462598|NCT02522234|EXPERIMENTAL|F-627 240 µg/kg|"F-627 at the dose of 240 mcg/kg administered by s.c. injection on Day 2 of each cycle for up to 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
62462599|NCT02522234|EXPERIMENTAL|F-627 320 µg/kg|"F-627 at the dose of 320 mcg/kg administered by s.c. injection on Day 2 of each cycle for 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
62462600|NCT01312922|EXPERIMENTAL|PNB01|oral, once daily administration
62462601|NCT01312922|ACTIVE_COMPARATOR|citalopram|oral, once daily administration
62654409|NCT02422654|EXPERIMENTAL|Concentration 2 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62654410|NCT02422654|EXPERIMENTAL|Concentration 3 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62654411|NCT02422654|EXPERIMENTAL|Concentration 3 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62462602|NCT01312922|SHAM_COMPARATOR|pipamperone|oral, once daily administration
62462603|NCT03814239||no protocol|liberal fluid therapy
62462604|NCT03814239||protocol|fluid therapy according to stroke volume variation (SVV) monitor, tranexamic acid administration, use of cell saver
62462605|NCT03329027|EXPERIMENTAL|Active Comparator-Vibrating Mode 1|Patients will receive vibrating capsule Vibrating Mode 1 for 8 weeks of treatment (5 capsules/week). Active Mode 1 and Active Mode 2 differ in their vibration sessions
62462606|NCT03329027|EXPERIMENTAL|Active Comparator-Vibrating Mode 2|Patients will receive vibrating capsule Vibrating Mode 2 for 8 weeks of treatment (5 capsules/week). Active Mode 1 and Active Mode 2 differ in their vibration sessions
62654412|NCT02422654|EXPERIMENTAL|Concentration 3 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62654413|NCT02422654|EXPERIMENTAL|Concentration 3 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62654414|NCT02422654|EXPERIMENTAL|Concentration 3 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
62654415|NCT05944796|EXPERIMENTAL|Diathermy|The experimental group will receive 10 diathermy sessions.
62654416|NCT05944796|PLACEBO_COMPARATOR|Placebo|The placebo comparator, will receive 10 placebo sessions.
62654417|NCT03816046|EXPERIMENTAL|Technique 1 The Quadrant technique|Intervention: 25 Botulinum Toxin injections. 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
62462607|NCT03329027|SHAM_COMPARATOR|Sham Comparator|Patients will receive sham capsule for 8 weeks of treatment (5 capsules/week). The Sham capsule is visually similar to the active capsules (Active Mode 1 and Active Mode 2, which differ in their vibration sessions) but without the active components.
62462608|NCT04165564||Group 1 - Screening|Participants in this group will be 55-77 years old and currently smoke or were former smokers with 30 pack-years or more (and quit less than 15 years ago)
62462609|NCT04165564||Group 2 - Incidental|Participants in this group will be \> 45 years old and currently smoke or were former smokers with 10 pack-years or more (and quit less than 15 years ago)
62462610|NCT02994186||Surgical Weight Loss|Patients in this group are those that will be undergoing bariatric surgery (either Roux-en-Y gastric bypass or vertical sleeve gastrectomy).
62654418|NCT03816046|EXPERIMENTAL|Technique 2 the six injection technique|Intervention: 6 Botulinum Toxin injections. will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units
62654419|NCT04646629|EXPERIMENTAL|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment"
62089490|NCT04307602|ACTIVE_COMPARATOR|Children without disabilities|Exercise intervention on spinning bikes
62288037|NCT02116621|EXPERIMENTAL|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
62288038|NCT02116621|NO_INTERVENTION|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
62288039|NCT02772757|ACTIVE_COMPARATOR|Standard of Care group|Standard of Care group will receive the standard, face-to-face hearing aid fitting and verification approach
62462611|NCT02994186||Medical Weight Loss|Patients in this group are those who are being enrolled in a supervised medical weight loss program.
62462612|NCT00163826||Trauma Patients|Major trauma patients
62462613|NCT05754008|EXPERIMENTAL|AURORA Care Strategy|Participants will receive the AURORA Care Strategy in addition to their usual diabetes care.
62462614|NCT05754008|NO_INTERVENTION|Usual Care|No intervention will be employed. This arm will continue to receive their usual diabetes care.
62462615|NCT04526964|OTHER|Intervention Group (IGr)|Participants of the intervention group (IGr) receive self-management support and skills training based on the modular self-management curriculum during the inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up and a supplementary app.
62462616|NCT04526964|NO_INTERVENTION|Control Group (CGr)|Participants in the control group (CGr) receive the standard follow-up procedures (care as usual).
62462617|NCT05334147||Anlotinib in combination with chemotherapy|anlotinib12mg qd p.o. d1-14/21day/cycle；eribulin 1.4 mg/m2，d1\&d8/21day/cycle；capecitabine 1000 mg/m2，bid，d1-14/21day/cycle.
62654420|NCT04646629|SHAM_COMPARATOR|sham electroacupuncture treatment|"sham electroacupuncture treatment participants in the control group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
62654421|NCT01759914||Potent topical steroid-treated|Patients treated with potent topical steroids
62654422|NCT01759914||Superpotent topical steroid-treated|Patients treated with superpotent topical steroids
62089491|NCT04921605|EXPERIMENTAL|Tricuspid regurgitation|Subjects received the Dragonfly system for the treatment of tricuspid regurgitation.
62288040|NCT02772757|EXPERIMENTAL|Average RECD group|This group will have their hearing aid fitting via the coupler using average RECD values during the fitting
62654423|NCT04023708||Cohort I: CYD-TDV exposed pregnant women and offspring|Pregnant women of any age and their offspring who were inadvertently exposed to CYD-TDV anytime during the pregnancy or in the 30 days preceding their LMP
62288041|NCT02772757|EXPERIMENTAL|Measured RECD group|This group will have their hearing aid fitting via the coupler using measured RECD values during the fitting
62288042|NCT05812391|ACTIVE_COMPARATOR|test group|Supra-gingival erythritol powerder air polishing Sub-gingival erythritol powerder air polishing Supra-gingival debridement Sub-gingival debridement
62288043|NCT05812391|ACTIVE_COMPARATOR|conventional group|Supra-gingival debridement Sub-gingival debridement Polishing with polishing paste
62462618|NCT05334147||chemotherapy|eribulin 1.4 mg/m2，d1\&d8/21day/cycle；capecitabine 1000 mg/m2，bid，d1-14/21day/cycle.
62462619|NCT03136666|EXPERIMENTAL|Nifedipine + Candesartan cilexetil|Coadministration of single doses of nifedipine and candesartan tablets
62654424|NCT02030873|EXPERIMENTAL|Virtual simulation training first|Participants in this arm receive virtual simulation training before dissection training.
62654425|NCT02030873|NO_INTERVENTION|Dissection training first|Participants in this arm receive dissection training first and then virtual simulation training.
62119932|NCT01700400|EXPERIMENTAL|Experimental Phase I Dose Escalation|"Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3~Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3~Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3~Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3"
62120169|NCT03814252|EXPERIMENTAL|Lesion-targeted ablation with MRI-TULSA|Intervention: Targeted lesion based thermoablation of MRI-visible biopsy proven clinically significant prostate cancer. Ablative effect is aimed to cover lesion with 5 mm MRI based healthy tissue overlap wherever possible but not compromising viability of critical tissues, mainly the wall of rectum.
62089492|NCT05583747|EXPERIMENTAL|Treatment Course A: E-field Modeling|Your Magnetic Resonance Image (MRI) results and rTMS calibration information (motor threshold) will be used to create a brain model and identify the targeted location, iTBS coil position and intensity for your iTBS rTMS treatment. You will undergo iTBS rTMS treatment in this study for 6 weeks. There will be 5 iTBS treatment sessions per week, lasting approximately 3 minutes each, once daily for 5 days in a row (always Monday to Friday). Each day after treatment, you will also complete a brief set of questionnaires to track your symptoms, which will take 15 minutes. After every 5 treatments, you will complete an extra interview that will take an additional 30 minutes. There will also be two follow-up visits at 1 and 4 weeks after the end of treatment, each lasting approximately 1 hour. During these follow-up visits, you will be asked to complete a brief set of questionnaires and interviews to monitor your symptoms.
62089493|NCT05583747|ACTIVE_COMPARATOR|Treatment Course B: Beam F3|The targeted iTBS rTMS treatment location and intensity will be determined via standard parameters, specifically anatomical landmarks and your rTMS calibration information (motor threshold). You will undergo iTBS rTMS treatment in this study for 6 weeks. There will be 5 iTBS treatment sessions per week, lasting approximately 3 minutes each, once daily for 5 days in a row (always Monday to Friday). Each day after treatment, you will also complete a brief set of questionnaires to track your symptoms, which will take 15 minutes. After every 5 treatments, you will complete an extra interview that will take an additional 30 minutes. There will also be two follow-up visits at 1 and 4 weeks after the end of treatment, each lasting approximately 1 hour. During these follow-up visits, you will be asked to complete a brief set of questionnaires and interviews to monitor your symptoms.
62089494|NCT02521064||Exclusive Enteral Nutrition (EEN)|The patient will be admitted to hospital for placement of the nasogastric tube and commencement of exclusive enteral nutrition (EEN). Nutritional feeds will consist of a semi-elemental (whey-peptide based) formula that will make up all of the patient's daily caloric needs (120% of BMR). Feeds will slowly be titrated up to full volume and strength during the hospital stay. The patient will receive instructions how to decrease the number of hours of feeds once at home. The patient will be seen in clinic at two weeks and will receive a phone call from the dietician at 4 weeks to assess progress and symptom improvement. At 8 weeks, food will start to be reintroduced slowly, as per the dietician's instructions.
62089495|NCT02521064||Prednisone|Patients who receive the prednisone intervention will follow the Division of Pediatric Gastroenterology and Nutrition protocol for corticosteroid induction therapy, with 2 weeks of high dose IV/PO prednisone (maximum 40mg/day) followed by a 6 week wean (approximately decreasing 5mg/day per week). The patient will receive a phone call from the nurse practitioner at two weeks and will be seen in clinic at 4 weeks to assess progress and symptom improvement.
62089496|NCT05481749||Neuropsico-Ger|People aged 80 or more years, non-institutionalized, and without pathologies potentially affecting cognitive status.
62089497|NCT05857137|EXPERIMENTAL|Active TMS|Participants will receive single-session administration of TMS. Functional MRI will be acquired before and immediately after the intervention.
62089498|NCT05857137|PLACEBO_COMPARATOR|Placebo TMS|Participants will also receive single session administration of placebo TMS (at least two days apart from the day of the active TMS). Functional MRI will be acquired before and immediately after the intervention.
62089499|NCT00465712|EXPERIMENTAL|A|Transabdominal amnioinfusion performed before external cephalic version
62089500|NCT00465712|NO_INTERVENTION|V|Without transabdominal amnioinfusion
62089501|NCT01028703||Donors|"110 will be cases that undergo uninephrectomy"
62089502|NCT01028703||Controls|"110 controls"
62288044|NCT01884792|PLACEBO_COMPARATOR|Sitting Oral Glucose Tolerance Test|An OGTT is performed while the subject sits at their desk for the entire 2-hour period. 5 blood sugar measurements are taken and a 75g dextrose beverage is consumed following the first, baseline blood sugar reading. The blood sugar is then measured every 30 minutes up to 120 min.
62462620|NCT03648944|EXPERIMENTAL|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
62089503|NCT05401422|ACTIVE_COMPARATOR|Pulsed dye laser|Laser
62089504|NCT05401422|ACTIVE_COMPARATOR|Doxycycline|Drug
62089505|NCT05401422|ACTIVE_COMPARATOR|Brimonidine gel 0.33%|Topical drug
62089506|NCT05871242|EXPERIMENTAL|Treatment arm|Treatment with Lactobacillus crispatus M247
62288045|NCT01884792|EXPERIMENTAL|Standing Oral Glucose Tolerance Test|The participant stands at their desk for the duration of the 2-hour blood sugar test. The same procedure is performed as in the sitting condition.
62288046|NCT01884792|PLACEBO_COMPARATOR|Sitting Continuous Glucose Monitor|A continuous blood glucose monitor is worn for 5 days while at work. In the sitting condition the participant only sits at their desk for the duration of the week. Blood sugar is monitored 4 times per day to calibrate the CGM and an accelerometer is worn to track physical activity.
62654426|NCT00589719||2000,3000,4000|Children at risk for asthma were identified using a cross-sectional asthma screening survey.
62462621|NCT03648944|ACTIVE_COMPARATOR|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
62654427|NCT02141555|ACTIVE_COMPARATOR|Vaginal misoprostol|Participants will insert four misoprostol tablets (total of 800 micrograms) deeply into the vagina with their fingers.
62654428|NCT02141555|EXPERIMENTAL|Buccal Misoprostol|Participants will place two tablets of misoprostol between their gum and cheek on each side (total 800 micrograms), then swish and swallow the remnants after 30 minutes.
62654429|NCT03300765|EXPERIMENTAL|Apatinib with IMRT|Participants will receive apatinib (0.5g, daily) for two cycles followed by intensity modulated radiation therapy (Primary site and lymph nodes: 66 Gy/33F, metastatic site: 40-60Gy/20-30F)
62654430|NCT00966433|EXPERIMENTAL|Spontaneous ventilation|Pt's will be allowed to breathe spontaneously through the PLMA during surgery without the assistance of positive pressure ventilation.
62654431|NCT00966433|EXPERIMENTAL|Pressure support ventilation|Pt's will receive positive pressure assistance with each spontaneous breath through the PLMA.
61905211|NCT03598114|NO_INTERVENTION|Control Condition|"* In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training~* The control group will receive a follow-up survey inviting them to evaluate their progress on creating their sustainability plan. Responses on the follow-up survey do not impact participants' standing in the study"
61905212|NCT00661518||1|Patients scheduled for conventional aneurysm repair
61905213|NCT00661518||2|Patients scheduled for endovascular aneurysm repair
62654432|NCT00966433|ACTIVE_COMPARATOR|Pressure control ventilation|Pt.'s will be placed on the ventilator and ventilated with pressure control. through the PLMA.
62654433|NCT04660045|EXPERIMENTAL|Acalabrutinib|Acalabrutinib 100 mg will be administered orally twice daily continuously in 28-day cycles until treatment is discontinued for any reason.
62654434|NCT06298149|EXPERIMENTAL|Turtle Island Tales|All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
62654435|NCT01384877|EXPERIMENTAL|Lidocaine|Lidocaine
62654436|NCT01384877|PLACEBO_COMPARATOR|Placebo (D5W)|Placebo first as compared with lidocaine first
62654437|NCT01225302|EXPERIMENTAL|Arm A|
62654438|NCT01225302|EXPERIMENTAL|Arm B|
62654439|NCT02397525|EXPERIMENTAL|LIPO-202|
62654440|NCT01053832|OTHER|Ventricular Pace Suppression- ON|
62654441|NCT01053832|OTHER|Ventricular Pace Suppression- OFF|
62654442|NCT03738696|EXPERIMENTAL|Liposomal bupivacaine Interscalene Block|"Interscalene block:~* 10cc (133mg) liposomal bupivacaine;PLUS~* 10cc 0.25% bupivacaine"
62654443|NCT03738696|ACTIVE_COMPARATOR|Ropivacaine Interscalene Catheter|"* 20cc 0.25% bupivacaine interscalene block; PLUS~* Ropivacaine 0.25% interscalene catheter (6ml/hr for 48hrs)"
62654444|NCT05684107|ACTIVE_COMPARATOR|IPACK block|
61905216|NCT01801345|OTHER|Rested|Subjects will perform the scenario, once during a normal workday (rested)
61905217|NCT01801345|ACTIVE_COMPARATOR|Fatigued|Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued).
62654445|NCT05684107|ACTIVE_COMPARATOR|sciatic nerve block|
62654446|NCT05684107|ACTIVE_COMPARATOR|adductor canal block|
62654447|NCT03795948|OTHER|PROM Evaluation for stroke patients|Patient will be enrolled and PROMs will be collected.
61905218|NCT04408378||mild pneumonia|The patients who has followed in the ward
61905219|NCT04408378||severe pneumonia|The patiens who has followed in the intensive care unit
61905220|NCT04408378||control group|patients who has not covid 19 pneumonia
61905223|NCT04279106|EXPERIMENTAL|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62089507|NCT05871242|NO_INTERVENTION|Control arm|No Probiotic treatment
62654448|NCT06443827|EXPERIMENTAL|amantadine sulphate and placebo with schema A-B-A-B|"To obtain solid evidence of amantadine sulphate effects and their temporal dynamics, we conducted a double-blind, placebo-controlled, crossover (within subjects) study with an A-B-A-B treatment scheme, in which placebo (A) and amantadine sulphate (B) intervention sessions alternated weekly in the same patient for a total of four weeks (A1-B1-A2-B2)."
62654449|NCT00700635|EXPERIMENTAL|Menactra® Group 1|Participants aged 2 to \< 4 years
62654450|NCT00700635|EXPERIMENTAL|Menactra® Group 2|Participants aged 4 to \< 6 years
62654451|NCT00700635|ACTIVE_COMPARATOR|Menactra® Group 3|Participants aged 6 to \< 11 years
62654452|NCT02455193|EXPERIMENTAL|Exercise intervention|10 weeks of a moderate exercise intervention
62654453|NCT02455193|ACTIVE_COMPARATOR|Diet intervention|10 weeks of a diet intervention
62654454|NCT05880888|EXPERIMENTAL|Renuva Injection|Each subject will receive a single injection of up to 3ccs of Renuva into their diseased fat pad.
62654455|NCT04422886|EXPERIMENTAL|Physio+tDCS|Receives 20 minutes of active tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
62654456|NCT04422886|SHAM_COMPARATOR|Physio+sham|Receives 20 minutes of sham tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
62654457|NCT04016974|EXPERIMENTAL|Oral semaglutide|
62654458|NCT04016974|PLACEBO_COMPARATOR|Placebo|
62654459|NCT03852511|EXPERIMENTAL|Intravenous|Patients will receive three single doses of NG-350A by IV infusion, followed by multiple cycles of check point inhibitor treatment.
62654460|NCT01235221|EXPERIMENTAL|BIIB041 (Fampridine-SR)|Participants take 10 mg sustained-release tablets of fampridine twice daily for up to 27 months or until the product is commercially available.
61905224|NCT04279106|ACTIVE_COMPARATOR|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62288047|NCT01884792|EXPERIMENTAL|Standing Continuous Glucose Monitor|Participants are instructed to stand intermittently for at least half of their work day during this 5 day period. Blood sugar is monitored and physical activity is tracked with an accelerometer.
62288048|NCT03688217|EXPERIMENTAL|Philani Intervention Model+MOVIE (PIM+M)|Participants will receive the standard PIM perinatal home visiting program together with the MOVIE intervention (13 entertainment-education videos about infant feeding). The PIM is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others. The MOVIE videos will be integrated into the regular home visiting program.
62288049|NCT03688217|ACTIVE_COMPARATOR|Philani Intervention Model (PIM)|Participants will receive the standard PIM perinatal home visiting program, which is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
62462622|NCT02879877|EXPERIMENTAL|UCB7858 (intravenous)|Various single doses, administered to various cohorts.
62462623|NCT02879877|PLACEBO_COMPARATOR|Placebo (intravenous)|Single dose placebo comparator for each cohort of iv administration.
62462624|NCT02879877|EXPERIMENTAL|UCB7858 (subcutaneous)|Various single doses, administered to various cohorts.
62288050|NCT03553394|ACTIVE_COMPARATOR|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
62288051|NCT03553394|NO_INTERVENTION|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
62288052|NCT01575613|EXPERIMENTAL|Hotspot Targeting|Four hotspot-targeted interventions will be superimposed on ongoing control measures: hotspots will be targeted with a combination of IRS, long-lasting insecticide treated nets (LLINs), larviciding and a focal screening and treatment (FSAT)campaign.
62462625|NCT02879877|PLACEBO_COMPARATOR|Placebo (subcutaneous)|Single dose placebo comparator for each cohort of sc administration.
62462626|NCT05844722|EXPERIMENTAL|MBCT group|The intervention group were involved in MBCT intervention in addition to usual care. MBCT intervention was designed to consist of eight 1.5-hour group sessions over 6 consecutive weeks.
62462627|NCT05844722|ACTIVE_COMPARATOR|Control group|Received usual care (standard multidisciplinary stroke care) over 6 weeks.
62654461|NCT01730313|EXPERIMENTAL|Pyridoxine (B6)|Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks
62654462|NCT01730313|EXPERIMENTAL|Phenytoin|Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks
62654463|NCT01730313|EXPERIMENTAL|Sodium Valproate|Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks
62654464|NCT01730313|PLACEBO_COMPARATOR|Placebo|Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm
62654465|NCT02113527||Epigastric pain syndrome (EPS)|Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
62654466|NCT02113527||Postprandial distress syndrome (PDS)|Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
62288053|NCT01575613|NO_INTERVENTION|Control|Standard of care as determined by the Division of Malaria Control of the Kenyan Ministry of Health
61905225|NCT04279106|ACTIVE_COMPARATOR|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62288054|NCT06261411|EXPERIMENTAL|Lung Ultrasound|Lung ultrasound based on specified protocol as primary method of investigation
62288055|NCT06261411|NO_INTERVENTION|Routine Care|Routine care defined as conventional chest x-ray as primary method of investigation
62288056|NCT00649454|EXPERIMENTAL|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
62288057|NCT00649454|ACTIVE_COMPARATOR|2|Metaglip® Tablets 5 mg/500 mg
62462628|NCT00208026|EXPERIMENTAL|Pimecrolimus 1% Cream|Treatment with drug/Elidel. Single arm-open-label treatment arm. A Pilot Study of the Efficacy and Safety of Pimecrolimus Cream 1% for the Treatment of Netherton Syndrome:
62462629|NCT03693430|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
62654467|NCT02113527||Healthy subjects|Healthy subjects as control group
62654468|NCT02773225|EXPERIMENTAL|Eltrombopag + Ciclosporin A|"Eltrombopag, 75 mg film tablets, starting dose: 2 tablets (150 mg per day), daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
62654469|NCT02773225|PLACEBO_COMPARATOR|Placebo + Ciclosporin A|"Placebo for Eltrombopag 75 mg film tablets, 2 tablets, daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
61905226|NCT04279106|PLACEBO_COMPARATOR|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62462630|NCT03693430|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
62462631|NCT02326610|ACTIVE_COMPARATOR|hGH, ZOMACTON® (somatropin)|For infants in the treatment group receiving ZOMACTON® (somatropin) growth hormone by injection
62462632|NCT02326610|NO_INTERVENTION|No human growth hormone|No growth hormone is given.
62654470|NCT01994031|EXPERIMENTAL|Dose level A|Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
62654471|NCT01994031|EXPERIMENTAL|Dose level B|Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
62288058|NCT01841892|NO_INTERVENTION|Usual Care Control|
62288059|NCT01841892|EXPERIMENTAL|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
62288060|NCT02455401|EXPERIMENTAL|high dose remifentanil group|Intervention: high dose remifentanil will be administrated.
62288061|NCT02455401|EXPERIMENTAL|low dose remifentanil group|Intervention: low dose remifentanil will be administrated
62462633|NCT01285037|EXPERIMENTAL|LY2801653|"This study consists of a dose escalation of LY2801653 (Part A) followed by dose confirmation cohorts in four tumor types (adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver metastasis, and cholangiocarcinoma) (Part B).~Part C consists of dose determination for LY2801653 in combination with cetuximab in participants with head and neck squamous cell carcinoma followed by an expansion cohort.~Part D consists of dose determination for LY2801653 in combination with cisplatin in participants with cholangiocarcinoma followed by an expansion cohort.~Part E consists of dose determination for LY2801653 in combination with gemcitabine and cisplatin.~Part F consists of dose determination for LY2801653 in combination with ramicirumab."
62462634|NCT01014065||1|Patients with renal cell carcinoma scheduled to receive sunitinib
62288062|NCT02455401|PLACEBO_COMPARATOR|No remifentanil group|Intervention: no remifenatnil will be administrated
62654472|NCT01994031|EXPERIMENTAL|Dose level C|Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
62120170|NCT06075212||Blin-PTCY|Post-transplant cyclophosphamide is used as graft versus host disease (GvHD) prophylaxis. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation.
62120171|NCT06075212||Blin-ATG|Antithymocyte globulin is used as graft versus host disease (GvHD) prophylaxis. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation.
62288063|NCT00445887|EXPERIMENTAL|Arm I (levonorgestrel)|Patients receive oral levonorgestrel once daily.
62462635|NCT01342328|PLACEBO_COMPARATOR|Control|For this arm, the volunteer subject will receive a saline infusion during the sleep session.
62462636|NCT01342328|EXPERIMENTAL|Dexmedetomidine (DEX)|For this arm, the volunteer subject will receive a DEX infusion for sedation during the sleep session.
62462637|NCT01342328|EXPERIMENTAL|Propofol|For this arm, the volunteer subject will receive a propofol infusion for sedation during the sleep session.
62120172|NCT06075212||Control|Patients don't take blinatumomab treatment after transplantation.
62120173|NCT01899027|ACTIVE_COMPARATOR|Rosuvastatin Group|Patients will be randomized to receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
62462638|NCT05037006|EXPERIMENTAL|Group I-30|Inhalational anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
62462639|NCT05037006|EXPERIMENTAL|Group I-50|Inhalational anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
62288064|NCT00445887|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo once daily.
62288065|NCT05451719|EXPERIMENTAL|Fruquintinib Plus Capecitabine|Maintenance therapy with Fruquintinib Plus Capecitabine
62288066|NCT05451719|ACTIVE_COMPARATOR|Capecitabine|Maintenance therapy with Capecitabine
62462640|NCT05037006|EXPERIMENTAL|Group I-70|Inhalational anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
62462641|NCT05037006|EXPERIMENTAL|Group V-30|Intravenous anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
62462642|NCT05037006|EXPERIMENTAL|Group V-50|Intravenous anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
62462643|NCT05037006|EXPERIMENTAL|Group V-70|Intravenous anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
62462644|NCT02804737||Web Group|Patients given web site (aiddly) instructions for colonoscopy
62120174|NCT01899027|PLACEBO_COMPARATOR|Placebo group|Patients will be randomized to receive two overnight high doses of Placebo before RNA and another placebo dose 2 h before the procedure
62120175|NCT03160781|EXPERIMENTAL|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
62462645|NCT02804737||Paper Group|Patients given paper instructions for colonoscopy
62462646|NCT01760408||Home PN - pediatric|Pediatric patients (under 18) on Home PN
62654473|NCT01994031|EXPERIMENTAL|Dose level D|Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
62654474|NCT01994031|EXPERIMENTAL|Dose level E|Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
62654475|NCT01994031|ACTIVE_COMPARATOR|Comparator|Paclitaxel injection 175mg/m2 on day 1, each 21 days
62654476|NCT01883167|EXPERIMENTAL|Febuxostat|"Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: RDEA3170 10 mg or placebo qd."
62654477|NCT01883167|EXPERIMENTAL|RDEA3170|"Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: febuxostat 40 mg qd."
61905227|NCT05167240||Group 1|Group 1 - will constitute of participants with two repeated ABPM recordings (visits): the second visit performed between 01.04.2020 - 31.03.2021 (i.e., during the COVID-19 pandemic announced by the WHO in 11.03.2020) and the first visit 9-15 months before the second ABPM recording, but not later than 31.12.2019.
61905228|NCT05167240||Group 2|Group 2 - will constitute of participants with two repeated ABPM recordings (visits) - both visits performed before the pandemic: the second visit in 01.01.2019 - 31.12.2019 and the first visit 9-15 months before the second.
61905229|NCT03618355|EXPERIMENTAL|Cohort 1: 0.5 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg every week."
61905230|NCT03618355|EXPERIMENTAL|Cohort 2: 1 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg every week."
61905231|NCT03618355|EXPERIMENTAL|Cohort 3: 0.5 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg daily."
62089508|NCT02841722|OTHER|Biological samples|Only one arm in this pilot study. All patient will have a follow up and treatment as per standard care for this pathology. Specifically for the study all patients will have 8 additional blood samples to be drawn during the first 2 cycles of treatment (1 cycles is 21 days).
62089509|NCT04924101|EXPERIMENTAL|Pembrolizumab + MK-4830 + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle (cycle length = 3 weeks) every 3 weeks (Q3W) up to 35 administrations (up to approximately 2 years) or until disease progression (PD) or discontinuation, MK-4830 800 mg IV infusion on Day 1 of each cycle Q3W, up to 35 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m\^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
62089510|NCT04924101|EXPERIMENTAL|Pembrolizumab + Boserolimab + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle Q3W up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, boserolimab 30 mg IV infusion on Day 1 of each cycle (cycle length = 6 weeks) every 6 weeks (Q6W), up to 18 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m\^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
62119933|NCT06085755|EXPERIMENTAL|Trastuzumab deruxtecan + Afatinib|"The first part (PART A) will be in combination with T-DXd the starting dose of 20 mg afatinib MWF will be escalated to reach a maximum tolerated dose in patients with advanced gastric cancer patients with HER2-low, as defined by dose-limiting toxicity.~The second part (PART B) will be expansion cohort, in which Afatinib will be taken in combination with T-DXd according to the recommended Phase 2 dose(RP2D) confirmed through Part A from cycle 1."
62119934|NCT05386680|EXPERIMENTAL|OAV-101|Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
62119935|NCT02247713||Retrospective cohort|Participating centers will retrospectively provide demographic, tumor, treatment and follow-up details on at least 25 consecutive patients with stage III NSCLC previously treated with curative intent chemoradiotherapy (concurrent or sequential) in the period between 2010 and 2013.
62288067|NCT01894672|EXPERIMENTAL|LGX818|LGX818 capsules will be administered orally on a once -daily schedule (QD) dosing at a dose of 300 mg/day, 2 weeks on followed by a 2 week break. This schedule of 2 weeks on, followed by 2 weeks off, will continue for the duration of time the patients remains on the clinical trial. After the follow up visit patients will be contacted approximately every 12 weeks until they have received a subsequent therapy or until they have been off treatment for a year to monitor their survival.
62288068|NCT01505894|PLACEBO_COMPARATOR|Placebo - Young Subjects|Placebo - Young Subjects
62462647|NCT01760408||Adult patients on Home PN|Adult patients on Home PN
61905232|NCT03618355|EXPERIMENTAL|Cohort 4: 1 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg daily."
62119936|NCT02247713||Prospective cohort|Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
62462648|NCT04408365||COVID-19 patients|Adult COVID-19 patients admitted to intensive care units
62654478|NCT04146701||Acute heart failure|All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
62654479|NCT04146701||STEMI|All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
62654480|NCT04146701||NSTEMI|All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
62654481|NCT04146701||Ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF \<35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
62654482|NCT04146701||Non-ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF \<35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
62089511|NCT04924101|EXPERIMENTAL|Pembrolizumab + Lenvatinib + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each 3 week cycle (Q3W) up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, lenvatinib 8 mg once daily (QD) orally up to Cycles 1-4 cycles and up to 20 mg QD orally for Cycles 5-31 or until PD or discontinuation; etoposide 100 mg/m\^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
62089512|NCT05087732|EXPERIMENTAL|Stylage® M Lidocaïne|STYLAGE® M Lidocaine is a hyalorunic acid injectable gel with Lidocaine hydrochloride whose intended purpose is the filling of skin depressions on the face by dermal injection.
62089513|NCT05087732|ACTIVE_COMPARATOR|Stylage® M|STYLAGE® M Lidocaine is a hyalorunic acid injectable gel whose intended purpose is the filling of skin depressions on the face by dermal injection.
62288069|NCT01505894|PLACEBO_COMPARATOR|Placebo - Elderly Subjects|Placebo - Elderly Subjects
62288070|NCT01505894|EXPERIMENTAL|BI 409306 25 mg - Young Subjects QD|25 milligram (mg) of BI 409306 were administered in young subjects once daily (QD).
62288071|NCT01505894|EXPERIMENTAL|BI 409306 25 mg - Elderly Subjects QD|25 mg of BI 409306 were administered in elderly subjects once daily (QD).
62288072|NCT01505894|EXPERIMENTAL|BI 409306 50 mg - Young Subjects QD|50 mg of BI 409306 were administered in young subjects once daily (QD).
62288073|NCT01505894|EXPERIMENTAL|BI 409306 50 mg - Young Subjects BID|50 mg of BI 409306 were administered in young subjects twice daily (BID).
62288074|NCT01505894|EXPERIMENTAL|BI 409306 50 mg - Elderly Subjects QD|50 mg of BI 409306 were administered in elderly subjects once daily
62654483|NCT04146701||Sepsis|All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
62288075|NCT01505894|EXPERIMENTAL|BI 409306 100 mg - Young Subjects QD|100 mg of BI 409306 were administered in young subjects once daily (QD).
62288076|NCT01505894|EXPERIMENTAL|BI 409306 100 mg - Elderly Subjects QD|100 mg of BI 409306 were administered in elderly subjects once daily (QD).
62288077|NCT00727402||Observational|healthy patients fit into lotrafilcon A contact lenses for continuous wear
62288078|NCT00501228|EXPERIMENTAL|Filgrastim Injections|
62288079|NCT04792502|EXPERIMENTAL|Planned Therapy|
62288080|NCT02368548|EXPERIMENTAL|Pharmaceutical care program|"1. Initiated in the Emergency Department (ED):~   1. Review of home medication and medication reconciliation based on Primary Care data~  2. Patient interview. Assessment of the patient's knowledge on the pharmacological treatment~  3. Development of the pharmacological history and registration in the medical record~  4. Adequacy of drug therapy. Identification of Drug Related Problems including reconciliation errors (DRP) and communication to medical team~  5. Pharmacotherapy monitoring~  6. Treatment validation and medication reconciliation at discharge~2. During the hospitalization (if admission from the ED):~   1. Treatment review and medication reconciliation~  2. Pharmacokinetics monitoring~  3. Retrospective validation of prescriptions and assessment of drugs appropriateness. DRP identification and communication to medical team~  4. Pharmacotherapy monitoring~  5. Validation and medication reconciliation at discharge~  6. Patient education at discharge"
62288081|NCT02368548|OTHER|Standard Care|"Stages:~1. Pharmaceutical care program in the episode at the Emergency Department:~   a. There was no monitoring of the patient by the pharmacist. Retrospective validation of the prescriptions was not performed.~2. During the hospitalization (if admission from the ED):~   1. Pharmacokinetics monitoring~  2. Retrospective validation of prescriptions and assessment of drugs appropriateness."
62654484|NCT04146701||Healthy controls|Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
62654485|NCT03913962|EXPERIMENTAL|Patient|Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor
62654486|NCT03913962|ACTIVE_COMPARATOR|Control|healthy children sex- and age-matched
62654487|NCT05849857|EXPERIMENTAL|Subcutaneous mosunetuzumab|"The duration of each treatment cycle is 21 days.~Cycle 1 Day 1:~5 mg Mosunetuzumab SC~Cycle 1 Day 8:~45 mg Mosunetuzumab SC~Cycle 1 Day 15:~45 mg Mosunetuzumab SC~Cycle 2-8 Day 1:~45 mg Mosunetuzumab SC~Patients in complete remission after 8 cycles enter follow-up. Patients with stable disease or partial remission can receive up to a total of 17 cycles:~Cycle 9-17 Day 1:~45 mg Mosunetuzumab SC"
62654488|NCT03290768|EXPERIMENTAL|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
62654489|NCT02314013|ACTIVE_COMPARATOR|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
62654490|NCT02314013|NO_INTERVENTION|No antibiotic|bowel rest and then, discharge until tolerable soft diet.
62654491|NCT02634177|ACTIVE_COMPARATOR|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
62462649|NCT02754622||Observational Group|"* 2hours before planned physical rehabilitation patients will have their regular ventilator changed to the study ventilator by an ICU Consultant and patients will be clinical stable for 30mins prior to the start of the planned physical rehabilitation.~* Intended physical rehabilitation as planned will continue without change. This session will be observed by a member of the research team to ensure accurate documentation of the exact timing of performance of the physical rehabilitation activity.~* Patients will also undergo an assessment by the Medical Research Council Sum-score and maximal inspiratory pressure (all part of routine physiotherapy assessment).~* Following the physical rehabilitation session, the patient to rate their perceived exertion then patients will also undergo ultrasound assessment of peripheral skeletal muscle architecture.~* Patients return to their original ventilator after 30mins by an ICU Consultant."
62462650|NCT04354532||209 patients were submitted to primary LBSG|All patients submitted to primary Laparoscopic Banded Sleeve Gastrectomy were examined. Collected data included demographic factors, pre-operative weight, pre-operative BMI, operative time, surgical complications, and clinical outcomes in terms of short and mid-term weight loss.
62462651|NCT01124929|ACTIVE_COMPARATOR|Arm 1: Category I treatment for 6 months|Anti-tuberculosis drugs
62462652|NCT01124929|ACTIVE_COMPARATOR|Arm 2: Category I treatment for 9 months|Anti-tuberculosis drugs,
62288082|NCT02674945||Wireless Activity tracker: Fitbit|Patients with brain tumor(s) will be give a wireless activity tracker (fitbit flex) to use during treatment. They will complete quality of life surveys and a sleep survey.
62288083|NCT03325322|EXPERIMENTAL|Treatment|Fisetin 20 mg/kg/day, orally for 2 consecutive days
62288084|NCT03325322|PLACEBO_COMPARATOR|Placebo|Placebo capsules orally for 2 consecutive days
62288085|NCT00838591|EXPERIMENTAL|1|MN-221 given i.v. 1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min \[600 μg\] + 13.3 μg/min for 45 min \[600 μg\]) as an adjunct to the standard of care for acute exacerbation of asthma.
62288086|NCT00838591|PLACEBO_COMPARATOR|Placebo|Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v. 1-hour infusion with a regimen as described for MN-221.
62288087|NCT04523740|EXPERIMENTAL|Placebo replacement|Participants will discontinue the paracetamol treatment, and be administered 6 to 8 tablets of placebo per day
62288088|NCT04523740|ACTIVE_COMPARATOR|Usual care with paracetamol|Participants will continue the paracetamol treatment, and be administered 6 to 8 tablets of 500mg paracetamol per day
62288089|NCT04188730|EXPERIMENTAL|Lofexidine (granules for reconstitution), fasted|Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.
62288090|NCT04188730|ACTIVE_COMPARATOR|LUCEMYRA (lofexidine) tablets, fasted|Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours
62462653|NCT03716011|OTHER|DAPT 3M or DAPT 12M|After stent implantation in DAPT 3M or DAPT 12M
62462654|NCT03991026|EXPERIMENTAL|Healthy food and Education/Cooking Classes|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, healthy eating attitudes, and demographics. Every week for 6 weeks, participants will pick-up a healthy food bag (e.g. fresh vegetables) for a $3 co-pay and attend an hour-long education classes at East Baltimore Medical Center. All participants will complete a survey at healthy food bag pick-up or an education class. Surveys at bag pick-up will ascertain outcomes like vegetable consumption. Surveys at education classes will ascertain outcomes like healthy eating attitudes. At 6 weeks, all participants will complete a follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again at 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
62654492|NCT02634177|PLACEBO_COMPARATOR|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
62654493|NCT03920800||Conservative management - progression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, with progressive lesions or lesions remaining present after 2 years of follow-up.
62288091|NCT04188730|EXPERIMENTAL|Lofexidine (granules for reconstitution), fed|Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.
62288092|NCT05611073||Distance with Minimal Intermediate Visual Acuity Group|Patients with bilateral implantation of Eyhance IOLs. And defined by BCDVA of 0.1 logMAR or better but a DCIVA of 0.4 logMAR or worse.
62288093|NCT05611073||Distance with Enhanced Intermediate/Near Visual Acuity Group|Patients with bilateral implantation of Eyhance IOLS. And defined by BCDVA of 0.1 logMAR or better and a DCIVA of 0.3 logMAR or better.
62288094|NCT02131857|EXPERIMENTAL|Staff|active interventional program based on Mindfulness training
62288095|NCT02131857|EXPERIMENTAL|Parents|active interventional program based on Mindfulness training
62288096|NCT02131857|EXPERIMENTAL|Patients with CF|active interventional program based on Mindfulness training
62288097|NCT00582556|ACTIVE_COMPARATOR|1|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
62288098|NCT00582556|ACTIVE_COMPARATOR|2|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given at mo 6
62288099|NCT00582556|ACTIVE_COMPARATOR|3|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
62288100|NCT05807009|EXPERIMENTAL|core exercise|the patients will receive seven core exercises two times a week for eight weeks
62288101|NCT04453735|ACTIVE_COMPARATOR|Intervention|Atorvastatin mylan 40 mg once daily
62288102|NCT04453735|NO_INTERVENTION|Control|No statin therapy
62288103|NCT01820715|EXPERIMENTAL|600㎍ of DA-3030 Injection|600㎍ of DA-3030 is injected once a day, for 5 continuous days.
62288104|NCT01820715|PLACEBO_COMPARATOR|Placebo|Placebo(a salin drip) is injected once a day, for 5 continuous days.
62089514|NCT01536782|ACTIVE_COMPARATOR|Bolus|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
62089515|NCT01536782|ACTIVE_COMPARATOR|Gravity|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
62089516|NCT01536782|ACTIVE_COMPARATOR|Pump|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
62089517|NCT03766828||inside-out-access technique with inside-out access device|
62089518|NCT03766828||access technique including Sharp recanalization|
62462655|NCT03991026|NO_INTERVENTION|Control Group|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, cooking habits, food security, healthy eating attitudes, and demographics. As a control group, participants will not partake in the healthy food bag pick-ups or cooking classes therefore they will not fill out those associated surveys. After the 6 weeks of the intervention, control participants will be given the follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again after 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
62462656|NCT00610090|EXPERIMENTAL|Treatment - UniFit AAA Stent Graft|
62089519|NCT00654940|ACTIVE_COMPARATOR|A|
62089520|NCT00654940|PLACEBO_COMPARATOR|B|
62089521|NCT01212263|EXPERIMENTAL|Clomiphene Citrate plus HP uFSH|Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
62089522|NCT01212263|ACTIVE_COMPARATOR|Step-up HP uFSH|HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter
62089523|NCT01663675||Trisomy 21 (Down syndrome)|Trisomy 21 (Down syndrome)
62288105|NCT03695029|EXPERIMENTAL|treatment group|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
62462657|NCT04558905|ACTIVE_COMPARATOR|Usual Medical Care Model|All the patients will receive face-to-face medical visits
62089524|NCT03068286|EXPERIMENTAL|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
62089525|NCT03068286|EXPERIMENTAL|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
62089526|NCT03068286|EXPERIMENTAL|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
62288106|NCT03695029|NO_INTERVENTION|control group|control group receive no drug, only follow-up
62288107|NCT06220006|EXPERIMENTAL|Pulsed Field Ablation|Pulmonary vein isolation using the Farapulse Pulsed Field Ablation System (Boston Scientific)
62288108|NCT06220006|ACTIVE_COMPARATOR|Cryoballoon Ablation|Pulmonary vein isolation using the Medtronic Cryoballoon Ablation System
62288109|NCT03883269|EXPERIMENTAL|Erythromycin 4%|Erythromycin 4% topical gel formulation, BID, 4 weeks
62288110|NCT03883269|EXPERIMENTAL|Clindamycin 1%|Clindamycin 1% topical lotion formulation, BID, 4 weeks
62288111|NCT03883269|PLACEBO_COMPARATOR|ethanol solution|70% topical ethanol solution, BID, 4 weeks
62654494|NCT03920800||Conisation|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital by means of conisations.
62654495|NCT03920800||Conservative management - spontaneous regression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, who showed a spontaneous regression of the lesions during the 2 years follow-up.
62654496|NCT00375661|NO_INTERVENTION|interferon|
62288112|NCT00454207|EXPERIMENTAL|sildenafil citrate (UK-92,480)|sildenafil citrate 20 mg TID
62462658|NCT04558905|EXPERIMENTAL|Hybrid Medical Care Model|The patients will receive alternating face-to-face medical visits and video medical consultations
62462659|NCT02778230|EXPERIMENTAL|Pea Fiber|Two fiber snacks fortified with 5 g/each of pea fiber (Best Pea Fiber 200) will be consumed each day for a period of two weeks.
62462660|NCT02778230|OTHER|Control|Two control snacks will be consumed each day for a period of two weeks.
62462661|NCT01475396|EXPERIMENTAL|Aerobic Exercise|
62288113|NCT00093613|EXPERIMENTAL|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity."
62462662|NCT01475396|EXPERIMENTAL|Anaerobic Exercise|
62089527|NCT04349579|EXPERIMENTAL|Rifamycine|Rifamycine is a broad spectrum semi-synthetic antibiotic that acts on gram-positive and gram-negative microorganisms. As a local application, it has areas of use in dentistry such as washing fistula mouths, maxillary sinus and abscess wounds and treating osteomyelitis.
62089528|NCT04349579|ACTIVE_COMPARATOR|Saline|Saline, also known as saline solution, is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds. It is also used to dilute other drugs to be injected and to wash the operation site in dental surgery operations. It is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.
62089529|NCT01924234|ACTIVE_COMPARATOR|morphine|Volunteers are given morphine injection
62089530|NCT01924234|ACTIVE_COMPARATOR|remifentanil|Volunteers are given remifentanil infusion
62089531|NCT00451997|EXPERIMENTAL|Gleevec + Low-Dose Ara-C|
62089532|NCT06696898|EXPERIMENTAL|Somatosensory Motor Control & Myofascial Release|A series of proprioceptive and neuromuscular control exercises targeting lumbar stability and pain reduction.Somatosensory Motor Control \& Myofascial Release Procedure.MFR is Manual therapy technique that focused on releasing fascial restrictions to improve lumbar mobility and decrease pain.
62288114|NCT03251885||women with preterm labor|pregnant women \< 37 weeks of gestations with regular uterine contractions and \> 3 cm dilation, \> 80% effacement
62288115|NCT03251885||women with term pregnancy|pregnant women \> 37 weeks of gestation
62288116|NCT06160401|EXPERIMENTAL|Singletine（DC407） ascending dose|Single ascending dose
62462663|NCT01475396|NO_INTERVENTION|Unchanged condition|
62288117|NCT06160401|EXPERIMENTAL|Singletine（DC407）food influence group|Food influence group
62288118|NCT06160401|PLACEBO_COMPARATOR|Singletine placebo comparator(Single ascending dose)|Single ascending dose
62462664|NCT03585530|EXPERIMENTAL|treatment group|
62288119|NCT06160401|PLACEBO_COMPARATOR|Singletine placebo comparator(food influence group)|Food influence group
62089533|NCT06696898|ACTIVE_COMPARATOR|Sensorimotor training|Somatosensory motor control are Structured exercises aimed at enhancing proprioception and motor control to reduce pain and improve function in sciatica patients.
62462665|NCT01434108|EXPERIMENTAL|Ornithine-phenylacetate|Administration of OP (OCR-002) during 5 days in addition to standard treatment of gastrointestinal bleeding.
62462666|NCT01434108|PLACEBO_COMPARATOR|Saline iv|Administration of control infusion (saline infusion) during 5 days in addition to standard treatment of gastrointestinal bleeding.
62462667|NCT00724256|EXPERIMENTAL|1|
62462668|NCT00724256|ACTIVE_COMPARATOR|2|
62462669|NCT05173207||Cardiothoracic surgical patients|Subjects will undergo one simultaneous instrumental examination of swallowing and concurrent monitoring of metrics of respiratory-swallow physiology. Research exam will be performed at bedside within Cardiac \& Thoracic Intensive Care Units during their early postoperative recovery.
62462670|NCT00828035|OTHER|1, REL|rel group : patients with light endoscopic robot
62462671|NCT00828035|ACTIVE_COMPARATOR|2, AO|AO group : Patients with surgery assistant
62462672|NCT00537225|EXPERIMENTAL|A-Exercise group|Home based exercise
62462673|NCT00537225|NO_INTERVENTION|B- Usual Care|Exercise as usually prescribed by provider
62462674|NCT01063543||patients with blood sample|Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity
61905244|NCT04167878|EXPERIMENTAL|ACDF with 3D printed biodegradable cervical fusion cage|A resorbable cervical interbody cage made of PCL-TCP.
62089534|NCT02696785|EXPERIMENTAL|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
62089535|NCT02696785|EXPERIMENTAL|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
62288120|NCT00308165|EXPERIMENTAL|Topotecan|Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
62288121|NCT06154902||Treated with idecabtagene vicleucel|
62288122|NCT06154902||Eligible for idecabtagene vicleucel|Eligible for idecabtagene vicleucel treatment but not treated
62288123|NCT01976949|ACTIVE_COMPARATOR|Social-networking intervention|Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
61905245|NCT04167878|ACTIVE_COMPARATOR|ACDF with PEEK cage|A structural PEEK cage with autologous bone.
62462675|NCT01245322|ACTIVE_COMPARATOR|Lactobacilli|different lactobacilli.
62462676|NCT02603250||Wicking|50% of the 132 children enrolled in the study will have their Hb measured using the wicking method of HemoCue® 201+ blood collection.
62462677|NCT02603250||Gravity|50% of the 132 children enrolled in the study will have their Hb measured using the gravity method of HemoCue® 201+ blood collection.
62462678|NCT04879888|EXPERIMENTAL|Vacuna|Triple-negative breast cancer patients with specific tumor mutation, with six doses of peptide-pulsed autologous dendritic cells after surgery.
62462679|NCT03554707|EXPERIMENTAL|SGT-53 with radiation or drugs|"Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed.~Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle."
62462680|NCT00150462|EXPERIMENTAL|CFZ 1.2 mg/m²|Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462681|NCT00150462|EXPERIMENTAL|CFZ 2.4 mg/m²|Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462682|NCT00150462|EXPERIMENTAL|CFZ 4.0 mg/m²|Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462683|NCT00150462|EXPERIMENTAL|CFZ 6.0 mg/m²|Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462684|NCT00150462|EXPERIMENTAL|CFZ 8.4 mg/m²|Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462685|NCT00150462|EXPERIMENTAL|CFZ 11.0 mg/m²|Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462686|NCT00150462|EXPERIMENTAL|CFZ 15.0 mg/m²|Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462687|NCT00150462|EXPERIMENTAL|CFZ 20.0 mg/m²|Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
61905249|NCT05621525|EXPERIMENTAL|Part A Dose Escalation and Part B Dose Expansion|"Part A: Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).~Part B: Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)"
61905250|NCT04526821|EXPERIMENTAL|Bovine Lactoferrin|Bovine Lactoferrin plus standard measures of personal protection.
61905251|NCT04526821|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin plus standard measures of personal protection.
62089536|NCT02696785|PLACEBO_COMPARATOR|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
61905252|NCT02675556|EXPERIMENTAL|Allogeneic hMSCs|Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
61905253|NCT02675556|PLACEBO_COMPARATOR|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
61905254|NCT02675556|EXPERIMENTAL|Pilot - Allogeneic hMSCs|Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
61905257|NCT01875679|ACTIVE_COMPARATOR|Conventional residency training|This group will continue their regular surgical training without any specific intervention.
61905258|NCT01875679|EXPERIMENTAL|Comprehensive Surgical Coaching (SCS)|The participants will receive an analysis of the technical performance as observed on baseline recordings of the index procedure. Training needs will be identified and a personalized coaching concept will be designed. Coaching sessions will include video debriefing of the participant's performance (sample recordings will be submitted by the participant during the sessions) and video assisted behavioral modeling using examples of good and poor technical performance. Coaching will also target increasing awareness of weaknesses and potential pitfalls in surgical technical task execution (error recognition).
62288124|NCT01976949|ACTIVE_COMPARATOR|Control group|12 week wait-list control subjects will be able to join a group after they complete the 12-week assessment and will be asked to complete a 24-week assessment in order to measure change over time. Subjects will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
62462688|NCT00150462|EXPERIMENTAL|CFZ 27.0 mg/m²|Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
62462689|NCT00150462|EXPERIMENTAL|CFZ 20/27 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
62462690|NCT00150462|EXPERIMENTAL|CFZ 20/27 mg/m² + DEX|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
62462691|NCT01099943|EXPERIMENTAL|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
62089537|NCT02696785|ACTIVE_COMPARATOR|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
62089538|NCT02694679|NO_INTERVENTION|Random 0|The CBNH intervention will be delivered to 0% of population targeted households in the village.
61905262|NCT06530979|EXPERIMENTAL|Nutritional education program intervention|Nutritional education program intervention (NEP group n=30) profound hearing-impaired people who will receive tailored nutritional education program intervention utilizing Saudi-Sign Language supplied by a sign language interpreter in the videos and person during sessions.
61905263|NCT06530979|NO_INTERVENTION|Control|Control (C group n=31) Profound hearing-impaired people who will non- receive tailored nutritional education program intervention utilizing Saudi-Sign Language
62089539|NCT02694679|ACTIVE_COMPARATOR|Random 5|The CBNH intervention will be delivered to a random 5% of targeted households in the village.
62089540|NCT02694679|ACTIVE_COMPARATOR|Random 10|The CBNH intervention will be delivered to a random 10% of targeted households in the village.
62089541|NCT02694679|ACTIVE_COMPARATOR|Random 20|The CBNH intervention will be delivered to a random 20% of targeted households in the village.
62089542|NCT02694679|ACTIVE_COMPARATOR|Random 30|The CBNH intervention will be delivered to a random 30% of targeted households in the village.
62089543|NCT02694679|ACTIVE_COMPARATOR|Random 50|The CBNH intervention will be delivered to a random 50% of targeted households in the village.
62089544|NCT02694679|ACTIVE_COMPARATOR|Random 75|The CBNH intervention will be delivered to a random 75% of targeted households in the village.
62089545|NCT02694679|ACTIVE_COMPARATOR|Random 100|The CBNH intervention will be delivered to a random 100% of targeted households in the village.
62089546|NCT02694679|NO_INTERVENTION|Friendship 0|CBNH 0% of population targeted
62089547|NCT02694679|EXPERIMENTAL|Friendship 5|The CBNH intervention will be delivered to 5% of households identified through friendship nomination.
62089548|NCT02694679|EXPERIMENTAL|Friendship 10|The CBNH intervention will be delivered to 10% of households identified through friendship nomination.
62089549|NCT02694679|EXPERIMENTAL|Friendship 20|The CBNH intervention will be delivered to 20% of households identified through friendship nomination.
62089550|NCT02694679|EXPERIMENTAL|Friendship 30|The CBNH intervention will be delivered to 30% of households identified through friendship nomination.
62089551|NCT02694679|EXPERIMENTAL|Friendship 50|The CBNH intervention will be delivered to 50% of households identified through friendship nomination.
62288125|NCT05501626|ACTIVE_COMPARATOR|Active TBS arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks comprising 21 sections.
62462692|NCT01099943|NO_INTERVENTION|No education, no implemented decision support tools|Clinics randomized to the control will not participate in the education intervention and implementation of decision support tools.
62462693|NCT02421952||Single Cohort|All subjects will be asked to assess their pain and nausea using the visual analogue scales (VAS), the modified faces scale and the BARF scale as described below in the preoperative and postoperative areas.
61905265|NCT06219798||Name of Arm 1: Study group|Description: Full participation (medical + dietitian+ specialist nurse)
61905266|NCT06219798||Name of Arm 2: Control 1|Description: Partial participation (medical+ dietitian OR specialist nurse)
61905267|NCT06219798||Name of Arm 3: Control 2|Description: No participation (medical visit only)
62089552|NCT02694679|EXPERIMENTAL|Friendship 75|The CBNH intervention will be delivered to 75% of households identified through friendship nomination.
62089553|NCT02694679|EXPERIMENTAL|Friendship 100|The CBNH intervention will be delivered to 100% of households identified through friendship nomination.
62089554|NCT05343481|EXPERIMENTAL|Experimental: Group 1 ChAdOx1-HBV, MVA-HBV and nivolumab|Day 1: ChAdOx1-HBV 1 x 2.5 10\^10 vp IM injection Day 29: MVA-HBV 1 x 10\^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
62089555|NCT05343481|EXPERIMENTAL|Experimental: Group 2 ChAdOx1-HBV, MVA-HBV and nivolumab, MVA-HBV and nivolumab|Day 1: ChAdOx1-HBV 1 x 2.5 10\^10 vp IM injection Day 29: MVA-HBV 1 x 10\^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion Day 85: MVA-HBV 1 x 10\^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
62089556|NCT05343481|EXPERIMENTAL|Experimental: Group 3 ChAdOx1-HBV, MVA-HBV, nivolumab, MVA-HBV|Day 1: ChAdOx1-HBV 1 x 2.5 10\^10 vp IM injection Day 29: MVA-HBV 1 x 10\^8 pfu IM injection Day 36: Nivolumab 0.3 mg/kg IV infusion Day 85: MVA-HBV 1 x 10\^8 pfu IM injection
62089557|NCT02781064|ACTIVE_COMPARATOR|Atorvastatin 20mg|Atorvastatin to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
62089558|NCT02781064|PLACEBO_COMPARATOR|Placebo - Microcrystalline Cellulose|Placebo to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
62089559|NCT03420235|NO_INTERVENTION|Control group|Control group will receive standard care alone.
62089560|NCT03420235|EXPERIMENTAL|Home monitoring group|Intervention will consist of a home monitoring program added to standard care.
62089561|NCT04286282|ACTIVE_COMPARATOR|Standard of Care|The first 100 participants with HIV and depression will receive standard of care including SSRI therapy.
62089562|NCT04286282|EXPERIMENTAL|Standard of Care + Group Support Psychotherapy|The second 100 participants with HIV and depression will receive standard of care, including SSRI therapy, and group support psychotherapy.
62089563|NCT04286282|ACTIVE_COMPARATOR|Standard of Care (Non-Depressed)|100 participants with HIV and without depression will receive standard of care therapy for HIV and no depression treatment.
62089564|NCT00083174|OTHER|Exemestane|one 25 mg tablet daily in am
62288126|NCT05501626|SHAM_COMPARATOR|Sham TBS arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks comprising 21 sections.
61905268|NCT00936728|EXPERIMENTAL|Arm A (white wine)|Patients consume white wine twice daily for 3-4 weeks.
61905269|NCT00936728|ACTIVE_COMPARATOR|Arm B (non-wine nutritional supplement)|Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
62089565|NCT05220124|EXPERIMENTAL|Immunotherapy with Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 3-4 treatment cycles,21 days per cycle.
62089566|NCT05220124|NO_INTERVENTION|Immunotherapy without Probiotics|control group, Immunotherapy without Probiotics
62089567|NCT05547659|ACTIVE_COMPARATOR|multimodal|pregabalin/ acetaminophen/ celecoxib
62089568|NCT05547659|ACTIVE_COMPARATOR|unimodal|Pregabalin
62089569|NCT05547659|NO_INTERVENTION|control|
62089570|NCT04770597|EXPERIMENTAL|Intervention|CO2 values on sensor visible to staff
62089571|NCT04770597|SHAM_COMPARATOR|Sham control|CO2 values on sensor not visible to staff
62288127|NCT01362582|NO_INTERVENTION|Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Subjects in the control group receive Best Supportive Nutritional Care. BSNC is defined as nutritional consultation and recommendation by experienced ecotrophologists."
62288128|NCT01362582|EXPERIMENTAL|PN, Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Patients receive also Best Supportive Nutritional Care defined as nutritional consultation and recommendation by experienced ecotrophologists.~Intervention: Supportive Parenteral Nutrition"
61905275|NCT05504967|ACTIVE_COMPARATOR|dexamethasone|"12.5mg dexamethasone + saline solution peramygdalin infiltration in each loca (25mg in total).~Single dosage pre-incisional."
61905276|NCT05504967|ACTIVE_COMPARATOR|ropivacain|"18.75 mg ropivacain + saline solution peramygdalin infiltration in each loca (37mg in total).~Single dosage pre-incisional."
62089572|NCT05012423|PLACEBO_COMPARATOR|SAD Cohorts 1 to 6: Participants Receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo.
62089573|NCT05012423|EXPERIMENTAL|SAD Cohorts 1 to 6: Participants receiving ECC0509|Participants in each SAD cohort will be randomized to receive 1 of 6 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, or 60 mg).
62089574|NCT05012423|PLACEBO_COMPARATOR|MAD Cohorts 1 to 4: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
62288129|NCT04582760|EXPERIMENTAL|early mobilization Arm|In addition to conventional bedside physical therapy, the mobilization program will be administered for 30 mins per session, two sessions per day, 7 days per week, until the patients are discharged from the ICU.
62654497|NCT02629978|EXPERIMENTAL|radiofrequency ablation|In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
62654498|NCT04923451|ACTIVE_COMPARATOR|Patient with sexual addiction - active stimulation|25 patients with sexual addiction will be stimulated by active tDCS during 5 consecutive days
62654499|NCT04923451|SHAM_COMPARATOR|Patient with sexual addiction - sham stimulation (placebo)|25 patients with sexual addiction will be stimulated by sham tDCS stimulation (placebo) during 5 consecutive days
62654500|NCT06169332||Computed Tomography|Experimental computed tomography protocol: a few minutes after the administration of the contrast medium at a very low dose of radiation performed only in those patients in whom there is a doubt of thrombosis in the early arterial phase.
62654501|NCT00624208|ACTIVE_COMPARATOR|1|Intravenous injection of droperidol 20 mcg.kg-1 and saline (group 1)
62654502|NCT00624208|ACTIVE_COMPARATOR|2|Intravenous injection of ondansetron 0.1 mg.kg-1 and saline (group 2
62654503|NCT00624208|ACTIVE_COMPARATOR|3|Intravenous injection of droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1 (group 3)
62654504|NCT00624208|PLACEBO_COMPARATOR|4|Intravenous injection of saline and saline (group 4)
62089575|NCT05012423|EXPERIMENTAL|MAD Cohorts 1 to 4: Participants receiving ECC0509|Participants will be randomized to receive a once-daily dose of 1 of 4 escalating doses (3 mg, 10 mg, 30 mg, 60 mg) for 14 days.
62089576|NCT01339221||Cohort A|Children confirmed with G1 and/or P\[8\] cases from the RotaBel study
62089577|NCT01339221||Cohort B|Children hospitalized for severe gastroenteritis in the study hospitals and tested positive for rotavirus
62654505|NCT04326374|EXPERIMENTAL|TransCon hGH|"TransCon hGH will be self-administered or injected by parents once weekly. The dose will be adjusted based on subject's weight.~The treatment will continue 52 weeks."
62654506|NCT04326374|ACTIVE_COMPARATOR|Daily hGH|"Daily hGH will be self-administered or injected by parents once daily. The dose will be adjusted based on subject's weight.~The treatment will continue 52 weeks."
62654507|NCT01552486|EXPERIMENTAL|Chiropractic Spinal Manipulative Therapy|
62288130|NCT04582760|NO_INTERVENTION|non-early mobilization Arm|Conventional bedside physical therapy will be administered for 30 mins per session, one session per day, 5 days per week (only on working days), until the patients are discharged from the ICU.
62654508|NCT01552486|OTHER|Usual Care|
62089578|NCT00765362|EXPERIMENTAL|1|Subjects who are candidates for a total knee replacement and meet the inclusion/exclusion criteria of the study.
62089579|NCT01881438||Participants exposed to oral fluoroquinolones|Oral fluoroquinolones in this study are ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxacin, norfloxacin, and ofloxacin.
62288131|NCT00275561|EXPERIMENTAL|Fluticasone|Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks
62288132|NCT00275561|PLACEBO_COMPARATOR|Placebo|Placebo inhaler swallowed bid for 6 weeks
62288133|NCT02989337||hyperemesis gravidarum with dehydration|The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration
62654509|NCT00710658|EXPERIMENTAL|1|Patients had access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as to a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
62654510|NCT00710658|NO_INTERVENTION|2|The control group receiving usual care
62654511|NCT00988338||Trinity Evolution|
62654512|NCT02484521|ACTIVE_COMPARATOR|Schizophrenia patients|Patients diagnosed with Schizophrenia. Will be assigned to PPI monitoring device protocol, according to unified protocol and have questionnaires to assess their status.
62654513|NCT02484521|OTHER|Healthy subject|This group would be assigned to PPI monitoring device protocol, according to a unified protocol similar to group of patients but not to questionnaires.
62654514|NCT02199574|EXPERIMENTAL|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
62654515|NCT05517590|ACTIVE_COMPARATOR|Tranexamic acid and group (Group I)|In Group I, 1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
62654516|NCT05517590|PLACEBO_COMPARATOR|Saline group (Group II)|Group II placebo will be administered to the control group, and 100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
62089580|NCT03540979|ACTIVE_COMPARATOR|Estrogen|Endometrial preparation: Estrogen supplements (Estradiol 6mg/d) will be started at the 2nd-3rd day of the cycle. First US scan will be performed after 10 days. If necessary, adjusting the estradiol doses will be performed according to the physician decision. After achieving trilinear endometrial thickness ≥8mm progesterone supplements (Endometrin 100mg\*3/d) will be administrated. Embryo transfer will be performed after completing 5 days of progesterone supplements (at the 6th day after starting the progesterone supplements).
62462694|NCT06202443|EXPERIMENTAL|Early Physical Therapy (PT)|PT will be delivered two times a week for 8 weeks by a licensed physical therapist. Participants will start PT approximately 2 weeks after hospital discharge
62654517|NCT02957552|EXPERIMENTAL|Treatment with Mesenchymal Stem Cells|"Two doses of 1 x 10\^6 MSCs/kg body weight:~* first administration intraoperatively via intraportal infusion~* second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)~Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
62654518|NCT00091858|EXPERIMENTAL|Darbepoetin alfa 6.75 mcg/kg Q4W|
62654519|NCT00091858|PLACEBO_COMPARATOR|Placebo Q4W|
62654520|NCT02846961||Crohn's disease|Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13
62462695|NCT06202443|ACTIVE_COMPARATOR|Delayed Physical Therapy (PT)|PT will be delivered two times a week for 8 weeks by a licensed physical therapist. Participants will start PT approximately 3 months after hospital discharge.
62462696|NCT01076452|ACTIVE_COMPARATOR|STN|Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
62462697|NCT01076452|ACTIVE_COMPARATOR|GPi|Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
62462698|NCT03455348|NO_INTERVENTION|cathete to less than 4 four centimeters to the wrist joint|
62654521|NCT02846961||Ulcerative colitis|Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13
62654522|NCT03352284|EXPERIMENTAL|Straumann Pure Ceramic Implant|Replacement of single tooth gaps with a Zirconia implant
62654523|NCT00724776|EXPERIMENTAL|1|Open-label treatment with albinterferon alfa 2b escalating single dose
62654524|NCT04909762|OTHER|Early rehabilitation and mobilisation|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package, provided by health care professionals from multiple disciplines and parents/carers within intensive care settings to promote recovery, both physical (e.g. movement, functional activities, ambulation) and non-physical (e.g. speech, play, psychological, cognitive). In adult intensive care, ERM has been shown in clinical trials to improve long term physical functioning and return to independence. It can also shorten the length of ventilation and stay in intensive care and hospital with significant economic benefit.
62654525|NCT06397482|EXPERIMENTAL|Encapsulated Calcium Butyrate|Subjects will be instructed to consume one 600 mg capsule daily, on an empty stomach, at least 30 minutes before their first meal.
62654526|NCT01741870|PLACEBO_COMPARATOR|Control|No intervention was given. All subjects received routine care
62654527|NCT01741870|ACTIVE_COMPARATOR|Received nutrition supplement as needed|Subjects in this group received 50 g/day soy protein-based nutritional supplement (containing 9.5 g protein, 250 kcal energy and all essential micro-nutrients) whenever subjects BMI is below 24 and MNA score also below 24.
62654528|NCT00125918|PLACEBO_COMPARATOR|1|Placebo
62654529|NCT00125918|ACTIVE_COMPARATOR|2|2.5 mg tadalafil
61905277|NCT05504967|EXPERIMENTAL|ropivacain + dexamethasone|"18.75mg ropivacain + 12.5mg dexamethasone peramygdalin infiltration (in each loca).~Single dosage pre-incisional."
61905278|NCT05504967|PLACEBO_COMPARATOR|placebo|Saline solution (NaCl 0.9%) peramygdalin infiltration (in each loca). Single dosage pre-incisional. 4 syringes must be prepared, two for each of the tonsil sites.
62119937|NCT02553460|EXPERIMENTAL|Treatment|"Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.~Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine."
62119938|NCT05216120|EXPERIMENTAL|Pemigatinib|Participants will be provided with a bottle of pemigatinib tablets on Day 1 of each cycle (one cycle = 21 days). A bottle contains 4.5 mg X 42 tablets total. Each pemigatinib bottle is sufficient for one cycle. Resupply will be provided as necessary on Day 1 of each cycle.
62119939|NCT04424303||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).
62119940|NCT01701453|EXPERIMENTAL|6 months group|6 months duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
62119941|NCT01701453|EXPERIMENTAL|12 months or longer group|12 months or longer duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
62119942|NCT04603625|EXPERIMENTAL|sitting position centering femoral heads|sitting position centering femoral heads according to Lespargot diagram
62119943|NCT04603625|ACTIVE_COMPARATOR|Usual postural management|sitting with the trunk aligned and hips abducted to facilitate activities of daily living
62119944|NCT01800513|EXPERIMENTAL|Endometrial Biopsy|Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.
62462699|NCT03455348|ACTIVE_COMPARATOR|catheter to more than four centimeters to the wrist joint|
62654530|NCT00125918|ACTIVE_COMPARATOR|3|10 mg tadalafil
62089581|NCT03540979|EXPERIMENTAL|Letrozole|Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg\*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
62462700|NCT02763111|EXPERIMENTAL|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
62089582|NCT03457194||Pregnant women|"150 participants (pregnant women at least 18 years of age and meeting eligibility criteria) will be enrolled and administered the FluQuadri, the quadrivalent influenza vaccine which will be administered by single-dose intramuscular injection.~Single-dose intramuscular injection of Adacel - DTP vaccine (multiple actives) will also be administered to all enrolled pregnant women who are at gestation 28 weeks or greater at the time of enrolment.~Where the vaccines are to be co-administered, FluQuadri will be administered into the dominant arm and Adacel into the non-dominant arm.~Pregnant women will be at a gestation of 20 weeks or greater at the time of enrolment. The vaccines administered are currently licensed and recommended in Australia to be given during pregnancy."
62089583|NCT03500705|EXPERIMENTAL|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening) while observing the reflection of the exercising limb in the mirror (Mirror Therapy) which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
62089584|NCT03500705|ACTIVE_COMPARATOR|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening). Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
62089585|NCT04648891|NO_INTERVENTION|Control|Patients will receive standard of care laryngeal injection of Botox via a transcricothyroid approach without additional anesthesia
62089586|NCT04648891|EXPERIMENTAL|Lidocaine|Patients will receive standard of care laryngeal injection of Botox via a transcricothyroid approach following subcutaneous injection of lidocaine (approximately 2 minutes before Botox injection).
62462701|NCT02763111|EXPERIMENTAL|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
62462702|NCT02763111|EXPERIMENTAL|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
62654531|NCT00125918|ACTIVE_COMPARATOR|4|20 mg tadalafil
62654532|NCT00125918|ACTIVE_COMPARATOR|5|40 mg tadalafil
62654533|NCT03170414||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
62654534|NCT02616705||IgG4-related sclerosing cholangitis|Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
62654535|NCT02616705||Controls|cholangiocarcinoma, PSC, and other patients with biliary strictures
62089587|NCT04648891|EXPERIMENTAL|Vibrating Wand|Patients will receive standard of care laryngeal injection of Botox via a transcricothyroid approach while using the vibrating wand.
62089588|NCT04125017|OTHER|effect of using LASER pulse|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
62089589|NCT04125017|OTHER|Micro-needle Technique|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
62089590|NCT01347645|ACTIVE_COMPARATOR|1|Experimental Irinotecan plus E7820
62089591|NCT01347645|ACTIVE_COMPARATOR|2|FOLFIRI alone
62089592|NCT05382455||Delphi Panel|A team of experts in the use AI technology in medicine together with experts in PRISMA, STARD-AI, CONSORT-AI, SPIRIT-AI, TRIPOD-AI, PROBAST-AI, CLAIM-AI and DECIDE-AI will evaluate the PRISMA-AI extension reporting guidelines
62462703|NCT02763111|PLACEBO_COMPARATOR|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
62462704|NCT05319938|ACTIVE_COMPARATOR|CAF only|Only Coronally Advanced Flap technique
62462705|NCT05319938|EXPERIMENTAL|CAF+CGF|Concentrated Growth Factor (CGF) applied together with Coronally Advanced Flap (CAF) technique
62462706|NCT05319938|EXPERIMENTAL|CAF+A-PRF|Advanced Platelet-Rich Fibrin (A-PRF) applied together with Coronally Advanced Flap (CAF) technique
62462707|NCT04347642|ACTIVE_COMPARATOR|Umbilical port|A Hasson port will be inserted at the level of the umbilicus,in the midline, traversing only aponeurotic layers.
62288134|NCT02989337||Control group|The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms
62462708|NCT04347642|EXPERIMENTAL|Paraumbilical port|A bladeless 12mm port will be inserted lateral to the midline, traversing aponeurotic layers and rectus abdominis muscle.
62654536|NCT03755817|EXPERIMENTAL|Scenar application|Application of SCENAR device on
62654537|NCT03755817|PLACEBO_COMPARATOR|Scenar application with the device off|Application of SCENAR device off
62654538|NCT05634291|EXPERIMENTAL|Standard of Care followed by AR digital treatment|Standard of care period without active intervention followed by Digital treatment with active intervention
62654539|NCT02433717|EXPERIMENTAL|Paliperidone ER|Six-week paliperidone ER
62654540|NCT04451083|EXPERIMENTAL|FOY-305|
62119945|NCT01800513|SHAM_COMPARATOR|Control|Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.
62119946|NCT05991908|EXPERIMENTAL|Flu-Bu2-Mel140|Patients receive fludarabine, busulfan and melphalan as conditioning regimen
62462709|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
62462710|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
62462711|NCT05890157|EXPERIMENTAL|Test ScRp+PRF|This site will treated by ScRp+PRF
62462712|NCT05890157|NO_INTERVENTION|Control ScRp|This site will treated by ScRp only
62462713|NCT02733120|EXPERIMENTAL|Healthy matched controls|Study Day: The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
62654541|NCT03803696|ACTIVE_COMPARATOR|Enhanced Standard Care|"* Baseline data collection, registration and randomization~* Inform primary transplant clinician of sexual dysfunction causing distress~* Receive American Cancer Society sexual educational material"
62119947|NCT05991908|ACTIVE_COMPARATOR|Flu-Bu4|Patients receive fludarabine and busulfan as conditioning regimen
62119948|NCT03247543|PLACEBO_COMPARATOR|Placebo|Placebo, qd, oral capsule
62119949|NCT03247543|ACTIVE_COMPARATOR|200mg SPN-812|200mg SPN-812, qd, oral capsule
62119950|NCT03247543|ACTIVE_COMPARATOR|400mg SPN-812|400mg SPN-812, qd, oral capsule
62119951|NCT03396848|EXPERIMENTAL|SHAReClinic|All participants will have access to the online clinic
62119952|NCT04656886|EXPERIMENTAL|Ketalar|0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.
62119953|NCT04656886|PLACEBO_COMPARATOR|Saline|Single, intravenous, steady state infusion over 40min.
62119954|NCT06164327|EXPERIMENTAL|BEBT-908 combined with R|"BEBT-908 for Injection,dosage of administration:22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle."
62119955|NCT06164327|EXPERIMENTAL|BEBT-908 combined with R-GemOx|"BEBT-908 for Injection,dosage of administration:15mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle."
62119956|NCT06164327|EXPERIMENTAL|BEBT-908 combined with R-ICE|"BEBT-908 for Injection,dosage of administration:15mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Etoposide Injection,dosage of administration:100mg/m\^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle."
62119957|NCT06164327|EXPERIMENTAL|BEBE-908 monotherapy (alternative cohort 1)|BEBT-908 for Injection,dosage of administration:22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.
62119958|NCT06164327|EXPERIMENTAL|BEBT-908 combined with R-GemOx（alternative cohort 2）|"BEBT-908 for Injection,dosage of administration:22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 2nd cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle in the 3rd to 6th cycles, and 21 days as a cycle.~Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle in the 3rd to 6th cycles, and 21 days as a cycle.~Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle in the 3rd to 6th cycles, and 21 days as a cycle."
62119959|NCT01814150||Oncology Institute, Meir Medical Center|Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center
62119960|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
62119961|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
62119962|NCT04187326|EXPERIMENTAL|6 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test.
62462714|NCT02733120|EXPERIMENTAL|Adults with Autism Spectrum Disorder|The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
62462715|NCT06132698|EXPERIMENTAL|Enrolled patients were treated with an immune checkpoint inhibitor combined with pemetrexed intrathe|
62462716|NCT05564819|EXPERIMENTAL|Treatment group|After recovering and returning to the ward, acetaminophen (10mg/kg) was taken orally immediately; once every 6 hours, a total of 4 times.
62462717|NCT05564819|PLACEBO_COMPARATOR|placebo group|The same amount of sterilized water was administered orally at the same time points.
62462718|NCT05402852|EXPERIMENTAL|Drug：EuBone® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
62462719|NCT05402852|PLACEBO_COMPARATOR|control：placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
62462720|NCT04528420|EXPERIMENTAL|Optimised arm|Patients will be taken care of early and optimally way.
62462721|NCT04528420|NO_INTERVENTION|Standard arm|Patients will be monitored as in standard practice
62462722|NCT04347746|ACTIVE_COMPARATOR|Clinical group|Individuals with bilateral idiopathic CTS with clinical criteria and mild to moderate ENMG severity and symptom evolution time above six months.
62462723|NCT04347746|ACTIVE_COMPARATOR|Surgical group|Individuals with bilateral idiopathic CTS with clinical criteria and severe ENMG in at least one hand and symptom evolution time above six months. These will be submitted to surgery on the severe hand and if equal severity on both hands, the dominant hand will be operated, with the patient's consent.
62654542|NCT03803696|ACTIVE_COMPARATOR|Multimodal Intervention to Address Sexual Dysfunction|"* Baseline data collection, registration and randomization~* 3 Monthly visits with trained study nurse practitioners~  * Referral to specialist if~ * Psychological etiology~ * Sexual Trauma~ * Relationship Discord~ * Concern for Malignancy or anatomic scarring requiring surgery"
62654543|NCT05300386||generalized anxiety with oxygen desaturation index less than 5|we enrolled patients with generalized anxiety with oxygen desaturation index of less than 5 and examed the basic physical conditions and the effectiveness of antidepressant treatment.
62119963|NCT04187326|EXPERIMENTAL|12 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test. Participants in this group will complete this task twelve month after their first visit.
62119964|NCT05049538||Observational (biospecimen collection, Pap smear)|Patients undergo collection of blood samples for liquid biopsy during pre-treatment consultation before hysterectomy, after hysterectomy but before starting any chemotherapy, and at the end of last chemotherapy cycle. Patients also undergo collection of tissue samples during hysterectomy. Patients may also undergo Pap smears before and after hysterectomy.
62462724|NCT04200482|ACTIVE_COMPARATOR|Arm A (low dose nutrition and PA class, eHealth intervention)|Participants attend one diet and physical activity class delivered remotely via Zoom and receive an eHealth communication intervention for 6 months.
62462725|NCT04200482|EXPERIMENTAL|Arm B (high dose nutrition and PA class, eHealth intervention)|Participants attend 12 twice monthly diet and physical activity online sessions delivered remotely via Zoom and receive an eHealth communication intervention for 6 months.
62462726|NCT04104165|ACTIVE_COMPARATOR|Intermittent catheterization|women who are catheterized intermittently every 6-8 hours up to a total time of 48 hours
62462727|NCT04104165|ACTIVE_COMPARATOR|Continous catheterization|women which will have an indwelling catheter inserted for 24 hours
62462728|NCT02164448|EXPERIMENTAL|dexmedetomidine group|
62462729|NCT02164448|PLACEBO_COMPARATOR|control group|
62654544|NCT05300386||generalized anxiety with oxygen desaturation index more than 5|we enrolled patients with generalized anxiety with oxygen desaturation index of more than 5 and examed the basic physical conditions and the effectiveness of antidepressant treatment.
62654545|NCT00464685|EXPERIMENTAL|700 µg Dexamethasone Implant and Laser Photocoagulation|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
62119965|NCT01420393|ACTIVE_COMPARATOR|Rhythm Control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
62119966|NCT01420393|ACTIVE_COMPARATOR|Rate Control|Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
62119967|NCT02327611|EXPERIMENTAL|Custodiol|Renal perfusion with Custodiol (cold crystalloid solution enriched with histidine-tryptophan-ketoglutarate).
62119968|NCT02327611|ACTIVE_COMPARATOR|enriched Ringer's lactate solution|Renal perfusion with cold Ringer's lactate solution enriched with methylprednisolone 125 mg /L and mannitol 12.5 g /L.
62119969|NCT01259102|EXPERIMENTAL|No Rest|BTDS 10 with no application site rest period prior to application of second BTDS
62119970|NCT01259102|EXPERIMENTAL|7-Day Rest|BTDS 10 with 7-day rest period prior to application of second BTDS
62119971|NCT01259102|EXPERIMENTAL|14-Day Rest|BTDS 10 with 14-day rest period prior to application of second BTDS
62119972|NCT01259102|EXPERIMENTAL|21-Day Rest|BTDS 10 with 21-day rest period prior to application of second BTDS
62119973|NCT01259102|EXPERIMENTAL|28-Day Rest|BTDS 10 with 28-day rest period prior to application of second BTDS
62119974|NCT04761783||Prospective arm|Patients will receive SIGNATERA™ test results and the immunotherapy treatment regimen, dosing schedule, duration of treatment, number of cycles, and modifications during treatment will be at the discretion of the HCP. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
62462730|NCT01815073|EXPERIMENTAL|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
62288135|NCT03104842|EXPERIMENTAL|Arm A Transplantation|Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Induction Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd), after intensification another 4 cycles of I-KRd as consolidation will be followed by IKR maintenance until PD or Toxicity
62288136|NCT03104842|EXPERIMENTAL|Arm B No-Transplantation|Patients \> 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd) (6 Cycles Induction, 2 Cycles Intensification, 4 Cycles Consolidation),to be followed by I-KR maintenance util PD or Toxicity
62288137|NCT02616913|EXPERIMENTAL|R,R-monatin|150 mg single dose
62462731|NCT01815073|EXPERIMENTAL|Live Attenuated Varicella Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
62462732|NCT01815073|EXPERIMENTAL|Live Attenuated JE Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
62462733|NCT05251025|EXPERIMENTAL|Passive sustained stretching|Passive sustained stretching along with conventional treatments
62462734|NCT05251025|EXPERIMENTAL|Myofascial Release|Myofascial Release Technique along with conventional treatments
62462735|NCT05738382|EXPERIMENTAL|BG2109 75mg|oral, once a day
62462736|NCT05738382|EXPERIMENTAL|BG2109 150mg|oral, once a day
62654546|NCT00464685|SHAM_COMPARATOR|Sham Implant and Laser Photocoagulation|Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
62654547|NCT02479490|EXPERIMENTAL|Prednisone + Everolimus|Prednisone + Everolimus
62654548|NCT05696600|EXPERIMENTAL|Thick periodontal phenotype|Scaling and root planing and open flap debridement in patients with stage II and stage III periodontitis
62654549|NCT05696600|ACTIVE_COMPARATOR|Thin periodontal phenotype|Scaling and root planing and open flap debridement in patients with stage II and stage III periodontitis
62654550|NCT02402062|EXPERIMENTAL|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
62654551|NCT04832737|EXPERIMENTAL|Intervention|SDT theory-based psychotherapeutic treatment model
61905281|NCT05984069||Patients on etiologies|Patients over 18 admitted in ICU for all etiologies with mechanical ventilation over 5 days or length of stay in ICU over 10 days will be included
62288138|NCT02616913|ACTIVE_COMPARATOR|Moxifloxacin|400 mg tablet single dose
62462737|NCT05738382|EXPERIMENTAL|BG2109 200mg|oral, once a day
62462738|NCT05738382|ACTIVE_COMPARATOR|Cetrorelix|0.25mg, Subcutaneous injection, once a day
62462739|NCT01697696|EXPERIMENTAL|NVA237 dose 1|NVA237 dose 1
62654552|NCT04832737|NO_INTERVENTION|Control|Wait List
61905282|NCT00692536|ACTIVE_COMPARATOR|1|NNR
61905283|NCT00692536|ACTIVE_COMPARATOR|2|MPD
62462740|NCT01697696|ACTIVE_COMPARATOR|Long-acting beta 2-agonist (LABA)|QAB149
62462741|NCT01058278|ACTIVE_COMPARATOR|Prednisone acetate 1%|A topic cortisone-based treatment
62462742|NCT01058278|ACTIVE_COMPARATOR|diclofenac 0.1%|an non-steroidal anti-inflammatory drug
62462743|NCT01058278|PLACEBO_COMPARATOR|Artificial Tears|Pharmasciences DIN: 02229570
62654553|NCT01352039|EXPERIMENTAL|Heparin Sodium - Eurofarma|
62462744|NCT00098826|EXPERIMENTAL|Treatment (ispinesib)|"Induction chemotherapy: Patients receive SB-715992 IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Consolidation chemotherapy: Patients achieving CR, PR, or SD after induction chemotherapy receive up to 4 additional courses of SB-715992 beyond CR, PR, or SD.~Cohorts of 3-6 patients receive SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 9 patients are treated at the MTD."
62654554|NCT01352039|ACTIVE_COMPARATOR|Heparin Sodium - APP Pharmaceuticals|
62654555|NCT06521242|EXPERIMENTAL|Patient Education|The RAM-Based Training and Hypertension Training Manual were given to the intervention group for 8 weeks, once a week, for 2 hours each session. The patients in the intervention group were called during the 1st and 3rd weeks of the study, and telephone counseling was provided. Reminders were made for important points in RAM-based hypertension training in these meetings.
62654556|NCT06521242|NO_INTERVENTION|Control Group|Routine nursing care was given to the patients in this group without any training.
62654557|NCT01478646|EXPERIMENTAL|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
62654558|NCT01478646|EXPERIMENTAL|Reflectory breathing therapy|first: reflectory breathing therapy second: conventional breathing therapy
62654559|NCT01563783|ACTIVE_COMPARATOR|Woman Suitable for Myomectomy or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or Myomectomy (laparoscopic or abdominal).
61905284|NCT04734678||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.
61905285|NCT04734678||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.
62288139|NCT02616913|PLACEBO_COMPARATOR|Placebo|placebo single dose
62288140|NCT06549803|EXPERIMENTAL|Skin adhesive bond|a group which skin closure was performed using Leukosan Adhesive skin bond
62288141|NCT06549803|ACTIVE_COMPARATOR|skin stapler|a group which skin closure was performed using skin stapler
62288142|NCT04760002||Atrial Fibrillation Patients|"Atrial fibrillation patients are to be investigated for sleep apnea by the a home-monitoring device.~Other inclusion criteria are:~\>18 years \<90 years"
62462745|NCT03236207|EXPERIMENTAL|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
62462746|NCT03236207|ACTIVE_COMPARATOR|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
62089593|NCT02578420|PLACEBO_COMPARATOR|open-label placebo|"Participants (N=40) will have the information that they are receiving an inert cream (i.e. placebo). Placebo will be described as an inert or inactive cream, with no medication in it. Additionally, participants will be told that placebo has been shown in rigorous clinical testing to produce significant mind-body self-healing processes. The placebo administration will be combined with the following scientific rationale/verbal suggestion: (a) placebos are effective analgesics, (b) classical conditioning as a possible mechanism of this effect, (c) compliance is important for outcome and (d) positive expectations increase placebo effects, but are not necessary."
62089594|NCT02578420|SHAM_COMPARATOR|deceptive placebo|"Participants (N=40) will have the information that they are receiving an analgesic cream (Antidolor, containing Lidocain), while in fact they will receive an inert cream, only. Antidolor will be described as an analgesic cream."
62089595|NCT02578420|PLACEBO_COMPARATOR|control group|Participants (N=40) will have the information that they are receiving an inert control cream.
62462747|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
62462748|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
62462749|NCT03920657|EXPERIMENTAL|Deferasirox|patients will be assigned to a fixed dose of 3.5 mg/kg/day of DFX FCT.
62462750|NCT03395444|ACTIVE_COMPARATOR|Study Group|Pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
62462751|NCT03395444|SHAM_COMPARATOR|Control Group|Sham pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
62462752|NCT01728922|ACTIVE_COMPARATOR|Healthy control - 5,000 IU vitamin D|13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
62654560|NCT01563783|ACTIVE_COMPARATOR|Woman Suitable for UAE or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or uterine artery embolization (UAE).
61905286|NCT00600119|PLACEBO_COMPARATOR|A|Placebo
61905287|NCT00600119|EXPERIMENTAL|B|NKTR-118
62089596|NCT02578420|NO_INTERVENTION|no treatment group|"Participants (N=40) will be told that they are in the no treatment group and that they will not receive an analgesic cream."
62089597|NCT03257488|ACTIVE_COMPARATOR|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
62462753|NCT01728922|ACTIVE_COMPARATOR|Healthy control - 10,000 IU vitamin D|13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
61905288|NCT01139008|ACTIVE_COMPARATOR|metronidazole 1% gel|
62462754|NCT01728922|PLACEBO_COMPARATOR|CIS - placebo|15 patients will be administered placebo and all outcome measures will be assessed.
62654561|NCT01219608|ACTIVE_COMPARATOR|Glutamine 0.5 g/kg/day|
62654562|NCT01219608|ACTIVE_COMPARATOR|Glutamine 1 g/kg/day|
62654563|NCT01219608|PLACEBO_COMPARATOR|Enteral Nutrition|
61905289|NCT01139008|ACTIVE_COMPARATOR|azelaic acid 15% gel|
61905290|NCT02255435|EXPERIMENTAL|Part 1 Omaveloxolone Capsules 2.5 and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg administered orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
62089598|NCT03257488|ACTIVE_COMPARATOR|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
62288143|NCT03108716|EXPERIMENTAL|hamate hook removal|The patients were assigned to hamate hook removal(n=13).
62288144|NCT03108716|EXPERIMENTAL|microscrew internal fixation|The patients were assigned to the microscrew internal fixation after open reduction (n=11).
62288145|NCT03108716|EXPERIMENTAL|short-arm tube-type plaster fixation|The patients were assigned to the short-arm tube-type plaster fixation (conservative treatment) (n=4).
62288146|NCT01384292|EXPERIMENTAL|1 (part A and B)|Oral treatment
62288147|NCT01384292|EXPERIMENTAL|2 (part A and B)|Oral treatment
62288148|NCT01384292|PLACEBO_COMPARATOR|3 (part A only)|Oral treatment
62288149|NCT05472389|OTHER|Patients, adults and children, with Dravet Syndrome|An homogenous population of patients with DS. The patients will have a prospective baseline period of 3 to 6 months duration in order to collect seizure frequency. After this period, all patients will then undergo a 24-48 hours video-EEG recordings and a full-night polysomnography
62288150|NCT00712374|EXPERIMENTAL|Intervention|Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post
62288151|NCT03419858|EXPERIMENTAL|Mindfulness Meditation Group|"Subjects participated in four sessions (20 min/session) of mindfulness training. Participants were taught that perceived sensory events are momentary and fleeting and require no further evaluation. They were asked to close their eyes, relax and to focus on the flow of their breathing and simply let go of discursive thoughts."
62288152|NCT03419858|ACTIVE_COMPARATOR|Placebo Meditation Group|The purpose of this intervention was to lead subjects to attend to one's breathing in a non-evaluative manner. Subjects were instructed to sit with a straight posture, closed eyes, and to take a deep, slow breaths every 2-3 minutes.
62089599|NCT04651231|ACTIVE_COMPARATOR|tight flap technique group (forty patients-group A)|in this arm forty patients did tight flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to close the apex of triangular scleral flap tightly and two releasable stitches were used at the sides of triangular scleral flap.
62089600|NCT04651231|EXPERIMENTAL|loose flap technique (securing sutures) group (forty patients-group B).|in this arm forty patients did loose flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to secure the edges of the flap at the apex of and two-four releasable stitches were used at the sides of triangular scleral flap in group B.
62089601|NCT01994733|EXPERIMENTAL|Intensive phosphate control|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of \< 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
62089602|NCT01994733|ACTIVE_COMPARATOR|Liberalized phosphate control|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
62089603|NCT06108141|EXPERIMENTAL|Resident Education And Counseling on Household (REACH) Firearm Safety|Resident participants will complete a modified online self-guided American Academy of Pediatrics (AAP) Safer curriculum. Next, residents will complete REACH individually with a trained facilitator.
62089604|NCT06108141|ACTIVE_COMPARATOR|Modified AAP Safer|Resident participants will complete a modified online self-guided American Academy of Pediatrics (AAP) Safer curriculum.
62089605|NCT05495451|EXPERIMENTAL|Mediterranean diet and Personalized training|"36 participants will participate to the following lifestyle changes for 6 months:~Behavioral: Lifestyle changes Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet.~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
62089606|NCT05495451|ACTIVE_COMPARATOR|Intermittent Fasting Intervention|Between 3 and 6 months, 24 participants (on a total of 36) will progressively integrate intermittent fasting 16:8 (5 times/week for 12 weeks) and 20:4 (2 times/week for 4 weeks)
61905291|NCT02255435|EXPERIMENTAL|Part 1 Omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) Capsules, 10 mg administered orally once daily for 12 weeks
62089607|NCT03250312|ACTIVE_COMPARATOR|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
62089608|NCT03250312|NO_INTERVENTION|The control group|"The control group will wait in another room for approximately 30 minutes.~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
62089609|NCT00184119|EXPERIMENTAL|Psychiatric Intensive Care Unit|
62089610|NCT00184119|ACTIVE_COMPARATOR|Whole acute unit|
62089611|NCT04982965|EXPERIMENTAL|Active THC|Participants will be administered 400mg of vaporized cannabis (5.1%) before pain testing and fMRI.
62089612|NCT04982965|PLACEBO_COMPARATOR|Placebo THC|Participants will be administered 400mg of vaporized cannabis (\<.1%) before pain testing and fMRI.
62089613|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
62089614|NCT03464396||Preterm infant study visits|"Preterm infants Study Visits~1. Bedside Physiology Study at 28, 32, 36, 40, and 52 weeks GA.~2. Respiratory tests:~   * Carotid Body Function Test will be completed at 32, 36, 40 and 52 weeks GA~  * Room Air Challenge (RAC) or Hypoxia Challenge Test (HCT) will be completed at 36 weeks GA~  * Effects of nasal cannula flow be completed at 28, 32, 36, 40 and 52 weeks GA~3. Magnetic Resonance Imaging (MRI): Completed on a subset of infants between 37-40 weeks GA or before discharge, whichever comes first.~4. Echocardiogram (Echo): Completed at 32, 36 and 52 weeks GA~5. Blood sample: Obtained at 32, 36 and 52 weeks GA"
62089615|NCT05108389||Pregnant women with kidney disease|Pregnant women with kidney disease. No intervention.
62462755|NCT01728922|ACTIVE_COMPARATOR|CIS - 5,000 IU vitamin D|15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.
62462756|NCT01728922|ACTIVE_COMPARATOR|CIS - 10,000 IU vitamin D|15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.
62462757|NCT01728922|PLACEBO_COMPARATOR|Healthy control - placebo|13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.
62462758|NCT01247545|PLACEBO_COMPARATOR|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
62654564|NCT05832372||Normal colonoscopy group|Individuals with normal colonoscopy examination
62654565|NCT05832372||Colorectal polyps group|Individuals with colorectal polyps diagnosed by colonoscopy
61905292|NCT02255435|EXPERIMENTAL|Part 1 Omaveloxolone Capsules 20 mg|Omaveloxolone (RTA 408) Capsules, 20 mg administered orally once daily for 12 weeks
61905293|NCT02255435|EXPERIMENTAL|Part 1 Omaveloxolone Capsules 40 mg|Omaveloxolone (RTA 408) Capsules, 40 mg administered orally once daily for 12 weeks
61905294|NCT02255435|EXPERIMENTAL|Part 1 Omaveloxolone Capsules 80 mg|Omaveloxolone (RTA 408) Capsules, 80 mg administered orally once daily for 12 weeks
61905295|NCT02255435|EXPERIMENTAL|Part 1 Omaveloxolone Capsules 160 mg|Omaveloxolone (RTA 408) Capsules, 160 mg administered orally once daily for 12 weeks
61905296|NCT02255435|EXPERIMENTAL|Part 1 Omaveloxolone Capsules 300 mg|Omaveloxolone (RTA 408) Capsules, 300 mg administered orally once daily for 12 weeks
62089616|NCT02705326|EXPERIMENTAL|Opti-Speech|Speech treatment will be guided by Opti-Speech's visual feedback of tongue movement during speech
62089617|NCT02865434|EXPERIMENTAL|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62288153|NCT03419858|ACTIVE_COMPARATOR|Slow-Breathing Group|A validated (Chalaye et al., 2009) slow breathing training regimen was employed, using fluctuating light, to teach individuals to independently lower their respective respiration rate. Subjects practiced lowering their respiration rates across four, 20 minute sessions.
62288154|NCT00578123|OTHER|1 Questionnaire|Quality of Life Questionnaires
62288155|NCT02856750|EXPERIMENTAL|gabapentin|gabapentin 300 mg three times daily x 30 d
62288156|NCT02856750|NO_INTERVENTION|placebo|no gabapentin administered to this arm.
62288157|NCT02930174|ACTIVE_COMPARATOR|Respironics V-60, then Draeger V500|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm one applies the Respironics V-60, then the Drager V-500.
62288158|NCT02930174|ACTIVE_COMPARATOR|Draeger V500, then Respironics V-60|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm two applies the Drager V-500, then the Respironics V-60.
62288159|NCT02452502|ACTIVE_COMPARATOR|moderate dose|Drug: Atorvastatin Atorvastatin 20 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
62462759|NCT01247545|ACTIVE_COMPARATOR|Remote ischaemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
62654566|NCT02950389|EXPERIMENTAL|Group A|Six bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, followed by 2 weeks of 6 on-line HFR session with HFR17 dialysis filter, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
62654567|NCT02950389|EXPERIMENTAL|Group B|Six on-line HFR session with HFR17 dialysis filter for 2 weeks, followed by 2 weeks of 6 o bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
62654568|NCT01683526|ACTIVE_COMPARATOR|Direct laryngoscopy|Intubation will be done using direct laryngoscopy
62288160|NCT02452502|EXPERIMENTAL|high dose|Drug: Atorvastatin Atorvastatin 80 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
62288161|NCT06322719|EXPERIMENTAL|Hyperangulated videolaryngoscope|Tracheal intubation facilitated by a hyperangulated videolaryngoscope
62288162|NCT06322719|ACTIVE_COMPARATOR|Macintosh videolaryngoscope|Tracheal intubation facilitated by a videolaryngoscope with a Macintosh type blade
61905297|NCT02255435|PLACEBO_COMPARATOR|Part 1 Placebo Capsules|Placebo capsules administered orally once daily for 12 weeks
61905298|NCT02255435|PLACEBO_COMPARATOR|Part 2 Placebo Capsules|Placebo capsules administered orally once daily for 48 weeks
61905299|NCT02255435|EXPERIMENTAL|Part 2 Omaveloxolone Capsules 150 mg|Omaveloxolone (RTA 408) Capsules, 150 mg administered orally once daily for 48 weeks
62654569|NCT01683526|ACTIVE_COMPARATOR|Video laryngoscopy|Intubation will be done using video laryngoscopy
62654570|NCT00390689|EXPERIMENTAL|Pramipexole 0.25 mg once daily|Pramipexole 0.25 mg given once daily
62654571|NCT00390689|EXPERIMENTAL|Pramipexole 0.5 mg once daily|Pramipexole 0.5 mg given once daily
61905300|NCT04498481||Breast cancer patients|HR+/HER2- advanced/metastatic breast cancer patients in the USA.
61905304|NCT02862756|EXPERIMENTAL|patient with endovascular treatment|
62654572|NCT00390689|EXPERIMENTAL|Pramipexole 0.75 mg once daily|Pramipexole 0.75 mg given once daily
62654573|NCT02373527|NO_INTERVENTION|Standard - Strict Fasting|No food after midnight the night before the procedure and will be allowed to drink clear liquids up to 2 hours prior to the procedure.
62654574|NCT02373527|EXPERIMENTAL|Non Fasting|No Fasting prior to catheterization. Usual meal on the day of the procedure and allowed to drink as usual.
62654575|NCT00511719|EXPERIMENTAL|Technosphere Insulin|Technosphere Insulin Inhalation Powder
62654576|NCT00511719|ACTIVE_COMPARATOR|Actrapid|Subcutaneous regular human insulin
62654577|NCT01009567|SHAM_COMPARATOR|Control|Receive human albumin 20% infusion
62654578|NCT01009567|EXPERIMENTAL|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
62654579|NCT05257616|OTHER|Control Group|Questionnaires were given to the participants. Before the initiation of treatment, procedure and consent details were explained and verbally translated into the native languages of participants, followed by the written signed approval on the questionnaire. Cervical ranges were measured using inclinometer which included neck flexion, extension, left and right side bending. Succeeding it were vitals in which oxygen saturation, heart rate, blood pressure, ventilation rate were jotted along with pain measurement using NPRS scale.
62654580|NCT05257616|ACTIVE_COMPARATOR|Experimental Group|Questionnaires were given to the participants. Before the initiation of treatment, procedure and consent details were explained and verbally translated into the native languages of participants, followed by the written signed approval on the questionnaire. Cervical ranges were measured using inclinometer which included neck flexion, extension, left and right side bending. Succeeding it were vitals in which oxygen saturation, heart rate, blood pressure, ventilation rate were jotted along with pain measurement using NPRS scale.
61905310|NCT01926340||Early maintenance treatment group|Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
61905311|NCT01926340||Early discontinuation group|Drug (placebo) during the 12-month randomized phase of the study
61905314|NCT04579887|EXPERIMENTAL|Brain changes triggered by PH induction in Parkinson's disease|Clinical and neuropsychological evaluations + Sensorimotor task for PH-induction
62288163|NCT06348121|EXPERIMENTAL|Probiotic group|one bag/day WecProB, before meal
61905315|NCT06266793|ACTIVE_COMPARATOR|Holmium Laser|Participants in this arm are randomized to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser
62089618|NCT02865434|EXPERIMENTAL|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62288164|NCT06348121|PLACEBO_COMPARATOR|Placebo|Maltodextrin, one bag/day, before meal
62089619|NCT02865434|EXPERIMENTAL|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62462760|NCT01851733|EXPERIMENTAL|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"* Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.~* Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.~* Biomarker blood draws will be drawn at different time points.~* DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
62462761|NCT01851733|EXPERIMENTAL|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"* Patients undergo MLA (MRI-guided laser heat ablation).~* Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.~  * DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
62462762|NCT01515826|EXPERIMENTAL|VIGADEXA Gel|VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
62462763|NCT01515826|ACTIVE_COMPARATOR|VIGADEXA Solution|VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
62462764|NCT01646788|EXPERIMENTAL|Experimental|NMB's PTA Balloon catheter with Paclitaxel drug
62089620|NCT02865434|EXPERIMENTAL|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62089621|NCT02865434|EXPERIMENTAL|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62089622|NCT02865434|EXPERIMENTAL|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62462765|NCT05350137|ACTIVE_COMPARATOR|Group A: 100% oxygen|After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen.
62462766|NCT05350137|EXPERIMENTAL|Group B: Carbon dioxide|After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide.
62462767|NCT03338660|PLACEBO_COMPARATOR|Control (Placebo)|Subjects will receive infusion of placebo (saline).
62654581|NCT00420745|EXPERIMENTAL|Rotarix Group|All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
61905316|NCT06266793|ACTIVE_COMPARATOR|Thulium Laser|Participants in this arm are randomized to be treated using the Olympus Soltive SuperPulsed Thulium Fiber Laser
61905317|NCT04915950|EXPERIMENTAL|Temanogrel (Stage A Dose 1)|
61905318|NCT04915950|EXPERIMENTAL|Temanogrel (Stage A Dose 2)|
61905319|NCT04915950|PLACEBO_COMPARATOR|Placebo (Stage A)|
62089623|NCT02865434|EXPERIMENTAL|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62089624|NCT02865434|EXPERIMENTAL|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62089625|NCT02865434|EXPERIMENTAL|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
62288165|NCT05986942||Dex|patients using dexmedetomidine infusion
62288166|NCT05986942||Fen|patients using fentanyl for induction
61905320|NCT04915950|EXPERIMENTAL|Temanogrel (Stage B Dose 1)|
61905321|NCT04915950|EXPERIMENTAL|Temanogrel (Stage B Dose 2)|
61905322|NCT04915950|PLACEBO_COMPARATOR|Placebo (Stage B)|
62288167|NCT05359107|EXPERIMENTAL|"The Free From Pain Exercise Book"|"Participants who consent and are randomised into Group 1 (experimental group) will be provided with the Free From Pain Exercise Book. Participants in Group 1 will be asked to independently engage in the exercises included in the book throughout the entire 6 month study period. They will be advised to either do all 3 sets of exercises 3 times a week or to do the neck and low back exercises twice a week and the Otago exercises 3 times a week. The exercises should take around an hour to complete each day.~Furthermore, it will be recommended that participants in this group read one information chapter and one metaphor each week for 12 weeks, to ensure that they absorb the information fully and do not overbear themselves with information."
61905323|NCT02576184|EXPERIMENTAL|Biologic Mesh|Biologic mesh placed in retromuscular position
61905324|NCT02576184|EXPERIMENTAL|Synthetic Mesh|Synthetic mesh placed in retromuscular position
62089626|NCT02865434|EXPERIMENTAL|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
62119975|NCT04761783||Control arm|Control cases must have undergone immunotherapy treatment and have follow-up data available in their medical record at the participating site for two years following initiation of immunotherapy or death.
62462768|NCT03338660|ACTIVE_COMPARATOR|Platelet storage routine|Subjects will receive infusion of platelets stored by routine method.
62462769|NCT03338660|EXPERIMENTAL|Platelet storage experimental|Subjects will receive infusion of platelets stored by a novel methodology.
62462770|NCT02567838|EXPERIMENTAL|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
62462771|NCT02567838|PLACEBO_COMPARATOR|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
62462772|NCT03203447|ACTIVE_COMPARATOR|Active|Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection
62462773|NCT03203447|SHAM_COMPARATOR|Control|Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure
62462774|NCT00878397|EXPERIMENTAL|1|Free distribution of long lasting insecticide nets to school children and their younger siblings
62462775|NCT00878397|EXPERIMENTAL|2|No school-based delivery of long lasting insecticide nets in the first year, followed by free delivery in the second year
62462776|NCT01101802|ACTIVE_COMPARATOR|Mycophenolate mofetil|Patients were given 1gm bd mycophenolate mofetil for 8 weeks
62462777|NCT01101802|PLACEBO_COMPARATOR|Sugar pill|
62462778|NCT04286802|EXPERIMENTAL|Salt-meter|Patients received salt-meter in conjunction with dietary education by trained dietician to help monitoring the salt content in food, as well as usual care by their primary physicians.
61905325|NCT02576184|NO_INTERVENTION|No Mesh|No mesh
62462779|NCT04286802|ACTIVE_COMPARATOR|Control|Patients received dietary education by trained dietician and usual care by their primary physicians.
62462780|NCT06134778|EXPERIMENTAL|IMT group|Inspiratory muscle training group
62462781|NCT04172454|EXPERIMENTAL|AK104|AK104 in subjects with advanced melanoma and other selected advanced solid tumor including PD-1/PD-L1 relapsed/refractory tumors)
62654582|NCT00420745|PLACEBO_COMPARATOR|Placebo Group|All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
62654583|NCT05240690|EXPERIMENTAL|Umbilical Cord Blood Derived MAK Immune Cells|
62654584|NCT00052338|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, followed 1 hour later by bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a clinical or radiographic response may continue receiving bortezomib beyond 6 courses.
61905328|NCT02735824||patients with suspected PID|From included patients with suspected primary immunodeficiency (PID), i.e. patients with recurrent/unusual infection, immune dysregulation and/or susceptibility to malignancies from whom consent to participate was obtained, nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
61905329|NCT02735824||healthy relatives of patients with PID|From healthy relatives of patients with suspected PID from whom consent to participate was obtained, nucleated cells will be used for genetic testing in order to compare their genetic information with the one form their relatives with suspected PID.
61905330|NCT02735824||Healthy volunteers|From healthy volunteers from whom consent to participate was obtained, nucleated blood cells will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement. The data obtained will be compared to age matched patients with suspected PID.
62119976|NCT02508038|EXPERIMENTAL|TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate|Patients with high-risk leukemia (who are at least one year of age and who have not received TBI as conditioning for a previous HSCT) will receive myeloablative conditioning with ATG, Fludarabine, Thiotepa, and TBI. All other subjects will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotepa, and Melphalan prior to transplant with a KIR/KIR ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCR-αβ+ and CD19+ cells. Patients will receive 5 doses of zoledronate (at 28 day intervals) starting 28 days after stem cell transplant.
62119977|NCT02613806|EXPERIMENTAL|D group (dexmedetomidine)|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion with microperfusion pump at the beginning of the surgery,and continued till end of surgery.
62462782|NCT05280262|OTHER|Group 1 Asymptomatic|"Group 1 - Prospective cohort of children and young adults enrolled at diagnosis and followed longitudinally~Patients will be evaluated at 5 time-points (Baseline - Follow Up 1-4 \[FU1-4\]) during therapy using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. In addition one saliva sample (or stored DNA from a remission bone marrow sample extracted during routine trial procedures) will be collected as a source of germline DNA and a clinical report form will be completed at study entry and at completion of the study. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
62654585|NCT01586325|EXPERIMENTAL|Panel 1|Study participants will receive double-blind treatment with JNJ-47910382 30 mg or matching placebo. Participants in each of Panel will be treated sequentially (ie, participants in Panel 1 will be treated before participants in Panel 2, participants in Panel 2 will be treated before participants in Panel 3).
62654586|NCT01586325|EXPERIMENTAL|Panel 2|Study participants will receive double-blind treatment with JNJ-47910382 90 mg or matching placebo. Participants in each of Panel will be treated sequentially.
61905333|NCT04500847|ACTIVE_COMPARATOR|Group 1|25 MCI and mild to moderate AD subjects
61905334|NCT04500847|PLACEBO_COMPARATOR|Group 2|10 MCI and mild to moderate AD subjects
61905335|NCT04475705|ACTIVE_COMPARATOR|Sevoflurane group|patients in this group will receive inhalation anaesthesia with sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
61905336|NCT04475705|ACTIVE_COMPARATOR|propofol group|patients in this group will receive intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
61905341|NCT01437306|EXPERIMENTAL|Lofexidine following overnight fast|A single dose of lofexidine (400 mcg or 2 x 200 mcg tablets) will be given to subjects following a minimum 10 hour overnight fast.
61905342|NCT01437306|EXPERIMENTAL|Lofexidine Following a High Fat Meal|A single dose of lofexidine 400 mcg (or 2 x 200 mcg tablets) will be administered to subjects following a standard high-fat meal.
62119978|NCT02613806|ACTIVE_COMPARATOR|C group (saline)|The patients received equal volume normal saline by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
62119979|NCT05846841|ACTIVE_COMPARATOR|Usual Care|The arm will represent usual care in the primary care clinics. Physicians will receive a report designed to recommend guideline-based tobacco treatment. Patients will receive a report on guideline-based advice about smoking cessation and a brief discussion with a behavior interventionist.
62119980|NCT05846841|EXPERIMENTAL|PrecisionTx|Physicians will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment. Patients will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment, and a brief discussion with a behavior interventionist.
62119981|NCT03081949|ACTIVE_COMPARATOR|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
62119982|NCT03081949|NO_INTERVENTION|Control|No treatment
62119983|NCT01207362||Young adult|
62119984|NCT01207362||Older adult|
62119985|NCT00727038|EXPERIMENTAL|1|Lucentis (ranibizumab) with conventional treatment
62119986|NCT00727038|NO_INTERVENTION|2|Conventional treatment
62119987|NCT01366664|EXPERIMENTAL|001|Treatment sequence 1 Treatment Period 1 (stable dose of terazosin \[2 to 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2 to 10 mg\] + placebo administered orally once daily for 5 days)
62119988|NCT01366664|EXPERIMENTAL|002|Treatment sequence 2 Treatment Period 1 (stable dose of terazosin \[2 to 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2 to 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
62119989|NCT06393244|EXPERIMENTAL|the intervention group|a theory-based home-based multi-component exercise training
62119990|NCT06393244|NO_INTERVENTION|the waiting list control group|the waiting list control
62119991|NCT02470949|EXPERIMENTAL|Low Social Status|Low Social Status Condition in Monopoly Game.
62119992|NCT02470949|EXPERIMENTAL|High Social Status|High Social Status Condition in Monopoly Game
62119993|NCT04785989||Group A: Healthy volunteers|Healthy volunteers are defined as people without a history of cancer
62119994|NCT04785989||Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
62119995|NCT04785989||Group B subset-2: Treatment naïve CLL patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
62119996|NCT04785989||Group C:Treatment naïve CLL patients with high systemic disease burden|Treatment naïve CLL patients with high systemic disease burden
62119997|NCT06079320|EXPERIMENTAL|Sisunatovir|
62288168|NCT05359107|ACTIVE_COMPARATOR|"The Back Book"|"Participants who consent and are randomised into Group 2 (control group) will be provided with The Back Book. Participants in Group 2 will be asked to ensure that they read the book in its entirety during the 12-week intervention period and refer to relevant sections during the follow-up period for advice if required."
62288169|NCT02670603|EXPERIMENTAL|Experimental arm|In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
62288170|NCT02670603|OTHER|Control arm|"In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2.~This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm."
62462783|NCT05280262|OTHER|Group 2 Symptomatic|"Group 2 - Children and young adults with Stroke-like syndrome/PRES and /or seizures (SPS)~Following a diagnosis of SPS, patients and their families can be approached for informed consent to enter this study within 4 weeks following SPS event. If consent is obtained, patients will be evaluated at up to 7 timepoints, or until end of treatment, using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. Follow up visit 2 will take place at 12 months, with Follow up 3-7 \[FU3-7\] scheduled at 6 monthly timepoints. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
62462784|NCT05498805|EXPERIMENTAL|experimental group|PD-1 inhibitor combined with radiotherapy, whether PD-1 inhibitor was used alone or in combination with other drugs was determined by the investigator. According to the lesion sties, SBRT or hyperfractionated radiotherapy was used.
62462785|NCT05498805|ACTIVE_COMPARATOR|controlled group|PD-1 inhibitor without radiotherapy, whether PD-1 inhibitor was used alone or in combination with other drugs was determined by the investigator.
62462786|NCT04925648|ACTIVE_COMPARATOR|Cohort A|Dasatinib 100mg once daily orally for 14 Days
62462787|NCT04925648|ACTIVE_COMPARATOR|Cohort B|Dasatinib 100mg once daily and Darolumatide 600 mg twice daily orally for 14 Days
62462788|NCT04929626|ACTIVE_COMPARATOR|Nebulized Ventolin|Nebulized Ventolin will given to 1st group after every 20 min for 1 hour
62462789|NCT04929626|EXPERIMENTAL|Nebulized Magnesium Sulphate + Ventolin|Dose of Nebulized Magnesium sulphate will vary in 3 subgroups.
62462790|NCT05141097|EXPERIMENTAL|Treatment|Being cared for by an Integrative Medicine provider
62654587|NCT01586325|EXPERIMENTAL|Panel 3|Study participants will receive double-blind treatment with JNJ-47910382 200 mg (maxiumum dose) or matching placebo. Participants in each of Panel will be treated sequentially.
62654588|NCT05145972|ACTIVE_COMPARATOR|• Group P|Ultrasound guided SHPN will be done by injecting 10 ml of Phenol 10 %.
62462791|NCT05141097|NO_INTERVENTION|Control|Being cared for by conventional medicine provider
62654589|NCT05145972|ACTIVE_COMPARATOR|• Group LP|Ultrasound guided SHPN will be done by injecting 10 ml Phenol 10 % then injecting 3 ml Lidocaine 10%.
62119998|NCT06079320|PLACEBO_COMPARATOR|Placebo|
62462792|NCT02592161|EXPERIMENTAL|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
62462793|NCT02592161|PLACEBO_COMPARATOR|Placebo comparator|Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks
62462794|NCT06413290||PIFP block group|Before the anesthesia induction, PIFP block will be performed
62462795|NCT06413290||Control group|No intervention
62462796|NCT06292871|EXPERIMENTAL|Intervention Group|Pregnant women with GDM receiving additional support via social media platform continuously for 1 month, in addition to the usual care management.
62654590|NCT02556749|EXPERIMENTAL|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
62654591|NCT02556749|PLACEBO_COMPARATOR|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
62119999|NCT03107403|EXPERIMENTAL|Healthy subjects|
62120000|NCT02042898|ACTIVE_COMPARATOR|Restrictive transfusion strategy|Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is \<75 g/L (\<7.5 g/dL;\<4.7mmol/L) intraoperatively and/or postoperatively
62120001|NCT02042898|ACTIVE_COMPARATOR|Liberal transfusion strategy|Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is \<95 g/L (\<9.5 g/dL\<5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or \<85 g/L (\< 8.5 g/dL;\<5.3mmol/L) on the ward.
62120002|NCT03959839|EXPERIMENTAL|Endoscopic Treatment|Rectal Endoscopic Submucosal Dissection
62120003|NCT03959839|EXPERIMENTAL|Minimally Invasive Laparoscopic Local Surgical Treatment|Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)
62120004|NCT03706261|EXPERIMENTAL|Offspring Cohort|Racially/ethnically diverse subjects with or without a positive family history of Alzheimer's disease (AD) will have one PET scan with 18F-MK-6240 over a 30 to 60-minute scanning period, and one PET scan with 18F-Florbetaben over a 20-minute scanning period.
62120005|NCT00126308|EXPERIMENTAL|Immediate|poly-L-lactic acid injections
62120006|NCT00126308|ACTIVE_COMPARATOR|Delayed|poly-L-lactic acid injections
62120007|NCT02770495|EXPERIMENTAL|Postoperative endoscopic recurrence|Patients with a diagnosis of Crohn's disease who undergo an ileo-colonic curative resection
62120008|NCT00756730|OTHER|Switch to DRV/r (800mg/100mg) QD|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
62120009|NCT00756730|OTHER|Switch to ATV/r (300mg/100mg QD)|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study
62120010|NCT00841633|NO_INTERVENTION|1|No induced hypertension (reference group)
61905346|NCT05451485||Young volunteers|Volunteers with age between 20-30 years
61905347|NCT05451485||Old volunteers|Volunteers with age between 65-75 years
62089627|NCT02865434|EXPERIMENTAL|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
62089628|NCT06146738||Palliative Care|Best supportive care without surgical intervention
62089629|NCT06146738||Tumor biopsy|Tumor biopsy
62089630|NCT06146738||Tumor resection|Maximal safe resection of the tumor
62462797|NCT06292871|ACTIVE_COMPARATOR|Control Group|Pregnant women with GDM under usual care management.
62462798|NCT05297266|EXPERIMENTAL|Patients with replanted extremity monitored by tissue CO2|Patients with traumatic amputation of a limb who are undergoing replantation surgery and are monitored postoperatively with IscAlert biosensor measuring local tissue CO2 and temperature in the replanted extremity
61905349|NCT04086498|EXPERIMENTAL|ketogenic-mediterranean diet with phytoextracts|The KEMEPHY diet (Paoli et al., 2011) is a mediterranean calorie-controlled ketogenic protocol (about 900 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg). Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (Lodi et al., 2016).
61905350|NCT04086498|ACTIVE_COMPARATOR|Ketogenic Diet|The KD is a protocol in which all foods containing carbohydrate are excluded, whereas meat, eggs, fish, ham, green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants can be eat without any limit. This protocol allows the use of oil, lemon juice (2 tbs/day), spices and aromatic herbs with a limitation of the use of saturated fats like butter, margarine and lard. Coffee, tea and herbal tea could be sweetened with sweeteners
61905351|NCT04086498|ACTIVE_COMPARATOR|Mediterranean Diet|The MD is a balanced calorie-controlled diet. The calorie intake was 1200 Kcal/day of which 15% were proteins, 60% carbohydrates and 25% fat. In this protocol was highlighted the use of the typical ingredients of the mediterranean tradition, such as extravirgin olive oil, vegetables, fruits, fish, lean meat and whole grain cereals.
62089631|NCT02040792|PLACEBO_COMPARATOR|Placebo|Placebo
62089632|NCT02040792|EXPERIMENTAL|44 mcg|TD-4208
62462799|NCT05847062|ACTIVE_COMPARATOR|patients operated on by means of an inverted shoulder prosthesis with medialized component|patients meeting the inclusion criteria who underwent surgery for a rotator cuff tear using an inverted shoulder prosthesis with a medially rotated center of rotation.
62462800|NCT05847062|ACTIVE_COMPARATOR|patients operated by means of inverted shoulder prosthesis with lateralized component|patients meeting the inclusion criteria who underwent surgery for a rotator cuff tear using an inverted shoulder prosthesis with a lateralized center of rotation.
62462801|NCT05575219|ACTIVE_COMPARATOR|Usual care (without protocolized clonidine initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
62089633|NCT02040792|EXPERIMENTAL|88 mcg|TD-4208
62089634|NCT02040792|EXPERIMENTAL|175 mcg|TD-4208
62288171|NCT04303000|EXPERIMENTAL|Opioid Overdose Education and Naloxone Distribution|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will be provided with a naloxone nasal spray kit (4mg).
62288172|NCT04303000|ACTIVE_COMPARATOR|Opioid Overdose Education|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will receive information about pharmacies in their area where they can purchase a naloxone kit.
62288173|NCT00167674|ACTIVE_COMPARATOR|B|Combined short-course Zidovudine/Nevirapine
62288174|NCT00167674|EXPERIMENTAL|A|HAART during pregnancy and 6 months postpartum
62288175|NCT04539093||End-stage heart failure patients requiring lvad support|Patients with end-stage heart failure with reduced ejection fraction, requiring mechanical circulatory support.
62288176|NCT00667576|EXPERIMENTAL|Paricalcitol 2 µg ± 1 µg|Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg
62288177|NCT00667576|EXPERIMENTAL|Paricalcitol 2 µg ± 2 µg|Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg
62654592|NCT02587936|EXPERIMENTAL|Collaborative model|Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator
62089635|NCT02040792|EXPERIMENTAL|350 mcg|TD-4208
62089636|NCT06006130|ACTIVE_COMPARATOR|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered at 10 Hz, 1500 pulses targeting the hand representation of the left primary motor cortex. rTMS delivery will require \~11 min to complete. In Experiment 1, this intervention will be performed for 1 session (\~11min). In Experiment 2, this intervention will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
62089637|NCT06006130|SHAM_COMPARATOR|Sham rTMS|Sham rTMS will be delivered at as a placebo control. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active rTMS. In Experiment 2, this intervention will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
62089638|NCT02057380|EXPERIMENTAL|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
62089639|NCT02057380|EXPERIMENTAL|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
62089640|NCT02057380|EXPERIMENTAL|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
62288178|NCT00667576|EXPERIMENTAL|Paricalcitol 4 µg ± 1 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg
62288179|NCT00667576|EXPERIMENTAL|Paricalcitol 4 µg ± 2 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg
62288180|NCT00667576|OTHER|Maxacalcitol 5 or 10 µg ± 2.5 µg|Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg
62089641|NCT02057380|EXPERIMENTAL|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
62288181|NCT03856944|EXPERIMENTAL|ReSTOR Toric|Patients will be bilaterally implanted, with the Toric ReSTOR +2.5D model implanted in the dominant eye and the Toric ReSTOR +3.0D model implanted in the non-dominant eye. Patients will self-select for multifocal implantation.
62288182|NCT03135145|ACTIVE_COMPARATOR|Lite Run Gait Trainer|Participants will be using the Lite Run Gait Trainer to assist them in weightbearing and walking after SDR or SEMLS surgery.
62288183|NCT03135145|PLACEBO_COMPARATOR|Usual Treatments|Participants will be using current treatments used in clinical practice to assist them in weightbearing and walking after SDR or SEMLS surgery.
62288184|NCT02789657|EXPERIMENTAL|Optimal- 18 weeks|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
62288185|NCT02789657|EXPERIMENTAL|Sub-optimal with AC|12 weeks (4 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post 12 weeks, initiation of doxorubicin and cyclophosphamide for 4 cycles (6 weeks), followed by surgery.
62288186|NCT02789657|EXPERIMENTAL|Optimal with AC|Less than 18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab, followed by initiation of doxorubicin and cyclophosphamide. Post treatment, patients will undergo surgery.
62654593|NCT02587936|NO_INTERVENTION|Standard Care|Group to receive regular care
62089642|NCT02057380|EXPERIMENTAL|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
62089643|NCT02057380|EXPERIMENTAL|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
62089644|NCT02057380|EXPERIMENTAL|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
62089645|NCT02057380|EXPERIMENTAL|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
62089646|NCT02057380|EXPERIMENTAL|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
62089647|NCT02057380|EXPERIMENTAL|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 \& 11 (cycles 1-8) and Days 1, 8, 15 \& 22 (cycles 9+)
62089648|NCT02057380|EXPERIMENTAL|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 \& 11 (cycles 1-8) and Days 1, 8, 15 \& 22 (cycles 9+)
62288187|NCT02789657|EXPERIMENTAL|Sub-optimal no AC|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
62462802|NCT05575219|EXPERIMENTAL|Intervention (protocolized clonidine initiation)|A protocol for clonidine initiation will be implemented based on the time on dexmedetomidine and the average hourly dose of dexmedetomidine.
62654594|NCT05686941||Healthy Volunteers|Employees of the Host organisation in the Respiratory Team who meet the inclusion criteria
62288188|NCT04726332|EXPERIMENTAL|XL102 Single-Agent Dose-Escalation Cohorts|"Subjects will be separated into three separate groups of cohorts. Formulation A consists of: Fasted, with approximately 9 cohorts (A-FC) starting at 20 mg (qd and/or bid) of XL102, Food-Effect Dose-Escalation at 40 mg qd of XL102, with approximately 3 cohorts (A-FE) and Non-Fasted, with approximately 6 cohorts (A-NF).~Formulation B consists of additional cohorts: Fasted (A-FCFB) starting at 40 mg (qd and/or bid) of XL102 and Non-Fasted (A-NFCFB).~The dose of the remaining A-FE cohorts will be determined by the Cohort Review Committee (CRC) as well as that of the A-NF, and A-NFCFB cohorts."
62288189|NCT04726332|EXPERIMENTAL|XL102 Single-Agent Expansion Cohorts|The Maximum Tolerated Dose (MTD) or recommended dose from the dose-escalation stage may be further explored in subjects with triple-negative breast cancer (TNBC) (Cohort D), epithelial ovarian cancer (EOC) (Cohort E), hormone receptor-positive breast cancer (HR+ BC) (Cohort F), and metastatic castration-resistant prostate cancer (mCRPC) (Cohort G).
62288190|NCT04726332|EXPERIMENTAL|XL102 + Fulvestrant Dose-Escalation Cohorts|Subjects with HR+ BC (Cohort B) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
62089649|NCT02057380|EXPERIMENTAL|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 \& 11 (cycles 1-8) and Days 1, 8, 15 \& 22 (cycles 9+)
62288191|NCT04726332|EXPERIMENTAL|XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts|Subjects with mCRPC (Cohort C) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
62089650|NCT02773251|EXPERIMENTAL|hyaluronic acid-carboxymethylcellulose treatment group|the HA/CMC treatment group after laparoscopic pelvic surgery
62089651|NCT02773251|NO_INTERVENTION|control group|the HA/CMC non-treatment group after laparoscopic pelvic surgery
62288192|NCT04726332|EXPERIMENTAL|XL102 + Fulvestrant Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with HR+ BC (Cohort H).
62288193|NCT04726332|EXPERIMENTAL|XL102 + Abiraterone/Prednisone Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with mCRPC (Cohort I).
62288194|NCT01727258|EXPERIMENTAL|Mouth Rinse|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
62288195|NCT01727258|ACTIVE_COMPARATOR|Fluoride Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
61905358|NCT05592860|EXPERIMENTAL|Mobile application|Mobile application to enter glucose level
61905359|NCT05592860|PLACEBO_COMPARATOR|Daily Diary|Daily Diary to record glucose level
62288196|NCT01727258|ACTIVE_COMPARATOR|Potassium Nitrate Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.
62288197|NCT00503256||CLL - Linkage Families|Gene identification related to Chronic lymphocytic leukemia (CLL) development
62654595|NCT05686941||Patients with suspected Inducible laryngeal Obstruction (ILO)|Patients referred to a Tertiary referral centre who are suspected of having ILO
62089652|NCT06258239|OTHER|Enhanced communication|"In the enhanced communication study arm the nurse will say to the patient: I will now give you a combination of two drugs that will greatly ease your pain. One of the two drugs is morphine, which is a drug from the opioid family, which is the strongest drug family for pain relief that medicine has to offer. This drug is very effective against severe pain after surgery. In addition, the second drug is called XEFO. This drug is from the family of non-steroidal anti-inflammatory drugs. We know that the combination of these two drugs is particularly successful in reducing the kind of pain that you experience. According to my experience, you will feel significant pain relief very soon. I will come to you every 10 minutes to assess if you are still in pain. As long as you are suffering from pain, I will continue to give you additional doses of the treatment. We are allowed to give up to 4 doses of treatment. As the treatment is very strong, not everyone needs all 4 doses."
62089653|NCT06258239|OTHER|Normal communication|In the normal communication study arm the communication between the nurse and patients will be as usual in clinical practice - i.e. - no instruction are given to the nurses regarding on how to communicate with patients while administrating the treatment.
62089654|NCT06323538||vegans|vegan diet: no products of animal origin
62089655|NCT06323538||vegetarians|vegetarian diet: no meat and fish, but dairy products and eggs
62089656|NCT06323538||pescetarians|pescetarian diet: no meat, but fish
62288198|NCT04101175||Request for abortion|Patient in first trimester of pregnancy in request for abortion
62462803|NCT02259270||ASTRA-1|"All patients discharged from the participating hospitals between July 2012 and July 2013.~Determination of long term use of AST before, during and after hospitalisation based on dispensing data, no record review."
62462804|NCT02259270||ASTRA-2|Random selected subset of patients in ASTRA-1 with startup of AST in the hospital and AST at discharge. Record review for appropriateness of indication of startup of AST.
62462805|NCT02609139|EXPERIMENTAL|<=400mg Modified Release Tablets, Fasted|Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions
62462806|NCT02609139|EXPERIMENTAL|100mg Modified Release Tablets, Fasted|100 mg PF-06650833 modified release tablets administered under fasted conditions
62462807|NCT02609139|EXPERIMENTAL|20mg Modified Release Tablets, Fasted|20 mg PF-06650833 modified release tablets administered under fasted conditions
61905366|NCT02258776|ACTIVE_COMPARATOR|Pomegranate Extract|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate extract on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
62089657|NCT06323538||mixed diet|mixed diet: plant-based foods and animal-based foods
62089658|NCT03779451|ACTIVE_COMPARATOR|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery
62089659|NCT03779451|ACTIVE_COMPARATOR|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily at bedtime starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
62089660|NCT03779451|NO_INTERVENTION|control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
62089661|NCT00547261|EXPERIMENTAL|Arm A|1 hour IV infusion D1
62089662|NCT00547261|EXPERIMENTAL|Arm B|1 hour IV infusion D1, D8, D15
62089663|NCT05743764|EXPERIMENTAL|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
62089664|NCT05743764|ACTIVE_COMPARATOR|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
62089665|NCT05743764|ACTIVE_COMPARATOR|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
62288199|NCT06435702||Darolutamide in addition to androgen deprivation therapy|Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
62288200|NCT06435702||androgen deprivation therapy only|The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
62288201|NCT01279057|EXPERIMENTAL|Test|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
62288202|NCT01279057|ACTIVE_COMPARATOR|Reference|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
62288203|NCT01279057|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray administered once daily for 14 days.
62288204|NCT00938730|EXPERIMENTAL|1. YM150, Dose W, twice daily|
62288205|NCT00938730|EXPERIMENTAL|2. YM150, Dose X, once daily|
62288206|NCT00938730|EXPERIMENTAL|3. YM150, Dose X, twice daily|
62089666|NCT05313009|EXPERIMENTAL|STAGE 1: SAFETY LEAD IN (n=6-18, depending on number of DLs explored)|SAFETY LEAD IN (n=6-18, depending on number of DLs explored) 3+3 design dependent on DLTs
62089667|NCT05313009|EXPERIMENTAL|STAGE 2: EFFICACY (n=12)|EFFICACY (n=12)
62288207|NCT00938730|EXPERIMENTAL|4. YM150, Dose Y once daily|
62288208|NCT00938730|EXPERIMENTAL|5. YM150, Dose Y twice daily|
62288209|NCT00938730|EXPERIMENTAL|6. YM150, Dose Z, once daily|
62288210|NCT00938730|ACTIVE_COMPARATOR|7. Warfarin|
62462808|NCT02609139|EXPERIMENTAL|<= 400mg Modified Release Tablets, Fed|Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake
62462809|NCT02609139|EXPERIMENTAL|100mg Modifed Release Tablets, Fed|100 mg PF-06650833 modified release tablets administered with high fat meal food intake
62462810|NCT02609139|EXPERIMENTAL|20mg Modified Release Tablets, Fed|20 mg PF-06650833 modified release tablets administered with high fat meal food intake
62462811|NCT02961309|EXPERIMENTAL|Active THC|5.6% THC via smoked marijuana cigarette
62462812|NCT02961309|EXPERIMENTAL|Placebo|Placebo THC via smoked cigarette
62654596|NCT01284543|ACTIVE_COMPARATOR|Busin glide delivery of donor graft|Use of the Busin glide to insert the donor graft
61905367|NCT02258776|ACTIVE_COMPARATOR|Pomegranate Juice|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate juice on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
62089668|NCT02033993|ACTIVE_COMPARATOR|Arm 1|Nab-Paclitaxel - 260mg/m2: q21 days
62089669|NCT02033993|ACTIVE_COMPARATOR|Arm 2|Paclitaxel - 175mg/m2: q21 days
62089670|NCT02451280|EXPERIMENTAL|Unilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and UAT training in each session.
62089671|NCT02451280|EXPERIMENTAL|Bilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and BAT training in each session.
62089672|NCT02451280|EXPERIMENTAL|Robot-Assisted Training Group|Participants will receive 6 weeks of RT training using the BMT in each session.
62089673|NCT04069390|EXPERIMENTAL|Cardioskin-Neuronaute|
62089674|NCT01355783|ACTIVE_COMPARATOR|E7777 + CHOP Chemotherapy|
62089675|NCT01355783|ACTIVE_COMPARATOR|CHOP alone|
62089676|NCT04218760|EXPERIMENTAL|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day and have 3 sets of blood samples drown.
62089677|NCT00683449|EXPERIMENTAL|IV infusion of MN-221|MN-221 total dose of 240 mcg
62089678|NCT00683449|PLACEBO_COMPARATOR|MN-221 PLACEBO|i.v. infusion of MN-221 Placebo for 15 min
61905368|NCT02258776|PLACEBO_COMPARATOR|Placebo|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of placebo on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
62089679|NCT05568485|EXPERIMENTAL|Telerehabilitation|Telerehabilitation was applied to the group with rheumatism
62089680|NCT02891590|EXPERIMENTAL|DTRMWXHS-12|DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.
62089681|NCT05284721|ACTIVE_COMPARATOR|Care Coordination Phase III|Family member participants randomized to the active control will receive two brief psychoeducation sessions, two brief check ins across one month and linked to appropriate services.
62089682|NCT05284721|EXPERIMENTAL|Family Peer Navigator model Psychosis Phase III|Family member participants randomized to the Family Peer Navigator condition will participate in two sessions for introduction/assessment, four individual psychoeducation sessions, and six brief check ins delivered by Family Peer Navigators.
62089683|NCT06303778|ACTIVE_COMPARATOR|Standard Care|Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.
62089684|NCT06303778|EXPERIMENTAL|Combined MAUD+SD-App|In addition to standard MAUD care, participants assigned to the MAUD+SD-App condition will receive access to the Stand Down app at randomization.
62288211|NCT06044896|EXPERIMENTAL|Supine Positioning|The participant will be in the supine position.
61905371|NCT06390072|EXPERIMENTAL|Self-hypnosis|"The audio-guided self-hypnosis practice was sourced from the Reveri App (reveri.com), developed by Dr. David Spiegel, and entitled Hypnosis Prep for Workout"
61905372|NCT06390072|ACTIVE_COMPARATOR|Ankle Education|"The ankle education video, entitled Ankle Sprain Rehab Exercises was sourced from the Physio Tutors YouTube channel"
61905373|NCT03041831||Older adult individual interviews|The investigators will conduct 8 semi-structured 60-minute interviews with patient participants.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
61905374|NCT03041831||Clinician individual interviews|The investigators will conduct 6 semi-structured 60-minute interviews with primary care clinicians who care for older adult populations.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
62089685|NCT03909165|EXPERIMENTAL|Part A. Sugammadex 2 mg/kg|Participants received a single intravenous (IV) bolus of sugammadex at 2 mg/kg for moderate NMB reversal.
62089686|NCT03909165|EXPERIMENTAL|Part A. Sugammadex 4 mg/kg|Participants received a single IV bolus of sugammadex at 4 mg/kg for deep NMB reversal.
62089687|NCT03909165|EXPERIMENTAL|Part B. Sugammadex 2 mg/kg|Participants received a single IV bolus of sugammadex at 2 mg/kg for moderate NMB reversal.
62089688|NCT03909165|EXPERIMENTAL|Part B. Sugammadex 4 mg/kg|Participants received a single IV bolus of sugammadex at 4 mg/kg for deep NMB reversal.
62089689|NCT03909165|ACTIVE_COMPARATOR|Part B. Neostigmine|Participants received a single IV bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg) based on availability and/or contraindications, for moderate NMB reversal.
62089690|NCT02602457|EXPERIMENTAL|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
62089691|NCT02602457|EXPERIMENTAL|High-Intensity Interval Training|High-Intensity Interval Training
62089692|NCT05010694|EXPERIMENTAL|Monotherapy Dose Escalation.|Treatment with GH35 alone, conducted until disease progression, intolerance or end of study.
62089693|NCT05374083|EXPERIMENTAL|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as demineralized dentin block graft and inserted in the extraction socket and covered then suturing
62288212|NCT06044896|EXPERIMENTAL|Body Lateral Positioning|The participant will be in the body lateral position at 30 degrees.
62654597|NCT01284543|EXPERIMENTAL|Tan EndoGlide for insertion of the donor graft|Use of the Tan EndoGlide for insertion of the donor graft
61905375|NCT03041831||Community leader individual interviews|The investigators will conduct 4 semi-structured 60-minute interviews with community leaders.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
61905376|NCT03041831||Focus group discussions|The investigators will lead four 90-minute focus group discussions consisting of 6-8 older adult participants each. The goal of these focus groups is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
62089694|NCT05374083|ACTIVE_COMPARATOR|Alveolar ridge preservation using particulate deproteinized bovine bone graft|Atraumatic extraction of non-restorable teeth, then the socket will be packed by particulate deproteinized bovine bone graft and covered then suturing
62089695|NCT06697990|EXPERIMENTAL|Iruplinalib|The treatment will be administrated for 16 weeks, after which the treatment regimen was determined by the investigator.
62089696|NCT00048854|ACTIVE_COMPARATOR|1|Participants will receive treatment as usual
62089697|NCT00048854|EXPERIMENTAL|2|Participants will take sertraline
62288213|NCT03043144||End stage renal disease|Observational study, no intervention
62288214|NCT03233932|ACTIVE_COMPARATOR|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
62288215|NCT03233932|EXPERIMENTAL|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
62288216|NCT01630525||Prodromal AD participants|
62288217|NCT01630525||Typical AD participants|
62288218|NCT01630525||Control participants|
62288219|NCT04622345|EXPERIMENTAL|VSJ-110 Solution|
62288220|NCT04622345|PLACEBO_COMPARATOR|Placebo Solution|
62288221|NCT01961544|EXPERIMENTAL|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
62089698|NCT01134809||Major abdominal surgery|Patients having major abdominal surgery
62089699|NCT04889885|EXPERIMENTAL|High-intensity laser therapy (HILT)|The participants in the intervention group were treated by HILT which was applied to the knee joint (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
62089700|NCT04889885|SHAM_COMPARATOR|Sham laser|The control group received a sham laser by the same laser machine (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
62288222|NCT00914381|ACTIVE_COMPARATOR|CRA + CM|Community Reinforcement Approach (CRA) combined with Contingency Management (CM)
62654598|NCT02019355|EXPERIMENTAL|calcipotriol plus 5-fluorouracil|calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
62654599|NCT02019355|ACTIVE_COMPARATOR|5-fluorouracil plus vaseline|5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
62654600|NCT02661308|EXPERIMENTAL|Systematic bright light exposure|Systematic bright light exposure for 30 min. for 4 weeks
62654601|NCT02661308|ACTIVE_COMPARATOR|Systematic dim light exposure|Systematic dim light exposure for 30 min. for 4 weeks
62654602|NCT00218413|EXPERIMENTAL|1|
62654603|NCT00218413|EXPERIMENTAL|2|
62654604|NCT00218413|EXPERIMENTAL|3|
62654605|NCT00218413|EXPERIMENTAL|4|
62089701|NCT00170235|EXPERIMENTAL|1|Prehabilitation (exercises pre surgery)
62089702|NCT00170235|ACTIVE_COMPARATOR|2|Usual care as provided by the institution
62089703|NCT04201951|ACTIVE_COMPARATOR|Tranexamic group|Group A will receive 1gm Tranexamic acide diluted in 20 ML 5% glucose water
62089704|NCT04201951|PLACEBO_COMPARATOR|Placebo group|Group B will receive 30ML 5% glucose water
62089705|NCT05828784|OTHER|35 consecutive patients|
62288223|NCT00914381|ACTIVE_COMPARATOR|TSF + CM|Twelve-Step Facilitation (TSF) combined with Contingency Management (CM)
62288224|NCT00914381|ACTIVE_COMPARATOR|CRA + VC|Community Reinforcement Approach (CRA) combined with Voucher Control (VC)
62288225|NCT00914381|ACTIVE_COMPARATOR|TSF + VC|Twelve-Step Facilitation (TSF) combined with Voucher Control (VC)
62288226|NCT05009901|EXPERIMENTAL|Alpha Lipoic Acid|alpha lipoic acid PO 600 mg daily for 8 weeks
62288227|NCT05009901|PLACEBO_COMPARATOR|Placebo|placebo PO daily for 8 weeks
62288228|NCT05904444|EXPERIMENTAL|daily training|Patients underwent microperimetric training on everyday
62288229|NCT05904444|EXPERIMENTAL|alternately training|Patients underwent microperimetric training on every other day
62288230|NCT05313438|EXPERIMENTAL|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care.
62288231|NCT04724148|EXPERIMENTAL|Injecting 1~2mg/kg fentanyl intravenously.|"1. Measuring HVPG after the preparation of TIPS in patients with portal hypertension;~2. Measuring HVPG again 5 minutes later after injecting 1\~2mg/kg fentanyl intravenously."
62288232|NCT03462095|NO_INTERVENTION|no Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance
62288233|NCT03462095|EXPERIMENTAL|Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance
62288234|NCT06164769|EXPERIMENTAL|blockade of arteries in laparoscopic pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
62288235|NCT00579813|NO_INTERVENTION|1|Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.
62462813|NCT02359474|EXPERIMENTAL|Trabectedin with regional hyperthermia|"Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.~Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs)."
62462814|NCT02359474|ACTIVE_COMPARATOR|Trabectedin|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
62462815|NCT02203448||FACET WEDGE spinal system|The FACET WEDGE spinal system provides additional stability to a spinal segment to enhance fusion conditions.
62462816|NCT05729061|NO_INTERVENTION|Participant with normal assistive device|Normal assistive device refers to the habitual assistive device that may be prescribed by a provider of care or no assistive device if the individual does not normally use.
62462817|NCT05729061|OTHER|Participant with intervention|Intervention refers to investigational assistive devices or commercially available assistive devices that individuals may use during this study.
62462818|NCT04983706|EXPERIMENTAL|MRI/Ultrasound Fusion Saturation Biopsy|
62462819|NCT01658293|EXPERIMENTAL|thermal stimulation|The experimental group receiving heat and cold-water stimulation, 30 minutes a session, five sessions a week for six weeks.
61905379|NCT03802058|EXPERIMENTAL|Nab-paclitaxel|Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy
61905380|NCT01009372|EXPERIMENTAL|breaks during laparoscopic surgery|Intraoperative Breaks were instituted in the intervention group. The other group operated conventionally without breaks
61905383|NCT05867641|OTHER|VR&R Therapy|Recruited dyads will include one person diagnosed with dementia and their informal caregiver (i.e., family/friend). The caregiver will assist their loved ones with dementia to use VR-therapy at home. Caregivers may use the time while their loved ones are engaged for respite, remaining nearby to supervise and assist.
61905384|NCT03692819|ACTIVE_COMPARATOR|placebo|Periodontal debridement treatment will be performed in a single session after the therapy will be administered the Placebo Oral Tablet twice a day for 21 days.
61905385|NCT03692819|EXPERIMENTAL|Metronidazole and Amoxicillin|Periodontal debridement treatment in a single session Metronidazole 400mg + Amoxicillin 500mg every 8 hours for 7 days.
61905386|NCT03692819|EXPERIMENTAL|Lactobacillus reuteri|Periodontal debridement treatment in a single session Lactobacillus reuteri Oral Drops twice a day for 21 days.
61905387|NCT02067975|OTHER|Healthy Controls|All participants will receive both 6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3, and will also receive Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3. The order in which participants receive either placebo or tryptophan will be randomized (ie. placebo first study visit day tryptophan on second study day, or tryptophan on first study day and placebo on second study day)
61905388|NCT02067975|OTHER|Schizophrenia Related Disorders|All participants will receive both 6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3, and will also receive Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3. The order in which participants receive either placebo or tryptophan will be randomized (ie. placebo first study visit day tryptophan on second study day, or tryptophan on first study day and placebo on second study day)
61905391|NCT02583217||Ketamine|Ketamine+propofol
61905392|NCT02583217||Remifentanyl|Remifentanyl+propofol
61905393|NCT03264118|ACTIVE_COMPARATOR|Control|Decontamination of furcation defect with scaling and root planing only.
61905394|NCT03264118|EXPERIMENTAL|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
62654606|NCT00218413|EXPERIMENTAL|5|
62288236|NCT00579813|ACTIVE_COMPARATOR|2|Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
61905395|NCT03035877|EXPERIMENTAL|Multisystemic Therapy-Emerging Adults|This group will receive Multisystemic Therapy-Emerging Adults.
62089706|NCT03649789||No Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of greater than 0.1 mL saliva/min.
62089707|NCT03649789||Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of less than 0.1 mL saliva/min.
62288237|NCT04918563|ACTIVE_COMPARATOR|nitroglycerin|"NO donor (Nitropohl) vs pgysiological saline~1mg/ml nitorhlycerin"
62288238|NCT04918563|ACTIVE_COMPARATOR|acethylcholine|10 mg/ml acetylcholine vs physiological saline
62288239|NCT01984515|EXPERIMENTAL|Team Red Primary Care|Eligible patients will receive the Referral Management System in primary care
61905396|NCT03035877|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
62089708|NCT05711628|ACTIVE_COMPARATOR|Arm A (chemotherapy regimen, HDT-ASCT)|"SALVAGE THERAPY: Patients receive 1 of 3 chemotherapy regimens as clinically indicated: 1) ifosfamide IV, carboplatin IV, and etoposide IV; 2) gemcitabine IV, vinorelbine IV, and pegylated liposomal doxorubicin IV; or 3) brentuximab vedotin IV and bendamustine IV. Patients then undergo a PET/CT scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment.~HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.~MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated."
62288240|NCT03235687|EXPERIMENTAL|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
62288241|NCT03235687|NO_INTERVENTION|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
62288242|NCT03190187|ACTIVE_COMPARATOR|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
62288243|NCT03190187|SHAM_COMPARATOR|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
62462820|NCT01658293|ACTIVE_COMPARATOR|control group|The control group receiving the similar intensity of ergometer exercise as the experimental group.
62462821|NCT01161615|PLACEBO_COMPARATOR|Placebo|Therapy with placebo
62462822|NCT01161615|EXPERIMENTAL|MRX-7EAT|Therapy with experimental drug
62462823|NCT00854308|EXPERIMENTAL|MetMAb + Erlotinib|MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
62462824|NCT00854308|PLACEBO_COMPARATOR|Placebo + Erlotinib|Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.
62462825|NCT03443765||Patients with Pityriasis alba|
62462826|NCT03443765||Healthy participants (control group)|
62462827|NCT03859466|EXPERIMENTAL|Intervention Arm|In the intervention arm, 300 shockwave impulses per coronary supply territory, at an energy flux density of 0.38mJ/mm2 and a frequency 3Hz, are applied in direct contact with the ischaemic myocardium of the left ventricle. The intervention is performed during CABG surgery after bypasses are fully established while still on cardiopulmonary bypass.
62462828|NCT03859466|NO_INTERVENTION|Sham Control Arm|In the sham control arm, the same manipulations are performed with an inactive shockwave applicator in direct contact with the ischaemic myocardium of the left ventricle as in the intervention arm. The sham treatment is performed during CABG surgery after bypasses are fully established while still on cardiopulmonary bypass.
62654607|NCT06412822||STONE group|Adult subjects with kidney stones disease
62654608|NCT06412822||NON STONE group|Control group: patients with acute and/or chronic kidney disease (CKD) without stones
62654609|NCT06156566|ACTIVE_COMPARATOR|Tecovirimat|Oral treatment with tecovirimat 200 mg capsules. Twice daily three capsules orally. Duration of treatment: 14 days (28 administrations).
62654610|NCT06156566|PLACEBO_COMPARATOR|Placebo|Matching placebo to tecovirimat capsules. Twice daily three capsules orally. Duration of treatment: 14 days (28 administrations).
62654611|NCT00829556|EXPERIMENTAL|1|
62654612|NCT00829556|NO_INTERVENTION|2|Standard Surgical skin preparation
62089709|NCT05711628|EXPERIMENTAL|Arm B (chemotherapy regimens+pembrolizumab, HD-ASCT)|"SALVAGE THERAPY: Patients receive pembrolizumab IV plus 1 of 3 chemotherapy regimens specified in Arm A as clinically indicated. Patients then undergo a PET scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment.~HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.~MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated."
62654613|NCT05531253||Main cohort|Patients undergoing cardiac surgery who will have a pulmonary artery catheter in-situ at the time of admission to cardiac intensive care postoperatively.
62654614|NCT01899092|EXPERIMENTAL|Escalating Dose of TT-034|The study contains one dose escalation arm with active drug.
62654615|NCT02270476||Early diagnosed (ED)|Children diagnosed with CF in the first 4 months of life.
62654616|NCT02270476||Late diagnosed (LD)|Children diagnosed with CF after the first 4 months of life.
62654617|NCT03552406|EXPERIMENTAL|Dose-Escalation of ISU104 (Dose-Level 1)|1 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
62654618|NCT03552406|EXPERIMENTAL|Dose-Escalation of ISU104 (Dose-Level 2)|3 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
62654619|NCT03552406|EXPERIMENTAL|Dose-Escalation of ISU104 (Dose-Level 3)|5 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
62654620|NCT03552406|EXPERIMENTAL|Dose-Escalation of ISU104 (Dose-Level 4)|10 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
62654621|NCT03552406|EXPERIMENTAL|Dose-Escalation of ISU104 (Dose-Level 5)|20 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
61905397|NCT01934647|EXPERIMENTAL|1 mg MK-8892|Participants will receive a single oral dose of 1 mg MK-8892.
61905398|NCT01934647|EXPERIMENTAL|4 mg MK-8892|Participants will receive a single oral dose of 4 mg MK-8892.
62089710|NCT03394664|EXPERIMENTAL|Very-Low Carbohydrate Diet|Feeding study. Dietary composition (approximately): 75% fat
62089711|NCT03394664|EXPERIMENTAL|High-Carbohydrate Low-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
62089712|NCT03394664|EXPERIMENTAL|High-Carbohydrate High-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars.
62089713|NCT02225275|EXPERIMENTAL|Treatment (lenalidomide, obinutuzumab)|Patients receive obinutuzumab IV over 3-4 hours on days 1, 2, 8, and 15 of course 1 and day 1 of courses 2-6 and lenalidomide PO QD on days 9-28 of course 1 and days 1-28 of all subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable toxicity.
62089714|NCT06067529||Premature ovarian insufficiency group|
62089715|NCT05335174||HPI monitor|
62089716|NCT01985698|EXPERIMENTAL|Robotic-assisted resection|patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.
62288244|NCT02334150|EXPERIMENTAL|CSEA group|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
62288245|NCT02334150|NO_INTERVENTION|Control group|Women in the control group were not provided any analgesia during labor.
62288246|NCT03538769|NO_INTERVENTION|Baseline group|This will be the pre and post alert phase where e-alerts will not be sent to providers
62288247|NCT03538769|OTHER|Alert group|This will be the phase when e-alerts will be sent to the provider
62654622|NCT03552406|EXPERIMENTAL|Dose-Expansion of ISU104 (Group 1: Monotherapy)|ISU104 20 mg/kg to be administered every three weeks (Q3W) as monotherapy
62654623|NCT03552406|EXPERIMENTAL|Dose-Expansion of ISU104 (Group 2: Combination therapy)|ISU104 20 mg/kg (or decreased dose) Q3W in combination with cetuximab\* 250 mg/m2 QW (\*Initial dose: 400 mg/m2)
62654624|NCT00687700|EXPERIMENTAL|All subjects|Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.
62288248|NCT03393026|EXPERIMENTAL|Lurasidone 40-160 mg|Lurasidone 40-160 mg
62654625|NCT02868944|EXPERIMENTAL|experimental group|sequential combined spinal epidural with local anesthetic injection associated with morphine
62654626|NCT02868944|ACTIVE_COMPARATOR|control group|sequential combined spinal epidural with local anesthetic injection alone
62654627|NCT01303484|PLACEBO_COMPARATOR|MDn|Maltodextrin
62654628|NCT01303484|ACTIVE_COMPARATOR|B-GOS|Prebiotic
62654629|NCT02357459|EXPERIMENTAL|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
62654630|NCT02357459|PLACEBO_COMPARATOR|Normal Saline|Single 5 mL intra-articular (IA) injection
62654631|NCT02357459|ACTIVE_COMPARATOR|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
62654632|NCT03318562|EXPERIMENTAL|TNBC Cohort|female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received \>=1 prior cancer therapy regimen for metastatic disease
61905399|NCT01934647|EXPERIMENTAL|8 mg MK-8892|Participants will receive a single oral dose of 8 mg MK-8892.
61905400|NCT03876236||Rest|Quiet rest in supine position, 2 hrs.
61905401|NCT01590381||personnel in medical training - COURSE 1|
61905402|NCT01590381||personnel in medical training - COURSE 2|
62089717|NCT01985698|ACTIVE_COMPARATOR|Laparoscopic resection|patients with low rectal cancer receiving laparoscopic abdominoperineal resection.
61905403|NCT01590381||personnel in medical training - COURSE 3|
62089718|NCT01433653|EXPERIMENTAL|CG-CBT|
62089719|NCT01433653|NO_INTERVENTION|wait list control|
62654633|NCT03318562|EXPERIMENTAL|HCC Cohort|male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed \>=1 systemic therapy, which must include sorafenib, or are intolerant to multikinase inhibitor therapies
62654634|NCT02549118|EXPERIMENTAL|Tenoxicam|Intravenous administration of tenoxicam, a lyophilisate with 20 mg to be dissolved and diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
62089720|NCT02796443||Early laparoscopic cholecystectomy (ELC)|Operation within 72 hours after onset of symptoms
62089721|NCT02796443||Intermediate cholecystectomy (ILC)|Operation within 14 days after onset of symptoms
62089722|NCT02796443||Delayed LC (DLC)|Operation after 6-12 weeks
62089723|NCT02796443||Elective laparoscopic cholecystectomy|Biliary colic with no acute cholecystitis
62120011|NCT00841633|EXPERIMENTAL|2|Induced hypertension with a MAP of 30 mmHg above the average MAP on the previous day; during 24-36 hours, until a perfusion CT scan has been performed
62120012|NCT03368937|EXPERIMENTAL|Tandem t:slim X2 with Control-IQ Technology|Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
62120013|NCT01886430|EXPERIMENTAL|Functional Electrical Stimulation|Functional Electrical Stimulation for 10 days
62120014|NCT01886430|PLACEBO_COMPARATOR|Control Electrical Stimulation|Control Electrical Stimulation for 10 days
62120015|NCT01340261||Pediatric Pain Rehab Patients|
62120016|NCT04255888|ACTIVE_COMPARATOR|Thick periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
62120017|NCT04255888|ACTIVE_COMPARATOR|Thin periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
62120018|NCT00624026|EXPERIMENTAL|1|
62089724|NCT04346303|OTHER|Short-term Interactive Video Games|Short-term video games will be applied to patients with mental illness who are staying in communities. Games will be applied in a group-activity format with 8 to 12 patients in each session. The interventions will be conducted at a two sessions per week for a 3-week long period. There are 3 time points for data collection, including 2-weeks before the intervention, the week before the intervention, and the week after the intervention. Each patient will be his/her own controlled comparison.
62654635|NCT02549118|ACTIVE_COMPARATOR|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
61905404|NCT01590381||personnel in medical training - COURSE 4|
62089725|NCT01521143|EXPERIMENTAL|Part A - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10\^6 viable dendritic cells/mL.
62288249|NCT02867631|NO_INTERVENTION|Enhanced control|Regular care as provided by the community based organization from which the convenience sample is recruited with one year of assessments only
62288250|NCT02867631|EXPERIMENTAL|Intervention|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
62288251|NCT03414957||Malay PCOS women|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who fulfilled these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria
62288252|NCT03414957||Malay women without PCOS|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who did not fulfill these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria.
62288253|NCT03594968||polycystic ovary syndrome (PCOS)|"Presence of ≥2 of the following:~1. oligomenorrhea and/or anovulation~2. Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism."
62462829|NCT02700464|EXPERIMENTAL|Bladder EpiCheck Urine Test|Bladder EpiCheck Urine Test
62462830|NCT02700464|ACTIVE_COMPARATOR|Gold Standard|Cystoscopy and pathology
62462831|NCT01066806|EXPERIMENTAL|high calcium diet|
62089726|NCT01521143|PLACEBO_COMPARATOR|Part A - Placebo|Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
62089727|NCT01521143|EXPERIMENTAL|Part B - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10\^6 viable dendritic cells/mL.
62089728|NCT01521143|NO_INTERVENTION|Part B - Observational standard of care|Participants in this group did not receive any treatment during the study.
62288254|NCT03594968||healthy|healthy patients who had no polycystic ovary
62288255|NCT05290363|EXPERIMENTAL|Patients with axial spondyloarthritis participating in the study|People with axial spondylarthritis (60 participants),
62288256|NCT05290363|EXPERIMENTAL|Patients with peripheral spondyloarthritis participating in the study|People with peripheral spondylarthritis (30 participants).
62288257|NCT03452267|EXPERIMENTAL|Metformin|
62288258|NCT03452267|EXPERIMENTAL|Pioglitazone|
62288259|NCT03452267|PLACEBO_COMPARATOR|Placebo|
62288260|NCT05430269|EXPERIMENTAL|Intervention group|ICU patients who developed diarhea after a course of antibiotic therapy treated with Faecal bacteriotherapy (FBT) delivered as enema
62288261|NCT05430269|ACTIVE_COMPARATOR|Control group|ICU patients who developed diarhea after a course of antibiotic therapy treated standard-of-care protocolised treatment of postantibiotic diarhea
62288262|NCT02586714||Normal weight|
62288263|NCT02586714||Overweight|
62288264|NCT02586714||Obese|
62288265|NCT00935935||HIV older than 50 years|
62288266|NCT03557567||MO patients|
62288267|NCT03557567||OI patients|
61905405|NCT01590381||personnel in medical training - COURSE 5|
62462832|NCT01066806|ACTIVE_COMPARATOR|normal calcium diet|
62462833|NCT00952406||Survey of Women PFDs|Women with PFDs
62462834|NCT02808702|EXPERIMENTAL|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
62462835|NCT03300934|EXPERIMENTAL|closed loop glucose control system|Closed loop glucose control system
62462836|NCT03300934|NO_INTERVENTION|CSII Pump treatment|CSII Pump treatment without the integrated algorithm and glucose sensor
62462837|NCT00338481|ACTIVE_COMPARATOR|1|
62089729|NCT06450535|EXPERIMENTAL|Autogenous onlay block from retromolar bone|"In the first intervention, a bone block harvested from the donor site was fixed with osteosynthesis titanium screws to the recipient site as an onlay graft to achieve a horizontal enlargement of the alveolar ridge.~● Placement of the bone graft was always guided by an augmentation template"
62089730|NCT06450535|ACTIVE_COMPARATOR|Cortical shell technique from retromolar bone|"The harvested cortical plate was then split longitudinally in two parts using a microsaw, and thinned with the bone scraper to achieve a plate of 1 mm thickness.~* The plate was fixed at a distance from the residual ridge with 2 screws.~* Autogenous bone particles, collected with the bone scraper, were tightly packed into the gap between the plate and the recipient site."
62089731|NCT02460744|EXPERIMENTAL|Single arm treatment with radiation|Patients with breast cancer will be given adjuvant hypofractionated radiotherapy
62089732|NCT04055480|ACTIVE_COMPARATOR|Closed-loop using standard rapid-acting insulin|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
62089733|NCT04055480|EXPERIMENTAL|Closed-loop using faster insulin aspart|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using faster insulin aspart~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
62089734|NCT06697795|EXPERIMENTAL|Virtual Reality-Assisted Hypnotherapy+Physiotherapy Group|Participants in this arm will undergo a conventional physical therapy program for 3 weeks (15 sessions) supervised by physiotherapists. Additionally, during each physical therapy session, participants will receive a 20-minute Virtual Reality (VR)-assisted hypnotherapy session using the HypnoVR software.
62089735|NCT06697795|ACTIVE_COMPARATOR|Standard Treatment Group|Participants in this arm will undergo a conventional physical therapy program for 3 weeks (15 sessions) supervised by physiotherapists.
62089736|NCT02714985||confirmed chikungunya cases|cases with confirmed chikungunya fever and included for follow-up as per protocol
62089737|NCT01311089||Robotic thyroidectomy group|Robotic thyroidectomy group is the patient group who underwent robot-assisted endoscopic thyroid surgery using a gasless, trans-axillary approach.
62089738|NCT01311089||conventional open thyroidectomy group|Conventional open thyroidectomy group is th patient group who underwent thyroid surgery via neck incision.
62089739|NCT04752540|EXPERIMENTAL|Mild hepatic impairment|120 mg olorofim
62089740|NCT04752540|EXPERIMENTAL|Moderate hepatic impairment|60 to 120 mg olorofim
62089741|NCT04752540|ACTIVE_COMPARATOR|Normal hepatic function|120 mg olorofim
62288268|NCT04122287|EXPERIMENTAL|levofloxacin-tetracycline-containing quadruple group|patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d
61905406|NCT01590381||personnel in medical training - COURSE 6|
61905407|NCT01590381||personnel in medical training - COURSE 7|
62089742|NCT06229886|EXPERIMENTAL|Study Participants|Application of positive-end-expiratory-pressure on mechanically ventilated patients while performing point-of-care-ultrasound.
62462838|NCT00338481|ACTIVE_COMPARATOR|2|
61905408|NCT01590381||personnel in medical training - COURSE 8|
61905409|NCT01590381||personnel in medical training - COURSE 9|
61905410|NCT01590381||personnel in medical training - COURSE 10|
61905411|NCT00288899|OTHER|Arm 1|standard VA surgical iMedConsent process
61905412|NCT00288899|EXPERIMENTAL|Arm 2|enhanced version of VA surgical iMedConsent process (repeat-back)
61905413|NCT02403466|EXPERIMENTAL|Resident Handoff Bundle|bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
62089743|NCT06285526||Group HIPEC|Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy (HIPEC)
62089744|NCT06285526||Group CDP|Cephalic DuodenoPancreatectomy (CDP)
62089745|NCT06407479|EXPERIMENTAL|proprioceptive|proprioceptive neuromuscular facilitation technique application
62089746|NCT06407479|EXPERIMENTAL|eccentric|eccentric muscle training technique application
61905414|NCT03927482|EXPERIMENTAL|CARES mobile app|Participants in this arm will receive 12 weeks of text messages and use of the smart phone mobile app that provides support for alcohol risk reduction.
62462839|NCT03688373|EXPERIMENTAL|Exposure-in-big-steps|In the big steps exposure sessions the adolescent moves in three a set pace of big steps from bottom to top (1-5-10) in their fear hierarchy. From 0-5 in the first session and from 5-10 in the second session.
62462840|NCT03688373|EXPERIMENTAL|Exposure-in-small-steps|In the small steps exposure sessions the adolescent moves in a step-by-step pace of their own choice from bottom to top in their fear hierarchy, for example from 1 to 2 to 3 to in the first session and from 4 to 5 to 6 etc. in the second session.
62462841|NCT02693210|ACTIVE_COMPARATOR|Group A: Methotrexate|Participants will receive methotrexate at dosage \>=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.
62089747|NCT06407479|ACTIVE_COMPARATOR|Control|no intervention group
62462842|NCT02693210|EXPERIMENTAL|Group B: Rituximab Monotherapy|Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.
62462843|NCT02693210|EXPERIMENTAL|Group C: Rituximab and Cyclophosphamide|Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.
62462844|NCT02693210|EXPERIMENTAL|Group D: Methotrexate and Rituximab|Participants will receive \>=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.
62462845|NCT04096703|NO_INTERVENTION|Expectant management of EGJOO Group|The participants randomized to this group will receive expectant management of EGJOO. Expectant management is evaluating whether symptoms improve over time without an intervention
62462846|NCT04096703|EXPERIMENTAL|Pneumatic dilation of EGJOO Group|The participants randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific).
62462847|NCT02079766|EXPERIMENTAL|High Risk of CTE|Flortaucipir PET scans in subjects at high risk of developing CTE (former National Football League players)
62462848|NCT02079766|EXPERIMENTAL|Control|Flortaucipir PET scans in former non-contact athletes
62462849|NCT00654264|OTHER|1|Patients will have water immersion on first day and sitting in a tub without water on the second day.
62462850|NCT00654264|OTHER|2|Patients will sit in a tub without water on the first day and have water immersion on the second day.
62462851|NCT03291548|EXPERIMENTAL|Quinoa Biscuit|The quinoa-enriched biscuits containing 7.11g quinoa flour.
62462852|NCT03291548|PLACEBO_COMPARATOR|Control biscuit|The placebo control biscuit: an iso-energetic, matched product in terms of appearance, taste, texture and smell.
62462853|NCT02967159|EXPERIMENTAL|Treatment A (Abediterol )|Treatment A: The subjects will receive Abediterol 2.5 μg via DPI
62089748|NCT05883319|ACTIVE_COMPARATOR|cervical mobilization|Cervical mobilization methods will be applied to 1st group for 3 days / week for 6 weeks.
62089749|NCT05883319|ACTIVE_COMPARATOR|clinical pilates exercises|clinical pilates exercises will be applied to 2nd group,for 3 days / week for 6 weeks.
62089750|NCT05883319|ACTIVE_COMPARATOR|cervical mobilization and clinical pilates exercises|cervical mobilization and clinical pilates exercises will be applied to 3rd group,for 3 days / week for 6 weeks.
62089751|NCT06477354|EXPERIMENTAL|At-home|Subjective auditory function assessments with the hearWHO app. Tinnitus survey. Participants take ACEMg softgel capsules daily, self-administered orally.
62089752|NCT05799053|EXPERIMENTAL|Peppermint oil capsules (Tempocol®)|"Enteric-coated capsule containing 182mg of Peppermint Oil that release the oil in the small intestine, to be taken orally.~Age: 8-11 years old: 2 times daily for 8 weeks, if needed upped to 3 times daily after 4 weeks Age: 12-18: 3 times daily for 8 weeks, if needed upped to 3 times two capsules daily after 4 weeks"
62462854|NCT02967159|EXPERIMENTAL|Treatment B (AZD7594)|Treatment B: The subjects will receive AZD7594 440 μg via DPI
62462855|NCT02967159|EXPERIMENTAL|Treatment C (AZD7594/abediterol )|Treatment C: The subjects will receive AZD7594/ abediterol 440 μg/2.5 μg FDC via DPI
62462856|NCT02967159|EXPERIMENTAL|Treatment D (AZD7594 and abediterol)|Treatment D: The subjects will receive AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
62462857|NCT01780415||Bastovit|all the patients that have supernumerary embryos to vitrify at blastocyst stage
62462858|NCT02183415|EXPERIMENTAL|BI 1356 BS, low dose|
62462859|NCT02183415|EXPERIMENTAL|BI 1356 BS, medium dose|
62462860|NCT02183415|EXPERIMENTAL|BI 1356 BS, high dose|
62462861|NCT02183415|PLACEBO_COMPARATOR|Placebo|
62462862|NCT06130371||major depressive disorder group|female MDD patients with moderate levels of depressive symptoms, mostly recruited from psychotherapist offices and the outpatient clinic of the university.
62462863|NCT06130371||premenstrual dysphoric disorder group|female participants suffering from premenstrual dysphoric disorder, as confirmed by prospective ratings of premenstrual symptoms via an app during two consecutive menstrual cycles.
62288269|NCT04122287|ACTIVE_COMPARATOR|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
62654636|NCT03636633|ACTIVE_COMPARATOR|Control Group|"Standard respiratory physiotherapy~Patients in this group will receive standard respiratory physiotherapy two times a day, 7 days a week for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
62654637|NCT03636633|EXPERIMENTAL|Training Group|"Standard respiratory physiotherapy and inspiratory muscle train~In addition to the standard respiratory physiotherapy program, patients in this group will receive 3 sets of inspiratory muscle training with 10 repetitions twice a day for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
62089753|NCT05799053|PLACEBO_COMPARATOR|Placebo|Capsule containing microcrystalline cellulose, to be taken orally. Age: 8-11 years old: 2 times daily for 8 weeks, if needed upped to 3 times daily after 4 weeks Age: 12-18: 3 times daily for 8 weeks, if needed upped to 3 times two capsules daily after 4 weeks
62089754|NCT05799053|EXPERIMENTAL|Peppermint sweets (Wilhelmina®)|"Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.~Age: 8-11 years old: 2 times daily for 8 weeks, if needed upped to 3 times daily after 4 weeks Age: 12-18: 3 times daily for 8 weeks, if needed upped to 3 times two capsules daily after 4 weeks"
62089755|NCT04078100||group A|underwent mitral valve surgery through transseptal approach.
62288270|NCT01902940||Natural History|Assessment of natural history in IBM and CCFDN
62288271|NCT00546364|EXPERIMENTAL|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|
62288272|NCT00546364|EXPERIMENTAL|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|
62654638|NCT00753519|EXPERIMENTAL|Real iTBS|iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes that standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals. The 2 sec trains were repeated 20 times every 10 sec. iTBS was applied to the primary motor and the dorsolateral prefrontal cortex bilaterally.
62654639|NCT00753519|SHAM_COMPARATOR|Sham iTBS|The sham coil was placed in the same areas, and made a similar sound as the rTMS but was without a magnetic pulse.
61905415|NCT03927482|ACTIVE_COMPARATOR|Alcohol Education|Those randomized to the control arm will be given access to an online alcohol education intervention; Check Your Drinking (CYD: www.CheckYourDrinking.net). CYD provides normative feedback on the user's drinking habits relative to his/her peers.
61905416|NCT02674204|EXPERIMENTAL|Study Agent|One atorvastatin 20 mg oral capsule per day
61905417|NCT02674204|PLACEBO_COMPARATOR|Control|One matching placebo daily
62089756|NCT04078100||group B|underwent mitral valve surgery through conventional left atrial approach.
62089757|NCT03703206|EXPERIMENTAL|ACB + iPACK|Patients scheduled for TKA will be randomized to receive an adductor canal block with an additional ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK).
62089758|NCT03703206|NO_INTERVENTION|ACB w/o iPACK|Patients enrolled in this arm will receive the standard of care adductor canal block (ACB) prior to their total knee arthoplasty.
62288273|NCT00546364|ACTIVE_COMPARATOR|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|
62288274|NCT03757884|EXPERIMENTAL|Virtual Pod|Mindfulness breathing, privacy screen, noise cancelling headphones, diagnostic checklist, diagnostic support on-line application
62462864|NCT06130371||healthy controls|healthy controls
62462865|NCT05353764|EXPERIMENTAL|SNB group|patients in the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine.
62462866|NCT05353764|NO_INTERVENTION|control group|patients in control group will receive general anesthesia without nerve block.
62462867|NCT04406441|NO_INTERVENTION|Standard of Care|Participants will attend regularly scheduled well child visits (WCV) that follow standard clinical guidelines. Well child visits will include review of history, age-appropriate measurements (height/length, weight, body mass index (BMI), blood pressure), sensory and developmental screenings, physical exam, immunizations, oral health review, and anticipatory guidance (preventive counseling).
62288275|NCT02268162|NO_INTERVENTION|Routine Bronchoscopy|Participants in the group will receive routine bronchoscopy.
62288276|NCT02268162|EXPERIMENTAL|Routine Bronchoscopy with a guiding equipment|Participants in the group will receive routine bronchoscopy combined with a guiding equipment. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
62288277|NCT02268162|EXPERIMENTAL|Routine Bronchoscopy with two or more guiding equipments|Participants in the group will receive routine bronchoscopy combined with two or more guiding equipments. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
62288278|NCT05801237|EXPERIMENTAL|Dose Escalation|
61905418|NCT05174182|EXPERIMENTAL|A novel treatment approach|"The experimental intervention were first comprised and tested in a large cohort of 10-14-year-old adolescents with a similar condition (patellofemoral pain) and was associated with a successful outcome after 12 weeks.~Afterwards, the intervention was changed slightly to target adolescents with Osgood Schlatter and then pilot-tested in a cohort of 51 participants. In this cohort, most participants needed more time to progress through exercises and sport, and the investigators have therefore piloted extending the intervention further in the clinic, with more success on these aspects.~The experimental intervention will contain an active approach with self-management of load and progressive exercise therapy throughout the treatment course, delivered through 4 one-on-one visits lasting approximately 20 minutes (at months 0, 1, 2, 3) with a physiotherapist and an accompanying leaflet with written and illustrated exercise description, and advice and information."
62462868|NCT04406441|ACTIVE_COMPARATOR|Patient Reported Outcome|Arm 2 builds on the standard of care WCV by adding a patient reported outcome measure, the Family Nutrition and Physical Activity risk assessment, to inform family-centered preventative counseling during clinical care.
61905419|NCT05174182|ACTIVE_COMPARATOR|Usual care|The investigators have performed a step-wise mixed-methods sub-study to investigate current standard of care in the most common settings in Denmark (Sports Physiotherapists mainly from private primary practice, and Orthopedic Surgeons caring for these patients, invited from all public secondary care orthopedic departments in Denmark). Results were then combined with reports from patients seen in the clinic (n=34) who were questioned in detail on what modalities and advice they had previously received. The results were mostly compatible with the recent international survey of clinicians treating Osgood-Schlatter. With the findings from this process the investigators have developed a patient-aimed leaflet, which will contain vignettes and elaborations of the multimodal approaches included in the standardized usual care package, which will be implemented through four visits (at months 0, 1, 2, 3) with a physiotherapist (mirroring the plan of care of the experimental group).
61905420|NCT03406741|EXPERIMENTAL|Child with Hirschsprung's disease|Neuropsychological assessment at elementary school
61905421|NCT01409070||Azacitidine|200 MDS patients taking Azacitidine will be assessed
62288279|NCT02744976|EXPERIMENTAL|Prediabetes, metformin|Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations
62288280|NCT02744976|ACTIVE_COMPARATOR|Prediabetes, lifestyle|Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations
61905422|NCT01409070||Decitabine|100 MDS patients taking Decitabine will be assessed
61905423|NCT00167778|EXPERIMENTAL|Arm 1|Novel prosthetic pylon
62089759|NCT05084300|EXPERIMENTAL|Pain Neuroscience Education|Pain neuroscience education in addition medical treatment. Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system.
62288281|NCT00355316|EXPERIMENTAL|Stage IV Breast Cancer|Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
62288282|NCT00355316|OTHER|Healthy Volunteers|Baseline blood draw.
62288283|NCT02525289|NO_INTERVENTION|Control Group|six hours after extubation receiving breathing exercises. After 48 hour postoperative time, sitting on armchair and keeping the erect position and walking in the same place.
62288284|NCT02525289|ACTIVE_COMPARATOR|Bed Rotation Group|six hours after extubation receiving breathing exercises and submitted the continuous rotational bed therapy in the first postoperative day until 48 hours.
62288285|NCT02525289|ACTIVE_COMPARATOR|Orthostatic Group|six hours after extubation receiving breathing exercises and changing the body position following the sequence: sitting on the bed, sitting on the bed with the feet on the floor , standing and walking in the same place, in the first postoperative day until 48 hours.
61905424|NCT00167778|ACTIVE_COMPARATOR|Arm 2|rigid pylon
61905425|NCT02942940|ACTIVE_COMPARATOR|mobile app|
61905426|NCT02942940|ACTIVE_COMPARATOR|in-person|
62089760|NCT05084300|OTHER|Usual care|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
62089761|NCT04890132|EXPERIMENTAL|Normal Controls|normal control participants - no history of neurologic or inner ear disease
62288286|NCT01213030|ACTIVE_COMPARATOR|10 mCi HX4|Patient will be injected with \[F-18\] FMISO
62288287|NCT01213030|ACTIVE_COMPARATOR|10 mCi FMISO|Patient will be injected with \[F-18\] HX4
62288288|NCT05359393|EXPERIMENTAL|resectable group|In this group, we propose a combination therapy, preoperative short-course radiotherapy followed by neoadjuvant chemotherapy and anti-PD-1 immunotherapy, for microsatellite-stable patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis.
62288289|NCT05762926|EXPERIMENTAL|Experimental|Experimental: Neuronavigation system guided halocranial application of focused sound wave pulses, using the Storz Neurolith™ equipment.
62288290|NCT05762926|ACTIVE_COMPARATOR|Active Comparator|Neuronavigation system guided halocranial application without sound waves pulses, using the Storz Neurolith™ sham equipment, prepared to block the sound waves.
61905427|NCT04503408||cystic fibrosis with abnormal glucose tolerance|cystic fibrosis with abnormal glucose tolerance Cystic fibrosis patients with descripted that impaired glucose tolerance or cystic fibrosis related diabetes by oral glucose tolerance test
62089762|NCT04890132|EXPERIMENTAL|Peripheral Vestibular Dysfunction|"Patients with unilateral vestibular damage due to monophasic illness such as vestibular neuritis or vestibular schwannoma (VS).~For VS patients, the investigators will test them in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months)."
62089763|NCT02554513|ACTIVE_COMPARATOR|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
62089764|NCT02554513|ACTIVE_COMPARATOR|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
62089765|NCT06004063|EXPERIMENTAL|Enteral nutrition (EN)-Group 1|Participants will receive enteral feeding (directly into the stomach) based on your ability to receive your daily caloric needs by mouth. Participants will be monitored by a dietician and may receive feeding by vein to achieve caloric goals.
62089766|NCT06004063|ACTIVE_COMPARATOR|Standard care parenteral nutrition (PN)-Group 2|Participants will receive the standard of care. Participants will be monitored by a dietician to see if the participants are able to receive your daily caloric needs by mouth. Some participants may be able to receive oral dietary supplements, but if this is not possible or not enough, participants will begin receiving standard of care feeding by vein.
62288291|NCT02840331|EXPERIMENTAL|St. John's Wort & PDD, PDT|St. John's Wort 900 milligram once oral preoperative \& intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
61905428|NCT04503408||cystic fibrosis with normal glucose tolerance|cystic fibrosis with normal glucose tolerance Cystic fibrosis patients with descripted that normal glucose tolerance by oral glucose tolerance test
61905429|NCT03838094|ACTIVE_COMPARATOR|MTA Group|pulpotomy technique using fast-setting mineral trioxide aggregate (MTA) to be considered the control group for vital pulp therapy and was placed over the amputated pulps for 18 months. This group will be compared with the Biodentine group as the intervention group
61905430|NCT03838094|EXPERIMENTAL|Biodentine group|3 mm- thick Biodentine covered radicular pulp to allow pulp regeneration
61905431|NCT06455969|NO_INTERVENTION|CONTROL (men + women)|The control group will maintain their habitual exercise, diet, and sleep patterns, all of which will be monitored throughout the study.
61905432|NCT06455969|ACTIVE_COMPARATOR|STRESS (men + women): Multi-Stressor Training|Research volunteers will be randomized into the stress exposure group (STRESS) will undergo a 4-week exercise training program consisting of 5 consecutive days of strenuous physical training followed by 2 days of recovery (energy balance, no structured exercise). The exercise training program will consist of military-relevant physical training exercises (e.g., load carriage, aerobic and resistance exercises) that progressively increase in duration and intensity to increase exercise energy expenditure. Participants will perform multiple exercises per day using a variety of endurance and muscle loading modalities designed to mimic movements typically observed during real-life military operations.
62089767|NCT02221479|ACTIVE_COMPARATOR|Granulocyte colony-stimulating factor (G-CSF) alone|G-CSF administered up to 8 days
62089768|NCT02221479|EXPERIMENTAL|G-CSF plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
62089769|NCT04100954|EXPERIMENTAL|Reinforced prosthesis|Implementation of a reinforced prosthesis with silver coating and double valve, whatever which type of prosthesis the patient previously had.
62089770|NCT04100954|ACTIVE_COMPARATOR|Standard prosthesis|Implementation of a standard prosthesis (simple valve, not reinforced), similar to the prosthesis the patient previously had.
62089771|NCT00877851|EXPERIMENTAL|1 Computer-based Program|Use of Computer-based Program for 12 weeks
62089772|NCT00877851|NO_INTERVENTION|2 Control|Usual care and list of useful websites
62089773|NCT04121273|EXPERIMENTAL|CAR-T cells|CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.
62089774|NCT02128503|OTHER|HBV DNA level monitoring|Group with HBV DNV level being monitored regularly
62089775|NCT04729140|ACTIVE_COMPARATOR|Ivermectin plus Doxycycline|"Ivermectin 200 mcg/kg on day 1 and day 2-plus doxycycline 100 mg tablets twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~\>110 kg 7 tablets"
62288292|NCT03257189|OTHER|Single Arm|"This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices.~This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention."
62089776|NCT04729140|ACTIVE_COMPARATOR|Ivermectin plus Placebo|"Ivermectin 200 mcg/kg on day 1 and day 2-plus placebo tablet twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin and Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~\>110 kg 7 tablets"
62089777|NCT04729140|PLACEBO_COMPARATOR|Placebo plus Placebo|"Placebo (number of tablets according to weight) plus placebo twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~\>110 kg 7 tablets"
62089778|NCT06297564|ACTIVE_COMPARATOR|Progesterone primed endometrial protocol|The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day
62089779|NCT06297564|EXPERIMENTAL|Gonadotropin-releasing hormone antagonist protocol|The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH \>10 IU/L, the presence of at least one follicle with mean diameter \>14 mm, or serum E2 level \>600 pg/mL.
62089780|NCT02244593|NO_INTERVENTION|Mammography screening only|"This group will receive their standard of care mammogram only. Participants in this arm will not receive the FAST MRI.~Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram."
62089781|NCT02244593|EXPERIMENTAL|FAST MRI and mammogram screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram. The intervention is the addition of the FAST Breast MRI.
62089782|NCT02062190|ACTIVE_COMPARATOR|resveratrol|
62654640|NCT02369653|EXPERIMENTAL|Apixaban|"Children aged 1 to \<18 years weighing 6 to \<35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days.~Children aged 1 to \<18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects \< 5years and \< 35 kg may be administered 0.5-mg tablets only"
62654641|NCT02369653|PLACEBO_COMPARATOR|No systemic anticoagulant prophylaxis|No systemic anticoagulant prophylaxis
62089783|NCT02062190|PLACEBO_COMPARATOR|corn starch|"(10 patients) 100mg 2x/day~1 month"
62089784|NCT03259347|EXPERIMENTAL|Counter-attitudinal therapy|Counter-attitudinal therapy (CAT) is dissonance-based group intervention. CAT consists of behavioral, written, and verbal exercises in which participants discuss the costs of pursuing the thin ideal and behaviors that are used to pursue the thin ideal. The intervention is 8 sessions long (1-hr each) and is administered by a trained facilitator who uses an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
62089785|NCT03259347|ACTIVE_COMPARATOR|Educational-support group|The educational support group intervention that is representative of typical treatment groups offered at universities and community settings. For the current study, the educational support group was designed to match the dissonance group on treatment modality (group-based), duration (8 1-hr sessions), and use of an intervention script administered by a trained facilitator. In the intervention sessions, participants will be provided with a basic education about eating disorders, support for themselves and fellow group members, and learn mindfulness techniques.Participants will be asked to complete weekly homework assignments.
62089786|NCT06306430||PTB|Subjects with a pulmonary TB
62089787|NCT06306430||PNTM|Subjects with pulmonary NTM
62089788|NCT06306430||extraPTB|Subjects with extrapulmonary TB
62089789|NCT06306430||HC|Healthy controls donors
62089790|NCT06235164||neoadjuvant immunochemotherapy group|The immune checkpoint inhibitors (ICIs) used for neoadjuvant immunotherapy in this study included sintilimab, nivolumab, and camrelizumab. Neoadjuvant chemotherapy regimens were primarily categorized into two- and three-agent regimens. The two-agent regimens included: SOX (S-1 + oxaliplatin), CapeOx (capecitabine + oxaliplatin), AS (S-1 + nab-paclitaxel), FOLFOX (oxaliplatin + fluorouracil) and DS (S-1 + docetaxel). The three-agent regimens included: FLOT (docetaxel + oxaliplatin + fluorouracil), DOS (docetaxel + oxaliplatin + S-1) and POF (paclitaxel + oxaliplatin + fluorouracil). Dosages were calculated based on drug monographs, guidelines, and patient body surface area. The patients underwent LG within 4-6 weeks after completing neoadjuvant therapy.
62654642|NCT06516120||Healthy elderly|Group of participants who have no prior history of stroke
62654643|NCT06516120||Stroke survivor|Group of participants who have been through a stroke
62654644|NCT01566370|EXPERIMENTAL|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind
62654645|NCT01566370|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group
62654646|NCT01787838|OTHER|health education, audit and feedback|Focused health education for staff and patients.
62654647|NCT02646163|EXPERIMENTAL|REP 2055|Treatment with REP 2055
62654648|NCT03328065||Stable patients, early responders to treatment and caregivers|
62654649|NCT03328065||Stable patients and intermediate responders and c|Stable patients and intermediate responders to treatments and caregivers
62654650|NCT03328065||Doctors|
61920023|NCT00088998|EXPERIMENTAL|docetaxel + bevacizumab + capecitabine|"Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years."
62089791|NCT06235164||neoadjuvant chemotherapy group|Neoadjuvant chemotherapy regimens were primarily categorized into two- and three-agent regimens. The two-agent regimens included: SOX (S-1 + oxaliplatin), CapeOx (capecitabine + oxaliplatin), AS (S-1 + nab-paclitaxel), FOLFOX (oxaliplatin + fluorouracil) and DS (S-1 + docetaxel). The three-agent regimens included: FLOT (docetaxel + oxaliplatin + fluorouracil), DOS (docetaxel + oxaliplatin + S-1) and POF (paclitaxel + oxaliplatin + fluorouracil). Dosages were calculated based on drug monographs, guidelines, and patient body surface area. The patients underwent LG within 4-6 weeks after completing neoadjuvant therapy.
62089792|NCT02362633|EXPERIMENTAL|Real tDCS|Subjects will receive real tDCS treatment for ten times for two weeks (five times per week).
62089793|NCT02362633|SHAM_COMPARATOR|Sham tDCS|Subjects will receive sham tDCS treatment for ten times for two weeks (five times per week).
62089794|NCT06148259|ACTIVE_COMPARATOR|Sodium glucose cotransporter 2 inhibitors|patients with diabetes treated with sodium glucose cotransporter 2- Dapagliflozin
62089795|NCT06148259|ACTIVE_COMPARATOR|Dipeptidyl peptidase 4 inhibitors|patients with diabetes treated with Dipeptidyl peptidase 4 inhibitor-sitagliptin
62089796|NCT03902340|EXPERIMENTAL|TENS|Treatment by non-pharmacological transcutaneous electric nerve stimulation (TENS)
62089797|NCT03902340|ACTIVE_COMPARATOR|level 2 systemic analgesic treatments|Treatment by level 2 analgesic pharmacological treatment indicated in the treatment of chronic nociceptive pain of moderate to severe intensity.
62089798|NCT01808443|ACTIVE_COMPARATOR|Cryotherapy|Cryotherapy, at most 4 times
62288293|NCT01854346|EXPERIMENTAL|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
62089799|NCT01808443|EXPERIMENTAL|laser|laser, at most 4 times
62089800|NCT04784273||All study patients|Device - DynaNail - Utilization of a novel dynamic compression pseudoelastic intramedullary nail
62089801|NCT06484764|EXPERIMENTAL|CT-fluoroscopy guided robot-assisted percutaneous needle biopsy group|Remote controlled, CT-fluoroscopy guided, robot-assisted biopsy procedure of thoracic and abdominal lesions
62288294|NCT01854346|NO_INTERVENTION|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
62288295|NCT02984800|EXPERIMENTAL|Group I|Patients will receive one PVB injection at L1-L2 .
62089802|NCT06484764|ACTIVE_COMPARATOR|Freehand needle biopsy group under the CT guidance|Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions
62089803|NCT04018443||patients admitted ti surgical ICU after major surgery|patient admitted to surgical ICU after major surgery for post-operative close monitoring, assessment and resuscitation of the intravascular volume status
62089804|NCT03443596|ACTIVE_COMPARATOR|Early intensive BP control|BP in participants in this arm is treated aggressively, lowered and maintained at systolic blood pressure between 140-160mmHg, within 6 hours of stroke onset and maintained in this range for first 72 hours.
62089805|NCT03443596|NO_INTERVENTION|Guidelined based BP control|Participants are treated according to the current international guidelines in thrombolysed acute ischemic stroke patients, i.e., less than 180/105mmHg
62089806|NCT03005288|EXPERIMENTAL|BYM338 10 mg/kg|Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
62089807|NCT03005288|PLACEBO_COMPARATOR|Placebo|Placebo, every 4 weeks until week 44 (12 doses)
62089808|NCT02569229||Patients with Cystic Fibrosis|Patients between 10-20 years of age with genetically determined cystic fibrosis followed at the university children's hospital Basel and university children's hospital Kinderklinik Bern, Switzerland. All patients will get the diagnostics for glucose tolerance with 3 different methods (CGMS, OGTT and optionally IVGTT).
62089809|NCT01164163|EXPERIMENTAL|Treatment (Ruxolitinib)|
62089810|NCT02461511||Therapeutic Education + Documentation|diabetic patient hospitalized patient particpating in therapeutic education program
62089811|NCT02461511||No Therapeutic Education No Documents|diabetic patient hospitalized patient without therapeutic education program no documentation submitted
62089812|NCT02461511||Documentation, No Therapeutic Education|diabetic patient hospitalized patient without therapeutic education program documentation submitted
62288296|NCT02984800|EXPERIMENTAL|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
62288297|NCT01783067|EXPERIMENTAL|Iron and zinc biofortified pearl millet|Participants in the experimental arm consume pearl millet which has been biofortified with iron and zinc.
62288298|NCT01783067|ACTIVE_COMPARATOR|Pearl millet|Participants in the control arm consume non-biofortified pearl millet.
62288299|NCT02199132||Nasopharyngeal Carcinoma|
61920024|NCT03407300|ACTIVE_COMPARATOR|Docetaxel|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel alone.
62288300|NCT00825604|NO_INTERVENTION|Without PCI|Optimized medical treatment, physical training and smoking cessation
62288301|NCT00825604|ACTIVE_COMPARATOR|With PCI|optimized medical treatment, physical training and smoking cessation with complimentary treatment with percutaneous coronary intervention(PCI)
62288302|NCT04051957|EXPERIMENTAL|Isosorbide Mononitrate|
62288303|NCT04051957|PLACEBO_COMPARATOR|Placebo|
62288304|NCT03908944|ACTIVE_COMPARATOR|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
61920025|NCT03407300|ACTIVE_COMPARATOR|Docetaxel plus XH1|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel plus Chinese traditional medicine XH1.
62089813|NCT00372567|EXPERIMENTAL|A|
62089814|NCT00372567|ACTIVE_COMPARATOR|B|
62089815|NCT05051098||TherVacB Subgroup|"No interventions. The participating study centers of the EU funded project TherVacB recruit patients with stricter inclusion- and exclusion criteria, hence forming a sub-cohort."
62089816|NCT01397487|OTHER|one single arm|All patients are included to complete a biopsy of half part of the embryos
62089817|NCT02687919|EXPERIMENTAL|Modified Paleo Diet Intervention (MPDI)|Consumed a modified Paleo diet, described as nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
62089818|NCT02687919|NO_INTERVENTION|Usual Care|Typical physician recommendations for MS.
62089819|NCT01537653|EXPERIMENTAL|SAR231893 (REGN668), Dose Level 4|Dose Level 4
62089820|NCT01537653|PLACEBO_COMPARATOR|Placebo|Placebo
62089821|NCT01537653|EXPERIMENTAL|SAR231893 (REGN668), Dose Level 1|Dose Level 1
62089822|NCT01537653|EXPERIMENTAL|SAR231893 (REGN668), Dose Level 2|Dose Level 2
62089823|NCT01537653|EXPERIMENTAL|SAR231893 (REGN668), Dose Level 3|Dose Level 3
62288305|NCT03908944|EXPERIMENTAL|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
62288306|NCT06154967|EXPERIMENTAL|ICIs regimen: tislelizumab 200mg every 3 weeks, the first dose was given 7 days after the last SBRT|
62288307|NCT02382094|EXPERIMENTAL|Arm AA(anti-androgen)|Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
61905433|NCT06455969|EXPERIMENTAL|SUPPRESS (men): Multi-Stressor Training + Zoladex + AndroGel 1.25g|In addition to participating in the multi-stressor training program, male participants randomized to the GnRH suppressed (SUPPRESS) group will be administered a long-acting GnRH agonist (Zoladex) by trained medical professionals to suppress endogenous gonadal steroids. Following GnRH agonist administration, men will be administered 1.25g/day (SUPPRESS) of topical 1% testosterone gel (AndroGel, Abbvie, North Chicago, IL) to be applied to the shoulders, upper arms, and/or stomach area daily.
61920026|NCT02048189|OTHER|Intensified multiple injections|
61920027|NCT02048189|OTHER|Pumps|
62288308|NCT02382094|OTHER|Arm TAB (Total androgen blockade)|Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
62288309|NCT02664155|EXPERIMENTAL|DOA : Direct Oral Anticoagulants|"The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:~* Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months~* Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months."
62462869|NCT04406441|ACTIVE_COMPARATOR|Patient Reported Outcome + Food Care|Participants will receive all Arm 2 components, in addition to be referred to both the Geisinger Wellness Program for a Parent Training Program and a grocery store nutritionist for a tour aligned with the Cooking Matters program.
62462870|NCT02298465|ACTIVE_COMPARATOR|Prone ESWL|ESWL for distal ureteric stone is performed in the traditional prone position
62654651|NCT03328065||Patients in therapeutic escape and their caregivers|
62654652|NCT05944432|ACTIVE_COMPARATOR|FreeStyle Libre system|FreeStyle Libre 3 continuous glucose monitoring system
62654653|NCT05944432|OTHER|Standard of care (control)|Self monitoring of blood glucose
62089824|NCT02303743|ACTIVE_COMPARATOR|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
62462871|NCT02298465|EXPERIMENTAL|Supine ESWL|ESWL for distal ureteric stone is performed in the supine position, with the shockwave generator head placed at a 30 degree angle to the vertical at the patient's gluteal muscles. Thus, the shockwaves will travel via the greater and lesser sciatic foramina to reach the stone
62462872|NCT05449249|EXPERIMENTAL|Long-term fasting|Long-term fasting according to the Buchinger Wilhelmi fasting program.
61920028|NCT05602311||Group SDB|Children were divided into two groups according to whether they had SDB, group SDB: experimental group (SDB children), group control: control group (typical development children)
62089825|NCT02303743|ACTIVE_COMPARATOR|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
62089826|NCT00670982|EXPERIMENTAL|First line treatment|Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week
62089827|NCT00670982|EXPERIMENTAL|Second line treatment|Patients with 1 prior line for metastatic breast cancer will receive bevacizumab intravenously every two weeks, vinorelbine intravenously once per week, and trastuzumab intravenously once per week.
62089828|NCT02706626|EXPERIMENTAL|Cohort A: Disease progression after next generation ALK TKI|Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent. Patients enrolled regardless the number of lines of therapy
62089829|NCT02706626|EXPERIMENTAL|Cohort B: Disease progression after alectinib as first-line therapy|Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent. Patients enrolled after first-line alectinib
62089830|NCT02706626|EXPERIMENTAL|Cohort C: Disease progression after brigatinib|Brigatinib at 240 mg daily until progressive disease, unacceptable toxicity, withdrawal of consent. Patients enrolled after treatment on brigatinib at the standard dose brigatinib
62089831|NCT02729792|EXPERIMENTAL|Single site rTMS|"Each treatment session will consist of:~1200 pulses of iTBS over a posterior target location followed by a 60 minute interval, then 1200 pulses of iTBS over an anterior target location."
62089832|NCT02729792|ACTIVE_COMPARATOR|Dual site rTMS|"Each treatment session will consist of:~600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location followed by a 60 minute interval, then 600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location."
62089833|NCT04049721|ACTIVE_COMPARATOR|Standard of Care without HBO|Intravenous access and fluid resuscitation (standard of care treatment)
62089834|NCT04049721|EXPERIMENTAL|HBO + Standard of Care|Ten daily treatment sessions of HBO at 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks
62089835|NCT00619476|PLACEBO_COMPARATOR|Placebo|placebo
62089836|NCT00619476|EXPERIMENTAL|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
62089837|NCT00619476|EXPERIMENTAL|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
62462873|NCT03855332|PLACEBO_COMPARATOR|Placebo|"All participants will undergo three phases in random order:~The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily"
62462874|NCT03855332|EXPERIMENTAL|Sildenafil|25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily
62089838|NCT00619476|EXPERIMENTAL|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
62089839|NCT02178462||Primary ovarian cancer patients|Intervention will not be administered.
62089840|NCT02178462||Primary endometrial cancer patients|Intervention will not be administered.
62089841|NCT02178462||Benign gynecological disease patients|Intervention will not be administered.
62089842|NCT02178462||Healthy controls|Intervention will not be administered.
62089843|NCT05124899|EXPERIMENTAL|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter \[mg/cm\^2\]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62089844|NCT05124899|EXPERIMENTAL|CAP Herbal Mint|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of CAP Herbal Mint will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62089845|NCT05124899|EXPERIMENTAL|CAP Mountain Berry|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of CAP Mountain Berry will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62089846|NCT05124899|ACTIVE_COMPARATOR|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62462875|NCT03855332|ACTIVE_COMPARATOR|Cilostazol|50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)
62089847|NCT04824443|EXPERIMENTAL|Participants who were hospitalized for COVID-19|Participants will be post-cancer treatment patients who were hospitalized for COVID-19.
62462876|NCT02661529|ACTIVE_COMPARATOR|Transesophageal Echocardiogram|Patients undergoing an Transesophageal Echocardiogram (TEE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
62654654|NCT01642368|PLACEBO_COMPARATOR|Regular Diet|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
62089848|NCT04884698|EXPERIMENTAL|Phrenic nerve stimulation with Stimit Activator|
62089849|NCT05349318|ACTIVE_COMPARATOR|Hyperbaric Oxygen Therapy active arm|The protocol comprises of 60 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive HBOT twice a week.
62089850|NCT05349318|SHAM_COMPARATOR|Sham active arm|The protocol comprises of 60 consecutive Sham sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive Shan sessions twice a week.
62089851|NCT05414565||Vivity IOL|Subjects previously implanted with Vivity or Vivity toric IOL
62089852|NCT05414565||Aspheric Monofocal IOL|Subjects previously implanted with an aspheric monofocal or monofocal toric IOL
62462877|NCT02661529|ACTIVE_COMPARATOR|Transthoracic Echocardiogram|Patients undergoing an Transthoracic Echocardiogram (TTE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
62089853|NCT00482105|OTHER|A|"This research study proposes to use a non-invasive method to capture superficial cells on pigmented skin lesions that are suspected of being early melanomas. This non-invasive biopsy technology has been developed and patented by DermTech International. RNA in skin cells captured by this method will be profiled in order to diagnose the nature of the lesion (i.e. malignant melanoma or not). A successful outcome of this proposal would create a candidate non-invasive diagnostic assay based on a gene expression profile for identifying early stage melanomas"
62089854|NCT04560907|EXPERIMENTAL|Aquablation|
62089855|NCT04560907|ACTIVE_COMPARATOR|HoLEP|
62089856|NCT04821999|EXPERIMENTAL|group I|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
61905434|NCT06455969|EXPERIMENTAL|SUPPRESS (women): Multi-stressor training + Zoladex + Placebo patch|In addition to participating in the multi-stressor training program, male participants randomized to the GnRH suppressed (SUPPRESS) group will be administered a long-acting GnRH agonist (Zoladex) by trained medical professionals to suppress endogenous gonadal steroids. Following GnRH agonist administration, women in the SUPRESS group will receive a placebo transdermal patch.
62462878|NCT05632770|EXPERIMENTAL|Stepped Collaborative Care (Intervention)|Patients in the intervention condition will receive a stepped collaborative care intervention that includes posttraumatic concern elicitation, proactive care management, medication, and psychotherapy elements targeting posttraumatic stress disorder (PTSD) and related comorbidity.
62654655|NCT01642368|ACTIVE_COMPARATOR|Medium Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
62654656|NCT01642368|ACTIVE_COMPARATOR|High Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
62654657|NCT00739232|ACTIVE_COMPARATOR|Active|Active
61905435|NCT06455969|EXPERIMENTAL|REPLACE (men): Multi-Stressor Training + Zoladex + AndroGel 5g|Following GnRH agonist administration, men will be administered 5g/day (REPLACE) of topical 1% testosterone gel (AndroGel, Abbvie, North Chicago, IL) to be applied to the shoulders, upper arms, and/or stomach area daily.
61905436|NCT06455969|EXPERIMENTAL|REPLACE (women): Multi-Stressor Training + Zoladex + Climara Pro Patch|Following GnRH agonist administration, women, the REPLACE group will receive a transdermal estradiol (0.045 mg/day) + levonorgestrel (0.015 mg/day) patch (Climara Pro, Bayer, NJ) to be placed on a clean, dry area of the skin on the lower
61905437|NCT05900206|EXPERIMENTAL|T-DXd (cycles 1-3)|Trastuzumab Deruxtecan, administered every three weeks for three courses. Further treatment is decided by the intrinsic molecular (PAM50) subtype of the tumor.
61905438|NCT05900206|ACTIVE_COMPARATOR|Standard treatment (TCHP or PCHP; cycles 1-3)|TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab) or PCHP (Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab), administered every three weeks for three courses. Further treatment is decided by the intrinsic molecular (PAM50) subtype of the tumor.
61905439|NCT05900206|OTHER|ER-positive and Luminal (cycles 4-6)|Ribociclib, letrozole, trastuzumab, pertuzumab
61905440|NCT05900206|OTHER|ER-negative and Luminal, or Basal-like, or Normal-like (cycles 4-6)|Epirubicin and Cyclophosphamide in case of no complete radiologic response after the initial three courses. In case of complete radiologic response, treatment from cycles 1-3 (T-DXd or TCHP/PCHP) will continue instead for three more courses.
62089857|NCT04821999|NO_INTERVENTION|group II|No treatment
62288310|NCT02664155|ACTIVE_COMPARATOR|SOC : Standard Of Care|The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
62288311|NCT04061083|EXPERIMENTAL|Continuous Endotracheal Cuff Pressure Control|Continuous endotracheal cuff pressure control using smart cuff manager during the first 48 hours of intubation in the intensive care unit
62654658|NCT00739232|PLACEBO_COMPARATOR|Placebo|Placebo
62654659|NCT06040320|EXPERIMENTAL|Polatuzumab vedotin + Rituximab (Safety Lead-in Low Risk/Interim Complete Remission)|"* Cycle 1 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~ * Day 8: rituximab~ * Day 15: rituximab~* Cycle 2 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~* After Cycle 2, a response assessment will be performed. Patients who show a complete response (and are therefore determined to be low risk) will continue to receive polatuzumab vedotin + rituximab on Day 1 of each 21-day cycle for 4 additional cycles (6 cycles of treatment total)."
61905441|NCT05900206|OTHER|HER2-enriched (cycles 4-6)|The same treatment with T-DXd or TCHP/PCHP administered every three weeks for three more courses will continue from cycles 1-3
61920029|NCT05602311||Group control|Children were divided into two groups according to whether they had SDB, group SDB: experimental group (SDB children), group control: control group (typical development children)
61920030|NCT01466140|NO_INTERVENTION|Control group|Patients in the control group were asked to participate in a patient satisfaction study. They were asked to fill in a questionnaire with respect to patient satisfaction.
62462879|NCT05632770|ACTIVE_COMPARATOR|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|Patients in the control condition will receive usual trauma center care with American College of Surgeons (ACS) required psychosocial screening and referral.
62462880|NCT06399822|ACTIVE_COMPARATOR|Capillaroscopy|In the capillaroscopy group, the capillaroscopy will be performed in the month following recruitment.
62462881|NCT06399822|OTHER|Control|In the control group, the capillaroscopy will be performed six months (+/- 2 weeks) after recruitment.
62654660|NCT06040320|EXPERIMENTAL|Polatuzumab vedotin + Rituximab (Expansion Low Risk/Interim Complete Remission)|"* Cycle 1 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~ * Day 8: rituximab~ * Day 15: rituximab~* Cycle 2 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~* After Cycle 2, a response assessment will be performed. Patients who show a complete response (and are therefore determined to be low risk) will continue to receive polatuzumab vedotin + rituximab on Day 1 of each 21-day cycle for 4 additional cycles (6 cycles of treatment total)."
61920031|NCT01466140|EXPERIMENTAL|Use of request card|Patients in the intervention group were told that the practice was participating in a patient satisfaction study, and they were given an envelope with information about the 'doorknob phenomenon' and a request card. The envelope for the control group only consisted of information about a patient satisfaction study, without any information on the 'doorknob phenomenon', and without a request card. Both groups received the same letter with patient information about the study.
62089858|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
62089859|NCT05399888|PLACEBO_COMPARATOR|Placebo Q12W|Participants will receive BIIB080-matching placebo, intrathecal (IT) injection, once on Day 1 and then once every 12 weeks (Q12W) for up to 72 weeks, during the placebo-controlled period. Eligible participants will enter the LTE period, during which they will be randomized to receive BIIB080 high dose, IT injection, either Q12W or once every 24 weeks (Q24W) for an additional 96 weeks.
62288312|NCT04061083|EXPERIMENTAL|Intermittent Endotracheal Cuff Pressure Control|Intermittent cuff pressure control through manual manometer measurement performed 3 times per day during the first 48 hours of intubation in the intensive care unit
62288313|NCT04061083|NO_INTERVENTION|Standard Care|ET cuff pressure control will be provided with pilot balloon fingers during the first 48 hours of intubation in the intensive care unit
62288314|NCT00675597|EXPERIMENTAL|1|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients with Resected Stage I-III Non-small Cell Lung Cancer
62288315|NCT02257047|EXPERIMENTAL|RYR|Patients under the treatment of red yeast rice
62288316|NCT02257047|SHAM_COMPARATOR|Control|Patients under the treatment of tea
62089860|NCT05399888|EXPERIMENTAL|BIIB080 Low Dose Q24W|Participants will receive a low dose of BIIB080, IT injection, Q24W from Week 1 up to 72 weeks and BIIB080-matching placebo, IT injection, once at Weeks 12, 36, and 60 during the placebo-controlled period. Eligible participants will enter the LTE period, during which they will continue to receive BIIB080 low dose, IT injection, Q24W for an additional 96 weeks.
62089861|NCT05399888|EXPERIMENTAL|BIIB080 High Dose Q24W|Participants will receive a high dose of BIIB080, IT injection, Q24W from Week 1 up to 72 weeks and BIIB080-matching placebo, IT injection, once at Weeks 12, 36, and 60 during the placebo-controlled period. Eligible participants will enter the LTE period, during which they will continue to receive BIIB080 high dose, IT injection, Q24W for an additional 96 weeks.
62089862|NCT05399888|EXPERIMENTAL|BIIB080 High Dose Q12W|Participants will receive a high dose of BIIB080, IT injection, once on Day 1 and then Q12W for up to 72 weeks during the placebo-controlled period. Eligible participants will enter the LTE period, during which they will continue to receive BIIB080 high dose, IT injection, Q12W for an additional 96 weeks.
62089863|NCT00696293|EXPERIMENTAL|1|"Duloxetine + clinical management~NOTE -- THIS WORK WAS CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. THE CLINICALTRIALS.GOV DESCRIPTION OF THE STUDY WAS UPDATED 1/5/16 TO UPDATE THE OPEN LABEL NATURE OF THIS WORK. THIS IS WHAT IS REPORTED HERE AND HAS BEEN PEER REVIEWED AND PUBLISHED."
62089864|NCT04547803|EXPERIMENTAL|Video Visit and Standard of Care|Participants will participate in a video visit and standard of care
62089865|NCT04547803|ACTIVE_COMPARATOR|Standard of Care|Participants will participate in standard of care for discharged patients.
62089866|NCT05202236|EXPERIMENTAL|selective FGFR1-3 inhibitor|
62089867|NCT06051760|EXPERIMENTAL|NV-001|The patients will be treated with vaccines generated based on their tumor tissues.Various doses will be tested according to the protocol.
62089868|NCT02955433|EXPERIMENTAL|Rideshare|The intervention arm will receive an appointment reminder and free transportation for one appointment to travel between the patient's home and primary care clinic using a rideshare-based transportation service.
62089869|NCT02955433|NO_INTERVENTION|Control|The control arm will receive an appointment reminder, but no free transportation offer.
62288317|NCT01382160|EXPERIMENTAL|adalimumab|40 mg every two weeks, by subcutaneous way
62736372|NCT01221753|EXPERIMENTAL|TPF Induction Chemotherapy followed by Chemoradiotherapy|Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.
62089870|NCT03569917|EXPERIMENTAL|patient under Ceftriaxone treatment|
62089871|NCT04975789|NO_INTERVENTION|Usual Care Control|Standard of Care
62089872|NCT04975789|EXPERIMENTAL|InfoViz Intervention|Pain information visualization (InfoViz) tool, Trained interpreters will use the InfoViz tool twice, before and during the clinical encounter
62288318|NCT04744974|EXPERIMENTAL|Mediterranean diet|Participants will be given dietician counseling on a Mediterranean diet
62288319|NCT04744974|EXPERIMENTAL|DASH diet|Participants will be given dietician counseling on a DASH diet
62288320|NCT06259799|EXPERIMENTAL|Smart Water Bottle|Participants in the intervention group will be prompted by the water bottle to drink (bottle will light up red) whenever they are behind on fluid intake recommendations for the day. The bottle will be linked to a smart phone application that participants will be instructed to download on their personal mobile device, but they will log into this device using a researcher provided username and password. The bottle will encourage male participants to consume 2.5 L and for female participants to consume 2.0 L of fluid. Participants will be asked to use this bottle to consume all water and enter any additional sources of fluid using the mobile application. The intervention group will also be asked to record their daily perceived thirst, first morning urine color, and body mass as a means of self-monitoring daily changes in hydration status, using a provided paper log.
62462882|NCT05735925|EXPERIMENTAL|Hidradenitis Suppurativa (HS) Patients|"* Skin swab sampling for bacteriological analysis~* Four skin biopsies:~a 6-mm and a 4-mm section skin biopsies on a lesional area (inflammatory nodules) a 6-mm and a 4-mm section skin biopsies on a non lesional area~- blood sample (16 mL)"
62288321|NCT06259799|NO_INTERVENTION|Control|The control group will be asked to go about daily activities as normal. They will not receive the water bottle and will not be asked to track daily measures of thirst, morning urine color, or body mass.
62288322|NCT02495922|ACTIVE_COMPARATOR|A1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
62288323|NCT02495922|EXPERIMENTAL|A2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
62288324|NCT02495922|EXPERIMENTAL|B1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
62288325|NCT02495922|EXPERIMENTAL|B2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
62736373|NCT05262777|EXPERIMENTAL|GP0112|GP0112 Single injection and optional touch up injection and re-treatment with GP0112
62288326|NCT02149680||Experimental group|Patient who has had an epidural blood patch following accidental dura puncture during pregnancy
62462883|NCT05735925|NO_INTERVENTION|Healthy Subjects|blood sample (16 mL)
62462884|NCT02005705|ACTIVE_COMPARATOR|Outpatient|
62462885|NCT02005705|ACTIVE_COMPARATOR|Inpatient|
62462886|NCT04570904||Early HCWs|Health Care Workers vaccinated early prior to the influenza season
62462887|NCT04570904||Late HCWs|Health Care Workers vaccinated just prior to the influenza season
62462888|NCT04570904||Inpatients|Inpatients recruited for evaluation of new approaches to influenza diagnosis
62288327|NCT02149680||Control Group|Women in the same group, equal numbers of those with or without epidurals, without accidental dural puncture, similar parity would constitute the control group. They would be chose at random, 10 times the number in the experimental group (n = 600).
62288328|NCT02572284|EXPERIMENTAL|Dose Escalation of SBRT|Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
62288329|NCT00995254|NO_INTERVENTION|Control group|Control group will ONLY receive SHI after completion of the study
62288330|NCT00995254|EXPERIMENTAL|Intervention group|Intervention group will receive smoking hygiene intervention (SHI) at three individualized contacts.
62462889|NCT03733925|EXPERIMENTAL|Golimumab|Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24. Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
62462890|NCT02729376|EXPERIMENTAL|Single dose of [14C]-galeterone|\[14C\]-galeterone will be supplied as 325 mg capsules (powder in capsule \[PIC\]). The treatment to be administered will be 2600 mg (\~500 µCi) (8 x 325 mg capsules).
62462891|NCT00555230|EXPERIMENTAL|1|Rosuvastatin
62462892|NCT00555230|PLACEBO_COMPARATOR|2|Placebo
62462893|NCT01033565|EXPERIMENTAL|Natrol|Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days
62462894|NCT00440297|EXPERIMENTAL|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
62462895|NCT00440297|ACTIVE_COMPARATOR|ENGERIX-B™2|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
62462896|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
62462897|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
62462898|NCT00905853|ACTIVE_COMPARATOR|Ventricular Tachycardia Ablation|Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
62462899|NCT00905853|ACTIVE_COMPARATOR|Escalated Antiarrhythmic Drug Therapy|Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.
62462900|NCT02305823|ACTIVE_COMPARATOR|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
62462901|NCT02305823|ACTIVE_COMPARATOR|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
62462902|NCT02305823|ACTIVE_COMPARATOR|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
62462903|NCT03769285|EXPERIMENTAL|Nicotinamide|
62462904|NCT03769285|PLACEBO_COMPARATOR|Placebo|
62089873|NCT03297775||RA with Sub-clinical ILD|"Subjects will be followed annually until study closure.~Assessments are as follows:~1. Clinical (Annual): Demographics, health-related behaviors, co-morbidities, medications, respiratory symptoms, rheumatologic assessment, quality of life~2. Physiologic (3-5 yrs FU): Lung function on Pulmonary Function Test (PFT)~3. Radiologic (3-5 yrs FU): HRCT scan of chest~4. Genetic (3-5 yrs FU): Blood sample collection for RNA~5. Biologic (3-5 yrs FU): Blood sample collection for other blood markers"
62089874|NCT03297775||RA with No-ILD|"Subjects will be followed annually until study closure.~Assessments are as follows:~1. Clinical (Annual): Demographics, health-related behaviors, co-morbidities, medications, respiratory symptoms, rheumatologic assessment, quality of life~2. Physiologic (3-5 yrs FU): Lung function on Pulmonary Function Test (PFT)~3. Radiologic (3-5 yrs FU): HRCT scan of chest~4. Genetic (3-5 yrs FU): Blood sample collection for RNA~5. Biologic (3-5 yrs FU): Blood sample collection for other blood markers~Note: Certain follow-up procedures may not occur for every subject and will be determined by the research team."
62288331|NCT01701622|EXPERIMENTAL|Allopurinol, febuxostat|Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.
62288332|NCT03543683||osimertinib and aspirin|Osimertinib starting at a dose of 80 mg once a day, orally with meals.The intervention is aspirin which is starting at a dose of 100 mg once a day, orally with meals.Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
62462905|NCT01565096|EXPERIMENTAL|Vildagliptin plus Metformin|Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
62654661|NCT06040320|EXPERIMENTAL|Polatuzumab vedotin + Rituximab + CHP (Safety Lead-in High Risk/Lack of Interim Complete Remission))|"* Cycle 1 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~ * Day 8: rituximab~ * Day 15: rituximab~* Cycle 2 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~* After Cycle 2, a response assessment will be performed. Patients who show anything other than a complete response (and are therefore determined to be high risk) will receive polatuzumab vedotin + rituximab + CHP (cyclophosphamide + doxorubicin + prednisone) on Day 1 of each 21-day cycle for 4 additional cycles, followed by 2 final cycles of CHP alone on Day 1 (8 cycles of treatment total)."
62089875|NCT03752736|ACTIVE_COMPARATOR|Extended intervention|"Upon completion of the two-week baseline period and two-week standard intervention period, the two classrooms assigned to the Extended intervention condition will receive the I wear sunscreen everyday song-based video intervention daily for two additional weeks."
62288333|NCT03543683||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
62462906|NCT01565096|ACTIVE_COMPARATOR|Glimepirid plus Metformin|Metformin (1000 mg BID) + Glimepiride (individual dosage)
62462907|NCT01771705|EXPERIMENTAL|Dose adjust group (NFAT)|Within 4 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.
62462908|NCT01771705|NO_INTERVENTION|Standard of care group|A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.
62288334|NCT00669617|EXPERIMENTAL|Ind 150μg, Salm/flut, Ind 300μg, Placebo, Salbut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Placebo, Salbutamol 200 μg (Salbut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62288335|NCT00669617|EXPERIMENTAL|Ind 300μg, Ind 150μg, Salbut, Salm/flut, Placebo|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo. At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62462909|NCT03750097|EXPERIMENTAL|Walking protocol|Walking for 250 steps with comfortable walking velocity (CWV), slow walking velocity (SWV: CWV - 20%) and fast walking velocity (FWV: CWV + 20%) with sufficient rest between conditions.
62462910|NCT00686959|EXPERIMENTAL|Arm A: Pemetrexed + Cisplatin and TRT|"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (Concurrent Phase) for three 21-day cycles, followed by a 3-5 week Recovery Period, then treated with consolidation chemotherapy with pemetrexed (Consolidation Phase) for up to four 21-day cycles~Concurrent Phase:~Pemetrexed: 500 milligrams per meter squared (mg/m\^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.~Cisplatin: 75 mg/m\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray \[Gy\] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.~Consolidation Phase:~Pemetrexed: 500 mg/m\^2, IV on Day 1 of each 21-day cycle up to 4 cycles"
62462911|NCT00686959|ACTIVE_COMPARATOR|Arm B: Etoposide + Cisplatin and TRT|"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (Concurrent Phase) for two 28-day cycles, followed by a 3-5 week Recovery Period, then received consolidation treatment with cytotoxic chemotherapy of choice (Consolidation Phase) for up to 2 cycles~Concurrent Phase:~Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\^2, IV on Days1, 8, 29, and 36~Consolidation Phase options:~Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"
62462912|NCT01709474|EXPERIMENTAL|Vitamin D3 6000 IU|6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
62462913|NCT01709474|ACTIVE_COMPARATOR|Vitamin D3 400 IU|400 IU/day of vitamin D3 by mouth daily.
62462914|NCT03101878|EXPERIMENTAL|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
62462915|NCT03101878|PLACEBO_COMPARATOR|Placebo|Saline .9%
62462916|NCT01475448|EXPERIMENTAL|Sedentary older adults - running|Sedentary older adults (60 years old or more) recruited from local community
62462917|NCT01475448|ACTIVE_COMPARATOR|Sedentary older adults - walking|Sedentary older adults (60 years old or more) recruited from local community
62462918|NCT03151057|EXPERIMENTAL|Idelalisib 100mg|"Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant"
62736374|NCT05262777|ACTIVE_COMPARATOR|Restylane Lyft Lidocaine|Restylane Lyft Lidocaine Single injection and optional touch up injection and re-treatment with Restylane Lyft Lidocaine
62462919|NCT03151057|PLACEBO_COMPARATOR|Placebo oral tablet|Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
62462920|NCT00998374||Pyloric-sparing vs. non-pyloric sparing|Pyloric: SG \& DS Non-pyloric: RYGB
62462921|NCT00867542||past IUGR|3-4 y old children with past IUGR
61905442|NCT03118661|EXPERIMENTAL|Maraviroc after allo-HCT|"* Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1~* Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is \<50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
61905443|NCT01737593|ACTIVE_COMPARATOR|Acetaminophen PR|Acetaminophen PR (20-40mg/kg) after induction of Anesthesia (acetaminophen is in suppository form and given rectally)
62089876|NCT03752736|NO_INTERVENTION|Maintenance|"The two classrooms assigned to the Maintenance condition will continue to receive a two- minute window for sunscreen application, but no I wear sunscreen everyday song-based video instruction.~Change trajectories from Time 3-Time 4 (two-week follow up) will be compared by follow-up assignment condition and will provide preliminary information about dosing and maintenance effects."
62089877|NCT01427387|EXPERIMENTAL|Part-1 ASP group|ASP0456 receiving group
62462922|NCT00867542||control|3-4 y old healthy children
62462923|NCT04353791|ACTIVE_COMPARATOR|Experimental arm OST-122|24 subjects will be randomized to receive OST-122 orally daily for 28 days
61905444|NCT01737593|ACTIVE_COMPARATOR|Acetaminophen PO-low dose|Acetaminophen PO (10mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
62089878|NCT01427387|PLACEBO_COMPARATOR|Part-1 Placebo group|Placebo treatment
61905445|NCT01737593|ACTIVE_COMPARATOR|Acetaminophen PO-high dose|Acetaminophen PO (20mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
61905446|NCT04960839|NO_INTERVENTION|Standard group|Standard loco-regional treatment without prophylactic contralateral breast irradiation
62089879|NCT01427387|EXPERIMENTAL|Part-2 group|cross-over study group to evaluate food effect on ASP0456 plasma concentration
62089880|NCT02496988|OTHER|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
62462924|NCT04353791|PLACEBO_COMPARATOR|Control arm Placebo|8 subjects will be randomized to receive placebo orally daily for 28 days
62462925|NCT01781598||Patients treated with Patient specific instruments in TKA|
62462926|NCT04351074|ACTIVE_COMPARATOR|group A , LIFT|39 patients underwnt ligation of the intersphincteric track( LIFT) for treatment of transsphincteric fistula
62462927|NCT04351074|ACTIVE_COMPARATOR|group B fistulectomy|39 patients under went fistulectomy for treatment of transsphincteric fistula
62462928|NCT01798836|EXPERIMENTAL|Oestradiol and ultrashort GnRH agonist/antagonist protocol|Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
61905447|NCT04960839|EXPERIMENTAL|Prophylactic irradiation group|Standard loco-regional treatment with prophylactic contralateral breast irradiation
62089881|NCT02496988|OTHER|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
62089882|NCT04884984|EXPERIMENTAL|CLL1 positive relapsed or refractory acute myeloid leukemia|
62654662|NCT06040320|EXPERIMENTAL|Polatuzumab vedotin + Rituximab + CHP (Expansion High Risk/Lack of Interim Complete Remission)|"* Cycle 1 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~ * Day 8: rituximab~ * Day 15: rituximab~* Cycle 2 (21 days)~  * Day 1: polatuzumab vedotin + rituximab~* After Cycle 2, a response assessment will be performed. Patients who show anything other than a complete response (and are therefore determined to be high risk) will receive polatuzumab vedotin + rituximab + CHP (cyclophosphamide + doxorubicin + prednisone) on Day 1 of each 21-day cycle for 4 additional cycles, followed by 2 final cycles of CHP alone on Day 1 (8 cycles of treatment total)."
62654663|NCT01658410|ACTIVE_COMPARATOR|BQ-123|
62654664|NCT01658410|PLACEBO_COMPARATOR|NaCl|
61905448|NCT05827471||Tumor group|First diagnosis of colon cancer.
61905449|NCT05827471||Control group|Healthy people.
61905450|NCT06069440|EXPERIMENTAL|swimmers|
61905451|NCT05122702|EXPERIMENTAL|Active Arm|"18.75g of Modified Shenling Baizhu San granules will be taken twice daily for 12 weeks."
62089883|NCT03356067|SHAM_COMPARATOR|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope.
62089884|NCT03356067|EXPERIMENTAL|Gastric endoscopic peroral pyloromyotomy|Experimental per-oral endoscopic myotomy of the pyloric sphincter
62089885|NCT03650738|EXPERIMENTAL|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
62089886|NCT06479993|EXPERIMENTAL|Chlorella supplementation|Supplementation of chlorella (6g/day for 3-weeks)
62462929|NCT01798836|ACTIVE_COMPARATOR|GnRH agonist or antagonist protocol.|Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF
62089887|NCT06479993|PLACEBO_COMPARATOR|Placebo supplementation|Supplementation of placebo (6g/day for 3-weeks)
62089888|NCT03147092|EXPERIMENTAL|Hypertension group|Hypertensive patients will be counseled to initiate life style changes as weight loss, salt reduction, exercise, reduced alcohol consumption, smoking cessation and fresh fruits and vegetables in their diets. Drug treatment will be started for subjects that are not responding to nonpharmacological treatment. The anti-hypertensive medications will be Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet, atenolol and Losartan potassium 50 mg. All of these anti-hypertensive drugs are available in the PPP. If BP control is not yet obtained, other antihypertensive drugs will be requested: clonidine, spironolactone, hydralazine and amlodipine.
62089889|NCT02658292|ACTIVE_COMPARATOR|NAFT900|NAFT900 (Naftifine hydrochloride foam, 3%)
62288336|NCT00669617|EXPERIMENTAL|Salm/flut, Placebo, Ind 150μg, Salbut, Ind 300μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo, Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62288337|NCT00669617|EXPERIMENTAL|Salbut, Ind 300μg, Placebo, Ind 150μg, Salm/flut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg), Placebo, Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62288338|NCT00669617|EXPERIMENTAL|Placebo, Salbut, Salm/flut , Ind 300μg, Ind 150μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Placebo, Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62462930|NCT04843878||Positive|Subjects that tested positive for COVID-19 based on the clinical gold standard PCR test.
62288339|NCT05662514|EXPERIMENTAL|Probiotic group|Esomeprazole 20 mg and bismuth 2g twice daily before meals, amoxicillin 1 g, and clarithromycin 500 mg twice daily after meals, probiotic once a day with one packet each time 2 hours after taking medicine above in the evening, for 2 weeks.
62288340|NCT05662514|PLACEBO_COMPARATOR|Placebo group|Esomeprazole 20 mg and bismuth 2g twice daily before meals, amoxicillin 1 g, and clarithromycin 500 mg twice daily after meals, placebo once a day with one packet each time 2 hours after taking medicine above in the evening, for 2 weeks.
62288341|NCT00151892|EXPERIMENTAL|SPD476|Mesalazine
62654665|NCT00872547|ACTIVE_COMPARATOR|1|Resurfacing system
61905452|NCT05122702|PLACEBO_COMPARATOR|Placebo Arm|18.75g of placebo granules will be taken twice daily for 12 weeks.
61905453|NCT01604733||HYPERCHOLESTEROLEMIC PATIENTS|
62288342|NCT00151892|ACTIVE_COMPARATOR|Asacol|
62654666|NCT00872547|ACTIVE_COMPARATOR|2|Large Metal-on-Metal Total Hip Replacement
62654667|NCT06492915|EXPERIMENTAL|Chiauranib plus albumin-paclitaxel and gemcitabine|Participants received Chiauranib oral administration once daily. Albumin-paclitaxel Injection and Gemcitabine Injection administered intravenously on Days 1, 8 and 15 of each 28-day cycle.
62654668|NCT05241951|EXPERIMENTAL|Clinical Pharmacist in Transition of Care|A clinical pharmacist will be provided as a patient discharges from one of four University of Washington (UW) medical centers to one of 14 post acute skilled nursing facilities randomized to the intervention arm. The coordinating transitional pharmacist will conduct (1) a comprehensive medication review including medication reconciliation, adjustment, and monitoring during the transitional period from hospital to SNF, 2) a structured handoff between clinical teams at the hospital and SNF.
61905454|NCT00770575|EXPERIMENTAL|Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD|
61905455|NCT00770575|ACTIVE_COMPARATOR|Atorvastatin 20mg to 40 mg QD|
61905456|NCT04204876||patients with GCA|All patients presenting with a new diagnosis of LV-GCA and all patients already treated for LV-GCA and planned for treatment termination
61905457|NCT04944680|NO_INTERVENTION|Control group|Stroke patients accept the traditional rehabilitation alone.
62089890|NCT02658292|PLACEBO_COMPARATOR|Vehicle|Vehicle Foam
62089891|NCT00005594|EXPERIMENTAL|ISIS 2503|All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
62089892|NCT00968838|EXPERIMENTAL|Non-radiated White Blood Cell Transfusion|Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
62288343|NCT00570648|EXPERIMENTAL|1|1% sodium hyaluronate (Healoon) applied at the end of surgery to the surface of the corneal transplant
62462931|NCT04843878||Negative|Subjects that tested negative for COVID-19 based on the clinical gold standard PCR test.
62736375|NCT01134744||Chest trauma|chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination
61905458|NCT04944680|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation group|Stroke patients accept the Transcranial Direct Current Stimulation alone.
61905459|NCT04944680|ACTIVE_COMPARATOR|Motor imagery group|Stroke patients do the motor imagery alone.
62089893|NCT00968838|EXPERIMENTAL|White Blood Cell Transfusion|Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
62462932|NCT06131502|ACTIVE_COMPARATOR|Real FUS|The treatment volume and plan will be defined by the neurosurgeon. The ExAblate MRgFUS system will automatically compute the number of sonications, and the (per sonication spot) phase and amplitude corrections necessary for the system to produce a focal spot at each of the desired locations. The target selected for this study is the anterior limb of the internal capsule (ALIC). The target will be approximately 7-10mm rostral to the anterior edge of the anterior commissure, in the ventral part of the ALIC. A central point in the targeted area will be targeted with a low dose, sub-lethal energy level sonication to confirm the targeting accuracy on the MR images. Focal point position and/or transducer location will be adjusted as necessary.
62654669|NCT05241951|NO_INTERVENTION|Patient transitions from hospital to post-acute care|Patient will transition from one of four University of Washington (UW) medical centers to one of 14 post-acute skilled nursing facilities randomized to the control arm. Patients will receive the standard discharge process.
62654670|NCT04226157|EXPERIMENTAL|Home Blood Pressure Self Management|The HBPS group will check their blood pressure at home daily using a smart BP cuff with telemonitoring capability (Home Qardio) and guided to use a self-titration plan between office visits for persistently elevate blood pressures.
61905460|NCT04944680|EXPERIMENTAL|Transcranial Direct Current Stimulation and motor imagery group|Stroke patients accept the Transcranial Direct Current Stimulation and do the motor imagery at the same time.
61905461|NCT05337020|EXPERIMENTAL|Intervention group|240 patients will receive the questionnaire to assess patients vision on telemedicine.
61905462|NCT05952752|PLACEBO_COMPARATOR|Dexamethsone|4 mg will be given for this group IV
61905463|NCT05952752|EXPERIMENTAL|Dexemedetomidine|12 ug will be given IV infusion for this group
61905464|NCT05289401|ACTIVE_COMPARATOR|ESPB|Unilateral erector spinae block will be performed in the lateral position . 0.5 mL/Kg of bupivacaine 0.125% will be injected taking care not to exceed the maximum recommended dose (2 mg/kg of bupivacaine)
61905465|NCT05289401|ACTIVE_COMPARATOR|CB|caudal block performed in lateral position . bolus of 1.2 ml/Kg bupivacaine 0.125% .
62089894|NCT03638856|EXPERIMENTAL|Misoprostal group|Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy
62288344|NCT00570648|NO_INTERVENTION|2|Nothing applied at the end of surgery
62462933|NCT06131502|SHAM_COMPARATOR|Sham FUS|The sham procedure will be identical in planning and execution to the ExAblate procedure with the only exception being that the energy output will be 0 for the sham-treated subjects. To perform the sham treatment, the sonication will be performed with energy output disabled. For sham subjects, the physician will interact with a subject in a similar manner and for a similar duration to simulate an actual procedure. When possible, the treating physician may determine a sonication (treatment) time for sham subjects to be similar to that which is occurring in the ExAblate procedure to maintain consistency between treatment arms. It should be noted that all treatment times of both treatment arms will be captured in the study CRF.
62462934|NCT00902876|EXPERIMENTAL|Mucograft + CAF|Mucograft in combination with coronally advanced flap (CAF)
62462935|NCT00902876|EXPERIMENTAL|CAF|Coronally advanced flap (CAF) alone
62462936|NCT00758186|EXPERIMENTAL|Colonic-stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction.
62462937|NCT00758186|ACTIVE_COMPARATOR|Emergency surgery|Emergency surgery: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction.
61905466|NCT04382989||Mothers of extremely preterm infants|(gestational age \< 28 weeks)
61905467|NCT04382989||Mothers of very preterm infants|(gestational age 28 - 31 weeks)
61905468|NCT04382989||Mothers of moderate and late preterm infants|(gestational age 32 - 36 weeks)
61905469|NCT04382989||Mothers of term infants|(gestational age ≥ 37 weeks)
61905470|NCT01199367|EXPERIMENTAL|Dose escallation|
62089895|NCT03638856|NO_INTERVENTION|Placebo group|Patients were take placebo 2 tab per oral 3 hour before hysteroscopy
62089896|NCT02708641|EXPERIMENTAL|AML patients|pembrolizumab 200 mg given IV once every three weeks
62288345|NCT01454076|EXPERIMENTAL|Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg|Ixazomib 2.5 milligram (mg), capsule B, orally, once on Day 1 and 15 along with ketoconazole 400 mg, tablets, orally, once daily from Day 12 to 25 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
62462938|NCT04810377|EXPERIMENTAL|EUS-guided gastroenterostomy in malignant gastric outlet obstruction|The patients with malignant gastric outlet obstruction will be confirmed as follows: Histopathological report of cancer, thoracoabdominal tomography and impaired tolerance to oral feeding (tolerance to liquids only or null).
62462939|NCT06219473|EXPERIMENTAL|Fascia Lata (Study group)|It includes eight patients seeking for implant placement in the upper anterior areas and implants will be placed with the application of fascia lata allograft membrane.
62462940|NCT06219473|EXPERIMENTAL|PRF (Study group)|It includes eight patients seeking for implant placement in the upper anterior area and implants will be placed with the application of PRF.
62654671|NCT04226157|ACTIVE_COMPARATOR|Usual Care|The Usual Care group will have their blood pressure monitored and medications adjusted by their primary care provider.
62736376|NCT02107625|EXPERIMENTAL|Diet A i.e. Low FODMAP diet|The patients are thoroughly informed verbally and in writing how to eat according to the low FODMAP diet. The diet imply restrictions in carbohydrate intake and the patients need to follow a list with yes/no-foods for 4 weeks.
62089897|NCT00709891|EXPERIMENTAL|cobas® 4800 HPV Test|The cobas 4800 human papillomavirus (HPV) Test combines in a single assay the identification of pooled high-risk oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), as well as genotypes 16 and 18 individually.
62654672|NCT01189266|EXPERIMENTAL|Arm 1 Phase I Vorinostat 180 mg/m^2|Patients in phase I received vorinostat at 180 mg/m\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62654673|NCT01189266|EXPERIMENTAL|Arm 2 Phase 1 Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62089898|NCT01237678|EXPERIMENTAL|IMGN901 with carboplatin and etoposide|Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
62089899|NCT01237678|ACTIVE_COMPARATOR|Carboplatin and Etoposide|Patients will receive Carboplatin and etoposide for up to 6 cycles.
62288346|NCT01454076|EXPERIMENTAL|Arm 2: Ixazomib 4 mg Capsule A or B|Ixazomib 4 mg, capsule A, orally, once on Day 1 followed by ixazomib 4 mg, capsule B once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, once on Day 1 followed by ixazomib 4 mg, capsule A once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
62462941|NCT06219473|ACTIVE_COMPARATOR|Connective tissue Graft(Control group)|It includes eight patients seeking for single implant placement at the upper anterior area and those patients will be received their implants with subepithelial connective tissue graft.
62462942|NCT01307098|EXPERIMENTAL|Sebelipase alfa 0.35 mg/kg|Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
62654674|NCT01189266|EXPERIMENTAL|Arm 3 Phase II Evaluation Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\^2/ day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
61905471|NCT03195400||CC Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 obese CC adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20.
62654675|NCT02305979||Treatment with Loratadine|Treatment with Loratadine
61905472|NCT03195400||TT Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 TT subjects will be enrolled in this group. An anticipated 50 obese TT adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will be enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20
61905473|NCT05178368||Early aortic valve replacement|Asymptomatic severe aortic stenosis patients randomised to early aortic valve replacement
61905474|NCT05178368||Standard care|Asymptomatic severe aortic stenosis patients randomised to 'watchful waiting' until symptom onset.
61905475|NCT00798759|EXPERIMENTAL|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
61905476|NCT00798759|ACTIVE_COMPARATOR|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
61905477|NCT04268823|EXPERIMENTAL|QBW251|Oral use, one capsule twice daily.
61905478|NCT04268823|PLACEBO_COMPARATOR|Placebo|Oral use, one capsule twice daily.
62089900|NCT01025661|NO_INTERVENTION|Waiting list control|The waiting list controls did not receive any intervention during the study period.
62654676|NCT04005872|EXPERIMENTAL|Nano Silver Fluoride|2 drops of nano silver fluoride (NSF) applied on the last soft carious layer using micro brush
62089901|NCT04560582||Kidney Transplant Patients with Failed Allograft|All participants are assigned to a single cohort of kidney transplant patients with failed allograft requiring dialysis.
62089902|NCT01617083|ACTIVE_COMPARATOR|Azithromycin|Antibiotic used to treat infections.
62089903|NCT01617083|PLACEBO_COMPARATOR|Placebo|Compound thickening agent with sugar and flavor additives.
62089904|NCT05387005|EXPERIMENTAL|UBT|
62089905|NCT05387005|EXPERIMENTAL|HpSA|
62089906|NCT05387005|EXPERIMENTAL|Both|
62089907|NCT05387005|EXPERIMENTAL|Two-stage screening method|
62089908|NCT05733923|ACTIVE_COMPARATOR|Traditional excavation|Mechanical caries Removal with low-speed Carbide Burs on a micromotor handpiece with air and water cooling.
62089909|NCT05733923|EXPERIMENTAL|Sodium Hypochlorite CMCR|chemomechanical caries removal using Sodium Hypochlorite Gel 2.5%.
62089910|NCT05733923|EXPERIMENTAL|Papacarie duo CMCR|chemomechanical caries removal using Papacarie duo.
62089911|NCT05733923|EXPERIMENTAL|Selecti-solve CMCR|chemomechanical caries removal using Selecti-solve Gel.
62089912|NCT05733923|EXPERIMENTAL|Brix3000 CMCR|chemomechanical caries removal using Brix3000.
62089913|NCT04159896|EXPERIMENTAL|Treatment (ESK981, nivolumab)|Patients receive ESK981 PO QD for 5 consecutive days per week, followed by a 2-day break. Patients also receive nivolumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62089914|NCT05498974||Individuals diagnosed with type 1 diabetes|All patients diagnosed with type 1 diabetes of all ages.
62089915|NCT05498974||Individuals with diabetes who had an age of onset <= 20 years.|All patients with diabetes who had an age of onset \<= 20 years.
62288347|NCT01454076|EXPERIMENTAL|Arm 3: Ixazomib 4 mg Fasted or Fed|Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
62288348|NCT01454076|EXPERIMENTAL|Arm 4: Ixazomib 4 mg + Rifampin 600 mg|Ixazomib, 4 mg, capsule B, orally, once on Day 8 along with rifampin 600 mg, capsule, orally, once daily from Day 1 to 14 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
62288349|NCT01454076|EXPERIMENTAL|Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg|Ixazomib, 2.5 mg, capsule B, orally, once on Day 6 along with clarithromycin, 500 mg, tablet, orally, twice daily from Day 1 to 16 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
62288350|NCT02626676|EXPERIMENTAL|Educational Programme Group|Stage 5D Chronic Kidney Disease Patients on high-efficiency hemodialysis programme - 4-hour sessions, 3 times a week will be followed up
62654677|NCT04005872|ACTIVE_COMPARATOR|Calcium Hydroxide|Calcium hydroxide placed on the last soft carious layer approaching the pulp
62288351|NCT04590456|EXPERIMENTAL|Placebo group|
62462943|NCT01307098|EXPERIMENTAL|Sebelipase alfa 1 mg/kg|Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
62288352|NCT04590456|EXPERIMENTAL|PEMF group|
62288353|NCT01907620|OTHER|Normal pregnancy|women pregnant
62089916|NCT04037111|EXPERIMENTAL|drug treatment and active VNS|At the same time, actice VNS, escitalopram oxalate tablets were treated for 2 months.
62089917|NCT04037111|SHAM_COMPARATOR|drug treatment and sham VNS|It received oxacillin oxalate tablets and sham VNS for 2 months.
62089918|NCT04037111|OTHER|drug treatment|The dose of escitalopram oxalate tablets was maintained at 10-20mg/ day without VNS stimulation.
62089919|NCT06283602|OTHER|Kahramanmaraş Sütçü İmam University|Patient who apply to our clinic for routine paediatric treatment for the included in the study
62089920|NCT01877603||type 2 diabetes|We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined.
62089921|NCT02117336|EXPERIMENTAL|P1446A-05|
62089922|NCT01285219|ACTIVE_COMPARATOR|AOB,pegylated filgrastim to filgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
62288354|NCT01907620|OTHER|pregnancy complicated by pre-eclampsia|women with pregnancy complicated by pre-eclampsia
62462944|NCT01307098|EXPERIMENTAL|Sebelipase alfa 3 mg/kg|Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.
62462945|NCT01205295||Mental disorders|Preoperative and postoperative screening of mental disorders and efficacy of treatment in hip and shoulder patient.
62654678|NCT02637596|EXPERIMENTAL|RFA group|Twenty-fourth consecutive patients with histologically proved pancreatic cancer \[stage IIb (n=4), III (n=15), IV (n=5) \]underwent intraoperative RFA of primary tumor.
62654679|NCT05242211|OTHER|Healthy|Healthy participants will do both cycle ergometer and treadmill exercise
62654680|NCT00758992||Immunodeficient mice|Please see the Study Description for complete information.
62654681|NCT02408341||Routine clinical practice of induction anesthesia|There was no intervention, just monitoring of clinical routine practice using non-invasive Doppler tissue imaging.
62654682|NCT02715453|EXPERIMENTAL|Intervention on frailty|Intervention on frailty in addition to the usual care by the cardiologist. A multidisciplinary team (physicians, nurses and physiotherapists and nutritionists) will carry out the intervention on frailty
61905479|NCT03316911|EXPERIMENTAL|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
61905480|NCT03316911|NO_INTERVENTION|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
62089923|NCT01285219|ACTIVE_COMPARATOR|BOA,ﬁlgrastim to pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
62288355|NCT02599584|EXPERIMENTAL|precritical staff|4 min of precritical team staff for anticipation of risk and role attribution during the critical events if they occur. athe staff will take place after briefing of the scenario and before the start of the scenario.
62288356|NCT02599584|NO_INTERVENTION|control|screening of normal labs results during 4 min, after briefing of the scenario and before the start of the scenario
62654683|NCT02715453|NO_INTERVENTION|Control|Conventional strategy consisting only of the usual care by the cardiologist
62288357|NCT04541914|EXPERIMENTAL|Validation group|Evaluation for diagnostic efficacy of peripheral blood marker-based molecular diagnostic method for antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT)
62462946|NCT03245086||Transanal hemorrhoid dearterialization (THD)|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing transanal hemorrhoid dearterialization (THD).
62462947|NCT03245086||Ferguson hemorrhoidectomy|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing Ferguson hemorrhoidectomy.
62089924|NCT02681822||Healthy young subjects|Healthy young Chinese Han subjects aged 18-30
62089925|NCT06197880|EXPERIMENTAL|Bimaxillary protrusion|En masse retraction
62654684|NCT00677638|EXPERIMENTAL|1|Embracer implantation
62654685|NCT01772862|NO_INTERVENTION|Only conventional supportive care|The children receive conventional supportive care with respect to physical training
62089926|NCT02479867|EXPERIMENTAL|A Test|Test drug (Duricef) 1 tablet contains 1 gm Cefadroxil
62089927|NCT02479867|EXPERIMENTAL|B Reference|Reference drug (Biodroxil) 1 tablet contains 1 gm Cefadroxil
62089928|NCT03229889|ACTIVE_COMPARATOR|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
62089929|NCT03229889|ACTIVE_COMPARATOR|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
62089930|NCT03229889|ACTIVE_COMPARATOR|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
62089931|NCT03229889|PLACEBO_COMPARATOR|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
62089932|NCT03708380|EXPERIMENTAL|Dietary intervention|Community-based dietary intervention to Black and African American barbers identified as having previously undiagnosed diabetes and prediabetes
62089933|NCT03410485|ACTIVE_COMPARATOR|Control (C Group )|Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
62089934|NCT03410485|EXPERIMENTAL|Monitoring (M Group )|Intervention for intraoperative analgesic administration will be based on the NOL index (to keep it below 25). Intervention for the desflurane administration will be based on the BIS index (to keep it between 40-60).
62089935|NCT06089876|EXPERIMENTAL|"Strava Application"|STRAVA is an application that allows you to record your physical activity. Using GPS, it allows you to record the distance traveled with different types of physical activity (walking, running, swimming, among others). In addition, it allows you to create a community and clubs within the same community with which you can propose group trails.
62288358|NCT01425099|EXPERIMENTAL|Part 1|In Part 1, approximately 12 healthy subjects will receive DTG 50mg q24h for 5 days in Period 1. Subjects will then be administered DTG 50mg q24h in combination with prednisone 60mg for 5 days followed by a 5 day taper (60 mg Days 1-5, 50 mg Day 6, 40 mg Day 7, 30 mg Day 8, 20 mg Day 9 and 10 mg Day 10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
62462948|NCT04754178||Down syndrome|Down syndrome patients and their parents
62654686|NCT01772862|EXPERIMENTAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
61905481|NCT01785862|EXPERIMENTAL|Drug|V0498, Ibuprofen 25 mg
62089936|NCT06089876|NO_INTERVENTION|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
62089937|NCT00333515|EXPERIMENTAL|1|Administration of one of 3 doses (dose escalation) of the active drug (HuBChE). (Dose-escalation proceeds only after safety evaluation and after the previous dosage has been found to be acceptable by an independent Data Safety Monitoring Board.)
62089938|NCT00333515|PLACEBO_COMPARATOR|2|Administration of placebo
62288359|NCT01425099|EXPERIMENTAL|Part 2|If DTG Cτ is reduced by more than 50% in Part 1, Part 2 will be carried out where a second cohort of subjects will receive DTG 50mg q24h DTG for 5 days in Period 1 followed by DTG 50mg q24h in combination with prednisone 20mg for 5 days followed by a 5 day taper (20 mg Days 1-5, 10 mg Days 6 and 7, 5 mg Days 8-10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
62462949|NCT04754178||Control group|Healthy children and their parents
62462950|NCT01787058||Dubai Cares beneficiary|Pupils who attend a school that has benefitted from a water, sanitation and hygiene intervention as part of the Dubai Cares program.
62462951|NCT01787058||Control|Pupils who attend a school of the same size and location as a school that benefitted from a water, sanitation and hygiene (WASH) intervention through the Dubai Cares program, but which has not benefitted from that program or any other WASH program since 2009.
62462952|NCT03084081|ACTIVE_COMPARATOR|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
62089939|NCT04550754||Patients hospitalized for tramadol withdrawal|Patients hospitalized for tramadol withdrawal in Montpellier University Hospital and Nîmes University Hospital from 01/01/2015 to 31/12/2019
62089940|NCT01345461||Healthy adult volunteers|Twelve healthy adult volunteers (6 men, 6 women)
62462953|NCT03084081|EXPERIMENTAL|CryoPen|Single freeze treatment consists of one five-minute freeze
62462954|NCT03084081|EXPERIMENTAL|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
62462955|NCT06213688|OTHER|Cases|Patients with atopic dermatitis or psoriasis
62462956|NCT06213688|OTHER|Controls|Patients have consulted or been hospitalized for dermatological reasons without psoriasis or atopic dermatitis
62462957|NCT05833594||Experimental|Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
62462958|NCT05833594||Comparator|Whole-course nutrition Combined With Chemoradiotherapy±ICIs
62462959|NCT04245566|EXPERIMENTAL|Prostatic Artery Embolization (PAE)|PAE will be performed as an inpatient or outpatient procedure by interventional radiologists who are familiar with the procedure and according to established techniques. A unilateral femoral sheath is placed in the right common femoral artery under local anaesthesia. The prostatic arterial supply is identified by selective internal iliac arteriography. Prostatic arteries are selectively catheterised and embolised by use of 250-600 μm microspheres . PAE is performed bilaterally if possible and considered successful in the absence of the normal blush of the prostate and stasis of flow in the prostate arteries on angiography after embolisation.
62654687|NCT00672802|EXPERIMENTAL|Ramelteon 16 mg QD and Placebo QD|
62654688|NCT03680027|NO_INTERVENTION|Control Group|In 'Control group' participants had 6 week follow-up without any intervention.
61905482|NCT01785862|PLACEBO_COMPARATOR|Placebo|Placebo
61905483|NCT04981613|EXPERIMENTAL|Experimental group|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
61905484|NCT04981613|NO_INTERVENTION|Control group|irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
61905485|NCT01024309|ACTIVE_COMPARATOR|Mini-Posterior Approach|Mini-Posterior surgical approach for total hip arthroplasty
61905486|NCT01024309|EXPERIMENTAL|Direct Anterior Approach|Direct Anterior surgical approach for total hip arthroplasty
61905487|NCT02060916|EXPERIMENTAL|PAZ320|Patients will all take part in the control arm of the study and then be crossed over into treatment with PAZ320 at two different dosages.
61905488|NCT05439213|EXPERIMENTAL|Group 1|adrenaline 0,33 mg per litter
61905489|NCT05439213|EXPERIMENTAL|Group 2|adrenaline 1 mg per litter
61905490|NCT03870958|EXPERIMENTAL|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
61905491|NCT03870958|ACTIVE_COMPARATOR|Control|Children allocated to this group will receive the same dietary advices and brushing instructions described in the control arm.
61905492|NCT00670943||A|Patients with stable CAD with scheduled discontinuation of clopidogrel
61905493|NCT00670943||B|Patients with stable CAD not taking clopidogrel
61905494|NCT03897439|ACTIVE_COMPARATOR|Usual Care (UC)|196 African American smokers will receive 12 weeks of smoking cessation counseling and 18 weeks of nicotine patch.
61905495|NCT03897439|EXPERIMENTAL|Optimized Care (OPT)|196 African American smokers will receive 12 weeks of smoking cessation counseling. They will receive the nicotine patch and up to two pharmacotherapy adaptations (VAR, BUP+NP) based on verified smoking status at Weeks 2 and 6 for a total of 18 weeks of pharmacotherapy.
61905496|NCT06529978|EXPERIMENTAL|Phase 1- Mapping Only|For Phase 1, the goal is to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.
61905497|NCT06529978|EXPERIMENTAL|Phase 2- Map Guided Ablation|The Phase 2 goal is the initial development and evaluation of a CoreMap-guided tailored ablation strategy.
62654689|NCT03680027|EXPERIMENTAL|Interventional Group|In 'Interventional group' participants had 6 week follow-up and during that period of time, they were asked to consume 40g/day walnut. Participants in intervention group was ensured to consume all 40g of walnut every day, during their snack times for 6 weeks.
61905500|NCT05612932|OTHER|control group-immediate retainer delivery|Retainer will be given to the patients immediately \[Just after debonding\].
61905501|NCT05612932|ACTIVE_COMPARATOR|experimental group- delayed retainer delivery|Retainer will be delivered to the patients 7 days post debonding.
61905502|NCT05120557|EXPERIMENTAL|Main arm|Main study arm
61905503|NCT06394167|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-993.
61905504|NCT06394167|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.
61905505|NCT06394167|PLACEBO_COMPARATOR|Placebo Part A|Participants will be randomized to receive placebo matched to VX-993.
61905506|NCT06394167|PLACEBO_COMPARATOR|Placebo Part B|Participants will be randomized to receive multiple doses of placebo matched to VX-993.
61905507|NCT05253001|EXPERIMENTAL|study group|use mobile chatbot approach to improve prenatal education
61905508|NCT05253001|PLACEBO_COMPARATOR|controp group|a traditional approach to prenatal education
61905509|NCT04274998|EXPERIMENTAL|AD/MCI or HC|Main Study: Subjects are diagnosed with Alzheimer's Disease (AD)/Mild Cognitive Imparment (MCI) or are healthy volunteers/controls (HC).
61905510|NCT04274998|EXPERIMENTAL|AD/MCI or HC with Genetic Polymorphism|Sub-Study: Subjects have a specific genetic polymorphism andare diagnosed with Alzheimer's Disease (AD)/Mild Cognitive Imparment (MCI) or are healthy volunteers/controls (HC).
61905511|NCT03540550|EXPERIMENTAL|Dietary intervention|
62089941|NCT01719640|EXPERIMENTAL|MSC+MC|infusion of BMMSC+BMMNC and insulin injection
62089942|NCT01719640|ACTIVE_COMPARATOR|MC|infusion of BMMNC and insulin injection
62288360|NCT06330779|EXPERIMENTAL|Yoga-group|8 weeks ,once a week, instructor led trauma-adapted yoga intervention.
62288361|NCT06330779|NO_INTERVENTION|Controll|Waiting list
62288362|NCT04350333|EXPERIMENTAL|CBT-I group|Five sessions composed of: psychoeducation on sleep change during pregnancy and postpartum; sleep hygiene principles; stimulus control technique, sleep restriction technique (f this technique will be too difficult for the participants to be apply, a replacement and less disabling technique will be applied: sleep compression); psychoeducation on the child's sleep at birth and on the change in the sleep-wake cycle in the early stages of the child's life; cognitive control technique; cognitive reconstruction technique and de-catastrophization; relapses prevention.
62089943|NCT01719640|ACTIVE_COMPARATOR|Insulin|insulin injection
62288363|NCT04350333|ACTIVE_COMPARATOR|Assertive communication training|Five sessions composed of: psychoeducation and explanation of the importance of emotional and cognitive factors for good sleep. Psychoeducation about the concept of assertiveness, explanation of the passive, aggressive and assertive style; explanation and exercises regarding self-esteem and positive self-image; explanation of the development of sleep of the child in the first years of life; explanation and exercises on the phase of the management of feedback and requests; conflict management; relapses prevention.
62288364|NCT02002143|ACTIVE_COMPARATOR|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
62462960|NCT04245566|PLACEBO_COMPARATOR|Pharmocotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations. Thus, patients with a prostate size smaller than 40mL will be treated with 0.4 mg tamsulosin once daily, while patients with larger prostates will be treated with 0.4 mg tamsulosin plus 0.5 mg dutasteride once daily during the complete study follow-up.
62462961|NCT01624064|ACTIVE_COMPARATOR|Enalapril, Proteinuria < 1g/day|
62089944|NCT04628416|EXPERIMENTAL|Experimental arm|
62462962|NCT01624064|PLACEBO_COMPARATOR|Calcium, Proteinuria < 1g/day|
62462963|NCT01624064|ACTIVE_COMPARATOR|Enalapril, Proteinuria > 1g/day|
62654690|NCT03997877|ACTIVE_COMPARATOR|Control|"The usual physical activity valued by the YPAS questionnaire (Yale Physical Activity Survey) will be maintained. The questionnaire allows to calculate the time in physical activity expressed in hours / week, the energy expenditure expressed in MET-h / week and the summary index of physical activity that takes into account the frequency and duration of physical activity and oscillates from 0 to 137. A value below 51 identifies sedentary patients. Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
62678911|NCT03393975|EXPERIMENTAL|Prophylaxis Cohort I|Participants randomized to SOC arm in prophylactic treatment cohort will receive a single dose intravenous (IV) infusions of 40 international units per kilogram (IU/kg) BAX-930 ORT product followed by a PK dose of their current SoC at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for 6 months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.
61905512|NCT04911192|NO_INTERVENTION|systemic thrombolysis group|patients without any contraindications for systemic fibrinolytic therapy will be treated with traditional systemic thrombolysis (intravenous administration of streptokinase).
61905513|NCT04911192|ACTIVE_COMPARATOR|mechanical fragmentation group|patients will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy.
62089945|NCT04628416|OTHER|Control|
62089946|NCT03853590|ACTIVE_COMPARATOR|Laparoscopic Adjustable Gastric Band|Subjects who elected to undergo Laparoscopic Adjustable Gastric Band intervention were examined prior to surgery and at 2, 3, 6 months after operation.
62089947|NCT03853590|EXPERIMENTAL|Roux-en-Y gastric bypass surgery|Subjects who elected to undergo Roux-en-Y gastric bypass surgery were examined prior to surgery and at 2, 3, 6 months after operation.
62089948|NCT06427538|EXPERIMENTAL|Saline Intervention Arm|Patient will receive 20 mL sterile saline flushes into their catheter by study team members every 6 ± 2 hours. If patients are receiving intrapleural tissue plasminogen activator and deoxyribonuclease therapy, each treatment will be considered one flush.
62089949|NCT06427538|NO_INTERVENTION|No Intervention Arm|Patient will receive a saline flush as needed, to restore patency of a chest tube considered blocked. No routine flushes will be administered.
62089950|NCT04446975|NO_INTERVENTION|BPA Off|No best-practice alert (BPA) message is displayed to providers.
62089951|NCT04446975|EXPERIMENTAL|BPA On|BPA message is displayed to providers based on patient opioid intake as reported in the electronic health record (EHR).
62089952|NCT02809027|ACTIVE_COMPARATOR|Ginger|Ginger capsule (500 mg), oral form, 2 capsules 3 time after meal for 3 days
62089953|NCT02809027|SHAM_COMPARATOR|Placebo|Placebo capsule, oral form, 2 capsules 3 time after meal for 3 days
62462964|NCT01624064|PLACEBO_COMPARATOR|Calcium, Proteinuria > 1g/day|
62462965|NCT06155630|EXPERIMENTAL|3D printed mandibular implant overdenture|First appointment: The first visit will consist of scanning the patients' existing upper complete denture and lower mandibular implant overdenture by using a desktop scanner. In the lab, the .stl files will be 3D printed using a DLP 3D printer. Second clinical appointment: the interim printed dentures will be adjusted with wax for the desired lip support and VD. Secondary impressions will be taken to refine fit. Maxillary and mandibular interim printed dentures will be scanned separately and together with an intraoral scanner. Patient's face will also be scanned by a face scanner. 2nd lab session: .stl files will be superimposed for the digital pathway. Teeth and denture bases will be designed virtually. Dentures bases will be manufactured by a DLP 3D printer with Dentca Resin. Dentures will receive Dentsply Portrait 3D teeth. Dentures will be finished and polished, and sandblasted in the attachment sockets. 4th appointment: denture delivery.
61905514|NCT04911192|ACTIVE_COMPARATOR|In Situ thrombolysis group|patients will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC(Swan-Ganz pulmonary artery catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
61905516|NCT01203644|ACTIVE_COMPARATOR|Bupivacaine HCl|(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
61905517|NCT01203644|ACTIVE_COMPARATOR|SKY0402|Low dose, low-mid dose, mid-dose, and high dose
61905518|NCT03456882|ACTIVE_COMPARATOR|RNS60|RNS60 for injection, i.e. in the IV bags, is produced using 0.9% Sodium Chloride for injection. RNS60 for inhalation, i.e. in the syringes, is produced using 0.9% Sodium Chloride for irrigation. Syringes and IV bags are to remain refrigerated at 2 to 8°C (36 to 46°F) when not in use. RNS60 meets its stability specification for 12 months.
61905519|NCT03456882|PLACEBO_COMPARATOR|NORMAL SALINE|"Normal saline (NS) for injection, i.e. in the IV bags, is packaged 0.9% Sodium Chloride for injection. NS for inhalation, i.e. in the syringes, is packaged 0.9% Sodium Chloride for irrigation. NS does not require refrigerated storage for use. However, for blinding purposes refrigeration is required before distributing to subjects. NS meets stability specifications for 24 months.~RNS60 has been tested in three Phase I safety studies, NCT01264783, NCT01057498, and NCT01511302 in the USA, and a Phase IIa (NCT02422121) study in UK without any safety concern. Two other Investigator initiated Phase IIa trials are currently ongoing, one in Mass General Hospital (NCT02525471), and one in the University of Zurich (with University of Innsbruck as a second site)."
61905520|NCT01617226|ACTIVE_COMPARATOR|azacitidine|azacitidine (75mg/m2) by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. This should be delivered in a 5-2-2 schedule
62089954|NCT06475235|EXPERIMENTAL|Induction Treatment:|"Participants will be enrolled and will complete procedures as follows, starting at Dose Level 0 for Methotrexate and Temozolomide:~* Baseline visit with assessments and imaging.~* Imaging on cycles 3 and 6 only.~  * Cycles 1 through 3:~    ---Days 3 and 10 of 14 day cycle: Predetermined dose of Rituximab 1x daily.~ * Cycles 1, 3, 5, and 7:~    ---Days 7 through 11 of 14 day cycle: Predetermined dose of Temozolomide 1x daily.~ * Cycles 1 through 8:~    ---Day 1 of 14 day cycle: Predetermined dose of Methotrexate 1x daily.~ * Cycles 1, 4, 7~ * Day 10 of 14 day cycle: Predetermined dose of Pembrolizumab 1x daily. Treatment will de-escalate per protocol if greater than or equal to 2 out of 6 participants experience a dose-limiting toxicity."
62462966|NCT06155630|ACTIVE_COMPARATOR|traditional mandibular implant overdenture|"The first visit will be the same. For the conventional pathway, the 2nd lab session will consist of pouring the impressions (type 4 stone), mounting the casts in arcon semi-adjustable articulator, removing the printed teeth, and replacing it with wax rim and acrylic tooth setup (Dentsply Portrait - same shape, size and shade used for 3D printed dentures).~A 3rd appointment will be used for wax try-in for the conventional pathway. For the digital pathway, participants will have a chance to appraise their smile on a computer screen (virtual try-in, done remotely) and request modifications.~Denture bases will be manufactured with conventional heat-polymerized resins, and participants will return for a 4th appointment for delivery, including chairside pick-up of attachments (GC Reline resin). Two short-term adjustments will be scheduled 24-72 h and 7 days after delivery, and then weekly until the dentures are comfortable."
62462967|NCT00968552||Patients undergoing stent placement|Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care.
62678912|NCT03393975|EXPERIMENTAL|Prophylaxis Cohort II|Participants randomized to BAX-930 arm in prophylactic cohort will receive a PK dose of their current SoC product followed by a single dose IV infusions of 40 IU/kg BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT once Q2W for the next six months followed by SOC for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
61905521|NCT01617226|ACTIVE_COMPARATOR|azacitidine and vorinostat|Patients will receive (75mg/m2) azacitidine by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. Azacitidine should be delivered in a 5-2-2 schedule. Vorinostat (300mg bid) will be taken orally for 7 consecutive days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles. (Day 3 is defined as the 3rd day of azacitidine administration).
62089955|NCT06475235|EXPERIMENTAL|Consolidation Treatment:|"4-8 weeks after the completion of Induction Cycle 8, the study doctor will determine if it is appropriate to move on to consolidation therapy and participants will complete:~* Imaging every other cycle.~* Cycles 1 through 15:~  * Day 1 of 42 day cycle: Lumbar puncture~ * Day 1 of 42 day cycle: Predetermined dose of Pembrolizumab 1x daily.~* End of treatment visit with lumbar puncture and imaging.~* Follow up"
62089956|NCT06094933|EXPERIMENTAL|Mobile Anger Reduction Intervention (MARI)|Participants in this arm will download the MARI application (app) on their own smart phone device and will use the app for a period of 4 weeks.
62089957|NCT06094933|ACTIVE_COMPARATOR|Health Education Condition (HED)|Participants in this arm will download the HED application (app) on their own smart phone device and will use the app for a period of 4 weeks.
62089958|NCT05700708||Cirrhosis with Refractory Ascites|
62089959|NCT03704298|EXPERIMENTAL|Phase 1: Cohort 1: Axicabtagene Ciloleucel + Utomilumab 10 mg|Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation (CD) 19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered. Participants also will receive utomilumab 10 mg on Day 1, IV infusion, once every 4 weeks (Q4W) for 6 months or until progressive disease, whichever came first.
62089960|NCT03704298|EXPERIMENTAL|Phase 1: Cohort 2: Axicabtagene Ciloleucel + Utomilumab 30 mg|Participants will receive cyclophosphamide 500 mg/m\^2/day IV and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered. Participants also will receive utomilumab 30 mg on Day 1, IV infusion, Q4W for 6 months or until progressive disease, whichever came first.
62089961|NCT03704298|EXPERIMENTAL|Phase 1: Cohort 3: Axicabtagene Ciloleucel + Utomilumab 100 mg|Participants will receive cyclophosphamide 500 mg/m\^2/day IV and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered. Participants also will receive utomilumab 100 mg on Day 1, IV infusion, Q4W for 6 months or until progressive disease, whichever came first.
62089962|NCT03704298|EXPERIMENTAL|Phase 1: Cohort 4: Axicabtagene Ciloleucel + Utomilumab 200 mg|Participants will receive cyclophosphamide 500 mg/m\^2/day IV and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered. Participants also will receive utomilumab 200 mg on Day 1, IV infusion, Q4W for 6 months or until progressive disease, whichever came first.
62089963|NCT03704298|EXPERIMENTAL|Phase 1: Cohort 5: Axicabtagene Ciloleucel + Utomilumab 400 mg|"Participants will receive cyclophosphamide 500 mg/m\^2/day IV and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered. Participants also will receive utomilumab 400 mg on Day 1, IV infusion, Q4W for 6 months or until progressive disease, whichever came first.~However, as the study was early terminated, no participants were enrolled in Cohort 5 of the study."
62089964|NCT03704298|EXPERIMENTAL|Phase 2: Axicabtagene Ciloleucel + Utomilumab|"Participants will receive cyclophosphamide 500 mg/m\^2/day IV and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel and utomilumab based on the dose and schedule selected to move forward from the Phase 1 portion of the study as recommended by the internal safety review team.~However, as the study was early terminated, no participants were enrolled in Phase 2 of the study."
62089965|NCT04917380||Gram-negative bacteria group|Gram-negative bacteria intracranial infection after neurosurgery
61905522|NCT01666340|EXPERIMENTAL|high intensity aerobic training|Exercise intervention: High intensity group performing high intensity training where they are required to raise their heart rate several times during the workout and reach perceived exhaustion of 16 on a Borg scale
62089966|NCT04917380||Gram-positive bacteria group|Gram-positive bacteria intracranial infection after neurosurgery
62089967|NCT06696807||traditional therapy group|who received nitrate esters, CCBs, anti-platelet agents, and statins
62089968|NCT06696807||immunomodulatory therapy group|who received glucocorticosteroids and/or IVIG in addition to traditional therapy.
62089969|NCT01632865|EXPERIMENTAL|recanalization and stenting|
62654691|NCT03997877|EXPERIMENTAL|Intervention|"It is intended that the exercise program have a duration of 6 months and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule and without the need for instruments or special facilities. In this sense the walk is adjusted to these assumptions and the goal of 10.000 steps / day can encourage compliance.~The subjects assigned to the intervention group will be supervised and trained by a physiotherapist who will explain the training program and resolve the doubts raised by the patient.~Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
62654692|NCT00379405|EXPERIMENTAL|A|Saquinavir (Invirase): 2 capsules (500 mg) / 12 hours
61905523|NCT01666340|OTHER|Moderate intensity training|Exercise intervention: Moderate intensity Group of people asked to perform moderate training where they exercise at a given intensity (moderate as per Borg scale) for a certain amount of time
61905525|NCT04495205|EXPERIMENTAL|Non-eugenol containing periodontal packs with PRF|Non-eugenol containing periodontal packs with PRF after gingival de-pigmentation
61905526|NCT04495205|PLACEBO_COMPARATOR|Non-eugenol containing periodontal packs|Non-eugenol containing periodontal packs after gingival de-pigmentation
61905527|NCT05667077|EXPERIMENTAL|amantadine|The group that was treated with amantadine
62089970|NCT02114008|ACTIVE_COMPARATOR|Abbreviated fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin).
62089971|NCT02114008|ACTIVE_COMPARATOR|Traditional fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test).
62288365|NCT02002143|EXPERIMENTAL|Group Appointments (GAs)|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
61905528|NCT05667077|NO_INTERVENTION|control|The group that was not treated
61905529|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
62288366|NCT04317755|EXPERIMENTAL|Intervention|Comic-based body image programme
62288367|NCT04317755|NO_INTERVENTION|Control|Schools lessons as usual
62288368|NCT00460980|OTHER|Virtual reality laparoscopic simulator|"Virtual reality laparoscopic simulator training:~Residents will participate in a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience."
62288369|NCT01770327|PLACEBO_COMPARATOR|Group 1 (placebo) - Water|This group will drink water in 1st trial
62654693|NCT00379405|NO_INTERVENTION|2|IP o NNUCS + 2 NUCS as a HAART therapy .
62462968|NCT01655628|EXPERIMENTAL|GC chemotherapy plus CIK cells|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks); however,the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus 8 cycles CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
62654694|NCT00742937|PLACEBO_COMPARATOR|A|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of vitamin E will be administer.
62654695|NCT00742937|EXPERIMENTAL|B|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of 200,000 UI of retinol palmitate (vitamin A)plus vitamin E will be administer.
62654696|NCT01278368|ACTIVE_COMPARATOR|Preoperative chemotherapy (PCHT)|Patients who underwent pancreatic resection after PCHT.
62654697|NCT01278368|ACTIVE_COMPARATOR|Control|Patient who underwent pancreatic resection without preoperative therapy
62288370|NCT01770327|EXPERIMENTAL|Group 2 (Intervention) - Milk|This group will drink Non-Fat Milk in 1st trial
62288371|NCT01770327|EXPERIMENTAL|Group 3 (Intervention) - Orange Juice|This group will drink Orange Juice in 1st trial
62288372|NCT01770327|EXPERIMENTAL|Group 4 (Intervention) - Iced Tea|This group will drink Iced Tea in 1st study
62654698|NCT03839641|EXPERIMENTAL|High Fat Meal First|Arm 1 participants randomized to receive high fat meal first, and low fat meal second
61905530|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
61905531|NCT00831818||1|Mothers of healthy infants who breastfeed on demand
61905532|NCT00831818||2|Mothers of healthy infants who do not breastfeed
61905533|NCT02284841|EXPERIMENTAL|Hilotherm cooling face mask|Use of Hilotherm cooling face mask post-operatively following surgical wisdom tooth removal to evaluate the incidence of pain and swelling
61905534|NCT02284841|NO_INTERVENTION|No Hilotherm|No intervention following surgical wisdom tooth removal (same patient), therefore the patient is their own control.
62089972|NCT03250325|EXPERIMENTAL|Split dose of 5x10^9 TBI-1301|Split dose of 5x10\^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.
62089973|NCT04019821|ACTIVE_COMPARATOR|Normal Bolus|Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).
62654699|NCT03839641|EXPERIMENTAL|High Fat Meal Second|Arm 2 participants randomized to receive low fat meal first, and high fat meal second
62654700|NCT02935270||Stroke Survivors|Individuals who have experienced a unilateral hemispheric stroke
62654701|NCT05125445|EXPERIMENTAL|Crestally positioned implants|
62089974|NCT04019821|EXPERIMENTAL|Super Bolus|Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.
62089975|NCT01005771|EXPERIMENTAL|GF-001001-00 2%|
62089976|NCT01005771|EXPERIMENTAL|GF-001001-00 1%|
62089977|NCT01005771|EXPERIMENTAL|GF-001001-00 0.25%|
62089978|NCT01005771|PLACEBO_COMPARATOR|Placebo|
62089979|NCT02956967||Patients receiving Nivestim|
62089980|NCT01668147|EXPERIMENTAL|Control|Session 1: Control (no pretreatment) - IV 10-14 mCi of \[11C\] desmethyl-loperamide (dLop) with PET/CT imaging
62089981|NCT01668147|ACTIVE_COMPARATOR|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV 10-14 mCi of \[11C\]dLop with PET/CT imaging
62089982|NCT01668147|ACTIVE_COMPARATOR|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV 10-14 mCi of \[11C\]dLop with PET/CT imaging
62089983|NCT00747929|PLACEBO_COMPARATOR|S-2367 Placebo|Placebo + reduced calorie diet
62089984|NCT00747929|EXPERIMENTAL|S-2367 800 mg|S-2367 800 mg q.d. + reduced calorie diet
62089985|NCT00747929|EXPERIMENTAL|S-2367 1600 mg|S-2367 1600 mg q.d. + reduced calorie diet
62089986|NCT03328559|OTHER|early stage bronchial cancer|Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
62089987|NCT03328559|OTHER|advanced stage bronchial cancer|Patients locally moved forward or at a metastatic stage handled by chemotherapy
62089988|NCT05897736||peri-implant patient|Patients with diagnosed peri-implantitis
62089989|NCT03511183|EXPERIMENTAL|alternative regiment|"The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage.~The second stage: continue to apply another plan until there is progress or intolerance."
62089990|NCT03511183|PLACEBO_COMPARATOR|classical regiment|Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.
62089991|NCT00225420|OTHER|Single Arm Intervention|Single Arm Intervention where after enrollment (or prior to enrollment but before starting radiotherapy) patients will initially receive leuprolide acetate (Lupron®) intramuscular (IM). Patients will begin adaptive external-beam radiation therapy 2-3 months following the initiation of hormonal therapy. Each patient receives a dose of docetaxel at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight weeks.
62288373|NCT01722461|EXPERIMENTAL|Active treatment|Ulthera System treatment
62288374|NCT01722461|SHAM_COMPARATOR|Sham treatment|Ulthera System delivering no ultrasound energy
62654702|NCT05125445|ACTIVE_COMPARATOR|Subcrestally positioned implants|
62089992|NCT06474416|EXPERIMENTAL|BD111 dose 1 group|1.25E+06 TU/eye
62089993|NCT06474416|EXPERIMENTAL|BD111 dose 2 group|2.5E+06 TU/eye
62089994|NCT06474416|EXPERIMENTAL|BD111 dose 3 group|5.0E+06TU/eye
62089995|NCT06474416|EXPERIMENTAL|BD111 dose 4 group|10E+06 TU/eye
62089996|NCT06474416|ACTIVE_COMPARATOR|Positive control group|"Triple-drugs therapy group: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
62288375|NCT04992702|EXPERIMENTAL|Animated Video|The information in the ACL animated video (https://vimeo.com/281721823) was displayed as a story of a typical athlete who sustained an injury and how this could be prevented through evidence-based prevention strategies.
62288376|NCT04992702|ACTIVE_COMPARATOR|Web-based Article|The active control group received commonly accessed information from a WebMD web-based article on ACL injury prevention.
62462969|NCT01655628|ACTIVE_COMPARATOR|GC chemotherapy|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
62288377|NCT04992702|PLACEBO_COMPARATOR|Placebo control|The placebo control group intervention received an educational video from the CDC about concussions that is comparable in duration to that of the ACL video (https://youtu.be/fSRWF44wgn8).
62462970|NCT01702584||stent assisted embolization|stent assisted embolization of intracranial aneurysm
62462971|NCT05525026|EXPERIMENTAL|Non-invasive facial remodeling|Treatment with the BTL-785-7 applicator to the BTL-785F system.
62462972|NCT03456947|NO_INTERVENTION|control group|the patients receive routine preoperative preparation without having Pregabalin
61905543|NCT01331889||Potassium concentration|plasma potassium concentrations in the Fluid Management System (FMS) reservoir, arterial blood, and central venous blood
61905544|NCT06251531|EXPERIMENTAL|GD-TG-PBI|Goal-Directed Therapist-Guided Play-Based Intervention
61905545|NCT06251531|NO_INTERVENTION|Control Group|Routine therapy
61905546|NCT03836001|PLACEBO_COMPARATOR|Placebo Oral Tablet|Participants will undergo two months of dosing with a placebo (inactive drug or sugar pill), followed by one month of washout. After the washout period, all participants were invited to participate in an open-label extension study with serlopitant 5 mg daily. The duration of the open-label extension study was either 12 months (for those who enrolled before May 2020) or 3 months (for those who registered after May 2020) due to drug availability.
61905547|NCT03836001|ACTIVE_COMPARATOR|Serlopitant Tablet|Participants will undergo two months of Serlopitant 5mg daily per oral, followed by one month of washout. After the washout period, all participants were invited to participate in an open-label extension study with serlopitant 5 mg daily. The duration of the open-label extension study was either 12 months (for those who enrolled before May 2020) or 3 months (for those who registered after May 2020) due to drug availability.
62089997|NCT03291795|EXPERIMENTAL|Exercise Intervention|
62089998|NCT02723877|EXPERIMENTAL|Eribulin and PQR309|PQR309 in combination with standard approved dose of eribulin mesylate 1.4 mg/m2 intravenous (iv) on days 1 and 8 in a period of 21 days per cycle will be investigated. . PQR309 will be administered maximum 15 minutes after eribulin iv dosing.
62288378|NCT04856137|EXPERIMENTAL|single arm|ruxolitinib, paclitaxel, and rituximab
62288379|NCT06541431||Sample Collection Cohort|This group will contain patients that undergo gastrointestinal surgeries, namely hepatobiliary, colorectal, trauma, and acute care procedures, and received an abdominal drain. Samples of abdominal drainage fluid will be collected daily from each patient.
62288380|NCT01755663|EXPERIMENTAL|Ivabradine|Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
62288381|NCT01755663|ACTIVE_COMPARATOR|metoprolol|Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
62288382|NCT05995392|EXPERIMENTAL|Treatment|Subjects receive topical spironolactone ophthalmic solution, 0.005 mg/cc four times a day for 4 weeks.
62288383|NCT05995392|PLACEBO_COMPARATOR|Placebo|Subjects receive topical spironolactone vehicle as placebo four times a day for 4 weeks.
62288384|NCT06267963|EXPERIMENTAL|Cohort 1|Participants will receive one dose of \[14C\] PF-07220060 by mouth
62462973|NCT03456947|EXPERIMENTAL|Pregabalin150mg group|the patients receive 150mg pregabalin 60 minutes prior to the surgery
62462974|NCT03456947|EXPERIMENTAL|Pregabalin300mg group|the patients receive 300mg pregabalin 60 minutes prior to the surgery
62462975|NCT02781727|EXPERIMENTAL|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
62462976|NCT02781727|ACTIVE_COMPARATOR|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
62462977|NCT02873910|EXPERIMENTAL|IQP-AS-119|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
62462978|NCT02873910|PLACEBO_COMPARATOR|Placebo|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
62462979|NCT02637232||Mirvaso® / Onreltea TM|
62462980|NCT02578953|EXPERIMENTAL|Sequence 1-Dutasteride test product and then Reference product|Participants will receive treatment A in period 1 and treatment B in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
62462981|NCT02578953|EXPERIMENTAL|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment B in period 1 and treatment A in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
62654703|NCT02633774|ACTIVE_COMPARATOR|Rhythm control group|1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation 2. check the echo, brain perfusion CT and K-MOCA on baseline 3. confirm a thrombus through the TEE 4. Cardioversion after 1 month 5. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines) 6. If AF recur, RFCA 7. check the brain perfusion CT, K-MOCA after 3M and 12M
62089999|NCT06528782|EXPERIMENTAL|Pecha Kucha Group|Pregnant women who meet the inclusion criteria assigned to the Pecha Kucha group will be informed about the study and their written and verbal consent will be obtained. Pregnant women will be asked to fill out the 'Introductory Characteristics Information Form', the 'Antenatal Breastfeeding Self-Efficacy Scale Short Form' and the 'Infant Feeding Attitude Scale (IOWA)' before the training at the first encounter, and then breastfeeding training prepared by the Pecha Kucha method will be given. 2 weeks after the training, she will be followed up by phone and asked to answer the Pospartum Breastfeeding Self-Efficacy Scale Short Form, Infant Feeding Attitude Scale (IOWA) and Visual Comparison Scale Satisfaction (VAS-M) scale. 4 weeks after the training, she will be asked to answer the Pospartum Breastfeeding Self-Efficacy Scale Short Form, Infant Feeding Attitude Scale (IOWA) and Visual Comparison Scale Satisfaction (VAS-M) scale.
62090000|NCT06528782|NO_INTERVENTION|Control Group|Pregnant women who meet the inclusion criteria and who are assigned to the control group will be informed about the study and their written and verbal consent will be obtained. Pregnant women will be asked to fill out the 'Descriptive Characteristics Information Form', 'Antenatal Breastfeeding Self-Efficacy Scale Short Form' and 'Infant Feeding Attitude Scale (IOWA)' at the first encounter. After 2 weeks, she will be followed up by telephone and asked to answer the Pospartum Breastfeeding Self-Efficacy Scale Short Form, Infant Feeding Attitude Scale (IOWA) and Visual Comparison Scale Satisfaction (VAS-M). After 4 weeks, she will be asked to answer the Pospartum Breastfeeding Self-Efficacy Scale Short Form, Infant Feeding Attitude Scale (IOWA) and Visual Comparison Scale Satisfaction (VAS-M).
62090001|NCT06187181|PLACEBO_COMPARATOR|G. I : Completely edentulous patients|videofluroscopy for completely edentulous patients
62090002|NCT06187181|ACTIVE_COMPARATOR|G.II: patients with complete dentures|complete denture construction for edentulous patient and videofluroscopy evaluation
62090003|NCT06187181|ACTIVE_COMPARATOR|G.III: patients with implant overdentures|construction of implant overdenture and videofluroscopy evaluation
62090004|NCT05455658|EXPERIMENTAL|Prevention (STEMVAC vaccine, sargramostim)|Patients receive STEMVAC vaccine with sargramostim ID every month for 3 months in the absence of disease progression or unacceptable toxicity. Patients then receive STEMVAC vaccine with sargramostim ID booster injections 3 months after the 3rd vaccination and 6 months after the 1st booster vaccination.
62090005|NCT05525975|NO_INTERVENTION|Control/Standard of Care|This arm will follow the standard of care practices of the Shoulder Surgery Department at UIHC, and will work as a control group.
62288385|NCT06267963|EXPERIMENTAL|Cohort 2|Participants will take one dose of PF-07220060 by mouth and one dose as an IV (intravenous) infusion of \[14C\] PF-07220060.
62654704|NCT02633774|ACTIVE_COMPARATOR|Rate control group|1. No AAD, just anticoagulation 2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin) 3. check the echo, brain perfusion CT and K-MOCA on baseline 4. check the brain perfusion CT and K-MOCA after 3M and 12M 5. Without the treatment about antiarrythmia and rhythm control, diffication of rate control, the subject will be drop out for study.
62654705|NCT04834596||patients without hepatic metastases|hepatic scanner of 100 patients with colorectal cancer without hepatic metastases will be analysed
62090006|NCT05525975|EXPERIMENTAL|Education Arm|"Participants in this arm will receive at their preoperative work-up visit a brochure and will watch an educational video. Both educational materials (brochure and video) will address information about opioid medications, pain management techniques and properly disposal of any excess opioid medication. In addition, participants receive an envelope in which they will be able to dispose their unused opioid pills. These envelopes will be the same ones used in our pilot study (IRB# 202012142). The disposal method consists of secured, labeled envelopes to dispose of the excess of Opioid medication. These envelopes will be provided by Sharps Compliance, Inc., a company that manages pharmaceutical waste disposal programs for healthcare facilities. Through their TakeAway Medication Recovery System Envelope (USPS) they allow the collection and disposal of controlled substances (Schedules II-IV) and non-controlled medications."
62288386|NCT02668614|EXPERIMENTAL|WR-22 model microwave sensor|
62288387|NCT04184817||Medical data collection|The medical data of patients diagnosed by Achondroplasia will be collected. The radiological data will analyse to evaluate the severity of stenosis as well as its clinical tolerance and evolution.
62288388|NCT05407987|EXPERIMENTAL|Iron Therapy Arm|500 or 1000mg of IV Ferric Derisomaltose in 100mL normal saline will be administered intravenously over 1 hour. Participants with bodyweight \<50kg will receive 500mg, participants with bodyweight \>50kg will receive 1000mg to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg bodyweight.
62288389|NCT05407987|PLACEBO_COMPARATOR|Placebo Arm|100mL of normal saline will be administered intravenously over 1 hour between 21 and 90 days preceding surgical intervention.
62288390|NCT03494647|ACTIVE_COMPARATOR|Cheetah Heel Cup|Subjects randomly assigned to this group will receive the Cheetah Heel Cup at their initial visit.
62288391|NCT03494647|ACTIVE_COMPARATOR|The X Brace|Subjects randomly assigned to this group will receive the X Brace at their initial visit.
62288392|NCT03135366|ACTIVE_COMPARATOR|Standard of Care (Control)|
62090007|NCT04145336|ACTIVE_COMPARATOR|5cm PDS group|All patients in this group receive 5cm 5-Fr PDS.
62090008|NCT04145336|EXPERIMENTAL|7cm PDS group|All patients in this group receive 7cm 5-Fr PDS.
62090009|NCT04612309||Treated|Patient with colorectal cancer already treated with immunotherapy
62288393|NCT03135366|EXPERIMENTAL|Keheala Intervention (Treatment)|The intervention consisted of a daily request for self-verification of medication adherence, access to a supporter via a chat client, and information about TB.
62288394|NCT01286493|EXPERIMENTAL|Rabies vaccines on day 0 and 3|Cell culture Rabies vaccines on day 0 and 3
62654706|NCT04834596||patients with synchronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with synchronous hepatic metastases will be analysed
62090010|NCT04415593|EXPERIMENTAL|high dose of peanut|20 patients
62090011|NCT04415593|ACTIVE_COMPARATOR|low dose of peanuts|20 patients
62090012|NCT03574701|EXPERIMENTAL|A: Vitamin A and Olfactory Retraining|Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
62090013|NCT03574701|EXPERIMENTAL|B: Vitamin A|Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
62090014|NCT03574701|NO_INTERVENTION|C: Standard of Care|Group C: This study group will receive only standard of care .
62090015|NCT02685293|EXPERIMENTAL|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
62654707|NCT04834596||patients with metachronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with metachronous hepatic metastases will be analysed
62654708|NCT02425085|EXPERIMENTAL|multi-endodiathermy retinectomy group|Patients receive multi-endodiathermy retinectomy
62654709|NCT02425085|ACTIVE_COMPARATOR|relaxing retinectomy|Patients receive relaxing retinectomy
62288395|NCT06366243|EXPERIMENTAL|Emraclidine 30 mg + Esomeprazole 40 mg|Participants will receive a single oral dose of 30 milligrams (mg) emraclidine on Day 1 of Treatment Period 1. After 6 days following the single dose of emraclidine in Treatment Period 1, participants will receive 40 mg esomeprazole, orally, once daily (QD) on Days 1 to 5 of Treatment Period 2. On Day 6 of Period 2, participants will receive 40 mg esomeprazole followed by a single oral dose of 30 mg emraclidine.
62654710|NCT02138383|EXPERIMENTAL|Dose Escalation and Dose Expansion|"Dose Escalation: To find the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.~Dose Expansion: To find the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel."
61905550|NCT04070911|EXPERIMENTAL|patients in the water group|water group: Patients in the water group were performed oral water after their accession to PACU.
61905551|NCT04070911|EXPERIMENTAL|patients in the ice group|ice group, Patients in the ice group were performed oral ice popsicle after their accession to PACU.
62288396|NCT01260558|ACTIVE_COMPARATOR|Arm 1|Sirolimus-Permanent-Polymer Eluting Stent
61905552|NCT04070911|NO_INTERVENTION|no intervention group|control group, the control group patients have performed rutin treatment and care without any other intervention
61905553|NCT05638919||Oral Antiviral Group|Study participant initiated with oral antiviral (nirmatrelvir plus ritonavir or molnupiravir) for the treatment of COVID-19
61905554|NCT05638919||Non Oral Antiviral Group|Study participant not initiated with oral antiviral for the treatment of COVID-19
61905555|NCT03672929||Patients who received the Allofit IT with HXPE|Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
61905556|NCT05981781|ACTIVE_COMPARATOR|ultrasound guided peng block in paediatric hip surgery|Patients will receive US-guided PENG block with 0.5 ml/kg of bupivacaine 0.25% after induction of general anaesthesia.
61905557|NCT05981781|ACTIVE_COMPARATOR|ultrasound guided caudal epidural block in paediatric hip surgery|Patients will receive US-guided caudal block with 0.5 ml/kg of bupivacaine 0.25% after induction of general anaesthesia.
62288397|NCT01260558|ACTIVE_COMPARATOR|Arm 2|Sirolimus-Polymer-free Eluting Stent
62654711|NCT01937299|EXPERIMENTAL|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
62288398|NCT01270334||ph above cutoff|
62288399|NCT01270334||PH under cutoff|
62288400|NCT01796002|EXPERIMENTAL|Experimental: Romidepsin plus CHOP|"Patients in experimental arm receive romidepsin plus CHOP (Ro-CHOP) administered in 3 week cycles for 6 cycles.~Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks."
62288401|NCT01796002|ACTIVE_COMPARATOR|Standard: CHOP|Patients in control Arm receive cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
61905560|NCT00732836|EXPERIMENTAL|HAI Abraxane MTD|Dose escalation beginning Day 1, Cycle 2 dose level 180 mg/m\^2 for maximum tolerated dose (MTD) of Hepatic Arterial Infusion of Abraxane (HAI Abraxane) following same dose intravenous Abraxane in Cycle 1 of 21 day cycle.
61905561|NCT00732836|EXPERIMENTAL|HAI Abraxane Expansion|HAI Abraxane dose expansion at MTD or dose level 3 (260 mg/m\^2) if MTD not defined.
61905562|NCT02908490|EXPERIMENTAL|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
61905563|NCT02908490|PLACEBO_COMPARATOR|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
62654712|NCT01937299|PLACEBO_COMPARATOR|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
62090016|NCT02685293|PLACEBO_COMPARATOR|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
62288402|NCT01254669|NO_INTERVENTION|control, standard of care|Mothers assigned to the Control Group received the low-literacy, standard-practice, HPV-vaccine information sheet
62288403|NCT01254669|EXPERIMENTAL|BNI-brief Negotiated Interview|The BNI intervention addressed mothers' beliefs, values, and concerns about HPV prevention and takes their priorities for health and well-being into account.
62288404|NCT00951821|EXPERIMENTAL|Concurrent treatment|Concurrent treatment - experimental condition: Adolescent participants and their parents will receive concurrent cognitive behavioral therapy.
62288405|NCT00951821|ACTIVE_COMPARATOR|Adolescent treatment only|Adolescent treatment only - Active Comparator: Only adolescent participants will receive cognitive behavioral therapy.
62288406|NCT02521155|EXPERIMENTAL|Intervention group|Safeguard Your Smile an oral health literacy intervention.
62288407|NCT02521155|NO_INTERVENTION|Control group|No intervention, only a conventional pamphlet will be given.
62288408|NCT02050412|OTHER|Cat fur scratch test|
62288409|NCT04544722|EXPERIMENTAL|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
62288410|NCT04544722|ACTIVE_COMPARATOR|Lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
62288411|NCT00826735|EXPERIMENTAL|Guided imagery|The experimental group received a relaxation focused guided imagery intervention to use through the remainder of pregnancy plus a physiologic guided imagery intervention during the third stage of labor. These interventions were scripted and prerecorded on CDs.
62288412|NCT00859755|EXPERIMENTAL|ARRY-403|
62288413|NCT00859755|PLACEBO_COMPARATOR|Placebo|
62654713|NCT03811938|ACTIVE_COMPARATOR|Pulmonary Vein Isolation|Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.
61905564|NCT00361634|EXPERIMENTAL|Etanercept|Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
62288414|NCT01075347|ACTIVE_COMPARATOR|Autologous serum use|Patients treated with additional 20% autoserum after diabetic vitrectomy or penetrating keratoplasty
62654714|NCT03811938|EXPERIMENTAL|Low voltage ablation|Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.
62654715|NCT03335176|EXPERIMENTAL|Endurance and Resistance Training Exercise|
61905569|NCT01376687||Pain free|No pain in the cervical spine
61905570|NCT01376687||Pain|Pain of 3 or greater on a VAS scale for the cervical spine
61905571|NCT03414892|EXPERIMENTAL|Globalagliatin Hydrochloride (SY-004)|If subjects tolerate 20mg of Globalagliatin Hydrochloride (SY-004) for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
61905572|NCT03414892|PLACEBO_COMPARATOR|Placebo|If subjects tolerate 20mg of Placebo for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
61905573|NCT02410343|PLACEBO_COMPARATOR|Placebo|Placebo was injected subcutaneously once weekly on the same day and time for 24 weeks. To maintain the blind, placebo could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 to match the effect of dose titration.
61905574|NCT02410343|EXPERIMENTAL|TV-1106|TV-1106 was injected subcutaneously once weekly on the same day and time for 24 weeks. A common starting dose was 5.0 mg. Doses could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
62090017|NCT01686295|EXPERIMENTAL|iRestore Hair Rejuvenation System|Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
62288415|NCT01075347|PLACEBO_COMPARATOR|Non-autologous serum use|Patients treated with traditional medication(0.1% betamethasone, 0.3% gentamicin and 0.4% tropicamide eye drops application 4 times daily) after diabetic vitrectomy or penetrating keratoplasty
62288416|NCT05312008|EXPERIMENTAL|Clamp|Clamped alcohol exposure, repeated tests of subjective and cognitive effects of alcohol, 2 sessions (intranasal oxytocin or placebo), double blind
62288417|NCT05312008|EXPERIMENTAL|Progressive work for alcohol|Progressive work alcohol exposure, 2 sessions (intranasal oxytocin or placebo), double blind
62090018|NCT01686295|SHAM_COMPARATOR|Sham Device Arm|This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
62090019|NCT04374565|EXPERIMENTAL|Study participants|A total of 29 eligible subjects will be enrolled to receive high titer anti-SARS-CoV-2 plasma. Participants will be compared to a historical control group via retrospective chart review.
62090020|NCT06349486|ACTIVE_COMPARATOR|bismuth-amoxicillin-vonoprazan triple therapy|vonoprazan 20mg twice a day + amoxicillin 750mg four times a day + tripotassium dicitrate bismuthate 300mg four times a day
62090021|NCT06349486|ACTIVE_COMPARATOR|vonoprazan-amoxicillin dual therapy|vonoprazan 20mg twice a day + amoxicillin 750mg，Four times a day
62288418|NCT03387787|EXPERIMENTAL|GlucoTab Treatment Arm|Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
62654716|NCT03335176|NO_INTERVENTION|Control group|Usual care
62090022|NCT06349486|ACTIVE_COMPARATOR|proton pump inhibitor-based standard triple therapy|rabeprazole 20mg twice a day + amoxicillin 1gm twice a day + clarithromycin 500mg twice a day
62288419|NCT05261854|EXPERIMENTAL|Deep cervical muscle training using pressure biofeedback and conventional Exercises|"The duration of preesure biofeedback includes 3 sets in a session with 10 repetitions each with 2 minutes of rest between sets and 5 days a week for 6 weeks.~Conventional exercises like Stretching and strengthening of neck flexor muscles will include 10 repetitions, each held for 10s with rest of 2 minutes between sets. The session will be conducted for 6 weeks, 5 days a week."
62288420|NCT05261854|EXPERIMENTAL|conventional exercises for Neck pain|Only conventional exercises like stretching and strengthening of neck flexor muscles will be given.
62288421|NCT03198689|EXPERIMENTAL|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use
62288422|NCT05503290|NO_INTERVENTION|Control|
62288423|NCT05503290|ACTIVE_COMPARATOR|Lullaby Project|Participants assigned to the intervention group will meet virtually with a professional musician for 5-7 sessions over the course of 10 weeks. Each session will last approximately 1.5 hours and will be conducted via Zoom.
62288424|NCT03454373|EXPERIMENTAL|Incentive for return to care|"Standard of care HIV primary care services, including counseling to return to care, plus a one-time re-start incentive of 22,500 TZS to return to care."
62654717|NCT05753800|EXPERIMENTAL|Experimental group|This group receives motor intervention sessions with the Intorus device
61905583|NCT02672696|EXPERIMENTAL|FluoroMap group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use the FluoroMap 3D reconstruction system (Stryker Inc) with the standard fluoroscopy to help him place the cephalic screw in the femoral head."
62654718|NCT05753800|NO_INTERVENTION|Control group|This group receives no motor intervention sessions with the Intorus device
61905584|NCT02672696|NO_INTERVENTION|Test group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use only the standard fluoroscopy to help him visualize the position of the cephalic screw in the femoral head."
61905585|NCT04891640|ACTIVE_COMPARATOR|TNFi Standard Therapy|Continue fixed standard treatment (i.e., no change from current therapy)
61905586|NCT04891640|EXPERIMENTAL|TNFi fixed longer dosing intervals|Fixed longer dosing intervals of TNFi (i.e., increased time between doses)
61905587|NCT04891640|EXPERIMENTAL|TNFi Therapy Withdrawal|Stop TNFi treatment
61905588|NCT06353022|EXPERIMENTAL|Teclistamab and Lenalidomide|Patients treated with Teclistamab and Lenalidomide for finite duration.
61905589|NCT06353022|EXPERIMENTAL|Talquetamab andTeclistamab|Patients treated with Teclistamab and Talquetamab for finite duration
61905590|NCT04109508|EXPERIMENTAL|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
61905591|NCT04109508|EXPERIMENTAL|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
62090023|NCT04457271|EXPERIMENTAL|Goal Management Training (GMT)|Participants in this arm will attend 9 weekly, 2-hour group GMT appointments.
62090024|NCT04457271|NO_INTERVENTION|Wait List|Participants in this arm will receive no treatment for approximately 21 weeks (at which point, they will be offered the same, standard GMT treatment).
62090025|NCT03270579|EXPERIMENTAL|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of \[18F\]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of \[18F\]JNJ-64511070.
62090026|NCT03270579|EXPERIMENTAL|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of \[18F\]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of \[18F\]JNJ-64511070 and to model the tissue specific kinetics of \[18F\]JNJ-64511070 in the human brain with the appropriate arterial IF.
62090027|NCT06049693|EXPERIMENTAL|Iron supplementation|Iron supplementation will be provided in the form of ferrous gluconate 300mg twice a day for a period of 1 month
62090028|NCT06049693|NO_INTERVENTION|Control|Control patients will be recruited on the ground of no form of iron prehabilitation
62090029|NCT02909361||Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
62090030|NCT01897857|EXPERIMENTAL|DM kidney transplantation|patient with DM undergoing undergoing kidney transplantation
62090031|NCT01897857|ACTIVE_COMPARATOR|without DM undergoing kidney transplantation|patient without DM undergoing undergoing kidney transplantation
62288425|NCT03454373|NO_INTERVENTION|Comparator|Standard of care HIV primary care services, including counseling to return to care.
62654719|NCT03088059|EXPERIMENTAL|Patient Cohort B1|Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
62090032|NCT02150850||Registry|Patients who have who have sustained an AFF that consent to participating in the registry only.
62288426|NCT01016873|EXPERIMENTAL|16 Gy IRay|16 Gy IRay + PRN Lucentis®
62288427|NCT01016873|SHAM_COMPARATOR|Sham 16 Gy IRay|Sham 16 Gy IRay + PRN Lucentis®
62654720|NCT03088059|EXPERIMENTAL|Patient Cohort B2|Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
62654721|NCT03088059|EXPERIMENTAL|Patient Cohort B3|Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
61905592|NCT04109508|EXPERIMENTAL|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
61905593|NCT04109508|EXPERIMENTAL|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
62090033|NCT02150850||Cases|Patients who have sustained an AFF that consent to participating in the registry and undergoing EOS® imaging.
62090034|NCT02150850||Controls|For each case we will identify one age- (± 5 years), sex-, height- (± 6 cm) and cumulative bisphosphonate or denosumab exposure ( ±2 years) matched control who has not sustained an AFF to undergo EOS® imaging.
62654722|NCT03088059|EXPERIMENTAL|Patient Cohort B4|Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
62090035|NCT05899764|EXPERIMENTAL|BRIV Experimental|25 subjects with MCI or AD who meet inclusion criteria will receive the drug: brivaracetam. A scalp EEG will record their brain activity for 6 days at the hospital. On nights 4 and 5, we will intravenously administer brivaracetam. Doses will vary depending on their effects on epileptic activity. We will determine whether brivaracetam 25 mg IV suppresses the number of epileptic events and pHFOs by \>50%, which is analogous to our preclinical investigations with this drug in AD models. If the 50% suppression is reached, the same dosage will be repeated the following night to ensure reproducibility. If the 50% suppression is not reached, then the dosage of brivaracetam will be increased to 50 mg the following night. Once the depth electrode is surgically removed, subjects will go home with a supply of brivaracetam. They will take the drug for 12 months.
62090036|NCT03530020|ACTIVE_COMPARATOR|monolithic zirconia crowns|Monolithic zirconia attracts many dentists worldwide due to its excellent mechanical properties, biocompatibility and appreciate aesthetics
62090037|NCT03530020|EXPERIMENTAL|lithium silicate crowns|A lithium silicate glass ceramic is newly introduced to the market. After crystallization, it exhibits an ideal combination of aesthetics and strength with translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns.
62090038|NCT04798105|SHAM_COMPARATOR|tDCS sham|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in sham mode.
62090039|NCT04798105|ACTIVE_COMPARATOR|tDCS anodal|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in anodal/excitatory mode.
62090040|NCT00768599|ACTIVE_COMPARATOR|1|Econazole Nitrate Cream 1%
62090041|NCT00768599|EXPERIMENTAL|2|Econazole Nitrate Foam 1%
62090042|NCT00768599|PLACEBO_COMPARATOR|3|Vehicle Foam
61905594|NCT04109508|EXPERIMENTAL|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
62090043|NCT05416437|ACTIVE_COMPARATOR|Device arm|The patients in the device arm will get the Pneumocool device to channel medical air to their face to alleviate dyspnea
62288428|NCT01016873|EXPERIMENTAL|24 Gy IRay|24 Gy IRay + PRN Lucentis®
62288429|NCT01016873|SHAM_COMPARATOR|Sham 24 Gy IRay|Sham 24 Gy IRay + PRN Lucentis®
62288430|NCT02707185|OTHER|Physicians|"Physician in training:~All internal medicine (IM), emergency medicine (EM), anesthesia (A), surgery (S) residents and all hospital ICU nurses."
62654723|NCT03088059|EXPERIMENTAL|Patient Cohort B5|Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
62654724|NCT03088059|EXPERIMENTAL|Patient Cohort I1|Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
61905595|NCT04109508|EXPERIMENTAL|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
61905598|NCT03537469|EXPERIMENTAL|CTU Mega 20 real device|A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
61905599|NCT03537469|SHAM_COMPARATOR|CTU Mega 20 sham device|A single-session of sham CTU Mega 20 on the corresponding primary right-hand motor area (magnetic field = 0 Tesla; intensity = 0 J; frequency of impulses = 7Hz; duration = 15 minutes). The sham stimulation did not provide a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
61905600|NCT05045989|EXPERIMENTAL|Residence-based asymptomatic SARS-CoV-2 testing|The aim of the RB-TPP was to increase and maintain participation of students in regular COVID-19 testing in university residences. The R-TPP was delivered over 4 weeks in April-May 2021 and required asymptomatic students to take a saliva test for COVID-19, twice weekly for four weeks. This was combined with relaxed social restrictions within the residence during the study period (i.e., removing the need for 2 metre distancing between students living in the same residence), surge testing and enhanced support for students who were required to self-isolate (i.e., welfare and financial support).
61905605|NCT02237534|ACTIVE_COMPARATOR|Calcium carbonate|Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration \<4.5 mg/dL. Maximum dose is 3,000 mg/day.
61905606|NCT02237534|EXPERIMENTAL|Lanthanum carbonate|Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration \<4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.
61905607|NCT05466370||AKI|Acute Kidney Injury
61905608|NCT05466370||ARF|Acute Respiratory Failure
61905609|NCT05466370||AKI and ARF|Acute Kidney Injury and Acute Respiratory Failure
61905610|NCT05466370||no complication|no complication
61905611|NCT02081859|PLACEBO_COMPARATOR|Conventional grading|Embryos will be scored based on conventional criteria.
62090044|NCT05416437|PLACEBO_COMPARATOR|Standard of Care arm|The patients in the standard of care arm can get a fan or any other supportive care that is currently available in the hospital for alleviating dyspnea
62090045|NCT02174198|EXPERIMENTAL|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
62090046|NCT02174198|NO_INTERVENTION|No Bone Graft|No placement of BioOss at the time of implant placement
62090047|NCT01853163|OTHER|GBCA|Patients who have received GBCAs in the past
62288431|NCT02707185|OTHER|Nurses|Nurses in Training
62288432|NCT01444300|EXPERIMENTAL|Dalfampridine|
62288433|NCT01444300|PLACEBO_COMPARATOR|Placebo|
62654725|NCT03088059|EXPERIMENTAL|Patient Cohort I2|Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
62090048|NCT05694507|EXPERIMENTAL|Experimental group|In the experimental group, participants will go through one assigned chatbot each day for 10 days, with the sequence of the assigned chatbot randomized. One group of participants will receive chatbot notifications for 10 days, another group of participants will not receive chatbot notifications. They can freely access all chatbots after the completion of post-evaluation. After completing the pre-evaluation questionnaire, they will complete 2 more sets of questionnaires, including a post-evaluation 11 days after group allocation, and a follow-up questionnaire 21 days after group allocation. All participants will be able to access the chatbot materials in an online platform after they have completed the research.
61905612|NCT02081859|ACTIVE_COMPARATOR|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
62090049|NCT05694507|NO_INTERVENTION|Waitlist control group|In the waitlist control group, participants are to refrain from using the chatbot until they finished the follow-up questionnaire. One group of participants will receive study notifications for 10 days, another group of participants will not receive study notifications. After completing the pre-evaluation questionnaire, they will complete 2 more sets of questionnaires, including a post-evaluation 11 days after group allocation, and a follow-up questionnaire 21 days after group allocation. All participants will be able to access the chatbot materials in an online platform after they have completed the research.
62654726|NCT03088059|EXPERIMENTAL|Patient Cohort I3|Patient who are progressing prior PD(L)1 after having received at least 2 months of anti-PD(L)-1 will receive INCAGN01876.
62654727|NCT03452787||Boston Puerto Rican Health Study (NCT01231958)|40 with CC and 40 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, \<22 grams/day, high, ≥22 grams/day.
61905613|NCT05896436|EXPERIMENTAL|Emotion Focused Therapy|Participants will receive 12 weekly 1-hour sessions of Emotion Focused Therapy with a trained student therapist.
61905614|NCT05896436|NO_INTERVENTION|Wait list control|No intervention; waitlist control group will receive intervention once the data collection during the intervention period has concluded.
62090050|NCT03605017|EXPERIMENTAL|VREFT: Wonderkin Treatment|Administered by computer
62090051|NCT03605017|ACTIVE_COMPARATOR|VREFT: Attention Control|Administered by computer
62090052|NCT02391220|ACTIVE_COMPARATOR|Symbiotic|LCA symbiotic fermented milk, 180 g pot, twice daily.
62654728|NCT03452787||GOLDN (NCT00083369)|107 participants with CC genotype and 272 with TT genotype for APOA2 rs5082.
62288434|NCT02204631|EXPERIMENTAL|Head and Neck Educational Handbook|"* Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~* After enrollment and baseline data collection, the participant will be given the handbook. The clinician giving out the handbook will give an overview of the handbook and flip through the important sections. The clinician will encourage the participant to bring it back and forth.~* Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception)."
62288435|NCT02204631|NO_INTERVENTION|Non Head and Neck Educational Handbook|"* Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~* The first group of participants will not receive the handbook but will receive the current standard care in the head and neck disease center.~* Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception).~* At completion of Phase I, all 30 participants will also be given a copy of the handbook and an accompanying questionnaire."
62288436|NCT05473065|EXPERIMENTAL|Multiaxial Prosthetic Foot Emulator (PFE)|The multiaxial Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how prosthesis users will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
62288437|NCT05473065|ACTIVE_COMPARATOR|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
61905616|NCT00666484|EXPERIMENTAL|Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2|"OEPA (28day cycle):~Vincristine 1.5mg/m\^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m\^2 iv d1-5 Prednisolone 60mg/m\^2 po d1-15 Adriamycin 40mg/m\^2 iv d1 and 15"
62090053|NCT02391220|PLACEBO_COMPARATOR|Placebo|heat-treated fermented milk, 180 g pot, twice daily.
62090054|NCT04253821|ACTIVE_COMPARATOR|Forward head posture|
62288438|NCT06424496|OTHER|An intervention study (a quasi-experimental design)|An intervention study (a quasi-experimental design)pre\&post
62288439|NCT04225325|ACTIVE_COMPARATOR|A: SYMTUZA|TAF/FTC 245 mg/200 mg single tablet QD +DRV /cobicistat 800 mg /150 mg single tablet QD
62288440|NCT04225325|ACTIVE_COMPARATOR|B: DESCOVY+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DTG 50 mg QD
62288441|NCT04225325|EXPERIMENTAL|C: SYMTUZA+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DRV/cobicistat single tablet QD + +DTG 50 mg QD
62288442|NCT00289913|EXPERIMENTAL|VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
62288443|NCT00289913|EXPERIMENTAL|PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
62288444|NCT00289913|EXPERIMENTAL|VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
61905617|NCT00666484|EXPERIMENTAL|Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2|"OEPA (28 day cycle) Vincristine 1.5mg/m\^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m\^2 iv d1-5 Prednisolone 60mg/m\^2 po d1-15 Adriamycin 40mg/m\^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m\^2 iv d1 and 8 Vincristine 1.5mg/m\^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m\^2 po d1-15\* Prednisolone 40mg/m\^2 po d1-15"
62090055|NCT04253821|ACTIVE_COMPARATOR|Non-Forward head posture|
62090056|NCT06613659||Treatment cohort of integrated traditional Chinese and Western Medicine|Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposure group was treated with syndrome differentiation of traditional Chinese medicine combined with conventional Western Medicine (treatment cohort of integrated traditional Chinese and Western Medicine).
62090057|NCT06613659||Western medicine treatment queue|The non exposure group (Western medicine treatment cohort) used conventional western medicine treatment but not standardized TCM syndrome differentiation treatment.
62090058|NCT04947124|EXPERIMENTAL|1% QLS-101|dosed once a day for 14 days as either first or second dosing period per randomization
62090059|NCT04947124|EXPERIMENTAL|2% QLS-101|dosed once a day for 14 as either first or second dosing period per randomization
62288445|NCT00289913|EXPERIMENTAL|PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ was administered.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
62090060|NCT06330818|EXPERIMENTAL|Moyamoya patients|Newly diagnosed Moyamoya patients who will follow a standardized imaging and biosampling protocol. Possible surgical or conservative treatment will not be influenced by this study.
62090061|NCT06330818|NO_INTERVENTION|Control group|Healthy patients and patients with intracerebral atherosclerotic disease are used as comparators for the results of biosampling.
62090062|NCT01115998|EXPERIMENTAL|Power wheelchair|
62288446|NCT00289913|EXPERIMENTAL|VAQTA™/VAQTA™ (Stage 2)|"Day 1: The first dose of VAQTA™ was administered.~Week 24: The second dose of VAQTA™ was administered."
62090063|NCT01115998|OTHER|Control group|
62090064|NCT02462083|EXPERIMENTAL|IDP-118 Lotion|IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.
62654729|NCT03452787||Framingham Heart Study (NCT00005121)|73 with CC and 170 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, \<22 grams/day, high, ≥22 grams/day.
61905618|NCT00666484|EXPERIMENTAL|Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4|"OEPA (28 day cycle) Vincristine 1.5mg/m\^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m\^2 iv d1-5 Prednisolone 60mg/m\^2 po d1-15 Adriamycin 40mg/m\^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m\^2 iv d1 and 8 Vincristine 1.5mg/m\^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m\^2 po d1-15\* Prednisolone 40mg/m\^2 po d1-15"
61905619|NCT00935246|EXPERIMENTAL|Antidepressant treated group|Antidepressant treated group: depressed patients treated with Escitalopram
61905620|NCT00935246|NO_INTERVENTION|other antidepressant treated group|other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
61905621|NCT03873740|EXPERIMENTAL|Single vaccine group A|This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
61905622|NCT03873740|EXPERIMENTAL|Single vaccine group B|This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
61905623|NCT03873740|EXPERIMENTAL|Sequential vaccination group A|One dose injection of EV71 inactived vaccines(Vero cells) on Day 0，following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
62090065|NCT03660072||Empliciti combination therapy|Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
62288447|NCT02229422|EXPERIMENTAL|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~* On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~* On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~* On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~* On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
62090066|NCT02580825|ACTIVE_COMPARATOR|Biofeedback gait retraining|The intervention program will take four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
62288448|NCT03783949|ACTIVE_COMPARATOR|Standard arm (arm A)|Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w)
62288449|NCT03783949|EXPERIMENTAL|First experimental arm (arm B)|Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w)
62288450|NCT03783949|EXPERIMENTAL|Second experimental arm (arm C)|Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w)
62090067|NCT02580825|ACTIVE_COMPARATOR|Exercise|The control group will receive the same training program: four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). This group will not provide the biofeedback.
61905624|NCT03873740|EXPERIMENTAL|Sequential vaccination group B|One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0，following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
62090068|NCT00924664|EXPERIMENTAL|Tanezumab 20 mg|
62090069|NCT00924664|EXPERIMENTAL|Tanezumab 10 mg|
61920032|NCT01631019|ACTIVE_COMPARATOR|with mobile phone assistance|In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
62090070|NCT05571800|EXPERIMENTAL|Mango Supplement|Participants will consume 120g of fresh mango per day for 24 weeks
62090071|NCT05571800|PLACEBO_COMPARATOR|Placebo Matched Supplement|Participants will consume 200g isocaloric granola bar per day for 24 weeks
62090072|NCT02711072|PLACEBO_COMPARATOR|control group|
62090073|NCT02711072|ACTIVE_COMPARATOR|infiltration group|
62090074|NCT05029856|EXPERIMENTAL|Group A- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
62090075|NCT05029856|EXPERIMENTAL|Group B- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
62090076|NCT05029856|EXPERIMENTAL|Group C- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
62090077|NCT05029856|EXPERIMENTAL|Group D - SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 5 μg SII B.1.351 Vaccine + 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
62090078|NCT05029856|EXPERIMENTAL|Group E -SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 6 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
62288451|NCT05804799||Liver CT study group|"Patients with a suspicion of focal liver lesions had the plan to perform a contrast-enhanced liver CT scan.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
62288452|NCT01545960||Healthy Volunteers|
62288453|NCT06257914||Cataract|Patients with cataract in both eyes
62288454|NCT01460784||N=60|Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
62090079|NCT05029856|EXPERIMENTAL|Group F- SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 10 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
62090080|NCT05029856|EXPERIMENTAL|Group G- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
61920033|NCT01631019|PLACEBO_COMPARATOR|with free walk|Patients in the control group were educated the same exercise protocol, but were only verbally asked to freely take the walking exercise training at home. The adherence to the walking exercise at home was reported by the patients themselves at every return visits. All the patients received ISWT, spirometry and blood sample for inflammatory biomarkers at baseline, 1, 2, 3 and 6 months.
62090081|NCT05029856|EXPERIMENTAL|Group H- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|1 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose on Days 0.
62090082|NCT00169741|OTHER|cohort|
62090083|NCT05142228|ACTIVE_COMPARATOR|Erenumab-aooe|"Erenumab-aooe 140 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®"
62090084|NCT05142228|PLACEBO_COMPARATOR|Placebo|"Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 andvisit 3 for a total of 3 cycles.~Other name: Placebo"
62090085|NCT02393664|EXPERIMENTAL|Nonintubated group|Patients undergoing thoracoscopic surgery using nonintubated technique with propofol and bupivacaine.
62090086|NCT02393664|ACTIVE_COMPARATOR|Intubated group|Patients undergoing thoracoscopic surgery using intubated general anesthesia with sevoflurane and rocuronium.
62090087|NCT03739879|EXPERIMENTAL|Inspiratory muscle training (IMT)|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
62090088|NCT06013488|EXPERIMENTAL|Intervention Arm|Participants (health workers) allocated to this arm continue to receive the traditional weekly supervision delivered by their supervisor, assigned by the health system, in a face-to-face mode in groups of 1:20 (1 supervisor for a group of \~20 health workers). In addition, participants receive a 5-day residential coaching workshop involving character-strengths based strategies to reduce work-stress, followed by supplemental 8- to 10-week remote telephonic coaching support, after the workshop when they resume work (and experience stressors). The weekly coaching support calls typically last for 30-45 minutes and are delivered by an assigned intervention coach (by the study team) to the health worker (1:1).
62090089|NCT06013488|ACTIVE_COMPARATOR|Control Arm|Participants (health workers) allocated to this arm receive the traditional weekly supervision delivered by their supervisor, assigned by the health system, in a face-to-face mode in groups of 1:20 (1 supervisor for a group of \~20 health workers).
62090090|NCT04742244|PLACEBO_COMPARATOR|Placebo|0 mg LVE/capsule, 2capsule/day, 14days
62090091|NCT04742244|EXPERIMENTAL|Lemon Verbena extract|200 mg LVE/capsule, 2capsule/day, 14days
62288455|NCT01460784||N=600|Cross-sectional study of patients undergoing clinical PET/CT to identify active brown fat. No intervention. Enrolled 405 participants.
62090092|NCT04502667|EXPERIMENTAL|cholecalciferol (Vitamin D)|Children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally during hospitalization
62090093|NCT04502667|NO_INTERVENTION|Control|No intervention
62288456|NCT01460784||N=220|Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
62288457|NCT06054217|EXPERIMENTAL|Study Cohort 1|Participants who were previously enrolled, dosed, and completed approximately 43 days of TID EV administration. Participants are crossed over to receive BID administration of EV for approximately 43 additional days.
62288458|NCT06054217|EXPERIMENTAL|Study Cohort 2|Participants are randomized to receive BID administration of EV for approximately 85 days.
62288459|NCT06054217|EXPERIMENTAL|Study Cohort 3|Participants are randomized to receive TID administration of EV for approximately 85 days
62288460|NCT05136625|ACTIVE_COMPARATOR|Control|Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine)
62288461|NCT05136625|EXPERIMENTAL|Treatment|Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine) Transnasal sphenopalatine ganglion block (Levobupivacaine 7,5%)
62288462|NCT00381407|EXPERIMENTAL|1|Participants will receive organizational skills training program
62288463|NCT00381407|EXPERIMENTAL|2|Participants will receive contingency management program
62288464|NCT00381407|NO_INTERVENTION|3|Participants will receive wait list condition
62288465|NCT02298114|EXPERIMENTAL|neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine. The electrodes will be placed over the motor points of the following muscles: pectoral muscles (fibres of the pectoralis major muscle) and rectus abdominis muscles (bilaterally) The first training session will have a duration of 30 minutes , which will then be extended by 1 minute for every 2 days of administration. The intensity will be increased until muscle contraction is visible or palpable or, intensity will be adjusted according to tolerance associated conventional physiotherapy. Neuromuscular electrical stimulation will be applied held until extubation end conventional respiratory and motor physiotherapy until discharge from the ICU.
62288466|NCT02298114|SHAM_COMPARATOR|Conventional physiotherapy|Conventional physiotherapy will be administered by professionals from the physiotherapy department twice a day, for 30 minutes. The protocol will include upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method (two series of 10 repetitions for each bilateral diagonal), manual bronchial hygiene exercises, such as thoracic vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary. Associated will receive placebo electrical stimulation, in this case the procedure is the same, but intensity is set to a sensory level, not high enough to provoke either visible or palpable muscle contractions.
62090094|NCT02681276|EXPERIMENTAL|Irrigation with 3% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 3 % NaOCl irrigation during instrumentation. If the patient's first visit was on an uneven date the concentration of the irrigant was 3 %.
62090095|NCT02681276|ACTIVE_COMPARATOR|Irrigation with 0.5% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 0.5 % NaOCl irrigation during instrumentation. If the patient's first visit was on an even date the concentration of the irrigant was 0.5 %.
62288467|NCT03160560|ACTIVE_COMPARATOR|Test-Unflavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.
62090096|NCT03250780|EXPERIMENTAL|Patients with extensive colitis|Patients with extensive colitis, for at least 8-10 years, already on the surveillance programme or newly referred whilst attending their outpatients IBD clinic at Leeds Teaching Hospitals NHS Trust will be screened by one of the research doctors who will be performing the surveillance colonoscopy.
62090097|NCT04136028|EXPERIMENTAL|intervention/treatment|Anakinra (Kineret)
62090098|NCT06043804||healthy pregnant woman|healthy pregnant woman
62090099|NCT06043804||Pregnant women with recurrent pregnancy loss|Spontaneous abortion of three or more consecutive sexual partners
62288468|NCT03160560|ACTIVE_COMPARATOR|Test-Flavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution with mint flavoring.
62462982|NCT05940662|EXPERIMENTAL|Immediate Implant Placement|"Immediate implant placement~1. The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~2. After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
62462983|NCT05940662|EXPERIMENTAL|Early Implant Placement|"Early implant placement~1. The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~2. Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~3. After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
62654730|NCT01163617|EXPERIMENTAL|Current/Physiolis Syringe|Self-injection using current syringe at Week 0 (Visit 1), self-injection using Physiolis syringe at Week 2 (Visit 2) (Phase A)
62654731|NCT01163617|EXPERIMENTAL|Physiolis/Current Syringe|Self-injection using Physiolis syringe at Week 0 (Visit 1), self-injection using current syringe at Week 2 (Visit 2) (Phase A)
62090100|NCT01029249||ACTG A5257 participants|Participants in this study will also be enrolled in ACTG A5257.
62090101|NCT06186505|EXPERIMENTAL|Phase 1a|Phase 1a will be undertaken in 10 healthy volunteers to assess the effects of the AirGlove device on lower limb arterial flow, tissue perfusion, and product usability following a single session. Measurements will be taken just prior to device application, and then again at the time of device removal.
62288469|NCT03160560|PLACEBO_COMPARATOR|Placebo|CloSYS Oral Rinse product (no chlorine dioxide)
62288470|NCT02108925|EXPERIMENTAL|Supplementary oxygen|Study subjects receive, in randomized order, either supplementary 30% oxygen or air (21% Oxygen) from a gas tight bag
61905634|NCT05813223|EXPERIMENTAL|Gefapixant treatment|Participants will asked to take an oral tablet containing 45mg Gefapixant twice daily (BID).
61905635|NCT01646333|ACTIVE_COMPARATOR|Supportive Therapy|The supportive therapy offers patients and support persons the opportunity to discuss and reflect upon both Parkinson's Disease and non-Parkinson's Disease related problems.
61905636|NCT01646333|EXPERIMENTAL|Memory and Problem-Solving Intervention|The memory and problem solving training consists of a day calendar manual and note taking system and problem solving techniques. The neurocognitive memory intervention was adapted from a 6-week manualized day calendar and note taking system previously evaluated in an amnestic MCI sample and a brain tumor sample. The problem solving intervention was adapted from an originally 12-week intervention, which was later adapted into a 6-week brain tumor sample.
61905637|NCT04015375|EXPERIMENTAL|Dapsone gel, 7.5% (Torrent Pharmaceuticals Ltd.)|Topical, once daily for 84 days
61905638|NCT04015375|ACTIVE_COMPARATOR|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical, once daily for 84 days
62090102|NCT06186505|EXPERIMENTAL|Phase 1b|Phase 1b will be undertaken in 20 PAD patients with intermittent claudication to assess the effects of the AirGlove device on lower limb arterial flow, tissue perfusion, quality of life and product usability both in a single session, and following a 12-week trial of heat therapy. Measurements will be taken just prior to device application, and then again at the time of device removal at the start of the trial, and again at week 12 (in line with the recommended duration of SET).
62090103|NCT06186505|EXPERIMENTAL|Phase 1c|Phase 1c will be undertaken in 10 PAD patients with critical limb ischaemia Rutherford stage 4 (rest pain). Lower limb arterial flow, tissue perfusion, pain scores, quality of life, and product usability will be assessed both in a single session and following a 2-12 week trial of heat therapy.
62090104|NCT06615414||40 MPN patients|"Inclusion criteria:~* patients with confirmed diagnosis of myeloproliferative neoplasms of one of the following:~* Essential thrombocythemia (ET)~* Polycythemia vera (PV)~* Primary myelofibrosis (PMF)~* Adults aged 18 years and older.~* who accept to participate in the study in Assiut university hospital.~Exclusion criteria:~* Patients with secondary erythrocytosis or thrombocytosis due to other underlying conditions (e.g., chronic hypoxia, tumors) will be excluded.~* Patients who have experienced a myocardial infarction, stroke, heart failure, Hypertension, or significant cardiovascular event before diagnosis of MPN~* Patients with severe comorbid conditions that could confound results, such as:~* Severe renal or hepatic impairment~* Active malignancies other than MPN~* Pregnant or lactating women should be excluded due to potential risks associated with cardiovascular evaluations.~* at age group below 18 years old.~* who refused to participate in the study."
62090105|NCT06615414||40 healthy patients|An external control group will consist of age- and gender-matched individuals without any hematological disorders or significant cardiovascular conditions. They will be recruited from health care workers
62288471|NCT03585140|ACTIVE_COMPARATOR|Normal Diet|Participants will receive a normal diet according to their metabolic status.
62288472|NCT03585140|EXPERIMENTAL|Low glycemic diet|Participants will receive a low-glycemic index and load diet according to their metabolic status. Milk and vitamin supplements will be eliminated from the diet.
62288473|NCT02091180|EXPERIMENTAL|Mannitol|Patients will receive 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
62288474|NCT02091180|PLACEBO_COMPARATOR|Control|Patients will receive normal saline
61905639|NCT04015375|PLACEBO_COMPARATOR|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical, once daily for 84 days
62288475|NCT02245048||Stress Echocardiography (SE)|Subjects will undergo CIMT measurements.
62288476|NCT03089957|EXPERIMENTAL|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
62288477|NCT03089957|PLACEBO_COMPARATOR|Control group|Control group will be in usual care without any intervention.
61905640|NCT01936090|EXPERIMENTAL|Treatment (bortezomib, TBI, melphalan, stem cell transplant)|"Conditioning regimen: Patients receive bortezomib IV on days -5 and -2, TBI BID on days -5 and -2, and melphalan IV over 1 hour on days -4 and -3.~Transplant: Patients undergo autologous bone marrow or peripheral blood stem cell transplant on day 0."
61905641|NCT05019118|EXPERIMENTAL|Intervention/treatment|"Dairy foods made with UNICLA milk Participants (n = 45) ingested UNICLA milk and dairy products (yogurt and cheese) for three months.~UNICLA milk is characterised by an improved nutritional composition, obtained by modifying cow's diet, feeeding the dairy cows with a sufficient and balanced ration, which recreates the fatty acid profile of the spring.~This ration includes pastures, high-quality forages and, among other components, a significant amount of flax seeds, which constitute a source of unsaturated fatty acids such as omega-3 and selenised yeast, as a source of organic selenium.~Consequently, UNICLA milk and dairy products are naturally enriched in selenium and ω-3 PUFA.~The daily intake reflects the usual consumption habits, being the recommended amounts of 200 ml of milk and 125 g of yogurt per day and 400g of fresh cheese per week"
61905642|NCT05019118|PLACEBO_COMPARATOR|Conventional milk|"Participants (n = 45) ingest milk and conventional dairy products daily for 3 months.~Daily intake reflects usual dairy consumption habits in real life conditions, without forcing or inducing increased consumption. Therefore, the recommended amounts are 200 ml of milk and 125 g of yogurt per day and 400 g of fresh cheese per week"
62288478|NCT05948215|EXPERIMENTAL|Jing Si Herbal Tea Liquid Packet|Participants received Jing Si Herbal Tea Liquid Packet 15 mg tablet orally once daily for 28 days.
62288479|NCT05948215|PLACEBO_COMPARATOR|Jing Si Herbal Tea Liquid Packet Placebo|Participants received Jing Si Herbal Tea Liquid Packet Placebo 15 mg tablet orally once daily for 28 days.
62288480|NCT04858893||Subjects affected from Parkinsonims|Scores of MMSE, FAB MoCA were summarized to calculate the CoMDA scores, than they were used to develop the Neural Net 91 classificator
62288481|NCT04858893||Health Controls|CoMDA was administered and total score was calculate to develop the Neural Net 91 classificator
62288482|NCT03472508|SHAM_COMPARATOR|0 mg folic acid|Enalapril Maleate (10mg) with 0 mg folic acid
62288483|NCT03472508|ACTIVE_COMPARATOR|0.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg)
62288484|NCT03472508|ACTIVE_COMPARATOR|0.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg) with 0.2 mg folic acid
62288485|NCT03472508|ACTIVE_COMPARATOR|0.8mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg)
62288486|NCT03472508|ACTIVE_COMPARATOR|1.2mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.4 mg folic acid
62288487|NCT03472508|ACTIVE_COMPARATOR|1.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.8 mg folic acid
62288488|NCT03472508|ACTIVE_COMPARATOR|2.0mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.2 mg folic acid
62288489|NCT03472508|ACTIVE_COMPARATOR|2.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.6 mg folic acid
62288490|NCT00254566|EXPERIMENTAL|1|
62288491|NCT00254566|ACTIVE_COMPARATOR|2|
62090106|NCT05168644|EXPERIMENTAL|Drug: Niclosamide Inhalation Powder|"PART A (SAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 0.5 mg, Cohort 2: 2 mg, Cohort 3: 6 mg.~PART B (MAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects will receive Niclosamide Inhalation Powder BID for a total of 9 doses. Subjects in Cohort 4 will receive 3 mg BID, Cohort 5: 6 mg BID."
62288492|NCT05430620|EXPERIMENTAL|I-HMPO2|intermittent surface oxygenation during hypothermic machine perfusion (surface oxygenation interrupted during organ transport)
62288493|NCT05430620|ACTIVE_COMPARATOR|C-HMPO2|continuous surface oxygenation during HMP (surface oxygenation during the whole machine preservation period included organ transport)
62462984|NCT05940662|ACTIVE_COMPARATOR|Late Implant Placement|"Late implant placement~1. The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~2. Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~3. After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
62288494|NCT06174350|EXPERIMENTAL|experimental group|Cognitive behavioral therapy will be applied to the individuals in the experimental group who were exposed to the earthquake.
62288495|NCT06174350|EXPERIMENTAL|Placebo group|No intervention will be applied to the control group of individuals exposed to the earthquake.
62462985|NCT02550340||Acute alcohol intake|Visitors of the Munich Octoberfest or similar events who fulfil in- and exclusion criteria
62288496|NCT02835170|EXPERIMENTAL|Autologous immunoglobulin|Intramuscular injection of autologous immunoglobulin (IgG)
62288497|NCT02835170|PLACEBO_COMPARATOR|Placebo|Intramuscular injection of normal saline
62288498|NCT02149225|EXPERIMENTAL|APVAC1 and 2 vaccine plus polyICLC and GMCSF concurrent to TMZ|
62288499|NCT00542620|EXPERIMENTAL|Mixed injection|
62288500|NCT00542620|ACTIVE_COMPARATOR|Separate injection|
62288501|NCT01900002|EXPERIMENTAL|Treatment (sorafenib tosylate, TheraSphere)|Patients receive sorafenib tosylate PO BID. After 4 weeks, patients receive yttrium Y 90 glass microspheres IA. Courses of sorafenib tosylate repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62288502|NCT00511043|EXPERIMENTAL|All pts|PTK787
62288503|NCT05112796|EXPERIMENTAL|VST technique|
62288504|NCT05112796|ACTIVE_COMPARATOR|PET technique|
62288505|NCT04075435|OTHER|All subjects|This arm will include all subjects, individuals will administer a high CBD, low THC full spectrum sublingual solution twice daily on a variable dosing schedule.
61905643|NCT01920100||Memory clinic|People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
61905644|NCT01920100||Nursing homes|People admitted to a nursing home recruited from municipalities in Hedmark, Oppland, Nord-Trøndelag and Bergen (n=1000). Baseline assessments take place when the person is admitted to the nursing home. The patients will be assessed every six months over a three-year follow-up period. The first participant was included in March 2012, and baseline inclusion will be completed in December 2013.
61905645|NCT01920100||In-home care|People 70 years of age or older receiving in-home care recruited from municipalities in Hedmark, Oppland, Oslo, Østfold and Buskerud (n=995). The patients will be assessed three times over a three-year follow-up period. Baseline inclusion started in April 2009 and the final assessments will take place in December 2013.
61905646|NCT01920100||People without dementia|"People without dementia recruited from Nord-Trøndelag, Drammen and Oslo (n=400).~The participants will be assessed three times over a three-year follow-up period. Baseline inclusion will take place in autumn 2012 and the last follow-up will take place in autumn 2015."
61905647|NCT02149849|NO_INTERVENTION|Standard lateral positioning|
61905648|NCT02149849|EXPERIMENTAL|Modified lateral positioning|Modified lateral positioning. This will ensure less pressure and stretch on shoulder than standard lateral positioning.
62462986|NCT01279460||CKD Cohort of patients with renal insufficiency|patients with renal insufficiency grade II-IV
61905655|NCT02797002||Chronic non specific neck pain|Experiencing neck pain for at least 3 months in the last year
61905656|NCT02797002||Without neck pain (asymptomatic)|No history of neck pain
61905657|NCT01507064|ACTIVE_COMPARATOR|Group A|Patients who undergo to LA without sorafenib pretreatment
61905658|NCT01507064|EXPERIMENTAL|Group B|Patients who are treated with sorafenib before LA
61905659|NCT04175990|EXPERIMENTAL|Progestogen|Oral Dydrogesterone 10mg tds was given from day 1 of menses till day of trigger
62090107|NCT05168644|PLACEBO_COMPARATOR|Drug: Placebo|"PART A (SAD): Placebo will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects (Part A) will receive a single dose of Placebo.~PART B (MAD): Placebo inhalation powder will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects (Part B) will receive Placebo inhalation powder BID for a total of 9 doses."
62462987|NCT03898297||Healthy control|60 psychiatrically-healthy subjects will be enrolled as controls may participate in MRI or fMRI, \[1H\]MRS and/or \[13C\]MRS, \[18F\]FPEB and/or \[11C\]APP311 PET scans, cognitive testing
61905660|NCT04175990|NO_INTERVENTION|standard combine minimal stimulation protocol|Oral clomiphene citrate 100mg daily given from day 1 till day 10 of menses with additional gonadotrophin (Menopur 225mg daily) from day 3 of menses till trigger day
61905661|NCT01996839|EXPERIMENTAL|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
61905662|NCT01996839|ACTIVE_COMPARATOR|Vehicle (BID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
61905663|NCT01996839|EXPERIMENTAL|Loteprednol Etabonate Gel (TID)|Loteprednol Gel 0.38% administered three times daily (TID).
61905664|NCT01996839|ACTIVE_COMPARATOR|Vehicle (TID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID).
62462988|NCT03898297||MDD|30 subjects with major depressive disorder (MDD) may participate in MRI or fMRI, \[1H\]MRS and/or \[13C\]MRS, \[18F\]FPEB and/or \[11C\]APP311 PET scans, cognitive testing
62654732|NCT01163617|EXPERIMENTAL|Current/Physiolis Autoinjector|Self-injection using current autoinjector at Week 0 (Visit 1), self-injection using Physiolis autoinjector at Week 2 (Visit 2) (Phase A)
62288506|NCT02424279|ACTIVE_COMPARATOR|Surgical treatment|Patients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.
62654733|NCT01163617|EXPERIMENTAL|Physiolis/Current Autoinjector|Self-injection using Physiolis autoinjector at Week 0 (Visit 1), self-injection using current autoinjector at Week 2 (Visit 2) (Phase A)
62288507|NCT02424279|NO_INTERVENTION|Conservative Treatment|Patients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.
61905667|NCT06128265|EXPERIMENTAL|Sleep Extension|Participants that are in the sleep extension group will have their time in bed extended by 2 hours. This can include going to bed earlier and/or waking up later.
62654734|NCT01163617|EXPERIMENTAL|Physiolis Autoinjector at 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at storage temperature (2° to 8°C) (Phase B)
62654735|NCT01163617|EXPERIMENTAL|Current Autoinjector 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at storage temperature (2° to 8°C) (Phase B)
62654736|NCT01163617|EXPERIMENTAL|Physiolis Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at room temperature (20° to 27°C) (Phase B)
62654737|NCT01163617|EXPERIMENTAL|Current Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at room temperature (20° to 27°C) (Phase B)
61905668|NCT06128265|EXPERIMENTAL|Sleep Regularity|Participants in the sleep regularity group will have consistent bedtimes (within 30min).
61905669|NCT02395172|EXPERIMENTAL|Avelumab|
62288508|NCT05038527|EXPERIMENTAL|ABM/P-15 bone graft|Group A: Bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15)
62288509|NCT05038527|NO_INTERVENTION|Standard treatment|Group B: Standard bone graft which is a mix of locally harvested bone and a morselized femoral head (allogenic)
62462989|NCT03898297||Bipolar|30 subjects with bipolar disorder may participate in MRI or fMRI, \[1H\]MRS and/or \[13C\]MRS, \[18F\]FPEB and/or \[11C\]APP311 PET scans, cognitive testing
62462990|NCT05688514|EXPERIMENTAL|Innovalve TMVR System|MV replacement with Innovalve MR system
62090108|NCT05674968|EXPERIMENTAL|Managing Challenging Behaviors in ADHD|This is a 7-session behavioral parent training delivered to children ages 3-7 referred to the study after an initial ADHD diagnosis or when challenging behaviors are identified by their medical provider.
62090109|NCT05674968|NO_INTERVENTION|Wait List|Families assigned to the wait list will complete measures at baseline, 14 weeks, and 24 weeks. After 24 weeks they will be offered the experimental treatment.
62288510|NCT05378009|EXPERIMENTAL|group A|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
62288511|NCT05378009|ACTIVE_COMPARATOR|Group B|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
62288512|NCT02898480|EXPERIMENTAL|Remote ischemic conditioning|
62288513|NCT01970176|ACTIVE_COMPARATOR|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
62654738|NCT05917340|EXPERIMENTAL|Arm- 1( Intervention arm with aspirin)|Intensified with high dose rifampicin, moxifloxacin, aspirin and steroids in the initial two months.
62654739|NCT05917340|EXPERIMENTAL|Arm -2 (Intervention arm without aspirin)|Intensified with high dose rifampicin, moxifloxacin and steroids in the initial two months.
62654740|NCT05917340|ACTIVE_COMPARATOR|Arm -3 (Control)|Regimen as per the current National Tuberculosis Elimination Program in India.
62654741|NCT02177994|EXPERIMENTAL|Group A ceftriaxone after cord clamping|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone via l intravenous infusion single dose after cord clamping."
62654742|NCT02177994|ACTIVE_COMPARATOR|Group B ceftriaxone before skin incision|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone vial intravenous infusion single dose 30-60 minutes before skin incision."
61905670|NCT02395172|ACTIVE_COMPARATOR|Docetaxel|
61905671|NCT05526300|ACTIVE_COMPARATOR|The standard care group|
61905672|NCT05526300|EXPERIMENTAL|Intelligent intervention group|
61905673|NCT05282602|EXPERIMENTAL|Wii Fit Based Exercises|Group A will receive Wii fit Based Exercises
61905674|NCT05282602|EXPERIMENTAL|Proprioceptive Training|Group B will receive proprioceptive training
61905681|NCT02385656|EXPERIMENTAL|Intervention group|Subjects who take modafinil for cancer-related fatigue for 4 weeks.
62090110|NCT06215729|EXPERIMENTAL|the experimental group|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment. The experimental group additionally underwent computer-assisted cognitive training, which generated training content of corresponding difficulty based on the patient's cognitive impairment assessment results. The training was conducted seven days a week, once a day, for a duration of 30-45 minutes per session.
62090111|NCT06215729|ACTIVE_COMPARATOR|the control group|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment.The control group was given conventional cognitive training.
62288514|NCT01970176|PLACEBO_COMPARATOR|Placebo|Subject will receive Placebo daily for a total of 12 weeks
62654743|NCT03772873||MIPE|Patients undergoing minimally invasive pilonidal excision with trephination.
62654744|NCT03772873||Other|Patients undergoing a different procedure for pilonidal disease.
62090112|NCT02991287||Chronic post-surgical pain patients|Patients scheduled for differents types of surgery (inguinal, hernia repair, abdominal hysterectomy, vaginal hysterectomy, and thoracotomy).
62090113|NCT06113029||Healthy group|Participants not known to have neither chronic liver diseases nor Psychiatric disorders
62090114|NCT06113029||Diseased group|Participants known to have chronic liver diseases
62090115|NCT00630539|PLACEBO_COMPARATOR|Subjects on placebo|Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks
62090116|NCT00630539|EXPERIMENTAL|Subjects on ospemifene 5 mg/day|Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks
62090117|NCT00630539|EXPERIMENTAL|Subjects on ospemifene 15 mg/day|Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks
62090118|NCT00630539|EXPERIMENTAL|Subjects on ospemifene 30 mg/day|Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks
62090119|NCT01258218||Accent MRI Group|
62090120|NCT02621788|EXPERIMENTAL|First Year Residents|Stress Management and Resiliency Training for Residents (SMART-R) delivered to first year residents in the departments of medicine and psychiatry at Massachusetts General Hospital
62288515|NCT02054182|ACTIVE_COMPARATOR|Vitamin D|Vitamin D 2 500 IU daily from enrolment until hospital discharge
62288516|NCT02054182|PLACEBO_COMPARATOR|Placebo|Placebo
62288517|NCT00142948|EXPERIMENTAL|Naltrexone|Naltrexone Oral 50 mgs daily
62288518|NCT00142948|PLACEBO_COMPARATOR|Placebo|1 to 1 comparison of Naltrexone to placebo
62288519|NCT03409874|EXPERIMENTAL|Dry Needling and Spinal Manipulation|
62288520|NCT03409874|ACTIVE_COMPARATOR|Interocclusal Appliance, NSAIDs and TMJ Mobs|
62288521|NCT01541293|EXPERIMENTAL|Intrauterine Lidocaine|The experimental arm will receive 100mg lidocaine (5mL of 2% concentration) instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
62090121|NCT01538446|EXPERIMENTAL|1: Monitoring Arm|Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
62090122|NCT01538446|ACTIVE_COMPARATOR|2: Conventional Arm|Conventional Arm: fixed dose of prasugrel 5 mg
62090123|NCT01511536|EXPERIMENTAL|Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
61905685|NCT06532240|EXPERIMENTAL|Methylene Blue|Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution. Methylene Blue(1 mg/kg/IBW iv over 30min+0.25mg/kg/h x 6h) x 5-days/ discontinution of norepinephrine /ICU discharge (whichever occurred first).
62090124|NCT01511536|EXPERIMENTAL|Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 25 mg/m\^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
62288522|NCT01541293|PLACEBO_COMPARATOR|Intrauterine Saline|Placebo arm will receive 5mL of normal saline instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
62288523|NCT02471157||Eugonadal|Eugonadal men
61905686|NCT06532240|PLACEBO_COMPARATOR|Placebo|5% dextrose solution in a volume to match experimental arm component.
61905687|NCT01542424||BIAsp 30 users|
61905688|NCT01542424||IDet users|
62288524|NCT02471157||Hypogonadal|Hypogonadal men
62288525|NCT02615457|EXPERIMENTAL|Arm I|Patients taking Huaier Granule for adjuvant treatment after the triple negative breast cancer has been surgically removed. The Huaier Granule (Qidong Gaitianli Medicines Co., Ltd.) should be given orally from the 3rd day after surgery up to 5 years after surgery or until study termination.
62288526|NCT02615457|NO_INTERVENTION|Arm II|Patients not taking Huaier Granule after the triple negative breast cancer has been surgically removed.
62288527|NCT02210663|EXPERIMENTAL|veliparib (ABT-888)|
61905689|NCT04247542|EXPERIMENTAL|Ibezapolstat|Active investigational antibacterial agent: ibezapolstat 450 mg po Q12H x 10 days
62288528|NCT02393209|EXPERIMENTAL|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m\^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
61905690|NCT04247542|ACTIVE_COMPARATOR|Vancomycin|Standard of care: Vancomycin 125 mg po Q6H x 10 days
61905691|NCT01998568||Corneal edema|Intraocular pressure measurement
62090125|NCT01511536|EXPERIMENTAL|Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m\^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
62090126|NCT06067425|EXPERIMENTAL|Cohort 1|
62090127|NCT06067425|EXPERIMENTAL|Cohort 2|
62090128|NCT06067425|EXPERIMENTAL|Cohort 3|
62090129|NCT03697460|EXPERIMENTAL|INCB018424|INCB018424 Cream
62288529|NCT02393209|EXPERIMENTAL|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m\^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
62288530|NCT02393209|EXPERIMENTAL|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m\^2 IV infusion on Days 1 and 8 of a 21-day cycle.
62288531|NCT02393209|EXPERIMENTAL|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m\^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
62090130|NCT03724474|EXPERIMENTAL|Be SMART Condition|"Subjects randomly assigned to the Be SMART condition (n=30) will first meet with a credentialed health coach to help create personally relevant weekly, short-term (6-weeks) and long-term (12-weeks) PA and sleep goals, and an initial action and coping plan. At 6- weeks (study mid-point), Be SMART subjects will complete a short telephonic booster session with the health coach. Throughout the 12-week intervention, our agent-based feedback system will communicate weekly messages via short message service (SMS) based on their weekly goal achievement, informed by the continuous collection of their Fitbit data. In addition, subjects in the Be SMART condition will also take their morning blood pressure using a blue-tooth enabled device that wirelessly sends this data to the Be SMART server."
62090131|NCT03724474|ACTIVE_COMPARATOR|Fitbit Only Condition|Subjects who are randomly assigned to the active control condition (n=30) will receive a Fitbit device and wireless blood pressure monitor (same as Be SMART condition). However, subjects in the Fitbit Only condition will not meet with a health coach for establishing SMART goals and creating an action/coping plan, nor will Fitbit Only subjects receive any feedback messages or prompts from the Be SMART server, although data from their Fitbit devices will be continuously collected throughout the q12 week intervention.
62090132|NCT05885945||dysmenorrhea|primary dysmenorrhea
62090133|NCT05885945||control|control not pain
62090134|NCT00840320|EXPERIMENTAL|1|Repeat doses of active at escalating doses
62090135|NCT00840320|PLACEBO_COMPARATOR|2|Repeat doses of placebo
62090136|NCT04647136|ACTIVE_COMPARATOR|Fertility Health Screening|Clinic-based fertility health screening and counselling
62288532|NCT03204149|EXPERIMENTAL|Treatment group|"The treatment group will be treated with the MC-8XL laser device, emitting 808 nm laser beam with a green laser beam.~Intervention: MC-8XL low level laser device and Standard wound care"
62288533|NCT03204149|SHAM_COMPARATOR|Control group|"The control group will receive treatment with a sham laser device, emitting a low power green light with inactive Infrared (IR) laser for indication only.~Intervention: Sham laser device and Standard wound care"
61905694|NCT02482831||Diabetes|Diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
62090137|NCT04647136|ACTIVE_COMPARATOR|Fertility Awareness Tools|Online intervention to provide fertility education and behavioural nudge for optimal reproductive timing.
62090138|NCT04647136|NO_INTERVENTION|Control|No intervention but exposed to usual information from the media on fertility and family benefits (no different from general population).
62090139|NCT04705974|EXPERIMENTAL|Fascia iliaca block|ultrasound-guided fascia iliaca block with predetermined dose of 0.4% ropivacaine will be performed.
61905695|NCT02482831||non-Diabetes|Non-diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
61905696|NCT04802122|EXPERIMENTAL|Sevoflurane group|Patients in this group will receive Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) for induction to anesthesia and to facilitate endotracheal intubation (without the use of muscle relaxant) and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia plus muscle relaxant until study completion.
61905697|NCT04802122|ACTIVE_COMPARATOR|Propofol group|Patients in this group will receive a standard anesthesia induction involving Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% for induction to anesthesia and to facilitate endotracheal intubation and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia.
62288534|NCT05881382|ACTIVE_COMPARATOR|Dutogliptin + Filgrastim|Participants will receive BID SC injections of 60 mg dutogliptin for 14 days in co-administration with 10 µg/kg filgrastim for 5 days.
62654745|NCT02428400|EXPERIMENTAL|TG1050|"TG1050 SD cohort, administered SC as a single injection: 9.0 Log \[10\^9\] 10.0 Log \[10\^10\], 11.0 Log \[10\^11\] virus particles~TG1050 MD cohort, administered SC as 3 once weekly injections:9.0 Log \[10\^9\] 10.0 Log \[10\^10\], 11.0 Log \[10\^11\] virus particles~TG1050 Part B cohort, dose(s) and schedule to be determined"
62654746|NCT02428400|PLACEBO_COMPARATOR|Placebo|"Placebo SD cohort, administered SC as a single injection: 9.0 Log \[10\^9\] 10.0 Log \[10\^10\], 11.0 Log \[10\^11\] virus particles~Placebo MD cohort, administered SC as 3 once weekly injections: 9.0 Log \[10\^9\] 10.0 Log \[10\^10\], 11.0 Log \[10\^11\] virus particles~Placebo Part B cohort, dose(s) and schedule to be determined"
62654747|NCT02990052|ACTIVE_COMPARATOR|Volar plating|Volar fixed-angle plating for dislocated distal radius fracture after closed reduction.
62654748|NCT02990052|ACTIVE_COMPARATOR|Conservative treatment|Primary conservative treatment (closed reduction and casting) for dislocated distal radius fracture.
62654749|NCT05448638|EXPERIMENTAL|transversus thoracic muscle plane block+pectoral nerves block|the combination of transversus thoracic muscle plane and pectoral nerves blocks
62654750|NCT05448638|ACTIVE_COMPARATOR|pectoral nerves block|the pectoral nerves block only
62654751|NCT00678457|EXPERIMENTAL|ondansetron/olanzapine|"ondansetron (4 μg/kg b.i.d.)~olanzapine (9 μg/kg)"
62654752|NCT00678457|PLACEBO_COMPARATOR|placebo|placebo
62654753|NCT05531955|EXPERIMENTAL|Pirfenidone group|Drug name:Pirfenidone Dosage Form:capsule Dosage:200mg three times a day in 1st week;400mg three times a day in 2ndweek;600mg three times a day in 3rd week\~52th week.
61905698|NCT04602234|EXPERIMENTAL|LUS group|
61905699|NCT04602234|NO_INTERVENTION|No LUS group|
62090140|NCT04705974|EXPERIMENTAL|Femoral nerve block|ultrasound-guided ultrasound-guided femoral nerve block with predetermined dose of 0.4% ropivacaine will be performed.
62090141|NCT04705974|EXPERIMENTAL|Pericapsular nerve group block (PENG block)|ultrasound-guided ultrasound-guided pericapsular nerve group block with predetermined dose of 0.4% ropivacaine will be performed.
62090142|NCT01873677|PLACEBO_COMPARATOR|Vehicle|Proper quantity twice a day
62090143|NCT01873677|EXPERIMENTAL|M518101|Proper quantity twice a day
62288535|NCT05881382|PLACEBO_COMPARATOR|Placebo-Dutogliptin + Placebo-Filgrastim|Randomized participants will receive BID SC injections of dutogliptin placebo for 14 days in co-administration with filgrastim placebo for 5 days.
62654754|NCT05531955|PLACEBO_COMPARATOR|Placebo group|Drug name:Placebo Dosage Form:capsule Dosage:200mg three times a day in 1st week;400mg three times a day in 2ndweek;600mg three times a day in 3rd week\~52th week.
61905702|NCT01473368|ACTIVE_COMPARATOR|prebiotic (Saccharomyces boulardii)|500 mg, 2 times daily for 14 days
62090144|NCT00542945|EXPERIMENTAL|A|Heart Failure nonischemic ethiology
62090145|NCT00542945|ACTIVE_COMPARATOR|B|
62090146|NCT06698224|ACTIVE_COMPARATOR|scTS|This arm will receive 20 sessions of spinal cord transcutaneous stimulation (scTS) combined with physical therapy.
62090147|NCT06698224|EXPERIMENTAL|scTS+PNS|This arm will receive 20 sessions of paired application of spinal cord transcutaneous stimulation (scTS) and peripheral nerve stimulation (PNS) followed by scTS combined with physical therapy.
62090148|NCT05990920|EXPERIMENTAL|Cohort 1|SNK02 will be administered as an IV infusion weekly for 8 weeks.
62090149|NCT01228383|EXPERIMENTAL|CL184+PVRV|CL184 with rabies vaccine (PVRV)
62090150|NCT01228383|ACTIVE_COMPARATOR|HRIG+PVRV|HRIG with rabies vaccine
62090151|NCT01228383|PLACEBO_COMPARATOR|Placebo+PVRV|Placebo with rabies vaccine (PVRV)
62090152|NCT01228383|EXPERIMENTAL|CL184+HDCV|CL184 with rabies vaccine (HDCV)
62288536|NCT03804671|EXPERIMENTAL|All Subjects|Test treatment T followed by Reference treatment R
62288537|NCT06226363|EXPERIMENTAL|LNF1901 monotherapy|
62654755|NCT02062697|OTHER|Ovarian Epithelial Cancer|"* Lavage of the Cavum uteri and proximal fallopian tubes~* Liquid-PAP (Papanicolaou) smear"
62654756|NCT05037279|EXPERIMENTAL|Verity-BCG|"* Bacillus Calmette-Guérin (BCG): Strain Russian BCG-I~* Freeze-dried powder for bladder instillation"
62654757|NCT05037279|ACTIVE_COMPARATOR|OncoTICE|"* Standard of Care~* Bacillus Calmette-Guérin (BCG): Strain TICE~* Freeze-dried powder for bladder instillation"
62654758|NCT00089388|EXPERIMENTAL|Arm I (low dose cilengitide)|Patients receive cilengitide IV at a lower dose over 1 hour twice weekly for 4 weeks.
62654759|NCT00089388|EXPERIMENTAL|Arm II (higher dose cilengitide)|Patients receive cilengitide IV at a higher dose over 1 hour twice weekly for 4 weeks.
62654760|NCT04002986|EXPERIMENTAL|Women at intermediate/high risk of breast cancer|Women age 35 years old identified at intermediate/high risk of breast cancer will receive genetic testing
62654761|NCT03889132||Premenopausal women with obesity|
62654762|NCT03889132||Postmenopausal women with obesity|
62654763|NCT03889132||Men with obesity|
62654764|NCT03889132||Premenopausal women without obesity|
62654765|NCT03889132||Postmenopausal women without obesity|
62654766|NCT03889132||Men without obesity|
62654767|NCT03515408|EXPERIMENTAL|Real rTMS (motor area)|Real rTMS targeting motor area for 30 min
62654768|NCT03515408|EXPERIMENTAL|Real rTMS (parietal gyrus)|Real rTMS targeting parietal gyrus for 30 min
62654769|NCT03515408|EXPERIMENTAL|Real rTMS (both brain area)|Real rTMS targeting motor area and parietal gyrus for 15 min, separately
62654770|NCT03515408|SHAM_COMPARATOR|Sham rTMS|Sham rTMS targeting motor area and parietal gyrus for 15 min, separately
62654771|NCT01925417|EXPERIMENTAL|RBX2660 (microbiota suspension)|enema-based delivery of RBX2660
62654772|NCT04226443|ACTIVE_COMPARATOR|Group 1|In Group 1(n=50); continuous infusion of intravenous midazolam (Dormicum, Deva Pharmaceutical, Turkey) at a dose of 0.02 to 0.04 mg/kg/h was started at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
62654773|NCT04226443|ACTIVE_COMPARATOR|Group 2|in Group 2 (n=49), intravenous bolus doses of midazolam at a dose of 0.015 mg/kg every 10 minutes were administered at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
62654774|NCT03781271|EXPERIMENTAL|Fraction 1-Addition of EMN|During the fraction 1 insertion, the custom MRI-compatible vaginal cylinder will be placed in the patient, and will contain the 6 degree-of-freedom (DOF) sensor. The electromagnetic navigation system and computer will have been setup in the operating room (OR) prior to the procedure and will be used to actively insert up to 25 catheters into the target. The catheters will be inserted using a custom metallic stylet that has a custom 5-DOF sensor embedded in the tip for tracking its position in real-time. The physician may use ultrasound for assistance in target visualization as well. Catheter deflections will be detected and corrected for in real-time by the radiation oncologist as the catheter is inserted into the patient during the procedure, this will occur when the EM system is in use.
61905703|NCT01473368|ACTIVE_COMPARATOR|antibiotic (Amoxicillin Clavulanate)|875/125 mg 2 times daily at least 1 hour before meals for 7 days
62090153|NCT01228383|PLACEBO_COMPARATOR|Placebo+HDCV|Placebo with rabies vaccine (HDCV)
62090154|NCT01102296|ACTIVE_COMPARATOR|male homosexuals|HIV-uninfected male homosexuals will be provided 2 doses of HAV vaccine, which will be administered at baseline and 6th month of follow-up.
62090155|NCT01102296|ACTIVE_COMPARATOR|HIV-infected male homosexuals, group1|HIV-infected male homosexuals will be provided 3 doses of HAV vaccine, which will be administered at baseline, 1st, and 6th month of follow-up.
62090156|NCT01102296|ACTIVE_COMPARATOR|HIV-infected male homosexuals, group 2|HIV-infected male homosexuals will be provided 2 doses of hepatitis A vaccine, which will be administered at baseline and 6th month of follow-up.
62090157|NCT01781702|EXPERIMENTAL|Pelubiprofen 30 mg|Pelubiprofen 30 mg, tid
62090158|NCT01781702|ACTIVE_COMPARATOR|Celebrex 200 mg|Celebrex 200 mg, tid
62090159|NCT05535036|EXPERIMENTAL|dexamethasone group|patients received 8mg(2ml) of intravenous dexamethasone after spinal anesthesia
62090160|NCT05535036|PLACEBO_COMPARATOR|placebo group|patients received 2ml of a saline solution after spinal anesthesia
62090161|NCT05035264|ACTIVE_COMPARATOR|Neutral head position|Laryngeal mask will be inserted after anaesthesia induction in neutral head position
62090162|NCT05035264|ACTIVE_COMPARATOR|Sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
62090163|NCT05035264|EXPERIMENTAL|Beyond sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
62090164|NCT02886936|EXPERIMENTAL|Transtibial Testing|This is a feasibility and effectiveness study to assess the iFIT transtibial prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
62090165|NCT02886936|EXPERIMENTAL|Transfemoral Testing|This is a feasibility and effectiveness study to assess the iFIT transfemoral prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
62090166|NCT05126446|EXPERIMENTAL|aortic dissection involving the aortic arch|Aortic dissection involving the aortic arch was diagnosed in patients requiring revascularization of the aortic arch and its branches
62090167|NCT00425542|EXPERIMENTAL|Outpatient treatment|
62090168|NCT00425542|NO_INTERVENTION|Inpatient care|
62090169|NCT00178620|EXPERIMENTAL|Group A: Full dose pre-hospital fibrinolysis|Patients transported by participating EMS units and that were fibrinolytic eligible and treated with full dose, pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase and randomized to a second 10-unit dose of reteplase).
62090170|NCT00178620|EXPERIMENTAL|Group B: Half dose pre-hospital fibrinolysis followed by urgent PCI|Patients transported by participating EMS units and that were fibrinolytic eligible and treated with a half dose pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase) and randomized to urgent catheterization with percutaneous coronary intervention (PCI).
62654775|NCT03781271|EXPERIMENTAL|Fraction 3-Addition of EMN|For the second group of patients in the trial the same protocol will be followed as in the first group, the only difference will be that the electromagnetic navigation is used during the second implantation procedure immediately preceding fraction 3 as opposed to fraction 1, the time at which it was used for the first group of patients.
62090171|NCT00178620|ACTIVE_COMPARATOR|Group C: Fibrinolytic ineligible patients receiving primary PCI|Patients transported by participating EMS units and that were fibrinolytic ineligible and treated with primary PCI alone and that were prospectively analyzed for comparison.
62090172|NCT00178620|ACTIVE_COMPARATOR|Group D: Patients transferred in and treated with primary PCI|Patients not transported by participating EMS units but were transferred in and treated with primary PCI alone and that were prospectively analyzed for comparison.
62288538|NCT04566484|EXPERIMENTAL|BBV87vaccine(BBV87 20 µg/ BBV87 40 µg)|"The test article, inactivated Chikungunya virus vaccine 'BBV87', is available in a 2 mL clear glass USP Type 1 vial that contains a single dose of 0.5 mL of the vaccine as singlehuman dose (SHD). Vials are stoppered and sealed with tear-down aluminum seals.~• Route: BBV87 vaccine will be given to participants intramuscularly in the deltoid region of the upper arm. 0.5 mL of the investigational vaccine (BBV87 20 µg/ BBV87 40 µg) will be administered."
62090173|NCT05645913||Atrial fibrillation with oral anticoagulant|patients who were newly receiving an oral anticoagulant for atrial fibrillation during study period
62090174|NCT01910558|ACTIVE_COMPARATOR|Alpha-cyclodextrin and digestible starch|Supplementation with three grams alpha cyclodextrin with three grams of digestible starch
62090175|NCT01910558|EXPERIMENTAL|Alpha-cyclodextrin|Supplementation with six grams of alpha-cyclodextrin
62288539|NCT04566484|PLACEBO_COMPARATOR|Normal Saline|Each 0.5 ml vial of placebo will contain normal saline.The placebo will be given to participants intramuscularly in the deltoid region of the upper arm.0.5 mL of placebo will be administered.
62288540|NCT01253239||TECNIS/ReZoom|Patients who received a TECNIS multifocal IOL in one eye and a ReZoom multifocal IOL in the opposite eye.
62654776|NCT00634504|EXPERIMENTAL|A|High-dose methotrexate, leucovorin, and Voraxaze
62090176|NCT01910558|PLACEBO_COMPARATOR|Digestible Starch|Supplementation with six grams of digestible starch
62090177|NCT00847093|EXPERIMENTAL|Cream|Experimental group receiving either medicated topical cream or placebo cream
62090178|NCT02817503|EXPERIMENTAL|Standard BP control|"SBP within 140 - \<150 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
62090179|NCT02817503|ACTIVE_COMPARATOR|Moderate BP control|"SBP within 130 - \<140 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
61905704|NCT01473368|ACTIVE_COMPARATOR|combination (prebiotic and antibiotic)|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
62654777|NCT00634504|ACTIVE_COMPARATOR|B|High-dose methotrexate and leucovorin without Voraxaze (glucarpidase)
62090180|NCT02817503|ACTIVE_COMPARATOR|Intensive BP control|"SBP \<130 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
62090181|NCT06696911|EXPERIMENTAL|Core Stability Exercises and Motor Imagery|Core stability exercises are voluntary movements designed to maintain the balance, functional mobility, gait, fear of falling, and anticipatory postural adjustment among stroke survivors. Motor perception or motor imagery (MI) is a mental task that involves visualizing a physical movement without actually doing the action
62090182|NCT06696911|ACTIVE_COMPARATOR|Core Stability Exercises|Core stability exercises are voluntary movements designed to maintain the balance, functional mobility, gait, fear of falling, and anticipatory postural adjustment among stroke survivors.
62090183|NCT01400893|EXPERIMENTAL|CRRT + SCD|Patients with a diagnosis of AKI requires CRRT will be randomized
62090184|NCT01400893|NO_INTERVENTION|CRRT alone|Patients with a diagnosis of AKI requires CRRT will be randomized
62090185|NCT05148767|EXPERIMENTAL|Neoadjuvant chemoradiotherapy based on irinotecan|Locally advanced rectal cancer patients who were treated with irinotecan-based neoadjuvant chemoradiotherapy regimen can be enrolled in this group.
62090186|NCT03004599|OTHER|Transcatheter Aortic Valve Implantation (TAVI)|
62090187|NCT03660943|PLACEBO_COMPARATOR|Placebo|Matching placebo of 2.0 mL for IA injection
62090188|NCT03660943|EXPERIMENTAL|CNTX-4975-05|Pre-filled glass syringes administered as a single 2.0 mL IA injection
62090189|NCT02471846|EXPERIMENTAL|Anti-PD-1/PD-L1 Relapsed Cohort I|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade and achieved best response of confirmed complete or partial response, or stable disease will receive GDC-0919, at the MTD or maximum administered dose (MAD) determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
62090190|NCT02471846|EXPERIMENTAL|Anti-PD-1/PD-L1 Relapsed Cohort II|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade and achieved unconfirmed partial response or stable disease will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
62288541|NCT01253239||TECNIS/TECNIS|Patients who received TECNIS multifocal IOLs in both eyes
62654778|NCT04571203|EXPERIMENTAL|Phase I Study of Combined DD Kidney and HCT Transplant|Single arm Phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion
62654779|NCT05156008|NO_INTERVENTION|Group A|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by standard palpation of vein under strict aseptic measures. Application of tourniquet on upper arm, palpation of vein, disinfection of skin and insertion of cannula. After two unsuccessful punctures, UGVA operator will step in and perform insertion of cannula with ultrasound.~Medical staff will note:~* number of attempts~* time to obtain vascular access~* type of cannula~* DIVA score"
61905705|NCT01473368|NO_INTERVENTION|control|
61905706|NCT01425463|EXPERIMENTAL|Ferrous (II) Glycine Sulphate Complex|Ferrous (II) Glycine Sulphate Complex treatment with 567.7 mg three times a day (t.i.d.) for 12 weeks plus Placebo to Polyferose.
61905707|NCT01425463|ACTIVE_COMPARATOR|Polyferose|Polyferose treatment with 150 mg twice daily (b.i.d) for 12 weeks plus Placebo to Ferrous (II) Glycine Sulphate Complex.
61905708|NCT05356156|EXPERIMENTAL|Closure of the mesenteric defects|Closure of the mesenteric defects will be performed after radical gastrectomy in patients with gastric or esophagogastric junction adenocarcinoma.
61905709|NCT05356156|ACTIVE_COMPARATOR|Non-closure of the mesenteric defects|Non-closure of the mesenteric defects will be performed after radical gastrectomy in patients with gastric or esophagogastric junction adenocarcinoma.
61905710|NCT05318742|ACTIVE_COMPARATOR|Fewer Laser Spots|Group A patients underwent endolaser PRP with a range of 200-300 shots during PPV
61905711|NCT05318742|ACTIVE_COMPARATOR|Higher Laser Spots|Group B patients underwent endolaser PRP with a range of 500-600 shots during PPV
61905712|NCT03523598|PLACEBO_COMPARATOR|Placebo gel + Normal Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
62288542|NCT00680836|ACTIVE_COMPARATOR|Treatment Group|These patients have IBS and are receiving the rifaximin.
62288543|NCT00680836|PLACEBO_COMPARATOR|Placebo group|These patients have IBS and are receiving the placebo.
62288544|NCT02077790|NO_INTERVENTION|Substantial Equivalence|The CASIA Cornea/Anterior Segment OCT SS-1000 was used on all subjects for this study.
62288545|NCT01030692|PLACEBO_COMPARATOR|Placebo|Placebo capsules as control
62288546|NCT01030692|ACTIVE_COMPARATOR|Rivastigmine 3 mg|Rivastigmine 3 mg
61905713|NCT03523598|EXPERIMENTAL|Placebo Gel + Potassium Nitrate Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the Potassium nitrate toothpaste (Sensodyne).
61905714|NCT03523598|EXPERIMENTAL|Potassium Nitrate Gel + Normal Toothpaste|The patient will receive the application of 5% Potassium nitrategel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
62288547|NCT01030692|ACTIVE_COMPARATOR|Rivastigmine 6 mg|Rivastigmine 6 mg
62288548|NCT01030692|ACTIVE_COMPARATOR|Huperzine A 0.4 mg|Huperzine A 0.4 mg
62090191|NCT02471846|EXPERIMENTAL|Biopsy Cohort A|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive GDC-0919 during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
62288549|NCT01030692|ACTIVE_COMPARATOR|Huperzine A 0.8 mg|Huperzine A 0.8 mg
62654780|NCT05156008|OTHER|Group B|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by ultrasound guided vascular access under strict aseptic measures. With or without tourniquet applied on upper arm operator will prescan vasculature of arm to choose applicable vein. After disinfection of skin optimal vein is on plain part of arm and cannula must not end in flection (elbow, wrist) of arm.~Medical staff will note:~* number of attempts, if 2 attempts fail, another operator will perform insertion~* time to obtain vascular access~* diameter of vein~* type of cannula~* DIVA score"
62654781|NCT00797563|OTHER|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system (BGMS) Apollo Blood Glucose Monitoring System with capillary blood; healthcare professionals use the new BGMS with subject capillary and venous blood.
62654782|NCT04465422|EXPERIMENTAL|Intervention Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~The research at this stage is based on the theoretical framework of the MOHO model and the clinical practice of OTPF-3. Clinical experts are requested to assist in providing relevant suggestions as a reference for modifying intervention activities. Design OT@tcpc service model for occupational therapy intervention activities. The event design is based on the 4 systems of determinationl, habits, performance and environment, and 2 events are designed for each to be carried out in a group. Each activity includes 4 parts: warm-up, activity, feedback and homework. Each activity group will be explained separately so that the occupational therapist of the group can complete it under the guidance."
62654783|NCT04465422|ACTIVE_COMPARATOR|Control Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~This study was approved by the Institutional Review Board of Taipei City Hospital. After informed consent, the patients signed the consent form for this study and became the participant of this study.~Each activity group will be explained separately so that the participants of each group can complete it under the guidance. The group description includes: activity title, activity time (location), MOHO theory system, group purpose, activity content, equipment or materials, precautions, etc."
62654784|NCT01782092||Chiropractic & Diabetes|All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.
62654785|NCT01582451|EXPERIMENTAL|LY2605541|Administered by subcutaneous (SQ) injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications (OAMs) whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
62654786|NCT01582451|ACTIVE_COMPARATOR|Insulin glargine|Administered by SQ injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG. Insulin glargine will be used alone or in combination with up to 3 pre-study OAMs whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
62654787|NCT01207960|ACTIVE_COMPARATOR|EMDR|Eye Movement Desensitization and Reprocessing
62654788|NCT01207960|NO_INTERVENTION|WLC|Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
62654789|NCT02787304|EXPERIMENTAL|SHP626 5 Milligram (mg)|Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
62654790|NCT02787304|EXPERIMENTAL|SHP626 10 Milligram (mg)|Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
62654791|NCT02787304|EXPERIMENTAL|SHP626 20 Milligram (mg)|Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
61905722|NCT05227092|EXPERIMENTAL|3D OPTIMIZED WMN MPRAGE|"* At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~* At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set."
62090192|NCT02471846|EXPERIMENTAL|Biopsy Cohort B|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive atezolizumab during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
62288550|NCT04796519|EXPERIMENTAL|Unilateral TKA|Unilateral total knee arthroplasty group (UTKA) consisted of patients who did not undergo a second TKA within 3 months of the first TKA
62288551|NCT04796519|EXPERIMENTAL|Bilateral TKA|bilateral total knee arthroplasty group (BTKA) were those who had a second TKA within 12 months after initial TKA
62288552|NCT03765593||Study group 1|Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.
62288553|NCT03765593||Study group 2|Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.
62288554|NCT03765593||Study group 3|Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.
62288555|NCT03765593||Control group|Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.
62288556|NCT02065544|EXPERIMENTAL|behavioral weight loss and exercise|weight loss and exercise lifestyle intervention over a 6 month period
62654792|NCT02787304|PLACEBO_COMPARATOR|Placebo (PBO)|Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
62654793|NCT04103008||Group A|single coronary artery lesion
62654794|NCT04103008||Group B|multiple coronary artery lesions
62654795|NCT04132713||Control group|20 healthy volunteers were included in the healthy control group
62288557|NCT00723684|PLACEBO_COMPARATOR|Placebo group|This group will receive no real EEG-Neurofeedback.
62288558|NCT00723684|EXPERIMENTAL|NF group|This group will receive real EEG-Neurofeedback
62288559|NCT00750984|EXPERIMENTAL|1|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
62288560|NCT00750984|ACTIVE_COMPARATOR|2|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
62288561|NCT04880122|EXPERIMENTAL|Nursing home residents/staff members|Matched venous blood/dried blood spots collection in a single arm.
62288562|NCT05750472||Neck Pain Group|group evaluated with scales
62288563|NCT05750472||Healthy Group|group evaluated with scales
62288564|NCT05650021|OTHER|SpaceOAR Vue and fiducial marker|After enrollment, patients will be treated per the standard of care, including the use of daily CBCT for image guided radiotherapy. The investigator will review the CBCT on the first day of treatment and align in such a way that the fiducials match up but also that the radio-opaque SpaceOAR lines up to within 5mm. If the SpaceOAR does not line up to within 5mm, the investigator will consider an intervention such as having the patient get off the table to pass gas, have a bowel movement, additional counseling about diet and bowel movement habits, or potentially even re-simulation. These daily CBCT images are aligned to the CT simulation images by way of aligning the fiducial markers on the respective imaging data sets. The CBCT images acquired during their first five fractions of radiotherapy will be imported into MIM software.
62288565|NCT00883883|EXPERIMENTAL|1|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
62288566|NCT00883883|ACTIVE_COMPARATOR|2|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
62288567|NCT05495347||Registry of patients|
62654796|NCT04132713||Disease group|30 patients with advanced breast cancer developed hand-foot syndrome after capecitabine administration
62654797|NCT04098835|EXPERIMENTAL|ASCEND|ASCEND combines computer-based cognitive training exercises, homework exercises to enhance cognition, and coaching sessions delivered in-person and via telephone/videoconference by a neuropsychologist. ASCEND includes 24 total computer training sessions of 30 minutes each, for a total of 12 hours. ASCEND includes 8 coaching sessions of 45 minutes each. The computer exercises aim to improve attention, working memory (WM), and cognitive control through a series of engaging and interactive computer games (e.g., card games, driving simulation). The homework exercises and coaching sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to daily life and to develop further strategies to compensate for attention and WM difficulties in daily life.
62288568|NCT00563147|EXPERIMENTAL|A|tivozanib (AV-951) plus temsirolimus
62654798|NCT02213783|ACTIVE_COMPARATOR|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 2-5 days
62654799|NCT02213783|EXPERIMENTAL|Extended infusion arm|Infusion of 0.5 g of imipenem for 4 hr every 6 hr for 2-5 days
62090193|NCT02471846|EXPERIMENTAL|Dose-Escalation Cohort(s)|Approximately 6 to 65 participants will be enrolled and treated at escalating doses of GDC-0919 in combination with fixed-dose atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio. Successive groups of at least 3 participants will be evaluated during a 21-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage. The MTD or MAD, whichever is reached first, will be considered for the expansion stage.
62288569|NCT01245088|EXPERIMENTAL|chondroitin sulfate|400 mg (one table) TID
62288570|NCT04211129|EXPERIMENTAL|acupuncture group|Receiving acupuncture and moxibustion
62288571|NCT04211129|SHAM_COMPARATOR|sham acupuncture group|Receiving sham acupuncture and sham moxibustion
62288572|NCT01105637|OTHER|Exercise|
62288573|NCT02184637|EXPERIMENTAL|Cohort 1- TQ w/DHA+PQP|Tafenoquine (TQ) will be co-administered with Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) on Day 1. DHA+PQP alone will be administered at 24 hours (h) (Day 2) and 48 h (Day 3) post first dose administration.
62654800|NCT06036472|EXPERIMENTAL|Subgingival therapy|Participant will receive standard periodontal treatment consisting of two sessions of supra- and subgingival debridement (steps 1 and 2) under local anesthesia following current guidelines for periodontal therapy in patients with periodontitis (Herrera et al., 2022; Sanz et al., 2020). The use of chlorhexidine (0.12%) and cetylpyridinium chloride (0.05%) mouthwash will be prescribed twice a day for 15 days (Perio-Aid®, Dentaid, Barcelona, Spain). If needed, hopeless teeth might be extracted during this step.
62288574|NCT02184637|EXPERIMENTAL|Cohort 2 - TQ w/AL|Tafenoquine co-administered with Artemether + Lumefantrine (AL) on Day 1. AL alone will be administered at 8h (Day 1), 24h and 36h (Day 2), 48h and 60 h (Day 3) post first dose administration.
62654801|NCT06036472|OTHER|Supragingival therapy|Periodontal treatment consisting of two sessions of supragingival debridement with anesthesia (step 1) and administration of a placebo mouthwash (FluorAid®, Dentaid, Barcelona, Spain), twice a day for 15 days.
62090194|NCT02471846|EXPERIMENTAL|Expansion Cohorts|Approximately 160 participants (40 per diagnosis) with NSCLC, RCC, TNBC, and UBC will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with Atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
62288575|NCT02184637|EXPERIMENTAL|Cohort 3 - DHA+PQP alone|Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration
62288576|NCT02184637|EXPERIMENTAL|Cohort 4 - AL alone|Artemether + Lumefantrine will be administered on Day 1 and 8h, 24 and 36h (Day 2), 48h and 60 h(Day 3) post first dose administration
62654802|NCT06251947|EXPERIMENTAL|experimental group|Efbemalenograstim Alfa should be administered subcutaneously, 20mg per injection, within 24-48 hours after the completion of each chemotherapy cycle.
62654803|NCT05617365|EXPERIMENTAL|Treatment|All subjects in the Treatment group will receive OMT a minimum 4 times and a maximum of 8 times at the physician's (JJR) discretion (Jull et al., 2002). All subjects in the Treatment group will be taught the THE. This voluntary head retraction/protrusion exercise protocol engages the RCPm muscles in eccentric and isometric contractions that should strengthen the muscles and thereby increase CSA.
62654804|NCT05617365|NO_INTERVENTION|Control|All subjects assigned to the Control group will be allowed to continue to receive conservative care. It is understood that any care that they receive will be prescribed on an individual basis. A participant could therefore receive any combination of medical, physio therapeutic and psychological care. It would also be expected that some form of pain management will be a priority for participants with moderate to severe symptoms. Subjects assigned to the Control group will not receive OMT and will not be taught the THE protocol.
62654805|NCT02239432||Suspected Adenocarcinoma of the Lung|Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
62654806|NCT02239432||Healthy Control|Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
62090195|NCT00884819|EXPERIMENTAL|1|fenofibrate 200mg/daily for 6 months
62090196|NCT00884819|PLACEBO_COMPARATOR|2|Placebo match for 6 months
62090197|NCT05685680|ACTIVE_COMPARATOR|Group A laparoscopic group|group A laparoscopic surgery
62090198|NCT05685680|ACTIVE_COMPARATOR|Group B|Group B open surgery
62288577|NCT02184637|EXPERIMENTAL|Cohort 5 - TQ alone|A single dose of Tafenoquine will be administered on Day 1
62288578|NCT04187235||Keyhole rapair|74 patients who undervent parastomal hernia repair with keyhole technique 1997-2009
62288579|NCT04187235||Sugarbaker repair|61 patients who undervent parastomal henia repair a.m. Sugarbaker 2009-2015
62654807|NCT02239432||Age-matched controls with proven solid lung malignancy|Patients with biopsy-proven advanced solid malignancy of the lung
62654808|NCT01762787|ACTIVE_COMPARATOR|Effect of Aspirin|Positive control as previously used in the cantharidin blister experimental model of inflammation
62654809|NCT01762787|EXPERIMENTAL|Effect of steroid - Prednisolone|Prednisolone selected as steroids should provide the most robust positive control anti-inflammatory therapy
62654810|NCT01762787|EXPERIMENTAL|Cantharidin exposure to optimise blister formation|Cantharidin exposure to optimise blister formation
62090199|NCT05440799|EXPERIMENTAL|BI 1819479|
62090200|NCT05440799|PLACEBO_COMPARATOR|Placebo|
62654811|NCT02339636||case group|100 patients with vulgaris psoriasi without arthritis
62654812|NCT02339636||control group|100 age-matched patients with other skin diseases without arthritis
62090201|NCT06163716|NO_INTERVENTION|Regular health advice control (RHA) group.|Participants randomized to the control group followed preventive programs already ongoing at their Primary Care Unit regarding physical activity, socialization, and smoking and alcohol usage. Visits to the GP and nurse depended on personal demands and necessities; nevertheless, annual consultation was recommended for all patients over 60 years old.
62288580|NCT01813994|PLACEBO_COMPARATOR|Control group|Without simvastatin
62288581|NCT01813994|EXPERIMENTAL|Statin group|With simvastatin
62654813|NCT00649688|EXPERIMENTAL|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
62090202|NCT06163716|EXPERIMENTAL|Multidomain intervention (MD-Int) group|The MD-Int program was designed to provide tools and routines that participants could incorporate into daily living activities and reinforce the social environment. Although the program included standardized guidelines and exercises, each participant was considered individually, adapting nutritional requirements and physical and cognitive activity according to individual needs and abilities. This methodology is based on the FINGER trial design but has been adapted to local resources and the healthcare system. GPs and nurses were involved in the follow-up visits. Most intervention activities were carried out at the local Primary Care Centre. Local town hall resources such as group activities for older adults at the municipality sports centre and current outdoor sports activities were incorporated in the study.
62090203|NCT05039424|ACTIVE_COMPARATOR|Endoscopic per-oral pyloromyotomy (POP)|Participants will undergo Endoscopic per-oral pyloromyotomy (POP).
62090204|NCT05039424|SHAM_COMPARATOR|Sham / Control Arm|Participants will undergo a diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption. Following the 12-week blinded trial period, these participants will be unblinded and offered Endoscopic per-oral pyloromyotomy (POP) if they remain symptomatic.
62090205|NCT05742724|EXPERIMENTAL|THC/CBD|Oral THC 0.1mg/kg and CBD 2.5mg/kg
62090206|NCT00293462|ACTIVE_COMPARATOR|Arm I: GM-CSF Group (GG)|Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
62090207|NCT00293462|ACTIVE_COMPARATOR|Arm II: Salt & Soda Group (SS)|Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
62090208|NCT00293462|ACTIVE_COMPARATOR|Arm III: Salt & Soda Switched to GM-CSF (SG)|Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
62654814|NCT00649688|ACTIVE_COMPARATOR|2|Lopressor HCT® Tablets 100/50 mg
62654815|NCT03582683|EXPERIMENTAL|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
62090209|NCT06263257|EXPERIMENTAL|Intervention Group|For the intervention group, the first measurement (afternoon of the day before surgery) will include State-Trait Anxiety Inventory and General Comfort Questionaire, the second measurement (Postoperative Day 5 - discharge day) will include State Anxiety Inventory and General Comfort Questionaire. The sessions of the Mandala Art Therapy training program for the intervention group will be conducted as follows: Session 1 on Postoperative Day 5 - discharge day (after the scales), Session 2 on 1st Control (1 week after surgery), Session 3 on 2nd Control (2 weeks after surgery), and the third measurement at 3rd Control (1 month after surgery).
62090210|NCT06263257|NO_INTERVENTION|Control Group|"After obtaining consent from eligible participants within the scope of the study, the first measurement (STAI and GCQ) will be conducted on the afternoon of the preoperative day. Participants in this group will not be aware of their group assignment. The second measurement will be taken on postoperative day 5, the day of discharge (SAI and GCQ).~The third measurement will be carried out during the participant's 3rd check-up after discharge (one month after surgery) for both STAI and GCQ. The intervention group's program will be shared with the control group participants on a voluntary basis after their discharge."
62288582|NCT01027117|ACTIVE_COMPARATOR|Treatment A|Revatio 20 mg intact tablet. This is the reference treatment arm.
62288583|NCT01027117|EXPERIMENTAL|Treatment B|Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce.
62654816|NCT03582683|ACTIVE_COMPARATOR|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
62654817|NCT01710423|EXPERIMENTAL|Immediate Intervention|Peer mentoring intervention ('Cooking with Friends')
62654818|NCT01710423|NO_INTERVENTION|Delayed Entry Control|
62288584|NCT01027117|EXPERIMENTAL|Treatment C|Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP).
62288585|NCT00657384|EXPERIMENTAL|acid tranexamic|acid tranexamic
62288586|NCT00657384|PLACEBO_COMPARATOR|2|Nacl 0.9%
62288587|NCT01670994|EXPERIMENTAL|ALT-801 0.04mg/kg|
62288588|NCT01670994|EXPERIMENTAL|ALT-801 0.06mg/kg|
62654819|NCT04342169|EXPERIMENTAL|HCQ|Participants randomized to the HCQ arm will receive HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days. The drug dose (2.4 gm over 5 days) falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of \>20.
62654820|NCT04342169|PLACEBO_COMPARATOR|Placebo|Those randomized to placebo will receive a placebo to be taken on the same schedule.
62654821|NCT02873663|EXPERIMENTAL|heavy drinkers|Plasma and head hair collection
62654822|NCT02873663|EXPERIMENTAL|teetotalers|Plasma and head hair collection
62090211|NCT05123274|ACTIVE_COMPARATOR|Individual Care Counseling|After completing the baseline survey, each participant will receive a 20-minute individual counseling session focused on HIV medical care. The session will convey that effective HIV treatment is now available at no cost, protects health, and that most individuals who are in treatment can lead long and healthy lives. Referral will be made and assistance provided in accessing LGBT-friendly HIV medical care, mental health, substance abuse, and other services.
62654823|NCT04639882|EXPERIMENTAL|Control-Remote-$0|"In this condition, Participants:~* receive attention control feedback~* complete the baseline and intervention procedure remotely~* are compensated $0 for completing the baseline and intervention procedure"
62654824|NCT04639882|EXPERIMENTAL|Control-Remote-$30|"In this condition, Participants:~* receive attention control feedback~* complete the baseline and intervention procedure remotely~* are compensated $30 for completing the baseline and intervention procedure"
62654825|NCT04639882|EXPERIMENTAL|Control-InPerson-$0|"In this condition, Participants:~* receive attention control feedback~* complete the baseline and intervention procedure in the research lab~* are compensated $0 for completing the baseline and intervention procedure"
62654826|NCT04639882|EXPERIMENTAL|Control-InPerson-$30|"In this condition, Participants:~* receive attention control feedback~* complete the baseline and intervention procedure in the research lab~* are compensated $30 for completing the baseline and intervention procedure"
62654827|NCT04639882|EXPERIMENTAL|PNF-Remote-$0|"In this condition, Participants:~* receive personalized normative feedback~* complete the baseline and intervention procedure remotely~* are compensated $0 for completing the baseline and intervention procedure"
62090212|NCT05123274|EXPERIMENTAL|Social Support Mobilization|In addition to the post-baseline 20-minute individual counseling session, each participant in this arm will attend five main intervention sessions and two booster sessions that have three inter-related objectives: (1) ensuring that participants understand that viral suppression through ART maintains health and protects others; (2) increasing resilience and feelings of self-worth; and (3) guiding participants in identifying, accessing, and mobilizing social resources for both general psychosocial support and also specific supports for HIV care. For individuals who have potential supports in their social environment, the intervention will seek to mobilize or increase the frequency and quality of interactions with them. For participants who are presently socially isolated or whose social resources are not supportive of HIV care, the intervention will help to build new social ties with potentially supportive life figures.
62654828|NCT04639882|EXPERIMENTAL|PNF-Remote-$30|"In this condition, Participants:~* receive personalized normative feedback~* complete the baseline and intervention procedure remotely~* are compensated $30 for completing the baseline and intervention procedure"
62654829|NCT04639882|EXPERIMENTAL|PNF-Inperson-$0|"In this condition, Participants:~* receive personalized normative feedback~* complete the baseline and intervention procedure in the research lab~* are compensated $0 for completing the baseline and intervention procedure"
62090213|NCT05518123|EXPERIMENTAL|Rimegepant 75 mg|
62090214|NCT05518123|PLACEBO_COMPARATOR|Placebo|
62090215|NCT04581239|ACTIVE_COMPARATOR|Active neural mobilization|Therapist supervised active neural mobilization of sciatic nerve in lumber radiculopathy patients
62090216|NCT04581239|EXPERIMENTAL|passive neural mobilization|Therapist done passicive neural mobilization of sciatic nerve in lumber radiculopathy patients
62090217|NCT04311073|EXPERIMENTAL|Tranexamic Acid|Patients will receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline 15 minutes prior to initial surgical incision time
62090218|NCT04311073|PLACEBO_COMPARATOR|Placebo|Patients will receive an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision
62654830|NCT04639882|EXPERIMENTAL|PNF-Inperson-$30|"In this condition, Participants:~* receive personalized normative feedback~* complete the baseline and intervention procedure in the research lab~* are compensated $30 for completing the baseline and intervention procedure"
62288589|NCT02567448|ACTIVE_COMPARATOR|COPD Group|Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
61905728|NCT02204124|ACTIVE_COMPARATOR|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
61905729|NCT02204124|EXPERIMENTAL|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
62090219|NCT06517758|EXPERIMENTAL|Iptacopan|Iptacopan orally for 6 months (double-blind) followed by open-label iptacopan for an additional 24 months
62090220|NCT06517758|PLACEBO_COMPARATOR|Matching Placebo|Placebo orally for 6 months (double-blind) followed by open-label iptacopan for 24 months
62090221|NCT03904082|ACTIVE_COMPARATOR|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4 vertebral level will performed preoperatively to patients in the ESP group (Group I).
62090222|NCT03904082|ACTIVE_COMPARATOR|Serratus Anterior Plane Block Group (SAP)|Single- shot ultrasound (Esaote Mylab30 )guided SAP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) the T4 vertebral level will performed preoperatively to patients in the SAP group( Group II).
62288590|NCT02567448|ACTIVE_COMPARATOR|Normal Control Group|Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.
62090223|NCT03904082|PLACEBO_COMPARATOR|Control Group|The Control group receive no intervetion ( Group III).
62090224|NCT02900027|EXPERIMENTAL|IONIS-APOC-III-LRx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
62288591|NCT05709808|EXPERIMENTAL|Mixed group|"This taping technique is designed to guard against lateral ankle sprains. Kinesio-tape will be applied to the unstable ankle for a lateral ankle sprain. 4 strips of the tape with different stretching percentages will be applied while the ankle joint in a relaxed position.~ankle exercises will be conducted for 8 weeks, 3 times/ week, each session will last for 60 minutes.~A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed."
62654831|NCT04649424|EXPERIMENTAL|CanSwab - 1st|CanSwab will be swabbed first
62654832|NCT04649424|EXPERIMENTAL|CanSwab - 2nd|CanSwab will be swabbed second.
61905732|NCT03126344|EXPERIMENTAL|King Vision video laryngoscope|
61905733|NCT03126344|EXPERIMENTAL|McGrath MAC video laryngoscope|
61905734|NCT03126344|ACTIVE_COMPARATOR|Macintosh|
61905735|NCT05364333|SHAM_COMPARATOR|Sham RIPC|Control patients will be submitted to 3 cycles of sham RIPC. Each cycle of Sham RIPC consists of a pseudo ischemia of the left upper limb caused by inflating a blood pressure cuff to 20mmHg for 5 minutes followed by 5 minutes of reperfusion time.
61905736|NCT05364333|EXPERIMENTAL|RIPC|Patients in the intervention group will be submitted to 3 cycles of RIPC. For each cycle of RIPC, a blood pressure cuff will be inflated at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time.
62288592|NCT05709808|ACTIVE_COMPARATOR|Exercise group|received exercises and proprioceptive training similar as described in the experimental group
62288593|NCT05709808|EXPERIMENTAL|Kinesio-tape group|will receive Kinesio-tape only as described in the mixed group This taping technique is designed to guard against lateral ankle sprains. Kinesio-tape will be applied to the unstable ankle for a lateral ankle sprain. 4 strips of tape with different stretching percentages will be applied while the ankle joint in a relaxed position.
62288594|NCT05434884|EXPERIMENTAL|OV group|Patients will receive occlusal veneer restorations
61905737|NCT02710955|EXPERIMENTAL|Thickened infant formula|
62288595|NCT05434884|EXPERIMENTAL|EN group|Patients will receive endocrown restorations
62090225|NCT02900027|PLACEBO_COMPARATOR|Placebo (Normal Saline)|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
62288596|NCT06180850||Cases|Participants with lipedema
62090226|NCT02213679|EXPERIMENTAL|Guanidinoacetic acid|Supplementation with dietary guanidinoacetic acid
62090227|NCT02213679|PLACEBO_COMPARATOR|Placebo|Supplementation with cellulose
62090228|NCT02152436||Before simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured before simulation-based curriculum
62090229|NCT02152436||After simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured after simulation-based curriculum
62288597|NCT06180850||Controls|Participants without lipedema
62288598|NCT03261115|NO_INTERVENTION|Control group|Topical Anesthesia
62288599|NCT03261115|EXPERIMENTAL|Study group|No topical anesthesia
62288600|NCT01571479|NO_INTERVENTION|2-mm mini-instrument (M-LC)|M-LC is three-port laparoscopic cholecystectomy using a 2-mm mini-instrument.
62288601|NCT01571479|NO_INTERVENTION|conventional instrument(C-LC)|C-LC is conventional three port laparoscopic cholecystectomy
62288602|NCT03761329|ACTIVE_COMPARATOR|Bier's block|Upperarm intravenous regional anesthesia (Bier's block) with lidocaine 0.5% 40ml
62288603|NCT03761329|EXPERIMENTAL|Mini-Bier's block|Forearm intravenous regional anesthesia (mini-Bier's block) with lidocaine 0.5% 25ml
62288604|NCT01124565|EXPERIMENTAL|RT001|RT001 (Botulinum Toxin Type A) Topical Gel
62288605|NCT01184690|ACTIVE_COMPARATOR|Single-operator DBE|Single-operator double-balloon endoscopy
62288606|NCT01184690|ACTIVE_COMPARATOR|Dual-operator DBE|Dual-operator double-balloon endoscopy
62288607|NCT01916278|EXPERIMENTAL|Emervel Lips Lidocaine|
62090230|NCT03213041|EXPERIMENTAL|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
62090231|NCT00714233|EXPERIMENTAL|1|Metformin
62288608|NCT01916278|EXPERIMENTAL|Juvéderm Volbella with Lidocaine|
62288609|NCT04485455|EXPERIMENTAL|iTBS Therapy|Teenage participants with depression will receive iTBS therapy using a Transcranial Magnetic Stimulation (TMS) protocol delivering electro-magnetic stimulation
61905743|NCT04371302||Intensive Care Unit nurses|Nurses working in the Intensive care Unit of an exclusive Covid-19 hospital in Malaysia, during the Covid-19 pandemic
61905744|NCT01980485|ACTIVE_COMPARATOR|Feedback on lung age and exhaled carbon monoxide|
61905745|NCT01980485|SHAM_COMPARATOR|No lung age feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
62090232|NCT00714233|EXPERIMENTAL|2|Oral Contraceptive Pills
62090233|NCT00714233|ACTIVE_COMPARATOR|3|lifestyle modification program
62090234|NCT00714233|PLACEBO_COMPARATOR|4|placebo to active metformin arm
62090235|NCT03772314|ACTIVE_COMPARATOR|Modafinil|Participants in this study arm will take modafinil.
62090236|NCT03772314|EXPERIMENTAL|Amphetamine-dextroamphetamine|Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).
62090237|NCT01092624|EXPERIMENTAL|Pessary and solifenacin|
62090238|NCT01092624|PLACEBO_COMPARATOR|Pessary and placebo|
62090239|NCT04116320|EXPERIMENTAL|Cohort 1, primary regimen (Regimen 1a)|FUSA therapy and standard of care PD-1 blockade. FUSA therapy will be administered on day 8.
62090240|NCT04116320|EXPERIMENTAL|Cohort 1, secondary regimen (Regimen 2a)|FUSA therapy, standard of care PD-1 blockade, and intratumoral poly-ICLC will be administered on day 8.
62288610|NCT02660125|ACTIVE_COMPARATOR|endometrial scratch injury|endometrial scratch done before ICSI cycle
62288611|NCT02660125|NO_INTERVENTION|control|IcSI cycle without prior endometrial injury
62288612|NCT00643630|EXPERIMENTAL|1|Twice daily topical application
62288613|NCT00643630|PLACEBO_COMPARATOR|2|Twice daily topical application
62288614|NCT03628027|EXPERIMENTAL|Treatment Algorithm|The treatment algorithm arm will be the experimental arm in which GPs use the computerised decision support tool to guide their prescribing of antidepressants.
62288615|NCT03628027|NO_INTERVENTION|Treatment-as-usual|The treatment-as-usual arm will comprise GPs prescribing antidepressants and providing care as they typically would.
62288616|NCT01327755|EXPERIMENTAL|Selenium|
62288617|NCT01327755|PLACEBO_COMPARATOR|Placebo|
62288618|NCT01422954|ACTIVE_COMPARATOR|Chloroquine immunisation|This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
62090241|NCT04116320|EXPERIMENTAL|Cohort 2, primary regimen (Regimen 1b)|FUSA therapy will be administered on day 1.
62090242|NCT04116320|EXPERIMENTAL|Cohort 2, secondary regimen (Regimen 2b)|FUSA therapy and intratumoral poly-ICLC will be administered on day 1.
62090243|NCT00801242|EXPERIMENTAL|Degarelix 240 mg / 80 mg|
62090244|NCT03471468|EXPERIMENTAL|kinetics of microparticles under chemotherapy|kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
62288619|NCT01422954|EXPERIMENTAL|Mefloquine immunisation|This group will receive mefloquine prophylaxis and infected mosquito-bites.
62288620|NCT01422954|PLACEBO_COMPARATOR|Mefloquine control|This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
62090245|NCT02055859|OTHER|single session radiosurgery|single session radiosurgery (gold standard)
62090246|NCT02055859|EXPERIMENTAL|multisession radiosurgery|multisession radiosurgery (3 fraction)
62090247|NCT00528190|EXPERIMENTAL|Itraconazole|Itraconazole 5mg/kg/day for 24 weeks
62090248|NCT00528190|PLACEBO_COMPARATOR|Placebo|Placebo/day for 24 weeks
62090249|NCT03109106|EXPERIMENTAL|PCT Arm|"oAntibiotic management includes use of a validated PCT algorithm in addition to clinical judgment, other laboratory values, and microbiological pathogen identification. Subjects will be enrolled and data collected prospectively in 2017.~Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge."
62090250|NCT03109106|NO_INTERVENTION|Control Group|Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
62090251|NCT05297123|EXPERIMENTAL|ATRA/arsenic Group|"ATRA 20mg 3 times a day for 8 weeks Arsenic can be given intravenously (ATO) or oral Realgar-Indigo naturalis formula(RIF) ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given) RIF 60 mg/kg/d for 8 weeks The total dose can be appropriately adjusted according to the side-effects of the drug. 4 weeks for 1 course. If the patient has obvious side effects, the treatment should stop for 2 weeks. Each patient will be received at least two courses.~Quality of life assessments are performed every 2 months. After the end of the course of treatment, the condition is mainly evaluated based on the platelet count and bone marrow smear. If the treatment is effective, the above regimen can be continued; if not, the study is withdrawn."
62090252|NCT01968005|PLACEBO_COMPARATOR|Placebo|Therapy with placebo
62090253|NCT01968005|EXPERIMENTAL|Etoreat®(Etodolac-Lidocaine Topical Patch)|Therapy with experimental drug
62090254|NCT05861089||vascular surgery candidates|End-tidal CO2 will be measured day before surgery. Post-operative cardiovascular and pulmonary complications will be monitored fron the hospital stay, or first 30 days.
62090255|NCT05282199|EXPERIMENTAL|IMT group|In the group of post-COVID patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
62288621|NCT02733029|EXPERIMENTAL|Sonazoid contrast|The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
62462991|NCT02441309|EXPERIMENTAL|A. Mifamurtide only|"Treatment Weeks 1-6 (post 1st biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 13-36:~Mifamurtide 2mg/m2, IV infusion, once/week."
62462992|NCT02441309|EXPERIMENTAL|B. Ifosfamide (Followed by Mifamurtide)|"Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
62462993|NCT02441309|EXPERIMENTAL|C. Ifosfamide + Mifamurtide|"Treatment Weeks 1-6:~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, each given at least 3 days apart, for 6 weeks.~Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, given at least 3 days apart, for 6 weeks. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
62462994|NCT03512366|EXPERIMENTAL|Desarsda's technique|"These patients wil be operated by the Desarda's technique without using any prosthetic mesh. A strip of external oblique aponeurosis will be used to strengthen the defect.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia~Intervention:~A strip will be separated from the upper leaf of the external oblique aponeurosis keeping its insertion and continuity with the muscle intact. This strip will be sutured with the inguinal ligament below and the muscle arch or conjoint tendon above behind the spermatic cord to form the new inguinal floor. Continuous non absorbable prolene 2-0 suture will be used to secure it to the inguinal ligament inferiorly , and will be secured superiorly to the internal oblique muscle using interrupted absorbable vicryl sutures."
62090256|NCT01449929|EXPERIMENTAL|dolutegravir 50mg once daily (OAD)|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
62288622|NCT02733029|NO_INTERVENTION|Medical Review|Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
62288623|NCT04828863||Index subjects|25 young adults with MSUD who are 21 years and older.
62288624|NCT04828863||Control subjects|25 age-matched siblings or acquaintances who do not have MSUD and are 21 years and older
62654833|NCT02747927|PLACEBO_COMPARATOR|Placebo|Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0).
62654834|NCT02747927|EXPERIMENTAL|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received TDV, SC injection, based on the randomization on Day 1 (Month 0).
62090257|NCT01449929|ACTIVE_COMPARATOR|darunavir 800mg OAD in combination with ritonavir 100mg OAD|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
62288625|NCT04901572|OTHER|QART Imaging|"Cells will be individually selected with the system's micromanipulator under bright-field imaging. The cells will be representative of the cell population to be selected in ICSI procedures, covering the entire range of human sperm cell dimensions. Each selected cell will be simultaneously imaged by the QART system in two modalities:~1. Standard brightfield.~2. QART's imaging methodology."
62288626|NCT00797420|OTHER|Loading Dose|Loading Dose
62288627|NCT00797420|OTHER|Loading & high dose|Loading dose \& high dose Fluconazole
62288628|NCT03242954|ACTIVE_COMPARATOR|Adolescents: Consent Condition 1|Autonomous minor consent
62288629|NCT03242954|ACTIVE_COMPARATOR|Adolescents: Consent Condition 2|Adult permission required
62654835|NCT04132219|EXPERIMENTAL|Immediate Intervention Group|"Dyads randomized to the Immediate Intervention Group will receive a Welcome Box at completion of the baseline assessment. The Welcome Box will include two of each of the following: 1) Letters describing the project logistics and the important roles of each dyad member); 2) WiFi-enabled Scales (with instructions to weigh daily); 3) Portion Doctor ®Tableware (with instructions to use the portion plates at least once a day); 4) Fitbit® Inspire Activity Monitors (with instructions to share data with the dyad member and the study office); and 5) Instructions on how to create a secured account on the DUET website and instructions for logging on."
62288630|NCT03242954|ACTIVE_COMPARATOR|Adolescents: Consent Condition 3|Parental permission required
62288631|NCT03242954|ACTIVE_COMPARATOR|Parents: Consent Conditions 1-3|Autonomous minor consent, adult permission required, and parental permission required
62288632|NCT04741373|PLACEBO_COMPARATOR|Group of health education|
62288633|NCT04741373|ACTIVE_COMPARATOR|Group of health education and rehabilitation exercise|
62288634|NCT04741373|EXPERIMENTAL|Group of health education,exercise and ONS|
62288635|NCT06546748||Mini-crush Stenting Group|
62288636|NCT06546748||Double kissing-crush Stenting Group|
62288637|NCT03012555||Sickle Cell Disease and Vitamin D deficiency|
62288638|NCT00342368|ACTIVE_COMPARATOR|1|CPAP through an helmet
62288639|NCT00342368|NO_INTERVENTION|2|O2 therapy with conventional face mask
62288640|NCT04704622|ACTIVE_COMPARATOR|dexmedetomidine group|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
62288641|NCT04704622|ACTIVE_COMPARATOR|ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
62288642|NCT04704622|ACTIVE_COMPARATOR|midazolam|midazolam intranasal injection,0.2 mg/kg, once, 30 min preoperative
62288643|NCT02790866|EXPERIMENTAL|LuCaS Decision Aid|Access to LuCaS, a web-based lung cancer screening decision aid
62288644|NCT02790866|ACTIVE_COMPARATOR|NCI Website|Access to NCI website on lung cancer screening
62288645|NCT03569202|EXPERIMENTAL|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
62288646|NCT03569202|ACTIVE_COMPARATOR|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
62090258|NCT06324955|ACTIVE_COMPARATOR|Common/Standard Language Group|
62462995|NCT03512366|ACTIVE_COMPARATOR|Lichtenstein's technique|"These patients will be operated using prosthetic mesh described as Lichtenstein's tension free mesh hernioplasty.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia.~Intervention :~A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring. Laterally, 2 cm silt will be made through the mesh to accommodate the cord. while the two tails will be sutured to create a new deep ring made of mesh."
62462996|NCT05007288|EXPERIMENTAL|RET Treated Eye Plus INhance Group|Participants randomized to receive the restorative eye treatment (RET) intervention on either the left or right eyelid will administer the RET cream on the eyelid daily for 4 consecutive weeks prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
62462997|NCT05007288|EXPERIMENTAL|RET Untreated eye Plus INhance Group|Participants randomized to not receive the RET intervention will not receive any intervention prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
62462998|NCT03583606|EXPERIMENTAL|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (2 x 10\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10\^11 vp) intramuscularly into the opposite arm on Day 8, n = 20
62090259|NCT06324955|EXPERIMENTAL|Positive Language Group|
62090260|NCT04317170|EXPERIMENTAL|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia.
62462999|NCT03583606|EXPERIMENTAL|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (2 x 10\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
62463000|NCT03583606|EXPERIMENTAL|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (2 x 10\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10\^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
62463001|NCT02377622|EXPERIMENTAL|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis
61905753|NCT04663490||simple acute diverticulitis|Ninety-one percent (n=295) were categorized as simple acute diverticulitis
62463002|NCT02377622|EXPERIMENTAL|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis
61905754|NCT04663490||complicated acute diverticulitis|9% (n=30) presented were categorized as complicated acute diverticulitis
62090261|NCT04317170|NO_INTERVENTION|No Music|Patients will undergo their routine procedure without being played music.
62090262|NCT00486915|ACTIVE_COMPARATOR|Left Atrial Appendage Exclusion|
62090263|NCT00486915|NO_INTERVENTION|Control|
62090264|NCT04925700|EXPERIMENTAL|Probiotic Lozenge|
62090265|NCT04925700|PLACEBO_COMPARATOR|Placebo Lozenge|
62090266|NCT03359681|ACTIVE_COMPARATOR|metformin hydrochloride|metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
62090267|NCT03359681|PLACEBO_COMPARATOR|placebo oral capsule|placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
62090268|NCT04088994|EXPERIMENTAL|pathological model|The children assigned to the experimental group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a model with a similar manipulation strategy but improved with respect to the child's current abilities.
62090269|NCT04088994|ACTIVE_COMPARATOR|Healthy model|The children assigned to the control group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
62090270|NCT01462201|EXPERIMENTAL|Group 1 - Non Invasive Ultrasound|Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
62090271|NCT01462201|EXPERIMENTAL|Group 2 - Non Invasive Ultrasound|Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
62090272|NCT05104931|EXPERIMENTAL|Nanoformed Piroxicam IR Tablet|orally delivered nanoformed piroxicam immediate release tablets (20mg)
62090273|NCT05104931|ACTIVE_COMPARATOR|Felden (piroxicam) Tablets|orally delivered Felden (piroxicam) tablets (20mg)
62090274|NCT05104931|ACTIVE_COMPARATOR|Brexidol (piroxicam) Tablets|orally delivered Brexidol (piroxicam) tablets (20mg)
62090275|NCT02829424|ACTIVE_COMPARATOR|Experimental group|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the control group and according to the Summary of Product Characteritics (SmPC) MTX: 15 mg a week orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX will be initiated within 7 days after the start of the anti TNF alpha agent
62090276|NCT02829424|PLACEBO_COMPARATOR|Control group|"Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent~All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the experimental group and according to the SmPC Placebo-MTX orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX-placebo will be initiated within 7 days after the start of the anti TNF alpha agent"
62288647|NCT00896532|PLACEBO_COMPARATOR|Placebo|"Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
62288648|NCT00896532|ACTIVE_COMPARATOR|Alendronate|"Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation."
62288649|NCT00896532|ACTIVE_COMPARATOR|Teriparatide|Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
62288650|NCT00896532|EXPERIMENTAL|Romosozumab 70 mg QM|"Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
62288651|NCT00896532|EXPERIMENTAL|Romosozumab 140 mg Q3M|"Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
62463003|NCT02377622|ACTIVE_COMPARATOR|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis
62463004|NCT02377622|ACTIVE_COMPARATOR|FX CorDiax 800 dialyzer|FX CorDiax 800 dialyzer in high volume hemodiafiltration
62090277|NCT01770860|ACTIVE_COMPARATOR|6660|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
62090278|NCT01770860|ACTIVE_COMPARATOR|4314|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
62090279|NCT01770860|ACTIVE_COMPARATOR|8336|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
62090280|NCT01770860|PLACEBO_COMPARATOR|4840|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
62090281|NCT01770860|NO_INTERVENTION|0000|"Device: 0000~At each daily visit, designated study personnel will cut out the center pad of the bandage and apply only the adhesive tabs around the assigned wound site.~Other Names:~* Sheer Strips~* BAND-AID® with QuiltVent™ Pad Technology~Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site."
62090282|NCT02404246|EXPERIMENTAL|Intervention Arm|Intervention evaluated the feasibility, acceptability, and effectiveness of a structured peer support intervention based on the Certified Peer Specialist Program of the Depression and Bipolar Support Alliance (DBSA).
62090283|NCT02404246|NO_INTERVENTION|Usual Care|Usual Care
62090284|NCT06697353||Study Cohort|Patients who initiated on-label use of vericiguat (i.e. patients treated with at least one HF therapy who initiated vericiguat with a starting dose of 2.5 mg). Adult patients with Heart Failure (HF) diagnosis code between March 2021 and July 2024, initiating vericiguat between September 2021 and July 2024, with HF diagnosis prior to index date, and with at least 180 days of observation prior to index date.
62090285|NCT06697353||Sub-Cohort a|"derived from the study cohort, and defined as: With (a1) /without (a2) recent worsening of HF (WHF). With recent WHF will be defined as HF hospitalization within 6 months or outpatient intravenous diuretic dispensation (Anatomical Therapeutic Chemical (Classification System) (ATC) codes C03 and receipt code) within 3 months.~Without recent WHF will be defined as no HF hospitalization for 6 months and no outpatient Intravenous (IV) diuretic use for 3 months"
62090286|NCT06697353||Sub-Cohort b|"derived from the study cohort, and defined as: Time from WHF event to vericiguat initiation. Within patients with recent WHF, patients will further be classified according to the timing from WHF event as: HF hospitalization in the previous 3 months, HF hospitalization in the previous 3-6 months, and outpatient IV diuretics (without HF hospitalization) in the previous 3 months.~Note that patients who have a record of hospitalization both in the previous 3 months and the previous 3-6 months will be classified in HF hospitalization in the previous 3-6 months."
62090287|NCT06697353||Sub-Cohort c|"derived from the study cohort, and defined as: With (c1)/without (c2) Angiotensin Receptor Neprilysin Inhibitor (ARNI). With ARNI will be defined as presence of prescription or dispensation of sacubitril/valsartan (ATC code C09DX04), within the 90 days prior to index date (exclusive).~Without ARNI will be defined as absence of prescription or dispensation of sacubitril/valsartan (ATC code C09DX04), within the 90 days prior to index date (exclusive)."
62090288|NCT06697353||Sub-Cohort d|"derived from the study cohort, and defined as: With (d1)/without SGLT2i (d2). With SGLT2i will be defined as presence of prescription or dispensation of dapagliflozin (ATC code A10BK01) and empagliflozin (ATC code A10BK03) within the 90 days prior to index date (exclusive).~Without SGLT2i will be defined as absence of prescription or dispensation of dapagliflozin (ATC code A10BK01) and empagliflozin (ATC code A10BK03) within the 90 days prior to index date (exclusive)."
62463005|NCT01976286|ACTIVE_COMPARATOR|Salicylic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
62463006|NCT01976286|ACTIVE_COMPARATOR|Glycolic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
62463007|NCT00822497|EXPERIMENTAL|1|Music-Based Imagery
62463008|NCT00822497|EXPERIMENTAL|2|Music Alternate Engagement
62463009|NCT00822497|NO_INTERVENTION|Control|Debridement under standard care with no music therapy interventions
62463010|NCT02750124|ACTIVE_COMPARATOR|HPV self sampling test sent|A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
62463011|NCT02750124|ACTIVE_COMPARATOR|HPV self sampling test ordered|An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
62463012|NCT02750124|ACTIVE_COMPARATOR|Nurse navigator contact|An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
62090289|NCT06697353||Sub-Cohort e|"derived from the study cohort, and defined as: Number of foundational therapies (i.e., ACEi, ARB, ARNI, ACEi/ARB, ACEi/ARB/ARNI, BB, MRA and SGLT2i). Presence/absence of each foundational therapy - ACEi (enalapril \[ATC code C09AA02\] and lisinopril \[ATC code C09AA03\]), ARB (candesartan \[ATC code C09CA06\]), ARNI (sacubitril-valsartan \[ATC code C09DX04\]), ACEi/ARB, ACEi/ARB/ARNI, BB (bisoprolol \[ATC code C07AB07\] and carvedilol \[ATC code C07AG02\]), MRA (spironolactone \[ATC code C03DA01\] and eplerenone \[ATC code C03DA04\]) and SGLT2i (dapagliflozin \[ATC code A10BK01\] and empagliflozin \[ATC code A10BK03\]) - will be assessed within the 90 days prior to index date (exclusive).~The number of foundational therapies present will be categorized by none, mono therapy, dual therapy, triple therapy, and quadruple therapy."
62090290|NCT06697353||Sub-Cohort f|derived from the study cohort and defined as: Age group. Age group will be categorized as \<65, 65 to \<75, and ≥75 years
62090291|NCT06697353||Sub-Cohort g|derived from the study cohort, and defined as: sex (will be categorized as male and female)
62090292|NCT06697353||Sub-Cohort h|"derived from study cohort and described as: Body mass index categories. Body mass index is defined as a person's weight in kilograms divided by the square of the person's height in meters (kg/m2), and will be categorized as underweight (\<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), pre-obesity (25.0-29.9 kg/m2), and obesity (≥30.0 kg/m2).~The body mass index value closest to the index date and prior to the index date will be used for this classification. If multiple body mass index values exist, the value closest to the index date will be used."
62090293|NCT06697353||Sub-Cohort i|derived from study cohort and described as: With chronic kidney disease (all; stage ≥3). With chronic kidney disease (CKD) will be defined by the presence of the N18 International Classification of Diseases, 10th revision (ICD-10 code( within 180 days prior to index date . A subset of CKD stage ≥3 will be identified with the N18.3-N18.5 ICD-10 codes.
62090294|NCT06697353||Sub-Cohort j|"derived from study cohort and described as: Up-titration level of vericiguat at 3 months. Up-titration level for vericiguat at 3 months of treatment will be categorized as vericiguat dosage: 2.5 mg, 5 mg, 10 mg or other dose.~Note that when patients' up-titration level has increased to the upper level within 3 months, unless the level at 3 month remains at the upper level, the patients will not be considered up-titrated."
62090295|NCT06697353||Sub-Cohort k|"derived from study cohort and described as: Adherent (k1) vs. non-adherent (k2) to vericiguat within 3 months. Adherence to vericiguat within 3 months of treatment will be defined as a medication possession ratio (MPR) of ≥80%.~Non-adherent to vericiguat within 3 months of treatment will be defined as MPR\<80% ."
62288652|NCT00896532|EXPERIMENTAL|Romosozumab 140 mg QM|"Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
62463013|NCT02750124|PLACEBO_COMPARATOR|Control|The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
62463014|NCT05915702|EXPERIMENTAL|Gadoquatrane - Approved Macrocyclic GBCA|Participants will receive one intravenous injection of gadoquatrane before or during MRI in Period 1, followed by one intravenous injection of any approved macrocyclic GBCA before or during MRI in Period 2.
62463015|NCT05915702|EXPERIMENTAL|Approved Macrocyclic GBCA - Gadoquatrane|Participants will receive one intravenous injection of any approved macrocyclic GBCA before or during MRI in Period 1, followed by one intravenous injection of gadoquatrane before or during MRI in Period 2.
62463016|NCT05494567|ACTIVE_COMPARATOR|Tadalafil / solifenacin combination therapy|Patients will be treated by combination of Tadalafil 5 mg + solifenacin 10 mg once daily for 12 weeks
62463017|NCT05494567|ACTIVE_COMPARATOR|Tamsulosin / solifenacin combination therapy|Patients will be treated by combination of Tamsulosin 0.4 mg + solifenacin 10 mg once daily for 12 weeks
62288653|NCT00896532|EXPERIMENTAL|Romosozumab 210 mg Q3M|"Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
62288654|NCT00896532|EXPERIMENTAL|Romosozumab 210 mg QM|"Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
62288655|NCT05038137|EXPERIMENTAL|Time restricted feeding|daily eating period of 8 hours, before 8 PM
62288656|NCT05038137|ACTIVE_COMPARATOR|Control|daily eating period ≥ 12 hours
62463018|NCT06165562|EXPERIMENTAL|Pressure Supporting Ventilation (PSV) and EEG-guided Emergence group|"Pressure support ventilation will be applied from the start of subcutaneous suture until extubation. At the end of surgery, sevoflurane will be discontinued, and the attending anesthesiologist will perform tracheal extubation after observing the 'zipper opening' pattern on the EEG spectrogram, indicating the patient's recovery of consciousness. For safety reason, extubation will also be guided by the following processed EEG indices thresholds:~1. 95% spectral edge frequency (SEF) ≥ 23~2. Patient state index (PSI) ≥ 64"
62463019|NCT06165562|ACTIVE_COMPARATOR|Conventional Emergence group|Conventional full-awake extubation will be performed based on the routine practice of our institution. At the end of surgery, sevoflurane will be stopped, and the attending anesthesiologist will lead the emergence process, allowing the patient to breathe spontaneously and providing intermittent manual assistance if necessary. Extubation will be performed when the patient meets the following criteria: obeys commands such as eye-opening or hand-grip, tidal volume \> 5 ml/kg, end-tidal carbon dioxide \< 45 mmHg, spontaneous respiratory rate 10 to 20 breaths/min.
62288657|NCT02532348||HIV Patients with antiretroviral therapy|Blood samples in HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors) and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load under 40 cp/ml.
62288658|NCT02532348||HIV patients without antiretroviral therapy|Blood samples in HIV patients never treated by antiretroviral therapy
62288659|NCT06296121|EXPERIMENTAL|BCD-264|"Blinded period: BCD-264 (daratumumab) will be administered intravenously once weekly for the first 8 weeks (Cycles 1 and 2), then once every two weeks for 16 weeks (Cycles 3, 4, 5 and 6). The total duration of the blinded treatment period is 6 cycles.~Open-label period: starting from Day 1 of Cycle 7, the subjects will receive open-label BCD-264 once every 4 weeks"
62288660|NCT06296121|ACTIVE_COMPARATOR|Darzalex|"Blinded period: Darzalex (daratumumab) will be administered intravenously once weekly for the first 8 weeks (Cycles 1 and 2), then once every two weeks for 16 weeks (Cycles 3, 4, 5 and 6). The total duration of the blinded treatment period is 6 cycles.~Open-label period: starting from Day 1 of Cycle 7, the subjects will receive open-label BCD-264 once every 4 weeks"
62288661|NCT01948830|ACTIVE_COMPARATOR|Group I ranibizumab 0.5 mg monthly|Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
62288662|NCT01948830|ACTIVE_COMPARATOR|Group II ranibizumab 0.5 mg TER|Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
62288663|NCT01220414|ACTIVE_COMPARATOR|Men|
62288664|NCT01220414|ACTIVE_COMPARATOR|Women|
62288665|NCT01302873|EXPERIMENTAL|BGG492|
62288666|NCT01302873|PLACEBO_COMPARATOR|Placebo|
62288667|NCT02491385|EXPERIMENTAL|TEA|thoracic epidural analgesia group
62288668|NCT02491385|ACTIVE_COMPARATOR|iv-PCA|intravenous patient controlled analgesia group
62288669|NCT00454493|ACTIVE_COMPARATOR|fish oil|
62288670|NCT00454493|PLACEBO_COMPARATOR|placebo|
62288671|NCT03844009|EXPERIMENTAL|Debriefing|Participant's of the debriefing group had a computer integrated debriefing at the end of each scenario of the computer-based simulator
62463020|NCT03358849|EXPERIMENTAL|experimental group|
62288672|NCT03844009|NO_INTERVENTION|No debriefing|Participant's of the debriefing group had no computer integrated debriefing at the end of each scenario of the computer-based simulator
62288673|NCT05123560||women attending first-trimester ultrasound|All women attending their first-trimester ultrasound and meeting the inclusion criteria will be invited to participate
62288674|NCT02317107||Concussion|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they receive a diagnosis of concussion, defined as a complex pathophysiological process affecting the brain, induced by biomechanical forces. If they agree to participate, they will be placed in the concussion group and assessed at each visit to the clinic. No intervention will be administered.
62288675|NCT02317107||Control|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they come to the clinic for an injury unrelated to brain function or a lower extremity function (which may affect normal gait patterns). If they agree to participate, they will be placed in the control group and assessed at each visit to the clinic. No intervention will be administered.
62288676|NCT02475889||RFA group|patients who received hepatic RFA followed by primary tumor resection were assigned to the RFA group
62288677|NCT02475889||Non-RFA group|patients who received initial primary tumor resection without RFA
62288678|NCT04384237|EXPERIMENTAL|Er,Cr:YSGG laser-aided CSF|Experimental: Er, Cr: YSGG laser-aided Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment of the orthodontic treatment by inserting the laser tip at an angle of 10-15º to the radicular surface
62463021|NCT01682083|EXPERIMENTAL|Dabrafenib and trametinib|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
62463022|NCT01682083|PLACEBO_COMPARATOR|Dabrafenib and trametinib placebos|Subjects received matching placebos orally for 12 months
62463023|NCT05918263|EXPERIMENTAL|Group A: 16-Week HIIT Exercise Program|"Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:~* Testing visits at Week 1, 9, and 19 for physical exams, physical fitness and function assessments, survey questionnaires, and cardiopulmonary fitness assessment.~* Virtual, aerobic training sessions three times weekly with trained oncology exercise specialist."
62288679|NCT04384237|ACTIVE_COMPARATOR|Conventional CSF|Fiberotomy comparator: this arm is going to receive a blade conventional Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment by inserting a surgical blade into the gingival sulcus at an angle like that in the laser-aided CSF.
62288680|NCT02718859|ACTIVE_COMPARATOR|irreversible electroporation (IRE)|Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy
62288681|NCT02718859|EXPERIMENTAL|IRE & NK cells|Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells
62288682|NCT05798052|OTHER|Low-High stress group|Complete the first simulated clinical scenario in the low stress condition, then complete the second simulated scenario in the high stress condition.
62288683|NCT05798052|OTHER|High-Low stress groups|Complete the first simulated clinical scenario in the high stress condition, then complete the second simulated scenario in the low stress condition.
62288684|NCT03346330|EXPERIMENTAL|TRK-750, single and multiple doses|
62288685|NCT03346330|PLACEBO_COMPARATOR|Placebo, single and multiple doses|
62288686|NCT05274646||E1784K (glu1784lys) in SCN5A expressing either Long QT syndrome type 3 or Brugada syndrome|
62288687|NCT05274646||E1784K (glu1784lys) in SCN5A expressing both syndromes (Long QT syndrome and Brugada syndrome)|
62288688|NCT04409704|EXPERIMENTAL|10 Hz|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 4-6 weeks
62288689|NCT00456690|EXPERIMENTAL|1|Thalassemia Mayor Patients
62288690|NCT00738816|OTHER|Intervention|Systematic medication review
62288691|NCT04029857|ACTIVE_COMPARATOR|Group I (standard of care)|Patients receive standard of care nutritional supplementation.
62288692|NCT04029857|EXPERIMENTAL|Group II (Impact Advanced Recovery)|Patients receive Impact Advanced Recovery PO or via feeding tube BID on days 1-7 for weeks 1, 3, and 5 during chemotherapy and radiation therapy before surgery. Starting 5-7 days before surgery, patients receive Impact Advanced Recovery PO TID until surgery. Within 2 days following surgery, patients may continue to receive Impact Advanced Recovery via feeding tube at the discretion of the treating physician.
62288693|NCT01552902|EXPERIMENTAL|Lisdexamfetamine dimesylate|
62288694|NCT01552902|ACTIVE_COMPARATOR|Methylphenidate Hydrochloride|
62678913|NCT03393975|EXPERIMENTAL|On Demand Cohort I|Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
62288695|NCT01552902|PLACEBO_COMPARATOR|Placebo|
62288696|NCT05876403|ACTIVE_COMPARATOR|Conventional|"The protocol for controlled group will consist of 35-60years old participants with moderate to severe COPD.~At baseline measurements will be collected and COPD assessment test (CAT) and Modified Borg Scale will be taken. Participants will then be made to perform breathing and aerobic exercises (3sessions per week) for 6 weeks and after every 2 weeks outcome measures will be evaluated using chest expansion, spirometry, and 6 minutes walk test (6MWT) along with CAT and Modified Borg Scale."
62288697|NCT05876403|EXPERIMENTAL|PNF Techniques|The same protocol will be followed for the 30 participants of experimental group where after the baseline measurements, participants will perform breathing and aerobic exercises along with PNF techniques (3 sessions per week for 6 weeks). The outcome Measures will be measured after every 2 weeks through Spirometry, CAT, Modified Borg Dyspnea Scale and 6 minutes walk test
62288698|NCT03189979|EXPERIMENTAL|Club Fit|Intervention includes exposure to physical activity and healthy eating intervention policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
62288699|NCT00434967|NO_INTERVENTION|4|Placebo
62288700|NCT00434967|ACTIVE_COMPARATOR|2|Candesartan cilexetil
62288701|NCT00434967|ACTIVE_COMPARATOR|3|Hydrochlorothiazide (HCT)
62288702|NCT00434967|EXPERIMENTAL|1|Candesartan cilexetil + Hydrochlorothiazide Combination
62288703|NCT03839108|ACTIVE_COMPARATOR|Paraffin wax group|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
62288704|NCT03839108|EXPERIMENTAL|Prolotherapy group|"Drug = prolotherapy (%15 dextrose solution) into hand joints~%15 dextrose solution will be injected into medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period."
62288705|NCT06031077||Cardiologist Assessed Conditions.|The consultant Cardiologist will decide on the various types of presentations and symptoms that will be use full in generating this study.
62090296|NCT06697353||Sub-Cohort l|"derived from study cohort and described as: Persistent (l1) vs. non-persistent (l2) to vericiguat within 3 months. Treatment discontinuation within 3 months of treatment will be identified by a gap of \>30 days between successive prescription records or between the last prescription record and the end of follow-up. Persistent within 3 months will be defined as no treatment discontinuation within 3 months of treatment.~Non-persistent within 3 months to vericiguat will be defined as treatment discontinuation within 3 months of treatment."
62288706|NCT05396209|ACTIVE_COMPARATOR|Hydrated Amniotic Membrane Plug|Patients suffering from refractory macular holes as documented by spectral-domain OCT will undergo pars plan vitrectomy with Hydrated Amniotic Membrane insertion into the macular hole.
62288707|NCT05396209|ACTIVE_COMPARATOR|ILM filling|The ILM filling technique, in which free ILM is plug into the macular hole area
62288708|NCT05396209|ACTIVE_COMPARATOR|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
62090297|NCT06697353||Sub Cohort m|derived from study cohort and described as: Index date categories. Patients will be classified according to the year of inclusion as follows: September 2021 to August 2022 vs. September 2022 to July 2024.
62090298|NCT06697353||Sub Cohort n|derived from the study cohort and described as: Discontinuing ARNI before initiating vericiguat. Patients with a prescription/dispensation of ARNI within the 90 days prior to index date (exclusive) and no prescription/dispensation of ARNI within the 90 days after the index date (inclusive).
62288709|NCT00788905|EXPERIMENTAL|A|"Subject will continue conventional hemodialysis therapy for one week (no intervention phase) and then swtich to the Allient system for two weeks (active comparator phase)."
62090299|NCT05323721|NO_INTERVENTION|Control - No SMC|This arm will not receive any SPAQ
62090300|NCT05323721|ACTIVE_COMPARATOR|Intervention SMC - SPAQ|This arm will receive SPAQ as seasonal malaria chemoprevention
62090301|NCT05323721|ACTIVE_COMPARATOR|Intervention SMC - SP|This arm will receive SP as seasonal malaria chemoprevention
62090302|NCT05611619|NO_INTERVENTION|Control|Single study night with no noise exposure, to determine normal baseline sleep
62090303|NCT05611619|EXPERIMENTAL|Study 1: High level continuous flow tyre noise (A1)|Single study night in first experimental study arm, with traffic noise to determine consequences of sleep disturbance by high level, continuous flow traffic noise. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
62288710|NCT02327260|EXPERIMENTAL|Video + MI for CR|This group receives the educational video and an MI session for CR participation.
62288711|NCT02327260|EXPERIMENTAL|MI for medication adherence|This group receives an MI session for taking prescribed cardioprotective medications.
62288712|NCT02327260|NO_INTERVENTION|Control group (standard care)|The control group receives standard care while hospitalized.
62288713|NCT06417554|EXPERIMENTAL|Treatment group A: SHR-A2102 + Adebrelimab injection|
62288714|NCT06417554|EXPERIMENTAL|Treatment group B: SHR-A2102|
62288715|NCT02254915|EXPERIMENTAL|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy (SHTC) with mitomycin C (RITE) intravesical therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
62288716|NCT02254915|ACTIVE_COMPARATOR|Bacillus Calmette-Guérin|Intravesical BCG therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
62288717|NCT05758090|EXPERIMENTAL|Group NIPE|Intraoperative fentanyl administration will be guided by NIPE protocol
62288718|NCT05758090|PLACEBO_COMPARATOR|Group Control|Intraoperative fentanyl administration will be guided by clinical signs
62288719|NCT01631669|EXPERIMENTAL|Celebrex|Receive Celebrex
62288720|NCT01631669|NO_INTERVENTION|Control|no placebo administered
62288721|NCT04336163|EXPERIMENTAL|Prospective Study Group|For the experimental group, the laser surgeon will be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on the measurements.
62288722|NCT04336163|OTHER|Prospective Control Group|For the control group, the laser surgeon will not be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on standard of care, intuition, and experience.
62288723|NCT03295214|ACTIVE_COMPARATOR|Acetaminophen 975mg Per Os|975mg of Acetaminophen given by mouth
62288724|NCT03295214|ACTIVE_COMPARATOR|Acetaminophen 1000mg Intravenous|1000mg of Acetaminophen given intravenously
62288725|NCT05586126||Sevoflurane|patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by using sevoflurane
62288726|NCT05586126||Control|patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by means of intravenous medication, such as propofol, midazolam, esketamine of fentanyl
62288727|NCT05316714|EXPERIMENTAL|IPP Nanofat Grafting|Nanofat surgical grafting in albuginea penile tunica
62288728|NCT03345056|OTHER|included cases|vitrectomy done with planned foveal separation and followed for the result
62288729|NCT05670626|OTHER|non comparative interventional study|patients with high refractive error will do phakic ICL after preoperative assessment of anterior segments parameters and post-operative ICL vault will be measured using pentacam
62288730|NCT06548841||SARS-CoV2 positive patients|Patients recruited at Personal Genomics (center based in Verona, partner of the European project ECLIPSE), retrospective cohort.
62288731|NCT06548841||SARS-CoV2 negative patients|Patients recruited at Personal Genomics (centre based in Verona), retrospective cohort.
62288732|NCT06548841||P. aeruginosa positive patients|Patients recruited at IRCCS Azienda Ospedaliero-Universitaria di Bologna, prospective cohort.
62288733|NCT06548841||P. aeruginosa negative patients|Patients recruited at IRCCS Azienda Ospedaliero-Universitaria di Bologna, prospective cohort.
62288734|NCT06548841||L. infantum positive patients|Patients recruited at IRCCS Azienda Ospedaliero-Universitaria di Bologna, retrospective and prospective cohort.
62288735|NCT06548841||L. infantum negative patients|Patients recruited at IRCCS Azienda Ospedaliero-Universitaria di Bologna, retrospective and prospective cohort.
62288736|NCT06018649|EXPERIMENTAL|Short ambulatory balneotherapy (SAB)|Group I will be given a complex of balneological procedures: swimming pool 20 min, 34-36° mineral/geothermal water procedure 20 min, sapropel wrapping 20 min, salt therapy 25 min. Duration of treatment - 6 days, outpatient.
62288737|NCT06018649|EXPERIMENTAL|Long ambulatory balneotherapy (LAB)|"Group II will be given a complex of balneological procedures as group I- swimming pool 20 min, 34-36° mineral/geothermal water procedure 20 min, sapropel wrapping 20 min, salt therapy 25 min.~Duration of treatment - 11 days, outpatient treatment."
62288738|NCT06018649|EXPERIMENTAL|Combined nature resources treatment (CNT)|"Group III will be given a complex of balneological procedures like groups I and II plus natural therapy procedure developed by the researchers: a 45-minute walk in nature (forest, seaside), a complex of simple strength and breathing low-intensity exercises, sensory impulses (landscape , forest smells - aromatherapy, natural sounds of nature, collecting nature's goodies (berries, pine cones, leaves, etc.), awareness therapy, heliotherapy.~Duration - 11 days., outpatient treatment."
62090304|NCT05611619|EXPERIMENTAL|Study 1: Medium level continuous flow tyre noise (B1)|Single study night in first experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level, continuous flow traffic noise. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
62090305|NCT05611619|EXPERIMENTAL|Study 1: High level, discrete traffic tyre noise (A2)|Single study night in first experimental study arm, with traffic noise events to determine consequences of sleep disturbance by high level traffic noise comprised of single, discrete traffic events. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
62288739|NCT06018649|EXPERIMENTAL|Long inpatient balneotherapy (LIB)|"Group IV will be accommodated in the research/resort center and will receive balneological treatment (as groups I and II).~Duration of treatment 11 days, inpatient treatment."
62288740|NCT06018649|ACTIVE_COMPARATOR|Nature therapy (NT)|Group V will be given only the natural therapy procedure (as in group III). Duration 11 days, outpatient, self-managed according instructions and training provided.
62090306|NCT05611619|EXPERIMENTAL|Study 1: Medium level, discrete traffic tyre noise (B2)|Single study night in first experimental study arm, with traffic noise events to determine consequences of sleep disturbance by moderate level traffic noise comprised of single, discrete traffic events. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
62090307|NCT05611619|EXPERIMENTAL|Study 2: Medium level composite wheel tyre noise (A1)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level traffic noise comprised of composite wheel types.
62288741|NCT06018649|NO_INTERVENTION|Control|Group VI - the control group, the participants of which will not be given any procedures. Duration 11 days.
62288742|NCT02958943|EXPERIMENTAL|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation.
62288743|NCT02958943|NO_INTERVENTION|No Alert|Each provider in the non-alert group will receive no such notification.
62288744|NCT06299189|EXPERIMENTAL|A self-guided internet delivered intervention|MinADHD: 7 self-help modules Interventions: Behavioural
62288745|NCT03269981|EXPERIMENTAL|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
62288746|NCT03269981|ACTIVE_COMPARATOR|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
62288747|NCT00000479|EXPERIMENTAL|1|Vitamin E (600 IU every other day) and aspirin (100 mg every other day)
62288748|NCT00000479|EXPERIMENTAL|2|Vitamin E (600 IU every other day) and placebo
62090308|NCT05611619|EXPERIMENTAL|Study 2: Low level composite wheel tyre noise (B1)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by low level traffic noise comprised of composite wheel types.
62090309|NCT05611619|EXPERIMENTAL|Study 2: Medium level air-filled tyre noise (A2)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level traffic noise comprised of traditional air-filled wheel types.
62090310|NCT05611619|EXPERIMENTAL|Study 2: Low level air-filled tyre noise (B2)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by low level traffic noise comprised of traditional air-filled wheel types.
62463024|NCT05918263|EXPERIMENTAL|Group B: 16-Week Usual Care|"Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:~* Testing visits at Week 1 and 18 for physical exams, physical fitness and function assessments, and survey questionnaires.~* Upon completion of post-intervention assessments, participants will have the option to take part in the 16-week HIIT exercise program."
62090311|NCT04668144|ACTIVE_COMPARATOR|Prasugrel|Prasugrel only administered at the start of PCI
62090312|NCT04668144|EXPERIMENTAL|Prasugrel + Cangrelor|Cangrelor plus prasugrel concomitantly administered at the start of PCI
62090313|NCT04668144|ACTIVE_COMPARATOR|Cangrelor followed by Prasugrel|Cangrelor administered at the start of PCI plus prasugrel administered at the end of the cangrelor infusion
62288749|NCT00000479|EXPERIMENTAL|3|Aspirin (100 mg every other day) and placebo
62090314|NCT05377710|EXPERIMENTAL|Glycobone|Patients will be implanted at T0 with Glycobone
62090315|NCT01321073|EXPERIMENTAL|DelIVery for Pulmonary Arterial Hypertension Single Arm|All subjects were enrolled for implantation of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection.
62090316|NCT06696183|EXPERIMENTAL|Cohort 1|GILT d1-d28 VEN d1-d7 AZA d1-d7
62090317|NCT06696183|EXPERIMENTAL|Cohort 2|GILT d8-d28 VEN d1-d7 AZA d1-d7
62090318|NCT06696183|EXPERIMENTAL|Cohort 3|GILT d1-d28 VEN d1-d14 AZA d1-d7
62090319|NCT06696183|EXPERIMENTAL|Cohort 4|GILT d8-d28 VEN d1-d14 AZA d1-d7
62090320|NCT02663258|EXPERIMENTAL|Pembrolizumab arm|All participants treated with Pembrolizumab, 200mg iv, 3weekly
62090321|NCT05986019|EXPERIMENTAL|Active tFUS|tFUS will be administered within the MRI scanner. Participants receive two, 10-min sessions of active tFUS spread 10 min apart targeting the nucleus accumbens.
62090322|NCT05986019|SHAM_COMPARATOR|Sham tFUS|The sham sessions will include a transducer that is connected in a similar fashion to that of active tFUS, however the cable will not be plugged into the system, thus no ultrasound will be delivered to the participant. Participants will not know or be told whether they are receiving active- or sham- tFUS.
62090323|NCT04648306||Impella cohort|Single arm study of patients who underwent non-emergent percutaneous coronary intervention with prophylactic Impella support
62090324|NCT01039090|ACTIVE_COMPARATOR|Per os dopaminergic treatment|
62090325|NCT01039090|EXPERIMENTAL|Continuous Apomorphine infusion|
62090326|NCT06433466|EXPERIMENTAL|Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities|Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group).
62090327|NCT06433466|ACTIVE_COMPARATOR|Videos featuring influencers showing healthy lifestyle activities|Young adults were randomly shown 10 videos, featuring influencers promoting healthy lifestyle activity alone (control).
62090328|NCT00890474|EXPERIMENTAL|Moxibustion|
62090329|NCT00890474|NO_INTERVENTION|Control|
62090330|NCT06431022|EXPERIMENTAL|Self-directed webSTAIR|Participants on the Research, and Education Center (RESTORE) waitlist randomized to this arm will receive the self-managed web-administered Skills Training in Affective and Interpersonal Regulation (webSTAIR).
62288750|NCT00000479|PLACEBO_COMPARATOR|4|Placebo and placebo
62463025|NCT05214001|EXPERIMENTAL|Almotriptan|12.5 mg almotriptan taken orally once
62463026|NCT05214001|ACTIVE_COMPARATOR|Ubrogepant|50 mg ubrogepant taken orally once
62463027|NCT03333291|EXPERIMENTAL|Fecal transplantation|Duodenal transfer of healthy donor fecal suspension
62463028|NCT05412173|OTHER|RT-sequence|The volunteers will take 1 capsule (200 mg) of Lagevrio (R), 200 mg capsules (Merck Sharp \& Dohme (UK) Limited, UK) in Period 1, and 1 capsule (200 mg) of Molnupiravir (T), 200 mg capsules (Valenta Pharm, Russia) in Period 2.
62463029|NCT05412173|OTHER|TR-sequence|The volunteers will take 1 capsule (200 mg) of the drug Molnupiravir (T), capsules, 200 mg (Valenta Pharm JSC, Russia) in Period 1, and 1 capsule (200 mg) of the drug Lagevrio (R), capsules, 200 mg (Merck Sharp \& Dohme (UK) Limited, UK) in Period 2.
62288751|NCT05594784|EXPERIMENTAL|Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax|"For Induction cycle, olverembatinib will be given orally 40mg every other day. Patients with CMR, olverembatinib will be reduced to 30 mg every other day.~Induction and consolidation cycles combined with a certain period of venetoclax.~Reduced-intensity chemotherapy regimens consist mainly of vincristine and prednisone. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy."
62288752|NCT01320605|EXPERIMENTAL|Weekly HP802247 treatment|
62288753|NCT04909528|EXPERIMENTAL|Experimental Group|Low-level tragus stimulation
62288754|NCT04909528|SHAM_COMPARATOR|Control Group|Sham stimulation
62288755|NCT05797714|EXPERIMENTAL|TMF treatment group|TMF 25mg QD, from baseline to 144 weeks
62090331|NCT06431022|ACTIVE_COMPARATOR|webSTAIR with coaching from a Community Health Worker (CHW)|Participants on the RESTORE waitlist randomized to this arm will receive the web-administered Skills Training in Affective and Interpersonal Regulation (webSTAIR) with coaching support from a CHW.
62090332|NCT05881785|EXPERIMENTAL|Treatment group 1|GR1501 low dose
62288756|NCT05797714|NO_INTERVENTION|Blank control group|No antiviral therapy is given. If ALT\>2 ULN (40 IU/L) for HBeAg-positive patients or \> ULN for HBeAg-negative patients during the study period, blank control group can be switched to TMF treatment once a day, 25mg/ time orally until the end of the study.
62288757|NCT01858233|EXPERIMENTAL|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
62463030|NCT02588677|EXPERIMENTAL|Masitinib (3.0) & Riluzole|masitinib 3 mg/kg/day + riluzole
61905772|NCT00815555||1|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
62090333|NCT05881785|EXPERIMENTAL|Treatment group 2|GR1501 high dose
62090334|NCT05881785|PLACEBO_COMPARATOR|treatment group 3|placebo
62090335|NCT03059992|EXPERIMENTAL|Ibrexafungerp (SCY-078)|Ibrexafungerp (SCY-078), 750mg/day orally administered for up to 180 days with loading dose of 1500mg/day (for 2 days) for invasive fungal diseases.
62090336|NCT01697137|NO_INTERVENTION|Usual Care|Following enrollment, participants will visit with their primary care provider per usual.
62090337|NCT01697137|EXPERIMENTAL|Participant Video and Provider Cueing|Participants will watch a video prior to meeting with their provider. Participants will then cue their providers to discuss organ donation with them.
62090338|NCT00061100|EXPERIMENTAL|RISE intervention|Targeted RISE intervention- Behavior therapy Rise
62090339|NCT00061100|ACTIVE_COMPARATOR|Standard Education|Education intervention. Standard prevention education
62288758|NCT01858233|NO_INTERVENTION|Routine care|standard dietary counseling
62288759|NCT06426940||intraoperative anesthesia-related critical events|
62463031|NCT02588677|EXPERIMENTAL|Masitinib (4.5) & Riluzole|masitinib 4.5 mg/kg/day (2) + riluzole
62463032|NCT02588677|PLACEBO_COMPARATOR|Placebo & Riluzole|Matched placebo
62288760|NCT06426940||postoperative 1 hour (h)anesthesia-related critical events|
62463033|NCT01807637|EXPERIMENTAL|transcranial direct current stim|tDCS will be applied using a Soterix constant current stimulator with 5 x 5 cm (25cm2) carbon rubber electrodes (Covidien 664 REFX 2x2) applied to the scalp with 10-20 conductive paste. The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere \[established during TMS motor threshold testing (Baseline Testing) and the functional MRI assessment\]. The cathodal electrode will be placed over the contralateral motor cortex.
62463034|NCT01807637|PLACEBO_COMPARATOR|sham tDCS|Sham stimulation will be performed by turning the stimulator off after the initial sensory experience (30 seconds).
62654836|NCT04132219|OTHER|Delayed Intervention Group|"Participants assigned to the Delayed Intervention Group will receive a Welcome Box which on the outside is identical (and also is comparably weighted with bottled water) to that given to the Immediate Intervention group. This box would include: 1) Letters describing the project logistics and the important roles of each dyad member; and 2) monthly online study newsletters on topics unrelated to diet and exercise, but still of interest to cancer survivors and dyad members such as coping with stress, reducing exposure to radiation, sun safety, etc. to enhance retention and will be offered the opportunity to receive the online intervention after completing final 6-month assessments."
62654837|NCT05237375||The MIDWIZE model|"Pregnant women giving birth during at Naguru maternity ward during the intervention period~It's only Sub/study 2 in this PhD project which is a clinical trial and which is described onwards.~Sub-study 2 will include all women above the age of 18 with uncomplicated full-term pregnancies and births (i.e. between weeks 37 + 0 - 42 + 0) giving birth at the delivery ward during the implementation phase.~Data will be collected during the implementation of the quality improvement components."
62654838|NCT05237375||The MIDWIZE model - postintervention|"Pregnant women giving birth at Naguru maternity ward 3 and 6 months post intervention period.~Sub-study 2 will include all women above the age of 18 with uncomplicated full-term pregnancies and births (i.e. between weeks 37 + 0 - 42 + 0) giving birth at the delivery ward 3 and 6 months after the implementation phase.~Data will be collected after implementing the quality improvement components. The post-measurement data will be collected on the chosen components six months after project implementation to measure if the midwife-led quality improvement project has been sustained."
62654839|NCT05237375||The MIDWIZE model - scaling up|The intervention will be scaled up at three additional sites and will include all women above the age of 18 with uncomplicated full-term pregnancies and births (i.e., between weeks 37 + 0 - 42 + 0) giving birth at the delivery ward during the implementation phase.
62654840|NCT02620280|ACTIVE_COMPARATOR|Carbo-abrax, surgery, anthra|Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
62654841|NCT02620280|EXPERIMENTAL|Carbo-abrax-MPDL3280A, surgery, anthra|Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
62654842|NCT04547751||Adult|Patients aged 18yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
62654843|NCT04547751||Minor|Patients aged 14-17yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
62654844|NCT02090881|EXPERIMENTAL|ultrasound scan in ages 2-16 years|Children aged 2-16 years of age with Sickle Cell Disease and under the care of consultant haematologist as part of the NHS screening programme.
62654845|NCT06034184|EXPERIMENTAL|Using Virtual Reality for training and learning mass casualty incidents|The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
62654846|NCT06034184|NO_INTERVENTION|Standard education and training|Standard education, including lectures and paper exercises
62288761|NCT04415398|EXPERIMENTAL|Delivery of automated external defibrillators using drones|"Three drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating feasibility in:~* Operational feasibility (Legislation, Weather conditions, conflict in airspace)~* Participant feasibility (Failure to respond; Dispatcher, Drone-pilot, Air traffic controller)~* Technological feasibility (Drone technology, software, winch-system , 4G network, radio communication"
62288762|NCT04920773|EXPERIMENTAL|Ayurveda Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati
62288763|NCT04920773|ACTIVE_COMPARATOR|Usual Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
62288764|NCT00934102|ACTIVE_COMPARATOR|Lotrafilcon A|Lotrafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
62288765|NCT00934102|ACTIVE_COMPARATOR|Narafilcon A|Narafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
62288766|NCT00934102|ACTIVE_COMPARATOR|Galyfilcon A|Galyfilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
62288767|NCT01294384|EXPERIMENTAL|New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
62288768|NCT01294384|EXPERIMENTAL|New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
62288769|NCT01294384|ACTIVE_COMPARATOR|Refresh Tears®|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
62288770|NCT00797693|EXPERIMENTAL|Vaginal Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
62288771|NCT00797693|EXPERIMENTAL|Oral Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
62288772|NCT05448014|EXPERIMENTAL|CFT group intervention|Compassion Focused Therapy in Group on the internet
62288773|NCT05448014|NO_INTERVENTION|Control group|Waiting list
62463035|NCT03643328|EXPERIMENTAL|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
62090340|NCT02357758|ACTIVE_COMPARATOR|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
62090341|NCT02357758|NO_INTERVENTION|Healthy Population|Healthy population
62090342|NCT02357758|NO_INTERVENTION|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
62090343|NCT02128646|EXPERIMENTAL|Treatment Group 1|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 1 will have an open surgery for abdominal hernia repair.
62090344|NCT02128646|EXPERIMENTAL|Treatment Group 2|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 2 will have a laparoscopic abdominal hernia repair.
62288774|NCT03141944||Apathetic patients|"De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
62288775|NCT03141944||Non-apathetic patients|"De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
62288776|NCT04937010|ACTIVE_COMPARATOR|Industry standard stimulation|Standard sub threshold stimulation parameters
62288777|NCT04937010|SHAM_COMPARATOR|Experimental stimulation|Sham stimulation
62288778|NCT03341260|EXPERIMENTAL|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg tablet to be administered one hour before treatment.
62288779|NCT03341260|PLACEBO_COMPARATOR|Placebo|Placebo to be administered one hour before treatment.
62288780|NCT02913313|EXPERIMENTAL|Part 1A: Dose Escalation Monotherapy|
62288781|NCT02913313|EXPERIMENTAL|Part 1B: Dose Escalation Combination Therapy|
62288782|NCT02913313|EXPERIMENTAL|Part 2A: Expansion Monotherapy|
62288783|NCT02913313|EXPERIMENTAL|Part 2B: Expansion Combination Therapy|
62288784|NCT02913313|EXPERIMENTAL|Part 1C: Triplet Cohort|
62288785|NCT02913313|EXPERIMENTAL|Part 2C: Triplet Expansion|
62463036|NCT02252731|EXPERIMENTAL|warfarin and FG-4592|Single dose of warfarin and Multiple doses of FG-4592 in combination with a single dose of warfarin
62654847|NCT02204189|EXPERIMENTAL|TongFuSan|TongFuSan 1g per time, change every day, the duration is seven days
62288786|NCT03863314|ACTIVE_COMPARATOR|In-Person Simulation|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
62288787|NCT03863314|EXPERIMENTAL|Virtual Simulation|Participants will experience virtual simulations of different workplace scenarios such as medical error and workplace harassment via Virtual Reality headset.
62288788|NCT05266404|EXPERIMENTAL|Treatment A (Test Formulation): Dapagliflozin/Sitagliptin FDC tablet|Subjects will receive single dose of dapagliflozin/sitagliptin fixed dose combination (FDC) (test formulation).
62288789|NCT05266404|ACTIVE_COMPARATOR|Treatment B (Reference Formulation): Dapagliflozin+Sitagliptin|Subjects will receive single dose of dapagliflozin 10 mg tablet + sitagliptin 100 mg tablet co-administered as individual tablets (reference formulation).
62288790|NCT05510960||General surgery residents|39 participants
62288791|NCT05510960||Urology residents|14 participants
62288792|NCT05510960||Pediatric surgery residents|7 participants
62288793|NCT05744427|EXPERIMENTAL|Dose escalation and expansion period|in dose escalation and expansion period，total 9 dose groups were designed. Subjects will be give dose 1.0, 2.1, 4.2, 5.3, 6.3, 7.3, 8.4, 9.4 and 10.5 mg/kg Q3W based on DLT results.
62463037|NCT02253797|EXPERIMENTAL|TPV/r followed by 14C-radiolabeled TPV|Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir
62463038|NCT03726788|EXPERIMENTAL|Botulinum Toxin Type A 100U|one intra-articular injection in the painful knee 30 days after the inclusion visit
62090345|NCT02128646|ACTIVE_COMPARATOR|Control Group 1|Patients scheduled in Control Group 1 will have an open surgery for abdominal hernia repair. The Control Group patients will receive traditional treatment.
62090346|NCT02128646|ACTIVE_COMPARATOR|Control Group 2|Patients scheduled in Control Group 2 will have laparoscopic abdominal hernia repair. The Control Group patients will receive traditional treatment.
62090347|NCT06697665|EXPERIMENTAL|Participant Group|Treatment includes LM103 injection and PD-1
62090348|NCT01656941||d-Transposition of the Great Arteries|Neonates with d-transposition of the great arteries (dTGA) undergoing the arterial switch operation with cardiopulmonary bypass
62288794|NCT05744427|EXPERIMENTAL|cohort 1 in phase II|
62288795|NCT05744427|EXPERIMENTAL|cohort 2 in phase II|
62288796|NCT05744427|EXPERIMENTAL|cohort 3 in phase II|
62288797|NCT05744427|EXPERIMENTAL|cohort 4 in phase II|
62288798|NCT05744427|EXPERIMENTAL|cohort 5 in phase II|
62654848|NCT03789877|EXPERIMENTAL|Group I (home-based walking program, rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
62090349|NCT01656941||Single ventricle cardiac disease|Neonates with single ventricle cardiac disease (SVCD) undergoing stage I surgical palliation (Norwood) with cardiopulmonary bypass
62090350|NCT00972712|EXPERIMENTAL|A|Bortezomib and Tipifarnib
62463039|NCT03726788|EXPERIMENTAL|Botulinum Toxin Type A 200U|one intra-articular injection in the painful knee 30 days after the inclusion visit
62288799|NCT01361841|OTHER|ophtalmic solution,|Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
62288800|NCT00854646|EXPERIMENTAL|ON 01910.Na|The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.
62288801|NCT06078657|EXPERIMENTAL|IBI110 combined with Sintilimab|
62288802|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
62288803|NCT06369714|ACTIVE_COMPARATOR|Medication group|The medication group will take Methylphenidate Hydrochloride Extended-Release Tablets with a fixed dose for eight weeks.
62654849|NCT03789877|ACTIVE_COMPARATOR|Group II (home-based exercise program, sham rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo sham repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
62654850|NCT01868672|NO_INTERVENTION|Control|Participant receives usual care.
62654851|NCT01868672|EXPERIMENTAL|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
62654852|NCT05173311|EXPERIMENTAL|Application use arm|The early childhood education and care (ECEC) professionals in the intervention arm groups were instructed to use the application with a tablet computer at least 1-2 times a week during the intervention period (3-4 weeks) and to record the number of tasks completed by their group in a logbook. In addition, we recommended that each group focus on at least six vegetables or fruits during the intervention period.
62654853|NCT05173311|NO_INTERVENTION|Control arm|The control arm groups were instructed to continue their normal routines during the intervention period. They were instructed to refrain from introducing any novel food education methods during the intervention period.
62654854|NCT06193135|EXPERIMENTAL|Elonva|Patients will undergo controlled ovarian stimulation with Corifolitropin α (Elonva), 100-150 micrograms (100 in\< 60kg and 150 ≥ 60 kg) + Progevera 10 mg.
62288804|NCT06369714|EXPERIMENTAL|Digital therapeutics group|The digital therapeutics group will complete 30 training sessions within 8 weeks.
62288805|NCT06369714|EXPERIMENTAL|Combination group|The combination group will take Methylphenidate Hydrochloride Extended-Release Tablets while undergoing digital therapeutics.
62288806|NCT04769791|EXPERIMENTAL|cuff inflation by the residual volume|LMA will be inserted with the initial inflating volume correspondent to residual volume group ( RV group): volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 ml syringe without plunger is connected to the laryngeal cuff for 5 minutes.
62463040|NCT03726788|ACTIVE_COMPARATOR|Triamcinolone Hexacetonide 20 MG/ML|one intra-articular injection in the painful knee 30 days after the inclusion visit
62463041|NCT04408404||Type A aortic dissection|Patient operated for type A acute aortic dissection between 01 January 2007 and 31 December 2017 in Dijon Burgundy University Hospital
62654855|NCT06193135|ACTIVE_COMPARATOR|Puregon|Patients will undergo controlled ovarian stimulation with Folitropin β (Puregon) + Progevera 10 mg.
62654856|NCT01066377|EXPERIMENTAL|Prebiotic and probiotic mix|Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested). Probiotic: 10\^8 - 10\^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
62654857|NCT01066377|PLACEBO_COMPARATOR|Maltodextrin/milk powder|
62654858|NCT02511717|SHAM_COMPARATOR|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
62654859|NCT02511717|ACTIVE_COMPARATOR|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
62654860|NCT02664688|EXPERIMENTAL|Lumbar stabilization exercises|Home exercise program to perform daily for 6 months
62654861|NCT02664688|ACTIVE_COMPARATOR|Flexor Exercises|Home exercise program to perform daily for 6 months
62654862|NCT03821597|EXPERIMENTAL|Sequential compression devices|Sequential compression devices (SCDs) are applied during surgery.
62288807|NCT04769791|EXPERIMENTAL|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group):
62654863|NCT03821597|ACTIVE_COMPARATOR|No sequential compression devices|No sequential compression devices are applied.
62654864|NCT05930288|EXPERIMENTAL|Walking exercise|Patients receive routine care and exercise as required.
62654865|NCT05930288|NO_INTERVENTION|Control|Patients receive only routine care.
62654866|NCT04582617|ACTIVE_COMPARATOR|Cocoa extract + multivitamin|
62654867|NCT04582617|ACTIVE_COMPARATOR|Cocoa extract + multivitamin placebo|
62654868|NCT04582617|ACTIVE_COMPARATOR|Cocoa extract placebo + multivitamin|
62654869|NCT04582617|PLACEBO_COMPARATOR|Cocoa extract placebo + multivitamin placebo|
62654870|NCT01021189|EXPERIMENTAL|1|AZD1446
62654871|NCT01021189|PLACEBO_COMPARATOR|2|Placebo
62654872|NCT01801540|EXPERIMENTAL|0% arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
62654873|NCT01801540|OTHER|5 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
62654874|NCT01801540|OTHER|10 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
62654875|NCT01801540|OTHER|0 % arabinose meal Starch|A meal containing two bons with butter and cheese, The and water
62654876|NCT01801540|OTHER|5 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
62654877|NCT01801540|OTHER|10 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
62654878|NCT02137798|EXPERIMENTAL|CARTOUNIVU|Radiofrequency catheter ablation of atrial fibrillation will be performed using fluoroscopy image integrated 3-dimentional electroanatomical mapping system
62654879|NCT02137798|ACTIVE_COMPARATOR|CARTO3|Radiofrequency catheter ablation of atrial fibrillation will be performed using 3-dimentional electroanatomical mapping system without fluoroscopy image integration technique
62654880|NCT06097832|EXPERIMENTAL|NXC-201 CAR-T|"The dose escalation phase will include the following doses:~Cohort 1 - 150×10\^6 CAR-positive (CAR+) T cells (3 patients) Cohort 2 - 450×10\^6 CAR-positive (CAR+) T cells (3 patients) The dose expansion phase will then proceed."
62654881|NCT02172547||COPD patients who stopped smoking during treatment|
62654882|NCT02475148|EXPERIMENTAL|Part 1: Cohort 1|Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.
62288808|NCT04769791|EXPERIMENTAL|unchanged cuff inflation volume|LMA will be inserted with the initial inflating volume correspondent to unchanged volume group (NV group): LMA is unpacked and used without inflating or deflating the cuff.
62654883|NCT02475148|EXPERIMENTAL|Part 1: Cohort 2|Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.
62654884|NCT02475148|EXPERIMENTAL|Part 1: Cohort 3|Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.
62654885|NCT02475148|EXPERIMENTAL|Part 1: Cohort 4|Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.
62654886|NCT02475148|EXPERIMENTAL|Part 1: Cohort 5|Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.
62654887|NCT02475148|EXPERIMENTAL|Part 1: Cohort 6|Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.
62654888|NCT02475148|EXPERIMENTAL|Part 2: Cohort 7|Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
62654889|NCT02475148|EXPERIMENTAL|Part 3: Cohort 8|Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
62654890|NCT04759547|EXPERIMENTAL|Handheld ultrasound-assisted technique|Participants will be received labor combined epidural-spinal analgesia using handheld ultrasound
62090351|NCT03503838|EXPERIMENTAL|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
62090352|NCT03503838|NO_INTERVENTION|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
61905786|NCT00941629|ACTIVE_COMPARATOR|Cognitive Processing Therapy FTF|Cognitive Processing Therapy delivered in traditional face-to-face sessions (FTF)
61905787|NCT00941629|EXPERIMENTAL|Cognitive Processing Therapy TMH|Cognitive Processing Therapy delivered over videoconferencing equipment to a distant location (or telemental health; TMH)
62090353|NCT04671290||Control|Carbapenem (imipenem, or meropenem, or ertapenem) as first-line therapy or after receiving up to 72 hours of other antibiotics (including aminoglycosides).
62288809|NCT05904392|EXPERIMENTAL|Intervention|Music played prior to intravitreal injection
62654891|NCT04759547|ACTIVE_COMPARATOR|Conventional palpation-guided technique|Participants will be received labor combined epidural-spinal analgesia using conventional landmark-guided technique
62654892|NCT04490460|PLACEBO_COMPARATOR|First 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. Double blind 50% Placebo capsules identical to those containing WB-0031 and 50% WB-0031
62654893|NCT04490460|ACTIVE_COMPARATOR|Second 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. All participants receiving WB-0031.
62654894|NCT03764124||Kidney recipients|Kidney recipients aged over 18 and of all sexes recruited between 2007 and 2020 from the Centre Hospitalier Universitaire de Liege, who have e-GFR follow-up and data from protocol and for cause biopsies available at 1-year post transplant. PET/CT imaging will be performed with patient's approval for protocol and per cause biopsies we performed. Data will be collected in the follow up such as clinical, biological and histological data.
62654895|NCT03931070|EXPERIMENTAL|Mechanically ventilated|Participants who are on mechanical ventilator at the time of study enrollment.
62654896|NCT03931070|EXPERIMENTAL|Non mechanically ventilated|Participants who are not on mechanical ventilator at the time of study enrollment.
62654897|NCT02721069|EXPERIMENTAL|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
62654898|NCT04108390|EXPERIMENTAL|Intervention group|Individuals for this group will be treat with a dry needling intervention at the gluteus medius trigger point.
62654899|NCT04108390|ACTIVE_COMPARATOR|Control group|Individuals for this group will be treat with a dry needling technique at 1,5 cm from the trigger point (not in the trigger point).
62654900|NCT03039478|ACTIVE_COMPARATOR|Xylitol 7g in 300mL tap water|12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube
62654901|NCT03039478|ACTIVE_COMPARATOR|Xylitol 17g in 300mL tap water|12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube
62654902|NCT03039478|ACTIVE_COMPARATOR|Xylitol 35g in 300mL tap water|12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube
62654903|NCT03039478|ACTIVE_COMPARATOR|Erythritol 10g in 300mL tap water|12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
62654904|NCT03039478|ACTIVE_COMPARATOR|Erythritol 25g in 300mL tap water|12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube
62654905|NCT03039478|ACTIVE_COMPARATOR|Erythritol 50g in 300mL tap water|12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube
62654906|NCT03001102|SHAM_COMPARATOR|Bathing with 4% Chlorhexidine gluconate|Two baths with chlorhexidine using precise methods, including to scrubb the whole body with 50mL of undiluted solution, at night before surgery and the morning of surgery.
62654907|NCT03001102|EXPERIMENTAL|Bathing with10% PVPI degermante|Two baths with PVPI using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
62090354|NCT04671290||Cases|Temocillin above 50% of the time of effective antibiotic therapy duration. Temocillin had to be given as first-line therapy or after receiving a maximum of 5 days of other antibiotics (including carbapenems and aminoglycosides).
62288810|NCT05904392|NO_INTERVENTION|Control|No music played.
62288811|NCT02932956|EXPERIMENTAL|GAP T cells + Fludarabine and Cytoxan|GPC3-Car (GAP T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
62288812|NCT04886271|EXPERIMENTAL|HX009|
62288813|NCT04873492|OTHER|Retrospective Aggressive MS patients|Patients from who the clinical outcome is already known and classified as poor based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
62463042|NCT00202982|ACTIVE_COMPARATOR|glatiramer acetate 20 mg|glatiramer acetate 20 mg
62463043|NCT00202982|ACTIVE_COMPARATOR|glatiramer acetate 40 mg|glatiramer acetate 40 mg
62654908|NCT03001102|ACTIVE_COMPARATOR|Bathing with soap without antiseptic.|Two baths with soap using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
62654909|NCT04302597|ACTIVE_COMPARATOR|Staples|Women who underwent repeated cesarean section with skin closure using staples.
62654910|NCT04302597|EXPERIMENTAL|Tissue adhesive|Women who underwent repeated cesarean section with skin closure using 2-octylcyanoacrylate tissue adhesive.
62654911|NCT03804619|EXPERIMENTAL|Left DLPFC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
62654912|NCT03804619|EXPERIMENTAL|ACC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
62090355|NCT06634459|ACTIVE_COMPARATOR|Reia System|Participants receiving the commercially available RS will be fit with one of three available pessary sizes and will receive an applicator corresponding to their pessary size.
62090356|NCT06634459|ACTIVE_COMPARATOR|Standard Pessary Care|Participants receiving SPC will be fit with a Gellhorn pessary or ring with/without support without knob pessary per standard clinical protocol.
62090357|NCT02485795||Pain patients|Observational; Patients presenting to interventional pain management centers for therapy.
61905795|NCT06297785|OTHER|Nurse-delivered, gut-directed hypnotherapy|
62090358|NCT03082885|EXPERIMENTAL|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
62090359|NCT03082885|NO_INTERVENTION|control group|Patients receive treatment based on standard Therapy
62090360|NCT02859597|EXPERIMENTAL|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
62090361|NCT02859597|ACTIVE_COMPARATOR|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
62090362|NCT02354248|EXPERIMENTAL|Stroke patients|The patients will be submitted to a triple stimulation examination.
62090363|NCT02354248|ACTIVE_COMPARATOR|Control Subjects|This group of patients did not suffer from a stroke. They will also be submitted to a triple stimulation examination.
62090364|NCT06184477||prolonged hospitalization after tonsillectomy|Prolonged hospitalization refers to prolonged discharge time and readmission.
62090365|NCT06184477||normal hospitalization time|normal hospitalization time for pediatric patients accepted as 1 night stay.
62288814|NCT04873492|OTHER|Retrospective Non Aggressive MS patient|Patient from who the clinical outcome is already known and classified as non-aggressive based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
62654913|NCT06031285|EXPERIMENTAL|Perioperative of Sinitilimab, bevacizumab biosimilar plus TACE-HAIC for PVTT-HCC|Perioperative of Sinitilimab, bevacizumab biosimilar and TACE-HAIC for HCC patients with PVTT
62654914|NCT04208230||Subjects diagnosed with type 2 diabetes mellitus|Subjects with type 2 diabetes defined as those with (1) history and diagnosis of T2D and pharmacologic treatment for a minimum of 3 years OR (2) history and diagnosis of T2D with documented HgbA1C of 6.5 or higher for a minimum of 3 years if they are not under pharmacologic treatment (i.e., diet-controlled)
62654915|NCT04208230||Control|Non-diabetic control group. These subjects must not have pre-diabetes.
62654916|NCT00596492|ACTIVE_COMPARATOR|High Dose|
62090366|NCT05785845|EXPERIMENTAL|Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR)|In this study, consenting and eligible patients will receive a prescription dose of 55 Gy in 5 fractions (when possible) delivered on consecutive business days with adaptation based on daily anatomic changes as per clinical standard of care.
62090367|NCT02187211|EXPERIMENTAL|Minocycline Low Dose|Participants in this arm will receive a low dose (200mg/day) of Minocycline for 10 days
62090368|NCT02187211|EXPERIMENTAL|Minocycline High Dose|Participants in this arm will receive a high dose (400mg/day) of Minocycline for 10 days
62090369|NCT02187211|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive the Placebo for 10 days
62288815|NCT04873492|OTHER|Healthy volunteers|Prospective arm use as comparator.
62654917|NCT00596492|ACTIVE_COMPARATOR|Low Dose|
62654918|NCT00962598|PLACEBO_COMPARATOR|Corn Oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
62654919|NCT00962598|EXPERIMENTAL|Omega-3 Fatty Acids|The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
62463044|NCT02731157|EXPERIMENTAL|Transfusion with rejuvenated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
62463045|NCT02731157|ACTIVE_COMPARATOR|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
62463046|NCT00760110||1 Morning hypertension and normotension|Based on HBP, subjects were divided into MH and MN patients
62463047|NCT00760110||2 Clinic hypertension and normotension|Based on CBP, subjects were divided into CH and CN patients
62463048|NCT01141426|ACTIVE_COMPARATOR|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
62654920|NCT03750565|EXPERIMENTAL|Cohort 1|Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
61905798|NCT05922800|EXPERIMENTAL|Electro Press Needle|Body acupoints of Yintang (GV29), Dazhui (GV14), Guanyuan (CV4), bilateral Zigong (EX-CA1), and bilateral Sanyinjiao (SP6) and auricular acupoints of Heart (CO15), Chuiqian (LO4) and Shenmen (TF4) will be selected for treatment. Auricular acupoints on right and left ear will be stimulated alternatively, one side on each time.The treatment will last 40mins for each session, 3 sessions a week (ideally every other day) for a succession of 6 weeks.
62654921|NCT03750565|EXPERIMENTAL|Cohort 2|Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
62654922|NCT03750565|EXPERIMENTAL|Cohort 3|Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
62654923|NCT03750565|EXPERIMENTAL|Cohort 4|Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
62654924|NCT03965364||INCRAFT|Endovascular abdominal aortic aneurysm repair
62654925|NCT01544231||Patients|Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
62654926|NCT02515786|EXPERIMENTAL|oxygen humidification|Oxygen by nasal catheter delivery will be humidified by bubles.
62288816|NCT04873492|OTHER|Prospective MS patients|MS patients from who the clinical outcome will be established at the end of the follow up. Blood sample will be collected after the first event to validate molecules of interest from OMIC results by using FACS a different technology and classify MS patient.
62654927|NCT02515786|NO_INTERVENTION|Dry oxygen|oxygen by nasal catheter delivery will be dry
62654928|NCT05317351|ACTIVE_COMPARATOR|"Standard Colonoscopy (SC)"|"Subjects enrolled to arm 1 (SC) will undergo colonoscopy using a standard colonoscope."
61905799|NCT05922800|ACTIVE_COMPARATOR|Gamma-Oryzanol|The patients in this group were given 10mgx100 tablets/bottle of gamma-oryzanol tablets (Tianjin Lishen Pharmaceutical), 20mg each time, three times a day, for 6 months.
61905800|NCT05471713||PD with AutD|Parkinson's disease with autonomic dysfunction
62288817|NCT02312973|EXPERIMENTAL|Arm 1|Single oral dose of 75 mg molidustat (fasted) in subjects on hemodialysis (at start of hemodialysis and on a hemodialysis free day,respectively)
62288818|NCT02312973|EXPERIMENTAL|Arm 2|Single oral dose of 75 mg molidustat (fasted) in subjects on peritoneal dialysis (after start of peritoneal dialysis intervall and, optionally, after the start of a peritoneal dialysis-free intervall,respectively)
61905801|NCT05471713||PD without AutD|Parkinson's disease without autonomic dysfunction
62654929|NCT05317351|ACTIVE_COMPARATOR|"Artificial Intelligence Aided Colonoscopy (GI Genius™) (AI)"|"Subjects enrolled to arm 2 (AI) will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)"
62654930|NCT05317351|EXPERIMENTAL|Combined Artificial Intelligence (GI Genius™) and G-EYE® Colonoscopy (AG)|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
62654931|NCT05370118|EXPERIMENTAL|Telerehabilitation physical activity behavioral (TPAB) intervention|Individuals in the TPAB intervention will participate in a weekly session for 12 weeks with their primary caregiver and the research interventionist (RH). Established behavior-change techniques will be used in the TPAB intervention, based largely on the combination of the Social Cognitive Theory, Control Theory, and Operant Conditioning,43 including behavioral techniques, and patient-centered communication (e.g., motivational interviewing).44 The behavior-change techniques are designed to target and improve daily steps. Individuals in the CTL group will receive usual care and no intervention over the 12 weeks.
62654932|NCT05370118|NO_INTERVENTION|Control Group|Individuals in the CTL group will receive usual care and no intervention over the 12 weeks.
62654933|NCT05830565||Food Supplement|Single dose of food Supplement Based on L-theanine, Passionflower and Rhodiola Extracts
62654934|NCT02993367|EXPERIMENTAL|the Butylphthalide Soft Capsules group|600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
61905802|NCT00512629|EXPERIMENTAL|Omegaven|Omegaven is a fish based intravenous fat emulsion
61905803|NCT00512629|ACTIVE_COMPARATOR|Intralipid|
62288819|NCT02312973|EXPERIMENTAL|Arm 3|Single oral dose of 75 mg molidustat (fasted) in healthy subjects
61905809|NCT01488513|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive sphingosine kinase-2 inhibitor ABC294640 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61905810|NCT05539989|EXPERIMENTAL|VPM1002 Vaccine Arm|Participants stratified by HIV and M.tb sensitization status.
61905811|NCT05539989|EXPERIMENTAL|BCG Vaccine Arm|Participants stratified by HIV and M.tb sensitization status.
61905812|NCT05539989|PLACEBO_COMPARATOR|Placebo Arm|Participants stratified by HIV and M.tb sensitization status.
61905813|NCT01644747|ACTIVE_COMPARATOR|active tDCS|a group named G1 and treated by medication with SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and 10 sessions of active anodal tDCS at 2 sessions per day (1 morning and 1 afternoon with a gap of 3h) for 5 days with an electric current 2 mA.
62090370|NCT04822753|EXPERIMENTAL|Platelet Rich Plasma injection to lumbar facet joint|Platelet Rich Plasma injection to lumbar facet joint
62090371|NCT04822753|PLACEBO_COMPARATOR|Placebo injection to lumbar facet joint|Placebo injection to lumbar facet joint
62090372|NCT05818397|EXPERIMENTAL|Self-Compassion Intervention|
62090373|NCT04099953|EXPERIMENTAL|dialysis patients|Dialysis patients were evaluated by objective diagnostic tests.
62090374|NCT04099953|EXPERIMENTAL|Control group|Healthy individuals
62463049|NCT01141426|EXPERIMENTAL|Intensive Short-Term Dynamic Psychotherapy (ISTDP) Group|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
62463050|NCT03657329|EXPERIMENTAL|Suspicion of sleep-disordered breathing|Dreem
62463051|NCT00847678|EXPERIMENTAL|1|Mycograb + Amphotericin B + 5 flucytosine
62090375|NCT06417255|EXPERIMENTAL|kinesiotape application|
62463052|NCT00847678|PLACEBO_COMPARATOR|2|Placebo + Amphotericin B + 5 flucytosine
62463053|NCT00847678|EXPERIMENTAL|3|Mycograb + Amphotericin B
62463054|NCT03447678|EXPERIMENTAL|Pembrolizumab|subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC
62463055|NCT03629249|EXPERIMENTAL|QAW039 150 mg|QAW039 150 mg once daily orally
61905814|NCT01644747|SHAM_COMPARATOR|sham tDCS|a group named G2 and treated by medication with SSRIs or SNRIs for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and sham tDCS.
61905815|NCT04183361||Patients with noise exposure and salivary cortisone|"1. male and female~2. ages 19-35~3. exposure to noise level ≥ 85 dB (A) per week at the workplace~4. work in noise from 1 to 16 years~5. workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)~6. unilaterally or bilaterally normal otoscopic findings~7. unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
62090376|NCT06417255|ACTIVE_COMPARATOR|foam roller application|
62090377|NCT03628924|EXPERIMENTAL|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
62090378|NCT03628924|EXPERIMENTAL|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
62090379|NCT03628924|EXPERIMENTAL|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
62090380|NCT06303830|ACTIVE_COMPARATOR|Control group|Sodium nitrate, once a day for 14 days
62090381|NCT06303830|EXPERIMENTAL|Bariatric group|Sodium nitrate, once a day for 14 days
62090382|NCT05811208||surgical ICU patients|All surgical patients on the inpatient ward in the Department of Anesthesiology and Intensive Care
62090383|NCT04570085|EXPERIMENTAL|Caffeine|after a 3 weeks up titration period, 1 capsule of 200 mg twice a day during 27 weeks (ie 400mg/day)
62090384|NCT04570085|PLACEBO_COMPARATOR|placebo|after a 3 weeks up titration period, 2 capsules per day during 27 weeks
62463056|NCT03629249|EXPERIMENTAL|QAW039 450 mg|QAW039 450 mg once daily orally
62463057|NCT03629249|PLACEBO_COMPARATOR|Placebo|Placebo to QAW039 once daily orally
62463058|NCT04475965|EXPERIMENTAL|Group 1 20% maximal voluntary isometric contraction|Patients in group 1 received a five-series Isometric Contraction of shoulder external rotators at 20% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
62463059|NCT04475965|ACTIVE_COMPARATOR|Group 2 80% maximal voluntary isometric contraction|Patients in group 2 received a five-series Isometric Contraction of shoulder external rotators at 80% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
62463060|NCT05110677||Study group|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus gastrocnemius of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~Physical assessment: Color-Coded Duplex Sonography/treadmill examination to determine actual walking distance/Ankle-Brachial-Index/defined walking distance of 150 meters under medical supervision"
62090385|NCT01342653|EXPERIMENTAL|NIPS plus HIPEC plus adjuvant chemotherapy|
62090386|NCT00616161|EXPERIMENTAL|1|Istaroxime dose of 0.5 microgram/kg body weight/minute of iv infusion for six ours
62090387|NCT00616161|EXPERIMENTAL|2|Istaroxime dose of 1.0 microgram/kg body weight/minute of iv infusion for six ours
62090388|NCT00616161|EXPERIMENTAL|3|Istaroxime dose of 1.5 microgram/kg body weight/minute of iv infusion for six ours
62090389|NCT00616161|PLACEBO_COMPARATOR|4|Placebo iv infusion for six ours
62463061|NCT00056160|EXPERIMENTAL|CC-5013/Dex|CC-5013 (lenalidomide) plus oral high-dose dexamethasone
62463062|NCT00056160|EXPERIMENTAL|Placebo/Dex|Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
62463063|NCT05488613||Midostaurin|Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
62654935|NCT02993367|PLACEBO_COMPARATOR|the placebo group|60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
62654936|NCT03638466|ACTIVE_COMPARATOR|Single dose of SPN-810|Subjects will be treated with medium dose of SPN-810
62654937|NCT03638466|PLACEBO_COMPARATOR|Placebo|Subjects will be treated with a matching Placebo
62090390|NCT03232177|EXPERIMENTAL|Anagre Cap.|twice a day
62090391|NCT03605875|EXPERIMENTAL|Web-App|A customized web-app tool to be used by patients to communicate concerns to their nephrologist
62463064|NCT02019056|PLACEBO_COMPARATOR|Placebo|enteric coated capsule
62463065|NCT02019056|EXPERIMENTAL|MG 500mg|Metadoxine + garlic oil
62463066|NCT02019056|EXPERIMENTAL|MG 1000mg|Metadoxine + garlic oil
62654938|NCT01202591|EXPERIMENTAL|AZD4547 + exemestane|Safety run-in: AZD4547 plus exemestane
62654939|NCT01202591|EXPERIMENTAL|AZD4547 + fulvestrant|A Randomised phase IIa: AZD4547 plus fulvestrant
62654940|NCT01202591|PLACEBO_COMPARATOR|Placebo + fulvestrant|Randomised phase IIa: Matching placebo plus fulvestrant
62090392|NCT03605875|ACTIVE_COMPARATOR|Paper|A customized paper tool to be used by patients to communicate concerns to their nephrologist
62090393|NCT06697613||CRS-HIPEC|
62090394|NCT06696976|EXPERIMENTAL|Group A (telerehabilitation of neuropathic pain, physical function and quality of life)|"Group A will receive Telerehabilitation of 60 minutes with short resting intervals .Treatment will be given 3 times per week for 12 weeks.~1. warm up of 5 minutes~2. Nerve gliding exercises of 10 minutes~3. Balance exercises of 20 minutes~4. Resistance training of 20 minutes~5. cold down of 5 minutes"
62463067|NCT02019056|SHAM_COMPARATOR|Metadoxine 500mg|enteric coated capsule
62654941|NCT06412003|EXPERIMENTAL|Home-based balance training group|Participants will perform the home-based balance training program for 30-40 minutes per session, 3 days per week for 12 weeks not including the two weeks of education and familiarization.
62654942|NCT03493971|ACTIVE_COMPARATOR|Carotid artery stenting (CAS)|Carotid revascularization performed using CAS
62090395|NCT06696976|EXPERIMENTAL|Group B (clinical rehabilitation of neuropathic pain, physical function and quality of life)|"Group B will receive Clinical rehabilitation of 60 minutes with short resting intervals .Treatment will be given 3 times per week for 12 weeks.~1. warm up of 5 minutes~2. Nerve gliding exercises of 10 minutes~3. Balance exercises of 20 minutes~4. Resistance training of 20 minutes~5. cold down of 5 minutes"
61905816|NCT04183361||Patients without noise exposure and salivary cortisone|"1. male and female~2. ages 19-35~3. no exposure to noise level ≥ 85 dB (A) per week at the workplace~4. work in noise from 1 to 16 years~5. workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)~6. unilaterally or bilaterally normal otoscopic findings~7. unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
62090396|NCT06563531|ACTIVE_COMPARATOR|Elastic compression|
62654943|NCT03493971|ACTIVE_COMPARATOR|Carotid endarterectomy (CEA)|Carotid revascularization performed using CEA
62090397|NCT06563531|EXPERIMENTAL|No elastic compression|
62090398|NCT01333761|EXPERIMENTAL|TCD/Cardiox FDS/TEE testing|All patients enrolled will be evaluated with TCD and Cardiox FDS and TEE for the presence of RTLS.
62654944|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
62654945|NCT02157844||COPD|Subjects with diagnosis of COPD
62654946|NCT02157844||OSA|Subjects with diagnosis of OSA
62654947|NCT02157844||controls|Gender, age, BMI matched controls
62654948|NCT04308135||vascular parkinsonism|the investigators will recruit 30 patients diagnosed as Vascular Parkisonism ,
62654949|NCT04308135||Parkinson's disease|50 patients diagnosed as Parkinson Disease
62654950|NCT04308135||Controls|30 healthy controls.
62654951|NCT02254824|ACTIVE_COMPARATOR|Normal-dose statin|Lifestyle modification with Normal-dose statin
62654952|NCT02254824|ACTIVE_COMPARATOR|Lifestyle modification + Xuezhikang|Lifestyle changes with Xuezhikang
62090399|NCT05046483||Cohort with type 1 diabetes (T1D) and type 2 diabetes (T2D)|Prospectively followed cohort of people with new onset of ST-segment elevation myocardial infarction and diabetes mellitus (type 1 or type 2) according to the American Diabetes Association (ADA) and German Diabetes Society (DDG) criteria (HbA1c ≥6.5% or pathological oral glucose tolerance test (OGTT)), aged 18-80 years at inclusion into the study
62090400|NCT05046483||Cohort of normal glucose tolerant people (NGT)|Prospectively followed cohort of healthy people with new onset of ST-elevation myocardial infarction and normal glucose tolerance status (HbA1c \<5.7% and normal OGTT), aged 18-80 years at inclusion into the study
62090401|NCT05046483||Cohort of people with impaired glucose metabolism (IGM)|Prospectively followed cohort of people with new onset of ST-elevation myocardial infarction and impaired glucose metabolism, usually called prediabetes including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) and/or HbA1c 5.7-6.4%, aged 18-80 years at inclusion into the study
62463068|NCT00855738|OTHER|1.0|
62654953|NCT02254824|ACTIVE_COMPARATOR|Lifestyle modification|Lifestyle modification
62654954|NCT04270955|ACTIVE_COMPARATOR|Symptomatic, standard of care|Patients in this group will be offered all procedures and care deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
62654955|NCT04270955|EXPERIMENTAL|Symptomatic, MMA embolization + standard of care|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Symptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
62654956|NCT04270955|ACTIVE_COMPARATOR|Asymptomatic, standard of care|Patients in this group will be offered all procedures deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
62654957|NCT04270955|EXPERIMENTAL|Asymptomatic, standard of care + MMA embolization|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Asymptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
62654958|NCT00765076|EXPERIMENTAL|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0
62654959|NCT00765076|ACTIVE_COMPARATOR|Fluarix elderly Group|Subjects aged \>= 65 years receiving 1 dose of Fluarix vaccine at Day 0
62654960|NCT00765076|ACTIVE_COMPARATOR|Fluarix young Group|Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0
62654961|NCT02251639|EXPERIMENTAL|Oral Imaging and Cytology|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors. Oral cavity inspected using a standard white light headlamp. Oral cavity then examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device. Exfoliative cells for cytology from an abnormal area (if present) and from a contralateral normal appearing area obtained using a brush.
62654962|NCT04069858|EXPERIMENTAL|Baracle|Chronic hepatitis B patients who swiched to Baracle® 1 mg from Baraclude® 1 mg treatment as mono- or combination therapy after the development of antiviral resistance to nucleos(t)ide analogues
62654963|NCT02513875|EXPERIMENTAL|vitamin D with diet and lifestyle|vitamin D supplementation along with diet and lifestyle modification was given
61905821|NCT01277003|EXPERIMENTAL|Aculife Magnetic Wave Therapist|patients with carpal tunnel syndrome treated with Aculife
61905822|NCT01277003|ACTIVE_COMPARATOR|TENS|patients with carpal tunnel syndrome treated by TENS
62090402|NCT01954043|EXPERIMENTAL|Arm A|Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
62090403|NCT02511561|EXPERIMENTAL|0.1 mL OTO-201|Ciprofloxacin
62654964|NCT02513875|PLACEBO_COMPARATOR|placebo with diet and lifestyle modification|placebo with diet and lifestyle modification was given
61905825|NCT06514989|EXPERIMENTAL|Low-residue nutrition formula podwer combined with 2 liters of polyethylene glycol|
61905826|NCT06514989|ACTIVE_COMPARATOR|Self-prepared low-residue diet combined with 3 liters of polyethylene glycol|
61905827|NCT01567839|EXPERIMENTAL|4% Lidocaine|1.8 mL of 4% lidocaine with 1:100,000 epinephrine
62090404|NCT02511561|EXPERIMENTAL|0.2 mL OTO-201|Ciprofloxacin
62288820|NCT03496753|EXPERIMENTAL|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
62288821|NCT03496753|NO_INTERVENTION|Control|The control group will receive orientation regarding breast care and adequate breastfeeding techniques. The experimental group will receive the same orientation plus phototherapy sessions using a device developed especially for the treatment of nipple trauma. Both groups will be followed up for six consecutive weeks.
62288822|NCT02423096||Schizophrenia|Patients with schizophrenia will be treated with antipsychotic drugs as routine care (i.e., risperidone, haloperidol, sulpiride, olanzapine, quetiapine).
62288823|NCT02423096||Healthy controls|No special intervention will be provided for healthy controls.
62288824|NCT01978002||Group 1 (Clinic Patients)|Women who have documented urinary status from surveys completed.
62288825|NCT01978002||Group 2 (Community Sample)|Women who have a clinical diagnosis of IC/BPS or OAB, and who have undergone urodynamic testing within the preceding 6 months as part of their routine clinical care.
62288826|NCT03270956|EXPERIMENTAL|Renal Autologous Cell Therapy (REACT)|Renal Autologous Cell Therapy (REACT) Treatment - Patients will receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
61905828|NCT01567839|EXPERIMENTAL|4% Articaine|1.8 mL of 4% articaine with 1:100,000 epinephrine
61905829|NCT01567839|EXPERIMENTAL|4% Prilocaine|1.8 mL of 4% prilocaine with 1:200,000 epinephrine
61905830|NCT04668027|EXPERIMENTAL|chronic airway disease group|Before the test, patients with FEV1/FVC≥0.7 are divided into the provocation test group, patients with FEV1/FVC \<0.7 are divided into the dilation test group.
62090405|NCT02511561|EXPERIMENTAL|0.4 mL OTO-201|Ciprofloxacin
62288827|NCT02144779|ACTIVE_COMPARATOR|Usual care|No treatment for this group
62288828|NCT02144779|EXPERIMENTAL|Assigned to palliative care team|The intervention group will be assigned to a palliative care team member that will facilitate communication and meetings between families and the medical team
62288829|NCT05035680|ACTIVE_COMPARATOR|Arm i - Seasonal influenza vaccine|Single 0.5 mL intramuscular (IM) injection of an unadjuvanted seasonal influenza vaccine
61905831|NCT03847441|ACTIVE_COMPARATOR|Group I|
61905832|NCT03847441|ACTIVE_COMPARATOR|Group II|
62288830|NCT05035680|EXPERIMENTAL|Arm ii - SWE and unadjuvanted seasonal influenza vaccine|Single 0.8 mL IM injection of SWE mixed with unadjuvanted seasonal influenza vaccine
62288831|NCT05035680|ACTIVE_COMPARATOR|Arm iii - MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
61905833|NCT03847441|ACTIVE_COMPARATOR|Group III|
61905834|NCT03847441|PLACEBO_COMPARATOR|Group IV|
61905835|NCT04489069|OTHER|Clinical, neuropsychological and MRI evaluations|
61905836|NCT05122598|ACTIVE_COMPARATOR|Computerized Olfactory Training (COT) Device with olfactory stimulants|COT device with olfactory stimulants consists of daily 40 cycles of intervention with a combination of olfactory stimulation and training tasks, lasting \~45 minutes, delivered once daily over 6 months period by the participant or their partner/caregiver.
62090406|NCT03260842||Pancreatic Cysts|Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
62090407|NCT03260842||High Risk Individuals|Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
62288832|NCT00771472|EXPERIMENTAL|Vorinostat|
62654965|NCT03629301|EXPERIMENTAL|ID-DPP group|Internet-delivered intervention based on the DPP
62654966|NCT03629301|OTHER|Wait-list Group|
62654967|NCT03550209|EXPERIMENTAL|LCPUFA Oil Supplement, Low Dose|25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
62463069|NCT00677118|EXPERIMENTAL|Concurrent and adjuvant|Concurrent chemoradiotherapy plus adjuvant chemotherapy
62463070|NCT00677118|ACTIVE_COMPARATOR|Concurrent|Concurrent chemoradiotherapy
62288833|NCT05682014|EXPERIMENTAL|İntervention Group|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
62090408|NCT00979173|EXPERIMENTAL|AC480|Patients who are not on enzyme inducing anti-epileptic drugs (EIAEDs) and are scheduled to undergo salvage surgical resection treated with preoperative AC480 at 300 mg BID followed by post-surgical AC480 at 300 mg BID.
62288834|NCT05682014|NO_INTERVENTION|Control Group|Only one session online breastfeeding training will be given and the training brochure for this training will be delivered to the participants via whatsapp.
62288835|NCT05175170|EXPERIMENTAL|Decision-aid|Participants will spend up to one hour freely navigating the web-based decision aid. They will complete pre- and post-test measures to determine if using the decision-aid website increased knowledge and impacted decision self-efficacy regarding fertility and fertility preservation.
62463071|NCT02419456|EXPERIMENTAL|MK-2048A Intravaginal Ring (IVR) (Low Dose)|The MK-2048A IVR (Low Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
62654968|NCT03550209|EXPERIMENTAL|LCPUFA Oil Supplement, Medium Dose|50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
62463072|NCT02419456|EXPERIMENTAL|MK-2048A IVR (Original Dose)|The MK-2048A IVR (Original Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
62654969|NCT03550209|EXPERIMENTAL|LCPUFA Oil Supplement, High Dose|75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
62654970|NCT03550209|PLACEBO_COMPARATOR|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
62463073|NCT03704220|OTHER|Single anti-thrombotic treatment|Single anti-thrombotic treatment
62463074|NCT03095846|EXPERIMENTAL|Winter Swimmers|Individualized cooling protocol
62463075|NCT03095846|EXPERIMENTAL|Not-winter Swimmers|Individualized cooling protocol
62654971|NCT02820415||infertile couples undergoing ICSI for PGS/PGT|patients aged between 29.0 and 42.3 years, with basal FSH on day 3 between 2.9 and 12.0 IU/l. Undergoing 36 patients for RIF or RM. In each couple, the two partners had a normal karyotype. The patients underwent one to two cycles of ovarian stimulation to vitrify and accumulate oocytes and a last (second or third) cycle of ovarian stimulation. Ovarian stimulation was performed by the administration of recombinant FSH and LH (Gonal-F and Luveris: Merck-Serono, London, UK or Puregon, MSD, Franklin Lakes, USA) from cycle day 3 and luteal gonadotrophin-releasing hormone antagonist flexible schema (Cetrotide : Merck-Serono, London, UK).
62654972|NCT01184911|EXPERIMENTAL|SP|Asymptomatic parasitemic pregnant women who receive the standard dose of sulfadoxine-pyrimethamine for prevention of placental malaria
62654973|NCT05424120|ACTIVE_COMPARATOR|Manual aspiration|pleural fluid is drained using a standard thoracentesis kit and via a syringe and three-way stopcock
62654974|NCT05424120|ACTIVE_COMPARATOR|Wall suction|pleural fluid is drained using a standard thoracentesis kit and by attaching tubing to wall suctioning set at -50 mmHg continuously
62654975|NCT05424120|ACTIVE_COMPARATOR|Vacuum bottle drainage|pleural fluid is drained using a standard thoracentesis kit and tubing that attaches to a glass vacuum container
62654976|NCT00903201|EXPERIMENTAL|Treatment A|20 mg of SB656933
62654977|NCT00903201|EXPERIMENTAL|Treatment B|50 mg of SB656933
61905837|NCT05122598|SHAM_COMPARATOR|Sham/COT Device|This is COT device that uses compressed room air scented with phenylethylamine (rose scent) instead of olfactory stimulants and has shape pattern matching tasks instead of cognitive tasks, in order to blind users to their treatment assignment. Similar to the COT, sham COT will be used daily for 45 minutes.
61905838|NCT05843786|EXPERIMENTAL|Interferon gamma treatment|Interferon gamma treatment (100 micrograms /day during 5 days)
61905839|NCT05843786|PLACEBO_COMPARATOR|Placebo|The comparator drug (placebo) is an injectable solution of sodium chloride 0.9%
61905840|NCT02881567|EXPERIMENTAL|Daclizumab|
61905841|NCT02128685|ACTIVE_COMPARATOR|Dydrogesterone|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
61905842|NCT02128685|PLACEBO_COMPARATOR|Placebo pill|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
61905843|NCT03260049||1|there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
61905844|NCT03260049||2|there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
61905845|NCT03260049||3|there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
61905846|NCT04572152|EXPERIMENTAL|AK119/ AK104|Single-arm
61905847|NCT01646164||Dill seed|used dill seed infusion (1 tablespoon whole dill seed seeped in a half or whole cup boiling water for 3-4 min)
62090409|NCT03818997|EXPERIMENTAL|BTC Cohort|Patient in BTC cohort will receive immune therapy and DKN-01 IV until PD
62654978|NCT00903201|EXPERIMENTAL|Placebo|Placebo
61905848|NCT01646164||No used Dill seed|those who had not used any herbal drugs were placed at the control group
61905849|NCT05960292|ACTIVE_COMPARATOR|Vaginal Hysterectomy (Group)|About 28 female patients will have vaginal vault closure by vaginal approach
62288836|NCT03972072|EXPERIMENTAL|Single Intervention Arm|daily imaging for MR-IGRT once weekly offline plan adaptation subjective/objective LENT-SOMA xerostomia-evaluation including flow measurements at baseline, 6 month-, 12 month- and 24 month-follow up EORTC-QoL questionnaires at baseline, 6 month-, 12 month- and 24 month-follow up
61905850|NCT05960292|ACTIVE_COMPARATOR|Abdominal Laparoscopic Hysterectomy (Group)|About 28 female patients will have vaginal vault closure by Abdominal Laparoscopic approach
61905851|NCT05229497|EXPERIMENTAL|Phase Ib#Dosage regimen 1#|Subjects receive AK112 (20 mg/kg Q3W) + AK117 (30 mg/kg QW)
61905852|NCT05229497|EXPERIMENTAL|Phase Ib#Dosage regimen 2#|Subjects receive AK112 (20 mg/kg Q3W) + AK117 (45 mg/kg QW)
61905853|NCT05229497|EXPERIMENTAL|Phase II#Cohort 1#|Head and neck squamous cell carcinoma (HNSCC): AK112 (20 mg/kg Q3W)
61905854|NCT05229497|EXPERIMENTAL|Phase II#Cohort 2#|HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)
61905855|NCT05229497|EXPERIMENTAL|Phase II#Cohort 3#|HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)+Carboplatin/cisplatin+5-fluorouracil
61905856|NCT01685398|PLACEBO_COMPARATOR|normal saline|normal saline 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
61905857|NCT01685398|EXPERIMENTAL|0.5% timolol maleate eye drop|0.5% timolol maleate solution 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
62090410|NCT03818997|EXPERIMENTAL|EGC cohort: DKN-01/atezolizumab + paclitaxel (Arm 1)|Patient randomized in the EGC Arm 1 will receive immune therapy, DKN-01 and chemotherapy intravenously (IV) until PD.
62090411|NCT03818997|EXPERIMENTAL|EGC cohort: DKN-01/atezolizumab without paclitaxel (Arm 2)|Patient randomized in the EGC Arm 2 will receive immune therapy and DKN-01 IV until PD
62090412|NCT04296942|EXPERIMENTAL|1/M7824 (Bintrafusp alfa) + Bavarian Nordic (BN)-Brachyury|"Arm 1 - Triple Negative Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury."
61905858|NCT02069275|EXPERIMENTAL|Immediate mobilization|Immediate mobilization after coronary angiography or percutaneous coronary intervention
61905859|NCT02069275|ACTIVE_COMPARATOR|Two hours bedrest|Bedrest two hours after coronary angiography or percutaneous coronary intervention
61905860|NCT02983279|EXPERIMENTAL|Dietary counseling, caloric restriction diet|Patients then undergo 25% caloric intake for 3-12 weeks prior to definitive cancer surgery.
61905861|NCT03581461|EXPERIMENTAL|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
61905862|NCT03826784|EXPERIMENTAL|BHA|Subjects treated with BHA + standard of care
61905863|NCT03826784|NO_INTERVENTION|Control|Subjects treated as per standard of care
62090413|NCT04296942|EXPERIMENTAL|2/M7824 + BN-Brachyury + Ado-trastuzumab emtansine (T-DM1)|"Arm 2 - Estrogen receptor (ER)-/progesterone receptor (PR)-/Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury. These investigational agents will be added to standard of care treatment called Ado-trastuzumab emtansine (T-DM1)."
62288837|NCT05211778|NO_INTERVENTION|Control Group|This group will continue to receive the routine standard of care during their treatment journey.
61905864|NCT03087799|EXPERIMENTAL|Brief Behavioral Treatment for Sleep|
61905865|NCT03087799|NO_INTERVENTION|Wait List Control|
61905866|NCT04931888|EXPERIMENTAL|Intervention|The intervention arm will receive the EMPOWER curriculum between the pre- and post-evaluations.
61905867|NCT04931888|OTHER|Waitlist|"The waitlist control arm will receive the EMPOWER curriculum after the evaluations. They will receive a second set of evaluations at the same time as the post evaluations of the control arm."
61905868|NCT05424770|EXPERIMENTAL|experiment group|During the 3 weeks in which the subjects related to pain control are explained, the standard lecture (explanation with ppt presentation) will be made as in the normal course of the course. Afterwards, puzzle activities prepared by the researcher will be implemented and students will be actively involved in the process.
61905869|NCT05424770|NO_INTERVENTION|control group|During the 3 weeks in which the subjects related to pain control are explained, the standard lecture (explanation with ppt presentation) will be made as in the normal course of the course.
61905870|NCT03314571||non applicable|
61905871|NCT06333600|ACTIVE_COMPARATOR|Group minoxidil (Treatment group)|Topical application of Minoxidil 5% solution
61905872|NCT06333600|ACTIVE_COMPARATOR|Group calcipotriol (Treatment group)|Topical application of vitamin D3 analogue (Calcipotriol ointment)
61905873|NCT06333600|PLACEBO_COMPARATOR|Group 3 (Negative control group)|This group will be given saline
61905874|NCT05143788|EXPERIMENTAL|New surgical plan group|The investigators use monopolar stimulators to determine and retain the tumor margin within 5mm from the posterior limb of the inner capsule in type III motor area glioma patients.
62463076|NCT03000296|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
62463077|NCT00862550|EXPERIMENTAL|Group 1|Acupuncture (Areas known to help dry mouth)
62654979|NCT03260400|EXPERIMENTAL|New Grafts|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the participant will have a shorter surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After another healing period, experiments with prosthetic control and sensory feedback will begin.
62654980|NCT03260400|EXPERIMENTAL|Existing Grafts|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The participant will have a short surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After a healing period, experiments with prosthetic control and sensory feedback will begin.
62654981|NCT02252263|EXPERIMENTAL|Arm 1: Elotuzumab + Lirilumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Lirilumab every 4 wks Intravenous solution for Up to 2 yrs, depending on response
62654982|NCT02252263|EXPERIMENTAL|Arm 2: Elotuzumab + Urelumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Urelumab every 4 wks Intravenous solution for Up to 26 weeks, depending on response
62654983|NCT06472557||SCA27B|Participants with genetically confirmed SCA27B (OMIM 620174), i.e. ≥250 uninterrupted GAA repeat expansions in FGF14, will be recruited. Target sample size for the SCA27B cohort is 200 participants.
62654984|NCT06472557||SCA27B risk subjects|First-degree relatives at risk for SCA27B, both with known and unknown carrier status, will be included to capture presymptomatic disease stages. Target sample size for the risk cohort is 50 participants
62654985|NCT06472557||Unrelated healthy controls|Unrelated healthy controls may undergo the same study procedures as the SCA27B cohort to determine age-related effects on the multimodal outcomes. Target sample size for the control cohort is 50.
62463078|NCT00862550|EXPERIMENTAL|Group 2|Acupuncture (Areas not known to help dry mouth)
62090414|NCT04296942|EXPERIMENTAL|3/M7824 + BN-Brachyury + T-DM1 + Entinostat|"Estrogen receptor (ER)-/progesterone receptor (PR)-/Human Epidermal Growth Factor Receptor 2 (HER2)+ Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury as well as to an oral histone deacetylase (HDAC) inhibitor called entinostat. These investigational agents will be added to standard of care treatment called Ado-trastuzumab emtansine (T-DM1). (T-DM1)."
62090415|NCT00740662||1|Distal gastric bypass
62090416|NCT03244137||Pulmonary rehabilitation|The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
62090417|NCT03691584|EXPERIMENTAL|BAL PK study|Bronchoalveolar lavage procedure performed at either 2, 4, 8, or 24 hours after final dose of TP-6076 on Day 4
62654986|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
62288838|NCT05211778|EXPERIMENTAL|Digital Education Group|In addition to the standard of care, this group will complete an audiovisual digital education module during their postoperative stay in hospital.
62288839|NCT02148367|ACTIVE_COMPARATOR|Erythropoietin (EPO)|Participants (n=20) will receive EPO with a dose of 40,000 IU EPO subcutaneously (s.c.) once weekly for 4 weeks.
62463079|NCT04089982|ACTIVE_COMPARATOR|Varenicline|Varenicline BID
62463080|NCT04089982|PLACEBO_COMPARATOR|Placebo|
62463081|NCT04063358|EXPERIMENTAL|Lucentis injected Pre-operatively|Lucentis injected 2 weeks before cataract surgery
62463082|NCT04063358|ACTIVE_COMPARATOR|Lucentis injected intra-operatively|Lucentis injected during the course of the surgery by cataract surgeon.
62463083|NCT04063358|EXPERIMENTAL|Lucentis injected post-operatively|Lucentis injected 2 weeks after cataract surgery
62463084|NCT05526950|ACTIVE_COMPARATOR|Treated|"Treatment using the medical cytokine adsorption device in conjunction with lung transplantation"
62654987|NCT05848063|EXPERIMENTAL|Group A: Global hip muscles strengthening exercises|Group A Group A will receive hot packs along with all hip muscle strengthening exercises. All exercises were performed for 3 sessions per week for 6 weeks. Outcome measures will be taken at baseline, in 3rd week, and at the end of the 6th week.
62654988|NCT05848063|ACTIVE_COMPARATOR|Group B: Hip abductors strengthening exercises|Group B will receive hot packs along with Hip abductors strengthening. A baseline assessment will be done on eligible participants. 3 sessions were given 3 days per week, Outcome measures will be taken at baseline, in 3rd week, and at the end of the 6th week.
62654989|NCT05000762||Patients with diabetes mellitus|Patients with type 2 diabetes mellitus
62288840|NCT02148367|PLACEBO_COMPARATOR|placebo|Participants (n=10) will receive placebo s.c. once weekly for 4 weeks
62463085|NCT05526950|NO_INTERVENTION|Non-treated|No additional treatment in conjunction with lung transplantation
62463086|NCT04031131|ACTIVE_COMPARATOR|Intervention Arm|topical anaesthetic gel and lubricating gel
62463087|NCT04031131|PLACEBO_COMPARATOR|Control Arm|lubricating gel alone
62654990|NCT01895842|EXPERIMENTAL|Ruxolitinib|"Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.~If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1."
62654991|NCT03056924||Vedolizumab monotherapy|IBD patients on vedolizumab monotherapy, all patients will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
61905875|NCT05143788|ACTIVE_COMPARATOR|Traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified by stimulator, the positive points are retained in order to preserve the motor function while all the non-positive points of the tumor are resected.
61905876|NCT05396716|EXPERIMENTAL|transcutaneous electrical acupoint stimulation|
62090418|NCT05073081|EXPERIMENTAL|Prehabilitation|The 8-week prehabilitation program will be delivered online using synchronous and asynchronous sessions delivered by either a physiotherapist, chiropractor or kinesiologist. There will be 4 individual exercises sessions delivered synchronously using Zoom or Physitrack in which motivational interviewing and graded activity exercises will be conducted. Participants will also be asked to exercise at least 3 times a week using the asynchronous exercise videos. The exercises will be individualized on participants functional ability and personal goals identified at baseline, with a focus on muscle strengthening, stretching, improving spinal flexibility and stability. There will be a booster session at 6-weeks post-op. Participants will also undergo 5 group educational sessions, which will provide information regarding: goal setting, pain education, self-management, pacing, post-operative expectations, exercise recommendations, and information regarding their upcoming surgery.
62090419|NCT05073081|ACTIVE_COMPARATOR|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice. This generally consists of one session with an anesthesiologist, a nurse and access to our online videos.
62090420|NCT05018962|EXPERIMENTAL|Cutting balloon followed by paclitaxel coated balloon|
62090421|NCT01884987||group one will receive non-GM1 conservative therapy|"Group one will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
62090422|NCT01684488|ACTIVE_COMPARATOR|Waitlist+EducAid|Immediately following enrollment, participants do not immediately receive any intervention. At 3 months, they are enrolled in EducAid educational programming for the 2012-2013 academic year.
62090423|NCT01684488|NO_INTERVENTION|Waitlist|Participants do not receive any intervention throughout the trial period. Once the trial has concluded, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
62288841|NCT00974220|PLACEBO_COMPARATOR|placebo|nebulized 0.9% saline placebo
62288842|NCT00974220|EXPERIMENTAL|fentanyl|nebulized fentanyl citrate (50 mcg)
62288843|NCT01552057|EXPERIMENTAL|Duloxetine 60 mg|Duloxetine hydrochloride up to 60 milligrams (mg) orally for 15 weeks
62288844|NCT01552057|PLACEBO_COMPARATOR|Placebo|Placebo orally for 15 weeks
62654992|NCT03056924||vedolizumab + immunomodulator|IBD patients receiving combination treatment with vedolizumab and concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine), will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and/or receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
62654993|NCT03056924||biologic + immunomodulator|IBD patients on other biologic therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab) with concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine) and receivePneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
61905877|NCT05396716|NO_INTERVENTION|Control|
61905878|NCT05545280|ACTIVE_COMPARATOR|Neostigmine|Reversal of Neuromuscular Block by Neostigmine.
61905879|NCT05545280|ACTIVE_COMPARATOR|Sugammadex|Reversal of Neuromuscular Block by Sugammadex.
61905880|NCT03219775|EXPERIMENTAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab~* If CR/PR: Nivolumab Maintenance Mono-Therapy~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~* If CR/PR: Nivolumab Maintenance Mono-Therapy~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
62090424|NCT01684488|EXPERIMENTAL|YRI only|Immediately following enrollment, participants complete the YRI. They are then placed on a waitlist for the remainder of the trial. At the end of the trial, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
62463088|NCT04167410|NO_INTERVENTION|control group|We did not perform any intervention on the patients in the control group. These patients received routine glycaemia control and healthcare provided to diabetic patients undergoing surgical intervention in the department of general surgery.After receiving written informed consent, the first part of the data collection form on the socio-demographic and disease characteristics of the patients were completed face-to-face. The BG levels of the patients and the medications and insulin used for glycaemic control were recorded one night before surgery. The anxiety levels of the patients were evaluated on the morning of surgery using State-Trait Anxiety Inventory . The second part of the data collection form , which included information on glycaemic management, glycaemia levels and the medications and insulin used on the morning of surgery and during surgery, intensive care stay and the clinical period, was filled in by the nurse on the monitoring and anaesthesia forms.
62654994|NCT03056924||non-immunosuppressive therapy|IBD patients not taking any immunosuppressive therapy (these patients may be taking oral or topical 5-aminosalicylates) and recive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
62654995|NCT01481467|EXPERIMENTAL|Intervention|Influenza vaccination implementation strategy applied.
62654996|NCT01481467|NO_INTERVENTION|Control|Usual care.
62654997|NCT05138562|PLACEBO_COMPARATOR|Placebo|4 Placebo capsules
62090425|NCT01684488|EXPERIMENTAL|YRI+EducAid|Immediately following enrollment, participants complete the YRI. Participants are then immediately enrolled in EducAid educational programming for the 2012-2013 academic year.
62090426|NCT01201564|ACTIVE_COMPARATOR|intraperitoneal onlay mesh repair|
62090427|NCT01201564|ACTIVE_COMPARATOR|sublay mesh repair|
62463089|NCT04167410|EXPERIMENTAL|intervention group|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. management was conducted by nurses in line with the protocol. Data on glycaemic management of the intervention group was similar to the control group.the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protoco
62654998|NCT05138562|ACTIVE_COMPARATOR|TU2670 High Dose|320mg, QD
62654999|NCT05138562|ACTIVE_COMPARATOR|TU2670 Medium Dose|240 mg, QD
62655000|NCT05138562|ACTIVE_COMPARATOR|TU2670 Low Dose|120 mg, QD
62655001|NCT04817878||Late preterm infant group|Gestational age 33 weeks-36 weeks
62655002|NCT04817878||Very premature infant group|Gestational age 28 weeks-32 weeks
62655003|NCT04817878||Super preterm infant group|Gestational age less than 28 weeks
62655004|NCT02064062|EXPERIMENTAL|Autologous Mesenchymal Stem Cells|
62655005|NCT05743907|EXPERIMENTAL|DA-2811|DA-2811 + Forxiga placebo
62655006|NCT05743907|ACTIVE_COMPARATOR|Forxiga|Forxiga + DA-2811 placebo
62655007|NCT01336270||MELANOMA 10mm|patients with a melanoma larger than 10mm or with cutaneous metastasis
62655008|NCT01336270||STAGE III MELANOMA|stage III melanoma patients who shall undergo a regional lymph node dissection
62655009|NCT01336270||SENTINEL NODE PROCEDURE|retrospective study of patients who underwent a sentinel node procedure
62655010|NCT01336270||STAGE IV MELANOMA|stage IV patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
61905881|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
61905882|NCT02303392|EXPERIMENTAL|Treatment (selinexor, ibrutinib)|Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61905883|NCT05363254|EXPERIMENTAL|Cohort 1: Marlboro Gold Box|Subjects will self-assign to a Cohort 1 based on their self-reported use of Marlboro Gold as their usual brand of combustible cigarettes.
61905884|NCT05363254|EXPERIMENTAL|Cohort 2: Newport Box|Subjects will self-assign to a Cohort 2 based on their self-reported use of Newport as their usual brand of combustible cigarettes.
62090428|NCT00950209|ACTIVE_COMPARATOR|euglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l."
62090429|NCT00950209|ACTIVE_COMPARATOR|euglycaemic hyperinsulinic clamp with Endolipide and heparin|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l but will be also infused with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids."
62288845|NCT00531960|ACTIVE_COMPARATOR|Bevacizumab, Chemotherapy|Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m\^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m\^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m\^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (\*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
62288846|NCT00531960|EXPERIMENTAL|Bevacizumab, Erlotinib|Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal.
62288847|NCT03883074|EXPERIMENTAL|GERDOff® Plus|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate Melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
62463090|NCT06312371|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
62463091|NCT06312371|ACTIVE_COMPARATOR|Nasogastric Tube Feeding|the group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
62463092|NCT04519437|EXPERIMENTAL|REGN10933+REGN10987|
61905885|NCT05363254|EXPERIMENTAL|Cohort 3: HTP device with mode A (20023145) and non-combusted cigarette variant 42001401|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
62288848|NCT03883074|PLACEBO_COMPARATOR|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
61905886|NCT05363254|EXPERIMENTAL|Cohort 4: HTP device with mode B (20022187) and non-combusted cigarette variant 42001401|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
61905887|NCT05363254|EXPERIMENTAL|Cohort 5: HTP device with mode A (20023145) and non-combusted cigarette variant 42001399|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
61905888|NCT05363254|EXPERIMENTAL|Cohort 6: HTP device with mode B (20022187) and non-combusted cigarette variant 42001399|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
61905889|NCT05363254|EXPERIMENTAL|Cohort 7: HTP device with mode A (20023145) and non-combusted cigarette variant 40007386|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
61905890|NCT05363254|EXPERIMENTAL|Cohort 8: HTP device with mode B (20022187) and non-combusted cigarette variant 40007386|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
61905891|NCT05363254|EXPERIMENTAL|Cohort 9: HTP device with mode A (20023145) and non-combusted cigarette variant 42001402|Subjects will self-assign to one of 2 non-menthol flavor variant cohorts (Cohort 9 and 10) of non-combusted cigarette products based on their self-reported flavor usage history.
62463093|NCT04519437|PLACEBO_COMPARATOR|Placebo|
61905892|NCT05363254|EXPERIMENTAL|Cohort 10: HTP device with mode B (20022187) and non-combusted cigarette variant 42001402|Subjects will self-assign to one of 2 non-menthol flavor variant cohorts (Cohort 9 and 10) of non-combusted cigarette products based on their self-reported flavor usage history.
61905893|NCT01585675||Diagnosis/treatment of lung cancer|Specimen Banking
62463094|NCT04556565||General population|A representative sample of the general adult population (including those tele-working and working outside of home)
61905894|NCT01661842|EXPERIMENTAL|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 96 study visit."
61905895|NCT01661842|EXPERIMENTAL|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
61905896|NCT06173180|ACTIVE_COMPARATOR|VACS-Minifiks (VACS-D)|During the surgical procedure, this group operated with VACS-Minifiks.
61905897|NCT06173180|ACTIVE_COMPARATOR|Transobturator Tape (TOT)|During the surgical procedure, this group operated with the commercially available Transobturator Tape (TOT).
62288849|NCT04362709||Postoperative complications|
62288850|NCT04362709||No postoperative complications|
62288851|NCT05265767|EXPERIMENTAL|Autologous HSCT CD68-ET3-LV gene therapy|Autologous gene modified peripheral blood stem cell transplantation for patients with severe hemophilia A (FVIII \<1%).
62288852|NCT05173584|EXPERIMENTAL|Levalbuterol Arm|
62288853|NCT05173584|ACTIVE_COMPARATOR|Albuterol Arm|
62288854|NCT04210271|EXPERIMENTAL|HIV Self-testing|brief intervention to teach and support consistent self-testing with a friend
62463095|NCT04556565||Cases and contacts|Recently isolated or quarantined COVID-19 cases and close contacts
62288855|NCT04210271|ACTIVE_COMPARATOR|Generic Self-screening|time and attention control providing basic self-screening education on a range of health outcomes
62655011|NCT03772223|EXPERIMENTAL|Treatment sequence 1 (ABC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler \[BDA MDI\] - PT027) , Treatment B (Budesonide metered dose inhaler \[BD MDI\] - PT008), and Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
61905898|NCT03851172|EXPERIMENTAL|Nepafenac and cyclopentolate|Nepafenac 1 mg eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
62288856|NCT03032783|EXPERIMENTAL|Treatment (TBI, DLI, chemotherapy, HSCT)|Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
62288857|NCT04684654|EXPERIMENTAL|Part A (SAD)|Single Ascending Dose (SAD)
62288858|NCT04684654|PLACEBO_COMPARATOR|Part A (SAD) Placebo|
62288859|NCT04684654|EXPERIMENTAL|Part B (MAD)|Multiple Ascending Dose (MAD)
62288860|NCT04684654|PLACEBO_COMPARATOR|Part B (MAD) Placebo|
62288861|NCT04684654|EXPERIMENTAL|Part C (pSS)|Primary Sjögren's Syndrome (pSS)
62288862|NCT04684654|PLACEBO_COMPARATOR|Part C (pSS) Placebo|
62288863|NCT05313880||Digital tool Survey|Sequential patients from the 4 heart failure clinics at our institution will be offered to take part in the study.
62288864|NCT06148961|EXPERIMENTAL|intervention group|"botox injection prior to surgical intervention by 5 to 10 days A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
61905899|NCT03851172|EXPERIMENTAL|Ketorolac and cyclopentolate|Ketorolac 0.5% eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
62288865|NCT06148961|ACTIVE_COMPARATOR|control group|"A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
62288866|NCT04724161||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Changara, Guro, and Chemba districts.
62288867|NCT05012878|EXPERIMENTAL|Cardiac rehabilitation - High intensity interval training (HIIT)|Patients attending cardiac rehabilitation randomized to HIIT.
62288868|NCT05012878|ACTIVE_COMPARATOR|Cardiac rehabilitation - Moderate intensity continuous training (MICT)|Patients attending cardiac rehabilitation randomized to MICT.
61905900|NCT03851172|PLACEBO_COMPARATOR|Cyclopentolate and saline 0.9%|Cyclopentolate eye drops two times before surgery and saline 0.9% eye drops two times before cataract surgery
62090430|NCT00950209|ACTIVE_COMPARATOR|hyperglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose."
62655012|NCT03772223|EXPERIMENTAL|Treatment sequence 2 (BCA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler \[BD MDI\] - PT008), Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler \[BDA MDI\] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
62655013|NCT03772223|EXPERIMENTAL|Treatment sequence 3 (CBA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007), Treatment B (Budesonide metered dose inhaler \[BD MDI\] - PT008), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler \[BDA MDI\] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
62655014|NCT03772223|EXPERIMENTAL|Treatment sequence 4 (ACB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler \[BDA MDI\] - PT027), Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007), and Treatment B (Budesonide metered dose inhaler \[BD MDI\] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
62655015|NCT03772223|EXPERIMENTAL|Treatment sequence 5 (BAC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler \[BD MDI\] - PT008), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler \[BDA MDI\] - PT027), and Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
62655016|NCT03772223|EXPERIMENTAL|Treatment sequence 6 (CAB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler \[BDA MDI\] - PT027), and Treatment B (Budesonide metered dose inhaler \[BD MDI\] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
62655017|NCT04564599||alcohol- and drug-related motor vehicle collisions|Number of alcohol- and drug-related motor vehicle collisions
61905901|NCT03525964|EXPERIMENTAL|Individualized treatment|"The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast after surgery. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
62090431|NCT04245033|EXPERIMENTAL|IPTsc arm|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment in school children (IPTsc) will be given in all wards in the IPTsc arm at an interval of four months, three times a year.
62090432|NCT04245033|NO_INTERVENTION|Control|No intervention will be given to wards randomised in this arm
62288869|NCT05012878|PLACEBO_COMPARATOR|Cardiac rehabilitation - control|The control group (12 week period) will include participants who have declined cardiac rehabilitation.
62655018|NCT04564599||auto-ped alcohol- and drug-related collisions|Number of auto-ped alcohol- and drug-related collisions
62655019|NCT02896166|EXPERIMENTAL|microwave ablation|The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
62655020|NCT01416571|EXPERIMENTAL|Influenza A (H5N1) Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
62655021|NCT03613870|ACTIVE_COMPARATOR|PermeaDerm|Participants receive PermeaDerm dressing for wound treatment until wounds have healed completely
62288870|NCT05012878|NO_INTERVENTION|Healthy control group|Healthy age-matched adults without cardiovascular disease, who will complete baseline assessments only. No intervention period.
61905902|NCT03525964|ACTIVE_COMPARATOR|Control group 1|"For the patients allocated to non-operative treatment the injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
62463096|NCT04556565||Healthcare workers|Healthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers)
62655022|NCT03613870|ACTIVE_COMPARATOR|Mepilex Ag|Participants receive Mepilex Ag dressing for wound treatment until wounds have healed completely
62655023|NCT00255177|PLACEBO_COMPARATOR|Placebo|
62655024|NCT00255177|ACTIVE_COMPARATOR|150 mg daily|
62655025|NCT00255177|ACTIVE_COMPARATOR|300mg daily|
62655026|NCT00255177|ACTIVE_COMPARATOR|300mg twice daily|
62655027|NCT05486273|EXPERIMENTAL|Groupe OC (Onco-Coaching)|"You will be offered 6 coaching sessions at a rate of one session per month. The first session will take place in the month following your inclusion in the study.~The study also includes the evaluation, by quality of life questionnaires, of the well-being variables (Self-efficacy, Capabilities, PANAS and Life Satisfaction, Hope, Anxiety and Depression in hospital, Subjective well-being and Health benefit).~They should be completed at the time of inclusion in the protocol at 1, 3, 6, 9 and 12 months after inclusion. The purpose of these interviews is to ask more specific questions about the impact of the program."
62463097|NCT04322500|OTHER|Group A: conservative|conservative treatment
62463098|NCT04322500|EXPERIMENTAL|Group B: probiotics|in addition to the conservative treatment they receive a probiotics mixture (Streptococcus thermophilus ST10, Lactococcus lactis LLCO2 and Lactobacillus delbrueckii subsp. bulgaricus LDB01)
62655028|NCT05486273|ACTIVE_COMPARATOR|Groupe C (Contrôle)|the patient will have standard management including also questionnaires and semi-structured interviews within the same time frame as the experimental arm.
62655029|NCT03210532|EXPERIMENTAL|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
62655030|NCT03210532|ACTIVE_COMPARATOR|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
62655031|NCT03210532|ACTIVE_COMPARATOR|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
62655032|NCT04885608|EXPERIMENTAL|PReGe|Group that will perform the intervention with therapeutic exercise.
62655033|NCT06387017|OTHER|all patients|
62655034|NCT03813108|EXPERIMENTAL|1: NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes under mefloquine prophylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
62655035|NCT03813108|EXPERIMENTAL|2: Low dose NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 5 NF135.C10 infected Anopheles mosquitoes under mefloquine prophylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
62655036|NCT03813108|EXPERIMENTAL|3: NF135 CPS-immunization (A/L) challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemether/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes.
62655037|NCT03813108|EXPERIMENTAL|4: NF135 CPS-immunization (A/L) challenged by NF54|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemether/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
62655038|NCT03813108|OTHER|5: Control group challenged by NF135.C10 Cohort A|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
62288871|NCT05012878|OTHER|Cardiac rehabilitation - observational|This observational group will include patients who are completing an exercise-based cardiac rehabilitation program in line with standard care but are not part of the randomized exercise protocol groups (HIIT or MICT). Participants in this group will be combined with HIIT and MICT (as exercise-based cardiac rehabilitation group) for Aims 1b and 2b.
62463099|NCT05980156|EXPERIMENTAL|Intermittent Preventive Treatment with dihydroartemisinin-piperaquine (IPT-DP)|All students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
62090433|NCT03015740|EXPERIMENTAL|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.
62288872|NCT04972877|ACTIVE_COMPARATOR|Treatment group|Treatment group protocol：participants will receive electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
62288873|NCT04972877|SHAM_COMPARATOR|Control group|Control group protocol：participants will receive sham electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
62655039|NCT03813108|OTHER|6: Control group challenged by NF54 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
62655040|NCT03813108|OTHER|7: Control group challenged by NF135 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
62090434|NCT02543450|EXPERIMENTAL|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
62090435|NCT02543450|ACTIVE_COMPARATOR|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
62090436|NCT04394624|EXPERIMENTAL|Ramucirumab + SAR408701|Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.
62288874|NCT03624738|ACTIVE_COMPARATOR|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
62655041|NCT05534542|ACTIVE_COMPARATOR|core stabılızatıon|use of ıntradıalıtıc core stabılızatıon ın hemodıalysıs patıents
62288875|NCT03624738|ACTIVE_COMPARATOR|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
62288876|NCT04356456|EXPERIMENTAL|Lumenato Supplement|Lumenato oleoresin
62288877|NCT04356456|PLACEBO_COMPARATOR|Placebo|paraffin oil
62655042|NCT05534542|ACTIVE_COMPARATOR|aerobıc exercıse|use of ıntradıalıtıc aerobıc exercıse ın hemodıalysıs patıents
62655043|NCT04173949|EXPERIMENTAL|Ramipril 2.5 MG|Ramipril 2.5 MG orall, daily.
62288878|NCT02337387|EXPERIMENTAL|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
62288879|NCT02337387|EXPERIMENTAL|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
62288880|NCT02337387|PLACEBO_COMPARATOR|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
62288881|NCT02337387|EXPERIMENTAL|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
62463100|NCT05980156|EXPERIMENTAL|Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus chloroquine (IPT-SPCQ)|All students are treated at each intervention. Treatment will be with SP + CQ (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
62463101|NCT05980156|NO_INTERVENTION|Control|Students will not receive preventive treatment.
62463102|NCT04196322||Controlled|
62463103|NCT04196322||Uncontrolled|
62463104|NCT02515422|ACTIVE_COMPARATOR|Group 1, Ketamine|Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.
62655044|NCT04763967||PedSCath|Subjects in this arm will be catheterized with the PedSCath Pediatric Urinary Cather.
62463105|NCT02515422|ACTIVE_COMPARATOR|Group 2, Bupivacaine|Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.
62463106|NCT02515422|ACTIVE_COMPARATOR|Group 3, Ketamine+Bupivacaine|Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.
62463107|NCT02515422|PLACEBO_COMPARATOR|Group 4, Placebo|Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.
62655045|NCT04763967||Retrospective Control|Generated from 2016 and 2018 anonymized subject data from the clinical sites.
62090437|NCT04394624|EXPERIMENTAL|Ramucirumab + pembrolizumab +SAR408701|Participants will be treated with tusamitamab ravtansine and ramucirumab and pembrolizumab to assess the tolerability of the combination
62090438|NCT04075292|EXPERIMENTAL|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity
62288882|NCT04106154|EXPERIMENTAL|Intervention|The kinesiology intervention will involve physical activity education appropriate to the MC\&D delivered in a group format through twelve 2.5-hour weekly sessions49 (30 hours of kinesiology support). The sessions will combine participation in physical activities appropriate to the MC\&D with education and goal-setting discussions. Each week, children will be guided to develop an individualized SMART (Specific, Measurable, Agreed upon, Realistic, Time-based) plan for changing their activity behaviour. Their weekly SMART plan, which will require an additional 2 hours per week, will specify the home/community activities they will do prior to the next session.
62288883|NCT04106154|NO_INTERVENTION|Control|Patients in the control group will continue with clinical care as usual. To encourage their cooperation, children in the control group will be offered the intervention after all of their study visits have been completed.
62288884|NCT01540643||Abdominal aortic aneurysm|
62288885|NCT02224898||Definite/Suspected Chronic Pancreatitis|Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
62288886|NCT02224898||Healthy Control Group|Patients with no history of chronic gastrointestinal symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and are not currently experiencing gastrointestinal symptoms. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
62288887|NCT04402801||Standard of Care Telemedicine Cohort|This cohort will have telemedicine visits in lieu of in-person clinic visits
62288888|NCT04402801||Standard of Care In-Person Cohort|
62288889|NCT01587066|ACTIVE_COMPARATOR|Quetiapine fumarate|
62288890|NCT01587066|ACTIVE_COMPARATOR|Divalproex sodium|
62463108|NCT04464798|EXPERIMENTAL|Cohort A- Monotherapy in R/R lymphoma subjects|Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
62463109|NCT04464798|EXPERIMENTAL|Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects|"Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.~* Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.~* Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC administration at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
62463110|NCT04464798|EXPERIMENTAL|Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects|"Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.~* Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~* Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6."
62655046|NCT05980546|NO_INTERVENTION|Group 1 Standard TKA|"The standard TKA group will receive the standard of care analgesia. Those in the control group will be given 7 mg of the preservative dexamethasone intravenously.~The standard group will be given 2-5 mg of intravenous midazolam and up to 100 mcg fentanyl for sedation and analgesia while the peripheral nerve blocks and spinal anesthesia are being performed. All patients will receive a spinal anesthetic (1.5% mepivacaine 52.5 - 60mg) as well as the standard adductor canal block and infiltration between the popliteal artery and posterior knee capsule block (20 ml of 0.25% bupivacaine with 2 mg preservative free dexamethasone for each block)."
62090439|NCT04075292|ACTIVE_COMPARATOR|Rituximab and Chlorambucil|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles
62090440|NCT04660968|EXPERIMENTAL|Dyadic Health Behaviour Change Intervention|The dyadic health behaviour change intervention is a 10 sessions program provided over 16 weeks. It includes nutritional, physical activity and sedentary related information, as well as couples-based adaptation of motivational interviewing, self-monitoring, goals setting, stimulus control, problem-solving, and relapse prevention as well as specific strategies to support their partner's autonomy and intrinsic motivation.
62288891|NCT05830383|EXPERIMENTAL|PDCA circular management|The countermeasure 1-ABC rescue training:Clarify the positions and perform their duties; Countermeasure 2-Advanced Life Support (ACLS) training: Clear division of labor and strengthen the cooperation Tune; Countermeasure 3-Objective Structural Clinical Test (OSCE Exam): Objective, orderly, and organized assessment
62288892|NCT02866864||Subjects with animal allergy|Subjects who suffer from allergic symptom during contact with animal
62288893|NCT02866864||Subjects without animal allergy|Subjects who do not suffer from allergic symptom during contact with animal
61905903|NCT03525964|ACTIVE_COMPARATOR|Control group 2|"The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
61905904|NCT00156936|EXPERIMENTAL|Medisorb naltrexone 380 mg (VIVITROL)|
61905905|NCT00156936|EXPERIMENTAL|Oral naltrexone to Medisorb naltrexone 380 mg (VIVITROL)|
61905906|NCT04756336|EXPERIMENTAL|LTX-109 treatment|Patients are treated with LTX-109 gel, 3% w/w twice daily (morning- evening) by application on active hidradenitis lesions during the intervention period of 6 weeks
61905907|NCT05918471|EXPERIMENTAL|Very Low Energy Diet + Standard Counselling|All patients in the intervention group will receive standard patient counselling on weight loss and an active VLED protocol. The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Patients will receive a three-week supply. They will be instructed to consume four packets daily. This provides a total energy intake of 900 kcal. Patients will also be able to consume up to 2 cups of low-calorie vegetables per day along with the meal replacement product. They will be provided with a handout containing specific instructions. Patients will keep self-report diaries of their dietary intake and activity levels.
62090441|NCT04660968|ACTIVE_COMPARATOR|Dyadic nutrition counselling intervention|The couples-based nutrition counselling intervention is a 10 sessions program provided over 16 weeks. Topics are based on Dietitians of Canada's Practice-based Evidence in Nutrition discussions. Participants are also encouraged to meet the current physical activity recommendations. Both members of the couples are seen at the same, but no intervention target specifically the behaviour change process or the romantic relationship.
62090442|NCT04834024|EXPERIMENTAL|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|
62090443|NCT04834024|ACTIVE_COMPARATOR|lenalinomide|
62090444|NCT03099785|ACTIVE_COMPARATOR|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
62090445|NCT03099785|ACTIVE_COMPARATOR|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
61905908|NCT05918471|NO_INTERVENTION|Standard Counselling Alone|The control group patients will receive standard counselling for weight loss without prescription of a specific preoperative weight loss intervention, as this is meant to be a pragmatic trial. Currently, there are no standardized interventions aimed at optimizing obese patients prior to undergoing non-bariatric surgery. Briefly, counselling will consist of the surgeon, at the time of the preoperative clinic visit, discussing weight loss strategies such as decreased caloric intake and increased physical activity. Patients will not receive prescriptions for preoperative VLEDs, any other weight loss supplement, or any physical activity intervention aimed at promoting weight loss prior to surgery. Patients will keep self-report diaries of their dietary intake and activity levels.
61905909|NCT00660686|EXPERIMENTAL|1|Progressive resistance training program 3 times a week for 12 months
61905910|NCT00660686|ACTIVE_COMPARATOR|2|Seated flexibility training 3 times a week for 12 months
62090446|NCT03099785|PLACEBO_COMPARATOR|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
62090447|NCT03811561|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide once weekly as subcutaneous (s.c., under the skin) injection added to standard of care.
62090448|NCT03811561|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (semaglutide) once weekly as subcutaneous subcutaneous (s.c., under the skin) injection added to standard of care.
62288894|NCT04788420||Sorafenib group|Patients assigned to this group received sorafenib post-transplantation.
62463111|NCT04464798|EXPERIMENTAL|Cohort D -CC-220 monotherapy in participants with aggressive B-cell lymphoma and follicular lymphoma|
61905911|NCT01929941|EXPERIMENTAL|Group 1 INCB047986|
61905912|NCT01929941|EXPERIMENTAL|Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel|
61905913|NCT03310307|ACTIVE_COMPARATOR|vitamin D3|50,000 IU
62090449|NCT04376983|NO_INTERVENTION|Control|Patients will get no intervention
62090450|NCT04376983|EXPERIMENTAL|Intervention|Patients will transmit their CRT data every week (first 6 weeks) and then every two week to the Heart Centre Hasselt. The physical activity data will be used to deliver a tailored motivational message to the patient to increase physical activity in this group.
62288895|NCT04788420||Control group|Patients assigned to this group did not receive sorafenib or any other FLT3 inhibitor post-transplantation until reaching the primary outcome.
62463112|NCT04464798|EXPERIMENTAL|Cohort E - CC-220 and rituximab in participants with aggressive B-cell lymphoma|
62463113|NCT04464798|EXPERIMENTAL|Cohort F - CC-220 and rituximab with follicular lymphoma grade 1-3a|
61905914|NCT03310307|PLACEBO_COMPARATOR|Placebo|Similar in size, shape and color to vitamin D3
61905915|NCT04986358|OTHER|Patient cohorte|Cohort of patients who will benefit from surgical management of their Hallux Valgus with post-operative follow-up at 2 years
61905916|NCT04529356|SHAM_COMPARATOR|Simple acetaminophen treatment|Acetaminophen will be taken when patients suffered from headache during the study. No specific dosage and frequency was required for this group as long as the participants record the exact drug usage.
61905917|NCT04529356|ACTIVE_COMPARATOR|Simple acetaminophen combined with low-frequency rTMS|Apart from acetaminophen usage, low frequency TMS (1HZ) will be used in patients three times a month for 6 months.
62090451|NCT04760444|EXPERIMENTAL|Peer Leader Diabetes Self-Management Support (PLDSMS)|Participants in the PLDSMS arm will receive 10 hours of group diabetes self-management education (DSME) with a certified diabetes care and education specialist. After the DSME group sessions, the group will complete 6 1-hour weekly diabetes self-management support (DSMS) session led by two peer leaders.
62655047|NCT05980546|EXPERIMENTAL|Group 2 Genicular TKA|"The genicular group will receive the study intervention of a genicular nerve block and anterior femoral cutaneous nerve block. The intervention group (genicular nerve block/anterior femoral cutaneous nerve block) will receive additional nerve blocks totaling 30 ml of 0.25% bupivacaine with 4 mg preservative-free dexamethasone (5 ml for each block: SMGN, IMGN, SLGN, NVI; 10ml for AFCN).~The genicular group will be given 2-5 mg of intravenous midazolam and up to 100 mcg fentanyl for sedation and analgesia while the peripheral nerve blocks and spinal anesthesia are being performed. All patients will receive a spinal anesthetic (1.5% mepivacaine 52.5 - 60mg) and the standard adductor canal block and infiltration between the popliteal artery and posterior knee capsule block (20 ml of 0.25% bupivacaine with 2 mg preservative free dexamethasone for each block)."
62655048|NCT02908347|EXPERIMENTAL|MP1032|"Test Product:~100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days"
62655049|NCT02908347|EXPERIMENTAL|Placebo|"Placebo to MP1032:~2 capsules of Placebo are provided orally twice daily for 42 days"
62655050|NCT04456127|NO_INTERVENTION|Standard of Care|Scar section does not receive CO2 laser therapy.
62655051|NCT04456127|EXPERIMENTAL|Factional CO2|Scar section receives fractional CO2 laser therapy.
61905918|NCT04529356|EXPERIMENTAL|Simple acetaminophen combined with high-frequency rTMS|Apart from acetaminophen usage, high frequency TMS (10HZ) will be used in patients three times a month for 6 months.
62090452|NCT04760444|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive 10 hours of group diabetes self-management education (DSME) with a certified diabetes care and education specialist.
62090453|NCT02424461|ACTIVE_COMPARATOR|7 day-antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days~Placebo of ofloxacine for 7 days"
62090454|NCT02424461|ACTIVE_COMPARATOR|14-day antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days"
62090455|NCT04453787|EXPERIMENTAL|Arch support orthoses with forefoot medial wedge|The intervention of this group include orthoses with arch support and added forefoot medial wedge.
62090456|NCT04453787|EXPERIMENTAL|Arch support orthoses|The intervention of this group include orthoses with arch support.
62090457|NCT04453787|SHAM_COMPARATOR|Flat insole|This group will wear a flat insole. It is made from ethylene-vinyl acetate copolymer with 4mm thickness. It only provide shock absorbtion.
62090458|NCT04860128|EXPERIMENTAL|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
62288896|NCT01555229|EXPERIMENTAL|Intermittent drainage|Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
62288897|NCT01555229|ACTIVE_COMPARATOR|Continuous drainage.|Continuous subglottic secretion drainage at -20 mmHg.
62655052|NCT06228339|EXPERIMENTAL|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
62655053|NCT06228339|ACTIVE_COMPARATOR|Xatral® XL 10 mg|Xatral® XL 10 mg (Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets)(Reference Drug)
62655054|NCT05018780|EXPERIMENTAL|Muscle Energy Technique|"Post isometric relaxation: Patient will perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds and than participants will be asked to relax the contraction with an exhalation. This will be repeated five times in one session.~- Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
62736377|NCT02107625|EXPERIMENTAL|Diet B, i.e. Traditional IBS diet|The patients are thoroughly informed verbally and in writing how to eat according to traditional IBS dietary advices. The diet imply adapting to regular dietary habit with meals 6 times a day, no to big meals, to chew food thoroughly, to peel fruits and vegetables, no carbonated beverages, no chewing gum, no soft drinks, no sugar-free candies, or cookies. Reduce spicy foods, coffee, alcohol, onion, pulses, and fatty foods. Keep strictly to the dietary advice for 4 weeks.
62736378|NCT04651764|EXPERIMENTAL|Robotically assisted transanal endoluminal resection of rectal lesion|
61905919|NCT02227940|EXPERIMENTAL|Arm 1 (ceritinib MTD then with gemcitabine alone)|"Dose Escalation Cohort 1: Patients with advanced solid tumors for whom gemcitabine hydrochloride-based therapy is clinically appropriate receive ceritinib PO (QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 1E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors who previously progressed on gemcitabine hydrochloride-based therapy receive ceritinib and gemcitabine hydrochloride as in the dose escalation cohort 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
61905920|NCT02227940|EXPERIMENTAL|Arm 2 (ceritinib MTD then with gemcitabine and nab-paclitaxel)|"Dose Escalation Cohort 2: Patients with advanced pancreatic cancer receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 2E: Once the MTD of ceritinib has been determined, patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation as in the dose escalation cohort 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62288898|NCT01745809||Severe Asthmatics|Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
62288899|NCT01745809||Healthy non-smokers|Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
62288900|NCT03679325|ACTIVE_COMPARATOR|vitamine D|a dose once a week
62288901|NCT03679325|PLACEBO_COMPARATOR|vitamine D placebo|a dose once a week
62288902|NCT03073746|EXPERIMENTAL|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
62463114|NCT04464798|EXPERIMENTAL|Cohort G - CC-220 plus obinutuzumab in participants with follicular lymphoma grade 1-3a|
62655055|NCT05018780|EXPERIMENTAL|Sacral Manipulation|"* To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~* To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~* Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
62090459|NCT04860128|EXPERIMENTAL|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
62090460|NCT04860128|EXPERIMENTAL|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
62090461|NCT04860128|EXPERIMENTAL|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
62090462|NCT04860128|NO_INTERVENTION|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
62090463|NCT00201526||Study group|RCT
62090464|NCT00201526||Control group|RCT
62090465|NCT05562830|EXPERIMENTAL|Zilovertamab vedotin|Participants will receive zilovertamab vedotin 2mg/kg administered on Day 1 and Day 8 of each 3 week cycle (Q3W) until documented disease progression or any other discontinuation criterion is met.
62090466|NCT06325202|EXPERIMENTAL|current HCL non-user: HCL x 24 months|Hybrid closed loop device over a 24-month period for individuals currently not using a hybrid closed loop device
62090467|NCT06325202|EXPERIMENTAL|current HCL non-user: HCL x 12 months, then HCL x an additional 12 months|Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months
62090468|NCT06325202|EXPERIMENTAL|current HCL non-user: HCL x 12 months, then HCL + HARPdoc x 12 months|Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months
62090469|NCT06325202|ACTIVE_COMPARATOR|current HCL non-user: Usual Care and My HypoCOMPaSS x 12 months, then HCL x 12 months|Usual Care and My HypoCOMPaSS education over 12 months for individuals currently not using a hybrid closed loop device, then hybrid closed loop device for 12 months
62090470|NCT06325202|ACTIVE_COMPARATOR|current HCL non-user: Usual Care and My HypoCOMPaSS x 24 months|Usual Care and My HypoCOMPaSS education over 24 months for individuals currently not using a hybrid closed loop device
62090471|NCT06325202|EXPERIMENTAL|current HCL user: HCL x 24 months|Hybrid closed loop device over a 24-month period for individuals currently using a hybrid closed loop device
62090472|NCT06325202|EXPERIMENTAL|current HCL user: HCL x 12 months, then HCL x an additional 12 months|Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months
62090473|NCT06325202|EXPERIMENTAL|current HCL user: HCL x 12 months, then HCL + HARPdoc x 12 months|Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months
62090474|NCT06325202|ACTIVE_COMPARATOR|current HCL user: HCL and My HypoCOMPaSS x 12 months, then HCL x 12 months|Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device for 12 months
62090475|NCT06325202|ACTIVE_COMPARATOR|current HCL user: HCL + My HypoCOMPaSS x 12 months, then HCL + My HypoCOMPaSS + HARPDOC x 12 months|Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device plus My HypoCOMPaSS eduction + HARPdoc education for 12 months
62090476|NCT06325202|EXPERIMENTAL|current HCL user: HCL + My HypoCOMPaSS x 24 months|Hybrid closed loop device plus My HypoCOMPaSS education over a 24-month period for individuals currently using a hybrid closed loop device
62090477|NCT00793390||inflammatory breast cancer cases|inflammatory breast cancer cases
62090478|NCT00793390||non-inflammotory breast cancer cases|non-inflammatory breast cancer cases
62655056|NCT02925468|EXPERIMENTAL|Intervention group|A standard initial lateral cephalogram radiograph will be taken of all subjects, unless this is already available within the specified age range. An intra-oral scanner will be used to accurately record the occlusal relationships prior to insertion of the fixed anterior bite plane (bite turbos) (T0) and repeated immediately after placement (T1). Each subject will then be re-scanned on a six weekly basis for a period of six months (T2-T5). Conventional clinical photographs and three-dimensional stereophotogrammetry will be used to assess the vertical facial relationships at T0-T5. A further lateral cephalogram radiograph will be taken at T5.
62736379|NCT04154423|ACTIVE_COMPARATOR|Glow! Group Prenatal Care|Group prenatal care with wrap around services.
61905921|NCT02227940|EXPERIMENTAL|Arm 3 (ceritinib MTD then with gemcitabine and cisplatin)|"Dose Escalation Cohort 3: Patients with advanced solid tumors for whom gemcitabine hydrochloride and cisplatin-based therapy is clinically appropriate receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 3E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and cisplatin as in the dose escalation cohort 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
61905922|NCT02512484||high risk TB individuals attending A&E Departments|Assessment against inclusion/exclusion criteria in terms of risk of TB. If eligible, assessment and testing as appropriate for active or latent TB
61905923|NCT05451316||Upadacitinib|Adolescents and adults with moderate to severe prurigo-type AD, who are prescribed UPA according to the label and practice in Japan.
62090479|NCT00793390||visitor controls without cancer|visitor controls without breast cancer- those visiting cancer patients
61905924|NCT02252341|PLACEBO_COMPARATOR|placebo|"Dietary Supplement: N-Acetyl-Cysteine Phase 4 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Primary Outcome Measure:~Hamilton Depression Rating Scale \[Time Frame: baseline, 1, 2, 3 months\] \[Designated as safety issue: Yes\]~Secondary Outcome Measures:~Carbon Oxide exhalation \[Time Frame: basal, 1, 2, 3 months\] \[Designated as safety issue: Yes\]~Other Pre-specified Outcome Measures:~Biological outcome measures \[Time Frame: baseline and 3 months\] \[Designated as safety issue: Yes\] inflammatory and oxidative stress biomarkers N-Acetyl-cysteine 1800 mg / day will be taken for 12 weeks versus placebo 12 weeks."
62288903|NCT03073746|EXPERIMENTAL|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
62288904|NCT03073746|NO_INTERVENTION|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
62288905|NCT00629395|EXPERIMENTAL|1|Participate in 12 week computer program.
62288906|NCT03303001|EXPERIMENTAL|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
62655057|NCT02925468|NO_INTERVENTION|Control group|A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
62655058|NCT01355965|EXPERIMENTAL|Cohort 1 - One dose of cells|Subjects receive one dose of 1x108 cells on day 0 followed by one dose of 1x109 autologous transfected anti-mesothelin CAR T cells on day 7.
62288907|NCT03303001|ACTIVE_COMPARATOR|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
62288908|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
62288909|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
62288910|NCT03464669||Control group|Absence of prenatal education
62288911|NCT06454708|EXPERIMENTAL|Clascoterone Cream 1%|
62288912|NCT05293730|EXPERIMENTAL|Community Health Worker (CHW)-Led Hybrid In-Person/Telehealth Program Pathway (eFRIEND)|Participants in the eFRIEND arm will receive regularly scheduled in-person and telehealth contacts with a CHW.
62288913|NCT05293730|ACTIVE_COMPARATOR|Usual Care|Usual care group will be monitored passively for outcomes under a waiver of informed consent
62288914|NCT02404987||Nutritional Supplement|Free living and residing and nursing home malnourished patients
62288915|NCT03339492|ACTIVE_COMPARATOR|Active PEMF|Subjects have 2 out of 3 chance to get the active device which emits a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
62288916|NCT03339492|SHAM_COMPARATOR|Control/placebo PEMF|Subjects have a 1 out of 3 chance to get the control/placebo device which does not emit a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
62655059|NCT01355965|EXPERIMENTAL|Cohort 2 - three doses of cells|receive three doses of 1x108 cells on day 0, 2, 4 (Monday-Wednesday-Friday (MWF) of Cycle 1) followed by three doses of 1x109 T cells on day 7, 9, 11 (MWF of Cycle 2). Total target dose for Cohort 2 is 3.3x109 cells.
62655060|NCT00879216|PLACEBO_COMPARATOR|Sugar pill|
62655061|NCT00879216|EXPERIMENTAL|VA106483|
62655062|NCT01116531|ACTIVE_COMPARATOR|Duloxetine and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
62736380|NCT04154423|ACTIVE_COMPARATOR|Individual Prenatal Care- CPSP|Individual prenatal care with supplemental services covered by CPSP.
62736381|NCT03604172|EXPERIMENTAL|Cognitive behavioral therapy|16-week cognitive behavioral therapy intervention for binge eating disorder
62736382|NCT03604172|OTHER|Waitlist control|16-weeks on waitlist then participants will be provided with 16-weeks of cognitive behavioral therapy
62736383|NCT01967797|EXPERIMENTAL|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
62736384|NCT01967797|NO_INTERVENTION|Control|Though the controls will have knowledge of the '5A's of Obesity Management', they will not be receiving 5As Team Intervention.
62736385|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 1|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
62288917|NCT03049449|EXPERIMENTAL|Chimeric Antigen Receptor (CAR)+ T cells|All patients will be receiving starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0 and Cyclophosphamide: 300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
62288918|NCT05274126|EXPERIMENTAL|Patient group (single group)|300 Patients involved in the recovery process.
62288919|NCT05322408|EXPERIMENTAL|Administer HCW9218|"Administer HCW9218 as monotherapy at assigned dose by SC injection once every 3 weeks. Dose Level~-1 - 0.1 mg/kg~1. - (start) 0.25 mg/kg~2. - 0.5 mg/kg~3. - 0.8 mg/kg~4. - 1.2 mg/kg"
62288920|NCT04168294||sedation group|Patients undergo sedative esophagogastroduodenoscopy (EGD) and are intravenous injected propofol in bolus
62090480|NCT02554435|ACTIVE_COMPARATOR|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
62090481|NCT02554435|EXPERIMENTAL|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
62090482|NCT02223689|EXPERIMENTAL|Skin Affix|Surgical adhesive
62090483|NCT03954067|EXPERIMENTAL|Dose Escalation - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
62288921|NCT04168294||control group|patients undergo conventional EGD
62655063|NCT01116531|ACTIVE_COMPARATOR|Pregabalin and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
62288922|NCT01091636|EXPERIMENTAL|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Ovarian Cancer after primary cytoreductive surgery or interval cytoreductive surgery
62288923|NCT01091636|NO_INTERVENTION|No HIPEC|Primary cytoreductive surgery or interval cytoreductive surgery
62288924|NCT04922866||elderly patients following hepatectomy|elderly patients (aged ≥65 years) scheduled for any type of liver resection
62288925|NCT02673255|EXPERIMENTAL|Sanofi Pasteur (Tenivac)|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
62655064|NCT03953547||search for antiplatelet resistance|Patients who were hospitalized in the vascular medicine department and who benefited from a search for antiplatelet resistance between April 2014 and November 2017.
62288926|NCT02673255|EXPERIMENTAL|MassBiologics|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: MassBiologics, Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
62655065|NCT04155645|EXPERIMENTAL|Cohort 1|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 1 injection (8 subjects) or matching placebo (3 subjects).
62463115|NCT03100903|EXPERIMENTAL|BI 655130 low dose SC|Subject received single low dose BI 655130 solution as subcutaneous (SC) injection on day 1.
62463116|NCT03100903|EXPERIMENTAL|BI 655130 high dose SC|Subject received single high dose BI 655130 solution as subcutaneous (SC) injection on day 1.
62463117|NCT03100903|EXPERIMENTAL|BI 655130 high dose IV|Subject received single high dose BI 655130 solution as 30 minutes intravenous (IV) infusion on day 1.
62463118|NCT05815056|ACTIVE_COMPARATOR|drug intervention|drug induced sedation
62463119|NCT05815056|EXPERIMENTAL|digital sedation|hypnosis induced by a virtual reality device
62090484|NCT03954067|EXPERIMENTAL|Dose Escalation - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
62090485|NCT03954067|EXPERIMENTAL|Dose Expansion (Monotherapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
62288927|NCT02637817||Control Group|Neonates with no evidence of brain lesions on conventional MRI.
62288928|NCT02637817||Patients Group|Neonates with PWML diagnosed by conventional MRI.
62288929|NCT06290440|ACTIVE_COMPARATOR|Pharmacist-led counselling|
62288930|NCT06290440|EXPERIMENTAL|Telepharmacy-led counselling|
62288931|NCT00899652||All Patients|Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
62288932|NCT05123235|EXPERIMENTAL|Physical Activity|The intervention will last 11 weeks, and participants in the intervention group will have individual weekly web-meeting using a video conferencing platform. The weekly meeting is expected to last approximately 30 minutes. During this meeting, participants will report on the past week's physical activity goals, failures and successes, set goals for the next week, discuss that week's behavioral strategy to promote physical activity for that week, and engage around 5 minutes of physical activity. The topics that will be discussed in the newsletters and weekly meetings will include behavioral strategies for physical activity changes. Those in the control group will also be contacted weekly for 11 weeks and will be asked about their physical activity levels for the past week. These meetings will also occur using video conferencing and last 5 minutes.
62288933|NCT05123235|NO_INTERVENTION|Control|During the 11 weeks the participants in the control group will have a weekly check in meeting using a video conferencing platform. The weekly meeting is expected to last approximately 5 minutes. During this meeting, participants will report on the past week's physical activity levels.
62288934|NCT01356381|EXPERIMENTAL|vildagliptin|
62288935|NCT01356381|EXPERIMENTAL|Placebo|
62288936|NCT04515030||Primary glaucoma|"Primary glaucoma patients were diagnosed based on guidelines \[1-2\]. Patients with a confirmed diagnosis of primary glaucoma were enrolled and classified into the acute angle-closure crisis (AACC), primary angle-closure glaucoma (PACG), and primary open-angle glaucoma (POAG) subgroups.~1. Prum BE, Herndon LW, Moroi SE, et al. Primary Angle Closure Preferred Practice Pattern® Guidelines. Ophthalmology 2016;123:P1-40. doi:10.1016/j.ophtha.2015.10.049~2. Prum BE, Rosenberg LF, Gedde SJ, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern® Guidelines. Ophthalmology 2016;123:P41-111. doi:10.1016/j.ophtha.2015.10.053"
62288937|NCT04515030||Senile cataract|"Senile cataract patients were diagnosed based on guideline \[3\]. Patients with a confirmed diagnosis of senile cataract were enrolled and considered as controls for aqueous humor-related analysis.~\[3\] Olson RJ, Braga-Mele R, Chen SH, et al. Cataract in the Adult Eye Preferred Practice Pattern®. Ophthalmology 2017;124:P1-119. doi:10.1016/j.ophtha.2016.09.027"
62288938|NCT04515030||Normal control|Normal people without ocular diseases were enrolled as normal control.
62288939|NCT01073579||Sabril®|All patients in the U.S. who are prescribed Sabril must participate in this patient registry in order to receive Sabril.
62288940|NCT03262376|EXPERIMENTAL|Mineral + vits + botanical A|Mineral and vitamin complex combined with Botanical A
62288941|NCT03262376|EXPERIMENTAL|Mineral + vits + botanical B|Mineral and vitamin complex combined with Botanical B
62288942|NCT03262376|EXPERIMENTAL|Mineral+vits +botanical A+Botanical B|Mineral and vitamin complex combined with Botanical A and Botanical B
62463120|NCT03481205|EXPERIMENTAL|Ischemic Conditioning|Doctormate device used en route to the comprehensive stroke center
62655066|NCT04155645|EXPERIMENTAL|Cohort 2|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 2 injection (8 subjects) or matching placebo (3 subjects).
62288943|NCT03262376|PLACEBO_COMPARATOR|Placebo|Cellulose crystalline placebo
62288944|NCT03896295|EXPERIMENTAL|M281|
62463121|NCT04978766|EXPERIMENTAL|Interactive Book Reading Group|Participants in this arm will take baseline measures, will receive the intervention and will take posttest measures.
62463122|NCT04978766|NO_INTERVENTION|Control Group|Participants in this arm will take baseline and posttest measures. For ethical purposes, they will receive the intervention after posttest measures are taken.
62655067|NCT04155645|EXPERIMENTAL|Cohort 3|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 3 injection (8 subjects) or matching placebo (3 subjects).
62655068|NCT02619188||Hyperemesis gravidarum|Hyperemesis gravidarum patients admitted to hospital PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis), Intervention at discharge : PUQE-form, Nutritional form and Blood sampling
62655069|NCT02619188||Control: Healthy pregnant women|Outpatients NOT subjected to severe nausea and emesis (PUQE-score \<13). PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis).
62655070|NCT04055870||Undergone EUS-guided liver biopsy at MDMC|Undergone EUS-guided liver biopsy at MDMC
62655071|NCT02802228|EXPERIMENTAL|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
62655072|NCT02802228|PLACEBO_COMPARATOR|Placebo|90 day course of placebo following intravenous dose of 5% dextrose in water (D5W)
62655073|NCT00294658|ACTIVE_COMPARATOR|Thymectomy plus prednisone|Procedure: Extended Transsternal Thymectomy plus prednisone treatment
61905925|NCT02252341|PLACEBO_COMPARATOR|N-Acetyl-Cysteine|"Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Official Title: Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder~Primary Outcome Measure:~Hamilton Depression Rating Scale \[Time Frame: baseline\] \[Designated as safety issue: Yes\]~Secondary Outcome Measures:~Carbon Oxide exhalation \[Time Frame: basal, 1, 2, 3 months\] \[Designated as safety issue: Yes\]~Other Pre-specified Outcome Measures:~Biological outcome measures \[Time Frame: baseline and 3 months\] \[Designated as safety issue: Yes\] inflammatory and oxidative stress biomarkers~Placebo will be taken for 12 weeks."
62655074|NCT00294658|PLACEBO_COMPARATOR|Prednisone alone|Drug: prednisone alone protocol
62655075|NCT00026130|EXPERIMENTAL|Gemcitabine + 5FU + XRT|Chemo and radiation therapy in the treatment of non-metastatic pancreatic cancer
62655076|NCT02471443||Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
62655077|NCT04459338|EXPERIMENTAL|Saline, Then Exendin-9,39|A week or two after screening, participants were admitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.
61905926|NCT06012994||GAS|
62090486|NCT03954067|EXPERIMENTAL|Dose Expansion (Monotherapy) - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
62288945|NCT04555109||COVID-19 Convalescents|The cohort will include up to 1000 persons recovered from COVID-19, ages 17 - 65, that will provide a written consent form to participate in the study, complete questionnaires and provide a blood sample.
62655078|NCT04459338|EXPERIMENTAL|Exendin-9,39, Then Saline|A week or two after screening, participants were admitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.
61905927|NCT06012994||Control|
61905928|NCT04206280|EXPERIMENTAL|Pedometer group|This group will be given a pedometer following radical prostatectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 2,000/day. POD 3-6: 3,000/day. POD 7-9: 4,000/day. POD 10-14: 5,000/day.
62288946|NCT02147444||Non-valvular atrial fibrillation|"* Patients diagnosed with non-valvular atrial fibrillation~* Patients who are treated or will be treated with rivaroxaban"
62288947|NCT05295537|ACTIVE_COMPARATOR|PERCUTANEOUS LIVER BIOPSY (PLB)|Patients randomized to percutaneous liver biopsy.
62288948|NCT05295537|EXPERIMENTAL|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS - LB)|Patients randomized to EUS-guided liver biopsy
62288949|NCT03486392|EXPERIMENTAL|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
62288950|NCT03486392|EXPERIMENTAL|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
62288951|NCT03486392|EXPERIMENTAL|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
62288952|NCT03486392|PLACEBO_COMPARATOR|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
62463123|NCT01973348|EXPERIMENTAL|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
62463124|NCT01973348|ACTIVE_COMPARATOR|2-hour eye patching|2-hour eye patching for moderate amblyopia
62463125|NCT01973348|EXPERIMENTAL|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
62463126|NCT01973348|ACTIVE_COMPARATOR|6-hour eye patching|6-hour eye patching for severe amblyopia
62463127|NCT02437279|ACTIVE_COMPARATOR|Arm A|Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
62655079|NCT04706377|ACTIVE_COMPARATOR|Active treatment group|Patients were given oral dispersible tablet with 1000μg of vitamin B12 daily for 12 months.
62655080|NCT04706377|PLACEBO_COMPARATOR|Placebo group|Patients were given placebo tablet similar to the tablet given to the active group once a day for 12 months.
62655081|NCT00352118|EXPERIMENTAL|Chemotherapy + Low Dose Radiation|Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.
62736386|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 2|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
62736387|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 3|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
61905929|NCT04206280|ACTIVE_COMPARATOR|Control group|This is the control group. Following radical prostatectomy, subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
62090487|NCT03954067|EXPERIMENTAL|Dose Expansion (Monotherapy Induction) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1, 8, 15 and 22 of the first 28 day cycle. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
61905930|NCT01717053|EXPERIMENTAL|Abiraterone acetate|Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate.
62090488|NCT03954067|EXPERIMENTAL|Dose Expansion (Combination Therapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
62090489|NCT03954067|EXPERIMENTAL|Dose Expansion (Combination Induction Therapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1, 8, 15 and 22 of first 28 day cycle at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
62288953|NCT03486392|ACTIVE_COMPARATOR|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
62288954|NCT00770848|OTHER|Phase 1b - AMG 102|Phase 1b is an open-label study with AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed, will be administered by IV Q3W in combination with MP.
62288955|NCT00770848|EXPERIMENTAL|Phase 2 Arm A - AMG 102 + MP|AMG 102 safe dose level in phase 1b in combination with MP, will be administered by IV Q3W.
62288956|NCT00770848|PLACEBO_COMPARATOR|Phase 2 Arm C- PLACEBO|Placebo in combination with MP, will be administered by IV Q3W.
62288957|NCT00770848|EXPERIMENTAL|Phase 2 Arm B - AMG 102 + MP|Safe dose level in phase 1b of AMG 102 + MP will be administered by Q3W
62288958|NCT01023984|ACTIVE_COMPARATOR|TEM - Transanal Endoscopic Microsurgery|TEM under general anesthesia
62288959|NCT01023984|ACTIVE_COMPARATOR|ESD - Endoscopic Submucosal Dissection|ESD under sedation
62288960|NCT04601480|NO_INTERVENTION|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
62288961|NCT04601480|EXPERIMENTAL|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
62288962|NCT04601480|EXPERIMENTAL|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration \& Nudge intervention.
62288963|NCT04601480|EXPERIMENTAL|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration \& nudge interventions.
62288964|NCT02208960|EXPERIMENTAL|Neonatal Kit|Mothers in the neonatal kit clusters will receive a neonatal kit and training on how to use the kit components during their third trimester of pregnancy. The kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Community Health Workers will be equipped with a hand-held battery operated scale to identify low birth weight newborns.
62288965|NCT02208960|EXPERIMENTAL|Neonatal Stimulation|During home visits in the 3rd trimester, mothers in the neonatal stimulation clusters will be taught 3 core messages pertaining to neonatal stimulation. First, mothers will be taught how to make eye contact and talk to their child. This type of interaction encourages social inclusion, attachment, and development of social-communication skills. Second, mothers will be taught techniques to foster responsive feeding and caregiving. Finally, mothers will be encouraged to sing songs and nursery rhymes, including those with gentle touch in order to support the development of communication skills, and introduce a tactile component to caregiving. These messages will be reiterated at subsequent home visits by the CHW after the baby is born.
62288966|NCT02208960|EXPERIMENTAL|Neonatal Kit and Neonatal Stimulation|Participants in this arm of the study will receive both a neonatal kit (described in Arm 1) and neonatal stimulation (described in Arm 2).
62463128|NCT02437279|ACTIVE_COMPARATOR|Arm B|A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
62463129|NCT05888870|EXPERIMENTAL|SCT800 combined with Daratumumab|ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) and treated with Daratumumab 8mg/kg 4-8 times. Other immunosuppressants could be added after 3 months.
62655082|NCT01865851|ACTIVE_COMPARATOR|Start with Classic Face Mask Group|The volunteers will be asked to breathe normally (Tidal Volume Breathing) through face mask for 5 minutes. After 5 minutes, the volunteers will be asked to breathe room air for 5 minutes and then breathe through a NuMask for 5 minutes. This will be followed by room air breathing for 5 minutes. At the end of the 5 minutes of room air breathing, the same volunteers will be asked to breathe through the face mask for 5 minutes.
61905931|NCT04705493||CASE GROUP|Lidco rapid examination and echo examination were done to septic shock patients then the passive leg raising test was done and fluid responder cases were given mini fluid challenge and fluid challenge
61905932|NCT00892801|EXPERIMENTAL|Treatment|RAD001 + radiation therapy
61905933|NCT04781933|ACTIVE_COMPARATOR|Treatment with Combo|3 dietary supplements will be given
61905934|NCT04781933|PLACEBO_COMPARATOR|Treatment with Placebo|3 placebos will be given
61905935|NCT00123643|EXPERIMENTAL|Rosiglitazone|
61905936|NCT00123643|ACTIVE_COMPARATOR|Glyburide|
62090490|NCT03954067|EXPERIMENTAL|Dose Expansion (Combination Therapy) - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
62090491|NCT02721459|EXPERIMENTAL|Dose Escalation|Escalating Doses of XL888 with Vemurafenib plus Cobimetinib.
62090492|NCT03050294|ACTIVE_COMPARATOR|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
62288967|NCT02208960|NO_INTERVENTION|Control (Standard Care)|"In control clusters, CHWs will visit the home according to the regular schedule (same as in the intervention clusters) and deliver the standard CHW post-natal care that consists of talking to mothers about:~* Exclusive breastfeeding and proper nutrition for both the mother and the baby.~* Ensuring warmth to the baby.~* Full immunization and growth monitoring of newborn.~* Hygiene and sanitation practices.~* Family Planning and promote the proper use of Insecticides Treated Nets.~* Identifying any danger sign/complication for both mothers and new-borns and refer for prompt treatment (within 24 hours) for management and treatment.~* Promoting the use of services such as birth registration.~* Giving advice on proper care of the umbilical cord."
62288968|NCT03536442||Intervention (CBT)|"As there is only one arm in this trial, this will be described in intervention."
62288969|NCT02525549|EXPERIMENTAL|Test product|Adapalene and Benzoyl Peroxide Gel
62288970|NCT02525549|ACTIVE_COMPARATOR|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
62288971|NCT02525549|PLACEBO_COMPARATOR|Placebo product|Placebo gel
62288972|NCT02239172|EXPERIMENTAL|12.5 µg + Alhydrogel|vaccine
62463130|NCT05888870|ACTIVE_COMPARATOR|SCT800 alone|ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) alone. Other immunosuppressants could be added after 3 months.
61905937|NCT06058208|EXPERIMENTAL|Baby Smell Group|"Firstly the baby beret worn by the researcher on the baby will be removed at the end of the 12th hour (at the 12th hour and 24th hour of the hospitalization in the clinic) and taken to the Obstetrics and Gynecology Service on the same floor as the NICU without waiting;Odor stimulation will be applied in the form of 30 sec odor-30 sec standby-30 sec odor-30 sec standby-30 sec odor. A total of 4 rSO2 values, including the initial value and the average of the values during three 30 sec stimulation, will be recorded in the Cortical and Breast Oxygenation Follow-up Form. The amount of the first amount of milk, the total amount of milk until the 12th hour, the amount of oral fluid intake, the amount of milk until the 24th hour (12th hour -24th hour) and the amount of oral fluid intake will be recorded in the Milk Amount Follow-up Form."
61905938|NCT06058208|EXPERIMENTAL|Baby Smell and Visual Stimulus Group|Firstly the baby video (visual stimulus) and beret worn by the researcher on the baby will be removed at the end of the 12th hour (at the 12th hour and 24th hour of the hospitalization in the clinic) taken by researcher and taken to the clinic on the same floor as the NICU without waiting; Once the initial rSO2 value has been recorded, the mother will be instructed to sniff the beret uninterruptedly until further warning by the researcher and to watch the image of her baby unfolding on the tablet fixed to the floor during the entire measurement process. Odor stimulation to the mother will be applied in the form of 30 sec odor-30 sec waiting-30 sec odor-30 sec waiting-30 sec odor respectively, and visual stimulation will be applied as uninterrupted 2.5 min. At the end of 24 hours, the Mother-Baby Interaction Form and the MIBS tool will be re-applied as the final test.
61905939|NCT06058208|NO_INTERVENTION|Control Group|The intervention and data collection process in the control group is the same as the intervention in the odor group; As a placebo instead of odor stimulation, the odorless beret will be offered in the same conditions.
62090493|NCT03050294|EXPERIMENTAL|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
62090494|NCT03050294|ACTIVE_COMPARATOR|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
62288973|NCT02239172|EXPERIMENTAL|25 µg + Alhydrogel|vaccine
62288974|NCT02239172|EXPERIMENTAL|50 µg + Alhydrogel|vaccine
62288975|NCT02239172|EXPERIMENTAL|100 µg + Alhydrogel|vaccine
62288976|NCT06549075|EXPERIMENTAL|Personnalized modular therapeutic support|
62288977|NCT06549075|ACTIVE_COMPARATOR|Standard Specialized Palliative Consultation Service|
62463131|NCT01481805||Hepatocellular carcinoma patients treated with sorafenib|
62463132|NCT06078956|ACTIVE_COMPARATOR|Investigational Device|
62463133|NCT06078956|OTHER|Predicate device|
62463134|NCT04510285|EXPERIMENTAL|Trastuzumab and Pembrolizumab|"Trastuzumab will be administered on an every 3 week dosing schedule, with initial loading dose of 8 mg/kg as a 90 minute infusion, followed by trastuzumab 6 mg/kg every 3 weeks.~The planned dose of pembrolizumab for this study is 200 mg every 3 weeks."
62463135|NCT05087134|EXPERIMENTAL|11C-Choline PET/CT for Lymphangioleiomyomatosis (LAM)|The patients were injected with 11C-Choline of 5-10mCi and underwent PET/CT scan 20\~40min after the injection.
62736388|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 4|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
62655083|NCT01865851|ACTIVE_COMPARATOR|Start with NuMask Group|The volunteers will be asked to breathe through the NuMask for 5 minutes, followed by room air breathing for 5 minutes, then 5 minutes of breathing through the face mask. This will be followed by room air breathing for 5 minutes and then 5 minutes of NuMask breathing.
62655084|NCT00455871|ACTIVE_COMPARATOR|Lucentis plus Reduced Fluence PDT same day|
62655085|NCT00455871|ACTIVE_COMPARATOR|Lucentis plus reduced fluence PDT 1-2 weeks later|
62090495|NCT03050294|EXPERIMENTAL|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
62090496|NCT03693222|EXPERIMENTAL|tramadol use|Cases were assessed as intravenous opioid with 1 mg/kg tramadol hydrochloride
62090497|NCT03693222|EXPERIMENTAL|quadratus lumborum block|Cases were assessed asquadratus lumborum block for postoperative analgesia
62090498|NCT05962840|PLACEBO_COMPARATOR|Placebo arm|Patients with active AAV will be treated with Rituximab and glucocorticoid to induce remission. And the placebo of Telitacicept would be given 80 mg every week subcutaneously for 12 months. Glucocorticoid would be tapered as recommended by 2022 EULAR AAV recommendation (as protocol of PEXIVAS study)
61905940|NCT02980809|EXPERIMENTAL|Apatinib and topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5, apatinib 250mg/d, every 21 days, until disease progression.
61905941|NCT02980809|PLACEBO_COMPARATOR|Topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days, until disease progression.
61905942|NCT04055428|EXPERIMENTAL|Sacubitril/Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
61905943|NCT04055428|ACTIVE_COMPARATOR|Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
61905944|NCT01433250|EXPERIMENTAL|AIN 457 Core|(10mg/kg i.v.). AIN 457 core study /AIN 457 Extension
62288978|NCT02151344|EXPERIMENTAL|Cohort 1|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
62288979|NCT02151344|EXPERIMENTAL|Cohort 2|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
62288980|NCT02151344|EXPERIMENTAL|Cohort 3|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
62655086|NCT00107497|ACTIVE_COMPARATOR|Control|50Gy in 25 fractions of radiation therapy over 5 weeks
62655087|NCT00107497|ACTIVE_COMPARATOR|Test group 1|30Gy in 5 fractions of radiation therapy over 5 weeks
62655088|NCT00107497|ACTIVE_COMPARATOR|Test group 2|28.5Gy in 5 fractions of radiation therapy over 5 weeks
62655089|NCT02805738|EXPERIMENTAL|Experimental Group|once a time per a day, CKD-390 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
62655090|NCT02805738|ACTIVE_COMPARATOR|Active comparator Group|once a time per a day, Viread 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
61905945|NCT01433250|EXPERIMENTAL|AIN457 Placebo Core|(10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension
61905946|NCT04164511||Patients with post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy and receiving 2 daily ice creams for 2 weeks after surgery. Standard analgesic therapy available.
62090499|NCT05962840|EXPERIMENTAL|Telitacicept treatment arm|Patients with active AAV will be treated with Rituximab and glucocorticoid to induce remission. And the Telitacicept would be given 80 mg every week subcutaneously for 12 months. Glucocorticoid would be tapered as recommended by 2022 EULAR AAV recommendation (as protocol of PEXIVAS study)
62090500|NCT04798703|EXPERIMENTAL|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|
62090501|NCT03436121|EXPERIMENTAL|Experimental Arm|Participants will be assigned to receive a single dose of IV ketamine (0.3 mg.kg) + midazolam
62090502|NCT03436121|ACTIVE_COMPARATOR|Active Placebo Arm|Participants will be assigned to receive a single dose of IV placebo + midazolam
62736389|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 5|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
62736390|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 6|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
62736391|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 7|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
62463136|NCT02829970|EXPERIMENTAL|SUCCEEDS Program|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will be engaged about personalized alcohol feedback and identify life values and specific activities important to those values.
61905947|NCT04164511||Patients without post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy, not receiving any ice cream for 2 weeks after surgery. Standard analgesic therapy available.
61905948|NCT04610281|NO_INTERVENTION|Control|"Wards without the Inner Garden biofeedback tool"
61905949|NCT04610281|EXPERIMENTAL|Inner Garden|"Wards with the Inner Garden biofeedback tool"
61905950|NCT03800394||HIV only|Adolescents aged 10-19 years with HIV infection
61905951|NCT03800394||HIV/TB|Adolescents aged 10-19 years with HIV and TB coinfection
62090503|NCT04788017|ACTIVE_COMPARATOR|ziresovir|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~* If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~* If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~* If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
61905952|NCT02586441|EXPERIMENTAL|Electroencephalography|"1. Standard monitoring included electrocardiogram, noninvasive arterial blood pressure, pulse oximetry, and BIS-VISTATM sensor at OR.~2. Raw EEG in a steady state was collected for 5 minutes.~3. Anesthesia was induced with intravenous 1% propofol (1.5-2.5 mg/kg) and rocuronium bromide (0.6 mg/kg)~4. Mechanical ventilation was initiated~5. Anesthesia was maintained with desflurane at an end-tidal concentration of 6-7 %, with a fraction of inspired oxygen of 0.5 (fresh gas flow; O2 1.5 L/min and air 2.5 L/min).~6. On completion of the surgery, all anesthetic gases were discontinued and the FiO2 was increased to 1.0.~7. After extubation, BIS-VISTA TM monitoring was stopped."
61905953|NCT00960726|EXPERIMENTAL|NOV-002|
61905954|NCT05237206|EXPERIMENTAL|SUPLEXA|autologous cellular therapy comprised predominantly of NK, NK-T, and T cells stored in cryogenic media
62090504|NCT04788017|PLACEBO_COMPARATOR|placebo|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~* If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~* If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~* If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
62090505|NCT04986540|EXPERIMENTAL|Cohort 1|A single subcutaneous injection of SHR-1906/placebo dose 1 in healthy subjects
62288981|NCT02151344|EXPERIMENTAL|Cohort 4|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
62288982|NCT02151344|EXPERIMENTAL|Cohort 5|Participants will receive one dose of the inactivated subvirion H7N9 vaccine at Day 0 and one dose at Day 28.
61905955|NCT05207345|EXPERIMENTAL|Experimental Group|"90-minute session divided into:~* 45 minutes of core stability treatment~* 45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
61905956|NCT05207345|ACTIVE_COMPARATOR|General Group|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
61905957|NCT03310060|ACTIVE_COMPARATOR|Tisseel combined Tranexamic acid|"Drug: Tisseel® Applied on potential bleeding sites. The entire content was 4 mL.~Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery"
62288983|NCT03700099|OTHER|Study cohort|Docetaxel 75 mg/m2 i.v. every 3 weeks for 6-10 cycles. Upon disease progression after docetaxel, participants will receive enzalutamide 160 mg p.o. daily until limiting toxicity or disease progression.
62288984|NCT01273441|ACTIVE_COMPARATOR|Sequential treatment:|
62463137|NCT02829970|ACTIVE_COMPARATOR|Living a Healthy College Lifestyle|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will engage in discussion focused on experiences as an emerging adult.
61905958|NCT03310060|PLACEBO_COMPARATOR|Tranexamic acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery
61905959|NCT01024621|EXPERIMENTAL|1|confocal laser endomicroscopy
61905960|NCT01024621|ACTIVE_COMPARATOR|2|standard endoscopy
62288985|NCT01273441|EXPERIMENTAL|Concomitant treatment|
62463138|NCT02682602||Diseased Hip|Subjects will have a diseased hip which requires replacement, which will be implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA.
62463139|NCT02682602||Normal Hip|Subjects will have a normal hip.
61905961|NCT05020015|EXPERIMENTAL|Part 1: Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 200×10\^6 anti-CD19 chimeric antigen receptor (CD19-CAR+) viable NK cells, single-dose, intravenously, once on Day 0.
61905962|NCT05020015|EXPERIMENTAL|Part 1: Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 800×10\^6 CD19-CAR+ viable NK cells, single-dose, intravenously, once on Day 0.
61905963|NCT05020015|EXPERIMENTAL|Part 1: Dose Expansion: Cohort 1A (LBCL 3L+): TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 200×10\^6/ 800×10\^6 CD19-CAR+ viable NK cells, single-dose, intravenously, once on Day 0 to determine RP2D.
62090506|NCT04986540|EXPERIMENTAL|Cohort 2|A single subcutaneous injection of SHR-1906/placebo dose 2 in healthy subjects
62090507|NCT04986540|EXPERIMENTAL|Cohort 3|A single subcutaneous injection of SHR-1906/placebo dose 3 in healthy subjects
62090508|NCT04986540|EXPERIMENTAL|Cohort 4|A single subcutaneous injection of SHR-1906/placebo dose 4 in healthy subjects
62090509|NCT04986540|EXPERIMENTAL|Cohort 5|A single subcutaneous injection of SHR-1906/placebo dose 5 in healthy subjects
62090510|NCT04986540|EXPERIMENTAL|Cohort 6|A single subcutaneous injection of SHR-1906/placebo dose 6 in healthy subjects
61905964|NCT05020015|EXPERIMENTAL|Part 1: Dose Expansion: Cohort 2A (iNHL 3L+): TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Indolent Non-Hodgkin Lymphoma (iNHL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 200×10\^6/ 800×10\^6 CD19-CAR+ viable NK cells, single-dose, intravenously, once on Day 0 to determine RP2D.
61905965|NCT05020015|EXPERIMENTAL|Part 1: Dose Expansion: Cohort 1B (LBCL 3L+): TAK-007- 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 800×10\^6 CD19-CAR+ viable NK cells, intravenously, once on Days 0, 7 and 14 to determine RP2D.
61905966|NCT05020015|EXPERIMENTAL|Part 1: Dose Expansion: Cohort 1C (LBCL 2L): TAK-007- 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 800×10\^6 CD19-CAR+ viable NK cells, intravenously, once on Days 0, 7 and 14 to determine RP2D.
62090511|NCT06530654|ACTIVE_COMPARATOR|Standard treatment group|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
62090512|NCT06530654|EXPERIMENTAL|Cartoon movie- passive distraction group|Children watch cartoons on a screen mounted dental unit during the treatment.
62463140|NCT02682602||Implanted Group|All subjects from the Diseased Hip group were implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA
62463141|NCT02188641|OTHER|Diet|Low-fat diet
61905967|NCT05020015|EXPERIMENTAL|Part 2: Cohort 1- LBCL|Participants with LBCL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 at the RP2D, intravenously.
62090513|NCT06530654|EXPERIMENTAL|AG-active distraction group|"A tablet will be used for AG notation. How to use AG will be shown to the pediatric patient just before the treatment. Since it is aimed to keep the verbal communication of the dentist with the child at the lowest level, a similar tell-show-do technique used in the control group will be digitally simulated on the AG. The instruments that the dentist will use during the procedure will be promoted on AG using animated content."
62090514|NCT01167270|ACTIVE_COMPARATOR|Parenting Insight|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
62090515|NCT01167270|PLACEBO_COMPARATOR|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the AAP guidelines and the Academy's guide for health supervision, Bright Futures
62090516|NCT03066388|EXPERIMENTAL|Pulse pressure variations|Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.
62090517|NCT02242461|PLACEBO_COMPARATOR|Rhodiola placebo capsules|starch
62090518|NCT02242461|EXPERIMENTAL|Rhodiola Crenulata|Rhodiola Crenulata
62090519|NCT06280560||Natural Cycle (NC)|No hormonal stimulation
62463142|NCT02188641|OTHER|Exercise|3-day/week exercise programme
62463143|NCT02188641|OTHER|Diet and exercise|healthy low fat diet and 3day/week exercise programme
62463144|NCT02188641|OTHER|Healthy lifestyle (Control) group|Control group was provided with health education using videotaped presentation
62736392|NCT06200597|EXPERIMENTAL|Part 1: (LAD603) Cohort 8|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
62090520|NCT06280560||Controlled Ovarian Stimulation (COS) + Luteal Phase Support (LPS)|Hormonal fresh transfer protocol
62288986|NCT05785195|EXPERIMENTAL|Inhaled Nitric Oxide (iNO)|iNO 20ppm，≥8 hours/day for 3 days
61905968|NCT05020015|EXPERIMENTAL|Part 2: Cohort 2- iNHL|Participants with iNHL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 at the RP2D, intravenously.
61905969|NCT04381039|EXPERIMENTAL|customized insole group|
62090521|NCT06280560||HRT programmed artificial cycle|Delayed hormonal transfer protocol
62090522|NCT06280560||Endometrial receptivity reference group|No hormonal stimulation
62090523|NCT05925959|NO_INTERVENTION|Upfront Surgery|
62090524|NCT05925959|ACTIVE_COMPARATOR|Preoperative Weight Management Program|
62090525|NCT05072990||Observational group|
62736393|NCT06200597|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive single ascending dose of matching placebo SC injection on Day 1.
62463145|NCT06495905|EXPERIMENTAL|Multimodal Treatment|"1. combination drug therapy：liposomal amphotericin B + posaconazole or Isavuconazole：3-5mg/kg/day+ Posaconazole 300 mg once daily; target blood trough concentration is \>1ug/mL; if posaconazole is unavailable, Isavuconazole 200 mg once daily may be an alternative.~2. transbronchoscopic local precision infusion of amphotericin B: Maximum dose not more than 30mg per session~3. transoral nebulized inhalation of amphotericin B：amphotericin B 10mg + 5ml of sterilized water for injection, inhalation 2/day.~4)transbronchoscopic interventional debridement"
62463146|NCT05375201|EXPERIMENTAL|VR skateboarding training|specific rehabilitation exercise for improving postural balance
62463147|NCT03863730|EXPERIMENTAL|Profermin Plus®|Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
62463148|NCT03863730|ACTIVE_COMPARATOR|Fresubin®|Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator.
62090526|NCT04786886|EXPERIMENTAL|Virtual Reality Visual Field Group|Participants in this group will have virtual reality visual field testing during standard of care follow-up visit.
62090527|NCT05631574|EXPERIMENTAL|Escalation Phase|"Dose Escalation Phase will group all disease indications (NSCLC, PDAC, and CRC) together to assess the safety of each dose level.~Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose)."
62090528|NCT05631574|EXPERIMENTAL|Expansion Phase|"Dose Expansion Phase will enroll additional subjects independently in each disease indication:~Cohort 1: Participants with NSCLC~Cohort 2: Participants with PDAC~Cohort 3: Patients with CRC~Cohorts 1, 2, and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug."
62090529|NCT03160911|EXPERIMENTAL|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
62090530|NCT03160911|ACTIVE_COMPARATOR|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
62090531|NCT06483802|EXPERIMENTAL|ASP2016|Participants will receive a single dose of ASP2016. Participants will also receive daily prednisolone beginning 1 day prior to ASP2016 dose and for at least 16 weeks after ASP2016 dose, in order to suppress the immune response to ASP2016.
62090532|NCT04931173|ACTIVE_COMPARATOR|Group A: IV and Oral antibiotics (IVA+OA)|Patients will receive cefazolin 2g IV and metronidazole 500 mg IV administered by the anesthesiologist within 60 minutes prior to the skin incision on the day of surgery. Standardized re-dosing of cefazolin 2g IV will occur every 4 hours and metronidazole 500 mg IV will occur every 8 hours during the surgical procedure. Following surgery, no further IVA will be given for SSI prophylaxis. In addition, patients will self-administer 1g neomycin and 1g metronidazole orally at 1500, 1700 and 2300 hours the day before surgery. Following this, they will not receive any further OAs for SSI prophylaxis.
62090533|NCT04931173|ACTIVE_COMPARATOR|Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA)|Patients will receive IVA and OA per Group A. In addition, patients will stay on clear fluids and self-administer a 2L polyethylene glycol MBP orally, between 1500 and 2300 hours on the day before surgery.
62090534|NCT02292667|EXPERIMENTAL|TAP BLOCK|"Patients included in the ETAP group will receive the combination of a bilateral ultrasound-guided Transversus Abdominis Plane (TAP) block and a multimodal intravenous analgesia protocol for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The TAP block consists in 2 ultrasound-guided injections of Ropivacaine 0.375% on each side of the abdominal wall between the internal oblique and transversus abdominis muscles: 1 subcostal injection and 1 supra-iliac injection (i.e 10 ml of Ropivacaine 0.375% by injection).~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
62288987|NCT00388947||1|AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)
62288988|NCT02140255|EXPERIMENTAL|Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
62288989|NCT02140255|EXPERIMENTAL|Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
62288990|NCT02140255|EXPERIMENTAL|Cohort 1, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
62288991|NCT02140255|EXPERIMENTAL|Cohort 2, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
62463149|NCT01771965|NO_INTERVENTION|Usual care|No intervention.
62463150|NCT01771965|EXPERIMENTAL|CB Intervention|Cognitive Behavioral one-on-one single session administered by phone
62463151|NCT03968549|PLACEBO_COMPARATOR|Placebo|These patients will receive capsules containing vegetable oil and corn starch
62736394|NCT06200597|EXPERIMENTAL|Part 2: (LAD603) Cohort A|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
62736395|NCT06200597|EXPERIMENTAL|Part 2: (LAD603) Cohort B|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
62288992|NCT02140255|EXPERIMENTAL|Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01|Participants will receive 2 NRTIs + NVP + RAL + VRC01.
62288993|NCT02140255|EXPERIMENTAL|Cohort 1, Regimen 3RD: 2 NRTIs + NVP + RAL switch to 2 NRTIs + DTG|Participants will receive 2 NRTIs + NVP + RAL with subsequent switch to 2 NRTIs + DTG upon reaching 28 days of age and 3 kg body weight.
62288994|NCT02140255|EXPERIMENTAL|Cohort 1, Regimen 3RDV7: 2 NRTIs + NVP + RAL + VRC07-523LS switch to 2 NRTIs + DTG + VRC07-523LS|Participants will receive 2 NRTIs + NVP + RAL + VRC07-523LS with subsequent switch to 2 NRTIs + DTG + VRC07-523LS upon reaching 28 days of age and 3 kg body weight.
62288995|NCT00473876|ACTIVE_COMPARATOR|1|Receiving Metformin for 4 months
62463152|NCT03968549|ACTIVE_COMPARATOR|Probiotic|These patients will receive capsules containing Lactobacillus acidophilus
62463153|NCT04966455|NO_INTERVENTION|Control group|No intervention
62655091|NCT01549574|EXPERIMENTAL|crizotinib/crizotinib+esomeprazole crossover|Each subject in this study will receive two treatments (A and B) separated by at least 14 days of washout period. Treatment A is a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule. Treatment B consists of 40 mg daily esomeprazole dose from Day 1 to Day 5 and a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5.
62655092|NCT02856217|ACTIVE_COMPARATOR|tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal tunneling in SCP: creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum.
61905970|NCT04830098|EXPERIMENTAL|Stabilization group|Stabilization group will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
62288996|NCT00473876|PLACEBO_COMPARATOR|2|Matched Placebo for 4 months
62655093|NCT02856217|ACTIVE_COMPARATOR|non-tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal non-tunneling group in SCP: incised and sutured peritoneum between vaginal apex and sacrum
62655094|NCT04262349|EXPERIMENTAL|intervention|"Every week because of differences in the number of pregnant women who attended the school participating women were divided into two groups using a random number table created in the program via the computer itself. The purpose of the study was explained to pregnant women, informed consent form and data collection tools of the study were collected by face to face interview technique. In the first interview to all pregnant women; Personal Information Form, Course Information Form, Pittshburg Sleep Quality Index (PUKI) and General Self-Efficacy Scale were applied. Pregnant women in the intervention group were given a two-session training program to improve sleep quality and Sleep Guide and Safe Baby Sleep Conditions Brochure."
62655095|NCT04262349|NO_INTERVENTION|control|"Pregnant women in the control group were subjected to routine practice without any training given by the researcher. Four weeks after the completion of the sleep training, all pregnant women were contacted by telephone and the data collection tools were applied for the second time and the final test applications were completed. After completion of the data collection process made a new plan for training to improve the quality of sleep to pregnant women in the control group and the Sleep Guide and Safe Baby Sleep Conditions Brochure is given."
62655096|NCT00674726||Group I|Patients with acute appendicitis
62655097|NCT00674726||Group II|Patients with acute gastroenteritis
62655098|NCT02564341|EXPERIMENTAL|TEACH Collaborative Care Intervention|Physicians randomized to the intervention will receive: 1) collaboration with an IT enabled nurse care manager; 2) physician education and academic detailing; and 3) facilitated access to a specialist in addictions to help manage the most challenging HIV-infected patients on COT.
62655099|NCT02564341|NO_INTERVENTION|Standard of Care Control|Physicians in the control group will receive information summarizing guidelines for COT but will not have access to the support of the TEACH intervention.
62288997|NCT04324645||Active Symptom Monitoring via Noona|Participants will undergo a single training session on how to use the Noona software no more than 4-12 weeks before starting therapy. They can start using the software immediately after the training session. Patients will be invited to complete either the Chest Radiotherapy (if radiotherapy alone), Chemotherapy-18 (if chemoradiation therapy), or Bone Radiotherapy (if other) module at baseline, every other week throughout therapy, and during follow up for 90-days. Patients will be encouraged by the treatment team to complete the baseline symptom report prior to starting any therapy and to complete the reports during therapy and in follow up. Patients will also complete the EORTC QLQ-C30 and the NCCN Distress Thermometer at baseline (no more than 12 weeks before starting therapy), within 1 week of completing therapy, and at 90-days follow up. Patients will be encouraged to use Noona's other features beyond invited modules and PRO inventories, such as the diary during the study
62655100|NCT04578938|EXPERIMENTAL|Ketamine + Cognitive Training|
62655101|NCT04578938|SHAM_COMPARATOR|Ketamine + Sham Training|
61905971|NCT04830098|EXPERIMENTAL|Manipulation group|Manipulation group be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
61905972|NCT04830098|EXPERIMENTAL|Stabilization and Manipulation group|Stabilization and Manipulation group will be given both stabilization exercises and manipulation exercises.
62463154|NCT04966455|EXPERIMENTAL|Experimental group|Supplementation of 50 g daily of rainsins for 3 months
62463155|NCT03205553|ACTIVE_COMPARATOR|Standard of Care (SoC) Treatment Group|The SoC group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice and subsequently serially reduced in silo (staged silo reduction) until the bowel contents are at the level of fascia and deemed suitable for closure. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons.
61905973|NCT04830098|NO_INTERVENTION|Control group|No application will be made in the control group.
62090535|NCT02292667|ACTIVE_COMPARATOR|CONTROL|"Patients included in the CONTROL group will receive a multimodal intravenous analgesia protocol alone for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
62288998|NCT02197377|ACTIVE_COMPARATOR|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
62288999|NCT02197377|EXPERIMENTAL|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
62289000|NCT01955707|EXPERIMENTAL|natalizumab|300 mg single intravenous (IV) injection
62289001|NCT01955707|PLACEBO_COMPARATOR|Placebo|A single IV dose of placebo
62289002|NCT01832740|EXPERIMENTAL|0,75 Hz stimulation|slow transcranial oscillating stimulation (\~0,75Hz) during periods of Slow Wave Sleep
62289003|NCT01832740|EXPERIMENTAL|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
62289004|NCT06075381|EXPERIMENTAL|Conventional management plus Pulmonary Expansion Device (PED)|The conventional management used in the intensive care unit as a lung expansion strategy in patients with tracheostomy plus Pulmonary Expansion Device (PED).
62655102|NCT04578938|ACTIVE_COMPARATOR|No-infusion (TAU) + Cognitive Training|
62655103|NCT04578938|SHAM_COMPARATOR|No-infusion (TAU) + Sham Training|
62289005|NCT06075381|ACTIVE_COMPARATOR|Conventional management alone|Conventional management employed in the intensive care unit as a lung expansion strategy in tracheostomized patients, without utilizing the Pulmonary Expansion Device (PED).
62289006|NCT04695873|EXPERIMENTAL|Treatment Group|Foam Cushion, applied daily on Days 1, 2 and 3 of the investigation.
62655104|NCT04556175|EXPERIMENTAL|Oral Health|Motivational interviewing sessions will involve in-person visits by Community Health Workers focused on the mitigation of behavioral risk factors for early childhood caries, with two sessions provided before childbirth and four more sessions at 6, 12, 18 and 24 months after childbirth. Children receive up to 4 fluoride varnish applications during the study. Early cohort of enrollees will be followed up in a 7th visit solely for oral health assessment.
62289007|NCT04695873|NO_INTERVENTION|No Treatment Group|No treatment
62655105|NCT04556175|ACTIVE_COMPARATOR|Healthy Lifestyle|Didactic educational sessions delivered in-person by Community Health Workers cover nutrition and diet, physical activity, breastfeeding/formula feeding, substance use, mental/emotional health, personal and family goals, prenatal/postpartum health care access, labor and delivery, family support, infant/child care, oral health, and development milestones. Children receive up to 2 fluoride varnish applications during the study. Early cohort enrollees will be followed up in a 7th visit solely for oral health assessment.
62655106|NCT03638791||Healthy controls|Matched Controls without treatment
61905974|NCT04682119|EXPERIMENTAL|LY3526318 (Part A)|LY3526318 administered orally as single ascending doses.
61905975|NCT04682119|EXPERIMENTAL|LY3526318 (Part B)|LY3526318 administered orally as multiple doses.
61905976|NCT04682119|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally.
61905977|NCT04682119|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered orally.
61905978|NCT03849391|EXPERIMENTAL|Skate group|This group takes Skate Skin extract for 12 weeks
62289008|NCT02949128|EXPERIMENTAL|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks for 26 weeks in the Initial Evaluation Period.~After the Initial Evaluation Period, participants could enter an Extension Period and receive ravulizumab until the product registration or approval (in accordance with country-specific regulations) or for up to 4.5 years, whichever occurs first."
62289009|NCT02698098||Compulsory Drug Detention Center|Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
62655107|NCT03638791||OCD|Exposure and response inhibition
62655108|NCT00630292|EXPERIMENTAL|1|
62655109|NCT05409391|EXPERIMENTAL|AI|Insulin Titration System Based on Deep Learning
62655110|NCT00859690||Sleep Disorder - Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have Obstructive Sleep Apnea (OSA).
61905979|NCT03849391|PLACEBO_COMPARATOR|Placebo group|This group takes Placebo for 12 weeks
61905980|NCT00874926||Group 1|
61905981|NCT00067938|OTHER|Arm 1|Open label single arm study
61905982|NCT03673397|EXPERIMENTAL|Aerobic exercise|Patients allocated to the intervention group will perform a single bout of supervised aerobic exercise. The starting time will be approximately 1630 hrs. The exercise mode will be a bicycle ergometer. After a warm-up period, during which the intensity is gradually increased, an intensity of 80% of the individual anaerobic threshold will be maintained for 30 minutes. The intensity level was chosen based on clinical experience that this corresponds to an approximate rate of perceived exertion of 13 (on a scale from 6-20) in this population.
61905983|NCT03673397|NO_INTERVENTION|Control|Individuals allocated to the control group will be placed in a room with analogous conditions to the exercise group concerning light, temperature and absence of music at the same time as individuals performing the exercise intervention. The control group will be asked to remain seated and read magazines.
61905984|NCT00726401|ACTIVE_COMPARATOR|1|
61905985|NCT00726401|PLACEBO_COMPARATOR|2|
62655111|NCT00859690||Sleep Disorder - Not Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have a sleep disorder other than Obstructive Sleep Apnea (OSA).
62655112|NCT05955066|EXPERIMENTAL|Baricitinib|Patients randomized into JAKi group will receive one capsule of baricitinib (4mg) daily for 24 weeks.
62655113|NCT05955066|PLACEBO_COMPARATOR|Placebo|Patients randomized into placebo group will receive one capsule of placebo daily for 24 weeks.
62090536|NCT05934318|EXPERIMENTAL|L-citrulline arm|L-citrulline arm is the intervention arm consisting of a twice daily 6.0 g sachet, each containing 5.000 g of quality-assured L-citrulline powder, 0.672 g maltodextrin and 0.286 g lactose anhydrous, 0.03 g citric acid, 0.012 g lemon flavour + antenatal standard of care with enhanced monitoring. The sachets will be provided at enrolment and each subsequent monthly ANC visit.
62090537|NCT05934318|NO_INTERVENTION|Placebo arm|Placebo arm is the control arm consisting of a twice daily 6.0 g sachet of quality-assured placebo, each consisting of 3.6 g maltodextrin and 2.358 g lactose monohydrate, 0.03 g citric acid, 0.012 g lemon flavour + antenatal standard of care with enhanced monitoring. The sachets will be provided at enrolment and each subsequent monthly ANC visit.
62090538|NCT06340529|ACTIVE_COMPARATOR|Between equals|Physiotherapy students who do not participate in the simulation, but they do observe the simulation and participate in the debriefing.
62090539|NCT06340529|EXPERIMENTAL|Self appraisal|Physiotherapy students who participate in the simulation in all its phases.
62090540|NCT06340529|ACTIVE_COMPARATOR|Lecturers|Teachers observing the intervention and participate as patients and in the debriefing
62090541|NCT05455463|EXPERIMENTAL|Online aphasia-adapted physical activity class|Will receive the physical activity intervention.
62090542|NCT05455463|NO_INTERVENTION|Usual routine control|Engage in physical activity per usual routine.
62090543|NCT02442297|EXPERIMENTAL|HER2-specific T cells - High Risk|Subjects with HER2 staining of Grade 3 (51-100% of cells staining for HER2) and intensity scores of 3+ will be assigned to the High Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
62090544|NCT02442297|EXPERIMENTAL|HER2-specific T cells - Standard Risk|All other patients not meeting the high risk description will be assigned to the Standard Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
62090545|NCT06696586|EXPERIMENTAL|group 1|patients will received lidocaine with dose 250 mg and fentanyl infusion in dose of 200 µg in rate 10ml /hr using 50ml syringe pump
62090546|NCT06696586|EXPERIMENTAL|group 2|patients will receive lidocaine 250 mg in addition to fentanyl injection in dose 100 µg by shots
62655114|NCT05743972|EXPERIMENTAL|CEUS-guided core biopsy group|
62655115|NCT05743972|ACTIVE_COMPARATOR|US-guided core biopsy group|
62655116|NCT04561791|EXPERIMENTAL|Feasibility of TCE & Prevalence of BE|"1. Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment~2. Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH"
62655117|NCT03079830|ACTIVE_COMPARATOR|Ropivacaine continous infusion|Piritramid
62655118|NCT03079830|SHAM_COMPARATOR|Saline continous|Piritramid
62655119|NCT02318264|EXPERIMENTAL|Distal to Proximal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting distal by knee and ending proximal by hip.
62655120|NCT02318264|EXPERIMENTAL|Proximal to Distal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting proximal by hip and ending distal by knee.
62090547|NCT06086002|ACTIVE_COMPARATOR|Overlapping ablation with single antenna|
62090548|NCT06086002|EXPERIMENTAL|Simultaneous ablation with two antennas|
62090549|NCT03663712|EXPERIMENTAL|4 x 10^6 PFU|Dose level 1. Subjects were assigned to receive 4 x 10\^6 PFU of talimogene laherparepvec.
62090550|NCT03663712|EXPERIMENTAL|4 x 10^7 PFU|Dose level 2. Subjects were assigned to receive 4 x 10\^7 PFU of talimogene laherparepvec.
62090551|NCT03663712|EXPERIMENTAL|4 x 10^8 PFU|Dose level 3. Subjects were assigned to receive 4 x 10\^8 PFU of talimogene laherparepvec.
62090552|NCT01265082||Patients in remission with pruritus|
62090553|NCT01265082||Patients in remission without pruritus|
62090554|NCT01515358|PLACEBO_COMPARATOR|Placebo|Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
62090555|NCT01515358|EXPERIMENTAL|LY3000328|Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
62090556|NCT03826212|EXPERIMENTAL|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
62090557|NCT03826212|PLACEBO_COMPARATOR|Placebo|Placebo 1,600 mg/day for 12 weeks.
62090558|NCT05078021||Normal control|Healthy, non-asthmatic control subjects
62090559|NCT05078021||Mild asthma|Requiring low dose inhaled corticosteroid (ICS) plus as needed short acting beta-agonist (SABA) or as needed ICS-Formoterol.
62090560|NCT05078021||Moderate asthma|Low dose ICS-Long acting beta-agonist (LABA) maintenance + ICS-LABA reliever or SABA reliever
62090561|NCT05078021||Severe asthma|Medium to high dose ICS-LABA maintenance + as needed SABA or ICS-formoterol
62090562|NCT01583946||Male low past-oriented SWB|
62090563|NCT01583946||Male high past-oriented SWB|
62090564|NCT01583946||Female low past-oriented SWB|
62090565|NCT01583946||Female high past-oriented SWB|
62090566|NCT01583946||Black Female high past-oriented SWB|
62090567|NCT01583946||Black Female low past-oriented SWB|
62655121|NCT05366686|EXPERIMENTAL|Frailty and Quality of Life in Patients With Heart Failure|Patients in this group will receive a 12 week exercise program including: (1) one 40-60 minute individual consultation (teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls); (2) provided exercise booklet, exercise log, exercise video; (3) Nutritional consultation; (4) telephone follow-up once per week for 12 weeks
62090568|NCT01583946||Black male low past-oriented SWB|
62090569|NCT01583946||Black male high past-oriented SWB|
62090570|NCT02069587|EXPERIMENTAL|Pomegranate|The women in this group will drink pomegranate juice
62090571|NCT01155245||Forteo (teriparatide)|postmenopausal women with osteoporosis
62090572|NCT01155245||Forteo (teriparatide) with AFF|Women with atypical femur fractures
62289010|NCT02698098||Voluntary Treatment Center|Voluntary drug treatment facilities, called 'Cure and Care' centers in Malaysia, that provide methadone maintenance therapy in addition to psychosocial interventions, recreational programming, and vocational training, among other activities.
62289011|NCT02510352||Rotator cuff tear|patients with a symptomatic rotator cuff tear treated without surgical repair
62289012|NCT04698525|ACTIVE_COMPARATOR|Valproate group|This is a well know antiepileptic drug with efficacy as a preventive tic treatment in episodic migraine
62289013|NCT04698525|ACTIVE_COMPARATOR|Memantine|This is a possible preventive treatment in episodic migraine
62289014|NCT01577238|EXPERIMENTAL|VivaGel|
62289015|NCT01577238|PLACEBO_COMPARATOR|HEC Placebo|
62289016|NCT02850419|EXPERIMENTAL|ThermoDox (40mg/m2)+hyperthermia+RT|Treatment will consist of up to six cycles of LTLD combined with hyperthermia every 21 days with the first day of each cycle being Day 1. ThermoDox will be administered at a dose of 40 mg/m2. Thermal dose is a one-hour treatment at a temperature between 40 and 43°C at the target site. At Cycle 1, radiotherapy will begin and will be combined with hyperthermia. A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
62289017|NCT05936762|EXPERIMENTAL|Neoial|Treatment with the MD
62289018|NCT01940484||Chronic Renal Anemia Participants|Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
62289019|NCT00834015|OTHER|Experimental|combined strength and aerobic training
62289020|NCT03283085|EXPERIMENTAL|Ulcerative Colitis (UC): Ontamalimab 25 mg|Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years.
62655122|NCT05366686|NO_INTERVENTION|Frailty and Quality of Life|Patients in this group maintain their daily life activities, and there is no intervention given.
62655123|NCT05622149|NO_INTERVENTION|Control|No intervention
62655124|NCT05622149|EXPERIMENTAL|Diet Only|Subjects were given calorie and macronutrient intake goals and were told to hit those goals as closely as possible on a daily basis for 16 weeks.
62655125|NCT05622149|EXPERIMENTAL|Training Only|Subjects were given a 3 times per week supervised resistance training program for 16 weeks
62655126|NCT05622149|EXPERIMENTAL|Diet plus Training|Subjects were given calorie and macronutrient intake goals and were told to hit those goals as closely as possible on a daily basis for 16 weeks. Subjects were given a 3 times per week supervised resistance training program for 16 weeks
62090573|NCT04714216|EXPERIMENTAL|Hybrid closed-loop (HCL) automated insulin delivery (AID)|Hybrid closed-loop (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote monitoring and device operation capabilities will be deployed to hospitalized patients admitted to the general medical/surgical floor with diabetes (type 1 or type 2) requiring insulin therapy.
62090574|NCT00741273|EXPERIMENTAL|Proellex 25 mg healthy|Proellex 25 mg in healthy females
62090575|NCT00741273|EXPERIMENTAL|Proellex 25 mg Impaired|Proellex 50 mg in hepatically impaired females
62090576|NCT02945202|OTHER|All Eyes|All eyes undergo the same interventions. These are the following examinations: Biometry, Refraction and Corneal Topography. The examinations take place 6 months after surgery
62090577|NCT01395771|EXPERIMENTAL|Phone call|New cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
62090578|NCT03212365|OTHER|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
62090579|NCT03212365|EXPERIMENTAL|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
62090580|NCT02535338|EXPERIMENTAL|Treatment (erlotinib hydrochloride, onalespib lactate)|Patients receive erlotinib hydrochloride PO daily and onalespib lactate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
62090581|NCT01659138|EXPERIMENTAL|SAR339658|SAR339658 at Weeks 0, 2, 4, and 6
62090582|NCT01659138|PLACEBO_COMPARATOR|Placebo|Placebo at Weeks 0, 2, 4, and 6
62289021|NCT03283085|EXPERIMENTAL|UC: Ontamalimab 25mg then 75 mg|Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.
62289022|NCT03283085|EXPERIMENTAL|UC: Ontamalimab 75 mg|Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.
62463156|NCT03205553|EXPERIMENTAL|Direct Peritoneal Resuscitation (DPR) Treatment Group|The DPR group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice. At the time of silo placement for staged procedure, the JP drain will be sterilely placed intra-abdominally through the top of the silo. Subjects will be treated with adjuvant direct peritoneal resuscitation (DPR) and subsequently serially reduced in silo until the abdomen is closed (during the entirety of silo placement), which is usually four to five days.
62655127|NCT01454752|ACTIVE_COMPARATOR|Intermittent parasite clearance|Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
62289023|NCT03283085|EXPERIMENTAL|Crohn's disease (CD): Ontamalimab 25 mg|Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.
62289024|NCT03283085|EXPERIMENTAL|CD: Ontamalimab 25mg then 75 mg|Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.
62289025|NCT03283085|EXPERIMENTAL|CD: Ontamalimab 75 mg|Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.
62090583|NCT00355667|ACTIVE_COMPARATOR|A|Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
62090584|NCT00355667|ACTIVE_COMPARATOR|B|Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
62090585|NCT01260662|ACTIVE_COMPARATOR|Propofol|Deep sedation using propofol
62090586|NCT01260662|EXPERIMENTAL|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
62090587|NCT01260662|EXPERIMENTAL|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
62090588|NCT02955277|EXPERIMENTAL|TECH protocol|TECH protocol - Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-25 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by six weekly sessions (of 60 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist.
62289026|NCT03153839|EXPERIMENTAL|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
62289027|NCT03153839|NO_INTERVENTION|Control group|71 infants who will not practice the programme. They only will be evaluated.
62289028|NCT02377895|EXPERIMENTAL|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
62655128|NCT01454752|PLACEBO_COMPARATOR|Control|Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo
62655129|NCT04388423|EXPERIMENTAL|Group S|
62655130|NCT04388423|EXPERIMENTAL|Group C|
62289029|NCT02377895|ACTIVE_COMPARATOR|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
62289030|NCT01756456|EXPERIMENTAL|1_rhNGF10_Phase 1_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
62463157|NCT06427057|EXPERIMENTAL|UC|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus standard regimen （gemcitabine or albumin paclitaxel) neoadjuvant treatment with no more than 6 cycles.
62655131|NCT06085144||Galcanezumab|Postpartum women both nursing and receiving treatment for migraine with galcanezumab.
62655132|NCT00864071|EXPERIMENTAL|A|Griseofulvin 125 mg/5 mL Suspension, single dose
62289031|NCT01756456|EXPERIMENTAL|2_rhNGF20_Phase 1_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
62289032|NCT01756456|PLACEBO_COMPARATOR|3_vehicle group_Phase 1_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
62289033|NCT01756456|EXPERIMENTAL|4_rhNGF10_Phase 2_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
62655133|NCT00864071|ACTIVE_COMPARATOR|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
62655134|NCT02679846|EXPERIMENTAL|Standardized protocol of AEDs withdrawal|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
62655135|NCT02679846|NO_INTERVENTION|Current practice|Centers will continue their current practice
62655136|NCT02862509|EXPERIMENTAL|Budesonide nasal instillation|budesonide(0.5mg/2ml) 1 respule plus normal saline solution 120ml instilled in vertex to floor position daily
61905986|NCT02870322|ACTIVE_COMPARATOR|Fruit and Vegetable CSA Prescription|"Study participants randomized to the CSA group will be expected to pick up their weekly CSA box at University Health Services and to commit to using and consuming as much of the produce as they are able. CSA group participants will also be required to attend two cooking and food preparation classes coordinated by Slow Food UW. The classes will teach study participants how to properly clean and prepare the fruits and vegetables from a weekly CSA box, and also offer techniques and show them how to cook the foods in a healthy manner. These classes will also educate study participants on the benefits of eating fruits and vegetables and buying them from local farmers. These two classes will only exist for study participants in this fruit and veggie CSA group. Participants in the CSA group will also be required to take a field trip to the farm providing their CSA share, which will offer the opportunity for participants to gain a better understanding of from where their food comes."
62463158|NCT06427057|EXPERIMENTAL|RCC|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus standard regimen （TKI，e.g. sunitinib, pezopanib) neoadjuvant treatment with no more than 6 cycles.
62655137|NCT02862509|PLACEBO_COMPARATOR|Normal saline nasal instillation|Normal saline solution instilled in vertex to floor position daily
62655138|NCT04920669|EXPERIMENTAL|erector spinae block|erector spinae block with 20 ml bupivacaine
62655139|NCT04920669|EXPERIMENTAL|erector spinae block + dexmedetomidine|erector spinae block with 19 ml bupivacaine + dexmedetomidine
62655140|NCT04920669|NO_INTERVENTION|control group|standard general anesthesia without any block
62655141|NCT02918344||Standard sagittal split osteotomy group|Patients undergoing sagittal split osteotomy without paste application
62655142|NCT02918344||Cohort/Hydroset group|Patients undergoing sagittal split osteotomy with paste application
61905987|NCT02870322|ACTIVE_COMPARATOR|Bikeshare Prescription|"Study participants randomized to the bikeshare group will be expected to use B-cycle bikes for transportation and/or recreation as much as is safe and appropriate. Bikeshare group participants will be required to attend one bicycle use/safety course. This course will introduce the B-cycle program, demonstrate use of the B-cycle station, provide information use of helmets and safety gear, and provide information on the basics of cycling and keeping yourself safe and comfortable while riding in traffic. The study participants in this group will also be required to attend a class on the benefits of exercise, including bicycling, among other forms of physical activity. This class will be offered by the University Health Services Wellness program. B-cycle usage, including estimated distance traveled and frequency of use, will be tracked via the B-cycle Madison website."
61905988|NCT02870322|NO_INTERVENTION|Control|"Study participants in the control group will receive continued usual care from University Health Services providers, which includes educational brochures on healthy eating and exercising, plus a cash payment. Control group participants are not part of a wait-list group."
61905989|NCT04953988|EXPERIMENTAL|Robotic surgery group|
61905990|NCT04953988|ACTIVE_COMPARATOR|Manual operation group|
61905991|NCT05668611|EXPERIMENTAL|Primary Training|4 Ministry of Health nurses will be trained by expert trainers to become certified in focused echocardiography acquisition and interpretation in order to screen patients for rheumatic heart diseases
61905992|NCT05668611|EXPERIMENTAL|Secondary Training|The 4 Ministry of Health nurses trained in Aim 1 will then train and certify 3 other nurses from their clinics in focused echocardiography acquisition interpretation.
61905993|NCT03246386|EXPERIMENTAL|Obese subjects|Subjects with a BMI\>35 kg/m2
61905994|NCT03246386|ACTIVE_COMPARATOR|Non-obese subjects|Subjects with a BMI\>18.5 and \<25 kg/m2
61905995|NCT06031389|EXPERIMENTAL|Henagliflozin|On the basis of basic treatment, the patients in the Hengglinide（tabuletta） intervention group were given Hengglinide once a day, 10mg or 5mg each time in the morning, and continued to intervene for 12 months.
61905996|NCT06031389|PLACEBO_COMPARATOR|Placebo|The blank control group was treated with placebo (starch tablets) once a day, 10mg or 5mg each time, taken in the morning for 12 months.
61905997|NCT02268929|OTHER|Control Group|Patients treated by usual customary medical practice (Usual Care)
61905998|NCT02268929|OTHER|Intervention Group|"Patients treated with Integrated Personalized Diabetes Management"
62090589|NCT02955277|ACTIVE_COMPARATOR|standard care or active standard care|Participants will receive standard occupational therapy with no TECH protocol. or Will receive active standard care: six weekly group sessions (60 minutes) for cognitive training using puzzle games. The setting will includes small groups of 5-6 participants, with no self training at home.
62655143|NCT00205166|ACTIVE_COMPARATOR|1|Caffeine 400 mg PO 1 hour before adenosine infusion
62655144|NCT00205166|ACTIVE_COMPARATOR|2|Caffeine 200 mg po one hour before adenosine infusion
62655145|NCT01608594|EXPERIMENTAL|Ipilimumab 10 mg/kg + HDI|Ipilimumab 10 mg/kg + standard dose IFN alpha
62655146|NCT01608594|EXPERIMENTAL|Ipilimumab 3mg/kg + HDI|Ipilimumab 3mg/kg + standard dose IFN alpha
62736396|NCT06200597|EXPERIMENTAL|Part 2: (LAD603) Cohort C|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
62655147|NCT00409825|EXPERIMENTAL|Part 1|Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 3, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 4: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.
62655148|NCT06519630|EXPERIMENTAL|Rehabotics Intervention Group|Rehabotics Intervention Group received Physiotherapy through the Rehabotics system.
62090590|NCT04201015|NO_INTERVENTION|Standard rate-response settings|Patients allocated to standard rate-response settings.
62090591|NCT04201015|ACTIVE_COMPARATOR|Rate-response settings off|Patients allocated to deactivated rate-response settings.
62090592|NCT04201015|EXPERIMENTAL|Optimized rate-response settings|Patients allocated to optimised rate-response settings.
62090593|NCT04060784|EXPERIMENTAL|Immediate implant placement and provisionalization|On the control group, Implant will be placed immediately after tooth extraction. The gap between the implant and buccal bone will be filled with bone graft. Temporary crown will be attached to implant fixture.
62090594|NCT04060784|EXPERIMENTAL|Socket shield technique|On the test group, Implant will be placed immediately after tooth extraction. A piece of root shield will be retained intentionally at facial side. Temporary crown will attached to implant fixture.
62289034|NCT01756456|EXPERIMENTAL|5_rhNGF20_Phase 2_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
62289035|NCT01756456|PLACEBO_COMPARATOR|6_vehicle group_Phase 2_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
62289036|NCT00850746|PLACEBO_COMPARATOR|A. Placebo|
62289037|NCT00850746|EXPERIMENTAL|B. Ym443 Lower Dose|
62289038|NCT00850746|EXPERIMENTAL|C. YM443 Higher Dose|
62289039|NCT00850746|ACTIVE_COMPARATOR|D. Moxiflocxacin|
62655149|NCT06519630|ACTIVE_COMPARATOR|Traditional Physiotherapy Group|Traditional Physiotherapy Group received Physiotherapy.
62289040|NCT05593848|EXPERIMENTAL|Experimental Group (Intratissue Percutaneous Electrolysis Group)|"The treatment to be performed in the Intratissue percutaneus electrolysis Group will consist of:~1. Palpation and localization of the myofascial trigger points in the infraspinatus muscle of the affected shoulder.~2. Application of the ultrasound-guided intratissue percutaneus electroysis technique (1 or 2 approaches) on the myofascial trigger points with the greatest clinical manifestations for the subject. The needle will remain at intramuscular level without movement and a galvanic current discharge will be applied in the area, through the needle, whose intensity will oscillate between 0.5 and 3 milliAmperes (mA).~3. Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain."
62289041|NCT05593848|ACTIVE_COMPARATOR|Active Control Group (Dry Needling Group)|"The treatment to be performed in the Dry Needling Group will consist of:~1. palpation and localization of myofascial trigger points in the infraspinatus muscle of the affected shoulder.~2. Application of the ultrasound-guided dry needling technique (1 or 2 approaches) on the myofascial trigger points with major clinical manifestations for the subject. The physiotherapist will move the needle into the muscle using Hong's rapid entry and exit technique.~3. Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain."
62289042|NCT02024984|EXPERIMENTAL|Group A|Luteal Phase Administration of Clomiphene (50mg twice per day for 5 days)
62289043|NCT02024984|ACTIVE_COMPARATOR|Group B|Follicular Phase Administration of Clomiphene Citrate in PCOS(50mg twice per day for 5 days)
62090595|NCT06554808||Income|"1. 0-9999 Euros~2. 10 000-29 999 Euros~3. 30 000-49 999 Euros~4. \> 50 000 Euros"
62289044|NCT03844867|EXPERIMENTAL|Filippo Cea and Carmel|Subjects \<65 years.
62090596|NCT06554808||Educational level|"1. Low - compulsory school (9 years)~2. Medium - upper secondary school (additional 2-4 years)~3. High - included education beyond that level (university)"
62090597|NCT03251378|EXPERIMENTAL|3 mg Dose Escalation|3 mg of Fruquintinib (HMPL-013), capsule taken orally, daily, 3 weeks on, 1 week off
62090598|NCT03251378|EXPERIMENTAL|5 mg Dose Escalation|5 mg of Fruquintinib (HMPL-013), capsule taken orally, daily, 3 weeks on, 1 week off
62090599|NCT03251378|EXPERIMENTAL|Fruquintinib Expansion Cohort A|5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with advanced solid tumors of any type.
62090600|NCT03251378|EXPERIMENTAL|Metastatic Colorectal Cancer Expansion Cohort B (prior trifluridine/tipiracil or regorafenib)|5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
62655150|NCT06055387|EXPERIMENTAL|Frail group|All patients receive a frailty assessment within 7 days before initiating treatment, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The frail group will receive management and recommendations based on the specific impairment domain.
62090601|NCT03251378|EXPERIMENTAL|Metastatic Colorectal Cancer Expansion Cohort C (no prior trifluridine/tipiracil or regorafenib)|5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
62655151|NCT06055387|NO_INTERVENTION|Non-frail group|All patients receive a frailty assessment within 7 days before initiating treatment, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The non-frail group will not receive additional interventions, but the clinical physicians will still provide appropriate treatment based on the patient's condition.
62655152|NCT03091439|EXPERIMENTAL|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
62090602|NCT03251378|EXPERIMENTAL|Metastatic Breast Cancer (HR positive, HER2 negative) Expansion Cohort D|5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
62655153|NCT03091439|ACTIVE_COMPARATOR|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
62655154|NCT03290651|EXPERIMENTAL|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
62655155|NCT03290651|PLACEBO_COMPARATOR|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
62655156|NCT01577914|EXPERIMENTAL|Carvedilol Tablets USP 12.5 mg|Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
62090603|NCT03251378|EXPERIMENTAL|Metastatic Breast Cancer (TNBC) Expansion Cohort E|5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
62655157|NCT01577914|ACTIVE_COMPARATOR|Coreg®|Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
62655158|NCT02059239|EXPERIMENTAL|Chemo plus Autologous Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant
62655159|NCT02059239|EXPERIMENTAL|Chemo plus Allogeneic Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant
62655160|NCT02169232|ACTIVE_COMPARATOR|Videolaryngoscope|Intubation by videolaryngoscope
62655161|NCT02169232|ACTIVE_COMPARATOR|Fiberoptic|Intubation by fibroscope
62655162|NCT05706701|EXPERIMENTAL|Nicotine vaping group visit 1|Subjects will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their first of two visits. In the first visit, participants will use the ENDS device with one nicotine form and four fluxes in random order. Participants will be instructed to attend the lab for a second visit, to test the four fluxes but with the other nicotine form.
62090604|NCT02008058||Single Arm|Surveys, diaries, clinical assessments of men with metastatic castrate-resistant prostate cancer
62289045|NCT00944827|EXPERIMENTAL|GTE|The experimental group will receive 20 mg atorvastatin (Lipitor) daily and 600 mg. of pure catechin in capsules
62289046|NCT00944827|PLACEBO_COMPARATOR|CON|The control group will receive 20 mg atorvastatin (Lipitor) and Placebo in identical capsules containing 600 mg placebo for 12 weeks
62736397|NCT06200597|EXPERIMENTAL|Part 2: (LAD603) Cohort D|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
62289047|NCT03168867|NO_INTERVENTION|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
62289048|NCT03168867|EXPERIMENTAL|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
62289049|NCT01144585|EXPERIMENTAL|RIPC|those who receive RIPC and RIPoC before and after CPB
62655163|NCT05706701|EXPERIMENTAL|Nicotine vaping group visit 2|The same subjects from visit 1 will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their second study visit, using the opposite nicotine form that was used during the first visit.
61905999|NCT01929499|EXPERIMENTAL|synchronous CIK group|"After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months.~For CapeOx regimen:~3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles.~For mFolfox6 regimen:~Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles."
61906000|NCT01929499|EXPERIMENTAL|sequence CIK group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later.
61906001|NCT01929499|NO_INTERVENTION|control group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）.
61906002|NCT02895126|EXPERIMENTAL|"Appui Parental program (44 cases)"|
61906003|NCT02895126|OTHER|Regular parental support (44 cases)|Usual intervention
61906004|NCT05061043|ACTIVE_COMPARATOR|Group A|Routine physical therapy treatment
61906005|NCT05061043|EXPERIMENTAL|Group B:|Routine physical therapy along with orofacial therapy
61906006|NCT01883453|PLACEBO_COMPARATOR|Saline+glucose nasal spray|A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week
61906007|NCT01883453|ACTIVE_COMPARATOR|Nasal spray with glucose oxidase+glucose|A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
62289050|NCT01144585|PLACEBO_COMPARATOR|Control|this group have same pneumatic cuff around their arm, but it is not inflated.
62289051|NCT01364805|EXPERIMENTAL|PK Intravenous Vitamin C and Gemcitabine|Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
62289052|NCT03370770||patients with EGFR mutation-positive NSCLC|(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
62289053|NCT02472847|PLACEBO_COMPARATOR|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
62090605|NCT02310490|ACTIVE_COMPARATOR|Right Side DA-13-007, Left Side Sculptra|DA-13-007 right with left side Sculptra left side
62090606|NCT02310490|ACTIVE_COMPARATOR|Left Side DA-13-007, Right Side Sculptra|DA-13-007 left with Sculptra right side
62090607|NCT01974687|EXPERIMENTAL|Group A: Healthy|Healthy participants will receive sequentially higher doses of uprifosbuvir (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.
62090608|NCT01974687|EXPERIMENTAL|Group B: GT1 HCV-infected, treatment naive on Day 1|HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of uprifosbuvir (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.
62090609|NCT01974687|EXPERIMENTAL|Group C: GT1 HCV-infected on Days 1-7|HCV GT1 participants will receive uprifosbuvir (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
62090610|NCT01974687|EXPERIMENTAL|Group D: GT2 through GT6 HCV-infected on Days 1-7|HCV GT2 - GT6 participants will receive uprifosbuvir (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
62289054|NCT02472847|ACTIVE_COMPARATOR|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
61906008|NCT00954096|EXPERIMENTAL|Transdermal nicotine patch or placebo|A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
62090611|NCT01974687|EXPERIMENTAL|Group E: GT1 HCV-infected on Days 1-7, mild hepatic impairment|HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.
62090612|NCT01974687|EXPERIMENTAL|Group F: GT1 HCV-infected on Days 1-7, + Itraconazole|HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered uprifosbuvir 300 mg from Day 1 to Day 7.
62090613|NCT02949310|PLACEBO_COMPARATOR|Control|Placebo use instead of nefopam
62090614|NCT02949310|EXPERIMENTAL|Nefopam|Intraoperative use of nefopam 40 mg
62463159|NCT05177588|EXPERIMENTAL|Metformin|Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
62090615|NCT04662034|EXPERIMENTAL|Device plus Standard of Care|Device plus Standard of Care
62289055|NCT01586988|EXPERIMENTAL|IMAGE Intervention|mothers are provided the IMAGE Parenting and Self-Care intervention
62289056|NCT01586988|NO_INTERVENTION|Control|Standard care.
62289057|NCT01290627||Knee Prosthesis LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
62090616|NCT04662034|OTHER|Standard of Care|Standard of care drug treatment
62090617|NCT03317561||Myocardial injury|Subjects who have had an increase in troponin T level (\> 99 percentile) in the perioperative period shall form the cases.
62289058|NCT01290627||Knee Prosthesis Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
62289059|NCT01290627||Control|Subjects with normal knees
62463160|NCT05177588|NO_INTERVENTION|Standard of Care|Patients in the control arm will continue the SOC medications
61906009|NCT05846607|EXPERIMENTAL|experiment|"The data will be collected in two phases. Firstly, after a fasting period of eight hours, the participants received ultrasound scan by expert doctor with the objective of measuring the fasting gastric antrum area in supine and right lateral decubitus(RLD)position(phase 1).Then the expert made the grading according to the ultrasound image.~In phase 2, the participant will ingest 0 to 400ml of the study drink described below randomly. The individual will be immediately positioned in the supine position and another ultrasound scan will be carried out. Again in the RLD position."
61906010|NCT01464281|EXPERIMENTAL|48-week standard treatment|48-week standard treatment by Peginterferon alfa 2a 180µg/week
62289060|NCT03135249|OTHER|Alemtuzumab treatment.|"Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:~Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.~Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution."
62463161|NCT02209480|EXPERIMENTAL|Alexander Technique|5 lessons of AT, each lasting up to 45 minutes, weekly intervals The lessons aimed at sensory awareness of everyday movements and movement sequences, such as sitting, walking, lying, or lifting in order to replace habitual patterns using conscious control; and different techniques were applied, such as demonstration, verbal instructions, hands on techniques and others
62736398|NCT06200597|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive multiple ascending dose of matching placebo SC injection on Days 1, 8 15, and 22.
61906011|NCT01464281|ACTIVE_COMPARATOR|96-week prolonged treatment|96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
62090618|NCT03317561||Control|Subjects who do not have an increase in troponin T level (\< 99 percentile) in the perioperative period shall form the controls.
62090619|NCT05173051|EXPERIMENTAL|Ability of Swallowing solid placebos vs. a crushed placebo|During routine FEES examination, patients are sequentially being given 3 different solid placebos pills and one crushed placebo mixed with semisolid texture.
62090620|NCT06089187|ACTIVE_COMPARATOR|Saline Group|Anesthesia machine's APL valve will be adjusted to a pressure of 20 cmH20, and during ventilation with a balloon, the endotracheal tube cuffs will be inflated with saline in such a way that there will be no leakage sound from the patient's mouth.
62090621|NCT06089187|PLACEBO_COMPARATOR|Air Group|Anesthesia machine's APL valve will be adjusted to a pressure of 20 cmH20, and during ventilation with a balloon, the endotracheal tube cuffs will be inflated with air in such a way that there will be no leakage sound from the patient's mouth.
62090622|NCT02156115||healthy volunteers|healthy volunteers
62090623|NCT02156115||lymphatic patients|lymphatic patients
62090624|NCT02156115||relatives|relatives
62090625|NCT03553862|NO_INTERVENTION|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
62090626|NCT03553862|EXPERIMENTAL|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
62289061|NCT03097380|EXPERIMENTAL|AZD2115|
62289062|NCT03097380|ACTIVE_COMPARATOR|Spiriva (Tiotropium)|
62289063|NCT03097380|EXPERIMENTAL|[11C]AZ13754366|
62289064|NCT01436721|NO_INTERVENTION|Surgicel® absorbable Haemostat|
62289065|NCT05821270|EXPERIMENTAL|Yoga|Yoga practice: 12-week program of Ashtanga Vinyasa Yoga Supta for 1h twice a week
62289066|NCT05821270|NO_INTERVENTION|Waiting list|Only mandatory pilot trainig that everyone in the academy receives
62289067|NCT02153099|EXPERIMENTAL|Cohort 1: TAK-058 15 mg|TAK-058 15 mg, 100 mL oral solution, once on Day 1.
62289068|NCT02153099|EXPERIMENTAL|Cohort 2: TAK-058 30 mg|TAK-058 30 mg, 100 mL oral solution, once on Day 1.
62289069|NCT02153099|EXPERIMENTAL|Cohort 3: TAK-058 45 mg|TAK-058 45 mg, 100 mL oral solution, once on Day 1.
62289070|NCT02153099|EXPERIMENTAL|Cohort 4: TAK-058 5 mg|TAK-058 5 mg, 100 mL oral solution, once on Day 1.
62289071|NCT02153099|EXPERIMENTAL|Cohort 5: TAK-058 75 mg|TAK-058 75 mg, 100 mL oral solution, once on Day 1.
62289072|NCT02153099|EXPERIMENTAL|Cohort 6: TAK-058 150 mg|TAK-058 150 mg, 100 mL oral solution, once on Day 1.
62289073|NCT02153099|PLACEBO_COMPARATOR|Cohort 1-6: Placebo|TAK-058 placebo-matching, 100 mL oral solution, once on Day 1.
62289074|NCT05367102|EXPERIMENTAL|In Person|Participants will receive all services in person, including participating in the initial intake process, and attending all workshops.
62090627|NCT05617235|NO_INTERVENTION|Conventional Physiotherapy and Rehabilitation|A training will be given including information about the postoperative recovery process, the purpose of respiratory physiotherapy and rehabilitation, the importance of physiotherapy and rehabilitation in the postoperative period, attention to speed up recovery and prevention of complications, breathing exercises, coughing training, posture exercises, early mobilization and its importance, and answering patient questions.The program includes progressive ambulation and progressive shoulder and rib cage exercises. These exercises will be performed under the supervision of a physiotherapist from the first postoperative day. The exercises will be advanced every day by increasing the number of repetitions.
62090628|NCT05617235|EXPERIMENTAL|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. All tapes were applied by the same physiotherapist on clean and shaved skin (if necessary). Investigators applied kinesiology taping as described below:~1. In order to stimulate the facilitation of the diaphragmatic function, a 5 cm wide kinesiological tape was applied on the skin.~2. Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~3. In addition, kinesiology taping can be performed on the trigger pain point of the patient (usually above the pectoralis major).~The kinesiology tape can stay for 3-4 days if the patient does not develop any discomfort. After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
62090629|NCT05322980||Microcephaly|Infants with primary microcephaly.
62090630|NCT05322980||Control|Infants without primary microcephaly.
62090631|NCT03372486|ACTIVE_COMPARATOR|Bupivacaine plus naloxone|Patients will receive brachial plexus block using bupivacaine plus naloxone.
62090632|NCT03372486|PLACEBO_COMPARATOR|Bupivacaine|Patients will receive brachial plexus block using bupivacaine.
62090633|NCT03300817|EXPERIMENTAL|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
62090634|NCT05284097|EXPERIMENTAL|Study Intervention|"Subjects will receive the following study vaccines as a 0.5 mL IM injection into the deltoid:~* Ad26.ZEBOV at a dose of 5x10\^10 vp on Day 1~* MVA-BN-Filo at a dose of 1x10\^8 Inf U on Day 57"
62090635|NCT06018428|EXPERIMENTAL|Experimental: ADX-914|200mg dose of ADX-914 administered via injection under the skin every 2 weeks for a total of 24 weeks.
62289075|NCT05367102|EXPERIMENTAL|Virtual (Zoom)|Participants will complete their intake process in person, but will complete all workshops virtually through Zoom.
62289076|NCT03489733|EXPERIMENTAL|Intervention Group|Infant Formula with hydrolyzed protein and breast milk until at least 120 days of life
61906012|NCT02747472|PLACEBO_COMPARATOR|Placebo|Infusion of saline
61906013|NCT02747472|ACTIVE_COMPARATOR|GIP(1-42)|Infusion of agonist, GIP(1-42)
61906014|NCT02747472|EXPERIMENTAL|GIP-A|Infusion of GIP-A alone
62090636|NCT06018428|PLACEBO_COMPARATOR|Placebo Comparator|ADX-914 matched placebo administered via injection under the skin every 2 weeks for a total of 24 weeks.
62090637|NCT00641953|EXPERIMENTAL|A|IMX-150 (0.3%) 0.5 g topically BID each foot
62289077|NCT03489733|EXPERIMENTAL|Control Group|Infant Formula with intact protein and breast milk until at least 120 days of life
62289078|NCT03489733|NO_INTERVENTION|Breast Fed Group|Exclusively breast ilk until at least 120 days of life
62289079|NCT04707638||Parkinson's disease or dystonia patients|Patients with Parkinson's disease or dystonia and underwent STN DBS under general anesthesia in neurosurgery department
62289080|NCT01749384|EXPERIMENTAL|Treatment (bevacizumab, tivantinib)|Patients receive bevacizumab IV over 30-90 minutes on days -15, 1, and 15 (day -15 of course 1 only) and tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62289081|NCT05172544|EXPERIMENTAL|Low Dose Sentinel|3 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
62289082|NCT05172544|EXPERIMENTAL|Low Dose Expanded|7 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 2 subject will receive placebo IM on Days 1 and 29.
61906015|NCT02747472|EXPERIMENTAL|GIP-A + GIP(1-42)|Infusion of GIP-A and GIP(1-42)
62289083|NCT05172544|EXPERIMENTAL|High Dose Sentinel|3 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
62289084|NCT05172544|EXPERIMENTAL|High Dose Expanded|7 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
62289085|NCT00679458|EXPERIMENTAL|1.|Study drug: buprenorphine and ultra-low-dose naloxone
61906016|NCT05867979|EXPERIMENTAL|patients with DSD and inconclusive molecular diagnosis|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
61906017|NCT02721953|EXPERIMENTAL|Hypocaloric diet plus butyrate|Hypocaloric diet plus butyrate
61906018|NCT02721953|PLACEBO_COMPARATOR|Hypocaloric diet plus placebo|Hypocaloric diet plus placebo
62090638|NCT00641953|EXPERIMENTAL|B|IMX-150(0.6%) 0.5 g topically BID to each foot
62090639|NCT00641953|PLACEBO_COMPARATOR|C|Placebo 0.5 g topically BID to each foot for 4 weeks
62090640|NCT05962424|EXPERIMENTAL|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
62090641|NCT00136903|ACTIVE_COMPARATOR|Prochymal® - 2 Million cells/kg|Participants will receive Prochymal® consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
62090642|NCT00136903|ACTIVE_COMPARATOR|Prochymal® - 8 Million cells/kg|Participants will receive Prochymal® consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
62090643|NCT05766163|ACTIVE_COMPARATOR|DaVinci system|Robot-assisted radical prostatectomy is carried out through daVinci platform.
62090644|NCT05766163|EXPERIMENTAL|Hugo system|Robot-assisted radical prostatectomy is carried out through Hugo platform.
62090645|NCT05766163|EXPERIMENTAL|Versius system|Robot-assisted radical prostatectomy is carried out through Versius platform.
62090646|NCT00891085||Open Lung Ventilation|within 24 hours of arrival trauma patients with ISS \>25 will be randomized to BiVent (APRV)
62090647|NCT00891085||SIMV|within 24 hours of arrival trauma patients with ISS \>25 will be randomized to either SIMV or BiVent
62090648|NCT05306457|EXPERIMENTAL|CNS10-NPC-GDNF - Group A|Unilateral, Motor Cortex, 0.25x10\^6 cells in 10 µL/site, 21 sites (5.25x10\^6 total cells) - Motor cortex corresponding to the non-dominant hand
62090649|NCT05306457|EXPERIMENTAL|CNS10-NPC-GDNF - Group B|Unilateral, Motor Cortex, 0.5x10\^6 cells in 10 µL/site, 21 sites (10.5x10\^6 total cells) - Motor cortex corresponding to the non-dominant hand
62090650|NCT05306457|EXPERIMENTAL|CNS10-NPC-GDNF - Group C|Unilateral Motor Cortex, 0.5x10\^6 cells in 10 µL/site, 21 sites (10.5x10\^6 total cells) - Motor cortex corresponding to the dominant hand
62090651|NCT02224014||Lendormin D tablets|
62090652|NCT02156362|OTHER|follow up|
62090653|NCT02402179|EXPERIMENTAL|Tryptophan Amino Acid|13.2, 26.4, 39.7, 52.9% of the mean tryptophan requirement of 3.78 mg/kg/d will be given to subjects.
62090654|NCT06586216|EXPERIMENTAL|Cohort 1|No renal impairment
62289086|NCT00679458|ACTIVE_COMPARATOR|2.|Study drug: buprenorphine
62289087|NCT00885079|EXPERIMENTAL|Rebamipide|Instillation,4 times/day for 4 weeks
62289088|NCT00885079|ACTIVE_COMPARATOR|Hyaluronate|Instillation,6 times/day for 4 weeks
62289089|NCT03696472|EXPERIMENTAL|robotic-assisted left colonic resection|Standard left colonic resection assisted by Davinci Robotic
62289090|NCT03696472|ACTIVE_COMPARATOR|laparoscopic left colonic resection|Standard laparoscopic left colonic resection
62289091|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
62289092|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of \>21 mmHg required
62289093|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of \< 21 mmHg
62289094|NCT02532478||Stoma reversed|Patients whose ileostomy have been closed after laparoscopic low anterior resection
62463162|NCT02209480|ACTIVE_COMPARATOR|Heat pad application|5 treatments by means of a heat pad, 15-0 minutes, sitting or lying position, quiet room Heat pad: Zapp-Sack® contained certain grains and a ginger extract, and could be heated up in the microwave.
62463163|NCT02209480|ACTIVE_COMPARATOR|guided imagery|guided imagery relaxation technique , 45 minutes, 5 sessions in weekly rhythm including body scan, breathing relaxation, visualization
62090655|NCT06586216|EXPERIMENTAL|Cohort 2|Severe renal impairment
62289095|NCT02532478||Stoma not-reversed|Patients whose ileostomy have not been closed due to some problems
62463164|NCT04835246|EXPERIMENTAL|Spectra IMDx|"The physician will be asked to give a diagnosis of the lesion under White light endoscopy (WLE) firstly and the endoscopic diagnosis result will be recorded on case report form. Then the physician will introduce the probe of Spectra IMDx system to contact and assess the lesion. The Spectra IMDx system will detect the scattering light signal from the lesion and assess the risk of the lesion being high-grade intraepithelial neoplasia or gastric cancer, and display the result on the Spectra IMDx screen. The Spectra IMDx assessment will be recorded on case report form. Both the patient and doctor will be blinded from the results from Spectra IMDx system.~After Spectra IMDx system examination, the physician takes biopsy sample(s) in suspected lesion for further histopathological diagnosis."
62090656|NCT06586216|EXPERIMENTAL|Cohort 3|Moderate renal impairment
62090657|NCT04412564|EXPERIMENTAL|TQ-B3101 capsules|TQ-B3101 capsules 300mg bid administered orally in 28-day cycle.
62090658|NCT05692843|OTHER|Start of Cyclosporin treatment|"Patients will receive the starting dose used in routine clinical practice (maximum dose of 3 mg/kg/day is standard practice in our center).~Once the patient is included in the clinical trial their therapeutic management will be carried out according to usual clinical practice, but additional procedures will be performed:~1. The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life;~2. Biological samples will be obtained (blood and urine) for biochemical, kinetic, pharmacogenetic and immunological biomarker analysis to identify variables associated to CsA treatment."
62090659|NCT05692843|OTHER|Receiving or received cyclosporin|"If the patient is receiving cyclosporine therapy, a blood sample for pharmacogenetic analysis will be obtained at screening; also, at discretion of the treating physician, biological samples will be obtained (blood and urine) in this visit and in the follow-up visits to assess biochemical and kinetic variables. Clinical data (scales) will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.~If the patient received cyclosporine previously but is no longer under CsA therapy, a blood sample will be extracted at screening for pharmacogenetic analysis. Clinical data (scales) will be collected from clinical records."
62090660|NCT01101906|EXPERIMENTAL|Arm A: OSI-906|150 mg BID
62090661|NCT01101906|PLACEBO_COMPARATOR|Arm B: Placebo|Placebo BID
62090662|NCT06296251|PLACEBO_COMPARATOR|Placebo treatment|Placebo treatment (Microcrystaline cellulose): 1 capsule/day
62090663|NCT06296251|ACTIVE_COMPARATOR|Active low dose of plant derived phenolics|Active low dose of plant derived phenolics via 1 capsule/day
62090664|NCT06296251|ACTIVE_COMPARATOR|Active high dose of plant derived phenolics|Active high dose of plant derived phenolics via 1 capsule/day
62090665|NCT03431519||Group A|The subjects received VP with PEEK and Sr-HA
62090666|NCT03431519||Group B|The subjects received VP with PEEK and PMMA
62090667|NCT04560361|EXPERIMENTAL|Electroacupuncture group|Choose the appropriate position according to the patient's herpes site, and routinely disinfect the skin. Paste the fixed insulating pad on the acupoint, and use a 0.30×40mm acupuncture needle to penetrate the skin 10mm obliquely through the fixed insulating gasket at Ashi point; According to the above operation, the SJ6 and GB34 point of the affected side are directly penetrated into the skin 15-20mm. The local Ashi point connects the two poles of the electroacupuncture device according to the first and last points of the long axis of the painful part, and the SJ6 and GB34 point on the affected side are connected to the poles of the electroacupuncture device. Electroacupuncture waveform is continuous wave, frequency is 2Hz, and current intensity is 1-5mA (causing slight tremor of the skin around the acupuncture point without pain). Continue the electroacupuncture treatment for 30 minutes.
62090668|NCT04560361|SHAM_COMPARATOR|Sham electroacupuncture group|Participants randomly assigned to the sham electroacupuncture (SA) group received sham electroacupuncture by using placebo blunt needles at the same acupoints. After disinfecting the skin and placing the sterile insulating adhesive pads on unilateral Zhigou, Yanglingquan and Ashi points, placebo blunt needles are inserted through the pads and reach the insulating adhesive layer, causing the participants to feel the needle resistance (a sensation of needle insertion). Other procedures, electrode placements, parameter of electroacupuncture apparatus and treatment settings are the same as in the EA group, but with no skin penetration or electricity output.
62090669|NCT04922021|EXPERIMENTAL|LEO 138559|Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
61906019|NCT03271645|EXPERIMENTAL|Space from depression|Space from depression is an 8 module CBT-based intervention.
62090670|NCT04922021|PLACEBO_COMPARATOR|Placebo|Participants will receive injections of placebo from Week 0 (baseline) to Week 16 (end of treatment).
61906020|NCT03271645|EXPERIMENTAL|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
62090671|NCT03620071|EXPERIMENTAL|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
62090672|NCT03620071|EXPERIMENTAL|Control|Standard Care
61906021|NCT03271645|EXPERIMENTAL|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
61906022|NCT03271645|ACTIVE_COMPARATOR|Face-to-face counselling|Face-to-face counselling
61906023|NCT00726843|ACTIVE_COMPARATOR|1|8 weeks of Yoga, followed by 8 weeks of follow-up
61906024|NCT00726843|ACTIVE_COMPARATOR|2|8 weeks of follow-up, followed by 8 weeks of yoga
61906025|NCT01210040|ACTIVE_COMPARATOR|Folic Acid|2.8mg of Folic Acid given weekly
61906026|NCT01210040|EXPERIMENTAL|Folic Acid and Iron|2.8mg Folic Acid and 60mg Iron given weekly
61906027|NCT06530433|ACTIVE_COMPARATOR|SoC|Standard of Care
61906028|NCT06530433|EXPERIMENTAL|eCSS|enhanced CFR support system (eCSS)
62090673|NCT05392582||Young|Young healthy adult participants
62289096|NCT05459376|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive an assessment, classification as to McKenzie method (MDT) syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine ; will receive basic information about low back pain (LBP), its prevalence and prognosis; plus how and why to exercise; and types of responses that may occur in response to the exercise program. Guidance for performing the exercises at home. Dry suction cup application with 6 size 1 acrylic cups (4.5 cm internal diameter) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae, bilaterally according to the acupoint boundaries, B23, B24 and B25 . This group will consist of performing MDT exercises and dry cupping with 2 suctions for 10 minutes, 2 times a week, for 8 weeks.
62289097|NCT05459376|SHAM_COMPARATOR|Sham Group|The sham group will follow the same principles of evaluation, classification and intervention according to the McKenzie method (MDT) (described in the intervention group) and will have a placebo dry cup application with 6 size 1 acrylic cups (4.5 cm internal diameter) with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of placebo dry cupping for 10 minutes, 2 times a week, for 8 weeks. However, cups will be prepared with small holes \<2 mm in diameter to release negative pressure in seconds.
62289098|NCT00977470|EXPERIMENTAL|Erlotinib|Erlotinib 150 mg oral daily
62289099|NCT00977470|EXPERIMENTAL|Erlotinib and Hydroxychloroquine|Erlotinib 150 mg oral daily plus Hydroxychloroquine (HCQ) 1000 mg oral daily
62289100|NCT02139150|EXPERIMENTAL|Serial FLT PET Imaging|"Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this body scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma)."
62289101|NCT00506857|EXPERIMENTAL|Busulfan + Fludarabine|Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m\^2 IV daily for 4 days.
62289102|NCT01005160|EXPERIMENTAL|CKD501|
62289103|NCT01097629|EXPERIMENTAL|Suvorexant HD|Drug
62655164|NCT00608920|EXPERIMENTAL|SPECT lymph node mapping|"1. Diagnostic pelvic CT~2. Nuclear tracer injection (Tc-99m) - same time as the ACCULOC seed implantation~3. CT simulation (2 hours after prostate markers are placed)~4. SPECT lymphoscintigraphy (first set of images 3-6 hours after injection and second set may be obtained 18-24 hours after injection)"
62289104|NCT01097629|EXPERIMENTAL|Suvorexant LD|Drug
62655165|NCT03834090|EXPERIMENTAL|rESWT|the group receiving rESWT
62655166|NCT03834090|ACTIVE_COMPARATOR|supervised exercises|the group receiving supervised exercises
62655167|NCT01294514||Healthy Volunteers|Healthy volunteers ASA Class 1
62655168|NCT00521495|EXPERIMENTAL|A|Surface magnetic field strength at target 450 Gauss permanent magnet
62655169|NCT00521495|EXPERIMENTAL|B|Surface field strength at target 150 Gauss permanent magnet
62289105|NCT01097629|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62289106|NCT01486576|ACTIVE_COMPARATOR|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
62289107|NCT01486576|PLACEBO_COMPARATOR|Sodium Chloride 9 mg/ml|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
62289108|NCT01639326|EXPERIMENTAL|Irinotecan high doses|Patients will receive irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
62289109|NCT01639326|ACTIVE_COMPARATOR|Irinotecan standard doses|Patients will receive irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours
62655170|NCT00521495|ACTIVE_COMPARATOR|C|
62655171|NCT06045260|EXPERIMENTAL|7.4 Gbq Dose|"Patients with less than 2 risk factors out of the following will receive a dose equal to 7.4 GBq of the experimental radiopharmaceutical 177Lutetium-DOTATOC:~* Pre-existing renal impairment (Creatinine \> 1.5 mg/dl and/or eGFR or creatinine clearance \>50 and \< 60 ml/min) or(chemotherapy, local external radiotherapy);~* Patients who have received earlier nephrotoxic treatment modalities (chemotherapy, local external field radiation);~* Relevant renal morphological abnormalities;~* Previously major (G3-4) iatrogenic toxicities;~* ECOG = 2;~* Any previous Peptide Receptor Radionuclide Therapy;~* Type 1 or 2 diabetes not controlled with therapy;~* Arterial hypertension not controlled with therapy;~* Extension of disease = 4 according to tumor burden Krenning scale (9);~* Age (\>80 years)."
62736399|NCT02258568|EXPERIMENTAL|Smoking abstinence counseling|Telephone motivational counseling sessions supporting smoking abstinence
62736400|NCT02258568|NO_INTERVENTION|Control|Do not receive telephone motivational counseling sessions supporting smoking abstinence
62090674|NCT05392582||Older|Older healthy adult participants
62090675|NCT03766594|ACTIVE_COMPARATOR|Sildenafil group|Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
62090676|NCT03766594|ACTIVE_COMPARATOR|Control group|Includes 45 women who received placebo oral tablets (apparently identical to Respatio(R) 25mg tablets, four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
62090677|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
61906029|NCT01906944|ACTIVE_COMPARATOR|Trigger point injection|Trigger point injection under ultrasound guidance into the fascial layer above the external oblique or rectus muscle, whichever corresponds to patient's identifiable trigger point. The injectate will include 5 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
61906030|NCT01906944|ACTIVE_COMPARATOR|Transversus abdominis plane block|Injection into transversus abdominis plane layer under ultrasound guidance on the affected side along the mid-axillary line. The injectate will include 10 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
61906031|NCT02338882|EXPERIMENTAL|Bi flex M multifocal intraocular lens|Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
61906032|NCT02338882|ACTIVE_COMPARATOR|Bi flex 1.8 monofocal intraocular|Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
61906033|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
61906034|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
61906035|NCT03504046|EXPERIMENTAL|Artificial Pancreas App|After completing a 1 week open-loop run in period, subjects will use the APS APP for a 48-hour period in an observed transitional environment.
61906036|NCT00892840|EXPERIMENTAL|Panels 1 to 7 (BMS-820836 or Placebo)|
61906037|NCT03118908|EXPERIMENTAL|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
61906038|NCT03118908|PLACEBO_COMPARATOR|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
61906039|NCT03400267|ACTIVE_COMPARATOR|paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
62090678|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
62090679|NCT06228703|NO_INTERVENTION|Airvo 3 high-flow nasal cannula device with flow set at 20 L/min|A new high-flow nasal cannula device (Airvo 3) will be used in the study, with the flow set at 20 L/min
62289110|NCT00426348|ACTIVE_COMPARATOR|1|In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
62289111|NCT00426348|EXPERIMENTAL|2|Valsartan(80-160mg/day) + Probucol(750mg/day)
62090680|NCT06228703|NO_INTERVENTION|HFT 750 high-flow nasal cannula device with flow set at 20 L/min|A new high-flow nasal cannula device (HFT 750) will be used in the study, with the flow set at 20 L/min
62090681|NCT06228703|EXPERIMENTAL|Airvo 3 high-flow nasal cannula device with flow set at 40 L/min|Airvo 3 will be used with the flow set at 40 L/min
62289112|NCT03862027|EXPERIMENTAL|Esophageal Balloon catheter|All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed \> 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
62463165|NCT03555305|EXPERIMENTAL|Insulin Glargine|Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).
62463166|NCT03555305|ACTIVE_COMPARATOR|Lantus|Participants received 0.5 U/Kg of Lantus subcutaneously.
61906040|NCT03400267|ACTIVE_COMPARATOR|fentanyl|
61906041|NCT00757328||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
62090682|NCT06228703|EXPERIMENTAL|Airvo 3 high-flow nasal cannula device with flow set at 60 L/min|Airvo 3 will be used with the flow set at 60 L/min
62090683|NCT06228703|EXPERIMENTAL|HFT 750 high-flow nasal cannula device with flow set at 40 L/min|HFT 750 will be used with the flow set at 40 L/min
62090684|NCT06228703|EXPERIMENTAL|HFT 750 high-flow nasal cannula device with flow set at 60 L/min|HFT 750 will be used with the flow set at 60 L/min
62090685|NCT01314092|EXPERIMENTAL|Group 1|Low dose group
62090686|NCT01314092|EXPERIMENTAL|Group 2|high dose group
61906042|NCT02113397||Continuous Therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
61906043|NCT02113397||Cyclic therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.
61906044|NCT04727021|EXPERIMENTAL|Treatment A: Single oral dose of a 20 mg tablet rivaroxaban|"2-way crossover: The subjects will receive the following treatments in a randomized order:~* Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~* Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
62090687|NCT06015295|EXPERIMENTAL|18F-Fluciclovine (Axumin)|Participants are expected to be in this research study for about 6-12 months. Participants will have up to 6 visits for screening tests, Axumin PET-CT scans, and information collection.
62736401|NCT02972346|EXPERIMENTAL|ACTH(+)|routine treatment + ACTH
62736402|NCT02972346|NO_INTERVENTION|ACTH(-)|routine treatment
62090688|NCT04785287|EXPERIMENTAL|Arm I (BMS-986218, SBRT)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 IV over 30 minutes on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT on days 36-39 (days 8-11 of cycle 2).
62090689|NCT04785287|EXPERIMENTAL|Arm II (BMS-986218, SBRT, nivolumab)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 and SBRT as in Arm 1. Beginning cycle 2, patients also receive nivolumab IV over 30 minutes starting on day 1. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62090690|NCT03318744|EXPERIMENTAL|aspirin 100mg|Participants will be given aspirin 100mg once per day.
62463167|NCT03806777|EXPERIMENTAL|Intra-nasal dexmedetomidine|A single dose of dexmedetomidine, determined by a biased coin algorithm (min: 1 mcg/kg; max: 4 mcg/kg or 200mcg), will be delivered intranasally 45min before an MRI scan.
62736403|NCT02097719|ACTIVE_COMPARATOR|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
62736404|NCT02097719|ACTIVE_COMPARATOR|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
61906045|NCT04727021|EXPERIMENTAL|Treatment B: Single oral dose of 20 mg rivaroxaban, granules|"2-way crossover: The subjects will receive the following treatments in a randomized order:~* Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~* Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
61906046|NCT03390114|EXPERIMENTAL|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
61906047|NCT03390114|NO_INTERVENTION|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
61906048|NCT03220451|EXPERIMENTAL|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
61906049|NCT02975232|EXPERIMENTAL|Treatment|F\&V economic incentive with Cooking Matters store tour
61906050|NCT02975232|NO_INTERVENTION|Control|no intervention
61906051|NCT01267357||Serous papillary endometrial ca patients|30 patients diagnosed with SP endometrial ca
61906052|NCT01267357||Endometrioid endometrial ca|32 patients diagnosed with Endometrioid endometrial ca
61906053|NCT04206241||High-risk infants|"Mother answered yes to any of the following questions on a risk-screening tool:~* Mother diagnosed with HIV in labor and delivery?~* Mother start ART after 32 weeks' gestation?~* Maternal viral load above 1000 copies/ml in the 3rd trimester?~* Mother seroconvert during pregnancy?~* Was the mother not adhering to ART during pregnancy?"
61906054|NCT04206241||Low-risk infants|Mothers did not answer affirmatively to any of the four screening questions
61906055|NCT03736915|ACTIVE_COMPARATOR|1 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
61906056|NCT03736915|ACTIVE_COMPARATOR|3 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
61906057|NCT03736915|ACTIVE_COMPARATOR|5 cc needle with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
61906058|NCT00311584|EXPERIMENTAL|Disease measurable by CT or MRI scan (Irinotecan/Temozolomide)|Measurable by CT scan (Computed Tomography) or MRI scan (Magnetic Resonance Imaging). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62090691|NCT03318744|PLACEBO_COMPARATOR|placebo|Participants will be given placebo oral tablets once per day.
62090692|NCT02992665|EXPERIMENTAL|Ca ionophore|Artificial activation of the oocytes using Calcium ionophore in the cases of severe male factor infertility.
62090693|NCT02992665|EXPERIMENTAL|Placebo|Placebo was used to control the group of Calcium ionophore
62090694|NCT02165423|EXPERIMENTAL|Control|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
62090695|NCT02165423|EXPERIMENTAL|Intervention|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
62090696|NCT04525300|EXPERIMENTAL|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
62090697|NCT04525300|PLACEBO_COMPARATOR|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
62463168|NCT02895711||Patients with urolithiasis|To record the effective radiation dose to the patient during endourologic procedures to treat urolithiasis
62463169|NCT03099174|EXPERIMENTAL|Cohort A|Xentuzumab + Abemaciclib (Dose 1)
62463170|NCT03099174|EXPERIMENTAL|Cohort B|Xentuzumab + Abemaciclib + Letrozole (Dose 2)
62463171|NCT03099174|EXPERIMENTAL|Cohort C|Xentuzumab + Abemaciclib + Anastrozole (Dose 3)
62463172|NCT03099174|EXPERIMENTAL|Cohort D|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
62463173|NCT03099174|EXPERIMENTAL|Cohort E|Xentuzumab + Abemaciclib (Dose 1)
62463174|NCT03099174|EXPERIMENTAL|Cohort F|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
62090698|NCT05050370|EXPERIMENTAL|Lifestyle-integrated exercise and care support|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and cancer-related information with personalized support.
62090699|NCT05708898|EXPERIMENTAL|Pharyngeal exerciser group|In this group, the device will be placed around the neck overlying the laryngeal cartilage. Patients are asked to follow exercise regimen: to perform 30 swallows at 15 seconds interval against minimal resistance of 20 mm Hg applied by pharyngeal exerciser over larynx during the first 2 weeks. This is repeated 3 times per day and the external resistance is increased every 2 weeks from 20 to 30 mm Hg and subsequently from 30 to 40 mm Hg in another 2 weeks.
62289113|NCT05531747|EXPERIMENTAL|Physiopathologic exploration|A non randomised study with one arm, addind experimental acts to standard of care (skin biopsy and biological sample ) in order to explore Hidradenitis Suppurativa physiopathology
62289114|NCT05277974|ACTIVE_COMPARATOR|Group B.|group B will receive Inj Bupivicain only in Erector Spinae Plane Block.
62289115|NCT05277974|ACTIVE_COMPARATOR|Group D|group D will receive Inj Bupivicain plus Dexamethasone in Erector Spinae Plane Block.
62289116|NCT04937504|ACTIVE_COMPARATOR|STAIR-PC Group|Participants in the Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) group will complete five (30 minute each) therapist-led sessions in-person or via Telehealth for up to 12 weeks.
62463175|NCT03099174|EXPERIMENTAL|Cohort D1|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
62463176|NCT03099174|EXPERIMENTAL|Cohort D2|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
62090700|NCT05708898|SHAM_COMPARATOR|Sham exerciser group|In this group, sham device will be placed around the neck overlying the laryngeal cartilage. No external pressure will be applied during exercise. These patients will be asked to follow the exercise regimen: to perform repetitive tongue protrusion for 5 times without any pressure. This will be repeated 3 times a day for 6 weeks.
62289117|NCT04937504|EXPERIMENTAL|WebSTAIR Group|Participants in the WebSTAIR group will complete 10 self-guided, web-based modules for up to 12 weeks.
62289118|NCT02673229|ACTIVE_COMPARATOR|Collagenase Santyl|Applied topically (2 mm thickness once daily)
62289119|NCT02673229|SHAM_COMPARATOR|Bacitracin|Applied topically (2 mm thickness) once daily
62289120|NCT00694057|PLACEBO_COMPARATOR|Placebo|Placebo capsules BID
62289121|NCT00694057|EXPERIMENTAL|Active|HE3286 10 mg (5 mg BID)
62463177|NCT00076934|EXPERIMENTAL|1|Participants receive Regimen 1 for 4 months
62463178|NCT00076934|EXPERIMENTAL|2|Participants receive Regimen 2 for 4 months
62463179|NCT00076934|EXPERIMENTAL|3|Participants receive Regimen 3 for 4 months
62463180|NCT00076934|EXPERIMENTAL|4|Participants receive Regimen 4 for 4 months
62463181|NCT04041843|EXPERIMENTAL|Abixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
62463182|NCT02636959|ACTIVE_COMPARATOR|high volume saline irrigation (HVSI)|High volume nasal spray, NeilMed® Sinus Rinse, is a high saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
62463183|NCT02636959|ACTIVE_COMPARATOR|low volume saline irrigation (LVSI)|Low volume nasal spray, Salinex Rinse, is a low saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
62463184|NCT03397862|EXPERIMENTAL|Corplex Donepezil TDS 5 mg/day|Subjects will receive Corplex Donepezil TDS 5 mg/day during Induction, Challenge, and Re-Challenge phase.
62463185|NCT03397862|PLACEBO_COMPARATOR|Vehicle TDS|Subjects will receive Vehicle TDS during Induction, Challenge, and Re-Challenge phase.
62463186|NCT03252353|ACTIVE_COMPARATOR|Octreotide capsules|Octreotide capsules
62463187|NCT03252353|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo capsules
62463188|NCT03460951||CIDP patients|15 patients with CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy ) who satisfy the definite CIDP criteria of the Joint Task Force of the EFNS and PNS 1 (situations A and B according to the French CIDP work group2), and who agree to undergo cervical MRI.
62463189|NCT03460951||Normal volunteers|15 healthy subjects matched for age and gender to CIDP patients
62736405|NCT02210988|EXPERIMENTAL|acupuncture|The acupuncture treatment for the intervention group was provided once daily for 2 weeks.
62736406|NCT03851887|EXPERIMENTAL|treatment group|TAI combine SBRT
62289122|NCT00318292|EXPERIMENTAL|PLA|Active preemptive local analgesia.
62289123|NCT00318292|PLACEBO_COMPARATOR|Placebo|Placebo for preemptive local analgesia.
62289124|NCT01100489|EXPERIMENTAL|Arm I|Patients undergo breast-conserving surgery consisting of partial mastectomies followed by external beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
62289125|NCT04613986|NO_INTERVENTION|Standard|Standard of care according to our current in house SOP
62289126|NCT04613986|EXPERIMENTAL|Treatment|Standard of care according to our current in house SOP + Therapeutic Plasmaexchange (d1, 3, 5)
62090701|NCT03557255|ACTIVE_COMPARATOR|levosimendan|Levosimendan was prepared in a concentration of 25 µg/ml and infusion was commenced at a rate of 0.1 µg/kg/minute without loading and continued for 24 hours before surgery.The dose was doubled if an increase of \> 20 mmHg in systolic blood pressure (SBP) could not be obtained within 2 hours after starting the infusion. Indications for dose reduction were the development of hypotension (SBP \< 80 mmHg) or tachycardia (heart rate \> 120 beats/min) persisting for more than 10 minute or (premature beats in a frequency exceeding 6/min or occurrence of a significant arrhythmia occurring in runs). The infusion medication would be discontinued should such occurrences persist despite dose reduction.
62090702|NCT03557255|ACTIVE_COMPARATOR|control|In the control group ,an identical saline infusion regimen was employed instead of levosimendan . Both patient and care giver were blinded for the study.
62090703|NCT04763291|NO_INTERVENTION|Control group|Continue habitual diet and lifestyle.
62090704|NCT04763291|EXPERIMENTAL|Fruit, Vegetable and Berry (FVB) group|Participants have to ingest an encapsulated juice powder concentrate, otherwise continue their habitual diet and lifestyle.
62090705|NCT04763291|EXPERIMENTAL|Omega group|Participants have to ingest a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
62090706|NCT04763291|EXPERIMENTAL|Fruit, Vegetable, Berry and Omega (FVBO) group|Participants have to ingest an encapsulated juice powder concentrate along with a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
62090707|NCT06689475|EXPERIMENTAL|Psychoacoustic group|The psychoacoustic approach group will listen to normal heart sounds (S1, S2), abnormal heart sounds (S3, S4) and murmur sounds from the audio file uploaded to their mobile phones in the laboratory environment through headphones for 500 repetitions each.
62090708|NCT06689475|EXPERIMENTAL|Simulation group|The simulation group will practice auscultation of heart sounds in a one-to-one and repetitive manner, working with a high reality simulator. Trainers will act as facilitators during the cardiac auscultation practice of the students in the intervention groups.
62090709|NCT06689475|NO_INTERVENTION|Control group|The control group will continue with the standard education.
62090710|NCT04174560|EXPERIMENTAL|Cohort 1|Single dose (3.5x10\^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10\^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
62090711|NCT04174560|EXPERIMENTAL|Cohort 2|Single dose (3.5x10\^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10\^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
62090712|NCT04174560|EXPERIMENTAL|Cohort 3|Single dose (3.5x10\^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10\^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
62090713|NCT04834362|EXPERIMENTAL|Analog insulin arm|Patients treated with insulin analog regimen will receive 50% of total daily dose as basal insulin glargine at the same time of day and 50% as insulin aspart given in 3 equally divided doses at 6 am, 12 pm and 6 pm.
62090714|NCT04834362|ACTIVE_COMPARATOR|Human insulin arm|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm
62090715|NCT04321876||NMG IM 211 E Chicago Ave|
62090716|NCT04321876||NMG IM ARKES|
62090717|NCT04321876||NMG IM 1460 N Halsted St|
62090718|NCT04321876||NMG IM 201 E Huron St|
62090719|NCT04321876||NMG Integrative Medicine 150 E Huron St|
62090720|NCT04321876||NMG IM 1776 N Milwaukee Ave|
62090721|NCT04321876||NMG IM 20 S Clark St|
62090722|NCT04321876||NMG IM FM 1704 Maple Ave|
62090723|NCT04321876||NMG IM 259 E Erie St|
62090724|NCT04321876||NMG IM 1135 S Delano Ct|
62090725|NCT04321876||NMG IM 1333 W Belmont Ave|
62090726|NCT02688036|EXPERIMENTAL|hypofractionated CRT|hypofractionated concurrent chemoradiotherapy
62090727|NCT02688036|ACTIVE_COMPARATOR|conventionally fractionated CRT|conventionally fractionated concurrent chemoradiotherapy
62090728|NCT05962398||CSL222|Participants who received CSL222 and completed either the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891) will be followed up from Year 5 after administration of CSL222 in parent study up to Year 15.
62090729|NCT05398341||Prospective Cohort|There will be a prospective cohort for all subjects scheduled to undergo ACL surgery with the BEAR Implant that are willing to provide consent.
62090730|NCT05398341||Retrospective Cohort|A retrospective cohort will be available for all subjects treated with the BEAR Implant at each participating site. There is no control group.
62090731|NCT02770079||Gestational diabetes|10 women with gestational diabetes
62090732|NCT06425302|EXPERIMENTAL|Rituximab + Chemotherapy|R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone) or Rituximab + Bendamustine
62090733|NCT06425302|EXPERIMENTAL|Golcadomide Dose 1 + Rituximab|
62090734|NCT06425302|EXPERIMENTAL|Golcadomide Dose 2 + Rituximab|
62090735|NCT04808869|SHAM_COMPARATOR|Control|Cycling at 70 rpm 3 times/week without any blood flow restriction cuffs
62090736|NCT04808869|EXPERIMENTAL|BRF 60% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in one leg.
62090737|NCT04808869|EXPERIMENTAL|BFR 80% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in one leg.
62090738|NCT04808869|EXPERIMENTAL|BFR Bilateral 60%|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in both legs.
62090739|NCT04808869|EXPERIMENTAL|BFR 80% Bilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in both legs.
62655172|NCT06045260|EXPERIMENTAL|5.5 Gbq Dose|"Patients with al least 2 risk factors out of the following will receive a dose equal to 5.5 GBq of the experimental radiopharmaceutical 177Lutetium-DOTATOC:~* Pre-existing renal impairment (Creatinine \> 1.5 mg/dl and/or eGFR or creatinine clearance \>50 and \< 60 ml/min) or(chemotherapy, local external radiotherapy);~* Patients who have received earlier nephrotoxic treatment modalities (chemotherapy, local external field radiation);~* Relevant renal morphological abnormalities;~* Previously major (G3-4) iatrogenic toxicities;~* ECOG = 2;~* Any previous Peptide Receptor Radionuclide Therapy;~* Type 1 or 2 diabetes not controlled with therapy;~* Arterial hypertension not controlled with therapy;~* Extension of disease = 4 according to tumor burden Krenning scale (9);~* Age (\>80 years)."
62289127|NCT03504826|EXPERIMENTAL|Locomotor training using adaptive robot|The intervention will consist of 60 sessions of locomotor training using the HAL adaptive robot. The training sessions will be scheduled 5 days per week for 12 weeks. A physical therapist with expertise in SCI walking rehabilitation and use of the HAL will oversee all intervention sessions. The intervention sessions will include up to a total of 40 minutes of stepping time, which may take up to 2 hours to complete due to set up time and rest breaks.
62655173|NCT04685954|EXPERIMENTAL|Bulk-Fill|Filtek™ Bulk Fill Posterior, 3M ESPE, St. Paul MN, USA (FB)
62655174|NCT04685954|EXPERIMENTAL|Incremental|Filtek Ultimate Universal, 3M ESPE, St. Paul MN, USA (FU)
62655175|NCT06525519|EXPERIMENTAL|ATLG-20 mg/kg|ATLG 20mg/kg group refers to treatment with ATLG in the total dose of 20mg/kg.
61906059|NCT00311584|EXPERIMENTAL|Disease eval by bone marrow or MIBG (Irinotecan/Temozolomide)|Evaluation by bone marrow or MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61906060|NCT01198613|PLACEBO_COMPARATOR|Placebo|
61906061|NCT01198613|EXPERIMENTAL|ToleroMune Ragweed Regimen 1|
62090740|NCT03425136|EXPERIMENTAL|SAIA (Systems Analysis & Improvement)|Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
62090741|NCT03425136|NO_INTERVENTION|Control|Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
62090742|NCT03155191|EXPERIMENTAL|Dose Level -1 to 2|"0.3 to 3 x 10\^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.~cohort -1: 3×10\^5 cells/kg cohort 1: 1×10\^6 cells/kg cohort 2: 3×10\^6 cells/kg."
62090743|NCT00771628|EXPERIMENTAL|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
62655176|NCT06525519|EXPERIMENTAL|ATLG-30mg/kg|ATLG 30mg/kg group refers to treatment with ATLG in the total dose of 30mg/kg.
62655177|NCT03098979|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
62736407|NCT06405165|EXPERIMENTAL|Knowledge level of nursing students|
61906062|NCT01198613|EXPERIMENTAL|ToleroMune Ragweed Regimen 2|
61906063|NCT01198613|EXPERIMENTAL|ToleroMune Ragweed Regimen 3|
61906064|NCT01198613|EXPERIMENTAL|ToleroMune Ragweed Regimen 4|
61906065|NCT00756912|EXPERIMENTAL|1|
61906066|NCT06529926|OTHER|Control Group|Treated with classical physiotherapy (Hotpack+TENS+Ultrasound) program. A 20-minute hotpack was applied to the lumbar area. TENS and ultrasound were applied as electrotherapy agents. The TENS application was made with the Chattanooga Intelect Advanced Combo device. Conventional tens was applied at a frequency of 100 Hz for 20 min with a current of 100 μs. The ultrasound application was made with the Chattanooga Intelect Advanced Combo device. Lumbar area was administered at a dose of 1 MHz, 1.5 W/cm² using a 5 cm diameter cap for 6 min. In the first session, the physiotherapist had the patient explain the exercises (posterior pelvic tilt exercise, hip flexors stretching exercise, lumbar extensors stretching exercise, abdominal muscle strengthening exercise, SLR exercise, pelvic elevation exercise, cat-camel exercise and lumbar extensor strengthening exercise). Afterwards, patients were advised to rest for 1 minute between exercises, 1 time a day and for 4 weeks, 5 days a week.
62090744|NCT00771628|ACTIVE_COMPARATOR|2 Malleable|
62289128|NCT00368706|EXPERIMENTAL|1|
62289129|NCT00368706|ACTIVE_COMPARATOR|2|
61906067|NCT06529926|EXPERIMENTAL|IASTM Treatment Group|IASTM application was applied at an angle of 45° in a direction parallel to the muscle fibers for about 20 seconds. Immediately afterwards, a total of 40 seconds of treatment time was applied by treating the muscle fibers at a 45° angle with the instrument for an additional 20 seconds in a direction perpendicular to them. In other words, for each area (paraspinal muscles, gluteus maximus and gluteus medius muscles, hamstrings), a total of 2 minutes was applied to the right and left sides separately for 40x3 seconds. Paraspinal muscles were treated from caudal to cranium, gluteal muscles from proximal to distal and hamstring muscles from popliteal fossa to gluteal line. Stretching was provided by exercises applied to the control group. After the cold application, IASTM application was made, the cold-pack was applied to each area for 5 minutes. (The application was performed by a trained and experienced physiotherapist and with a stainless steel gua sha device).
61906068|NCT01317550|EXPERIMENTAL|Armodafinil + Placebo|Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks
62090745|NCT00901485|EXPERIMENTAL|autotitrating NIV|approximately 6 weeks using domiciliary nocturnal autotitrating non-invasive ventilation
62090746|NCT00901485|ACTIVE_COMPARATOR|Standard non-invasive ventilation|approximately 6 weeks using domiciliary nocturnal standard non-invasive ventilation
62289130|NCT06130332|EXPERIMENTAL|PD-1 with chemotherapy|"Tirellizumab, Carboplatin,albumin-bound paclitaxel Patients receive Tirellizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Then surgery.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles~Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
62655178|NCT03098979|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
62655179|NCT03098979|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
62655180|NCT03098979|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
62655181|NCT03098979|EXPERIMENTAL|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
62655182|NCT03098979|PLACEBO_COMPARATOR|Placebo|Chronic heart failure with preserved ejection fraction
61906069|NCT01317550|EXPERIMENTAL|Minocycline + Placebo|Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks
61906070|NCT01317550|EXPERIMENTAL|Armodafinil + Minocycline|Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks
61906071|NCT01317550|PLACEBO_COMPARATOR|Placebos|Placebo Capsules orally once/day for 10 weeks
61920034|NCT05929820|EXPERIMENTAL|Protect Your Colon™ (Intervention)|Patients randomized to Protect Your Colon™ will be directed to go through the website at least 2 days before their clinic appointment. Those who finish the decision aid will then review their personalized report which details their priorities in selecting a screening test as well as the test that best matches their values. Patients will also be encouraged to bring their personalized report with them to the visit to discuss with their doctor. All intervention participants will also receive a reminder via email one day before their scheduled clinic visit. They will be reminded to go through the Protect Your Colon™ website before the clinic visit and to bring their personalized report with them to the visit.
62090747|NCT05812755|ACTIVE_COMPARATOR|Vericiguat|10 mg vericiguat administered orally once daily for three days (through day of surgery)
62655183|NCT03773588|ACTIVE_COMPARATOR|Closed-Loop propofol Target control infusion|Closed loop target controlled infusion(TCI) TIVA with propofol using BD TCI pumps guided by entropy and SPI
62090748|NCT05812755|PLACEBO_COMPARATOR|Placebo|placebo administered orally once daily for three days (through day of surgery)
62090749|NCT02133274|NO_INTERVENTION|Standard oncologic care|Standard oncologic care
62655184|NCT03773588|ACTIVE_COMPARATOR|Open-loop propofol target control infusion|Open-loop target controlled infusion of propofol using BD TCI pumps based on Schnider effect site algorithm
62655185|NCT05532878||Study group|stable PD patients with non-valvular AF
62736408|NCT06405165|EXPERIMENTAL|Effect of flipped education-Jigsaw learning model|
62736409|NCT05937256|ACTIVE_COMPARATOR|Group Q|(n=30) will receive unilateral quadratus lumborum block type III
62736410|NCT05937256|ACTIVE_COMPARATOR|Group E|(n=30) will receive unilateral erector spinae plane block
62090750|NCT02133274|EXPERIMENTAL|Early Palliative Care|A first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
62090751|NCT02133274|EXPERIMENTAL|Psychosocial plus early Palliative Care|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy plus early palliative care. Regarding the early Palliative Care, a first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
62090752|NCT00813007||Questionnaire|Radical trachelectomy outcomes for cervical cancer
62090753|NCT06231485|EXPERIMENTAL|Socialization and sex education (STEPS2)|Weekly virtual one hour one-on-one sessions with Study Health Educator on the STEPS2 curriculum for 6-weeks. Topics include: the human body, decision-making, sexually transmitted diseases, pregnancy, birth control, pregnancy and parenting, and going to the doctor.
62289131|NCT06130332|OTHER|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
62289132|NCT03573167|ACTIVE_COMPARATOR|In-Person Motivational Interviewing|In-Person Motivational Interviewing (MI) is the standard form of MI treatment delivered in person face to face at the primary care office. MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping participants to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling in-person with the participant for one session of MI lasting approximately 30 minutes.
62655186|NCT02104687|ACTIVE_COMPARATOR|Flow|The Flow therapeutic algorithm will be responsible for adjustment of intraoperative interventions - volumotherapy and administration of vasoactive drugs, with the aim to maintain the CI value \>2.5 l/m/m2 (FTc - flow time \<330 ms was chosen as variable defining preload; PV, peak velocity \<70 ms-1 will be used as a variable defining contractility; SVR, total systemic vascular resistance between 1000-1800 cdyn.s/cm5m2 will be used as variable defining after load). After the desired values of CI have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
62090754|NCT06231485|OTHER|Nutrition and physical activity (STYH)|"The comparison curriculum has been shown in a previous study to improve knowledge around nutrition and exercise, but should not change sexual and reproductive health outcomes.~Weekly virtual one hour group sessions (6-10 participants) with Study Health Educator on the Steps To Your Health (STYH) curriculum for 6-weeks. Topics include: nutrition, exercise, stress management, changing your way of thinking, and behaviors to stay healthy."
62090755|NCT05830916||ITP with thrombosis|"History taking including any medical history, family history, drug intake, arterial or venous thrombotic events.~Venous blood samples will be collected by vein puncture under aseptic precautions for:~Routine laboratory investigations:~Complete blood picture with assessment of platelet count. Coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and D-dimer.~Liver and Kidney functions test.~Specific laboratory investigations:~Antiphospholipid antibodies assay which includes:~Lupus anticoagulant (LA) by diluted Russel viper venom method. Anti β2glycoprotien І (β2GPІ), by enzyme-linked immunosorbent assay (ELISA). Anticardiolipin by (ELISA).~Detection of Microparticles and their subtypes by flow cytometry:~Annexin-v for all microparticles. CD 41 for platelet microparticles. CD 146 for endothelial microparticles."
62090756|NCT05830916||ITP without thrombosis|"History taking including any medical history, family history, drug intake, arterial or venous thrombotic events.~Venous blood samples will be collected by vein puncture under aseptic precautions for:~Routine laboratory investigations:~Complete blood picture with assessment of platelet count. Coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and D-dimer.~Liver and Kidney functions test.~B- Specific laboratory investigations:~Antiphospholipid antibodies assay which includes:~Lupus anticoagulant (LA) by diluted Russel viper venom method. Anti β2glycoprotien І (β2GPІ), by enzyme-linked immunosorbent assay (ELISA). Anticardiolipin by (ELISA).~Detection of Microparticles and their subtypes by flow cytometry:~Annexin-v for all microparticles. CD 41 for platelet microparticles. CD 146 for endothelial microparticles."
62090757|NCT06696157|EXPERIMENTAL|single-arm of an uncontrolled trial of the PRSS intervention for MOUD initiation|
62090758|NCT06198517|EXPERIMENTAL|Moxibustion|
62090759|NCT06198517|ACTIVE_COMPARATOR|Control|
62090760|NCT03104569|EXPERIMENTAL|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ during ERCP when injection of contrast agent
62090761|NCT03104569|NO_INTERVENTION|Injection of normal contrast agent|Normal temperature nonionic contrast agent can be used in ERCP when injection of contrast agent
62463190|NCT03460951||Charcot-Marie-Tooth disease type 1A patients (CMT-1A)|15 CMT-1A patients (proven by genetic testing), will be included as Charcot-Marie-Tooth disease type 1A patients (CMT-1A) is one of the main differential diagnoses of CIDP characterized by the diffuse demyelination of peripheral nerves.
62463191|NCT05498480|EXPERIMENTAL|Cohort 1: Relatlimab Dose 1 + Nivolumab|
62463192|NCT05498480|EXPERIMENTAL|Cohort 2: Relatlimab Dose 2 + Nivolumab|
62463193|NCT05374590|EXPERIMENTAL|Efgartigimod or Efgartigimod PH20 SC|Patients receiving Efgartigimod IV treatment or Efgartigimod PH 20 SC treatment
62463194|NCT01346397||cyclosporine group|cyclosporine group - after alemtuzumab induction cyclosporine was administered
62655187|NCT02104687|ACTIVE_COMPARATOR|Press|The Press therapeutic algorithm will be responsible for adjustment of intraoperative interventions based upon standard pressure parameters and will include volumotherapy and administration of vasoactive drugs, with the aim to maintain the desired values of MAP of 65-105 mmHg and CVP 8-12 mmHg. After the desired values of MAP and CVP have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
62655188|NCT01115270||Hydrocephalus Patients|Those patients diagnosed with Normal Pressure Hydrocephalus.
62655189|NCT01115270||Normal Participants|Individuals who are not diagnosed with Normal Pressure Hydrocephalus.
62655190|NCT04452669|EXPERIMENTAL|Study Treatment|Up to 10 days of inhaled epoprostenol delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
62090762|NCT05860816||Primary Care Physiotherapists working in the Spanish public health system|A sample of primary care physiotherapists fill out a survey on their knowledge of chronic pain management and the approach they use to treat patients with chronic pain.
62090763|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
62090764|NCT01901549|ACTIVE_COMPARATOR|PCI+Renal denervation|
62289133|NCT03573167|EXPERIMENTAL|Mobile MI|Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
62289134|NCT03573167|NO_INTERVENTION|Waitlist Control|After consenting to participate in the study, the Waitlist control participants receive no intervention for one (1) month, and then the Waitlist control participants are contacted by the investigators for follow up..
62090765|NCT01901549|ACTIVE_COMPARATOR|PCI alone|
62090766|NCT03461887|EXPERIMENTAL|Exercise intervention|Home-based, minimal equipment exercise training program.
62463195|NCT01346397||tacrolimus group|tacrolimus group - after alemtuzumab induction tacrolimus was administered
62463196|NCT01389102|PLACEBO_COMPARATOR|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
62655191|NCT04452669|PLACEBO_COMPARATOR|Placebo Control|Up to 10 days of inhaled 0.9% sodium chloride solution delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
62655192|NCT05529433|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is a simple technique based on preservation of sound tooth structure and minimal patient's discomfort.
62289135|NCT02542176|EXPERIMENTAL|Freeze-dried Whole Grape Powder|
62289136|NCT02542176|PLACEBO_COMPARATOR|Grape Powder Placebo|
62463197|NCT01389102|PLACEBO_COMPARATOR|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
62463198|NCT01389102|PLACEBO_COMPARATOR|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
62463199|NCT01389102|ACTIVE_COMPARATOR|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
62463200|NCT01389102|ACTIVE_COMPARATOR|Estradiol transdermal two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
62463201|NCT01389102|ACTIVE_COMPARATOR|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
62655193|NCT05529433|EXPERIMENTAL|Smart Burs|Smart Burs are minimally invasive technique which selectively removes the infected carious dentin leaving the affected intact dentin.
62090767|NCT03461887|NO_INTERVENTION|Control|Usual care (study participation does not have any impact on regular treatment or treatment decisions, including participation in other exercise training programs or rehabilitation programs)
62090768|NCT06666205||Type 2 DM patients|This study focuses on patients with Type 2 diabetes and examines the impact of carbohydrate quality on sleep quality and depression. Participants were assessed using a demographic questionnaire, and their dietary carbohydrate intake was analyzed. Sleep patterns were monitored, and depression levels were measured using validated assessment scales. The study aims to investigate the relationship between carbohydrate quality, sleep health, and depression in this population.
62090769|NCT03050840|OTHER|Self-monitoring|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage (SSB) consumption via text messaging. The Way to Health platform will record data.
62090770|NCT03050840|EXPERIMENTAL|Self-monitoring plus gamification|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage consumption via text messaging. Participants will be awarded medals and points based on meeting step per day and SSB consumption goals The Way to Health platform will be used to record data.
62090771|NCT00859417|ACTIVE_COMPARATOR|1|Traditional surgical method without prosthesis
62090772|NCT00859417|EXPERIMENTAL|2|Surgical method with Perigee prosthesis
62090773|NCT03614858|EXPERIMENTAL|Cohort 1|Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
62090774|NCT06556030|PLACEBO_COMPARATOR|Control|physiological saline 50 cc
62090775|NCT06556030|EXPERIMENTAL|botulinum toxin|Intramuscular injection into the flat muscles of the abdominal wall of 300/500 Units of botulinum toxin A dissolved in 100 cc of physiological saline, distributed in 5 points on each side of the abdomen in the first 48 hours after leaving the abdomen open.
62289137|NCT01227967|EXPERIMENTAL|Combination Therapy|Amantadine, Ribavirin, Oseltamivir
62289138|NCT01227967|ACTIVE_COMPARATOR|Oseltamivir monotherapy|Oseltamivir
62289139|NCT03855501|ACTIVE_COMPARATOR|Mineral trioxide aggregate|The root canals were gently instrumented with K-files and copious irrigation was done with 2.5% sodium hypochlorite(NaOCI) by means of a 30 gauge endodontic irrigating needle . After drying with large sterile paper points, calcium hydroxide(CH) paste was mixed with saline and applied to the root canal with a lentulo spiral filler at low speed. A cotton pellet was used to gently compress CH into the root canal and its placement was examined radiographically before placing ZOE as temporary restoration into the access cavity. After one week, CH was removed from the canal by using both the files and the irrigation with 2.5% NaOCI and 17% ethylenediaminetetraacetic acid (EDTA). A final irrigation was made with 2% chlorhexidine (CHX) before obturation. Following drying the root canal with sterile paper points, MTA was placed with a MTA Endo Gun into the apical portion of canals with a minimum 4-mm thickness and adapted to the canal walls with an endodontic hand plugger.
62289140|NCT03855501|ACTIVE_COMPARATOR|Calcium hydroxide|After using the same biomechanical root canal preparation protocol, the root canal was filled to working length with CH paste. Both clinical and radiographical examinations were performed to evaluate the barrier formation and periapical healing. When a continuous hard tissue barrier was observed apically on radiographs that was verified by clinical probing and complete or significant periapical healing was noticed, the root canal was obturated and coronary restorations were completed as done in MTA group
62307951|NCT04946344|EXPERIMENTAL|Diet & Exercise|Participants will attend an exercise class 3 days/week for 3 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant will be prescribed an individual walking prescription by the exercise leader, which will be adjusted accordingly, as each participant progresses throughout the 3 months. The exercise will be of moderate intensity. Alternate forms of aerobic exercise, such as but not limited to stationary bike, elliptical trainer, or treadmill walking, can be used in place of over-ground walking. This choice could be based on participant preference, the limitations of the exercise facility, or the participant's pain level.
62090776|NCT04339478||Autofluorescence|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
62090777|NCT04339478||Control|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection without autofluorescence device. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands"
62090778|NCT03152565|EXPERIMENTAL|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
62090779|NCT02273011||single shot spinal anesthesia|single shot spinal anesthesia for caesarean section was executed for anesthesia, oral analgesic medication was applicated for postoperative analgesia.
62090780|NCT02273011||combuned spinal epidural anesthesia|combined spinal epidural anesthesia for caesarean section was executed for anesthesia, epidural and oral analgesic medication was applicated for postoperative analgesia.
62090781|NCT04007003|EXPERIMENTAL|optimal injection technique|Subjects will be trained on site regarding optimal insulin injection technique, including avoiding injections in lipohypertrophy areas and proper rotation. Furthermore subjects are provided with access codes to watch online training modules on the Becton Dickinson (BD) and Me(TM) platform
62090782|NCT00783718|EXPERIMENTAL|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
62655194|NCT05529433|EXPERIMENTAL|Chemo-Mechanical Caries Removal (CMCR)|A chemical agent which selectively removes the carious dentin by breaking the denatured collagen fibers making them soft and preserving the healthy dentin without drilling.
62090783|NCT00783718|PLACEBO_COMPARATOR|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
62090784|NCT05395143|EXPERIMENTAL|Atorvastatin and zinc|46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and Zinc. Zinc tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
62090785|NCT05395143|PLACEBO_COMPARATOR|Atorvastatin and placebo|46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and placebo. Placebo tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
62090786|NCT04673175|EXPERIMENTAL|Ceftolozane-Tazobactam|Participants receive ceftolozane-tazobactam by injection directly into the vein (intravenously, IV) every 8 hours for 10-14 days.
62090787|NCT03805360|SHAM_COMPARATOR|ESP block with normal saline|An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
62090788|NCT03805360|EXPERIMENTAL|ESP block with local anesthetic|An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.
62090789|NCT01649440||Normal control|Healthy volunteers
62090790|NCT01649440||SIRS|"1. temperature \>38 ℃ or \<36℃;~2. pulse rate\>90 beats/min;~3. ventilatory rate\>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)\<32mmHg;~4. white blood cell count\>12,000μL-1 or \<4000μL-1 or \>10% immature cells"
62090791|NCT01649440||sepsis|sepsis is defined as SIRS plus confirmed infection.
62307952|NCT04946344|ACTIVE_COMPARATOR|Attention Control|The attention control intervention will cover an 3 month period. There will be two face to face group meetings over the 3 months, with one meeting each at months 1 and 3; and during the other months (month 2) participants will receive a combination of text messages, emails, and phone calls based on continued monitoring of participant needs and delivered via their preferred mode of contact.
62655195|NCT06080126|OTHER|Control|
62090792|NCT01649440||severe sepsis|"1. sepsis associated with organ dysfunction, hypoperfusion, or hypotension.~2. sepsis with arterial hypotension, despite adequate fluid resuscitation."
62090793|NCT01649440||death|sepsis patients within 48 hours before death.
62090794|NCT03049982|OTHER|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
62090795|NCT04255875|EXPERIMENTAL|Treatment Healthy Participants|Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326
62090796|NCT04255875|PLACEBO_COMPARATOR|Placebo Healthy Participants|Participants will receive matching placebo
62655196|NCT06080126|OTHER|Intervention|
62655197|NCT05244096||COVID+|COVID + positive individuals from March 15 2020 to Nov 30, 2021
62090797|NCT04255875|EXPERIMENTAL|Treatment for SCD|Participants will receive a multiple dose of subcutaneous PF-07209326
62090798|NCT04120337|EXPERIMENTAL|RemovAid Device + lidocaine patch|Test device with lidocaine patch for local anesthesia
62090799|NCT04120337|EXPERIMENTAL|RemovAid Device + lidocaine injection|Test device with lidocaine injection for local anesthesia
62090800|NCT04120337|ACTIVE_COMPARATOR|Standard removal technique + lidocaine injection|Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia
62090801|NCT06158347|EXPERIMENTAL|HBOT group|Hyperbaric oxygen therapy allows the patient to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied while gradually increasing the atmospheric pressure from normal atmospheric pressure to 1.5 atmospheres absolute (ATA). If the intensity acceptable to the clinical research subject is lower than 1.5 ATA, maintain it at the point acceptable to the research subject and record that value.
62090802|NCT06158347|NO_INTERVENTION|control group|The control group will receive systemic education in dermal care and will be under the instruction of usual self-care.
62655198|NCT05762575||control group|The volunteers in control group study traditional knotting technology,
62655199|NCT05762575||new knotting group|The volunteers in experimental group study new knotting technology.
62655200|NCT05320042|EXPERIMENTAL|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
62655201|NCT05320042|ACTIVE_COMPARATOR|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
62655202|NCT01176656||SU|T2DM patients with a prescription for a sulfonylurea but no insulin
62463202|NCT04657770|EXPERIMENTAL|Telerehabilitation|Patients will receive 36 treatment sessions over 6 weeks, consisting of 3 sessions/week that are supervised rehab therapy sessions (which begin with a 30-minute videoconference with the licensed OT or PT), alternating with 3 sessions/week of unsupervised rehab therapy sessions whereby the patient follows the instructions on the screen to engage in rehab therapy. Because patients sometimes miss a session, e.g., due to a conflict, we allow up to 8 weeks for patients to complete their 36 rehab therapy sessions.
62463203|NCT03588624|EXPERIMENTAL|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
61920035|NCT05929820|NO_INTERVENTION|Usual Care (Control)|The usual care group will be managed according to the providers' customary practices: CRC screening discussions, if any, are at the discretion of the provider as Cedars-Sinai does not employ a standardized approach. Patients randomized to the control arm will not be sent any materials before their clinic appointment.
62090803|NCT04548232||LSG in obese|Patients with obesity underwent LSG. Divided into simple obese patients (without complications) and obese patients with complications
62090804|NCT04548232||Control group|healthy individuals with normal BMI
62090805|NCT00665561||Maraviroc exposed|
62289141|NCT04561232|OTHER|Locomotor Learning|"This study has three phases. The first phase of the study will be the observation of early spontaneous leg movements which will be measured monthly from 1-4 months of age.~The prone locomotor intervention phase using the Self-Initiated Prone Progression Crawler (SIPPC) will occur from 5-9 months of post-term age, or end earlier if the child achieves the ability to crawl six feet. Treatment will occur at an intensity of 3 times per week for 15-30 minutes. Infants will use the SIPPC for the duration of each therapy session~The upright locomotor intervention phase using DWS will occur from 9-18 months of age, or begin earlier if the child achieves the ability to crawl six feet before 9 months of age, and end earlier if the child achieves independent walking before 18 months of age. Treatment will occur at an intensity of 3 times per week for 30 minutes. Infants will receive dynamic weight support (DWS) for the duration of the 30-minute therapy session."
62289142|NCT04052841|EXPERIMENTAL|MGD-thermal pulsation group|A 12 minutes LIPIFLOW treatment was performed.
62289143|NCT04052841|EXPERIMENTAL|MGD-IPL group|IPL was performed every 3 weeks，3 times in total (0, 3w, 6w).
62463204|NCT00397488|EXPERIMENTAL|Sunitinib|This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
62463205|NCT05000619|EXPERIMENTAL|Outreach Postcard|This group receives a postcard with a stock image on the front and a message encouraging regular visits to manage health on the back.
62289144|NCT04052841|EXPERIMENTAL|MGD-manual warm compresses|Manual warm compresses were performed every 2 weeks，5 times in total (0, 2w, 4w, 6w, 8w).
62289145|NCT04052841|NO_INTERVENTION|Normal health subject group|Normal health subject without intervention.
62289146|NCT06278688|EXPERIMENTAL|Precision probiotics|The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/)
62289147|NCT06278688|PLACEBO_COMPARATOR|Placebo (wait-list group)|Placebo packets or capsules will be composed of maize starch only and be identical in appearance, weight, and smell. After completing trials, the Placebo group will be provided with a 6- month precision probiotic supplement.
62289148|NCT01042808||1|HIV-1 Infected patients treated with Isentress
62289149|NCT01099969|EXPERIMENTAL|Glidescope with non-styletted Endotrol ETT|The patients in this arm will be intubated using a Glidescope videolaryngoscope with non-styletted Endotrol endotracheal tube (ETT).
62463206|NCT05000619|EXPERIMENTAL|Humorous Postcard|This group receives a postcard with with a cartoon image and a visit-related joke on the front and a humorous message on the back, with additional information about why visits are important, and what to expect at the appointment.
62090806|NCT00665561||Maraviroc unexposed|
62090807|NCT04330846|EXPERIMENTAL|EBD group|"* Post-procedural admission in the Short Stay Unit (SSU).~* Superficial sedation by endoscopist or anesthesiologist depending on the center.~* Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion.~* A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation.~* Dilation failure will be considered if \> 2 dilations are required."
62090808|NCT04330846|EXPERIMENTAL|SEMS group|"* Post-procedural admission in the Short Stay Unit (SSU).~* Superficial sedation by endoscopist or anesthesiologist depending on the center.~* Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist~* Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion.~* Removal time of the prosthesis 4 weeks."
62090809|NCT06100029|EXPERIMENTAL|Intervention group|lavender aromatherapy
62090810|NCT06100029|PLACEBO_COMPARATOR|Control group|distilled water
62090811|NCT05559892|EXPERIMENTAL|Diabetes-Tailored CCTs (DM-CCT) Intervention|Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions). Therefore, they will only receive cash transfer payments if they attend two sessions per month.
62289150|NCT01099969|ACTIVE_COMPARATOR|Glidescope with styletted regular ETT|The patientsin this arm will be intubated using the glidescope videolaryngoscope and regular endotracheal tube (ETT) with gliderite stylet.
62289151|NCT01099969|EXPERIMENTAL|McGrath with non-styletted Endotrol ETT|The patients in this arm will be intubated using McGrath videolaryngoscope and non-styletted Endotrol endotracheal tube (ETT).
62090812|NCT05559892|ACTIVE_COMPARATOR|Unconditional Cash Transfer-UCTs Intervention|Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
62090813|NCT03169361||Ixazomib 4 mg|The usual adult dosage for oral administration is 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle will be repeated for 6 cycles. The dose may be reduced appropriately according to the patient's condition. Participants will receive interventions as part of routine medical care.
62090814|NCT04685343|EXPERIMENTAL|fMRI and laboratory pain induction|
62090815|NCT03610217|EXPERIMENTAL|Interstitial lung disease induction|
62090816|NCT03610217|EXPERIMENTAL|Pulmonary arterial hypertension|
62090817|NCT03610217|EXPERIMENTAL|Raynaud's phenomenon|
62090818|NCT03610217|EXPERIMENTAL|Digital ulcers|
62090819|NCT03610217|EXPERIMENTAL|Inflammatory arthritis|
62090820|NCT03610217|EXPERIMENTAL|Gastroesophageal reflux|
62090821|NCT03610217|EXPERIMENTAL|Bacterial overgrowth|
62289152|NCT01099969|ACTIVE_COMPARATOR|McGrath with with styletted regular ETT|The patients receiving this arm will be intubation using McGrath videolaryngoscope and regular endotracheal tube (ETT) with Gliderite stylet.
62090822|NCT03610217|EXPERIMENTAL|Constipation|
62090823|NCT03610217|EXPERIMENTAL|Skin involvement|
62090824|NCT03610217|EXPERIMENTAL|Pain|
62090825|NCT04244175|EXPERIMENTAL|High Dose: CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Day 92 during the treatment period.
62090826|NCT04244175|EXPERIMENTAL|Low Dose: CVL-865 7.5 mg|Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg until Day 92 during the treatment period.
62090827|NCT04244175|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo matched to CVL-865 tablets orally BID until Day 92 during the treatment period.
62289153|NCT04415424|EXPERIMENTAL|Treatment arm A - 4CMenB vaccine|4CMenB vaccine will be administered as an intramuscular injection in 0.5 ml single-dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
62289154|NCT04415424|PLACEBO_COMPARATOR|Treatment arm B - placebo|Placebo will be administered as an intramuscular injection in 0.5 ml single dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
62090828|NCT05665595|EXPERIMENTAL|Pembrolizumab/Vibostolimab|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to \~1 year).
62090829|NCT05665595|ACTIVE_COMPARATOR|Pembrolizumab|Adult participants receive 200 mg and adolescent participants ≥40 kg receive 2 mg/kg (up to a max of 200 mg) pembrolizumab via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to \~1 year).
62090830|NCT01891032||the patients with open partial nephrectomy|the adult patients with open partial nephrectomy
62090831|NCT01891032||laparoscopic|the adult patients with laparoscopic partial nephrectomy
62090832|NCT01891032||VAMS|the adult patients with VAMS partial nephrectomy
62090833|NCT01891032||robotic|the adult patients with robotic partial nephrectomy
62090834|NCT05861284|EXPERIMENTAL|Single-pulse TMS over the primary motor cortex|We will administer single-pulse TMS to the primary motor cortex while measuring motor responses and just before a skill-learning task.
62090835|NCT05861284|EXPERIMENTAL|Paired-pulse TMS over the primary motor cortex|We will administer paired-pulse TMS to the primary motor cortex while measuring motor responses and just before a skill-learning task.
62090836|NCT05861284|SHAM_COMPARATOR|Sham TMS over the primary motor cortex|We will administer sham TMS to the primary motor cortex while measuring motor responses and before a skill-learning task.
62090837|NCT00628628|EXPERIMENTAL|Group A|As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
62090838|NCT00628628|EXPERIMENTAL|Group B|Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily
62090839|NCT06180382|EXPERIMENTAL|Adalimumab with optimisation|Patients with Crohn's disease will be included. They will have Adalimumab with optimisation as treatment.
62090840|NCT06180382|EXPERIMENTAL|Vedolizumab|Patients with Crohn's disease will be included. They will have Vedolizumab as treatment.
62090841|NCT02186938|NO_INTERVENTION|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
62289155|NCT02856165|EXPERIMENTAL|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (Fisher\&Paykel (F\&P), NZ)
62289156|NCT02856165|ACTIVE_COMPARATOR|Low-flow oxygen therapy|Low-flow oxygen therapy with standard nasal canula
62090842|NCT02186938|EXPERIMENTAL|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
62090843|NCT03883646|EXPERIMENTAL|Mindfulness|Mindfulness
62090844|NCT03883646|EXPERIMENTAL|Relapse Prevention|
62289157|NCT04863963||Milligan Morgan|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Milligan-Morgan hemorrhoidectomy surgery.
62655203|NCT01176656||Antidiabetic without SU|T2DM patients with an oral antidiabetic drug other than an SU, and no insulin
62463207|NCT05000619|EXPERIMENTAL|Physician Letter|This group receives a personalized letter signed by a physician with information about why visits are important, and what to expect at the appointment.
62463208|NCT05000619|NO_INTERVENTION|No-contact Control|This group will not receive a study mailer during the trial.
62655204|NCT01176656||Insulin|T2DM patients using insulin, with or without other oral antidiabetics
61920036|NCT03346798|EXPERIMENTAL|Food Photography|On the first visit, participants will engage in food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
62090845|NCT03883646|NO_INTERVENTION|Waitlist Control|
62090846|NCT03883646|NO_INTERVENTION|Treatment as Usual|
62090847|NCT06697054|EXPERIMENTAL|Two different tracers as a sentinel lymph node agent will be compared in early cervical cancer|Two different tracers, one charcoal carbon dye and other indocyanine used as sentinel lymph node agent will be compared in early cervical cancer in terms of detection rates, sensitivity, specificity, negative and positive predictive value. Both tracers will be used in the patient.
62090848|NCT02669719|EXPERIMENTAL|chemotherapy followed dendritic cells|pemetrexed and carboplatin chemotherapy followed dendritic cells infusion from Cycle 3
62090849|NCT02669719|ACTIVE_COMPARATOR|chemotherapy|pemetrexed and carboplatin chemotherapy only
62090850|NCT05386719|OTHER|Early stage breast cancer survivors|Patients with history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins
62090851|NCT03328520|EXPERIMENTAL|First Year Students in Wellness FYIs|
62090852|NCT01982760|EXPERIMENTAL|DDAVP|Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
62463209|NCT05493930||development set;|RC patients from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College
62655205|NCT02969278|EXPERIMENTAL|Vulvar cancer patients cN0 unfit for sentinel node biopsy|"All invasive vulvar cancer patients with cN0 status:~* T \> 4 cm;~* multicentric tumors (mono or bilateral);~* primary lesion completely excised during prior diagnostic surgery~* patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0~* previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy"
62655206|NCT00896064|EXPERIMENTAL|Formulation 1|
62655207|NCT00896064|EXPERIMENTAL|Formulation 2|
62090853|NCT01982760|NO_INTERVENTION|No DDAVP|Patients Will not receive DDAVP prior to Rhinoplasty
62090854|NCT01394991|EXPERIMENTAL|001|Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
62090855|NCT01394991|EXPERIMENTAL|002|Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
62090856|NCT02147990|EXPERIMENTAL|Rociletinib Mono-Therapy, T790M +ve (625mg BID)|Starting dose of 625mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
62463210|NCT05493930||external validation sets 1|RC patients from Changhai Hospital, Naval Medical University
62463211|NCT05493930||external validation sets 2|RC patients from the Second Affiliated Hospital of Harbin Medical University
62736411|NCT05937256|NO_INTERVENTION|Group C|(n=30) will be control group receiving no intervention, managed only with conventional analgesia
62736412|NCT06205563|EXPERIMENTAL|Arm A|
62736413|NCT06205563|ACTIVE_COMPARATOR|Arm B|
61920037|NCT03346798|EXPERIMENTAL|Non-Food Photography|On the first visit, participants will engage in non-food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
62090857|NCT02147990|EXPERIMENTAL|Rociletinib Mono-Therapy, T790M +ve (500mg BID)|Starting dose of 500mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
62090858|NCT02147990|EXPERIMENTAL|Rociletinib Mono-Therapy, T790M -ve (500mg BID)|Starting dose of 500mg rociletinib, taken twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
62090859|NCT06614647|EXPERIMENTAL|Intervention group (IG)|Patients with curatively resected stage I or low risk stage II colorectal cancer, residing in Central or North region, Denmark.
62090860|NCT06614647|NO_INTERVENTION|Standard-of-care group (SG)|Patients with curatively resected stage I or low risk stage II colorectal cancer, residing in South or Capital region, Denmark.
62090861|NCT06356259|EXPERIMENTAL|IRX-010 Part A (SAD)|A single dose of IRX-010 will be administered intravenously
62090862|NCT06356259|PLACEBO_COMPARATOR|Placebo Part A (SAD)|Placebo administered intravenously
62090863|NCT06356259|EXPERIMENTAL|IRX-010 Part B(MAD)|Multiple doses of IRX-010 will be administered intravenously
62090864|NCT06356259|PLACEBO_COMPARATOR|Placebo Part B(MAD)|Placebo administered intravenously
61920038|NCT02577783|EXPERIMENTAL|PDD arm|patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )
62090865|NCT01932944||No treatment|
62090866|NCT02359149|EXPERIMENTAL|nurse|intravitreal injections with anti-VEGF agents given by a nurse
62090867|NCT02359149|ACTIVE_COMPARATOR|physician|intravitreal injections with anti-VEGF agents given by a physician
62090868|NCT02734368||Healthy non-smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
62090869|NCT02734368||Asymptomatic smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
62090870|NCT02734368||COPD subjects|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
62090871|NCT03917043|EXPERIMENTAL|APG-2449|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 30-40 patient at the MTD/RP2D dose level.
62289158|NCT04863963||Dearterialization with mucopexy|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Doppler-guided or non-Doppler guided HAL surgery associated with mucopexy
62289159|NCT04257331|EXPERIMENTAL|SREIA group|Participants in this arm will be families who attend the first wave of the two rounds of delivery. They will be the intervention group.
62463212|NCT01934621|EXPERIMENTAL|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice. Participants use printed workbooks to learn and apply this method.
62289160|NCT04257331|NO_INTERVENTION|Waitlist Control|Participants in this arm will be families who attend the second wave of the two rounds of delivery. They will be the control group.
62655208|NCT03386227|NO_INTERVENTION|Prophylactic antibiotics|Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
62655209|NCT03386227|EXPERIMENTAL|No antibiotic prophylaxis.|Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.
62655210|NCT06403800||Cross-sectional study|In the cross-sectional study group, we will enroll approximately 1400 miners and community members from an ongoing community-based, screening program, which is led by Kibong'oto Infectious Diseases Hospital (KIDH), and from incident TB cases from the local Mererani health centre and KIDH clinic.
62655211|NCT06403800||Cohort group|We will enroll the prospective cohort group of 410 small-scale tanzanite miners from within the cross-sectional study group (nested). They will be sampled from specific mines chosen by a random stratified sample of mines.
62655212|NCT01242319||Multi-modal practice intervention|15 intervention practices receive academic detailing, patient activation computer kiosk, decision supported PDA, and coronary risk factor management toolbox
62655213|NCT01242319||Usual care|15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines
62655214|NCT01560338||Pediatric after Cardiac Arrest|Pediatric patients greater than 3 kg. and less than 18 years suffering cardiac arrest who have been given or currently receiving morphine and/or midazolam and receiving hypothermia.
62289161|NCT04755829||Group 1|Normal screening mammogram (BIRADS 1 or 2)
62289162|NCT04755829||Group 2|Abnormal screening mammogram (BIRADS 3 to 6)
62289163|NCT02620904|ACTIVE_COMPARATOR|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
61906072|NCT02923921|EXPERIMENTAL|Pegilodecakin + FOLFOX|Pegilodecakin 5 microgram per kilogram (μg/kg) dosed as one of the following 2 fixed doses: 0.4 milligram (mg) for participants weighing ≤80 kg or 0.8 mg for participants weighing\>80 kg on Days 1-5 and Days 8-12 subcutaneously (SC) plus FOLFOX \[dl-Leucovorin (dl-LV) 400 milligram per meter square (mg/m2) and oxaliplatin 85 mg/m2 followed by bolus 5-fluorouracil (5-FU) 400 mg/m2 and a 46 to 48 hour infusion of 5- FU 2400 mg/m2\] initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression. After discontinuation of FOLFOX in the absence of tumor progression \[that is (i.e., completion of the planned 12 cycles or unacceptable FOLFOX related toxicity\], Pegilodecakin 10µg/kg maintenance treatment administered as one of the 2 fixed doses, either 0.8 mg for participants weighing ≤80 kg or 1.6 mg for participants weighing\>80 kg.
62289164|NCT02620904|PLACEBO_COMPARATOR|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
62289165|NCT03954626|EXPERIMENTAL|RTH258|Intravitreal injection
62289166|NCT01431183|ACTIVE_COMPARATOR|mailed reminder notice|Seasonal influenza vaccination reminder sent by postal mail
62289167|NCT01431183|NO_INTERVENTION|No reminder notice|No seasonal influenza vaccination reminder sent by postal mail
62289168|NCT01286584|ACTIVE_COMPARATOR|varenicline group|
62090872|NCT05693805|EXPERIMENTAL|Tai Chi Group|Participants randomized to this arm will receive a standardized Tai Chi protocol developed for veterans, adapted by the investigators, and administered by experienced VA Tai Chi instructors.
62090873|NCT05693805|ACTIVE_COMPARATOR|Wellness Group|Participants randomized to this arm will receive a wellness program that has been successfully used by the investigators in other studies of veterans with chronic pain.
62090874|NCT01668875|EXPERIMENTAL|Treatment condition|In intervention period patients were received head-down 30 degree postural drainage position for 10 min.
62090875|NCT01668875|EXPERIMENTAL|Sham condition|In intervention period patients were received horizontal supine lying for 10 min.
62090876|NCT01363947|EXPERIMENTAL|Dose Escalation Cohort (DNIB0600A)|Participants will receive IV infusions of DNIB0600A at doses ranging from 0.2 milligrams/kilogram (mg/kg) to 2.8 mg/kg q3w until dose-limiting toxicity (DLT) is reached, or up to 28 cycles.
62090877|NCT01363947|EXPERIMENTAL|Expansion Cohort (DNIB0600A)|Participants will receive 2.4 mg/kg, by IV infusion, of DNIB0600A q3w for up to 26 cycles.
62090878|NCT02062905|EXPERIMENTAL|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
62090879|NCT02062905|PLACEBO_COMPARATOR|PV|PV (placebo drug delivery vehicle)
62090880|NCT05937672|EXPERIMENTAL|Cold Atmospheric Plasma (CAP)|We are proposing an open-label extension study of a floating electrode-dielectric barrier device (FE-DBD), a Cold Atmospheric Plasma (CAP) device for the treatment of Verrucae Vulgaris and Molluscum Contagiosum. While novel to the medical field, and especially to dermatology, there are already a number of publications regarding its use on human skin in adults and children. CAP devices utilize noble gases (such as helium) to deliver plasma state matter to the skin. As its name implies, the generated plasma stream is of near skin temperature and it exists on normal atmospheric pressure. During the generation of the plasma there is no electric contact with the patient. The treatment does not increase skin surface temperature and the used helium gas, the same as used for balloons, being a noble gas does not cause a chemical reaction with the skin. The flow of the gas is slow, thus there is no mechanical effect on the skin.
62090881|NCT02451293|ACTIVE_COMPARATOR|Melatonin (N-acetyl-5-methoxytryptamine)|Melatonin (N-acetyl-5-methoxytryptamine) 25 mg oral administration 1 hour before bedtime for 12 weeks.
62090882|NCT02451293|PLACEBO_COMPARATOR|Placebo|Comparable placebo pill, oral administration 1 hour before bedtime for 12 weeks.
62090883|NCT02062411|EXPERIMENTAL|CBT with booster sessions|Participants will receive 12 cognitive-behavioral therapy sessions weekly and 3 booster sessions monthly following our protocol.
62090884|NCT02062411|ACTIVE_COMPARATOR|CBT only|Participants will only receive 12 cognitive-behavioral therapy sessions weekly.
62090885|NCT02062411|NO_INTERVENTION|waiting|Participations will not be treated with CBT and keep waiting for 12 weeks for comparison.
62090886|NCT03906474|EXPERIMENTAL|Group 1|A third blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to two blood-stage challenges in the VAC063 trial. Group 1 will be challenged in parallel with Groups 2 (undergoing a second challenge) and 3 (malaria-naïve controls).
62090887|NCT03906474|EXPERIMENTAL|Group 2|A second blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to one blood-stage challenge in the VAC063 trial. Group 2 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 3 (malaria-naïve controls).
62090888|NCT03906474|EXPERIMENTAL|Group 3|Malaria-naïve controls will receive a primary blood-stage controlled human P. falciparum malaria infection. Group 3 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 2 (undergoing a second challenge).
62090889|NCT03341806|EXPERIMENTAL|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
62090890|NCT03972293|EXPERIMENTAL|Within-participant Micro-randomization|"Each week in the study, with probability .25 for each, a participant is randomized to receive either a week of mood notifications, activity notifications, sleep notifications, or no notifications.~If the participant is assigned to receive mood, activity, or sleep notifications on a given week, then, for every day of that week the participant is randomized to: send notification on that day (with probability .5), or to not send a notification on that day (with probability .5)."
62090891|NCT03972293|EXPERIMENTAL|No intervention|Participants in this arm will not receive any notifications for the entire duration of the trial. Primary and secondary outcomes will still be collected on participants in arm 2 through the study app and Fitbit.
62090892|NCT04448327|EXPERIMENTAL|Active tVNS|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle
62090893|NCT04448327|SHAM_COMPARATOR|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
62090894|NCT06691971||Patients diagnosed with acute asthma exacerbation|Patients diagnosed with acute asthma exacerbation
62090895|NCT06691971||Patient with a non-cardiac AND non-pulmonary chief complaint and discharge diagnosis|Patient with a non-cardiac AND non-pulmonary chief complaint and discharge diagnosis
62289169|NCT01286584|PLACEBO_COMPARATOR|placebo group|
62289170|NCT06359184|EXPERIMENTAL|yoga|Yoga will be practiced 1 hour a day, 2 days a week for 8 weeks, for a total of 16 hours.
62655215|NCT01385644|EXPERIMENTAL|1*10^6 MSC / kg|Placental MSC
61906073|NCT02923921|ACTIVE_COMPARATOR|FOLFOX|FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression.
61906074|NCT02434588|EXPERIMENTAL|Bhattacharjee ring|
61906075|NCT00274833|EXPERIMENTAL|Radiation Therapy, Temozolomide, and Erlotinib|
61906076|NCT02494063||Sentinel lymph node (SLN)|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
62090896|NCT01089556|EXPERIMENTAL|Duloxetine|"Initial Treatment:~Duloxetine 30 milligram (mg) daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week~Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks"
62090897|NCT01089556|EXPERIMENTAL|Pregabalin+Duloxetine|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 300 mg (150 mg twice daily) daily for 8 weeks~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks"
62090898|NCT01089556|EXPERIMENTAL|Pregabalin|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 450 mg (300 mg in the morning, 150 mg in the evening) daily for 1 week~Pregabalin 600 mg (300 mg twice daily) daily for 7 weeks"
62090899|NCT01089556|EXPERIMENTAL|Duloxetine + Pregabalin|"Initial Treatment:~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 60 mg daily for 8 weeks~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks"
62289171|NCT06359184|PLACEBO_COMPARATOR|control|No intervention is applied for 8 weeks.
62289172|NCT03841552|EXPERIMENTAL|Augmented Feedback|The exercises were conducted with the aim of improving postural- and movement control and awareness of the lumbar spine in both treatment groups. Both groups received nine 30-minute therapy sessions, during which they performed a series of exercises from an exercise catalogue. The exercises were selected based on their compatibility with the AF-system. Each patient performed impairment-specific exercises. The AF group received additional AF feedback during both the therapy sessions and the home exercise program, by combining the exercises with games designed to target movement control, body awareness, and stabilisation exercises.
62289173|NCT03841552|ACTIVE_COMPARATOR|Control Group|The control group performed the impairment-specific exercises without AF. The control group was able to receive conventional visual feedback, such as use of mirrors, as deemed appropriate by the therapists but no AF.
62655216|NCT01385644|EXPERIMENTAL|2*10^6 MSC / kg|Placental MSC
62655217|NCT06231524||Validation cohort|A cohort of consecutive patients from the Sixth Affiliated Hospital of Sun Yat-sen University is used for model validation.
62655218|NCT04092075|EXPERIMENTAL|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
62655219|NCT04092075|SHAM_COMPARATOR|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
62655220|NCT00091819|EXPERIMENTAL|Telavancin|
62655221|NCT00091819|ACTIVE_COMPARATOR|Vancomycin|
62655222|NCT01089179|EXPERIMENTAL|Torrent's Metformin tablets 500 mg|
62655223|NCT01089179|ACTIVE_COMPARATOR|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
62655224|NCT01775098|EXPERIMENTAL|Allopurinol|treatment with allopurinol
62655225|NCT01775098|PLACEBO_COMPARATOR|placebo|placebo comparator
61906077|NCT02494063||Control|Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
61906078|NCT05389852|ACTIVE_COMPARATOR|intravenous dexmedetomidine|Patients will receive intravenous dexmedetomidine 1 mcg/kg just after the supraclavicular brachial plexus block is completed
61906079|NCT05389852|PLACEBO_COMPARATOR|Placebo|Patients will receive intravenous placebo (normal saline) just after the supraclavicular brachial plexus is completed
61906080|NCT02382484|EXPERIMENTAL|Treatment|"The study was a single arm, unblinded, treatment only study. Each patient served as his or her own control.~Treatment delivered by a dual chamber pacing system (BackBeat Medical) which was able to generate stimulating patterns with characteristics that are different than the common pacemaker.~The study was limited to hypertensive patients who were also already scheduled to undergo an invasive electrophysiology procedure."
61906081|NCT01624246|EXPERIMENTAL|Ceftaroline fosamil/Avibactam|
62655226|NCT05490082|ACTIVE_COMPARATOR|Mirabegron arm|50 mg PO once daily
62655227|NCT05490082|ACTIVE_COMPARATOR|Propevirine arm|15 mg PO twice daily
62655228|NCT05490082|ACTIVE_COMPARATOR|Solifenacin arm|10 mg PO once daily
61906082|NCT02102659|EXPERIMENTAL|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium."
61906083|NCT02102659|ACTIVE_COMPARATOR|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
61906084|NCT01860729|EXPERIMENTAL|Anacetrapib|100 mg tablet, oral, once daily for 24 weeks
61906085|NCT01860729|PLACEBO_COMPARATOR|Placebo|Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks
61906086|NCT00946218||Part A|Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
62655229|NCT05490082|PLACEBO_COMPARATOR|Placebo arm|starch tablet once daily
62655230|NCT01492959||Insulin human|
62655231|NCT02290184|EXPERIMENTAL|Intervention - PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
62655232|NCT02290184|ACTIVE_COMPARATOR|Active control - pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
62655233|NCT01686893|ACTIVE_COMPARATOR|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
61906087|NCT00946218||Part B|Children with definitive dengue infection enrolled for gene expression analysis.
61906088|NCT04504851|ACTIVE_COMPARATOR|Arm A (Standard of Care)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid
61906089|NCT04504851|EXPERIMENTAL|Arm B (Standard of Care plus Rosuvastatin)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol PLUS rosuvastatin, then 16 weeks rifampicin, isoniazid
62090900|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
62090901|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
62090902|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
62090903|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
62090904|NCT03987581|EXPERIMENTAL|CBT + mCM + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment, mobile contingency management for alcohol abstinence, and a monetary incentive for 30-day abstinence at the 6-month follow-up.
62090905|NCT03987581|EXPERIMENTAL|CBT + mCM + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and mobile contingency management for alcohol abstinence. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up.
62090906|NCT03987581|EXPERIMENTAL|CBT alone + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and a monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
62090907|NCT03987581|ACTIVE_COMPARATOR|CBT alone + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
62090908|NCT03674606|EXPERIMENTAL|Routine low-dose aspirin|Subjects shall receive standard antenatal care as well as taking oral low-dose aspirin from the eligibility visit until 36-week gestation once daily, as prescribed by the research clinician. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
62090909|NCT03674606|NO_INTERVENTION|No aspirin|No low-dose aspirin will be prescribed. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
62289174|NCT02278913|EXPERIMENTAL|Basal Bolus (Glargine and Glulisine)|Basal bolus: with Insulin analogs (glargine and glulisine), 50% of total daily dose as glargine given before breakfast and 50% as glulisine insulin given in three equally divided doses before each meal.
62289175|NCT02278913|ACTIVE_COMPARATOR|Human Insulin|Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin. NPH insulin dose given as 2/3 in the morning before breakfast and 1/3 before dinner. Regular insulin given in three equally divided doses before each meal
62289176|NCT01353989||>60 years|
62289177|NCT01353989||< 40 years|
62463213|NCT01934621|PLACEBO_COMPARATOR|Attention Control|The attention control intervention will control for the non-specific effects of strategy training. The therapists will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. In lieu of the strategy training workbook materials, participants will complete a daily journal, and discuss their entries during attention control sessions.
62655234|NCT01686893|ACTIVE_COMPARATOR|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
61906090|NCT03370705|ACTIVE_COMPARATOR|CT group|78 patients will be treated by conventional treatment : antiplatelet therapy + ACE inhibitor +/- Statin in patients with cholesterol total level \> 1,35 g/l
62289178|NCT01451801|OTHER|HBsAg|
62655235|NCT00104689|EXPERIMENTAL|Capecitabine + Oxaliplatin|Patients receive oral capecitabine once daily on days 1-14 and oxaliplatin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
62655236|NCT06098183|EXPERIMENTAL|Whey protein isolate, then Non-caloric placebo|Participants will randomly consume a whey protein isolate (Dymatize ISO-100) mixed with 6 oz of water prior to exercise. After a minimum of 48 hrs they will consume a non-caloric placebo (6 oz of water) prior to exercise.
62655237|NCT06098183|PLACEBO_COMPARATOR|Non-caloric placebo, then Whey protein isolate|Participants will randomly consume a non-caloric placebo (6 oz of water) prior to exercise. After a minimum of 48 hrs they will consume a whey protein isolate (Dymatize ISO-100) mixed with 6 oz of water prior to exercise.
62655238|NCT03437967|OTHER|ABAB|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~ABAB initial period is active treatment - LASER.~Active Treatment:~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation."
62736414|NCT06316856|EXPERIMENTAL|Autologous CD5 CAR T-cells|After a lymphodepleting regimen, the patients will receive autologous CD5 CAR T-cell infusion.
62090910|NCT03674606|ACTIVE_COMPARATOR|Test-indicated low-dose aspirin|The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk \> 1:8 must start low-dose aspirin treatment immediately. Participants with a risk \< 1:8 will be excluded.
62090911|NCT01425762|EXPERIMENTAL|Choice Group|
62090912|NCT01425762|ACTIVE_COMPARATOR|No Choice Group|
62289179|NCT06351033||Placebo|Placebo: control group made up of subjects affected by maculopathy - eligible according to the study protocol - subjected to traditional elective treatments only (including intravitreal Anti-VEGF injections).
62289180|NCT06351033||Ozonized Oil|Ozonized Oil: intervention group made up of subjects affected by maculopathy - eligible according to the study protocol - subjected to the traditional treatments of choice (including anti-VEGF intravitreal injections) who receive supplementary treatment with the intake of HOO gastro-resistant capsules.
62090913|NCT05925881|ACTIVE_COMPARATOR|Lower Trapezius Tendon Transfer|The lower trapezius tendon transfer arm will consist of patients randomized to this surgical procedure. This is an arthroscopically assisted open procedure that involves harvesting of the lower trapezius muscle tendon and re-grafting it onto to shoulder to repair massive rotator cuff tears.
62090914|NCT05925881|ACTIVE_COMPARATOR|Bridging Reconstruction Repair|"The bridging reconstruction repair arm will consist of patients randomized to this surgical procedure. This operation is arthroscopic, and involves the insertion of a human dermal allograft to the rotator cuff, sutured and anchored in a bridging fashion to repair massive rotator cuff tears."
61906091|NCT03370705|EXPERIMENTAL|Sulodexide + CT group|"78 patients will be treated by :~* Sulodexide (250ULS, twice daily , oral administration)~* Conventional treatment : antiplatelet agents + ACE inhibitor +/- Statin in patients with cholesterol total level \> 1,35 g/l"
61906092|NCT01381562|EXPERIMENTAL|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
61906093|NCT01381562|EXPERIMENTAL|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
61906094|NCT01381562|ACTIVE_COMPARATOR|Meropenem 1G|q8h administered via IV infusion, plus saline placebo
61906095|NCT02081885|EXPERIMENTAL|Tricalcium Phosphate / Chitosan|
61906096|NCT02081885|ACTIVE_COMPARATOR|Autologous Graft|
61906097|NCT02130102||Users of ModuLAAr|A group of volunteers (aged 60+), living in assisted living homes, will be provided with module based technical solutions to improve their independency and quality of life.
62090915|NCT05391204|ACTIVE_COMPARATOR|Healthy Volunteers|To answer the question of reproducibility of the measurement (1st objective), half of the group control will carry out two handover of the battery of functional tests to a week apart.
62289181|NCT03195517|EXPERIMENTAL|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Institute of Università degli Studi di Perugia. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.~Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.~This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls."
61906098|NCT04622943|EXPERIMENTAL|firearms safety|Children will spend two 45-minute sessions engaged on ShootSafe, an internet-based training program on firearms safety.
61906099|NCT04622943|ACTIVE_COMPARATOR|nutrition|Children will spend two 45-minute sessions engaged on nourishinteractive.com, an internet-based training program on nutrition and exercise.
61906100|NCT02123251|EXPERIMENTAL|Financial Incentives Group|Participants (159) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
62090916|NCT05391204|EXPERIMENTAL|Patients Volunteers|To answer the question of reproducibility of the measurement (1st objective), half the group patient will perform two examinations at two months apart.
62090917|NCT04370236|PLACEBO_COMPARATOR|Placebo + Standard of Care|Patients will receive placebo + standard medical care
62090918|NCT04370236|EXPERIMENTAL|INB03 + Standard of Care|Patients will receive INB03 + standard medical care
62090919|NCT00311792|EXPERIMENTAL|1|Simulator training
62090920|NCT00311792|ACTIVE_COMPARATOR|2|Traditional Clinical education at operating room
62090921|NCT00209729|EXPERIMENTAL|1|Docetaxel plus S-1
62090922|NCT03012217||Specimens that meet inclusion criteria|
61906101|NCT02123251|NO_INTERVENTION|Control Group|Participants (161) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
61906102|NCT06491368||Less than 12 months|This group consists of women who have had their previous cesarean section less than 12 months before the current scheduled elective cesarean section.
61906103|NCT06491368||12-24 months|This group includes women whose previous cesarean section was 12 to 24 months before their current scheduled elective cesarean section.
61906104|NCT06491368||25-36 months|This group is comprised of women who had their last cesarean section between 25 and 36 months prior to the current scheduled elective cesarean section.
61906105|NCT06491368||37-48 months|This group consists of women whose previous cesarean section occurred 37 to 48 months before the current scheduled elective cesarean section.
62655239|NCT03437967|OTHER|BABA|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~BABA initial period is sham treatment - LOW LEVEL LASER.~LOW LEVEL LASER treatment:~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels."
61906106|NCT06491368||More than 48 months|This group includes women who had their last cesarean section more than 48 months before their current scheduled elective cesarean section.
62289182|NCT03195517|NO_INTERVENTION|No additional physical exercise|Usual recommendations for prevention of fractures in adults and elderly.
62289183|NCT06490861|EXPERIMENTAL|Paragit|Sleeve to quantify symptoms
62736415|NCT06316856|EXPERIMENTAL|Prior stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|After a lymphodepleting regimen, the patients will receive prior SCT donor-derived CD5 CAR T-cell infusion.
62307953|NCT06414122|EXPERIMENTAL|WB-EMS|Intervention group receives multimodal therapy with whole-body electromyostimulation and exercise therapy (WB-EMS) as well as conventional nutritional counseling with guidelines and digital nutritional coaching
61906107|NCT00294762|EXPERIMENTAL|Erlotinib|150 mg erlotinib daily
61906108|NCT00294762|EXPERIMENTAL|Erlotinib + chemotherapy (intercalated)|carboplatin AUC 6 on Day 1 to 21 days, paclitaxel 200 mg/m2 on Day 1 to 21 days, erlotinib 150 mg Days 2-15 for 4 cycles then erlotinib 150 mg daily until progression, withdrawal of consent, or unacceptable toxicity
61906109|NCT03478865|EXPERIMENTAL|Participants|Participants with age-related macular degeneration
61920039|NCT02577783|ACTIVE_COMPARATOR|PAD arm|patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )
62090923|NCT02748512|EXPERIMENTAL|FAI Insert administered using the Mk II inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
62655240|NCT05267717||Control/Normal (no-pessary) group|"All participants will must meet the criteria in order to be eligible: a singleton gestation, pregnant women recruited between 18+0 - 24+6 weeks of gestation, maternal age ≥18 years, the ability to sign approved consent form to participate in the study.~Moreover for a normal cohort are being enrolled only asymptomatic pregnant women with no risk factors for spontaneous preterm birth"
62655241|NCT05267717||Pessarry group|"All participants will must meet the criteria in order to be eligible: a singleton gestation, pregnant women recruited between 18+0 - 24+6 weeks of gestation, maternal age ≥18 years, the ability to sign approved consent form to participate in the study.~Moreover both for a pessary cohort additional cohort-specific criteria need to be met. Those are: suspected short cervix and confirmotian with transvaginal ultrasound - TVUS (CL \< 3rd percentile at gestational age at measurement) according to Salomon at al."
62090924|NCT02748512|ACTIVE_COMPARATOR|FAI Insert administered using the Mk I inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
62090925|NCT05314283|EXPERIMENTAL|DV3395 C1|
62090926|NCT05314010|EXPERIMENTAL|MIL62|
62090927|NCT05314010|PLACEBO_COMPARATOR|Placebo|
62090928|NCT02165982||Patients controles|Inpatients suffering from anorexia nervosa at Institut Mutualiste Montsouris
62307954|NCT06414122|ACTIVE_COMPARATOR|CONTROL|Control group receives multimodal therapy with moderate conventional exercise training in a group and conventional nutritional counselling with guidelines and digital nutritional coaching
62655242|NCT02031172||Subjects with Dry Eye Disease|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
62090929|NCT02165982||Individus sains témoins|Healthy controls selected from the general population
62090930|NCT00498277||Spinal MRI|
62307955|NCT01410591|ACTIVE_COMPARATOR|10-mm covered stent group|Patients treated with 10-mm covered stent.
62090931|NCT00740285|EXPERIMENTAL|1|
62090932|NCT00740285|PLACEBO_COMPARATOR|2|
62090933|NCT00725582|EXPERIMENTAL|A|
62090934|NCT00725582|PLACEBO_COMPARATOR|B|
62090935|NCT06696391|EXPERIMENTAL|Venous Excess Ultrasound (VEXUS)-Guided Management|
62307956|NCT01410591|ACTIVE_COMPARATOR|8-mm covered stent group|Patients treated with 8-mm covered stent.
62463214|NCT05537051|EXPERIMENTAL|PM1021 150 mg, 450 mg, 900 mg or 1200 mg monotherapy or in combination with PM8001 (20 mg/kg)|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
62463215|NCT03124420|ACTIVE_COMPARATOR|Group A (Drug: 7-day triple therapy)|Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
62463216|NCT03124420|SHAM_COMPARATOR|Group B (Drug: 14-day triple therapy)|Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).
62463217|NCT04423263|EXPERIMENTAL|Intervention|Receives bilateral internal iliac artery occlusion
62090936|NCT06696391|NO_INTERVENTION|Control Arm|Investigators will provide patients with the standard of care according to the Surviving Sepsis Campaign guidelines. This includes fluid resuscitation, the recommended mean arterial pressure target of ≥65 mmHg, early broad-spectrum antibiotics, source control when applicable, vasopressor support with norepinephrine as the first-line agent, stress-dose corticosteroids, early nutrition, and lung-protective mechanical ventilation when required. Clinicians may utilize hemodynamics assessment tools such as dynamic measures of fluid responsiveness and point-of-care ultrasound.
62090937|NCT02945020|EXPERIMENTAL|Dabigatran etexilate mesylate+Odalasvir+Simeprevir|All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
62090938|NCT00614744|EXPERIMENTAL|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
62090939|NCT00614744|ACTIVE_COMPARATOR|Normothermia|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
62090940|NCT05117034|EXPERIMENTAL|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
62090941|NCT05117034|PLACEBO_COMPARATOR|Placebo|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
62090942|NCT06343779|EXPERIMENTAL|Arm 1|Deucrictibant administered for first HAE attack, placebo administered for second HAE attack.
62090943|NCT06343779|EXPERIMENTAL|Arm 2|Placebo administered for first HAE attack, deucrictibant administered for second HAE attack.
62090944|NCT04888923||Healthy Controls|General public population, including females and males, who are over the age of 18, with a mixture of races and ethnicities representative of North Carolina.
62090945|NCT01257165|EXPERIMENTAL|Zopiclone 5 mg|Zopiclone 5 mg pill + placebo pill + placebo drink
62090946|NCT01257165|EXPERIMENTAL|Zopiclone 10 mg|2 x zopiclone 5 mg pills + placebo drink
62090947|NCT01257165|ACTIVE_COMPARATOR|Ethanol 0.8 g/L|2 x placebo pills + ethanol 50 g/70 kg
62090948|NCT01257165|PLACEBO_COMPARATOR|Placebo|2 x placebo pills + placebo drink
62090949|NCT05337969|EXPERIMENTAL|Metformin and Vildagliptin 850/50 mg Tablet|1 tablet of Metformin and Vildagliptin 850/50 mg as single-dose administration
62463218|NCT04423263|ACTIVE_COMPARATOR|Control|Does not receive bilateral internal iliac artery occlusion
61906110|NCT01988701||Allogeneic SCT Groups|Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
62090950|NCT05337969|ACTIVE_COMPARATOR|EUCREAS® 50/850mg Tablet|1 tablet of EUCREAS® 50/850mg (each film-coated tablet contains Vildagliptin 50mg and Metformin hydrochloride 850mg) as single-dose administration
62090951|NCT03114995|EXPERIMENTAL|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
62090952|NCT03114995|NO_INTERVENTION|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
62463219|NCT01532674|EXPERIMENTAL|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy and scaling and root planing
62090953|NCT03114995|NO_INTERVENTION|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
62090954|NCT03290469|EXPERIMENTAL|15 day cWGS and Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 15 days of the sample receipt while still undergoing standard of care (SOC).
62090955|NCT03290469|NO_INTERVENTION|Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 60 days of the sample receipt while still undergoing standard of care (SOC).
62307957|NCT01171521|EXPERIMENTAL|DermaClose Group|DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.
62463220|NCT01532674|ACTIVE_COMPARATOR|scaling and root planing|Only scaling and root planing
62655243|NCT02031172||Subjects with Sjogren's Syndrome|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
62655244|NCT02031172||Healthy Controls|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
62736416|NCT06316856|EXPERIMENTAL|Newly matched donor-derived CD5 CAR T-cells|After a lymphodepleting regimen, the patients will receive newly matched donor-derived CD5 CAR T-cell infusion.
61906111|NCT01988701||Autologous SCT group|Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
61906112|NCT00147550|EXPERIMENTAL|1|
61906113|NCT00213993|EXPERIMENTAL|A|antiperspirant topically to one foot once daily
61920040|NCT00982696|EXPERIMENTAL|Single Arm|Opioid Growth Factor (OGF)
61920041|NCT00786851|EXPERIMENTAL|1|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
62736417|NCT05778864|EXPERIMENTAL|LY3473329 (Control)|LY3473329 administered orally to participants with normal renal function
62090956|NCT03313089||PSAN + MNP|"PSAN (Papas más nutritivas project) + MNP (micronutrients powders):~Children of the families beneficiaries of Community Schools of Family Agriculture of the municipalities of Cumbal, Carlosama Guachucal and Túquerres, who are part of the project Papas más nutritivas and exposed to project activities in which they work on topics related to food and nutritional security, equity and gender, production and entrepreneurship, Additionally, the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses (specified in the MNP only group). After the delivery of MNP, advising, measurements of weight and height, clarification of doubts regarding fortification with MNP, nutrition education, and accompaniment by the project staff will take place."
62090957|NCT03313089||MNP only|"Cohort of exposed to MNP (micronutrients powders):~Children who will receive MNP delivered through the hospital or institutional health service providers of the municipalities of Guachucal and Carlosama, following the protocol for the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses: the first period consists of the taking of MNP for 2 months, followed by a rest period of 4 months and continues again by another MNP intake for 2 months and rest for 4 months, and exposed to dissemination of basic information with regard to MNP and monitoring by growth and development that is routinely performed by health staff."
62090958|NCT03352050|ACTIVE_COMPARATOR|ground beef|ground beef instead of mushrooms
62090959|NCT03352050|ACTIVE_COMPARATOR|Mushroom|2 servings of mushrooms
62090960|NCT03405181|EXPERIMENTAL|Training with additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet with an additional weight characterized by 20% of the total mass of the upper limb placed on both wrists. This training will be adopted for the adequate weight intervention group and low weight intervention group.
62090961|NCT03405181|PLACEBO_COMPARATOR|Training without additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet without additional weight, placed on both wrists. This training will be adopted for the adequate weight placebo group and low weight placebo group.
62090962|NCT05215756|EXPERIMENTAL|Healthy Subjects|Cold pressor test will be performed 3 times. transcutaneous Vagal nerve stimulation will be administered in the 2nd and 3rd cold pressor tests.
62090963|NCT06696664||Case group|Case group (HBsAg negative conversion group): 120 CHB patients who achieved clinical cure after continuous treatment with PEG-IFN-α for more than 24 weeks.
62090964|NCT06696664||Control group|Control group: 300 CHB patients who were continuously treated with PEG-IFN - α for more than 24 weeks without clinical cure.
62090965|NCT05160025|OTHER|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
62090966|NCT01421771|ACTIVE_COMPARATOR|Treatment to an intensive BP goal|Treatment to a pre-dialysis standardized dialysis unit systolic blood pressure of 110-140 mm Hg
62090967|NCT01421771|PLACEBO_COMPARATOR|Treatment to standard BP goal|Treatment to a pre-dialysis Standardized dialysis unit systolic BP of 155-165 mm Hg
62090968|NCT02243072|EXPERIMENTAL|Fit Familes plus Standard Medical Care|Participants will receive the intervention Fit Families plus Standard Medical Care which is an adaptation of Multisystemic Therapy for Type 1 Diabetes delivered by Community Health Workers (CHWs) in addition to standard medical care.
62090969|NCT02243072|NO_INTERVENTION|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
62090970|NCT04121208|ACTIVE_COMPARATOR|Active drug: JNJ-40346527|"A single initial randomisation site will be set up for Part 1 that will assign participants to JNJ-40346527 300 mg Bis in die - twice a day (BID) or placebo in a 2:1 ratio.~A second randomisation site will be setup for Part 2 depending on which scenario is adopted.~Either a Part 2, Scenario 1 site will assign participants to JNJ-40346527 150 mg BID, JNJ-40346527 50 mg BID or placebo in a 2:2:1 ratio or a Part 2, Scenario 2 site will assign participants to JNJ-40346527 150-50 mg BID or placebo in a 2:1 ratio."
62090971|NCT04121208|PLACEBO_COMPARATOR|Placebo|Non-active study drug
62736418|NCT05778864|EXPERIMENTAL|LY3473329 (Mild Renal Impairment)|LY3473329 administered orally to participants with mild renal impairment
62736419|NCT05778864|EXPERIMENTAL|LY3473329 (Moderate Renal Impairment)|LY3473329 administered orally to participants with moderate renal impairment
62736420|NCT05778864|EXPERIMENTAL|LY3473329 (Severe Renal Impairment)|LY3473329 administered orally to participants with severe renal impairment
61920042|NCT03495544||Hereditary BC|Pathogenic germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
62736421|NCT05778864|EXPERIMENTAL|LY3473329 (End-Stage Renal Disease)|LY3473329 administered orally to participants with end-stage renal disease
62736422|NCT03393897||Hemodynamic instability with hypotension|
62463221|NCT01944267|ACTIVE_COMPARATOR|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
62289184|NCT01750255|PLACEBO_COMPARATOR|Control|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life, adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
62655245|NCT02722967|EXPERIMENTAL|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
61906114|NCT05288062|EXPERIMENTAL|Cohort A (lenalidomide, dexamethasone)|Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
61906115|NCT05288062|EXPERIMENTAL|Cohort B (lenalidomide, dexamethasone)|Patients with newly diagnosed multiple myeloma receive treatment as in Cohort A.
61920043|NCT03495544||Sporadic BC|Without germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
62289185|NCT01750255|ACTIVE_COMPARATOR|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment.
62289186|NCT00689247|EXPERIMENTAL|A|AZD1305 given as oral solution
62289187|NCT00689247|EXPERIMENTAL|B|AZD1305 given as iv infusion
62289188|NCT03079440|EXPERIMENTAL|TEMCAP|Temozolomide plus Capecitabine
62289189|NCT05943730|EXPERIMENTAL|Seismofit Validity|Participants will undergo a seismocardiography assessment, whilst supine, using the seismofit device. This will estimate their peak oxygen consumption. Participants will then undergo a maximal cardiopulmonary exercise test (CPET), where peak oxygen consumption will be measured. The Seismofit estimated peak oxygen consumption will be compared with CPET measured peak oxygen consumption (unless prespecified criteria for a maximal exercise test are not met).
62289190|NCT06185855||Malignant|Malignant Breast Lesion Group: This group would include patients diagnosed with breast cancer who have undergone breast lesion surgery and had preoperative ultrasound examinations at the hospital.
62289191|NCT06185855||Benign|Benign Breast Lesion Control Group: This group would consist of patients with benign breast lesions, who also underwent breast lesion surgery and had preoperative ultrasound examinations.
62289192|NCT06313437|EXPERIMENTAL|Dose Escalation Revumenib|"Standard 3+3 design for a recommended phase 2 dose of Revumenib per dose-limiting toxicity rules. Cycles are 28 days.~* Baseline~* Induction Cycle:~  * Days 1-3: Predetermined dose of Daunorubicin 1x daily~ * Days 1-7: Predetermined dose of Cytarabine~ * Days 8-21: Predetermined dose of Midostaurin 2x daily~ * Days 8-28: Predetermined dose of Revumenib 2x daily~* End of Induction visit~* Follow-up~* Reinduction Cycle: Therapy will be administered in the hospital~  * Days 1-2: Predetermined dose of Daunorubicin 1x daily~ * Days 1-5: Predetermined dose of Cytarabine~ * Days 8-21: Predetermined dose of Midostaurin 2x daily~ * Days 8-28: Predetermined dose of Revumenib 2x daily~* End of reinduction visit~* Follow-up~* Consolidation Cycle: Therapy will be administered in the hospital~  * Days 1, 3, and 5: Predetermined dose of Cytarabine~ * Days 8-21: Predetermined dose of Midostaurin 2x daily~ * Days 8-28: Predetermined dose of Revumenib 2x daily~* End of consolidation visit~* Follow up"
62289193|NCT06313437|EXPERIMENTAL|Dose-Expansion Revumenib|"Cycles are 28 days~* Baseline visit and assessments~* Induction Cycle:~  * Days 1-3: Predetermined dose of Daunorubicin 1x daily~ * Days 1-7: Predetermined dose of Cytarabine~ * Days 8-21: Predetermined dose of Midostaurin 2x daily~ * Days 8-28: Predetermined dose of Revumenib 2x daily~* End of Induction visit~* Follow-up~* Reinduction Cycle: Therapy will be administered in the hospital~  * Days 1-2: Predetermined dose of Daunorubicin 1x daily~ * Days 1-5: Predetermined dose of Cytarabine~ * Days 8-21: Predetermined dose of Midostaurin 2x daily~ * Days 8-28: Predetermined dose of Revumenib 2x daily~* End of Reinduction visit~* Follow-up~* Consolidation Cycle: Therapy will be administered in the hospital~  * Days 1, 3, and 5: Predetermined dose of Cytarabine~ * Days 8-21: Predetermined dose of Midostaurin 2x daily~ * Days 8-28: Predetermined dose of Revumenib 2x daily~* End of Consolidation visit~* Follow up"
62289194|NCT00650611|ACTIVE_COMPARATOR|Low-Dose Ziprasidone|
62289195|NCT00650611|ACTIVE_COMPARATOR|High-Dose Ziprasidone|
62289196|NCT04939688|EXPERIMENTAL|Patients requiring a CT scan in the search for cranial lesions following head trauma|All patients will undergo both conventional dose AND ultra low-dose CT scans in the search for cranial lesions following head trauma.
62289197|NCT02113787|ACTIVE_COMPARATOR|Pharmacokinetic study, topamed|"For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day."
62289198|NCT02113787|ACTIVE_COMPARATOR|Pharmacokinetic study, topamax|"For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day."
62655246|NCT01239589||1|patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
62655247|NCT01239589||2|patients admitted as for an acute bipolar manic episode and treated with quetiapine XR
62655248|NCT00981123||1|
62655249|NCT00779337|EXPERIMENTAL|Single group study|Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.
61920044|NCT01988480|EXPERIMENTAL|Image-guided surgery|Image-guided implant placement
61920045|NCT01988480|SHAM_COMPARATOR|sinus graft|Sinus lift surgery : Patients receive sinus graft before implant placement
61920046|NCT02159274||BCS without oncoplastic techniques|BCS without oncoplastic techniques
61920047|NCT02159274||BCS with oncoplastic techniques|BCS with oncoplastic techniques.
62090972|NCT02193633|EXPERIMENTAL|AZD2014 3 on/4 off & weekly paclitaxel|3 days on, 4 days off AZD2014 BD administered orally Days 1-3 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
62090973|NCT02193633|EXPERIMENTAL|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 BD administered orally Days 1-2 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
62090974|NCT04238455|SHAM_COMPARATOR|Control Group|Sham serratus anterior plane block plus usual car
62090975|NCT04238455|ACTIVE_COMPARATOR|Treatment Group|Serratus anterior plane block plus usual care
62090976|NCT00772928|EXPERIMENTAL|Pentacel™ concurrently with Prevnar®|Participants had Pentacel™ concurrently administered with Prevnar®
62090977|NCT00772928|EXPERIMENTAL|Pentacel™ staggered schedule with Prevnar®|Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule).
62090978|NCT01859195||Focus Group Stage|\~20-24 participants, to comprise 3-6 focus groups
62090979|NCT01859195||Cognitive Interview Stage|\~12-16 participants in individual cognitive interviews
62090980|NCT02932111|EXPERIMENTAL|Osteopathic session|The osteopath put fingers on abdominal projection of the junction and sinks deeply into the abdomen until it perceives the trigger zone. Once in contact with the sphincter, it performs friction in the hourly sense, vibration, inhibitions or rebounds.
62289199|NCT06083584||Positive controls|6 patients already in database. The 6 confirmed splicing mutations are: DCTN1 (NM_004082.5): c.3209G\>T, OPTN (NM_001008211.1) : c.1613-7T\>G, FUS (NM_004960.4) : c.764+8T\>A, GRN (NM_002087.4): c.835+1G\>A, GRN (NM_002087.4): c.709-3C\>G, SPG11 (NM_025137.4): c.3039-5T\>G
62289200|NCT06083584||Negative controls|30 patients with familial hypercholesterolemia. The absence of splicing anomalies in the SLA genes after confirmation by RT-PCR followed by Sanger sequencing of the absence of anomalies for the 6 variants listed above for each of the 30 individuals.
62289201|NCT06083584||Exploratory cohort|156 ALS: 20 ALS patients with splice variants predicted to be deleterious by in silico prediction software; 136 panel-analysis-negative ALS patients (priority will be given to familial ALS)
62289202|NCT02837679|EXPERIMENTAL|Intervention|Geriatric follow up
62289203|NCT02837679|NO_INTERVENTION|Control|Usual care
62289204|NCT03707457|EXPERIMENTAL|Arm A: Nivolumab + anti-GITR|Patients receive nivolumab intravenously (IV) over 30 minutes and anti-GITR intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62289205|NCT03707457|EXPERIMENTAL|Arm B: Nivolumab + IDO1 inhibitor|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1 and IDO1 inhibitor daily by mouth. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62289206|NCT03707457|EXPERIMENTAL|Arm C: Nivolumab + Ipilimumab|Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab intravenously (IV) over 90 minutes on Day 1. Courses repeat every 21 days for up to 4 doses. After ipilimumab is discontinued, courses of nivolumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62289207|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 1|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
62090981|NCT02932111|PLACEBO_COMPARATOR|Placebo manipulative session|The Osteopath will touch the patient's limbs at the same place of osteopathic manipulative treatment, but without any intention of treatment and without any known and indexed reproduction techniques to simulate an osteopathic treatment, without its benefits.
62090982|NCT05939622|EXPERIMENTAL|fMRI with subsequent injection of active drug (Ethyl methyl hydroxypyridine succinate + Meldonium)|Arm 1 (n=15) performed structural and functional MRI and received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10 days
62090983|NCT05939622|PLACEBO_COMPARATOR|fMRI with subsequent injection of placebo|Arm 2 (n=15) performed structural and functional MRI and received Placebo in the same way.
62090984|NCT01186861|EXPERIMENTAL|Arm A: OSI-906 plus erlotinib|OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1
62090985|NCT01186861|PLACEBO_COMPARATOR|Arm B: placebo plus erlotinib|placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1
62289208|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 2|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
62090986|NCT02677246|EXPERIMENTAL|Denosumab|Phase 1, 3+3 design with inter-patient dose escalation from 1mg/kg/dose to 2mg/kg/dose, and possibility of a dose de-escalation of 0.5mg/kg/dose, A modification of 3+3 design is implemented to take into account the achievement of bone resorption blockade by Denosumab. CTX is a biologic marker of bone resorption. Provided a decrease of CTX blood level will be observed under the lower limit (2,5th percentile) for age and sex, or under 20% of the pre-treatment level, there will be no reason to continue escalating the dose. This modified 3+3 design prevents exposure of children to dose escalations that would not be needed regarding the medical and biological aims of this trial.
62655250|NCT04971655|EXPERIMENTAL|Music therapy group|When individuals with diabetes apply to diabetes education after their polyclinic examination, music therapy will be applied in addition to routine monitoring and applications throughout the education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered as options to the individuals in the intervention group and will be listened to throughout the process. During the training, the selected music will be played over the loudspeaker. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
62289209|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 3|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
62090987|NCT03294265|EXPERIMENTAL|Peer support group|"Patients who accept to participate in the protocol and are randomized to the intervention group will be invited to five sessions, one per bimester, that will be carried out in our facilities until their next appointment to the centre (fifth visit). All of them will be coordinated by a group leader.~Interventions are made each bimester in 2 hours in peer support sessions in which the patients discuss and reinforce the following topics: grief stages, control goals, self-care activities, adequate diet planning and diminish sedentary lifestyle."
62090988|NCT03294265|ACTIVE_COMPARATOR|Control group|"Patients who accept to participate in the protocol and are randomized to the control group will receive weekly messages and reminders about self-care to their cell phones via WhatsApp.~Interventions are made by sending each week a self-care reminder via WhatsApp and questionnaires about self-care activities and drugs"
61920048|NCT02425072|EXPERIMENTAL|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
62090989|NCT05786586|EXPERIMENTAL|650 nm low-level red-light, plus single vision spectacle lenses|Children in the treatment group are expected to receive 6 minutes irradiation of 650 nm low-level red-light daily, divided into two times a day, each lasting for 3 minutes. Single vision spectacle lenses are allowed for myopic children.
62090990|NCT05786586|NO_INTERVENTION|Control|Single vision spectacle lenses are allowed for myopic children. No intervention was given.
62090991|NCT04511130|EXPERIMENTAL|MT-401 following HSCT|Treatment with MT-401 at 90 days following HSCT
62289210|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 4|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
62289211|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 5|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
62289212|NCT00814385|ACTIVE_COMPARATOR|vaccine arm 6|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
62289213|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 7|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
62289214|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 8|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
62289215|NCT00814385|ACTIVE_COMPARATOR|Vaccine arm 9|No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks
62289216|NCT02750202|ACTIVE_COMPARATOR|Quadrivalent HPV vaccine|Three doses of 4 HPV vaccine is given at registered intervals.
62289217|NCT02750202|SHAM_COMPARATOR|Hepatitis B vaccine|Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.
62289218|NCT02612376||AD, DS, Mild Cognitive Impairment|Persons with age-related Mild Cognitive Impairment (MCI) or Alzheimer Disease (AD) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.
62289219|NCT02612376||Healthy Controls|"* Community-dwelling controls~* An Informant (study partner) available to complete functional interviews/survey measures annually."
62090992|NCT04511130|NO_INTERVENTION|Standard of Care following HSCT|Standard of Care
62090993|NCT04511130|EXPERIMENTAL|MT-401 following relapse|Treatment with MT-401 following relapse after first HSCT
62090994|NCT06697535|EXPERIMENTAL|Low-dose JYP0061 + Reduced Dose Glucocorticoids (Group A)|Participants in this group will receive JYP0061, starting with a higher dose for the initial weeks, followed by a reduced maintenance dose. In addition, participants will receive a regimen of glucocorticoids, starting with intravenous administration and transitioning to oral dosing with a gradually tapering dose over time.
62090995|NCT06697535|ACTIVE_COMPARATOR|Standard Dose Glucocorticoids (Groups B1 and B2)|Participants in this group will receive a standard glucocorticoid regimen, starting with intravenous glucocorticoids at higher doses, with doses tapering over time, and then transitioning to an oral glucocorticoid regimen that also tapers gradually. During the second phase, adjustments may be made based on the participant's clinical response.
62090996|NCT06697535|EXPERIMENTAL|High-dose JYP0061 (Group C)|Participants in this group will receive a higher dose of JYP0061 for the initial weeks, followed by a lower maintenance dose for the remainder of the study period.
62090997|NCT05221398||Immune checkpoint inhibitors based adjuvant therapy|Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
62655251|NCT04971655|NO_INTERVENTION|Control group|When individuals apply to diabetes education after their polyclinic examinations, routine monitoring and application will be made throughout the education. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
61906116|NCT05288062|EXPERIMENTAL|Cohort C (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed or refractory multiple myeloma receive lenalidomide PO QD on days 1-14 in combination with dexamethasone PO QD on days 1, 8 and 15 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
62090998|NCT05221398||Without adjuvant therapy|Patients in this arm will not receive any adjuvant therapy.
62090999|NCT06697574|EXPERIMENTAL|Psychoeducation and Hypnotherapy Group|30 Patients randomized to undergo psychoeducation and hypnotherapy
62091000|NCT06697574|ACTIVE_COMPARATOR|Psychoeducation Group|30 Patients selected for psychoeducation with out hypnotherapy
62091001|NCT06697574|NO_INTERVENTION|Non intervention group - retrospectively analyzed|30 age matched patients from the oral mucosal clinic who's course and presentation of lichen planus would be retrospectively analyzed
62091002|NCT06339983|EXPERIMENTAL|Manual Scar Mobilization:|Group will undergo manual scar mobilization therapy. In this therapy, deep pressure on some point of the area of the scar will be given which will be perpendicular to the skin which will be followed by skin rolling. The manual therapy will include different techniques such as rolling, stroking, superficial rubbing, deep rubbing, breaking up, and pinching. The therapy will continue for 15 minutes.
62289220|NCT02299960||HFpEF|patients with heart failure with preserved ejection fraction
62289221|NCT02299960||HFrEF|patients with heart failure with reduced ejection fraction
62289222|NCT02299960||AH|patients with hypertension
61906117|NCT05288062|EXPERIMENTAL|Cohort D (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed multiple myeloma after lenalidomide maintenance receive treatment as in Cohort C.
61906118|NCT06155019||Non comparative|switch from etravirine to doravirine, with no change in associated antiretroviral drugs, will be assessed retrospectively
62091003|NCT06339983|ACTIVE_COMPARATOR|Myofascial Cupping Therapy|Group will receive myofascial cupping therapy. In this method, the patient will lie down on the bed with an exposed scar area. Application areas will be cleaned and herbal oil or cream will be applied. A disposable plastic cup (5cm) will be positioned at THE selected area of the cesarean scar. Then, negative pressure will be applied using a mechanical vacuum pump, the cup will be gently slid around the selected area rhythmically to get a massage-like effect for approximately 5-15 minutes. Then the cup will be removed gently. After this, the application areas will be cleaned.
62289223|NCT02299960||Nephropathy|patients with diabetic nephropathy
62289224|NCT02157454|EXPERIMENTAL|Website access|Two-week access to the colorectal cancer module of the website www.krankheitserfahrungen.de
62289225|NCT02157454|NO_INTERVENTION|Control|Participants who are randomized to the control group don't have access to the website until they have finished the last questionnaire at 6 weeks follow up.
62289226|NCT02651090|EXPERIMENTAL|sonazoid|treatment arm with sonazoid
62289227|NCT02867397|OTHER|Teysuno (S1) in combination with epirubicin and oxaliplatin|
62289228|NCT04573673|EXPERIMENTAL|PTNS verum|Patients will be treated with transcutaneous tibial neuro-stimulation with one 30-minute session daily for a period of 12 weeks.
62289229|NCT04573673|SHAM_COMPARATOR|PTNS placebo|Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for 12 weeks (same treatment regimen as the experimental group).
61906119|NCT00538083|EXPERIMENTAL|1, 2|acute phase, solid dark chocolate, placebo
61906120|NCT00538083|EXPERIMENTAL|3, 4, 5|acute phase, sugared cocoa, sugar-free cocoa, placebo
62091004|NCT02851199|ACTIVE_COMPARATOR|study group 1|1. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the prone position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. Finally the participants will performed additional 3 minutes of hyperventilation in the sitting position
62289230|NCT04491227||Kidney disease in COVID-19|"Chronic Kidney Disease (CKD): Known diagnosis of chronic kidney disease; prior evidence of markers of kidney damage for 3 months (microalbuminuria, proteinuria \>300mg/24 hrs or abnormalities in imaging tests) or the presence of glomerular filtration rate (GFR) \<60 mL/min/1.73 m2 for 3 months calculated with CKD-EPI equation, with or without other signs of kidney damage as described above.~ESKD: Patients that are dialysis dependent.~Suspected AKI: Oliguria (\<200 mL/6 hours) and any AKI-related clinical signs or symptoms (see table 1) or urinalysis/dipstick abnormality. All suspected AKI cases must be confirmed prior to enrollment.~Confirmed AKI: Meeting of at least one of the modified KDIGO Criteria~* Increase or decrease in serum creatinine \>0.3 mg/dl from reference in 48 hours~* Increase or decrease in serum creatinine \> 50% from reference in 7 days~* Urine output \< 400 ml/day~Functioning Kidney transplant:"
62289231|NCT05743933||Study group|Accidental adrenal tumor with 1mg-DST cortisol \>50nmol/L
62289232|NCT05743933||Control group|Accidental adrenal tumor with 1mg-DST cortisol ≤50nmol/L
62289233|NCT03636906|EXPERIMENTAL|RSV1D Pooled Group|"Subjects received the interventions as follows:~* Either 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31 and any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).~* Or 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31."
62289234|NCT03636906|EXPERIMENTAL|RSV2D Pooled Group|"Subjects received the interventions as follows:~* Either 2 doses of experimental RSV (GSK3389245A) higher dose formulation (administered at Day 1 and Day 31) and followed by any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).~* Or 2 doses of experimental RSV (GSK3389245A) higher dose formulation administered at Day 1 and Day 31."
62307958|NCT00772850||Antegrade nailing, humeral fractures|We included patient's age and gender, fracture location, fracture cause, presence of nail removal, post-operative period and comorbidity or associated disease as independent variables. Fracture location was either humeral neck or humeral shaft. Humeral neck fractures were defined as fractures above surgical neck of the humerus. Meanwhile, humeral shaft fractures were defined as fractures below surgical neck of the humerus and 5 cm above the olecarnon fossa. Humeral shaft fractures were separated into three groups: proximal third shaft fractures, middle third shaft fractures and distal third shaft fractures. Fracture causes included simple falls and traffic accidents.
61906121|NCT00538083|EXPERIMENTAL|6, 7, 8|sustained phase, sugared cocoa, sugar-free cocoa, placebo
61906122|NCT03101553|EXPERIMENTAL|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
62091005|NCT02851199|ACTIVE_COMPARATOR|study group 2|2. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the sitting position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. . Finally the participants will performed additional 3 minutes of hyperventilation in the
62289235|NCT03636906|ACTIVE_COMPARATOR|Comparator_Placebo Pooled Group|"Subjects received either one of interventions schedules as follows:~* 3 doses of GSK's multicomponent meningococcal B vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).~* 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).~* 3 doses of GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 31, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Day 1 and Day 121).~* 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 31 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 1 and 61) .~* 2 doses of Placebo alone (administered at Days 1 and 31)."
62289236|NCT05200260|EXPERIMENTAL|Upfront cytoreductive surgery with maintenance therapy|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
62289237|NCT05200260|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy with maintenance therapy|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
62289238|NCT01851837|ACTIVE_COMPARATOR|Group I|Study group I (57 participants) received the continuous training of exercise time.
62289239|NCT01851837|ACTIVE_COMPARATOR|Group II|Study group II (58 participants) received the interval training of exercise time.
62289240|NCT01402245|NO_INTERVENTION|Pneumonia group|Patients with Pnc pneumonia
62289241|NCT01402245|ACTIVE_COMPARATOR|PPV Group|Volunteers immunized with Pnc polysaccharide vaccine
62289242|NCT01402245|ACTIVE_COMPARATOR|PCV Group|Volunteers immunized with Pnc conjugate vaccine
62289243|NCT05450614|EXPERIMENTAL|Thrive app|In the Thrive group, access to the application and information regarding its use will be made available to participants. Reassessments and data collection will be performed at 5 points including baseline, 4 weeks, 8 weeks, 12 weeks and 6 months. These five evaluations will be carried out through questionnaires sent to the participants.
62307959|NCT03750838|EXPERIMENTAL|Text Messaging Intervention Group|Participants in the Text Messaging Intervention condition will be provided a predetermined number of messages per week (based partially on responses from Phase 2 focus group) for 6 weeks delivered on Thursdays, Fridays, and Saturdays, which are the most common days of the week that heavy drinking occurs as well as other days and times that focus group participants indicated would be the most helpful.
61906123|NCT03101553|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove \& Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
61906124|NCT01762137|ACTIVE_COMPARATOR|Coiling|Coiling
61906125|NCT01762137|ACTIVE_COMPARATOR|Flow Diversion|Flow Diversion
61906126|NCT03320551|EXPERIMENTAL|Nutrition Education Immersion Program|Assessing if a one week lifestyle interventions can lead to long term health benefits.
61906127|NCT06071429|EXPERIMENTAL|MAGNITUDE BRS|Participants who receive the MAGNITUDE BRS device will be included in this arm
61906128|NCT06071429|ACTIVE_COMPARATOR|Percutaneous Transluminal Angioplasty (PTA)|Participants who receive a PTA device will be included in this arm
61906129|NCT00586092|OTHER|1|This trial employs a phase I design with a dose escalation stage (stage I) and an expansion stage (stage 2) to better describe the tolerability of this combination and the effect of this combination on several biomarkers. In this second stage there will be two groups, each with ten patients, to better describe the tolerability of the bevacizumab/ABT-510 combination and the effect of this combination on several biomarkers. The primary objective of this study is to estimate the MTD/recommended phase II dose regimen. All other objectives are exploratory in nature.
61906130|NCT02603666|OTHER|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
61906131|NCT05246865|EXPERIMENTAL|Women with PCOS|Women with polycystic ovary syndrome
61906132|NCT05246865|EXPERIMENTAL|Age and BMI-matched healthy volunteers|Otherwise healthy women without PCOS but matching in age and body mass index to the above group
61906133|NCT01741402|EXPERIMENTAL|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
61906134|NCT01741402|ACTIVE_COMPARATOR|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
61906135|NCT05037435|EXPERIMENTAL|The pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried)|Live attenuated bovine-human \[UK\] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
61906136|NCT05037435|PLACEBO_COMPARATOR|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
61906137|NCT02208687|EXPERIMENTAL|Energetic|Self management group program aimed at reconditioning and social participation
61906138|NCT02208687|OTHER|Control group|Usual care
62289244|NCT05450614|ACTIVE_COMPARATOR|TCCG|"Participants selected for the TCCG group will undergo a new randomization, which will select 50% of patients for immediate start of online sessions and the remainder for inclusion in a waiting list. Participants selected for immediate start will start the CBCT sessions at the time of the initial assessment and will be reassessed at the same points as the Thrive group, also through self-administered online questionnaires.~The waiting list will last for 12 weeks, with assessment through self-applicable online scales at the end of the period. Patients who present PHQ≥ 9 will then start online CBCT sessions, according to the protocol above."
61906139|NCT03467685|PLACEBO_COMPARATOR|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
61906140|NCT03467685|EXPERIMENTAL|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
61906141|NCT06432283||advanced cancer (stage III and IV) patients aged 60 years and above.|advanced cancer (stage III and IV) patients aged 60 years and above who are receiving treatment at the mentioned institution. The research subjects voluntarily participate and sign informed consent forms.
61906142|NCT00948220|EXPERIMENTAL|Treatment|Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
61906143|NCT00948220|NO_INTERVENTION|Control|Chronic hepatitis C patients without standard antiviral therapy
62091006|NCT06696547|ACTIVE_COMPARATOR|Active CRB-iTBS|Patients received a total of 30 sessions active CRB-iTBS targeting contralesional lateral cerebellum, 5 days a week for 3 weeks. The cerebellar region to be targeted, on the opposite side of the cerebral lesion, was determined by measuring 3 cm lateral and 1 cm inferior of the inion, which is the anatomical prominence on the occipital bone (3L1I). Stimulation intensity was set at 80% of the active motor threshold (AMT). AMT was defined as the lowest intensity required for a motor-evoked potentials (MEP) above 200 µV in at least 50% of 10 trials when the patient was contracting targeted muscle 10% on the maximum voluntary contraction. Stimulation was administered as 3-burst pulses at a frequency of 50 Hz, with 2-second stimulation repeated every 10 seconds period. This continued for a total duration of 190 seconds, delivering 600 pulses. Each CRB-iTBS session was performed in 2 sessions before daily rehabilitation programs. Thus, 1200 pulses were applied per day.
62091007|NCT06696547|SHAM_COMPARATOR|Sham CRB-iTBS|Patients received a total of 30 sessions sham CRB-iTBS targeting contralesional lateral cerebellum, 5 days a week for 3 weeks. The cerebellar region to be targeted, on the opposite side of the cerebral lesion, was determined by measuring 3 cm lateral and 1 cm inferior of the inion, which is the anatomical prominence on the occipital bone (3L1I). However, sham coil was used for stimulation. Therefore, no real stimulation was applied to the patients. Instead, a sensation mimicking real stimulation was created through the sham coil, with sounds and sensations on the scalp as if stimulation were occurring. Each sham CRB-iTBS session was performed in 2 sessions before daily rehabilitation programs.
62091008|NCT06615687|EXPERIMENTAL|Inverted T -Shape Free Gingival Graft|
62091009|NCT06615687|ACTIVE_COMPARATOR|Free Gingival Graft|
62091010|NCT02181959|EXPERIMENTAL|Pharmaton® with DMAE|
62091011|NCT02181959|ACTIVE_COMPARATOR|Pharmaton® without DMAE|
62091012|NCT02181959|PLACEBO_COMPARATOR|Placebo|
62091013|NCT05764603|EXPERIMENTAL|Participants|
62091014|NCT06698185|EXPERIMENTAL|Materna Prep Device|Materna Prep Device
62091015|NCT06698185|SHAM_COMPARATOR|Sham Control|Sham Control
62091016|NCT02980679|EXPERIMENTAL|CTC and G-PERT Imaging|One experimental (CTC) and one standard (G-PERT) scan, at least 48 hours apart, before thyroid surgery. The order of the scans will be randomized.
62091017|NCT02134275|EXPERIMENTAL|Whole body vibration training|Whole body vibration training (timed stand on vibration platform) 3 20-minute sessions per week for 6 months
62091018|NCT02134275|PLACEBO_COMPARATOR|Control group|No significant changes to diet, exercise and lifestyle.
62091019|NCT06477406|EXPERIMENTAL|High-CBD Sublingual Product|A custom-formulated, hemp-derived, full-spectrum high-CBD sublingual solution; 0.75mL of solution will be self-administered three times daily (TID) for the duration of the CBD phase.
62091020|NCT06477406|PLACEBO_COMPARATOR|Placebo|Placebo solution (0.75mL) will be self-administered TID for the duration of the placebo phase.
62091021|NCT06349785|EXPERIMENTAL|study group A|Assigned Children in the study will receive manual hyperinflation and standard physical therapy program. Manual hyperinflation (MHI): Manual hyperinflation will be performed by single physical therapist using a silicone resuscitator bag . The resuscitator bag (maximum volume of 500 mL) was connected to a pressure manometer with an oxygen flow of 10 L. min-1 with the total duration of session in group A will be 15 minutes, daily for 2 weeks
62091022|NCT06349785|ACTIVE_COMPARATOR|study group B|- Children in study group B will receive standard Physical therapy program including suction, percussion and vibration with total duration of session in group a will be 15 minutes, daily for 2 weeks
62655252|NCT05683821|EXPERIMENTAL|Enhanced outreach|Quarterly outreach via letter and applicable patient-preferred modalities, including e-mail and/or text messaging, offering both standard person-to-person treatment options (quitline referral, primary care provider referral, cessation counseling and treatment in a randomized clinical trial) and self-guided, remote treatment options (mailed nicotine replacement therapy samples and/or facilitated enrollment in a Smokefree.gov texting program). Patients in clinics assigned to this arm will also have the option to initiate treatment by phone or online. Patients may also receive outreach calls from Tobacco Care Managers offering the person-to-person treatments at their health systems 1-30 days following a visit to a participating clinic.
62655253|NCT05683821|ACTIVE_COMPARATOR|Standard outreach|One mailed letter at study initiation outlining available person-to-person treatment options (quitline referral, primary care provider referral, cessation counseling and treatment in a randomized clinical trial) and how to initiate treatment by phone. Patients may also receive outreach calls from Tobacco Care Managers offering the person-to-person treatments at their health systems 1-30 days following a visit to a participating clinic.
62655254|NCT02753881|ACTIVE_COMPARATOR|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
62655255|NCT02753881|ACTIVE_COMPARATOR|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
62655256|NCT02538991|EXPERIMENTAL|Bulkamid|
62655257|NCT02538991|ACTIVE_COMPARATOR|Tension-free Vaginal Tape|
62655258|NCT00053326|EXPERIMENTAL|Treatment (fenretinide)|Patients receive oral fenretinide 3 times daily (or 2 times daily if over 18 years of age) on days 1-7. Treatment repeats every 3 weeks for up to 30 courses in the absence of disease progression or unacceptable toxicity.
62655259|NCT03972540|EXPERIMENTAL|Mindful eating intervention|The mindful eating intervention was taught by a mindfulness-based stress reduction instructor certified by the Center of Mindfulness at the University of Massachusetts Medical School.
62655260|NCT02335944|EXPERIMENTAL|Phase IB part- NSCLC with EGFR activating mutations|NSCLC participants who have previously documented EGFR mutation and progressed on EGFR TKI treatment. Participants were treated at a starting dose of 50 mg once a day for EGF816 and 200 mg twice a day for INC280 in fasted state
62655261|NCT02335944|EXPERIMENTAL|Phase II- Group 1 (EGFRmut, any T790M, any MET, 2/4L antineoplastic, EGFR TKI resistant)|NSCLC participants with previously documented activating EGFR mutation, with any T790M and MET dysregulation status, who received one to three lines of systemic antineoplastic therapy prior to study entry including one line maximum of first or second generation EGFR TKI and who progressed on this EGFR TKI treatment line. Participants were treated at the RP2D of INC280 and EGF816 in fasted state
62655262|NCT02335944|EXPERIMENTAL|Phase II- Group 2 (EGFRmut, de novo T790M, any MET, 1/3L antineoplastic, EGFR TKI naïve)|NSCLC participants harboring T790M mutation in de novo setting, irrespective of the activating mutation status who are treatment naïve or received maximum 2 lines of systemic antineoplastic therapy prior to study entry, but no therapy known to inhibit EGFR. Participants were treated at the RP2D of INC280 and EGF816 in fasted state
61906144|NCT04644315|EXPERIMENTAL|ALK-positive Solid Tumors|Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
62289245|NCT04236544|EXPERIMENTAL|PExMS and DECIMS-Wiki|After allocation, the intervention group will receive access via a data-protected study platform (www.erecover.de) to PExMS and DECIMS-Wiki for a two-week period. The former is a multimedia website providing experiential information. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
62655263|NCT02335944|EXPERIMENTAL|Phase II- Group 3 (EGFRmut, T790M negative, any MET, 1L antineoplastic)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, and any MET status who never received any prior line of systemic antineoplastic systemic therapy prior to study entry. Participants were treated at the RP2D of INC280 and EGF816 in fasted state
61906145|NCT00779259|ACTIVE_COMPARATOR|Theophylline alone|baseline theophylline pharmacokinetics
62289246|NCT04236544|ACTIVE_COMPARATOR|DECIMS-Wiki|After allocation, the control group will receive access to the DECIMS-Wiki for a two-week period. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
61906146|NCT00779259|ACTIVE_COMPARATOR|Quinine alone|baseline quinine pharmacokinetics at steady state
61906147|NCT00779259|EXPERIMENTAL|Theophylline with steady state quinine|Theophylline pharmacokinetics in the presence of steady state quinine and quinine pharmacokinetics in the presence of theophylline.
61906148|NCT05030285|EXPERIMENTAL|Intervention|People who are randomised into the intervention arm will undergo 6 weekly psychotherapy sessions
61906149|NCT05030285|NO_INTERVENTION|Control|People who are randomised into the control arm will undergo usual care
61906150|NCT01916291|EXPERIMENTAL|Propess insertion|
62289247|NCT00962273|EXPERIMENTAL|Pandemic Stress Vaccine - Interactive|
62289248|NCT00962273|ACTIVE_COMPARATOR|Pandemic Stress Vaccine - Didactic|
62289249|NCT00962273|NO_INTERVENTION|Wait list|Some participants are assigned to an eight week waiting condition prior to the course commencing.
62289250|NCT01348737|EXPERIMENTAL|AZD3839|Oral Treatment
62289251|NCT01348737|PLACEBO_COMPARATOR|AZD3839 Placebo|Oral Treatment
62655264|NCT02335944|EXPERIMENTAL|Phase II- Group 4 (EGFRmut, any T790M, any MET, 1L (treatment naïve) 2-3L antineoplastic)|NSCLC participants with previously documented EGFR activating mutations and any T790M and MET status who were treatment naïve or failed maximum 2 prior lines of any systemic antineoplastic therapy for advanced disease. Participants were treated at the RP2D of INC280 and EGF816 in fed state
62655265|NCT02335944|EXPERIMENTAL|Phase II- Group 5 (EGFRmut, T790M-, MET GCN≥5, 2L, EGFR TKI resistant)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, acquired MET amplification who have progressed on one prior line of therapy for advanced/metastatic NSCLC disease. Participants were to start with INC280 monotherapy (twice a day) and would have had the opportunity to continue to combination of EGF816 (once a day) and INC280 (twice a day) based on radiological disease progression evaluation by investigator's assessment per RECIST 1.1
62091023|NCT03623711|EXPERIMENTAL|Escitalopram group|including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.
62091024|NCT03623711|EXPERIMENTAL|Duloxetine group|including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.
62091025|NCT03623711|EXPERIMENTAL|Bupropion group|including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.
62289252|NCT01743573|EXPERIMENTAL|yoga training|Yoga training
62289253|NCT01743573|NO_INTERVENTION|control|no yoga training
62289254|NCT02908399|EXPERIMENTAL|Thermal Imaging|Imaging using a thermal camera
62289255|NCT04011202|EXPERIMENTAL|VR Group|Receives the VR protocol
62289256|NCT04011202|NO_INTERVENTION|Control Group|Receives regular care
62289257|NCT04141657||Group 1 (0-17 years)|We will observe the treatment course in ICU pediatric patients, register adverse events (AEs) and serious adverse events (SAEs) if occur, and assess patient health status at the end of the performed therapy.
62655266|NCT03806816|EXPERIMENTAL|HYPOTHERMIA / MELATONIN group|HIE infants who will receive melatonin in addition to the routine cooling treatment
62655267|NCT03806816|EXPERIMENTAL|HYPOTHERMIA / PLACEBO group|HIE infants who will not receive melatonin in addition to the routine cooling treatment
62091026|NCT03623711|PLACEBO_COMPARATOR|Healthy control|50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.
62289258|NCT01693445|EXPERIMENTAL|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
62655268|NCT02424695|EXPERIMENTAL|Single Gabapentin Enacarbil Arm|"Gabapentin Enacarbil (Gen) 600 mg will be administered once daily for 4 weeks~Matching placebo will be administered once daily for one week prior initiation of treatment with GEn"
62655269|NCT04789980||Patients|Patients with locally advanced or metastatic pancreatic cancer who plan to receive palliative chemotherapy
62655270|NCT01720966||Laparoscopy|Patients who will undergo liver resection who have a laparoscopically performed colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
62655271|NCT01720966||Laparotomy|Patients who will undergo liver resection who have an open colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
61906151|NCT00995566||Thelin Registry Patients|
61906152|NCT00763503|EXPERIMENTAL|CD 2027|
61906153|NCT03254459|EXPERIMENTAL|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
61906154|NCT03254459|ACTIVE_COMPARATOR|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
62091027|NCT05041647|EXPERIMENTAL|High CBD [25:1]|"* 1 dose (1 mL) of HIGH CBD~* 50 mg/ml CBD and 2 mg/ ml THC"
62091028|NCT05041647|EXPERIMENTAL|Low CBD [5:1]|"* 1 dose (1 mL) of LOW CBD~* 10 mg/ml CBD and 2 mg/ ml THC"
62091029|NCT05041647|PLACEBO_COMPARATOR|Placebo|"* 1 dose (1 mL) of PLACEBO~* No active ingredients"
62091030|NCT05789355|EXPERIMENTAL|NUV001|Daily supplementation with NUV001 1000 mg
62091031|NCT03888703|EXPERIMENTAL|Treatment|
62289259|NCT01742429|EXPERIMENTAL|Levofloxacin-bismuth therapy|14 day levoﬂoxacin and bismuth-containing therapy:PPI,bismuth, amoxicillin, levoﬂoxacin
62289260|NCT01742429|ACTIVE_COMPARATOR|classical quadruple therapy|14 day classical quadruple therapy:PPI,bismuth, metronidazole, tetracycline
62289261|NCT01989221|OTHER|Placebo followed by Sancuso|Placebo at baseline for one week followed by Sancuso® (granisetron transdermal system) 3.1 mg/24 hours for two weeks
62289262|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
62289263|NCT00783016|EXPERIMENTAL|Morphine|
62289264|NCT00783016|NO_INTERVENTION|Placebo|
62289265|NCT01071187|EXPERIMENTAL|Varenicline|Treatment with varenicline with 0,5mg daily on day 1-3, 1mg daily on day 4-7 and 2mg daily on day 8-84.
62289266|NCT01071187|PLACEBO_COMPARATOR|Placebo|
62289267|NCT01487603||confirmed or suspected lung cancer|
62289268|NCT03775707|EXPERIMENTAL|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62289269|NCT01907386|OTHER|QSE-LSME and SSWI ultrasound|"QSE-LSME and SSWI ultrasound examinations combined with a clinically required CT-scan. We will screen 3 groups of 15 patients each, with at least one-year follow-up after EVAR, matched for sex, age and aneurysm diameter at baseline (before EVAR).~Group 1. Patients without endoleak and a maximal diameter reduction at one year of at least 10% and a volume reduction of 20%.~Group 2. Patients with a stable sac volume and diameter (less than 10% volume and 5% diameter variation within a year).~Group 3. Patients with type I, type II or type V endoleak (endotension) with more than 10% diameter progression and 20% volume progression."
62655272|NCT05269329|EXPERIMENTAL|XC8, film-coated tablets, 20 mg/day|
62655273|NCT05269329|EXPERIMENTAL|XC8, film-coated tablets, 40 mg/day|
62655274|NCT05269329|EXPERIMENTAL|XC8, film-coated tablets, 80 mg/day|
62655275|NCT05269329|PLACEBO_COMPARATOR|Placebo|
62655276|NCT03520530|EXPERIMENTAL|Mouth Guard|Patients will push in the second stage of labor without use of mouth guard
62655277|NCT03520530|NO_INTERVENTION|Control|Patients will push in the second stage of labor without use of mouth guard
62655278|NCT01214278|EXPERIMENTAL|Supplement 1|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules
62655279|NCT01214278|EXPERIMENTAL|Supplement 2|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)
62091032|NCT03888703|NO_INTERVENTION|Control|
62289270|NCT00291720|ACTIVE_COMPARATOR|Spironolactone|25mg spironolactone daily
62289271|NCT00291720|PLACEBO_COMPARATOR|Placebo|matching placebo medication for the control group
62655280|NCT01214278|EXPERIMENTAL|Supplement 3|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules
62655281|NCT01214278|EXPERIMENTAL|Supplement 4|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)
62655282|NCT02648685||normal glycaemic metabolism|100 subjects
62655283|NCT02648685||Type 2 Diabetes|300 subjects
62655284|NCT03733236|EXPERIMENTAL|Active Stimulation|The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
62655285|NCT05266768|EXPERIMENTAL|IBI346|Single arm
62655286|NCT01813279|EXPERIMENTAL|patients|
62655287|NCT01836120|EXPERIMENTAL|Raltitrexed plus Docetaxel|
62655288|NCT01836120|ACTIVE_COMPARATOR|Docetaxel|
62655289|NCT03348995|EXPERIMENTAL|Bridge-Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing an absorbable implant (the BEAR Implant) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into
62655290|NCT03548779|EXPERIMENTAL|Pre-visit prep / usual care + exome seq|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care and will be offered research exome sequencing."
62091033|NCT02007447|ACTIVE_COMPARATOR|OCYTOCINA - SPRAY NASAL|OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
62091034|NCT02007447|PLACEBO_COMPARATOR|Placebo|Placebo - twice per day for 8 weeks
62091035|NCT06475677|EXPERIMENTAL|OrthoCor Advanced System|
62655291|NCT03548779|EXPERIMENTAL|Pre-visit prep / usual care|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care."
62655292|NCT03548779|EXPERIMENTAL|No prep / usual care + exome seq|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care and will be offered research exome sequencing."
62655293|NCT03548779|NO_INTERVENTION|No prep / usual care|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care."
62655294|NCT05708885|ACTIVE_COMPARATOR|Striated esophagus deglutitive motor function healthy adults|Testing of manometric, impedance and biomechanical measurements during swallowing in healthy volunteer adult subjects.
62091036|NCT04007887|EXPERIMENTAL|Intervention|Post-MI patients attending an adult education program designed to inform and motivate them on how to best control cardiovascular risk factors as a means to offer optimized secondary prevention of cardiovascular events
62091037|NCT04007887|NO_INTERVENTION|Controls|Usual care for post-MI patients
62289272|NCT01785355||Dental treatment|Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
61906155|NCT02116530|EXPERIMENTAL|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:~* Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~* Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~* Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~* olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
62091038|NCT05049525|ACTIVE_COMPARATOR|Itraconazole and Terbinafine|During the first 4 weeks itraconazole will be administered alone at 200 mg twice daily, followed by itraconazole 200 mg twice daily and terbinafine 250 mg twice daily for the remaining 16 weeks. Both drugs will be administered orally.
62091039|NCT05049525|PLACEBO_COMPARATOR|Placebo|During the first 4 weeks a placebo will be administered alone at 200 mg twice daily, followed by placebo 200 mg twice daily and another placebo 250 mg twice daily for the remaining 16 weeks. Both placebos will be administered orally.
62091040|NCT06614868|EXPERIMENTAL|Treatment Group|Participants receiving acceptance and commitment therapy
62289273|NCT00974415|EXPERIMENTAL|treatment|CO2 treatment
62289274|NCT00974415|SHAM_COMPARATOR|sham|sham treatment
62289275|NCT02145494|EXPERIMENTAL|Treatment|Radiotherapy
62289276|NCT01905475|EXPERIMENTAL|POL6326|POL6326 intravenous infusion
62655295|NCT05708885|ACTIVE_COMPARATOR|Striated esophagus deglutitive motor function in patients with ineffective esophageal motility|Testing of manometric, impedance and biomechanical measurements during swallowing in adult patients with ineffective esophageal motility.
62655296|NCT05708885|ACTIVE_COMPARATOR|Striated esophagus deglutitive motor function patients with symptoms but normal esophageal manometry|"Testing of manometric, impedance and biomechanical measurements during swallowing in adult patients with symptoms of dysphagia but normal esophageal manometry by the Chicago Classification criteria."
62289277|NCT01905475|PLACEBO_COMPARATOR|Placebo|Placebo intravenous infusion
62289278|NCT02221492|ACTIVE_COMPARATOR|granulocyte colony-stimulating factor alone|G-CSF administered up to 8 days
62289279|NCT02221492|EXPERIMENTAL|granulocyte colony-stimulating factor plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
62289280|NCT05220592|EXPERIMENTAL|Internet-based recovery training program (n=35)|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week.
62289281|NCT05220592|NO_INTERVENTION|Wait-list control group (n=34)|Wait-list control group received equal and parallell assessment and eligibility procedure as the experimental conditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
62289282|NCT01371461||Patients prescribed PAXIL|Patients with depression or depressed state prescribed PAXIL during study period
62289283|NCT02520986|EXPERIMENTAL|Carbon dioxide Laser ablation|Excision of genital warts using a carbon dioxide laser, ie CO2 Laser
62289284|NCT02520986|ACTIVE_COMPARATOR|Electrocoagulation|Excision of genital warts using a superficial electrical coagulation mode, ie spray coagulation
62289285|NCT00003141|EXPERIMENTAL|Treatment (combination chemotherapy, PBSC transplant)|Pts undergo conventional surgery for diagnosis \& max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) \& undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
62289286|NCT05827796|EXPERIMENTAL|Cohort 1: IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine)|Subjects will be treated with IN10018 25 mg/50 mg/100 mg, once daily, oral+ albumin-bound paclitaxel 125 mg/m2 IV infusion on Days 1 and 8 of each 21-Day Cycle+ gemcitabine 1000 mg/m2 IV infusion on Days 1 and 8 of each 21-Day Cycle.
62307960|NCT03750838|NO_INTERVENTION|Assessment Only Control|Participants in the assessment only control will not receive any text messages, but will complete all survey assessments on the same schedule as the Text Message Intervention Group.
62655297|NCT00437762|EXPERIMENTAL|1|Botulinum Toxin A Injection
62655298|NCT00437762|PLACEBO_COMPARATOR|2|Placebo injection
62655299|NCT02094365|EXPERIMENTAL|ALS-008176|ALS-008176 drug substance for oral suspension
62655300|NCT02094365|PLACEBO_COMPARATOR|vehicle alone|Vehicle alone
62655301|NCT01513590|EXPERIMENTAL|IDegAsp BID|
62655302|NCT01513590|ACTIVE_COMPARATOR|BIAsp 30 BID|
61906156|NCT02116530|ACTIVE_COMPARATOR|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:~* Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~* Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~* Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~* placebo"
61906157|NCT04140760|ACTIVE_COMPARATOR|Probiotic|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid probiotic (Symprove) daily following manufacturers guidelines for a period of 12 weeks."
61906158|NCT04140760|PLACEBO_COMPARATOR|Placebo|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid placebo daily for a period of 12 weeks following the same guidelines as for the probiotic."
62289287|NCT05827796|EXPERIMENTAL|Cohort 2: IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine)+KN046|Subjects will be treated with IN10018 25 mg/50 mg/100 mg, once daily, oral+ albumin-bound paclitaxel 125 mg/m2 IV infusion on Days 2 and 8 of each 21-Day Cycle+ gemcitabine 1000 mg/m2 IV infusion on Days 2 and 9 of each 21-Day Cycle+KN046 5 mg/kg IV infusion on Day 1 of each 21-Day Cycle.
62289288|NCT06253416|ACTIVE_COMPARATOR|Exercise group|The exercise group was received a home exercise program consist of stretching and strengthening exercises, which was demonstrated by a physiotherapist and supported by visual cards. The exercises were shown to the patients in practice for at least 5 repetitions three days a week for 12 weeks. The exercise tracking form was given to the patients. The patients were called by the physiotherapist every week by telephone, and were allowed to fill out the exercise tracking form and adapt to exercise. Once every four weeks, patients were called to the hospital a total of three times and exercises were shown again in practice. Exercises started with stretching exercises; for ten seconds for three times with ten seconds of rest between each exercise. After stretching exercises extremity strengthening exercises were practiced with half-kilogram weights for the upper and lower extremities, each exercise is performed ten times with ten seconds of rest.
62289289|NCT06253416|ACTIVE_COMPARATOR|Control group|The control group was told to exercise freely and without supervision. They were advised to exercise regularly, only verbally.
62289290|NCT00984204|EXPERIMENTAL|Treatment arm|
62289291|NCT03183544|EXPERIMENTAL|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
62289292|NCT05210595|EXPERIMENTAL|Control group|Clopidogrel 75 mg/day as maintenance dose
61906159|NCT00934648|EXPERIMENTAL|1|
61906160|NCT02220088|EXPERIMENTAL|TAI of FOLFOX|Retreatment With Transcatheter arterial infusion of oxaliplatin , fluorouracil, and leucovorin
61906161|NCT02220088|ACTIVE_COMPARATOR|Sorafenib|treatment with sorafenib
61906162|NCT04314791||US scan with calculation of the PAI|
61906163|NCT05638789|ACTIVE_COMPARATOR|EST alone|
61906164|NCT05638789|ACTIVE_COMPARATOR|EST + EPLBD|
61906165|NCT05554562||Injured athletes|Athletes suffering a groin injury
61906166|NCT03360864|EXPERIMENTAL|Therapeutic Education Program|"Patient randomized in this arm will attend a 1 day long validated Therapeutic Education Program.~This program will take place within 6 months after biologic treatment initiation."
61906167|NCT03360864|NO_INTERVENTION|No therapeutic Education Program|Patient randomized in this arm will not attend a Therapeutic Education Program within 12 months after biologic treatment initiation.
61906168|NCT05070780||Healthy Subjects|
61906169|NCT05070780||Patients with rigidity|
61906170|NCT05070780||Patients with spasticity|
61906171|NCT01394640||Healthy Volunteers|Healthy people without any serious comorbidity (no immunosuppressive treatment, no autoimmune disease, no cancer) receiving the same vaccine
61906172|NCT01394640||Onco-hematologic patients|Patients with lymphoma or myeloproliferative diseases or multiple myeloma either receiving chemotherapy or in follow-up or treated with allogeneic hematopoietic stem cell transplant.
61906173|NCT02619539||Trauma patients|All patients having / suspected to have severe trauma injuries admitted to participating centers.
62289293|NCT05210595|EXPERIMENTAL|Treatment group 1|De-escalation strategy dose receive ticagrelor 60 mg twice daily
62289294|NCT05210595|EXPERIMENTAL|Treatment group 2|De-escalation strategy dose receive ticagrelor 45 mg twice daily
62289295|NCT03658226|EXPERIMENTAL|Therapy|Psychodynamic Interpersonal Therapy (PIT)
62289296|NCT04551014|EXPERIMENTAL|With EverLift|Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.
62289297|NCT04551014|EXPERIMENTAL|Without EverLift|Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.
62289298|NCT03919643||SLE patients with nephritis|No intervention. Peripheral blood and urine samples will be obtained
62289299|NCT03919643||SLE patients with without nephritis|No intervention. Peripheral blood and urine samples will be obtained
62289300|NCT03919643||Healthy controls (blood donors)|No intervention. Peripheral blood and urine samples will be obtained
62091041|NCT02559817|EXPERIMENTAL|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to \<35 kg~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
62289301|NCT03803878||Group 1|Group 1 is anticipated to consist of 300 women with MUI, and the categorization function of MESA questionnaire will be validated among those patients.
62289302|NCT03803878||Group 2|Group 2 is anticipated to consist of 282 women with urgency-predominant MUI.
62091042|NCT02559817|EXPERIMENTAL|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to \<35 kg~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
62091043|NCT02559817|EXPERIMENTAL|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to \<35 kg~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
62091044|NCT02559817|EXPERIMENTAL|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
62091045|NCT02559817|PLACEBO_COMPARATOR|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age~Placebo solid oral capsule in children 12-17 years of age"
62091046|NCT02916472|EXPERIMENTAL|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
62091047|NCT02916472|ACTIVE_COMPARATOR|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
62091048|NCT04637035|EXPERIMENTAL|Supportive Oncology Care at Home|"Participants will receive the Supportive Oncology Care at Home program for 14 days following their discharge from the hospital.~The Supportive Oncology Care at Home intervention consists of three key components:~* Daily monitoring of patient-reported symptoms, vital signs, and body weight.~* Medically Home care based on algorithmic changes in patients' daily symptoms, vital signs, and body weight.~* Structured communication with the oncology team regarding care delivered to ensure continuity of care."
62091049|NCT05737030|EXPERIMENTAL|L-ornithine-L-aspertate|L-ornithine-L-aspertate 18g per day
62091050|NCT06692725||Taxanes combined with carboplatin sequential anthracycline|Paclitaxel, liposome paclitaxel, docetaxel, or albumin paclitaxel combined with carboplatin for 4 cycles, followed by anthracycline combined with cyclophosphamide for 4 cycles, and PD-1 inhibitor was used at the same time
62091051|NCT06692725||Taxanes combined with carboplatin|paclitaxel, liposome paclitaxel, docetaxel, or albumin paclitaxel combined with carboplatin for 6 cycles, and PD-1 inhibitor was used at the same time
62091052|NCT01692262|EXPERIMENTAL|Part A Group 1 Intermittent|Recruitment suspended and will not be re-opened. See intervention description below.
62091053|NCT01692262|EXPERIMENTAL|Part A Group 2 Intermittent|Recruitment complete. See intervention description below.
62289303|NCT03803878||Group 3|Group 3 is anticipated to consist of 94 women with urgency-predominant MUI.
62289304|NCT05585255||Acute ischemic stroke patients|Acute ischemic stroke patients with large vessel occlusion who received mechanical thrombectomy therapy and are successfully revascularized
62289305|NCT01232699|ACTIVE_COMPARATOR|Internet Obesity Treatment|Participants will attend weekly class sessions on line and track food and exercise in an on-line journal.
62289306|NCT01232699|EXPERIMENTAL|Internet Obesity Treatment with MI|Participants will attend weekly classes on line, record food and exercise in an on-line journal, and will have no more than 6 individual motivational interviewing sessions.
62091054|NCT01692262|EXPERIMENTAL|Part B|This part of the study will not be conducted following a review of data from Part A. See intervention description below.
62289307|NCT01232699|EXPERIMENTAL|Contingent MI|Intervention is the same as for the MI arm, however participants will only receive MI if meeting certain treatment participation conditions.
62289308|NCT06433076||Preference respiratory effort|The preference respiratory effort group was defined by either 1.5≤P0.1≤3.5 cmH2O, 5≤ predicted Pmus≤10 cmH2O, or predicted ΔPL≤20 cmH2O.
62289309|NCT06433076||Insufficiency respiratory effort|The insufficiency respiratory effort group was defined by either P0.1\<1.5 cmH2O or predicted Pmus \< 5 cmH2O.
62289310|NCT06433076||Excessive respiratory effort|The excessive respiratory effort group was defined by either P0.1 \> 3.5 cmH2O, predicted Pmus \> 10 cmH2O, or predicted ΔPL \> 20 cmH2O.
62289311|NCT05075668|ACTIVE_COMPARATOR|OSA support via CPAP face mask|Auto-titrated according to the settings made by sleep physicians, FiO2 0.21
62289312|NCT05075668|ACTIVE_COMPARATOR|OSA support via HFNC at 20 L/min|High flow nasal insufflation of air (FiO2 0.21) at 20 L/min
62289313|NCT05075668|ACTIVE_COMPARATOR|OSA support via HFNC at 30 L/min|High flow nasal insufflation of air (FiO2 0.21) at 30 L/min
62289314|NCT05075668|ACTIVE_COMPARATOR|OSA support via HFNC at 40 L/min|High flow nasal insufflation of air (FiO2 0.21) at 40 L/min
62091055|NCT05929846||In-Person|Participants will be assessed by a LiveWell specialist to assess functional goals and baseline capacity and design an individualized program. LiveWell specialist may also refer participants for an assessment with a physiotherapist based on a pre-defined criteria including redflag for serious conditions. Participants will engage in a 12-week program consisting of 45 minute sessions 3 times a week. Day 1 will include individualized program at the fitness center, Day 2 will include a group class exercises ending with mindfulness activities, action planning and education. Day 3 will consist of an independent day when participants can attend other classes at the YMCA or repeat the fitness center. In addition, there will be 12 virtual videos of education on self-management that will be discussed during the group activity day (Day 2) .
62289315|NCT00103012|EXPERIMENTAL|Effect of G. Biloba on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba).
62289316|NCT00103012|EXPERIMENTAL|Effect of Echinacea on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Echinacea purpurea).
62289317|NCT00103012|EXPERIMENTAL|Effect of P. ginseng on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Panax ginseng).
62655303|NCT06099275||Preeclampsia|People with preeclampsia will be recruited at the time of diagnosis or suspected diagnosis of preeclampsia, according to accepted definitions of preeclampsia,2 nulliparous, singleton pregnancy, ≥ 20 weeks' gestation, without any preexisting cardiovascular, hepatic, or respiratory problems, no preexisting uterine abnormality including benign tumors, or placental adhesive disorder, not in labor, prior to treatment for preeclampsia, body mass index ≤ 40 kg/m2, age 18 to 50 years. Preeclampsia with severe features will be defined using the American College of Obstetrics and Gynecology definition
62289318|NCT05490706|EXPERIMENTAL|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner
62289319|NCT05490706|EXPERIMENTAL|Walking|Performing a 30 minute walk after dinner
62289320|NCT05490706|NO_INTERVENTION|Non exercise control|Performing no exercise after dinner
62289321|NCT06076668|EXPERIMENTAL|Group D (n=30)|patients will receive intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
62289322|NCT06076668|EXPERIMENTAL|Group M (n=30)|patients will receive oral melatonin tablet 3 mg at 9:00 p.m.
62655304|NCT06099275||Healthy Normotensive|Healthy pregnant people will be defined as American Society of Anesthesiologists (ASA) Classification II with no significant medical or surgical illness, nulliparous (first pregnancy beyond 20 weeks' gestation), non-smokers, singleton pregnancy with no uterine abnormalities and normally defined placentation. They will not be receiving any vasoactive medication including salbutamol or thyroid replacement hormones or have ruptured membranes.
62655305|NCT03823157|EXPERIMENTAL|Tai Chi|Tai Chi exercise
62655306|NCT06133257|ACTIVE_COMPARATOR|GD Group|Patients will take oral clear fluids with carbohydrates content 2 hours preoperatively and intraoperative fluid intake will be guided by Inferior vena cava(IVC) diameter.
62655307|NCT06133257|ACTIVE_COMPARATOR|C Group|the standard fluid management group patients will be fasting 6 hours preoperatively and will receive intraoperative fluid in standard manner.
62655308|NCT05926492|EXPERIMENTAL|Surufatinib plus chemotherapy|Patients were to receive surufatinib plus chemotherapy every 30 days as neoadjuvant treatment. After receiving 2 cycles of treatment, patients will be evaluated for tumor necrosis rate.
62655309|NCT05926492|ACTIVE_COMPARATOR|Chemotherapy|Patients were to receive chemotherapy every 30 days as neoadjuvant treatment. After receiving 2 cycles of treatment, patients will be evaluated for tumor necrosis rate.
62655310|NCT00247286|EXPERIMENTAL|a|Weighted vaginal cones used to perform pelvic floor exercises
62655311|NCT00247286|ACTIVE_COMPARATOR|b|Biofeedback
62655312|NCT01273259|EXPERIMENTAL|200 mg /day arm|
62655313|NCT01273259|EXPERIMENTAL|25 mg/day arm|
62655314|NCT03873064||patients with solid tumor|All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
62655315|NCT04993846||Pancreatic cancer patients - Explorative phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments. An oral microbiota (dental plaque) sample will be collected and a periodontal and dental assessment will be performed, before any therapeutic procedure, together with orthopantomography
62289323|NCT06076668|PLACEBO_COMPARATOR|Control group|patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
62655316|NCT04993846||Healthy controls - Explorative phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
62655317|NCT04993846||Pancreatic cancer patients - Validation phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments.
62289324|NCT05643664|ACTIVE_COMPARATOR|Standart technology|the zone of aortic and main artery clamping is determined by the surgeon intraoperatively.
62289325|NCT05643664|EXPERIMENTAL|Artificial intellect|"The multispiral computed tomography data is evaluated using artificial intelligence and the definition of safe zones of aortic and main artery clamping is performed. Intraoperatively, clamping is performed in the settlement zones."
62289326|NCT03390140|EXPERIMENTAL|Group|ReInventing Yourself after SCI structured group CBT and ReInventing Yourself after SCI study-specific workbook
62289327|NCT03390140|ACTIVE_COMPARATOR|Indiv|ReInventing Yourself after SCI study-specific workbook and ReInventing Yourself after SCI YouTube videos
62289328|NCT03390140|NO_INTERVENTION|Control|No group sessions, no YouTube videos, no workbook
62289329|NCT00656890|PLACEBO_COMPARATOR|2|sterile saline for injection
62289330|NCT00656890|EXPERIMENTAL|1|MDX-1100 for injection
62289331|NCT05356767||post-thromboticsyndrome|suffering from PTS (Villalta score) at 2 years after operation.
62289332|NCT05356767||n-post-thromboticsyndrome|none of PTS (Villalta score) at 2 years after operation.
62289333|NCT03733912||Pregnancy|Infertile women undergoing in vitro fertilization cycle got pregnancy successfully. The pregnancy persisted over 12 weeks.
62289334|NCT03733912||Non-pregnancy|Infertile women undergoing in vitro fertilization cycle failed to reach pregnancy.
62289335|NCT03663166|EXPERIMENTAL|Radiation and Chemotherapy|Thoracic Radiotherapy with cytotoxic platinum based chemotherapy with cytotoxic platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology) and Ipilimumab.
62289336|NCT03663166|EXPERIMENTAL|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) after completion of radiation and chemotherapy for up to 12 cycles until progression.
62655318|NCT04993846||Healthy controls - Validation phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
62289337|NCT05100537|EXPERIMENTAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
62289338|NCT05100537|ACTIVE_COMPARATOR|CONTROL GROUP|no intervention
62289339|NCT02649257|EXPERIMENTAL|MC 6125 AS IOL + CTR|All patients received the same procedure: cataract surgery with phakoemulsification, implantation of a capsular tension ring (CTR13/11) and implantation of an intraocular lens (MC 6125 AS).
62655319|NCT04993846||IPMN patients controls - Validation phase|Patients suffering from IPMNs evaluated at outpatients clinics or scheduled for surgery.
62655320|NCT03236792|EXPERIMENTAL|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
62289340|NCT05840614|EXPERIMENTAL|The remote family support program plus TAU|Behavioral: The remote family support program Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.
62289341|NCT05840614|NO_INTERVENTION|Treatment as Usual|Treatment as usual administrated by physician.
62289342|NCT02078349|EXPERIMENTAL|Solid Tumors|"Patients will receive Selinexor once weekly (Schedule 1) or twice weekly (Schedule 2) or three times a week (Schedule 3) orally at a starting dose of 50 mg/m² (Schedule 1) and 40mg/m2 (Schedule 2) and 20mg/m2 (Schedule 3).~One cycle is 28 days for Schedule 1 and Schedule 3 and 21 days for Schedule 2. Treatment will continue until disease progression or the development of unacceptable toxicities."
62289343|NCT00989989|EXPERIMENTAL|Adjunctive treatment|Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.
62655321|NCT01408693|ACTIVE_COMPARATOR|Anterior minimal invasive approach, AMIS|AMIS in 95 randomized patients.
61906174|NCT00060359|EXPERIMENTAL|Treatment (paclitaxel poliglumex, carboplatin)|"DOSE-ESCALATION PHASE: Patients receive CT-2103 IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of CT-2103 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of treatment.~FEASIBILITY PHASE: Once the MTD of CT-2103 is determined, an additional 20-40 patients receive treatment at that dose level combined with carboplatin as above."
61906175|NCT02114658|EXPERIMENTAL|Arm 1|Sorafenib 400 mg bid continuous dose
62655322|NCT01408693|ACTIVE_COMPARATOR|Trans-gluteal approach, CLAS|CLAS in 95 randomized patients.
62655323|NCT00862992|EXPERIMENTAL|1|
62655324|NCT00862992|EXPERIMENTAL|2|
62655325|NCT00862992|EXPERIMENTAL|3|
61906176|NCT05414734|EXPERIMENTAL|SAD HHT120|Subjects will receive a single dose of HHT120 from 7 doses.
62091056|NCT05929846||e-Health|Participants will be assessed by a LiveWell specialist to assess functional goals and baseline capacity and provide recommendation on exercise modifications and the program. LiveWell specialist may also refer participants for an assessment with a physiotherapist based on a pre-defined criteria including redflag for serious conditions. Participants will engage in a 12-week program consisting of 45 minute sessions 3 times a week. They will be provided with 3 exercise videos (including 3 levels of exercises per video) and will also have access to the on-demand YMCA platform for additional videos. In addition, there will be 12 virtual videos of education on self-management that will be discussed during follow-up phone calls. Participants will also be provided with an action planning document to complete at home. All online participants will have a phone call with the LiveWell specialist at 3 and 7 weeks to discuss the program, action planning and the education materials.
62655326|NCT02514863||Patients undergoing CMR|"Assessment of hemodynamic function using:~* CMR~* EV with an inter-electrode gap (lower pair) of 5 cm~* EV with an inter-electrode gap (lower pair) of 15 cm"
61906177|NCT05414734|PLACEBO_COMPARATOR|SAD Placebo|Subjects will receive a single dose of matched Placebo.
61906178|NCT05414734|EXPERIMENTAL|MAD HHT120|Subjects will receive a mutiple-dose of HHT120 twice daily for 7 days from 3 doses.
62655327|NCT02026141|EXPERIMENTAL|Dexmedetomidine arm|"Standardized pre-op meds and spinal anesthetic.~Once the patient's spinal is performed, patient will receive the following:~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr~Infusion will be stopped after the last staple or suture is performed on the incision.~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA."
62655328|NCT02026141|PLACEBO_COMPARATOR|Saline Placebo|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation."
62655329|NCT04518085|EXPERIMENTAL|Hypnosis + iACT|Single 20 minute medical hypnosis session delivered pre-surgery plus internet-based acceptance and commitment therapy delivered post-surgery
62655330|NCT04518085|ACTIVE_COMPARATOR|Mindfulness + treatment as usual (TAU)|Single 20 minute mindfulness session delivered pre-surgery plus treatment as usual post-surgery
61906179|NCT05414734|PLACEBO_COMPARATOR|MAD Placebo|Subjects will receive a mutiple-dose of matched placebo twice daily for 7 days.
61906180|NCT05414734|EXPERIMENTAL|FE K-C|Subjects will receive a single dose of HHT120 in the morning in fasted condition in Period 1; followed by a single dose of HHT120 administered in the morning in fed condition in Period 2. A washout period of 7 days will be maintained between 2 periods.
61906181|NCT05414734|EXPERIMENTAL|FE C-K|Subjects will receive a single dose of HHT120 in the morning in fed condition in Period 1; followed by a single dose of HHT120 administered in the morning in fasted condition in Period 2. A washout period of 7 days will be maintained between 2 periods.
61906182|NCT04160975|EXPERIMENTAL|Black R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
61906183|NCT04160975|EXPERIMENTAL|Black R/Race C/Layperson/Standard Script|Video which contains a racially concordant actor playing a layperson and reading a standard script. The receiver of the message will be Black.
61906184|NCT04160975|EXPERIMENTAL|Black R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
61906185|NCT04160975|EXPERIMENTAL|Black R/Race D/Doctor/Acknowledgement Script|Video which contains a racially discordant actor playing a doctor and reading an acknowledgement script. The receiver of the message will be Black.
61906186|NCT04160975|EXPERIMENTAL|White R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
61906187|NCT04160975|EXPERIMENTAL|White R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
61906188|NCT06255197||Patients with surgically resected lung cancer|Patients who were diagnosed with lung cancer and received surgical resection in participating medical centers during the designed study period.
61906189|NCT00985920|EXPERIMENTAL|Tranexamic acid, 1.5 g|1.5 g of tranexamic acid in 50 cc of normal saline solution is given to the patients.
61906190|NCT00985920|EXPERIMENTAL|Tranexamic acid, 3.0 g|3.0 g of tranexamic acid in 50 cc of normal saline is given to the patients.
62655331|NCT05927688||Patients whose physician used the electronic platform to access ePRO|
62655332|NCT05927688||Patients whose physician did not used the electronic platform and did not access ePRO|
62463222|NCT01944267|ACTIVE_COMPARATOR|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
62655333|NCT04444869|OTHER|Open label single-arm study|All patients will receive concurrent cisplatin and radiation therapy with radiation dose de-escalation to clinically and radiologically uninvolved lymph nodes.
62655334|NCT04719559|OTHER|Post-Thyroidectomy Hypertrophic Scar|Patients had all presented a persistent hypertrophic scar at the neck region for more than 1 year after their thyroidectomy.
61906191|NCT00985920|PLACEBO_COMPARATOR|Placebo, saline|50 cc of sterile normal saline solution is given to the patients.
62655335|NCT00833326|EXPERIMENTAL|ARRY-334543 + docetaxel + prophylactic growth factors|
62655336|NCT01337934|PLACEBO_COMPARATOR|Lactated Ringer|Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
62655337|NCT01337934|ACTIVE_COMPARATOR|Albumin|Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
62655338|NCT00888745|EXPERIMENTAL|1|
61906192|NCT03658876|ACTIVE_COMPARATOR|EPO group|
61906193|NCT03658876|ACTIVE_COMPARATOR|Iron group|
61906194|NCT04120298|EXPERIMENTAL|Supervised exercise group|"The intervention group will participate in a 9-month exercise intervention. The exercise program will start with a 6-month period, where patients participate in a supervised multimodal exercise program twice a week supplemented with unsupervised exercises. The multimodal exercise program comprises aerobic-, resistance- and balance components. After completing the initial six-month period, one supervised session will be replaced by one unsupervised session until month nine.~Unsupervised exercises will be supported by an activity tracker (FitBit) and an exercise App specifically designed for the EFFECT trial"
61906195|NCT04120298|NO_INTERVENTION|Control group|Patients randomized to the control group will also receive an activity tracker (like the intervention group). We will advice control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150min/week in line with the current exercise guidelines.
61906196|NCT04144127|EXPERIMENTAL|Soccer Group|Participants in the soccer group will participate in soccer drills and other fitness routines (two 1-hour sessions per week). They will meet with the soccer coach after the soccer sessions to discuss the lifestyle education topics (Life's Simple 7 education topics). During the soccer sessions participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
61906197|NCT00988650|ACTIVE_COMPARATOR|North American diet|Control North American diet for five weeks in isocaloric conditions
62289344|NCT00989989|EXPERIMENTAL|Monotherapy treatment|Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.
62655339|NCT00888745|PLACEBO_COMPARATOR|2|
62655340|NCT04017962|EXPERIMENTAL|Hematopoietic cell transplantation/HCT|"Participants will be hematopoietic cell transplantation (HCT) recipients with a history of CMV infection. INTERVENTIONAL COHORT: Patients receive letermovir PO QD (or IV over 1 hour for patients unable to receive PO) for 14 weeks in the absence of disease progression or unacceptable toxicity.~OBSERVATIONAL COHORT: Patients undergo collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180."
61906198|NCT00988650|EXPERIMENTAL|Mediterranean diet|Mediterranean diet for five weeks in isocaloric conditions
61906199|NCT00988650|EXPERIMENTAL|weight loss period|Weight loss period of 20-week (minimum 5% reduction in body weight)
61906200|NCT00988650|ACTIVE_COMPARATOR|Weight stabilizing mediterranean diet|Mediterranean diet for five weeks in isocaloric weight stabilizing conditions
61906201|NCT01529775|EXPERIMENTAL|Osseotite Certain Tapered Prevail|Osseotite Certain Tapered Prevail design with platform switching feature
61906202|NCT01529775|ACTIVE_COMPARATOR|Osseotite Certain Tapered|Osseotite Certain Tapered implant with non-platform switching design
62289345|NCT00989989|ACTIVE_COMPARATOR|Laser control|Active laser treatment plus sham intravitreal injections.
62289346|NCT03311971|SHAM_COMPARATOR|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
61906203|NCT05392413||reactive group|According to the treatment effect, the patients were divided into two groups: reactive and non-reactive.
61906204|NCT05392413||non-reactive group|According to the treatment effect, the patients were divided into two groups: reactive and non-reactive.
61906205|NCT01944280|EXPERIMENTAL|intervention|The intervention group will receive a 20 minute massage during each hemodialysis treatment for 2 weeks. Most patients receive dialysis 3 times per week resulting in 6 massage sessions. The massage will include both feet and legs up to and including the knee. Massage will include general light centripetal friction and point compression to bellies and myotendinous junction of muscles of the foot and calf not to exceed a perceived pain of 6 on a scale of 1 to 10, 10 being most severe and 1 being no pain.
61906206|NCT01944280|NO_INTERVENTION|control|usual care
61906207|NCT05365685|EXPERIMENTAL|adolescents with obesity|There is only one arm as this is an acute randomized study comparing three different conditions within the same sample of participants.
61906208|NCT04671446||Severe eosinophilic asthma and/or EGPA|
62091057|NCT05781529|EXPERIMENTAL|Injectable platelets rich fibrin|Injectable platelets rich fibrin was prepared where 10 ml of patient venous blood was centrifuged without anti-coagulants (plain plastic glass-coated) at 700 rpm speed for only 3 minutes, xenograft was mixed with I-PRF to make sticky bone, sticky bone was placed into extraction socket till the socket was fully filled up to the gingival margin
62091058|NCT05781529|EXPERIMENTAL|Hyaluronic acid|Hyaluronic acid (HA) syringe containing 1 mL of cross-linked hyaluronic at a concentration of 20 mg/ml in a saline phosphate buffer solution at sterilized content was used. HA was mixed with particulate xenograft 1:10 ratio to form a putty consistency for condensation and was placed into extraction socket till the socket was fully filled up to the gingival margin
62091059|NCT05781529|ACTIVE_COMPARATOR|Xenograft|Xenograft was mixed with saline, placed in extraction socket till the socket is fully filled up to the gingival margin
61906209|NCT04671446||Other respiratory conditions|Milder asthma, other vasculitides, eosinophilic COPD, and/or eosinophilic oesophagitis
61906210|NCT04671446||Healthy controls|
61906211|NCT02537288|EXPERIMENTAL|Placebo matched to fedovapagon|One dose of placebo (matched to fedovapagon)
62655341|NCT01987115|EXPERIMENTAL|Fascial Manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
61906212|NCT02537288|EXPERIMENTAL|Fedovapagon 2 mg|One dose of 2 mg fedovapagon
61906213|NCT02537288|EXPERIMENTAL|Fedovapagon 20 mg|One dose of 20 mg fedovapagon
61906214|NCT02537288|EXPERIMENTAL|Moxifloxacin 400 mg (open label)|One dose of moxifloxacin 400 mg (open label)
61906215|NCT03031002|EXPERIMENTAL|Exposure Treatment|Participants of this arm receive two 60-minute sessions of exposure treatment for spider fear
61906216|NCT03031002|NO_INTERVENTION|No Exposure Treatment|Participants of this arm receive no exposure or other adequate treatment
61906217|NCT04732390|PLACEBO_COMPARATOR|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
61906218|NCT04732390|ACTIVE_COMPARATOR|Group (M)|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5. .
61906219|NCT01879644|ACTIVE_COMPARATOR|Neurofeedback with Psychoeducation (NF + PE)|Neurofeedback plus Parental Psychoeducation
61906220|NCT01879644|ACTIVE_COMPARATOR|Self-Management with Psychoeducation (SM + PE)|Self-management + parental psychoeducation
61906221|NCT01879644|ACTIVE_COMPARATOR|NF+PE and additional Social Support (SU)|Neurofeedback + parental psychoeducation enhanced with social support
61906222|NCT01879644|ACTIVE_COMPARATOR|SM+PE and additional Social Support (SU)|Self-management + parental psychoeducation enhanced with social support
61906223|NCT01757158|EXPERIMENTAL|Cs-131 brachytherapy seeds|sub-lobar resection plus cesium-131 brachytherapy
61906224|NCT01811056|NO_INTERVENTION|In-Center Use of Mifepristone|Participants who choose to take mifepristone in the center
61906225|NCT01811056|EXPERIMENTAL|Out-of-Center Use of Mifepristone|Participants who choose to take the mifepristone outside of the center
61906226|NCT01191567|ACTIVE_COMPARATOR|Conventional treatment|
61906227|NCT01191567|EXPERIMENTAL|VAC treatment|
61906228|NCT04359381|EXPERIMENTAL|kinesiotaping|by kinesiotaping during menstruation for 3 successive menstruation
61906229|NCT04359381|EXPERIMENTAL|pilate exercises|pilate exercises, 3 sessions per week for 3 months
62091060|NCT01511627|ACTIVE_COMPARATOR|General Anesthesia|
62091061|NCT01511627|EXPERIMENTAL|General Anesthesia + Spinal Anesthesia|
62091062|NCT02988375|EXPERIMENTAL|dCBTI|Online access to the digital CBTI program Sleepio
62091063|NCT02988375|PLACEBO_COMPARATOR|Sleep Education|Weekly email messages with sleep hygiene recommendations
62655342|NCT01987115|ACTIVE_COMPARATOR|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
62655343|NCT04043026||WP1: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease
62655344|NCT04043026||WP1: AF + no CKD|Anticoagulated participants with atrial fibrillation and no chronic kidney disease
62655345|NCT04043026||WP1: no AF + CKD|Anticoagulated participants with chronic kidney disease and no atrial fibrillation
62289347|NCT03311971|EXPERIMENTAL|Virtual reality glasses|Patient undergoing conventional analgesic therapy after total knee replacement and treated with virtual glasses
62289348|NCT04931836|EXPERIMENTAL|Experimental Group|Participants in this group will complete the physical activity intervention.
62289349|NCT04931836|NO_INTERVENTION|Control Group|Participants in this group will be asked to maintain their normal level of physical activity.
62289350|NCT03377920|EXPERIMENTAL|Severe asthma patients; COPD patients|Cross sectional study Lung function measurement
62289351|NCT01880307|EXPERIMENTAL|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
62289352|NCT01880307|ACTIVE_COMPARATOR|Step-up|Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
62289353|NCT02313740||Healthy adults group|Healthy adults aged 18 to 59 years Butantan Fragmented Inactivated Trivalent Influenza Vaccine
62655346|NCT04043026||WP1: no AF + no CKD|Anticoagulated participants without atrial fibrillation or chronic kidney disease
62655347|NCT04043026||WP2: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease, and are commencing statin therapy
61906230|NCT03584581|EXPERIMENTAL|Olive polyphenols|
61906231|NCT03584581|PLACEBO_COMPARATOR|Control|
62091064|NCT01455740|EXPERIMENTAL|Provider Visit Incentive (PVI)|"Participants were told that they would receive $30 after attending each scheduled provider visit (a CCT).~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 21 individuals to the PVI arm."
62289354|NCT02313740||Elderly group|Elderly aged over than 60 years completed Butantan Fragmented Inactivated Trivalent Influenza Vaccine
62289355|NCT04872491||Participants With UC or CD|Participants diagnosed with UC or CD who are prescribed and will start treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, 6, and every 8 weeks thereafter for up to 54 weeks will be observed prospectively for 72 weeks.
62289356|NCT04244344|EXPERIMENTAL|interventional|"all High fall risk subjects who meet the criteria by STRATIFY Tool"
62289357|NCT03835091||Patient with mechanical ventilation and sedation|All patient hospitalized in intensive care under sedation and mechanical ventilation without neurologic disorder
62655348|NCT02965170||MS Tysabri|Patients with relapsing forms of multiple sclerosis and who are currently undergoing Tysabri® therapy at Rocky Mountain Multiple Sclerosis Research Group.
62655349|NCT02453048|EXPERIMENTAL|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
62655350|NCT02453048|EXPERIMENTAL|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
61906232|NCT00361933|EXPERIMENTAL|1|
62655351|NCT02453048|EXPERIMENTAL|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
62655352|NCT02453048|EXPERIMENTAL|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
62655353|NCT05273359|ACTIVE_COMPARATOR|Benralizumab Intervention|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
62655354|NCT05273359|PLACEBO_COMPARATOR|Benralizumab Placebo|15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
62655355|NCT05273359|OTHER|Comparison (control) group; no intervention|15 subjects (\<150 eosinophils/microliter) will not receive any intervention.
61906233|NCT04263584|EXPERIMENTAL|Copanlisib and R-CHOP chemotherapy|All patients will receive 6 cycles of R-CHOP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/ m², vincristine 1.4 mg/m² (dose capped at 2 mg or 1 mg for individuals above 60 years of age), prednisolone 500 mg. In addition, copanlisib at a dose of 60 mg will be administered on days 1 and 8 of each 21-day cycle of R-CHOP in the first 6 patients. If dose limiting toxicity (DLT) occurs in no more than one out of these 6 patients during cycle 1, additional 6 patients at 60 mg will be enrolled and treated for at least 1 cycle before opening the phase II portion of the study. If a DLT is observed in 2 or more of the first 6 patients during cycle 1 the dose of copanlisib will be reduced to 45 mg on days 1 and 8 for the next 6 patients. The data of the safety run-in analysis (first 12 patients) will be presented to the Data Safety Monitoring Board and the recommended phase 2 dose will be determined.
61906234|NCT03010371|EXPERIMENTAL|Positive Psychotherapy|A group of breast cancer survivors are randomly allocated to the presential version of the positive psychotherapy
62289358|NCT05976256|ACTIVE_COMPARATOR|Kinesiotape|Patients receives the additional treatment with kinesiotaping (and also standard treament)
62289359|NCT05976256|SHAM_COMPARATOR|sham tape|patient receives an additional treatment with sham tape (without elastic features) (and also standard treatment)
62655356|NCT04479072|ACTIVE_COMPARATOR|Intervention Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of aspirin 81 mg.
62655357|NCT04479072|PLACEBO_COMPARATOR|Placebo Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of a placebo pill
62655358|NCT04479072|NO_INTERVENTION|Observational Arm|60 subjects will be placed in the observational arm. These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.
61906235|NCT03010371|EXPERIMENTAL|Positive Online Psychotherapy|A group of breast cancer survivors are randomly allocated to the online version of the positive psychotherapy
62289360|NCT05976256|NO_INTERVENTION|control group|patient receives the standard treamtment without additional tape treatment
62289361|NCT04923594|ACTIVE_COMPARATOR|NLS-2 (mazindol extended release)|2 mg dosed orally, once daily for 1 week; followed by 3 mg dosed orally, once daily for up to 3 weeks (total of 4 weeks)
62655359|NCT01563081|EXPERIMENTAL|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution
62655360|NCT03385538|EXPERIMENTAL|Clopidogrel non-responders|Increasing doses og Clopidogrel depending on PRU values measured on VerifyNow
61906236|NCT03010371|EXPERIMENTAL|Cognitive Behavioral Therapy|A group of breast cancer survivors are randomly allocated to the presential cognitive behavioral therapy (Cognitive Behavioral Stress Management, CBSM)
62289362|NCT04923594|PLACEBO_COMPARATOR|Placebo|Dosed orally, once daily for up to 4 weeks
62289363|NCT03983499|EXPERIMENTAL|Special Intervention|The special intervention (SI) arm addresses glycemic control, medication adherence, control of modifiable CVD risk factors, health behavior change, and psychosocial and cultural barriers to self-management. The SI arm consists of a collaborative care team approach with four main elements including: 1) Specialized clinical care by a medical provider; 2) Specialized behavioral health care by a behavioral health provider; 3) Group-based chronic disease self-management education by peer-leaders; 4) Intensive, proactive care coordination facilitated by a patient registry and electronic health records.
62289364|NCT03983499|NO_INTERVENTION|Usual Care|Participants randomized to the Usual Care (UC) arm continue to see their primary care provider and receive referrals to health education. At the discretion of the provider, UC patients are screened and referred to behavioral health (BH) care.
62289365|NCT01185847|EXPERIMENTAL|A non-squamous|
62289366|NCT01185847|EXPERIMENTAL|A squamous|
62289367|NCT01185847|ACTIVE_COMPARATOR|B non-squamous|
62289368|NCT01185847|ACTIVE_COMPARATOR|B squamous|
62655361|NCT00970554|ACTIVE_COMPARATOR|Patching only|
62655362|NCT00970554|EXPERIMENTAL|Patching plus telescope group|
62655363|NCT04005742||Healthy|Participants recruited to the healthy arm of the BORICC Study (BORICC1) at baseline.
62655364|NCT04005742||Polyp|Participants recruited to the polyp arm of the BORICC Study (BORICC2) at baseline, with a prior history of polyps.
62655365|NCT02543840|EXPERIMENTAL|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
62289369|NCT03371563||elderly patients|
62655366|NCT02543840|PLACEBO_COMPARATOR|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
62655367|NCT03640819|EXPERIMENTAL|Tattooing of biopsied node|The biopsied node will be tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or separate visit under ultrasound guidance.
61906237|NCT02970682|EXPERIMENTAL|Aromatase Inhibitor|SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
61906238|NCT02970682|EXPERIMENTAL|Fulvestrant|SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
62289370|NCT03371563||middle-aged patients|
62289371|NCT03371563||controls|
62289372|NCT03371563||young patients|
62655368|NCT06059144|EXPERIMENTAL|Induced hypertension using norepinephrine|"Standard care and peripheral intravenous norepinephrine. Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.~Standard care includes antithrombotic treatments according to the physician's choice and ESO recommendations"
62655369|NCT06059144|NO_INTERVENTION|Standard care|Standard care includes antithrombotic treatments according to the physician's choice and ESO recommendations
62655370|NCT05252338|EXPERIMENTAL|Younger Adults group aged 18-55 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
62655371|NCT05252338|EXPERIMENTAL|Adults group aged ≥65 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
62655372|NCT05264532|EXPERIMENTAL|Arm A (video via text message)|Participants receive a 2-minute information-graphic video via text message consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives that they can share with family via text message, email, or social media.
62655373|NCT05264532|ACTIVE_COMPARATOR|Arm B (letter via standard U.S. mail)|Participants receive family letter via U.S. postal service mail consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives.
61906239|NCT02970682|EXPERIMENTAL|Tamoxifen|SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).
61906240|NCT04655196|EXPERIMENTAL|Internet-based self-help + weekly feedback by a coach|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text, audio and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly feedback by a coach.
61906241|NCT04655196|EXPERIMENTAL|Internet-based self-help + weekly automated messages|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text-, audio- and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly automated messages in order to increase motivation.
61906242|NCT04655196|NO_INTERVENTION|Waiting control group|
62289373|NCT02893345|EXPERIMENTAL|Safe@Home Intervention Group|Participants receive: (1) computer-generated, personalized assessment of abilities, risk, and recommended next steps; (2) 2 person-family education visits to develop a shared understanding of client strengths and risks, set goals, develop better ways to work as a team, and problem-solve; (3) 8 in-home visits in which personal transition trainer/life skills coach provides training, compensatory strategies, and social/technological supports on self-selected activities. The ten visits last 90-120 minutes and ideally take place over a three month period.
62289374|NCT02893345|ACTIVE_COMPARATOR|Usual Care Group|Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
62289375|NCT01993472|EXPERIMENTAL|Andrographolides with Capecitabine|Capecitabine1250mg/m2 , bid，d1-14，q3w, Andrographolides 500mg，qd，d1-14，q3w;
62289376|NCT01993472|ACTIVE_COMPARATOR|Capecitabin alone|Capecitabine1250mg/m2 , bid，d1-14，q3w,
61906243|NCT04863183|ACTIVE_COMPARATOR|Group 1 (control-Triamcinolone acetonide)|Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).
61906244|NCT04863183|EXPERIMENTAL|Group 2 (experimental- CELLISTEM-OA)|CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time).
61906245|NCT00859027|EXPERIMENTAL|Risedronate|35 mg by mouth every week as directed
61906246|NCT00859027|PLACEBO_COMPARATOR|risedronate placebo tablet|Calcium and vitamin D
61906247|NCT00732940|EXPERIMENTAL|Belimumab Q2WKS|Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
62289377|NCT01557790|EXPERIMENTAL|Proton RT|Subjects receive proton radiation for seminoma
62307961|NCT06479005|EXPERIMENTAL|interventional feasibility study arm|Patients will receive a wearable device to monitor vital parameters continuously from the first round of chemo until the last cycle (approx 15 weeks).
62307962|NCT05175859||Early tracheostomy|Tracheostomy time before day 10 following endotracheal airway management and invasive ventilation.
62307963|NCT05175859||Late tracheostomy|Tracheostomy time after day 11 following endotracheal airway management and invasive ventilation.
62655374|NCT01392781||normoweight PCOS patients|
62655375|NCT01392781||normoweight controls|
62655376|NCT01392781||overweight plus obese PCOS patients|
62655377|NCT01392781||overwqeight plus obese controls|
62655378|NCT01222299|EXPERIMENTAL|Arm 1 - Low Dose|bepotastine besilate nasal product - low dose
62307964|NCT05101707|EXPERIMENTAL|CIMT + taVNS|The investigators will deliver taVNS paired with 40h of Constraint Induced Movement Therapy for unilateral weakness/hemiplegia
62307965|NCT01591590|EXPERIMENTAL|All Patients|This is an Interventional, Non Therapeutic arm
62655379|NCT01222299|EXPERIMENTAL|Arm 2 - Medium Dose|bepotastine besilate nasal product - medium dose
62655380|NCT01222299|EXPERIMENTAL|Arm 3 - High Dose|bepotastine besilate nasal product - high dose
62655381|NCT01222299|PLACEBO_COMPARATOR|Arm 4 - Placebo|placebo comparator nasal product
62655382|NCT01821313|EXPERIMENTAL|Moderate exercise|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The moderate exercise group will begin with a five-minute warm-up, cycling at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the moderate group will cycle for 30 minutes at 65-70% of maximal heart rate. The subject will then complete a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
62655383|NCT01821313|ACTIVE_COMPARATOR|High Intensity Interval Exercise (HIIE)|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The subjects in the HIIE group will begin with a five-minute warm-up at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the HIIE group will perform 10, two-minute exercise bouts at 90-95% of maximal heart rate, with one minute of active recovery at 55% of maximal heart rate between each interval for a total of 30 minutes. They will complete the test with a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
62655384|NCT01260129|EXPERIMENTAL|Silodosin 8 mg|
62655385|NCT01260129|EXPERIMENTAL|Silodosin 4 mg|
62655386|NCT04179630|EXPERIMENTAL|Aldafermin (NGM282)|Administered by subcutaneous injection
62091065|NCT01455740|EXPERIMENTAL|Incentive Choice (IC)|"Participants were given a choice between the CCT described in the PVI arm and a commitment contract, which made the $30 payment conditional on the patient attending the provider visit AND meeting an ART adherence threshold.~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 19 individuals to the IC arm."
62655387|NCT02478333|EXPERIMENTAL|ALS-008176 (250 mg) or Placebo|Participants will receive ALS-008176, 250 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
62655388|NCT02478333|EXPERIMENTAL|ALS-008176 (500 mg) or Placebo|Participants will receive ALS-008176, 500 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
62289378|NCT01705015|EXPERIMENTAL|UCFit plus direct feedback about exercise|Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs. These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged. Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters. Graphical displays that can be used for feedback will be available at the patient's bedside. The staff, patient and family will be able to view these bar graphs.
62289379|NCT01705015|PLACEBO_COMPARATOR|UCFit plus encouraged exercise|These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs. The coordinator will only encourage these subjects to try to increase their total cycling time. These bar graphs will not be posted, but will be left by the bedside.
62289380|NCT00372892|ACTIVE_COMPARATOR|A|Rituximab
62289381|NCT00372892|PLACEBO_COMPARATOR|B|Saline placebo iv infusion
62289382|NCT01354132|ACTIVE_COMPARATOR|n-acetyl-cysteine|N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks
62289383|NCT01354132|PLACEBO_COMPARATOR|Placebo|matching effervescent tablets in water 2 in am and 1 in pm
62655389|NCT02478333|EXPERIMENTAL|ALS-008176 (750 mg) or Placebo|Participants will receive ALS-008176, 750 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
62655390|NCT03769493|EXPERIMENTAL|Mobile After-Care Support (MACS) app|All participants will download the MACS app to their mobile phone (or a study provided phone, as needed). The app runs through the third-party platform, mEMA, designed by Ilumivu. It is designed to prompt engagement through questions and tailored responses at multiple times throughout the day and provide brief interventions.
61906248|NCT00732940|EXPERIMENTAL|Belimumab 3X/WK|Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
61906249|NCT04554056|EXPERIMENTAL|MW05 300μg/kg|Subjects will receive MW05(300 μg/kg s.c.) on day 3 of each cycle (6\~10 a.m.)
62091066|NCT01455740|NO_INTERVENTION|Passive Control (PC)|The study also included 70 individuals in a PC arm, who did not receive financial incentives. Individuals in the PC arm were not enrolled in the randomized trial but met basic study eligibility criteria during the same time period.
62655391|NCT05729321||Epicutaneo-caval catheter removed electively|This is a pilot study designed to evaluate the patency of the Epicutaneo-caval catheter after its closure for 1 hour in order to assess the feasibility of possible Taurolidine lock-terapy in Epicutaneo-Caval Catheters.
61906250|NCT04554056|EXPERIMENTAL|MW05 500μg/kg|Subjects will receive MW05(500 μg/kg s.c.) on day 3 of each cycle (6\~10 a.m.)
62289384|NCT05331911|EXPERIMENTAL|Propofol Group|The propofol group was maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
62655392|NCT04319224|EXPERIMENTAL|Vopratelimab|Participants will continue to receive vopratelimab monotherapy per parent protocol.
61906251|NCT04554056|ACTIVE_COMPARATOR|PEG-rhG-CSF|Subjects will receive PEG-rhG-CSF(100 μg/kg s.c.) on day 3 of each cycle (6\~10 a.m.)
61906252|NCT02909387|EXPERIMENTAL|Stratum A|This group will be the first to receive the Project UPLIFT intervention, a distance-delivered mindfulness-based cognitive therapy intervention. The intervention is conducted by phone for one hour once a week for 8 weeks.
62289385|NCT05331911|EXPERIMENTAL|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
61906253|NCT02909387|ACTIVE_COMPARATOR|Stratum B|This group will also receive the Project UPLIFT intervention at crossover, after a 10-week waiting period.
61906254|NCT04248621|EXPERIMENTAL|Intermittent Androgen Deprivation|ADT including luteinizing hormone-releasing hormone (LHRH) agonist and antagonist, antiandrogen, or maximum androgen blockade (MAB) should be withdrawn after 6 months of ADT, if the prostate-specific antigen (PSA) reaches its nadir (\< 4 ng/dL) and serum testosterone reaches castration level (\< 50 ng/dL).
61906255|NCT04248621|ACTIVE_COMPARATOR|Continuous Androgen Deprivation|ADT including LHRH agonist and antagonist, antiandrogen, or MAB without any discontinuation during study period.
61906256|NCT02346773|ACTIVE_COMPARATOR|ω-3 LC-PUFA group|The intervention product was a full fat (80%) margarine. The active intervention product contained 590 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) per 10-g daily serving.
61906257|NCT02346773|PLACEBO_COMPARATOR|Placebo group|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
62289386|NCT05725304||kidney cancer|RCC arms: Retrospective studies for ccRCC (N=100) and nccRCC (N=100). The studies aim to obtain clinical information to correlate with genetic characterization of RCCs of all types.
62289387|NCT05725304||urothelial cancer|UC arm: This is a prospective study for UC originated from the translational epithelium in the urinary tract (N=300). The study aims to obtain cancer tissues that originated from bladder (N=100), ureter (N=100), and renal pelvis (N=100).
62289388|NCT00747487|EXPERIMENTAL|1|Idebenone
62289389|NCT00747487|PLACEBO_COMPARATOR|2|Placebo
62289390|NCT01499173|EXPERIMENTAL|Stroke preparedness intervention|Youth and adults from predominately African American churches in Flint will be enrolled to undergo a faith-based, scientific theory-driven, peer-led behavioral intervention utilizing a pre-post test design.
62289391|NCT02060422|PLACEBO_COMPARATOR|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
62289392|NCT02060422|EXPERIMENTAL|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
62289393|NCT03381456|EXPERIMENTAL|Healthy subject|LICI
62289394|NCT03381456|EXPERIMENTAL|Dystonic subject|LICI
62289395|NCT01105390|EXPERIMENTAL|Treatment (rilotumumab, cisplatin, pemetrexed disodium)|Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
62289396|NCT01763164|EXPERIMENTAL|MEK162|
62289397|NCT01763164|ACTIVE_COMPARATOR|Dacarbazine|
62289398|NCT05309824||Atrial fibrillation|
62289399|NCT05309824||Left ventricular hypertrophy|
62289400|NCT05309824||Pulmonary hypertension|
62289401|NCT05309824||Coronary atherosclerotic heart disease|
62289402|NCT05309824||Heart failure with retained ejection fraction|
62289403|NCT03842566||20-29 Years Old|
62289404|NCT03842566||30-39 Years Old|
62289405|NCT03842566||40-49 Years Old|
62289406|NCT03842566||50-59 Years Old|
62289407|NCT03842566||60-69 Years Old|
62655393|NCT04319224|EXPERIMENTAL|Vopratelimab with ipilimumab|Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
62655394|NCT04319224|EXPERIMENTAL|Vopratelimab with nivolumab|Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.
62655395|NCT05745168||MSM-TGW|
62655396|NCT00966576|EXPERIMENTAL|Brinzolamide/Timolol Maleate Fixed Combination|
62655397|NCT05557214|EXPERIMENTAL|Audit and Feedback Letter|This group will receive 2 audit and feedback letters and a study closure letter.
62655398|NCT05557214|NO_INTERVENTION|No Audit and Feedback Letter|This group will only receive a study closure letter.
62289408|NCT03842566||70-79 Years Old|
62289409|NCT02319876||Severe sepsis|Patients with severe sepsis
61906258|NCT00505778|ACTIVE_COMPARATOR|Mesalamine (Asacol) Once-Daily|an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
62289410|NCT02319876||SIRS patient|Patients after elective surgeries presented with SIRS but without sepsis
62289411|NCT02319876||Volunteer|Volunteers
61906259|NCT00505778|ACTIVE_COMPARATOR|Mesalamine (Asacol) Twice-Daily|an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)
62655399|NCT00457353|ACTIVE_COMPARATOR|1|Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
61906260|NCT00955305|ACTIVE_COMPARATOR|Arm A (CPB)|Patients receive carboplatin intravenously (IV) over 30 minutes, paclitaxel IV over 3 hours, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab may continue in the absence of disease progression or unacceptable toxicity.
62655400|NCT00457353|PLACEBO_COMPARATOR|2|Administration of Oral rehydration therapy
61906261|NCT00955305|EXPERIMENTAL|Arm B (CPB+cixutumumab)|Patients receive carboplatin, paclitaxel, and bevacizumab as in Arm A. Patients also receive cixutumumab (IMC-A12) IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab and cixutumumab may continue in the absence of disease progression or unacceptable toxicity.
61906262|NCT04405466||Group 1|Workers working within a production area
61906263|NCT04405466||Group 2|Workers working within a laboratory area
62655401|NCT03808766|OTHER|Tumor <=3cm|Embolization with particulate or liquid embolic agent
61906264|NCT04405466||Group 3|Workers working within other areas
61906265|NCT02300636|EXPERIMENTAL|Training: open kinetic|"Co-contraction training in open kinetic chain position~8 weeks, 3 days in a week"
62289412|NCT03367871|EXPERIMENTAL|Pembrolizumab, Chemotherapy, Bevacizumab|On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin area under the curve (AUC) 5; and Bevacizumab 15mg/kg (IV).
62289413|NCT01838044|EXPERIMENTAL|Arm A|The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
62289414|NCT01838044|OTHER|Arm B|The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
62289415|NCT05717348|EXPERIMENTAL|Part 1 dose escalation|ES014 doses will be escalated in patients with advanced solid tumors.
62655402|NCT03808766|OTHER|Tumor >3cm to 7cm|Embolization with particulate or liquid embolic agent
62655403|NCT03808766|OTHER|Tumor > 7cm|Embolization with particulate or liquid embolic agent
62655404|NCT02480296|EXPERIMENTAL|MYK-461|Oral Tablet x 28 days
62655405|NCT02480296|PLACEBO_COMPARATOR|Placebo|Oral Tablet x 28 days
62655406|NCT00359476|EXPERIMENTAL|1|
62655407|NCT06425016|OTHER|Laparoscopic Sleeve Gastrectomy (LSG)|Sleeve Gastrectomy completed using laparoscopic technique
62289416|NCT05717348|EXPERIMENTAL|Part 2 dose expansion|Part 2 of the study will consist of 4 expansion cohorts at the recommended optimal biological dose determined in Part 1 dose escalation.
62463223|NCT01944267|ACTIVE_COMPARATOR|Apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
62655408|NCT06425016|ACTIVE_COMPARATOR|Robotic Sleeve Gastrectomy (RSG)|Sleeve Gastrectomy completed using robot assistance
62655409|NCT04640116|EXPERIMENTAL|TIPS combined with microwave ablation|
61906266|NCT02300636|EXPERIMENTAL|Training: closed kinetic|"Co-contraction training in closed kinetic chain position~8 weeks, 3 days in a week"
62289417|NCT01077765|EXPERIMENTAL|treatment|treatment
61906267|NCT02300636|ACTIVE_COMPARATOR|Training: Standard ACL rehabilitation|"Standard ACL rehabilitation~8 weeks, 3 days in a week"
62655410|NCT02478827|EXPERIMENTAL|Working Memory group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games are adaptive. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
62289418|NCT06520566||Black Birthing Patients enrolled in Holistic Care Partner Program (HCP)|Black birthing patients enrolled in HCP will be invited to participate in a brief survey and/or a qualitative interview throughout 1 year of their enrollment.
62463224|NCT02377947||Patients with cirrhosis (grade 3 & 4 per west haven cr.)|Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema
61920049|NCT03377088|PLACEBO_COMPARATOR|Almond Oil|Patients will be given Almond Oil for inhalation on cotton balls as a control. Almond Oil has been shown to act as a placebo when compared to our variable, Rosa Damascena oil. To ensure blinding, this arm will act to always deliver a scent to a patient, blinding them to whether they are receiving a known aromatherapy or a common scent.
62091067|NCT06445920||CIPONV|The occurrence of PONV with the simplified PONV impact scale score of 5 or more.
62091068|NCT06445920||Non-CIPONV|There was no occurrence of PONV, or if PONV occurred, the simplified PONV impact scale score was less than 5.
62091069|NCT00414414|ACTIVE_COMPARATOR|prednisone|
62289419|NCT06520566||Historical Control Group|The historical control group will consist of Black patients who gave birth at NYU and are receiving usual perinatal care. The control cases will not be selected until the entire HCP cohort is enrolled as the HCP cohort data are needed for the matching procedure.
62289420|NCT06520566||Partner or Support Person of enrolled birthing people|Black birthing patients partners or support person will be invited to participate in a brief survey and/or a qualitative interview throughout 1 year of their enrollment.
62091070|NCT00414414|PLACEBO_COMPARATOR|placebo|
62091071|NCT05768555|ACTIVE_COMPARATOR|Whole body vibration intervention at 40 Hz|40 Hz frequency WBVT
62091072|NCT05768555|ACTIVE_COMPARATOR|Whole body vibration intervention at 25 Hz|25 Hz frequency WBVT
62091073|NCT05768555|ACTIVE_COMPARATOR|Whole body vibration intervention at 0 Hz|0 Hz frequency WBVT
62289421|NCT00682656|ACTIVE_COMPARATOR|A - N- methyl glucamine|Glucantime® , max day of 1,215 mg
62289422|NCT00682656|EXPERIMENTAL|B - Azithromycin|Zithromax ® , one dose 500 mg
62463225|NCT04213690||Patients with Lupus|Patients who have been diagnosed with Lupus
62463226|NCT03206177|EXPERIMENTAL|Paclitaxel/Carboplatin + Galunisertib|"Patients will receive the following in every cycle (1 cycle=28days).~* Paclitaxel - 175 mg/m2 over 3 hours via IV on Day 1~* Carboplatin - AUC 6\* (or AUC 5\*) over 1 hour via IV on Day 1~* Galunisertib - 150mg orally twice a day on Days 4-17"
61906268|NCT06278428||early onset developmental epileptic encephalopathy|"Select one that meets all 5 of the following criteria:~1. Diagnosed with EIDEE or EIMFS or ISS or SMEI or EMAS (according to ILAE's diagnostic criteria 2022)~2. Diagnosed with drug-resistant epilepsy according to ILAE 2010 criteria (according to ILAE's diagnostic criteria 2010)~3. Age at the start of participating in the study ranged from 0 to 23 months old~4. Relatives agree to participate in the research~5. There is no medical history of any diagnosis of hypoxic encephalopathy or inflammatory encephalopathy or traumatic encephalopathy or cerebral infarction or cerebral hemorrhage."
61906269|NCT02767297|EXPERIMENTAL|Part 1: Single dose (cross over)|FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
62463227|NCT03952143|EXPERIMENTAL|LY900014|Participants received 100 units per milliliter (U/mL) LY900014 subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
62655411|NCT02478827|EXPERIMENTAL|Processing Speed group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the processing speed training, which involves three games: Line It Up, Sliding Search, and Bubble Math. These games are designed to engage processes involving thinking speed. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks
61906270|NCT02767297|EXPERIMENTAL|Part 2: Multiple dose (dose level 1)|FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
62463228|NCT03952143|ACTIVE_COMPARATOR|Insulin Lispro|Participants received 100 U/mL insulin lispro (Humalog) given SC 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
62463229|NCT01071122|EXPERIMENTAL|Arm 1|
62463230|NCT01071122|ACTIVE_COMPARATOR|Arm 2|
62463231|NCT01071122|ACTIVE_COMPARATOR|Arm 3|
62463232|NCT00951925||No Treatment|
62463233|NCT04770961|SHAM_COMPARATOR|Cryoablation|1. Cryoablation of intercostal nerves + Sham ESP catheter with saline infusion.
61906271|NCT02767297|EXPERIMENTAL|Part 2: Multiple dose (dose level 2)|FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
61906272|NCT02767297|EXPERIMENTAL|Part 2: Multiple dose (dose level 3)|FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
61906273|NCT02767297|EXPERIMENTAL|Part 3: Single dose|FDL169 test formulation administered as a single dose in CF subjects
61906274|NCT03002467|EXPERIMENTAL|PESI score|treating physicians must formally calculate PESI and report in the clinical record form\* each day of hospitalization on top of routine clinical practice (standard care)
62463234|NCT04770961|EXPERIMENTAL|ESP + Cryoablation|2. Cryoablation of intercostal nerves + ESP catheter with local anesthetic infusion.
62463235|NCT05363878|EXPERIMENTAL|Native HEALTH Condition|Participants randomized to the Native HEALTH condition will complete the Native HEALTH intervention. This is a newly developed cultural program designed to reduce harm from alcohol use and improve quality of life among people in Kingsclear First Nation.
62463236|NCT05363878|NO_INTERVENTION|Wait-List Control|Participants randomized to the wait-list control group will complete the Native HEALTH intervention after two months.
62463237|NCT02697331|ACTIVE_COMPARATOR|progesterone|74 patients will receive progesterone pessary 200mg twice daily
62463238|NCT02697331|PLACEBO_COMPARATOR|Placebo|74 patients will receive placebo
62463239|NCT03649971|EXPERIMENTAL|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
62463240|NCT03649971|EXPERIMENTAL|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
62463241|NCT03649971|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
62463242|NCT03202576|NO_INTERVENTION|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
62463243|NCT03202576|EXPERIMENTAL|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
62463244|NCT04633109||normal weight|Normal weight adults with BMI ranging from 18.5-24.9; men and women; age range 18-69years; written informed consent
62463245|NCT04633109||obese|Subjects with obesity as defined by BMI \>= 30; men and women; age range 18-69 years; written informed consent
62463246|NCT02008305|EXPERIMENTAL|protocol of optimization ALARA|protocol of optimization ALARA protocol of optimization of doses
62463247|NCT02008305|ACTIVE_COMPARATOR|protocol of opimization Philips|protocol of optimization Philips usual protocol of optimization of doses
62463248|NCT01361802|ACTIVE_COMPARATOR|Ambroxol Spray 2.5mg|Ambroxol Spray Low Dose
62463249|NCT01361802|ACTIVE_COMPARATOR|Ambroxol Spray 5mg|Ambroxol Spray Medium Dose
62463250|NCT01361802|ACTIVE_COMPARATOR|Ambroxol Spray 10mg|Ambroxol Spray High dose
62463251|NCT01361802|PLACEBO_COMPARATOR|Placebo Spray|Placebo Spray
62463252|NCT04403425||Emergency laparotomy, obstruction|Patients undergoing emergency laparotomy for intestinal obstruction in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
62091074|NCT02358590|EXPERIMENTAL|HAPA menu-based mini-video|This group will watch mini-videos, which are multi-target menu-based interventions designed to deliver information about vitamin D adherence and its effect on osteoporosis
62091075|NCT02358590|ACTIVE_COMPARATOR|Standard care|This group will be advised by the treating physician to take vitamin D
62655412|NCT02478827|NO_INTERVENTION|Control group|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, a post-assessment will be completed.
62091076|NCT03835117|EXPERIMENTAL|Wide-spectrum nutritional supplement|The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion.
62091077|NCT03835117|PLACEBO_COMPARATOR|Placebo control|Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing.
62091078|NCT00681811|EXPERIMENTAL|HGT-1111 100 U/kg|
62463253|NCT04403425||Emergency laparotomy, perforation|Patients undergoing emergency laparotomy for perforated ventricle or intestine in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
62463254|NCT06302374|EXPERIMENTAL|Cohort 1 GR2001 0.01mg/kg/placebo|Four subjects will be randomly assigned to receive either GR2001 or placebo at a 3:1 ratio (i.e. 3 subjects receive GR2001 and 1 with placebo).
62463255|NCT06302374|EXPERIMENTAL|Cohort 2 GR2001 0.02mg/kg/placebo|Ten subjects will be randomly assigned to receive either GR2001 or placebo at a 4:1 ratio (i.e. 8 subjects receive GR2001 and 2 with placebo).
62655413|NCT02182804|EXPERIMENTAL|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
62655414|NCT00506675|ACTIVE_COMPARATOR|Intensive|42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
62655415|NCT00506675|ACTIVE_COMPARATOR|Weaning|For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)
62655416|NCT02222467|EXPERIMENTAL|Klox BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for venous leg ulcers.
62655417|NCT04799990||Risankizumab|Participants will receive risankizumab as prescribed by their physician.
62091079|NCT00681811|EXPERIMENTAL|HGT-1111 200 U/kg|
62655418|NCT04799990||Comparator Group 1|Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.
62655419|NCT04799990||Comparator Group 2|Participants will receive non-biologic systemic small molecules as prescribed by their physician.
62655420|NCT01045785||aspirin responsive|PFA Col/EPI normal
62655421|NCT01045785||aspirin resistance|PFA Col/epi showed resistance
62655422|NCT02313714|EXPERIMENTAL|Neuromuscular stimulation|The patients will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
62655423|NCT02313714|PLACEBO_COMPARATOR|Sham Group|The patients will receive very low electric muscular stimulation with a no biological or clinical effects
62655424|NCT05679986||Recent small subcortical infarction within 72 hours from stroke onset to admission|Recent small subcortical infarction (RSSI) is defined as small deep infarctions in the territory of perforating arteries with maximum axial diameters (MAD) of less than 20 mm. In this study, RSSIs in the territories of lenticulostriate area, pons are enrolled.
62655425|NCT01269294|EXPERIMENTAL|001|TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A
62091080|NCT05735015|EXPERIMENTAL|Treatment|All participants given 5 days of encaleret twice daily
62091081|NCT02109887||PCP with true CMV co-infection|
62091082|NCT02109887||PCP with innocent bystander CMV|
62091083|NCT02109887||PCP without any evidence of CMV|
61906275|NCT03002467|NO_INTERVENTION|Standard care|standard care (i.e. no formally calculation of PESI on top)
61906276|NCT04294056|EXPERIMENTAL|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
62091084|NCT02181205|EXPERIMENTAL|placebo|sphenopalatine ganglion block performed with normal saline as the placebo
62091085|NCT02181205|ACTIVE_COMPARATOR|bupivacaine|sphenopalatine ganglion block performed with bupivacaine
62091086|NCT04974502|EXPERIMENTAL|Non-smoker group|
62091087|NCT04974502|EXPERIMENTAL|Smoker group|
62091088|NCT03442920|EXPERIMENTAL|Obese women|Obese women who participated exercise programme.
62091089|NCT03442920|NO_INTERVENTION|Normal weighted|Normal weighted women with non-periodontitis
62091090|NCT05548127|EXPERIMENTAL|ARV-471 in combination with Abemaciclib|ARV-471 administered orally once daily (QD) and Abemaciclib orally twice daily (BID) on 28-day cycle
62091091|NCT02349113|EXPERIMENTAL|Estrogens|Estrogens treatment: Intervention with short course (3 weeks) of treatment with transdermal estrogen (0.1mg/d)
62091092|NCT02781155|OTHER|Self administration of moxibustion|Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments
62091093|NCT05121870|EXPERIMENTAL|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|standard of care (SOC) plus UC-MSCs
62091094|NCT05121870|PLACEBO_COMPARATOR|Placebo|SOC plus placebo.
62655426|NCT01269294|OTHER|002|Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A
62655427|NCT01269294|OTHER|003|Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D
62655428|NCT01269294|EXPERIMENTAL|004|TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
62655429|NCT01269294|OTHER|005|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C
62655430|NCT01269294|OTHER|006|Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C
62091095|NCT06409585||Heart failure with preserved ejection fraction|Participants will undergo baseline echocardiography and hybrid cardiac PET-MR with 200MBq of 68Ga-FAPI or 18F-AlF-FAPI. A follow-up echocardiogram and cardiac MRI will be undertaken a year later.
62091096|NCT06409585||Hypertrophic cardiomyopathy and Hypertensive heart disease|Participants will undergo baseline echocardiography and hybrid cardiac PET-MR with 200MBq of 68Ga-FAPI or 18F-AlF-FAPI. A follow-up echocardiogram and cardiac MRI will be undertaken a year later.
62091097|NCT06409585||Cardiac Sarcoidosis|Participants will undergo baseline echocardiography and hybrid cardiac PET-MR with 200MBq of 68Ga-FAPI or 18F-AlF-FAPI. A follow-up echocardiogram and cardiac MRI will be undertaken a year later.
62091098|NCT06409585||Arrhythmogenic cardiomyopathy|Participants will undergo baseline echocardiography and hybrid cardiac PET-MR with 200MBq of 68Ga-FAPI or 18F-AlF-FAPI. A follow-up echocardiogram and cardiac MRI will be undertaken a year later.
62091099|NCT06409585||Myocarditis|Participants will undergo baseline echocardiography and hybrid cardiac PET-MR with 200MBq of 68Ga-FAPI or 18F-AlF-FAPI. A follow-up echocardiogram and cardiac MRI will be undertaken a year later.
62091100|NCT06409585||Takotsubo cardiomyopathy|Participants will undergo baseline echocardiography and hybrid cardiac PET-MR with 200MBq of 68Ga-FAPI or 18F-AlF-FAPI. A follow-up echocardiogram and cardiac MRI will be undertaken a year later.
62091101|NCT02046642|ACTIVE_COMPARATOR|Maternal rest in left lateral position|"women in maternal rest in left lateral position group rested in the left lateral position for 15 minutes and then rested in the right lateral position for another 15 minutes."
62091102|NCT02046642|ACTIVE_COMPARATOR|Maternal rest in right lateral position|"Women in maternal rest in right lateral position group started resting in the right lateral position for 15 minutes and then rested in the left lateral position for another 15 minutes."
62091103|NCT03487874|EXPERIMENTAL|Interscalene block with C8 root block|The 5th to 8th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
62091104|NCT03487874|ACTIVE_COMPARATOR|Conventional interscalene block|The 5th to 7th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
62091105|NCT01515319|EXPERIMENTAL|2mg Y242 (Part A)|Y242 single dose, subcutaneous
62091106|NCT01515319|EXPERIMENTAL|7.5mg Y242 (Part A)|Y242 single dose, subcutaneous
62091107|NCT01515319|EXPERIMENTAL|15mg Y242 (Part A)|Y242 single dose, subcutaneous
62091108|NCT01515319|EXPERIMENTAL|30mg Y242 (Part A)|Y242 single dose, subcutaneous
62091109|NCT01515319|EXPERIMENTAL|60mg Y242 (Part A)|Y242 single dose, subcutaneous
62091110|NCT01515319|EXPERIMENTAL|90mg Y242 (Part A)|Y242 single dose, subcutaneous
62091111|NCT01515319|PLACEBO_COMPARATOR|Placebo - Part A|0.9% saline
62091112|NCT01515319|EXPERIMENTAL|60mg Y242 (Part B1)|Y242 single subcutaneous dose, administered once a week for 5 weeks
62091113|NCT01515319|EXPERIMENTAL|90mg Y242 (Part B2-B4)|Y242 single subcutaneous dose, administered once a week for 5 weeks
62091114|NCT01515319|PLACEBO_COMPARATOR|Placebo - Part B|0.9% saline
62091115|NCT04003974|EXPERIMENTAL|Treatment|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
62091116|NCT04003974|PLACEBO_COMPARATOR|Placebo|FSHD1 patients with genetic confirmation will receive a Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
61906277|NCT04294056|ACTIVE_COMPARATOR|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
62091117|NCT04675411|OTHER|usual care|After a fall leading to hip fracture, patients are cared for by orthopedists and receive internal fixation or arthroplasty. Consultations for internal medicine care are occasionally made depending on the patient's condition. During the first 1 to 2 days after surgery, nurses teach patients how to exercise while still in bed, using caution while changing their position. Pain-relief medications and antibiotics are also administered (for 2-3 days). The first day after surgery, physical therapy usually starts with rehabilitation training only on patients receiving arthroplasty. The average hospital stay is 5 to 7 days. After hospital discharge, very few patients use in-home or community rehabilitation or are admitted to a 2-week subacute rehabilitation unit. Patients usually come back to the clinic around 1, 3, 6, and 12 months after hospital discharge. However, adherence to this follow-up schedule is poor. Telephone follow-ups are seldom used.
62091118|NCT04675411|EXPERIMENTAL|Smart Care Model|"The smart care model (SCM) will contain the components of geriatric assessment, continuous rehabilitation, and discharge planning.~Sensors will be installed in bedrooms and living areas of the patient's home to receive signals from the smart clothing. Instant alerts and feedbacks from research nurses to family caregivers about the patient's condition and activity level will be provided."
62091119|NCT02893540|EXPERIMENTAL|Metronomic|accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)
62091120|NCT02893540|ACTIVE_COMPARATOR|Conventional|accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)
61906278|NCT03069521|OTHER|EndoArt®|EndoArt® Artificial Endothelial Layer
61906279|NCT04735640|EXPERIMENTAL|Nurse-led teleconsultation group|9-month nurse-led telephone-based personalized behavioural intervention.
61906280|NCT04735640|ACTIVE_COMPARATOR|SMS group|Behavioural intervention by means of short text messages.
62091121|NCT03946657|ACTIVE_COMPARATOR|The Inhalation Group|Sevoflurane (1 minimum alveolar concentration \[MAC\]) were used in the Inhalation group for the maintenance of anesthesia.
62091122|NCT03946657|ACTIVE_COMPARATOR|The TIVA (total intravenous anesthesia) Group|Propofol infusion (4-8 mg/kg of total body weight/h) were used in the TIVA group.
62091123|NCT03477682|EXPERIMENTAL|Early Ambulation Group|The patient will remain on bed rest for one day following surgery and will be encouraged to be out of bed and ambulating on the second day following surgery.
62091124|NCT03477682|NO_INTERVENTION|Standard Group|The patient will remain on bed rest for five days following surgery and will be encouraged to be out of bed and ambulating on the sixth day following surgery.
62091125|NCT06696404|EXPERIMENTAL|NA group|Nerve block anesthesia group(NA) Intervention: combined Lumbar Plexus and Sacral Plexus Block, with sedation or laryngeal mask anesthesia (induction with Propofol 1-3mg/kg, Sufentanil 0.1-0.4ug/kg)
62091126|NCT06696404|ACTIVE_COMPARATOR|GA group|General anesthesia was performed as an endotracheal intubation combined with iliac fascial block (0.33 ropivacaine 30 ml)
62091127|NCT06696404|ACTIVE_COMPARATOR|SA group|Spinal anesthesia was performed as a standard care of spinal anesthetic
62289423|NCT06503315||cases group|Clinical assessment is based on the presence of symptoms (low vs. high) and the previous history of exacerbation( ECOPD) (≤ 1 moderate ECOPD in the previous year vs. more than one severe (hospitalized) ECOPD). Using these two dimensions, GOLD 2023 proposes to classify COPD patients in one of three groups (A, B, or E) .
62091128|NCT02794961|EXPERIMENTAL|CD22 CAR-T|Enrolled patients will receive three escalating doses of autologous CAR-T.
62091129|NCT02691065|EXPERIMENTAL|Integrase Inhibitor|Switch from protease inhibitor-based regimen to raltegravir-based regimen
62091130|NCT02691065|NO_INTERVENTION|Protease inhibitor|Continuation of protease-inhibitor based regimen
62289424|NCT06503315||control group|The control group includes 70 asymptomatic smokers and will be matched with cases by sex, age, smoking status, lacking chronic diseases in the respiratory system as malignancy and bronchial asthma
62289425|NCT01007526|EXPERIMENTAL|CCRT plus VIDL|CCRT followed by VIDL chemotherapy Concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation
62463256|NCT06302374|EXPERIMENTAL|Cohort 3 GR2001 0.05mg/kg/placebo/HTIG|24 subjects will be randomly assigned to receive GR2001 or placebo or HTIG(250IU) at a 1:1:1 ratio (i.e. 8 subjects receive GR2001, 8 with placebo and 8 with HTIG).
62091131|NCT04170426|EXPERIMENTAL|Phase 1 ARM 0|9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1
62091132|NCT04170426|ACTIVE_COMPARATOR|Phase 2 ARM 1|30 subjects receive three doses of 2.0-2.86×10\^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a
62091133|NCT04170426|PLACEBO_COMPARATOR|Phase 2 ARM 2|15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a
62091134|NCT01047072|EXPERIMENTAL|Arm I (transplant)|Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
62091135|NCT01047072|ACTIVE_COMPARATOR|Arm II (nontransplant)|Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
62289426|NCT01256541|EXPERIMENTAL|Kristalose|Kristalose as Bowel Evacuant
62289427|NCT02185378|ACTIVE_COMPARATOR|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
62289428|NCT02185378|ACTIVE_COMPARATOR|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
62289429|NCT05253456|EXPERIMENTAL|intervention group|patients underwent our newly modified technique for hypospadias repair
62289430|NCT01511757|EXPERIMENTAL|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
62289431|NCT01511757|ACTIVE_COMPARATOR|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
62289432|NCT02029742|EXPERIMENTAL|Community Health Worker Intervention|Community Health Workers will have scheduled interactions with subjects and will customize text messaging jointly with each youth and parent and initiate text message reminders to both parent and youth for months 4-6.
62091136|NCT03605186|EXPERIMENTAL|Chamomile oral cryotherapy|"1. The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).~2. Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~3. Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~4. Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
62091137|NCT03605186|ACTIVE_COMPARATOR|Oral cryotherapy|"1. The plain icecubes will be prepared in the clinic with 400 mL of distilled water.~2. Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~3. Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~4. Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
62091138|NCT01232556|EXPERIMENTAL|1|Inotuzumab ozogamicin+rituximab
62091139|NCT01232556|ACTIVE_COMPARATOR|2|Investigator's choice of (1) rituximab+gemcitabine, or (2) rituximab+bendamustine
62091140|NCT03194061|EXPERIMENTAL|Hypofractionated chemoradiation|20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
62091141|NCT04803084||Advanced Pathology|Breast magnetic resonance imaging (MRI) as a preliminary predictive biomarker for breast cancer treatment response.
62091142|NCT00557505|EXPERIMENTAL|PF-03732010|Single Arm study
62091143|NCT02482909|EXPERIMENTAL|Hepatic resection|Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
62091144|NCT02482909|EXPERIMENTAL|Radiofrequency ablation|Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.
62091145|NCT02453646|EXPERIMENTAL|NexSite HD Patients|NexSite HD patient catheter device placement
62091146|NCT01630499|EXPERIMENTAL|Tailored Lifestyle Intervention (TLI)|Participants randomized to the TLI condition will receive a 3-month weight management program tailored to the specific needs of women in remission from breast cancer.
62091147|NCT01630499|ACTIVE_COMPARATOR|Commercial Weight Loss Program (CLWP)|Participants randomized to the CWLP condition will receive a 3-month commercial weight loss program (i.e., Weight Watchers) at no cost.
62289433|NCT02029742|ACTIVE_COMPARATOR|Education|Those randomized to the Education group will continue usual care, and will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
62091148|NCT03215225||Root canal treatment|
62091149|NCT02649790|EXPERIMENTAL|Part A1: RRMM- KPT-8602 single agent; QoDx5/week|Participants received KPT-8602 once daily for 5 days per week (QDx5/week) at escalated doses (completed).
62091150|NCT02649790|EXPERIMENTAL|Part A2: RRMM- KPT-8602 single agent; QoDx3/week|Participants received KPT-8602 once daily for 3 days per week (QoDx3/week). The starting dose for Part A2 will be informed by Part A1 (completed).
62091151|NCT02649790|EXPERIMENTAL|Part B: RRMM- KPT-8602 with low-dose dexamethasone; QDx5/week|Participants received KPT-8602 for 5 consecutive days (QDx5/week) in combination with low dose dexamethasone (20 milligram \[mg\] on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle) (completed).
62091152|NCT02649790|EXPERIMENTAL|Part C: CRC- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
62091153|NCT02649790|EXPERIMENTAL|Part D: mCRPC- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
62091154|NCT02649790|EXPERIMENTAL|Part E: mCRPC- KPT-8602 with abiraterone and corticosteroids|Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A in combination with abiraterone and corticosteroids. Participants continued to receive the dose and schedule of abiraterone and corticosteroids that they were receiving at the time of enrollment (completed).
62091155|NCT02649790|EXPERIMENTAL|Part F: High-risk Myelodysplastic Syndrome (MDS)- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A. In select cases (for example, participants achieving stable disease \[SD\], hematological improvement \[HI\], partial response \[PR\] and tolerating treatment, etc.), the dose may be escalated 1 level based on safety and efficacy considerations (completed).
62091156|NCT02649790|EXPERIMENTAL|Part F Phase 2: RR High-risk MDS- KPT-8602 single agent|Participants will be enrolled at recommended Phase 2 doses (RP2D) of 10 mg daily on Days 1 to 5 of each week, in a dose expansion, based upon the results from the Phase 1 portion of Part F.
62289434|NCT01113320|PLACEBO_COMPARATOR|Placebo|
62289435|NCT01113320|ACTIVE_COMPARATOR|Safinamide|
62289436|NCT04171739|OTHER|Cohort A|Itraconazole DDI
62289437|NCT04171739|OTHER|Cohort B|Rifampicin DDI
62289438|NCT05786157|EXPERIMENTAL|alcohol administration paradigm|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
62289439|NCT00708370|ACTIVE_COMPARATOR|COACH|
62091157|NCT02649790|EXPERIMENTAL|Part G: Newly Diagnosed Intermediate/High-Risk MDS -KPT-8602 with ASTX727|Participants will receive KPT-8602 once daily at escalated doses. The starting dose for KPT-8602 is 5 mg orally once daily from Day 8 to Day 28 (Weeks 2 to 4) on a 28-day cycle in combination with ASTX727.
62091158|NCT02649790|EXPERIMENTAL|Part H: AML Maintenance Therapy- KPT-8602 single agent|Participants with high-risk acute myeloid leukemia (AML) prior to transplant will be enrolled to receive maintenance therapy with KPT-8602 post-allogeneic stem cell transplantation. The dose for KPT-8602 will be 10 mg (RP2D from Part F) oral, to be administered once daily from Day 1 to Day 21 (Weeks 1 to 3) on a 28-day cycle.
62091159|NCT04066543|ACTIVE_COMPARATOR|TACE group|Device: Transcatheter arterial chemoembolization(TACE)
62091160|NCT04066543|EXPERIMENTAL|TACE+Anlotinib group|Device: Transcatheter arterial chemoembolization Drug: Anlotinib Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
62091161|NCT06005103|EXPERIMENTAL|(A) Patients diagnosed with moderate to severe depression without psychotic symptoms|"In total, 40 patients will be allocated to this arm.~(In total, 101 patients will be included in the study. Data for the initial 21 patients included in the study could not be used to assess the antidepressant effect, why an increased number of participants was needed to secure the power for the trial. The technical difficulties have been addressed)"
62091162|NCT06005103|SHAM_COMPARATOR|(B) Patients diagnosed with moderate to severe depression without psychotic symptoms|"In total, 40 patients will be allocated to this arm.~(In total, 101 patients will be included in the study. Data for the initial 21 patients included in the study could not be used to assess the antidepressant effect, why an increased number of participants was needed to secure the power for the trial. The technical difficulties have been addressed)"
62091163|NCT02451930|EXPERIMENTAL|Necitumumab + Pembrolizumab|"Part A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies).~Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology.~Part C were Japan participants. Part C were Japan participants."
62091164|NCT00115180||Hispanic|Hispanic patients with long bone fractures no intervention
62091165|NCT00115180||White|White patients with long bone fractures no intervention
62091166|NCT00115180||African-American|African-American patients with long bone fracture no intervention
62091167|NCT05230082|EXPERIMENTAL|Immediate Start|Patients will receive acupuncture treatment two times per week for 12 weeks.
62091168|NCT05230082|ACTIVE_COMPARATOR|Delayed start|Patients will act as control group for the first 12 weeks then will receive acupuncture treatment two times per week for 12 weeks.
62091169|NCT03141164|EXPERIMENTAL|Training|Computerized vision training
62091170|NCT03141164|SHAM_COMPARATOR|Control|Sham
62091171|NCT06258993|EXPERIMENTAL|Affect-based Exercise Prescription (Affect-Rx)|
62091172|NCT06258993|ACTIVE_COMPARATOR|Effort-based Exercise Prescription (RPE-Rx)|
62091173|NCT01224561||Constitutional thinness|Women with a a body mass index of less than 16.5 kg/m2
62091174|NCT01224561||Healthy Volonteer|Women with a body mass index between 20 and 25 kg/m2
62091175|NCT04683497|EXPERIMENTAL|CE-IOUS|Patients with pancreatic cancer undergoing surgery with the performance of CE-IOUS
62091176|NCT06128863|OTHER|single arm|"Systemic therapy with pembrolizumab and eftilagimod alpha is given concurrently with radiotherapy.~Surgery is scheduled 5-6 weeks after completion of radiotherapy."
62091177|NCT05717075|OTHER|Group A (Parents Round, then no special round)|Parents of enrolled patient receive the intervention for two weeks after the consent to the study (Period I). For two weeks after the intervention in Period I, the parents do not receive the intervention (Period II).
62289440|NCT00708370|PLACEBO_COMPARATOR|Standard Care|
62463257|NCT06302374|EXPERIMENTAL|Cohort 4 GR2001 0.1mg/kg/placebo|Ten subjects will be randomly assigned to receive either GR2001 or placebo at a 4:1 ratio (i.e. 8 subjects receive GR2001 and 2 with placebo).
62091178|NCT05717075|OTHER|Group B (no special round, then Parents Round)|Parents of enrolled patient receive no intervention for two weeks after the consent to the study (Period I). For two weeks after Period I, the parents receive the intervention (Period II).
62091179|NCT02763098|EXPERIMENTAL|Remi 0.1|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses \[(0.1), 0.2, 0.3 µg/kg/min\] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
62091180|NCT02763098|EXPERIMENTAL|Remi 0.2|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses \[0.1, (0.2), 0.3 µg/kg/min\] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-RoiFrance) for two minutes.
62091181|NCT02763098|EXPERIMENTAL|Remi 0.3|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses \[0.1, 0.2, (0.3) µg/kg/min\] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
62289441|NCT01133964|EXPERIMENTAL|milk|skim milk
62289442|NCT01133964|EXPERIMENTAL|casein drink|
62289443|NCT01133964|EXPERIMENTAL|whey drink|
62289444|NCT01133964|SHAM_COMPARATOR|water|
62289445|NCT01051089|EXPERIMENTAL|Lifestyle modification|supervised exercise with diet education
62289446|NCT01051089|NO_INTERVENTION|Control|Control (ordinary care with usual education)
61906281|NCT05330884|EXPERIMENTAL|vaccine - Bacille Calmette-Guérin vaccine (BCG )|Bacille Calmette-Guérin vaccine (BCG ) dose 0.1ml intradermal
62289447|NCT01941589|ACTIVE_COMPARATOR|present 5-ASA arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
62091182|NCT02024243||Venous leg ulcers|Patients visiting the Indiana University Health Comprehensive Wound Center, with a chronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT \& infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
62091183|NCT06447974|OTHER|Pre and post intervention|A single arm for measurement both pre and post introduction of intervention
62091184|NCT06093529||Respondents to second-line therapy|Immune markers in ITPpatients Respondant to second line therapy
62091185|NCT06093529||Non-Respondents to second-line therapy|Immune markers in ITPpatients nonrespondant to second line therapy
61906282|NCT05330884|OTHER|Chemoprophylaxis - as per NTEP guidelines|Oral chemoprophylaxis: according to the existing standard of care (NTEP guidelines) Either six months of isoniazid (10mg/kg) or Rifapentine and isoniazid weekly for 3 months for DS TB Levofloxicillin or standard of care drug for DR TB: 15-20mg/kg/day
61906283|NCT00824733|EXPERIMENTAL|Arm I: Treatment (PF03512676 in combination with Trastuzumab)|12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
61906284|NCT03157700|EXPERIMENTAL|REAL media|Participants in this group will be assigned to use the REAL media curriculum.
61906285|NCT03157700|NO_INTERVENTION|Programming as usual|Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
62091186|NCT06291077|EXPERIMENTAL|Belatacept group|Belatacept group
62091187|NCT06291077|ACTIVE_COMPARATOR|anticalcineurin group|anticalcineurin group
62091188|NCT01051011|EXPERIMENTAL|1|
61906286|NCT00748852|EXPERIMENTAL|1|JTT-302, 400 mg
62091189|NCT01051011|EXPERIMENTAL|2|
62091190|NCT01051011|ACTIVE_COMPARATOR|3|
62463258|NCT06302374|EXPERIMENTAL|Cohort 5 GR2001 0.2mg/kg/placebo|Ten subjects will be randomly assigned to receive either GR2001 or placebo at a 4:1 ratio (i.e. 8 subjects receive GR2001 and 2 with placebo).
62655431|NCT01269294|PLACEBO_COMPARATOR|007|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D
61906287|NCT05035602||Oesophagectomy|Patients who have undergone oesophageal cancer resection.
61906288|NCT05035602||Gastrectomy|Patients who have undergone gastric cancer resection.
61906289|NCT05035602||Control group|A cohort consisting of healthy controls who have not been diagnosed with, or have undergone treatment for oesophageal or gastric cancer.
61906290|NCT01534858|EXPERIMENTAL|Partial and full thickness burns with split thickness grafts|
61906291|NCT01956344|EXPERIMENTAL|Immediate Treatment|Cognitive-behavioral therapy
61906292|NCT01956344|NO_INTERVENTION|Delayed Treatment|This group will receive the cognitive-behavioral therapy after a 16 week delay
61906293|NCT01956344|NO_INTERVENTION|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment and will be used a a healthy comparator group.
62091191|NCT06697522|EXPERIMENTAL|0.01% Atropine|Atropine Sulfate Eye Drops, conc. 0.01%
62091192|NCT06697522|PLACEBO_COMPARATOR|Blank Solvent|Blank solvent placebo
61906294|NCT01295879|EXPERIMENTAL|Ergocalciferol|Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
62091193|NCT02237079|EXPERIMENTAL|Bazedoxifene/Conjugated Estrogens (BZA/CE)|"Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications."
62091194|NCT02237079|PLACEBO_COMPARATOR|Placebo|"Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind. Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind."
62091195|NCT04818879|EXPERIMENTAL|Interventional group|
62463259|NCT06302374|EXPERIMENTAL|Cohort 6 GR2001 0.1mg/kg/placebo|Eighteen subjects will be randomly assigned to receive either GR2001 or placebo at a 2:1 ratio (i.e. 12 subjects receive GR2001 and 6 with placebo) followed by a dose of Tetanus Toxoid（TT） on Day0.
62463260|NCT06302374|EXPERIMENTAL|Cohort 7 GR2001 0.2mg/kg/placebo|Eighteen subjects will be randomly assigned to receive either GR2001 or placebo at a 2:1 ratio (i.e. 12 subjects receive GR2001 and 6 with placebo) followed by a dose of Tetanus Toxoid（TT） on Day0.
62655432|NCT02609490|EXPERIMENTAL|Treatment-Azilsartan|Azilsartan tabelts
61906295|NCT01104532|EXPERIMENTAL|Dosing Regimen 1|
61906296|NCT01104532|EXPERIMENTAL|Dosing Regimen 2|
61906297|NCT01104532|EXPERIMENTAL|Dosing Regimen 3|
62091196|NCT04818879|SHAM_COMPARATOR|Control group|
62091197|NCT04871087|OTHER|Allay lamp (narrow band green light)|Comparing effects of NBGL vs. white light on anxiety level before and after psychotherapy treatment sessions.
62091198|NCT04415892|OTHER|Healthy volunteers|Young, healthy male volunteers to characterize the DBF changes upon cinnamaldehyde and capsaicin, including the reproducibility.
62091199|NCT04415892|OTHER|Paclitaxel Patients|Group of patients after treatment with paclitaxel.
62655433|NCT02609490|ACTIVE_COMPARATOR|Positive Control-olmesartan medoxomil|olmesartan medoxomil tablets
61906298|NCT01104532|EXPERIMENTAL|Dosing Regimen 4|
62091200|NCT04415892|OTHER|Paclitaxel Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Paclitaxel Patients.
62091201|NCT04415892|OTHER|Oxaliplatin Patients|Group of patients after treatment with oxaliplatin.
62091202|NCT04415892|OTHER|Oxaliplatin Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Oxaliplatin Patients.
62091203|NCT04415892|OTHER|Longitudinal Paclitaxel Patients|Group of patients who are treated with paclitaxel.
62289448|NCT01941589|ACTIVE_COMPARATOR|5-ASA naive arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
62289449|NCT01941589|ACTIVE_COMPARATOR|present 5-ASA arm 2|IV corticosteroids only / PO Methylprednisolone
62655434|NCT02839317||Biological in pediatric CD|75 pediatric-onset CD Biological
62655435|NCT02839317||Biological in pediatric controls|75 pediatric controls matched on gender, age and area of residence Biological
61906299|NCT03330392|EXPERIMENTAL|AGP|take two tablets per day (500 mg/day) for 8 weeks.
61906300|NCT03330392|PLACEBO_COMPARATOR|Placebo|take two tablets per day for 8 weeks.
62091204|NCT04415892|OTHER|Longitudinal Oxaliplatin Patients|Group of patients who are treated with oxaliplatin.
62289450|NCT01941589|ACTIVE_COMPARATOR|5-ASA naive arm 2|IV corticosteroids only / PO Methylprednisolone
62289451|NCT00927420||1|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
62289452|NCT03625531|EXPERIMENTAL|Personalized acupuncture|Two sets of acupoints will be selected for the two types. The basic acupoint-prescription includes CV 4, CV 6, CV 12 and SP 6 bilaterally, ST 25 bilaterally, EX-CA 1 bilaterally, ST 40 bilaterally and SP 9 bilaterally. Additional point ST 36 bilaterally and moxibustion as adjuvant therapy will be added for the type of yang deficiency of spleen and kidney, while additional points K 13, LR 3 for the type of yin deficiency of liver and kidney. Besides, flexible modifications of 2-3 acupoints will be performed according to patients special symptoms.
62307966|NCT01568944|EXPERIMENTAL|Oral Antibiotic and Oral Rinse|Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
62655436|NCT02839317||Biological in elderly CD|75 elderly-onset CD Biological
62655437|NCT02839317||Biological in elderly controls|75 elderly controls matched on gender, age and area of residence Biological
61906301|NCT06251401|EXPERIMENTAL|In-person cardiac rehabilitation|Those randomized to in-person cardiac rehabilitation group
61906302|NCT06251401|EXPERIMENTAL|Virtual cardiac rehabilitation|Those randomized to the virtual, home-based rehabilitation group
61906303|NCT04136119||healthcare professionals|doctors, pharmacists and dieticians who are involved in prescribing vitamins and micronutrients to critically ill patients
61906304|NCT03972891|EXPERIMENTAL|12-weeks intervention break|The intervention break starts as soon as 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy. The intervention break will last for 12 weeks.
61906305|NCT03972891|NO_INTERVENTION|traditional therapy|After 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy, the children will maintain their traditional therapy until more than 90% of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations (max. 12 weeks).
61906306|NCT03900689||Health Services Research - Part 1 Survey|Participants will be asked to complete a series of surveys. This will be preferentially completed on the same day of the visit but may be completed at a subsequent visit, over the telephone or taken home and sent back to the clinic.
61906307|NCT03900689||Health Services Research - Part 2 - Focus Group|Patients identified in Part 1 will be offered participation in the focus groups in Part 2. All patients enrolled in Part 1 will be considered for participation in Part 2. Approximately 30 total patients will be invited to participate. Patients who agree to be contacted will receive a telephone call or contacted in clinic and invited to participate in the Part 2 focus group.
61906308|NCT03063047|ACTIVE_COMPARATOR|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
61906309|NCT03063047|ACTIVE_COMPARATOR|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
62091205|NCT01133509|OTHER|gardisil|gardisil
62091206|NCT03151421|EXPERIMENTAL|Home air quality monitoring and feedback|Home air quality monitoring and feedback
62091207|NCT03715374|EXPERIMENTAL|PRF+ABB treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A prf membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
62091208|NCT03715374|ACTIVE_COMPARATOR|Collagen Membrane + ABB treated patients|Periodontal surgery with collagen membrane is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A collagen membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
62091209|NCT04524182|OTHER|control group|There was no intervention in the control group during the study (At the end of study all patients were received home-based exercise)
62655438|NCT00651846|EXPERIMENTAL|Arm 1|
62655439|NCT00651846|ACTIVE_COMPARATOR|Arm 2|
62655440|NCT06458270|EXPERIMENTAL|Label group|Participants will receive a manipulated restaurant menu featuring salt warning labels next to menu items that are high in salt.
62655441|NCT06458270|NO_INTERVENTION|Control group (no label)|Participants will receive a standard restaurant menu (no labels).
62091210|NCT04524182|EXPERIMENTAL|mobilization group|"Lumbo-sacral mobilization was applied to the mobilization group. Lumbo-sacral mobilization techniques were applied for 10 minutes to lumbo-sacral region in the supine position.~(At the end of study all patients were received home-based exercise)"
62091211|NCT01938417||adult patients treated with Osteoset® T (tobramycin sulfate)|10 g or 20 g of Osteoset® T
62091212|NCT05420532|EXPERIMENTAL|Exergaming Group|A video game-based physical activity training will be applied under a physiotherapist supervision for 1 days/week for 8 weeks.
62091213|NCT06284109|EXPERIMENTAL|Cryoanalgesia|Participants will receive cryoanalgesia with the The iovera° system.
62091214|NCT06284109|SHAM_COMPARATOR|Sham Cryoanalgesia|Participants will receive Sham cryoanalgesia with the The iovera° system.
62655442|NCT06078982|EXPERIMENTAL|Combination of Disitamab Vedotin and Toripalimab|Participants will receive Disitamab Vedotin + Toripalimab every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
61906310|NCT02338570|OTHER|Everolimus|All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
61906311|NCT00613912||A|Ambulant patients with major depression
61906312|NCT01557634|EXPERIMENTAL|Closed-loop with diluted insulin|Insulin pump therapy using diluted insulin (20 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
61906313|NCT01557634|ACTIVE_COMPARATOR|Closed-loop with non-diluted insulin|Insulin pump therapy using standard non-diluted insulin (100 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
61906314|NCT02578576||patients with flare-up|Disease flare-up is demonstrated by coloscopy at one month after resection.
61906315|NCT02578576||patients without flare-up|No flare-up is found by coloscopy at one month after resection.
61906316|NCT05107752|EXPERIMENTAL|Stellate ganglion block (SGB) treatment during cognitive processing therapy (CPT)|Participants will receive 12 sessions of cognitive processing therapy (CPT) for PTSD combined with SGB during the first week of CPT.
61906317|NCT05107752|EXPERIMENTAL|SGB three months after completing CPT|Participant will receive 12 sessions of cognitive processing therapy (CPT) for PTSD and will receive SGB three months after completing the CPT sessions.
61906318|NCT04182464|EXPERIMENTAL|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
61906319|NCT04182464|PLACEBO_COMPARATOR|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
61906320|NCT02476656||GPNC|CenteringPregnancy group prenatal care
61906321|NCT02476656||IPNC|Individual prenatal care
61906322|NCT01809587|EXPERIMENTAL|IQP-PO-101|Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)
61906323|NCT00566202|EXPERIMENTAL|JNJ-18038683|
61906324|NCT00566202|PLACEBO_COMPARATOR|Placebo|
61906325|NCT00566202|ACTIVE_COMPARATOR|Escitalopram|
61906326|NCT04532580||AI- Aided performances|
61906327|NCT04532580||AI- Unaided performances|
62091215|NCT05034575|EXPERIMENTAL|Novice and experienced medical personnel|Participants will be asked to complete two tasks each taking approximately 10 minutes while wearing eye-tracking technology to understand focus of gaze during laryngeal endoscopy and stroboscopy interpretation.
62091216|NCT06615388||Physically active females|Physically active females with and with low energy availability
62091217|NCT03878082|ACTIVE_COMPARATOR|propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
62091218|NCT03878082|ACTIVE_COMPARATOR|propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
62091219|NCT03878082|PLACEBO_COMPARATOR|IVPCA|pain control with IVPCA
61906328|NCT00305929|EXPERIMENTAL|1|Treatment with Tookad VTP
61906329|NCT04475198|EXPERIMENTAL|Single Ascending Dose: Cohort 1|5 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
61906330|NCT04475198|EXPERIMENTAL|Single Ascending Dose: Cohort 2|10 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
61906331|NCT04475198|EXPERIMENTAL|Single Ascending Dose: Cohort 3|15 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
61906332|NCT04475198|EXPERIMENTAL|Single Ascending Dose: Cohort 4|22 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
61906333|NCT04475198|EXPERIMENTAL|Single Ascending Dose: Cohort 5|33 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
61906334|NCT04810689|EXPERIMENTAL|XFBD Arm|XFBD (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
61906335|NCT04810689|PLACEBO_COMPARATOR|Placebo Arm|Placebo (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
61906336|NCT01795768|EXPERIMENTAL|Single Treatment Arm|16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.
61920050|NCT03377088|EXPERIMENTAL|Rose Oil|Patients will be given Rosa Damascena oil on cottons balls as a variable. This oil has been shown to significantly lower acute pain levels on the visual analog pain scale when compared to placebo of distilled water or Almond Oil.
62091220|NCT04770090|EXPERIMENTAL|Early stage cervical cancer|Patients with cervical cancer eligible for surgery, stage IA1 to IB2
62655443|NCT02991521|EXPERIMENTAL|FAST examination after Right sided roll (FASTeR)|Subjects will have a standard FAST exam, and will then be rolled onto their right side and the FAST exam will be repeated.
62091221|NCT05716633||Acute Pancreatitis|Patients with acute pancreatitis will undergo serial MRI
62091222|NCT00861978|PLACEBO_COMPARATOR|1|
62091223|NCT00861978|EXPERIMENTAL|2|
62091224|NCT04231110|EXPERIMENTAL|FMT and vedolizumab|People who are initiating vedolizumab per standard of care for ulcerative colitis will also be offered FMT weekly for 6 weeks.
62091225|NCT00231179|EXPERIMENTAL|Home visiting Intervention|Home visiting intervention group.
62091226|NCT00231179|PLACEBO_COMPARATOR|Control|Control condition did not receive any services.
62091227|NCT06426407||Vasopressin plus norepinephrine|Patients with septic shock ordered vasopressin as an adjunct to norepinephrine
62091228|NCT06426407||Norepinephrine|Active control cohort of patients with septic shock who are only receiving norepinephrine
62091229|NCT05593575|EXPERIMENTAL|SPH3127-1|1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
62091230|NCT05593575|EXPERIMENTAL|SPH3127-2|2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
62289453|NCT03625531|EXPERIMENTAL|Fixed acupuncture|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.
62289454|NCT03625531|ACTIVE_COMPARATOR|Letrozole|Women in the letrozole group will be given letrozole (Femara, Novartis Pharmaceuticals, Basel, Switzerland) from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
62091231|NCT05593575|EXPERIMENTAL|SPH3127-3|4 tablet of SPH3127 (50 mg) ，1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
62091232|NCT05593575|EXPERIMENTAL|SPH3127-4|4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan , orally, once daily for 12 consecutive weeks
62091233|NCT01803126||atherosclerosis|No treatment.
62289455|NCT03625531|PLACEBO_COMPARATOR|Placebo letrozole|Women will receive placebo letrozole with no acupuncture from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. Placebo letrozole will be given in the same way as letrozole.
62289456|NCT04153084||High volume electrolytes Polyethylene Glycol (PEG 4000) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using high volume electrolytes PEG (Bohm solution®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
62655444|NCT00808925|EXPERIMENTAL|research arm|
62655445|NCT03197636||Malignant melanoma patients|40 patients with metastatic melanoma are included. Patients are admitted to Department of Oncology, Aarhus University Hospital (AUH). The patients are recruited to the study from the outpatient clinic of the Department of Oncology when they are about to begin treatment with pembrolizumab.
62655446|NCT03197636||Healthy controls|20 Healthy volunteers (HV) are included, matched by age and gender.
61920051|NCT05983783|EXPERIMENTAL|Rezvilutamide+ADT+Docetaxel|"Rezvilutamide: 240 mg (3 tablets of 80 mg each) orally once daily (QD), can be taken with or without food.~Docetaxel 6 cycles"
62091234|NCT05334381|EXPERIMENTAL|Adapted STAT-ED|The intervention will assist the family in following up with mental health referral recommendations provided by ED staff and eliciting families' preferences in regards to race and gender of providers, convenience of provider, and type of treatment. This assistance could involve help with the initial telephone contact, getting to appointments, and preparing for the appointments. The patient navigator will communicate with the family in person, by telephone, and/or by text messaging as per family's preference. This once to twice a week communication with both the youth and their parent will promote mental health care initiation and identify barriers and problem-solving solutions.
62091235|NCT05334381|ACTIVE_COMPARATOR|Standard Enhanced Treatment|After discharge from the Children's Hospital of Philadelphia emergency department, the participant will be given a list of resources and referrals for mental health treatment by the hospital social work team. Phone call contact will be made to follow up on the initiation of treatment from the referral recommendations given at discharge.
62091236|NCT06099743|NO_INTERVENTION|ASCENT Stakeholder Interviews|Enrolled stakeholders will be sent the study description and proposed intervention content to review. They will complete a semi-structured interview with trained study staff to obtain feedback on the proposed intervention.
62091237|NCT06099743|EXPERIMENTAL|ASCENT Open Pilot|"Enrolled patients will receive an intervention manual and will participate in six weekly or biweekly individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 6 weeks, 12 weeks, and 16 weeks, as well as an exit interview after the intervention."
62091238|NCT06099743|EXPERIMENTAL|Pilot RCT: ASCENT Arm|"Enrolled patients will receive an intervention manual and will participate in six weekly or biweekly individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 6 weeks, 12 weeks, and 16 weeks."
62091239|NCT06099743|ACTIVE_COMPARATOR|Pilot RCT: Control Arm|"Participants will receive usual supportive care, which includes referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician.~Participants will be asked to complete surveys at baseline, 6 weeks, 12 weeks, and 16 weeks."
62091240|NCT05846087|EXPERIMENTAL|Treatment|Three weeks of sleep retraining therapy - behavioral component of cognitive behavioral therapy for insomnia. This will be self-delivered by participants digitally using the smart phone App 'SleepFix'.
62091241|NCT05846087|ACTIVE_COMPARATOR|Control|Sleep health education modules delivered each week for three weeks. Modules contain information about sleep and insomnia; how insomnia affects other aspects of life; what activities influence health sleep (sleep hygiene) and information designed to dispel false beliefs about sleep
62091242|NCT05200390|EXPERIMENTAL|Continuous Glucose Monitor|Adult patients with Type 2 Diabetes on any anti-diabetic regimen utilizing continuous glucose monitors for 3 months
62091243|NCT04323735|ACTIVE_COMPARATOR|Low Dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 \]LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
62091244|NCT04323735|ACTIVE_COMPARATOR|High dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
62091245|NCT02372331|NO_INTERVENTION|Conventional perioperative management|"* Preop usual biliary drainage~* Preop smoking and alcohol~* Preop parenteral nutrition~* Oral bowel preparation (mechanical bowel preparation )~* Preoperative fasting \> 12 hours~* Pre-anesthetic medication~* Anti-thrombotic prophylaxis~* Antimicrobial prophylaxis and skin preparation~* Intravenous analgesia : PCA~* Prevention of postoperative nausea and vomiting (PONV) (X)~* Incision : surgeon direction~* Avoiding hypothermia~* Nasogastric intubation (O)~* Postop glycemic control~* Positive fluid balance~* Perianastomotic drain removal over POD #5~* Somatostatin analogues~* Transurethral catheter removal~* Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)~* Postop routine artificial nutrition (O), soft diet at POD #5~* Early and scheduled mobilization"
62091246|NCT02372331|EXPERIMENTAL|ERAS perioperative management|"* behavioral intervention (counselling, audit)~* dietary supplement~* procedure (preoperative and postoperative)~* drug"
62091247|NCT01361815|OTHER|H-Coil Deep TMS Treatment|
62091248|NCT01786343|EXPERIMENTAL|Decitabine - 5 Day Regimen|Decitabine 20 mg/m2 by vein daily for 5 days.
62091249|NCT01786343|EXPERIMENTAL|Decitabine - 10 Day Regimen|Decitabine 20 mg/m2 by vein daily for 10 days.
62091250|NCT06551246|EXPERIMENTAL|Solifenacin 5 mg + add-on solifenacin 5 mg|Group 1A: Solifenacin 5 mg for 6 weeks, and if non-complete response after 6 weeks add-on solifenacin 5 mg for 12 weeks.
62091251|NCT06551246|EXPERIMENTAL|Solifenacin 5 mg + add-on mirabegron 25 mg|Group 1B: Solifenacin 5 mg for 6 weeks, and if non-complete response after 6 weeks add-on mirabegron 25 mg for 12 weeks.
62091252|NCT06551246|EXPERIMENTAL|Mirabegron 25 mg + ad-on mirabegron 25 mg|Group 2A: Mirabegron 25 mg for 6 weeks, and if non-complete response after 6 weeks add-on mirabegron 25 mg for 12 weeks.
62091253|NCT06551246|EXPERIMENTAL|Mirabegron 25 mg + add-on solifenacin 5 mg|Group 2B: Mirabegron 25 mg for 6 weeks, and if non-complete response after 6 weeks add-on solifenacin 5 mg for 12 weeks.
62091254|NCT02536690|ACTIVE_COMPARATOR|Group P|Induction with propofol bolus. Dose will be started at 1 mg/kg and will be adjusted as described in summary.
62091255|NCT02536690|ACTIVE_COMPARATOR|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary.
62091256|NCT02536690|ACTIVE_COMPARATOR|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by midazolam 0.03 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary."
62091257|NCT06042998|EXPERIMENTAL|Robotic group|Robotic gastrectomy
62091258|NCT06042998|ACTIVE_COMPARATOR|Laparoscopic group|Laparoscopic gastrectomy
62091259|NCT00062868|EXPERIMENTAL|LMP1/2 CTLs (ALCI - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
62091260|NCT00062868|EXPERIMENTAL|LMP1/2 CTLs (ALCI - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
62091261|NCT00062868|EXPERIMENTAL|LMP1/2 CTLs (ALCI - Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
62091262|NCT00062868|EXPERIMENTAL|LMP2A CTLs (ALASCER - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
62091263|NCT00062868|EXPERIMENTAL|LMP2A CTLs (ALASCER - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant
62091264|NCT00062868|EXPERIMENTAL|LMP2A CTLs (ALASCER - Group C)|Patients receiving CTLs following allogeneic stem cell transplant
62091265|NCT00062868|EXPERIMENTAL|LMP1/2 CTLs (ALCI - Expansion Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
62091266|NCT00062868|EXPERIMENTAL|LMP1/2 CTLs (ALCI - Expansion Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
62091267|NCT00062868|EXPERIMENTAL|LMP1/2 CTLs (ALCI - Expansion Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
62091268|NCT02300311|EXPERIMENTAL|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
62655447|NCT04017377|EXPERIMENTAL|Chemotherapy+ Radiation therapy|"Chemotherapy: Patients firstly receive an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m\^2 up to 70 mg/m\^2, Patients secondly receive weekly cisplatin (40 mg/m\^2). Treatment repeats every week until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic. Concurrent chemotherapy is a weekly regimen during radiotherapy. Patients will complete at least 4 cycles of concurrent chemoradiotherapy, until the maximal tolerated dose (MTD) appeared.~Radiation therapy: Patients also receive pelvic radiation therapy once daily (Monday-Friday) for a total of 28 fractions and intracavitary brachytherapy twice a week for a total 5 fractions. Complete radiotherapy within 55 days."
62655448|NCT05066984|EXPERIMENTAL|structured, multidisciplinary and personalized post-ICU care|structured, multidisciplinary and personalized post-ICU care
62655449|NCT05066984|NO_INTERVENTION|Ususal care|Usual care
62655450|NCT02640560||Children with food allergy|"Children with food allergy to nuts, hazelnuts, walnuts, shellfish and mollusks (1-14 years old).~The Parents of the cases children will compile a Food allergy questionnaire"
61920052|NCT05983783|ACTIVE_COMPARATOR|Rezvilutamide+ADT|Rezvilutamide: 240 mg (3 tablets of 80 mg each) orally once daily (QD), can be taken with or without food.
62091269|NCT02300311|PLACEBO_COMPARATOR|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
62091270|NCT01627340|EXPERIMENTAL|Diabetes Group|Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
62091271|NCT01627340|ACTIVE_COMPARATOR|Control Group|Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62091272|NCT04690283|PLACEBO_COMPARATOR|Placebo-control group|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and placebo treatment twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
62091273|NCT04690283|EXPERIMENTAL|Treatment group I|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Huangqi Guizhi Wuwu granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
62091274|NCT04690283|EXPERIMENTAL|Treatment group II|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Danggui Sini granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
62091275|NCT01941914|EXPERIMENTAL|Calcium electroporation|"The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment.~Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume."
62091276|NCT05514470|EXPERIMENTAL|Patients|Patients with mutations in genes encoding cytosolic aminoacyl-tRNA synthetases and cared at Necker Hospital.
62091277|NCT05968521|EXPERIMENTAL|Cardiac Rehabilitation (Intervention)|Participants allocated to the intervention group will receive a cardiac rehabilitation (CR) programme which will involve education, exercise, and a psychological component.
62091278|NCT05968521|ACTIVE_COMPARATOR|Treatment as usual (Control)|Participants allocated to the control group will receive treatment as usual.
62091279|NCT04807179|EXPERIMENTAL|Alexandrite Laser|Single arm, self-controlled
62091280|NCT01447355|EXPERIMENTAL|Prevention (cholecalciferol)|Participants receive cholecalciferol PO twice weekly for up to 8-9 weeks.
62091281|NCT06605677||All doctors with valid medical license in Tawam and Al Ain Hospitals|The group excludes infectious disease physicians and microbiologists.
62091282|NCT04973618|EXPERIMENTAL|APVO436|CD123 and CD3 epsilon bispecific antibody
62091283|NCT03633903|ACTIVE_COMPARATOR|Mindfulness|Mindfulness: Eight sessions, twice per week over four weeks. Surveys administered prior to each session.
62091284|NCT03633903|NO_INTERVENTION|Control|Treatment as usual (i.e., pharmacotherapy, psychotherapy, etc.) for the four week duration with twice weekly surveys administered.
62091285|NCT03859700|EXPERIMENTAL|DBV712 250mcg|
62091286|NCT05963867|EXPERIMENTAL|Cohort 1|
62091287|NCT05963867|EXPERIMENTAL|Cohort 2|
62091288|NCT00680693|EXPERIMENTAL|1|Mindfulness-based stress management 8-week program
62091289|NCT00680693|ACTIVE_COMPARATOR|2|Psycho-educational support group for women with IBS
62091290|NCT01477788||women, sonographic ovarian mass|women that will arrive to the sonographic unit of the gynecological department with the sonographic diagnosis of ovarian mass
62091291|NCT04270513||EVT by Flying Intervention Team in primary stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, for whom a Flying Intervention Team is flown to the primary stroke center in order to perform endovascular treatment.
62091292|NCT04270513||EVT after secondary transfer to comprehensive stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, who are transferred to a comprehensive stroke center for endovascular treatment.
62091293|NCT04044794|ACTIVE_COMPARATOR|Standard Care|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a monetary gift of $60 that can be used to purchase health-promoting supplies to support weight management.
62655451|NCT02640560||Healthy Children|Healthy Children (1-14 years old) The Parents of the control children will compile a Control questionnaire
62091294|NCT04044794|EXPERIMENTAL|Daily Self-Weighing|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a commercially available wireless scale. Participants will be instructed to weigh daily and view their weight on the scale's digital display.
62091295|NCT03725943|EXPERIMENTAL|Healthy adults|Dreem
62091296|NCT01472627||Bortezomib treatment|Subjects receiving standard of care regimen including Bortezomib
62091297|NCT02173353||Pancreas cancer|Develope a stand, cradle or robotic arm to hold the ultrasound probe, to obtain an ultrasound just before a standard radiation therapy treatment is given.
62091298|NCT05927961||aldosterone-producing adenoma|Histopathology shows a clear boundary between adrenal adenoma and surrounding normal tissue.
61920053|NCT03402048|ACTIVE_COMPARATOR|control arm|"At discretion of the treating phisician. Common chemotherapic regimens include:~Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle.~Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
62091299|NCT05927961||unilateral hyperplasia|Histopathology shows no clear boundary between adrenal hyperplasia and surrounding normal tissues.
62091300|NCT05703347|ACTIVE_COMPARATOR|Condition 1|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091301|NCT05703347|ACTIVE_COMPARATOR|Condition 2|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
62091302|NCT05703347|ACTIVE_COMPARATOR|Condition 3|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091303|NCT05703347|ACTIVE_COMPARATOR|Condition 4|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
62091304|NCT05703347|ACTIVE_COMPARATOR|Condition 5|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091305|NCT05703347|ACTIVE_COMPARATOR|Condition 6|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
62091306|NCT05703347|ACTIVE_COMPARATOR|Condition 7|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091307|NCT05703347|ACTIVE_COMPARATOR|Condition 8|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
62091308|NCT05703347|ACTIVE_COMPARATOR|Condition 9|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091309|NCT05703347|ACTIVE_COMPARATOR|Condition 10|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
62091310|NCT05703347|ACTIVE_COMPARATOR|Condition 11|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091311|NCT05703347|ACTIVE_COMPARATOR|Condition 12|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
62091312|NCT05703347|ACTIVE_COMPARATOR|Condition 13|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091313|NCT05703347|ACTIVE_COMPARATOR|Condition 14|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
62091314|NCT05703347|ACTIVE_COMPARATOR|Condition 15|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
62091315|NCT05703347|EXPERIMENTAL|Condition 16|Core intervention, Sleep goal, Sleep guidance messaging, Caregiver-directed loss-framed incentive, Supportive feedback.
62091316|NCT05634889|NO_INTERVENTION|Standard|Radiotherapy to the remaining breast after breast conserving surgery or chest wall after mastectomy, and regional axillary lymph node levels I-IV. Internal mammary nodes are included in the target volume if the tumor has a central/medial localization in the breast.
62655452|NCT04933565|EXPERIMENTAL|ORG-129|Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort
62655453|NCT04933565|PLACEBO_COMPARATOR|Placebo|Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort
62091317|NCT05634889|EXPERIMENTAL|Intervention|No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery. Chest wall radiotherapy after mastectomy only in case of wide spread multifocality.
62091318|NCT02455479|OTHER|Cohort 1: 100µg|Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
62091319|NCT02455479|OTHER|Cohort 2: 316 µg|Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
62091320|NCT02455479|OTHER|Cohort 3: 1000µg|Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
62091321|NCT01712685|EXPERIMENTAL|Renal Cell Carcinoma|
62091322|NCT01982071|EXPERIMENTAL|Treatment group|Intravenous (IV)
62091323|NCT03972423||IRCTC group|- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.
62091324|NCT03972423||CONTROL group|- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.
62091325|NCT03699124|ACTIVE_COMPARATOR|GP 1: two doses of FD MVA-BN--Lot 1|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 1
62091326|NCT03699124|ACTIVE_COMPARATOR|GP 2: two doses of FD MVA-BN--Lot 2|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 2
62091327|NCT03699124|ACTIVE_COMPARATOR|GP 3: two doses of FD MVA-BN--Lot 3|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 3
62091328|NCT04261920|EXPERIMENTAL|Single decoction group: Huangqi Guizhi Wuwu decoction|The dosage of granules: Sheng huangqi granule 5.5g/bag, Guizhi granule 0.9g/bag, Baishao granule 1.6g/bag, Ganjiang granule 1.7g/bag, Dazao granule 7g/bag. Take twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
62091329|NCT04261920|PLACEBO_COMPARATOR|Simulator group: Huangqi Guizhi Wuwu decoction Placebo|The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
62655454|NCT01184872|EXPERIMENTAL|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
61906337|NCT05919706|EXPERIMENTAL|Experimental Group|Pre-test data were collected from patients with Patient Information and Follow-up Form, Diabetes Self-Management Scale (DSMQ) and Short Form-36 Quality of Life Scale (SF-36). After the pre-test, a educational program and a game-based mobile technology application were carried out for 4 weeks, 2 days a week at intervals. After the educational program were completed, motivational interviews were conducted once a week for 4 weeks. In this process, it was ensured that the game-based mobile technology application continued. Post-test data were collected with DSMQ and SF-36 at 2 months (8 weeks after the pre-test). After the post-test, the patients were followed up for 4 weeks. After the follow, with the Patient Information and Follow-up Form, DSMQ, SF-36, and the Satisfaction Questionnaire the follow-test data was collected.
62091330|NCT04435080||Non-rehabilitation|The patients hospitalised in ICU who were provided all the intensive care managements except for rehabilitation interventions (discharged from intensive care unit before April 14, 2020)
62091331|NCT04435080||Rehabilitation|The patients hospitalised in ICU who were provided rehabilitation interventions in addition to all the intensive care managements. (discharged from intensive care unit after April 14, 2020)
62091332|NCT03522428|ACTIVE_COMPARATOR|Receiving treatment|Adding vitamin B12 at a dose of 5 μg / 100 days, custom folic acid therapy and iron supplements
62091333|NCT03522428|NO_INTERVENTION|Control group|Standard prenatal care (custom folic acid therapy and iron supplements)
62091334|NCT06697587|EXPERIMENTAL|eCREAT|"eCREAT consists of four guided internet modules delivered over four weeks (one each week), see intervention description below for further details."
62091335|NCT06301399|EXPERIMENTAL|Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy|"Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.~PD-1 (or PD-L1) inhibitors and targeted drugs: Select first-line PD-1 (or PD-L1) inhibitors and VEGFR targeted drugs according to clinical routine treatment, and administer according to the original first-line combination therapy dosage until progression or intolerable toxic reactions occur."
62091336|NCT03087721|EXPERIMENTAL|1x2 HIIT-LV, 3 times a week, 24 min|
62091337|NCT03087721|ACTIVE_COMPARATOR|CAE, moderate intensity, 3 times a week, 36 min|
62091338|NCT02548195|EXPERIMENTAL|GEMOX|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2; every three weeks for 6-8 cycles in total.
62091339|NCT02548195|ACTIVE_COMPARATOR|Capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
62091340|NCT04652895||Moderate-to-severe traumatic brain injury inpatients|Moderate-to-severe traumatic brain injury inpatients
62091341|NCT04979390|EXPERIMENTAL|Treatment group|
62091342|NCT01031043|EXPERIMENTAL|Topical Bethanechol|patients will be given either 5 mg (first phase) or 10 mg (second phase) of bethanechol in 1 ml of solution containing an absorption enhancer. Administration will be performed by throat spray device
62091343|NCT04019522|EXPERIMENTAL|Hypoxia|During each session, study participants will receive a single sequence of AIH, consisting of 15 x 60-seconds periods of hypoxia alternating with 90-seconds of normoxia (21% O2), for a total of 30 minutes, whilst in a seated upright position. AIH will be applied by directing gas flow to a reservoir bag connected via plastic tubing to a non re-breathing facemask/respiratory valve system while the participants are in a seated position. Defined gas mixtures will be delivered by manual adjustment of one-way valves attached to a hypoxia generator.
62091344|NCT05144815|EXPERIMENTAL|IPC + Exercise protocol group|Patients in this group (n=16) will undergo ischaemic preconditioning (IPC) plus an endurance training protocol.
62091345|NCT05144815|SHAM_COMPARATOR|Sham IPC + Exercise protocol group|Patients in this group (n=16) will undergo sham ischaemic preconditioning (IPC) plus an endurance training protocol.
62091346|NCT00717119||1|Patients with sprain of ankle treated with NSAID
62091347|NCT03282019|EXPERIMENTAL|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
62091348|NCT03282019|ACTIVE_COMPARATOR|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
62091349|NCT01029600|ACTIVE_COMPARATOR|Arthroscopic Capsulotomy|Arthroscopic capsular release
62091350|NCT01029600|ACTIVE_COMPARATOR|Distention with steroid|Arthrographic distention with contrast, saline, steroid and local anaesthetic
62091351|NCT04440969|EXPERIMENTAL|Intervention|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks. (Week 1 - 24)
62091352|NCT04440969|EXPERIMENTAL|Wait-list control|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks after Intervention Group has completed intervention. (Week 25 - 48)
62091353|NCT04089176|ACTIVE_COMPARATOR|protocal A|Carbetocin versus placebo
62091354|NCT04089176|ACTIVE_COMPARATOR|protocal B|Oxytocin versus placebo
62091355|NCT06339112|EXPERIMENTAL|Playing with toy nebulizer|The child who needs to take inhaler medication is taken to the observation room. Before starting the procedure, the child will be introduced to the toy nebulizer. The toy nebulizer is shown to the child as an example and allowed to play with it so that the level of fear can be reduced.
62289457|NCT04153084||Low volume electrolytes PEG (PEG 3350) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using low volume electrolytes PEG (Movicol®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
62289458|NCT04153084||Sodium picosulfate cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using sodium picosulfate (Picoprep®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
62463261|NCT06302374|EXPERIMENTAL|Cohort 8 GR2001 0.1mg/kg/ GR2001 0.2mg/kg/ HTIG|"Thirty six subjects will be randomly assigned to receive GR2001(0.1mg/kg) or GR2001(0.2mg/kg) or HTIG(250IU) at a 1:1:1 ratio (i.e. 12 subjects receive GR2001(0.1mg/kg), 12 with GR2001(0.2mg/kg) and 12 with HTIG).~Seventy two subjects will be randomly assigned to receive GR2001(0.1mg/kg) or GR2001(0.2mg/kg) or HTIG(250IU) at a 1:1:1 ratio (i.e. 24 subjects receive GR2001(0.1mg/kg), 24 with GR2001(0.2mg/kg) and 24 with HTIG) followed by one dose of Tetanus Toxoid（TT） on Day0 and Day28."
61920054|NCT03402048|EXPERIMENTAL|experimental arm|"Treatment prescriptions will be based on gene analysis:~* Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.~* Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.~* Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.~* Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.~* Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.~* Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
62091356|NCT06339112|EXPERIMENTAL|Cartoon|Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. 2-3 minutes before starting drug treatment, the child will be allowed to watch cartoons according to his age group and will be encouraged to do so throughout the procedure. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application of the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
62289459|NCT03785054|EXPERIMENTAL|Cohort 1|6 subjects receiving a single dose of 1 mg capsule HTL0014242 and 2 subjects receiving matching placebo oral capsule
62463262|NCT06433674|EXPERIMENTAL|Zinc Sulfate|The experimental group will receive \~1 mg/kg/day of elemental enteral Zinc
62091357|NCT06339112|NO_INTERVENTION|Control|Routine care will be provided.
62091358|NCT00410384|PLACEBO_COMPARATOR|Placebo|Placebo
62091359|NCT00410384|EXPERIMENTAL|Belimumab 1 mg/kg|Belimumab 1 mg/kg
62091360|NCT00410384|EXPERIMENTAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg
62091361|NCT02365896|OTHER|TLDG or LADG|To complete the distal gastrectomy with Billroth-II reconstruction and D2 lymphadenectomy for locally advanced gastric cancer with TLDG or LADG
62091362|NCT01272011|EXPERIMENTAL|Phase 1 Arm (Pilot)|Individuals were exposed to intermittent hypoxia and locomotor training to establish our interventions (set up lab, train personnel, develop study protocols/interventions, etc)
62091363|NCT01272011|EXPERIMENTAL|Phase 2 Arm (LTF)|Individuals were exposed to 10 days of intermittent hypoxia to determine the effect of this intervention on ventilatory long-term facilitation, as measured by minute ventilation
62091364|NCT01272011|OTHER|Phase 3 Arm (Ventilatory Loading)|Individuals were exposed to 10 days of intermittent hypoxia to determine changes in ventilatory loading.
62289460|NCT03785054|EXPERIMENTAL|Cohort 2|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62289461|NCT03785054|EXPERIMENTAL|Cohort 3|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62289462|NCT03785054|EXPERIMENTAL|Cohort 4|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62289463|NCT03785054|EXPERIMENTAL|Cohort 5|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62289464|NCT03785054|EXPERIMENTAL|Cohort 6|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62091365|NCT06085092|EXPERIMENTAL|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
62091366|NCT06085092|ACTIVE_COMPARATOR|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or selfesteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight, but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
62091367|NCT02393261|EXPERIMENTAL|A 2500mlGroup|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
62091368|NCT02393261|ACTIVE_COMPARATOR|B 2000mlGroup|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
62091369|NCT01359410|ACTIVE_COMPARATOR|Stapled transection with mesh reinforcement|Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
62091370|NCT01359410|NO_INTERVENTION|Stapled transection without mesh reinforcement|
62091371|NCT03968991|ACTIVE_COMPARATOR|Healthy volunteer group|male or female healthy volunteers
62091372|NCT03968991|EXPERIMENTAL|Subjects with acquired visual impairment|visual acquired disability
62655455|NCT01184872|ACTIVE_COMPARATOR|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
62655456|NCT04192682|EXPERIMENTAL|Anlotinib Combined With Sintilimab|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
62655457|NCT04884568|EXPERIMENTAL|Exufiber|This is an open, non-randomised , single arm study
62655458|NCT00942851|EXPERIMENTAL|active|AH-8 containing topical intervention
62655459|NCT00942851|PLACEBO_COMPARATOR|placebo|topical intervention WITHOUT AH-8
62655460|NCT03736720|EXPERIMENTAL|Treatment (liposomal irinotecan, leucovorin, fluorouracil)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin IV over 30 minutes, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 28 days for in the absence of disease progression or unacceptable toxicity.
62655461|NCT03136575|ACTIVE_COMPARATOR|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
62655462|NCT03136575|PLACEBO_COMPARATOR|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
62655463|NCT05107037|EXPERIMENTAL|TQ-B3234 capsule|"In the dose escalation phase, enrolled subjects first received a single dose on an empty stomach for a 3-day observation period. If Dose limiting toxicity (DLT) did not occur, continuous multiple doses were continued, once a day on an empty stomach for a treatment cycle of 28 days.~After the dose escalation phase was completed, cohort extension studies were conducted according to the identified phase ii clinical recommended doses.type I neurofibromatosis （NF1） patients and malignant peripheral nerve sheath tumors （MPNST） patients were selected."
62655464|NCT03530696|EXPERIMENTAL|T-DM1 with palbociclib|T-DM1 is given intravenously every 21 days (day 1 of each cycle) Palbociclib is administered orally on days 5-18 of each cycle
62655465|NCT03530696|EXPERIMENTAL|Single Agent T-DM1|T-DM1 is given intravenously every 21 days (day 1 of each cycle)
62091373|NCT03968991|EXPERIMENTAL|Subjects with congenital visual impairment|Visual congenital disability
62091374|NCT04822298|EXPERIMENTAL|Part 1: Dose Exploration|The dose exploration part of the study will estimate the MTD and/or the RP2D.
62289465|NCT03785054|EXPERIMENTAL|Cohort 7|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62091375|NCT04822298|EXPERIMENTAL|Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC|Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.
62091376|NCT04822298|EXPERIMENTAL|Part 2: Dose Expansion - Cohort 2 Squamous NSCLC|Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.
62307967|NCT01568944|OTHER|Standard Treatment|Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
62091377|NCT03738579|ACTIVE_COMPARATOR|Control Group|After standard of care debridement and irrigation (using normal saline), Mepilex foam dressing will be used. Foam dressing will be used throughout the study, including for mid-week dressing changes.
62091378|NCT03738579|ACTIVE_COMPARATOR|Antibacterial Control|After standard of care debridement and irrigation (using normal saline), Mepilex AG foam dressing will be used. This dressing will be used throughout the study, including for mid-week dressing changes.
62091379|NCT03738579|EXPERIMENTAL|Next Science Group|Standard of care debridement will be performed as well as irrigation using TorrentX Wound Wash,then BlastX Wound gel will be applied to the wound before covering treatment site with Mepilex foam dressing (no AG component). BlastX will re-applied again mid-week during mid-week dressing change.
62091380|NCT06116643|EXPERIMENTAL|Standard Active Therapy plus SPHi|Participants will undergo the standard active therapy of ulcerative colitis plus the addition of the ProGo medical food.
62091381|NCT03232190|EXPERIMENTAL|INTNIC|NICU Intervention Group Web Application Infants \< 32 weeks
62091382|NCT03232190|NO_INTERVENTION|CNIC|NICU Control Group No Web Application Infants \< 32 weeks
62091383|NCT03232190|NO_INTERVENTION|CMAT|Maternity Unit Control Group No Web Application Infants \> 37 weeks
62091384|NCT02162732|EXPERIMENTAL|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
62091385|NCT02401399|PLACEBO_COMPARATOR|regular diet|The patients receive regular diet of 900 Kcal/day during 15 days before surgery
62091386|NCT02401399|ACTIVE_COMPARATOR|high protein formula|The patients receive high protein formula during 15 days before surgery
62091387|NCT02401399|EXPERIMENTAL|Immunonutrition|The patients receive Immunonutrition during 15 days before surgery
62091388|NCT00902382||1|Infertile women who conceive spontaneously
62289466|NCT03785054|EXPERIMENTAL|Cohort 8|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62289467|NCT03785054|EXPERIMENTAL|Cohort 9|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
62655466|NCT05218876|EXPERIMENTAL|Low- to moderate intensity strength and endurance training|Participants will perform a combination of strength and endurance training with low-to moderate-intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
62091389|NCT00902382||2|Infertile women who conceive on various ovulation stimulation medications
62091390|NCT05759806|EXPERIMENTAL|ADHF patients|ADHF patients with compromised response to diuretics treated with Nephronyx system
62091391|NCT00082290|EXPERIMENTAL|a massage|About 45 minute massage
62091392|NCT00082290|EXPERIMENTAL|visit with a volunteer|45 minute visit
62091393|NCT00082290|EXPERIMENTAL|period of quiet time|45 minutes of quiet time
62091394|NCT04094909|EXPERIMENTAL|Rh-endostatin + chemotherapy+Pembrolizumab|The subjects are 186, including Squamous and Non-Squamous NSCLC. Squamous NSCLC receives rh-endostatin at a dose of 15mg/m2 for 5 days and 200 mg of pembrolizumab at day 1 in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. all the patients with squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and \[nab\]-paclitaxel (100mg/m2) for the first 4 cycles. For non-squamous NSCLC, rh-endostatin at dose of 15mg/m2 for 5 days, 200 mg of pembrolizumab at day 1 and pemetrexed (500mg/m2,d1) are given in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. Non-squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and pemetrexed (500mg/m2,d1) for the first 4 cycles.
62289468|NCT05311384|EXPERIMENTAL|Keys intervention|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period.
62289469|NCT06055166|EXPERIMENTAL|untreated surgically resectable rectal cancer|
62289470|NCT06055166|EXPERIMENTAL|untreated locally advanced unresectable non-small cell lung cancer|
62463263|NCT06433674|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a similar amount of sterile water in a colored syringe
62463264|NCT04707040|EXPERIMENTAL|Neurocognitive Exercise Program Group|The group received NEP for 10 weeks, one hour per week conducted by the same physiotherapist with 6 years of experience in this field. Children with ADHD were given home exercises for the other six days of the week without a NEP session. Home exercises were followed with an exercise diary under the control of children's parents. The home exercise program consisted of visual-motor and auditory-motor coordination tasks (daily 15 min).
62289471|NCT06055166|EXPERIMENTAL|untreated locally advanced unresectable esophageal squamous cell carcinoma|
62289472|NCT06055166|EXPERIMENTAL|untreated locally advanced unresectable cervical carcinoma|
62307968|NCT01334112|EXPERIMENTAL|Axitinib|Oral Axitinib (5mg, twice daily) will be administered to all patients
62307969|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
62463265|NCT02099981|EXPERIMENTAL|Control Group|Control subjects will receive AG.
62463266|NCT02099981|EXPERIMENTAL|Type 1 diabetes|Type 1 diabetic subjects will receive AG.
62463267|NCT03401996|EXPERIMENTAL|Real tDCS|
62091395|NCT03824236|EXPERIMENTAL|P-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
62091396|NCT03824236|EXPERIMENTAL|NP-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and not protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
62091397|NCT03824236|NO_INTERVENTION|InfectivityCtrl group|Healthy subjects, between and including 18 and 55 years of age, who did not receive, in the current study, any immunization but underwent sporozoite challenge.
62091398|NCT02970747||Car/Len/Dex (KRd)|Patients treated with carfilzomib, lenalidomide and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
62091399|NCT02970747||Car/Dex (Kd)|Patients treated with carfilzomib and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
62091400|NCT02970747||Car/Dex/Dara (KdD)|Patients treated with carfilzomib, dexamethasone and daratumumab dosage form, dosage, frequency and duration of treatment according to current SmPC
62091401|NCT01607970|EXPERIMENTAL|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
62289473|NCT05868421|EXPERIMENTAL|Support Person Coaching Call and Written Materials|Support persons will receive written material resources on support strategies to stop smoking, and resources on how to stop smoking. Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The coaching session will be delivered by research staff by phone or video call. Veteran smokers will receive written smoking cessation resource and referral information for VHA and non-VHA EBCT options.
62289474|NCT05868421|ACTIVE_COMPARATOR|Written Materials Only|Support persons will receive written material resources on support strategies to stop smoking, and resources on how to stop smoking. Veteran smokers will receive written smoking cessation resource and referral information for VHA and non-VHA EBCT options.
62289475|NCT00842933|EXPERIMENTAL|Experimental group|Corticosteroids discontinued 24 hours after cessation of vasopressor therapy or 7 days, which ever comes first.
62463268|NCT03401996|SHAM_COMPARATOR|Sham tDCS|
62463269|NCT05539222|ACTIVE_COMPARATOR|Food voucher plus health and nutritional education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group.
62463270|NCT05539222|NO_INTERVENTION|Food voucher|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group.
62463271|NCT02738190|ACTIVE_COMPARATOR|Albumin|5% Albumin to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and albumin to reach the standard volume administered to these patients (400 ml)
62463272|NCT02738190|ACTIVE_COMPARATOR|Fresh Frozen Plasma|Fresh Frozen Plasma to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and plasma to reach the standard volume administered to these patients (400 ml)
62091402|NCT01607970|PLACEBO_COMPARATOR|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
62091403|NCT04428970||TBI patients with ICP monitoring|Patients with severe TBI (GCS\<9 on arrival) receiving invasive ICP monitoring
62091404|NCT02968940|EXPERIMENTAL|Avelumab and hypofractionated radiation therapy(HFRT)|"* Avelumab 10 mg/kg intravenously (IV) every 2 weeks.~* Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
62091405|NCT05117840||Lung Cancer Screening Cohort|Individuals at high-risk of lung cancer undergoing standard of care screening as per USPSTF guidelines. All subjects will undergo low-dose CT scanning as per guidelines and an investigational blood-draw will be taken from all enrolled subjects.
62091406|NCT04603521||Hypertrophic cardiomyopathy (HCM)|Survival after Myectomy Operation
62091407|NCT06405074|OTHER|LIFU/Sham|double-blind, sham-controlled, crossover study in N=44 individuals with Tobacco Use Disorder
62091408|NCT06405074|OTHER|Sham/LIFU|double-blind, sham-controlled, crossover study in N=44 individuals with Tobacco Use Disorder
62091409|NCT01146808|EXPERIMENTAL|ADV plus hepatitis B vaccination|Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
62091410|NCT04317768|EXPERIMENTAL|Study group|They will be educated and motivated by an intensive program consisting of verbal instructions, Power Point lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
62091411|NCT04317768|OTHER|Control group|They will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
62091412|NCT02731404|OTHER|IPPV ventilation|standard intermittent positive pressure ventilation in patients undergoing laparoscopic cholecystectomy
62091413|NCT02731404|OTHER|HFJV ventilation|high frequency jet ventilation in patients undergoing laparoscopic cholecystectomy
62463273|NCT01544127|EXPERIMENTAL|MI-SI+TAU|Motivational Interviewing to Address Suicidal Ideation
61906338|NCT05919706|NO_INTERVENTION|Control Group|Pre-test data were collected from patients with Patient Information and Follow-up Form, Diabetes Self-Management Scale DSMQ) and Short Form-36 Quality of Life Scale (SF-36). After the pre-test data were collected, no intervention was applied to the patients for 3 months (12 weeks), except for routine nursing care. Posttest data were collected with DSMQ and SF-36 2 months (8 weeks) after the pretest data. After the last test, the patients were followed up for 4 weeks, and 3 months (12 weeks) after the start of the study, the Patient Information and Follow-up Form (only the parts containing the features related to the disease and metabolic control variables), DSMQ and SF-36 Scale and follow-up test data were collected.
62091414|NCT02605499|EXPERIMENTAL|UV-C light disinfection|During intervention UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
62091415|NCT02605499|NO_INTERVENTION|Control|During control period there will be standard discharge and daily room cleaning only, with no UV-C light disinfection.
62091416|NCT05156801|EXPERIMENTAL|ArchSinus stent|Post-FESS implantation of the study device (ArchSinus) into ethmoid sinus cavity
62091417|NCT05156801|ACTIVE_COMPARATOR|Propel stent|Post-FESS implantation of the comparator device (Propel) into ethmoid sinus cavity.
62091418|NCT05156801|ACTIVE_COMPARATOR|NasoPore packing|Post-FESS implantation of the comparator device (NasoPore) into ethmoid sinus cavity.
62091419|NCT01041547||Healthy adults|healthy adults with BMI below 32, between ages 19-60 yrs, both males and females
62091420|NCT05943587|EXPERIMENTAL|Chronic pain group|30-45 minute individual sessions of culture-sensitive PNE4kids training will be applied.
62091421|NCT05943587|ACTIVE_COMPARATOR|Control Group|30-45 minute individual sessions of standard education training will be applied.
62091422|NCT04848896|EXPERIMENTAL|CORI|Subjects in need for total knee arthroplasty (TKA) as decided by their doctor and treated with CORI Robotics System.
62091423|NCT04848896|ACTIVE_COMPARATOR|Conventional Procedure|Subjects in need for total knee arthroplasty (TKA) as decided by their doctor and treated with conventional approach with conventional manual instrumentation.
62463274|NCT01544127|EXPERIMENTAL|MI-SI-R+TAU|Motivational Interviewing to Address Suicidal Ideation Revised
62463275|NCT01544127|OTHER|TAU Alone|Treatment as usual
62463276|NCT01506466|OTHER|additional examinations/measurements|
62463277|NCT05378126|OTHER|Neurological cohort|All patients included in the study wil have a neurological examination
62463278|NCT06250010||Cohort 1: tissue samples (healthy and tumor taken from the same patient)|Tissue samples (healthy and tumor taken from the same patient) collected at the Institute's Biobank (starting from 2017) (retro-prospective). The data relating to the neoplastic pathology will also be indicated: histotype, grading, FIGO stage. And data on oncological follow-up: any intra or post-operative complications, any adjuvant therapies, type and date of any recurrence/metastasis, type of treatment, any recurrence, date and manner of death
62463279|NCT06250010||Cohort 2: tissue samples (decidualized endometrium and trophoblast taken from it patient)|The tissue samples (decidualized endometrium and trophoblast taken from it patient) which will be collected from the Gynecology and Obstetrics Unit of the Polyclinic Federico II University of Naples (prospective) and transferred to the Regina National Cancer Institute Elena, IRE-IFO
62463280|NCT04786184|EXPERIMENTAL|CALM Breathing|
62463281|NCT04786184|ACTIVE_COMPARATOR|Wait-List Control|
62463282|NCT00604877|EXPERIMENTAL|1|
62091424|NCT05395572|EXPERIMENTAL|Tape|Kinesio tape will be applied to the neck to help facilitate underactive muscles and ROM will be assessed
62091425|NCT05395572|NO_INTERVENTION|Control|ROM will be assessed before tape application to determine any changes
62091426|NCT04145687|ACTIVE_COMPARATOR|Metformin|
62091427|NCT04145687|PLACEBO_COMPARATOR|Placebo|
62091428|NCT02081391|EXPERIMENTAL|Tapentadol immediate-release (IR)|"In the first 24 hours, tapentadol oral solution at a dose of 1.25 mg/kg body weight was given every 4 hours (±15 min) to participants aged 6 months to less than 18 years (maximum individual dose of tapentadol was 100 mg). Participants from 30 days to less than 6 months were dosed with 0.5 mg/kg body weight every 4 hours. Participants from birth to less than 30 days of age were dosed with 0.1 mg/kg body weight every 4 hours.~After 24 hours and up to 72 hours, the dose could be reduced based on the investigator's judgment."
62091429|NCT02081391|PLACEBO_COMPARATOR|Placebo|Matching placebo oral solution was administered every 4 hours (±15 min) up to 72 hours.
62091430|NCT05886738|EXPERIMENTAL|Obese|Individuals with obesity will be recruited. Obesity will be defined as having a body mass index \>= 30 kg/m2 or a waist circumference of \> 88cm (females) or \>102 cm (males).
62091431|NCT05886738|ACTIVE_COMPARATOR|Lean|Lean individuals will be recruited and will act as the reference arm such that we will compare responses of individuals with obesity to the lean group. This group will be defined as having a BMI between 18.5-24.9 kg/m2 and a waist circumference of less than 88 cm (females) or 102 cm (males)
62091432|NCT01551589|EXPERIMENTAL|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
62289476|NCT00842933|ACTIVE_COMPARATOR|Standard of care group|Standard corticosteroid therapy given for 7 days as treatment for adrenal insufficiency during septic shock.
62307970|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
62463283|NCT00604877|ACTIVE_COMPARATOR|2|
62463284|NCT05376007|EXPERIMENTAL|Playing serious game 'Broodles'|"The participants allocated to this group will play the newly developed serious game 'Broodles' after pre-test assessment. Children will play the serious game without the parent or the help of a caregiver. Parents and children will make complementary worksheets together and parents will read an information brochure.~Concomitant care as usual is allowed during the study.~A parent-child pair is labelled as one participant."
62463285|NCT05376007|NO_INTERVENTION|Waitlist control group|"The participants allocated to this group will play the serious game 'Broodles' after follow-up assessment.~Concomitant care as usual is allowed during the study."
62463286|NCT05163093||Angle closure glaucoma patients with or without abnormal zonular.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
62091433|NCT01551589|ACTIVE_COMPARATOR|Elective Nodal Irradiation (ENI)|Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
62091434|NCT00735800|ACTIVE_COMPARATOR|Supportive Counseling|
62091435|NCT00735800|EXPERIMENTAL|Problem-Solving|
62091436|NCT04265547|EXPERIMENTAL|Intervention Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Participants in the intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion.
62289477|NCT04815837|EXPERIMENTAL|Intervention|"Participants received the following interventions:~1. Viewing a video promoting Human Papillomavirus (HPV) vaccination~2. Receiving discount coupons~3. Visiting the project webpage~4. Receiving follow-up reminders"
62289478|NCT02325544|EXPERIMENTAL|CBT+SMC|12 sessions of Cognitive Behavioural Therapy adapted for DS (plus one booster session) plus standardised medical care
62289479|NCT02325544|ACTIVE_COMPARATOR|SMC|Standardised medical care provide by neurologist and/or psychiatrist
62289480|NCT03089788|OTHER|Home-based test and skin test|
62289481|NCT05900804|EXPERIMENTAL|Intervention Group|"* On the 3rd postoperative day, patient information form, patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in the patient room. Afterwards, the training prepared in line with the fracture liaison service model will be verbally explained to the patients and then the booklet prepared by taking expert opinion will be given to the patients.~* 3rd week patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in orthopedics and traumatology outpatient clinic.~* 3rd month patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied at home visit."
62289482|NCT05900804|NO_INTERVENTION|Control group|"* On the 3rd postoperative day, patient information form, patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in the patient room.~* Week 3 patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in orthopedics and traumatology outpatient clinic.~* 3rd month patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied at home visit. Afterwards, the training prepared in line with the fracture liaison service model will be verbally explained to the patients and then the booklet prepared by taking expert opinion will be given to the patients."
62289483|NCT02548065|ACTIVE_COMPARATOR|Balneotherapy|"Daily thermal-mineral bath with mineral water named Debole of Vetriolo for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)"
62463287|NCT05163093||Patients with age-related cataract.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
62463288|NCT03785548||Mirror group|This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room.
62463289|NCT03785548||No mirror group|This group of patients decline a mirror, and they will undergo the standard pelvic examination.
62463290|NCT01463761||high-level athletes|High-level athlete, enrolled in a Ministry-recognized Pôle
62463291|NCT02815319|ACTIVE_COMPARATOR|Standard of care|Physician's treatment recommendation for dexamethasone premedication
62463292|NCT02815319|ACTIVE_COMPARATOR|8mg PO dexamethasone|8mg PO dexamethasone premedication
62289484|NCT02548065|PLACEBO_COMPARATOR|Placebo|daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
62289485|NCT00588367||1|Suspected pancreatic ductal adenocarcinoma.
61906339|NCT01261780|SHAM_COMPARATOR|Sham device|Sham therapy device to area of painful chemotherapy induced peripheral neuropathy (CIPN) for 45 minutes daily x 10 days
62289486|NCT00588367||2|Chronic pancreatitis and slated for decompression treatment.
62289487|NCT00588367||3|Autoimmune pancreatitis.
61906340|NCT01261780|ACTIVE_COMPARATOR|MC-5A treatment|MC-5A therapy to the area of painful CIPN for 45 minutes daily for a total of 10 days.
61906341|NCT05887778|ACTIVE_COMPARATOR|placebo injection|5ml of 0,9% sodium chloride - before the popliteal nerve block
61906342|NCT05887778|ACTIVE_COMPARATOR|0,1mg/kg Dexamethasone|0,1mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
61906343|NCT05887778|ACTIVE_COMPARATOR|0,2 mg/kg Dexamethasone|0,2 mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
61906344|NCT05668988|EXPERIMENTAL|DZD9008|
61906345|NCT05668988|ACTIVE_COMPARATOR|Platinum-based Chemotherapy|
61906346|NCT02979860|NO_INTERVENTION|Typical sleep schedule|"Children in this arm will be asked to maintain their current sleep schedule. No prescription will be provided other than to sleep how they typically would sleep."
61906347|NCT02979860|EXPERIMENTAL|Enhance time in bed by 90 min/night|Sleep duration - 90 minutes: Children in this arm will be asked to get into bed and to turn their lights out 90 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
61906348|NCT02979860|EXPERIMENTAL|Enhance time in bed by 45 min/night|Sleep duration - 45 minutes:Children in this arm will be asked to get into bed and to turn their lights out 45 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
61920055|NCT00350454|ACTIVE_COMPARATOR|A|Drug eluting stent using biodegradable polymer BP stent
61920056|NCT00350454|ACTIVE_COMPARATOR|B|polymer-free drug eluting stent PF stent
61920057|NCT00350454|ACTIVE_COMPARATOR|C|permanent polymer using stents PP stent
62091437|NCT04265547|NO_INTERVENTION|Control Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion. Control arm participants will be offered the chemical-free products, cleaning supplies, and air filter at this time.
62091438|NCT05450263|ACTIVE_COMPARATOR|Sub-acute low back pain active intervention|To assess the efficacy of IET on the chronification of LBP, participants who are found to have a higher risk of pain chronification due to the presence of a biomarker (positive mPFC-Nac connectivity) will be randomized to the intervention group (IET)
62091439|NCT05450263|SHAM_COMPARATOR|Sub-acute low back pain passive intervention|Control group, treatment as usual.
62091440|NCT05450263|NO_INTERVENTION|No intervention|
62091441|NCT05698355|EXPERIMENTAL|Telerehabilitation group|"Multimodal self-treatment-based telerehabilitation will be implemented with a video conference method. For telerehabilitation, at each session, manual therapy techniques, (i.e., stretching, myofascial release, and tissue desensitization), sex education, and pelvic floor muscle relaxation massages with a pelvic wand (i.e., relaxation, stretching) using small intra-vaginal wand were used. Women were also asked to perform home exercises resembling those performed under supervision five times per week as well as auto-insertion exercises with a pelvic wand in addition to desensitization techniques three times per week.~Sessions consist of 60 minutes. Telerehabilitation will take place 2 days a week for 12 weeks."
62091442|NCT05698355|NO_INTERVENTION|Education group|60 minutes of video recording training will be given about pelvic pain relaxation exercises.
62091443|NCT04187911|EXPERIMENTAL|Intervention - Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. DDP aims to treat trauma-related problems and Attachment Disorders over about 20 1-hour sessions using the core communication techniques of Playfulness, Acceptance, Curiosity and Empathy (PACE)
62091444|NCT04187911|ACTIVE_COMPARATOR|Control - Services as Usual (SAU)|SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise.
62091445|NCT03780205||Bilateral Group|Patients have bilateral amblyopia, which is defined that best-corrected visual acuity of \<20/30 each eye.
62091446|NCT03780205||Unilateral Group|Patients have unilateral amblyopia, which is defined that best-corrected visual acuity of \<20/30 in the amblyopic eye; and interocular difference of best-corrected visual acuity at least two logMAR lines.
62091447|NCT01018043||001|Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
62091448|NCT06615167|EXPERIMENTAL|ALZGUARD Intervention Group|All participants wil use the ALZGAURD smartphone-based digital therapeutic(DTx) to assess cognitive function for detecting dementia.
62091449|NCT04597411|EXPERIMENTAL|Group A (mCRPC who have received prior ARPI and chemotherapy, but are PSMA RLT naïve)|Men that have received prior cytotoxic chemotherapy and ARPI (e.g., abiraterone or enzalutamide), who HAVE NOT been previously treated with 177Lu-PSMA-617 radioligand therapy or 177Lu-PSMA I\&T will receive a dose of 225\^Ac-PSMA-617 via intravenous injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
62091450|NCT04597411|EXPERIMENTAL|Group B (mCRPC who have not had prior ARPI or chemotherapy, and are PSMA RLT naïve)|Men previously treated with luteinizing hormone-releasing hormone (LHRH) agonists or orchiectomy and primary anti-androgen therapy that have not received prior cytotoxic chemotherapy or novel androgen axis drugs (e.g., abiraterone or enzalutamide) will receive a dose of 225Ac-PSMA-617 via intravenous injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
62091451|NCT04597411|EXPERIMENTAL|Group C (mCRPC who have received prior PSMA RLT)|Men with progressive metastatic castration resistant prostate cancer (mCRPC) who HAVE been previously treated with 177Lu-PSMA-617 radioligand therapy or 177Lu-PSMA I\&T will receive a dose of 225Ac-PSMA-617 via intravenous injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles. Prior chemotherapy and/or novel androgen axis drugs not required.
62091452|NCT05140993|EXPERIMENTAL|extended support|providing extended emotional and orientation support
62091453|NCT05140993|NO_INTERVENTION|common practice|The hospital routine clinical standard- not providing extended emotional and orientation support
62091454|NCT04646447|EXPERIMENTAL|L-serine treatment|All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.
62091455|NCT01084421|EXPERIMENTAL|Computer based intervention|Participants receive content about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general.
62091456|NCT01084421|NO_INTERVENTION|Wait list control group|Participants will receive the computer based intervention at 3 months follow-up
62091457|NCT01600950|EXPERIMENTAL|LY2963016|A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
62091458|NCT01600950|ACTIVE_COMPARATOR|Lantus|A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
62091459|NCT01996644|EXPERIMENTAL|Setraline|250 mg DCS (setraline) versus placebo plus exposure
62091460|NCT01996644|PLACEBO_COMPARATOR|placebo|Placebo group plus exposure
62289488|NCT02906254||ECIL-4 guidelines group|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st February 2014 to 30th November 2014, antibiotics were stopped when patients had been afebrile for more than 48 hours, as recommended by the ECIL-4 guidelines"
62463293|NCT00959660|ACTIVE_COMPARATOR|Exercise Training|Exercise participants will undergo a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
62091461|NCT03875495|EXPERIMENTAL|Temferon|"Autologous CD34+-enriched hematopoietic progenitor cells exposed ex vivo to a specific lentiviral vector encoding for the human IFN-ɑ2 gene.~Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of IFN-ɑ2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny."
62091462|NCT04391075||Exposed|Pudendal nerve block provided
62091463|NCT04391075||Not exposed|Pudendal nerve block is NOT provided
62091464|NCT06564831|ACTIVE_COMPARATOR|Standard of Care|Other: Standard of Care Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.
62091465|NCT06564831|EXPERIMENTAL|SLAM + SOC|Single layer amniotic membrane (SLAM) + SOC
62091466|NCT06478719|PLACEBO_COMPARATOR|placebo|4\*Placebo oral capsule each time, TID (three times a Day). treatment period: start two weeks before TACE until eight weeks after TACE.
62091467|NCT06478719|EXPERIMENTAL|low dose FB-1603 (990mg/day)|2\*FB-1603 165 mg oral capsule and 2\*Placebo oral capsule each time, TID (990 mg/day). treatment period: start two weeks before TACE until eight weeks after TACE.
62091468|NCT06478719|EXPERIMENTAL|high dose FB-1603 (1980mg/day)|4\*FB-1603 165 mg oral capsule each time, TID (1980 mg/day). treatment period: start two weeks before TACE until eight weeks after TACE.
62091469|NCT02022514|EXPERIMENTAL|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
62091470|NCT02022514|ACTIVE_COMPARATOR|Conventional medical treatment|Conventional medical treatment
62655467|NCT05218876|EXPERIMENTAL|High intensity strength and endurance training|Participants will perform a combination of strength and endurance training with high intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
62091471|NCT03016013|PLACEBO_COMPARATOR|Placebo plus MTX|Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose. All subjects received RC-18 treatment once a week from week 24 to week 48.
62091472|NCT03016013|EXPERIMENTAL|Experimental: RC18 160 mg+MTX|Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
62091473|NCT04002479|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62091474|NCT03138083|EXPERIMENTAL|Module 1 Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
62655468|NCT05859230|EXPERIMENTAL|The probiotic drink study group|Older adults between 60-90 years of age, diagnosed with Mild Cognitive Impairment, will participate in an 18-week long study consisting of the probiotic drink consumption for 12 weeks, followed by a 6-week follow-up period.
62091475|NCT03138083|EXPERIMENTAL|Module 1 Monotherapy Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
62091476|NCT03138083|EXPERIMENTAL|Module 1 Monotherapy Expansion Cohort(s)|Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
62091477|NCT03138083|EXPERIMENTAL|Module 2 Combination with EGFR-TKI Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
62091478|NCT03138083|EXPERIMENTAL|Module 2 Combination with EGFR-TKI Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
62091479|NCT03138083|EXPERIMENTAL|Module 2 Combination with EGFR-TKI Expansion Cohort|Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)
62091480|NCT06697470||Critically Ill Patients in ICU|This cohort consists of adult patients aged over 18 years who are admitted to the ICU at Epicura Hornu Hospital between October 14, 2024, and November 15, 2024 (to be updated). The study will investigate muscle thickness variations and fluid balance using ultrasound and bioelectrical impedance analysis (BIA). Informed consent will be obtained from the patients or their legal representatives.
62091481|NCT06697912||Infant treated with bubble CPAP and receiving blended air/oxygen|
62091482|NCT03362619|EXPERIMENTAL|CC-EIEs|Autologous cervical cancer specific engineered immune effectors (EIEs)
62091483|NCT05874999|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease (COPD)|People with chronic obstructive pulmonary disease (COPD) (n = 16)
62091484|NCT05874999|ACTIVE_COMPARATOR|Healthy Controls (HC)|Healthy controls matched on age, sex and objectively measured physical activity (n = 16)
62091485|NCT04427722||MPS-Flex Total Knee Joint Prostheses|Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
62091486|NCT05553561|ACTIVE_COMPARATOR|IRPL Therapy|17 patients with moderate to severe evaporative dry eye disease will treated with 3 sessions of IRPL therapy.
62463294|NCT00959660|ACTIVE_COMPARATOR|Dietary Intervention|A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb) weight loss per week.
62655469|NCT05859230|PLACEBO_COMPARATOR|The placebo drink study group|The older adults between 60-90 years of age, diagnosed Mild Cognitive Impairment, participate in the total 18-week longed study consisting of the placebo milk drink consumption for 12 weeks, followed by a 6-week follow-up period.
62655470|NCT04742218|EXPERIMENTAL|Fasted-Fed|Single dose of K-877 administered in a fasted condition on Day 1 (Treatment Period 1) and postprandially on Day 4 (Treatment Period 2)
62091487|NCT05553561|ACTIVE_COMPARATOR|Non IRPL Therapy|17 patients with moderate to severe evaporative dry eye disease will treated with traditional methods of MGD
62091488|NCT06119087|EXPERIMENTAL|Mechanical insufflation|Participants will be asked to perform mechanical insufflation using the BiWaze cough device as 5 sets of 5 insufflations twice daily for 6 months.
62091489|NCT04627883|OTHER|Group 1:2|Patients in the control group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2.
62091490|NCT04627883|OTHER|Group 2:1|Patients in the IRV group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1.
62091491|NCT06176612|EXPERIMENTAL|Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent total hip replacement|
62091492|NCT03697226|EXPERIMENTAL|Dose 1|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
62091493|NCT03697226|EXPERIMENTAL|Dose 2|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
62091494|NCT03697226|EXPERIMENTAL|Dose 3|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
62091495|NCT03697226|EXPERIMENTAL|Dose 4|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
62091496|NCT03697226|EXPERIMENTAL|Dose 5|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
62091497|NCT00365417|EXPERIMENTAL|Doxorubicin+Cyclophosphamide+Bevacizumab|
62091498|NCT06339047|EXPERIMENTAL|Projector Kaleidoscope|Children in the projector kaleidoscope group will be watched for approximately 5 minutes before induction into the operating room.
62091499|NCT06339047|EXPERIMENTAL|Cartoon|Children in the cartoon group will be asked which cartoon they want to watch from the cartoon pool and will be shown the cartoon they want. The cartoon duration is approximately 5 minutes.
62091500|NCT06339047|NO_INTERVENTION|Control|Routine care will be given
62091501|NCT03205020||women with preterm labor|
62091502|NCT03205020||women delivered at full term|
62091503|NCT01120574|NO_INTERVENTION|1|Oxygen therapy group.
62091504|NCT01120574|ACTIVE_COMPARATOR|2|Home mechanical ventilation plus oxygen therapy group.
62091505|NCT05256303|EXPERIMENTAL|Home Hospital care|Patients receive hospital-level care in their home, as a substitute to traditional hospital care.
62091506|NCT05256303|ACTIVE_COMPARATOR|Traditional Hospital care|Patients receive hospital-level care in the hospital.
62463295|NCT00959660|ACTIVE_COMPARATOR|Attention control|Attention control participants will be provided a counseling session regarding general health education at baseline and will be contacted by staff via telephone every 2 weeks to discuss general health status.
62463296|NCT00959660|ACTIVE_COMPARATOR|Diet and Exercise|A hypocaloric diet will be developed to achieve a 2450 kcal/week deficit in addition to undergoing a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
62463297|NCT05194722|EXPERIMENTAL|Orthopedic spine patients|In addition to participating in semi-structured interviews and usability testing of the study interventions, participants in this arm will receive one month of access to Wysa. They will complete measures of clinical effectiveness and hypothesized behavioral targets at baseline and one-month follow-up.
62091507|NCT04482855|EXPERIMENTAL|Group 1 (laser group)|Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
62091508|NCT04482855|NO_INTERVENTION|Group 2 (wait-list control group)|Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
62091509|NCT06614322|EXPERIMENTAL|Period 1 - Placebo, Placebo, Duloxetine, Duloxetine, Pregabalin, Pregabalin|Participants will be randomized to 1 of the 6 possible treatment sequences
62289489|NCT02906254||short-course antibiotic therapy|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st December 2014 to 30th September 2015, antibiotics were stopped on day 5 in febrile or afebrile patients (short-course antibiotic therapy)."
62289490|NCT03467178|EXPERIMENTAL|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
62289491|NCT03467178|OTHER|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
62289492|NCT03502512|EXPERIMENTAL|Arm I (REVOLVE technique)|Patients undergo reconstructive surgery with REVOLVE technique.
62289493|NCT03502512|EXPERIMENTAL|Arm II (PureGraft technique)|Patients undergo reconstructive surgery with PureGraft technique.
61920058|NCT00413478|EXPERIMENTAL|5-Azacytidine|5-Azacytidine 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
62091510|NCT06614322|EXPERIMENTAL|Period 2 - Duloxetine, Pregabalin, Placebo, Pregabalin, Duloxetine, Placebo|Participants will be randomized to 1 of the 6 possible treatment sequences
62091511|NCT06614322|EXPERIMENTAL|Period 3 - Pregabalin, Duloxetine, Pregabalin, Placebo, Placebo, Duloxetine|Participants will be randomized to 1 of the 6 possible treatment sequences
62091512|NCT03172793|EXPERIMENTAL|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
62091513|NCT03172793|EXPERIMENTAL|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
62091514|NCT03172793|EXPERIMENTAL|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
62289494|NCT02397473|EXPERIMENTAL|Galcanezumab 300mg|Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
62289495|NCT02397473|PLACEBO_COMPARATOR|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
62289496|NCT03567902|EXPERIMENTAL|Group A|C-MAC videolaryngoscope intubation -\> Direct laryngoscope intubation
62655471|NCT04742218|EXPERIMENTAL|Fed-Fasted|Single dose of K-877 administered postprandially on Day 1 (Treatment Period 1) and in a fasted condition on Day 4 (Treatment Period 2)
62655472|NCT00557141||1|Age \> 18 years, Asthma with irregular or regular use of short acting beta-agonists and / or: Asthma treatment with inhaled steroids, Ability to understand the questionnaire
62655473|NCT02015078||African Americans|Targets are family members attending African American family reunions.
62655474|NCT00761878|ACTIVE_COMPARATOR|Skin treatment|
62289497|NCT03567902|EXPERIMENTAL|Group B|Direct laryngoscope intubation -\> C-MAC videolaryngoscope intubation
62289498|NCT02413203|EXPERIMENTAL|Celecoxib|Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.
62655475|NCT03861039|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
62655476|NCT03861039|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
62655477|NCT03861039|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
61920059|NCT02318576|NO_INTERVENTION|Control|This group will do nothing for the 12 week program.
61920060|NCT02318576|EXPERIMENTAL|Cognitive Trained Group|This group will train three time a week for one hour on the given computerized cognitive training website for the 12 week program.
62289499|NCT02413203|PLACEBO_COMPARATOR|Placebo|Oral administration of a single placebo pill.
61920061|NCT02326311|ACTIVE_COMPARATOR|Fixed INTERIM TKI|"Intervention: fixed intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)"
62289500|NCT04354428|PLACEBO_COMPARATOR|Ascorbic acid and Folic acid|Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)
62655478|NCT01781247|EXPERIMENTAL|Intervention group|Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
62289501|NCT04354428|EXPERIMENTAL|Hydroxychloroquine and Folic Acid|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days \[Days 2 to 5\])
62289502|NCT04354428|EXPERIMENTAL|Hydroxychloroquine and Azithromycin|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).
62289503|NCT04354428|EXPERIMENTAL|Lopinavir-ritonavir|LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)
62289504|NCT04354428|PLACEBO_COMPARATOR|Ascorbic acid|Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days
62463298|NCT01038791|ACTIVE_COMPARATOR|usual ventilation|application of usual mechanical ventilation without humidification system
62289505|NCT04123821|EXPERIMENTAL|Group A|Nasopharyngeal airway with 5L/min oxygen through nasal cannula
62091515|NCT00855192|EXPERIMENTAL|mindfulness-based therapy|mindfulness-based meditation
62091516|NCT00855192|EXPERIMENTAL|interpersonal therapy|psycho-educational
62091517|NCT01161160|EXPERIMENTAL|AREPANRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (\<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
62091518|NCT01161160|EXPERIMENTAL|PANDEMRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (\<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Pandemrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
62091519|NCT01161160|EXPERIMENTAL|AREPANRIX GROUP|Healthy male or female children aged 3 to less than (\<) 10 years at the time of study vaccination, who received 1 pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
62091520|NCT03727360|EXPERIMENTAL|Exercise Training|Group exercise and treadmill walking
62091521|NCT03727360|ACTIVE_COMPARATOR|Flexibility Control|Group exercise and flexibility exercise
62091522|NCT05172999|ACTIVE_COMPARATOR|LNG-IUS|enrolled patients will receive LNG-IUS for 6 months or longer till complete response
62289506|NCT04123821|NO_INTERVENTION|Group B|5 L/min oxygen through nasal cannula alone
62463299|NCT01038791|EXPERIMENTAL|heated humidifier|mechanical ventilation with heated humidifier
62463300|NCT01038791|EXPERIMENTAL|heat and moisture exchanger|mechanical ventilation with heat and moisture exchanger
62463301|NCT04742478||Eligible subjects who underwent RA prior to PCI (with informed consent taken to join the study)|Informed consent to be obtained either prior to PCI with rotational atherectomy planned or within 48 hours after rotational atherectomy. There will be data collection of history/demographics, laboratory results, symptoms, any serious adverse events recording for this cohort as well as a telephone follow up at 12months post rotational atherectomy.
62463302|NCT04742478||Eligible subjects who underwent RA prior to PCI (without informed consent taken to join the study)|Subjects that were demised or refused to give consent will fall under this cohort. The data collection of this cohort will be done through screening of in-hospital data via available local PCI database/registry.
62463303|NCT05364632|EXPERIMENTAL|Behavioral Intervention|Participants will undergo an eight-week behavioral intervention protocol (once a week) aimed at increasing the level of physical activity, consisting of a brief educational program: brief education for asthma and benefits of physical activity and behavioral intervention based on Social Cognitive Theory and the Theory of Stages of Behavior Change.
62463304|NCT05364632|EXPERIMENTAL|Aerobic Training|Participants will undergo an eight-week aerobic training protocol (twice a week) on a treadmill, each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down.
62091523|NCT05172999|EXPERIMENTAL|LOX+LNG-IUS|enrolled patients will receive LNG-IUS plus polyethylene glycol loxenatide for treatment.
62091524|NCT02376933|EXPERIMENTAL|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
62091525|NCT06697951|OTHER|single arm|Newborns with mild to moderate respiratory distress whose caregivers give permission will be enrolled into the study
62091526|NCT02602249|NO_INTERVENTION|Experimental Group A(control group)|saline infusion and follow up
62091527|NCT02602249|EXPERIMENTAL|Experimental Group B|MUC1-gene-DC-CTL will be used against tumor cells.
62091528|NCT02602249|EXPERIMENTAL|Experimental Group C|MUC1-peptide-DC-CTL will be used against tumor cells.
62091529|NCT03356873|EXPERIMENTAL|Active|Vitamin D 5000 units capsules, 20 capsules per week during four weeks (total 400,000 units)
62091530|NCT03356873|PLACEBO_COMPARATOR|Placebo|Identical placebo capsules, 20 capsules per week during four weeks
62091531|NCT02851043|EXPERIMENTAL|pneuRIP(breathing with resistance)|Testing the subjects breathing with resistance
62463305|NCT05290311||COMB|The 'combined' or 'COMB' group received cognitive behavioural therapy next to pharmacotherapy for ADHD in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
62463306|NCT05290311||PHA|The 'pharmacotherapy' group or 'PHA' received pharmacotherapy for ADHD only in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
62463307|NCT00778505|EXPERIMENTAL|1|closed-loop administration of propofol and remifentanil using bispectral index as the controller
62463308|NCT00778505|ACTIVE_COMPARATOR|2|manual administration of propofol and remifentanil according to bispectral index values
62463309|NCT06164782||General Pupulation of China|General Pupulation of China
62463310|NCT00011570|OTHER|1|
62463311|NCT06327607||Control group|Standard iter of treatment for breast cancer
62463312|NCT06327607||Experimental group|Psychosexuological intervention
62463313|NCT04807621|ACTIVE_COMPARATOR|Platelets|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, a platelet transfusion.
62463314|NCT04807621|EXPERIMENTAL|Fibrinogen|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, fibrinogen concentrate.
62091532|NCT02851043|NO_INTERVENTION|Respitrace system (Carefusion) (breathing without resistance)|Testing subjects breathing without resistance
62655479|NCT01781247|ACTIVE_COMPARATOR|Control group|Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.
61906349|NCT02979860|EXPERIMENTAL|Regularize sleep schedule|Sleep timing: Children in this arm will be asked to get into bed at a consistent bedtime each night and wake at a consistent time each morning such that time in bed achieved during baseline is maintained during the 4-week experimental phase; only timing of bedtimes/wake times will be manipulated in this arm.
62091533|NCT03997942||proprioceptive neuromuscular facilitation|PNF will be applied to randomly selected patients.
62091534|NCT03997942||Mirror therapy|Mirror therapy will be applied to randomly selected patients.
62091535|NCT03997942||Standart therapy|Standard treatment will be applied to randomly selected patients.
62091536|NCT01095718|EXPERIMENTAL|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
62091537|NCT01095718|ACTIVE_COMPARATOR|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step.Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance. Then the therapist asks immediately to the patient to do the steps."
62289507|NCT02536287|EXPERIMENTAL|total PTX without autotransplantation|all parathyroid glands were found and removed
62655480|NCT02585206|NO_INTERVENTION|Arm 1|"All 4 factors off - standard text message program~Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity OFF"
62655481|NCT02585206|ACTIVE_COMPARATOR|Arm 2|Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity ON
62655482|NCT02585206|ACTIVE_COMPARATOR|Arm 3|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity OFF
62655483|NCT02585206|ACTIVE_COMPARATOR|Arm 4|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity ON
62655484|NCT02585206|ACTIVE_COMPARATOR|Arm 5|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity OFF
62655485|NCT02585206|ACTIVE_COMPARATOR|Arm 6|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity ON
62655486|NCT02585206|ACTIVE_COMPARATOR|Arm 7|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity OFF
62655487|NCT02585206|ACTIVE_COMPARATOR|Arm 8|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity ON
62655488|NCT02585206|ACTIVE_COMPARATOR|Arm 9|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity OFF
61906350|NCT03800017|EXPERIMENTAL|Hyperoxia|During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.
61906351|NCT03800017|PLACEBO_COMPARATOR|Healthy Controls|During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.
61906352|NCT01127789|EXPERIMENTAL|non-invasive brain stimulation|
61906353|NCT02495571|EXPERIMENTAL|ALS Patients|Study Group: Evaluation of the cough reflex and the voluntary cough by spirometer and nebulizer
61906354|NCT02495571|OTHER|Healthy Subjects|Control group matched by aged and sex with the study group
61906355|NCT01054833|EXPERIMENTAL|Needleless sling|Needleless® sling
61906356|NCT03007810|EXPERIMENTAL|Hemay005|Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
61906357|NCT03007810|PLACEBO_COMPARATOR|Placebo|Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
62289508|NCT02536287|ACTIVE_COMPARATOR|total PTX with autotransplantation|all parathyroid glands were found and removed,and then a portion of it is sliced into 1\*1\*1 mm pieces for autotransplantation
62289509|NCT02713451|ACTIVE_COMPARATOR|Liberal Oxygenation (LO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
62463315|NCT02680626|EXPERIMENTAL|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine in their bilateral transversus abdominis plane blocks
62463316|NCT02680626|ACTIVE_COMPARATOR|Non-magnesium|Participants in this arm will receive saline + ropivacaine in their bilateral transversus abdominis plane blocks
62463317|NCT05342285||normal FMD|SLE femals patientd with normal flow mediated whose ages from 18 to 45yrs
62463318|NCT05342285||abnormal FMD|SLE femals with abnormal flow mediated dikation ages between 18 to 45yrs old
62463319|NCT05342285||Normal female|normal femals whise ages from 18 to 45yrs old
62463320|NCT00874237|OTHER|Treatment sequence ABC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
62463321|NCT00874237|OTHER|Treatment sequence ACB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
62463322|NCT00874237|OTHER|Treatment sequence BCA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
62463323|NCT00874237|OTHER|Treatment sequence BAC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
62091538|NCT01095718|ACTIVE_COMPARATOR|Trial and Error|"Trial and Error refers to the regular unstructured learning and is considered as control condition.~Here the patient is encouraged to complete the task. When there is mistake, the therapist corrects it. Verbal cues will only be provided if the patient is unable to find and complete the correct next step or commit mistakes. The therapist use general instruction: Here is task, I will ask you to actions, followed by specific instruction, and I will help you after you have tried."
61906358|NCT02432352|EXPERIMENTAL|Intervention|Families are randomly allocated to a behavioral intervention arm (called Our Family Our Future) focusing on reducing sexual risk behavior in adolescents and reducing or maintaining symptoms that fall below the clinically significant range for depression. Arms will be allocated using urn randomization.
62091539|NCT03869242|EXPERIMENTAL|Experimental treatment arm|RT with concomitant TMZ and NovoTTF-200A for 6 weeks followed by up to 24 months of maintenance TMZ in combination with NovoTTF-200A.
62091540|NCT03869242|ACTIVE_COMPARATOR|control arm|RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with NovoTTF-200A.
62091541|NCT02341781||Relapsed,Progressed,Refractory or Intolerant to ibrutinib|MCL subjects who received lenalidomide after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment
61906359|NCT02432352|NO_INTERVENTION|Control|Families are randomly allocated to the control arm (which receives standard usual care, and then offered the intervention after outcome assessments as a wait-list) using urn randomization.
62655489|NCT02585206|ACTIVE_COMPARATOR|Arm 10|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity ON
62655490|NCT02585206|ACTIVE_COMPARATOR|Arm 11|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity OFF
61906360|NCT00943449|EXPERIMENTAL|4SC-201|
61906361|NCT00943449|EXPERIMENTAL|4SC-201 + Sorafenib|
61906362|NCT01816945|EXPERIMENTAL|Access to MOMBA web-based application|Study will provide the subject with a smartphone, pay the data plan, and facilitate access to the web-based application for purposes of researching the acceptability of the application, the operating and functioning of it, and its impact on maternal mental health.
61906363|NCT01816945|NO_INTERVENTION|Smartphone only|Study will provide the subject with a smartphone and pay the data plan. Weekly assessments are completed through internet survey links sent via text message.
61906364|NCT05787600|EXPERIMENTAL|Perhyal rinse|Participants will be given the test interventions,Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing.
62091542|NCT06614842|EXPERIMENTAL|Common Factors Group Therapy|We will use a general common factors psychotherapy utilizing only psychotherapeutic techniques common to most forms of psychotherapy (e.g., listening and communication skills)
62655491|NCT02585206|ACTIVE_COMPARATOR|Arm 12|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity ON
61906365|NCT05787600|ACTIVE_COMPARATOR|Chlorhexidine 0.12%|Participants will be given the positive-control, Chlorhexidine 0.12%, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing.
62091543|NCT03054974|EXPERIMENTAL|Modern rehabilitation treatment|Modern rehabilitation treatment
62091544|NCT03054974|EXPERIMENTAL|Modern rehabilitation &TCM|Modern rehabilitation treatment and traditional Chinese medicine
62091545|NCT03054974|EXPERIMENTAL|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment and Baimai Ruangao
62091546|NCT03054974|EXPERIMENTAL|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine treatment
62655492|NCT02585206|ACTIVE_COMPARATOR|Arm 13|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity OFF
61906366|NCT05787600|PLACEBO_COMPARATOR|Placebo Product|Participants will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing.
61906367|NCT06298942|EXPERIMENTAL|natural band|to use an round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy
61906368|NCT06298942|ACTIVE_COMPARATOR|silicone band|to use a synesthetic band with sleeve gastrectomy
61906369|NCT00781573|EXPERIMENTAL|1|Clopidogrel (75 mg/day) is continued for another year at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
62463324|NCT00874237|OTHER|Treatment sequence CAB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
62463325|NCT00874237|OTHER|Treatment sequence CBA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
62463326|NCT00812357||1|Patients treated with Symbicort basic treatment
62655493|NCT02585206|ACTIVE_COMPARATOR|Arm 14|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity ON
62655494|NCT02585206|ACTIVE_COMPARATOR|Arm 15|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity OFF
62655495|NCT02585206|ACTIVE_COMPARATOR|Arm 16|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity ON
62655496|NCT02585206|NO_INTERVENTION|WEB|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program."
62655497|NCT02585206|ACTIVE_COMPARATOR|WEB+OA_TXT|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program PLUS optimal-adherence text message program from Phase I."
62655498|NCT06102551||The primary group|
62655499|NCT06102551||The recurrent group|
62091547|NCT03483077|PLACEBO_COMPARATOR|Placebo matching BI 730460|Placebo tablet(s) matching BI 730460 tablet(s) administered orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
62091548|NCT03483077|EXPERIMENTAL|2 milligram (mg) - BI 730460|A single dose of 2 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
62091549|NCT03483077|EXPERIMENTAL|8 mg - BI 730460|A single dose of 8 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
62091550|NCT03483077|EXPERIMENTAL|25 mg - BI 730460|A single dose of 25 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
62091551|NCT03483077|EXPERIMENTAL|50 mg - BI 730460|A single dose of 50 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
62091552|NCT03483077|EXPERIMENTAL|100 mg - BI 730460|A single dose of 100 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
62091553|NCT03483077|EXPERIMENTAL|200 mg - BI 730460|A single dose of 200 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
62091554|NCT03656016||study group|patients with congenital and acquired disorders that can alter the CSF dynamics will undergo phase-contrast magnetic resonance imaging
62091555|NCT03656016||control group|age matched healthy individuals will undergo phase-contrast magnetic resonance imaging
62091556|NCT01809210|EXPERIMENTAL|Selumetinib+standard chemotherapy|Selumetinib plus gemcitabine; or pemetrexed and cisplatin or carboplatin
62091557|NCT04171804|ACTIVE_COMPARATOR|Active|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
62091558|NCT04171804|SHAM_COMPARATOR|Sham|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
62091559|NCT03998462|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
62289510|NCT02713451|EXPERIMENTAL|Conservative Oxygenation (CO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
62289511|NCT02794337|ACTIVE_COMPARATOR|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
62463327|NCT00812357||2|Patients treated with Symbicort basic treatment + treatment of symptoms as needed
62655500|NCT00959751|EXPERIMENTAL|NXN-188 600 mg|3 x 200 mg capsules, PRN
62655501|NCT00959751|PLACEBO_COMPARATOR|Placebo|3 x 0 mg capsules, PRN
62091560|NCT03998462|PLACEBO_COMPARATOR|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
62655502|NCT04075149|EXPERIMENTAL|Spironolactone|16 weeks without medication, then 16 weeks with medication, then 12 months without medication; spironolactone 50 mg tablets: 50-100 mg orally twice daily (1.7-3.3 mg/kg/24 hr)
62655503|NCT02638532|OTHER|Foot Fat Pad Grafting|All subject who enter into the study will undergo the fat pad grafting procedure to either the Heel or Forefoot based on the discretion of the PI, Co-investigator and the study subject.
62655504|NCT02159638|OTHER|comparisson CGM accuracy|Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose
62655505|NCT02859298|EXPERIMENTAL|Suspicion of threat of premature delivery|10 consecutive patients arriving at the Brugmann maternity with suspicion of a threat of premature delivery will be encouraged to participate in this study, before the onset of any tocolytic treatment. The patient will receive an standard examination of the cervix and at the same time a polarimetric measurement.
62091561|NCT00549497|OTHER|GW870086X|
62091562|NCT06614387|ACTIVE_COMPARATOR|Infliximab arm|Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass \> 40 kg) and 10 mg/kg (body mass \< 40kg).
62091563|NCT06614387|EXPERIMENTAL|Vedolizumab arm|Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass \> 40 kg) and 10 mg/kg (body mass \< 40kg).
62091564|NCT02476630||Study subjects|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as blood gases(ScvO2) from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
62091565|NCT05362526|EXPERIMENTAL|HFOT (High flow with tracheostomy interface)|Patient will be placed on heated humidified high flow after surgery.
62091566|NCT05362526|ACTIVE_COMPARATOR|COT (Conventional Oxygen Therapy)|Pt will be placed on conventional oxygen therapy after surgery.
62655506|NCT02859298|ACTIVE_COMPARATOR|Normal pregnancy|10 control patients, with the same term of pregnancy, will be benefit from the same measurements.
62091567|NCT03069469|OTHER|Experimental Treatment|"Dose Escalation Phase: Increasing doses of vimseltinib beginning at 10 milligram (mg) once daily (QD) for 28 day cycles until disease progression or unacceptable toxicity.~Expansion Phase: Dosing of different patient cohorts at the dose level determined from the Dose Escalation Phase of the study."
62091568|NCT02584790|OTHER|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
62091569|NCT02798094||Depressed Participants|No intervention
62289512|NCT02794337|EXPERIMENTAL|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
62289513|NCT04310644||Postural Orthostatic Tachycardia Syndrome|Patients with orthostatic intolerance because of Postural orthostatic tachycardia syndrome diagnosed in our outpatient clinic by tilt table examination.
62463328|NCT06119841|EXPERIMENTAL|Tonsillectomy|Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.
62655507|NCT02738502|EXPERIMENTAL|Single Group|Intervention: Darunavir monotherapy darunavir/ritonavir 600 mg/100mg twice day in monotherapy.
62655508|NCT00919672|ACTIVE_COMPARATOR|Sacral nerve stimulation ON-OFF|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
62655509|NCT00919672|ACTIVE_COMPARATOR|Sacral nerve stimulation OFF-ON|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
62655510|NCT03851289|EXPERIMENTAL|test (PRF-CS)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and calcium sulfate was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
62655511|NCT03851289|ACTIVE_COMPARATOR|control (PRF-X)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and xenograft (MinerOss® X) was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
62655512|NCT01170650|EXPERIMENTAL|Arm A|EC145 + Pegylated Liposomal Doxorubicin (PLD)
62655513|NCT01170650|ACTIVE_COMPARATOR|Arm B|placebo + Pegylated Liposomal Doxorubicin (PLD)
61906370|NCT00781573|NO_INTERVENTION|2|Clopidogrel (75 mg/day) is stopped at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
61906371|NCT03007004|EXPERIMENTAL|Botulinum toxin group|400 units in one injection site（0.2mL） Total 2000 units（1.0mL） （For both hands total 4000 units; 2.0 mL）
61906372|NCT03007004|SHAM_COMPARATOR|Physiological saline (control drug) group|"0.2mL in one injection site~Total 1.0mL (For both hands total 2.0 mL)"
61906373|NCT03444480|EXPERIMENTAL|Remimazolam Tosylate 1|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered
61906374|NCT03444480|EXPERIMENTAL|Remimazolam Tosylate 2|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered
61906375|NCT00129662|EXPERIMENTAL|Intervention arm|Pictorial action plan
61906376|NCT05094518|EXPERIMENTAL|Reminder|Participants will fill the sociodemographic and health history form. Participants will receive reminders in the form of push notifications for prenatal checkup dates automatically generated according to their pregnancy start data or initial check-up appointment for 6 months. Reminders will be sent at the following intervals: 1) 2 weeks before the appointment, 2) 1 day before the appointment, and 3) on the day of appointment. After this date, participants will receive push notifications asking whether they went to the appointment or not weekly for 1 month. This reminder algorithm will be used for each prenatal checkup for a total of four appointments: once in first trimester, once in second trimester and two in third trimester, using the World Health Organization and Turkish Ministry of Health prenatal checkup calendar. At the end of 6 months of follow up period, participants will be contacted via phone call to ask for any remaining appointments or unanswered notifications.
61906377|NCT05094518|NO_INTERVENTION|Informed Control No Reminder|Participants will fill the sociodemographic and health history form. Their contact information will be gathered. Participants will be contacted at the end of 6 months and will be asked about the number of the prenatal care appointments they have attended during their pregnancy.
62655514|NCT04632121||Group A|will receive standard treatment + 20 mg nicorandil prior to PPCI, and then maintained on 20 mg b.i.d for 3 months .
62655515|NCT04632121||Group B|will be given standard treatment, without nicorandil loading or maintainance.
62655516|NCT03667287|EXPERIMENTAL|Full-thickness skin graft|Repair of parastomal hernia with full-thickness skin graft, placed intraperitoneally, as reinforcement.
62091570|NCT02798094||Healthy Control Participants|No intervention
62091571|NCT05638230||HIgh HFA-PEFF points (≥5)|
62091572|NCT05638230||Low to intermediate HFA-PEFF points (<5)|
62091573|NCT05188963|ACTIVE_COMPARATOR|Women with postvoid residual volume cut-off at 150 ml|
62091574|NCT05188963|EXPERIMENTAL|Women with postvoid residual volume cut-off at 250 ml|
62091575|NCT02950545|EXPERIMENTAL|Placebo, Spherical, then Toric Lenses|Crossover order 1
62091576|NCT02950545|EXPERIMENTAL|Placebo, Toric, then Spherical Lenses|Crossover order 2
62091577|NCT02950545|EXPERIMENTAL|Spherical, Placebo, then Toric Lenses|Crossover order 3
62091578|NCT02950545|EXPERIMENTAL|Spherical, Toric, then Placebo Lenses|Crossover order 4
62091579|NCT02950545|EXPERIMENTAL|Toric, Placebo, then Spherical Lenses|Crossover order 5
62091580|NCT02950545|EXPERIMENTAL|Toric, Spherical, then Placebo Lenses|Crossover order 6
62091581|NCT06181877||Hemiplegic Patients|Patients with hemiplegia after stroke
62091582|NCT03738241|EXPERIMENTAL|Arm 1|Participants will have prior administration of 2013 A/H7N9 IIV with MF59. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
62091583|NCT03738241|EXPERIMENTAL|Arm 2|Participants will have prior administration of 2013 A/H7N9 IIV with AS03. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
62091584|NCT03738241|EXPERIMENTAL|Arm 3|Participants will have prior administration of 2013 A/H7N9 IIV 15 mcg or 45 mcg unadjuvanted. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
62091585|NCT03738241|EXPERIMENTAL|Arm 4|Participants will have prior administration of 2013 A/H7N9 IIV + MF59 or AS03 (1st) then 2013 A/H7N9 IIV 15 mcg (2nd). Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
62091586|NCT03738241|EXPERIMENTAL|Arm 5|Participants who are A/H7 IIV-Naïve. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
62091587|NCT02728518|EXPERIMENTAL|Nebulized Amikacin|patients in this arm will take amikacin nebulizer 400 mg twice daily in addition to standard beta lactam
62091588|NCT02728518|ACTIVE_COMPARATOR|Amikacin Intravenous|patients in this arm will take intravenous (IV) amikacin 20 mg/kg once daily in addition to standard beta lactam
62091589|NCT02903628|EXPERIMENTAL|eye health education|
62091590|NCT05146011||Single stage pathway|
62091591|NCT05146011||Two stage pathway|
62091592|NCT03261635|ACTIVE_COMPARATOR|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
62091593|NCT03261635|EXPERIMENTAL|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
62091594|NCT03114046|EXPERIMENTAL|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
62091595|NCT02408419|EXPERIMENTAL|Local anesthetic|15 ml. of local anesthetic
62091596|NCT02408419|PLACEBO_COMPARATOR|Saline|15 ml. of saline
62289514|NCT04310644||Ehlers Danlos Syndrome|Patients with hypermobile or classical EDS who are already diagnosed including genetical testing for classical or vascular EDS and Marfan Syndromes
62289515|NCT04310644||Autoimmune autonomic neuropathy/Pure autonomic failure|Patients who have an autoimmune autonomic neuropathy based on clinical diagnosis and antibody testing in our outpatient clinic. Cardial MIBG Scintigraphy should have been performed.
61906378|NCT05094518|NO_INTERVENTION|Uninformed Control No Reminder|"Participants will fill the sociodemographic and health history form. No contact information will be gathered. The purpose of this arm is to estimate the true baseline for the number of visits without any extra attention given by the medical staff."
61906379|NCT02660138|EXPERIMENTAL|600 U Dysport® Group|
61906380|NCT02660138|PLACEBO_COMPARATOR|600 U Dysport® Placebo Group|
61906381|NCT02660138|EXPERIMENTAL|800 U Dysport® Group|
61906382|NCT02660138|PLACEBO_COMPARATOR|800 U Dysport® Placebo Group|
61906383|NCT00949494|ACTIVE_COMPARATOR|Synvisc|
61906384|NCT00949494|PLACEBO_COMPARATOR|Placebo|
61906385|NCT01877876||Patient undergoing spine surgery|
61906386|NCT04277806|NO_INTERVENTION|Standard group|No interventions would be conducted in this group and the preterm infants would be fed in the normal way.
61906387|NCT04277806|EXPERIMENTAL|Intervention group|The preterm infants in this group would be fed according to the new process.
61906388|NCT01671579|OTHER|Pediatric small bowel Crohn disease|Subjects with previously diagnosed PSBCD (pediatric small bowel Crohn disease)who are scheduled for a clinically MRE (magnetic resonance enterography)imaging exam.
61906389|NCT00575341|ACTIVE_COMPARATOR|1|substitution of DHEA-hormone, oral, once daily
61906390|NCT00575341|PLACEBO_COMPARATOR|2|substitution of placebo, oral, once daily
61906391|NCT01937429|EXPERIMENTAL|Colonoscopy with blue indigo Carmin®|Patients undergoing from a colonoscopy with instillation of tepid water (30°C) tinged with indigo Carmin® (0,08/1000) during the endoscope insertion from the anus to the caecum, and with insufflation of air only during withdrawal from the caecum to the anus.
61906392|NCT01937429|ACTIVE_COMPARATOR|Standard colonoscopy|Standard colonoscopy with insufflation of air
61920062|NCT02326311|EXPERIMENTAL|Progressive INTERIM TKI|"Intervention: progressive intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)"
61920063|NCT02853630|ACTIVE_COMPARATOR|Metformin|Tablet Metformin 1000 - 2500 mg/day for 96 weeks
61920064|NCT02853630|EXPERIMENTAL|Vildagliptin|Tablet Vildagliptin 100mg/day for 96 weeks
62091597|NCT05687942|EXPERIMENTAL|REBUILD|REBUILD is an investigational medical device (bioabsorbable anchor and deployment instruments) used with third party suture to close the abdominal wall. As the suture and Anchor absorb, abdominal wall forces gradually transfer to the organizing scar, one of the tenets of successful wound tensile strength acquisition. After full absorption, no permanent material remains that would otherwise alter normal anatomy, anisotropic properties, or compliance of the abdominal wall (Deeken, 2017).
62091598|NCT06302790|ACTIVE_COMPARATOR|Molli Suit Apply Group (Device On)|Evaluations will be made before the children are dressed in the Mollii Suit, and the evaluations will be repeated after the children are dressed and practiced for 60 minutes.
62091599|NCT06302790|PLACEBO_COMPARATOR|Mollii Suit Placebo Group (Device Off)|Evaluations will be made before the children are dressed in the Mollii Suit, and the evaluations will be repeated after the children are dressed and applied for 60 minutes with the device in off mode.
62091600|NCT06302790|NO_INTERVENTION|Control Group|Children will be evaluated and the evaluations will be repeated 60 minutes later.
62091601|NCT01356238|EXPERIMENTAL|MRC media|Use MRC media in the human IVF-ET program
62091602|NCT01356238|ACTIVE_COMPARATOR|Sydney IVF media|Use Sydney IVF media in the human IVF-ET program
62091603|NCT06042920|EXPERIMENTAL|Deucravacitinib|
62289516|NCT04310644||Healthy controls|Healthy controls with no documented cardiovascular or neurological disorders and no symtoms of autonomic failure/dizziness/fainting
62289517|NCT04310644||others|Patients who have comorbidities as mast cell activation syndrome, chronic fatigue and/or Post COVID syndrome, based on clinical diagnosis in our outpatient clinic.
62289518|NCT02138734|EXPERIMENTAL|N-803+BCG|(Phase Ib and IIb) for BCG-naive patients
62655517|NCT03667287|ACTIVE_COMPARATOR|Synthethic mesh|Repair of parastomal hernia with best available conventional method, using synthetic mesh material as reinforcement
62655518|NCT02362022|PLACEBO_COMPARATOR|Group Saline|Group Saline (Group S) received i.v saline 0.9 % in 10 ml volume (n=30)
62289519|NCT02138734|ACTIVE_COMPARATOR|BCG alone|(Phase IIb) for BCG-naive patients
62289520|NCT02312804|EXPERIMENTAL|Dose Escalation|To determine the MTD/RP2D of BGJ398 when combined with carboplatin and paclitaxel in subjects with locally advanced for metastatic solid tumors.
62289521|NCT02312804|EXPERIMENTAL|Expansion Cervical Cancer|To assess the anti-tumor effect of BGJ398 when combined with carboplatin and paclitaxel in cervix cancer.
62289522|NCT00848744|EXPERIMENTAL|topical salicylic acid 1.0% cream|
62289523|NCT00830921||1|"Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept."
61920065|NCT03932097|EXPERIMENTAL|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
61920066|NCT03932097|ACTIVE_COMPARATOR|Active Control Materials|NIAAA materials on underage drinking for parents
61920067|NCT06520540|ACTIVE_COMPARATOR|HDM1002 100 mg|
61920068|NCT06520540|ACTIVE_COMPARATOR|HDM1002 200 mg|
61920069|NCT06520540|ACTIVE_COMPARATOR|HDM1002 400 mg|
61920070|NCT06520540|PLACEBO_COMPARATOR|Placebo|
62289524|NCT00474240|PLACEBO_COMPARATOR|1|
62289525|NCT00474240|ACTIVE_COMPARATOR|2|
62289526|NCT00474240|EXPERIMENTAL|3|
62289527|NCT00474240|EXPERIMENTAL|4|
62655519|NCT02362022|ACTIVE_COMPARATOR|Group Morphine 1|Group Morphine 1 (Group M1) received i.v morphine 0.1 mg kg-1, in 10 ml volume (n=30)
61920071|NCT05762770|NO_INTERVENTION|standard ICSI|Only spermatozoa with a moving tail but no forward motion will be selected for use in ICSI.
61920072|NCT05762770|EXPERIMENTAL|PICSI (intervention)|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
61920073|NCT04572516|EXPERIMENTAL|Topical group|Topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
62091604|NCT06042920|PLACEBO_COMPARATOR|Placebo followed by Deucravacitinib|
61906393|NCT04955600||elderly patients with multimorbidity, relatives, health care personal|The care team consists of four nurses, two of whom are employed by the region and two by the municipality, 20 municipally employed assistant nurses and one physician. Other professions associated with the team are psychologist, dietitian, pharmacist, counsellor, physiotherapist, occupational therapist, and family consultants. All participants in the team will be invited to participate in the study. The technology will be place in 20-25 patients' home and patients and family members will be invited to participate in the study. Self-care education will be given to the patients and family members according to the middle-range theory of self-care of chronic illness.
62091605|NCT00412867|EXPERIMENTAL|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
62463329|NCT06119841|EXPERIMENTAL|Expansion sphincter pharyngoplasty|In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
62091606|NCT04223596|EXPERIMENTAL|Experimental: Brigatinib Arm|Brigatinib 90 mg for the first 7 days and then 180 mg daily thereafter for QW4 cycles of duration (28 days +- 3 days)
62091607|NCT01823120|NO_INTERVENTION|No text messages|Patients in the non-intervention group will not receive any text messages. However, they will also receive the routine outpatient follow-up arrangements associated with attendance at an ED with self-harm including the provision of a contact phone number for the Samaritans.
62289528|NCT00474240|EXPERIMENTAL|5|
62091608|NCT01823120|EXPERIMENTAL|Supportive and interactive text messages|We will deliver daily supportive and informative text messages for one month followed by one supportive and informative text message every other day the second month and then one weekly text message the third month to patients in the intervention group after they have been discharged from the ED following an episode of self-harm. Supportive text messages will mainly target relieving the patients of mood symptoms and providing them with strategies for dealing with suicidal thoughts while the informative ones will provide patients with a dedicated mobile phone number through which they can receive interactive support from the Samaritans. The text messages will encourage participants to text the Samaritans in times of crisis. Please see appendix I for examples of the relevant text messages.
62289529|NCT00474240|EXPERIMENTAL|6|
62463330|NCT00206544|ACTIVE_COMPARATOR|1|Tamoxifen 40 mg daily
62463331|NCT00206544|ACTIVE_COMPARATOR|2|Progesterone 20 mg daily
62091609|NCT04896905||Isolation group with active Covid19|Patients assigned to rehab which had to be treated in isolation wards dur to active disease
62289530|NCT02344576|NO_INTERVENTION|Control: Usual Care|Patients and caregivers will receive the current usual education and consent process for DT LVAD at each hospital. This often means viewing consent forms and industry materials.
62463332|NCT00206544|PLACEBO_COMPARATOR|3|Placebo daily
62289531|NCT02344576|EXPERIMENTAL|DT LVAD Decision Support Intervention|In the intervention phase of the study, patients and caregivers will receive the new decision support intervention, which consists primarily of decision aid materials about DT LVAD. The standard consent process will also still take place, but will be supplemented with additional decision support.
62289532|NCT05294029||All subjects with neuromotor disability|
62289533|NCT01466842|OTHER|Catheter ablation|
62463333|NCT06491524|EXPERIMENTAL|7.5Fr flexible ureteroscope combined 10Fr ureteral access sheath|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone \<2cm
62463334|NCT03962023||Patient cohort|Routine follow-up of patients in the Cardiological Functional Explorations department - Valve Disease Centre for their primary mitral insufficiency by prolapse
61906394|NCT00995033|EXPERIMENTAL|NicVAX conjugate vaccine|
61906395|NCT00995033|PLACEBO_COMPARATOR|Placebo|Biological
62289534|NCT01466842|NO_INTERVENTION|Antiarrhythmic drugs|Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
61906396|NCT02358291|ACTIVE_COMPARATOR|open discectomy|patients diagnosed as lumbar disc herniation undergoing open simple discectomy(OD)
62289535|NCT00815958|EXPERIMENTAL|A|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
62289536|NCT00815958|ACTIVE_COMPARATOR|B|Reaming with conventional reamer
62463335|NCT01167309|ACTIVE_COMPARATOR|Part 1 SAD|four diffferent doses
62463336|NCT01167309|PLACEBO_COMPARATOR|Part 2a MAD|three doses
61906397|NCT02358291|ACTIVE_COMPARATOR|microendoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy(MED)
61906398|NCT02358291|ACTIVE_COMPARATOR|transforaminal endoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy(TELD)
62463337|NCT01167309|ACTIVE_COMPARATOR|Part 2b|0.24 mg LEO 27847
62463338|NCT01167309|ACTIVE_COMPARATOR|Part 2c|0.24 mg LEO 27847
62463339|NCT01167309|PLACEBO_COMPARATOR|Parat 2a MAD|one dose
62463340|NCT02039362|OTHER|tenofovir|tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth
62463341|NCT00969800|EXPERIMENTAL|Active Cleverin Gel|Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
62463342|NCT00969800|SHAM_COMPARATOR|Inactive Cleverin Gel|Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
62463343|NCT01824537|ACTIVE_COMPARATOR|HPV vaccine, Gardasil 9|HPV vaccine intervention: The intervention vaccine will be Gardasil 9, a 9-valent vaccine by Merck. This vaccine was chosen because it allows for the observation of 9 HPV outcomes (HPV 6, 11, 16 and 18) (the other available vaccine, Cervarix, protects against HPVs 16 and 18, only).
62655520|NCT02362022|ACTIVE_COMPARATOR|Group Morphine 2|Group Morphine 2 (Group M2) received i.v morphine 0.2 mg kg-1, in 10 ml volume (n=30)
62655521|NCT02754453|OTHER|Behavioral|
62655522|NCT06329167|EXPERIMENTAL|Daphnetin treatment group|Daphnetin capsule 150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.
62655523|NCT06329167|ACTIVE_COMPARATOR|Aescuven Forte group|Aescuven Forte oral tablet 150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
62289537|NCT00395967|EXPERIMENTAL|All Patients|Patients who were predicted to be unable to mobilize a minimum number of cells (≥2\*10\^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.
62289538|NCT03981159|EXPERIMENTAL|Active group (under physical training)|Subjects belonging to this arm underwent physical training for three months, twice per week (60 minutes per session).
62091610|NCT04896905||Post-Covid-group|Patients assigned to rehab after active disease, still having restrictions in activity and particiaption
62091611|NCT04896905||Control group|Pateints assigned to rehabilitation in the same time period without any signs of Sars-coV-2 infection
62091612|NCT06683768||Monotherapy Cohort|Adult patients with untreated hypertension who initiated antihypertensive monotherapy (excluding angiotensin receptor neprilysin inhibitor \[ARNI\]).
62091613|NCT06683768||Single-pill Combination (SPC) Cohort|Adult patients with untreated hypertension who initiated single-pill combination antihypertensive therapy.
62091614|NCT04477200|EXPERIMENTAL|Phase 0 - Recurrent glioblastoma (GBM) / gliosarcoma (GS)|Mycophenolate mofetil
62091615|NCT04477200|EXPERIMENTAL|Phase 1 - Recurrent GBM / GS|Mycophenolate mofetil; radiation therapy
62289539|NCT03981159|NO_INTERVENTION|Passive group (no physical training)|Subjects served as controls.
61906399|NCT03755544||Asthma patients|"Male or female patients with diagnosed asthma who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
61906400|NCT03755544||COPD patients|"Male or female patients with diagnosed COPD who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
61906401|NCT03176537|PLACEBO_COMPARATOR|Placebo|Gel, daily
61906402|NCT03176537|EXPERIMENTAL|TRT|Testosterone Replacement Therapy
61906403|NCT05187273|EXPERIMENTAL|intervention|
61906404|NCT05187273|NO_INTERVENTION|control|
62289540|NCT01928628|ACTIVE_COMPARATOR|Lercanidipine 10mg|1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
62289541|NCT01928628|EXPERIMENTAL|Lercanidipine10mg /Valsartan 80mg|1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
62289542|NCT01928628|EXPERIMENTAL|Lercanidipine 10mg /Valsartan 160mg|1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
62289543|NCT04749394|EXPERIMENTAL|Experimental Arm|Camrelizumab plus apatinib as consolidation therapy
62289544|NCT02051907|EXPERIMENTAL|KAM1403 Gel|A group treated with KAM1403 for the study period.
62289545|NCT02051907|SHAM_COMPARATOR|Aloevera Gel|A group treated with Aloevera Gel for the study period
61906405|NCT00966875|EXPERIMENTAL|3 mg LY2439821 (bDMARD-naive population)|3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)\]
61906406|NCT00966875|EXPERIMENTAL|10 mg LY2439821 (bDMARD-naive population)|10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
62091616|NCT04477200|EXPERIMENTAL|Phase 1 - Newly Diagnosed GBM / GS|Mycophenolate mofetil; radiation therapy; temozolomide
62091617|NCT05900999|EXPERIMENTAL|Survivors of stroke in early stages of recovery|
62091618|NCT03793335||Gastric cancer prevention|This prospective study consists of 40,000 participants; after randomization, each arm has 20,000 participants. Arm 1: participants receive H. pylori stool antigen test; Arm 2: participants receive the combination of H. pylori stool antigen test and serum pepsinogen test.
62091619|NCT03793335||Colorectal cancer prevention|This prospective study consists of 40,000 participants; after randomization; each arm has 20,000 participants. Arm 1: participants with positive fecal immunochemical test (FIT) receive routine referral confirmatory diagnosis approach; Arm 2: participants with positive FIT receive routine referral confirmatory diagnosis approach and participants with high FIT results receive additional aggressive referral confirmatory diagnosis approach.
62289546|NCT01299727|EXPERIMENTAL|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
62289547|NCT01299727|EXPERIMENTAL|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
62463344|NCT01824537|PLACEBO_COMPARATOR|Hepatitis A vaccine|"The placebo comparator will be Avaxim, by Sanofi Pasteur. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a placebo comparator. Gardasil 9 requires administration of 3 doses, while Avaxim only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Avaxim vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months."
62289548|NCT01299727|EXPERIMENTAL|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
62289549|NCT05448625||High Ischemic Group|"1. Acute myocardial infarction (AMI)~2. ≥ 2 stents implanted~3. bifurcation lesion~4. Left main lesion~5. Lesion treated with rotational atherectomy~6. Chronic total occlusion (CTO) lesion"
62289550|NCT01424592||Study Group|Hospitalized inpatients referred by a general medicine service for evaluation of obstructive sleep apnea.
62289551|NCT02047669|EXPERIMENTAL|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
62289552|NCT02047669|ACTIVE_COMPARATOR|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
62289553|NCT02905734|EXPERIMENTAL|nicotine replacement patch|Single administration of a nicotine patch (14 mg or 21 mg, according to the Heaviness of Smoking Index)
62289554|NCT02905734|PLACEBO_COMPARATOR|placebo patch|Single administration of a placebo patch
62289555|NCT03729882|OTHER|EUS-guided gallbladder drainage|"In one arm, Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) will be performed by using a 3,8 mm therapeutic echoendoscope and a lumen apposing metal stent ( Hot AXIOS™ Stent and Electrocautery Enhanced Delivered System; Boston Scientific Corporation, Natick, MA, USA) after conventional biliary drainage with self-expandable metallic stents during endoscopic retrograde cholangiopancreatography (ERCP).~All procedures will be performed under general anesthesia."
62289556|NCT03729882|OTHER|Non EUS-guided gallbladder drainage|"In the other arm, patients will undergo conventional biliary drainage with self-expandable metallic stent placement during ERCP evaluation without prophylactic EUS-GBD and will be considered as a Non EUS-guided gallbladder drainage.~All procedures will be performed under general anesthesia."
62289557|NCT00256295|EXPERIMENTAL|Gemcitabine plus Oxaliplatin|Gemcitabine given 1000 mg/m2 IV over 100 minutes Every 21 days. Oxaliplatin given 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days.
62289558|NCT01583478|ACTIVE_COMPARATOR|incobotulinumtoxinA 20 units|Three patients will be randomly assigned to receive 20 units total of incobotulinumtoxinA to the glabellar region.
62289559|NCT01583478|ACTIVE_COMPARATOR|incobotulinumtoxinA 40 units|Three patients will be randomly assigned to receive 40 units total of incobotulinumtoxinA to the glabellar region.
62289560|NCT01583478|ACTIVE_COMPARATOR|incobotulinumtoxinA 60 units|Three patients will be randomly assigned to receive 60 units total of incobotulinumtoxinA to the glabellar region.
62289561|NCT01583478|ACTIVE_COMPARATOR|incobotulinumtoxinA 80 units|Three patients will be randomly assigned to receive 80 units total of incobotulinumtoxinA to the glabellar region.
62289562|NCT01583478|ACTIVE_COMPARATOR|incobotulinumtoxinA 100 units|Three patients will be randomly assigned to receive 100 units total of incobotulinumtoxinA to the glabellar region.
62289563|NCT03320655|ACTIVE_COMPARATOR|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
61906407|NCT00966875|EXPERIMENTAL|30 mg LY2439821 (bDMARD-naive population)|30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
61906408|NCT00966875|EXPERIMENTAL|80 mg LY2439821 (bDMARD-naive population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
61906409|NCT00966875|EXPERIMENTAL|180 mg LY2439821 (bDMARD-naive population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
62289564|NCT03320655|EXPERIMENTAL|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
62289565|NCT04536220||pancreatic mass diagnosed benign|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.
62289566|NCT04536220||pancreatic mass diagnosed malignant|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.
61906410|NCT00966875|EXPERIMENTAL|80 mg LY2439821 (TNFa-IR population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)\]
61906411|NCT00966875|EXPERIMENTAL|180 mg LY2439821 (TNFa-IR population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
61906412|NCT00966875|PLACEBO_COMPARATOR|Placebo (bDMARD-naive population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
61906413|NCT00966875|PLACEBO_COMPARATOR|Placebo (TNFa-IR population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
61906414|NCT05948865|EXPERIMENTAL|Part A, Dose Escalation|Participants receive escalating doses of CPO301 of 0.6 mg/kg, 1.8mg/kg, 3.6 mg/kg, 4.8 mg/kg, 6.4 mg/kg and 8 mg/kg administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.
61906415|NCT05948865|EXPERIMENTAL|Part B, Dose Expansion|Participants receive CPO301 at the recommended phase 2 dose (RP2D) determined in Part A, administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.
61906416|NCT05941871|EXPERIMENTAL|Control|Group that will follow a low-calorie diet with a standard daily energy distribution for 4 months
61906417|NCT05941871|EXPERIMENTAL|Intervention|Group following a low-calorie diet with a different daily energy distribution according to their chronotype for 4 months
61906418|NCT01128764|EXPERIMENTAL|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
61906419|NCT01128764|ACTIVE_COMPARATOR|CBT for depression|CBT for depression only
61906420|NCT05563870|ACTIVE_COMPARATOR|Endoscopic Drainage Arm|Patients randomized to this arm will undergo biliary stenting only
61906421|NCT05563870|EXPERIMENTAL|COMBO-RFA Arm|Patients randomized to this arm will undergo same-session endoluminal radiofrequency ablation followed by biliary stenting
61906422|NCT03935568|EXPERIMENTAL|Single Dose Placebo|Patients randomized to receive Placebo
61906423|NCT03935568|EXPERIMENTAL|Single Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
61906424|NCT03935568|EXPERIMENTAL|Multiple Dose (Placebo)|Patients randomized to receive Placebo
61906425|NCT03935568|EXPERIMENTAL|Multiple Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
61906426|NCT00685009||1|Women from the Women's Health Initiative study taking estrogen hormone therapy
61906427|NCT00685009||2|Women from the WHI study taking estrogen plus progesterone hormone therapy
61906428|NCT00685009||3|Women from the WHI study taking placebo
61906429|NCT03835416|EXPERIMENTAL|WL-Control|0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability.
61906430|NCT03835416|EXPERIMENTAL|WL-Protein|\>30 g of high quality protein per meal, 1.2 g protein/kg body weight/day. Fourteen servings of high quality (30 g/serving) protein (lean meats, low fat dairy products) provided to participants each week to increase compliance.
61906431|NCT06299488|EXPERIMENTAL|Intervention: Montmorency Cherry + Apocynum Venetum|Sip2Sleep® is a proprietary formula of Montmorency tart cherry extract and Venetron®, a purified, powdered extract derived from Apocynum Venetum. Recommended dose is ¼ teaspoon which contains 553 mg (1:5 fruit extract) of Montmorency tart cherry and 25mg of Venetron® leaf extract. The compound was prepared as an oral dropper, consumed alone or in water 30-60 minutes prior to bedtime. The study was conducted over a period of four weeks, consisting of two weeks without intervention and two weeks with intervention as follows: (1 week off (baseline) - 1 week on - 1 week off - 1 week on) for each participant
61906432|NCT06299488|NO_INTERVENTION|No intervention: Typical Sleep Routine|"The study was conducted over a period of four weeks, consisting of two weeks without intervention and two weeks with intervention (ABAB) as follows: (1 week off (baseline) - 1 week on - 1 week off - 1 week on) for each participant.~Participants did not consume any intervention or placebo during this time."
61906433|NCT04380064|EXPERIMENTAL|Study Group|Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment
61906434|NCT04380064|ACTIVE_COMPARATOR|Control Group|Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment
61906435|NCT03196388|EXPERIMENTAL|Enzalutamide with External|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
61906436|NCT02678494|EXPERIMENTAL|Neurofeedback training|Neurofeedback training: self-administered at home for 3 months. 3-5 sessions per week initially, then at least once a week. Each session consists of 5-6 blocks of 5 minute training.
61906437|NCT06248047||conventional repair|the patients will undergo repair with no regard to the vessels .then follow up by uroflow ,ascending urethrogram and penile doppler .
61906438|NCT06248047||the new technique|the patients will undergo repair with sparing of the vessels .then follow up by uroflow ,ascending urethrogram and penile doppler .
61906439|NCT00407901||A, B|A: High functioning visually challenged (legally blind) B: Low-functioning visually challenged (legally blind)
62091620|NCT02623556|EXPERIMENTAL|TB subjects|"720 cases TB (Tuberculosis) subjects who meet the standard respectively are divided average into two groups through a randomized and blind method.~360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h."
62091621|NCT02623556|EXPERIMENTAL|non-TB subjects with lung disease and suspected TB subjects|360 cases non-TB subjects with lung disease and suspected TB subjects,who meet the standard respectively are divided average into different groups through a randomized and blind method. 180 non-TB subjects with lung disease are injected ESAT6-CFP10(10ug/ml) in left arm and TB-PPD in right arm. 180 non-TB subjects with lung disease are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. The study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
62289567|NCT01226290|EXPERIMENTAL|VizAblate treatment|VizAblate System: subject acts as her own control
61906440|NCT01206322|EXPERIMENTAL|Insulin vs. placebo|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
61906441|NCT01206322|OTHER|Healthy vs. Diabetic|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
61906442|NCT03698344|EXPERIMENTAL|Biodiesel exhaust exposure|A single arm study in which first a filtered air baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute biodiesel exhaust will start.
61906443|NCT02811874|EXPERIMENTAL|diabetes education|Four community health workers receive a one-month diabetes education program (intervention group, patients n= 62)
61906444|NCT02811874|ACTIVE_COMPARATOR|education in other areas|Four community health workers receive an education course in other health issues (control group, patients n= 56).
61920074|NCT04572516|EXPERIMENTAL|Injection group|20 units of BTX_A (2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
61920075|NCT05942209||ECO-LEAK transvaginal ultrasound|A transvaginal ultrasound is performed with a transrectal enema performed routinely during 4th-6th post-operative day
62289568|NCT02548702|EXPERIMENTAL|Community-based sport|Patients with type 2 diabetes will receive motivational counselling and will be allocated to a low intensity community-based sporting activity (Fit4Life programme) depending on their interests and perceived barriers to taking part.
62655524|NCT03341520|EXPERIMENTAL|interventional arm|Obinutuzumab Injection \[Gazyva\] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9
61906445|NCT03268421|EXPERIMENTAL|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
61906446|NCT03268421|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem-solving, and using calming self-statements.
61906447|NCT03268421|ACTIVE_COMPARATOR|Graded Aerobic Exercise|Graded aerobic exercise (GAE) utilizes a circuit-training approach with short intervals of exercise interspersed with brief rest breaks.
62289569|NCT02548702|NO_INTERVENTION|Control|One in 10 participants will be allocated to a control group who do not receive the intervention
62289570|NCT05728788||Patients treated with antineoplastic agents|50 patients treated with antineoplastic agents will be enrolled.
62289571|NCT00699192|EXPERIMENTAL|Amlodipine/Valsartan 5/80 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
62289572|NCT00699192|ACTIVE_COMPARATOR|Amlodipine/Valsartan 5/40 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
62289573|NCT00699192|ACTIVE_COMPARATOR|Amlodipine 5 mg|1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
62289574|NCT02678429|ACTIVE_COMPARATOR|DBS programming, standard of care|DBS settings determined from the standard Neurologist symptomatic response first then change to settings from Atlas
62289575|NCT02678429|EXPERIMENTAL|DBS progamming from Atlas|DBS settings determined from the a functional atlas first then change to settings determined by standard of care
62289576|NCT02086331|ACTIVE_COMPARATOR|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
62289577|NCT02086331|ACTIVE_COMPARATOR|PAD|Symptomatic peripheral arterial disease
62289578|NCT02086331|ACTIVE_COMPARATOR|DM|Symptomatic diabetic peripheral neuropathy
62289579|NCT01496157|EXPERIMENTAL|Patients with Primary Prostate Cancer|Patients will be imaged with 18F-DCFBC
62289580|NCT01151683|ACTIVE_COMPARATOR|Magnesium|Magnesium chelate 600 mg per day
62289581|NCT01151683|PLACEBO_COMPARATOR|Placebo|Placebo 4 capsules per day
62289582|NCT01711242|EXPERIMENTAL|capecitabine/Oxaliplatin/radiotherapy|"sequence chemoradiotherapy following radical resection~sequence chemoradiotherapy two cycles of XELOX + concurrent chemoradiotherapy + two cycles of XELOX.~Postoperative radiotherapy regimen: Radiotherapy consisted of 4500 centigray of radiation at 180 centigray per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Concurrent chemotherapy regimen: capecitabine 825 mg/m² twice daily Postoperative chemotherapy regimen: see arm 2"
62655525|NCT01348243|EXPERIMENTAL|Clodronate 200 mg|
62655526|NCT01348243|ACTIVE_COMPARATOR|Clodronate 100 mg|
62655527|NCT01603160||Emergency Department Staff|"Interventions put in place in the Emergency Department will effect most staff who work in the ED, but different sub-groups will be approached for participation in specific aspects of the study:~* All ED attending and resident physicians and ED nurses will be invited to complete the SCD Attitudes survey.~* Select ED Staff will be invited to be members of the QI team and will be invited to participate in the FMECA.~* Members of the QI team will be invited to participate in a focus group."
61906448|NCT00712400|ACTIVE_COMPARATOR|1|Latanoprost 0.005%, Xalatan®
61906449|NCT00712400|PLACEBO_COMPARATOR|2|Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)
61906450|NCT01700439|EXPERIMENTAL|EDWARDS INTUITY valve|All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.
61906451|NCT01332461||COPD Patients|Patients over the age of 40 with a COPD-related hospital or ER visit
61906452|NCT02885571|ACTIVE_COMPARATOR|MAD for subjective compliance|MAD for subjective compliance group wears the same SomnoDent Flex with DentiTrac to objective group, but they are subjected to be prescribed based on the subjective compliance data, which are acquired from patient's explanation. Compliance (average daily time,
61906453|NCT02885571|EXPERIMENTAL|MAD for objective compliance|MAD for objective compliance group wears the same SomnoDent Flex with DentiTrac to subjective group, but they are subjected to be prescribed based on the objective compliance data, which are acquired from data recorded within SomnoDent Flex with DentiTrac.
61906454|NCT03683732||Frenchteenagers|
61906455|NCT03094507|EXPERIMENTAL|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
61906456|NCT03094507|EXPERIMENTAL|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
62463345|NCT01861210|EXPERIMENTAL|Couples Counseling and Testing|Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.
62463346|NCT01861210|ACTIVE_COMPARATOR|Individudal Counseling and Testing|"Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention's Fundamentals of HIV Prevention Counseling training."
62463347|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
62463348|NCT05924763|EXPERIMENTAL|BiCRI|Biphasic Cartilage Repair Implant
62463349|NCT01096420|EXPERIMENTAL|acupuncture|
62463350|NCT01096420|ACTIVE_COMPARATOR|topiramate|
62463351|NCT02598882|ACTIVE_COMPARATOR|treadmill|patients will be 30 minutes of activity on treadmill, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
62463352|NCT02598882|ACTIVE_COMPARATOR|videogame|patients will be 30 minutes of activity with video games, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
62463353|NCT05731297||women victims of CRSV|"* Inclusion criteria: Women victims of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study.~* Exclusion criteria: Pregnant women and women under 18 years old."
62463354|NCT05731297||women without a history of CRSV|"* Inclusion criteria: women without a history of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study.~* Exclusion criteria: Pregnant women and women under 18 years old."
61906457|NCT05040113|EXPERIMENTAL|CBP-307|Take CBP-307orally at 30 min ± 2 min after the start of high-fat breakfast intake
61906458|NCT01256190|EXPERIMENTAL|Fibrocaps + Gelatin sponge|Topical Fibrocaps powder followed by application of gelatin sponge
61906459|NCT01256190|ACTIVE_COMPARATOR|Gelatin Sponge|approved device for surgical bleeding
61906460|NCT04606680|EXPERIMENTAL|Heat application group|Participants will receive heat application at acupoints plus lifestyle modification. Participants will receive heat application treatment once every other day, 3 times per week, for 4 consecutive weeks.
62091622|NCT02606669|EXPERIMENTAL|Intermittent Fasting|"The intervention of interest here is the Intermittent Energy Restriction (IER) or the Intermittent Fasting approach, specifically, the 5:2 diet, where adherence to this dietary intervention consists of fasting for two consecutive days and consuming enough to meet energy requirements for the remaining five non-fasting days. In this study, fasting will be achieved by using a meal replacement product (Optifast®) supplemented by two scoops of protein powder (Propass®) and a multivitamin, making a total of 540kcal (54g protein, 60g carbohydrates) for each fasting day."
62463355|NCT00430287||1: Primary open angle glaucoma|Patients with a form of primary open angle glaucoma
62463356|NCT00430287||2: No known eye disease (controls)|Patients with no known eye disease (controls)
61906461|NCT04606680|EXPERIMENTAL|Medicated plaster group|Participants will receive medicated plaster at acupoints plus lifestyle modification. Participants will receive medicated plaster at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
61906462|NCT04606680|EXPERIMENTAL|Herb-partitioned moxibustion group|Participants will receive herb-partitioned moxibustion at acupoints plus lifestyle modification. Participants will receive herb-partitioned moxibustion at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
61906463|NCT04958954||Cohort 1a: Pre-COVID|All participants meeting eligibility criteria in the Pre-COVID-19 period (immediately preceding the emergence of COVID-19) (Time Period 1) from 01 December 2018 to 30 November 2019
61906464|NCT04958954||Cohort 1b: Pre-COVID|All participants with evidence of an influenza vaccination and meeting eligibility criteria in the Pre-COVID-19 period (immediately preceding the emergence of COVID-19) (Time Period 1) from 01 December 2018 to 30 November 2019
61906465|NCT04958954||Cohort 2: Active-COVID|All participants meeting eligibility criteria in the Active-COVID-19 period, Pre-Emergency Use Authorization (EUA) period (following the emergence of COVID-19 but before the first COVID-19 vaccine EUA) (Time Period 2) from 01 December 2019 to 10 December 2020 (1 day prior to first United States SARS-CoV-2 vaccine EUA)
62091623|NCT02606669|NO_INTERVENTION|Control|Diet and Physical Activity advice only. No treatment plan.
62463357|NCT02511626||Case group|Women with a surgically confirmed diagnosis of endometriosis
62463358|NCT02511626||Control group 1|Women without any evidence of endometriosis (= no clinical symptom and/or no surgical evidence of endometriosis)
62463359|NCT02511626||Control group 2|Women without endometriosis (surgically confirmed) but chronic abdominal/pelvic pain due to other reasons (e.g. Crohn's disease, colitis etc)
62463360|NCT02763085|EXPERIMENTAL|Basic Filling Material|Fillings made with a new dental filling material.
62463361|NCT05873881|PLACEBO_COMPARATOR|Colchicine versus placebo|Randomization to colchicine or placebo
62463362|NCT05873881|EXPERIMENTAL|Thiamine versus no thiamine|Randomization to thiamine or to no thiamine in a PROBE design
62463363|NCT01276730|EXPERIMENTAL|Group A|Treatment consists of Interferon, given as a sub-cutaneous injection, 3 times per week for 4 weeks, 20 mg Retinoic Acid tablets, 2 times a day for 30 days. starting from the first day of radiation.
62289583|NCT01711242|ACTIVE_COMPARATOR|capecitabine/Oxaliplatin|"chemotherapy alone following radical resection~Drug: chemotherapy alone following radical resection Postoperative chemotherapy regimen: The XELOX regimen was administrated: Oxaliplatin, 130mg/m2/day on day1, i.v. 2h; Capecitabine 1000mg/m²/day twice daily d1-14; every 21 days repeated, for 4 cycles."
62463364|NCT01276730|ACTIVE_COMPARATOR|Group B|"Treatment consists of radiation and chemotherapy using Cisplatin. Cisplatin, given intravenously, will be administered on the first day of each week, mixed with saline solution, before and after the Cisplatin infusion.~Radiation will be given for a few minutes daily, five days a week, for approximately 5 weeks.~Two weeks after completion of external radiotherapy, subject will receive internal radiation (brachytherapy) once a week for two weeks. For this internal radiation a specially designed instrument will be inserted into the vagina that will be connected to a machine for a few minutes."
61906466|NCT04958954||Cohort 3: Post-EUA|All mRNA-1273 vaccinated participants meeting eligibility criteria in the Post-EUA period (Time Period 3) from date of first United States SARS-CoV-2 vaccine EUA to 31 December 2022
62091624|NCT05744869|EXPERIMENTAL|SBAT Implementation|"For schools randomized to implementing SBAT, the program will include the components already available in comparison (usual care) schools (asthma symptom screening forms, access to telemedicine visits, and protocol for initiating DOT), as well as the following elements that will be facilitated with the support of an implementation team:~1. telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT~2. school-based DOT of preventive asthma medications~3. follow-up telemedicine asthma control assessments~4. centralized case management support and care coordination"
62091625|NCT05744869|ACTIVE_COMPARATOR|Usual Care|During student health services orientation, the SBAT team will recommend school-based DOT for all children with persistent or poorly controlled asthma, and will provide a simple asthma screening survey to assess symptoms and a written protocol for initiating DOT. Telemedicine visits and DOT are available for all children in the school district, but the implementation team will not help to facilitate these components within the usual care schools.
62091626|NCT04609150||Multiple myeloma patients with vertebral fractures|Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events
62091627|NCT02338258|EXPERIMENTAL|The Anti-rotational plate group|The method was used to control the rotational unstabilization at the fracture site
62091628|NCT02338258|PLACEBO_COMPARATOR|Exchanged Intramedullary nailing group|the method Provided the axial and rotational stability
62091629|NCT01893528|EXPERIMENTAL|REGN2009 dose level 1|Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
62091630|NCT01893528|EXPERIMENTAL|REGN2009 dose level 2|Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
62289584|NCT03812406|EXPERIMENTAL|FAUCS|Patients undergoing a cesarean section using the FAUCS technique
62289585|NCT03812406|ACTIVE_COMPARATOR|Control|Patients undergoing a cesarean section using the traditional (Misgav-Ladach) technique
62289586|NCT00312455|EXPERIMENTAL|1|Drug Treatment
62289587|NCT00312455|PLACEBO_COMPARATOR|2|Placebo treatment
62289588|NCT03379519|EXPERIMENTAL|Multi-domain Attention Training (MAT)|Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).
62289589|NCT03379519|ACTIVE_COMPARATOR|Passive information activities (PIA)|The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).
61906467|NCT06153680|EXPERIMENTAL|One medical device as investigational device|
61906468|NCT00446680|EXPERIMENTAL|1|
61906469|NCT00446680|PLACEBO_COMPARATOR|2|
61906470|NCT03950921|EXPERIMENTAL|Patient Safety Display Arm|Patient Safety Display in patient room
61906471|NCT03950921|NO_INTERVENTION|Control Arm|Usual Care
61906472|NCT00223782|OTHER|1|
61906473|NCT02743611|EXPERIMENTAL|Arm 1 Does Escalation|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.~Rimiducid may be administered in response to treatment-related toxicity."
62091631|NCT01893528|EXPERIMENTAL|REGN2009 dose level 3|Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
62091632|NCT05167526|PLACEBO_COMPARATOR|Part 1: ASP8731 Placebo|Participants receive a single dose of matching placebo under fasting conditions.
62289590|NCT02562547||All Vaginal Births|The application of the Hem-Avert Perianal Stabilizer
62091633|NCT05167526|EXPERIMENTAL|Part 1: ASP8731 3mg|Participants receive a single dose of ASP8731 3mg under fasting conditions.
62463365|NCT01763385|EXPERIMENTAL|Erlotinib & secondary brain radiotherapy|Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.
62463366|NCT01763385|OTHER|Erlotinib & concurrent brain radiotherapy|Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons
61906474|NCT02743611|EXPERIMENTAL|Arm 2 Dose Escalation|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.~Rimiducid may be administered in response to treatment-related toxicity."
61906475|NCT02743611|EXPERIMENTAL|Arm 1 Part 2 Dose Expansion|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701 at the recommended cell dose level.~Rimiducid may be administered in response to treatment-related toxicity."
61906476|NCT02743611|EXPERIMENTAL|Arm 2 Part 2 Dose Expansion|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701 at the recommended cell dose level.~Rimiducid may be administered in response to treatment-related toxicity."
61906477|NCT01765959|ACTIVE_COMPARATOR|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
62091634|NCT05167526|EXPERIMENTAL|Part 1: ASP8731 12mg|Participants receive a single dose of ASP8731 12 mg under fasting conditions.
62091635|NCT05167526|PLACEBO_COMPARATOR|Part 2: Placebo|Participants receive a multiple matching dose of placebo twice daily for 14 days under fasting conditions.
62091636|NCT05167526|EXPERIMENTAL|Part 2: ASP8731 6mg|Participants receive ASP8731 6mg twice daily for 14 days under fasting conditions.
62091637|NCT05167526|EXPERIMENTAL|Part 1: ASP8731 6mg|Participants receive a single dose of ASP8731 6 mg of under fasting conditions.
62091638|NCT04561414|OTHER|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope
62091639|NCT04561414|OTHER|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The control group use Ureteral stent (Cook Ireland Ltd.)
62289591|NCT02440334|EXPERIMENTAL|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
62463367|NCT04734964|NO_INTERVENTION|Control group|Participants underwent only common physical education classes twice per week for 45 minutes each and no additional after-school exercises.
62463368|NCT04734964|EXPERIMENTAL|Coordinative exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
62463369|NCT04734964|EXPERIMENTAL|Cardiovascular exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
62463370|NCT01709760|EXPERIMENTAL|methotrexate & ENIA11|ENIA11 25 mg, sc twice weekly
62463371|NCT01709760|ACTIVE_COMPARATOR|methotrexate & Placebo|Placebo, sc twice weekly
61920076|NCT05942209||ECO-LEAK with other diagnostic method (Computed Tomography Scan or rectoscopy)|Women with colo-rectal anastomosis with a CT-SCAN (Computed Tomography Scan) or rectoscopy image test performed routinely during 4th-6th post-operative day and a transvaginal ultrasound
62091640|NCT05361746|EXPERIMENTAL|SBU+ Treatment Group|Either 1 tooth (for Subjects with 2 eligible teeth) or 2 teeth (for Subjects with 4 eligible teeth) with Class-V NCCLs will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive .
62091641|NCT05361746|ACTIVE_COMPARATOR|SBU Control Group|Either 1 tooth (for Subjects with 2 eligible teeth) or 2 teeth (for Subjects with 4 eligible teeth) with Class-V NCCLs will undergo restoration(s) using the predicate device, Scotchbond Universal (SBU) Adhesive.
62289592|NCT02297789|EXPERIMENTAL|Headgear 1|Full Face Mask with Headgear 1
62289593|NCT02297789|EXPERIMENTAL|Headgear 2|Full Face Mask with Headgear 2
62289594|NCT04671836|EXPERIMENTAL|Lorazepam first|This arm comprises of participants who were randomized to receive lorazepam 1 mg prior to the first MRI scan and then placebo on the second MRI scan a week later.
62289595|NCT04671836|PLACEBO_COMPARATOR|Placebo first|This arm comprises of participants who were randomized to receive placebo prior to the first MRI scan and then lorazepam 1 mg orally prior to the second MRI scan a week later.
61906478|NCT01765959|ACTIVE_COMPARATOR|Cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 How to solve problems, planning for the future"
61906479|NCT04193462|EXPERIMENTAL|Post-partum depression- Dyadic psychotherapy|Mothers and infants will be treated with 8 weeks dyadic psychotherapy at their home using video-feedback of mother-infant interaction to discuss main issues in the mother-infant relationship.
61906480|NCT04193462|ACTIVE_COMPARATOR|Post-partum depression- Psycho-educational therapy|8 weeks of supportive therapy for the mother at her house, involving the baby. Each session will include different aspects of psycho-education regarding development of the baby.
62091642|NCT05170542|EXPERIMENTAL|Camrelizumab+S-1|
62091643|NCT04895787|EXPERIMENTAL|Aerobic exercise group (AEX)|Gait training followed by 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle.
62091644|NCT04895787|EXPERIMENTAL|Resistance exercise group (REX)|Gait training followed by 20 minutes of resistance training targeting major muscle groups.
62091645|NCT04895787|ACTIVE_COMPARATOR|Conventional physical therapy group (CPT)|Gait training followed by 20 minutes of conventional PT programs that do not involve aerobic or resistance exercise.
62289596|NCT01219842|ACTIVE_COMPARATOR|INVASIVE (INV) group|Modern endovascular and/or open revascularization according to the recommendations in the TASC II document.
62463372|NCT05584943||84 patients on ASA chronic treatment|A total of 84 patients on chronic treatment with low-dose ASA (enteric coated, Cardio aspirin 100 mg/die Bayer, Milan, Italy) once daily (o.d.) for at least 1 month
61906481|NCT04193462|NO_INTERVENTION|Control- Healthy mothers and their babies|No intervention for 8 weeks.
61906482|NCT01683097|NO_INTERVENTION|Control|Questionnaire
61906483|NCT01683097|EXPERIMENTAL|Intervention|Standardized explanation followed by questionnaire
61906484|NCT02634190||Triple negative women|Women 30 years of age or older coming for routine cervical screening who tested triple negative at baseline with the interventions: Thinprep® LBC, HR HC2® HPV DNA and APTIMA® HPV Assay
61906485|NCT02634190||Women tested positive|Women who tested positive in any of the tests Thinprep® LBC, HR HC2® HPV DNA or APTIMA® HPV Assay will undergo colposcopy and be followed up over a ten year period and subjects who tested positive during the follow up assessment will be followed up over a 5 year period on a yearly basis
61906486|NCT02812498|EXPERIMENTAL|Teleconsultation|Teleconsultation for patients affected by type 1 diabetes mellitus
61906487|NCT02812498|OTHER|Control|Standard visit in outpatient clinic for the same type of patients
61906488|NCT01605630|EXPERIMENTAL|Family-based cancer literacy intervention|
62091646|NCT04895787|ACTIVE_COMPARATOR|Control group (CON)|Gait training followed by 20 minutes of rest (sitting on a chair and read magazines).
62091647|NCT04831164||Case|Patients with MRI confirmed rotator cuff tears
62091648|NCT04831164||Control|Patients without rotator cuff tears
62289597|NCT01219842|ACTIVE_COMPARATOR|NON-INVASIVE (NON) group|Patients receiving only best medical treatment (BMT).
62289598|NCT05572476|EXPERIMENTAL|Experimental Arm A: treatment by lurbinectedin and durvalumab|Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of lurbinectedin and durvalumab
62289599|NCT05572476|OTHER|Standard Arm B: treatment by carboplatin and etoposide|Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of carboplatin and etoposide
62289600|NCT00005724|OTHER|Minimal Intervention Group|Pamphlets on healthy eating mailed to participants.
62289601|NCT00005724|EXPERIMENTAL|Health Counselor Intervention Group|Food for Heart program, a structured diet treatment program for low-income patients with high cholesterol, given by health counselor at 4 treatment visits.
62289602|NCT00005724|EXPERIMENTAL|Computer Program Intervention Group|User-friendly interactive computer program providing dietary counseling tailored to the needs of the participant.
62289603|NCT05438173|EXPERIMENTAL|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
61906489|NCT01605630|ACTIVE_COMPARATOR|Control|Standard of care
61906490|NCT00042471|EXPERIMENTAL|Pramlintide acetate (AC137) injection|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
61906491|NCT03488511|EXPERIMENTAL|Intervention group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of six small protein and energy enriched meals and snacks that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
61906492|NCT03488511|NO_INTERVENTION|Control group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
61906493|NCT01689493|NO_INTERVENTION|usual care|usual care arm, without SMS reminder
61906494|NCT01689493|ACTIVE_COMPARATOR|patient education and daily SMS|Multifaceted patient centered intervention including : collaborative care, patient education , and daily SMS.
61906495|NCT00978757|EXPERIMENTAL|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
61906496|NCT00978757|PLACEBO_COMPARATOR|Placebo|Placebo: saline solution
61906497|NCT00786435||1|Those with a cervical spinal cord injury
61906498|NCT00786435||2|Those with a thoracic spinal cord injury
61906499|NCT00786435||3|Healthy, control group
62091649|NCT05946876|EXPERIMENTAL|A (XH-S003)|"Participants will receive an oral dose of XH-S003 once daily on scheduled day(s).~Dosage: Part A : 50mg,100mg, 200mg, 25mg \& 400mg Part B : 25mg, 50mg, 100mg. Part C : 200 mg"
62091650|NCT05946876|PLACEBO_COMPARATOR|B (Placebo)|Participants will receive oral matching placebo once daily on scheduled day(s)
62091651|NCT00057811|EXPERIMENTAL|Group B (chemotherapy, protective therapy, monoclonal antib.)|Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
62091652|NCT00057811|EXPERIMENTAL|Group C (Chemotherapy, monoclonal antibody therapy)|Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.
62463373|NCT05584943||Healthy subject|9 healthy subjects, not on ASA treatment, as controls.
62091653|NCT03668782||immediate cord clamping|Tthe umbilical cord of neonates was cut and clamped.
62091654|NCT03668782||umbilical cord milking.|Tthe umbilical cord of neonates was milked.
62091655|NCT04183192|EXPERIMENTAL|Arm A: Mepolizumab low dose|Single dose of mepolizumab 3 mg SC
62463374|NCT01367340|EXPERIMENTAL|Exercise and physical activity|
62463375|NCT01367340|ACTIVE_COMPARATOR|Exercise only|
62463376|NCT03828734|EXPERIMENTAL|TMS to frontal cortex followed by TMS to parietal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
62463377|NCT03828734|EXPERIMENTAL|TMS to parietal cortex followed by TMS to frontal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
61906500|NCT04540510|ACTIVE_COMPARATOR|OPEP therapy added to standard pneumonia care|The intervention group will be asked to use an OPEP device twice daily, with the help of study investigators, for a total of at least 5 minutes per session. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the pneumonia.
61906501|NCT04540510|ACTIVE_COMPARATOR|Standard pneumonia care|The control group will continue to receive the usual care that their hospital team prescribe for them to treat the pneumonia.
61906502|NCT02547961|EXPERIMENTAL|HER2-CAR-T|In interventional studies, participants are assigned to accept HER-2-targeting CAR T Cells infusion so that researchers can evaluate the effects and safety of the CAR-T cell.
61906503|NCT02547961|NO_INTERVENTION|No Intervention|
61906504|NCT03002090|EXPERIMENTAL|Iron trained|
61906505|NCT03002090|EXPERIMENTAL|Iron Untrained|
61906506|NCT03002090|EXPERIMENTAL|BZKL Trained|
61906507|NCT03002090|EXPERIMENTAL|BZKL Untrained|
61906508|NCT03002090|EXPERIMENTAL|Placebo Trained|
61906509|NCT03002090|PLACEBO_COMPARATOR|Placebo Untrained|
61906510|NCT01251536|OTHER|Arm B - standard dose of cetuximab|Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
61906511|NCT01251536|EXPERIMENTAL|Arm A - dose escalation of cetuximab|Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.
61906512|NCT01342237|EXPERIMENTAL|topotecan|
62091656|NCT04183192|EXPERIMENTAL|Arm B: Mepolizumab low intermediate dose|Single dose of mepolizumab 6 mg SC
62091657|NCT04183192|EXPERIMENTAL|Arm C: Mepolizumab high intermediate dose|Single dose of mepolizumab 12 mg SC
62091658|NCT04183192|EXPERIMENTAL|Arm D: Mepolizumab high dose|Single dose of mepolizumab 24 mg SC
62091659|NCT04183192|EXPERIMENTAL|Arm E: Reslizumab low dose|Single dose of reslizumab 0.1 mg/kg IV
62463378|NCT04920708|EXPERIMENTAL|Palbociclib + Fulvestrant + Ipatasertib (Interventional arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to interventional arm receive Palbociclib + Fulvestrant + Ipatasertib. n = 87.
62463379|NCT04920708|ACTIVE_COMPARATOR|Palbociclib + Fulvestrant (Comparison arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to Comparison arm receive Palbociclib + Fulvestrant. n = 87.
62463380|NCT04920708|ACTIVE_COMPARATOR|Standard of Care (No ctDNA observational arm)|Where no ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 50.
62463381|NCT04920708|ACTIVE_COMPARATOR|Standard of Care (Low ctDNA observational arm)|Where low ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 100.
62463382|NCT00533663|EXPERIMENTAL|Standard Care + Healing Touch (HT)|A a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy. It occurs every other week (during their infusion).
62463383|NCT00533663|ACTIVE_COMPARATOR|Standard Care + Guided relaxation|Guided relaxation every other week (during their infusion).
62463384|NCT00533663|ACTIVE_COMPARATOR|standard care only|Standard care
62091660|NCT04183192|EXPERIMENTAL|Arm F: Reslizumab intermediate low dose|Single dose of reslizumab 0.2 mg/kg IV
62289604|NCT05438173|ACTIVE_COMPARATOR|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
62289605|NCT03033329|EXPERIMENTAL|Single intravenous doses of MRX-4|Single escalating intravenous doses of MRX-4 from 150 mg to 1800 mg
62289606|NCT03033329|PLACEBO_COMPARATOR|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-4
62463385|NCT04857125|ACTIVE_COMPARATOR|Multicomponent intervention|Pre-, intra- and postoperative interventions applied using the Fast-IM method.
62463386|NCT04857125|NO_INTERVENTION|Standard care|Patients are receiving standard care.
62463387|NCT01643005|ACTIVE_COMPARATOR|Active Control Group|For the active control group we will use Nurturing Parenting Groups currently being run by the community collaborator.
62289607|NCT03033329|ACTIVE_COMPARATOR|Multiple intravenous doses of MRX-4|Twice daily escalating intravenous doses of MRX-4 for 10 days: 600 mg, 900 mg, 1200 mg, and 1500 mg
62655528|NCT03062371|EXPERIMENTAL|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
62655529|NCT03456934|EXPERIMENTAL|Experimental Group|Modified infant formula given from 3 to 12 months of age, as per standard requirement.
62655530|NCT03456934|ACTIVE_COMPARATOR|Control Group|Standard infant formula given from 3 to 12 months of age, as per standard requirement.
62655531|NCT03456934|NO_INTERVENTION|Breast-fed Reference Group|Non-randomized infants who are predominantly breast-fed at time of enrollment.
62289608|NCT03033329|PLACEBO_COMPARATOR|Multiple intravenous doses of placebo|Twice daily intravenous doses of placebo to match MRX-4 for 10 days
62289609|NCT03033329|ACTIVE_COMPARATOR|Single dose of intravenous and oral MRX-4|Crossover of single dose of intravenous and oral MRX-4
62289610|NCT01628926|EXPERIMENTAL|SPM 962|SPM 962 transdermal patch
62289611|NCT01628926|ACTIVE_COMPARATOR|Ropinirole|Ropinirole tablet
62289612|NCT01628926|PLACEBO_COMPARATOR|Placebo|SPM962 placebo patch and Ropinirole placebo tab
62463388|NCT01643005|EXPERIMENTAL|Relationship Strengthening HIV Prevent.|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
62463389|NCT03737578|EXPERIMENTAL|Daily hemodialysis patients|"Description: End stage renal disease patients starting daily hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
62463390|NCT03737578|ACTIVE_COMPARATOR|Conventional hemodialysis patients|"Description: End stage renal disease patients currently treated by conventional hemodialysis or starting conventional hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
62463391|NCT02223741||Korean medicine conjugate rehabilitation|those with more than 30 days of herbal drugs or more than 12 times of acupuncture (Korean medical treatment) within six months in addition to conventional rehabilitation
62655532|NCT02025608|EXPERIMENTAL|Pramipexole|Pramipexole, 0.25 mg, daily for 4 weeks
62289613|NCT04600167|EXPERIMENTAL|Isoniazid and Rifapentine (INH-RPT)|Participants in intervention arm will receive an oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
62655533|NCT02025608|PLACEBO_COMPARATOR|Placebo|Placebo, daily for 4 weeks
62655534|NCT01998360|EXPERIMENTAL|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and sealing wound with tissue adhesive
62091661|NCT04183192|EXPERIMENTAL|Arm G: Reslizumab high intermediate dose|Single dose of reslizumab 0.4 mg/kg IV
62091662|NCT04183192|EXPERIMENTAL|Arm H: Reslizumab high dose|Single dose of reslizumab 0.8 mg/kg IV
62091663|NCT04183192|PLACEBO_COMPARATOR|Arm I: Placebo|Single dose of placebo
62289614|NCT04600167|PLACEBO_COMPARATOR|Control|Participants in the control arm will receive placebo once weekly for 12 weeks.
62307971|NCT05634564|EXPERIMENTAL|Concurrent radiochemotherapy combined with immunotherapy|Participants will receive tislelizumab plus gemcitabine and nab-paclitaxel in cycles of 21 days. Non-progressors will plus concurrent radiotherapy during the 3rd cycle of chemotherapy. After 4-6 cycles treatment, Multiple disciplinary team (MDT) will evaluate whether to undergo radical surgery.
62091664|NCT06697249||RR patients|Patients after biological aortic root replacement
62307972|NCT04605679|EXPERIMENTAL|Recipient of HCV positive kidney graft|A single center, open-label, pilot study examining 20 adult HCV negative kidney transplant patients who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after kidney transplantation, unless extenuating clinical circumstances arise (such as the development of fibrosing cholestatic HCV, which would prompt earlier treatment, or clinical events or comorbidities which would prompt delay in treatment).
62655535|NCT01998360|ACTIVE_COMPARATOR|Surgical control|Surgical circumcision using forceps guided, dorsal slit, or sleeve method
62463392|NCT02223741||Conventional rehabilitation|those with one of the treatments; physical, occupational, speech-language or cognitive-behavioral therapies
62655536|NCT02295137|EXPERIMENTAL|pre-procedure image guidance|
62091665|NCT06697249||VSRR patients|Patients after valve-sparing aortic root replacement
62091666|NCT03860077|EXPERIMENTAL|Very Low Nicotine Content Cigarettes|
62091667|NCT03860077|ACTIVE_COMPARATOR|Normal Nicotine Content Cigarettes|
62091668|NCT02938728||Melanoma|Advanced melanoma treated by immunotherapies
62091669|NCT04287751|OTHER|Overnight Oximetry|Participants record simultaneously overnight oximetry on night 1 and continue with prolonged recordings alone for a total of 4 nights
62655537|NCT03186352|EXPERIMENTAL|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
61906513|NCT05402605|ACTIVE_COMPARATOR|ICSI with AOA|"The oocytes were transferred into the calcium ionophore activation solution for two times of post-ICSI AOA (Ionomycin concentration of 10 µM).~Then the oocytes will be washed several times using the medium drops in dish AOA and dish ICSI, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2."
61906514|NCT05402605|ACTIVE_COMPARATOR|ICSI without AOA|Post-ICSI oocytes will be cultured in drops containing the Sage - 1 - StepSM medium (maximum 3 oocytes per drop) at 37oC, 6% CO2 and 5% O2 in K-system G185 incubator.
61906515|NCT05697185|EXPERIMENTAL|the evolocumab plus statin therapy|Patients with AIS are treated with atorvastatin (40mg) daily and evolocumab (420 mg) every months throughout the study period
62307973|NCT02801357|EXPERIMENTAL|lofexidine with tapering buprenorphine|Enrolled subjects must be on a daily dose of between 8 - 24 mg of buprenorphine for at least 30 days. Once enrolled, subjects will receive lofexidine as follows: Days 1 through 3, 0.6 mg 4 times daily (QID; 2.4 mg daily); Days 4 through 6, 0.8 mg QID (3.2 mg daily), and Day 7 0.8 mg at 8 AM. Subjects will take their scheduled lofexidine doses at approximately 8 AM, 1 PM, 6 PM and 11 PM. Subjects will also reduce their current buprenorphine dose by at least 4 mg on Day 1.
62655538|NCT06228976|EXPERIMENTAL|Intervention Arm|One or two tailored messages will be sent to participants everyday at designated time for 12 weeks
62655539|NCT06228976|ACTIVE_COMPARATOR|Education Arm|One tailored message will be sent to participants everyday at designated time for 12 weeks
62655540|NCT06228976|ACTIVE_COMPARATOR|Control arm|One tailored message will be sent to participants everyday at designated time for 12 weeks
62655541|NCT06470581|ACTIVE_COMPARATOR|Local anesthetics|Total volume of 0.375% ropivacaine 3 mL will be injected in phase 2.
62655542|NCT06470581|EXPERIMENTAL|Botulinum toxin A|Total volume of BTX-A 75U in normal saline 3ml will be injected in phase 2.
62655543|NCT03998631|PLACEBO_COMPARATOR|Saline Flush|This is the control arm. The TEVAR or TAVI device will be flushed with at least 60mL of standard saline to reduce bubbles in the reservoir prior to deployment. This is the standard of care.
62655544|NCT03998631|EXPERIMENTAL|Carbon Dioxide and Saline Flush|Carbon dioxide flush of the TEVAR or TAVI device followed by saline flush.
62655545|NCT02353780|ACTIVE_COMPARATOR|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
62655546|NCT02353780|ACTIVE_COMPARATOR|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
62655547|NCT02353780|ACTIVE_COMPARATOR|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
61906516|NCT05697185|NO_INTERVENTION|the statin alone therapy|Patients with AIS are treated with atorvastatin (40mg) daily throughout the study period.
61906517|NCT00109590|EXPERIMENTAL|Arm A: LPV/r x 7d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and BID for 7 days postpartum, ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally twice daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 7 days postpartum, LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 7 days postpartum.
62655548|NCT02179619|EXPERIMENTAL|Dermalax(Deep)|subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
62655549|NCT02179619|ACTIVE_COMPARATOR|Restylane|Subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
62655550|NCT04042792||ADA for ≥12 weeks and concomitant MTX therapy|PiRD patients with ADA for ≥12 weeks and concomitant MTX therapy (oral or subcutaneous)
62655551|NCT04042792||ADA for ≥ 12 weeks without MTX|PiRD patients with ADA for ≥ 12 weeks without MTX ≥ 12 weeks (or never exposed to MTX)
61906518|NCT00109590|EXPERIMENTAL|Arm B: no LPV/r|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 30 days postpartum.
61920077|NCT05942209||CT-SCAN and/or rectoscopy|Women with colo-rectal anastomosis with a CT-SCAN or rectoscopy image test performed routinely during 4th-6th post-operative day
62091670|NCT01192087|EXPERIMENTAL|Cetuximab arm|patients receive weekly cetuximab in combination with IMRT and carbon ion boost
62091671|NCT05880693|EXPERIMENTAL|group 1|"The first group (group 1): (n= 28): Received a loading dose of dexmedetomidine 1 μg/kg in a normal saline 0.9% solution of 100 ml 10 minutes before anesthesia induction and then a 0.4 ug/kg/h via syringe infusion pump during the time of surgery.~."
62091672|NCT05880693|EXPERIMENTAL|group 2|The second group (group 2): (n= 28): Received magnesium sulfate 30 mg/kg as a loading dose in a saline 0.9% solution of 100 ml infusion through the syringe pump10 minutes before anesthesia induction and then a 10 mg/kg/h via syringe infusion pump during the time of surgery
62289615|NCT01997151|EXPERIMENTAL|Healthy Pregnancy: Step by Step|Pregnant women interacted with a multiple behavior change iPad- delivered program at federally funded health centers. The 20-30 minute program offered onscreen assessments of Transtheoretical Model strategies of change, and then provided individually tailored feedback messages matched to their readiness to change for relevant target behaviors. The program addressed smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption. The feedback screens were interactive and engaging. The messages were written at a 4th-5th grade level and were reviewed for multicultural relevancy. Participants in the treatment group interacted with the program up to 3 times during pregnancy. A printed multiple behavior change guide also was distributed. All program components are available in English and Spanish.
62655552|NCT04265001|ACTIVE_COMPARATOR|Control group|Topical cholrhexidine hydrochloride 125 mg/100 ml available commercially (Hexitol; Arab Drug Company for Pharmaceutical and Chemical Industries, Cairo, Egypt) mouthwash. Topical cholrhexidine hydrochloride mouthwash treatment has been repeated three times per day for one week.
62655553|NCT04265001|EXPERIMENTAL|Hyaluronic acid group (HA group)|Topical hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash (Aftamed; Bioplaxpharma, UK).Topical hyaluronic acid mouthwash treatment has been repeated three times per day for one week.
62655554|NCT03088397|EXPERIMENTAL|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
62655555|NCT03088397|ACTIVE_COMPARATOR|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
62655556|NCT03088397|ACTIVE_COMPARATOR|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
62655557|NCT00083915|ACTIVE_COMPARATOR|Auto Transplant w/ High Dose Melphalan|Autologous transplant with High Dose Melphalan alone
62655558|NCT00083915|ACTIVE_COMPARATOR|Auto Transplant w/ Melphalan + DT Pace|Melphalan plus Dexamethasone, Thalidomide, CisPlatinum, Adriamycin, Cyclophosphamide, and Etoposide
62655559|NCT03526705|EXPERIMENTAL|nb-uvb|psoriasis patients will receive 26 sessions of nb-uvb phototherapy
62655560|NCT02335853||women with metabolic syndrome and overactive bladder|"women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:~1. Abdominal obesity, defined as a waist circumference in men ≥88 cm~2. Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides~3. Serum HDL cholesterol \<40 mg/dL (1 mmol/L) in men and \<50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C~4. Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure~5. Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose"
62655561|NCT02335853||women with overactive bladder|women with urinary urgency+frequency+nocturia
62655562|NCT02335853||healthy control group|women not overactive bladder and metabolic syndrome
62655563|NCT04582526|EXPERIMENTAL|Intervention arm|BMS program
62655564|NCT03037242|OTHER|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
62655565|NCT00382356|EXPERIMENTAL|study drug|Open label, single arm
62655566|NCT01869374|EXPERIMENTAL|Magnetic Seizure Therapy (MST)|MagVenture MagPro MST device
62655567|NCT01869374|ACTIVE_COMPARATOR|RUL ECT|Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
62655568|NCT03246945|EXPERIMENTAL|Study Arm|Patient-Parent Dyad receiving photography instructions prior to taking photographs of skin conditions
62655569|NCT03246945|NO_INTERVENTION|Control Arm|Patient-Parent Dyad not receiving photography instructions prior to taking photographs of skin conditions
62655570|NCT02952417||STEMI and NSTEMI Women|Women with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
62655571|NCT02952417||STEMI and NSTEMI Men|Men with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
62655572|NCT03518684|NO_INTERVENTION|Group 1|Group 1 in which they will receive the standard care during labor and delivery without the use of the obstetrical gel
61906519|NCT00109590|EXPERIMENTAL|Arm C: LPV/r x 30d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 30 days postpartum,LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 30 days postpartum.
61906520|NCT02414529|PLACEBO_COMPARATOR|Placebo group|"Placebo group B: single blinded to patients, receive 6 capsule PO (placebo) at once.~Subjects are blinded then they will crossover groups"
61906521|NCT02414529|ACTIVE_COMPARATOR|Treatment group|"Group A will receive 6 capsules (50.000 units/each) of vitamin D2(ergocalciferol) at once.~Subjects are blinded then they will crossover groups."
61906522|NCT03462511|ACTIVE_COMPARATOR|Control Group|"Dyads randomized to the control group will receive:~Standard care and Education handouts."
61906523|NCT03462511|EXPERIMENTAL|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
61906524|NCT00117052|ACTIVE_COMPARATOR|During dialysis visit|Cinacalcet is given during the dialysis visit
61906525|NCT00117052|ACTIVE_COMPARATOR|Post-dialysis meal|Cinacalcet is administered with a post-dialysis meal
62091673|NCT04535375|OTHER|Preterm infants < 28 weeks gestational age|For infants born before 28 0/7 weeks, standard of care consists of brain ultrasound performed on admission, day 1, day 2, day 3, day 7, and then weekly until discharge.
62091674|NCT04535375|OTHER|Preterm infants born between 28 0/7 and 31 6/7 weeks|For infants born between 28 0/7 and 31 6/7 weeks, brain ultrasound is performed on admission, once between day 1 and 3, once between day 7 and 10, and then 2-weekly until discharge or transfer.
62091675|NCT06206044||Study Cohort|Healthy pregnant women of BMI between 20 and 40 kg/m2, height between 5 feet 2 inches and 5 feet 10 inches, who are having cesarean delivery under spinal or combined spinal epidural anesthesia.
62289616|NCT01997151|NO_INTERVENTION|Usual Care|Pregnant women received regular prenatal care as delivered by the health care center from where they were receiving care. Standard informational March of Dimes brochures related to the target behaviors were distributed to usual care participants.
62655573|NCT03518684|EXPERIMENTAL|Group 2|Group 2 in which they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel according to the study protocol. Those 2 groups will be further divided into 4 subgroups where the parity will be accounted for (nulliparous \[never delivered beyond 20 weeks of gestation in a previous pregnancy\] or primiparous or more)
62655574|NCT01570764|EXPERIMENTAL|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
62655575|NCT01570764|PLACEBO_COMPARATOR|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
62655576|NCT03426904|EXPERIMENTAL|Neoadjuvant FOLFOX|4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX
62655577|NCT03426904|ACTIVE_COMPARATOR|Conventional adjuvant FOLFOX|surgery followed by 12 cycles of FOLFOX
62655578|NCT01474343|EXPERIMENTAL|SAF-301|
62655579|NCT05051163|EXPERIMENTAL|Ceftriaxone|Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily
62655580|NCT05051163|ACTIVE_COMPARATOR|Ampicillin and Gentamicin|"1. Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly~2. Gentamicin will be administered intravenously at a dose 5mg/kg once daily"
61906526|NCT05734417|EXPERIMENTAL|Probiotic|Intervention consists of daily administration of excipient plus Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day administered daily for 4-weeks
61906527|NCT05734417|PLACEBO_COMPARATOR|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
61906528|NCT02553356|EXPERIMENTAL|Fasted|PT2385 taken after fasting.
61906529|NCT02553356|EXPERIMENTAL|Non-Fasting|PT2385 taken after eating a high calorie meal.
62289617|NCT03526289|ACTIVE_COMPARATOR|GIP infusion|5 hours of continuously GIP1-42 infusion
62289618|NCT03526289|PLACEBO_COMPARATOR|Saline|5 hours of continuously saline infusion
62289619|NCT02948361|EXPERIMENTAL|QT Ultrasound breast scan|
62289620|NCT03667001|EXPERIMENTAL|Lidocaine Hydrochloride|"* 1.5 mg/kg lean body mass lidocaine (lidocaine 1%) bolus I.V. as general anesthesia steady state concentration is accomplished~* 1.5 mg/kg lean body mass/h lidocaine I.V. with beginning of surgical procedures~* after completion of surgery: transfer to PACU, pain evaluation for 48 hours~* duration of intervention: lidocaine infusion up to four hours from completion of surgery, or till transfer to surgical ward"
61906530|NCT05286645|ACTIVE_COMPARATOR|real stimulation|Participants will receive active tDCS once daily for two weeks. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions.
61906531|NCT05286645|PLACEBO_COMPARATOR|sham stimulation|Participants will receive sham tDCS once daily for two weeks. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
62289621|NCT03667001|PLACEBO_COMPARATOR|Saline Solution|"* 0.15 ml/kg lean body mass saline 0.9% bolus I.V. as general anesthesia steady state concentration is accomplished~* 0.15 ml/kg lean body mass/h saline 0.9% I.V. with beginning of surgical procedure~* after completion of surgery: transfer to PACU, pain evaluation for 48 hours~* duration of intervention: saline infusion up to four hours from completion of surgery, or till transfer to surgical ward"
62289622|NCT01649336|EXPERIMENTAL|MEK162 + paclitaxel|
62655581|NCT00481039||1|Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
62655582|NCT02685930||Pneumonia without ICU stewardship involvement|Patients receiving \>24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Antibiotic choice and duration of therapy will not be influenced by the dedicated ICU stewardship team.
62655583|NCT02685930||Pneumonia with ICU stewardship involvement|Patients receiving \>24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Recommendations for antibiotic choice and duration of therapy will be provided by the dedicated ICU stewardship team (consisting of pulmonary fellows and ICU pharmacists)
61906532|NCT03179202|EXPERIMENTAL|Peripheral Nerve Stimulation|All study subjects will have up to 4 Leads placed in their low back, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
61906533|NCT02379689|ACTIVE_COMPARATOR|injectable placental tissue extract called BioDGenesis|This study will compare injectable placental tissue extract called BioDGenesis (Active Product)
62289623|NCT02349126|EXPERIMENTAL|Treatment Group|ARC-520 Injection
62289624|NCT02310048|EXPERIMENTAL|MT-1303-FormA|MT-1303, Capsule Formulation A
62289625|NCT02310048|EXPERIMENTAL|MT-1303-FormB|MT-1303, Capsule Formulation B
61906534|NCT02379689|PLACEBO_COMPARATOR|Placebo|injectable Tissue Suspension Solution (TSS) (Placebo). The Active Product is supplied by BioD, LLC (BioD).
61906535|NCT05761795|EXPERIMENTAL|IVMED-85 Low Dose and placebo|Total subjects n=6 n=4 IVMED 85 Low Dose n=2 placebo BID for 1 month
61906536|NCT05761795|EXPERIMENTAL|IVMED-85 Mid Dose and placebo|Total subjects n=6 n=4 IVMED 85 Mid Dose n=2 placebo BID for 1 month
61906537|NCT05761795|EXPERIMENTAL|IVMED-85 High Dose and placebo|Total subjects n=6 n=4 IVMED 85 High Dose n=2 placebo BID for 1 month
62289626|NCT02857218|EXPERIMENTAL|Diagnostic (ferumoxytol, MRI)|Patients receive ferumoxytol IV over 15 minutes and then undergo ferumoxytol-enhanced MRI (Magnetic Resonance Imaging) after 24-36 hours and before surgery at week 12.
61906538|NCT05761795|EXPERIMENTAL|IVMED-85 Low Dose|Total subjects n=48 IVMED 85 Low Dose BID for 12 month
61906539|NCT05761795|EXPERIMENTAL|IVMED-85 Mid Dose|Total subjects n=48 IVMED 85 Mid Dose BID for 12 month
62289627|NCT01587989|ACTIVE_COMPARATOR|A Methotrexate|
62289628|NCT01587989|EXPERIMENTAL|B Methotrexate Placebo|
62091676|NCT02818816|EXPERIMENTAL|Brimonidine Tartrate 0.2% (2mg/mL)|One (I) drop of brimonidine tartrate 0.2% (2mg/mL) will be placed in the randomized eye preoperatively thirty minutes before robotic-assisted radical laparoscopic prostatectomy (RALP)
61906540|NCT05761795|EXPERIMENTAL|IVMED-85 High Dose|Total subjects n=48 IVMED 85 High Dose BID for 12 month
61906541|NCT05761795|PLACEBO_COMPARATOR|Placebo|Total subjects n=54 Placebo BID for 12 month
61906542|NCT03924557|ACTIVE_COMPARATOR|Genotyping Intervention Supportive Care|For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.
61906543|NCT03924557|NO_INTERVENTION|Delayed Genotyping Intervention Supportive Care|For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.
61906544|NCT00748020|ACTIVE_COMPARATOR|group 1|Erythematogenic irradiation scheme
62091677|NCT02818816|PLACEBO_COMPARATOR|Carboxymethylcellulose Eye Drops|One drop of Carboxymethylcellulose eye drops will be placed in the randomized eye half an hour before RALP
61906545|NCT00748020|ACTIVE_COMPARATOR|group 2|Suberythematogenic irradiation scheme
61906546|NCT05716672||240mg group|Maintenance of the 240mg dose for 12 weeks after the first administration of Lazertinib
61906547|NCT05716672||160mg group|Reduction of the 160mg dose for 12 weeks after the first administration of Lazertinib
61906548|NCT01221285|EXPERIMENTAL|German cockroach allergenic extract|Participants will receive weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
61906549|NCT03086187|OTHER|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
61906550|NCT02724540|EXPERIMENTAL|Arm 1 - BE|Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.
62091678|NCT04577820|EXPERIMENTAL|garetosmab|
62091679|NCT04176614|EXPERIMENTAL|cereal-legume snack|Certain amount of cereal-legume snack daily for 12 weeks
62655584|NCT06069362|EXPERIMENTAL|Manual physiotherapy and neurodynamic exercises|"The treatment applied forms part of the routine clinical practice and includes the following:~* Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve root.~* Home neurodynamic sliders of the upper limb and cervical mobility exercises."
62655585|NCT05635617||Lower extremity fracture|High energy lower extremity fractures
62655586|NCT02898467||diabetics|Type 2 diabetic patients exhibiting fasting glycemia value over 7 mmol/L or glycated hemoglobin value over 6.5% or type 2 diabetic patients under oral anti-diabetic treatment or type 2 diabetic patient under insulin treatment and in which diabetes has been diagnosed after the age of 45 y
62655587|NCT02898467||non-diabetics|patients without diagnosed diabetes exhibiting fasting glycemia value under 7 mmol/L
62655588|NCT05053867|EXPERIMENTAL|Group A: Inhaled tranexamic acid|will receive 500 mg/5ml nebulized tranexamic acid every 8 hours for at least 3 days, and up to 5 days
62655589|NCT05053867|OTHER|Group B: Usual Care|usual care
62655590|NCT02193295|EXPERIMENTAL|Lifestyle Intervention|Caloric Restriction to reverse lipid-induced insulin resistance.
62655591|NCT02193295|EXPERIMENTAL|Baseline Assessment of Hepatic Mitochondrial Fat Oxidation|Tracer study to assess hepatic mitochondrial fat oxidation (PINTA).
62655592|NCT00706797|ACTIVE_COMPARATOR|Usual care|Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold).
62655593|NCT00706797|ACTIVE_COMPARATOR|ETN + MTX|Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-filled syringe) plus continuation of current dose of Methotrexate (MTX) either oral (PO), SC, or intramuscular (IM).
62655594|NCT06190028|EXPERIMENTAL|IRIDIUM A gel|Patients will receive IRIDIUM® A gel (four boxes to be used and one spare box) and they will be instructed to bilaterally apply 1 drop per eye onto the conjunctival sac 2 times a day for 60 days (one application during the day and one before going to sleep).
62655595|NCT04769297|EXPERIMENTAL|Sublingual Micro-Dose Ketamine|Ketamine micro-dose 37.5mg compounded sublingual daily administration
62655596|NCT06184282|EXPERIMENTAL|MEBO group|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
62655597|NCT06184282|ACTIVE_COMPARATOR|Control Group|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
62655598|NCT02131688|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome|
62655599|NCT06108921|EXPERIMENTAL|xylitol|In the xylitol group, 5% xylitol solutions were first prepared by mixing two packs of 10 mg xylitol powder with 400 mL of sterile water in the container of the irrigator. Nasal irrigation was performed by using a Sanvic SH903 pulsatile irrigator (Yun-Wang Industrial Co., Tainan, Taiwan). When irrigating the nose, patients irrigated both of their nasal cavities each with 200 mL of solutions once a day. Patients performed nasal irrigations for 2 months.
62655600|NCT06108921|PLACEBO_COMPARATOR|saline|In the saline group, the normal saline solution was prepared by mixing 2 packs of 1.8 mg salt powder with 400 mL of sterile water in the container of the irrigator. Nasal irrigation was performed by using a Sanvic SH903 pulsatile irrigator (Yun-Wang Industrial Co., Tainan, Taiwan). When irrigating the nose, patients irrigated both of their nasal cavities each with 200 mL of solutions once a day. Patients performed nasal irrigations for 2 months.
61906551|NCT02724540|EXPERIMENTAL|Arm 2 - TACE|Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
62091680|NCT04176614|ACTIVE_COMPARATOR|cereal snack|Certain amount of cereal snack daily for 12 weeks
62091681|NCT02522520|ACTIVE_COMPARATOR|Pedometer intervention|"Individual progressive pedometer intervention of low to moderate intensity.~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
62289629|NCT00826813|EXPERIMENTAL|stenting|The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
62289630|NCT02484027|EXPERIMENTAL|statin-therapy|Rosuvastatin orally at a dose of 20mg daily is assigned to patients immediately for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
62655601|NCT04249024|EXPERIMENTAL|Laser treatment|Laser treatment with diode laser 970nm and settings 1.2W in intervals of max 20s, until satisfactory removal of diseased epithelium and granulation tissue.
62655602|NCT04249024|ACTIVE_COMPARATOR|Mucosal flap surgery|Conventional mucosal flap surgery of affected dental implant.
62655603|NCT01979900|EXPERIMENTAL|Vaccae|Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
62655604|NCT01979900|PLACEBO_COMPARATOR|Placebo|Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
62463393|NCT05056077|EXPERIMENTAL|Condition I (text, health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
62463394|NCT05056077|EXPERIMENTAL|Condition II (text, health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
62091682|NCT02522520|ACTIVE_COMPARATOR|Pedometer + hospital based intervention|"Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
62091683|NCT02937844|EXPERIMENTAL|Anti-PD-L1 CSR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10\^4 /kg to 1×10\^7 /kg.
61906552|NCT02724540|EXPERIMENTAL|Arm 3 - DEB - CLOSED|Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.
62463395|NCT05056077|EXPERIMENTAL|Condition III (text, health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
61906553|NCT04320758|EXPERIMENTAL|single crown in dental aesthetic zone|teeth in dental aesthetic zone
61906554|NCT04320758|EXPERIMENTAL|teeth need single crown in dental aesthetic zone|teeth in dental aesthetic zone
62091684|NCT05293496|EXPERIMENTAL|Cohort -1|vobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks
62091685|NCT05293496|EXPERIMENTAL|Cohort 1|vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
62091686|NCT05293496|EXPERIMENTAL|Cohort 2|vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
62463396|NCT05056077|EXPERIMENTAL|Condition IV (text, health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages and use digital health tool kit for 48 weeks.
62655605|NCT01658839|EXPERIMENTAL|Travoprost|Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days
61906555|NCT04635800|EXPERIMENTAL|Cohort 1|Cohort 1; open-label, non-randomized, single administration
62091687|NCT05293496|EXPERIMENTAL|Cohort 3|vobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks
62091688|NCT05293496|EXPERIMENTAL|Cohort 4|vobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks
62289631|NCT02484027|SHAM_COMPARATOR|non-statin-therapy|No statins is assigned to patients for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
61906556|NCT04635800|EXPERIMENTAL|Cohort 2|Cohort 2; open-label, non-randomized, single administration
61906557|NCT04635800|EXPERIMENTAL|Cohort 3|Cohort 3, open-label; non-randomized, single administration
61906558|NCT04635800|EXPERIMENTAL|Cohort 4|Cohort 4, open-label, non-randomized, single administration
61906559|NCT03101111|EXPERIMENTAL|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
62091689|NCT05293496|EXPERIMENTAL|Cohort 5|vobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks
61906560|NCT03101111|ACTIVE_COMPARATOR|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
61906561|NCT02527577|EXPERIMENTAL|ropivacaïne chlorhydrate monohydrate|
61906562|NCT02527577|PLACEBO_COMPARATOR|placebo|
61906563|NCT04958395||Myocardial bridge|Measure FFR and d-FFR
62091690|NCT05293496|EXPERIMENTAL|Cohort Expansion|maximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks
62289632|NCT00152633|ACTIVE_COMPARATOR|Losartan|Treatment with Losartan.
61906564|NCT02122068|EXPERIMENTAL|Mentalizing Imagery Therapy|Meditation and mindfulness 4 week program
62289633|NCT00152633|ACTIVE_COMPARATOR|Betablocker|Treatment with Metoprolol.
62289634|NCT01413386|EXPERIMENTAL|Paclitaxel Eluting Covered Metal Stent|
62091691|NCT03644134|EXPERIMENTAL|Intervention Group|Assessment of physiological stress and sleep pattern intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns
62091692|NCT03644134|NO_INTERVENTION|Control Group|The control protocol only includes (i) information session (ii) pre-assessment (initial assessment and (iii) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
62289635|NCT01413386|ACTIVE_COMPARATOR|Covered Metal Stent|
62289636|NCT02933918|EXPERIMENTAL|Probiotics|
62289637|NCT04894955|EXPERIMENTAL|Main study group|
62289638|NCT01486420|ACTIVE_COMPARATOR|Open surgery|
62289639|NCT01486420|ACTIVE_COMPARATOR|Corticosteroid Injection|
62289640|NCT04668898||LRRK2 Parkinson Disease|Individuals with LRRK2-related Parkinson Disease
61906565|NCT02122068|ACTIVE_COMPARATOR|Relaxation cd|Listening to a relaxation cd
61906566|NCT04295031||DM2 without renal disease|patients with type 2 diabetes with normal renal function
61906567|NCT04295031||DM2 with renal impairment|patients with type 2 diabetes with impaired renal function
61906568|NCT05048511||Normal|Women with sufficient vitamin D level, when 25(OH)D \>20 ng/ml
61906569|NCT05048511||Deficient|women deficiency vitamin D level, when 25(OH)D \<20 ng/ml
61906570|NCT01158001|EXPERIMENTAL|Psychotherapy via telemedicine|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in a novel format - interacting with a therapist via videoconferencing.
61906571|NCT01158001|ACTIVE_COMPARATOR|Face-to-face (in person) psychotherapy|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in the traditional format - in person with a therapist.
61906572|NCT03428919|ACTIVE_COMPARATOR|Intracytoplasmic Sperm Injection (ICSI)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen."
61906573|NCT03428919|ACTIVE_COMPARATOR|In Vitro Fertilization (IVF)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium.~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen."
61906574|NCT04471285|ACTIVE_COMPARATOR|true acupuncture|patient will get treatment according to the point the will help the symphysiolysis according to the Alternative medicine
61906575|NCT04471285|SHAM_COMPARATOR|Sham acupuncture|patient will get treatment according to the point the will NOT help the symphysiolysis according to the Alternative medicine
61906576|NCT04195542||women in obstetric ward in Rennes CHU|women in obstetric ward in Rennes CHU
61906577|NCT04195542||CHU professionals|All CHU professionals contacted via their email address
61906578|NCT06313788|EXPERIMENTAL|Possession Group|"Participants will be presented with two leaflets about a branded band-aid, which specify its functions, e.g., stop bleeding, protect wounds and reduce pain. Participants read its analgesic component and mechanism (e.g., reduces pain sensitization of peripheral nerves) to induce a positive expectation that the branded bandage can effectively help them alleviate pain. Next, participants rate their perceived effectiveness of the band-aid and their use intention. In order to mask the purpose of the study, they will also answer other distractor marketing questions, such as to guess the price of the band-aid and their impression on the package design of the band-aid.~Participants in possession group will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference."
62091693|NCT06532552|ACTIVE_COMPARATOR|VA group|Azacitidine 75mg/m2 subcutaneous daily for 7 days and Venetoclax orally once daily (100mg d1, 200mg d2, 400mg d3-28). Patients received 2 cycles of VA, the bone marrow aspirate will be done on the 21-28th day in the each cycle. If the result is partial remission (PR)/no response (NR) at the end of the cycle 2, the patients need to withdraw from the trial. If the bone marrow assessment is complete remission (CR)/CR with incomplete hematologic recovery (CRi)/morphologic leukemia-free state (MLFS), the patients will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy or declines, continue with the same regimen until progression or recurrence of the disease, and the patients need to withdraw from the trial. If the patients fit for intensive chemotherapy, patients will receive chemotherapy with other regimens or transplantation, and the patients need to withdraw from the trial if progression or recurrence of the disease.
62289641|NCT04668898||GBA Parkinson Disease|Individuals with GBA-related Parkinson Disease
62289642|NCT04668898||Idiopathic Parkinson Disease|Individuals with Idiopathic (without any known genetic cause) Parkinson Disease
62289643|NCT04668898||LRRK2 non-manifesting carriers|Individuals without Parkinson Disease who have a LRRK2 mutation
62289644|NCT04668898||GBA non-manifesting carriers|Individuals without Parkinson Disease who have a GBA mutation
62289645|NCT04668898||Healthy control|Individuals without a personal or family history (1st or 2nd degree) of a neurodegenerative disease
62289646|NCT02472457|PLACEBO_COMPARATOR|Free Diet|No dietary restrictions
62289647|NCT02472457|ACTIVE_COMPARATOR|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
62289648|NCT02737865|EXPERIMENTAL|SMI and sonazoid (single arm)|Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line
61906579|NCT06313788|NO_INTERVENTION|No Possession Group|Like participants in the possession condition, participants in the no-possession condition will also be first introduced to the function of a branded band-aid using the leaflet advertisement and asked to complete the marketing survey. They will be verbally thanked for their participation to take part in the marketing interview, but they will not be given any first-aid bandage as a souvenir.
61906580|NCT06174142|EXPERIMENTAL|High-Frequency ESWT Group|This arm will receive extracorporeal shockwave therapy (ESWT) with a higher frequency setting of 15 Hz and an intensity/pressure of level 3. Participants will receive a total of 1800 impulses per session for 6 sessions, with one session per week, alongside a selected physical therapy program.
61906581|NCT06174142|EXPERIMENTAL|Low-Frequency ESWT Group|Experimental
61906582|NCT06174142|SHAM_COMPARATOR|Sham ESWT Control Group|Participants in the control group will undergo a sham shockwave therapy protocol, which simulates ESWT treatment without actual therapeutic effects, to serve as a comparison for the active treatments. They will also engage in the same physical therapy program as the other two arms.
62091694|NCT06532552|EXPERIMENTAL|VACl group|Azacitidine 75mg/m2 subcutaneous Daily for 7 days, Venetoclax orally once daily (100 mg d1, 200mg d2, 400mg d3-28) and Cladribine 5mg/m2 intravenous (IV) over approximately 1 to 2 hours, daily on days 1-3. Patients received 2 cycles of VACl treatments, the bone marrow aspirate will be done on the 21-28th day in the each cycle. If the bone marrow assessment is PR/NR at the end of the cycle 2, the patients need to withdraw from the trial. If the bone marrow assessment is CR/CRi/MLFS, the patients will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy or declines, continue with the same regimen until progression or recurrence of the disease, and the patients need to withdraw from the trial. If the patients fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patients need to withdraw from the trial if progression or recurrence of the disease.
62307974|NCT06433427||Non-Frail without Multimorbidity (NFWoM)|Individuals aged 65 years or older without frailty and without multimorbidity. This group will serve as a reference for participants who are not frail and do not have multiple chronic conditions.
62307975|NCT06433427||Frail with Multimorbidity (FWM)|Frail individuals aged 65 years or older who have multimorbidity. This group will include participants who exhibit frailty and have two or more chronic diseases.
62463397|NCT05056077|EXPERIMENTAL|Condition IX (health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
61906583|NCT02923024|NO_INTERVENTION|Usual Care|This arm will be usual care and there will be no intervention.
61906584|NCT02923024|EXPERIMENTAL|Information|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent.
61906585|NCT02923024|EXPERIMENTAL|Information and Financial Incentives|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. Physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians receive a financial incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event.
61906586|NCT01981577||Patients with Parkinson's Disease|
61906587|NCT01981577||Healthy volunteers|
61906588|NCT00608946|EXPERIMENTAL|1|efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear
61906589|NCT00608946|PLACEBO_COMPARATOR|2|placebo
61906590|NCT06134011||Cancer tissues|
61906591|NCT06134011||Normal adjacent tissues|
61906592|NCT05342038|EXPERIMENTAL|Single Arm|T-02
61906593|NCT04440605||cI|clincal TNM stage I
61906594|NCT04440605||cII|clinical TNM stage II
61906595|NCT04440605||cIII|clinical TNM stage III
62091695|NCT06532552|EXPERIMENTAL|VACh group|Azacitidine 75mg/m2 subcutaneous daily for 7 days, Venetoclax orally once daily (100mg d1, 200mg d2, 400mg d3-28) and Chidamide 10mg orally daily for 12 days. Patients received 2 cycles of VACh treatments, the bone marrow aspirate will be done on the 21-28th day in the each cycle. If the bone marrow assessment is PR/NR at the end of the cycle 2, the patients need to withdraw from the trial. If the bone marrow assessment is CR/CRi/MLFS, the patients will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy or declines, continue with the same regimen until progression or recurrence of the disease, and the patients need to withdraw from the trial. If the patients fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patients need to withdraw from the trial if progression or recurrence of the disease.
62091696|NCT06532552|EXPERIMENTAL|VACl Alternating With VACh group|Patients received 1 cycle of VACl and 1 cycle of VACh treatment, the bone marrow aspirate will be done on the 21-28th day in the each cycle. If the bone marrow assessment is PR/NR at the end of the cycle 2, the patients need to withdraw from the trial. If the bone marrow assessment is CR/CRi/MLFS, the patients will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy or declines, continue with the VACl alternating with VACh until progression or recurrence of the disease, and the patients need to withdraw from the trial. If the patients fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patients need to withdraw from the trial if progression or recurrence of the disease.
62091697|NCT05436054|ACTIVE_COMPARATOR|Picoprep|"Picoprep®:~Active substances: An envelope Picoprep® contains 10 mg sodium picosulfate, 3,5 g magnesium oxide, and 12 g citric acid.~Mechanism of action: Sodium picosulfate is a peristaltic agent that increases the peristalsis of the intestine. Magnesium oxide and citric acid are osmotic agents to increase water content in the bowel.~Dosage and administration: consist of 2 envelopes, the first envelope, after dissolving in 150 ml water, should be taken 10-18 hours before the colonoscopy, then at least 250mlX5 clear fluid (not only water) over the next hours before the second dose is taken. The second envelope should be taken 4-6 hours before colonoscopy followed by 250mlX3 clear fluid (not only water) over the next hours before colonoscopy. The total fluid intake is approximately 2.3 L."
62091698|NCT05436054|EXPERIMENTAL|Plenvu|"Plenvu®:~Active substances:~Dose nr. 1~1 envelope contains 1 g potassium chloride, 100 g macrogol 3350, 2 g sodium chloride, and 9 g sodium sulfate.~Dose nr. 2 1 envelope A contains 1,2 g potassium chloride, 40 g macrogol 3350, and 3,2 g sodium chloride.~1 envelope B contains 7,54 g ascorbic acid (Vit. C) and 48,11 g sodium ascorbate.~Mechanism of action: Macrogol 3350 is an osmotic laxative. The added electrolytes are to prevent electrolyte shifting and systemic disturbances.~Dosage and administration: two separate nonidentical 500 ml doses are given. 2-day regime: dose nr.1 envelope is dissolved in 500 ml post water and drunk over 30 minutes. Should be taken at 6 o'clock evening before colonoscopy day. Dose nr.2 envelope A and B are dissolved in 500 ml post water and drunk over 30 minutes. Should be taken at 6 o'clock on the morning of colonoscopy day.~After each dose of the dissolved Plenvu®, the patient should drink at least 500ml clear fluid."
62091699|NCT04918108||inflammatory subphenotype|
62091700|NCT03905382|OTHER|Qualitaitve|Qualitaitve
62091701|NCT03923673|EXPERIMENTAL|Subjects with Heart Failure with Preserved Ejection Fraction|Subjects with Heart Failure with Preserved Ejection Fraction (HFpEF) will receive a minimally invasive treatment called a pericardiotomy.
62091702|NCT02897284|EXPERIMENTAL|Mindfulness 8 weeks|Mindfulness-based intervention with 8 weekly sessions
62091703|NCT02897284|ACTIVE_COMPARATOR|Mindfulness 2 weeks|Mindfulness-based intervention with 2 weekly sessions
62091704|NCT02897284|NO_INTERVENTION|Control|waiting list
62655606|NCT00565461|EXPERIMENTAL|Group 1|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
62091705|NCT03393520|PLACEBO_COMPARATOR|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
62091706|NCT03393520|EXPERIMENTAL|AVP-786; Dose 1|Participants will receive AVP-786 (Dose 1) capsules administered twice a day over a 12-week period.
62091707|NCT03393520|EXPERIMENTAL|AVP-786; Dose 2|Participants will receive AVP-786 (Dose 2) capsules administered twice a day over a 12-week period.
62091708|NCT02927769|EXPERIMENTAL|Nivolumab + brentuximab vedotin|
62091709|NCT02927769|EXPERIMENTAL|brentuximab vedotin + bendamustine|
62091710|NCT00649662|EXPERIMENTAL|1|Ciprofloxacin Extended-Release Tablets 1000 mg
62091711|NCT00649662|ACTIVE_COMPARATOR|2|Cipro® XR Tablets 1000 mg
62091712|NCT05398653|EXPERIMENTAL|MIL62|
62091713|NCT05398653|ACTIVE_COMPARATOR|Ciclosporin|
62091714|NCT06615596|ACTIVE_COMPARATOR|on-OAC|"In the cohort assigned to the on-OAC arm, which entails the continuation of Oral Anticoagulant (OAC) therapy, patients were prescribed Non-Vitamin K Antagonist Oral Anticoagulants (NOACs), specifically dabigatran, rivaroxaban, or apixaban, for a duration of 24 months following randomization. The dosing regimen was as follows: (1) Standard dosage included rivaroxaban at 20mg daily, apixaban at 5mg twice daily, and dabigatran at 150mg twice daily. (2) Reduced dosage was administered in cases where patients were aged over 75 years, had a body weight less than 50kg, or exhibited creatinine clearance below 50ml/min."
62091715|NCT06615596|EXPERIMENTAL|off-OAC|In the off-OAC, involving the discontinuation of OAC therapy, patients had their OAC treatment terminated post-randomization, and no placebo medication was administered as a substitute.
62655607|NCT00565461|EXPERIMENTAL|Group 2|40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
62655608|NCT00565461|EXPERIMENTAL|Group 3|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
61920078|NCT05769127|EXPERIMENTAL|Intervention|All subjects participating in the diabetes prevention program will be offered body composition analysis and liver fat analysis, before, during, and after the lifestyle intervention
61920079|NCT06148389|EXPERIMENTAL|lowest dose group|4 subjects will be randomized to receive lowest dose of STSA-1301 subcutaneous injection or dose-matched placebo (First cohort)
62655609|NCT00565461|EXPERIMENTAL|Group 4|40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
62655610|NCT03746509|EXPERIMENTAL|Low-High Treatment|Participants in the low-high treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
62655611|NCT03746509|EXPERIMENTAL|High-Low Treatment|Participants in the high-low treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency once a week for a duration of 4 weeks (low intensity).
62655612|NCT03746509|ACTIVE_COMPARATOR|Low-High Comparator|Participants in the low-high comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
61920080|NCT06148389|EXPERIMENTAL|low dose group|8 subjects will be randomized to receive low dose of STSA-1301 subcutaneous injection or dose-matched placebo (Second cohort)
61920081|NCT06148389|EXPERIMENTAL|middle dose group|8 subjects will be randomized to receive middle dose of STSA-1301 subcutaneous injection or dose-matched placebo (Third cohort)
61920082|NCT06148389|EXPERIMENTAL|high dose group|8 subjects will be randomized to receive high dose of STSA-1301 subcutaneous injection or dose-matched placebo (Fourth cohort)
62091716|NCT06165107||Ischemic stroke|"We retrospectively gathered information on patients admitted for acute first-ever ischaemic stroke between January 2012 and January 2022. The following individuals were excluded from the study: 1) Those under 18 years of age; and 2) Pregnant women.~The variables gathered included the primary test parameters of patients within 24 hours of admission, encompassing age, gender, smoking and alcohol consumption status, arterial blood pressure, fat-related indicators, comorbidities, and the primary treatments administered within the initial 24 hours."
62091717|NCT03369951|EXPERIMENTAL|Minocin® IV|200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
62091718|NCT01438229|EXPERIMENTAL|renal artery ablation|Catheter-based RF ablation in renal artery
62091719|NCT04117061|NO_INTERVENTION|Control|Patient gets usual diagnostic path: after inconclusive ultrasound is refered to CT scan.
62091720|NCT04117061|ACTIVE_COMPARATOR|Observation|Patient after inconclusive primary evaluation is observed in emergency room for 8-12 hours and after the clinical evaluation, laboratory results and ultrasound examination is repeated.
62091721|NCT01800955|EXPERIMENTAL|resistive capacitive diathermy|in the resistive capacitive diathermy protocol patients are administered the resistive capacitive diathermy treatment for a thirty minutes session, three times per week for a total of ten sessions
62091722|NCT01800955|SHAM_COMPARATOR|sham placebo group|"The sham treatment is administered with the resistive capacitive diathermy device set on on but not active (not supplying energy) with the same type of application, the same frequency and duration of experimental diathermy group"
62091723|NCT05527470|ACTIVE_COMPARATOR|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
62289649|NCT02848937||Bath with citrate|"Each patient will participate in two phases of the study. The first phase has the aim to identify the concentration of calcium in the bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium (4 weeks). Each week, the concentration of calcium in the bath with citrate is increased from 1.5-, to 1.65, to 1.75 mM.~•Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.•All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study"
62307976|NCT06433427||Frail without Multimorbidity (FWoM)|Frail individuals aged 65 years or older without multimorbidity. This group will help assess frailty in the absence of multiple chronic conditions.
62307977|NCT01075425|EXPERIMENTAL|Arm I|Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62307978|NCT05840705|EXPERIMENTAL|Total knee arthroplasty|
61906596|NCT04197310|EXPERIMENTAL|Nivolumab and Cabozantinib|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~* Cabozantinib will be administered at a dose of 40mg orally, once daily~* Nivolumab will be given at a dose of 240mg every 14 days, intravenously~Retreat Phase (Optional)~* Participants may elect to stop nivolumab and cabozantinib with confirmed CR after at least 24 weeks of treatment.~* Participants who elect to stop and then the condition progresses after stopping study treatment may be eligible to resume nivolumab and cabozantinib therapy.~* This resumption will be termed as a retreatment second course phase and is available only while the study remains open and the subject meets specified criteria."
62655613|NCT03746509|ACTIVE_COMPARATOR|High-Low Comparator|Participants in the high-low comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency once a week for a duration of 4 weeks (low intensity).
61906597|NCT05158400|EXPERIMENTAL|Cases|
61906598|NCT05956444|EXPERIMENTAL|Treatment Group|Treated with both the treatment programs determined on the basis of the NDT and conventional physiotherapy. Programs prepared specifically for each child, in a 45-minute single session, 2 days a week, for 8 weeks in total. Each child was given a treatment program tailored to their needs.
61906599|NCT05956444|ACTIVE_COMPARATOR|Control Group|Treated with only the treatment programs determined on the basis of conventional physiotherapy.
61906600|NCT05469698|OTHER|Standard Care|All participants will receive standard care by the Tobacco Treatment Research Program. This includes nicotine replacement therapy such as patches, gum, or lozenges, counseling by a Tobacco Treatment Specialist, and complete questionnaires.
61906601|NCT02966054|EXPERIMENTAL|Intervention|"Patients will be provided with a booklet from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors. The intervention group will be given a Fitbit® Flex to wear throughout the study and will receive daily text messages to support increased physical activity."
62091724|NCT05527470|EXPERIMENTAL|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
62091725|NCT06697236||patient|90 intensive care patients
62289650|NCT02848937||Bath with citrate and Ca_eq|"Each patient will participate in two phases of the study. In the second phase will evaluate the effectiveness of the purification concentrate with 1 mM citrate and Ca_eq compared to the concentrate with 3 mM acetate and 1.5 mM calcium. For each of the sessions will be used the following materials:~* Filter high permeability (Kuf\> 20ml/mmHg);~* Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.~* All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study."
62289651|NCT03409822|OTHER|Placenta previa|
62655614|NCT04140110|EXPERIMENTAL|Intervention group|Achieving SBP level of \<120 mmHg within 1 hour after randomisation, and maintaining this level at least 72 hours.
62289652|NCT01130129|EXPERIMENTAL|Ex-vivo treatment of platelets|Ex-vivo treatment of platelets
62655615|NCT04140110|NO_INTERVENTION|Control group|Maintaining SBP 140-180mmHg, and BP lowering treatment can be given only when BP level ≥150 mmHg in order to achieve the target of ≥140 mmHg, and maintaining this level at least 72 hours.
62655616|NCT05404100||Severe aortic valve stenosis|Patients with severe AS planned to undergo AVR, either as surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).
62091726|NCT06697236||patient's relatives|a maximum of 90 of the patient's relatives
62091727|NCT01539941|EXPERIMENTAL|Medication Integration Protocol|
62091728|NCT03179540|EXPERIMENTAL|non-operative management|Patients with low rectal cancer who have achieved a complete clinical response following chemoradiotherapy will undergo active follow-up with regular clinical visits, physical exam, endoscopy and imaging assessments at regular intervals for 2 years to assess for tumour re-growth or spread to the liver and lungs
62289653|NCT02764541|EXPERIMENTAL|Arm A Tamoxifen followed by Endocrine Therapy|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
62307979|NCT00914342||Upper-GI symptoms in primary-care patients|
62655617|NCT05694650||Focus|Participants will be asked about your previous experiences providing cancer care at MD Anderson and your thoughts on providing hospital care at home
62655618|NCT05694650||Interview|Participants will be asked about your previous experiences providing cancer care at MD Anderson and your thoughts on providing hospital care at home
62091729|NCT00114959|EXPERIMENTAL|Homoharringtonine + Imatinib Mesylate|Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m\^2 by continuous 24-hour intravenous infusion daily on Days 1-5 of each 4 week treatment cycle, and imatinib mesylate (Gleevec) by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML.
62091730|NCT06621329|NO_INTERVENTION|Standard of Care Medications for Headache|Control arm participants will receive standard of care medications, as defined in a headache protocol, to treat subarachnoid associated headache.
62091731|NCT06621329|EXPERIMENTAL|Transnasal SPG Block and Standard of Care Medications|Intervention arm participants will receive standard of care medications, as defined in a headache protocol, with the addition of transnasal SPG blocks when a predefined threshold is met per the study protocol.
62091732|NCT06617962||Study participants with high clinical suspicion of MOGAD|"Based on the Chinese Expert Consensus on the Diagnosis and Treatment of Myelin Oligodendrocyte Glycoprotein Immunoglobulin MOG-IgG Antibody Associated Diseases and the Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria in2023"
62091733|NCT06617962||Control group|including 30 participants in the study of other inflammatory CNS diseases, 30 participants in the study of non-inflammatory CNS and 30 participants in the study of healthy people
62091734|NCT01289184||control|
62091735|NCT01289184||exposure 2-3 years|
62091736|NCT01289184||exposure 3-5 years|
62091737|NCT01289184||exposure 5-10 years|
62091738|NCT01289184||exposure >15 years|
62091739|NCT05326373|ACTIVE_COMPARATOR|Healthy Group|Subjects without gingivitis (\</= 3 bleeding sites) will use stannous fluoride toothpaste
62091740|NCT05326373|ACTIVE_COMPARATOR|Unhealthy Group|Subjects with gingivitis (\>/= bleeding 20 sites) will use stannous fluoride toothpaste
62655619|NCT02632318|EXPERIMENTAL|Light|Dawn simulation for 30 minutes prior to habitual wake time
62655620|NCT02632318|NO_INTERVENTION|No light|Darkness for 30 minutes prior to habitual wake time
62655621|NCT04828499|EXPERIMENTAL|Progressive Cracking Technique|Patients with hard nucleus cataract were treated with Progressive Cracking Technique.
61906602|NCT02966054|NO_INTERVENTION|Control|"Patients in the control arm will be provided with a booklet at baseline from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors."
61906603|NCT02043899|EXPERIMENTAL|Single Arm Trial|This was a single arm trial, all patients were to undergo the same assessments and interventions.
62091741|NCT06270511|EXPERIMENTAL|Part A: Open Label|Participants will receive different formulations of S-337395 without food and with food.
62091742|NCT06270511|EXPERIMENTAL|Part B: Double Blind|Participants will receive S-337395 or placebo.
62091743|NCT06073964|EXPERIMENTAL|TRUST Intervention group|Formerly Internally Displaced Persons living in Lira district, northern Uganda afflicted with primary trauma and experiencing domestic violence will be trained in the community-based utilization of the 'Trauma Resilience \& Understanding Self-help Therapy'.
62091744|NCT06073964|NO_INTERVENTION|Control group|Age and gender cross-matched formerly Internally Displaced Persons living in Lira district, northern Uganda afflicted with primary trauma and experiencing domestic violence will not be trained in the community-based utilization of the 'Trauma Resilience \& Understanding Self-help Therapy'.
62091745|NCT02929290|EXPERIMENTAL|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
62091746|NCT05806099|EXPERIMENTAL|MBS303|
62655622|NCT04828499|EXPERIMENTAL|Conventional Chop Technique|Patients with hard nucleus cataract were treated with Conventional Chop Technique.
62655623|NCT01971177|EXPERIMENTAL|Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
62655624|NCT01971177|ACTIVE_COMPARATOR|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
62655625|NCT00851591|EXPERIMENTAL|Fenugreek category 1|receive fenugreek
62655626|NCT00851591|PLACEBO_COMPARATOR|Placebo Category 2|receive placebo
62091747|NCT01697787|OTHER|Amodiaquine-Artesunate|ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
62091748|NCT01697787|OTHER|Artemether-Lumefantrine|AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
62091749|NCT01484444||gastrointestinal cancer|
62091750|NCT05004480|EXPERIMENTAL|Surgical Mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill while wearing surgical mask
62091751|NCT05004480|EXPERIMENTAL|Non mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill without wearing surgical mask
62091752|NCT06614218||MIMS Surgery Cohort|This cohort consists subjects treated with MIMS® Device as a standalone procedure during time period (27 Sep 2023 - 31 May 2025), and with documented post-operative follow-up available in the medical charts.
62655627|NCT04683575|EXPERIMENTAL|experimental group|Patients with differentiated thyroid carcinoma with low blood selenium are treated with selenium yeast（dosage form：capsule dosage：200μg bid duration: 5 years）.
62655628|NCT04683575|PLACEBO_COMPARATOR|Placebo control group|Patients with differentiated thyroid cancer with low blood selenium are given placebo treatment（dosage form：capsule dosage：200μg bid duration: 5 years）
62091753|NCT06613581|EXPERIMENTAL|Implementation of home-based follow-up|All patients within the PROMISE study are included in the 'experimental' arm. The study is set up as an implementation study, meaning that the home-based method of follow-up is applied to all patients in the study.
62289654|NCT02764541|EXPERIMENTAL|Arm B Letrozole Followed By Endocrine Therapy|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
62289655|NCT02764541|EXPERIMENTAL|Tamoxifen Followed By Endocrine Therapy and Palbociclib|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
62289656|NCT02764541|EXPERIMENTAL|Letrozole Followed By Endocrine Therapy and Palbociclib|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
62289657|NCT00856310|ACTIVE_COMPARATOR|Cohort 1|Dose 1 REGN475
62289658|NCT00856310|ACTIVE_COMPARATOR|Cohort 2|Dose 2 of REGN475
62289659|NCT00856310|ACTIVE_COMPARATOR|Cohort 3|Dose 2 of REGN475
62289660|NCT00856310|ACTIVE_COMPARATOR|Cohort 4|Dose 1 of REGN475
62289661|NCT00856310|ACTIVE_COMPARATOR|Cohort 5|Dose 2 of REGN475
62289662|NCT00856310|ACTIVE_COMPARATOR|Cohort 6|Dose 1 REGN475 subcutaneous administration
62091754|NCT04494321|ACTIVE_COMPARATOR|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
62091755|NCT04494321|EXPERIMENTAL|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
62091756|NCT04494321|ACTIVE_COMPARATOR|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
62091757|NCT06614803|ACTIVE_COMPARATOR|taVNS combined with slow breathing|For taVNS combined with slow breathing group,after preparing the skin with an alcohol pad, electrodes were attached to the tragus and cymba conchae of the left ear,and under the guidance of the device's video, the participants were instructed to perform six slow and relaxed breaths per minute (0.1Hz), while the built-in parameters of the device delivered stimulation during the 5 seconds of exhalation.The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs, and a burst frequency of 2000Hz, 5s ON-5s OFF;stimulation time:20min.
62289663|NCT00856310|ACTIVE_COMPARATOR|Cohort 7|Dose 2 REGN475 subcutaneous administration
62289664|NCT03700957|EXPERIMENTAL|Docosahexaenoic Acid Group|participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days
62289665|NCT03700957|PLACEBO_COMPARATOR|Control Group|participants will recieve placebo
62289666|NCT03936387|EXPERIMENTAL|Bilateral erector spinae blocks|Bilateral erector spinae block catheters are placed at end of the sternotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. Patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH.
61920083|NCT06148389|EXPERIMENTAL|highest dose group|8 subjects will be randomized to receive highest dose of STSA-1301 subcutaneous injection or dose-matched placebo (Fifth cohort)
62091758|NCT06614803|ACTIVE_COMPARATOR|taVNS with normal breathing|For taVNS with normal breathing group,without video guidance on the stimulation device, the participants breathed freely while receiving normal tVNS intervention.Electrodes were attached to the tragus and cymba conchae of the left ear. The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs, 5s ON-5s OFF, and a burst frequency of 2000Hz, ;stimulation time:20min.
62091759|NCT06614803|ACTIVE_COMPARATOR|slow breathing with sham taVNS|For slow breathing with sham taVNS group,the participants followed the video instructions to perform slow breathing while wearing the stimulation electrodes, but the device only outputted stimulation for one minute and then stopped.
62289667|NCT05383924|ACTIVE_COMPARATOR|postplacental IUD (PP-IUD) insertion|patients will have immediate postplacental IUD insertion
62655629|NCT04683575|NO_INTERVENTION|No intervention group|Patients with differentiated thyroid cancer with low blood selenium are not treated.
62655630|NCT01446705||No Exchange|Patients in this arm will represent Veterans seen at the Indianapolis VA Medical Center (VAMC) for whom information exchange has not been activated.
62091760|NCT06614803|SHAM_COMPARATOR|normal breathing with sham taVNS|For normal breathing with sham taVNS group,the device were set to output stimulation for only one minute and then stop, and the participants breathed normally
62091761|NCT03303274|EXPERIMENTAL|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally before subclavian venous catheterization.
62091762|NCT03303274|NO_INTERVENTION|Supine|Catheterization of right subclavian vein in supine position.
62091763|NCT04494373|EXPERIMENTAL|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
62289668|NCT05383924|ACTIVE_COMPARATOR|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit
62289669|NCT02484469|EXPERIMENTAL|Exposed|The Virtual Human Project videos and Team-Based learning session about leprosy
62289670|NCT02484469|PLACEBO_COMPARATOR|Unexposed|Standard Team-Based learning session about leprosy
62289671|NCT03975192|EXPERIMENTAL|Intervention Group|50% of subjects will be randomized to the Intervention group and will receive percutaneous electric nerve field stimulation (PENFS) through the BRIDGE Device for 120 hours to treat withdrawal symptoms in patients following opiate exposure in the PICU.
62289672|NCT03975192|NO_INTERVENTION|Standard of Care Group|50% of subjects will be randomized to the Standard of Care group and will receive be started on the standardized PICU Methadone wean for patients following opiate exposure in the PICU.
62307980|NCT00782080|EXPERIMENTAL|Sedariston|Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.
62307981|NCT00782080|PLACEBO_COMPARATOR|Placebo campsule|Placebo provided by the company given orally in capsules (size 1 )twice daily
62307982|NCT05578521|PLACEBO_COMPARATOR|Cerebralcare pills placebo group|This group will receive Cerebralcare pills placebo, 2 packages, twice a day, from the day of randomization to 6 months.
62307983|NCT05578521|EXPERIMENTAL|Cerebralcare pills group|This group will receive Cerebralcare pills, 2 packages, twice a day, from the day of randomization to 6 months.
62091764|NCT04494373|ACTIVE_COMPARATOR|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
62091765|NCT06685276|EXPERIMENTAL|Study arm|"Fruquintinib Sintilimab Chidamide~Treatments are administered until disease progression or toxicity intolerable."
62289673|NCT03085784|EXPERIMENTAL|Loading Dose|"20 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, \& 12. At week 12, patient will be followed \& treated per treat \& extend protocol.~Treat \& Extend Protocol entails patients being extended as long as:~* Absence of retinal fluid (resolution of intraretinal \& subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable \& can be considered dry.) AND~* \< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
62289674|NCT03085784|EXPERIMENTAL|Treat and Extend|"20 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated \& followed per the treat \& extend protocol.~Treat \& Extend Protocol entails patients being extended as long as:~* Absence of retinal fluid (resolution of intraretinal \& subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable \& can be considered dry.) AND~* \< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
62091766|NCT03563638||GDM group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study,and excluded if they had multiple pregnancy, pre-gestational diabetes mellitus, hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness,and fetal abnormalities occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
62091767|NCT03563638||NGT group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. Women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (PGDM), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. if there were fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.those who not met the criteria were the NCT group.
62289675|NCT01748799|OTHER|Sequence 1|Self-titrated placebo - Self-titrated Sativex - Fixed dose Sativex - Fixed dose placebo
62289676|NCT01748799|OTHER|Sequence 2|Fixed dose placebo - Fixed dose Sativex - Self-titrated Sativex - Self-titrated placebo
62289677|NCT01748799|OTHER|Sequence 3|Fixed dose placebo - Fixed dose Sativex - Self-titrated placebo - Self-titrated Sativex
62289678|NCT01748799|OTHER|Sequence 4|Fixed dose Sativex - Fixed dose placebo - Self-titrated placebo - Self-titrated Sativex
62289679|NCT01748799|OTHER|Sequence 5|Self-titrated Sativex - Self-titrated placebo - Fixed dose Sativex - Fixed dose placebo
62289680|NCT01748799|OTHER|Sequence 6|Self-titrated Sativex - Self-titrated placebo - Fixed dose placebo - Fixed dose Sativex
62289681|NCT01748799|OTHER|Sequence 7|Self-titrated placebo - Self-titrated Sativex - Fixed dose placebo - Fixed dose Sativex
62289682|NCT01748799|OTHER|Sequence 8|Fixed dose Sativex - Fixed dose placebo - Self-titrated Sativex - Self-titrated placebo
61920084|NCT00277641|EXPERIMENTAL|1|lamotrigine
61920085|NCT00277641|PLACEBO_COMPARATOR|2|
62091768|NCT03498261|ACTIVE_COMPARATOR|Gabapentin|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
62289683|NCT02308644|EXPERIMENTAL|Bevacizumab|Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
62289684|NCT02308644|SHAM_COMPARATOR|Sham|Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
62289685|NCT02502864|EXPERIMENTAL|Standard of Care + Surveys|Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
62091769|NCT03498261|PLACEBO_COMPARATOR|Placebo|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
62091770|NCT04680936|ACTIVE_COMPARATOR|low dose dextrose arm (5% dextrose)|Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
62289686|NCT05595538|EXPERIMENTAL|Intubated COVID-19 patients admitted to the ICU.|Participants intubated who consent immediately before intubation to receive more than one dose of COVID-19 convalescent plasma.
62289687|NCT03244358|EXPERIMENTAL|Epalrestat|Epalrestat added to standard treatment
62289688|NCT01956214|EXPERIMENTAL|FES exercise|Participants will receive FES
62289689|NCT01956214|SHAM_COMPARATOR|Mock FES exercise|participant will receive Mock FES
62655631|NCT01446705||Enrolled in Exchange|"Patients in this arm will represent Veterans seen at the Indianapolis VAMC for whom information exchange has been activated by the patient choosing to opt-in."
62655632|NCT03547128||Parents with newborns recruited from 1992-5|Parents of newborns recruited from 8 Iowa hospitals in 1992-5
62091771|NCT04680936|ACTIVE_COMPARATOR|high dose dextrose arm (15% dextrose)|Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
62655633|NCT02120404|NO_INTERVENTION|Control group (GC)|Control group: no esmolol administration
62655634|NCT02120404|EXPERIMENTAL|Group 10 (G10)|Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
62289690|NCT03713190|ACTIVE_COMPARATOR|Empagliflozin|SGLT-2 inhibitor
62289691|NCT03713190|PLACEBO_COMPARATOR|placebo|A substance without specific pharmacology principles.
62655635|NCT02120404|EXPERIMENTAL|Group 20 (G20)|Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
62655636|NCT00439621|EXPERIMENTAL|1|
62655637|NCT00439621|EXPERIMENTAL|2|
62655638|NCT00439621|EXPERIMENTAL|3|
62655639|NCT00439621|PLACEBO_COMPARATOR|4|
62655640|NCT00639509|EXPERIMENTAL|Treatment (monoclonal antibody therapy)|Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
62655641|NCT06462677||Manitoba whole blood donors|All whole blood donors giving blood in Manitoba will be collected for Babesia NAT testing to understand the prevalence of babesiosis in the Canadian province of Manitoba
62655642|NCT02243514||Resistant hypertension|
62655643|NCT02243514||Essential hypertension|
62655644|NCT02243514||Chronic heart failure|
62655645|NCT02243514||Control|
62289692|NCT02159807|ACTIVE_COMPARATOR|1.25 mg Bupivacaine|1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
62289693|NCT02159807|ACTIVE_COMPARATOR|1.66 mg Bupivacaine|1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
62655646|NCT04546763||Paroxysmal Atrial Fibrillation Patients|This will be a single arm study of patients with paroxysmal atrial fibrillation. Subjects will be wearing the Study Watch and Zio XT Patch concurrently for up to 14 days.
62655647|NCT01018979|EXPERIMENTAL|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
62655648|NCT01018979|EXPERIMENTAL|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
62655649|NCT03579667|EXPERIMENTAL|Diet intervention|
62655650|NCT03579667|NO_INTERVENTION|Control|
62655651|NCT06518226|EXPERIMENTAL|Ultrahypofractionated MRgRT in 2 fractions|MRgRT to the prostate in 2 fractions of 12 Gy, with a focal boost of 13.5 Gy to the gross tumor volume (GTV), administered over the course of 8 days.
62289694|NCT02159807|ACTIVE_COMPARATOR|2.5 mg Bupivacaine|2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
62289695|NCT04213404|EXPERIMENTAL|Ribociclib-spartalizumab|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
62655652|NCT06518226|ACTIVE_COMPARATOR|Standard of care: MRgRT in 5 fractions|MRgRT to the prostate in 5 fractions of 7.25 Gy to the prostate without focal boost, administered over the course of 16-18 days.
62655653|NCT01026935|EXPERIMENTAL|sutured mesh|200 patients are randomized to inguinal hernia repair with sutured light weight (38g/m2) polypropylene mesh (Lichtenstein repair)
62655654|NCT01026935|EXPERIMENTAL|non-sutured mesh|200 patients are randomized to receive a light weight mesh that adheres to tissues with polylactic micro hooks without sutures
62655655|NCT02246777|EXPERIMENTAL|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
62655656|NCT06557681|EXPERIMENTAL|Experimental Group|Receives conventional therapy (physical therapy)
61920086|NCT00844168|EXPERIMENTAL|Treatment (adjuvant sorafenib tosylate after liver transplant)|Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62289696|NCT05818670|ACTIVE_COMPARATOR|tamsulosin|patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) treated by tamsulosin with 12 months follow up
62289697|NCT05818670|ACTIVE_COMPARATOR|tadalafil|patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) treated by tadalafil 5 mg with 12 months follow up
62289698|NCT04689230|ACTIVE_COMPARATOR|upper eyelid blepharoplasty|"traditional upper eyelid blepharoplasty : upper eyelid entire length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with subcuticular 6/0 vicryl suture"
62655657|NCT06557681|EXPERIMENTAL|Control Group|Receives conventional therapy (physical therapy)
62655658|NCT01267578|EXPERIMENTAL|peptide vaccination|
62655659|NCT04441125||case group|The mothers in the case group will receive oxytocin induction before and after delivery(n:44).
62655660|NCT04441125||control group|The mothers in the control group will not receive any oxytocin induction before delivery, and will receive oxytocin induction in the end of delivery(n:44)
62655661|NCT02804893|ACTIVE_COMPARATOR|VATS GROUP|VATS lobectomy or segmentectomy
62655662|NCT02804893|ACTIVE_COMPARATOR|RATS GROUP|Robotic lobectomy or segmentectomy
62655663|NCT06033378|EXPERIMENTAL|Cerebral blood flow|Change in cerebral blood flow with increased systemic blood pressure
62655664|NCT03634423|EXPERIMENTAL|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
62091772|NCT04680936|ACTIVE_COMPARATOR|Isotonic saline arm (0.9% NaCl)|Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
62091773|NCT06252623|EXPERIMENTAL|Drug: Exenatide 2 mg [Bydureon]|Participants will receive once-weekly subcutaneous exenatide (2 mg) injections for 6 weeks.
62091774|NCT06252623|PLACEBO_COMPARATOR|Drug: Placebo|Participants will receive once-weekly subcutaneous saline (i.e., placebo) injections for 6 weeks.
62289699|NCT04689230|EXPERIMENTAL|small incision technique|"medial upper eyelid 4 mm length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with interrupted 6/0 vicryl sutures"
62289700|NCT06013774|EXPERIMENTAL|Hybrid imaging during the pre-treatment procedure of radioembolization|Hybrid imaging will be performed on patients undergoing the pre-treatment procedure of radioembolization
62289701|NCT03008187|EXPERIMENTAL|SEL24/MEN1703|"SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.~* Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients.~* Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1."
62289702|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
62289703|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
62289704|NCT02920060|EXPERIMENTAL|Levetiracetam|patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min
62289705|NCT02920060|ACTIVE_COMPARATOR|Sodium valproate|patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min
62289706|NCT03474055|EXPERIMENTAL|LBRV-PV Lot A|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
62289707|NCT03474055|EXPERIMENTAL|LBRV-PV Lot B|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
62289708|NCT03474055|EXPERIMENTAL|LBRV-PV Lot C|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
62289709|NCT03474055|ACTIVE_COMPARATOR|ROTASIIL|The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
62289710|NCT02154399|EXPERIMENTAL|Treatment (EF5)|Patients receive EF5 IV over 1-2.5 hours. Beginning 24-55 hours later, patients undergo tumor hypoxia measurement using a polarographic needle electrode and intraoperative tumor measurement before undergoing surgical biopsy or resection.
62091775|NCT02839083|PLACEBO_COMPARATOR|Thoracic Paravertebral group|Ultrasound guided thoracic paravertebral block
62091776|NCT02839083|ACTIVE_COMPARATOR|Pecs II group|Ultrasound guided Pecs II block
62091777|NCT01819090|ACTIVE_COMPARATOR|No ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an usual (with no ventilation switch control) Elysee 150 ventilator while speaking
62091778|NCT01819090|ACTIVE_COMPARATOR|Ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an Elysee 150 ventilator with a ventilation switch control allowing them to control ventilation while speaking
62091779|NCT04907487||SEP|With Multiple Sclerosis as defined by McDonald's revised clinical or radiological spatial and temporal dissemination criteria
62091780|NCT04907487||NO SEP|For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease
62091781|NCT04399564|ACTIVE_COMPARATOR|temporary hemodialysis catheters|one arm-temporary hemodialysis catheter
62091782|NCT04399564|EXPERIMENTAL|long-term hemodialysis catheters|another arm-long term hemodialysis catheter
62289711|NCT04756414|EXPERIMENTAL|Treatment group|Patients recieve treatment from standard protocol at a gastroenterology unit. No specific adjustments is made for study purposes. Baseline data is collected before treatment and then again after treatment (POST).
62289712|NCT01646359|EXPERIMENTAL|corrected flow time|
62289713|NCT03216382|EXPERIMENTAL|Attention Training Technique|Participants in this arm will listen to the Attention Training Technique. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
62289714|NCT03216382|PLACEBO_COMPARATOR|Control Condition|Participants in this arm will listen to the control condition recording. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
62289715|NCT00940004|ACTIVE_COMPARATOR|cytokine matured DC|vaccination with autologous dendritic cells matured with standard cytokine cocktail and electroporated with mRNA encoding tumor associated antigens
62289716|NCT00940004|EXPERIMENTAL|TLR ligand matured DC|vaccination with autologous TLR-ligand matured dendritic cells electroporated with mRNA encoding tumor associated antigens
62289717|NCT05941104||Frail group|
62289718|NCT05941104||Non-frail group|
62289719|NCT02073487|EXPERIMENTAL|T-DM1 + Lapatinib + Abraxane|T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
62289720|NCT02073487|ACTIVE_COMPARATOR|Trastuzumab + Pertuzumab + Paclitaxel|Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.
62289721|NCT01536301|ACTIVE_COMPARATOR|Morphine|The patients in this arm will have post-operative analgesia including morphine (patient controlled analgesia).
62289722|NCT01536301|EXPERIMENTAL|Oxycodone|The patients in this arm will have post operative analgesia including oxycodone (patient controlled analgesia).
61920087|NCT02300727|ACTIVE_COMPARATOR|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
62091783|NCT03909464||Patients receiving neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving known neurotoxic agents. Common neurotoxic agents include vinca alkaloids (ie. vincristine), taxanes (ie. Taxol), platins (ie. Oxaliplatin) and some other drugs beyond these categories (ie. Bortezomib).~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~* EORTC-QLQ CIPN20 Questionnaire~* Michigan Neuropathy Screening Instrument Questionnaire"
62091784|NCT03909464||Patients receiving non-neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving agents with negligible or doubtful risk of neurotoxicity.~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~* EORTC-QLQ CIPN20 Questionnaire~* Michigan Neuropathy Screening Instrument Questionnaire"
62091785|NCT03656900|EXPERIMENTAL|BA9/BA46|
62091786|NCT03656900|EXPERIMENTAL|BA46/BA9|
62091787|NCT04142125|EXPERIMENTAL|Experimental (riva + ASA)|Rivaroxaban 2.5mg bid + aspirin 81mg qd
62091788|NCT04142125|ACTIVE_COMPARATOR|Control (ASA alone)|Aspirin 81 mg qd
62091789|NCT02836977|EXPERIMENTAL|maintenance therapy|Patients will receive oral tegafur-uracil 400mg/day (100mg/Cap., 2 capsules each time, twice a day), combined with oral folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day), and continue for one year.
62091790|NCT02836977|ACTIVE_COMPARATOR|observation arm|Patients will be observed following adjuvant oxaliplatin-based regimen.
62091791|NCT05037370|EXPERIMENTAL|LASIK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
62289723|NCT01268293|EXPERIMENTAL|1|
62289724|NCT00758784|EXPERIMENTAL|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
61920088|NCT02300727|EXPERIMENTAL|Curcumin|Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
62091792|NCT05037370|EXPERIMENTAL|PRK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
62091793|NCT02612662|EXPERIMENTAL|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
62091794|NCT02612662|EXPERIMENTAL|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
62289725|NCT02066792|EXPERIMENTAL|Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
62289726|NCT02066792|ACTIVE_COMPARATOR|Pre-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
62289727|NCT02066792|PLACEBO_COMPARATOR|Placebo|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
62289728|NCT02066792|ACTIVE_COMPARATOR|Non-Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
62289729|NCT06021249|SHAM_COMPARATOR|Group of Control (Part I experiment)|Traditional ventilation strategies
62289730|NCT06021249|EXPERIMENTAL|Group of traditional lung-protective ventilation (Part I experiment)|Traditional lung-protective ventilation strategies
62289731|NCT06021249|EXPERIMENTAL|Group of innovative lung-protective ventilation (Part I experiment)|Innovative lung-protective ventilation strategies
62289732|NCT06021249|EXPERIMENTAL|Group of traditional & innovative ventilation (Part I experiment)|Traditional \& innovative lung protection ventilation strategies
62289733|NCT06021249|SHAM_COMPARATOR|Group of Control (Part II experiment)|"1. lung-protective ventilation；~2. negative pressure extubation"
62463398|NCT05056077|EXPERIMENTAL|Condition V (text, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
62463399|NCT05056077|EXPERIMENTAL|Condition VI (text, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
62463400|NCT05056077|EXPERIMENTAL|Condition VII (text, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
62655665|NCT03634423|EXPERIMENTAL|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
62091795|NCT02612662|EXPERIMENTAL|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
62463401|NCT05056077|EXPERIMENTAL|Condition VIII (text)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks.
62463402|NCT05056077|EXPERIMENTAL|Condition X (health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
62463403|NCT05056077|EXPERIMENTAL|Condition XI (health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
62655666|NCT03634423|EXPERIMENTAL|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
61920089|NCT02300727|OTHER|Curcumin-MTD|"Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)"
62091796|NCT02612662|EXPERIMENTAL|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
62091797|NCT02612662|EXPERIMENTAL|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
62463404|NCT05056077|EXPERIMENTAL|Condition XII (health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks.
62463405|NCT05056077|EXPERIMENTAL|Condition XIII (health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
62463406|NCT05056077|EXPERIMENTAL|Condition XIV (health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
62463407|NCT05056077|EXPERIMENTAL|Condition XV (support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
62463408|NCT05056077|EXPERIMENTAL|Condition XVI (study booklet)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer.
62655667|NCT03634423|EXPERIMENTAL|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
62655668|NCT03634423|EXPERIMENTAL|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
62091798|NCT02612662|EXPERIMENTAL|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
62655669|NCT03634423|EXPERIMENTAL|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
61920090|NCT00876603||1|
61920091|NCT00876603||2|
61920092|NCT00876603||CSM - ACDF|Cervical spondylotic myelopathy treated with anterior cervical decompression and fusion
62289734|NCT06021249|EXPERIMENTAL|Group of positive pressure extubation (Part II experiment)|"1. lung-protective ventilation；~2. positive pressure extubation"
62091799|NCT05456685|EXPERIMENTAL|MIRV + Carboplatin|On Day 1 of every 3-week cycle (Q3W) for 6 cycles, MIRV will be given at the dosage of 6 mg/kg of AIBW along with carboplatin given at area under the AUC5 administered through intravenous (IV) infusion (maximum dosing per National Comprehensive Cancer Network \[NCCN\] guidelines \[NCCN 2021\]). Upon completion of carboplatin plus MIRV treatment, single-agent MIRV will be continued at the tolerated dose on Day 1 Q3W in participants with investigator determined stable disease (SD), complete response (CR) or partial response (PR).
62091800|NCT06615544|EXPERIMENTAL|New dual-cure adhesive|The newly developed dual-cure adhesive will be used for the placement of indirect restorations.
62091801|NCT05675774|EXPERIMENTAL|Dual Energy CT|Patients with acute stroke who receive intervention in the form of thrombolysis or EVT will receive dual-energy CT at the 24-hour mark in lieu of conventional single-energy CT.
62091802|NCT03092544|ACTIVE_COMPARATOR|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
62091803|NCT03092544|ACTIVE_COMPARATOR|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
62091804|NCT03092544|NO_INTERVENTION|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
62091805|NCT03092544|NO_INTERVENTION|Normal Control 1|10 normal controls (younger cohort, mean age 38)
62091806|NCT03092544|NO_INTERVENTION|Normal Control 2|10 normal controls (younger cohort, mean age 58)
62091807|NCT04237454|EXPERIMENTAL|Infrared Imaging undertaken|
62091808|NCT02217995|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in ten 2.5 hour group sessions with 15 participants per group.
62289735|NCT06021249|EXPERIMENTAL|Group of breathing training (Part II experiment)|"1. lung-protective ventilation；~2. negative pressure extubation；~3. postoperative breathing training"
62289736|NCT06021249|EXPERIMENTAL|Group of positive pressure extubation & breathing training (Part II experiment)|"1. lung-protective ventilation；~2. positive pressure extubation；~3. postoperative breathing training"
62289737|NCT03457961||Adjunctive Perampanel|A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
62289738|NCT05619965|ACTIVE_COMPARATOR|Awake Glidoscope Videolaryngoscope|Awake endotracheal intubation of cervical trauma patients by Glidoscope Videolaryngoscope
62463409|NCT01735409|EXPERIMENTAL|1-day regimen|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
62463410|NCT01735409|EXPERIMENTAL|2-day regimen|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
62655670|NCT03634423|EXPERIMENTAL|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
61920093|NCT00876603||CSM - Cervical laminoplasty|Cervical spondylotic myelopathy treated with cervical laminoplasty
62091809|NCT02217995|NO_INTERVENTION|Waitlist|Wait list as per usual.
61920094|NCT01856283|EXPERIMENTAL|Nilotinib|study of nilotinib 300 mg BID
61920095|NCT01631955||Cystitis|female with cystitis symptoms
61920096|NCT06345664|OTHER|Diagnostic assessments and intervention|All families get a diagnostics and intervention recommendations.
62091810|NCT01882894|EXPERIMENTAL|Custom PFO orthosis|This is a custom made orthosis
62091811|NCT01882894|PLACEBO_COMPARATOR|Faux foot orthosis|Foam insert without arch support
62091812|NCT05096390|EXPERIMENTAL|axitinib + pembrolizumab|"Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.~Pembrolizumab will be administrated intravenously (IV) over 30 minutes at the dose of 200 mg every 3 weeks according to recent summary of product characteristics (SPC) together with axitinib."
62091813|NCT05096390|ACTIVE_COMPARATOR|axitinib alone (control)|Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.
61920097|NCT00459979|EXPERIMENTAL|Sunitinib|
62091814|NCT00409240|EXPERIMENTAL|MEDIC Intervention|Receives pharmacist-led behavioral and pharmacologic group intervention for cardiac risk reduction
62091815|NCT00409240|NO_INTERVENTION|Usual Care|Patient continued on usual care
62091816|NCT03635788|EXPERIMENTAL|Arm A: LA ART|In Step 1, participants will receive SOC oral ART regimen for up to 24 weeks. In Step 2, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks (optional), followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by an RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 3, participants will receive a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks until the end of Step 2. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
62289739|NCT05619965|ACTIVE_COMPARATOR|Awake Fiberoptic bronchoscope|Awake endotracheal intubation of cervical trauma patients by Fiberoptic bronchoscope
62289740|NCT03787914|EXPERIMENTAL|Intervention arm|Intervention arm patients were served by outreach mobile teams for oral anti-TB treatment under DOTS at the place of their convenience by health care professionals
62289741|NCT03787914|ACTIVE_COMPARATOR|Control arm|Control arm patients were given the traditional facility based DOTS treatment. Control arm was not served by the outreach mobile teams.
62463411|NCT01735409|EXPERIMENTAL|3-day regimen|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
62463412|NCT00055315|ACTIVE_COMPARATOR|STEPPS|Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes
62091817|NCT03635788|ACTIVE_COMPARATOR|Arm B: SOC Oral ART|In Step 1, participants will receive SOC oral ART regimen for up to 24 weeks. In Step 2, participants will continue SOC oral ART regimen for 52 weeks. In Step 3, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks (optional), followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by an RPV-LA maintenance dose and CAB-LA maintenance dose every 4 weeks until the end of Step 3. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
62091818|NCT06548412|EXPERIMENTAL|Safety Lead-in: CTX-009+ Durvalumab+Gemcitabine+cisplatin|Participants will be administered treatment on an outpatient basis
62091819|NCT06548412|EXPERIMENTAL|Expansion: CTX-009+ Durvalumab+Gemcitabine+cisplatin|Participants will be administered treatment on an outpatient basis
62091820|NCT06696573|EXPERIMENTAL|Prophylactic NSAID Group for Pain Management in Medical Abortion|Participants in this group will receive a prophylactic administration of a non-steroidal anti-inflammatory drug (NSAID) to manage pain before its onset during the medical abortion process for pregnancies between 13 and 22 weeks. The intervention will involve the use of a generic NSAID (e.g., Ibuprofen), administered in oral tablet form at a specified dosage, such as 400 mg. The medication will be taken prior to the expected onset of uterine contractions and will be monitored for efficacy and safety throughout the duration of the procedure. The administration may be repeated based on the clinical protocol, with an appropriate frequency adjusted according to the needs and response of the participant. The aim is to evaluate pain reduction, overall satisfaction, and any potential side effects or adverse events associated with this prophylactic approach.
62091821|NCT06696573|EXPERIMENTAL|On-Demand NSAID Group for Pain Management in Medical Abortion|Participants in this group will receive non-steroidal anti-inflammatory drugs (NSAIDs) on an as-needed basis during the medical abortion process for pregnancies between 13 and 22 weeks. The administration will occur once participants report experiencing pain, with the goal of managing pain symptoms as they arise. The intervention involves a specified dosage of a generic NSAID (e.g., Ibuprofen) in oral tablet form, typically 400 mg, administered as required to control pain. The effectiveness of on-demand NSAID administration will be evaluated in terms of pain relief, safety, and participant satisfaction throughout the procedure.
62091822|NCT06668480|EXPERIMENTAL|SNAGS + Conventional PT Group|"Participants of this group receive conventional physical therapy.Hot pack and tens ( 10 min each)~* Sustained natural apophyseal glides to painful or restricted movement~* 4 sets of 4 repetition per session~* Strengthening of deep neck flexor"
62091823|NCT06668480|EXPERIMENTAL|SNAGS+Strengthening of lower fibers trapezius+Conventional PT Group|"* Participants of this group receive conventional physical therapy. It will comprise of hot pack for 10 minutes, TENs at 80-100 Hz over trapezius for 10 minutes.~* Sustained natural apophyseal glides to painful or restricted movement.4 sets of 3-5 repetition per session.~* Strengthening of deep neck flexors~* Then strengthening exercises of lower fibers of trapezius"
62091824|NCT05656313|EXPERIMENTAL|Narrow reference beamformer|
62289742|NCT03884465|EXPERIMENTAL|Inhaled dry powder treprostinil (LIQ861)|Full study population receives inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg or 100μg capsule strengths.
62289743|NCT02803957|EXPERIMENTAL|Treatment Group|Subjects with degenerative mitral valve insufficiency treated with artificial chordae implanted using the NeoChord DS1000
62289744|NCT02803957|ACTIVE_COMPARATOR|Control Group|Subjects with degenerative mitral valve insufficiency treated with standard surgical mitral valve repair
62307984|NCT05942690|EXPERIMENTAL|experimental|"The intervention evaluated is a technique of prolonged abdominal manual pressure centered on the zone of restriction of mobility called trigger point with diaphragmatic aim."
61920098|NCT03007108|EXPERIMENTAL|healthy infants|
61920099|NCT01251146|EXPERIMENTAL|Bisoprolol|
61920100|NCT01251146|ACTIVE_COMPARATOR|Atenolol|
61920101|NCT05783882|EXPERIMENTAL|Arm 1|
61920102|NCT05489588|EXPERIMENTAL|GORE® VIAFORT Vascular Stent|GORE® VIAFORT Vascular Stent
62091825|NCT05656313|ACTIVE_COMPARATOR|Novel beamformer approach|
62091826|NCT05229510|EXPERIMENTAL|50 mg/mL Virazole (10 ml total volume)|50 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
62091827|NCT05229510|EXPERIMENTAL|50 mg/mL Virazole (20 ml total volume)|50 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
62655671|NCT03634423|EXPERIMENTAL|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
62289745|NCT03666351|EXPERIMENTAL|The intensive care group|"The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -\> Losartan and Amlodipine 5/50 mg -\> Losartan and Amlodipine 5/100 mg -\> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
62289746|NCT03666351|EXPERIMENTAL|The usual care group|"The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -\> Losartan and Amlodipine 5/50 mg -\> Losartan and Amlodipine 5/100 mg -\> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
62289747|NCT06427551||15 ml local anesthetic|in this group of patients the peng block was performed with 15 ml of ropivacaine, whose dose was obtained on the weight
62289748|NCT06427551||20 ml local anesthetic|in this group of patients the peng block was performed with 20 ml of ropivacaine, whose dose was obtained on the weight
62289749|NCT06427551||30 ml local anesthetic|in this group of patients the peng block was performed with 30 ml of ropivacaine, whose dose was obtained on the weight
62289750|NCT00918944|OTHER|Control arm|Practices with the EHR implemented will be randomized have the asthma disease management tools available passively (the control group).
62289751|NCT00918944|OTHER|Intervention arm|The intervention sites will have decision support alerts and reminders activated to guide providers toward these tools in the appropriate situations.
62463413|NCT00055315|PLACEBO_COMPARATOR|Treatment as Usual|"Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes.~TAU for this BPD population includes medical management, group and individual therapy."
62463414|NCT00819741|EXPERIMENTAL|Repaglinide + metformin|Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
62463415|NCT00819741|ACTIVE_COMPARATOR|Repaglinide|Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.
62463416|NCT01237522|ACTIVE_COMPARATOR|Homozygote for the A270S wildetype|
62463417|NCT01237522|ACTIVE_COMPARATOR|Homo- or heterozygote for A270S minor alleles|
62463418|NCT00384852|EXPERIMENTAL|A|1.0 mg/mL rhBMP-2/CPM + SOC
62463419|NCT00384852|EXPERIMENTAL|B|2.0 mg/mL rhBMP-2/CPM + SOC
62463420|NCT00384852|ACTIVE_COMPARATOR|C|Buffer/CPM + SOC
62463421|NCT00384852|OTHER|D|Standard of Care Alone (SOC)
62463422|NCT03706989|EXPERIMENTAL|EEG for cardiac surgery patients|Patients who undergo elective cardiac surgery with cardiopulmonary bypass, from 18 to \>75 years old.
62463423|NCT00488865|OTHER|Intravascular Filter Device|
62655672|NCT03634423|EXPERIMENTAL|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
62655673|NCT03634423|EXPERIMENTAL|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
62655674|NCT03634423|EXPERIMENTAL|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
62655675|NCT03634423|EXPERIMENTAL|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
62655676|NCT06277375|EXPERIMENTAL|Slow stroke back massage|The application to the experimental group will be done 3 days a week for 10 minutes for a total of 30 minutes.
62655677|NCT06277375|NO_INTERVENTION|Control Group|No intervation. Routine care.
62091828|NCT05229510|EXPERIMENTAL|100 mg/mL Virazole (10 ml total volume)|100 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
62091829|NCT05229510|EXPERIMENTAL|100 mg/mL Virazole (20 ml total volume)|100 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
62091830|NCT05229510|PLACEBO_COMPARATOR|Placebo|Placebo aerosolized and administered until solution depleted
62091831|NCT06697262|EXPERIMENTAL|remote temperature monitoring device|
62655678|NCT00968162|EXPERIMENTAL|Dose de-escalation|
62655679|NCT03860155|EXPERIMENTAL|allo-APZ2-ACLF|Application of IMP into peripheral vein (arm) by use of a perfusor.
62655680|NCT04508816|EXPERIMENTAL|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or GP regimen (Gemcitabine 1.0g/m2, D1, 8 + DDP 25mg/m2 , D1-3, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
62655681|NCT05392400|ACTIVE_COMPARATOR|Control|"Currently, the standard of care for Cesarean section patients includes covering the closed incision with a sterile bandage to reduce the chance of infection, and approximately 48 hours of post-op hospitalization and wound surveillance. The control group will receive post-operative wound dressings consistent with the current standard of care."
62655682|NCT05392400|EXPERIMENTAL|Experimental|Patients randomized to the Experimental group will receive treatment with Steri3x immediately following closure of the Cesarean section incision. Participants in the experimental group will receive approximately 48 hours of post-op hospitalization and wound surveillance.
62655683|NCT05293795|ACTIVE_COMPARATOR|3d printed model|Mother r is given 3D printed model of fetus' face
62655684|NCT05293795|PLACEBO_COMPARATOR|Placebo|Mother is given printed picture of 3D ultrasound of fetus
62655685|NCT05293795|NO_INTERVENTION|Control|Standard of Care
62655686|NCT06514131|EXPERIMENTAL|Experimental group|Participants enrolled in the experimental arm will receive a perineal hygiene with pre-moistened wipes without water.
62655687|NCT06514131|NO_INTERVENTION|Control group|Participants enrolled in the no intervention arm will receive perineal hygiene with soapy disposable knobs and water.
62655688|NCT03335527|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h during mechanical ventilation, for a maximum of 3 days
62655689|NCT03335527|PLACEBO_COMPARATOR|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 3 days
62091832|NCT06697262|ACTIVE_COMPARATOR|home temperature monitoring by a nurse|
62655690|NCT02101151|EXPERIMENTAL|Vitamin D3 group|supplemented with 6000IU cholecalciferol/day for 3 months, followed by 3000 IU cholecalciferol/day for next 3 months
62655691|NCT02101151|PLACEBO_COMPARATOR|Placebo group|Placebo (starch) capsules identical to vitamin D capsules in appearance
62655692|NCT05304325||Obese with type 2 diabetes|
62655693|NCT05304325||Obese insulin-sensitive|
62655694|NCT05304325||Obese insulin-resistant|
62091833|NCT01559090|EXPERIMENTAL|1|MEDI-546 100 mg IV
62091834|NCT01559090|EXPERIMENTAL|2|MEDI-546 300 mg IV
62091835|NCT01559090|EXPERIMENTAL|3|MEDI-546 1000 mg IV
62655695|NCT02707497|EXPERIMENTAL|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
62655696|NCT02707497|PLACEBO_COMPARATOR|placebo|The control group will not use any platelet-increased drugs.
62289752|NCT05015309|EXPERIMENTAL|SH3765 tablet|Daily oral administration of SH3765 tablet
62289753|NCT05282732||aHD: Acute haemodialysis patients|
62289754|NCT05282732||cHD: Chronic haemodialysis patients|
62289755|NCT06277973|EXPERIMENTAL|Immediate Stabilization Procedure|"Participants in this arm will answer questionnaires and go through the intervention according to this schedule:~Day 1 - questionnaires (T1) Day 4 - intervention Day 7 - questionnaires (T2) Day 97 - follow up questionnaires (T3)"
62289756|NCT06277973|OTHER|Waiting list|"Participants in this arm will answer questionnaires and do the intervention according to this schedule:~Day 1 - questionnaires (T0) Day 7 - questionnaires (T1) Day 11- intervention Day 14- questionnaires (T2) Day 104- follow up questionnaires (T3) Thus, unlike in the experimental arm, the intervention will be delayed by a week and participants will fill out questionnaires one additional time, a week before they begin the same protocol as the experimental arm."
62655697|NCT03595397|ACTIVE_COMPARATOR|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
62655698|NCT03595397|ACTIVE_COMPARATOR|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
62289757|NCT00285532||Home test kit|
62655699|NCT03595397|ACTIVE_COMPARATOR|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
62655700|NCT05429996||Individuals with hypermobile EDS|Skin biopsy collection
62655701|NCT05429996||Individuals with classical EDS|Skin biopsy collection
62655702|NCT01314729|ACTIVE_COMPARATOR|Fiber-reinforced-composite retainer|
62655703|NCT01314729|ACTIVE_COMPARATOR|composite-wire retainer|
62289758|NCT05332119|EXPERIMENTAL|Virtual reality|The intervention will consist of the use of VR glasses during the removal of chest drains. The VR content has been developed by VR Pharma Immersive Technologies (LtD). Its main objective is to improve patient experience and have better management of pain and anxiety. Chest drains are removed following the usual protocol.
62289759|NCT05332119|SHAM_COMPARATOR|Control group|Patients in the control group will be cared for with the usual care protocol.
62289760|NCT06280547||School children aged 6-15 years old|"School children aged (6 to15) years old. Children with or without previous dental experience. Children who agree to participate in the study along with a parent/guardian consent.~Children without any mental or physical disabilities."
62289761|NCT00189462|ACTIVE_COMPARATOR|Montelukast|Treatment with montelukast for 4 months (4 mg per day)
62655704|NCT03749161|EXPERIMENTAL|Lentis comfort|Patient will receive the low-add multifocal IOL during cataract surgery
62655705|NCT03749161|EXPERIMENTAL|Lentis L-313|Patient will receive the monofocal IOL Lentis L-313 during cataract surgery
62655706|NCT02054156|ACTIVE_COMPARATOR|azithromycin and TIS|azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
62655707|NCT02054156|PLACEBO_COMPARATOR|placebo and TIS|placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
62655708|NCT02025075|EXPERIMENTAL|Deep Neuromuscular Block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
62655709|NCT02025075|ACTIVE_COMPARATOR|Moderate Neuromuscular block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
62655710|NCT00557466|EXPERIMENTAL|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62289762|NCT00189462|PLACEBO_COMPARATOR|Placebo|Treatment with placebo for 4 months
62289763|NCT00686556|EXPERIMENTAL|Cohort -1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 12 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
62289764|NCT00686556|EXPERIMENTAL|Cohort 1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 15 Gy on Days -5 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
62289765|NCT00686556|EXPERIMENTAL|Cohort 2|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 18 Gy on Days -6 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
62289766|NCT00686556|EXPERIMENTAL|Cohort 3|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 21 Gy on Days -7 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
62289767|NCT00686556|EXPERIMENTAL|Cohort 4|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 24 Gy on Days -8 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
62289768|NCT03088969||patient with a chronic back pain|
62307985|NCT00813839|EXPERIMENTAL|1 SmartCare|automated ventilator controlled adjustment of pressure support
62091836|NCT05716165|EXPERIMENTAL|self-comparison|"Volunteers will be asked to wear a knee brace on each limb during one of the training sessions. At the end of this training session, a questionnaire will be given to the volunteer to evaluate knee stability, range of motion, confidence when walking, and fear of falling.~The volunteers will then have to participate in 2 test sessions: one with and one without knee braces.~The patient will perform tests (Unipodal balance on flat ground, 30s chair stand test, 2,5m up and go test, 6 min-walk) with and without the proprioceptive knee brace in a randomized order.~At the end of the tests with and without knee brace, a questionnaire will be given to the volunteer to evaluate the stability of the knee, the range of motion, the confidence when walking, the fear of falling, as well as a satisfaction questionnaire about the device.~There is also a satisfaction questionnaire regarding the proprioceptive knee brace to be completed at the end of the study."
62091837|NCT01982344|EXPERIMENTAL|mini-exchange-room (G2)|the other group will utilize disposable mini-exchange-room group
62289769|NCT03291561|EXPERIMENTAL|Electroacupuncture group|Electroacupuncture Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
62289770|NCT03291561|PLACEBO_COMPARATOR|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu, sanli and bilateral Tian shu.
62289771|NCT01919892|EXPERIMENTAL|Lithium 450-900mg/day|An Open-Label, 6-week Pilot Study of Flexible Dose of Lithium in Bipolar Depression: The Effectiveness of Lower Lithium Levels
62289772|NCT05690659|EXPERIMENTAL|cavitation ultrasonic lipolysis|on abdomen 2 sesions / week for 10 sessions , Treatment head was griped perpendicular to abdomen, and make slow circular motion with marked pressure.2 sesions / week for 10 sessions
62463424|NCT00814463|ACTIVE_COMPARATOR|Post-operative SRS|All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
62463425|NCT01085045|EXPERIMENTAL|Inhaled PT003 (Dose 1)|PT003 MDI Dose 1
62655711|NCT00557466|EXPERIMENTAL|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62655712|NCT00557466|EXPERIMENTAL|Indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62091838|NCT01982344|NO_INTERVENTION|usual care (G1)|The one group perform traditional PD procedure (G1)
62091839|NCT02392455||A|
62091840|NCT02403674|EXPERIMENTAL|Doravirine, Tenofovir, Lamivudine|Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
62091841|NCT02403674|ACTIVE_COMPARATOR|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
62289773|NCT05690659|EXPERIMENTAL|RUSI guided core muscle exercise|"2 sesions / week for 10 sessions For diaphragm muscle the transducer was placed on the sub costal region to visualize diaphragm muscle on the screen aiming to use US as a visual feedback procedure. instructed to have 5 seconds to contract the diaphragm muscle by deep breathing and hold the contraction. At the end of the 5-second period, the image was saved on the screen, and the measurement of the resultant increase in thickness was performed. Each subject performed a total of 10 contractions (intervention session) For transverse abdominis exercise,. draw in your umbilicus toward the spine without moving back or pelvis, while comfortably breathing in and out, for 10 seconds hold and then 15 seconds rest in between, it was repeated 3 sets of ten while keeping the transducer perpendicular to the surface of the skin in a transverse plane halfway between the ASIS and the lower ribcage along the anterior axillary line"
62289774|NCT05690659|EXPERIMENTAL|combination of cavitation and RUSI|combination of cavitation and RUSI 2 sesions / week for 10 sessions
62289775|NCT03972631|PLACEBO_COMPARATOR|Lifestyle education|The participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
62289776|NCT03972631|EXPERIMENTAL|Intensive Lifestyle Intervention|The participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
62289777|NCT05850936|EXPERIMENTAL|Intervention arm|medical reduction of IOP by eyedrops
62463426|NCT01085045|EXPERIMENTAL|Inhaled PT003 (Dose 2)|PT003 MDI Dose 2
62463427|NCT01085045|EXPERIMENTAL|Inhaled PT005 (Dose 1)|PT005 MDI Dose 1
62463428|NCT01085045|EXPERIMENTAL|Inhaled PT005 (Dose 2)|PT005 MDI Dose 2
62463429|NCT01085045|PLACEBO_COMPARATOR|Inhaled Placebo|Placebo MDI
62463430|NCT01085045|ACTIVE_COMPARATOR|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Tiotropium Bromide inhalation powder
62463431|NCT01085045|ACTIVE_COMPARATOR|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
62463432|NCT01085045|EXPERIMENTAL|Inhaled PT001 (Dose 1)|PT001 MDI Dose 1
62463433|NCT03079128|EXPERIMENTAL|Intervention|Weight Watchers Intervention
62463434|NCT05625022|EXPERIMENTAL|Lianhua Qingke plus conventional therapy|
62463435|NCT05625022|NO_INTERVENTION|Conventional therapy|
62463436|NCT00986297|OTHER|arm one|IGRT
62463437|NCT02853682||presence of a vascular dysfunction|plasma
62463438|NCT02853682||absence of vascular dysfunction|plasma
62091842|NCT05765032|EXPERIMENTAL|SHR-A1921|A1：SHR-A1921+Adebrelimab A2：SHR-A1921+Carboplatin A3：SHR-A1921+Cisplatin A4：SHR-A1921+Bevacizumab A5：SHR-A1921+Adebrelimab+Carboplatin A6：SHR-A1921+Adebrelimab+Cisplatin B1：SHR-A1921+Adebrelimab B2：SHR-A1921+Adebrelimab+Carboplatin/Cisplatin
62091843|NCT05619887|PLACEBO_COMPARATOR|Sea level control|Sea level exercise will be completed after the administration of 1 mL of isotonic saline into the intrathecal (spinal) space between L3-L4.
62091844|NCT05619887|EXPERIMENTAL|Sea level experimental (muscle reflex suppression)|Sea level exercise will be completed after the administration of 0.25 mL of fentanyl into the intrathecal (spinal) space between L3-L4.
62091845|NCT05619887|PLACEBO_COMPARATOR|High altitude control|High altitude exercise will be completed after the administration of 1 mL of isotonic saline into the intrathecal (spinal) space between L3-L4.
62655713|NCT00557466|EXPERIMENTAL|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62655714|NCT00557466|ACTIVE_COMPARATOR|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62655715|NCT00557466|PLACEBO_COMPARATOR|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
62091846|NCT05619887|EXPERIMENTAL|High altitude experimental (muscle reflex suppression)|High altitude exercise will be completed after the administration of 0.25 mL of fentanyl into the intrathecal (spinal) space between L3-L4.
62091847|NCT00165152|ACTIVE_COMPARATOR|Genetic Counseling|
62091848|NCT00165152|ACTIVE_COMPARATOR|Informed Consent Counseling|
62091849|NCT06023550||Complicated sinonasal infection|Group of patients with a complicated sinonasal infection, including local or systemic complications.
62091850|NCT06023550||Complicated ear or temporal bone infection|Group of patients with a complicated ear or temporal bone infection, including local or systemic complications.
62091851|NCT06023550||Complicated neck soft tissue infection|Group of patients with a complicated neck soft tissue infection, including local or systemic complications.
62091852|NCT06023550||Complicated laryngeal infection|Group of patients with a complicated laryngeal infection, including local or systemic complications.
62091853|NCT01573143|PLACEBO_COMPARATOR|Sugar pill|Placebo
62091854|NCT01573143|EXPERIMENTAL|Rosuvastatin|Rosuvastatin (20 mg od)
62091855|NCT02016872|EXPERIMENTAL|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
62091856|NCT06698081|NO_INTERVENTION|Standard Informed Consent Form + Verbal Information|The first group will be informed of the Standard Informed Consent Form and Verbal Information during the preoperative process.
62091857|NCT06698081|ACTIVE_COMPARATOR|Standard Informed Consent Form + Verbal Information + Multimedia|The second group will be informed of the Standard Informed Consent Form, Verbal Information, and Multimedia.
62091858|NCT00104611|ACTIVE_COMPARATOR|TMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks
61906604|NCT02663934|EXPERIMENTAL|Exercise (EXS)|All EXS sessions will be at an exercise facility at the WUSTL medical campus. Sessions will be offered weekdays. Each session will start with range of motion exercises. Participants will follow an individualized exercise training prescription based on baseline cardiovascular testing. Individual aerobic exercise intensity is based on % of maximum heart rate achieved during the baseline cardiorespiratory fitness test. The target exercise HR will start at 50% and progress to 85% HR reserve. During aerobic exercise, a battery-operated HR monitor will monitor HR. Exercise intensity \& duration will be increased as the participant acclimates to the exercise prescription. Adaptation is determined when a given exercise intensity yields a lower HR than prior sessions conducted at the same intensity.
62091859|NCT00104611|PLACEBO_COMPARATOR|Placebo|Treatment 5 days/week for up to 6 weeks
62091860|NCT05252988|EXPERIMENTAL|Arm A|"1. Neratinib 240 mg (six 40mg tablets) orally once daily for 13 cycles (C) (1 C = 28 days), unless patient discontinues earlier.~2. Mandatory loperamide 4 mg (2 tablets/capsules) orally, 3 times a day (total 12 mg a day) starting Day (D) 1 of neratinib and for the first 14 days. Then, 4 mg (2 tablets/capsules) orally, 2 times a day (total 8 mg a day) until the end of C2 (D56); thereafter, loperamide will be administered PRN (without exceeding 16 mg per day)."
62091861|NCT05252988|EXPERIMENTAL|Arm B|"1. Neratinib 120 mg for Week 1 (C1D1 - C1D7), followed by 160 mg neratinib for Week 2 (C1D8 - C1D14), followed by 240 mg neratinib for Week 3 and thereafter for 13 cycles inclusive, until cycle 13 day 28 (unless patient discontinues earlier).~2. Loperamide to be administered PRN only (without exceeding 16 mg per day)."
62289778|NCT05850936|NO_INTERVENTION|control arm|follow up without medication
62289779|NCT06368726|ACTIVE_COMPARATOR|Traditional ASD approach|The childs receive their tradicional interventions, Risperidone according to child's weight, diet, educational or speech therapies, pictographs.
62289780|NCT06368726|EXPERIMENTAL|This group of childs will receive tDCS sessions|This children receive 100 sessions during 12 monts in 4 groups of 25 sessions 2 per week of 30 minutes with a separation between them of at least 72 hours
62289781|NCT05019937|EXPERIMENTAL|Multifaceted implementation strategy|Schools randomized to this arm will be exposed to a multifaceted implementation strategy, which contains five implementation components
62655716|NCT02585765|EXPERIMENTAL|Pioglitazone|Subjects will receive 8 weeks of daily pioglitazone (30mg/day).
62655717|NCT02585765|PLACEBO_COMPARATOR|Placebo|Subjects will receive 8 weeks of daily placebo capsules.
62463439|NCT03171155|EXPERIMENTAL|XPro System|Implantation of XPro System during percutaneous vascular closure
62463440|NCT00724230||Arm 1|Overall study population.
61920103|NCT03891160|EXPERIMENTAL|Group A - 3D models|Group A will receive 3-D printed models will be used for pre-VAD planning. For patients in Group A, the surgeon will complete a questionnaire 1) after reviewing 2D imaging data and 2) after reviewing a patient specific 3D model. The investigators primary outcome measure will be an improvement in the clarity of cannula and VAD site demonstration. The investigators hypothesize that the 3D models will more clearly demonstrate the sites of cannula and VAD placement as compared to 2D imaging.
62091862|NCT05252988|EXPERIMENTAL|Arm C|"1. Neratinib 240 mg (six 40-mg tablets) orally once daily for 13 C, unless patient discontinues earlier.~2. Mandatory loperamide 4 mg (2 tablets/capsules) orally, 3 times a day (total 12 mg a day) for the first 14 days. After the first 14 days, 4 mg (2 tablets/capsules) orally, 2 times a day (total 8 mg a day) to complete a total of 28 days.~3. Mandatory colesevelam 1,875 mg (three 625-mg capsules orally), 2 times a day for the first month (28 days). After day 28, any prophylaxis or treatment for diarrhoea could be administered PRN, if loperamide not to exceed 16 mg per day."
62091863|NCT02695043|EXPERIMENTAL|MMPET Group|This group of subjects will be comprised of a subset of culturally diverse patients admitted to the Bellevue the Traumatic Brain Injury Unit at Bellevue. Treatment will focus on improving awareness and comprehension of TBI and its long-term consequences, fostering increased trust in the TBI rehabilitation team, and conveying the importance of continued TBI follow up to maximize recovery.
62091864|NCT02695043|ACTIVE_COMPARATOR|Control Group|The Control Group will be comprised of equally diverse subset of patients who will receive Standard of Care Treatment.
62289782|NCT05019937|ACTIVE_COMPARATOR|Single implementation strategy|Schools randomized to this arm will be exposed to a single implementation strategy, which contains one implementation component
62463441|NCT00715702|EXPERIMENTAL|1|Patients with Moderate renal impairment and matched volunteers
62091865|NCT04510337|ACTIVE_COMPARATOR|Standard rocuronium|patients received rocuronium 0.6mg/kg
62091866|NCT04510337|EXPERIMENTAL|Magnesium|patients received 100 ml saline with 50mg/kg magnesium sulphate infusion over 10 minutes
62091867|NCT04165369||Patients with extended surgical exposures|Patients with extended surgical exposures requiring postoperative observation.
62289783|NCT05489393||Individuals with DRPLA|This registry is for people with a diagnosis of Dentatorubral-pallidoluysian atrophy (DRPLA)
62289784|NCT02251912|EXPERIMENTAL|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
62289785|NCT02251912|PLACEBO_COMPARATOR|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
62289786|NCT04363333||High Probability of OSA|Based on a sleep questionnaire
62289787|NCT04363333||Low Probability of OSA|Based on a sleep questionnaire
62289788|NCT04781075|EXPERIMENTAL|TAP Block with Exparel|TAP Block with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of bupivacaine diluted in 55 mL of normal saline
62289789|NCT04781075|ACTIVE_COMPARATOR|TAP Block with bupivicaine|TAP Block with 30 mL (5mg/mL) of bupivacaine diluted in 70 mL of normal saline
62289790|NCT01420510|EXPERIMENTAL|Adelmidrol|Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients
62463442|NCT00715702|EXPERIMENTAL|2|Patients with Mild or Severe renal impairment and matched volunteers. Type of patient group determined after safety review of 1st group data
62463443|NCT02735122|EXPERIMENTAL|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
61906605|NCT02663934|ACTIVE_COMPARATOR|Social Interaction Stretching (SIS)|This group will serve as a control group against which to gauge the effects of aerobic and resistance training on cognitive function. Participants in this group will follow the same schedule and format as the EXS group. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program. These SIS participants will receive instructions on stretching, range of motion, limbering, and toning; but the intensity will be far less than that achieved in the EXS classes. Activities will focus on flexibility enhancement. As the participant's level of flexibility increases, stretches with increasing levels of difficulty will be incorporated into the program.
61906606|NCT04772326||PrEP patients undergoing follow-up at Tourcoing hospital|
61906607|NCT01547559|NO_INTERVENTION|part1:blank control|NO maintain drugs with Hp negative patients.
61906608|NCT01547559|EXPERIMENTAL|part1:teprenone 1|maintain treatment with Teprenone for Hp negative patients
61906609|NCT01547559|EXPERIMENTAL|part1:EAC-T|eradication of Hp with triple treatment
61906610|NCT01547559|EXPERIMENTAL|part1：EA-EMC-T|eradication of Hp with sequential therapy
61906611|NCT01547559|ACTIVE_COMPARATOR|part1：T-T|Teprenone as maintain drugs for Hp positive patients
61906612|NCT01547559|EXPERIMENTAL|part2:GGA group|Geranylgeranylacetone plus diclofenac sodium for patients with rheumatic diseases
62091868|NCT06424912|EXPERIMENTAL|Treatment Group|Subjects undergo Vivifi's surgical procedure for treatment of BPH.
62091869|NCT06654700|EXPERIMENTAL|Herpes Zoster vaccine（Commercial-scale batch 1 group）|Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule
62091870|NCT06654700|EXPERIMENTAL|Herpes Zoster vaccine（Commercial-scale batch 2 groups）|Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule
62091871|NCT06654700|EXPERIMENTAL|Herpes Zoster vaccine（Commercial-scale batch 3 groups）|Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule
62091872|NCT05592652|OTHER|simple post-traumatic stress disorder|Patients suffering from PTSD according to DSM-5 diagnostic features
62463444|NCT02735122|ACTIVE_COMPARATOR|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
62463445|NCT02735122|ACTIVE_COMPARATOR|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
62463446|NCT02735122|PLACEBO_COMPARATOR|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
61906613|NCT01547559|NO_INTERVENTION|part2:control group|diclofenac sodium only for patients with rheumatic diseases
61906614|NCT03005184|EXPERIMENTAL|S/V+Pla, S/V+I, Enal+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61906615|NCT03005184|EXPERIMENTAL|S/V+Pla, Enal+I, S/V+I, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61906616|NCT03005184|EXPERIMENTAL|S/V+Pla, Enal+Pla, Enal+I, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61906617|NCT03005184|EXPERIMENTAL|S/V+I, S/V+Pla, Enal+I, Enal+P|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61920104|NCT03891160|NO_INTERVENTION|Group B - Control|Group B will be the controls and will not receive a 3D model.
61920105|NCT04761627|ACTIVE_COMPARATOR|Continued-use Group (Ustekinumab)|Participants will receive subcutaneous injection of ustekinumab up to Week 52.
62091873|NCT05592652|OTHER|complex post-traumatic stress disorder|Patients suffering from CPTSD according to CIM-11 diagnostic features
62091874|NCT05592652|OTHER|volonteer trauma +|non clinical volunteer with traumatic exposure
62091875|NCT05592652|OTHER|volonteer trauma -|non clinical volunteer without traumatic exposure
62091876|NCT03918135|EXPERIMENTAL|Paracetamol|Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 100 patients
62091877|NCT03918135|EXPERIMENTAL|İbuprofen|İbuprofen 400mg of ibuprofen (intrafen 400mg/4ml solution Gen ilaç sanayi,Turkey ) intravenous (IV) was given 100 patients
62091878|NCT05823727|EXPERIMENTAL|Collagen Peptides|10 grams per day for 24 weeks
62463447|NCT02648347|EXPERIMENTAL|Vadadustat|
62463448|NCT02648347|ACTIVE_COMPARATOR|Darbepoetin alfa|
62463449|NCT02335840|EXPERIMENTAL|One dose of coffee|Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
62091879|NCT05823727|PLACEBO_COMPARATOR|Placebo|10 grams per day maltodextrin for 24 weeks
62289791|NCT01420510|PLACEBO_COMPARATOR|Placebo|Efficacy of Placebo in preventing vaginitis in oncologic patients
62289792|NCT00929955|ACTIVE_COMPARATOR|Ondansetron|
62463450|NCT02335840|EXPERIMENTAL|Two doses of coffee|Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
62463451|NCT02335840|EXPERIMENTAL|Three doses of coffee|Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
62091880|NCT00408161|ACTIVE_COMPARATOR|1|prize contingency management (CM) plus standard case management treatment -- patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals
62091881|NCT00408161|ACTIVE_COMPARATOR|2|standard case management treatment
62091882|NCT02861261|EXPERIMENTAL|Group A|
62091883|NCT02861261|EXPERIMENTAL|Group B|
62289793|NCT00929955|ACTIVE_COMPARATOR|Simvastatin|
62289794|NCT00929955|PLACEBO_COMPARATOR|Placebo|
62289795|NCT00420511|EXPERIMENTAL|Sitagliptin|Sitagliptin 100mg once a day (od) by mouth (po)
61906618|NCT03005184|EXPERIMENTAL|S/V+I, Enal+Pla, S/V+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61906619|NCT03005184|EXPERIMENTAL|S/V+I, Enal+I, Enal+Pla, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61906620|NCT03005184|EXPERIMENTAL|Enal+Pla, S/V+Pla, S/V+I, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61906621|NCT03005184|EXPERIMENTAL|Enal+Pla, S/V+I, Enal+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
62091884|NCT02861261|EXPERIMENTAL|Group C|
62091885|NCT02861261|PLACEBO_COMPARATOR|Group D|
62091886|NCT01543685|EXPERIMENTAL|Indomethacin 40 mg TID|
62091887|NCT01543685|EXPERIMENTAL|Indomethacin 40 mg BID|
62091888|NCT01543685|EXPERIMENTAL|Indomethacin 20 mg TID|
62091889|NCT01543685|ACTIVE_COMPARATOR|Celecoxib 200 mg|
62091890|NCT01543685|PLACEBO_COMPARATOR|Placebo|
62091891|NCT01657682|EXPERIMENTAL|Cohort A - No prior FLT3 TKI exposure|Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
62091892|NCT01657682|EXPERIMENTAL|Cohort B - Prior therapy with FLT3 TKI|Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
62091893|NCT03853798|EXPERIMENTAL|Cohort 1|"Participants who received placebo in Study AG348-C-006 will enroll in Cohort 1.~Part 1 (Dose Optimization Period, 12 weeks): Participants will begin by receiving 5 milligrams (mg) orally, twice a day. Each participant's dose of AG-348 may be increased to 20 mg twice a day and then to 50 mg twice a day depending on their response to AG-348 and tolerability.~Part 2 (Fixed Dose Period, 12 weeks): Last dose received in Part 1, twice a day.~After completion of Part 2, participants who, in the opinion of the Investigator, have demonstrated clinical benefit from AG-348 treatment will continue AG-348 treatment in the Continued Treatment Period."
62091894|NCT03853798|EXPERIMENTAL|Cohort 2|"Participants who received AG-348 in Study AG348-C-006 will enroll in Cohort 2.~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-006."
62091895|NCT03853798|EXPERIMENTAL|Cohort 3|"Participants who received AG-348 in Study AG348-C-007 will enroll in Cohort 3.~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-007."
62289796|NCT00420511|PLACEBO_COMPARATOR|Placebo arm|Placebo once a day (od) by mouth (po)
62289797|NCT03162848|EXPERIMENTAL|SystemCHANGE intervention|The SystemCHANGE™ intervention utilizes the Socioecological Model and Plan-Do-Check Act model as its framework and focuses on changing the individual's environment to change behavior using small experiments with feedback.
62289798|NCT03162848|NO_INTERVENTION|Attention Control|The attention control group will receive education at baseline, 1 month, and 2 months following America Heart Association brochures.
62307986|NCT00813839|ACTIVE_COMPARATOR|2 spontaneous breathing Trial|daily SBT on minimum pressure support
62655718|NCT02668068|ACTIVE_COMPARATOR|Control Group|Large volume whole-lung lavage (WLL) only
62289799|NCT05401747|OTHER|Healthy lifestyle intervention|All cases will be assessed before and after intervention for cognitive changes.
62289800|NCT00705978|EXPERIMENTAL|1|
62289801|NCT00705978|PLACEBO_COMPARATOR|2|
61906622|NCT03005184|EXPERIMENTAL|Enal+Pla, Enal+I, S/V+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
62091896|NCT02084082|EXPERIMENTAL|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
62289802|NCT03778437|ACTIVE_COMPARATOR|landmark techniques|Subclavian vein catheterization is performed without the guidance of ultrasound. The needle was inserted 1 cm inferior and 1 cm lateral to the junction of the middle and medial thirds of the clavicle (infraclavicular approach)
62289803|NCT03778437|EXPERIMENTAL|ultrasound-guided with aiming method|Subclavian vein catheterization is performed with our newly proposed aiming method with the guidance of ultrasound.
62289804|NCT03778437|EXPERIMENTAL|ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique.
62289805|NCT00877630||1:endoscopic group|patients underwent endoscopic thyroidectomy
62289806|NCT00877630||2:conventional group|patients underwent open thyroidectomy
62289807|NCT03598907||Standard management of coagulopathy|"The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy."
62289808|NCT03598907||POC management of coagulopathy|"group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss."
62289809|NCT03611699|ACTIVE_COMPARATOR|Umeclidinium bromide/vilanterol|Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that acts to reduce the amount of air trapped in the lungs at the end of of expiration.
62289810|NCT03611699|PLACEBO_COMPARATOR|Placebo|A placebo inhaler will be administered to serve as a control comparator to the umeclidinium bromide/vilanterol inhaler.
62289811|NCT05904626|ACTIVE_COMPARATOR|ELGN-2112 Human insulin [rDNA]|
62289812|NCT05904626|PLACEBO_COMPARATOR|Placebo|
62289813|NCT01323907|EXPERIMENTAL|Omegaven|Omegaven IV lipid emulsion administration for infants with life threatening parenteral nutrition associated liver disease
62289814|NCT05112731||First Ischemic Cardiac Event|Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up
62307987|NCT06070038|EXPERIMENTAL|Immediate Intervention Group|Immediate intervention group. Participants assigned to the immediate intervention group will be delivered materials over a three-month period as a series of four zoom hosted workshops, online content, and a social support group.
62307988|NCT06070038|OTHER|Waitlist Control Group|Wait-List Control Group. Participants in the follow-up group will be delivered intervention materials following the third data collection timepoint.
62463452|NCT02335840|EXPERIMENTAL|Three doses of decaffeinated coffee|Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
62463453|NCT05078138|EXPERIMENTAL|Exogenous Erythropoietin|Recombinant human Erythropoietin subcutaneous injection of 50 IU/kg body mass 3 times per week for 4 week
62289815|NCT04418921|EXPERIMENTAL|Experimental Group|"Intervention on self-regulation will be carried out through a non-immersive virtual reality platform, SR-Mrehab: Un colegio emocionante in which students must conduct a series of activities designed specifically for this purpose. These activities will be performed by the children using mainly their hands to manage the virtual objects showed in the screen. To do this, our system make use of a Kinect motion sensor connected to the computer to control the body movements of the children. Moreover, our system records some relevant data of the execution of these activities for further analysis of the children's performance.The exercises will be divided into two blocks, emotional regulation (ER) and cognitive regulation (CR), in a total of 10 sessions, once a week, performing an exercise of each block per session. Each session will consists of 60 minutes. ."
62655719|NCT02668068|EXPERIMENTAL|Experimental Group|Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation
61920106|NCT04761627|EXPERIMENTAL|Switching Group (Ustekinumab - ABP 654)|Participants will initially receive injection of ustekinumab up to Week 16. Thereafter, starting from Week 28, participants will switch between ABP 654 and ustekinumab every 12 weeks up to Week 52.
62091897|NCT02084082|EXPERIMENTAL|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
62091898|NCT02084082|EXPERIMENTAL|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
62289816|NCT04418921|ACTIVE_COMPARATOR|Control group|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom (5, 49). Each session will last 50 minutes, just like in the experimental group. The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation. The activities are similar for the experimental group, but the virtual reality system will not be used. It will be held in parallel in another room of the school, on the same day and time, carried out by occupational therapists and students from the students in the last year of occupational therapy degree.
62289817|NCT03012581|EXPERIMENTAL|Nivolumab|Nivolumab 240 mg IV over 60 minutes every 14 days.
62289818|NCT01419132|PLACEBO_COMPARATOR|High doses furosemide|administration of furosemide alone
62289819|NCT01419132|EXPERIMENTAL|HSS plus furosemide|administration of hypertonic saline solution plus high doses of furosemide bid
62289820|NCT05345470|PLACEBO_COMPARATOR|0 grams of chia seeds|3 cookies (30 grams)
62289821|NCT05345470|EXPERIMENTAL|3 grams of chia seeds|3 cookies (30 grams)
62289822|NCT05345470|EXPERIMENTAL|5 grams of chia seeds|3 cookies (30 grams)
62289823|NCT05345470|EXPERIMENTAL|7 grams of chia seeds|3 cookies (30 grams)
62289824|NCT04589598|EXPERIMENTAL|FNS|those who are treated with femoral neck system (FNS)
61906623|NCT03005184|EXPERIMENTAL|Enal+I, S/V+Pla, Enal+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
61906624|NCT03005184|EXPERIMENTAL|Enal+I, S/V+I, S/V+Pla, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
62091899|NCT02084082|EXPERIMENTAL|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
62091900|NCT05787379|EXPERIMENTAL|Providers receiving Long-COVID Concordant Care Training|Providers randomized to this arm will receive concordant care training.
62289825|NCT04589598|ACTIVE_COMPARATOR|MCS|those who are treated with multiple cannulated screw (MCS)
62091901|NCT05787379|ACTIVE_COMPARATOR|Providers receiving Education Packet Training|Providers randomized to this arm will receive education packet training
62289826|NCT01402219|ACTIVE_COMPARATOR|Iopamiro-370|
62463454|NCT06011538|EXPERIMENTAL|On-line SDD LH website resource (intervention)|Patients allocated the experimental arm will be provided with the link to the SDD LH patient information website (https://www.mydaycasehysterectomy.com).The option of this educational material will be in addition to the standard verbal and written patient information provided by the BWCH.
62289827|NCT01402219|ACTIVE_COMPARATOR|Visipaque 320|
62289828|NCT00393718|EXPERIMENTAL|Liraglutide|Liraglutide 0.9 mg + glibenclamide placebo
62289829|NCT00393718|ACTIVE_COMPARATOR|Glibenclamide|Glibenclamide 1.25-2.5 mg + liraglutide placebo
62289830|NCT03501927|ACTIVE_COMPARATOR|FOCUS (focused cardiac ultrasound)|Patients allocated to FOCUS will receive a preoperative FOCUS examination in conjunction with a standard anesthetic preoperative evaluation.
62289831|NCT03501927|NO_INTERVENTION|Control|Patients allocated til control arm will receive a standard anesthetic preoperative evaluation according to hospitals' standards.
62289832|NCT00877344|EXPERIMENTAL|1|Immediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
62289833|NCT00877344|EXPERIMENTAL|2|Interval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
62289834|NCT05533060||TBI group|patients with traumatic brain injury (TBI) treated surgically
62289835|NCT05533060||RN group|relatively normal (RN) participants including patients with other brain diseases, for example, gliomas, meningiomas, and schwannomas, treated surgically
62289836|NCT04141176|EXPERIMENTAL|Spiri+|new CPAP device
62289837|NCT02970695|ACTIVE_COMPARATOR|Treatment arm 1|"To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. The subjects will be asked to wear a pair of laser protective goggles so as to blind them during treatment."
62289838|NCT02970695|ACTIVE_COMPARATOR|Treatment arm 2|Subjects will receive LAT. A laser device (Pointer Pulse™) will be used in this study.
62289839|NCT02970695|EXPERIMENTAL|Treatment arm 3|Subjects will receive a combined approach that includes the use of LAT plus MAT. LAT will be administered prior to MAT application on the selected auricular points, and the procedures used will be similar to the procedures described for Group 1 and Group 2.
62289840|NCT00755079|PLACEBO_COMPARATOR|Arm 1|group of persons with spinal cord injury will receive blinded placebo capsule
62289841|NCT00755079|EXPERIMENTAL|Arm 2|group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
62289842|NCT05391243|OTHER|Follicular phase|LLETZ performed during the follicular phase of the menstrual cycle
61906625|NCT03005184|EXPERIMENTAL|Enal+I, Enal+Pla, S/V+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
62289843|NCT05391243|OTHER|Luteal phase|LLETZ performed during the luteal phase of the menstrual cycle
62463455|NCT06011538|ACTIVE_COMPARATOR|Standard practice for information provision (control)|Patients allocated the control group will receive standard BWCH information only.
62655720|NCT03477175|EXPERIMENTAL|Cohort A : Lenvatinib|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
62655721|NCT03477175|EXPERIMENTAL|Cohort B: Lenvatinib plus Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
62289844|NCT04864457||Normal|Patients without coronary atherosclerotic burden
62289845|NCT04864457||Chronic coronary syndrome (CCS)|"CCS covers the different stages of development of coronary heart disease in addition to the clinical manifestations dominated by acute coronary thrombosis, including asymptomatic myocardial ischemia, vasospasm, and microcirculatory lesions. The six most common types of CCS include:Suspected coronary heart disease and stable angina symptoms, whether or not patients with dyspnea; Patients with newly emerged heart failure or left ventricular dysfunction suspected of CAD; Patients with no symptoms or stable symptoms within 1 year after ACS, or patients with recent revascularisation; Patients with or without symptoms more than 1 year after initial diagnosis or revascularization; Patients with angina pectoris, suspected vasospasm or microcirculatory diseases; Asymptomatic patients with coronary heart disease are found during screening."
62289846|NCT04864457||Acute coronary syndrome (ACS)|ACS is a group of clinical syndromes commonly characterized by acute myocardial ischemia, including unstable angina pectoris (UA); Acute non-ST-segment elevation myocardial infarction (NSTEMI); Acute ST-segment elevation myocardial infarction (STEMI).
62289847|NCT04644848|EXPERIMENTAL|Pre-sentinel node biopsy ultrasonographical tattooing|Preoperative ultrasonographical tattooing of the suspicious lymph nodes. Sentinel Lymph Node Biopsy (SLNB),
62289848|NCT05726357|ACTIVE_COMPARATOR|standard root canal treatment|standard root canal treatment
62289849|NCT05726357|ACTIVE_COMPARATOR|Pulpotomy|vital pulp therapy
62289850|NCT02774993|EXPERIMENTAL|Doxycycline|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
62463456|NCT02649803|OTHER|community hospital|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the nearest community hospital or Shanghai Children's Medical Center, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to install asthma APP at their smart phone to follow up."
62463457|NCT02502110|EXPERIMENTAL|rosuvastatin 20mg/day|To receive oral rosuvastatin 20mg/day and regular therapy from 7 days before ablation and last for 3 months.
62463458|NCT02502110|NO_INTERVENTION|blank control|Regular therapy from 7 days before ablation and last for 3 months. Regular medicines used for AF includes warfarin, metoprolol sustained release tablet, amiodarone, perindopril and irbesartan.
62091902|NCT02741011|OTHER|Radiological imaging|Mentally handicapped patients underwent sedation anesthesia with IV Propofol and then tomographic images were obtained with NewTom 5G. Orthopantomographies (OPGs) were obtained by processing the raw images and radiological examination of the patients were performed on OPGs.
62091903|NCT02394886|EXPERIMENTAL|ALLO-ASC-DFU|ALLO-ASC-DFU treatment with conventional care
62091904|NCT02786979|EXPERIMENTAL|Beraprost sodium tablet and Aspirin combination group|Oral
62091905|NCT02786979|EXPERIMENTAL|Aspirin Group|Oral
61906626|NCT02324634|EXPERIMENTAL|ES intervention|Electrical stimulation (ES) twice a day, 5 days a week, for 3 months
61906627|NCT02324634|NO_INTERVENTION|Control|Usual care only
61906628|NCT06431971|EXPERIMENTAL|Talineuren|Participants receive standard of care PD treatment + 720 mg of Talineuren i.v. weekly for 18 infusions (18 weeks).
61906629|NCT06431971|PLACEBO_COMPARATOR|Placebo|Participants receive standard of care PD treatment + placebo (0.9% NaCl) i.v. weekly for 18 infusions (18 weeks).
62091906|NCT06256302|EXPERIMENTAL|Transverses abdominis plane block|
62091907|NCT06256302|ACTIVE_COMPARATOR|Local wound infiltration|
61920107|NCT04432220|EXPERIMENTAL|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
61920108|NCT04432220|NO_INTERVENTION|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
61920109|NCT00846170|ACTIVE_COMPARATOR|probiotics|patients with IBS that will receive investigational treatment for 4 weeks
62091908|NCT06278389|EXPERIMENTAL|Stage 1: ACC017 and placebo|The trial is conducted sequentially from the low-dose cohorts, namely, 5 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg（tentative), respectively. Participants are given a single dose of ACC017 tablets or placebo under the fasting condition.
62091909|NCT06278389|EXPERIMENTAL|Stage 2: ACC017 and FTC/TAF (Descovy）|Stage 2 is a single center, randomized, open-label FE and DDI study with a tentative dose of 40 mg. The stage was planned to enroll 12 healthy participants (both male and female) who are randomly assigned to either the fasting-postprandial or postprandial-fasting arm at a 1:1 ratio. Eligible healthy participants are admitted on D-1 and received a single oral dose of ACC017 tablets on the day of administration of each cycle under the fasting or postprandial condition with a washout period of 7 days during the two-week period. After completing the washout of the second cycle, participants are assessed by the investigator to enter into the DDI study and receive a single oral dose of ACC017 tablets with FTC/TAF tablets under the fasting condition.
61920110|NCT00846170|PLACEBO_COMPARATOR|Placebo|cross over of patients from arm 1
62091910|NCT03749356|EXPERIMENTAL|Once-Daily Tacrolimus|One arm: TacroBell SR Cap.
62463459|NCT04236960|EXPERIMENTAL|18~55 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
62655722|NCT03477175|EXPERIMENTAL|Cohort C: Comparator drug|"The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo.~For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo."
62091911|NCT04509284|EXPERIMENTAL|Training|Participants with persistent pain after breast cancer treatment will receive 24 sessions of individualized progressive total body resistance training, supervised by a certified strength and conditioning specialist.
61920111|NCT05583669|EXPERIMENTAL|DS-2325a SC|Participants who will be randomized to receive DS-2325a as a fixed dose subcutaneous (SC) injection (starting dose 300 mg).
62091912|NCT04509284|OTHER|Control|Participants with persistent pain after breast cancer treatment will be instructed to continue their everyday lifestyle and be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
62091913|NCT02158065|NO_INTERVENTION|Usual care|Patients will receive information (leaflet) and guidance on the benefits associated with increased physical activity in COPD patients and their health status
62091914|NCT02158065|EXPERIMENTAL|Coaching program|In addition to usual care, patients will receive the coaching program
62463460|NCT04236960|EXPERIMENTAL|2~17 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
62655723|NCT01518062|EXPERIMENTAL|Low dose|
62655724|NCT01518062|EXPERIMENTAL|Medium dose|
62655725|NCT01518062|EXPERIMENTAL|High dose|
62655726|NCT00229801|NO_INTERVENTION|MRI|
61920112|NCT05583669|EXPERIMENTAL|Placebo SC|Participants who will be randomized to receive placebo as a subcutaneous (SC) injection.
62091915|NCT01188122|EXPERIMENTAL|AnapnoGuard|
62091916|NCT01244828|EXPERIMENTAL|Asenapine|Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
62091917|NCT05421845|EXPERIMENTAL|Lifestyle intervention group|Participants will be given mobile- and hospital-based lifestyle interventions. The mobile-based interventions including dietary guidance, exercise supervision and weight monitoring will be conducted by trained physicians through WeChat group on cell phone every 1 to 2 weeks. Participants need to report their physical activity and weight information every week through WeChat group. Hospital-based intervention is a ≥5 minutes one-to-one and face-to-face personalized lifestyle counselling leading by a trained physician every 4 weeks during \<14 weeks of gestation, every 2 weeks during 14-28 weeks of gestation, and once a week during ≥28 weeks of gestation. Participants' dietary information will be collected for any 3 consecutive days chosen by participants during 12-14 weeks of gestation, 24-28 weeks of gestation and \>36 weeks of gestation respectively using a food frequency questionnaire.
62091918|NCT05421845|NO_INTERVENTION|control group|Participants in control group will be managed in accordance with the standard practice.
62655727|NCT04747340|EXPERIMENTAL|Training for Awareness, Resilience and Action (TARA)|12 weekly online sessions, each 90 minutes, 6 participants/group. For participants \<18 years at CAP, parents/legal guardians will participate in parts of the sessions. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
62091919|NCT03848312|EXPERIMENTAL|Computerized Cognitive Training|Participants will complete computerized cognitive training.
62091920|NCT03848312|ACTIVE_COMPARATOR|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities.
62091921|NCT04505124|EXPERIMENTAL|FutureMe|"Participants use the FutureMe app for 12 weeks. The app has the following functionality:~* Opportunity to personalize one's avatar~* Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)~* Feedback on health behaviors represented through a Future-self avatar (consequential and visual feedback)~* Individualized shopping tipps"
62091922|NCT04505124|ACTIVE_COMPARATOR|Control|"Participants use the a control app for 12 weeks. The control app has the following functionality:~* Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)~* Feedback on health behaviors represented through conventional dashboards (numeric \& text feedback)~* Individualized shopping tipps"
62091923|NCT05980221|OTHER|Pancreatic cancer (main cohort)|investigation of PEI and the metabolome of patients with pancreatic cancer in the fed and fasted state
62463461|NCT04236960|EXPERIMENTAL|7~23 mos|2 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between the first and second dose.
62463462|NCT04236960|EXPERIMENTAL|3 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between every two doses.
62463463|NCT04236960|EXPERIMENTAL|2 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. Two-month interval between every two doses.
62463464|NCT03966365|EXPERIMENTAL|PRO-122|- Dosage: 1 drop every 12 hours, in both eyes
62463465|NCT03966365|ACTIVE_COMPARATOR|Krytantek Ofteno®|- Dosage: 1 drop every 12 hours, in both eyes
62463466|NCT05070676|EXPERIMENTAL|Lateral cephalometric radiographs of pre-adolescent patients (8-13) years old.|
62737306|NCT05594485||Retrospective collection of DICOM patient files for the period 15-17 August|To collect the CXR data for retrospective study, we addressed a municipal hospital in the Czech Republic that provides healthcare services to up to 130,000 residents of a medium-sized city (approximately 70,000 inhabitants) and the surrounding area. 127 anonymized CXR images were collected between August 15 and 17, 2022, and subsequently submitted to five independent radiologists of varying experience for annotation. The selected radiologists were asked to assess whether the CXR image shows any of the 12 abnormalities mentioned above. Pediatric CXR images (under 18 years of age), scans with technical problems (poor image quality, rotation), and images in lateral projection were excluded from the dataset.
62091924|NCT05980221|OTHER|Sub-study cohorts: Chronic pancreatitis, cystic fibrosis, NET patients on SSAs|investigation of PEI and the metabolome of patients with other causes of PEI in the fed and fasted state
62289851|NCT02774993|PLACEBO_COMPARATOR|Placebo|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
62463467|NCT01701024|ACTIVE_COMPARATOR|ACYC|ACYC active, topically applied to the face for 12 weeks
61920113|NCT05685628|EXPERIMENTAL|Cinnamon dressing group|Use of the cinnamon dressing for 14 days
61920114|NCT05685628|ACTIVE_COMPARATOR|Charcoal dressing Group|Use of the charcoal dressing for 14 days
62091925|NCT05980221|OTHER|Dosing arm|Investigation metabolome of patients pre and post initiation of PERT as part of their PEI care
62091926|NCT03880383|EXPERIMENTAL|Group 1 - Coaching|"Upon enrollment to the study, parents in this group will have immediate access to the full intervention:~* Coaching: Telephone contact with coaches, who will provide information, education and support about the child's development. Coaching will be adapted to family needs, situation, preferences and child's condition.~* Online parent education: Parents will be provided access to empowering online tools, such as educational resources, chosen or developed by other parents and researchers.~* Peer support tools: Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge."
62091927|NCT03880383|OTHER|Group 2- Partial and delayed coaching|"Parents in this group will have delayed and partial access to coaching, at the end of the 18-month period. Parents in this group will have a one-time session with a developmental coach who can give them guidance about their child's development. Parents in this group will also then get access to online parent education and peer support tools, indefinitely, until the online platform is de-activated.~\* Both arms/groups\* will obtain usual care for their child, in addition and independent of full or partial coaching."
62091928|NCT06659887|ACTIVE_COMPARATOR|Low group|Low flow 100% O2 AT 2 L/min
62091929|NCT06659887|ACTIVE_COMPARATOR|Moderate group|Low flow 100% O2 AT 4 L/min
62289852|NCT00124345|EXPERIMENTAL|1|
62737307|NCT01503684||Patients with sepsis|Patients who are admitted to ICU with the diagnosis of sepsis
61920115|NCT05451342||ARDS|Patients who meet the diagnostic criteria of ARDS
62463468|NCT01701024|PLACEBO_COMPARATOR|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
62463469|NCT00946166|PLACEBO_COMPARATOR|Placebo Control|Subjects receive standard treatment for pneumonia and a simvastatin-like placebo
62737308|NCT01301287|EXPERIMENTAL|Chlorella|
62289853|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score \< 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
62289854|NCT03223571||Controls|Healthy people with no history of neurological pathologies
62289855|NCT01989130|EXPERIMENTAL|Real-time results with Cepheid Xpert CT/NG Test|Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
62289856|NCT01989130|ACTIVE_COMPARATOR|Batched results with Roche AMPLICOR CT/NG test|Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
62289857|NCT04120688|ACTIVE_COMPARATOR|Effect on surgery|Duration of surgery, degree of manipulation of the transplant
62289858|NCT04120688|ACTIVE_COMPARATOR|Success of transplantation|Normal eruption and root development of the transplant
62463470|NCT00946166|EXPERIMENTAL|Simvastatin|Subjects receive simvastatin in addition to standard pneumonia treatment
62463471|NCT05440903|EXPERIMENTAL|Mindfulness|Participants in the experimental arm are asked to use a mindfulness smartphone application called Headspace. Headspace offers pre-recorded introductory mindfulness meditation audio instructions guided by experienced meditation teachers. Study participants are instructed to voluntarily complete 10 minutes of Headspace twice per day for 14 days, a total recommended dose of 280 minutes. Mindfulness practice begins the day after the baseline interview (i.e., intervention day 1). Participants are encouraged to listen at two separate times each day to support habit formation and to maximize daily exposure with low time burden. As participants have minimal prior experience with mindfulness attributed to the study eligibility criteria, all recommended trainings are at the beginner level. Participants have access to all sessions offered and are not restricted to a particular sequence.
62463472|NCT05440903|PLACEBO_COMPARATOR|Psychoeducation|"Participants in the psychoeducation arm listen to TEDTalks audio recordings by experts on field-specific topics. Study participants are instructed to complete 10 minutes of TEDTalks twice per day for 14 days. Sessions were selected by the study team to be of interest to the public yet not include content on meditation, smoking, or content appearing to cue behavior change associated with smoking. Like the Mindfulness condition, participants in the Psychoeducation condition begin the practice the day after the baseline interview. Participants are told to listen at two separate times each day to maximize daily exposure with low time burden. Additionally, participants are instructed to listen with full mindful attention and return attention to the audio when attention drifts to match the Mindfulness instruction and emphasize the importance of sustaining attention for each 10-minute period. Participants have access to all sessions offered and are not restricted to a particular sequence."
62463473|NCT01497652|ACTIVE_COMPARATOR|Treatment Group|Treatment group will receive Rasagiline (Azilect) 1mg daily
62463474|NCT01497652|PLACEBO_COMPARATOR|Placebo Group|will receive placebo daily
62463475|NCT03336411|ACTIVE_COMPARATOR|mHealth|
62463476|NCT03336411|EXPERIMENTAL|Personalized mHealth|
62463477|NCT03611478|EXPERIMENTAL|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
62463478|NCT03611478|PLACEBO_COMPARATOR|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
62463479|NCT00819507|EXPERIMENTAL|Vanos Cream|glucocorticoid cream
62463480|NCT01284439|EXPERIMENTAL|TearA|
62463481|NCT01284439|EXPERIMENTAL|TearB|
62737309|NCT03726658|EXPERIMENTAL|AGN-241751 3mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
62463482|NCT05457101|EXPERIMENTAL|with AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS.
62463483|NCT05457101|NO_INTERVENTION|without AI-based biliopancreatic EUS navigation system|The endoscopists in the contrpl group performs the examination routinely without special prompts.
61920116|NCT05451342||Non-ARDS|Patients without ARDS
61920117|NCT03238846|NO_INTERVENTION|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
62091930|NCT06659887|ACTIVE_COMPARATOR|High group|Low flow 100% O2 AT 8 L/min
62091931|NCT02235610|NO_INTERVENTION|Standard Group|"Recipients receive standard donor lungs as per current clinical practice.~No experimental procedures will be carried out."
62091932|NCT02235610|EXPERIMENTAL|EVLP Group|Recipients receive reconditioned EVLP donor lungs and current standard of care for lung transplant is administered.
62289859|NCT03973476|EXPERIMENTAL|Intervention group|Mothers received a phone support service with their midwife during the 8 weeks after childbirth.
62289860|NCT03973476|NO_INTERVENTION|Control group|Mothers received standard postpartum care
62289861|NCT02965378|EXPERIMENTAL|Arm I - AZD4547|Participants receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62289862|NCT02965378|EXPERIMENTAL|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~-closed to accrual 12/18/2015"
62289863|NCT02965378|EXPERIMENTAL|Arm III - AZD4547 re-registration|Participants in Arm II eligible for re-registration receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62289864|NCT02653950|ACTIVE_COMPARATOR|Traditional|a control arm of patients undergoing traditional septoplasty for DNS
62289865|NCT02653950|EXPERIMENTAL|Endoscopic|patients undergoing endoscopic septoplasty.
62289866|NCT01422005|EXPERIMENTAL|Experimental group|Simultaneous Bimanual training: Patients who have had either an acute/subacute and a Chronic stroke will get training on the devices.
62737310|NCT03726658|EXPERIMENTAL|AGN-241751 10mg|AGN-241751, oral administration, once per day
62737311|NCT03726658|EXPERIMENTAL|AGN-241751 25mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
62289867|NCT01422005|ACTIVE_COMPARATOR|Control Group|Conventional Occupational Therapy: Patients who have had either an acute/subacute and Chronic Stroke with hemiperisis will get conventional therapy.
62289868|NCT05030714|EXPERIMENTAL|Single Arm|Patients will perform visual field testing with the Humphrey Visual Field Analyzer and with the custom head-mounted device.
62289869|NCT01111604|ACTIVE_COMPARATOR|mFOLFOX-6|mFOLFOX-6
62463484|NCT03416777|ACTIVE_COMPARATOR|Meat-based diet (MBD)|Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
62463485|NCT03416777|EXPERIMENTAL|Meat-based alpha-tocopherol (MBD-T)|Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
62463486|NCT03416777|EXPERIMENTAL|Pesco-vegetarian (PVD)|Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
62289870|NCT01111604|EXPERIMENTAL|mFOLFOX-6 + Ramucirumab|mFOLFOX-6 + Ramucirumab
62289871|NCT01111604|EXPERIMENTAL|mFOLFOX-6 + Icrucumab|mFOLFOX-6 + Icrucumab
62289872|NCT04902235|EXPERIMENTAL|CRH administration|Experimental: CRH administration
62289873|NCT04902235|PLACEBO_COMPARATOR|Placebo administration|Control: Placebo administration
62463487|NCT02932878|EXPERIMENTAL|DSXS topical|administered twice daily for 28 days
62463488|NCT01162226|EXPERIMENTAL|training program|
62737312|NCT03726658|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B
62737313|NCT03786224|EXPERIMENTAL|Abstinent|
62289874|NCT03084133|EXPERIMENTAL|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.~Intervention 'Therapeutic Education Strategy'"
62289875|NCT03084133|NO_INTERVENTION|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
62091933|NCT06695169||Nurses in ICU or Acute Care who administer medications using Smart infusion pumps|"(A) Nurses from 8 acute and intensive care units (659 nurses total) will be invited to complete a survey about using the pumps.~(B) Of these 659 nurses, 48 will join focus groups to share detailed thoughts on pump use.~(C) Another 48 nurses will practice using the pumps in a simulation setting.~The study will also review 200 patient records to check for any differences in documentation errors of IV medication volumes when using pump-EHR integration versus manually programming the pumps. Additionally, the study will analyze pump data from the last 6 months to see how often the technology is used and what types of alerts and programming errors occur. Furthermore, 20 healthcare team members will participate in interviews to understand the barriers and facilitators of technology use."
62091934|NCT06502015||autoimmune disease|clinical diagnosis with autoimmune disease of central nervous system
62289876|NCT04024592|EXPERIMENTAL|children|
62091935|NCT06502015||health control|age- and sex-matched control individuals
62091936|NCT04908761|EXPERIMENTAL|Transmuscular quadratus lumborum block group|Patients assigned to the Transmuscular Quadratus Lumborum (TQL) block group receive the Transmuscular Quadratus Lumborum block in a lateral decubitus position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
62289877|NCT02647151|ACTIVE_COMPARATOR|METHYLAMINOLEVULINATE HYDROCHLORIDE|METHYLAMINOLEVULINATE HYDROCHLORIDE (MAL)cream 160mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
62289878|NCT02647151|EXPERIMENTAL|AMINOLEVULINIC ACID HYDROCHLORIDE|AMINOLEVULINIC ACID HYDROCHLORIDE (ALA) gel 78mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
62289879|NCT00537433|NO_INTERVENTION|Standard counseling|Families in the control group receive standard care, including routine counseling regarding medications prescribed from their physician and post-visit counseling by the pediatric nursing staff. Dosing instruments are given at the discretion of the physician or nurse.
62289880|NCT00537433|EXPERIMENTAL|Pictogram|Parents randomized to the pictogram-based intervention group receive medication counseling utilizing the pictogram-based medication instruction sheets. These sheets help to facilitate medication counseling, including teaching about dosage and adherence.
62289881|NCT04196257|EXPERIMENTAL|BP1001-A monotherapy|Dose escalation of BP1001-A monotherapy
62289882|NCT04196257|EXPERIMENTAL|BP1001-A and Paclitaxel|Dose expansion of selected dose of BP1001-A with paclitaxel
62463489|NCT06121193|ACTIVE_COMPARATOR|Patients - Wait-List Control|"Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered at 3-months after the clinic visit electronically and by mail.~• A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
62463490|NCT06121193|EXPERIMENTAL|Experimental: Patients - PREVENT Tool|"Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered immediately following the clinic visit, and monthly for 3-months after the clinic visit electronically and by mail~• At the clinic visit, the provider will use the PREVENT tool to discuss CVH risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources."
62091937|NCT04908761|PLACEBO_COMPARATOR|Control group|For patients assigned to the control group, 30cc of 0.9% normal saline is used for Transmuscular Quadratus Lumborum block.
62289883|NCT01214486|EXPERIMENTAL|Raltegravir|
62289884|NCT01169779|EXPERIMENTAL|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD up to Week 24.
62289885|NCT01169779|PLACEBO_COMPARATOR|Placebo|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, followed by 20 mcg QD up to Week 24.
62289886|NCT02227576|EXPERIMENTAL|Romiplostim|Romiplostim lyophilized formulation is a white, solide cake that is reconstituted with sterile water for injection.
62655728|NCT04747340|ACTIVE_COMPARATOR|Standard Treatment|Standard treatment (ST) as given at each participating study site. ST is based on the health practitioners' knowledge, experience, current guidelines and both the practitioners' and participants' preferences. For young people with depression The Swedish National Board of Health and Welfare recommends social support and psychoeducation (as first priority), Selective Serotonin reuptake inhibitors (as second priority) and cognitive behavioral therapy (as second priority). These recommendations are generally followed and given as stand-alone treatment or in different combinations. In our study we have no control over which of these treatments are given in the ST-arm, nor the combination or timing of them. To obtain data on what treatment has been given in the ST-arm we will go through the individual medical records of all participants at the conclusion of data collection.
62655729|NCT02967575||1- or 2-level cTDR|patients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
62655730|NCT06480630|EXPERIMENTAL|basiliximab group|
62655731|NCT05052905|EXPERIMENTAL|Study|Exercises
62655732|NCT04363476|EXPERIMENTAL|Intervention|8-week exercise and education intervention. Two 60-minute physiotherapist-lead group exercise classes with education incorporated will be delivered weekly for 8 weeks (16 classes). In addition, participants will complete a 30-minute home exercise session once a week for 8-weeks (8 sessions). After the intervention, the group will enter a 16-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
62655733|NCT04363476|OTHER|Control|The control group will not receive an intervention during the first 8-weeks of the study. Being a step-wedge design, this group will receive the same 8-week exercise and education intervention later, after the intervention group has completed the intervention and the post-intervention testing. After the control group has completed the 8-week intervention, they will enter an 8-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
62091938|NCT01688102|ACTIVE_COMPARATOR|Oral Vitamin D3|Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain \<35 ng/ml, subjects will receive additional doses of oral vitamin D.
62091939|NCT01688102|ACTIVE_COMPARATOR|Ultraviolet Light|Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain \<35 ng/ml, subjects will receive additional doses of narrow band UVB.
62091940|NCT05455944|ACTIVE_COMPARATOR|Pregabalin Group|Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery
62289887|NCT06042673|EXPERIMENTAL|Pomegranate seed oil|Participants will be asked to consume breakfast (0 minute) containing pomegranate seed oil
62655734|NCT00891813|EXPERIMENTAL|Zemplar (paracalcitol)|
62091941|NCT05455944|PLACEBO_COMPARATOR|Control Group|Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery
62091942|NCT06394661|EXPERIMENTAL|Serplulimab group|NabPE+Sluritumab group（Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serulizumab 4.5mg/Kg ivgtt on Day 3）every 3 weeks for 6 cycles. Then paticipants will receive surgery and Serulizumab will be given as monotherapy every 3 weeks up to 6 months from the begining of the treatment.
62091943|NCT02703532|EXPERIMENTAL|Stroke Survivors with CARE-CITE Carepartners|Stroke survivors with a carepartner randomized to the CARE-CITE intervention. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
62091944|NCT02703532|EXPERIMENTAL|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
62091945|NCT02703532|ACTIVE_COMPARATOR|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
62091946|NCT02703532|ACTIVE_COMPARATOR|Stroke Survivors with Traditional Education Carepartners|Stroke survivors with a carepartner randomized to receive traditional education. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
62289888|NCT06042673|PLACEBO_COMPARATOR|mixed vegetable oil|Participants will be asked to consume breakfast (0 minute) containing mixed vegetable oil
62289889|NCT01243268||Patients with essential hypertension|
62289890|NCT01339442|EXPERIMENTAL|Dose Level 1 - Phase 1A|"BKM120 80 mg PO daily.~Fulvestrant 500 mg IM on Days 1 \& Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
62289891|NCT01339442|EXPERIMENTAL|Dose Level 2 - Phase IA|"BKM120 100 mg PO daily.~Fulvestrant 500 mg IM on Days 1 \& Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
62289892|NCT01339442|EXPERIMENTAL|Phase IB|"BKM120 (dose to be determined in Phase IA)PO 5 days on/ 2 days off per week.~Fulvestrant 500 mg IM on Days 1 \& Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
62289893|NCT01339442|EXPERIMENTAL|Cohort C|"BKM120 (dose determined in Phase IA) PO daily.~Fulvestrant 500 mg IM on Day 1 and Day 15 during Cycle 1 then monthly on Day 1 of subsequent cycles."
62289894|NCT05641883|EXPERIMENTAL|Experimental|All eligible patients that are enrolled with receive the CardiaMend patch soaked in amiodarone
62655735|NCT03004040||Case|older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)
62655736|NCT03004040||Control|matched control subjects (non-LCII)
62655737|NCT01981083|EXPERIMENTAL|Egg albumin-based protein supplement|Powder form, dosage 30 g daily, duration 6 months
62655738|NCT01981083|ACTIVE_COMPARATOR|Renal-specific oral supplement|Liquid form, dosage 237 ml (one can) daily, duration 6 months
62655739|NCT00883727|EXPERIMENTAL|stem cells|
62655740|NCT00883727|PLACEBO_COMPARATOR|Placebo|
62655741|NCT04525196|EXPERIMENTAL|Physical activity.|Patients will benefit a physical activity program during their dialysis session.
62655742|NCT04525196|NO_INTERVENTION|No physical activity.|Patients will have access to their dialysis sessions without additional physical activity.
62655743|NCT05374278|EXPERIMENTAL|Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers|Establish \[18F\]RP-115 safety in the clinic with male and female PET imaging.
62655744|NCT05374278|EXPERIMENTAL|Cohort 2B - [18F]RP-115 in patients with AD|Comparison of \[18F\]RP-115 PET binding between AD patients and age-matched cognitively normal controls and between AD and FTD
62463491|NCT06121193|NO_INTERVENTION|Providers|-All eligible providers will be sent questionnaires electronically to their email at baseline, following provider training and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline.
62655745|NCT05374278|EXPERIMENTAL|Cohort 2C - [18F]RP-115 in patients with FTD|Comparison of \[18F\]RP-115 PET binding between AD patients and age-matched cognitively normal controls and between AD and FTD
62655746|NCT05374278|EXPERIMENTAL|Cohort 2A - [18F]RP-115 in age-matched controls|Comparison of \[18F\]RP-115 PET binding between AD patients and age-matched cognitively normal controls and between AD and FTD
62655747|NCT01587677||Confirmed tuberculosis|
62091947|NCT01219465|EXPERIMENTAL|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
62091948|NCT00698152||ArComXL® polyethylene|ArComXL® polyethylene
62091949|NCT06658600|ACTIVE_COMPARATOR|Guideline-Based Group (Guideline Group)|"Physicians use a RF-CL table (risk factor weighted clinical likelihood table) to calculate the probability of obstructive CHD.~This approach aligns with current clinical guidelines to assist in decision-making."
62289895|NCT03990870|EXPERIMENTAL|Experimental Treatment|dCBGT + WASABI
62289896|NCT03990870|ACTIVE_COMPARATOR|Active Comparator|dCBGT Only
62091950|NCT06658600|EXPERIMENTAL|AI-Assisted Group (AI Group)|"Physicians receive CHD probability estimates and diagnostic recommendations from an AI model based on retinal photographs.~The AI tool provides individualized obstructive CHD probabilities, leveraging retinal biomarkers associated with cardiovascular risk."
62091951|NCT00550108|NO_INTERVENTION|A|Observation of pancreatic cysts
62091952|NCT00550108|EXPERIMENTAL|B|Ethanol lavage of pancreatic cysts
62307989|NCT01689389||Main study population|"All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.~Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months."
62655748|NCT01587677||Confirmed non-tuberculous mycobacterial infection|
62655749|NCT01587677||Confirmed bronchial carcinoma|
62655750|NCT01587677||Suspected tuberculosis but confirmed alternative diagnosis|
62655751|NCT05001048|EXPERIMENTAL|Low Altitude|Participants will be assessed at an altitude of \<1050m.
62655752|NCT05001048|EXPERIMENTAL|Early Acclimatization to High Altitude|Participants will be assessed on day 2 or 3 of a high-altitude expedition at 3,800m.
62655753|NCT05001048|EXPERIMENTAL|Late Acclimatization to High Altitude|Participants will be assessed on day 9 or 10 of a high-altitude expedition at 3,800m.
62655754|NCT00640289|EXPERIMENTAL|A|Treatment
62655755|NCT01883674|EXPERIMENTAL|Milk proteins|This group will do a resistance training + milk proteins (milk beverage)
62655756|NCT01883674|EXPERIMENTAL|Essential amino acids (add to soya bvg)|This group will do a resistance training + essential amino acids (added to soya beverage)
62655757|NCT01883674|PLACEBO_COMPARATOR|No protein (control)|This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)
62655758|NCT00750269|EXPERIMENTAL|Level 1: 8.0 Gy/FX|SBRT 40.0 Gy
62289897|NCT02222402|EXPERIMENTAL|INTRA-DIALYTIC EXERCISE TRAINING|"Using a modified cycle ergometer, aerobic exercise will be performed in a semi-recumbent position, 3 times per week during the first two hours of haemodialysis. The initial prescription will be set in the moderate intensity range of 40-60% of peak aerobic capacity, progressing to 75% level by the end of the intervention.~Twice per week patients will also complete lower extremity muscular conditioning exercise, using ankle weights, after the aerobic cycling exercise."
62655759|NCT00750269|EXPERIMENTAL|Level 2: 8.5 Gy/FX|SBRT 42.5 Gy
62655760|NCT00750269|EXPERIMENTAL|Level 3: 9.0 Gy/FX|SBRT 45.0 Gy
61920118|NCT03238846|EXPERIMENTAL|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
62655761|NCT00750269|EXPERIMENTAL|Level 4: 9.5 Gy/FX|SBRT 47.5 Gy
62289898|NCT02222402|NO_INTERVENTION|HAEMODIALYSIS RENAL REPLACEMENT THERAPY|"Haemodialysis is the most common dialysis (renal replacement) treatment for kidney failure.~They may also receive dietary advice, counselling, input from social workers, and other forms of educational support."
62289899|NCT04217395||Reinforced support: X-ailes program users|
62289900|NCT03105739|EXPERIMENTAL|Anesthetised|LMA removal once the halogenated anesthetic turned off
62289901|NCT03105739|ACTIVE_COMPARATOR|Awake|LMA removal once the patient fully regained consciousness
62289902|NCT06260514|EXPERIMENTAL|APR-1051|Dose Escalation based on BOIN Design
62655762|NCT00750269|EXPERIMENTAL|Level 5: 10.0 Gy/FX|SBRT 50.0 Gy
62655763|NCT00750269|EXPERIMENTAL|Level 6: 10.5 Gy/FX|SBRT 52.5 Gy
62655764|NCT00750269|EXPERIMENTAL|Level 7: 11.0 Gy/FX|SBRT 55.0 Gy
62655765|NCT00750269|EXPERIMENTAL|Level 8: 11.5 Gy/FX|SBRT 57.5 Gy
62655766|NCT00750269|EXPERIMENTAL|Level 9: 12.0 Gy/FX|SBRT 60.0 Gy
62655767|NCT05000827|EXPERIMENTAL|PSMA PET/CT based indication for ePLND:|"1. Node-negative PSMA PET/CT \[N0\] and M0: do not perform ePLND~2. Node-positive PSMA PET/CT \[N1\] and M0: perform ePLND"
62655768|NCT05000827|ACTIVE_COMPARATOR|Nomogram-based indication for ePLND (standard of care)|Nomogram-based indication for ePLND (conform current EAU guidelines)
62655769|NCT06157437|EXPERIMENTAL|Focal pulse ablation system|
62655770|NCT03665324||Veteran athletes with Supraventricular arrhythmias|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age\> 35 years) with documented paroxysmal supraventricular arrhythmias.
62655771|NCT03665324||Veteran athletes without supraventricular arrhythmia|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age\> 35 years) without documented supraventricular arrhythmia.
62655772|NCT02702544|EXPERIMENTAL|neutral position|the patient is in the neutral position, located on his back on a flat surface
62655773|NCT02702544|EXPERIMENTAL|legs raised for 20 degrees|patient is placed on a flat surface, legs raised for 20 degrees, supported around ankles
62463492|NCT04548440|EXPERIMENTAL|Preoperative Sintilimab plus Nab-paclitaxel and Cisplatin|"Patients receive the following regimen every 3 weeks:~Sintilimab 200mg IV on Day 1; Albumin-bound paclitaxel 125 mg/m2 IV on Day 1 and Day 8; Cisplatin 75mg/m2 IV on Day 1; Standard hydration regimen on Day 0-3~After 2-4 cycles, radiological evaluation and multidisciplinary assessment will be performed. If radical resection is possible, surgery is to be performed 3-6 weeks after the last chemotherapy session. In the case of a R0 resection, the investigator will decide whether to perform adjuvant therapy depending on the patient's condition; in the case of R1 or R2 resection, concurrent chemoradiotherapy is recommended. If the multidisciplinary assessment considers that radical resection is not possible, radical concurrent chemoradiotherapy is performed."
62463493|NCT00840138||1|Patients with common bile duct injury after open cholecystectomy
62463494|NCT00840138||2|Patients with common bile duct injury after laparoscopic cholecystectomy
62463495|NCT03616106|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
62463496|NCT01474668|EXPERIMENTAL|A|Experimental
62463497|NCT04712071|EXPERIMENTAL|Ketamine|40 minutes intravenous infusion of 0.5 mg/kg ketamine.
62463498|NCT06383962||Prospective|All patients for whom the decision has been made to have the Synergy Disc system implanted and give informed consent will be enrolled in this study, following country-specific requirements.
62463499|NCT06383962||Retrospective|Patients who have previously received the Synergy Disc system in the last ten years are eligible for inclusion in the retrospective data collection; a waiver of consent, or an informed consent, for the retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations.
62463500|NCT01390844|EXPERIMENTAL|Boceprevir|PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
62463501|NCT01390844|ACTIVE_COMPARATOR|Control|PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.
62463502|NCT00336479|PLACEBO_COMPARATOR|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks.
62463503|NCT00336479|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks.
62289903|NCT00585234||1|We intend to photograph male and female subjects from age 1 through skeletal maturity. Healthy children will be photographed to determine the normative characteristics of thoracic function using this technique. We will also enroll patients with thoracic pathology to determine how digital imaging can document thoracic dysfunction. There are no specific disease related exclusion criteria. Participation is voluntary.
62289904|NCT00834054||Double-lung transplanted patients|
62655774|NCT02702544|EXPERIMENTAL|legs raised for 30 degrees|patient is placed on a flat surface, legs raised for 30 degrees, supported around ankles
62655775|NCT02702544|EXPERIMENTAL|legs raised for 45 degrees|patient is placed on a flat surface, legs raised for 45 degrees, supported around ankles
61920119|NCT03238846|EXPERIMENTAL|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
62289905|NCT02031094||Major resection|Patients undergoing resection of \>3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
62289906|NCT02031094||Minor resection|Patients undergoing resection of \</= 3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
62655776|NCT02702544|EXPERIMENTAL|legs raised for 60 degrees|patient is placed on a flat surface, legs raised for 60 degrees, supported around ankles
61920120|NCT01772095||Patients with Dementia|Patients diagnosed with dementia and evaluated by specific Alzheimer disease scales
62289907|NCT02109081|EXPERIMENTAL|Dexamethasone|Patients will be administered dexamethasone 10 mg at induction of anesthesia
62655777|NCT03035019|EXPERIMENTAL|Lantern for primary care patients|All patients between the ages of 20-65 at specific primary care practices and score 5 or greater on the GAD7 questionnaire are offered the Lantern app to help with stress/anxiety.
62655778|NCT00589459||1|non-diabetic women with acute coronary syndrome (ACS)
62655779|NCT00589459||2|non-diabetic men with acute coronary syndrome (ACS)
62655780|NCT04562909||Premature children|Premature children born before than 32 weeks were included.
61920121|NCT01897376|OTHER|Pfannenstiel incision|
61920122|NCT01897376|OTHER|vertical skin incision|
61920123|NCT06288789|EXPERIMENTAL|Experimental group|65 years and above older adults
62289908|NCT02109081|PLACEBO_COMPARATOR|Placebo-2.5 cc of saline|Patients will be administed placebo at induction of anesthesia
62289909|NCT00661583|EXPERIMENTAL|Ranibizumab alone|Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
62289910|NCT00661583|EXPERIMENTAL|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
62289911|NCT00661583|ACTIVE_COMPARATOR|MMC alone|MMC therapy alone (n=10)
61906630|NCT05037578|EXPERIMENTAL|Project Grace|This intervention will be delivered through church-based multilevel activities by trained church leaders using religiously/ culturally-tailored study materials (sermon guides, responsive readings, educational games, brochures, educational/testimonial videos) packaged in a culturally-tailored. Intervention churches will receive the Project Grace Tool Kit and intervention implementation directions to seek cognitive screening. These churches will hold a Project Grace Kickoff event, where a sermon, and other tool kit materials will be distributed. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities over 4 months. Delivery of intervention components will coincide with existing, multilevel activities that occur in churches through: a) church-wide services, b) outreach ministry groups; and c) individual level activities (e.g., text/voice/email health promotion messages from church) over 4 months.
62091953|NCT05183555|EXPERIMENTAL|Patients with definite IE will be included and referred for 18F-FDG PET/CT in the study|Fourteen patients with definite IE according to the modified Duke criteria (Li) will be included and referred for 18F-FDG PET/CT in the study. A 68Ga-DOTATOC PET/CT scan will be performed specifically for research at 24 hours.
62091954|NCT00227747|EXPERIMENTAL|Radiothérapie + Xelox|
62091955|NCT00227747|ACTIVE_COMPARATOR|Radiothérapie + Capécitabine|
62289912|NCT04207476|EXPERIMENTAL|Treatment arm|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
62289913|NCT04207476|PLACEBO_COMPARATOR|Placebo|Placebo magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
62655781|NCT04562909||Healthy Control Group|Age matched healthy controls
62091956|NCT03717194|EXPERIMENTAL|Ertugliflozin|Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor
62091957|NCT03717194|PLACEBO_COMPARATOR|Control group|Placebo in addition to their preexisting metformin and/or DPP4 inhibitor
62091958|NCT01760655|EXPERIMENTAL|Treatment (RIC and allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28"
62091959|NCT04991389|EXPERIMENTAL|Phase 1 - Contrast 129Xe MRI ages 5-18|The research team will collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Phase contrast MRI of inhaled gas. (4) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
62289914|NCT02730156|EXPERIMENTAL|Altitude exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
62289915|NCT00548548|EXPERIMENTAL|Bevacizumab|Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
62289916|NCT00548548|PLACEBO_COMPARATOR|Placebo|Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
62289917|NCT01653730|EXPERIMENTAL|Eclipse 3 portable oxygen concentrator|Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
62655782|NCT00607893|SHAM_COMPARATOR|Sham CPAP|Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
62655783|NCT00607893|ACTIVE_COMPARATOR|Treatment CPAP|Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
61906631|NCT05037578|ACTIVE_COMPARATOR|Standard Control|Standard information churches will receive standard dementia education information. These churches will receive: a) non-tailored project materials collected from mental health organizations and b) standard community-based mental health screening events) coordinated by their Community Health Liaisons. These churches will receive all Project Grace Tool Kit materials and implementation training after the completion of assessments.
62463504|NCT00336479|EXPERIMENTAL|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks.
62091960|NCT04991389|EXPERIMENTAL|Phase 2 - Contrast 129Xe MRI ages 3-18|The research team plans to collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
62091961|NCT04316455|EXPERIMENTAL|Integrative Yoga Therapy|Participants engaging in a 6-week chronic pain self-management program. Intervention: Integrative Yoga Therapy
62091962|NCT02213900|EXPERIMENTAL|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
62091963|NCT02213900|PLACEBO_COMPARATOR|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
62091964|NCT05454189|ACTIVE_COMPARATOR|4-week IPD Flushing Schedule|IPD standard maintenance flushes and port assessments every 4 weeks.
62091965|NCT05454189|EXPERIMENTAL|12-week IPD Flushing Schedule|IPD standard maintenance flushes and port assessments every 12 weeks.
62091966|NCT05284188|ACTIVE_COMPARATOR|Open Modified Broström operation group|Patients who accept an open modified Broström operation
62091967|NCT05284188|ACTIVE_COMPARATOR|Arthroscopic Modified Broström operation group|Patients who accept an arthroscopic modified Broström operation
62091968|NCT03589482|EXPERIMENTAL|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
62091969|NCT03589482|ACTIVE_COMPARATOR|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
62091970|NCT03341026|OTHER|Induction day 1, 4, 7, 14|Patient will come to the hospital on day 1, 4, 7 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
62091971|NCT03341026|OTHER|Induction day 1, 7, 10, 14|Patient will come to the hospital on day 1, 7, 10 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
62289918|NCT01653730|EXPERIMENTAL|iGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
61906632|NCT00870103|EXPERIMENTAL|Vigadexa eye drops|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
62091972|NCT02643771|EXPERIMENTAL|Diabetic group|Subjects with Chronic Periodontitis and Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
62463505|NCT00336479|EXPERIMENTAL|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 12 weeks.
62463506|NCT01870856|EXPERIMENTAL|Spectacles, Stage 1|Spectacles per participant's habitual perscription worn for 2 weeks
62091973|NCT02643771|EXPERIMENTAL|Nondiabetic group|Subjects with Chronic Periodontitis and without Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
62091974|NCT06250439|EXPERIMENTAL|Adult patients with peripheral VA-ECMO for refractory cardiogenic shock|Adult patients with peripheral VA-ECMO for refractory cardiogenic shock, hospitalized in medical ICU of Pitié Salpêtrière Hospital, AP-HP Paris
62091975|NCT05265988|EXPERIMENTAL|Meridian|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
62091976|NCT02733133|EXPERIMENTAL|Uncovered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and cover the area before engaging in contact with the female partner.
62091977|NCT02733133|EXPERIMENTAL|Covered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and will not cover the area before engaging in contact with the female partner.
62091978|NCT03599115|EXPERIMENTAL|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
62289919|NCT01653730|EXPERIMENTAL|EverGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
62289920|NCT01653730|NO_INTERVENTION|Control portable oxygen concentrator|6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
62463507|NCT01870856|ACTIVE_COMPARATOR|1-DAY ACUVUE, Stage 1|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
62289921|NCT01990157|EXPERIMENTAL|TAB08|Multiple TAB08 administrations as intravenous infusions.
62091979|NCT03599115|ACTIVE_COMPARATOR|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
62091980|NCT03899155|EXPERIMENTAL|A1: Nivolumab Monotherapy Dose 1|
62091981|NCT03899155|EXPERIMENTAL|A2: Nivolumab Monotherapy Dose 2|
62289922|NCT02773797|PLACEBO_COMPARATOR|IN-DEX 1.0 mcg/kg, intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Intranasal-Dexmedetomidine (IN-DEX) intranasal 1.0 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
62289923|NCT02773797|PLACEBO_COMPARATOR|IN-DEX, 1.5 mcg/kg intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label IN-DEX intranasal 1.5 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
62289924|NCT02773797|ACTIVE_COMPARATOR|Placebo - Saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Placebo - Saline will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
62289925|NCT00049387|EXPERIMENTAL|Treatment (tipifarnib, temozolomide, radiation therapy)|See Detailed Description
62289926|NCT01096914|ACTIVE_COMPARATOR|Radiofrequency|patients treated with percutaneous radiofrequency ablation
62289927|NCT01096914|ACTIVE_COMPARATOR|laser|Patients treated with percutaneous laser ablation
62289928|NCT05679414||Study group|Covid 19 patients in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample.Follow up patient for 28 days as regard development of vascular thrombotic manifestation
62289929|NCT05679414||Control group|Healthy subjects in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample.
62307990|NCT01689389||Schizophrenia SoC sample|Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
62463508|NCT01870856|EXPERIMENTAL|DAILIES TOTAL1, Stage 2|Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
62463509|NCT01870856|ACTIVE_COMPARATOR|1-DAY ACUVUE, Stage 2|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
62463510|NCT01464970|ACTIVE_COMPARATOR|SIE Vessels Both Clamped|
62463511|NCT01464970|ACTIVE_COMPARATOR|SIE Vessels both Unclamped|
62463512|NCT01464970|ACTIVE_COMPARATOR|SIE Artery Unclamped; Vein Clamped|
62463513|NCT01464970|ACTIVE_COMPARATOR|SIE Artery Clamped, SIE Vein Unclamped|Superficial Inferior Epigastric Artery Clamped; Vein Unclamped
62463514|NCT02355431|EXPERIMENTAL|Itacitinib plus erlotinib|
62463515|NCT02355431|ACTIVE_COMPARATOR|Placebo plus erlotinib|
62091982|NCT03899155|EXPERIMENTAL|B1: Nivolumab + Ipilimumab|
62091983|NCT03899155|EXPERIMENTAL|B2: Nivolumab + Ipilimumab + Cabozantinib|
62091984|NCT03899155|EXPERIMENTAL|B3: Nivolumab + Ipilimumab + Trametinib|
62091985|NCT03899155|EXPERIMENTAL|C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1|
62091986|NCT03899155|EXPERIMENTAL|C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2|
62091987|NCT03899155|EXPERIMENTAL|C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1|
62091988|NCT03899155|EXPERIMENTAL|C4: Relatlimab + Nivolumab SAV Dose 2|
62091989|NCT03899155|EXPERIMENTAL|C5: Relatlimab + Nivolumab + Ipilimumab|
62091990|NCT03899155|EXPERIMENTAL|C6: Relatlimab + Nivolumab + Capecitabine|
62091991|NCT03899155|EXPERIMENTAL|C7: Relatlimab + Nivolumab SAV Dose 3|
62091992|NCT03899155|EXPERIMENTAL|C10: Relatlimab + Nivolumab SAV Dose 4|
62463516|NCT02726581|EXPERIMENTAL|Investigational Arm|"Nivolumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
62463517|NCT02726581|ACTIVE_COMPARATOR|Control Arm|"Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
62463518|NCT02726581|EXPERIMENTAL|Exploratory Arm|"Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
62463519|NCT06061146|EXPERIMENTAL|Arm A|"Tislelizumab + S1 + Radiotherapy Drug: Tirellizumab IV infusion，200 mg/3w, for 1 year~Drug: S1 PO, 40\~60mg，BID（d1-14，d22-35，two cycles）~Radiation: Radiation Concurrent Radiation, 1.8Gy/f, 28f"
62463520|NCT06061146|ACTIVE_COMPARATOR|Arm B|"S1 + Radiotherapy~Drug: S1 PO, 40\~60mg，BID（d1-14，d22-35，two cycles）~Radiation: Radiation Concurrent Radiation, 1.8Gy/f, 28f"
62289930|NCT02218229|EXPERIMENTAL|Shock waves|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
62289931|NCT02218229|NO_INTERVENTION|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
62091993|NCT03899155|EXPERIMENTAL|C12: Relatlimab + Nivolumab SAV Dose 5|
62289932|NCT02537041|OTHER|healthy volunteers|to obtain normal values diastolic myocardial stiffness references. The objective will be to confirm the increase with age in myocardial stiffness assessed by elastography in healthy subjects.
62289933|NCT02537041|OTHER|diastolic Heart Failure|older patients with isolated diastolic HF (EF\> 45%, 60-80 years, n = 20) and infiltrative cardiomyopathy restrictive-type amyloidosis (n = 20) . The objective will be to study the results of elastography on two separate clinical types of IC diastolic well identified.
62289934|NCT02537041|OTHER|systolic Heart Failure|"elderly patients with heart failure with impaired ejection (\<45%) fraction, but no segmental dysfunction.~The evaluation of myocardial stiffness by elastography in all these patients will be compared to conventionally ultrasound and biological parameters currently used for diagnosis of elderly's diastolic HF"
62463521|NCT05405725|EXPERIMENTAL|ENZ215|ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
62463522|NCT05405725|ACTIVE_COMPARATOR|Prolia|Prolia Injection:- 60 mg Denosumab (Prolia) will be administered subcutaneously on day 1.
62463523|NCT02472366|OTHER|laser|laser with or without prior history of intraocular corticosteroid therapy
62463524|NCT02472366|OTHER|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
62463525|NCT01561274|ACTIVE_COMPARATOR|2 ml bupivacaine|2 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg of bupivacaine.
62289935|NCT03437421|EXPERIMENTAL|Type II diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
62289936|NCT03437421|EXPERIMENTAL|Type I diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
62289937|NCT00682058||LABS patients|Bariatric surgery patients with 35\>BMI kg/m2\<60 prior to surgery will undergo follow-up post-bariatric surgery.
62289938|NCT01224548|EXPERIMENTAL|vegan group|participants from sites of this group will receive vegan nutritional intervention starting from Feb 2011
62091994|NCT03899155|EXPERIMENTAL|C8: Relatlimab + Nivolumab SAV + PDCT Dose 1|
62463526|NCT01561274|ACTIVE_COMPARATOR|1.5 ml bupivicaine.|1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 12.5 mg of bupivacaine.
62463527|NCT06336291|EXPERIMENTAL|Arm A|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
62463528|NCT06336291|EXPERIMENTAL|Arm B|Patients will be treated with on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles
62463529|NCT06336291|EXPERIMENTAL|Arm C|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
61906633|NCT02275884|ACTIVE_COMPARATOR|Dark chocolate (85% cocoa)|Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
62091995|NCT03899155|EXPERIMENTAL|C9: Relatlimab + Nivolumab SAV + Bevacizumab|
62091996|NCT03899155|EXPERIMENTAL|C11: Relatlimab + Nivolumab SAV + PDCT Dose 2|
62091997|NCT03899155|EXPERIMENTAL|D1: Nivolumab + Temozolomide|
62289939|NCT01224548|NO_INTERVENTION|control group|participants from sites of the control group will not receive the same nutritional information until June 2011
62289940|NCT01278576|EXPERIMENTAL|Intramuscular ending Targeting|Botox 200 units placed at the upper 2/10-3/10 length of the GCM
62289941|NCT01278576|ACTIVE_COMPARATOR|Midbelly Targeting|A total of 200 units will be placed at the four quadrants of the midbelly portion of the GCM.
62091998|NCT03899155|EXPERIMENTAL|D2: Nivolumab + Rucaparib|
62091999|NCT03899155|EXPERIMENTAL|D3: Nivolumab + Daratumumab|
62289942|NCT03425708|ACTIVE_COMPARATOR|Treatment group1|Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.
62289943|NCT03425708|ACTIVE_COMPARATOR|Treatment group2|Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
62289944|NCT03425708|NO_INTERVENTION|Control group|Treatment of CKD patients with hyperuricaemia with conventional methods.
62289945|NCT06005454|EXPERIMENTAL|Children with Pneumonia in intensive care unit receiving fish oil and the standard treatment|
62289946|NCT06005454|NO_INTERVENTION|Children with Pneumonia in intensive care unit receiving the standard treatment only|
62289947|NCT00591279||A|Barium enema and colonoscopy at one and three years after entry.
62463530|NCT06336291|EXPERIMENTAL|Arm D|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
62463531|NCT06336291|EXPERIMENTAL|Arm E|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
62289948|NCT00591279||B|Barium enema and colonoscopy at three years only after entry.
62289949|NCT01429571||Systemic and local antibiotics|
62289950|NCT01429571||Local antibiotics|
62289951|NCT01429571||No antibiotics|
62289952|NCT03595202|OTHER|Step1:4㎎ TID|TS-143 12mg total dose/day or Placebo
62289953|NCT03595202|OTHER|Step2:11㎎ TID|TS-143 33mg total dose/day or Placebo
62289954|NCT05618392||single group assignment|only one arm. Each patient complete numerical scale questionnaire (0-10)
62289955|NCT02862769|EXPERIMENTAL|Lidocaine infusion|first group (lidocaine group) will include those who receive a intraoperative lidocaine infusion (Induction bolus dose of 1.5 mg/kg body weight followed by a continous lidocaine infusion
62289956|NCT02862769|PLACEBO_COMPARATOR|Saline Infusion|The second group will include those who receive a intraoperative placebo i(Induction bolus dose of 1.5 mg/kg body weight of lidocaine followed by a continous saline infusion at the same rate as the lidocaine infusion.
62289957|NCT01223092||Patients undegoing infertility treatment|Male and female patients undergoing infertility treatment
62289958|NCT04459845|ACTIVE_COMPARATOR|Parent Child Interaction Therapy|Parents and children will receive 12 weekly sessions of PCIT.
62289959|NCT04459845|ACTIVE_COMPARATOR|Child Parent Psychotherapy|Parents and children will receive 12 weekly sessions of CPP
62092000|NCT03899155|EXPERIMENTAL|D4: Nivolumab + Bevacizumab|
62092001|NCT03899155|EXPERIMENTAL|E1: Bevacizumab Monotherapy|
62092002|NCT03899155|EXPERIMENTAL|E2: Regorafinib Monotherapy|
62092003|NCT03899155|EXPERIMENTAL|E4: Leucovorin + Oxaliplatin + Fluorouracil|
62092004|NCT03899155|EXPERIMENTAL|E5: Enzalutamide Monotherapy|
62092005|NCT03899155|EXPERIMENTAL|E6: Sunitinib Monotherapy|
62092006|NCT03899155|EXPERIMENTAL|E7: Rucaparib Monotherapy|
62092007|NCT03899155|EXPERIMENTAL|E8: Capecitabine Monotherapy|
62092008|NCT03899155|EXPERIMENTAL|E9: Cabozantinib Monotherapy|
62092009|NCT03899155|EXPERIMENTAL|E10: Pemetrexed Monotherapy|
62092010|NCT03899155|EXPERIMENTAL|E11: Pembrolizumab Monotherapy|
62092011|NCT03899155|EXPERIMENTAL|E3: Leucovorin + Fluorouracil|
62092012|NCT06336434|EXPERIMENTAL|Q4W Switch|Pregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression on oral antiretroviral therapy willing to switch to an every four week (Q4W) CAB LA + RPV LA regimen.
62092013|NCT06336434|EXPERIMENTAL|Q8W Switch|Pregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression on oral antiretroviral therapy willing to switch to an every eight week (Q8W) CAB LA + RPV LA regimen.
62289960|NCT03618641|EXPERIMENTAL|Nivolumab and CMP-001 Combination|"Prime Phase -Nivolumab 240mg, IV Infusion, every two weeks starting with Cycle 2 ( Cycles 2, 4, 6) for 6 weeks in combination with CMP-001, 5mg, Injection, at Week 1 and the remaining injections, 10 mg will be administered Weeks 2 -7.~Boost Phase -Nivolumab 240mg, IV Infusion, every two weeks, over a 46 week period in combination with CMP-001, 5mg, administered every 4 weeks for 1 year."
62289961|NCT04484350|EXPERIMENTAL|Intensive Blood Pressure management|Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
62289962|NCT04484350|ACTIVE_COMPARATOR|Standard Blood Pressure management|Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
62289963|NCT00135629|EXPERIMENTAL|Immunotherpy Arm|12 patients received active injections of an alum-adsorbed grass pollen vaccine
62289964|NCT00135629|PLACEBO_COMPARATOR|Placebo Arm|6 patients received placebo injections
62289965|NCT01357213|PLACEBO_COMPARATOR|Arm 2|Placebo in all three cohorts
62289966|NCT01357213|EXPERIMENTAL|Arm 1|XOMA 3AB in 3 dose levels/cohorts A, B or C.
62289967|NCT02730260|ACTIVE_COMPARATOR|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
62463532|NCT06336291|EXPERIMENTAL|Arm F|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
62463533|NCT00590408|ACTIVE_COMPARATOR|1|
62463534|NCT00590408|PLACEBO_COMPARATOR|2|
62463535|NCT02605395|EXPERIMENTAL|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
62463536|NCT02605395|EXPERIMENTAL|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
62463537|NCT05372406||training group|elderly patients (aged ≥ 65 years) elderly patients undergo surgeries
62289968|NCT02730260|EXPERIMENTAL|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
62289969|NCT06418178|EXPERIMENTAL|Treatment Arm|Open label, within-subjects treatment arm. Participants receive 120mg + optional 60mg supplement. There will be from one to five dosing sessions that occur three to five weeks apart. Each dosing session is followed by three integration psychotherapy sessions.
62289970|NCT05601245|EXPERIMENTAL|High voltage pulsed current|Twenty patients with chronic wounds will be managed by the high-voltage pulsed current for 45 as the total treatment duration and the polarity will be reversed after 22 minutes, three sessions per week for six weeks.
62289971|NCT05601245|EXPERIMENTAL|Microcurrent therapy|Twenty patients with chronic wounds will be managed by microcurrent therapy for 40 minutes, three sessions per week for six weeks.
62289972|NCT05389488|ACTIVE_COMPARATOR|Control Arm|Subjects will receive standard of care intermittent compression therapy using the current devices used in the clinical space.
62289973|NCT05389488|EXPERIMENTAL|Study Arm|Subjects will receive compression therapy from the OsciPulse system.
62463538|NCT05372406||external validation group|elderly patients (aged ≥ 65 years) elderly patients undergo surgeries
62463539|NCT05741437|EXPERIMENTAL|Sequence 1|"* Period 1: D745, D150 - A single oral dose of 2 tablets under food intake condition~* Period 2: CKD-378 - A single oral dose of 1 tablet under food intake condition"
62463540|NCT05741437|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-378 - A single oral dose of 1 tablet under food intake condition~* Period 2: D745, D150 - A single oral dose of 2 tablets under food intake condition"
62463541|NCT04361266|EXPERIMENTAL|Rotium patch recipient|Subjects with Rotium nano scaffold patch included in rotator cuff repair construct
62289974|NCT01629407||Glaucoma|Patients with glaucoma
62463542|NCT04361266|ACTIVE_COMPARATOR|Control|Subjects undergoing non-patch augmented rotator cuff repair
62463543|NCT02131129|EXPERIMENTAL|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
62463544|NCT02131129|SHAM_COMPARATOR|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
62463545|NCT03773848|EXPERIMENTAL|A- hook plate|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with hook plate. X-ray was applied to check the grade of reduction before the operation is completed.
62289975|NCT03119012|ACTIVE_COMPARATOR|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
62289976|NCT03119012|ACTIVE_COMPARATOR|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
62289977|NCT02594644|EXPERIMENTAL|10-minute Incubation with Microneedle Roller & Sham|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
62463546|NCT03773848|EXPERIMENTAL|B- tightrope|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with tightrope. X-ray was applied to check the grade of reduction before the operation is completed.
62463547|NCT06085300|EXPERIMENTAL|sentence recast in Spanish only|A trained, bilingual SLP will treat the targeted structure at a rate of \~ 1 recast per minute, for 16 hours spread over 9 weeks to obtain a planned dose of 912-1008 recasts (960 +/- 5%). Following evidence on enhanced conversational recasting, the SLP will obtain the child's attention before recasting and systematically vary the lexical items in the recasts. Children receiving monolingual Spanish therapy will have the entire treatment session conducted in Spanish.
62092014|NCT06336434|EXPERIMENTAL|Q4W Continuation|Pregnant people 19 4/7 weeks gestation or less with HIV-1 viral suppression who were using every 4 week CAB LA + RPV LA at and since conception and are willing to continue their current CAB LA + RPV LA regimen.
62092015|NCT06336434|EXPERIMENTAL|Q8W Continuation|Pregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression who were using every 8 week CAB LA + RPV LA at and since conception and are willing to continue their current CAB LA + RPV LA regimen.
62289978|NCT02594644|EXPERIMENTAL|20-minute Incubation with Microneedle Roller & Sham|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
62289979|NCT03709602||Adolescents ages 11 to 14 years|Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017
62289980|NCT03709602||Parent of adolescents|Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
62463548|NCT06085300|EXPERIMENTAL|sentence recast in English only|A trained, bilingual SLP will treat the targeted structure at a rate of \~ 1 recast per minute, for 16 hours spread over 9 weeks to obtain a planned dose of 912-1008 recasts (960 +/- 5%). Following evidence on enhanced conversational recasting , the SLP will obtain the child's attention before recasting and systematically vary the lexical items in the recasts. Children receiving monolingual English therapy will have the entire treatment session conducted in English.
62655784|NCT02712853||Autism Spectrum Disorder (ASD)|"Age at enrollment: 18 months to 6 years with established DSM-5 diagnosis of autism spectrum disorder. Exclusion criteria include:~wards of the state syndromic autism (attributed to a known genetic mutation) active periodontal infection active upper respiratory infection"
62092016|NCT04007809|EXPERIMENTAL|New-onset Type 1 diabetes|
62092017|NCT06252662|ACTIVE_COMPARATOR|Liposomal bupivacaine and bupivacaine plain erector spinae plane block|Erector spinae plane block performed on the surgical side (left, right or bilateral) as appropriate based on planned surgical consent. Utilizing ultrasound to see the fascial layers and guide the needle placement under direct visualization. Block will include 1.33% liposomal bupivacaine 10ml plus 0.25% bupivacaine plain 20 ml per side of the block.
62289981|NCT03709602||Cohort of Adolescents From Electronic Health Record (EHR)|A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.
62289982|NCT03109431|EXPERIMENTAL|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
62307991|NCT01689389||Bipolar SoC sample|Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant \[N06A\], antipsychotic (other than Quetiapine XR) \[N05A\] or mood stabilizer (including lithium \[N05AN\], valproate \[N03AG01\], and lamotrigine \[N03AX09\].
62307992|NCT06184581|EXPERIMENTAL|Lithium|tablet
62307993|NCT06184581|ACTIVE_COMPARATOR|Lamotrigine|tablet
62463549|NCT06085300|EXPERIMENTAL|sentence recast - Bilingual (Spanish+English) intervention|Treatment will differ from monolingual therapy in that the child will be seen by two SLPs in keeping with one-person one-language models. This allows us to ensure that the dose in each language is controlled and supports the use of both languages evenly in therapy. Sessions will alternate between English-only therapy and Spanish-only therapy - thus the child will receive 8 hours of therapy treating the selected target in English and 8 hours treating the selected target in Spanish. A child in bilingual therapy will receive approximately 456-504 (480 +/- 5%) recasts in each language for a total of 912-1008 recasts combined.
62463550|NCT03965377|EXPERIMENTAL|Home Safety Hero game play|Home Safety Hero is parental psychoeducational computer game to prevent childhood injuries
62463551|NCT05620225|EXPERIMENTAL|Axon Therapy + CMM|"Subjects will be consented, screened, and then undergo a 7-day baseline assessment period. Subjects will be asked to record pain, numbness, and sleep scores via a twice daily electronic diary. Subjects who meet inclusion criteria, including diary compliance, will undergo an in-clinic baseline evaluation (Day 1), be randomized, and start their treatments.~All subjects will return to the clinic for treatments as follows:~● Day 1 - 30: 6 treatments~* Week 1: 3 treatments~* Week 2-4: Weekly treatments~All subjects will return to the clinic for follow-up assessment at Day 30 (± 5 days). At the Day 30 visits subjects will be asked if they want to participate in Phase 2 of the study."
62463552|NCT05620225|SHAM_COMPARATOR|Sham + CMM|"Subjects will be consented, screened, and then undergo a 7-day baseline assessment period. Subjects will be asked to record pain, numbness, and sleep scores via a twice daily electronic diary. Subjects who meet inclusion criteria, including diary compliance, will undergo an in-clinic baseline evaluation (Day 1), be randomized, and start their treatments.~All subjects will return to the clinic for treatments as follows:~● Day 1 - 30: 6 treatments~* Week 1: 3 treatments~* Week 2-4: Weekly treatments~All subjects will return to the clinic for follow-up assessment at Day 30 (± 5 days). At the Day 30 visits subjects will be asked if they want to participate in Phase 2 of the study."
62463553|NCT01213901|EXPERIMENTAL|1|"Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.~Injections will be given in a random order and the technician will be blinded to the injection.~Each patient will evaluate the comfort of the injection by completing a visual analog scale."
62463554|NCT02307734|EXPERIMENTAL|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately.
62463555|NCT02307734|ACTIVE_COMPARATOR|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
62289983|NCT03109431|EXPERIMENTAL|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
62289984|NCT05790486|EXPERIMENTAL|The Intervention: Take a Break plus Nicotine replacement therapy (NRT) Sampling|Motivational text messages, challenge quizzes, goal-setting, coping mini-games, and recognition \& rewards. Nicotine lozenges will be given to all participants in both randomized groups.
62463556|NCT06433141|ACTIVE_COMPARATOR|bio-flex crown|bio-flex crown will be used as a final restoration for pulp treated primary molar, selection of suitable sized crown , it will be cement with glass ionomer cement after pulpotmy procdure clincal performance, parent satsification ,bacterial adherence will be evaluated with a follow up period 1 year
62463557|NCT06433141|ACTIVE_COMPARATOR|endo-crown|endo-crown will be used as a final restoration for pulp treated primary molar, after pulpotomy procdure endo-crown preperation design will be done and CAD/CAM, endo crown will be luted according to e-max protocol clincal performance, parent satsification ,bacterial adherence will be evaluated with a follow up period 1 year
62463558|NCT06433141|OTHER|zirconia crown|zirconia crown will be used as a final restoration for pulp treated primary molar, selection of suitable sized crown after preperation of tooth and use try-in kit to select siutable size ,zirconia is sensitive for blood contamination , it will be cement with glass ionomer cement after pulpotmy procdure clincal performance, parent satsification ,bacterial adherence will be evaluated with a follow up period 1 year
61906634|NCT02275884|SHAM_COMPARATOR|White chocolate (0% cocoa)|Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
62289985|NCT05790486|ACTIVE_COMPARATOR|The Comparison: Nicotine replacement therapy (NRT) Sampling without Take a Break|Nicotine lozenges will be given to all participants in both randomized groups. The goal of the comparison group is to isolate the effect of the Take a Break experience.
62289986|NCT05790486|EXPERIMENTAL|The Enhanced Program: Community Paramedicine Standard Plus Enhanced Implementation Program|The Enhanced Program will include strategies described in the Standard Program plus training of local champions.
62289987|NCT05790486|ACTIVE_COMPARATOR|The Standard Program: Community Paramedicine Standard Implementation Program|The standard program will include training, resources, and access to the e-refer tool.
62289988|NCT03205202|ACTIVE_COMPARATOR|Cocoa extract + multivitamin|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin"
62307994|NCT05739708|OTHER|Asthma patients|
61906635|NCT04034797|EXPERIMENTAL|Photo|
61906636|NCT04034797|ACTIVE_COMPARATOR|No photo|
61906637|NCT05683353||Patients with SARS-CoV-2 positive hematologic tumors|Patients with SARS-CoV-2 positive hematologic tumors over 18 years old excluding patients with severe diseases associated with other systems.
62463559|NCT05119439|NO_INTERVENTION|71-77 days of gestational age|Pregnant people whose pregnancies are estimated to have a gestational age of 71-77 days. (Participants in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
62463560|NCT05119439|EXPERIMENTAL|78-84 days of gestational age|Pregnant people whose pregnancies are estimated to have a gestational age of 78-84 days.
62463561|NCT00216463|EXPERIMENTAL|A|Slow load with every other week maintenance
62463562|NCT00216463|EXPERIMENTAL|B|Slow load with every other week maintenance
62463563|NCT00216463|EXPERIMENTAL|C|No load; once weekly maintenance
62289989|NCT03205202|ACTIVE_COMPARATOR|Cocoa extract + multivitamin placebo|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin placebo"
62289990|NCT03205202|ACTIVE_COMPARATOR|Cocoa extract placebo + multivitamin|"Dietary Supplement: Multivitamin~Dietary Supplement: Cocoa extract placebo"
62289991|NCT03205202|PLACEBO_COMPARATOR|Cocoa extract placebo + multivitamin placebo|"Dietary Supplement: Cocoa extract placebo~Dietary Supplement: Multivitamin placebo"
62289992|NCT02586805|EXPERIMENTAL|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
62289993|NCT02586805|EXPERIMENTAL|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
62289994|NCT02586805|EXPERIMENTAL|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
62289995|NCT02586805|PLACEBO_COMPARATOR|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
62289996|NCT00808444|EXPERIMENTAL|Synflorix Clinical Lot & Infanrix Group|Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
62289997|NCT00808444|EXPERIMENTAL|Synflorix Commercial Lot Infanrix Group|Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
62289998|NCT03266679|OTHER|Patients receiving metacognition-based intervention|Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker \& Klion) - weekly for a period of 12 months. No control/comparison group.
62289999|NCT03554044|EXPERIMENTAL|Cohort I (talimogene laherparepvec, chemotherapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with one of the following chemotherapies: paclitaxel (IV), nab-paclitaxel IV, or gemcitabine / carboplatin IV.~Cycles repeat every 21 days until disease progression or unacceptable toxicity"
62290000|NCT03554044|EXPERIMENTAL|Cohort II (talimogene laherparepvec, endocrine therapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-21 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses.~Cycles repeat every 28 days until disease progression or unacceptable toxicity"
62290001|NCT01666223|EXPERIMENTAL|Colesevelam|
62290002|NCT01666223|EXPERIMENTAL|Chenodeoxycholic acid|
62463564|NCT00216463|EXPERIMENTAL|D|No load; once weekly maintenance
62463565|NCT00216463|EXPERIMENTAL|E|No load; once weekly maintenance
62463566|NCT01614730|SHAM_COMPARATOR|Modified Neurotech Vital Device|Checking to see no contraction is stimulated during treatment with the Modified Neurotech Device
62463567|NCT01614730|ACTIVE_COMPARATOR|Neurotech Vital Device|Checking to see a contraction is stimulated during treatment of the Neurotech Vital Device
62092018|NCT06252662|EXPERIMENTAL|Bupivacaine plain with dexmedetomidine|Erector spinae plane block performed on the surgical side (left, right or bilateral) as appropriate based on planned surgical consent. Utilizing ultrasound to see the fascial layers and guide the needle placement under direct visualization. Block will include 0.25% bupivacaine plain 30 ml plus dexmedetomidine 0.5 mcg/kg per side of the block.
62290003|NCT01666223|EXPERIMENTAL|Colesevelam + chenodeoxycholic acid|
62463568|NCT06214208|EXPERIMENTAL|30 Hz Frequency|Intervention will be applied with a 30 Hz frequency.
62290004|NCT01666223|EXPERIMENTAL|Placebo|
62463569|NCT06214208|EXPERIMENTAL|50 Hz Frequency|Intervention will be applied with a 50 Hz frequency.
62463570|NCT06214208|EXPERIMENTAL|80 Hz Frequency|Intervention will be applied with an 80 Hz frequency.
62463571|NCT05567965|EXPERIMENTAL|Intensified home care intervention + Training|Users will receive an intensification in their home care intervention for dependence, receiving an intervention of a minimum of 1 hour per day and a maximum of 3.5 hours, to support their activities of daily living. The intensification will be personalised according to the specific needs of the user that the professionals consider necessary to attend. The weekly distribution of the intervention will be flexible in terms of timetables, as agreed between professional and informal caregivers. In addition, each informal caregiver will receive multimodal online training with the aim of providing knowledge, skills and attitudes that empower them to face the challenge of caring, guaranteeing quality care, preventing situations that may negatively affect both the person and the family dynamics and enabling an optimal evolution in caregiving.
62290005|NCT05689619|EXPERIMENTAL|Silibinin|Silibinin (STAT3 inhibitor) 1 g/day taken orally every day
62655785|NCT02712853||Control|"Age 18 months to 6 years without autism spectrum disorder (may have typical development or developmental delay without autism - as defined by negative MCHAT-R or negative ADOS-II evaluation)~Exclusion criteria include:~wards of the state active periodontal infection active upper respiratory infection"
62092019|NCT06417645|EXPERIMENTAL|BIS predicted vs real|After slow propofol induction and standard monitoring with BIS EEG monitor. The propofol infusion guided by iTIVA simulator (Android / iOS) using Eleveld kinetic model. LOC (defined as loss of response to loud call and shoulder movement-touch), the same concentration of propofol will be maintained for 5 minutes to assess EEG stability. .Intubation will proceed as usual, starting remifentanil at 4.5 ng/ml and rocuronium bromide 0.6 mg/kg. After 5 min and before the start of surgery, propofol will be infused at 15 mg/kg/h until 1% BSR is reached, observed on the BIS monitor, and then return to the rate that represents the LOC concentration. EEG data shall be retrieved from the BIS monitor via USB. Post hoc using the software tivatrainer.com we will simulate the Eleved calculated plasma concentration and the Bis prediction with our BIS real data.
62092020|NCT06697561|EXPERIMENTAL|Patient education group|"receives the Evidence-Based Education Program for people with hand dysfunction in scleroderma (which includes: educational handbook on self-care for hand dysfunction in scleroderma, multimedia teaching materials, and individualized consultations)."
62092021|NCT06697561|NO_INTERVENTION|control group|Receives usual care
62092022|NCT06341517|ACTIVE_COMPARATOR|Active|Active intermittent theta burst stimulation (iTBS) to the cerebellum at 80% of active motor threshold.
62092023|NCT06341517|PLACEBO_COMPARATOR|Placebo|Sham intermittent theta burst stimulation (iTBS) to the cerebellum
62092024|NCT06452706|EXPERIMENTAL|TQB2102 for injection|7.5mg/kg TQB2102, intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle.
62092025|NCT05550337|EXPERIMENTAL|Test: Trifarotene Cream, 0.005%|Trifarotene Cream, 0.005%, Apply to the affected areas of the face once daily for 84 days.
62092026|NCT05550337|ACTIVE_COMPARATOR|AKLIEF®|AKLIEF® (Trifarotene Cream, 0.005%), Apply to the affected areas of the face once daily for 84 days.
62092027|NCT05550337|PLACEBO_COMPARATOR|Vehicle Product|Vehicle of the Test Product, Cream, Apply to the affected areas of the face once daily for 84 days.
62092028|NCT04751864|EXPERIMENTAL|Active Arm|Participants receive active device for the full 8 week study
62092029|NCT04751864|SHAM_COMPARATOR|Sham Arm|Participants receive sham device for the first 4 weeks, and then at the week 5 cross over, receive the active device.
62092030|NCT02272465||Received blood products during transport|There is no intervention as this is an observational study. The first group will be the patients that received blood products during the helicopter transport from the scene of the injury per standard of care guidelines at the participating institutions.
62092031|NCT02272465||Received crystalloid during transport|There is no study intervention. The second group will be the patients that did not receive blood products during the helicopter transport because blood products are not available or part of the standard of care during flight.
62290006|NCT05689619|PLACEBO_COMPARATOR|Placebo|Placebo 1 g/day taken orally every day
62290007|NCT05808257|EXPERIMENTAL|Thulium Fibre Laser (TFL)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Thulium fibre laser (TFL)
62290008|NCT05808257|EXPERIMENTAL|Holmium:Yttrium-Aluminum-Garnet (Ho:YAG)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Holmium:Yttrium-Aluminum-Garnet (Ho:YAG) laser
62290009|NCT01470677|EXPERIMENTAL|application of Tachosil fibrin patches|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group.
62290010|NCT01470677|NO_INTERVENTION|Control group|In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
62290011|NCT00284830|ACTIVE_COMPARATOR|1|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
62290012|NCT00284830|NO_INTERVENTION|2|conventional dual-chamber pacing
62290013|NCT00382967|EXPERIMENTAL|Datscan Product|
62290014|NCT00382967|NO_INTERVENTION|Control|
62290015|NCT01734876|EXPERIMENTAL|Tactile Touch|Tactile Touch is given to the active arm
62290016|NCT01734876|ACTIVE_COMPARATOR|Rest To Music|Rest to Music. Rest for 30-60 minutes, aroma therapy, quit music in the background, well temepered room, lying position
62290017|NCT03424161|OTHER|Secret RF|Treatment with Secret RF for skin quality
62290018|NCT05121415||Experimental group:|patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
62290019|NCT05121415||Control group|patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
62290020|NCT01690845|NO_INTERVENTION|Control|Patients with severe HH will be treated with standard medical therapy (i.e. vasopressor support with norepinephrine in refractory hypotension = RR mean \< 65 mmHg, positive inotropic support with dobutamine if the central venous oxygen saturation \< 70%, renal replacement therapy in case of severe metabolic acidosis and/or renal failure, antibiotic treatment in case of suspected or proven infection, mechanical ventilation in case of severe hypoxemia or hypercapnia and/or GCS \<= 8.
62290021|NCT01690845|EXPERIMENTAL|MARS-Group|20 patients will be allocated by randomization to the MARS arm. Additionally to standard medical therapy they will receive 4 MARS sessions on three consecutive days, MARS® therapy will be applied for at least 12 hours per session. Thereafter, MARS® treatment will be continued if the patient still has increasing aminotransferase levels, requires vasopressor support or suffers from cholestasis (defined as serum bilirubin levels \> 5 mg/dL) for 3 sessions again. There will be a maximum of 7 MARS ® sessions per patient.
62290022|NCT04301427|OTHER|Obese patient|
62307995|NCT02846077||College students|College students will be monitored and will complete online surveys, install apps on their mobile phones, wear physiological sensors and provide saliva samples for later assay.
62307996|NCT06511661||R0 group|Patients with NSCLC who underwent R0 surgery according to the R stage proposed by IASLC.
62463572|NCT05567965|ACTIVE_COMPARATOR|Conventional home care intervention|Participants will continue with their conventional home care intervention for dependence, comprising activities that are mainly carried out at the users' home and are oriented towards supporting their activities of daily living. This intervention is of personalised attention and its average intensity is about 20 minutes per day.
62463573|NCT02804204||Anti-TNF|
62463574|NCT02069665|EXPERIMENTAL|Injection, medications and application|"Intravenous injection: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co., Ltd;~Medications: according to TCM syndrome differentiations;~* Wind-heat blocking lungs pattern (feng re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Zhi Ke San (herbal powder to relieve cough)~* Phlegm-heat blocking lungs pattern (tan re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Hua Tan San (herbal powder to remove phlegm)~External application: Fuxiong San"
62463575|NCT02069665|ACTIVE_COMPARATOR|Injection and medications|"Intravenous injection: Ribavirin Injection;~Medications: symptomatic therapies~* Guaifenesin Syrup, for removing phlegm, relieving gasp-cough;~* Ibuprofen Suspension, and salbutamol in case of different symptoms"
61906638|NCT05683353||People with SARS-CoV-2 positive without underlying diseases|People with SARS-CoV-2 positive without underlying diseases over 18 years old excluding people with severe diseases associated with other systems.
62290023|NCT06412692|EXPERIMENTAL|The Motivational Interviewing Technique|The Motivational Interviewing Technique Group (n=36) An equal number of patients will be classified by gender. Before the interview, each adolescent: Informed Consent Form, Personal Information Form, Social Anxiety Scale for Adolescents, Children's General Quality of Life Scale, and KINDL Epilepsy Quality of Life Module for Children will be applied. Interviews will be held in the training room next to the Child Neurology Polyclinic. In our study; The motivational interviewing technique will be applied to the experimental group individually by the researcher at 2-week intervals, including a preliminary interview and 6 motivational interview sessions. Each motivational interview will last approximately 40-50 minutes. One day before the motivational interview day, the experimental group will be informed by calling their registered phone numbers. The surveys will be re-administered after the end of the interview sessions. Surveys will be administered again after 1 month.
61906639|NCT05456282|EXPERIMENTAL|AMPS first, then SHAM|Participants will receive first one session of automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold. Then, after a 2-week washout, they will receive one session of a simulated automated mechanical peripheral stimulation (SHAM) with intensity at the sensory threshold.
62290024|NCT06412692|NO_INTERVENTION|No Intervention|No Intervention Group (n=36) Equal numbers of patients will be stratified according to gender. Adolescents without intervention; Patient Consent Form, Personal Information Form, Social Anxiety Scale in Adolescents, Child's General Quality of Life Scale, KINDL Epilepsy Quality of Life Module in Children will be applied. Routine follow-up and treatment will continue. The duration of the pre-interview and 6 motivational interviews will be calculated and the scales will be applied again.The surveys will be administered again after 1 month.
62307997|NCT06511661||R(un) group|Patients with NSCLC who underwent R(un) surgery according to the R stage proposed by IASLC.
62307998|NCT03797443|EXPERIMENTAL|AA NABPLAGEM|Ascorbic Acid Paclitaxel protein-bound cisplatin gemcitabine
62463576|NCT02904577||Training and validation cohort|"One cohort: from this cohort 2/3 of patients will be randomly separated after registration in training sample, to develop a prognostic model, and 1/3 in test sample, to validate the prognostic score obtained from the prognostic model.~The training cohort aims to develop a prognostic model and a resulting score, on the basis of clinical, biochemical and blood count parameters, in patients with non-follicular indolent lymphomas.~Intervention: any treatment, watch and wait policy included~The validation cohort is aims to assess the prognostic score on a collected set of data in parallel but independently of the sample training.~Intervention: any treatment, watch and wait policy included"
62463577|NCT00595062|EXPERIMENTAL|1|
62092032|NCT05709548|NO_INTERVENTION|control group|patients who undergo urgent laparoscopic cholecystectomy according to the usual technique without the administration of indocyanine green
62307999|NCT00098059|EXPERIMENTAL|Famciclovir, pediatric oral formulation|single-arm
62308000|NCT02677779|EXPERIMENTAL|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
62308001|NCT02677779|ACTIVE_COMPARATOR|Traditional surgery|Ulcer debridement with traditional surgery
62092033|NCT05709548|ACTIVE_COMPARATOR|intervention group|Patients who undergo urgent laparoscopic cholecystectomy for acute cholecystitis with the administration of indocyanine green preoperatively.
61906640|NCT05456282|SHAM_COMPARATOR|SHAM first, then AMPS|Participants will receive first one session of simulated automated mechanical peripheral stimulation (SHAM) with intensity at the sensory threshold. Then, after a 2-week washout, they will receive one session of automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold.
61906641|NCT02507037|EXPERIMENTAL|gum+PEG|used 2L PEG+sugarless gum
61906642|NCT02507037|PLACEBO_COMPARATOR|PEG|only used 2L PEG
62092034|NCT04795427|EXPERIMENTAL|asciminb arm|Patients will receive asciminib (40 mg BID continuous)
62092035|NCT04795427|EXPERIMENTAL|best available treatment arm|Patients will receive best available therapy chosen by investigator
62092036|NCT06189508|EXPERIMENTAL|A: Single NXT007 SC Injection Into Abdomen|
62092037|NCT06189508|EXPERIMENTAL|B: Single NXT007 SC Injection Into Upper Arm|
62092038|NCT06189508|EXPERIMENTAL|C: Single NXT007 SC Injection Into Thigh|
62092039|NCT06189508|EXPERIMENTAL|D: Single NXT007 IV Infusion|
62092040|NCT02609555|EXPERIMENTAL|TEM perineal Rectopexy|TEM perineal rectopexy: triple repair technique , Perineal rectopexy with a polyprolene mesh assisted by TEM technique, postanal repair to close the postanak space then finally anal cerclage to hold the rectum in place for one month.
62092041|NCT02153385|EXPERIMENTAL|Yoga group|Two yoga sessions per week for 8 weeks
62092042|NCT02153385|NO_INTERVENTION|Control group|Usual level of physical activity; no involvement in any yoga practice during the course of the study
62092043|NCT01620827|ACTIVE_COMPARATOR|Hospital Landline|Subjects in this arm have all of their follow-up phone calls placed from a hospital landline number.
62092044|NCT01620827|ACTIVE_COMPARATOR|Private Cell Phone|Subjects in this arm have all of their follow-up phone calls placed from a private cell phone number.
62092045|NCT02056119|ACTIVE_COMPARATOR|Jet Nebulizer Arm|"The Jet Nebulizer Protocol:~* Physician order received for subject, randomization to jet nebulizer occurred.~* Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~* Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~* Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
62092046|NCT02056119|EXPERIMENTAL|Vibrating Mesh Nebulizer Arm|"* Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~* Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~* Aerosol treatment delivered per physician order.~* Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
62092047|NCT05714670|NO_INTERVENTION|standard of care|patients will receive oral MMF initial dose of 1200 mg/m2/day, no more than 2000 mg/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day second regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids
62092048|NCT05714670|EXPERIMENTAL|Curcumin Oral Capsule group|"patients will receive oral 1000 mg of curcumin capsules daily in addition to their standard treatment for three months.~Standard treatment includes: oral MMF initial dose of 1200 mg/m2/day, no more than 2000 m g/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day~second regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids"
62463578|NCT05753605||Oura Ring Arm|Participant will be provisioned an Oura smartring.
62655786|NCT03661775|EXPERIMENTAL|controlled group|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour
62655787|NCT03661775|EXPERIMENTAL|Experimental group|group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
62655788|NCT02826213||Kidney : perfusion device lifeport|Each donor (n=140) will provide one kidney for pulsatile perfusion.
62655789|NCT02826213||Kidney : perfusion device waves|Each donor (n=140) will provide one kidney for continuous perfusion.
62655790|NCT01763229|EXPERIMENTAL|transthoracic echocardiography|
62655791|NCT05209698||Ethnic groups- Jews and Arabs|Data will be extracted from electronic medical records for all people with PD residing in a specific HMO district according to a record-based survey (e.g., individuals whose medical records include a diagnosis of PD). Currently, there are 2500 patients with PD in that district. In the second part of the study, a sub-sample of 100 Jewish and 100 Arab Patients with Parkinson's disease will be asked to answer standardized questionnaires.
62655792|NCT02026466||CAD with CTO|Subjects will have Coronary Artery Disease with a diagnosed Chronic Total Occlusion: a coronary artery with TIMI flow of zero(no flow) for at least three months.
62655793|NCT04075448|EXPERIMENTAL|Control - 50g Walnut|Control condition followed by experimental condition.
62655794|NCT04075448|EXPERIMENTAL|50 g Walnut - Control|Experimental condition followed by control condition.
62655795|NCT06461754||Succeeded Group (SG)|Group of patients who succeeded weaning from mechanical ventilation
62655796|NCT06461754||Failed Group (FG)|Group of patients who failed weaning from mechanical ventilation
62655797|NCT02190201|EXPERIMENTAL|videolaryngoscope|DLT intubation with McGrath videolaryngoscope
62655798|NCT02190201|ACTIVE_COMPARATOR|Direct laryngoscope|DLT intubation with Macintosh laryngoscope
62655799|NCT00757653|ACTIVE_COMPARATOR|1|Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
62655800|NCT00757653|EXPERIMENTAL|2|
62655801|NCT00757653|ACTIVE_COMPARATOR|3|
62655802|NCT04573270|EXPERIMENTAL|COVID-19 Patients Experimental|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
62655803|NCT04573270|PLACEBO_COMPARATOR|COVID-19 Patients Placebo|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
62092049|NCT04813042|EXPERIMENTAL|Working Out Dads|Fathers allocated to the Working Out Dads (WOD) arm will receive the intervention program. WOD is a 6-week manualised program. The weekly 90 minute sessions combine a one hour facilitated discussion by a male facilitator trained in delivery of WOD and a 30-minute gym workout provided by a personal trainer. The group size ranges from 6-10 fathers, with 14 groups running over the study period. The weekly sessions are provided in the evenings, in local gyms or a community setting (e.g., maternal child health centre, local council rooms, local hall, local park, Tweddle Child \& Family Health Service).
62463579|NCT05753605||BYOD (Bring Your Own Device) Arm|Participant will use their personal wearable.
62463580|NCT01817062||Neonates|Neonates with very low birth weight and surgery therapy of acute abdomen
62655804|NCT04573270|EXPERIMENTAL|Healthcare Providers Experimental|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
62655805|NCT04573270|PLACEBO_COMPARATOR|Healthcare Providers Placebo|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
62655806|NCT00733798|EXPERIMENTAL|1|
62655807|NCT03157089|EXPERIMENTAL|All patients|
62655808|NCT01110941|EXPERIMENTAL|SOL|single arm
62655809|NCT03318172|EXPERIMENTAL|Group C spinal cord stimulator|Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
62655810|NCT03318172|ACTIVE_COMPARATOR|Group H spinal cord stimulator|Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.
62655811|NCT04199520|EXPERIMENTAL|surgery combined with systemic therapy|surgery combined with systemic therapy
62655812|NCT04199520|ACTIVE_COMPARATOR|systemic therapy|systemic therapy
62655813|NCT00662337|EXPERIMENTAL|1|Diphenydramine HCl
62655814|NCT00963235|EXPERIMENTAL|1|
62655815|NCT02880423|OTHER|salpingectomy group I|salpingectomy during cesarean section for sterilization
62655816|NCT02880423|ACTIVE_COMPARATOR|tubal ligation group II|tubal ligation in cesarean section
62655817|NCT05948306|EXPERIMENTAL|Patient-centered skin care group|A patient-centered skin care protocol developed according to the Stetler Model will be applied to the experimental group.
62655818|NCT05948306|NO_INTERVENTION|Routine skin care group|The routine skin care of the ICU will be applied to the control group during the study.
62655819|NCT02034006|EXPERIMENTAL|Ranibizumab|Patients treated with a single ranibizumab 0.5 mg/0.05ml intravitreal injection
62655820|NCT02166112||Permacol mesh placement|No intervention performed
62655821|NCT03247309|EXPERIMENTAL|IMA201 Product|"* Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~* One dose of IMA201 product will be infused intravenously. Up to four dose levels will be evaluated. At least two patients per cohort will be treated.~* Post-infusion of IMA201 product, administration of low-dose recombinant human interleukin-2"
62655822|NCT05238662|ACTIVE_COMPARATOR|Group A|pedicle screw fixation on one side and intervertebral cage on the other sided
62655823|NCT05238662|ACTIVE_COMPARATOR|Group B|pedicle screw fixation and interbody cage on the same side
62655824|NCT00169832|EXPERIMENTAL|Rosiglitazone (Avandia)|
62655825|NCT00169832|PLACEBO_COMPARATOR|Placebo|
62655826|NCT03245606||Patients with Non Alcoholic Fatty Liver Disease|"Patients (240) will undergo a medical examination in order to analyse their medical history and check inclusion and non-inclusion criterions.~Then will be performed:~* a liver biopsy~* an abdominal MRI~* a transient elastography"
62092050|NCT04813042|ACTIVE_COMPARATOR|Usual Care|Fathers allocated to the Usual Care arm will receive the clinical care typically provided to parents experiencing mental health difficulties by an Early Parenting Centre or community health service. Within 2 weeks of baseline assessment, Usual Care participants will receive a brief psychological consultation from Tweddle's Clinical Manager.
62092051|NCT04649359|EXPERIMENTAL|Elranatamab (cohort A)|BCMA-CD3 bispecific antibody
62092052|NCT04649359|EXPERIMENTAL|Elranatamab (cohort B)|BCMA-CD3 bispecific antibody
62290025|NCT02103140|EXPERIMENTAL|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
62290026|NCT02103140|NO_INTERVENTION|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
62290027|NCT02103140|EXPERIMENTAL|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
62290028|NCT04968444|ACTIVE_COMPARATOR|one to one traditional physiotherapy|For clarity, 1-1 physiotherapy takes the form of a private consultation between patient and therapist. A discussion of symptoms is had and an individual physical examination is undertaken to explore what is mechanically causing their pain and what can be offered to help. This is also when the initial outcome scores are taken. Treatments are then offered which can take the form of exercise therapy, massage, and manual therapy. Symptoms are regularly monitored for effectiveness of treatment and adjusted accordingly. The number of sessions that forms their treatment is variable depending on response to treatment and how they are coping. At the final session the end outcome scores will be taken.
62308002|NCT03991637|EXPERIMENTAL|NICMP Spectral Reading|Non-invasive spectral data is collected from this arm to function as the intervention of interest.
62092053|NCT04060680|EXPERIMENTAL|Implant Attempt|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
62092054|NCT04060680|EXPERIMENTAL|Continued Access Implant Attempt|Continued Access for United States
62092055|NCT05101330|NO_INTERVENTION|Pilot Trial A, Usual Care arm|At recruitment, participants will be dispensed with new medication provided together with PMLs in English. After 2 weeks, data will be collected during a home visit and no changes will be made to the PMLs. After another 2 weeks, data will be collected and Rx Cap pill bottles will be retrieved.
62092056|NCT05101330|EXPERIMENTAL|Pilot Trial A, Intervention arm|At recruitment, participants will be dispensed new medication in Rx Cap pill bottles provided with PMLs in English. After 2 weeks, a home visit will be conducted, where the English PMLs will be switched out with bilingual PMLs. A final home visit will be done after another 2 weeks, and the labels will be switched back to the standard-issue PMLs issued by SGH, and the Rx Cap pill bottles will be retrieved.
62092057|NCT05101330|NO_INTERVENTION|Pilot Trial B, Usual Care arm|At recruitment, participants will be dispensed new medication in Rx Cap pill bottles provided with PMLs in English. After 2 weeks, data will be collected and Rx Cap bottles will be retrieved.
62092058|NCT05101330|EXPERIMENTAL|Pilot Trial B, Intervention arm|At recruitment, participants will be dispensed new medication in Rx Cap pill bottles, provided with bilingual PMLs. After 2 weeks, data will be collected accordingly during the home visit and Rx Cap bottles will be retrieved. Bilingual labels will be removed and participants will resume usage of standard-issue SGH PMLs.
62092059|NCT03185429|EXPERIMENTAL|Experimental|"Drug:Cyclophosphamide~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
62463581|NCT01883271|EXPERIMENTAL|High intensity aerobic interval training|Older adults will complete 8 weeks of high intensity aerobic interval exercise training.
62655827|NCT04841889|OTHER|Associated factors with decannulation|Collection of demographic, biological, ventilatory, respiratory and extra-respiratory parameters at the admission and the end of stay in the respiratory weaning center. Lung and diaphragm ultrasound, swallowing and muscles assessment will be performed.
62655828|NCT03739892|OTHER|stroke patients|stroke patients with upper limb motor deficit receiving standard care of rehab
62655829|NCT02902575|EXPERIMENTAL|Laparoscopic-assisted Gastrectomy|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
62655830|NCT05245162||Participants|Study participants with breast cancer
62655831|NCT05245162||Participants partner|Study participants partner
62655832|NCT04555447|EXPERIMENTAL|Healthy-agavins|Agavins are branched neo-fructans and were supplemented for a 5-week dose-escalation period in lean participants
62655833|NCT04555447|PLACEBO_COMPARATOR|Healthy-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in lean participants
62655834|NCT04555447|EXPERIMENTAL|Obese-agavins|Agavins are branched neo-fructans that were supplemented for a 5-week dose-escalation period in obese participants
62655835|NCT04555447|PLACEBO_COMPARATOR|Obese-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in obese participants
62655836|NCT04319705|EXPERIMENTAL|Azithromycin|Azithromycin, 500mg capsule, 3 times per week, during a 12-week period, administered orally
62655837|NCT04319705|PLACEBO_COMPARATOR|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP, capsule, 3 times per week, during a 12-week period, administered orally
62655838|NCT05888519|OTHER|FID123300/FID123301/FID122505|FID123300 ocular lubricant in Period 1, followed by FID12330 ocular lubricant in Period 2, followed by FID122505 ocular lubricant in Period 3, as randomized. For each period, the subject will receive one drop in each eye for one day. A 1-4 day washout will separate each period.
62655839|NCT05888519|OTHER|FID123301/FID122505/FID123300|FID123301 ocular lubricant in Period 1, followed by FID122505 ocular lubricant in Period 2, followed by FID123300 ocular lubricant in Period 3, as randomized. For each period, the subject will receive one drop in each eye for one day. A 1-4 day washout will separate each period.
62655840|NCT05888519|OTHER|FID122505/FID123300/FID123301|FID122505 ocular lubricant in Period 1, followed by FID123300 ocular lubricant in Period 2, followed by FID123301 ocular lubricant in Period 3, as randomized. For each period, the subject will receive one drop in each eye for one day. A 1-4 day washout will separate each period.
62655841|NCT02472405|ACTIVE_COMPARATOR|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
62655842|NCT02472405|ACTIVE_COMPARATOR|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
62655843|NCT02472405|NO_INTERVENTION|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
62655844|NCT02641054|EXPERIMENTAL|CVXL-0107 then cross-over to placebo|"Study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa.~Cross-over to placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa"
62463582|NCT01883271|EXPERIMENTAL|Continuous moderate intensity exercise|Older adults will complete 8 weeks of continuous moderate intensity exercise training.
62737314|NCT02789436|EXPERIMENTAL|L. reuteri Prodentis® lozenges|"15 subjects~Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). Probiotic lozenges are used twice daily for 28 days."
61906643|NCT04048278|EXPERIMENTAL|Lidocaine Hydrochloride|The IV bolus and infusions of lidocaine to those patients assigned to the lidocaine group will be started in the operating room and will continue until 24 h later. The group receiving the lidocaine infusion will first be administered a 1.0 - 1.5 mg/kg loading infusion over 5 minutes followed by a 1.0 - 1.5 mg/kg/h infusion for 24 h
61906644|NCT04048278|PLACEBO_COMPARATOR|Saline Solution for Injection|The group receiving the saline infusion will be administered an equivalent volume of saline infused over 5 min followed by a saline infusion at the same flow rate as that used in the lidocaine group for 24 h (1.0 - 1.5 mg/kg/hr)
61906645|NCT01361360||control|
61906646|NCT01361360||hypercapnia|
61906647|NCT01067924|EXPERIMENTAL|Motivational interviewing|
61906648|NCT01067924|ACTIVE_COMPARATOR|Standard of care|
62463583|NCT01883271|NO_INTERVENTION|Non-exercise control group|Older adults assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
62092060|NCT05660369|EXPERIMENTAL|Safety Run-In Phase|"* Participant enrollment will be staggered by 30 days for up to 3 participants.~* Participants will receive 1 infusion of CARv3-TEAM-E.~* Phase will be expanded up to 6 participants if any Dose-Limiting Toxicities DLTs occur.~* After all participants have been enrolled, there will be an evaluation made by the Data Safety Monitoring Board (DSMB) and the FDA to determine the safety of enrollment into additional arms."
62092061|NCT05660369|EXPERIMENTAL|Arm 1: Recurrent Glioblastoma (GBM), EGFRvIII Positive|"* Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw.~* CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36.~* Participants will be followed for 2 years post-treatment."
62092062|NCT05660369|EXPERIMENTAL|Arm 2: Newly Diagnosed GBM, EGFRvIII Positive|"* Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw.~* CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36.~* Participants will be followed for 2 years post-treatment."
62092063|NCT05660369|EXPERIMENTAL|Arm 3: Recurrent GBM, EGFRvIII Negative|"* Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw.~* CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36.~* Participants will be followed for 2 years post-treatment."
62092064|NCT04793100|EXPERIMENTAL|Follow-up for 1 year|
62092065|NCT02552511||Exposure|Perinatal factors exposure
62092066|NCT03356860|EXPERIMENTAL|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
62092067|NCT03356860|ACTIVE_COMPARATOR|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
62092068|NCT06036979|ACTIVE_COMPARATOR|Paravertebral Block Group|This group will receive combined general anaesthesia with preoperative ultrasound guide paravertebral plane block
62092069|NCT06036979|ACTIVE_COMPARATOR|Erector Spinae Block Group|This group will receive combined general anaesthesia with preoperative ultrasound guided erector spinae plane block
62092070|NCT06036979|OTHER|Control Group|This group will receive balanced general anesthesia using intravenous (0.1mg/kg) morphine, 30 mg ketorlac and 1 gm paracetamol).
62092071|NCT02925871|EXPERIMENTAL|Co-designed person-centred care transitions|Co-designed person-centred care transitions from stroke unit to rehabilitation in the home
62092072|NCT02925871|ACTIVE_COMPARATOR|Current care transitions|Current care transitions from the stroke unit to rehabilitation in the home
62092073|NCT05515536|EXPERIMENTAL|Vatiquinone|Participants with FA who were previously treated with vatiquinone at an investigational site and completed participation in a prior PTC Therapeutics (PTC)-sponsored clinical study will continue to receive the same dose/formulation of vatiquinone (unless there has been a change in age and/or weight that meets the criteria for a different dose/formulation as described below; dose/formulation will also be changed if participants meet the criteria for a different dose/formulation during study treatment): If \<7 years of age, participants will receive an oral solution (100 milligrams \[mg\]/milliliter \[mL\]) 3 times a day (TID) at one of the following doses: 15 mg/kilogram (kg) if body weight \<13 kg, or 200 mg if body weight ≥13 kg. If ≥7 years of age, participants will receive a capsule formulation (200 mg) orally TID at one of the following doses: 200 mg if body weight ˂25 kg, or 400 mg if body weight ≥25 kg.
62092074|NCT06310122|EXPERIMENTAL|Group (A) treatment group|Group (A) will receive extracorporeal shockwave therapy and (Ultrasound, stretching and strengthening exercises)
62092075|NCT06310122|EXPERIMENTAL|Group (B) traditional group|Group (B) will receive (Ultrasound, stretching and strengthening exercises)
62092076|NCT04002089|EXPERIMENTAL|Cohort 1 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.
62290029|NCT04968444|ACTIVE_COMPARATOR|BOOST workshop group|The BOOST workshop is a novel approach whereby participants are invited to a 2.5 hour interactive session. Subjective discussion at the start is had about how people are affected and impacted by their back pain, and outcome scores are completed. Then during the 2.5 hours there is a delivery of information and a practical exercise component to better inform the participants on how to manage their back pain and understand it better. Following this on 3 separate occasions, 1 month apart further top up information is sent to ensure they remember exercises and advice on practical management if a flare up occurs or they are struggling to fit activity in to day to day routines. Finally, at 3 months, there participants are invited back to complete the outcomes scores but also to discuss any concerns they are having and be given any advice to support them continuing with managing with any ongoing symptoms.
62092077|NCT04002089|EXPERIMENTAL|Cohort 2 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.
62290030|NCT03185689|EXPERIMENTAL|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
62092078|NCT04002089|EXPERIMENTAL|Cohort 3 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only
62092079|NCT04002089|ACTIVE_COMPARATOR|Cohort 4 - bupivacaine|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.
62092080|NCT06117683|ACTIVE_COMPARATOR|Bag mask ventilation with Adult Sotair device|The anesthesia provider will manually bag ventilate with the Adult Sotair® device for 3 minutes.
61906649|NCT02773108||Hospitalized|Hospitalized psychiatric patients
61906650|NCT02773108||Daily hospital|
61906651|NCT02773108||Outpatients|
62290031|NCT03185689|NO_INTERVENTION|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
62290032|NCT04002167|EXPERIMENTAL|Neurofeedback|The Neurofeedback group will receive 12 sessions of computerized cognitive intervention combined with neurofeedback in the lab.
62290033|NCT04002167|ACTIVE_COMPARATOR|Cognitive Training|The Cognitive Training group will receive 12 sessions of computerized cognitive intervention in the lab.
62290034|NCT04002167|NO_INTERVENTION|Waitlist|Both Neurofeedback and Cognitive Training groups will be assigned to waitlist before starting the corresponding intervention.
62290035|NCT06311032||Vignettes with Risk Stratification Tool|"Physicians will be posed with a series of three clinical case vignettes. Each vignette describes an IPMN of varying severity, and the physician will be asked determine whether they would continue or discontinue clinical surveillance in each case. Participants in this arm will be provided a risk stratification tool (DART-1) when presented with their clinical case vignettes.~The DART-1 is a 5-question tool which calculates the probability (%) of IPMNs without worrisome features or high-risk stigmata at diagnosis."
62290036|NCT06311032||Vignettes without Risk Stratification Tool|Physicians will be posed with a series of three clinical case vignettes. Each vignette describes an IPMN of varying severity, and the physician will be asked determine whether they would continue or discontinue clinical surveillance in each case. Participants in this arm will be not be provided a risk stratification tool when presented with their clinical case vignettes.
62290037|NCT04892563|EXPERIMENTAL|ESPB Block|Patients with rib fracture randomized to block group
62463584|NCT01883271|NO_INTERVENTION|Young Healthy controls|Young healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
62655845|NCT02641054|PLACEBO_COMPARATOR|Placebo then cross-over to CVXL-0107|"Placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa.~Cross-over to study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa"
62290038|NCT04892563|ACTIVE_COMPARATOR|Standard Care|Patients with rib fracture receiving IV analgesia/standard care
62290039|NCT05447702|EXPERIMENTAL|Camrelizumab + Apatinib + Chemotherapy|Participants received neoadjuvant therapy with four 4-week cycles of camrelizumab (200 mg, q2w) plus apatinib (250 mg, qd) and nab-paclitaxel (125 mg/m2, qw), followed by four 2-week cycles of camrelizumab (200 mg, q2w) plus apatinib (250 mg, qd) and epirubicin (90 mg/m2, q2w) + cyclophosphamide (600 mg/m2, q2w).
62290040|NCT02605525|EXPERIMENTAL|SM101 12 mg/kg|Human soluble recombinant Fcγ Receptor IIB
62463585|NCT05134792|NO_INTERVENTION|No intravenous immunoglobulin (IVIG)|The control group are burn patients with inclusion criteria that did not receive IVIG.
62655846|NCT05759910|PLACEBO_COMPARATOR|Placebo group|4 capsules per day containing 275mg of Maltodextrin
62655847|NCT05759910|EXPERIMENTAL|BrainPhyt High dose|4 capsules per day containing 275mg of BrainPhyt
62655848|NCT00485836|SHAM_COMPARATOR|Sham injection|
62655849|NCT00485836|EXPERIMENTAL|Ranibizumab injection 0.3 mg|
62655850|NCT00485836|EXPERIMENTAL|Ranibizumab injection 0.5 mg|
62655851|NCT05666973|ACTIVE_COMPARATOR|Group 1: Scalpel|"Skin Incision for inguinal hernia repair will be given by Stainless steel blade no.10.~Open Mesh Hernioplasty"
62655852|NCT05666973|EXPERIMENTAL|Group 2 : Electrocautery|"Open Mesh Hernioplasty~Skin Incision for inguinal hernia repair will be given by following:~* Cautery machine: Erbe VIO 300 S~* Cut setting: Cut:30 Coagulate:30~* Cautery tip (tip pointed)~* Mode: Monopolar"
62655853|NCT03810443|EXPERIMENTAL|pulmonary arterial hypertension|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
62655854|NCT03169439|OTHER|hepatic focal lesions and pancreatic masses|
62290041|NCT02605525|EXPERIMENTAL|SM101 24 mg/kg|Human soluble recombinant Fcγ Receptor IIB
62290042|NCT02605525|PLACEBO_COMPARATOR|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2
62463586|NCT05134792|EXPERIMENTAL|Intravenous immunoglobulin (IVIG) group|Pediatric burn patients between 1and 5 years with 10% or greater burn area of TBSA within 24 hours of onset of burn will receive intravenous immunoglobulin.
62655855|NCT01555814|EXPERIMENTAL|Amisulpride|For 4 weeks, all patients will be treated with amisulpride open label.
62655856|NCT03555929|EXPERIMENTAL|Dexamethasone|Dexamethasone 8 mg/2cc I.V. 90 minutes after axillary block
62655857|NCT03555929|PLACEBO_COMPARATOR|Normal saline|Normal saline 2cc I.V., 90 minutes after axillary block
62655858|NCT02022917|EXPERIMENTAL|Epithelial Ovarian Cancer|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab 21 day cycles of carboplatin, paclitaxel, and bevacizumab
62655859|NCT02059109|EXPERIMENTAL|Single|Staff will work alone to assemble the Belmont Rapid Infuser
62290043|NCT04345419|EXPERIMENTAL|Remdesivir|Remdesivir with standard of care treatment standard of care treatment
62463587|NCT01976377||Stage I, II, III, IV HNSCC|Stage I, II, III, IV HNSCC reveive treatment in NTUH
62463588|NCT03828058|EXPERIMENTAL|Envarsus XR|Envarsus XR orally administered Daily
62463589|NCT03828058|ACTIVE_COMPARATOR|Prograf|"Prograf PO administered twice daily Generic Name: tacrolimus~Dosage of prograf will be determined by trough levels and adjusted accordingly"
62463590|NCT05791032|EXPERIMENTAL|AtaCor EV-ICD Lead System|Subjects implanted with the AtaCor EV-ICD Lead
62463591|NCT04503993|EXPERIMENTAL|Hepatitis B Healthy Planet Arm|This is a single arm study where all patients eligible patients will receive a hepatitis B order set
62655860|NCT02059109|EXPERIMENTAL|Pair|Staff will work in pairs to assemble the Belmont Rapid Infuser
62655861|NCT03170713|ACTIVE_COMPARATOR|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
62655862|NCT03170713|ACTIVE_COMPARATOR|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
62655863|NCT03170713|PLACEBO_COMPARATOR|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
62655864|NCT01997658|EXPERIMENTAL|Methylprednisolone|Injection, 500 mg, single use, over 15 to 20 minutes.
62655865|NCT01997658|PLACEBO_COMPARATOR|Control|In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).
62655866|NCT02910232||1|The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.
62655867|NCT04780399|EXPERIMENTAL|Yangxue Qingnao pills high dose group|Yangxue Qingnao pills 7.5 g per time,2 times per day.
62655868|NCT04780399|EXPERIMENTAL|Yangxue Qingnao pills lower dose group|Yangxue Qingnao pills 5 g per time,2 times per day, and placebo identified to Yangxue Qingnao pills 2.5 g per time, 2 times per day.
62655869|NCT04780399|PLACEBO_COMPARATOR|Placebo group|Placebo identified to Yangxue Qingnao pills 7.5 g per time,2 times per day
62655870|NCT05948488||Children with cystic fibrosis|Children over 8 and under 18 with cystic fibrosis. Children must be represented by their parent.
62655871|NCT02202252|EXPERIMENTAL|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
62655872|NCT02202252|EXPERIMENTAL|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
62655873|NCT05230901|OTHER|Control group|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care
62655874|NCT05230901|EXPERIMENTAL|Spironolactone|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.)
62655875|NCT05230901|EXPERIMENTAL|Spironolactone + Dihydralazine|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.) + Dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg / d p.o. in fast acethylators, confirmed by genetic testing)
62655876|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
62655877|NCT03873532|EXPERIMENTAL|Active group|300 mg of surufatinib is given by oral administration once a day (QD) every 3 weeks;
62655878|NCT03873532|ACTIVE_COMPARATOR|Control group|In each 3-week cycle, Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID) for 2 weeks, followed by 1 week rest period (equivalent to 2500 mg/m2 total daily dose).
62655879|NCT04221971|EXPERIMENTAL|AML patients with NK cells infusion|The relapsed/refractory AML patient received Flu+CTX (Flu 25mg/m2 (-6d to -2d)，CTX 1.0g/m2 (-6d to -5d) and haploidentical NK cells infusion postchemotherapy for at least 48 hours. NK cell dose was over 1+E07/ kg with 3 consecutive infusions. NK cells infusion interval was 1 day.
62290044|NCT04345419|PLACEBO_COMPARATOR|Standard of care|Standard of care treatment alone.
62290045|NCT00627237|EXPERIMENTAL|Immediate start|Starts the 12 week intervention immediately after enrollment
62290046|NCT00627237|EXPERIMENTAL|Waitlist group|Starts the 12 week intervention 12 weeks after initial enrollment
62290047|NCT01765894||Normal glucose tolerance subjects|Healthy controls. If any medication then paused 3 days prior to test days. BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description.
62655880|NCT01701310|EXPERIMENTAL|Ferric carboxymaltose|
62655881|NCT01701310|ACTIVE_COMPARATOR|Ferrous Sulphate|
62655882|NCT05581563|ACTIVE_COMPARATOR|tourniquet use|knee replacement surgery with the aid of a tourniquet - a tight band placed around the thigh that restricts blood flow to the knee.
62655883|NCT05581563|SHAM_COMPARATOR|without tourniquet use|knee replacement surgery without the aid of a tourniquet - a tight band placed around the thigh that restricts blood flow to the knee.
62655884|NCT04814446|EXPERIMENTAL|Gardasil 9®|Nonavalent HPV vaccine
62290048|NCT01765894||DM2|"Type 2 diabetics in diet treatment or type 2 diabetics who have paused their oral medication for 3 whole days.~Insulin treatment is an exclusion criteria. If any other medication then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description."
62655885|NCT04814446|PLACEBO_COMPARATOR|Placebo|NaCl 0.9 % solution for injection
62655886|NCT05636943|EXPERIMENTAL|Adapted Intimacy Enhancement|Participants receive intimacy enhancement sessions and read a booklet about intimacy and metastatic breast cancer
62655887|NCT05636943|ACTIVE_COMPARATOR|Intimacy Facts & Resources|Participants read a booklet about intimacy and metastatic breast cancer.
62655888|NCT02349438|EXPERIMENTAL|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
62655889|NCT02349438|ACTIVE_COMPARATOR|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
62655890|NCT02064244||Acute renal failure in ICU|Ultrasound for measurement of Inferior Vena Cava size
62290049|NCT01765894||DM2 + Metformin|"Type 2 diabetics in metformin treatment. Insulin treatment is an exclusion criteria. If any other medication (besides from metformin) then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description"
62290050|NCT00734084|OTHER|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
62290051|NCT04752761|OTHER|DIG-PROMs-k|Patients who underwent TKA are given conventional and digital OKS surveys. Patients adhesion to both surveys will be compared.
62655891|NCT01160614|EXPERIMENTAL|ORF Tablets|ORF Tablets
62655892|NCT06478290|EXPERIMENTAL|curcumin, omega-3, and vitamin D (COD)|Acumin™Turmeric Complex/Dr. D's Ultra BioTurmeric: 500 mg/day (oral, 2 tablets taken by mouth), Vitamin D: 2500 IU/day (oral, 1 tablet taken by mouth), Omega-3: 900 mg day (oral, 1 tablet taken by mouth)
62655893|NCT04548245||Term|
62655894|NCT04548245||Preterm|
62655895|NCT03837847|EXPERIMENTAL|Health Coaching|Participants in this group will receive health coaching calls
62290052|NCT01433211||No treatment|
62290053|NCT01296048||Body Analysis|
62290054|NCT01261403|EXPERIMENTAL|Group 1|1 Unit of PDA001 or 4 units Vehicle Control intravenous on Day 0 and Day 7
62290055|NCT01261403|EXPERIMENTAL|Group 2|4 Units PDA001 or 4 units Vehicle Control intravenous (Placebo) on Day 0 and Day 7
62290056|NCT01261403|PLACEBO_COMPARATOR|Vehicle control|Placebo - Vehicle Control Arm
61906652|NCT03961698|EXPERIMENTAL|Cohort A (TNBC)|"IPI-549 in combination with front-line treatment. Cohort A will include two sub-cohorts: Cohorts A1 and A2.~Cohort A1: Approximately 30 patients with locally advanced and/or metastatic TNBC with programmed death-ligand 1 (PDL1) positive disease based on immunohistochemistry (IHC) defined as IC1/2/3.~Cohort A2: Approximately 30 patients with locally advanced and/or metastatic TNBC with PDL1 negative disease based on IHC defined as IC0."
61906653|NCT03961698|EXPERIMENTAL|Cohort B (RCC)|"IPI-549 in combination with front-line treatment. Cohort B will include two sub-cohorts: Cohorts B1 and B2.~Cohort B1: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 positive disease based on IHC defined as IC1/2/3.~Cohort B2: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 negative disease based on IHC defined as IC0."
61906654|NCT00444678|EXPERIMENTAL|Cetuximab, Capecitabine and Oxaliplatin|
61906655|NCT04796064|EXPERIMENTAL|low-intensity aerobic training group|
61906656|NCT04796064|EXPERIMENTAL|high-intensity aerobic training group|
61906657|NCT03968939|NO_INTERVENTION|Control group (Usual Care)|"Control Group (Usual Care): Participants do not use any type of sleep education or non-prescription sleep medications to assist with getting a good night's sleep."
61906658|NCT03968939|ACTIVE_COMPARATOR|Sleep Hygiene Education|"Sleep Hygiene Education: Participants are provided a Sleep Hygiene Education Brochure containing information about getting a good night's sleep."
61906659|NCT03968939|ACTIVE_COMPARATOR|Over-the-counter sleep aids (25 mg Benadryl + 3mg melatonin)|"Participants are given both:~1. Over-the-counter sleep aids:25 mg Diphenhydramine (Benadryl) and 3mg oral melatonin to be taken before bedtime;~2. and a Sleep Hygiene Education Brochure containing information about getting a good night's sleep."
61906660|NCT06156709|ACTIVE_COMPARATOR|Group I|"The patients will be given 10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Level of sensory block will be tested by testing with ice from S2 dermatome cephally.~Analgesia will be maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 5 ml of 0,125% bupivacain solution."
61906661|NCT06156709|ACTIVE_COMPARATOR|Group II|"The patients will be given 20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Analgesia will be maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 5 ml of 0,125% bupivacain solution."
61906662|NCT00627575|ACTIVE_COMPARATOR|Lamotrigine|Subjects will receive 40 milligram (mg) of Atrovastatin from Days 1-7, from Days 8-56 subjects will receive Lamotrigine and Subjects will receive 300 mg/day of Lamotrigine and 40 mg/day of atorvastatin each morning on Days 57-77.
61906663|NCT00627575|ACTIVE_COMPARATOR|phenytoin|Subjects will receive 40 mg of Atrovastatin from Days 1-7, from Days 8-28, subjects will receive 4mg/kg/day of phenytoin in the morning and will continue to take 40 mg/day of atorvastatin each morning. Subjects will receive taper dose of phenytoin from Days 29-30.
61906664|NCT03034239|EXPERIMENTAL|Insect protein group|Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
61906665|NCT03034239|PLACEBO_COMPARATOR|Placebo group|Exercise + isocaloric carbohydrate 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Carbohydrate supplementation (isocaloric to protein group) after each training + before sleep at training days, and once in the morning at non training days.
61906666|NCT00076453|EXPERIMENTAL|1|Participants will wear lateral wedge orthotic inserts.
61906667|NCT00076453|ACTIVE_COMPARATOR|2|Participants will wear standard orthotic inserts.
61906668|NCT06250335|EXPERIMENTAL|Arm 1|Patients receive prebiotic food-enriched snacks and supportive nutritional counseling to increase prebiotic foods in diet.
61906669|NCT06013813|EXPERIMENTAL|Distal radial approach|"* Clean and dry the puncture site.~* Simple lidocaine 2% is infiltrated.~* The artery is punctured in the radial distal zone, and a 6 Fr hydrophilic radial introducer is placed with the Seldinger technique.~* Verapamil 2.5 mg and Heparin 5000 IU are administered.~* PCI is performed.~* Finally, the introducer is withdrawn with the patent hemostasis technique, and a radial compression device is placed (prelude mostly or terumo)."
62463592|NCT05067647|EXPERIMENTAL|Thoracic, Urologic, Ear, Nose and Throat (ENT) Procedures|Any thoracic, urologic, or ENT procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use. Participants will be considered enrolled when the ENSEAL X1 device has been attempted to be used for a vessel transection during thoracic, urologic, or ENT procedures.
62463593|NCT03056937||Obese with metabolic syndrome|bariatric surgery
61906670|NCT06013813|ACTIVE_COMPARATOR|Conventional radial approach (proximal radial approach).|"* Clean and dry the puncture site.~* Simple lidocaine 2% is infiltrated.~* The artery is punctured in the radial proximal zone, and a 6 Fr hydrophilic radial introducer is placed with the Seldinger technique.~* Verapamil 2.5 mg and Heparin 5000 IU are administered.~* PCI is performed.~* Finally, the introducer is withdrawn with the patent hemostasis technique, and a radial compression device is placed (terumo)."
62463594|NCT03056937||Obese without metabolic syndrome|bariatric surgery
62463595|NCT03056937||Healthy|Control
61906671|NCT02730195|EXPERIMENTAL|Pioglitazone & TKI therapy|Patients receive pioglitazone PO QD on days 1-28. Patients also start or continue the same tyrosine kinase inhibitor (TKI) therapy at the pre-discontinuation doses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
61906672|NCT02649348|OTHER|pre-operative prehabilitation|Patients in the pre-operative prehabilitation group required the exercise intervention protocol, which included climbing six flights of stairs at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction following abdominal surgery by using a full elastic breathable abdominal bandage.
62463596|NCT03769844|EXPERIMENTAL|IV GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
62092081|NCT06117683|NO_INTERVENTION|Mechanical Ventilation|The anesthesia provider will remove the bag valve mask and Adult Sotair® device and connect the patient to the mechanical ventilator. The recording of pressure and flow will last for 3 minutes.
62092082|NCT00795132|ACTIVE_COMPARATOR|Related BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
62092083|NCT00795132|ACTIVE_COMPARATOR|Unrelated BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
62092084|NCT00795132|ACTIVE_COMPARATOR|Unrelated Blood Cord|Blood Cord donated from a donor unrelated to the participant/recipient
62092085|NCT05703542|EXPERIMENTAL|Dose Escalation BXCL701|"Dose escalation will occur using a 3+3 dose escalation approach, evaluating 4 different dose levels of BXCL701.~During each 28 day study cycle participants will take BXCL701 2x daily for up to 12 cycles."
62092086|NCT03491124|SHAM_COMPARATOR|Sham Treatment|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will also receive a sham intervention, pointing a laser pointer to the ear without turning the laser on.
62092087|NCT03491124|EXPERIMENTAL|Auricular Acupuncture|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will receive up to five ASP needles per ear placed in the predetermined BFA pattern. Needles are placed until the participant states pain is reduced 1/10.
62092088|NCT06059313||Behavioral variant of frontotemporal disorder (bvFTD)|A group of participants who fulfill Rascovsky criteria (2011) for behavioural variant Frontotemporal Dementia
62463597|NCT03769844|EXPERIMENTAL|SQ GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
62655896|NCT03837847|ACTIVE_COMPARATOR|Control group|Participants in this group will receive 6 educational guides
62655897|NCT02346604||Mild COPD|Symptomatic smokers with mild COPD
62655898|NCT02346604||Healthy Control|Non-smokers, matched to mild COPD group for age (at least 50 years) and gender
62655899|NCT05612321|ACTIVE_COMPARATOR|Traditional supine position|Participants enrolled in the Control Group undergo vacuum-assisted delivery in traditional supine position (supine with 90 degrees bended legs on footrests)
62655900|NCT05612321|EXPERIMENTAL|All-fours position|Participants enrolled in Experimental Group experience vacuum application in all-fours position.
62655901|NCT06515782|EXPERIMENTAL|Arm 1: FMD + Mediterranean Diet|In the first 6 months, participants will start the Mediterranean diet and undergo 3 cycles of FMD. Participants will then switch to the Mediterranean diet alone for another 6 months.
62655902|NCT06515782|ACTIVE_COMPARATOR|Arm 2: Mediterranean Diet + FMD|Participants will start with Mediterranean diet alone for the first 6 months and after that they will undergo FMD for 3 cycles while still on a Mediterranean diet.
62655903|NCT00675350|EXPERIMENTAL|Homoharringtonine|
62655904|NCT01860989|EXPERIMENTAL|Cohort 1|6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
62655905|NCT01860989|EXPERIMENTAL|Cohort 2|6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
62655906|NCT01860989|EXPERIMENTAL|Cohort 3|6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
62655907|NCT01860989|EXPERIMENTAL|Cohort4|6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
62655908|NCT06209242|EXPERIMENTAL|Cast immobilization|Using cast immobilization with sugar tong and short arm splinting
62655909|NCT06209242|EXPERIMENTAL|Percutaneous pinning|Using k-wire percutaneous pinning
62655910|NCT00720278|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo nasal spray
62655911|NCT00720278|EXPERIMENTAL|Astepro 0.1%|0.1% azelastine hydrochloride nasal spray
62655912|NCT00720278|EXPERIMENTAL|Astepro 0.15%|0.15% azelastine hydrochloride nasal spray
62655913|NCT03355027|EXPERIMENTAL|Alirocumab Treatment Arm|30 patients with stable cardiovascular disease to receive Alirocumab 150mg \& prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
62655914|NCT03355027|ACTIVE_COMPARATOR|Comparator Treatment Arm|30 patients with stable cardiovascular disease to receive Ezetimibe 10mg \& prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
62655915|NCT04658589|EXPERIMENTAL|Laparoscopic distal gastrectomy|Laparoscopic distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
61906673|NCT02649348|NO_INTERVENTION|Comparator|Patients in the control group did not need to undergo this pre-rehabilitation protocol and prepared conventionally.
62655916|NCT04658589|ACTIVE_COMPARATOR|Open distal gastrectomy|Open distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
62655917|NCT05234671|EXPERIMENTAL|Exercise group|The exercise group will perform a supervised combined (e.g., aerobic and resistance training) 12-week exercise programme, twice per week adjunct to the patient's standard care.
62655918|NCT05234671|NO_INTERVENTION|Control group|The control group will not perform the exercise programme and will receive only the standard care.
62092089|NCT06059313||Phenocopy frontotemporal dementia (phFTD)|A group of participants who fulfill who fulfill Rascovsky criteria (2011) for possible behavioural variant Frontotemporal Dementia and have no imaging abnormalities.
62655919|NCT05814796||Obese patients|BMI\>30
62655920|NCT05814796||Non obese|Overweight: BMI = 25-29.9 Normal weight: BMI = 18.5-24.9
62655921|NCT02875080|EXPERIMENTAL|OPC-34712 disintegrating tablet with water|OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
62655922|NCT02875080|EXPERIMENTAL|OPC-34712 disintegrating tablet without water|OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
62655923|NCT02875080|EXPERIMENTAL|OPC-34712 conventional tablet with water|OPC-34712 (4 mg) conventional tablet is administered with water.
62655924|NCT03315637|EXPERIMENTAL|Fetoscopic repair of spina bifida|This is a single arm study, all patients will receive a fetoscopic repair of the spina bifida
62655925|NCT06024122||Patients with a mTBI|Children with a mTBI aged 3 to 5 years (i.e., up to 71 months and 31 days, i.e., before the 6th birthday) recruited from the paediatric emergency department of Rennes University Hospital.
62655926|NCT06024122||Control with an orthopaedic injury|Children with an orthopaedic injury aged 3 to 5 years (i.e., up to 71 months and 31 days, i.e., before the 6th birthday) recruited from the paediatric emergency department of Rennes University Hospital.
62655927|NCT03024372|ACTIVE_COMPARATOR|Conventional sutures|AV fistula creation with sutures
62092090|NCT06059313||Frontal variant of Alzheimer disease|A group of participants who fulfill Ossenkopele criteria (2022)
62092091|NCT06059313||Bipolar disorder|A group of participants who fulfill CIM 10 criteria
62092092|NCT06495411|EXPERIMENTAL|pranayama-|Patients will perform breathing exercises every two hours from the 4th hour after surgery until discharge. Then, their pain will be evaluated with the Visual analog scale before and after exercise at the 6th hour, 12th hour, 24th hour and at discharge.
62092093|NCT06495411|EXPERIMENTAL|deep breathing -|Patients will perform breathing exercises every two hours from the 4th hour after surgery until discharge. Then, their pain will be evaluated with the Visual analog scale before and after exercise at the 6th hour, 12th hour, 24th hour and at discharge.
62092094|NCT06495411|EXPERIMENTAL|control|Patients will not undergo any postoperative intervention. Then, their pain will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
62092095|NCT01000870|EXPERIMENTAL|Access MNI-513 and PET Imaging|
62092096|NCT06285773|ACTIVE_COMPARATOR|Group PR = RIFPB and PIFB group|Recto-intercostal fascial plane block (RIFPB) and Pecto-intercostal fascial plane block (PIFB) will be applied
62092097|NCT06285773|OTHER|Group Control|No block will be applied.
62092098|NCT05446662|NO_INTERVENTION|control group|After randomization, the patients in the control group will be given pre- and post-operative nursing care without any intervention.
62092099|NCT05446662|EXPERIMENTAL|case group|Patients in the case group after randomization will choose one or more of the music therapy, aromatherapy, progressive relaxation exercises and massage therapies according to their health care needs.
62092100|NCT01738711|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy|Patient in this arm receive 2-6 sessions of cognitive behavioural therapy
61906674|NCT02893579|EXPERIMENTAL|Early Intervention|Stress reduction intervention 1 time a month
62092101|NCT01738711|PLACEBO_COMPARATOR|Written information on CBT|Patients in this arm do not receive sessions of CBT but receive written information on anxiety control as per standard practice
62092102|NCT01125202|EXPERIMENTAL|SCT-based behavioral intervention|Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary counseling intervention based on Social Cognitive Theory. Dietary counseling is paired with Personal Digital Assistant-based dietary self-monitoring.
62655928|NCT03024372|ACTIVE_COMPARATOR|Anastoclips|AV fistula creation with clips
62655929|NCT04158609||Group 1|Pregnant women with CPR value below 1, based on Doppler indices assessment
62655930|NCT04158609||Group 2|Pregnant women with CPR value equal to or above 1, based on Doppler indices assessment
61906675|NCT02893579|EXPERIMENTAL|Delayed Intervention|Wait list Control
62092103|NCT01125202|ACTIVE_COMPARATOR|Attention control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
62092104|NCT01643395|EXPERIMENTAL|vertebroplasty|
62092105|NCT01643395|OTHER|conservative therapy (brace)|
62092106|NCT00508976|EXPERIMENTAL|3|
62092107|NCT00508976|EXPERIMENTAL|2|
62092108|NCT00508976|EXPERIMENTAL|4|
62092109|NCT00508976|ACTIVE_COMPARATOR|1|
62092110|NCT06647303|EXPERIMENTAL|Surgical candidate|Participants who are undergoing surgical consultation
62655931|NCT02196831|EXPERIMENTAL|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
62655932|NCT02196831|PLACEBO_COMPARATOR|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
62655933|NCT04034472|OTHER|Cardiometabolic risk in women with obesity|The use of interactive digital technology as adjuvant tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However. it was note fully investigated if this can contribute to decrease inflammatory markers in obese women. In the present investigate it was amied to evaluate the effects of clinical approach associated to use of electronic means on inflammatory markers in women with obesity.
62655934|NCT01842204|EXPERIMENTAL|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
62655935|NCT01842204|PLACEBO_COMPARATOR|non-active kit|Patient receives a non-active kit.
62092111|NCT06647303|EXPERIMENTAL|Stakeholder Focus Group|Participants have previous experience with surgery
62092112|NCT06647303|EXPERIMENTAL|Surgeons|Surgeons from the University of Wisconsin-Madison Department of Surgery with an outpatient surgical clinic who treat adult patients at UW Health
62092113|NCT04734041|OTHER|Integrative Medicine|Anti-inflammatory (Mediterranean) diet, as well as general behavioral and psychosocial support.
62092114|NCT05012930|EXPERIMENTAL|Study Provided Diet - Meat|A group of complementary foods provided to participants by researchers.
62092115|NCT05012930|EXPERIMENTAL|Study Provided Diet - Plant|A group of complementary foods provided to participants by researchers.
62092116|NCT05012930|EXPERIMENTAL|Study Provided Diet - Dairy|A group of complementary foods provided to participants by researchers.
62092117|NCT05012930|PLACEBO_COMPARATOR|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
62092118|NCT03456063|EXPERIMENTAL|Arm A: Atezolizumab + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy~Platinum-based chemotherapy may include:~* carboplatin + pemetrexed~* carboplatin + nab-paclitaxel~* cisplatin + pemetrexed~* cisplatin + gemcitabine~Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab"
62092119|NCT03456063|PLACEBO_COMPARATOR|Arm B: Placebo + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy~Platinum-based chemotherapy may include:~* carboplatin + pemetrexed~* carboplatin + nab-paclitaxel~* cisplatin + pemetrexed~* cisplatin + gemcitabine~Participants will receive best supportive care and monitoring after surgery"
62092120|NCT03020355|EXPERIMENTAL|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
62092121|NCT03020355|ACTIVE_COMPARATOR|not Placental Blood Drainage|In the control group, the clamped cord will not released.
62092122|NCT06422026|ACTIVE_COMPARATOR|APCP I|
62092123|NCT06422026|ACTIVE_COMPARATOR|APCP II|
62092124|NCT06422026|PLACEBO_COMPARATOR|Placebo|
62092125|NCT02205879|EXPERIMENTAL|pregabalin|
62092126|NCT02205879|PLACEBO_COMPARATOR|Placebo|
62092127|NCT01091181|ACTIVE_COMPARATOR|high incision group|hysterotomy at cesarean performed 2 cm above plica vesicouterina
62092128|NCT01091181|ACTIVE_COMPARATOR|low incision group|hysterotomy at cesarean performed 2 cm below plica vesicouterina
62092129|NCT06528132|EXPERIMENTAL|social worker-led MBI (enhanced with peer supporters)|Participants in the social worker-led modified MBI group will receive mindfulness training from social workers. In addition, they will receive support from peer supporters.
62092130|NCT06528132|EXPERIMENTAL|social worker-led MBI (without peer supporters)|Participants in the social-worker led modified MBI group will receive mindfulness training from social workers.
62655936|NCT01731548|EXPERIMENTAL|study arm|"For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy（1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks）"
62655937|NCT01731548|ACTIVE_COMPARATOR|control arm|"For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
62655938|NCT00847314||Group 1|
62655939|NCT00482833|EXPERIMENTAL|ARM A - ATO/ATRA|
62655940|NCT00482833|ACTIVE_COMPARATOR|ARM B - ATRA|
62655941|NCT05375318||Adults patients with astrocytoma grade 4|
61906676|NCT05397704|EXPERIMENTAL|desaturation|Controlled desaturation studies are conducted by changing the alveolar oxygen tension (or pressure, PAO2). This is achieved by a dedicated gas delivery system, RespirAct RAMR (Thornhill Research, Toronto, ON). The attained PAO2 then determines the arterial oxygen tension (PaO2) at the alveolar-arterial interspace in the lung. The arterial oxygen tension (PaO2) will then determine the arterial oxygen saturation (SaO2) and in turn, the pulse oximeter oxygen saturation (SpO2). The step down changes in the alveolar oxygen tension (PAO2) will result in the corresponding step down changes in SaO2/SpO2 from 100 to 70%.
62092131|NCT06528132|NO_INTERVENTION|Care as usual group|The care as usual group will receive usual service provided in District Elderly Community Centres (DECC) and Integrated Community Centre for Mental Wellness (ICCMW).
61906677|NCT02294968|EXPERIMENTAL|Family Startup|Family Startup plus usual pre- and postnatal care
61906678|NCT02294968|NO_INTERVENTION|Control|Usual pre- and postnatal care
62092132|NCT04068597|EXPERIMENTAL|CCS1477 dose escalation NHL/MM|CCS1477 monotherapy
62092133|NCT04068597|EXPERIMENTAL|CCS1477 dose escalation AML/Higher risk MDS|CCS1477 monotherapy
62092134|NCT04068597|EXPERIMENTAL|CCS1477 expansion phase NHL/Peripheral T-cell lymphoma|CCS1477 monotherapy
62308003|NCT03991637|ACTIVE_COMPARATOR|Venipuncture CMP|"A standard CMP blood draw is performed to function as the gold standard reference value.~Specifically, the outcome of the experimental arm is cross-validated against the active comparator arm to determine the NICMP accuracy, relative to the venipuncture method."
62092135|NCT04068597|EXPERIMENTAL|CCS1477 monotherapy expansion and combination dose finding and expansion - MM|CCS1477 monotherapy, CCS1477 combination with pomalidomide-dexamethasone
62092136|NCT04068597|EXPERIMENTAL|CCS1477 monotherapy expansion and combination dose finding and expansion - AML|CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax
62308004|NCT04430348|EXPERIMENTAL|PTX-35 Dose Level 1|Dose Level 1: PTX-35 0.01 mg/kg
62308005|NCT04430348|EXPERIMENTAL|PTX-35 Dose Level 2|Dose Level 2: PTX-35 0.03 mg/kg
62655942|NCT03662568|EXPERIMENTAL|Part A:Group A|Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.
62655943|NCT03662568|EXPERIMENTAL|Part A:Group B|Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.
62655944|NCT03662568|EXPERIMENTAL|Part B:Group C|Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.
62655945|NCT03662568|EXPERIMENTAL|Part B:Group D|Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.
62655946|NCT06532942|EXPERIMENTAL|(Part A) MKND-201 SAD|Part A involves a Single Ascending Dose (SAD) study with three cohorts. In each cohort, participants will receive a single dose of MKND-201 or placebo for one day. The doses will be categorized as Target Dose, High Dose, and Very High Dose. Allocation is randomized and double-blind, maintaining a ratio of 3:1 (MKND-201:placebo). Participants will use a breath-powered inhaler, which aerosolizes the powder for lung delivery
62655947|NCT06532942|EXPERIMENTAL|(Part B) MKND-201 MAD|Part B involves a Multiple Ascending Dose (MAD) study with two cohorts. In each cohort, participants will receive MKND-201 or placebo twice daily (BID) at either the Target Dose or High Dose. Allocation is randomized 3:1 (MKND-201:placebo) and double-blind. Participants will use a breath-powered inhaler, which aerosolizes the powder for lung delivery
62092137|NCT04068597|EXPERIMENTAL|CCS1477 monotherapy expansion and combination dose finding and expansion - Higher risk MDS|CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax
62463598|NCT03769844|EXPERIMENTAL|IV GM-CSF 250 mcg/m2/dose|If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
62463599|NCT03769844|EXPERIMENTAL|SQ GM-CSF 250 mcg/m2/dose|If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
62092138|NCT03941301|EXPERIMENTAL|Bright treatment light|
62092139|NCT03941301|PLACEBO_COMPARATOR|Red light|
62655948|NCT06532942|PLACEBO_COMPARATOR|Placebo|Administered as a single dose or BID using the same number of cartridges as MKND-201 participants in the same cohort
62092140|NCT06032949|OTHER|Vialize|Vialize is a lyophilized dehydrated complete human placental membrane allograft.
62655949|NCT01694238|ACTIVE_COMPARATOR|Cruciate incision|Cruciate incision in the abdominal wall fascia
61906679|NCT06148649|EXPERIMENTAL|HEC88473 dose1|T2DM subjects, receiving a weekly dose of HEC88473 dose1
62092141|NCT02656043|ACTIVE_COMPARATOR|XPF-005|Active treatment: XPF-005 Gel
62092142|NCT02656043|PLACEBO_COMPARATOR|Vehicle gel|Placebo: XPF-005 Vehicle Gel
62092143|NCT04714411||Retrospective Cohort|A historical matched case cohort
62092144|NCT04714411||Prospective Cohort|Subjects will be screened daily via review of the EMR reports of inpatient admissions. Those receiving antibiotics with a notated source of skin/soft tissue infection or OM will be further reviewed to determine if the source of infection is a DFI with or without suspected or confirmed Acute osteomyelitis.
62092145|NCT05468203|EXPERIMENTAL|Dapagliflozin|Dapaliflozin 10mg tablet administered once daily while in ICU for up to 30 days
62092146|NCT05468203|PLACEBO_COMPARATOR|Matched Placebo|Matched placebo tablet administered once daily while in ICU for up to 30 days
62092147|NCT06576193|EXPERIMENTAL|Safe Dates for Young Parents (SDYP)|Participants will receive and complete SDYP intervention activities focused on healthy relationships and intimate partner violence (IPV) prevention plus standard services offered at the study site.
62092148|NCT06576193|NO_INTERVENTION|Standard Services Only|Participants will only receive standard-of-care programming that typically includes services such as one-on-one strength-based case management and comprehensive sex education. The standard services will not address IPV or healthy relationships content that composes the SDYP intervention. Referrals to additional services will be offered to all participants, as needed.
62463600|NCT01063556|EXPERIMENTAL|1|
62463601|NCT01063556|EXPERIMENTAL|2|
62092149|NCT03808922|EXPERIMENTAL|Cohort 1 and Cohort 2 Treatment|DAS181 4.5mg qd x 7 OR 10 days
62463602|NCT02457520|EXPERIMENTAL|Single treatment arm|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
62463603|NCT01113606|ACTIVE_COMPARATOR|Obagi Nu-Derm System (ONDS)|
62463604|NCT01113606|ACTIVE_COMPARATOR|Standard of Care|
62092150|NCT03808922|PLACEBO_COMPARATOR|Cohort 1 and Cohort 2 Placebo|Placebo qd x 7 OR 10 days
62463605|NCT02019290|EXPERIMENTAL|bitopertin-Midazolam|
62463606|NCT02612337|EXPERIMENTAL|OTO-104|12 mg dexamethasone
62463607|NCT02612337|PLACEBO_COMPARATOR|Placebo|
62463608|NCT01202448|ACTIVE_COMPARATOR|DLBCL with risk factor|Patients have any of risk factors for secondary CNS involvement
62655950|NCT01694238|EXPERIMENTAL|Circular incision|Circular incision in the fascia
62655951|NCT01694238|EXPERIMENTAL|Mesh enforced cruciate incision|Mesh enforcement and then cruciate incision in the abdominal wall fascia
62655952|NCT01269944||Medial compartment knee osteoarthritis|Patients with medial compartment osteoarthritis of the knee, as proven by x-rays and clinical examination
62655953|NCT03200821|EXPERIMENTAL|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
62290057|NCT04194060|EXPERIMENTAL|Enhanced recovery after surgery group|"ERAS GROUP~* Tracheal intubation.~* Short acting anesthetic agents,avoid opioid agents~* Omental patch repair with placement of sub hepatic drain~* Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~* Post operative nausea and vomiting prophylaxis.~* Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~* Initiation of feeding-Oral sips on day 1, step up day 2 onward~* Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~* Removal of urinary catheter-after weaning from the effect of general anesthesia.~* Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~* Avoid opiod analgesics."
62290058|NCT04194060|ACTIVE_COMPARATOR|Conventional group|"CONVENTIONAL GROUP~* Tracheal intubation~* Short acting anesthetic agents, avoid opiod anesthesia agents.~* Omental patch repair along with sub hepatic drain placement.~* Post operative nausea and vomiting prophylaxis.~* Ambulation-as per patients' own request.~* Initiation of oral feed- after passage of 1st flatus.~* Nasogastric tube removal-output \<300ml/day with resolution of ileus.~* Removal of urinary catheter- when patient sits on bed side/ambulate.~* Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~* Patient will receive opiod analgesics.~I"
62463609|NCT04725708|EXPERIMENTAL|normoxy|"Group 1(n=50) FiO2%40, PaO2\<180 ve PaO2≥80mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored.~An rSO2 less than 45% triggered an alarm, the anesthesiologist timed the event, and after 60 seconds initiated an intervention protocol means; PaO2 levels were checked, PaO2\> 100 mmHg was achieved, if not improved, pump blood flow, mean arterial pressure were increased, if there is still no response and hematocrit \<20%, patients were scheduled for erythrocyte transfusion until the rSO2 was restored to at least 60% at both probes.In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months."
62290059|NCT06213428|ACTIVE_COMPARATOR|Active: Probiotic|"Progressive Perfect Probiotic 120 Billion CFU containing the following strains will be used:~Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium animalis subsp.lactis, Bifidobacterium breve, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium bifidum, Bifidobacterium longum subsp. Longum.~Participants will be required to take one capsule a day, for 28 days."
62290060|NCT06213428|PLACEBO_COMPARATOR|Placebo Probiotic|A placebo that is identical in capsule size and colour to the active probiotic capsule will be used. This will ensure participants and experimenters are masked during each intervention period. Participants will be required to take one capsule a day for 28 days.
62463610|NCT04725708|EXPERIMENTAL|hyperoxia|Group 2(n=50) FiO2%100, PaO2≥180mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored..In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months.
62463611|NCT05292651|EXPERIMENTAL|PSP technique|"The definitions of the PSP technique are:~* Predilatation is mandatory with a balloon diameter equal to or maximally 0.5 mm less than the distal reference vessel diameter. We hypothesize that this lesion preparation and fracture of the calcium may result in better stent apposition, less recoil and higher minimal stent area (MSA) Also see endpoints.~* The DES should be deployed at 2 atm. above the nominal pressure. This relatively low stent deployment pressure may prevent stent edge dissections.~* The postdilatation is mandatory with a shorter length and (at least 0.25mm) larger diameter non-compliant balloon at 16 atm. The apposition, minimal stent area (MSA) and recoil may improve with this large, high pressure postdilatation. The slightly shorter balloon can prevent edge dissections."
62463612|NCT05292651|ACTIVE_COMPARATOR|Direct Stenting|• The DES is directly placed without any lesion preparation and deployed at a pressure at the discretion of the operator. Ideally a pressure would be achieved in which angiographic expansion of the DES is complete (without significant dog-boning)
62463613|NCT04807270|ACTIVE_COMPARATOR|T-LAB / PRP KIT|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP KIT injection in 3 sessions will be applied.
62463614|NCT04807270|ACTIVE_COMPARATOR|T-LAB / PRP INJECTION SYRINGE|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied.
62463615|NCT04807270|ACTIVE_COMPARATOR|SALINE|In the first group, Platelet-rich plasma (PRP) prepared with SALINE injection in 3 sessions will be applied.
62290061|NCT04850183|EXPERIMENTAL|Intervention group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the intervention group at baseline. The patients were assigned to the intervention group at random and participated in a one-to-one training program consisting of a 30-min onset session. The Rheumatoid Arthritis Patient Education Booklet prepared by the researchers was administered to patients in the intervention group during education. In the 3rd month, all forms were applied again to the patients in the intervention group.
62290062|NCT04850183|NO_INTERVENTION|Control group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the control group at baseline. In the 3rd month, the same forms were applied to the untrained patients in the control group.
62463616|NCT03408119|EXPERIMENTAL|Group A|100g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
62463617|NCT03408119|EXPERIMENTAL|Group B|50g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
62463618|NCT03408119|PLACEBO_COMPARATOR|Group C|800 IU vitamin D and 450 mg elemental calcium
62463619|NCT02175238|EXPERIMENTAL|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
62463620|NCT02175238|ACTIVE_COMPARATOR|BI 691751 fasted|single dose BI 691751 in fasted state
62463621|NCT05437549|OTHER|PVI|
62463622|NCT06496516||Hospitalized patients with flare of ulcerative colitis|
62655954|NCT03200821|ACTIVE_COMPARATOR|Gemcitabine|1000 µg/m\^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
62655955|NCT06098040|EXPERIMENTAL|group 2 - FGM continuous|Patients will be asked to wear the sensor FreeStyle Libre2 continuously
62092151|NCT03808922|EXPERIMENTAL|Cohort 3|DAS181 4.5mg qd x 7 OR 10 days (≥ 40 kg) DAS181 2.5mg qd x 7 OR 10 days (\< 40kg)
62290063|NCT03921996|EXPERIMENTAL|arm A: ePLND|Radical prostatectomy with extended pelvic lymph node dissection
62290064|NCT03921996|ACTIVE_COMPARATOR|arm B: no PLND|Radical prostatectomy only
62290065|NCT04156321|EXPERIMENTAL|Intervention|Group I (intervention) will receive 150 gm of Sajna shak/bora (Moringa) added with 25 gm concenstrated dal with 100 gm of rice as mid-morning snack in selected school 5 times a week for 6 months
62290066|NCT04156321|NO_INTERVENTION|Control arm|Group II (Control) will rice, concenstrated dal and potato vaji. Both groups will receive calorie matched meal (411 kcal)
62290067|NCT04480619|EXPERIMENTAL|Ga-68-PEG-Αvβ3-IAC PET/CT|Companion Ga-68 PET diagnostic for tumor targeted therapy
62290068|NCT06415370|EXPERIMENTAL|HDHM and Social Interaction (Intervention)|"Home delivered healthy meals are delivered in-person, including a friendly visit with the participant if the participant desires. Student companions will also contact participants at least one time weekly for telephone reassurance and to provide resource referrals."
62290069|NCT06415370|NO_INTERVENTION|HDHM Only (Control)|Home delivered healthy meals are delivered directly to the participant or dropped off at the participant's home in a cooler at their front door if they are not available. Any interaction will be limited.
62463623|NCT01748630|ACTIVE_COMPARATOR|Dexmedetomidine, Midazolam|dexmedetomidine (group DEX); starting dose, 0.4 μg•kg-1•h-1,with intermittent fentanyl
62463624|NCT01748630|ACTIVE_COMPARATOR|Midazolam|midazolam (group MDZ); starting dose, 0.1 mg•kg-1•h-1
61906680|NCT06148649|EXPERIMENTAL|HEC88473 dose2|T2DM subjects, receiving a weekly dose of HEC88473 dose2
62092152|NCT03808922|EXPERIMENTAL|Cohort 4|DAS181 4.5mg qd x 7 OR 10 days
62092153|NCT03808922|EXPERIMENTAL|DAS181 COVID-19 Treatment|DAS181 4.5mg q12h x 7 OR 10 days
62092154|NCT03808922|PLACEBO_COMPARATOR|DAS181 COVID-19 Placebo|Placebo q12h x 7 OR 10 days
62092155|NCT03548922||Pectus carinatum|Demographic data (age, sex), pressure of correction, Tanner stage, Risser stage, Haller index, pectus carinatum protrusion measurements of patients with pectus carinatum will be recorded and association of them with pressure of correction will be investigated.
62092156|NCT01730417|EXPERIMENTAL|Radiation dosimetry|no carrier added metaiodobenzylguanidine
62092157|NCT02931162|EXPERIMENTAL|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
62290070|NCT03820245|EXPERIMENTAL|Bixin|Consumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
62290071|NCT03820245|EXPERIMENTAL|Norbixin|Consumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
62290072|NCT03820245|ACTIVE_COMPARATOR|Lycopene|Consumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
62290073|NCT03820245|PLACEBO_COMPARATOR|Placebo|Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
62290074|NCT05477186|EXPERIMENTAL|Part A: CV0501 Dose Cohort 1 (12 μg)|Enrollment will be staggered, beginning with Group 1a (12 μg, younger adults). Initiation of enrollment in Group 1b (12 μg, older adults) will depend on Safety Review Team (SRT) review of safety data up to Day 8 from a minimum of 10 participants in Group 1a.
62290075|NCT05477186|EXPERIMENTAL|Part A: CV0501 Dose Cohort 2 (25 μg)|For both Group 2a (younger) and Group 2b (older age), initiation of enrollment in the subsequent group at the next dose level for Cohorts 2-5 will depend on SRT review of safety data up to Day 8 from a minimum of 10 participants, from the previous dose level in the same age group.
62290076|NCT05477186|EXPERIMENTAL|Part A: CV0501 Dose Cohort 3 (50 μg)|For both Group 3a (younger) and Group 3b (older age), initiation of enrollment in the subsequent group at the next dose level for Cohorts 2-5 will depend on SRT review of safety data up to Day 8 from a minimum of 10 participants, from the previous dose level in the same age group.
62290077|NCT05477186|EXPERIMENTAL|Part A: CV0501 Dose Cohort 4 (75 μg or 100 μg)|For each of the groups in Cohort 4, Group 4a (younger) and Group 4b (older age),the SRT may recommend a dose specified by the dosing scenarios in the protocol, based on their review of all available safety data. The SRT will use the same approach, independently, to select the dose levels for older participants (Group 4b) and younger participants (Group 4a).
62463625|NCT06146153||Class I|(medium U-vault)
62463626|NCT06146153||Class II|(deep-vault)
62463627|NCT06146153||Class III|flat vault
62308006|NCT04430348|EXPERIMENTAL|PTX-35 Dose Level 3|Dose Level 3: PTX-35 0.10 mg/kg
62463628|NCT00711464|EXPERIMENTAL|100 mg|modafinil 100 milligrams oral dose
62463629|NCT00711464|EXPERIMENTAL|200 mg|modafinil 200 mg oral dose
62463630|NCT00711464|EXPERIMENTAL|400 mg|modafinil 400 mg oral dose
62655956|NCT06098040|EXPERIMENTAL|group 3 - FGM intermittent|will be asked to wear the sensor FreeStyle Libre2 intermittently
62655957|NCT06098040|ACTIVE_COMPARATOR|group 1- SMBG|Patients will be asked to test capillary blood glucose as recommended by subjects' usual provider
61906681|NCT06148649|EXPERIMENTAL|HEC88473 dose3|T2DM subjects, receiving a weekly dose of HEC88473 dose3
62463631|NCT00711464|PLACEBO_COMPARATOR|Placebo|Single oral placebo capsule
62463632|NCT02158182|EXPERIMENTAL|lactulose|
62463633|NCT02158182|EXPERIMENTAL|L-ornithine L-aspartate|
62463634|NCT02158182|EXPERIMENTAL|Rifaximin|
62463635|NCT02158182|PLACEBO_COMPARATOR|Placebo|
62463636|NCT06101225|EXPERIMENTAL|RegularMente Intervention|"1. Relaxation exercises, breathing and closing the eyes, focusing on body parts;~2. The proposal of a guided imagery through narrated scripts, leading children through the visualization of beautiful scenarios and exposure to Social and Emotional Learning content - based on the Collaborative for Academic, Social, and Emotional Learning framework (CASEL), in three major themes: Me with myself (self-awareness and self-management); Me with the others (social-awareness and relationships skills); Me with the world (responsible decision making and social awareness);~3. Instructions for self-regulation of body posture and the use of touch (shoulders) to support children in posture regulation."
61906682|NCT06148649|PLACEBO_COMPARATOR|Placebo|T2DM subjects, receiving a weekly dose of placebo
62290078|NCT05477186|EXPERIMENTAL|Part A: CV0501 Dose Cohort 5 (100 μg, 150 μg or 200 μg)|For each of the groups in Cohort 5, Group 5a (younger) and Group 5b (older age), the SRT may recommend a dose specified by the dosing scenarios in the protocol, based on their review of all available safety data. The SRT will use the same approach, independently, to select the dose levels for older participants (Group 5b) and younger participants (Group 5a).
62308007|NCT04430348|EXPERIMENTAL|PTX-35 Dose Level 4|Dose Level 4: PTX-35 0.30 mg/kg
62308008|NCT04430348|EXPERIMENTAL|PTX-35 Dose Level 5|Dose Level 5: PTX-35 1.0 mg/kg
62463637|NCT06101225|ACTIVE_COMPARATOR|Relaxation|Relaxation exercises, breathing and closing the eyes, focusing on body parts.
62463638|NCT06101225|OTHER|Control|No intervention - regular school activities.
61906683|NCT06148649|ACTIVE_COMPARATOR|Dulaglutide|T2DM subjects, receiving a weekly dose of dulaglutide
61906684|NCT03278119||Sleep Apnea|"Overall 56~* both male and female~* age group 55 to 75 years, having mild to severe obstructive sleep apnea~* in good general health with no significant comorbidities~* Located for the most part in boroughs of New York City"
61906685|NCT03278119||No Sleep Apnea|"Overall 56~* both male and female~* age group 55 to 75 years, without OSA~* in good general health with no significant comorbidities~* Located for the most part in boroughs of New York City"
61906686|NCT03686267|EXPERIMENTAL|intervention (I1)|Lithium disilicate crowns over titanium abutments covered by a layer of opaque porcelain
61906687|NCT03686267|EXPERIMENTAL|Intervention (I2)|Lithium disilicate crowns over titanium abutments covered by lithium disilicate (high opacity) coping
62290079|NCT05477186|EXPERIMENTAL|Part B: CV0501 Dose Cohort 6 (3 μg)|Part B, designed to comprise 2 single age group cohorts, Group 6a (≥18 to \<65 years old) will start based on the first interim analysis of safety and immunogenicity data, provided that the SRT assesses the 12 μg dose to be immunogenic and safe.
62655958|NCT01567514|ACTIVE_COMPARATOR|Glass-ionomer cement lining|Presence of glass-ionomer cement lining in posterior resin composite restorations.
62655959|NCT01567514|NO_INTERVENTION|No glass-ionomer cement lining|Absence of glass-ionomer cement lining in posterior resin composite restorations
62655960|NCT04309513|ACTIVE_COMPARATOR|Step Counter to motivate physical activity|Participants will be encouraged to work up to achieving at least 10,000 steps a day, higher if possible and reasonable, as measured by a wearable device.
62655961|NCT04309513|EXPERIMENTAL|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device.
62655962|NCT00537836|EXPERIMENTAL|ZK 283197, 3 mg|Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks
62655963|NCT00537836|PLACEBO_COMPARATOR|Matching placebo|Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks
62655964|NCT00537836|EXPERIMENTAL|ZK 283197, 2 mg|Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks
62655965|NCT00537836|ACTIVE_COMPARATOR|17ß-estradiol|Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
62655966|NCT02260271||Database Entry/Biospecimen Collection|Medical information of infants born with HIE entered into RedCap database. In addition, Blood, urine, buccal samples will be collected.
62655967|NCT02398344|EXPERIMENTAL|1- tDCS ACTIVE|1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes, intensity 2mA With Simulator anodic electro stimulation from bloodstream on right and left temporal cortex region (T3 area) and cathodic position in contralateral supraorbital region to anode (Fp2), associated Cardiac Frequency Variability (HRV) as measured by spectral analysis by spectral analysis Polar RS800 cx.
62655968|NCT02398344|EXPERIMENTAL|2- tDCS SHAM|Placebo tDCS will be administered using Tct Research 1 CH tdcs Simulator model 101 and will follow the same procedures as active tDCS active, but the tDCS device will only be switched on for 30 seconds.
62655969|NCT01303419|EXPERIMENTAL|CE-BMRI|Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
62655970|NCT04144816||Passive Birth Cohort|"This will be a multicenter, prospective, observational cohort study conducted across the Lyon Public hospital maternity (HFME : Hospital for women, mother and children, Croix-Rousse, Lyon-Sud) recruited from the general population.~Infants born between October 2019 and march 2020. At birth the remains (after diagnosis use) of cord blood samples will be store. Groups of RSVh cases and control will be class at one year of age using the hospital data (RSV must be confirmed by RT-PCR). Parents will be informed of the protocol. If enrolled available hospital data will be use and RSV serology testing perform on the store blood cordon."
62655971|NCT02912936|EXPERIMENTAL|Ketogenic medium chain triglyceride drink|Lactose-free skim milk drink containing 25 g of MCT oil per 250 ml.
62655972|NCT02912936|PLACEBO_COMPARATOR|Placebo|Lactose-free skim milk drink containing high-oleic sunflower oil in the equivalent amount of energy as the active arm.
62655973|NCT05228340|EXPERIMENTAL|Intervention|Flexor tenotomy
62655974|NCT05228340|NO_INTERVENTION|Controle|Usual-care
62655975|NCT04345224|EXPERIMENTAL|Dynamic tape|The gluteal muscle group will be covered with a dynamic tape.
62655976|NCT04345224|EXPERIMENTAL|Rigid tape|The gluteal muscle group will be covered with a rigid tape.
62655977|NCT04345224|SHAM_COMPARATOR|Sham tape|The gluteal muscle group will be covered with a paper tape - a sham application.
62655978|NCT01259999|EXPERIMENTAL|Energy dense formula|
62655979|NCT03921983|EXPERIMENTAL|LTOT +|COPD patients with long term oxygenotherapy
62655980|NCT03921983|ACTIVE_COMPARATOR|LTOT -|COPD patients without chronic hypoxemia (no LTOT)
62655981|NCT05253508|EXPERIMENTAL|Healthy human participants|ring-block anaesthesia with lidocaine in one of the two visits
62655982|NCT02674659|EXPERIMENTAL|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
62655983|NCT02674659|EXPERIMENTAL|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
61906688|NCT03686267|ACTIVE_COMPARATOR|Lithium disilicate crowns over uncovered titanium abutments|Lithium disilicate crowns over uncovered titanium abutments directly without masking
62290080|NCT05477186|EXPERIMENTAL|Part B: CV0501 Dose Cohort 7 (6 μg)|Part B, designed to comprise 2 single age group cohorts, Group 7a (≥18 to \<65 years old) will start based on the first interim analysis of safety and immunogenicity data, provided that the SRT assesses the 12 μg dose to be immunogenic and safe.
62290081|NCT06075823|EXPERIMENTAL|Interventional|TEER + Optimal Medical Therapy
62737315|NCT02789436|PLACEBO_COMPARATOR|Placebo lozenges|"15 subjects~Placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.Placebo lozenges are taken twice daily for 28 days."
62737316|NCT00586872||1|patients with barretts esophagus and/or early esophageal adenocarcinoma who have undergone endoscopic mucosal resection
62737317|NCT01003236|PLACEBO_COMPARATOR|placebo|1 tablet 3 times daily
62737318|NCT01003236|EXPERIMENTAL|Milk Thistle extract|1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day
62737319|NCT05310123|EXPERIMENTAL|AC-11|6 months of treatment with AC-11
62737320|NCT05315934|EXPERIMENTAL|Upper Body Aerobic Exercise|Participants will perform 30 minutes of arm-crank cycling at a moderate exercise intensity based off the participants perceived RPE13
62737321|NCT05315934|EXPERIMENTAL|Lower Body Aerobic Exercise|Participants will perform 30 minutes of static cycling at a moderate exercise intensity based off the participants perceived RPE13
62290082|NCT06075823|ACTIVE_COMPARATOR|Control|Optimal Medical Therapy alone
62463639|NCT01388270|ACTIVE_COMPARATOR|Evodial|a pre-heparin-coated hemodialysis filter
62655984|NCT03301259|EXPERIMENTAL|wave -one reciprocating system|"The reciprocating single file systems WaveOne (Maillefer, Ballaigues, Switzerland) provide more flexibility of the M-wire Ni-Ti alloy, greater resistance to cyclic fatigue and better handling of narrow and curved canals than the traditional Ni-Ti instruments Root canal preparation will be done with theWaveOne System with strict adherence to the manufacturer's instructions. After coronal preflaring with File ISO 21 taper 8% instrument with 2.5% sodium hypochlorite as the irrigant, working length was determined and a glide path will created.~The Red file R 25 taper 8% will be used for preparing the mesial canal; and the Black ISO 40 taper 8% file will be used for preparing the distal canals where there is only a single canal."
62655985|NCT03301259|EXPERIMENTAL|OneShape|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
62655986|NCT04912076|EXPERIMENTAL|BM41|"9 treatment visits where subcutaneous injections with solution of the test drug BM41 (adsorbed to aluminium hydroxide) in a blinded fashion starting with 12.5 nanogram increasing to 20 microgram which is maintenance dose. Subsequently 3 maintenance doses will be given.~Please look at the results in the original article."
62655987|NCT04912076|PLACEBO_COMPARATOR|Placebo|Placebo consisting of only aluminium hydroxide will be administered blinded in amounts according to BM41.
61906689|NCT03148691|PLACEBO_COMPARATOR|Vehicle|Vehicle Topical Solution
62655988|NCT04912076|ACTIVE_COMPARATOR|Alutard|Alutard SQ (ALK) will serve as the comparator and administration is open. Up-dosing is performed according to the official cluster scheme, reaching maintenance of 100.000 SQ-E
62655989|NCT01242787|ACTIVE_COMPARATOR|Entecavir 0.5 mg|Entecavir 0.5 mg
62655990|NCT01242787|EXPERIMENTAL|LB80380|Optimal dose of LB80380 (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
61906690|NCT03148691|ACTIVE_COMPARATOR|A-101 Low Dose|A-101 Low Dose Topical Solution
61906691|NCT03148691|ACTIVE_COMPARATOR|A-101 High Dose|A-101 High DoseTopical Solution
61906692|NCT01004198|EXPERIMENTAL|MP4OX - 250|250 mL dose
61906693|NCT01004198|EXPERIMENTAL|MP4OX - 500|500 mL dose
61906694|NCT01004198|ACTIVE_COMPARATOR|Ringers Lactate solution|500 mL dose
61906695|NCT02024152|EXPERIMENTAL|JDP-205 IV high dose|
61906696|NCT02024152|EXPERIMENTAL|JDP-205 IV low dose|
61906697|NCT02024152|EXPERIMENTAL|JDP-205 IM high dose|
61906698|NCT02024152|ACTIVE_COMPARATOR|Control|
62290083|NCT01727960||Korean Male Adolescents|students from two academic high schools
62290084|NCT01860560|EXPERIMENTAL|CPAP First / HFT Second|Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study
62290085|NCT01860560|EXPERIMENTAL|HFT First / CPAP Second|Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.
62290086|NCT00970606|PLACEBO_COMPARATOR|Placebo tablet|Placebo
62290087|NCT00970606|EXPERIMENTAL|Rosuvastatin (crestor)|Experimental arm
62463640|NCT01388270|NO_INTERVENTION|170 H|Conventional filter
61906699|NCT01838759||Hypovolemic hyponatremia|"Negative values of Overhydration measured by Bioimpedance spectroscopy"
61906700|NCT01838759||Hypervolemic hyponatremia|"Positive values of Overhydration measured by Bioimpedance spectroscopy"
61906701|NCT00205920|EXPERIMENTAL|single|BLVR Treatment
62463641|NCT02501005|EXPERIMENTAL|Treatment Group 1 (TG1)|Prophylactic VT ablation prior to ICD implantation
62655991|NCT04783662||Robust|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal to 0
61906702|NCT05324761|ACTIVE_COMPARATOR|Pregabalin|A dose of 75 mg of Pregabalin twice daily for one month will be prescribed to each patient enrolled this study arm
61906703|NCT05324761|ACTIVE_COMPARATOR|Gabapentin|A dose of 300 mg of Gabapentin twice daily for one month will be prescribed to each patient enrolled this study arm
62290088|NCT03690154|EXPERIMENTAL|FN-1501|
61906704|NCT04822805|EXPERIMENTAL|Treatment with Anlotinib|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
61906705|NCT05337397||Prior pTa low grade Non-Muscle invasive bladder cancer|Patient with recurrent Pta low grade Non-Muscle invasive bladder cancer, with negative urine cytology, and tumor size between 1 and 3 cm.
61906706|NCT00969982|EXPERIMENTAL|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
61906707|NCT00969982|ACTIVE_COMPARATOR|misoprostol|Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
61906708|NCT03034603|EXPERIMENTAL|Nutri-jelly with PEITC|Continuous intake of 200 g Nutri-jelly with 20 mg PEITC per day, five days per week for 3 months.
61906709|NCT03034603|PLACEBO_COMPARATOR|Nutri-jelly|Continuous intake of 200 g Nutri-jelly per day, five days per week for 3 months.
61906710|NCT03467100|EXPERIMENTAL|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
61906711|NCT03467100|PLACEBO_COMPARATOR|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
62092158|NCT02931162|SHAM_COMPARATOR|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
62092159|NCT01870609|ACTIVE_COMPARATOR|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
62092160|NCT01870609|PLACEBO_COMPARATOR|Placebo|2 placebo tablets, administered orally, twice daily
62092161|NCT00003377|OTHER|Radiation therapy plus concurrent weekly chemotherapy|
61906712|NCT01116778|EXPERIMENTAL|eN-Lac® Capsules|
61906713|NCT01116778|OTHER|Placebo Capsules|
61906714|NCT02101164|ACTIVE_COMPARATOR|Treatment Group A|1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses.
61906715|NCT02101164|ACTIVE_COMPARATOR|Treatment Group B|1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses.
61906716|NCT02086032|EXPERIMENTAL|micronized progesterone|1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.
61906717|NCT02086032|EXPERIMENTAL|dydrogesterone|1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.
61906718|NCT00979667|EXPERIMENTAL|Oseltamivir|
61906719|NCT00979667|EXPERIMENTAL|Zanamivir|
61906720|NCT00979667|PLACEBO_COMPARATOR|Placebo of Oseltamivir|
61906721|NCT02587611|EXPERIMENTAL|Elemental liquid diet|"Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg \[13C\]sodium acetate and healthy subjects drink it within 5 min.~Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg \[13C\]sodium acetate and is administered within 15 min using the gastrostomy tube."
61906722|NCT02587611|ACTIVE_COMPARATOR|Standard semi-solid diet|"Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg \[13C\]sodium acetate and healthy subjects drink it within 5 min.~Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg \[13C\]sodium acetate and is administered within 15 min using the gastrostomy tube."
61906723|NCT00749710|ACTIVE_COMPARATOR|1|immediate operation - ORIF - of hip fracture in patient treated with clopidogrel
61906724|NCT00749710|ACTIVE_COMPARATOR|2|ORIF - surgical treatment patients not on antiaggregant therapy
61906725|NCT00608569|EXPERIMENTAL|mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.
62290089|NCT03228563|EXPERIMENTAL|Probiotics|Taking two capsules of probiotics twice daily for 12 months.
62290090|NCT03228563|NO_INTERVENTION|Healthy control|Healthy volunteers were: no hypertension (Blood pressure\<140/90mmHg), no diabetes (Glucose AC 70\~100mg/dl), no hyperlipidemia (Cholesterol Total 130\~200mg/dL、Triglyceride\<150mg/dL), no urinary protein (-) and normal renal function (eGFR\>90), after signing the consent form, the stool samples will be collected.
61906726|NCT00608569|ACTIVE_COMPARATOR|non-mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.
61906727|NCT04892368|ACTIVE_COMPARATOR|Home supervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions. They will also receive 3-4 home visits by physiotherapists between recruitment and surgery, to conduct exercises in their homes.
61906728|NCT04892368|NO_INTERVENTION|Home unsupervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions.
61906729|NCT01859546|NO_INTERVENTION|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
61906730|NCT01859546|EXPERIMENTAL|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
61906731|NCT05536388||Parkinson's Disease|Subjects in this group will have a diagnosis of Parkinson's disease with or without a known GBA gene mutation.
61906732|NCT05536388||Gaucher Disease|Subjects in this group with have a diagnosis of Gaucher disease with or without a known GBA gene mutation.
61906733|NCT05536388||Healthy Control|Subjects in this group will serve as healthy controls.
61906734|NCT03348189||Observational|Healthy males and females
62655992|NCT04783662||Pre Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is 1 or 2
62655993|NCT04783662||Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal or greater than 3
62655994|NCT04134390|EXPERIMENTAL|Cabozantinib|Cabozantinib 40 mg p.o. once daily in 28-day cycles.
62655995|NCT01805999|EXPERIMENTAL|7 g Ispaghula|Volunteer will take 7 g of ispaghula 3 times daily for one week
62655996|NCT01805999|PLACEBO_COMPARATOR|7 g placebo|Volunteer will take 7 g of a placebo 3 times a day for one week
62655997|NCT01805999|ACTIVE_COMPARATOR|3.5g ispaghula + 3.5 g placebo|Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
62655998|NCT06235554|EXPERIMENTAL|intervention|
62655999|NCT05844462|EXPERIMENTAL|Experimental arm|Oral Tadalafil 40 mg or Tadalafil 20 mg \[(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)\].
62656000|NCT05844462|PLACEBO_COMPARATOR|Control arm|Oral Placebo 40 mg or Placebo 20 mg \[(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)\].
62656001|NCT00185159|EXPERIMENTAL|1|olmesartan medoxomil
62656002|NCT00185159|PLACEBO_COMPARATOR|2|placebo
62092162|NCT03082300|EXPERIMENTAL|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
62656003|NCT02101567|ACTIVE_COMPARATOR|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
62656004|NCT02101567|ACTIVE_COMPARATOR|Oxytocin and Methergine (methyl ergometrine)|The second group of patients included in the study will be given Oxytocin 5 IU ampoule by intravenous infusion and Methergine 0.2 mg IV after delivery of fetal head.
62656005|NCT01020422|NO_INTERVENTION|Breast hypertrophy|Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
62656006|NCT01020422|EXPERIMENTAL|Reduction Mammaplasty|Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
62656007|NCT02625584|OTHER|Shared Reading Control|Reading Together - Shared Reading Control. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will not be trained to read with their child. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
62656008|NCT02625584|EXPERIMENTAL|Dialogic Reading|Reading Together - Dialogic Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a dialogic reading style. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
62290091|NCT02232256|EXPERIMENTAL|CALPXT96|"1. 1st treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)~2. 2 week wash out period~3. 2nd treatment period: 4 weeks placebo (two capsules hs at bedtime)"
61906735|NCT04293744|EXPERIMENTAL|Colloid priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL PrimECC.
62290092|NCT02232256|PLACEBO_COMPARATOR|Placebo|"1. 1st treatment period: 4 weeks placebo (two capsules hs at bedtime)~2. 2 week wash 'out' period~3. 2nd treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)"
62290093|NCT04184687|EXPERIMENTAL|Nanofractures treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction with concomitant treatment of the cartilaginous lesions with nanofractures technique.
62290094|NCT04184687|ACTIVE_COMPARATOR|no treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction. Cartilaginous lesions won't be treated
62737322|NCT05667883||Remission|
62737323|NCT05667883||Non-remission|
62737324|NCT00893152||Group 1|Male veterans (focus groups and individual interviews)
62737325|NCT00893152||Group 2|Female veterans (focus groups and individual interviews)
61906736|NCT04293744|ACTIVE_COMPARATOR|Standard priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).
61906737|NCT03513341||Maastricht University First Year Students|Maastricht University 2017-2018 undergraduate first year students are invited to participate in the study. The participants are invited to complete a demographics questionnaire, wear an ActivPAL accelerometer for 7 days, and to complete daily diaries (modified International Physical Activity Questionnaire) for 7 days.
62737326|NCT00893152||Group 3|Family members of participating veterans (focus groups and individual interviews)
62737327|NCT01384552|ACTIVE_COMPARATOR|Normal Weight, Unrestrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737328|NCT01384552|ACTIVE_COMPARATOR|Normal Weight, Restrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737329|NCT01384552|ACTIVE_COMPARATOR|Normal Weight, Restrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737330|NCT01384552|ACTIVE_COMPARATOR|Overweight, Unrestrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737331|NCT01384552|ACTIVE_COMPARATOR|Overweight, Unrestrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737332|NCT01384552|ACTIVE_COMPARATOR|Overweight, Restrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737333|NCT01384552|ACTIVE_COMPARATOR|Overweight, Restrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737334|NCT01384552|ACTIVE_COMPARATOR|Normal Weight, Unrestrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
62737335|NCT02570724|ACTIVE_COMPARATOR|Blood Patch arm|Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.
62737336|NCT02570724|ACTIVE_COMPARATOR|"Drug: injection of HES  Voluven®  patch arm"|"Drug: injection of HES  Voluven®  into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds"
62737337|NCT03107858|ACTIVE_COMPARATOR|Norepinephrine|
62737338|NCT03107858|ACTIVE_COMPARATOR|Dopamine|
62737339|NCT05234918|EXPERIMENTAL|(Kedo S plus file study group)|Group1: Kedo S plus file study group (The teeth will be instrumented by Kedo S plus file)
62737340|NCT05234918|EXPERIMENTAL|(Kidzo-file study group)|Group2: Kidzo file study group (The teeth will be instrumented by Kidzo file)
62737341|NCT05234918|EXPERIMENTAL|(Manual K-file control group)|Group3: Manual K-file control group (The teeth will be instrumented by Manual K-file)
62737342|NCT04891575|ACTIVE_COMPARATOR|Active Control Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes who is randomized to this arm will attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The index participant will attend the sessions as an individual and will receive standard individual-focused lifestyle modification education.
62737343|NCT04891575|EXPERIMENTAL|Family Dyad Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes and a co-participating family member will together attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The dyadic intervention sessions also incorporate family-focused throughout each session to encourage dyadic support.
62737344|NCT04963036|EXPERIMENTAL|Entropy and NOL-Guided Goal Directed Anesthesia|
62737345|NCT04963036|ACTIVE_COMPARATOR|Standard of Care Group (Entropy and blinded NOL)|
62737346|NCT03402594|NO_INTERVENTION|No oxygen|No oxygen supplementation given
62463642|NCT02501005|OTHER|Treatment Group 2 (TG2)|ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter
62463643|NCT01837654|EXPERIMENTAL|Plantarflexion - 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
62092163|NCT03082300|EXPERIMENTAL|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
62463644|NCT01837654|EXPERIMENTAL|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
61906738|NCT04844710|EXPERIMENTAL|Treatment|Manual acupuncture and standard care
61906739|NCT04844710|OTHER|Control|Standard care only
62092164|NCT03082300|EXPERIMENTAL|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
62656009|NCT02625584|EXPERIMENTAL|Pausing for Reading|Reading Together - Pausing for Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a style which involves pausing, recasting and open questioning. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
62092165|NCT04872712|ACTIVE_COMPARATOR|Press Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with Press Needles treatment will be treated with 2-week needle retention, 20-second pressing 3 times a day and needle replacement performed every 5 days. The needles are inserted 0.9 mm deep at the acupuncture points HT7 Shenmen, PC6 Neiguan, ST36 Zusanli and SP6 Sanyinjiao.
62092166|NCT04872712|ACTIVE_COMPARATOR|Filiform Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with filiform needles treatment will be treated with 20-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The needles are inserted approximately 12 mm deep at the acupuncture points HT7 Shenmen and PC6 Neiguan and 25 mm deep at the ST36 Zusanli and SP6 Sanyinjiao.
62092167|NCT01085487||Group 1|
62092168|NCT01085487||Group 2|
62092169|NCT01085487||Group 3|
62092170|NCT05000190|EXPERIMENTAL|250 mg citicoline|Opaque capsule
62092171|NCT05000190|PLACEBO_COMPARATOR|0 mg citicoline|Opaque capsule matched in appearance to the active capsule
62092172|NCT02442544|PLACEBO_COMPARATOR|Placebo|maltodextrin 3.3 g orally/ day for 12 weeks
62290095|NCT04788082|NO_INTERVENTION|Control|Standard of care (not involving 3D printing)
62290096|NCT04788082|EXPERIMENTAL|3D Model|3D printed models (at least one rigid blood volume model and one flexible shell model) will be used for surgical planning.
62290097|NCT04201743|ACTIVE_COMPARATOR|1 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 1 mL NyDYN injection.
62290098|NCT04201743|ACTIVE_COMPARATOR|2 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 2 mL NyDYN injection.
62290099|NCT06037356|EXPERIMENTAL|Prostatic Urethral Lift|Prostatic urethral lift implants will be placed in patients under local anesthesia or monitored anesthetic care. The number of implants used will depend on intra-operative findings, ranging from 2 to 8 implants per patient.
62463645|NCT03098108|EXPERIMENTAL|CCPT|
62463646|NCT00594347|EXPERIMENTAL|Group A|Pneumo 23
62463647|NCT00594347|ACTIVE_COMPARATOR|Group B|Prevnar
62463648|NCT04773470|EXPERIMENTAL|Spinal Muscle Atrophy|All patients with Spinal Muscle Atrophy type 1 to 4
62463649|NCT01215266|ACTIVE_COMPARATOR|Sorafenib|
61906740|NCT00568633|EXPERIMENTAL|Allo-HSCT + TLI + ATG|"Participants achieving complete remission after consolidation therapy \& who have 5 of 6 HLA-match sibling donor to provide PBSC harvest for transplant. Pre-transplant subjects receive:~* Total lymphoid radiation (TLI) Days -11 to -7, and Days -4 to -1 (2 fractions on day -1)~* Anti-thymocyte globulin (ATG) Days -11 to -7~* Methylprednisolone Days -11 to -7~* Cyclosporine (CSP) Days -4 to +2~* 5+ of 6 HLA-matched CD34+ cells on Day 0~* Mycophenolate mofetil (MMF), Day 0 to Day +28"
62092173|NCT02442544|EXPERIMENTAL|Prebiotic|1:1 oligofructose: inulin 8 g orally /day for 12 weeks
62092174|NCT03909139||BMAC Application|"Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.~BMAC application at the time of arthroscopic labral repair."
62290100|NCT06037356|ACTIVE_COMPARATOR|TURP|Transurethral resection of prostate (TURP) will be performed under spinal or general anesthesia as per usual care.
62308009|NCT04430348|EXPERIMENTAL|PTX-35 Dose Level 6|Dose Level 6: PTX-35 3.0 mg/kg
62463650|NCT01215266|PLACEBO_COMPARATOR|Placebo|
62463651|NCT00784823|EXPERIMENTAL|Phase I Cohort - Bortezomib 1 mg/m2|Bortezomib at 1 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
62463652|NCT00784823|EXPERIMENTAL|Phase I Cohort - Bortezomib 1.3 mg/m2|Bortezomib at 1.3 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
62463653|NCT00784823|EXPERIMENTAL|Phase I Cohort - Bortezomib 1.6 mg/m2|Bortezomib at 1.6 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
62656010|NCT02971826|EXPERIMENTAL|Thrombectomy using the REVIVETM SE device|Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke
62463654|NCT00784823|EXPERIMENTAL|Phase II Cohort|Bortezomib at 1.6 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
62092175|NCT03909139||No BMAC Application|"Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.~No BMAC application at the time of arthroscopic labral repair."
62092176|NCT06648096|EXPERIMENTAL|Afatinib|Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)
62092177|NCT06696989|EXPERIMENTAL|Group A ( Frenkel's exercises)|In this group, participants will receive Frenkel's exercises for the lower limb in lying, sitting, and standing positions. And for the upper limb.
62092178|NCT06696989|EXPERIMENTAL|Group B (Core Stability Exercises)|Participants will receive core stability exercises, i.e., abdominal draw-in, roll-up, superman, and bridging.
62092179|NCT06298032|EXPERIMENTAL|Olamkicept - Part A|
62092180|NCT06298032|PLACEBO_COMPARATOR|Placebo - Part A|
62463655|NCT01524653|EXPERIMENTAL|Rosuvastatin First, Placebo Last|This arm will receive rosuvastatin during the first treatment period followed by placebo in the second treatment period after washout.
62290101|NCT01889602|EXPERIMENTAL|Topiramate 100mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 100mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
62092181|NCT06298032|EXPERIMENTAL|Olamkicept - Part B|
62092182|NCT06298032|PLACEBO_COMPARATOR|Placebo - Part B|
62092183|NCT04569708|EXPERIMENTAL|Children and adolescents with epilepsy and controls|Closed loop auditory stimulation during nap
62092184|NCT06340126|EXPERIMENTAL|active tissue release technique group|The group will be treated by active release techniques for 4 weeks, 3 sessions per week. One session will be for 10 minutes. Before each session, an ice pack is applied to the groin area for inflammation if present.
62092185|NCT06340126|ACTIVE_COMPARATOR|Relaxation exercises Group|Group B will be treated by relaxation exercises only. Relaxation exercises include breathing exercises, pelvic floor exercises, and postural exercises.
62092186|NCT01492855|EXPERIMENTAL|Operative treatment|
62290102|NCT01889602|EXPERIMENTAL|Topiramate 150mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 150mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
62290103|NCT01889602|EXPERIMENTAL|Topiramate 200mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 200mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
62463656|NCT01524653|EXPERIMENTAL|Placebo First, Rosuvastatin Last|This arm will receive placebo during the first treatment period followed by rosuvastatin in the second treatment period after washout.
62092187|NCT01492855|EXPERIMENTAL|Conservative treatment|
62092188|NCT00547664|EXPERIMENTAL|A|
62656011|NCT04213911||Morbid obese|BMI\>40 kg/m2
62656012|NCT04213911||Non-obese|BMI\<30 kg/m2
62092189|NCT00547664|PLACEBO_COMPARATOR|B|
62092190|NCT03708068|EXPERIMENTAL|Early Exclusive Enteral Nutrition|"Feeds will start at least at 80% of reference daily fluid intake from day one of life.~Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feed."
62092191|NCT03708068|NO_INTERVENTION|Conventional Enteral Nutrition|"Infants will be fed as per current Neonatal Intensive Care Unit feeding tables:~1. Infants with birth weight 1000-1500 g will be fed on 15-20 ml/kg human milk in day one. Feeds will be advanced by 15-20 ml/kg per day on second day onwards until infant reaches full enteral feeds.~2. Infants with birth weight \>1500 g will be started on 20-30 ml/kg per day on day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feeds."
62656013|NCT02671968|EXPERIMENTAL|CGM group|
62092192|NCT01427907|EXPERIMENTAL|Phoslyra - Calcium Acetate Oral Solution|The investigational compound is calcium acetate oral solution (COS) or Phoslyra. It is a pale, light greenish-yellow clear liquid with a characteristic black cherry odor and flavor for oral ingestion. Each 5 mL of COS contains 667 mg calcium acetate equal to 169 mg of elemental calcium. Each subject will follow their usual prescription.COS will be taken either prior to or during meals and snacks.
62463657|NCT01370408|EXPERIMENTAL|Palonosetron|"All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation~Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO"
62463658|NCT05848245|EXPERIMENTAL|low suction|It is a small and narrow in diameter help to remove saliva , blood and debris and provide a clear vision to healthcare worker. It will be used as conventional way; low suction will be hanged on patient mouth and moved it thoroughly as needed it, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand.
62092193|NCT01427907|ACTIVE_COMPARATOR|Sevelamer Carbonate|Sevelamer carbonate is an anion exchange resin that binds phosphate in the gastrointestinal tract and is a buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients. Each film-coated tablet of sevelamer carbonate (trade name Renvela™) contains 800 mg of sevelamer carbonate on an anhydrous basis. Subjects will receive sevelamer tablets according to their prescription.
62092194|NCT05866445|EXPERIMENTAL|Hypertensive|Hypertensive patients
62092195|NCT05866445|EXPERIMENTAL|Normotensive participants|Normotensive participants with no high blood pressure
62092196|NCT04890665|EXPERIMENTAL|Experimental: Self-applied psychological intervention for healthcare workers|Participants in this group will receive 9 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, stress, burnout, fatigue compassion, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life. The participants will have the option to do 3 extra modules that are complimentary for the intervention.
62092197|NCT04890665|ACTIVE_COMPARATOR|Control: Self-applied psychological intervention for healthcare workers|The participants in this group will receive exactly the same intervention but delivered through a therapist in a weekly session through an online video call. The participants will be informed also about the 3 extra modules and briefly what it is the contents of these modules so they can accept or not receive these extra contents.
62290104|NCT03595696|EXPERIMENTAL|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes for Core Muscle Strength training and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
62290105|NCT03595696|ACTIVE_COMPARATOR|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks (Core Muscle Strength Training).
62290106|NCT05769231|EXPERIMENTAL|Intervention group|
62290107|NCT05769231|NO_INTERVENTION|Control group|Waitlist control
62290108|NCT02280850|EXPERIMENTAL|Guanxin Shutong Capsule|3 capsules once, tid, Oral Duration: 4 weeks
62290109|NCT02280850|PLACEBO_COMPARATOR|Placebo Capsule|"Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD.~3 capsules once, tid, Oral Duration: 4 weeks"
62290110|NCT04389177|EXPERIMENTAL|Pembrolizumab+ Paclitaxel+Cisplatin|Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks
62290111|NCT00073840|ACTIVE_COMPARATOR|I|Levalbuterol 90 ųg QID (manufacturing site A or B)
62290112|NCT00073840|ACTIVE_COMPARATOR|II|Racemic Albuterol 180 ųg QID
62290113|NCT00073840|PLACEBO_COMPARATOR|III|Placebo QID
62290114|NCT00166387||Phase I, II, III|Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
62290115|NCT02867007|EXPERIMENTAL|KHK2455 + Mogamulizumab|"Part 1 (Dose Escalation Part): Will identify the MTD for the KHK2455 monotherapy run-in and for the combination regimen (KHK2455 monotherapy \[Cycle 0\] followed by KHK2455 +mogamulizumab combination \[Cycle 1\]).~Part 2 (Expansion Part): Subjects with a selected tumor type will be enrolled and treated with the recommended dose of KHK2455 established in Part 1 in combination with mogamulizumab."
62290116|NCT05028803|EXPERIMENTAL|Phenylbutyrate|Volunteers will recieve 5 grams of Sodium Phenylbutyrate daily for 3 weeks (21 days). Sodium Pheburane will come in granuale form and 5 grams will be dosed every day.
62290117|NCT03023904|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks for up to 2 years (104 weeks) in the absence of disease progression or unacceptable toxicity.
62656014|NCT02671968|NO_INTERVENTION|Control group|
62656015|NCT04670211||Tooth-borne distractor|Maxillary distraction with the use of a tooth-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
62737347|NCT03402594|ACTIVE_COMPARATOR|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
62092198|NCT04626921|EXPERIMENTAL|Active treatment with 30 mg of CNM-Au8|Highly pure elemental Au nanocrystals are suspended in deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) concentrated up to 0.5 mg/mL (500 ppm) Au.
62092199|NCT03826563|PLACEBO_COMPARATOR|Placebo|Subjects will receive pill placebo nightly
62290118|NCT04206150|ACTIVE_COMPARATOR|Group 1(femoral triangle apex)|the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal)
62290119|NCT04206150|ACTIVE_COMPARATOR|Group 2(femur length/15*2 cm above)|the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1
62290120|NCT04206150|ACTIVE_COMPARATOR|Group 3(femur length/15 cm below)|the adductor canal catheter is inserted femur length/15cm below the location where the nerve block performed in group 1.
62290121|NCT00670787|ACTIVE_COMPARATOR|Combination pill|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
62290122|NCT00670787|NO_INTERVENTION|Control group|combination therapy of angiotensin receptor antagonists (losartan potassium 50mg, candesartan 8mg, valsartan 80mg, telmisartan 40mg or olmesartan 20mg) and thiazide or thiazide-like diuretics (hydrochlorothiazide 6.25-12.5mg, trichlormethiazide 0.5-1.0mg, indapamide 0.5-1.0mg or chlorthalidone 6.25-12.5mg)
62290123|NCT05035121|EXPERIMENTAL|milk supplement|The milk group provided 200 mL milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
62656016|NCT04670211||Bone-borne distractor|Maxillary distraction with the use of a bone-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
62656017|NCT04670211||Hybrid distractor|Maxillary distraction with the use of a hybrid distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
62656018|NCT01360307||Major Depressive Disorder Patients|
62656019|NCT04849013|PLACEBO_COMPARATOR|Placebo + Placebo|
62656020|NCT04849013|ACTIVE_COMPARATOR|Mescaline-100 + Placebo|
62656021|NCT04849013|ACTIVE_COMPARATOR|Mescaline-200 + Placebo|
62656022|NCT04849013|ACTIVE_COMPARATOR|Mescaline-400 + Placebo|
62656023|NCT04849013|ACTIVE_COMPARATOR|Mescaline-800 + Placebo|
62656024|NCT04849013|ACTIVE_COMPARATOR|Mescaline-800 + Ketanserin|
62656025|NCT04383132|EXPERIMENTAL|Abdominal Binder Intervention Group|Patients randomized to Abdominal Binder Intervention Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy.
62656026|NCT04383132|SHAM_COMPARATOR|Sham Group|Sham Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure
62656027|NCT04705662|OTHER|Ferrous Sulphate|This is a single arm study, all participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
62656028|NCT01471990|ACTIVE_COMPARATOR|PACAP38|
62656029|NCT01471990|ACTIVE_COMPARATOR|VIP|
62656030|NCT01776229|EXPERIMENTAL|Behavioral|Exposure, Relaxation, \& Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
62656031|NCT01776229|NO_INTERVENTION|Waitlist Control|All potential participants will be evaluated and some will be randomly placed in the control group, following the five-week treatment phase, participants in the control group will be re-evaluated and offered the treatment
62656032|NCT02143687|EXPERIMENTAL|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
62656033|NCT02143687|EXPERIMENTAL|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
62656034|NCT02143687|ACTIVE_COMPARATOR|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
62656035|NCT02143687|PLACEBO_COMPARATOR|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
61906741|NCT00568633|ACTIVE_COMPARATOR|Best Standard Care|"Regular medical care for participants who achieve complete remission after standard consolidation therapy, but do not have a 5 of 6 HLA-match sibling donor. Treatment may consist of:~* Additional consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation"
61906742|NCT05795634|OTHER|Trier Social Stress Test|All participants in the study will get undergo the same stress procedure
61906743|NCT06017999|EXPERIMENTAL|high dose|XG005 1250 mg Q12 hours
62656036|NCT02270268|EXPERIMENTAL|pectin|a kind of soluble dietary fiber
62656037|NCT02270268|PLACEBO_COMPARATOR|Placebo|maltodextrin
62656038|NCT04381715||YY1|YY1 intragenic pathogenic variant
62656039|NCT02374242|ACTIVE_COMPARATOR|Cohort 1 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
62656040|NCT02374242|ACTIVE_COMPARATOR|Cohort 2 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
62656041|NCT02374242|ACTIVE_COMPARATOR|Cohort 3 Nivolumab and Ipilimumab|Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.
62656042|NCT02429440|EXPERIMENTAL|Study Arm 1|Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
62092200|NCT03826563|EXPERIMENTAL|Melatonin|Subjects will receive oral melatonin tablets 2.5-10mg nightly for 2 weeks. All will receive melatonin 5mg for one week, then at the 1 week visit, the dose can be continued at 5mg or adjusted to 2.5mg or 10mg nightly based on clinical assessment of patient response and side effects.
62092201|NCT05727683|EXPERIMENTAL|JWCAR029 Treatment|"A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before JWCAR029 infusion.~Potential JWCAR029 doses:~Dose level 1: 0.10×10\^6 CAR+ T cells/kg Dose level 2: 0.30×10\^6 CAR+ T cells/kg Dose level 3: 0.75×10\^6 CAR+ T cells/kg Dose level 4: 1.0×10\^6 CAR+ T cells/kg"
62092202|NCT00430677|EXPERIMENTAL|Abatacept 30 mg/kg+Corticosteroids+MMF|Short-term Period
62656043|NCT02429440|ACTIVE_COMPARATOR|Study Arm 2|Intradermal application of peptide vaccine with Montanide ISA-51
62092203|NCT00430677|EXPERIMENTAL|Abatacept 10 mg/kg+Corticosteroids+MMF|Short-term Period
62656044|NCT05481437||Brentuximab Vedotin|Participants will receive Brentuximab Vedotin injection 50 mg once every 2 weeks and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine).
62656045|NCT01452347|EXPERIMENTAL|Dabigatran etexilate|Patient dose dependent on screening CrCl levels and TT
62656046|NCT01452347|ACTIVE_COMPARATOR|warfarin|warfarin doses to maintain INR levels
62656047|NCT01268735|EXPERIMENTAL|Lubricating eyedrops containing HP-guar|
62656048|NCT01822743|EXPERIMENTAL|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
62656049|NCT01822743|SHAM_COMPARATOR|Sham comparator|sham Osteopathic pterygopalatine node compression
62656050|NCT00793975|EXPERIMENTAL|IMC-1121B|"All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.~A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.~When all patients complete a cohort, dose escalation to the next cohort will occur."
62656051|NCT00116142|OTHER|Arm1: Androgen Suppression Therapy + Radiation Therapy|Androgen Suppression Therapy and Radiation therapy
62656052|NCT00116142|EXPERIMENTAL|Arm 2: Docetaxel + Androgen Suppression Therapy + Radiation Therapy|Docetaxel plus androgen suppression therapy and radiation therapy
62656053|NCT01572792|EXPERIMENTAL|1|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
62092204|NCT00430677|EXPERIMENTAL|Placebo+Corticosteroids+MMF|Short-term Period
62092205|NCT00430677|EXPERIMENTAL|Abatacept 10mg/kg|Long-term Extension Period
62092206|NCT05362916|EXPERIMENTAL|Letermovir|40 patients with CMV infection will be treated with Letermovir
62092207|NCT05362916|NO_INTERVENTION|Controls|20 patients with CMV infection will not be given Letermovir
62656054|NCT01572792|EXPERIMENTAL|2|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
62656055|NCT01572792|ACTIVE_COMPARATOR|3|Aclidinium bromide 400 μg
62656056|NCT01572792|ACTIVE_COMPARATOR|4|Formoterol Fumarate 12 μg
62656057|NCT01572792|PLACEBO_COMPARATOR|5|Placebo
62656058|NCT03160170|EXPERIMENTAL|Use of Cobb device|Use of SISTER device during surgery
62656059|NCT03160170|NO_INTERVENTION|Control|Standard exposure technique and instruments will be used during surgery
61906744|NCT06017999|EXPERIMENTAL|low dose|XG005 750 mg Q12 hours
61906745|NCT06017999|PLACEBO_COMPARATOR|placebo|placebo Q12 hours
62092208|NCT01253200|EXPERIMENTAL|Blazer® Open-Irrigated Ablation Catheter|Patients treated with the Blazer® Open-Irrigated Ablation Catheter
62092209|NCT01253200|ACTIVE_COMPARATOR|Control Catheter|Patients treated with an open-irrigated radiofrequency ablation catheter that has received FDA market approval for the treatment of type 1 atrial flutter( Biosense Webster ThermoCool® ablation catheters (NaviStar™, EZ Steer, or SF) or St. Jude Medical ablation catheters (Therapy™ Cool Path™ or Safire BLU™),
62092210|NCT01939938|EXPERIMENTAL|All Subjects-Nasal and Oronasal PAP Mask|Each subject will be imaged in a dynamic MRI with both a oronasal and nasal mask at pressures of 5, 10, and 15 cm of H2O.
62656060|NCT02469857|EXPERIMENTAL|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
62656061|NCT02469857|PLACEBO_COMPARATOR|NaCl 0.9%|NaCl 0.9%, IV, single dose
62656062|NCT03982537|EXPERIMENTAL|Nature's Blend N-Acetyl-L-Cysteine 600 mg with Chemotherapy|The treatment with NAC will be given twice daily for at least 10 days with the goal to cover the window of opportunity time between the treatment decision for CRT and the beginning of treatment (usually 14-21 days).
62656063|NCT03982537|OTHER|Standard of Care Chemotherapy (CONTROL)|Patients will receive definitive or adjuvant concurrent chemotherapy and radiotherapy as per standard of care
62656064|NCT06349278|EXPERIMENTAL|Intervention|Patients will undergo surgery for primary pancreatic cancer and liver metastases.
62656065|NCT04087447||Thyroidectomy group|patient undergoing thyroidectomy for simple nodular goiter
62463659|NCT05848245|ACTIVE_COMPARATOR|intraoral suction|Intraoral suction is attached to high volume excavation hose and provide continuous suction with a bite block, tongue, and oral pathway protection.It will be used as conventional way; intraoral suction will be hanged on patient mouth and moved it thoroughly as needed it, high suction will be moved with scaler, and extraoral suction where on right hand side of patient, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand.
62463660|NCT05848245|EXPERIMENTAL|high & low suction|"Low section is a small and narrow in diameter help to remove saliva , blood and debris and provide a clear vision to healthcare worker.~High section is a large tube designed to suction large amount of air volume and droplet. It will be used as conventional way; low suction will be hanged on patient mouth and moved it thoroughly as needed it, high suction will be moved with scaler, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand."
62092211|NCT02783482|EXPERIMENTAL|GC5107|GC5107 Immune globulin intravenous (human) solution, 10% liquid
62092212|NCT02477826|EXPERIMENTAL|Arm A: Nivolumab|Nivolumab intravenously (IV) as specified
62092213|NCT02477826|EXPERIMENTAL|Arm B: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab IV as specified
62092214|NCT02477826|EXPERIMENTAL|Arm C: Nivolumab + Platinum doublet chemotherapy|Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
62290124|NCT05035121|EXPERIMENTAL|soy milk supplement|The soy milk group provided 200 mL soy milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
62290125|NCT05035121|PLACEBO_COMPARATOR|control|The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
62290126|NCT04268719||Gastro-Esophageal Reflux Disease|Patients defined as having GERD as per Lyon Consensus
62656066|NCT03870490|EXPERIMENTAL|Healthy Subjects|VNRX-5133 + cefepime
62656067|NCT01603602|EXPERIMENTAL|BOTOX® 3 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
62656068|NCT01603602|EXPERIMENTAL|BOTOX® 6 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
62656069|NCT01603602|PLACEBO_COMPARATOR|Placebo|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
62656070|NCT01285544|EXPERIMENTAL|Lipinon-test formulation of atrovastain - 20mg|
62656071|NCT01285544|ACTIVE_COMPARATOR|Lipitor- branded formuation of atorvastatin-20mg|
62656072|NCT02921165|ACTIVE_COMPARATOR|Group 1|Non hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
61906746|NCT03254108|EXPERIMENTAL|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
61906747|NCT03254108|EXPERIMENTAL|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
62092215|NCT02477826|EXPERIMENTAL|Arm D: Platinum doublet chemotherapy|Chemotherapy administered on specified days of IV chemotherapy
62092216|NCT01314495|ACTIVE_COMPARATOR|Abatacept|Abatacept administered as a 30 minute intravenous infusion
62092217|NCT01314495|PLACEBO_COMPARATOR|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
62092218|NCT00710723|EXPERIMENTAL|1|vitrification
62092219|NCT00710723|NO_INTERVENTION|2|Slow freezing
62092220|NCT05506345|EXPERIMENTAL|intervention group|The intervention group carried out a series of creative drama workshops based on social interaction theory on the basis of routine nursing teaching.
62092221|NCT05506345|NO_INTERVENTION|control group|The control group adopted conventional nursing teaching methods (conventional nursing teaching methods included safety education, healthy lifestyle, role positioning of nursing students, nursing etiquette, communication skills, nursing professional theory and skill training, nursing career planning, and clinical one-on-one teaching, according to plan to complete the teaching task).
62092222|NCT00998816|PLACEBO_COMPARATOR|Placebo capsules|one placebo capsule will be administered 1 hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12h BID for 10 days following lateral thoracotomy.
62092223|NCT00998816|ACTIVE_COMPARATOR|pregabalin capsules|Pregabalin capsules (150mg) will be administered one hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12 hours (BID) for 10 days following lateral thoracotomy.
62290127|NCT04268719||Non-acid Reflux|Patient excluded for GERD as per Lyon Consensus
62290128|NCT02557087|EXPERIMENTAL|Hyoscine|Intravenous administration of Hyoscine N-butylbromide diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
62290129|NCT02557087|ACTIVE_COMPARATOR|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
62308010|NCT02862210|EXPERIMENTAL|Lithium carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
62308011|NCT02862210|PLACEBO_COMPARATOR|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels provided by an unblinded study team member.
62308012|NCT04425850||IVER+|Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
62092224|NCT03347045|EXPERIMENTAL|Trimodal Prehab & ERP|"Trimodal prehab includes:~1. Guided exercise program at Repsol Place in Calgary, Alberta 2x/week, hosted by the Total Cardiology group. Home-exercise program for another 3x/week.~2. Nutritional optimization with a high-protein oral supplement, along with nutritional counseling and access to a Registered Dietitian on site.~3. Anxiety reduction workshop and take-home anxiety reduction program."
62092225|NCT03347045|ACTIVE_COMPARATOR|No Prehab; ERP Alone|The active comparator group will be given a home exercise program, nutrition education, and a take-home anxiety reduction program.
62092226|NCT01220674||community dwelling older adults, normal controls|men and women 55 years of age or older who are cognitively intact.
61906748|NCT03254108|EXPERIMENTAL|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
62092227|NCT01220674||community dwelling older adults, mild cognitive impairment|men and women 55 years of age or older who have minimal cognitive decline (MMSE 20-24).
62092228|NCT03906487|EXPERIMENTAL|Intimate partner violence|The women in this arm must have suffered at least two physical aggressions. They will be recruited in the study as part of their coming to the consultation of intentional injury of the medico-legal unit of the University Hospital Toulouse.
62092229|NCT03906487|ACTIVE_COMPARATOR|Control group|The women in this group are women who have never experienced domestic violence or have experienced a potentially traumatic event. These women will be recruited by a call for volunteers.
62092230|NCT01488110|EXPERIMENTAL|Migraine medical device|Treatment with an active nasal probe
62092231|NCT01488110|PLACEBO_COMPARATOR|Inactive migraine medical device|Treatment with an inactive nasal probe.
62092232|NCT06459986||Spinal anaesthesia|Participants scheduled for orthopaedic surgery performed in spinal anaesthesia with or without sedation
62092233|NCT06268860|EXPERIMENTAL|Rocatinlimab Vial|Participants will receive rocatinlimab vial solution SC
62092234|NCT06268860|EXPERIMENTAL|Rocatinlimab Prefilled Syringe|Participants will receive rocatinlimab prefilled syringe solution SC
62092235|NCT01245777|EXPERIMENTAL|ferric carboxymaltose|Hb\> 11 g/dl and Ferritin \< 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and \< 11g/dl; Ferritin \< 35 (controlled by CRP): 700 mg Hb ≥9 and \< 10 g/dl; Ferritin \< 35 (controlled by CRP): 800 mg Hb \< 9g/dl; Ferritin \< 35 (controlled by CRP): 900 mg
62092236|NCT02338609|EXPERIMENTAL|Everolimus|All patients will have been previously treated with everolimus as part of CRAD001M2301. Continued treatment with everolimus is allowed but not required for participation in this study.
62092237|NCT05906628|EXPERIMENTAL|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
62092238|NCT05906628|PLACEBO_COMPARATOR|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
62092239|NCT00605878||Grouo 3|Healthy (pediatric) controls
62092240|NCT00605878||Group 1|Healthy (adult) volunteers
62092241|NCT00605878||Group 2|AD patients
62092242|NCT00605878||Group 4|Patients diagnosed with the primary immunodeficiency hyperIgE syndrome (HIES)
62092243|NCT00605878||Group 5|Patients diagnosed with the primary immunodeficiency Wiskott-Aldrich Syndrome (WAS)
62092244|NCT00605878||Group 6|Patients diagnosed with the combined immunodeficiency associated with DOCK8 mutation (DOCK8)
62092245|NCT01212705|EXPERIMENTAL|ASV|
62092246|NCT03818308|EXPERIMENTAL|Sofosbuvir and Velpatasvir|SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks
62092247|NCT06438393||Stable chest pain and unknown CAD who underwent CTCA and CCS in the same scanning session|CAD: Presence of minimal coronary artery disease (i.e., coronary stenosis 0-25%) Normal coronary arteries: No visible coronary atherosclerosis
62092248|NCT04866342|EXPERIMENTAL|Servo control - Masimo oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
62092249|NCT04866342|ACTIVE_COMPARATOR|Servo control - Nellcor oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
62092250|NCT02243007|EXPERIMENTAL|Folfirinox-ARM A|"Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel~* Treatment will be administered on an outpatient basis and will include intravenous administration of the FOLFIRINOX regimen on predetermined days.~* After completion of FOLFIRINOX all patients without progressive disease will proceed with radiation therapy with the standard dose of capecitabine.~* Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
62092251|NCT02243007|EXPERIMENTAL|Gemcitabine/nab-Paclitaxel- Arm B|"* Treatment will be administered on an outpatient basis. Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel).~* Intravenous administration of the Gemcitabine/Nab-paclitaxel regimen on predetermined days of each 28 day treatment cycle (unless a delay is mandated by toxicity criteria). A cycle of Gemcitabine/Nab-paclitaxel will constitute a 28 day treatment period.~* After Gemcitabine/Nab-paclitaxel, all patients without progressive disease will proceed to radiation therapy with the standard dose of capecitabine~* Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
62308013|NCT04425850||IVER-|Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.
62656073|NCT02921165|EXPERIMENTAL|Group 2|Hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
62656074|NCT02921165|EXPERIMENTAL|Group 3|Non Hypertensive Intervention: On normal saline rinses.
62656075|NCT05600478||Japan|A group of ICU physical therapists working in Japan.
62656076|NCT05600478||Philippines|A group of ICU physical therapists working in the Philippines.
62308014|NCT06449625|ACTIVE_COMPARATOR|Semaglutide|Semaglutide active drug 0.25-0.5mg, once-weekly, injection
62092252|NCT05775289|EXPERIMENTAL|Arm A: Tobemstomig + Platinum-Based Chemotherapy|"Participants with non-squamous (NSQ) NSCLC will receive induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin, all on Day 1 every 3 weeks (Q3W) for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig together with pemetrexed until disease progression or treatment discontinuation.~Participants with squamous (SQ) NSCLC will receive blinded tobemstomig in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21 day cycles, followed by blinded tobemstomig (on Day 1) Q3W until disease progression or treatment discontinuation."
62092253|NCT05775289|ACTIVE_COMPARATOR|Arm B: Pembrolizumab + Platinum-Based Chemotherapy|"Participants with NSQ NSCLC will receive induction treatment with blinded pembrolizumab in combination with pemetrexed and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by a maintenance therapy with blinded pembrolizumab together with pemetrexed Q3W until disease progression or treatment discontinuation.~Participants with SQ NSCLC will receive blinded pembrolizumab in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by blinded pembrolizumab (on Day 1) Q3W until disease progression or treatment discontinuation."
62092254|NCT04361747|EXPERIMENTAL|nursing counseling intervention|The nursing counseling intervention was implemented by a maternity nursing instructor. During the 12-week prenatal genetic testing evaluation period, experimental-group participants received three nursing consultation sessions plus regular care, while their control-group peers received regular care only. The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
62092255|NCT04361747|NO_INTERVENTION|control group|control group participants received regular care only
62092256|NCT03093090|ACTIVE_COMPARATOR|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
62092257|NCT03093090|ACTIVE_COMPARATOR|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
62092258|NCT03093090|ACTIVE_COMPARATOR|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
62092259|NCT03093090|ACTIVE_COMPARATOR|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
62092260|NCT01275053|EXPERIMENTAL|Leptin|
62290130|NCT02608632|EXPERIMENTAL|Group 1 (RDN guided by HFS)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access. After that high-frequency stimulation (HFS) was used before the initial and after each radiofrequency (RF) delivery within the renal artery. RDN was considered to have been achieved when the sudden increase of blood pressure (\> 15 mm Hg from invasive arterial monitoring) was eliminated in response to HFS.~RF ablations of 8-12 watts (impedance drop \>10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by \> 5 mm) were performed both longitudinally and rotationally within each renal artery."
62290131|NCT02608632|ACTIVE_COMPARATOR|Group 2 (RDN as standard procedure)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access.~RF ablations of 8-12 watts (impedance drop \>10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by \> 5 mm) were performed both longitudinally and rotationally within each renal artery. High-frequency stimulation (HFS) was performed before and after RDN to just to verify the response of BP"
62463661|NCT05848245|EXPERIMENTAL|extra-oral suction & low suction|"EOS is used to remove aerosol and droplet that arising from patient mouth and filtering air. The device starts from air volume level 1 to level 10.~Low section is a small and narrow in diameter help to remove saliva , blood and debris and provide a clear vision to healthcare worker. It will be used as conventional way; low suction will be hanged on patient mouth and moved it thoroughly as needed it, and extraoral suction where on right hand side of patient, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand."
62656077|NCT05600478||Taiwan|A group of ICU physical therapists working in Taiwan.
62656078|NCT01034553|EXPERIMENTAL|Arm I|Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.
62656079|NCT01799694|EXPERIMENTAL|Autologous Expanded Stem Cells|Inject of Autologous Adipose-derived expanded stem cells
62092261|NCT00279422|PLACEBO_COMPARATOR|placebo|
61906749|NCT03254108|EXPERIMENTAL|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
62092262|NCT00279422|EXPERIMENTAL|visilizumab|
62092263|NCT04082455|EXPERIMENTAL|carbon ion radiotherapy|carbon ion radiotherapy
62092264|NCT04129580|EXPERIMENTAL|Treatment-As-Usual (TAU) + reSET-O|Participants randomly assigned to this arm will receive their TAU alongside the use of the app, reSET-O.
62092265|NCT04129580|NO_INTERVENTION|TAU only|Participants randomly assigned to this arm will receive their TAU only (no use of the app, reSET-O).
62092266|NCT06340789|ACTIVE_COMPARATOR|Treatment resistant schizophrenia patients with augmentation of sodium benzoate 2g/day|with sodium benzoate 2g/day
62092267|NCT06340789|PLACEBO_COMPARATOR|Treatment resistant schizophrenia patients with augmentation of placebo|with placebo
62092268|NCT00480441|ACTIVE_COMPARATOR|1|Dronabinol+ BRENDA therapy
62092269|NCT00480441|PLACEBO_COMPARATOR|2|Placebo+BRENDA therapy
62092270|NCT05102903|OTHER|A(RT)|"Reference drug BR1016B 1 tablet is administered once in fasted state. After having a break of 7 days or more, study drug BR1016A 1 tablet is administered once in fasted state."
62092271|NCT05102903|OTHER|B(TR)|"Study drug BR1016A 1 tablet is administered once in fasted state. After having a break of 7 days or more, reference drug BR1016B 1 tablet is administered once in fasted state."
62092272|NCT06438757|EXPERIMENTAL|JYB1904: Dose-1|
62092273|NCT06438757|EXPERIMENTAL|JYB1904: Dose-2|
62092274|NCT06438757|EXPERIMENTAL|JYB1904: Dose-3|
62092275|NCT06438757|ACTIVE_COMPARATOR|Omalizumab|
62092276|NCT05388006|EXPERIMENTAL|Treatment (acalabrutinib, durvalumab, venetoclax)|"Patients receive acalabrutinib PO BID on days 1-28, durvalumab IV over 1 hour on day 1, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-90. Treatment repeats every 90 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
62092277|NCT03566589|EXPERIMENTAL|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
62092278|NCT05513235|EXPERIMENTAL|Intervention|Parents of eligible children and youth with special healthcare needs will use a digital personal record mobile application to coordinate care for six months.
62092279|NCT02728219|EXPERIMENTAL|hepatectomy|Comparison of Treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion
62092280|NCT02728219|ACTIVE_COMPARATOR|TACE|
62092281|NCT01253980|ACTIVE_COMPARATOR|Amoxicillin|Amoxicillin
62092282|NCT01253980|PLACEBO_COMPARATOR|Placebo suspension|Placebo
62092283|NCT02848235|NO_INTERVENTION|Group 1 (Standard of Care)|Participants in group 1 will receive the standard of care for the Prevention of Mother to Child Transmission (PMCTC) of HIV from the clinic's Mentor Mothers.
62092284|NCT02848235|EXPERIMENTAL|Group 2 (Standard of Care + EMMA)|Participants in group 2 will receive the standard of care for Prevention of Mother to Child Transmission (PMCTC) of HIV plus study-specific enhanced care interventions from the clinic's Mentor Mothers.
62092285|NCT01824082|EXPERIMENTAL|Ropivacaine 0.5%|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: normal saline.
62092286|NCT01824082|PLACEBO_COMPARATOR|Normal saline (salt water) infusion|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of normal saline placebo fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: ropivacaine 0.5%.
62290132|NCT00709202|ACTIVE_COMPARATOR|1|Subjects assigned to this arm will receive Betahistine.
62290133|NCT00709202|PLACEBO_COMPARATOR|2|Subjects in this group will received placebo.
62290134|NCT03227809|EXPERIMENTAL|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
62290135|NCT03227809|EXPERIMENTAL|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
62290136|NCT03227809|NO_INTERVENTION|Control|Parents receive treatment as usual of incoming university student parents
62290137|NCT00888667||ICD patient with frequent PVCs|
62463662|NCT05848245|EXPERIMENTAL|extra-oral suction and intraoral suction|"EOS is used to remove aerosol and droplet that arising from patient mouth and filtering air. The device starts from air volume level 1 to level 10.~High section is a large tube designed to suction large amount of air volume and droplet. It will be used as conventional way; intraoral suction will be hanged on patient mouth and moved it thoroughly as needed it, and extraoral suction where on right hand side of patient, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand."
61906750|NCT03254108|ACTIVE_COMPARATOR|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
61906751|NCT00618098|EXPERIMENTAL|Octaplex (human prothrombin complex concentrate)|Participants to receive1 or more Octaplex infusions intravenously until their International Normalized Ratio (INR) was \< 1.5.
62290138|NCT00607048|OTHER|Schedule A|Schedule A (CP-870,893 administration schedule)
62290139|NCT00607048|OTHER|Schedule B|Schedule B (CP-870,893 administration schedule)
62290140|NCT05029050|EXPERIMENTAL|Dexmedetomidine (D)|Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
62290141|NCT05029050|EXPERIMENTAL|Clonidine (C)|Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
62290142|NCT05029050|PLACEBO_COMPARATOR|Placebo (P)|Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
62290143|NCT00480857|EXPERIMENTAL|Docetaxel|
62290144|NCT00600171|PLACEBO_COMPARATOR|Placebo|Placebo Multi dose dry powder inhlaer
62290145|NCT00600171|EXPERIMENTAL|GW642444M|GW642444M
62290146|NCT04171609|EXPERIMENTAL|Cancer survivors|Adult survivors of any kind of cancer (except for minor skin cancer) are eligible to participate
62290147|NCT01444755||1-Neoadjuvant Chemotherapy|This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
62290148|NCT01444755||2 Surgery|Surgery will be performed in patients of this arm.
62308015|NCT06449625|PLACEBO_COMPARATOR|Placebo|Semaglutide placebo, once-weekly, injection
62308016|NCT05712668|ACTIVE_COMPARATOR|Standard Pre-operative Counseling|Participants will receive standard counseling.
62463663|NCT04274686|EXPERIMENTAL|Bag-Mask Ventilation with Tegaderm|Patients will receive bag-mask ventilation with Tegaderm placement
62092287|NCT03923608||strength test|The maximum strength test of external shoulder rotators will be performed on 5 different tools with specific protocols.
62308017|NCT05712668|EXPERIMENTAL|Standard Pre-operative Counseling plus Asynchronous Telemedicine|Participants will receive standard counseling plus access to a 5 minute video reviewing their in-office counseling.
62308018|NCT01804855|ACTIVE_COMPARATOR|W82GO|Usual face-to-face care as per the W82GO multidisciplinary treatment intervention (phase 1 for 6 weeks and phase 2 for 46 weeks).
62656080|NCT00121875||Turner syndrome|Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
62656081|NCT00121875||Control / idiopathic short stature|Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy
61906752|NCT00618098|ACTIVE_COMPARATOR|Fresh frozen plasma|Participants to receive1 or more fresh frozen plasma infusions intravenously until their International Normalized Ratio (INR) was \< 1.5.
61906753|NCT05066542|ACTIVE_COMPARATOR|NDPP Standard of Care SOC|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
61906754|NCT05066542|EXPERIMENTAL|NDPP + Basketball (BB)|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30-minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and bi-weekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
61906755|NCT02971033|PLACEBO_COMPARATOR|placebo|placebo
61906756|NCT02971033|EXPERIMENTAL|20mg/day ezetimibe|20mg/day ezetimibe
61906757|NCT02971033|EXPERIMENTAL|40mg/day ezetimibe|40mg/day ezetimibe
61906758|NCT00206232|ACTIVE_COMPARATOR|Spironolactone|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
61906759|NCT00206232|PLACEBO_COMPARATOR|Placebo|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
61906760|NCT00114790|EXPERIMENTAL|BNCT.|Boronophenylalanine-based BNCT.
61906761|NCT05714644|ACTIVE_COMPARATOR|Mailed FIT Kit|A FIT kit mailed to the patient's home
61906762|NCT05714644|ACTIVE_COMPARATOR|Cologuard|A Cologuard test mailed to the patient's home
61906763|NCT05986201||40 patients|There were 33 (82.5%) males and 7 (17.5%) females aged 32-87 years, with a mean age of 67.8 years.
61906764|NCT04244305|EXPERIMENTAL|Treadmill Training|"Participants in the treadmill training group will perform endurance training during the post-operative period using a treadmill (Salter Housewares, UK) for a minimum of 20 sessions. Intensity of training will be set according to 80% of the mean speed achieved during the 6MWT for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week.~After the endurance training, participants will perform resistance training for 20 - 30 minutes for conditioning of the main muscles in the upper and lower limbs using elastic bands, dumbbells and body-weight exercises. Intensity will progressively increase up to 70% of the maximum isometric strength measured with a hand-held dynamometer. Volume of training will also increase from 1 to 3 sets of 12 repetitions each. When needed patients will also be taught breathing exercises and airway clearance techniques."
61906765|NCT04244305|ACTIVE_COMPARATOR|Cyclo-ergometry Training|Participants in this group will perfom endurance training during the post-operative period using a cycle ergometer (Monark 828e, Monark AB, Sweeden) for a minimum of 20 sessions. Intensity of training will be set according to the results of a symptom-limited incremental cycle-ergometry test performed on the first day to achieve 80% of the maximal workload obtained for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week. Participants in this group will also perfom resistance training and breathing exercises as in the treadmill training group.
61906766|NCT05251402|ACTIVE_COMPARATOR|Group A - Patinet Education|If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.
61906767|NCT05251402|ACTIVE_COMPARATOR|Group B - Patient Education with Nutrition Counseling|If you are assigned to this group, you will receive the same patient education on asthma and health as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.
61906768|NCT04801264|EXPERIMENTAL|68Ga-PSMA, PET/CT and 177Lu-EB-PSMA-617 therapy|All patients diagnosed with ACC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
61906769|NCT05859737|EXPERIMENTAL|Disaster Preparedness Education Program (SIMAH)|
61906770|NCT05859737|ACTIVE_COMPARATOR|Disaster and Emergency Management Presidency (AFAD) Education Program|
61906771|NCT04773080||esophageal cancer surgery|patients undergoing elective esophageal surgery for cancer
61906772|NCT01734889|EXPERIMENTAL|Orfadin suspension|Drug: nitisinone, oral suspension
61906773|NCT01362010|EXPERIMENTAL|Topical Minocycline Foam FXFM244 - 4%|Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
61906774|NCT01362010|EXPERIMENTAL|Topical Minocycline Foam FXFM244 - 1%|Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
61906775|NCT01362010|PLACEBO_COMPARATOR|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
62290149|NCT04142645|EXPERIMENTAL|Intervention|The intervention group (i.e. all eligible and consented residents of 2 NHs) will receive the OptiMEDs intervention: the combination of an electronic decision support tool (for the appraisal of potentially inappropriate medication use, anticholinergic use, or medications that can be de-prescribed in view of limited life expectancy) with focused nurse observations (using a list of potential medication-related symptoms based on the individual medication chart of the nursing home residents), that will serve as the basis during a multidisciplinary medication review with the input of GPs, trained community pharmacists and nurses.
62463664|NCT04274686|ACTIVE_COMPARATOR|Bag-Mask Ventilation without Tegaderm|Patients will receive bag-mask ventilation without Tegaderm placement
62092288|NCT03923608||Endurance test|"Test designed by the Laboratory of Sports Physical Therapy (LAFIDE) of FCT / UNESP - Presidente Prudente, used in the prescription of training for gain of localized muscular endurance. Will be realized in the tools: Isokinetic dynamometer, elastic bands, pulley and halter.~The test will consist of the maximum possible repetitions (until fatigue) with loads of 70%, 80% and 90% of the maximum force (in different sessions)."
62092289|NCT06611514|EXPERIMENTAL|intravaginal Prasterone|
62092290|NCT01386216|EXPERIMENTAL|Bone Marrow Cell Concentrate|Bone Marrow Cell Concentrate Prepared Using the Magellan System
62092291|NCT01374490|EXPERIMENTAL|Crofelemer|
62092292|NCT04721509|EXPERIMENTAL|Smartphone-based telemedicine|
62092293|NCT04721509|NO_INTERVENTION|Conventional management without telemedicine|
62092294|NCT06693024||neratinib|After standard anti-HER2 neoadjuvant/adjuvant therapy, sequential targeted therapy with neratinib for 1 year
62092295|NCT06693024||control group|After standard anti-HER2 neoadjuvant/adjuvant therapy, no sequential targeted therapy
62092296|NCT04880343|NO_INTERVENTION|Group (C)|Control
62092297|NCT04880343|EXPERIMENTAL|Group (A)|Treatment
62092298|NCT04880343|EXPERIMENTAL|Group (B)|Treatment
62092299|NCT04094844|ACTIVE_COMPARATOR|Roadmap 2.0|"Roadmap 2.0 mobile app + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).~Includes caregivers of adult patients and caregivers of pediatric patients"
62092300|NCT04094844|EXPERIMENTAL|Roadmap 2.0 with Positive Activities|"Roadmap 2.0 mobile app (patients), Roadmap 2.0 with mobile Positive Activities app (caregivers) + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).~Includes caregivers of adult patients and caregivers of pediatric patients"
62092301|NCT00994279|ACTIVE_COMPARATOR|Arm 1: Yoga Intervention|Yoga Intervention
62463665|NCT04512547|EXPERIMENTAL|Obese Asthmatics|Obese patients that come to Duke that have been diagnosed with Asthma will be approached.
62092302|NCT00994279|ACTIVE_COMPARATOR|Arm 2: Educational Wellness Group|Educational Wellness Group
62092303|NCT06616636|EXPERIMENTAL|Rezatapopt + Azacitidine|Participants will receive treatment on an inpatient or outpatient basis.
62092304|NCT06616636|EXPERIMENTAL|Rezatapopt + Azacitidine + Venetoclax|Participants will receive treatment on an inpatient or outpatient basis.
62092305|NCT05185440|ACTIVE_COMPARATOR|GIFTSS Training Only|Training for college health center clinicians and staff in implementation of GIFTSS Training
62656082|NCT05306704|PLACEBO_COMPARATOR|Control Arm: Olive oil|In control arm participants will receive Placebo (Olive Oil) orally in all visits i.e from visit 1 to visit 4. Allocation of arms will be as per the pre-created random list.
62656083|NCT05306704|ACTIVE_COMPARATOR|Vitamin-D|In the Vitamin-D arm, participants will receive Vitamin-D (100000 IU) orally in all visits i.e from visit 1 to visit 4. Allocation of arms will be as per the pre-created random list.
61906776|NCT00027872|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.
62092306|NCT05185440|EXPERIMENTAL|GIFTSS Training and Learning Collaborative|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative to support implementation
62092307|NCT05185440|EXPERIMENTAL|GIFTSS Training and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with provider scripts to support implementation
62092308|NCT05185440|EXPERIMENTAL|GIFTSS Training, Learning Collaborative, and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative as well as provider scripts to support implementation
62092309|NCT04308616||Psoriasis|Patients with psoriasis
62092310|NCT04580654|EXPERIMENTAL|CSL312 (Cohort 1a, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
62092311|NCT04580654|EXPERIMENTAL|CSL312 (Cohort 1b, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
62092312|NCT04580654|EXPERIMENTAL|CSL312 (Cohort 2, high dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
62092313|NCT04580654|EXPERIMENTAL|CSL312 (Cohort 3, low dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
62092314|NCT04580654|EXPERIMENTAL|CSL312 (Cohort 4, high dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
62092315|NCT03347838|EXPERIMENTAL|Nivolumab Injection [Opdivo]|240 mg IV every 2 weeks for 4 doses
62290150|NCT04142645|NO_INTERVENTION|Control|The control group (i.e. all eligible and consented residents of one control NH) will receive usual care .
62290151|NCT06140771|SHAM_COMPARATOR|0.76% Sodium Monofluorophosphate Dentifrice|
62290152|NCT06140771|SHAM_COMPARATOR|1.15% Sodium Monofluorophosphate Dentifrice|
62290153|NCT06140771|ACTIVE_COMPARATOR|Marketed 0.454% Stannous Fluoride Dentifrice|
62290154|NCT06140771|ACTIVE_COMPARATOR|0.454% Stannous Fluoride Dentifrice|
62290155|NCT00889044|EXPERIMENTAL|clopidogrel by chewing|
62463666|NCT04512547|ACTIVE_COMPARATOR|Obese Non-Asthmatics|The obese non-asthmatics will be collected from an IRB pre-approved Healthy Volunteer Data Repository.
62656084|NCT02502448|NO_INTERVENTION|Control group|patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
61906777|NCT01561196|ACTIVE_COMPARATOR|Ultrasound guided arterial cannulation|The arterial needle is placed using ultrasound monitoring for guiding the operator.
61906778|NCT01561196|ACTIVE_COMPARATOR|Conventional cannulation|the arterial needle is placed using the traditional method and lidocaine. The operator decides where to place the needle in the forearm
62092316|NCT05243797|EXPERIMENTAL|Arm A: Teclistamab-Lenalidomide (Tec-Len)|Teclistamab will be administered via a subcutaneous injection (SC)
62092317|NCT05243797|ACTIVE_COMPARATOR|Arm B Lenalidomide Alone (Len)|Lenalidomide orally.
62092318|NCT05243797|EXPERIMENTAL|Arm C Teclistamab-Alone (Tec)|Teclistamab will be administered via a subcutaneous injection (SC)
62656085|NCT02502448|ACTIVE_COMPARATOR|Acute normovolemic hemodilution group|patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
62656086|NCT01991314|EXPERIMENTAL|Ferrous sulphate|Ferrous sulphate 200mg twice daily for 6 weeks
62092319|NCT06696131|EXPERIMENTAL|TNK|Participants would be given TNK through a brain catheter to dissolve an intracerebral blood clot after a hemorrhage.
62092320|NCT05058391|EXPERIMENTAL|Elaprase 0.5 mg/kg|Participants will receive a single dose of Elaprase 0.5 milligrams per kilogram (mg/kg) body weight, intravenous infusion on Day 1, Week 1 followed by every week up to end of treatment (EOT) (Day 358, Week 52).
62290156|NCT00889044|PLACEBO_COMPARATOR|Placebo|
62290157|NCT01130922|EXPERIMENTAL|Moxifloxacin IV|
62463667|NCT01988909|EXPERIMENTAL|WR 279,396|All patients with the same Study drug: WR 279,396 (Topical Paromomycin and Gentamicin Cream)
62656087|NCT02967445|EXPERIMENTAL|Cervical pessary|Arabin Pessary
62656088|NCT02967445|ACTIVE_COMPARATOR|Cervical cerclage|McDonald Cerclage
62656089|NCT01369550|PLACEBO_COMPARATOR|High-oleic sunflower oil-containing foods|Subjects will consume 3 servings of foods containing high-oleic sunflower oil plus 3x500 mg high-oleic sunflower oils softgels per day.
62656090|NCT01369550|ACTIVE_COMPARATOR|Eicosapentaenoic acid|Subjects will consume 3 x 500 mg eicosapentaenoic acid ethyl ester in softgels plus 3 servings of high-oleic sunflower oil-containing foods per day
62290158|NCT01130922|ACTIVE_COMPARATOR|Moxifloxacin oral|
62463668|NCT05342597|EXPERIMENTAL|Group A|A single oral dose of MT-1186 with fasted condition in period 1, meal 1 condition in period 2, meal 2 condition in period 3, meal 3 condition in period 4, and meal 4 condition in period 5.
62656091|NCT01369550|EXPERIMENTAL|SDA soybean oil-containing foods|Subjects in this arm will consume 3 servings of SDA soybean oil-containing foods plus 3 x 500 mg high-oleic sunflower oil softgels per day.
62656092|NCT00845182|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm
62656093|NCT00845182|EXPERIMENTAL|Exenatide|Exenatide: 15 subjects will be randomized to receive Exenatide
62656094|NCT00845182|EXPERIMENTAL|Drug Pioglitazone and Drug Exentatide|Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide
62656095|NCT05256264||Control group|Sevoflurane
62290159|NCT01207830|EXPERIMENTAL|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
62290160|NCT03619629|EXPERIMENTAL|Kinesio-taping|Kinesiotape will be applied both ankles.
62290161|NCT03619629|EXPERIMENTAL|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied both ankles.
62092321|NCT05064514|EXPERIMENTAL|Transcatheter Tricuspid Valved Stent Graft intervention|Participants who have carcinoid heart disease with severe symptomatic tricuspid regurgitation and with a significant backflow in the caval and hepatic veins will be treated with the implantation of the Transcatheter Tricuspid Valved Stent Graft
62092322|NCT01201083||HIV-|This study measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 105 HIV- recently tested men who have sex with men (MSM) and followed them for a year.
62290162|NCT03619629|SHAM_COMPARATOR|Sham Kinesio-taping|Sham kinesio-taping technique will be applied both ankles.
62290163|NCT03619629|SHAM_COMPARATOR|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement will be applied both ankles.
62290164|NCT00961961|OTHER|Lithium plus Fluoxetine Phase I|All participants were started in this arm. Those who met criteria for entry into Phase II were then randomized to one of the two Phase II arms.
62656096|NCT05256264||Low dose ketamine group|Sevoflurane + 3µg/kg/min ketamine infusion
62656097|NCT05256264||High dose ketamine group|Sevoflurane + 6µg/kg/min ketamine infusion
62656098|NCT02337127|ACTIVE_COMPARATOR|Arm A|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive Lamivudine extending therapy for 5 years.
62656099|NCT02337127|NO_INTERVENTION|Arm B|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive follow-up.
62656100|NCT02124226|EXPERIMENTAL|Methotrexate|Starting dose of 7.5 mg/week + folic acid the day after for 3 weeks as add-on therapy to their existing medication. Study treatment dosage will be increased, the maintenance dose will be 10 mg/week + folic acid the day after for 27 weeks
62092323|NCT01201083||HIV+ Acutely Infected|This study enrolled and followed 125 acutely infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
62290165|NCT00961961|OTHER|Lithium plus Placebo Phase I|No participants began their participation on Lithium plus Placebo.
62290166|NCT00961961|EXPERIMENTAL|Lithium plus Fluoxetine Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to continue on both compounds.
62290167|NCT00961961|PLACEBO_COMPARATOR|Lithium plus Placebo Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to switch from Fluoxetine to placebo.
62290168|NCT03431233|EXPERIMENTAL|Group 1|protein enriched bar-\>commercial cereal bar-\>water
62290169|NCT03431233|EXPERIMENTAL|Group 2|protein enriched bar-\>water-\>commercial cereal bar
62290170|NCT03431233|EXPERIMENTAL|Group 3|commercial cereal bar-\>protein enriched bar-\>water
61906779|NCT05165498||Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures|Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures who will have placed a thoracic epidural catheter to manage their perioperative analgesia.
62290171|NCT03431233|EXPERIMENTAL|Group 4|commercial cereal bar-\>water-\>protein enriched bar
62290172|NCT03431233|EXPERIMENTAL|Group 5|water-\>protein enriched bar-\>commercial cereal bar
62290173|NCT03431233|EXPERIMENTAL|Group 6|water-\>commercial cereal bar-\>protein enriched bar
62290174|NCT03411395|PLACEBO_COMPARATOR|Placebo drink|A standardized breakfast meal will be provided together with carbonated water containing aroma
62656101|NCT02124226|PLACEBO_COMPARATOR|Matched placebo|Placebo pills
62656102|NCT04311957|ACTIVE_COMPARATOR|Boosted PI Group|"Continuation of the same second-line regimen taken prior to entry:~This includes either Lopinavir/ritonavir (LPVr) 400 mg/100 mg BID or Atazanavir/ritonavir (ATV/r) 300 mg/100 mg QD~plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)."
62290175|NCT03411395|EXPERIMENTAL|5AA+CrPic Water Dose 1|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA and CrPic
62290176|NCT03411395|EXPERIMENTAL|5AA+CrPic Water Dose 2|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/2 of Dose 1) and CrPic
62290177|NCT03411395|EXPERIMENTAL|5AA+CrPic Water Dose 3|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/4 of Dose 1) and CrPic
62290178|NCT02868203|ACTIVE_COMPARATOR|OCT at 3 months|OCT at 3 months and 12 OCT at 3 months
62290179|NCT02868203|ACTIVE_COMPARATOR|OCT at 6months|OCT at 6 months and 12 OCT at 3 months
61906780|NCT02453815|EXPERIMENTAL|arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to receive an arterial catheter at surgery, then the subject will be placed in the experimental arm of the study.
62290180|NCT02055625|EXPERIMENTAL|Mesenchymal stromal cell treatment|Biological: Mesenchymal stromal cells
62290181|NCT05887999|EXPERIMENTAL|LY3532226|
62290182|NCT05887999|PLACEBO_COMPARATOR|Placebo|
62290183|NCT04864587||Restorative colectomy with ileoanal pouch|Patients with restorative colectomy with ileoanal pouch who receive pouchoscopy for detection of pouchitis or neoplasm
62290184|NCT05821361|EXPERIMENTAL|HAIC+cadonilimab+bev|
62463669|NCT05342597|EXPERIMENTAL|Group B|A single oral dose of MT-1186 with meal 1 condition in period 1, meal 2 condition in period 2, meal 3 condition in period 3, fasted condition in period 4, and meal 4 condition in period 5.
62463670|NCT05342597|EXPERIMENTAL|Group C|A single oral dose of MT-1186 with meal 2 condition in period 1, meal 3 condition in period 2, fasted condition in period 3, meal 1 condition in period 4, and meal 4 condition in period 5.
62656103|NCT04311957|EXPERIMENTAL|B/F/TAF Group|Combination tablet of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
62290185|NCT00456313|ACTIVE_COMPARATOR|arm 1|
62290186|NCT01365156|EXPERIMENTAL|EPLND + Chemoradiation|Group 1: Extraperitoneal laparoscopic lymphadenectomy followed by chemoradiation therapy
62290187|NCT01365156|ACTIVE_COMPARATOR|Chemoradiation|Group 2: standard-of-care chemoradiation therapy only
62290188|NCT04421326||Patients with acute ischemic stroke|Patients undergoing Mechanical Thrombectomy for large vessel occclusion with acute ischemic stroke
62290189|NCT00282126|EXPERIMENTAL|1|Participants will receive 90 meq of potassium citrate.
62290190|NCT00282126|EXPERIMENTAL|2|Participants will receive 60 meq of potassium citrate.
62290191|NCT00282126|PLACEBO_COMPARATOR|3|Participants will receive placebo.
62290192|NCT02104284|OTHER|Normal controls, methacholine positive|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in normal controls
62656104|NCT02421042|EXPERIMENTAL|Lenvatinib|Subjects determined to be eligible for the protocol will receive either a 5- or 10-mg single oral dose of lenvatinib on Day 1, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].
62290193|NCT02104284|OTHER|Normal controls, mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in normal controls.
62290194|NCT02104284|ACTIVE_COMPARATOR|Asthma, Methacholine|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in asthmatics
62290195|NCT02104284|ACTIVE_COMPARATOR|Asthma, Mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in asthmatics
62290196|NCT01661790|EXPERIMENTAL|Bevacizumab & Cisplatin|Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
62290197|NCT01661790|ACTIVE_COMPARATOR|Cisplatin|Cisplatin 30mg by intrapleural given every two weeks
62290198|NCT01695421|EXPERIMENTAL|Functional electrical stimulation|Burst modulated alternating rectified current with a 10 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
62290199|NCT01695421|EXPERIMENTAL|Medium-frequency alternating current|Burst modulated alternating current with a 2500 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
62290200|NCT01695421|EXPERIMENTAL|Burst-modulated alternating current|Burst modulated alternating current with a 4000 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts.
62290201|NCT01695421|PLACEBO_COMPARATOR|Placebo|Training with the intensity of 5 mA.
62290202|NCT02582996|EXPERIMENTAL|Cefalium®|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
62290203|NCT02582996|ACTIVE_COMPARATOR|Tylenol®|Acetaminophen
62290204|NCT05858190|EXPERIMENTAL|DEB group|paclitaxel-coated balloon (Orchid, Acotec Scientific Holdings Limited, Beijing, China)
62290205|NCT05858190|PLACEBO_COMPARATOR|POB group|
62290206|NCT02746510|EXPERIMENTAL|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV) or a pathogenic sequence variation (exome trio sequencing).
62308019|NCT01804855|EXPERIMENTAL|Smartphone|Usual care for Phase 1 of treatment. Treatment during Phase 2 of intervention using the Reactivate smartphone application only.
62308020|NCT00765479|EXPERIMENTAL|Arm I|Patients receive an oral soy protein isolate beverage once daily.
62308021|NCT00765479|PLACEBO_COMPARATOR|Arm II|Patients receive an oral casein placebo beverage once daily.
62463671|NCT05342597|EXPERIMENTAL|Group D|A single oral dose of MT-1186 with meal 3 condition in period 1, fasted condition in period 2, meal 1 condition in period 3, meal 2 in period 4, and meal 4 condition in period 5.
62463672|NCT02770625|EXPERIMENTAL|ISU302|60 U/kg (once every 2 weeks for 6 months)
62656105|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
62092324|NCT01201083||HIV+ Chronically Infected|This study enrolled and followed 91chronicially infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
62656106|NCT00520000|ACTIVE_COMPARATOR|Weekly Arm|Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle
62092325|NCT03803917|OTHER|Treatment|Injection with freshly collected autologous adipose tissue
62092326|NCT06692556|ACTIVE_COMPARATOR|Adjuvant radiotherapy|"Radiation therapy should be started within 8 to 10 weeks after surgery.~An equivalent dose of 45 to 50 Gy will be delivered on the operating bed. The irradiation techniques used may be either external radiation therapy with high-energy photons or electrons or brachytherapy. Patients will be monitored regularly until the date of the first local, regional or metastatic relapse, or until the date of death if they do not relapse.~Regardless of the type of relapse, remedial treatments will be left to the The investigator's discretion; they will be collected in the data collection book as well as data on subsequent relapses, up to the first metastatic relapse."
62092327|NCT06692556|NO_INTERVENTION|Surveillance|"Patients will not receive any treatment after surgery and will be monitored regularly until the date of their first local, regional or metastatic relapse, or until the date of death if they do not relapse.~Regardless of the type of relapse, the treatment to be used is left to the discretion of the investigator; it will be collected in the data collection book as well as data on subsequent relapses up to the first metastatic relapse."
62092328|NCT05232136|EXPERIMENTAL|OH2|This arm include two doses (1x10e6, 1x10e7 CCID50/mL) of OH2 injection，the 1x10e6 CCID50/mL dose group should be delivered before the 1x10e7 CCID50/mL dose group.
62092329|NCT02851511|EXPERIMENTAL|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
62092330|NCT02851511|EXPERIMENTAL|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
62092331|NCT02851511|EXPERIMENTAL|Educational Training + Active Stimulation|This arm receives educational training combined with active tDCS.
62092332|NCT02851511|EXPERIMENTAL|Educational Training + Sham Stimulation|This arm receives educational training combined with sham tDCS.
62290207|NCT05302635|EXPERIMENTAL|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
62308022|NCT00482001|EXPERIMENTAL|donepezil|donepezil, capsule, 5mg daily once daily for 14 days
62308023|NCT00482001|PLACEBO_COMPARATOR|placebo|placebo (cornstarch), capsule, once daily for 14 days
62308024|NCT04358978|ACTIVE_COMPARATOR|posterior mesh no attachment|laparoscopic sacral colpopexy with no fixation of posterior mesh
62656107|NCT00520000|EXPERIMENTAL|Every 3 week Arm|Carboplatin day 1, abraxane day 1, every 21 day cycle
61906781|NCT02453815|PLACEBO_COMPARATOR|no arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to not receive an arterial catheter at the time of surgery, then the subject will be placed in the placebo comparator arm of the study.
61906782|NCT00165802|EXPERIMENTAL|1|
61906783|NCT00921895|EXPERIMENTAL|Device Testing|Patients with conjunctivitis will be tested with the RPS Adeno Detector IV
62308025|NCT04358978|ACTIVE_COMPARATOR|posterior mesh attachment|laparoscopic sacral colpopexy with fixation of posterior mesh by suture
62308026|NCT04671680||Pregnant women with suspected placenta accreta|Pregnant women undergoing cesarean delivery with suspected placenta accreta spectrum.
62656108|NCT00520000|EXPERIMENTAL|Arm C|Carboplatin day 1, abraxane day 1, 8 every 21 day cycle
62656109|NCT01583088|EXPERIMENTAL|phenic nerve stimulation|effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
62656110|NCT01583088|SHAM_COMPARATOR|sham|sham phenic nerve stimulation
62656111|NCT01256307|EXPERIMENTAL|training group|training and educational program
62656112|NCT01256307|OTHER|control group|
62656113|NCT00148798|EXPERIMENTAL|Cetuximab plus chemotherapy|cetuximab + cisplatin + vinorelbine
62656114|NCT00148798|ACTIVE_COMPARATOR|Chemotherapy alone|cisplatin + vinorelbine alone
61906784|NCT01464957|EXPERIMENTAL|Newsletter intervention|Semi-tailored newsletter intervention for parents and children
62092333|NCT04811651|EXPERIMENTAL|Treatment group|intravenous umbilical cord derived mesenchymal stem cells
62092334|NCT04811651|PLACEBO_COMPARATOR|Placebo Comparator|intravenous placebo solution with the same appearance as the treatment group.
62092335|NCT00705640|EXPERIMENTAL|Arm 1A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
62092336|NCT00705640|EXPERIMENTAL|Arm 1B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
62092337|NCT00705640|EXPERIMENTAL|Arm 1C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
62092338|NCT00705640|EXPERIMENTAL|Arm 1D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
62092339|NCT00705640|EXPERIMENTAL|Arm 1E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
62092340|NCT00705640|EXPERIMENTAL|Arm 2A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
62092341|NCT00705640|EXPERIMENTAL|Arm 2B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
62092342|NCT00705640|EXPERIMENTAL|Arm 2C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
62092343|NCT00705640|EXPERIMENTAL|Arm 2D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
62092344|NCT00705640|EXPERIMENTAL|Arm 2E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
62092345|NCT06686875||Post surgical group|
62092346|NCT06696118|EXPERIMENTAL|Mid-foot osteoarthritis|
62092347|NCT06029218|EXPERIMENTAL|1DB|One daily Beam treatment
62092348|NCT06029218|ACTIVE_COMPARATOR|2DB|Two daily beam goldstandard
62092349|NCT01190670|EXPERIMENTAL|Part 1, Group 1|ASP015K, low dose followed by high dose, with oral tacrolimus
62092350|NCT01190670|EXPERIMENTAL|Part 1, Group 2|ASP015K, high dose followed by low dose, with oral tacrolimus
62092351|NCT01190670|EXPERIMENTAL|Part 2|ASP015K high dose with intravenous tacrolimus
62092352|NCT04737174|EXPERIMENTAL|ES-481|Administered as 25 mg oral gelatin capsules
62092353|NCT02856529|EXPERIMENTAL|Intervention|A BICSL certified trainer conduct the intervention. It includes hand on training session standardized in a scientific way. The participants trained on hand hygiene and use of PPE. Also, it includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator.
61906785|NCT01464957|NO_INTERVENTION|Usual care|No newsletter intervention
62092354|NCT02856529|ACTIVE_COMPARATOR|Control|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
62092355|NCT03862521|EXPERIMENTAL|Low carbohydrate diet group|Low carb diet, carbohydrates make up 30-40% of total daily calories.
62092356|NCT03862521|EXPERIMENTAL|Very low carbohydrate diet|Very low carb diet, carbohydrates make up 20-29% of total daily calories.
62092357|NCT03460717|EXPERIMENTAL|Intervention group: PNFS-TMC|Procedure- The patients in the intervention group were examined and the most painful points over the knee with the avoidance of the proposed site for skin incision for a future knee replacement operation were marked. The marked points received an intervention in the form of application of Peripheral Nerve Field Stimulation by Thermal Micro-Cautery (PNFS-TMC), an intense heat by metal rod was applied to the painful points for 0.3 to 0.5 seconds. The patients to receive 4 sessions over a period of 8 weeks with 2 weeks rest after every session.
62092358|NCT03460717|NO_INTERVENTION|Control group: Stepladder analgesics|Patients with painful knee osteoarthritis and on the waiting list for a total knee replacement surgery and declined to have PNFS-TMC were included in the control group. The control group received the stepladder analgesic protocol for pain management. The analgesic protocol was managed by the orthopaedic team without any interference by the investigators.
62092359|NCT04911114|EXPERIMENTAL|Intervention Arm|This is a single arm pilot study of group base exercise
62092360|NCT05791721|ACTIVE_COMPARATOR|Etoricoxib group|One hour preoperatively, preemptive, single-dose etoricoxib tablet in dosage of 90 mg will be administered orally
62656115|NCT02544789|EXPERIMENTAL|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
62092361|NCT05791721|ACTIVE_COMPARATOR|Dexamethasone group|One hour preoperatively, preemptive, single-dose dexamethasone in dosage of 4 mg will be administered intramuscularly
62463673|NCT05941481|EXPERIMENTAL|neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody|"1. Immunotherapy combined with chemotherapy (2 cycles): Intravenous tislelizumab (200mg, d1, q21d) in combination with XELOX regimen (capecitabine 1000 mg/m2 bid\*14d + oxaliplatin 130mg/m2, d1, q21d);~2. Concurrent radiotherapy: Within one week after the first initiation of chemo-immunotherapy, concurrent hypofractionated radiotherapy will be started: intensity modulated radiotherapy was given for tumors, total dose:30Gy/12f, 2.5Gy/f.~3. D2 resection will be received three to five weeks after the completion of neoadjuvant therapy."
62092362|NCT05791721|NO_INTERVENTION|Control group|In this group, one hour preoperatively no medication will be administered
62092363|NCT02301234|PLACEBO_COMPARATOR|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
62092364|NCT02301234|EXPERIMENTAL|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
62092365|NCT02301234|EXPERIMENTAL|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
62463674|NCT05724810|EXPERIMENTAL|Active deep transcranial magnetic stimulation (dTMS)|Each treatment consists of 60 trains, each lasting 3 sec and interleaved with a 15 sec delay. The entire treatment is delivered over 20 min. The treatment goes for 5 days/week and for a total of 3 weeks.
62737348|NCT03402594|EXPERIMENTAL|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
62092366|NCT03302910|EXPERIMENTAL|Short Stay Unit|Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
62092367|NCT03302910|ACTIVE_COMPARATOR|Standard of Care|Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
62092368|NCT04635878||Sepsis group|patients suffering from sepsis hospitalized in intensive care unit
62092369|NCT04635878||Control group|patients without infection hospitalized in intensive care unit
62737349|NCT06119971|EXPERIMENTAL|ACUPLUS|ACU+ : patients receives stimulation on the true experimental points (Yin-Tang + Shen-Men)
62092370|NCT05842343|EXPERIMENTAL|Acute anorexia nervosa|patient diagnose for a first episode of pure restrictive anorexia nervosa will be included. They will have stool sample and Food intake evaluation.
62737350|NCT06119971|PLACEBO_COMPARATOR|ACUMOINS|"ACU- : patients receives stimulation on placebo points (sham point)"
62737351|NCT03358355|EXPERIMENTAL|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
62737352|NCT04535817|EXPERIMENTAL|Treatment Group|Subjects will receive subcutaneous treatment of 300mg of omalizumab during the 24-week treatment period. One injection will be administered every 4 weeks.
62737353|NCT01266252|EXPERIMENTAL|Dexmedetomidine|
62737354|NCT05236725|NO_INTERVENTION|Standard of Care (SOC)|Subjects randomized to SOC arm are provided with the appropriate standard of care depending upon their risk level (as determined by their individual provider or WFBMC Maternal-Fetal Medicine provider)
62737355|NCT05236725|EXPERIMENTAL|Remote Blood Pressure Monitoring (rBPM)|"Subjects randomized to rBPM arm receive the appropriate standard of care depending upon their risk level, as well as the remote BP monitoring app (BabyScripts) and Bluetooth enabled BP cuff/monitor, and will receive the following equipment and monitoring:~* a specialized, Bluetooth enabled BP monitoring cuff (Clinically Validated, A\&D Medical Wireless Blood Pressure Monitor-Upper Arm (Appendix 2)~* BP monitoring smart phone app, BabyScripts™~* Verbal and written instructions, to conduct BP checks at home"
62737356|NCT03461549||Healthy adults|Evaluate sensor performance on both lower limbs of healthy adult subjects for pressure sensing and skin temperature sensing.
62737357|NCT03461549||Venous Leg Ulcer Adults|Evaluate sensor performance on both lower limbs of adult subjects with an active venous leg ulcer or history of a venous leg ulcer for pressure sensing and skin temperature sensing.
62737358|NCT01399983||pulmonary hypertension|patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
62737359|NCT04532294|EXPERIMENTAL|BGB-DXP593: Dose Level A|Participants will receive BGB-DXP593 10 mg/kg on Day 1
62737360|NCT04532294|EXPERIMENTAL|BGB-DXP593: Dose Level B|Participants will receive BGB-DXP593 30 mg/kg on Day 1
62737361|NCT04532294|EXPERIMENTAL|Placebo|Placebo to match (PTM) BGB-DXP593 on Day 1
62737362|NCT05064501||Asthma and COVID19 infection|Asthma and COVID19 infection
62737363|NCT05064501||Asthma without COVID19 infection|Asthma and COVID19 infection
62737364|NCT05700058|EXPERIMENTAL|Super-Whey protein Dose 1|All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
62092371|NCT05842343|EXPERIMENTAL|Chronic anorexia nervosa|Patient diagnose for anorexia nervosa at least 5 years ago and still maintaining a significant thinness will be included. They will have stool sample and Food intake evaluation.
62092372|NCT05842343|PLACEBO_COMPARATOR|Healthy control|Healthy Patient will be included. They will have stool sample and Food intake evaluation.
62092373|NCT05328440|EXPERIMENTAL|Arm A|HR-positive/HER2-positive MBC
62092374|NCT05328440|EXPERIMENTAL|Arm B|HR-negative/HER2-positive MBC
62092375|NCT05482568|EXPERIMENTAL|SHR-A1811 combined with Pyrotinib/SHR-A1811 combined with SHR-1316|
62092376|NCT03328052|EXPERIMENTAL|MYnd Analytics PEER Online directed therapy|Patients in this arm will receive anti-depressants as recommended by the PEER Online algorithm as described below.
62092377|NCT03328052|SHAM_COMPARATOR|Conventional therapy|Patients in this arm will receive anti-depressants as chosen by the physician without guidance by the PEER Online algorithm.
62092378|NCT06615622||Case|Patients with immune mediated peripheral nerve disorders GB syndrome and CIDP
62290208|NCT05302635|NO_INTERVENTION|Control group|"Students will be given training on nasogastric tube insertion and nasogastric tube application will be demonstrated with the demonstration method in the laboratory and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will apply the scenario on the model in the skill laboratory and will wear uniforms. The student will be given 5 minutes for preparation. Students will be taken to the application one by one and 15 minutes of practice time will be given. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance in the debriefing session. Each session will last 20-30 minutes. Students will be given a post-test."
62463675|NCT05724810|SHAM_COMPARATOR|Sham|Active and sham cards do not differ in appearance, and both coils are enclosed within the same helmet, enabling double-blind administration. The same procedure will be done, the only difference is that the sham card does not deliver any stimulation.
62463676|NCT02628834|EXPERIMENTAL|Fascial mobilization|First day intervention: Patients will take fascial mobilization techniques to management of plantar flexor spasticity
62463677|NCT02628834|EXPERIMENTAL|Stretching exercise|Second day intervention:Patients will take fascial mobilization techniques to management of plantar flexor spasticity
62656116|NCT02598310|EXPERIMENTAL|nab-paclitaxel plus trastuzumab|Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.
62092379|NCT06615622||Control|Healthy control matching group
62092380|NCT01174992|EXPERIMENTAL|Evicel|
62092381|NCT01174992|OTHER|Sutures only|
62092382|NCT05099887|OTHER|wound application|Application of Procenta as wound cover
62092383|NCT02123966|EXPERIMENTAL|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
62092384|NCT05298384|EXPERIMENTAL|Study Group|Individuals with nocturia as a result of idiopathic edema and autonomic failure will be assigned to wearing knee high then thigh high compression stockings to assess the effect on weight gain during the day and the number of nocturia events.
62092385|NCT00759200|EXPERIMENTAL|alb-interferon arm 1|
62290209|NCT02379325|EXPERIMENTAL|Lets Quit|Given text message
62092386|NCT00759200|EXPERIMENTAL|alb-interferon arm 2|
62290210|NCT02379325|ACTIVE_COMPARATOR|Pamplets education|Given pamplets on smoking and complication
62463678|NCT02628834|NO_INTERVENTION|Healthy Volunteers|Healthy individuals will only be evaluated with no intervention
62092387|NCT00759200|EXPERIMENTAL|alb-interferon arm 3|
62092388|NCT00759200|EXPERIMENTAL|alb-interferon arm 4|
62092389|NCT00759200|ACTIVE_COMPARATOR|peg-interferon|
62092390|NCT06175390|EXPERIMENTAL|Cohort A: early Triple Negative Breast Cancer|"Patients will receive neoadjuvant therapy with four cycles of 1200 mg of atezolizumab and 600 mg of Tiragolumab every 3 weeks in combination with nab-paclitaxel 100 mg/m2 on days 1, 8, and 15, every 3 weeks plus carboplatin AUC 5 on days 1 every 3 weeks then four cycles of 1200 mg of atezolizumab (Tecentriq®, Roche) and 600 mg of Tiragolumab (Roche) every 3 weeks in combination with Doxorubicin 60 mg/m2 plus Cyclophosphamide 600 mg/m2.~After surgery, patients will receive adjuvant treatment with atezolizumab plus tiragolumab every 3 weeks for up to nine cycles (in patients with germline BRCA1/2 mutation eligible to adjuvant olaparib, tiragolumab and atezolizumab will not be resumed after surgery)."
62092391|NCT06175390|EXPERIMENTAL|Cohort B: metastatic Triple Negative Breast Cancer|"Patients will receive atezolizumab 1680 mg administered by IV infusion Q4W, plus tiragolumab 840 mg administered by IV infusion Q4W, plus nab-paclitaxel 100 mg/m2 administered by IV infusion d1, d8, d15 of every 28-day cycle.~Treatments will be administered until disease progression or limiting toxicity."
62092392|NCT03074981|EXPERIMENTAL|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
62290211|NCT05302323|OTHER|Disposable Drapes|group using disposable surgical drapes
62290212|NCT05302323|OTHER|Reusable Drapes|group using reusable surgical drapes
62290213|NCT01856114|EXPERIMENTAL|Fentanyl Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
62290214|NCT01856114|PLACEBO_COMPARATOR|Placebo Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
62463679|NCT01157091|EXPERIMENTAL|Arm I|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62463680|NCT01311908||Surgery, Roux-en-Y , reflux esophagitis|Patients with roux-en-Y reconstruction (study group)
62463681|NCT01311908||surgery, traditional gastrojejunostomy|Traditional gastrojejunostomy reconstruction (control group).
62656117|NCT00745602|EXPERIMENTAL|1|Patients referred for elective direct current cardioversion (DCCV) of atrial fibrillation.
62656118|NCT03092232|EXPERIMENTAL|Cohort 1_Active and Matching Placebo|
62092393|NCT02914067|EXPERIMENTAL|Cohort 1|"* Prior to surgery, subjects will have a complete standard of care history and physical exam by the neurosurgeon and then undergo peri-diagnostic neurocognitive testing utilizing the NIH Toolbox Cognitive Battery computer testing software for iPad (will take 45 minutes). The peri-diagnostic period will be defined as the period from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later.~* Participants will also undergo a rsfcMRI during their standard of care MRI imaging which will add 15 minutes to their scan time"
62092394|NCT02914067|EXPERIMENTAL|Cohort 2|"* Patients with diagnosis of a posterior tumor will undergo neurocognitive testing utilizing the NIH Toolbox. Testing will be every 6 months for children currently receiving therapy and annually for those that have completed all therapy for a total of 3 sessions. During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of time. rsfcMRI will be obtained every 6 months for children currently receiving therapy and annually for those that have completed therapy for a total of 3 rsfcMRIs for each patient.~* Patients in Cohort 1 will also be eligible to continue with the longitudinal assessment as just described. These participants will then undergo repeat neurocognitive testing using the NIH toolbox 6-9 months for an additional 3 testing sessions. rsfcMRI will be obtained during their follow-up imaging at 6-9 month intervals for a total of 3 additional rsfcMRIs (4 total scans)."
62092395|NCT02914067|EXPERIMENTAL|Cohort 3|"* During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.~* rsfcMRI will be obtained annually for total of 3 rsfcMRIs for each patient."
62092396|NCT02914067|EXPERIMENTAL|Cohort 4 Arm A|"Undergo the following MRI images: RSFC MRI, T2/T1 MRI, and DTI.~* Will complete cognitive testing using the NIH Toolbox Cognitive Battery~* All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients \<18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients \< 18 years of age."
62463682|NCT01118247|EXPERIMENTAL|pure Ti|Cup and stem partly coated with pure titanium
62463683|NCT01118247|ACTIVE_COMPARATOR|pure Ti and HA|Cup and stem partly coated with pure titanium, and fully coated with HA.
62463684|NCT02620670|ACTIVE_COMPARATOR|Individuals with obesity|Body mass index (BMI) is 30.0 to 39.9 kg / m2 and a waist circumference greater than 80 cm in women and 90 cm for men Physical activity of moderate intensity for 3 days
62656119|NCT03092232|EXPERIMENTAL|Cohort 2_Active and Matching Placebo|
62656120|NCT03092232|EXPERIMENTAL|Cohort 3_Active and Matching Placebo|
62463685|NCT02620670|ACTIVE_COMPARATOR|Individuals with normal weight|Body mass index BMI is 18.5 to 24.9 kg / m2 with lower waist circumference of 80 cm for women and 90 cm for men Physical activity of moderate intensity for 3 days
62463686|NCT01168557|EXPERIMENTAL|Stress-Echo and EIT|Patients who routinely undergo stress-echocardiography will additionally be measured by EIT using a rubber belt, which will be placed around their chest
62463687|NCT01589783||Pregnant or newly post partum women|
62463688|NCT01589783||family practice physicians and obstetricians|
62463689|NCT02468778|EXPERIMENTAL|HeartMate PHP (Roll-in)|Participants who receive a HeartMate PHP device without randomisation will be included in this arm
62656121|NCT02084342|PLACEBO_COMPARATOR|Group TN|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min, before incision.Then at 1mg/kg/h, IV pump, until the surgery is over.~Normal saline (NS) 100ml IV for 20min, before incision."
62656122|NCT02084342|EXPERIMENTAL|Group TD|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min,before incision.Then at 1mg/kg/h,IV pump,until the surgery is over.~Desmopressin acetate injection at 0.3μg/kg dissolved in 100ml NS, IV for 20min, before incision."
62656123|NCT04243668|EXPERIMENTAL|ANTI REFLUX MUCOSAL ABLATION THERAPHY|In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.
62092397|NCT02914067|EXPERIMENTAL|Cohort 4 Arm B|"* During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.~* Will complete cognitive testing using the NIH Toolbox Cognitive Battery~* All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients \<18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients \< 18 years of age."
62092398|NCT01750996|NO_INTERVENTION|Usual Care control (Parenting tips)|Participants randomized to usual care will have access to a brief information website containing brief parenting tips but will not receive Strongest Families Intervention
62092399|NCT01750996|EXPERIMENTAL|Strongest Families|Strongest Families intervention
62092400|NCT05224687||Daptomycin are dosed solely by pharmacists|Daptomycin at two institutions are dosed solely by pharmacists
62092401|NCT05224687||daptomycin protocol is not used and dose by the provider|daptomycin PTD is optional or not utilized at the other institutions.
62092402|NCT01866475|ACTIVE_COMPARATOR|Renal Disease|Those with mild to moderate renal disease and had an EZ-IO for 48 hours
62092403|NCT01866475|ACTIVE_COMPARATOR|Diabetes|Those with controlled diabetes and had an EZ-IO for 48 hours
62092404|NCT01866475|ACTIVE_COMPARATOR|Renal disease and diabetes|Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours
62092405|NCT01866475|ACTIVE_COMPARATOR|Healthy adults|Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours
62092406|NCT04123366|EXPERIMENTAL|Olaparib+Pembrolizumab|Participants receive olaparib 300 mg via oral tablet 2 times each day PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 21-day cycle. Participants may receive olaparib+pembrolizumab for up to approximately 2 years.
62092407|NCT05002543||MANTRA Aortic Sub-study|"Subjects diagnosed with aortic valve disease who are considered suitable to undergo aortic valve replacement with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Tissue Valve:~* Perceval® PLUS SUTURELESS AORTIC HEART VALVE~* Perceval® S SUTURELESS AORTIC HEART VALVE~Mechanical Valves:~* Bicarbon™ Bileaflet Heart Valve Prostheses Models:~  * Bicarbon Fitline Aortic (LFA)~ * Bicarbon Slimline Aortic (LSA)~ * Bicarbon Overline Aortic (LOV)~* Carbomedics Prosthetic Heart Valve Models:~  * Standard Aortic Valve~ * Reduced Aortic Valve~ * Supra-Annular Aortic Valve (Top Hat)~ * Orbis™ Aortic Valve~Ascending Aorta Prostheses~* CARBOMEDICS-CARBO-SEAL™~* CARBOMEDICS CARBO-SEAL™ VALSALVA"
62092408|NCT05002543||MANTRA Mitral/Tricuspid Sub-study|"Subjects diagnosed with mitral and/or tricuspid valve disease who are considered suitable to undergo mitral valve repair/replacement and/or tricuspid valve repair with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Annuloplasty Rings:~* SOVERING™ ANNULOPLASTY DEVICE models~  * annuloplasty ring, mitral model~ * annuloplasty band, mitral and tricuspid models~* Carbomedics Annuloplasty Ring models:~  * CARBOMEDICS ANNULOFLO®~ * CARBOMEDICS ANNULOFLEX®~* Memo Annuloplasty Ring o MEMO 3D™ SEMIRIGID ANNULOPLASTY RING~Mitral Valves:~* Bicarbon™ Bileaflet Heart Valve Prostheses Models:~  o Bicarbon Fitline Mitral (LFM)~* Carbomedics Prosthetic Heart Valve Models:~  * Standard Mitral Valve~ * Orbis™ Mitral Valve~ * OptiForm® Mitral Valve"
62656124|NCT00327535|EXPERIMENTAL|Mircera 6.3 micrograms/kg|
62092409|NCT05002543||MANTRA Memo 4D Sub-study|Subjects diagnosed with mitral valve disease who are considered suitable to undergo mitral valve repair with a CORCYM Memo 4D annuloplasty ring can be included in this study.
62092410|NCT06691893|NO_INTERVENTION|No RELiZORB|Patients will receive tube feeds (via nasogastric or nasojejunal tube) without the use of RELiZORB
62290215|NCT00358813|EXPERIMENTAL|Subjects receiving casopitant|Eligible subjects will receive a 100 milligrams oral dose of casopitant once daily for five consecutive days.
62463690|NCT02468778|EXPERIMENTAL|HeartMate PHP (Randomised)|Participants who receive a HeartMate PHP device after randomisation will be included in this arm
62656125|NCT00327535|EXPERIMENTAL|Mircera 9 micrograms/kg|
62463691|NCT02468778|ACTIVE_COMPARATOR|Any Abiomed Impella® (Randomised)|Participants who receive any Abiomed Impella® Device approved for use in high-risk PCI after randomisation will be included in this arm
62656126|NCT00327535|EXPERIMENTAL|Mircera 12 micrograms/kg|
62656127|NCT00327535|ACTIVE_COMPARATOR|Darbepoetin alfa|
62656128|NCT03867435||Individuals with DM1|Individuals with myotonic dystrophy type 1 (DM1)
62656129|NCT03867435||Individuals with DM2|Individuals with myotonic dystrophy type 2 (DM2)
62656130|NCT00922311|EXPERIMENTAL|Aliskiren|
62656131|NCT04011072|ACTIVE_COMPARATOR|Infrared treatment arm|Far infrared radiation will be given for 40 minutes on the skin above the patients fistula in each dialysis session for one year
62290216|NCT04208295||Patients|Type 2 diabetics
62290217|NCT04208295||Healthy controls|Matched healthy controls
62290218|NCT03151486|EXPERIMENTAL|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
62290219|NCT03151486|EXPERIMENTAL|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
62656132|NCT04011072|NO_INTERVENTION|Control arm|The control group will not receive any intervention, but will be followed with the same data as the treatment group
62656133|NCT01088386||Patients|All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program
62656134|NCT04943224|EXPERIMENTAL|R1 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 Disease Activity Score (DAS) in three consecutive tests in three month intervals.
62656135|NCT04943224|EXPERIMENTAL|R2 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 Disease Activity Score (DAS) in in five consecutive tests in three month intervals.
62656136|NCT05605990|EXPERIMENTAL|Nurse group|Using an innovative tourniquet (Acusense Nonpneumatic tourniquet) for the standard of care
62092411|NCT06691893|EXPERIMENTAL|RELiZORB|Patients will receive tube feeds (via nasogastric or nasojejunal tube) with the use of RELiZORB
62092412|NCT06334497|EXPERIMENTAL|Letermovir+Valganciclovir|Daily administration of Letermovir plus Valganciclovir
62092413|NCT06334497|ACTIVE_COMPARATOR|Letermovir Placebo+Valganciclovir|Daily administration of Letermovir placebo plus Valganciclovir
62092414|NCT01411280|PLACEBO_COMPARATOR|Laboratory trial|Compare methylphenidate to placebo in an acute laboratory trial
62092415|NCT01411280|EXPERIMENTAL|Home/School trial|Low dose and moderate dose methylphenidate are compared to placebo in a home and school trial
62092416|NCT01204970||COPD|COPD Gold class 1-4
62092417|NCT01204970||Transplant|Lung transplant recipients
62092418|NCT01204970||Control|Patients with normal spirometric data
62092419|NCT04043611|ACTIVE_COMPARATOR|Conservative physical therapy management|Tens and hot pack , Soft tissue mobilization , Maitland's Lumbar segmental mobilization, Traction, Neurodynamics, Active Stretching, McKenzie Prone Extension Exercises
62092420|NCT04043611|EXPERIMENTAL|ELDOA|Conservative physical therapy management + ELDOA positions
62092421|NCT01235585|EXPERIMENTAL|Bitopertin oral dose level 1|
62092422|NCT01235585|EXPERIMENTAL|Bitopertin oral dose level 2|
62092423|NCT01235585|PLACEBO_COMPARATOR|Placebo|
62092424|NCT05455996|EXPERIMENTAL|MDMA-assisted therapy|Participants will receive 3-dosing model of MDMA-assisted therapy (includes 9 non-drug therapy sessions)
62092425|NCT05030376|EXPERIMENTAL|patients with ileostomy without type 2 diabetes|intraileal glucose or saline infusion via ileostomy
62092426|NCT05030376|EXPERIMENTAL|patients with ileostomy with type 2 diabetes|intraileal glucose or saline infusion via ileostomy
62092427|NCT05349084|OTHER|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
62092428|NCT05487469|EXPERIMENTAL|Thymosin alpha 1|
62092429|NCT05487469|SHAM_COMPARATOR|Blank control|
62092430|NCT02314455|EXPERIMENTAL|D-xylose, water, honey|"* 25 grams of D-xylose~* 10 cc of water~* 2 teaspoons of honey"
62092431|NCT00767715|EXPERIMENTAL|A|Patients will be given olanzapine
62092432|NCT00767715|ACTIVE_COMPARATOR|B|Patients will be given either haloperidol or zuclopentixol
62656137|NCT02308878|NO_INTERVENTION|Treatment-as-usual|This group consists of treatment-as-usual for opioid dependence syndrome.
62092433|NCT03672539|EXPERIMENTAL|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and days 1 and 3 of cycle 2 and gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~CONSOLIDATION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and gemtuzumab ozogamicin over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~MAINTENANCE CYCLE: Patients receive gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
62092434|NCT05105152|EXPERIMENTAL|DARIC-33|
62092435|NCT02948946||Neuroendocrine Tumor (NET) Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage NET of gastroenteropancreatic (GEP) or lung origin; In the first stage of the study (initial 50 patients) only potential participants with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
62092436|NCT02948946||Non-NET Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage gastrointestinal (GI) malignancies.
62290220|NCT03151486|EXPERIMENTAL|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
62092437|NCT05002361|ACTIVE_COMPARATOR|Treatment A+B|24 mg dexamethasone i.v. perioperatively
62092438|NCT05002361|PLACEBO_COMPARATOR|Placebo|Placebo (isotonic saline) i.v. perioperatively
62092439|NCT02662244|EXPERIMENTAL|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
62092440|NCT01077661||Patients administrated Nebivolol|There is only one group. This group includes patients administrated Nebivolol
62092441|NCT00986089||women who have an IUD placed at the time of c-section|
62092442|NCT01615809|EXPERIMENTAL|Amphotericin B (ABELCET®)|"Drug: AMPHOTERICIN B Dosage form: Abelcet® 5mg/ml administered by inhalation. Dosage: 10 ml (50 mg) for the first week with a frequency twice a week. Dosage: from the second week onwards 5 ml (25 mg) with a frequency of a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.~Duration: 4-5 prophylaxis courses defined as each administration period during a neutropenia period, with a 4-6 weeks length considering the duration of neutropenia."
62092443|NCT06672900|EXPERIMENTAL|ALG-000184|Single or multiple doses of ALG-000184, an investigational HBV capsid assembly modulator
62092444|NCT06672900|EXPERIMENTAL|Carbamazepine|Multiple doses of carbamazepine, a strong CYP3A4 inducer, to evaluate potential drug-drug interactions with ALG-000184
62092445|NCT06672900|EXPERIMENTAL|Itraconazole|Multiple doses of itraconazole, a strong CYP3A4 inhibitor, to evaluate potential drug-drug interactions with ALG-000184.
62092446|NCT00864058|EXPERIMENTAL|A|Gabapentin 400 mg capsules
62092447|NCT00864058|ACTIVE_COMPARATOR|B|Neurontin 400 mg capsules
62092448|NCT02724761|EXPERIMENTAL|Experimental: Racemic Epinephrine|Over the Counter (OTC) - 0.5 mL Nebulized Racemic Epinephrine
62092449|NCT02724761|PLACEBO_COMPARATOR|Placebo: 0.9% Normal Saline|0.5 mL 0.9% Normal Saline
62656138|NCT02308878|EXPERIMENTAL|Mobile health cognitive stimulation|Cognitive stimulation using mobile technology with m-Health applications.
62656139|NCT01698788|EXPERIMENTAL|TPHM removal without ozurdex|Comparison of taut posterior hyaloid removal with (Group B)and without intraoperative ozurdex(Group A)
62656140|NCT01698788|EXPERIMENTAL|TPHM removal with ozurdex|Comparison of TPHM removal with (Group B) and without (Group A)Ozurdex
62092450|NCT01239615||healthy volunteers|
62092451|NCT06297096|EXPERIMENTAL|combined therapy Nintedanib + Tocilizumab with or without standard treatment + extended diagnostics|tocilizumab pre-filled syringe 162 mg subcutaneously once a week nintedanib tablets 150 mg twice a day or 2 x 100 mg a day
62092452|NCT06297096|ACTIVE_COMPARATOR|standard treatment (reference group) + extended diagnostics|mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
62092453|NCT01218685||Health adults|
62092454|NCT01218685||Health children|
62092455|NCT01218685||Pregnants|
62092456|NCT01218685||Elderly over 65 years old|
62092457|NCT01218685||HIV patients|
62092458|NCT01218685||Kidney transplant|
62092459|NCT01218685||Oncologic patients|
62092460|NCT01218685||Rheumatologic adult patients|
62092461|NCT01218685||Rheumatologic children patients|
62092462|NCT05040243|EXPERIMENTAL|Treatment Group|"On the basis of conventional acupuncture treatment combined with acupoint application of Yanqing Zhitong Ointment.~Acupuncture point:Weizhong,Shenshu,Dachangshu,Jaji,Ashi Acupoint application:Pain in the lumbar spine, Mingmen, Yaoyangguan, Shenshu (double), Ashi (6 points in total); Within 3 inches beside the spine on both sides of the waist, Shenshu (double), Dachangshu (double), Ashi (6 points in total); 3 inches away from the sides of the spine on both sides of the waist, Shenshu (double), Zhishi (double), Ashi (6 points in total).~Stick to each point for about 4 hours. If there is a burning sensation or obvious itching or other discomfort on the part after application, it can be removed in advance.~Three times a week( Monday, Wednesday, and Friday). Course of treatment: each course lasts for 2 weeks, a total of 2 courses of continuous treatment."
62656141|NCT04145817|EXPERIMENTAL|genetic counselling|Genetic counselling (PRS for risk estimation) and questionnaires in the participating Cancer Genetic Clinics for healthy woman relative of a person first tested in the family (index case) who received a positive genetic test result or a negative non-informative test result
62656142|NCT04192331|EXPERIMENTAL|2/3dose strategy|HER2 negative advanced breast cancer patient
62656143|NCT04192331|ACTIVE_COMPARATOR|3/4dose strategy|HER2 negative advanced breast cancer patient
62656144|NCT05663970|EXPERIMENTAL|Virtual Group Social ABCs|- Participants complete the Group Social ABCs intervention program
62656145|NCT05663970|NO_INTERVENTION|Active Control Condition|"* Participants complete the active control condition:~* 3 bi-weekly (virtual) group-based sessions (i.e., groups of 4-8 parents, over 6 weeks)~* psychoeducational curriculum not related to social-communication delivered by study personnel not directly involved in the intervention arm~* Families may access any available services in their communities (i.e., treatment as usual), which are recorded~* Families will be offered the option to do Group Social ABCs intervention program after completing the Control phase"
62656146|NCT04814797||"CF children with gas trapping"|"CF children with gas trapping will be defined by a ratio between the difference of functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of \>10%"
62092463|NCT05040243|SHAM_COMPARATOR|Control Group|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
62092464|NCT04010175|ACTIVE_COMPARATOR|Control group|
62092465|NCT04010175|EXPERIMENTAL|Experimental group 1|Moderate frequency cognitive distance training
62092466|NCT04010175|EXPERIMENTAL|Experimental group 2|High frequency cognitive distance training
62092467|NCT04372511|EXPERIMENTAL|Binaural Beats|Group A : use of stereo headphones that generate sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
62092468|NCT04372511|NO_INTERVENTION|No sounds|Group B : use of stereo headphones with a white background noise
62092469|NCT02679768|ACTIVE_COMPARATOR|Circadian Reinforcement Therapy|Circadian reinforcement therapy
62092470|NCT02679768|PLACEBO_COMPARATOR|Standard treatment|Standard treatment
62092471|NCT03042442||Patients with pancreatic cancer|Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
62092472|NCT03042442||health patients (controls)|Health patients
62092473|NCT00770211|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
62092474|NCT00770211|PLACEBO_COMPARATOR|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
62092475|NCT04590144|EXPERIMENTAL|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead
62092476|NCT01214447||Low - OSND less than 22|
62092477|NCT01214447||Moderate - OSND score 23-27|
62092478|NCT01214447||Normal - OSND score 28-32|
62092479|NCT06696456||Study Participants|Individuals with otoferlin gene-mediated hearing loss who received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial
62092480|NCT06214143|EXPERIMENTAL|T3011|
62092481|NCT04949399|EXPERIMENTAL|BOTOX|BOTOX (OnabotulinumtoxinA) was injected into the platysma muscle on Day 1
62290221|NCT03151486|EXPERIMENTAL|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
62290222|NCT03151486|EXPERIMENTAL|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
62656147|NCT04814797||"CF children without gas trapping"|"CF children without gas trapping will be defined by a ratio between the difference of the functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of ≤10%"
62656148|NCT03770819|PLACEBO_COMPARATOR|Placebo group|Application of placebo gel followed by sham Photodynamic therapy
62656149|NCT03770819|ACTIVE_COMPARATOR|Zinc oxide gel group|Application of Zinc oxide gel followed by sham Photodynamic therapy.
62656150|NCT03770819|EXPERIMENTAL|PDT group|Application of placebo gel followed by Photodynamic therapy.
62656151|NCT03770819|EXPERIMENTAL|Zinc oxide and PDT group|Application of Zinc oxide gel followed by Photodynamic therapy.
62290223|NCT03151486|EXPERIMENTAL|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
62290224|NCT03151486|EXPERIMENTAL|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
62290225|NCT03151486|EXPERIMENTAL|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
62290226|NCT03151486|EXPERIMENTAL|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
62290227|NCT03151486|EXPERIMENTAL|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
62290228|NCT01646099|EXPERIMENTAL|Sun Protection Education|Distribution of the internet-based sun protection educational program.
62290229|NCT01646099|NO_INTERVENTION|Control|Distribution of general skin care information.
62656152|NCT03368417|ACTIVE_COMPARATOR|Usual Care|Usual care from SingHealth Polyclinics which includes non-wireless HBPM. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
62656153|NCT03368417|EXPERIMENTAL|Wireless HBPM System|Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
62656154|NCT03368417|EXPERIMENTAL|Wireless HBPM System and Incentives|Usual care from SingHealth Polyclinics with wireless HBPM system and BP monitoring incentives. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
62656155|NCT03147963|EXPERIMENTAL|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
62656156|NCT03147963|ACTIVE_COMPARATOR|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
62656157|NCT02178332|EXPERIMENTAL|Yhteispeli, whole school programme|Yhteispeli-programme aims to support children's socio-emotional skills and well being at schools. Schools receive the Yhteispeli manual and teachers receive 3 and head masters 2 lecture days about use of Yhteispeli methods including group discussions and exercises. In addition every school is visited 4 times to support the use of Yhteispeli methods. (Lectures for the head masters March 2013 - November 2013, teachers August 2013 - January 2014)
62656158|NCT02178332|ACTIVE_COMPARATOR|Two theoretical lectures|Teachers receive two theoretical lectures on development of children's socio-emotional skills (3 hours in November 2013 and 3 hours in March 2014 ).
62092482|NCT04949399|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the platysma muscle on Day 1
62092483|NCT06308978|EXPERIMENTAL|FT819|Participants with moderate to severe active SLE.
62092484|NCT04576780||Referred Patients with Large, Complex Colorectal Polyps|Patients referred from outside community care hospitals or ambulatory endoscopy centers to the therapeutic endoscopy group at St. Michaels Hospital via the new integrated management pathway for endoscopic resection of a large or complex colorectal polyp.
62092485|NCT06697340||Group I|Intensive Care patients admitted to tertiary intensive care unit and treated more than 24 hours
62092486|NCT00743405|OTHER|Cohort 1|Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan
62092487|NCT00743405|OTHER|Cohort 2|Subjects will be receive GSK1034702 5 mg following the dose escalation plan
62092488|NCT01761422||SLE active flare|Patients who are having an active flare of their lupus confirmed by labs
62290230|NCT05435820|EXPERIMENTAL|BCW group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: continuous wave iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
62290231|NCT05435820|EXPERIMENTAL|BPW-1 group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: pulsed wave, 10 Hz; 50% duty cycle iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
62656159|NCT02022553|EXPERIMENTAL|rectal cancer, surgery|
62656160|NCT02022553|ACTIVE_COMPARATOR|rectal cancer, RACHEL, surgery|
62092489|NCT01972087|NO_INTERVENTION|Control|Participants randomized to the control arm receive no telephone simulation training.
62092490|NCT01972087|EXPERIMENTAL|Simulation Training|Participants randomized to the intervention arm receive telephone simulation training.
62092491|NCT06405334||PD-Postural Instability|Veterans with postural instability
62463692|NCT01938547|EXPERIMENTAL|clevidipine|"An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).~Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range."
62463693|NCT04829162|EXPERIMENTAL|Mother with obesity, daughter with obesity|Image of a mother with obesity and a daughter with obesity.
62737365|NCT05700058|EXPERIMENTAL|Super-Whey protein Dose 2|All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
62092492|NCT06698107|EXPERIMENTAL|Intervention group|
62092493|NCT06698107|ACTIVE_COMPARATOR|Control group:|
62290232|NCT05435820|EXPERIMENTAL|BPW-2 group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: pulsed wave, 40-50 Hz; 50% duty cycle iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
62290233|NCT05435820|SHAM_COMPARATOR|SHAM group|"NIR-TLT dose:~i. Treatment site(s): none ii. Temporal format: none iii. Average radiance: 0 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 0 kJ"
62290234|NCT06151392|ACTIVE_COMPARATOR|Probiotic group|probiotic will be administered to this group of pediatric patients with ventriculitis
62290235|NCT06151392|ACTIVE_COMPARATOR|Zinc group|Zinc will be administered to this group of pediatric patients with ventriculitis
62290236|NCT06151392|ACTIVE_COMPARATOR|Probiotic and Zinc group|probiotic and Zinc will be administered to this group of pediatric patients with ventriculitis
62290237|NCT06151392|NO_INTERVENTION|Control group|interventional drug will not be administered to this group of pediatric patients with ventriculitis
62290238|NCT02254343|EXPERIMENTAL|proximal robot-assisted therapy|treatment programs will target to shoulder and elbow portions of upper extremity via the InMotion2 robotic system
62463694|NCT04829162|EXPERIMENTAL|Mother with obesity, daughter without obesity|Image of a mother with obesity and a daughter without obesity.
62463695|NCT04829162|EXPERIMENTAL|Mother without obesity, daughter with obesity|Image of a mother without obesity and a daughter with obesity.
62737366|NCT05700058|EXPERIMENTAL|Super-Whey protein Dose 3|All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
62092494|NCT04285229|EXPERIMENTAL|Ixekizumab|Participants received Ixekizumab during the double-blind and extended treatment periods (i.e.,) starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during the follow-up period.
62092495|NCT04285229|PLACEBO_COMPARATOR|Placebo|Participants received placebo every four weeks (Q4W) by subcutaneous (SC) injection during the double-blind period. During the extension period, they received starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during follow-up period.
62092496|NCT05464784|EXPERIMENTAL|MN-001|
62092497|NCT05464784|PLACEBO_COMPARATOR|MN-001 Placebo|The placebo comparator is a tablet identical in appearance to MN-001.
62092498|NCT05980052|EXPERIMENTAL|Static weekly physical activity goal of 150 minutes/week|Participants will receive a physical activity action planning intervention and assigned a static weekly physical activity goal of 150 minutes/week of moderate-intensity activity; action planning sessions will focus on the participant achieving this weekly goal.
62290239|NCT02254343|EXPERIMENTAL|distal robot-assisted therapy|the InMotion3 robot system will be used to execute treatment programs focus on wrist movements. It includes three degrees of freedom to allow wrist flexion/extension, abduction/adduction, and pronation/supination.
62290240|NCT02254343|ACTIVE_COMPARATOR|individualized intensive therapy|individualized occupational therapy which is dose-match to robot-assisted therapy, based on task-oriented principle.
62290241|NCT00611247|EXPERIMENTAL|Methylated AGAT Promoter (Group 1)|Induction: 200 mg/m2/day oral Temozolomide x 7 days
62290242|NCT00611247|EXPERIMENTAL|Un-Methylated AGAT Promoter (Group 2)|Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days
62290243|NCT00544921|EXPERIMENTAL|50 mg|
62290244|NCT00544921|EXPERIMENTAL|100 mg|
62290245|NCT00544921|EXPERIMENTAL|250 mg|
62290246|NCT00544921|EXPERIMENTAL|500 mg|
62290247|NCT00544921|EXPERIMENTAL|750 mg|
62290248|NCT00544921|EXPERIMENTAL|1000 mg|
62290249|NCT00544921|PLACEBO_COMPARATOR|Placebo|
62290250|NCT00961987|EXPERIMENTAL|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
62092499|NCT05980052|EXPERIMENTAL|Incremental weekly physical activity goal increase|Participants will receive a physical activity action planning intervention and assigned a weekly physical activity goal that is 20% greater than the level of moderate-intensity physical activity performed the previous week; action planning sessions will focus on the participant achieving their assigned goal.
62092500|NCT05980052|EXPERIMENTAL|Self-selected weekly physical activity goal|Participants will receive a physical activity action planning intervention and will self-select their own moderate-intensity physical activity goal each week; action planning sessions will focus on helping participants achieve their self-selected goal.
62092501|NCT05980052|EXPERIMENTAL|No stated weekly physical activity goal (comparison group)|Participants will receive a physical activity action planning intervention that does not include explicitly stated physical activity goals to achieve.
62092502|NCT04861064|EXPERIMENTAL|Treatment Group|
62290251|NCT00961987|ACTIVE_COMPARATOR|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
62290252|NCT02952976|ACTIVE_COMPARATOR|Abthera|Patients with open abdomen submitted to treatment with the Abthera dressing
62290253|NCT02952976|ACTIVE_COMPARATOR|Barker|Patients with open abdomen submitted to treatment with the Baker dressing
62656161|NCT06343324|EXPERIMENTAL|Experimental|"Individuals in the experimental group will be informed about the mobile application. The web-based mobile application called Training for Living with NIV prepared by the researcher will be installed on the mobile phone of the individual or his caregiver. They will be asked to log in to the web-based NIV Living Training mobile application twice a week to reinforce their knowledge, and text message alerts will be sent via mobile phone. Patient Descriptive Characteristics Form, S³-NIV Questionnaire and Insomnia Severity Index scales will be applied to the experimental group as pre-test data. The scales will be applied again to the experimental group, which continues education for 8 weeks, in the 4th week and the 8th week."
62092503|NCT05905055|EXPERIMENTAL|co-administration of cefepime and nacubactam|co-administration of 2 g cefepime and 1 g nacubactam q8h (60 min. infusion)
62092504|NCT05905055|EXPERIMENTAL|co-administration of aztreonam and nacubactam|co-administration of 2 g aztreonam and 1g nacubactam q8h (60 min. infusion)
62290254|NCT04897867|EXPERIMENTAL|CoolSculpting® Elite System|Participants received up to two CoolSculpting® Elite treatment sessions for the abdomen and flanks plus optional additional body areas 8 weeks apart. At the investigator's discretion, per treatment session, up to 8 treatment cycles were performed for the midsection, and if applicable, up to 2 treatment cycles for the submental area, up to 4 cycles to upper arms, and up to 4 cycles each to inner and/or outer thighs.
62092505|NCT05905055|ACTIVE_COMPARATOR|BAT|Best Available Therapy
62092506|NCT04450433||Baseline table of patients|
62092507|NCT04450433||Differential metabolites of two groups of control patients|
62092508|NCT04450433||Functional verification of differential metabolites|
62290255|NCT01554787|EXPERIMENTAL|Chinese Herb Astragalus membranaceus|
62290256|NCT01554787|PLACEBO_COMPARATOR|Placebo|
62290257|NCT01083667|EXPERIMENTAL|Pyrimethamine|Open label. Only one arm will receive the intervention.
62290258|NCT05375279||LSGB vs EMB|Patients who already underwent EMB within the last six months with confirmed Amyloid Transthyretin -wild type (ATTRwT) will undergo LSGB.
62290259|NCT05559307|EXPERIMENTAL|Xingnaojing injection group|"Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.~Interventions:~Drugs:Xingnaojing injection Other: Standard care (eg. antiplatelet drugs and statins)"
62463696|NCT04829162|EXPERIMENTAL|Mother without obesity, daughter without obesity|Image of a mother without obesity and a daughter without obesity.
62463697|NCT04829162|EXPERIMENTAL|Mother with obesity, son with obesity|Image of a mother with obesity and a son with obesity.
62737367|NCT04966312|OTHER|study group|mothers receiving routine education plus digital video disk before surgery
62737368|NCT04966312|OTHER|control group|mothers receiving routine education
61906786|NCT03534479|EXPERIMENTAL|CVID-IVIgG, polyclonal IgG i.v. infusion|The patients of the CVID-IVIgG, polyclonal IgG infusion, group are studied five weeks from their last therapeutic polyclonal IgG i.v. infusion (IVIgG). On the mornings of day 0, vascular reactivity of the brachial artery, assessed as Flow mediated dilation (FMD), is measured and blood collected for biochemistry (baseline). Immediately after the FMD measurements and the blood collection, the 24 patients receive half dose of IVIgG necessary to treat their disease (400 mg/kg body weight in 10% solution). Twenty-four hours later, before infusing the second half of the dose of the IVIgG, vascular reactivity is again measured and blood collected. Vascular reactivity is again measured 1, 2, and 3 weeks after the first IVIgG infusion.
61906787|NCT02166944|EXPERIMENTAL|tamoxifen|tamoxifen 40 mg daily for one year
61906788|NCT02166944|PLACEBO_COMPARATOR|placebo|placebo drugs
62290260|NCT05559307|NO_INTERVENTION|Standard care group|"Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care (eg. antiplatelet drugs and statins)"
62290261|NCT05535647|EXPERIMENTAL|Regorafenib and HAIC|Regorafenib HAIC with FOLFOX
62290262|NCT05535647|ACTIVE_COMPARATOR|FOLFOX|FOLFOX
62656162|NCT06343324|NO_INTERVENTION|Control Group|"Written educational material was sent to individuals in the control group. Patient Descriptive Characteristics Form, S³-NIV Questionnaire and Insomnia Severity Index scales will be applied as pre-test data to the control group, which is not given any training other than written material. During the 8-week period, the scales will be applied to the control group again in the 4th week and the 8th week. After the 8th week data collection, web-based NIV Survival Training will also be given to individuals in the control group."
62656163|NCT02292251|ACTIVE_COMPARATOR|Device-assisted therapy|30 hours of therapy with the ArmeoPower device, a commercially available device for arm rehabilitation
61906789|NCT05665192||Cohort 1|Participants that have discontinued RUX therapy and initiated FEDR prospectively
61906790|NCT04829084|EXPERIMENTAL|Intervention Arm|Health education
61906791|NCT04829084|NO_INTERVENTION|Control Arm|No health education
61906792|NCT04017195|EXPERIMENTAL|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.
62290263|NCT01201213|ACTIVE_COMPARATOR|Extradural bupivacaine|Local anesthetic
62290264|NCT01201213|ACTIVE_COMPARATOR|Extradural levobupivacaine|local anaesthetic
62290265|NCT01201213|ACTIVE_COMPARATOR|Extradural ropivacaine|local anaesthetic
62290266|NCT01201213|ACTIVE_COMPARATOR|Intrathecal bupivacaine|local anaesthetic
62290267|NCT01201213|ACTIVE_COMPARATOR|Intrathecal levobupivacaine|local anaesthetic
62290268|NCT01201213|ACTIVE_COMPARATOR|Intrathecal ropivacaine|local anesthetic
62290269|NCT04217369|NO_INTERVENTION|Control|A control arm. The participant will be given a version of the Diabits app without predictions of blood glucose enabled. They will then use the Diabits app as if they were using their usual companion app to manage their diabetes for the duration of the study.
62290270|NCT04217369|EXPERIMENTAL|Intervention|The intervention arm. The participants in this arm will be provided with a version of the Diabits app which provides predictions of where their blood glucose will be one hour into the future, based on historic data and user inputs. The participant will then manage their blood glucose using these predictions for the duration of the study.
62290271|NCT00909155|ACTIVE_COMPARATOR|Depressed; Venlafaxine treatment|Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
62290272|NCT00909155|ACTIVE_COMPARATOR|Depressed; Fluoxetine treatment|Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
62290273|NCT00909155|NO_INTERVENTION|Control|Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication
62656164|NCT02292251|ACTIVE_COMPARATOR|Therapy-based occupational therapy|30 hours of conventional occupational therapy that emphasizes task-oriented training.
62656165|NCT04646278|EXPERIMENTAL|Hyperemic stimuli|Hyperemic stimuli of coronary flow by adenosine or nicorandil injection
62656166|NCT05326516|EXPERIMENTAL|Revumenib and Chemotherapy Regimen 1|Participants with acute lymphoblastic leukemia/mixed phenotype acute leukemia (ALL/MPAL) will receive revumenib every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 1.
62290274|NCT00490542|PLACEBO_COMPARATOR|Placebo arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.
62656167|NCT05326516|EXPERIMENTAL|Revumenib and Chemotherapy Regimen 2|Participants with ALL/MPAL or acute myeloid leukemia (AML) will receive revumenib every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 2.
62656168|NCT03438266|EXPERIMENTAL|JUVÉDERM VOLUMA® XC Injectable Gel with Cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
62656169|NCT03438266|OTHER|JUVÉDERM VOLUMA® XC Injectable Gel with Needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
62656170|NCT02098772|EXPERIMENTAL|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
62656171|NCT02098772|ACTIVE_COMPARATOR|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
62656172|NCT05572931|SHAM_COMPARATOR|Sham comparator|In addition to the routine analgesic (Acetaminophen 500mg, TID), the patients were treated with sham FSN at the 1st, 24th, and 48th hours after surgery. The sham FSN was used a fine acupuncture needle without swaying movement and reperfusion approach.
62656173|NCT05572931|EXPERIMENTAL|Experimental|In addition to postoperative routine analgesic (Acetaminophen 500mg, TID), patients were received FSN treatment. The FSN insertion point and time are the same as control group. And then we performed swaying movement and reperfusion approach.
62656174|NCT00903968|EXPERIMENTAL|Phase I Dose Level 1|Phase I Dose Level 1 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
62290275|NCT00490542|ACTIVE_COMPARATOR|Geodon arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received Geodon.
62656175|NCT00903968|EXPERIMENTAL|Phase I Dose Level 2|Phase I Dose Level 2 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
62656176|NCT00903968|EXPERIMENTAL|Phase I Dose Level 3|Phase I Dose Level 3 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
62656177|NCT00903968|EXPERIMENTAL|Phase I Dose Level 4|Phase I Dose Level 4 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
62656178|NCT00903968|EXPERIMENTAL|Phase I Dose Level 5|Phase I Dose Level 5 patients received plerixafor 320ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
62656179|NCT00903968|EXPERIMENTAL|Phase I Dose Level 5B|Phase I Dose Level 5B patients received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
62290276|NCT05700266|EXPERIMENTAL|Rivaroxaban and Aspirin|Rivaroxaban (2.5mg orally twice a day for 90 days) and Aspirin (100mg once a day for 1 year)
62290277|NCT05700266|ACTIVE_COMPARATOR|Clopidogrel and Aspirin|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days) and Aspirin (100mg once a day for 1 year)
62290278|NCT02965157|EXPERIMENTAL|CART20|
62656180|NCT00903968|EXPERIMENTAL|Phase I Dose Level 6|Phase I Dose Level 6 patients received plerixafor 400ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
62656181|NCT00903968|EXPERIMENTAL|All Phase I Participants|All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
62656182|NCT00903968|EXPERIMENTAL|All Phase II Participants|All Phase I participants received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13, bortezomib 1.3 mg/m2 intravenously or subcutaneously days 3, 6, 10, and 13, and dexamethasone 40mg orally days 3, 6, 10, and 13 of each 21 day cycle during induction. In maintenance, participants received plerixafor, bortezomib, and dexamethasone days 1, 8, 15, and 22 of each 35 day cycle. Participants were treated until disease progression or unacceptable toxicity.
62656183|NCT02186028|EXPERIMENTAL|Vitamin D 400 IU|"Vitamin D-400IU/ml- 1ml daily~Neonates will be administered Vitamin D 400 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
62463698|NCT04829162|EXPERIMENTAL|Mother with obesity, son without obesity|Image of a mother with obesity and a son without obesity.
62463699|NCT04829162|EXPERIMENTAL|Mother without obesity, son with obesity|Image of a mother without obesity and a son with obesity.
62463700|NCT04829162|EXPERIMENTAL|Mother without obesity, son without obesity|Image of a mother without obesity and a son without obesity.
62463701|NCT04829162|EXPERIMENTAL|Father with obesity, daughter with obesity|Image of a father with obesity and a daughter with obesity.
62463702|NCT04829162|EXPERIMENTAL|Father with obesity, daughter without obesity|Image of a father with obesity and a daughter without obesity.
62463703|NCT04829162|EXPERIMENTAL|Father without obesity, daughter with obesity|Image of a father without obesity and a daughter with obesity.
62463704|NCT04829162|EXPERIMENTAL|Father without obesity, daughter without obesity|Image of a father without obesity and a daughter without obesity.
62290279|NCT06127329|EXPERIMENTAL|BAI combine with DEB-BACE|"Procedure: BAI combine with DEB-BACE: bronchial infusion chemotherapy combined with drug-loaded microsphere embolization of EqualSpheres~1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
62290280|NCT05357456||autonomous cortisol secretion|Patients admitted to the hospital with adrenal incidentalomas are evaluated for adrenal function, and then ACS patients are diagnosed based on the serum cortisol ≥ 50 nmol/L following the 1 mg dexamethasone suppression test and without any other signs or symptoms of cortisol excess.Patients with ACS will undergo a physical exam, cognitive function test as well as structural and functional brain MRI at baseline and 12 months after their surgery or conservative treatment.
62290281|NCT05357456||non-functioning adrenal adenomas|Patients admitted to the hospital with adrenal incidentalomas are evaluated for adrenal function, and then non-functioning adrenal adenomas patients are diagnosed based on the serum cortisol \< 50 nmol/L following the 1 mg dexamethasone suppression test .Patients with non-functioning adrenal adenomas will undergo a physical exam, cognitive function test as well as structural and functional brain MRI at baseline.
62290282|NCT05848934||CAD（coronary heart disease ）surgical treatment|
62290283|NCT05848934||CAD（coronary heart disease ）conservative treatment|
62290284|NCT05848934||HC （Healthy controls）|
62290285|NCT03566940|EXPERIMENTAL|Group 1: Low Dose IPV Based on Sabin Strains (sIPV)|Participants will receive intramuscular (IM) injection of the low dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of conventional Salk IPV (cIPV) at approximately 24 weeks after the third vaccination (38 weeks of age).
62290286|NCT03566940|EXPERIMENTAL|Group 2: Intermediate Dose sIPV|Participants will receive IM injection of the intermediate dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
62463705|NCT04829162|EXPERIMENTAL|Father with obesity, son with obesity|Image of a father with obesity and a son with obesity.
62463706|NCT04829162|EXPERIMENTAL|Father with obesity, son without obesity|Image of a father with obesity and a son without obesity.
62463707|NCT04829162|EXPERIMENTAL|Father without obesity, son with obesity|Image of a father without obesity and a son with obesity.
62463708|NCT04829162|EXPERIMENTAL|Father without obesity, son without obesity|Image of a father without obesity and a son without obesity.
62463709|NCT01231490|EXPERIMENTAL|Active|
61906793|NCT04017195|EXPERIMENTAL|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1, followed by Treatment A to the left buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
62463710|NCT01231490|PLACEBO_COMPARATOR|Placebo|
62463711|NCT01732978|OTHER|Babies|Any child born in the University Hospital of Saint Etienne (inborn) whatever its term birth, hospitalized in a neonatal unit at the time of registration (after 37 weeks of gestation for preterm infants) or maternity
62463712|NCT03744715|EXPERIMENTAL|Poziotinib|Poziotinib will be taken by the patient orally, once daily with food and a glass of water at approximately the same time. The dose will be the last dose received or at the standard starting dose of 16 mg poziotinib. If a dose is missed, it may be taken any time during the day preferably with food, but at least 8 hours prior to the next scheduled dose.
62463713|NCT05312697|EXPERIMENTAL|Setrusumab QM -->Setrusumab QM|"During Retreatment Period: Setrusumab will be administered via intravenous (IV) infusion once a month (QM) for 12 months.~During Extension Period: Setrusumab will be administered via IV infusion QM for at least 12 months or until commercially available."
62463714|NCT05312697|EXPERIMENTAL|Setrusumab QM --> Setrusumab TBD|"During Retreatment Period: Setrusumab will be administered via IV infusion QM for 12 months.~During Extension Period: Setrusumab will be administered via IV infusion at a dose frequency to be determined (TBD) for at least 12 months or until commercially available."
62463715|NCT05606562|EXPERIMENTAL|Dental treatment|All participants will be offered dental treatment for free.
62463716|NCT01609322|ACTIVE_COMPARATOR|Education about falls|In-person education about falls with a health educator.
62463717|NCT01609322|EXPERIMENTAL|Activity, Balance, Learning, and Exposure|Intervention combining medication review, exercise, home safety evaluation, and exposure therapy.
62463718|NCT01450462|EXPERIMENTAL|Vitamin D (cholecalciferol)|
62463719|NCT01450462|PLACEBO_COMPARATOR|Placebo|
62290287|NCT03566940|EXPERIMENTAL|Group 3: High Dose sIPV|Participants will receive IM injection of the high dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
62463720|NCT06151678||UK population survey|The UK population who accessed the electronic survey link disseminated via social media and via a gatekeeper at a Scottish council
62656184|NCT02186028|ACTIVE_COMPARATOR|Vitamin D 200IU|"Vitamin D 400IU/ml : 0.5ml daily~Neonates will be administered Vitamin D 200 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
62290288|NCT03566940|ACTIVE_COMPARATOR|Group 4: Conventional Salk IPV (cIPV)|Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
62463721|NCT06151678||Participants attending online webinars|Individuals who signed up for an online webinar related to persistent pain. This group offered quantitative feedback via online surveys and qualitative data via interview.
62463722|NCT06151678||Participants who attended in person seminars during a community outreach tour|Individuals who attended six different venues across the English county of Lincolnshire. This group offered quantitative feedback via paper and online surveys and qualitative data via interview.
62463723|NCT06151678||Brain bus cohort|Participants who attended a pop up interactive tent with practical demonstrations to improve pain related knowledge. This group offered quantitative feedback via paper postcards and qualitative data via interview.
61906794|NCT04017195|EXPERIMENTAL|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment B to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
61906795|NCT04017195|EXPERIMENTAL|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment A to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
61906796|NCT00856011||1|Diabetic patients with carpal tunnel syndrome
62463724|NCT06151678||Community outreach tour volunteers|Focus groups were arranged for those who volunteered to lead and deliver the community outreach tour
61906797|NCT00856011||2|Non-diabetic patients with carpal tunnel syndrome
61906798|NCT05278598|ACTIVE_COMPARATOR|ESPB group|Erector Spinae Plane Block
61906799|NCT05278598|ACTIVE_COMPARATOR|TPVPB group|Thoracic Paravertebral Plane Block
61906800|NCT05278598|ACTIVE_COMPARATOR|QLPB group|Quadratus Lumborum Plane Block
61906801|NCT02029378|EXPERIMENTAL|Eculizumab|Eculizumab, 900 mg intravenously once a week
61906802|NCT02029378|PLACEBO_COMPARATOR|Placebo|Matched placebo, intravenously once a week
61906803|NCT00316108|EXPERIMENTAL|Arm 1|
61906804|NCT04176653|PLACEBO_COMPARATOR|Placebo|
61906805|NCT04176653|EXPERIMENTAL|0.3 mg/kg|
62290289|NCT02007551|EXPERIMENTAL|Mealtime Intervention|The mealtime intervention group will receive a trained peer volunteer to their home once weekly for 8 weeks to prepare and share a meal with them.
62308027|NCT03865342|EXPERIMENTAL|Noom Coach DPP|Individuals will receive special instructions on how to use the app and will self-monitor their weight, exercise and receive daily DPP core content through the app over 16 weeks plus guidance from a coach, and will thereafter receive post-core DPP content up to 52 weeks.
62308028|NCT03865342|NO_INTERVENTION|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the DPP curriculum."
62463725|NCT03025945|EXPERIMENTAL|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
62463726|NCT03025945|PLACEBO_COMPARATOR|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
62463727|NCT04437862|EXPERIMENTAL|Q Revascularization System|
62463728|NCT03799029|ACTIVE_COMPARATOR|active control group low-intensity|Low intensity version of the same cognitive training program Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
62463729|NCT03799029|EXPERIMENTAL|experimental training group cognitive training|a multifactorial cognitive program that tackles working memory, attention, inhibition, planification and reasoning Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
62463730|NCT03799029|NO_INTERVENTION|control healthy participants|Just a control group including healthy participants No intervention
62463731|NCT01273337|EXPERIMENTAL|ALD-401|ALD-401 is derived from Autologous Bone Marrow of the Stroke Subject
62463732|NCT01273337|SHAM_COMPARATOR|Sham Comparitor|Sham Bone Marrow harvest and sham dosing procedure.
62656185|NCT02741934||Preterm cohort|Among the infants who were born and admitted to Seoul National University Hospital from 2008 to 2009, the birth weight of the infants less than 1,500g or gestational age less than 32 weeks patients were enrolled.
62290290|NCT04042194|EXPERIMENTAL|Thickened with T-PRF|Following local anaesthesia, the measurement of soft tissue thickness at three points \[1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)\] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and T-PRF was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
62290291|NCT04042194|ACTIVE_COMPARATOR|Thickened with CTG|Following local anaesthesia, the measurement of soft tissue thickness at three points \[1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)\] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and CTG was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
62290292|NCT03599180||Knee Osteoarthritis group|KOA patients without accept treat in the past month
62290293|NCT03599180||Control group|Heathly volunteers
62290294|NCT03588741|EXPERIMENTAL|Turoctocog alfa|
62290295|NCT01393977|NO_INTERVENTION|control|Outpatient in hospital
62290296|NCT01393977|ACTIVE_COMPARATOR|rehabilitation|interventions: rehabilitation
62290297|NCT01393977|EXPERIMENTAL|Stem Cell Transplantation|interventions: stem cell transplantation
62290298|NCT02894229|NO_INTERVENTION|No intervention wait-list|This arm will receive no intervention for approximately the first 4 months. At the conclusion of the 4-month period, this group will receive a 6-week cognitive-behavioral therapy (CBT) group
62290299|NCT02894229|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction(MBSR)|This arm will receive 6 weekly, 2-hour groups that focuses on mindfulness meditation for stress reduction
61906806|NCT04176653|EXPERIMENTAL|1.0 mg/kg|
61906807|NCT04176653|EXPERIMENTAL|3.0 mg/kg|
61906808|NCT04176653|EXPERIMENTAL|10.0 mg/kg|
61906809|NCT03560518|EXPERIMENTAL|Rapastinel 450mg|Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)
61906810|NCT03560518|EXPERIMENTAL|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
61906811|NCT03560518|PLACEBO_COMPARATOR|Placebo|Placebo (prefilled syringe, weekly IV administration)
62290300|NCT02894229|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT) Group|This are will receive 6 weekly, 2-hour groups that focus on cognitive-behavioral skills for stress
62290301|NCT00688909|EXPERIMENTAL|Letrozole|Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.
62290302|NCT03124069|EXPERIMENTAL|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
62463733|NCT03678038|EXPERIMENTAL|rotator interval injection|patient received ultrasound-guided steroid injection via rotator interval
62463734|NCT03678038|ACTIVE_COMPARATOR|posterior recess injection|patient received ultrasound-guided steroid injection via posterior recess
62092509|NCT02637505|ACTIVE_COMPARATOR|Arthroscopic microfracture (MF)|"The AM group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The cartilage is cut sharp forming a rim of 90 degrees. The calcified layer is removed using a curette before an arthroscopic awl is then used to perform multiple holes (microfractures) from the periphery towards the center. The microfractures are 3 - 4 mm apart and 2 - 4 mm deep into the subchondral bone. The correct and successful technique is confirmed by direct visualization: while reducing the fluid pump pressure, the release of marrow fat droplets and blood will be observed."
62463735|NCT04587778|EXPERIMENTAL|Esketamine ((S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan."
62092510|NCT02637505|SHAM_COMPARATOR|Arthroscopic debridement (AD)|The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The lesion is stabilized, debriding all loose or marginally attached cartilage from the surrounding rim to form a stable edge of healthy cartilage around the defect using a ring curette, where cartilage slops down to the defect.
62092511|NCT05335135||Pre-Implementation|Usual care will be provided during all ED patient encounters.
62092512|NCT05335135||Post-Implementation|TriageGo-MDW CDS will be made available during all ED patient encounters at two points in the ED care continuum: (1) shortly after arrival during initial ED triage (First Triage) and (2) after initial laboratory results have been populated within the EHR. General illness severity estimates will be provided to nurses at ED triage in the form of recommended triage acuity scores (CDS for First Triage). General illness severity estimates along with estimated risk for specific outcomes including sepsis and septic shock will be presented to clinicians after laboratory results have populated (CDS for Early Assessment). TriageGO-MDW risk estimates will be generated by machine learning algorithms using routinely available clinical data as predictor inputs. Nurses and clinicians will receive risk estimates within existing EHR workflows, along with brief and rapidly interpretable explanations of the logic driving each risk estimate.
62092513|NCT03513211|EXPERIMENTAL|Dose escalation arm|Suba-itraconazole in combination dose escalating hydroxychloroquine H
62290303|NCT00754156|ACTIVE_COMPARATOR|1 ABRA plus KCI ABThera or KCI VAC|ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
62290304|NCT00754156|ACTIVE_COMPARATOR|KCI V.A.C. Therapy or ABThera Alone|KCI V.A.C. Therapy ABThera Alone
62290305|NCT03404778||Biomet Comprehensive Reverse Shoulder|Subjects in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Shoulder System.
62290306|NCT00952757||1.|Patients diagnosed of schizophrenia or bipolar disorder with APS-related hyperprolactinaemia who have been switched to quetiapine based on the clinician's judgement
62290307|NCT01487421||SIT|
62290308|NCT01774214|EXPERIMENTAL|A|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm A, subjects will perform the Push-Pull Technique of manual fluid resuscitation first, followed by the Disconnect-Reconnect Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
62290309|NCT01774214|EXPERIMENTAL|B|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm B, subjects will perform the Disconnect-Reconnect Technique of manual fluid resuscitation first, followed by the Push-Pull Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
62290310|NCT01262183|EXPERIMENTAL|Concurrent chemoradiation therapy with panitumumab|
62290311|NCT01262183|ACTIVE_COMPARATOR|Concurrent chemoradiation therapy without panitumumab|
62290312|NCT01961115|EXPERIMENTAL|Treatment (epacadostat, MELITAC 12.1)|Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.
62290313|NCT04273074|OTHER|preoperative sonographic assessment group|preoperative sonographic assessment to airway
62463736|NCT04587778|EXPERIMENTAL|Racemic ketamine ((R,S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan."
62463737|NCT04587778|EXPERIMENTAL|Pilot study II: Esketamine ((S)-Ketamine)|In a cross-over study design, esketamine will be administered during the first scan and placebo during the second scan.
62463738|NCT01194609|EXPERIMENTAL|Low dose radiation, Immune cell therapy|Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks
62463739|NCT02883452|ACTIVE_COMPARATOR|Cohort 1: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
62463740|NCT02883452|EXPERIMENTAL|Cohort 2: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
61906812|NCT06531980|EXPERIMENTAL|Modi-application|8-weeks interventions provided by the mobile application Modi. Therapist-guided intervention
62092514|NCT03513211|EXPERIMENTAL|Phase II: Dose expansion arm|Suba-itraconazole with recommended phase II dose of hydroxychloroquine as determined by phase I arm.
62092515|NCT01677039|ACTIVE_COMPARATOR|Treatment A|
62290314|NCT00254306||1|"ex-ecstasy users"
62290315|NCT00254306||2|control subjects
62463741|NCT02883452|EXPERIMENTAL|Cohort 3: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
62463742|NCT02883452|EXPERIMENTAL|Cohort 4: CT-P13 SC 240 mg|CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
62463743|NCT02883452|EXPERIMENTAL|Arm 1: CT-P13 SC 120/240 mg|CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
61906813|NCT06531980|ACTIVE_COMPARATOR|Treatment as usual|The group will receive treatment as usual.
61906814|NCT04099394|EXPERIMENTAL|Behavioral Health|Ten behavioral health classes.
62463744|NCT02883452|ACTIVE_COMPARATOR|Arm 2: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)
62463745|NCT02349893|EXPERIMENTAL|RFA treatment|RFA treatment performed with CelonProSleep plus device
61906815|NCT04099394|ACTIVE_COMPARATOR|Health Education|Ten health education classes covering healthy aging.
62092516|NCT01677039|EXPERIMENTAL|Treatment B|
62092517|NCT01677039|EXPERIMENTAL|Treatment C|
62463746|NCT03437304|EXPERIMENTAL|Immunose™ FLU 1%|Immunose™ FLU 1%. QIV, 30 μg HA/strain and 1% Endocine™ 200 μl for intranasal administration, 2 dosing occasions.
62656186|NCT02741934||Term control cohort|The infants who were born from 2008 to 2009 with term gestational age will be enrolled.
62290316|NCT01269164|EXPERIMENTAL|Face Transplantation|Surgical Procedure Composite Facial Transplant
62290317|NCT03283202|EXPERIMENTAL|Avadomide (CC-122) plus R-CHOP-21|Avadomide (CC-122) by mouth (PO) at varying dose levels (Ph 1) on Days 1 through 5 and Days 8 through 12 plus Rituxan 375 mg/m2 by intravenous (IV) infusion, cyclophosphamide 750mg/m2 by IV infusion, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 (max is 2.0 mg) IV and 100 mg PO prednisone/prednisolone on Days 1 through 5 of each 21-day treatment cycles for up to 6 total treatment cycles (approximately 18 weeks or 4 months)
62463747|NCT03437304|EXPERIMENTAL|Immunose™ FLU 2%, 200 μl|Immunose™ FLU 2%. QIV, 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration, 2 dosing occasions.
62290318|NCT01231412|ACTIVE_COMPARATOR|Arm I (MMF and CSP)|Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
62290319|NCT01231412|EXPERIMENTAL|Arm II (MMF, CSP, and Sirolimus)|Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
62463748|NCT03437304|EXPERIMENTAL|Immunose™ FLU 2%, 300 μl|Immunose™ FLU 2%, 300 μl. QIV, 30 μg HA/strain and 2% Endocine™, 300 μl for intranasal administration, 2 dosing occasions.
62463749|NCT03437304|EXPERIMENTAL|Influenza antigen|Influenza antigen. QIV, 30 μg HA/strain, 200 μl for intranasal administrations, 2 dosing occasions.
62463750|NCT03437304|PLACEBO_COMPARATOR|Placebo|Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
61906816|NCT01587768||Patients with a definite case of acute liver injury|"The information recorded in the patients' medical record met all the criteria to be classified as idiopathic acute liver injury and the patient presents with at least with one of the following conditions (A+B or A+C):~A - A diagnosis of liver injury (codes listed in tables 1a, 1b, 1c) with a referral to a specialist or hospital.~Together with B - An increase of more than two times the upper limit of the normal range in alanine aminotransferase (ALT) or C - A combined increase in aspartate aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin provided one of them is twice the upper limit of the respective normal range."
61906817|NCT01587768||Patients with a probable case of acute liver injury|The information recorded in the patients' medical file was compatible with idiopathic acute liver injury, but not fulfilling all conditions and criteria to be defined as definite case. For example, patients identified with a READ or ICPC code for acute liver injury with a hospitalization or visit to a specialist but without complete laboratory criteria or patients identified with a READ or ICPC code for acute liver injury without a referral to a hospital/specialist, and with or without complete laboratory data.
62092518|NCT03537014|EXPERIMENTAL|MDMA-assisted therapy|Administration of 80 or 120 mg midomafetamine HCl with a supplemental dose 1.5 to 2 hours later of 40 or 60 mg midomafetamine HCl, respectively, in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart.
62290320|NCT01231412|EXPERIMENTAL|Arm 0 (CSP and Sirolimus)|Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
62290321|NCT04387097||gradual withdrawal following by drip-infusion of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated. Following by drip-infusion of remifentanil for 30 minutes was administered immediately after tracheal extubation.
62463751|NCT03437304|EXPERIMENTAL|i.m comparator and Immunose™ FLU 2%|i.m comparator: QIV 15 μg HA/strain, 500 µl for a single intramuscular administration, and Immunose FLU 2%: QIV 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration. A second dose of Immunose FLU 2% will be administered 3 weeks later.
62463752|NCT03437304|ACTIVE_COMPARATOR|i.m comparator|i.m comparator. QIV 15 μg HA/strain, 500 µl for a single intramuscular administration.
62463753|NCT04611789|EXPERIMENTAL|LY3832479|Participants received single subcutaneous dose of 350 milligrams (mg) and 1000 mg LY3832479.
62463754|NCT04611789|PLACEBO_COMPARATOR|Placebo|Participants received single subcutaneous dose of Placebo.
62463755|NCT03222765|PLACEBO_COMPARATOR|Placebo|"* Placebo~* Lifestyle modification (diet and physical activity recommendations)"
62463756|NCT03222765|EXPERIMENTAL|Metformin|"* Metformin~* Lifestyle modification (diet and physical activity recommendations)"
62463757|NCT03222765|EXPERIMENTAL|Linagliptin|"* Linagliptin~* Lifestyle modification (diet and physical activity recommendations)"
62463758|NCT03222765|EXPERIMENTAL|Linagliptin and Metformin|"* Fixed dose combination of Linagliptin and metformin~* Lifestyle modification (diet and physical activity recommendations)"
62463759|NCT02152566|EXPERIMENTAL|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
62463760|NCT02221765|EXPERIMENTAL|Arm 1|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg."
62463761|NCT02221765|EXPERIMENTAL|Arm 2|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.~Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously."
62463762|NCT03918486||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
62463763|NCT04874545|EXPERIMENTAL|Propofol group|Maintenance of anaesthesia will be done using Propofol total intravenous anesthesia (TIVA) 6-12 mg/ kg/h by syringe pump, 100 % O2.
62656187|NCT06480708|EXPERIMENTAL|Ketogenic diet group|20 participants will be randomized to a ketogenic diet group and will consume the ketogenic diet for 14 days prior to undergoing open heart surgery.
62656188|NCT06480708|ACTIVE_COMPARATOR|Control diet group|20 participants will be randomized to a control diet group and will consume the control diet for 14 days prior to undergoing open heart surgery.
61906818|NCT01587768||Non-cases|Any potential or probable case that was excluded in one of the previous steps and those with insufficient data to determine their case status. Patients presenting normal liver function tests (LFTs), alcohol related problems, gallbladder disease, pancreatic disease, or other liver diseases with clear aetiology such as viral, alcoholic or autoimmune, or presence of other well defined pathology known to cause acute liver injury will be considered non-cases.
62092519|NCT03537014|PLACEBO_COMPARATOR|Placebo with therapy|Administration of inactive placebo in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart
62290322|NCT04387097||gradual withdrawal of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated.
62290323|NCT05466643|EXPERIMENTAL|DWP16001|
62290324|NCT05466643|PLACEBO_COMPARATOR|Placebo|
62290325|NCT03670030|EXPERIMENTAL|ABI-009|In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.
62290326|NCT02479789|EXPERIMENTAL|Lidocaine|Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.
62290327|NCT02479789|PLACEBO_COMPARATOR|Placebo|Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.
62463764|NCT04874545|ACTIVE_COMPARATOR|sevoflurane group|Maintenance of anaesthesia will be done using sevoflorane1.5-2%, 100 % O2.
62463765|NCT05140070|EXPERIMENTAL|Intervention|Mousse with prebiotic
62290328|NCT05136274|ACTIVE_COMPARATOR|Medical treatment|By administering a single intramuscular dose of 50mg / m2 / Sc of Methotrexate.
62290329|NCT05136274|ACTIVE_COMPARATOR|Surgical treatment|Will be performed by laparoscopy or laparotomy, using the Linear Salpingostomy technique.
62463766|NCT05140070|ACTIVE_COMPARATOR|Control|Mousse without prebiotic
62463767|NCT04013425|EXPERIMENTAL|Ice Cream Cone Technique|Atraumatic extraction followed by addition of barrier membrane and xenograft in the socket.
62463768|NCT04013425|NO_INTERVENTION|Spontaneous Healing|Spontaneous Healing after Atraumatic Extraction
62463769|NCT02911662|EXPERIMENTAL|3-day treatment|Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
62463770|NCT02911662|ACTIVE_COMPARATOR|7-day treatment|Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
62463771|NCT05699980||Patient aged 60 or over presenting to their general practitioner|Patient aged 60 or over presenting to his general practitioner (among the 20 general practitioners recruited in Lorraine (eastern France))
62463772|NCT02555111|EXPERIMENTAL|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
62463773|NCT02555111|NO_INTERVENTION|untreated|the patient won't receive any treatment during his study participation.
62463774|NCT02264106|EXPERIMENTAL|Lefradafiban tablet with pantoprazole|
62656189|NCT05936307|ACTIVE_COMPARATOR|15 healthy participants active then placebo|15 healthy participants will receive a session of active HD-tDCS and then a session of placebo HD-tDCS.
62656190|NCT05936307|PLACEBO_COMPARATOR|15 healthy participants placebo then active|15 healthy participants will receive a session of placebo HD-tDCS and then a session of active HD-tDCS.
62463775|NCT02264106|ACTIVE_COMPARATOR|Lefradafiban tablet|
62463776|NCT02264106|EXPERIMENTAL|Lefradafiban double chamber sachet with pantoprazole|
62656191|NCT03391895|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive a home based exercise program. Home based exercise program includes deep diaphragmatic breathing exercises, resistive local expansion exercise on the collapsed areas in scoliosis concave sides, dynamic lumber stabilization, strengthening of inter scapular muscles, posture and stretching exercises once a day for 8 weeks. One of the exercise sessions was supervised by physiotherapist each week.
62290330|NCT03157531|EXPERIMENTAL|B-Laser™ Atherectomy System|B-Laser™ Atherectomy System
62290331|NCT04887571||Observational ACS Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an acute coronary syndrome will be recruited into the PERFUSION registry across the study duration.
62290332|NCT05238376|EXPERIMENTAL|Patient|These are patients who are 90 (±30) days post-allogeneic hematopoietic stem cell transplant. Patients will complete 12 weeks of exercise training. Patients will also complete assessments to evaluate physical function, cognitive function, mental health, social support, nutrition and diet, symptoms, quality of life, and financial status. They will use devices to capture activity data and vital signs. They will collect bio-specimens to assess microbiota and biomarkers.
62308029|NCT03229577|EXPERIMENTAL|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga workshop is a nationally-recognized program focused on teaching yoga-based breathing techniques.
62656192|NCT03391895|EXPERIMENTAL|Training Group|In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
62656193|NCT05276739|EXPERIMENTAL|Bright light|Participants will receive a 6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake). Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
62737369|NCT02348034|EXPERIMENTAL|Prevena Dressing|This group will receive prevena dressing after the elective colorectal surgery
61906819|NCT04355585|EXPERIMENTAL|Male|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
61906820|NCT04355585|EXPERIMENTAL|Female|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
61906821|NCT03496779|EXPERIMENTAL|Experimental|"Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.~Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.~Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions."
61906822|NCT01580137||healthy conscripts|non allergic subjects who have not a history of recurrent rhinosinusitis
61906823|NCT01580137||subjects with recurrent rhinosinusitis|subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
62463777|NCT02264106|ACTIVE_COMPARATOR|Lefradafiban double chamber sachet|
62463778|NCT05245643|OTHER|Patients with severe and resistant Anorexia Nervosa|12 consecutive patients fulfilling the inclusion criteria and consenting to participate in the research, recruted in the three inclusion centers.
62463779|NCT01190163|EXPERIMENTAL|A|
62463780|NCT01190163|ACTIVE_COMPARATOR|B|
62463781|NCT04449666||Experimental group|Patients undergoing neurological rehabilitation after aneurysmal subarachnoid hemorrhage
62463782|NCT04449666||Control group|Healthy adults controlled for age, gender and educational status
62463783|NCT05626894|EXPERIMENTAL|StrokeWear Motor and Behavioral Intervention|
62463784|NCT05626894|SHAM_COMPARATOR|Usual Care|
62463785|NCT02155205|EXPERIMENTAL|Telotristat etiprate|Single dose of telotristat etiprate followed by a 7-day washout.
62463786|NCT02155205|ACTIVE_COMPARATOR|Moxifloxacin|Single dose of moxifloxacin followed by a 7-day washout.
62463787|NCT02155205|PLACEBO_COMPARATOR|Placebo|Single dose of placebo with a 7-day washout to follow.
62290333|NCT05238376|EXPERIMENTAL|Caregiver|These are the assigned caregivers for the transplant patients. Caregivers will complete 12 weeks of exercise training. Caregivers will also complete assessments to evaluate physical function, caregiver support, and physical activity and exercise. They will collect bio-specimens to assess microbiota.
62290334|NCT01369121|EXPERIMENTAL|Xerecept|All patients will receive hCRF (XERECEPT)
62290335|NCT02455674||Age under 6 years|"All children 1 to 6 years~Used formula for weight calculation:~Children 1-5 years: Weight (kg) = (2 × age in years) + 8"
62290336|NCT02455674||Age over 6 years|"All children 6 to 12 years~Used formula for weight calculation:~Children 6-12 years: Weight (kg) = (3 × age in years) + 7"
62290337|NCT05409287|EXPERIMENTAL|Immediate Implant Loading|A provisional single implant crown will be mounted on an implant, placed 16 weeks post tooth extraction, immediately after implant placement. Occlusion will be adjusted, so that there is no occlusal contact with the 8 µm Shim Stock foil (Hanel Shim Stock Foil; Coltène/Whaledent AG, Altsätten, Switzerland), but contact with 40µm occlusion foil (Hanel Articulating Paper, Coltène/Whaledent AG, Altsätten, Switzerland) during static occlusion. All dynamic contacts will be eliminated by intraoral grinding with a diamond bur, and the occlusal surface will be polished afterward. The screw access channel will be sealed by a Teflon strip and a provisional light-polymerizing resin (Telio CS, Ivoclar Vivadent AG, Schaan, Liechtenstein). In case of a mini-flap on the buccal aspect, the flaps will then be sutured around the implant healing cap or the implant provisional with single interrupted sutures. Finally, a periapical radiograph will be taken, using the customized x-ray tray.
62290338|NCT05409287|ACTIVE_COMPARATOR|Early Implant Loading|A provisional single implant crown will be mounted on an implant, placed 16 weeks post tooth extraction, 4 weeks after implant placement. Occlusion will be adjusted, so that there is no occlusal contact with the 8 µm Shim Stock foil (Hanel Shim Stock Foil; Coltène/Whaledent AG, Altsätten, Switzerland), but contact with 40µm occlusion foil (Hanel Articulating Paper, Coltène/Whaledent AG, Altsätten, Switzerland) during static occlusion. All dynamic contacts will be eliminated by intraoral grinding with a diamond bur, and the occlusal surface will be polished afterward. The screw access channel will be sealed by a Teflon strip and a provisional light-polymerizing resin (Telio CS, Ivoclar Vivadent AG, Schaan, Liechtenstein). In case of a mini-flap on the buccal aspect, the flaps will then be sutured around the implant healing cap or the implant provisional with single interrupted sutures. Finally, a periapical radiograph will be taken, using the customized x-ray tray.
62290339|NCT00950170|EXPERIMENTAL|1|The investigator treats subjects with ReFacto AF in the usual care setting.
62290340|NCT01707992|PLACEBO_COMPARATOR|Placebo-Controlled Phase: Placebo|Participants will receive 2 capsules of placebo (matching to laquinimod 0.6 milligrams \[mg\]) once daily orally for up to 24 months.
62463788|NCT02615847|EXPERIMENTAL|Memantin arm|Memantinhydrochlorid, administered once per day during 12 month. Dosage is from 0-20 mg.
62463789|NCT00535860|EXPERIMENTAL|50 mcg|ViaDerm transdermal delivery
62463790|NCT00535860|EXPERIMENTAL|80 mcg|Add Via-Derm transdermal delivery
62463791|NCT00535860|ACTIVE_COMPARATOR|20 mcg|Subcutaneous injection
62463792|NCT00667862|EXPERIMENTAL|Panobinostat|Participants with metastatic hormone refractory prostate cancer received 20 milligrams per meter square (mg/m\^2) of panobinostat intravenously (i.v.) on Days 1 and 8 of a 21-day cycle. Treatment continued until disease progression as per investigator, intolerable toxicity, start of new cancer therapy, death, or withdrawal of consent.
62463793|NCT02266264|EXPERIMENTAL|100 milligrams of hydrocortisone|100 milligrams per day of hydrocortisone is the starting dosage.
61906824|NCT03059355|EXPERIMENTAL|Pilot Phase: Group 1 (UCMSCs - 20 million)|Three (3) subjects will be treated with a single administration of 2 x 10\^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
61906825|NCT03059355|EXPERIMENTAL|Pilot Phase: Group 3 (UCMSCs - 100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10\^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
61906826|NCT03059355|EXPERIMENTAL|Pilot Phase: Group 2 (BMMSCs - 20 million)|Three (3) subjects will be treated with a single IV administration of 2 x 10\^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
61906827|NCT03059355|EXPERIMENTAL|Pilot Phase: Group 4 (BMMSCs -100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10\^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
61906828|NCT03059355|EXPERIMENTAL|Group A (UCMSCs - 100 million)|Participants randomized to receive a single administration of 1 x 10\^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
62463794|NCT02266264|ACTIVE_COMPARATOR|200 milligrams of hydrocortisone|200 milligrams per day of hydrocortisone is the starting dosage.
62463795|NCT04231838|ACTIVE_COMPARATOR|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
62463796|NCT04231838|ACTIVE_COMPARATOR|Intervention Arm (Arm B)|Participant switches to using C-F NDS
62463797|NCT01377805||Multiple Sclerosis patients|Multiple sclerosis patients
62463798|NCT03194412|EXPERIMENTAL|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
62463799|NCT03194412|EXPERIMENTAL|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
62463800|NCT03194412|EXPERIMENTAL|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
62463801|NCT03194412|EXPERIMENTAL|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
62463802|NCT03194412|NO_INTERVENTION|Control group|Without intervention
62656194|NCT05276739|EXPERIMENTAL|Time-restricted eating|Participants will consume 4 identical meals, as in the other groups, except that the meal window will be restricted to 6.5 hours instead of 12 hours (meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (\<3 lux) throughout the 16-hour wake episode.
62290341|NCT01707992|EXPERIMENTAL|Placebo-Controlled Phase: Laquinimod 0.6 mg|Participants will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for up to 24 months.
62290342|NCT01707992|EXPERIMENTAL|Placebo-Controlled Phase: Laquinimod 1.2 mg|Participants will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for up to 24 months.
61906829|NCT03059355|EXPERIMENTAL|Group B (BMMSCs - 100 million)|Participants randomized to receive a single administration of 1 x 10\^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
61906830|NCT03059355|PLACEBO_COMPARATOR|Group C (Placebo)|Participants randomized to receive a single administration of placebo via peripheral intravenous infusion.
62290343|NCT01707992|EXPERIMENTAL|Active Treatment Phase: Laquinimod 0.6 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 0.6 mg treatment group after 01 January 2016, will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for 24 months.
62290344|NCT01707992|EXPERIMENTAL|Active Treatment Phase: Laquinimod 1.2 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 1.2 mg treatment group prior to 01 January 2016, will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for 24 months.
62290345|NCT01707992|NO_INTERVENTION|Active Treatment Phase: Off Drug|Participants who were discontinued from treatment with laquinimod 1.2 mg during the placebo-controlled phase due to sponsor decision after 01 January 2016 will continue the active-treatment phase off drug for 24 months.
62290346|NCT01998542|EXPERIMENTAL|AlloStim+CRCL|AlloStim priming followed by AlloStim+CRCL priming and AlloStim IV. 3 cycles
62290347|NCT01285349|EXPERIMENTAL|Couple-based HIV prevention|7-session couple-based HIV/STI risk reduction intervention (CSTI)
62290348|NCT01285349|ACTIVE_COMPARATOR|Individual HIV/STI Prevention|7-session individual HIV/STI intervention comparison condition (ISTI) provided to the index participant alone, which is identical in content to the CSTI.
62290349|NCT01285349|PLACEBO_COMPARATOR|Couple Wellness Promotion|7-session couple-based stress reduction intervention (CSR) that serves as an attentional control condition.
62463803|NCT06083389|ACTIVE_COMPARATOR|traditional technique of facial exercises along with electrical stimulation of facial muscles.|facial muscle exercise active exercises will be initiated, which is performed in front of a mirror in sitting position. The patient will be instructed for activities like blowing air in the mouth, nasal flaring, smiling, raising and frowning of the eyebrows, opening and closing of the eye, clenching of the teeth and holding straw in mouth, suck and blow out air, show as if blowing a balloon for 20 minutes each session, for 3 sessions/ week for 6 weeks.
62463804|NCT06083389|ACTIVE_COMPARATOR|Kabat technique arm along with stimulation of facial muscles.|"During the Kabat rehabilitation session, the patients will perform specific diagonal and spiral movements, involving the following three muscle fulcrums:~* Upper fulcrum: includes the frontalis, corrugator \& orbicularis oculi muscles.~* Intermediate fulcrum: includes the common elevator muscle of the upper lip and nasalis.~* Lower fulcrum: includes the risorius, zygomaticus major, the orbicularis oris and buccinator. (Khanzada et al., 2018).~The manipulation of these three fulcra will be carried out by utilizing contralateral contraction and the basic proprioceptive stimulation comprising stretching, maximal resistance, manual contact and verbal input.~Kabat sessions will be 3 sessions / week for 6 weeks."
62463805|NCT04029610|ACTIVE_COMPARATOR|Local anesthesia of lidocaine and arterial blockage on the arm|Local anesthesia of lidocaine and arterial blockage on the arm
62463806|NCT04029610|EXPERIMENTAL|Local anesthesia with lidocaine and adrenalin|Local anesthesia with lidocaine and adrenalin
62463807|NCT00653471|ACTIVE_COMPARATOR|Lean|Lean patients
62463808|NCT00653471|ACTIVE_COMPARATOR|Obese no OSA|Obese patients without osa
62463809|NCT00653471|ACTIVE_COMPARATOR|Obese osa|Obese patients with osa
62463810|NCT03204266|EXPERIMENTAL|Immunonutrition: ARS + Omega-3 Fatty Acids|"Participants take 1 ounce (30mls) of Arginine recovery supplement (ARS) four times daily 5 days preoperatively and 14 days postoperatively.~Participants also given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively."
62463811|NCT03204266|NO_INTERVENTION|No Immunonutrition|Participants receive regular enhanced recovery after surgery (ERAS)/Optimized Surgical Journey (OSJ) education and follow up.
62656195|NCT05276739|SHAM_COMPARATOR|Control|Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (\<3 lux) throughout the 16-hour wake episode.
62290350|NCT00972699|EXPERIMENTAL|Mentor Mothers Intervention|In the intervention arm, participants will receive the Department of Health-delivered Prevention of Mother to Child Transmission (PMTCT) program plus the Project Masihambisane mentor mothers support program. HIV positive mentor mothers, who have been through the PMTCT program, will be recruited and trained to deliver the intervention to pregnant mothers living with HIV.
62290351|NCT00972699|NO_INTERVENTION|Control|Mothers living with HIV in the standard of care control clinics will receive the Department of Health-delivered PMTCT program.
62737370|NCT02348034|NO_INTERVENTION|Conventional dressing|This group will receive conventional dressing after the elective colorectal surgery
62737371|NCT04479059|EXPERIMENTAL|İntracavitary fluid flushing|
62737372|NCT04479059|NO_INTERVENTION|Control group|
61906831|NCT04023838|PLACEBO_COMPARATOR|Right conventional radial approach|After local anesthesia on right wrist area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
62290352|NCT01592994|NO_INTERVENTION|control|control participants received basic messages on the utility of condoms in protecting from HIV and other STIs, and they were informed about local HIV/STI counseling and testing services.
62308030|NCT03229577|EXPERIMENTAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a nationally-recognized program focused on teaching mindfulness techniques.
62737373|NCT00395278||HIV negative|HIV negative without Kaposi sarcoma
62737374|NCT00395278||HIV positive|HIV positive without Kaposi sarcoma
62656196|NCT04023968|EXPERIMENTAL|YESplus workshop|Your Enlightened Side, plus more (YESplus) is an four-day, 15-hour integrative life skills workshop with a strong emphasis on breathing techniques and social connectedness. In addition to specific contemplative techniques such as yoga, mindfulness meditation, and compassion meditation that help cultivate inner peace, YESplus incorporates discussions and other activities to facilitate social connectedness, leadership, and community service. During the workshop, participants have ample time to learn and practice the Sudarshan Kriya Yoga (SKY) technique, as well as to ask questions. SKY has four sequential, form- and rhythm-specific breathing components interspersed with normal breathing while sitting in a relaxed position with eyes closed, followed by Yoga Nidra. A certified instructor with a minimum of 1,000 hours of SKY instruction training will lead each workshop.
62463812|NCT00885456|EXPERIMENTAL|PREVENT program|12-week program of exercise and education to induce physiological and behavioral changes needed to reduce vascular risk factors.
62463813|NCT00885456|ACTIVE_COMPARATOR|Usual Care|Average of three visits to the Neurovascular Clinic for a neurological and health assessment, counseling regarding stroke/TIA and diagnostic test results, and assessment, modification and education of secondary prevention factors
62463814|NCT02924883|EXPERIMENTAL|Trastuzumab Emtansine + Atezolizumab|Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
62463815|NCT02924883|ACTIVE_COMPARATOR|Trastuzumab Emtansine + Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
62463816|NCT02648607|EXPERIMENTAL|Customised Orthosis|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
62092520|NCT03976362|EXPERIMENTAL|Pembrolizumab + Carboplatin + Taxane + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until centrally verified progressive disease, physician decision or intolerable toxicity."
62290353|NCT01592994|EXPERIMENTAL|RHANI Wives Intervention|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT) and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
62463817|NCT06340139|ACTIVE_COMPARATOR|Conventional Treatment|Conventional treatment group will receive Trampoline jumping, gym ball exercises, sensory diet (joint compressions, deep pressure, head massage) for 4 days a week for 6 weeks
62463818|NCT06340139|EXPERIMENTAL|Experimental treatment|the Vestibulo ocular reflex exercises added with conventional treatment will be given to the second group. Vestibulo-ocular reflex exercises will be performed in phases with phase 1 being a fixation point and phase 2 including head and eye movements. Vestibulo ocular reflex exercises will be started from a 5-minute duration and gradually increased to 60 minutes duration
62463819|NCT06266806|NO_INTERVENTION|Control Group|The control group will not receive individual counseling; they will go through the hospital's routine monitoring and counseling process.
62656197|NCT04023968|ACTIVE_COMPARATOR|WOW! workshop|"A comparison workshop titled Wisdom On Wellness (WOW!) will be implemented to control for potential expectancy effects, time commitment, group-based interactions, and wisdom/knowledge of YESplus that is anticipated to have beneficial effects on stress management and well-being, allowing for more rigorous evaluation of the contemplative practices and other activities unique to the YESplus workshop. This workshop differs from YESplus due to the increased focus on cognitive approaches to conceptualizing and managing stress (e.g. thoughts about the past and future versus present moment), and absence of physical or somatic activities."
62737375|NCT00395278||HIV positive KS|HIV positive with Kaposi sarcoma
62656198|NCT05307107|EXPERIMENTAL|Intervention group (IG)|Participants are educators working in health and social care education receiving 8 work week-SHINE.
62092521|NCT03976362|ACTIVE_COMPARATOR|Pembrolizumab + Carboplatin + Taxane + Olaparib Placebo|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS matching maintenance olaparib placebo twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib placebo until centrally verified progressive disease, physician decision or intolerable toxicity."
62290354|NCT03633279|EXPERIMENTAL|Branched Chain Amino Acid|Branched Chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg). one packet at 6pm and two at 9pm.
62290355|NCT03633279|PLACEBO_COMPARATOR|Placebo|Equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
62092522|NCT06447272|SHAM_COMPARATOR|Sham IMT|conventional treatment + sham IMT
62092523|NCT06447272|EXPERIMENTAL|Target IMT|conventional treatment + target IMT
62092524|NCT03606460|EXPERIMENTAL|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
62290356|NCT05249049|EXPERIMENTAL|e-OPRA Implant System for Transtibial Amputees|Implantation of e-OPRA Implant System in lower limb.
62290357|NCT00412477|EXPERIMENTAL|Group 1 - LFn-p24 ISOug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
62290358|NCT00412477|EXPERIMENTAL|Group 2 - LFn-p24 300ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
62290359|NCT00412477|EXPERIMENTAL|Group 3 - LFn-p24 450ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
62656199|NCT05307107|NO_INTERVENTION|Control group (CG)|Participants are educators working in health and social care education without the program continuing their normal daily routines receiving SHINE for their voluntary use after this study (waitlist).
62290360|NCT05650034|EXPERIMENTAL|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H\&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H\&N SCCs ( pN0 or by PETCT).
62290361|NCT03275909|EXPERIMENTAL|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
62737376|NCT06596616||Liver|Patients who have had clinically indicated MRI scans for liver lesions.
61906832|NCT04023838|ACTIVE_COMPARATOR|Left distal radial approach|After local anesthesia on left anatomical snuffbox area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
61906833|NCT02155387||Coronary artery bypass graft surgery|with cardiopulmonary bypass
62290362|NCT03275909|NO_INTERVENTION|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
62290363|NCT03068715|EXPERIMENTAL|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
62737377|NCT01653587|ACTIVE_COMPARATOR|Transradial approach|Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis
62463820|NCT06266806|EXPERIMENTAL|Intervention Group|Individual counseling will be provided to the intervention group within the scope of the Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP), based on Denis's Breastfeeding Self-Efficacy theory and hypnobreastfeeding philosophy. EMÖZGEDAP, which will be applied to pregnant women and their family relatives, will consist of 5 sessions lasting 7.5 hours (2 sessions with the woman and her family relatives, two sessions with the woman alone, and one with her family relatives alone).
62463821|NCT02679053|EXPERIMENTAL|Exercise (IG)|Aerobic exercise three times per week on indoor bicycles at 60 to 75% of maximal heartrate aiming at a weekly total of 17.5kcal/kg bodyweight for 6 consecutive weeks. The exercise will take place under supervision. At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
62463822|NCT02679053|PLACEBO_COMPARATOR|Control (CG)|Basic stretching and mobilisation program 3 times per week each for approx. 40 minutes, also under supervision for 6 consecutive weeks. At the end of every week physical fitness is evaluated by the queens step test.At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
62463823|NCT00060307|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62463824|NCT00913705|EXPERIMENTAL|1|The patients will be randomized to receive taxol (Paclitaxel) and carboplatin as adjuvant or as neoadjuvant regimen or to surgery alone
62463825|NCT01944930|EXPERIMENTAL|Narrow Band Imaging Laparoscopy First|Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
62463826|NCT01944930|EXPERIMENTAL|Standard White-Light Laparoscopy First|Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
62463827|NCT03514771|OTHER|All Subjects|All subjects will have one side of their face treated with the laser and one side not treated to serve as the control.
62463828|NCT03262012|EXPERIMENTAL|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
62463829|NCT03262012|EXPERIMENTAL|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
62463830|NCT03262012|EXPERIMENTAL|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
62463831|NCT03262012|ACTIVE_COMPARATOR|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
62092525|NCT03606460|EXPERIMENTAL|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
62092526|NCT03670602|EXPERIMENTAL|Episodic Future Thinking (EFT)|Participants will generate positive future cues that will be accessed via an electronic app to engage in EFT.
62463832|NCT04874389||Recreationally active males and females|"Subjects to be considered recreationally must regularly engage in \>150 min/wk of physical activity (e.g., resistance training, sport or activity specific exercise, group exercise, or aerobic exercise). Healthy participants, defined as not currently injured, or recovering from an injury within the past 12 months, or undergone surgery within the last 12 months, or with any known history of moderate to severe traumatic brain injury resulting in impaired judgment or inability to make sound decisions or mild traumatic brain injury (mTBI, also commonly named concussion) within the last 12 months."
62463833|NCT04874389||Athletes or performing artists with reported history of concussion|Participants will be considered if they are recreationally active or considered an athletic performer (i.e.,history of participation in athletics at the university, amateur, elite or professional levels, or a military veteran), or a performing artist (i.e., stunt actors, circus artists, dancers or acrobats) with reported history of concussion incident(s), with most recent incident occurring \>1 month and less than five years from the study testing dates.
62463834|NCT02134405|EXPERIMENTAL|Rebamipide and Esomeprazole|Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks
62463835|NCT02134405|ACTIVE_COMPARATOR|Rebamipide and placebo|Placebo drug with Rebamipide 100mg tid
62463836|NCT03827174|ACTIVE_COMPARATOR|Comparison intervention|Return To Work Coordination: external and internal coordination regarding sick leave. Establishment of a common return to work plan between employer and employee.
62463837|NCT03827174|EXPERIMENTAL|Experimental intervention|"Return To Work Coordination + Behaviour Change Ability Programme~Behaviour Change Ability Programme:~1. Return to work coordination~2. Education for employers and employees in pain neuroscience, validation, and problem-solving~3. Patient specific goal setting for return to work~4. Exercise and behavioural skills training related to return to work"
62463838|NCT01546766||Subjects with diabetes|(Subjects that have been diagnosed with diabetes).
62463839|NCT01546766||Control volunteers|(Subjects with no history of ocular problems).
62463840|NCT01546766||Subjects with retinal conditions|(Subjects with a history of retinal disorders except diabetes).
62463841|NCT02799108|EXPERIMENTAL|patients|children with drug-resistant partial epilepsy, in whom preoperative assessment is indicated
62463842|NCT06364280|ACTIVE_COMPARATOR|BVM-only|Initial strategy of airway management using Bag-Valve-Mask (BVM) only.
62463843|NCT06364280|ACTIVE_COMPARATOR|BVM followed by SGA [BVM+SGA]|Initial strategy of airway management using Bag-Valve-Mask (BVM) followed by Supraglottic Airway (SGA).
62463844|NCT06364280|ACTIVE_COMPARATOR|BVM followed by ETI [BVM+ETI]|Initial strategy of airway management using Bag-Valve-Mask (BVM) followed by Endotracheal Intubation (ETI).
62092527|NCT03670602|PLACEBO_COMPARATOR|Daily Check in (DCI)|Participants will be asked to access an electronic app daily, but will receive no cues.
62092528|NCT04166968|SHAM_COMPARATOR|Control Group|neuromotor training and placebo stimulation
62092529|NCT04166968|EXPERIMENTAL|Group 1|neuromotor training and cathodal stimulation over the unaffected hemisphere
62092530|NCT04166968|EXPERIMENTAL|Group 2|neuromotor training and anodal stimulation over the affected hemisphere
62290364|NCT03068715|SHAM_COMPARATOR|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
62290365|NCT00404092|EXPERIMENTAL|1st cohort|70mg caspofungin 1x/day
62092531|NCT05515874|NO_INTERVENTION|Arm 1 - MRI Brain with Gadavist|A research MRI exam that uses the signal from a finger pulse oximeter to synchronize the MRI scan to the subjects heart beat will be acquired. The Gadavist contrast injection will be used during this MRI examination to provide images of cerebral blood flow which will serve as reference standard to identify regions of the brain compromised by cerebral vascular disease. The experimental MRI scan in this case is intended to measure the utilization of oxygen by the brain which is believed to be a predictor of future stroke. All arm 1 procedures will be performed either at Northwestern or University of Chicago.
62290366|NCT00404092|EXPERIMENTAL|2nd cohort|100mg caspofungin 1x/day
62290367|NCT00404092|EXPERIMENTAL|3rd cohort|150mg caspofungin 1x/day
62463845|NCT05088005||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin \>5% (\>10% in smokers).
62463846|NCT05554822|EXPERIMENTAL|Single antiplatelet therapy (SAPT)|"Single antiplatelet therapy composed of aspirin 100 mg OD, organized as follows:~Aspirin-naïve: aspirin 325 mg will be given 12-24 hours before the procedure and continued after the intervention at the dose of 100 mg OD up to 6-month follow-up.~Aspirin-treated: periprocedural aspirin 100 mg OD will be given and continued up to 6-month followup."
62463847|NCT05554822|ACTIVE_COMPARATOR|Double antiplatelet therapy (DAPT)|"Double antiplatelet therapy composed of aspirin 100 mg OD plus Clopidogrel 75 mg OD, organized as follows:~Aspirin-naïve: aspirin 325 mg will be given 12-24 hours before the procedure and continued after the intervention at the dose of 100 mg OD up to 6-month follow-up. Clopidogrel will be given with a 300 mg loading dose of clopidogrel approximately 12 hours before the procedure and then clopidogrel 75 mg OD will be given from the day of intervention up to 3 months. At 3 months clopidogrel will be stopped.~Aspirin-treated: periprocedural aspirin 100 mg OD will be given and continued up to 6-month followup. Clopidogrel will be given with a 300 mg loading dose of clopidogrel approximately 12 hours before the procedure and then clopidogrel 75 mg OD will be given from the day of intervention up to 3 months. At 3 months clopidogrel will be stopped."
62463848|NCT01351220|ACTIVE_COMPARATOR|Basic dissemination|
62463849|NCT01351220|ACTIVE_COMPARATOR|Organizational dissemination|
62463850|NCT05100381|EXPERIMENTAL|Experimental group|The experimental group will comprise 20 participants with chronic non-specific low back pain. The treatment will include dry needling of the lumbar multifidus muscle and routine physical therapy. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. Routine physical therapy will include low level laser therapy and motor control training. The treatment will last 3 weeks, 6 sessions, twice a week.
62463851|NCT05100381|PLACEBO_COMPARATOR|Control group|"The control group will comprise 20 participants with chronic non-specific low back pain. The treatment will include sham dry needling of the lumbar multifidus muscle and routine physical therapy. The sham dry needling method consists of the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes. Routine physical therapy will include low level laser therapy and motor control training. The treatment will last 3 weeks, 6 sessions, twice a week."
62463852|NCT01269801|ACTIVE_COMPARATOR|Botox Cosmetic|onabotulinumtoxinA for injection
62737378|NCT01653587|ACTIVE_COMPARATOR|Transfemoral approach|Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis
62737379|NCT00712686|ACTIVE_COMPARATOR|A1|
62737380|NCT00712686|ACTIVE_COMPARATOR|B1|
62290368|NCT00404092|EXPERIMENTAL|4th cohort|200mg caspofungin 1x/day
62290369|NCT06077084|ACTIVE_COMPARATOR|Moderate intensity|
62290370|NCT06077084|ACTIVE_COMPARATOR|High intensity|
62290371|NCT03388593|PLACEBO_COMPARATOR|Placebo|Placebo in addition to standard therapy
62290372|NCT03388593|EXPERIMENTAL|rhNRG-1|rhNRG-1 in addition to standard therapy
62290373|NCT04312087|EXPERIMENTAL|MLND|Modified lateral neck dissection (compartment II-V) is performed in all patients.
62290374|NCT04312087|EXPERIMENTAL|SLNB|Sentinel lymph node biopsy in the lateral neck is performed. The decision of neck dissection is based on the result of sentinel lymph node biopsy.
62290375|NCT06069661|EXPERIMENTAL|Single-Arm|Device: F2 Filter and Delivery System
62290376|NCT04847388||ART-naive HIV Patients with substance abuse and without substance abuse|Group A Group B
62290377|NCT04847388||Group A and B|Group A: ART-naive HIV seropositive with H/O substance abuse Group B: ART-naive HIV seropositive without H/O substance abuse
62290378|NCT04897490||Adult APL in first line|Patients \>/= 18 years old with recent diagnosis of acute promyelocytic leukemia who receive treatment with ATO/ATRA according to our local guidelines. HR patients will receive 2-3 additional doses of idarubicin.
62463853|NCT01269801|ACTIVE_COMPARATOR|JUVÉDERM|JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
62463854|NCT00641394|EXPERIMENTAL|1|Psychotherapy: Emotional Freedom Techniques (EFT), a psychotherapy intervention with a somatic component
62463855|NCT00641394|ACTIVE_COMPARATOR|2|Psychotherapy: Cognitive Behavioral Therapy (CBT), a psychotherapy intervention
62656200|NCT03911388|EXPERIMENTAL|HSV G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
62656201|NCT04970082|EXPERIMENTAL|FFR followed by FFR-DWP (investigation)|The FFR measurement is performed with the standard method first followed by the FFR measurement with the DWP method.
62656202|NCT04970082|EXPERIMENTAL|FFR-DWP (investigation) followed by FFR|The FFR measurement is performed with the DWP method first followed by the FFR measurement with the standard method.
62092532|NCT05515874|NO_INTERVENTION|Arm 2 - MRI Brain with Tc-99m-HMPAO tracer|This type of MRI shows the flow of blood in different areas of the brain and will be performed at University of Chicago. This is done with a tracer called Tc-99m-HMPAO, injected through a vein in the arm. HMPAO is Technetium-99m hexamethyl propylenamine oxime and used clinically to assess blood supply in the brain. This MRI will be performed one hour after the injection of this tracer at University of Chicago and will last up to one hour. A tracer is a specially designed drug that is bound to a radioactive material. Tracers are designed to act like natural products in the body allowing imaging to look at how the body is working. Tracers are designed to look at very specific organ functions and, in this case, brain.
62092533|NCT05515874|EXPERIMENTAL|Arm 3 - Feumoxytol infusion and MRI Brain|An intravenous ferumoxytol infusion (before the patient leaves Northwestern or University of Chicago after stroke care or at another visit) and an MRI exam 72 hours later. This MRI examination will last approximately 30 minutes and will not involve gadavist. All arm 3 procedures will be performed either at Northwestern or University of Chicago.
62092534|NCT05103774||Group A: children exposed to any type of radiation or contrast|Group A: children exposed to any type of radiation or contrast
62092535|NCT05103774||Group B : children not exposed to an type of radiation or contrast|Group B : children not exposed to an type of radiation or contrast
62092536|NCT06085833|OTHER|Human subjects requiring breast biopsy|All patients referred to participating study sites for a core needle or vacuum-assisted breast biopsy are eligible for this study. Upon consent, a diagnostic biopsy will be measured by the sponsor's device before returning to the standard of care pathway.
62092537|NCT01164787|EXPERIMENTAL|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
62092538|NCT01164787|ACTIVE_COMPARATOR|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
62092539|NCT00278564|EXPERIMENTAL|Hematopoietic stem cell transplantation|Intervention as hematopoietic stem cells transplantation after conditioning regimen: Autologous hematopoietic stem cells will be injected after conditioning regimen
62092540|NCT01590069|EXPERIMENTAL|Treatment (aerosolized aldesleukin)|Patients receive aerosolized aldesleukin QD on days 1-21. Courses repeat every 28 days in the absence of disease progression of unacceptable toxicity.
62092541|NCT03661970||Normal subjects hearing group|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
62092542|NCT03661970||Cochlear implant subjects with good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
62092543|NCT03661970||Cochlear implant subjects without good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
62463856|NCT00641394|NO_INTERVENTION|3|
62463857|NCT04321564||Nullipar pregnant women|
62463858|NCT04321564||multipar pregnant women|
62463859|NCT02076022|ACTIVE_COMPARATOR|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
61906834|NCT02155387||Pulmonary metastasectomy by thoracotomy|with one lung ventilation
61906835|NCT02155387||Minimal invasive mitral valve surgery|with cardiopulmonary bypass and one lung ventilation
62092544|NCT05630469||Depression|Depressive patients (pharmaco-resistant) undergoing electroconvulsive therapy
62463860|NCT02076022|EXPERIMENTAL|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
62463861|NCT02939729|EXPERIMENTAL|Prehabilitation|This group will receive standard preoperative information and education and be provided with a physiotherapy prehabilitation programme. This programme will be carried out from time of consenting to participate in the study until day of admission to surgery for cardiac or thoracic surgery. The prehabilitation programme consists of: walking programme, deep breathing exercises and tidal volume measurement using the incentive spirometer.
62463862|NCT02939729|NO_INTERVENTION|Standard Care|This group will receive standard preoperative information and education only.
62463863|NCT02563808|ACTIVE_COMPARATOR|Standard Decision Aid|The brochure with standard information on surgery for early-stage breast cancer
62463864|NCT02563808|EXPERIMENTAL|Post-surgical Regret Decision Aid|The brochure that incorporates additional information on the rates of regret after surgical treatment of early-stage breast cancer.
62463865|NCT04161365|EXPERIMENTAL|Urethral stricture patients|Patients suffering from urethral stricture are treated with direct visual internal urethrotomy (DVIU). Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
62656203|NCT06179940|EXPERIMENTAL|Food selectivity group (1) in pairs|15 Children in the experimental group who will undergo the treatment perform the procedure in pairs.
62656204|NCT06179940|EXPERIMENTAL|Food selectivity Group (2) in individual mode|15 Children in the comparator group who will undergo the treatment perform the procedure in individual mode.
62290379|NCT02928952|EXPERIMENTAL|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
62656205|NCT01757015|PLACEBO_COMPARATOR|Placebo|Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
62092545|NCT05589727||Patients with VAP - ANVISA criteria|Patients notified with Ventilator-Associated Pneumonia (VAP) when using the current ANVISA criteria.
62290380|NCT02928952|NO_INTERVENTION|DSME alone|Usual care control
62290381|NCT01946178|EXPERIMENTAL|Focused ultrasound treatment|Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.
62290382|NCT05427578||Remitted depression|Patients in full remission of a major depressive disorder (rMDD)
62290383|NCT05427578||Healthy participants at risk|Healthy participants with increased MDD risk (having a 1st-degree relative with MDD)
62290384|NCT05427578||Healthy participants low risk|Healthy participants with low MDD risk (having no 1st-degree relatives with MDD)
62290385|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
62656206|NCT01757015|EXPERIMENTAL|NVA237|NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
62656207|NCT01099956||diabetes group|
62092546|NCT05589727||Patients with VAP - NHSN criteria|Patients notified with Ventilator-Associated Pneumonia (VAP) when using the Ventilator-Associated Events (VAE) criteria defined by the NHSN.
62092547|NCT04990882||Low Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of less than 30 studies.
62092548|NCT04990882||Intermediate Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 30 studies and less than 300 studies.
62290386|NCT05568771|EXPERIMENTAL|Core exercise group|In the study, the exercise group was set as Istanbul University Club Basketball Team, and the control group was set as Galatasaray Basketball Club. While the 1st group, which is the exercise group, applied the additional warm-up program to the core training program to be included in the routine training of the team, for 8 weeks,
62290387|NCT05568771|NO_INTERVENTION|Control group|the 2nd group, the control group, continued their routine training programs.
62656208|NCT01099956||control group|
62656209|NCT02229838|EXPERIMENTAL|BIBB 1464 MS single rising dose fed|
62290388|NCT05340504|EXPERIMENTAL|Group A: N-Acetylcysteine, then Washout, then Placebo Oral Capsule|Group A will receive NAC 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive Placebo Oral Capsule 2 times a day for 14 days and have another MRI exam on day 14.
62308031|NCT03229577|EXPERIMENTAL|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
62308032|NCT03229577|NO_INTERVENTION|Control|The control group will receive no intervention.
62463866|NCT05406791|EXPERIMENTAL|Sensor-enabled digital mental health intervention (DMHI)|"Patients randomized to sensor-enabled DMHI condition will use Ksana Health's Vira mobile therapy platform with support from a study coach"
62463867|NCT05406791|EXPERIMENTAL|Experimental: Control Treatment (CT)|Participants randomized to the CT condition will use a Mood Education App designed by researchers at the University of Virginia to deliver psychoeducational content to help people self-manage symptoms of depression, anxiety, and stress.
62463868|NCT01695720|EXPERIMENTAL|VisionScope Imaging (VSI) Exam|A VisionScope Imaging (VSI) Exam is diagnostic arthroscopic procedure. Through a natural or surgical opening, an endoscope is inserted through a cannula to illuminate and visualize the interior cavity of a joint.
62463869|NCT06302530|EXPERIMENTAL|Group A (Strayer):|This group will consist of patients with isolated gastrocnemius contracture who will be operated with the Strayer technique. This consists of ultrasound-guided surgical recession of the gastrocnemius tendon distally.
62463870|NCT06302530|EXPERIMENTAL|Group B (Plantar transection):|This group will include patients with mild contracture of the triceps suralis who will undergo surgery by ultrasound-guided transection of the plantar tendon on the medial aspect of the gastrocnemius.
62656210|NCT02229838|EXPERIMENTAL|BIBB 1464 MS tablet fasted|
62656211|NCT02229838|ACTIVE_COMPARATOR|BIBB 1464 MS solution fasted|
62656212|NCT02229838|PLACEBO_COMPARATOR|BIBB 1464 MS placebo|
62656213|NCT06371391||DCH|The inclusion criteria for the Danish Diet Cancer and Health (DCH) cohort were age between 50 and 64 y, residing in the greater Copenhagen or Aarhus area and without a cancer diagnosis. From 1993 to 1997, 160,725 Danes were invited to participate of whom 57,053 participants accepted the invitation and were enrolled in the study. All participants completed detailed questionnaires at enrolment and trained staff members measured height, weight, and waist circumference.
61906836|NCT06022289|EXPERIMENTAL|Monotherapy or combination therapy based on Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
62092549|NCT04990882||High Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 300 studies.
62463871|NCT05733884|EXPERIMENTAL|Daily Disposable Multifocal Soft Contact lenses, PEGAVISION, Taiwan|Subjects will be asked to wear the lenses for 8 hours a day, at least 7 days a week. Contact lenses are worn and replaced every day. All subjects will be followed for 1 year after device allocation and will undergo brief clinical assessments at 1 day, 1 week, 1, 3, 6, 9, and 12 months.
62656214|NCT06371391||DNC|The Danish Nurse Cohort (DNC) was initiated by sending questionnaires to the members of the Danish Nurse Organization in 1993 and 1999. Among 33,704 eligible female nurses aged 44-93 years who either worked or were retired in 1993 or 1999, 28,731 participants (85·2%) were included in the DNC. Upon enrolment, participants answered a comprehensive questionnaire on body mass index (BMI), lifestyle factors (smoking, alcohol consumption, physical activity, and dietary habits), self-reported diseases and reproductive health, and working conditions.
62656215|NCT06371391||SDPP|The Stockholm Diabetes Preventive Programme (SDPP) is a prospective cohort aimed at investigating the aetiology of type 2 diabetes and cardiometabolic risk factors. The cohort comprises 34 486 men and women aged 35-56 years who lived in five municipalities in Stockholm County 1992-1998. A sub-sample of 7,949 individuals were invited to a clinical examination at baseline and were followed up 2002-2006 and 2014-2017. During the clinical examinations, blood pressure was measured along with anthropometric measurements, blood samples were collected, oral glucose tolerance tests were administered, and participants answered extensive questionnaires concerning lifestyle factors, health status, socioeconomic characteristics, and psychosocial conditions
62656216|NCT06371391||SIXTY|The SIXTY cohort is based on a random sample of every third man and woman living in Stockholm County, who were born in 1937 and 1938. A total of 4,232 subjects were recruited 1997-1999 to investigate risk factors for cardiovascular disease. People were 59- 61 years at enrolment. Measurements of anthropometric indices and blood pressure were made at recruitment and fasting blood samples were collected. In addition, a comprehensive questionnaire was completed, including information on socioeconomic, medical and lifestyle factors.
62656217|NCT06371391||SALT|The Screening Across the Lifespan Twin Study (SALT) included a total of about 45 000 twins born 1958 and earlier from the Swedish Twin Registry who were interviewed 1998-2002. Those 7,043 who resided in Stockholm County at recruitment are included in the present project. People were 42-97 years at enrolment. The interview collected data on zygosity, diseases, use of medication, occupation, education and lifestyle habits. In a subgroup of around 2,500 subjects, a clinical examination was made, including blood sampling and anthropometrics as well as blood pressure measurements
62656218|NCT06371391||SNAC-K|"The Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) was established 2001-2004 and included 3,363 residents aged 60-104 years in Kungsholmen, Stockholm. The aim was to investigate the ageing process and identify possible preventive strategies to improve health and care in elderly adults. Information was collected through social interviews and clinical examinations, including assessment of physical and cognitive functioning.~Follow-up investigations are performed at intervals of three to six years depending on age"
62656219|NCT06371391||MDC|The Malmö Diet and Cancer (MDC) study is a population based prospective cohort study. People were enrolled into the cohort between 1991 and 1996, and eligible participants were men born between 1923 and 1945 and women born between 1923 and 1950, living in the city of Malmö. Swedish reading and writing skills were required. People were 44-73 years at enrolment. The data collection was done both using questionnaires and interviews, including data on dietary habits, socio-economics, medical history and lifestyle factors. The total number of study subjects were 28,098.
62737381|NCT04191304|EXPERIMENTAL|Benralizumab arm|1x Benralizumab SC injection
62737382|NCT04191304|PLACEBO_COMPARATOR|Placebo arm|1x Benralizumab matching placebo SC injection
62737383|NCT03332199|NO_INTERVENTION|Control|Participants in the control group received standard treatment from oncologists and nurses at Hanoi Medical University Hospital.
62463872|NCT05733884|ACTIVE_COMPARATOR|Omafilcon A, dual-focus optical design, USA|Subjects will be asked to wear the lenses for 8 hours a day, at least 7 days a week. Contact lenses are worn and replaced every day. All subjects will be followed for 1 year after device allocation and will undergo brief clinical assessments at 1 day, 1 week, 1, 3, 6, 9, and 12 months.
61906837|NCT02604329|EXPERIMENTAL|intervention|"Radiation : use of Oncolase Digi therapy laser diode"
61906838|NCT05873166|EXPERIMENTAL|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
61906839|NCT05873166|SHAM_COMPARATOR|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|
62463873|NCT06037122||group R-BID|rabeprazole 10mg, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth pectin 200 mg or bismuth potassium citrate 220mg twice daily, all drugs given for 14 days
62463874|NCT06037122||group V-BID|vonoprazan 20mg, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth pectin 200 mg or bismuth potassium citrate 220mg twice daily, all drugs given for 14 days
62092550|NCT03434743|EXPERIMENTAL|Rehabilitative Intervention|Experimental rehabilitative intervention consists of non-nutritive sucking on emptied breast, one time per day for 10 minutes.
62290389|NCT05340504|EXPERIMENTAL|Group B: Placebo Oral Capsule, then Washout, then N-Acetylcysteine|Group A will receive Placebo Oral Capsule 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive NAC 2 times a day for 14 days and have another MRI exam on day 14.
62290390|NCT03624816|EXPERIMENTAL|Restylane Defyne|injection with Restylane Defyne
62290391|NCT03624816|NO_INTERVENTION|Control|no-treatment control
62290392|NCT05963763|OTHER|Career Navigator Coaching|"Participants randomized into this group will be invited to participate in the quantitative and qualitative surveys. At baseline, participants in Group1 will receive the intervention- tailored coaching sessions with the Career Navigator which will continue until the end of the 6th month.~The intervention will be tailored for each participant according to their need. The Career Navigator will be in charge to plan and develop tools to help the participant achieve their own goals."
62290393|NCT05963763|OTHER|Delayed Career Navigator Coaching|"Participants randomized into this group will be invited to participate in the quantitative and qualitative surveys For the first six months, participants in Groups 2 will not receive the intervention and will function as a control group. When the study reaches the sixth-month Group 2 participants will receive the intervention - tailored coaching sessions with the Career Navigator.~The intervention will be tailored for each participant according to their need. The Career Navigator will be in charge to plan and develop tools to help the participant achieve their own goals."
62290394|NCT02509559|ACTIVE_COMPARATOR|Propanolol|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one Propranolol-CT 80 mg film-coated tablet.
62092551|NCT03434743|ACTIVE_COMPARATOR|Control Intervention|Control active comparator intervention consists of non-nutritive sucking on a pacifier, one time per day for 10 minutes.
62092552|NCT01056211|ACTIVE_COMPARATOR|hypopigmented scars treated with laser|patients with hypopigmented scars treated with Starlux 300 Lux 1540nm Fractional laser hand piece
62463875|NCT06037122||group V-QD|vonoprazan 20mg once daily, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth pectin 200 mg or bismuth potassium citrate 220mg twice daily, all drugs given for 14 days
62463876|NCT04719949|EXPERIMENTAL|Behavioral Activation (BA) Therapy|Participants complete four sessions of BA, 60-90 minutes per session.
62092553|NCT01056211|PLACEBO_COMPARATOR|hypopigmented scars treated without laser|patients with hypopigmented scars treated without laser
62092554|NCT01056211|ACTIVE_COMPARATOR|hypertrophic scars treated with laser|
62092555|NCT01056211|PLACEBO_COMPARATOR|hypertrophic scars not treated with laser|
62463877|NCT04719949|ACTIVE_COMPARATOR|Problem Solving Therapy (PST)|Participants complete four sessions of PST, 60-90 minutes per session.
62290395|NCT02509559|PLACEBO_COMPARATOR|Placebo|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one placebo capsule.
62290396|NCT06005584|ACTIVE_COMPARATOR|High Frequency SCS|Participants will be randomly assigned to this arm for up to 6 weeks
62290397|NCT06005584|ACTIVE_COMPARATOR|Burst SCS|Participants will be randomly assigned to this arm for up to 6 weeks
62092556|NCT01056211|ACTIVE_COMPARATOR|scars due to grafts and reconstructions treated with laser|scars due to grafts and reconstructions in the head and neck region
62290398|NCT06005584|SHAM_COMPARATOR|Sham SCS|Participants will be randomly assigned to this arm for up to 6 weeks
62463878|NCT01263704|EXPERIMENTAL|Rituximab plus Fludarabine and Cyclophosphamide|Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.
62463879|NCT05320679||Study Group|Patients who have musculoskeletal pain
62463880|NCT01366079|EXPERIMENTAL|Position change|Position change group
61906840|NCT03769610|ACTIVE_COMPARATOR|Inpatient Foley catheter|Subjects will be admitted to a room on labor and delivery and will be monitored with the external fetal monitor (EFM) and tocometer (a device to monitor contractions). If she is contracting less than every 2 minutes, intravenous (IV) Pitocin will be started at 2 milliunits/minute and increased per hospital protocol. While on pitocin, she will remain on continuous EFM and tocometer. She will also be kept on a clear liquid diet with intravenous fluids per standard protocol. If the Foley catheter has not been expulsed in 24 hours, it will be removed. After expulsion or removal of the Foley catheter, induction may proceed as deemed clinically appropriate by the managing physician. No further cervical ripening will be performed after the Foley catheter is expulsed/removed, or after 24 hours.
61906841|NCT03769610|EXPERIMENTAL|Outpatient Foley catheter|Subjects are asked to return to the hospital \~12 hours after placement. Subjects are to return to the hospital if they develop heavy vaginal bleeding, decreased fetal movement, rupture of membranes, or increasingly painful or frequent contractions requiring an epidural or pain relief. Once admitted, subjects will be evaluated for expulsion of the catheter. If the catheter is in place IV Pitocin will be started. If the catheter has been expulsed, the induction will proceed as deemed clinically appropriate. After 24 hours, if the Foley catheter is still in the cervix it will be removed and the induction will proceed as deemed clinically appropriate.
62463881|NCT01366079|ACTIVE_COMPARATOR|Left lateral|Left lateral position
61906842|NCT06080568||Mitochondrial myopathy|Individuals with pathogenic mtDNA mutations
61906843|NCT06080568||Control|Individuals without mtDNA mutations
62092557|NCT01056211|PLACEBO_COMPARATOR|grafts and reconstructions scars not treated with laser|scars due to grafts and reconstructions in the head and neck region
62092558|NCT02459340|EXPERIMENTAL|patient group|Inpatient setting (cPTSD, DDNOS, DIS): Trauma-adapted psychotherapy (individual and group setting), body-related, cognitive stabilization groups, pharmacotherapy, and other non-verbal treatment modalities (e.g. music, art, and occupational therapy)
62092559|NCT02459340|NO_INTERVENTION|healthy control group|passive control group
62290399|NCT05406908|EXPERIMENTAL|fractionated-dose intradermal tozinameran|10 micrograms (0.1 mL) of tozinameran administered intradermally to the deltoid area of the non-dominant arm with a sterile 30-gauge needle.
62092560|NCT04873817||IonicRF Generator and compatible accessories|IonicRF Radiofrequency Generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator will be used.
62092561|NCT04639206|EXPERIMENTAL|HOBSCOTCH group|Participants in this study arm will receive the HOBSCOTCH intervention immediately.
62092562|NCT04639206|NO_INTERVENTION|Wait-listed control|Participants in this study arm will be wait-listed for 6 months and will then receive the HOBSCOTCH intervention.
62290400|NCT05406908|ACTIVE_COMPARATOR|standard intramuscular tozinameran|30 micrograms (0.3 mL) of tozinameran administered intramuscularly to the deltoid area of the non-dominant arm with a sterile 25-gauge needle.
62290401|NCT03514082||Adolescent Idiopathic Scoliosis|Subjects with AIS who are beginning to the conservative treatment.
61906844|NCT04908943|EXPERIMENTAL|Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)|RENEW was created by researchers, doctors, and patients with scleroderma. It is a web-based peer-led program to help manage energy and symptoms in people who have scleroderma.
62092563|NCT01391156|EXPERIMENTAL|Minoxidil|
62092564|NCT01391156|ACTIVE_COMPARATOR|MinoxidilFinasteride|
62092565|NCT06614075||Adults|Overweight and obese adults
62290402|NCT00470821|PLACEBO_COMPARATOR|A - placebo|Identical tablets without the active principles. Each evening, nurses are requested to give 2 tablets at 8 PM and 12 PM
62290403|NCT00470821|ACTIVE_COMPARATOR|B - melatonin|Identical tablets containing melatonin 3 mg Nurses are requested to give two tablets daily, at 8 PM and 12 PM.
62290404|NCT05494307|EXPERIMENTAL|Terbutaline plus danazol|Terbutaline: A dose of 2.5 mg three times daily for 16 weeks Danazol: A dose of 200 mg twice daily for 16 weeks
62463882|NCT05800652|EXPERIMENTAL|Experimental|Experimental: First-year nursing students (mentees) undergoing a mentoring program 20 mentees were included in the experimental group.The mentoring program focuses on developing students' life skills. The mentoring program continued for 12 weeks. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The frequency and duration of individual interviews were determined by the needs of the mentee.
62092566|NCT06582147|OTHER|Social needs screening and referral care|As a step wedge cluster randomized trial all sites will be assigned to receive the intervention in a randomized order. There is no difference in the intervention by site, the only difference is the timing of the beginning of the intervention. Therefore, we have only identified one arm.
62092567|NCT02338921|ACTIVE_COMPARATOR|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor~Sitagliptin"
62092568|NCT02338921|ACTIVE_COMPARATOR|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors~Dapagliflozin"
62092569|NCT02338921|ACTIVE_COMPARATOR|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist~Lobeglitazone"
62656220|NCT06371391||SMC|The Swedish Mammography Cohort, part of SIMPLER (Swedish Infrastructure for Medical Population-based Life-course and Environmental Research; www.simpler4 health.se), a population-based prospective cohort study was established 1987-90 when all 90,303 women living in Uppsala and Västmanland counties, born 1914-48, were invited to a mammography screening and to respond to a questionnaire (74% response rate). In 1997, the 56,030 participants who were still living in the study area were invited to respond to a 2nd extended questionnaire, (response rate 70 %). In the present project, we included the women from Uppsala County taking part in the 1997 investigation (n= 20,407) women for residential exposure to air pollution, road traffic noise and urban greenness.
62737384|NCT03332199|EXPERIMENTAL|Intervention|In addition to standard care provided by oncologists and nurses at Hanoi Medical University Hospital as described above, participants assigned to the intervention group received the psychoeducational intervention delivered by the nurse researcher.
61906845|NCT04908943|NO_INTERVENTION|Waitlist|Participants will be asked about changes in health status, and use of any new treatments or services at 6 and 12 weeks.
62092570|NCT04415268|EXPERIMENTAL|Multitreatment|"Pharmacological treatment per standard of care (whole study length, starting on week 1).~Supervised exercise protocol (phase 1, 8 weeks starting on week 9). Unsupervised exercise protocol (phase 2, 8 weeks starting on week 17)."
62092571|NCT03423901|EXPERIMENTAL|ABO/HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)
62092572|NCT03423901|EXPERIMENTAL|ABO incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation
62092573|NCT03423901|EXPERIMENTAL|HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation
62092574|NCT05676073|EXPERIMENTAL|SHEN26 dose 1|SHEN26 capsule 200mg. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
62290405|NCT05494307|ACTIVE_COMPARATOR|Danazol monotherapy|Danazol: A dose of 200 mg twice daily for 16 weeks
62290406|NCT00955058|ACTIVE_COMPARATOR|cyproterone compound|Before and after treatment
62290407|NCT00955058|EXPERIMENTAL|oral contraceptive pill|Treatment
62290408|NCT03906253|EXPERIMENTAL|Factionated Laser Resurfacing - Right Arm|Right forearm treatment of fractionated laser resurfacing.
62290409|NCT03906253|EXPERIMENTAL|Factionated Laser Resurfacing - Left Arm|Left forearm treatment of fractionated laser resurfacing.
62290410|NCT02773966|EXPERIMENTAL|Arm A: Kypho-IORT|balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
62290411|NCT02773966|ACTIVE_COMPARATOR|Arm B: EBRT|external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)
62290412|NCT00723957|EXPERIMENTAL|Ixabepilone, 32 mg/m^2 + Carboplatin (AUC 6)|
62290413|NCT00723957|ACTIVE_COMPARATOR|Paclitaxel, 200 mg/m^2 + Carboplatin (AUC 6)|
62092575|NCT05676073|EXPERIMENTAL|SHEN26 dose 2|SHEN26 capsule 400mg. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
62290414|NCT03838484|EXPERIMENTAL|Healthy: placebo first, nicotine last|Healthy controls will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
62290415|NCT03838484|EXPERIMENTAL|Healthy: nicotine first, placebo last|Healthy controls will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
62290416|NCT03838484|EXPERIMENTAL|SCZ: placebo first, nicotine last|Subjects with schizophrenia (SCZ) will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
62290417|NCT03838484|EXPERIMENTAL|SCZ: nicotine first, placebo last|Subjects with schizophrenia (SCZ) will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
62290418|NCT05655403|EXPERIMENTAL|Step training group|The participants assigned to the ST condition will receive a 40-minute ST session twice a week for 12 weeks. The sessions will be delivered at community centers for older adults by an instructor with at least 5 years of experience in dementia care. Each session will consist of a 5-minute flexibility exercise warm-up, a 30-minute stepping exercise, and a 5-minute cool-down. A non-slip plastic mat marked with two standing panels and a number of removable stepping panels that can be secured to the plastic mat using hook-and-loop fasteners will be used as the exercise device. While standing on the standing panels, the participants will receive verbal instructions to (1) use one of their feet to step on a specific stepping panel and (2) return the stepping foot to the standing panel multiple times throughout every session.
62092576|NCT05676073|PLACEBO_COMPARATOR|SHEN26 placebo|Placebo matching the SHEN26 capsule. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
62092577|NCT06501300|EXPERIMENTAL|Intervention|"Teachers and relevant school staff six 90-minute supervised group lessons with a 1-2 week space between each time.~School leaders attend three 90-minute sessions adapted to them"
62092578|NCT06501300|NO_INTERVENTION|Waitlist Control|Receives no intervention, business as usual. Receives intervention the following year.
62092579|NCT05906329|OTHER|Low-dose radiotherapy combined with conventional radiotherapy after immunotherapy resistance|By using enhanced CT to locate the chest, abdomen, and pelvis, the target area was delineated. The lesion was a visible lymph node with a short diameter of ≥ 1cm, and there was metastasis confirmed by two deputy chief physicians based on enhanced MR and PET/CT examination results. Select the primary lesion, the largest metastatic lesion, or the lesion causing symptoms, and perform routine segmentation (1.8-2Gy/f, 40Gy-60Gy). For the remaining lesions, at least one easily assessable and measurable lesion should be selected as the observation lesion. Unselected lesions (≤ 10) should be given 1.6Gy/f, 1f/w, 4-6 times in total. The immunotherapy plan is carried out according to the specific dose and interval of the original immune plan. Usually, immunotherapy is combined with radiotherapy at a frequency of once every 3 weeks until progression.
62092580|NCT05756842|EXPERIMENTAL|Honey-based gel consumption|A honey-based gel will be administered to participants in this arm.
62092581|NCT01911221|EXPERIMENTAL|rMenB+OMV NZ|A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
62092582|NCT05381038|EXPERIMENTAL|QPOP + CURATE.AI|Participants will undergo two study stages: QPOP drug selection and CURATE.AI-guided dosing modulation. In the QPOP drug selection stage, participants will undergo a baseline biopsy for organoid generation and subsequently receive treatment as per SOC. During this time, QPOP will identify optimal drug combinations for the participant based on ex vivo experiments on the participant's organoid. Participants who are identified via QPOP to potentially benefit from azacitidine in combination therapy (azacitidine + docetaxel, azacitidine + paclitaxel or azacitidine + irinotecan) will move on to the CURATE.AI-guided dosing modulation stage with treatment with azacitidine. Azacitidine treatment will begin once disease progression after SOC treatment is determined based on CT scans. Only azacitidine dose in the selected azacitidine combination will be modulated by CURATE.AI
62092583|NCT04548609|EXPERIMENTAL|Inhibitory Control/ Fear Extinction|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62092584|NCT04548609|EXPERIMENTAL|Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
62092585|NCT02941185|OTHER|Devit-3 Oral Drop 400 IU|supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
62290419|NCT05655403|ACTIVE_COMPARATOR|Wait-list control group|The participants assigned to the WC condition will then receive usual care for 12 weeks. After completing the 12-week assessment, they will complete the ST program.
62290420|NCT00883493|EXPERIMENTAL|Quetiapin fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
62290421|NCT00883493|EXPERIMENTAL|Quetiapin fumarate XR+Lithium carbonate|Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
62463883|NCT05800652|NO_INTERVENTION|Control|No Intervention: Control group 20 mentees were included in the control group. After the follow-up test was applied to the students in the experimental group, a three-week mentoring program was applied to the control group.
62656221|NCT06371391||DNHC|Danish National Health Survey (DNHS): This cohort included 177 639 persons aged 16 years and older randomly selected across Denmark who answered a questionnaire in 2010 or 2013.40 Information on age, sex, education and labor market affiliation was obtained from national registers. The questionnaire focused on sex, age, cohabiting status, education, occupation, smoking, alcohol consumption, diet, physical activity and anthropometric data.
62656222|NCT01869309|NO_INTERVENTION|Non-HPR group|The non-HPR group will have PD and genetic testing, with no change in medication.
62656223|NCT01869309|ACTIVE_COMPARATOR|HPR Group|This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.
62290422|NCT02524431|ACTIVE_COMPARATOR|Glaucoma subjects|During glaucoma surgery, collection of trabecular meshwork tissue during surgery that is not needed is cut away from the surgical site. The physician will keep this tissue for analysis by the researchers at Wills Eye Hospital and Thomas Jefferson University Center for Translational Medicine.
62656224|NCT03428373|EXPERIMENTAL|Len-Dex+Rivaroxaban|Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
62290423|NCT02524431|ACTIVE_COMPARATOR|Control cadaver eyes|control cadaver eye are ordered and the collection of trabecular meshwork tissue during surgery and is processed at Thomas Jefferson University
62290424|NCT06255873|EXPERIMENTAL|ketogenic diet with L - Carnitine supplementation.|Patients with drug resistant epilepsy who received ketogenic diet with L - Carnitine supplementation.
62463884|NCT03496922|EXPERIMENTAL|Tobacco Products|Participants will be asked to sample ventilated and unventilated cigarettes (and possibly alternative nicotine products such as cigarillos). During the experimental sessions, they will be given the opportunity to purchase ventilated and unventilated cigarettes (and possibly alternative nicotine products) using an account balance in the Experimental Tobacco Marketplace. However, besides the required sampling session, participants will not be required to purchase any nicotine products.
62290425|NCT06255873|ACTIVE_COMPARATOR|ketogenic diet.|Patients with drug resistant epilepsy who received ketogenic diet only.
62290426|NCT03563300|ACTIVE_COMPARATOR|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
62463885|NCT00467220|NO_INTERVENTION|Control|Subjects will follow all study tasks but will not be required to follow a calorie-restricted meal plan.
62092586|NCT02941185|ACTIVE_COMPARATOR|Devit-3 Oral Drop 800 IU|Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
62092587|NCT02941185|ACTIVE_COMPARATOR|Devit-3 Oral Drop 1000 IU|Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
62092588|NCT06036030|EXPERIMENTAL|bitter melon fruit extract (Momordica charantia) with primaquine|For three days, a combination of 500 mg of bitter melon fruit extract (Momordica charantia) and 325 mg of bitter melon fruit content (13.50 mg/kg body weight) was administered. those with Plasmodium falciparum and Plasmodium vivax malaria received a single dosage of primaquine (0.25 mg/kg body weight) once daily, with those with Plasmodium falciparum malaria receiving it for 14 days.
62092589|NCT06036030|ACTIVE_COMPARATOR|dihydroartemisinin+piperaquine+ primaquine|DHP (fixed dosage combination tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine) was administered to the group for 3 days, with primaquine being administered for 14 days to patients with Plasmodium vivax and 1 day initially to those with Plasmodium falciparum without difficulties. Body weight is taken into consideration while setting therapy parameters (age 15 years, \>40-60 kg: 3 tablets; \>60-80 kg: 4 tablets; 80 kg: 5 tablets).
62092590|NCT03781960|EXPERIMENTAL|Abemaciclib & Nivolumab|Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.
62092591|NCT06484751|EXPERIMENTAL|Intervention|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
62092592|NCT01582243|EXPERIMENTAL|Vildagliptin plus metformin (SPC)|Eligible participants received oral vildagliptin 50 mg plus metformin 500 mg (SPC) twice daily from week 1 to week 24.
62092593|NCT03645603|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
62092594|NCT03645603|PLACEBO_COMPARATOR|Placebo|saline solution for IV infusion. The administration of infusion will follow the experimental drug.
62092595|NCT03459729|EXPERIMENTAL|Antitumor B|ATB will be administered on an outpatient basis.
62092596|NCT05674903|EXPERIMENTAL|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets involved in pain perception Intervention: Device: Diadem prototype
62092597|NCT05674903|SHAM_COMPARATOR|Sham stimulation|Low-intensity transcranial focused ultrasound stimulation using unfocused wave Intervention: Device: Diadem prototype
62092598|NCT00374621|ACTIVE_COMPARATOR|Misoprostol|
62092599|NCT00374621|ACTIVE_COMPARATOR|Misoprostol with Isosorbide Mononitrate|
62092600|NCT01547104|ACTIVE_COMPARATOR|Glimepiride-ratiopharm|Glimepiride (1-4mg) as add on therapy
62092601|NCT01547104|EXPERIMENTAL|Trajenta|Linagliptin 5 mg as add on therapy
62092602|NCT05390580|EXPERIMENTAL|Stimulation with Transcutaneous Auricular Vagal Nerve Stimulator|All patients will be fitted with the device, the investigator will attach adhesive contacts to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period, the investigator will stimulate the auricular branch of the vagus nerve. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 µm, and and a fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation.
62092603|NCT05390580|SHAM_COMPARATOR|Control - Transcutaneous Auricular Vagal Nerve Stimulator - Sham|All patients will be fitted with the device, the investigator will attach adhesive contacts to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period. Patients assigned to the controls arm will have electricity applied to the the great auricular nerve (cervical nerve branch), the lobule of the ear. The investigator will stimulate the lobule of the ear. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 µm, and and a fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation.
62290427|NCT03563300|PLACEBO_COMPARATOR|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
62290428|NCT01499290|EXPERIMENTAL|CAZ-AVI + Metronidazole|IV treatment
62656225|NCT03428373|ACTIVE_COMPARATOR|Len-Dex+ASA|Patients MM will receive Len-Dex combination and ASA 81 mg daily
62737385|NCT03470194|ACTIVE_COMPARATOR|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
62290429|NCT01499290|ACTIVE_COMPARATOR|Meropenem|IV treatment
62290430|NCT03670459|EXPERIMENTAL|Group 1|Patients in G1 will receive traditional physical therapy program (balance exercises) for twelve sessions; day after day
62290431|NCT03670459|EXPERIMENTAL|Group 2|Patients in G2 will receive Cawthorne Cooksey Exercises in addition to traditional physical therapy program for twelve sessions; day after day .
62290432|NCT03670459|EXPERIMENTAL|Group 3|Patients in G3 will receive vestibular habituation exercises in addition to traditional physical therapy program for twelve sessions; day after day.
62290433|NCT04488458|EXPERIMENTAL|MBEC and MIC susceptibility testing|"For all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin, fusidic acid, ciprofloxacin/levofloxacin and clindamycin.~MBEC cut-off for replacement with 2nd or 3rd line antibiotic: RIF MBEC/MIC \> 8; LEV MBEC/MIC \> 5; FUS MBEC/MIC \> 3; CLI MBEC/MIC \> 4; LIN MBEC/MIC \> 2; T/S MBEC \> MIC~Second line of treatment:~RIF and Fusidic acid 500 mg TID (ter in die) RIF and Clindamycin 450 - 600 mg TID LEV and Fusidic acid 500 mg TID LEV and Clindamycin 450 mg TID~Third line of treatment:~Linezolid 600 mg BID (bis in die) Sulfamethoxazole/Trimethoprim 800/160 mg TID Clindamycin 450 mg TID and Fusidic acid 500 mg TID"
62290434|NCT04488458|ACTIVE_COMPARATOR|MIC susceptibility testing|If the causative bacterium is susceptible according to MIC diagnostics, the patient will follow the first line of treatment: Rifampicin 750-900 mg/day + Levofloxacin 750 mg BID
62290435|NCT02506738|ACTIVE_COMPARATOR|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
62290436|NCT02506738|NO_INTERVENTION|Control|Patients in the control group received the usual care.
62290437|NCT05596266|EXPERIMENTAL|CD5 CAR-T|This cohort will be administrated with T cells transduced with lentivirus vectors expressing CD5 CAR.
62463886|NCT00467220|OTHER|Alternate Day Fasting Arm|Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
62290438|NCT03160729|ACTIVE_COMPARATOR|High dose|Dexamethasone 24 mg
62290439|NCT03160729|ACTIVE_COMPARATOR|Low dose|Dexamethasone 8 mg
62290440|NCT05229939||Development cohort|kidney transplant recipients in 3 centres in France: Necker, Saint-Louis and Toulouse hospitals
62290441|NCT05229939||Validation cohort 1|kidney transplant recipients from Montpellier Hospital, France
62290442|NCT05229939||Validation cohort 2|kidney transplant recipients from Lyon Hospital, France
62290443|NCT05229939||Validation cohort 3|kidney transplant recipients from Tenon Hospital, France
62290444|NCT05229939||Validation cohort 4|kidney transplant recipients from Saint-Etienne Hospital, France
62290445|NCT05229939||Validation cohort 5|kidney transplant recipients from Mayo Clinic Hospital, USA
62290446|NCT05229939||Validation cohort 6|kidney transplant recipients from Bergamo hospital, Italy
62290447|NCT05229939||Validation cohort 7|kidney transplant recipients from Zagreb hospital, Croatia
62463887|NCT00467220|OTHER|Calorie Restriction|Subjects in this arm will be asked to follow a calorie-restricted meal plan, daily, for three months.
62463888|NCT01700244|EXPERIMENTAL|Pacemaker|
62290448|NCT03228121|EXPERIMENTAL|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
62290449|NCT03228121|EXPERIMENTAL|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
62290450|NCT00692367|OTHER|Exercise|Structured exercise program
62290451|NCT01904799|OTHER|Cognitive Assessment|
62290452|NCT02858427|EXPERIMENTAL|depressed with suicide attempt (SA)|elderly depressed patients with a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
62290453|NCT02858427|EXPERIMENTAL|depressed without a history of SA|elderly depressed patients without a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
62290454|NCT00888355|PLACEBO_COMPARATOR|1|Placebo
62290455|NCT00888355|EXPERIMENTAL|2|Losartan 50 q.a.m.
62290456|NCT00888355|EXPERIMENTAL|3|Losartan 25 b.i.d.
62463889|NCT06366477|EXPERIMENTAL|Vibration stimulation combined with task-oriented training|
62463890|NCT03616990|ACTIVE_COMPARATOR|Usual Care (Control)|"Usual care. These individuals will receive linkages to community-based services only. These linkages will be made while in the Discharge Area of the Cook County Jail. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.~Receives: TASC Service Linkages - Discharge Area Only"
62290457|NCT00888355|EXPERIMENTAL|4|Losartan 25 q.a.m.
62092604|NCT06131073|EXPERIMENTAL|speed endurance production (SEP) training along with conventional training.|"Group A along with conventional regime will be given SEP. It will be given 3 days/week.~The SEP protocol consisted of 6-8 reps of 20-s all-out bouts interspersed with 120 seconds of passive recovery between repetitions. During each 20-s bout, players carried out single shuttle runs of approximately 140-150 m (70-75 + 70-75 m, depending on the group) at their full maximal effort. SEP protocol will be given 3 times/ week for 8th weeks"
62290458|NCT02076165|EXPERIMENTAL|ABC-I|"Participants completed a 5 session intervention, Acceptance and the Behavioral Changes to Treat Insomnia (ABC-I). This was considered the new treatment being studied."
62463891|NCT03616990|EXPERIMENTAL|Supportive Release Center (Treatment)|"These individuals will receive SRC services: an overnight stay at the SRC, linkages to community-based services made at the SRC or in the discharge area of the CCJ if they choose not to visit the SRC facility, and access to an Advanced Practice Nurse. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.~Receives: TASC Service Linkages - Discharge Area Only -OR- SRC Overnight Stay, TASC Services Linkages - SRC Onsite, APN Appointment"
62463892|NCT00880568|EXPERIMENTAL|MK-1496 20 mg (21-Day Cycle)|Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle
62463893|NCT00880568|EXPERIMENTAL|MK-1496 40 mg (21-Day Cycle)|Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle
62463894|NCT00880568|EXPERIMENTAL|MK-1496 80 mg (21-Day Cycle)|Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle
62290459|NCT02076165|ACTIVE_COMPARATOR|CBT-I|"Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the standard care treatment."
62290460|NCT00630045|EXPERIMENTAL|1|2\~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis
62290461|NCT00630045|ACTIVE_COMPARATOR|2|no neoadjuvant chemotherapy, resect the liver metastasis directly
62290462|NCT00191854|EXPERIMENTAL|Gemcitabine + Paclitaxel|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles."
62463895|NCT00880568|EXPERIMENTAL|MK-1496 120 mg (21-Day Cycle)|Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle
62463896|NCT00880568|EXPERIMENTAL|MK-1496 20 mg (28-Day Cycle)|Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
62463897|NCT00880568|EXPERIMENTAL|MK-1496 40 mg (28-Day Cycle)|Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
62463898|NCT00880568|EXPERIMENTAL|MK-1496 80 mg (28-Day Cycle)|Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
62463899|NCT00880568|EXPERIMENTAL|MK-1496 100 mg (28-Day Cycle)|Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
62463900|NCT00880568|EXPERIMENTAL|MK-1496 120 mg (28-Day Cycle)|Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
62290463|NCT00191854|EXPERIMENTAL|Gemcitabine + Carboplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles."
62463901|NCT03026348|ACTIVE_COMPARATOR|Treatment Group A|Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
62290464|NCT00191854|EXPERIMENTAL|Gemcitabine + Cisplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles"
62290465|NCT01920802|EXPERIMENTAL|olanzapine|5mg BID olanzapine for up to 4 weeks
62290466|NCT01920802|EXPERIMENTAL|iloperidone|6mg BID iloperidone up to 4 weeks
62290467|NCT01920802|PLACEBO_COMPARATOR|placebo|BID placebo up to 4 weeks
62308033|NCT03852225||OHCA patients|Patients resuscitated for out-of-hospital cardiac arrest of non-traumatic origin and investigated by intra-arrest echocardiography.
62463902|NCT03026348|ACTIVE_COMPARATOR|Treatment Group B|Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
62463903|NCT03026348|ACTIVE_COMPARATOR|Treatment Group C|Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
62092605|NCT06131073|EXPERIMENTAL|conventional exercise|"* A standardized 10-minute warm-up consisting of jogging .~* Multidirectional dynamic stretching of lower extremity muscles (Hamstring, Quadriceps Calf), for 30 seconds each~* Jumping (submaximal ankle and squat jumps) will be used for all soccer players before regime starts~* Exercises including squats; Nordic hamstrings; core rotations and barbell rowing, lunges , hamstrings kicks, side way lunges, standing chest press, crunches (90s rest); core rotations; bounding jumps and fast shifting lunges Each exercise will consists of 3\*10, after each exercise 90 seconds rest will be given. These exercises will be given to 3 times a week for 8 weeks"
62290468|NCT05184907|EXPERIMENTAL|RME Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing with 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
62290469|NCT05184907|ACTIVE_COMPARATOR|Information Only Arm|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
62290470|NCT01284504|EXPERIMENTAL|Celecoxib|Celecoxib, 200 mg tab
62092606|NCT05764512|EXPERIMENTAL|Intervention group|Is the group to which endorphin massage will be applied. Endorphin massage is a gentle touch and massage method that can improve the relaxation state in the body through the skin surface.
62463904|NCT03026348|ACTIVE_COMPARATOR|Treatment Group D|Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
62463905|NCT03026348|ACTIVE_COMPARATOR|Treatment Group E|Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
62092607|NCT05764512|NO_INTERVENTION|Control gruop|No application will be made.
62092608|NCT05470660|EXPERIMENTAL|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing
62290471|NCT01284504|PLACEBO_COMPARATOR|Placebo|placebo, tab
62290472|NCT02844465|EXPERIMENTAL|Treatment|Visualase MRI-guided laser ablation procedure
62290473|NCT05489081|EXPERIMENTAL|Implementation Resource Package Group|Teachers in this group will receive an implementation support package and receive support in using it within their classroom management practice. Also within the intervention group (experimental), will be students nested in the classrooms of the teachers that are assigned to the intervention group.
62290474|NCT05489081|NO_INTERVENTION|Control Group|Within the control group (no intervention), teachers in this group will not receive the implementation support package nor extra support during the study period. They will continue to receive implementation support as usual. Also within the control group (no intervention) will be students nested in the classrooms of the teachers that are assigned to the control group.
62290475|NCT06418620|EXPERIMENTAL|Treatment A|Fasted, venglustat tablet swallowed with water
62092609|NCT05470660|ACTIVE_COMPARATOR|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
62092610|NCT01691989|EXPERIMENTAL|aleglitazar|
62092611|NCT01691989|EXPERIMENTAL|placebo|
62092612|NCT06697652||hospital readmission|hospital readmission for complications
62290476|NCT06418620|EXPERIMENTAL|Treatment B|Fasted, venglustat tablet chewed and swallowed without water
62290477|NCT06418620|EXPERIMENTAL|Treatment C|Fed, venglustat tablet swallowed with water
62290478|NCT00670007|EXPERIMENTAL|Zemaira®|
62290479|NCT03995719|OTHER|Preoperative education|Each patient had individual consultation several days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
62463906|NCT03026348|ACTIVE_COMPARATOR|Treatment Group F|Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
62463907|NCT03026348|ACTIVE_COMPARATOR|Treatment Group G|Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
62463908|NCT03026348|ACTIVE_COMPARATOR|Treatment Group H|Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
62463909|NCT03026348|ACTIVE_COMPARATOR|Treatment Group J|Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
62463910|NCT03026348|ACTIVE_COMPARATOR|Treatment Group K|Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
62463911|NCT03026348|ACTIVE_COMPARATOR|Treatment Group L|Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
62463912|NCT03026348|PLACEBO_COMPARATOR|Treatment Group M|Day 0 Phosphate Buffer Day 21 Phosphate Buffer
62656226|NCT06369688|EXPERIMENTAL|Intervention group|Educational packages including a pamphlet, brochure, and visual poster that outlines three key components of the IDEAL SKIIN CARES bundle (Education, Assessment of patient's condition and Care intervention) will be provided along with sub-items. These materials will be explained in detail by a trained research assistant in a workshop. Patients will be encouraged by the research assistant to actively participate in PIP self-care activities following the IDEAL SKIIN CARES approach shortly after recruitment and will continue to provide patient education throughout the study period. This training will begin before data collection and will be maintained as needed. Each hospital's study investigator will oversee the training activities at their site to guarantee consistency and adherence to the intervention protocol. In addition, patients will receive the IDEAL SKIIN CARES bundle from WSNs.
62092613|NCT02023203|EXPERIMENTAL|LP PTFE|Placement of Large Pore PTFE mesh for inguinal hernia treatment
62290480|NCT03995719|OTHER|Postoperative education|Each patient had individual consultationseveral days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
62290481|NCT06134297|EXPERIMENTAL|Aerobic Exercise Group|Aerobic exercise using a cycle ergometer lasting 15 consecutive minutes with load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age).
62656227|NCT06369688|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive training in an unrelated topic, specifically respiratory care. This training will involve the distribution of educational pamphlets, brochures, and visual posters outlining key aspects of respiratory care, mirroring the approach taken with the intervention group. Despite the focus on respiratory care education, patients in the placebo group will also benefit from specialized PIP care through the IDEAL SKIIN CARES bundle, administered by trained WSNs. These WSNs will provide interventions focused on PIP strategies based on the IDEAL SKIIN CARES bundle, ensuring that patients in the placebo group receive comprehensive wound care support throughout the study period.
62656228|NCT06369688|NO_INTERVENTION|Control group|The control group will not receive any relevant or irrelevant training or educational materials. They will only receive routine standard care for the PIP care bundle, following the care plans as routine by the hospital.
62290482|NCT06134297|EXPERIMENTAL|Anaerobic Exercise Group|Muscle strength training using shin guards and elastic bands to promote muscle overload, generating maximum force production, where the contraction time should not exceed 20 seconds.
62290483|NCT06134297|EXPERIMENTAL|Mixed Exercise Group|Exercises through alternation between aerobic and anaerobic overload (performing the exercises from the previously mentioned groups on alternate days), in a 1:1 ratio until the end of the physical rehabilitation program.
62290484|NCT02511977||overdenture with annual maintenance|Rehabilitation should be: overdenture with at least 2 implants placed in the mandible and 3 implants in the maxilla per person. They were divided into two groups: Group I: Annual maintenance for the past seven years
62290485|NCT02511977||overdenture whitout annual maintenance|Group II: individuals who have not returned for the last seven years. Individuals who said they went to the dentist at least once a year, for whatever treatment, were included in the maintenance group. Individuals who denied any visit to the dentist in the last seven years were included in the no maintenance group.
62290486|NCT00323284|ACTIVE_COMPARATOR|A--iStent plus Cataract Surgery|iStent plus Cataract Surgery
62290487|NCT00323284|ACTIVE_COMPARATOR|B--Cataract Surgery Only|Cataract Surgery only
62290488|NCT00237133|EXPERIMENTAL|Letrozole|
62737386|NCT03470194|ACTIVE_COMPARATOR|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
62290489|NCT04315467|EXPERIMENTAL|SGM-101|SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.
62308034|NCT04909021|EXPERIMENTAL|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1
62463913|NCT02071719||Sunitinib|
61906846|NCT02757638|EXPERIMENTAL|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
62092614|NCT02023203|ACTIVE_COMPARATOR|SP-PPL|Placement of Small Pore polypropylene mesh for inguinal hernia treatment
62092615|NCT06697158|EXPERIMENTAL|Treatment Group|"This study is planned as a prospective quasi-experimental design (pre-test, intervention, post-test). The study will be conducted at the Women's Health and Lymphedema Unit of the Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Abant İzzet Baysal University, Bolu, Turkey. All participants will provide written informed consent before participating in the study.~Participants The study aims to include a total of 31 patients who develop unilateral upper extremity lymphedema following breast cancer surgery. The inclusion criterion for lymphedema diagnosis will be a difference of more than 2 cm in circumferential measurements between both arms. Only individuals diagnosed with lymphedema by a physician will be included in the study."
62092616|NCT02991885|EXPERIMENTAL|HAL-MPE1|HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract
62308035|NCT04909021|EXPERIMENTAL|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2
62463914|NCT02071719||Sorafenib|
62463915|NCT02071719||Everolimus|
62463916|NCT02071719||Pazopanib|
62656229|NCT01537367|EXPERIMENTAL|Enhanced contact only|"Patients allocated to the Enhanced contact only arm will receive:~HIV information and education~* Specific to importance of coming to care regularly~* Generic and tailored components~* Approximately 10 minutes in length~Enhanced contact over time~* Collect locator information~* Follow-up contact after medical visit (face-to-face or phone)~* Appointment reminders (telephone, e-mail, text message)~* Periodic telephone contact across time (support, update locator info, refer any unmet needs to Case Manager)~* Attempt to make immediate contact following a missed visit and re-schedule appointment (use locator contact info)"
62656230|NCT01537367|EXPERIMENTAL|Enhanced contact plus behavioral skills|Enhanced contact plus behavioral skills is the longer experimental intervention arm.
62290490|NCT04348851|EXPERIMENTAL|4-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
62092617|NCT02991885|PLACEBO_COMPARATOR|HAL-MPE1 placebo|HAL-MPE1 placebo without modified peanut extract
62463917|NCT02071719||Axitinib|
62092618|NCT03504605|EXPERIMENTAL|Self-compassion intervention|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. They will then receive the online self-compassion intervention as detailed in Sirois, Bögels and Emerson (in revision). This involves parents in the experimental condition being given a validated set of instructions asking them to reflect on the event and write self-compassionate responses (see intervention).
62092619|NCT03504605|NO_INTERVENTION|Control|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. Those in the control condition will be asked to re-read the account of the event and make notes about factual information (e.g. time of day, who was there, etc.). It should be noted that if the SCI is found to reduce state shame and increase state self-compassion, it will be offered to participants in the control group.
62092620|NCT01827280|EXPERIMENTAL|Metformin|Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
62092621|NCT01827280|EXPERIMENTAL|Vildagliptina|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
62092622|NCT03753087|EXPERIMENTAL|Empagliflozin|Patients will receive standard care for Heart Failure and Diabetes Mellitus + Empagliflozin 10mg once daily
62290491|NCT04348851|EXPERIMENTAL|8-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
62463918|NCT00890526|EXPERIMENTAL|1|Full treatment = Counseling + sound therapy.
62290492|NCT04348851|ACTIVE_COMPARATOR|8-Week Attention Control|The Registered Nurses (RNs) will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare provider.
62290493|NCT04348851|NO_INTERVENTION|Standard Care|Caregivers receiving standard of care
62290494|NCT03898635||Background group|The treatment regimen does not include linezolid throughout the treatment course.
62463919|NCT00890526|EXPERIMENTAL|2|Counseling + placebo sound therapy.
62463920|NCT00890526|EXPERIMENTAL|3|No Counseling + Sound Therapy
62656231|NCT01537367|ACTIVE_COMPARATOR|Standard of Care|Patients assigned to control arm will receive the standard services offered to all patients at the clinic.
62656232|NCT01753063|EXPERIMENTAL|Patient Expectations|At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
62092623|NCT03753087|ACTIVE_COMPARATOR|Control|Patients will receive standard care for Heart Failure and Diabetes Mellitus with no SGLT-2 inhibitors
62092624|NCT00343798|EXPERIMENTAL|Treatment (umbilical cord blood transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1.~TRANSPLANTATION : Patients undergo double-unit umbilical cord blood transplantation comprising unmanipulated umbilical cord blood unit IV over 20-30 minutes, and 4-6 hours later patients receive ex vivo-expanded umbilical cord blood cells IV over 30 minutes on day 0.~GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS: Patients receive cyclosporine IV every 8 or 12 hours on days -3 to 100, followed by a taper to at least day 180. Patients also receive MMF IV every 8 hours on days -3 to 5 and then PO, if tolerated, on days 6-30."
62092625|NCT02018861|EXPERIMENTAL|Parsaclisib 5 mg QD|Parsaclisib 5 milligrams (mg) as an oral tablet once a day (QD) in 21-day treatment cycles
62092626|NCT02018861|EXPERIMENTAL|Parsaclisib 10 mg QD|Parsaclisib 10 mg as oral tablets QD in 21-day treatment cycles
62092627|NCT02018861|EXPERIMENTAL|Parsaclisib 15 mg QD|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
62092628|NCT02018861|EXPERIMENTAL|Parsaclisib 20 mg QD|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
62092629|NCT02018861|EXPERIMENTAL|Parsaclisib 30 mg QD|Parsaclisib 30 mg as oral tablets QD in 21-day treatment cycles
62092630|NCT02018861|EXPERIMENTAL|Parsaclisib 45 mg QD|Parsaclisib 45 mg as oral tablets QD in 21-day treatment cycles
62092631|NCT02018861|EXPERIMENTAL|Parsaclisib 20 mg + itacitinib (INCB039110) 300 mg|Parsaclisib 20 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
62092632|NCT02018861|EXPERIMENTAL|Parsaclisib 30 mg + itacitinib (INCB039110) 300 mg|Parsaclisib 30 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
62092633|NCT02018861|PLACEBO_COMPARATOR|Parsaclisib 15 mg QD + R-ICE|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 milligrams per meters squared (mg/m\^2) intravenously (IV) on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m\^2 IV on Day 3 of each cycle, carboplatin area under the curve (AUC) = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m\^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration
62092634|NCT02018861|PLACEBO_COMPARATOR|Parsaclisib 20 mg QD + R-ICE|20 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 mg/m\^2 IV on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m\^2 IV on Day 3 of each cycle, carboplatin AUC = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m\^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration.
62290495|NCT03898635||Background-linezolid group|Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.
62290496|NCT03898635||Linezolid initial group|Linezolid was in initial treatment regimen.
62290497|NCT02357511|EXPERIMENTAL|Study goup|Vital values are being measured for the time of two hours at postoperative setting at postanesthesia care unit. A novel method is compared to golden standard: invasive measurement. Also Saturation measurements are being compared between standard and study monitor.
62656233|NCT02037087|EXPERIMENTAL|Good household prenatal practice (GHPP)|The GHPP arm receives SMS messages regarding knowledge on nutrition, labor, non-medical pain management, breastfeeding, and depression. This arm also receives messages delivered to the control group.
62092635|NCT06217718|EXPERIMENTAL|Telenursing Interventions Group|Participants in this group will receive five hours of face-to-face empowerment training. After the training, the experimental group will be monitored remotely by the researcher nurse via tele-nursing interventions for 12 weeks. Participants will be given a pulse oximeter, symptom diary, action plan, oxygen saturation-pulse monitoring chart. Participants will be asked to measure their oxygen saturation and pulse once a day for 12 weeks and record it on the chart. Participants will also be asked to record their complaints in their symptom diary. Participants will be called by the researcher every two weeks (on Thursdays) and informative and reminding text messages prepared specifically for the disease will be sent to the participants three times a week for 12 weeks. Participants will be able to reach the researchers by phone whenever they need.
62092636|NCT06217718|NO_INTERVENTION|No Intervention Group|Participants in this group will be given a pulse oximeter, symptom diary, action plan, oxygen saturation-pulse monitoring chart. No intervention will be taken.
62092637|NCT05359159||Post-COVID patients|Patients recovered from Sars-CoV2 infection
62092638|NCT05359159||healthy control patients|Patients who did not have Sars-CoV2
62092639|NCT01459822||Survival Group|
62092640|NCT01459822||Death Group|
62092641|NCT00723320|NO_INTERVENTION|P+N|placebo without lifestyle intervention
62092642|NCT00723320|EXPERIMENTAL|D+N|Atorvastatin 10mg/d
62092643|NCT00723320|EXPERIMENTAL|P+A|lifestyle intervention without Atorvastatin
62092644|NCT00723320|EXPERIMENTAL|D+A|lifestyle intervention and Atorvastatin 10mg/d
62290498|NCT04000477|EXPERIMENTAL|Kevorkian curette|
62290499|NCT04000477|EXPERIMENTAL|Cytobrush|
62290500|NCT00619957|PLACEBO_COMPARATOR|1|Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
62290501|NCT00619957|EXPERIMENTAL|Risedronate|35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years
62290502|NCT04798287||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
62290503|NCT04798287||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
62290504|NCT04529655||Sepsis|Patients admitted to the ICU with sepsis will be enrolled and monitored at time sequential time points during their treatment
62290505|NCT03170830|EXPERIMENTAL|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
62290506|NCT03170830|EXPERIMENTAL|unstable angina disease control group|Age:\>18 years.Unstable angina patients meet the diagnostic criteria.
62463921|NCT00890526|PLACEBO_COMPARATOR|4|No counseling + Placebo sound therapy.
62092645|NCT01551836|OTHER|Paracetamol formulation 1|Higher dose level of marketed paracetamol (compared to the other dosage arm)
62290507|NCT03170830|EXPERIMENTAL|acute myocardial infarction group|Age:\>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
62290508|NCT05693402||Group 1 consisting of treated patients using OFA|Group 1 consisted of 56 (Mean age was 54±14 years)
62290509|NCT05693402||Group 2 consisting of treated patients using NOFA|Group 2 consisted of 60 patients (Mean age was 51±12 years)
62290510|NCT06302257|ACTIVE_COMPARATOR|lidocaine alone|Bolus: 20mL MLAC% of lidocaine, administered as incremental test dose over 5 minutes; as in all routine epidurals by our hospital protocol, the incremental test dose is preferred to using classical surgical test doses (which expose the patient to excessive local anesthetic concentrations).
62290511|NCT06302257|EXPERIMENTAL|Chlorprocaine only|Bolus: 20mL MLAC% of chlorprocaine, administered as incremental test dose over 5 minutes; as above, no other test doses are used.
62290512|NCT06302257|EXPERIMENTAL|Lidocaine-chlorprocaine combination|Bolus: 10mL MLAC% of lidocaine plus 10mL MLAC% of chlorprocaine, mixed in a 20mL syringe, administered as incremental test dose over 5 minutes; as above, no other test doses are used.
62290513|NCT00200265|EXPERIMENTAL|1|Behavioral: diet
62290514|NCT00200265|EXPERIMENTAL|2|Behavioral: diet
62290515|NCT00200265|PLACEBO_COMPARATOR|3|Behavioral: diet
62290516|NCT04049019|EXPERIMENTAL|Urine collection, children with nocturnal enuresis|"The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.~The child will be asked to perform home recordings for seven days consisting of measurements of diaper weight and first morning voided volume and a two-day frequency-volume chart."
62290517|NCT04049019|ACTIVE_COMPARATOR|Urine collection, healthy children|The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.
62290518|NCT02863198|ACTIVE_COMPARATOR|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
62290519|NCT02863198|NO_INTERVENTION|non endometrial injury|non endometrial injury was done only for patient of the control group
62290520|NCT02080052|EXPERIMENTAL|Robot-assisted prostate biopsy|
62290521|NCT04187092|EXPERIMENTAL|KneeBright group|Participants in this group will perform exercises aimed to improve the muscle strength, balance and precision. Participants will perform exercises three times a week for 12 weeks. Each session will last for an hour. Some of the exercises will be performed with the KneeBright Device while playing a video game.
62290522|NCT04187092|ACTIVE_COMPARATOR|Standard Rehabilitation group|Participants in this group will perform exercises with the same focus and frequency. No exercises will be performed with the KneeBright device.
62656234|NCT02037087|EXPERIMENTAL|Care seeking (CS)|The CS arm receives SMS messages which include danger-sign recognition and reminders for government-subsidized projects. This arm also receives messages delivered to the control group.
62092646|NCT01551836|OTHER|Paracetamol formulation 2|Lower paracetamol concentrations
61906847|NCT02757638|EXPERIMENTAL|Obese subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one pre-surgery, one post-surgery): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
62290523|NCT02781792|EXPERIMENTAL|Arm 1: Temozolomide morning|"* Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m\^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).~* FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
62290524|NCT02781792|EXPERIMENTAL|Arm 2: Temozolomide evening|"* Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).~* FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
62290525|NCT04175470|EXPERIMENTAL|Arm A: Discontinue treatment after first treatment cycle|
62290526|NCT04175470|EXPERIMENTAL|Arm B: Continue treatment until progression|
62656235|NCT02037087|EXPERIMENTAL|Full bank of SMS|This arm receives the SMS messages delivered to the GHPP, CS and control group.
62656236|NCT02037087|NO_INTERVENTION|Control|"Control group receives SMS messages regarding:~* Reminders of prenatal visits and certified skilled attendance of labor (status quo);~* Fetal development in different gestational stages.~The three experimental groups receive the control messages as well."
62656237|NCT05419518|EXPERIMENTAL|Palliative radiation dose escalation|The prescribed dose is 50 Gy in 10 fractions. The total dose can be reduced to 40 Gy and the total number of fractions can be reduced to 8 fractions in non-spine metastases to achieve the normal tissue constraints.
62656238|NCT05419518|NO_INTERVENTION|Therapeutic benefit|Radiation will be delivered as per protocol. For participants experiencing unacceptable toxicity related to study treatment, yet obtaining therapeutic benefit, participants will be allowed to continue treatment, if well tolerated at the discretion of the investigator.
62656239|NCT04179643|EXPERIMENTAL|3.25E13vg AB-1002|Intracoronary Infusion of 3.25E13vg AB-1002 up to 6 subjects
62656240|NCT04179643|EXPERIMENTAL|1.08E14vg AB-1002|Intracoronary Infusion of 1.08E14vg AB-1002 to 6 subjects
62656241|NCT04179643|EXPERIMENTAL|PLN-R14Del patients: 3.25E13vg AB-1002|Intracoronary Infusion of AB-1002 at 3.25E13vg up to 6 subjects with PLN-R14Del genetic mutation
62656242|NCT01147835|PLACEBO_COMPARATOR|Placebo Lollipop|The placebo group will ingest the same herbal lollipop formula without the active ingredient.
62656243|NCT01147835|EXPERIMENTAL|Chinese Licorice Root|The experimental group will ingest the herbal lollipop formula with the active ingredient.
62656244|NCT06037980|EXPERIMENTAL|Preoperative chemotherapy|Triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment followed by surgery and adjuvant chemotherapy
62656245|NCT06037980|ACTIVE_COMPARATOR|Upfront surgery|Standard upfront surgery and adjuvant chemotherapy
61906848|NCT04670250||newly diagnosed patients with ulcerative colitis|patients who are newly diagnosed to have ulcerative colitis who are above 18 years old,not pregnant and not known to have cancer colon
61906849|NCT02269540|EXPERIMENTAL|Sertraline and n-acetylcysteine|Sertraline and n-acetylcysteine for seven weeks of treatment
61906850|NCT02269540|EXPERIMENTAL|Citalopram and n-acetylcysteine|Citalopram and n-acetylcysteine for seven weeks of treatment
61906851|NCT02269540|EXPERIMENTAL|Existing medication treatment & NAC|Existing depression medication treatment and n-acetylcysteine for seven weeks of treatment
62290527|NCT02749149||Cardiac Surgery|Patients undergoing cardiac surgery: coronary artery bypass graft (CABG); valve replacement/repair; or transcatheter aortic valve implantation (TAVI) surgery
62290528|NCT04472728|EXPERIMENTAL|BIO101|BIO101 350 mg bid
62290529|NCT04472728|PLACEBO_COMPARATOR|Placebo|Placebo
62290530|NCT03072602|EXPERIMENTAL|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
62290531|NCT03072602|ACTIVE_COMPARATOR|White|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
62290532|NCT02530645|EXPERIMENTAL|OnTrack + BMI|Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
62656246|NCT05833815|EXPERIMENTAL|Additional Everolimus|Everolimus 10 mg. PO/day in addition to standard of care
61906852|NCT05154305|EXPERIMENTAL|Children 6 months post acute treatment|children and adolescents between 6 months and 8 years post acute cancer treatment
61906853|NCT05830617|EXPERIMENTAL|real tACS|Real tACS will be delivered by applying two conductive electrodes over the left and right central areas, for 30 minutes/day (Monday-to-Friday), for two weeks, with the following parameters: sinewaves at 40Hz, peak-to-peak amplitude=1mA, 3s ramping-up and ramping-down. Intensity will be lowered if perceived as uncomfortable.
61906854|NCT05830617|SHAM_COMPARATOR|sham tACS|Sham tACS will consist of only 30s of stimulation.
61906855|NCT05315908|ACTIVE_COMPARATOR|Automated call|Patients receive up to two automated phone calls in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
61906856|NCT05315908|ACTIVE_COMPARATOR|Text messaging|Patients receive up to two text messages in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
61906857|NCT02970240||ME/CFS group|Patients with a verified diagnosis of ME/CFS according to the Canada criteria
61906858|NCT02970240||Fatigue group|Patients with fatigue, but not ME/CFS
62092647|NCT02711995|EXPERIMENTAL|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
62092648|NCT02711995|ACTIVE_COMPARATOR|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
62290533|NCT02530645|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
61906859|NCT02970240||Control group|Healthy control persons
61906860|NCT03878433|ACTIVE_COMPARATOR|Drug|Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast
62290534|NCT01015508|OTHER|High predisposition|High predisposition for weight regain
62290535|NCT01015508|OTHER|low predisposition|low predisposition for weight regain
62463922|NCT05963321|ACTIVE_COMPARATOR|Active cerebellum electrode and active M1 electrode|"* The patient will receive active cerebellar stimulation with the anode electrode positioned in the cerebellum and active cortical stimulation with the anode electrode placed in the primary motor cortex.~* In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~* The equipment will apply a current of 2 mA for 20 minutes."
62656247|NCT05833815|OTHER|Control|Standard of care alone i.e Capecitabine and Oxaliplatin or Gemcitabine and oxaliplatin
61906861|NCT03878433|PLACEBO_COMPARATOR|No Drug|2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo
61906862|NCT04094415||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
61906863|NCT03190733|EXPERIMENTAL|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
61906864|NCT03190733|ACTIVE_COMPARATOR|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
62092649|NCT03675724|EXPERIMENTAL|Treatment|Fisetin 20mg/kg/day, orally for 2 consecutive days
62092650|NCT03675724|PLACEBO_COMPARATOR|Placebo|Placebo capsules orally for 2 consecutive days
62656248|NCT03318341|OTHER|Real then Sham|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies real stimulation in the first month. The device applies sham stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
62290536|NCT01015508|OTHER|Medium predisposition|Medium predisposition for weight regain
62290537|NCT01731002|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
62290538|NCT01731002|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
62290539|NCT01731002|ACTIVE_COMPARATOR|Latanoprost Ophthalmic Solution 0.005%|1 drop to study eye once daily
62290540|NCT04608214|EXPERIMENTAL|Alisporivir|Administration of alisporivir and standard of care (SOC)
62656249|NCT03318341|OTHER|Sham then Real|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies sham stimulation in the first month. The device applies real stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
62656250|NCT03579888|EXPERIMENTAL|Treatment (fludarabine, cyclophosphamide, CD19 T cell)|"CHEMOTHERAPY: Patients receive fludarabine IV over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.~T-CELL INFUSION: Patients receive autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells IV over 15-30 minutes on day 0."
62656251|NCT05512559||remimazolam|general anesthesia induction with 6mg/kg/hr continuous infusion of remimazolam. general anesthesia maintenance with 1mg/kg/hr continuous infusion of remimazolam.
62656252|NCT00474019|EXPERIMENTAL|1|Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg
62656253|NCT03197129|EXPERIMENTAL|SADE waiting room|children that will wait in the SADE waiting room
62656254|NCT03197129|NO_INTERVENTION|Traditional waiting room|children that will wait in the traditional waiting room
62656255|NCT04652089|EXPERIMENTAL|Experimental arm: Simvastatin|Simvastatin 20mg capsule once a day for 7 days
62656256|NCT04652089|PLACEBO_COMPARATOR|Control arm: Placebo|Placebo capsule once a day for 7 days
62656257|NCT00657605|EXPERIMENTAL|Recombinant methionyl human leptin|Participants with congenital leptin deficiency will receive the Recombinant methionyl human leptin intervention subcutaneously, once a day with a dose of 0.02 to 0.04 mg/kg (adjusted according to weight loss).
62656258|NCT03844737|EXPERIMENTAL|VisuXL® Treatment|
62656259|NCT03344471|OTHER|women with PTSD after preterm deliver|
62656260|NCT03344471|OTHER|women without PTSD after preterm deliver|
62656261|NCT00127803|PLACEBO_COMPARATOR|Placebo|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28, and 56, respectively.
62656262|NCT00127803|EXPERIMENTAL|Low dose vaccine|Participants will receive a 2 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively.
62656263|NCT00127803|EXPERIMENTAL|Medium dose vaccine|Participants will receive a 10 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
62656264|NCT00127803|EXPERIMENTAL|High dose vaccine|Participants will receive a 50 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
62656265|NCT00025337|EXPERIMENTAL|Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)|Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
62656266|NCT00025337|EXPERIMENTAL|Arm II (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
62656267|NCT00025337|EXPERIMENTAL|Arm III (bevacizumab)|Patients receive bevacizumab as in arm I.
62656268|NCT00782964||1|Outpatient with major depressive disorder, who has a change in pharmacological therapeutical plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent) for at least 6 weeks.
62656269|NCT01578382||Hypertensive ischemic leg ulcer|"Twenty consecutive patients with Martorell HYTILU as defined in:~Arch Dermatol 2010;146:961-968"
62656270|NCT01578382||Calciphylaxis|"Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:~Vasa 1998;27:137-143"
62092651|NCT06519370|EXPERIMENTAL|FDA018-ADC|Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62092652|NCT06519370|ACTIVE_COMPARATOR|Investigator's Choice of Chemotherapy (ICC)|Participants will receive ICC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until disease progression, unacceptable toxicity or death.
62092653|NCT03454243|EXPERIMENTAL|RXDX-106|
62290541|NCT04608214|ACTIVE_COMPARATOR|Standard of care (SOC)|Locally accepted regimen protocols for patient care
62290542|NCT04291144||Patients|Inclusion criteria are mild to moderate DLB, age above 50, ability to give informed consent.
62290543|NCT04291144||Healthy controls|Age above 50.
61906865|NCT02836639|EXPERIMENTAL|Busulfan, Etoposide, Bendamustine|All patients will receive the conditioning regimen followed by autologous stem cell transplantation.
62092654|NCT03884231||Infinity DBS System with MR Conditional labelling|The Infinity DBS system with MR Conditional labelling includes a primary cell implantable pulse generator designed to deliver low-intensity electrical pulses to targeted structures in the brain.
62092655|NCT04219293|OTHER|Microneedling with NO PRP|Patient will receive Standard of Care micro needling on randomized side of the face.
62092656|NCT04219293|ACTIVE_COMPARATOR|Microneedling WITH PRP|Patient will receive Standard of care microneedling with PRP on randomized side of the face.
62092657|NCT03306186|EXPERIMENTAL|HemoSpec|Diagnosis of sepsis using HemoSpec device
62290544|NCT05685940|EXPERIMENTAL|Standard of care - risankizumab|Patients will continue to receive risankizumab according to the standard dosing schedule: subcutaneous injections at weeks 0 and 4, then every 12 weeks (2x 75mg).
62092658|NCT00515164|EXPERIMENTAL|Group 1|Treatment will be administered in 2 treatment sessions.
62290545|NCT04819321|EXPERIMENTAL|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
62290546|NCT01349309|EXPERIMENTAL|Swallowing Exercise Group|Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.
62290547|NCT01349309|NO_INTERVENTION|Control|Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.
62290548|NCT01219556||Group 1|
62656271|NCT01578382||Venous ulcer (controls)|"Twenty subjects with venous ulcers (CEAP C4-6) as described in:~J Vasc Surg. 2004 Dec;40(6):1248-52"
62656272|NCT00047827|EXPERIMENTAL|1|
62656273|NCT03832478|EXPERIMENTAL|Virtual Reality Headset Given|Virtual Reality headset (Samsung Gear VR) with mindfulness meditation app is given for patient use prior to surgery date and for duration of postoperative stay.
62656274|NCT02494011|EXPERIMENTAL|traditional exercise (group I)|"Mobilization:2 strokes per one second and repeated 6 times during session~* stretching exercise: 15 to 20 minutes~* passive range of motion: 5 minutes at beginning and at end~* active range of motion: 20 repetition~* oedema control: 15s active contraction of fingers of 15s relax for 3 times"
62656275|NCT02494011|EXPERIMENTAL|russian current stimulation (group II)|The frequency was 2.5 kHz for 15 minutes
62656276|NCT02494011|EXPERIMENTAL|CKC (group III)|"wall press exercise - plyometric exercise-Quadruped rhythmic stabilization- press up exercise~closed kinetic chain exercises performed 10 times and each week 2 more repetitions added as a progression"
62656277|NCT03031925|EXPERIMENTAL|SLE patients|Systemic Lupus Erythematosus
62656278|NCT03031925|ACTIVE_COMPARATOR|control subjects|age- and sex-matched control subjects
62656279|NCT05709093|EXPERIMENTAL|Lemzoparlimab in combination with AZA|
62092659|NCT00515164|EXPERIMENTAL|Group 2|Treatment will be administered in a single treatment session.
62092660|NCT05824221|EXPERIMENTAL|Active rTMS (15 Hz)|Active stimulation of LDLPFC (15 Hz; 100% of RMT; 40 trains with 60 stimuli per train; inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
62290549|NCT06192979|OTHER|Rapid Response Group|Daratumumab, bortezomib, dexamethasone
62290550|NCT06192979|OTHER|Non-Rapid Response Group|Daratumumab, venetoclax, dexamethasone
62290551|NCT02773329|EXPERIMENTAL|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive exercise program (game-based exercise) intervention twice a week for 6 weeks.
62656280|NCT05709093|ACTIVE_COMPARATOR|AZA monotherapy|
62656281|NCT01604772|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62656282|NCT06391411|NO_INTERVENTION|Control|Healthy controls received no intervention
62656283|NCT06391411|EXPERIMENTAL|Micronutrient supplementation+ Aflibercept 2 mg, 0.05 ml|Patients received intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen and daily supplementation with a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg) for 6 months
62656284|NCT06391411|ACTIVE_COMPARATOR|Aflibercept 2 mg, 0.05 ml|Patients received only intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) for 6 months
62656285|NCT03907215|OTHER|Treatment A and B|"On Day 1 and Day 2, subjects will EITHER receive:~* a single dose of 50 mg ACT-541468 (Treatment A) on Day 1 and a single dose of ACT- 541468 placebo (Treatment B) on Day 2 OR~* a single dose of ACT-541468 placebo (Treatment B) on Day 1 and a single dose of 50 mg ACT-541468 (Treatment A) on Day 2."
62656286|NCT03907215|OTHER|Treatment C, D, E, and F|"From Day 3 to Day 10, subjects will on each day receive:~• a single dose of 20 mg citalopram and EITHER a single dose of ACT-541468 placebo OR a single dose of 50 mg ACT-541468."
62656287|NCT02066116|EXPERIMENTAL|Kinect-based Rehabilitation|
62092661|NCT05824221|SHAM_COMPARATOR|Sham rTMS|A pre-programmed software set sham stimulation by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the RMT so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
62092662|NCT05824221|NO_INTERVENTION|Healthy Control|Subject without diagnosis of Cocaine Use Disorder or other major psychiatric disorder.
61906866|NCT00472680|EXPERIMENTAL|1|High Dietary Protein
62092663|NCT05036694|OTHER|Ambulatory HIV positive patients|Ambulatory HIV positive patients with signs and symptoms of TB, and Ambulatory HIV positive patients with advanced disease and CD4 less than 200 cell.
62290552|NCT02773329|ACTIVE_COMPARATOR|Intervention without game-based exercise|Subjects will be receiving non-technology based foot and ankle exercise twice a week for 6 weeks
62290553|NCT05888896|EXPERIMENTAL|anti-hypertensive drugs|Methyldopa tablets 250 mg will be used oral to reduce hypertension
62656288|NCT02066116|ACTIVE_COMPARATOR|Self-exercises education|
62656289|NCT04179214|EXPERIMENTAL|Group I Experimental: thoracic manipulation|The experimental group will receive thoracic manipulation along with conventional pt protocol.
62656290|NCT04179214|ACTIVE_COMPARATOR|Group II Control|this group of participant will receive Conventional physical therapy protocol
62656291|NCT04323592||Exposed to Methylprednisolone|Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
62656292|NCT04323592||Non-exposed to Methylprednisolone|Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.
62656293|NCT01254877|PLACEBO_COMPARATOR|Placebo Ondansetron - sugar pill|Placebo is an oral preparation made to appear and taste like the active drug preparation.
62656294|NCT01254877|EXPERIMENTAL|low dose ondansetron (0.2 mg bid)|
62656295|NCT01254877|EXPERIMENTAL|moderate dose ondansetron (0.8 mg bid)|
62656296|NCT04571593|EXPERIMENTAL|Digital Yoga Nidra|"Participants will voluntarily complete a \~30-minute remote Yoga Nidra practice, synchronously (through Zoom Wednesdays at 10 pm ET) or asynchronously (through YouTube, using the Zoom recording, any time they like).~They may voluntarily repeat this practice as often as they like. Recordings are updated weekly, to reflect the ongoing Zoom class. Yoga Nidra scripts from Satyananda Saraswati's Yoga Nidra book (1976) are used for this class."
62656297|NCT02305316|EXPERIMENTAL|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
62656298|NCT02305316|EXPERIMENTAL|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
62656299|NCT03059368|EXPERIMENTAL|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
62656300|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
62656301|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
62656302|NCT06259526|PLACEBO_COMPARATOR|Placebo group|
62656303|NCT06259526|EXPERIMENTAL|JS1-1-01 low-dose group|
62656304|NCT06259526|EXPERIMENTAL|JS1-1-01 medium dose group|
62656305|NCT06259526|EXPERIMENTAL|JS1-1-01 high-dose group|
61906867|NCT00472680|ACTIVE_COMPARATOR|2|Normal Dietary Protein
61906868|NCT02785770|EXPERIMENTAL|PF-04447943 low dose|25 mg of PF-04447943
61906869|NCT02785770|EXPERIMENTAL|PF-04447943 high dose|100 mg of PF-04447943
61906870|NCT02785770|PLACEBO_COMPARATOR|Placebo|Matching placebo for PF-04447943
62656306|NCT06259526|ACTIVE_COMPARATOR|Active drug group|
62656307|NCT02058095|ACTIVE_COMPARATOR|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
62656308|NCT02058095|PLACEBO_COMPARATOR|Placebo|Subject will receive Placebo daily for a total of 12 weeks
62290554|NCT05888896|EXPERIMENTAL|anti-hypertensive drugs+foot reflexology|Methyldopa tablets 250 mg and foot reflexology sessions for 8 weeks ( 30 min 2 times per week) will be used to reduce hypertension
62463923|NCT05963321|ACTIVE_COMPARATOR|Sham cerebellar electrode and active M1 electrode|"* The patient will receive sham cerebellar stimulation with the anode electrode positioned in the cerebellum and active cortical stimulation with the anode electrode placed in the primary motor cortex.~* In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~* The equipment will apply a current of 2 mA for 20 minutes."
62290555|NCT01418495||Ancillary-Correlative (pharmacokinetics of ch14.18)|Patients undergo blood sample collection at baseline and during and after course 1, 3, or 5 of treatment for pharmacokinetic analysis. Some patients undergo blood sample collection at baseline and during and after two treatment courses (1 and 3, 1 and 5, or 3 and 5).
62092664|NCT05763459|EXPERIMENTAL|ABBV-CLS-7262|ABBV-CLS-7262 + Digoxin + Rosuvastatin
61906871|NCT02785770|ACTIVE_COMPARATOR|Moxifloxacin|400 mg of moxifloxacin
62290556|NCT00806104|EXPERIMENTAL|1|Fructo-oligosaccharides
62290557|NCT00806104|PLACEBO_COMPARATOR|2|Maltodextrins
62290558|NCT03825913|ACTIVE_COMPARATOR|Exercise Intervention|"Subjects in the exercise group will participate in a 3-month exercise program at the University of Miami UHealth Fitness and Wellness Center. Participants will complete two exercise sessions a week, each 45-60 minutes long and on a one-on-one basis.~In addition to two site visits, the participants will receive a tailored daily home-based walking plan. The participants will use physical activity trackers (Fitbit®), with an ultimate goal of achieving 10,000 steps by the end of the intervention.~Participants in the exercise intervention will complete 24 sessions."
62308036|NCT04909021|EXPERIMENTAL|Dosage Group 3: RSV Vaccine Dosage 3 (Single-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3
62463924|NCT05963321|ACTIVE_COMPARATOR|Active cerebellum electrode and sham M1 electrode|"* The patient will receive active cerebellar stimulation with the anode electrode positioned in the cerebellum and sham cortical stimulation with the anode electrode placed in the primary motor cortex.~* In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~* The equipment will apply a current of 2 mA for 20 minutes."
62656309|NCT05053490|EXPERIMENTAL|Static Stretching|Participants will perform static stretching on day 1 and dynamic stretching after the switching.
62656310|NCT05053490|EXPERIMENTAL|dynamic stretching|Participants will perform dynamic stretching on day 1 and static stretching after the switching.
61906872|NCT05083780|EXPERIMENTAL|mFORFIRINOX, Chlorphenesin Carbamate, Hydroxychloroquine|
62092665|NCT05493371|EXPERIMENTAL|Empagliflozin|
62092666|NCT05238597|EXPERIMENTAL|A197 Ophthalmic Solution, High Dose|
62092667|NCT05238597|EXPERIMENTAL|A197 Ophthalmic Solution, Low Dose|
62092668|NCT05238597|PLACEBO_COMPARATOR|A197 Vehicle Control|
62092669|NCT05238597|ACTIVE_COMPARATOR|Active Comparator|
62092670|NCT03908242|EXPERIMENTAL|Salvianolic Acid A|2 anticipated doses are 90 mg and 180 mg.
62092671|NCT03908242|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
62092672|NCT03149211|ACTIVE_COMPARATOR|Cohort 1|Subjects will receive current standard HAART treatment as the active control group.
62092673|NCT03149211|EXPERIMENTAL|Cohort 2|Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.
62092674|NCT01852162|EXPERIMENTAL|Dabigatran|Dabigatran 150mg
62092675|NCT01852162|PLACEBO_COMPARATOR|Placebo|Placebo
62092676|NCT06263985|OTHER|Subjects undergoing a pelvic organ prolapse repair procedure using Axis Dermis biologic mesh|This is a single are which will be composed of subjects with Stage II or greater pelvic organ prolapse who have agreed to undergoing a pelvic organ prolapse repair procedure using Axis Dermis biologic mesh. They will undergo the procedure and be followed for a period of 3 years.
62092677|NCT06613958|OTHER|Group 1|Order of interventions: Sedentary - Active morning - Active Evening
62092678|NCT06613958|OTHER|Group 2|Order of the interventions: Sedentary - Active Evening - Active Morning
62092679|NCT03783533|EXPERIMENTAL|Adolescent Target Users of Behavioral Activation (BA) App|Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.
62092680|NCT04364945|PLACEBO_COMPARATOR|Control group|General anesthesia is maintained using sevoflurane only. Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
62092681|NCT04364945|EXPERIMENTAL|Dexmedetomidine-remifentanil(DEX-R) group|General anesthesia is maintained using sevoflurane, dexmedetomidine (1 mcg/kg loading, and 1 mcg/kg/hr continuous infusion) and remifentanil (0.1-0.2 mcg/kg/min). Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
62092682|NCT05240859||Geleli|RA patients treated with Geleli
62092683|NCT06522737|EXPERIMENTAL|Duvelisib|Duvelisib will be administered orally twice daily (BID) in 28-day cycles.
62092684|NCT06522737|ACTIVE_COMPARATOR|Gemcitabine or Bendamustine|Participants will receive the investigator's choice of gemcitabine or bendamustine. The regimen to be used after randomization must be selected by the investigator prior to randomization. Gemcitabine will be administered intravenously (IV) on days 1, 8, and 15 of each 28-day cycle for up to 6 cycles. Bendamustine will be administered IV on days 1 and 2 of each 21-day cycle for up to 6 cycles.
62308037|NCT04909021|EXPERIMENTAL|Dosage Group 3a: RSV Vaccine Dosage 3 (Two-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3 followed by a second identical dose of the investigational RSV vaccine 28 days later
62290559|NCT03825913|SHAM_COMPARATOR|Wellness Intervention|For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
62092685|NCT01447797|EXPERIMENTAL|HCP0912|Irbesartan/Atorvastatin combination tablet
62092686|NCT01447797|ACTIVE_COMPARATOR|Irbesartan and Atorvastatin|coadministration of irbesartan and atorvastatin
62092687|NCT06347107|EXPERIMENTAL|Robotic subretinal tPA injection group|The purpose of this study is to determine the feasibility of subretinal injection of tPA assisted by a prototype robotic device.
62092688|NCT03526445|ACTIVE_COMPARATOR|Glucagon|3 hours i.v. infusion of Glucagon (4 ng/kg/min).
62092689|NCT03526445|PLACEBO_COMPARATOR|Saline|3 hours i.v. infusion of saline
62092690|NCT06576596|NO_INTERVENTION|Standard induction of anaesthesia in the child.|Control group: in this group, standard induction of anaesthesia is performed without the use of apnoeic oxygenation.
62092691|NCT06576596|EXPERIMENTAL|Experimental group: standard induction is supplemented by apnoeic oxygenation.|In the experimental group, apnoeic oxygenation is used in addition to standard anaesthesia induction.
62656311|NCT04507113|EXPERIMENTAL|Lumbar radiculopathy|Patients with acute lumbar radiculopathy (less than 3 months of evolution)
62656312|NCT01544881|EXPERIMENTAL|TI Inhalation Powder|Technosphere Insulin Inhalation Powder using the Gen2C inhaler
62290560|NCT02305563|EXPERIMENTAL|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
62290561|NCT02305563|EXPERIMENTAL|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
62290562|NCT02305563|EXPERIMENTAL|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
62290563|NCT02305563|OTHER|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
62656313|NCT01544881|ACTIVE_COMPARATOR|RAA|Rapid Acting Analog
61906873|NCT05179343|EXPERIMENTAL|Active arm|Participants in this arm will receive the active AffeX-CT device.
62092692|NCT06049134|EXPERIMENTAL|Arm Group A (PCV20)|Participants will receive 1 dose of the vaccine
62092693|NCT06049134|EXPERIMENTAL|Arm Group B (PCV20)|Participants will receive 2 doses of the vaccine
62290564|NCT04617808||Headache pattern|Telephone call from center 15 for the headache pattern
62290565|NCT05487794|EXPERIMENTAL|Group 1 (T100)|
62290566|NCT05487794|NO_INTERVENTION|Group 1 (T0)|
62290567|NCT00929240|ACTIVE_COMPARATOR|Avastin (bevacizumab)|
62290568|NCT00929240|EXPERIMENTAL|Avastin (bevacizumab) + Xeloda (capecitabine)|
62290569|NCT04668508|EXPERIMENTAL|anlotinib combined with radiation|
62656314|NCT03736304|PLACEBO_COMPARATOR|Usual care|Patients will receive standard clinical care by the doctor in charge.
62656315|NCT03736304|EXPERIMENTAL|AKI alert|An AKI alert will send to the the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
62656316|NCT04985162|EXPERIMENTAL|Intervention|Intervention group (n=10) received differential learning based physiotherapy program: 3 times a week ordinary physiotherapy, 2 times a week differential learning based on physiotherapy, total 3 weeks
62656317|NCT04985162|ACTIVE_COMPARATOR|Control|Control group (n=10) received ordinary physiotherapy program 5 times a week, total 3 weeks
62656318|NCT04943783|EXPERIMENTAL|Atorvastatin|Atorvastatin, 20mg once a day, for six months
62656319|NCT04943783|NO_INTERVENTION|No drug|no drug
62656320|NCT03104413|EXPERIMENTAL|Risankizumab Dose 1 (Induction Period 1)|Participants randomized to receive risankizumab dose 1 in Induction Period 1.
62656321|NCT03104413|EXPERIMENTAL|Risankizumab Dose 2 (Induction Period 1)|Participants randomized to receive risankizumab dose 2 in Induction Period 1.
62656322|NCT03104413|PLACEBO_COMPARATOR|Placebo (Induction Period 1)|Participants randomized to receive placebo for risankizumab in Induction Period 1.
62290570|NCT03227874|EXPERIMENTAL|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
62290571|NCT03227874|EXPERIMENTAL|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
62656323|NCT03104413|EXPERIMENTAL|Risankizumab Dose 1 (Induction Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
62656324|NCT03104413|EXPERIMENTAL|Risankizumab Dose 2 (Induction Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
62656325|NCT03104413|EXPERIMENTAL|Risankizumab Dose 3 (Induction period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
62656326|NCT02612857|PLACEBO_COMPARATOR|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
62656327|NCT02612857|EXPERIMENTAL|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
62656328|NCT02612857|EXPERIMENTAL|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
62656329|NCT00751127|ACTIVE_COMPARATOR|Timolol|
62656330|NCT00751127|EXPERIMENTAL|PhXA41|
62656331|NCT04695561|EXPERIMENTAL|Self Myofascial Relaxation|In addition to the exercises applied to the participants in the control group, the participants in this group used Foam Roller, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
62656332|NCT04695561|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|In addition to the exercises applied to the participants in the control group, the participants in this group used Instrument Assisted Soft Tissue Mobilization, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
62656333|NCT04695561|ACTIVE_COMPARATOR|Only Exercise (Control)|Stretching and strengthening exercises for the hip flexors, hip extensors and iliotibial band were shown to the participants in the control group for 6 weeks every day of the week.
62656334|NCT01993199|ACTIVE_COMPARATOR|deep biopsy|
62656335|NCT06224049|EXPERIMENTAL|hNeo-T|The escalating doses of hNeo-T in this study will be 5\*10\^7 cells and1\*10\^8 cells.
62656336|NCT01532089|ACTIVE_COMPARATOR|Arm A (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
62656337|NCT01532089|EXPERIMENTAL|Arm B (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride as in Arm A and bevacizumab IV over 30-90 minutes on day 1. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
62656338|NCT02101294|EXPERIMENTAL|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
62656339|NCT05071924|EXPERIMENTAL|PLH Teens Original|The original in-person PLH programme is delivered by community-based workers in low-resource settings. Implementation occurs in a group-based format with both joint parent and teen sessions (10 sessions) and separate parent and teen sessions (4 sessions).
62308038|NCT04909021|PLACEBO_COMPARATOR|Placebo (Single-dose)|Participants in this arm will receive a single intranasal dose of placebo
62092694|NCT00839982|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive clofarabine PO QD on days 1-5 and low-dose cytarabine SC BID on days 1-10 or SC QD on days 1-14. Treatment repeats every 21-28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62092695|NCT00938561||With and without Chronic Kidney Disease|A cohort of 10 patients subjects with and without kidney disease exhibiting a broad range of age and kidney function
62092696|NCT04985383|EXPERIMENTAL|AKST1210 device|AKST1210 column will be connected in series for the duration of each hemodialysis session.
62092697|NCT06522932|EXPERIMENTAL|Cohort 1: 64Cu-GRIP B PET imaging|Participants with NHL will undergo 64Cu-GRIP B PET before and after CD19-directed CAR-T therapy. Three participants will undergo post-treatment 64Cu-GRIP B PET at the Day 8 time point, three participants will undergo post-treatment 64Cu-GRIP B PET at the Day 15 (+/- 3) time point, and three participants will undergo post-treatment 64Cu-GRIP B PET Day 22 (+/- 3) time point. An optional soft tissue biopsy will be collected following the post-treatment PET. Participants will be followed up for 12 months after the final PET scan.
62290572|NCT02557425||Maternal SP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of sulfadoxine-pyrimethamine (SP), and children receive every 3 month dihydroartemisinin-piperaquine (DP). No intervention is given in the observational PROTECT study.
62290573|NCT02557425||Maternal 3 dose DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive every 3 month DP.No intervention is given in the observational PROTECT study.
62290574|NCT02557425||Maternal 3 dose DP/Child monthly DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive monthly DP. No intervention is given in the observational PROTECT study.
62290575|NCT02557425||Maternal monthly DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every 3 month DP. No intervention is given in the observational PROTECT study.
62463925|NCT05963321|SHAM_COMPARATOR|Sham cerebellar electrode and sham M1 electrode|"* The patient will receive sham cerebellar stimulation with the anode electrode positioned in the cerebellum and sham cortical stimulation with the anode electrode placed in the primary motor cortex.~* In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~* The equipment will apply a current of 2 mA for 20 minutes."
62092698|NCT06522932|EXPERIMENTAL|Cohort 2: Expansion Phase 64Cu-GRIP B PET imaging|Participants with NHL will undergo 64Cu-GRIP B PET before and after CD19-directed CAR-T therapy with one of the three time points chosen based on 64Cu-GRIP B uptake determined in Cohort 1. An optional soft tissue biopsy will be collected following the post-treatment PET. Participants will be followed up for 12 months after the final PET scan.
62092699|NCT01037543|EXPERIMENTAL|Cohort 1|1.1 mcg/kg of HM10460A, placebo, or Neulasta
62092700|NCT01037543|EXPERIMENTAL|Cohort 2|3.3 mcg/kg HM10460A, placebo or Neulasta
62463926|NCT02461771|EXPERIMENTAL|Pegcetacoplan Cohort 1|4 mg of pegcetacoplan 100 μL IVT injection
62463927|NCT02461771|EXPERIMENTAL|Pegcetacoplan Cohort 2|10 mg of pegcetacoplan 100 μL IVT injection
62463928|NCT02461771|EXPERIMENTAL|Pegcetacoplan Cohort 3|20 mg of pegcetacoplan 100 μL IVT injection
62463929|NCT06327022|EXPERIMENTAL|Social media-based electronic bibliotherapy|Eight weekly sessions of social media-based electronic bibliotherapy
62463930|NCT06327022|OTHER|Usual care|Routine services provided by community centers
62463931|NCT01964092|EXPERIMENTAL|Individual Placement and Support|Individual Placement and Support (IPS) is a well-defined intervention aiming to help people with disabilities participate in the competitive labor market by working in jobs they prefer with the professional help that they need. IPS actively facilitates job acquisition and provides ongoing support once the client is employed.
62092701|NCT01037543|EXPERIMENTAL|Cohort 3|10 mcg/kg of HM10460A, placebo, or Neulasta
62092702|NCT01037543|EXPERIMENTAL|Cohort 4|30 mcg/kg of HM10460A, placebo, or Neulasta
62092703|NCT01037543|EXPERIMENTAL|Cohort 5|90 mcg/kg or HM10460A, placebo, or Neulasta
62092704|NCT01037543|EXPERIMENTAL|Cohort 6|270 mcg/kg of HM10460A, placebo, or Neulasta
62092705|NCT00684502|EXPERIMENTAL|1|Oral solution.
62092706|NCT00684502|PLACEBO_COMPARATOR|2|Oral solution
62092707|NCT06696651|EXPERIMENTAL|Electrical Myostimulation|twenty females will receive EMS session per week ( 20mins / week ) and following healthy diet for 6 weeks .
62092708|NCT06696651|ACTIVE_COMPARATOR|Myofascial Release|twenty female will receive myofascial release sessions ( 2 sessions / week) and following healthy diet for 6 weeks .
62092709|NCT06696651|ACTIVE_COMPARATOR|Healthy diet|twenty females following healthy diet only for 6 weeks.
62092710|NCT00970411|EXPERIMENTAL|KRN951|
62290576|NCT02557425||Maternal monthly DP/child monthly DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every monthly DP. No intervention is given in the observational PROTECT study.
62290577|NCT02798926||with the use of a polyethylene bag|
62290578|NCT02798926||without the use of a polyethylene bag|
62290579|NCT05825690||LGI1- Patients|Patients affected by autoimmune encephalitis with antibodies against LGI1
62092711|NCT06394336|EXPERIMENTAL|Experimental group|People with PF who will receive the usual treatment (oral analgesic/anti-inflammatory drug) prescribed by the primary care physician and will also participate in the therapeutic exercise programme.
62290580|NCT01124825|ACTIVE_COMPARATOR|IGel|Subjects will receive an IGel(TM) airway induction and maintenance of positive pressure ventilation
62092712|NCT06394336|ACTIVE_COMPARATOR|Non-experimental group|Individuals with PF who will receive the usual treatment (oral analgesic/anti-inflammatory drug) prescribed by the primary care physician
62290581|NCT01124825|ACTIVE_COMPARATOR|King Airway|Subject will receive a KING-LTS-D(TM) for induction and maintenance of positive pressure ventilation
62656340|NCT05071924|EXPERIMENTAL|PLH Teens Hybrid|The hybrid delivery of PLH Teens consists of 8 sessions delivered to parents via WhatsApp (ParentChat-Teens) and 4 sessions delivered to parents and adolescents in person.
62656341|NCT00612235||Lamotrigine Monotherapy|Lamotrigine Monotherapy
62656342|NCT00612235||Levetiracetam Monotherapy|Levetiracetam Monotherapy
61906874|NCT05179343|SHAM_COMPARATOR|Sham arm|Participants in this arm will receive the sham (inactive) AffeX-CT device.
62092713|NCT04682574|ACTIVE_COMPARATOR|vitamin C|The dose would be 30 grams a day (10 grams TDS) for 3 days with standard treatment
62092714|NCT04682574|NO_INTERVENTION|Placebo|Distill water in the same dose with same standard treatment
62092715|NCT06426771||Low AMH Levels-|AMH levels: those with low AMH levels (\<1.2 ng/ml): 30 participants
62092716|NCT06426771||Normal AMH levels-|normal AMH levels (1.2-3.32 ng/ml): 30 participants
62092717|NCT06426771||High AMH levels-|high AMH levels (\>3.32 ng/ml): 30 Participants
62092718|NCT00196742||Patients with Fabry disease|No experimental intervention is given. A patient with Fabry Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
62290582|NCT00675025|EXPERIMENTAL|Prior Donepezil-DB|All participants started with a dose of 2.5 mg/day (2.5 mL/day). Dose escalations occurred in 2.5 mg/day increments every 2 weeks (steady state levels assumed to have been reached) to a maximum dose of 10 mg/day, according to the participant's weight schedule and the Investigator's judgment of safety and tolerability. Re-titration was done to maintain the blinding of the double-blind study (E2020-A001-219). Doses could be decreased due to tolerability and could be increased or decreased to maintain a maximum dose of 0.1 to 0.2 mg/kg/day based on the participant's weight at clinic visits during the study duration.
62656343|NCT00612235||Carbamazepine Monotherapy|Carbamazepine Monotherapy
62290583|NCT06358014|EXPERIMENTAL|The combination group is estrogen combined with SSRIs for 8 weeks|The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/d (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs.
62656344|NCT00612235||Normal control (no epilepsy)|Normal control (no epilepsy)
62656345|NCT05168904|EXPERIMENTAL|Phase I Dose escalation|Phase 1 = fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4-week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
62656346|NCT05168904|EXPERIMENTAL|Phase 2|Recommended fadraciclib phase 2 dose and schedule administered orally in 28-day cycles.
62656347|NCT04183101|EXPERIMENTAL|Aliskiren treatment|Patients will be randomized to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for 6 months. After 6 months the patients will be switched to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for the coming 2,5 years.
62656348|NCT04183101|ACTIVE_COMPARATOR|Enalapril treatment|Patients will be randomized to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for 6 months. After 6 months the patients will be switched to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for the coming 2,5 years.
62656349|NCT02460731|EXPERIMENTAL|Fresh Frozen Plasma|Fresh Frozen Plasma \[young (\<30 years of age) healthy male donors\]
62656350|NCT05172570|NO_INTERVENTION|No Gabapentin|Patients will not receive any gabapentin postoperatively after open thoracotomy
62656351|NCT05172570|ACTIVE_COMPARATOR|300 mg Gabapentin 3X per day|Patients will receive 300mg gabapentin 3x a day after open thoracotomy
62656352|NCT05172570|ACTIVE_COMPARATOR|300 mg Gabapentin once per day at night|Patients will receive 300mg gabapentin once a day at night after open thoracotomy
62290584|NCT06358014|PLACEBO_COMPARATOR|SSRIs for 8 weeks|This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs.
62656353|NCT05669157|EXPERIMENTAL|Current practice: radiography request by physician|No interventions will be performed. There is no change in current practice.
62656354|NCT05669157|EXPERIMENTAL|Radiography request by the nurse|the intake and referral nurse will request a radiography if required according to the local cooperation protocol
62656355|NCT00302471|EXPERIMENTAL|1600 mg twice a day|MK0429
62656356|NCT00302471|EXPERIMENTAL|200 mg twice a day|MK0429
62656357|NCT00302471|EXPERIMENTAL|800 mg twice a day|MK0429
62656358|NCT00302471|EXPERIMENTAL|400 mg twice a day|MK0429
62656359|NCT04466189||Pancreatic Cancer Patients Treated With Proton Beam Therapy|Pancreatic Cancer Patients Treated With Proton Beam Therapy
62656360|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
62656361|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
62656362|NCT05201417|NO_INTERVENTION|control group A|patients continue their usual HIV management no intervention
62656363|NCT05201417|OTHER|intervention group B|patients continue their usual HIV management, patients will benefit from an adapted physical activity program for 12 weeks
62656364|NCT01113775||presence of right ventricle dysfunction|
62290585|NCT01769937|EXPERIMENTAL|H.P. Acthar Gel SQ injection|Patients will administer single dose (80 units) of Acthar subcutaneously every day for 10 days (with a possible 5 day dosing rescue).
62290586|NCT02463461|EXPERIMENTAL|ActiSleep Activity Monitor|Subjects placed in this group will given an ActiSleep Activity Monitor for the one night of the study.
62463932|NCT01964092|ACTIVE_COMPARATOR|Ordinary employment schemes|The control group will receive treatment as usual in terms of the ordinary employment schemes offered to this group, primarily Work with assistance and/or Traineeship in a sheltered business.
62463933|NCT02828917|EXPERIMENTAL|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
62656365|NCT01113775||absence of right ventricle dysfunction|
62656366|NCT01179516|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
62656367|NCT01179516|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
62656368|NCT01179516|EXPERIMENTAL|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
62656369|NCT00655889|EXPERIMENTAL|Active|
62656370|NCT05994183|EXPERIMENTAL|Dexamethasone Administration|Dexamethasone will be given orally to all consented participants. Two doses will be administered within 12-48 hours, with at least the 1st dose administered during the bronchiolitis hospitalization. If the participant is discharged before the 2nd dose, it will be administered at home.
62656371|NCT05992441||breast cancer|This group will consist of women who have received breast cancer and will be based on participant volunteerism.
62656372|NCT03687424|ACTIVE_COMPARATOR|Normal weight 18<BMI<30 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62656373|NCT03687424|ACTIVE_COMPARATOR|Obese 30<BMI<40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62656374|NCT03687424|ACTIVE_COMPARATOR|Morbidly obese BMI ≥40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62656375|NCT03687424|EXPERIMENTAL|Normal weight 18<BMI<30 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62656376|NCT03687424|EXPERIMENTAL|Obese 30<BMI<40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62656377|NCT03687424|EXPERIMENTAL|Morbidly obese BMI ≥40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62656378|NCT04236778|EXPERIMENTAL|Cohort 1|Cohort 1 received oral vancomycin followed by a single dose of VE303.
62656379|NCT04236778|EXPERIMENTAL|Cohort 2|Cohort 2 received oral vancomycin followed by a single day of 5 doses of VE303.
62656380|NCT04236778|EXPERIMENTAL|Cohort 3|Cohort 3 received oral vancomycin followed by a single day of 10 doses of VE303.
62656381|NCT04236778|EXPERIMENTAL|Cohort 4|Cohort 4 received oral vancomycin followed by 5 days of 10 doses daily of VE303.
62656382|NCT04236778|EXPERIMENTAL|Cohort 5|Cohort 5 received oral vancomycin followed by 14 days of 10 capsules daily of VE303
62656383|NCT04236778|EXPERIMENTAL|Cohort 6|Cohort 6 received 21 days of 10 doses daily of VE303
62656384|NCT04236778|EXPERIMENTAL|Cohort 7|Cohort 7 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
62656385|NCT04236778|EXPERIMENTAL|Cohort 8|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
62656386|NCT04236778|EXPERIMENTAL|Cohort 9|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
62092719|NCT00196742||Pregnant women with confirmed diagnosis of Fabry|No experimental intervention is given. Pregnant women with confirmed diagnosis of Fabry that are participating in the Fabry Registry and consented to participate in the Fabry Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with agalsidase beta) and irrespective of the commercial product with which she may be treated.
62092720|NCT03424239|EXPERIMENTAL|Drug: Zoledronic Acid, Calcium+Vitamin D|Subjects will receive a single intravenous infusion of zoledronic acid (5 mg). Supplemental calcium citrate + vitamin D (500mg+500IU) and vitamin D3 (1000 IU) will be dispensed throughout the study to fit individual needs.
62092721|NCT04269200|ACTIVE_COMPARATOR|Arm A (control)|Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
62092722|NCT04269200|EXPERIMENTAL|Arm B (durvalumab+placebo)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
62092723|NCT04269200|EXPERIMENTAL|Arm C (durvalumab+olaparib)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
62092724|NCT02922543||Relapsed or refractory multiple myeloma (MM) patients|Relapsed or refractory MM patients in the special use-results surveillance (all-case surveillance) (hereinafter referred to as the all-case surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the all-case surveillance and this surveillance.
62092725|NCT06697873|EXPERIMENTAL|Experimental Group:A|21 participants will receive both Rhythmical stabilization and closed chain kinetic exercise followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes
62092726|NCT06697873|EXPERIMENTAL|Experimental Group:B|21 participants will receive Rhythmical stabilization training program followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes.
62092727|NCT02343614|EXPERIMENTAL|ARM A|Patients undergoing treatment with oral celecoxib
61906875|NCT02465554||No atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of 0. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into No atherosclerosis/endothelial function normal and No atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
61906876|NCT02465554||Atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have non-critical plaque (\<50% diameter) and at least 1 high risk feature according to the ROMICAT indices. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into atherosclerosis/endothelial function normal and atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
62656387|NCT04236778|PLACEBO_COMPARATOR|Vancomycin only|This cohort only received oral vancomycin.
61906877|NCT03763513|ACTIVE_COMPARATOR|ESWT|the first group:The group that will receive Extra corporeal shock wave therapy
61906878|NCT03763513|EXPERIMENTAL|ESWT+KT|the second group:The group that will receive Extra corporeal shock wave therapy + Kinesiotaping application
62092728|NCT06216028|NO_INTERVENTION|Standard of Care|Standard of care IA injection may include cortisone or hyaluronic acid (HA) as per discretion of the Principal Investigator
62092729|NCT06216028|EXPERIMENTAL|Bone Marrow Aspirate Concentrate (BMAC)|Cell suspension for infusion. 50 mL of Bone Marrow Aspirate collected, and 10-15 mL BMAC injected to knee(s)
62092730|NCT06696677|ACTIVE_COMPARATOR|Marked Laparoscopic graspers group|in this arm, the graspers will be marked by a sterile tape, 5 cm in length. This will help for accurate measuring of the whole intestine.
62092731|NCT06696677|ACTIVE_COMPARATOR|3D CT scan group|In this arm, all patients involved in the study will have a pre-operative CT scan, for which a 3D reconstruction will be done and measure the whole small intestinal length.
62092732|NCT00013026|OTHER|Arm 1|
62092733|NCT06698159|ACTIVE_COMPARATOR|Control strategy|Pulmonary vein isolation by 28 mm balloon cryoablation
62092734|NCT06698159|EXPERIMENTAL|Experimental strategy|Pulmonary vein isolation by 31 mm balloon cryoablation
62092735|NCT00913679|ACTIVE_COMPARATOR|Posterior approach|Posterior surgical approach in hip resurfacing arthroplasty
62092736|NCT00913679|ACTIVE_COMPARATOR|Anterolateral approach|Anterolateral surgical approach in hip resurfacing arthroplasty
62092737|NCT06640751|EXPERIMENTAL|Intervention|The intervention group, based on the three core elements of the PROCEED model (predisposing, enabling, and reinforcing factors), aims to influence the health behaviors of patients with hypertension.
62092738|NCT06640751|NO_INTERVENTION|Control|During the study, control participant will be provided with existing community health education on hypertension.
62092739|NCT02926534||Smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
62092740|NCT02926534||Ex-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago
62092741|NCT02926534||Never-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)
62092742|NCT03608020|ACTIVE_COMPARATOR|WBRT + BMX-001|Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
62092743|NCT03608020|NO_INTERVENTION|Whole Brain Radiation Therapy|Whole brain radiation therapy per standard of care.
62092744|NCT02877537|EXPERIMENTAL|Asthma child|
62290587|NCT02463461|EXPERIMENTAL|Jawbone Activity Monitor|Subjects placed in this group will given a Jawbone Activity Monitor for the one night of the study.
61906879|NCT01030666|EXPERIMENTAL|doxycycline|"The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects~* modified/simplified papilla preservation flap; scaling~* Prefgel/Emdogain~* 0.12% chlorhexidine gluconate solution~* Ibuprofen 400 mg (if necessary)~* 1% chlorhexidine gluconate gel (if necessary)"
62290588|NCT02463461|EXPERIMENTAL|Actiwatch 2 Activity Monitor|Subjects placed in this group will given an Actiwatch 2 Activity Monitor for the one night of the study.
62092745|NCT02877537|EXPERIMENTAL|Control adult|
62092746|NCT02877537|EXPERIMENTAL|Control child|
62092747|NCT05859724|PLACEBO_COMPARATOR|Placebo|Placebo (for NM26-2198) for subcutaneous (SC) injection in healthy volunteers (HVs) on Day 1 (SAD Cohorts) and on Days 1, 8, 15, and 22 (MAD Cohorts)
62092748|NCT05859724|EXPERIMENTAL|NM26-2198|NM26-2198 10mg, 50mg, 150mg, 300mg, 400mg, 600mg, and 900mg for SC injection in HVs on Day 1 (SAD Part A); NM26-2198 150mg and 300mg for SC injection in patients with AD on Days 1, 8, 15, and 22 (MAD Part B); NM26-2198 150mg and 300mg for SC injection in HVs on Days 1, 8, 15, and 22 (MAD Part C)
62092749|NCT06248476|ACTIVE_COMPARATOR|iTBS + robotic rehabilitation|iTBS combined with robotic rehabilitation and conservative treatment applied to patients with chronic incomplete spinal cord injury
62290589|NCT02463461|EXPERIMENTAL|FitBit Activity Monitor|Subjects placed in this group will given a FitBit Activity Monitor for the one night of the study.
62290590|NCT02463461|EXPERIMENTAL|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects placed in this group will given an Actigraph by Ambulatory Monitoring Activity Monitor for the one night of the study.
62290591|NCT02075801||Defective amalgam restorations|"Treatment Groups:~A. Sealing of amalgam margin defects: Defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Sealant, 3MESPE)was applied over the defective area. The sealant was polymerized with a photo curing unit (Curing-Light 2500, 3MESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B. Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr, Orange, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C. Control Group: The defective restorations did not receive any treatment."
62290592|NCT02145962|ACTIVE_COMPARATOR|Forearm tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the medical services site of the Autonomous University of Nuevo Leon, Monterrey, Mexico. These study patients should receive treatment in the forearm region.
62290593|NCT02145962|ACTIVE_COMPARATOR|Thorax tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the IMSS Regional General Hospital N. 1 and Servicios de Salud de Morelos, Cuernavaca, Mexico. These study patients received treatment in the thorax region.
62290594|NCT05042726|EXPERIMENTAL|cTBS First|The first stage, participants received cTBS treatment for a total of 10 times during two weeks, then followed up for eight weeks; the second stage, participants are treated with pseudo-stimulation for a total of 10 times during two weeks, then followed up for 8 weeks similarly.
62656388|NCT01155765|EXPERIMENTAL|Prasugrel|Prasugrel per os 10 mg/day
61906880|NCT01030666|PLACEBO_COMPARATOR|placebo|"The patients of the control group will take placebo once a day for 7 days after regenerative therapy of an infrabony defect~* modified/simplified papilla preservation flap; scaling~* Prefgel/Emdogain~* 0.12% chlorhexidine gluconate solution~* Ibuprofen 400 mg (if necessary)~* 1% chlorhexidine gluconate gel (if necessary)"
61906881|NCT02243462|OTHER|No pre-op warming|No pre-warming in bay before surgery.
62092750|NCT06248476|ACTIVE_COMPARATOR|rTMS + robotic rehabilitation|rTMS combined with robotic rehabilitation and conservative treatment applied to patients with chronic incomplete spinal cord injury
62092751|NCT06248476|SHAM_COMPARATOR|sham iTBS + robotic rehabilitation|Sham iTBS combined with robotic rehabilitation and conservative treatment applied to patients with chronic incomplete spinal cord injury
62092752|NCT04323319|EXPERIMENTAL|ESWT Group|Patients in the ESWT group will be treated with ESWT once a week for 4 weeks. Each patient was treated with epine calcaneus and its surroundings. The treatment dose of 10 Hz, 2.5 bar, 2000 shock wave with BTL L-6000 SWT device will be applied by the same therapist. Patient completed plantar fascia and gastrocnemius streching exercises right after treatment. The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
62290595|NCT05042726|EXPERIMENTAL|Pseudo-stimulation First|The first stage, participants received pseudo-stimulation treatment for a total of 10 times during two weeks, then followed up for eight weeks; the second stage, participants are treated with cTBS for a total of 10 times during two weeks, then followed up for 8 weeks similarly.
62290596|NCT03471325|EXPERIMENTAL|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
62290597|NCT03471325|EXPERIMENTAL|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
62290598|NCT03471325|EXPERIMENTAL|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
62092753|NCT04323319|EXPERIMENTAL|Graston Technique® Group|The application was carried out by Graston Technique® (GT®) certified, a therapist with orthopedic rehabilitation and soft tissue treatments for over 12 years. GT® instruments were used to diagnose and treat the damaged soft tissue of gastrocnemius and plantar fascia. The application protocol and the instruments used according to the regions were determined with reference to the GT® manual. GT® treatment can be given to the same region twice a week. A minimum of 2 days break was given between the applications. Gastrocnemius and plantar fascia application completed in 5 minutes in one leg. GT2, GT4 and GT6 instruments used for application.The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
62092754|NCT04323319|EXPERIMENTAL|Control Group|Stretching group was accepted as the control group. the patient monitored once a week at the hospital and continue home stretching program at home. These patients will be given information about plantar fasciitis as well as other groups. Plantar fascia and gastrosoleus self-stretching exercises will be required to be performed twice a day for thirty seconds and three repetitions for 4 weeks. The patients will be followed with an exercise follow-up form.
62092755|NCT05725343|EXPERIMENTAL|Canakinumab|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.
62092756|NCT05725343|PLACEBO_COMPARATOR|Placebo|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.
62290599|NCT03471325|PLACEBO_COMPARATOR|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
62290600|NCT03737656|EXPERIMENTAL|Progesterone Vaginal Ring (Group A)|Insertion of the vaginal ring on Day 1 and continuous use until 91 days of treatment are completed. In this group, 28 participants will be included.
62656389|NCT01155765|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel per os 150 mg/day
62290601|NCT03737656|EXPERIMENTAL|Progesterone Vaginal Ring (Group B)|Insertion of the vaginal ring on Day 1, removal for 2 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
62290602|NCT03737656|EXPERIMENTAL|Progesterone Vaginal Ring (Group C)|Insertion of the vaginal ring on Day 1, removal for 4 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
62290603|NCT03521947||One group of children below 18 years old|
62290604|NCT04626414|ACTIVE_COMPARATOR|30 mg ferric maltol capsule in a fed condition|Single dose of 30 mg ferric maltol capsule in a fed condition
62290605|NCT04626414|ACTIVE_COMPARATOR|30 mg ferric maltol capsule in a fasted condition|Single dose of 30 mg ferric maltol capsule in a fasted condition
62656390|NCT00627107|EXPERIMENTAL|A|A group of paraplegics.
62092757|NCT00101725|EXPERIMENTAL|125 mg crofelemer|
62092758|NCT00101725|EXPERIMENTAL|250 mg crofelemer|
62290606|NCT04626414|EXPERIMENTAL|30 mg (5 ml) ferric maltol suspension in a fed condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition
62290607|NCT04626414|EXPERIMENTAL|30 mg (5 ml) ferric maltol suspension in a fasted condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition
62290608|NCT01082484|EXPERIMENTAL|Treprostinil|Treprostinil iontophoresis (250, 25 and 2.5 microM)
62290609|NCT01082484|EXPERIMENTAL|Iloprost|Iloprost iontophoresis (200, 20 and 2 microM)
62290610|NCT01082484|PLACEBO_COMPARATOR|NaCl 0.9%|
62290611|NCT01658514|EXPERIMENTAL|Met DR|One dose of 1000 mg metformin delayed-release
62290612|NCT01658514|ACTIVE_COMPARATOR|Met XR|One dose of 1000 mg metformin extended-release
62290613|NCT01658514|PLACEBO_COMPARATOR|Placebo|One dose of Placebo
62656391|NCT05884619|EXPERIMENTAL|Dual-target deep brain stimulation|This is a single arm, prospective, open label clinical study, participants who fit inclusion and don't fit exclusion criteria, completed physical anti-addiction treatments and surgical implantation standard will start DBS system stimulation and adjust parameters after 10-14 days of implantation. Then after stimulation for 9-32 weeks, they will be evaluated for treatment efficacies. This study is extendable, with agreements from participants, long term efficacy and safety follow-up study will be performed after 32 weeks ± 7 days of following, once every 2-3 months.
62092759|NCT00101725|EXPERIMENTAL|500 mg crofelemer|
62092760|NCT00101725|PLACEBO_COMPARATOR|placebo|
62092761|NCT01822821|EXPERIMENTAL|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
62092762|NCT01822821|PLACEBO_COMPARATOR|Placebo|Patients will receive up to four doses of IV placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
62092763|NCT06501872|EXPERIMENTAL|Main Arm|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
62092764|NCT06501872|EXPERIMENTAL|Expanded Access Arm|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal, thoracic, or abdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair in an expanded use population.
62092765|NCT03589924|EXPERIMENTAL|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
62092766|NCT03589924|ACTIVE_COMPARATOR|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
62092767|NCT06377683|EXPERIMENTAL|177Lu-Dansyl-PSMA|177Lu-Dansyl-PSMA A maximum of 2 cycles of 50 mCi (1.85 GBq) 177Lu-Dansyl-PSMA, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks. Subsequent cohorts received an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed.
62092768|NCT02646553||Children refered to the obesity clinic.|All children refered to the obesity clinic for examination and optionally treatment are invited.
62092769|NCT05098470|ACTIVE_COMPARATOR|Metformin|
62092770|NCT05098470|ACTIVE_COMPARATOR|Insulin Glargine|
62092771|NCT05098470|EXPERIMENTAL|Dorzagliatin|
62092772|NCT05194007|EXPERIMENTAL|Experimental -Frondanol|Eligible participants will receive Frondanol capsule orally (1000 mg capsule twice daily) for 6 months
62092773|NCT05194007|PLACEBO_COMPARATOR|Placebo|Eligible participants will receive placebo capsule (twice daily) for 6 months
62092774|NCT05914324|NO_INTERVENTION|Controls|Controls will be managed routinely by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the standard care device. After the child has had an oxygen saturation measurement, the study data collector will conduct oxygen saturation measurements using the control device and a reference device.
62092775|NCT05914324|EXPERIMENTAL|Phefumla|Phefumla arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the Phefumla device. After the child has had an oxygen saturation measurement, the study data collector will conduct oxygen saturation measurements using the Phefumla device and a reference device. All final patient clinical management decisions will be made based on the reference device measurement.
62092776|NCT05914324|EXPERIMENTAL|LB-01|LB-01 arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the LB-01 device. After the child has had an oxygen saturation measurement, the study data collector will conduct oxygen saturation measurements using the LB-01 device and a reference device.
62290614|NCT04405219|SHAM_COMPARATOR|smokers (S)|
62290615|NCT04405219|ACTIVE_COMPARATOR|non smokers (NS)|
62290616|NCT02804360|EXPERIMENTAL|therapy|Dexamethasone injection
62290617|NCT00516919|EXPERIMENTAL|1|Xenical + behavioral intervention
62290618|NCT00516919|ACTIVE_COMPARATOR|2|Placebo + behavioral intervention
62656392|NCT02997540||female breast ultrasound exam|females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination
62656393|NCT05871476|ACTIVE_COMPARATOR|Intervention district|An information, communication, education and hygiene intervention, developed in collaboration with local health authorities, will aim to improve hygiene and decrease antibiotic use.
62092777|NCT05310773|EXPERIMENTAL|Community Stigma Awareness and Education Workshop and HTS/ART/PrEP Only|Communities/catchment areas randomized to this arm will complete the community stigma assessments and will receive the community stigma awareness and education workshops. Couples will have access to standard HIV testing services (HTS) with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) but not the Couples Health CoOp Plus (CHC+) intervention.
62092778|NCT05310773|EXPERIMENTAL|Community Stigma Awareness and Education Workshop and HTS/ART/PrEP with CHC+|Communities/catchment areas randomized to this arm will complete the community stigma assessments and will receive the community stigma awareness and education workshops. Couples will have access to the Couples Health CoOp Plus (CHC+) intervention and standard HTS with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP).
62092779|NCT05310773|NO_INTERVENTION|No Community Stigma Awareness and Education Workshop and HTS/ART/PrEP Only|Communities/catchment areas randomized to this arm will complete the community stigma assessments but will not receive the community stigma awareness and education workshops. Couples will have access to standard HIV testing services (HTS) with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) but not the Couples Health CoOp Plus (CHC+) intervention.
62092780|NCT05310773|EXPERIMENTAL|No Community Stigma Awareness and Education Workshop and HTS/ART/PrEP with CHC+|Communities/catchment areas randomized to this arm will complete the community assessments but not the community stigma awareness and education workshops. Couples will have access to the Couples Health CoOp Plus (CHC+) intervention and standard HIV testing services (HTS) with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP).
62290619|NCT01562028|EXPERIMENTAL|Erlotinib plus bevacizumab|Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
62656394|NCT05871476|ACTIVE_COMPARATOR|cohort care at the hospital|"A laminated note (yellow for suspicious CRE carrier: green for (CRE-) patients and red for (CRE+) patients) should be put on the front of the patients' bed."
62656395|NCT02682758|OTHER|Patients of normal weight|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index of less than 30.
62656396|NCT02682758|OTHER|Obese patients|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index equal to or more than 30.
62656397|NCT06222567|EXPERIMENTAL|Pumping individual|Clinical indication for pumping
62656398|NCT05608863|ACTIVE_COMPARATOR|Combined intervention|The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting
62656399|NCT05608863|ACTIVE_COMPARATOR|individual intervention|The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting
62656400|NCT00646516|EXPERIMENTAL|1|
62656401|NCT04311632|EXPERIMENTAL|Arm 1|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
62656402|NCT04311632|EXPERIMENTAL|Arm 2|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
62656403|NCT04311632|ACTIVE_COMPARATOR|Arm 3|ATG administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
62656404|NCT04272515|EXPERIMENTAL|BA patients and their parents|"* Collection of blood samples from BA patients and their parents~* Collection of explanted liver tissue and skin biopsy of BA patients"
62656405|NCT04377659|EXPERIMENTAL|Intubation/Mechanical Ventilation|Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
62656406|NCT04377659|EXPERIMENTAL|Respiratory Support|In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)
62656407|NCT00689741|EXPERIMENTAL|A|
62656408|NCT00689741|PLACEBO_COMPARATOR|B|
62656409|NCT04285411|EXPERIMENTAL|ARMS SpO2 70-100%|Comparison to Reference CO-Oximetry
62656410|NCT00715208|EXPERIMENTAL|VELCADE R-CAP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
62656411|NCT00715208|EXPERIMENTAL|VELCADE R-CP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
62656412|NCT03922373|EXPERIMENTAL|Benzonatate|
62656413|NCT05759793|EXPERIMENTAL|CAR-GPRC5D cells|"The tolerability and safety of CARGPRC5D cells will be assessed according to the 3+3 doseescalation design.There will be three dose levels, 0.5×10\^6, 1.0×10\^6, 2.0x10\^6cells/kg. For each level, 3-6 subjects will be enrolled."
62656414|NCT04796961|OTHER|Implementation Intervention|All participants will receive the implementation intervention.
62463934|NCT03292653|PLACEBO_COMPARATOR|Placebo|Participants were randomized to matching placebo to sotagliflozin administered as two tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
62092781|NCT02548793|ACTIVE_COMPARATOR|VSI Kit|Education: CPR Training using the CPR Anytime VSI Kit Individuals will learn chest-compression only CPR (no rescue breaths) using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
62092782|NCT02548793|EXPERIMENTAL|Mobile Application|Education: CPR Training via Mobile App Individuals will learn chest-compression only CPR (no rescue breaths) using a newly developed mobile training application.
62092783|NCT05899049|EXPERIMENTAL|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 18 administrations (up to \~2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
62463935|NCT03292653|EXPERIMENTAL|Sotagliflozin 200 mg|Participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
62463936|NCT03292653|EXPERIMENTAL|Sotagliflozin 400 mg|Participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
62463937|NCT04188106|EXPERIMENTAL|Hydroxyzine and Varenicline|Participants enrolled in the study will take the FDA approved starter kit of varenicline for the first week of medication administration (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7). During the first week, participants will also receive hydroxyzine dosed in a similar manner, 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night. After the first week, participants will receive the FDA-approved dose of varenicline (1 mg twice daily) combined with hydroxyzine, 25 mg in the morning and 50 mg at nighttime. All medications will be dosed orally.
62463938|NCT01010542|ACTIVE_COMPARATOR|ILV-095|
62092784|NCT05899049|EXPERIMENTAL|Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (co-formulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered IV Q6W for up to 18 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
62092785|NCT05899049|ACTIVE_COMPARATOR|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 18 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
62463939|NCT01010542|PLACEBO_COMPARATOR|placebo|
62463940|NCT01860105|ACTIVE_COMPARATOR|75mg MDCO-157|iv
62463941|NCT01860105|ACTIVE_COMPARATOR|150mg MDCO-157|iv
62463942|NCT01860105|ACTIVE_COMPARATOR|300mg MDCO-157|iv
62463943|NCT01860105|ACTIVE_COMPARATOR|300mg PLAVIX|oral
62463944|NCT02167165||Digoxin and AF|Patients consulting the emergency deprtment (ED) for AF and receiving Digoxin treatment
62463945|NCT02747615|OTHER|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
62463946|NCT02747615|ACTIVE_COMPARATOR|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
62463947|NCT06387186|EXPERIMENTAL|Leucine-Enriched Essential Amino Acid powder (LEAA)|Leucine-Enriched Essential Amino Acid powder (LEAA) as an add-on to a classic ketogenic diet (KD)
62656415|NCT00529035|EXPERIMENTAL|Interleukin-2|"Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)"
62656416|NCT02965482|ACTIVE_COMPARATOR|Aerogen Solo|Volumetric method of methacholine challenge testing performed using the Aerogen Solo nebulizer
62092786|NCT01013675|EXPERIMENTAL|1|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
62092787|NCT01013675|ACTIVE_COMPARATOR|2|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
62092788|NCT05049629|EXPERIMENTAL|Eye 1|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
62092789|NCT05049629|ACTIVE_COMPARATOR|Eye 2|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
62092790|NCT05376579||siponimod|patients treated with siponimod
62463948|NCT00773422|EXPERIMENTAL|naltrexone + varenicline|naltrexone (25mg) + varenicline (2mg)
62463949|NCT00773422|EXPERIMENTAL|varenicline|varenicline 2mg
62463950|NCT00773422|PLACEBO_COMPARATOR|placebo|placebo control
62463951|NCT00842595|EXPERIMENTAL|R NIMP|(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5
62656417|NCT02965482|ACTIVE_COMPARATOR|Wright|Two-minute tidal breathing method of methacholine challenge testing performed using the Wright nebulizer
62656418|NCT00870675||ventriculomegaly|Pregnant women carrying a fetus with the ultrasound finding of enlarged ventricles (ventriculomegaly).
62656419|NCT02640209|EXPERIMENTAL|Arm 1|
62656420|NCT01408641|EXPERIMENTAL|Topiramate|Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.
62290620|NCT01752023|EXPERIMENTAL|Cisplatin + Gemcitabine with SUBATM-itraconazole|SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.
62092791|NCT06500949|EXPERIMENTAL|Vagus nerve pulmonary branch block group (V group)|After thoracotomy, under direct thoracoscopic visualization, 2.5 ml of 0.375% ropivacaine was injected in proximity to the main trunk of the pulmonary branches of the vagus nerve.
62290621|NCT01752023|ACTIVE_COMPARATOR|Cisplatin + Gemcitabine|Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
62092792|NCT06500949|PLACEBO_COMPARATOR|Control group (C group)|After thoracotomy, under direct thoracoscopic visualization, 2.5 ml of normal saline was administered in the vicinity of the principal trunk of the pulmonary branches of the vagus nerve.
62656421|NCT01408641|PLACEBO_COMPARATOR|Placebo (Sugar Pill)|Placebo arm will receive matching capsules without topiramate.
62656422|NCT06440512|EXPERIMENTAL|A Chocolate Arm|"Intervention period 1:The group will consume 50 grams of dark chocolate daily for two weeks.~Washout period: Two-weeks~Intervention period 2: The group will consume 40 grams of white chocolate daily for two weeks."
62656423|NCT06440512|EXPERIMENTAL|B Chocolate Arm|"Intervention period 1:The group will consume 40 grams of white chocolate daily for two weeks.~Washout period: Two-weeks~Intervention period 2: The group will consume 50 grams of dark chocolate daily for two weeks"
62656424|NCT05018793|EXPERIMENTAL|Treatment Group|Single intrathecal injection of 100 million cells
62656425|NCT04955756|EXPERIMENTAL|mNGS group|
62656426|NCT04955756|EXPERIMENTAL|PCR group|
62656427|NCT00470548|EXPERIMENTAL|Phase I: Abraxane and Alimta|Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days.
62656428|NCT00470548|EXPERIMENTAL|Phase II: Abraxane and Alimta|Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days.
62092793|NCT04087096|EXPERIMENTAL|Denosumab|Denosumab 60mg subcutaneous injection every 6 months
62290622|NCT01225666|EXPERIMENTAL|Weekly low dose|MOD-4023
62290623|NCT01225666|EXPERIMENTAL|Weekly middle dose|MOD-4023
62290624|NCT01225666|EXPERIMENTAL|Weekly high dose|MOD-4023
62290625|NCT01225666|EXPERIMENTAL|Every-other week dose|MOD-4023
62290626|NCT06528600|EXPERIMENTAL|Hymovis One|Treatment with 4 mL of Hymovis ONE® in the Intra-articular space
62290627|NCT06528600|ACTIVE_COMPARATOR|Monovisc|Treatment with 4 mL of Monovisc™ in the Intra-articular space
62290628|NCT01780792|EXPERIMENTAL|Dance Dance Revolution game play|Dance Dance Revolution video game play
62290629|NCT01780792|NO_INTERVENTION|control|individuals continue usual care for 8 weeks
62308039|NCT04909021|PLACEBO_COMPARATOR|Placebo (Two-dose)|Participants in this arm will receive a single intranasal dose of placebo followed by a second identical dose of placebo 28 days later
62656429|NCT01719328|EXPERIMENTAL|Vinyasa yoga|Group administered 60 minute vinyasa yoga classes delivered twice weekly for 8 weeks
62656430|NCT04861298|ACTIVE_COMPARATOR|Standard of care (SOC)|This arm will receive the standard of care (SOC) for COVID-19 as per the hospital guidelines.
62656431|NCT04861298|EXPERIMENTAL|Quercetin|This arm will receive standard of care + oral Quercetin for two weeks
62656432|NCT02049203|PLACEBO_COMPARATOR|Placebo|Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days.
62656433|NCT02049203|ACTIVE_COMPARATOR|Ataciguat|Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days
62092794|NCT04087096|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection every 6 months
62308040|NCT01088412||Treated|Participants treated with somatropin for improvement of growth
62656434|NCT04853485|ACTIVE_COMPARATOR|Active TMS targeting both cerebellum and right dorsolateral prefrontal cortex.|Subjects identified as with prominent negative symptoms will be randomized into active group, who will receive active rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
62656435|NCT04853485|SHAM_COMPARATOR|Sham TMS targeting both cerebellum and right dorsolateral prefrontal cortex|Subjects identified as with prominent negative symptoms will be randomized into sham group, who will receive sham rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
62092795|NCT03513861|EXPERIMENTAL|Aim 1: Parental FASTER tool training|The goal is to see whether the child's parent/ guardian can be trained in overall severity of illness assessment using the FASTER Tool, to match the performance of a professional.
62092796|NCT03513861|ACTIVE_COMPARATOR|Aim 2: Intervention group|The intervention group parents will be taught the FASTER assessment tool. Intervention group parents will each be asked to monitor their own hospitalized child hourly using the FASTER assessment tool, and put up color-coded flags indicating severity of illness to the healthcare team. Parents will record the frequency of healthcare provider assessments of their child over the 24 hour intervention period.
62656436|NCT04853485|ACTIVE_COMPARATOR|Active TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into active group, who will receive active rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
62656437|NCT04853485|PLACEBO_COMPARATOR|Sham TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into sham group, who will receive sham rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
62656438|NCT04853485|ACTIVE_COMPARATOR|Active deep TMS using Brainways H7 coil targeting ACC|Subjects identified as with positive symptoms will be randomized into active group, who will receive active deep rTMS over ACC using H7 coil.
62656439|NCT04853485|PLACEBO_COMPARATOR|Sham deep TMS using Brainways H7 coil targeting ACC|Subjects identified with positive symptoms will be randomized into sham group, who will receive sham deep rTMS over ACC using H7 coil.
62656440|NCT01806129|ACTIVE_COMPARATOR|Arm A (no intervention)|Patients undergo usual standard practice related to reproductive health.
62656441|NCT01806129|EXPERIMENTAL|Arm B (reproductive health program)|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
61906882|NCT02243462|ACTIVE_COMPARATOR|Pre-op forced air warming|A forced air warmer device (WarmTouch Convective Warming System) will be used to pre-warm patients in holding bay before surgery
61906883|NCT00216996||Burn patients|Receiving standard TPN with or without glutamine enrichment
61906884|NCT00561860|NO_INTERVENTION|1|This pathway represents our standard clinical protocol when a patient has been diagnosed with sleep apnea and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise.
62290630|NCT02853760|EXPERIMENTAL|Outdoor mountain hiking (M)|"First part of the intervention: an uphill walking phase on single trails and forest roads in a sparse forest with view on the mountainous region around Innsbruck for 6 km in around 1.5 hours together with the test leader. Regarding the walking intensity, the participants were instructed to choose a brisk without overspending pace (average speed: 4 km/h).~In the second part of the intervention, the participants were walking downhill on the same track for around 70 minutes back to the starting point to respond to the post-test (average speed: 5.2 km/h)."
62463952|NCT02548403|ACTIVE_COMPARATOR|PEG-Asc|group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
62656442|NCT01420744|EXPERIMENTAL|BT086 infusion|
62656443|NCT01420744|PLACEBO_COMPARATOR|1% Human Albumin infusion|
62656444|NCT02741778|OTHER|Minimally invasive group|"In this group, all manipulations are finished by laparoscopy and thoracoscopy.~1. Horizontal position, undergoing laparoscopy through 5-port method. The sequence: gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes ), gastric tube making, and jejunostomy.~2. Left lateral position, undergoing thoracoscopy through 3-port method. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection, gastro-esophageal anastomosis by using CEEA."
61906885|NCT00561860|EXPERIMENTAL|2|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
61906886|NCT03199755|ACTIVE_COMPARATOR|ACT|"Standard Artemisinin Combination Therapy (ACT) being used as currently approved antimalarial therapy at WHO and manufacturer recommended dosage. The specific ACT used is artemether-lumefantrine (Coartem). Form is scored tablets that each contain 20 mg artemether and 120 mg lumefantrine.~Tablets per dose, are given BID for 3 days as shown below:~Coartem tablets/dose by bodyweight; tablets/day morning and evening for total of 6 doses over 3 days~Body weight (kg) and Tablets: 5 to \<15 kg, 1 tab; 15 to \<25 kg, 2 tabs; 25 to \<35 kg, 3 tabs; 35 kg and over, 4 tabs."
62308041|NCT01088412||Untreated|Untreated participants with presence or history of neoplastic disease evaluated for endocrine or growth disorder or with any SHOX deficiency related disorder
62092797|NCT03513861|NO_INTERVENTION|Aim 2: Control Group|The control group parents will not be taught the FASTER assessment tool. Hence they will not be involved in monitoring their child, nor signaling severity of their child's illness per color-coded flag system. Control group parents will record the frequency of healthcare provider assessments of their child over the 24 hrs enrollment period.
62656445|NCT02741778|OTHER|Open group|"Right lateral position, Traditional thoracotomy through the 7th intercostal incision. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection.~Then,oped the diaphragm,undergoing gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes), gastric tube making, gastro-esophageal anastomosis by using CEEA. Nasointestinal tube is placed for feeding."
62092798|NCT04127565||Pre-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2013 to March 2014.~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units."
62092799|NCT04127565||Post-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2015 to March 2016.~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units.~Additionally analysis of all ambulance calls with telemedical support."
62463953|NCT02548403|ACTIVE_COMPARATOR|PEG-Asc with simethicone|group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
62656446|NCT01694134|ACTIVE_COMPARATOR|Corticoids|A group of patients will receive an intradiscal injection of Hydrocortancyl.
62463954|NCT02493270|EXPERIMENTAL|Adjunctive smoking cessation|non-surgical periodontal therapy and concurrent smoking cessation therapy
62463955|NCT03884088|EXPERIMENTAL|Experimental Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
62463956|NCT03884088|ACTIVE_COMPARATOR|Control Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
62656447|NCT01694134|SHAM_COMPARATOR|Local anaesthetic|A group of patients will receive an intradiscal injection of Lidocaine.
62092800|NCT05315804|EXPERIMENTAL|Amelogenin Group (A)|Amelogenins in gel will be applied in intraosseous periodontal defects, after Minimally Invasive Non Surgical Debridement (MINSD)
62656448|NCT05830747|EXPERIMENTAL|Prednisone group (PG)|Patients receiving a preoperative administration of prednisone 25 mg/os.
62092801|NCT05315804|ACTIVE_COMPARATOR|No-amelogenin Group (B)|Only Minimally Invasive Non Surgical Debridement (MINSD) will be performed
62656449|NCT05830747|PLACEBO_COMPARATOR|Control group (CG)|Patients receiving a preoperative administration of Placebo.
62656450|NCT04673500|EXPERIMENTAL|Propofol-lidocaine through large vein|Eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the antecubital fossa and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
62290631|NCT02853760|ACTIVE_COMPARATOR|Indoor treadmill walking (T)|"To ensure that all physical parameters were simultaneous to the outdoor mountain hiking condition, the distance, the difference in height, the average inclination of the track, and the time needed for the outdoor mountain hiking situation were measured in a pilot study.~First part: uphill walking, inclination: 10%, time: 1.5 hours, and speed: 4 km/h (resulting in 600 m difference in height). In accordance to possible differences in outdoor speed, the participants were allowed to change the treadmill's speed in a small range (3.8 to 4.2 km/h) to adapt to the wording brisk without overspending. Second part of the intervention contained 70 minutes of level walking on the same treadmills (5.2 km/h, 6km)."
62290632|NCT02853760|NO_INTERVENTION|Sedentary control condition (C)|The sedentary control situation was located in a quiet room at the university with access to computers. The participants were allowed to use the computers, to read, and to talk, but had to remain in a sedentary position. To control for possible differences in affective response due to the daytime, the sedentary control condition contained the same timing of the measurements than the intervention condition. Sociodemographic data were collected for 5 to 10 minutes in this condition using a web-based questionnaire.
62290633|NCT03198143|EXPERIMENTAL|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
62463957|NCT02088463|EXPERIMENTAL|Mobilization (manual therapy)|Mobilization (manual therapy) posterior- anterior at the L3 for 2 minutes in addition to the traditional treatment in the form of infra-red and ultrasound. The treatment duration for the three groups was 3 times/week for 4 weeks.
62463958|NCT02088463|PLACEBO_COMPARATOR|placebo mobilization|placebo mobilization applied without force application. The treatment duration for the three groups was 3 times/week for 4 weeks
62463959|NCT02088463|OTHER|Ultrasound and infrared therapy|ultrasound and infrared are a traditional treatment for low back painThe treatment duration for the three groups was 3 times/week for 4 weeks.
62463960|NCT02370719|EXPERIMENTAL|Intervention Group|Mobile application plus standard of care
62463961|NCT02370719|NO_INTERVENTION|Control Group|Standard of care
62656451|NCT04673500|PLACEBO_COMPARATOR|Propofol-lidocaine through small vein|Another eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the dorsum of hand and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
62656452|NCT04740853|EXPERIMENTAL|Sensory Integration Therapy+Special Education|"The therapy program was prepared and applied according to the Ayres theory and based on the basic principles of sensory integration therapy prepared by Parham depending on the evaluation results. Therapy was applied to the intervention group, with a 45-minute session+15 minutes of family information once a week for eight weeks, in addition to the special education sessions they received twice a week in special education institutions. The sensory integration therapy included sensory diet practices and activities consisting of vestibular, tactile, proprioceptive, auditory and visual stimuli.~The intervention group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. In the special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied."
62092802|NCT06290232|EXPERIMENTAL|Fetoscopic Laser Photocoagulation Surgery|Pregnant individuals diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation.
62092803|NCT04590235|EXPERIMENTAL|Selumetinib|All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. Then, selumetinib 25 mg/m\^2 oral twice daily will be administered continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first.
62463962|NCT05037760|EXPERIMENTAL|Arm 1a|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) monotherapy
62463963|NCT05037760|EXPERIMENTAL|Arm 1b|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
62463964|NCT05037760|EXPERIMENTAL|Arm 2a|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) monotherapy
62463965|NCT05037760|EXPERIMENTAL|Arm 2b|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
62463966|NCT01513486|EXPERIMENTAL|Immobilization with NMES|Immobilization with daily NMES
62463967|NCT01513486|PLACEBO_COMPARATOR|Immobilization without NMES|Immobilization without daily NMES
62463968|NCT02171637|EXPERIMENTAL|BIBW 2992|
62463969|NCT05712005||Group 1|Study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times. Next, study subjects will complete up to eight additional neuropsychological assessments, intermittently separated followed by the Cognivue Plus test.
62463970|NCT05712005||Group 2|Study subjects will complete up to eight additional neuropsychological assessments, intermittently separated followed by the Cognivue Plus test. Next, study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times.
61906887|NCT03199755|EXPERIMENTAL|DLA1|"Dried leaf Artemisia annua (DLA) from 0.25-1 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA1x: 5 to \< 15 kg, 1/4 tab; 15-30 kg, 1/2 tab; 1/2\>30 kg, 1 tab."
61906888|NCT03199755|EXPERIMENTAL|DLA2|"Dried leaf Artemisia annua (DLA) from 0.5-2 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA2x: 5 to \< 15 kg, 1/2 tab; 15-30 kg, 1 tab; \>30 kg, 2 tabs."
61906889|NCT02660840|EXPERIMENTAL|0.5 mg Test, then 0.5 mg reference|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first test, then reference)
61906890|NCT02660840|EXPERIMENTAL|0.5 mg reference, then 0.5 mg Test|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first reference, then test)
61906891|NCT02660840|EXPERIMENTAL|1 mg Test, then 1 mg reference|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first test, then reference)
61906892|NCT02660840|EXPERIMENTAL|1 mg reference, then 1 mg Test|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first reference, then test)
61906893|NCT02660840|EXPERIMENTAL|5 mg Test, then 5 mg reference|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first test, then reference)
61906894|NCT02660840|EXPERIMENTAL|5 mg reference, then 5 mg Test|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first reference, then test)
61906895|NCT00588861|ACTIVE_COMPARATOR|Answer® hip stem with Simplex Cement|Femoral stem replacement with Answer® hip stem \& Simplex Bone Cement
61906896|NCT00588861|ACTIVE_COMPARATOR|Answer® hip stem with Palacos Cement|Femoral stem replacement with Answer® hip stem \& Palacos Bone Cement
61906897|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
61906898|NCT05525078|EXPERIMENTAL|Switch Group|Participants in the Switch group will receive a 5-week supply of e-cigarettes.
61906899|NCT05525078|ACTIVE_COMPARATOR|Meds Group|Participants in the Meds Group will receive a 5-week supply of combination nicotine replacement therapy (transdermal nicotine patch and short-acting nicotine lozenge).
61906900|NCT05953441|EXPERIMENTAL|AI-powered group|Participants participated in a 2-hour Virtual Reality Simulation (VRS), which consisted of 2 simulation scenarios. Participants had to perform nursing assessment and management of virtual patient, followed by communicating with an AI virtual doctor.
61906901|NCT05953441|ACTIVE_COMPARATOR|Human-controlled group|Participants participated in a 2-hour Virtual Reality Simulation (VRS), which consisted of 2 simulation scenarios. Participants had to perform nursing assessment and management of virtual patient, followed by communicating with a doctor avatar controlled by the medical student.
61906902|NCT06154577||Obstructive sleep apnea patients|39 obstructive sleep apnea patients with hypoglossal nerve stimulation
61906903|NCT06154577||Healthy controls|15 healthy control participants
61906904|NCT02615626||Group 1|Periodontal healthy
61906905|NCT02615626||Group 2|Gingivitis, Non-surgical Periodontal Treatment
62092804|NCT03610633|EXPERIMENTAL|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
62092805|NCT03610633|PLACEBO_COMPARATOR|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
62092806|NCT06696352|EXPERIMENTAL|Partners4Pain|Community-based program that focuses on evidence based mind-body tools (mindfulness, cognitive behavioral approaches) for pain self-management in addition to pain education and physical exercises.
62290634|NCT03198143|PLACEBO_COMPARATOR|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
62656453|NCT04740853|ACTIVE_COMPARATOR|Special Education|The control group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. Within the scope of special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied.
62656454|NCT05866224|EXPERIMENTAL|Supervised home telerehabilitation program|COVID-19 patients will perform a total of 15 weeks of a telerehabilitation program combined with aerobic and strength exercises using the circuit training methodology. COVID-19 patients will carry out 3 weekly sessions on non-consecutive days to avoid unnecessary overload and maximize the adaptations, completing a total of 45 sessions
62656455|NCT05866224|NO_INTERVENTION|non-supervised control group|COVID-19 patients that will not perform the telerehabilitation program
62656456|NCT02788487|ACTIVE_COMPARATOR|CPAP1 use and TRD 2use|Wash-in period 1 week and Continuous positive airway pressure (CPAP) is used for 3 weeks then wash-out 1 week and Tongue retaining device (TRD) is used for another 3 weeks
62656457|NCT02788487|EXPERIMENTAL|TRD1 use and CPAP2 use|Wash-in period 1 week and Tongue retaining device (TRD) is used for 3 weeks then Wash-out period 1 week and Continuous positive airway pressure (CPAP) is used for another 3 weeks
62656458|NCT02442128|ACTIVE_COMPARATOR|Group1|comparison of different dosages of drugs ( Fentanyl / Propofol), fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
62092807|NCT06696352|ACTIVE_COMPARATOR|Keys to Wellbeing|Community-based program that focuses on general health and well-being education for pain self-management in addition to pain education and physical exercises.
62092808|NCT06566261|EXPERIMENTAL|ABA-101 Dose 1|Low Dose ABA-101
62092809|NCT06566261|EXPERIMENTAL|ABA-101 Dose 2|High Dose ABA-101
62092810|NCT04947969|EXPERIMENTAL|Rear laser acupuncture group|Patients in the Real laser acupuncture group will receive real laser pen irradiation.
62092811|NCT04947969|SHAM_COMPARATOR|Shame laser acupuncture group|Patients in the Shame laser acupuncture group will receive shame laser pen irradiation.
62092812|NCT04818320|EXPERIMENTAL|Favipiravir|Favipiravir treatment group (with standard of care),
62092813|NCT04818320|NO_INTERVENTION|Control|No favipiravir given. Standard of care only
62092814|NCT01576237||healthy apheresis donors|healthy blood donors for blood cell aphereses
62092815|NCT06698016|EXPERIMENTAL|Period 1: Nemtabrutinib|Participants receive a single dose of nemtabrutinib followed by a protocol specified wash-out period.
62092816|NCT06698016|EXPERIMENTAL|Period 2: Nemtabrutinib + Efavirenz|Participants receive oral doses of efavirenz once daily on Days 1 to 24 with a single oral dose of nemtabrutinib given with efavirenz on Day 11.
62092817|NCT00415155|EXPERIMENTAL|A|
62656459|NCT02442128|ACTIVE_COMPARATOR|Group 2|comparison of different dosages of drug ( Fentanyl / Propofol) ,fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
62656460|NCT02385318|EXPERIMENTAL|Test Product|Ingenol Mebutate
62656461|NCT02385318|ACTIVE_COMPARATOR|Reference product|Ingenol Mebutate
62656462|NCT02385318|PLACEBO_COMPARATOR|Placebo product|Placebo gel
62656463|NCT02795143|EXPERIMENTAL|Isotretinoin|"Isotretinoin will be given at the following dosage:~Dosing will be as listed on the table below.~Weight in Kg Total Daily Dose 40-49 Kg 40mg 50-89 Kg 80mg 90-150 Kg 120mg"
62656464|NCT02795143|PLACEBO_COMPARATOR|Placebo|Subjects will be given placebo capsules twice a day.
62656465|NCT01465269|EXPERIMENTAL|GIST Intervention|
62656466|NCT01465269|ACTIVE_COMPARATOR|Alternative Intervention|
62290635|NCT03198143|EXPERIMENTAL|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
62656467|NCT01260948|EXPERIMENTAL|Investigational Test Product|Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg
62656468|NCT01260948|ACTIVE_COMPARATOR|Reference Listed Drug|Aricept® Orally Disintegrating Tablets, 10 mg
62737444|NCT06280638|EXPERIMENTAL|Virtual stenting-guided incremental optimization strategy (VIOS)|"Virtual Stenting analysis is conducted based on pre-PCI CCTA angiograms by Imaging-Heart Team to determine simulated optimal treatment strategy according VIOS protocol. If the patient is assigned to the VIOS, the result of virtual stenting and recommended treatment strategy will be disclosed to the operator. The operator will then follow the recommended strategy to attempt to obtain the target optimal post-PCI FFR result. Blinded FFR must be obtained after PCI."
62092818|NCT04569461|EXPERIMENTAL|Single Arm|Subjects with unfavorable localized prostate cancer will be enrolled.This is a single arm, phase II study of pembrolizumab (Keytruda), SBRT, and Short-term Androgen Deprivation Therapy (STADT), known together as trimodality therapy, followed by radical prostatectomy 8 weeks after SBRT.
62092819|NCT03316443|ACTIVE_COMPARATOR|(Group G)|Glidescope group: 45 patients will be intubated by Glidescope (Group G). For endotracheal intubation with glidoscope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.
62656469|NCT00208975|ACTIVE_COMPARATOR|Fludarabine and Mitoxantrome followed by GM-CSF and Rituximab|"Initial patients (n=9) received fludarabine (25 mg/m2 IV) and mitoxantrone (10 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m2 IV) and cyclophosphamide (250 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8. All patients received dditional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
62656470|NCT05243706|NO_INTERVENTION|Control group|30 patients will receive Vincristine 1.5 mg/m2 (maximum: 2 mg) or Vinblastine 6 mg/m2 according to treatment protocol.
62656471|NCT05243706|EXPERIMENTAL|Loratadine group|30 patients will receive One tablet 10 mg orally once daily starting with vincristine or vinblastine administration for three cycles
62656472|NCT05243706|EXPERIMENTAL|diosmin 450mg / hesperidin 50 mg group|30 patients will receive 50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet orally twice daily starting with vincristine or vinblastine administration for three cycles
62656473|NCT04826562|EXPERIMENTAL|dolutegravir/lamivudine|dolutegravir/lamivudine
62656474|NCT01911091|EXPERIMENTAL|Group 1 - Regular exercise|Alternate interval training and aerobic training and exercise
62656475|NCT01911091|NO_INTERVENTION|Group 2 - Athlete exercise|Athletes are not given any intervention
62656476|NCT01911091|NO_INTERVENTION|Group 3 - Obese No Exercise|The Obese group will not receive intervention
62656477|NCT04141605||SherpaPak CTS Patients|Patients whose donor heart was transported with the SherpaPak CTS
62656478|NCT04141605||Standard Transport Patients|Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years
62656479|NCT04387968||agents in contact with the public|patients working with children, policemen, desk office
62656480|NCT04387968||agents with no contact with the public|administrative workers
62656481|NCT01060501|ACTIVE_COMPARATOR|5-FU|Standard arm Systemic drug administration of 5-FU (intravenous)
62656482|NCT01060501|EXPERIMENTAL|5-FU + folinic acid|Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
62656483|NCT01060501|EXPERIMENTAL|5-FU + Interferon-alpha|Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
62656484|NCT03753906|EXPERIMENTAL|Osmed® hydrogel expander implantation|Implantation of Osmed® hydrogel expander was done in subperiosteal positions using the pouch technique in the mandibular anterior region.
62656485|NCT01680614||At Risk Adult Drinkers|CASI
62656486|NCT04945811|EXPERIMENTAL|Interlukein 6 and procalcitonin|Interlukein 6 and procalcitonin levels in COVID 19 patients
62656487|NCT00817063|EXPERIMENTAL|Alitretinoin|Patients will receive alitretinoin 30mg capsule for up to 24 weeks
62092820|NCT03316443|EXPERIMENTAL|(Group M)|Macintosh group: 45 patients will be intubated by Macintosh laryngoscope (Group M).The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first, the laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced
62092821|NCT01868867|EXPERIMENTAL|Intervention|Receives on line training and text messaging for treatment
62092822|NCT01868867|NO_INTERVENTION|Treatment as Usual|Treatment as usual (TAU) for similar duration as intervention group. Intervention provided following TAU period.
62656488|NCT00817063|EXPERIMENTAL|Placebo|Patients will receive placebo 30mg capsule for up to 24 weeks
62656489|NCT05528848|EXPERIMENTAL|Opioid Use Disorder and Medication Assisted Treatment (OUD+/MAT-)|"Study imaging will be performed using a whole-body PET/CT scanner.~Each participant will receive ≤ 10 mCi of \[11C\]carfentanil intravenously (approximate range for most studies is anticipated to be 2-10 mCi ).~Participants will undergo dynamic PET/CT imaging of the brain and body. The scan will take approximately 90 minutes for each scan session. Study imaging will be performed using a whole-body PET/CT scanner.~For the first study scan, participants will receive \[11C\]carfentanil radiotracer alone. For the second study scan approximately 13 mcg/kg of naloxone will be administered by IV prior to the \[11C\]carfentanil injection. If both scans are done the same day, then the naloxone injection will be given before the second scan session and there will be a break between the two scan sessions of approximately 3 hours."
62737445|NCT06280638|SHAM_COMPARATOR|Standard angiographic strategy|"Virtual Stenting analysis is conducted based on pre-PCI CCTA angiograms by Imaging-Heart Team to determine simulated optimal treatment strategy according VIOS protocol. If the patient is assigned to the standard angiographic strategy, the result of virtual stenting and recommended treatment strategy will be blinded to the operator. The operator will then perform PCI based on international guidelines, local protocols and practice. Blinded FFR must be obtained after PCI."
62092823|NCT04692181|PLACEBO_COMPARATOR|Placebo + IV Meropenem|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
62092824|NCT04692181|ACTIVE_COMPARATOR|SYN-004 + IV Meropenem|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
62092825|NCT04692181|PLACEBO_COMPARATOR|Placebo + IV Piperacillin/Tazobactam|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
62092826|NCT04692181|ACTIVE_COMPARATOR|SYN-004 + IV Piperacillin/Tazobactam|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
62092827|NCT04692181|PLACEBO_COMPARATOR|Placebo + IV Cefepime|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
62092828|NCT04692181|ACTIVE_COMPARATOR|SYN-004 + Cefepime|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
62656490|NCT05528848|EXPERIMENTAL|Opioid Use Disorder Only (OUD+/MAT-)|"Study imaging will be performed using a whole-body PET/CT scanner.~Each participant will receive ≤ 10 mCi of \[11C\]carfentanil intravenously (approximate range for most studies is anticipated to be 2-10 mCi ).~Participants will undergo dynamic PET/CT imaging of the brain and body. The scan will take approximately 90 minutes for each scan session. Study imaging will be performed using a whole-body PET/CT scanner.~For the first study scan, participants will receive \[11C\]carfentanil radiotracer alone. For the second study scan approximately 13 mcg/kg of naloxone will be administered by IV prior to the \[11C\]carfentanil injection. If both scans are done the same day, then the naloxone injection will be given before the second scan session and there will be a break between the two scan sessions of approximately 3 hours."
62737446|NCT06300749|EXPERIMENTAL|Chiropractic Cervical Manipulation Group (CCMG)|Patients in both groups were placed in supine position and manipulation was applied to patients in the chiropractic cervical manipulation group.
62092829|NCT06162819|EXPERIMENTAL|GroupA|Amitriptyline group will be assessed at baseline and will be followed up at 6th week after treatment and at 12th week after treatment
62092830|NCT06162819|EXPERIMENTAL|Group B|Flunarizine group will be assessed at baseline and will be followed up at 6th week after treatment and at 12th week after treatment
62092831|NCT02616354|ACTIVE_COMPARATOR|Group I|"Group I received intravenous imipenem/cilastatin 1 g every 8 h (q8h) or 0.5g every 6 h (q6h) with optimized two-step infusion therapy (OTIT; rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours) Group I is more informative than Group II from PK parameters(%T\>MIC,AUC/MIC)."
62092832|NCT02616354|PLACEBO_COMPARATOR|Group II|"group II received intravenous imipenem/cilastatin 1g q8h or 0.5g q6h with extended infusion therapy (2-hours continuous infusion in a constant speed).~Group I is more informative than Group II from PK parameters(%T\>MIC,AUC/MIC)."
62290636|NCT03198143|PLACEBO_COMPARATOR|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
62737447|NCT06300749|SHAM_COMPARATOR|Control Group (CG)|Patients in both groups were placed in supine position and manipulation was applied to patients in the chiropractic cervical manipulation group.
62092833|NCT02271594|ACTIVE_COMPARATOR|Intervention|Intensive education on injection technique
62092834|NCT02271594|PLACEBO_COMPARATOR|Control|Standard education on injection technique
62290637|NCT01903265|EXPERIMENTAL|TNX-102 SL 2.8 mg|Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
62290638|NCT01903265|PLACEBO_COMPARATOR|Placebo|Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
62737448|NCT04497103|ACTIVE_COMPARATOR|control|The traditional rehabilitation program conducted for 40-min sessions, three times per week for 8 weeks for all children.
62092835|NCT06278961||Conrols - health term infants|Infants, less than 10 weeks of age at enrolment who were born full-term with typical development, birthweight \>2500g
62092836|NCT06278961||Bronchopulmonary dysplaspia|A history of bronchopulmonary dysplasia, defined as having a preterm birth (\<33 weeks' gestational age) and requiring supplemental oxygen beyond 36 weeks' gestational age
62092837|NCT06278961||Neonatal encephalopathy|term born infants who required hypothermic cooling treatment or had a diagnosis of hypoxic ischemic encephalopathy
62092838|NCT06278961||Congenital anomalies|Congenital anomalies of any kind eg cardiac, musculoskeletal, gastrointestinal
62092839|NCT06278961||Preterm birth|Preterm birth \<36 weeks gestational age
62092840|NCT06278961||Multiple gestation|One of a multiple gestation pregnancy
62092841|NCT06021990|EXPERIMENTAL|Clopidogrel group|The clopidogrel group will receive the intervention under study (clopidogrel 75mg once daily post-meal) for the study period along with the standard of care treatment as approved by the hospital based on national and international guidelines.
62290639|NCT00355121|EXPERIMENTAL|Group 1|DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
62092842|NCT06021990|NO_INTERVENTION|Standard of Care|The standard of care will receive treatment as approved by the hospital based on national and international guidelines.
61906906|NCT02615626||Group 3|Chronic Periodontitis, Non-surgical Periodontal Treatment
62290640|NCT00355121|EXPERIMENTAL|Group 2|DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
62290641|NCT00355121|EXPERIMENTAL|Group 3|Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
62290642|NCT06260592||intensive care nurses|Ethical compliance and humanistic care of intensive care nurses.
62290643|NCT00623519||1|Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole
62290644|NCT02318784|EXPERIMENTAL|Carfilzomib|"Carfilzomib will be administered as intravenous (IV) infusion over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of each 28-day cycle.~Cycle 1: First two doses of Carfilzomib 20 mg/m2 IV; subsequent doses at 56 mg/m2 IV~Cycle 2 onwards: Carfilzomib 56 mg/m2 IV"
61906907|NCT02962843|EXPERIMENTAL|IY TCM|Incredible Year (IY) Teacher Classroom Management (TCM) training, 6 full-day workshops (42 hours)
62092843|NCT03748264|ACTIVE_COMPARATOR|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant. Therapy information is available continuously to site staff personnel in the standard care arm.
62092844|NCT03748264|EXPERIMENTAL|DreamMapper Application|The DreamMapper Application group will receive the site's therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. Participants in this group will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously as well
62092845|NCT03748264|EXPERIMENTAL|DreamMapper Application with Therapist Assist|The DreamMapper Application wit Therapist Assist group will not receive the site's therapy initiation standard of care but will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, and their Philips Respironics mask. and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously as well
62092846|NCT04515784|EXPERIMENTAL|Active|Active arm- START-PTSD
62092847|NCT04761393||Patients with emphysema and eosinophilia in blood and sputum|blood eosinophils ≥300 cells/μL and sputum eosinophils \>3%
62656491|NCT05528848|EXPERIMENTAL|Healthy Controls (OUD-)|"Study imaging will be performed using a whole-body PET/CT scanner.~Each participant will receive ≤ 10 mCi of \[11C\]carfentanil intravenously (approximate range for most studies is anticipated to be 2-10 mCi ).~Participants will undergo dynamic PET/CT imaging of the brain and body. The scan will take approximately 90 minutes for each scan session. Study imaging will be performed using a whole-body PET/CT scanner.~For the 1st study scan, participants will receive \[11C\]carfentanil radiotracer alone. For the 2nd study scan approximately 13 mcg/kg of naloxone will be administered by IV prior to the \[11C\]carfentanil injection. If both scans are done the same day, then the naloxone injection will be given before the 2nd scan and there will be a break between the two scans of approximately 3 hours. For the optional 3rd study scan 4 mg capsule or 30 mL solution standard adult dose of loperamide hydrochloride will be given orally 45-75 minutes prior to the\[11C\]carfentanil injection."
62656492|NCT04516876|EXPERIMENTAL|Camp-based bimanual intensive training(BIT)|
62656493|NCT03499132||General anesthesia (with opioids)|orthopedic surgery plus general anesthesia
62656494|NCT03499132||Epidural anesthesia (without opioids)|orthopedic surgery plus epidural anesthesia (without opioids use)
62656495|NCT03499132||Subarachnoid anesthesia (with opioids)|orthopedic surgery plus subarachnoid anesthesia (plus intrathecal opioid)
62656496|NCT03499132||Regional anesthesia (without opioids)|orthopedic surgery plus regional anesthesia (peripheral nerve block, continous or single shot, without opioid use)
62656497|NCT02499562|EXPERIMENTAL|Hydronidone(180mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 2 capsules each time; with co-administration of placebo capsule, three times a day, 2 capsules each time, namely the daily dose of the investigational product is 180mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
62656498|NCT02499562|EXPERIMENTAL|Hydronidone(270mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 3 capsules each time; with co-administration of placebo capsule, three times a day, 1 capsules each time, namely the daily dose of the investigational product is 270mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
62656499|NCT02499562|EXPERIMENTAL|Hydronidone(360mg) & Entecavir|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 4 capsules each time; namely the daily dose of the investigational product is 360mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
62656500|NCT02499562|EXPERIMENTAL|Entecavir & Placebo(360mg)|placebo capsule 30mg/capsule placebo capsule, three times a day, 4 capsules each time. The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
62656501|NCT05395507|ACTIVE_COMPARATOR|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
62656502|NCT05395507|EXPERIMENTAL|Pegylated Interferon Alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
62656503|NCT06125418|EXPERIMENTAL|Customized group|patients who received customized healing abutments following implant placement. customized healing abutments will be fabricated with different macrogeometry and different emergence angle
62656504|NCT06125418|EXPERIMENTAL|Standard group|patients who received standard titanium healing abutments following implant placement
62656505|NCT00846599||1|High omega-3
62656506|NCT00846599||2|High saturated fat
62092848|NCT04761393||Patients with emphysema and paucicellular inflammation|sputum neutrophils \<65% and eosinophils \<3%
62092849|NCT04761393||Patients with emphysema and sputum neutrophilia|sputum neutrophils \>65% and sputum eosinophils \< 3%
62656507|NCT02420574|ACTIVE_COMPARATOR|ALB-BENDEX|albendazole, 400 mg, single oral dose, (BENDEX)
61906908|NCT02962843|NO_INTERVENTION|Comparison|No Incredible Year (IY) Teacher Classroom Management (TCM) training.
61906909|NCT03700684|EXPERIMENTAL|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
62092850|NCT03267147||antiCCP positive|"Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis~no intervention is given"
62092851|NCT03267147||antiCCP negative|Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
62290645|NCT01845545|NO_INTERVENTION|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
62656508|NCT02420574|ACTIVE_COMPARATOR|ALB-OVIS|albendazole, 400 mg, single-oral dose, (OVIS)
62092852|NCT05457842|EXPERIMENTAL|ASP5354 0.2 mg|Participant received a single dose of 0.2 milligrams (mg) intradermal injection of ASP5354 on day 1.
62092853|NCT05465694|ACTIVE_COMPARATOR|2-minute-time interval of per oral 24% sucrose|For infants in the 2-minute-time interval of per oral 24% sucrose was given prior to the heel lance intervention.
62290646|NCT01845545|EXPERIMENTAL|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
61906910|NCT03700684|EXPERIMENTAL|SpeechVive|Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
61906911|NCT03700684|ACTIVE_COMPARATOR|Control|Persons with Parkinsons disease do not receive voice intervention
61906912|NCT05141877|EXPERIMENTAL|Propofol Group|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
61906913|NCT05141877|EXPERIMENTAL|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
61906914|NCT05272345|EXPERIMENTAL|Fibromyalgia status before sexual therapy/ Fibromyalgia condition after sex therapy|"* Women with sexual dysfunction (FSFI score \< 26.55) in reproductive age (15-49 years) followed up with a diagnosis of fibromyalgia~* Women with sexual dysfunction (FSFI score \< 26.55) in reproductive age (15-49 years) followed up with a diagnosis of fibromyalgia and who were reevaluated for fibromyalgia after sexual therapy was given"
62092854|NCT05465694|ACTIVE_COMPARATOR|no time interval of per oral 24% sucrose|In no time interval of sucrose was given immediately prior to heel lance intervention.
62290647|NCT00348140|EXPERIMENTAL|Arm 1|Rosiglitazone Extended Release 2mg OD
62463971|NCT05712005||Group 3|Study subjects will complete the Cognivue Plus test followed by completing up to eight additional neuropsychological assessments, intermittently separated. Next, study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times.
62463972|NCT05761626||Patients with MP < 17 j/min|Patients with acute respiratory distress syndrome with MP \< 17 j/min
62463973|NCT05761626||Patients with MP ≥ 17 j/min|Patients with acute respiratory distress syndrome with MP ≥ 17 j/min
62656509|NCT02335281|EXPERIMENTAL|Standardized FMT|The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.
62463974|NCT03149653|EXPERIMENTAL|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
62463975|NCT03149653|ACTIVE_COMPARATOR|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
62656510|NCT02335281|ACTIVE_COMPARATOR|Mesalazine|This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.
62092855|NCT04491617|ACTIVE_COMPARATOR|Standard Opioid Protocol (Control)|Standard postoperative medications (opioids and non-opioids) are prescribed upon discharge after surgery
62092856|NCT04491617|EXPERIMENTAL|Restrictive Opioid Protocol (Intervention)|Only non-opioid analgesics (i.e. ibuprofen and acetaminophen) are prescribed upon discharge after surgery. Patients are allowed to request an opioid prescription if they so desire
62092857|NCT01767909|EXPERIMENTAL|Insulin (Humulin® R U-100)|120 subjects will take two daily doses of INI (20 IU bid for a total daily dose of 40 IU) approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
62290648|NCT00348140|EXPERIMENTAL|Arm 2|Rosiglitazone Extended Release 8mg OD
62290649|NCT00348140|PLACEBO_COMPARATOR|Arm 3|Placebo
62290650|NCT05059990|EXPERIMENTAL|Low Intensity Aerobic Exercises Group|stationary cycle for aerobic exercise
62290651|NCT05059990|ACTIVE_COMPARATOR|Active Exercises Group|Upper and lower limb range of Motion (ROM) \& stretching exercises uses in active exercise group
62290652|NCT01106547|EXPERIMENTAL|Methylprednisolone|
62290653|NCT01106547|PLACEBO_COMPARATOR|placebo/sodium chloride|
62290654|NCT01482533||Revision Total Hip Arthroplasty|
62290655|NCT01482533||Revision Total Knee Arthroplasty|
62656511|NCT00778050|EXPERIMENTAL|1|amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited
62656512|NCT00778050|ACTIVE_COMPARATOR|2|Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals (600mg dose)
62290656|NCT04376450|EXPERIMENTAL|Nonincised Papillae Surgical Approach|Nonincised papillae surgical approach is a papillae preservation technique, where an apical approach is carried out, without incisions or disinsertion of tissues at the level of the papillae or marginal tissues.
62290657|NCT04376450|ACTIVE_COMPARATOR|Entire Papilla Preservation Technique|Entire Papilla preservation technique is a tunnel-like procedure to preserve the defect associated papilla
62656513|NCT06067919|NO_INTERVENTION|usual care|
62656514|NCT06067919|EXPERIMENTAL|use of a decision tree to guide antibiotic prophylaxis prescription|
62656515|NCT00415467|EXPERIMENTAL|GliaSite Radiation Therapy System (RTS)|Surgical removal of brain tumor followed by GliaSite RTS targeted brachytherapy to the specific brain tumor site
62656516|NCT04976374|ACTIVE_COMPARATOR|Group A|Patients of group A will start dexmedetomidine (precedex 100 ug lmL, Hospira) infusion 0.4 ug {Kg}h after bolus of 0.5 ug 1 kg intravenously over 10 min
62290658|NCT03137979|EXPERIMENTAL|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
62290659|NCT03137979|EXPERIMENTAL|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
62290660|NCT03137979|OTHER|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
62290661|NCT05987748|EXPERIMENTAL|Morning exercise|Individuals will exercise train at 8 AM three times per week for 12 weeks.
62656517|NCT04976374|PLACEBO_COMPARATOR|Group B|Group B will recive a bolus of saline then saline infusion identical to group A
62656518|NCT04229823||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
62092858|NCT01767909|PLACEBO_COMPARATOR|Placebo|120 subjects will take two daily doses of placebo approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
62290662|NCT05987748|EXPERIMENTAL|Evening exercise|Individuals will exercise train at 8 PM three times per week for 12 weeks.
62290663|NCT03591900|ACTIVE_COMPARATOR|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
62092859|NCT04096157|EXPERIMENTAL|Isavuconazonium sulfate IV solution then capsules|Participants will first receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 2.
62463976|NCT03149653|NO_INTERVENTION|Comparator3|Healthy Control
62463977|NCT04092647|EXPERIMENTAL|ashwagandha|Ashwagandha
62656519|NCT04229823||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
62290664|NCT03591900|ACTIVE_COMPARATOR|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
62290665|NCT04727541|EXPERIMENTAL|Neoadjuvant therapy with Bintrafusp alfa|1200 mg of Bintrafusp alfa will be administered by intravenous infusion every 2 weeks for a total of 2 dosages (Q2W). Subsequently, the surgery will be performed.
62092860|NCT04096157|EXPERIMENTAL|Isavuconazonium sulfate capsules then IV solution|Participants will first receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 2.
62463978|NCT04092647|PLACEBO_COMPARATOR|placebo|Placebo
62092861|NCT00522184|EXPERIMENTAL|1|patient receiving etanercept intra-articular injection
62092862|NCT00522184|ACTIVE_COMPARATOR|2|patient receiving steroid intra-articular injection
62092863|NCT03571568|EXPERIMENTAL|BI-1206 IV|BI-1206 IV Standard 3+3 Dose-Escalation Design
62092864|NCT03571568|EXPERIMENTAL|BI-1206 SC|BI-1206 SC Adaptive Dose Escalation Design (Bayesian logistic regression model (BLRM)
62092865|NCT00602901|EXPERIMENTAL|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
62463979|NCT03326271||Lubinus SP2 stem|Patients treated with a cemented Lubinus SP2 stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
62463980|NCT03326271||Exeter stem|Patients treated with a cemented Exeter stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
62463981|NCT04336696|ACTIVE_COMPARATOR|Comparison between the studied groups regarding management.|The postoperative RAI scan after 1 month, showed a positive residual tumour in lateral LN in 70 patients in the controlled group and 13 patients in Group II, 8 patients in group III. In group I, Patients with residuals were submitted to RAI ablation.
62463982|NCT04336696|OTHER|Recurrence free survival|patients with total thyroidectomy only had shorter recurrence free survival
62463983|NCT01581450|EXPERIMENTAL|Tested drug|Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
62463984|NCT01581450|ACTIVE_COMPARATOR|Gas Active control|Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
62463985|NCT00685477|ACTIVE_COMPARATOR|Experimental Sequence ABC|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
62656520|NCT04229823||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
62092866|NCT00602901|EXPERIMENTAL|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
62092867|NCT00602901|ACTIVE_COMPARATOR|Usual Medical Care|Usual medical care - (Celebrex, Aleve, Bextra, Naproxen)
62092868|NCT00733460|EXPERIMENTAL|BF-PET|
62463986|NCT00685477|ACTIVE_COMPARATOR|Experimental Sequence ACB|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
62656521|NCT05504525|ACTIVE_COMPARATOR|Fascia iliaca block for postoperative pain management in hip arthroplasty|
62656522|NCT05504525|ACTIVE_COMPARATOR|Quadratus lumborum block for postoperative pain management in hip arthroplasty|
62656523|NCT01446185|OTHER|a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population|
62092869|NCT05841160|EXPERIMENTAL|200 mg ecopipam HCL|Single 200 mg dose of ecopipam HCL given as 2 x 100 mg ecopipam HCL oral tablets and 4 placebo oral tablets
62092870|NCT05841160|EXPERIMENTAL|600 mg ecopipam HCL|Single 600 mg dose of ecopipam HCL given as 6 x 100 mg ecopipam HCL oral tablets
62092871|NCT05841160|ACTIVE_COMPARATOR|400 mg moxifloxacin|Single 400 mg dose of moxifloxacin given as 1 x 400 mg oral tablet
62092872|NCT05841160|PLACEBO_COMPARATOR|Placebo|Single oral dose of 6 x placebo tablets
62092873|NCT06695728|EXPERIMENTAL|Hybrid Assistive Limb Group|exoskeleton
62092874|NCT04569214|PLACEBO_COMPARATOR|A - Placebo Control|4 tablets of placebo
62656524|NCT02001883|ACTIVE_COMPARATOR|Association low-dose statin and nutraceuticals|Patients will receive the association between low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin) and a commercially available nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
62092875|NCT04569214|EXPERIMENTAL|B - PAZ320 Low Dose|2 tablets of PAZ320 and 2 tablet of placebo
62463987|NCT00685477|ACTIVE_COMPARATOR|Experimental Sequence BAC|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
62463988|NCT00685477|ACTIVE_COMPARATOR|Experimental Sequence BCA|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
62092876|NCT04569214|EXPERIMENTAL|C - PAZ320 High Dose|4 tablet of PAZ320
62092877|NCT06697769|EXPERIMENTAL|Virtual Reality|Individual standard breastfeeding education was provided. After the training, they experienced the first breastfeeding simulation in a hospital environment for 5 minutes with virtual reality glasses. A week later (37. during the gestational week), they experienced the second breastfeeding simulation in a home environment for 5 minutes with virtual reality glasses. They completed the Prenatal Breastfeeding Self-efficacy Scale (final test). Finally, 1 after giving birth. and 2. they completed the Primiparous Breastfeeding Motivation Scale between months. Opinions were obtained from pregnant women who wanted to express their opinions about the virtual reality glasses breastfeeding simulation experiences.
62092878|NCT06697769|NO_INTERVENTION|Control|Before starting the study, pregnant women who will be included in the control group according to the inclusion criteria and randomization were informed by the researcher about the study. At the beginning of the study, the control group (36. during the week of pregnancy) pregnant women filled out the Socio-Demographic and Pregnancy Information Form, Prenatal Breastfeeding Self-efficacy Scale (pre-test). Then, individual standard breastfeeding training was given. A week later (37. during the week of pregnancy), they completed the Prenatal Breastfeeding Self-efficacy Scale (final test). Finally, 1 after giving birth. and 2. they completed the Primiparous Breastfeeding Motivation Scale between months.
62092879|NCT01077245|EXPERIMENTAL|MIYA-BM|MIYA-BM Fine Granules (CBM588)
62092880|NCT01077245|PLACEBO_COMPARATOR|Placebo|Placebo Fine Granules (without CBM588)
62092881|NCT03163992|EXPERIMENTAL|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
62092882|NCT01072929|EXPERIMENTAL|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
62463989|NCT00685477|ACTIVE_COMPARATOR|Experimental Sequence CAB|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
62463990|NCT00685477|ACTIVE_COMPARATOR|Experimental Sequence CBA|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
62656525|NCT02001883|ACTIVE_COMPARATOR|Low-dose statin|Patients will receive low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin)
62656526|NCT02238366||Prostate cancer patients|Patients recently diagnosed with prostate cancer requiring ADT.
62656527|NCT03284099|EXPERIMENTAL|intervention|ACEIs or ARBs will be switch to be taken before bedtime
62656528|NCT03284099|ACTIVE_COMPARATOR|control|ACEIs or ARBs will be taken in the morning as usual
62656529|NCT04055883|EXPERIMENTAL|DA-1229 5mg|Oral administration of DA-1229 5mg tablet once a day
62656530|NCT04055883|EXPERIMENTAL|DA-1229 10mg|Oral administration of DA-1229 10mg tablet once a day
62656531|NCT04055883|PLACEBO_COMPARATOR|DA-1229 Placebo|Oral administration of DA-1229 Placebo tablet once a day
62656532|NCT01423669||Community dwelling adult population|
62656533|NCT05522478||ADHD group|Children who were diagnosed with ADHD for the first time were classified in the ADHD group (n=33)
62092883|NCT01072929|EXPERIMENTAL|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
62092884|NCT01072929|PLACEBO_COMPARATOR|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
62656534|NCT05522478||treatment group|children with ADHD who were treated with MPH for a minimum of 3 months were classified in the treatment group (n=32)
62656535|NCT05522478||control group|typically developing children were classified in the third-the control group (n=20)
62656536|NCT02750423|ACTIVE_COMPARATOR|DHCA+RCP|Participants undergoing ascending aortic and hemiarch replacement will receive deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP).
62656537|NCT02750423|ACTIVE_COMPARATOR|MHCA+uSACP|Participants undergoing ascending aortic and hemiarch replacement will receive moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA+uSACP).
62092885|NCT05256043||Target Population|Adult patients age ≥ 18 admitted to the Stamford Hospital ICU between 9/14/11 and 11/30/19 with HbA1c available on admission and at least 4 blood glucose (BG) tests during ICU stay. Two groups were created; patients with previously undiagnosed diabetes (NDDM) compared to those with known diabetes (KDM) at the time of admission to the intensive care unit (ICU).
62092886|NCT05688371|ACTIVE_COMPARATOR|standard dose morphine|children will receive 0.05 mg morphine /kg.as a bolus dose dissolved in 50 ml normal saline and 10 microgram/kg continuous infusion
62092887|NCT05688371|ACTIVE_COMPARATOR|low dose morphine and dexmedetomidine|children will receive 0.02 mg morphine /kg bolus dose plus 0.2 µg/kg dexmedetomidine dissolved in 50 ml normal saline and10 microgram/kg continuous infusion .
62092888|NCT01664234|EXPERIMENTAL|laryngoscopy with simultaneous insufflation of oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
62092889|NCT01664234|PLACEBO_COMPARATOR|laryngoscopy without simultaneous oxygen insufflation|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
62092890|NCT06697184|EXPERIMENTAL|Part 1: Schedule Calibration|Participants will receive zanubrutinib monotherapy with fixed duration, followed by combination sonrotoclax with zanubrutinib at protocol-defined ramp-up schedules until target daily dose will be reached.
62656538|NCT05357495|EXPERIMENTAL|frustration and control fMRI tasks|all subjects complete one scanning session with frustration induction and one scanning session with the control task.
62656539|NCT01682031|PLACEBO_COMPARATOR|Arm I (placebo, cisplatin, and radiotherapy)|Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
62656540|NCT01682031|EXPERIMENTAL|Arm II (selenomethionine, cisplatin, and radiotherapy)|Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.
62092891|NCT06697184|EXPERIMENTAL|Part 2: Schedule Expansion|Participants will receive zanubrutinib monotherapy with fixed duration, followed by combination sonrotoclax with zanubrutinib at ramp-up schedules as determined in Part 1.
62092892|NCT01806415|EXPERIMENTAL|Fenobam 50 mg|Treatment regimen 1: Fenobam \[1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate\], oral administration of one 50 mg gelatin capsule.
62463991|NCT01425710||Pheochromocytoma Group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
62656541|NCT02322996||open label|After the surgery and the onset of moderate-severe pain, QST and PROMIS questionnaires will be repeated. Throughout these procedures, patients will rate their pain perception using a numeric rating scale. Approximately 2-3 hours after surgery at the onset of moderate pain, the rescue analgesic (toradol) will be administered via intramuscular injection. Again, QST and PROMIS protocols will be repeated after the drug is given and when patients report pain relief. A standard naproxen dose of 500 mg will be given to patients upon leaving the clinic and they will be instructed to take one pill orally each day before returning for evaluation after 48 hours.
62092893|NCT01806415|EXPERIMENTAL|Fenobam 100 mg|Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.
62092894|NCT01806415|EXPERIMENTAL|Fenobam 150 mg|Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.
62092895|NCT01806415|PLACEBO_COMPARATOR|Placebo arm|Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
62290666|NCT05513443|EXPERIMENTAL|PRIS 1, arm 1|"Men randomized to the experimental arms will be offered focal treatment of prostate cancer with IRE technology. IRE stands for irreversible electroporation and involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death."
62463992|NCT01425710||Control group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
62656542|NCT04697849|EXPERIMENTAL|CREST|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
62656543|NCT04697849|ACTIVE_COMPARATOR|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
62656544|NCT04600037|ACTIVE_COMPARATOR|Group 1|Patients received pregabalin (target dose 300 mg/day) and exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
62656545|NCT04600037|NO_INTERVENTION|Group 2|Patients received exercise therapy alone (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
62092896|NCT03756779|EXPERIMENTAL|Low Saturated Fat Diet|Goal will be to attain \<7% of daily calories from saturated fat. Replace it with energy from monounsaturated fat.
62092897|NCT03756779|ACTIVE_COMPARATOR|High Saturated Fat Diet|Goal will be to attain 15% of daily calories from saturated fat. Decrease intake of monounsaturated fat.
62092898|NCT02442414|EXPERIMENTAL|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
62092899|NCT01238575|EXPERIMENTAL|Extended-release guanfacine|
62092900|NCT01238575|PLACEBO_COMPARATOR|Inactive placebo|
62290667|NCT05513443|ACTIVE_COMPARATOR|PRIS 1, arm 2|Men eligible for radical prostatectomy and randomized to the control arm will undergo radical prostatectomy in line with national guidelines.
62290668|NCT05513443|EXPERIMENTAL|PRIS 2, arm 1|"Men randomized to the experimental arms will be offered focal treatment of prostate cancer with IRE technology. IRE stands for irreversible electroporation and involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death."
62656546|NCT05604300|ACTIVE_COMPARATOR|Vitamin E incorporated oat|Oral vitamin E incorporated oat supplementation
62656547|NCT05604300|PLACEBO_COMPARATOR|Placebo|Oral oat supplementation
62463993|NCT05059249|EXPERIMENTAL|Manual Traction|Moist heat packs \& TENS for ten minutes followed by Manual Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient.
62656548|NCT05604300|NO_INTERVENTION|Control|Control
62656549|NCT05927974||ICM Patients|Epillipsey Patients undergoing routine intracranial EEG monitoring for epilepsy.
62656550|NCT03403049|EXPERIMENTAL|Arm 1|Dose-escalation phase I clinical study. In the initial dose levels, 'dose-escalation' refers to an increase in the radiotherapy dose delivered using carbon ion radiotherapy along with a corresponding decrease in the dose delivered using photons.
62656551|NCT02171351|EXPERIMENTAL|effect of neuromuscular electrostimulation (NMES)|
62656552|NCT02171351|EXPERIMENTAL|effect of neuro electrostimulation (NES)|
62656553|NCT02171351|EXPERIMENTAL|effect of voluntary contractions (VC)|
62092901|NCT00800371||JIA|Patients with JIA
62092902|NCT06234397|EXPERIMENTAL|BH3120|Arm A: BH3120 Monotherapy
62092903|NCT06234397|EXPERIMENTAL|BH3120 + pembrolizumab|Arm B: BH3120 in combination with pembrolizumab
62092904|NCT05235113|ACTIVE_COMPARATOR|Remote Exercise with tele-exergame|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
62092905|NCT05235113|SHAM_COMPARATOR|home-based exercise without technology|Subjects will perform exercises at home without tele-exergaming platform twice a week.
62092906|NCT02180711|EXPERIMENTAL|Part 1: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Follicular Lymphoma subjects
62092907|NCT02180711|EXPERIMENTAL|Part 1: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive Follicular Lymphoma subjects
62092908|NCT02180711|EXPERIMENTAL|Part 2: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
62463994|NCT05059249|EXPERIMENTAL|Mechanical traction|Moist heat packs \& TENS for ten minutes followed by Mechanical Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient
62463995|NCT00213304|EXPERIMENTAL|varicella vaccine (VARIVAX)|varicella vaccine (VARIVAX)
62656554|NCT03218501|ACTIVE_COMPARATOR|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
62656555|NCT03218501|ACTIVE_COMPARATOR|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
62656556|NCT03218501|PLACEBO_COMPARATOR|Placebo|Placebo is to be administered orally once daily for 2 weeks
62290669|NCT05513443|ACTIVE_COMPARATOR|PRIS 2, arm 2|Men eligible for radiation therapy and randomized to the control arm will undergo radiation therapy in line with national guidelines.
62290670|NCT03446495||Trabectedin + PLD|Trabectedin + PLD according to SmPC
62656557|NCT00820378||atherosclerosis|Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors
62656558|NCT06403371|EXPERIMENTAL|Fluoride varnish group|Patients received a layer of fluoride varnish on their teeth before the start of orthodontic clear aligner therapy
62656559|NCT06403371|PLACEBO_COMPARATOR|Control group|Patients received a layer of normal saline on their teeth before the start of orthodontic clear aligner therapy
62656560|NCT04362826|EXPERIMENTAL|Novel probiotic|Investigational novel probiotic plus normal standard of care for breast cancer.
62656561|NCT04362826|PLACEBO_COMPARATOR|Placebo|Placebo plus normal standard of care for breast cancer.
62656562|NCT00702169||1|Premature and term newborn infants (male/female)
62656563|NCT06464159||Preeclampsia|Pregnancy with preeclampsia
62290671|NCT02235649|NO_INTERVENTION|TAU|Treatment as usual
62656564|NCT06464159||Pregnancies with intra uterine growth restriction (IUGR)|Pregnancy with intra uterine growth restriction (IUGR)
62656565|NCT06464159||Normal pregnancy|Pregnancy without preeclampsia and intra uterine growth restriction (IUGR) and complications
62656566|NCT02744586|EXPERIMENTAL|Strengthening our Vows (SOV) Group|"Participants in the SOV arm will participate in the Together HIV Free and Protecting My Spouse plans."
62290672|NCT02235649|ACTIVE_COMPARATOR|SOC+TAU|Social Cognition intervention + Treatment as Usual
62290673|NCT00863551|EXPERIMENTAL|Trospium Chloride Extended Release, 60 mg|Trospium Chloride Extended Release, 60 mg
62290674|NCT01724957||Patients with coronary bifurcation lesions|Only one group will be studied. The patient will be a slef-reference.
62463996|NCT03733600||Glaucoma|All patients followed for either early or moderate forms of primary or secondary open-angle glaucoma who had undergone surgery for Xen alone or in combination with cataract surgery for phacoemulisation of the lens.
62656567|NCT02744586|PLACEBO_COMPARATOR|Good Health Package Plus (GHPP) Group|Participants in the GHPP arm will receive education on the prevention of helminths, schistosomiasis, hypertension, diabetes, and diarrheal diseases through participatory and interactive group sessions.
62290675|NCT04232657|EXPERIMENTAL|Romosozumab Treatment (baseline to month 11)|Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.
62290676|NCT04232657|PLACEBO_COMPARATOR|Placebo (baseline to month 12)|Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.
62290677|NCT04232657|ACTIVE_COMPARATOR|Denosumab (month 12 to month 24)|Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).
62290678|NCT02598830|EXPERIMENTAL|Vitamin D3+str.training, COPD & Healthy|"Vitamin D3 capsules for 30 weeks:~* weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+~* weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~* weeks 15-17, familiarization period~* week 18, test period~* weeks 19-28, intervention period~* weeks 29-30, test period"
62308042|NCT05329792|EXPERIMENTAL|Treatment arm with L19IL2 /L19TNF|70 patients will be enrolled and treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks. The total dose/volume will be distributed among the target lesions defined at screening via single or multiple intralesional injections, according to lesions' size and number.
62656568|NCT05880719|EXPERIMENTAL|Computer-assisted music remediation groupe|All participants benefit from 10 sessions of computer-assisted music remediation.These 10 sessions are spread over 3 month every Week.
62656569|NCT00829153|EXPERIMENTAL|U clip|Anastomosis with U clips
62656570|NCT00829153|ACTIVE_COMPARATOR|2|Prolene anastomosis
62656571|NCT05956743|ACTIVE_COMPARATOR|intervention group|"Intervention Group: A total of 6 weeks of planning will be made with the working group.~1 week : Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~2.,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6 week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room.A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied."
62656572|NCT05956743|SHAM_COMPARATOR|Sham group|"1 week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes polyclinic training room.~6 week: Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained."
62656573|NCT02708056|OTHER|Sugammadex, Bridion|Drug were given intravenously by a anesthesiologist at the end of surgery
62656574|NCT04742699|EXPERIMENTAL|Z-Drug-mono cohort|Patients being treated with Z-drug monotherapy at registration
62656575|NCT04742699|EXPERIMENTAL|SUV-mono cohort|Patients being treated with SUV monotherapy at registration
62656576|NCT04742699|EXPERIMENTAL|SUV-combination cohort|Patients being treated with SUV and BZRA combination therapy at registration
62656577|NCT04742699|EXPERIMENTAL|RMT-combination cohort|Patients being treated with RMT and BZRA combination therapy at registration
62656578|NCT05668247|EXPERIMENTAL|Intervention|foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group. The bucket has a five-level water heating system (35-48 °C). It has a magnetic field and operates at 390 Watt. It has a splash shield. There are non-slip rubber legs on its bottom. it has heat protection feature for thermal insulation as it has a two-walled structure
62656579|NCT05668247|NO_INTERVENTION|Control|"On the first day (the first follow-up), Patient Information Form, PSQI (ANNEX-II) and Piper Fatigue Scale were applied to the patients in the control group whose consent was obtained in the first follow-up, through face-to-face interview. At the end of the 30th day (the second follow-up), PSQI and Piper Fatigue Scale were applied again to the patients who came for the outpatient clinic control.~The routine treatment of the control group was not interfered and no intervention was performed."
62656580|NCT00815074||1|Women in the military who have returned from deployment within the past 12 months.
62656581|NCT04187313|EXPERIMENTAL|Intervention|The intervention arm will comprise study participants who receive intervention package (i.e. private practitioners in the selected areas who agree to participate).
62656582|NCT04187313|NO_INTERVENTION|Control|Private practitioners in the control areas will receive no intervention.
62656583|NCT01272206|EXPERIMENTAL|A|
62656584|NCT01272206|EXPERIMENTAL|B|
62656585|NCT03418519|EXPERIMENTAL|CIMT group|"Two-hour mCIMT per day for 15 days (dosage = 30 hours)~24-hour restraint for 3 weeks"
62656586|NCT03418519|NO_INTERVENTION|Control group|no CIMT
62656587|NCT01071577||Healthy Volunteers|Healthy volunteers wanting to donate BMSC for allogeneic use
62656588|NCT01071577||Patients|Patients donating BMSC for autologous use
62290679|NCT02598830|PLACEBO_COMPARATOR|Placebo+str.training, COPD & Healthy|"Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~* weeks 15-17, familiarization period~* week 18, test period~* weeks 19-28, intervention period~* weeks 29-30, test period"
62463997|NCT04991090|EXPERIMENTAL|escalation|The gross tumor volume (GTV) was defined as gross disease determined on MRI scans. The clinical target volume (CTV) was defined as the GTV plus areas considered at significant risk of harboring microscopic area. The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost. The planning target volume (PTV) was generated by adding an 8-mm margin around the GTV, GTVnd, and CTV in all directions. Doses of 58 Gy, 50 Gy, and 45 Gy were delivered to PTV-GTVnd, PTV-GTV, and PTV-CTV at 25 fractions, respectively. The dose of the normal organs at risk was constrained to the following criteria: bowel bag, V50 ≤ 5%; bladder, V50 ≤ 50%; femoral heads, V50 ≤ 5% .
62656589|NCT05512975|EXPERIMENTAL|Control Porridge arm|Control/ regular protein porridge recipe, not containing any additional protein fortification.
62290680|NCT02582658||Chronic infection of HCV GT1 or GT4|Participants with confirmed chronic hepatitis C genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) ± Ribavirin (RBV) according to standard of care and in line with the current local label
62290681|NCT03638492|ACTIVE_COMPARATOR|2 cm margin of excision|Patients with CMM \>2 mm treated with an excision of 2-cm.
62290682|NCT03638492|ACTIVE_COMPARATOR|4 cm margin of excision|Patients with CMM \>2 mm treated with an excision of 4-cm.
62290683|NCT04975802|PLACEBO_COMPARATOR|0 mg coffeeberry beverage|Appearance-matched to the other products
62463998|NCT05106465||Konectom|Participants with a diagnosis of MS or clinically isolated syndrome who are enrolled in Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) and who own a smartphone model compatible with the Konectom platform will be enrolled.
62290684|NCT04975802|EXPERIMENTAL|100 mg coffeeberry beverage|Appearance-matched to the other products
62290685|NCT04975802|EXPERIMENTAL|300 mg coffeeberry beverage|Appearance-matched to the other products
62290686|NCT04975802|ACTIVE_COMPARATOR|75 mg caffeine beverage|Appearance-matched to the other products
62290687|NCT01511445|ACTIVE_COMPARATOR|ACDF with PEEK interbody cage|Anterior cervical discectomy and fusion (ACDF) with an interbody spacer made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is to be filled with local autologous bone harvested during the decompression phase of the procedure.
62290688|NCT01511445|EXPERIMENTAL|ACDF with Valeo CSC Ceramic Cage|ACDF with the Valeo CSC cage, a silicon nitride ceramic interbody cage. The center area of the cage is filled with porous silicon nitride. No autologous bone is used; the cage is soaked in patient blood.
62290689|NCT06501846|PLACEBO_COMPARATOR|Blind Endometrial Biopsy|A Pipelle® endometrial biopsy performed in the routine manner without ultrasound guidance.
62290690|NCT06501846|EXPERIMENTAL|Ultrasound Guided Endometrial Biopsy|A Pipelle® endometrial biopsy performed with transabdominal ultrasound guidance.
62463999|NCT00562445||1|Peptic bleeding
62464000|NCT00562445||2|Portal hypertension bleeding
62464001|NCT00562445||3|Severe acute pancreatitis
62464002|NCT05681247|EXPERIMENTAL|ezetimibe tablet|ezetimibe tablet test formulation at a single dose of 10 mg
61906915|NCT02749474||Pregnant women diagnosed with cancer|Any pregnant woman diagnosed with any cancer within 6 weeks prior to their last menstrual period, or up to 6 months after the end of their pregnancy can be enrolled.
61906916|NCT02618213|ACTIVE_COMPARATOR|Continous Positive Airway Pressure|CPAP is administered through a binasal tube fitted with a Benveniste gas jet administered with humified airflow. Start flow is 12-14 l/min and can be changed to maximum 15 or minimum 12 l/min. Oxygen can be supplied as needed to keep SpO2 (peripheral capillary Oxygen saturation) within acceptable limits.
61906917|NCT02618213|ACTIVE_COMPARATOR|High Flow Oxygenation Therapy|HFOT is administered by optiflow Junior ( Fisher\&Paykal Healthcare® Auckland, New Zealand) Start flow 12-14 l/min. Oxygen can be supplied as needed to keep Sp02 within acceptable limits
61906918|NCT05901844|OTHER|Perform two different tests on the same sample|The same sample is diagnosed using a Raman analyzer firstly and then diagnosed by paraffin pathology.
61906919|NCT05014633|EXPERIMENTAL|EI skills training|Individuals in the intervention group received the pertinent training. The duration of the training for the intervention group was 16 hours (four four-hour sessions). The whole training process lasted for one month. EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
62464003|NCT05681247|ACTIVE_COMPARATOR|ezetimibe tablet(Ezetrol ®)|ezetimibe tablet reference formulation at a single dose of 10 mg
62464004|NCT01194388||MicroFx™ PGLA Treated Subjects|
61906920|NCT05014633|NO_INTERVENTION|Control|Individuals in the control group did not receive any training
61906921|NCT05047419||Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 6 weeks post due date and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
61906922|NCT05047419||Not Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 9 months and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
61906923|NCT00495040|EXPERIMENTAL|Proton Radiotherapy|Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.
61906924|NCT06341790|NO_INTERVENTION|Group A-Normal diet|patients are advised normal diet for NAFLD
61906925|NCT06341790|EXPERIMENTAL|Group b-Millet Diet|Patients are given millets based diet (jowar)
62092909|NCT02180711|EXPERIMENTAL|Part 2: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
62092910|NCT02180711|EXPERIMENTAL|Part 3: acalabrutinib Regimen 1|acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
62092911|NCT05674526|EXPERIMENTAL|WU-NK-101 Monotherapy/Cetuximab combo Run-in|"WU-NK-101 is a non-engineered Natural Killer (NK) cell derived from peripheral blood mononuclear cells (PBMC) that is cytokine-reprogrammed, expanded, and cryopreserved to create an allogeneic enhanced memory-like anti-tumor NK cell therapy product.~Each 8 week cycle in dose escalation is divided into two 28- days segments. Patients will receive WU-NK-101 (Days 1 and 15) in the first segment and a combination of cetuximab (500mg/m2 on Days 29 and 43) plus WU-NK-101 (Days 30 and 44) in the second segment."
61906926|NCT03635411|EXPERIMENTAL|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
62092912|NCT05674526|EXPERIMENTAL|WU-NK-101 /Cetuximab Combo|Patients will receive cetuximab dosed at 500 mg/m2 on Days 1 and 15, and WU-NK-101 on Days 2 and 16, in each 4-week cycle. Depending on response patients may receive up to 6 cycles of treatment.
61906927|NCT03635411|PLACEBO_COMPARATOR|Placebo|Placebo given twice daily for 90 days
61906928|NCT01705067||Journey II BCS TKA|Subjects who previously received TKA with Journey II BCS Total Knee System
61906929|NCT01853618|EXPERIMENTAL|Pilot 1/Arm A1-Tremelimumab + RFA or TACE|Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
62092913|NCT06696625|EXPERIMENTAL|taVNS group|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution."
62290691|NCT02937805|EXPERIMENTAL|Moisturizing vaginal and vulvar sea buckthorn oil cream|Moisturizing non-hormonal vaginal and vulvar cream containing sea buckthorn oil as active ingredient (medical device product in development). Administered twice or once per day for 5 weeks. Post-menopausal women n= 55 + 45. Pre-menopausal women n=15
62092914|NCT06696625|SHAM_COMPARATOR|Control Group|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
62092915|NCT03944434|EXPERIMENTAL|single arm|"patients will receive anastrozole tablets (1 mg once daily) or letrozole tablets (2.5 mg once daily) + ribociclib tablets (600 mg day 1 to 21 in a 28 day cycle). Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, physician's decision, patient's refusal/consent withdrawal, or lost to follow-up.~A LHRH agonist (triptorelin 3,75 mg or leuprolide 3,75 mg or goserelin 3,6 mg, as injectable intramuscular (i.m.) or subcutaneous (s.c.) implant every 28 days) will be used in men."
62092916|NCT02785601|EXPERIMENTAL|I-1|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
62092917|NCT02785601|EXPERIMENTAL|I-2|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)
62092918|NCT02785601|EXPERIMENTAL|I-3|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;
62092919|NCT02785601|EXPERIMENTAL|I-4|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
62092920|NCT01094743|OTHER|galyfilcon A prototype lens / lotrafilcon B lens|The galyfilcon A prototype lenses will be worn during the first period and lotrafilcon B lenses will be worn during the second period. Each period consists of daily lens wear for one week.
62092921|NCT01094743|OTHER|lotrafilcon B lens / galyfilcon A prototype lens|The lotrafilcon B lenses will be worn during the first period and galyfilcon A prototype lenses will be worn during the second period. Each period consists of daily lens wear for one week.
62092922|NCT04573140|EXPERIMENTAL|Phase I adult (Stratum 1)|A maximum of 28 adult patients will be enrolled in dose-escalation study using the BOIN design with an initial embedded accelerated titration design (ATD).
62092923|NCT04573140|EXPERIMENTAL|Phase I pediatric (Stratum 2)|A maximum of 24 adult patients will be enrolled in dose-escalation study using 3+3 study design.
62092924|NCT00429702|EXPERIMENTAL|Benadryl® Ativan® Decadron® (BAD) Pump|Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
62290692|NCT02937805|ACTIVE_COMPARATOR|Moisturizing vaginal and vulvar cream|Moisturizing non-hormonal vaginal and vulvar cream (commercial medical device cream already on the market, not containing sea buckthorn oil). Administered once - twice per day for 5 weeks. Postmenopausal women n=55
62464005|NCT06022237|EXPERIMENTAL|Ibandronate|Ibandronate 150 mg once monthly in a supervised manner in front of student investigator and will be observed for 2 hours following ingestion. Patients will also receive Calcium 500mg BD and Vitamin D3 1000 mg OD
62092925|NCT00429702|ACTIVE_COMPARATOR|Control Arm Saline|Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
62092926|NCT04861051|OTHER|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
62092927|NCT02758678||1-patients with operating tumor|"1- 23 patients with operating tumor; In 1 group the specimens of blood will be collected day before surgery and 1-2 month after surgery. Will be collected: histopathology outcomes - type carcinoma, tumore volume and before surgery: morphology and coagulation system. Will be assessed correlation between mentioned above factors and concentration of P-selectin.~Will be compared concentration of P-selectin in 3 groups of patients.~Serum separation and Raman spectroscopy analysis. A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
62092928|NCT02758678||2-patients with advanced desease.|"2- ten patients with advanced and metastatic disease who received palliative RT (RT - radiotherapy);~In 2 group - the specimens of blood we collected before palliative treatment-radiotherapy. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.The Raman spectra (RS) assessed as above"
62092929|NCT02758678||3-patients with inoperable disease|"In group 3 - the specimens of blood we collected before radical treatment and one month after completion treatment. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
62464006|NCT06022237|ACTIVE_COMPARATOR|Placebo|Group B will receive placebo once monthly along with Calcium 500mg BD and Vitamin D3 1000 mg OD
62464007|NCT01642342|EXPERIMENTAL|Weekly Treatment (sEphB4-HSA)|Patients receive recombinant albumin fusion protein sEphB4-HSA IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62464008|NCT01642342|EXPERIMENTAL|Every 2 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62290693|NCT02937805|NO_INTERVENTION|Control|No moisturizing vaginal and vulvar cream for 5 weeks. Postmenopausal women n=55
62290694|NCT05426200|EXPERIMENTAL|Health Coaching|Patient will work with a health coach to improve self-management skills, and receive usual pre-transplant education.
62290695|NCT05426200|NO_INTERVENTION|Control|Patients will receive usual pre-transplant education.
62290696|NCT03335540|EXPERIMENTAL|Arm B|Combination therapy determined by biomarker assessment
62464009|NCT01642342|EXPERIMENTAL|Every 3 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62464010|NCT02011932||Healthy volunteers|
62464011|NCT02011932||Chronic hepatitis C|
62464012|NCT04913376|EXPERIMENTAL|Hilotherapy|
62464013|NCT04913376|NO_INTERVENTION|Standard care|
62464014|NCT00316745|ACTIVE_COMPARATOR|1|mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）
62092930|NCT06439953|EXPERIMENTAL|Irrisept Irrigation|Patients scheduled to undergo spinal instrumentation will receive intra-operative Irrisept irrigation.
62464015|NCT00316745|EXPERIMENTAL|2|IRIS ( Irinotecan and S-1 ) → mFOLFOX6
62092931|NCT06439953|ACTIVE_COMPARATOR|Vancomycin-saline Irrigation|Patients scheduled to undergo spinal instrumentation will receive intra-operative irrigation using vancomycin-saline irrigation.
62092932|NCT04358471|ACTIVE_COMPARATOR|Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection|Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0
62092933|NCT04358471|ACTIVE_COMPARATOR|Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection|Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0
62092934|NCT04358471|SHAM_COMPARATOR|Sham Intravitreal Injection|Intravitreal Sham injection administered once on Day 0
62290697|NCT03335540|EXPERIMENTAL|Arm C|Combination therapy determined by biomarker assessment
62656590|NCT05512975|EXPERIMENTAL|Dairy Protein Porridge arm|Porridge containing regular protein ingredients with dairy protein fortification (delical- a whey protein powder)
62656591|NCT05512975|EXPERIMENTAL|Plant Protein Porridge arm|Porridge containing regular protein ingredients with plant protein fortification (extruded soy and soya milk)
62656592|NCT01675726|OTHER|quality of life|
62656593|NCT03219580|ACTIVE_COMPARATOR|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
62656594|NCT03219580|PLACEBO_COMPARATOR|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
62656595|NCT05718596|EXPERIMENTAL|Sweeps laser|use of sweeps laser irrigation activation
62656596|NCT05718596|EXPERIMENTAL|pasif ultrasonic irrigation (PUI)|Pasif ultrasonic irrigation (PUI) -VDW Ultra
61906930|NCT01853618|EXPERIMENTAL|2/Arm A2 - Tremelimumab + RFA or TACE|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
62092935|NCT04272151|EXPERIMENTAL|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
62092936|NCT05434442|OTHER|1-simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator. They will also receive clinical routine training"
62092937|NCT05434442|OTHER|2-mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher. They will also receive clinical routine training"
62092938|NCT05434442|OTHER|3-control group|Clinical routine training will be given to caregivers in this group.
62092939|NCT02143531|ACTIVE_COMPARATOR|Group I|Patients will receive 4 mg of Ondansetron IV upon occurrence of nausea or vomiting
62290698|NCT03335540|EXPERIMENTAL|Arm D|Combination therapy determined by biomarker assessment
62290699|NCT03335540|EXPERIMENTAL|Arm F|Combination therapy determined by biomarker assessment
62092940|NCT02143531|ACTIVE_COMPARATOR|Group II|Patients will receive 1mg of Haloperidol IV upon occurrence of nausea or vomiting
62092941|NCT05590871|EXPERIMENTAL|Renal Denervation|Percutaneous renal denervation using the FlashPoint radio-frequency ablation system under the Columbus 3D mapping system guidance
62092942|NCT05590871|SHAM_COMPARATOR|sham|"For those subjects randomized to the sham procedure, renal artery angiography will serve as the sham procedure.~Subjects maintenance of anti-hypertensive medications."
62290700|NCT03335540|EXPERIMENTAL|Arm G|Combination therapy determined by biomarker assessment
62290701|NCT04461821||obstructive bronchitis/bronchiolitis|
62290702|NCT04461821||pneumonia|
62290703|NCT04461821||asthma|
62290704|NCT04461821||neurological diseases|
62290705|NCT04461821||type 1 diabetes (T1D)|
62290706|NCT04461821||pharmacotherapy with bronchodilators|
62290707|NCT04461821||pharmacotherapy with antibiotics|
62290708|NCT04461821||pharmacotherapy with antiviral medication|
62290709|NCT04461821||pharmacotherapy with antifungal medication|
62290710|NCT04461821||pharmacotherapy with antiepileptic medication|
62656597|NCT04138017|EXPERIMENTAL|ViviGen Cellular Bone Matrix|Patients will receive the vivigen cellular bone matrix
62656598|NCT03233256|EXPERIMENTAL|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
62656599|NCT00929669|EXPERIMENTAL|Pasireotide LAR|80 mg IM once monthly
62290711|NCT04461821||pharmacotherapy with immuno suppressants and immune-modulati|
62290712|NCT04461821||pharmacotherapy with anesthesia (including sedating, analges|
62290713|NCT06461598||Training cohort|
62290714|NCT06461598||Validation cohort|
62464016|NCT01785368|OTHER|Before guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period BEFORE the implementation of the referral guidelines.~\[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.\]~Intervention: Baseline observation"
61906931|NCT01853618|EXPERIMENTAL|3/Arm B - Tremelimumab + TACE|Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
62290715|NCT05868785|ACTIVE_COMPARATOR|Nocturnal parenteral nutrition|Patients will receive nocturnal parenteral nutrition, starting at 8pm
62290716|NCT05868785|EXPERIMENTAL|Diurnal parenteral nutrition|Patients will receive diurnal parenteral nutrition, starting at 8am
62290717|NCT02649101|EXPERIMENTAL|thalidomide plus chemotherapy|thalidomide tablet 100mg qn po
62290718|NCT02649101|ACTIVE_COMPARATOR|chemotherapy|Physician's choice chemotherapy. No constraints of the choice of chemotherapy drugs and regimens.
62464017|NCT01785368|OTHER|After guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period AFTER the implementation of the referral guideline.~\[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.\]~Intervention: Implementation of guidelines"
62464018|NCT04346927|EXPERIMENTAL|Study Group|The group to which the exercise protocol consisting of breathing exercises, posture exercises, peripheral muscle training and light aerobic exercises will be applied.
62290719|NCT01241500|EXPERIMENTAL|ON 01910.Na + best supportive care (BSC)|Patients will receive ON 01910.Na 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards and best supportive care (BSC).
62290720|NCT01241500|NO_INTERVENTION|Best supportive care (BSC)|Patients will receive best supportive care (BSC).
62290721|NCT01881646|EXPERIMENTAL|Positron emission tomography (PET)|Positron emission tomography (PET) using \[11C\]PBR28
62290722|NCT00589641|EXPERIMENTAL|CBT-RP + Enhanced TAU|CBT-RP augmenting relapse prevention intervention, in addition to enhanced treatment as usual, monthly check-ins, and monitoring
62290723|NCT00589641|ACTIVE_COMPARATOR|Enhanced TAU (Treatment as Usual)|Treatment as usual in the community, monthly monitoring regarding service use and needs, monitoring
62290724|NCT02285179|EXPERIMENTAL|tamoxifen and GDC-0032|20 mg tamoxifen QD and 4 MG GDC-0032 QOD
62290725|NCT02285179|PLACEBO_COMPARATOR|tamoxifen and placebo|20 mg tamoxifen QD and placebo QOD
62290726|NCT06325514||normal/variations of normal anatomical landmarks|patients that have normal oral findings or variations of normal anatomical landmarks such as: leukoedema, fordyce granules, linea alba, physiological pigmentations, torus palatinus, torus mandibularis, geographic tongue, fissured tongue
62464019|NCT04346927|ACTIVE_COMPARATOR|Control Group|group to be given an exercise brochure
62092943|NCT05972083|ACTIVE_COMPARATOR|Group S = SPSIPB group|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
62092944|NCT05972083|OTHER|Group C = Control group|The wound infiltration with 30 ml of 0.25% concentration of bupivacaine will be performed by the surgical team.
62290727|NCT06325514||low risk referral|patients that needs referral for a low risk of malignant transformation disease, such as: hemangiomas, fibromas, oral apthous ulcers, candidal infections, pemphigus valgaris, petechiae, frictional keratosis, smokers' melanosis.
61906932|NCT01853618|EXPERIMENTAL|4/Arm C (never opened)|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
61906933|NCT01853618|EXPERIMENTAL|5/Arm D - Tremelimumab + Cryoablation|Tremelimumab + Cryoablation
61906934|NCT01853618|EXPERIMENTAL|6/Arm E - Tremelimumab + RFA|Tremelimumab + Radiofrequency Ablation (RFA)
61906935|NCT05661084|EXPERIMENTAL|tACS(AG) + tDCS(PFC) combo active|Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
62092945|NCT02264574|EXPERIMENTAL|IBR + OB|Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.
62290728|NCT06325514||high risk referral|patients that needs referral for a high risk of malignancy or a premalignant disease, such as: oral lichen planus, leukoplakia, erythroplakia, squamous cell carcinoma.
62464020|NCT04469270|EXPERIMENTAL|Engensis|16 (ea) 0.25mg (0.5 mL) injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
61906936|NCT05661084|ACTIVE_COMPARATOR|tACS(AG) active + tDCS(PFC) sham|Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
61906937|NCT05661084|ACTIVE_COMPARATOR|tACS(AG) sham + tDCS(PFC) active|Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
62290729|NCT04268030||GBA mutation carriers with PD undergoing STN-DBS|
62290730|NCT04265664|EXPERIMENTAL|Telerehabilitation|Receives the telerehabilitation protocol
62464021|NCT04469270|PLACEBO_COMPARATOR|Placebo|16 0.5 mL injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
62464022|NCT00050778|ACTIVE_COMPARATOR|Interferon Beta-1a|
61906938|NCT05661084|SHAM_COMPARATOR|tACS(AG) sham + tDCS(PFC) sham|Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
61906939|NCT06398743||Stage II or III|Patients with stage II or III colorectal cancer
62092946|NCT02264574|EXPERIMENTAL|CLB + OB|"Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.~Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity."
62092947|NCT06320366|PLACEBO_COMPARATOR|Sham TMS|Participants have baseline assessments/evaluation, are admitted to the inpatient research unit, randomized via permuted block design to 5 days of sham TMS, and then have weekly study visits for the next 12 weeks.
62290731|NCT03018132|OTHER|Mental Health Screening Education and Referral|Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
61906940|NCT03463200|NO_INTERVENTION|Control group|It will not apply any tape.
62290732|NCT03619213|EXPERIMENTAL|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
62290733|NCT03619213|PLACEBO_COMPARATOR|Placebo|Placebo matching dapagliflozin.
61906941|NCT03463200|EXPERIMENTAL|Experimental group 1|Apply the KT with tension in the erector spine muscles.
61906942|NCT03463200|EXPERIMENTAL|Experimental group 2|Apply the KT without tension in the erector spine muscles.
61906943|NCT03463200|EXPERIMENTAL|Experimental group 3|Apply Micropore tape in the erector spine muscles.
61906944|NCT05873400||1|Myocardial Infarction patients who responded to aldosterone antagonist and didn't develope heart failure
61906945|NCT05873400||2|Myocardial Infarction patients who didn't respond to aldosterone antagonist and developed heart failure
61906946|NCT05873400||3|Control group who didn't receive aldosterone antagonist
61906947|NCT05648669|EXPERIMENTAL|Elagolix|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
61906948|NCT05648669|PLACEBO_COMPARATOR|Elagolix placebo|Placebo BID for the 6-month Treatment Period
61906949|NCT05391178|ACTIVE_COMPARATOR|Psoriasis|Psoriasis participants will be provided sleeves made from the Lumiton yarn to cover their arms. The participants will be instructed to wear the sleeves made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
61906950|NCT05391178|ACTIVE_COMPARATOR|Alopecia Areata|Alopecia areata participants will be provided a hat made from the Lumiton yarn. The participants will be instructed to wear the hat made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
62092948|NCT06320366|EXPERIMENTAL|Active TMS|Participants have baseline assessments/evaluation, are admitted to the inpatient research unit, randomized via permuted block design to 5 days of active TMS, and then have weekly study visits for the next 12 weeks.
62290734|NCT04553237||Patients over 90 years old|
62290735|NCT04553237||Patients between 70 and 89 years of age.|
62464023|NCT00050778|EXPERIMENTAL|Alemtuzumab 12 mg|
61906951|NCT05391178|ACTIVE_COMPARATOR|Polymorphous Light Eruption|Polymorphous light eruption participants will be provided a shirt made from the Lumiton yarn. The participants will be instructed to wear the shirt made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
61906952|NCT01989468|EXPERIMENTAL|Secukinumab (AIN457) 150 mg s.c.|1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
62290736|NCT04925960|EXPERIMENTAL|Epalrestat|Epalrestat will be administered orally, 3 times per day (TID) spaced out as evenly as possible over 24 hours in a divided dose starting on Day 1 of the Study.
62464024|NCT00050778|EXPERIMENTAL|Alemtuzumab 24 mg|
62464025|NCT02293083|EXPERIMENTAL|Lidocaine|Group L received trigger point injection with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline
61906953|NCT01989468|EXPERIMENTAL|Secukinumab (AIN457) 300 mg s.c.|2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
61906954|NCT01989468|PLACEBO_COMPARATOR|Placebo|Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
61906955|NCT05723471|EXPERIMENTAL|Adaptative Physical Activity|
61906956|NCT05723471|NO_INTERVENTION|Standard Exercise|
62092949|NCT01657032|EXPERIMENTAL|Lactobacillus GG and Smectite|"Children received:~* LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~* smectite, dose 3 g, once daily orally until diarrhea stopped"
62290737|NCT04925960|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally, 3 times per day (TID) spaced out as evenly as possible over 24 hours in a divided dose starting on Day 1 of the Study.
62290738|NCT02836561|EXPERIMENTAL|Intervention Message|Participants who are randomized to the intervention message will receive contraception information in advance of their appointment that may be helpful in their decision-making.
62290739|NCT02836561|NO_INTERVENTION|Control Message|Participants who are randomized to the control message will receive appointment logistic information that may be a helpful reminder.
62290740|NCT01316042|PLACEBO_COMPARATOR|sugar pill|2 pills per day for 12 months
62290741|NCT01316042|ACTIVE_COMPARATOR|Metformin|2 212.5mg pill/day for 12 months
62290742|NCT05789992|ACTIVE_COMPARATOR|Group 1 BIS under tetanic electrical stimulation|During tetanic electrical stimulation, and with propofol(random:3-5ug/ml) and remifentanil(random:0-3ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's BIS.
62290743|NCT05789992|ACTIVE_COMPARATOR|Group 2 eMAC under tetanic electrical stimulation|During tetanic electrical stimulation or intubation, and with propofol(random:3-5ug/ml) and remifentanil(random:0-3ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's eMAC.
62290744|NCT05789992|ACTIVE_COMPARATOR|Group 3 BIS under intubation|During intubation, and with propofol(random:3-5ug/ml) and remifentanil(random:3-5ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's BIS.
62290745|NCT05789992|ACTIVE_COMPARATOR|Group 4 eMAC under intubation|During intubation, and with propofol(random:3-5ug/ml) and remifentanil(random:3-5ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's eMAC.
62290746|NCT04824378||label 1|Baseline data measurement of this group of patients: arm circumference（positive） and ICG (positive).
62290747|NCT04824378||label 2|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (positive).
62290748|NCT04824378||label 3|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (negative).
62290749|NCT00105872|OTHER|Arm 1|
62290750|NCT02224235|EXPERIMENTAL|Group 1- COBRA 1 week DAPT|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
62290751|NCT02224235|ACTIVE_COMPARATOR|Group 2 - DES 6 month DAPT|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
62290752|NCT02224235|EXPERIMENTAL|Group 3 - COBRA Aspirin|COBRA PzF coronary stent followed by aspirin alone
62464026|NCT02293083|EXPERIMENTAL|Hyaluronidase|Group H received trigger point injection with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L\&H Pharm., Seoul, Korea) 600 iu/ml
62464027|NCT03117257|EXPERIMENTAL|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
62464028|NCT03117257|ACTIVE_COMPARATOR|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
62464029|NCT02346097|EXPERIMENTAL|Optimal electrical resynchronization|"Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Programming of the VV interval to obtain the narrowest QRS-width"
61906957|NCT02249637||Inguinal Orchidopexy|Patients with diagnosed palpable low inguinal cryptorchidism underwent inguinal approach as originally described by Schuller and Bevan.
61906958|NCT02249637||Novel Technique (Circumcision incision)|Patients with diagnosed palpable low inguinal cryptorchidism underwent novel technique- circumcision incision orchidopexy.
61906959|NCT05873127|EXPERIMENTAL|web-based guided self-help CBT-E|After randomization, 8-10 patients were assigned to self-help CBT-E group each time.
61906960|NCT05873127|EXPERIMENTAL|online group CBT-E|After randomization, 8-10 patients were assigned to online CBT-E group each time.
61906961|NCT05873127|NO_INTERVENTION|waiting group|After randomization, 8-10 patients were assigned to the waiting list each time, and they would be allocated to web-based guided self-help CBT-E or online group CBT-E randomly after a 12-week waiting period.
61906962|NCT05732402|EXPERIMENTAL|povetacicept 80mg|
61906963|NCT05732402|EXPERIMENTAL|povetacicept 240mg|
61906964|NCT04066712|EXPERIMENTAL|A: Normal (control) renal function|
61906965|NCT04066712|EXPERIMENTAL|B: Mild impairment renal function|
62290753|NCT02274688|NO_INTERVENTION|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
62290754|NCT02274688|EXPERIMENTAL|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.~Randomized and will be blindly assessed."
62290755|NCT06481137|EXPERIMENTAL|Positive initial (3-7 days following TAVI) electrophysiological study (EP+)|Permanent pacemaker implantation. Continuous ECG monitoring during 4 weeks. Second EP study 30-45 days after TAVI.
62290756|NCT06481137|OTHER|Negative initial (3-7 days following TAVI) electrophysiological study (EP-)|Continuous ECG monitoring during 4 weeks.
62290757|NCT04004949||study group (high scapular dyskinesia )|group A (30 patients): with high scapular dyskinesia scores
62290758|NCT04004949||control group (low or no scapular dyskinesia )|group B (30 patients): with low or no scapular dyskinesia scores. (30 patients): with low or no scapular dyskinesia scores.
62290759|NCT01592487||Lean BMI|BMI in the 25th - 75th percentile
62290760|NCT01592487||Overweight BMI|BMI in the 85th - 95th percentile
62308043|NCT02551172|EXPERIMENTAL|experimental sequence|Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816
62290761|NCT02203149|EXPERIMENTAL|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
62290762|NCT02203149|EXPERIMENTAL|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
62464030|NCT02346097|ACTIVE_COMPARATOR|Routine CRT-strategy, imaging guided|"Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads."
62464031|NCT00012948|OTHER|Arm 1|
62464032|NCT02064088|EXPERIMENTAL|Small volume|Local analgesia by one injection of 0,2 ml/kg of 0,2% lévobupivacaine
62464033|NCT02064088|EXPERIMENTAL|High volume|Local analgesia by one injection of 0,4 ml/kg of 0,1% lévobupivacaine
61906966|NCT04066712|EXPERIMENTAL|C: Moderate impairment renal function|
61906967|NCT04066712|EXPERIMENTAL|D: Severe impairment renal function|
62464034|NCT04857541||Health adult|
62464035|NCT04325100|EXPERIMENTAL|Switch - i|Individual sessions
62464036|NCT04325100|EXPERIMENTAL|Switch - g|Group programme
62464037|NCT00106548|EXPERIMENTAL|1|
62464038|NCT00106548|EXPERIMENTAL|2|
62464039|NCT00106548|PLACEBO_COMPARATOR|3|
62464040|NCT02401334|EXPERIMENTAL|Hernia Repair|Surgical repair for hernia with implantation of the Cook® Antimicrobial Hernia Repair Device.
62464041|NCT02146261|EXPERIMENTAL|1|Subcutaneous administration of E6011 50 mg
62464042|NCT02146261|EXPERIMENTAL|2|Subcutaneous administration of E6011 100 mg
62308044|NCT02551172|PLACEBO_COMPARATOR|comparative sequence|Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg
62464043|NCT02146261|EXPERIMENTAL|3|Subcutaneous administration of E6011 200 mg
62464044|NCT02146261|EXPERIMENTAL|4|Subcutaneous administration of E6011 400 mg
62464045|NCT02146261|PLACEBO_COMPARATOR|5|Subcutaneous administration of placebo
62464046|NCT01428830|EXPERIMENTAL|7-day catheterization|
62464047|NCT01428830|ACTIVE_COMPARATOR|14-day catheterization|
62464048|NCT03415802|EXPERIMENTAL|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area\<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area\>1.5 m2; D1-14, q3w)
62464049|NCT04903600|EXPERIMENTAL|Probiotics|32g probiotics fruit vegetable fiber powder product contained 1.12\*10(11) CFU of probiotics for 12 weeks
61906968|NCT04451213|EXPERIMENTAL|experimental|
61906969|NCT01967498|EXPERIMENTAL|montelukast|this arm will receive montelukast as the active intervention of the study
61906970|NCT01967498|PLACEBO_COMPARATOR|placebo|
61906971|NCT04193514|EXPERIMENTAL|Acceptance and Commitment Therapy|
62464050|NCT04903600|PLACEBO_COMPARATOR|Placebo|32g placebo contained only maltodextrin (100%) for 12 weeks
62464051|NCT03955237|ACTIVE_COMPARATOR|non glucose infusion group|Drug: LR infusion LR solution without glucose; the patients with preoperative blood glucose level higher than 90 mg/dL.
62464052|NCT03955237|ACTIVE_COMPARATOR|Drug:1% Dextrose infusion group|Drug:LR+ 1% Dextrose infusion LR solution with % 1 glucose: the patients with preoperative blood glucose level between 60-90 mg/dL,
62464053|NCT03955237|ACTIVE_COMPARATOR|2% Dextrose infusion group|Drug:LR+ 2 % Dextrose infusion Lactate ringer (LR) solution with % 2 glucose; the patients with preoperative blood glucose level lower than 60 mg/dL,
62464054|NCT03232372|EXPERIMENTAL|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
62092950|NCT01657032|PLACEBO_COMPARATOR|Lactobacillus GG and Placebo|"Children received:~* LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~* placebo (glucose), dose 3 g, once daily orally until diarrhea stopped"
62290763|NCT02203149|EXPERIMENTAL|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
62464055|NCT03232372|EXPERIMENTAL|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
62464056|NCT03232372|EXPERIMENTAL|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
62656600|NCT02140944||Pre-Transplant Cohort|HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant
62656601|NCT02140944||Post-Transplant Cohort|HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant
62464057|NCT02865538|PLACEBO_COMPARATOR|BAY3427080 Placebo|
62464058|NCT02865538|EXPERIMENTAL|50mg BAY3427080|
61906972|NCT04193514|NO_INTERVENTION|Treatment as Usual|
61906973|NCT05705089|EXPERIMENTAL|Rivaroxaban-based antithrombotic regimen|All patients assigned to the rivaroxaban-based antithrombotic regimen will receive rivaroxaban (15 mg once daily, orally) plus clopidogrel (75 mg daily, orally) plus aspirin (80 mg once daily, orally). Aspirin will be discontinued within 7 days of its initiation. The antithrombotic regimen (i.e., dual therapy) will be continued until three months after randomization.
62092951|NCT01700530|EXPERIMENTAL|Statin|Statins (40mg/day)for an average of 12 weeks
62092952|NCT01700530|EXPERIMENTAL|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
62092953|NCT01700530|ACTIVE_COMPARATOR|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk) for 12 weeks
62290764|NCT02203149|PLACEBO_COMPARATOR|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
62464059|NCT02865538|EXPERIMENTAL|100mg BAY3427080|
62464060|NCT02865538|EXPERIMENTAL|150mg BAY3427080|
62464061|NCT02865538|EXPERIMENTAL|300mg BAY3427080|
62464062|NCT06046846|EXPERIMENTAL|Asensei app intervention group|Participants randomised to the intervention group will be introduced to the mHealth prehabilitation programme delivered via a mobile app. Within this intervention group, participants will have access to a mHealth prehabilitation programme delivered and monitored via an app which will consist of a multimodal prehabilitation programme consisting of nutritional guidelines, improving well being and physical functioning prior to surgery.
62092954|NCT05976490|EXPERIMENTAL|NeuroPathways Open Pilot|"Enrolled patients will receive an intervention guide with information about navigating life with a brain tumor diagnosis, and will participate in four weekly or biweekly, individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 8 weeks and 12 weeks, as well as an exit interview after the intervention."
62656602|NCT00831844|EXPERIMENTAL|Group 1 - Recurrent or Refractory Hepatoblastoma|Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62656603|NCT00831844|EXPERIMENTAL|Group 2 - Recurrent or Refractory Synovial Sarcoma|Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62656604|NCT00831844|EXPERIMENTAL|Group 3 - Recurrent or Refractory Rhabdomyosarcoma|Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62656605|NCT00831844|EXPERIMENTAL|Grp 4-Recurrent or Refractory Adrenocortical Carcinoma|Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62290765|NCT02203149|EXPERIMENTAL|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
61906974|NCT05705089|ACTIVE_COMPARATOR|warfarin-based antithrombotic regimen|All patients assigned to the warfarin-based antithrombotic regimen will receive warfarin (overlapping with enoxaparin until reaching an INR goal of 2-2.5) plus clopidogrel (75 mg once daily, orally) plus aspirin (80 mg once daily, orally). Aspirin will be discontinued within 7 days of its initiation. The antithrombotic regimen (i.e., dual therapy) will be continued until three months after randomization.
61906975|NCT03096587|EXPERIMENTAL|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
61906976|NCT03096587|ACTIVE_COMPARATOR|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
62290766|NCT04019262|ACTIVE_COMPARATOR|40 Gy in 15 fractions|Patients randomized to 40 Gy in 15 fractions will receive 75 mg/m\^2 temozolomide per day for 15 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m\^2 for upto 1 year.
62290767|NCT04019262|ACTIVE_COMPARATOR|25 Gy in 5 fractions|Patients randomized to 25 Gy in 5 fractions will receive 150 mg/m\^2 temozolomide per day for 5 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m\^2 for upto 1 year.
62290768|NCT01736956|EXPERIMENTAL|Fetal Aortic Valvuloplasty|Subjects will undergo fetal aortic valvuloplasty
62290769|NCT01736956|NO_INTERVENTION|Control|Control group. Will receive standard prenatal and postnatal care.
62290770|NCT04222283|EXPERIMENTAL|open label, multicentric, non randomized|one arm study to evaluate the safety and efficacy of switching from ritonavir- or cobicistat- booster containing regimens to a fixed-dose combination (FDC) of tenofovir alafenamide (TAF), emtricitabine (FTC) and bictegravir (BIC) in over 65 years old HIV-1-infected patients with virological suppression. Polymedications and drug-drug interactions will be analysed.
61906977|NCT01232803|ACTIVE_COMPARATOR|2% N-9 gel|Rectal application of 2% N-9 gel
61906978|NCT01232803|PLACEBO_COMPARATOR|HEC placebo gel|Rectal application of HEC placebo gel
61906979|NCT01232803|NO_INTERVENTION|no-treatment arm|no intervention
61906980|NCT01232803|EXPERIMENTAL|Tenofovir 1% gel|rectal application of Tenofovir 1% gel
61906981|NCT01606917|EXPERIMENTAL|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity.
61906982|NCT01606917|NO_INTERVENTION|Usual care|Usual care
61906983|NCT04195971|EXPERIMENTAL|Liver CT with dual arterial phase|
61906984|NCT05622747|EXPERIMENTAL|Passive heating intervention|1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C)
61906985|NCT06123013|EXPERIMENTAL|Music assisted relaxation|Participants will receive a tailored music-assisted relaxation and imagery intervention
61906986|NCT01160419|OTHER|FLOT|Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles
62290771|NCT03437447|EXPERIMENTAL|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
62092955|NCT05976490|EXPERIMENTAL|NeuroPathways Pilot RCT|"Enrolled patients will receive an intervention guide with information about navigating life with a brain tumor diagnosis, and will participate in four weekly or biweekly, individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 8 weeks and 12 weeks."
62092956|NCT05976490|ACTIVE_COMPARATOR|Usual supportive care|"Participants will receive usual supportive care, which includes referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician.~Participants will be asked to complete surveys at baseline, 8 weeks and 12 weeks."
62092957|NCT04914312|EXPERIMENTAL|Maqui berry extract and omega-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
62092958|NCT04914312|PLACEBO_COMPARATOR|Control|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
62092959|NCT02016924|EXPERIMENTAL|Cohort 1: Part A and Part B|Participants ages 12 to \<18 years old will receive cobicistat 150 mg with either ATV or DRV plus background regimen (BR). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
62092960|NCT02016924|EXPERIMENTAL|Cohort 2|Participants aged 6 to \<12 years old and ≥25 to \<40kg will receive cobicistat 150 mg and F/TAF 200/25 mg with either ATV or DRV.
62290772|NCT03437447|EXPERIMENTAL|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
62290773|NCT03437447|EXPERIMENTAL|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
62290774|NCT01245647|PLACEBO_COMPARATOR|Sugar Pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
62290775|NCT01245647|ACTIVE_COMPARATOR|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
62290776|NCT02910427|PLACEBO_COMPARATOR|Na salt|regular salt
62290777|NCT02910427|ACTIVE_COMPARATOR|K salt|potassium-enriched salt
62464063|NCT06046846|NO_INTERVENTION|Standard Pre-Operative Care group|The control group will receive standard pre-operative care within NHS Lothian for patients undergoing surgery for oesophago-gastric cancer which includes the enhanced recovery after surgery pathway. This pathway includes a pre-assessment, verbal advice only on prehabilitation interventions surrounding nutrition, well being and physical activity as well as a follow up post treatment.
62092961|NCT02016924|EXPERIMENTAL|Cohort 3|Participants age ≥ 2 years old will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.
62092962|NCT02016924|EXPERIMENTAL|Cohort 4 (Group 1)|Participants age ≥ 4 weeks old weighing 14 to \< 25 kg will receive cobicistat tablet for oral suspension (TOS) 90 mg, once daily and F/TAF TOS 120/15 mg, once daily with either ATV or DRV or lopinavir boosted by ritonavir (LPV/r). Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, minimum age and weight for DRV is ≥ 3 years and ≥ 15 kg; participants receiving LPV/r will not receive cobicistat TOS.
62092963|NCT02016924|EXPERIMENTAL|Cohort 4 (Group 2)|Participants age ≥ 4 weeks old weighing 10 to \< 14 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 60/7.5 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
62092964|NCT02016924|EXPERIMENTAL|Cohort 4 (Group 3)|Participants age ≥ 4 weeks old weighing 6 to \< 10 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 30/3.75 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
62092965|NCT02016924|EXPERIMENTAL|Cohort 4 (Group 4)|Participants age ≥ 4 weeks old weighing 3 to \< 6 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 15/1.88 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
62092966|NCT02016924|EXPERIMENTAL|Cohort 5 (Group 1)|Participants ages ≥ 4 weeks old weighing ≥ 10 to \< 14 kg will receive F/TAF TOS 60/7.5 mg, once daily with the third unboosted drug.
62092967|NCT02016924|EXPERIMENTAL|Cohort 5 (Group 2)|Participants ages ≥ 4 weeks old weighing ≥ 6 to \< 10 kg will receive F/TAF TOS 30/3.75 mg, once daily with the third unboosted drug.
62092968|NCT02016924|EXPERIMENTAL|Cohort 5 (Group 3)|Participants ages ≥ 4 weeks old weighing ≥ 3 to \< 6 kg will receive F/TAF TOS 15/1.88 mg, once daily with the third unboosted drug.
62290778|NCT02910427|ACTIVE_COMPARATOR|K/Mg salt|potassium and magnesium-enriched salt
62290779|NCT01070329|EXPERIMENTAL|Duloxetine|
62290780|NCT01070329|PLACEBO_COMPARATOR|Placebo|
62290781|NCT02351232|EXPERIMENTAL|Intervention|Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
62290782|NCT02351232|PLACEBO_COMPARATOR|Placebo|Placebo; daily subcutaneous injection; 1.8 mg; 6 months
62290783|NCT02303925|EXPERIMENTAL|coils|
62290784|NCT06314724|EXPERIMENTAL|Varicella vaccine group|Participants will receive a single dose of investigational varicella vaccine on Day 0.
62290785|NCT06314724|ACTIVE_COMPARATOR|Varivax|Participants will receive a single dose of Varivax on Day 0.
62290786|NCT00838357|EXPERIMENTAL|Plerixafor|Plerixafor added to a G-CSF Mobilisation regimen
62290787|NCT01705626||Participants diagnosed with small fiber polyneuropathy no obvious etiology|Participants aged between 18 and 85 years, diagnosed with small fiber polyneuropathy of no obvious etiology, without diagnosis of alcoholism and not undergoing chemotherapy for cancer
62290788|NCT04091893|ACTIVE_COMPARATOR|Usual care/wait list|
62290789|NCT04091893|EXPERIMENTAL|Art Rx|
62290790|NCT04091893|EXPERIMENTAL|Artful Meditation|
62290791|NCT04091893|EXPERIMENTAL|Art Rx + Artful Meditation|
61906987|NCT05864092|NO_INTERVENTION|Control Arm|The control arm will be a retrospective chart review of patients ages 6 to 21 who present to the pediatric emergency department with sickle cell VOC listed as one of their diagnoses with the aim of identifying pain scores in accordance with medications received and identifying final disposition and identifying time in the emergency department and time to ED disposition. We aimed to review 100 charts. We found that 84 met inclusion criteria.
61906988|NCT05864092|EXPERIMENTAL|Trial Arm|The trial arm will be a prospective, convenience sampling of up to 100 patients ages 6 to 21 years who present to the pediatric emergency department with VOC listed as either their main complaint or as one of multiple complaints as identified by health care provider at time of presentation and meet inclusion criteria. The intervention will be virtual reality headset which will be offered simultaneously with standard medication therapy. We actually enrolled 17 patients who met inclusion criteria.
61906989|NCT01143740|EXPERIMENTAL|Single Arm|
61906990|NCT05736029||Non-operable NSCLC patients receiving ICI therapy|Patients with non-operable stage IIIB-IV NSCLC treated with immune check inhibitor anti cancer treatment as a standard of care
62092969|NCT05919108|ACTIVE_COMPARATOR|Treatment A (endocrine therapy)|Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
62290792|NCT01762514|NO_INTERVENTION|Program I|Patients with American Joint Cancer Committee/Union Internationale Contre le Cancer (UICC/AJCC) 2010 Stage I and II; Radiotherapy applied
62290793|NCT01762514|EXPERIMENTAL|Program II|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine every-other-day regimen
62290794|NCT01762514|ACTIVE_COMPARATOR|Program III|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine everyday regimen
62290795|NCT01762514|NO_INTERVENTION|Program IV|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied
62290796|NCT01762514|EXPERIMENTAL|Program V|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine every-other-day regimen
62290797|NCT01762514|ACTIVE_COMPARATOR|Program VI|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine everyday regimen
62290798|NCT06032221|OTHER|device feasibility|All participants issued with Thermidas device
62290799|NCT00898092||Group 1|Peripheral blood and bone marrow samples are analyzed to assess gene expression using polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays. Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
62290800|NCT05133830|EXPERIMENTAL|Treatment Arm 1|Participants will receive OCA at dose level 1, 4 hours after the linerixibat administration
62290801|NCT05133830|EXPERIMENTAL|Treatment Arm 2|Participants will receive OCA at dose level 2 along with linerixibat
62290802|NCT05133830|EXPERIMENTAL|Treatment Arm 3|Participants will receive OCA at dose level 1 along with linerixibat
62656606|NCT00831844|EXPERIMENTAL|Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
61906991|NCT05736029||Operable NSCLC Patients Receiving ICI as Neoadjuvant or Adjuvant Therapy|Patients with operable stage II-IIIA NSCLC, treated with immune check inhibitor in the neoadjuvant or adjuvant setting
62464064|NCT03875755|EXPERIMENTAL|Myo Inositol|The women will receive 2 caps of Myo Inositol with acid folic a day, until delivery
62656607|NCT00831844|EXPERIMENTAL|Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease|Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62464065|NCT03875755|PLACEBO_COMPARATOR|Placebo|The women will receive 2 caps of placebo (acid folic) a day, until delivery
61906992|NCT05736029||Healthy volunteers|Sex and aged matched non-diseased volunteers
61906993|NCT00393510|ACTIVE_COMPARATOR|Traditional Chinese Medicine|12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
61906994|NCT00393510|PLACEBO_COMPARATOR|Placebo|Placebo was made with starch and colouring materials. Given to patient orally twice a day
62290803|NCT05133830|EXPERIMENTAL|Treatment Arm 4|Participants will receive OCA at dose level 2, 4 hours after the linerixibat administration
62290804|NCT05947240|EXPERIMENTAL|upper extremity aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist. Training intensity will adjust according to 50 80 % of max HR or intensity of dyspnea to 4 points on modified Borg scale (MBS) for at least 15 45 min,3 times/week over 6 weeks.
62464066|NCT01206153|EXPERIMENTAL|metformin|
62656608|NCT00831844|EXPERIMENTAL|Grp 7-Neuroblastoma with measurable disease|Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
61906995|NCT04832100||Patients with primary fibromyalgia|Adults with complaints of chronic widespread pain at the outpatient department of KMUH were consecutively enrolled over a 5-year period from June 2021 to June 2026. Participants were interviewed by experienced neurologists , and those who fulfilled the 2011 American College of Rheumatology (ACR) criteria for FM were recruited .
61906996|NCT04832100||Healthy controls|Age- and sex-matched subjects without pain and soreness were also prospectively recruited as healthy controls.
62656609|NCT00831844|EXPERIMENTAL|Group 8 - Recurrent Osteosarcoma|Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
61906997|NCT00391209|EXPERIMENTAL|1|
62092970|NCT05919108|EXPERIMENTAL|Treatment B (endocrine therapy, neratinib)|Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
62092971|NCT06508749|EXPERIMENTAL|Group 1-Step 1a Entry|"Receiving PGDM1400LS first~Step 1a includes a single-agent safety lead-in period for PGDM1400LS (Group 1), followed by three bNAbs administered on a rotating schedule while participants continue to receive ART. A pharmacokinetic assessment will be conducted for the three bNAbs."
62092972|NCT06508749|EXPERIMENTAL|Group 2-Step 1a Entry|"Receiving PGT121.414.LS first~Step 1a includes a single-agent safety lead-in period for PGT121.414.LS (Group 2), followed by three bNAbs administered on a rotating schedule while participants continue to receive ART. A pharmacokinetic assessment will be conducted for the three bNAbs."
62092973|NCT06508749|EXPERIMENTAL|Step 1b Entry|"ATI Only. For anyone directly enrolling in the Step 3 ATI and not participating in Steps 1 or 2~In Step 1b participants receive three bNAbs administered on a rotating schedule while continuing to receive ART."
62464067|NCT05737992|EXPERIMENTAL|Exercise group|Patients in the intervention group will do high intensity interval training (HIIT) in water. In this study, HIIT training will be short intervals (30 seconds) of movements and 15 seconds of rest.Exercises will be done in a floating position in the deep part. The intervention will be done 3 sessions weekly. The length will be 8 weeks.
62464068|NCT05737992|NO_INTERVENTION|Control group|The patients will continue their usual medication and their usual physical activity.
62464069|NCT00041496|EXPERIMENTAL|Arm 1|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo
62464070|NCT00041496|PLACEBO_COMPARATOR|Arm 2|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo
62656610|NCT00831844|EXPERIMENTAL|Group 9 - Recurrent or Refractory Wilms Tumor|Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
61906998|NCT00391209|EXPERIMENTAL|2|
61906999|NCT04586387|EXPERIMENTAL|Brain stimulation over bicep muscle than finger (FDI) muscle.|Brain stimulation will occur over two sessions. Both sessions will occur with sham stimulation then active stimulation. There will be a 3 day rest period between the two muscle groups.
61907000|NCT04586387|EXPERIMENTAL|Brain stimulation over than finger (FDI) muscle than bicep muscle.|Brain stimulation will occur over two sessions. Both sessions will occur with sham stimulation then active stimulation. There will be a 3 day rest period between the two muscle groups.
61907001|NCT04431674|EXPERIMENTAL|MRg-FUS MB Treatment|Patients with locally advanced breast cancer (LABC) and chest wall tumours will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
61907002|NCT02730793|ACTIVE_COMPARATOR|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
61907003|NCT02730793|EXPERIMENTAL|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
61907004|NCT03112954|EXPERIMENTAL|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
61907005|NCT03112954|EXPERIMENTAL|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
61907006|NCT00411580|EXPERIMENTAL|1|CAD106
61907007|NCT00411580|PLACEBO_COMPARATOR|2|Placebo
62464071|NCT03335761|EXPERIMENTAL|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
62656611|NCT00831844|EXPERIMENTAL|Group 10 - Recurrent or Refractory Retinoblastoma|Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62656612|NCT01244659|EXPERIMENTAL|Tacrolimus from EMS|Group 1: Tacrolimus from EMS + Myfortic® + Steroids
62092974|NCT06508749|EXPERIMENTAL|Step 2a|In Step 2a participants discontinue ART and receive three bNAbs administered on a rotating schedule.
62656613|NCT01244659|ACTIVE_COMPARATOR|Prograf|Group 2: Prograf® + Myfortic® + Steroids
62092975|NCT06508749|EXPERIMENTAL|Step 2b|In Step 2b participants remain off ART and continue to receive three bNAbs administered on a rotating schedule.
62092976|NCT06508749|EXPERIMENTAL|Step 3 progression|ATI Only. Participants discontinue ART and bNAbs. For participants progressing to Step 3 after participating in Steps 1 and 2
61907008|NCT01806662|EXPERIMENTAL|Treatment Arm (Ustekinumab first, Then Placebo)|Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of the study.
62092977|NCT06508749|EXPERIMENTAL|Group 3- Step 3 Direct Entry|ATI Only. Participants discontinue ART. For anyone directly enrolling in the Step 3 ATI and not participating in Steps 1 or 2
62464072|NCT03335761|EXPERIMENTAL|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
62092978|NCT05569005|ACTIVE_COMPARATOR|THS|Subjects who are not willing to quit smoking.
62092979|NCT05569005|ACTIVE_COMPARATOR|Cigarette|Subjects who are not willing to quit smoking.
62092980|NCT05569005|ACTIVE_COMPARATOR|Smoking Abstinence|Subjects who are willing to quit smoking.
62092981|NCT04209686|EXPERIMENTAL|Cohort 1 - Measurable Disease|All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.
62464073|NCT03335761|EXPERIMENTAL|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
62656614|NCT04277585|EXPERIMENTAL|OASIS Clients|Clients of the OASIS Program who live at least 45 minutes away from an Early Psychosis Coordinated Specialty Care Program and are willing to engage in some of their services through telehealth.
62656615|NCT04492670|EXPERIMENTAL|Tui-na and oral Chinese medicine|8 sessions of 20 minutes Tui-na for 4 weeks and take study medication (Herbal granules) twice daily concomitantly for 4weeks
62290805|NCT05947240|EXPERIMENTAL|active alternating movements for the upper limbs a|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
62464074|NCT05336708|EXPERIMENTAL|Acupressure group|The acupressure (experimental) group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
62092982|NCT04209686|EXPERIMENTAL|Arm 2: Cohort 2-Unmeasurable Disease|All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.
62092983|NCT06615037||Group A: Symptomatic dysmenorrhea|According to WaLLID Scale Questionnaire
62092984|NCT06615037||Group B: Asymptomatic dysmenorrhea|According to WaLLID Scale Questionnaire
62092985|NCT04900389||Case Group: Nurses with COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark the answer Yes to the question Have you been diagnosed with COVID-19? 5th question; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
62092986|NCT04900389||Kontrol Group: Nurses who have not had COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark No to the question Have you been diagnosed with COVID-19? And move on to the 4th question in the same section.~The 5th question in Annex 2 of the questionnaire form; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
62092987|NCT04892303|OTHER|High-risk thyroid cancer patients|All study patients will have histologically confirmed recurrence of thyroid cancer that is incompletely responsive to initial surgery.
62092988|NCT05437250||CLL patients treated with acalabrutinib at their physician's discretion|In each center, all patients meeting the inclusion criteria and no exclusion criteria will be offered to participate in this study.
62092989|NCT02721758|EXPERIMENTAL|Brief Motivational Intervention|Single, 60-minute, manualized behavioural intervention designed to support cardiac rehabilitation enrollment, informed by principles of motivational interviewing
62092990|NCT02721758|NO_INTERVENTION|Usual Care|Standard encouragement to enroll in cardiac rehabilitation, and meeting with a researcher to complete study questionnaires
62092991|NCT01023178|ACTIVE_COMPARATOR|Vivelle-Dot|17Beta Estradiol - transdermal
62092992|NCT01023178|ACTIVE_COMPARATOR|Premarin|Conjugated estrogens
62092993|NCT01023178|ACTIVE_COMPARATOR|Estrace|17beta Estradiol
62092994|NCT01445639|EXPERIMENTAL|Dexmedetomidine group|
62092995|NCT01445639|PLACEBO_COMPARATOR|Placebo group|
62092996|NCT01694875||No Treatment|
62092997|NCT01190384|EXPERIMENTAL|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
62464075|NCT05336708|SHAM_COMPARATOR|Sham Acupressure Group|The sham acupressure group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
62092998|NCT01190384|ACTIVE_COMPARATOR|Couscous plus Fiber|Soup with added fiber; has a low ORAC value. Subject serving is isocaloric to the experimental Bean soup.
62092999|NCT01190384|ACTIVE_COMPARATOR|Couscous plus Grape Seed Extract|Control for ORAC value of the Bean soup; for examining the effect of fiber in the bean soup.
62093000|NCT06068153|EXPERIMENTAL|Treatment Arm|Sotorasib + Lenvatinib
62093001|NCT00910884||Arm I|Patients receive oral GRAS supplements daily for 12 months or as possible within the patient's parameters.
62093002|NCT00910884||Arm II|Patients do not receive supplements.
62093003|NCT00539045||A|The study population will consist of patients who are admitted to The New York Presbyterian Hospital-Weill Medical College of Cornell University (NYP-WMC) with ST elevation myocardial infarctions (STEMI). STEMI will be established based on standard clinical and ECG criteria.
62093004|NCT05791877|EXPERIMENTAL|cerebral palsy group|Respiratory sensor will measure breathing in patients with Cerebral palsy
62093005|NCT00430378|EXPERIMENTAL|Acupuncture|Acupuncture Before the Radiation Treatment
62464076|NCT03206619||Social, Local and Mobile|Patients having smoking cessation standard care (behavioral and pharmacological therapy) and using the SoLoMo mobile app that sends them motivational messages.
62093006|NCT00430378|EXPERIMENTAL|Standard Care|Standard Care Without Acupuncture
62093007|NCT06363383|EXPERIMENTAL|MB-001 capsules|Hard shell capsules for oral use as a single administration or multiple daily administrations over five consecutive days
62093008|NCT06363383|PLACEBO_COMPARATOR|Placebo capsules|Matching hard shell placebo capsules for oral use as a single administration or multiple daily administrations over five consecutive days
62093009|NCT01248221|EXPERIMENTAL|Healthy subjects|The subject will consume the test meal containing \[13C\]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
62290806|NCT03835650||PGP|Patients in early postpartum period experiencing PGP, confirmed with dedicated functional tests
62290807|NCT03835650||no PGP|Patients in early postpartum period, with no symptoms and signs of PGP
62290808|NCT05877131|ACTIVE_COMPARATOR|Levobupivacaina|Levobupivacaine 0.125% , dosage 10 ml frequency 1 one dosis duration 1 hour
62290809|NCT05877131|ACTIVE_COMPARATOR|Ropivacaina|Ropivacaine 2 % , dosage 10 ml frequency 1 one dosis duration 1 hour
62464077|NCT03973983|EXPERIMENTAL|Ultrasound-guided pudendal nerve injection group|Patients who received Ultrasound-guided pudendal nerve injections
62093010|NCT01248221|EXPERIMENTAL|Dyspeptic subjects|The subject will consume the test meal containing \[13C\]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
62656616|NCT04492670|OTHER|Tui-na|8 sessions of 20 minutes Tui-na for 4 weeks
62093011|NCT06532279|PLACEBO_COMPARATOR|Arm 1 (placebo)|Patients receive cisplatin QW or Q3W and undergo image-guided intensity-modulated radiation therapy QD 5 days per week for 7 weeks per SOC. In addition to usual symptom management, patients receive placebo SC as early as 96 hours and no later than one hour prior to their first dose of radiation therapy, and as early as 96 hours and no later than 48 hours prior to first dose of cisplatin. Patients then receive placebo SC BIW for 8 weeks (16 doses). Patients also undergo CT and/or MRI on study and may optionally undergo collection of blood, serum, and/or plasma throughout the study.
62093012|NCT06532279|EXPERIMENTAL|Arm 2 (BMX-001)|Patients receive cisplatin QW or Q3W and undergo image-guided intensity-modulated radiation therapy QD 5 days per week for 7 weeks per SOC. In addition to usual symptom management, patients receive BMX-001 SC as early as 96 hours and no later than one hour prior to their first dose of radiation therapy, and as early as 96 hours and no later than 48 hours prior to first dose of cisplatin. Patients then receive BMX-001 SC BIW for 8 weeks (16 doses). Patients also undergo CT and/or MRI on study and may optionally undergo collection of blood, serum, and/or plasma throughout the study.
62093013|NCT05111093|EXPERIMENTAL|all participants|All participants will be provided with the ARC-IM Investigational System (implantable and non-implantable parts)
62093014|NCT00582790|EXPERIMENTAL|1|Interleukin-2 subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles in combination with Zoledronic acid IV on day 1 of every 4 week (28 days) cycle.
62093015|NCT03685747|EXPERIMENTAL|Vancomycin|A single 20 mg/kg intraperitoneal dose in 1-liter of 7.5% icodextrin solution of vancomycin will be administered. Sparse blood sampling will be obtained during an overnight 12-hour dwell and during the exchange period.
62093016|NCT04248075||Control|Patients who do not want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
62093017|NCT04248075||Dexmedetomidine|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, dexmedetomidine is administered for sedation during surgery."
61907009|NCT01806662|PLACEBO_COMPARATOR|Placebo Arm (Placebo first, Then Ustekinumab)|Since there is a crossover design, each patient will be in the placebo arm for 16 weeks of the study. If a patient begins in the placebo arm, they will switch over to the treatment arm at week 16.
62093018|NCT04248075||Propofol|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, propofol is administered for sedation during surgery."
62093019|NCT04248075||Midazolam|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, midazolam is administered for sedation during surgery."
62093020|NCT04145102|NO_INTERVENTION|negative control|restoration will applied without any treatment
62308045|NCT02424539|EXPERIMENTAL|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
62464078|NCT03973983|EXPERIMENTAL|Finger-guided pudendal nerve injection group|Patients who received Finger-guided pudendal nerve injections
62093021|NCT04145102|EXPERIMENTAL|hesperidine|hesperidine will be applied for remaining caries then restoration will be applied
62093022|NCT04145102|EXPERIMENTAL|propolis|propolis will be applied for remaining caries then restoration will be applied
62093023|NCT04145102|EXPERIMENTAL|silver diamine fluoride|silver diamine fluoride will be applied for remaining caries then restoration will be applied
62093024|NCT05162768|EXPERIMENTAL|Elamipretide|0.75 mL of 80mg/mL solution of elamipretide for a single daily SC dose of 60mg elamipretide
62656617|NCT02517723|EXPERIMENTAL|SIC + NET|Waiting List + Standard Inpatient Care + Narrative Exposure Therapy
62656618|NCT02517723|ACTIVE_COMPARATOR|SIC + DBT|Waiting List + Standard Inpatient Care + Dialectical Behavior Therapy
62656619|NCT05649501|EXPERIMENTAL|proprioceptive neuromuscular facilitation techniques|Experimental group will receive proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional physical therapy.
62656620|NCT05649501|ACTIVE_COMPARATOR|traditional physical therapy|this group will receive conventional therapy (ROMs, stretching, strengthening).
61907010|NCT01144299|EXPERIMENTAL|Fluarix Adult Group|Subjects aged 18 to 60 years received one dose of Fluarix™.
61907011|NCT01144299|EXPERIMENTAL|Fluarix Elderly Group|Subjects aged \> 60 years received one dose of Fluarix™.
61907012|NCT00794898|EXPERIMENTAL|Arm 1|Remicade in the treatment of patients with active RA despite treatment with MTX.
62464079|NCT06062914||oral nutritional supplement group|Only oral nutritional supplement was used as enteral nutrition, including but not limited to Ensure®, Nutrison® and etc.
62464080|NCT06062914||no-oral nutritional supplement group|no enteral nutrition was received
62656621|NCT02763618|ACTIVE_COMPARATOR|Group A: Theta/beta ratio Neurofeedback|"In this condition, participants will receive three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
62656622|NCT02763618|ACTIVE_COMPARATOR|Group B: Theta/beta ratio Neurofeedback|"In this condition, participants will receive nine baseline sessions and continue with eight theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
61907013|NCT00934843|EXPERIMENTAL|Single dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive ONE dose intravenous methylprednisolone (IVMP) prior to heart surgery.
61907014|NCT00934843|EXPERIMENTAL|Two Dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
62093025|NCT05162768|PLACEBO_COMPARATOR|Placebo|0.75 mL of 80mg/mL solution of matching placebo for a single daily SC dose of 60mg
62093026|NCT05750511||metastatic melanoma|1,000 subjects with metastatic melanoma stage III or IV suitable for systemic treatment from centers of the German Dermatologic Cooperative Oncology Group (DeCOG)
62464081|NCT03426241||smoking chronic periodontitis|
62464082|NCT03426241||non-smoking periodontitis|
62656623|NCT02763618|PLACEBO_COMPARATOR|Group C: Placebo Neurofeedback training|Three baseline sessions and continue with 14 placebo training sessions. The placebo training will be a previously recorded Neurofeedback session of a participant in group A (receiving 14 real Neurofeedback sessions). Before the participants in group C (placebo trainings) start, they will be matched to a participant in group A, and receive the exact same (prerecorded) feedback per session of their matched participant. In this way, participants in the placebo training are then made to think that the video and EEG feedback is their own, however they are actually not able to influence the continuation of the video.
62656624|NCT01404481||Single use group|New catheter for each Clean Intermittent Self Catheterisation (CISC), then discard.
61907015|NCT00357760|EXPERIMENTAL|Arm A (higher dose of VEGF Trap)|Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62093027|NCT06085729|EXPERIMENTAL|Dose Escalation and Monotherapy Maintenance|Participants will be assigned to a study group and dose level of ADI-PEG20 based on when participant join this study. Up to 2 dose levels of ADI-PEG20 may be tested. Up to 15 participants will be enrolled per dose level.
62093028|NCT01606189|EXPERIMENTAL|GW-1000-02|Active treatment.
62093029|NCT01606189|EXPERIMENTAL|GW-2000-02|Active treatment.
62464083|NCT03426241||smoking healthy|
62464084|NCT03426241||non-smoking healthy|
62464085|NCT03635125|NO_INTERVENTION|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
62464086|NCT03635125|ACTIVE_COMPARATOR|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
62464087|NCT03635125|ACTIVE_COMPARATOR|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
62093030|NCT01606189|PLACEBO_COMPARATOR|Placebo|Placebo control.
62464088|NCT03635125|OTHER|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
62464089|NCT03832257|EXPERIMENTAL|ECHO CT Intervention|Weekly video conference between hospitalist at Beth Israel and skilled nursing facilities.
62464090|NCT03832257|OTHER|Matched Non- Participating Facilities|Matched non-participating facilities
62464091|NCT04121364|EXPERIMENTAL|Tetranite|All patients enrolled in study will receive the dental adhesive with a dental implant. The robustness of the dental implant stability will be assessed at various time points.
62464092|NCT01683032|EXPERIMENTAL|Experimental: Healthy adults|Participants, aged 21-40 years, will be recruited through an advertisement posted at the University of Haifa (including the website of Haifa University).
62464093|NCT01500876|EXPERIMENTAL|Study Arm|Single Arm
62464094|NCT05454553|EXPERIMENTAL|Patients with left sided breast cancer who are planned for|"one of the following heart sparing techniques :~* DIBH radiotherapy~* IMRT"
61907016|NCT00357760|EXPERIMENTAL|Arm B (lower dose of VEGF Trap)|Patients receive a lower dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, the dose of ziv-aflibercept (VEGF Trap) may be escalated to the higher dose in Arm A.
61907017|NCT00761644|EXPERIMENTAL|Doxil, Bevacizumab + Temsirolimus|"Doxil day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.~Bevacizumab day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.~Temsirolimus days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes."
61907018|NCT06151080|EXPERIMENTAL|LO-CHOP|Lenalidomide combined with G-CHOP
61907019|NCT00220922|EXPERIMENTAL|1|injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
61907020|NCT00220922|EXPERIMENTAL|2|injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
61907021|NCT01037192|EXPERIMENTAL|Vanco once daily|Subject receives vancomycin 30 mg/kg dose
61907022|NCT01037192|ACTIVE_COMPARATOR|Vanco twice daily|Subject receives vancomycin 15 mg/kg twice daily
62093031|NCT03033914|EXPERIMENTAL|< 60 years of age with advanced stage (HL) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of A(B)VD and 8 doses of nivolumab. In dose level 1, patients will receive nivolumab in combination with AVD during cycle 6 only followed by 6 additional doses of nivolumab. In subsequent dose levels, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3. A PET scan will be performed after 2 cycles of ABVD and those with a PET-negative response (defined by Deauville 1, 2 or 3) will proceed with 4 additional cycles of ABVD or AVD (per treating physician preference).
62093032|NCT03033914|EXPERIMENTAL|60 years of age and older with HL (any stage) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of AVD and 12 doses of nivolumab. In this cohort, patients will receive nivolumab in combination with AVD during cycles 5 and 6 only, followed by 8 additional doses of nivolumab. In subsequent cohorts, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3. Prophylactic growth factor support is mandatory for all patients on Cohort B and should be used per the treating physician's discretion for all other patients.
62093033|NCT06442189||3. month|Once the baseline values have been determined at the first visit, all tests are repeated after the diet has been followed for 3 months.
62093034|NCT06696755|EXPERIMENTAL|Group 1: Icalcaprant Dose A|Participants will receive oral Icalcaprant dose A once daily for 6 weeks and followed for 4 weeks.
62464095|NCT05086783|EXPERIMENTAL|Video-based coaching|Participants in the intervention arm will receive the standard surgical teaching while in the operating room (master-apprentice model (MAM)), plus the intervention of reviewing the recorded video with the surgical coach after performing their first attempt at laparoscopic closure of the vaginal vault.
61907023|NCT05624333|OTHER|VO group|Vegan diet followed by Omnivorous diet
62464096|NCT05086783|PLACEBO_COMPARATOR|Standard surgical teaching|Participants in the control arm will receive the standard surgical teaching while in the operating room (master-apprentice model-(MAM)).
61907024|NCT05624333|OTHER|OV group|Omnivorous diet followed by Vegan diet
61907025|NCT05464953|ACTIVE_COMPARATOR|Formulated Posterior Sub Tenon Triamcinolone|
61907026|NCT05464953|ACTIVE_COMPARATOR|Posterior Sub Tenon Triamcinolone alone|
61907027|NCT05464953|ACTIVE_COMPARATOR|suprachoroidal Triamcinolone|
61907028|NCT01385397|EXPERIMENTAL|Preceptorship and virtual community|
61907029|NCT02216110||Surgery group|Patients who underwent surgery as treatment of early gastric cancer
61907030|NCT02216110||ESD group|Patients who underwent endoscopic submucosal dissection (ESD) as treatment of early gastric cancer, instead of surgery
61907031|NCT05401058|EXPERIMENTAL|Experimental group|Droperidol 1.25mg/0.5ml
61907032|NCT05401058|PLACEBO_COMPARATOR|Placebo group|Normal saline 0.5ml
61907033|NCT01719744|EXPERIMENTAL|ENMD-2076|ENMD-2076 capsules, 275 mg once daily, by mouth.
62093035|NCT06696755|EXPERIMENTAL|Group 2: Icalcaprant Dose B|Participants will receive oral Icalcaprant dose B once daily for 6 weeks and followed for 4 weeks.
62656625|NCT01404481||Re use of catheters group|"Use same catheter for 1week- Cleaning with sunlight liquid soap, air dry or dry with lint free towel, store in a snap lock bag.~Discard catheter and snap lock bag at end of each week."
62093036|NCT06696755|PLACEBO_COMPARATOR|Group 3: Placebo for Icalcaprant|Participants will receive oral placebo for Icalcaprant daily for 6 weeks and followed for 4 weeks.
62093037|NCT06450184|EXPERIMENTAL|Pimavanserin Capsule|Pimavanserin 34 mg Capsule
62093038|NCT06450184|ACTIVE_COMPARATOR|NUPLAZID® Capsules|NUPLAZID® (Pimavanserin) capsules 34 mg per capsule
62093039|NCT04286555|ACTIVE_COMPARATOR|DASH4D diet with lower sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 1500 mg/day
62464097|NCT02109354|ACTIVE_COMPARATOR|HIV Regimen + Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
62656626|NCT03183206|EXPERIMENTAL|Group A|In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor
62656627|NCT03183206|EXPERIMENTAL|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
62656628|NCT03183206|EXPERIMENTAL|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery
62656629|NCT01289522|EXPERIMENTAL|cetuximab|Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according
62656630|NCT01649765|EXPERIMENTAL|Arm 1|belimumab 10mg/kg IV monthly
62656631|NCT01649765|PLACEBO_COMPARATOR|Arm 2|Normal Saline IV monthly
62656632|NCT02234271|ACTIVE_COMPARATOR|Health Educator Arm|Health Educator for contraception information
62656633|NCT02234271|EXPERIMENTAL|Mobile Health Application Arm|Plan A Birth Control - iPad based application for contraception information
62656634|NCT06436417||Control|Patients who do not undergo prehabilitation.
62656635|NCT06436417||Prehabilitation|Patients who undergo trimodal prehabilitation including physical exercise, nutritional supplementation, and psychological support.
62656636|NCT05987384|PLACEBO_COMPARATOR|Placebo group|Sunflower oil capsules
62656637|NCT05987384|EXPERIMENTAL|D3 ARA group|ARA capsules
62656638|NCT05987384|EXPERIMENTAL|D6 ARA group|Sunflower oil capsules and ARA capsules
62656639|NCT02310308|ACTIVE_COMPARATOR|xylitol chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
62656640|NCT02310308|EXPERIMENTAL|Xylitol-magnolia chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
62656641|NCT02310308|PLACEBO_COMPARATOR|Control chewing gum|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
62656642|NCT00479752|ACTIVE_COMPARATOR|A|"FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m²."
62093040|NCT04286555|ACTIVE_COMPARATOR|DASH4D diet with higher sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 3700 mg/day
62656643|NCT00479752|ACTIVE_COMPARATOR|B|"FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
62656644|NCT02818673|EXPERIMENTAL|Ascites in Patients With Cirrhosis|Patients will be further classified according to the refractory or sensitive ascitis
62656645|NCT01056276|EXPERIMENTAL|Treatment|Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
62656646|NCT04060836|EXPERIMENTAL|group A|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse reference drug Xyntha (group A), then experimental drug (group B). All participants who completed the study will enter the prophylaxis group study.
62656647|NCT04060836|EXPERIMENTAL|group B|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse experimental drug (group B), then reference drug Xyntha (group A). All participants who completed the study will enter the prophylaxis group study.
62656648|NCT00998283|EXPERIMENTAL|Cohort 1|Administration of HM10460A 5μg/kg or Placebo
62656649|NCT00998283|EXPERIMENTAL|Cohort 2|Administration of HM10460A 15μg/kg or placebo
62656650|NCT00998283|EXPERIMENTAL|Cohort 3|Administration of HM10460A 45μg/kg or placebo
62656651|NCT00998283|EXPERIMENTAL|Cohort 4|Administration of HM10460A 135μg/kg or placebo
62656652|NCT00998283|EXPERIMENTAL|Cohort 5|Administration of HM10460A 350μg/kg or placebo
62656653|NCT02834273|EXPERIMENTAL|Therapeutic Workshop|Therapeutic Workshop (patients following therapeutic education workshops during their hospitalization)
62656654|NCT02834273|NO_INTERVENTION|Usual care|
62656655|NCT03018327||Case group|250 Renal Transplant Recipients; 125 women and 125 men
62656656|NCT03018327||Control group|250 healthy controls; 125 women and 125 men
62656657|NCT05839977|EXPERIMENTAL|Individual telerehabilitation group|20 patients with multiple sclerosis
62656658|NCT05839977|ACTIVE_COMPARATOR|Video based exercise group|20 patients with multiple sclerosis
62656659|NCT05839977|NO_INTERVENTION|Control group|20 patients with multiple sclerosis
62656660|NCT01877798|EXPERIMENTAL|△PCO2/Ca-vO2|△PCO2/Ca-vO2 directed group
62656661|NCT01877798|EXPERIMENTAL|ScvO2|ScvO2 directed group
62093041|NCT04286555|ACTIVE_COMPARATOR|Comparison diet with lower sodium|Dietary pattern that is typical of what many Americans with diabetes eat, with sodium level of 1500 mg/day
62656662|NCT01983631|EXPERIMENTAL|WBV group|Stage 1: Short-term Whole body vibration(3 minutes in half-squatting position)
62656663|NCT01983631|NO_INTERVENTION|Non-WBV group|Stage 1 : Controlled group
62656664|NCT01983631|EXPERIMENTAL|training group|Stage 2: Long-term WBV training (3 sessions per week for 4 weeks)
62656665|NCT01983631|NO_INTERVENTION|non-training group|Stage 2: Controlled group
62656666|NCT01503788|ACTIVE_COMPARATOR|periprocedural sedation with midazolam|periprocedural sedation with IV midazolam 5-10 minutes before diagnostic lumbar puncture
62656667|NCT01503788|NO_INTERVENTION|No intervention|Participants will undergo the diagnostic lumbar puncture as routinely practiced
62656668|NCT01944423|EXPERIMENTAL|PSRT_DCS|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
62656669|NCT01944423|PLACEBO_COMPARATOR|PSRT_PBO|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill placebo dose one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
62656670|NCT00825006|NO_INTERVENTION|Control|Dual site pacing (LV tip electrode and RV tip electrode)
62656671|NCT00825006|EXPERIMENTAL|Triple site pacing|Triple site pacing(LV tip electrode,RV tip electrode and RV ring electrode)
62656672|NCT03365648|EXPERIMENTAL|Lertal® + standard therapy|Lertal® double-layer tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
62656673|NCT03365648|PLACEBO_COMPARATOR|Placebo + standard therapy|Placebo tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
62656674|NCT01939457|EXPERIMENTAL|misoprostol|400 mcg misoprostol sublingually
62656675|NCT01092923|EXPERIMENTAL|Air/Oxygen|Sevoflurane with Air/Oxygen Mix
62656676|NCT01092923|EXPERIMENTAL|sevoflurane in N2O/O2|
61907034|NCT00977847|EXPERIMENTAL|Interactive Voice Response Practice|"The introductory letter to patients will allow them an opportunity to opt-out of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR."
62290810|NCT03286972||PET/MRI|"All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner."
61907035|NCT00977847|EXPERIMENTAL|Wireless Tablet PC Practice|Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
62093042|NCT04286555|OTHER|Comparison diet with higher sodium|Dietary pattern that is typical of what many Americans with diabetes eat, with sodium level of 3700 mg/day
62093043|NCT04917692|EXPERIMENTAL|empagliflozin|empagliflozin 2.5 mg daily
62093044|NCT00615082|EXPERIMENTAL|Mindfulness-Based Stress Reduction|"Behavioral: Mindfulness-Based Stress Reduction~Other Names:~MBSR An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching."
62093045|NCT00615082|ACTIVE_COMPARATOR|Caregiver Education & Social Support|"Behavioral: Caregiver Education \& Social Support~Other Names:~CESS An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format."
62093046|NCT05898932||Medical Management|Participants will be managing condition with medication
62290811|NCT02321592|ACTIVE_COMPARATOR|Arm A|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 8 consecutive weeks.~Arm A ist closed."
62290812|NCT02321592|ACTIVE_COMPARATOR|Arm B|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 2 consecutive weeks followed by a weekly appication 6 consecutive weeks.~Arm B is closed."
62290813|NCT02321592|ACTIVE_COMPARATOR|Arm C|AFM13 is administered for five consecutive days a week as continuous infusion for 8 consecutive weeks
62290814|NCT03931018|EXPERIMENTAL|70 grams alcohol|"Males and Females: Alcohol 70 grams (220 ml Vodka Absolut®), single dose, oral administration~- 70 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
62290815|NCT03931018|EXPERIMENTAL|100 grams alcohol|"Males: Alcohol 100 grams (312 ml Vodka Absolut®), single dose, oral administration~- 100 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
62464098|NCT02109354|ACTIVE_COMPARATOR|HIV Vaccine Regimen|Participants will receive a placebo for tetanus vaccine by injection (placebo tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a placebo for hepatitis B vaccine series (months 7.5, 8.5, 13)
62464099|NCT02109354|PLACEBO_COMPARATOR|Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of a placebo for the experimental canarypox HIV vaccine (placebo for ALVAC-HIV; months 1, 2), than 2 injection of a placebo protein HIV vaccine boost (placebo for AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
62464100|NCT05110209||Aflibercept|Patients/patient eyes who were treated only with aflibercept in 2019
62464101|NCT05110209||Ranibizumab|Patients/patient eyes who were treated only with ranibizumab in 2019
62464102|NCT05110209||Bevacizumab|Patients/patient eyes who were treated only with bevacizumab in 2019
62464103|NCT05110209||≥2 Different Anti- VEFGFs|Patients/patient eyes who were treated with ≥2 different anti-VEGFs in 2019
62093047|NCT05898932||Surgical Management|Participants will be managing condition with a surgery
62093048|NCT00556543|OTHER|Treatment|
62093049|NCT00597870|EXPERIMENTAL|Treatment of Thoracic Lesions|Endoluminal treatment of thoracic lesions
62093050|NCT02438917||Hepatitis C|Patients who are about to begin HCV treatment
62093051|NCT05764720|EXPERIMENTAL|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system
62290816|NCT00542191|EXPERIMENTAL|Neoadjuvant metronomic AC followed by weekly TC|Neoadjuvant chemotherapy with metronomic AC followed by weekly TC then surgery
62290817|NCT01371630|EXPERIMENTAL|Arm I (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description Arm I
62464104|NCT00545545|EXPERIMENTAL|Arm 1, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
62464105|NCT00545545|EXPERIMENTAL|Arm 1, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
62464106|NCT00545545|EXPERIMENTAL|Arm 1, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
62464107|NCT00545545|EXPERIMENTAL|Arm 2, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
62464108|NCT00545545|EXPERIMENTAL|Arm 2, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
62656677|NCT05920226||A: 150 patients with indications for pacemakers implantation;|"* men or women over 60 years of age~* with signed informed consent form~* in presence of cardiac pathology and arrhythmia requiring pacemakers implantation.~* without active cancer or remission period less than 5 years;~* without decompensated somatic pathology;~* without active viral hepatitis, HIV or syphilis.~Patients will be under observation for 2 years (inclusion in the study, visit 1, 12, 24 months after inclusion in the study)."
62093052|NCT06613386|EXPERIMENTAL|IBDPS intervention|"Caregivers receive the IBDPS alongside usual care.~* Grounded in the theories of empowerment and Timing It Right (TIR), the IBDPS delivers continuous, individualized support through an information-based platform from admission to one month postdischarge, facilitating seamless integration of discharge preparation across both online and offline environments.~* Upon admission, caregivers register via WeChat, receiving tailored, stage-specific guidance on key topics such as Growth, Feeding, and Sleep, aligned with the evolving needs of preterm infants. They can submit nursing concerns and assess their emotional state, with healthcare providers offering ongoing guidance. When the infant's condition stabilizes, caregivers can schedule NICU visits and engage in supervised bedside care training. Prior to discharge, hands-on training is provided. Postdischarge, caregivers upload growth data for continuous monitoring, with the option of home nurse visits."
62656678|NCT05920226||B: 150 patients without pacemakers implantation;|"* men or women over 60 years of age~* with signed informed consent form~* in presence of cardiac pathology and arrhythmia not requiring pacemaker implantation.~* without active cancer or remission period less than 5 years;~* without decompensated somatic pathology;~* without active viral hepatitis, HIV or syphilis."
62656679|NCT04682301||Aims I-II|"AIM I: Participants attend a focus group over 1-1.5 hours providing feedback on refining potential methods of SDM.~AIM II: Participants receive the SDM intervention developed in Aim I and provide feedback. Participants may attend a telephone interview over 45 minutes 1 month later."
62656680|NCT02880501|EXPERIMENTAL|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled will undergo proximal femoral nail antirotation (PFNA) implantation.
62656681|NCT04355273|EXPERIMENTAL|Heparin with a concentration of 2 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
62656682|NCT04355273|EXPERIMENTAL|Heparin with a concentration of 4 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
62656683|NCT04355273|PLACEBO_COMPARATOR|normal saline|normal saline is placed in a pressure bag with a pressure of 300 mmHg
62656684|NCT05732389|EXPERIMENTAL|nivolumab + ipilimumab|"Patients will be treated with 1 or 2 cycles of combination immunotherapy:~Cycle 1: Nivolumab 3 mg/kg days 1 and 15 \& ipilimumab 1 mg/kg day 1 Cycle 2: Nivolumab 3 mg/kg days 50 and 65 \& ipilimumab 1 mg/kg day 50"
62656685|NCT01848028||Fumaric acid esters|Intervention: Drug: conventional systemic: Fumaric acid esters, including Dimethylfumarate, all dosages, frequencies and durations prescribed
62656686|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
62656687|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
62656688|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
62656689|NCT01848028||Etanercept|Intervention: Biological and biosimilars: Etanercept, all dosages, frequencies and durations prescribed
62656690|NCT01848028||Infliximab|Intervention: Biological and Biosimilars/-identicals: Infliximab, all dosages, frequencies and durations prescribed
62656691|NCT01848028||Adalimumab|Intervention: Biological and Biosimilars: Adalimumab, all dosages, frequencies and durations prescribed
62656692|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
62093053|NCT06613386|NO_INTERVENTION|Usual care|"Receive the usual care.~* Routine admission education includes inpatient guidelines, breast milk storage, and receiving processes.~* During hospitalization, healthcare providers are responsible for all infant care. Caregivers can visit three times a week at scheduled times, with visiting days arranged by the odd or even numbers of the inpatient ID. Visits are conducted via live video, allowing caregivers to consult with doctors about the infant's condition.~* Upon discharge, healthcare providers educate caregivers on discharge precautions and preterm infant care methods.~* Follow-up is conducted through phone calls and outpatient visits."
62093054|NCT03459495|ACTIVE_COMPARATOR|Group A|Group A: ultrasound group
62093055|NCT03459495|PLACEBO_COMPARATOR|Group P|Group P: placebo ultrasound group
62093056|NCT04692337|EXPERIMENTAL|Ommaya Reservoir placement|Subjects undergoing surgery for a confirmed or suspected brain tumor will have an Ommaya Reservoir placed at the time of surgery.
62093057|NCT06552416|EXPERIMENTAL|Cohort -1|50 × 106 cells flat dose, 1 dose infused on Day 0
62093058|NCT06552416|EXPERIMENTAL|Cohort 1|100 × 106 cells flat dose, 1 dose infused on Day 0
62093059|NCT06552416|EXPERIMENTAL|Cohort 2|200 × 106 cells flat dose, 1 dose infused on Day 0
62464109|NCT00545545|EXPERIMENTAL|Arm 2, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
62464110|NCT04487262|ACTIVE_COMPARATOR|Day O chest tube removal|"Chest tubes maybe removed ten hours after arrival at the intensive care provided standardized removal criteria are fulfilled:~1. blood loss through chest tubes less than 200 ml during the last four hours~2. no air leak~3. the patient extubated and mobilized It remains at the discretion of the attending cardiac surgeon to postpone chest tube removal in cases of increased bleeding risk, due to circumstances which develop during the perioperative period"
62656693|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
62656694|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
62656695|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
62656696|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
62656697|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
61907036|NCT00977847|EXPERIMENTAL|Internet Portal Practice|Patients in this practice will receive the informational letter either by email or mail one month before their scheduled visit. It will have directions to access the MFHP website and how to transfer data through the hospitals secure internet portal (Patient Gateway). About 1/3 of patients are signed up to use this service. Those who do not have a Patient Gateway account will be provided with directions on how to establish this service. Patients will be required to have a Gateway account to ensure that the MFHP data file is sent securely to the correct EHR record. Patients in this arm will receive an initial email or letter with a single follow-up reminder sent 2 weeks later. For patients who participate, the completed family history data will be transmitted to the patient's EHR.
62093060|NCT06552416|EXPERIMENTAL|Cohort 3|400 × 106 cells flat dose, 1 dose infused on Day 0
62290818|NCT01371630|EXPERIMENTAL|Arm II (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description Arm II
62290819|NCT01371630|EXPERIMENTAL|Arm III (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description Arm III
62290820|NCT02343692|EXPERIMENTAL|Radiofrequency abalation|"Intervention: Endoscopic Ultrasound (EUS) guided radiofrequency ablation (RFA) of cystic tumours of the pancreas~Device: An RFA generator (ERBE VIO 300D, Dolby medical products, Scotland)~Procedure: Delivery of sequential doses of electrical energy at 10W for a total of up to 4 minutes 30 seconds (3 x 90 second applications) to ablate the cystic lesion.~Ablation of cystic tumours of the pancreas"
62290821|NCT03706586|ACTIVE_COMPARATOR|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
61907037|NCT00977847|ACTIVE_COMPARATOR|Usual Care Physician Assesment Practice|Usual standard family history assessments will be conducted by physicians during the patient visit. This arm will allow us to account for any temporal trends in family history assessment.
61907038|NCT04698096||metabolic syndrome|Patients with metabolic syndrome
61907039|NCT04698096||Healthy volunteers|Healthy volunteers
61907040|NCT02635932|EXPERIMENTAL|Functional Splint group|Patient will be using the functional splint during their activity daily life
61907041|NCT02635932|ACTIVE_COMPARATOR|Night Splint group|Patients will use the night splint during the sleep time
61907042|NCT01217307|EXPERIMENTAL|Metformin|metformin 500mg twice daily during 4 months
62093061|NCT06552416|EXPERIMENTAL|Cohort 4 (optional)|up to 400 × 106 cells flat dose TBD based on data from Cohorts 1-3; may include split dosing, dosing with or without lymphodepleting conditioning regimen, or dosing with or without HMA
62093062|NCT03930979||Clearsight measurements|All patients presenting to the ED who have a painful condition for which procedural sedation is required will undergo Clearsight measurements
62290822|NCT03706586|EXPERIMENTAL|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
62290823|NCT00331435|ACTIVE_COMPARATOR|1|FA-guided PDT
62290824|NCT00331435|EXPERIMENTAL|2|ICG-guided PDT
62464111|NCT04487262|ACTIVE_COMPARATOR|Day 1 chest tube removal|"Chest tubes are removed in the early morning of the first postoperative day, provided standardized removal criteria are fulfilled:~1. blood loss through chest tubes less than 200 ml during the last four hours~2. no air leak~3. the patient extubated and mobilized It remains at the discretion of both the attending surgeon and anestesiologist to remove chest tubes prematurely in cases of drain-induced, severe analgetic resistant, intractable pain resistant to analgetic treatment."
62464112|NCT00881088|NO_INTERVENTION|1|Patients randomized to the no intervention group
62464113|NCT00881088|EXPERIMENTAL|Nadroparin|Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
61907043|NCT01217307|PLACEBO_COMPARATOR|Placebo|Placebo twice daily during 4 months
62093063|NCT02888795|EXPERIMENTAL|hypertonic dextrose prolotherapy|
62464114|NCT00881088|EXPERIMENTAL|Fondaparinux|Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
62464115|NCT03979703|EXPERIMENTAL|Intervention group|Intervention will be a 12 week yoga class
61907044|NCT02325869|EXPERIMENTAL|Bell Balloon Catheter|The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
61907045|NCT05185206|ACTIVE_COMPARATOR|Analysis of post-operative sensitivity after caries removal using conventional steel bur|Caries will be excavated using a carbide on one side of the arch and restoration will be done with Cention-N(commercially available restorative material) as per manufacturer's instructions.Thermal stimulation (refrigerant spray Endo-Ice) will be used to evaluate the type of sensitivity. The pain intensity will be recorded with the Visual Analog Scale.
62093064|NCT05357196|OTHER|PT-112 in Combination with Gemcitabine Injection|PT-112 in combination with Gemcitabine injection for the treatment of patients with advanced solid tumors
62093065|NCT06696430||Control Group (Baseline)|This group includes healthcare staff and patients prior to the intervention. Baseline data will be collected on TENS usage rates, pain levels, and opioid consumption to assess initial practices in postoperative pain management.
62093066|NCT06696430||Intervention Group X1 (Education + superusers)|"Healthcare staff and patients following an educational intervention. This phase includes sessions on TENS usage and support from designated superusers to increase knowledge and skills related to TENS for postoperative pain management."
62093067|NCT06696430||Intervention Group X2 (Nudging)|Healthcare staff exposed to nudging strategies designed to enhance the use of TENS, which is currently available in routine care but underutilized. This phase involves visual prompts, reminders, and environmental cues aimed at making TENS more salient and encouraging its use for postoperative pain management.
62093068|NCT01276535|EXPERIMENTAL|Erchonia MLS + Erchonia THL|"The Erchonia® MLS contains 5 independent diodes: 4 each emitting 17 milliwatt (mW) 635 nanometers (nm) of red laser light and the fifth diode emitting 17 mW, 405 nm of blue laser light.~The Erchonia THL is a single diode pulsed laser that emits 4.9 milliwatts (mW) of red 635 nanometer (nm) light."
62093069|NCT01650311||Healthy controls|Healthy control group will include participants consenting prior to colorectal cancer screening.
62093070|NCT01650311||CD patient groups|The patient groups will include patients with clinical diagnosis of CD.
62290825|NCT02633540|EXPERIMENTAL|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
62290826|NCT01332448||Orlistat 120|Orlistat 120mg tid
62290827|NCT01332448||Orlistat 60|Orlistat 60 mg tid
62290828|NCT01332448||Placebo|No active drug
62290829|NCT03462251|EXPERIMENTAL|Arm A|Combination of ribociclib and aromatase inhibitor or fulvestrant
62290830|NCT03462251|ACTIVE_COMPARATOR|Arm B|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
62290831|NCT05522426|EXPERIMENTAL|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
62290832|NCT02954380|EXPERIMENTAL|ZIO/ILR|THe Zio ILR arm will already have an ILR implanted for standard of care and will receive the Zio patch
62290833|NCT03561402||Patients with active disease|From the cohort of patients receiving teriflunomide - 1 tablet (14 mg) daily, the investigators will identify patients that have active disease..
62290834|NCT03561402||Patients with stable disease|From the cohort of patients receiving teriflunomide (as above), the investigators will identify patients that have stable disease.
62290835|NCT06251011|NO_INTERVENTION|Control group|Receive an advice and a leaflet for cardiopulmonary rehabilitation.
62290836|NCT06251011|EXPERIMENTAL|Physiotherapy group|Receive the physical therapy training via video call (Pulmonary training, Calisthenic exercise, Upper and lower limbs strengthening exercise, Core stabilizer exercise, Aerobic exercise) at day 3, 6, 9, 12, 16, and 21 after positive in COVID-19 testing and also receive advise and a leaflet for cardiopulmonary rehabilitation.
62290837|NCT04876547||In pregnancy|Appendectomy in pregnancy (n=12)
62290838|NCT04876547||In postpartum|Appendectomy in postpartum first six week (n=20)
62290839|NCT02237690|EXPERIMENTAL|doxorubicin hydrochloride liposome（Libaoduo）|Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma) after at least 4-weeks.
62290840|NCT02237690|ACTIVE_COMPARATOR|doxorubicin hydrochloride liposome|Use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
62290841|NCT01097928||Patients undergoing Pulmonary Embolectomy|
62290842|NCT05105763|OTHER|feedback training on single joint first|Participants in Subgroup 1 will first undergo Condition B in the first visit and then Condition A in the second visit.
62290843|NCT05105763|OTHER|sequential feedback training on multi-joint first|Participants in Subgroup 2 will start with Condition A in the first visit and then undergo Condition B in the second visit.
62290844|NCT03580330|EXPERIMENTAL|Intervention Group|
62093071|NCT01650311||UC patient group|The patient groups will include patients with clinical diagnosis of UC.
62290845|NCT03580330|NO_INTERVENTION|Control Group|
62290846|NCT02236169|EXPERIMENTAL|Ipratropium bromide|
62290847|NCT02236169|ACTIVE_COMPARATOR|ATROVENT|
62290848|NCT03878485|EXPERIMENTAL|Stereotactic MRI-guided Adaptive Radiotherapy|-Radiotherapy will consist of stereotactic body therapy to the spine, to be given over either a two or five fraction course, delivered once daily or once every other day for a period of one to two weeks, for a total of two or five treatments (depending on whether a 2 or 5 fraction course is selected).
62290849|NCT05647330|EXPERIMENTAL|Hydroxychloroquine combined with gemcitabine|"1. Hydroxychloroquine sulfate tablets: twice a day, each time (600mg). Continuous oral administration. Until the disease progresses or becomes intolerable.~2. gemcitabine was administered intravenously at a dose of 1000mg/m2 for 30min,d1, 8, and every 3 weeks (21 days) until disease progression or intolerable toxicity, with a maximum duration of 2 years."
62290850|NCT01580930|NO_INTERVENTION|Control group|Group had outcome measures collected and were instructed to not change activity and sedentary time behavior
62290851|NCT01580930|EXPERIMENTAL|Exercise|Participants performed 5 days per week, 40 min per session of exercise training under direct supervision of personal trainer.
62290852|NCT01580930|EXPERIMENTAL|Sedentary time reduction|participants were give strategies to reduce sedentary time
62093072|NCT04976036|EXPERIMENTAL|Nintedanib|nintedanib 150 mg once a day for 2 weeks, then twice a day for 14 weeks
62093073|NCT04976036|PLACEBO_COMPARATOR|Placebo|placebo 150 mg once a day for 2 weeks, then twice a day for 14 weeks
62290853|NCT01580930|EXPERIMENTAL|exercise plus sedentary time reduction|Participants completed exercise training (5 days per week, 40 min per session) plus were given sedentary time reduction intervention
62290854|NCT03389945|ACTIVE_COMPARATOR|25G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 25 gauge spinal needle.
62290855|NCT03389945|EXPERIMENTAL|27G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 27 gauge spinal needle.
62290856|NCT00408863|ACTIVE_COMPARATOR|Tibolone|Tibolone 2.5 mg/day
62290857|NCT00408863|PLACEBO_COMPARATOR|Placebo|Placebo
62290858|NCT00799526|EXPERIMENTAL|Ex Vivo Transplantation|Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
62290859|NCT04426305|EXPERIMENTAL|Intervention arm|psychosocial support
62290860|NCT04426305|ACTIVE_COMPARATOR|control arm|care as usual
62290861|NCT01126580|EXPERIMENTAL|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
62290862|NCT01126580|EXPERIMENTAL|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
62290863|NCT01126580|ACTIVE_COMPARATOR|Metformin|"Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52~Placebo: subcutaneously (SC), once weekly for 52 weeks"
62290864|NCT04349137|EXPERIMENTAL|In-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a synchronized (in-phase) manner at a frequency of 6Hz
62290865|NCT04349137|ACTIVE_COMPARATOR|Anti-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a desynchronized (anti-phase, i.e. with a difference of 180deg) manner at a frequency of 6Hz
62464116|NCT03979703|NO_INTERVENTION|Control group|Control group will not participate in the 12 week yoga class but will participate in Surveys, 6 minute walking test, lung function test, and biomarker analysis. Furthermore, they will be offered a yoga class after the study.
62464117|NCT06128811|EXPERIMENTAL|Group 1|Participants who will receive rubber dam isolation followed by DryShieled will be considered group 1.
62464118|NCT06128811|ACTIVE_COMPARATOR|Group 2|Participants who will receive DryShieled followed by rubber dam isolation will be considered group 2.
62464119|NCT02870920|ACTIVE_COMPARATOR|Best Supportive Care|Best supportive care available
62656698|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
62093074|NCT05533697|EXPERIMENTAL|Arm 1a (Dose Escalation): mRNA-4359 Alone|Participants will be administered mRNA-4359 at an applicable dose as monotherapy.
62093075|NCT05533697|EXPERIMENTAL|Arm 1b (Dose Confirmation): mRNA-4359 in Combination with Pembrolizumab|Participants will be administered mRNA-4359 in combination with pembrolizumab at an applicable dose.
62093076|NCT05533697|EXPERIMENTAL|Arm 2 (Dose Expansion): mRNA-4359 in Combination with Pembrolizumab|Participants will be administered mRNA-4359 in combination with pembrolizumab at an applicable dose.
62290866|NCT04349137|SHAM_COMPARATOR|Sham tACS|A sham transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC at a frequency of 6Hz using physical vibrations instead of electrical current
62290867|NCT06322082|EXPERIMENTAL|Pilates and Shock Wave group|30 patients will receive Pilates exercises combined with Low Intensity Extracorporeal Shock Wave Therapy and conventional pelvic floor muscle exercises
62290868|NCT06322082|EXPERIMENTAL|Shock Wave group|30 patients will receive Low Intensity Extracorporeal Shock Wave Therapy and conventional pelvic floor muscle exercises.
62290869|NCT06322082|EXPERIMENTAL|Pilates group|30 patients will receive Pilates exercises and conventional pelvic floor muscle exercises
62290870|NCT06322082|EXPERIMENTAL|control group|30 patients will receive conventional pelvic floor muscle exercises
62290871|NCT01453881|EXPERIMENTAL|Spacer|Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
62290872|NCT01453881|ACTIVE_COMPARATOR|Comparator|Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
62290873|NCT04474327|EXPERIMENTAL|Intervention group|"The intervention group will receive Montelukast Sodium for 10 days in addition to the conventional antibiotic therapy regimen and other supportive measures according to the policy of neonatal units and patients' needs. Montelukast sodium will be given at a dose according to body weight (1.5 kg to 2 kg, will be given 1.5 mg; greater than 2 kg, 2 mg will be given) this dose was calculated according to ( Kim et al. (2015). Four mg of the drug will be dissolved in four ml milk and 1.5 - 2 ml milk only will be given once daily at 9 pm via an orogastric tube or by oral administration for 10 days and patients of this group will be closely observed for development of Montelukast side effects as diarrhea, colic, vomiting, fever and cough (Adelsberg et al. 2005)."
61907046|NCT05185206|EXPERIMENTAL|Analysis of post-operative sensitivity after caries removal using polymer bur|Caries will be excavated using a polymer on one side of the arch and restoration will be done with Cention-N(commercially available restorative material) as per manufacturer's instructions.Thermal stimulation (refrigerant spray Endo-Ice) will be used to evaluate the type of sensitivity. The pain intensity will be recorded with the Visual Analog Scale.
62093077|NCT05548530||Stereotactic intracranial hematoma puncture treatment group|Check the CT slice of the patient's brain, find out the patient's largest hematoma level, measure the coordinates of the puncture center, locate and mark the skull surface according to the measured coordinates, select the puncture point under the stereotaxic instrument, Mainly avoid important blood vessels, nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
62093078|NCT05548530||drug treatment group|General treatment: Based on high-level nursing care and close and continuous attention to the patient's vital signs, the patient is instructed to stay in bed continuously, give oxygen, and instruct the patient to avoid emotional agitation, etc. ②Special treatment: use hemostatic drugs, control blood pressure to prevent rebleeding, control blood sugar, control body temperature, anti-epilepsy, prevent infection, dehydration and lower intracranial pressure, etc. Multisystem complications such as tract hemorrhage should be actively managed.
62290874|NCT04474327|NO_INTERVENTION|Control group|The control group will receive antibiotics and other supportive measures according to the policy of neonatal units and patients' needs.
62290875|NCT04022564||The subjects are diagnosed as MS patient|The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'.
62290876|NCT05896007|EXPERIMENTAL|ZR-chemo|Drug: Zanubrutinib, Rituximab and MTX (or TMZ, if intolerant to MTX)
62290877|NCT06064760|EXPERIMENTAL|Experimental group|The experimental group is given the Workshop on Strengths and Competences to Improve Psychological Wellbeing and Quality of Life of Grandparents.
62290878|NCT06064760|NO_INTERVENTION|Control group|The control group is not given the Workshop on Strengths and Competences to Improve Psychological Wellbeing and Quality of Life of Grandparents.
62290879|NCT02347631|EXPERIMENTAL|Alcon DAILIES TOTAL1, and ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
62290880|NCT02347631|ACTIVE_COMPARATOR|ACUVUE TruEye and Alcon Dailies Total 1|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm \& 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
62656699|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
62656700|NCT01848028||Guselkumab|Intervention: Biological: Guselkumab all dosages, frequencies and durations prescribed
62656701|NCT01848028||Brodalumab|Intervention: Biological: Brodalumab, all dosages, frequencies and durations prescribed
62290881|NCT02038348|OTHER|PET with 18F-FDOPA|
62290882|NCT02755402|EXPERIMENTAL|Rapid evaluation|Transient elastography, Xpert HCV Viral load, medical and nurse visits
61907047|NCT01779817|OTHER|child born to hyperthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
61907048|NCT01779817|OTHER|child born to euthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
61907049|NCT03751657|EXPERIMENTAL|Insulin 287|Participants will receive once weekly insulin 287 and once daily placebo in combination with metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i) during 26 weeks of treatment period.
62290883|NCT02200484|EXPERIMENTAL|Parent Training/Obesity Prevention|Mother-child dyads randomized to the active intervention in the pilot study will be administered 8 weeks of a combined parenting training and obesity prevention program that was adapted through analysis of formative research interviews with adolescent mothers with feedback from an expert panel of multidisciplinary research team members and community members.
62290884|NCT02200484|ACTIVE_COMPARATOR|8-week Wellness Program (Control)|Participants randomized to control condition during intervention piloting will receive print-based health and wellness materials once weekly for 8-weeks + 2 follow up telephone calls at the beginning and conclusion of the 8-week program.
62290885|NCT03377647|ACTIVE_COMPARATOR|Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
62290886|NCT03377647|ACTIVE_COMPARATOR|Year three intervention|Both interventions will occur in the Chinle Agency during year three.
62290887|NCT03377647|ACTIVE_COMPARATOR|Year four intervention|Both interventions will occur in the Fort Defiance during year four.
62656702|NCT01848028||Tildrakizumab|Intervention: Biological: Tildrakizumab, all dosages, frequencies and durations prescribed
62656703|NCT01848028||Risankizumab|Intervention: Biological: systemic Risankizumab, all dosages, frequencies and durations prescribed
62656704|NCT01848028||Bimekizumab|Intervention: Biological: Bimekizumab, all dosages, frequencies and durations prescribed
62656705|NCT01848028||Tofacitinib|Intervention: JAK-Inhibitor: Tofacitinib, all dosages, frequencies and durations prescribed
61907050|NCT03751657|ACTIVE_COMPARATOR|Insulin glargine|Participants will receive once daily insulin glargine and once weekly placebo in combination with metformin with or without DPP4i during 26 weeks of treatment period.
62093079|NCT05548530||decompressive craniectomy treatment group|Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.
62093080|NCT05548530||Neuroendoscopic treatment group|The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
62093081|NCT06462833||postmenopausal osteoporosis|Patients followed in the Physical Medicine and Rehabilitation outpatient clinic with a diagnosis of postmenopausal osteoporosis.
62093082|NCT05626452|NO_INTERVENTION|Usual Care|The current mechanisms used at each healthcare site to assess HIV risk/ take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
62093083|NCT05626452|EXPERIMENTAL|Intervention|Implementation of 1) Patient Education, 2) Provider PrEP training, 3) EMR optimization, and 4) PrEP navigation, and the effect of these intervention components on the ability of each site to assess HIV risk/take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP-eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
62093084|NCT01989715|EXPERIMENTAL|adult patients waiting for orthognathic surgery|
62290888|NCT04703023||COPD|Secretions are collected from Bronchoscopy in clinical routine in COPD patients
62290889|NCT04703023||lung healthy|Secretions are collected from Removal of endotracheal tubes after elective surgery in lung healthy patients
62656706|NCT01848028||Upadacitinib|Intervention: JAK-Inhibitor: Upadacitinib, all dosages, frequencies and durations prescribed
62093085|NCT06247098|EXPERIMENTAL|Xenograft - Autogenous 1:4|Sinus grafted with a ratio of Xenograft - Autogenous 1:4
62093086|NCT06247098|ACTIVE_COMPARATOR|Xenograft alone|Sinus grafted with Xenograft only
62290890|NCT02281890||Proven sepsis|Children included in the INIS trial in whom pathogenic organisms (i.e. bacteria or fungi) were cultured from blood and/or cerebrospinal fluid during the sepsis period at the time of study inclusion
62290891|NCT02281890||Clinical sepsis|Children included in the INIS trial in whom no pathogenic organisms (i.e. bacteria or fungi) were cultured from blood or cerebrospinal fluid during the sepsis period at the time of study inclusion
62290892|NCT04508907|EXPERIMENTAL|Arm 1: Pre-emptive Treatment Arm|Single arm study were all recipients of HCV viremic organs will receive combination therapy.
62290893|NCT01135732||study group-previous sphincterotomy|
62656707|NCT01848028||Baricitinib|Intervention: JAK-Inhibitor: Baricitinib, all dosages, frequencies and durations prescribed
62656708|NCT01848028||Deucravacitinib|Intervention: JAK-Inhibitor: Deucravacitinib, all dosages, frequencies and durations prescribed
62290894|NCT01135732||control group-not previous sphincterotomy|
62656709|NCT01848028||Ixekizumab|Intervention: Biological: Ixekizumab, all dosages, frequencies and durations prescribed
62656710|NCT05255107|SHAM_COMPARATOR|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard-of-care treatment and Sham CXL and administration of artificial tears.
62656711|NCT05255107|EXPERIMENTAL|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. PESCHKE-L Solution is a riboflavin 5'-phosphate 0.23% ophthalmic solution that functions as a photosensitizer and is indicated for use with the PXL Platinum 330 Illumination System. Designed to be used when there is epithelial disruption as can occur with a corneal ulcer or wound. It does not contain benzalkonium chloride. It is intended to achieve rapid absorption.
62656712|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
62656713|NCT01636843|EXPERIMENTAL|60 mg|
62656714|NCT01636843|EXPERIMENTAL|120 mg|
62656715|NCT01636843|EXPERIMENTAL|240 mg|
61907051|NCT03140215|ACTIVE_COMPARATOR|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
62290895|NCT01321489|EXPERIMENTAL|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
62290896|NCT01321489|ACTIVE_COMPARATOR|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
62290897|NCT04323930|EXPERIMENTAL|eyeWatch|
62290898|NCT04323930|EXPERIMENTAL|Trabeculectomy|
62290899|NCT06355882|ACTIVE_COMPARATOR|Grupo de estudo (Lidocaine with epinephrine)|Anesthetic lidocaine 2% with epinephrine 1:100.000
62290900|NCT06355882|ACTIVE_COMPARATOR|Grupo controle (Lidocaine)|Anesthetic lidocaine 2%
62656716|NCT01636843|EXPERIMENTAL|Placebo|
61907052|NCT03140215|ACTIVE_COMPARATOR|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
61907053|NCT04858191||Pediatric PCD|Pediatric participants with PCD
62656717|NCT02043067||new HIV clinic enrollees|All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.
62656718|NCT00855608|EXPERIMENTAL|adalimumab arm|intravitreal mode of delivery
62656719|NCT06282055||Women with T1D|Women living with T1D who are willing to share their diabetes management and menstrual cycle data.
62290901|NCT03791632|NO_INTERVENTION|witness|2 control CE2 classes without oral sensitization actions
62290902|NCT03791632|EXPERIMENTAL|group intervention 1|2 CE2 classes with a classical lecture style presentation
62290903|NCT03791632|EXPERIMENTAL|group intervention 2|2 CE2 classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
62290904|NCT03791632|EXPERIMENTAL|group intervention 3|2 CE2 classes with digital media intervention
62656720|NCT04525092|ACTIVE_COMPARATOR|Conventional Hemodialysis|Participants will receive intermittent HD for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode HD).
62656721|NCT04525092|EXPERIMENTAL|Pre-dilution Hemodiafiltration|Participants will receive intermittent pre-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode pre-dilution HDF).
62656722|NCT04525092|EXPERIMENTAL|Post-dilution Hemodiafiltration|Participants will receive intermittent post-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode post-dilution HDF).
62290905|NCT03052647|ACTIVE_COMPARATOR|Subcuticular arm|closure technique that the Adhesive Latch arem (dermaclip) arm is being compared to
62290906|NCT03052647|ACTIVE_COMPARATOR|Adhesive Latch Arm (Demaclip arm)|This is the arm which the adhesive latch system is used and it is being compared to the arm of subcuticular
62290907|NCT03211182|EXPERIMENTAL|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
62290908|NCT03211182|NO_INTERVENTION|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
62290909|NCT02939131|EXPERIMENTAL|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
62290910|NCT02939131|ACTIVE_COMPARATOR|Enhanced Standard of Care|Enhanced Standard of Care (ESC)
62290911|NCT01488006||Bigliani/Flatow Shoulder System|Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
62464120|NCT02870920|EXPERIMENTAL|Durvalumab plus Tremelimumab and Best Supportive Care|Tremelimumab 75mg IV 60 minutes Day 1, cycles 1-4 Durvalumab 1500mg IV 60 minutes Day 1 every 28 days. Plus best supportive care
62656723|NCT03261401|PLACEBO_COMPARATOR|Part A: Placebo (Pooled)|Participants received capsules containing 50 milligram (mg) of placebo matched similar to M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose.
62656724|NCT03261401|EXPERIMENTAL|Part A: Cohort 1 SAD: M5717 50 mg|Participants received single ascending dose (SAD) of 50 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656725|NCT03261401|EXPERIMENTAL|Part A: Cohort 2 SAD: M5717 100 mg|Participants received SAD of 100 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656726|NCT03261401|EXPERIMENTAL|Part A: Cohort 3 SAD: M5717 200 mg|Participants received SAD of 200 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656727|NCT03261401|EXPERIMENTAL|Part A: Cohort 4 SAD: M5717 400 mg|Participants received SAD of 400 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62093087|NCT02688621|ACTIVE_COMPARATOR|Internet only|Participants will be required to attend a weekly Internet chat session with your group members and one of the behavioral weight control therapists. Participants will learn the principles of managing eating and exercise behaviors in weekly, hour-long chat sessions and by completing weekly lessons. Participants are asked to self-monitor foods and exercise through the use of a smartphone ap. Participants will wear a tracking device that monitors steps. All participants will be contacted via e-mail individually, by their group leader who will monitor their progress and offer advice and encouragement. Meetings are weekly for 24 weeks and monthly for 12 months.
62093088|NCT02688621|EXPERIMENTAL|Internet + Incentives|Participants are given the same intervention as described for the internet only group, with the exception that they will have the opportunity to earn financial incentives. Financial incentives will be based on participants weight loss, and compliance with certain weight loss behaviors including meeting exercise goals, self-monitoring foods consumed, and daily weighing and reporting.
62290912|NCT00054132|EXPERIMENTAL|Treatment (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62290913|NCT03521791|EXPERIMENTAL|PRO-155|Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
62290914|NCT03521791|PLACEBO_COMPARATOR|Placebo|Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
62290915|NCT05114772|ACTIVE_COMPARATOR|Recurrent Atrial fibrillation|patients developed Recurrent Atrial fibrillation catheter ablation
62290916|NCT05114772|ACTIVE_COMPARATOR|NO Recurrent Atrial fibrillation|patients didn't develop Recurrent Atrial fibrillation catheter ablation
62290917|NCT03489330||Northwestern Memorial Hospital data|Inpatient intravenous vancomycin use
62290918|NCT03489330||Henry Ford Hospital data|Inpatient intravenous vancomycin use
62290919|NCT03489330||University of Michigan Hospital data|Inpatient intravenous vancomycin use
62290920|NCT01369940||NICHD Fetal Growth Study - Twin Gestations|"Women with dichorionic twin gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2012-2013) in this prospective cohort study.~Intervention: No intervention"
62290921|NCT01543620||Patients with cystic fibrosis treated with aminoglycosides|
62290922|NCT01543620||Patients with cystic fibrosis not treated with aminoglycosides|
62290923|NCT00862251|EXPERIMENTAL|Ezetimibe/simvastatin|
62290924|NCT00862251|ACTIVE_COMPARATOR|Doubling statin dose|
62464121|NCT02987985|EXPERIMENTAL|Opioid-free anesthesia|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis
62464122|NCT02987985|ACTIVE_COMPARATOR|Opioid-sparing anesthesia|Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis
62464123|NCT02603224|EXPERIMENTAL|MRG-201|
62290925|NCT00862251|ACTIVE_COMPARATOR|Rosuvastatin|
62290926|NCT02155400|EXPERIMENTAL|Prototype development|10 patients (this phase will be terminated once prototype is confirmed ready) Intervention: prototype device
62290927|NCT02155400|ACTIVE_COMPARATOR|Treatment arm - Prototype|- 18 patients Intervention: Prototype device (heating both sole of foot and popliteal fossa with compression)
62290928|NCT02155400|ACTIVE_COMPARATOR|Control arm - Forced Air Warming Blanket|18 patients Intervention: Forced air warming blanket (Bair hugger)
62290929|NCT02155400|ACTIVE_COMPARATOR|Comparison - Sole of foot only|9 patients heating sole of foot only Intervention: prototype device
62290930|NCT02155400|ACTIVE_COMPARATOR|Comparison - Popliteal fossa only|9 patients heating popliteal fossa only Intervention: prototype device
62308046|NCT02424539|EXPERIMENTAL|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
62464124|NCT02603224|PLACEBO_COMPARATOR|Placebo|
62290931|NCT02295722|EXPERIMENTAL|Gemcitabine/Melphalan Condition + ASCT|"Day -1 -~* IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.~* immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.~Day 0~•Stem cell infusion~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity."
62290932|NCT02953041|EXPERIMENTAL|LAMA Treatment|Inhalation of 50mcg glycopyrronium from Breezhaler device 1 hour prior to methacholine challenge
61907054|NCT01491113|EXPERIMENTAL|Group A: Normal renal function|"Subjects who have normal renal function (CLcr \>80 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~* Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose~* Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose"
61907055|NCT01491113|EXPERIMENTAL|Group B: Mild renal impairment|"Patients who have mild renal impairment (50\<CLcr \<80 mL/min/1.73 m\^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~* Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose~* Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose"
62290933|NCT02953041|EXPERIMENTAL|uLABA Treatment|Inhalation of 75mcg indacaterol from Breezhaler device 1 hour prior to methacholine challenge
62093089|NCT04868396||Glioblastoma patients|Glioblastoma patients selected to undergo surgical removal of a glioblastoma (based on MRI image).
62093090|NCT04600622|EXPERIMENTAL|Intervention Arm|Participants will receive Rural Diabetes One-Day Education and Care program (R-D1D). A one time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
62093091|NCT04600622|ACTIVE_COMPARATOR|Active Comparator|Participants will receive diabetes education materials.
62093092|NCT05267015|ACTIVE_COMPARATOR|coronally advanced flap with connective tissue graft|After randomization a subepithelial connective tissue graft along with coronally advanced flap is applied to one maxillary quadrant to cover the recession.
62093093|NCT05267015|EXPERIMENTAL|coronally advanced flap with platelet rich fibrin membranes|After randomization platelet rich fibrin membranes along with coronally advanced flap are applied to the other maxillary quadrant to cover the recession.
62093094|NCT05932329|ACTIVE_COMPARATOR|Sweet Taste|The intervention will be provided to participants in written form, in an opaque sealed envelope.
62093095|NCT05932329|ACTIVE_COMPARATOR|Taste|The intervention will be provided to participants in written form, in an opaque sealed envelope.
62093096|NCT05932329|ACTIVE_COMPARATOR|No Taste|The intervention will be provided to participants in written form, in an opaque sealed envelope.
62093097|NCT03177564|ACTIVE_COMPARATOR|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
62093098|NCT03177564|ACTIVE_COMPARATOR|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
61907056|NCT01491113|EXPERIMENTAL|Group C: Moderate renal impairment|"Patients who have moderate renal impairment (30\<CLcr \< 50 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~* Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose~* Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose"
62290934|NCT02953041|EXPERIMENTAL|Combo Treatment|Inhalation of 50mcg glycopyrronium from one Breezhaler device, and 75mcg indacaterol from a second Breezhaler device, all one hour prior to methacholine challenge
62290935|NCT02684305|EXPERIMENTAL|Administration of Propess|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~1.Administration of Propess for additional 24 hours."
62290936|NCT02684305|EXPERIMENTAL|Intravenous oxytocin infusion + balloon|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~2. Intravenous oxytocin infusion combined with intracervical balloon administration, inflated with 60cc of saline."
62290937|NCT04550182|EXPERIMENTAL|Individual positioning schedule|Pressure ulcer prevention cares are provided according to the positioning schedule for every patient.
62290938|NCT04550182|NO_INTERVENTION|Standard care|Pressure ulcer prevention cares are provided according to usual practice of the ICU. Frequency and modality of positioning applied to the patients are collected.
62290939|NCT01848275|ACTIVE_COMPARATOR|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
62290940|NCT01848275|EXPERIMENTAL|Group 2|group 2 received ablation at proximal of bilateral renal arteries
62290941|NCT01483677|EXPERIMENTAL|Nintendo Wii|Subjects in this arm of the study play a game (Boomblox) on the Nintendo Wii for 30 minutes.
62290942|NCT01483677|ACTIVE_COMPARATOR|Playstation2|Subjects in this arm of the study play a game (Time Crisis 2) on the Playstation 2 for 30 minutes.
61907057|NCT01491113|EXPERIMENTAL|Group D: Severe renal impairment|"Patients who have severe renal impairment (CLcr \<30 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~* Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose~* Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose"
61907058|NCT01491113|EXPERIMENTAL|Group E: End-stage renal disease|"Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3.~The 4-h Hemodialysis are scheduled as follows:~1. Dialysis: 44 h to 48 h after the first dose (Day 3)~2. Dialysis: 92 h to 96 h after the first dose (Day 5)~3. Dialysis: 140 h after the first dose (Day 7)~Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44\*, 44.25\*, 44.5\*, 45\*, 46\*, 47\*, 48\*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing.~49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis.~\*Inflow blood, outflow blood, and dialysate fluid will be collected."
61907059|NCT00753740|EXPERIMENTAL|12mg/m2/dose|12mg per meter squared per dose
62093099|NCT03177564|EXPERIMENTAL|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
62290943|NCT05651945|EXPERIMENTAL|Cardiac rehabilitation group|Traditional medically supervised center-based cardiac rehabilitation program; including 36 sessions (30-50 minutes) of a progressive exercise program and educational sessions for cardiovascular disease (CVD) risk factors.
62290944|NCT05651945|NO_INTERVENTION|Standard of care|Depending on functional deficits, conventional rehabilitation therapies can include physical therapy, occupational therapy, and/or speech therapy sessions with 2-3 visits per week. Participants will receive their standard of care therapies as prescribed by their treating physicians.
62290945|NCT05312957|ACTIVE_COMPARATOR|Group ESP|The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected and When the block needle touched the transverse process,Then, 20 ml of 0.25% bupivacaine was administered to this area, and an ESP block was applied
62290946|NCT05312957|NO_INTERVENTION|Group Control|Group Control: Tramadol HCL was administered from vein with a patient-controlled analgesia device after extubation.
62290947|NCT01883505|EXPERIMENTAL|ND0612|levodopa and carbidopa solution
62290948|NCT01883505|PLACEBO_COMPARATOR|Placebo|Saline
62464125|NCT04517162|ACTIVE_COMPARATOR|Active comparator or polymerized type I collagen|1.5 mL of polymerized type I collagen every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
62464126|NCT04517162|PLACEBO_COMPARATOR|Placebo comparator o placebo|1.5 mL of placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
62093100|NCT02973126|OTHER|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
62093101|NCT05469360|EXPERIMENTAL|NIO752 - Dose A - Cohort 1|A single intrathecal injection of Dose A
62093102|NCT05469360|PLACEBO_COMPARATOR|Matching placebo - Cohort 1|A single intrathecal injection of artificial cerebrospinal fluid (CSF)
62290949|NCT00241748||1|Rhabdomyolysis Case Subjects
62290950|NCT00241748||2|Heart and Vascular Health Study statin users - control group 1
62290951|NCT00241748||3|Cardiovascular Health Study statin users - control group 2
62290952|NCT05415748|EXPERIMENTAL|Tamsulosin 0.4 mg or 0.8 mg, Then Placebo|Participants first received Tamsulosin 0.4 mg or 0.8 mg taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks. After a washout period of 1 week, the participants then received Placebo tablet taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks.
62464127|NCT01469026|ACTIVE_COMPARATOR|Early PET/CT|
62464128|NCT01469026|ACTIVE_COMPARATOR|Conventional diagnostics including CT|
62464129|NCT03866330|ACTIVE_COMPARATOR|osteoarthritis of the knee|Intraarticular injection of WJMSC
61907060|NCT00753740|EXPERIMENTAL|15mg/m2/dose|15mg per meter squared per dose
62093103|NCT05469360|EXPERIMENTAL|NIO752 Dose B - Cohort 2|A single intrathecal injection of Dose B
62093104|NCT05469360|PLACEBO_COMPARATOR|Matching placebo - Cohort 2|A single intrathecal injection of artificial cerebrospinal fluid (CSF)
62093105|NCT05469360|EXPERIMENTAL|NIO752 OLE|Multiple intrathecal injections of Dose A
62290953|NCT05415748|EXPERIMENTAL|Placebo, Then Tamsulosin 0.4 mg or 0.8 mg|Participants first received Placebo tablet taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks. After a washout period of 1 week, the participants then received Tamsulosin 0.4 mg or 0.8 mg taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks.
62290954|NCT01993888|EXPERIMENTAL|EVARREST® Fibrin Sealant Patch|EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts - a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
62290955|NCT01993888|OTHER|Standard of Care (SoC)|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).
62308047|NCT02424539|PLACEBO_COMPARATOR|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
62464130|NCT03866330|ACTIVE_COMPARATOR|osteoarthritis of the hip|Intraarticular injection of WJMSC
62464131|NCT03866330|ACTIVE_COMPARATOR|osteoarthritis of the glenohumeral joint|Intraarticular injection of WJMSC
62464132|NCT04277026|EXPERIMENTAL|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals. The intervention will take place two times per week for four weeks (Weeks 1-4). During weeks 5-8 the experimental group will continue treatment as usual and will not be receiving the mindful walking intervention.
62464133|NCT04277026|NO_INTERVENTION|Control|Participants will engage in treatment as usual during the first four weeks and will not be receiving the experimental intervention (mindful walking) during weeks 1-4. After the experimental group completes the mindful walking intervention, the control group will complete the mindful walking intervention (weeks 5-8).
62464134|NCT00171821|EXPERIMENTAL|ICL670 (Deferasirox)|
62464135|NCT01908725|EXPERIMENTAL|Lamazym|1 mg Lamazym/kg body weight
62308048|NCT06510335|EXPERIMENTAL|Lavender essential oil-based product system|Participants used the system in a sequential additive series. They used only the oil blend aromatically for 1 week, then the aromatic blend plus a topical stick application for 1 week, and then, for 4 weeks, the aromatic blend, the topical stick, and took 2 capsules of the dietary supplement nightly.
62464136|NCT06041061|EXPERIMENTAL|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
62464137|NCT06041061|PLACEBO_COMPARATOR|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
62464138|NCT04000100|PLACEBO_COMPARATOR|Control group|This group received supraclavicular block using 25mL of 0. 5% bupivacaine and 1 mL normal saline
62308049|NCT04831944|EXPERIMENTAL|Treatment Group 1 : Severe hepatic impairment|Child Pugh (CP) assessment score of 10-14 points
62464139|NCT04000100|ACTIVE_COMPARATOR|Neostigmine group|This group received 25 mL 0. 5% bupivacaine and 1 mL neostigmine (0.5 mg)
62093106|NCT05389358|EXPERIMENTAL|Intervention|"The Asiphephe (meaning Let us stay safe) intervention is a problem-solving therapy manual delivered in a one-on-one setting by lay health workers during routine antenatal care. Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours). Asiphephe includes illustrated job aids, participant workbook, intervention checklist, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts."
62093107|NCT05389358|ACTIVE_COMPARATOR|Enhanced standard of care|The enhanced standard of care condition will entail a clinic-wide training (5 hours) on IPV, mental health, and HIV care in order to sensitize staff to the nature of the research. The clinic will receive access to established referral network to which participants can gain additional help with violence exposure or mental ill health. Participants in this arm will also be observed for adverse events and social harms, with referrals made appropriately by study staff.
62093108|NCT00895479|EXPERIMENTAL|Trinam|Graft placement plus Trinam therapy
62464140|NCT05701215|EXPERIMENTAL|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months after stop of TKI
62464141|NCT00881556|EXPERIMENTAL|RIC Group|"Reduced Intensity Transplant Conditioning (RIC):~Palifermin (Kepivance®) 60 mcg/kg/day for 6 days Fludarabine 30 mg/m2 IV x 1 for 6 days Busulfan 4 mg/kg/day IV divided BID for 4 days Lorazepam 0.02-0.05 mg/kg for 5 days Alemtuzumab 20 mg/m2 IV for 5 days Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days"
62464142|NCT01184196|ACTIVE_COMPARATOR|Arm 1|Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
62464143|NCT01184196|ACTIVE_COMPARATOR|Arm 2|Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.
62464144|NCT03432247|EXPERIMENTAL|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
62464145|NCT03432247|ACTIVE_COMPARATOR|Verbal-based support|Six 45-minute individual verbal support sessions
62464146|NCT05326659|EXPERIMENTAL|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
62464147|NCT05326659|PLACEBO_COMPARATOR|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
62464148|NCT02218905|EXPERIMENTAL|Sit to stand test|One minute sit to stand in 40 inches armless chair. Fatigue, breathlessness and failure to maintain tempo will lead to decease the test
62464149|NCT03004105|EXPERIMENTAL|Intermittent Arm - Selumetinib + Durvalumab|Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
62464150|NCT03004105|EXPERIMENTAL|Safety Run In|"Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.~Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.~During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status."
62464151|NCT03004105|EXPERIMENTAL|Continuous Arm - Selumetinib + Durvalumab|"Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.~Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle."
62464152|NCT04594278|EXPERIMENTAL|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
62464153|NCT03436225|OTHER|Group one|Group one will receive dexamethasone orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
62464154|NCT03436225|OTHER|Group two|Group two will receive dexamethasone parenteral (0.15mg /kg /dose) twice daily for 3 to 5 days.
62464155|NCT03436225|OTHER|Group three|Group three will receive inhaled nebulized budesonide (1 mg/2ml) twice daily for 3 to 5 days.
62656728|NCT03261401|EXPERIMENTAL|Part A: Cohort 5 SAD: M5717 600 mg|Participants received SAD of 600 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656729|NCT03261401|EXPERIMENTAL|Part A: Cohort 6 SAD: M5717 1000 mg|Participants received SAD of 1000 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656730|NCT03261401|EXPERIMENTAL|Part A: Cohort 7 SAD: M5717 1250 mg|Participants in SAD received an oral dose of 1250 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
61907061|NCT00753740|PLACEBO_COMPARATOR|Placebo|5% dextrose infusion (placebo)
61907062|NCT01876940|ACTIVE_COMPARATOR|Fiberoptic Intubation performed by an expert|Tracheal intubation will be performed by an expert anesthesia attending with and without use of the air-Q
61907063|NCT01876940|EXPERIMENTAL|Fiberoptic Intubation performed by a novice|Tracheal intubation will be performed by an anesthesia trainee with and without use of the air-Q
61907064|NCT05738590||inflammatory muscle disease|
61907065|NCT05738590||degenerative muscle disease|
61907066|NCT03505840||antiphospholipid group|pregnant ladies in the third trimester who have antiphospholipid syndrome
61907067|NCT03505840||control group|pregnant ladies in the third trimester who have no medical disorders with pregnancy
61907068|NCT02906982|EXPERIMENTAL|Gum health formulation in intra-oral device|The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
61907069|NCT02906982|EXPERIMENTAL|Gum health formulation on toothbrush|The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
61907070|NCT02906982|NO_INTERVENTION|Control group (split-mouth design)|The control group did not receive the interventional gum health formulation. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night. In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
61907071|NCT02207946|EXPERIMENTAL|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
62093109|NCT00895479|NO_INTERVENTION|Control|Graft placement surgery alone
61907072|NCT02207946|PLACEBO_COMPARATOR|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
61907073|NCT05128708|ACTIVE_COMPARATOR|open right hemicolectomy|participants diagnosed as operable right sided colon cancer were enrolled in this study and did open combined medial and caudal resection procedure
61907074|NCT05128708|ACTIVE_COMPARATOR|laparoscopic right hemicolectomy|participants diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic combined medial and caudal resection procedure
62093110|NCT06696222|ACTIVE_COMPARATOR|Vegetarian yogurt alternative|Participants will consume vegatarian based alternatives instead of ordinary yogurt.
62656731|NCT03261401|EXPERIMENTAL|Part A: Cohort 8 SAD: M5717 1800 mg|Participants in SAD received an oral dose of 1800 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656732|NCT03261401|EXPERIMENTAL|Part A: Cohort 9 SAD: M5717 2100 mg|Participants in SAD received an oral dose of 2100 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656733|NCT03261401|EXPERIMENTAL|Part C: Challenge Cohort 2 M5717 150 mg|Participants received single oral dose of 150 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656734|NCT03261401|EXPERIMENTAL|Part C: Challenge Cohort 1 M5717 400 mg|Participants received single oral dose of 400 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
61907075|NCT00799851|ACTIVE_COMPARATOR|Variceal band ligation|VBL was performed with a multiband ligation device (Euroligator System®). The first band was placed at or close to the gastroesophageal junction, with subsequent bands being placed proximally in a slightly spiral pattern. All visible varices within the distal esophagus were treated, with a maximum of 10 bands being placed in each session. There was a 3-week interval between each treatment session. When VBL was technically impossible due to scarring, sclerotherapy with ethanolamine oleate was performed on thin vessels.
61907076|NCT00799851|ACTIVE_COMPARATOR|cyanoacrylate injection|"CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®). Before injection of the Histoacryl-Lipiodol mixture, the catheter was filled up with 1 ml of Lipiodol. After puncturing the EV, the mixture was injected inside it and followed by injection of 1 ml of distilled water. Finally the catheter was retracted. To minimize the risk of embolism, a maximum of two medium or large vessels, in opposite walls, were treated in each session and not more than 0.5 ml of Histoacryl® was injected into each vessel.~A second injection was performed in any EV that maintained blood flow (medium or large size, blue, depressive at palpation with the catheter), in a bi-weekly interval basis. A chest x-ray was performed to evaluate the location of the Histoacryl-Lipiodol solution. Small vessels were treated with ethanolamine oleate sclerotherapy."
61907077|NCT00038389|EXPERIMENTAL|Vioxx MTD|
61907078|NCT03310762|EXPERIMENTAL|Alma Sana Bracelet Arm|Subjects in this arm will receive a vaccine reminder and tracker bracelet developed by Alma Sana Inc. This bracelet uses a combination of symbols and numbers to denote the entire vaccine schedule a child is supposed to receive before the age of 2 years. Shapes indicate vaccines, and numbers signify the child's age.
61907079|NCT03310762|EXPERIMENTAL|Simple Silicon Bracelet Arm|Subjects in this arm will receive a simple silicon bracelet. This bracelet has six symbols to remind parents that their child needs to get at least six vaccination visits before he reaches 2 years of age. The first five symbols are represented by a crescent shape and the sixth symbol is represented by a star shape to denote that the child is fully immunized.
61907080|NCT03310762|NO_INTERVENTION|Control Arm|Subjects in this arm will not receive any bracelet/intervention.
61907081|NCT02739178|EXPERIMENTAL|GSF Sanitation intervention|This arm will receive the GSF sanitation intervention, a community-level sanitation intervention
61907082|NCT02739178|NO_INTERVENTION|Comparator|This arm will receive the GSF intervention in 2017 or later.
61907083|NCT05970354|ACTIVE_COMPARATOR|EMLA Cream|5 grams will be applied to patient's cervix 7 minutes before gynecological procedure
61907084|NCT05970354|PLACEBO_COMPARATOR|VersaPro Cream|5 grams will be applied to patient's cervix 7 minutes before gynecological procedure
61907085|NCT06472076|EXPERIMENTAL|Dostarlimab plus belrestotug|
61907086|NCT06472076|ACTIVE_COMPARATOR|Pembrolizumab plus placebo|
61907087|NCT03167281|NO_INTERVENTION|tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.
61907088|NCT03167281|EXPERIMENTAL|Early tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.
61907089|NCT04642157|EXPERIMENTAL|ELIOS group|In addition to receiving the same generic mental health resources as in the control group, the participants of the ELIOS arm will benefit from the intervention of the ELIOS team.
61907090|NCT04642157|OTHER|control group|Participants of the control arm will receive generic professional help contacts.
61907091|NCT05562401|EXPERIMENTAL|Coconut Water|To determine if Coconut Water is more effective on hydration status than Sport Drink in adolescents who perform physical exercise.
61907092|NCT05562401|ACTIVE_COMPARATOR|Sport Drink|To determine if Coconut Water is more effective on hydration status than Sport Drink in adolescents who perform physical exercise.
61907093|NCT02602756|ACTIVE_COMPARATOR|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
62093111|NCT06696222|PLACEBO_COMPARATOR|Placebo: Ordinary yogurt based diet|Participants will consume regular yogurt.
61907094|NCT02602756|EXPERIMENTAL|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
62093112|NCT06696222|ACTIVE_COMPARATOR|Vegetarian meat alternative|The participants will consume a vegetarian alternative to meat.
62093113|NCT06696222|PLACEBO_COMPARATOR|Placebo - ordinary meat diet|The participants will consume an ordinary meat based diet.
62093114|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
62093115|NCT06211257|NO_INTERVENTION|Control group : standard PCP|Patient will receive standard support PCP
62464156|NCT03436225|OTHER|Group four|Group four will receive symptomatic treatment in form of inhaled nebulized salbutamol(0.15mg/kg/ dose) daily every 6-8 hours.
62464157|NCT03262688|EXPERIMENTAL|INL-001|Bupivacaine HCl collagen-matrix implant
61907095|NCT06240364|EXPERIMENTAL|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
61907096|NCT06240364|PLACEBO_COMPARATOR|Placebo|Daily intake of one tablet for 84 days. This tablet is organoleptically indistinguishable from the experimental tablet.
62464158|NCT03262688|ACTIVE_COMPARATOR|Infiltration|Bupivacaine HCl infiltration
61907097|NCT02872506|ACTIVE_COMPARATOR|medical treatment by Anti TNF|The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time
61907098|NCT02872506|ACTIVE_COMPARATOR|ileocecal resection|The surgical treatment group are the patients operated on for the first time by means of ileocecal resection laparoscopic or laparotomy
61907099|NCT02754700|EXPERIMENTAL|Biofeedback Hip|Hip focused biofeedback with neuromuscular training
62464159|NCT02243930|EXPERIMENTAL|Cap|Sigmoidoscopy with cap
62464160|NCT02243930|NO_INTERVENTION|No cap|Sigmoidoscopy without cap
62093116|NCT06211257|EXPERIMENTAL|Experimental group : demateralized PCP|Patient will receive standard support PCP and dematerialized PCP (ePCP)
62093117|NCT05417997|EXPERIMENTAL|Research Arm|"Kunamin® 20 capsules 500mg daily plus; Standard therapy interventions determined and prescribed by investigators including:~* Favipiravir: 1,600 mg (8 tablets) by mouth twice daily for 5 days.~* Enoxaparin: 40 mg SQ daily if D-dimer \< 3000 ng/mL \*or\* plt \< 100,000~* Enoxaparin: 0.5 mg/kg SQ twice daily if D-dimer \>3000 ng/mL \*and\* plt \< 100,000~* Lansoprazole: 30 mg (one tablet) by mouth, once a day for 7 days.~* Paracetamol: 500 mg (one tablet) by mouth, up to one tablet every 4 to 6 hours in case of fever (100.4°F/38°C or higher).~* Ceftriaxone: 500 mg IV once a day for 5-7 days.~* Clarithromycin: 250 mg (one tablet) twice a day for 5-7 days.~* Methylprednisolone: 80 mg/kg IV bolus, followed by an infusion of 80 mg/day in 240 mL normal saline at 10 mL/h."
62093118|NCT05417997|PLACEBO_COMPARATOR|Control arm|"According to MOH of Turkey, which required a standard treatment including the following drugs as placebo:~* Favipiravir~* Enoxaparin~* Enoxaparin~* Lansoprazole~* Paracetamol~* Ceftriaxone/ Clarithromycin~* Methylprednisolone"
62093119|NCT03486197|EXPERIMENTAL|Treatment (Pembrolizumab, neutron radiation therapy)|Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
62093120|NCT04435795|ACTIVE_COMPARATOR|Ciclesonide inhaled and nasal|Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled ciclesonide 600mcg BID x 14 days
62093121|NCT04435795|PLACEBO_COMPARATOR|Placebo|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
62093122|NCT03509012|EXPERIMENTAL|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
62093123|NCT03509012|EXPERIMENTAL|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
62093124|NCT03509012|EXPERIMENTAL|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
62093125|NCT03509012|EXPERIMENTAL|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
62093126|NCT03509012|EXPERIMENTAL|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
62093127|NCT03509012|EXPERIMENTAL|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
62093128|NCT03509012|EXPERIMENTAL|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
62093129|NCT03509012|EXPERIMENTAL|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
62093130|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2019|
62093131|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2020|
62093132|NCT05990881|ACTIVE_COMPARATOR|Control|Patients in this group will receive standard-of-care corticosteroid injections.
62093133|NCT05990881|EXPERIMENTAL|Botulinum Toxin|Patients in this group will receive a Botulinum Toxin injection.
62093134|NCT05965362||Infective endocarditis group|Patients diagnosed with infective endocarditis.
62093135|NCT06070597|EXPERIMENTAL|Arm 1: Iclepertin treatment+ Placebo to Moxifloxacin|Placebo to moxifloxacin (Day 1) + Iclepertin (Day 1-12) + Placebo to moxifloxacin (Day 13
62093136|NCT06070597|EXPERIMENTAL|Arm B1: Iclepertin Placebo treatment + Moxifloxacin|Moxifloxacin (Day 1) + Placebo to iclepertin (Day 1-12) + Placebo to moxifloxacin (Day 13) - Arm B1
62093137|NCT06070597|EXPERIMENTAL|Arm B2: Iclepertin Placebo treatment + Placebo to Moxifloxacin|Placebo to moxifloxacin (Day 1) + Placebo to iclepertin (Day 1-12) + Moxifloxacin (Day 13) - Arm B2
62093138|NCT03245164|EXPERIMENTAL|Physiotherapy group exercises|This group continued physiotherapy group exercises for 12 weeks.
62464161|NCT05031884||MGIR3-US group|using MGIR3-US to do ultrasonic examinations.
62093139|NCT03245164|EXPERIMENTAL|Basketball program|Basketball educaiton was presented for 12 weeks.
62093140|NCT03245164|NO_INTERVENTION|Control group|This group did not continue any physical activity regularly.
62093141|NCT05601843|EXPERIMENTAL|TENS Arm|Participants randomized to receive treatment with TENS in addition to standard care.
62464162|NCT05031884||control group|using conventional B-mode ultrasound to do ultrasonic examinations.
62656735|NCT03261401|EXPERIMENTAL|Part C: Challenge Cohort 3 M5717 800 mg|Participants received single oral dose of 800 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
62656736|NCT02608606|NO_INTERVENTION|oral administration of tacrolimus|Oral administration of tacrolimus (FK506) in the usal dose and measuring plasmatic levels at hours 0, 0.5, 1, 2, 3, 4 and 6. Measuring AUC.
61907100|NCT02754700|EXPERIMENTAL|Biofeedback Knee|Knee focused biofeedback with neuromuscular training
62308050|NCT04831944|EXPERIMENTAL|Treatment Group 2 : Moderate hepatic impairment|Child Pugh (CP) assessment score of 7-9 points
62656737|NCT02608606|ACTIVE_COMPARATOR|sublingual administration of tacrolimus|sublingual administration of tacrolimus (FK506) in the dose that allows similar plasmatic level at time 0 compared with the oral administration, and measuring plasmatic levels at hours 0, 0.5, 1 , 2, 3 , 4 and 6. Measuring AUC.
62656738|NCT01950663|EXPERIMENTAL|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
61907101|NCT02754700|ACTIVE_COMPARATOR|Neuromuscular Training|Neuromuscular Training component
61907102|NCT06148844|NO_INTERVENTION|Control Group|The routine preparation procedure in this group in the hospital will be applied by the nurses responsible for preoperative preparation. After pre-operative preparation, the child, parent and nurse will be asked to fill out the anxiety and fear scales to evaluate the child's anxiety and fear levels.
62656739|NCT06436638||Group Airway|Group to receive non-invasive ventilation support via nasal airway during dental extraction under deep sedation.
62093142|NCT05601843|NO_INTERVENTION|Control Arm|Participants randomized to not receive treatment with TENS. These participants receive standard care only.
62093143|NCT06698029|EXPERIMENTAL|VIM radiosurgery with RebrAIn targeting technique|VIM radiosurgery with RebrAIn targeting technique (model VIM-RS-LAT-1.0)
62656740|NCT06436638||Group Mask|Group to receive non-invasive ventilation support via nasal CPAP mask during dental extraction under deep sedation
62093144|NCT06698029|NO_INTERVENTION|VIM radiosurgery standard targeting technique|VIM radiosurgery standard targeting technique
62093145|NCT03894943|EXPERIMENTAL|General|All subjects will undergo ordinary surgical treatment for their lumbar disc herniation. Experimentally, all subjects participating in the study will receive PET/CT scans and sensory testing as specified below.
62093146|NCT06696235|EXPERIMENTAL|Accelerated initiation of CRRT|In the accelerated-strategy group, RRT is initiated as soon as possible and within 6 hours after patients have met full eligibility criteria.
62308051|NCT04831944|EXPERIMENTAL|Treatment Group 3 : Mild hepatic impairment|Child Pugh (CP) assessment score of 5-6 points
62308052|NCT04831944|EXPERIMENTAL|Treatment Group 4 : Normal hepatic impairment|Normal hepatic function
62308053|NCT01479725|EXPERIMENTAL|Ulcerative IC|HBOT for ulcerative IC
62308054|NCT01479725|EXPERIMENTAL|Non-Ulcerative IC|HBOT for non-ulcerative IC
62656741|NCT00970580|EXPERIMENTAL|BIIB022 in Combination with Paclitaxel and Carboplatin|BIIB022 in Combination with Paclitaxel and Carboplatin
62093147|NCT06696235|ACTIVE_COMPARATOR|Standard initiation of CRRT|"Clinicians were discouraged from initiating RRT until the development of one or more of the following criteria.~* Serum potassium \> 6.5 mmol/L~* Serum potassium\> 6.0 mmol/L persisting despite medical treatment~* Metabolic acidosis (pH \< 7.15 and PaCO2 \< 35 mmHg or serum bicarbonate \< 12 mmol/L)~* Blood urea nitrogen level ≥100 mg/dL~* Oliguria (≤0.3 ml/kg/hour) or anuria for 48h or more~* Diuretics refractory fluid overload or pulmonary edema"
62093148|NCT03617874|ACTIVE_COMPARATOR|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
62093149|NCT03617874|PLACEBO_COMPARATOR|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
62464163|NCT06351683|EXPERIMENTAL|MitoQ group|2x20mg MitoQ (mitoquinol mesylate) capsules taken orally daily before breakfast for 4 months
62093150|NCT01728389|EXPERIMENTAL|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
62093151|NCT01536262|OTHER|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
62093152|NCT01536262|OTHER|Olodaterol|Olodaterol solution for inhalation - RESPIMAT
62093153|NCT01536262|OTHER|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
62093154|NCT06696248|EXPERIMENTAL|Carvedilol + Alverine Group|On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.
62093155|NCT05474846|EXPERIMENTAL|Combination Therapy (BLT+MT+MP with CBT)|Patients receive Melatonin (called MT) PO QD for 6 weeks, Methylphenidate (called MP) PO BID for 6 weeks, Bright Light Therapy (called BLT) for 30 minutes daily for 6 weeks, and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
62093156|NCT05474846|EXPERIMENTAL|Placebo (CLT+ placebo MT + placebo MP with CBT)|Patients receive placebo Melatonin (called placebo MT) PO QD for 6 weeks, placebo Methylphenidate (called placebo MP) PO BID for 6 weeks, Control Light Therapy (called CLT) for 30 minutes daily for 6 weeks and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
62093157|NCT05474846|EXPERIMENTAL|Bright light and Melatonin (BLT + MT+ placebo MP with CBT)|Patients receive Bright Light Therapy (called BLT) for 30 minutes daily for 6 weeks, Melatonin (called MT) PO QD for 6 weeks, placebo Methylphenidate (called placebo MP) PO BID for 6 weeks, and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
62093158|NCT05474846|EXPERIMENTAL|Methylphenidate (CLT + placebo MT + MP with CBT)|Patients receive Control Light Therapy (called CLT) for 30 minutes daily for 6 weeks, placebo Melatonin (called placebo MT) PO QD for 6 weeks, Methylphenidate (called MP) PO BID for 6 weeks, and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
62093159|NCT05508516|EXPERIMENTAL|Shugan Dingtong decoction|Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
62093160|NCT05508516|ACTIVE_COMPARATOR|duloxetine hydrochloride|Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
62093161|NCT02705911|EXPERIMENTAL|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
62093162|NCT02705911|ACTIVE_COMPARATOR|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
62093163|NCT02705911|NO_INTERVENTION|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
62093164|NCT06081101|ACTIVE_COMPARATOR|Corticosteroid|Patients will receive ultrasound guided corticosteroid injection to see pain relief after injection
62464164|NCT06351683|PLACEBO_COMPARATOR|Placebo Control group|2 placebo capsules taken orally daily before breakfast for 4 months
62464165|NCT06185777|EXPERIMENTAL|Exercise oncology counseling and referal|Identification \& brief consultation Screening: Needs assessment for exercise therapy Information / educational talk Consultation with the patient Risk assessment (with physician clearance) Consultation Referral to exercise therapy
62464166|NCT02910037|EXPERIMENTAL|patients enrolled for mNGS testing|Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
62464167|NCT03962673|EXPERIMENTAL|UVB- exposure|Each participant will receive a pre-determined dose of UVB light. Serum Vitamin D and microbiome samples of each participant will be compared before and after the UVB light exposures.
62656742|NCT02921100|OTHER|Conventional cytology|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo a conventional cytology.
62656743|NCT02921100|OTHER|DNA ploidy test|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo DNA ploidy test.
62464168|NCT05778448|EXPERIMENTAL|BCI-FES-VR|Participants look at an external screen displaying the VR avatar participant's arms while performing wrist dorsiflexion MI in random order (left or right). The BCI system detects the ERD of the motor area corresponding to correct MI. Then, visual feedback with the VR and motor-tactile feedback with the discharge of the FES is delivered. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
62093165|NCT06081101|ACTIVE_COMPARATOR|Ketorolac|Patients will receive ultrasound guided ketorolac injection to see pain relief after injection
62093166|NCT06515184|ACTIVE_COMPARATOR|CoQ10 Arm 1|PharmaNord Ubiquinone 100mg/1x day
62290956|NCT06057311|EXPERIMENTAL|Hippotherapy Group|"The sessions for the HTG were conducted on horseback by a leader, side walker, and physiotherapist while the child was mounted on the horse. Before mounting, the child was dressed in the safety equipment of a helmet and rider vest by the physiotherapist and was directed to mount the horse from the mounting steps. In the first week of training, the cases received adaptation training. Within the training, 7 min of simple sitting on the horse were performed. In this position, the child was able to caress the horse's neck with one or both hands, rest while the horse walked, and 10 standing (or for those who could not do this, the horse was in a standing position)n the stirrups exercises were performed while holding the retaining strap."
62290957|NCT06057311|EXPERIMENTAL|Equine-Assisted Activities Therapy Group|Under the guidance of the physiotherapist, the children in the EAATG performed routine care of the horse, such as grooming, feeding, and hoof care. During equine-assisted activities, the physiotherapist ensured the correct positioning of the child's body when approaching the horse using equipment and during movement. The study participants groomed the horse, wiped the horse's feathers with a towel, combed the mane, checked the hooves, cleaned out any grit, and performed the procedures for the horse to go out. Finally, the child gave food and water to the horse, said farewell and left the therapy area.
62290958|NCT06057311|OTHER|Control Group|The children in the control group were evaluated at the same time as the other groups but were not included in any therapy. All assessments were conducted at baseline and 6 weeks later. When the study was completed, the subjects in this group were permitted 10 sessions of hippotherapy if they so wished.
62290959|NCT05192343|EXPERIMENTAL|Virtual Reality and nature sounds|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain will apply to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires will apply, before and during the HSG procedure, the Virtual Reality and nature sounds application group watch a video with a nature view with virtual reality glasses.Glasses will introduce before the procedure. Before the procedure started, glasses will put on and training will given to continue watching the video by wearing glasses during the procedure. The women will be included in the Virtual Reality and nature sounds intervention group will make to watch a video with a nature view for 15 minutes and listening nature sounds before and during the HSG procedure. Each woman was shown the same video.
62290960|NCT05192343|EXPERIMENTAL|nature sounds|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain will apply to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires will apply, a nature-based sound will play to the women in the nature sounds group before and during the HSG shooting.Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes.
62290961|NCT05192343|NO_INTERVENTION|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention will perform. Both groups will re-evaluated using the same scales after the hysterosalpingography.
62290962|NCT04574726|EXPERIMENTAL|virtual environment|Balance test in virtual environment with a virtual reality software executed in a 6DOF Occulus Quest helmet and a motion capture software with a Kinect Azure DK camera.
62290963|NCT04574726|ACTIVE_COMPARATOR|reel environment|Balance test in real environment with a motion capture software and a Kinect Azure DK camera.
62290964|NCT02512458|EXPERIMENTAL|Cabazitaxel|Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
62290965|NCT01535235|ACTIVE_COMPARATOR|ACE Inhibitor|Active group
62290966|NCT01535235|PLACEBO_COMPARATOR|Placebo|Placebo group
62290967|NCT06002464|ACTIVE_COMPARATOR|ESP|Post operative analgesia with bilateral continuous erector spinae plane block catheter
62290968|NCT06002464|EXPERIMENTAL|ESP ACU|Post operative analgesia with bilateral continuous erector spinae plane block catheter combined with daily session of acupuncture
62290969|NCT01523483|EXPERIMENTAL|Progesterone|Patients in this arm will receive two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
62290970|NCT01523483|PLACEBO_COMPARATOR|placebo|Patients will receive two placebo capsules placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
62290971|NCT04023084|EXPERIMENTAL|Atopic Dermatitis Group|Receive crisaborole intervention
62290972|NCT02613208||Participants With Metastatic Breast Cancer|Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
62290973|NCT05158894||Ubrelvy-Exposed Women With Migraine|Pregnant women with migraine who took at least 1 dose of Ubrelvy, the exposure of interest, at any time during pregnancy as part of routine care.
62290974|NCT05158894||Qulipta-Exposed Women With Migraine|Pregnant women with migraine who took at least 1 dose of Qulipta, the exposure of interest, at any time during pregnancy as part of routine care.
62290975|NCT05158894||Ubrelvy/Qulipta-Unexposed Women With Migraine|Pregnant women with migraine who have never taken Ubrelvy and/or Qulipta, OR discontinued Ubrelvy 2 days prior or Qulipta 5 days prior to conception.
62308055|NCT04926155|EXPERIMENTAL|Metformin+ADT+abiraterone|Patients in this arm will be treatet with metformin plus ADT and abiraterone
62464169|NCT05778448|ACTIVE_COMPARATOR|BCI-FES|Same procedure as arm 1 (BCI-FES-VR), but the difference is that the participant's hands replace the VR system. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
62464170|NCT05778448|ACTIVE_COMPARATOR|BCI-VR|Same procedure as arm 1 (BCI-FES-VR), but the FES is removed. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
62656744|NCT02821845||Control|Individuals with no spinal cord injury or other neurological deficits.
62656745|NCT02821845||Untrained and Trained SCI Hip and Knee|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Untrained individuals will complete 3 baseline measures and then complete eccentric training which will focus on rehabilitation of the hip joint or knee joint.
62656746|NCT03502109|EXPERIMENTAL|Intervention group|Medication review with follow-up every 2 months, conducted by a trained pharmacist.
62656747|NCT03502109|NO_INTERVENTION|Control group|Usual care by physicians, nurses and dietitians.
62656748|NCT02970864|EXPERIMENTAL|Polynerve|Participants found to have a nerve gap of at least 5 mm and no greater than 20mm will undergo repair with the Polynerve.
62656749|NCT02430233|EXPERIMENTAL|micronized progesterone 400 mg|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
62093167|NCT06515184|ACTIVE_COMPARATOR|CoQ10 Arm 2|PharmaNord Ubiquinone 100mg/3x day
62093168|NCT06515184|PLACEBO_COMPARATOR|Placebo Arm|Placebo (made by PharmaNord, matches active treatment)
62093169|NCT01799954|OTHER|NYVAC Prime / NYVAC + AIDSVAX® B/E Boost vs. Placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a NYVAC vaccine prime and NYVAC + AIDSVAX® B/E boost. Twenty participants will get vaccines and 4 will get only placebos.
62093170|NCT01799954|OTHER|NYVAC + AIDSVAX® B/E Prime / Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of priming and boosting with the vaccines NYVAC + AIDSVAX® B/E. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 1 to see if the priming makes a difference in the body's immune response.
62093171|NCT01799954|OTHER|DNA prime + NYVAC + AIDSVAX® B/E Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 4 to see if the priming makes a difference in the body's immune response.
62093172|NCT01799954|OTHER|DNA+AIDSVAX® B/E prime / NYVAC+AIDSVAX® B/E boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine + AIDSVAX® B/E priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 3 to see if the priming makes a difference in the body's immune response.
62093173|NCT04900363|EXPERIMENTAL|AK112|Subjects receive AK112 monotherapy intravenously (IV) until no more benefits from treatment.
62093174|NCT00219401|EXPERIMENTAL|Neonatal 7vPCV|Receive study vaccine (Prevnar) at birth, 1 and 2 months
62093175|NCT00219401|EXPERIMENTAL|Infant 7vPCV|Receive the study vaccine (Prevnar) at 1, 2 and 3 months
62290976|NCT04899635||Diseased cardiac tissue|Heart muscle or cells (cardiomyocytes) will be obtained from patients undergoing cardiac surgery, namely coronary artery bypass grafting or for severe valvular heart disease.
62290977|NCT04899635||Healthy cardiac tissue|Healthy donor hearts from deceased individuals that are not transplantable due to technical reasons
62290978|NCT02996877||Guideline Directed Medical Therapy|Patients who have an initial treatment strategy of using guideline-directed medical therapy only.
62290979|NCT02996877||Percutaneous Coronary Intervention|Patients who will have a Percutaneous Coronary Intervention as the initial treatment strategy along with guideline directed medical therapy.
62290980|NCT00820326|ACTIVE_COMPARATOR|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
62290981|NCT00820326|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
62656750|NCT02430233|NO_INTERVENTION|No treatment|No treatment
62656751|NCT01737528||TAVR Patients|Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.
62290982|NCT01955616|ACTIVE_COMPARATOR|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
62093176|NCT00219401|PLACEBO_COMPARATOR|Control|Do not receive study vaccine (Prevnar)
62093177|NCT03150368|EXPERIMENTAL|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
62093178|NCT05306444|EXPERIMENTAL|CLN-418: Part 1|"Experimental Part 1: Dose escalation~Intravenous IV administrations of CLN-418 on Day 1 of each 21 day treatment cycle~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee"
62093179|NCT05306444|EXPERIMENTAL|CLN-418: Part 2|"Experimental Part 2: Dose Expansion~Treatment administered at Maximum Tolerated Dose (MTD) and / or Recommended Phase 2 Dose (RP2D) established in Part 1"
62093180|NCT06226870|EXPERIMENTAL|NSRCT Group|Non-surgical root canal therapy
62093181|NCT06226870|EXPERIMENTAL|VPT Group|vital pulp therapy
62093182|NCT06226870|EXPERIMENTAL|VPT+PRF Group|vital pulp therapy with PRF
62093183|NCT04651348|EXPERIMENTAL|MIL95|
62290983|NCT01955616|PLACEBO_COMPARATOR|Placebo|by subcutaneous injection daily in the morning
62290984|NCT00643240|EXPERIMENTAL|111 In-BU-12|111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.
62290985|NCT00404521|EXPERIMENTAL|Arm 1|
62290986|NCT03047499||Scar Length|
62290987|NCT03047499||Vancouver scar scale|
62290988|NCT03047499||Scar width|
62290989|NCT05675449|EXPERIMENTAL|Part 1 Dose Escalation|Non randomized Elranatamab plus Carfilzomib and Dexamethasone
62290990|NCT05675449|EXPERIMENTAL|Part 2A Dose Escalation|Non randomized Elranatamab plus Maplirpacept
62290991|NCT05675449|EXPERIMENTAL|Part 2B Dose Randomization|Randomized dose level Elranatamab plus Maplirpacept
62290992|NCT06248957||Patients with immune dysregulation|Patients sampled before and during different immunomodulatory therapies due to immune system dysregulation.
62656752|NCT01240694|EXPERIMENTAL|CEP-33457|Participants will receive 200 micrograms (mcg) of CEP-33457
62093184|NCT04996875|EXPERIMENTAL|bezuclastinib|
62093185|NCT06336044|EXPERIMENTAL|Standard patients|Patients treated with the experimental Medical Device
62093186|NCT03939221|EXPERIMENTAL|intervention of infrared lamp and acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6(neiguan) and ST36(zusanli) for one minutes) for our patient for the cold limbs, pain control and constipation problems.
62093187|NCT05212948|EXPERIMENTAL|S-268019-b, Then Placebo|Participants will first receive a dose of S-268019-b via intramuscular (IM) injection on Day 1 and Day 29 during the initial vaccination period. After the initial vaccination period, participants will then receive a placebo IM injection (matching S-268019-b) on Day 225 and Day 253.
62093188|NCT05212948|EXPERIMENTAL|Placebo, Then S-268019-b|Participants will first receive a dose of placebo IM injection (matching S-268019-b) on Day 1 and Day 29 during the initial vaccination period. After the initial vaccination period, participants will then receive S-268019-b IM injection on Day 225 and Day 253.
62290993|NCT06248957||Healthy subjects|Age-matched healthy individuals sampled longitudinally
62290994|NCT02563301|ACTIVE_COMPARATOR|McGrath Series 5|Videolaryngoscope used to perform indirect (video) laryngoscopy and tracheal intubation
62656753|NCT01126424|EXPERIMENTAL|Solifenacin|Participants received 21 days of treatment with 5 mg solifenacin, in tablet form once a day.
62656754|NCT01126424|ACTIVE_COMPARATOR|Oxybutynin|Participants received 21 days of treatment with 10 mg oxybutynin (1 x 5 mg twice daily) in capsule form.
62656755|NCT01126424|PLACEBO_COMPARATOR|Placebo|Participants received 21 days of treatment with placebo.
62656756|NCT02730104||Cohort A: Patients with small bowel NET|Patients with small bowel NET (including appendiceal NETs)
62656757|NCT02730104||Cohort B: Patients with gastric NET|Patients with gastric NET (gastroduodenal)
62656758|NCT02730104||Cohort C: Patients with pancreatic NET|
62656759|NCT02730104||Cohort D: Patients with colorectal NET|Patients with colorectal NET (this includes mid-gut)
62656760|NCT02730104||Cohort E: Unknown primary tumor|
62093189|NCT05946746|EXPERIMENTAL|PeptiStrong - fava bean hydrolysate preparation|PeptiStrong 2.4g/day will be supplemented as 5 capsules (480mg each) taken with approx. 150mL water at breakfast once per day for 56 days
62093190|NCT05946746|PLACEBO_COMPARATOR|Silicated micro-crystalline cellulose (SMCC)|The placebo 2.4g/day will be supplemented as 5 capsules taken with approx. 150mL water at breakfast once per day for 56 days
62093191|NCT06382545|EXPERIMENTAL|20 participants treated with Fanta (Pepsi gold) (FPG)|aged 20 to 50 years
62656761|NCT04075175|EXPERIMENTAL|S315 human monoclonal antibody|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo (0.9% Sodium Chloride)) with escalation of a fixed dose of S315
62656762|NCT04075175|PLACEBO_COMPARATOR|0.9% sodium chloride (NaCl)|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo(0.9% Sodium Chloride)) with escalation of a fixed dose of S315
62656763|NCT02385890|EXPERIMENTAL|Bagel control|100% wheat flour
62093192|NCT06382545|EXPERIMENTAL|20 participants treated with M3-pro+ Gold (assorted) (MPG) rotary files|aged 20 to 50 years
62093193|NCT00409708|ACTIVE_COMPARATOR|1|
62093194|NCT00409708|OTHER|2|
62093195|NCT03308058|EXPERIMENTAL|Breastfeeding Computer education|Breastfeeding Computer education
62093196|NCT03308058|NO_INTERVENTION|Printed Educational material|Printed educational material
62093197|NCT04463043|EXPERIMENTAL|SelfBACK app|The selfBACK app in addition to usual care
62093198|NCT04463043|ACTIVE_COMPARATOR|e-Help webpage|The e-Help webpage in addition to usual care
62093199|NCT04463043|ACTIVE_COMPARATOR|Usual care|Usual care only
62093200|NCT01890161|EXPERIMENTAL|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
62290995|NCT02563301|ACTIVE_COMPARATOR|Macintosh|Laryngoscope used to perform direct laryngoscopy and tracheal intubation
62290996|NCT02407626|EXPERIMENTAL|Sevoflurane|Volatile anesthesia for elective cardiac surgery
62290997|NCT02407626|ACTIVE_COMPARATOR|Propofol|Total intravenous anesthesia for elective cardiac surgery
62290998|NCT03674021|EXPERIMENTAL|Intervention Arm|Patients in the intervention arm will receive the Chest Pain Choice visual aid prior to discussion with their primary physician regarding disposition.
62656764|NCT02385890|EXPERIMENTAL|Bagel with pea flour|Pea flour
62656765|NCT02385890|EXPERIMENTAL|Bagel with pea fibre|Pea fibre
62656766|NCT02385890|EXPERIMENTAL|Bagel with pea protein|Pea protein
62656767|NCT02385890|EXPERIMENTAL|Bagel with pea flour + pea protein|Pea flour + pea protein
62656768|NCT02385890|EXPERIMENTAL|Bagel with pea fibre + pea protein|Pea fibre + pea protein
62656769|NCT00988026|EXPERIMENTAL|Minocycline 100 mg|Minocycline
62656770|NCT00988026|ACTIVE_COMPARATOR|Lymecycline 300 mg|Group B: Lymecycline
62656771|NCT06127732|EXPERIMENTAL|Phytosterol|Participants received diet plus phytosterols (2.6 g of phytosterols per day) prescribed and supplied in 650 mg gelatin capsules, to be used four capsules a day along with meals(Fitocor®, Farmoquímica, Brazil) and divided into two meals.for 12 weeks.
62656772|NCT06127732|NO_INTERVENTION|Control: diet alone|Participants received diet alone recommended for 12 weeks.
62656773|NCT00218010||Methadone maintained lactating women|Methadone maintained women who chose to breastfeed their infants provided breast milk and plasma samples for this study.
62656774|NCT02954770||Fitbit® challenger|The residents who participated a Fitbit® challenge study about one year ago
62290999|NCT03674021|NO_INTERVENTION|Control Arm|Patients in the control arm will not receive the Chest Pain Choice visual aid and will receive standard care.
61907103|NCT06148844|EXPERIMENTAL|Interactive robot group|In addition to the routine preparation procedure interactive robot will be used to preparation as a therapeutic approach. The interactive robot will accompany to the child the preparation for the surgery. Then, the features of the interactive robot will be explained to the children and parents and it will be introduced to the children. The interactive robot will meet the child with its speech feature and the robot will accompany to child to the operating room entrance. The child will be informed that he/she can request the interactive robot to follow him/her if he/she wishes. The child will be transferred to the operating room accompanied by the nurse, researcher and robot. After pre-operative preparation, the child, parent and nurse will be asked to fill out the anxiety and fear scales to evaluate the child's anxiety and fear levels.
61907104|NCT01018784|EXPERIMENTAL|MORAb-009|
61907105|NCT03963167||Patient in treatment with BDP/FF/G fixed combination|
62656775|NCT02741284|EXPERIMENTAL|No Oxygen|Room air
61907106|NCT04104126|ACTIVE_COMPARATOR|Standard of Care Physical Therapy|Patients with Achilles injury are prescribed PT for their treatment, therefore physical therapy is a standard of care treatment for patients with tendon pathology.
61907107|NCT04104126|EXPERIMENTAL|Blood flow restriction (BFR) therapy|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff.
62291000|NCT06110650|EXPERIMENTAL|surufatinib|surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
61907108|NCT05633030|ACTIVE_COMPARATOR|operated using UAS during flexible ureteroscopy|
61907109|NCT05633030|ACTIVE_COMPARATOR|operated using PCN during flexible ureteroscopy|
61907110|NCT02874170|EXPERIMENTAL|drepanocytose affected patient|
61907111|NCT02874170|OTHER|Healthy volunteers|
62093201|NCT01890161|PLACEBO_COMPARATOR|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
62093202|NCT06696872|EXPERIMENTAL|Core exercises|The participants were taught how to contract their deep abdominal muscles to obtain core muscle activation. The patient should be contracting the abdominal muscles, lifting her lower belly up away from pubic bone, while breathing slowly and normally. The patient should not hold her breath
62291001|NCT05833802||the virtual cohort|the virtual cohort that enroll in silico clinical trial (ISCT), and will be treated by virtual anti-cancer drug.
62291002|NCT05833802||the real cohort|the real cohort that enroll in real word study, and will be treated by anti-cancer drug.
62291003|NCT02555163|EXPERIMENTAL|HoLERBT|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor
62656776|NCT02741284|ACTIVE_COMPARATOR|Oxygen|10L oxygen by nonrebreather mask
62656777|NCT02467816|EXPERIMENTAL|School lunch intervention|Intervention schools (6 middle and 6 high) will receive the complete school lunch intervention for two school years.
62656778|NCT02467816|NO_INTERVENTION|School lunch control|Control schools (6 middle and 6 high) will not receive the school lunch intervention for two school years. Lunch delivery will proceed as normal.
62291004|NCT02555163|ACTIVE_COMPARATOR|cTURBT|Conventional Transurethral Resection Of Bladder Tumors
62656779|NCT01516099|EXPERIMENTAL|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
61907112|NCT04838717|ACTIVE_COMPARATOR|BPG Arm|BPG injections will be performed at the participating center
61907113|NCT04838717|EXPERIMENTAL|Doxycycline Arm|Dispensing of Doxycycline 100 mg is carried out at one time at V0 - Inclusion visit.
61907114|NCT00924040|EXPERIMENTAL|BL22 Immunotherapy|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
62656780|NCT01516099|EXPERIMENTAL|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
62656781|NCT04553094|NO_INTERVENTION|Group 1|No physical training
62656782|NCT04553094|EXPERIMENTAL|Group 2|Endurance training
61907115|NCT05698875|OTHER|Test meal 1|High glycaemic load breakfast meal
61907116|NCT05698875|OTHER|Test meal 2|High glycaemic lead with additional 10g protein breakfast meal
62656783|NCT04553094|EXPERIMENTAL|Group 3|Muscle building training
62656784|NCT04553094|EXPERIMENTAL|Group 4|Training combining endurance + muscle building
62093203|NCT06696872|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation|The hold-relax proprioceptive neuromuscular facilitation stretching protocol consisted of passively moving the dominant leg into a position where the subjects felt mild discomfort and holding that position for 30 seconds. Subjects were then asked to isometrically contract the stretched muscle for 10 seconds; this were followed by muscle relaxation in the same position for 30 seconds, before being stretched to a new point of mild discomfort. The leg were then released
62291005|NCT02421250|EXPERIMENTAL|Radical-7 Non-invasive Hgb Monitor|We use the Radical-7 Noninvasive Hgb Monitor device (provided by Masimo Corporation from Irvine USA) to measure hemoglobin levels in patients in the experimental group.
62656785|NCT04254757|OTHER|Percutaneous endoscopic surgery group|
61907117|NCT05698875|OTHER|Test meal 3|Medium glycaemic load breakfast meal
62093204|NCT06086808|EXPERIMENTAL|Group A|Resistance Training Group
62093205|NCT06086808|ACTIVE_COMPARATOR|Group B|General Fitness and Toning Group
62093206|NCT04712565|EXPERIMENTAL|Astra Tech Implant System Profile EV|Implants with sloped marginal configuration without bone augmentation are used.
62656786|NCT04254757|OTHER|Open decompression and fusion surgery group|
61907118|NCT01426542|EXPERIMENTAL|Topiramate|
61907119|NCT01426542|ACTIVE_COMPARATOR|Control|These infants will undergo surgery, but will not receive topiramate
61907120|NCT05864456|EXPERIMENTAL|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement with Prizvalve Pro™ transcatheter aortic valve system
61907121|NCT02896322|EXPERIMENTAL|Cyberknife|APBI with cyberknife after breast conserving surgery in breast cancer
62093207|NCT04712565|ACTIVE_COMPARATOR|Astra Tech Implant System EV|Implants with regular neck design and GBR procedure fixed with two membrane pins will be used.
62291006|NCT02421250|NO_INTERVENTION|Control|We will use standard-of-care for control group and not use the SpHb monitor.
61907122|NCT05510271|EXPERIMENTAL|White Noise|
62656787|NCT05505552|EXPERIMENTAL|Vitamin K|Participants receive 1 mg/d phylloquinone orally for 24 weeks
62656788|NCT05505552|PLACEBO_COMPARATOR|Placebo|Participants receive daily placebo matching phylloquinone for 24 weeks
62093208|NCT02474615|EXPERIMENTAL|TOOTH ENDODONTIC SURGERY - PBEA|Endodontic surgery 15 teeth - PBEA
62093209|NCT02474615|EXPERIMENTAL|TOOTH ENDODONTIC SURGERY -MTA|Endodontic surgery 15 teeth - MTA
62093210|NCT05741411|EXPERIMENTAL|Concussed youth at risk for prolonged symptoms|
62093211|NCT01737268|EXPERIMENTAL|FK949E Elderly Participants|After 2 days of dose-titration, elderly participants received either FK949E 150 mg or FK949E 300 mg once daily at bedtime from day 3 to week 52. Dose increase and reduction was allowed following dose increase or reduction guidelines and at the investigator's discretion. After which, participants went through a follow-up period of 1 week. For participants, who completed or discontinued treatment at FK949E 300 mg, a dose-tapering period was placed before proceeding to the follow-up period, and FK949E 150 mg was administered once daily for 1 week in this period.
62093212|NCT03802877|ACTIVE_COMPARATOR|Resource bank|The web-based resource bank includes information and perspectives about GDM, nutrition, and physical activity. The information is presented through video capsules, on-line text, printable pdfs, and podcasts. It is presented by health care professionals and patients.
62093213|NCT03802877|EXPERIMENTAL|Resource bank and ePlatform|In addition to resource bank access, participants will receive a digital scale, physical activity monitor (pedometer), and ePlatform log-in information. They will track daily weights and step counts. They will receive prompts to access educational and motivational tools based on the data that they enter and whether or not they enter data. The investigators will use the ePlatform developed by StepsCount, a Canadian pedometer company with a well-developed ePlatform for pedometer data upload, tracking, and automated messaging. The company is permitting us further customization for study purposes. Data will be uploaded onto a secure cloud-based platform controlled by the pedometer and digital scale companies.
62093214|NCT03802877|EXPERIMENTAL|Resource bank and health coach|"In addition to resource bank access, the coach will contact the participant weekly (telephone, text, email) to discuss progress and challenges in terms of achieving physical activity goals, rate of GWG, and maintaining health eating patterns, as well as any concerns.Participants not randomized to a coaching strategy will be advised to consult with their treating healthcare team directly if they develop symptoms of concern.~The coach will encourage participants to track their weight gain and physical activity (e.g., walks, classes, activity lists, etc.) and to share this information. However, they will not have access to the study ePlatform and will not be provided with pedometers or digital scales."
62656789|NCT01915316||Prostate cancer|Men. Subjects have undergone primary and at least one secondary prostate biopsy with negative diagnostics. Elevated PSA (Prostate Specific Antigen), typically above 10 ng/mL.
62656790|NCT00482092|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo administered as intravenous (IV) infusions.
62656791|NCT00482092|ACTIVE_COMPARATOR|Prochymal® - Low dose|Participants will receive a total dose of Prochymal® 600 x 10\^6 cells, IV infusion, on four days, once daily.
62093215|NCT03802877|EXPERIMENTAL|Resource bank with ePlatform and coach|Participants will have resource bank access as well as ePlatform and coaching interventions.The health coach will have access to the data on the ePlatform. They will receive telephone calls from the research assistant/health coach if they are off target despite the platform tools and support. They will be encouraged to consult the resource bank and will brainstorm with the health coach to decide how to achieve their GWG and step count targets.
62093216|NCT00465361|NO_INTERVENTION|Baseline Performance|Observation of baseline performance
62656792|NCT00482092|ACTIVE_COMPARATOR|Prochymal® - High dose|Participants will receive a total dose of Prochymal® 1200 x 10\^6 cells, IV infusion, on four days, once daily.
62656793|NCT04399447||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
62656794|NCT04399447||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
62656795|NCT04399447||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
62656796|NCT04399447||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
62656797|NCT04399447||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
62656798|NCT04399447||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
62093217|NCT00465361|EXPERIMENTAL|Post-intervention Performance|Observation of performance post-intervention
62093218|NCT01999660||SpaceOAR™|prostate cancer patient prophetically treated by SpaceOAR™
62464171|NCT00436553|EXPERIMENTAL|Verteporfin With Standard Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
62093219|NCT00670540||1|patients with suspected Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
62093220|NCT02374502|EXPERIMENTAL|Brief Intervention Group|Participants in this intervention group will receive a twelve week 'Brief Intervention' delivered by a physiotherapist. Participants will have an initial consultation with a physiotherapist, followed by a number of follow-up sessions. The number and timing of follow-up sessions will be at the participant's discretion (a minimum of 3 and a maximum of 11 over the duration of the study). The follow-up sessions can be face-to-face, over the telephone, or video conferencing depending on participant preference. Participants may additionally opt-in for a weekly email or text message reminder of physical activity goals.
62093221|NCT02374502|NO_INTERVENTION|Control Group|Participants in this control group will be asked to continue with their current levels of physical activity.
62093222|NCT06128317||MIR (Myocardial Infarction Registry)|All patients presenting to the Emergency Department with suspected acute coronary syndrome
62093223|NCT02453529|EXPERIMENTAL|WCK 4873|Oral tablets
62093224|NCT06104150|EXPERIMENTAL|Intervallic submaximal test|Intervallic exercise test
62093225|NCT01438437|ACTIVE_COMPARATOR|Percutaneous acetic acid|
62464172|NCT00436553|ACTIVE_COMPARATOR|Ranibizumab Monotherapy|Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
62656799|NCT00189930|ACTIVE_COMPARATOR|1|High dose
62656800|NCT00189930|ACTIVE_COMPARATOR|2|Low dose
62291007|NCT02441361|NO_INTERVENTION|control|Subjects will undergo bariatric surgery and no exercise training will be prescribed.
62291008|NCT02441361|EXPERIMENTAL|exercise training|Subjects will undergo bariatric surgery and exercise training will be prescribed.
62656801|NCT00189930|PLACEBO_COMPARATOR|3|
61907123|NCT05510271|EXPERIMENTAL|Yakson touch|
61907124|NCT05510271|NO_INTERVENTION|Control|
61907125|NCT02524483|EXPERIMENTAL|Therapeutic Challenge Group|The Therapeutic Challenge Group will complete the Therapeutic Challenge Program twice a day, five days each week for 6 weeks.
62093226|NCT01438437|ACTIVE_COMPARATOR|Radiofrequency ablation|
62291009|NCT04371796|EXPERIMENTAL|Sintilimab injection|"* Drugs: Eligible patients received two doses of intravenous sintilimab (200 mg) every 3 weeks (Q3W). Each infusion time is 30-60min.~* Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 6-8 weeks after the first dose."
62291010|NCT05530057|EXPERIMENTAL|Eribulin + SB3|- Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.
62291011|NCT05530057|ACTIVE_COMPARATOR|Eribulin monotherapy|- Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.
62291012|NCT00999830|EXPERIMENTAL|IPH 2101 0.2 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
62656802|NCT06003413||Osteoarthritic Knee|"* Knees with Kellgren-Lawrence Stage 2-4 will admitted to this group~* Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~* Outcome Measures in Rheumatology (OMERACT) Ultrasound scores for knee will be evaluated~* Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer"
62291013|NCT00999830|EXPERIMENTAL|IPH2101 2.0 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
62656803|NCT06003413||Healthy Knee|"* Healthy knees will be admitted to this group~* Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~* Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer"
62656804|NCT00521183|EXPERIMENTAL|CldC + H4U|
62656805|NCT01493817||Basic science (biomarker analysis)|Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample are then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.
62656806|NCT05723770|EXPERIMENTAL|Perfluorohexyloctane|
62656807|NCT05803707|EXPERIMENTAL|Home-based Adapted Physical Activity|Home-based Adapted Physical Activity sessions by videoconference
62656808|NCT05576896|EXPERIMENTAL|Treatment (Hydroxychloroquine)|
62656809|NCT03824431||patients with endoscopic microerosions|"==Patients with typical symptoms of Gastroesophageal Reflux Disease(GERD):~1- High resolution definition with NBI endoscopic findings of mucosal microerosions in distal esophagus .~."
62656810|NCT03824431||patients without microerosions|2- High resolution definition with NBI endoscopic without findings of mucosal microerosions in distal esophagus .
62656811|NCT06516471|EXPERIMENTAL|Mixed Reality Navigation System Group|Patients will receive receive surgery guided by mixed reality technique navigation system.
62656812|NCT06516471|ACTIVE_COMPARATOR|Conventinal Navigation System Group|Patients will receive receive surgery guided by traditional navigation system.
61907126|NCT02524483|ACTIVE_COMPARATOR|Therapeutic Exercise Group|The Therapeutic Exercise Group will complete the Therapeutic Exercise Program twice a day, five days each week for 6 weeks.
61907127|NCT02880956|PLACEBO_COMPARATOR|Placebo|Placebo for ABBV-8E12 every 4 weeks for 96 weeks
62093227|NCT02402972|EXPERIMENTAL|IPC plus AC|"patients treated with intraoperative intraportal chemotherapy (IPC) plus adjuvant chemotherapy (AC; mFOLFOX6).; IPC: During the operation, one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein within 5 minutes just before ligation.~AC: All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.\[1\] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0."
62656813|NCT04818775|EXPERIMENTAL|HemaClear|
62656814|NCT04818775|ACTIVE_COMPARATOR|Pneumatic Tourniquet|
62656815|NCT03252626|ACTIVE_COMPARATOR|Alprostadil|Based on the standard medical care, 2ml of Alprostadil
62656816|NCT03252626|PLACEBO_COMPARATOR|Normal saline|Based on the standard medical care, 2ml of 0.9% saline as the placebo
61907128|NCT02880956|EXPERIMENTAL|ABBV-8E12 300 mg|ABBV-8E12 300 mg every 4 weeks for 96 weeks
61907129|NCT02880956|EXPERIMENTAL|ABBV-8E12 1000 mg|ABBV-8E12 1000 mg every 4 weeks for 96 weeks
61907130|NCT02880956|EXPERIMENTAL|ABBV-8E12 2000 mg|ABBV-8E12 2000 mg every 4 weeks for 96 weeks
62291014|NCT06200350|EXPERIMENTAL|Experimental group|This group will carry out the tailored training proposed by de recommender system, and followed and encouraged by the blockchain dApp.
62291015|NCT06200350|ACTIVE_COMPARATOR|Control group|This group will continue with the traditional training planned.
62291016|NCT06214988|EXPERIMENTAL|selective approach to defunctioning stoma|With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
62308056|NCT04926155|NO_INTERVENTION|ADT+abiraterone|Patients in this arm will be treatet with ADT and abiraterone, Abiraterone 1000mg once daily until disease progression.
62656817|NCT05076227||BNT162b2/BNT162b2 - 3 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 3 weeks as boost vaccination
62656818|NCT05076227||ChAdOx1/ChAdOx1 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and also receiving AstraZeneca as boost vaccination after 12 weeks
62656819|NCT05076227||ChAdOx1/BNT162b2 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and receiving BioNTech as boost vaccination after 12 weeks
62656820|NCT05076227||BNT162b2/BNT162b2 - 6 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 6 weeks as boost vaccination
62656821|NCT04712461|EXPERIMENTAL|SUPPORTS Implementation Model|The SUPPORTS implementation model will consist of a package of implementation strategies aimed at improving EBP sustainment through reducing provider burnout and turnover and improving organizational climate. The content and structure of SUPPORTS will be informed by the occupational health literature (e.g., psychoeducation about burnout, mindfulness training, or changes involvement of providers in organizational decision-making) and from a needs and context assessment.
61907131|NCT01116856|EXPERIMENTAL|Nutrition|This groups will follow a diet.
61907132|NCT01116856|EXPERIMENTAL|Nutrition + resistance training|In this group, nutrition and resistance training will be combined.
61907133|NCT01116856|EXPERIMENTAL|Nutrition + aerobic training|In this group nutrition and aerobic training will be combined.
61907134|NCT01116856|EXPERIMENTAL|Nutrition + mixed training|In this group the nutrition will be combined with 50% of resistance training plus 50% of aerobic training.
61907135|NCT01303224|EXPERIMENTAL|Ibodutant low dose|Oral tablet, to be given once daily in fasting conditions.
61907136|NCT01303224|EXPERIMENTAL|Ibodutant intermediate dose|Oral tablet, to be given once daily in fasting conditions.
61907137|NCT01303224|EXPERIMENTAL|Ibodutant high dose|Oral tablet, to be given once daily in fasting conditions.
61907138|NCT01303224|PLACEBO_COMPARATOR|Placebo|Oral tablet, to be given once daily in fasting conditions.
62093228|NCT02402972|ACTIVE_COMPARATOR|AC|patients treated with adjuvant chemotherapy (AC; mFOLFOX6) alone after surgery; Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.\[1\] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0.
62093229|NCT00004136|EXPERIMENTAL|Heat Therapy|
62093230|NCT00973947|OTHER|Control|Immobilisation: Standard headrest plus individual customised mask (orfit)
62093231|NCT00973947|OTHER|TRial Arm|Immobilisation: Customised headrest plus individual customised mask (orfit)
62093232|NCT06009783|EXPERIMENTAL|Intervention arm - ChatGPT|Patient's interested in participating in the intervention group will be provided a secure ChatGPT account. They will have the opportunity to converse with ChatGPT to ask any potential questions they may have regarding their upcoming vasectomy. Patient's will then be seen for the standard pre-vasectomy consultation.
62093233|NCT06009783|NO_INTERVENTION|Control arm - no ChatGPT|No intervention - standard of care
61907139|NCT03649308|EXPERIMENTAL|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
61907140|NCT03649308|ACTIVE_COMPARATOR|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
61907141|NCT06088602|EXPERIMENTAL|Cryo-group|Postoperative cryoneurolysis of the superficial genicular nerves, i.e., the infrapatellar branches of the saphenous nerve (ISN) and the anterior femoral cutaneous nerve (AFCN).
61907142|NCT06088602|SHAM_COMPARATOR|Sham-group|Postoperative sham cryoneurolysis of the lower extremity.
62093234|NCT06697275|ACTIVE_COMPARATOR|Standard method|"In this standard method, before the treatment, the procedure of inserting the needle into the implantable port is explained to the child. The patient is comfortably installed and the treatment start using the standard method which consist on distracting the patient by singing, story telling, talking etc..~Use of local anesthesic cream and +/- anxiolytic gas"
61907143|NCT03317327|EXPERIMENTAL|Nivolumab|Nivolumab, intravenous every 2nd week (1 cycle = 2 weeks), dose escalation schedule (1.0, 3.0 mg/kg), for a maximum of 12 months or until disease progression.
62291017|NCT06214988|NO_INTERVENTION|routine use of defunctioning stoma|With randomisation to this control arm (systematic approach), a defunctioning stoma is constructed using the marked stoma site. A loop ileostomy is fashioned using an ileal loop close to the ileocecal valve, while a loop colostomy can be derived from either the transverse or a redundant left colon.
61907144|NCT02879487|ACTIVE_COMPARATOR|Coagulation mode|Colpotomy will be performed by monopolar needle electrode using coagulation mode
61907145|NCT02879487|ACTIVE_COMPARATOR|Cut mode|Colpotomy will be performed by monopolar needle electrode using cut mode
61907146|NCT05095532|EXPERIMENTAL|BM-MSCs at 20x10^6|One time infusion of islets plus BM-MSCs at 20x10\^6/patient, n=14
61907147|NCT05095532|EXPERIMENTAL|BM-MSCs at 50x10^6|One time infusion of islets plus BM-MSCs at 50x10\^6/patient, n=14
61907148|NCT05095532|PLACEBO_COMPARATOR|Placebo|One time infusion of islets only.
61907149|NCT01873469||Radiochemotherapy|glioblastoma patients with indication to radiochemotherapy
61907150|NCT05737615|EXPERIMENTAL|Participants with Pancreatic Cancer|Participants have histologically confirmed primary or metastatic pancreatic ductal adenocarcinoma
61907151|NCT04062903|ACTIVE_COMPARATOR|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed.
61907152|NCT04062903|ACTIVE_COMPARATOR|Delayed Appointment|Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
62093235|NCT06697275|ACTIVE_COMPARATOR|Interactive virtual reality|"Before the treatment, the caregiver explains the procedure of inserting the needle into the implantable port. A general explanation is given on the VR device (how the headphones and headsets are placed), presentation of the virtual worlds to choose from, description of the course of the session (virtual travel is guided by a voice). For the interactive virtual reality, the mode of operation will be explained as the actions are validated using the eyes.~The patient is then installed comfortably. The caregiver helps the child to put on the headphones and headset correctly. Before starting the care procedure, the caregiver will wait about 5 minutes after the start of the viewing to make sure the child is completely immersed in the virtual reality. The software is turned off about 3 minutes after the end of the care procedure.~Use of local anesthesic cream."
62093236|NCT06697275|ACTIVE_COMPARATOR|Hypnotic virtual reality|"Before the treatment, the caregiver explains the procedure of inserting the needle into the implantable port to the child. A general explanation is given on the VR device (how the headphones and headsets are placed), presentation of the virtual worlds to choose from, description of the course of the session (virtual travel is guided by a voice). The patient is then installed comfortably. The caregiver helps the child to put on the headphones and headset correctly. Before starting the care procedure, the caregiver will wait about 5 minutes after the start of the viewing to make sure the child is completely immersed in the virtual reality. The software is turned off about 3 minutes after the end of the care procedure.~Use of local anesthesic cream."
62093237|NCT04971694||Inclusion Group|Infants born at \<30 weeks and/or \<1500g that were admitted to BUMCP between January 1, 2019 and December 31, 2020
62656822|NCT04712461|NO_INTERVENTION|Implementation as Usual|Agencies in the Implementation as Usual condition will have implementation strategies tied to the implementation of EBPs that these agencies in the community are already using (i.e., the study will measure the implementation strategies being used by the agency but will not provide any additional strategies). There will be no strategies related to reducing provider burnout and turnover and improving organizational climate.
62656823|NCT05475509|EXPERIMENTAL|virtual reality group (nature videos were watched by wearing virtual reality glasses)|In the experimental group, saliva sample will be taken before chemotherapy, Personal Information Form, State Anxiety Scale and VAS pre-test questionnaires will be applied, pre-test questionnaires will be applied to measure vital signs, and then virtual reality glasses will be introduced to the patients and the duration will vary between 3-10 minutes for a total of 30 minutes. A saliva sample will be taken and a post-test will be applied, with virtual reality glasses, videos with music background, park, nature and seaside walks, underwater, museum trips, videos that the patient wants to watch and can change whenever they want. Each patient will be shown the same video.
62093238|NCT06615063|EXPERIMENTAL|Splint Group|These neonates receive peripheral intravenous cannulation with limb splinting.
62093239|NCT06615063|NO_INTERVENTION|Non-Splint Group|These neonates receive peripheral intravenous cannulation without limb splinting.
62656824|NCT05475509|NO_INTERVENTION|Control Group|Personal Information Form, State Anxiety Scale and VAS pre-test questionnaires will be applied to the patients who accepted to participate in the study, saliva sample will be taken from the control group before chemotherapy, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made and saliva sample will be taken.
62656825|NCT03776045|NO_INTERVENTION|Standard care|This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study.
62656826|NCT03776045|EXPERIMENTAL|Standard care plus exercise|This group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy.
62656827|NCT06520384|EXPERIMENTAL|Radiofrequency group|Patients will receive radiofrequency.
62656828|NCT06520384|EXPERIMENTAL|30% alcohol group|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
62656829|NCT06520384|EXPERIMENTAL|50% alcohol group|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
62656830|NCT06520384|EXPERIMENTAL|70% alcohol group|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
61907153|NCT02815826||Barefoot training|16 weeks of progressive barefoot running training
61907154|NCT00254579|EXPERIMENTAL|15 mg/kg CP-675,206|
62656831|NCT02771964||All patients|All patients receive both types of quality of life assessment, thus serving as their own controls.
61907155|NCT01465685|EXPERIMENTAL|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
61907156|NCT03508791|ACTIVE_COMPARATOR|Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the Trendelenberg position
61907157|NCT03508791|ACTIVE_COMPARATOR|reverse Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the reverse Trendelenberg position
61907158|NCT02901327|EXPERIMENTAL|Lumbar Stabilisation Exercise|30 minute lumbar stabilization exercise, 3 times per week for 8 weeks.
61907159|NCT02901327|ACTIVE_COMPARATOR|Treadmill walk exercise|Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
61907160|NCT02491944|EXPERIMENTAL|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of \[14C\]AZD9291
61907161|NCT05427877|EXPERIMENTAL|Heating Device Application|Heating devices will be applied to the trunk and extremities of the body.
61907162|NCT00222131|PLACEBO_COMPARATOR|1|Placebo
61907163|NCT00222131|ACTIVE_COMPARATOR|2|Esomeprazole
61907164|NCT03982134|EXPERIMENTAL|PDR001 with Panobinostat|All enrolled patients will be treated with a combination of PDR001 at 400mg every 4 weeks and panobinostat. Dose and frequency of Panobinostat will vary depending upon the dose-level cohort of the study participants. Each participant will be assigned to a particular dose-level cohort.
61907165|NCT00308581|EXPERIMENTAL|Active 1|"Q4W regimen~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol"
62093240|NCT06443697||Delayed CIPONV|Patients experiencing CIPONV between 25 and 120 hours post-surgery.
61907166|NCT00308581|EXPERIMENTAL|Active 2|"Q2W regimen~- every 2 weeks: 400 mg Certolizumab Pegol"
61907167|NCT03856281|EXPERIMENTAL|Intervention Group A|LymphAssist IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
62093241|NCT06443697||Non-delayed CIPONV|Patients not experiencing CIPONV between 25 and 120 hours after surgery.
62464173|NCT00436553|EXPERIMENTAL|Verteporfin With Reduced Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
62291018|NCT01727089|ACTIVE_COMPARATOR|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62464174|NCT01318499|EXPERIMENTAL|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
62737449|NCT04497103|EXPERIMENTAL|task oriented training|Task-oriented training TOT group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
61907168|NCT03856281|EXPERIMENTAL|Intervention Group B|Sequential IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
61907169|NCT04605614|EXPERIMENTAL|Treatment (pembrolizumab, 64Cu-DOTA-pembrolizumab, PET)|Patients receive pembrolizumab IV over 30 minutes, and within 6 hours also receive 64Cu-DOTA-pembrolizumab via slow IV push over \> 1 minute on day 0. Patients then undergo PET over 60 minutes on day 1.
61907170|NCT01932879|EXPERIMENTAL|Blackberry|Participants will consume blackberries twice/day as part of a 1-week controlled diet.
61907171|NCT01932879|OTHER|Control|Participants will consume jello twice/day as part of a 1-week controlled diet.
61907172|NCT03349398|ACTIVE_COMPARATOR|the group of Roux-en-Y|
61907173|NCT03349398|EXPERIMENTAL|the group of Uncut Roux-en-Y|
62291019|NCT01727089|EXPERIMENTAL|Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)|Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
61907174|NCT06025136|EXPERIMENTAL|Intervention Group|Patients who are visited in their rooms on the evening of the day before the surgery will be given a gel pillow with a cooling surface feature for night use. Patients will be asked to note the time they go to bed for a night's sleep and the time they wake up on the morning of the surgery. If patients stop using pillows at night, they will be asked to inform the investigator when they come to their room in the morning.Patients will be visited again on the morning of the surgery day.The Richard Campbell Sleep Scale was used to evaluate the nighttime sleep quality of the patients;General Comfort Scale to evaluate comfort.
62093242|NCT04259970|EXPERIMENTAL|Phase 1|Phase 1 will include implementation of a centralized analysis program of repeated 129Xe MRI scanning in CF patients with mild lung disease to define the intra-subject variability of the primary outcome ventilation defect percentage (VDP). Patients will undergo baseline 129Xe MRI scanning and repeated measurements the same day, as well as at 28 days (± 7 days). Phase 1 will establish the intra-subject reproducibility to facilitate future use of 129Xe MRI in multi-site studies. Furthermore, the reproducibility limits defined will inform the overall design of future studies and will compare to established pulmonary function and multiple-breath washout testing (via measurement of the lung clearance index, LCI).
62291020|NCT02071238|EXPERIMENTAL|Pamphlet|Patient group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
62656832|NCT02528227|EXPERIMENTAL|Language Curriculum|The Language Intervention group will receive some of the known methods for early language development. Six lessons will include: Knowing your Baby, Reading Aloud, Sing-A-Long, Mimicking First Sounds, Language Game and Narrating Your Day. Parents will receive feedback every 2 weeks from a Language Environment Analysis digital language processor (LENA).
62656833|NCT02528227|PLACEBO_COMPARATOR|Health and Safety Curriculum|Parents will receive six lessons on important infant safety topics including, feeding safety, care seat safety, bath safety, back to sleep/SIDS prevention, taking a temperature and signs of infection, infection control methods and vaccine information. Parents will receive LENA feedback at discharge from NICU.
62656834|NCT00620906|OTHER|A|Manipulation
62656835|NCT02265653|EXPERIMENTAL|BIIL 284 BS tablet C|
62656836|NCT02265653|EXPERIMENTAL|BIIL 284 BS tablet D|
62656837|NCT02265653|ACTIVE_COMPARATOR|BIIL 284 BS WIF tablet|
62656838|NCT01367041|EXPERIMENTAL|Bone loss|Postmenopausal women with osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
62656839|NCT01367041|EXPERIMENTAL|Normal|Postmenopausal women without osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
62656840|NCT05033041|ACTIVE_COMPARATOR|Group 1 Study Drug Metoclopramide|Intravenous administration of 10 mg metoclopramide
61907175|NCT06025136|NO_INTERVENTION|Control Group|The patients who were visited in their rooms on the evening of the day before the operation will be given pillows that have the same characteristics as the pillows that the patients in the study group will use, but do not have a gel surface, to use at night. Patients will be asked to note the time they go to bed for a night's sleep and the time they wake up on the morning of the surgery.Participants in the control group will receive no other interventions.Patients will be visited again on the morning of the surgery day.The Richard Campbell Sleep Scale was used to evaluate the nighttime sleep quality of the patients;General Comfort Scale to evaluate comfort levels.
61907176|NCT03610100|EXPERIMENTAL|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
62464175|NCT01318499|ACTIVE_COMPARATOR|Nepafenac 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
62656841|NCT05033041|PLACEBO_COMPARATOR|Group 2 Study Drug Placebo|Intravenous administration of sterile normal saline
62656842|NCT00718601|EXPERIMENTAL|1|3+3 cohort dose escalation
62656843|NCT05274282|EXPERIMENTAL|Animation Therapy Group|10 sessions of Animation Therapy (1 session/week)
62464176|NCT01318499|PLACEBO_COMPARATOR|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
62656844|NCT05274282|NO_INTERVENTION|Control Group|No intervention
61907177|NCT03610100|ACTIVE_COMPARATOR|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
61907178|NCT05046197||Work Package 1 - patients and carers|"Qualitative interview of 48 Patients, or their carers where the patient lacks capacity, who have had a ReSPECT form completed in the previous 6 months. To include:~12 patients living in care homes 12 patients living at home (nearing the end of their life) 12 patients living at home (not nearing the end of their life)"
61907179|NCT05046197||Work Package 1 - GPs|Qualitative interview of 30 General Practitioners who are involved in the ReSPECT process
61907180|NCT05046197||Work Package 1 - Care home managers|Qualitative interview of 24 care home managers.
61907181|NCT05046197||Work Package 2 - Focus groups/interviews (Members of the Public)|Qualitative interview of 30 members of the public with an interest in healthcare regarding attitudes to the ReSPECT process.
61907182|NCT05046197||Work Package 2 - Focus groups/interviews (Health and Social Care Professionals)|Qualitative interview of 30 Non-GP Health and Social Care Professionals regarding attitudes to the ReSPECT process.
62656845|NCT02515929|EXPERIMENTAL|Oligomeric Proanthocyanidins|90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days
62656846|NCT02515929|PLACEBO_COMPARATOR|Placebo|Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days
61907183|NCT05046197||Work Package 2 - Focus groups/interviews (Faith Leaders)|Qualitative interview of 8 faith leaders regarding attitudes to the ReSPECT process.
62656847|NCT06466200|OTHER|dentin hypersensitivity group|patients with at least one tooth with a diagnosis of dentin hypersensitivity (DH) with dentin exposure related to gum recession and/or erosive lesion or with a diagnosis of DH with a gingival margin flush with the amelocementary junction. In patients with multiple teeth with DH, the study will consider the most painful tooth according to the EVA score on the air jet test.
61907184|NCT05046197||Work Package 2 - Survey (Members of the Public)|Survey of 1000 members of the public to measure public awareness and acceptability of emergency care treatment plans
62291021|NCT02071238|NO_INTERVENTION|No pamphlet, individual|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
62291022|NCT02071238|EXPERIMENTAL|Group Consultation|Patient group that will receive informed consent discussion in a group-format.
62464177|NCT00731705||1|Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants OR First-degree relatives of patients evaluated for stem cell transplantation
62656848|NCT06466200|OTHER|control group|Control group: The group of patients without DH will consist of patients from the study centers who meet the inclusion criteria and agree to participate.
62464178|NCT01722474|EXPERIMENTAL|ASI Device|Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
62656849|NCT02474836|ACTIVE_COMPARATOR|Atopic subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
62656850|NCT02474836|ACTIVE_COMPARATOR|Non atopic subjects|Healthy volunteers
62656851|NCT02474836|OTHER|Allergic Subjects|
62656852|NCT05945407|EXPERIMENTAL|Myometrial invasion group|Pelvic enhanced magnetic resonance imaging or transvaginal color Doppler ultrasound suggests that the tumor invades less than one half of the myometrium.
62656853|NCT05945407|OTHER|No myometrial invasion group|Pelvic enhanced magnetic resonance imaging or transvaginal color Doppler ultrasound suggests that the tumor is limited to the endometrium.
62656854|NCT01458977|EXPERIMENTAL|TDF/FTC (3 months) + Placebo (6 months)|TDF/FTC (3 months) + Placebo (6 months)
62656855|NCT01458977|PLACEBO_COMPARATOR|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)
62656856|NCT02127853|EXPERIMENTAL|Gabapentin|gabapentin pretreatment
62656857|NCT02127853|PLACEBO_COMPARATOR|Placebo|placebo drug pretreatment
61907185|NCT05046197||Work Package 2 - Survey (GPs)|Survey of 1000 GPs to measure the views of GPs nationally regarding the use of emergency care treatment plans including ReSPECT, in primary care.
62291023|NCT05408611|EXPERIMENTAL|Experimental (acupressure) group|Acupressure (complementary and integrative medicine method) Acupressure will be applied individually to the experimental group for 18-20 minutes three times a day for three menstrual cycles (approximately 3 months). Data collection forms will be applied 4 times in total, before the intervention, within 5 minutes after acupressure, at the end of Cycle 1 and cycle 2 (each cycle is 28 days).
62464179|NCT02627924||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
61907186|NCT05046197||Work Package 3 - Patient records|Patient records of 413 patients within 12 CCGs in England who have had a ReSPECT form completed in the previous 12 months
62464180|NCT04869787|OTHER|SCD Treatment|Pediatric patients receiving SCD + CRRT for up to 10 days
61907187|NCT05922670|EXPERIMENTAL|SGM BH-Works Implementation|For this phase of the study, the adapted version of the BH-works program (SGM BH-Works) will be implemented into LGBTQ+ Community Organizations. The BH-Works program offers screening, training, and referral coordination.
61907188|NCT05766358||Placebo|
61907189|NCT05766358||Tirzepatide|
62464181|NCT05594472|EXPERIMENTAL|Ozonated olive oil|ozonated oil will be applied to on one lesion followed by gauze for 5 consecutive days.
62464182|NCT05594472|ACTIVE_COMPARATOR|Topical garamycin cream|conventional topical treatment will be applied to a comparable lesion followed by gauze for 5 consecutive days.
62464183|NCT06197529|EXPERIMENTAL|S1 Homeostatic Plasticity-Pain|"Anodal tDCS CP3 1mA FP2 -1mA~4x4 patch on the dorsum of the hand"
61907190|NCT01800461|EXPERIMENTAL|OPC-Stroke, Usual care|OPC-Stroke - 10 weekly sessions of goal setting followed by problem solving process
62093243|NCT04259970|EXPERIMENTAL|Initiation of CFTR Modulator|Phase 2 will be an observational study of patients assessed before and after the clinical initiation of triple-combination modulator therapy (after presumed FDA and Health Canada approval). The primary endpoint for Phase 2 is the change of VDP after 28 days of triple-combination modulator therapy. Within Phase 2, this study will also address how highly-effective modulator therapies affect lung function trajectories by measuring 129Xe MRI at 28 days (± 7 days), 6 months (± 28 days), and 12 months (± 28 days) after start of therapy (paralleling time points of the PROMISE study). Finally, to understand how 129Xe MRI can be used in combination with existing measures of lung function (e.g. spirometry, multiple breath washout), the investigators will directly compare the repeated data collected in both Phase 1 and Phase 2 to these established measures of lung function that are currently used in observational and interventional studies.
62093244|NCT00961493|EXPERIMENTAL|1|
61907191|NCT01800461|OTHER|Usual care|Usual care - Follow-up by physician and possible receipt of home care services
61907192|NCT05471583||Main group|There is only one group in the study. It is observational.
61907193|NCT00535964||1|Psychologically healthy adolescents, evenly divided across the various stages of smoking uptake
61907194|NCT03156647||idiopathic Parkinson disease|
61907195|NCT03156647||iatrogenic parkinsonian syndrome|
61907196|NCT03156647||healthy volunteers|
61907197|NCT01037894|EXPERIMENTAL|Acupuncture|Acupuncture and conventional rehabilitation
61907198|NCT01037894|ACTIVE_COMPARATOR|Control|Conventional rehabilitation only
61907199|NCT02816827|EXPERIMENTAL|E-AG-01|550 mg of 2 capsules having AG-01 and AG-07 will be administered orally twice daily for one day.
61907200|NCT02816827|EXPERIMENTAL|E-AG-02|550 mg of 2 capsules having AG-05 and AG-06 will be administered orally twice daily for one day.
61907201|NCT02816827|EXPERIMENTAL|E-AG-03|550 mg of 2 capsules having AG-01 and AG-05 will be administered orally twice daily for one day.
61907202|NCT02816827|EXPERIMENTAL|E-AG-04|550 mg of 2 capsules having AG-06 and AG-07 will be administered orally twice daily for one day.
62464184|NCT06197529|PLACEBO_COMPARATOR|S1 Homeostatic Plasticity-NoPain|"Anodal tDCS C3 1mA FP2 -1mA~4x4 patch on the dorsum of the hand"
62464185|NCT06197529|SHAM_COMPARATOR|S1 Homeostatic Plasticity-Sham|"Sham tDCS C3 FP2~4x4 patch on the dorsum of the hand"
62464186|NCT06197529|ACTIVE_COMPARATOR|M1 Homeostatic Plasticity|"Anodal tDCS C3 1mA FP2 -1mA~4x4 patch on the dorsum of the hand"
62464187|NCT03248362|EXPERIMENTAL|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
62464188|NCT03248362|SHAM_COMPARATOR|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
62464189|NCT04336930||Cardiac Arrest group|Patients remaining comatose after a cardiac arrest
62464190|NCT04499729|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU will be the treatment that is provided through the Rush Collaborative Care program as part of their service
62464191|NCT04499729|EXPERIMENTAL|IntelliCare|Patients will be offered IntelliCare as part of their care in the Rush Collaborative Care service. Patients who agree will download the IntelliCare app, which provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
62464192|NCT00611819|EXPERIMENTAL|1|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
62464193|NCT00611819|ACTIVE_COMPARATOR|2|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
62464194|NCT04470180|EXPERIMENTAL|Virtual Teach-to-Goal (V-TTG)|They will be randomized to receive education via a virtual learning module.
62464195|NCT04470180|ACTIVE_COMPARATOR|standardized brief intervention|Intervention that mimics usual care to deliver inhaler technique education.
62464196|NCT02313688|EXPERIMENTAL|Group A|Group A: Patients in the Group A will underwent D2 total gastrectomy and with 3±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
62464197|NCT02313688|EXPERIMENTAL|Group B|Patients in the Group B will underwent D2 total gastrectomy and with 5±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
62464198|NCT02549651|EXPERIMENTAL|MEDI4736|
62464199|NCT02549651|EXPERIMENTAL|MEDI4736 and tremelimumab|
62656858|NCT06042075||Health professionals|Health professionals working at Angers Maternity Unit include gynecologists, pediatricians, residents (gynecology and pediatric residents), childcare assistants, nursing auxiliaries and midwives.
62656859|NCT02253342|EXPERIMENTAL|WCK 2349|Subjects will receive oral doses of WCK 2349 administered twice-daily for five days starting on Day 1
62656860|NCT05324202|OTHER|Nd:YAG treatment arm|
61907203|NCT04330729|EXPERIMENTAL|Dialysis patients|Patients will tablet acetylsalicylic acid 75mg x 1 for 4 weeks.
62656861|NCT03600259||Acute Myocardial Infarction|
61907204|NCT02141477|EXPERIMENTAL|Omacetaxine + Decitabine|"Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
62093245|NCT00961493|ACTIVE_COMPARATOR|2|
62656862|NCT06436859|EXPERIMENTAL|Experiment|Stress ball group
62656863|NCT06436859|NO_INTERVENTION|Control group|Routine care
61907205|NCT03439683||Physicians|"Definition: Physicians working in the ICU for at least 50% of their time in the hospital~Intervention: Survey about patient-ventilator asynchrony"
61907206|NCT03439683||Nurses|"Definition: Nurses working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
62093246|NCT03829969|EXPERIMENTAL|Toripalimab|Toripalimab combine with paclitaxel and cisplatin
62291024|NCT05408611|PLACEBO_COMPARATOR|Plasebo group|"Placebo acupressure will be performed at any point within 1.5 cm of the actual acupressure points.~Plasebo acupressure will be applied individually to the experimental group for 18-20 minutes three times a day for three menstrual cycles (approximately 3 months). Data collection forms will be applied 4 times in total, before the intervention, within 5 minutes after acupressure, at the end of Cycle 1 and cycle 2 (each cycle is 28 days)."
62656864|NCT03029390|EXPERIMENTAL|Berberine hydrochloride|"Berberine capsules, 500 mg, three per day before each meal during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)"
62656865|NCT03029390|EXPERIMENTAL|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
62656866|NCT04575870||Treatment Group 1: 90 min waiting period|Participants undergo their planned tracheobronchoscopy + 90 minute waiting period prior to modified functional endoscopic swallowing exam
62656867|NCT04575870||Treatment Group 2: 66 min waiting period|Participants undergo their planned tracheobronchoscopy + 66 minute waiting period prior to modified functional endoscopic swallowing exam
62656868|NCT04575870||Treatment Group 3: 46 min waiting period|Participants undergo their planned tracheobronchoscopy + 46 minute waiting period prior to modified functional endoscopic swallowing exam
62656869|NCT02713672|EXPERIMENTAL|Intervention group|Psychiatric patients with a CYP2D6 or CYP2C19 PM or IM genotype, using antidepressants or antipsychotics metabolized by CYP2D6 or CYP2C19
61907207|NCT03439683||Respiratory Therapists|"Definition: Respiratory Therapists working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
61907208|NCT00564057|EXPERIMENTAL|1|candesartan 8-16 mg once daily
61907209|NCT00564057|ACTIVE_COMPARATOR|2|lercanidipine 10-20 mg once daily
61907210|NCT03160794|EXPERIMENTAL|[18F] DCFPyL PET/MRI|"\[18F\] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.~Lesions identified through \[18F\] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery."
62093247|NCT03829969|PLACEBO_COMPARATOR|placebo|Placebo combine with paclitaxel and cisplatin
62093248|NCT05838183||OSA group|Sleep detection was performed in OSA patients，And according to the severity of the analysis, obtain the corresponding biological specimens, the relevant detection
62291025|NCT00120003|EXPERIMENTAL|Candesartan Cilexetil|Candesartan Cilexetil
62656870|NCT02713672|NO_INTERVENTION|Control group|Psychiatric patients with a CYP2D6 or CYP2C19 EM genotype using antidepressants or antipsychotics
61907211|NCT03619057||> 18 years|
61907212|NCT03619057||10 to 18 years|
62093249|NCT05838183||Interstitial lung disease group|Bronchoscopy was performed to obtain alveolar lavage fluid in ILD patients and lung tissue was obtained for ROSE and NGS in appropriate patients
62291026|NCT00120003|PLACEBO_COMPARATOR|Placebo|Placebo
62464200|NCT02549651|EXPERIMENTAL|MEDI4736 and AZD9150|
62093250|NCT00739453|EXPERIMENTAL|Schedule 1|OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
62291027|NCT03018548|EXPERIMENTAL|subject blood drawns|subjects will have blood drawn which will then be exposed to blast via CO2 cartridge
62291028|NCT05046756|EXPERIMENTAL|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
62291029|NCT05046756|NO_INTERVENTION|Education brochure|Control group is provided general education through the hospital brochure.
62656871|NCT03007875|EXPERIMENTAL|High-activity natural killer|In this group, the patients will receive multiple times of high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62093251|NCT00739453|EXPERIMENTAL|Schedule 2|OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
62093252|NCT00739453|EXPERIMENTAL|Schedule 3|OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
62093253|NCT02381899||BR in CLL|Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.
62093254|NCT02883543|EXPERIMENTAL|icotinib plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy.
62656872|NCT03007875|NO_INTERVENTION|ControL|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62656873|NCT04686331||Suspected CAP|All patients admitted to the emergency department with suspected community-acquired pneumonia (CAP) assessed by the receiving physician
62656874|NCT03901300|EXPERIMENTAL|Fundamental Motor Skills (FMS)|The FMS group will utilize the PLAY FMS app that provides instructional lessons, peer modeling videos, and activity breaks to deliver 720 minutes of targeted, structured FMS instruction time to the child over a 12 week period.
62656875|NCT03901300|ACTIVE_COMPARATOR|Unstructured Physical Activity|The active comparator group will use a version of the PLAY app that provides instructional lessons to promote the equivalent dosage of unstructured physical activity for the child.
62093255|NCT02883543|ACTIVE_COMPARATOR|icotinib|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib monotherapy.
62093256|NCT02883543|ACTIVE_COMPARATOR|chemotherapy plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy.
62656876|NCT05091242|EXPERIMENTAL|Clonidine|Participants receive Clonidine solution for injection, 3 microg/kg, administered intravenously once over 2 minutes approximately 20 minutes before end of procedure. Injection is administered from a dilated solution of Clonidine 15 microg/mL (ie., 0.2 mL/kg).
62656877|NCT05091242|PLACEBO_COMPARATOR|Placebo|Participants receive Sodium Chloride isotonic (9mg/mL) solution for injection administered intravenously once over 2 minutes approximately 20 minutes before end of procedure. Dosage is administered according to weight: 0.2 mL/kg.
62656878|NCT01714934||IPF|IPF patients diagnosed according to clinical and radiological findings
61907213|NCT05630391|EXPERIMENTAL|Intervention|In the process of teaching personnel protective equipment (PPE) use with the scenario-based high-fidelity simulation mannikin, a simulation application was made with 26 students. The simulation scenario was implemented with 13 groups consisting of 3 students each playing different roles (nurse, head nurse, patient relative). Throughout the scenario, the students who played the role of the nurse and the head nurse simulated the PPE wearing-removal practice in a way to cover all steps of the process (preparation, implementation, and evaluation). During the implementation of the scenario, the student playing the role of the patient's relative provided guiding clues to the nurse when needed. Debriefing was started right after the simulation. Frequency of administration the implementation of each group is once and the debriefing stage where the learning process was reinforced and lasted 30 minutes.
62093257|NCT05339906|EXPERIMENTAL|ZOV.ai digital therapy candidate|"The arm will use a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms.~The total length of the audio stimuli is 5 minutes."
62093258|NCT04027361|ACTIVE_COMPARATOR|Amphetamine ER Tablets, 20 mg|Double-blind amphetamine extended-release tablets, 20 mg dose, single tablet, administered at baseline
62656879|NCT01714934||NON IPF|Other interstitial lung diseases such as sarcoidosis or hypersensitivity pneumonitis diagnosed as per clinical and radiological findings
62656880|NCT04143048||The construction of Gene detection technology flow|At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored. It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).
62737450|NCT04497103|EXPERIMENTAL|Xbox kinect|Xbox training group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
62737451|NCT03060993|PLACEBO_COMPARATOR|Placebo|35 mg of tetrahydrocannabinol/cannabidiol (LT1.0/LT1.0 %) in vaporized form. Placebo will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
62093259|NCT04027361|PLACEBO_COMPARATOR|Placebo|Matching double-blind placebo tablets, 20 mg dose, single tablet, administered at baseline
62093260|NCT06615583|EXPERIMENTAL|C-REX arm|Patients will receive the C-REX device during sigmoid or high rectal resection. They will be instructed to follow a low residue diet and administered with a stool softener for five days after the surgical intervention. Approximately ten days after surgery, patients will release the study device and the anastomosis will be assessed with digital endoscopy.
62093261|NCT04536025||Prosthetists|Up to 24 prosthetists who are actively providing prosthetic care to people with lower limb amputation will be recruited for participating in focus groups to describe their decisional needs for providing prostheses to people with lower limb amputation.
62093262|NCT04536025||People with lower limb amputation|An estimated 14 people within 1 year from lower limb amputation, receiving their first prosthesis will be recruited for individual semi-structured interviews to describe their decisional needs for provision of a prosthesis.
62656881|NCT04143048||Establishment of non-invasive gene testing technology process|In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors. About 50 patients were planned to be enrolled. Peripheral blood was collected once for each patient and the blood volume was 10mL. Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion . DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.
62093263|NCT04536025||Expert working group|The expert working group will consist of at least 5 and up to 12 people with LLA actively receiving prosthetic care, and at least 5 and up to 12 prosthetic care providers with greater than 5 years of experience. Individuals will be invited to join the expert working group based on expertise, and representation of key stakeholders relevant to the prosthetic design process.
62093264|NCT00839202|EXPERIMENTAL|FVIII immuno-assay|The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
62093265|NCT00924989|EXPERIMENTAL|Arm A: OSI-906|150 mg twice daily
62093266|NCT00924989|PLACEBO_COMPARATOR|Arm B: Placebo|Matching placebo twice daily
62093267|NCT06533332|EXPERIMENTAL|ERX-315|Active investigational therapy
62093268|NCT04376476|EXPERIMENTAL|Children group E1|Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
62093269|NCT04376476|EXPERIMENTAL|Children group E2|Children with confirmed COVID-19 infection requiring hospitalization will be recruited within participating centers (mostly in emergency and intensive care units). Data will be recorded (clinical examination, biology, immunology, virology measurements) during their hospital stay (day 0, day 7, in case of worsening) and a phone call performed at day 14 (or onsite visit if patient still hospitalized).
62093270|NCT04376476|EXPERIMENTAL|Children group E3|Children with confirmed non-COVID-19 viral infection requiring hospitalization will be recruited within participating centers (mostly in intensive care units). At inclusion, data will be recorded (clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
62093271|NCT04582045||low risk, silver impregnated|low risk, silver impregnated
62093272|NCT04582045||low risk, border bandage|low risk, border bandage
62656882|NCT04143048||Prospective cohort (double-blind recommended)|Peripheral blood of about 150 patients was collected once and the blood volume was 10mL . Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion. Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm. DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients.
62656883|NCT05556252|EXPERIMENTAL|Intervention Group|
62656884|NCT05556252|PLACEBO_COMPARATOR|Control Group|
62093273|NCT04582045||high-risk, silver impregnated|high-risk, silver impregnated
62093274|NCT04582045||high-risk, wound vacuum|high-risk, wound vacuum
61907214|NCT05630391|OTHER|Control|The 26 students who constituted the control group performed the personnel protective equipment (PPE) wearing-removal practice once under the supervision of the researcher at the Fundamentals of Nursing skills laboratory. Frequency of administration the implementation of each group is once. The students applied experiential learning principles through active experience and reflective observation.
62464201|NCT03236753|EXPERIMENTAL|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
61907215|NCT05324904|ACTIVE_COMPARATOR|group 1|this group will be intralesionaly injected with vitamin D3
61907216|NCT05324904|ACTIVE_COMPARATOR|group 2|this group will be intralesionally injected with acyclovir
61907217|NCT06085976|EXPERIMENTAL|Treatment arm (octreotide)|This patient will receive the treatment: Octreotide charge 100 mcgr + continuous infusion during the surgery 25 mcgr/h
61907218|NCT06085976|EXPERIMENTAL|Placebo arm (saline solution)|This patient will receive physiologic saline solution at the same infusion
62656885|NCT06308783|EXPERIMENTAL|Diaphragmatic Breathing|Diaphragmatic breathing, also known as deep breathing, is based on breathing slowly and widely, expanding the abdomen and then the ribs on inspiration and emptying as much air as possible on exhalation.
61907219|NCT04220879||Malignant Glaucoma|To determine the biometric measurements.
61907220|NCT04220879||Fellow Eyes|To determine the biometric measurements.
61907221|NCT04220879||Matched Eyes|To determine the biometric measurements.
61907222|NCT03353740|EXPERIMENTAL|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
61907223|NCT06084975||Kimura technique (KT)|Spleen preservation is accomplished by sparing the splenic vessels.
61907224|NCT06084975||Warshaw technique (WT)|Spleen preservation is accomplished by sacrificing the splenic vessels and maintaining vascularity through the preserved short gastric and left gastroepiploic vessels.
61907225|NCT00588029||1|breast cancer patients
61907226|NCT00588029||2|control subjects without breast cancer
61907227|NCT03629275|EXPERIMENTAL|CTX0E03 Drug Product and delivery device|20 million neural stem cells
61907228|NCT03629275|SHAM_COMPARATOR|Placebo|Sham Surgery
61907229|NCT02051933|ACTIVE_COMPARATOR|Botox|"Botox: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
61907230|NCT02051933|PLACEBO_COMPARATOR|Placebo|"Placebo: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
62093275|NCT05878353|EXPERIMENTAL|Subgingival instrumentation plus local doxycycline|Gentle debridement plus local doxycycline administered 2 weeks prior to periodontal regeneration.
62656886|NCT06308783|EXPERIMENTAL|Global Postural Reeducation|Global Postural Re-education (GPR) is a technique described by Philippe Souchard that is based on the active and sustained stretching of muscle chains by performing specific postures. Breathing plays a fundamental role in the development of exercise, influencing the structures of the body and its functioning.
61907231|NCT05271500|ACTIVE_COMPARATOR|group(1)|40 post covid 19 patients will receive laser acupuncture
61907232|NCT05271500|PLACEBO_COMPARATOR|group(2)|40 post covid patients will receive placebo laser acupuncture in which laser will be off
61907233|NCT03772002|EXPERIMENTAL|HCV screening|
61907234|NCT02171910|ACTIVE_COMPARATOR|Doxapram|Propofol sedation with a doxapram 1mg/kg i.v. bolus at induction and an i.v. infusion 1mg/kg/h) during the procedure
61907235|NCT02171910|PLACEBO_COMPARATOR|Placebo|Propofol sedation with a placebo i.v. bolus at induction and a placebo i.v. infusion during the procedure
62093276|NCT05878353|ACTIVE_COMPARATOR|Subgingival instrumentation alone|Gentle debridement alone performed 2 weeks prior to periodontal regeneration.
62093277|NCT01697761|EXPERIMENTAL|Treatment Group|treat by moxibustion and acupuncture
62093278|NCT01697761|EXPERIMENTAL|Control Group|treat by Sham acupuncture and moxibustion
62093279|NCT04242394||Chronic gallbladder diseases|Routine ERCP participants with chronic gallbladder diseases
62464202|NCT03236753|SHAM_COMPARATOR|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
62291030|NCT05360589||Shoulder non-specific pain|68 adult gender-balanced subjects will be enrolled, reporting unilateral, atraumatic, and non-specific shoulder pain68 healthy subjects who regularly perform sports activities (at least one weekly session).
62291031|NCT05360589||Controls|68 healthy subjects who regularly perform sports activities (at least one time/week) without shoulder pain will be recruited.
62291032|NCT06316284||Chronic kidney disease group|Patients with stage 3-5 CKD (eGFR CKD-EPI \<60 mL/min/1.73 m2)
62093280|NCT04242394||Without Chronic gallbladder disease|Routine ERCP participants without chronic gallbladder diseases
62093281|NCT01686932|EXPERIMENTAL|Vildagliptin followed by Sitagliptin|Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
62093282|NCT01686932|EXPERIMENTAL|Sitagliptin followed by Vildagliptin|Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
62291033|NCT06316284||Healthy controls|Healthy normotensive patients (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \<140/90 mmHg)
62291034|NCT06316284||Hypertensive Group|Hypertensive patients without CKD (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \>140/90 mmHg)
62656887|NCT06308783|NO_INTERVENTION|Control Group|No treatment
62093283|NCT00943423|ACTIVE_COMPARATOR|Arm I|Within 6 weeks after completion of course 3 of chemotherapy, patients undergo involved field radiotherapy to disease areas.
62093284|NCT00943423|EXPERIMENTAL|Arm II|Patients receive no further treatment.
62093285|NCT06321159|EXPERIMENTAL|Intervention Group|mobile application
62093286|NCT06321159|NO_INTERVENTION|Control Group|Control Group
62093287|NCT05099666|EXPERIMENTAL|Lurbinectedin + Doxorubicin Phase I|"The phase 1b trial will follow a standard 3+3 design. Upon determination of the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lurbinectedin plus doxorubicin. A treatment cycle will be defined as 21 consecutive days. Treatment will be administered on an outpatient basis~* Lurbinectedin~* Doxorubicin"
62291035|NCT04492566|EXPERIMENTAL|AID Evaluation|"After completing a 1-2 week CGM run-in period, subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
62291036|NCT02480530|NO_INTERVENTION|Control|Patients will be given educational material on the importance of adherence to statin medications. The GlowCaps device will be set to only record adherence.
62737452|NCT03060993|ACTIVE_COMPARATOR|Cannabis|35 mg of cannabis (tetrahydrocannabinol/cannabidiol; 18.0/LT1.0 %) in vaporized form. THC/CBD will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
62737453|NCT04644146||SEVERE|Patients affected by SARS-CoV2 infection with severe lung dysfunction needing oxygen complementation and critical care supports - criteria 18-70yr old and without any comorbidities
62093288|NCT05099666|EXPERIMENTAL|Lurbinectedin + Doxorubicin at RP2D|"The randomized two arm phase 2 trial will begin following the determination of the RP2D for lurbinectedin and doxorubicin.~* Participants will be randomized 1:1 to enroll to either Arm 1 or Arm 2~* Participants enrolled to Arm 1 will receive Lurbinectedin with Doxorubicin at the RP2D defined during the phase 1b portion of the trial."
62464203|NCT02726425|EXPERIMENTAL|Second Life Participants|Half of participants will receive the Diabetes Self Management Medical Group Visits intervention while meeting in the virtual world (Second Life platform)
62093289|NCT05099666|ACTIVE_COMPARATOR|Doxorubicin Monotherapy|"The randomized two arm phase 2 trial will begin following the determination of the RP2D for lurbinectedin and doxorubicin.~* Participants will be randomized 1:1 to enroll to either Arm 1 or Arm 2~* Participants enrolled to Arm 2 will receive Doxorubicin at the standard dose of 75 mg/m2"
62093290|NCT03088540|ACTIVE_COMPARATOR|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
62093291|NCT03088540|EXPERIMENTAL|cemiplimab|cemiplimab regimen as monotherapy as per study protocol
62093292|NCT06090435|EXPERIMENTAL|Therapeutic exercise plus motor imagery|
62093293|NCT06090435|EXPERIMENTAL|Therapeutic exercise plus action observation|
62093294|NCT06090435|ACTIVE_COMPARATOR|Therapeutic exercise|
62464204|NCT02726425|ACTIVE_COMPARATOR|Face-to-Face Participants|The other half of the participants will receive the Diabetes Self Management Medical Group Visitsintervention while meeting face-to-face in person at Boston Medical Center.
62737454|NCT04644146||CONTROL|Patients affected by SARS-CoV2, as shown by PCR and/or antigen testing diagnosis and without any or minor clinical expression
62093295|NCT03356483|EXPERIMENTAL|Psilocybin|Psilocybin (0.25mg/kg)
62093296|NCT03356483|PLACEBO_COMPARATOR|Niacin|Niacin (250mg)
62093297|NCT03957980|OTHER|Telehealth Intervention First|The participants in this arm of the study received occupational therapy via telehealth in the first 12 weeks of enrollment, then received no other intervention for the duration of the study.
62093298|NCT03957980|OTHER|No Intervention First|The participants in this arm of the study did not receive an intervention in the first 12 weeks of enrollment, but received occupational therapy via telehealth during the second 12 weeks of enrollment.
62093299|NCT02467153|EXPERIMENTAL|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
62093300|NCT02467153|PLACEBO_COMPARATOR|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
62093301|NCT00031447|PLACEBO_COMPARATOR|Placebo|
62093302|NCT00031447|EXPERIMENTAL|Acyclovir|
62464205|NCT06064136|EXPERIMENTAL|Patient with ilio-psoas conflict and having a tenotomy indication|
62464206|NCT03115840||Adults (≥18 years old) with critical illness|
62737455|NCT05117684||Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
62093303|NCT00857844||Group 1|Normal GFR (\>90ml/min/1.73m2). Stage I CKD
62093304|NCT00857844||Group 2|GFR between 30-59ml/min/1.73m2. Stage III CKD
62093305|NCT00857844||Group 3|GFR between 15-29ml/min/1.72m2. Stage IV CKD
62093306|NCT03067467||Brain Tumor Patients|Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.
62093307|NCT03128203|EXPERIMENTAL|Oxytocin|
62093308|NCT03128203|PLACEBO_COMPARATOR|Placebo|
62093309|NCT03480971|ACTIVE_COMPARATOR|Active 1000 mg Tempol Solution|Patients will take 1000 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
62093310|NCT03480971|PLACEBO_COMPARATOR|Placebo Solution|Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)
62093311|NCT04606888|EXPERIMENTAL|Transcutaneous electrical acupoint stimulation group|Transcutaneous electrical acupoint stimulation group patients received Transcutaneous electrical acupoint stimulation (Neiguan \[PC6\], Yintang \[GV 29\], Zusanli \[ST36\]) for 30 min before the induction of anaesthesia until the end of the surgery and the night before operation, the first, second and third night after operation 30 min once a day with an altered frequency 2/100 Hz, disperse-dense waves, adjusted electricity intensity which was less than 10 mA.
62093312|NCT04606888|NO_INTERVENTION|Control group|In Control group, except the electronic stimulation was not applied, the treatment was the same as the Transcutaneous electrical acupoint stimulation group.
62093313|NCT06696950|EXPERIMENTAL|Group A|Group A received Multimodal gait training with Rhythmic auditory stimulation
62093314|NCT06696950|EXPERIMENTAL|Group B|Group B Multimodal Gait training without rhythmic auditory stimulation
62093315|NCT05233085|EXPERIMENTAL|Cohort 1: AZD4041 Dose Level 1|Participants will receive oral solution of AZD4041 dose level 1 once daily (QD) directly into the mouth using a syringe from Days 1 to 14.
62093316|NCT05233085|EXPERIMENTAL|Cohort 2: AZD4041 Dose Level 2|Participants will receive oral solution of AZD4041 dose level 2 QD directly into the mouth using a syringe from Days 1 to 14.
62093317|NCT05233085|EXPERIMENTAL|Cohort 3: AZD4041 Dose Level 3|Participants will receive oral solution of AZD4041 dose level 3 QD directly into the mouth using a syringe from Days 1 to 14.
62093318|NCT05233085|PLACEBO_COMPARATOR|Cohorts 1-3: Pooled Placebo|Participants will receive oral solution of placebo equivalent to AZD4041 volume QD directly into the mouth using a syringe from Days 1 to 14.
62093319|NCT00839228|EXPERIMENTAL|Perhexiline|perhexiline 100mg o bd for 3 months
62737456|NCT05117684||Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
62291037|NCT02480530|EXPERIMENTAL|Individual Feedback|In addition to educational material on adherence to statin medications, the research coordinator will review set-up of personal reminders for the GlowCaps device which will be set to glow and buzz when the medication is missed. In addition, patients will receive information on the weekly adherence feedback report.
62291038|NCT02480530|EXPERIMENTAL|Feedback Friend|The patient will be given educational material on the importance of adhering to statin medications. The research coordinator will review set-up of alarm features of GlowCaps device. Similar to Arm 2, patients will be given information on interpretation of weekly adherence feedback report. If the patient chooses a family/friend, they will be called and provided information on the interpretation of weekly adherence feedback report. If the patient chooses a reciprocal partner, they will be assigned to another patient who has made a similar choice
62464207|NCT05754632|EXPERIMENTAL|BFR Intervention Group|"In addition to the standard ACL rehabilitation protocol, the experimental group will complete 2 exercises using the Delfi BFR cuff 2x/week for 8 weeks during their treatment session at Connecticut Children's Sports Physical Therapy on the second post-operative visit. Cuff size will be determined by patient thigh circumference Limb occlusion pressure will be determined in supine position and all exercises will be completed at 80% occlusion.~Long Arc Quadriceps (LAQ) progression Shuttle progression Post-op visit 2- 2 weeks Quadriceps Set Standing Straight Leg Raise 2 weeks-4 weeks Available range LAQ Standing terminal knee extension 4 weeks-8 weeks LAQ (0-90°) Single Limb Shuttle/Leg Press"
62464208|NCT05754632|NO_INTERVENTION|No Intervention/Control Group|"In addition to the standard ACL rehabilitation protocol, the control group will complete the same exercises as the experimental group starting on the second post-operative visit.~Long Arc Quadriceps (LAQ) progression Shuttle progression Post-op visit 2- 2 weeks Quadriceps Set Standing Straight Leg Raise 2 weeks-4 weeks Available range LAQ Standing terminal knee extension 4 weeks-8 weeks LAQ (0-90°) Single Limb Shuttle/Leg Press"
62093320|NCT00839228|PLACEBO_COMPARATOR|Placebo|Placebo one tablet bd for 3 months
62093321|NCT02745769|EXPERIMENTAL|Ramucirumab + Merestinib|Ramucirumab intravenously (IV) on day 1 and day 15 in combination with merestinib orally once a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
62093322|NCT02745769|EXPERIMENTAL|Ramucirumab + Abemaciclib|"Ramucirumab IV on day 1 and day 15 in combination with abemaciclib orally twice a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.~On June 21st 2017 the Ramucirumab + Abemaciclib arm was cancelled with no participants enrolled."
62656888|NCT01401166|EXPERIMENTAL|Cohort 1: SC (SID) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
62093323|NCT04462913||Healthy control|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
62093324|NCT04462913||Patients with sports injuries|According to the previous clinical diagnosis, patients who has suffered the sports injuries(including hip, knee, and ankle joint diseases).
62093325|NCT04462913||Patients with degenerative osteoarthritis|According to the previous clinical diagnosis, patients who has suffered the degenerative osteoarthritis.
62093326|NCT04668781|ACTIVE_COMPARATOR|Epidural analgesia|
62093327|NCT04668781|EXPERIMENTAL|Wound catheter analgesia|
62093328|NCT03688295|OTHER|experimental group|no antibiotherapy post surgery for complicated acute appendicitis (CAA)
62093329|NCT03688295|ACTIVE_COMPARATOR|control group|antibiotherapy post surgery for complicated acute appendicitis (CAA)
62291039|NCT00430755|OTHER|Inpatients of hospital|"All patients who were admitted to the departments of nephrology or cardiology in a tertiary hospital in Germany.~The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
62093330|NCT05712811|ACTIVE_COMPARATOR|Group A cryotherapy|Cryotherapy Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
62093331|NCT05712811|ACTIVE_COMPARATOR|Group B Topical TCA 90%|Topical TCA 90 % Warts in Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline
62093332|NCT03007342|EXPERIMENTAL|Experimental group|Oral tablet 1000 mg of Amoxicillin/ clavulanic acid combination every 12 hours for five days.
62093333|NCT03007342|PLACEBO_COMPARATOR|control group|Oral tablet placebo every 12 hours for five days.
62093334|NCT05406986|EXPERIMENTAL|the group to which the care bundle will be applied|"Patients with a score of 13 or higher on the Braden QD medical instrument risk assessment scale.~Patients with attached nasogastric tube, intubation tube and saturation probe."
62093335|NCT05406986|NO_INTERVENTION|group not to be interfered with|Patients with attached nasogastric tube, intubation tube and saturation probe.
62656889|NCT01401166|EXPERIMENTAL|Cohort 1: IV then SC (SID) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
62291040|NCT01639430||Geriatric patients ED|Consecutive patients \>= 75 years in the emergency department.
62291041|NCT05491759|EXPERIMENTAL|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle The dose will be consumed orally with 250 mL water.
62291042|NCT05491759|EXPERIMENTAL|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle The dose will be consumed orally with 250 mL water.
62656890|NCT01401166|EXPERIMENTAL|Cohort 2: SC (Vial) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
62656891|NCT01401166|EXPERIMENTAL|Cohort 2: IV then SC (Vial) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
62093336|NCT06396390|EXPERIMENTAL|Progestin Primed Ovarian Stimulation (PPOS)|In this patient group, progestin based protocol is going to be the main course of treatment.
62093337|NCT06396390|ACTIVE_COMPARATOR|GnRH Antagonist Stimulation|In this patient group, GnRH Antagonist treatment protocol is going to be the main course of treatment.
62291043|NCT05491759|EXPERIMENTAL|Product 3 - Standard Fish Oil Triglyceride|"1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).~The dose will be consumed orally with 250 mL water."
62291044|NCT05444712|ACTIVE_COMPARATOR|Chemotherapy|"The chemotherapy is one of the following regimen administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices and European Medical Agency (EMA) approval :~* Cyclophosphamide, doxorubicin, Vincristine and prednisone: (CHOP)~* Cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone: (CHOEP)~* Brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone: (BV-CHP) for ALCL lymphoma only (based on EMA approval)"
62291045|NCT05444712|ACTIVE_COMPARATOR|Chemotherapy + ASCT|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices:~Patients with ASCT strategy in Complete Response after 6 cycles will receive a High Dose Therapy (HDT) composed of BCNU, etoposide, cytarabine and melphalan (BEAM) as conditioning regimen before transplantation. That consolidation phase will lasts between 2 to 3 months"
62291046|NCT01009528|EXPERIMENTAL|Intervention|Admission to electronic feedback system
61907236|NCT01788813|EXPERIMENTAL|GSK2245035 Arm|Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).
62093338|NCT00516581||no HAART|Patients that no received HAART
62093339|NCT00516581||with HAART|Patients that received HAART
62093340|NCT02439255|EXPERIMENTAL|Arm I Black raspberry(BRB) nectar|Participants receive BRB nectar PO QD for 12 weeks.
61907237|NCT01788813|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)
62093341|NCT02439255|PLACEBO_COMPARATOR|Arm II (placebo nectar)|Participants receive placebo nectar PO QD for 12 weeks.
62656892|NCT06022575||Telehealth Integrated Care Group|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
62656893|NCT06022575||Conventional Group|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
61907238|NCT00710125|EXPERIMENTAL|GPX-150 for Injection|GPX-150 is administered IV on Day 1, followed by a 20 day rest period, every 3 weeks.
62093342|NCT01540435|NO_INTERVENTION|Postoperative Arm (Arm A)|"FOLFOX:~Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery."
62291047|NCT01009528|NO_INTERVENTION|control|Control group. No special attention
62291048|NCT00083161|EXPERIMENTAL|Oral cyclophosphamide plus standard cisplatin with etoposide|"1. Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3~2. Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles~3. Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle"
62291049|NCT00631631||Mifamurtide (L-MTP-PE)|Mifamurtide (L-MTP-PE), intravenous, at a dose of 2 mg/m\^2 twice weekly (at least 3 days apart) for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
62464209|NCT06048419|EXPERIMENTAL|Go Move Home Program|Goal driven home program
62656894|NCT03443297|EXPERIMENTAL|Early Feeding group|Active ingredient: maternal expressed breast milk Time of initiation of first feeding: 24 to 48 hours of age. Doses: Initially 4 hourly feeding will be started with 0.5 ml and 1 ml expressed breast milk in babies with birth weight \<1200 grams and \>1200 grams respectively. On the following day 3 hourly, thereafter 2 hourly feeding will be provided in both groups. Gradually amount of feeding will be increased after reaching 2 hourly feeding at the rate of 10 ml/kg/day for initial 10 days then 20ml/kg/day in 2 aliquots till full feeding(150ml/kg/day).For babies with birth weight \<1200 gram, rate of feeding advancement 10 ml/kg/day till full feeds. Time of starting first feeding and time to reach full feeding, both will be documented in a questionnaire for each patient.
62656895|NCT03443297|NO_INTERVENTION|Late Feeding group|Feeding with maternal breast milk will be given in conventional way
61907239|NCT02423967|ACTIVE_COMPARATOR|Transplant uses fresh familial stool|Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
62291050|NCT06329479|EXPERIMENTAL|Multi-modal intervention|Single arm study receiving a multi-modal intervention
62464210|NCT06091007|ACTIVE_COMPARATOR|200 mg Magnesium|Participant will take 200 mg of magnesium citrate daily for 4 weeks
62464211|NCT06091007|ACTIVE_COMPARATOR|400 mg Magnesium|Participant will take 400 mg of magnesium citrate daily for 4 weeks
62464212|NCT03447717|EXPERIMENTAL|ActiGait|Patients who get the ActiGait implant
62656896|NCT01138241||1|ARV experience (TDF based HAART)
61907240|NCT02423967|EXPERIMENTAL|Transplant uses frozen anonymous stool|Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
61907241|NCT00864916|EXPERIMENTAL|1|Participants will receive pentoxifylline and combination antiretroviral therapy (cART).
61907242|NCT00864916|ACTIVE_COMPARATOR|2|Participants will receive placebo and cART.
62464213|NCT01359566|ACTIVE_COMPARATOR|Arbaclofen placarbil 15 mg BID|Arbaclofen placarbil (XP19986 SR4) 15 mg every morning and every evening
62464214|NCT01359566|ACTIVE_COMPARATOR|Arbaclofen placarbil 30 mg BID|Arbaclofen placarbil (XP19986 SR4) 30 mg every morning and every evening
62464215|NCT01359566|ACTIVE_COMPARATOR|Arbaclofen placarbil 45 mg BID|Arbaclofen placarbil (XP19986 SR4) 45 mg every morning and every evening
62464216|NCT01359566|PLACEBO_COMPARATOR|Placebo|Placebo every morning and every evening
62464217|NCT03951532||children with hyperthyroidism|children and adolescents (6 months -17 years included) whose data are present in the SNIIRAM database (DCIR data) and beneficiaries of the general health insurance scheme during the study period (01/01/2006-31/12/2017)
62464218|NCT01568476|ACTIVE_COMPARATOR|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
62093343|NCT01540435|EXPERIMENTAL|Perioperative Arm (Arm B)|"Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.~FOLFOXIRI + bevacizumab:~bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively."
62093344|NCT03934905|ACTIVE_COMPARATOR|sulforaphane|Processed SFN-rich extract will be purchased in form of caplets from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts from Nutramax Labs will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Size of the caplet will be about 2 cm in length. Dosing will be based on weight and will be dosed daily for 12 weeks.
62093345|NCT03934905|PLACEBO_COMPARATOR|Placebo|Placebo caplets will comprise of microcrystalline cellulose from Nutramax Labs and will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Placebo pills will be identical in appearance to the sulforaphane pills and will be dosed in a similar manner (identical number of pills based on weight, daily dosing and for 12 weeks)
62093346|NCT06203262|EXPERIMENTAL|Ventricular Tachycardia (VCAS-I)|Patients with ventricular tachycardia meeting class II-a/b indications in European guideline for catheter ablation, with a clinical VT event detected by an implanted ICD
62093347|NCT06203262|EXPERIMENTAL|Premature Ventricular Contractions (VCAS-II)|For VCAS-II group, patients with symptomatic frequent unifocal premature ventricular complexes (PVCs) meeting class II-a/b indications based on European guidelines for catheter ablation. For VCAS-II, documentation of frequent PVCs by 24 hours Holter with \>15% PVC burden for asymptomatic patients and \>5% PVC burden for symptomatic patients within the last 60 days.
62656897|NCT01138241||2|ARV experience (non TDF based ART)
62093348|NCT06665113|EXPERIMENTAL|Standard anti-Parkinson's disease medication treatment + taVNS real stimulation|"For the real stimulation group, two modified point electrodes will deliver stimulation near the auricular branch of the vagus nerve in the left concha cymba.~Each Parkinson's disease patient will receive one 30-minute stimulation session per day(at least 5 days per week) for 270 consecutive days."
62093349|NCT06665113|SHAM_COMPARATOR|Standard anti-Parkinson's disease medication treatment + taVNS sham stimulation|For the sham stimulation group, two modified point electrodes will deliver stimulation to the earlobes.Each Parkinson's disease patient will receive one 30-minute stimulation session per day(at least 5 days per week) for 270 consecutive days.
62093350|NCT04161222|EXPERIMENTAL|Experimental group|The control group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
62093351|NCT04161222|EXPERIMENTAL|Control group|The control group will perform a typical warm-up of competitive football.
62093352|NCT02068885|EXPERIMENTAL|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
62093353|NCT02068885|EXPERIMENTAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
62093354|NCT02068885|ACTIVE_COMPARATOR|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
62656898|NCT01138241||3|ARV Naive
62656899|NCT00894192|ACTIVE_COMPARATOR|Wavefront guided lenses|
62656900|NCT00894192|PLACEBO_COMPARATOR|Conventional lenses|
62656901|NCT00262925|EXPERIMENTAL|Treatment (chemotherapy, enzyme inhibitor therapy)|"INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone."
62656902|NCT06339840|EXPERIMENTAL|Low-carbohydrate diet group|During the 12-week intervention, the first 8 weeks constitute the weight loss phase, where a low-carbohydrate diet, combined with meal replacement and daily dietary intake, is employed. Lifestyle guidance is provided on a one-to-one basis, accompanied by monitoring through a mobile platform. The subsequent 4 weeks involve the transition phase, during which personalized dietary and lifestyle adjustments are made
62656903|NCT06339840|OTHER|Health Education Group|12 weeks of one-on-one health promotion and mobile platform monitoring
61907243|NCT01054547|PLACEBO_COMPARATOR|Liposomal ropivacaine, topical|The topical anesthetics were applied at the region of right and left maxillary lateral incisors at the buccal mucosa.
61907244|NCT01054547|PLACEBO_COMPARATOR|Liposomal ropivacaine, palatal mucosa|Topical formulations were applied at the palatal mucosa at the right canine region and efficacy of topical formulations was accessed through insertion of a 30 gauge needle and injection of anesthetic solution.
61907245|NCT01757340|NO_INTERVENTION|Weight maintenance|Weight maintenance with normal protein and leucine intake
61907246|NCT01757340|ACTIVE_COMPARATOR|Weight loss with normal protein intake|
61907247|NCT01757340|EXPERIMENTAL|Weight loss with leucine supplementation|
61907248|NCT01725659|EXPERIMENTAL|Motor Learning|subjects are provided with intensive motor learning training of the upper limb
61907249|NCT01725659|EXPERIMENTAL|Robotics and Motor Learning|subject are provided with intensive motor learning and robotics training of the upper limb
61907250|NCT01725659|EXPERIMENTAL|Motor learning and FES|subjects are provided with intensive motor learning and surface FES (Functional Electrical Stimulation) of the upper limb
62093355|NCT05588882|ACTIVE_COMPARATOR|Wavefront-guided LASIK|Wavefront-guided LASIK for myopia and myopic astigmatism
62093356|NCT05588882|ACTIVE_COMPARATOR|Topography-guided LASIK|Topography-guided LASIK for myopia and myopic astigmatism
62093357|NCT04103047||SAD group|Adult surgical patients who are due to undergo general anaesthesia and requiring SAD insertion will be identified on the day of surgery.
62093358|NCT06615193|EXPERIMENTAL|HDM2005|"In dose escalation phase, participants will be administered escalating doses of HDM2005 at 0.3\~2.75mg/kg IV on Day 1 of repeated 21-day cycles.~In dose expansion phase, participants will be administered to recommended dose for expansion (RDE) of HDM2005 on Day 1 of repeated 21-day cycles ."
62093359|NCT00593164|EXPERIMENTAL|1|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous magnesium sulfate (30 mg per kg IV over 15 min).
62093360|NCT00593164|ACTIVE_COMPARATOR|2|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous normal saline.
62656904|NCT01691664|ACTIVE_COMPARATOR|Only radiation therapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
62737457|NCT04539613||group1|Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added
61907251|NCT03908489|EXPERIMENTAL|intervention we want to test vital pulpotomy using garlic oil|interventional group as garlic oil pulpotomy dressed in zinc oxide powder
61907252|NCT03908489|ACTIVE_COMPARATOR|control or comparator as mta vital pulpotomy in primary molars|mta vital pulpotomy in primary molars
62093361|NCT02174133||patients after HTX|
62093362|NCT02174133||patients after LVAD implantation|
61907253|NCT06081322|EXPERIMENTAL|Phase Ia: Dose escalation|To determine the therapeutic dose of 177Lu-EB-FAPI using a 3 + 3 dose-escalation mode
62093363|NCT02174133||patients with coronary heart disease|
62093364|NCT02174133||healthy volunteers|
62093365|NCT06400654||unresectable locally advanced neuroendocrine carcinoma|patients with extra-pulmonary, advanced neuroendocrine carcinomas
62464219|NCT01568476|ACTIVE_COMPARATOR|Interneural|sciatic nerve blockade at the site of bifurcation
62093366|NCT06400654||mixed Adeno-neuroendocrine carcinomas|composed at least by 30% of a neuroendocrine (NE) and a non-neuroendocrine (non-NE) component based on the 2019 World Health Organization (WHO) classification
62093367|NCT02719951|EXPERIMENTAL|autistic patients|\[18F\]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
62656905|NCT01691664|EXPERIMENTAL|Radiation therapy plus DC-CIK cellular therapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~DC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
62656906|NCT04943393||Individuals with PKU|Adults with early-treated PKU
62656907|NCT04943393||Individuals without PKU|Adults without PKU who are otherwise healthy
62656908|NCT02479282|OTHER|group A|natural cesarean section
62093368|NCT02719951|EXPERIMENTAL|FXS patients|\[18F\]FPEB PET imaging MRI Biological samples
62093369|NCT02719951|EXPERIMENTAL|Healthy subjects|\[18F\]FPEB PET imaging MRI Biological samples
62093370|NCT03016897||Group 1|Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
62291051|NCT02913248|EXPERIMENTAL|Conventional periodontal treatment|35 subjects diagnosed with manifest periodontitis, which will all receive standardized treatment according to protocol. In brief, this treatment includes professional tooth cleaning and thorough instruction in self-performed oral hygiene procedures. Clinical registrations and collection of microbiological samples (subgingival and saliva) will performed at baseline and 2, 6 and 12 weeks after treatment.
62093371|NCT03016897||Group 2|Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
62093372|NCT03016897||Group 3|Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
62093373|NCT06452394|EXPERIMENTAL|NEOadjuvant DOXYcycline|"neoadjuvant chemotherapy (4 cycles epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 q3W followed by 4 cycles weekly paclitaxel (D1, D8, D15) 80 mg/m2)~+ doxycycline (200 mg/day from D5 to D18 of each cycle)"
62291052|NCT04675047||healthy control|healthy control
62291053|NCT00670826|EXPERIMENTAL|1|Use of the Dynatherm Medical vitalHEAT vH2 Temperature Management System to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
62093374|NCT04485780|PLACEBO_COMPARATOR|Botulinum toxin injection during surgery|Patients in this group underwent Botulinum toxin injection during surgery
62093375|NCT04485780|EXPERIMENTAL|Botulinum toxin injection one week before surgery|Patients in this group underwent Botulinum toxin injection at the outpatient clinic one week before surgery
62093376|NCT04715178||Patients with suspected or confirmed pediatric solid tumors|Patients with suspected or confirmed pediatric solid tumors
62464220|NCT04000217|ACTIVE_COMPARATOR|Written Exposure Therapy|Written exposure therapy (Sloan et al., 2012) is a brief evidence-based treatment for PTSD (US Dept. of VA \& DoD, 2017), wherein patients are asked to write about their trauma memories for 30 minutes, with therapist instruction and feedback before and after each writing exercise.
62656909|NCT02479282|OTHER|group B|traditional cesarean section
62656910|NCT02515227|EXPERIMENTAL|6MHP (6 Melanoma helper peptide) vaccine + Pembrolizumab|6MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
62656911|NCT05478109|EXPERIMENTAL|[14C]XZP-3287|Eligible healthy male subjects received a single oral 360 mg (radioactivity of 50µCi) dose of \[14C\]XZP-3287
62656912|NCT01282788|NO_INTERVENTION|Traditional Diet|Infants in communities randomized to the traditional diet arm will not receive food supplements.
62656913|NCT01282788|EXPERIMENTAL|Cereal|All infants in communities randomized to the Cereal Arm will receive caterpillar cereal from 6-18 months of age.
62656914|NCT00587457|EXPERIMENTAL|CAT-8015 5 microgram per kilogram (mcg/kg)|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
61907254|NCT06081322|EXPERIMENTAL|Phase Ib: Dose expansion-pancreatic cancer cohort|In pancreatic cancer cohort, patients will receive the first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no more than 4 cycles.
61907255|NCT06081322|EXPERIMENTAL|Phase Ib: Dose expansion-cholangiocarcinoma cohort|In cholangiocarcinoma cohort, patients will receive the first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no more than 4 cycles.
62291054|NCT00670826|ACTIVE_COMPARATOR|2|Use of the Arizant Healthcare Bair Hugger Temperature Management System \& Bair Hugger Upper Body Blanket to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
62291055|NCT05332860||Immediate Extubation or IE|patients were extubated in the operating room (OR) or in 6 hours after surgery
62291056|NCT05332860||Early Extubation or EE|patients were extubated within 6-48 hours of admission to the ICU
61907256|NCT04772638|EXPERIMENTAL|PLAY intervention|The PLAY intervention with educators, parents and children
61907257|NCT04772638|PLACEBO_COMPARATOR|Wait list control|
61907258|NCT00755209|PLACEBO_COMPARATOR|Transamin|"Drug: tranexamic acid~Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours"
61907259|NCT00313183|EXPERIMENTAL|1|single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects
61907260|NCT04411784||Main group|Patient with Acute Severe Ulcerative Colitis based on Modified Truelove and Witts Severity Index managed during the study period
61907261|NCT04411784||Control Group|Patients with ASUC managed in the unit from 1st Jan to 31st June 2019
61907262|NCT00179491|ACTIVE_COMPARATOR|Group 1|604 patients received intercessory prayer after being informed they may or may not receive prayers (Group 1)
62291057|NCT05332860||Delayed Extubation or DE|patients were extubated sometime after 48 hours or not extubated
62291058|NCT02246972|EXPERIMENTAL|VRET Immediate treatment|Participants will be randomized to receive Virtual Reality Exposure Therapy (VRET) immediately
62291059|NCT02246972|ACTIVE_COMPARATOR|Waitlist|6 weeks standard of care, then Virtual Reality Exposure Therapy (VRET) treatment.
62291060|NCT03913663|ACTIVE_COMPARATOR|study group|20 patient with hemineglect, minimum 6 months post stroke
62737458|NCT04539613||group2|Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)
61907263|NCT00179491|NO_INTERVENTION|2|597 patients did not receive prayer after being informed they may or may not receive prayer (Group 2)
62291061|NCT03913663|ACTIVE_COMPARATOR|control group|20 patient with hemineglect, minimum 6 months post stroke
61907264|NCT00179491|EXPERIMENTAL|Group 3|601 patients received intercessory prayer after being informed they would receive it (Group 3).
61907265|NCT03104660|EXPERIMENTAL|CE certified mitral valve repair systems|CE certified transcatheter mitral valve repair systems
61907266|NCT04938297|EXPERIMENTAL|Primary CNS Lymphoma，age>65|8 cycles of induction ZR2 , followed by Zanubrutinib or Lenalidomide maintenance for CR/PR fit patients through randomization by 1:1 ration
61907267|NCT04938297|EXPERIMENTAL|Recurrent/refractory primary CNS lymphoma|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
62093377|NCT01788020|EXPERIMENTAL|DRC+Bortezomib|"Induction experimental arm (Arm B):~Cycle 1:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5~Cycle 2-6:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
62093378|NCT01788020|ACTIVE_COMPARATOR|DRC|"Induction standard arm (Arm A)~Cycle 1:~Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5;~Cycle 2-6:~Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
62093379|NCT04497311||SARS-CoV-2|Patients with a SARS-CoV-2 polymerase chain reaction positive test upon admission to the emergency department.
62093380|NCT04497311||H1N1 influenza|Patients with an influenza H1N1 polymerase chain reaction positive test upon admission to the emergency department.
61907268|NCT04938297|EXPERIMENTAL|Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
61907269|NCT04375657|EXPERIMENTAL|TRIIM Treatment|
62093381|NCT04172987|EXPERIMENTAL|Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)|Participants received a 28-day packet of a combination oral contraceptive (OC) containing 21 days of tablets that consist of active ingredients (0.035 mg ethinyl estradiol (EE) and 0.25 mg norgestimate (NGM)) self-administered orally once-daily (QD) on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day.
62291062|NCT02747485|EXPERIMENTAL|organic left-sided regurgitant valve|
61907270|NCT04375657|ACTIVE_COMPARATOR|Active Control|
62291063|NCT05855733|EXPERIMENTAL|Radiofrequency|treatment of pilonidal disease according to the Fistura procedure
61907271|NCT03081156|ACTIVE_COMPARATOR|Glycopyrrolate/Formoterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
61907272|NCT03081156|PLACEBO_COMPARATOR|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
62093382|NCT04172987|EXPERIMENTAL|EE/NGM + Tirzepatide (Period 2)|Participants received a 28-day packet of a combination OC containing 21 days of tablets that consist of active ingredients (0.035 mg EE and 0.25 mg NGM) self-administered orally QD on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day and a single dose 5 mg tirzepatide administered subcutaneously (SC).
61907273|NCT05373888||Main|Enterostomy patients, including colostomates, ileostomates or jejunostomates.
62093383|NCT02214381|ACTIVE_COMPARATOR|Mycet/Cyclophosphamid|4 x Myocet 60 mg/m² q3w in combination with 4 x cyclophosphamide 600 mg/m² q3w depending on early response assessment by ultrasound or on toxicity profile.
62093384|NCT02214381|ACTIVE_COMPARATOR|Myocet/Cyclophosphamide/Paclitaxel|2 x Myocet 60 mg/m² q3w in combination with 2 x cyclophosphamide 600 mg/m² q3w followed by 6 x paclitaxel 80 mg/m² q1w depending on early response assessment by ultrasound or on toxicity profile.
62291064|NCT06091722||1|Mild group, the scores of both clinicians were ≤ grade 1
61907274|NCT01627834|EXPERIMENTAL|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
62093385|NCT06464341||Patients with clinical T1-4 N0-3 breast cancer at diagnosis treated with NAC|This cohort study retrospectively analyzed data from 62 centers in 18 countries, mostly members of the Oncoplastic Breast Consortium (OPBC) network. Patients with clinical T1-4 N0-3 breast cancer at diagnosis treated with neoadjuvant chemotherapy between March 2008 and May 2022 were included if they had isolated tumor cells only. ITCs were defined as clusters of tumor cells ≤0.2 mm or clusters of \<200 cells in a single cross-sectional image, determined by sentinel lymph node biopsy, targeted axillary dissection, or the MARI procedure (marking axillary lymph nodes with radioactive iodine seeds). Excluded: patients with inflammatory breast cancer, stage IV disease at presentation, axillary lymph node dissection as a primary procedure, and neoadjuvant endocrine therapy. Also excluded cases with micrometastases or macrometastases in any sentinel lymph nodes at frozen section or final pathology, and those where ITCs were detected by One Step Nucleic Acid Amplification.
61907275|NCT01627834|ACTIVE_COMPARATOR|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
62093386|NCT06692985||Single group|Patient of any age with suspicious skin lesions
61907276|NCT04618510|EXPERIMENTAL|SEED 1-dayPure EDOF soft contact lens|The participant will be requested to wear the daily disposable lens 8-10 hours per day and replaced daily. All participants will be followed for 12 months (followup visit schedule; 3 months, 6 months, 12 months) post-contact lens wear.
61907277|NCT04618510|SHAM_COMPARATOR|Single vision spectacle lens|The participant will be requested to wear the spectacle lens daily. All participants will be followed for 12 months (follow up visit schedule; 3 months, 6 months, 12 months) post spectacle lens wear.
61907278|NCT06022471||Stapes surgery|
61907279|NCT06393556|EXPERIMENTAL|Virtual reality|Care-as-usual + virtual reality intervention during a pre-operative visit
62093387|NCT06518473||Chronic obstructive pulmonary disease patients|Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria
62093388|NCT05873803|EXPERIMENTAL|Experimental: GR1802|GR1802 injection 300mg every two weeks for 16-week treatment
62093389|NCT05873803|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Placebo every two weeks for 16-week treatment
62291065|NCT06091722||2|Moderate group, one doctor scored grade 2, and the other doctor scored 1\~2;
62291066|NCT06091722||3|Moderate group, one doctor scored grade 2, and the other doctor scored 1\~2;
61907280|NCT06393556|NO_INTERVENTION|Control|Care-as-usual during a pre-operative visit
61907281|NCT02091505|EXPERIMENTAL|Intravitreal injection of Ranibizumab|
61907282|NCT04754217||Group 1|VAVGJ
61907283|NCT04754217||Group 2|CAVGJ
61907284|NCT01348477|EXPERIMENTAL|Elliptical domed mesh technique|84 adult patients with primary uncomplicated inguinal hernia, treated with an open preperitoneal elliptical mesh technique
61907285|NCT01348477|ACTIVE_COMPARATOR|Lichtenstein technique|84 adult patients with primary uncomplicated inguinal hernia treated with the Lichtenstein technique (gold standard)
62656915|NCT00587457|EXPERIMENTAL|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
62656916|NCT00587457|EXPERIMENTAL|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
62093390|NCT06696365|EXPERIMENTAL|Active iTBS|The intermittent theta burst (iTBS) will be delivered using the MagVenture MagPro X100 stimulator equipped with a Cool B-70 A/P (combined active \& sham) figure of eight coil. Treatment will be at 100% of MT. Treatment will be approximately 2 ½ minutes long. Each session will be 2-hours in length and consist of four treatments spaced 30 minutes apart. There will be a total of five sessions over the course of five to seven days.
62093391|NCT06696365|SHAM_COMPARATOR|Sham iTBS|The B70 A/P coil is also equipped with an active sham electric stimulation (e-stim) system that delivers a small current pulse synchronous to the TMS pulse, titrated to match the TMS sensations. This pulse is similar in duration and distribution to the current induced by the TMS pulse . This pulse will be delivered to the scalp adjacent to the stimulation site via disposable low-profile webbed EEG electrodes filled with electrolytic gel. Electrodes will be connected to the e-stim system via one of two identical cables allowing the operator to deliver either real or sham electric stimulation. Cables will be labeled to match the corresponding coil side so that each session always includes either active TMS or active e-stim, but never both.
62093392|NCT01144117|EXPERIMENTAL|Erythropoietin|Erythropoietin treated patients contra placebo.
62291067|NCT03509324|OTHER|duration of disease|different duration of disease receive insulin LISPRO
62291068|NCT01495455||Knee osteoarthritis|
62291069|NCT01495455||No knee pain/osteoarthritis|
62093393|NCT06559228|EXPERIMENTAL|ConnectedNest adults|adults undergoing active cancer therapy or in cancer survivorship seen in multi-site oncology practices within 3 MHealth Fairview sites and 3 Minnesota Oncology sites randomized to receive ConnectedNest
62093394|NCT06559228|ACTIVE_COMPARATOR|Standard of care adults|adults undergoing active cancer therapy or in cancer survivorship seen in multi-site oncology practices within 3 MHealth Fairview sites and 3 Minnesota Oncology sites randomized to receive standard of care
62291070|NCT05852639||Insulin|patients on insulin treatment for gestational diabetes
62291071|NCT05852639||Metformin|patients on metformin treatment for gestational diabetes
62291072|NCT01929083|EXPERIMENTAL|Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
62291073|NCT01929083|PLACEBO_COMPARATOR|Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
62291074|NCT00582894|OTHER|A|Preparative regimen of 1)Busulfex 3.2 mg/kg/day for 2 days, infused over 3 hours, on Day-6 and Day-5 2)Fludarabine 30 mg/m2/day for 5 days on Day-6 to D-2 and 3) Alemtuzumab 10 mg/day IV on days - 5 to -1
62656917|NCT00576537|EXPERIMENTAL|Dendritic Cell Immunotherapy|Patients who consent to participate in the study and receive the Dendritic Cell vaccine manufactured from their own tumor cells.
62656918|NCT04861181|EXPERIMENTAL|Pharmacokinetics, Dosage of Niraparib|Patients received 3 cycles of Niraparib (200 mg or 300 mg/day). Each cycle lasts 28 days. Serum niraparib assays will be performed for all patients over 3 courses immediately prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
62656919|NCT00442793|EXPERIMENTAL|1|
62656920|NCT00442793|ACTIVE_COMPARATOR|2|
62656921|NCT04542941|ACTIVE_COMPARATOR|Intervention arm|The participants will receive COVID Convalescent Plasma in addition to the standard of care received by all COVID 19 patients
62656922|NCT04542941|NO_INTERVENTION|Control arm|The participants under this arm will receive the COVID 19 standard of care
62291075|NCT02633449|EXPERIMENTAL|cognitive behavioral therapy + tDCS|Group cognitive behavioral therapy combined with tDCS
62291076|NCT02633449|ACTIVE_COMPARATOR|cognitive behavioral therapy + sham-tDCS|Group cognitive behavioral therapy combined with sham-tDCS
62464221|NCT04000217|ACTIVE_COMPARATOR|Imaginal Exposure Therapy|Imaginal exposure therapy will involve verbal recounting of trauma memories for 30 minutes with therapist instruction and feedback before and after each recounting exercise.
62464222|NCT01077596||New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006|All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.
62656923|NCT03534219|EXPERIMENTAL|Intervention Arm: EarPopper|"All patients in this arm will receive the EarPopper device.~Length of administration: 1 year Dose: Dosing of the EP device will be twice per day, once in the morning and once before bedtime. This is consistent with previous dosing which showed no adverse events and an excellent safety profile. 5, 6~Administration:~1. Hold nosepiece firmly against nostril opening creating a good, tight seal is crucial. Plug the other nostril closed.~2. Push button to start the airflow and swallow while the device is running.~3. Repeat on other nostril. After 5 minutes, repeat steps 1 - 3. This will complete one treatment.~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
62656924|NCT03534219|NO_INTERVENTION|Control|"All patients in this arm will not receive any intervention. EarPopper device will be given to this group at the end of follow-up period (1 year)~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
62656925|NCT05622903|EXPERIMENTAL|Treatment Group|Participants in the treatment group received up to $400 per month.
62656926|NCT05622903|ACTIVE_COMPARATOR|Control Group|Participants in the control group did not receive monthly cash benefits.
62093395|NCT02100722|ACTIVE_COMPARATOR|FFR guided PCI|Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity (or Onyx) drug-eluting stent (DES) as per usual routine. If the FFR is \>0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
62093396|NCT02100722|ACTIVE_COMPARATOR|CABG|CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
62093397|NCT05063916|EXPERIMENTAL|AK104|cadonilimab) can help to control neuroendocrine cervical cancer that is recurrent (has come back after treatment) or metastatic (has spread).
62093398|NCT01036087|EXPERIMENTAL|PNC + FEC|"PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and~FEC = 5-fluorouracil, epirubicin, and cyclophosphamide"
62093399|NCT02486705|ACTIVE_COMPARATOR|PTSD Family Coach Basic|PTSD Coach basic provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD and additional support resources.
62093400|NCT02486705|EXPERIMENTAL|PTSD Family Coach Full|PTSD Family Coach full provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD, additional support resources, tools for coping with caregiving-related stress, and tools for self-monitoring stress symptoms.
62093401|NCT04155424|EXPERIMENTAL|Eculizumab|"All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.~After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks."
62093402|NCT00707863|OTHER|Depressed Subjects Age: 18 - 25 yrs|Subjects receiving Escitalopram (trade name: Lexapro) that are in the age range of 18-25
62093403|NCT00707863|OTHER|Depressed Subjects Age: 16 - 50 yrs|Subjects receiving Escitalopram (trade name: Lexapro) in the age range of 26-50
62093404|NCT01580527|ACTIVE_COMPARATOR|total parenteral nutrition|
62656927|NCT05441904|EXPERIMENTAL|PXL770 500 and 750 mg|Each subject received 1 dose of PXL770 at 500 mg and 1 dose at 750 mg
62093405|NCT01580527|EXPERIMENTAL|Early enteral nutrition|
62291077|NCT02633449|PLACEBO_COMPARATOR|cognitive behavioral therapy|Group cognitive behavioral therapy only
62291078|NCT01511484|EXPERIMENTAL|Information-only|"Selected pages from the British National Health Service (NHS) information booklets \[5 A Day, Just Eat More (fruit \& veg); pages i, ii, 12-15, 20 \& 21\] and \[5 A Day, Just Eat More (fruit \& veg): What's it all about?; pages i-ii)\] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
62291079|NCT01511484|EXPERIMENTAL|Generic-appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
62291080|NCT01511484|EXPERIMENTAL|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
62291081|NCT04531267|ACTIVE_COMPARATOR|Individualized nutrition|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
61907286|NCT03798119|EXPERIMENTAL|Switch to TAF|Subjects who meet the inclusion and exclusion criteria will switch prior NUCs to TAF 25 mg/day for 96 weeks
62093406|NCT05621655|EXPERIMENTAL|Mid dose in toddlers (7-71 months old, 3 doses)|Mid dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
62464223|NCT04459273|EXPERIMENTAL|Basic science (68GA-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable).
62464224|NCT01346527||Type 2 diabetes|"1. Women will be diagnosed with type 2 DM (pre-gestational, White classification B or C class). Since the majority of women with B or C class DM are on insulin therapy in our clinic, we will recruit only women on insulin therapy (i.e. no oral diabetes medications).~2. HbA1C ≤ 8 for greater than 3 months32, 33.~3. All women will have confirmed singleton pregnancies.~4. Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~5. Pre-pregnancy BMI is anticipated to be \>30 (i.e. obese) from the data regarding the patient population of our clinic. Women with pre-pregnancy BMI between 23-40 will be included."
62464225|NCT01346527||Healthy, obese pregnant controls|"1. No diagnosis of type 1 or 2 diabetes or previous gestational DM.~2. Women with pre-pregnancy BMI between 30-45: control participants will be BMI matched to women with DM.~3. A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.~4. Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~5. Patients will have a singleton pregnancy with no fetal abnormalities (as determined by routine standard of care ultrasonography)."
62464226|NCT01346527||Healthy, Lean Controls|No diagnosis of type 1 or 2 diabetes or previous gestational DM. 2) Women with pre-pregnancy BMI between 21-25.9 3) A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
62464227|NCT04191993|EXPERIMENTAL|Direct Superior Approach (DSA)|Direct superior incision during surgery
62291082|NCT04531267|NO_INTERVENTION|Control group|Participants do not receive any supplements, they stay with the original medication plan.
62291083|NCT00358657|EXPERIMENTAL|Treatment (chemo, total-body irradiation, transplant)|See Detailed Description
62291084|NCT01486862|EXPERIMENTAL|BIAsp 30|
62464228|NCT04191993|ACTIVE_COMPARATOR|Posterior Approach (PA)|Posterior approach incision during surgery
62464229|NCT01536405|EXPERIMENTAL|MMRV (AMP)|Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
62464230|NCT01536405|ACTIVE_COMPARATOR|MMRV (2006 process)|Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process
62464231|NCT01958463|EXPERIMENTAL|Fecal microbiota transplantation|Fecal microbiota transplantation during colonoscopy.
62464232|NCT02100228|EXPERIMENTAL|Apixaban|
62464233|NCT02100228|ACTIVE_COMPARATOR|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
62464234|NCT03038048|EXPERIMENTAL|33 g needle - right eye|33 g needle for intravitreal injection of Lucentis or Eylea for right eye and 30 g needle for left eye
61907287|NCT01097031||Continuous Infusion|
61907288|NCT01097031||Intermittent Infusion|
61907289|NCT01097031||Infusion Continuous|
61907290|NCT03337919|EXPERIMENTAL|Nivolumab|Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
61907291|NCT05028361|OTHER|Simultaneous Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and IIV4 at Visit 1, saline placebo at Visit 2, and mRNA COVID-19 vaccine at Visit 3 (only for participants receiving their primary series of mRNA COVID-19 vaccine.)
61907292|NCT05028361|OTHER|Sequential Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and saline placebo at Visit 1, IIV4 at Visit 2, and mRNA COVID-19 vaccine at Visit 3 (only for participants receiving their primary series of mRNA COVID-19 vaccine.)
62093407|NCT05621655|EXPERIMENTAL|Mid dose in toddlers (7-71 months old, 2 doses)|Mid dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
62093408|NCT05621655|EXPERIMENTAL|High dose in toddlers (7-71 months old, 3 doses)|High dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
62093409|NCT05621655|EXPERIMENTAL|High dose in toddlers (7-71 months old, 2 doses)|High dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
62291085|NCT05726214|OTHER|Control Group|The control group received general recommendations for maintaining physically active and reducing sedentary behaviors. This was done verbally and through written material.
62464235|NCT03038048|EXPERIMENTAL|33 g needle - left eye|33 g needle for intravitreal injection of Lucentis or Eylea for left eye and 30 g needle for right eye
61907293|NCT01697410|EXPERIMENTAL|terlipressin|
61907294|NCT01697410|ACTIVE_COMPARATOR|norepinephrine|
61907295|NCT02879331|ACTIVE_COMPARATOR|10 coils in upper lobes|10 coils in upper lobes
61907296|NCT02879331|EXPERIMENTAL|15 coils in upper and lower lobes|15 coils in upper and lower lobes
61907297|NCT00839176|PLACEBO_COMPARATOR|Placebo|Placebo (w/o API)
61907298|NCT00839176|EXPERIMENTAL|2|5mg dose of RX-10100
61907299|NCT00839176|EXPERIMENTAL|3|10mg dose of RX-10100
61907300|NCT00839176|EXPERIMENTAL|4|15 mg dose of RX-10100
61907301|NCT02642744|OTHER|Attending nurse model|The attending nurse model of in-hospital care delivery aims to improve patient understanding, shared decision making, medication adherence, and reduce early readmissions after discharge to improve quality of life. On the inpatient stroke unit, the attending nurse will take ownership of essential aspects of an individual stroke patient's care, education, and transition out of the hospital. To further contribute to the patient's plan of care, the attending nurse will be present on daily teaching rounds.
61907302|NCT02642744|NO_INTERVENTION|Conventional inpatient nursing care|Standard of care nursing care patients receive while inpatient
62093410|NCT05621655|PLACEBO_COMPARATOR|Placebo in toddlers (7-71 months old, 3 doses)|Placebo in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
62093411|NCT05621655|PLACEBO_COMPARATOR|Placebo in toddlers (7-71 months old, 2 doses)|Placebo in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
62093412|NCT05621655|EXPERIMENTAL|Mid dose in infants (6-12 weeks of age, 3 doses at 4-week intervals)|Mid dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
62093413|NCT05621655|EXPERIMENTAL|Mid dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)|Mid dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
62093414|NCT05621655|EXPERIMENTAL|High dose in infants (6-12 weeks of age, 3 doses at 4-week intervals)|High dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
62093415|NCT05621655|EXPERIMENTAL|High dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)|High dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
62291086|NCT05726214|EXPERIMENTAL|Intervention Group|"The intervention group received the same recommendations as the control group. In addition, they participated in a multicomponent physical exercise program consisting of a) 1 face-to-face weekly multicomponent session (Rodriguez-Larrad et al. BMC Geriatrics (2017)), and b) 2 autonomous sessions at home following the Vivifrail program. Our targeted duration of 24 weeks was missed due to the lack of predisposition expressed by some participants, once the recruitment was completed, to continue during summer vacation. Therefore, the intervention was restructured to be carried out in 16 weeks.~Face-to-face supervised sessions lasted 1 hour and included strength, balance, and flexibility exercises (50%-75% of the 1 repetition maximum for strength exercises). The volume, intensity and difficulty of the exercises were individualized based on the initial performance of each participant, and progressed as the participants' physical capacity evolved."
62291087|NCT01965249|ACTIVE_COMPARATOR|Long stitch group|Long stitch suture technique Stitch interval = 10 mm; Lateral = 10 mm
62291088|NCT01965249|EXPERIMENTAL|Short stitch group|Short stitch technique for AWC stitch interval = 5 mm; Lateral 5 - 8 mm
62291089|NCT00800215|EXPERIMENTAL|1|
62291090|NCT00800215|PLACEBO_COMPARATOR|2|
62464236|NCT01866319|EXPERIMENTAL|Ipilimumab|Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).
62464237|NCT01866319|EXPERIMENTAL|Pembrolizumab Q2W|Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.
62093416|NCT05621655|PLACEBO_COMPARATOR|Placebo in infants (6-12 weeks of age, 3 doses at 4-week intervals)|Placebo in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
62093417|NCT05621655|PLACEBO_COMPARATOR|Placebo in infants (6-12 weeks of age, 3 doses at 8-week intervals)|Placebo in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
62093418|NCT02350361|EXPERIMENTAL|Endostar Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14
62093419|NCT02350361|ACTIVE_COMPARATOR|Standard Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo
62291091|NCT00800215|EXPERIMENTAL|3|
62291092|NCT00800215|PLACEBO_COMPARATOR|4|
62291093|NCT00217633|EXPERIMENTAL|Treatment (pelvic exenteration)|Patients undergo pelvic exenteration within 14 days after study entry.
62291094|NCT04702958||Torsemide|Patients enrolled in the TRANSFORM-HF study randomized to Torsemide, or patients prescribed Torsemide at hospital discharge
62291095|NCT04702958||Furosemide|Patients enrolled in the TRANSFORM-HF study randomized to Furosemide, or patients prescribed Furosemide at hospital discharge
62464238|NCT01866319|ACTIVE_COMPARATOR|Pembrolizumab Q3W|Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.
62464239|NCT04391062|EXPERIMENTAL|intraoperative PDT 400J/cm²|
62464240|NCT04391062|EXPERIMENTAL|intraoperative PDT 600J/cm²|
62464241|NCT04391062|EXPERIMENTAL|intraoperative PDT 800J/cm²|
62464242|NCT05188742|EXPERIMENTAL|Sequence A|mirabegron 50mg OD x 8 weeks, followed by mirabegron 50mg OD and TTNS for 4 weeks, followed by TTNS twice a week x 8 weeks
62291096|NCT01042444|EXPERIMENTAL|Embolic Protection Device|The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
62656928|NCT05037604||Cases|Patients diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
62291097|NCT02763956|EXPERIMENTAL|Gelstix|The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.
62291098|NCT02763956|PLACEBO_COMPARATOR|Placebo|Intradiscal saline solution (1 mL NaCl 0.9%) injection.
62291099|NCT06203301|NO_INTERVENTION|control group|No exercise intervention measures will be implemented. The patient will carry out daily life according to his past living habits and continue to be followed for at least one year.
62291100|NCT06203301|EXPERIMENTAL|resistance exercise group|Resistance exercise training begins before the patient undergoes concurrent chemoradiotherapy, radiotherapy, or chemotherapy. The patients were given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. After that, the patient is asked to regularly perform resistance exercise for at least 1 year.
62291101|NCT06203301|EXPERIMENTAL|walking group|Walking training begins before the patient undergoes simultaneous radiochemotherapy, radiation therapy, or chemotherapy, and requires continuous walking for 15 minutes at least twice a day and at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walking training. After that, ask the patient to walk regularly for at least 1 year.
62291102|NCT06203301|EXPERIMENTAL|resistance exercise and walking group|Before patients receive concurrent chemoradiotherapy, radiotherapy, or chemotherapy, they are given resistance exercise training and walking training for 12 consecutive weeks. After that, the patient is asked to regularly perform resistance exercise and walking for at least 1 year.
62291103|NCT02844127|OTHER|Apex First|Patients born in odd-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the apex and then in the septum. Final lead position will be determined at the discretion of the implanting physician.
62291104|NCT02844127|OTHER|Septum First|Patients born in even-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the septum and then in the apex. Final lead position will be determined at the discretion of the implanting physician
62291105|NCT04186611|EXPERIMENTAL|Early daily occupational therapy intervention|A daily occupational therapy intervention is performed with the patients included. The intervention will consist of assessment as well as early positioning and/or rehabilitation in activities of daily living.
62291106|NCT06108102||Post-stroke epilepsy|Stroke patients aged ≥18 years, with ischemic or hemorrhagic stroke, presenting with early or late onset post-stroke seizures.
62656929|NCT05037604||Control|Patients not diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
62656930|NCT00629902||A1|Patients with prosthesis-patient mismatch after mitral valve replacement
62291107|NCT06108102||No post-stroke epilepsy|Stroke patients aged ≥18 years, with ischemic or hemorrhagic stroke, presenting with no post-stroke seizures.
62291108|NCT00948740|EXPERIMENTAL|ergocalciferol|After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
62291109|NCT02418130|EXPERIMENTAL|UDCA004|UDCA004
62464243|NCT05188742|EXPERIMENTAL|Sequence B|TTNS twice a week x 8 weeks, followed by mirabegron 50mg OD and TTNS for 4 weeks, followed by mirabegron 50mg OD x 8 weeks
62464244|NCT00614952|EXPERIMENTAL|PR|
62464245|NCT00614952|ACTIVE_COMPARATOR|PSG|
62464246|NCT00533273|EXPERIMENTAL|AA4500 0.58 mg|
62656931|NCT00629902||A2|Patients without prosthesis mismatch after mitral valve replacement
62656932|NCT00104234|OTHER|rhASB/rhASB|N-acetylgalactosamine 4-sulfatase
62656933|NCT00104234|OTHER|Placebo/rhASB|
62656934|NCT02346318|EXPERIMENTAL|KS injection arm|Radiation and chemotherapy and compound Kushen Injection
62656935|NCT02346318|NO_INTERVENTION|Control arm|Radiation and chemotherapy
62291110|NCT02418130|PLACEBO_COMPARATOR|Placebo of UDCA004|Placebo of UDCA004
62291111|NCT06543628|EXPERIMENTAL|Treatment group|Participants will take tadalafil once daily at a dose of 5 mg for 6 months, in combination with LIPUS applied twice a week for 4 weeks, with the cycle repeated after a 4-week interval without treatment.
62291112|NCT06543628|ACTIVE_COMPARATOR|Control group|Participants will take tadalafil once daily at a dose of 5 mg for 6 months.
62464247|NCT00533273|PLACEBO_COMPARATOR|Placebo|
62464248|NCT06000709|EXPERIMENTAL|Ultrasound-guided Genicular Nerve Phenol Neurolysis|One time injection of 1.5 mL of phenol 6% at 3 target locations: superomedial, superolateral and inferomedial genicular nerves
62464249|NCT06000709|ACTIVE_COMPARATOR|Ultrasound-guided Intraarticular Steroid Injection|Intraarticular knee injection of 40 mg of methylprednisolone acetate in a volume of 5 mL of saline
62093420|NCT00593554|ACTIVE_COMPARATOR|1|Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
62093421|NCT00593554|EXPERIMENTAL|2|Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG
62093422|NCT02993497|EXPERIMENTAL|Respiratory monitoring group|
62093423|NCT04285502|NO_INTERVENTION|CONTROL GROUP|patients without a drain
62093424|NCT04285502|EXPERIMENTAL|CASE GROUP|Patients a drain inserted
62093425|NCT03025256|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab IV over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and beyond) in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1, 2, 8 of each cycle and end of treatment. Patients undergo CT or PET at baseline, cycle 5 and then every 8 weeks. Patients undergo MRI at baseline, cycles 3, 5, and then every 8 weeks.
62093426|NCT05051397|EXPERIMENTAL|HYPERCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=50mmHg will be targeted
62093427|NCT05051397|ACTIVE_COMPARATOR|NORMOCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=40mmHg will be targeted
62291113|NCT02663895|EXPERIMENTAL|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months
62656936|NCT04521868|EXPERIMENTAL|sulforaphane|The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia.
62656937|NCT04521868|PLACEBO_COMPARATOR|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
62656938|NCT05676437||Satisfied|Patients that are satisfied with their knee replacement, defined by OKS above PASS.
62656939|NCT05676437||Unsatisfied|Patients that are unsatisfied with their knee replacement, defined by OKS below PASS.
62656940|NCT00734565|EXPERIMENTAL|1|
62656941|NCT02320409|EXPERIMENTAL|Sulfatinib ,after general diet|First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
62656942|NCT02320409|EXPERIMENTAL|Sulfatinib, before general diet|First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake
62656943|NCT03884036|ACTIVE_COMPARATOR|Vitamin D group|Vitamin D 200,000 IU (1 cc) IM
62656944|NCT03884036|PLACEBO_COMPARATOR|Control group|Normal saline 1 cc IM
62656945|NCT00559000|NO_INTERVENTION|Waitinglist Control|
62093428|NCT00432159|EXPERIMENTAL|1-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level of the cervical spine, C3 to C7 inclusive.
62093429|NCT00432159|ACTIVE_COMPARATOR|1-level ACDF with plate|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at a single level of the cervical spine, C3 to C7 inclusive.
62093430|NCT00432159|EXPERIMENTAL|2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at two adjacent levels of the cervical spine, C3 to C7 inclusive.
62093431|NCT00432159|ACTIVE_COMPARATOR|2-level ACDF|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at two adjacent levels of the cervical spine, C3 to C7 inclusive.
62093432|NCT00432159|EXPERIMENTAL|Training: 1 & 2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level or multiple levels of the cervical spine, C3 to C7 inclusive. Training cohort.
62093433|NCT04425148|EXPERIMENTAL|tACS|40 Hz transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
62093434|NCT04425148|SHAM_COMPARATOR|Sham tACS|Sham transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
62093435|NCT06046872|OTHER|Report-back training program|Researchers participate in a training program on sharing personal results. Pre-and post-tests are administered to evaluate shifts in perspectives and wiliness to report-back before and after the training program. There is no control group.
62093436|NCT04232670|SHAM_COMPARATOR|EUS + SHAM|All subjects will undergo anesthesia administered sedation and endoscopic ultrasound (EUS). The endoscopist will assess the pancreas for parenchymal and ductal features of chronic pancreatitis and confirm the absence of exclusion criteria (such as the presence of an occult pancreatobiliary malignancy).
62656946|NCT00559000|EXPERIMENTAL|KIDNET|
62656947|NCT03611543||Screening Patients|100 Patients. Each patient who agrees to participate and is consented and is undergoing a routine screening mammogram will receive her normal 4 view 2D plus 3D combination imaging (Left Cranial Caudal (LCC), Left Mediolateral-Oblique (LMO), Right Cranial Caudal (RCC), Right Mediolateral-Oblique (RMLO)) mammogram, with the current standard paddle. In addition she will also receive a CC and a MLO in one of her breasts as determined by a randomization scheme with the new investigational curved paddle. The amount of compression applied to both mammograms will be that to achieve tautness.
62656948|NCT03611543||Diagnostic Patients|400 Patients. Patients who agree to participate, are consented and are undergoing a diagnostic exam will have her prescribed diagnostic 2D plus 3D combination imaging as well as a CC or MLO with both the standard paddle and the new investigational curved paddle compressed to tautness on the breast of interest. The order of the paddles will be randomized and the view (CC or MLO) will be based in the visibility of the area of interest for which the diagnostic imaging was ordered. (It is possible that one of the views is superior to assess the area of interest).
62656949|NCT00770367|EXPERIMENTAL|Pioglitazone then Placebo|18 volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take Pioglitazone for the first 12 week period of the study and then take the placebo for the final 12 weeks of the study.
62656950|NCT00770367|EXPERIMENTAL|Placebo then Pioglitazone|18 (other half of participants) volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take the placebo for the first 12 week period of the study and then take the Pioglitazone for the final 12 weeks of the study.
62656951|NCT04032938||the control group|30 healthy people as the control group.
62093437|NCT04232670|EXPERIMENTAL|EUS + Pancreatic Endotherapy|If randomized to ERCP with pancreatic endotherapy, the endoscopist will proceed with this intervention immediately following the completion of EUS and treatment allocation (during the same anesthesia). Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement. Overall technical success will be defined by the ability to insert at least one pancreatic stent across the dominant main pancreatic duct obstruction. Technical success for pancreatic stone treatment will be defined by the ability to remove all fluoroscopically visible main pancreatic duct stones.
62291114|NCT02514759|EXPERIMENTAL|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions (one per week at 40-50 minutes each) and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
62093438|NCT01097980|EXPERIMENTAL|Trazodone|Trazodone versus placebo in a randomized, double-blind manner
62093439|NCT01097980|PLACEBO_COMPARATOR|Placebo|Patients received placebo
62093440|NCT06506240|EXPERIMENTAL|Acupuncture group|Treatment will be administered by licensed practitioners with over five years of experience, in separate rooms to prevent patient interaction. The selected acupuncture points include LI11 , SP10, ST36, SP6, LR3, LI4, ST25, CV4, GV20, and superior GV29. Sterile disposable stainless-steel needles (0.3 mm×40 mm; Hwato brand, Suzhou Medical Appliance Factory, Suzhou, China) will be used. Patients will lie supine, and routine skin sterilization will be performed locally. Needles will be inserted at depths ranging from 10 to 30 mm at the designated acupuncture points. Each needle will be manually manipulated with lifting, thrusting, twirling, and rotating to elicit Deqi sensation (including soreness, numbness, distention, and heaviness). Needles will remain inserted for 30 minutes per session and manipulated three times, every 10 minutes. Acupuncture sessions will be conducted three times weekly over a six-week period.
62093441|NCT06506240|SHAM_COMPARATOR|Sham acupuncture group|Patients in the control group will undergo sham acupuncture using sterile disposable stainless-steel needles (0.3 mm×25 mm; Hwato brand, Suzhou Medical Appliance Factory, Suzhou, China). Needles will be inserted to depths of 2 to 3 mm at the same acupuncture points as in the acupuncture group. There will be no needle manipulation or attempt to induce Deqi sensation. Needles will be retained for 30 minutes per session.
62093442|NCT04187534|EXPERIMENTAL|Albumin Fluid Resuscitation Optimization Intervention|Our quality improvement intervention seeking to improve appropriate use and reduce inappropriate use of albumin for fluid resuscitation will consist of establishing a clinical champion, educating clinicians, changing the process for albumin ordering through development of an albumin order sheet, and providing quarterly unit-level audit/feedback data to clinicians on albumin utilization.
62291115|NCT02514759|NO_INTERVENTION|Control group|The control group received business as usual.
62291116|NCT01554657|EXPERIMENTAL|5 Days|
62291117|NCT01554657|PLACEBO_COMPARATOR|7 days|
62291118|NCT03065179|EXPERIMENTAL|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
62291119|NCT01284790|EXPERIMENTAL|Cochlear implants|
62291120|NCT04314050|ACTIVE_COMPARATOR|tramadol|1,5 mg /kg tramadol will perform intraoperatively in 100 ml saline within 15 minutes at 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
62291121|NCT04314050|ACTIVE_COMPARATOR|dexmedetomidine|1 mcg/kg dexmedetomidine bolus will perform after anesthesia induction and followed by infusion of 0.5 mcg/kg/h until 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
62656952|NCT04032938||the case group|60 patients were admitted to intensive care unit (ICU) as the case group after cardiac surgery and extracorporeal circulation. This group should contain 30 patients with fever and/or hemodynamic instability and 30 patients with normothermia and normal hemodynamic.
62656953|NCT00128843|EXPERIMENTAL|Exemestane|25mg/day per VO until progression disease, after this progression the patient could receive the another drug (comparator arm) ie Anastrozole by investigator decision
62656954|NCT00128843|ACTIVE_COMPARATOR|Anastrozole|1mg/day per VO until progression disease, after this progression the patient could receive the another drug (experimental arm) ie Exemestane by investigator decision
61907303|NCT03596541|EXPERIMENTAL|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
62291122|NCT04314050|PLACEBO_COMPARATOR|control|1 gr paracetamol will perform intraoperatively
62291123|NCT06183008|EXPERIMENTAL|Intravenous Immunoglobulin|3 courses Intravenous immunoglobulin, Infusion solution, 100mg/ml, 2g/kg over 3 days
62291124|NCT06183008|PLACEBO_COMPARATOR|Placebo|3 courses Saline infusion solution 0,9%, same volume as IVIG over 3 days
62291125|NCT00619502|EXPERIMENTAL|DTaP-IPV-Hep B-PRP~T Vaccine Group|Participants received a primary series of 3 vaccinations with DTaP-IPV-Hep B-PRP\~T, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-HepB-PRP\~T at 15 to 18 months of age in the present study
62291126|NCT00619502|ACTIVE_COMPARATOR|Pentaxim™ + Engerix B™ Vaccines Group|Participants received a primary series of 3 vaccinations with Pentaxim™ and Engerix B™ vaccines, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-Hep B-PRP\~T at 15 to 18 months of age in the present study.
62291127|NCT00003200|EXPERIMENTAL|Taxotere|"After the screening procedures confirm participation in the research study:~* Taxotere-Administered weekly for 1 hour (6 doses)~* Radiation Therapy (XRT) -5 days a week for 6 weeks~* Exam under anesthesia~* Neck Dissection (if indicated)"
62656955|NCT02355223|OTHER|FAST Implementation|This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
62656956|NCT00780832|ACTIVE_COMPARATOR|1|Caffeine reduction through diet and beverage counselling
61907304|NCT03596541|ACTIVE_COMPARATOR|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
61907305|NCT03165604|ACTIVE_COMPARATOR|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
62093443|NCT04187534|ACTIVE_COMPARATOR|Usual Practice|Stepped-wedge roll out of 'Albumin Fluid Resuscitation Optimization Intervention' will permit those ICUs wherein intervention has not yet been implemented to serve as controls. These ICUs will prescribe albumin according to usual practice and not be exposed to any components of the intervention.
62093444|NCT04524104|EXPERIMENTAL|Lumen treatment|Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at baseline and 16 weeks. Participant will receive an encrypted study iPad enabled with Lumen at baseline. They will complete 8 PST sessions beginning with 4 weekly and then 4 biweekly intervals (i.e., on weeks 1, 2, 3, 4, 6, 8, 10, 12) over 12 weeks on their assigned iPad. Participants will also complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 16), that is, 8 time series. Additionally, participants will complete depressive and anxiety symptoms questionnaire and user experience surveys at all PST sessions.
62093445|NCT04524104|NO_INTERVENTION|Waitlist Control|"Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at Baseline and 16 weeks.~Participant will receive an encrypted study iPad at baseline. Participants will complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 16), that is, 8 time series.~Participants in the waitlist control arm will only complete assessments but will have the option to receive Lumen at the end of the study. The PST module on the study iPad will be disabled until their 16-week assessment is completed, at which time they will have the option to complete 8 PST sessions on their assigned iPads."
62093446|NCT02990728|EXPERIMENTAL|Mirena® + metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
62093447|NCT02990728|ACTIVE_COMPARATOR|Mirena®|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
62656957|NCT00780832|ACTIVE_COMPARATOR|2|Anticholinergic medication
62291128|NCT01461681|EXPERIMENTAL|Symptom Management Service for heart failure|Subjects randomized to the SMS-HF group will receive a comprehensive PC consultation by the interdisciplinary PC team at each site consisting of a nurse practitioner, physician, social worker and chaplain with 6 months of follow up. All members of the PC team are experienced PC clinicians. The SMS-HF intervention is based on National Quality Forum preferred practices and the National Consensus Project guidelines for quality PC. The SMS-HF will include assessment and management of symptoms, particularly focused on depression, pain and dyspnea, and a discussion of goals of care.
62093448|NCT04314661|EXPERIMENTAL|Arthroscopy + Booster|After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
62291129|NCT01461681|NO_INTERVENTION|Usual cardiology care|The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
62291130|NCT02224131|EXPERIMENTAL|Monitoring Arm|dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay(TEG)
62291131|NCT02224131|ACTIVE_COMPARATOR|Conventional Arm|fixed dose regiment of both aspirin and clopidogrel in all patients following stent deployment according to international guidelines
62093449|NCT04314661|EXPERIMENTAL|Arthroscopy + Pre-Conditioning|After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
62093450|NCT04314661|EXPERIMENTAL|Non Arthroscopy + Booster|Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
62093451|NCT04314661|EXPERIMENTAL|Non Arthroscopy + Pre-Conditioning|Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
62093452|NCT01273558|NO_INTERVENTION|Part 1: no Intervention|In Part 1 of the study, patients will not receive any study drug.
62291132|NCT05765903|ACTIVE_COMPARATOR|Arm 1: Intervention A|"* Diagnosis education includes verbal 1:1 patient education by the Transitional Nurse Navigator (TNN) and a folder with Epic printed education and other handouts specific to that disease process.~* Follow-up appointment scheduling assistance, including transportation to the follow-up appointment. The Community Health Worker (CHW) or TNN will schedule the appointments for the PCP and other specialists within 1 week when available.~* Offer resources in the community post the 1:1 meeting with the patient to meet specific access to care challenges identified for that patient by the TNN or CHW.~* Provide weekly follow-up calls for one month by TNN or delegate.~* Social Determinants of Health (SDOH) assessment. Screenings by CHW regarding patients' SDOH and documentation in the EHR (Epic) of this SDOH assessment. If a patient demonstrates a need, a CHW will help identify and offer opportunities for the patient."
62093453|NCT01273558|EXPERIMENTAL|Part 2: canagliflozin|In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.
62093454|NCT05421273|EXPERIMENTAL|Active recharge burst stimulation|
62093455|NCT05421273|EXPERIMENTAL|Passive recharge burst stimulation|
62093456|NCT00761774|EXPERIMENTAL|Brivaracetam|Brivaracetam at flexible dosing up to 200mg /day
62291133|NCT05765903|EXPERIMENTAL|"Arm 2: Receives Intervention A and Intervention B"|"* Additional educational training using iPads. Education using iPad and/or teach-back components to reinforce the individualized disease and medication specific education. iPads are programmed with patient education from The Patient Channel. This visit will be completed by a TNN.~* Focus on readmission risk during Care Transition Rounds. Multi-disciplinary team conducts daily rounds to discuss patient. TNNs share the risk scores for the patients and discuss coordination of the patient receiving interventions and other resources suggested by team members.~* Home health care from Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH). Involves home visits to the patient, environmental assessments, and medication reconciliation from a home health nurse. Duration and specifications of home health care depend on the patient's needs. Participants will be assigned based on program eligibility and availability."
62291134|NCT04113967|EXPERIMENTAL|Biodanza Group|The biodanza program will consist of 12 sessions, one per week, during three months. Each session will last approximately 60 minutes and an introductory phase (10-15 minutes) and an experience phase (45 minutes) will be divided. It involves moving / dancing according to the suggestions of the monitor and the rhythm of the music.
62093457|NCT02802020|EXPERIMENTAL|WallFlex FCSEMS Recipients|"The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent. Patients who meet all eligibility criteria will receive the WallFlex Pancreatic stent for up to 6 months stent indwell and 6 months follow-up after stent removal. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study."
62093458|NCT03291600|EXPERIMENTAL|Virtual Psychiatric Care Group|Participants randomized to the intervention group will have the option to receive video-based psychiatrist care in addition to care as usual. Participants will be assigned to begin immediately after randomization.
62093459|NCT03291600|NO_INTERVENTION|Control Group|Women allocated to the control condition will receive care as usual (in-person psychiatric care) from the study site to which they were referred.
62656958|NCT01748149|EXPERIMENTAL|Vemurafenib|"Vemurafenib should be swallowed whole with 8 oz (1 cup) of water. Pharmacokinetic studies will determine if vemurafenib can be crushed. If patients receiving crushed tablets are felt to receive adequate exposure, then they will be allowed to participate in the expansion cohort. \[Patients approved to take crushed tablets should use a pill crusher and mix pill with 3-5 ml apple sauce\]. If not, then only patients able to swallow whole pills will be eligible.~The patient will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
62656959|NCT03454620|EXPERIMENTAL|GC1118 combination with irinotecan|GC1118 weekly(3mg or 4mg) + irinotecan 180mg/m2 biweekly dosing
62093460|NCT00812630|EXPERIMENTAL|1|In the second part of the trial, subjects will apply MENT or placebo gel transdermally for 12 weeks and will have 24-hour blood pressure monitoring at baseline, Week 6 and Week 12.
62093461|NCT02539758|EXPERIMENTAL|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
62291135|NCT04113967|NO_INTERVENTION|Treatment as usual Group|The control group will continue with its usual treatment and activities, without suffering any alteration. A measurement of the groups (control group and biodanza group) will be carried out before the start and after the end of the sessions.
62291136|NCT00728065|EXPERIMENTAL|1|White Bread (control)
62656960|NCT03454620|EXPERIMENTAL|GC1118 combination with FOLFIRI|GC1118 weekly(3mg or 4mg) + FOLFIRI biweekly dosing
62656961|NCT00434252|PLACEBO_COMPARATOR|Carboplatin+Paclitaxel+Placebo|
62656962|NCT00434252|EXPERIMENTAL|Carboplatin+Paclitaxel+Bevacizumab|
62656963|NCT03118882|ACTIVE_COMPARATOR|Diet Group|
62656964|NCT03118882|ACTIVE_COMPARATOR|Physical activity group|
62656965|NCT03118882|ACTIVE_COMPARATOR|Physical activity and diet group|
61907306|NCT03165604|ACTIVE_COMPARATOR|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
61907307|NCT02335814|EXPERIMENTAL|FLX925|
61907308|NCT03553992|EXPERIMENTAL|The Put It Out Project (POP-6):|a culturally tailored intervention developed for sexual and gender minority (SGM) young adults on Facebook
61907309|NCT03553992|EXPERIMENTAL|Tobacco Status Project (TSP-6):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
61907310|NCT01239992|EXPERIMENTAL|Niacin/ Laropiprant|
62656966|NCT03118882|NO_INTERVENTION|Control group|
62656967|NCT00635713|EXPERIMENTAL|1|Faslodex 125mg and Arimidex 1 mg
62656968|NCT00635713|EXPERIMENTAL|2|Faslodex 250mg and Arimidex 1mg
62656969|NCT01173250|ACTIVE_COMPARATOR|stapled ileoanal pouch without diverting ileostomy|
62656970|NCT01173250|PLACEBO_COMPARATOR|stapled ileoanal pouch with diverting ileostomy|
62656971|NCT03639415|EXPERIMENTAL|controlled-release oxycodone group|"Patients with moderate to severe pain accept CR oxycodone treatment and if any follow situations appears, then change the dose frequency from every 12 hours to every 8 hours or 6 hours.~1. Patients are satisfied with the pain control, but unable to tolerate nausea、vomit or dizziness, and can't get satisfactory pain control if reducing the CR oxycodone dose.~2. Patients are unsatisfied with the pain control, but can't increase the CR oxycodone dose because of intolerable nausea、vomit or dizziness."
62656972|NCT02950571|ACTIVE_COMPARATOR|Standard Care|Routine care is comprised of a high level of support from an interdisciplinary team with access to unit-specific and centralized programming
62291137|NCT00728065|EXPERIMENTAL|2|White Bread (control)
62291138|NCT00728065|EXPERIMENTAL|3|White bread with 7.32 grams Salba hispanica
62656973|NCT02950571|EXPERIMENTAL|Digital Picture Frames|"Setup: Over 1-2, approximately 30 minute meetings pictures will be uploaded onto the device from picture files provided by the participant and/or their family or an open online source (e.g., Google Images) that are relevant and of interest to the participant.~Installation: The picture frames are secured to a surface in the participant's room (most typically a table) by facilities staff. Participants are instructed in its use.~Check in: At midpoint (2 weeks) an RA will check in with the participant to informally discuss whether or not it continues to work, is being used, and if they want more pictures uploaded. If the latter is requested step 1 will be repeated."
62656974|NCT06084689|EXPERIMENTAL|Cohort A: soft-tissue sarcomas|Soft-tissue sarcomas
61907311|NCT00154089|EXPERIMENTAL|EM-1421|"Administration of EM-1421 intravaginally once per week for 3 weeks~Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)"
62291139|NCT00728065|EXPERIMENTAL|4|White bread with 15.58 grams Salba hispanica
62656975|NCT06084689|EXPERIMENTAL|Cohort B: Solid tumors|Solid tumors \[non-small cell lung cancer (NSCLC) or triple negative breast cancer (TNBC) or MMS colorectal cancer (MSS-CCR) or biliary tract cancer (BTC)\]
62656976|NCT04334369|SHAM_COMPARATOR|Single Vision Contact Lenses|
62656977|NCT04334369|EXPERIMENTAL|Multifocal Contact Lenses|
62656978|NCT03716960|EXPERIMENTAL|Pumpkin Seed Oil|This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
62656979|NCT03716960|PLACEBO_COMPARATOR|Placebo|This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
62656980|NCT04181788|EXPERIMENTAL|Arm A1 (Phase 1b)|
62656981|NCT04181788|EXPERIMENTAL|Arm B1 (Phase 1b)|
62656982|NCT04181788|EXPERIMENTAL|Arm A2 (Phase 2)|
62656983|NCT04181788|EXPERIMENTAL|Arm B2 (Phase 2)|
62656984|NCT01541748||AXIS Allograft Dermis|Participants receiving AXIS Allograft Dermis for anterior, posterior or combined (anterior and posterior) female pelvic floor repair.
61907312|NCT01870934||Telemedicine, Diabetes, foot ulcer|
61907313|NCT02285036|EXPERIMENTAL|A newly PPV23|The treatment pneumococcal vaccine was developed by Yunnan Walvax Biotech Co., Ltd (Walvax) China, is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae, including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in China. The dose of vaccine is an individual with a 0.5ml dose contains 23 kinds of pneumococcal polysaccharide serotypes each 25μg, and does not contain any preservatives. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
61907314|NCT02285036|ACTIVE_COMPARATOR|PNEUMOVAX 23|PNEUMOVAX 23 is an established US-licensed vaccine and manufactured by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
61907315|NCT00551928|ACTIVE_COMPARATOR|A|Oral therapy with Lenalidomide Melphalan and Prednisone.
61907316|NCT00551928|ACTIVE_COMPARATOR|B|High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)
61907317|NCT05977738|EXPERIMENTAL|Dose group 1: 16 mg|Pitavastatin 16 mg via oral route in the form of daily tablets for 6 days before SOC surgery
61907318|NCT05977738|EXPERIMENTAL|Dose group 2: 32 mg|Pitavastatin 32 mg via oral route in the form of daily tablets for 6 days before SOC surgery
61907319|NCT05977738|EXPERIMENTAL|Dose group 3: 48 mg|Pitavastatin 48 mg via oral route in the form of daily tablets for 6 days before SOC surgery
61907320|NCT02409030||Cognitively Healthy controls|"The neuropsychological test assessment must confirm that there is no cognitive impairment.~In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted."
61907321|NCT02409030||Alzheimer Disease|Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).
62291140|NCT00728065|EXPERIMENTAL|5|White bread with 24 grams Salba hispanica
62291141|NCT00728065|EXPERIMENTAL|6|Rice Milk (control)
62291142|NCT00728065|EXPERIMENTAL|7|Rice Milk (control)
62291143|NCT00728065|EXPERIMENTAL|8|Rice Milk with 7.32 grams Salba hispanica
62291144|NCT00728065|EXPERIMENTAL|9|Rice Milk with 15.58 grams Salba hispanica
62291145|NCT00728065|EXPERIMENTAL|10|Rice Milk with 24 grams Salba hispanica
62291146|NCT03009604|EXPERIMENTAL|Simethicone|women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation
62291147|NCT03009604|ACTIVE_COMPARATOR|Enema|women take 3 rectal Enema (8:00 pm, 12:00 am \& 8:00 am) and to fast over night before the operation.
62291148|NCT03631927||Patient|Patients admitted to participating ICUs on the specified dates
62291149|NCT05360550|EXPERIMENTAL|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|LSP-5415
62656985|NCT02255864|EXPERIMENTAL|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
62656986|NCT02198352|EXPERIMENTAL|BIBN 4096 BS - in single rising doses|
62656987|NCT02198352|PLACEBO_COMPARATOR|Placebo|
62291150|NCT05373550|NO_INTERVENTION|Comparison group: usual care|It is made up of women between 35 and 65 years old who are on the waiting list for surgical treatment (hysterectomy) of the gynecology service of the HGOLEA and receive routine care.
62656988|NCT00458835|ACTIVE_COMPARATOR|Ciclesonide 300 mcg intranasally via aqueous nasal spray|
62656989|NCT00458835|ACTIVE_COMPARATOR|Ciclesonide 300 mcg intranasally via HFA nasal aerosol|
62291151|NCT05373550|EXPERIMENTAL|Experimentation group: nursing education intervention with technological support.|It is made up of women between 35 and 65 years of age who are on the waiting list for surgical treatment (hysterectomy) in the gynecology service of the HGOIA. Women seen at this facility receive care similar to that previously described for the HGOLEA. This group will additionally receive the educational intervention of face-to-face nursing with technological support.
62291152|NCT01717534|EXPERIMENTAL|Heat-treated lactobacilli|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
62656990|NCT00458835|ACTIVE_COMPARATOR|Ciclesonide 320 mcg orally inhaled via HFA MDI|
62656991|NCT06438601|EXPERIMENTAL|Lens A (omafilcon A)|All participants will wear lens A for 15 minutes (Period 1).
62656992|NCT06438601|EXPERIMENTAL|Lens B (comfilcon A)|All participants will wear lens B for 15 minutes (Period 2).
62656993|NCT04358523|EXPERIMENTAL|ASC18 (D1,D4-13）;RDV + SOF(D27,D30-39)|ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 1 and day 4 to 13. RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 27 and day 30 to 39.
62656994|NCT04358523|EXPERIMENTAL|RDV + SOF (D1,D4-13）;ASC18(D27,D30-39)|RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 1 and day 4 to 13. ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 27 and day 30 to 39.
62656995|NCT00055237|EXPERIMENTAL|Cohort 1: Pts with HIV-associated Kaposi's Sarcoma|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
62656996|NCT00055237|EXPERIMENTAL|Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
62291153|NCT01717534|PLACEBO_COMPARATOR|Maltodextrin|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
62291154|NCT00714779|ACTIVE_COMPARATOR|1|Fluoxetine
62291155|NCT00714779|ACTIVE_COMPARATOR|2|Short-term psychodynamic psychotherapy
62656997|NCT00847028|EXPERIMENTAL|1|glucose 10%
62656998|NCT00847028|EXPERIMENTAL|2|glucose 20%
62656999|NCT00847028|EXPERIMENTAL|3|glucose 30%
62291156|NCT01572155|NO_INTERVENTION|Sham stimulation|No stimulation of nervus vagus
62291157|NCT01572155|ACTIVE_COMPARATOR|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
62291158|NCT01572155|ACTIVE_COMPARATOR|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
62291159|NCT01352481|EXPERIMENTAL|Intervention group|
62291160|NCT01352481|NO_INTERVENTION|Control group|
62291161|NCT00712348|EXPERIMENTAL|Taliglucerase alfa|Open label taliglucerase alfa treatment
62464250|NCT02297932|EXPERIMENTAL|Strength training|The intervention will consist of a Home-based Resistant Training Intervention. Participants randomized to the home-based progressive resistance training (PRT) condition and will be provided with a training manual, an exercise log book, and resistance training equipment. The training manual will consist of a detailed description of the exercises to be performed and how to progress over 4-months. The exercise logbook will allow participants to provide a detailed recording of each training session. Home-based PRT equipment will consist of elastic bands (Thera-Band®, Hygenic Corporation, Akron, OH) and weighted vests.
62657000|NCT00847028|PLACEBO_COMPARATOR|4|placebo: sterile water
62657001|NCT01878591||Women in active second stage of labour|Ultrasound examinations
62657002|NCT06305013||Participant of simulation course organised by Department of Simulation medicine|Participant of simulation course organised by Department of Simulation medicine
62291162|NCT01656525|EXPERIMENTAL|1|
62291163|NCT01656525|EXPERIMENTAL|2|
62291164|NCT01656525|EXPERIMENTAL|3|
62291165|NCT01656525|EXPERIMENTAL|4|
62657003|NCT00275613|EXPERIMENTAL|Rituximab, IV infusion|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
62657004|NCT00248560|EXPERIMENTAL|Gemcitabine, docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
62657005|NCT03380156|EXPERIMENTAL|Interventional|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
62657006|NCT03380156|PLACEBO_COMPARATOR|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
62657007|NCT03478280|ACTIVE_COMPARATOR|Brodalumab|Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
62657008|NCT03478280|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
62291166|NCT01157117|EXPERIMENTAL|Omalizumab/milk OIT|Participants receive blinded omalizumab injections every 2 to 4 weeks through Month 16 and unblinded omalizumab injections thereafter until the Month 28 desensitization oral food challenge (OFC). Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk OFC and discontinue omalizumab injections. If they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
62291167|NCT01157117|PLACEBO_COMPARATOR|Placebo for omalizumab/milk OIT|Participants receive blinded placebo for omalizumab injections every 2 to 4 weeks through Month 16; after unblinding the injections are discontinued. Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk oral food challenge (OFC); if they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
61907322|NCT02409030||Frontotemporal dementia|Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).
62291168|NCT01157117|NO_INTERVENTION|Untreated control|Participants did not receive any study intervention but provided regular blood draws at specific study time points to allow mechanistic comparisons with the participants in the other two groups who did receive study intervention.
62291169|NCT03316352|EXPERIMENTAL|Ultrasound-assisted|Ultrasound-assisted paramedian technique spinal anesthesia will be performed. A Preprocedural ultrasound scan will be performed for skin marking of entry site of spinal needle. Spinal anesthesia will be performed via paramedian approach using the skin marking site as entry point. 0.5% heavy bupivacaine will be administered into intrathecal space.
62291170|NCT03316352|ACTIVE_COMPARATOR|Landmark-guided|In these patients, spinal anesthesia will be performed via paramedian approach using conventional landmark palpation technique. Landmark-guided paramedian technique spinal anesthesia will be performed. 0.5% heavy bupivacaine will be administered into intrathecal space.
61907323|NCT02058823|PLACEBO_COMPARATOR|Arm 1: Real hypoxia and ¨Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 2.
61907324|NCT02058823|PLACEBO_COMPARATOR|Arm 2: Hypoxia placebo and Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the hypoxia placebo and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 1.
62093462|NCT06396195|ACTIVE_COMPARATOR|stainless steel crown|"Tooth preparation will involve using a tapered diamond bur to reduce the occlusal surface by 1-1.5mm. Special attention will be given to ensure a consistent occlusal reduction. Interproximal reduction will be carried out distally using a tapered diamond bur, with the rounding of line angles and achieving a knife-edge finish margin on the proximal surface while avoiding any ledge formation.~For crown selection, an appropriately sized crown will be chosen based on the mesiodistal width of the prepared tooth, and a trial fit will be performed to prevent blanching before cementation. The crown will be contoured and crimped using crown-contouring and crimping pliers. Afterward, the crown will be smoothed and polished along the entire margin using a rubber wheel. Finally, the crown will be cemented using type 1 Glass ionomer luting cement (Prevest Denpro, India ), and any excess material will be removed with an explorer. The final occlusion will be then verified."
62093463|NCT06396195|ACTIVE_COMPARATOR|bioflx crown|"Prior to preparation ,selection of crown size will be done by occlusal to occlusal comparison~- we will maintain cusp inclines and reduce the occlusal by 1-1.5 mm , including the central groove(Tip of football diamond ) buccal and lingual occlusal third of clinical crown will be reduced by football diamond proximal contact will be opened with adjacent teeth by 0.5 mm, creating a feather edge gingival margin ( tip of black stripe diamond ) Roundation all line angles will be done Buccal bulge reduction will be done while maintaining a snug fit Trial fit the crown. Seating direction will be lingual to buccal . Adjustment of the preparation as needed for snug /active fit which should provide some resistance to dislodgement Glass ionomer luting cement (Prevest Denpro, India ) will be used to cement the crown"
62093464|NCT02906683|EXPERIMENTAL|TAS-303 3mg|
62093465|NCT02906683|EXPERIMENTAL|TAS-303 6mg|
62093466|NCT02906683|PLACEBO_COMPARATOR|Placebo|
62093467|NCT05895630|EXPERIMENTAL|Interactive|The sessions will be given in groups of 5 to 10 people and will be interactive via Zoom (link will be sent to them by email). They will last 1h30min and will consist of 60min of physical activity, preceded and followed by 15 optional minutes of virtual social interaction with the kinesiologist and the other members of the group. Finally, if the participants are unable to attend the group session, a video of the course given will be available for them to follow afterwards via a website.
62093468|NCT05895630|EXPERIMENTAL|Video|The sessions will be done individually without interaction via pre-recorded videos. The videos demonstrate specific classes provided to the patients in this arm by a kinesiologist. Participants will be able to contact the kinesiologist by phone or email to ask questions about the sessions. The sessions will last 1h30min.
62291171|NCT03288948|ACTIVE_COMPARATOR|Standard Contrast Increment|
62093469|NCT05895630|NO_INTERVENTION|Control|The control will be instructed to continue their lifestyle habits throughout the study. These participants will not receive any intervention until their outcome measures at baseline and follow-up are recorded. At this point their participation is completed and they will be offered one of the two physical exercise programs. Therefore, this arm will be acting like a waitlist group.
62657009|NCT03779607|ACTIVE_COMPARATOR|IPS e.max Press(lithium di silicate)|Lithium disilicate reinforced glass ceramics are available in the market in two forms according to the technique of manufacturing, either heat pressed ingots or CAD/CAM blocks for milling. The heat pressed lithium disilicate glass ceramic consists of approximately 70% lithium disilicatecrystals(the main crystal phase) having a needle like shape that are embedded in a glassy matrix. The crystals length is about 3 to 6 μm. The heat pressed ingots are fully crystallized and the restoration is fabricated by the lost wax technique where the lithium disilicate ingots are pressed into the investment mold at high temperature. The pressed lithium disilicate has strong flexural strength values(range 400 ± 40 MPa)
62093470|NCT05740280|EXPERIMENTAL|iCP-NI|"Part A will comprise a single dose, sequential group design. Part A: 40 subjects will be studied in 5 groups (Groups A1 to A5). In each of Groups A1 to A5, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part A: Five proposed dose levels per protocol.~Part B will comprise a multiple dose, sequential group design. Part B: 24 subjects will be studied in 3 groups (Groups B1 to B3). In each of Groups B1 to B3, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part B: Proposed dose levels to be determined following review of available data from Part A."
62093471|NCT05740280|PLACEBO_COMPARATOR|Placebo|"Part A will comprise a single dose, sequential group design. Part A: 40 subjects will be studied in 5 groups (Groups A1 to A5). In each of Groups A1 to A5, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part A: Five proposed dose levels per protocol.~Part B will comprise a multiple dose, sequential group design. Part B: 24 subjects will be studied in 3 groups (Groups B1 to B3). In each of Groups B1 to B3, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part B: Proposed dose levels to be determined following review of available data from Part A."
62291172|NCT03288948|EXPERIMENTAL|Reduced Contrast Increment|
62464251|NCT02297932|ACTIVE_COMPARATOR|Stretching|Individuals in the comparator group will participate in a four month home-based stretching program developed by the National Multiple Sclerosis Society (NMSS). They will be provided text-based materials and asked to provide a weekly log book. In efforts to equate the attention received, individuals will come to KF at the same frequency as those receiving the PRT intervention and will also engage in the same number of sessions to assess their adherence to the program.
62657010|NCT03779607|EXPERIMENTAL|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
62657011|NCT05695287|OTHER|Propofol|Anesthesia
62657012|NCT05695287|OTHER|Isofluran|Anesthesia
62657013|NCT05695287|OTHER|Sevofluran|Anesthesia
61907325|NCT02058823|ACTIVE_COMPARATOR|Arm 3: Hypoxia and Valsartan|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the Valsartan during the first two weeks and, after the wash-out, receive the treatment of the arm 4.
62291173|NCT03288948|EXPERIMENTAL|No Contrast Increment|
62291174|NCT01392183|EXPERIMENTAL|Pazopanib|Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
62291175|NCT01392183|EXPERIMENTAL|Temsirolimus|Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
62291176|NCT01583426|EXPERIMENTAL|nab-Paclitaxel|nab-Paclitaxel (125 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
62291177|NCT01583426|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
62291178|NCT02407535|EXPERIMENTAL|Endometrial carcinoma patient|
62291179|NCT01893749|EXPERIMENTAL|CATCH-IT|"200 randomized teens 13-18 year old (inclusive) will be enrolled into the online program that contains 14 modules focused various therapeutic techniques, a booster session of 6 modules at the end of the online program and three 15 minute visits with their primary care doctor to discuss the benefits and disadvantages of the program.~Parents will also be invited to participant in a partnering online program involving 4 modules online and 1 optional module. They will be asked to then participate in three 15 minute interviews with a member of the study team to discuss the benefits and disadvantages of the program."
61907326|NCT02058823|ACTIVE_COMPARATOR|Arm 4: Hypoxia and Amlodipine|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the amlodipine during the first two weeks and, after the wash-out, receive the treatment of the arm 3.
61907327|NCT03689309|NO_INTERVENTION|1. Classic SBT (C-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but oxygen delivered through a heat humidifier filter that is usually connected on tracheotomy.
62464252|NCT00906165|ACTIVE_COMPARATOR|1- Immediately provisionalized|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
62093472|NCT04478747|ACTIVE_COMPARATOR|Transvaginal mesh|BSC mesh (A.M.I., Feldkirch, Austria) is attached to the sacrospinosus ligaments and to the apical part of the vagina.
62093473|NCT04478747|ACTIVE_COMPARATOR|Colposacropexy with the apical fixation only|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina.
62093474|NCT04478747|ACTIVE_COMPARATOR|Colposacropexy with the apical and the levator fixation|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina with fixation reaching to the level of the levator planes.
62093475|NCT04066998|EXPERIMENTAL|Conjunctivitis|Patients treated with Dupilumab with conjunctivitis
62291180|NCT01893749|NO_INTERVENTION|Health Education|"200 randomized teens, ages 13-18 year old (inclusive) receiving an online program with 14 modules that focus on general health education, depression, diet, exercise, hygiene and safety.~Parents will also be invited to participate in an online program with 4 modules that also focus on general health education."
62291181|NCT04801290||TIPS insertion|
62291182|NCT02286388|EXPERIMENTAL|Partial excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
62291183|NCT02286388|ACTIVE_COMPARATOR|Complete excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
62291184|NCT02286388|EXPERIMENTAL|Antibacterial dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
62291185|NCT02286388|ACTIVE_COMPARATOR|Conventional dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
62657014|NCT06552169|ACTIVE_COMPARATOR|Arm 1: Standard of Care (SOC)|"Arm 1: SOC-Subjects randomized to Arm 1 will be followed on the prescribed 2-drug SOC immunosuppression throughout the trial.~The study allowed SOC regimen is tacrolimus + sirolimus or everolimus."
62737459|NCT05281627||Emergency Laparotomy Patients|All adult patients (18+) who have undergone Emergency Laparotomy surgery, are recovering well (no illness which is expected to limit life to \<6m post op) and have sufficient English-language and cognitive skills to complete the study questionnaires.
62093476|NCT04066998|OTHER|No conjunctivitis|Patients treated with Dupilumab and showing no signs of ocular involvement
62093477|NCT05945511||Kidney transplant patients|KT recipients at Seoul national university hospital from January 2005 to July 2022.
62291186|NCT02321969|NO_INTERVENTION|Control|Without green tea extract (GTE) supplementation
62737460|NCT05281627||Family Caregivers|Adult (18+) family members, close friend or caregivers of the individual who has received EmLap treatment have sufficient English-language and cognitive skills to complete the study questionnaires.
62737461|NCT01586598|NO_INTERVENTION|control group|No intervention will be given to this control group. Spontaneous recovery of mandibular nerve will be assessed for sensory function.
62291187|NCT02321969|EXPERIMENTAL|GTE group|GTE supplementation for 12 months after polypectomy for colorectal adenomatous polyps
62291188|NCT04447053|EXPERIMENTAL|Belimumab + SOC|Patients will be administered Belimumab, 10mg/kg, intravenously (IV) (together with SOC) in 1 hour on days 0, 14, and 28, and then every 28 days (4 weeks) until week 48.
62291189|NCT04447053|NO_INTERVENTION|SOC only|Patients will receive SOC based on the discretion of attending physicians in accordance with the clinical disease manifestations of SLE and NUH practice of the treatment of SLE.
62737462|NCT01586598|EXPERIMENTAL|sensory retraining group|Sensory retraining protocol will be applied this group. Any facilitation of sensory function in mandibular nerve will be assessed.
61907328|NCT03689309|EXPERIMENTAL|2. High Flow Oxygen SBT (HFO-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
61907329|NCT06156293|EXPERIMENTAL|Stepped-care CBT-I group|"A total of 3 steps of sleep focused intervention will be provided, with the objectives to increase the awareness of sleep health, increase sleep literacy, establish good sleep hygiene and treat insomnia.~Step 1: self-help digital sleep focused program; Step 2: guided intervention; Step 3: individualized consultation."
61907330|NCT06156293|NO_INTERVENTION|Control group|Participants in the control group remain unexposed to the stepped-care sleep-focused intervention.
61907331|NCT02194257|EXPERIMENTAL|[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge|
61907332|NCT02194257|EXPERIMENTAL|[14C]-benzyl ambroxol oral solution + ambroxol lozenge|
62093478|NCT06684223||Patients who underwent laparoscopic or robotic right hemicolectomy with modifiedD3 from 2013 to 2020|Patients who underwent laparoscopic or robotic right hemicolectomy with modified D3 lymphadenectomy from 2013 to 2020 in 4 centers
62093479|NCT06684223||Patients who underwent laparoscopic or robotic right hemicolectomy with CME from 2013 to 2020|Patients who underwent laparoscopic or robotic right hemicolectomy with Complete mesocolic excision from 2013 to 2020 in 4 centers
62093480|NCT06614439|EXPERIMENTAL|Proximal gastrectomy|
62093481|NCT06614439|ACTIVE_COMPARATOR|Total gastrectomy|
62093482|NCT05565755|EXPERIMENTAL|Parents of adolescents who had a consultation with a group of IM-trained interns.|
62093483|NCT05565755|NO_INTERVENTION|Parents of adolescents who have not had a consultation with a group of IM trained interns.|
62657015|NCT06552169|EXPERIMENTAL|Arm 2A: TRACT/MONO mTOR|"Arm 2: TRACT/MONO- At the beginning of the trial, subjects randomized to Arm 2 will be maintained on the prescribed 2-drug SOC immunosuppression and have a single infusion of expanded Tregs (TRK-001) at Day +53 to +67 following living donor kidney transplantation.~At Month 3 post-transplant, Arm 2 TRACT/MONO subjects will be further randomized to either Arm 2A: TRACT/MONO mTOR or Arm 2B: TRACT/MONO CNI.~Subjects randomized to Arm 2A: TRACT/MONO mTOR who have a normal biopsy and no de novo donor specific antibodies at Month 3 will begin weaning of tacrolimus and will remain on a 1-drug regimen with either everolimus or sirolimus until the end of the trial."
62657016|NCT06552169|EXPERIMENTAL|Arm 2B: TRACT/MONO CNI|"Arm 2: TRACT/MONO- At the beginning of the trial, subjects randomized to Arm 2 will be maintained on the prescribed 2-drug SOC immunosuppression and have a single infusion of expanded Tregs (TRK-001) at Day +53 to +67 following living donor kidney transplantation.~At Month 3 post-transplant, Arm 2 TRACT/MONO subjects will be further randomized to either Arm 2A: TRACT/MONO mTOR or Arm 2B: TRACT/MONO CNI.~Subjects randomized to Arm 2B: TRACT/MONO CNI who have a normal biopsy and no de novo donor specific antibodies at Month 3 will begin weaning of the mTOR medication and will remain on a 1-drug regimen with low dose tacrolimus until the end of the trial."
62657017|NCT01777724|EXPERIMENTAL|Intervention|The intervention is a combination of Triple P Discussion Groups and Stress Control
62657018|NCT01777724|NO_INTERVENTION|Control|Waitlist control. Participants allocated to the waitlist control will be able to access the intervention after post-intervention equivalent measures have been completed.
62657019|NCT04538105|SHAM_COMPARATOR|Sham Injection|20cc of Normal Saline 0.9%
62657020|NCT04538105|EXPERIMENTAL|Articular Branch Block (ABB)|20cc of 0.5% Bupivacaine with epinephrine 1:200,000
61907333|NCT05170867|EXPERIMENTAL|Probiotic group|Two capsules of Hafnia alvei HA4597™ probiotic/day (5 x 107 CFU/day) for 90 days
61907334|NCT05170867|PLACEBO_COMPARATOR|Placebo group|Two identical capsules of placebo/day for 90 days
61907335|NCT05949034|EXPERIMENTAL|E-Cigarette Flavor 1 Condition|Participants will self-administer a flavored e-cigarette.
62093484|NCT06199401|EXPERIMENTAL|XJ-Procedure Group|"In the XJ-Procedure Group, Patients will be performed the standard Sun's procedure after general anesthesia, in which the end-to-end anastomosis between the artificial vessel and the aortic root is performed using the Vascular Grafts Eversion and Built-in Technique during the aortic root suture."
62093485|NCT06199401|NO_INTERVENTION|Control Group|"In the Control Group, Patients will be performed the standard Sun's procedure which involves aortic root anastomosis using the regular technique at each cardiovascular surgery center."
62093486|NCT05257837|EXPERIMENTAL|Gun safety vid x Movie clip - guns present|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure featuring guns.
62093487|NCT05257837|ACTIVE_COMPARATOR|Gun safety vid x Movie clip - guns absent|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure with the guns edited out.
62093488|NCT05257837|ACTIVE_COMPARATOR|Seatbelt safety video x Movie clip - guns present|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure featuring guns.
61907336|NCT05949034|EXPERIMENTAL|E-Cigarette Flavor 2 Condition|Participants will self-administer a flavored e-cigarette.
61907337|NCT05949034|EXPERIMENTAL|E-Cigarette Flavor 3 Condition|Participants will self-administer a flavored e-cigarette.
61907338|NCT00536211|EXPERIMENTAL|1|Exercise
61907339|NCT00536211|ACTIVE_COMPARATOR|2|Metformin
61907340|NCT02551991|EXPERIMENTAL|nal-IRI + 5-FU/LV + oxaliplatin|
62093489|NCT05257837|ACTIVE_COMPARATOR|Seatbelt safety video x Movie clip - guns absent|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a \~20 minute clip of either The Rocketeer or National Treasure featuring guns.
62093490|NCT01118962|EXPERIMENTAL|Lacosamide|"Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949).~Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses."
62464253|NCT00906165|ACTIVE_COMPARATOR|2- Delayed Loading|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
62464254|NCT03621579|OTHER|the RNFLT and CMT|the retinal nerve fiber layer (RNFLT) and macular thickness (CMT)
62657021|NCT05619224|EXPERIMENTAL|GEO+N|Neurodevelopmental stimulation intervention programme combined with an oral stimulation programme. They recives 10 sesions of 15 minutes of stimulation.
62657022|NCT05619224|EXPERIMENTAL|GEO|Oral stimulation programme. They recives 10 sesions of 15 minutes of stimulation.
62657023|NCT05037162|EXPERIMENTAL|Arm 1 - CimetrA-1|CimetrA-1, with a total dose containing a combination of Curcumin 40 mg, Boswellia 30 mg and Vitamin C 120 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
62657024|NCT05037162|EXPERIMENTAL|Arm 2 - CimetrA-2|CimetrA-2, with a total dose containing a combination of Curcumin 28 mg, Boswellia 21 mg and Vitamin C 84 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
62657025|NCT05037162|PLACEBO_COMPARATOR|Arm 3 - Placebo|Placebo, composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
62657026|NCT04443608|ACTIVE_COMPARATOR|Veltassa|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
62093491|NCT04700319|EXPERIMENTAL|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T cell infusion on relapsed or refractory hematological malignancies of CD19 / CD20+ B cell line
62464255|NCT03557762|EXPERIMENTAL|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
62464256|NCT03557762|OTHER|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
62464257|NCT03892694|ACTIVE_COMPARATOR|Treatment|MCS
62657027|NCT04443608|PLACEBO_COMPARATOR|Placebo|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
62657028|NCT00513539|ACTIVE_COMPARATOR|Arm A|Biliary Stenting alone
62093492|NCT05147987|EXPERIMENTAL|Intervention Group|Will be provided a discreet, hands-free, wearable breast pump with an associated App
62093493|NCT05147987|NO_INTERVENTION|Standard care group|Will be provided a standard mechanical breast pump with no associated App.
62464258|NCT03892694|SHAM_COMPARATOR|Sham Control|Sham
62093494|NCT05041634|EXPERIMENTAL|Single Group Pilot study pre/post|One group of 8 participants receiving 14 week intervention
62093495|NCT05360966|EXPERIMENTAL|AR-15512 Ophthalmic Solution (0.003%)|0.003% AR-15512 to be administered BID for 90 days. Both eyes will be treated.
62464259|NCT05851937|EXPERIMENTAL|Written language intervention|"Participants will receive 3 months of weekly written language intervention sessions via telepractice.~Participants will be assessed at three time points to monitor outcomes."
62464260|NCT05851937|NO_INTERVENTION|Periodic language check-up|Participants will be assessed at three time points to monitor outcomes.
62464261|NCT01245907|EXPERIMENTAL|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
62657029|NCT00513539|EXPERIMENTAL|Arm B|Photodynamic Therapy plus biliary stenting
62657030|NCT01975441|ACTIVE_COMPARATOR|standard treatment|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
62657031|NCT01975441|EXPERIMENTAL|DEC 6 mg/kg + Alb 400 mg x 1|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
62657032|NCT01975441|EXPERIMENTAL|DEC + ALB + IVM|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)
62657033|NCT03704740|EXPERIMENTAL|NBP607-QIV|One or two doses of 0.5mL of NBP607-QIV by intramuscular injection
62657034|NCT03704740|ACTIVE_COMPARATOR|Agrippal|One or two doses of 0.25mL of Agrippal by intramuscular injection
62657035|NCT03868371|ACTIVE_COMPARATOR|1. high - 2. low|These are the patients receiving a high phosphorous containing meal in the first trial day, and a low phosphorous containing meal in the second trial day.
62657036|NCT03868371|ACTIVE_COMPARATOR|1. low - 2. high|These are the patients receiving a low phosphorous containing meal in the first trial day, and a high phosphorous containing meal in the second trial day.
62657037|NCT06441799|EXPERIMENTAL|Home radiofrequency skin treatment instrument|Radiofrequency skin therapy instrument with medical ultrasound coupler is used for 20 minutes a day, 5 days a week
62657038|NCT06441799|PLACEBO_COMPARATOR|Medical ultrasound coupler|Medical ultrasound coupler is applied to the face for 20 minutes a day, 5 days a week
62464262|NCT01245907|NO_INTERVENTION|Waiting-list/control|No intervention for 10 weeks but the same registrations and diaries and forms as the interventional group
61907341|NCT02613273|EXPERIMENTAL|Experimental: Arm 1 (Aerobic Exercise)|Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
61907342|NCT02613273|EXPERIMENTAL|Experimental: Arm 2 (Resist. Exercise)|Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
62657039|NCT00484159|EXPERIMENTAL|1|Radiofrequency lumbar facet joint denervation only if positive response to 2 diagnostic facet blocks.
62657040|NCT00484159|EXPERIMENTAL|2|Radiofrequency lumbar facet joint denervation if positive response to single facet joint block.
62657041|NCT00484159|EXPERIMENTAL|3|Radiofrequency lumbar facet denervation without a diagnostic facet block.
62657042|NCT02841046|OTHER|group cardiac index|the treatment scheme of goal-directed fluid therapy(GDFT) use cardiac index（CI） as the primary judgment in group cardiac index,Patients in group cardiac index received a therapy with the goal of CI was no less than 2.5L•min-1•m-2 .
61907343|NCT02613273|NO_INTERVENTION|No Intervention: Arm 3 (Control)|Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
61907344|NCT06199583||Patellar tendinopathy|Contains athletes with patellar tendinopathy
61907345|NCT06199583||Non-patellar tendinopathy|Contains athletes without patellar tendinopathy
61907346|NCT04567901||Trauma Patients|The enrolled patients experienced trauma from different injuries and were hospitalized for treatment and admitted to the ICU. 700 older trauma patients (age equal to or more than 65 years) were finally included in the study.
61907347|NCT04550377|ACTIVE_COMPARATOR|Cannabidiol Group 1|40 participants will be titrated to a maximum dose of oral cannabidiol 800 mg daily over 2 weeks for a total of 8 weeks treatment.
62657043|NCT02841046|EXPERIMENTAL|group Stroke Volume Variation|the treatment scheme of goal-directed fluid therapy(GDFT) use Stroke Volume Variation（SVV）and cardiac index（CI）as the primary judgment in group Stroke Volume Variation,Patients in group Stroke Volume Variation received a therapy with SVV was less than 12% and CI was no less than 2.5L•min-1•m-2 .
61907348|NCT04550377|ACTIVE_COMPARATOR|Cannabidiol Group 2|40 participants will be titrated to a maximum dose of oral cannabidiol 400 mg daily over 2 weeks for a total of 8 weeks treatment.
61907349|NCT04550377|PLACEBO_COMPARATOR|Placebo Group|40 participants will be given a placebo for a total of 8 weeks treatment.
61907350|NCT04446390|EXPERIMENTAL|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care). Chew xylitol gum 2 pieces four times per day for 5 minutes after meals."
61907351|NCT04446390|ACTIVE_COMPARATOR|preventive regimen using Fluoride based toothpaste(colgate)|preventive regimen using Fluoride based toothpaste (colgate cavity protection). Participants will be using a fluoride-based toothpaste (colgate cavity protection), (1450 ppm Sodium monofluorophosphate). chew xylitol gum 2 pieces four times per day for 5 minutes after meals.
61907352|NCT01608022|EXPERIMENTAL|PF804|
62657044|NCT00022477|EXPERIMENTAL|BMS-247550|IV administration of BMS-247550 once every 21 days
61907353|NCT02325843|EXPERIMENTAL|human bone marrow MSC|5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.
62657045|NCT01246284|ACTIVE_COMPARATOR|A|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
62657046|NCT01246284|ACTIVE_COMPARATOR|B|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
62657047|NCT01246284|ACTIVE_COMPARATOR|C|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
62657048|NCT01246284|PLACEBO_COMPARATOR|D|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment.
62093496|NCT05360966|PLACEBO_COMPARATOR|Vehicle|AR-15512 vehicle to be administered BID for 90 days. Both eyes will be treated.
62657049|NCT00850577|ACTIVE_COMPARATOR|Paclitaxel/Carboplatin/CT-322|
62093497|NCT03248570|EXPERIMENTAL|DNA damage repair proficient group|Participants with mismatch repair (MMR) intact receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. If disease worsens while receiving pembrolizumab, participants may receive standard of care chemotherapy for 2-8 cycles
62657050|NCT00850577|ACTIVE_COMPARATOR|Paclitaxel/Carboplatin/Bevacizumab/Placebo|
62657051|NCT06060366||PE for CTEPH|CTEPH patients who were eligible for operation
62657052|NCT06060366||Medical treatment CTEPH|CTEPH patients who were not eligible for surgery of any reason and decided to follow up with medical treatment
62657053|NCT01298258|PLACEBO_COMPARATOR|placebo|control group
62657054|NCT01298258|EXPERIMENTAL|Aliskiren|Aliskiren 150 mh
62093498|NCT03248570|EXPERIMENTAL|DNA damage repair defective group|Participants with defective DNA repair receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. If disease worsens while receiving pembrolizumab, participants may receive standard of care chemotherapy for 2-8 cycles
62093499|NCT02947763|ACTIVE_COMPARATOR|multiple visit|multiple visit root canal treatment with triple antibiotic paste intracanal medication (a mixture of metronidazole, ciprofloxacin, and minocycline)
62464263|NCT04366401|ACTIVE_COMPARATOR|Conventional Dietary Advice|"The control group will consist of participants diagnosed on the schizophrenic spectrum who will receive conventional dietary counseling (n=25) on an individual basis.~In the control group, data will be collected on the psychopathological state (PANSS and PSP scales), and blood analysis (hemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
62657055|NCT02928484|ACTIVE_COMPARATOR|Test product|The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.
62657056|NCT02928484|PLACEBO_COMPARATOR|Placebo product|The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
61907354|NCT05972525|EXPERIMENTAL|Shared decision-making (SDM)|Patients will be informed by a nurse before being consulted by the surgeon randomized to SDM and use the in-consultation PtDA during the consultation on patients with severe hip or knee osteoarthritis
61907355|NCT05972525|NO_INTERVENTION|Usual practice|Patients will be informed by a nurse before being consulted by the surgeon randomized to usual practice during the consultation on patients with severe hip or knee osteoarthritis
62093500|NCT02947763|NO_INTERVENTION|single visit|single visit root canal treatment without any intra-canal medication
62657057|NCT04858464||Patients group|Individuals with primary Sjögren's syndrome
62657058|NCT06064448|ACTIVE_COMPARATOR|Western Medicine Section (Sildenafil)|"Sildenafil is an effective and commonly used oral PDE5 inhibitor in the treatment of ED.~In this study, the subjects in the western medicine group will take sildenafil citrate orally, 25mg/capsule, once a night, one capsule each time for 4 weeks."
62737463|NCT05541406|EXPERIMENTAL|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
62093501|NCT01960361|EXPERIMENTAL|ICE dental implant|Subjects implanted with ICE implant
62093502|NCT03081208|EXPERIMENTAL|Nolasiban 900 mg|
62093503|NCT03081208|PLACEBO_COMPARATOR|Placebo|
61907356|NCT02299518|EXPERIMENTAL|Cohort A (mitoxantrone, etoposide, cytarabine, selinexor)|Patients receive mitoxantrone hydrochloride IV, etoposide IV, and cytarabine IV QD on days 1-6 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment continues for 1 course (28 days). Further treatment is based on disease response. Patients achieving CR/CRi are evaluated for stem cell transplant; patients who do not proceed to transplant may receive selinexor as monotherapy in the absence of disease progression or unacceptable toxicity.
62737464|NCT05541406|ACTIVE_COMPARATOR|Control schools|Students in control schools will receive no intervention
62657059|NCT06064448|EXPERIMENTAL|Traditional Chinese medicine group (Ningmitai capsule)|"Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of Urinary and reproductive system disease (eg. CP/CPPS, ED) in China for more than twenty years.~In this study, the subjects took Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd., Sinopharm Zhunzi Z20025442), 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals for 4 weeks."
62093504|NCT02328014|EXPERIMENTAL|Dose Escalation and Expansion|"The acalabrutinib dose will be fixed and the ACP-319 dose will be escalated in each of three cohorts, and each cohort will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.~Expansion groups of up to 12 subjects for Germinal center B-cell (GCB) DLBCL and Non-GCB DLBCL to take a fixed dose of acalabrutinib and ACP-319. Each disease group will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals."
62093505|NCT05503680|EXPERIMENTAL|Yoga group|The experimental group is people living with HIV who will receive 120 minutes per week of yoga intervention.
62093506|NCT05503680|NO_INTERVENTION|Control group|In this study, the control group will receive standard care where participants usually receive various program from The local HIV clinic including general education program, health check-up, and oral antiretroviral regimen
62657060|NCT06064448|EXPERIMENTAL|Combined group (Ningmitai capsule + sildenafil)|In this study, the subjects will take Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd., Sinopharm Zhunzi Z20025442), 0.38 g/capsule, 4 capsules each time three times a day, after meals; Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
62657061|NCT05683067||Fontan Survivors|The investigator will include Fontan survivors between 16-50 years of age for the study.
62657062|NCT05683067||People operated for congenital heart diseases|The investigator will include people operated for other types of congenital heart diseases such as tetralogy of Fallot, transposition of great arteries between 16 and 50 years of age
62657063|NCT05683067||Healthy volunteers|The investigator will include healthy volunteers between 16 to 50 years of age for comparison purpose.
62093507|NCT06292702|EXPERIMENTAL|Traditional laparoscopic Burch procedure|Patients who were randomized to receive classic laparoscopic Burch colposuspension.
62093508|NCT06292702|EXPERIMENTAL|Modified laparoscopic Burch procedure:|Patients who were randomized to receive modified laparoscopic Burch colposuspension by applying lateral tension for the anterior vaginal wall before performing traditional anterior vaginal wall suspension toward Cooper's ligament.
62657064|NCT03820232||Surgical patients|Patients who were candidates for major or urological surgery under general anaesthesia will be observed. In particular, the core body temperature will be measured with both a single-use oesophageal probe and a SpotOn® heated controlled servo sensor.
62657065|NCT02247544|EXPERIMENTAL|Trabectedin|"Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).~Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response."
62657066|NCT03804307|ACTIVE_COMPARATOR|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
62657067|NCT03804307|EXPERIMENTAL|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
62657068|NCT03754543|ACTIVE_COMPARATOR|Testmeal A|A new, whole-grain infant cereal fortified with ferrous fumarate
62657069|NCT03754543|ACTIVE_COMPARATOR|Testmeal B|An alternative new whole-grain infant cereal recipe fortified with ferrous fumarate
62093509|NCT04941716|EXPERIMENTAL|Treatment (acalabrutinib, venetoclax)|"Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-28. Patients receive acalabrutinib alone for the first three 28 day cycles. Venetoclax is added beginning with Cycle 4. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo blood sample collection, bone marrow aspiration and biopsy, and CT or MRI throughout the trial."
62093510|NCT05382572||Patients|An individual diagnosed with PF or ILD, including those who are post lung transplant.
62093511|NCT05382572||Family Members|A family member (defined as biological parent, full or half-sibling, or biological child) of an individual with PF or ILD.
62093512|NCT05382572||Caregivers|An individual who has cared (currently or in the past) for an individual with PF or ILD.
62093513|NCT02578602|EXPERIMENTAL|Diagnostic (gadoxetate disodium MRI)|Patients receive gadoxetate disodium IV and then undergo enhanced liver MRI.
62093514|NCT00513903|ACTIVE_COMPARATOR|Minimal intervention|Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
62093515|NCT00513903|EXPERIMENTAL|Enhanced intervention|Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
62093516|NCT00513903|NO_INTERVENTION|Control|Control arm patients will not be seen by the clinical pharmacist.
62657070|NCT03754543|PLACEBO_COMPARATOR|Testmeal C|An existing, refined grain infant cereal fortified with ferrous fumarate
62093517|NCT01351038|EXPERIMENTAL|treatment|3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1
62093518|NCT02053311|ACTIVE_COMPARATOR|Arm A: Orteronel|300mg orteronel twice daily and best supportive care until disease progression
62657071|NCT03754543|ACTIVE_COMPARATOR|Testmeal D|An existing, whole-grain infant cereal fortified with ferrous fumarate
62093519|NCT02053311|ACTIVE_COMPARATOR|Arm B: Placebo|Placebo twice daily and best supportive care until disease progression
62093520|NCT06475703|ACTIVE_COMPARATOR|Isla digital wound monitoring + Standard follow-up|Patients in the intervention group will be contacted via SMS text message seven days, fourteen days and twenty-one days after surgery with the link request remaining open for 6 days until the next request is sent out. The exception being the last request link which will remain open until 30 days after surgery. In the requests patients are asked to submit a photo of their wound and complete the UKHSA wound surveillance questionnaire. Participants can also submit an image during the 30 days whenever they have a concern.
62657072|NCT03754543|ACTIVE_COMPARATOR|Testmeal E|An existing, whole-grain infant cereal fortified with ferrous bisglycinate
62657073|NCT04767451||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
61907357|NCT02299518|EXPERIMENTAL|Cohort B (etoposide, selinexor)|Patients receive etoposide PO QD on days 1-5 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment may repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving response after 4 courses discontinue treatment; patients achieving response may receive up to 4 courses of maintenance therapy every 8 weeks. Patients may then continue selinexor as monotherapy at the discretion of the principal investigator.
61907358|NCT02672020|EXPERIMENTAL|patients with adrenal tumor|
61907359|NCT03219658|EXPERIMENTAL|Parenting education sessions|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits.
61907360|NCT03219658|NO_INTERVENTION|Control|Attend one-on-one check-ins with the interdisciplinary team at STOMP; wait-listed control group.
61907361|NCT02799251||Collection of plasma cell rate|Post operative infections and their association with lymphopenia are assessed in this study for patients over 18 years of age undergoing digestive or thoracic cancer surgery under general anesthesia.
61907362|NCT03754439||Inborn|"* Infants born within Nottingham University hospitals~* \< 32 weeks gestational age~* \< 72 hours old"
61907363|NCT03754439||Transported|- Infants born outside of Nottingham University Hospitals or transferred between units Phase 1 \< 32 weeks gestational age and \<72 hours old Phase 2 any gestation and age
61907364|NCT03519542||Metastatic clear cell renal carcinoma (mRCC) patients|Metastatic clear cell renal carcinoma (mRCC) patients cadidates to receive Sunitinib 50 mg/day 4/2 schedule or Pazopanib 800mg/day until unaccetable toxicity or progression or death under standar clinical practice.
61907365|NCT06405945||Normal|HPV negative， TCT negative
61907366|NCT06405945||LSIL|HPV postive, TCT: CIN I or Colposcopy LSIL
61907367|NCT06405945||HSIL|HPV postive, TCT: CIN II-III or Colposcopy HSIL
61907368|NCT06405945||cervical cancer|HPV positive, Histopathology: cervical cancer
61907369|NCT00422084|EXPERIMENTAL|PA group|Pyronaridine artesunate (PA)
61907370|NCT00422084|ACTIVE_COMPARATOR|AL group|Arthemether lumefantrine (AL)
61907371|NCT01566214|EXPERIMENTAL|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
61907372|NCT01566214|NO_INTERVENTION|Usual Care|For those randomly assigned to the usual care group, they will receive standard-of-care by their regular primary care provider.
61907373|NCT02745145|EXPERIMENTAL|Abituzumab 1500 milligram (mg)|
61907374|NCT02745145|EXPERIMENTAL|Abituzumab 500 mg|
61907375|NCT02745145|PLACEBO_COMPARATOR|Placebo|
61907376|NCT03337828|ACTIVE_COMPARATOR|Alcohol-free beer with regular composition|Two cans (33 cl.) per day of an alcohol-free beer with regular carbohydrates composition.
61907377|NCT03337828|EXPERIMENTAL|Alcohol-free beer with modified composition|Two cans (33 cl.) per day of alcohol-free beer with modified carbohydrates composition. This include the substitution of regular maltose by isomaltulose and the addition of maltodextrin (fiber).
61907378|NCT04476173|EXPERIMENTAL|Methoxyflurane|Patients treated with inhaled methoxyflurane (3 mg)
61907379|NCT04476173|ACTIVE_COMPARATOR|Morphine|Patients treated with intravenous morphine (5 mg)
61907380|NCT03726450|EXPERIMENTAL|Andrositol Plus|all the patients will be treated for three months with a dietary supplement containing Myo-inositol, NAC, Folic acid, selenium, vitamin E, L-Arginine and L-Carnitine
61907381|NCT02727231|EXPERIMENTAL|day and night closed loop control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
61907382|NCT02727231|ACTIVE_COMPARATOR|usual insulin pump therapy management|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (FreeStyle Navigator CGM)
61907383|NCT05614856||Treatment Group|Patients affected by AIOD classified as TASC B, C or D involving aortic bifurcation and or the first 5mm of one of both common iliacs treated with the unibody endograft AFX (Endologix, Irvine, Calif)
62093521|NCT06475703|ACTIVE_COMPARATOR|Standard follow-up|Patients in the control group will have standard post-operative wound care follow-up for 60 days.
62093522|NCT06696638|EXPERIMENTAL|Intervention group|EIT-guided Phigh settings during APRV
62093523|NCT06696638|NO_INTERVENTION|Control group|Pplat-guided Phigh settings during APRV
62291190|NCT01596257|ACTIVE_COMPARATOR|bulk SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
62464264|NCT04366401|EXPERIMENTAL|Prebiotic/Probiotic Dietary Modulation|"In the intervention group (n=25), individual dietary counseling will be established through intensive nutritional counseling to provide a high prebiotic and probiotic food pattern.~In the experimental group, data will be collected on psychopathological status (Positive and Negative Syndrome Scale -PANSS- and Personal and Social Functioning Scale -PSP-), and blood tests (haemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
62464265|NCT03264898||Fecal Immunochemical Test (FIT) Group|Each participant will complete 5 different FITs, on a single stool sample collected in a hat. Each participant will undergo optical colonoscopy and their FIT results compared with their colonoscopy with biopsy results (if applicable). We will calculate the test characteristics of each FIT.
62464266|NCT01503307||Prenatal/Postpartum CHD Diagnosis|parent of a baby (prenatal or postpartum)who was recently found to have a heart defect.
62657074|NCT04767451||Control group|The study population will consist of 50 women with POI as a study group and 50 patients with normal healthy women as a control group. A volunteer group of healthy women who will be visited the gynecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
62657075|NCT03514953|EXPERIMENTAL|Reduced Physical Activity|Participants will reduce their physical activity level by \>5000 steps per day for two weeks.
61907384|NCT06294210|EXPERIMENTAL|Mobile app and wearable heart rate variability monitoring|A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
61907385|NCT03758755|EXPERIMENTAL|BFR Therapy|This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
62093524|NCT02028910|EXPERIMENTAL|Ondansetron|"The treatments in the form of cases numbered 1 vial of 50 ml of ondansetron 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions ondansetron syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
62093525|NCT02028910|PLACEBO_COMPARATOR|placebo|"The treatments in the form of cases numbered 1 vial of 50 ml of placebo 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions placebo syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
62093526|NCT02107274|ACTIVE_COMPARATOR|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
62093527|NCT02107274|PLACEBO_COMPARATOR|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
62291191|NCT01596257|EXPERIMENTAL|fractionated SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
62291192|NCT00355264|EXPERIMENTAL|Single Arm on Active Drug|"5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels~Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes involved in recycling."
62291193|NCT04006184||Endovenous Thermal Ablation|Limbs treated with either radiofrequency ablation or endovenous laser ablation
62291194|NCT04006184||Cyanoacrylate Closure|Limbs treated with cyanoacrylate closure system
62657076|NCT05106478||Moderate lateral Group|Patients will be anesthetized using ® AuraGain airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air and operation will undergo while patient's neck in moderate lateral position.
62291195|NCT04480151||IMPELLA™ alone as bridge to LVAD|patients assisted by IMPELLA™ pump alone during the days preceding the implantation of long term LVAD (at least 48 hours for patients for whom an ECLS was previously used)
61907386|NCT03758755|ACTIVE_COMPARATOR|No BFR|This group of patients will undergo physical therapy exercises per the current standard of care after their ACL reconstruction without BFR
61907387|NCT05784285|EXPERIMENTAL|Community-based activity program|Engagement in 8-week community-based activity program.
62291196|NCT04480151||ECLS alone or with IMPELLA™ as bridge to LVAD|patients assisted by ECLS (ExtraCorporeal life support) alone or simultaneously with IMPELLA™ until the implantation of LVAD
62291197|NCT01249235|ACTIVE_COMPARATOR|Patch|The operative eye will be patched.
62291198|NCT01249235|EXPERIMENTAL|Bandage Contact Lens|The operative eye will have a bandage contact lens
62291199|NCT03625388|OTHER|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
62291200|NCT03625388|OTHER|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
62291201|NCT02408692|ACTIVE_COMPARATOR|Normal BMI ECx1|5 normal weight women (BMI\<25 kg/m2) taking 1.5mg LNG
62093528|NCT06066424|EXPERIMENTAL|Dose Escalation|"Participants who are enrolled in Dose Escalation, Participants will be assigned to a dose level of TROP2- CAR-NK cells based on when you join this study. Up to 5 dose levels of TROP2-CARNK cells will be tested. At least 3 participants will be enrolled at each dose level.~The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TROP2-CAR-NK cells is found.~Participants who are enrolled in the Dose Expansion, Participants will receive TROP2-CAR-NK cells at the recommended dose that was found in the Dose Escalation."
62093529|NCT06066424|EXPERIMENTAL|Dose Expansion Cohort 1|"Participants who are enrolled in Dose Escalation, Participants will be assigned to a dose level of TROP2- CAR-NK cells based on when you join this study. Up to 5 dose levels of TROP2-CARNK cells will be tested. At least 3 participants will be enrolled at each dose level.~The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TROP2-CAR-NK cells is found.~Participants who are enrolled in the Dose Expansion, Participants will receive TROP2-CAR-NK cells at the recommended dose that was found in the Dose Escalation."
62093530|NCT06066424|EXPERIMENTAL|Dose Expansion Cohort 2|"Participants who are enrolled in Dose Escalation, Participants will be assigned to a dose level of TROP2- CAR-NK cells based on when you join this study. Up to 5 dose levels of TROP2-CARNK cells will be tested. At least 3 participants will be enrolled at each dose level.~The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TROP2-CAR-NK cells is found.~Participants who are enrolled in the Dose Expansion, Participants will receive TROP2-CAR-NK cells at the recommended dose that was found in the Dose Escalation."
62093531|NCT00329303|EXPERIMENTAL|Certolizumab Pegol (CZP) 200 mg|Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter.
62093532|NCT00329303|EXPERIMENTAL|Certolizumab Pegol (CZP) 400 mg|Subcutaneous injections of 400 mg every 2 weeks.
62093533|NCT05714839|EXPERIMENTAL|Part 1: Dose escalation of belantamab monotherapy|Belantamab will be administered in participants with RRMM until progressive disease (PD)
62093534|NCT05714839|EXPERIMENTAL|Part 2: Belantamab and belantamab mafodotin (delivered as separate drugs) dose range finding|Participants with RRMM will receive belantamab in combination with a fixed dose of belantamab mafodotin (delivered as separate drugs)
62291202|NCT02408692|ACTIVE_COMPARATOR|Obese BMI ECx1|5 obese women (BMI \>30 kg/m2) taking 1.5mg LNG
62291203|NCT02408692|ACTIVE_COMPARATOR|Obese BMI ECx2|5 obese women (BMI \>30 kg/m2) taking 3mg LNG
62291204|NCT05451420|EXPERIMENTAL|Group A|PegIFN α- 2b monotherapy, 180 μg/ week, 68 weeks of treatment, 24 weeks of follow-up after drug withdrawal
62464267|NCT02982408|EXPERIMENTAL|Low birth weight (LBW)|25 males born at term (weeks 39-41) in 1979-1981 with LBW (BW\<10th percentile)
62464268|NCT02982408|EXPERIMENTAL|Normal birth weight (NBW)|25 BMI- and age-matched males born at term (weeks 39-41) with normal birth weight (NBW) control individuals (BW: 50-90th percentile)
62093535|NCT05714839|EXPERIMENTAL|Part 1b: Optional belantamab mafodotin|Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin.
62093536|NCT02528955|ACTIVE_COMPARATOR|A:De-Intensification Radiotherapy (RT) primary tumor region|"A:De-Intensification Radiotherapy (RT) primary tumor region~* ≤ pT2, R ≥ 5 mm, L0, Pn0~* \> 3 lymph node metastasis or patients with \< 3 ipsilateral lymph node metastasis and a bilateral primary tumor without adequate contralateral neck dissection"
62093537|NCT02528955|ACTIVE_COMPARATOR|B:De-Intensification Radiotherapy contralateral lymph nodes|"* \> pT2 and/or R \< 5mm and/or L1 and/or Pn1~* ≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (\>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( \>= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
62093538|NCT02528955|ACTIVE_COMPARATOR|C:De-Intensification RT primary tumor region /contralateral LN|"* ≤ pT2, R ≥ 5 mm, L0, Pn0~* ≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (\>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( \>= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
62093539|NCT04429880|EXPERIMENTAL|Oxytocin|Oxytocin 17 micrograms infusion over 10 minutes
62093540|NCT03937271||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
62093541|NCT03937271||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 revised Systemic lupus erythematosus criteria
62093542|NCT03937271||Rheumatoid Arthritis|Rheumatoid Arthritis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2010 ACR/EULAR Rheumatoid Arthritis classification criteria
62093543|NCT03937271||Systemic Sclerosis|Systemic Sclerosis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1980 ACR eSystemic Sclerosis criteria
62093544|NCT03937271||Ankylosing spondylitis|Ankylosing spondylitis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1984 Ankylosing spondylitis Modified New York criteria
62093545|NCT03937271||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min
62657077|NCT05106478||Extreme lateral Group|Patients will be anesthetized using ® AuraGain airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air and operation will undergo while patient's neck in extreme lateral position.
62657078|NCT00532623|ACTIVE_COMPARATOR|Combination|
62657079|NCT00532623|ACTIVE_COMPARATOR|Seqeuntial|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
62657080|NCT02300610|EXPERIMENTAL|Dose Escalation|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).
62657081|NCT02300610|EXPERIMENTAL|Dose Expansion|Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
62291205|NCT05451420|ACTIVE_COMPARATOR|Group B|Patients had a lead-in period of 16 weeks before baseline, pegifn α- 2b single drug treatment for 24 weeks, 4 weeks after drug withdrawal, 16 weeks of introduction period, pegifn α- 2b was followed up for 24 weeks. The plan of the induction period is as follows: 1) from the first day of the induction period, GM-CSF is injected subcutaneously ® one hundred μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd.), 100 μg/ day, 5 consecutive days, one cycle every 4 weeks, 4 consecutive cycles. 2) On the third day of the induction period, recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (1.0ml/HBsAg 60 per dose) was injected subcutaneously μg. Shenzhen Kangtai Biological Products Co., Ltd.), 60 μ g. Once every 4 weeks for 4 consecutive cycles, the course of treatment was 68 weeks, and the patients were followed up for 24 weeks.
62291206|NCT01075178||Palivizumab-treated subjects (CASES)|HSCHD infants, \<2 yrs old at first dose of palivizumab
62291207|NCT01075178||Non-palivizumab-treated subjects (CONTROLS)|HSCHD infants, \<2 yrs old that did not receive palivizumab
62291208|NCT06023667|EXPERIMENTAL|SMART-IBD|The SMART-IBD app consists of educational content, medication reminders, and weekly app engagement challenges. App users will participate in weekly challenges that focus on topics such as adherence, sleep, and diary usage. Participants in this arm will complete one month of run-in diaries, one month of diaries during intervention, and one month of diaries post-intervention.
62291209|NCT06023667|NO_INTERVENTION|Attention Control|Participants in this arm will not receive any intervention content. Participants in this arm will complete one month of run-in diaries, one month of diaries during intervention and one month of diaries post-intervention.
62657082|NCT03315949|EXPERIMENTAL|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
62657083|NCT03315949|ACTIVE_COMPARATOR|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
62093546|NCT02651402|ACTIVE_COMPARATOR|FRIENDS for Life Train-the-Trainer|Therapists implement FRIENDS (a CBT protocol for students with anxiety) in the school setting, while supported by their supervisor assigned to the Train-the-Trainer (TT) implementation strategy (supervisors participate in training workshops on conducting supervision with active therapists).
62093547|NCT02651402|EXPERIMENTAL|Adapted FRIENDS Train-the-Trainer|Therapists implement an adapted version of FRIENDS (aFRIENDS) in the school setting while supported by their supervisor assigned to the TT strategy.
62291210|NCT03320499||echo doppler at the bed|
62291211|NCT03320499||echo doppler in the vascular exploration platform|
62291212|NCT01872455|ACTIVE_COMPARATOR|Group CON|patients who refused to assume the n-3 rich diet and continued their usual diet
62291213|NCT01872455|EXPERIMENTAL|Group DIET|the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
62291214|NCT04680117|OTHER|Cases with SA, classified by age group|Patient hospitalized for assessment of severe asthma
62291215|NCT04680117|OTHER|Controls among children w/ SA: frequent&infrequent exacerbators|Frequent exacerbators have 2 or more asthma severe exacerbations in the past years
62291216|NCT04343950|EXPERIMENTAL|Intervention 1: SMS reminders in colorectal cancer screening|SMS reminders will be sent to individuals who received an invitation letter from Colorectal Cancer Screening Program and haven't participated within 6 weeks.
62291217|NCT04343950|ACTIVE_COMPARATOR|Usual Care 1: Reminder letter in colorectal cancer screening|Reminder letters will be sent to individuals who received an invitation letter from the Colorectal Cancer Screening Program and haven't participated within 6 weeks.
62291218|NCT04343950|EXPERIMENTAL|Intervention 2: SMS reminders to return the screening test|SMS reminders will be sent to individuals who picked the fecal immunochemical test at the pharmacy and haven't returned it within 14 days.
62657084|NCT06212791||Patients under going catheter ablation|Patients undergoing catheter ablation for paroxysmal AF, reduction or elimination of arrhythmia burden
62291219|NCT04343950|ACTIVE_COMPARATOR|Usual Care 2: No intervention|No reminders will be sent.
62291220|NCT04343950|EXPERIMENTAL|Intervention 3: SMS invitation among prior participants|Invitation by SMS will be sent to women who previously participated in the Breast Cancer Screening Program.
62291221|NCT04343950|ACTIVE_COMPARATOR|Usual Care 3: Invitation letter|Letter invitations will be sent.
62291222|NCT01016626|EXPERIMENTAL|CKD-4101 tablet|
62291223|NCT01016626|ACTIVE_COMPARATOR|Mycophenolate Mofetil capsule|
62291224|NCT02992574|EXPERIMENTAL|Post Mastectomy Radiation Therapy (PMRT)|Post mastectomy radiotherapy will be given
62657085|NCT02987881|EXPERIMENTAL|Adult women with early stage localized endometrial cancer|Adult women with early stage localized endometrial cancer at least 2 months following hysterectomy
62657086|NCT05284253|EXPERIMENTAL|Gold microparticles|Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
62657087|NCT05284253|ACTIVE_COMPARATOR|Gold thiosulphate|Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
62657088|NCT06305845|EXPERIMENTAL|Digital crowns|"Crowns that are fabricated digitally by mean of CAD-CAM technology will be placed after preparation.~Tooth preparation will include 1.5-2 mm. occlusal reduction and proximal contacts will be opened and the entire clinical crown structure will be reduced by 0.8-1.0 mm.and the preparation will be finished with a subgingival finish line.~Upper and lower arches will be scanned with an intra oral scanner. A third scan of the occlusal bite is then performed in order to establish the patient's occlusion.~Brilliant Crios composite blocks will be milled with the CEREC MC X milling unit and the inner surface of the crown will be sandblasted followed by etching with 5% hydrofluoric acid for 60 seconds."
62093548|NCT02651402|EXPERIMENTAL|Adapted FRIENDS Train-the-Trainer Plus|Therapists implement aFRIENDS in the school setting while supported by their supervisor assigned to the Train-the-Trainer Plus (TT+) implementation strategy (supervisors participate in training workshops and receive further/on-going consultation on conducting supervision with active therapists).
62093549|NCT00591747|EXPERIMENTAL|1|Progressive resistance training program 3 times a week for 12 months
62093550|NCT00591747|ACTIVE_COMPARATOR|2|Flexibility training 3 times a week for 12 months
62093551|NCT03639675|EXPERIMENTAL|NVG patients|Japanese patients with neovascular glaucoma
62093552|NCT06570785||IOPS group|Patients with AAA undergoing standard EVAR according to the IFU using IOPS technology for visulisation of guidewires and catheter for the cannulation of contralateral limb.
62291225|NCT02992574|NO_INTERVENTION|Observation (No PMRT)|No adjuvant radiotherapy will be given.
62291226|NCT05383235|EXPERIMENTAL|Sexual offenders against children|sexual offenders against children
62291227|NCT05383235|ACTIVE_COMPARATOR|Healthy controls|Healthy controls
62291228|NCT04068857|EXPERIMENTAL|rTMS|
62291229|NCT04068857|SHAM_COMPARATOR|Sham|
62291230|NCT04139083||TVM group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with TVM
62291231|NCT04139083||LSC mesh suspension group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with LSC mesh suspension
62291232|NCT03561233|EXPERIMENTAL|proton pump inhibitor|omeprazole 20 mg twice daily
62291233|NCT00864240|EXPERIMENTAL|A|Clobex TM 0.05% Lotion, single exposure
62291234|NCT01712347||mCRC Participants|mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
62291235|NCT00840827|EXPERIMENTAL|all patients|Lenalidomide 10mg po daily/ CSA 250mg orally twice daily
62291236|NCT01396369|ACTIVE_COMPARATOR|Birth control|
62291237|NCT01396369|EXPERIMENTAL|Birth control plus Brevail|
62291238|NCT05014854|OTHER|Intervention|"Finger and tip pressures are assessed in two phases (A/B). Baseline measurements (A) are collected in the 1st and 2nd therapy session after inclusion. First, data is collected via SEMS (from 2nd grade) or via a sheet with standard forms (1st grade), followed by the recording of a standard sentence (from SEMS) or a standard form at the end of the session. The 2nd session is started and ended with the writing of the chosen standard set. Phase-A-measurements are recorded without feedback.~From the 3rd therapy session on SensoGrip is used with activated feedback (B). At the end of each session, the same standard set used in Phase A is written twice - once with and once without feedback. This order changes each time to minimize possible bias due to habitation to writing with SensoGrip. Data is recorded in both forms. Children can take SensoGrip home from the 4th session on and use it in daily life.~In the last session, SEMS or the standard forms are re-executed as initially applied."
62291239|NCT03452839|EXPERIMENTAL|Continuous infusion|"Patient randomized to continuous infusion group, will receive a continuous infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula and study day~1. for ClCr \> 50 ml/min: 3 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 12,5 ml/h.~2. for ClCr \< 50 ml/min: 2 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 8,3 ml/h.~This solution will be replaced every time its duration exceeds the stability in use stated by the producer"
62291240|NCT03452839|ACTIVE_COMPARATOR|Bolus|"Patient randomized to bolus group, will receive a bolus infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula):~1. for Cl-Cr \> 50 ml/min 1 g every 6 hours on first 24 hours, every 8 hours after~2. for Cl-Cr \< 50 ml/min 1 g every 8 hours on first 24 hours, every 12 hours after"
62291241|NCT00096161|EXPERIMENTAL|pentostatin, DLI, mycophenolate mofetil, cyclosporine|"Group I (pentostatin, DLI): Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.~Group II (pentostatin, DLI, mycophenolate mofetil, cyclosporine): Patients receive treatment as in group I. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD."
62291242|NCT02146586||Dystrophinopathies|
62291243|NCT02146586||Gold Standard Clinical Evaluators (GS-CEs)|
62291244|NCT02146586||Sites Clinical Evaluators (CEs)|
61907388|NCT03543488||Rheumatoid Arthritis Patients|Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.
61907389|NCT03543488||Healthy Women|Thirty-five healthy women, age- and body size-matched to the RA patients, were recruited as controls (CG).
61907390|NCT00662532|EXPERIMENTAL|Minocycline HCl|1 mg microspheres of minocycline hydrochloride
61907391|NCT00662532|NO_INTERVENTION|No Intervention|Control group receiving no drug intervention
62093553|NCT06570785||Conventional group|Patients with AAA undergoing standard EVAR according to the IFU using standardised approach and materials.
62093554|NCT05002478|EXPERIMENTAL|Prone Group|Turn patient in prone position after surfactant administration. After 6 hours turn patient in supine position and perform EIT and LUS.
62093555|NCT05002478|NO_INTERVENTION|Supine Group|Leave patient in supine position after surfactant administration. After 6 hours perform EIT and LUS.
62093556|NCT04727710|EXPERIMENTAL|Part 2: Couples-based mindfulness intervention|Mindfulness-based intervention + Usual care
62093557|NCT04727710|ACTIVE_COMPARATOR|Part 2: Usual care|Usual care
62093558|NCT05408650|EXPERIMENTAL|Aromatherapy massage group|The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position.
62093559|NCT05408650|NO_INTERVENTION|control group|The patients will receive the routine care of the ICU (such as decreased movements of the staff and soft light in the area at night).
62093560|NCT02106767|ACTIVE_COMPARATOR|Rosuvastatin|
62093561|NCT02106767|EXPERIMENTAL|Rifampin plus rosuvastatin|
62291245|NCT01495143|ACTIVE_COMPARATOR|Healthy group|Eight healthy volunteers (five males and three females) with a body mass index of 23.8 and without chronic metabolic disease or low back pain. They are all non-smokers and non-medicated.
62291246|NCT01495143|EXPERIMENTAL|Surgery group|"Two MD catheters is placed in the paraspinal muscle at the level of midpoint of incision bilaterally.~A reference catheter is placed in the deltoid muscle."
62291247|NCT00522067|EXPERIMENTAL|Arm 1|FLUAD
62464269|NCT03642548|EXPERIMENTAL|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
62464270|NCT03642548|PLACEBO_COMPARATOR|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
62464271|NCT05996510|ACTIVE_COMPARATOR|diseased shoulder|
62464272|NCT05996510|ACTIVE_COMPARATOR|sturdy shoulder|
62464273|NCT05612724|OTHER|SARS-CoV-2 testing|There is only one arm in this study- the study is a non-randomized pilot. All the subjects will be tested for SARS CoV 2 viral Antigen as described.
62464274|NCT04018339|EXPERIMENTAL|RTA 402 5mg or 10mg oral administration|
62464275|NCT04018339|PLACEBO_COMPARATOR|Placebo|
62464276|NCT05039190|ACTIVE_COMPARATOR|Experimental: HBM9161 (680mg )|HBM9161 680mg; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
62657089|NCT06305845|ACTIVE_COMPARATOR|Zirconia crowns|"Prefabricated zirconia crowns that are ready made and supplied in kits with their try-ins will be used in this arm.~Occlusal reduction of 1.5-2 mm. will be performed by a football diamond bur. The whole crown will be reduced by 0.8-1.0 mm by means of a tapered diamond stone. A shoulder finish line will be created. The try in crown will be tested. Then the shoulder finish line will be removed and the preparation will be extended subgingivally to a feather-edge."
62093562|NCT05590910|EXPERIMENTAL|Music Intervention Group|The music intervention group will receive a 15-minute music intervention and variables such as heart rate, blood pressure, anxiety, and academic performance will be measured.
62093563|NCT05590910|NO_INTERVENTION|Non-Music Control Group|Variables such as heart rate, blood pressure, anxiety, and academic performance will be measured.
62093564|NCT02034435|ACTIVE_COMPARATOR|Aim1-Low Sodium then High Sodium|"Subjects will be provided with a low sodium diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Placebo tablets for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Salt tables (150mEq) for 8days and assessments will be made."
62291248|NCT05233358|EXPERIMENTAL|HAIC combined with regorafenib and immune checkpoint inhibitors|Subjects received FOLFOX regimen HAIC treatment, within 2 weeks of regorafenib (28 days as a cycle, 80-160 mg qd regorafenib orally on days 1-21) and immune checkpoint inhibitors (continue treatment according to the original plan, 1 cycle every 3 weeks) treatment. HAIC treatment was repeated every 3 weeks for a maximum of six cycles.
62291249|NCT05233358|ACTIVE_COMPARATOR|TACE combined with regorafenib and immune checkpoint inhibitors|Choose traditional precise cTACE or dTACE treatment, and receive regorafenib within 2 weeks (28 days as a cycle, 80-160mg qd regorafenib orally on d1-21) and immune checkpoint inhibitors (continue treatment according to the original plan, every 3 weeks as a cycle) treatment. CT or MRI examination was repeated 4-6 weeks after the operation to evaluate whether there were active lesions. If there were still active lesions, one repeat TACE could be performed, and the number of TACE was less than 3 times.
62657090|NCT05509504|EXPERIMENTAL|Intervention|
62657091|NCT05509504|NO_INTERVENTION|Control|
62093565|NCT02034435|ACTIVE_COMPARATOR|Aim 1-high salt diet then low salt diet|"Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Salt tables (150mEq) for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Placebo tablets for 8days and assessments will be made."
62291250|NCT00849017|EXPERIMENTAL|albiglutide|albiglutide weekly injection
62291251|NCT00849017|PLACEBO_COMPARATOR|placebo|albiglutide matching placebo
62291252|NCT00849017|EXPERIMENTAL|albiglutide up-titration|albiglutide weekly injection uptitration at week 12
62291253|NCT05787847|OTHER|Health Education|
62291254|NCT05787847|EXPERIMENTAL|Health Education plus Incentives for Abstinence|
62291255|NCT00594477|EXPERIMENTAL|IMRT|The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
62291256|NCT01684462|EXPERIMENTAL|Human Serum Albumin 20|Human Serum Albumin 20% 100cc intravenously infused over 4\~8h
62291257|NCT01684462|PLACEBO_COMPARATOR|0.9 % Normal saline|Treatment with same volume of normal saline
62291258|NCT05241249|EXPERIMENTAL|Bethanechol|Patients with borderline resectable pancreatic cancer and no contraindication to bethanechol therapy will receive bethanechol on day 1 and continue until 2 days prior to scheduled surgery for a minimum of 2 months.
62464277|NCT05039190|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Placebo; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
62464278|NCT04970992|EXPERIMENTAL|Dose escalation and cohort expansion Q1W|DZ-002 treatment once every week
62464279|NCT05352360|EXPERIMENTAL|Pilates Exercises with kinesiotaping|
62464280|NCT05352360|EXPERIMENTAL|Muscle energy technique with kinesiotaping|
62464281|NCT02498847|EXPERIMENTAL|ENGAGE intervention|8 in-person weekly treatment sessions with an occupational therapist of 30 minutes - 1 hour duration intervention content provided on website, homework assigned each week after intervention period, monthly calls conducted to check on health status
62464282|NCT02498847|NO_INTERVENTION|Usual Care|participated in usual care and received monthly calls to check on health status
62657092|NCT01650428|EXPERIMENTAL|FOLFOX & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
62657093|NCT01650428|EXPERIMENTAL|FOLFOXIRI & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Irinotecan - 165 mg/m2 IV over 1 hour, Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
61907392|NCT03860558|EXPERIMENTAL|Lifestyle Intervention|20 overweight men with T1D or T2D will undergo an intensive 3 month lifestyle intervention program aimed at improving metabolic health, glycemic control, and body weight.
61907393|NCT03860558|ACTIVE_COMPARATOR|No-Intervention Controls|10 overweight men with T1D or T2D will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
61907394|NCT03860558|ACTIVE_COMPARATOR|Healthy Controls|10 healthy men will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
61907395|NCT04828772||Cohort 1|COVID-19 participants receiving anticoagulants
61907396|NCT04828772||Cohort 2|COVID-19 participants not receiving anticoagulants
61907397|NCT04987359|EXPERIMENTAL|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling. The main objective of the structured exercise training is to improve cardiorespiratory fitness.
61907398|NCT04987359|NO_INTERVENTION|Waitlist Control|The waitlist control group will be asked to maintain their current exercise and dietary habits for the 10-week study period. Upon providing study endpoint data at week 10, control group participants will be offered a 4-week multimodal lifestyle program that is similar to the intervention group.
61907399|NCT02490345|ACTIVE_COMPARATOR|Gabapentin Administration|gabapentin 600mg orally every 8 hours x 48 hours
61907400|NCT02490345|PLACEBO_COMPARATOR|Placebo|Placebo , 1 tablet, orally every 8 hours x 48 hours
61907401|NCT00097981|ACTIVE_COMPARATOR|Thalidomide + dexamethasone|
61907402|NCT00097981|EXPERIMENTAL|Thalidomide + dexamethasone + DOXIL|
61907403|NCT03943537|EXPERIMENTAL|Intranasal Insulin (40 IU)|40 IU Novolin-R insulin will be administered one time using the ViaNase intranasal delivery device.
61907404|NCT02415842||H1N1_AS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42.
61907405|NCT02415842||H1N1_NAS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study -Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42
61907406|NCT02415842||H5N1_AS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21
61907407|NCT02415842||H5N1_NAS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21.
61907408|NCT02415842||H9N2_AS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed study Q-PAN H9N2-001 (116358) (A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
61907409|NCT02415842||H9N2_NAS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed studyQ-PAN H9N2-001 (116358)(A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
62291259|NCT04155502||Social media sites.|These participants will be recruited from advertisements posted on social media websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
62464283|NCT04406753|EXPERIMENTAL|Manual Therapy + Exercise Group|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
62464284|NCT04406753|ACTIVE_COMPARATOR|Exercise Group|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
62464285|NCT00535951|EXPERIMENTAL|LBH589|
62464286|NCT03524469||Normal weight|"Normal Weight will be defined as pre-pregnant BMI between 18.5-23.9 kg/m2 and passing the 28 week oral glucose tolerance test."
62657094|NCT02371005|OTHER|Measurement of the periodontal ligament space|Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.
62657095|NCT02371005|OTHER|Radiographic analysis of oro-facial manifestations|Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.
62657096|NCT00910585|EXPERIMENTAL|Active coaching|Telephone and in person coaching
61907410|NCT02415842||DQIV_NAS Group|Subjects 18-≤39 years of age (in D-QIV cohort of primary completed study FLU D-QIV-015 (201251) (A/Christchurch/16/2010 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012, B/Brisbane/60/2008)) who were administered 15 µg HA (no AS) of each of 4 strains (total 60 µg HA) at Day 0.
62291260|NCT04155502||Informational sites|These participants will be recruited from advertisements posted on informational websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
62291261|NCT04155502||Dating applications|These participants will be recruited from advertisements posted on dating applications. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
62291262|NCT02771834||Experimental|women with osteoporosis
62291263|NCT02771834||Control|women without osteoporosis
62291264|NCT03242655|EXPERIMENTAL|HCV GET-UP (Group Intervention)|HCV GET-Up (Group Evaluation and Treatment Uptake)
62291265|NCT03242655|NO_INTERVENTION|Control|Individual onsite HCV treatment at a primary care center
62291266|NCT06438328|ACTIVE_COMPARATOR|Left/ Right affected arm|
62657097|NCT00910585|ACTIVE_COMPARATOR|Usual care|Return to PCP for usual care
62657098|NCT05769101|EXPERIMENTAL|Multi-Ingredient Post-Workout Supplement|A 60 g dose of a commercially available Recovery supplement providing \~205 kcal including Proteins (+EAA), Carbohydrates, Creatine, and Vitamin D. Diluted in 350 ml of water.
62657099|NCT05769101|PLACEBO_COMPARATOR|Maltodextrin Supplement|An isoenergetic Maltodextrin supplement will be administered as placebo. Dissolved in 350 ml of water.
62657100|NCT05403918|ACTIVE_COMPARATOR|conventional physiotherapy|15 patients will receive conventional physiotherapy including a hot pack, TENS, therapeutic ultrasound, shoulder anteroposterior, posteroanterior, and inferior glides followed by active and active-assisted range of motion exercises, isometric exercises, Codman's pendulum exercises, wand, pulley, and finger ladder exercises.
62093566|NCT02034435|ACTIVE_COMPARATOR|Aim2- low salt diet and epleronone then amlodipine|Subjects on a low salt diet will receive Epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with Amlodipine 5mg for 8days and assessments will be made.
62291267|NCT06438328|OTHER|Grip strength|
62291268|NCT02567136||Amyotrophic Lateral Sclerosis|Patients with ALS
62291269|NCT02567136||Healthy Controls|Healthy control volunteers
62291270|NCT02747524|EXPERIMENTAL|Vita Mamba|Nutrient fortified peanut butter paste for 26 weeks.
62291271|NCT02747524|NO_INTERVENTION|Control|
62291272|NCT05851469|EXPERIMENTAL|RSP-26-01|
62291273|NCT05851469|EXPERIMENTAL|RSP-26-02|
62291274|NCT04928183|SHAM_COMPARATOR|Room Air Rebreathe|Rebreathe protocol will be completed with a room air syringe rather than CO
62291275|NCT04928183|EXPERIMENTAL|CO Rebreathe|Rebreathe protocol will be completed with Carbon Monoxide
62291276|NCT04364204|EXPERIMENTAL|Kangaroo mother care with bracelet|
62291277|NCT04364204|ACTIVE_COMPARATOR|Kangaroo mother care|
62291278|NCT01504932|EXPERIMENTAL|Arm I: BRB Lozenge|"Former oral cancer patients receive lozenges containing freeze-dried black raspberry (BRB) powder. They will take the lozenges four times each day (QID) by mouth (PO) for up to 6 months.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Black Raspberry (BRB) Lozenge Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
62093567|NCT02034435|ACTIVE_COMPARATOR|aim2- low salt diet and amlodipine then epleronone|Subjects on a low salt diet will receive Amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with Epleronone 50mg for 8days and assessments will be made.
61907411|NCT02415842||QPAN_C Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered 3.8 µg A/Indonesia/5/05 (H5N1) with AS03A on Day 0; phosphate buffer saline (PBS) preserved with 20 ppm thimerosal on Day 182; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Day 549.
61907412|NCT02415842||QPAN5_G Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered PBS preserved with 20 ppm thimerosal on Day 0; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Days 182 and 549.
61907413|NCT02415842||H5N1_VT Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed study H5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received two administrations of the adjuvanted (AS03A) pandemic influenza vaccine (3.8 µg) containing the Vietnam (VT) strain at Day 0 and Month 12.
62093568|NCT06691932||Mothers primarily feeding their baby expressed HM (Express Group)|
62657101|NCT05403918|EXPERIMENTAL|scapular stabilization exercises along with conventional physiotherapy|15 participants will receive conventional treatment along with scapular stabilization exercises program consisting of strengthening exercises (Middle Trapezius, Lower Trapezius, Serratus Anterior, and Rhomboid Muscles) and stretching exercises (Pectoralis Minor, Levator Scapulae, Upper Trapezius, Teres Major). Appropriate exercises will be given to patients according to the type of Scapular Dyskinesia.
62657102|NCT01777646|EXPERIMENTAL|MSC-NTF|
62657103|NCT02122419||lateral|spinal anesthesia performed during lateral position
61907414|NCT02415842||H5N1_IN Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed studyH5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received one administration(3.8 µg) of the adjuvanted (AS03A) pandemic influenza vaccine containing the Vietnam (VT) strain at Day 0 and one administration(3.8 µg) of the adjuvanted (AS03A) pandemic vaccine containing the Indonesia (IN) strain at Month 12.
61907415|NCT02415842||H5N1_PAS Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03B) pandemic vaccine with 1.9 µg HA (hemagglutinin) at Days 0 and 21.
62093569|NCT06691932||Mothers primarily feeding their baby directly at-the-breast (ATB Group)|
62093570|NCT04205032|EXPERIMENTAL|CARDIOSPACE II|Test of the different devices integrated in cardiospace II.
62093571|NCT02668835||Cohort 1|Idiopathic Parkinson's Disease as defined by the UK brain bank criteria and history of resting tremor.
62093572|NCT02668835||Cohort 2|Essential Tremor with history of resting tremor. Diagnosis made by a movement disorder specialist
62093573|NCT00393627|EXPERIMENTAL|1|Sleep Education Program: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
62093574|NCT00393627|PLACEBO_COMPARATOR|2|Routine medical care
62657104|NCT02122419||sitting|spinal anesthesia performed during sitting position
61907416|NCT02415842||H5N1_PCN Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered placebo at Days 0 and 21.
61907417|NCT06273137|EXPERIMENTAL|Positive affect treatment|PAT is a 15-week cognitive-behavioral therapy that focuses on increasing reward motivation and sensitivity at the neural, behavioral, and affective levels of analysis. These observed effects occur through PAT's effects on reward sensitivity and positive affect. Participants will be assigned to a therapist with training in cognitive-behavioral therapy who will meet with them weekly via telehealth.
62291279|NCT01504932|OTHER|Arm II: Biomarker Control|"Former oral cancer patients will not receive lozenges containing freeze-dried black raspberry (BRB) powder.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
62291280|NCT05588427|EXPERIMENTAL|Ketone group|Ketone esters will be provided
62291281|NCT05588427|PLACEBO_COMPARATOR|Placebo group|Ketone placebo will be provided
62464287|NCT03524469||Insulin resistant|"Insulin Resistance will be defined as meeting any of the following:~* pre-pregnant BMI ≥ 28 and failed the 28 week oral glucose screening test~* pre-pregnant BMI ≥ 28 and diagnosis of either A1 (diet controlled) or A2 (insulin-requiring) gestational diabetes during pregnancy, but insulin therapy discontinued after birth.~* pre-pregnant BMI ≥ 28 and diagnosed with type 2 diabetes during pregnancy~* pre-pregnant BMI ≥ 30, and unmediated."
62464288|NCT03659006|EXPERIMENTAL|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
62291282|NCT03913754||Lupus Patients with kidneys failure|Assessment of quality of life on everydays life trough questionnare
62291283|NCT03913754||Lupus Patients without kidneys failure|Assessment of quality of life on everydays life trough questionnare
62291284|NCT03607721|EXPERIMENTAL|DBS Patients Group|Body Motion Evaluation DARI
61907418|NCT06273137|NO_INTERVENTION|Waitlist|
61907419|NCT05711446|EXPERIMENTAL|Double Voiding|The participant will be instructed to void twice.
62464289|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
62291285|NCT03607721|ACTIVE_COMPARATOR|Control Group|Body Motion Evaluation DARI
62291286|NCT03576144|EXPERIMENTAL|BI 1265162|
62291287|NCT03576144|PLACEBO_COMPARATOR|Placebo|
62291288|NCT02639351|EXPERIMENTAL|LHD153R Formulation 1 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.
62291289|NCT02639351|EXPERIMENTAL|LHD153R Formulation 2 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.
62464290|NCT06485999||Teeth treated with the Biologically Oriented Preparation Technique (BOPT)|No interventions will be administered.
62464291|NCT01421030|OTHER|quality of life, clinical outcomes and costs|Quality of life, clinical outcomes and costs after two different treatment options in patients and closest relatives
62093575|NCT06132919|EXPERIMENTAL|MC2-25 cream|MC2-25 cream will be applied daily for 12 weeks
62657105|NCT06277167|EXPERIMENTAL|Human interferon alfa 1b inhalation solution (SAD)|Human interferon alfa 1b inhalation solution：200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups
62291290|NCT02639351|EXPERIMENTAL|LHD153R Formulation 3 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.
62291291|NCT02639351|EXPERIMENTAL|LHD153R Formulation 4 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.
62657106|NCT06277167|PLACEBO_COMPARATOR|Human interferon alfa 1b inhalation solution placebo (SAD)|Human interferon alfa 1b inhalation solution placebo ：200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups
62657107|NCT06277167|EXPERIMENTAL|Human interferon alfa 1b inhalation solution (MAD)|Human interferon alfa 1b inhalation solution drug product：1,200,000 IU, and 1,80,000 IU dose groups
62657108|NCT06277167|PLACEBO_COMPARATOR|Human interferon alfa 1b inhalation solution placebo (MAD)|Human interferon alfa 1b inhalation solution placebo ：1,200,000 IU, and 1,80,000 IU dose groups
62657109|NCT01084304||Active|Use of ovulation tests to aid conception
62657110|NCT01084304||Control|No ovulation tests to aid conception
62657111|NCT06518291|ACTIVE_COMPARATOR|nitrofurantoin group|
62291292|NCT02639351|ACTIVE_COMPARATOR|MenC Group|Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.
62291293|NCT03809897|EXPERIMENTAL|Varenicline|Patients randomized to the experimental arm will receive 3 days of 0.5 mg of varenicline, followed by 4 days of 1 mg of varenicline (until day 7). Finally, until week 12, they will receive 2 mg of varenicline. Varenicline is supplied in capsules and taken orally.
62291294|NCT03809897|ACTIVE_COMPARATOR|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21 mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
61907420|NCT05711446|ACTIVE_COMPARATOR|Regular Voiding|The participant will be instructed to void normally.
62464292|NCT05804890||ZORFLEX|Activated Carbon Cloth Dressing
62464293|NCT05804890||AQUACEL|Silver-Based Dressing
62464294|NCT05083221|EXPERIMENTAL|Hear-Talk-Activity audiological rehabilitation program|Audiological intervention program
62657112|NCT06518291|ACTIVE_COMPARATOR|Fosfomycin group|
62657113|NCT04926181|EXPERIMENTAL|Single Arm: Apalutamide + Cetrelimab|Participants will be given Apalutamide tablets combined with infusions of Cetrelimab in 28-day cycles, for up maximum of two years.
62657114|NCT02819128|OTHER|Homeless people|Populations of homeless households in Marseille.
62657115|NCT00452569|EXPERIMENTAL|A|Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
62657116|NCT00452569|EXPERIMENTAL|B|Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
62657117|NCT00452569|EXPERIMENTAL|C|Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
62657118|NCT00452569|ACTIVE_COMPARATOR|D|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
62657119|NCT05482867||Cohort 1|Cohort 1, healthy adults (n = 5), will receive an ICG infusion of 1 mg/min for 120 minutes.
62657120|NCT05482867||Cohort 2|If no dose limiting adverse effects are observed in Cohort 1, then Cohort 2, healthy adults (n = 10), will receive an ICG infusion of 2 mg/min for 120 minutes. If there are no dose limiting adverse events and there is evidence of ICG-labeling of PBMCs, the 2 mg/min infusion rate will be used for the remainder of the study.
61907421|NCT02483767|EXPERIMENTAL|standard chemotherapy with goserelin|standard chemotherapy with the GnRH agonist goserelin
62093576|NCT06132919|EXPERIMENTAL|MC2-25-vehicle|MC2-25 vehicle will be applied daily for 12 weeks
61907422|NCT02483767|ACTIVE_COMPARATOR|standard chemotherapy without goserelin|standard chemotherapy without goserelin
61907423|NCT01510457|PLACEBO_COMPARATOR|Sugar Pill|BID placebo
61907424|NCT01510457|EXPERIMENTAL|Milnacipran|Uptitration from 10mg to 50mg BID Milnacipran
61907425|NCT04882345|EXPERIMENTAL|Almonertinib group|Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
61907426|NCT05418309|EXPERIMENTAL|Tislelizumab and Nab-Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
61907427|NCT00118456|EXPERIMENTAL|1|Continuous daily dosing
61907428|NCT00118456|EXPERIMENTAL|2|Monday, Wednesday, Friday Dosing
61907429|NCT03259620|EXPERIMENTAL|CLS006|Furosemide Topical Gel, 0.125%
61907430|NCT03259620|EXPERIMENTAL|CLS006 Vehicle|Vehicle Topical Gel
62093577|NCT00987792||Group 1|
62093578|NCT03923387|EXPERIMENTAL|MynxGrip|MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
62291295|NCT00766792|EXPERIMENTAL|1|Nocturnal dialysis
62291296|NCT00766792|ACTIVE_COMPARATOR|2|Standard dialysis
62291297|NCT04092842|EXPERIMENTAL|Group intervention: Silicone prothesis|Breast cancer conservative surgery will be performed by removing the tumor according to the usual technique and then the defect generated will be filled with a silicone prosthesis of the same size. Said prosthesis will be covered with fat and subcutaneous cellular tissue and then the skin will be closed.
62291298|NCT04092842|ACTIVE_COMPARATOR|Group control: Usual surgical technique|Breast cancer conservative surgery will be performed according to the usual surgical technique, that is, removing the tumor and covering the defect by mobilizing the breast tissue and then closing the skin.
62464295|NCT05083221|NO_INTERVENTION|Control group|Waitlist control program
61907431|NCT03124667|EXPERIMENTAL|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
62464296|NCT00059865|EXPERIMENTAL|pemetrexed + gemcitabine|"Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
61907432|NCT03124667|ACTIVE_COMPARATOR|Video Condition|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
62464297|NCT05237310|ACTIVE_COMPARATOR|Standard Colonoscopy followed by CAD-EYE|Subjects will undergo standard colonoscopy immediately followed by CAD-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
62464298|NCT05237310|ACTIVE_COMPARATOR|CAD-EYE followed by Standard Colonoscopy|Subjects will undergo CAD-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
62464299|NCT05237310|ACTIVE_COMPARATOR|Standard Colonoscopy followed by combined CAD-EYE and G-EYE colonoscopy|Subjects will undergo standard colonoscopy immediately followed by combined CAD-EYE and G-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
62464300|NCT05237310|ACTIVE_COMPARATOR|Combined CAD-EYE and G-EYE colonoscopy followed by Standard Colonoscopy|Subjects will undergo combined CAD-EYE and G-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
62464301|NCT01726205|ACTIVE_COMPARATOR|pregabalin|perioperative pregabalin starting the evening before surgery, and for five days postoperatively
62464302|NCT01726205|ACTIVE_COMPARATOR|pregabalin and continuous wound infusion|Pregabalin as previous group and continuous infusion of ropivacaine 0.2% via a wound catheter
62464303|NCT01726205|PLACEBO_COMPARATOR|placebo|Placebo drug and normal saline infusion
62464304|NCT00704821|EXPERIMENTAL|Stage 1|In Stage 1, PTC299 will be given orally twice a day (BID) each day at about the same time each day for the first 28 days of each cycle. Each cycle will constitute a 4-week (28 days) period followed by a ≥2-week (14-day) washout period. Participants will be assigned to 0.3 milligrams (mg)/kilograms (kg)/dose BID, 0.6 mg/kg/dose BID, or 1.2 mg/kg/dose BID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
61907433|NCT02788279|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
62657121|NCT05482867||Cohort 3|Cohort 3, healthy elderly adults, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed in the satellite group, then a further 10 healthy elderly adults will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 3).
61907434|NCT02788279|EXPERIMENTAL|Cobimetinib + Atezolizumab|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
61907435|NCT02788279|ACTIVE_COMPARATOR|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
61907436|NCT05729867|EXPERIMENTAL|fully covered self-expanable metal stent with HCC|This prospective cohort is comprised of patients with malignant biliary obstruction caused by hepatocellular carcinoma who were treated with endoscopic biliary drainage using fully covered self expandable metal stent.
61907437|NCT01455909|EXPERIMENTAL|ITCA 650 60 mcg/day|
61907438|NCT01455909|ACTIVE_COMPARATOR|sitagliptin|sitagliptin 100 mg/day
62093579|NCT03923387|ACTIVE_COMPARATOR|Manual compression|Manual compression hemostasis
62093580|NCT04467957|EXPERIMENTAL|CF Cohort|16 Cystic Fibrosis Patients will undergo MRI imaging before and 6 months after initiation of triple-combination modulator therapy. Initiation of triple -combination modulator therapy will be determined by clinician and family prior to study enrollment. Hyperpolarized Xenon 129 will be administered through inhalation at two MRI imaging study visits.
61907439|NCT06282458|EXPERIMENTAL|Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily|"Approximately 50 subjects will be dosed with semaglutide injected once-weekly and enobosarm 3 mg QD by mouth (E3G) daily for approximately 112 days. Semaglutide dose escalation will occur as follows:~Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg~From Day 112 to Day 196, patients will continue to receive 3 mg enobosarm QD by mouth and will discontinue the semaglutide."
62657122|NCT05482867||Cohort 4|Cohort 4, AD patients, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed, then a further 10 AD patients will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 4). Recruitment of AD patients will begin if there are no dose limiting adverse effects observed in the satellite group of healthy elderly.
62657123|NCT03150212|EXPERIMENTAL|Saccharomyces cerevisiae CNCM I-3856|
62657124|NCT03150212|PLACEBO_COMPARATOR|Placebo|
61907440|NCT06282458|EXPERIMENTAL|Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily|"Approximately 50 subjects will be dosed with semaglutide injected once-weekly and enobosarm 6 mg QD by mouth (E3G) daily for approximately 112 days. Semaglutide dose escalation will occur as follows:~Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg~From Day 112 to Day 196, patients will continue to receive 6 mg enobosarm QD by mouth and will discontinue the semaglutide."
61907441|NCT06282458|PLACEBO_COMPARATOR|GLP-1 receptor agonist and Placebo QD by mouth (PG) daily|"Approximately 50 subjects will be dosed with semaglutide injected once-weekly and placebo QD by mouth (PG) daily for approximately 112 days. Semaglutide dose escalation will occur as follows:~Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg~From Day 112 to Day 196, patients will continue to receive placebo QD by mouth (PG) and will discontinue the semaglutide."
61907442|NCT02917811||ICU patients|
61907443|NCT02045030|EXPERIMENTAL|aflibercept and FOLFIRI|aflibercept and FOLFIRI
61907444|NCT05055492|NO_INTERVENTION|Control period|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
61907445|NCT05055492|ACTIVE_COMPARATOR|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
61907446|NCT03135418|EXPERIMENTAL|Intervention|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
62093581|NCT04467957|EXPERIMENTAL|Control Cohort|10 Healthy control study participants matched for age and gender will undergo one MRI imaging study visit. Hyperpolarized Xenon 129 will be administered through inhalation at one MRI imaging study visit.
61907447|NCT03135418|SHAM_COMPARATOR|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift a will be used to create an immersive visual environment.Patient will be watching the premade scenarios without interaction. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire, Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
62093582|NCT05365074||chloroprocaine anesthesia for arthroplasty|patients having predicted uncomplicated surgery for total or unicompartment knee arthroplasty of anterior access total hip arthroplasty, operated under spinal anesthesia with 50 mg of chloroprocaine
62093583|NCT05518825|EXPERIMENTAL|Fortimel/Nutridrink Compact Protein|Twice daily serving of the study product
62291299|NCT03663257||AneurysmFlow Observational Cohort|Subjects with unruptured, \>5mm saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent enrolled at the centers participating in this CARO study.
62093584|NCT04430517|EXPERIMENTAL|Mild Cognitive Impairment and Alzheimer's Dementia|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
62093585|NCT05636436|EXPERIMENTAL|Low dose vaccine group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62093586|NCT05636436|EXPERIMENTAL|Low dose adjuvant group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
62291300|NCT01990261||Erlotinib|Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
62291301|NCT03050164|EXPERIMENTAL|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
62657125|NCT05672875||Healthy and Symptomatic Subjects|Blood sample testing on the Anthrax LF Dx System
62657126|NCT01745510|EXPERIMENTAL|DHA Group|"DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.~They will receive one dose, administered by enteral feeding every 24 h during 14 days"
62657127|NCT01745510|PLACEBO_COMPARATOR|Control Group (Placebo)|"Control group will receive sunflower oil which is the excipient of the DHA in this study.~They will receive one dose every 24 h during 14 days."
62657128|NCT01548235||BIAsp 30 users|
62093587|NCT05636436|EXPERIMENTAL|High dose vaccine group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62093588|NCT05636436|EXPERIMENTAL|High dose adjuvant group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
62093589|NCT05636436|PLACEBO_COMPARATOR|Placebo group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
62093590|NCT05636436|EXPERIMENTAL|Low dose vaccine group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62093591|NCT05636436|EXPERIMENTAL|Low dose adjuvant group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
62657129|NCT02367560|ACTIVE_COMPARATOR|NDSSI|Participants in this arm of the trial will be referred for Needle decompression with subacromial steroid (Depo medrol) injection (NDSSI) as their treatment for calcific tendinitis
62657130|NCT02367560|ACTIVE_COMPARATOR|SWT|Participants in this arm of the trial will be referred for Shockwave therapy (SWT) using an Ultrasound device, delivered by a physiotherapist, as their treatment for calcific tendinitis
62291302|NCT03050164|ACTIVE_COMPARATOR|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
62291303|NCT03219164|EXPERIMENTAL|AZLI + Placebo|75 mg/ml of aztreonam will be administered thrice daily (TID) for 14 days followed by placebo to match (PTM) aztreonam TID for 14 days.
62291304|NCT03219164|EXPERIMENTAL|AZLI|75 mg/ml of aztreonam will be administered TID for 28 days.
62093592|NCT05636436|EXPERIMENTAL|High dose vaccine group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62093593|NCT05636436|EXPERIMENTAL|High dose adjuvant group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
62093594|NCT05636436|ACTIVE_COMPARATOR|Shingrix® group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).
62093595|NCT05636436|PLACEBO_COMPARATOR|Placebo group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
62093596|NCT06688708|EXPERIMENTAL|Use vibrating foot orthosis with tactile stimulation|"32 participants were assigned to use a vibrating foot orthosis (VFO) with tactile stimulation (using the VFO combined with a random 0-100 Hz square wave pulse stimulus with pseudorandom white noise via a stochastic resonance approach) at home for 30 days. Participants had to conduct intervention for 60 minutes a day. 90% VPT of each participant was chosen as the subthreshold stimulation level for tactile stimulation. Posttests were given by three consecutive appointments on the 1st day, the 15th day, and the 30th day.~Participants had to meet a prosthetist and orthotist (PO) at the experimental site on the three consecutive appointments for posttest evaluation.~After completing this intervention, participants were followed up the VPT level by evaluation every 7 days."
62093597|NCT06688708|SHAM_COMPARATOR|Use vibrating foot orthosis without tactile stimulation|"32 participants were assigned to use the VFO without tactile stimulation (using the VFO with only vibration 100 Hz frequency ) at home for 30 days. Participants were blinded. Even though there was no tactile stimulation, the device still performed vibration.~Posttests were given by three consecutive appointments on the 1st day, the 15th day, and the 30th day.~Participants had to meet a PO at the experimental site on the three consecutive appointments for posttest evaluation. Noted, there was no follow-up after completing this intervention."
62093598|NCT06698198|EXPERIMENTAL|Group 1: Pneumococcal Conjugate Vaccine (PCV) SP0202-I|Participants will receive 1 intramuscular injection of PCV formulation SP0202-I
62093599|NCT06698198|EXPERIMENTAL|Group 2: Pneumococcal Conjugate Vaccine (PCV) SP0202-II|Participants will receive 1 intramuscular injection of PCV formulation SP0202-II
62093600|NCT06698198|EXPERIMENTAL|Group 3: Pneumococcal Conjugate Vaccine (PCV) SP0202-III|Participants will receive 1 intramuscular injection of PCV formulation SP0202-III
62093601|NCT06698198|EXPERIMENTAL|Group 4: Pneumococcal Conjugate Vaccine (PCV) SP0202-IV|Participants will receive 1 intramuscular injection of PCV formulation SP0202-IV
62093602|NCT06698198|ACTIVE_COMPARATOR|Group 5: Prevnar 13®|
62093603|NCT04217785|ACTIVE_COMPARATOR|A-AT eye drops|Optive Fusion UD eye drops + Genteal lubricant gel
62093604|NCT04217785|ACTIVE_COMPARATOR|B-UCS eye drops|UCS eye drops + GentTeal lubricant gel
62093605|NCT04207255|EXPERIMENTAL|Cohort 2: Opaganib with abiraterone|
62093606|NCT04207255|EXPERIMENTAL|Cohort 3: Opaganib with enzalutamide|
62093607|NCT04207255|EXPERIMENTAL|Cohort 1a: Opaganib with abiraterone|
62657131|NCT01531634|ACTIVE_COMPARATOR|Dynamic Cognitive Intervention Group|Twelve Meetings of Dynamic Cognitive Intervention.
62093608|NCT04207255|EXPERIMENTAL|Cohort 1b: Opaganib with enzalutamide|
62093609|NCT05147805|EXPERIMENTAL|Treprostinil Palmitil Inhalation Powder|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
62093610|NCT05147805|PLACEBO_COMPARATOR|Placebo|Participants will be administered a placebo matching TPIP once per day for 16 weeks.
62093611|NCT02001090||CABG patients|Patients undergoing cardiac surgery for coronary artery disease with the use of heart-lung machine in St Olavs Hospital Trondheim University Hospital.
62093612|NCT05161715|EXPERIMENTAL|10mg obicetrapib tablets|10mg obicetrapib (5mg tablets) administered orally daily for 24 weeks
62093613|NCT04381897|EXPERIMENTAL|Group A: NAC 1800mg then Placebo|NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
62093614|NCT04381897|EXPERIMENTAL|Group B: Placebo then NAC 1800mg|NAC Placebo-matching solution, orally every 8 hours, for 8 weeks, followed by a 2-week wash-out period, followed by NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
62291305|NCT05317767|EXPERIMENTAL|Flu-M|300 children that will be vaccinated with a single dose of the Flu-M vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
62291306|NCT05317767|ACTIVE_COMPARATOR|Ultrix|300 children that will be vaccinated with a single dose of the Ultrix® vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
62291307|NCT00906438|PLACEBO_COMPARATOR|Control|
62291308|NCT00906438|EXPERIMENTAL|Treated|
62093615|NCT00027612|EXPERIMENTAL|irinotecan + carmustine and radiation|"Phase II (patients receiving concurrent EIACs or non-EIACs open to accrual as of 3/5/2005): Patients receive irinotecan at the recommended dose, carmustine, and cranial irradiation as in phase I.~Patients with disease progression are followed every 3 months for 5 years and then annually for up to 10 years.~Patients taken off study for reasons other than disease progression are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
62291309|NCT05638100||Rivaroxaban-H|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(20mg/15mg)
62657132|NCT01531634|NO_INTERVENTION|No Additional Intervention|
62737465|NCT05421130|OTHER|SP-GRIPFLOW|This is a single-arm clinical investigation. Enrolled subjects will have cerebral perfusion with the investigational device during surgical repair of the aortic arch. A total of 1-3 investigational devices will be used per subject.
62291310|NCT05638100||Rivaroxaban-M|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(10mg)
62291311|NCT05638100||Rivaroxaban-L|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(7.5mg)
62737466|NCT05339841|NO_INTERVENTION|Control group|Subjects monitored following usual-care.
61907448|NCT01185353|EXPERIMENTAL|1 mg LY3009104 once daily|Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
62291312|NCT03894345|EXPERIMENTAL|Open-label treatment with Prazosin|"Week 1 Day 1-3: 0.5 mg at bedtime Day 4-7: 1.0 mg at bedtime Week 2 Day 8-10: 2.0 mg at bedtime Day 11-14: 4.0 mg at bedtime Week 3 2 mg in the morning, 4 mg at bedtime Week 4 4 mg in the morning, 4 mg at bedtime Week 5 4 mg in the morning, 6 mg at bedtime Week 6 4 mg in the morning, 8 mg at bedtime~Dosage of Prazosin will be titrated at the discretion of the study physician."
62657133|NCT04470427|EXPERIMENTAL|mRNA-1273|"Part A (Blinded): Participants will receive 1 intramuscular (IM) injection of 100 microgram (μg) mRNA-1273 on Day 1 and on Day 29.~Part B (Open-label): Participants who receive mRNA-1273-matching placebo during Part A and choose to be unblinded by participating in Part B, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1 and Day 29. Participants who are only able to receive 1 dose of mRNA-1273 due to administrative reasons, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1, if the participant chooses.~Part C: Eligible participants in Part B who choose to receive booster dose of mRNA-1273, will receive 1 IM injection of 50 μg mRNA-1273 on Day 1."
62464305|NCT00704821|EXPERIMENTAL|Stage 2|In Stage 2, PTC299 will be given BID or 3 times a day (TID) orally each day at about the same time each day; therefore, 84 (for BID) or 126 (for TID) doses of PTC299 will be delivered during the 6-week (42-day) period in each cycle. Each participant will be assigned to 100 mg/dose BID, 100 mg/dose TID, 120 mg/dose TID, 160 mg/dose TID, or 200 mg/dose TID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
62464306|NCT00704821|EXPERIMENTAL|Stage 3|In Stage 3, PTC299 will be given BID or TID (for total of 42 \[for BID\] or 63 \[for TID\] doses) orally about same time per day starting on Day 1 in each 3-week (21-day) cycle. Starting dose will be 1 dose level below maximum tolerated dose (MTD) from Stage 2 or 80 mg/dose BID if 100 mg/dose TID in Stage 2 exceeds MTD. Dose escalation will be based on safety evaluations by Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant. Participants will also receive docetaxel as a 1-hour IV infusion on Day 1 per cycle at starting dose of 75 mg/m\^2 with body surface area calculation based on body weight. Dose will be sequentially reduced to 60 and 50 mg/m\^2 in participants with a docetaxel-related dose-limiting toxicity (DLT). Participants will be medicated with oral corticosteroids with docetaxel administration. Recommended dose is 8 mg BID dexamethasone for 3 days starting 1 day prior to docetaxel administration.
62657134|NCT04470427|PLACEBO_COMPARATOR|Placebo|Part A only: Participants will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29, if the participant chooses.
62657135|NCT01212510|OTHER|Tumor markers|measurement of tumor markers ( blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA )
62657136|NCT05722301|EXPERIMENTAL|Testosterone Therapy|
62657137|NCT05722301|PLACEBO_COMPARATOR|No Testosterone Therapy|
61907449|NCT01185353|EXPERIMENTAL|2 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
62093616|NCT04805645||Non-Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit which died before or on day 28 post ICU admission
62093617|NCT04805645||Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit whom are still alive on day 28 post ICU admission
62291313|NCT03849326|EXPERIMENTAL|"Non-fatigued patients"|
62291314|NCT03849326|EXPERIMENTAL|"Fatigued patients"|
62657138|NCT00997529|EXPERIMENTAL|1|
62291315|NCT00468897|EXPERIMENTAL|Treatment Arm AB|A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses.
62291316|NCT00468897|EXPERIMENTAL|Treatment Arm BA|A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses.
62657139|NCT05884450|EXPERIMENTAL|Experiment|In the experimental group, acupressure will be applied to the patients by the researchers twice a day, every day for two weeks, for 3 minutes to each point (Lu1, Lu10, P6).
62657140|NCT05884450|NO_INTERVENTION|Control|No application will be made to the control group.
61907450|NCT01185353|EXPERIMENTAL|4 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
61907451|NCT01185353|EXPERIMENTAL|8 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
61907452|NCT01185353|PLACEBO_COMPARATOR|Placebo once daily|Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
62291317|NCT02891421|OTHER|Therapeutic Horseback Riding|Therapeutic Horseback Riding: Veterans were matched to a horse by the instructor and occupational therapist for best fit and the same horse was ridden each week
62657141|NCT02318940|OTHER|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.~access will be through the femoral vein only"
61907453|NCT01185353|EXPERIMENTAL|2 mg LY3009104 twice daily|(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
61907454|NCT02445547|EXPERIMENTAL|UC-MSCs|UC-MSCs by peripheral intravenous infusion
61907455|NCT02445547|ACTIVE_COMPARATOR|control|received hormone maintenance therapy
61907456|NCT00539175|ACTIVE_COMPARATOR|2|active treatment with infrared light
61907457|NCT00539175|PLACEBO_COMPARATOR|1|sham (placebo) treatment without infrared light
62093618|NCT05585242|EXPERIMENTAL|Intervention|"The program consists of brief weekly videos, each addressing a particular Acceptance and Commitment Therapy technique to be implemented that week. Participants receive the videos by email from the researcher and watch them on their own. Each video also assigns a homework exercise for the participant to complete that week and includes a summary of the module."
62291318|NCT02891421|OTHER|Standard Care|Participants received standard care.
62291319|NCT00215930|EXPERIMENTAL|Double Agent Chemotherapy|Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of ERCC1 and RRM1.
62291320|NCT00872222|OTHER|Ceramic-on-Ceramic|Pinnacle™ Acetabular System with ceramic liner
62657142|NCT02318940|ACTIVE_COMPARATOR|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
62657143|NCT00849056|PLACEBO_COMPARATOR|placebo + pioglitazone (with or without metformin)|Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
62657144|NCT00849056|EXPERIMENTAL|albiglutide + pioglitazone (with or without metformin)|albiglutide weekly injection + pioglitazone (with or without meformin)
62657145|NCT01722799|EXPERIMENTAL|Drug elluting Balloon (DEB)|Is a coronary dilating device with Paclitaxel ® drug delivery, for dilatation and provisional spot bare metal stenting (BMS).
62737467|NCT05339841|EXPERIMENTAL|Intervention group|Subjects in the intervention group, in addition to usual-care, will download a mHealth App that contains educational information promoting healthy lifestyle behaviours. The participant will be also able to self-monitor his/her clinical status regarding hypertension, diabetes or hypercholesterolemia.
62464307|NCT00704821|EXPERIMENTAL|Stage 4|In Stage 4, PTC299 will be given orally each day continuously starting on first day of each cycle at about same time per day; so, 42 doses of PTC299 will be delivered for 3 weeks (21-day) in Cycle 1 (BID dosing), and 84 doses will be delivered for 3-weeks (21-day) in Cycle 2 and beyond (TID dosing). For Cycle 1, participants will be assigned to 600, 800, or 1000 mg/dose BID sequentially based on safety evaluations by Sponsor's medical monitor at enrollment. For Cycle 2 and beyond, participants will receive PTC299 160 mg/dose TID. During Cycle 1, Cohort 1 participants will eat a meal containing of ≤15 grams (g) of dietary fat and Cohort 2 participants will eat a meal containing of ≤25 g of dietary fat prior to each dose of PTC299. If ≤2 of 6 participants had experienced DLT during Cycle 1 in either diet plan, then the dose will be escalated to 800 mg BID in Cohort 3 at the optimal diet. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
62093619|NCT05585242|NO_INTERVENTION|Waistlist|Participants in the waitlist control condition will complete the same measures as the intervention group. After they have completed their one-month follow-up measures they will be given the opportunity to receive the intervention.
62093620|NCT02390297||Single|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
62093621|NCT05873842||PTA-assisted group|
62093622|NCT05873842||IVL-assisted group|
62093623|NCT01033643|EXPERIMENTAL|MK-3614 0.25 mg (Panel A)|Participants received 0.25 mg of MK-3614 twice daily (BID) every 12 hours orally for 10 days.
62093624|NCT01033643|EXPERIMENTAL|MK-3614 0.50/0.25 mg (Panel B)|Participants received 0.50 mg of MK-3614 in the morning (AM) and 0.25 mg of MK-3614 in the evening (PM) 12 hours apart orally for 10 days.
62093625|NCT01033643|EXPERIMENTAL|MK-3614 0.50/0.25 mg (Panel C Repeat)|Participants were to receive 0.75 mg of MK-3614 BID every 12 hours orally for 10 Days. Per protocol amendment, the Panel B dose was repeated, and participants received instead 0.50 mg of MK-3614 in the AM, and 0.25 mg of MK-3614 in the PM, 12 hours apart orally for 10 days.
62093626|NCT01033643|EXPERIMENTAL|MK-3614 0.50 mg (Panel D)|Participants received 0.50 mg of MK-3614 three times a day (TID) orally every 8 hours on Day 1 followed by a wash out period for Days 2, 3 and 0.50 mg of MK-3614 every 12 hours orally for 10 days (Days 4-13).
62093627|NCT01033643|EXPERIMENTAL|MK-3614 0.50 mg (Panel E)|Participants were to receive orally 0.50 mg of MK-3614 BID every 12 hours on Day 1 followed by 3 doses (0.50/0.50/0.25 mg) of MK-3614 each 8 hours apart on Day 2; three doses of 0.50 mg of MK-3614 8 hours apart on Days 3,4; and 0.75 mg of MK-3614 BID every 12 hours on Days 5-14. No participants were enrolled in this group.
62737468|NCT05712096||EVUSHELD Arm|Individuals given EVUSHELD for pre-exposure prophylaxis
62737469|NCT05712096||Concurrent Control Arm|Individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld
62093628|NCT01033643|PLACEBO_COMPARATOR|Placebo (All Panels)|Participants received a dose matched placebo orally according to randomization.
62093629|NCT06410443|EXPERIMENTAL|Glucocorticoids+routine treatment group|Dexamethasone retention enema
62093630|NCT06410443|ACTIVE_COMPARATOR|Routine treatment group|Routine treatment of acute radiation-induced intestinal injury according to the current practice guideline
62093631|NCT06667856|ACTIVE_COMPARATOR|Asynchronous telerehabilitation group|
62093632|NCT06667856|ACTIVE_COMPARATOR|Synchronous telerehabilitation group|
62093633|NCT00821236|ACTIVE_COMPARATOR|Wavelight|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
62093634|NCT00821236|ACTIVE_COMPARATOR|AMO/VISX CustomVue|AMO/VISX CustomVue™
62093635|NCT00821236|ACTIVE_COMPARATOR|LADARVision 4000 excimer laser|LADARVision 4000 excimer laser
62093636|NCT00672152|EXPERIMENTAL|A-WT1 derived peptides|"Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:~* WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL~* WT peptide #2: HLA-A24 restricted: CMTWNQMNL~* WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~* WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
62093637|NCT02928939||Multimorbid patients|
62093638|NCT06528496|EXPERIMENTAL|Participants with Neuroblastoma|Participants will receive 4 cycles of induction chemotherapy followed by a response-based intervention.
62093639|NCT01733134|EXPERIMENTAL|Standard therapy plus Tolvaptan|Patient in the interventional group will receive tolvaptan in addition to standard therapy
62093640|NCT01733134|PLACEBO_COMPARATOR|Standard therapy plus placebo|
61907458|NCT04610957|EXPERIMENTAL|The 1st group|included eighty (80) women receiving Clomiphene citrate (CC) in the form of (Clomid 50 mg tablet, Sanofi Aventis, France) at dose (100 mg/day in two divided doses, starting from day 3 to day 7 of the cycle), plus Phytoestrogens (Isoflavonoids) in the form of (RosaFem 800 mg tablet, DeluxLab, Egypt) at dose (1600 mg/day in two divided doses (each dose one tablet), starting from day 3 to day 12 of the cycle
61907459|NCT04610957|EXPERIMENTAL|The 2nd group|included eighty (80) women receiving Clomiphene citrate only, at dose (100 mg/day, starting from day 3 to day 7 of the cycle).
61907460|NCT00540618|ACTIVE_COMPARATOR|1|MEDI-507
62093641|NCT03695289|EXPERIMENTAL|iOTA-SMI|Participants randomized to iOTA-SMI arm will participate in a 16 week interactive obesity treatment approach (iOTA) program approach.
62093642|NCT03695289|ACTIVE_COMPARATOR|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly in-person health coaching visits for 16 weeks.
62093643|NCT01902901|ACTIVE_COMPARATOR|Usual care|Requested carrier status testing.
62093644|NCT01902901|EXPERIMENTAL|Whole Genome Sequencing|These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
62093645|NCT05929937|OTHER|Minimal Opioids|Standard of care 5 tablets of Oxycodone (5mg) every 6 hours as needed for pain
62093646|NCT05929937|OTHER|No opioids|Standard of care
62093647|NCT03541811||patients with hemophilia (16-45y)|not applicable (no intervention administered)
62093648|NCT03541811||peer-matched healthy control|not applicable (no intervention administered)
62093649|NCT03382821|ACTIVE_COMPARATOR|Transforaminal ESI with dexamethasone|Group 1: Transforaminal cervical ESI with dexamethasone sodium phosphate
62093650|NCT03382821|ACTIVE_COMPARATOR|Transforaminal catheter-targeted ESI with triamcinolone|Group 2: Catheter-targeted cervical ESI with triamcinolone acetonide
62464308|NCT04154579|EXPERIMENTAL|HeRe We Arts|This is an 8 week, arts-based session that includes educational \& experiential components. Topics include: Introduction to Arts \& Health; Music, Well-Being, \& Resilience; Movement \& Physical Activity; Art \& Well-Being; Writing \& Communication/Self-Expression; Theater \& Socialization; Art Appreciation \& a Healthy Brain; \& Summary/Integration of the Arts into Daily Lives.
61907461|NCT00540618|PLACEBO_COMPARATOR|2|
61907462|NCT00540618|ACTIVE_COMPARATOR|3|MEDI-507
61907463|NCT00540618|ACTIVE_COMPARATOR|4|MEDI-507
61907464|NCT03812237|EXPERIMENTAL|(EWB) Early Weight Bearing (2 Weeks Post-op)|Subjects in the EWB group were allowed to begin bearing 50 pounds (lbs) through their hindfoot in either the boot or the short leg cast at the two-week visit. They were allowed to advance their weightbearing as tolerated by 25 lbs every four days until full weightbearing through the hindfoot was achieved.
61907465|NCT03812237|NO_INTERVENTION|(SOC) Standard of Care Weight Bearing (6-8 Weeks Post-op)|Subjects in the SOC group were allowed to heel touch weightbear for balance only on the operative foot until the six to eight week visit. At this visit all subjects were placed into a short leg walking boot. Non-weightbearing patients were permitted to begin the progressive weightbearing protocol, without hindfoot restriction.
61907466|NCT02777320|EXPERIMENTAL|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
62093651|NCT03679130|EXPERIMENTAL|Structured exercise training (EXE)|Structured supervised exercise training (EXE) contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
62093652|NCT03679130|EXPERIMENTAL|Motivational counseling (MOT)|Motivational counseling supported by health technology (MOT) contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
62093653|NCT03679130|NO_INTERVENTION|Control group (CON)|Control group receiving standard treatment.
62093654|NCT06003101|EXPERIMENTAL|Bone marrow aspirate concentrate (BMAC)|Patients randomly allocated to receive BMAC will undergo hip arthroscopy and will receive PRP/PPP/BMAC application through the PI's standardized method of harvest, processing, and application.
62093655|NCT06003101|PLACEBO_COMPARATOR|Control|Patients allocated to the control cohort will receive standard of care hip arthroscopy without PRP/PPP/BMAC application.
62291321|NCT01267955|EXPERIMENTAL|Treatment (vismodegib)|Patients receive vismodegib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62291322|NCT04947475|EXPERIMENTAL|Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program|There are two objectives to the Brief Intervention. First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder.
62657146|NCT01722799|ACTIVE_COMPARATOR|Drug elluting coronary stent (DES)|The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm.
62464309|NCT04154579|ACTIVE_COMPARATOR|HeRe We Ed (Health Education Group)|This is an 8 week, non-arts-based health education session that includes educational \& some experiential components. Topics include: Introduction to Health, Resilience, \& Well-Being; Nutrition \& Healthy Eating; Exercise, Chair Yoga, \& Sleep; Mental Health, Stress Management, \& Life Satisfaction; Holistic Approaches: Wellness, Integrative Medicine, \& Complementary \& Alternative Medicine; Chronic Illnesses \& Chronic Pain; Health \& Behaviors; Summary \& Navigating the Healthcare System.
62464310|NCT03799653||Nurses|All subjects are registered nurses in Xiamen, China
62657147|NCT00596635|NO_INTERVENTION|Control Group|No cranberry capsules administered
61907467|NCT02777320|EXPERIMENTAL|Ibuprofen group|Second Group: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
61907468|NCT04628377||Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (JACC Cardiovascular Intervention 2020;13:1155-67), which evaluated invasive physiologic indices from culprit and non-culprit vessels of acute myocardial infarction patients. From the study cohort, 31 STEMI patients who underwent IMR measurement in culprit vessel after successful revascularization will be analyzed. In these patients, diagnostic accuracy of angiography-derived IMR will be compared with invasive IMR.
61907469|NCT04628377||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the culprit vessel after successful revascularization. Those patients have follow-up data after 10 years from index procedure. This cohort is STEMI subgroup derived from Institutional registry of Samsung Medical Center, whose results were previously published (JACC Cardiovascular Intervention. 2019 Apr 8;12(7):607-620.) Among 490 STEMI patients from the overall study cohorts, 309 patients with available angiograms and who were suitable for angiographic FFR and IMR measurement will be analyzed. Primary clinical outcome will be cardiac death at 10 years from index procedure. Secondary outcome will be any myocardial infarction, ischemia-driven revascularization, definite or probable stent thrombosis, congestive heart failure admission at 10 years from index procedure.
62093656|NCT05118932|EXPERIMENTAL|Mindful Movement Intervention|"The Mindful Movement Intervention (MMI) targets improved attentional, behavioral and emotional regulation through engagement of the motor system and mindful practice in school-age children. For this project, children will participate in the MMI twice a week for 45 minutes a session for the duration of the academic year. The intervention will be held during school hours to make it more accessible to all students and require fewer additional resources.~Briefly, there are five components that make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, a modified Tai Chi sequence, Imaginative Play, and Reflection.~One goal of this intervention is to help children to develop the skills needed to cope with naturally occurring changes and to adapt to their environment in a mindful, non-reactive manner. In this context, students are learning to control and manage their attention, behavior and emotion through implicit procedural learning."
62093657|NCT05118932|EXPERIMENTAL|Mindful Movement Intervention Family Based Component|In this additional component, participants and their families will have access to monthly Mindful Movement activities intended to reinforce concepts discussed in Mindful Movement class and foster familial relationships. The family-based component will include access to lesson plans and accompanying resources (e.g., videos, worksheets, audio tracks) once a month from October through May, that offer strategies to improve awareness of thoughts, emotions, and body. Families will also be expected to track their adherence to the lesson plans and provide feedback via a survey.
62093658|NCT05118932|EXPERIMENTAL|Mindful Movement Intervention Peer to Peer Mentorship Component|In this additional component, participants will have the opportunity to become student instructors and lead younger students in modified instructional classes.
62093659|NCT05118932|EXPERIMENTAL|Mindful Movement Intervention Community Education Component|In this additional component, participants will have the option to assist with the development of an instructional video that showcases students in the Mindful Movement program demonstrating mindful movement practices such as breathing techniques, yoga poses, and T'ai Chi movements.
62291323|NCT00032084|PLACEBO_COMPARATOR|Behavioral Intervention + Placebo|Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
62291324|NCT00032084|ACTIVE_COMPARATOR|Behavioral Intervention + Bupropion|Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .
62291325|NCT01533727|EXPERIMENTAL|Group A|Autologous CIK Transfusion plus Chemotherapy
62291326|NCT01533727|ACTIVE_COMPARATOR|Group B|chemotherapy alone
62657148|NCT00596635|ACTIVE_COMPARATOR|One cranberry capsule|1 650mg cranberry capsule daily
62657149|NCT00596635|ACTIVE_COMPARATOR|Two cranberry capsules|1 650 mg cranberry capsule twice daily (bid)
62464311|NCT04873310|EXPERIMENTAL|Triple P online with professional support|In the online version with professional support, the psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions, as well as answering questions and doubts that the participants may have regarding the program and its implementation.
62464312|NCT04873310|EXPERIMENTAL|Triple P online without professional support|In the version without professional support, the role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
62464313|NCT04873310|NO_INTERVENTION|Control group|Control group without any intervention.
62464314|NCT05818709|EXPERIMENTAL|HAC 22L|Participants will be randomized to receive HAC 22L on Day 1. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of HAC 22L during the follow-up period.
62464315|NCT05818709|OTHER|Control Group|Participants can opt to receive HAC 22L after a control period of 6 months. Participants will have the opportunity to receive an optional touch-up treatment and will be followed for an additional 6 months period.
62657150|NCT00486681||1|period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated)
61907470|NCT06131476|EXPERIMENTAL|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the TEST lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the CONTROL lubricating eye drops will be instilled.
62291327|NCT01272583|OTHER|Sequence A (sitagliptin→placebo)|Cross-over, both arms reveived the same intervention in different order.
62657151|NCT00486681||2|period II (warning activated).
62291328|NCT01272583|OTHER|Sequence B (placebo→sitagliptin)|Cross-over, both arms reveived the same intervention in different order.
62291329|NCT01341457|EXPERIMENTAL|LY2603618 + Gemcitabine|"Gemcitabine 1000 milligrams per meter squared (mg/m\^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.~Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met."
62291330|NCT04489992||Standard radiology studies with AI|"The experiment is conducted on 10 types of studies with AI:~1. Chest CT/ LDCT with different pathologies;~2. Abdominal CT with different pathologies;~3. Head CT with different pathologies;~4. MSS XR with different fractures~5. Spine XR with different pathologies;~6. MMG;~7. Brain MRI with different pathologies;~8. Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies~9. Knee joint MRI~10. Lesser pelvis MRI."
62291331|NCT04489992||Standard radiology studies without AI|"The experiment is conducted on 10 types of studies without AI:~1. Chest CT/ LDCT with different pathologies;~2. Abdominal CT with different pathologies;~3. Head CT with different pathologies;~4. MSS XR with different fractures~5. Spine XR with different pathologies;~6. MMG;~7. Brain MRI with different pathologies;~8. Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies~9. Knee joint MRI~10. Lesser pelvis MRI."
62291332|NCT01700829|ACTIVE_COMPARATOR|Midazolam|0.02 mg/kg, I.V. (in the vein)
62464316|NCT00558857|ACTIVE_COMPARATOR|DSM|Treatment using DSM to guide ablation
62657152|NCT02363088|NO_INTERVENTION|No intervention, 24-29 years|No intervention, group 24-29 years. Women will receive the written invitation to screening only
62657153|NCT02363088|EXPERIMENTAL|Messenger text message reminder, 24-29|Messenger text message reminder, group 24-29 years.
62291333|NCT01700829|ACTIVE_COMPARATOR|Ketamine|0.5 mg/kg, I.V. (in the vein)
62291334|NCT03514914|EXPERIMENTAL|CHARM2 Intervention|CHARM2 intervention will involve gender, culture \& contextually-tailored family planning and gender equity counseling for married couples. Two sessions for men delivered by male health providers and two sessions for women delivered by female providers.
62291335|NCT03514914|NO_INTERVENTION|Control|Control clusters will receive standard of care.
62291336|NCT04623957|EXPERIMENTAL|ForgTin|Patients randomized into group 1 will receive the ForgTin Medical Device for a duration of 3 months.
62291337|NCT04623957|NO_INTERVENTION|No intervention|Patients randomized into group 2 will receive no device for a duration of 3 months.
62291338|NCT00806221|EXPERIMENTAL|Emollient|Skin barrier protection from birth
62291339|NCT00832819|EXPERIMENTAL|E7080 (Dose Escalation Cohort)|This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
62464317|NCT01033305|PLACEBO_COMPARATOR|Placebo|
62464318|NCT01033305|EXPERIMENTAL|CyCol™|
62464319|NCT01097993|EXPERIMENTAL|1 = Tested product|
62464320|NCT01097993|ACTIVE_COMPARATOR|2 = Control product|
62464321|NCT02775357|EXPERIMENTAL|Enhanced HIV counseling and testing|In addition to standard HIV testing and counseling,men randomized to this arm received Measurement and communication of HIV risk from the HIV counselors using an index developed and validated through the Rakai community cohort study. Their risk was communicated to them and subsequent HIV risk reduction counseling including male circumcision was given.
62464322|NCT02775357|ACTIVE_COMPARATOR|Standard HIV testing and counseling|Men randomized to this arm were given standard HIV testing and counseling following the current Uganda Ministry of Health guidelines. Following the counseling HIV risk reduction counseling including male circumcision was given.
62464323|NCT01314417|EXPERIMENTAL|Methotrexate|400 μg/100 μL injection
62464324|NCT01603862|EXPERIMENTAL|ThinkingFit|
62464325|NCT05752994|ACTIVE_COMPARATOR|Home program group|The guardians will receive the education about autistic spectrum disorder and home program training.
62464326|NCT05752994|EXPERIMENTAL|Multisensory room group|The guardians in this group will receiver the educational program the same as the home program group plus the training in multisensory room.
62464327|NCT06179056||study group|
62464328|NCT02258620|EXPERIMENTAL|dinitrate isosorbide (intra venous)|dinitrate isosorbide by continuous intra venous injection (1 à 5 mg/h)
62657154|NCT02363088|NO_INTERVENTION|No intervention, 30-64 years|No intervention group 30-64 years, Women will receive the written invitation to screening only
62657155|NCT02363088|EXPERIMENTAL|Neutral text message reminder, 30-64|Neutral Text message, group 30-64 years
62657156|NCT02363088|EXPERIMENTAL|Messenger text message reminder, 30-64|Messenger text message reminder, group 30-64
62464329|NCT02258620|EXPERIMENTAL|dinitrate isosorbide (intra arterial)|dinitrate isosorbide 5 mg by direct administration intra arterial
62464330|NCT02258620|EXPERIMENTAL|nitroglycerine (transdermic)|nitroglycerine dermal patch15 mg/24h soit 67,2 mg/21 cm2
62093660|NCT04833140|ACTIVE_COMPARATOR|Estradiol|"Estradiol in the form of a transdermal patch 100 mcg daily (Vivelle-Dot generic).~Women with an intact uterus will also receive progesterone (100 mg) in the form of a vaginal tablet (Endometrin, Ferring Pharmaceuticals, Inc.) inserted daily for endometrial protection"
62093661|NCT04833140|PLACEBO_COMPARATOR|Placebo|Placebo patch (containing no estradiol) Women with an intact uterus will also receive vaginal placebo capsules (containing no progesterone)
62093662|NCT02519296|ACTIVE_COMPARATOR|Prolonged Exposure Therapy|"In total 30 Danish veterans will be recruited, who meet the ICD-10 diagnostic criteria for PTSD, and treated with PE.~Intervention with eight sessions of PE, psychometrics, blood analyses and fMRI."
62291340|NCT00832819|EXPERIMENTAL|E7080 (Expansion Cohort)|Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.
62291341|NCT01964404|EXPERIMENTAL|Marijuana cigarette and placebo capsule|3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
62464331|NCT02185872|ACTIVE_COMPARATOR|Aerobic and Resistance Training|Participants completed 24 exercise sessions based on current guidelines. Aerobic exercise (50 min) was performed on machines every session and resistance training (20 min) was performed on machines two sessions per week. Aerobic intensity was prescribed at 40-50% of heart rate reserve (HRR) Weeks 1-4 and 50-60% HRR Weeks 5-8. Resistance training was supervised by an ACE certified personal trainer. One-repetition maximums (1-RM) were assessed Week 1 (i.e., seated bicep curl, military press, seated lat pulldown, seated leg extension, triceps pulldown, bench press, reverse leg curl, seated leg press). For Weeks 2-3 participants completed, 3 sets of 15 reps at 50% 1-RM; Weeks 4-5, 3 sets of 12 reps at 60% 1-RM; Weeks 6-7, 3 sets of 10 reps at 70% 1-RM; Week 8, 3 sets of 8 reps at 75% 1-RM. Three sets of 15 unweighted crunches were completed each day. One minute of rest was taken between each set and each exercise.
62464332|NCT02185872|EXPERIMENTAL|High-intensity functional training|Participants completed a total of 24 sessions that were pre-programmed and led by a certified instructor (CrossFit Level 2), which lasted up to 60 minutes in duration. The first two class periods were structured as an introduction to common movements used in high-intensity functional training (HIFT; e.g., squats, deadlift, press, jerks, barbell, dumbbell, and medicine ball cleans, pullups, kettlebell swings, among others). No scheduled workouts were given on days 1 and 2. Beginning on day 3 each HIFT class consisted of 10-15 minutes of stretching and warmup, 10-20 minutes of instruction and practicing techniques and movements, and 5-30 minutes for the workout of the day, performed at vigorous intensity, relative to each person's ability and fitness level. All weights and movements were individually prescribed and recorded for each participant.
62464333|NCT00862979|ACTIVE_COMPARATOR|CNI-regimen|CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
62464334|NCT00862979|EXPERIMENTAL|CNI-free-regimen|CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids
62464335|NCT00639028|OTHER|1|Ankle echography
62464336|NCT00639028|OTHER|2|echography + stress radiography
62464337|NCT00639028|OTHER|3|stress radiography
62464338|NCT03687515|EXPERIMENTAL|budesonide inhalation suspension|
62464339|NCT03687515|ACTIVE_COMPARATOR|budesonide aqueous nasal spray|
62464340|NCT03687515|ACTIVE_COMPARATOR|oral steroids|
62657157|NCT02363088|EXPERIMENTAL|Social Norms A reminder, 30-64|Social Norms (population proportion) text message reminder, group 30-64 years
62657158|NCT02363088|EXPERIMENTAL|Social Norms B reminder, 30-64|Social Norms (population total) text message reminder, group 30-64 years
62291342|NCT01964404|EXPERIMENTAL|Dronabinol and placebo cigarette|Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.
62291343|NCT01964404|PLACEBO_COMPARATOR|Placebo cigarette and placebo capsule|Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
62291344|NCT02034487||Boys with delayed puberty|Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.
62464341|NCT02818842||Pregnant Women|"Medical and personal data will be collected for all the pregnant women who want to participate.~The source of data are :~* Primary Health Insurance Fund data~* Prenatal Diagnostic Center of Toulouse University Hospital data~* Mother and child protection data collection~* Medicalisation Program of Information Systems data"
62464342|NCT03638739|EXPERIMENTAL|Exercise|Participants will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS for 12 weeks at McMaster University. Following this, they will return to their normal daily activities for a further 12 weeks.
62464343|NCT03638739|EXPERIMENTAL|Wait-list Control|Participants will engage in their usual daily activities for the first 12 weeks of the study, then will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS at McMaster University for the 2nd 12 weeks.
62657159|NCT02363088|OTHER|Framed gain text reminder, 30-64|Framed gain text message reminder, group 30-64 years
62657160|NCT02363088|EXPERIMENTAL|Framed loss text reminder, 30-64|Framed loss text message reminder, group 30-64 years
62464344|NCT04971226|EXPERIMENTAL|Asciminib|Patients will take asciminib 80 mg QD under fasting conditions on ongoing basis; Patients will be randomized 1:1 asciminib versus Investigator selected TKIs
62464345|NCT04971226|ACTIVE_COMPARATOR|Investigator selected TKIs|"Patients will take on ongoing basis the Investigator selected TKIs that will include one of the below treatments:~Imatinib 400 mg QD administered with food Nilotinib 300 mg BID administered under fasting conditions Dasatinib 100 mg QD administered with or without a meal Bosotunib 400 mg QD administered with food"
62657161|NCT01093417|PLACEBO_COMPARATOR|Placebo|Participants that have been randomized into this arm will receive placebo pills.
62657162|NCT01093417|ACTIVE_COMPARATOR|Vitamin D 4000 IU|Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.
62657163|NCT05309772|EXPERIMENTAL|Biomarker arm|"All participants will have blood taken to test for BAT/MAT. Participants with a positive BAT/MAT will dispense from oral food challenge (OFC).~Participants with negative or inconclusive BAT/MAT will undergo OFC."
62093663|NCT02519296|ACTIVE_COMPARATOR|30 Danish veterans without PTSD|"A group of controls will be recruited consisting of age-appropriate same sex veterans who have participated in international missions similar to the patient group.~Observation with psychometrics, blood analyses and fMRI."
62093664|NCT06252675|EXPERIMENTAL|Treatment (obinutuzumab, glofitamab, pirtobrutinib)|Participants receive obinutuzumab IV on days 1 and 2 of cycle 1 for a total of 2 doses. Participants receive glofitamab IV on days 8 and 15 of cycle 1 and day 1 of remaining cycles. Cycles repeat every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Participants receive pirtobrutinib PO once a day (QD) on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo FDG-PET/CT at screening, after every 4 cycles through cycle 13 and then after every 6 cycles. Participants will undergo a bone marrow biopsy and aspiration at cycle 13 and blood sample collection throughout study and a tissue biopsy at relapse or progression.
62093665|NCT03661554|EXPERIMENTAL|single arm|"This clinical study, BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research, is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups."
62657164|NCT05309772|ACTIVE_COMPARATOR|Standard-of-care arm|All participants in the standard-of-care arm will have blood taken to test for BAT/MAT. Regardless of the result of BAT/MAT, all participants in this arm will undergo an oral food challenge, as per the current standard-of-care.
62657165|NCT06551844|NO_INTERVENTION|Standard of care (arm A)|Patients, who are randomly allocated into arm A will receive the standard of care (no study drug)
62093666|NCT06200571||Nulliparous women with low risk for preeclampsia|Nulliparous women with low risk for preeclampsia by FMF-screening in the first trimester. Follow-up in week 22-24, 32, 36 and 6 months after delivery wtih clinical measurements, ultrasound doppler, blood- and urin samples.
62291345|NCT06218927||Autologous hematopoietic stem cell transplantation (AHSCT)|Patients who underwent autologous hematopoietic stem cell transplantation (AHSCT).
62291346|NCT06218927||Disease-modifying therapy|Patients who undergo disease-modifying therapy - standard treatment.
62291347|NCT06055257|PLACEBO_COMPARATOR|Group 1 (Control)|"Standard of care treatment for ORN consisting of conservative measures (e.g. local irrigation, antiseptic mouthwash) and approximately 60 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2.4 ATA each, scheduled Monday to Friday for 12 weeks - i.e., 5 treatments per week). At the conclusion of the study and at the discretion of the clinical team, patients randomized to the control group with residual disease may be considered for the mPENTOCLO protocol.~Simultaneously, the 4-week mPENTOCLO pre-treatment phase will be started (as defined in the intervention section), followed by a sham/placebo mPENTOCLO treatment phase for a total of 12 months."
62291348|NCT06055257|EXPERIMENTAL|Group 2 (Intervention)|"Standard of care treatment as described for the control group (conservative measures and 60 HBOT treatments).~Simultaneously, a comprehensive oral regimen (mPENTOCLO) will be started, including a 4-week pre-treatment phase followed by a treatment phase for a total of 12 months, as defined in the Intervention section."
62657166|NCT06551844|EXPERIMENTAL|Molnupiravir (arm B)|Patients, who are randomly allocated into arm B, will receive 800mg po bid of Molnupiravir for 5 days
62657167|NCT06551844|EXPERIMENTAL|Monoclonal antibody (arm C)|Patients, who are randomly allocated into arm C, will receive a single dose of 6mg/Kg of the dengue monoclonal antibody via an intravenous line over 2 hours.
62291349|NCT05350787|EXPERIMENTAL|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10\^6 cells/kg of ThisCART19A
62291350|NCT05350787|EXPERIMENTAL|ThisCART19A 8×10^6 cells/kg as dose level 2|Patients will receive 8×10\^6 cells/kg of ThisCART19A
62464346|NCT01805934|ACTIVE_COMPARATOR|Group RBLF|receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
62464347|NCT01805934|ACTIVE_COMPARATOR|Group RA|receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
62464348|NCT01248247|EXPERIMENTAL|Group 1 - Erlotinib|Erlotinib 150 mg by mouth each day of a 28 day cycle.
62464349|NCT01248247|EXPERIMENTAL|Group 2 - Erlotinib + MK-2206|"Erlotinib 150 mg by mouth each day of a 28 day cycle.~MK-2206 135 mg by mouth every week of a 28 day cycle."
62291351|NCT05350787|EXPERIMENTAL|ThisCART19A 12×10^6 cells/kg as dose level 3|Patients will receive 12×10\^6 cells/kg of ThisCART19A
62291352|NCT05637255|EXPERIMENTAL|SYL1801 ophthalmic solution Low Dose once daily|42 treatment days
62291353|NCT05637255|EXPERIMENTAL|SYL1801 ophthalmic solution Middle Dose once daily|42 treatment days
62464350|NCT01248247|EXPERIMENTAL|Group 3 - AZD6244 + MK-2206|AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.
62464351|NCT01248247|EXPERIMENTAL|Group 4 - Sorafenib|Sorafenib 400 mg by mouth twice a day for a 28 day cycle.
62464352|NCT05246462|EXPERIMENTAL|Experimental group|Gynecological cancer patients in a chemotherapy unit in Trabzon were recruited in the study. Inclusion criteria for the study were volunteering to take part in the study, being able to read and write in Turkish, being 18 years of age or older, having been diagnosed with gynecological cancer, knowing that s/he had been diagnosed with cancer, having received at least one chemotherapy treatment and having cancer stage 2 or 3. Exclusion criteria in the study were having a verbal communication disability, having been diagnosed with psychotic and neurological disorders, having received, or receiving psychotherapy, living outside the city center of Trabzon, and receiving treatment at intervals longer than 21 days. The experimental group received 7 sessions of logotherapy interviews.
62657168|NCT05142735|EXPERIMENTAL|Experimental|N-Acetylcysteine 2000 mg (4 x 500-mg tablets) orally every morning for 8 weeks
62657169|NCT05142735|PLACEBO_COMPARATOR|Placebo Comparator|N-Acetylcysteine Placebo tablet matching N-Acetylcysteine orally every morning for 8 weeks
62657170|NCT00941928|EXPERIMENTAL|Haploidentical NK cells + Epratuzumab|Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m\^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m\^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
62657171|NCT01643213|EXPERIMENTAL|BSC approved SCS Trial Therapy w/ OMG|Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)
62657172|NCT01643213|ACTIVE_COMPARATOR|Non Boston Scientific SCS Trial Therapy|Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment
62657173|NCT05372159||Cognitively healthy adults|Eligible participants completed a 4-hour screening visit, and a consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
62657174|NCT05372159||Cognitively impaired adults|Eligible participants completed a 4-hour screening visit, and a consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
62657175|NCT05994807|EXPERIMENTAL|Cohort 1|Participants in Cohort 1 will receive DC-806 single dose on Day 1, and the second dose of DC-806 along with itraconazole after the wash-out period.
62657176|NCT05994807|EXPERIMENTAL|Cohort 2|Participants in Cohort 2 will receive DC-806 single dose on Day 1, and the second dose of DC-806 along with carbamazepine after the wash-out period.
62657177|NCT02865291|EXPERIMENTAL|ForConti device|Use the device up to 12 hours/day for 4 weeks
62657178|NCT05704712|EXPERIMENTAL|Message 1 - $100|Participants are offered an incentive of $100 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 1)
62657179|NCT05704712|EXPERIMENTAL|Message 2 - $100|Participants are offered an incentive of $100 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 2).
62093667|NCT06200571||Nulliparous women with high risk for preeclampsia without aspirin|Nulliparous women with high risk for preeclampsia by FMF-screening in the first trimester. Follow-up in week 22-24, 32, 36 and 6 months after delivery wtih clinical measurements, ultrasound doppler, blood- and urin samples.
62093668|NCT06200571||Nulliparous women with high risk for preeclampsia with aspirin|Nulliparous women with high risk for preeclampsia by FMF-screening in the first trimester. Follow-up in week 22-24, 32, 36 and 6 months after delivery wtih clinical measurements, ultrasound doppler, blood- and urin samples. Aspirin tablets 150 mg daily in the evening from first trimester to week 36 of pregnancy.
62093669|NCT01562743|EXPERIMENTAL|SPM 962|Rotigotine transdermal patch
62464353|NCT05246462|NO_INTERVENTION|Control group|Gynecological cancer patients in a chemotherapy unit in Trabzon were recruited in the study. Inclusion criteria for the study were volunteering to take part in the study, being able to read and write in Turkish, being 18 years of age or older, having been diagnosed with gynecological cancer, knowing that s/he had been diagnosed with cancer, having received at least one chemotherapy treatment and having cancer stage 2 or 3. Exclusion criteria in the study were having a verbal communication disability, having been diagnosed with psychotic and neurological disorders, having received, or receiving psychotherapy, living outside the city center of Trabzon, and receiving treatment at intervals longer than 21 days. The control group received standard nursing care.
62657180|NCT05704712|EXPERIMENTAL|Message 1 - $200|Participants are offered an incentive of $200 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 1).
62657181|NCT05704712|EXPERIMENTAL|Message 2 - $200|Participants are offered an incentive of $200 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 2).
62657182|NCT05704712|NO_INTERVENTION|Control|Participants complete all assessments, and are eligible to receive compensation for participating in the research components of the study.
62657183|NCT06063889||Knee OA Patients|This group consists of patients who have been diagnosed with knee osteoarthritis. They will be subjected to a series of tests to assess the maximal rate of force development of ankle muscles and their functional abilities.
62093670|NCT04872959|NO_INTERVENTION|Usual Care Arm|Will not use HealthReveal to titrate the doses of Entresto/ other treatments for HFrEF.
62291354|NCT05637255|EXPERIMENTAL|SYL1801 ophthalmic solution High Dose once daily|42 treatment days
62291355|NCT05636280|EXPERIMENTAL|schroth exercise group|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
62464354|NCT01944332|EXPERIMENTAL|gamete treatment- oocytes and sperm|The spermatozoa will be prepared in the standard fashion and utilized for injection after exposure to a membrane permeabilizing agent. Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The injected oocytes will be then exposed to the previously mentioned activating agents for the purpose of inducing embryo development. The successfully fertilized oocytes will be further kept in culture for up to 5 days as per standard IVF/ICSI.
62657184|NCT06063889||Healthy Control|This group will include healthy individuals without knee osteoarthritis. They will undergo the same series of tests to serve as a control group, enabling the comparison of results with the Knee OA Patients group.
62657185|NCT02349880|ACTIVE_COMPARATOR|control|5 hour cognitive training
62291356|NCT05636280|ACTIVE_COMPARATOR|traditional scoliosis exercise group|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
62657186|NCT02349880|EXPERIMENTAL|intervention|5 hour shared decision making training
62291357|NCT06001567|EXPERIMENTAL|Avatrombopag|Patients receive avatrombopag treatment 5-10 days.
62291358|NCT02871479|EXPERIMENTAL|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
62291359|NCT02871479|PLACEBO_COMPARATOR|Placebo cream|The vehicle cream
62291360|NCT02871479|EXPERIMENTAL|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
62657187|NCT04320537||MJ user|non-treatment-seeking chronic heavy marijuana (MJ) users of both sexes and all ethnicities between the ages of 21-40 years who are willing to follow the study protocol and abstinence from marijuana for three weeks
62657188|NCT04320537||Control|age- and sex-matched healthy control participants who are willing to follow the study protocol and remain in the study for three weeks
62657189|NCT05149105|EXPERIMENTAL|APC intervention|"In addition to multidisciplinary care (standard care), patients benefit from an Argon Plasma Coagulation (APC) intervention at D0.~The APC intervention should be repeted at Month 2 and Month 4."
62657190|NCT05149105|NO_INTERVENTION|Control|Patients are treated according to standard care (multidisciplinary care).
62657191|NCT01113242||A:|Patients with idiopathic PD and with MMSE \< à 26
62657192|NCT01113242||B:|Patients with idiopathic PD and with MMSE ≥ à 26
62657193|NCT02531685|EXPERIMENTAL|Cohort 1|13 subjects receive 0.1 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
62657194|NCT02531685|EXPERIMENTAL|Cohort 2|13 subjects receive 0.3 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
62657195|NCT02531685|EXPERIMENTAL|Cohort 3|13 subjects receive 1.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
62657196|NCT02531685|EXPERIMENTAL|Cohort 4|"A sentinel group of 5 subjects receive 2.0 mcg dmLT intradermally on days 1, 22, and 43. 1 subject receives placebo.~Safety data from days 1-14 in sentinel will be reviewed and upon approval to proceed, 8 additional subjects receive 2.0 mcg dmLT intradermally on days 1, 22 and 43. 2 subjects receive placebo."
62657197|NCT02531685|EXPERIMENTAL|Cohort 5|Up to 31 subjects receive TBD mcg dmLT intradermally on days 1, 22 and 43. 4 subjects receive placebo.
62291361|NCT05704114|EXPERIMENTAL|Treatment Arm|This is a single arm study. All participants are receiving the treatment.
62291362|NCT01029314||Cardiopulmonary bypass surgery|Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
62291363|NCT04752202|EXPERIMENTAL|Test group (group A)|The women were randomly assigned to group A. Test group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
62291364|NCT04752202|OTHER|Control group (group B)|The women were randomly assigned to group B. Control group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
62291365|NCT04274439|EXPERIMENTAL|Internet-Based Pain Education and Exercise|"Patients allocated to the intervention group will receive a login and password for individual access to the website designed for the study. The content of this intervention will include videos and animations based on pain education, physical activity promotion and general exercises. The pain education component will be based on the E-pain intervention developed by Reis et al (2017), which includes nine main features: (1) acceptance, (2 and 3) education about pain, (4) sleep hygiene, (5) recognizing stress and negative emotions, (6) increasing positive coping in lifestyle, (7) exercises, (8) communication and (9) relapse prevention. The exercise component will include general exercises aiming to improve strength, flexibility, control and coordination.~Patients in this group will also receive weekly text messages and a health coaching over the telephone. The text messages will include information on the benefits of exercises, motivation, and positive messages about dealing with pain."
62657198|NCT05207501|ACTIVE_COMPARATOR|Moderate-intensity intermittent training (MIIT)|The MIIT will be conducted on a cycle ergometer (Lode Ex. calibur Sport Ergometer, Lode B.V., the Netherlands) in normoxia (FiO2 = \~ 21%). The participants will perform the MIIT starting with the ergometer resistance set to obtain the %HRmax set (\~75-80%) during 5 minutes and will rest 5 minutes after each interval of exercise. The HRmax will be considered as 200 - age.
62657199|NCT05207501|EXPERIMENTAL|MIIT during intermittent hypoxic exposure (IHYP + MIIT)|A normobaric hypoxic chamber (ATS Altitude Training, Sydney, Australia) will be used for this protocol. The chamber (2.4 m x 5 m x 2.5 m) allows, via a filter and compressor system, to extract oxygen molecules and to reduce the fraction of inspired oxygen (FiO2) with no modification of the barometric pressure.
62657200|NCT05207501|EXPERIMENTAL|MIIT during intermittent blood flow restriction (IBFR + MIIT)|The IBFR + MIIT protocol will be performed while cycling in normoxia (FiO2 = \~ 21%). Elastic, pneumatic cuffs (BStrong, Park City, Utah, USA) will be administered as high as possible at the inguinal crease of the upper thigh and will be inflated during the cycling to the set pressure of 400 mmHg (except for the first training session, it will be of 250 mmHg to minimize soreness and to accustom patients to vascular occlusion training). The cuffs will be deflated at interval rest.
62093671|NCT04872959|EXPERIMENTAL|Interventional- Health Reveal|"The interventional arm will be provided tools to augment quality of care and build the patient and physician relationship through trust and shared goal-setting.~Prior to each patient appointment, on a customized GDMT Dashboard, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' electronic health record (EHR). The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, patient-reported outcomes/QOL will be assessed."
62093672|NCT04269070|ACTIVE_COMPARATOR|Move, Stand|Usual behavior condition, followed by the standing condition, followed by the LPA condition.
62093673|NCT04269070|ACTIVE_COMPARATOR|Stand, Move|Usual behavior condition, followed by the LPA condition, followed by the standing condition.
62291366|NCT04274439|ACTIVE_COMPARATOR|Online Booklet|The patients allocated to the control group will have access to an online booklet containing general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. They will also receive one phone call at week 4 and text messages once a week during the study period.
62291367|NCT03396289|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive conventional physiotherapy programme including balance exercises, 3 times a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other 2 sessions will be performed at home.
62291368|NCT03396289|EXPERIMENTAL|Training Group|In addition to conventional physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other sessions will be performed at home.
62291369|NCT00998439|EXPERIMENTAL|Paclitaxel coated balloon catheter|
62291370|NCT00998439|ACTIVE_COMPARATOR|uncoated balloon catheter (POBA)|
62464355|NCT03770598|ACTIVE_COMPARATOR|Distressed|Study participants who do indicate distress or who do meet criteria for depression or anxiety will be randomized to receive either treatment as usual (referral to Psychiatry or Psychology for evaluation and further treatment) or team based care model.
62464356|NCT03770598|ACTIVE_COMPARATOR|Non-Distressed|Study participants who do not indicate distress or who do not meet criteria for depression or anxiety will be randomize to monitoring only or to receive psycho-education regarding subjects that when used can promote wellness.
61907471|NCT06131476|EXPERIMENTAL|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the CONTROL lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the TEST lubricating eye drops will be instilled.
62093674|NCT06528769|EXPERIMENTAL|Treatment (all-trans retinoic acid [ATRA] and cemiplimab)|"Patients recieve ATRA at a starting dose of 150 mg/m2/day for 3 days orally prior to each cycle of Cemiplimab 350 mg IV q3 weeks for three cycles and then Cemiplimab monotherapy until the progress of disease or unacceptable toxicities develops.~Peripheral blood samples will be collected. Patients will undergo physical examination and imaging scans at baseline and then approximately every 6 weeks (2 cycles) for the first year of treatment and every 12 weeks thereafter"
62093675|NCT04581590|ACTIVE_COMPARATOR|Active group|In the group G1 will be administered: tDCS active + dual-task motor training + cognitive training.
62093676|NCT04581590|SHAM_COMPARATOR|Sham group|In the group G2 will be administered: tDCS active + dual-task motor training
62291371|NCT06166550|EXPERIMENTAL|Intervention|Parents of children suffering from neurodevelopmental disorders will be the participants. They will get in-person training on emotional intelligence, stress reduction, and wellbeing along with access to a mobile app aimed at enhancing their psychological wellbeing.
62291372|NCT06166550|ACTIVE_COMPARATOR|Control|This group will be in wait-list, get no intervention at the initial phase. They will get the intervention after the intervention period.
62291373|NCT04650633|EXPERIMENTAL|SHR-1701|R/M SCCHN subjects failure after 1 lines of platinum based chemotherapy or after anti PD-1/PD-L1 antibody therapy.
62291374|NCT01780233|EXPERIMENTAL|Fentanyl 400 µg sublingual spray + naltrexone 50 mg|Patients received a single administration of 400 µg of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally.
62291375|NCT01780233|ACTIVE_COMPARATOR|Actiq® 400 µg transmucosally + naltrexone 50 mg|Patients received a single administration of 400 µg of Actiq® transmucosally + naltrexone hydrochloride 50 mg orally.
62291376|NCT01780233|ACTIVE_COMPARATOR|Fentanyl citrate injection 100 µg iv + naltrexone 50 mg|Patients received a single administration of 100 µg of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally.
62464357|NCT06273033||Patients who have undergone last-generation CCTA and ICA.|
62464358|NCT00667095|EXPERIMENTAL|Botox and DMSO instillation|Botulinum-A Toxin (Botox) 300 units in 50 cubic centimeters of Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution
62464359|NCT00667095|PLACEBO_COMPARATOR|DMSO instillation|Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters
62464360|NCT00534443|EXPERIMENTAL|1|A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
62464361|NCT00765622||G2|G2 = control group (no incontinence)
62464362|NCT00765622||G1|G1 = urinary incontinence
62737470|NCT06474468|EXPERIMENTAL|Treatment group A/B|A：SHR-A2102+Adebrelimab B：SHR-A2102+Adebrelimab+Cisplatin
62737471|NCT00879034|EXPERIMENTAL|Zoledronic Acid,Pravastatin,and Lonafarnib|Lonafarnib;Zoledronic acid;Pravastatin
62737472|NCT03066323|ACTIVE_COMPARATOR|Tea extract|Rice with tea extract
62737473|NCT03066323|PLACEBO_COMPARATOR|No tea extract|Rice without tea extract
62657201|NCT05207501|EXPERIMENTAL|Moderate-intensity eccentric cycling (MIEC)|The MIEC will be conducted on a cycle ergometer (Excalibur, Lode, Groningen, The Nederlands) in normoxia (FiO2 = \~ 21%). The participants will be instructed to resist against the pedal movement (cadence set at 15 revolutions/min) to produce the required torque (set to obtain the 75-80%HRmax) indicated by visual feedback for 5 minutes and will rest 5 minutes after each interval of exercise. The HRmax will be considered as 200 - age. The HR responses will be monitored (Polar Electro Oy, Kempele, Finland).
62657202|NCT05873738||Group 1|Relapse
62657203|NCT05873738||Group 2|Smoking cessation
62657204|NCT03755466|ACTIVE_COMPARATOR|BARI|
61907472|NCT06476639|EXPERIMENTAL|Participants with normal/negative baseline groin ultrasounds - Intervention Group|Surgical removal of primary tumour and serial high-resolution bilateral groin ultrasound monitoring every 2 months and clinical examination every 3 months (n=120).
61907473|NCT06476639|NO_INTERVENTION|Participants with normal/negative baseline groin ultrasounds - Standard Group|Surgical removal of primary tumour and upfront full groin LND or sentinel node biopsy (SNB) based on clinician choice (according to local clinical practice management guidelines).
62093677|NCT04354311|EXPERIMENTAL|Experimental|"Anesthetic induction : total target-controlled intravenous anesthesia d was used with propofol and remifentanil. The effect site was then gradually increased to obtain a satisfaction depth of anesthesia. Assisted ventilation was then started by facemask ventilation (Sat O2\>95% and expired CO2 fraction normal, tidal volume of 8 mL/kg, a respiratory rate of 12 cycles per minute, with an FiO2 100% with no positive end expiratory pressure.~After stabilisation period of 2 minutes and record of the patient's parameters, a standardized nociceptive stimulation was applied at the level of the ulnar nerve (PTC of 50 Hz at 70 mA). The variation of ANI score and hemodynamic parameters were collected during the 2 following minutes.~After stabilization of ANI, orotracheal intubation was attempted. Maximal variation of heart rate (HR), blood pressure and the occurrence of somatic manifestations (intense cough, movement, tears) were recorded."
61907474|NCT06476639|NO_INTERVENTION|Participants with suspicious/indeterminate baseline groin ultrasound - Standard Treatment|Participants with suspicious/indeterminate baseline groin ultrasound (third group) will receive an upfront full groin LND or SNB, consistent with the current standard treatment, according to local clinical practice management guidelines.
62093678|NCT06696703|EXPERIMENTAL|Human Urinary Kallidinogenase for injection (HUK)|Patients in this arm will be given urinary kallidinogenase for injection，0.15 peptide nucleic acids (PNA)， once a day for 7days plus routine clinical treatment
62093679|NCT06696703|PLACEBO_COMPARATOR|sham-HUK treatment|Normal sodium chloride injection plus routine clinical treatment
62093680|NCT05080920|EXPERIMENTAL|Rosmalip®|Participants receive Rosmalip® (diterpene phenols 11,25 mg) 1 capsule orally once daily for 16 weeks
62093681|NCT05080920|PLACEBO_COMPARATOR|Placebo|Participants receive Placebo 1 capsule matching Rosmalip® orally once daily for 16 weeks
62657205|NCT03755466|ACTIVE_COMPARATOR|Bio|
62657206|NCT03755466|ACTIVE_COMPARATOR|Tofa|
62657207|NCT05746923||LECRA-HF patients|The study population consists of hospitalized patients with acute heart failure who are over 18 years of age, both women and men. Patients will be initially categorized into one of three groups based on the current European Society of Cardiology (ESC) heart failure guidelines based on left ventricular ejection fraction (LVEF) values: patients with reduced (LVEF ≤40%), mildly reduced (LVEF 41-49%) and preserved (LVEF ≥50%) ejection fraction.
62657208|NCT03823027|EXPERIMENTAL|Single-arm|The device will be taken before three daily main meals togteher with water. The dose will be escalated from 1g per main meal to the full dose of 3g per main meal. The device is provided in foil stick-packs packed in boxes with weekly supply. The treatment is for 12 weeks.
62657209|NCT04165057|ACTIVE_COMPARATOR|Group OMT|Optimal muscle tension management
62657210|NCT04165057|NO_INTERVENTION|Group Control|Conventional anesthetic management
62657211|NCT03617302|EXPERIMENTAL|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
61907475|NCT02192424|ACTIVE_COMPARATOR|Metformin alone|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
62093682|NCT03905811|EXPERIMENTAL|Active|Terazosin administered 5 mg once daily p.o. for 12 weeks
62093683|NCT03905811|PLACEBO_COMPARATOR|Placebo|Placebo administered once daily p.o. for 12 weeks
62291377|NCT04970667|EXPERIMENTAL|Flupentixol melitracen tablets|The patients were treated with Flupentixol melitracen tablets according to their own conditions
62657212|NCT03617302|PLACEBO_COMPARATOR|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
62657213|NCT02085551|EXPERIMENTAL|Mechanical thrombectomy by the Indigo System|
62657214|NCT01631188|EXPERIMENTAL|Aortic Valve Replacement|During surgery your doctor will utilize a new technique using surgical equipment that have already been FDA Approved for other indication. The combination of the equipment and technique will be experimental and will be closely evaluated during and after each case.
62657215|NCT02199496|EXPERIMENTAL|Cohort 1: Ustekinumab-Single-dose Phase 1, Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously then re-enrolled into the multi-dose phase. In multi-dose phase, subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
62657216|NCT02199496|EXPERIMENTAL|Cohort 2: Ustekinumab-Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
61907476|NCT02192424|EXPERIMENTAL|Metformin + Intermittent Insulin Therapy|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy, initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months). Participants will stop their metformin for 2 weeks every 3 months, during which time they will receive intermittent intensive insulin therapy for 2 weeks. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months.
62464363|NCT05502978|EXPERIMENTAL|Intervention group|The intervention group is third trimester pregnant women with 37 weeks of gestation who received blended education. Blended education is provided by cadres and nutritionists, both online and offline. Education consists of online assistance with digital booklets, videos via WhatsApp by cadres and consultation with nutritionists as well as home visits (offline/face-to-face) by cadres and the research team. One education is done during the third trimester at 37 weeks of gestation, second education is done at 38 weeks' gestation, the third education is done when the baby is 3 months old, all three of which are done online. Mother will be visited every month by cadres and the research team from birth to 7 month old. Consultation with a nutritionist is carried out via WhatsApp calls at critical times the failure rate in IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months
62464364|NCT02758665|EXPERIMENTAL|Obinutuzumab, Ibrutinib, Venetoclax|Obinutuzumab i.v.: Cycle 1 (3000 mg), Cycle 2-6 (1000 mg) Ibrutinib (tablet): Cycle 1-15 (420 mg daily) Venetoclax (tablet): Cycle 1 (last 7 days 20 mg daily), Cycle 2 (ramp up 50 mg to 400 mg) Cycle 3-12 (400 mg daily)
62464365|NCT03435081|EXPERIMENTAL|2 milligram (mg) Baricitinib|2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
62464366|NCT03435081|EXPERIMENTAL|1 mg Baricitinib|1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
61907477|NCT03495583|EXPERIMENTAL|Early introduction|Six commonly allergenic foods introduced (in a randomly assigned order) into the diets of exclusively breastfed infants from about 3 months of age.
62291378|NCT03437603|EXPERIMENTAL|Eltrombopag group|Starting dose is 25mg daily for the first 3 days, then increasing to 50mg for another week. Maintenance dosage is 50mg or 75 mg per day dependent on patients' status and doctors' opinion.Planned duration of treatment with eltrombopag is 8 weeks.When patients achieve persistent complete response for 2 weeks,they may stop medicine.
62291379|NCT02581995|EXPERIMENTAL|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
62291380|NCT03371355|PLACEBO_COMPARATOR|Pooled Placebo|Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).
62291381|NCT03371355|EXPERIMENTAL|Cohort B: ISIS 703802, 40 mg Q4W|Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.
62291382|NCT03371355|EXPERIMENTAL|Cohort C: ISIS 703802, 80 mg Q4W|Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.
62291383|NCT03371355|EXPERIMENTAL|Cohort A: ISIS 703802, 20 mg QW|Participants received ISIS 703802, 20 mg once every week for 26 doses.
62291384|NCT05981066|EXPERIMENTAL|IPM511 monotherapy|3+3 dose excalation. Paticipants will receive two cycle (QWX4 per cycle) IPM511 injection，I.M injection
62291385|NCT02921425|EXPERIMENTAL|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.
62291386|NCT04106388|EXPERIMENTAL|Virtual Behavioral Health Integration|All patients who meet eligibility criteria at sites where the virtual behavioral health program is offered will be considered exposed to the intervention.
62291387|NCT04106388|NO_INTERVENTION|Usual Care - Behavioral Health|All patients who meet eligibility criteria at sites where the virtual behavioral health program is not offered will be considered exposed to usual care.
62657217|NCT04607096|ACTIVE_COMPARATOR|Prediabetic subjects - cluster 3|Presence of a cluster 3 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
61907478|NCT03495583|NO_INTERVENTION|Standard introduction|Infants followed UK DoH standard advice for weaning
62657218|NCT04607096|ACTIVE_COMPARATOR|Prediabetic subjects - cluster 5|Presence of a cluster 5 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
61907479|NCT02321670|ACTIVE_COMPARATOR|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
61907480|NCT02321670|ACTIVE_COMPARATOR|Graft|Incision of the stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided.
61907481|NCT01989208|PLACEBO_COMPARATOR|Sugar capsule|One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.
61907482|NCT01989208|EXPERIMENTAL|SG1002|200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)
61907483|NCT06329284|OTHER|Serum Midkine|
62291388|NCT00432809|NO_INTERVENTION|Medical therapy|Intensive medical therapy for diabetes
62291389|NCT00432809|ACTIVE_COMPARATOR|Gastric Bypass|Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
62291390|NCT00432809|ACTIVE_COMPARATOR|Sleeve Gastrectomy|Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy
62291391|NCT00786708||NGAL|Urine that would otherwise be discarded will be obtained from a convenience sample of patients admitted to the hospital through the emergency room who meet the inclusion / exclusion criteria for this study.
62291392|NCT05020561|EXPERIMENTAL|Arm 1 - Group and Individual|Participants in this experimental Arm 1 will receive the 3 group sessions followed by 4 to 5 individual coaching sessions via phone calls that last 60 minutes each.
62291393|NCT05020561|EXPERIMENTAL|Arm 2 - Group only|Arm 2 will receive only the first 3 Life coach sessions (group session).
62291394|NCT05020561|NO_INTERVENTION|Arm 3 - Routine care|Arm 3 will receive routine care by the Breast clinic team for the entire course of the study.
62291395|NCT05759884|EXPERIMENTAL|anti-VEGF combined SML therapy group|The patients were treated with intravitreal injection of anti-VEGF drugs and SML therapy.
62657219|NCT04607096|ACTIVE_COMPARATOR|Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)|Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
62657220|NCT04607096|ACTIVE_COMPARATOR|Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)|Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
62657221|NCT01503047|EXPERIMENTAL|CLA group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
61907484|NCT01942850||No Treatment|Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.
62291396|NCT05759884|ACTIVE_COMPARATOR|anti-VEGF single therapy group|Only intravitreal injection of anti-VEGF drugs was given to patients.
62291397|NCT02168582||low back pain|
62291398|NCT04899583|EXPERIMENTAL|Treatment Group|a Sirolimus Coated Balloon
62291399|NCT04899583|ACTIVE_COMPARATOR|Control Group|a Paclitaxel Coated Balloon Catheter
62291400|NCT00362973||Hormone Receptor Positive Breast Cancer|Patients with hormone receptor positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of aromatase inhibitor and ovarian suppression (if premenopausal).
62291401|NCT00362973||HER-2/neu Positive Breast Cancer|Patients with HER-2/neu positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of trastuzumab.
62291402|NCT00631878|PLACEBO_COMPARATOR|Placebo|
62291403|NCT00631878|EXPERIMENTAL|10 mg/kg|10 mg/kg was given on Days 0, 14
62291404|NCT00631878|EXPERIMENTAL|30 mg/kg|30 mg/kg was given on Days 0, 14
62657222|NCT01503047|PLACEBO_COMPARATOR|Placebo group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.
62657223|NCT04947891||Study group|Patients will be treated with intensive recovery method after surgery.
62657224|NCT04947891||Control group|Patients will be treated with regular recovery method after surgery.
62657225|NCT04761250|EXPERIMENTAL|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
62657226|NCT01754649|ACTIVE_COMPARATOR|misoprostol vaginal 200 mcg|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
62657227|NCT01754649|PLACEBO_COMPARATOR|placebo|The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
62291405|NCT00631878|EXPERIMENTAL|60 mg/kg|60 mg/kg was given on Days 0, 14
62291406|NCT00631878|EXPERIMENTAL|90 mg/kg|90 mg/kg was given on Days 0, 14
62291407|NCT01119027||Surgeons|Surgeons and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience. .
62291408|NCT01119027||Trainee Surgeons|Surgeon and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience.
62291409|NCT03971721|EXPERIMENTAL|Wave Mattress Support|The mattress support will be delivered at the subject's home by professional staff of the sponsor (Hill-Rom) in the presence of the research coordinator or investigator. The subject will sleep on mattress support for the duration of study participation.
62291410|NCT06304324|PLACEBO_COMPARATOR|Sham Block|0.2% ropivacaine for popliteal nerve block
62291411|NCT06304324|ACTIVE_COMPARATOR|Dexamethasone|0.1mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
62291412|NCT06304324|ACTIVE_COMPARATOR|Dexmedetomidine|0.5ug/kg dexmedetomidine added to 0.2% ropivacaine for popliteal nerve block
62291413|NCT00932516|ACTIVE_COMPARATOR|South Beach Diet™ with SBD™ Products|
62291414|NCT00932516|ACTIVE_COMPARATOR|South Beach Diet™ alone|
62291415|NCT00932516|ACTIVE_COMPARATOR|Calorie restricted diet w/ SBD™ Products|
62291416|NCT00932516|ACTIVE_COMPARATOR|Calorie Restricted Diet alone|
62291417|NCT04217343||non-complement mediated pAMR(H+)|
62291418|NCT04217343||complement mediated pAMR(I+)|
62291419|NCT03993015||Patients attending the Obstetrical Emergency Unit|Patients attending the Obstetrical Emergency Unit of CHU Montpellier during 2018
62291420|NCT02718378|PLACEBO_COMPARATOR|No added active|placebo without estetrol
62291421|NCT02718378|ACTIVE_COMPARATOR|estetrol dose level 1|estetrol given in dose level 1
62291422|NCT02718378|ACTIVE_COMPARATOR|estetrol dose level 2|estetrol given in dose level 2
62291423|NCT02718378|ACTIVE_COMPARATOR|estetrol dose level 3|estetrol given in dose level 3
62291424|NCT04737044|NO_INTERVENTION|Study 1: Normal sugar|Control group will be required to continue consuming normal sugar intake for 8 weeks.
62291425|NCT04737044|EXPERIMENTAL|Study 1:Minimally refined brown sugar (MRBS)|Intervention group will be required to consume MRBS as added sugar based on their habitual diet for 8 weeks intervention.
62291426|NCT04737044|NO_INTERVENTION|Study 2: Normal sugar intake|- The control group will have no intervention and will continue with their normal daily intake for six months.
62464367|NCT03435081|PLACEBO_COMPARATOR|Placebo|Placebo administered orally every day.
62464368|NCT00874887|ACTIVE_COMPARATOR|Vigamox®|moxifloxacin 0.5% (m mg/mL), boric acid, sodium chloride, and purified water
62464369|NCT00874887|ACTIVE_COMPARATOR|Zymar®|gatifloxacin 0.3% (3 mg/mL), benzalkonium chloride 0.005%, edetate disodium; purified water and sodium chloride
62464370|NCT00709566|NO_INTERVENTION|Control|Waiting List control.
62464371|NCT00709566|ACTIVE_COMPARATOR|Exercise therapy|
62657228|NCT01852903|EXPERIMENTAL|calcium ascorbate|
62657229|NCT01852903|ACTIVE_COMPARATOR|ascorbic acid|
62657230|NCT01852903|PLACEBO_COMPARATOR|placebo|
62464372|NCT00709566|EXPERIMENTAL|Combined therapy|Combined Exercise therapy and Manual Therapy
62464373|NCT04083846|EXPERIMENTAL|Group 1|"1. Period 1: Reference drug~2. Period 2: Test drug 1~3. Period 3: Test drug 2"
62093684|NCT06698055|ACTIVE_COMPARATOR|aFW = Flywheel resistance exercise intervention group adults|FW undergo a twelve-week training intervention with alternating two to three sessions per week. At each training session the participant will perform four sets of leg press and a leg extension with seven repetitions per set in each machine were resistance is provided by a flywheel and a weight stack respectively.
62291427|NCT04737044|EXPERIMENTAL|Study 2: White sugar|"* Intervention group I will be advised to reduce sugar intake to no more than 10% from total energy intake.~* Intervention group I will be given white sugar for daily usage.~* Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~* For the first three months, one-to-one diet counseling will be conducted.~* Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
62291428|NCT04737044|EXPERIMENTAL|Study 2: MRBS|"* Intervention group II will be advised to reduce sugar intake to no more than 10% from total energy intake.~* Intervention group II will be given MRBS for daily usage.~* Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~* For the first three months, one-to-one diet counseling will be conducted.~* Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
62291429|NCT00158366|EXPERIMENTAL|1|Phase 1 participants who will receive behavioral training for 14 weeks
62291430|NCT00158366|ACTIVE_COMPARATOR|2|Phase 1 participants who will receive social skills training for 14 weeks
62464374|NCT04083846|EXPERIMENTAL|Group 2|"1. Period 1: Test drug 2~2. Period 2: Reference drug~3. Period 3: Test drug 1"
62464375|NCT04083846|EXPERIMENTAL|Group 3|"1. Period 1: Test drug 1~2. Period 2: Test drug 2~3. Period 3: Reference drug"
62464376|NCT04083846|EXPERIMENTAL|Group 4|"1. Period 1: Test drug 2~2. Period 2: Test drug 1~3. Period 3: Reference drug"
62464377|NCT04083846|EXPERIMENTAL|Group 5|"1. Period 1: Test drug 1~2. Period 2: Reference drug~3. Period 3: Test drug 2"
62464378|NCT04083846|EXPERIMENTAL|Group 6|"1. Period 1: Reference drug~2. Period 2: Test drug 2~3. Period 3: Test drug 1"
62464379|NCT01895296|EXPERIMENTAL|Pasireotide|pasireotide 300 microgram s.c. t.i.d.
61907485|NCT02224885|OTHER|addition of nCLE to help target biopsy|The patient, scheduled for a liver or lung CT-guided percutaneous biopsy or ablation will undergo a probe-based confocal laser endomicroscopy procedure after the imaging procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
62464380|NCT01895296|PLACEBO_COMPARATOR|Placebo|saline s.c. t.i.d.
61907486|NCT00313781|EXPERIMENTAL|A|For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
61907487|NCT00313781|ACTIVE_COMPARATOR|B|
61907488|NCT05423860||dementia|Patients with a diagnosis of dementia
62291431|NCT00158366|EXPERIMENTAL|3|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training alone for 24 months in Phase 2
62291432|NCT00158366|EXPERIMENTAL|4|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training plus biweekly booster treatments for 24 months in Phase 2
62291433|NCT06656403|OTHER|Study group|dry eye patients
61907489|NCT05423860||Prostate cancer|patients with a diagnosis of prostate cancer
61907490|NCT05423860||breast cancer|Patients with a diagnosis of breast cancer
62291434|NCT06656403|OTHER|Control group|non-dry eye patients
62291435|NCT00943995|OTHER|Treatment Arm|Getting Growth Hormone therapy TIW instead of nightly in the Pediatric Tanner 1 Hemodialysis population.
62291436|NCT00095563|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
62291437|NCT03746691|EXPERIMENTAL|Citalopram, 20 mg, IV|After placement of a high resolution impedance manometry catheter (transnasally), citalopram will be administered IV over 30 minutes (20 mg in 100ml saline). Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
62464381|NCT03874871||Function preserving gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.
62464382|NCT03874871||Standard gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.
62464383|NCT05843279|EXPERIMENTAL|Myofunctional therapy|The intervention group receives myofunctional therapy sessions in which orofacial exercises are performed.
62464384|NCT05843279|OTHER|Breastfeeding session|In this group, a session is held in which the posture and attachment of the baby to the mother's chest is assessed and corrected.
62464385|NCT03065582|EXPERIMENTAL|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
62464386|NCT03966560|EXPERIMENTAL|Primary open-angle glaucoma|"Participants over 40 years of age and diagnosed with primary open-angle glaucoma.~Medical treatment was initiated for the diagnosed participants."
61907491|NCT05423860||Normal|Patients without a diagnosis
61907492|NCT05423860||tramatic brain injury|patients with a diagnosis of traumatic brain injury
61907493|NCT03704753|ACTIVE_COMPARATOR|SAPB group A|SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
61907494|NCT03704753|PLACEBO_COMPARATOR|SAPB group B|SAPB single injection (placebo). 30ml of SodiumChloride 0.9 is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
61907495|NCT03704753|ACTIVE_COMPARATOR|SAPB group C|SAPB single injection and catheter. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery and a multi-holed catheter is left in place. 20ml of Ropivacaine 2mg/ml is injected every 12h through catheter postoperatively.
62093685|NCT06698055|ACTIVE_COMPARATOR|aWS = Weight stack resistance exercise intervention group adults|WS undergo a twelve-week training intervention with alternating two to three sessions per week. At each training session the participant will perform four sets of leg press and a leg extension with seven repetitions per set in each machine were resistance is provided by a flywheel and a weight stack respectively.
62093686|NCT06698055|NO_INTERVENTION|aCON = Control group adults|The CON group will continue living as normally with the aim of remaining at a constant activity level like that at baseline. All groups undergo a baseline test battery witch is repeated following the end of the training period. After the training period all groups enter in to a detraining period were no weight training of the lower limb will be conducted for eight weeks. Following the detraining period the test battery will once more be repeated.
62093687|NCT06698055|ACTIVE_COMPARATOR|cFW = Flywheel resistance exercise intervention group children|FW undergo a twelve-week training intervention with alternating two to three sessions per week. At each training session the participant will perform four sets of leg press and a leg extension with seven repetitions per set in each machine were resistance is provided by a flywheel and a weight stack respectively.
62093688|NCT06698055|ACTIVE_COMPARATOR|cWS = Weight stack resistance exercise intervention group children|WS undergo a twelve-week training intervention with alternating two to three sessions per week. At each training session the participant will perform four sets of leg press and a leg extension with seven repetitions per set in each machine were resistance is provided by a flywheel and a weight stack respectively.
62291438|NCT03746691|PLACEBO_COMPARATOR|Placebo, IV|After placement of a high resolution impedance manometry catheter (transnasally), placebo (saline 100ml) will be administered IV over 30 minutes. Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
62464387|NCT03966560|NO_INTERVENTION|Healthy|Healthy volunteers who do not have systemic disease that may affect the choroidal thickness and have no ocular features that may affect test measurements.
62464388|NCT01909076|ACTIVE_COMPARATOR|Control PCPs and their patients|PCPs randomized to the control condition will receive electronic decision support tools. Patients of control PCPs will receive education materials that will be developed and made available to both control and intervention patients.
61907496|NCT03704753|ACTIVE_COMPARATOR|SAPB group D|Continious intercostal catheter. 20ml of Ropivacaine 7,5mg/ml is injected through intercostal catheter, which i placed under thoracoscopic visualization. After single injection a continuous infusion of Ropivacaine 2mg/ml is started (weight dependent daily dosage).
62093689|NCT06698055|NO_INTERVENTION|cCON = Control group children|The CON group will continue living as normally with the aim of remaining at a constant activity level like that at baseline. All groups undergo a baseline test battery witch is repeated following the end of the training period. After the training period all groups enter in to a detraining period were no weight training of the lower limb will be conducted for eight weeks. Following the detraining period the test battery will once more be repeated.
62093690|NCT02040233|ACTIVE_COMPARATOR|BAY1067197 (10 mg)|
61907497|NCT03704753|ACTIVE_COMPARATOR|SIP group A|SIP single injection 20ml of Ropivacaine 7,5mg/ml is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
61907498|NCT03704753|PLACEBO_COMPARATOR|SIP group B|SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
62093691|NCT02040233|ACTIVE_COMPARATOR|BAY1067197|
62093692|NCT02040233|PLACEBO_COMPARATOR|Placebo (10 mg)|
61907499|NCT03602560|EXPERIMENTAL|Seladelpar 5-10 mg|
62657231|NCT01861392|ACTIVE_COMPARATOR|sensory-motor training|Guidelines + sensory-motor training.Evaluation Biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires ADDQoL and BESTest. The intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose.
62464389|NCT01909076|EXPERIMENTAL|Intervention PCPs and patients|The Intervention Condition has three main components: access to nurse care management, access to the patient registry, and academic detailing for intervention PCPs. Intervention PCPs will also receive the control intervention of electronic decision support tools, and patients of intervention PCPs will receive the same patient education materials as patients of control PCPs.
62464390|NCT02987491|EXPERIMENTAL|Exercise Metabolic Study Day|"Participants will perform a single bout of moderate intensity exercise on a cycle ergometer for 60 minutes.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
62464391|NCT02987491|NO_INTERVENTION|Resting Metabolic Study Day|"Participants will rest quietly in bed for 60 minutes and resting energy metabolism will be measured with a ventilated hood.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
62464392|NCT04331847||Quantitative observational descriptive study|among women presenting for abortion-related complications
62464393|NCT04331847||Qualitative study|among women with a near-miss or a potentially life-threatening complication
62657232|NCT01861392|ACTIVE_COMPARATOR|guidelines|receive the same guidelines and reviews that group orientation and training sensorineural engine and will be guided home exercises for postural twice a week 45 minutes for 12 weeks.
62657233|NCT02750293|ACTIVE_COMPARATOR|cholecalciferol|vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
62657234|NCT02750293|PLACEBO_COMPARATOR|placebo|placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
62657235|NCT04130087|EXPERIMENTAL|Selegiline Group|27 healthy participants who will be administered a single 10mg tablet of selegiline hydrochloride.
62464394|NCT04331847||Rapid health facility assessment with the health professional|in charge of Post-Abortion Care
62464395|NCT04331847||Knowledge Attitudes, Practice and Behavior quantitative survey|among health care providers involved in the management of abortion-related complications
62464396|NCT02137993|EXPERIMENTAL|A-prexa|A-prexa 5, 10mg
62464397|NCT02137993|ACTIVE_COMPARATOR|Zyprexa|Zyprexa 5, 10mg
62657236|NCT04130087|PLACEBO_COMPARATOR|Placebo Group|27 healthy participants who will be administered a single lactose tablet (placebo)
62657237|NCT02038192|EXPERIMENTAL|Living with Hope Program|"All participants in this group will receive the Living with Hope Program. It consists of viewing a 15 minute film on hope. Then for 5 minutes at the end of each day to write Stories of the Presentto work on over one month. Stories of the present is a directed journaling activity which includes writing challenges of the day, what was their hope that day and what would be their hope tomorrow."
62657238|NCT02038192|EXPERIMENTAL|Stories of the Present|Participants in this group will write Stories of the Present and not see the film.
62657239|NCT02038192|NO_INTERVENTION|Usual Care|Participants in this group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
61907500|NCT03602560|EXPERIMENTAL|Seladelpar 10 mg|
62464398|NCT01270919|OTHER|BioDuct Meniscal Repair Device|BioDuct Meniscal Repair Device
62657240|NCT03445169|EXPERIMENTAL|Fasting|Belzutifan tablets taken after fasting
62657241|NCT03445169|EXPERIMENTAL|Non-Fasting|Belzutifan taken after eating a high calorie meal
62657242|NCT01933724|EXPERIMENTAL|5 mg prednisone|Subjects will be randomized to 5 mg per day of prednisone for a 6 month period.
61907501|NCT03602560|PLACEBO_COMPARATOR|Placebo|
61907502|NCT00546598|OTHER|Duraloc Option COC Hip|
61907503|NCT03666156||Whole Sample|Female, caucasians, aged 18-65 years
62291439|NCT00079378|EXPERIMENTAL|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days.~Cohorts of 6 patients receive escalating doses of decitabine until the MEPD is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences DLT.~Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.~Cohorts of 3-6 patients receive escalating doses of valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity."
62464399|NCT03549364|EXPERIMENTAL|Endurance race|"1. baseline investigations with CT and lab tests~2. the same CT and lab tests \< 24h after an endurance race~3. CT and lab tests again about 1-2weeks after the race"
62464400|NCT04863586||Tested positive for SARS-CoV-2|Eligible participants who have had a positive SARS-CoV-2 test will be included in the case group of the study.
62464401|NCT04863586||Not tested for SARS-CoV-2|A random sample of age, sex, and DMT matched people with MS who have not been tested for SARS-CoV-2 will be included in the control group of the study.
62093693|NCT02040233|PLACEBO_COMPARATOR|Placebo|
62093694|NCT00568347||long acting bronchodilator|salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
62291440|NCT02005822|EXPERIMENTAL|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
62291441|NCT02005822|NO_INTERVENTION|Control|"Refusal control group:~Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remain unchanged.~Historical control group:~Infants with birth date 1-11-2011 till 1-07-2012 with sensorineural hearing loss and congenital CMV."
62291442|NCT04779502|EXPERIMENTAL|oregano|oregawash mouthwash was used twice times daily for 7 days
62291443|NCT04779502|PLACEBO_COMPARATOR|placebo|distilled water was used twice times daily for 7 days
62291444|NCT04779502|ACTIVE_COMPARATOR|chlorhexidine|Corsodyl with 0.2%CHX mouthwash was used twice times daily for 7 days
62291445|NCT06376721|EXPERIMENTAL|treatment arm|"Linperlisib:~Phase Ib：oral, 80 mg/d, QD; Phase II： oral, RP2D, QD.~Camrelizumab for Injection:~Phase Ib \& Phase II：intravenous drip, 200 mg/d, Q3W, administered on day 1 of each cycle (3 weeks in each cycle)~Pegaspargase:~Phase Ib \& Phase II：intramuscular injection，2500 IU/m2, Q3W, administered on day 1 of each cycle (3 weeks in each cycle)"
62291446|NCT03499509|EXPERIMENTAL|Low Glycemic Diet|
62291447|NCT03499509|PLACEBO_COMPARATOR|High Glycemic Diet|
62291448|NCT04108429|EXPERIMENTAL|Mobile self-help intervention|Participants will have open access to the IntelliCare system.
62291449|NCT02210338|EXPERIMENTAL|Karl Storz C-MAC|Intubation of patient using the Karl Storz C-MAC video laryngoscope
62464402|NCT00567177|ACTIVE_COMPARATOR|1|
62464403|NCT00567177|PLACEBO_COMPARATOR|2|
61907504|NCT01123993|NO_INTERVENTION|Lifestyle counselling|
61907505|NCT06166121|EXPERIMENTAL|ShenJu|On the basis of standardized drug treatment for Hyperlipidemia combined with carotid atherosclerosis, participants who met the inclusion criteria were randomly given ShenJu intervention on the day of inclusion, taking it twice a day for 90 days.
62464404|NCT02624557|EXPERIMENTAL|Moderate hepatic impairment group|Subjects with moderate hepatic impairment with Child-Pugh score 7 - 9
62464405|NCT02624557|EXPERIMENTAL|Severe hepatic impairment group|Subjects with severe hepatic impairment with Child-Pugh score 10 - 15
61907506|NCT06166121|PLACEBO_COMPARATOR|placebo|On the basis of standardized drug treatment for Hyperlipidemia combined with carotid atherosclerosis, participants who met the inclusion criteria were randomly given placebo granules on the day of inclusion, which were taken twice a day for 90 days (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
61907507|NCT01253811|EXPERIMENTAL|rFXIII 35 IU/kg|
61907508|NCT06374043|OTHER|Option 1 (D-D-P-P)|Week 1. Dapagliflozin 10 mg/day Week 2. Wash-out Week 3. Dapagliflozin 10 mg/day Week 4. Wash-out Week 5. Placebo Week 6. Wash-out Week 7. Placebo Week 8. Wash-out
62093695|NCT00568347||bronchodilator/ inhaled corticosteroid|fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
62093696|NCT00568347||C|Fluticasone 100mcg/salmeterol 50mcg
62093697|NCT02809911|OTHER|Sham of Provant|Sham of Provant Therapy System
62093698|NCT02809911|OTHER|Active Provant|Active Provant Treatment
62464406|NCT02624557|EXPERIMENTAL|Matching healthy control group|Subjects with apparent normal liver function matched to the hepatic impairment subjects by sex, race, age, and weight.
62464407|NCT04753710|EXPERIMENTAL|Chloroprocaine|Chloroprocaine 3% ocular gel
62464408|NCT04753710|PLACEBO_COMPARATOR|Placebo|Vehicle for chloroprocaine 3% ocular gel
62464409|NCT02210390|EXPERIMENTAL|Intervention|Psycho-education Sessions will be offered weekly basis
62464410|NCT02210390|NO_INTERVENTION|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
62464411|NCT03571880|EXPERIMENTAL|CNSLBP group|
62093699|NCT04599452|EXPERIMENTAL|10 patients with recurrent refractory elderly AML were treated|The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
62093700|NCT06366893|EXPERIMENTAL|Study group|The study group will be supplemented with DHA and AA emulsion for 28 days. Patients will be followed up until hospital discharge. The emulsion will be administered by nasogastric or orogastric tube together with the scheduled milk intake (from the bank or the mother's own with a differentiated amount of supplementation depending on the type of milk administered and the infant's weight).
62093701|NCT06366893|NO_INTERVENTION|Control group|The control group will not be supplemented with DHA and AA emulsion. Patients will be followed up until hospital discharge.
62093702|NCT01287338|EXPERIMENTAL|Lower Puncta Delivery|
62093703|NCT01287338|EXPERIMENTAL|Double Puncta Delivery|
62093704|NCT06414902|EXPERIMENTAL|18F-FAraG PET|Participants found to be eligible to take part in this study, participant will have a 18F-FAraG PET scan as described below. Before you start treatment, you will have standard-of-care imaging and then undergo the research 18F-FAraG PET scan. About 20 minutes before the injection of the 18F-FAraG imaging tracer, you will drink two 8-ounce bottles of water to help clear the imaging tracer from your kidneys.
62093705|NCT05604235|EXPERIMENTAL|Therapeutic strength exercise group|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. The protocol will be carried out in approximately 30 minutes.
62291450|NCT02210338|EXPERIMENTAL|Bonfils Intubation Fibrescope|Intubation of patient using Bonfils Intubation Fibrescope
62291451|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse \>90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
62291452|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
62464412|NCT03571880|ACTIVE_COMPARATOR|Healthy control group|
62464413|NCT04785677|EXPERIMENTAL|Comprehensive Trauma-Based Reentry Program|Participants will complete up to19 session comprehensive trauma-based reentry program.
62464414|NCT04785677|NO_INTERVENTION|Treatment as usual (TAU)|Participants will be receive all reentry services normally eligible to receive by the state or the community to which they are released.
62464415|NCT01520909|EXPERIMENTAL|Eltrombopag plus standard of care|Part 1, double-blind treatment group
61907509|NCT06374043|OTHER|Option 2 (D-P-D-P)|Week 1. Dapagliflozin 10 mg/day Week 2. Wash-out Week 3. Placebo Week 4. Wash-out Week 5. Dapagliflozin 10 mg/day Week 6. Wash-out Week 7. Placebo Week 8. Wash-out
61907510|NCT06374043|OTHER|Option 3 (D-P-P-D)|Week 1. Dapagliflozin 10 mg/day Week 2. Wash-out Week 3. Placebo Week 4. Wash-out Week 5. Placebo Week 6. Wash-out Week 7. Dapagliflozin 10 mg/day Week 8. Wash-out
62464416|NCT01520909|PLACEBO_COMPARATOR|Placebo plus standard of care|Part 1, double-blind treatment group
61907511|NCT06374043|OTHER|Option 4 (P-P-D-D)|Week 1. Placebo Week 2. Wash-out Week 3. Placebo Week 4. Wash-out Week 5. Dapagliflozin 10 mg/day Week 6. Wash-out Week 7. Dapagliflozin 10 mg/day Week 8. Wash-out
62464417|NCT01520909|EXPERIMENTAL|Eltrombopag plus standard of care (Part 2 open-label)|Part 2, open-label
62464418|NCT01345045|EXPERIMENTAL|ABT-639|ABT-639 twice daily for 6 weeks
61907512|NCT06374043|OTHER|Option 5 (P-D-P-D)|Week 1. Placebo Week 2. Wash-out Week 3. Dapagliflozin 10 mg/day Week 4. Wash-out Week 5. Placebo Week 6. Wash-out Week 7. Dapagliflozin 10 mg/day Week 8. Wash-out
61907513|NCT06374043|OTHER|Option 6 (P-D-D-P)|Week 1. Placebo Week 2. Wash-out Week 3. Dapagliflozin 10 mg/day Week 4. Wash-out Week 5. Dapagliflozin 10 mg/day Week 6. Wash-out Week 7. Placebo Week 8. Wash-out
62464419|NCT01345045|ACTIVE_COMPARATOR|pregabalin|pregabalin starting dose twice daily for week one then titrated up to maintenance dose twice daily for duration of the study
62291453|NCT05951283|NO_INTERVENTION|MDI|"All participants will have:~Continuous Glucose Monitoring Neuropathy Assessments and Pain Questionnaires ACR, Blood Tests"
62291454|NCT05951283|ACTIVE_COMPARATOR|Artificial Pancreas - Closed Loop|"All participants will have:~Continuous Glucose Monitoring Neuropathy Assessments and Pain Questionnaires ACR, Blood Tests"
62291455|NCT04599361||Patients with CHD|"outpatient cardiology practices, hospitals with a cardiology department and hospitals with a cardiology and heart surgery department (n=20) in Germany Patients with chronic coronary heart disease and 2- or 3-vessel or main-vessel disease who are being treated at one of the recruitment sites with a promptly planned intervention for myocardial revascularization who are insured with pre-specified German health insurance companies (BARMER or TK)~Patients will receive questionnaires."
62291456|NCT05354960||Validation of LIMB-Q questionnaire|We plan to validate the questionnaires for quality of life and functional impairment in a mixed study population. In addition, CROMs, specifically the active range of motion, the 2 PD, compara-tive circumference measurements, AOFAS and MFS will be collected. In addition, photo documen-tation of the operated lower extremity will be performed. The results obtained will be correlated with each other.
62291457|NCT00749333|EXPERIMENTAL|1|
62291458|NCT00749333|PLACEBO_COMPARATOR|2|
62291459|NCT00805415|EXPERIMENTAL|Arm 1|
62291460|NCT00805415|EXPERIMENTAL|Arm 2|
62291461|NCT02840136|EXPERIMENTAL|Standard of care|Sputum is collected from patients receiving standard of care therapy with IV piperacillin-tazobactam, ceftazidime or meropenem
62657243|NCT01933724|EXPERIMENTAL|0 mg prednisone|Subjects will be randomized to 0 mg per day of prednisone dose for a 6 month period.
61907514|NCT02400164|EXPERIMENTAL|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
61907515|NCT06531967||Necker hospital from Paris, France|Kidney recipients from Necker hospital
61907516|NCT06531967||Saint-Louis hospital from Paris, France|Kidney recipients from Saint-Louis hospital
61907517|NCT06531967||Bichat hospital from Paris, France|Kidney recipients from Bichat hospital
61907518|NCT06531967||Bretonneau hospital from Tours, France|Kidney recipients from Bretonneau hospital
61907519|NCT06531967||Toulouse hospital, France|Kidney recipients from Toulouse hospital
61907520|NCT06531967||KU Leuven, Belgium|Kidney recipients from KU Leuven
61907521|NCT06531967||Liege hospital from Belgium|Kidney recipients from Liege hospital
61907522|NCT06531967||Leiden University Medical Center from the Netherlands|Kidney recipients from Leiden University Medical Center
61907523|NCT06531967||Hospital of the University of Pennsylvania from Philadelphia, US|Kidney recipients from Hospital of the University of Pennsylvania
61907524|NCT06531967||Mayo Clinic from Phoenix, US|Kidney recipients from Mayo Clinic
61907525|NCT06531967||UCSF database|Kidney recipients data from real-world UCSF database
61907526|NCT06531967||AP-HP database|Kidney recipients data from real-world AP-HP database
61907527|NCT00648050|EXPERIMENTAL|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
61907528|NCT00648050|ACTIVE_COMPARATOR|2|Verelan® PM Extended-Release Capsules, 300 mg
61907529|NCT00225264|EXPERIMENTAL|Pioglitazone QD|
61907530|NCT00225264|ACTIVE_COMPARATOR|Glimepiride QD|
62291462|NCT01510327|EXPERIMENTAL|PROMUS Element|Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.
62291463|NCT05675007|EXPERIMENTAL|Colon-delivered multivitamin supplement|Within this arm, study subjects will consume a colon-delivered multivitamin supplement for 6 weeks. Subjects are instructed to consume the capsule daily during breakfast. The capsule must be taken orally with a glass of water.
62291464|NCT05675007|PLACEBO_COMPARATOR|Placebo|Within this arm, study subjects will consume a placebo capsule for 6 weeks. Subjects are instructed to consume the capsule daily during breakfast. The capsule must be taken orally with a glass of water.
62291465|NCT04957563|EXPERIMENTAL|experimental rehabilitation|recived olfactory rehabilitation
62291466|NCT04957563|NO_INTERVENTION|control|withouth olfactory rehabilitation
62464420|NCT01345045|PLACEBO_COMPARATOR|Placebo|Placebo twice daily for 6 weeks
62464421|NCT05328986||COVID|Patients who have had a confirmed diagnosis of COVID-19.
62657244|NCT02340455|EXPERIMENTAL|Pregabalin_male|
62657245|NCT02340455|EXPERIMENTAL|Pregabalin_female|
62657246|NCT02340455|ACTIVE_COMPARATOR|Placebo_male|
62291467|NCT06331624|EXPERIMENTAL|GRI-0621|GRI-0621 (tazarotene) 4.5mg, administered orally once daily (QD)
62291468|NCT06331624|EXPERIMENTAL|Placebo|Placebo 4.5mg, administered orally once daily (QD)
62291469|NCT00531193|OTHER|1|Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
61907531|NCT02700633||Those with pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
62093706|NCT05604235|EXPERIMENTAL|Passive mobilization group|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulohumeral complex and neurodynamics, where mobilisations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
62291470|NCT02768376|ACTIVE_COMPARATOR|General anesthesia group|General anesthesia group: Standard anesthetic technique will be applied.Anesthesia will be induced by propofol 1% (1-2 mg/kg), Fentanyl 1-2 mic/kg, and Atracurium 0.5 mg/kg then according to train of four response. Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
62291471|NCT02768376|EXPERIMENTAL|Spinal anesthesia group|While in sitting position; intrathecal injection using 25 G spinal needle using 3 mls of Bupivacaine 0.5% with 20 mic Fentanyl, at L 2-3 level the patient head will be lowered till sensory blockade of T6 obtained at least.
62291472|NCT01553149|EXPERIMENTAL|Arm I (low-dose lenalidomide)|Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62291473|NCT01553149|EXPERIMENTAL|Arm II (high-dose lenalidomide)|Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62291474|NCT03011125|PLACEBO_COMPARATOR|placebo|
62291475|NCT03011125|EXPERIMENTAL|Dexlansoprazole Injection|
62291476|NCT04321811||Participants|"Adult men and women currently in the United States and willing to provide written informed consent and:~* who are feeling sick but have not tested positive for COVID-19~* who are feeling sick and have tested positive for COVID-19~* People who are not feeling sick but want to participate"
62291477|NCT05642377|EXPERIMENTAL|HGR4113 300 mg Single Dose|Single oral dosing of HGR4113 300 mg
62291478|NCT05642377|PLACEBO_COMPARATOR|Placebo 300 mg Single Dose|Single oral dosing of placebo 300 mg
62291479|NCT05642377|EXPERIMENTAL|HGR4113 600 mg Single Dose|Single oral dosing of HGR4113600 mg
62291480|NCT05642377|PLACEBO_COMPARATOR|Placebo 600 mg Single Dose|Single oral dosing of placebo 600 mg
62291481|NCT05642377|EXPERIMENTAL|HGR4113 1200 mg Single Dose|Single oral dosing of HGR41131200 mg
62291482|NCT05642377|PLACEBO_COMPARATOR|Placebo 1200 mg Single Dose|Single oral dosing of placebo 1200 mg
62291483|NCT05642377|EXPERIMENTAL|HGR4113 200 mg Multiple Dose|Multiple oral dosing of HGR4113 200 mg, twice daily
62291484|NCT05642377|PLACEBO_COMPARATOR|Placebo 200 mg Multiple Dose|Multiple oral dosing of placebo 200 mg, twice daily
62291485|NCT05642377|EXPERIMENTAL|HGR4113 400 mg Multiple Dose|Multiple oral dosing of HGR4113 400 mg, twice daily
61907532|NCT02700633||Those without pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
61907533|NCT00633542|EXPERIMENTAL|TD|thalidomide-dexamethasone
61907534|NCT00633542|ACTIVE_COMPARATOR|ID|Interferon-dexamethasone
61907535|NCT05607212|EXPERIMENTAL|Kettlebell Swing Group|Participants will perform two-handed kettlebell swings
61907536|NCT05607212|ACTIVE_COMPARATOR|Active Comparator Group|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals.
61907537|NCT05607212|OTHER|Control group|participants will be educated on the benefit of a kettlebell swing.
61907538|NCT05046327|EXPERIMENTAL|20 mg Avatrombopag daily|Avatrombopag
61907539|NCT04308200|OTHER|CO-OP+NDT group|The CO-OP+NDT group received twelve sessions of CO-OP approach, with the baseline and end of treatment assessments, each lasting approximately one hour. Parents and / or caregivers were advised to observe sessions as often as possible to encourage adaptation and transfer to life. Furthermore, CO-OP+NDT group received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist.
62093707|NCT03112278|ACTIVE_COMPARATOR|Ceramic restorations|Ceramic ultrathin occlusal veneers
62291486|NCT05642377|PLACEBO_COMPARATOR|Placebo 400 mg Multiple Dose|Multiple oral dosing of placebo 400 mg, twice daily
62291487|NCT01804231|OTHER|18F-FCH PET/MRI imaging|Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)
62291488|NCT01480739|EXPERIMENTAL|1|AZD5069 100 mg capsules (50 mg BD) for 7 days
62291489|NCT01480739|EXPERIMENTAL|2|Placebo twice daily for 7 days
62291490|NCT05863611||25 individuals with frailty syndrome with type 2 diabetes|
62291491|NCT05863611||25 individuals without frailty syndrome with type 2 diabetes|
62291492|NCT05215184||Chronic Pain Patients|
62291493|NCT05215184||Healthy Controls|
62291494|NCT01530139|PLACEBO_COMPARATOR|Level 0|Level 0: Control group - participants will receive non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
62291495|NCT01530139|EXPERIMENTAL|Level 1|Level or Group 1: participants will receive personalised dietary advice based on their dietary intake data alone.
62291496|NCT01530139|EXPERIMENTAL|Level 2|Level or Group 2: participants will receive personalised dietary advice taking their dietary intake and phenotypic data ( obesity-related phenotypes and clinical biomarkers) into account.
62291497|NCT01530139|EXPERIMENTAL|Level 3|Level or Group 3 : participants will receive personalised dietary advice taking their dietary intake, phenotypic (obesity-related markers) and genotypic data into account.
62291498|NCT01815957|EXPERIMENTAL|Ranalozine|After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
62464422|NCT01689792|ACTIVE_COMPARATOR|CitraFleet|Administration of CitraFleet
62464423|NCT01689792|EXPERIMENTAL|MOVIPREP|Administration of MOVIPREP
62464424|NCT00354198|ACTIVE_COMPARATOR|corticosteroids|\[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
62464425|NCT00354198|EXPERIMENTAL|pentoxifylline + corticosteroids|\[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90
62464426|NCT02666300|EXPERIMENTAL|TaperGuard ETT|tracheal intubation with the TaperGuard ETT，the ETT cuff is Taper-shangped.
62464427|NCT05807932|EXPERIMENTAL|Venetoclax|Venetoclax treatment will be started orally once a day with food, one day before FLAMSA conditioning therapy and stopped the day before high-dose Treosulfan. The total duration of treatment with Venetoclax will be 6 days (day -11 to -6 before stem cell infusion). Patients with active disease at transplant will receive a 3-day ramp-up prephase of Ara-C (100mg total dose infused in 1h) with daily increasing doses of Venetoclax to prevent TLS during conditioning. Total treatment duration with Venetoclax in patients with active disease at transplant will be 8 days (day -13 to -6 before stem cell infusion).
62464428|NCT01983761|EXPERIMENTAL|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|"Fludarabine, Clofarabine, Busulfan, Anti-thymocyte Globulin (ATG), Total Body Irradiation (TBI) (Myeloablative) Day Treatment~* Day0 Admit, IV hydration, rituximab 375 mg/m2 (B cell malignancy)~* Day 1 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~* Day2 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~* Day3 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~* Day4 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000, rabbit ATG 1.25 mg/kg~* Day5 Low-dose TBI 2 Gy in AM, rabbit ATG 1.75 mg/kg~* Day6 Rest~* Day7 Rest~* Day8 Cord blood infusions"
62464429|NCT01983761|EXPERIMENTAL|Fludarabine, Melphalan, ATG (Reduced Intensity)|"Day Treatment~* Day0 Admit, hydration~* Day1 Fludarabine 40 mg/m2 IV~* Day2 Fludarabine 40 mg/m2 IV, rabbit ATG 1.25 mg/kg~* Day3 Fludarabine 40 mg/m2 IV, rabbit ATG 1.75 mg/kg~* Day4 Fludarabine 40 mg/m2 IV and Melphalan 140 mg/m2 IV~* Day5 Rest Day6 Cord blood infusions"
62464430|NCT03283943|EXPERIMENTAL|Durvalumab and focal radiotherapy|Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
62464431|NCT03027830|EXPERIMENTAL|iFR pressure-wire|
62464432|NCT03027830|ACTIVE_COMPARATOR|Conventional|
62093708|NCT03112278|ACTIVE_COMPARATOR|Composite resin restorations|Composite resin ultrathin occlusal veneers
62291499|NCT01622426|ACTIVE_COMPARATOR|New formula IgE mediated testing|Children with IgE-mediated CMA performed oral food challenge with the new formula
62291500|NCT01622426|ACTIVE_COMPARATOR|New formula non-IgE-mediated testing|Children with non-IgE-mediated CMA performed oral food challenge with the new formula
62291501|NCT04980131|EXPERIMENTAL|Group C|Group C were received PPSF with pointed lotus-style regulator
62464433|NCT03601962|EXPERIMENTAL|Aqualief® tablets|oral mucoadesive tablets
62464434|NCT03601962|PLACEBO_COMPARATOR|Placebo tablets|oral mucoadesive tablets
62464435|NCT05426005|EXPERIMENTAL|Cadonilimab|Cadonilimab alone
62657247|NCT02340455|ACTIVE_COMPARATOR|Placebo_female|
62291502|NCT04980131|EXPERIMENTAL|Group B|Group B were received PPSF with Flat ended lotus root regulator
62291503|NCT04980131|NO_INTERVENTION|Group A|Group A were received traditional PPSF
62291504|NCT06042374|EXPERIMENTAL|Study group|The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions.
62464436|NCT04921462|ACTIVE_COMPARATOR|Silastic group|included patients who underwent nasal septoplasty followed by insertion of silastic intranasal splint
62464437|NCT04921462|ACTIVE_COMPARATOR|Quilting group|included patients who underwent septoplasty followed by quilting suture (Septal through and through suture)
62464438|NCT05479110|EXPERIMENTAL|Experimental group|The experimental group was given four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
62464439|NCT05479110|ACTIVE_COMPARATOR|Control group|The control group was given case studies(text).
62464440|NCT01930227|EXPERIMENTAL|TEAS Treatment|Patients were given 30min of TEAS at PC6 after spinal anesthesia
62464441|NCT01930227|SHAM_COMPARATOR|Non-acupoint stimulation|Patients were given 30min of electrical stimulation at shoulder after spinal anesthesia
62737474|NCT04193111||Positive TMD pain screener|Patients who have ≥3 points on the TMD pain screener (0-7 range) are anticipated to have a painful TMD based on the DC/TMD and are therefore considered having a positive outcome on the TMD pain screener.
62291505|NCT06042374|SHAM_COMPARATOR|Control group|The athletes included in the CG performed only Standard Core Strengthening Exercises.
62093709|NCT01641003||Fresh tumor specimen|Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab.
62093710|NCT06688136|EXPERIMENTAL|transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block|Twenty ml of 0.4% ropivacaine was administered between the erector spinae muscle and the transverse process. Twenty ml of 0.4% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.
62291506|NCT04224935|ACTIVE_COMPARATOR|Leukocyte Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin will be used
62291507|NCT04224935|ACTIVE_COMPARATOR|connective tissue|connective tissue will be used
62464442|NCT01930227|NO_INTERVENTION|Control|No stimulation was given
62464443|NCT02728102|EXPERIMENTAL|Lenalidomide, vaccine, and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.
62291508|NCT00587535||Hemochromatosis|Hemochromatosis
62291509|NCT00587535||Living-related liver donation|Living-related liver donation
62291510|NCT05046028|EXPERIMENTAL|Test|50 patients with squamous cell head cancer over 18 years of age, receiving chemoradiation therapy, receiving 3 bottles (х 200 ml) of ONS with Protein Oncosensation with a neutral taste throughout the course of treatment.
62291511|NCT05046028|ACTIVE_COMPARATOR|Prospective Control group|50 patients over 18 years of age with squamous cell carcinoma of the head and neck, receiving chemoradiation therapy, receiving standard nutritional therapy with a neutral taste throughout the course of treatment.
62291512|NCT05046028|SHAM_COMPARATOR|Retrospective Control group|60 patients who received chemoradiotherapy earlier with standard nutritional support.
62291513|NCT00702143|EXPERIMENTAL|AD subjects|
62291514|NCT00702143|EXPERIMENTAL|MCI Subjects|MCI (mild cognitive impairment)
62291515|NCT00702143|EXPERIMENTAL|Healthy controls|
62291516|NCT01906749|PLACEBO_COMPARATOR|Placebo|Placebo
62464444|NCT02728102|ACTIVE_COMPARATOR|Lenalidomide and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.
62093711|NCT06688136|ACTIVE_COMPARATOR|Infiltration|Periarticular infiltration of 40 ml of 0.4% ropivacaine prior to closing the incision
62093712|NCT05890911||Study group|Participants with the diagnosis of sleep-disordered breathing
62093713|NCT05890911||Control group|Healthy participants without diagnosis of sleep-disordered breathing
62093714|NCT03393910|NO_INTERVENTION|Observational|Normal pelvic exam exposures: External exam followed by speculum exam, followed by bimanual exam
62093715|NCT03393910|ACTIVE_COMPARATOR|Experimental Pelvic Exam|Changing the order of the pelvic exam Intervention: External exam, bimanual exam,speculum exam
62093716|NCT03831438|OTHER|Dose escalation|"Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc).~Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period)."
62291517|NCT01906749|ACTIVE_COMPARATOR|Colchicine|Colchicine 0.5mg once daily for 24 months
62291518|NCT05657184|EXPERIMENTAL|REGEND001|Transplantation of autologous airway basal cells
62093717|NCT05196737|EXPERIMENTAL|Single Arm|All participants completed 2 weeks of the study. Baseline reflex measurements will be collected during the first week of the study (Visits 1-4). No dry needling will occur during this week, with the aim of tracking any natural variability in nervous system excitability at the same time points as reflex measurements during the intervention week. All participants who participated in baseline reflex measurements during week 1 will continue to the second week of the study (Visits 5-7). Participants will receive dry needling to relieve spasticity in the target calf muscle (middle gastrocnemius) during Visit 5. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to DDN, immediately after DDN, 90 minutes after DDN, 24 hours after DDN, and 72 hours after DDN. These assessments will examine how you move your leg and how your nervous system responds to non-invasive nerve stimulation.
62093718|NCT02141581|EXPERIMENTAL|Group A Fluzone® (IM)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)~2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study"
62291519|NCT05329116|ACTIVE_COMPARATOR|Intra-articular PRP|For PRP treatment, 8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection. Patients will receive a single session of PRP treatment.
62291520|NCT05329116|ACTIVE_COMPARATOR|Intra-articular PRP + periarticular mesotherapy|"In addition to single session PRP treatment, patients will receive 3 weeks of mesotherapy treatment once a week (the first session will be with PRP treatment).~Sterile and disposable needle tip (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used in mesotherapy. Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used."
62291521|NCT01459978||Early CUSUM result group|"Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity.~Phase 2: results of the CUmulative SUM (CUSUM) will be provided for a period of 12 months (Early CUSUM result group), Phase 3: maternity will continue to receive the results of the CUmulative SUM (CUSUM) for a period of 12 months,"
62657248|NCT00937950|OTHER|HPV-052 study subjects Group|The study group consisted of a subset of HPV-008 (NCT00122681) study subjects (15-25 years old at first study vaccination), who at their last study visit (Visit 10, Month 48) in HPV-008 (NCT00122681) study displayed normal cervical cytology, but were tested positive for oncogenic HPV infection, or were pregnant and hence no cervical sample could be collected at their HPV-008 (NCT00122681) concluding visit.
61907540|NCT04308200|OTHER|NDT group|NDT group received just NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity and postural reactions.
62093719|NCT02141581|EXPERIMENTAL|Group B Fluzone® Intradermal (ID)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)~2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study"
62093720|NCT02141581|EXPERIMENTAL|Group C 2011-2012 FluMist®|"Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.~FluMist was only used in the first year of study."
62093721|NCT02138513|EXPERIMENTAL|Online MBCT|
61907541|NCT00329056|EXPERIMENTAL|1|40 mg MitoQ OD
62093722|NCT02138513|EXPERIMENTAL|group MBCT|
62093723|NCT02138513|NO_INTERVENTION|Treatment as usual|3 months waiting list, subsequent assignment to group or online MBCT
62464445|NCT02728102|ACTIVE_COMPARATOR|Maintenance Lenalidomide|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.
62464446|NCT01558141|ACTIVE_COMPARATOR|Follicular flushing|Flushing follicles with embryo culture media prior to aspiration.
61907542|NCT00329056|EXPERIMENTAL|2|80 mg MitoQ OD
61907543|NCT00329056|PLACEBO_COMPARATOR|3|Placebo
61907544|NCT05109455|EXPERIMENTAL|Food supplement|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
61907545|NCT05109455|ACTIVE_COMPARATOR|Comparator|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
61907546|NCT03664349||Older Adult Participants and Informal/Formal Caregiver Pairs|A sub-cohort of approximately 10 participant-caregiver pairs will utilize SE9000 and communication strategies over a 4-6-week period between LVR visits.
62093724|NCT01857453|EXPERIMENTAL|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
62464447|NCT05614960|EXPERIMENTAL|2.4μg vitamin B12|Participants need to consume 4 sheets (5g) of dried purple laver (Nori) daily for 4 weeks.
62657249|NCT05731765||Patients aged ≥18 years with presumed normal intracranial pressure|
62464448|NCT05614960|EXPERIMENTAL|4μg vitamin B12|Participants need to consume 7 sheets (8g) of dried purple laver (Nori) daily for 4 weeks.
62464449|NCT05614960|NO_INTERVENTION|Control|No intervention
62464450|NCT01550900|EXPERIMENTAL|Metformin ER|Participants receive two tablets of Metformin ER 500 mg once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy. Dose will be reached in a gradual escalation scheme to improve gastrointestinal tolerance. If participants experience side effects during dose escalation regimen, they will be reduced to one tablet of 500 mg daily, and may continue taking 500 mg daily for the duration of the study.
62657250|NCT05731765||Patients aged ≥18 years with suspected raised intracranial pressure|
62657251|NCT04167813|ACTIVE_COMPARATOR|Active Treatment|Participants randomised to the active treatment arm will take 8-24mg/day of ondansetron.
62657252|NCT04167813|PLACEBO_COMPARATOR|Matched placebo|Participants randomised to the placebo treatment arm will take matched placebo, administered as tablets.
62657253|NCT02993276||Treatment Group|All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
62657254|NCT06492993|EXPERIMENTAL|Intervention|CHN provides educational sessions with patients at time points.
62657255|NCT06492993|NO_INTERVENTION|Standard of Care|Standard of care to inform participant about the screening recommendations and check ins.
62657256|NCT04818801|EXPERIMENTAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Participants received Recombinant two-component COVID-19 vaccine (CHO cell) 0.5ml reconstituted by adjuvant solution, 2 shots at a interval 21 days, intramuscular injection
62657257|NCT04818801|PLACEBO_COMPARATOR|Placebo|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 2 shots at a interval 21 days, intramuscular injection
62657258|NCT00896831|ACTIVE_COMPARATOR|L-ornithine-L-aspartate|5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
62657259|NCT00896831|PLACEBO_COMPARATOR|placebo|5 g (1 sachet) of placebo comparator three times per day for 60 days
62657260|NCT06066567|EXPERIMENTAL|Experimental: treatment group|
62657261|NCT06066567|ACTIVE_COMPARATOR|control group|
62657262|NCT03617887|EXPERIMENTAL|Experimental group|Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus:
62657263|NCT03617887|EXPERIMENTAL|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise
62657264|NCT02214472|EXPERIMENTAL|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
62657265|NCT02214472|PLACEBO_COMPARATOR|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
62657266|NCT06092151|EXPERIMENTAL|Silver Diamine Fluoride|SDF treatment for caries in the primary teeth of children included
62657267|NCT06092151|ACTIVE_COMPARATOR|Usual Care|Usual care determined by child's dentist for caries in their primary teeth
61907547|NCT03664349||Older Adult Participants|The pilot cohort of approximately 100 adults over age 60, with vision impairment, will complete the Hearing Handicap Inventory for the Elderly (HHIE), an assessment of perceived impact of hearing impairment, and an objective hearing evaluation.
61907548|NCT03664349||Formal/Informal Caregivers|Identified persons who assist willing and eligible older adult pilot participants with two or more ADLs/IADLs.
62464451|NCT01550900|ACTIVE_COMPARATOR|Placebo|Control group given matched Placebo once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy.
62657268|NCT01416779|EXPERIMENTAL|Writing Group|This group will receive the writing intervention.
62657269|NCT01416779|NO_INTERVENTION|No Intervention|Non Writing Group
62657270|NCT01451658|NO_INTERVENTION|EVL or GVS treatment|"Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)"
62657271|NCT01451658|EXPERIMENTAL|Endoscopic treatment combined propranolol|Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
62657272|NCT00197743|ACTIVE_COMPARATOR|Vitamin A|Vitamin A + Beta Carotene
62657273|NCT00197743|ACTIVE_COMPARATOR|Multivitamins|Vitamins B, C, and E
62657274|NCT00197743|ACTIVE_COMPARATOR|Vitamin A + Multivitamins|Vitamin A + Beta Carotene, Vitamins B, C, and E
62657275|NCT00197743|PLACEBO_COMPARATOR|Placebo|Placebo
62737475|NCT04193111||Negative TMD pain screener|Patients who have \<3 points on the TMD pain screener (0-7 range) are anticipated NOT to have a painful TMD based on the DC/TMD and are therefore considered having a negative outcome on the TMD pain screener.
62464452|NCT01868529|EXPERIMENTAL|Low dose|
62464453|NCT01868529|EXPERIMENTAL|Medium dose|
62464454|NCT01868529|EXPERIMENTAL|High dose|
62464455|NCT06316921||PCA group|Patients received epidural patient-controlled analgesia for postoperative pain.
62464456|NCT06316921||Control group|Patients received standard of care for postoperative pain.
62464457|NCT01390493|EXPERIMENTAL|neurofeedback, alpha power|
62093725|NCT06102902|EXPERIMENTAL|Treatment (ZEN003694, cetuximab, encorafenib)|Patients receive ZEN003694 PO QD on days 1-28 of each cycle, cetuximab IV over 120 minutes on days 1 and 15 of each cycle, and encorafenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA, CT or MRI, and collection of blood samples throughout the trial. Patients may also undergo biopsy at screening and on study.
62093726|NCT01068054|ACTIVE_COMPARATOR|tacrolimus|Tacrolimus arm: active 0.1% tacrolimus eye ointment BID + placebo eye drops QID
62093727|NCT01068054|ACTIVE_COMPARATOR|cyclosporine|2% cyclosporine eye drops apply QID + placebo eye ointment apply bid
62093728|NCT06380166||In vitro stability investigation|
62291522|NCT01459978||CUSUM result Delayed group|Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity Phase 2: the results of CUmulative SUM (CUSUM) will not be shared. Phase 3: group receive CUmulative SUM (CUSUM) result (CUSUM result Delayed group) during the same period 12 months
62291523|NCT03624647|EXPERIMENTAL|Power toothbrush|
62291524|NCT03624647|PLACEBO_COMPARATOR|Manual toothbrush|
62291525|NCT03762304||Intervention group|The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
62291526|NCT03762304||Control group|The control group consists of individuals with a measured blood pressure just below the hypertensive cut-off of 140 mmHg systolic and 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact lower bound on blood pressure will be determined empirically. These individuals were not given the care encouragement intervention.
62291527|NCT06199167|EXPERIMENTAL|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes.
62291528|NCT06199167|EXPERIMENTAL|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes.
62093729|NCT05640128|OTHER|Aldosterone in HPLC-MS/MS,|Aldosterone in HPLC-MS/MS measurement
62291529|NCT00928330|EXPERIMENTAL|A|
62291530|NCT00928330|EXPERIMENTAL|B|
62093730|NCT04428164||Hospitalized patients|Any patient admitted to the study units (MDMC: 10ST; MCMC: A6; MMMC: A3; MRMC: 3Medical ) that do not have any of the exclusion criteria
62093731|NCT02209961||glaucoma and ocular hypertension|glaucoma and ocular hypertension
62093732|NCT02481882|OTHER|Healthy Volunteers|Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
62093733|NCT02481882|OTHER|MS Patients|Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
62291531|NCT00928330|EXPERIMENTAL|C|
62291532|NCT05935384||Cohort 1: Unresectable Stage III/IV NSCLC|Blood samples collected will be banked
62291533|NCT05935384||Cohort 2: Stage IV Colorectal|Blood samples collected will be banked
62291534|NCT05935384||Cohort 3: Unresectable Stage III/IV Breast - HR+ HER2-|Blood samples collected will be banked
62291535|NCT05935384||Cohort 4: Unresectable Stage III/IV Breast - HR- HER2+|Blood samples collected will be banked
62291536|NCT05935384||Cohort 5: Unresectable Stage III/IV Breast - Triple Positive|Blood samples collected will be banked
62291537|NCT05935384||Cohort 6: Unresectable Stage III/IV Breast - Triple Negative|Blood samples collected will be banked
62291538|NCT00559689||1|receive once-daily administration of inhaled glucocorticosteroids at bedtime
62657276|NCT01951950|ACTIVE_COMPARATOR|Nicardipine|"Subjects will receive a 15 mcg/kg bolus of nicardipine as needed followed by an infusion initiated at 5 mg/hr. Nicardipine may be titrated every 5 minutes, increasing 5 mg/hr and administering 15 mcg/kg bolus every minute to a maximum dose of 15 mg/hr. If systolic blood pressure (SBP) is not maintained \< 140 mmHg 5 minutes after achieving the maximum dose of nicardipine, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
62737476|NCT04211792||Glaucoma suspect or patients|Patients who has or suspected Glaucoma will be approached for the recruitment into this study. IOP will be measured in the sitting position with Icare tonometers in a random order in both the eyes. IOP measurements by GAT will be taken after Icare measurements followed by CCT recording with ultrasound pachymeter.
62093734|NCT06546696|EXPERIMENTAL|COACH Intervention|"COACH intervenes at 3 levels: the individual child, the family, and the community.~Child-Level Intervention Content: We will direct skill-building lessons toward the child at developmentally appropriate levels.~Family-Level Intervention Content: Curricular components for parents are designed to leverage parents as agents of change for their children. As such, the group-based sessions includes realistic goal setting (SMART goals), strategies to navigate barriers, training in physical activity, and group-based accountability. During the session, parents and children will participate in a low to moderate physical activity.~Community-Level Content: The intervention is delivered in the context of a widely available community resource, local community centers across Middle Tennessee.~Online Platform: All participants will have access to an online on-demand health behavior change curriculum. Modules are self-paced and will take approximately 7 hours."
62093735|NCT06546696|ACTIVE_COMPARATOR|Adaptation Arm|The core components of the adaptation arm will mirror the COACH intervention arm. Each community center will be guided through a process of adapting the specific intervention content, and as such, will be unique to each of the 25 community centers randomized to this arm. In this way, the study tests the process of adapting the intervention, instead of a specific portfolio of adaptations.
62093736|NCT04572542|EXPERIMENTAL|Camrelizumab + Apatinib + nab-paclitaxel|Camrelizumab combined with Apatinib mesylate tablets and nab-paclitaxel in the second-line treatment of advanced gastric cancer
62093737|NCT01446003|EXPERIMENTAL|MK-8457-Placebo Sequence|Participants received MK-8457 100 mg twice daily (BID) for 10 days followed by Placebo for 10 days. Each treatment was separated by a 10-day washout.
62093738|NCT01446003|EXPERIMENTAL|Placebo-MK-8457 Sequence|Participants received Placebo for 10 days followed by MK-8457 100 mg BID for 10 days. Each treatment was separated by a 10-day washout.
62093739|NCT02335021|EXPERIMENTAL|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
62093740|NCT02335021|EXPERIMENTAL|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
62291539|NCT00559689||2|receive twice-daily administration of inhaled glucocorticosteroids
62291540|NCT04917926|EXPERIMENTAL|Financial and social intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, social incentives and weekly feedback on performance for 6 months.
62291541|NCT04917926|NO_INTERVENTION|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
62291542|NCT04917926|EXPERIMENTAL|Financial intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, and weekly feedback on performance for 6 months.
62291543|NCT06329934|EXPERIMENTAL|the intervention group|Establishment of a hierarchical monitoring and management team, Assessment of pressure injury, Communication, Intervention for pressure ulcer, Rehabilitation training
62291544|NCT06329934|ACTIVE_COMPARATOR|the control group|timely introduction of the current patient's condition to family members to alleviate their concerns, maintaining appropriate temperature (20 ℃\~22 ℃) and humidity (60.0%\~70.0%) in the ward, careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients, rehabilitation training
62291545|NCT03056443|EXPERIMENTAL|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
62291546|NCT03056443|NO_INTERVENTION|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
62291547|NCT03512236|EXPERIMENTAL|BC Pram Ins|Single subcutaneous injection of BC Pram Ins + injection of placebo (0.9% NaCl) to ensure the double dummy
62291548|NCT03512236|ACTIVE_COMPARATOR|Symlin® and Humulin®|Simultaneous subcutaneous injections avec pramlintide and human insulin
62291549|NCT03512236|ACTIVE_COMPARATOR|Humalog®|Single subcutaneous injection of lispro + injection of placebo (0.9% NaCl) to ensure the double dummy
62291550|NCT00930202|EXPERIMENTAL|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
62291551|NCT00930202|NO_INTERVENTION|Standard Care|No intervention
62291552|NCT05750992|ACTIVE_COMPARATOR|surgical TAP block|twenty-five pregnant women will receive surgical TAP block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
62464458|NCT04993664|EXPERIMENTAL|Pelacarsen group (TQJ230)|The first group will receive 80 mg of pelacarsen every month subcutaneously for 6 months.
61907549|NCT03968640|ACTIVE_COMPARATOR|CoQ10 group|The patients assigned to the CoQ10 group will receive the loading dose of CoQ10 (1,800 mg/day) for 4 weeks followed by the maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge, whichever comes first.
61907550|NCT03968640|PLACEBO_COMPARATOR|Placebo|Allocation-concealed placebo will be used as an appropriate control.
62093741|NCT02335021|EXPERIMENTAL|Sucralose + maltodextrin|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
62093742|NCT02335021|EXPERIMENTAL|Sucralose + Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
62093743|NCT05468489|EXPERIMENTAL|Serplulimab + chemotherapy|Serplulimab + chemotherapy (carboplatin-etoposide)
62657277|NCT01951950|ACTIVE_COMPARATOR|Esmolol|"Subjects will receive a 0.5 mg/kg bolus of esmolol as needed followed by an infusion initiated at 50 mcg/kg/min. Esmolol may be titrated every 5 minutes, increasing 50 mcg/kg/min and administering 0.5 mg/kg bolus every minute to a maximum dose of 200 mcg/kg/min. If SBP is not maintained \< 140 mmHg 5 minutes after achieving the maximum dose of esmolol, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
62657278|NCT03213717|EXPERIMENTAL|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
62657279|NCT03213717|ACTIVE_COMPARATOR|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
62657280|NCT03213717|ACTIVE_COMPARATOR|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
62657281|NCT02522741|EXPERIMENTAL|Parenting STAIR|
62657282|NCT03965585||Primary Infertility|Women with a diagnosed primary infertility undergoing hysteroscopy before IVF.
62657283|NCT03965585||Secondary Infertility|Women with a diagnosed secondary infertility undergoing hysteroscopy before IVF.
62657284|NCT03965585||Recurrent miscarriages|Women with recurrent miscarriages undergoing hysteroscopy before IVF.
62657285|NCT02630030|EXPERIMENTAL|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
62657286|NCT03469804|EXPERIMENTAL|Pembrolizumab|Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
62657287|NCT02827526|ACTIVE_COMPARATOR|Ketamine|Patients in the ketamine arm will receive an intraoperative and postoperative infusion of ketamine
62657288|NCT02827526|PLACEBO_COMPARATOR|Control|Patients in the control arm will receive an intraoperative and postoperative infusion of dextrose
62093744|NCT05468489|ACTIVE_COMPARATOR|Atezolizumab + chemotherapy|Atezolizumab + chemotherapy (carboplatin-etoposide)
62291553|NCT05750992|ACTIVE_COMPARATOR|US guided TAP block|25 pregnant women will receive US guided T.A.P block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
62464459|NCT04993664|PLACEBO_COMPARATOR|Placebo group|The first group will receive 80 mg of placebo every month subcutaneously for 6 months.
62464460|NCT03343795|EXPERIMENTAL|study group 1|oral progesterone
62093745|NCT05796791|EXPERIMENTAL|Treatment of tobacco use disorder with ketamine|
62093746|NCT01783457|EXPERIMENTAL|Individual psychoeducation|Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
62093747|NCT01783457|ACTIVE_COMPARATOR|Control|Usual treatment
62093748|NCT05209399|ACTIVE_COMPARATOR|Hip injection with prior local anesthesia|
62093749|NCT05209399|ACTIVE_COMPARATOR|Hip injection without prior local anesthesia|
62093750|NCT01883765|EXPERIMENTAL|Neurofeedback active|Active neurofeedback training, theta/beta-protocol
62093751|NCT01883765|SHAM_COMPARATOR|Neurofeedback sham|Neurofeedback training is simulated to subjects in this condition
62464461|NCT03343795|ACTIVE_COMPARATOR|study group 2|intramuscular progesterone
62464462|NCT03104166|EXPERIMENTAL|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
62464463|NCT03104166|ACTIVE_COMPARATOR|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
62657289|NCT01267279|PLACEBO_COMPARATOR|Placebo|
62657290|NCT01267279|EXPERIMENTAL|Zoledronic Acid|
62657291|NCT06128538|EXPERIMENTAL|Acupuncture Arm|No control
62657292|NCT05803317||Amputee patients|All patients with lower limb amputations, unilateral or bilateral, walking with or without technical aids hospitalized in the Rehabilitation Department of the CHU of Nîmes
62093752|NCT01883765|ACTIVE_COMPARATOR|Metacognitive Training|Metacognitive training, cognitive behavioral therapy
62657293|NCT01417416||with combat training stress|
62657294|NCT01417416||without combat training stress|
62093753|NCT06658522|EXPERIMENTAL|Sotatercept treatment|PAH patients receiving subcutaneous sotatercept injection
62093754|NCT06249711|ACTIVE_COMPARATOR|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets involved in food addiction
62093755|NCT06249711|SHAM_COMPARATOR|Sham stimulation|Zero-intensity transcranial focused ultrasound stimulation of deep brain targets involved in food addiction
62093756|NCT04058392|EXPERIMENTAL|Camu Camu|Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
62464464|NCT01288352|NO_INTERVENTION|Usual care|Usual care closely follows the suggestions laid out in the current European Society of Cardiology (ESC) guidelines for AF treatment. In addition to antithrombotic therapy and therapy of underlying heart disease, usual care usually consists of an initial attempt to control symptoms by rate control therapy. Rhythm control interventions are recommended when symptoms can not be controlled by optimal rate control therapy in the usual care group.
62657295|NCT00858988|EXPERIMENTAL|Rifaximin|
62657296|NCT00858988|PLACEBO_COMPARATOR|Placebo|
62657297|NCT00741611|EXPERIMENTAL|Mesh|Ablation with HD Mesh Ablation System
62093757|NCT06614478||hip fracture patients treated with surgery|Hip fracture patients treated with surgery. Frailty will be categorized based on the validated Groningen Frailty Indicator (GFI)
62291554|NCT01734148|EXPERIMENTAL|Experimental group (RELAX TO SLEEP program)|
62291555|NCT01734148|NO_INTERVENTION|Control group (Usual Care)|
62657298|NCT00741611|ACTIVE_COMPARATOR|Drug|Treatment with anti-arrhythmic drugs
62657299|NCT05649462||supplementary group|take vitamin D supplementation (400 IU/day) during VDZ treatment
62657300|NCT05649462||non-supplementary group|
62657301|NCT04298385||Individuals with oblique proximal phalanx fractures of finger|Traction orthosis and exercise
62737477|NCT04500392|ACTIVE_COMPARATOR|Control group|Oxygen(up to 6L/min) supplied with a regular nasal catheter
62737478|NCT04500392|EXPERIMENTAL|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
62737479|NCT05009173|ACTIVE_COMPARATOR|Stylet-in|Lumbar puncture performed keeping the stylet inside the needle until the practitioner reaches the appropriate location.
61907551|NCT03421769|EXPERIMENTAL|EA and AMLK|Corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe ocular burns.
61907552|NCT03421769|ACTIVE_COMPARATOR|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe ocular burns.
61907553|NCT05908643|EXPERIMENTAL|Treatment with pTTL|"A single dose of pTTL will be administered after pre-conditioning chemotherapy with Fludarabine (30 mg/m(2) body surface area) x 3 and Cyclophosphamide (300 mg/m(2) body surface area) x 3 on days -7 to -5. pTTL will usually be infused on day 1 (5 days after last chemotherapy) with the option of administering it on day -3 if judged preferable based on the T cell expansion kinetics during pTTL production. pTTL is administered as a fresh product directly after production.~Dose escalation will be applied. Cohort 1 (1 patient): 1 million (with an accepted range of down to -5%) viable cells per kg body weight~Cohort 2 (3 patients): 2.5 million (down to -5%) viable cells per kg body weight~Cohort 3 (3 patients): 5 million (down to -5%) viable cells per kg body weight~Cohort 4 (remaining patients): up to 1 billion viable cells"
61907554|NCT02256397|ACTIVE_COMPARATOR|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
61907555|NCT02256397|EXPERIMENTAL|Enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--\> will receive Home-centered comprehensive care with the propeller~* 5 and above--\> will receive home-centered comprehensive care with propeller and PIKO"
61907556|NCT02024178|EXPERIMENTAL|Ultrasound Imaging|Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure.
61907557|NCT00711178|ACTIVE_COMPARATOR|A|2 hours sunlight
61907558|NCT00711178|ACTIVE_COMPARATOR|B|3 hours of sunlight
61907559|NCT00358345||1|Intermediate AMD
61907560|NCT00358345||2|Newly diagnosed CNV
61907561|NCT03940768|EXPERIMENTAL|Lactobacillus plantarum 299v receivers|Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.
61907562|NCT03940768|PLACEBO_COMPARATOR|Placebo receivers|Sanprobi IBS placebo 2 capsules per day for 4 weeks.
62093758|NCT01026415|EXPERIMENTAL|1|midazolam +/- brentuximab vedotin
62093759|NCT01026415|EXPERIMENTAL|2|brentuximab vedotin +/- rifampin
62093760|NCT01026415|EXPERIMENTAL|3|brentuximab vedotin +/- ketoconazole
62093761|NCT01026415|EXPERIMENTAL|4|special populations
62093762|NCT06262334|EXPERIMENTAL|The Fade to Fitness Program|
62291556|NCT03967821||Intervention|
62291557|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
62291558|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
62291559|NCT02991599|EXPERIMENTAL|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62291560|NCT02991599|EXPERIMENTAL|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62291561|NCT05239845|ACTIVE_COMPARATOR|Investigational Supplement 1 (INV-1)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
62657302|NCT03834168|OTHER|Study Individuals|Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).
62657303|NCT04133389|EXPERIMENTAL|Growth Mindset of Personality|Experimental intervention
62657304|NCT04133389|PLACEBO_COMPARATOR|Growth Mindset of Athletic Ability|Control intervention
61907563|NCT04871191|ACTIVE_COMPARATOR|Rituximab + cDMARD|Rituximab will be administered at 375 mg/m²/week for four consecutive weeks. Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52. The choice of the cDMARD will be left to the treating clinician and will include either methotrexate, azathioprine or mycophenolate mofetil, but the choice will be preferably methotrexate. Methotrexate will be administered orally or subcutaneously at 0.3 mg/kg/week, azathioprine orally at 2-3 mg/kg/d and mycophenolate mofetil orally at 2-3 g/d.
62093763|NCT05046834|EXPERIMENTAL|cold application Group|a cold gel pack will be wrapped in gauze and placed directly on the skin in an area with a radius of about 5 cm to cover the chest tube. The cold gel package will remain on the skin surface for about 20 minutes.
62093764|NCT05046834|EXPERIMENTAL|Cold Application Group with Thermometer|10 of cold application. After a minute, the skin temperature will be measured with an infrared thermometer if the temperature has dropped below 13.6 o C, the procedure will be terminated. If the skin temperature has not decreased below 13.6 0 C, the application will be continued, the application will be terminated when the temperature drops below the specified temperature.
62657305|NCT01571791|PLACEBO_COMPARATOR|group SF|either saline infusion and intravenous fentanyl boluses
62657306|NCT01571791|ACTIVE_COMPARATOR|group KL|ketorolac-lidocaine infusion and intravenous saline boluses
62657307|NCT03195556|EXPERIMENTAL|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
62657308|NCT03195556|EXPERIMENTAL|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
62657309|NCT04877002|EXPERIMENTAL|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participated in two arms of the study:~One arm was for obtaining performance data of the Sona Saliva C-19 Rapid test and the comparator arm was to obtain data from the primary care route using approved RT-PCR testing."
62657310|NCT05997745|EXPERIMENTAL|study group|an intervention arm consisting of patients who will receive the locally manufactured protein-energy ration after a laparotomy indicated for generalized acute peritonitis
62657311|NCT05997745|ACTIVE_COMPARATOR|control group|patients who will receive the commercially available protein-energy ration after a laparotomy indicated for generalized acute peritonitis
61907564|NCT04871191|EXPERIMENTAL|Tocilizumab|Tocilizumab will be administered subcutaneously every week at a fixed dose of 162 mg per week.
61907565|NCT04871191|EXPERIMENTAL|Abatacept|Abatacept will be administered subcutaneously every week at a fixed dose of 125 mg per week.
61907566|NCT02991664|ACTIVE_COMPARATOR|Equia Forte, randomly applied|Placing glass ionomer restorations, the dentin and enamel of cavities were washed, and briefly dried. Equia Forte Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Forte Coat was applied and photocured for 20 seconds using a photo-curing light.
61907567|NCT02991664|ACTIVE_COMPARATOR|G-aenial Posterior, randomly applied|After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
61907568|NCT05324644|EXPERIMENTAL|Interventional group|32 randomly selected first-year students in the university, who voluntarily agreed to be recruited into the study and smoke and are considering quitting.
62093765|NCT05046834|NO_INTERVENTION|control Group|standard pain procedure.
62657312|NCT00272402|OTHER|1|Simulated case-based learning
62657313|NCT00272402|OTHER|2|EMR clinical decision support tool.
62657314|NCT00272402|NO_INTERVENTION|3|Control group
62657315|NCT05483647|ACTIVE_COMPARATOR|G1|Intravenous sedation with infiltrative local anaesthesia
62657316|NCT05483647|EXPERIMENTAL|G2|Intravenous sedation with bilateral Erector Spine Plane Block
62657317|NCT05769972|EXPERIMENTAL|Immersive Virtual Reality (Parkinson's disease)|
61907569|NCT05324644|NO_INTERVENTION|Control group|32 randomly selected first-year students in the university, who voluntarily agreed to be recruited into the study and smoke and are considering quitting.
61907570|NCT01270802|ACTIVE_COMPARATOR|Tenofovir/emtricitabine/efavirenz|Tenofovir/emtricitabine/efavirenz
62093766|NCT05587712|EXPERIMENTAL|Children ≥1 to <18 years old|Participants will receive a subcutaneous (SC) injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
61907571|NCT01270802|EXPERIMENTAL|Tenofovir/emtricitabine plus raltegravir|Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir
62093767|NCT06282770|EXPERIMENTAL|Brace With Electrical Diodes|The patient will be given a laser diode brace to wear for 1 year. At the defined time points following surgery (2, 4, 6, 8, 12, 24, 36 and 48 weeks), subjects will be asked to complete pain and ability-to-function questionnaires and submit scar/wound images to determine their status at each time interval.
62291562|NCT05239845|ACTIVE_COMPARATOR|Investigational Supplement 1 (INV-2)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
62464465|NCT01288352|OTHER|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy (Dronedarone, Amiodarone, Flecainide, Propafenone),~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
62657318|NCT05769972|ACTIVE_COMPARATOR|Computer-based cognitive rehabilitation (Parkinson's disease)|
62657319|NCT05769972|EXPERIMENTAL|Computer-based cognitive rehabilitation (Huntington's disease)|
62657320|NCT05769972|ACTIVE_COMPARATOR|Music-therapy (Huntington's disease)|
62657321|NCT02674503|EXPERIMENTAL|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
62657322|NCT02674503|PLACEBO_COMPARATOR|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
62657323|NCT02566005|ACTIVE_COMPARATOR|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
62657324|NCT02566005|ACTIVE_COMPARATOR|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
62657325|NCT02835066||Ancillary-Correlative (HRQOL, fitness and psychosocial health)|Patients scheduled for surgery, radiation therapy, or chemotherapy complete the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-core 30 (C30) and QLQ-Lung Cancer 13 (LC13) in addition to psychosocial health and smoking status questions from baseline up to 2 weeks prior to the start of treatment, 5-6 weeks after treatment begins, and 5-6 months from the start of treatment. During the same time points, patients also undergo function/fitness assessments including standard health measurements, short physical performance battery (SPPB), 6 minute walk test (6MWT), and a grip strength test.
62657326|NCT00423605|EXPERIMENTAL|1|
62657327|NCT01950702|ACTIVE_COMPARATOR|Lightwand intubation|"After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, traditional lightwand intubation was done by pre-specified anesthesiologist who experienced more than 100 times of lightwand intubation.~Patient's head were fixed at neutral position during all intubation period."
62657328|NCT01950702|EXPERIMENTAL|Laryngoscope assisted lightwand intubation|After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, lightwand intubation using specific device(Macintosh laryngosope, female:3/Male:4) was done by pre-specified anesthesiologist who experienced more than 100 times of laryngoscope assisted lightwand intubation.
61907572|NCT04129151|EXPERIMENTAL|PALBOCICLIB and GANITUMAB|"Participants receive up to 12 cycles of therapy (cycle duration=28 days).~* Palbociclib: Oral, 100mg, daily on days 1-21~* Ganitumab: Intravenous, 18mg/kg, days 1, 15~Per protocol, participants were monitored for dose-limiting toxicity over cycle one according to an interim safety analysis. The safety monitoring rule was triggered after 3 patients had enrolled, prompting an amendment according to Contingency Plan A which was a reduction of the palbociclib dose from 125mg (days 1-21)."
62291563|NCT05239845|ACTIVE_COMPARATOR|Investigational Supplement 1 (INV-3)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
61907573|NCT01943253|ACTIVE_COMPARATOR|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
61907574|NCT01943253|ACTIVE_COMPARATOR|Hybridknife ESD|"Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)~Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)"
61907575|NCT03708393|ACTIVE_COMPARATOR|Imagio IUS|Read 1 - Mammo (as available) + Imagio Ultrasound
61907576|NCT03708393|EXPERIMENTAL|Imagio (IUS+OA)|Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)
61907577|NCT03733990|EXPERIMENTAL|FP-1305 (bexmarilimab) 0.3 mg/kg|Part I, Dose-escalation FP-1305 0.3 mg/kg is administered in Q3W intervals
61907578|NCT03733990|EXPERIMENTAL|FP-1305 (bexmarilimab) 1 mg/kg|Part I and II, Dose-escalation FP-1305 1 mg/kg is administered in Q3W, Q2W or Q1W intervals
61907579|NCT03733990|EXPERIMENTAL|FP-1305 (bexmarilimab) 3 mg/kg|Part I and II, Dose-escalation FP-1305 3 mg/kg is administered in Q3W, Q2W or Q1W intervals
61907580|NCT03733990|EXPERIMENTAL|FP-1305 (bexmarilimab) 10 mg/kg|Part I and II, Dose-escalation FP-1305 10 mg/kg is administered in Q3W, Q2W or Q1W intervals
61907581|NCT03733990|EXPERIMENTAL|FP-1305 (bexmarilimab) 0.1 mg/kg|Part I Dose-escalation FP-1305 0.1 mg/kg is administered in three-week intervals
61907582|NCT03733990|EXPERIMENTAL|FP-1305 (bexmarilimab) 30 mg/kg|Part II Dose-escalation FP-1305 30 mg/kg is administered in Q3W, Q2W or Q1W intervals
61907583|NCT02251964|OTHER|rituximab|single arm study with Zr-89-rituximab immuno PET/CT
61907584|NCT04580810|EXPERIMENTAL|CBT4CBT in the Black Church|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of alcohol use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
62093768|NCT06282770|SHAM_COMPARATOR|Sham Brace Without Electrical Diodes|The patient will be given a sham/placebo laser diode brace to wear for 1 year. At the defined time points following surgery (2, 4, 6, 8, 12, 24, 36 and 48 weeks), subjects will be asked to complete pain and ability-to-function questionnaires and submit scar/wound images to determine their status at each time interval.
62093769|NCT01682538|ACTIVE_COMPARATOR|Orfadin capsules, fasting|Orfadin capsules, single dose, 30 mg
62291564|NCT05239845|PLACEBO_COMPARATOR|Control|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
62291565|NCT01676831|EXPERIMENTAL|topical resiquimod 0.06%|Topical resiquimod 0.06% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will be 3 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
61907585|NCT04580810|NO_INTERVENTION|Community Based Treatment as Usual|Treatment as usual, typically groups, offered by a specialty community based treatment center (MCCA)
61907586|NCT00705744|EXPERIMENTAL|I|
61907587|NCT02690571|SHAM_COMPARATOR|Filtered air exposure|One hour exposure to filtered air during intermittent exercise in controlled chamber, 6 hours after exposure bronchoscopy is performed.
62093770|NCT01682538|EXPERIMENTAL|Orfadin suspension, fasting|Orfadin suspension 4 mg/mL, single dose 30 mg (7,5 mL)
62093771|NCT01682538|EXPERIMENTAL|Orfadin suspension, with food|Orfadin suspension 4mg/mL, single dose 30 mg (7,5 mL)
62093772|NCT03330158|EXPERIMENTAL|ASTS device|Implantation of device ASTS (for ACTIVE TREATMENT SCOLIOSIS SYSTEM ) in children between 4 and 10
62093773|NCT06588205||Patients enrolled|Patient affected by DLBCL or HGBL with MYC alterations treated with standard R-chemotherapy regimens as first line treatment
62464466|NCT03212222|EXPERIMENTAL|Peek Acuity Screening|Cell phone application to be used for visual acuity screening.
62464467|NCT03212222|ACTIVE_COMPARATOR|Standard Visual Screening|Standard visual acuity screening administered at Duke University Eye Center regarded as the gold standard.
62464468|NCT00765648|ACTIVE_COMPARATOR|1|nicardipine intravenous
62464469|NCT00765648|ACTIVE_COMPARATOR|2|Labetalol
62657329|NCT06522321|EXPERIMENTAL|Radiographic Assessment of Bone Dimension Around Immediate with FDBA and i-PRF vs FDBA|TEST GROUP: FDBA and I-PRF with immediate implant placement. Local anesthesia is given. Atraumatic extraction is done. I-PRF is prepared by centrifugation procedure. Osteotomy is done at the selected site after radiographic assessment. Immediate implant is placement along with I-PRF and FDBA. Suture is placed at the surgical site.
62657330|NCT06522321|EXPERIMENTAL|Radiographic Assessment of Bone Dimensions Around Immediate Implants With FDBA and I-PRF vs FDBA|CONTROL GROUP: FDBA alone with immediate implant placement. Local anesthesia is given. Atraumatic extraction is done.Osteotomy is done at the selected site after radiographic assessment. Immediate implant is placement along with FDBA alone. Suture is placed at the surgical site.
62657331|NCT05345080|EXPERIMENTAL|Exposure-Reduction Intervention Group|The exposure-reduction (intervention) group receives a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), a customized asthma self-management plan and support developed using motivational interviewing methods, and a customized selection of supplies to help reduce key exposures likely exacerbating asthma symptoms.
62291566|NCT01676831|EXPERIMENTAL|topical resiquimod 0.03%|Topical resiquimod 0.03% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will begin 5 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
62291567|NCT05564338|EXPERIMENTAL|Treatment Arm A: sitravatinib + tislelizumab|sitravatinib once daily and tislelizumab once every 6 weeks, for up to 17 cycles (approximately 2 years)
62291568|NCT05564338|EXPERIMENTAL|Treatment Arm B: Placebo + tislelizumab|sitravatinib-matching placebo once daily and tislelizumab once every 6 weeks, for up to 17 cycles (approximately 2 years)
62291569|NCT05564338|EXPERIMENTAL|Treatment Arm C:Sitravatinib + Placebo|sitravatinib once daily and tislelizumab-matching placebo once every 6 weeks, for up to 17 cycles (approximately 2 years)
62657332|NCT05345080|NO_INTERVENTION|Phone-Call-Only Control Group|The phone-call-only (control) group provides self-reported information about health and environmental exposures. They receive follow-up phone calls every 6 weeks to maintain contact only. After exit, the phone-call-only (control) group receives assessment for allergies (optional) and the exposure-reduction intervention.
62657333|NCT06135714|PLACEBO_COMPARATOR|Arm A: Standard of care|Continuation of systemic drug therapy.
62291570|NCT05564338|EXPERIMENTAL|Treatment Arm D: Matching Placebo|sitravatinib-matching placebo once daily and tislelizumab-matching placebo once every 6 weeks, for up to 17 cycles (approximately 2 years)
62464470|NCT01798732|EXPERIMENTAL|Selective laser trabeculoplasty (Tango Laser, Ellex)|Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
62464471|NCT02215083|EXPERIMENTAL|L-Glutamine|All patients will receive 20-30 grams of l-glutamine daily for 9 weeks (+/- 1 week)
62657334|NCT06135714|EXPERIMENTAL|Arm B: Metastasis-directed therapy followed by Standard of care|Metastasis-directed therapy (radiation or surgery for oligometastasis) + systemic drug therapy.
62657335|NCT00484510|EXPERIMENTAL|Ascorbic Acid|
62657336|NCT00484510|PLACEBO_COMPARATOR|Placebo|
62737480|NCT05009173|ACTIVE_COMPARATOR|Stylet-out|The practitioner remove the stylet once he/she has passed the skin and moves the needle forward with the stylet.
62737481|NCT04776616|SHAM_COMPARATOR|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
62737482|NCT04776616|EXPERIMENTAL|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
62737483|NCT05820139|OTHER|control group (voids 2/3 of the volume backfilled)|control group
62737484|NCT05820139|ACTIVE_COMPARATOR|test group (voids ½ of the total volume backfilled)|test group)
62093774|NCT04612595||Group A|Group A are males with CKD stage 1-2.
62093775|NCT04612595||Group B|Group B are males with CKD stage 3-4.
62093776|NCT04612595||Group C|Group C are females with CKD stage 1-2.
62093777|NCT04612595||Group D|Group D are females with CKD stage 3-4.
62093778|NCT06647485|EXPERIMENTAL|PF-only|The PF-only arm includes patients with a clinical indication for ablation to manage their paroxysmal atrial fibrillation, who will undergo PVI using only PF energy
62093779|NCT06647485|EXPERIMENTAL|Hybrid (PF posterior/RF anterior)|The Hybrid arm includes patients with a clinical indication for ablation to manage their paroxysmal atrial fibrillation, who will undergo PVI using both PF and RF energy
62093780|NCT06647485|ACTIVE_COMPARATOR|RF-only|The RF-only arm includes patients with a clinical indication for ablation to manage their paroxysmal atrial fibrillation, who will undergo PVI using only RF energy
62093781|NCT00716573|EXPERIMENTAL|1|Introduction of everolimus associated with CNI (ciclosporin or tacrolimus) reduction (50%) to the current immunosuppression schedule
62093782|NCT00716573|NO_INTERVENTION|2|Maintain of their current immunosuppressive therapy
61907588|NCT02690571|EXPERIMENTAL|Biodiesel exhaust exposure|One hour exposure to biodiesel exhaust (generated at same running conditions as earlier studies with diesel exhaust at approximate particle matter concentration 300 mcg/m3) during intermittent exercise in controlled chamber. Six hours after exposure bronchoscopy is performed.
61907589|NCT01677429|EXPERIMENTAL|VR movie + balance challenge|VR-based balance training
61907590|NCT01677429|SHAM_COMPARATOR|still pictures from VR|Exposure to still pictures from the same VR scene but no balance challenge
61907591|NCT01677429|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Standard CBT protocol for the treatment of panic disorder
61907592|NCT05279391|ACTIVE_COMPARATOR|SOC|Patients included in this arm treated with the standard of care (SOC), including dexamethasone plus heparin, with or without the addition of antibiotics and remdesivir
61907593|NCT05279391|ACTIVE_COMPARATOR|TOCI|Patients included in this arm treated with the SOC plus Tocilizumab (single IV dose: 8mg/kg)
61907594|NCT05279391|ACTIVE_COMPARATOR|ANA|Patients included in this arm treated with the SOC plus Anakinra (200mg twice daily IV for 3-6 days, then 100 mg/twice daily, for up to 10 days in total)
61907595|NCT05279391|ACTIVE_COMPARATOR|COMBI|Patients included in this arm treated with the SOC plus the combination of Tocilizumab, Baricitinib and inhaled DNase (COMBI) as a rescue treatment.
62291571|NCT04107038|ACTIVE_COMPARATOR|General|Participants randomized to group A will receive general endotracheal anesthesia as their anesthetic procedure.
62291572|NCT04107038|ACTIVE_COMPARATOR|Sedation|Participants randomized to group B will receive monitored anesthesia care as their anesthetic procedure.
61907596|NCT04204980|EXPERIMENTAL|Dose escalation and full dose|"Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab~Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab"
61907597|NCT01062178|EXPERIMENTAL|comparison to biopsy|Comparing contrast enhanced US with biopsy result
61907598|NCT04128631||PET/CT|group of patients will do F-18FDG PET/CT scan after negative whole body scan with elevated serum thyroglobulin Antibody or Thyroglobulin levels.
61907599|NCT00108108|EXPERIMENTAL|HCD122|
61907600|NCT00720018|EXPERIMENTAL|Period 1|NP101 Patch
61907601|NCT00720018|EXPERIMENTAL|Period 2|NP101 Patch
61907602|NCT00720018|EXPERIMENTAL|Period 3|NP101 Patch
61907603|NCT00720018|EXPERIMENTAL|Period 4|NP101 Patch
61907604|NCT00720018|EXPERIMENTAL|Period 5|NP101 Patch
62291573|NCT02316834|EXPERIMENTAL|BMN 673|
62291574|NCT01773655||tissue|This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM.
62657337|NCT03279575|EXPERIMENTAL|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
61907605|NCT03276455|EXPERIMENTAL|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
61907606|NCT03986372|EXPERIMENTAL|PRP injection, once|PRP injection, once
62657338|NCT03279575|EXPERIMENTAL|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
62657339|NCT03279575|ACTIVE_COMPARATOR|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
62657340|NCT03279575|PLACEBO_COMPARATOR|Control|Physicians in this arm will not be asked to complete any intervention.
62657341|NCT06425640||Adults with type 1 diabetes|Adults with type 1 diabetes (25-50 years) will wear an accelerometer to objectively measure their 24-hour movement behaviors. An online questionnaire and food diary will be completed to gain insight into the explanatory variables of 24-hour movement behaviors. Information on glucose control will be collect through the continuous glucose monitor of the participant.
61907607|NCT03986372|EXPERIMENTAL|PRP injection, twice|PRP injection, twice, 2 weeks apart
62657342|NCT05849805|EXPERIMENTAL|Intracalvaria bone marrow injection group|Y-3 ，Intracalvaria bone marrow injection , continuous medication for 3 days, with standard treatment and management according to the related guidelines.
62657343|NCT05849805|SHAM_COMPARATOR|Conventional treatment group|standard treatment and management according to related guidelines
61907608|NCT03986372|EXPERIMENTAL|PRP injection, 3 times|PRP injection, 3 times, 2 weeks apart
61907609|NCT05617313|EXPERIMENTAL|Experimental Group|"Pembrolizumab will be given intravenously on Day 1 of the 21 day cycle (For all cycles).~GT103 dose will be determined by the safety lead in prior to the study. Dosing calculations should be based on actual body weight where applicable. It will be taken intravenously on Day 1 of the 21 day cycle (For all cycles)."
61907610|NCT01779791|EXPERIMENTAL|PCI-32765 (Ibrutinib)|
61907611|NCT03839043|EXPERIMENTAL|"Quit for a bit"|"Brief behavioral intervention (\~5 min) that focus on quitting smoking from the morning of surgery until one week after surgery + Quit for a bit SMS program."
62464472|NCT06078878|EXPERIMENTAL|Neurovascular Imaging|"Use of the Gentuity HF-OCT Imaging System with Vis-M Micro-Imaging Catheter (Gentuity Neurovascular Imaging System) as a diagnostic tool for intravascular imaging in the cerebrovasculature."
62291575|NCT01068444|EXPERIMENTAL|Pioglitazone|Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
62464473|NCT02186925||Bladder, Kidney and Prostate Cancer Patients|
62464474|NCT00909493|EXPERIMENTAL|Access to Pain Specialist|Network
62464475|NCT02701114|ACTIVE_COMPARATOR|Proximal|Proximal Adductor Canal Block
62464476|NCT02701114|ACTIVE_COMPARATOR|Distal|Distal Adductor Canal Block
62464477|NCT05026671|ACTIVE_COMPARATOR|Group DL|The control group consists of intubating the trachea with an endotracheal tube alone (without stylet).
62464478|NCT05026671|EXPERIMENTAL|Group DLS|The Experimental group consists of intubating the trachea with an endotracheal tube + stylet.
62464479|NCT05026671|EXPERIMENTAL|Group VL|The Experimental consists of intubating the trachea with an endotracheal tube + Video-laryngoscope
62464480|NCT05026671|EXPERIMENTAL|Group VLS|The Experimental consists of intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
62464481|NCT04022798|EXPERIMENTAL|Experimental group|Neural mobilization (NM), lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
62464482|NCT04022798|ACTIVE_COMPARATOR|Control group|lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
62464483|NCT04213326||Cancer Cohort|Subjects interested in the cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
62464484|NCT04213326||Non-Cancer Cohort|Subjects interested in the non-cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
62464485|NCT02373319|EXPERIMENTAL|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
62464486|NCT02373319|EXPERIMENTAL|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
62657344|NCT06082232|ACTIVE_COMPARATOR|Group M (midazolam group)|includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 1 mg midazolam (8 units of 5 mg/mL preservative-free midazolam loaded in a 40 unit insulin syringe).
62657345|NCT06082232|ACTIVE_COMPARATOR|Group D(dexmedetomidine group)|includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 5 mcg dexmedetomidine (2 units of 100 mcg/mL preservative-free dexmedetomidine loaded in a 40 unit insulin syringe).
62464487|NCT02373319|ACTIVE_COMPARATOR|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
62291576|NCT01068444|PLACEBO_COMPARATOR|Placebo|Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
62291577|NCT01849757|ACTIVE_COMPARATOR|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
62291578|NCT01849757|ACTIVE_COMPARATOR|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
62464488|NCT02373319|ACTIVE_COMPARATOR|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
62464489|NCT05856604|EXPERIMENTAL|Experimental|Improvisational Music Therapy - 45min, one 2 one intervention.
62464490|NCT05856604|ACTIVE_COMPARATOR|Active Control|Storytelling activity - 45min, one 2 one intervention.
62464491|NCT04258982||AECOPD group|The study incruit AECOPD patients with type II respiratory failure who need the NIV treatment.
62464492|NCT06391983|EXPERIMENTAL|resistance training|The intervention group attended online group education sessions on diabetes self management, as well as resistance exercise training sessions three times weekly; the sessions were approximately 40 minutes long and included 5 minutes of warm up, followed by 30 minutes of resistance exercises and 5 minutes of cool down. The resistance training consisted of ten upper-body and lower-body exercises using elastic band. The initial sessions were 1 to 2 sets of 6 to 8 repetitions at 45% of the one-repetition maximum (1 RM). It was increased progressively to 2 to 3 sets of 8 to 12 repetitions at approximately 55% of 1 RM. The 10 resistance exercises were reported elsewhere. Due to the Covid-19 pandemic, the participants performed resistance exercise at home, and 10 specific teaching videos (one video for each exercise) were provided for participants in this group. Wechat was used for attendance taking and communication.
62464493|NCT06391983|EXPERIMENTAL|Control Group|The control group was not asked to participate in any regular exercise. However, the group attended online group educational sessions about diabetes self management once a month, and were asked to record their daily physical activities. Online mini program Wechat was used for communication.
62464494|NCT05983562|EXPERIMENTAL|Experimental: Exogenous Ketone Supplement|Participants will be instructed to consume a total of 177 mL of the exogenous ketone supplement drink (for a total of 30 g of beta-hydroxybutyrate) per day (3 doses at 59 mL containing 10 g of beta-hydroxybutyrate each) for a period of 90 days.
62464495|NCT05983562|PLACEBO_COMPARATOR|Placebo Comparator: Inert placebo|Participants will be instructed to consume an equivalent volume (177 mL) of taste- and volume-matched placebo per day (3 doses at 59 mL) for 90 days.
62464496|NCT03744364|ACTIVE_COMPARATOR|Misoprostol|Group of women allocated to misoprostol induction.
62464497|NCT03744364|ACTIVE_COMPARATOR|Dinoprostone|Group of women allocated to dinoprostone induction.
62657346|NCT06082232|PLACEBO_COMPARATOR|Group C(control group)|includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 0.5 mL of 0.9% saline .
62737485|NCT03914430|EXPERIMENTAL|Breakfast meal with granola cereal and cultured dairy|
62737486|NCT03914430|EXPERIMENTAL|Breakfast meal with granola cereal and cultured non-dairy|
62657347|NCT06415630||training group|To determine potential predictive factors, the training group was subjected to LASSO regression analysis, which effectively eliminated several irrelevant or multicollinearity independent variables to reduce high-dimensional data.Seven models were initially constructed in the training group: multivariable logistics regression (MLR), decision-tree modeling, random forest, XGBoost, Support Vector Machines, k-nearest neighbors, and LightGBM.
61907612|NCT03839043|ACTIVE_COMPARATOR|"Quit for good"|"Brief behavioral intervention (\~5 min) that focus on quitting smoking permanently for as long as possible + Quit for good SMS program."
61907613|NCT01376518||respiratory failure|patients with respiratory failure and need of high positive end-expiratory pressure ventilation.
62093783|NCT05429255|EXPERIMENTAL|Aerobic Training|"Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's maximum heart rate based on age. The exercise program will start at 60% of max heart rate, and then will be increased by steps of 5% intensity every 2 weeks until participants reach 30 minutes of training at 80% intensity. In addition, rate of perceived exertion (Borg scale) will be assessed at each training session. Participants will be contacted weekly by email or phone to answer any questions about the exercise protocol and will be instructed to log each training session.~Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.~Subjects will be asked to use the bike for 1 month"
62291579|NCT01849757|PLACEBO_COMPARATOR|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
62464498|NCT03044171|EXPERIMENTAL|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
61907614|NCT00562315|OTHER|FACBC PET-CT and ProstaScint CT|Participants diagnosed with localized prostate carcinoma with subsequent definitive therapy or suspicion of recurrent cancer will undergo an FACBC PET-CT scan and the ProstaScinct CT.
61907615|NCT06518434|EXPERIMENTAL|Cannabis oil|Treatment with cannabis oil
62291580|NCT02432547|ACTIVE_COMPARATOR|Aflibercept Monotherapy|Intravitreal aflibercept injections according to a treat and extend regimen.
62464499|NCT03044171|EXPERIMENTAL|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
62657348|NCT06415630||testing group|Testing group was used to examine the performance of the seven prediction models, including discrimination and calibration performance. Finally, the model with best discrimination and calibration performance was used to construct nomogram for predicting reintubation.
61907616|NCT04732013||Study cohort|Single observational cohort of patients who meet study criteria
61907617|NCT05212545|PLACEBO_COMPARATOR|Placebo|10 g maltodextrin per day
61907618|NCT05212545|EXPERIMENTAL|Prebiotic Supplement|10 g Prebiotic supplement + maltodextrin per day
62464500|NCT01691508|EXPERIMENTAL|Mepolizumab|Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20
61907619|NCT05212545|EXPERIMENTAL|Prebiotic combination|10 g prebiotic supplement+ prebiotic oligosaccharide per day
61907620|NCT05212545|EXPERIMENTAL|prebiotic oligosaccharide|10 g maltodextrin + prebiotic oligosaccharide per day
62291581|NCT02432547|EXPERIMENTAL|Targeted laser therapy with Aflibercept|Targeted laser photocoagulation therapy to areas of peripheral retinal ischaemia and intravitreal aflibercept injections using a treat and extend regimen.
62291582|NCT01868321||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
62657349|NCT01260506|EXPERIMENTAL|VB-111|Antiangiogenic and vascular disruptive agent
61907621|NCT03027544|EXPERIMENTAL|experimental arm|"Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.~Intervention：tomotherapy"
61907622|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
61907623|NCT03708354|PLACEBO_COMPARATOR|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
61907624|NCT03708354|ACTIVE_COMPARATOR|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
62291583|NCT03341884|EXPERIMENTAL|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of ipatasertib (100 mg).
62291584|NCT03341884|EXPERIMENTAL|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of ipatasertib (100 mg).
62464501|NCT01691508|EXPERIMENTAL|Placebo|Placebo subcutaneous once every 4 weeks upto Week 20
62464502|NCT04211493|EXPERIMENTAL|Experimental-Condition|"20 minutes whole-body-workout with simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
62464503|NCT04211493|PLACEBO_COMPARATOR|Placebo-Condition|"20 minutes whole-body-workout without simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout they are stimulated with the lowest possible stimulation intensity (1). This is perceptible as a slight tingling sensation but the impulse intensity lies below the muscular threshold and therefore generates no muscular activity."
62657350|NCT01499407|ACTIVE_COMPARATOR|Standard abciximab bolus|
62657351|NCT01499407|EXPERIMENTAL|ClearWay-infused abciximab|
62657352|NCT01499407|EXPERIMENTAL|Thrombectomy plus ClearWay-infused abciximab|
62657353|NCT01499407|ACTIVE_COMPARATOR|Thrombectomy plus standard abciximab bolus|
62657354|NCT01346306|EXPERIMENTAL|DCS 1|
62657355|NCT01346306|EXPERIMENTAL|DCS 2|
62657356|NCT00089648|EXPERIMENTAL|1|
62657357|NCT04287179|EXPERIMENTAL|Semaglutide 0.50 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.50 mg.
61907625|NCT01414348|ACTIVE_COMPARATOR|Conventional rehabilitation|In-home work on problems in daily living.
61907626|NCT01414348|EXPERIMENTAL|Novel rehabilitation approach|
61907627|NCT01030640|PLACEBO_COMPARATOR|placebo|formulation without active drug
61907628|NCT01030640|ACTIVE_COMPARATOR|tanezumab|
61907629|NCT00107640|NO_INTERVENTION|Usual care|Patients not assigned to the experimental condition received usual care, which may or may not have included alcohol education.
62464504|NCT02019940|EXPERIMENTAL|Riluzole|Riluzole 50 mg orally twice per day
62464505|NCT00938171|ACTIVE_COMPARATOR|local anesthesia|local anesthesia with propofol sedation Target-controlled infusion (TCI) system will be used to maintain proper sedation level)
62657358|NCT04287179|ACTIVE_COMPARATOR|Semaglutide 0.25 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.25 mg.
62657359|NCT00836108|SHAM_COMPARATOR|1|spontaneous
62657360|NCT00836108|EXPERIMENTAL|2|coordinating arm elevation with inspiration
62657361|NCT00836108|EXPERIMENTAL|3|coordinating arm elevation with expiration
61907630|NCT00107640|EXPERIMENTAL|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
62464506|NCT00938171|ACTIVE_COMPARATOR|General anesthesia|Patients receiving general anesthesia
62657362|NCT05702632|ACTIVE_COMPARATOR|Group A|
62657363|NCT05702632|ACTIVE_COMPARATOR|Group B|
62657364|NCT04715490|EXPERIMENTAL|The Multimedia Symptom Management Program Intervention|The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support.
61907631|NCT01046435|PLACEBO_COMPARATOR|Supragingival scaling plus placebo|Plaque control instructions, supra gingival scaling and two placebos
61907632|NCT01046435|EXPERIMENTAL|Root planing plus antibiotics|Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days
61907633|NCT00870584|EXPERIMENTAL|Omalizumab|The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.
61907634|NCT00870584|PLACEBO_COMPARATOR|Placebo|Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.
62291585|NCT03341884|EXPERIMENTAL|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of ipatasertib (100 mg).
62291586|NCT03341884|EXPERIMENTAL|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of ipatasertib (100 mg).
62291587|NCT04917783|OTHER|Standard of Care|Caregivers in the standard of care-arm will receive immediate verbal feedback by a psychologist on their neurocognitive testing results, recommendations, and guidance for implementing recommendations (e.g., sending a 504 Plan request to the school). This report will contain information regarding background, test results, a summary and impressions, and bullet-pointed recommendations.
62291588|NCT04917783|EXPERIMENTAL|Health Literacy|"Participants randomized to the experimental health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations of their neurocognitive testing results along with the full written report. The domains listed as either satisfactory or needing help listed on the passport card will directly correspond to those listed on the full report."
62737487|NCT03914430|EXPERIMENTAL|Water|Energy-free control
62291589|NCT01665937|EXPERIMENTAL|STA-9090|Patients receiving STA-9090
62291590|NCT02304926|EXPERIMENTAL|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
62464507|NCT04287322|EXPERIMENTAL|Tactile-kinesthetic stimulation|Received tactile-kinesthetic stimulation three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
62657365|NCT04715490|ACTIVE_COMPARATOR|Control group|Participants in the control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
62657366|NCT04696198|EXPERIMENTAL|Range of motion|Treatment is based on a set diagnostic and therapeutic protocol and carried out by registered health care professionals that are additionally trained in manual therapy intervention. 30 minutes of treatment will be given once a week over a period of two months
61907635|NCT04866745|EXPERIMENTAL|Magnetotherapy plus exercise|"The patients will receive a total of 12 sessions, 3 sessions per week of magnetotherapy. The duration of treatment will be 20 minutes with a magnetic field frequency of 50Hz and a power of 100 Gauss.~After the magnetotherapy treatment, the patient will have to perform 12 sessions, 3 sessions per week of a program of therapeutic exercise with a duration of 25 minutes. This exercise program will be the same in the microwave and sham groups."
61907636|NCT04866745|PLACEBO_COMPARATOR|Sham Magnetotherapy plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of sham magnetotherapy. For the simulated/sham magnetotherapy group, it will be applied in the same way as the real MT group, but the equipment will be programmed to apply 0 Gauss. The physiotherapist performing the application will not have access to the magnetotherapy parameters on the display of the device, but will only have to enter the code. After the application of sham magnetotherapy, the patient will have to perform a program of therapeutic exercise.
62093784|NCT05429255|ACTIVE_COMPARATOR|Exergame Training|"The Nintendo wii system will be used as the rehabilitation exergame system in the study. Wii-fit games will be used and the subjects will be shown to system at the initial assessment. Participants will be instructed to play 30 minutes a day, 5 days per week for 1 month. Participants will be contacted weekly by email or phone to answer any questions about the exercise protocol and will be instructed to log each training session.~Subjects will record duration of exercise, perceived exertion, balance challenge, and which games they played."
62657367|NCT04696198|OTHER|Standard care|Standard care
62657368|NCT02111044|ACTIVE_COMPARATOR|Octreotide|Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks
62657369|NCT02111044|EXPERIMENTAL|ITF2984 500 mcg|ITF2984 500 mcg sc twice a day (b.i.d) for 4 weeks
62657370|NCT02111044|EXPERIMENTAL|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
62657371|NCT02111044|EXPERIMENTAL|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
62657372|NCT05151913||Previous ICP, recurrence|Pregnant women with at least one previously completed parturition with ICP and ICP during the present study
62093785|NCT06201065|EXPERIMENTAL|Experimental arm|Hepatic arterial infusion chemotherapy plus lenvatinib and toripalimab
62657373|NCT05151913||Previous ICP, non-recurrence|Pregnant women with at least one previously completed parturition with ICP and no ICP during the present study
62093786|NCT06201065|ACTIVE_COMPARATOR|Control arm|Hepatic arterial infusion chemotherapy plus lenvatinib
62093787|NCT00661908||1|insulin-treated diabetic subjects of North-western part of Switzerland
62291591|NCT02304926|EXPERIMENTAL|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
62657374|NCT05151913||No previous ICP|Pregnant women with at least one previously completed parturition with no previous ICP and no ICP during the present study
62657375|NCT01241929|EXPERIMENTAL|video decision aid|Video decision aid arm
62464508|NCT04287322|EXPERIMENTAL|Recorded maternal voice|Listened to recorded maternal voice stimulation, three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
62657376|NCT01241929|NO_INTERVENTION|Usual Care -- Verbal Description Arm|Verbal description of CPR (i.e., without the video).
62657377|NCT03273972|EXPERIMENTAL|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
62657378|NCT03273972|OTHER|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
62291592|NCT01062477|EXPERIMENTAL|Study Group 1|Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
62291593|NCT01062477|EXPERIMENTAL|Study Group 2|Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
62291594|NCT01062477|ACTIVE_COMPARATOR|Study Group 3|Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
62291595|NCT05054855|EXPERIMENTAL|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention.
62291596|NCT05054855|ACTIVE_COMPARATOR|Abbreviated Treatment|Steps of the Control Condition. Following an inperson session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
62291597|NCT01767402|EXPERIMENTAL|PhtD Group 1|Subjects will receive PhtD vaccine formulation 1 without any adjuvant.
62291598|NCT01767402|EXPERIMENTAL|PhtD Group 2|Subjects will receive adjuvanted PhtD vaccine formulation 2.
62657379|NCT02624596|EXPERIMENTAL|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
62657380|NCT02624596|ACTIVE_COMPARATOR|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
62657381|NCT05675800|EXPERIMENTAL|Psilocybin Active Dose Treatment A|Psilocybin
62657382|NCT05675800|EXPERIMENTAL|Psilocybin Active Dose Treatment B|Psilocybin
62657383|NCT05324917||lymphoma patients|Patients with Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and other mature B-lymphoma patients. Patients were randomly divided into two groups for PK blood collection. There were 12 blood sampling sites in each group.
62657384|NCT05324917||Patients with B lymphoproliferative diseases|Patients with hematopoietic stem cell transplantation and Epstein-Barr virus associated b-cell lymphoproliferative diseases, b-cell lymphoproliferative changes, immune thrombocytopenia, and autoimmune hemolytic anemia. Patients were randomly divided into two groups for pharmacokinetics blood collection. There were 12 blood sampling sites in each group.
62657385|NCT00049569|EXPERIMENTAL|Arm I|See detailed description.
62657386|NCT00049569|EXPERIMENTAL|Arm II|See detailed description.
62657387|NCT03699423|ACTIVE_COMPARATOR|0.01% atropine eye drops|Participants will receive one drop per eye every night for two weeks
62657388|NCT03699423|ACTIVE_COMPARATOR|0.02% atropine eye drops|Participants will receive one drop per eye every night for two weeks
62657389|NCT03699423|ACTIVE_COMPARATOR|0.03% atropine eye drops|Participants will receive one drop per eye every night for two weeks
62657390|NCT02137811||Patients that received MICK assay|Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) test performed
62657391|NCT06524661||Patients with RRD who underwent pars plana vitrectomy with|AS-oct measuring the anterior chamber angle and corneal changes after pars plana vitrectomy with silicone oil 1000cs injection
62657392|NCT01692756|EXPERIMENTAL|Kenalog or Placebo|Kenalog® (40mg) or saline placebo injection 1-2 days after ACL injury and 12-14 days later.
62657393|NCT01692756|EXPERIMENTAL|Kenalog then placebo|Subjects will initially receive 40mg injection of Kenalog® 1-2 days after injury and saline placebo at 12-14 days post injury.
62291599|NCT01767402|EXPERIMENTAL|PhtD Group 3|Subjects will receive adjuvanted PhtD vaccine formulation 3.
62291600|NCT01767402|EXPERIMENTAL|PhtD Group 4|Subjects will receive adjuvanted PhtD vaccine formulation 4.
62291601|NCT01767402|EXPERIMENTAL|PhtD Group 5|Subjects will receive adjuvanted PhtD vaccine formulation 5.
62291602|NCT01767402|ACTIVE_COMPARATOR|23 PPV Group|Subjects will receive the Pneumovax 23TM vaccine and NaCl.
62291603|NCT04343651|PLACEBO_COMPARATOR|Placebo|The placebo comparator consists of the formulation buffer for leronlimab, i.e., the placebo is the same as the active arm without leronimab. The placebo is presented in the same container closure at the same fill volume as the active (nominal 1mL fill volume). The formulation buffer contains histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
62464509|NCT04287322|NO_INTERVENTION|Control|Received only standard nursery care
62464510|NCT01027143|EXPERIMENTAL|omega-3 fatty acids|3 softgels (EPA, DHA) twice daily
62657394|NCT01692756|EXPERIMENTAL|Kenalog only|Subjects will receive two consecutive (40 mg) intra-articular injections of Kenalog®
62657395|NCT01692756|PLACEBO_COMPARATOR|Placebo|subjects will receive two consecutive intra-articular saline placebo injections at the same time periods.
62657396|NCT04474106|EXPERIMENTAL|ESWT|The extracorporeal shockwave therapy is applied once at the level of lesion and 5 segments above and below; or below the occiput (in lesions higher than C6) and above the sacrum (in lesions lower than T12). In addition, the ESWT is applied to the soles of both feet on the medial side of the plantar surface. The ESWT is applied as soon as possible within 48 hours post-injury.
62657397|NCT04474106|SHAM_COMPARATOR|Control|In the control group, the same procedure is performed, but without the device emitting extracorporeal shock waves using a dummy head.
62657398|NCT00078520|EXPERIMENTAL|Dose Level 1|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
62737488|NCT05965050|OTHER|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
62464511|NCT01027143|PLACEBO_COMPARATOR|control|Soybean oil: 3 matched softgel caps twice daily
62464512|NCT06222645|ACTIVE_COMPARATOR|Indocyanine green (ICG) imaging system|Using Indocyanine green (ICG) imaging system fluorescence imaging to assess gastrointestinal tissue blood perfusion during gastrointestinal surgery
62464513|NCT06222645|EXPERIMENTAL|imaging photoplethysmography (iPPG)|Using imaging photoplethysmography (iPPG) to assess gastrointestinal tissue blood perfusion during gastrointestinal surgery
62657399|NCT00078520|EXPERIMENTAL|Dose Level 2|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
62657400|NCT00078520|EXPERIMENTAL|Dose Level- Fixed Dose|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
62657401|NCT00634972|EXPERIMENTAL|1|
62657402|NCT00634972|PLACEBO_COMPARATOR|2|
62657403|NCT00559078||CAH|Women diagnosed with CAH (either simple virilizing or salt-losing)
62657404|NCT05962697|EXPERIMENTAL|SA controller|Synergy assistance controller
62657405|NCT05962697|OTHER|early testing|up to 5 participants testing the SA controller in one visit
62657406|NCT02032485|EXPERIMENTAL|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green in patients with peritoneal carcinomatosis from colorectal cancer before the surgery
62657407|NCT06141005|EXPERIMENTAL|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected or diagnosed of lung cancer will undergo bronchoscopic procedure for generic alteration with Next Generation Sequencing.
62657408|NCT05953415|ACTIVE_COMPARATOR|active iTBS group|active iTBS coupled with conventional cognitive therapy
62657409|NCT05953415|SHAM_COMPARATOR|sham iTBS group|sham iTBS coupled with conventional cognitive therapy
62657410|NCT06103045|EXPERIMENTAL|unilateral mirror therapy (UMT)|Participants will receive 30 minutes unilateral mirror therapy and then 30 minutes conventional occupational therapy in each treatment session. there will be 20 consecutive sessions (5 times per week, lasting 4 weeks totally)
62657411|NCT06103045|EXPERIMENTAL|Bilateral Mirror Therapy (BMT)|Participants will receive 30 minutes bilateral mirror therapy and then 30 minutes conventional occupational therapy in each treatment session. there will be 20 consecutive sessions (5 times per week, lasting 4 weeks totally)
62657412|NCT06103045|PLACEBO_COMPARATOR|Conventional Occupational Therapy (COT)|Participants will receive 60 minutes conventional occupational therapy in each treatment session. there will be 20 consecutive sessions (5 times per week, lasting 4 weeks totally)
62657413|NCT02069314|EXPERIMENTAL|Whey protein supplementation|50 grams of whey blended into frozen drink
62657414|NCT02069314|EXPERIMENTAL|Carbohydrate supplementation|50 grams of polycose blended into frozen drink
62657415|NCT01946945|NO_INTERVENTION|Control - Standard ART treatment|
62657416|NCT01946945|EXPERIMENTAL|Test - PGS|All embryos will be hatched on day 3. Patients will have hatching blastocysts (\*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (\*) replaced on a thawed cycle.
62657417|NCT03197727|OTHER|GC Saliva-Check BUFFER|Saliva test pH Buffering capacity Flow rate
62657418|NCT03440320|EXPERIMENTAL|MY-Skills Intervention - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
62657419|NCT03440320|ACTIVE_COMPARATOR|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
62657420|NCT05082480|EXPERIMENTAL|Hyaluronic acid (HA)|Hyaluronic acid (HA)
62657421|NCT05082480|PLACEBO_COMPARATOR|Saline|Saline
62657422|NCT05076786|EXPERIMENTAL|Chidamide + Etoposide + Cisplatin/Carboplatin|Experimental arm will be treated by chidamide combined with etoposide and cisplatin/carboplatin regimen for 4-6 cycles.
62657423|NCT05141253|EXPERIMENTAL|RD133 treatment group|"Administration of RD133 Three dose groups of 1.0×10\^6 CAR-T/kg, 3.0×10\^6 CAR-T/kg, and 6.0×10\^6 CAR-T/kg RD133 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.~RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of RD133 will be infused in a single infusion within 30 minutes on day 0."
62657424|NCT01687933|EXPERIMENTAL|three-dimensional glasses (Virtual Reality glasses)|Women in case group used the glasses for 30 minutes
62464514|NCT04364568|EXPERIMENTAL|Symptomatic group at three month|"Rivermead Post-Concussion Syndrome \>= 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
62464515|NCT04364568|EXPERIMENTAL|Asymptomatic group at three month|"Rivermead Post-Concussion Syndrome \< 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
62464516|NCT04203030|EXPERIMENTAL|Physical Activity|16 week physical activity intervention
62093788|NCT06536751|EXPERIMENTAL|Photobiomodulation (PBM) Treatment Group|Photobiomodulation therapy sessions will be carried out in the physiotherapy environment on the University, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght (01 point per gastroc, muscle). All patients will received the PBM protocol + the standard physiotherapy rehabilitation treatment of the institute not linked to the study, and which the patient already uses regularly.
62657425|NCT01687933|EXPERIMENTAL|usual care|Women in control group did not use the glasses.
62657426|NCT03979404|EXPERIMENTAL|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
62657427|NCT00312442|EXPERIMENTAL|WST 09|Treatment with WST09-mediated VTP
62657428|NCT01413802|EXPERIMENTAL|Thyroid surgery.|Patients who undergo thyroid surgery during which intra operative continuous nerve monitoring will be used.
62657429|NCT05091255|EXPERIMENTAL|Patients|
62657430|NCT03858322|EXPERIMENTAL|Carboplatin + Paclitaxel|"* Paclitaxel will be administered intravenously 3 times per cycle~* Carboplatin will be administered intravenously 3 times per cycle"
62657431|NCT03858322|EXPERIMENTAL|Cyclophosphamide + Paclitaxel|"* Paclitaxel will be administered intravenously 3 times per cycle~* Cyclophosphamide will be administered once per cycle"
62657432|NCT03025204|ACTIVE_COMPARATOR|GAP Surgical Access (GAP + OFD, 15 patients)|Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.
62657433|NCT03025204|EXPERIMENTAL|GAP Surgical Access + EMD (GAP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
62657434|NCT03025204|ACTIVE_COMPARATOR|GCP Surgical Access + EMD (GCP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
62657435|NCT00540917|EXPERIMENTAL|cooling spray|cooling spray during laser treatment
62657436|NCT03653481|EXPERIMENTAL|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
62657437|NCT03653481|PLACEBO_COMPARATOR|Placebo|Maltodextrin placebo administered for 8 weeks
62657438|NCT06222307|EXPERIMENTAL|Game-Based Exercises|The participants will engage in game-based exercise training twice a week for a total of 6 weeks. Each session will last for 45 minutes, and to ensure participants' sustained engagement, the activities will vary weekly. Here's an outline of the weekly activities:
62657439|NCT06222307|NO_INTERVENTION|Control|No intervention will be applied to the control group
62291604|NCT04343651|EXPERIMENTAL|700mg Leronlimab|Each vial of active contains 175mg of leronlimab at a concentration of 175mg/ml (nominal 1mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
62657440|NCT02572167|EXPERIMENTAL|Brentuximab Vedotin + Nivolumab|Brentuximab vedotin plus nivolumab
62291605|NCT03024216|EXPERIMENTAL|Arm 1|Atezolizumab1200 mg IV week 1 and week 4 followed by Sipuleucel-T administered weeks 6, 8, and 10
62291606|NCT03024216|EXPERIMENTAL|Arm 2|Sipuleucel-T administered week 1, 3, and 5 followed by Atezolizumab1200 mg IV weeks 7 and 10
62291607|NCT03054363|EXPERIMENTAL|Phase 1b|Tucatinib 300 mg PO BID, palbociclib 125 mg PO daily 21 days on and 7 days off, and letrozole 2.5 mg PO daily on a 28 day cycle length.
62291608|NCT03054363|EXPERIMENTAL|Phase II|Tucatinib 300 mg BID; palbociclib 75 mg PO daily 21 days on, 7 days off; letrozole 2.5 mg PO daily.
62291609|NCT03996447|OTHER|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI
62291610|NCT03996447|OTHER|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI
62291611|NCT01147614|ACTIVE_COMPARATOR|specialty mental health care referral|
62291612|NCT01147614|EXPERIMENTAL|Brief Cognitive Behavioral Therapy|
62291613|NCT06487013|EXPERIMENTAL|MRgHIFU treatment arm|Subjects will be randomized to MRgHIFU treatment arm and will pass the Screening Fail criteria preceded in normal fashion to MRgHIFU treatment at the same session.
62291614|NCT06487013|SHAM_COMPARATOR|Sham treatment arm|Subjects who will be randomized to sham treatment arm and passed the Screening Fail Criteria (i.e. MRI Screening and Sonication Screening) will undergo a sham MRgHIFU treatment with sonication energy disabled.
62291615|NCT05499520|NO_INTERVENTION|Currently Smoking, No Message Condition|Participants will receive no anti-smoking messages. They will receive the threat message during the baseline survey. Outcomes will be measured before and immediately after seeing the threat message, and at 1 month.
62657441|NCT05709613|NO_INTERVENTION|No feedback device|This group will have no access to the feedback device
62464517|NCT00207857||With and Without PFTs|
62657442|NCT05709613|EXPERIMENTAL|Feedback device|This group will have access to the feedback device
62737489|NCT05965050|EXPERIMENTAL|Ultrasound Therap|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
62737490|NCT02295696|EXPERIMENTAL|Intervention group|Intervention arm : EMMA consultations
62737491|NCT02295696|NO_INTERVENTION|Control group|Control arm: Usual care/consultations
62737492|NCT01032603|ACTIVE_COMPARATOR|Bilateral lateral rectus recession|Bilateral lateral rectus recession surgery
62737493|NCT01032603|ACTIVE_COMPARATOR|Unilateral lateral rectus recession|Unilateral lateral rectus recession w/ medial rectus resection surgery
62093789|NCT06536751|PLACEBO_COMPARATOR|Photobiomodulation (PBM) Placebo Group|PBM placebo therapy sessions will be carried out with the same characteristics of PBM treatment Group but with device turned off. All patients will received also the standard physiotherapy rehabilitation treatment of the institute not linked to the study, and which the patient already uses regularly.
62093790|NCT06566482|EXPERIMENTAL|Dexmedetomidine-esketamine combination|Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
62657443|NCT04428749||Study group|"1. Participants are screened using the Yale Swallow Protocol (YSP) 2-4 hours after extubation:~   Ability to swallow is assessed by an ICU nurse using the YSP. If the YSP is negative, the patient may start oral feeding and drinking. In case of a positive YSP, the screening may be repeated within the next 24 hours provided the patient improves clinically. If YSP continues to be positive the patient is referred to assessment by a speech language pathologist (SLP).~2. Participants are screened within 24 hours:~To evaluate YSP against the FEES, the patient undergoes 1) YSP performed by an ICU nurse followed by 2) FEES performed by a SLP (until PAS\>6 (aspiration on any food consistency on the Penetration Aspiration Scale (20)). The SLP will be blinded to the assessment made by the ICU nurses. Patients will follow recommendations for oral feeding and drinking as given by the SLP."
62657444|NCT01311323|EXPERIMENTAL|PCI with DES implantation|Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
62657445|NCT01311323|ACTIVE_COMPARATOR|CABG|Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
62657446|NCT06433284|ACTIVE_COMPARATOR|Inverted flap|Patients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.
62657447|NCT06433284|EXPERIMENTAL|Amniotic membrane hydrogel|Patients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling, amniotic membrane hydrogel filling and SF6 tamponade.
62657448|NCT01462604||HER2 overexpressing metastatic or advanced breast cancer pts|
62657449|NCT05473845|EXPERIMENTAL|Acupressure|Acupressure intervention
62657450|NCT05473845|EXPERIMENTAL|Reiki|Reiki intervention
62657451|NCT05473845|NO_INTERVENTION|Control|No intervention.
62657452|NCT01385605||female patients|ICSI treatment because of male subfertility
62657453|NCT03866694|EXPERIMENTAL|BRIGHT|Building Resilience through Intervention: Growing Healthier Together (BRIGHT) weekly home-based intervention from the third trimester of pregnancy through 6 months postpartum. A licensed clinician meets with mother and infant to promote attunement and optimal parent-child interactions. Additionally, the mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic
62464518|NCT03687736|OTHER|AbobotulinumtoxinA|Open-label
62464519|NCT04548453|EXPERIMENTAL|Uterine EMG during labor|Multichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor.
62093791|NCT06566482|PLACEBO_COMPARATOR|Placebo|Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
62093792|NCT04569279|ACTIVE_COMPARATOR|Warfarin arm|Patients randomly assigned to (W) group will receive an adjusted dose of warfarin with targeted INR of 2.0 to 3.0.
62657454|NCT03866694|ACTIVE_COMPARATOR|STAR/TAU+|The mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic.
62657455|NCT01374737|OTHER|dexmedetomidine, children|
62657456|NCT05887492|EXPERIMENTAL|Dose Escalation|Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD
62657457|NCT05887492|EXPERIMENTAL|Dose Expansion in NSCLC with KRAS Mutation|Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab
62657458|NCT05887492|EXPERIMENTAL|Dose Expansion in NSCLC with KRAS Wild type|Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab
62657459|NCT05887492|EXPERIMENTAL|Dose Expansion in Advanced or Metastatic Solid Tumors|Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab
62657460|NCT00424008|EXPERIMENTAL|MF/F MDI 200/10 mcg BID|Mometasone furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily.
62657461|NCT00424008|ACTIVE_COMPARATOR|F/SC DPI 250/50 mcg BID|Fluticasone propionate/salmeterol (F/SC) 250/50 mcg BID
62093793|NCT04569279|EXPERIMENTAL|Rivaroxaban arm|Patients randomly assigned to (R) group will receive 20mg rivaroxaban daily if CrCl\>50 mL/min using Cockcroft-Gault equation or 15mg rivaroxaban daily if CrCl 30-50 mL/min.
62464520|NCT01258725|EXPERIMENTAL|amnioinfusion|The investigators propose an open trial comparing baseline Doppler waveforms in the uteroplacental and fetal pulmonary circulation in patients presenting with severe, idiopathic olighydramnios (AFI\<5, no apparent ethiopathology), managed either with single or with serial amnioinfusions. The patients will be followed up weekly in the fetomaternal unit, Dept. of ObGyn for measuring AFI repeatedly to assess the need for further infusions. These will be carried out when the AFI falls below 5cm again
62464521|NCT00563264|ACTIVE_COMPARATOR|1|Participants receive monthly newsletter (for 10 months) including general health and reading information for child and mother and incentives for completing the baseline and 2 follow-up assessments
62464522|NCT00563264|EXPERIMENTAL|2|Mothers and preschoolers in the intervention group will receive monthly mailed family kits that encourage interactive mother/child exercises for healthy lifestyle change. Mailings are supported by counseling calls and two in-person motivational/informational group sessions. The content of the intervention addresses parenting skills, healthy eating, and physical activity. Families can earn $40 for returning postcards describing their activities in the past month.
62464523|NCT02405325|EXPERIMENTAL|Physical Activity|The program will be run by peer Leaders and senior center staff with the support of UCSD staff. Participants will work towards a 2000 increase in daily steps through self-paced incidental walking and peer led group walks.
62464524|NCT02405325|NO_INTERVENTION|Usual Care|Measurement at baseline, 6, 12, 18 and 24 months only with a health related event at each time point.
62464525|NCT01310660||Nulliparous|
62464526|NCT03583593|EXPERIMENTAL|DIAMEL|Study group that receives the active product.
62464527|NCT03583593|PLACEBO_COMPARATOR|Placebo|Control group receiving double-blind placebo.
62464528|NCT01037283|OTHER|Interpersonal and Social Rhythm Therapy|All participants receive eight sessions of Interpersonal and Social Rhythm Therapy.
62657462|NCT04765904|ACTIVE_COMPARATOR|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding drilling
62657463|NCT04765904|EXPERIMENTAL|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a topical therapeutic agent for managing caries lesions in young children
62657464|NCT03012737|OTHER|MPV arm|Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
62464529|NCT03187145||diabetic patients|
62464530|NCT03187145||healthy control|
62464531|NCT02713022||Breast Cancer|DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
62464532|NCT02713022||Prostate Cancer|DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
62464533|NCT05133778|EXPERIMENTAL|Sweet orange and pomegranate extract|Supplementation
62464534|NCT05133778|PLACEBO_COMPARATOR|Maltodextrin|Supplementation
62657465|NCT05285007|EXPERIMENTAL|Primary Intervention Group|The experimental group will receive two interventions to increase dorsiflexion range of motion.
62657466|NCT05285007|ACTIVE_COMPARATOR|Minimal Intervention Group|The minimal intervention group will read and infographic and complete 5 minutes of treadmill walking.
62464535|NCT01393288|PLACEBO_COMPARATOR|Ondansetron|
62464536|NCT01393288|PLACEBO_COMPARATOR|Lorazepam|
62464537|NCT01393288|PLACEBO_COMPARATOR|Aprepitant|
62464538|NCT01026623|EXPERIMENTAL|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60-70 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62464539|NCT03047265|EXPERIMENTAL|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
62464540|NCT03047265|ACTIVE_COMPARATOR|Cisplatin|Cisplatin combine with IMRT
62464541|NCT01853553|EXPERIMENTAL|Spironolactone|Active arm
62464542|NCT01853553|PLACEBO_COMPARATOR|Sugar Pill|Placebo
62464543|NCT06518343|EXPERIMENTAL|Pomegranate extract|1.5 grams L-carnitine (Carnipure®) + 1.6 grams pomegranate extract (Dermogranate®) in hydroxypropyl methylcellulose (HPMC) capsules
62464544|NCT06518343|PLACEBO_COMPARATOR|Microcrystalline cellulose|1.5 grams L-carnitine (Carnipure®) + 1.5 grams microcrystalline cellulose (MCC, Redwells Health) in hydroxypropyl methylcellulose (HPMC) capsules
62464545|NCT05909579|EXPERIMENTAL|3 month PelvicSense(R) program|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
62464546|NCT03146247|OTHER|One arm|all patients receive same dose and dosing regimen with Apremilast
62464547|NCT06254677||Acute tubular injury (ATI) only|Kidney biopsy with features of acute tubular injury only, no other pathology detected
62464548|NCT06254677||Concurrent diagnosis of acute tubular injury with any other pathology|Kidney biopsy with features of acute tubular injury AND other pathology. Non-ATI pathology includes but not limited to diagnosis of any type of glomerulonephritis, vasculitis, hereditary nephritis, thrombotic microangiopathy, kidney transplant rejection, podocytopathy, diabetic or hypertensive nephropathy, interstitial nephritis, pyelonephritis, amyloidosis, malignancy or paraneoplastic related kidney disease.
62464549|NCT06254677||Biopsies with no acute tubular injury (neg control)|Kidney biopsy with any diagnosis other than (no features of) acute tubular injury
62464550|NCT03827044|EXPERIMENTAL|Avelumab|6 months of 2 weekly Avelumab
62464551|NCT03827044|NO_INTERVENTION|No intervention|After standard adjuvant 5FU based chemotherapy, patients will have no active intervention but will start standard follow up.
62464552|NCT01652794|EXPERIMENTAL|Treatment (carboplatin, gemcitabine hydrochloride, and SBRT)|Patients also receive carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on day 1 and undergo SBRT on days 2-4.
62464553|NCT05983874|EXPERIMENTAL|Group 1: BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)
62464554|NCT05774860||All healthy participants|All healthy participants will undergo behavioral assessment and fMRI or EEG
62464555|NCT01270503|EXPERIMENTAL|Menactra® Group 1|Participants aged 2 to 11 on enrollment
62464556|NCT01270503|EXPERIMENTAL|Menactra® Group 2|Participants aged 12 to 17 on enrollment
62464557|NCT01270503|EXPERIMENTAL|Menactra® Group 3|Participants aged 18 to 55 on enrollment
62464558|NCT03106610|EXPERIMENTAL|Nivolumab|"Participants receive Nivolumab by vein over about 60 minutes on Day 1 of Cycles 1-3 before scheduled surgery. Each study cycle is 14 days (2 weeks).~Questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery."
62464559|NCT04832399||Natalizumab|Natalizumab 300 mg is administered by intravenous infusion once every 4 weeks.
62464560|NCT02884232||Workers exposed to wood dust|
62464561|NCT03067207|EXPERIMENTAL|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
62464562|NCT03067207|OTHER|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
62464563|NCT05034653|EXPERIMENTAL|Intermittent Fasting Healthy Plate (IFHP)|Dry fasting from dawn to dusk for two days a week (Monday and Thursday) and Healthy Plate for the rest of the week. Female participants were discouraged from fasting during their menstruation period.
62464564|NCT05034653|ACTIVE_COMPARATOR|Healthy Plate|Practice the Healthy Plate concept in at least one meal every day
62464565|NCT03453125|EXPERIMENTAL|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
62464566|NCT03453125|ACTIVE_COMPARATOR|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
62464567|NCT01123265||Anti-TNF|
62464568|NCT01123265||Methotrexate|
62464569|NCT01759901|EXPERIMENTAL|Pringle|Intermittent vascular inflow occlusion applied during liver resection
62093794|NCT06610370||Children with Spastic Cerebral Palsy|95 children with spastic cerebral palsy were included. Gross Motor Function Measure-88 (GMFM-88) and Gross Motor Function Classification System (GMFCS) were applied to the cases before and after the Selective Dorsal Rhizotomy (SDR) surgery.
61907637|NCT04866745|ACTIVE_COMPARATOR|Microwave plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of microwave therapy. The duration of the session will be 20 minutes, 10 minutes on the anterior side and 10 minutes on the posterior side of the joint in case of unilateral knee osteoarthritis. In the case of bilateral knee osteoarthritis, the MW will be applied 20 minutes over the anterosuperior side of both knees. After the microwave session, the patient will have to perform a program of therapeutic exercise.
61907638|NCT01374100|ACTIVE_COMPARATOR|Standard Exercise|See methods below - standard strength and endurance training
61907639|NCT01374100|EXPERIMENTAL|Qigong exercise|See methods below - medical QiGong therapy session
61907640|NCT05179174||patients with uveal melanoma|51 patients with a diagnosed with uveal melanoma; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, diseases kidney, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
61907641|NCT05179174||healthy controls|51 age sex matched controls, patients with diagnosed with cataracts; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, kidney diseases, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
61907642|NCT05022667|EXPERIMENTAL|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the total thyroidectomy procedure.
62464570|NCT01759901|NO_INTERVENTION|Non-Pringle|No vascular inflow occlusion applied during liver resection
61907643|NCT05022667|NO_INTERVENTION|Standard of Care|The surgeon will not use the PTeye and will proceed with the total thyroidectomy as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
62093795|NCT05193942|EXPERIMENTAL|Intervention|From baseline to 4-month post-test, participants in the intervention arm will have access to the Our Plan web app program.
62093796|NCT05193942|OTHER|Informational control|From baseline to 4-month post-test, participants in the informational control arm will not have access to the Our Plan web app program. Participants will instead receive a webpage with information about HIV/STI prevention options and resources to represent the current equivalent of a standard of care for online HIV resources.
61907644|NCT04427826|EXPERIMENTAL|Patient admitted for acute Exacerbation of Chronic Obstructive|Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and required NIV
61907645|NCT05014737||Patients with low risk of PONV|
61907646|NCT05014737||Patients with high risk of PONV|
61907647|NCT05160142|EXPERIMENTAL|Intervention|Participate in the DICE program, which entails culinary and diabetes educational programming delivered weekly for 10 consecutive weeks.
62464571|NCT02947230|EXPERIMENTAL|Tailored Knowledge Translation|During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.
62464572|NCT02947230|NO_INTERVENTION|Control group|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.
62093797|NCT05317689|ACTIVE_COMPARATOR|Oral & Sublingual Psilocin, & Oral Psilocybin|Every participant will be administered Oral Psilocin, Sublingual Psilocin, and oral psilocybin in a randomized order.
62093798|NCT05317689|ACTIVE_COMPARATOR|Sublingual Psilocin|Depending on a number of factors, participants may complete a fourth session where they receive sublingual psilocin for the second time.
62093799|NCT05613036|EXPERIMENTAL|Cohort 1: Formulation 1 (Cycle 1) then BI 907828 (Cycle 2 onwards)|
62093800|NCT05613036|EXPERIMENTAL|Cohort 2: BI 907828 (T) then Formulation 2 (R) (Cycle 1) then BI 907828 (Cycle 2 onwards)|
62093801|NCT03711838|EXPERIMENTAL|N-Acetylcysteine|N-Acetylcysteine supplementation: Orally, 40 mg/kg per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 40mg/kg per day in 3 doses (250 ml each).
61907648|NCT03729271|EXPERIMENTAL|Rifaximin and breath tests|Rifaximin 550mg three times a day for 14 days. Breath tests (glucose and lactulose) will be completed prior to Rifaximin treatment and at week 13 of the study.
62464573|NCT04567186|EXPERIMENTAL|Test/Control/Control|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Test/Control/Control).
62464574|NCT04567186|EXPERIMENTAL|Control/Test/Test|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Control/Test/Test).
62464575|NCT01768858||Participants receiving adalimumab|Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), or ulcerative colitis (UC) received 40 mg adalimumab every two weeks.
62093802|NCT03711838|ACTIVE_COMPARATOR|Placebo|Placebo administration: Orally 750 ml per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 750 ml per day in 3 doses (250 ml each).
62093803|NCT02369523|ACTIVE_COMPARATOR|liposomal bupivacaine (LB) (Exparel)|Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
62093804|NCT02369523|ACTIVE_COMPARATOR|Ropivacaine cocktail (PIC)|400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
62093805|NCT02369523|ACTIVE_COMPARATOR|continuous femoral nerve blocks (cFNB)|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
62464576|NCT04335396||adult patients with diabetes mellitus|Subgroup 1 - consecutive patients with diabetes mellitus with scleredema skin disorder Subgroup 2 - consecutive patients with diabetes mellitus without scleredema Subgroup 3 - patients with diabetes and scleredema - already cared in the tertiary center of the Rheumatology Department of the University of Pécs, in Hungary.
62464577|NCT02601482|EXPERIMENTAL|Control (CON)|No exercise intervention.
62657467|NCT02551146|EXPERIMENTAL|A Locator with retention elements|"GC Pilier Locator abutment with retention elements:~For patients in the experimental group (arm A) the connection of the full dentures to the implants will be achieved by fitting the dentures with GC Pilier Locator abutments with retention elements."
62657468|NCT02551146|ACTIVE_COMPARATOR|B Locator without retention elements|"GC Pilier Locator abutment without retention elements:~For patients with the active comparator (arm B) the full dentures will get Pilier Locator abutments without retention elements and thus no connection to the implants."
62657469|NCT03598296|EXPERIMENTAL|Group A:Group Tube|Patients are inserted the large size tube (28F).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
62657470|NCT03598296|EXPERIMENTAL|Group B:Group Ball|Patients are inserted the small size tube connects with a negative pressure ball(drainage ball).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
62657471|NCT06003764|EXPERIMENTAL|Pulsed electromagnetic field group|Pulsed electromagnetic
62657472|NCT06003764|PLACEBO_COMPARATOR|Placebo group|traditional skin care
62657473|NCT04172233|EXPERIMENTAL|Phase I: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0 and 4 by subcutaneous injection
62657474|NCT04172233|EXPERIMENTAL|Phase I: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0 and 4 by subcutaneous injection
62657475|NCT04172233|EXPERIMENTAL|Phase I: AK101 270 mg|Biological: AK101 AK101 270 mg on Week 0 and 4 by subcutaneous injection
62657476|NCT04172233|PLACEBO_COMPARATOR|Phase I: Placebo|Biological: Placebo Placebo on Week 0 and 4 by subcutaneous injection
62657477|NCT04172233|EXPERIMENTAL|Phase II: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0, 4 and 16 by subcutaneous injection
62657478|NCT04172233|EXPERIMENTAL|Phase II: AK101 90 mg|Biological: AK101 AK101 90 mg on Week 0, 4 and 16 by subcutaneous injection
62657479|NCT04172233|EXPERIMENTAL|Phase II: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0, 4 and 16 by subcutaneous injection
62657480|NCT04172233|PLACEBO_COMPARATOR|Phase II: Placebo to AK101|Drug: Placebo Placebo on Week 1 and 4 by subcutaneous injection, and then AK101 on Week 12 16 by subcutaneous injection
62657481|NCT03788330|EXPERIMENTAL|Fresh air system with filtration|A fresh air ventilation system combined with PM2.5 filtration is applied in one primary school classroom.
62657482|NCT03788330|PLACEBO_COMPARATOR|Fresh air system with no filtration|A fresh air ventilation system with no PM2.5 filtration is applied in a parallel classroom.
62657483|NCT03788330|NO_INTERVENTION|Natural ventilation|Natural ventilation system was applied in the 3rd classroom as normal.
62657484|NCT02490579||Facebook Survey Group|"During June, 2015, approximately 1200 women will be recruited through Facebook advertisements targeted at English-speaking women age 18-50 years living in the United States. Advertisements will contain 3 key features: an image, a caption, and ad copy followed by a link to the survey website. Individuals who click on the study link in the advertisement will be redirected to the study's Qualtrics web page where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics."
62093806|NCT04388852|EXPERIMENTAL|Treatment (valemetostat, ipilimumab)|Patients receive valemetostat PO QD on days 1-21 and ipilimumab IV over 90 minutes on day 1 of cycles 1 and 3. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62093807|NCT06522867|EXPERIMENTAL|Intraocular pressure measure|
62291616|NCT05499520|EXPERIMENTAL|Currently Smoking, Single Message Immediate|Participants will receive a single anti-smoking message followed by the threat message during the baseline survey. Outcomes will be measured before seeing the anti-smoking message and threat message, immediately after seeing the threat message, and at 1 month.
61907649|NCT01771809|EXPERIMENTAL|SHP647 75 mg|Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
62093808|NCT04455724|EXPERIMENTAL|Negative Pressure Incisional Wound Therapy|A PREVENA™ PEEL \& PLACE™ system kit will be applied to the surgical wound and assembled in the operating room following closure by primary intent. The system will be set for a negative pressure of -125mmHg. The dressing will be left in place for 7 days post-operation, during which the patient may be discharged from hospital. The dressing will only be removed or changed if the treating physician has suspicion of one of the complications included in the primary composite outcome or is planning re-intervention on the surgical site.
62093809|NCT04455724|ACTIVE_COMPARATOR|Standard sterile dressing|A sterile island dressing will be applied to the surgical wound in the operating room following closure by primary intent, which will be removed on post-operative day 2 and left open to air unless there is ongoing discharge.
62093810|NCT06365047|EXPERIMENTAL|Investigative Arm- Using an 8% Arginine toothpaste|For the study period (12 weeks), subjects in the Investigative Arm will be instructed to brush their teeth with an 8% Arginine toothpaste.
61907650|NCT01771809|EXPERIMENTAL|SHP647 225 mg|Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
61907651|NCT06227182||Healthy individuals|Healthy individuals between 18 and 70 years old.
61907652|NCT06227182||Patients with FSHD|Individuals with clinically and genetically proven FSHD type 1 or type 2.
62093811|NCT06365047|ACTIVE_COMPARATOR|Control Arm- a 1000 ppm F toothpaste|For the study period (12 weeks), subjects in the Control Arm will be instructed to brush their teeth with Control Arm- a 1000 ppm F toothpaste.
61907653|NCT02364336|EXPERIMENTAL|HBeAg positive|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg and HBeAg positivity
61907654|NCT02364336|EXPERIMENTAL|HBeAg negative|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg positivity and HBeAg negativity
61907655|NCT01640574|EXPERIMENTAL|DHA-P 7 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
62093812|NCT05731141||First Degree Relatives|Siblings or parents of patients.
62291617|NCT05499520|EXPERIMENTAL|Currently Smoking, Single Message 1 Week Delay|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one week later in a separate survey. Outcomes will be measured before seeing the anti-smoking message at baseline, immediately after seeing the threat message at 1 week, and at 1 month.
62464578|NCT02601482|EXPERIMENTAL|Normal Interval Walking (IW-60).|Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
62464579|NCT02601482|EXPERIMENTAL|Time-reduced Interval Walking (IW-45)|Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
62657485|NCT02490579||Clinical Survey Group|During June-August, 2015, approximately 500 women will be recruited at routine obstetric visits to the University of Michigan's outpatient clinics. Women who check in for an Ob appointment will be offered the opportunity to participate in an anonymous online survey. Individuals who express interest in participating will be provided with a laptop and headphones and directed to the survey Qualtrics site where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
62093813|NCT05731141||Patients|Patients with lymphatic anomalies.
62464580|NCT05789602|EXPERIMENTAL|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-460372 administered, once daily (QD).
62464581|NCT05789602|EXPERIMENTAL|Dose Expansion|Oral tablets administered at MTD/RP2D defined dose. Each treatment cycle will be 21 days in duration with BPI-460372 administered, once daily (QD)
62737494|NCT03309254|EXPERIMENTAL|High Glycemic Index|White Bread with Turkey breast meat (2 slices) Turkey Breast (7 slices) Chamomile Tea with 25 grams glucose Almonds 15 grams
62737495|NCT03309254|EXPERIMENTAL|Low Glycemic Index|Multi-grain Bread with Turkey breast meat (2 slices) Turkey Breast (6 slices) Chamomile Tea with 25 grams fructose Cashews 10 grams
62737496|NCT01895400|ACTIVE_COMPARATOR|Renexin|Renexin 1T bid for 12 weeks
62093814|NCT03135353|EXPERIMENTAL|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
62093815|NCT03135353|EXPERIMENTAL|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
62464582|NCT01988974|EXPERIMENTAL|Alert for AF Program|1) participation in the Alert for Atrial Fibrillation program ) .
62464583|NCT01988974|ACTIVE_COMPARATOR|Attention control condition|2) participation in the healthy sleep program
62464584|NCT00535054|EXPERIMENTAL|Tears Again|All subjects shall be treated with Tears Again.
62464585|NCT00989924||Diabetes mellitus|The Diabetic patient who receives follow-up at NTUH diabetics caring network
62464586|NCT03164889|EXPERIMENTAL|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
62464587|NCT03164889|ACTIVE_COMPARATOR|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
62093816|NCT00124982|EXPERIMENTAL|Open-label Abatacept (ABA)-Previous User|In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
62093817|NCT00124982|EXPERIMENTAL|Open-label ABA-Current User|In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
62093818|NCT00124982|EXPERIMENTAL|Long-term ABA|Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
62093819|NCT05119855|EXPERIMENTAL|Concomitant Group|Participants will receive the first dose of 9vHPV vaccine and first dose of mRNA-1273 vaccine on Day 1; participants will then receive the second dose of mRNA-1273 vaccine at Month 1 and the second dose of 9vHPV vaccine at Month 6.
62093820|NCT05119855|EXPERIMENTAL|Non-concomitant Group|Participants will receive the first and second doses of mRNA-1273 vaccine on Day 1 and at Month 1, respectively; participants will then receive the first and second doses of 9vHPV vaccine at Months 2 and 8, respectively.
62464588|NCT04584268|EXPERIMENTAL|mindfulness|3 30 minute in person interventions as well as promotion and involvement of self-guided meditations on the Insight Timer smart phone application
62657486|NCT02490579||Social Network Group|Once a pregnant participant completes the survey, she will be asked to provide her email address. If she is willing to do so, Qualtrics will automatically send her an email containing a weblink to the survey for her social network. She can then provide this link to 1 or 2 social network members that she feels influence her health behaviors during pregnancy. These members are asked similar questions about their response to the video, as well as some additional questions about how they advise their pregnant person about different health topics. It is necessary to provide a unique weblink to her, so that the survey responses from the pregnant woman and her unique social network members can be linked.
62657487|NCT01949896|OTHER|Intervention: NPO|"Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.~Pro-inflammatory cytokine response will be monitored at 3 times points."
62657488|NCT01949896|OTHER|Control: Continue feedings|"Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.~Pro-inflammatory cytokine response will be monitored at 3 times points."
62657489|NCT04857177|EXPERIMENTAL|CKD-701|Drug: CKD-701 (proposed ranibizumab biosimilar)
62657490|NCT04857177|ACTIVE_COMPARATOR|Lucentis®|Drug: Lucentis® (ranibizumab)
62657491|NCT04796467|EXPERIMENTAL|68Ga-PSMA617 and 68Ga-P16-093 PET/CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a PET/CT scan after intravenous administration of 68Ga-PSMA617 and 68Ga-P16-093, respectively.
62093821|NCT05769374|EXPERIMENTAL|Two player mode(parental involvement) in AVG play|the parent involvement group requires one parent to accompany the child to complete the experimental task
62093822|NCT05769374|EXPERIMENTAL|Single player mode in AVG play|the single-person model and the child need to complete the experimental task under the parent's supervision.
62093823|NCT05769374|ACTIVE_COMPARATOR|children did not engage in any AVGs play|children did not engage in any AVGs play nor any other structured school-based PA programs beyond physical education.
62093824|NCT02721199||Prospective Cohort|Neural Respiratory Drive Automated EMGpara assessment
62093825|NCT06254599|EXPERIMENTAL|SY-3505|SY-3505, single agent, 600 mg oral capsules, QD, continuously
62093826|NCT06254599|ACTIVE_COMPARATOR|Crizotinib|Crizotinib, single agent, 250 mg oral capsules, BID, continuously
62093827|NCT01644123||Nursing home residents|
62093828|NCT05416749|EXPERIMENTAL|8MW2311|
62093829|NCT03461042|EXPERIMENTAL|Arm R|Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
62093830|NCT03461042|PLACEBO_COMPARATOR|Arm PL|Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
62464589|NCT04584268|ACTIVE_COMPARATOR|control|standard medical resident education
62464590|NCT05343143|OTHER|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
62464591|NCT02898545|OTHER|SEEQ monitor|Subjects will be monitored via use of the SEEQ monitor
62657492|NCT01785901||Target subject population 1500|Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China
62657493|NCT02934178|EXPERIMENTAL|Cohort 1: WRSS1 3 x 10³ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
62657494|NCT02934178|EXPERIMENTAL|Cohort 2: WRSS1 3 x 10⁴ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
62657495|NCT02934178|EXPERIMENTAL|Cohort 3: WRSS1 3 x 10⁵ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
62737497|NCT01895400|PLACEBO_COMPARATOR|Placebo|Placebo 1T bid for 12 weeks
62093831|NCT04096365|EXPERIMENTAL|Subcostal temporary extracardiac pacing lead|All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.
62657496|NCT02934178|EXPERIMENTAL|Cohort 4: WRSS1 3 x 10⁶ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
62657497|NCT02934178|PLACEBO_COMPARATOR|Cohort 1: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.
62093832|NCT04042467|EXPERIMENTAL|Greenlight Plus|"Families will receive the Greenlight intervention plus a health information technology (HIT) intervention aimed at supporting family goal-setting and behavior change.~This design allows us to determine if HIT and the asynchronous support it provides between well-child visits can promote additional behavior change and obesity prevention."
62093833|NCT04042467|ACTIVE_COMPARATOR|Greenlight|During each of the recommended well child visits from 0-24 months, pediatric residents, trained in clear health communication skills and shared goal-setting, will use the Greenlight Toolkit of low literacy, age- specific, parent education booklets to promote healthy family behaviors and obesity prevention.
62464592|NCT02898545|NO_INTERVENTION|Standard of care|Subjects will not wear the SEEQ monitor or may have a pre-existing implanted device capable of detecting atrial fibrillation
62464593|NCT06373705|NO_INTERVENTION|Conventional surgical planning discussion without cardiac simulator|Conventional surgical planning discussion without cardiac simulator
62464594|NCT06373705|EXPERIMENTAL|Surgical planning discussion with aid of cardiac simulator|Surgical planning discussion with aid of cardiac simulator
62657498|NCT02934178|PLACEBO_COMPARATOR|Cohort 2: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.
62657499|NCT02934178|PLACEBO_COMPARATOR|Cohort 3: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.
62657500|NCT02934178|PLACEBO_COMPARATOR|Cohort 4: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.
62657501|NCT01811719|EXPERIMENTAL|Enhanced NFP (NFP+)|"Enhanced NFP(NFP+)provides for the usual NFP services plus a three-prong experimental preventive intervention:~1. Structured and regularly occuring assessments for intimate partner violence (IPV);~2. McFarlane and Parker Brochure Driven Intervention for women experiencing IPV, including safety planning, referrals, and advocacy; and~3. Markman and Stanley Within My Reach Training which is a skills-based curriculum delivered to all participants focusing on improving relationship deicsions and outcomes."
62657502|NCT01811719|ACTIVE_COMPARATOR|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
62657503|NCT01250938|EXPERIMENTAL|ESI - Community Outreach|All families receive the same Early Social Intervention - Community Outreach (ESI-CO) treatment for 3 months in addition to 6 months of community resource support.
62657504|NCT01560702|ACTIVE_COMPARATOR|Autologous blood|Patients will be injected by autologous blood at the edge of actively bleeding ulcer
62657505|NCT01560702|OTHER|Epinephrine injection|Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
62657506|NCT04002895|EXPERIMENTAL|Foliglurax|
62657507|NCT03646539|EXPERIMENTAL|Smartphone use + treatment as usual|Participants will receive treatment as usual and use the smartphone app for the management of mood.
62657508|NCT03646539|ACTIVE_COMPARATOR|Treatment as usual|Participants will receive treatment as usual.
62657509|NCT03101345|OTHER|nutrition product|Peptamen® 1.5 Vanilla, orally administration
62657510|NCT02572154|OTHER|Cases|men from couples with RPL after natural pregnancies, had blood and sperm samples for sperm DNA fragmentation exploration
62657511|NCT02572154|OTHER|Controls|men from couples who have a child consequently to a natural pregnancy, had blood and sperm samples for sperm DNA fragmentation exploration
62093834|NCT01641861|EXPERIMENTAL|Control arm|control arm is dental caries removal using the conventional method. Dental caries will be removed using rotary instrument following the usual procedures employed by the dentist.
62657512|NCT05112705|ACTIVE_COMPARATOR|Ultrasound Group|Patients will be receiving twice weekly proximal lower limb ultrasound
62657513|NCT05112705|NO_INTERVENTION|Control Group|Proximal lower limb ultrasound will be performed as per the treating team discretion
62657514|NCT02857153|EXPERIMENTAL|Low-level MAP|According to grouping, MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
62657515|NCT02857153|EXPERIMENTAL|High-level MAP|According to grouping, MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
62657516|NCT01144832|PLACEBO_COMPARATOR|placebo capsule|
62657517|NCT01144832|ACTIVE_COMPARATOR|ebastine|
62657518|NCT01050153|ACTIVE_COMPARATOR|Control (standard of care)|Dalteparin sodium 5000IU subcutaneously daily
62657519|NCT01050153|EXPERIMENTAL|TEG-guided thromboprophylaxis|Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
62657520|NCT03149315|EXPERIMENTAL|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
62657521|NCT00527059|EXPERIMENTAL|1|patients with acute heart failure
62464595|NCT03916094|EXPERIMENTAL|HLX22 group|HLX22, at four dose levels (3, 10, 25mg/kg), to be intravenously injected once every three weeks; Study drugs given until disease progression, one year of treatment, withdrawal from the study or death
62657522|NCT00527059|ACTIVE_COMPARATOR|2|standard therapy for heart failure
61907656|NCT01640574|EXPERIMENTAL|DHA-P 14 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
62657523|NCT02130219|EXPERIMENTAL|Chronic daily headache group|"Patients with chronic daily headache with suspicion of intracranial hypertension selected. Selection based on clinical symptoms (headache description, leading symptoms)and para-clinical pathological findings (optical nerve papilla edema). Not enough evidence to diagnose any other headache type. Simultaneous CSF pressure measurements and non-invasive ICP measurement will be performed.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT."
62657524|NCT02130219|EXPERIMENTAL|Multiple sclerosis group|"Multiple sclerosis (MS) group patients selected based on clinical symptoms and brain MRI changes typical for the disease. Diagnosis based on McDonalds criteria. CSF test for oligoclonal bands required as supporting diagnostic criteria. Patients selected with disease relapse symptoms. Simultaneous noninvasive ICP and CSF pressure measured.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
62657525|NCT02130219|EXPERIMENTAL|Stroke group|"Patients selected for this group have stroke/intracranial hemorrhage that might be complicated with intracranial hypertension. Stroke/intracranial hemorrhage diagnosed based on clinical findings and changes on brain CT/MRI. Patients with stroke less than 33% of middle cerebral artery territory included. Patients with intracranial hemorrhage 20-40 ml volume included. Patients unable to cooperate or sign informed consent excluded.~Bilateral non-invasive ICP measurements performed. Results compared with brain MRI/CT lesion volume, mid-line shift.~Interventions: non-invasive intracranial pressure measurement; brain MRI/CT"
61907657|NCT01640574|ACTIVE_COMPARATOR|Chloroquine 7 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
62093835|NCT01641861|EXPERIMENTAL|Intervention arm|Intervention arm is dental caries removal using Papacarie®. The dentist will apply Papacarie® to dental cavity in order to soften the carious dentine. Dental caries will be removed using hand instrument.
62093836|NCT05926791||Educated group with product|"Subjects receiving the SPF50+ sunscreen product and a targeted educational action~* Route of administration: Topical~* Application duration: from 5 up to 21 days~* Application modalities: The investigational product will be applied during the outdoor sun exposure on all exposed parts of the body (face and body). The investigational product will be applied in sufficient amount to cover the exposed areas (2mg/cm2 recommended), 15 to 30 minutes before each sun exposure. The product should be reapplied as many times as required during sun exposure (systematic reapplication of the product after sweating and/or swimming and/or wiping)."
62093837|NCT05926791||Control group|Subjects receiving neither product nor targeted education
62093838|NCT04688021|EXPERIMENTAL|Tocilizumab cohort|Each patient receives Tocilizumab (8 mg/kg, i.v.) on day -1 added to conventional acute GVHD prophylaxis regimen (CsA+MTX+low-dose MMF+ATG) of haploidentical HSCT.
62093839|NCT00915850|EXPERIMENTAL|Anticancer drug|docetaxel, cisplatin and 5-FU
62093840|NCT04873713|NO_INTERVENTION|No Intervention: internal hip rotation|internal hip rotation pre measurement with knee and hip flexion at 90º, internal hip rotation will be performed
62464596|NCT00827853|EXPERIMENTAL|1|Conventional angioplasty balloon post-dilation of nitinol self expanding stents
61907658|NCT01640574|ACTIVE_COMPARATOR|Chloroquine 14 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
61907659|NCT03693560|EXPERIMENTAL|vildagliptin / metformin|Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
61907660|NCT03693560|EXPERIMENTAL|glimepiride / metformin.|Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
61907661|NCT00811642|EXPERIMENTAL|Posaconazole|Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
61907662|NCT05202964||Tolerance and adherence to oral antibiotics in patients managed for BJI|Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery
61907663|NCT04671732||Fenestrated endovascular aortic aneurysm repair (FEVAR)|
61907664|NCT04671732||Open repair (OR)|
61907665|NCT06093074|EXPERIMENTAL|intervention group|Feasibility trial study group.
61907666|NCT04271618|ACTIVE_COMPARATOR|Traditional Treatment Arm|Participants in this group will receive conventional rehabilitation program for postural correction 2 hours/3 sessions' weekly/3 successive months.
62093841|NCT04873713|EXPERIMENTAL|Experimental: internal hip rotation|internal hip rotation post experimental application measurement with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
62464597|NCT00827853|EXPERIMENTAL|2|Cryoplasty balloon post-dilation
62464598|NCT03734497|ACTIVE_COMPARATOR|Group Control|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
62464599|NCT03734497|EXPERIMENTAL|Group Preloading|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
62464600|NCT03734497|EXPERIMENTAL|Group Carotis FTc|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
62464601|NCT00803478|ACTIVE_COMPARATOR|Hinge position|superior vs. temporal
61907667|NCT04271618|EXPERIMENTAL|TheraTogs Undergarment Arm|Participants in this group will receive the same conventional rehabilitation program as in traditional group in addition to wearing of TheraTogs soft orthotic undergarment with strapping system.
61907668|NCT02069964||Prospective hemi-neck RT|
62093842|NCT04873713|PLACEBO_COMPARATOR|Placebo Comparator: internal hip rotation|internal hip rotation post placebo application measurement with Placebo tape Application with knee and hip flexion at 90o, internal hip rotation will be performed
62093843|NCT01278537|EXPERIMENTAL|Empowerment, shared-decision making,|Patients receive a booklet with informations. Assessment of health-related risk factors. Assessment of psychological and physical social support Delirium protection. Early mobilization.
62093844|NCT01278537|NO_INTERVENTION|control group|
61907669|NCT04374227|EXPERIMENTAL|Treatment Group|The treatment group received three osteopathic manipulative treatments once a week for three weeks. The osteopathic manipulative treatment was a full body treatment based upon Dr. Zink's model of a common compensatory pattern.
61907670|NCT04374227|NO_INTERVENTION|Control Group|This group received an osteopathic structural exam once a week for three weeks without any treatment performed.
61907671|NCT01597167|EXPERIMENTAL|Magnesium sulfate crossover|IV infusion of magnesium sulfate followed by 5-day washout period and crossover to 5% dextrose (placebo)
61907672|NCT01597167|PLACEBO_COMPARATOR|Placebo crossover|IV infusion of 5% dextrose with 5 day washout and crossover to magnesium sulfate
61907673|NCT05251389|EXPERIMENTAL|A: FMT from an ICI non-responding donor|Patients will receive FMT from an ICI non-responding donor (defined as ≥20% increase according to RECIST 1.1 criteria within the past 3 months). Patients will continue their anti-PD-1 treatment.
61907674|NCT05251389|EXPERIMENTAL|B: FMT from an ICI responding donor|Patients will receive FMT from an ICI responding donor (defined as ≥30% decrease or disappearance of all lesions according to RECIST 1.1 criteria within the past 24 months). Patients will continue their anti-PD-1 treatment.
61907675|NCT01175681|EXPERIMENTAL|treatment|remote ischaemic preconditioning
61907676|NCT01175681|NO_INTERVENTION|untreated|control
62464602|NCT00803478|ACTIVE_COMPARATOR|Hinge width|45 vs 90 degrees
61907677|NCT00620932|NO_INTERVENTION|Control Group|These patients will continue with whatever routine exercise they already engage in.
61907678|NCT00620932|EXPERIMENTAL|Exercise Arm|These patients will participate in a controlled, supervised exercise program.
61907679|NCT05921045||time 0 and 6 months answers|questionnaire answers after first training and after re-training on shoulder dystocia model
61907680|NCT05413824||COVID-19 survivors|Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who survived.
61907681|NCT05413824||COVID-19 Deceased|Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who died.
61907682|NCT02775929|OTHER|PrEP as a bridge to ART|FTC-TDF PrEP for HIV uninfected partners and ART for HIV infected partners
62093845|NCT03682536|EXPERIMENTAL|Luspatercept|
62093846|NCT03682536|ACTIVE_COMPARATOR|Epoetin alfa|
62093847|NCT04634877|EXPERIMENTAL|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m\^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m\^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
61907683|NCT04764474|EXPERIMENTAL|Treatment|All patients will be administered HMPL-306 orally QD
61907684|NCT04641338|EXPERIMENTAL|Intervention group|
61907685|NCT04641338|ACTIVE_COMPARATOR|Control group|
61907686|NCT02844062|EXPERIMENTAL|anti-EGFRvIII CAR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti-EGFRvIII CAR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10\^4 /kg to 1×10\^7 /kg
61907687|NCT01870323|EXPERIMENTAL|SMART Behavioral Group|Intervention condition which has access to SMART Group Wall on Facebook and receives privately-delivered weekly behavioral modules. (SMART Facebook Group + video-based behavioral modules)
61907688|NCT01870323|ACTIVE_COMPARATOR|SMART Informational Group|Comparison condition (i.e., attentional control) has access to SMART Group Wall on Facebook, and receives privately-delivered weekly text-based messages with generic content. (SMART Facebook Group + NO video-based behavioral modules)
61907689|NCT01248104|ACTIVE_COMPARATOR|Tranexamic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The TXA group re- ceived a bolus of 10 mg / kg over 15 minutes fol- lowed by an infusion of 1 mg/kg/hr.
61907690|NCT01248104|ACTIVE_COMPARATOR|Aminocaproic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The EACA group received a bolus of 100 mg / kg given over 15 minutes shortly after induction of anesthesia followed by an infusion of 10 mg/kg/hr.
61907691|NCT00926315|EXPERIMENTAL|calcitriol|calcitriol supplementation (0.25 mcg 2x/d)
62291618|NCT05499520|EXPERIMENTAL|Currently Smoking, Single Message 1 Month Delay|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one month later in a separate survey. Outcomes will be measured before seeing the anti-smoking message at baseline, and immediately after seeing the threat message at 1 month.
62464603|NCT00803478|ACTIVE_COMPARATOR|Flap Thickness|110 vs 130 microns
62464604|NCT00824148|EXPERIMENTAL|Real-time glucose monitoring|Use of Guardian REAL-Time Continuous Glucose Monitoring System, (Medtronic Minimed, Northridge, CA) for 1 month, followed by observation for 2 months.
62464605|NCT00824148|ACTIVE_COMPARATOR|Self-monitoring of plasma glucose|Conventional self-monitoring of plasma glucose by finger-prick sampling for 1 month, followed by 1 month observation.
62464606|NCT02172105|EXPERIMENTAL|BI 1744 CL|
62464607|NCT02172105|PLACEBO_COMPARATOR|Placebo|
61907692|NCT03201081|EXPERIMENTAL|training group|The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
62464608|NCT01297348||Lybrel®|Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism \[VTE\] and women not diagnosed with VTE).
62464609|NCT01297348||Other OCs containing 20μg of ethinyl estradiol|Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
62464610|NCT00119379|EXPERIMENTAL|uridine supplementation|NucleomaxX 36 grams TID every other day
62464611|NCT00119379|ACTIVE_COMPARATOR|Switch to Tenofovir|Switch of AZT or d4T to Tenofovir Disoproxil Fumarate
62464612|NCT04691830|EXPERIMENTAL|group IA|"Preschool cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
62464613|NCT04691830|ACTIVE_COMPARATOR|group IB|preschool control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the preschool age control group.
62464614|NCT04691830|EXPERIMENTAL|group IIA|"School age cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
62464615|NCT04691830|ACTIVE_COMPARATOR|group IIB|School age control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the school age control group.
62464616|NCT00830401|NO_INTERVENTION|1|One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
62464617|NCT00830401|ACTIVE_COMPARATOR|2|One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.
62464618|NCT03343730|EXPERIMENTAL|Non-mydriatic color fundus photography|All participants will receive Non-mydriatic color fundus photography with the RetinaVue camera at an already scheduled annual physical exam or follow up clinic visit with their primary care provider (PCP).
61907693|NCT03201081|NO_INTERVENTION|control group|The control group, did not participate in the motivational resistance-training program.
61907694|NCT00428584|EXPERIMENTAL|1|interferon beta-1a
61907695|NCT00428584|ACTIVE_COMPARATOR|2|interferon beta-1b
61907696|NCT04006626||PET group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT
61907697|NCT04006626||FES group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT and 18F-FES PET/CT
62093848|NCT04634877|PLACEBO_COMPARATOR|Placebo + Chemotherapy|Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m\^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m\^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
62093849|NCT03667326|ACTIVE_COMPARATOR|Low-Dose Aspirin (LDA) Intervention Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.
62093850|NCT03667326|PLACEBO_COMPARATOR|Placebo Control Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.
62093851|NCT03667326|NO_INTERVENTION|Healthy Controls Group|Subjects who are healthy volunteers (n = 10) without severe preeclampsia prior to delivery.
62464619|NCT03343730|ACTIVE_COMPARATOR|Standard of Care (Control)|All patients will also receive a referral for a dilated eye exam with an eye care professional. A yearly dilated exam as referred by the PCP.
62464620|NCT01621165|ACTIVE_COMPARATOR|prazosin|Add prazosin to usual medications and monitor manic symptoms and for adverse effects
62464621|NCT01621165|PLACEBO_COMPARATOR|Placebo|
62464622|NCT00994253|EXPERIMENTAL|Aliskiren|"Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day.~Patients will be assigned to the treatment arm containing aliskiren. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + aliskiren 150-300mg"
61907698|NCT04837326|EXPERIMENTAL|Heel Lance Blood Sampling in Facilitated Tucking Position|The infants were put in facilitated tucking position by an experienced newborn nurse. They were put in facilitated tucking position so that their arms and legs were in a flexed midline position close to their trunk in a side-lying position. They were positioned so that they could move their extremities freely. They were held in facilitated tucking position for 120 seconds before the procedure. They were kept in facilitated tucking position until the blood sample was taken from the right heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
61907699|NCT04837326|EXPERIMENTAL|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|The mother, whose privacy was protected, embraced the infant for 120 seconds before the procedure. The infant was embraced by the mother during the heel lance blood sampling from the left heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
62464623|NCT00994253|ACTIVE_COMPARATOR|Hydrochlorothiazide|"HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day.~Patients will be assigned to the treatment arm containing HCTZ. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + HCTZ 12.5-25mg"
62464624|NCT05218798|ACTIVE_COMPARATOR|Continous Treadmill Running Test|One of the four testing conditions the subject will be allocated to is a Continous Treadmill Running Test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration (\[LA-\]).
62464625|NCT05218798|ACTIVE_COMPARATOR|Continous 2-mile run test|One of the four testing conditions the subject will be allocated to is a Continous 2-mile run test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration (\[LA-\]).
62464626|NCT05218798|ACTIVE_COMPARATOR|30-15 Intermittent Fitness Test - first trial|"Aerobic capacity will be measured using the field-based 30-15IFT test. This intermittent, incremental test consists of 30-second shuttle runs interspersed with 15-second active recovery periods. Running speed will be set at 8 km/h for the first 30-second run and increased by 0.5 km/h in each 30-second phase thereafter. The speed of the last successfully completed stage will be recorded as the test result, i.e. the maximum running speed (V) during IFT. Vo2max will be estimated by the following equation:~Vo2max IFT (ml/min/kg) = 28.3 - 2.15G - 0.741A - 0.0357BM + 0.058A X VIFT + 1.03VIFT where G stands for subjects gender, A for age and BM for body mass, respectively."
62464627|NCT05218798|ACTIVE_COMPARATOR|30-15 Intermittent Fitness Test - second trial|The procedures will be the same as previously described
62464628|NCT02956772|EXPERIMENTAL|TACE plus Arsenic Trioxide|Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
62464629|NCT02956772|ACTIVE_COMPARATOR|TACE|Patients in this group are to receive a single dose of TACE treatment on day 1. TACE treatment is repeated every 9 weeks for 27 weeks.
62464630|NCT04497181|EXPERIMENTAL|Experimental group|
62464631|NCT04497181|SHAM_COMPARATOR|Control group|
62464632|NCT00939003|EXPERIMENTAL|Adalimumab|
62464633|NCT00939003|PLACEBO_COMPARATOR|Placebo|
62464634|NCT00939003|EXPERIMENTAL|Open-label Adalimumab|
62464635|NCT03685565|EXPERIMENTAL|Dermabond with underlying steristrips|
62464636|NCT03685565|ACTIVE_COMPARATOR|Dermabond|
62657526|NCT02130219|EXPERIMENTAL|Normal pressure hydrocephalus group|"Patients meeting normal pressure hydrocephalus diagnosis criteria selected to compare invasive CSF pressure versus non-invasive ICP.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
62657527|NCT01865773|EXPERIMENTAL|HFR|We selected 8 inflamed chronic HD patients, which underwent a single 240 minutes HFR session
62657528|NCT04170413||CeVUS Urodynamic|patients undergoing urodynamic study with CeVUS
62657529|NCT05092087||Control group/ non-regularity group|those who completed 8 consultations by average interval time more than 3 weeks were in the non-regularity group
61907700|NCT04837326|EXPERIMENTAL|Heel Lance Blood Sampling Using White Noise|The 'Don't Let Your Baby Cry, PT.2' track from the 'Colic' album by Orhan Osman using the 'The Happiest Baby' album by Dr. Harvery Karp which was composed only of intrauterine was made listened to the infants via Xperia Ultra Mp3 Player for 120 seconds before and 120 seconds after the heel lance blood sampling procedure. While white noise was made listened to the infants before, during and after the procedure, Digital Sound LeverMeter brand noise measurement device was put at a distance of 50 cm from the infant and the ambient noise level was adjusted as 55 dB. The blood samples were taken by the researcher after inserting the lancet in the first try.
61907701|NCT04837326|NO_INTERVENTION|Control Group|Suitable environmental conditions (ambient temperature, silent environment, etc.) were ensured in the study room for the infant's comfort. A saturation probe was inserted to the right wrist of the infant to monitor him/her. A video record was taken for 120 seconds without any intervention to the infants before and after the heel lance blood sampling procedure. The blood samples were taken by the researcher after inserting the lancet in the first try. Heel lance was performed in clinical routine for preterm infants in the control group.
62464637|NCT02304809|EXPERIMENTAL|VEMURAFENIB|"all eligible patients entering the study will receive oral Vemurafenib as monotherapy.~Vemurafenib ZELBORAF 240 mg tablets Per OS 960 mg twice daily, to a total daily dose of 1,920 mg Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks Safety will be assessed continuously~Treatment will be pursed until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient refusal."
62464638|NCT00404430||Exacerbated COPD patients|Patients with exacerbated COPD
62464639|NCT00404430||Stable COPD patients|Patients with stable COPD
62464640|NCT00721747|EXPERIMENTAL|Unique arm|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
62464641|NCT04886973|EXPERIMENTAL|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
62464642|NCT04886973|EXPERIMENTAL|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) < 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
62464643|NCT02385409||Elective Total Hip- or Knee arthroplasty patients|Patients scheduled for elective Hip- or knee replacement at Hvidovre Hospital, Denmark.
62464644|NCT02711852|EXPERIMENTAL|Duvelisib|Participants received the same dose from their previous duvelisib study. All doses were taken twice daily. Two dose reductions were allowed per participant, but doses were not less than 10 milligrams (mg). Participants received duvelisib until disease progression or unacceptable toxicity.
62464645|NCT03060694||Diabetes group|Patients in this group are recruited from both departments of endocrinology and gastroenterology. The diagnosis of diabetes is confirmed by medical history, using anti-diabetic medicines or laboratory tests.
62464646|NCT03060694||Non-diabetes group|Patients in this group are recruited from department of gastroenterology. The exclusion of diabetes is confirmed by medical history or laboratory tests.
62464647|NCT00860405|EXPERIMENTAL|1|Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
62464648|NCT00860405|ACTIVE_COMPARATOR|2|Control drug: Human serum albumin (HSA 50g/L)
62464649|NCT05677204||Acute Achilles tendinopathy|No intervention will be given
62464650|NCT02435225|EXPERIMENTAL|Mindfulness group|Participation in a 12 week mindfulness therapy group.
62464651|NCT01841866|ACTIVE_COMPARATOR|deep anesthetic state|LMA removal
62464652|NCT01841866|PLACEBO_COMPARATOR|awake|LMA removal
62464653|NCT00936871|EXPERIMENTAL|Part A|Lersivirine Tolerability
62464654|NCT00936871|EXPERIMENTAL|Part B|Thorough QTc
62464655|NCT01095692|ACTIVE_COMPARATOR|only surgery|
62464656|NCT01095692|EXPERIMENTAL|surgery + TOT|
62657530|NCT05092087||test group/ regularity group|those who completed the consultations and interval time within in 3 weeks were in the higher regularity
62657531|NCT06524518|SHAM_COMPARATOR|MRD-negative follow-up|
62657532|NCT06524518|NO_INTERVENTION|MRD-positive follow-up|
62657533|NCT06524518|EXPERIMENTAL|MRD-positive adaptive therapy|
62657534|NCT06270615||Prehospital severe trauma patients|Every severe trauma patient 18 years of age or older to be admitted to a participating center excluding those already diagnosed with active hemorrhage from computed tomography findings and those with prior traumatic cardiac arrest
61907702|NCT06139627|EXPERIMENTAL|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians receive the geriatric assessment summary and assessment-based recommendations, which are provided prior to beginning chemotherapy and radiation, at the midpoint of chemotherapy and radiation treatment, and at the end of treatment. Patients also undergo blood and stool sample collection during screening and on study.
62464657|NCT01185821|EXPERIMENTAL|BAF312 10 mg/2 mg|10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
62464658|NCT01185821|EXPERIMENTAL|BAF312 2 mg/2 mg|2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
62464659|NCT01185821|EXPERIMENTAL|BAF312 1.25 mg/2 mg|1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
62657535|NCT05123950||Cohort 1|Participants diagnosed with R/M SCCHN between 01-Jan-2014 and 31-Dec-2016
62657536|NCT05123950||Cohort 1- Augment|Participants newly initiating 1L treatment for R/M SCCHN between 01-Jun-2017 and 01-Jun-2018
62657537|NCT06342882||patients with dysphagia (study)|In this study, patients who received PAS score 1 were included in the group without dysphagia (control group); and patients who were scored between 2 to 8 were included in the group with dysphagia (study group).
62657538|NCT06342882||patients without dysphagia (control)|In this study, patients who received PAS score 1 were included in the group without dysphagia (control group); and patients who were scored between 2 to 8 were included in the group with dysphagia (study group).
62657539|NCT01735812|EXPERIMENTAL|symptomatic UF|
62657540|NCT06478914|EXPERIMENTAL|NEMS group (group A)|the first experimental group consisted of 30 patients, to which neuromuscular electric stimulation (NMES) was applied
61907703|NCT06139627|ACTIVE_COMPARATOR|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams, per usual care. Patients also undergo blood and stool sample collection during screening and on study.
61907704|NCT02885116|PLACEBO_COMPARATOR|oxygen supplementation|right heart catheterization will be done in hypoxemic patients with supplemental oxygen
61907705|NCT02885116|ACTIVE_COMPARATOR|Nasal high flow (NHF) supplementation|right heart catheterization after during NHF (20 min) use with 35 l/min
61907706|NCT02605291|EXPERIMENTAL|Experimental arm 1|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
61907707|NCT02605291|EXPERIMENTAL|Experimental arm 2|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
61907708|NCT02605291|EXPERIMENTAL|Experimental arm 3|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
61907709|NCT01049945|EXPERIMENTAL|Arm I|Patients receive dexamethasone orally or IV on days 1, 8, 15, and 22; bendamustine hydrochloride IV over 30 minutes on days 1 and 2; and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
61907710|NCT04231552|EXPERIMENTAL|Chemotherapy and PD1 inhibitor|CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
61907711|NCT04170972|EXPERIMENTAL|Exercise and vivo insulin stimulation in TBC1D4 gene-variants|Acute exercise and in vivo insulin stimulation in homozygote carriers of a p.ARg684T TBC1D4 gene-variant.
61907712|NCT04170972|EXPERIMENTAL|Exercise and vivo insulin stimulation in matched controls|Acute exercise and in vivo stimulation in none carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant.
62464660|NCT01185821|EXPERIMENTAL|BAF312 .5 mg/2 mg|.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
62464661|NCT01185821|EXPERIMENTAL|BAF312 .25 mg/2 mg|.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
62464662|NCT00336622|EXPERIMENTAL|Experimental|Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
62464663|NCT00336622|ACTIVE_COMPARATOR|Control|Off-the-shelf splint
62464664|NCT04510077|EXPERIMENTAL|Prevention (SmartQuit)|Patients use the SmartQuit program to learn and practice skill modules as often as they wish over 6 months.
62464665|NCT00488774|PLACEBO_COMPARATOR|Placebo|Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
62464666|NCT00488774|EXPERIMENTAL|Golimumab 1 milligram (mg) per kilogram (kg)|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
62464667|NCT00488774|EXPERIMENTAL|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
62464668|NCT00488774|EXPERIMENTAL|Golimumab 4 mg per kg|Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
62657541|NCT06478914|EXPERIMENTAL|LIL group (group B)|The second experimental group consisted of 30 patients to which the low intensity laser (LIL) was applied
62657542|NCT00549055||1|Patients who obtained reimbursement of Macugen.
62093852|NCT04170023|EXPERIMENTAL|Open-label ALXN2050 Monotherapy|"Experimental: Open-label ALXN2050 Monotherapy ALXN2050 orally administered~Group 1: Patients with PNH who are treatment naïve~Group 2: Patient with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN)~Group 3: Patients with PNH who have received danicopan monotherapy during study ACH471-103"
62093853|NCT02039700|EXPERIMENTAL|Lesinurad and [14C]lesinurad|Single oral dose of lesinurad and single infusion of \[14C\]lesinurad
62291619|NCT05499520|EXPERIMENTAL|Currently Smoking, Single Message 1 Month Delay, Repeated Exposure|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one month later. Participants will also receive repeated exposures of a single anti-smoking message at 1, 2, and 3 weeks in separate surveys. Outcomes will be measured before seeing the anti-smoking message at baseline and immediately after seeing the threat message at 1 month.
62464669|NCT05123495||Device Briefing Tool Implementation|Surgical departments which receive training on use of the Device Briefing Tool
62464670|NCT05123495||Comparator|Surgical departments that do not receive training on use of the Device Briefing Tool
62464671|NCT01758627|NO_INTERVENTION|Peritoneal dialysis group|
61907713|NCT00895102|ACTIVE_COMPARATOR|1. ABT-333 Capsule vs ABT-333 Tablet|400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose
62464672|NCT01758627|EXPERIMENTAL|Conventional treatment group|medical treatment such as diuretics
62464673|NCT03726866|EXPERIMENTAL|Sequence 1|Sequence 1
62464674|NCT03726866|EXPERIMENTAL|Sequence 2|Sequence 2
62657543|NCT02309359|PLACEBO_COMPARATOR|Placebo q2w + MTX|Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
62464675|NCT03726866|EXPERIMENTAL|Sequence 3|Sequence 3
62657544|NCT02309359|EXPERIMENTAL|ALX-0061 75 mg q4w + MTX|ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
62657545|NCT02309359|EXPERIMENTAL|ALX-0061 150 mg q4w + MTX|ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
62093854|NCT06616779||GlucoTab Group|
62464676|NCT03726866|EXPERIMENTAL|Sequence 4|Sequence 4
62464677|NCT03726866|EXPERIMENTAL|Sequence 5|Sequence 5
62464678|NCT03726866|EXPERIMENTAL|Sequence 6|Sequence 6
62464679|NCT02763865|EXPERIMENTAL|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
62464680|NCT02763865|SHAM_COMPARATOR|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
62464681|NCT01110005|ACTIVE_COMPARATOR|D5 Lactated Ringer's solution (D5LR)|IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.
62464682|NCT01110005|ACTIVE_COMPARATOR|Lactated Ringer's solution (LR)|Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.
62464683|NCT05101044|EXPERIMENTAL|Acceptance-based Behavioral Therapy (ABBT) Intervention|All recruited individuals will receive ABBT intervention. ABBT involves 2 sessions delivered within about a week of each other, consisting of a 20-25 minute session 1, and a 10 minute session 2.
62464684|NCT06364709|EXPERIMENTAL|Criterion-learning practice|This is a single-arm study.
62464685|NCT05448430|EXPERIMENTAL|predominant negative symptoms|iTBS for predominant negative symptoms
61907714|NCT00895102|ACTIVE_COMPARATOR|2. ABT-333 Tablet|ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)
61907715|NCT00895102|PLACEBO_COMPARATOR|3. Placebo|Placebo tablets, QD, single ascending doses
61907716|NCT02607748|EXPERIMENTAL|18F-NaF PET and coronary CTA imaging|18F-NaF PET and coronary CTA imaging
62464686|NCT05448430|NO_INTERVENTION|positive symptoms|
62464687|NCT05448430|NO_INTERVENTION|healthy control|
62657546|NCT02309359|EXPERIMENTAL|ALX-0061 150 mg q2w + MTX|ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
61907717|NCT02595645|EXPERIMENTAL|Polypectomy and NGS|All patients which underwent screening colonoscopy and fulfilling the inclusion criteria are eligible. Polyps were biopsied and underwent histopathological and genetic analyses
62093855|NCT06616779||Retrospective Control Group|
62093856|NCT02444442|ACTIVE_COMPARATOR|Renal Denervation|participants randomised to undergo renal denervation
62093857|NCT02444442|SHAM_COMPARATOR|Sham control|participants randomised to undergo sham procedure
62093858|NCT06465576|EXPERIMENTAL|Abrupt withdrawal of solifenacin|
62093859|NCT06465576|EXPERIMENTAL|Gradual withdrawal of solifenacin|
62093860|NCT06465576|EXPERIMENTAL|Abrupt withdrawal of mirabegron|
62093861|NCT06465576|EXPERIMENTAL|Gradual withdrawal of mirabegron|
62093862|NCT06465576|EXPERIMENTAL|Abrupt withdrawal of solifenacin + mirabegron|
62093863|NCT06465576|EXPERIMENTAL|Gradual withdrawal of solifenacin + mirabegron|
62093864|NCT06183047||patients with neuroendocrine tumours|We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
62093865|NCT05475223|OTHER|Prospective|Standard of Care for Diagnosis and management of neonatal jaundice + End Tidal Carbon Monoxide measurement value
62093866|NCT04752696|EXPERIMENTAL|Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU|The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m\^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m\^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m\^2 leucovorin and 2400 mg/m\^2 fluorouracil (5-FU).
62093867|NCT04752696|EXPERIMENTAL|Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU|Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m\^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m\^2 leucovorin and 2400 mg/m\^2 fluorouracil (5-FU).
62093868|NCT04524442|EXPERIMENTAL|GEP-NET|One dose of arginine/lysine solution administered intravenously over a 4-hour period
62093869|NCT02862054|EXPERIMENTAL|Splenectomy|Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology
62657547|NCT02309359|EXPERIMENTAL|ALX-0061 225 mg q2w + MTX|"ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.~The last study drug administration was at the Week 22 visit."
62657548|NCT04626505|EXPERIMENTAL|Ziltivekimab 15 mg|Participants will receive ziltivekimab 15 mg for 12 weeks.
62657549|NCT04626505|EXPERIMENTAL|Ziltivekimab 30 mg|Participants will receive ziltivekimab 30 mg for 12 weeks.
62657550|NCT04626505|PLACEBO_COMPARATOR|Placebo (ziltivekimab)|Participants will receive placebo (ziltivekimab) for 12 weeks.
61907718|NCT01222156|EXPERIMENTAL|CGCI navigation|Subjects with CGCI navigation to specific target intracardiac anatomical sites
62093870|NCT05321628|EXPERIMENTAL|iCBT + Decision Support Tool|Internet-based Cognitive Behavioural Therapy where therapists have traditional clinical routines and supervision and also use a clinical decision support tool.
62657551|NCT02383615|ACTIVE_COMPARATOR|DTSNB|Distal transsartorial saphenous nerve block
62657552|NCT02383615|ACTIVE_COMPARATOR|ACSNB|Adductor canal saphenous nerve block
62093871|NCT05321628|ACTIVE_COMPARATOR|Traditional iCBT|Internet-based Cognitive Behavioural Therapy with traditional clinical routines and supervision.
62093872|NCT02724020|ACTIVE_COMPARATOR|Arm A: Single-agent Everolimus 10 mg QD|Everolimus 10 mg capsules, orally, once daily in a 28-day treatment cycle until disease progression, consent withdrawal, death, or transfer to the Post-trial Access (PTA) program (Median duration of treatment was 15.43 weeks up to end of study).
62093873|NCT02724020|EXPERIMENTAL|Arm B: Single-agent MLN0128 30 mg QW|MLN0128 30 mg capsules, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.64 weeks up to end of study).
62093874|NCT02724020|EXPERIMENTAL|Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD|MLN0128 4 mg and MLN1117 200 mg capsules, orally, both once daily for 3 days per week (QD X 3) on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.43 weeks up to end of study).
62093875|NCT05706025|EXPERIMENTAL|Enterotracker|The EnteroTracker® is a capsule device that includes an absorbent string. The trailing end of the string is taped to the cheek and the capsule is swallowed with 8-12 ounces of water. The capsule dislodges the string as it travels to the proximal small intestine. The capsule continues through the remainder of the GI tract, leaving a string in the esophagus, stomach, and duodenum. Following a 60-minute dwell time, the string is removed via the subjects' mouth and processed for analysis. Subjects will be coached to ease any potential anxieties and answer any questions. A preparatory video can be used for education if desired.
62291620|NCT05499520|EXPERIMENTAL|Currently Smoking, Three Messages Immediate|Participants will receive three anti-smoking messages, followed by the threat message during the baseline survey. Outcomes will be measured before seeing the anti-smoking messages and threat message, immediately after seeing the threat message, and at 1 month.
62657553|NCT00817791|EXPERIMENTAL|HBO|
62657554|NCT05013801|EXPERIMENTAL|Cosmetic Facial Serum Q69|Cosmetic facial serum. To be used twice daily on lesional areas of the face for 12 weeks.
62657555|NCT05013801|OTHER|2% Hydroquinone|2% hydroquinone cream to be used twice daily on lesional areas of the face as directed by the dermatologist for no longer than 8 weeks.
62657556|NCT03977480|ACTIVE_COMPARATOR|Hemay007 400 mg BID group|Patients will orally take Hemay007 tablets 400 mg BID for 12 weeks.
62657557|NCT03977480|ACTIVE_COMPARATOR|Hemay007 800 mg QD group|Patients will orally take Hemay007 tablets 800 mg QD for 12 weeks.
61907719|NCT02452827||Primary Chronic Neck Pain|Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated.
61907720|NCT02452827||Control|Patients without neck pain who have undergone MRI for any reason. Biomechanical parameters of neck movements will be investigated.
61907721|NCT01087788|EXPERIMENTAL|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
62093876|NCT06614816|EXPERIMENTAL|Live Attenuated Varicella vaccine candidates|The test group received the freeze-dried live attenuated VarV developed by Beijing Minhai Biotechnology Co., LTD., which are derived from the Oka strain, cultured and harvested from inoculated MRC-5 human diploid cells inoculated human diploid cells (MRC-5), and then lyophilized with appropriate stabilizers.
62093877|NCT06614816|ACTIVE_COMPARATOR|Marketed Live Attenuated Varicella vaccine|the active control group received VarV produced by Changchun BCHT Biotechnology Co.,which are derived from the Oka strain, cultured and harvested from inoculated MRC-5 human diploid cellsinoculated human diploid cells (MRC-5), and then lyophilized with appropriate stabilizers.
62093878|NCT06314061|EXPERIMENTAL|Intervention group|Participants in the intervention group will wear the CGM-device Dexcom G7, and real-time alerts on dysglycaemia and rapidly increasing or falling glucose levels will alert the nursing staff.
62657558|NCT03977480|ACTIVE_COMPARATOR|Hemay007 600 mg BID group|Patients will orally take Hemay007 tablets 600 mg BID for 12 weeks.
62657559|NCT03977480|PLACEBO_COMPARATOR|placebo group|Patients will orally take placebo tablets for 12 weeks.
62657560|NCT05571813|EXPERIMENTAL|Sequence 1|Period1: D958 Period2: CKD-341 Formulation I Period3: CKD-341 Formulation II
62657561|NCT05571813|EXPERIMENTAL|Sequence 2|Period1: CKD-341 Formulation II Period2: D958 Period3: CKD-341 Formulation I
62657562|NCT05571813|EXPERIMENTAL|Sequence 3|Period1: CKD-341 Formulation I Period2: CKD-341 Formulation II Period3: D958
62657563|NCT05571813|EXPERIMENTAL|Sequence 4|Period1: CKD-341 Formulation II Period2: CKD-341 Formulation I Period3: D958
62657564|NCT05571813|EXPERIMENTAL|Sequence 5|Period1: CKD-341 Formulation I Period2: D958 Period3: CKD-341 Formulation II
62657565|NCT05571813|EXPERIMENTAL|Sequence 6|Period1: D958 Period2: CKD-341 Formulation II Period3: CKD-341 Formulation I
62657566|NCT03946527|EXPERIMENTAL|lanreotide arm|Patients with a histopathologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability who meet the inclusion/exclusion criteria. Approximately 40 patients will be enrolled.
62657567|NCT00468832||Ongoing Duchenne Muscular Dystrophy (DMD) Cohort|340 patients currently enrolled participants with DMD.
62657568|NCT00468832||New Young Duchenne Muscular Dystrophy (DMD) Cohort|Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
62657569|NCT00468832||Typically Developing Control Cohort|Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.
62657570|NCT02987868|ACTIVE_COMPARATOR|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
62657571|NCT02987868|PLACEBO_COMPARATOR|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
62657572|NCT01873144|ACTIVE_COMPARATOR|HSS (3%) + epinephrine|Nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria.
62093879|NCT06314061|NO_INTERVENTION|Control group|Participants in the control group will wear a blinded CGM device. The nursing staff will monitor glucose levels with standard care using POC blood glucose measurements.
62657573|NCT01873144|EXPERIMENTAL|HHHFNC+epinephrine+Normal Saline(0.9%)|Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria.
62093880|NCT06477939|ACTIVE_COMPARATOR|Radiotherapy plus Temozolomide|
62093881|NCT06477939|EXPERIMENTAL|Administration of L-TC on top of Radiotherapy plus Temozolomide|
62093882|NCT01905865||Parent|Persons aged 18 years or older who have a child with an undiagnosed medical condition, who have applied to the Undiagnosed Diseases Network, and have been assigned to the NIH.
62093883|NCT06697015|ACTIVE_COMPARATOR|Pendulum Exercises|Eighteen participants will perform pendulum exercises, which involve gently swinging the arm to relax shoulder muscles and improve mobility. This low-impact exercise is intended to alleviate tension and increase circulation in the rotator cuff, making it ideal for early-stage shoulder rehabilitation.
62093884|NCT06697015|ACTIVE_COMPARATOR|Serratus Punch Exercises|Eighteen participants will engage in serratus punch exercises, extending the arm in a controlled punching motion to strengthen the serratus anterior muscle. This exercise promotes shoulder stability and supports rotator cuff function, aiming to reduce pain and improve shoulder control.
62657574|NCT00324155|EXPERIMENTAL|Arm A: Ipilimumab and Dacarbazine|In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
62093885|NCT05995171||Esophageal atresia arm|Patient with esophageal atresia
62093886|NCT05995171||control arm|Patient without esophageal atresia
62464688|NCT01386294|EXPERIMENTAL|Tenofovir 1% vaginal gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
62464689|NCT01386294|PLACEBO_COMPARATOR|Universal placebo gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
62657575|NCT00324155|ACTIVE_COMPARATOR|Arm B: Placebo and Dacarbazine|
62657576|NCT02061657|EXPERIMENTAL|Myomectomy, rectal Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
62657577|NCT02061657|ACTIVE_COMPARATOR|Myomectomy, Placebo|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
62657578|NCT01829347|EXPERIMENTAL|ELAD (plus Standard of Care)|ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
62657579|NCT01829347|OTHER|Standard of Care (Control)|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
62657580|NCT06091319||Acute atherosclerotic disease event group|Patients with a recent ACS (i.e. STEMI or NSTEMI), stroke or transient ischemic attack.
62657581|NCT06091319||Control|A control population of patients with known vascular disease but without recent ACS, stroke/TIA.
62657582|NCT04685811|EXPERIMENTAL|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
62657583|NCT02332759|EXPERIMENTAL|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
62657584|NCT04128995|ACTIVE_COMPARATOR|Medical Therapy and Bariatric Surgery in Youth with Type 2 Diabetes|Youth with type 2 diabetes undergoing bariatric surgery, n=45
62657585|NCT04128995|ACTIVE_COMPARATOR|Medical Therapy in Youth with Type 2 Diabetesin Youth with Type 2 Diabetes|Youth with type 2 diabetes receiving medical management, n=45
62093887|NCT05842824||Disease Cohort|Observational
62093888|NCT05842824||Engaged Cohort|Observational
62291621|NCT05499520|EXPERIMENTAL|Currently Smoking, Three Messages 1 Week Delay|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one week later in a separate survey. Outcomes will be measured before seeing the anti-smoking messages at baseline, immediately after seeing the threat message at 1 week, and at 1 month.
62464690|NCT05478395||Questionnaires assessed adolescents and young adults|"1. Internet users aged 14-35;~2. Be able to read and communicate in Chinese."
62464691|NCT06181071|OTHER|Distal Fatigue of The Lower Extremity|Distal muscle fatigue of the lower extremity involves the plantar and dorsiflexor muscles of the ankle.
62464692|NCT06181071|OTHER|Proximal Fatigue of The Lower Extremity|Proximal muscle fatigue of the lower extremity involves hip flexor and extansor muscles.
62464693|NCT03481998|EXPERIMENTAL|Cohort 1 (Part 1)|Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
62464694|NCT03481998|EXPERIMENTAL|Cohort 2 (Part 1)|SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
62464695|NCT03481998|EXPERIMENTAL|SHR6390 + Letrozole or anastrozole (Part 2)|SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
62657586|NCT04128995|ACTIVE_COMPARATOR|Bariatric Surgery in Youth with Obesity|Youth with no obesity undergoing bariatric surgery, n=10
62657587|NCT00497107|ACTIVE_COMPARATOR|1|The Control Group (UFT + Calcium Folinate)
62657588|NCT00497107|EXPERIMENTAL|2|The PSK Group (UFT + Calcium Folinate + PSK)
62657589|NCT05041465|EXPERIMENTAL|French Green Clay Mask|
62657590|NCT05041465|EXPERIMENTAL|Rhassoul Clay Mask|
62657591|NCT05041465|EXPERIMENTAL|Bentonite Clay Mask|
62657592|NCT04275037|EXPERIMENTAL|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
62657593|NCT04275037|ACTIVE_COMPARATOR|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
62657594|NCT04275037|NO_INTERVENTION|Control Group|The control group will receive usual medical care
62657595|NCT01330927|EXPERIMENTAL|VA106483 0.5 mg|
62657596|NCT01330927|EXPERIMENTAL|VA106483 1 mg|
62657597|NCT01330927|EXPERIMENTAL|VA106483 2 mg|
62657598|NCT01330927|EXPERIMENTAL|VA106483 4 mg|
62657599|NCT01330927|PLACEBO_COMPARATOR|Sugar pill|
62093889|NCT05168371|EXPERIMENTAL|CBT-O|Women randomized to this arm will receive access to the eight modules of Cognitive-Behavioural Therapy-Online (CBT-O). Participants will meet weekly via Zoom with treatment navigators during the 8-12 weeks that it takes to complete the program.
62093890|NCT05168371|EXPERIMENTAL|MBT-O|Women randomized to this arm will receive access to the eight modules of Mindfulness-Based Therapy-Online (MBT-O). Participants will meet weekly via Zoom with treatment navigators during the 8-12 weeks that it takes to complete the program.
62291622|NCT05499520|EXPERIMENTAL|Currently Smoking, Three Messages 1 Month Delay|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one month later in a separate survey. Outcomes will be measured before seeing the anti-smoking messages at baseline, and immediately after seeing the threat message at 1 month.
62291623|NCT05499520|EXPERIMENTAL|Currently Smoking, Three Messages 1 Month Delay Repeat Exposure|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one month later. Participants will also receive repeated exposures of three anti-smoking messages at 1, 2, and 3 weeks in separate surveys. Outcomes will be measured before seeing the anti-smoking messages at baseline and immediately after seeing the threat message at 1 month.
62291624|NCT05499520|NO_INTERVENTION|Not Currently Smoking, No Message Condition|Participants will receive no anti-smoking messages. They will receive the threat message during the baseline survey. Outcomes will be measured before and immediately after seeing the threat message, and at 1 month.
62291625|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Single Message Immediate|Participants will receive a single anti-smoking message followed by the threat message during the baseline survey. Outcomes will be measured before seeing the anti-smoking message and threat message, immediately after seeing the threat message, and at 1 month.
62291626|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Single Message 1 Week Delay|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one week later in a separate survey. Outcomes will be measured before seeing the anti-smoking message at baseline, immediately after seeing the threat message at 1 week, and at 1 month.
62291627|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Single Message 1 Month Delay|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one month later in a separate survey. Outcomes will be measured before seeing the anti-smoking message at baseline, and immediately after seeing the threat message at 1 month.
62291628|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Single Message 1 Month Delay, Repeated Exposure|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one month later. Participants will also receive repeated exposures of a single anti-smoking message at 1, 2, and 3 weeks in separate surveys. Outcomes will be measured before seeing the anti-smoking message at baseline and immediately after seeing the threat message at 1 month.
62657600|NCT02339337|EXPERIMENTAL|RGT group|For subjects who were randomized into the RGT group, the duration of Peg-IFN and RBV therapy was abbreviated to 24 weeks in subjects with HCV genotype 1, a pre-treatment low viral load (LVL, \< 400000 IU/mL) and RVR (defined asHCV RNA \<50 IU/mL at 4th week of therapy); the duration was 16 weeks in subjects with HCV genotype 2/3 and RVR.
62657601|NCT02339337|ACTIVE_COMPARATOR|GGT group|Subjects who were randomized into the GGT group received Peg-IFN and standard dose RBV (1200 mg/day) for 48 weeks in subjects infected with HCV genotype 1 or Peg-IFN and low dose RBV (800 mg/day) for 24 weeks in subjects infected with HCV genotype 2/3; the patients were then followed for 6 months.
61907722|NCT01087788|EXPERIMENTAL|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
61907723|NCT01087788|PLACEBO_COMPARATOR|Placebo|"Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.~After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W)."
61907724|NCT01087788|OTHER|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
61907725|NCT01087788|OTHER|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
62093891|NCT05168371|NO_INTERVENTION|Wait-List Control|Participants who are randomized to the wait-list group will complete two baseline online questionnaire/assessment batteries before being randomized to one of the active treatment groups. Participants will be randomized into one of the active treatment groups after a 10 week waiting period.
62093892|NCT04950543||Meditation|
62093893|NCT04539041|EXPERIMENTAL|Cohort A NIO752|4 injections of NIO752 at dose A
62657602|NCT05104593|EXPERIMENTAL|Intervention tested (CAREPATH)|The intervention tested will be the CAREPATH system.
62657603|NCT05104593|NO_INTERVENTION|Control group|Control group, no intervention
62657604|NCT05510492|EXPERIMENTAL|EXPERIMENTAL GROUP|EXPERIMENTAL GROUP CONSISTS OF 47 NURSES.
62657605|NCT05510492|EXPERIMENTAL|CONTROL GROUP|CONTROL GROUP CONSISTS OF 48 NURSES.
62657606|NCT04094428||Intensive care unit patient|All intensive care unit patients staying for at least 72 hours on the ICU and patients dying within 72 hours
62657607|NCT00472238|EXPERIMENTAL|1, Training|Group for training therapy
62657608|NCT00472238|ACTIVE_COMPARATOR|2, Control|
62657609|NCT05195151|EXPERIMENTAL|Probiotics|taking a capsule containing the probiotics 15 d before and 15 d after booster shot.
62657610|NCT05195151|PLACEBO_COMPARATOR|Control|taking a capsule containing a placebo 15 d before and 15 d after booster shot.
62657611|NCT00397579|EXPERIMENTAL|SL-401|Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
61907726|NCT01087788|OTHER|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
62657612|NCT00481676|EXPERIMENTAL|Omalizumab 75-375 mg|Omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
62657613|NCT00481676|PLACEBO_COMPARATOR|Placebo to omalizumab|Placebo to omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
62657614|NCT03212937|EXPERIMENTAL|Selinexor and ICE Chemotherapy|
62093894|NCT04539041|EXPERIMENTAL|Cohort B NIO752|4 injections of NIO752 at dose B
62093895|NCT04539041|PLACEBO_COMPARATOR|Placebo|4 injections of placebo
62093896|NCT04539041|EXPERIMENTAL|Cohort C NIO752|4 injections of NIO752 at dose C
62093897|NCT04539041|EXPERIMENTAL|Cohort D NIO752|4 injections of NIO752 at dose D
62093898|NCT04539041|EXPERIMENTAL|Cohort E NIO752|4 injections of NIO752 at dose E
62657615|NCT02593240|EXPERIMENTAL|Human Performance Institute©|These participants will be part of the intervention sites and will receive the Human Performance Institute© intervention for the duration of the study (18 months).
62093899|NCT06099821|EXPERIMENTAL|Patients resistant to PD1/PDL1 blockade|Patients with microsatellite instability-high digestive system cancers resistant to PD-1/PD-L1 blockade
62093900|NCT06453187|EXPERIMENTAL|Venous Leg Ulcers with a Urinary Bladder Matrix (UBM) sheet device|Participants will receive treatment with Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62093901|NCT06453187|EXPERIMENTAL|Diabetic Foot Ulcers with Urinary Bladder Matrix (UBM) sheet device|Participants will receive treatment with Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62291629|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Three Messages Immediate|Participants will receive three anti-smoking messages, followed by the threat message during the baseline survey. Outcomes will be measured before seeing the anti-smoking messages and threat message, immediately after seeing the threat message, and at 1 month.
62657616|NCT02593240|EXPERIMENTAL|The iDiet® with Voucher|These participants will be part of the intervention sites and will receive the iDiet® with Voucher for the duration of the study (18 months).
62657617|NCT02593240|EXPERIMENTAL|The iDiet® with Food|These participants will be part of the intervention sites and will receive the iDiet® with Food for the duration of the study (18 months).
62657618|NCT02593240|NO_INTERVENTION|Wait-listed control|These participants will be part of the control sites and will participate in outcome assessments for a 6-month period only.
62657619|NCT02442908|EXPERIMENTAL|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
62657620|NCT02442908|PLACEBO_COMPARATOR|Placebo|An isocaloric placebo comparator
62657621|NCT05504915||Participants with IBD|Participants diagnosed with IBD (UC or CD) who switched from vedolizumab IV to vedolizumab SC treatment during routine clinical practice, will be observed prospectively for up to 12 months from switch.
62657622|NCT05396690|EXPERIMENTAL|remimazolam group|"In the Remimazolam group as an induction dose 6 mg/kg/h of remimazolam with 0.5-1.0 mcg/kg of sufentanil was injected together. If consciousness was lost, rocumerone 1 mg/kg was given intravenously, and endotracheal intubation was performed when sufficient muscle relaxation was achieved 2 minutes later.~Maintenance of anesthesia is achieved by using a programmed infusion pump with remimazolam 1 mg/kg/h (up to 2 mg/kg/h) and sufentanil effect site concentration of 0.4 to 0.5 to reach the appropriate depth of anesthesia. The optimal level of anesthesia is based on maintaining a bispectral index (BIS) of 35-65."
62657623|NCT05396690|OTHER|sevoflurane group|After injection of 2-5 mg of midazolam and 0.5-1.0 mcg/kg of sufentanil as an induction dose, 1 mg/kg of rocumerone is given intravenously when consciousness is lost, and endotracheal intubation is performed when sufficient muscle relaxation is achieved 2 minutes later. For maintenance of anesthesia, the concentration of sevoflurane and sufentanil effect site concentration is 0.4 to 0.5 to reach the appropriate depth of anesthesia, and the optimal degree of anesthesia is based on maintaining the BIS 35 to 65.
62657624|NCT05337826|EXPERIMENTAL|Single Arm|
62657625|NCT02453022|EXPERIMENTAL|Danirixin HBr + Danirixin FB + Omeprazole|Subjects will receive danirixin FB 50 milligram (mg) immediate release (IR) tablet, single dose, in the fed state (treatment A), danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment B), danirixin HBr 50 mg IR tablet, single dose, in the fasted state (treatment C), or danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment D) as per randomization in period 1 to 4. In treatment Period 5, subjects will receive danirixin HBr 50 mg IR table, single dose, in the fed state with concomitant, steady state OMP (40 mg once daily for 5 days) (treatment E). Subject will receive treatment with washout period of 5 days in one of the four sequence DCABE, ADBCE, BACDE, CBDAE.
62657626|NCT01499589||RA in block room|Performing regional anesthesia in the block room
62657627|NCT01499589||RA inside OR|Performing regional anesthesia inside the main orthopedic operating room
62464696|NCT03481998|EXPERIMENTAL|SHR6390 + Fulvestrant Cohort 3 (Part 1)|SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
62464697|NCT03481998|EXPERIMENTAL|SHR6390 + Fulvestrant Cohort 4 (Part 1)|SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
62291630|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Three Messages 1 Week Delay|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one week later in a separate survey. Outcomes will be measured before seeing the anti-smoking messages at baseline, immediately after seeing the threat message at 1 week, and at 1 month.
62291631|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Three Messages 1 Month Delay|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one month later in a separate survey. Outcomes will be measured before seeing the anti-smoking messages at baseline, and immediately after seeing the threat message at 1 month.
62464698|NCT04249271||euthyroid, no antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO \<100 IU/ml repeated serum sampling
62464699|NCT04249271||borderline euthyroid, no antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO \<100 IU/l repeated serum sampling
62464700|NCT04249271||hypothyroidism, no antibodies|TSH \>4.5 mIU/l and anti-TPO \<100 IU/ml repeated serum sampling
62464701|NCT04249271||euthyroid, with antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO \>100 IU/ml repeated serum sampling
62464702|NCT04249271||borderline euthyroid, with antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO \>100 IU/l repeated serum sampling
62464703|NCT04249271||hypothyroidism, with antibodiesal|TSH \>4.5 mIU/l and anti-TPO \>100 IU/ml repeated serum sampling
62464704|NCT05782647|EXPERIMENTAL|Cuffless BP monitoring|Investigational device Omron HeartGuide® 6410T
62464705|NCT05782647|ACTIVE_COMPARATOR|Beat-to-beat BP monitoring|Continuous finger BP monitoring (Finometer®, Finapres Medical Systems, Enchede, The Netherlands, and Task Force® monitor, CNSystem, Graz, Austria), based on the photoplethysmographic volume clamp method
62464706|NCT02104960||PROOF|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date. (NCT00759304)
62464707|NCT04181853|ACTIVE_COMPARATOR|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
62464708|NCT04181853|ACTIVE_COMPARATOR|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
62464709|NCT04181853|NO_INTERVENTION|No Intervention: Control group|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
62464710|NCT02024646|EXPERIMENTAL|210 mg brodalumab|Administered via subcutaneous injections.
62464711|NCT02024646|EXPERIMENTAL|140 mg brodalumab|Administered via subcutaneous injection.
62464712|NCT02024646|PLACEBO_COMPARATOR|Placebo|Administered via subcutaneous injection until week 24.
62464713|NCT06086574||Patients diagnosed with stage 3 NSCLC|"Patients will receive standard of care curative-intent radiotherapy treatment as decided by their primary oncologist. This includes radical radiotherapy, sequential chemoradiotherapy and concurrent chemoradiotherapy +/- consolidation immunotherapy.~No changes in treatment. Patients will have data collected at baseline, during radiotherapy and for one year following radiotherapy. This longitudinal collection will include blood for circulating-tumour DNA analysis, electronic PROMS and radiomic analysis of standard of care imaging."
62657628|NCT05952999||Hospital at Home Care|The population for this study includes adult patients who are acutely ill and presenting to the emergency room, and are discharged to their home for hospital-level care in the home setting. The patients in this cohort may also include those who are discharged from the hospital early, but receive hospital-level care in the home setting.
62093902|NCT06453187|EXPERIMENTAL|Venous Leg Ulcers with AmnioExcel Plus|Participants will receive treatment with AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62093903|NCT06453187|EXPERIMENTAL|Diabetic Foot Ulcers with AmnioExcel Plus|Participants will receive treatment with AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62291632|NCT05499520|EXPERIMENTAL|Not Currently Smoking, Three Messages 1 Month Delay Repeat Exposure|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one month later. Participants will also receive repeated exposures of three anti-smoking messages at 1, 2, and 3 weeks in separate surveys. Outcomes will be measured before seeing the anti-smoking messages at baseline and immediately after seeing the threat message at 1 month.
62291633|NCT04201379||neck pain patients|servical disk hernisi servical spondilosis servical problems
62464714|NCT01530880|EXPERIMENTAL|Intravenous Ibuprofen|Patients assigned to the ibuprofen treatment group will receive a 400 mg IV ibuprofen bolus over 30 minutes followed by an infusion of ibuprofen at 85 mg/hr.
62464715|NCT01530880|OTHER|Standard of Care|Patients assigned to the standard of care group will be given 650 mg of oral acetaminophen and continue to receive 650 mg of oral acetaminophen every 6 hours as needed to maintain temperature \< 38.3 C (100.9 F).
62291634|NCT04201379||control|healthy people
62291635|NCT03430310|EXPERIMENTAL|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
62291636|NCT03430310|PLACEBO_COMPARATOR|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
62291637|NCT00331760|OTHER|Endometrial Cancer: IMRT|Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks.
62291638|NCT00331760|OTHER|Cervical Cancer: IMRT + Chemotherapy (cisplatin)|Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks and concurrent weekly cisplatin 40 mg/m\^2 for five weeks.
62291639|NCT06296563|EXPERIMENTAL|HAIC+Adebrelimab+apatinib|Neoadjuvant therapy with Adebrelimab combined with apatinib and FOLFOX-HAIC for 2 cycles (1 treatment cycle every 21 days, apatinib only used for the first cycle), and surgery was performed 14-28 days after the end of treatment. After 28 days of surgery, patients will continue to receive adjuvant treatment with Adebrelimab combined with apatinib.
62464716|NCT02830516||Lung elastance - transpulmonary pressure|Lung elastance and transpulmonary pressure measured by tidal esophageal pressure variations and by performing a PEEP step
62464717|NCT03027115|EXPERIMENTAL|Treatment|treatment with a selective alpha1-adrenoceptor antagonist
62464718|NCT03027115|NO_INTERVENTION|Control|no treatment
62291640|NCT06178068|ACTIVE_COMPARATOR|Group 1; jet nebulizer group|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min.
62093904|NCT06453187|ACTIVE_COMPARATOR|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
62093905|NCT03486743|EXPERIMENTAL|Intervention arm|Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.
62093906|NCT03486743|NO_INTERVENTION|Control arm|Participants in the intervention arm will only be asked to complete a survey.
62093907|NCT06556004|EXPERIMENTAL|Stage IIIC and IV melanoma patients|TRIMELVax will be administered from 10x106 melanoma cells / mL. The dose schedule considers 4 immunizations distributed as follows: the first dose on day 0, the second dose on day 28, the third dose on day 56, and the fourth dose on day 84. Conditioned tumor lysate from 10x106 melanoma cells / mL will be administered s.c. at 500 µL / dose.
62093908|NCT06417905|EXPERIMENTAL|Supervised Exercises|Exercises were done 3 times a week for 12 weeks with a physiotherapist
62093909|NCT06417905|EXPERIMENTAL|Video based Exercises|Exercises were done 3 times a week for 12 weeks by subjects via videos
62657629|NCT05952999||Traditional Hospital Care|The population for this study includes adult patients who are acutely ill and presenting to the emergency room who elect not to be discharged, choose to be cared for in the hospital setting.
62657630|NCT02745730|ACTIVE_COMPARATOR|Glucose|Shake sweetened with glucose
62657631|NCT02745730|ACTIVE_COMPARATOR|Fructose|Shake sweetened with fructose
62657632|NCT02745730|EXPERIMENTAL|Sucralose|Shake sweetened with sucralose
62657633|NCT02745730|EXPERIMENTAL|Allulose|Shake sweetened with allulose
62657634|NCT01995916|EXPERIMENTAL|Mindfulness Intervention|Mindfulness Based Stress Reduction Intervention
62093910|NCT06417905|NO_INTERVENTION|Control Group|Only postural education were given
62093911|NCT02994706|EXPERIMENTAL|Home monitoring|Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
62093912|NCT02994706|ACTIVE_COMPARATOR|Clinical Care|Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
62093913|NCT05452629|EXPERIMENTAL|Mindfulness Induction|A brief and single session of mindfulness practice for 30-minute.
62093914|NCT05452629|EXPERIMENTAL|Relaxation Induction|A brief and single session of self-directed relaxation for 30-minute.
62093915|NCT05452629|NO_INTERVENTION|Control Condition|Open thinking.
62093916|NCT01060566|EXPERIMENTAL|VX-770|
62093917|NCT01060566|EXPERIMENTAL|Midazolam|
62657635|NCT01995916|ACTIVE_COMPARATOR|Social Support Group|Social Support Group Intervention
62657636|NCT06195423|EXPERIMENTAL|Stop OsteoARthritis (SOAR) program|Participants with a first-time ACL tear followed by reconstruction surgery randomized to the SOAR program group will complete a 6-month SOAR program (one-time Knee Camp, weekly home-based exercise therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more SOAR program participants. Physiotherapists and SOAR participants will be randomly paired.
62657637|NCT06195423|ACTIVE_COMPARATOR|Living Well after ACLR|Participants with a first-time ACL tear followed by reconstruction surgery randomized to the minimal control (Living Well after ACLR) group will complete a 6-month minimal intervention control program (educational video, workbook, activity tracking, and one 1:1 physiotherapist counseling session).
62093918|NCT01060566|EXPERIMENTAL|Rosiglitazone|
62093919|NCT01060566|EXPERIMENTAL|Fluconazole|
62093920|NCT06697600|EXPERIMENTAL|UR-GOAL Intervention|Patients will view an AML video, complete the best-worst scaling, and be provided with a summary report consisting of their priorities; they will will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view the same AML video and be provided with the same summary report. Oncologists will be provided with a summary report consisting of the patient's geriatric assessment, priorities, and perception of prognosis; they will be asked to review and discuss at upcoming clinical visits.
62657638|NCT01568541|ACTIVE_COMPARATOR|Children' toothpaste|Children's toothpastes
62093921|NCT06697600|NO_INTERVENTION|Attention Control Arm|Patients will view a nutritional video, complete a nutrition questionnaire, and will be provided with a nutrition handout and asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view the nutritional video, and will be provided with a nutrition handout and asked to review and discuss at upcoming clinical visits. Oncologists will be provided with the patient's completed nutrition questionnaire and asked to review and discuss at upcoming clinical visits.
62093922|NCT00258479|EXPERIMENTAL|Modafinil|
62093923|NCT00258479|PLACEBO_COMPARATOR|Placebo|
62657639|NCT01568541|ACTIVE_COMPARATOR|Regular toothpastes|Regular toothpastes
62657640|NCT02494024|EXPERIMENTAL|Single dose C2N-8E12 level 1|Single IV infusion of C2N-8E12
62093924|NCT00258479|NO_INTERVENTION|Nicotine Replacement Therapy|The effects of nicotine replacement therapy will be investigated - alone and in combination with modafinil - on nicotine withdrawal in nicotine-dependent adolescents.
62657641|NCT02494024|EXPERIMENTAL|Single dose C2N-8E12 level 2|Single IV infusion of C2N-8E12
62657642|NCT02494024|EXPERIMENTAL|Single dose C2N-8E12 level 3|Single IV infusion of C2N-8E12
62657643|NCT02494024|EXPERIMENTAL|Single dose C2N-8E12 level 4|Single IV infusion of C2N-8E12
62657644|NCT02494024|PLACEBO_COMPARATOR|Single dose placebo|Single IV infusion of placebo
62093925|NCT02783105|EXPERIMENTAL|Musical intervention|"Music is provided through headphones: Two 30-min musical sessions per day (one in the morning and one in the evening) beginning at the onset of desedation (Day 0) until day 21.~Both have inverted U shape."
62657645|NCT00513799|ACTIVE_COMPARATOR|1: Hygiene Education|"Intensive education on prevention of skin infections through improvements in personal hygiene (also serves as control group)"
62093926|NCT02783105|SHAM_COMPARATOR|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
62093927|NCT00724061|EXPERIMENTAL|PEG-IFN-α-2b + UV therapy|Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).
62093928|NCT02981134||bioabsorbable scaffold|Patients with BVS(bioabsorbable scaffold) for coronary stenosis
62093929|NCT02474511||general anesthesia|In this group，the patient is received radiofrequency ablation under general anesthesia.
62093930|NCT02474511||local anesthesia|In this group，the patient is received radiofrequency ablation under local anesthesia.
62657646|NCT00513799|ACTIVE_COMPARATOR|2: Hygiene education + mupirocin|Application of mupirocin in the nasal mucosa alone
62657647|NCT00513799|ACTIVE_COMPARATOR|Education + mupirocin + chlorhexidine|A combination of nasal application of mupirocin and chlorhexidine showers
62657648|NCT00513799|ACTIVE_COMPARATOR|4: Education + mupirocin + bleach baths|A combination of nasal application of mupirocin and bathing in dilute bleach water
62657649|NCT05363280|EXPERIMENTAL|OBD finding cohort at low dose|Subject in low dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
62657650|NCT05363280|EXPERIMENTAL|OBD finding cohort at middle dose|Subject in middle dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
62657651|NCT05363280|EXPERIMENTAL|OBD finding cohort at high dose|Subject in high dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
62093931|NCT05603806||RA new treatment starts|Adult rheumatoid arthritis patients starting treatment on adalimumab or upadacitinib
62093932|NCT01364220|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
62657652|NCT02811159|EXPERIMENTAL|Telapristone Acetate 12 mg|Telapristone acetate 12 milligrams (mg), orally, once daily for two 18-weeks courses (Treatment Courses 1 and 2) separated by an off-drug interval (ODI).
62657653|NCT04044937|EXPERIMENTAL|Population 1: Intracranial neoplasms (glial or metastatic disease)|Participants with intracranial neoplasms (glial or metastatic disease) with concern for recurrence or progression on conventional imaging (e.g., MRI) will receive F-18 fluoroethyltyrosine (FET) injected intravenously over approximately 1 minute and receive a single PET image lasting up to 40 minutes. Repeat FET PET will be offered to adult patients.
62657654|NCT04044937|EXPERIMENTAL|Population 2: Suspected glial neoplasms|Participants with suspected glial neoplasms (Grade 2-4) planning to undergo a non-investigational biopsy or surgery prior to non-investigational, primary treatment (radiation therapy and/or surgery) will receive F-18 fluoroethyltyrosine (FET) injected intravenously over approximately 1 minute and receive a single PET image lasting up to 40 minutes. Repeat FET PET will be offered to adult patients.
62657655|NCT03407482|EXPERIMENTAL|GDC-0853 (200mg) BID|Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).
62093933|NCT01364220|PLACEBO_COMPARATOR|Placebo|Placebo tablet, once daily, for 14 days
62093934|NCT02109679|EXPERIMENTAL|Treatment A|multiple doses BI 187004
62093935|NCT02109679|EXPERIMENTAL|Treatment B|multiple doses BI 187004 + multiple doses metformin
62093936|NCT02109679|EXPERIMENTAL|Treatment C|multiple doses metformin
62093937|NCT06696820|EXPERIMENTAL|PCSK9 inhibitors combined with atorvastatin/rosuvastatin|
62093938|NCT06696820|SHAM_COMPARATOR|Atorvastatin/rosuvastatin|
62291641|NCT06178068|ACTIVE_COMPARATOR|Group 2; dry air nebulizer group|In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer.
62291642|NCT06178068|ACTIVE_COMPARATOR|Group 3; Classic nebülizer group|For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used.
62291643|NCT00957541|EXPERIMENTAL|CRT Therapy|All patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
62291644|NCT01908595|EXPERIMENTAL|M518101|Proper quantity twice daily
62291645|NCT03202693|EXPERIMENTAL|PA-824|\[14C\]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient \[14C\]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
62291646|NCT03864796||cases of newly diagnosed ITP|no intervention
62291647|NCT03864796||cases of ITP after responding to treatment|no intervention
62291648|NCT03864796||healthy subjects|no intervention
62657656|NCT04908501||Intervention group|Services of the non-transversal clinical departments of the Bordeaux University Hospital willing to participate to the programme.
62657657|NCT04908501||Control group|Services of the non-transversal clinical departments of the Bordeaux University Hospital not willing to participate to the programme.
62657658|NCT04925440|EXPERIMENTAL|Probiotic|Probiotic capsules. Participants will consume 2 capsules once a day for 8 weeks.
62657659|NCT04925440|PLACEBO_COMPARATOR|Placebo|Placebo capsules. Participants will consume 2 capsules once a day for 8 weeks
62657660|NCT00666250|NO_INTERVENTION|Baseline|Baseline values off chocolate supplement
62657661|NCT00666250|EXPERIMENTAL|Low Dose|Low dose of dietary supplement 30 ml tid (Activ Xocai Drink)
62291649|NCT05289960|OTHER|patients eligible for weaning by spontaneous breathing trial|
62291650|NCT05289960|OTHER|non invasive ventilation after weaning|
62291651|NCT01048346|EXPERIMENTAL|supported employment|Study consists of one experimental group and one control group. The intervention group received IPS
62657662|NCT00666250|EXPERIMENTAL|High-dose|High dose of dietary supplement 90 ml tid (Xocai Activ drink)
62657663|NCT00516646|ACTIVE_COMPARATOR|1|ALT-711 200 mg bid
61907727|NCT01087788|OTHER|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
61907728|NCT01022398|EXPERIMENTAL|Vitamin D|Subjects will receive Vitamin D supplementation 10,000 international units of cholecalciferol (vitamin D3) by mouth weekly
61907729|NCT01022398|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo (an exact replica of the vitamin D capsule that does not contain any medically active substance) by mouth weekly
61907730|NCT03909594|EXPERIMENTAL|Nerve Block with Bupivacaine an|Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
62657664|NCT00516646|PLACEBO_COMPARATOR|2|
62657665|NCT00583544|PLACEBO_COMPARATOR|1|
62657666|NCT00583544|EXPERIMENTAL|2|
62657667|NCT05295589|ACTIVE_COMPARATOR|Arm I (standard of care chemotherapy)|"Patients receive either paclitaxel IV OR pegylated liposomal doxorubicin hydrochloride IV, OR topotecan hydrochloride IV while on study.~Patients undergo CT scan while on study and may undergo MRI throughout the study."
62291652|NCT05071131|ACTIVE_COMPARATOR|Inulin|15 grams inulin per day for 7 days, followed by 30 grams inulin per day for 28 days
62291653|NCT05071131|PLACEBO_COMPARATOR|Placebo|15 grams maltodextrin per day for 7 days, followed by 30 grams maltodextrin per day for 28 days
62291654|NCT06642545|EXPERIMENTAL|Disitamab Vedotin +RC148|
62291655|NCT06642545|ACTIVE_COMPARATOR|Albumin-bound Paclitaxone OR Albumin-bound Paclitaxone +Toripalimab|
62291656|NCT01755832||Pool exercise group|Patients with inflammatory rheumatic disease
62291657|NCT02043886|ACTIVE_COMPARATOR|Acarbose|Acarbose 50mg by mouth at minute 0 of the Meal Test.
62291658|NCT02043886|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet at 0 minutes of Meal Test.
62291659|NCT00643383|ACTIVE_COMPARATOR|1|
62291660|NCT00643383|PLACEBO_COMPARATOR|2|
62291661|NCT01337349|PLACEBO_COMPARATOR|Sugar Pill|Placebo control Group with sugar pill three times daily for 6 months
62291662|NCT01337349|EXPERIMENTAL|Pentoxifylline|Pentoxifylline 400mg tablets to be taken three times daily for 6 months
62291663|NCT03824301|ACTIVE_COMPARATOR|Volume-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with volume-controlled ventilation
62291664|NCT03824301|ACTIVE_COMPARATOR|Pressure-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with pressure-controlled ventilation
62093939|NCT04643353|EXPERIMENTAL|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia)with SMOOTH mode setting, which enables non-ablative, thermal-only operation). The parameters are selected based on extensive preclinical and clinical studies.~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
62291665|NCT03824301|NO_INTERVENTION|No ventilation|During cardiopulmonary bypass period the patients were disconnected from ventilator
62291666|NCT04597476|EXPERIMENTAL|Fucoidan Group|Fucoidan powder at 4.4 g per sachet (dose) for oral administration. Fucoidan 4.4 g, PO, bid for 24 weeks
62657668|NCT05295589|EXPERIMENTAL|Arm II (copanlisib, olaparib)|Patients receive copanlisib hydrochloride IV and olaparib PO while on study. Patients undergo CT scan while on study and may undergo MRI throughout the study.
62291667|NCT04597476|PLACEBO_COMPARATOR|Potato starch|Potato starch at 4.4 g per sachet (dose) for oral administration. Potato starch 4.4 g, PO, bid for 24 weeks
62657669|NCT02474641|ACTIVE_COMPARATOR|Standard radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
62291668|NCT03778489|EXPERIMENTAL|Hypertensive|Men and women in age-group 35-65 years Resting blood pressure of \>140/90 mmHg non or only anti-hypertensive medication
62291669|NCT03778489|ACTIVE_COMPARATOR|Control|Men and women in age-group 35-65 years Resting blood pressure of \<140/90 mmHg no medication
62291670|NCT05543590|EXPERIMENTAL|Experimental group: receiving plasmapheresis|
62291671|NCT05543590|OTHER|Control group : no treatment|
62291672|NCT03471026||pCMS+|Children undergoing infratentorial craniotomy for brain tumour resection whom develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
62093940|NCT04643353|ACTIVE_COMPARATOR|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
62093941|NCT03677024|EXPERIMENTAL|SLN arm|"Experimental:~1. Intra-operative sentinel lymph node (SLN) mapping with indocyanin green injected into the stroma of the cervix.~2. Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceeds to a total hysterectomy.~If only unilateral SLN are detected, surgeons will proceed to pelvic lymphadenectomy on the opposite side.~If non SLN are detected, surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy."
62093942|NCT03677024|NO_INTERVENTION|Lymphadenectomy arm|Surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy.
61907731|NCT03909594|ACTIVE_COMPARATOR|Nerve Block with Bupivacaine al|Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
62093943|NCT03992638|EXPERIMENTAL|L-PRF membrane|Periodontal plastic surgical procedures (coronally advanced flap, CAF) in combination with a double layer autologous leucocyte and platelet-rich fibrin (L-PRF) membrane.
62093944|NCT03992638|ACTIVE_COMPARATOR|Control|CAF
62093945|NCT06614361|EXPERIMENTAL|Experimental Condition 1|Core session
62093946|NCT06614361|EXPERIMENTAL|Experimental Condition 12|Core session, nurse-led SDM
62093947|NCT06614361|EXPERIMENTAL|Experimental Condition 3|Core session, Text messages
62093948|NCT06614361|EXPERIMENTAL|Experimental Condition 4|Core session, nurse-led SDM, text messages
62291673|NCT03471026||pCMS-|Children undergoing infratentorial craniotomy for brain tumour resection whom do not develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
62291674|NCT03471026||Controls|Healthy control children whom have never undergone intracranial surgery have had advanced MRI sequences acquired
62093949|NCT06614361|EXPERIMENTAL|Experimental Condition 5|Core, lottery prize
62291675|NCT01973855|EXPERIMENTAL|TCM and Western Medicine|TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine：Ribavirin 10-15mg per kg every time
62291676|NCT01973855|PLACEBO_COMPARATOR|Western Medicine|Western Medicine：Ribavirin 10-15mg per kg every time
62291677|NCT00420030|ACTIVE_COMPARATOR|1|Arm 1 - routine upfront administration of Reopro (Abciximab)
62291678|NCT00420030|OTHER|2|Reopro (Abciximab) only if needed - according to physician
62291679|NCT05680558|EXPERIMENTAL|UVA Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis System|TREATMENT with THERAKOS® CELLEX Photopheresis System on two consecutive days every 2 weeks for the first 3 months; then once per month for following 9 months.
61907732|NCT06151509|OTHER|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62093950|NCT06614361|EXPERIMENTAL|Experimental Condition 6|Core session, nurse-led SDM, lottery prize
62093951|NCT06614361|EXPERIMENTAL|Experimental Condition 7|Core, text messages, lottery prize
62093952|NCT06614361|EXPERIMENTAL|Experimental Condition 8|Core, nurse-led SDM, text messages, lottery prize
62093953|NCT06614361|EXPERIMENTAL|Experimental Condition 9|Core, peer navigation
62093954|NCT06614361|EXPERIMENTAL|Experimental Condition 10|Core, nurse-led SDM, peer navigation
61907733|NCT06151509|OTHER|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62093955|NCT06614361|EXPERIMENTAL|Experimental Condition 11|core, text messages, peer navigation
62093956|NCT06614361|EXPERIMENTAL|Experimental Condition 13|core, lottery prize, peer navigation
62093957|NCT06614361|EXPERIMENTAL|Experimental Condition 14|core, SDM, lottery prize, peer navigation
62657670|NCT02474641|EXPERIMENTAL|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
61907734|NCT04625296||Healthcare professional|Communities Health professionals (doctors, nurses, physiotherapist) Working in the city, In metropolitan France, Having managed patients with COVID-19
61907735|NCT05426499||Patients requiring cefotaxime treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
61907736|NCT05426499||Patients requiring meropenem treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
62093958|NCT06614361|EXPERIMENTAL|Experimental Condition 15|core, text messages, lottery, peer navigation
62657671|NCT04503460|EXPERIMENTAL|Single treatment arm|"All participants who are deemed eligible for inclusion in the study following screening will be enrolled into a single experimental arm which will comprise the following sequential stages:~1. Baseline sampling; participants only use 'as required' ipratropium bromide when needed (1 week)~2. Salmeterol xinafoate monotherapy 50 μg twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)~3. Washout period; participants only use 'as required' ipratropium bromide when needed (2 weeks)~4. Salmeterol xinafoate 50 μg / fluticasone propionate 250 μg combination therapy twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)"
61907737|NCT05426499||Patients requiring fluconazole treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
61907738|NCT05426499||Patients requiring isavuconazole treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
61907739|NCT05426499||Patients requiring anidulafungin treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
61907740|NCT03027791|EXPERIMENTAL|Parishoners at HUMC|African-American adults aged 18-85 who attend services at Holman United Methodist Church will be exposed to Group Sessions for 12 weeks and Virtual Reality for 6 weeks.
61907741|NCT02480946|EXPERIMENTAL|Single Ascending Dose and Food Effect|Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.
61907742|NCT02480946|EXPERIMENTAL|Multiple Ascending Dose|Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.
61907743|NCT02480946|EXPERIMENTAL|Relative Bioavailability|Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.
61907744|NCT02480946|EXPERIMENTAL|Drug-Drug Interaction with Methotrexate|Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.
61907745|NCT04696211|EXPERIMENTAL|Experimental group|The music-with-movement exercise program (MMEP) is an 8-week program. In the first 4 weeks a center-based program will be offered in the District Elderly Centers, and from week 1 to week 8 home-based and digital-based activities will be delivered via a WhatsApp group.
61907746|NCT04696211|NO_INTERVENTION|Control group|The participants in the control group will continue to receive their usual care and receive a one-page pain management pamphlet.
61907747|NCT03927560|EXPERIMENTAL|Robotic Assisted Percutaneous Coronary Intervention|
62093959|NCT06614361|EXPERIMENTAL|Experimental Condition 16|core, SDM, text message, lottery, peer navigation
62093960|NCT06614361|EXPERIMENTAL|Experimental Condition 2|Core, SDM
62093961|NCT06696209|ACTIVE_COMPARATOR|Analysis of the withdrawal time of the Upper Gastrointestinal Endoscopy|
62657672|NCT04139525|EXPERIMENTAL|unfractionated heparin and 8% trisodium citrate|Unfractionated heparin and 8% trisodium citrate.
62657673|NCT02953691|EXPERIMENTAL|Galacto-Oligosaccharides (GOS)|Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
61907748|NCT04796870|EXPERIMENTAL|Experimental: Online Brain and Balance Training|Individuals that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 8-week virtual balance and cognitive training intervention performed three times a week.
62737498|NCT03784911||During Cancer Treatment Group|Participants' body composition will be estimated using a SOZO device at 5 different time points across their cancer treatment. Participant will also complete questionnaires and physical assessments during each study visit. These include waist \& hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, cancer distress assessment, ECOG performance status, hand grip strength test, and 24-hour food recall. DEXA scans will be performed before treatment and after completion of treatment.
61907749|NCT02834845|EXPERIMENTAL|Sevoflurane|
62093962|NCT06696209|ACTIVE_COMPARATOR|Analysis of the total time of the Upper Gastrointestinal Endoscopy|
62093963|NCT05877404||Gynecologic Oncologists|Gynecologic Oncologists and gynecologic oncology fellows-in-training from around the world, who are members of the Society of Gynecologic Oncology (SGO).
62093964|NCT05013190||Participants With Multiple Myeloma (MM)|Participants diagnosed with MM (newly diagnosed multiple myeloma \[NDMM\] and first relapse multiple myeloma \[FRMM\]) using International Myeloma Working Group (IMWG) criteria who received a bortezomib/carfilzomib-based triple-drug regimens for more than 2 cycles as initial therapy, achieved at least partial response (PR) as defined by IMWG criteria, and are ready to start receiving an ixazomib containing therapy prescribed by their treating physician will be observed prospectively for 24 months.
62093965|NCT05177081|EXPERIMENTAL|Home BIA Monitoring group|Preemptive management by Body fluid monitoring system (BWA ON + App + Web)
61907750|NCT02834845|EXPERIMENTAL|Desflurane|
61907751|NCT02868827|EXPERIMENTAL|Cholecalciferol|This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
62737499|NCT03580278|EXPERIMENTAL|Cohort 1:75 mg ABY-035/AFO2|Cohort 1: 75 mg ABY-035/AFO2, once daily for 14 days
61907752|NCT02868827|PLACEBO_COMPARATOR|Placebo|This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)
61907753|NCT02081066|OTHER|patients with cardiovascular risk factors|
61907754|NCT00527891||Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI Scan
61907755|NCT00514748|ACTIVE_COMPARATOR|1|Patients who receive breast reconstruction with bilateral DIEP flap based on bilateral vessel pedicles
61907756|NCT00514748|EXPERIMENTAL|2|Patient who receive breast reconstruction with vessel interconnected DIEP flap based on one vessel pedicle
61907757|NCT03351205|EXPERIMENTAL|Uterine cavity barrier only|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
61907758|NCT03351205|EXPERIMENTAL|hormone|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
61907759|NCT01723644|OTHER|PCT guidance|"Group of patient  Procalcitonin  where the initiation and the stop of the antibiotic treatment are made according to a strategy guided by the PCT"
62093966|NCT05177081|NO_INTERVENTION|Control group|Usual heart failure management (Outpatient follow-up and medical treatment)
62657674|NCT02953691|PLACEBO_COMPARATOR|Maltodextrin (Placebo)|Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
62093967|NCT00562965|EXPERIMENTAL|A|Subjects will receive rituximab intravenously at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered intravenously at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days.
62093968|NCT00562965|ACTIVE_COMPARATOR|B|Subjects will receive the investigator's choice from the following rituximab-containing regimens: R-CVP or R-FND. The investigator's choice of therapy will be administered every 21 days. Dosing for R-CVP will be intravenous rituximab at a dose of 375 mg/m2 on day 1, intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1, intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 intravenous on day 1, mitoxantrone 10 mg/m2 intravenous on day 2, fludarabine 25 mg/m2 intravenous on days 2 through 4 and oral dexamethasone 20 mg/day on days 1-5.
62093969|NCT03076801|EXPERIMENTAL|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
62093970|NCT03076801|NO_INTERVENTION|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
62657675|NCT05165784|ACTIVE_COMPARATOR|V technique|Researcher will perform the V tecnique on the patient's inguinal area
62291680|NCT05655117|EXPERIMENTAL|AI-based screening for early detection of diabetic retinopathy and macular Oedema|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
62291681|NCT05655117|NO_INTERVENTION|Routine screening for diabetic retinopathy and macular oedema|The Routine screening for diabetic retinopathy and macular oedema in diabetics during a routine visit to an eye care clinic at the primary care centre.
62291682|NCT01136239|PLACEBO_COMPARATOR|Placebo|Placebo (600mg twice daily)
62291683|NCT01136239|ACTIVE_COMPARATOR|N-acetylcysteine|N-acetylcysteine (600mg twice daily)
62657676|NCT05165784|ACTIVE_COMPARATOR|palpation tecnique|Researcher will perform the V tecnique on the patient's inguinal area
62291684|NCT01032629|PLACEBO_COMPARATOR|Placebo|Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
62657677|NCT04280952|EXPERIMENTAL|CONVIVO|tumor tissue identification with the CONVIVO system
62657678|NCT02186041||De-Novo patients|Patients tested and de novo implanted with Interstim®. These patients will be followed-up for 5 years after the implant visit.
62657679|NCT02186041||Device replacement|Patients implanted with Interstim® for a device replacement. These patients will be followed-up for 5 years after the implant visit.
62657680|NCT02186041||Not-implanted patients|Patients who are tested and are not implanted with the Interstim® system. The data of the follow up of the test will be captured up to one year after the end-test visit
62657681|NCT06113978|ACTIVE_COMPARATOR|Thoracoscopic sympathectomy for palmar hyperhidrosis in children and adolescents|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
62657682|NCT06113978|ACTIVE_COMPARATOR|Thoracoscopic sympathotomy for palmar hyperhidrosis in children and adolescents|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
61907760|NCT01723644|OTHER|clinical reassessment|Group of patient where the initiation and the stop of the antibiotic treatment make following on clinical criteria and paraclinic not including the PCT.
62093971|NCT02323880|EXPERIMENTAL|Treatment (selinexor)|Patients receive selinexor PO on either a twice weekly (days 1, 3, 8, 10, 15, 17) or once weekly (days 1, 8, 15, and 22) schedule. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62093972|NCT01147770|EXPERIMENTAL|stop progesterone|
62093973|NCT06103422|EXPERIMENTAL|Streaming of patients and administration of tests|35 patients who met the inclusion criteria were divided into surgical groups. Patients with indications for upper jaw surgery were divided into Le Fort I operation, patients with lower jaw surgery were divided into Sagittal Split Ramus operation, and double jaw surgery groups. Localized taste tests and whole-mouth taste tests were applied to the patients.
62657683|NCT06113978|ACTIVE_COMPARATOR|Thoracoscopic sympathetic chain clipping for palmar hyperhidrosis in children and adolescents|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
62657684|NCT02402036|EXPERIMENTAL|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
62657685|NCT04865705|EXPERIMENTAL|Tilelizumab+Albumin Paclitaxel + Carboplatin/Cisplatin|Tilelizumab 200mg d1 Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1IV,Q3W \*2cycles
62657686|NCT02306668||Ocular surface discomfort|There are no interventions with this observational study
62657687|NCT00879177|ACTIVE_COMPARATOR|Group A|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
62657688|NCT00879177|EXPERIMENTAL|Group B|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
62464719|NCT00487669|EXPERIMENTAL|Paclitaxel Poliglumex with Pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued.
62464720|NCT03192696|EXPERIMENTAL|Treatment Cohort|Atherectomy of in-stent restenosis
62464721|NCT00620022|EXPERIMENTAL|Indacaterol 300 μg followed by placebo|Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62464722|NCT00620022|EXPERIMENTAL|Placebo followed by indacaterol 300 μg|Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62464723|NCT05275205|EXPERIMENTAL|UBX1325|
62464724|NCT05275205|ACTIVE_COMPARATOR|Aflibercept (EYLEA ®)|
62657689|NCT00548327|ACTIVE_COMPARATOR|Atomoxetine|"Atomoxetine 80 mg final dose. Arm lasts 14 days.~Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopathology ratings"
62657690|NCT00548327|PLACEBO_COMPARATOR|Placebo|"Placebo administered for 14 days. Schedule Atomoxetine 25 mg Placebo Day 1 (or Day 22), Atomoxetine 40 mg Placebo Day 2-3 (or Days 23-24), Atomoxetine 60 mg Placebo Days 4-5 (or Days 25-26), Atomoxetine 80 mg Placebo Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging and neuropsychological testing in addition to psychopathology ratings"
62093974|NCT06103422|EXPERIMENTAL|Repetition of tests at certain intervals|Gustatory functions were evaluated by administering localized taste tests and whole mouth taste tests preoperatively and at postoperative 1st, 3rd, and 6th months.
62093975|NCT05798728|ACTIVE_COMPARATOR|Inpatient Vaginal Misoprostol|These participants will receive intravaginal Misoprostol in the inpatient setting per our standard hospital protocol for cervical ripening.
62093976|NCT05798728|EXPERIMENTAL|Outpatient transcervical foley balloon|These participants will receive a catheter which will be placed by a physician present in the clinic, however, patient are discharged home for 12 hours until their time of induction of labor.
62093977|NCT05706662|EXPERIMENTAL|ProFlor|patients underwent to inguinal hernia repair with use of ProFlor dynamic scaffold
62093978|NCT05706662|ACTIVE_COMPARATOR|Lichtenstein|patients underwent to Lichtenstein inguinal hernia repair
62093979|NCT04314128|OTHER|Patients suspected of IIH at baseline|"Intervention: TOS and TCD measurements at baseline, and at routine follow-ups.~Healthy controls will be recruited to match the patients."
62093980|NCT01340833|EXPERIMENTAL|Study Medication|GSK2118436
62291685|NCT01032629|EXPERIMENTAL|Canagliflozin (JNJ-28431754) 100 mg|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
62464725|NCT02881255|OTHER|Subcutaneous ICD|Patient will receive a subcutaneous implantable cardioverter defibrillator (Boston Scientific EMBLEM)
62093981|NCT05691803|EXPERIMENTAL|Exercise intervention|"Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 12 weeks.~Participants are invited to a 12 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first three weeks and then two sessions per week for week 4-12. A follow-up session is also included after 12 weeks."
62093982|NCT01141179|EXPERIMENTAL|LEO 27847|
62093983|NCT02274246|EXPERIMENTAL|Gadobutrol|Gadobutrol in Healthy volunteers
62093984|NCT00189280|EXPERIMENTAL|imiqimod 5% cream|
62093985|NCT06287073||New JARDIANCE® users with chronic kidney disease (CKD)|Patients with CKD starting JARDIANCE® for the first time in accordance with the approved label in Korea
62093986|NCT05736770|EXPERIMENTAL|Respiratory rehabilitation and out of bed mobilization group|The Respiratory rehabilitation and out of bed mobilization group will perform 4 exercises.
62093987|NCT05736770|ACTIVE_COMPARATOR|Conventional exercise program group|The conventional exercises program will perform conventional exercises
62464726|NCT02881255|OTHER|Transvenous ICD|Patient will receive a single-chamber, transvenous implantable cardioverter defibrillator (from any manufacturer) which as the capability for remote monitoring.
62464727|NCT05487274|ACTIVE_COMPARATOR|Total Shoulder Arthroplasty (anatomic) + augmented glenoid component|"TSA procedure involves replacing the worn-out ball and socket joint with prosthetic components. An additional surgical technique, augmented glenoid component implantation is performed when there is missing bone in the shoulder and is currently being done as standard of care. This technique is used particularly when a large amount of instability within the shoulder joint is present. This technique attempts to realign and restore balance to the shoulder joint using artificial components."
62657691|NCT00346437|EXPERIMENTAL|1|Ad5FGF-4
62657692|NCT00346437|EXPERIMENTAL|2|Ad5FGF-4
62093988|NCT04893798|EXPERIMENTAL|Sayana Press, Upper Arm injection|Sayana Press, administered subcutaneously into upper arm
62093989|NCT04893798|ACTIVE_COMPARATOR|Sayana Press, anterior thigh|Sayana Press, administered subcutaneously into anterior thigh
62093990|NCT04893798|ACTIVE_COMPARATOR|Sayana Press, abdomen|Sayana Press, administered subcutaneously into abdomen
62093991|NCT05299086|PLACEBO_COMPARATOR|As needed INCs|"Use placebo everyday, and INCs as needed when the nasal symptom aggravated~INCs = Fluticasone furoate nasal spray Placebo = Normal saline nasal spray~Doses Fluticasone furoate nasal spray (27.5 mg/spray) age\<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily Normal saline nasal spray age\<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily"
62093992|NCT05299086|ACTIVE_COMPARATOR|Regular INCs|"Use INCs everyday, and placebo as needed when the nasal symptom aggravated~INCs = Fluticasone furoate nasal spray Placebo = Normal saline nasal spray~Doses Fluticasone furoate nasal spray (27.5 mg/spray) age\<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily Normal saline nasal spray age\<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily"
62093993|NCT05697640|ACTIVE_COMPARATOR|Vericiguat Oral Tablet|"Tested IMP: Vericiguat (film-coated tablet). Authorization status: Not authorised in this targeted therapeutic indication; Vericiguat is authorized for the dosages that will be administered in this trial for another indication. The tablets used in this trial are no trade product, but a special trial product produced and provided by the marketing authorization holder Bayer.~Administration: Once daily (oral). Planned dosage: Three different dosages starting with 2.5 mg for two weeks, followed by 5 mg for two weeks and 10 mg for six weeks. The general IMP titration regimen was investigated and proven to be safe (max. dosages 10 mg/day) in patients with heart failure and reduced ejection fraction (Armstrong et al., 2020)."
62657693|NCT00346437|PLACEBO_COMPARATOR|3|Placebo
62657694|NCT03698149|EXPERIMENTAL|Electrocorticography-based brain computer interface|
62291686|NCT01032629|EXPERIMENTAL|Canagliflozin (JNJ-28431754) 300 mg|Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
62291687|NCT04232826|EXPERIMENTAL|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
62464728|NCT05487274|ACTIVE_COMPARATOR|Reverse Shoulder Arthroplasty|RSA procedure is similar to a TSA, however the orientation of the ball and socket joint is placed in the reverse position
62464729|NCT02939092|EXPERIMENTAL|Pomegranate peel extract|Pomegranate is antimicrobial, anti inflammatory and antioxidant
62464730|NCT02939092|ACTIVE_COMPARATOR|Chlorhexidine|Chlorhexidine mouthwash is antiplaque treatment and effective against gingivitis
62464731|NCT01035060||Older Adult|Healthy Men and Women Over 70 Years of Age
62464732|NCT01035060||Young Adult|Healthy Men and Women Aged 18-30 Years
62657695|NCT02135198|EXPERIMENTAL|2 mg AZD7325|2 mg AZD7325 in orange capsule, Size 0, single oral dose
62657696|NCT02135198|EXPERIMENTAL|10 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, singe oral dose
62657697|NCT02135198|PLACEBO_COMPARATOR|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, single oral dose
62657698|NCT02768155|EXPERIMENTAL|AF 4.0|Amniotic Fluid 4.0ml dose
62657699|NCT02768155|EXPERIMENTAL|AF 2.0|Amniotic Fluid 2.0ml dose
62657700|NCT02768155|PLACEBO_COMPARATOR|Placebo|Saline Placebo Control
62737500|NCT03580278|EXPERIMENTAL|Cohort 2: 150 mg ABY-035/AFO2|Cohort 2: 150 mg ABY-035/AFO2 once daily for up to 28 days
62737501|NCT02501668||Lung cancer in population|Lung cancer cases in sample population (670,258 cases)
62737502|NCT02501668||COPD in population|COPD cases (670,258 cases)
62737503|NCT02501668||COPD with lung cancer|Lung cancer in COPD
62737504|NCT02501668||ILD without IPF|Interstitial lung disease (ILD) cases without idiopathic pulmonary fibrosis (IPF)
62737505|NCT02501668||ILD with lung cancer|Lung cancer cases in ILD
62737506|NCT02501668||Idiopathic pulmonary fibrosis|Idiopathic pulmonary fibrosis cases
62657701|NCT02812043|EXPERIMENTAL|Amorolfine|This group of patients will receive only amorolfine nail lacquer to apply on the affected nail and the KOH examination and fungal culture will be performed every month
62093994|NCT05697640|PLACEBO_COMPARATOR|Placebo Oral Tablet|"Comparator IMP: Placebo (film-coated tablet). Authorization status: Not authorised. The tablets used in this trial are no trade product, but a special trial product produced and provided by the marketing authorization holder Bayer.~Administration: Once daily (oral). Planned dosage: Three different dosages starting with 2.5 mg for two weeks, followed by 5 mg for two weeks and 10 mg for six weeks to have identical conditions to verum."
61907761|NCT03225859|EXPERIMENTAL|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
61907762|NCT00647569|EXPERIMENTAL|A|No previous major abdominal surgery
62093995|NCT05753709|ACTIVE_COMPARATOR|EE|End-to-end anastomosis, done in a conventionally described hand-sewn technique using sutures
62093996|NCT05753709|ACTIVE_COMPARATOR|SSSA|Stapled side-to-side anastomosis of the stoma using a linear cutter stapling device
62093997|NCT05753709|ACTIVE_COMPARATOR|HSSA|Hand-sewn anastomosis of the stoma using suturing of bowel loops placed in a side to side orientation
62093998|NCT02488772|EXPERIMENTAL|Treatment Group|Patients allocated to treatment group will be supplied with sleep interventions (sleep mask and ear plugs), and standardized instructions of use.
62291688|NCT01485614|EXPERIMENTAL|Sitagliptin|Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
62657702|NCT02812043|EXPERIMENTAL|Long-pulsed Nd:YAG|This group of patients will receive only the long-pulsed Nd:YAG (Cynergy®, 5 Carlisle Road Westford, MA USA) fluence 35-45 J/Cm2, spot size 4mm for 2 passes each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
62464733|NCT00234078|EXPERIMENTAL|0.5% OPC-12759|0.5% OPC-12759 (rebamipide) ophthalmic suspension
62657703|NCT02812043|EXPERIMENTAL|Amorolfine+Long-pulsed Nd:YAG|This group of patients will receive both amorolfine nail lacquer and the long-pulsed Nd:YAG laser treatment each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
62657704|NCT00858286|EXPERIMENTAL|Stable dosing with SERETIDE, short acting B-2agonist as needed|Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
62657705|NCT00858286|EXPERIMENTAL|Maintenance treatment with SYMBICORT and SYMBICORT as needed|Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
62678914|NCT03393975|EXPERIMENTAL|On Demand Cohort II|Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg \[+/- 4 IU/kg\] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg \[+/- 2 IU/kg\] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg \[+/- 1.5 IU/kg\] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
61907763|NCT00647569|EXPERIMENTAL|B|Previous major abdominal surgery
61907764|NCT03685890|EXPERIMENTAL|ILP + Nivolumab|The day before planned ILP, the patient will receive one infusion of nivolumab 480mg
61907765|NCT03685890|PLACEBO_COMPARATOR|ILP + Placebo|The day before planned ILP, the patient will receive one infusion of placebo
61907766|NCT03834558|NO_INTERVENTION|Control Group|They will follow their daily routine without added exercise
61907767|NCT03834558|EXPERIMENTAL|Intervention Group|They will perform the mixed exercise program
61907768|NCT00735579||Study group|Patients undergoing major abdominal surgery
61907769|NCT02989987|ACTIVE_COMPARATOR|Narrative Exposure Therapy|According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
61907770|NCT02989987|ACTIVE_COMPARATOR|Treatment-as-usual|Social support (provided on demand)
62093999|NCT02488772|ACTIVE_COMPARATOR|Control Group|Patients allocated to control group will be assessed for sleep quality, but not offered sleep mask and ear plugs. They will receive standard of care as decided by treating emergency physician.
62094000|NCT02783183|EXPERIMENTAL|YHD1119|Pregabalin 300mg
62094001|NCT02783183|ACTIVE_COMPARATOR|Lyrica|Pregabalin 150mg
62464734|NCT00234078|EXPERIMENTAL|1% OPC-12759|1% OPC-12759 (rebamipide) ophthalmic suspension
62464735|NCT00234078|EXPERIMENTAL|2% OPC-12759|2% OPC-12759 (rebamipide) ophthalmic suspension
62464736|NCT00234078|PLACEBO_COMPARATOR|placebo|placebo of OPC-12759 (rebamipide) ophthalmic suspension
62464737|NCT01828697|ACTIVE_COMPARATOR|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:~* Fixed low dose nadroparin, or;~* Fixed low dose enoxaparin, or;~* Fixed low dose dalteparin, or;~* Fixed low dose tinzaparin."
62094002|NCT06490094|EXPERIMENTAL|Inquiry Based Stress Reduction|Inquiry Based Stress Reduction (IBSR) program
62094003|NCT06490094|NO_INTERVENTION|Control group|Postpartum mothers who are randomly assigned to not receive the Inquiry-Based Stress Reduction (IBSR) intervention
62094004|NCT06088901|EXPERIMENTAL|Arm 1: First Occurrence|All patients who meet criteria and consent to involvement will be treated per institutional protocols with a tube thoracostomy. Chest tube size will be determined by the physician of record. Once the chest tube is placed, it will be placed to suction for a minimum of two minutes to allow for lung re-expansion while 2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture (preferably a previously established intravenous catheter). This blood will then be injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
62094005|NCT06088901|EXPERIMENTAL|Arm 2: Recurrence|All patients who meet criteria and provide informed consent will be treated per institutional protocols with a thoracoscopic blebectomy and mechanical pleurodesis or pleurectomy. At the conclusion of the procedure, 2 ml/kg of whole blood (max 100 ml) obtained via venipuncture will be injected into the pleural space. The chest tube will be left clamped for 180 minutes post-procedure and then placed back to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
62094006|NCT04186169|PLACEBO_COMPARATOR|Arm 1: Paroxysmal AF - PVI arm|The subjects with paroxysmal AF undergo pulmonary vein isolation (PVI).
62464738|NCT01828697|ACTIVE_COMPARATOR|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.~* Intermediate dose nadroparin, or;~* Intermediate dose enoxaparin, or;~* Intermediate dose dalteparin, or;~* Intermediate dose tinzaparin."
62464739|NCT03314688|ACTIVE_COMPARATOR|Usual Care Group|"Standardized breast cancer follow up care and materials regarding treatment (i.e., chemotherapy and endocrine therapy when relevant).~Lifestyle intervention books for breast cancer survivors at the end of the study. Women will also be offered a counselling session with a registered study dietician at the end of the study."
62094007|NCT04186169|PLACEBO_COMPARATOR|Arm 2: Persistent AF - PVI arm|The subjects with persistent AF undergo pulmonary vein isolation (PVI).
62464740|NCT03314688|EXPERIMENTAL|Dietary/Physical Activity Intervention|Eleven 30-min counseling sessions over six months (weekly, then biweekly, then monthly) with additional sessions in the latter 6 months (5 additional monthly sessions for a total of 16 sessions), timed with their oncology visit or via telephone if not coming in for oncology visit. Sessions focus on motivating health dietary choices and physical activity (home-based program).
62464741|NCT00856388|EXPERIMENTAL|Treatment (Reduced intensity allogeneic stem cell transplant)|"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.~Note: \*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan."
62094008|NCT04186169|EXPERIMENTAL|Arm 3: Persistent AF - PVI + Fat-targeted ablation|The subjects with persistent AF undergo pulmonary vein isolation (PVI) and additional ablation to target the inflammatory fat tissue
62094009|NCT04653051||Patients who received DVR Plating System|
62291689|NCT01485614|PLACEBO_COMPARATOR|Placebo/Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
62464742|NCT06022302|EXPERIMENTAL|High-fiber diet|The high-fiber diet will consist of foods rich in dietary fiber such as coarse vegetables, wholegrain bread, and fruits representing a broad range of dietary fibers aiming for ≈40 g of fiber/10 MJ.
62464743|NCT06022302|EXPERIMENTAL|Low-fiber diet|The low-fiber diet will consist of foods poor in fiber such as white bread and refined foods aiming for ≈10 g of fiber/10 MJ.
62464744|NCT00096265|ACTIVE_COMPARATOR|Arm I|Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
62678915|NCT02440529|ACTIVE_COMPARATOR|(Intervention Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management plus aid
62678916|NCT02440529|ACTIVE_COMPARATOR|(Control Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management.
62678917|NCT00348374|ACTIVE_COMPARATOR|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
62737507|NCT02501668||IPF with lung cancer|Lung cancer cases in IPF patients
62737508|NCT02501668||Connective tissue disorder with ILD|CTD with ILD cases
62737509|NCT02501668||CTD ILD with lung cancer|Lung cancer cases in CTD with ILD
62737510|NCT02501668||CTD without ILD|CTD with ILD cases in sample population
62737511|NCT02501668||CTD without ILD with lung cancer|Lung cancer in CTD without ILD
62737512|NCT01301066|EXPERIMENTAL|Pitavastatin 4 mg QD|
62737513|NCT01301066|ACTIVE_COMPARATOR|Pravastatin 40 mg QD|
62737514|NCT02120781|EXPERIMENTAL|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
62737515|NCT02120781|PLACEBO_COMPARATOR|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
62737516|NCT03850093|ACTIVE_COMPARATOR|gabapentin|gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative
62737517|NCT03850093|ACTIVE_COMPARATOR|bisoprolol|bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative
62737518|NCT03850093|PLACEBO_COMPARATOR|control|placebo was given to patients of control group 2 hours preoperative
62737519|NCT01672281|EXPERIMENTAL|vibrox training|
62657706|NCT00998946|EXPERIMENTAL|Pralatrexate|"Participants received pralatrexate at an initial dose of 30 mg/m\^2, as IV push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline on Days 1, 8 and 15 of a 4-week cycle (weekly for 3 weeks with 1 week of rest) until criteria for discontinuation per protocol were met. The initial dose of 30 mg/m\^2 may be reduced to 20 mg/m\^2 weekly, permitted per protocol defined criteria. If pralatrexate 20 mg/m\^2/week was not tolerated, pralatrexate had to be discontinued. Dose re-escalation was not allowed once dose reduction was done.~Participants had dietary supplement of vitamin B12 and folic acid along with pralatrexate. Vitamin B12, given as 1mg IM, within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days post last dose of pralatrexate. Folic acid was given 1mg daily, orally, for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days post last dose of pralatrexate."
62657707|NCT01286350|NO_INTERVENTION|Control|Participants randomized control will continue with usual clinical care.
62094010|NCT04696471|EXPERIMENTAL|Left ventrolateral prefrontal cortex (vlPFC)/Left SS/Left vlPFC sham|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~* left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~* left SS cTBS (cTBS applied to the left somatosensory area)~* left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
62291690|NCT01485614|ACTIVE_COMPARATOR|Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
62291691|NCT01485614|PLACEBO_COMPARATOR|Placebo/Sitagliptin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
62657708|NCT01286350|EXPERIMENTAL|Intervention|"Participants randomized to intervention will receive the FL3X Flexible Lifestyle Empowering Change intervention. Adolescents will be paired with a health coach to help learn strategies for improving diabetes control"
62657709|NCT01163799|EXPERIMENTAL|Alefacept (ASP0485)|Safety and efficacy of alefacept in combination with alemtuzumab induction and calcineurin inhibitor (CNI) and corticosteroid withdrawal.
62657710|NCT04067999||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
62657711|NCT00889434|ACTIVE_COMPARATOR|EGCG|Two cycles comprising 28 days of continuous daily treatment with EGCGgiven 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
62657712|NCT00889434|ACTIVE_COMPARATOR|Tocotrienol|
62657713|NCT00889434|OTHER|EGCG + Tocotrienol|Combination of both arms
62657714|NCT02895737|OTHER|balloon-expandable TAVI without cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection
62657715|NCT02895737|OTHER|balloon-expandable TAVI with cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection
62657716|NCT02895737|OTHER|self-expandable TAVI without cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection
62094011|NCT04696471|EXPERIMENTAL|Left vlPFC/Left vlPFC sham/Left SS|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~* left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~* left SS cTBS (cTBS applied to the left somatosensory area)~* left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
61907771|NCT04568824|EXPERIMENTAL|GraphoLearn reading intervention|GraphoLearn is a research-based treatment, delivered as an engaging computer game. Players match auditory targets (e.g., phonemes, rimes) to visual targets (single letters, letter sequences, words). The complexity of the items within each level is ordered such that at each level, the most frequent and regular mappings are introduced first based on measures such as orthographic/phonological neighborhood size and morphological family size. GraphoLearn allows the children to practice and reinforce lessons at their own individual trial pace and provides a record of performance progress that can be used to guide analyses.
62291692|NCT06055634||patients more than 40 years|
62291693|NCT06055634||patients less than 40 years|
62291694|NCT06055634||controls|
62291695|NCT03326934|SHAM_COMPARATOR|Milk Chocolate|Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
62291696|NCT03326934|EXPERIMENTAL|Dark Chocolate|Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
62291697|NCT01284803|EXPERIMENTAL|experimental arm|
62657717|NCT02895737|OTHER|self-expandable TAVI with cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection
61907772|NCT04568824|ACTIVE_COMPARATOR|Vektor math control|We selected an active control to maximize the specificity of the treatment outcomes; to this end, math games are among the most commonly used. Game sessions support learning numerical mathematical skills and cognition related to mathematical skills. In addition to math, this game contains training tasks for visuospatial working memory, spatial visualization and visuospatial reasoning. The overall theme of the game and feedback style are similar to those in GraphoLearn.
61907773|NCT01398917|ACTIVE_COMPARATOR|short-term stenting|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
62094012|NCT04696471|EXPERIMENTAL|Left SS/Left vlPFC sham/Left vlPFC|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~* left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~* left SS cTBS (cTBS applied to the left somatosensory area)~* left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
62291698|NCT03631576|EXPERIMENTAL|Arm 1|CD123/CLL1 CAR-T Cells treat
62657718|NCT00254072|ACTIVE_COMPARATOR|Smaller Stapler|3.5 mm Circular Stapler
62657719|NCT00254072|ACTIVE_COMPARATOR|Larger Stapler|4.8 mm Circular Stapler
62737520|NCT01672281|EXPERIMENTAL|resistance training|
62737521|NCT04257968|EXPERIMENTAL|Diagnostic intervention|Complete diagnostic intervention
61907774|NCT01398917|ACTIVE_COMPARATOR|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
61907775|NCT02551510|ACTIVE_COMPARATOR|Suture|Skin incision closure with standard subcuticular technique
61907776|NCT02551510|ACTIVE_COMPARATOR|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl®
61907777|NCT01431638|EXPERIMENTAL|Canakinumab 150mg|Canakinumab 150mg in prefilled syringe subcutaneously
61907778|NCT03776370||Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
62094013|NCT04696471|EXPERIMENTAL|Left SS/Left vlPFC/Left vlPFC sham|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~* left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~* left SS cTBS (cTBS applied to the left somatosensory area)~* left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
62291699|NCT04439890|EXPERIMENTAL|Anlotinib hydrochloride capsule + chemotherapy|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
62291700|NCT04439890|PLACEBO_COMPARATOR|Placebo + chemotherapy|Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
62291701|NCT05299658|EXPERIMENTAL|Open label extension|This is an unblinded open-label extension, all participants will be on active drug.
62291702|NCT03345186|EXPERIMENTAL|Nurse led plus standard of care|Nurse Led Patient Management Programme to Improve Outcomes in Gout and Standard of care for gout patients, including nurse delivered patient education and follow up
62291703|NCT03345186|NO_INTERVENTION|Standard of care|Standard of care for gout patients
62291704|NCT03406533|EXPERIMENTAL|Group F|Sedated with midazolam and fentanyl
62291705|NCT03406533|EXPERIMENTAL|Group DR|Sedated with midazolam, dexmedetomidine and remifentanil
62291706|NCT03406533|EXPERIMENTAL|Group DF|Sedated with midazolam, dexmedetomidine and fentanyl
62291707|NCT03406533|EXPERIMENTAL|Group PR|Sedated with midazolam, propofol and remifentanil
62291708|NCT05238584|NO_INTERVENTION|Total omentectomy|Total or subtotal gastrectomy with D2 lymphadenectomy and total omentectomy.
61907779|NCT03776370||The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery
62291709|NCT05238584|EXPERIMENTAL|Partial omentectomy|Total or subtotal gastrectomy with D2 lymphadenectomy and partial omentectomy.
62291710|NCT06222944|EXPERIMENTAL|Anlotinib, TQB2450 and Albumin-bound Paclitaxel|"* Cohort 1: Anlotinib + albumin-bound paclitaxel;~* Cohort 2: TQB2450 + albumin-bound paclitaxel;~* Cohort 3: Anlotinib + TQB2450 + albumin-bound paclitaxel.~Anlotinib: 12mg PO, QD, D1-14, Q3W;~TQB2450: 1200 mg, IV, D1, Q3W;~Albumin-bound paclitaxel: 125mg/m2 IV Day 1,8, Q3W.~Until disease progression or intolerable toxicity or patient withdrawal of consent."
62291711|NCT01166048|PLACEBO_COMPARATOR|Milk powder pill|Patients will receive 2 placebo pills per day for a period of 4 weeks.
62291712|NCT01166048|EXPERIMENTAL|Duloxetine|In the experimental arm of the study patients will receive duloxetine, which will be titrated up to a dosage of 120mg over a period of two weeks and continued at this dosage for two weeks.
62291713|NCT03804541|EXPERIMENTAL|[14C]Ensartinib|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of \[14C\]Ensartinib to healthy Chinese male subjects。
62291714|NCT05766722|EXPERIMENTAL|All patients 18 years old or older undergoing uncomplicated cataract surgery.|
62291715|NCT01714466|EXPERIMENTAL|Part A, arm 1|Evening dose of TF048. Morning dose of TF043
62291716|NCT01714466|EXPERIMENTAL|Part A, arm 2|Evening dose of TF043. Morning dose of TF048
62291717|NCT01714466|EXPERIMENTAL|Part A, arm 3|Evening dose of TF047. Morning dose of TF043
62291718|NCT01714466|ACTIVE_COMPARATOR|Part A, arm 4|MOVIPREP (Both evening and morning dose)
62291719|NCT01714466|EXPERIMENTAL|Part B, arm 1|IMP selected based on the optimal dosing sequence and volume identified from Part A
62291720|NCT01714466|EXPERIMENTAL|Part B, arm 2|IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
62291721|NCT01714466|ACTIVE_COMPARATOR|Part B, arm 3|IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
62657720|NCT03650647|ACTIVE_COMPARATOR|Indirect Pulp Capping|"Nonselective removal to hard dentine (formerly complete excavation or complete caries removal) : removal of soft dentin, only hard dentine is left on the cavity, so that demineralized dentine free of bacteria is completely removed.~Intervention: Total soft and leathery caries removal. Carious dentin removal"
62657721|NCT03650647|EXPERIMENTAL|Stepwise excavation|"Stepwise removal is carious tissue removal in 2 stages, i.e., visits. Soft carious tissue is left over the pulp in the first step, while peripheral dentine is prepared to hard dentine to allow a complete and durable seal of the lesion. A provisional restoration is placed, which should be sufficiently durable to last up to 6 months to allow changes in the dentine and pulp to take place. After this period, a second excavation is done and, if there is hard dentin formed, the tooth is restored.~Intervention: Part of the soft caries is removed. Final restoration is placed on the second visit. Carious dentin removal"
61907780|NCT05574855||Group I subjects (T)|Neonates with gestational age ≥35, who experienced an episode of perinatal ischaemia and who were qualified for hypothermia treatment according to the Standards of Medical care of Neonates in Poland will be enrolled to the subject group (T)
61907781|NCT05574855||Group II controls (N)|Healthy, term neonates, who underwent echocardiography on days 3-7 of life (after closure of ductus arteriosus, or with trace, insignificant haemodynamic ductus arteriosus) for reasons such as difficult adaptation, gestational diabetes of the mother etc.
62094014|NCT04696471|EXPERIMENTAL|Left vlPFC sham/Left SS/Left vlPFC|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~* left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~* left SS cTBS (cTBS applied to the left somatosensory area)~* left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
62291722|NCT01714466|EXPERIMENTAL|Part B, arm 4|MOVIPREP used in both evening and morning dose
62291723|NCT00645086|ACTIVE_COMPARATOR|A|
62464745|NCT00096265|EXPERIMENTAL|Arm II|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62464746|NCT00096265|EXPERIMENTAL|Arm III|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
62657722|NCT03650647|EXPERIMENTAL|Selective caries removal|"Selective caries removal: only part the soft dentine is removed, so soft carious tissue is left over the pulp, while peripheral enamel and dentine are prepared to hard dentine, to allow a tight seal and placement of a durable restoration.~Intervention: Part of the soft caries is removed. Final restoration is place over the soft dentin. Carious dentin removal"
62291724|NCT00645086|ACTIVE_COMPARATOR|B|
62291725|NCT03886844||Prolacta group|Infants, who received a human milk fortifier based on human milk (12/2015-11/2018), started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity
62291726|NCT03886844||"Frauenmilch Supplement=FMS group"|Infants, who received a human milk fortifier based on bovine milk (05/2012-06/2015), started with an enteral intake of 100 ml/kg
62291727|NCT00924703|EXPERIMENTAL|rAvPAL-PEG|rAvPAL-PEG in varying doses dependent on safety and efficacy.
62678918|NCT00348374|EXPERIMENTAL|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
62291728|NCT05897814|EXPERIMENTAL|Parturients|Adult patients admitted to the delivery room of Necker-Enfants Malades hospital maternity with an epidural catheter.
62464747|NCT03423056|EXPERIMENTAL|Preoperative exercise program|"The individualized aerobic training program will be developed according to Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks.~Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed as follows:~Week 1: heart rate target: 50% of maximum heart rate Week 2: heart rate target: 60% of maximum heart rate Week 3: heart rate target: 70% of maximum heart rate Week 4: heart rate target: 60% of maximum heart rate The aerobic exercise will be carried on a treadmill or in a stationary bicycle, according to the patient's preferences and will be supervised by a physical therapist."
62464748|NCT06064799||Group I|14 healthy volunteers
62464749|NCT06064799||Group II|14 periodontitis participants with stage III grade B Periodontitis
62464750|NCT06064799||Group III|14 periodontitis participants with stage III grade C Periodontitis
61907782|NCT03834649|ACTIVE_COMPARATOR|Mucograft|Soft tissue augmentation of the defective alveolar ridge using Mucograft inside the prepared vestibular pouch leaving part of the mucograft exposed at the crestal area and will be sutured using 5/0 suture material around the defect margin and secured in the vestibular pouch.
62094015|NCT04696471|EXPERIMENTAL|Left vlPFC sham/Left vlPFC/Left SS|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~* left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~* left SS cTBS (cTBS applied to the left somatosensory area)~* left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
62094016|NCT03275103|EXPERIMENTAL|Arm A: Single Step Dose Escalation for Cevostamab|Study drug will be administered intravenously on a 21-day cycle. The step-up dose will be given on Cycle 1 Day 1 and the target dose will be given on C1D8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
62094017|NCT03275103|EXPERIMENTAL|Arm B: Double Step Dose Escalation for Cevostamab|In Cycle 1, participants will receive 2 step-up doses and a target dose. The step-up dose will be given on Cycle 1 Day 1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
62094018|NCT03275103|EXPERIMENTAL|Arm C: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
62094019|NCT03275103|EXPERIMENTAL|Arm D: Double Step Dose Expansion for Cevostamab|The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
62094020|NCT03275103|EXPERIMENTAL|Arm E: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
62291729|NCT01805180|OTHER|Arm 1: Spectra Optia followed by COBE Spectra|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device followed by the COBE Spectra device.
62291730|NCT01805180|OTHER|Arm 2: COBE Spectra followed by Spectra Optia|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device followed by Spectra Optia.
62291731|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
62657723|NCT01018290||Navigated TMS examination|20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles
62291732|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
62291733|NCT00670709||1|Subjects with mild or moderate Huntington's Disease
62291734|NCT00670709||2|Normal Controls
62464751|NCT00431600|EXPERIMENTAL|1|12 healthy male subjects
62657724|NCT02278211||Study Cohort|Patients hospitalised with myocardial infarction and angiographically proven multivessel coronary artery disease
62657725|NCT01614418|EXPERIMENTAL|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation using BARRX HALO90 catheter
62657726|NCT02446951||ED Jaundice Patients|Patients presenting to the ED in either the implementation period or pre-implementation period.
62657727|NCT02429466|EXPERIMENTAL|Guadecitabine (SGI-110)|
61907783|NCT03834649|EXPERIMENTAL|Partially de-epithelialized connective tissue graft|Soft tissue augmentation of the defective alveolar ridge using Partially de-epithelialized connective tissue graft by preparing vestibular pouch at the defect site and place the de-epithelialized part inside the pouch leaving the epithelialized part sutured and exposed at the crestal area
61907784|NCT05031039||Female Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians females that have unilateral or bilateral cleft lip and palate deformity
61907785|NCT05031039||Male Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians males that have unilateral or bilateral cleft lip and palate deformity
62094021|NCT03275103|EXPERIMENTAL|Arm F: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
62657728|NCT01283347|EXPERIMENTAL|18F-DTBZ for Parkinson's Disease|"25 age-matched healthy volunteers will be enrolled. For assessing the correlation between the 18F-DTBZ binding and the severity of disease, the patients with PD will be divided into three groups according to their motor scores: mild, moderate, and advanced. We will enroll 25 patients in each group. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study, as one screening visit, one imaging visit, and one safety evaluation visit.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
62094022|NCT03275103|EXPERIMENTAL|Arm G: Double Step Dose Expansion for Cevostamab|The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
62657729|NCT05074537||MRI Participants|
62094023|NCT03275103|EXPERIMENTAL|Arm H: Triple Step Dose Escalation for Cevostamab|In Cycle 1, participants will receive 3 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 2-4, 8, and 9-11. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
62094024|NCT03275103|EXPERIMENTAL|Arm I: Triple Step Dose Expansion for Cevostamab|The triple step dose expansion stage of the study may use the dosing and assessment schedule from the triple step dose escalation arm in Cycle 1, based on data from Arm H.
62094025|NCT03275103|EXPERIMENTAL|Arm J: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
62094026|NCT03275103|EXPERIMENTAL|Arm K: Compressed Double Step Dose Expansion for Cevostamab|In Cycle 1, participants will receive 2 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 4, and 8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
62094027|NCT06335758||Patients receiving solid oral medication as a standard of care.|Solid oral medication administered via the ReX Remote Digital Nurse.
62657730|NCT05074537||PET/CT Participants|
62657731|NCT05074537||CT Participants|
61907786|NCT05637060|EXPERIMENTAL|Test Group|Subjects will take their assigned study medication (Vaptor 20mg), after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time. Those subjects who received Test Drug in first period will receive Reference drug in 2nd period of the study.
61907787|NCT05637060|ACTIVE_COMPARATOR|Reference Group|Subjects will take their assigned study medication (Crestor 20mg), after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time. Those subjects who received Reference Drug in first period will receive Test drug in 2nd period of the study.
61907788|NCT04028271|EXPERIMENTAL|experimental|local anesthesia applyed with Comfort in system
62094028|NCT01429961|EXPERIMENTAL|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1-14
62657732|NCT00066456|EXPERIMENTAL|Treatment (chemosensitization, radiation, docetaxel)|Patients receive docetaxel IV over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. Within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. Treatment continues in the absence of unacceptable toxicity.
62657733|NCT06107023|EXPERIMENTAL|Intervention Group|action observation and upper extremity activities
62094029|NCT04506190||Robotic-assisted revisional bariatric surgery|Subjects who undergo robotic-assisted revisional bariatric surgery
62094030|NCT06575400|EXPERIMENTAL|SRD Part: BI 3804379|SRD= Single rising dose
62094031|NCT06575400|PLACEBO_COMPARATOR|SRD Part: Placebo matching BI 3804379|
61907789|NCT04028271|ACTIVE_COMPARATOR|conventional injection|local anesthesia applyed with conventional syringe
62094032|NCT06575400|EXPERIMENTAL|MRD Part: BI 3804379|MRD=Multiple rising dose.
62094033|NCT06575400|PLACEBO_COMPARATOR|MRD Part: Placebo matching BI 3804379|
62291735|NCT02341612|EXPERIMENTAL|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion (CWI) immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
62094034|NCT03090217|EXPERIMENTAL|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
62094035|NCT03090217|ACTIVE_COMPARATOR|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
62094036|NCT06562725|NO_INTERVENTION|standard ventilator settings|"Patients randomized in the control group standard ventilator settings will be left on the ventilator settings previously chosen by the attending physician, except Inspired Oxygen Fraction(FiO2) increased to 100%"
62094037|NCT06562725|EXPERIMENTAL|specific ventilator settings|"Patients randomized in the experimental group special ventilator settings will receive ventilator settings aimed at reducing airway pressure during FOB. This includes : inspiratory flow \<25 L/min, tidal volume = 5 mL/Kg, inspiratory time = 1 sec, respiratory frequency \<20c/min, PEEP = 5 cmH2O, and FiO2 = 100%"
62094038|NCT02113111||Fasting|Patients being admitted to an internal integrative medicine hospital and referred to therapeutic fasting therapy
62291736|NCT02341612|EXPERIMENTAL|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
62291737|NCT02341612|EXPERIMENTAL|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
62291738|NCT02341612|EXPERIMENTAL|whole body criotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
61907790|NCT05893953|EXPERIMENTAL|Normal Healthy Students(Condition A)|sitting in a standard chair wearing an immediately feedback device
61907791|NCT05893953|EXPERIMENTAL|Normal Healthy Students(Condition B)|sitting in a gym-ball
61907792|NCT05893953|EXPERIMENTAL|Normal Healthy Students(Condition C)|sitting in a standard chair(control group)
61907793|NCT01790243|EXPERIMENTAL|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
62094039|NCT01702038|EXPERIMENTAL|Rituximab|Participants will receive an intravenous infusion of rituximab on Days 0 and 14
62291739|NCT02341612|EXPERIMENTAL|passive recovery|The control group was not exposed to treatment after the EIMD protocol.
62291740|NCT02296060|EXPERIMENTAL|6 minutes walking test|
62291741|NCT03017209|EXPERIMENTAL|Locally-prepared bar|The bar is similar to one tested recently in a pilot study and is a locally prepared bar designed to facilitate growth and cognitive development. It will provide 300 kcal/day and will have ≈20-30% of energy from protein (of which 25-50% is from an animal protein source), 20-35% from total carbohydrate and ≈40-60% from fat. The bar will be fortified with vitamins and minerals to meet USAID recommendations for moderate malnutrition and Dietary Reference Intake recommendations for at-risk and healthy children of the ages studied, and at the same time will not exceed Upper Level nutrient recommendations for any micronutrient. Ingredients in the bar will be a combination of local products and imported shelf-stable ingredients.
62291742|NCT03017209|ACTIVE_COMPARATOR|USAID Corn Soy Blend Plus|The usual-intervention condition will be 300 kcal/day of USAID Corn Soy Blend Plus cooked in the usual manner with fortified vegetable oil (10:3 ratio) and sugar. The community health workers or other designated villagers will prepare the supplement freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
62291743|NCT03017209|PLACEBO_COMPARATOR|Locally-purchased rice|The placebo condition will be 300 kcal/day of locally-purchased rice cooked with a small amount of oil (10:2 ratio), which mimics the usual breakfast of children in this region. The community health workers or other designated villagers will prepare the rice freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
62291744|NCT02971592|EXPERIMENTAL|Experimental|
62291745|NCT02971592|PLACEBO_COMPARATOR|Placebo|
62291746|NCT02519114|EXPERIMENTAL|Bone MarrowTransplantation|KIR-mismatched haploidentical bone marrow transplantation
62291747|NCT05421000|EXPERIMENTAL|WALANT|Wide awake local anesthesia without tourniquet was used for surgery
62464752|NCT03929393|EXPERIMENTAL|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
61907794|NCT01790243|ACTIVE_COMPARATOR|Standard Uncoated Angioplasty Balloon|PTA Catheter
61907795|NCT02329340|ACTIVE_COMPARATOR|Am Academy of Pediatrics print materials|In-person session to read online version of American Academy of Pediatrics The Injury Prevention Program (TIPP sheets) childhood injury prevention print materials, followed by access to the TIPP sheets for 30 days.
62657734|NCT06107023|SHAM_COMPARATOR|Control Group|sham action observation and upper extremity activities
62291748|NCT05421000|ACTIVE_COMPARATOR|Locoregional anesthesia and tourniquet|Locoregional anesthesia (normally axillary block) and tourniquet was used for surgery
62291749|NCT04828824|EXPERIMENTAL|COCR Arm|Participants in the COCR arm will receive three packs of combined oral contraceptive pills (35mcg ethinyl estradiol/norgestimate) and a specific protocol for their use for bothersome bleeding.
62094040|NCT00655434||SAA|Sexually Active Adults- Intercourse in the last twelve months with at least one sexual partner. Subjects must be ≥ 18 years old. No more than 60% of one gender.
62094041|NCT02939404||healthy volunteers|non-diabetic healthy volunteers at a stable weight
62094042|NCT04906382|EXPERIMENTAL|Treatment (tislelizumab)|"Chemo naïve patients receive tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients who are chemotherapy naive with progressive disease, stable disease, or partial response, also receive carboplatin IV and paclitaxel IV every 21 days per standard of care for 6-9 cycles at the discretion of the treating physician.~Patients who have received prior chemotherapy will receive single agent tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
62657735|NCT02016118||Ialuril|Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
62657736|NCT02016118||Standard of care|Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.
62094043|NCT00689104|PLACEBO_COMPARATOR|Placebo|Participants received matching mirabegron placebo tablets and matching tolterodine slow release (SR) placebo capsules orally once a day for 12 weeks.
62094044|NCT00689104|EXPERIMENTAL|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
62094045|NCT00689104|EXPERIMENTAL|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
62094046|NCT00689104|ACTIVE_COMPARATOR|Tolterodine SR 4 mg|Participants received tolterodine SR 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 weeks.
62094047|NCT06682117|EXPERIMENTAL|treatment arm|Patients will received DC vaccine infusions.
62464753|NCT03929393|ACTIVE_COMPARATOR|Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
62657737|NCT03258606||Individuals with affected capacity to consent|Individuals with who were unable to consent and were allowed by protocol to give surrogate consent.
62464754|NCT05335863|EXPERIMENTAL|Experimental|Ingestion of FontActiv® DiaBest high protein/hypercaloric
62094048|NCT02089451|EXPERIMENTAL|FIAsp|Each subject will be randomised to a treatment sequence consisting of 5 treatment periods
62094049|NCT06650150||PRISm|cigarette smokers with FEV1 below 80%
62094050|NCT06650150||preCOPD|cigarette smokers with normal pft
62657738|NCT04211896|EXPERIMENTAL|anlotinib plus nivolumab|
62094051|NCT06650150||COPD|cigarette smokers with FEV1/FVC less than 70%
62094052|NCT05663892|EXPERIMENTAL|Investigational Population (Group 1) - Trans women living with HIV|"Trans women living with HIV, taking:~* Biktarvy~* Oral 17(Beta)-Estradiol"
62094053|NCT05663892|ACTIVE_COMPARATOR|Comparator Population (Group 2) - Cis Women Living with HIV|"Cis women living with HIV, taking:~-Biktarvy"
62094054|NCT05663892|ACTIVE_COMPARATOR|Comparator Population (Group 3) - Trans Women Living without HIV|"Trans women living without HIV, taking:~-Oral 17(Beta)-Estradiol"
62094055|NCT02698462|OTHER|FIT and Questionnaire|Six thousand persons eligible for the national CRC screening program will be selected. They will be selected from four areas that are considered representative of the Netherlands. All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
62094056|NCT06611761||SHAC block + anterior SSN block|Group of patients undergoing shoulder arthroscopy who underwent a block of the anterior capsule of the shoulder (SHAC block) with the suprascapular nerve block (SSN block) performed via an anterior approach with 20 ml of 0.20% ropivacaine
62094057|NCT06611761||Posterior SSN + AN blocks|Group of patients undergoing shoulder arthroscopy who underwent a suprascapular and axillary nerve block performed via a posterior approach with 20 ml of 0.20% ropivacaine
62094058|NCT04840147|EXPERIMENTAL|Intervention|JointRep® plus microfracture
62094059|NCT04840147|OTHER|Control|Microfracture alone
62094060|NCT05859997|EXPERIMENTAL|BRL-301|Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
62094061|NCT04833556||Postpartum haemorrhage|Patients undergoing cesarean delivery with postpartum haemorrhage (blood loss more than or equal to 1,000 ml.)
62094062|NCT00224133|EXPERIMENTAL|Silodosin|Silodosin 8 mg per day with food
62094063|NCT00892229|ACTIVE_COMPARATOR|Buccal Misoprostol|Group one: 50 patients with first trimester missed abortion received buccal misoprostol
62094064|NCT00892229|ACTIVE_COMPARATOR|Vaginal Misoprostol|Group two: 5 patients received vaginal misoprostol
62094065|NCT00892229|ACTIVE_COMPARATOR|Buccal and Vaginal Misoprostol|"50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.~Each group was randomly allocated (1,3,5,... for the buccal group \& 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol."
62094066|NCT05145556|EXPERIMENTAL|Videolaryngoscopy (McGrath Macintosh)|First pass success rate using the videolaryngoscopy
62291750|NCT04828824|NO_INTERVENTION|SOC Arm|Participants in the SC arm will be offered care according to our standardized protocol, which may include STI testing, reassurance and monitoring, prescription of COCs if desired, or removal.
62291751|NCT06138145|SHAM_COMPARATOR|Group A|No Video w/ monetary incentive
62291752|NCT06138145|EXPERIMENTAL|Group B|Generic video w/ monetary incentive
62464755|NCT05335863|PLACEBO_COMPARATOR|Control|Ingestion of glucose standard solution
62657739|NCT02689960|OTHER|vaginal administration first|Intervention first visit: vaginal administration of 100mg prednisone suppository, Intervention second visit: rectal administration of 100mg prednisone suppository
62291753|NCT06138145|EXPERIMENTAL|Group C|Appeal video w/ monetary incentive
62291754|NCT06138145|SHAM_COMPARATOR|Group D|Non-Incentive and no video
62291755|NCT00619008|EXPERIMENTAL|1|Ad libitum low carbohydrate diet
62291756|NCT00619008|EXPERIMENTAL|2|Ad libitum high complex carbohydrate diet
62464756|NCT02867930|ACTIVE_COMPARATOR|Group D|Dexmedetomidine- drug used for moderate sedation prepared as 200 mic in 20 ml syringe.with intravenous loading dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
62464757|NCT02867930|ACTIVE_COMPARATOR|Group KF|Ketamine+Propofol -drugs used for sedation-as ratio 1:3with 19ml of 1% propofol + 1.3ml ketamine(50mg/ml) as loading intravenous infusion dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
62464758|NCT06372457||Participants with Hypertrophic Cardiomyopathy (HCM)|Participants with an available HCM diagnosis date and without evidence of an HCM phenocopy
62464759|NCT06372457||Participants treated with mavacamten.|
62291757|NCT00619008|EXPERIMENTAL|3|Energy-restricted high complex carbohydrate diet
62291758|NCT02747914|EXPERIMENTAL|Transcranial magnetic stimulation therapy|Group of patients treated with rTMS low than 5Hz
62464760|NCT04776525|EXPERIMENTAL|Sequential ifosfamide and doxorubicin|Four cycles ifosfamide 9 g/m2 and four cycles doxorubicin 80 mg/m2. Each cycle has a duration of 14 days.
62464761|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
62291759|NCT02747914|ACTIVE_COMPARATOR|Conventional exercise treatment|Group of patients treated with conventional exercise
62464762|NCT02866422||OCD|
62464763|NCT02866422||Healthy Controls|
62291760|NCT04711837|EXPERIMENTAL|HSK3486|HSK3486 for induction of general anesthesia.
62291761|NCT04711837|ACTIVE_COMPARATOR|Propofol|Propofol for induction of general anesthesia.
62291762|NCT04453774|EXPERIMENTAL|Covi19 patients receiving intervention|We will collect self-reported symptoms via a questionnaire, temperature and oxygen saturation will be entered by the patient and passive near continuous sensing of heart rate, audio for cough detection, respiratory rate, cough and physical activity from a smart watch. The smart watch then transmits this sensor data to the paired smartphone.
62291763|NCT01176045||Pre-surgical treatment|Patients who are pre \& post-surgical treated with ocular lubricants.
62291764|NCT01176045||Non-presurgical treatment|Patients who are only post-surgical treated with ocular lubricants
62291765|NCT01832961|EXPERIMENTAL|flutter valve exercises|30 minutes of breathing exercises with flutter device
62291766|NCT01832961|SHAM_COMPARATOR|flutter-sham exercises|30 minutes of breathing exercise with flutter-sham device
62291767|NCT01451593|EXPERIMENTAL|phenytoin|active arm of trial 1:1 allocation active versus placebo
62464764|NCT03902028|EXPERIMENTAL|Reinforced multidisciplinary follow-up|"Entrance medication reconciliation performed by a pharmacist~* Patient compliance evaluation~* Patient quality of life evaluation~* Pharmaceutical analysis with focus on medication optimization with a specific check-list (according to ESC 2016 recommendations)~* Hospitalisation discharge medication reconciliation~* Patient pharmaceutic interview at the hospitalisation discharge~* Transmission of informations to the general practitioner and the pharmacist's patient~* Multidisciplinary consult at 1 month after hospitalisation discharge"
62464765|NCT03902028|NO_INTERVENTION|Standard care|"* Drug review by a paramedic or a pharmacist~* Pharmaceutical analysis~* Therapeutic optimisation based on the usual practices care of the cardiologic department~* Writing of the prescription given on leaving hospital based on the usual care of the department~* Treatments explanations and support to the patient on the usual care~* Transmission of the hospitalisation report to the patient general practitioner as the usual practice~* Medical consult in usual time frames (an average of 1 month after hospitalisation discharge) at the patient location of choice"
62464766|NCT01591447|EXPERIMENTAL|Solithromycin (CEM-101)|A single oral dose of 1200 mg solithromycin
62291768|NCT01451593|PLACEBO_COMPARATOR|placebo|1:1 allocation active versus placebo
62291769|NCT02610309|EXPERIMENTAL|Family-Based Crisis Intervention|The Family-Based Crisis Intervention (FBCI) is a single-session intervention that takes place in the Emergency Department. Adolescents randomized to the experimental condition received a standard psychiatric evaluation followed by the experimental intervention. FBCI was administered by licensed psychiatric social workers who were trained in the intervention. The research clinician provided FBCI to the suicidal adolescent and his/her parent(s)/guardian(s) in a 60-90 minute session in which she helped the adolescent and family develop a joint crisis narrative of the problem and taught them cognitive-behavioral skill-building, therapeutic readiness, psycho-education about depression, and safety planning.
62291770|NCT02610309|NO_INTERVENTION|Treatment As Usual|Treatment as usual included an emergency psychiatry evaluation (standard care).
62291771|NCT03443167|ACTIVE_COMPARATOR|Intervention group|Training on emergency telephone numbers and mnemonics
62291772|NCT03443167|SHAM_COMPARATOR|Control group|Sham generic formation on the cardiopulmonary arrest.
62291773|NCT02006771|EXPERIMENTAL|Southern Chinese meal|White rice (1 bowl), stir fried Choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
62291774|NCT02006771|EXPERIMENTAL|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
62291775|NCT02006771|EXPERIMENTAL|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil plus Coca-cola classic (21 fluid ounces)
62291776|NCT02006771|EXPERIMENTAL|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
62291777|NCT05567523|EXPERIMENTAL|Group D0.25, Group D0.5, Group D0.75|Dexmedetomidine will be administered at different initial loading doses (0.25/0.5/0.75 μg/kg within 15min) following same maintained dosage ( 0.5μg/kg/h) in Group D0.25/D0.5/D0.75.
62291778|NCT05567523|PLACEBO_COMPARATOR|Group NS, Group MD|In Group NS, patients will be pumped 0.1ml/kg of normal saline for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation. In Group MD, patients will be administrated with midazolam 0.03mg/kg at the beginning of anesthesia induction.
62291779|NCT00430144|EXPERIMENTAL|CKD-602|
62291780|NCT03758586|ACTIVE_COMPARATOR|Study group|Surgical residents undergoing spatial skill training.
62291781|NCT03758586|SHAM_COMPARATOR|Control group|Surgical residents not undergoing spatial skill training.
62464767|NCT01591447|EXPERIMENTAL|Solithromycin 1000 mg|A single oral dose of 1000 mg solithromycin
62464768|NCT04589091||Group(1): Patient who underwent PRK|
62464769|NCT04589091||Group(2): Patient underwent LASIK|
62464770|NCT02516657|EXPERIMENTAL|Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
62464771|NCT04455581|EXPERIMENTAL|Treatment group|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
62464772|NCT02648334|ACTIVE_COMPARATOR|IN.PACT drug coated balloon|IN.PACT drug coated balloon
62464773|NCT02648334|EXPERIMENTAL|Lutonix drug coated balloon|Lutonix drug coated balloon
62464774|NCT00998556|EXPERIMENTAL|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
62464775|NCT00998556|NO_INTERVENTION|Control Group|The control group will receive standard therapy for heart failure. Part of this therapy are ACE inhibitors. Since ACE inhibitors are potentially harmful for the baby when getting into the breast milk, it is necessary to stop lactation in the control group as well.To stop lactation, application of bromocriptine (2.5mg/day) for up to one week.
61907796|NCT02329340|EXPERIMENTAL|Family Safety 1-2-3|In-person session to view video and text-based interactive web site on injury prevention information and strategies, followed by 8 emails delivered over a 30-day period inviting participant to view additional child safety videos.
62464776|NCT02072486|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
62464777|NCT04071860||discovery and learning cohort|Data from this cohort will be used to develop the software algorithms
62464778|NCT04071860||Validation|Data from this cohort will be used to validate the software algorithms
62464779|NCT00996788|EXPERIMENTAL|Rebamipide|Rebamipide 100 mg tid for 28 days
62464780|NCT05113966|EXPERIMENTAL|Trilaciclib + Sacituzumab Govitecan-hziy|During the Treatment Phase patients will receive trilaciclib + sacituzumab govitecan-hziy on days 1 \& 8 of a 21 day cycle. Trilaciclib is administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion to be completed within 4 hours prior to the start of sacituzumab govitecan-hziy.
62464781|NCT00413764|EXPERIMENTAL|1|tibolone
62464782|NCT00413764|ACTIVE_COMPARATOR|2|transdermal continuous combined E2-NETA (estradiol-norethisterone)
61907797|NCT04335305|EXPERIMENTAL|Tocilizumab plus Pembrolizumab (MK-3475)|"Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose) as an intravenous infusion over 60 minutes; single dose Pembrolizumab (MK3475) 200 mg as an intravenous infusion over 30 minutes; single dose.~Patients who are showing no clinical improvement in respiratory function after 12 hours could receive an additional dose of tocilizumab at the same dose level of the first administration. Patients who are showing SpO2 ≤ 94% on room air could receive an additional administration of pembrolizumab (MK-3475) at the same recommended dose after 3 weeks from treatment initiation and/or an additional dose of tocilizumab after 4 weeks from treatment initiation at physician's discretion."
62094067|NCT05145556|EXPERIMENTAL|conventional direct laryngoscopy|First pass success rate using the conventional direct laryngoscopy
62291782|NCT05405556|EXPERIMENTAL|Patients and providers only aware of study eGFR values more than 25% below baseline|Any study-related eGFR value more than 25% below the baseline measurement will be reported to the patient and treating physician.
62291783|NCT05405556|OTHER|Patients and providers aware of all study eGFR values|All study-related eGFR measurements will be reported to the treating physician and patient.
62291784|NCT05939297||people with coronary heart disease|In order to measure the self-management and self-efficacy levels of the patients,Heart Health Self-efficacy and Self-Management Scale , Self-Care Management Scale in Chronic Diseases, general self-efficacy scales will be applied to the patients.
62291785|NCT00386841|ACTIVE_COMPARATOR|A Escitalopram 10 mg|Escitalopram 10 mg
62464783|NCT01971619||SACS cohort|patients with acute myocardial infarction at Severance hospital
62464784|NCT00804063||1|glaucoma patients
62464785|NCT00804063||2|non-glaucoma controls
62464786|NCT01371162|EXPERIMENTAL|A1 Healthy Volunteers|
62291786|NCT00386841|PLACEBO_COMPARATOR|Placebo|Placebo
62291787|NCT01586845|EXPERIMENTAL|Voclosporin|Voclosporin
62291788|NCT01586845|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus
62291789|NCT03313960|ACTIVE_COMPARATOR|"One Drop | Premium with Afrezza"|
62464787|NCT01371162|PLACEBO_COMPARATOR|A2|
62464788|NCT01371162|EXPERIMENTAL|B1 HCV Infection|
62464789|NCT01371162|PLACEBO_COMPARATOR|B2|
62464790|NCT05341622|EXPERIMENTAL|Arm 1: Box + Text + Reminder|Box + Text + Reminder
62464791|NCT05341622|EXPERIMENTAL|Arm 2: Box + Text + No Reminder|Box + Text + No Reminder
62464792|NCT05341622|EXPERIMENTAL|Arm 3: Box + No Text + Reminder|Box + No Text + Reminder
62464793|NCT05341622|EXPERIMENTAL|Arm 4: Box + No Text + No Reminder|Box + No Text + No Reminder
62464794|NCT05341622|EXPERIMENTAL|Arm 5: Standard Mail + Text + Reminder|Standard Mail + Text + Reminder
62464795|NCT05341622|EXPERIMENTAL|Arm 6: Standard Mail + Text + No Reminder|Standard Mail + Text + No Reminder
62464796|NCT05341622|EXPERIMENTAL|Arm 7: Standard Mail + No Text + Reminder|
62464797|NCT05341622|EXPERIMENTAL|Arm 8: Standard Mail + No Text + No Reminder|Standard Mail + No Text + No Reminder
62464798|NCT02198586||No treatment|The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717).
62464799|NCT02214264|EXPERIMENTAL|Loving-Kindness training|Participants receive Loving-Kindness meditation training for approximately 12 minutes.
62464800|NCT02214264|EXPERIMENTAL|Breath Awareness training|Participants receive Breath Awareness meditation training for approximately 12 minutes.
62464801|NCT02214264|EXPERIMENTAL|Gratitude training|Participants will receive Gratitude training for approximately 12 minutes.
62094068|NCT02059915|EXPERIMENTAL|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62094069|NCT02059915|EXPERIMENTAL|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62464802|NCT02214264|OTHER|Control|Participants write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
62657740|NCT02689960|OTHER|rectal administration first|Intervention first visit: rectal administration of 100mg prednisone suppository, Intervention second visit: vaginal administration 100mg prednisone suppository
62657741|NCT03710811||Type 2 Diabetes|drug naive Type 2 Diabetes received insulin therapy
62657742|NCT03710811||normal control|healthy volunteers as normal control
62657743|NCT06266013|EXPERIMENTAL|intervention group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
62657744|NCT06266013|NO_INTERVENTION|control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
62657745|NCT06266013|ACTIVE_COMPARATOR|activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 15% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
62657746|NCT03922932||Group A: PDR|This group will consist of 30 subjects with active proliferative diabetic retinopathy (PDR) and 30 subjects with treated PDR.
62657747|NCT03922932||Group B: NPDR|This group will consist of 60 subjects with severe non-proliferative diabetic retinopathy (NPDR), 60 subjects with moderate NPDR, and 60 subjects with mild NPDR.
62657748|NCT03922932||Group ME: Macular Edema|This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.
62657749|NCT03922932||Group C: DM without Retinopathy|This group will consist of 60 subjects with diabetes mellitus (DM) who do not have retinopathy.
62657750|NCT03922932||Group D: Healthy Controls|This group will consist of 50 subjects with healthy eyes who do not have diabetes.
62094070|NCT02059915|EXPERIMENTAL|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62094071|NCT02059915|EXPERIMENTAL|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62094072|NCT03086694||group surgery|using medications to maintain low stable blood pressure
62464803|NCT03488186|EXPERIMENTAL|Lansoprazole Capsules|Lansoprazole Capsules of Beijing Sihuan Pharm, 30 mg
62094073|NCT02459587|EXPERIMENTAL|Crisis Line Facilitation (CLF)|Crisis Line Facilitation
62094074|NCT02459587|PLACEBO_COMPARATOR|Enhanced Usual Care (EUC)|Enhanced Usual Care
62464804|NCT03488186|ACTIVE_COMPARATOR|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules of Takeda Pharmaceutical Company Limited, 30 mg
62464805|NCT02327130|EXPERIMENTAL|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
62464806|NCT04795609|ACTIVE_COMPARATOR|Interventional group|Early mobilization postoperative programme based on supervised aerobic exercise, resistance and flexibility training or to standard rehabilitation care
62464807|NCT04795609|NO_INTERVENTION|Control group|Bed restriction strategy for 5 days
62464808|NCT05165537|EXPERIMENTAL|NIMM_MRS|testing of new MRS methods
62657751|NCT03104023|ACTIVE_COMPARATOR|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
62657752|NCT03104023|EXPERIMENTAL|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
62094075|NCT06697288|EXPERIMENTAL|Tested product group|Volunteers using the investigational product handed over to them
62094076|NCT06697288|ACTIVE_COMPARATOR|Control group|Volunteers using their own sun protection routine
62094077|NCT06413615|EXPERIMENTAL|HER2 Low Metastatic/Recurrent Breast Cancer|Enrolled Subjects will receive a 5.4 mg/kg IV dose of FDA022-BB05 on Day 1 of each cycle Q3W
62094078|NCT06413615|EXPERIMENTAL|HER2 Expressing Metastatic/Recurrent Endometrial Cancer|Enrolled Subjects will receive a 5.4 mg/kg IV dose of FDA022-BB05 on Day 1 of each cycle Q3W
62464809|NCT01678638|ACTIVE_COMPARATOR|Early inguinal hernia (IH) repair|IH repair before NICU discharge
62678919|NCT03153202|EXPERIMENTAL|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
62678920|NCT03153202|EXPERIMENTAL|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
62094079|NCT06413615|EXPERIMENTAL|HER2 Overexpressing/Mutant Metastatic/Recurrent Solid tumor|Enrolled Subjects will receive a 5.4 mg/kg IV dose of FDA022-BB05 on Day 1 of each cycle Q3W
62464810|NCT01678638|ACTIVE_COMPARATOR|Late inguinal hernia (IH) repair|IH repair as outpatient at approximately 55-60 weeks post-menstrual age
62657753|NCT06433648|ACTIVE_COMPARATOR|Transfemoral Amputee participants: Ottobock Cleg4 + Ottobock foot; Hybrid Knee + Polycentric Ankle|"Participant is fit with the commercially available device (Ottobock Cleg 4/Ottobock foot), they will receive standard of care clinical training for 3-4 sessions over 4 weeks, plus 1 session for outcome assessments.~Participant is then fit with the SRALAB Hybrid knee and SRALAB Polycentric Ankle prosthesis, they again will receive clinical training for 3-4 sessions over 4 weeks, plus 1 session for outcome assessments."
62736791|NCT02250079|ACTIVE_COMPARATOR|Conventional group|): Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
62291790|NCT03313960|OTHER|"One Drop | Premium without Afrezza"|
62291791|NCT03478618|ACTIVE_COMPARATOR|Group R|30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative.
62291792|NCT03478618|ACTIVE_COMPARATOR|Group L|30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative.
62291793|NCT02599506||breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy
62291794|NCT02158559|EXPERIMENTAL|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
62291795|NCT02158559|PLACEBO_COMPARATOR|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
62464811|NCT02417805|EXPERIMENTAL|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
62464812|NCT02417805|EXPERIMENTAL|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
62094080|NCT00525057|EXPERIMENTAL|Treatment (dalteparin)|Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
62464813|NCT02417805|EXPERIMENTAL|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
62464814|NCT02417805|ACTIVE_COMPARATOR|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
62464815|NCT01604694|EXPERIMENTAL|TAP Block with levobupivacaïne|
62464816|NCT01604694|PLACEBO_COMPARATOR|TAP Block with Placebo|
62094081|NCT05091372|EXPERIMENTAL|Belantamab mafodotin|belantamab mafodotin by vein over about 30 minutes on Day 1 of each cycle
62094082|NCT05091372|EXPERIMENTAL|Lenalidomide|lenalidomide by mouth every day of each cycle
62291796|NCT01935895||Exercise on Blood Pressure Reactivity|To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
62291797|NCT01636492|EXPERIMENTAL|Bitopertin|
62291798|NCT01636492|PLACEBO_COMPARATOR|Placebo|
62291799|NCT04378426|EXPERIMENTAL|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50%nitrous oxide and 50% oxygen plus intravenous saline
62291800|NCT04378426|ACTIVE_COMPARATOR|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
62464817|NCT04132778|EXPERIMENTAL|Intervention - Asthmatuner|Asthmatuner (Medituner AB, Stockholm, Sweden) is a CE-marked cloud-computing-based system with a healthcare interface and a downloadable patient app (Android or iOS).The intended use of Asthmatuner is to automate asthma self-management by letting patients register symptoms and measure forced expiratory volume in one second (FEV1) with a Bluetooth spirometer (MIR, SmartOne). The patient then receives immediate feedback on the status of symptom control (controlled, partly controlled or uncontrolled), and a treatment recommendation, with an image of the correct inhaler or other type of medication and the dose. Symptom control is quantified based on lung function; litre to percentage of personalised best FEV1, using a cut-off ≤80% and symptoms during the last week based on four questions: 1) need for rescue medication more than twice due to asthma symptoms, 2) any daytime symptoms, 3) nocturnal symptoms/awakenings, and 4) limitation in physical activities.
62464818|NCT04132778|NO_INTERVENTION|Control group - Traditional asthma management|Traditional self-management is defined as all other types of non-digital asthma management. This could be treatment plan written on paper or by oral communication to patient/caregiver on asthma treatment.
62464819|NCT02409693||Myringotomy with tube insertion|Patients who received surgically inserted ear tubes.
62464820|NCT00445003|EXPERIMENTAL|Sham injection plus laser|Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
62464821|NCT00445003|EXPERIMENTAL|0.5mg Ranibizumab plus laser|Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
62291801|NCT05836298|PLACEBO_COMPARATOR|Periodontitis quadrant Scaling root planing (SRP)|Each selected subject underwent quadrant SRP
62464822|NCT00445003|ACTIVE_COMPARATOR|4-mg Triamcinolone Acetonide plus Laser|4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
62464823|NCT03603314|EXPERIMENTAL|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
62464824|NCT03603314|EXPERIMENTAL|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
62464825|NCT03603314|PLACEBO_COMPARATOR|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
62464826|NCT02566278|EXPERIMENTAL|Obstructive Sleep Apnea|Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) \> 3 months to verify the Pcrit measurement obtained by the clinical equipment.
62464827|NCT00649025|EXPERIMENTAL|1|FlutiForm 250/10ug
62464828|NCT00649025|ACTIVE_COMPARATOR|2|SKP Fluticasone 250ug
62464829|NCT00649025|ACTIVE_COMPARATOR|3|Flovent Fluticasone HFA
62464830|NCT00020826||gastric adenocarcinoma|No protocol specific interventions. Both palliative or curative treatment allowed.
62464831|NCT05921955|NO_INTERVENTION|air group|the patients of the air group receive the 2L/min with air pattern by the Optiflow high-flow nasal cannula system from anesthesia to fetal delivery.
62291802|NCT05836298|ACTIVE_COMPARATOR|MINST treatment|Non surgical periodontal treatment performed with Minimally invasive non-surgical therapy (MINST) approach
62291803|NCT02160860||Children|Children
62291804|NCT05763602|EXPERIMENTAL|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (PDI Profend) will be applied to the patients' noses 60 minutes before surgery to repair HELEF and approximately 12 hours after the first application. If the patient will have additional HELEF repair in the 6 month followup period, intranasal PVI will be applied in a similar manner for each procedure.
62291805|NCT05763602|NO_INTERVENTION|Concurrent Control|Standard of Care. This will be usual care at each participating site for subjects enrolled in the Baseline period.
62291806|NCT02493348|EXPERIMENTAL|Continuous 40 Hz Rhythmic Sensory Stimulation|The intervention consists of Rhythmic Sensory Stimulation of a continuous sine wave single-frequency stimulation (40 Hz). The treatment prescription is 30 minutes daily 40 Hz Rhythmic Sensory Stimulation, 5 days per week, for five weeks of treatment, for a total of 25 sessions.
62291807|NCT02493348|ACTIVE_COMPARATOR|Intermittent Rhythmic Sensory Stimulation|The stimulation consists of random and intermittent complex wave gamma-range RSS with peaks at 45 Hz and 95 Hz, for 30 minutes daily stimulation, 5 days per week, for a total of five weeks of treatment.
62291808|NCT00793767|PLACEBO_COMPARATOR|placebo|placebo
62291809|NCT00793767|EXPERIMENTAL|Erythropoietin|acute administration of erythropoietin
62291810|NCT01846455|EXPERIMENTAL|Hepatic Impairment: Child-Pugh A|Participants with chronic liver disease and classified as Child-Pugh Grade A had a score of 5-6 (out of 15) which correlates with a good prognosis. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
62464832|NCT05921955|EXPERIMENTAL|HFNO group|For HFNO group, a flow rate of 40L/min, with 100% oxygen concentration and a temperature of 37℃ by the Optiflow high-flow nasal cannula system from anesthesia to fetal delivery.
62464833|NCT05430698|EXPERIMENTAL|PD-1antibody plus GEMOX|PD-1 antibody plus GEMOX was given as postoperative adjuvant therapy
62464834|NCT03804762|EXPERIMENTAL|patients received treatment of TS-RECS|
62464835|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
62464836|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
62736792|NCT00778336||Limb Ischemia|Patients presenting with limb ischemia for treatment
61907798|NCT04335305|NO_INTERVENTION|Continued Standard of Care|Standard care per local written policies or guidelines comprises, as necessary and at physician's discretion, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, glucocorticoid, tocilizumab, virally targeted agents, chloroquine or hydroxychloroquine.
62736793|NCT00778336||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
62291811|NCT01846455|EXPERIMENTAL|Hepatic Impairment: Child-Pugh B|Participants with chronic liver disease and classified as Child-Pugh Grade B had a score of 7-9 (out of 15) which correlates with significant functional liver compromise. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
62736794|NCT00778336||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
61907799|NCT05948384|ACTIVE_COMPARATOR|PNF Group|For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds
61907800|NCT05948384|OTHER|Mirror Therapy Group|"Mirror treatment is a sort of motor imagery in which the patient exercises his unaffected limb while looking at himself in the mirror. It involves placing the affected limb behind a mirror. The mirror is positioned so the reflection of the opposing limb appears in place of the hidden limb. The patient then looks into the mirror on the side with unaffected limb and makes mirror symmetric movement. It will implemented for about 30 minutes with 2, 2 minutes rest in between. Patient will perform as many repetitions as they could of knee flexion \& extension, ankle dorsiflexion \& plantarflexion and functional tasks (rolling the foot over the roller, reaching would be accomplished by asking the patient to reach towards objects through his leg e.g. touching the feet to a certain object at a particular height and distance, cycling) depending on patient's ability to do so."
61907801|NCT00883688|EXPERIMENTAL|Bevacizumab + Lapatinib|"Bevacizumab 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle). Lapatinib Pills of 700 mg/m\^2/dose given orally 2 times each day."
62291812|NCT01846455|EXPERIMENTAL|Hepatic Impairment: Child-Pugh C|Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
62291813|NCT01846455|EXPERIMENTAL|HCV Without Hepatic Impairment|Participants with hepatitis C virus (HCV) without hepatic impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
61907802|NCT04605705||Group 1|NIRS values will be recorded during the surgery and until 24 hours postoperatively. No intervention will be done.
61907803|NCT04605705||Group 2|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
61907804|NCT05641389||Monitoring Group|Participants will be monitored via a transdermal monitor for four weeks. They will give four breath samples a day for these weeks as well as 5 Blood spot samples.
62291814|NCT01846455|ACTIVE_COMPARATOR|No Hepatic Disease or Impairment|Participants with no hepatic disease or impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
62291815|NCT01067820|EXPERIMENTAL|RVX000222, 200 mg daily|
62291816|NCT01067820|PLACEBO_COMPARATOR|Placebo|
62736795|NCT00778336||Other Thrombotic Conditions|Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.
62094083|NCT06571656|OTHER|Sequence 1|FID123359/ FID123360/ FID123361/FID121843: One drop in each eye, test formulation or ocular lubricant as randomized, at respective Investigational Product visit. A total of 4 drops per eye will be instilled. Investigational Product visits will be separated by 2 to 7 days.
62291817|NCT05478694||Ablative Therapy Group|Enrolled subjects will undergo the ablative therapy as part of their standard of care treatment
62291818|NCT04967131||PNF group|Proprioceptive Neuromuscular Fascilitation exercises were given this group
62291819|NCT04547322|EXPERIMENTAL|VR application group|The experimental group received VR application in the preoperative period for 10 minutes.
62736796|NCT03770741|EXPERIMENTAL|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
62736797|NCT03770741|OTHER|Treatment as usual|Treatment according local guidelines and practices.
61907805|NCT05872854|EXPERIMENTAL|HyBryte (0.25 % Hypericin) with Visible Light|HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 24 (±6) hours later starting at 5 J/cm\^2. Drug application/light sessions will be done twice a week (at least 2 calendar days apart) for up to 54 weeks.
62094084|NCT06571656|OTHER|Sequence 2|FID123360/ FID123361/FID121843/ FID123359: One drop in each eye, test formulation or ocular lubricant as randomized, at respective Investigational Product visit. A total of 4 drops per eye will be instilled. Investigational Product visits will be separated by 2 to 7 days.
62094085|NCT06571656|OTHER|Sequence 3|FID123361/FID121843/FID123359/ FID123360: One drop in each eye, test formulation or ocular lubricant as randomized, at respective Investigational Product visit. A total of 4 drops per eye will be instilled. Investigational Product visits will be separated by 2 to 7 days.
62094086|NCT06571656|OTHER|Sequence 4|FID121843/FID123359/ FID123360/ FID123361: One drop in each eye, test formulation or ocular lubricant as randomized, at respective Investigational Product visit. A total of 4 drops per eye will be instilled. Investigational Product visits will be separated by 2 to 7 days.
62094087|NCT01739517|EXPERIMENTAL|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
62094088|NCT04273685|EXPERIMENTAL|Intervention Condition|Cognitive remediation training, cognitive behavioural therapy, social recovery therapy
62094089|NCT04273685|ACTIVE_COMPARATOR|Control Condition|Treatment as usual (TAU),non-directive counselling
62291820|NCT04547322|NO_INTERVENTION|Control group|The control group received the routine procedure in the unit clinic where the study was conducted. The routine procedure of the unit includes patients are taken to the operating room on a stretcher and wait on the stretcher in the surgery waiting room until the operation room is prepared.
62464837|NCT05381766|EXPERIMENTAL|Intervention Group - CSA Model|English-, Chinese-, Spanish-, and Bangladeshi-speaking community members (adults 18+ years) residing in Sunset Park and surrounding neighborhoods will participate in a culturally adapted systems-level program for improving diet. The intervention will be evaluated through baseline and follow-up surveys and skin carotenoid assessments.
62736798|NCT03711370|EXPERIMENTAL|Opaque Bottle Group|This group was given a set of opaque bottles to use during infant feedings for a full 12-week period.
61907806|NCT02656225|EXPERIMENTAL|Ejiao compound|The participants in experimental group receive Ejiao compound (20ml, twice daily) orally for 4 weeks.
61907807|NCT02656225|ACTIVE_COMPARATOR|Niferex|The participants in control group receive Polysaccharide Iron Complex(Niferex)(150mg per tablet, once daily) orally after breakfast over 4 weeks.
62094090|NCT04910542|OTHER|EpI-Net community intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
62094091|NCT04483544|EXPERIMENTAL|Treatment|PD-1 inhibitor pembrolizumab, in combination with the PARP inhibitor olaparib
62094092|NCT02401529|EXPERIMENTAL|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
62094093|NCT02401529|ACTIVE_COMPARATOR|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
62094094|NCT02783950|OTHER|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
62094095|NCT02783950|NO_INTERVENTION|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
62094096|NCT01938664|EXPERIMENTAL|Candesartan w Cognitive Behavior Therapy|Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
61907808|NCT03545971|EXPERIMENTAL|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
61907809|NCT03545971|EXPERIMENTAL|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
62094097|NCT01938664|PLACEBO_COMPARATOR|Placebo w Cognitive Behavior Therapy|Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
62094098|NCT02396030|ACTIVE_COMPARATOR|Magnesium sulfate 50% - 1g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 1g/hour of intravenous magnesium sulfate, for 24 hours
62736799|NCT03711370|ACTIVE_COMPARATOR|Clear Bottle Group|This group was given a set of clear bottles to use during infant feedings for a full 12-week period.
61907810|NCT03545971|EXPERIMENTAL|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
61907811|NCT03545971|EXPERIMENTAL|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
62094099|NCT02396030|EXPERIMENTAL|Magnesium sulfate 50% - 2g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 2g/hour of intravenous magnesium sulfate, for 24 hours
62094100|NCT05429021|EXPERIMENTAL|IV Cohort 1|Single intravenous (IV) dose 1 of IMM-BCP-01 or matching placebo
62094101|NCT05429021|EXPERIMENTAL|IV Cohort 2|Single intravenous (IV) dose 2 of IMM-BCP-01 or matching placebo
62291821|NCT05759299||Patients undergoing anesthesia in operating room and outside operating room|Patients undergoing elective or emergency tracheal intubation to receive general anesthesia for surgery in operating room or outside operating room (e.g. endoscopy and radiology unit, cardiology lab cath)
62464838|NCT05381766|NO_INTERVENTION|Control Group|Mexican-identifying community members (adults 18+ years) residing in Mott Haven, Bronx and Chinese-identifying community members (adults 18+ years) residing in Chinatown, Manhattan and Flushing, Queens will form the comparison community. Recruited participants from the comparison communities will complete evaluation components (surveys and skin carotenoid assessments) but not receive the intervention.
62464839|NCT05070286||Young people with MS and NMOSD|"Young people aged 10-25 years, who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-structured interviews."
62464840|NCT05070286||Parents of young people with MS and NMOSD|"Parents of young people aged 10-25 who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-Structured Interviews"
62464841|NCT05070286||Clinicians|Health care practitioners from medical, nursing and AHP backgrounds with at least two years' experience in NMOSD and MS.
62464842|NCT06086951|EXPERIMENTAL|Pai.ACT Group|Parents allocated to this experimental group will gain complete access to the Pai.ACT mobile app.
62736800|NCT04072835|EXPERIMENTAL|Etripamil NS|Participants self-administered etripamil NS 70 mg. After implementation of protocol amendment 2.1 (16 March 2021), participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if PSVT symptoms persisted
62736801|NCT04072835|NO_INTERVENTION|Not Treated|Participants not treated with etripamil NS for a PSVT episode.
61907812|NCT03545971|EXPERIMENTAL|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
61907813|NCT03545971|EXPERIMENTAL|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
62736802|NCT05426967|EXPERIMENTAL|Arm 1|Active rTMS/Individualized Connectome Targeting (ICT)
62736803|NCT05426967|EXPERIMENTAL|Arm 2|Active rTMS/resting state functional MRI (rsfMRI)-based targeting
62736804|NCT05426967|SHAM_COMPARATOR|Arm 3|Sham rTMS
62736805|NCT06660589||People with COPD|People with COPD
62736806|NCT05020834|EXPERIMENTAL|Functional Electrical Stimulation Group|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
61907814|NCT03545971|EXPERIMENTAL|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
61907815|NCT03545971|EXPERIMENTAL|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
61907816|NCT00383474|EXPERIMENTAL|Arm I|Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
61907817|NCT05111301|EXPERIMENTAL|Basal Insulin Only (Group A)|"* 2 to 4 week CGM run-in~* 2 to 4 week pump run-in~* 6 weeks Control-IQ technology use"
61907818|NCT05111301|EXPERIMENTAL|Multiple Daily Injections (Group B)|"* 2 to 4 week CGM run-in~* 2 to 4 week pump run-in~* 6 weeks Control-IQ technology use"
62094102|NCT05429021|EXPERIMENTAL|IV Cohort 3|Single intravenous (IV) dose 1 of IMM-BCP-01 or matching placebo
62094103|NCT05429021|EXPERIMENTAL|IV Cohort 4 (optional)|Single intravenous (IV) dose 4 of IMM-BCP-01 or matching placebo
62094104|NCT00940017|EXPERIMENTAL|1|
62291822|NCT02221609|EXPERIMENTAL|Treatment based on Movement System Impairment based model|Treatment based on Movement System Impairment based classification model is composed by patient education, analysis and modification of daily living activities and prescription of specific exercises
62291823|NCT02221609|ACTIVE_COMPARATOR|General exercise|The general exercise program consists of stretching exercises of the trunk and lower limbs muscles and strengthening exercises of the trunk muscles (Hayden et al., 2005; Rainville et al., 2004).
62291824|NCT02229773|EXPERIMENTAL|BIBB 1464 MS low dose|
62094105|NCT06337643|EXPERIMENTAL|MVX01 Vaccine - Cohort 1|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 10 μg Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years,
62094106|NCT06337643|EXPERIMENTAL|MVX01 Vaccine or Placebo - Cohort 2|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 30 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years
62094107|NCT06337643|EXPERIMENTAL|MVX01 Vaccine or Placebo - Cohort 3|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 60 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years
62464843|NCT06086951|ACTIVE_COMPARATOR|Control Group|Parents allocated to this comparator group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
62094108|NCT06337643|EXPERIMENTAL|MVX01 Vaccine or Placebo - Cohort 4|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 90 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years
62094109|NCT06337643|EXPERIMENTAL|MVX01 Vaccine or Placebo - Cohort 5|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 90 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 60-75 years
62094110|NCT03887962|EXPERIMENTAL|Virtual Environment feedback|"Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a virtual path displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist."
62094111|NCT03887962|ACTIVE_COMPARATOR|Control|Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.
62094112|NCT04776213|EXPERIMENTAL|Mavenclad®|
62094113|NCT02335268|EXPERIMENTAL|Group 1|"Stratification into group 1 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are +3~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
62094114|NCT02335268|EXPERIMENTAL|Group 2|"Stratification into group 2 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -1 or -2~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
62094115|NCT02335268|EXPERIMENTAL|Group 3|"Stratification into group 3 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -6~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
62094116|NCT03064503|EXPERIMENTAL|Healthy volunteers|Sedentary healthy subjects will be recruited in this study. MRI, skin auto-fluorescence measures and blood sampling will be performed
62094117|NCT00233129|ACTIVE_COMPARATOR|Standard Treatment|cognitive rehabilitation day treatment program
62464844|NCT05814926|EXPERIMENTAL|Healthy Control|Each healthy participant will receive a single dose of GP681
61907819|NCT00950885|PLACEBO_COMPARATOR|Placebo|placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
61907820|NCT00950885|EXPERIMENTAL|Low dose melatonin|0.5 mg melatonin
62094118|NCT00233129|EXPERIMENTAL|Top-Down|"cognitive rehabilitation day treatment program that incorporates systematic top down treatment of executive function deficits (problem solving and emotional regulation training), systematic treatment of attention deficits, and modular, contextual and embedded approaches to treatment."
62094119|NCT06650930|EXPERIMENTAL|Oral calcium carbonate|Patients take a single dose of oral calcium carbonate 3000mg
62094120|NCT02708459|ACTIVE_COMPARATOR|Control|Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
61907821|NCT00950885|EXPERIMENTAL|High dose melatonin|3.0 mg melatonin
61907822|NCT00689260|ACTIVE_COMPARATOR|1 - Log Aware|Dose Log Aware (patient is aware that the device records their injection information) Half the subjects in the log aware arm will complete a diary. The other half in the log aware arm will not complete the diary.
62094121|NCT02708459|ACTIVE_COMPARATOR|Bupevecaine group|Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
61907823|NCT00689260|ACTIVE_COMPARATOR|2 - Log Unaware|Dose Log Unaware (patient is not aware that the device records their injection information) Half the subjects in the log unaware arm will complete a diary. The other half in the log unaware arm will not complete the diary.
62094122|NCT02708459|ACTIVE_COMPARATOR|Dex group|catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
62094123|NCT03140293|ACTIVE_COMPARATOR|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
62094124|NCT03140293|EXPERIMENTAL|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
62094125|NCT00913432|EXPERIMENTAL|masitinib 3 mg|masitinib 3 mg/kg/day
62094126|NCT00913432|EXPERIMENTAL|masitinib 6 mg|masitinib 6 mg/kg/day
62464845|NCT05814926|EXPERIMENTAL|Mild, Child-Pugh A|Each participant with Child-Pugh A will receive a single dose of GP681
61907824|NCT03980353||Children before entrance in primary school|Children with type 1 diabetes, who are too young to go to primary school at the start of the school year 2018-2019, followed in the Diabetology Department of Lyon Pediatric Hospital.
61907825|NCT04497883|EXPERIMENTAL|Cohort A: Non-Hispanic, Caucasian|Non-Hispanic, Caucasian group participants will receive 400 milligram (mg) maribavir tablets orally once on Day 1 during treatment period 1.
62094127|NCT00162942|ACTIVE_COMPARATOR|Adacolumn|Adacolumn, ten apheresis sessions within 9 weeks
62094128|NCT00162942|SHAM_COMPARATOR|Sham|Sham, ten apheresis sessions within 9 weeks
62094129|NCT03940261|EXPERIMENTAL|High Intensity Interval Training|
62094130|NCT03940261|ACTIVE_COMPARATOR|Continuous Moderate Intensity Training|
62094131|NCT00991744|EXPERIMENTAL|Liposomal cytarabine|Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL
62094132|NCT00991744|ACTIVE_COMPARATOR|Intrathecal triple|Intrathecal methotrexate, cytarabine and prednisolone
62094133|NCT04222387|EXPERIMENTAL|Participants with hair dye|Hair dye product with pPD Type Aromatic Amines used up to 1 month before
62094134|NCT03031639||Endoscopic|This group is the patients who underwent endoscopic approaches thyroidectomy.
62464846|NCT05814926|EXPERIMENTAL|Moderate; Child-Pugh B|Each participant with Child-Pugh B will receive a single dose of GP681
62094135|NCT03031639||Conventional|This group is the patients who underwent conventional approach thyroidectomy
62464847|NCT05932095|EXPERIMENTAL|TCM Daoyin intervention group|Participants randomized to TCM Daoyin intervention group receive health education plus a TCM Daoyin training program. The TCM Daoyin training program was a 12-week, instructor-led group training program.
62094136|NCT03003962|EXPERIMENTAL|Arm 1: Durvalumab|Anti-PD-L1 monoclonal Antibody monotherapy
62736807|NCT05020834|EXPERIMENTAL|TheraTogs Group|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
61907826|NCT04497883|EXPERIMENTAL|Cohort B: Japanese Descent|Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1 followed by 200 mg or 800 mg maribavir tablets orally once on Day 1 during treatment period 2 followed by 800 mg or 200 mg maribavir tablets orally once on Day 1 during treatment period 3 in cross-over fashion. A washout period of 72 hours will be maintained between treatment period 1, 2, and 3.
62094137|NCT03003962|ACTIVE_COMPARATOR|Arm 2: Standard of Care|Standard of Care Platinum-Based chemotherapy
62094138|NCT05064280|OTHER|Cohort 1|Patients with TNBC and brain metastases
62094139|NCT05064280|OTHER|Cohort 2|Patients with NSCLC and brain metastases
62094140|NCT05064280|OTHER|Cohort 3|Patients with other solid tumor types and brain metastases
62094141|NCT06613750|EXPERIMENTAL|Sitagliptin and Gliclazide Group|Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks.
62094142|NCT06613750|ACTIVE_COMPARATOR|Metformin Group|Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks.
62094143|NCT04038047||Core|Cystic Fibrosis patients prescribed elexacaftor, tezacaftor and ivacaftor CFTR modulator therapy (TCT).
62094144|NCT03782038|EXPERIMENTAL|Micro-coring of scars with MCD|Micro coring of acne scars and straie will be conducted in up to 3 treatments and followed 6 months post last treatment with MCD.
62094145|NCT02561455|EXPERIMENTAL|Gilteritinib 40 mg|Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
61907827|NCT03152006|NO_INTERVENTION|Control|The control arm does not receive the ACT intervention.
61907828|NCT03152006|EXPERIMENTAL|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
61907829|NCT03541915|EXPERIMENTAL|Mg group|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
61907830|NCT03541915|PLACEBO_COMPARATOR|Control group|Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.
62094146|NCT02561455|EXPERIMENTAL|Gilteritinib 80 mg|Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
62094147|NCT02561455|EXPERIMENTAL|Gilteritinib 120 mg|Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
62094148|NCT02561455|EXPERIMENTAL|Gilteritinib 200 mg|Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
62094149|NCT00461448|ACTIVE_COMPARATOR|1 Potassium supplement|Patients received an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
62094150|NCT00461448|PLACEBO_COMPARATOR|2 Grape Juice|Patients received same amount of grape juice for 28 days.
62094151|NCT03282123|EXPERIMENTAL|MDMA-assisted therapy|Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
62464848|NCT05932095|ACTIVE_COMPARATOR|Health education control group|Participants randomized to the health education control group only receive health education and no additional training program.
62464849|NCT02819934|EXPERIMENTAL|Arm1|experimental group
62094152|NCT04157764|EXPERIMENTAL|APD|
62736808|NCT05119374|EXPERIMENTAL|Investigational SenseGuard Device|All subjects use SenseGuard Device for twice daily monitoring of respiratory parameters.
62736809|NCT03593122|EXPERIMENTAL|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
62736810|NCT02579421|ACTIVE_COMPARATOR|Males - Progesterone|200 mg progesterone BID
62736811|NCT02579421|PLACEBO_COMPARATOR|Males - Placebo|placebo BID
62094153|NCT01169519|ACTIVE_COMPARATOR|Sildenafil|Pharmacokinetic and hemodynamic evaluation following sildenafil administration
62657754|NCT06433648|EXPERIMENTAL|Transfemoral Amputee participants: Ottobock CLeg4 + Polycentric Ankle, Hybrid Knee + Passive Ankle|"For this arm, transfemoral amputees will participate in an AB/BA randomized crossover study.~Before each arm of the cross-over, baseline data will be taken with the Ottobock Cleg 4/Ottobock foot or their clinically prescribed microprocessor knee unit/foot.~Condition A is CLeg + Polycentric Ankle~Condition B is SRALab Hybrid knee + Passive Ankle~Subjects will participate in 2 sessions over 2 weeks, each lasting 2-3 hours to have the device tuned for the specific condition (A or B). On the third week, they will participate in 2 visits to complete functional outcome measures, biomechanical and metabolic assessments. They will then switch conditions, and repeat the protocol for the second condition.~There will not be a washout period between conditions, but subjects will complete outcome measures with the Ottobock Cleg 4/Ottobock foot or their clinically prescribed microprocessor knee unit/foot prior to each arm of the crossover to obtain baseline data."
62657755|NCT06433648|EXPERIMENTAL|Transfemoral Amputee participants: SRALAB Hybrid knee + Polycentric Ankle, Ottobock Cleg4 + OB foot|"During this arm, participants will receive intensive clinical training with the SRALAB Hybrid knee + Polycentric Ankle twice per week over 8 weeks, lasting 2-3 hours. Training will include patient-driven therapy to achieve participants' individual therapy goals, functional mobility and community skills.~At the end of the 8-week training period, subjects will complete the same set of functional outcome measures, biomechanical and metabolic assessments in previous arms.~To complete this arm, participants will again complete training and outcome measures with the Ottobock Cleg4/Ottobock or their clinically prescribed microprocessor knee unit/foot over 3 visits."
62657756|NCT01692067||D0|Not deployed
62657757|NCT01692067||D1|Deployed to combat-related regions once
62657758|NCT01692067||D2|Deployed to combat related regions more than once
62094154|NCT01924481|EXPERIMENTAL|low theobromine & low caffeine|Drink 1
62094155|NCT01924481|EXPERIMENTAL|low theobromine & high caffeine|Drink 2
62094156|NCT01924481|EXPERIMENTAL|high theobromine & low caffeine|Drink 3
62094157|NCT01924481|ACTIVE_COMPARATOR|no theobromine & high caffeine|Drink 4
62094158|NCT00866216|EXPERIMENTAL|1|Azithromycin Monohydrate 600mg Tablets
62464850|NCT04661384|EXPERIMENTAL|Treatment (IL13Ralpha2-CAR T cells)|Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1. Treatment repeats every 7 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62094159|NCT00866216|ACTIVE_COMPARATOR|2|Zithromax (Azithromycin Dihydrate) 600mg Tablets
62094160|NCT05930899||CVD Group|CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.
62094161|NCT05930899||Control Group|"control groups will be defined as:~1. No echocardiographic evidence of AS (or any aortic valve abnormality) and~2. 60 years of age"
62094162|NCT05292131|EXPERIMENTAL|Test|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-2mL presentation (test).
62094163|NCT05292131|OTHER|Reference|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-1x2mL presentation (reference).
62094164|NCT03805958|EXPERIMENTAL|Pre-procedure|Confirmed landmark by ultrasound scan before procedure
62094165|NCT03805958|ACTIVE_COMPARATOR|Real time|Confirmed landmark by ultrasound scan during procedure
62094166|NCT06581874|SHAM_COMPARATOR|Emergency|Adult patients presenting to the emergency department of the Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, whether or not referred by their general practitioner.
62094167|NCT06581874|EXPERIMENTAL|Med@Psy Platform|Adult patients referred by their general practioner for a psychiatric consultation via the med@psy system.
62094168|NCT02634645||Patients with Barrett's Esophagus|Patients with non-dysplastic Barrett's esophagus, patients with Barrett's related dysplasia which includes low-grade dysplasia, high-grade dysplasia and intramucosal cancer who will be evaluated and treated with endoscopic eradication therapies (EET).
61907831|NCT02057328|ACTIVE_COMPARATOR|NEBIVOLOL|Patients of the group of nebivolol will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP \< 130/80 mm Hg) will continue on the same medication scheme. Patients still classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range 12,5 mg hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
61907832|NCT02057328|ACTIVE_COMPARATOR|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisarta daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP \< 130/80 mm Hg) will continue on the same medication scheme. Patients classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. The same procedure will be repeated at the end of the 6th month from the beginning of the study. Patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
61907833|NCT01830400||Eslicarbazepine Acetate tablets|
62657759|NCT01692067||D3|Deployed outside of the continental US but not to combat related regions
62657760|NCT02803463|ACTIVE_COMPARATOR|Peritoneal Closure|open appendectomy with peritoneal closure
62657761|NCT02803463|ACTIVE_COMPARATOR|Peritoneal Non Closure|open appendectomy without peritoneal closure
62657762|NCT05422508|EXPERIMENTAL|MG1111(BARICELA) arm|0.5ml, single dose, subcutaneous injection
62657763|NCT05422508|ACTIVE_COMPARATOR|VARIVAX arm|0.5ml, single dose, subcutaneous injection
62657764|NCT05422508|ACTIVE_COMPARATOR|Suduvax arm|0.5ml, single dose, subcutaneous injection
62657765|NCT06078670|EXPERIMENTAL|Triple Negative Breast Cancer|CVL218+Toripalimab+Paclitaxel For Injection (Albumin Bound)
61907834|NCT03777462|ACTIVE_COMPARATOR|Group A of neoadjuvant chemotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
61907835|NCT03777462|EXPERIMENTAL|Group B of neoadjuvant chemoradiotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
61907836|NCT03777462|EXPERIMENTAL|Group C of neoadjuvant chemoradiotherapy|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
61907837|NCT04745260|EXPERIMENTAL|Intranasal Midazolam and Intranasal Fentanyl|Study participants assigned to the combination (experimental) group will receive a weight-based dose of intranasal Fentanyl (50mcg/mL concentration at 2mcg/kg up to 100mcg) followed by intranasal Midazolam (5mg/mL concentration at 0.2mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
61907838|NCT04745260|ACTIVE_COMPARATOR|Intranasal Midazolam|Study participants assigned to the control (active comparator) group will receive only intranasal Midazolam (5mg/mL concentration at 0.3mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
62291825|NCT02229773|PLACEBO_COMPARATOR|Placebo|
62291826|NCT02229773|ACTIVE_COMPARATOR|Pravastatin|
62291827|NCT02229773|EXPERIMENTAL|BIBB 1464 MS medium dose|
62657766|NCT06078670|EXPERIMENTAL|Stomach cancer|CVL218+Sintilimab+Paclitaxel Injection
62657767|NCT06078670|EXPERIMENTAL|Intestinal cancer|CVL218+Sintilimab+Fruquintinib
62657768|NCT00984945|ACTIVE_COMPARATOR|H5 VLP vaccine 5 µg|
62657769|NCT00984945|ACTIVE_COMPARATOR|H5 VLP vaccine 10 µg|
62657770|NCT00984945|ACTIVE_COMPARATOR|H5 VLP vaccine 20 µg|
62657771|NCT00984945|PLACEBO_COMPARATOR|Placebo (Formulation buffer)|
62657772|NCT06281249|EXPERIMENTAL|Intrathecal neuraxial procedure|Participants undergoing surgery, receiving neuraxial intrathecal anesthesia with block placement in part by the investigational device.
62657773|NCT03572296|PLACEBO_COMPARATOR|Placebo|No polyphenols or fibre will be delivered in a low sugar drink.
62657774|NCT03572296|EXPERIMENTAL|Polyphenol and fibre|Blackcurrant extract (800 mg total polyphenols) and pulp (source of fibre) will be delivered in a low sugar drink.
62657775|NCT03572296|EXPERIMENTAL|Fibre|Pulp (source of fibre) will be delivered in a low sugar drink.
62657776|NCT04233229|EXPERIMENTAL|closed-loop and home care services|automated insulin delivery system (Closed-loop) with tailored Home Healthcare Provider (HHP) services
62657777|NCT04233229|ACTIVE_COMPARATOR|usual care|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
61907839|NCT02331095|ACTIVE_COMPARATOR|Anticoagulation|Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
61907840|NCT02331095|EXPERIMENTAL|Atorvastatin + anticoagulation|In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment
62094169|NCT02634645||Patients with invasive esophageal cancer|Patients with invasive esophageal cancer who will be treated with surgery (esophagectomy), chemotherapy, radiation, and palliative treatment modalities.
62094170|NCT00708097|EXPERIMENTAL|NaF toothpaste(1450 ppmF)|Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
62094171|NCT00708097|ACTIVE_COMPARATOR|NaF toothpaste (1400 ppmF)|Study toothpaste containing 1400 ppm F as NaF
62464851|NCT02381210||CLINICALLY CONFIRMED PREECLAMPSIA|Pregnant women with clinical diagnosis of preeclampsia (severe, mild or superimposed) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
62657778|NCT00283959|EXPERIMENTAL|Migalastat|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week extension period.
62657779|NCT02565251|EXPERIMENTAL|Sepsis grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
62657780|NCT02565251|EXPERIMENTAL|Sepsis grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
62657781|NCT02565251|EXPERIMENTAL|Soc septic grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
62657782|NCT02565251|EXPERIMENTAL|Soc septic grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
62657783|NCT01179399|EXPERIMENTAL|TAK-960|
61907841|NCT03817047|EXPERIMENTAL|Physical active learning (PAL)|"Three components:~1. Physical education (60 minutes)~2. Physical active learning (30 minutes)~3. Physical activity (30 minutes)"
61907842|NCT03817047|EXPERIMENTAL|Don't worry - be happy|"Two components:~1. Physical education (60 minutes) - don't worry class~2. Physical activity (60 minutes) - be happy class"
61907843|NCT03817047|NO_INTERVENTION|Control group|Current practice
62094172|NCT00708097|ACTIVE_COMPARATOR|NaMFP/NaF toothpaste (1450 ppmF)|Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
62094173|NCT00708097|ACTIVE_COMPARATOR|NaF toothpaste (675 ppmF)|Study toothpaste containing 675 ppm F as NaF
62094174|NCT00708097|PLACEBO_COMPARATOR|Placebo toothpaste (0 ppmF)|Fluoride free placebo toothpaste (0 ppm F)
62094175|NCT04655313|EXPERIMENTAL|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
62094176|NCT04006860|EXPERIMENTAL|SHC014748M: Fast + Fed|Participants will receive a single oral dose of SHC014748M capsules in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fed condition on Day 8 of treatment period 2.
62094177|NCT04006860|EXPERIMENTAL|SHC014748M: Fed + Fast|Participants will receive a single oral dose of SHC014748M capsules in fed condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fasted condition on Day 8 of treatment period 2.
62094178|NCT05186090|EXPERIMENTAL|24-week resistance exercise program|Participants will engage in supervised 24-week resistance exercise program with goal of maintaining 180 minutes of exercise per week.
62094179|NCT05186090|NO_INTERVENTION|Wait-list control group|Control group will be asked to maintain their usual lifestyle.
62291828|NCT02229773|EXPERIMENTAL|BIBB 1464 MS high dose|
62657784|NCT06551805||Safety assessment and the diagnostic value of Ferumoxytol.|Drug Name: Ferumoxytol Dosage Form: Injection Dosage: 3 mg/kg Administration Frequency: Single intravenous injection
62657785|NCT04563325|ACTIVE_COMPARATOR|Experimental|"\< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~=/\> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
62657786|NCT04563325|ACTIVE_COMPARATOR|Standard|"IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:~\< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~\>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
62657787|NCT06228989|EXPERIMENTAL|Extraction therapy|"Patients exclusive treated with extraction therapy of any first permanent molars due to severe MIH.~Affected first permanent molars were dignosed with MIH degree 4-6."
62736812|NCT02579421|ACTIVE_COMPARATOR|Females - Progesterone|200 mg progesterone BID
62291829|NCT04550026|EXPERIMENTAL|Inhalation of HTP|Inhalation of HTP for 30 minutes
62291830|NCT04550026|ACTIVE_COMPARATOR|Sham inhalation of HTP|Sham usage of HTP for 30 minutes
62291831|NCT02467998||NPWT treated wounds|NPWT from any FDA cleared NPWT device including
62291832|NCT05258461|EXPERIMENTAL|The intervention group|The intervention group will receive conventional adverse event management and have access to the smartphone app during chemotherapy.
62291833|NCT05258461|ACTIVE_COMPARATOR|The control group|The control group will receive conventional adverse event management during chemotherapy. Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience.
62291834|NCT06416501||screening|Patients who were detected through any screening test were categorized into the screening group
62291835|NCT06416501||nonscreening|Patients who were detected based on symptoms formed the non-screening group.
62291836|NCT01982591||Ancillary-Correlative (heavy metal and neurotoxicity)|Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment.
62291837|NCT01271140|EXPERIMENTAL|Insulin/dextrose clamp|
62657788|NCT06228989|EXPERIMENTAL|Restorative therapy|"Patients exclusive treated with restorative therapy of any first permanent molars due to severe MIH.~Affected first permanent molars were dignosed with MIH degree 4-5."
62657789|NCT06228989|EXPERIMENTAL|Extraction therapy and Restorative therapy|"Patients undergoing combined treatment of both extraction therapy and restorative therapy of their first permanent molars due to MIH.~Affected first permanent molars treated with extraction therapy were dignosed with MIH degree 6.~Affected first permanent molars treated with restorative therapy were dignosed with MIH degree 4-5."
62657790|NCT06228989|NO_INTERVENTION|Control patients|Patients devoid of any enamel developmental defects, attending the Public Dental Service in Region Västra Götaland, constituted a basis for the control patients. These controls were matched in terms of gender, age, and socio-economic factors, with each study patient paired with seven potential control patients.
62657791|NCT00733434|EXPERIMENTAL|1|Patients receiving PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
62657792|NCT00733434|PLACEBO_COMPARATOR|2|Patients receiving 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
62657793|NCT00432432|PLACEBO_COMPARATOR|2|placebo with infliximab
62657794|NCT06027437|EXPERIMENTAL|Treatment A|
62657795|NCT06027437|EXPERIMENTAL|Treatment B|
62657796|NCT06027437|EXPERIMENTAL|Treatment C|
62657797|NCT03276299|ACTIVE_COMPARATOR|test 1|six minute walking test
62657798|NCT03276299|EXPERIMENTAL|test 2|six minute walking test
62657799|NCT03276299|EXPERIMENTAL|test with encouragement|six minute walking test
62657800|NCT03276299|ACTIVE_COMPARATOR|test without encouragement|six minute walking test
62657801|NCT03507101||Invasive GAS infection study patients|
62657802|NCT03047252|EXPERIMENTAL|Experimental group|"Home-based rehabilitation sessions performed with the novel digital biofeedback system.~Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol."
62657803|NCT03047252|ACTIVE_COMPARATOR|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
62657804|NCT03196141|ACTIVE_COMPARATOR|Healthy volunteers|"Part#1: 15 healthy volunteers; 2 assessment sessions. Session 1: StO2 vs. EndoPAT Method comparison analysis; both StO2 and EndoPAT will be applied simultaneously \& pulse oximeter probes placed bilaterally on fingers. Baseline readings will be taken for 5 minutes. The blood pressure cuff will be inflated to suprasystolic pressure and StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Session 2: This session will occur within 1 week of session 1. This session is to determine the consistency of the response.~All probes will be applied as in session 1 and cycles of 10 minutes for 3 sessions will be done. All the measurements in session 1 will be captured in session 2.~This will determine inter-day variability. (total time is 53 min)."
62736813|NCT02579421|PLACEBO_COMPARATOR|Females - Placebo|placebo BID
62094180|NCT04359056|NO_INTERVENTION|control|patients for the observational phase. This corresponds to usual cares where no clinical pharmacy activities will be performed
62291838|NCT04653519|EXPERIMENTAL|Virtually guided minimally invasive preparation|
62736814|NCT01948219|EXPERIMENTAL|ENTegral Artificial Larynx implant|ENTegral Artificial Larynx implantation
62291839|NCT05850078|EXPERIMENTAL|FB101|Microbial intervention using product FB101
62291840|NCT05850078|EXPERIMENTAL|FB101 diluted|Microbial intervention using diluted FB101
62291841|NCT05850078|PLACEBO_COMPARATOR|Placebo|Saline water
62291842|NCT01147926|PLACEBO_COMPARATOR|Placebo|Placebo
62291843|NCT01147926|ACTIVE_COMPARATOR|Prucalopride|1 milligram (mg) or 2 mg
62291844|NCT03156803|EXPERIMENTAL|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
62291845|NCT03156803|NO_INTERVENTION|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
62291846|NCT00267735|NO_INTERVENTION|Module 1 Only|
62291847|NCT00267735|EXPERIMENTAL|Modules 1, 2, and 3|
62291848|NCT03268356|OTHER|AGN1 Treatment|Subjects who have suffered a fragility hip fracture in one hip, sign the consent form and meet the inclusion and none of the exclusion of the study will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) in the non-fractured hip.
62291849|NCT00895063|EXPERIMENTAL|Vocal Exercise|Subject will speak continually for one hour following injection of botulinum toxin.
62291850|NCT00895063|PLACEBO_COMPARATOR|Silence|Subject will remain silent for one hour following injection of botulinum toxin.
62291851|NCT04852640|EXPERIMENTAL|Active Rehabilitation Program (ARP)|Participants will be treated for symptomatic shoulder instability with the evidence-based, targeted treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. Exercises in the ARP include: Low-load and high-duration rotator cuff strengthening exercises, progressive scapular muscle endurance training, plyometric strengthening exercises, and surface electromyographic (EMG) biofeedback. Each prescribed exercise in the ARP will be increased to match the participant's function at the discretion of the study clinician. Although the components of the ARP will be pre-determined, the parameters and volumes of the components will be determined and documented over the treatment phase.
62657805|NCT03196141|ACTIVE_COMPARATOR|Pregnant women with normal BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness."
62657806|NCT03196141|ACTIVE_COMPARATOR|Pregnant women with high BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness.~Participants with hypertension will be followed in conjunction with routine clinical follow-up at 2, 6 and 12 weeks post-partum."
62657807|NCT00250588|EXPERIMENTAL|Problem solving + care coordination|Problem solving skills training and asthma care coordination
62657808|NCT00250588|EXPERIMENTAL|Asthma care coordination|Asthma care coordination
62657809|NCT00250588|ACTIVE_COMPARATOR|Wait-list control|Usual care
62657810|NCT03176914|EXPERIMENTAL|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
62657811|NCT03176914|ACTIVE_COMPARATOR|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
62657812|NCT04004182|ACTIVE_COMPARATOR|OGTT session|Oral Glucose Tolerance test (OGTT)
62657813|NCT04004182|ACTIVE_COMPARATOR|Fruit bar|Fruit bar Plus Oral Glucose Tolerance test (OGTT)
62464852|NCT02381210||CLINICALLY HEALTHY|Pregnant women admitted to the hospital for delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
62291852|NCT04852640|EXPERIMENTAL|Nonspecific Passive Intervention (NPI)|Participants will be treated for symptomatic shoulder instability with the non-specific, generalized treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. The NPI consists of a general approach to treating shoulder pain with passive modalities for pain modulation. These interventions are commonly practiced but have little evidence to support their use in the treatment of symptomatic shoulder instability. Although the components of the NPI will be pre-determined, the parameters and volumes of the components will be determined and documented by a study clinician over the treatment phase.
62464853|NCT05833581|EXPERIMENTAL|Single Intervention Study Arm|All participants with HF will be evaluated by their HF providers who will use the NYHA Classification Guide to assist with assignment of HF class. The participant will then complete a 6-minute walk test. Subsequently participating providers will utilize the guide to assess and assign the class of their HF patients in practice.
62464854|NCT03518281|PLACEBO_COMPARATOR|Placebo|
62464855|NCT03518281|EXPERIMENTAL|Treatment|Whole Cell Euglena delivering βeta Glucan
62464856|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
62464857|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
62464858|NCT02312700|EXPERIMENTAL|Interactive empowerment (IEm) group|Intervention: Patients fill in the questionnaire online and their profile (obtained from their answers) is immediately sent to the physician
62464859|NCT02312700|SHAM_COMPARATOR|Control|Intervention: Patients fill in the questionnaire online, but their profile (obtained from their answers) is not sent to the physician
62657814|NCT04004182|EXPERIMENTAL|Fruit bar with bilberry|Fruit bar with addition of 600 mg bilberry anthocyanins Plus Oral Glucose Tolerance test (OGTT)
62657815|NCT04004182|EXPERIMENTAL|Fruit bar with bilberry and apple|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols Plus Oral Glucose Tolerance test (OGTT)
62094181|NCT04359056|EXPERIMENTAL|Interventional|patients for the interventional phase where clinical pharmacy activities will be performed at each step of the care pathway: from hospitalization to home care.
62291853|NCT04812561|EXPERIMENTAL|Bronch™ group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day, 800 mg/day as Bronch™)
62464860|NCT03681145|EXPERIMENTAL|Group A-Intervention|Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
62464861|NCT03681145|EXPERIMENTAL|Group B-Wait-list|Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
62464862|NCT02602041||Patients with breast cancer and partners|We will invite 10 women with early stage breast cancer (BC) and their partners for a semi-structured interview.
62464863|NCT02602041||Patients with testicular cancer and partners|We will invite 10 men with disseminated testicular cancer (TC) and their partners for a semi-structured interview.
62737522|NCT05407012|EXPERIMENTAL|Intervention of the barrier enhancing preparation|Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
62094182|NCT04155853|ACTIVE_COMPARATOR|Interposition Arthroplasty|Fascia lata interposition arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
62291854|NCT04812561|PLACEBO_COMPARATOR|Placebo group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day)
62291855|NCT03982550|NO_INTERVENTION|Control Period|Participants will serve as their own controls. All 12-week control periods will take place before the RT intervention to ensure that results are not confounded by detraining effects or long-term cognitive benefits of RT. In addition, a control period equal in duration to the intervention allows direct within-subjects statistical comparisons, accounting for each participants' baseline and rate of aging - i.e. age-associated cognitive decline and arterial stiffening. Participants will not be monitored, but may be contacted for scheduling.
62291856|NCT03982550|EXPERIMENTAL|Intervention Period|Participants will perform a periodized and progressive total-body RT program emphasizing development of lower and upper body strength. All 36 training sessions (3 days per week for 12 weeks) will be performed at the CERC, supervised by an exercise specialist. Participants will be encouraged to continue normal activities of daily living and eating routines outside the RT program of the present study. Because this is a proof-of concept study on normal aging, participants may be contacted for scheduling, but will not be monitored outside of training.
62291857|NCT03807531|OTHER|Treatment with TSS|This is a single-arm study. Participating subjects will be treated with the Temporary Spur Stent System (TSS)
62291858|NCT04323371||Acute decompensated heart failure|patients admitted with Acute decompensated heart failure Complicated by cardiogenic shock
62464864|NCT01739101|EXPERIMENTAL|Intervention group|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
62464865|NCT01739101|NO_INTERVENTION|Control group 1|The control group 1 answered a baseline questionnaire in the waiting room and received standard care.
62464866|NCT01739101|NO_INTERVENTION|Control group 2|The control group 2 received standard care.
62464867|NCT00560443|ACTIVE_COMPARATOR|1|children 4-17 y. old with not compound bone fracture treated with ketorolac
62657816|NCT01562444|OTHER|TBE_R Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to rapid (R) schedule i.e., on days 0, 7 (+3) and 21 (+7) in the parent study (V48P7) and who were administered 1 booster dose of Encepur adults either 12-18 months after R schedule completion or in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination (for those subjects boostered before V48P7E1 study start, the blood draw occurred annually starting from \>6 years up to \>10 years after booster vaccination).
61907844|NCT04754945|EXPERIMENTAL|Treatment (isatuximab, chemotherapy)|"All patients will receive Isatuximab plus dexamethasone 4 mg PO/IV days weekly. Based on tolerance, patients will add to their treatment subcutaneous Velcade (earliest time to add Velcade is cycle 1 day 15) and intravenous cyclophosphamide (earliest time to add cyclophosphamide is cycle 4 day 1)~Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month for 12 months in the absence of disease progression or unacceptable toxicity."
62094183|NCT04155853|ACTIVE_COMPARATOR|Hematoma and Distraction Arthroplasty|Hematoma and Distraction Arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
62291859|NCT04126824|ACTIVE_COMPARATOR|Bupivacaine|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine and contrast to enable visualization of the nerve block under fluoroscopy.
62464868|NCT00560443|EXPERIMENTAL|2|children 4-17 y. old with not compound bone fracture treated with tramadol
62464869|NCT03006445|EXPERIMENTAL|FYU-981|
62657817|NCT01562444|OTHER|TBE_C Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
62657818|NCT01562444|OTHER|TBE_AC Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to accelerated conventional (AC) schedule i.e., on days 0, 14 (+3) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
62657819|NCT01922193|EXPERIMENTAL|Test Group|
62657820|NCT01922193|ACTIVE_COMPARATOR|Control Group|
62657821|NCT04709887|OTHER|Rate of popliteal artery stenosis < 50%, W.|If the rate of popliteal artery stenosis of patients \< 50%, the patients only receive the wound treatment.
62657822|NCT04709887|OTHER|Rate of popliteal artery stenosis < 50%, WT.|If the rate of popliteal artery stenosis of patients \< 50%, the patients receive the wound treatment and tibial transverse transport surgery.
62657823|NCT04709887|OTHER|Rate of popliteal artery stenosis ≥ 50%, WV.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and vascular intervention surgery.
62657824|NCT04709887|OTHER|Rate of popliteal artery stenosis ≥ 50%, WT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and tibial transverse transport surgery.
62657825|NCT04709887|OTHER|Rate of popliteal artery stenosis ≥ 50%, WVT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment, vascular intervention and tibial transverse transport surgery.
62657826|NCT01795612|OTHER|Arm A|6-month ETP, during adjuvant or neoadjuvant therapy
61907845|NCT01608256||mild cognitive impairment|men and women, aged 50 to 70. The inclusion criteria are:diagnosis of MCI (given by a neurologist), valid driver's license and driving experience of at least a year. the exclusion criteria are: people diagnosed with other neurological damage such as: dementia, CVA and head injury, people with sensory or motor impairment.
62094184|NCT05750030|EXPERIMENTAL|FMT combined with Atezolizumab plus Bevacizumab|
62094185|NCT01637558|NO_INTERVENTION|Main TB cohort|Children with tuberculosis 0-12 years of age
62094186|NCT01637558|EXPERIMENTAL|Lopinavir/Ritonavir - Cases|children 3-20 kg with tuberculosis and indication for LPV/r-based ART
62657827|NCT01795612|OTHER|Arm B|6-month ETP, after adjuvant or neoadjuvant therapy
62657828|NCT01795612|OTHER|Arm C|12-monthETP, during and after adjuvant or neoadjuvant treatment
62657829|NCT03883373||Cortical group|Group of patient who had an alveolar bone graft with cancellous bone and a cortical block
62657830|NCT03883373||Cancellous group|Group of patient who had an alveolar bone graft with cancellous bone only
62657831|NCT00480116|ACTIVE_COMPARATOR|1|
62657832|NCT00480116|ACTIVE_COMPARATOR|2|
62094187|NCT01637558|EXPERIMENTAL|Lopinavir/Ritonavir - Controls|Children 3-20 kg on LPV/r-based ART; no TB
62094188|NCT01637558|EXPERIMENTAL|Nevirapine arm|children with TB and indication for nevi rapine-based ART
62464870|NCT06079645|ACTIVE_COMPARATOR|Triamcinolone acetonide (2mg/ml) injections through syringes and needles|Triamcinolone at a concentration of 2mg/ml will be injected on one side of the randomized vulva using a syringe and needle.
62464871|NCT06079645|ACTIVE_COMPARATOR|Triamcinolone acetonide (40mg/ml) through microinjections with needles|Triamcinolone at a concentration of 40mg/ml will be injected on the other side of the randomized vulva using a tattoo machine.
62464872|NCT03613922|EXPERIMENTAL|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
62464873|NCT03613922|ACTIVE_COMPARATOR|Routine Physiotherapy Group|Only routine physiotherapy program was applied
62464874|NCT01636609|EXPERIMENTAL|Arm I (tosedostat, cytarabine)|Participants receive tosedostat PO QD on days 1-28 and cytarabine SC BID on days 1-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62464875|NCT01636609|EXPERIMENTAL|Arm II (tosedostat, azacitidine)|Participants receive tosedostat PO QD on days 1-28 and azacitidine IV over 10-40 minutes or SC on days 1-7. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62094189|NCT05938868|EXPERIMENTAL|Group A (LIPUS group)|This group will include 17 patients who received Dental Implant Surgery. Patients will be treated with low intensity pulsed ultrasound in addition to standard care.
62094190|NCT05938868|EXPERIMENTAL|Group B (LLLT group)|This group will include 17 patients who received Dental Implant Surgery. The patients will be irradiated with low level diode laser therapy (GaAs) in addition to standard care.
62094191|NCT05938868|ACTIVE_COMPARATOR|Group C (Control group)|This group will include 17 patients who received Dental Implant Surgery. Patients will be treated with standard care only after surgery for 2 weeks.
62464876|NCT04881903|EXPERIMENTAL|MIST intervention followed by MIRA intervention|These are both mobile interventions that use interpretation bias modification (IBM) techniques to reduce cognitive biases. The MIST app targets suicidal cognitions and the MIRA app targets hostile interpretation bias (which contributes to anger). The MIRA application has already been developed, but the MIST application is newly developed based on the same procedures. All participants will complete the MIST intervention and provide feedback so that we can refine it. We will also be collecting EMA data on to examine how changes to suicide cognitions and hostile interpretation bias (by use of the two apps) affects suicidal ideation and functioning.
62464877|NCT05962879|EXPERIMENTAL|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for teens at risk of a mental illness.
62464878|NCT05962879|NO_INTERVENTION|Waitlist|A one year waitlist period where participants will not participate in Resilience Training for Teens. Following that one year waitlist period, they can participate in Resilience Training for Teens.
62464879|NCT01346163|ACTIVE_COMPARATOR|PF-03654746|H3 receptor antagonist currently being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS) as well as with Alzheimer's disease.
62464880|NCT01346163|PLACEBO_COMPARATOR|Placebo|
62464881|NCT02512393|EXPERIMENTAL|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
62464882|NCT02512393|SHAM_COMPARATOR|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
62464883|NCT00911898|EXPERIMENTAL|MM-111|
62464884|NCT02412215|EXPERIMENTAL|Toric Nanoflex IOL|Phacoemulsification with toric Nanoflex IOL implantation
62464885|NCT00720330|ACTIVE_COMPARATOR|Ropivacaine|Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
62464886|NCT00720330|ACTIVE_COMPARATOR|Lidocaine/ketamine|Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
62464887|NCT00720330|PLACEBO_COMPARATOR|Placebo|General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery
62094192|NCT01235429|EXPERIMENTAL|Educational|Participants will receive 12 diabetes self-management educational lessons in a small group setting located within the participating communities and delivered by trained community health workers.
62464888|NCT01582126|EXPERIMENTAL|Group balance training early start|
62094193|NCT01235429|ACTIVE_COMPARATOR|Delayed education|The delayed education group will receive the same intervention after the intervention group has completed the educational lessons and all participants have completed the follow-up assessments.
62291860|NCT04126824|EXPERIMENTAL|Bupivacaine and Triamcinolone|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine plus triamcinolone mixed with contrast to enable visualization of the nerve block under fluoroscopy.
62464889|NCT01582126|EXPERIMENTAL|Group balance training late start|
62464890|NCT05300139||Patients included in the ULTREC study who had a recurrence of deep vein thrombosis|Patients who have a baseline CDUS diagnosis of recurrent DVT as identified in the ULTREC study.
62464891|NCT06341322|NO_INTERVENTION|Control|Participants do not receive a reminder letter, which is treatment as usual.
62464892|NCT06341322|EXPERIMENTAL|Standard letter|Participants receive a reminder letter which is based on the current colorectal cancer screening invitation.
62464893|NCT06341322|EXPERIMENTAL|Behaviorally informed letter|Participants receive a reminder letter which incorporates several behavioral components, including an active choice prompt, social norm, simplification, chunking and call to action.
62657833|NCT00480116|ACTIVE_COMPARATOR|3|
62657834|NCT02341079|ACTIVE_COMPARATOR|Femoral Nerve Blockade|Femoral nerve block delivered via indwelling femoral nerve catheter
62094194|NCT01403844|OTHER|Skin Carotenoids|Skin carotenoids will be measured under conditions of depletion or repletion
62291861|NCT00476099|EXPERIMENTAL|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|
62291862|NCT00476099|ACTIVE_COMPARATOR|Budesonide 200 µg plus formoterol 6 µg DPI|
62291863|NCT00476099|ACTIVE_COMPARATOR|Formoterol 12 µg DPI|
62291864|NCT01662648|EXPERIMENTAL|Paliperidone ER: Lack of efficacy|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.
61907846|NCT01608256||Healthy people|Men and women, ages 50-70. the inclusion criteria are: healthy people with out neurological disease or psychiatric illness, have valid driver's license and driving experience of at least a year.
62094195|NCT04568096|ACTIVE_COMPARATOR|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
62094196|NCT04568096|PLACEBO_COMPARATOR|The standard therapy|The infected patients will receive the standard therapy for COVID-19 for 14 days
62094197|NCT03176134|EXPERIMENTAL|Cohort 1: Tedizolid phosphate 6 to <12 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.
62094198|NCT03176134|ACTIVE_COMPARATOR|Cohort 1: Comparator 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.
62094199|NCT03176134|EXPERIMENTAL|Cohort 2: Tedizolid phosphate 2 to <6 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.
62094200|NCT03176134|ACTIVE_COMPARATOR|Cohort 2: Comparator 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.
62094201|NCT03176134|EXPERIMENTAL|Cohort 3: Tedizolid phosphate 28 Days to <2 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.
62094202|NCT03176134|ACTIVE_COMPARATOR|Cohort 3: Comparator 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.
62094203|NCT03176134|EXPERIMENTAL|Cohort 4: Tedizolid phosphate Birth to <28 Days Term and Preterm Neonates|Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study (NCT03217565) covering the age range.
62094204|NCT03176134|ACTIVE_COMPARATOR|Cohort 4: Comparator Birth to <28 Days Term and Preterm Neonates|Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days.
62464894|NCT06341322|EXPERIMENTAL|Behaviorally informed letter + testing kit|Participants receive the behaviorally informed letter plus the colorectal home testing kit, which removes the current barrier of having to request a kit.
62464895|NCT00528606|EXPERIMENTAL|AA4500 0.58 mg|
62657835|NCT02341079|EXPERIMENTAL|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of bupivacaine liposome
62657836|NCT06319833|EXPERIMENTAL|Physical activity interacting with a video|This experimental condition involves engaging in physical activity interspersed with rest periods. The type of exercises are based on phase I.
62657837|NCT06319833|NO_INTERVENTION|Control condition|
62657838|NCT01605903|EXPERIMENTAL|Treatment with Ibuprofen|Children in the experimental group will receive grape-flavored ibuprofen 100mg/5 mL. Ibuprofen will be dispensed at 10mg/kg (max dose 600 mg) will be dispensed Q6 hours x 9 days.
62657839|NCT01605903|ACTIVE_COMPARATOR|Treatment with Acetaminophen|Children in the active comparator group will receive grape flavored acetaminophen 160 mg/5 ml. Acetaminophen will be dispensed at 15 mg/kg (max dose 650/mg) Q6 hours x 9 days.
61907847|NCT00201162|EXPERIMENTAL|Intervention|dietary supplement soy protein containing isoflavones
61907848|NCT00201162|PLACEBO_COMPARATOR|Placebo|dietary supplement casein placebo
61907849|NCT02160132|EXPERIMENTAL|A 1-2-3Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
62094205|NCT04304469||women|women consulting for domestic violence
62094206|NCT01260974|EXPERIMENTAL|Caspofungin|Study group
62094207|NCT00716664|EXPERIMENTAL|1|The experimental group receives the intervention in addition to normal optimal care
62094208|NCT00716664|ACTIVE_COMPARATOR|2|The active comparator, or control group, receives normal optimal care only
62094209|NCT02675855|EXPERIMENTAL|GrafixPRIME®|GrafixPRIME® is cryopreserved human placental membrane Patients will be fitted with off-loading devices
62094210|NCT02675855|ACTIVE_COMPARATOR|Active Comparator|Wound cover, Dressing Application Patients will be fitted with off-loading devices
62464896|NCT00528606|PLACEBO_COMPARATOR|Placebo|
62464897|NCT03366805|ACTIVE_COMPARATOR|Wound Care Video|Wound Care Patient Education Video
62464898|NCT03366805|EXPERIMENTAL|Pain Management Video Group|Pain Management Patient Education Video
62464899|NCT02403765||Family cases|Family-based Parkinson patients carrying genetic variants associated with the disease
62464900|NCT02403765||Family controls|Family-based Control subjects
62464901|NCT03233646||Case|Patients with (MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)
62464902|NCT03233646||Controls|Controls will be recruited from the relatives/attendants of study participants or will be patients themselves and will not have a neurodegenerative disease diagnosis.
62657840|NCT05073471|EXPERIMENTAL|PSE Only|Participants will exercise their hands, arms, shoulders, and torso with musical cues provided by neurologic music therapist. A simple gross/fine movements and emotional level will be assessed before and after each session. During the session, participants will be measured their brainwaves using electroencephalography (EEG) to understand their neurophysiological responses. Participant's motion will be also captured to acquire kinematic quantities.
62657841|NCT05073471|EXPERIMENTAL|PSE+tDCS|Participants in this group will proceed with the same procedure as PSE only group, but tDCS modulation will be additionally provided.
62657842|NCT05106569||SUNY Upstate|One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.
62657843|NCT05106569||Atrium Health|One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.
62657844|NCT05939167|PLACEBO_COMPARATOR|placebo control|use saline
62657845|NCT05939167|EXPERIMENTAL|mesenchymal stem cells standard treatment|transplant mesenchymal stem cells for 3 times
62657846|NCT05939167|EXPERIMENTAL|mesenchymal stem cells enhanced treatment|transplant mesenchymal stem cells for 6 times
62657847|NCT02969018|EXPERIMENTAL|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
62291865|NCT01662648|EXPERIMENTAL|Paliperidone ER: Lack of tolerability, compliance or other|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.
62094211|NCT06148753|EXPERIMENTAL|Eternal Renewal Regenerating Face Serum|"Participants will be required to apply the test product in the morning and before sleeping at night.~After thoroughly cleansing and toning the face, the participants will apply 2-3 drops onto clean dry fingers and massage over the entire face until fully absorbed.~The product should be followed with the participants' preferred moisturizer."
62291866|NCT02327299|EXPERIMENTAL|FePP|Bouillon fortified with 4mg FePP
62464903|NCT00841178|ACTIVE_COMPARATOR|Surgery|Patients undergo Surgery under a general anaesthetic.
62464904|NCT00841178|EXPERIMENTAL|EVLT|Patients undergo EVLT under a local anaesthetic.
62657848|NCT02969018|EXPERIMENTAL|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
62657849|NCT02969018|EXPERIMENTAL|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
62094212|NCT00185484|EXPERIMENTAL|Arm 1|
62094213|NCT05406492||Patients udergoing ECMO|Population who have been taking antibiotics or antiplatelets or sedatives/analgesics during Extracorporeal Membrane Oxygenation
62094214|NCT02522052|EXPERIMENTAL|Blue mussel diet|5 meals a week including blue mussels
62094215|NCT02522052|ACTIVE_COMPARATOR|Meat/control diet|5 meals a week including meat
62094216|NCT05675371||1a - Typically developing (ages 16-30 months)|Typically developing toddlers ages 16 - 30 months (chronological age).
62094217|NCT05675371||1a - ASD/DD (ages 16-30 months)|Toddlers ages 16-30 months with autism spectrum disorder and/or related developmental delay who are undergoing applied behavioral analysis (ABA) or related therapies.
62094218|NCT05675371||1b - Typically developing (ages 31-84 months)|Typically developing children ages 31-84 months (chronological age).
62094219|NCT05675371||1b - ASD/DD (ages 31-84 months)|Children ages 31-84 months with autism spectrum disorder and/or related developmental delay who are undergoing applied behavioral analysis (ABA) or related therapies.
62291867|NCT02327299|EXPERIMENTAL|FePP + Stabilizer|Bouillon fortified with 4mg FePP + Stabilizer
62291868|NCT02327299|EXPERIMENTAL|FeSO4|Bouillon fortified with 4mg FeSO4
62291869|NCT02327299|EXPERIMENTAL|FeSO4 + Stabilizer|Bouillon fortified with 4mg FeSO4 + Stabilizer
62291870|NCT01300104|EXPERIMENTAL|Exercise and whole grain rye|
62291871|NCT01300104|ACTIVE_COMPARATOR|No prescriptions|
62291872|NCT01790490|EXPERIMENTAL|K1|Ketamine 0.41 mg/kg infused over 52 min (K1)
62291873|NCT01790490|EXPERIMENTAL|K2|Ketamine 0.71 mg/kg infused over 52 min (K2)
62291874|NCT01790490|EXPERIMENTAL|LZP|Lorazepam 2 mg infused over 52 minutes (LZP)
62291875|NCT06314087|ACTIVE_COMPARATOR|Control arm: Arm #1|
62291876|NCT06314087|EXPERIMENTAL|Experimental arm: Arm #2|Personalized tumor peptide vaccine + conventional treatment including radiotherapy group
62291877|NCT02935972|ACTIVE_COMPARATOR|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
62464905|NCT05636241|ACTIVE_COMPARATOR|control group|The participants in the control group will be attended to conventional physiotherapy program.
62464906|NCT05636241|EXPERIMENTAL|study group|The participants in the study group will be attended to whole body vibration training program.
62464907|NCT01772537|NO_INTERVENTION|Open repair of thoracoabdominal aneurysms|These will be patients undergoing an open repair of thoracoabdominal aneurysms with or without cardiopulmonary bypass. The will be observational only.
62464908|NCT01772537|ACTIVE_COMPARATOR|Stent graft repair of thoracoabdominal aneurysms isoflurane|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive isoflurane as their primary anesthetic.
62657850|NCT02969018|EXPERIMENTAL|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
62657851|NCT02969018|EXPERIMENTAL|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
61907850|NCT02160132|ACTIVE_COMPARATOR|B 1-3-5Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
61907851|NCT04903470|EXPERIMENTAL|Effect of atropine on the defecation|Atropine is an anticholinergic drug and expected to inhibit rectal contractions and inhibit evacuation of the rectal balloon. Each subject will be studied twice once with and once without atropine.
62291878|NCT02935972|ACTIVE_COMPARATOR|Local|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
62291879|NCT02935972|ACTIVE_COMPARATOR|Combined|received intravenous diazepam 5 mg slowly just before TRUS probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
62291880|NCT02800460|OTHER|Deep brain stimulation with fMRI-3T|Patients will have a 3T-fMRI before their usual MRI-1,5T
62291881|NCT03968419|EXPERIMENTAL|Canakinumab monotherapy|Participants received 200 mg of canakinumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
61907852|NCT04903470|EXPERIMENTAL|Effect of bisacodyl on the defecation|Bisacodyl is a stimulant of rectal contraction and expected to facilitate evacuation of rectal balloon (fecobionics device). Each subject will be studied twice, once with and once without bisacodyl.
62094220|NCT04339218|EXPERIMENTAL|Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin|Cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
62094221|NCT04339218|ACTIVE_COMPARATOR|Arm pembrolizumab-pemetrexed-carboplatin|Combination of Pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
62094222|NCT04488874|EXPERIMENTAL|Sodium Lactate|Intravenous Molar Sodium Lactate is administered during the first surgical incision. The dose is 2.5mL/kg.
62094223|NCT04488874|ACTIVE_COMPARATOR|Mannitol 20%|Intravenous mannitol 20% is administered during the first surgical incision. The dose is 5mL/kg (1g/kg).
62094224|NCT04230161||Standard LLIN|This group receives Yahe LN ITNs during the mass distribution campaign.
62094225|NCT04230161||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
62094226|NCT04230161||Standard LLIN and IRS|This group receives Yahe LN ITNs during the mass distribution campaign and IRS.
62094227|NCT04837950|EXPERIMENTAL|Before pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview before pulling diaphragmatic suture
62094228|NCT04837950|EXPERIMENTAL|After pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview after pulling diaphragmatic suture
62094229|NCT02833454|ACTIVE_COMPARATOR|direct insertion single bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using single bundle technique.
62291882|NCT03968419|EXPERIMENTAL|Canakinumab + pembrolizumab|Participants received 200 mg of canakinumab in combination with 200 mg of pembrolizumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
62291883|NCT03968419|EXPERIMENTAL|Pembrolizumab monotherapy|Participants received 200 mg of pembrolizumab every 3 weeks for a maximum duration of 6 weeks prior to surgery
62291884|NCT03906682|EXPERIMENTAL|RAP Club program|RAP Club is a 12-session universal prevention program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
62291885|NCT03906682|ACTIVE_COMPARATOR|Healthy Topics program|Like RAP Club, Healthy Topics is a 12-session program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
62291886|NCT02627040|ACTIVE_COMPARATOR|InterTan Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail with an InterTan device (two-integrated screws)
62291887|NCT02627040|ACTIVE_COMPARATOR|Gamma 3 Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail and Gamma 3 locking nail (single screw)
62291888|NCT04607395||pre-operative radiographs of deep carious lesion|
62291889|NCT05051956||CDK4/6 inhibitors|The patient who is started on one of the CDK 4/6 inhibitors (palbociclib 125 mg 3 weeks on 1 week off) or ribociclib 600 mg 3 weeks on 1 week off) will be followed up for adverse events.
62291890|NCT06146894|EXPERIMENTAL|Single cone technique (Bioceramic Sealer)|
62291891|NCT06146894|EXPERIMENTAL|lateral condensation technique (Bioceramic Sealer)|
62291892|NCT06146894|EXPERIMENTAL|Warm Vertical condensation technique (Bioceramic Sealer)|
62291893|NCT06146894|EXPERIMENTAL|lateral condensation technique (AH plus Sealer)|
62291894|NCT06146894|EXPERIMENTAL|Warm Vertical condensation technique (AH plus Sealer)|
61907853|NCT04955678|EXPERIMENTAL|ZG-801|
61907854|NCT04955678|PLACEBO_COMPARATOR|Placebo|
61907855|NCT01253707|EXPERIMENTAL|Dose Escalation|
61907856|NCT01640431|EXPERIMENTAL|Lumbar stabilization exercises|In the Segmental Stabilization group exercises the focus is on the transversus abdominis and lumbar multifidus muscles.
61907857|NCT01640431|EXPERIMENTAL|TENS group|In this group, patients are treated with TENS in the lumbar region for an hour.
61907858|NCT00678678|ACTIVE_COMPARATOR|I - Spirometer|
61907859|NCT00678678|ACTIVE_COMPARATOR|II - Kit Epap®|Device with Spring load by mask,produced by Brazil (critical med)
62094230|NCT02833454|EXPERIMENTAL|anatomical double bundle ACLR|Patients with ACL rupture undergo double bundle anterior cruciate ligament reconstruction.
62094231|NCT02833454|EXPERIMENTAL|anatomical single bundle ACLR|Patients with ACL rupture undergo single bundle anterior cruciate ligament reconstruction.
62094232|NCT02833454|ACTIVE_COMPARATOR|direct insertion double bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using double bundle technique.
62094233|NCT06542432|EXPERIMENTAL|Experimental: Intervention|Participants will receive their integrated risk score result for coronary artery disease.
62094234|NCT06542432|NO_INTERVENTION|No Intervention: Control|Participants will only receive standard of care ASCVD Pooled Cohorts Equation (ASCVD PCE), and disclosure of integrated risk score result will be deferred until 3 years after enrollment.
62291895|NCT04839861|ACTIVE_COMPARATOR|Mightier Online Games|6 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier online games at least 3 times a week for the 6 week duration.
62094235|NCT06490523||ICU survivors|Acute hypoxemic respiratory failure patients on invasive mechanical ventilation who survive to ICU discharge
62094236|NCT06490523||ICU non-survivors|Acute hypoxemic respiratory failure patients on invasive mechanical ventilation who do not survive to ICU discharge
62464909|NCT01772537|ACTIVE_COMPARATOR|Stent graft repair of thoracoabdominal aneurysms propofol|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive propofol as their primary anesthetic.
62464910|NCT02325141|ACTIVE_COMPARATOR|LSG|patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
62464911|NCT02325141|ACTIVE_COMPARATOR|BTX-LSG|patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
62464912|NCT00584922||AF ablation group|Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
62094237|NCT04744662|EXPERIMENTAL|Treatment Group A|ONL1204 Ophthalmic solution (dose A) administered by intravitreal injection
62094238|NCT04744662|EXPERIMENTAL|Treatment Group B|ONL1204 Ophthalmic solution (dose B) administered by intravitreal injection
62094239|NCT04744662|SHAM_COMPARATOR|Treatment Group C|sham injection without penetrating the eye
62291896|NCT04839861|EXPERIMENTAL|Mightier Online Plus Offline Family Games|6 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier online games at least 3 times a week for the 6 week duration. Parents will be encouraged to play Mightier offline Family Games at least once a week for the 6 week duration.
62464913|NCT00724477||Subjects treated with INEGY|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY
62464914|NCT00377390||Cockroach sensitive|
62291897|NCT02419027|EXPERIMENTAL|GI Flora|Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
62464915|NCT00377390||Control (cockroach insensitive)|
62464916|NCT00408070|EXPERIMENTAL|I|This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
62464917|NCT02400957|EXPERIMENTAL|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized.
62464918|NCT02400957|EXPERIMENTAL|Placebo|Half of the mouth was applied placebo. Allocation was randomized.
62464919|NCT01658228|OTHER|Donepezil Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
62464920|NCT01658228|OTHER|Placebo Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
62464921|NCT01658228|OTHER|Citalopram|An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
61907860|NCT03470727|EXPERIMENTAL|Citrate arm|Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free
61907861|NCT02891928|EXPERIMENTAL|with rocker sole|patient were wearing the rocker soles shoes during investigation
62657852|NCT02969018|EXPERIMENTAL|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
62094240|NCT00487721|EXPERIMENTAL|Silibin-Phytosome|Subjects in this group will take Silibin-Phytosome 13 grams daily, in three divided doses for 2-10 weeks.
62094241|NCT00487721|NO_INTERVENTION|Control|Patients in this arm will not take any intervention.
62094242|NCT06555432||All Participants|Participants with post-transplant CMV infection and/or disease who are refractory and/or resistant to one or more prior therapy (including ganciclovir, valganciclovir, foscarnet or cidofovir) will be treated with LIVTENCITY tablet as per treating physician's discretion in a routine clinical practice setting, according to the approved labelling and will be observed prospectively for up to a 20-week period.
62094243|NCT05979194|OTHER|Labor care guide|In this study, we shall determine the effectiveness and other implementation outcomes of the new LCG using Proctor implementation outcome framework among HCPs delivering women across Mbarara District and Mbarara City and evaluate the diagnostic accuracy of the new WHO LCG versus the partogram in detecting prolonged labour and reducing rates of obstructed labour among women delivering in Mbarara district. We shall use local contextualized data from qualitative one-on-one key informant interviews in objective 1 from HCPs and Ministry of Health official involved in labour monitoring and implementation. The WHO labour care guide shall be refined and a Ugandan Ministry of Health prototype designed. An appropriated training and implementation strategy informed by the HCPs themselves shall be used to deliver the content to HCPs in all pilot sites.
62094244|NCT06487026|EXPERIMENTAL|MRgHIFU treatment arm|Subjects will receive MRgHIFU treatment by using ArcBlate Focused Ultrasound Ablation System.
62291898|NCT02419027|PLACEBO_COMPARATOR|placebo|Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
62464922|NCT01658228|OTHER|Venlafaxine|For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
62464923|NCT01178619||AGA|
62464924|NCT01178619||symmetrical IUGR|
62464925|NCT01178619||asymmetrical IUGR|
62464926|NCT04097730|PLACEBO_COMPARATOR|Standard Therapy|Participants in this arm will receive topical 0.5% moxifloxacin plus topical placebo plus sham corneal cross-linking.
61907862|NCT02891928|PLACEBO_COMPARATOR|without rocker sole|patient were wearing normal shoes during investigation
62094245|NCT06549036|EXPERIMENTAL|Intervention Group|Veterans randomized to the intervention arm will receive a decision aid in the mail along with decision coaching on PSA screening from a Veteran Veteran-peer-navigator decision coach. The intervention will be administered prior to the Veteran patient's appointment with the provider.
62291899|NCT03614572|EXPERIMENTAL|Group MI|The structure and content of the active intervention programme will be developed and adopted on the basis of previous research on sleep educational programme and motivational interviewing techniques. The whole treatment package consists of 4 sessions of group therapy (n=6-8) followed by 3 week daily text reminders.
62291900|NCT03614572|NO_INTERVENTION|Control group|Control group will no receive any intervention
62464927|NCT04097730|EXPERIMENTAL|Early Steroids|Participants in this arm will receive topical 0.5% moxifloxacin plus topical steroids plus sham corneal cross-linking.
61907863|NCT01007630|ACTIVE_COMPARATOR|Rasagiline|0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
61907864|NCT01007630|PLACEBO_COMPARATOR|Placebo|0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
62291901|NCT04736823|EXPERIMENTAL|Part1 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
62464928|NCT04097730|EXPERIMENTAL|Cross-Linking plus Early Steroids|Participants in this group will receive topical 0.5% moxifloxacin plus topical steroids plus corneal cross-linking.
62657853|NCT02969018|EXPERIMENTAL|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
61907865|NCT05330715|OTHER|Advanced Mobile Stroke Unit|Prehospital treatment of patients with an advanced Mobile Stroke Unit. The advanced Mobile Stroke Unit is an ambulance equipped with a computed tomography scanner, and additional diagnostic devices, such as point-of-care-laboratory and telemedicine to enable the team to diagnose and initiated specialised treatment of emergency patients at the emergency site.
62094246|NCT06549036|NO_INTERVENTION|Control Group|Veteran patients in the control arm will receive a decision aid alone in the mail without any additional counseling prior to their office visit.
62291902|NCT04736823|EXPERIMENTAL|Part1 Cohort2(AK112 + Pemetrexed +Carboplatin)|Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
62291903|NCT04736823|EXPERIMENTAL|Part1 Cohort3(AK112 + Docetaxel)|Subjects receive AK112 plus Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
62464929|NCT02670057|EXPERIMENTAL|Transnasal SPG block|
61907866|NCT05330715|OTHER|Conventional ambulance|Prehospital emergency care with conventional ambulances.
62464930|NCT04484493|EXPERIMENTAL|mometasone nasal spray|Patients will receive topical corticosteroid nasal spray (mometasone furoate nasal spray) in appropriate dose of 2 puff in each nostril (100 µg once daily) beside olfactory training.
62464931|NCT04484493|NO_INTERVENTION|control|Patients will not receive topical corticosteroid nasal spray but only olfactory training.
62657854|NCT02969018|PLACEBO_COMPARATOR|Placebo|12 weeks once daily placebo
62657855|NCT06530693|ACTIVE_COMPARATOR|Standard transport protocol|Standard EMS stroke transport protocol
61907867|NCT00906971|ACTIVE_COMPARATOR|Laxatives|Magnesium hydroxide for which the dosage varied according to individual needs (a minimum of 2 ml/kg), and received guidance regarding fiber-rich foods, water and toilet training. Patients attended weekly consultations with a pediatric gastroenterologist.
62464932|NCT04444557||Turkish hemodialysis patients|Turkish patients undergoing in-center hemodialysis
62464933|NCT04444557||Temporarily protected Syrian hemodialysis patients|Temporarily protected Syrian patients undergoing in-center hemodialysis
62657856|NCT06530693|ACTIVE_COMPARATOR|OPUS-i Protocol|Experimental OPUS-i protocol
61907868|NCT06286709|ACTIVE_COMPARATOR|Faecal Microbiota Transplant (FMT)|FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
61907869|NCT06286709|PLACEBO_COMPARATOR|FMT Placebo|FMT Placebo is 50mL aliquots of 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v.
62657857|NCT05470998|NO_INTERVENTION|control group|this group will include 25 patients who will receive their standard therapy for 3 months
62657858|NCT05470998|ACTIVE_COMPARATOR|L-Arginine group|this group will include 25 patients who will receive L-Arginine 0.1-0.2 g/kg/day and their standard therapy for 3 months
61907870|NCT03323788||Aim 1|Aim 1. To determine whether the transcription factor expression response to exercise is dysregulated in muscle from type 2 diabetic patients. We will test the hypothesis that MZF1, NFKB1, RELA, SP1/KLF and EGR1 responses to an acute exercise bout are reduced in insulin resistant patients with type 2 diabetes.
61907871|NCT03323788||Aim 2|"Aim 2. To determine how insulin resistance changes the response of post-translational modifications of SP1/KLF family and MZF1 transcription factors to acute exercise in muscle from type 2 diabetic patients. We will test the hypothesis that:~1. SP1/KLF2, 4, and 6 and phosphorylation/acetylation and MZF1 phosphorylation is altered in response to acute exercise.~2. The response of SP1/KLF2, 4, and 6 phosphorylation and acetylation and MZF1 phosphorylation to acute exercise is abnormal in patients with type 2 diabetes."
62094247|NCT03445481|EXPERIMENTAL|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
62094248|NCT06614894|EXPERIMENTAL|Ambroxol Hydrochloride 30mg - 9mg/kg/day|Ambroxol Hydrochloride 30mg Dose escalation: Initial dose of 9mg/kg/day (or max dose 150mg TID)
62094249|NCT06614894|EXPERIMENTAL|Ambroxol Hydrochloride 30mg - 18mg/kg/day|Ambroxol Hydrochloride 30mg Dose escalation: 18mg/kg/day (or max dose 300mg TID)
62094250|NCT06614894|EXPERIMENTAL|Ambroxol Hydrochloride 30mg - 27mg/kg/day|Ambroxol Hydrochloride 30mg Dose escalation: 27mg/kg/day (or max dose 1350mg QD)
62094251|NCT03796689|EXPERIMENTAL|Smartphone-linked|
62464934|NCT05525871|EXPERIMENTAL|Nitrates and Citrulline Malate|Gel elaborated from fruit puree with high polyphenol content, with the addition of nitrates and citrulline malate as study supplements. addition of nitrates and citrulline malate as study supplements.
62464935|NCT05525871|PLACEBO_COMPARATOR|Control product|Consumption of placebo product (Fruit puree)
62464936|NCT01746329|EXPERIMENTAL|Tea|Oral intake of tea containing 75 grams of glucose
62464937|NCT01746329|EXPERIMENTAL|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
62464938|NCT01746329|PLACEBO_COMPARATOR|Placebo|Oral intake of 75 grams of glucose in water
62464939|NCT00280553|NO_INTERVENTION|patient controlled analgesia (PCA) only|
62657859|NCT00071981|EXPERIMENTAL|Arm I (12MP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising 12 melanoma peptides restricted by Class I MHC (12MP) emulsified with sargramostim (GM-CSF) and Montanide ISA-51 (incomplete Freund's adjuvant) or Montanide ISA-51 VG (ISA-51) intradermally (ID) and subcutaneously (SC) on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
62657860|NCT00071981|EXPERIMENTAL|Arm II (12MP/Tet)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
62657861|NCT00071981|EXPERIMENTAL|Arm III (12MP/6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 6 melanoma helper peptides (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
62657862|NCT00071981|EXPERIMENTAL|Arm IV (6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising melanoma helper peptide vaccine (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
62094252|NCT03796689|ACTIVE_COMPARATOR|Standard|
62464940|NCT00280553|OTHER|PCA and pump with saline infusion for up to five days|
62464941|NCT00280553|OTHER|PCA and bupivicaine infusion for up to five days|
62464942|NCT01612520|ACTIVE_COMPARATOR|telecoaching|
62464943|NCT01612520|NO_INTERVENTION|control|
62464944|NCT04572386|ACTIVE_COMPARATOR|Light cure universal bond|light cured 3m single bond universal
62464945|NCT04572386|ACTIVE_COMPARATOR|self cure universal bond|self-cure universal bond (Palfique, Tokuyama, Japan)
62464946|NCT00189293|EXPERIMENTAL|1|Imiquimod 5% cream
62464947|NCT00189293|OTHER|2|vehicle cream
62291904|NCT04736823|EXPERIMENTAL|Part2 (AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
62094253|NCT03789253||AS cohort with progression|AS cohort with tumor progression
62291905|NCT04736823|EXPERIMENTAL|Part3 group A(AK112 + Docetaxel)|Subjects receive AK112 plus Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
62291906|NCT04736823|EXPERIMENTAL|Part3 group B(AK112)|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
62291907|NCT04736823|EXPERIMENTAL|Part3 group C(Docetaxel)|Subjects receive Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
62291908|NCT00544934|EXPERIMENTAL|250 mg|
62291909|NCT00544934|EXPERIMENTAL|500 mg|
62291910|NCT00544934|EXPERIMENTAL|750 mg|
62291911|NCT00544934|PLACEBO_COMPARATOR|Placebo|
62657863|NCT04690426|PLACEBO_COMPARATOR|Cohort 1, Low Dose, Placebo|Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals
62657864|NCT04690426|EXPERIMENTAL|Cohort 1, Low Dose, PRV-101|Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
62657865|NCT04690426|PLACEBO_COMPARATOR|Cohort 2, High Dose, Placebo|High dose of placebo by intramuscular injection, 3 doses at 4-week intervals
62657866|NCT04690426|EXPERIMENTAL|Cohort 2, High Dose, PRV-101|High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
62094254|NCT03789253||AS cohort without progression|AS cohort without tumor progression
62094255|NCT00730418|EXPERIMENTAL|doxazosin 4mg|doxazosin 4mg group
62094256|NCT00730418|EXPERIMENTAL|doxazosin 8mg|doxazosin 8mg group
62094257|NCT01205282|EXPERIMENTAL|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). There will be 14 weeks of active treatment.
62291912|NCT04149314|ACTIVE_COMPARATOR|Interventional|Interventional group (hemodynamic optimization based on HPI).
62291913|NCT04149314|NO_INTERVENTION|Control|Control group (blinded HPI monitoring, standard anesthesia care).
62291914|NCT04285320|ACTIVE_COMPARATOR|Intravesical antibiotic instillation|
62094258|NCT01205282|PLACEBO_COMPARATOR|Placebo|
62291915|NCT04285320|ACTIVE_COMPARATOR|Oral antibiotic suppressive therapy|
62291916|NCT04261530|EXPERIMENTAL|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
62291917|NCT04261530|EXPERIMENTAL|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
62291918|NCT04261530|EXPERIMENTAL|Self-care|It is a 7-months 2 hours-session (1 session per month) of self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
62291919|NCT04261530|EXPERIMENTAL|Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
62291920|NCT00582517|ACTIVE_COMPARATOR|Group A External Brace|Group A will have a non-invasive range of motion external brace placed following surgery
62291921|NCT00582517|EXPERIMENTAL|Group B Compass Knee Hinge|Group B will have a Compass Knee Hinge placed
62291922|NCT02130414|ACTIVE_COMPARATOR|Sandimmun® IV|Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)
62291923|NCT02130414|EXPERIMENTAL|CyCol® capsules|CyCol®: 75 mg OD \& BID for 7 days
62291924|NCT02130414|EXPERIMENTAL|CyCol® capsules 37.5 mg|CyCol®: 37.5 mg OD or BID for 7 days
62291925|NCT02130414|EXPERIMENTAL|CyCol® capsules, 150 mg|CyCol®: 150 mg OD or BID for 7 days
62291926|NCT05555004|EXPERIMENTAL|TEST1|
62291927|NCT05555004|EXPERIMENTAL|TEST2|
62291928|NCT03735719||STEMI patients|Patients with first STEMI treated with primary PCI are recruited in this study.
62464948|NCT02613000||All enrolled patients/Group A|500 consecutive adult patients will be enrolled in Part A (clinical data)
62094259|NCT00859014|EXPERIMENTAL|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.
62094260|NCT00308061|EXPERIMENTAL|FMP1/AS02A Vaccine|500 uL of FMP1/AS02A is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
62291929|NCT03735719||Control group|The control group will consist of patients with risk factors for cardiovascular diseases, but without history of coronary artery disease or heart failure.
62291930|NCT01800188||Dialysis|Patients with dialysis dependent ESRD and normal fasting glucose will undergo a meal test during a hemodialysis and hemodiafiltration session. A meal test without dialysis is optional.
62291931|NCT01775748|OTHER|Active First|Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day
62291932|NCT01775748|OTHER|Placebo First|Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day
62291933|NCT04361864||RUTI|patients with at least 3 episodes of UTI during 2019
62657867|NCT04730492||Renal Transplantation|Renal Transplantation
62657868|NCT04730492||Hernias reparation post renal transplantation|Hernias reparation post renal transplantation
62291934|NCT04361864||UTI|patients with one or two episodes of UTI during 2019
62657869|NCT00005988|EXPERIMENTAL|in vitro-treated bone marrow transplantation|"* Donor bone marrow will be harvested on Day -2~* Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.~* Bone marrow will be infused intravenously~* Cyclophosphamide will be administered IV once daily~* Total Body Irradiation (TBI) will be delivered per institutional practice~* Methylprednisolone will be administered IV as 4 doses separated by 12 hours,"
61907872|NCT03323788||Aim 3|"Aim 3. To define the response of miRNAs to acute exercise in healthy and insulin resistant muscle from obese and type 2 diabetic patients. We will test the hypotheses that:~1. The exercise-induced increases in expression of miR-378 members and miR-128 are lower in obese and type 2 diabetic muscle than in lean healthy controls.~2. FOXO1 expression, a target of miR-378 and miR-128, is higher in obese and type 2 diabetic muscle and this is accompanied by decreased FOXO1 phosphorylation.~3. The exercise-induced increases in expression of miR-30 family members, miR-10a, miR-422a, and miR-532 are lower in obese and type 2 diabetic muscle.~4. There are novel miRNAs that regulate the transcriptional program induced by acute exercise and are dysregulated in insulin resistance."
61907873|NCT03323788||Aim 4|Aim 4. To determine whether treatment with PPAR-Alpha agonist fibrate derivatives suppresses the normal gene expression response to acute exercise. We will test the hypothesis that Gemfibrozil treatment inhibits the normal transcriptional response to exercise.
61907874|NCT03322319|EXPERIMENTAL|left Ventricular Hypertrophy|Patients with left ventricular wall thickness measuring 15mm or more, or patients with a suggestive left ventricular echogenicity. Procedure/surgery will be performed following a diagnostic tree.
61907875|NCT05614934|ACTIVE_COMPARATOR|S3|Standard clarithromycin triple
61907876|NCT05614934|EXPERIMENTAL|V3|Vonoprazan triple
61907877|NCT05614934|EXPERIMENTAL|V2|Vonoprazan dual
61907878|NCT04083625|EXPERIMENTAL|carbetocin|100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
61907879|NCT04083625|PLACEBO_COMPARATOR|placebo|10 cm syringe normal saline IV given just before skin incision of myomectomy.
61907880|NCT00228215|NO_INTERVENTION|Usual care|
61907881|NCT00228215|EXPERIMENTAL|TIPS Intervention|
61907882|NCT06079229||Patients over 70 undergoing pancreatic cancer surgery at the Édouard Herriot Hospital.|This is a non-comparative study, in which all subjects with histologically proven pancreatic cancer (all types) on biopsy or surgical specimen, operated on for this cancer (by cephalic duodenopancreatectomy or left pancreatectomy) at the Édouard Herriot Hospital since July 2021, aged 70 or older at the time of surgery, will be included in the same group.
61907883|NCT01793870|EXPERIMENTAL|Treatment A (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 milligram \[mg\]) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
61907884|NCT01793870|EXPERIMENTAL|Treatment B (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
61907885|NCT01793870|EXPERIMENTAL|Treatment C (33.75 mg total maximum dose)|Single oral dose of carvedilol (31.25 mg) as a 1 x 25 mg immediate release tablet, a 1 x 6.25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
61907886|NCT01793870|EXPERIMENTAL|Treatment D (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg x immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fed conditions.
62657870|NCT01453231|NO_INTERVENTION|Control|No surgery
61907887|NCT05870982|EXPERIMENTAL|Early time restricted eating|Participants will asked to follow early time restricted eating
61907888|NCT05870982|EXPERIMENTAL|Late time restricted eating|Participants will be asked to follow late time restricted eating
61907889|NCT05870982|ACTIVE_COMPARATOR|Daily caloric restriction|Participants will be instructed to follow daily caloric restriction
61907890|NCT01402427|ACTIVE_COMPARATOR|Verapamil|
61907891|NCT01402427|PLACEBO_COMPARATOR|Placebo|
61907892|NCT03021161|EXPERIMENTAL|intervention group|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 (probiotic formula).
61907893|NCT03021161|PLACEBO_COMPARATOR|Placebo Oral Capsule|The control group will receive once daily similar capsules containing placebo.
61907894|NCT02835040|EXPERIMENTAL|CAP Service|
61907895|NCT02835040|ACTIVE_COMPARATOR|Usual care|
61907896|NCT01463007|EXPERIMENTAL|Radiation|AccuBoost APBI- 34.0 Gy in 10fx
61907897|NCT01463007|EXPERIMENTAL|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
61907898|NCT04415242|ACTIVE_COMPARATOR|suspension group|Arm on the side operated at 90 ° abduction, 90 ° anti-drive, resting on an arm support.
61907899|NCT04415242|EXPERIMENTAL|supported group|Arm on the operated side at 0 ° abduction, 90 ° anti-pulsation, resting on an adjustable support arm support located opposite the patient's head.
61907900|NCT01466829|PLACEBO_COMPARATOR|Control|Control patients treated with placebo.
61907901|NCT01466829|ACTIVE_COMPARATOR|Intervention|Daily injection with Parathyroid hormone
62291935|NCT00379951|EXPERIMENTAL|1|Arm 1: ertapenem sodium
62291936|NCT01808560|EXPERIMENTAL|LipiFlow Pre-treatment|Subjects randomized to the LipiFlow Pre-Treatment group receive a 12-minute LipiFlow System treatment for MGD in both eyes one month prior to cataract surgery.
62291937|NCT01808560|NO_INTERVENTION|Untreated Control|Subjects randomized to the untreated control group receive no MGD treatment prior to cataract surgery.
61907902|NCT06531889|ACTIVE_COMPARATOR|classical physiotherapy program|The group in classical physiotherapy program; n=25 (3 days per week for six weeks)
61907903|NCT06531889|EXPERIMENTAL|core stabilization group|The group in which core stabilization was also performed in addition to classical physiotherapy program; n=25 (3 days per week for 6 weeks)
61907904|NCT01351779||Progressive glaucoma|Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
61907905|NCT02303418|ACTIVE_COMPARATOR|Carbetocin|100 µgm of Carbetocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
62464949|NCT02613000||Patients with blood and urine sampling/Group B|Patients with informed consent signed (anticipated 200 out of 500 patients) will participate in Part A (clinical data) and B (intestinal-specific biomarkers from blood and urine)
62291938|NCT01808560|EXPERIMENTAL|LipiFlow Post-treatment|Subjects in the untreated control group receive a 12-minute crossover treatment with the LipiFlow System in both eyes three months after cataract surgery.
62291939|NCT04920240|PLACEBO_COMPARATOR|routine group|"In accordance with the intensive care unit hospital infection prevention and control norms requirements"
61907906|NCT02303418|ACTIVE_COMPARATOR|Oxytocin|5 mg of oxytocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
61907907|NCT05402371|EXPERIMENTAL|Cohort A: Rencofilstat 75 mg|Eighty-four (84) biopsy-proven NASH F2/F3 subjects to complete study on Rencofilstat 75 mg daily.
61907908|NCT05402371|EXPERIMENTAL|Cohort B: Rencofilstat 150 mg|Eighty-four (84) biopsy-proven NASH F2/F3 subjects to complete study on Rencofilstat 150 mg daily.
61907909|NCT05402371|EXPERIMENTAL|Cohort C: Rencofilstat 225 mg|Eighty-four (84) biopsy-proven NASH F2/F3 subjects to complete study on Rencofilstat 225 mg daily.
61907910|NCT05402371|PLACEBO_COMPARATOR|Cohort D: Placebo|Eighty-four (84) biopsy-proven NASH F2 / F3 subjects to complete study on matching placebo.
61907911|NCT01122056|ACTIVE_COMPARATOR|A = Active group|Patients will receive interactive exercise training session from an experienced multiple sclerosis
61907912|NCT01122056|NO_INTERVENTION|B = Control group (Placebo Comparator)|Patients will receive general advice about benefits/side effects of physical activity in multiple sclerosis.
61907913|NCT01004276|EXPERIMENTAL|Improved module|
61907914|NCT01004276|NO_INTERVENTION|Standard module|
61907915|NCT04333303|EXPERIMENTAL|Advance Care Planning Program|Implementation of a complex regional Advance Care Planning program.
61907916|NCT04333303|NO_INTERVENTION|Care as usual|
61907917|NCT03663556||Very Preterm Infants|Newborn infants with less than 32 weeks admitted in the NICU.
61907918|NCT05636800|EXPERIMENTAL|Microwave Treatment (Swift System)|3-4 Watts applied locally for up to a 3 second burst to each AK lesion, repeated 3 times per lesion. Burst is defined as a single delivery of microwave energy. There will be approximately 20 seconds between each repeat dose.
61907919|NCT05636800|NO_INTERVENTION|No Treatment|No Treatment administered
61907920|NCT02828670||patient|
61907921|NCT02828670||control|
61907922|NCT01418508|NO_INTERVENTION|low protein diet|Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
61907923|NCT01418508|EXPERIMENTAL|low protein diet plusα-keto acid|0.6g of proteins per kilo of body weight per day
61907924|NCT01418508|EXPERIMENTAL|very low protein diet plus α-keto acid|0.3g of proteins per kilo of body weight per day
62291940|NCT04920240|EXPERIMENTAL|Experimental group|Implement a multi-center unified ICU high-frequency contact surface standardized cleaning and disinfection mode
61907925|NCT04457622|EXPERIMENTAL|Main study group|All participants signed up for experiment 1, 2, 3 or 4 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses
61907926|NCT06392373|EXPERIMENTAL|Carbohydrate plus protein|Study beverages consumed over the initial 3 hours recovery phase from aerobic exercise, consuming 0.9g CHO/kg/hr + 0.3g PRO/kg/hr during high altitude exposure.
61907927|NCT06392373|ACTIVE_COMPARATOR|Carbohydrate|Study beverages consumed over the initial 3 hours recovery phase from aerobic exercise, consuming1.2g CHO/kg/hr during high altitude exposure.
62291941|NCT02371850|EXPERIMENTAL|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
62291942|NCT00100048|EXPERIMENTAL|600 mg monotherapy|MK0518 600 mg twice daily
62291943|NCT00100048|EXPERIMENTAL|400 mg monotherapy|MK0518 400 mg twice daily
62657871|NCT01453231|EXPERIMENTAL|thighplasty|
62291944|NCT00100048|EXPERIMENTAL|200 mg monotherapy|MK0518 200 mg twice daily
62291945|NCT00100048|EXPERIMENTAL|100 mg monotherapy|MK0518 100 mg twice daily
62094261|NCT00308061|ACTIVE_COMPARATOR|Imovax Rabies Vaccine|1 mL of Imovax Rabies Vaccine is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
62094262|NCT06613789|EXPERIMENTAL|Part A, Group 1: 426c.Mod.Core-C4b (20 mcg)|Participants will receive 426c.Mod.Core-C4b (20 mcg) alone to be administered as two 0.25-mL intramuscular (IM) doses, one into each thigh at weeks 0, 12, and 28.
62464950|NCT05561335|EXPERIMENTAL|Hearing Aid use for listening to speech in a common difficult situation|The hearing aids will be worn in two different programs, each with a different microphone configuration. The participants will listen to speech while wearing the hearing aids and alternate programs to form their opinions about these programs; they will only know that they are rating different settings, not what the settings are. They will then rate their listening experiences via rating scales to determine their preferences.
62464951|NCT02731365|EXPERIMENTAL|DBS LFP Activa PC+S|The study aims at testing a slightly modified device (battery) that is similar to the approved system that has the potential of offering future patients a closed loop system with automatic adjustments of stimulation. The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming.
62464952|NCT02535494|NO_INTERVENTION|Standard Training|Participants receive our standard overdose training.
62464953|NCT02535494|EXPERIMENTAL|Extensive Training|Participant receives an more in-depth, extensive training concerning opioid overdose.
62464954|NCT02535494|EXPERIMENTAL|Extensive Training w/ Significant Other|Participant and their significant other both receive a more in-depth, extensive training concerning opioid overdose.
62094263|NCT06613789|EXPERIMENTAL|Part A, Group 2: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (0.3 mcg) + Alum (250 mcg)|Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (0.3 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
62094264|NCT06613789|EXPERIMENTAL|Part A, Group 3: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (0.75 mcg) + Alum (250 mcg)|Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (0.75 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
62094265|NCT06613789|EXPERIMENTAL|Part A, Group 4: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (1.5 mcg) + Alum (250 mcg)|Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (1.5 mcg) and aluminum hydroxide suspension (Alum) (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
62291946|NCT00100048|PLACEBO_COMPARATOR|placebo monotherapy|Placebo to MK0518 twice daily
62291947|NCT00100048|EXPERIMENTAL|600 mg combo therapy|MK0518 600 mg + tenofovir + lamivudine
62291948|NCT00100048|EXPERIMENTAL|400 mg combo therapy|MK0518 400 mg + tenofovir + lamivudine
62291949|NCT00100048|EXPERIMENTAL|200 mg combo therapy|MK0518 200 mg + tenofovir + lamivudine
62464955|NCT06124235|EXPERIMENTAL|Coated Miniscrew|Device Place stent for accurate position of miniscrew, x-ray, inserting miniscrew, xray for showing position of miniscrew, then use Visual analoge scale for pain assessment for first 7 days, peri-implant health and mobility check each month for 3 month and success rate after 4 month.
62464956|NCT06124235|ACTIVE_COMPARATOR|Uncoated Miniscrew|Device Place stent for accurate position of miniscrew, x-ray, inserting miniscrew, xray for showing position of miniscrew, then use Visual analoge scale for pain assessment for first 7 days, peri-implant health and mobility check each month for 3 month and success rate after 4 month.
62657872|NCT04146883|EXPERIMENTAL|Post procedural antibiotics treatment|This group was treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin) and post procedural oral prophylactic antibiotics
62657873|NCT04146883|NO_INTERVENTION|Pre procedural antibiotics treatment only|This group was only treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin).
62094266|NCT06613789|ACTIVE_COMPARATOR|Part B, Group 5: 426c.Mod.Core-C4b (20 mcg) + 3M-052-AF (TBD)* + Alum (250 mcg)|Participants will receive 426c.Mod.Core-C4b (20 mcg) admixed with 3M-052-AF (TBD) and Alum (250 mcg) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
62094267|NCT06613789|PLACEBO_COMPARATOR|Part B, Group 6: Placebo|Participants will receive Placebo (Tris Sodium Chloride (NaCl) buffer ) to be administered as two 0.25-mL IM doses, one into each thigh at weeks 0, 12, and 28.
62094268|NCT00333580||Group 1|
62657874|NCT04729517|ACTIVE_COMPARATOR|Azelastine Hydrochloride|Patients that will receive azelastine hydrochloride are defined as the active control arm.
62094269|NCT06348186|OTHER|Guidebook|
62291950|NCT00100048|EXPERIMENTAL|100 mg combo therapy|MK0518 100 mg + tenofovir + lamivudine
62291951|NCT00100048|ACTIVE_COMPARATOR|EFV combo therapy|efavirenz + tenofovir + lamivudine
62657875|NCT04729517|EXPERIMENTAL|AI201901|Patients that will receive AI201901 are defined as the test arm.
62657876|NCT03697356|EXPERIMENTAL|Rituximab&Bortezomib&Lenalidomide&Dexamethasone|Rituximab\&Bortezomib\&Lenalidomide\&Dexamethasone
62094270|NCT06348186|EXPERIMENTAL|Guidebook and Myofascial Reorganization® (RMF).|
62094271|NCT03730298|EXPERIMENTAL|American Ginseng|American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months
62094272|NCT03730298|PLACEBO_COMPARATOR|Placebo|Placebo: 1 cpr twice a day orally for 3 months
62094273|NCT04827225||PoPPY Group|Mother, Father and child born prematurely
62291952|NCT04804891|EXPERIMENTAL|Cell Therapy|Patients will receive an infusion containing 1x106/kg CD34+ cells. No more than 104 CD34+ T cells per kg recipient weight will be included in the infusion. Cadaveric donor CD34 cell infusion will occur at any time between post-operative day 11 to day 13 following transplantation.
62291953|NCT04804891|NO_INTERVENTION|Control|Patients who do not consent to receive donor CD34 cell infusion or whose donor family declines consent for research use of donor bone marrow will receive their usual standard of care.
62291954|NCT02310373|EXPERIMENTAL|Nicotine free hookah (herbal/steam stones) smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after nicotine free hookah smoking.
62657877|NCT01551173|EXPERIMENTAL|Fluvastatin sodium Extended Release Tablet|Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks
61907928|NCT02630043|EXPERIMENTAL|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
61907929|NCT05990595|EXPERIMENTAL|Adlay with white rice|Group A eat cooked adlay with white rice to replace their carbohydrates: a box of 200 grams of adlay rice per day
62094274|NCT03324685|EXPERIMENTAL|BIIB074 150 mg and Oral Contraceptive|Participants will receive BIIB074 in tablet form in 150 mg doses every 8 hours on prescription (TID) on days 1-7 and on days 26-32. OC will be taken in tablet form (ethinyl estradiol 30 micrograms and levonorgestrel 150 micrograms) once daily (QD) on days 12-32.
62094275|NCT01941823||Carnitine CRRT, prospective|CRRT patients given carnitine in TPN as part of clinical protocol. Will evaluate total and free, carnitine and acylcarnitine profile as well as cardiac function by standard and speckle tracking echo weekly during CRRT.
62094276|NCT01941823||CRRT Control, retrospective|Retrospective control group, CRRT patients who did not receive carnitine supplementation during CRRT and had carnitine levels measured and echo performed during CRRT.
62094277|NCT01941823||ICU Control (non-CRRT), prospective|Critically ill ICU patients not receiving any exogenous carnitine, and not receiving CRRT, will have total and free carnitine and acylcarnitine profile measured weekly during CRRT.
62094278|NCT06685289|EXPERIMENTAL|donafenib combined with capecitabine|
62094279|NCT06685289|ACTIVE_COMPARATOR|capecitabine|
62094280|NCT06086431|PLACEBO_COMPARATOR|Placebo|0.2% ropivacaine for erector spinae plane block
62094281|NCT06086431|ACTIVE_COMPARATOR|Dexamethasone|0.2% ropivacaine + 0.1mg/kg Dexamethasone for erector spinae plane block
62094282|NCT06086431|ACTIVE_COMPARATOR|Dexmedetomidine|0.2% ropivacaine + 0.1ug/kg Dexmedetomidine for erector spinal plane block
62094283|NCT05758688|EXPERIMENTAL|Adjuvant Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)|The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions. The volume treated will include the whole pelvis according to Radiation Therapy Oncology Group post-hysterectomy pelvis guidelines.
62094284|NCT06697171|ACTIVE_COMPARATOR|Control|No COI Disclosure (Control). Only @brandname is tagged in the social media post narrative body.
62094285|NCT06697171|EXPERIMENTAL|Group 1 Not an Ad Disclosure|Disclosure includes @brandname and #NotAnAd in the social media post narrative body.
62094286|NCT06697171|EXPERIMENTAL|Group 2 Basic Disclosure|Disclosure includes @brandname and #ad in the narrative body of the social media post.
62094287|NCT06697171|EXPERIMENTAL|Group 3 Basic + Paid Partnership Disclosure|"Disclosure includes a branded paid partnership in the header and a tag for the industry partner, @brandname and #ad immediately at the beginning of the post, and #ad and #sponsored at the bottom of the narrative body of the social media post."
62094288|NCT06697171|EXPERIMENTAL|Group 4 Basic + Paid Partnership + Image label|Disclosure includes the same attributes as Group 3, with the addition of #ad appearing on the post image itself.
62094289|NCT05948098|EXPERIMENTAL|Facilitated Tucking Position|"Prior to the procedure, parents will be informed about facilitated tucking position practices.Heel blood will be drawn from newborns after facilitated tucking position practices are performed. The pain of newborns will be evaluated with the Neonatal Pain Diagnostic Scale (NIPS) before, during and after the procedure. Practice:~For the facilitated tucking position, the lower and upper extremities of the newborn will be kept in lateral flexion and close to the midline. Meanwhile, the researcher's hand will be gently held on the baby's head and the other hand on the baby's hips, without restricting the baby's movements. The facilitated tucking position will be given one minute before the heel blood collection and will be maintained for one minute during and after the blood collection."
62094290|NCT05948098|EXPERIMENTAL|Gentle Human Touch|"Before the procedure, parents will be informed about gentle human touch practice. After Gentle human touch practice, heel blood will be taken from newborns. The pain of newborns will be evaluated with the Neonatal Pain Diagnostic Scale (NIPS) before, during and after the procedure. Practice:~For the Gentle human touch practice, the researcher will place one hand on the newborn's top (head) above the brow line and the other hand on the lower abdomen covering the baby's waist and hips. Gentle human touch practice will be started 10-15 minutes before the procedure and will continue throughout the process and until 15 minutes after the end of the process."
62094291|NCT05948098|NO_INTERVENTION|Control Group|"During the heel blood collection, no procedures other than routine procedures applied in the clinic will be applied. The pain of newborns will be evaluated with the Neonatal Pain Diagnostic Scale (NIPS) before, during and after the procedure."
62291955|NCT04522869|EXPERIMENTAL|Umbilical cord blood - derived mesenchymal stem cells|17 patients with BA underwent Kasai operation and then will received two doses of UC-MSCs at 1x106 cells/kg (body weight) administered via hepatic artery
62291956|NCT04522869|NO_INTERVENTION|Control group|17 patients with BA will be conducted Kasai operation only
62657878|NCT01551173|ACTIVE_COMPARATOR|Fluvastatin sodium Immediate Release Capsule|Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks
62291957|NCT03347149||Pre-Phase (Control)|no Alarm Advisor Software installed
62291958|NCT03347149||Post-Phase (Observation)|Alarm Advisor Software implemented
62657879|NCT05660876|OTHER|Fistulotomy|Standard fistulotomy was done in this arm
62657880|NCT05660876|OTHER|Fistulotomy with marsupialization|This arm consists of fistulotomy in which marsupialization was done
62657881|NCT00143507|EXPERIMENTAL|Ivabradine|
62657882|NCT00143507|PLACEBO_COMPARATOR|Placebo|
62657883|NCT02017717|EXPERIMENTAL|Arm N:Nivolumab|Cohort 1, 1c, 1d and 2: Nivolumab specified dose on specified days
62737523|NCT05407012|NO_INTERVENTION|Absence of the barrier enhancing preparation|Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
61907930|NCT05990595|PLACEBO_COMPARATOR|White rice|Group B ate a box of 200 grams of cooked white rice per day
62657884|NCT02017717|EXPERIMENTAL|Arm N + I:Nivolumab + Ipilimumab|"Cohort 1: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days~Cohort 1b: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days"
62464957|NCT02566928|EXPERIMENTAL|Decolonization and Decontamination|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, oral antibiotics, and antibiogram-based antibiotic prescribing, and 2) a home-based intervention implemented by Community Health Workers/Promotoras that includes index patient and household member education and instructions to complete a decolonization and decontamination regimen, along with printed materials describing a standard hygiene protocol for reducing household contamination. Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of 2% mupirocin ointment to the anterior nares with a clean cotton applicator for five days, as well as daily bathing with chlorhexidine wash for five days. The household decontamination hygiene protocol includes the use of hand-washing, surface disinfection, and laundering.
62657885|NCT02017717|ACTIVE_COMPARATOR|Arm B: Bevacizumab|Cohort 2: Bevacizumab specified dose on specified days
61907931|NCT02113800|EXPERIMENTAL|Single Arm|"Patients receive Everolimus orally, 10 mg/day.~The end of study will be performed when tumor progression has been observed for 28 patients. Patients who are still under treatment at that time may continue with chemotherapy at the discretion of the investigator, but will be excluded from the study."
62464958|NCT02566928|NO_INTERVENTION|Usual Care|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, and oral antibiotics, as well as antibiogram-based antibiotic prescribing, and 2) printed materials describing a standard hygiene protocol for reducing household contamination.
62464959|NCT05189405||INVOcell IVC|IVF using intravaginal incubation with INVOcell device for embryo development.
62464960|NCT05189405||Traditional IVF (tIVF)|Traditional IVF using laboratory equipment and incubators for embryo development
62657886|NCT02714647|EXPERIMENTAL|Experimental|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on accuracy over speed prior to practicing the motor task. Participants will also have extended deadlines (750 ms) throughout the task to ensure an accuracy preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
62657887|NCT02714647|SHAM_COMPARATOR|Control|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on speed over accuracy prior to practicing the motor task. Participants will also have short deadlines (250 ms) throughout the task to ensure a speed preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
61907932|NCT01837459||Obese-Normal|Obese with Apnea Hypopnea index (AHI) \<1
61907933|NCT01837459||Obese-SDB|Obese and with AHI\>1
61907934|NCT01837459||Lean-Normal|Non-obese with AHI\<1
61907935|NCT01837459||Lean-SDB|Non-obese with AHI\>1
61907936|NCT02150694|EXPERIMENTAL|Apelin agonist infusion|Studies to measure change in blood flow in response to apelin agonists (1/10/100nmol) using forearm venous occlusion plethysmography and Aellig hand vein technique.
61907937|NCT02150694|EXPERIMENTAL|Apelin receptor antagonist infusion|Aellig hand vein technique will be used to investigate the change in vein diameter in response to an apelin blocking agent
61907938|NCT02150694|EXPERIMENTAL|Apelin agonist/antagonist co-infusion|Forearm blood flow study to measure blood flow by forearm venous occlusion plethysmography following intraarterial infusion of apelin receptor agonists and antagonist.
61907939|NCT04685161|EXPERIMENTAL|Surgical extrusion|Novel and alternative treatment option for horizontal crown root fractured maxillary incisors
61907940|NCT04685161|ACTIVE_COMPARATOR|Fibre post|Treatment modality normally used for crown-root fractured tooth
61907941|NCT02910505|EXPERIMENTAL|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
61907942|NCT05596383|EXPERIMENTAL|Intervention group|Vitamin D, dosage form chewable tablet, dosage 5000 IU, frequency every day, duration six months
61907943|NCT05596383|PLACEBO_COMPARATOR|control group|Placebo (microcrystalline,calcium carbonate, sodium starch), dosage form chewable tablet, frequency every day, duration six month
61907944|NCT04307615|EXPERIMENTAL|Oxygen + CPAP-treatment|
61907945|NCT04307615|ACTIVE_COMPARATOR|Oxygen-treatment|
62657888|NCT06241950|EXPERIMENTAL|Delandistrogene Moxeparvovec after Imlifidase Infusion|Participants may receive 1 or 2 doses of imlifidase, depending on rAAVrh74 antibody titer results. Then, based on their rAAVrh74 antibody titer, eligible participants may receive 1 dose of delandistrogene moxeparvovec infusion.
62094292|NCT03946202|EXPERIMENTAL|Radiotherapy + radiation sensitiser|Patients randomised to the test group will receive standard radiotherapy for breast cancer + a radiation sensitiser
62094293|NCT03946202|NO_INTERVENTION|Radiotherapy alone|Patients randomised to the control group will receive standard radiotherapy for breast cancer alone
62094294|NCT05922436|EXPERIMENTAL|QLG2071|QLG2071 25mg: 50ml
62094295|NCT05922436|ACTIVE_COMPARATOR|Cleviprex®|Cleviprex® 25mg: 50ml
62291959|NCT04223609|EXPERIMENTAL|Oxycodone, Then Placebo|Participants first receive initial dose of oxycodone 5 mg tablet followed by a 30-minute rest period to allow for onset of medication effect. This rest period will be followed by a standardized set of oculomotor testing for 40 minutes. After the initial testing, a second dose of oxycodone 5 mg tablet will be administered followed by a 30-minute rest period to allow for the onset of the second dose. The second rest period will be followed by a second round of standardized oculomotor testing for 40 minutes. Participants will then return approximately 4 to 6 days to repeat the standardized oculomotor testing with placebo.
62291960|NCT04223609|EXPERIMENTAL|Placebo, Then Oxycodone|Participants first receive initial dose of placebo 5 mg tablet followed by a 30-minute rest period to allow for onset of medication effect. This rest period will be followed by a set of standardized oculomotor testing for 40 minutes. After the initial testing, a second dose of placebo 5 mg tablet will be administered followed by a 30-minute rest period to allow for the onset of the second dose. The second rest period will be followed by a second round of standardized oculomotor testing for 40 minutes. Participants will then return approximately 4 to 6 days to repeat the standardized oculomotor testing with oxycodone.
62291961|NCT03026738|EXPERIMENTAL|Laparoscopic anterior mesh rectopexy|A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
62291962|NCT03026738|ACTIVE_COMPARATOR|Laparoscopic posterior mesh rectopexy|"Mobilization of the mesorectum posteriorly from the sacral promontory to the pelvic floor. Lateral stalks will not be divided. Bowel resection and circumferential division of the peritoneum will not be done in this study. A T-shaped polypropylene mesh will be placed with the vertical leg laying flush with the anterior surface of the sacrum, and secured to the promontory and sacrum with three absorbable sutures. The mesh wings will be sutured to the lateral sides of the rectum/mesorectum with two absorbable sutures on each side. The visceral peritoneum will be left open."
62291963|NCT06340217|EXPERIMENTAL|Treatment|The patient will receive WMT once daily for a duration of 2 days
61907946|NCT03948477|OTHER|Pantoprazole/Placebo|Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2
62094296|NCT00377598|EXPERIMENTAL|TAK-583 5 mg QD|
62291964|NCT06340217|PLACEBO_COMPARATOR|Control|The patient will receive a placebo of equal volume once daily for a duration of 2 days
62291965|NCT06273969|EXPERIMENTAL|Osteopathic Manipulative Treatment|The OMT protocol is designed to target the somatic dysfunction associated with TOS.
62291966|NCT00428402||Focus Group|Participant is a 4th-8th grade student in select schools from Bastrop Independent School District (BISD).
62291967|NCT04122599|OTHER|Melatonin versus standard care|Melatonin is tested versus standard care
62094297|NCT00377598|EXPERIMENTAL|TAK-583 25 mg QD|
62094298|NCT00377598|EXPERIMENTAL|TAK-583 50 mg QD|
62094299|NCT00377598|EXPERIMENTAL|TAK-583 100 mg QD|
62094300|NCT00377598|PLACEBO_COMPARATOR|Placebo QD|
62094301|NCT04970238|EXPERIMENTAL|Levosimendan group|
62094302|NCT04970238|PLACEBO_COMPARATOR|placebo group|
62094303|NCT01766518|EXPERIMENTAL|MY-REPT capsule|MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally
62094304|NCT06609902|EXPERIMENTAL|Future Self-BD|Experimental Arm utilizing the Future Self-BD Intervention.The Future Self group will attend 6 virtual sessions during which they will be encouraged to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. All participants will complete the adjusting amount discounting task. All participants will also receive brief, CBT-based smoking cessation counseling. This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
62094305|NCT06609902|ACTIVE_COMPARATOR|Daily Check-Ins|Active comparator arm utilizing Daily Check-Ins (DCI). The DCI group will attend 6 virtual sessions during which they will complete the adjusting amount discounting task and receive brief, CBT-based smoking cessation counseling (consistent with counseling received by Future Self-BD). This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
62094306|NCT03337750|EXPERIMENTAL|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
62291968|NCT01784796|EXPERIMENTAL|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction program
62737524|NCT05430503||Long COVID|Caucasian subjects with a history of SARS CoV-2 infection confirmed by nasopharyngeal swab with real-time polymerase-chain reaction were included in the study. They were referred to investigators' pulmonary function laboratory after being tested negative for SARS-CoV-2, because of dyspnea, fatigue, and exercise intolerance persisting or occurring at least 3 months after the COVID-19 acute phase and lasting ≥2 months.
62094307|NCT02368886|EXPERIMENTAL|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
62291969|NCT01784796|ACTIVE_COMPARATOR|Health education program|8 week Health Education program
62291970|NCT05330026|EXPERIMENTAL|Yoga practitioner|"The RUSI protocol for taking measurements with ultrasound for physiotherapists will be followed. Three measurements of each of the explorations will be made with the average of the three, pausing for 30 seconds between each repetition.~Three variables will be analyzed: diaphragm thickness, its rate of contraction, and diaphragmatic excursion, all of them at rest, ujjayi breathing, and pursed-lip breathing."
62291971|NCT05330026|ACTIVE_COMPARATOR|Non yoga practitioner|"Each subject will have previously received (one week before taking the measurements) the instructions where the main researcher will have shown him what calm diaphragmatic breathing is like, as well as forced breathing at maximum inspired volume with neutral breathing, yoga breathing (ujjayi ) and pursed-lip breathing. During that week prior to taking measurements, the subjects should practice each breath for 20 minutes a day in order to have a good awareness of how to perform them correctly.~The RUSI protocol for taking measurements with ultrasound for physiotherapists will be followed. Three measurements of each of the explorations will be made with the average of the three, pausing for 30 seconds between each repetition.~Three variables will be analyzed: diaphragm thickness, its rate of contraction, and diaphragmatic excursion, all of them at rest, ujjayi breathing, and pursed-lip breathing."
62291972|NCT06015490|EXPERIMENTAL|Conditioned Stimulus: Sucrose (aim 1)|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose.
62291973|NCT06015490|EXPERIMENTAL|Conditioned Stimulus: Glucose (aim 1)|Participants will undergo exposure sessions with flavored beverage solutions containing glucose.
62291974|NCT06015490|EXPERIMENTAL|Conditioned Stimulus: Fructose (aim 1)|Participants will undergo exposure sessions with flavored beverage solutions containing fructose.
62291975|NCT06015490|EXPERIMENTAL|Conditioned Stimulus: Sucrose (aim 2)|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose.
62291976|NCT06015490|EXPERIMENTAL|Conditioned Stimulus: High Fructose Corn Syrup (aim 2)|Participants will undergo exposure sessions with flavored beverage solutions containing high fructose corn syrup.
62291977|NCT06015490|EXPERIMENTAL|Conditioned Stimulus: Sucrose + Non-nutritive Sweetener (aim 2)|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose and a non-nutritive sweetener.
62291978|NCT03440944|ACTIVE_COMPARATOR|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
62291979|NCT03440944|ACTIVE_COMPARATOR|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
62291980|NCT06052956|EXPERIMENTAL|MB-PDT at pre-defined dose plus standard of care abscess drainage|Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, and laser illumination at an optical power defined by their abscess size.
62291981|NCT06052956|EXPERIMENTAL|MB-PDT at patient-specific dose plus standard of care abscess drainage|Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, optical spectroscopy, and laser illumination. The optical power for laser illumination will be determined by their abscess morphology and the results of optical spectroscopy.
62291982|NCT06052956|OTHER|Standard of care abscess drainage|Each subject in this arm will receive standard of care abscess drainage
62291983|NCT00124280|EXPERIMENTAL|previously treated with chemotherapy only|patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI
62291984|NCT00124280|EXPERIMENTAL|previously treated with chemotherapy + small|patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
62291985|NCT01413958|EXPERIMENTAL|Phenylephrine|
62291986|NCT01413958|PLACEBO_COMPARATOR|Placebo|
62291987|NCT05671276|ACTIVE_COMPARATOR|Standard Antiplatelet Therapy|DAPT (aspirin 100 mg and clopidogrel 75 mg) from 45 days to 6 month-follow-up, then aspirin alone
62291988|NCT05671276|EXPERIMENTAL|Half-Dose NOAC|Long-term half-dose NOAC (rivaroxaban 10 mg after 45 days)
62291989|NCT03359902|EXPERIMENTAL|Initial tVNS|This group will receive transcutaneous vagal nerve stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
62291990|NCT03359902|EXPERIMENTAL|Initial Sham|This group will receive sham stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
61907947|NCT03948477|OTHER|Placebo/Pantoprazole|Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2
62291991|NCT04338490|EXPERIMENTAL|Intervention|
62291992|NCT04338490|NO_INTERVENTION|Control|
62291993|NCT04742673|PLACEBO_COMPARATOR|Placebo|"Participants will flow through the trial in the following manner:~1. Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~2. Pre-randomization phase: twice daily assessments of mental status~3. Randomize delirious patients: IV guanfacine or placebo~4. Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~5. Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~6. Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
62464961|NCT03968718|EXPERIMENTAL|Systematic ePROMs Assessment|"Intervention: The intervention is constituted by a Systematic ePROMs Assessment in routine cancer care in a comprehensive cancer centre.~This will involve preliminary sensitization and training of both clinicians and patients towards the use of ePROMs.~Data filled in by patients through electronic devices will be prompt made available to the clinician during the patient examination."
62291994|NCT04742673|EXPERIMENTAL|IV Guanfacine|"Participants will flow through the trial in the following manner:~1. Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~2. Pre-randomization phase: twice daily assessments of mental status~3. Randomize delirious patients: IV guanfacine or placebo~4. Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~5. Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~6. Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
62291995|NCT05943080|EXPERIMENTAL|PCI + ACB Group|Firstly, perioperative application is performed in the anatomical space between the posterior capsule and the popliteal artery before implantation. In the application, a 22G 10 cm needle is used in the form of 20 ml 0.25% bupivacaine + 2.0 μg/mL of epinephrine.For the adductor canal block, which will be applied by the anesthesiologist at the end of the operation, first of all, the femoral artery and nerve in the inguinal region are visualized while the patient is in the supine position, accompanied by ultrasonography. Afterwards, the artery is followed distally and the adductor canal and the femoralarter inside it and the nerve are visualized. At the level just below the sartorius muscle, a simultaneous needle is visualized by ultrasonography and 7m of 0.5%bupivacaine + 8ml of 0.9% saline solution is injected into the adductor canal. Appropriate drug distribution is confirmed by ultrasonography and the procedure is terminated.
62464962|NCT03239990|EXPERIMENTAL|Incredible Years, Parent support|Incredible Years, Parent group supported by home visiting includes the Incredible Years Parent Training Program, Preschool Basic version, with 18-20 group meetings. Four home visits are added to the program to support parents in practicing new skills and to provide individual practical consultation.
62464963|NCT03239990|NO_INTERVENTION|Treatment as usual|The control group will receive treatment as usual
62094308|NCT02368886|EXPERIMENTAL|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade \>= 1.
62464964|NCT06061471|EXPERIMENTAL|Experimental: AK111 regimen 1|
62737525|NCT05430503||Healthy controls|Anthropometrically-matched healthy subjects, without history of COVID-19 and vaccinated against SARS-CoV-2 infection.
62737526|NCT02182778|EXPERIMENTAL|Gemcitabine/Cisplatin group|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
62737527|NCT02182778|EXPERIMENTAL|Gemcitabine/Cisplatin /S-1 group|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
62737528|NCT05336929|EXPERIMENTAL|education arm (n=30)|Roy adaptation model-based training was given to the training arm.
62737529|NCT05336929|NO_INTERVENTION|control arm (n=30)|Roy adaptation model-based training not given to the training arm
62737530|NCT06479512||patients with spinal induced hypotension|patients with hypotension after spinal anesthesia (SBP less than 90 mmHg, a decrease in SBP by more than 30% from the preoperative baseline value, or an MAP below 60 mmHg)
62737531|NCT06479512||patients without spinal induced hypotension|patients without spinal induced hypotension
62737532|NCT03776812|EXPERIMENTAL|Continuous Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
62737533|NCT03776812|EXPERIMENTAL|Intermittent Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
62737534|NCT03776812|ACTIVE_COMPARATOR|Nab-paclitaxel Comparator|Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
62737535|NCT04299152|EXPERIMENTAL|Stem Cell Educator therapy treat patients with SARS-CoV-2|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
62737536|NCT04299152|NO_INTERVENTION|Conventional treatment of patients with SARS-CoV-2|Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.
62737537|NCT01003756|EXPERIMENTAL|Knee Intervention|Patients undergoing Total Knee Replacement. Exercise 8-10 weeks preoperatively
62737538|NCT01003756|NO_INTERVENTION|Knee Control|Patients undergoing Total Knee Replacement. Receives standard instructions
62737539|NCT01003756|EXPERIMENTAL|Hip Intervention|Patient undergoing Total Hip Replacement. Exercise 8-10 weeks preoperatively
62737540|NCT01003756|NO_INTERVENTION|Hip Control|Patients undergoing Total Hip Replacement. Receives standard instructions
61907948|NCT03894007|EXPERIMENTAL|A: Experimental|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide + atezolizumab. In total seven courses of preoperative treatment. Response evaluations after course four.~Postoperatively, if pathologic complete response, patients receive 14 courses of adjuvant trastuzumab every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
61907949|NCT03894007|ACTIVE_COMPARATOR|B: Standard|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide. In total seven courses of preoperative treatment. Response evaluations after course four.~Postoperatively, if pathologic complete response patients receive 14 courses of adjuvant trastuzumab (combined with pertuzumab in case of high-risk disease features) every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
61907950|NCT04335214|OTHER|Interview|One to one interview with older people from moroccon origin in Belgium
61907951|NCT02721394|EXPERIMENTAL|Researcher Implemented FCT|Children receive functional communication training. Assessment and initial intervention sessions are completed by the researcher and family carers are trained to continue the intervention at home.
61907952|NCT02721394|EXPERIMENTAL|Family Carer Implemented FCT 1|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher in person.
61907953|NCT02721394|EXPERIMENTAL|Family Carer Implemented FCT 2|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher via videoconferencing and support from a family carer assistant in person.
61907954|NCT06289205|ACTIVE_COMPARATOR|Group 1|Group 1 will be regarded as control group and per operative methotrexate infusion will be used by mixing 75 mg of methotrexate into one litre of BSS solution.
62291996|NCT05943080|EXPERIMENTAL|IPACK block + ACB Group|First of all, for the adductor canal block, which will be applied by the anesthesiologist at the end of the operation, the femoral artery and nerve in the inguinal region are visualized by ultrasonography while the patient is in the supine position. Afterwards, the artery is followed distally and the adductor canal and the femoral arter inside it and the nerve are visualized. At the level just below the sartorius muscle, a simultaneous needle is visualized by ultrasonography and 7m of 0.5%bupivacaine + 8ml of 0.9% saline solution is injected into the adductor canal. Appropriate drug distribution is confirmed by ultrasonography and the procedure is terminated. then ACB is performed with the help of USG in the anatomical space between the posterior capsule and the popliteal artery. In practice, a 22G 10 cm needle is used in the form of 20 ml 0.25% bupivacaine + 2.0 μg/mL of epinephrine.
62308057|NCT01944215|ACTIVE_COMPARATOR|Arm 4 - Fast vs Fast + External Heating|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
62464965|NCT06061471|EXPERIMENTAL|Experimental: AK111 regimen 2|
62464966|NCT06231147|EXPERIMENTAL|Group A|horse riding simulator sessions with mirror visual feedback
62464967|NCT06231147|OTHER|Group B|horse riding simulator sessions without mirror visual feedback
62464968|NCT02646397|EXPERIMENTAL|Fosinopril,benidipine combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.
62464969|NCT02646397|EXPERIMENTAL|Fosinopril,hydrochlorothiazide combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus hydrochlorothiazide (12.5/25 mg）once daily for 6 months.
62464970|NCT03071029|EXPERIMENTAL|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
62094309|NCT02368886|EXPERIMENTAL|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
62291997|NCT05943080|OTHER|ACB Group (control)|"At the end of the operation by the anesthesiologist only adductor canal block is applied, while the patient is in the supine position, the femoral artery and nerve are visualized in the inguinal region under ultrasound guidance. Afterwards, the artery is followed distally and the adductor canal and the femoralarter inside it and the nerve are visualized. At the level just below the sartorius muscle, a simultaneous needle is visualized by ultrasonography and 7m of 0.5%bupivacaine + 8ml of 0.9% saline solution is injected into the adductor canal. Appropriate drug distribution is confirmed by ultrasonography and the procedure is terminated.~VAS values and opioid consumption will be recorded as the primary outcome of the patients who are taken to the service after the surgical procedure performed under spinal anesthesia without the use of a tourniquet. Post-operative 3. Hour-12. Hour -24. Hours -48th hour and 72nd hour."
62094310|NCT02368886|EXPERIMENTAL|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
62094311|NCT06374264|EXPERIMENTAL|Intervention|Participants will be asked to use MR-C-014 for 24 sessions (30 minutes each), 3 times a week for 8 weeks.
62094312|NCT01169805|EXPERIMENTAL|ONSERAN|
62094313|NCT01169805|EXPERIMENTAL|NASEA|
62094314|NCT01169805|EXPERIMENTAL|ALOXI|
62094315|NCT01169805|PLACEBO_COMPARATOR|normal saline|
62094316|NCT04704960||Lung metastases from colorectal cancer, local ablative therapy (surgery or radiation)|patients diagnosed with lung metastases from colorectal cancer and undergoing surgery or radiation for lumg metastasis
62094317|NCT04901975|EXPERIMENTAL|Spironolactone|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers \~1 year after the Fontan operation.~Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg.~Spironolactone administration will begin after the Fontan procedure in the hospital prior to discharge or at the first outpatient visit \~ 2 weeks after discharge."
62291998|NCT01381094|EXPERIMENTAL|AKB-6548 240 mg|
62094318|NCT04901975|NO_INTERVENTION|Observational|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers \~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
62291999|NCT01381094|EXPERIMENTAL|AKB-6548 370 mg|
62292000|NCT01381094|EXPERIMENTAL|AKB-6548 500 mg|
62292001|NCT01381094|EXPERIMENTAL|AKB-6548 630 mg|
62464971|NCT03071029|NO_INTERVENTION|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
62464972|NCT01719731|PLACEBO_COMPARATOR|Non-Education|This group will not receive the psychosocial education.
62292002|NCT01381094|PLACEBO_COMPARATOR|Placebo|
62292003|NCT03177161|EXPERIMENTAL|Postal Questionnaire|
62292004|NCT03177161|EXPERIMENTAL|Online Questionnaire|
62292005|NCT03177161|EXPERIMENTAL|Face-to-face Questionnaire|
62292006|NCT03177161|EXPERIMENTAL|Telephone Questionnaire|
62464973|NCT01719731|ACTIVE_COMPARATOR|Education|This group will receive the psychosocial education
62464974|NCT04646213|EXPERIMENTAL|Therapy|psychotherapeutic intervention
62737541|NCT01188551|EXPERIMENTAL|dexmedetomidine w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of dexmedetomidine 1mcg/kg given intranasally in OR.
62737542|NCT01188551|ACTIVE_COMPARATOR|fentanyl w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of fentanyl 2mcg/kg given intranasally in OR.
62292007|NCT02265484|EXPERIMENTAL|Lactulose + Rifaximin + Bromocriptine|
62292008|NCT02265484|ACTIVE_COMPARATOR|Lactulose+Rifaximin+Placebo|
62308058|NCT01944215|ACTIVE_COMPARATOR|Arm 3 - Fasting vs. Fasting + Caffeine|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
62464975|NCT00816569|EXPERIMENTAL|Keratoconus|One eye of Keratoconus patient
62737543|NCT01188551|EXPERIMENTAL|dexmedetomidine w/o midazolam|1 dose of dexmedetomidine 1mcg/kg given intranasally in OR without any pre-medication.
62737544|NCT01188551|ACTIVE_COMPARATOR|fentanyl w/o midazolam|1 dose of fentanyl 2mcg/kg given intranasally in the OR without any pre-medication.
62737545|NCT02705846||Mutation carriers with Prostate cancer|"Men with prostate cancer and a known pathogenic germline mutation in:~1. the BRCA1 or BRCA2 gene~2. the HOXB13 gene~3. The MSH2 gene~4. All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM)~5. The ATM gene~6. Other PCa predisposition genes"
62737546|NCT02705846||Mutation non carriers|"Men with prostate cancer who have tested negative for a mutation in one of the following genes:~1. the BRCA1 or BRCA2 gene~2. the HOXB13 gene~3. The MSH2 gene~4. All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM)~5. The ATM gene~6. Other PCa predisposition genes"
62464976|NCT05717257|EXPERIMENTAL|Dapagliflozin|Dapagliflozin will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
62657889|NCT02598115|NO_INTERVENTION|Before collarborative pharmaceutical care|"All clusters start in this arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
62464977|NCT05717257|NO_INTERVENTION|Control|Participants assigned to this group will continue the standard optimized medical therapy
62464978|NCT00914420|EXPERIMENTAL|Intrepide|Group A- Primary stenting with Intrepide trapidil eluting stent
62464979|NCT00914420|EXPERIMENTAL|Taxus|Group B Stenting with Taxus DES
62464980|NCT05528263|EXPERIMENTAL|Acupuncture|"* Breast cancer patients will be recruited who are scheduled to receive taxane-based chemotherapy (with or without anti-HER2 therapy) and who have no neuropathic symptoms at baseline.~  40 participants will be randomized into the acupuncture Arm:~* The acupuncture arm will receive a standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions)."
62292009|NCT05337618|EXPERIMENTAL|SD-Guided Care|In this arm, ECoG data will be reviewed for SDs in real-time using the bedside clinical CNS monitor. As a secondary measure, recognition of SDs will be facilitated by custom software on a laptop that receives data from the CNS monitor. Data on SD occurrence will be used to guide treatment in a tier-based therapeutic escalation and de-escalation protocol with the goal of SD suppression. Therapies to be used among the tiers include adjusted targets for MAP, CPP, PaCO2, plasma glucose, temperature, as well as ketamine pharmacotherapy. Changes between tiers are determined by the success or failure of SD suppression at the given treatment level.
62292010|NCT05337618|NO_INTERVENTION|Standard ICU Care|"Management in the Standard ICU Care arm will follow published national guidelines consisting of common ICU-based targets for physiologic intervention that are thought to mitigate the development of secondary brain injuries.~Continuous ECoG monitoring will be performed for seizure monitoring, but information on the course of SDs in these patients will not be used to guide care. To enforce blinding to SD-related ECoG data, the ECoG bedside software will be locked with password protection to prevent displays with frequency filtering and time/amplitude scales that are necessary to identify SDs."
62308059|NCT01944215|ACTIVE_COMPARATOR|Arm 2-Resting vs. Exercising|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be asked to perform moderate exercise on a treadmill for 6-10 minutes at a level of 70%-80% of maximum predicted heart rate. At \~10 minutes, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
62094319|NCT04901975|NO_INTERVENTION|Control|"The purpose of this study is to non-invasively characterize the fibrotic consequences of SV physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion (figure 1) along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.~Control subjects who are non-SV patients but who have normal heart function who are undergoing CMR for evaluation (eg patients undergoing CMR for vascular ring evaluation, family history of congenital heart disease but found to be normal, etc) will have study related MRI and CMR sequences performed."
61907955|NCT06289205|EXPERIMENTAL|Group 2|Group 2 will be regarded as the study group and will receive 500 µg of intra-silicon oil methotrexate at the end of the surgery and then at 1st, 2nd, 3rd , 4th and 6th post operative weeks.
62094320|NCT04901975|NO_INTERVENTION|Observational - 1A|"Subjects who were enrolled in this study in Spironolactone arm and patient's family would like to continue participation.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers \~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
62094321|NCT04901975|NO_INTERVENTION|Observational - 1B|"Subjects who were enrolled in other studies with intervention.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers \~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
62094322|NCT03496961|EXPERIMENTAL|Yan Nian Jiu Zhuan Fa|The kneading process will be done under the therapist guidance for 30 minutes with an average pressure of 5 Newton each time for 3 times every day.
62094323|NCT03496961|PLACEBO_COMPARATOR|cognitive psychology education|Psychological counseling and behavioral cognition education are conducted once a week and the rest 6 times online or by phone.
62094324|NCT03496961|NO_INTERVENTION|blank control|this group will have no therapeutic exercises or cognitive education when other two groups receive therapy.
62094325|NCT01209676|EXPERIMENTAL|IMCgp100|IMCgp100 will be injected cutaneously or subcutaneously into the metastasis, and peritumoral area if applicable
62094326|NCT06390553|ACTIVE_COMPARATOR|Conventional group|"Patients in the conventional treatment group will be given 15 minutes of walking training in addition to the 45 minutes of conventional Parkinson's rehabilitation program. Patients in the conventional treatment group will be trained in flexibility (lumbar extensors, hip flexors, hamstrings, pectorals), balance (weight transfer, static balance with stress loading) coordination (rotational and bilateral activities), respiratory (thoracic expansion, respiratory control), strength (hip circumference, abdomen, back extensors), stabilization, posture (chin tuck, scapular adduction) exercises will be given and the number of repetitions will be adjusted according to patient performance.~Walking training to be given to the conventional group will include walking in different directions, walking with arm swing, walking over blocks, stopping and restarting walking, and changing direction activities."
62292011|NCT06484335|ACTIVE_COMPARATOR|Active Arm|"For the primary objectives and endpoints, this study will enroll PLWH aged 18-60 years who initiated ART during Fiebig I-V AHI, are virologically suppressed (HIV-1 RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, and who meet study inclusion criteria into Groups 1 and 2.~• Active Arm - Group 1 will receive: i. VRC07-523LS and PGDM1400LS at Step 2, Week 0 ii. ART starting at Step 2, Week 1 iii. ChAdOx1.tHIVconsv1 and ChAdOx1.HIVconsv62 vaccination at Step 2, Week 4 iv. MVA.tHIVconsv4 and A244d11 gp120/ALFQ vaccination at Step 2, Weeks 12 and 20"
62292012|NCT06484335|PLACEBO_COMPARATOR|Comparator Arm|"For the primary objectives and endpoints, this study will enroll PLWH aged 18-60 years who initiated ART during Fiebig I-V AHI, are virologically suppressed (HIV-1 RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, and who meet study inclusion criteria into Groups 1 and 2.~• Comparator Arm - Group 2 will receive: i. VRC07-523LS and PGDM1400LS at Step 2, Week 0 ii. ART starting at Step 2, Week 1 iii. Placebo vaccination at Step 2, Weeks 4, 12 and 20"
62292013|NCT06484335|OTHER|Exploratory Arm|"This study will also enroll an Exploratory arm of PLWH aged 18-60 years who are diagnosed during Fiebig I-V AHI, have not yet initiated ART, and meet all study inclusion criteria into Group 3.~• Exploratory Arm - Group 3 will receive: i. VRC07-523LS and PGDM1400LS at Step 2, Week 0 ii. ART starting at Step 2, Week 0 iii. ChAdOx1.tHIVconsv1 and ChAdOx1.HIVconsv62 vaccination at Step 2, Week 12 iv. MVA.tHIVconsv4 and A244d11 gp120/ALFQ vaccination at Step 2, Weeks 20 and 28"
62292014|NCT00603239|EXPERIMENTAL|Exenatide twice daily (BID)|
62292015|NCT00603239|PLACEBO_COMPARATOR|Placebo|
62292016|NCT03837184|EXPERIMENTAL|Onasemnogene Abeparvovec-xioi|Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously.
62292017|NCT00295945||PCA|Patient-controlled intravenous analgesia
62292018|NCT00295945||PCEA|Perioperative patient-controlled epidural analgesia
62464981|NCT05528263|ACTIVE_COMPARATOR|Nature scenery videos with relaxation exercise|"* Breast cancer patients will be recruited who are scheduled to receive taxane-based chemotherapy (with or without anti-HER2 therapy) and who have no neuropathic symptoms at baseline.~  40 Participants will be randomized into the Control Arm:~* The control arm will receive and watch videos with nature scenery with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)"
62094327|NCT06390553|EXPERIMENTAL|Virtual reality group|Patients in the virtual reality group will be given a 45-minute conventional Parkinson's rehabilitation program similar to those in the conventional group, followed by 15 minutes of virtual reality walking training. Patients in the virtual reality group will be trained in flexibility (lumbar extensors, hip flexors, hamstrings, pectorals), balance (weight transfer, static balance with stress loading) coordination (rotational and bilateral activities), Respiratory (thoracic expansion, respiratory control), strength (hip circumference, abdomen, back extensors) stabilization, posture (chin tuck, scapular adduction) exercises will be given and the number of repetitions will be adjusted according to patient performance. Virtual reality applications increase the sense of reality in the individual with enriched virtual environments where sensory inputs are increased and provide the opportunity to perform activity training with a rich variety of tasks.
62464982|NCT04075461|EXPERIMENTAL|Undisplaced FNF + Arthroplasty|Arthroplasty is the typical surgery for a displaced femoral neck fracture
62464983|NCT04075461|ACTIVE_COMPARATOR|Undisplaced FNF + Internal fixation|Internal fixation is the typical surgery for an undisplaced femoral neck fracture
62094328|NCT06362941|EXPERIMENTAL|Nutrafol Hair Growth Supplement|5 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.
62094329|NCT06432998|EXPERIMENTAL|Perineal massage|Ten sessions of perineal massage, which will be carried out for fifty minutes, once a week, together with a health education program.
62094330|NCT06432998|ACTIVE_COMPARATOR|Treatment with dilators|A health education session will be held but then the use of vaginal dilators will be done according to the gold standard treatment.
62094331|NCT01505075|EXPERIMENTAL|Hypofractionated radiation|40 Gy in 5 fractions over 29 to prostate; 30 Gy in 5 fractions over 29 days to seminal vesicles
62094332|NCT06614010|EXPERIMENTAL|Group S1|Before anesthesia induction, an iliac fascia block was administered using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, dexmedetomidine was infused intravenously at a rate of 0.5 µg/kg/h.
62308060|NCT01944215|ACTIVE_COMPARATOR|Arm 1-Fasting vs. Fed|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
62464984|NCT02466594|OTHER|Hilotherm Clinic®|Intervention: Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
62464985|NCT03136380|EXPERIMENTAL|Part 1: Group A|Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
62464986|NCT03136380|EXPERIMENTAL|Part 1: Group B|Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
62094333|NCT06614010|EXPERIMENTAL|Group S2|Before anesthesia induction, an iliac fascia block was administered using a mixture of 0.375% ropivacaine and 1ug/kg dexmedetomidine (30ml) under ultrasound guidance. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
62464987|NCT03136380|EXPERIMENTAL|Part 1: Group C|Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
62464988|NCT03136380|EXPERIMENTAL|Part 2: Group D|Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
62464989|NCT03136380|EXPERIMENTAL|Part 2: Group E|Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.
62464990|NCT04970368|EXPERIMENTAL|Sentinel Node Surgical Staging|
62464991|NCT04970368|EXPERIMENTAL|Selective Surgical Staging|
62464992|NCT05192850||Metformin use|These participants were on metformin for any duration at any point in time in the study period
62464993|NCT05192850||No metformin use|These participants were never on metformin for any duration at any point in time in the study period
62464994|NCT01947218|EXPERIMENTAL|smoking COPD|
62464995|NCT01947218|EXPERIMENTAL|smoking without COPD|
62094334|NCT06614010|ACTIVE_COMPARATOR|Group C|Before anesthesia induction, an iliac fascia block was performed using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
62292019|NCT03314506|EXPERIMENTAL|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
62292020|NCT04879797|OTHER|Maternal Safety Bundles Implementation|The first intervention targets obstetric hemorrhage, severe hypertension and maternal health equity by implementing three relevant AIM bundles: Obstetric Hemorrhage, Severe Hypertension in Pregnancy, and Reduction of Peripartum Racial/Ethnic Disparities. The Perinatal Neonatal Quality Improvement Network (PNQIN) will facilitate this collaborative QI project and support participating hospitals by providing guidance, education, and technical assistance to hospitals to support implementation of bundles using the QI process. Implementation strategies are based on the Institute for Healthcare Improvement (IHI) improvement model and the AIM program implementation toolkit and have previously been used by PNQIN to implement the Obstetric Care for Women with Opioid Use Disorder AIM bundle in 22 hospitals, including the five hospitals for this study.
62308061|NCT03831503|EXPERIMENTAL|Cohort A - 0.5mg|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 0.5 mg DNA/dose. Inoculation will be administered as 0.5 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
62308062|NCT03831503|EXPERIMENTAL|Cohort B - 1mg|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 1 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
62464996|NCT01947218|OTHER|No Smoking Control|
62657890|NCT02598115|EXPERIMENTAL|After collarborative pharmaceutical care|"All clusters start in the No Intervention arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
61907956|NCT03714269|EXPERIMENTAL|Children with cerebral palsy of the spastic type|
62094335|NCT05638854|EXPERIMENTAL|Part A: SAD in Healthy Volunteers|Healthy volunteers will receive a single dose of ZB002 or placebo
62094336|NCT05638854|EXPERIMENTAL|Part B: MAD in RA Participants|RA participants will receive ZB002 or placebo every 4 weeks (Q4W) × 3 administrations
62094337|NCT03049111|EXPERIMENTAL|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
62094338|NCT04681417|EXPERIMENTAL|Study 1: Melphalan or Melphalan + Topotecan|Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
62464997|NCT01947218|EXPERIMENTAL|severe asthma|
62657891|NCT00404313|EXPERIMENTAL|1|MK0633 10 mg
62657892|NCT00404313|EXPERIMENTAL|2|MK0633 50 mg
62657893|NCT00404313|EXPERIMENTAL|3|MK0633 100 mg
62094339|NCT04681417|OTHER|Study 2: Etoposide, carboplatin and vincristine|Neoadjuvant chemotherapy involves 2 to 6 cycles of combined etoposide, carboplatin and vincristine in association with ophthalmologic treatments.
62094340|NCT05675306|EXPERIMENTAL|High Dose Frequency|This group will receive treatment 4x/week for 6 weeks
62094341|NCT05675306|ACTIVE_COMPARATOR|Low Dose Frequency|This group will receive treatment 2x/week for 12 weeks
62094342|NCT03224338|EXPERIMENTAL|: Dolutegravir (DTG)|
62094343|NCT05641467|EXPERIMENTAL|Video will be watched with virtual reality glasses during episiotomy repair|Views of nature with virtual reality glasses during episiotomy repair.
62094344|NCT05641467|NO_INTERVENTION|Control|It will be perform routine practice who the women in the control group.
62094345|NCT06104540|EXPERIMENTAL|Experimental I Liquid Vaseline|Liquid vaseline will be applied to the Experimental I group twice a day according to the oil application protocol
62094346|NCT06104540|EXPERIMENTAL|Experimental II Extra Virgin Olive Oil|Extra Virgin Olive Oil will be applied to the Experimental I group twice a day according to the oil application protocol
62094347|NCT06104540|EXPERIMENTAL|Control group|No application will be made to the control group other than the institution's recommendations.
62094348|NCT05368103|EXPERIMENTAL|Daxdilimab|Nine sets of Daxdilimab injections over a total of 32 weeks.
62094349|NCT05632484|EXPERIMENTAL|Newborns with a parent with HHT disease|16 newborns with one parent suffering HHT disease and carrying a mutation in the ACVRL1, ENG or SMAD4 gene will be included in this study.
62094350|NCT06615128||Systemic sclerosis patients|
62094351|NCT06615128||Healthy control|
62094352|NCT04688411|OTHER|MED-Go app Intervention|Participants will use MED-Go app intervention for a total of 12 weeks
62094353|NCT04688411|NO_INTERVENTION|Control Arm|Standard of care
62292021|NCT04879797|OTHER|Doula Services|The second intervention that this study evaluates is doula services. Investigators are evaluating doula services that are offered by two doula organizations at three hospitals. Investigators will provide top-up training to these doulas in order to provide some standardization and quality assurance of the services delivered. The training is developed and delivered by an obstetrician (Meadows) and doula (Gebel) and will take place among providers (staff associated with three chosen hospitals), patient navigators, and two doula groups, Birth Sisters and Accompany Doula Care, on factors that comprise the risk profile and how to offer targeted doula services to women who fit the risk profile. All sites will use standardized data instruments to evaluate the number of factors in the risk profile being met as well as standardized language and recruitment materials for mothers.
62094354|NCT01221077|EXPERIMENTAL|Arm A: Erlotinib plus OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
62292022|NCT01200433|ACTIVE_COMPARATOR|propofol|Subjects will be sedated with propofol.
62292023|NCT01200433|ACTIVE_COMPARATOR|dexmedetomidine|Subjects will be sedated with dexmedetomidine.
62464998|NCT00626184|PLACEBO_COMPARATOR|A|Placebo
62657894|NCT00404313|PLACEBO_COMPARATOR|4|placebo
62657895|NCT04461392|EXPERIMENTAL|Oncology patients|Patients diagnosed with cancer and treated with chemotherapy and/or radiotherapy
62657896|NCT06080815|ACTIVE_COMPARATOR|Group I: patients receive maxillary complete denture opposed to conventional mandibular overdenture|
62464999|NCT00626184|ACTIVE_COMPARATOR|B|Active study Drug: ALV003
62657897|NCT06080815|ACTIVE_COMPARATOR|Group II: patients receive maxillary complete denture opposed CAD/CAM overdenture|
62657898|NCT05502731|EXPERIMENTAL|Add-on filgotinib|Treatment with a combination therapy of MTX (7.5 - 15 mg once weekly) and filgotinib p.o. (200 mg once daily) for 24 weeks
62094355|NCT01221077|PLACEBO_COMPARATOR|Arm B: Erlotinib plus Placebo|As of 01 March 2013, the matching placebo is no longer being administered
62094356|NCT01140347|EXPERIMENTAL|Ramucirumab DP and BSC|
62094357|NCT01140347|PLACEBO_COMPARATOR|Placebo and BSC|
62657899|NCT05502731|ACTIVE_COMPARATOR|Add-on adalimumab|Treatment with a combination therapy of MTX (7.5 - 15 mg once weekly) and adalimumab s.c. (40 mg biweekly) for 24 weeks
62737547|NCT06552455||Higher Pressure|"Use of initial post-extubation pressures that are 2 cmH2O higher than the pre-extubation measured mean airway pressure (Paw). This can be via either CPAP (continuous positive airway pressure) or NIPPV (nasal intermittent positive pressure ventilation).~Higher CPAP: Initial set Paw level on CPAP = Pre-extubation measured Paw level + 2 cmH2O~Higher NIPPV: Initial set Paw level on NIPPV = Pre-extubation measured Paw level + 2 cmH2O"
62094358|NCT05640921|EXPERIMENTAL|Group-integrated Cognitive Behavioural Therapy (Gi-CBT)|The Gi-CBT sessions will cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience through post-traumatic situations and adversities.
62094359|NCT05640921|ACTIVE_COMPARATOR|Media Intervention|The second group will receive Media Orientation (MO). The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
62094360|NCT05793892|EXPERIMENTAL|Arm A|The order of administration of the test drug in both treatment areas in Arm A is the first, followed by the use of the control drug.
62094361|NCT05793892|ACTIVE_COMPARATOR|Arm B|The order of administration in both treatment areas in Arm B was the use of the control drug first, followed by the investigational drug.
62094362|NCT06270173|EXPERIMENTAL|Intervention|Tripod-Fix will be used to treat osteoporotic vertebral compression fractures.
62094363|NCT06649552|OTHER|SPI-CY assessment|all patients will undergo a SPI-CY interview
62657900|NCT02689622|EXPERIMENTAL|Evaluation of disease prognostic factors|Research of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
62094364|NCT00875147||with bevacizumab|Neoadjuvant chemotherapy with bevacizumab
62094365|NCT00875147||without Bevacizumab|Neoadjuvant chemotherapy without Bevacizumab
62094366|NCT04155099|EXPERIMENTAL|High dose|Capsules of active drug will be supplied in 8-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
62094367|NCT04155099|EXPERIMENTAL|Low dose|Capsules of active drug will be supplied in 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
62094368|NCT04155099|PLACEBO_COMPARATOR|pill quantity-matched Placebo|Capsules of inactive compound will be supplied in 8- or 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
62094369|NCT03582137|EXPERIMENTAL|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
62094370|NCT03582137|PLACEBO_COMPARATOR|placebo|Placebo oral solution
62094371|NCT01541319||Randomized to <= 10day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
62094372|NCT01541319||Randomized to >= 21day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
62094373|NCT01541319||Randomized but not transfused|Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
62094374|NCT01541319||Healthy volunteers|
62292024|NCT05349955|EXPERIMENTAL|Intensive guideline algorithm implementation|SGLT2i or GLP-1RA recommended in priority in subjects at very high/high CV risk. The targets of intervention will be achieved at HbA1C \<7%, blood pressure \<130/80mmHg， LDL-c\<1.8mmol/L at very high CV risk or \<2.6mmol/L at high CV risk patients, antiplatelet as secondary prevention of ASCVD.
62292025|NCT05349955|ACTIVE_COMPARATOR|Conventional guideline algorithm implementation|Treatment based on the current approaches implemented by local physicians(primary care physicians). Guideline based education and consults will be conducted to primary care physicians.
62292026|NCT05490992|NO_INTERVENTION|Car seat check-up traditional car seat educational method|Experiment-1a: This included 600 expectant parents who were educated by a certified child passenger safety technician with a traditional car seat educational approach. All participants were assessed at baseline, no-intervention traditional education, and follow-up, between June 1, 2015 and May 30, 2016
62292027|NCT05490992|EXPERIMENTAL|Behavioral Skills Training In-person Group A|Experiment-1b: This included another 600 expectant parents who were educated by a certified child passenger safety technician an in-person Behavioral Skills Training (BST) approach. All participants were assessed at baseline, BST, and follow-up, between June 1, 2016 and May 30, 2017.
62465000|NCT03686033|EXPERIMENTAL|Placebo, E2082 2.5 mg, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between all the treatment periods.
62465001|NCT03686033|EXPERIMENTAL|E2082 2.5 mg, E2082 25 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
62292028|NCT05490992|EXPERIMENTAL|Behavioral Skills Training In-person Group B|Experiment-2a: This included another 600 expectant parents who were educated by a certified child passenger safety technician an in-person Behavioral Skills Training (BST) approach. All participants were assessed at baseline, BST, and follow-up, between June 1, 2018 and June 30, 2019.
62465002|NCT03686033|EXPERIMENTAL|E2082 25 mg, Placebo, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
62465003|NCT03686033|EXPERIMENTAL|Placebo, E2082 25 mg, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
62737548|NCT06552455||Equal/Lower Pressure|"Use of initial post-extubation pressures that is equal to/lower than the pre-extubation measured mean airway pressure (Paw). This can be via either CPAP (continuous positive airway pressure) or NIPPV (nasal intermittent positive pressure ventilation).~Equal/Lower CPAP: Initial set Paw level on CPAP ≤ Pre-extubation measured Paw level~Equal/Lower NIPPV: Initial set Paw level on NIPPV ≤ Pre-extubation measured Paw level"
62737549|NCT02074670|EXPERIMENTAL|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
62737550|NCT04691245|EXPERIMENTAL|Intervention|Femoral access using 3D US
62737551|NCT04691245|ACTIVE_COMPARATOR|Control|Femoral access using 2D US
62737552|NCT01277705|EXPERIMENTAL|Group A|
62737553|NCT01277705|EXPERIMENTAL|Group B|
62737554|NCT01277705|ACTIVE_COMPARATOR|Group C|
62094375|NCT06576284||Personalized implant|This is an observational, prospective, single-cohort study conducted at the University of São Paulo, São Paulo, Brazil, involving individuals who received a personalized dental implant using the iDENTICAL Dental Implant System. The aim is to evaluate the safety, efficacy, and clinical viability of these customized implants over a 36-month follow-up period.
62094376|NCT06110117|EXPERIMENTAL|Nasal Spray|1 to 2 sprays per nostril of Sterimar Stop \& Protect Irritation \& Dryness for a minimum of 2 times (morning and evening) and, as needed, up to a maximum of 6 times per day (i.e. maximum 12 sprays per nostril each day) for seven days.
62094377|NCT06493279|EXPERIMENTAL|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product. 9 subjects will be involved in 3 doses cohort from low to high: 6E13 vg/person, 1.2E14 vg/person, and 2.4E14 vg/person, 3 subjects for each cohort.
62094378|NCT01341080|EXPERIMENTAL|Varenicline|
62292029|NCT05490992|EXPERIMENTAL|Behavioral Skills Training Telehealth|Experiment-2b: This included another 600 expectant parents who were educated by a certified child passenger safety technician a virtual telehealth version of Behavioral Skills Training (BST). All participants were assessed at baseline, BST-Telehealth, and follow-up, between April 1, 2020 and December 31, 2021.
62094379|NCT01341080|PLACEBO_COMPARATOR|Sugar pill|
62094380|NCT03032835||Study participants|No intervention
62094381|NCT06460467||Patients treated with 177Lu-DOTATATE|Patients treated with 177Lu-DOTATATE for a meningioma at the Nancy University Hospital and for a neuroencrine tumor in the EVADOVE study NCT04467567 (who underwent scintigraphy on D1, D4 and D7 (± 1 day)
62292030|NCT05698290||Health Department of Northwest Michigan|School providers (school nurses, mental health specialists) from the Health Department of Northwest Michigan.
62292031|NCT05698290||Michigan Association of School Nurses|School providers (nurses) from the Michigan Association of School Nurses.
62292032|NCT03798288|EXPERIMENTAL|Usual care + selfBACK|"The selfBACK system constitutes a data-driven decision support system that uses case-based reasoning to capture and reuse participant cases to suggest the most suitable self-management plan for participants. The system is an intelligent system delivering self-management plans tailored to individual participant characteristics. Information about participant characteristics is collected via a (baseline) questionnaire, weekly self-reports via the app on symptom progression etc., and a wristband that detect daily number of steps. The weekly plans are presented in an app to participants.~The weekly plan includes three categories of content;~1. information/education~2. recommended daily number of steps~3. recommended strength and flexibility exercises"
62292033|NCT03798288|ACTIVE_COMPARATOR|Usual care|Any diagnostic or treatment-related pathway (e.g. receive information, advice or treatment) as instructed by their health care professional. Patients are allowed to seek care, treatment or help elsewhere as normal.
62094382|NCT06697639|EXPERIMENTAL|Rehabilitation Group|In addition to routine postpartum care, small-sized WAFF air cushions will be issued during the hospitalization period to guide patients in performing the WAFF pelvic-abdominal mechanical rehabilitation exercises. Patients will also be instructed to join the experimental group's WeChat group. After discharge, researchers will upload WAFF pelvic-abdominal mechanical rehabilitation instructional videos. Patients are required to complete their rehabilitation exercises twice daily, each session lasting 10-15 minutes. Patients need to upload their exercise videos twice a week, and researchers will provide motion guidance based on the video content until the patient's postpartum follow-up examination. The abdominal rectus muscle, pelvic floor muscle function, and adherence to rehabilitation exercises will be assessed for patients in both groups at 6-8 weeks and 6 months postpartum.
62094383|NCT06697639|NO_INTERVENTION|Control Group|During hospitalization, routine postpartum education and discharge instructions will be provided, including the distribution of promotional brochures and guidance on performing puerperium recovery exercises. Patients will be instructed to join the control group's WeChat group. After discharge, researchers will upload instructional videos for the recovery exercises and urge patients to perform the postpartum recovery exercises twice daily, each session lasting 10-15 minutes. Patients are required to upload their exercise videos twice a week, and researchers will provide motion guidance based on the video content until the patient's postpartum follow-up examination.
62094384|NCT05732948|EXPERIMENTAL|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells PD-1 silent targeted to PSMA/PSMA administered one day after pretreatment with cyclophosphamide.
62094385|NCT03276364||Shock|
62292034|NCT00967265|EXPERIMENTAL|Introduction seminar|Psychoeducation for patients on waiting list
62292035|NCT00967265|ACTIVE_COMPARATOR|Usual care|Usual care
62292036|NCT03258892|EXPERIMENTAL|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
62292037|NCT03258892|EXPERIMENTAL|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
62657901|NCT03977207|EXPERIMENTAL|Levothyroxine|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (\>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is \>3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.~The intervention period is 24 weeks. Patients will undergo up to two subsequent dose titrations after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points. Patients whose TSH levels are higher or lower than the therapeutic TSH target of 0.5-3.0mIU/L will undergo a dose adjustment (+/- 25mcg), while those whose TSH levels are in target range will continue the prior dose."
62094386|NCT02395185|EXPERIMENTAL|Milk|Milk bottle administration
62094387|NCT02395185|EXPERIMENTAL|Water|Water bottle administration
62094388|NCT02395185|EXPERIMENTAL|Sucrose|Sucrose bottle administration
62094389|NCT02512146||Irritable bowel syndrome|Patients meeting Rome III criteria of irritable bowel syndrome. Intervention: colonoscopy.
62292038|NCT03011645|ACTIVE_COMPARATOR|Ziprasidone|Ziprasidone 60 mg tablet by mouth, once a day for one day.
62292039|NCT03011645|ACTIVE_COMPARATOR|Lorcaserin|Lorcaserin 20 mg tablet by mouth, once a day for one day.
62292040|NCT03011645|PLACEBO_COMPARATOR|Placebo Oral Tablet|Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.
62292041|NCT02063555|EXPERIMENTAL|DAR-901|"Intradermal administration at 0, 2 and 4 months~Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL"
62094390|NCT02512146||Normal controls|"Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.~Intervention: colonoscopy."
62094391|NCT03739411|EXPERIMENTAL|Cohort I (Hyperpolarized C13, MRI)|Participants receive hyperpolarized carbon C 13 pyruvate intravenously IV and undergo MRI. The second hyperpolarized 13 C injection/imaging will be started approximately 15 to 60 minutes after the first injection for those who are willing to receive two 13 C injections
62094392|NCT03739411|EXPERIMENTAL|Cohort II (Hyperpolarized C13, MRI)|Participants receive hyperpolarized carbon C 13 pyruvate IV and undergo MRI before treatment and 4 weeks after completion of cancer therapy given outside of this study.
62094393|NCT06148766|EXPERIMENTAL|Eternal Renewal Regenerating Face Cream|"Participants will be required to apply the test product in the morning and before bedtime at night.~After thoroughly cleansing and toning the face, the participants will take a pea-sized amount of face cream and apply it to the face, massaging over the entire face with small circular movements until the cream has fully absorbed."
62094394|NCT05388916||Cosentyx|Pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx
62292042|NCT02063555|ACTIVE_COMPARATOR|BCG|Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos
62292043|NCT02063555|PLACEBO_COMPARATOR|Sterile saline|Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos
62657902|NCT03977207|PLACEBO_COMPARATOR|Placebo|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (\>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is \>3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.~The intervention period is 24 weeks. Patients in the placebo arm will undergo an equivalent titration in placebo pills (as that of the experimental arm) after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points."
62657903|NCT03977818||patients with metastatic softtissue sarcomas diagnosed between 1990 and 2013|
62657904|NCT04153656|OTHER|Nurses|Subjects will be asked to commit to reading and studying Spiritual Flow.
62657905|NCT01767220|ACTIVE_COMPARATOR|Strategy 1- endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial.
62657906|NCT01767220|ACTIVE_COMPARATOR|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and ablation are done from endocardial and epicardial.
62657907|NCT01859000|EXPERIMENTAL|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
62094395|NCT05406934||healthy group|the healthy group, not diagnosed IBD
62094396|NCT05406934||IBD patients controlled by conventional treatment|controlled by conventional treatment and divided to UC group and Crohns group
62094397|NCT05406934||uncontrolled IBD patients on biological's treatment|divided to uc received biological and Crohns received biolgical
62094398|NCT05506644|EXPERIMENTAL|HRV-Biofeedback|
62094399|NCT06009380|EXPERIMENTAL|Intervention Group|In addition to the program given to the control group, the dual task program will be given to the study group progressively as previously stated (Silsupadol et al., 2006). These applications will be explained to the patients or their relatives face-to-face in the clinical environment after the initial evaluation and then sent and followed up by telerehabilitation method and patients will always have access to programs and education. In addition, both groups will be told that they can contact the researcher upon request.
62094400|NCT06009380|ACTIVE_COMPARATOR|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
62094401|NCT03312985|EXPERIMENTAL|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
62292044|NCT00989599|EXPERIMENTAL|compress of Chamomilla recutita infusion|Patients who developed phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
62094402|NCT03312985|PLACEBO_COMPARATOR|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
62465004|NCT03686033|EXPERIMENTAL|E2082 2.5 mg, Placebo, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
62465005|NCT03686033|EXPERIMENTAL|E2082 25 mg, E2082 2.5 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
62465006|NCT03225456|EXPERIMENTAL|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
62094403|NCT03574909|EXPERIMENTAL|Treatment Arm|"Treatment Arms: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda Pharma SL (Reg 59.210).~There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
62094404|NCT03574909|PLACEBO_COMPARATOR|Control Arm|"Placebos to be used are hard gelatin capsules (Sanitatis®) for patients randomized to the placebo arm. These capsules are externally identical to Tromalyt capsule. The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate (Sanitatis®) Placebo: There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
62094405|NCT00287638|ACTIVE_COMPARATOR|1|CPAP
62094406|NCT00287638|PLACEBO_COMPARATOR|2|no CPAP
62094407|NCT01772056|EXPERIMENTAL|Fluticasone, cream|fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant.
62094408|NCT01772056|PLACEBO_COMPARATOR|Placebo, cream|Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant.
62094409|NCT01658488|OTHER|Regular Rice|2 servings per day of non-fortified rice
62292045|NCT00989599|ACTIVE_COMPARATOR|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
62292046|NCT01879410|EXPERIMENTAL|UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm|Subjects will receive one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning via the NDPI and one inhalation of placebo in the morning and evening via ACCUHALER/DISKUS inhaler
62292047|NCT01879410|ACTIVE_COMPARATOR|FSC via ACCUHALER/DISKUS + placebo NDPI arm|Subjects will receive one inhalation of FSC 250/50 mcg in the morning and evening via ACCUHALER/DISKUS inhaler and one inhalation of placebo administered once-daily in the morning via NDPI
62094410|NCT01658488|OTHER|Iron-fortified Rice|2 servings per day of Rice enriched in iron for women with iron-deficient anemia to restore their blood counts more efficiently than the standard rice not enriched with iron.
62094411|NCT01581853|OTHER|Lopinavir/ritonavir 800 mg / 200mg|Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
62465007|NCT03225456|PLACEBO_COMPARATOR|Placebo|Participants will received match placebo, again in two doses in a single session
62465008|NCT01900964|ACTIVE_COMPARATOR|PTFE membrane|A non-resorbable PTFE (polytetrafluoroethylene) membrane will be used as a positive control treatment.
62465009|NCT01900964|EXPERIMENTAL|Collagen membrane|A resorbable collagen membrane will be used in the test group.
62094412|NCT06697860|EXPERIMENTAL|Radial Shockwave Therapy|Radial Shockwave therapy in Plantar Fasciitis.
62094413|NCT06697860|EXPERIMENTAL|Graston instrument|Graston Instrument assisted soft tissue mobilization on Plantar Fasciitis.
61907957|NCT04113590|EXPERIMENTAL|Transvaginal cholecystectomy under laparoscopic guidance|The removal of the gallbladder through several small incisions using a camera to see is called laparoscopic cholecystectomy. This study is being done to evaluate whether cholecystectomy can be performed through a natural orifice (the vagina) with minimal laparoscopic assistance (only one abdominal trocar versus four in the routine laparoscopic cholecystectomy).
62657908|NCT01859000|OTHER|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron \& Kaminer, 2004) as well as trauma (La Greca \& Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
61907958|NCT02065388|ACTIVE_COMPARATOR|Standard of care dosing for warfarin|Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
62094414|NCT03392532|OTHER|AOHG toric, then AO toric|Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
62094415|NCT03392532|OTHER|AO toric, then AOHG toric|Lotrafilcon B toric contact lenses, followed by lotrafilcon B toric contact lenses with HYDRAGLYDE, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
62094416|NCT03310463|EXPERIMENTAL|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute \[mL/min\] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
62094417|NCT03310463|EXPERIMENTAL|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate \[eGFR\] ≥60 to \<90 mL/min/1.73 meters squared \[m\^2\] calculated by the Modified Diet in Renal Disease \[MDRD\] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
62465010|NCT05422170||Patients undergoing transfemoral TAVI|Patients receiving 125 U/kg unfractioned heparin for periprocedural anticoagulation and 500U Protamine / 1000U Heparin at the end of the procedure
61907959|NCT02065388|EXPERIMENTAL|Genotype-guided dosingTaiwan algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
62094418|NCT03310463|EXPERIMENTAL|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to \<60 mL/min/1.73 m\^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
62292048|NCT04525729|EXPERIMENTAL|Rituximab+RASi(ACEI and/or ARB)|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject, combined with rituximab 1g(D1, D31 respectively, intravenous infusion). Add 1 g rituximab at 6 months.
62292049|NCT04525729|OTHER|RASi(ACEI and/or ARB）|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject.
62465011|NCT01789385|OTHER|dexmedetomidine|Precedex 200 mcg 2ml
62465012|NCT02419937|ACTIVE_COMPARATOR|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
62465013|NCT02419937|PLACEBO_COMPARATOR|Placebo|Blinded subjects will be randomized to placebo
61907960|NCT02065388|EXPERIMENTAL|Genotype-guided dosing IWPC algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
61907961|NCT01258569|ACTIVE_COMPARATOR|Entereg|
61907962|NCT01258569|PLACEBO_COMPARATOR|Placebo|
61907963|NCT02379130|EXPERIMENTAL|Family Nurture Intervention Group|Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
62292050|NCT04686422|EXPERIMENTAL|Tetric PowerFill Class I and II restorations|
62657909|NCT04660383|EXPERIMENTAL|IMT 50|"IMT intervention: IMT50 - 50% of the maximum inspiratory pressure (MIP), using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
62657910|NCT04660383|EXPERIMENTAL|IMT 30|"IMT intervention: IMT30 - 30% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
62657911|NCT04660383|SHAM_COMPARATOR|IMT 10|"IMT intervention: IMT10 - 10% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
62094419|NCT03310463|EXPERIMENTAL|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR \<30 mL/min/1.73 m\^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
62292051|NCT00484315|EXPERIMENTAL|TAXUS Element|
62657912|NCT02733419|EXPERIMENTAL|Enfuvirtide + OB (Not Randomized)|Participants will receive enfuvirtide 90 milligram (mg) twice daily (b.i.d.) and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants not meeting the randomization criteria will receive enfuvirtide 90 mg b.i.d and OB for next 24 weeks (up to Week 52).
62094420|NCT03310463|EXPERIMENTAL|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
62292052|NCT00484315|ACTIVE_COMPARATOR|TAXUS Express|
62292053|NCT00787436|NO_INTERVENTION|1|Standard of care with normal treatment
62292054|NCT00787436|ACTIVE_COMPARATOR|Thalidomide|Standard of care and treatment using Thalidomide
62292055|NCT04120922|OTHER|calcium carbonate|"Calcium based P-binder - calcium carbonate: Typical dose is 500mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
62292056|NCT04120922|OTHER|sevelamer carbonate|"Calcium (Ca) free P-binder - sevelamer carbonate: Typical dose is 800mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
62292057|NCT05047523|EXPERIMENTAL|ALXN1840|ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.
62292058|NCT05047523|ACTIVE_COMPARATOR|Standard of Care|Participants will receive their current therapy or initiate Standard of Care therapy.
62292059|NCT06129890|OTHER|M1 - DLPFC|"Initial primary motor cortex stimulation (M1) followed by cortex prefrontal cortex (DLPFC) :~rTMS of M1, washout, rTMS of DLPFC"
62292060|NCT06129890|OTHER|DLPFC - M1|"Initial cortex prefrontal cortex (DLPFC) stimulation followed by primary motor cortex stimulation (M1) :~rTMS of DLPFC, washout, rTMS of M1"
62657913|NCT02733419|EXPERIMENTAL|Enfuvirtide + OB (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive enfuvirtide 90 mg b.i.d. and OB for next 24 weeks (up to Week 52).
62657914|NCT02733419|EXPERIMENTAL|OB alone (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive OB alone for next 24 weeks (up to Week 52).
62094421|NCT01304524|EXPERIMENTAL|VGX 3100|
62094422|NCT01304524|PLACEBO_COMPARATOR|Placebo|
62094423|NCT05750745|EXPERIMENTAL|Test Dentifrice|Participants will be instructed to brush the two test teeth first, then the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Sensodyne Sensitivity \& Gum. After brushing, participants will be instructed to rinse once with 10 milliliters (mL) of water using the measuring cup provided.
62292061|NCT06391645|EXPERIMENTAL|MPC-NGF T1|19.2mg MPC wrapped NGF per week for 13 times
62292062|NCT06391645|EXPERIMENTAL|MPC-NGF T2|11.84mg MPC wrapped NGF per week for 13 times
62292063|NCT06391645|ACTIVE_COMPARATOR|X-NGF|19.2mg NGF per week for 13 times
62292064|NCT00745108|EXPERIMENTAL|Tibolone 1.25 mg|
62292065|NCT00745108|EXPERIMENTAL|Tibolone 2.5 mg|
62292066|NCT00745108|ACTIVE_COMPARATOR|CE/MPA|
62292067|NCT06195202||AI|Patients with AIs
62292068|NCT06195202||OFS+AI|Patients with OFS+AIs
62292069|NCT06195202||FUL|Patients with FUL
62308063|NCT03831503|EXPERIMENTAL|Cohort C - 2mg|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 2 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
62465014|NCT03354221|EXPERIMENTAL|Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale|Patients going through the six food elimination diet (clinically) for EoE will be asked to participate. During the initial 6 week elimination period, participants will return at 2, 4 and 6 weeks to swallow the cytosponge. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, \<15 phf would be considered a responder. Results of the histology will help the investigator to direct the future of the 6 food elimination diet to determine if a period of 6 weeks of initial elimination is necessary. The EEsAI Pro questionnaire measures symptomatic response to the elimination of the foods. The Likert Scoring Scale measures patient experience of the cytosponge and the upper endoscopy.
62465015|NCT03800251|OTHER|Fasting parturients at term|Fasting parturients at term, admitted for elective cesarean section, who consent to partake in the study
62465016|NCT00614471|ACTIVE_COMPARATOR|1|
62657915|NCT02511756|OTHER|Perfusion-computed tomography (CTP)|Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
62657916|NCT05072808|ACTIVE_COMPARATOR|Intervention Group|ED Providers randomized to the Intervention Group will be able to view the results of the parent-completed questionnaire, the Pediatric Asthma Control and Communication Instrument for the Emergency Department (PACCI-ED), and outpatient referral recommendations aligned with asthma severity.
62657917|NCT05072808|NO_INTERVENTION|Control Group|ED providers randomized to the Control Group will neither receive the results of the parent-completed PACCI-ED or specific recommendations for outpatient referrals. Patients randomized to the control group will receive usual care.
62657918|NCT05958563|EXPERIMENTAL|CPAP group|Continuous positive airway pressure (CPAP) for one year
62657919|NCT05958563|NO_INTERVENTION|Control group|No CPAP treatment
62657920|NCT03421457|EXPERIMENTAL|Lateral suspension|"Uterus-preserving Laparoscopic lateral suspension with mesh technique will be performed in this arm."
62657921|NCT03421457|EXPERIMENTAL|Sacrocervicopexy|"Uterus-preserving Laparoscopic sacrocervicopexy with mesh technique will be performed in this arm."
62657922|NCT03514602|EXPERIMENTAL|Multicomponent behavioral intervention|The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support.
62657923|NCT03514602|ACTIVE_COMPARATOR|Control|The control group will receive smoking cessation education only.
62465017|NCT00614471|EXPERIMENTAL|2|
62465018|NCT00614471|EXPERIMENTAL|3|
62657924|NCT04674527|EXPERIMENTAL|experimental group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.And elemene injectable emulsion will be given for 80 -120 ml/day in each 14-day cycle or 21-day cycle.
62657925|NCT04674527|EXPERIMENTAL|contral group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
62657926|NCT01856933|EXPERIMENTAL|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
62657927|NCT03370302|EXPERIMENTAL|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
62657928|NCT03370302|EXPERIMENTAL|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
62657929|NCT03641157||Group I Easy Intubation|Pediatric patients ages 0-3 years Easy Intubation (Cormach-Lehane score I-II)
62657930|NCT03641157||Group II Difficult intubation|Pediatric patients ages 0-3 years Difficult intubation (Cormach-Lehane score III-IV)
62657931|NCT05258071|EXPERIMENTAL|Pirepemat dose 1|Pirepemat tablets, dose 1 (mg), 2 tablets t.i.d. for 84 days.
62465019|NCT03872505|ACTIVE_COMPARATOR|Chemotherapy + Durvalumab|Arm A: Carboplatin, Paclitaxel and Durvalumab
62465020|NCT03872505|EXPERIMENTAL|Chemo + Durvalumab + Radiation Therapy|Arm B: Carboplatin, Paclitaxel and Durvalumab + Radiation Therapy
62465021|NCT05178095|EXPERIMENTAL|AI|Colonoscopy with AI
62657932|NCT05258071|EXPERIMENTAL|Pirepemat dose 2|Pirepemat tablets, dose 2 (mg), 2 tablets t.i.d. for 84 days.
62657933|NCT05258071|PLACEBO_COMPARATOR|Placebo|Placebo tablets, 2 tablets t.i.d. for 84 days.
62657934|NCT04059250|EXPERIMENTAL|Nobio flange|On the Nobio flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it the Nobio composite.
62657935|NCT04059250|PLACEBO_COMPARATOR|Traditional composite flange|On the traditional composite flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it a traditional composite.
62657936|NCT02362451|EXPERIMENTAL|1/Lead-in T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|All patients to receive autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine before randomization
62094424|NCT05750745|ACTIVE_COMPARATOR|Negative Control|Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Crest Cavity Protection Fresh Lime. After brushing, participants will be instructed to rinse once with 10 mL of water using the measuring cup provided.
62292070|NCT04058587|EXPERIMENTAL|Simmitinib tablet|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
62465022|NCT05178095|PLACEBO_COMPARATOR|No AI|Colonoscopy without AI
62657937|NCT02362451|EXPERIMENTAL|2/Active T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|Autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine after randomization
62657938|NCT02362451|PLACEBO_COMPARATOR|3/Placebo|Autologous elutriated monocyte vaccine placebo after randomization
62657939|NCT01840631|ACTIVE_COMPARATOR|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
62657940|NCT01840631|ACTIVE_COMPARATOR|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
62657941|NCT00998153|EXPERIMENTAL|1|RRFT
62657942|NCT00998153|ACTIVE_COMPARATOR|2|Usual care
62657943|NCT06188000|EXPERIMENTAL|Extra Virgin Olive Oil|The patients was given a capsule contained extra virgin olive oil 15 milliliters twice a day.
62657944|NCT06188000|ACTIVE_COMPARATOR|Olive Oil|The patients was given a capsule contained olive oil 15 milliliters twice a day.
62094425|NCT05750745|ACTIVE_COMPARATOR|Positive Control|Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Sensodyne Repair and Protect. After brushing, participants will be instructed to rinse once with 10 mL of water using the measuring cup provided.
62292071|NCT03892421|EXPERIMENTAL|Modified DHAP|Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.
62292072|NCT04614818||pulmonary lymphoepithelioma-like carcinoma|The primary site of lymphoepithelioma-like carcinoma locates in the lungs.
62657945|NCT06188000|PLACEBO_COMPARATOR|Placebo|The patients was given an empty capsule twice a day.
62657946|NCT01010100|EXPERIMENTAL|Arm 1|
62657947|NCT01010100|PLACEBO_COMPARATOR|Arm 2|
62657948|NCT05441813|EXPERIMENTAL|Standard of care + virgin coconut oil|Arm A: Standard of care + virgin coconut oil
62657949|NCT05441813|NO_INTERVENTION|Standard of Care|Arm B: Standard of care
62292073|NCT04614818||lymphoepithelioma-like carcinoma of thymus|The primary site of lymphoepithelioma-like carcinoma locates in the thymus.
62292074|NCT04614818||lymphoepithelioma-like carcinoma of salivary glands|The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.
62465023|NCT06213506|EXPERIMENTAL|Adults_Dose C Group|Adults 18-50 years of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose C vaccine at Day 1 and Day 57.
62465024|NCT06213506|ACTIVE_COMPARATOR|Adults_Control Group|Adults 18-50 years of age, part of the safety cohort, randomized to receive 1 dose of the MenACWY vaccine at Day 1 and 1 dose of Placebo at Day 57.
62465025|NCT06213506|EXPERIMENTAL|Children_Dose B Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose B vaccine at Day 1 and Day 57.
62657950|NCT03617588|EXPERIMENTAL|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
62657951|NCT06387316|OTHER|No Oral Stimulation|No oral stimulation is provided.
62657952|NCT06387316|OTHER|Oral Water Stimulation|Oral stimulation with water.
62657953|NCT06387316|OTHER|Oral Salt Stimulation|Oral stimulation with salt.
62657954|NCT06387316|OTHER|Oral Sucralose Stimulation|Oral stimulation with sucralose.
62657955|NCT06387316|OTHER|Oral Sucrose stimulation|Oral stimulation with sucrose.
62657956|NCT05827120||Thrombectomy plus local thrombolysis group|Thrombectomy plus local thrombolysis group - patients treated by mechanical thrombectomy mostly followed by catheter directed thrombolysis (CDT), or by pharmaco-mechanical thrombectomy (PMT) - combination of some form of mechanical disruption of the thrombus in conjunction with chemical lysis. Thrombolysis by alteplase 1mg/hour. Procedure followed by anticoagulation therapy.
62657957|NCT05827120||Local catheter directed thrombolysis alone group|Local catheter directed thrombolysis alone group - patients treated by dedicated catheter for local thrombolysis with side holes placed across the acute thrombus - continuous infusion of alteplase 1mg per hour simultaneously with unfractionated heparine in anticoagulation dosage. Without mechanical or pharmaco-mechanical thrombectomy. Procedure followed by anticoagulation therapy.
62292075|NCT04614818||lymphoepithelioma-like carcinoma of stomach|The primary site of lymphoepithelioma-like carcinoma locates in the stomach.
62292076|NCT04614818||lymphoepithelioma-like carcinoma of esophagus|The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.
62465026|NCT06213506|ACTIVE_COMPARATOR|Children_Control B Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.
61907964|NCT02379130|ACTIVE_COMPARATOR|Play and Nutrition Intervention Group|Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
61907965|NCT00947440|ACTIVE_COMPARATOR|Tablet 1 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.
62292077|NCT04614818||lymphoepithelioma-like carcinoma of liver|The primary site of lymphoepithelioma-like carcinoma locates in the liver.
62292078|NCT04614818||lymphoepithelioma-like carcinoma of ovaries|The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.
62292079|NCT04614818||lymphoepithelioma-like carcinoma of cervix|The primary site of lymphoepithelioma-like carcinoma locates in the cervix.
62292080|NCT04614818||lymphoepithelioma-like carcinoma of tonsil|The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.
62292081|NCT01527721|EXPERIMENTAL|CxL group|Volunteers of this group received CxL treatment.
62292082|NCT01527721|EXPERIMENTAL|tCxL group|Volunteers of this group received CxL combined with t-PRK treatment
62292083|NCT02658448|EXPERIMENTAL|GTx-024 3 mg|GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
62465027|NCT06213506|EXPERIMENTAL|Children_Dose C Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose C vaccine at Day 1 and Day 57.
62657958|NCT03655431|EXPERIMENTAL|Telerehabilitation|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment. The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package. Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
62465028|NCT06213506|ACTIVE_COMPARATOR|Children_Control C Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.
62465029|NCT06213506|EXPERIMENTAL|Infants_9M_Dose A Group|Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 85 and Day 169. These infants also receive an Expanded Program on Immunization (EPI) vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
62465030|NCT06213506|ACTIVE_COMPARATOR|Infants_9M_Control A Group|Infants 9 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPaHBV-IPV+Hib vaccine at Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
62657959|NCT00390013|ACTIVE_COMPARATOR|Gabapentin|Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
62292084|NCT04434976||delayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
62465031|NCT06213506|EXPERIMENTAL|Infants_9M_Dose B Group|Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 85 and Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
62094426|NCT06697366|EXPERIMENTAL|treatment|"The patients with Progressive Stage Gastric Cancer will be enrolled and given Sintilimab: 200 mg over 1 hour IV, given every 3 weeks. Irinotecan Liposome Injection II: 56.6 mg/m2 (free base) every 3 weeks, depending on the dose.~Sequence of administration: Sindilizumab and Irinotecan Liposome Injection II will be given sequentially.~Pre-treatment medication: Dexamethasone and antiemetic (or prophylactic irinotecan if preferred according to hospital practice)."
62094427|NCT01522339|EXPERIMENTAL|Safety of a Customized NICU MRI System|Device: GE OPTIMA MR430s with HDX/GE Electronics
62094428|NCT02821312|ACTIVE_COMPARATOR|Active in Group A1~A7|In each of Groups A1 to A7, 8 subjects will receive DA-8010.
62094429|NCT02821312|PLACEBO_COMPARATOR|Placebo in Group A1~A7|In each of Groups A1 to A7, 2 subjects will receive placebo.
62465032|NCT06213506|ACTIVE_COMPARATOR|Infants_9M_Control B Group|Infants 9 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPaHBV-IPV+Hib vaccine at Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
62465033|NCT06213506|EXPERIMENTAL|Infants_9M_Dose C Group|Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 85 and Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
62465034|NCT06213506|ACTIVE_COMPARATOR|Infants_9M_Control C Group|Infants 9 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPaHBV-IPV+Hib vaccine at Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
62657960|NCT00390013|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo titration and dosing for total of 8 weeks (Cross over)
62657961|NCT03716427|EXPERIMENTAL|Active Treatment- CT1812 560 mg|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole)
62657962|NCT02891967|OTHER|Bulk full composite (3M)|bulk fill composite in posterior class one cavities
62657963|NCT02891967|OTHER|Incremental packing composite resin|Nano resin composite (K Z350 xt) restoration in class one cavities
62657964|NCT05470803|EXPERIMENTAL|Cohort A: 03 doses Pfizer/Wyeth|Group 1: AstraZeneca/Fiocruz Group 2: Pfizer/Wyeth Group 3: Clover SCB-2019
62657965|NCT05470803|EXPERIMENTAL|Cohort B: 03 doses AstraZeneca/Fiocruz|Group 4: AstraZeneca/Fiocruz Group 5: Pfizer/Wyeth Group 6: Clover SCB-2019
62657966|NCT05470803|EXPERIMENTAL|Cohort C: 03 doses Sinovac/Butantan or 02 doses and 01 dose AstraZeneca/Fiocruz|Group 7: AstraZeneca/Fiocruz Group 8: Pfizer/Wyeth Group 9: Clover SCB-2019
62657967|NCT05470803|EXPERIMENTAL|Cohort D: 02 doses AstraZeneca/Fiocruz and 01 dose Alum/CpG adjuvanted 9 or 30 µg Clover SCB-2019|Group 10: Clover SCB-2019
62657968|NCT06093334|EXPERIMENTAL|Early therapeutic effects|Diagnosed acute lymphatic leukemia or Hodgkin's disease (HD) and completed induction therapy or radiotherapy, from 5 years to \<18 years
62657969|NCT06093334|EXPERIMENTAL|Late therapeutic effects|Diagnosed acute lymphatic leukemia or Hodgkin's disease (HD) and completed intensive therapy or radiotherapy, Patient in follow-up care, from 5 years to \<18 years
62094430|NCT02821312|ACTIVE_COMPARATOR|Active in Group B1~B4|In each of Groups B1 to B4, 8 subjects will receive DA-8010.
62094431|NCT02821312|PLACEBO_COMPARATOR|Placebo in Group B1~B4|In each of Groups B1 to B4, 2 subjects will receive placebo.
62094432|NCT04758507|EXPERIMENTAL|Donor FMT|Patients enrolled in this arm will receive donor FMT
62094433|NCT04758507|PLACEBO_COMPARATOR|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of saline solution)
62094434|NCT04660084|OTHER|Ultra-rapid molecular point-of-care testing|Extended and more rapid diagnostics on microbiological specimens and an active feedback to treating staff with results.
62094435|NCT04660084|NO_INTERVENTION|Standard of care|Standard collection of microbiological specimens and standard reply to treating staff.
62094436|NCT04842968|EXPERIMENTAL|Methylene blue|Methylene blue solution (50 mg in 30 ml of saline solution) was injected in the cannulated main supplying artery of the freshly removed specimen, ex vivo. Colorectal specimen was then processed in the routine pathological work-up way.
62094437|NCT04842968|NO_INTERVENTION|Control|Colorectal specimens were processed in the routine pathological work-up way.
62657970|NCT06093334|EXPERIMENTAL|Effects of hematopoietic stem cell transplantation|Diagnosed acute lymphatic leukemia, completed hematopoietic stem cell transplantation, from 5 years to \<18 years
62657971|NCT01703156|EXPERIMENTAL|Non-Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a patient has contraindications to any medications, they will not be administered. If a statin contraindication exists, other cholesterol-lowering medications may be administered. Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
62657972|NCT01703156|ACTIVE_COMPARATOR|Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a statin contraindication exists, other cholesterol-lowering medications may be administered. All patients will undergo noninvasive stress testing. Results of individual stress tests will be reviewed by a cardiologist. Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered. Likewise, medical treatment may be adjusted.
62657973|NCT05507177|EXPERIMENTAL|Group I|patients that are treated in group I receive a medication review from healthcare providers that have already received the communication training programme
62657974|NCT05507177|NO_INTERVENTION|Group II|patients that are treated in group II receive a medication review from healthcare providers that have not yet received the communication training programme
62657975|NCT01171534|ACTIVE_COMPARATOR|Vessel Loop fasciotomy closure|Fasciotomy closure using vessel loops and staples.
62657976|NCT01171534|EXPERIMENTAL|DermaClose fasciotomy closure|Fasciotomy closure via DermaClose device
62657977|NCT01389232|EXPERIMENTAL|SeriScaffold® Surgical Scaffold|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
62292085|NCT04434976||undelayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
62657978|NCT02911116|EXPERIMENTAL|Cohort 1 (Subcutaneous Only)|Subcutaneous injections of Ustekinumab at baseline.
62292086|NCT02750059|EXPERIMENTAL|TDF/3TC/EFV + Telmisartan|The subjects will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART
62292087|NCT02750059|ACTIVE_COMPARATOR|TDF/3TC/EFV only|Subjects will receive ART only
62094438|NCT06373848|EXPERIMENTAL|Vitamin E|Participants in Group A were administered 400 mg of Vitamin E supplements on a daily basis throughout the two-month study period. After the study concluded, the clinical periodontal parameters were reevaluated to assess any potential impact of the supplements on oral health.. To compare the total antioxidant capacity in saliva before and after the consumption of the Vitamin E supplements, as well as in individuals who did not receive any form of medication, 2 ml of non-stimulated saliva was collected from each participant at the commencement and conclusion of the study. These samples were then analyzed using UV-spectrophotometric methods to determine any variations in antioxidant levels.
62094439|NCT06373848|EXPERIMENTAL|Coq10|Participants in Group B were administered a daily dose of 30 mg of Coq10 supplements for two months. Following the study period, the clinical periodontal parameters were reevaluated to assess any potential impact of the supplements on oral health. To compare the total antioxidant capacity of saliva before and after the consumption of Coq10 supplements, as well as in individuals who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at the commencement and conclusion of the study. The collected samples were then analyzed using UV-spectrophotometric methods to determine any variations in antioxidant levels.
62465035|NCT06213506|EXPERIMENTAL|Infants_6W_Dose A Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
62465036|NCT06213506|ACTIVE_COMPARATOR|Infants_6W_Control A Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
62465037|NCT06213506|EXPERIMENTAL|Infants_6W_Dose B Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
62657979|NCT02911116|EXPERIMENTAL|Cohort 2 (IV and Subcutaneous)|Initial IV infusion of ustekinumab at baseline followed by one subcutaneous injection at Week 8. In participants who demonstrate an allergic reaction to the baseline IV infusion, the second dose at Week 8 can also be administered as an IV infusion instead of a subcutaneous injection.
61907966|NCT00947440|ACTIVE_COMPARATOR|Tablet 2 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.
61907967|NCT05903209||Software diagnosis|Software diagnosis with gold standard of 3 doctors' interpretation.
61907968|NCT00338182|EXPERIMENTAL|AZD1152|AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment)
61907969|NCT05900440|EXPERIMENTAL|Artificial Intelligence Group|
61907970|NCT05900440|ACTIVE_COMPARATOR|Non Artificial Intelligence Group|
61907971|NCT03459690|EXPERIMENTAL|Experienced meditators|Meditation ≥ 30 min per day for at least 5 days per week over the past 1 year
61907972|NCT03459690|EXPERIMENTAL|Novice meditators|No meditation practice in the previous year and \< 20 entire lifetime hours
62657980|NCT02022397||difficult intubation|general population necessitating tracheal intubation for general anesthesia
62094440|NCT06373848|ACTIVE_COMPARATOR|no-medication;|Group C was not administered any medication during the study period lasting two months. Following this period, the clinical periodontal parameters were evaluated once again. Moreover, to analyze the total antioxidant capacity in saliva before and after the consumption of these supplements, as well as in individuals who were not given any medication, 2 ml of non-stimulated saliva was gathered from every participant at the commencement and conclusion of the study. This analysis was conducted using UV-spectrophotometric techniques.
62292088|NCT00008385|PLACEBO_COMPARATOR|Arm I|Participants receive an oral yeast placebo as in arm II.
62465038|NCT06213506|ACTIVE_COMPARATOR|Infants_6W_Control B Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
62465039|NCT06213506|EXPERIMENTAL|Infants_6W_Dose C Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
62657981|NCT03080285|ACTIVE_COMPARATOR|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
62657982|NCT03080285|EXPERIMENTAL|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
62657983|NCT02186639||COPD|40 COPD patients (20 non-frequent and 20 frequent-exacerbators). No intervention.
62657984|NCT02186639||Controls|"Subjects with no apparent lung disease and normal lung function testing. Matched for age, gender and smoking history (pack years).~No intervention."
62094441|NCT05087238|OTHER|PVC-specific CBT|This novel CBT treatment for symptomatic PVC targets cardiac anxiety and symptom preoccupation related to PVC. Treatment is developed from the research groups treatment for Atrial Fibrillation and may be altered during the treatment period to better meet the needs of the patients. Patients receive 10 weeks of CBT delivered through face to face digital video sessions.
62094442|NCT01419847|ACTIVE_COMPARATOR|topical Penlac nail lacquer|3-1 randomization of active to placebo
62094443|NCT01419847|PLACEBO_COMPARATOR|Placebo|
62657985|NCT04419168|EXPERIMENTAL|cCBT|Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
62094444|NCT06376994|EXPERIMENTAL|Active air cleaner|The active arm will receive two active air cleaners with high efficiency particulate air (HEPA) filters which remove particulate matter (PM), as well as activated carbon filters to remove Nitrogen Dioxide (NO2) and other trace gases.
62094445|NCT06376994|SHAM_COMPARATOR|Sham air cleaner|The sham control treatment arm will receive two sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow, and overall appearance compared to active air cleaners, thus blinding participants to filter status.
62094446|NCT06696196|EXPERIMENTAL|smart watch|This study will use a prototype (MediaTek Sleep Watch) to acquire PPG, body movements, skin temperature, and skin conductance to validate the algorithm of sleep staging and sleep efficiency assessment. PSG will be used as gold standard for statistical analysis.
62094447|NCT01321229||With sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission Diagnosis and medical care by a sleeping disorder qualified specialist
62094448|NCT01321229||Without sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission
62094449|NCT06206681||Ultrapulse Carbon Dioxide Laser|The study investigates the use of the Ultrapulse Carbon Dioxide Laser for the excision of eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on.
62657986|NCT04419168|EXPERIMENTAL|m-Education|Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
62657987|NCT04419168|NO_INTERVENTION|Convenience Comparison|Not participating in the intervention. Participants will complete the baseline questionnaire battery only and the investigational team will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.
62657988|NCT03535415|EXPERIMENTAL|rhGH Injection|rhGH 0.05mg/kg/d by subcutaneous injection
62657989|NCT03535415|NO_INTERVENTION|Non-treatment control group|Only follow-up without treatment
62657990|NCT01449084|ACTIVE_COMPARATOR|early removal of pancreatic duct stent|immediate removal of the pancreatic duct stent at the end of the ERCP procedure
62657991|NCT01449084|NO_INTERVENTION|leaving the stent in place|the pancreatic duct stent is left in place
62657992|NCT02084797|EXPERIMENTAL|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
62657993|NCT02640079|EXPERIMENTAL|Cognitive behavioral therapy|Cognitive behavioral therapy aimed at reducing pain catastrophizing.
61907973|NCT01489241|NO_INTERVENTION|Usual care|Patients in the control group receive usual care and visit the outpatient department at 4 and at 12 weeks after discharge when pulse rate, oxygen saturation and spirometry is performed. In the case of clinical deterioration during the study, the patients contact as usual their general practitioner. Usual care of COPD patients consists of regular visits to the specialist or primary care clinics every time a medication change is made or a medical examination is needed
62094450|NCT06116110||Long-term Follow-Up|No intervention
62094451|NCT02723357|EXPERIMENTAL|Financial Coaching & Access to Services|Participants in this arm will receive monthly financial coaching and access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
62094452|NCT02723357|ACTIVE_COMPARATOR|Access to Services|Participants in this arm will receive access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
62657994|NCT02259387||Cases|Children with migraines will be placed into this group.
62657995|NCT02259387||Controls|Children without migraines or headaches will be placed into this group.
62657996|NCT00864981|EXPERIMENTAL|1|Bupropion HCI ER Tablets, 150 mg
62094453|NCT03168438|EXPERIMENTAL|Arm 1: Letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
62094454|NCT03168438|EXPERIMENTAL|Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.
62094455|NCT00451698|PLACEBO_COMPARATOR|3|acyanotic placebo
62657997|NCT00864981|ACTIVE_COMPARATOR|2|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
62657998|NCT03789006|ACTIVE_COMPARATOR|ATG|Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
62657999|NCT03789006|ACTIVE_COMPARATOR|BAS|Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
62658000|NCT01181882|EXPERIMENTAL|Fish Oil and Aspirin|
61907974|NCT01489241|EXPERIMENTAL|Telemonitoring|
62094456|NCT00451698|EXPERIMENTAL|4|acyanotic erythropoietin
62292089|NCT00008385|EXPERIMENTAL|Arm II|Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
62292090|NCT03502330|EXPERIMENTAL|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
62292091|NCT03502330|EXPERIMENTAL|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
62658001|NCT04866108|EXPERIMENTAL|Experimental|Fruquintinib, 4mg/d, qd po, 2 weeks on, 1 week off; Capecitabine: 825mg/m2, bid po, 2 weeks on, 1 week off
62658002|NCT01680796|EXPERIMENTAL|Active Treatment|"Dovitinib will be given at up to four different dose levels beginning with dose level 1 on a 5 days on/2 days off dosing schedule of each 21-day cycle.~Bortezomib will be given at two different dose levels intravenously on Days 1 and 8 of each 21-day cycle.~Dexamethasone will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle."
62658003|NCT02191501|EXPERIMENTAL|Pyloric restriction|Endoscopic method of pyloric restriction in order to decrease gastric emptying. The hypothesis is that this will cause and early and prolonged satiety which will inturn lead to decreased food consumption and lead to weight loss.
62465040|NCT06213506|ACTIVE_COMPARATOR|Infants_6W_Control C Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
62658004|NCT01230008||Radiotherapy in mediastinal lymphoma|Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
62658005|NCT01230008||Radiotherapy in mediastinal lymphoma|Radiotherapy will no be administered in patients treated with R-CHOP
62658006|NCT01230008||Radiotherapy in primary mediastinal lymphoma|Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
62658007|NCT00671749|EXPERIMENTAL|Study Treatment|"adapalene gel, 0.3%~Other Names:~Differin® Gel, 0.3% Applied once daily at bedtime~clindamycin/benzoyl peroxide gel~Other Names:~Duac® Gel Applied once daily in the morning"
62658008|NCT00691379|EXPERIMENTAL|1|Paclitaxel/Carboplatin/Bevacizumab
62658009|NCT01069211||ER expression : Low|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 3 or 4 point of total Allred score.
62658010|NCT01069211||ER expression : Intermediate|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 5 or 6 point of total Allred score.
62658011|NCT01069211||ER expression : High|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 7 or 8 point of total Allred score.
62658012|NCT00668239|ACTIVE_COMPARATOR|1|Laser treatment: laser was applied to the macular region according to the modified grid technique in inverted C, preserving 500 μ of the foveolus and avascular zone, with 100μ diameter shots, energy varying from 0.2 to 0.5 joules, with a time of exposure between 0.2 and 0.4 seconds. One hundred and fifty to 200 shots were applied according to the size of the retinal area². ND YAG laser (Crystal Focus (EMERED®) was used
62658013|NCT00668239|EXPERIMENTAL|2|triamcinolone as previously described
62658014|NCT06248489||Individuals with neck pain|
62658015|NCT06248489||Individuals without neck pain|
62658016|NCT00165698|ACTIVE_COMPARATOR|1|
61907975|NCT00243646|ACTIVE_COMPARATOR|no hormones|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
61907976|NCT00243646|ACTIVE_COMPARATOR|9 months of hormone therapy|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy
62658017|NCT00165698|ACTIVE_COMPARATOR|2|
62658018|NCT01461551|EXPERIMENTAL|Sevoflurane|
62658019|NCT01461551|EXPERIMENTAL|Propofol|
62658020|NCT01461551|EXPERIMENTAL|Combine of sevoflurane and propofol|
62658021|NCT01416662|OTHER|gemcitabine|gemcitabine
62658022|NCT03524209|OTHER|Surgery|Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
62658023|NCT03524209|OTHER|Brace|Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
62658024|NCT02402751|EXPERIMENTAL|Acquisition of normative database|Development, implementation and initiation of normative database (image and data) quantitative ultra high field MRI paramaters
61907977|NCT00837733|EXPERIMENTAL|Biopsy catheter|Biopsy catheter (Pipelle de Cornier, Prodimed, Neuilly-en-Thelle, France
62658025|NCT00700765||A|
62658026|NCT05333185|EXPERIMENTAL|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
62094457|NCT06593327|EXPERIMENTAL|Risk Assessment and Intensive Prevention Strategy|Primary care providers (PCP) randomized to the Risk Assessment and Intensive Prevention Strategy Arm will receive notification if any patients with diabetes under their care have high heart failure risk based on clinical or biomarker scores. Providers will receive recommendations, option for e-consultation, and referral to cardiometabolic risk management program.
62094458|NCT06593327|NO_INTERVENTION|Usual Care|Primary care providers randomized to the Usual care arm will not receive any notifications about patients with diabetes and their HF risk assessment.
62094459|NCT05910931||Patients undergoing ICG angiography|All women operated on in the breast unit who require a reduction mammoplasty, a skin-sparing mastectomy (or skin and nipple) with immediate reconstruction and local flaps for remodeling or implant coverage.
62465041|NCT06213506|EXPERIMENTAL|Infants_6W_Dose A_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
62658027|NCT05333185|NO_INTERVENTION|Control group|The control group will recieve standard diabetes treatment without any training intervention
62658028|NCT03823625|EXPERIMENTAL|ARM A: Nivolumab plus Ipilimumab|Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months. Platinum-based chemotherapy will be given up to 6 cycles.
62658029|NCT03823625|EXPERIMENTAL|ARM B: Platinum-based chemotherapy plus Nivolumab|Platinum-based chemotherapy will be given up to 6 cycles. Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months.
62658030|NCT06418867|EXPERIMENTAL|Intervention|Mindfulness intervention group
62658031|NCT06254339||OAGB cohort|Application of One-anastomosis gastric bypass (OAGB) procedure stated in IFSO/ASMBS.
62658032|NCT06254339||DJB-SG cohort|Application of Duodenojejunal bypass with sleeve gastrectomy (DJB-SG)) procedure stated in IFSO/ASMBS.
62658033|NCT05042297|ACTIVE_COMPARATOR|Combined Posterior and anterior ring fixation|Posterior ring fixation via a single posterior Sacroiliac screw or two Iliac wing plates. While anterior ring fixation was via a single para-symphyseal plate in Tile B2 injuries. Meanwhile, we used double superior and anterior symphyseal plates in Tile C1 injuries.
62658034|NCT05042297|EXPERIMENTAL|Isolated Posterior ring fixation|We used either two Sacroiliac screws in S1 and S2, or two Iliac wing plates.
62658035|NCT05259215||non-walking group|
62658036|NCT05259215||independently walking group|
62658037|NCT02215759|EXPERIMENTAL|BI 44370 TA|
62094460|NCT02813499||CARE Rule|Evaluation of the clinical suspicion of myocardial infarction and calculation of CARE rule.
62094461|NCT02810743|ACTIVE_COMPARATOR|ddAC-CP-Olaparib|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~CP; carboplatin/paclitaxel (CP) consisting of carboplatin (AUC 6) on day 1 and paclitaxel (80 mg/m2) on day 1,8 and 15 of a 21 days cycle. In total 4 courses of CP will be administered.~Olaparib will be administered in Dutch centers only, as monotherapy for one year at a dose of 300 mg BID, starting 3 weeks after adjuvant radiotherapy, or, if radiotherapy is not indicated, 3-5 weeks after the last CP cycle.~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
62658038|NCT02215759|PLACEBO_COMPARATOR|Placebo|
62658039|NCT00005047|EXPERIMENTAL|Arm I: M-VAC x 3|Patients with altered (+) p53, reconsented to randomization, randomized to three cycles of MVAC
62658040|NCT00005047|NO_INTERVENTION|Arm II: Observation|Patients with altered (+) p53, reconsented to randomization, randomized to observation
62658041|NCT00005047|NO_INTERVENTION|Arm III: Observation|Patients with unaltered (-) p53
62658042|NCT00005047|NO_INTERVENTION|Arm IV: Observation|Patients with altered (+) p53, patients did not consent to randomization
62658043|NCT02114684|ACTIVE_COMPARATOR|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
62658044|NCT02114684|ACTIVE_COMPARATOR|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
62658045|NCT06549634||Patients with multiple myeloma|Patients with multiple myeloma being newly initiated on daratumumab
62658046|NCT05441319||Chronic ankle instability group|After completing the evaluation form containing the demographic and clinical characteristics of all participants at their first visit, the Cumberland Ankle Instability Questionnaire (CAIT) scale will be completed and athletes with a CAIT score ≤ 25 will be assigned to the Chronic Ankle Instability Group;
62658047|NCT05441319||Control group|Athletes with a score \> 25 in the Cumberland Ankle Instability Questionnaire (CAIT) will be included in the Control Group.
62292092|NCT03502330|EXPERIMENTAL|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
62292093|NCT03502330|EXPERIMENTAL|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
62292094|NCT03502330|EXPERIMENTAL|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
62292095|NCT03502330|EXPERIMENTAL|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
62292096|NCT03502330|EXPERIMENTAL|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
62292097|NCT03502330|EXPERIMENTAL|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
62292098|NCT03502330|EXPERIMENTAL|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
62658048|NCT04689451||Perclose ProGlide|Perclose ProGlide group: use Perclose ProGlide to suture the artery
62658049|NCT04689451||Surgical Arterial Repair|Surgical Arterial Repair group : suture the artery by surgery
62658050|NCT01562990|EXPERIMENTAL|R-CMC544 and R-GEMOX|Treatment with R-CMC544 and R-GEMOX
62658051|NCT04399291||Residential care facility residents|Older adults recruited from care homes in Northern Ireland
62658052|NCT01045200||Follow-up|Patients curatively operated for rectal cancer
62658053|NCT05802355|EXPERIMENTAL|Manual Diaphragm Release|received 3sessions/ week for 12 consecutive weeks.
62658054|NCT05802355|EXPERIMENTAL|control group|received 3sessions/ week for 12 consecutive weeks.
62658055|NCT03033433|EXPERIMENTAL|DCB-DM101, 500 mg tablet, determination of optimal dose|Stage 1:Dose level 1(1 tablet of DCB-DM101 q.d. for 7 days orally);Dose level 2(2 tablets of DCB-DM101 q.d. for 7 days orally);Dose level 3(4 tablets of DCB-DM101 q.d. for 7 days orally) Stage 2:Optimum dose of DCB-DM101 determined in Stage 1 as add-on treatment in T2DM patients for 14 days, q.d., orally
62658056|NCT02690129|ACTIVE_COMPARATOR|Group I (Progesterone Group)|"Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.~* Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days.~* If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .~* Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation."
62658057|NCT02690129|PLACEBO_COMPARATOR|Group II ( Control group)|Will follow the same plan of management without progesterone support.
62658058|NCT03272204|OTHER|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
62658059|NCT03272204|OTHER|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
62658060|NCT03138681|PLACEBO_COMPARATOR|Placebo|
62658061|NCT03138681|EXPERIMENTAL|ATP|
62658062|NCT03138681|EXPERIMENTAL|phosphocreatine|
62658063|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
62658064|NCT01148732||Patient needed intubation in emergency department|
62658065|NCT01644214|NO_INTERVENTION|Pessary Check at 3 months|Patients seen at 3 month intervals for pessary check-ups is the most common interval check in our clinic so this arm is considered the control group.
62658066|NCT01644214|EXPERIMENTAL|6 month Pessary Check|Those that will be seen at 6 month follow-up visits for pessary maintenance will be considered the experimental group of the study.
62658067|NCT02052362|EXPERIMENTAL|Group 1 - Regimen A|8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
62658068|NCT02052362|EXPERIMENTAL|Group 2 - Regimen B|8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267
62658069|NCT04701996||cohort|sero-surveillance will start in a cohort of 800 adults (18-50y). In case of an established outbreak, this sample will be extended to 400 children (0-17y) and 400 elderly (50+y).
62658070|NCT00870727|EXPERIMENTAL|Arm 1. Aripiprazole oral product|Participants will receive Aripiprazole oral product with a minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
62658071|NCT00870727|PLACEBO_COMPARATOR|Arm 2. Placebo oral capsule|Participants will receive matching (identical in size and appearance to study drug) placebo oral capsules over 8-weeks of treatment.
62658072|NCT05040659||Anosmic patients|Anosmic patients will be recruited from Dr. Albers Smell Clinic at MGH and through past participation in research with known anosmia and permission to recontact. All consent and testing will occur on a phone/tablet app in the participant's home.
62292099|NCT01710930|EXPERIMENTAL|Study of predictive factors|
62292100|NCT00462787|EXPERIMENTAL|Clofarabine|This is a single arm phase I clinical trial to assess safety (morbidity and mortality) of a novel leukemia re-induction regimen. The first component of this trial is a phase I dose escalation study to determine the maximum tolerated dose (MTD) of the novel agent Clofarabine, when used in combination with topotecan, vinorelbine, thiotepa and dexamethasone. A total of three dose levels will be explored in this study.
62308064|NCT03831503|EXPERIMENTAL|Cohort D - 4mg|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
62094462|NCT02810743|ACTIVE_COMPARATOR|ddAC-mini CTC|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin (400 mg/m2; (or AUC=5 in patients with a calculated creatinine-clearance of \<100 ml/min)) days 1,2 thiotepa 250 mg/m2 day 2~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
62292101|NCT02493647|EXPERIMENTAL|Love, Sex, & Choices|Love, Sex, and Choices (LSC) is an engaging 12-episode video series to reduce HIV risk in young, adult predominately Black women. A peer video guide was added to the end of LSC episodes to provoke viewers to question their own sex scripts and consider their own need for change. Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods.
62292102|NCT02493647|NO_INTERVENTION|Attention-Time Control|The Control is a 12-episode popular web miniseries with a storyline that promotes respectful relationships. time and frequency are matched to the active intervention.
62292103|NCT00448292|EXPERIMENTAL|1|PRX-00023 taken twice daily, escalating from 40 mg to 80 mg to 120 mg
61907978|NCT02667353|OTHER|electroconvulsive therapy|only one arm in this study: patients who are treated with electroconvulsive therapy and have been given anesthesia with etomidate and succinylcholine
61907979|NCT00561977|ACTIVE_COMPARATOR|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
61907980|NCT00561977|ACTIVE_COMPARATOR|Low Saturated Fat|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal per day.
61907981|NCT00561977|ACTIVE_COMPARATOR|Combination Diet|Combination low saturated fat (≤7% of total calories);high fiber (\>30g fiber per day) -500 kcal from RMR, not less than 1200 kcal/day.
62658073|NCT05040659||Asymptomatic participants / Healthy participants|Asymptomatic participants recruited in a hospital setting (eg. healthcare workers and household members of symptomatic patients who are potentially COVID positive). No symptoms of COVID infection at the time of enrollment. Potential or definite exposure to SARS-CoV-2 virus without symptoms of upper respiratory infection (smell loss, taste loss, fever, myalgia, cough, nasal congestion, runny nose, shortness of breath). All consent and testing will occur on a phone/tablet app in the participant's home.
62658074|NCT05040659||Participants with a confirmed COVID-19 infection or related smell loss|Individuals who tested positive for SARS-CoV2 by an objective PCR or antigen test will be recruited to evaluate smell function weekly over 3 months. All consent and testing will occur on a phone/tablet app in the participant's home.
62658075|NCT01580956|OTHER|VARIABLE-PSV ventilatory mode|
62658076|NCT01580956|OTHER|STANDARD-PSV ventilatory mode|
62658077|NCT00130364|EXPERIMENTAL|1|Pimecrolimus
62658078|NCT00130364|PLACEBO_COMPARATOR|2|Pimecrolimus vehicle cream
62292104|NCT00448292|PLACEBO_COMPARATOR|2|Placebo taken twice daily, escalating from 40 mg to 80 mg to 120 mg
61907982|NCT01291485|EXPERIMENTAL|Lifestyle counseling|Intervention includes education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve HIV medication adherence and clinical outcomes.
61907983|NCT01291485|NO_INTERVENTION|Treatment as Usual|
61907984|NCT05049317|EXPERIMENTAL|FTME group|Participants will undergo laparoscopic FTME surgery.
61907985|NCT00129311|EXPERIMENTAL|1|Selegiline
61907986|NCT00129311|PLACEBO_COMPARATOR|2|Placebo
62658079|NCT03471819||Patients withf Atopic Dermatitis|Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.
62658080|NCT03471819||healthy volunteers|Normal individuals not complaining of any dermatological diseases
62658081|NCT01648764|EXPERIMENTAL|LY2334737 - Arm A|LY2334737 administered orally at escalating doses \[40 milligrams (mg) - 200 mg\] every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
62658082|NCT01648764|EXPERIMENTAL|LY2334737 - Arm B|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug then repeated (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
62658083|NCT06053190|EXPERIMENTAL|Speech Study|"The study is a within-subjects 2 x 3 factorial design. All participants are exposed to all experimental conditions or interventions"
62658084|NCT00639093|EXPERIMENTAL|1|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
62658085|NCT00639093|ACTIVE_COMPARATOR|2|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
62658086|NCT04765631||Patients with Type 2 diabetes|Subjects from 3 cohorts (QUALYOR, OFELY, STRAMBO) presenting type 2 diabetes
62658087|NCT04765631||Control subjects without Type 2 diabetes|Controls patients from 3 cohorts (QUALYOR, OFELY, STRAMBO) without type 2 diabetes
62658088|NCT06297967|EXPERIMENTAL|Acetic Acid|Topic application of a Acetic Acid 2% solution for 15 min, typically administered every 24h. The frequency of the treatments may be modified according to the evolution of the lesion at the discretion of the nurse in charge of the treatments
61907987|NCT06481280|EXPERIMENTAL|Test Formula|Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.
61907988|NCT06481280|PLACEBO_COMPARATOR|Placebo Formula|Infants will receive a placebo formula (=their previous formula) during the DBPCFC to compare against the test formula.
62094463|NCT05159908|PLACEBO_COMPARATOR|Placebo schedule|Participant follows Placebo schedule (13 weeks)
62094464|NCT05159908|EXPERIMENTAL|Dose schedule A|Participant follows Dose schedule A (13 weeks)
61907989|NCT02845219|EXPERIMENTAL|Oral contraceptive/SNAC/Oral Trial drug|
62094465|NCT05159908|EXPERIMENTAL|Dose schedule B|Participant follows Dose schedule B (13 weeks)
62465042|NCT06213506|EXPERIMENTAL|Infants_6W_Dose B_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
62658089|NCT06297967|ACTIVE_COMPARATOR|Control group|Topic application of Prontosan® for 15 min, typically administered every 24h. The frequency of the treatments may be modified according to the evolution of the lesion at the discretion of the nurse in charge of the treatments
62658090|NCT00376844|ACTIVE_COMPARATOR|External Beam Radiation Therapy|Postoperative pelvic radiotherapy
62094466|NCT05159908|EXPERIMENTAL|Dose schedule C|Participant follows Dose schedule C (13 weeks)
62094467|NCT01930617||Trondheim|Burr hole surgery with passive subdural drainage
62658091|NCT00376844|EXPERIMENTAL|Vaginal Brachytherapy|Postoperative vaginal brachytherapy
62658092|NCT02124174|EXPERIMENTAL|Vidaza and Valproic Acid|Vidaza and Valproic Acid
62658093|NCT02721888|EXPERIMENTAL|Main study|
62658094|NCT05426460|EXPERIMENTAL|AAT + tDCS|Approach Avoidance Task + Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
62658095|NCT05426460|SHAM_COMPARATOR|AAT + sham tDCS|Approach Avoidance Task with Sham Transcranial Direct Current Stimulation.
62658096|NCT05426460|ACTIVE_COMPARATOR|AC + tDCS|Active Control Task with Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
62658097|NCT05426460|SHAM_COMPARATOR|AC + sham tDCS|Active Control Task with sham Transcranial Direct Current Stimulation
62658098|NCT00092001|EXPERIMENTAL|1|
62658099|NCT04364490|EXPERIMENTAL|Experimental VF group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform advanced gait training sessions by the computerized BWS system without visual feedback; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
62658100|NCT04364490|EXPERIMENTAL|Experimental VF+ group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform the same advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
62658101|NCT04364490|ACTIVE_COMPARATOR|Control group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
62658102|NCT01991795|EXPERIMENTAL|Ticagrelor 60 mg|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
62658103|NCT01991795|PLACEBO_COMPARATOR|Ticagrelor placebo|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
62658104|NCT04926415|EXPERIMENTAL|Normal Weight|This arm consists of study participants with a body mass index (BMI) of less than 25. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
62658105|NCT04926415|EXPERIMENTAL|Overweight|This arm consists of study participants with a body mass index (BMI) of more than 25 but less than 30. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
62658106|NCT04926415|EXPERIMENTAL|Obese|This arm consists of study participants with a body mass index (BMI) of more than 30. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
62292105|NCT06091345|EXPERIMENTAL|Midodrine+Albumin+SMT|"* Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl Plus~* Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% .~In addition, standard medical therapy will be administered to patients in both the arms."
62292106|NCT06091345|ACTIVE_COMPARATOR|Midodrine+SMT|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% In addition, standard medical therapy will be administered to patients in both the arms.
62292107|NCT06545227||Early monitoring group|Women who are testing blood glucose four times a day from 28 weeks.
62094468|NCT01930617||Tromsø|Burr hole surgery with continuous irrigation
62094469|NCT01930617||Stockholm|Burr hole surgery with active subgaleal drainage
62094470|NCT03031704||Endoscopic mucosectomy|
62094471|NCT06065774|EXPERIMENTAL|The Laterally Closed Tunnel Technique with SCTG|"An aseptic field was required for all surgical procedures using povidine iodine. Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~* Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~* A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~* Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~* After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~* SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
62292108|NCT06545227||Late monitoring group|Women who have an oral glucose tolerance test at 28-32 weeks.
62292109|NCT01860937|EXPERIMENTAL|Cohort 1 (MRD)|Patients with no morphologic evidence of disease at the time of T cell infusion, (\<5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Cohort 1 patients will receive conditioning chemotherapy followed by 1x10\^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of End of Production (EOP) T cells, under or over estimation of CAR modified T-cells may occur. Patients may receive an altered fractionation of the total doses (e.g. ½ on Day 0 and ½ on Day +1) or up to 35% over total cell dose with approval by the participating site PI. In both cohorts, patients will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion and did not experience any non-hematologic grade 4 toxicities.
62292110|NCT01860937|EXPERIMENTAL|Cohort 2 (Morphologic Disease)|Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10\^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion \& did not experience any non-hematologic grade 4 toxicities.
62292111|NCT00271388|EXPERIMENTAL|Parameter Determination|Testing potential effects of GVS on the symptoms of neglect
62094472|NCT06065774|EXPERIMENTAL|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"An aseptic field was required for all surgical procedures using povidine iodine. Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~* Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~* A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~* Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~* After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~* collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
62465043|NCT06213506|EXPERIMENTAL|Infants_6W_Dose C_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
62094473|NCT06065774|EXPERIMENTAL|Modified Coronally Advanced Tunnel Technique with SCTG.|"* Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~* The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~* The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~* Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~* Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~* SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
62292112|NCT03216460|OTHER|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will participate in specific setpoint challenges, meal challenges, and exercise
62292113|NCT01349140|EXPERIMENTAL|Nerve Block|The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.
62292114|NCT04673383|EXPERIMENTAL|Healthy volunteers (active)|SPL026 to be administered by IV injection
62292115|NCT04673383|EXPERIMENTAL|Healthy volunteers (placebo)|SPL026-matched placebo to be administered by IV injection
62292116|NCT04673383|EXPERIMENTAL|Patients (active)|SPL026 to be administered by IV injection
62292117|NCT04673383|EXPERIMENTAL|Patients (placebo)|SPL026-matched placebo to be administered by IV injection
62658107|NCT02050204|EXPERIMENTAL|LEEF Industry only: Intervention|"Customized to the Leef (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
62658108|NCT02050204|NO_INTERVENTION|LEEF Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
62658109|NCT02050204|EXPERIMENTAL|TOMO Industry only: Intervention|"Customized to the Tomo (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
62658110|NCT02050204|NO_INTERVENTION|TOMO Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
62658111|NCT06377917|OTHER|Cleavage Stage Assisted Hatching (AH)|Current standard of care. Day 3 or cleavage stage embryos will have the zona pellucida hatched with a laser.
62658112|NCT06377917|EXPERIMENTAL|Blastocyst Stage Assisted Hatching (AH)|Blastocyst stage embryos on day 5,6 or 7 will have the zona pellucida hatched with a laser.
62658113|NCT01712516|EXPERIMENTAL|QVA149|27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
62658114|NCT01712516|ACTIVE_COMPARATOR|QAB149|27.5 ug b.i.d.
62658115|NCT01712516|ACTIVE_COMPARATOR|NVA237|12.5 ug b.i.d.
62658116|NCT01712516|PLACEBO_COMPARATOR|Placebo|b.i.d.
62658117|NCT02205645|EXPERIMENTAL|FibroFix™ Meniscus scaffold|The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
62658118|NCT04111315|ACTIVE_COMPARATOR|metamizole + educational intervention|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
62292118|NCT04890873|EXPERIMENTAL|ERX1000|"ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension~Proposed dose level for Part A: 4 mg and 8 mg~Proposed dose level for Part B: 4 and 8 mg. The dose administered will not exceed the highest dose administered in Part A."
62292119|NCT04890873|PLACEBO_COMPARATOR|Placebo|Reference product: Magnesium hydroxide carbonate powder prepared in an oral suspension
62292120|NCT01361256|EXPERIMENTAL|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
62292121|NCT00054847|ACTIVE_COMPARATOR|Saphenous Vein Graft|Saphenous Vein Graft
61907990|NCT01794338|EXPERIMENTAL|Bio-A Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected."
62094474|NCT06065774|EXPERIMENTAL|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"* Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~* The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~* The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~* Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~* Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~* collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
62465044|NCT06213506|ACTIVE_COMPARATOR|Infants_6W_Control_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last study intervention administration at Day 232, and the pentavalent vaccine (DTPw-HepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
62094475|NCT00183573|EXPERIMENTAL|1|Brief Motivational Intervention only
62094476|NCT00183573|EXPERIMENTAL|2|Brief Informational Intervention only
62094477|NCT00183573|EXPERIMENTAL|3|Brief Motivational Intervention + Intensive Informational Intervention
62094478|NCT00183573|EXPERIMENTAL|4|Brief Motivational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
62094479|NCT00183573|EXPERIMENTAL|5|Brief Informational Intervention + Intensive Informational Intervention
62292122|NCT00054847|ACTIVE_COMPARATOR|Radial Artery Graft|Radial Artery Graft
62292123|NCT02922387|EXPERIMENTAL|Varenicline + Behavioral support|varenicline and behavioral support
62094480|NCT00183573|EXPERIMENTAL|6|Brief Informational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
62094481|NCT05862233|EXPERIMENTAL|MIL62|
62292124|NCT02922387|ACTIVE_COMPARATOR|Behavioral support|behavioral support
62465045|NCT00378131|PLACEBO_COMPARATOR|1|
62465046|NCT00378131|EXPERIMENTAL|2|RC-1291 50mg
62658119|NCT04111315|ACTIVE_COMPARATOR|metamizole + standard care|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
62094482|NCT05862233|ACTIVE_COMPARATOR|Cyclosporine|
62094483|NCT03935997|EXPERIMENTAL|Intervention|Within the intervention arm 9 long-term care homes will receive the SPA-LTC program:3 in Ontario; 3 in Saskatchewan and 3 in Manitoba.
62094484|NCT03935997|NO_INTERVENTION|Control|Within the control arm 9 long-term care homes will receive the standard of care: 3 in Ontario; 3 in Saskatchewan and 3 in Manitoba.
62094485|NCT04135924|ACTIVE_COMPARATOR|walking nordic and respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will be submitted to respiratory muscle training (TMR) associated with the Nordic walking(NC) training .
62465047|NCT00378131|EXPERIMENTAL|3|RC-1291 100mg
62292125|NCT00866099|NO_INTERVENTION|"Normal Care"|Primary care practices randomly allocated will be given a summary of the NICE/SCIE dementia guidelines (2006) and offered workshop training and software at the end of the study.
62292126|NCT00866099|EXPERIMENTAL|Training|Practices randomly allocated to the intervention arm will be asked to participate in tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
62292127|NCT06211855||Idiopathic Polyhydramios Cases|The group with polyhydramnios was divided into two groups according to whether the CPR value was below 1.08 or 1.08 and above
62094486|NCT04135924|ACTIVE_COMPARATOR|walking nordic group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to Nordic walking training.
62094487|NCT04135924|ACTIVE_COMPARATOR|respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to respiratory muscle training protocol.
62465048|NCT01313949|NO_INTERVENTION|Usual Care|A total of 90 patients with diabetes will be recruited. Thirty will be selected for the training course and the other 60 will be compared as controls. These controls will receive their usual diabetes care.
62094488|NCT06466421|ACTIVE_COMPARATOR|Group 1: (Gabapentin group)|30 patients will receive Gabapentin 100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
62465049|NCT01313949|EXPERIMENTAL|Peer leader training|"Peer leaders are people with diabetes who had volunteered to undertake an extensive program of training. The purpose of this training is to make them effective in the provision of support and advice to their peers on a one-to-one basis via telecommunication.~These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program \[NLP\] trainer to ensure the adequacy of knowledge and skills of these mentors."
62094489|NCT06466421|EXPERIMENTAL|Group 2: (Fexofenadine group)|30 patients will receive Fexofenadine 60 mg orally once daily for 3 months.
62094490|NCT02673008|EXPERIMENTAL|MRD-directed DLI|For patients with MRD+ and without grade II/\>II aGVHD by day +60 post-transplantation, DLI was given once by day +60 and was then administered based on MRD and GVHD status. If patients were MRD negative, DLI was not given again; if patients were MRD positive and without GVHD, DLI was given monthly until GVHD occurred or MRD became negative or for a total of four times. For patients with NR or PR pre-transplantation and with MRD negative by day +60 post-transplantation, DLI was given once by day +90 regardless of MRD, and was then administered when MRD became positive. For patients with CR pre-transplantation and with MRD negative post-transplantation, DLI was not given unless MRD became positive.
62094491|NCT03635177|EXPERIMENTAL|Remote ischemic conditioning|The participant will conduct remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates to 200 mmHg and occludes blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min occlusion period is interspersed by 5 min.
62094492|NCT03635177|SHAM_COMPARATOR|Sham occlusion|The participant will conduct a sham procedure of remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates minimally and does not occlude blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min of sham occlusion is interspersed by 5 min.
62465050|NCT03048812|EXPERIMENTAL|O'Ring attachment (A)|One arm of our research will receive O'Ring attachment for 3 months and after this period they will recieve the second attachment Equator for more 3 months
62465051|NCT03048812|EXPERIMENTAL|Equator attachment (B)|The second arm of our research will receive Equator attachment for 3 months and after this period they will recieve the second attachement O Ring for more 3 months
62465052|NCT01903317||Topical Therapy|Subjects who use topical therapy as the standard treatment of care for their psoriasis.
62465053|NCT01903317||Phototherapy and Systemic Therapy|Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
62465054|NCT01903317||Biologic Therapy|Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
61907991|NCT01794338|ACTIVE_COMPARATOR|Strattice Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.."
62094493|NCT06118710|EXPERIMENTAL|Experimental premedication regimen|Local standard of care premedication regimen with an Histamine-1 antagonist (e.g. clemastine or cetirizine) without dexamethasone
62094494|NCT06118710|ACTIVE_COMPARATOR|Local standard of care premedication regimen|Local standard of care premedication regimen with an Histamine-1 antagonist (e.g. clemastine or cetirizine) with dexamethasone
62094495|NCT06632262|EXPERIMENTAL|Cohort 1|HER2-Gastric/Gastroesophageal Junction Cancer
62094496|NCT06632262|EXPERIMENTAL|Cohort 2|Urothelial carcinoma
62094497|NCT06632262|EXPERIMENTAL|Cohort 3|Non-small cell lung cancer
62292128|NCT06211855||low-risk pregnant women|The control group included low-risk pregnant women who did not have polyhydramnios. Women who had chromosomal or anatomical abnormalities, multiple pregnancies, oligohydramnios (AFI 5 cm), severe polyhydramnios, fetal growth restriction, elective cesarean section (CS), pre-existing conditions (hypertension, diabetes, thrombophilia), or obstetric complications (gestational hypertension, preeclampsia, gestational diabetes) were excluded.
62292129|NCT04581720|EXPERIMENTAL|Participants|The participants will be applied AMG and EMG on each arm of both arms when they finish routine monitoring before the induction of general anesthesia. After the participants being unconscious, we will find each participant's supramaximal current before injecting the neuromuscular blocking agents. During the operation, when the TOF count reaches 4 again and the height of T1 reaches 50% of baseline, we perform TOF tests using 4 currents (Supramaximal current, 0.7×supramaximal current, 0.5×supramaximal current, 0.3×supramaximal current), three times for respective current to figure out that low current can show the same level of TOF ratio as the supramaximal current. When the operation ends and the T1 reaches 100% of baseline, we perform TOF tests with 4 currents again. In the postanesthesia care unit, we use EMG only and perform TOF tests with 4 currents again. The participants can feel pain by the stimulants during the tests, so if they refuse the tests, we stop the tests and record it.
62292130|NCT01973257|EXPERIMENTAL|select from the option menu|select from the option menu
62292131|NCT04748263||Fronto-Temporal Dementia (FTD)|10 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
62658120|NCT04111315|ACTIVE_COMPARATOR|ibuprofen + educational intervention|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
62292132|NCT04748263||Alzheimer's Dementia (AD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
62292133|NCT04748263||Parkinson's Disease (PD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
62658121|NCT04111315|ACTIVE_COMPARATOR|ibuprofen + standard care|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
62292134|NCT04748263||Healthy volunteers|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
62292135|NCT05159414|EXPERIMENTAL|Glaucoma patients|Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
62292136|NCT05651347|PLACEBO_COMPARATOR|Placebo|Visually identical placebo tablets containing no active ingredient to the active treatment, administered three times a day.
62292137|NCT05651347|ACTIVE_COMPARATOR|Melatonin|10mg Melatonin tablets, administered three times a day (a total daily dose of 30mg per day)
62658122|NCT04858711|ACTIVE_COMPARATOR|ketamine-lidocaine-dexmedetomidine (KLD) group|combination of ketamine-lidocaine-dexmedetomidine in one syringe
62094498|NCT06632262|EXPERIMENTAL|Cohort 4|Other solid tumors
62094499|NCT00502281|ACTIVE_COMPARATOR|Group A|COS followed by TI
62094500|NCT00502281|ACTIVE_COMPARATOR|Group B|COS followed by IUI
62094501|NCT04983888|EXPERIMENTAL|Primary Focal Segmental Glomerulosclerosis (FSGS)|Subjects with immunosuppression-dependent or immunosuppression/treatment-resistant primary FSGS or contraindication/patient refusal to take high dose corticosteroids, will receive obinutuzumab 1 gram on day 1 and 1 gram on day 15, given intravenously and then an identical course at 6 months.
62658123|NCT04858711|ACTIVE_COMPARATOR|fentanyl (control) group|syringe of fentanyl
62292138|NCT04917770|EXPERIMENTAL|Sintilimab in combination with Multimodality Radiotherapy group|The dose of sintilimab was 200mg per dose, intravenously, once every 3 weeks. Multimodal radiotherapy methods: ①SBRT: ≥1 independent lesion was selected, with a single dose of 8-10Gy and a total dose of 40-60Gy, divided into 5-6 times of radiotherapy. The final frequency and total dose of radiotherapy were determined by the radiologist.② Low-dose radiotherapy: ≥1 independent lesion was selected, and the single dose, the final frequency of radiotherapy and the total dose were determined by the radiologist.
62292139|NCT03048630|EXPERIMENTAL|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
62658124|NCT02606305|EXPERIMENTAL|Regimen A (Mirvetuximab soravtansine + Bevacizumab)|Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
62292140|NCT03048630|OTHER|Delayed intervention|Delayed knowledge and behavioral intervention
62292141|NCT05288582|OTHER|Perfluorohexyloctane eye drop|Participants will have their tear lipid layer assessed. They will then have the eye drop instilled and will have an additional assessment of the tear lipid layer within 5 minutes of instillation of the the drop, and again 15 minutes after instillation.
62292142|NCT05079789|EXPERIMENTAL|Amiloride|Treatment wirh Amiloride, start dose 5 mg
62292143|NCT05079789|ACTIVE_COMPARATOR|Furosemide|Treatment with Furosemide, start dose 40 mg
62292144|NCT03403400|EXPERIMENTAL|VRWP Group|Vestibular Rehabilitation plus Walking with Pedometer Groupd
62292145|NCT03403400|ACTIVE_COMPARATOR|VRW Group|Vestibular Rehabilitation plus Walking without Pedometer Group
62465055|NCT05801497||Balneotherapy Group|Patients will receive a cycle of BT or a cycle of mud-bath therapy once daily for 12 days for a total duration of two weeks, in addition to their usual treatments for fibromyalgia. The bath can be performed both in a bathube or in a pool for 10 minutes, at a 37-38°C. The application of mud will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will relax for 20-30°C minutes. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica.
62658125|NCT02606305|EXPERIMENTAL|Regimen B (Mirvetuximab soravtansine + Carboplatin)|Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.
62292146|NCT03403400|NO_INTERVENTION|VR Group|Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
62292147|NCT01023789|EXPERIMENTAL|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation in the treatment of coronary artery disease
62292148|NCT03241446|EXPERIMENTAL|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
62658126|NCT02606305|EXPERIMENTAL|Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)|Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.
62658127|NCT02606305|EXPERIMENTAL|Regimen D (Mirvetuximab soravtansine + Pembrolizumab)|Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
62292149|NCT03241446|EXPERIMENTAL|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
62292150|NCT03241446|EXPERIMENTAL|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
62292151|NCT04804618||Healthy control group|aged ≥55 years old, no dementia, MCI or no family history of AD.
62292152|NCT04804618||Alzheimer's disease high-risk group|aged ≥55 years old, immediate family members of AD patients
62292153|NCT04804618||Alzheimer's disease group|aged ≥55 years old, diagnosed as AD patients
62292154|NCT04804618||Mild cognitive impairment group|patients ≥55 years of age, diagnosed with MCI
62292155|NCT04760184||COVID19 positives after autologous stem cell transplantation|All Swedish citizens treated with ASCT for malignant disease in Sweden from 1st January 2020 until 31st December 2020 who has tested positive for SARS-CoV-2 from start of conditioning until the end of the study period 31st March 2021.
62292156|NCT03742778|EXPERIMENTAL|Incentivizing reflection|"Participants will receive three texts each week asking a question to reflect on their latest workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you felt right after your last workout? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
62308065|NCT03831503|EXPERIMENTAL|Cohort E - 4mg Side Port|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device with Side Port needle.
61907992|NCT05637814|EXPERIMENTAL|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters and a ML CCHD screening algorithm will be assigning a prediction every minute.
61907993|NCT01871480|EXPERIMENTAL|Group A|Gefitinib combination with CIK cell immunotherapy
61907994|NCT01871480|ACTIVE_COMPARATOR|Group B|Gefitinib alone
61907995|NCT01595022|PLACEBO_COMPARATOR|Flexi ring FR01|
62094502|NCT00798265|EXPERIMENTAL|Cohort 1 - 0.5 mL dose injected intramuscular (IM)|0.5 mL dose injected intramuscular (IM) at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
62094503|NCT00798265|EXPERIMENTAL|Cohort 2 - 0.5 mL dose injected intramuscular (IM)|0.5 mL dose injected intramuscular (IM) at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
62658128|NCT02606305|EXPERIMENTAL|Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)|Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.
62658129|NCT00953433|EXPERIMENTAL|Endoflex tube|Use of Endoflex tube for intubation.
62658130|NCT00953433|ACTIVE_COMPARATOR|Endotracheal tube with stylet|Use of conventional endotracheal tube with a stylet for intubation.
61907996|NCT01595022|PLACEBO_COMPARATOR|Flexi ring FR20|
61907997|NCT01595022|PLACEBO_COMPARATOR|Ultra low dose LCS|
61907998|NCT02206178|EXPERIMENTAL|acetaminophen|"The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.~The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine~1. - decrease the antinociceptive effect of acetaminophen in comparison to a group control~2. - and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
62658131|NCT05035316|PLACEBO_COMPARATOR|Placebo|125 BD participants will receive placebo. Patients, clinicians and researchers will be blinded for the intervention
62658132|NCT05035316|ACTIVE_COMPARATOR|Active|125 BD participants will receive active treatment. Patients, clinicians and researchers will be blinded for the intervention
62658133|NCT04512495|OTHER|Patients with sarcoma|
62658134|NCT02078466|NO_INTERVENTION|Control group|Usual care
62658135|NCT02078466|EXPERIMENTAL|Assessment of functional ability|Assessment of functional ability and follow-up at home
62658136|NCT02329158||Arm: Exposed: Hydroxyethyl starch|Cardiac surgical patients exposed to 6% hydroxyethyl starch (130/0.4).
62658137|NCT02329158||Arm: Unexposed: Hydroxyethyl starch|Cardiac surgical patients not exposed to 6% hydroxyethyl starch (130/0.4).
62658138|NCT05355220|EXPERIMENTAL|silver spike point Therapy Group|One group will receive electrotherapy (silver spike point) for 10 mints along with conservative managment
61907999|NCT02206178|PLACEBO_COMPARATOR|placebo|"1. - decrease the antinociceptive effect of acetaminophen in comparison to a group control~2. - and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
61908000|NCT00814437||Donors|Oocyte donor
62094504|NCT00798265|ACTIVE_COMPARATOR|Cohort 3 - 0.5 mL dose injected intramuscular (IM)|0.5 mL dose injected intramuscular (IM) at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
62094505|NCT03578562|EXPERIMENTAL|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
62094506|NCT06441162|EXPERIMENTAL|Nebulized Hypertonic Saline + Chest Percussion Therapy|Participants with acute viral bronchiolitis will receive 3% nebulized hypertonic saline treatments combined with 3 minutes of chest percussion therapy. This will be administered every 6 hours.
62094507|NCT06441162|NO_INTERVENTION|Control Arm|Participants in the control arm will be analyzed via retrospective chart review; these participants will not be consented nor enrolled in the trial.
62465056|NCT05801497||Control Group|This group will include patients who will refuse the thermal treatment for personal reasons. Patients will continue their established routinary care for FS. The treatment must be stable for at least 3 months; some variations in analgesic consumption will be possible and will be collected in the clinical chart.
62658139|NCT05355220|ACTIVE_COMPARATOR|Conservative treatment group|2nd group will receive strengthening, stretching and stabilization exercises for prlvic girlde
62658140|NCT00942019||obese smokers|BMI \> 30 kg/m2 CO ≥ 15 ppm
62658141|NCT00942019||non-obese smokers|BMI \< 25 kg/m2 CO ≥ 15 ppm
62308066|NCT05838417|EXPERIMENTAL|Cohort-1|Individuals who identify as female at birth age 39-49 without a prior breast cancer diagnosis (including DCIS or LCIS) or known BCRA1/2 gene mutations.
62308067|NCT00519532|EXPERIMENTAL|Rotigotine|Rotigotine Transdermal Patch
62658142|NCT00942019||obese non-smokers|BMI \> 30 kg/m2 CO ≤ 6 ppm
62658143|NCT00942019||non-obese non-smokers|BMI \< 25 kg/m2 CO ≤ 6 ppm
62094508|NCT02694575||Other|Other - currently on other treatment (i.e., non-incretin based therapies)
62094509|NCT02694575||GLP-1|Currently on GLP-1 analogue therapy
62658144|NCT02452411|EXPERIMENTAL|Homework assignments using TEO system|Experimental: Homework assignments using TEO system. It is an internet-based system which allows the therapist to create homework sessions using multimedia materials (videos, images, texts, and narratives) and to offer and present this material to the patients through the Internet. Participants receive a CBT treatment for adjustment disorder supported by virtual reality and they do the homework assignments component using TEO at home over the Internet.
62094510|NCT02694575||DPP-4|Currently on DPP-4 inhibitor therapy
62094511|NCT05177848|EXPERIMENTAL|Exclusive cigarette smokers|Exclusive cigarette smokers will be recruited and will be exposed to all of the conditions described in the intervention section.
62094512|NCT05177848|EXPERIMENTAL|Dual cigarette/ nicotine vaping product users|Dual cigarette and nicotine vaping product users will be recruited and will be exposed to all of the conditions described in the intervention section.
62094513|NCT04907448|EXPERIMENTAL|IsoK-ST group|Participants in this group received the usual physical rehabilitation program in addition to an IsoK-ST program.
62094514|NCT04907448|ACTIVE_COMPARATOR|Control group|Participants in this group received the usual physical rehabilitation program only.
62094515|NCT04731714|OTHER|Experimental: rhythmic MNS, then arrhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS.
62094516|NCT04731714|OTHER|Experimental: arrhythmic MNS, then rhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS.
62094517|NCT00501241|PLACEBO_COMPARATOR|1|placebo twice daily
62292157|NCT03742778|EXPERIMENTAL|Incentivizing Exercise|"Participants will receive three texts each week asking a question for them to reflect on. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you are feeling now? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
62292158|NCT02093611|PLACEBO_COMPARATOR|Placebo|This arm will serve as the placebo supplementation.
62292159|NCT02093611|ACTIVE_COMPARATOR|ATP|This arm will serve as the treatment intervention, ATP
62292160|NCT02926807||Atopic Dermatis Subjects|30 subjects with atopic dermatitis
62292161|NCT02926807||Healthy Volunteers|30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
62292162|NCT00188578|EXPERIMENTAL|IMRT Gynecological Cancers|
61908001|NCT05623462|ACTIVE_COMPARATOR|Control Group|"Participants in the control group will receive conventional gait training (conventional physical therapy program) for one hour as the following.~* Part (1) Treadmill gait training without virtual reality. (for 30 minutes)~* Rest for 15 minutes between the first part and the second part.~* Part (2) Indoor open environment gait training exercises(over-ground gait training exercises.). (for 30 minutes)"
62094518|NCT00501241|EXPERIMENTAL|2|20 mg ATI-7505, BID for 4 weeks
62292163|NCT01125332|PLACEBO_COMPARATOR|group gel KY|
62292164|NCT01125332|EXPERIMENTAL|group gel lidocaine|
62292165|NCT03649919||1 spinal muscular atrophy, SMA|Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
62094519|NCT00501241|EXPERIMENTAL|3|40 mg ATI, BID, 4 weeks
62292166|NCT03649919||2 DMD|Progressive muscular dystrophy (DMD) is a group of hereditary skeletal muscle degeneration diseases. It is clinically characterized by slow and progressive development of muscle atrophy and muscle weakness. The inheritance can be divided into sexual chain recessiveness. Genetic type. For children with high suspected DMD/BMD, the current DMD diagnosis is preferred by MLPA method for detection of DNA in peripheral blood; MLPA diagnostic kit can only detect about 65% of large gene deletions or repeat types, thus detecting undetected gene mutations.
62292167|NCT03649919||3 X-linked adrenoleukodystrophy X-ALD|X-linked adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive hemiplegia are more common symptoms.
62465057|NCT01423760|EXPERIMENTAL|Tecemotide (L-BLP25)|
62465058|NCT01423760|OTHER|Observational|
62465059|NCT00158171|EXPERIMENTAL|1|Nicotine patch
62465060|NCT00158171|EXPERIMENTAL|2|Nicotine gum
62465061|NCT00158171|PLACEBO_COMPARATOR|3|Folic acid
62094520|NCT00501241|EXPERIMENTAL|4|80 mg ATI-4505, BID for 4 weeks
62094521|NCT00501241|EXPERIMENTAL|5|120 mg ATI-7505, BID for 4 weeks
62094522|NCT03717311|EXPERIMENTAL|13C enriched bran biscuit|The volunteers will consume 5 biscuits (100g) enriched with 13C bran with a 200 ml hot beverage in 15 minutes
62094523|NCT05678153||passive smokers children group (study group)|children whose parents reported having one or more family members smokes indoors in the presence of the child
62094524|NCT05678153||non-passive smokers children group (control group)|children whose parents reported not to have one or more family members smokes indoors in the presence of the child
62094525|NCT01613118|EXPERIMENTAL|RE-021 (Sparsentan) 200 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg.~Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
62094526|NCT01613118|EXPERIMENTAL|RE-021 (Sparsentan) 400 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg.~Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
62094527|NCT01613118|EXPERIMENTAL|RE-021 (Sparsentan) 800 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg.~Patients at \</= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
62094528|NCT01613118|ACTIVE_COMPARATOR|Irbesartan 300 mg|"The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks.~Patients at \</= 50kg will receive 150mg irbesartan for the 8 week duration."
62094529|NCT01995370|ACTIVE_COMPARATOR|Monotherapy group|"Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
62094530|NCT01995370|EXPERIMENTAL|DAPT group|"Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
62094531|NCT04551157|EXPERIMENTAL|Video Viewing|Participants will receive the intervention where they will view two patient information videos. The first video will be viewed within the first week of their inpatient stay and the second video will be viewed just before discharge.
62094532|NCT04551157|NO_INTERVENTION|Treatment as usual|No change to routine care.
62094533|NCT02638298|EXPERIMENTAL|NPWT dressing|
62094534|NCT02638298|PLACEBO_COMPARATOR|Standard dry gauze dressing|
62094535|NCT01293461|EXPERIMENTAL|CBX129801|
62094536|NCT01293461|PLACEBO_COMPARATOR|Placebo|
62465062|NCT05313425||Ectoine Eye|The right eye of the studied group will be given 2% Ectoine containig , 0.2% sodium hyaluronate eye drops(Ectohylo) hourly.
62465063|NCT05313425||Control eye|The left eye of the studied group will be give Carboxymethyl cellulose, 0.2% sodium hyaluronate eye drops(Polyfresh Extra) hourly.
62465064|NCT05599295|EXPERIMENTAL|Orbactiv|ORBACTIV is infused at 15mg/kg over 3 hours for all subjects not to exceed a dose of 1200mg.
62465065|NCT05599295|EXPERIMENTAL|Kimyrsa|"* KIMYRSA is infused at 15mg/kg over 1 hour for subjects ≥12 years old and weighing \>40 kg not to exceed a dose of 1200mg.~* KIMYRSA is infused at 15mg/kg over 3 hours in subjects \<12 years old or weighing ≤40 kg."
62658145|NCT02452411|EXPERIMENTAL|Homework assignments using Traditional method|The traditional way of applying homework assignments consists of reading and writing materials and audio session records. Participants receive a CBT treatment supported by virtual reality for adjustment disorder and they do the homework assignments component at home using traditional materials.
62658146|NCT01579864|ACTIVE_COMPARATOR|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary.
62658147|NCT01579864|EXPERIMENTAL|Rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
62658148|NCT01799083|EXPERIMENTAL|Decitabine|A continuous 5-day treatment of lower dose decitabine within 4-6 weeks is regarded as a treatment cycle, transfusion of auto-CIK cells or chemotherapy regimen may be used for patients.
62658149|NCT02145819|PLACEBO_COMPARATOR|A: spontaneous LH peak|In group A, embryos are thawed 4 days after LH surge, with a re-evaluation and transfer 5 days after LH surge.
62094537|NCT05288543|EXPERIMENTAL|Single Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (25 mg), Cohort 2 (50 mg), Cohort 3 (100 mg), Cohort 4 (200 mg), Cohort 5 (300 mg), Cohort 6 (400 mg), Cohort 7 (500 mg) and Cohort 8 (600 mg)
62094538|NCT05288543|EXPERIMENTAL|Multiple Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (100 mg), Cohort 2 (300 mg) and Cohort 3 (500 mg)
62094539|NCT05288543|PLACEBO_COMPARATOR|Part A (Placebo)|Placebo tablets identical to IPG7236 tablets Dosage form: Tablet Route of Administration: Oral
62094540|NCT04514042|ACTIVE_COMPARATOR|Standard procedure|Patients with Zenker's diverticulum treated with flexible endoscopy septotomy.
62094541|NCT04514042|EXPERIMENTAL|Investigational procedure|Patients with Zenker's diverticulum treated with peroral endoscopic myotomy.
62094542|NCT05008224|EXPERIMENTAL|Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation|"After completing Positron Emission Tomography (PET) scan 1 during eligibility screening, participants received pembrolizumab monotherapy intravenous (IV) for three 3-week cycles followed by PET scan 2.~Participants next received 2 phases of chemotherapy. In chemotherapy phase 1, all participants received doxorubicin in combination with vinblastine \& dacarbazine (AVD) IV for two 4-week cycles followed by PET scan 3. In chemotherapy phase 2, participants who were PET scan 3 negative, or positive and age ≥60 years, received up to 4 additional cycles of AVD IV, while participants who were PET scan 3 positive and age \<60 years received up to four 3-week cycles of escalated bleomycin in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, \& prednisone (escBEACOPP) IV.~All participants then received pembrolizumab consolidation IV for four 6-week cycles followed by a final PET scan."
62094543|NCT03888911|EXPERIMENTAL|High dose IQP-LU-104 (5120mg)|High dose treatment group
62465066|NCT05599295|ACTIVE_COMPARATOR|Standard of Care|"The following SoC medications below will be administered via IV infusion, per the package insert, and according to local rules and regulations. SoC medications cannot be used in combination with one another.~* Vancomycin~* Teicoplanin~* Clindamycin~* Daptomycin~* Semi-synthetic penicillins (e.g., nafcillin, oxacillin, cloxacillin)~* Cefazolin~* Ceftaroline"
62465067|NCT01474798|EXPERIMENTAL|RA-18C3|
62465068|NCT02794974|EXPERIMENTAL|with perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
62094544|NCT03888911|EXPERIMENTAL|Low dose IQP-LU-104 (2560mg)|Low dose treatment group
62292168|NCT03649919||4 tuberous sclerosis complex，TSC|Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease involving multiple systems. About 1 in every 6,000-10,000 people in TSC suffer from tuberous sclerosis, and children in the neurology department are diagnosed with developmental delay or seizures, and about 2/3 have no positive family history. Nearly 2 million people worldwide suffer from TSC, and there are about 200,000 in China.
62292169|NCT06068582|EXPERIMENTAL|Strengthening the brain|Participants receive 30 minutes of 1-on-1 fitness training, dietary advice, and mental coaching, in addition to twice 20 minutes fitness at home, and 60 minutes of cognitive training each week for four months.
62465069|NCT02794974|EXPERIMENTAL|without perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)
62094545|NCT03888911|PLACEBO_COMPARATOR|Placebo|Placebo group
62465070|NCT05151588|EXPERIMENTAL|Induction therapy followed by surgery and postoperative therapy|Induction chemotherapy with docetaxel 75mg/m2 on day 1, cisplatin 75mg/m2 on day 1, 5-FU 750mg from day 1 to day 5, given every 3 weeks for 3 cycles and tazemetostat 800mg twice daily orally for 3 cycles, followed by radical surgery or radical chemoradiation, and maintenance tazemetostat 800mg twice daily orally for 6 months
62658150|NCT02145819|ACTIVE_COMPARATOR|B: hCG|In group B, embryos are thawed 5 days after hCG administration, with a re-evaluation and transfer 6 days after hCG.
62658151|NCT00134719|EXPERIMENTAL|MenHibrix Group|Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
62658152|NCT00134719|ACTIVE_COMPARATOR|ActHIB + Meningitec Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
62658153|NCT00134719|ACTIVE_COMPARATOR|ActHIB/PedvaxHIB Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.
62658154|NCT03665545|ACTIVE_COMPARATOR|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
62658155|NCT03665545|EXPERIMENTAL|IMA950/Poly-ICLC and pembrolizumab|Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly- ICLC administered subcutaneously
62658156|NCT02049658||Healthy volunteers|Healthy volunteers measured by currently used healthy screening procedures
62658157|NCT02049658||Suspected breast cancer subjects|Suspected breast cancer subjects without pathological examination yet but will have it soon
62094546|NCT02060253|EXPERIMENTAL|ganetespib, paclitaxel, and trastuzumab with pertuzumab|Patients receive trastuzumab intravenously (IV) over 30 minutes on days 1, 8, 15, and 22, pertuzumab IV over 30 minutes every 3 weeks (only in Part II of the study, starting day 1), paclitaxel IV over 1 hour on days 1, 8, 15, and 22, and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. The MTD for ganetespib in combination with paclitaxel and trastuzumab is 150 mg/m2.
62094547|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
62094548|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.01 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
62094549|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.03 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
62094550|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.06 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
62094551|NCT01614756|EXPERIMENTAL|Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
62094552|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.3 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
62094553|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
62292170|NCT06068582|EXPERIMENTAL|Strengthening the mind|Partiicpants receive biweekly 1-on-1 coaching by a trained work-coach who has MS to identify challenges at work and implement solutions. It is completed when satisfactory solutions have been implemented for all challenges or after four months.
62658158|NCT02049658||Suspected lung cancer subjects|Suspected lung cancer subjects without pathological examination yet but will have it soon
62658159|NCT02049658||Suspected neurological tumor subjects|Suspected neurological tumor subjects without pathological examination yet but will have it soon
62094554|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
62094555|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 3 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
62094556|NCT01614756|EXPERIMENTAL|Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 10.0 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
62658160|NCT02049658||Suspected patients with gynecological tumor|Suspected subjects with gynecological tumors without pathological examination yet but will have it soon
62094557|NCT01614756|EXPERIMENTAL|Dose Escalation- BMS-981164 or Placebo (dose group 1)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose"
62658161|NCT04305600||Aim 1|Aim 1 participants will be recruited from participants in the first BRAIN study at VUMC.
62658162|NCT04305600||Aim 2|Aim 2 participants will be recruited from the ICU populations at both VUMC and RUMC.
61908002|NCT05623462|EXPERIMENTAL|Experimental Group|"Participants in the experimental group will receive a treatment program that is comprised of two parts.~* The first part included training, for (30 minutes), on The C-Mill virtual reality treadmill. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications. The C-Mill applies an augmented virtual reality environment, obstacle avoidance games, and a variety of balance challenges in a safe and controlled environment to increase walking adaptability and performance in everyday life.~* There will be 15 minutes rest between parts one and two of the training program~* The second part (conventional training program) (30 minutes) will include: Indoor open environment gait training exercises (over-ground gait training exercises.). (30 minutes)"
62094558|NCT01614756|EXPERIMENTAL|Dose Escalation- BMS-981164 or Placebo (dose group 2)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
62094559|NCT01614756|EXPERIMENTAL|Dose Escalation- BMS-981164 or Placebo (dose group 3)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
62094560|NCT01614756|EXPERIMENTAL|Dose Escalation- BMS-981164 or Placebo (dose group 4)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and \>1.0mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
62094561|NCT06345872|EXPERIMENTAL|Experimental|8 weeks of online CBT-I (1 session/week for 1 hour), followed by tapered withdrawal and motivational interviewing and check-ins.
62094562|NCT06345872|OTHER|Treatment as usual|Continuation of standard treatment for sleep and pain for 8 weeks, followed by tapered withdrawal and motivational interviewing and check-ins.
62292171|NCT06068582|NO_INTERVENTION|Enhanced usual care|Participants receiving general information about cognitive impairment in MS and following care as usual for four months.
62292172|NCT04088448|PLACEBO_COMPARATOR|Control group|Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
62658163|NCT06167902|EXPERIMENTAL|Ginseng oligopeptide group|
62658164|NCT06167902|PLACEBO_COMPARATOR|The placebo group|
62658165|NCT00080626|EXPERIMENTAL|Docetaxel|Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.
62094563|NCT04757558|ACTIVE_COMPARATOR|C-MAC-VS group|C-MAC-VS will be used to facilitate intubation
62658166|NCT01647178|ACTIVE_COMPARATOR|Manual closure|Patients are closed with a manual, straight wire, conventional closure technique
62658167|NCT01647178|ACTIVE_COMPARATOR|TORQ closure|Patients are undergo a TORQ assisted sternal closure
62658168|NCT00319371||1|women with vasospasm and difficulties of initiating sleep
62094564|NCT04757558|PLACEBO_COMPARATOR|control group|direct laryngoscopy using Macintosh laryngoscope will be done for DLT insertion.
62094565|NCT06287229|EXPERIMENTAL|Phase 1B + Phase 2|Participants found to be eligible to take part in this study, you will be assigned to a study phase (Phase 1B or Phase 2). Up to 10 participants will be enrolled in Phase 1B, and up to 30 will be enrolled in Phase 2. All participants will first receive cytoreductive therapy (inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD), followed by lymphodepletion chemotherapy and 1 dose of brexucabtagene autoleucel.
62094566|NCT01556243|EXPERIMENTAL|Breast conservation surgery and radiation therapy|Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy.
62292173|NCT04088448|EXPERIMENTAL|Metformin group|Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks
62292174|NCT01324830|EXPERIMENTAL|arm A|14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
62465071|NCT04641130|EXPERIMENTAL|Exposure to birch pollen|"Step 1: dose validation 16 subjects are exposed for 2 consecutive days (D1 + D2), to the same aerial concentration of Bet v1.~The main objective is achieved if the Abelson score is ≥ 5 on J1 or J2. If the main objective is achieved for the 60 ng/m3 concentration, 8 responder subjects will directly perform step 2.~If the main objective is not achieved for the 60 ng/m3 concentration, the subjects will be exposed between 7 to 10 days after exposure 1, to an allergen concentration of 120 ng/m3 (Exposure 2: D1 + D2).~Step 2: reproducibility Once the allergen concentration has been determined (step 1), 8 of the responder subjects from step 1 are exposed again to this same concentration, during 2 additional exposures (Exposure 3: D1 + D2 and Exposure 4: D1 + D2), at least 7 days apart.~A wash-out period of at least 7 days is observed between step 1 and 2. The duration of allergen exposure will be a maximum of 4 hours for all exposures."
62292175|NCT01324830|EXPERIMENTAL|arm B|5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
62658169|NCT00319371||2|women without vasospasm and no difficulties of initiating sleep
62658170|NCT03579537|EXPERIMENTAL|Hemodyalisis patients|group of patients in hemodialysis who performs the exercise program
62658171|NCT04908618|ACTIVE_COMPARATOR|digital impression with normal abutment for dental implant|digital impression using a ready-made abutment for dental implant
62658172|NCT04908618|EXPERIMENTAL|digital impression with scan abutment for dental implant|digital impression with scan body abutment for dental implant
62658173|NCT04908618|EXPERIMENTAL|open tray conventional dental implant impression|Digitized open tray dental implant impression
62658174|NCT04908618|EXPERIMENTAL|closed tray impression for dental implant|Digitized closed tray dental implant impression
62658175|NCT00750334|EXPERIMENTAL|Part A|clofarabine Dose Escalation
62658176|NCT00750334|EXPERIMENTAL|Part B|Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.
62658177|NCT03090906|EXPERIMENTAL|Control group: SCTG from palate|Soft tissue augmentation palate
62094567|NCT04794179|EXPERIMENTAL|Naida Link CROS device|Individuals 18+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
62094568|NCT06617455|EXPERIMENTAL|Arm I (fezolinetant, placebo)|Patients receive fezolinetant PO QD for 28 days in the absence of unacceptable toxicity. Patients then go through a washout period and take no study medication for the next 14 days. Following the washout, patients receive placebo PO QD for 28 days in the absence of unacceptable toxicity. Patients undergo collection of blood samples throughout the study.
62292176|NCT00716976|EXPERIMENTAL|STS Arm (sodium thiosulfate treatment)|Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.
62292177|NCT00716976|EXPERIMENTAL|Observation Arm (No sodium thiosulfate treatment)|Patients do not receive sodium thiosulfate.
62292178|NCT06488300|NO_INTERVENTION|Negative control group|Controls will receive no antiviral treatment (supportive treatment will remain the same as per the treating Physician's judgement)
61908003|NCT01395784|PLACEBO_COMPARATOR|Placebo Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
62292179|NCT06488300|EXPERIMENTAL|Ribavirin|
62292180|NCT06488300|EXPERIMENTAL|Molnupiravir|
62292181|NCT06488300|EXPERIMENTAL|Favipiravir|
62292182|NCT00947648|OTHER|"Raw Group"|Participants will eat cooked food and the addition of raw fruits and vegetables.
62658178|NCT03090906|EXPERIMENTAL|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
62658179|NCT06432439|EXPERIMENTAL|TEST GROUP|Isolated RT1 gingival recession treated by microneedling followed by Coronally Advanced Flap procedures
62658180|NCT06432439|ACTIVE_COMPARATOR|CONTROL GROUP|Isolated RT1 gingival recession treated by Coronally Advanced Flap procedures alone.
62658181|NCT04966429|ACTIVE_COMPARATOR|Maraviroc 150 mg per day|
62658182|NCT04966429|ACTIVE_COMPARATOR|Maraviroc 600 mg per day|
62094569|NCT06617455|EXPERIMENTAL|Arm II (placebo, fezolinetant)|Patients receive placebo PO QD for 28 days in the absence of unacceptable toxicity. Patients then go through a washout period and take no study medication for the next 14 days. Following the washout, patients receive fezolinetant PO QD for 28 days in the absence of unacceptable toxicity. Patients undergo collection of blood samples throughout the study.
62094570|NCT00836069|EXPERIMENTAL|PD 0332334-α2δ ligand (450mg)|PD 0332334, 450mg/day, for 8 weeks and then 2 weeks of dose tapering.
62094571|NCT00836069|EXPERIMENTAL|PD 0332334-α2δ ligand (600mg)|PD 0332334, 600mg/day, for 8 weeks and then 2 weeks of dose tapering.
62094572|NCT00836069|ACTIVE_COMPARATOR|Paroxetine|Paroxetine, 20mg/daym for 8 weeks and then 2 weeks of dose tapering.
62094573|NCT00836069|PLACEBO_COMPARATOR|Placebo|Inactive Substance (placebo) for 10 weeks.
62094574|NCT02295982|PLACEBO_COMPARATOR|Laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique
62094575|NCT02295982|ACTIVE_COMPARATOR|Hand assisted laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy
62094576|NCT06696560|OTHER|Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries.|Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries.
62292183|NCT00947648|OTHER|"Cooked Group"|Participants will eat only cooked foods.
62292184|NCT05309447||Patients with sLSS|Patients with Symptomatic Lumbar Spinal Stenosis (n=10)
62292185|NCT05309447||Young Controls|Young healthy control subjects (n=10)
62292186|NCT05309447||Age-Matched Controls|Age-matched healthy control subjects (n=10)
62292187|NCT05749835|EXPERIMENTAL|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland et al
62292188|NCT05749835|EXPERIMENTAL|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\\her head is cradled between your body and your right forearm (when you stand at his\\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
62658183|NCT04966429|PLACEBO_COMPARATOR|Placebo|
61908004|NCT01395784|EXPERIMENTAL|PIO 15 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
61908005|NCT01395784|EXPERIMENTAL|PIO 45 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
61908006|NCT03560700|EXPERIMENTAL|lactobacillus probiotic strain|60 billion CFU/day
61908007|NCT03560700|PLACEBO_COMPARATOR|placebo|
61908008|NCT00186953|OTHER|1|
62658184|NCT02838355|ACTIVE_COMPARATOR|Standard Respiration Monitoring|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring throughout their stay in the ICU.
62658185|NCT02838355|EXPERIMENTAL|Standard Respiration Monitoring + Continuous ETCO2-NC|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring and continuous end-tidal capnography monitoring via nasal cannula (ETCO2-NC) throughout their stay in the ICU.
62658186|NCT02313155|EXPERIMENTAL|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
62658187|NCT02313155|EXPERIMENTAL|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
62658188|NCT03641365|EXPERIMENTAL|Test group|Test group: Surgical template without metallic sleeves. In this case the surgical template has all been designed and fabricated in acrylic material by mean of stereolitographic technology.
62658189|NCT03641365|ACTIVE_COMPARATOR|Control group|Control group: Surgical template with metallic sleeves. Surgical template has designed and fabricated in acrylic material by mean of stereolitographic technology and metallic sleeves have been bonded after its production.
62658190|NCT04919161|ACTIVE_COMPARATOR|Body weight support system control group|In this arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system.
61908009|NCT00878436|EXPERIMENTAL|Arm A (120 mg/week)|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~40 mg Panobinostat 3 times per week (120 mg per week) for 2 consecutive weeks with one week rest"
62094577|NCT04690816||Healthy Volunteers|Healthy Volunteers to have a comparative group,without an underlying autoimmune disease or other significant medical problems
62094578|NCT04690816||Systemic Autoimmune Diseases|Patients with associated systemic autoimmune diseases.
62094579|NCT04774926|EXPERIMENTAL|Brolucizumab 6 mg|Participants will receive 3 monthly ocular injections followed by a q12w or q8w maintenance phase based on patient's disease activity (DA).
62094580|NCT06613763|EXPERIMENTAL|RAY1225 - Mild Renal Impairment|RAY1225 3mg administered SC to participants with mild renal impairment.
62094581|NCT06613763|EXPERIMENTAL|RAY1225 - Moderate Renal Impairment|RAY1225 3mg administered SC to participants with moderate renal impairment.
62094582|NCT06613763|EXPERIMENTAL|RAY1225 - Severe Renal Impairment|RAY1225 3mg administered SC to participants with severe renal impairment.
62094583|NCT06613763|EXPERIMENTAL|RAY1225 - Control|RAY1225 3 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.
62094584|NCT00736749||Observational (long-term follow-up)|Within 3 months of enrollment on ALTE05N1, patients receive a packet introducing the Long-Term Follow-Up Center (LTFC). Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, secure online form, or 24-hour toll-free telephone number. After initial contact, the LTFC will contact the patient annually
62094585|NCT03017456|NO_INTERVENTION|Usual Care (UC)|Patients in the UC arm will not receive the study intervention (behavioral) and instead will receive care according to usual practice. This usually involves a brief office visit (approximately 5-10 minutes) with pertinent history and physical examination related to surgical/radiation recovery, review of the pathology and general instructions regarding the next step in follow-up.
62094586|NCT03017456|ACTIVE_COMPARATOR|SCP-Intervention vs usual care|behavioral intervention vs control Patients in the SCP-Int arm will be asked to attend a one-time appointment with a trained oncology nurse. The SCP-Int is comprised of a 30-minute nurse-led face-to-face intervention and the provision of a tailored PC-specific SCP (PC-SCP). Persistent effects and concerns that are identified will prompt the development of a tailored management plan captured within the PC-SCP. Relevant patient education materials will be linked electronically. Nurses will use motivational interviewing techniques to effective in increase healthy behaviors and empower the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support.
62094587|NCT00536666|OTHER|1|Iron oligosaccharide
61908010|NCT00878436|EXPERIMENTAL|Arm B (60 mg/week)-Closed to accrual|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~20 mg Panobinostat 3 times per week (60 mg per week) for 2 consecutive weeks with one week rest"
62094588|NCT06628661||Solitary HCC larger than 6.5 cm without mVI|Operable solitary HCC larger than 6.5 cm without mVI
62292189|NCT06310148|EXPERIMENTAL|Participating in Chronic Disease Co-Care Pilot Scheme|Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
61908011|NCT05901389|EXPERIMENTAL|lidocaine|Patients in this group will receive continuous lidocaine infusion via closed chest drainage tube. The pulse infusion speed is 1ml / 30min, and the continuous infusion speed was 2ml / h.
62292190|NCT06310148|NO_INTERVENTION|Not participating in Chronic Disease Co-Care Pilot Scheme|Eligible non-CDCC participants will only be referred to the laboratories of a designated service provider by the research team for physical examination, blood tests, and urine test as a screening for DM and HT. No health management plans and necessary medication treatment would be provided to them in this study.
62292191|NCT06295445|EXPERIMENTAL|Group A: Control group|About 54 patients that will undergo treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management.
62292192|NCT06295445|EXPERIMENTAL|Group B: Study group|About 54 patients that will undergo cardio-pulmonary ultrasound guided management.
62465072|NCT04350580|EXPERIMENTAL|Intervention - IGIV|Participants in the intervention group will receive a 2g/Kg infusion of human immunoglobulin which should be started before the 96th hours after the start of mechanical ventilation in 4 injections of 0.5 g/Kg over 4 consecutive days.
62658191|NCT04919161|EXPERIMENTAL|Body weight support system with balance perturbations|Similar to the control group arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system, with the inclusion of 8 total balance perturbations each session, including 2 in the posterior, anterior, left lateral, and right lateral directions.
62658192|NCT04919161|NO_INTERVENTION|Historical Standard of Care control|Retrospective anonymized Berg Balance Score data of stroke inpatients was collected from an institutional report for fiscal year 2018. 2018 was chosen as it preceded the implementation of the ZeroG body weight support system and reflects a no-intervention control baseline. This data was then filtered to show only patients with a Berg score of 21 or greater to match the study's inclusion criteria.
62658193|NCT04866199||High-risk colon or bladder surgical patients|Patients who are diagnosed with colon or bladder cancer requiring surgical resection.
61908012|NCT05901389|PLACEBO_COMPARATOR|normal saline|Patients in this group will receive continuous normal saline infusion via closed chest drainage tube. The pulse infusion speed is same as the lidocaine group.
61908013|NCT00910507|EXPERIMENTAL|Exercise counseling|Each participant in the experimental group receives exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
62465073|NCT04350580|PLACEBO_COMPARATOR|Placebo|Participants of the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.
62094589|NCT06628661||Solitary HCC larger than 2 cm with mVI|Operable solitary HCC larger than 2 cm with mVI
62094590|NCT04545502||Gelsoft Plus - Straights and Bifurcated|Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.
62292193|NCT03796403|EXPERIMENTAL|diclofenac and bupivacaine group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
62465074|NCT04591405|EXPERIMENTAL|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day
62465075|NCT04591405|PLACEBO_COMPARATOR|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
62658194|NCT03473197|OTHER|Single Cohort (Healthy Volunteers)|Diacerein 1% topical ointment Intra-subject photoallergy (photosensitization) test
61908014|NCT00910507|ACTIVE_COMPARATOR|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
61908015|NCT02524600|EXPERIMENTAL|"New Technology IQ-SPECT applied to myocardial imaging"|
61908016|NCT02226679|EXPERIMENTAL|Algisyl-LVR device implantation|Algisyl-LVR™ employed as a method of left ventricular augmentation and restoration in patients with dilated cardiomyopathy. Algisyl-LVR™ will be injected into the myocardium under direct visualization during the surgical procedure.
61908017|NCT01888432|EXPERIMENTAL|Everolimus + reduced tacrolimus|Everolimus + reduced tacrolimus ± corticosteroids
61908018|NCT01888432|ACTIVE_COMPARATOR|Standard tacrolimus|Standard tacrolimus ± corticosteroids
61908019|NCT00917293|EXPERIMENTAL|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate, enteric-coated 2x 250mgs po bid.
61908020|NCT00917293|PLACEBO_COMPARATOR|Placebo|Placebo 2 pills, po bid.
61908021|NCT00930137|EXPERIMENTAL|High dairy trans fat|a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)
61908022|NCT00930137|ACTIVE_COMPARATOR|Low dairy trans fat diet|a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)
61908023|NCT03263650|EXPERIMENTAL|Cabazitaxel + Carboplatin|Cabazitaxel, Cabazitaxel and Carboplatin intravenously on day 1 of cycles 1-6. Prednisone by mouth twice daily on days 1-21 of cycles 1-6.
61908024|NCT03263650|EXPERIMENTAL|Olaparib Maintenance|Participants randomized to receive Olaparib by mouth twice daily on Day 1 of cycle 7.
61908025|NCT03263650|NO_INTERVENTION|Observation Only|Participants randomized to observation only beginning cycle 7.
61908026|NCT02117128|EXPERIMENTAL|Tranexamic acid, IA group|Tranexamic acid 1g, intra-articular injection, post-operationally
61908027|NCT02117128|ACTIVE_COMPARATOR|Tranexamic acid, IV group|Tranexamic acid, 1g, intravenous injection, post-operationally
61908028|NCT02117128|EXPERIMENTAL|Tranexamic acid, IV+IA group|Tranexamic acid, 1g, intravenous injection, post-operationally; Tranexamic acid, 1g, intra-articular injection, post-operationally
62465076|NCT04591405|EXPERIMENTAL|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day
62465077|NCT04591405|PLACEBO_COMPARATOR|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
62658195|NCT01513499|ACTIVE_COMPARATOR|Oxytocin|Intranasal oxytocin
62658196|NCT01513499|PLACEBO_COMPARATOR|Placebo|Intranasal placebo
62736815|NCT05087433|EXPERIMENTAL|İntervention Group|"Practicing Progressive Relaxation Exercises The training of the Zoom application progressive relaxation exercise for the nurses was done in two sessions for a total of 60 minutes. During the first interview, the definition, purpose, benefits, and application techniques of PRE were explained to the nurses in the intervention group. In the second session, the steps of progressive relaxation exercises were demonstrated by the trainer.~The trainer performed the PRE exercise online with the nurses. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month."
61908029|NCT00088556|EXPERIMENTAL|Triplet Combination of TLK286 Carboplatin & Paclitaxel|Experimental
61908030|NCT02172534|EXPERIMENTAL|Tiotropium bromide low|Single dose: 2.5 µg Tiotropium
61908031|NCT02172534|EXPERIMENTAL|Tiotropium bromide medium|Single dose: 5 µg Tiotropium
61908032|NCT02172534|EXPERIMENTAL|Tiotropium bromide high|Single dose: 10 µg Tiotropium
61908033|NCT02172534|EXPERIMENTAL|Tiotropium bromide low (28 days)|multiple dose: 2.5 µg Tiotropium
61908034|NCT02172534|EXPERIMENTAL|Tiotropium bromide medium (28 days)|Multiple dose: 5 µg Tiotropium
61908035|NCT02172534|PLACEBO_COMPARATOR|Placebo|single or multiple dose of Placebo
62094591|NCT04545502||Gelsoft Plus - Extra-Anatomical|Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.
62658197|NCT03972033|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing|"The DeprEND manualized protocol (Hofmann, Ostacoli, et al., 2015) is based on the eight-phase protocol by Shapiro (2001) that was adapted for the treatment of depression by the European Depression EMDR Network and used in previous studies (Hase et al., 2015; Hofmann et al., 2014; Ostacoli et al., 2018). EMDR targets will be selected using the Adaptive Information Processing model that looks for stressful events linked with depression. The DeprEnd Fidelity Rating Scale will be used to assess treatment fidelity. The scale will be completed by trained EMDR therapists who will listen to the audio recordings of the sessions.~In each centre, EMDR is provided by psychotherapists specialized in Level II EMDR and with a minimum of three years of experience in treating patients with depression. They receive extensive training and supervision in the manualized protocol established for the study, from a certified senior EMDR instructor."
62292194|NCT03796403|PLACEBO_COMPARATOR|bupivacaine only group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.
62658198|NCT03972033|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Treatment protocol is based on the principles described by Beck (Beck et al., 1979) will be utilized. The treatment includes behavioral activation and cognitive restructuring with homework assignments. In each centre, CBT treatment is performed by psychotherapists with certified training in CBT techniques and a minimum of three years of experience in treating patients with depression. They receive regular CBT supervision to ensure that the quality of their CBT treatment was maintained.
62658199|NCT05324189||More than mild (mtm) Diabetic Retinopathy (DR) Not Detected or Non referable DR|More than mild Diabetic Retinopathy (mtm DR) not detected or non referable DR using the iPredict's AI-based DR screening software utilizing color fundus imaging.
62658200|NCT05324189||More than mild (mtm) Diabetic Retinopathy (DR) Detected or Referable DR|More than mild Diabetic Retinopathy (mtm DR), moderate to severe DR detected, non proliferative DR detected, proliferative DR detected or referable DR using the iPredict's AI-based DR screening software utilizing color fundus imaging.
62658201|NCT01614704||Adjuvant treatment|Patients in this group will be offered the option of ovarien cryopreservation as well as the follow up of the follicule stock during chemotherapy.
62658202|NCT01614704||Neo adjuvant treatment|patients in this group will only have the follow up of the follicule stock.
62658203|NCT05538845||Screw|Screw fixation
62094592|NCT04545502||Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall|Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.
62094593|NCT04545502||Gelweave - Abdominal, Thoracic, Thoracoabdominal|"Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards:~* Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries.~* Thoracic aorta or arteries arising from the thoracic aorta.~* Abdominal and thoracic aorta requiring a thoracoabdominal repair"
62292195|NCT05877144|EXPERIMENTAL|ARM I (LiSWT)|Patients undergo nerve-sparing radical prostatectomy per standard of care. Patients then receive LiSWT treatment weekly for 6 weeks, then have a 6 week break, followed by 6 more weekly treatments. Patients also undergo DDUS at baseline and during follow up.
62292196|NCT05877144|SHAM_COMPARATOR|ARM II (sham LiSWT)|Patients undergo nerve-sparing radical prostatectomy per standard of care. Patients then receive sham LiSWT treatment weekly for 6 weeks, then have a 6 week break, followed by 6 more weekly treatments. Patients also undergo DDUS at baseline and during follow up.
62292197|NCT00876369||Urticaria/Angioedema|Subjects with chronic urticaria and/or angioedema
62292198|NCT00876369||allergy control|Subjects with physician diagnosed allergic rhinitis
62658204|NCT05538845||Suture button|Suture button
61908036|NCT01713933|EXPERIMENTAL|Ultherapy™ treatment|Each enrolled subject will receive a bilateral Ultherapy™ treatment of the upper arms
62465078|NCT02758691|EXPERIMENTAL|Intranasal Insulin|Healthy participants will self-administer 20 IU of Humulin® R U-100 with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
62658205|NCT02924961|EXPERIMENTAL|Triathlon Mobile-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
61908037|NCT04936984|EXPERIMENTAL|Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
61908038|NCT04936984|EXPERIMENTAL|Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
62292199|NCT00868790|EXPERIMENTAL|PLA→MK-3577 QD AM→MK-3577 QD PM→MK-3577 BID (Arm 1)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
62465079|NCT02758691|PLACEBO_COMPARATOR|Saline Placebo|Healthy participants will self-administer a saline solution with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
62465080|NCT05130554|EXPERIMENTAL|XEN45|The effect of XEN45 surgery on patients with primary open-angle glaucoma
62658206|NCT02924961|ACTIVE_COMPARATOR|Triathlon Fixed-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing
62658207|NCT00128388|EXPERIMENTAL|1 PFPP|Panic Focused Psychodynamic Psychotherapy
62658208|NCT00128388|ACTIVE_COMPARATOR|2 ART|Applied Relaxation Training
62094594|NCT04545502||Gelweave - Valsalva|Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.
62658209|NCT04217980|EXPERIMENTAL|Lung ultrasonography (LUS) group|Group 1: Lung ultrasonography is performed as the main (first) pulmonary image test
62658210|NCT04217980|ACTIVE_COMPARATOR|Chest X ray (CXR) group|Group 2: Chest X ray is performed as main (first) pulmonary image test
62094595|NCT05018585|EXPERIMENTAL|Diamyd|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
62465081|NCT02605148|EXPERIMENTAL|Gluten free diet|Gluten free diet during 18 months. The subjects will be referred to a nutritionist every 6 months. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
62658211|NCT05502172|EXPERIMENTAL|fish oil|Healthy individuals will be taking the composition of fish-derived oils BioMarine®Medical Immuno \& Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
62658212|NCT02916927|EXPERIMENTAL|Ketamine IV infusion|Ketamine 0.3 mg/kg in 100 mL normal saline minibag infused over 15 minutes. Placebo: 10 mL normal saline in syringe pushed over 1 minute. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
62465082|NCT02605148|ACTIVE_COMPARATOR|Normal diet|Normal diet. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
62465083|NCT00914394|ACTIVE_COMPARATOR|NG-monomethyl-L-arginine (L-NMMA)|
62465084|NCT00914394|ACTIVE_COMPARATOR|Phenylephrine|
62658213|NCT02916927|ACTIVE_COMPARATOR|Ketamine IV push|Ketamine 0.3 mg/kg in a syringe pushed over 1 minutes. Placebo: 100 mL normal saline minibag infused over 15 minutes. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
62658214|NCT05110612|EXPERIMENTAL|Extended Episodic Future Thinking|Participants will receive Episodic Future Thinking practice for 8 sessions.
62658215|NCT05110612|EXPERIMENTAL|Brief Episodic Future Thinking|Participants will receive Episodic Future Thinking practice for 2 sessions.
62658216|NCT05110612|SHAM_COMPARATOR|Control|Participants will receive sham Episodic Recent Thinking intervention.
62465085|NCT00914394|PLACEBO_COMPARATOR|Physiological saline solution|
62465086|NCT03365297|EXPERIMENTAL|Treatment|apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.
62465087|NCT05662163|ACTIVE_COMPARATOR|GROUP TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min). Blood will be taken from the patients at 0, 1 and 4 hours, centrifuged and stored at -80 degrees. From these examples, CK, CKMB, HIGH SENSITIVE TROPONIN, HFABP, IMA AND ALBUMIN will be studied.
62465088|NCT05662163|ACTIVE_COMPARATOR|GROUP INHALATION ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min). Blood will be taken from the patients at 0, 1 and 4 hours, centrifuged and stored at -80 degrees. From these examples, CK, CKMB, HIGH SENSITIVE TROPONIN, HFABP, IMA AND ALBUMIN will be studied.
62465089|NCT03850639|EXPERIMENTAL|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
61908039|NCT04936984|EXPERIMENTAL|Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
62094596|NCT05018585|PLACEBO_COMPARATOR|Placebo|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
62094597|NCT01764386|EXPERIMENTAL|NB + CLI|Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)
62465090|NCT03850639|NO_INTERVENTION|Wait list control|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 4 weeks.
62465091|NCT06284538|EXPERIMENTAL|WOUND-H|STUDY FOR THE ASSESSMENT OF THE EFFECTIVENESS OF A MEDICAL DEVICE BASED ON HYALURONIC ACID IN WOUNDS
62465092|NCT06284538|ACTIVE_COMPARATOR|Braccio controllo|NORMAL STANDARD THERAPIES FOR WOUND TREATMENT (CLEANING AND DISINFECTION)
62465093|NCT04455126|EXPERIMENTAL|Preservative-free tafluprost|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
62094598|NCT01764386|OTHER|Usual Care|"Usual Care (self-directed lifestyle intervention)~Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, and a pamphlet about weight loss by study site staff."
62094599|NCT03871933||AECOPD|acute exacerbation of COPD
62094600|NCT03871933||stable COPD|
62094601|NCT04689165|EXPERIMENTAL|Experimental Vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
62094602|NCT04689165|ACTIVE_COMPARATOR|Active Comparator Vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
62094603|NCT00565318|ACTIVE_COMPARATOR|A|
62094604|NCT00565318|PLACEBO_COMPARATOR|B|
62094605|NCT02117115|EXPERIMENTAL|CT scan with contrast|
62094606|NCT06613490|EXPERIMENTAL|anti CD19 CAR NK cells|
62465094|NCT02865122|EXPERIMENTAL|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
62465095|NCT02865122|EXPERIMENTAL|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
62465096|NCT02865122|PLACEBO_COMPARATOR|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
62094607|NCT00980278|ACTIVE_COMPARATOR|sinus lift plus dental implant|"Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: N/A; only sinus augmentation and dental implant"
62094608|NCT00980278|EXPERIMENTAL|sinus lift plus BRCs and dental implant|"transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant"
62292200|NCT00868790|EXPERIMENTAL|MK-3577 QD AM→PLA→MK-3577 BID→MK-3577 QD PM (Arm 2)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
62658217|NCT02165527|EXPERIMENTAL|x-ray with iXDA scan|Tota body scan taken by the Lunar iXDA. During the scan, subject will be asked to lay on their back. Following the Lunar iDXA scan, the computer of the Luna iXDA will calculate bone length. The calculation of bone length will be compared to a calculation from the subject's conventional x-ray to determine accuracy.
62658218|NCT02836769|EXPERIMENTAL|Rehabilitation Consult (RC)|Pilot testing: single group pre-post design
62292201|NCT00868790|EXPERIMENTAL|MK-3577 QD PM→MK-3577 BID→PLA→MK-3577 QD AM (Arm 3)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed MK- 3577 25 mg BID for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
62658219|NCT02920658|EXPERIMENTAL|NAVS Naphthalan|NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
62658220|NCT02920658|ACTIVE_COMPARATOR|0.05% Betamethasone dipropionate|0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; 0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
62658221|NCT06524531|EXPERIMENTAL|Experimental Group|"Pulsed RF Neuromodulation: Administered to the L2 and L3 segments bilaterally for 6 minutes each.~Leukocyte-Rich PRP Injection: Injected into the multifidus muscle. Physiotherapy: Standard physiotherapy regimen."
62658222|NCT06524531|EXPERIMENTAL|Control Group|Physiotherapy: Standard physiotherapy regimen only
62658223|NCT00112957|EXPERIMENTAL|rV- and rF-NY-ESO-1|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1, followed by subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169 or until observation of treatment-related ≥ grade 3 toxicity or disease progression.
62658224|NCT01794702|EXPERIMENTAL|Clofarabine + Cytarabine + Decitabine + Idarubicin|"Phase I - Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)~Phase II - Clofarabine 15 mg/m2 by vein over approximately 1 hour daily (number of days selected based on Phase I portion).~Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)"
62658225|NCT01691651|ACTIVE_COMPARATOR|Botulinum toxin type A|The group that will be subjected to the injection of botulinum toxin (subcutaneous injection of botulinum toxin type A).Subcutaneous botulinum toxin A injection will be performed in this group, (2.5 units per point application), at two points in a nasal and temporal extent of the orbicularis muscle.
62658226|NCT01691651|NO_INTERVENTION|Control|The group that will not be subjected to any intervention.
62658227|NCT03773783|ACTIVE_COMPARATOR|Twin Block|Twin Block appliance
62658228|NCT03773783|EXPERIMENTAL|Button and Bead|Button and Bead appliance
62658229|NCT03907189||Emergent Inflammation|Subjects with emergent inflammation detected by Podimetrics RTM Mat within the last week.
62658230|NCT03907189||No Inflammation|Subjects with no emergent inflammation detected by Podimetrics RTM Mat within the last week.
61908040|NCT04936984|EXPERIMENTAL|Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
61908041|NCT06434987||ATAAD patients undergoing Cardiopulmonary Bypass (CPB) with RIVP|ACP+RIVP under mild to moderate hypothermia
61908042|NCT06434987||ATAAD patients undergoing Cardiopulmonary Bypass (CPB) without RIVP|ACP only under mild to moderate hypothermia.
62658231|NCT00413803|OTHER|1|Four-hour dialysis session, blood flow rate 300-400 ml/min
61908043|NCT02081755|EXPERIMENTAL|Everolimus and Tacrolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID
61908044|NCT02081755|ACTIVE_COMPARATOR|Tacrolimus and Myfortic or CellCept or Imuran|Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID
61908045|NCT04195776|EXPERIMENTAL|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
61908046|NCT03570463||GLA:D Back|Two 1-hour group sessions of patient education 8 weeks of twice-weekly 1-hour supervised group exercise sessions
61908047|NCT00523367|NO_INTERVENTION|esomeprazole|
61908048|NCT04813003||Obesity group (group 1)|"Pilot phase:~5 adults with class II-III obesity (BMI≥35kg/m2) planned for bariatric surgery will undergo functional imaging and neurobehavioural tasks before bariatric surgery.~Refined protocol phase:~20 overweight adults (BMI≥30kg/m2 or BMI≥28kg/m2 with adiposity-related comorbidities (prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia)), referred for obesity treatment (surgical or non-surgical)."
62094609|NCT00005982|EXPERIMENTAL|Treatment (nelarabine)|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62094610|NCT06544642|EXPERIMENTAL|Part 1 - Single Ascending Dose in Healthy participants (Dose Escalation Cohort)|Participants will receive a single oral dose of ASP5502 or Placebo on Day 1.
62094611|NCT06544642|EXPERIMENTAL|Part 1 - Single Ascending Dose in Healthy participants (Food Effect Cohort)|Participants will receive a single oral dose of ASP5502 or Placebo under fasting conditions on period 1 Day 1 and single dose of ASP5502 or Placebo under fed conditions on period 2 Day 1.
62094612|NCT06544642|EXPERIMENTAL|Part 2 - Multiple Ascending Dose in Healthy participants|Participants will receive daily oral doses of ASP5502 or placebo for 14 days.
62094613|NCT06544642|EXPERIMENTAL|Part 3 - Repeated Dose in Participants with pSS|Participants will receive daily oral doses of ASP5502 for 28 days.
62094614|NCT06693934|OTHER|Low risk|Low risk progressors are those who are in the bottom 75% of the risk score based on both clinical and biogenetic risk markers
62465097|NCT02142556|EXPERIMENTAL|Quetiapine XR|Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.
62658232|NCT00413803|ACTIVE_COMPARATOR|2|Eight-hours dialysis session, blood flow rate 200-250 ml/min
62658233|NCT04479046|ACTIVE_COMPARATOR|Stainless steel crowns|3M ESPE
62658234|NCT04479046|EXPERIMENTAL|Zirconia crowns|Nu Smile
62658235|NCT04479046|EXPERIMENTAL|PMMA crowns|Dental Direkt
62658236|NCT00724893||Stage 1 Participants|Participants with CHC receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
61908049|NCT04813003||Control group (group 2)|"Pilot phase:~5 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age-, sex- and education will serve as a control group and undergo the same experiment.~Refined protocol:~20 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age and sex will serve as a control group and undergo the same experiment."
61908050|NCT05731050|EXPERIMENTAL|NM8074|All subjects will receive a dose of 15 mg/kg NM8074 every two weeks with a total of 6 doses, from Day 1 to Day 84 during the treatment period.
62094615|NCT06693934|OTHER|High risk progressors|High risk progressors are those who are in the top 25% of the risk score based on both clinical and biogenetic risk markers. They will undergo yearly OGTT to detect undiagnosed diabetes or impaired glucose tolerance (IGT) for early intervention. They will also receive low intensity team-based care with regular empowerment using webinars and whatsapp messages for 2 years.
62094616|NCT06693934|OTHER|Impaired glucose tolerance (IGT)|Subjects with IGT will receive team-based care including lifestyle modification and early use of metformin, subsidized weighing scale and CGM, supplemented by WhatsApp messages and webinars for empowerment for 2 years
62094617|NCT06693934|OTHER|Diabetes|Subjects with newly diagnosed diabetes will receive team-based care with structured assessment, JADE personalized report, testing for autoimmune markers, , subsidized CGM, weighing scale and medications with regular WhatsApp messages and webinars for empowerment for 2 years
62658237|NCT00724893||Stage 2 Participants|Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
62658238|NCT03491592|EXPERIMENTAL|Enhanced Physical Activity Intervention|A data driven enhanced Pasos Hacia La Salud intervention based on results and participant feedback from the motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention in the parent study.
61908051|NCT02858817|EXPERIMENTAL|51,200 PfSPZ|Three injections of 51,200 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
62658239|NCT03491592|ACTIVE_COMPARATOR|Original Physical Activity Intervention|The original Internet-based program is a computer expert system-driven, individually tailored Spanish language intervention, guided by Social Cognitive Theory (SCT) and the Transtheoretical Model (TTM).
62658240|NCT04547699|PLACEBO_COMPARATOR|HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein,
62094618|NCT01791426|EXPERIMENTAL|Artelac Rebalance|Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL.
62094619|NCT01791426|ACTIVE_COMPARATOR|Vismed|Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL.
62465098|NCT03736382|EXPERIMENTAL|Experimental Group|The experimental group is comprised of participants with OSA and hypertension \[either able bodied (Aim 1) or with spinal cord injury (Aim 2)\] that will be treated with mild IH and CPAP. In the present proposal, the mild IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The mild IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2) = 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
62658241|NCT04547699|EXPERIMENTAL|CYK+ high HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma),and 5ng/mL LIF (SRP9001 Sigma).
62658242|NCT04547699|ACTIVE_COMPARATOR|CYK+low HSA|A single step culture medium (SSCM; Global, Life Global) +2mg/ml (5% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma), and 5ng/mL LIF (SRP9001 Sigma).
62658243|NCT01007877|NO_INTERVENTION|No break|
62094620|NCT03042793|EXPERIMENTAL|Vaccination|Vaccine: PD-L1 peptide.
62292202|NCT00868790|EXPERIMENTAL|MK-3577 BID→MK-3577 QD PM→MK-3577 QD AM→PLA (Arm 4)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
62292203|NCT00868790|EXPERIMENTAL|PLA→MK-3577 BID→MK-3577 QD AM→MK-3577 QD PM (Arm 5)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
62465099|NCT03736382|SHAM_COMPARATOR|Control Group|The control group is comprised of hypertensive OSA participants \[either able bodied (Aim 1) or with spinal cord injury (Aim 2)\] that will be exposed to a sham protocol in addition to being treated with CPAP during sleep. The sham protocol will be administered during wakefulness for 15 days over a 3-week period. During the sham protocol the participants will be exposed to atmospheric levels of oxygen and carbon dioxide for the duration of the protocol.
62292204|NCT00868790|EXPERIMENTAL|MK-3577 QD AM→MK-3577 QD PM→PLA→MK-3577 BID (Arm 6)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4.
62658244|NCT01007877|PLACEBO_COMPARATOR|Placebo Energy Drink|During a 15 minute break, subjects consume a placebo energy drink
62292205|NCT00868790|EXPERIMENTAL|MK-3577 QD PM→MK-3577 QD AM→MK-3577 BID→PLA (Arm 7)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
62292206|NCT00868790|EXPERIMENTAL|MK-3577 BID→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 8)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
62658245|NCT01007877|EXPERIMENTAL|Red Bull Energy Drink|during a 15 minute break, subjects consume Red Bull Energy Drink
62658246|NCT03808246|EXPERIMENTAL|naive/realistic environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
62658247|NCT03808246|EXPERIMENTAL|informed/realistic environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
62658248|NCT03808246|EXPERIMENTAL|informed/laboratory-like environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
62658249|NCT03808246|EXPERIMENTAL|naive/laboratory-like environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
61908052|NCT02858817|EXPERIMENTAL|150,000 PfSPZ|Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
62094621|NCT06323668|EXPERIMENTAL|Cardiac implantable electronic device removal + empirical antibiotic therapy|"CIED removal + guideline antibiotic therapy (at least 10 days iv antibiotic therapy and then per oral treatment to 6 weeks total by POET criteria).~The antibiotic therapy is targeted according to microbiological analyses per microorganism.~The CIED removal will be done as soon as possible within 7 days."
62465100|NCT05275179||Posaconazole Therapeutic Drug Monitoring|Therapeutic Drug Monitoring of posaconzole is performed by measuring posaconazole concentrations in serum
61908053|NCT02858817|PLACEBO_COMPARATOR|Placebo|Three injections of NaCl 0,9% solution under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
61908054|NCT04008927|OTHER|All patients|All participants recruited during the RDS survey.
61908055|NCT04008927|OTHER|HCV infected patients|HCV-RNA assay (GeneXpert, Cepheid) will be performed to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL)
61908056|NCT04008927|OTHER|Patients with hepatitis C|Patients diagnosed with chronic hepatitis C will be prescribed with DAA treatment on research site. After one month they will be referred to conventional health structure for treatment follow-up.
61908057|NCT02793622|ACTIVE_COMPARATOR|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
61908058|NCT02793622|ACTIVE_COMPARATOR|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
61908059|NCT01525992|EXPERIMENTAL|Community Pharmacy-based Program|
61908060|NCT01525992|ACTIVE_COMPARATOR|Usual care|
61908061|NCT03320824|EXPERIMENTAL|New Dermal Filler|hyaluronic acid
61908062|NCT03320824|ACTIVE_COMPARATOR|Dermal Filler|hyaluronic acid
61908063|NCT03417401|EXPERIMENTAL|RVC with tPA for CRVO|Single arm phase I open label study were CRVO patients will have a vitrectomy with retinal vein cannulation and a single infusion of tPA (0.25mg/ml) intravenously with a maximum dose of 1mg.
61908064|NCT03452475|ACTIVE_COMPARATOR|Arterolane-piperaquine|Arterolane-piperaquine for 3 days
61908065|NCT03452475|ACTIVE_COMPARATOR|Arterolane-piperaquine+mefloquine|Arterolane-piperaquine + mefloquine for 3 days
61908066|NCT03452475|ACTIVE_COMPARATOR|Artemether-lumefantrine|Artemether-lumefantrine for 3 days
61908067|NCT02907840|EXPERIMENTAL|Recruitment|Lung aeration monitored by Swisstom BB2 during PEEP steps and recruitment maneuver
61908068|NCT04998968||Patients with permanent hypoparathyroidism after total thyroidectomy|Patients with permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region. Permanent hypoparathyroidism is defined as treatment with Calcium and/or vitamin D more than 12 months after surgery.
62658250|NCT01858948|EXPERIMENTAL|Quetiapine plus Omega|Patients will be randomized to EPA+DHA supplements (OmegaRx) at fixed dose of 3.0 g/day (EPA: 2.0 g, DHA: 1.0 g; 5 capsules/d) for 24 weeks.
62658251|NCT01858948|PLACEBO_COMPARATOR|Quetiapine plus Placebo|Patients will be randomized to similar in shape an color placebo supplements (corn oil)
62094622|NCT06323668|NO_INTERVENTION|Empirical antibiotic therapy|Guideline antibiotic therapy (at least 10 days iv antibiotic therapy and then per oral treatment to 6 weeks total by POET criteria). The antibiotic therapy is targeted according to microbiological analyses per microorganism.
62658252|NCT03304288|EXPERIMENTAL|low-dose rituximab & ATRA|rituximab 100mg once weekly for 6 weeks and oral all-trance retinoid acid 20mg/m\^2 qd for 12 weeks.
62658253|NCT03304288|ACTIVE_COMPARATOR|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
61908069|NCT04998968||Patients without permanent hypoparathyroidism after total thyroidectomy|Patients without permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region.
62292207|NCT00868790|EXPERIMENTAL|PLA→MK-3577 QD PM→MK-3577 BID→MK-3577 QD AM (Arm 9)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
62292208|NCT00868790|EXPERIMENTAL|MK-3577 QD AM→MK-3577 BID→MK-3577 QD PM→PLA (Arm 10)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
61908070|NCT04545970|ACTIVE_COMPARATOR|Anti-aging Serum|"Dosage form: Serum composed of water, thickener, and bioactive ingredients including antioxidants and peptides.~Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
62094623|NCT05565482|EXPERIMENTAL|Standard Transition Services + Work Chat|This arm will receive services as usual plus the Work Chat intervention over a series of a few weeks. We estimate approximately 15-18 hours of training will occur.
62465101|NCT03139019|EXPERIMENTAL|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
62658254|NCT00676143|EXPERIMENTAL|Bapineuzumab 0.5 mg/kg|
62658255|NCT00676143|PLACEBO_COMPARATOR|Placebo|
62658256|NCT04828967|EXPERIMENTAL|Hypnosis group|Hypnosis is added to the conventional group.
62658257|NCT04828967|NO_INTERVENTION|conventional group|only conventional group
62658258|NCT05080491|EXPERIMENTAL|Determination of thyroid profile and neuropsychological assessment|
62658259|NCT05112120||Single centre single arm observational cohort|Olumiant (4mg) will be administered in line with standard of care guidance. This is the standard dose in line with license for use in active moderate to severe RA. A dose adjustment from 4mg to 2mg is permitted during the study depending on side-effects
62292209|NCT00868790|EXPERIMENTAL|MK-3577 QD PM→PLA→MK-3577 QD AM→MK-3577 BID (Arm 11)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
62292210|NCT00868790|EXPERIMENTAL|MK-3577 BID→MK-3577 QD AM→PLA→MK-3577 QD PM (Arm 12)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
62292211|NCT00868790|EXPERIMENTAL|PLA→METF→MK-3577 QD AM→MK-3577 QD PM (Arm 13)|Domiciled participants were to receive oral treatment with dose-matched placebo to metformin (METF) for 4 weeks during Period 1, followed by metformin 1000 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Participants in this arm were administered metformin placebo during Period 1 and active metformin during Period 2.
62292212|NCT00868790|EXPERIMENTAL|METF→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 14)|Domiciled participants were to receive oral treatment with metformin 1000 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to metformin for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4. Participants in this arm were administered active metformin during Period 1 and metformin placebo during Period 2.
62658260|NCT04382482||Tachidino|This group is being treated through the web platform Tachidino for remote rehabilitation of reading and spelling disorders
62094624|NCT05565482|NO_INTERVENTION|Standard Transition Services|This arm will receive services as usual.
62094625|NCT04252937|EXPERIMENTAL|HAM8101 (Adrecizumab) : 0.5 mg/kg|HAM8101 (Adrecizumab) : 0.5 mg/kg
62094626|NCT04252937|EXPERIMENTAL|HAM8101 (Adrecizumab) : 2 mg/kg|HAM8101 (Adrecizumab) : 2 mg/kg
62094627|NCT04252937|EXPERIMENTAL|HAM8101 (Adrecizumab) : 8 mg/kg|HAM8101 (Adrecizumab) : 8 mg/kg
62094628|NCT06697002|EXPERIMENTAL|Group A|32 participants will be in control group,they will only perform lower tapezius strenghtening excercise and will not perform scapular mobility excercises.
62094629|NCT06697002|EXPERIMENTAL|Group B|32 participants will be in experimental group,they will perform scapular mobility excercise
62465102|NCT03139019|EXPERIMENTAL|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
61908071|NCT04545970|PLACEBO_COMPARATOR|Placebo Serum|"Dosage form: Serum composed of water and thickener. Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
62658261|NCT06212583|ACTIVE_COMPARATOR|Androgen deprivation therapy + Stereotactic ablative radiation|
62658262|NCT06212583|ACTIVE_COMPARATOR|Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate|
61908072|NCT00985036||Glioma|patients who are diagnosed with and are being treated for glioma
61908073|NCT00985036||meningioma|patients who are diagnosed with and are being treated for meningioma
62094630|NCT02700685|EXPERIMENTAL|Pycnogenol|"Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Subjects \< 30 kg body weight: 20 mg Pycnogenol/day Subjects \>= 30 kg body weight: 40 mg Pycnogenol/day"
62094631|NCT02700685|PLACEBO_COMPARATOR|Placebo|Placebo treatment (identical capsules containing excipients only)
62094632|NCT02700685|ACTIVE_COMPARATOR|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release. Subjects \< 30 kg body weight: 20 mg methylphenidate once per day Subjects \>= 30 kg body weight: 30 mg methylphenidate once per day
62094633|NCT05488379|NO_INTERVENTION|Individual well child care|Individuals randomized to the control arm will receive routine individualized well child care after birth hospital discharge.
62094634|NCT05488379|EXPERIMENTAL|Group well child care|Individuals randomized to the intervention arm will participate in group well child care after birth hospital discharge.
62094635|NCT06685185|EXPERIMENTAL|Part 1A: SAD: NNC0363-1063|Participants will receive single dose of NNC0363-1063 subcutaneously.
62094636|NCT06685185|PLACEBO_COMPARATOR|Part 1A: SAD: Placebo|Participants will receive NNC0363-1063 matching placebo subcutaneously.
62094637|NCT06685185|EXPERIMENTAL|Part 1B: SAD: NNC0363-1063|Participants will receive NNC0363-1063 subcutaneously.
62094638|NCT06685185|ACTIVE_COMPARATOR|Part 1B: SAD: Insulin degludec|Participants will receive insulin degludec subcutaneously.
62094639|NCT06685185|EXPERIMENTAL|Part 2: PoP: NNC0363-1063|Participants will receive NNC0363-1063 subcutaneously.
62094640|NCT06685185|EXPERIMENTAL|Part 3: MAD: NNC0363-1063|Participants will receive NNC0363-1063 subcutaneously.
62658263|NCT04058912||PATİENCE GROUP|"1. To be in the range of 18-40 years~2. Patients with an operation indication with \>=5 cm endometrioma~   1. Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)~  2. Patients who will be followed for IVF cycle due to infertility"
62094641|NCT06685185|ACTIVE_COMPARATOR|Part 3: MAD: Insulin degludec|Participants will receive insulin degludec subcutaneously.
62094642|NCT06520657|EXPERIMENTAL|CHW plus child weight management intervention|Participants in this arm will work with a community health worker for three months to address social risk factors (negative social determinants of health) prior to beginning a child weight management group treatment.
62094643|NCT06520657|ACTIVE_COMPARATOR|Child weight management intervention only|Participants in this arm will receive the standard of care which includes a one-time referral to community resources to meet their social needs. At three months they also begin the same child weight management group treatment as the experimental group.
62292213|NCT02285400|EXPERIMENTAL|Moderate COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
62292214|NCT02285400|EXPERIMENTAL|Severe COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
62094644|NCT02723656|ACTIVE_COMPARATOR|Proactive mailed care coordination|
62094645|NCT02723656|ACTIVE_COMPARATOR|Proactive telephone care coordination.|
62094646|NCT05692518|EXPERIMENTAL|MAGNET System, DI Bio-fragmentable|GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System
62292215|NCT03935516|EXPERIMENTAL|Flexed Elbow|The first group will be placed in a cast with the elbow bent.
62292216|NCT03935516|EXPERIMENTAL|Extended Elbow|The second will be placed in a cast with the elbow straight.
62292217|NCT06544109|EXPERIMENTAL|Arm Description:the Venatoclax regimen to prevent DS|The patient with suspected APL should be treated with ATRA or Venetoclx depending on its WBC counts and rapid diagnosis of APL was made at the same time. Once APL was diagnosed, patients were initially treated with ATRA 25 mg/m2/d and ATO 0.16 mg/kg/d. During the induction regimen, patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax and DS was suspected received dexamethasone or ruxolitinib.
62292218|NCT02156856||Hemodynamic optimisation|
62292219|NCT02156856||No hemodynamic optimisation|
62292220|NCT03680937||Immature oocytes vitrified before in vitro maturation|Immature oocytes will be vitrified using closed system vitrification with a semiautomatic method. After warming, a maturation culture will be performed during 36 hours
62292221|NCT03680937||Immature oocytes vitrified after in vitro maturation|A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
62292222|NCT03680937||Fresh oocytes|The culture of immature oocytes will be performed during 36 hours
62292223|NCT06160050|EXPERIMENTAL|BPC|
62292224|NCT06160050|NO_INTERVENTION|Treatment as usual|
62292225|NCT01871792|EXPERIMENTAL|Pitavastatin|Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention
62292226|NCT01871792|PLACEBO_COMPARATOR|Placebo|Placebo tablet for 7 days before coronary angiography/intervention
62292227|NCT04820751|EXPERIMENTAL|Cyproheptadine and standard care|"Start Cyproheptadine 8mg three times a day during 5 days. Dose will be reduced to 4mg three times a day if GFR inferior to 30ml/min/1.73m²~Standard management of COVID-19 infection according to current international guidelines"
62292228|NCT04820751|NO_INTERVENTION|Standard care|Standard management of COVID-19 infection according to current international guidelines
62292229|NCT03152942|EXPERIMENTAL|Progesterone alone|Progesterone 400 mg once daily until 34 weeks.
62292230|NCT03152942|ACTIVE_COMPARATOR|Progesterone and aminophylline.|Progesterone 400 mg and aminophylline 225 mg once daily until 34 weeks.
62292231|NCT03420534|EXPERIMENTAL|iloperidone in fasting|iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle
62658264|NCT04058912||PATİENCE-CONTROL GROUP|"1. To be in the range of 18-40 years~2. Patients with operation plan due to non-endometrioma ovarian pathologies~   1. Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)~  2. Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic"
62292232|NCT03420534|ACTIVE_COMPARATOR|placebo tablets in fasting|placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle
62094647|NCT05042063||Participants with cough as a symptom|This group will be composed of patients at the Clínica Universidad de Navarra that complain of having cough as a remarkable symptom.
62094648|NCT05042063||Validation subgroup 1|This subgroup will be composed by both, patients belonging to the main study group, as well as voluntaries, who will be asked to provide a series of elicited cough and non-cough sounds for validation purposes.
62094649|NCT05042063||Validation subgroup 2|This subgroup will be composed by inpatients admitted to the Clínica Universidad de Navarra with a diagnosis of respiratory disease, or presenting cough as a symptom, as well as healthy individuals. This group will be monitored with Hyfe Cough Tracker and Hyfe Air for a variable period of 6-24 hours, while they are recorded with a MP3 recorder connected to a lapel microphone.
62094650|NCT04107649|OTHER|Arm1|Participants in this arm receive usual post-operative care and complete all basic study activities, which include: attending 2 in-clinic visits at designated time-points, having regular check-in calls with study staff over the intervention period, wearing and returning waist-worn activity trackers at 5 time points over two years, and completing 6 study surveys.
62292233|NCT03420534|ACTIVE_COMPARATOR|placebo tablets in postprandial|placebo mimic iloperidone 1mg by mouth once for 6 days
62292234|NCT03420534|EXPERIMENTAL|iloperidone in postprandial|iloperidone 1mg by mouth once for 6 days
62658265|NCT02866981|EXPERIMENTAL|Observation|Patients that meet all inclusion and exclusion criteria are monitored every 2 months for two years or until a therapeutic intervention is warranted.
62658266|NCT03491488|EXPERIMENTAL|Intervention Group|"300 children in the randomly selected crèche classrooms receiving the Brain Games intervention.~The Brain Games intervention we propose in this project is designed to complement and improve current government efforts. Given the importance of executive functioning skills and the high plasticity around age three, early programs like the ones proposed here may be the most effective tool to reduce socioeconomic and intergenerational disparities, and thus nicely complement current social protection policies."
62658267|NCT03491488|NO_INTERVENTION|Control Group|300 children in the randomly selected creches classrooms receiving the regular Brazilian curriculum.
62658268|NCT03042689|EXPERIMENTAL|Regorafenib|
62658269|NCT05218902||Retrospectively enrolled cohort|Participants who initiate Azacitidine (AZA) before enrollment
62658270|NCT05218902||Prospectively enrolled cohort|Participants who initiate AZA initiation at enrollment
62658271|NCT00795574|EXPERIMENTAL|infliximab|Double blind placebo cross-over
62658272|NCT00795574|PLACEBO_COMPARATOR|Placebo|Double blind placebo controlled cross-over
62658273|NCT05391672|OTHER|Repair group|Repair of partial torn ACL by suturing stump and fixation to femoral footprint by anchors
62658274|NCT05391672|OTHER|Augmentation group|We will use hamstring graft in which fixation of graft will be by adjustable loop devices for femoral part fixation \& Bioscrews +/- staples for tibial part fixation
62658275|NCT03726476|EXPERIMENTAL|Patient Centered pre-op education|Patient centered pre-operative education and patient centered post-operative care.
62094651|NCT04107649|EXPERIMENTAL|Arm2|Participants in this arm receive usual post-operative care, complete all basic study activities (as described in arm 1) and receive the wrist-based activity tracker intervention.
62094652|NCT04107649|EXPERIMENTAL|Arm3|Participants in this arm receive usual post-operative care, complete all basic study activities (as described in arm 1), receive wrist-based activity tracker intervention, and receive the TAC(MI)+FI.
62094653|NCT06695858|SHAM_COMPARATOR|control group|Patients received bilateral sham ultrasound-guided ESPB using 20 mL normal saline on each side.
62094654|NCT06695858|EXPERIMENTAL|ESPB group|Patients received bilateral ultrasound-guided ESPB using 20 mL bupivacaine 0.25% on each side.
62094655|NCT04768686|EXPERIMENTAL|FLX475 and pembrolizumab combination therapy|"* Cohort 1: EBV negative / CPI naïve gastric cancer patient who has had a disease progression after at least 2 prior systemic treatments for advanced or metastatic gastric cancer~* Cohort 2: EBV positive / CPI naïve gastric cancer patient (as determined by standard methods, e.g. EBER ISH or LMP-1 IHC) who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer"
62094656|NCT01167023|EXPERIMENTAL|7.5 mg Prasugrel|Participants were to receive 7.5 milligrams (mg) of prasugrel orally, once daily if they weighed ≥60 kilograms (kg) and if pharmacodynamic (PD) measures indicated that the 5-mg prasugrel dose did not produce a steady-state PD response equivalent to inhibition of platelet activation (IPA) ≥25%. Because these criteria were not met, no participants received 7.5 mg of prasugrel.
62094657|NCT01167023|PLACEBO_COMPARATOR|Placebo|
62292235|NCT04304456||HA-BSI|Patients with HA-BSI treated in an ICU
62292236|NCT04147793||Controls|patients attneding for surgery with no known bladder disease
62292237|NCT04147793||Overactice sphincter|those with evidence of dysfunctional voiding
62292238|NCT04147793||Underactive sphincter|those with genuine stress incontinence
62292239|NCT02527356|EXPERIMENTAL|ROC-Stand group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (\>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-stand).
62658276|NCT03726476|ACTIVE_COMPARATOR|Routine Pre-op education|Participants will receive routine pre-operative education and post-op will receive a standardized number of narcotics
62658277|NCT00581204||Diagnostic Tool|Near-Infrared Diffuse Optical Spectroscopy Imaging
62658278|NCT05324696|PLACEBO_COMPARATOR|Treatment with placebo device|Device similar to the one developed, but which does not generate pressure
62658279|NCT05324696|EXPERIMENTAL|Treatment with a working device|Treatment with a functioning device, which generates the necessary pressure to open the Eustachian tube
62658280|NCT05324696|ACTIVE_COMPARATOR|Surgical treatment|Surgical treatment (myringotomy with placement of ventilation tubes) which is the treatment currently applied in children with otitis media with effusion that do not resolve with medical treatment and/or autoinflation
62094658|NCT01167023|EXPERIMENTAL|5 mg Prasugrel|
62094659|NCT06697899|EXPERIMENTAL|Fasting|Participants take TGRX-678 under fasting state
62292240|NCT02527356|ACTIVE_COMPARATOR|ROC-Sit group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (\>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-sit)
62292241|NCT02527356|ACTIVE_COMPARATOR|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (\>1.5 sd). Parents/caregivers and occupational therapists will be responsible for regular therapy.
62658281|NCT03915067|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo as superficial intramuscular injections administered to the platysma muscle on Day 1.
62658282|NCT03915067|EXPERIMENTAL|BOTOX® Low Dose|Participants received BOTOX® Low Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
62658283|NCT03915067|ACTIVE_COMPARATOR|BOTOX® High Dose|Participants received BOTOX® High Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
62658284|NCT01792232|ACTIVE_COMPARATOR|Filtered air|Exposure for 2 hours to filtered air followed by subject specific allergen placed in lung
62658285|NCT01792232|EXPERIMENTAL|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific allergen placed in lung
62658286|NCT01792232|ACTIVE_COMPARATOR|Filtered air control|Exposure for 2 hours to filtered air followed by subject saline placed in lung
62292242|NCT04939857|EXPERIMENTAL|experimental group|Trimetazidine was given 2 weeks before radiotherapy, 20 mg each time, three times a day for 3 months.
62658287|NCT01792232|ACTIVE_COMPARATOR|Diesel exhaust control|Exposure for 2 hours to diesel exhaust followed by saline placed in lung
62658288|NCT03342768|EXPERIMENTAL|TID|Messages will be sent 1-2 times per week containing information that aims to denormalise the tobacco industry.
62658289|NCT03342768|OTHER|Sugar sweetened beverages|Messages will be sent 1-2 times per week containing information on the adverse health effects of sugar sweetened beverages.
62658290|NCT01510756|EXPERIMENTAL|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
62094660|NCT06697899|EXPERIMENTAL|Low-fat Diet|Participants take TGRX-678 after low-fat meal intake
62094661|NCT06697899|EXPERIMENTAL|High-fat Diet|Participants take TGRX-678 after high-fat meal intake
62658291|NCT02924870|ACTIVE_COMPARATOR|Control group|Conventional management. Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
62658292|NCT02924870|EXPERIMENTAL|Intervention group|Conventional management plus health education program. In addition to conventional treatment and follow-up, the patients will be referred to a nursing consultation for perform two health education sessions, at 15 and 30 days after hospital discharge.
62658293|NCT04810156|ACTIVE_COMPARATOR|Cohort A: Steroids and MMF in grade 3-4 ir-hepatitis|Patients with ≥ 3 grade ir-hepatitis will be treated with high-dose steroids 2 mg/kg/day intravenously. A diagnostic liver biopsy will be taken. Patients with mixed or cholestatic liver injury patterns will be added UDCA. Treatment evaluation will be performed after 72 hours, patients in UDCA will be evaluated will be on day 7. Patients with sufficient steroid response defined as ≥ 20% reduction in ALT, AST, ALP or bilirubin at day 4 or day 7 will undergo steroid tapering with a transition to peroral steroids. Patients with initial insufficient treatment response, defined as less than \< 20% reduction in ALT, AST, ALP, or bilirubin, are considered as having a steroid-refractory condition and will be added MMF. In case of no response or increase of ALT, AST, ALP, or bilirubin during treatment with steroids plus MMF a third-line treatment may be introduced according to the individual treating hepatologist.
62094662|NCT00715286|ACTIVE_COMPARATOR|A|Conventional arm: primary surgery followed by chemotherapy
62094663|NCT00715286|EXPERIMENTAL|B|Neoadjuvant chemotherapy followed by interval debulking
62094664|NCT04283123|EXPERIMENTAL|Treatment|Participants assigned to this group will receive an automated bidet (TOTO Washlet S300e with remote control) and an occupational therapy intervention over 2-3 in-home visits.
62094665|NCT04283123|ACTIVE_COMPARATOR|Waitlist Control|Caregivers will wait for 30 days and then will be offered the intervention.
62094666|NCT03114943|EXPERIMENTAL|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
62094667|NCT03114943|ACTIVE_COMPARATOR|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
62094668|NCT03432533|ACTIVE_COMPARATOR|Romosozumab 210 mg QM: PFS|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
62094669|NCT03432533|ACTIVE_COMPARATOR|Romosozumab 210 mg QM: AI/Pen|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
62094670|NCT04086758|EXPERIMENTAL|Zolbetuximab|Participants will receive a loading dose-1 of zolbetuximab on Day 1 of Cycle 1, consists of 21 days, followed by subsequent lower dose-2 every 3 weeks until they meet the discontinuation criteria.
62094671|NCT01094171|EXPERIMENTAL|Poliorix Group|Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age. All vaccines were administered intramuscularly in the anterolateral side of the left thigh (Poliorix) and the right thigh (Infanrix).
62094672|NCT05338983|ACTIVE_COMPARATOR|Control: Traditional local anesthesia|After proper isolation and drying of the injection site, the topical anesthetic gel (20% benzocaine) will be applied to the injection site using sterile cotton tipped applicator for 60 seconds, then the anesthesia (2% mepivacaine hcl with 1:100000 epinephrine) will be administere
62292243|NCT04939857|NO_INTERVENTION|control group|No intervention
62292244|NCT02415790|EXPERIMENTAL|Part A: PK of E2027 in healthy adults|Part A consists of 6 sequential cohorts of healthy adults. There will be 8 participants in each cohort, with 6 participants randomized to E2027 and 2 participants to placebo.
62292245|NCT02415790|EXPERIMENTAL|Part B: PK and PD of E2027 in healthy adults|Part B consists of 4 sequential cohorts of healthy adult participants. There will be 8 participants in the 1st cohort, with 6 participants randomized to E2027 and 2 participants to placebo. In the 2nd to 4th cohorts, there will be 7 participants in each cohort, with 6 participants randomized to E2027 and 1 participant to placebo. Participants in the 2nd cohort will then receive placebo/the same dose of E2027 again after their washout period in the fed state for the evaluation of food effect.
62658294|NCT04810156|ACTIVE_COMPARATOR|Cohort B: Prednisolone versus MMF in steroiddependent ≥2 ir-hepatitis (randomized)|Patients who experienced relapse of ir-hepatitis of grade ≥2 during prednisolone tapering or within one months after ended tapering will be randomized to either 100% dose of current steroid dose or restart of steroid 0.5-1 mg/kg versus adding MMF (if the patient received prednisolone the tapering plan hereof is continued, prednisolone up to 25 mg can be added if clinical indicated). Treatment efficacy is evaluated after seven days, if sufficient response the patients continued treatment, in case of insufficient response a cross-over will be performed.
61908074|NCT04347603|EXPERIMENTAL|General Anesthesia|- General anesthesia : After pre-anesthetic preparation (25-50 mg Hydroxizine orally), the anesthesia induction will be performed by IV perfusion of Propofol 1 to 2 mg/kg, Sufentanyl for analgesia 0,2 to 0,4 µg/kg, curarisation with Atracurium 0,15 mg/kg. The anaethesia depth will be monitored by the bispectral index (BIS). Orotracheal intubation will be performed, the patient will be ventilated to controlled volume with 6-8 mL/kg of current volume based on expected body weight (PBW). The respiratory rate will be adjusted to have an ETCO2 between 35 and 45 mmHg. The anesthesia will be maintained through the Sevorane at 0.7-1 MAC, the average blood pressure will be controlled through a pressure cuff with a target between 60 and 80 mmHg. The Fio2 will be adapted to obtain saturation \> 94% with 5 cmH2O PEEP.
62292246|NCT02415790|EXPERIMENTAL|Part C: PK of E2027 in elderly cohorts|In Part C, 1 cohort of 8 healthy elderly participants will be enrolled, with 6 participants randomized to E2027 and 2 participants to placebo.
62094673|NCT05338983|EXPERIMENTAL|Group A (Warm group)|The topical anesthetic gel (20% benzocaine) will be applied to the injection site using sterile cotton tipped applicator for 60 seconds. The cartridge of anesthetic solution will be placed in the baby bottle warmer in 300 ml of cold water (21°C). The anesthetic fluid will be warmed to reach 37°C (98.6°F) ,then the local anesthesia((2% mepivacaine hcl with 1:100000 epinephrine) will be administered
62094674|NCT05338983|EXPERIMENTAL|Group B (Buffered group)|The topical anesthetic gel (20% benzocaine) will be applied to the injection site for 60 seconds,0.1ml of 8.4% of sodium bicarbonate will be removed from the 50 ml vial by one ml insulin syringe and directly injected into the local anesthetic cartridge. The cartridge will be shacked 5 times to mix the solution, then the local anesthesia(2% mepivacaine hcl with 1:100000 epinephrine) will be administered.
62094675|NCT05338983|EXPERIMENTAL|Group C (Buzzy group)|After the child setting on the dental chair,(20% benzocaine) topical anesthetic gel will be applied to the injection site for 60 seconds. He will be familiar with the Buzzy device by explaining how it works in simple words. The wings of the device will be kept in the freezer. Once the child is ready, the frozen wings will be attached to the device and Buzzy will be placed extra-orally above the area/cheek where local anesthetic will be delivered. Once Buzzy is being held in place by hand, press the button or switch on the top of Buzzy, then the anesthesia (2% mepivacaine hcl with 1:100000 epinephrine) will be administered.
62094676|NCT03206294|OTHER|pharmacist assessment intervention group|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
62094677|NCT06697457|ACTIVE_COMPARATOR|Conventional Treatment|Conventional treatment will include electrotherapy agents (TENS, ultrasound and hotpack) and chin tuck posture exercises.
62094678|NCT06697457|ACTIVE_COMPARATOR|Craniocervical Flexion Exercise Training|Patients will receive exercise in addition to conventional treatment. The exercises will be performed with an air-filled pressure stabilizer placed in the sub-occipital region.
62292247|NCT02415790|EXPERIMENTAL|Part D: PK of E2027 in healthy Japanese adults|In Part D, there will be 3 cohorts of 7 healthy adult Japanese participants, with 6 participants randomized to E2027 and 1 participant to placebo.
62292248|NCT02604264|ACTIVE_COMPARATOR|ClearGuard HD end cap|Treatment
62292249|NCT02604264|NO_INTERVENTION|Standard hemodialysis end cap|Control
62658295|NCT01373164|EXPERIMENTAL|Phase 1b: 80 mg Galunisertib + Gemcitabine|"Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
62658296|NCT01373164|EXPERIMENTAL|Phase 1b: 160 mg Galunisertib + Gemcitabine|"Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
62658297|NCT01373164|EXPERIMENTAL|Phase 1b: 300 mg Galunisertib + Gemcitabine|"Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
62094679|NCT06697457|ACTIVE_COMPARATOR|Dynamic Isometric Exercise Training|Patients will receive exercise in addition to conventional treatment. The exercises will be performed by the patient with an elastic band.
62094680|NCT06697457|ACTIVE_COMPARATOR|Static Isometric Exercise Training|Patients will receive exercise in addition to conventional treatment. The patient will perform isometric exercises with maximal effort against neck flexion, extension, lateral flexion and rotation with his/her hand in a sitting position.
62292250|NCT04782167|EXPERIMENTAL|Proprioception training|Researcher give proprioception protocol to one group
62292251|NCT04782167|EXPERIMENTAL|Brace|Researcher give BRace training to one group
62292252|NCT02964598|EXPERIMENTAL|Control|Minimal information on sleep timing
62292253|NCT02964598|EXPERIMENTAL|Psychoeducation|An extensive psychoeducational platform
62292254|NCT02964598|EXPERIMENTAL|Bright light|Bright light treatment with 10 000 lux at max
62292255|NCT02964598|EXPERIMENTAL|Gamified intervention|A new gamified intervention designed for mobile phones
62292256|NCT02964598|EXPERIMENTAL|Bright light and gamified intervention|A combination of the two
62292257|NCT02964598|EXPERIMENTAL|Sleep coaching|A new intervention protocol including a personified approach to solve problems and increase motivation for better sleep behavior
62292258|NCT02964598|EXPERIMENTAL|Sleep coaching + bright light|A combination of the two
62292259|NCT05431244|OTHER|Antiviral treatment in combination with low-dose gemcitabine|"For 1st \& 2nd cycle D1, 8, 15 Gemcitabine 30-300mg/m2 IV over 30 minutes D8-28 Valganciclovir 900mg qd Every 4 weeks~For 3rd \~ 6th cycle D1, 8, 15 Gemcitabine 30-300mg/m2 IV over 30 minutes D1-28 Valganciclovir 900mg qd Every 4 weeks"
62292260|NCT01526356|PLACEBO_COMPARATOR|Placebo|Cream only
62292261|NCT01526356|ACTIVE_COMPARATOR|0.1 % Rapamycin|0.1% Rapamycin cream
62292262|NCT01526356|ACTIVE_COMPARATOR|1% Rapamycin|1% Rapamycin cream
62094681|NCT00002956|EXPERIMENTAL|infusions of EBV specific cytotoxic T lymphocytes|Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression
62094682|NCT02121938||very low birth weight infants|Very low birth weight infants weighing 1500 grams at birth or less
62094683|NCT02114827|EXPERIMENTAL|Video|"Patients will view the 23-minute Guide to Stem Cell Transplantation video depicting the HSCT experience"
62094684|NCT02114827|ACTIVE_COMPARATOR|FAQ Sheet|Patients will receive HSCT FAQ sheet developed by the NCI at the NIH
62094685|NCT06608888||Non-OSA patients group|Healthy individuals (without snoring symptoms, AHI \< 5 events/h)；Simple snorers (with snoring symptoms, AHI \< 5 events/h)
62094686|NCT06608888||OSA patients|Patients diagnosed with OSA
62094687|NCT06208462|EXPERIMENTAL|Combined treatment group|"1. Preoperative treatment 3 weeks is a course of treatment HAIC (GEMOX) chemotherapy~   1. It is performed within one week after the identification of ICC~  2. Day 1 HAIC (GEMOX) Oxaliplatin 85mg/m2 + Gemcitabine 800mg/m2 Adebrelimab: Day 3 Adebrelimab 1200mg i.v. Lenvatinib 2# qd~2. Evaluation every 2 courses, up to 4 courses.~3. Liver resection: It is performed within 1 month after preoperative treatment.~4. Postoperative treatment: Day 1-14 Capecitabine 1200mg B.I.D."
62094688|NCT02847585|EXPERIMENTAL|Open label|water-soluble ubiquinol
62094689|NCT01126021|ACTIVE_COMPARATOR|Control|Given access to mental exercises but receives no rewards for use.
62094690|NCT01126021|EXPERIMENTAL|Atomistic|Each individual is awarded for his or her individual participation
62094691|NCT01126021|EXPERIMENTAL|Altruistic|Participants are paired and rewarded according to the other individual's participation.
62094692|NCT01126021|EXPERIMENTAL|Team-based|Teams compete against each other and receive rewards according to relative participation.
62094693|NCT04953156||Nitroglycerin|data of patients meeting the eligibility criteria and received nitroglycerine infusion will be retrieved from medical records.
62094694|NCT04953156||Dexmedetomidine|patients will receive dexmedetomidine bolus dose of 1 mic/kg over 20 minutes followed by intravenous infusion of 0.2-0.7 mic/kg/hr adjusted according to each patient hemodynamic response
62094695|NCT02553941|EXPERIMENTAL|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62094696|NCT05592431|EXPERIMENTAL|High Frequency Oscillatory Ventilation with Volume Guarantee (HFOV-VG )|After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV-VG ) will be assessed by doppler cerebral blood flow velocity measurements
61908075|NCT04347603|ACTIVE_COMPARATOR|Local Anesthesia|Local anesthesia at the device introduction site will be obtained by infiltration of Naropein.
62094697|NCT05592431|ACTIVE_COMPARATOR|High Frequency Oscillatory Ventilation (HFOV)|After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV) will be assessed by doppler cerebral blood flow velocity measurements
62094698|NCT05585762|EXPERIMENTAL|Ketone ester|Flavored ketone ester beverage 75 mL. Day 0 - 7: half of one bottle consumed daily. Day 8 to end (Week 12): one full bottle consumed daily.
61908076|NCT06065098|EXPERIMENTAL|Community health worker-led implementation strategy:|Individual coaching sessions; healthcare navigation; healthcare at community settings; church-based nutrition education and exercise programs; and self-monitoring of BP.
61908077|NCT06065098|EXPERIMENTAL|Group-based Education Strategy|Group-based education sessions; information on primary care physicians; and instruction on self-monitoring of BP.
62094699|NCT05585762|PLACEBO_COMPARATOR|Non-ketone placebo|Flavored beverage with bitter additive 75 mL. Matched for appearance, taste and calories. Day 0 - 7: half of one bottle consumed daily. Day 8 to end (Week 12): one full bottle consumed daily.
62094700|NCT04305678|EXPERIMENTAL|Single Arm|Patients with a biopsy proven diagnosis of eosinophilic fasciitis
62094701|NCT01987882||"A. Natural History or Watchful Waiting"|
62094702|NCT01987882||B. Serial Botulinum Toxin Injections +/- Abduction Bracing|
62094703|NCT01987882||C. Adductor (+/- psoas) Muscle Releases Alone|
62094704|NCT01987882||D. Hip Reconstructive Surgery|
62094705|NCT01987882||E. Salvage Hip Surgery|
62094706|NCT05404113|EXPERIMENTAL|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG + Conventional PT
62658298|NCT01373164|EXPERIMENTAL|Phase 2: Recommended dose of Galunisertib + Gemcitabine|"Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
62292263|NCT06450665|EXPERIMENTAL|VR Social Avoidance Intervention|The intervention group will go through three 30-minute VR sessions over a period of 3 weeks. Participants will need to complete a baseline survey before the VR sessions and a post-intervention survey after the VR sessions, as well as a 1-month follow-up survey.
62658299|NCT01373164|EXPERIMENTAL|Phase 2: Placebo + Gemcitabine|"Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
62658300|NCT01881425|EXPERIMENTAL|InnFocus MicroShunt|InnFocus MicroShunt
62658301|NCT01881425|ACTIVE_COMPARATOR|Trabeculectomy|glaucoma surgery to reduce IOP
61908078|NCT02720107|EXPERIMENTAL|fingolimod|Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).
61908079|NCT03699969|EXPERIMENTAL|Hypofractionated dose escalated VMAT|Hypofractionated dose escalated VMAT radiotherapy
61908080|NCT03699969|NO_INTERVENTION|Conventional concurrent chemoradiation|Conventional concurrent chemoradiation
61908081|NCT02015221|EXPERIMENTAL|ACTitouch|ACTitouch in sustained gradient compression mode during all waking hours (at least 10 hours per day) and intermittent pneumatic compression mode for 2 hours each day.
61908082|NCT02015221|ACTIVE_COMPARATOR|Standard Compression Garments|Standard Compression Garments of compression levels 30mmHg to 40mmHg during all waking hours each day.
62292264|NCT06450665|NO_INTERVENTION|Waitlist Control|The wait-list control group will complete the questionnaires in the same interval as the intervention group, with promise of receiving VR intervention after 1-month follow-up is over.
62292265|NCT01061281|ACTIVE_COMPARATOR|Tecnis MF IOL|
62292266|NCT01061281|ACTIVE_COMPARATOR|Crystalens AO IOL|
62292267|NCT03374280|EXPERIMENTAL|pemetrexed/cisplatin intercalating gefitinib|"pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.~pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable"
62292268|NCT03374280|ACTIVE_COMPARATOR|pemetrexed/cisplatin|pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable
62658302|NCT06535659||Single arm clinical investigation|
62658303|NCT01014676|ACTIVE_COMPARATOR|Probiotic milk|
62094707|NCT05404113|EXPERIMENTAL|deep friction massage|Cyriax deep friction massage+ Conventional PT
62658304|NCT01014676|PLACEBO_COMPARATOR|Standard milk|
62292269|NCT04313725|EXPERIMENTAL|Boost|Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.
62292270|NCT04313725|PLACEBO_COMPARATOR|Placebo|Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.
62094708|NCT02948543|EXPERIMENTAL|Treatment (Arm B):Intravesical BCG + MM|"Induction (weekly x 9); and followed by Maintenance (monthly x 9) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10\^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study.~Dosage of Mitomycin (MM) fixed at 40mg per instillation."
62094709|NCT02948543|OTHER|Treatment (Arm A): Intravesical BCG|"Induction (weekly x 6); and followed by Maintenance (monthly x 10) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10\^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study."
62094710|NCT01781338|EXPERIMENTAL|Induction Therapy|The kind of induction therapy is dependent on the respective sub-protocol.
62094711|NCT06467955|EXPERIMENTAL|Magnet System, DI Biofragmentable|GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System)
62094712|NCT02162940||patients taking statins|Visual anlogue score vas used to evaluate pain. The SF 36 test was used to evaluate quality of life.
62094713|NCT02162940||patients not taking statins|Visual anlogue score vas used to evaluate pain.The SF 36 test was used to evaluate quality of life.
62094714|NCT02427737|EXPERIMENTAL|Comfort Talk® Training|In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
62094715|NCT02427737|NO_INTERVENTION|Control|MRI sites not trained in Comfort Talk®.
62094716|NCT05931562|ACTIVE_COMPARATOR|Control|Participants will recieve dietary education based on the healthy eating guidleines provided by the Health Service Executive (HSE).
62094717|NCT05931562|EXPERIMENTAL|Fermented Foods|Fermented foods diet (4-6 portions/day)
62292271|NCT05533567|EXPERIMENTAL|Remimazolam group|"1. Induction of anesthesia Slowly injects remimazolam 0.4-0.6 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional remimazolam (0.05 mg/kg each time) is allowed. After the LoC, intravenous sufentanil 0.3 \~0.5ug/kg and cisatracurium besylate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~2. Maintenance of anesthesia remimazolam 0.4\~1.2 mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
62308068|NCT02441803|EXPERIMENTAL|Matched Sibling Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0."
62094718|NCT05931562|EXPERIMENTAL|High Fibre|High fibre diet (24-35 grams/day)
62094719|NCT05931562|EXPERIMENTAL|Combined Diet|Combined diet high in fibre and fermented foods (fibre aim 24-35 grams/day, fermented foods aim 4-6 portions/day)
62094720|NCT06003231|EXPERIMENTAL|Disitamab vedotin monotherapy|Disitamab vedotin monotherapy
62094721|NCT04402671|ACTIVE_COMPARATOR|non-crosslinked collagen membrane group|2 patients (1 male, 1 female)
62094722|NCT04402671|ACTIVE_COMPARATOR|glutaraldehyde cross-linked collagen membrane|2 patients (2 females)
62094723|NCT06698120|EXPERIMENTAL|Awake prone positioning|
62094724|NCT00272285|EXPERIMENTAL|1|Intravenous (IV)
62094725|NCT00272285|ACTIVE_COMPARATOR|2|Intravenous (IV)
62094726|NCT03568461|EXPERIMENTAL|CTL019|All patients who received tisagenlecleucel infusion.
62094727|NCT06613451|EXPERIMENTAL|Intervention Group|Mobil application
62094728|NCT06613451|ACTIVE_COMPARATOR|Control Group|standard undergraduate education
62094729|NCT05149144|EXPERIMENTAL|Experimental: audiosignal dataset creation and machine learning analysis|Experimental: audiosignal dataset creation and processing; machine learning analysis, empirical evaluations
62094730|NCT06697496|EXPERIMENTAL|Arm I (QuitBot chatbot)|Participants participate in the QuitBot program which involves chatbot messages over 42 days. Therapy description withheld to protect the integrity of the study.
62292272|NCT05533567|ACTIVE_COMPARATOR|Propofol group|"1. Induction of anesthesia Slowly injects propofol 2-4 mg/kg (about 1 min) until loss of consciousness (LoC), allowing additional propofol (0.5 mg/kg each time) if sedation is insufficient. after LoC, intravenous sufentanil 0.3 \~0.5ug/kg and cisatracurium besylate 0.1 mg/kg. after sufficient muscle relaxation and blood circulation stabilization, the tracheal tube was inserted under the sliding scope.~2. Maintenance of anesthesia propofol 4\~10mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
62292273|NCT04909606|EXPERIMENTAL|Nurse-led prevention program|Patients will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
62292274|NCT04909606|ACTIVE_COMPARATOR|Standard of care|Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)
62292275|NCT04818515|EXPERIMENTAL|Atogepant, Ubrogepant, and Coadministration|Participants will receive oral tablets of ubrogepant, followed be oral tablets of atogepant, followed by administration of oral tablets of atogepant and ubrogepant in combination, for a 30 day interventional period and a 7 day follow up period.
62292276|NCT05394415|EXPERIMENTAL|Tislelizumab plus chemoradiation group|In the single experimental arm, patients with nonresectable stage IIIb-IVa disease were subjected to receive neoadjuvant tislelizumab (200mg) plus chemoradiation (TP regimen plus 30Gy/12F irradiation) for conversion therapy. If conversion therapy succeeds, patients would proceed to surgery and adjuvant therapy. Otherwise, if patients were still not resectable after the conversion therapy, an additional radiation dose of 15Gy/6F would be scheduled for the ESCC lesions to achieve a definite radiotherapy dose, then, patients proceeded to consolidation therapy.
62292277|NCT04568837|EXPERIMENTAL|Corticosteroid|Participants in this group will receive a daily dose of corticosteroids on postoperative day one and two after spine fusion surgery
62465103|NCT03139019|EXPERIMENTAL|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
62465104|NCT03139019|NO_INTERVENTION|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
62465105|NCT01386593|OTHER|(A) Baseline|
62465106|NCT01386593|OTHER|(B) Inhibition|
62094731|NCT06697496|ACTIVE_COMPARATOR|Arm II (QuitBot texting)|Participants participate in the QuitBot program which involves text messages over 42 days. Therapy description withheld to protect the integrity of the study.
62094732|NCT01663337|ACTIVE_COMPARATOR|Cognitive Processing Therapy (CPT)|
62292278|NCT04568837|NO_INTERVENTION|Control|Participants in this group will receive no steroids on postoperative day one and two after spine fusion surgery.
62292279|NCT01614964|EXPERIMENTAL|AQ-13|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
62465107|NCT01386593|OTHER|(C) Induction|
62465108|NCT02006173|PLACEBO_COMPARATOR|Normal saline|Participants will be randomly assigned to nasolabial or nasolabial\&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.
62465109|NCT02006173|ACTIVE_COMPARATOR|Lidocaine|Participants will be randomly assigned to nasolabial or nasolabial\&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.
62465110|NCT05099822|EXPERIMENTAL|Administration of CC-97489|
62094733|NCT01663337|ACTIVE_COMPARATOR|Relapse Prevention Therapy (RP)|
62094734|NCT01663337|NO_INTERVENTION|Assessment Only (AO)|AO functions as a benchmark comparison condition. Consists of baseline assessment, daily interactive voice response (IVR) monitoring, and immediate post-test assessment. Not an active treatment
62465111|NCT05099822|EXPERIMENTAL|Administration of Placebo|
62465112|NCT06203522||MRI with Dexmedetomidin|"Mean age is compared between the pass and fail groups using a Student's t-test accounting for inequality of variances. MRI success rates are compared between subgroups using Fischer's exact tests. Finally, factors related to MRI success rates are investigated using multivariate logistic regression, including all the factors described above."
62465113|NCT05883956|ACTIVE_COMPARATOR|ABBA|Cycle 1: Oral decitabine/cedazuridine; Cycle 2: Subcutaneous azacitidine; Cycle 3: Subcutaneous azacitidine; Cycle 4: Oral decitabine/cedazuridine
62094735|NCT02272023|EXPERIMENTAL|9 sessions of Intensive Motivational Interviewing|Experimental condition will consist of 9 1-hour intensive motivational interviewing sessions.
62094736|NCT02272023|ACTIVE_COMPARATOR|1 Standard Motivational Interview plus 8 nutrition classes|The standard MI intervention will consist of a commonly used, single session of MI (50 minutes) plus 8 hours of nutrition education to achieve time and attention equivalence of study conditions.
62094737|NCT06249867|EXPERIMENTAL|Darifenacin Treatment|Patients in the Treatment arm will receive a daily dose of 1 or 2 darifenacin extended-release tablets.
62094738|NCT06249867|PLACEBO_COMPARATOR|Placebo|Patients in the Placebo arm will receive a daily dose of 1 or 2 placebo tablets.
61908083|NCT01336400||PGD-FISH|"Following couples opting for preimplantation genetic diagnosis on the basis of FISH:~* couples suffering a complex chromosomal rearrangement (CCR)~* couples with X-linked recessive disorders~* couples that carry a balanced chromosomal rearrangement"
61908084|NCT01336400||PGD-PCR|"Following couples opting for preimplantation genetic diagnosis on the basis of PCR:~-couples at risk for the transmission of monogenic diseases"
62292280|NCT01614964|ACTIVE_COMPARATOR|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention: Active Comparator: Coartem. Participants randomized to the Coartem arm will be treated with 80 mg artemether and 480 mg lumefantrine at the time of diagnosis and 8 hours later on day 1, the same doses (80 mg artemether and 480 mg lumefantrine) twice on day 2 (24 and 36 hours after diagnosis) and twice more on day 3 (48 and 60 hours after diagnosis) for total oral doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
62465114|NCT05883956|ACTIVE_COMPARATOR|BAAB|Cycle 1: Subcutaneous azacitidine; Cycle 2: Oral decitabine/cedazuridine; Cycle 3: Oral decitabine/cedazuridine; Cycle 4: Subcutaneous azacitidine
62094739|NCT05970731|ACTIVE_COMPARATOR|Beclomethasone|84 mcg of Beclomethasone administered twice in each nostril via a microsponge (Day 1 and Day 14)
61908085|NCT05304780|EXPERIMENTAL|experimental group|Needs-tailored nurse-led recovery program
61908086|NCT05304780|NO_INTERVENTION|Control group|existing community homecare services
62094740|NCT05970731|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% sodium chloride) administered twice in each nostril via a microsponge (Day 1 and Day 14)
62094741|NCT04259762|EXPERIMENTAL|Breast, Colorectal, and Cervical Cancer Screening|The investigators will train Community Health Representatives (CHRs) in interactive group discussions techniques. CHRs will administer 1 session/week, lasting approximately 2 hours, and conducted among 12 men or women ages 21-75 per cluster. The CHRs will distribute the cancer-specific (i.e., breast, colorectal, and cervical) small media during the first session and refer to it during the course of the 4 sessions. During the sessions, the CHRs will function as a facilitator linking information with practical skills. At the end of the 4-week INT, participants will receive a voucher to present to a designated point-person at the health center who would schedule the screening for the age- and gender-specific cancers.
62094742|NCT04259762|NO_INTERVENTION|Control|Historical control
62094743|NCT01289405|PLACEBO_COMPARATOR|placebo exercices|relaxation exercises and stretching neck, without therapeutic purpose.
62094744|NCT01289405|ACTIVE_COMPARATOR|phonoaudiologic therapy|isometric and isotonic exercises to improve posture, mobility and muscle tone of the soft palate, pharyngeal constrictor muscles, tip and base of tongue, cheeks and lips.
62292281|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
62292282|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
62465115|NCT02623543|EXPERIMENTAL|OrthoK|OrthoK lenses will be prescribed for subjects randomly and followed for 2yrs throughout wearing the lenses. There will be an enrollment appointment, dispense appointment, 1-day, 1-week, 1-month, 6-month, 12-month, and 24-month follow-ups.
61908087|NCT05908006||non-randomized, open-label study|All participants will have the same Laboratory and Diagnostic Assessments and Imaging Procedures.
61908088|NCT06210360|EXPERIMENTAL|Group A: NALIRIFOX + surgery + NALIRIFOX|Patients receive 8 cycles of NALIRIFOX. Then undergo surgery and receive 4 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV
61908089|NCT06210360|ACTIVE_COMPARATOR|Group B: surgery + NALIRIFOX|Patients receive 12 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV.
62094745|NCT04875260||Critically ill patients|Patients received critical care in the intensive care units
62094746|NCT05312814||Twin pregnancies undergoing non-invasive prenatal screening|"Women carrying a twin pregnancy undergoing non-invasive prenatal screening for zygosity and aneuploidy syndromes.~No drug/device will be administered; clinical data will be collected for research analysis."
62094747|NCT00550472|EXPERIMENTAL|Probiotic|intervention
62465116|NCT02623543|PLACEBO_COMPARATOR|Control|Subjects in the randomly assigned control will continue to wear their glasses throughout the 2yr follow-up period. There will be an enrollment appointment, 6-month, 12-month, and 24-month follow-ups.
62465117|NCT03488667|EXPERIMENTAL|mFOLFOX6 (Leucovorin-Fluorouracil-Oxaliplatin) + Pembrolizumab|"Drug: Pembrolizumab Dose: 200 mg Dose Frequency: Every three weeks (Q3W) Route: Intravenous (IV) infusion~Drug: Oxaliplatin Dose: 85 milligrams per meter squared (mg/m2) Dose Frequency: Every 2 weeks (Q2W) Route: IV infusion~Drug: Leucovorin Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV infusion~Drug: Fluorouracil Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV bolus~Drug: Fluorouracil Dose: 2,400 mg/m2 Dose Frequency: Q2W Route: IV continuous 46-hour infusion~Pembrolizumab will be administered at a fixed dose of 200 mg IV over 30 minutes every 3 weeks. Participants will receive 3 doses of the drug on Days 1, 22, 43 during the neoadjuvant phase of the study, and 12 doses of the drug on Days 1, 22, 43 during the adjuvant phase of the study (total 15 doses). Participants will receive 4 doses of mFOLFOX6 regimen on Days 1, 15, 29, 43 during the neoadjuvant phase of the study, and 4 doses during the adjuvant phase of the study (total 8 doses)."
62465118|NCT03927066|EXPERIMENTAL|Healthy Volunteer|All Volunteers will be studied at rest and during experimental condition (lower body negative pressure)
62465119|NCT03806062|ACTIVE_COMPARATOR|control group|10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
62465120|NCT03806062|ACTIVE_COMPARATOR|Laser group|"The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)"
62658305|NCT04172272|ACTIVE_COMPARATOR|Systemic multimodal analgesia only|"In the first group, patients will receive intravenous, systemic, multimodal analgesia: paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
62658306|NCT04172272|EXPERIMENTAL|TAP block only|In the second group there will be patients in who will be given the TAP block. The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacaine in 40 ml bilaterally. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
62658307|NCT04172272|EXPERIMENTAL|Combined TAP block with systemic multimodal analgesia|In the third group there will be patients who will be treated with TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
62094748|NCT01724203|ACTIVE_COMPARATOR|Lactobacillus rhamnosus|Formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20) at least three times daily for 12 weeks.
62292283|NCT03303989|EXPERIMENTAL|pegloticase + MMF|Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.
62292284|NCT03303989|PLACEBO_COMPARATOR|pegloticase + placebo|Participants randomized to this arm will receive pegloticase + placebo
62292285|NCT05333094|ACTIVE_COMPARATOR|American orthodontics brackets|"Roth prescription, 0.022 slot size"
62292286|NCT05333094|ACTIVE_COMPARATOR|FANTA brackets|"Roth prescription, 0.022 slot size"
62292287|NCT05333094|ACTIVE_COMPARATOR|MATT brackets|"Roth prescription, 0.022 slot size"
62292288|NCT03013465|OTHER|Control Diet|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of broccoli (control).
62465121|NCT03806062|ACTIVE_COMPARATOR|Electro acupuncture group|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes
62658308|NCT00658619|OTHER|400 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
62658309|NCT00658619|OTHER|200 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
62658310|NCT00658619|OTHER|400 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
62658311|NCT00658619|OTHER|200 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
62658312|NCT00658619|SHAM_COMPARATOR|Sham (no implant) Stage 2|Stage 2: sham in both eyes on Day 1 and Month 6.
62094749|NCT01724203|ACTIVE_COMPARATOR|Bifidobacterium animalis subsp. lactis|Formula containing 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10) at least three times daily for 12 weeks.
62292289|NCT03013465|ACTIVE_COMPARATOR|Brassica Diet|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily.
62465122|NCT02393157|EXPERIMENTAL|Central Nervous System (CNS) Negative|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
62465123|NCT02393157|EXPERIMENTAL|CNS Positive|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
62094750|NCT01724203|PLACEBO_COMPARATOR|Placebo|Placebo formula without probiotics at least three times daily for 12 weeks.
62465124|NCT01316549||Inpatient Pediatric Bone Marrow Transplant Recipients|All patients enrolled in this study will be located on the inpatient pediatric bone marrow transplant unit at University of California, San Francisco Benioff Children's Hospital.
62465125|NCT01576042|OTHER|Catheter ablation|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults
62465126|NCT01576042|OTHER|Antiarrhythmic medication|The choice of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
62465127|NCT05910632|EXPERIMENTAL|Eccentrically strengthened resistance exercise|Women who will be part of the eccentrically reinforced resistance group will perform using the multi-gym equipment with flywheel. Each workout will involve upper and lower extremities.
62094751|NCT05812794|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|
62094752|NCT01687270|EXPERIMENTAL|SOF+RBV|Participants will receive sofosbuvir+RBV for 24 weeks.
62094753|NCT01329120||Pectus excavatum|Patients who has undergone minimally invasive repair of pectus excavatum
62094754|NCT01329120||Pectus carinatum|Patients who has undergone open surgical repair of pectus carinatum
62094755|NCT04965493|EXPERIMENTAL|Arm A (PVR)|Fixed duration pirtobrutinib in combination with venetoclax and rituximab
62094756|NCT04965493|ACTIVE_COMPARATOR|Arm B (VR)|Venetoclax with rituximab
62094757|NCT03756389|EXPERIMENTAL|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.
62465128|NCT05910632|ACTIVE_COMPARATOR|Traditional resistance training|The control group (traditional resistance program) will carry out their interventions on gym machines for the lower limbs and free weights for the upper extremities.
62465129|NCT00468286|EXPERIMENTAL|A|Treatment group A: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months.
62465130|NCT00468286|EXPERIMENTAL|B|Treatment group B: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months.
62465131|NCT01745783|EXPERIMENTAL|Experimental|"Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.~Dose: 1-2x10\^6 cells/Kg"
62094758|NCT03756389|EXPERIMENTAL|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.
62094759|NCT06697925||Thor closure patients|Patients who achieved closure in during the THOR clinical trial
62094760|NCT05262556|EXPERIMENTAL|NP-101 (TQ Formula) + Nivolumab + Ipilimumab|
62094761|NCT05851378|EXPERIMENTAL|Cohort 1: Hyperpolarized Carbon-13 Alpha-ketoglutarate (HP 13C-aKG)|Cohort 1 will be comprised of 10 participants with Isocitrate dehydrogenase (IDH) mutant glioma who may or may not have received prior treatment for optimizing imaging protocol. Participants will be injected with 0.67ml/kg actual body weight of 100 millimolar (mM) of α-KG solution and have a single imaging scan.
62292290|NCT06100783|EXPERIMENTAL|Women using DMPA after 6 weeks postpartum|
62292291|NCT06100783|EXPERIMENTAL|Women using DMPA after 1 week postpartum|
62465132|NCT01745783|PLACEBO_COMPARATOR|Placebo Comparator|Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10\^6 cells/Kg
62658313|NCT01699984||Hospitalized patients|All patients hospitalized in 4 inpatient facilities in Northern Italy during 4 index-months.
62658314|NCT05598268|EXPERIMENTAL|T3011 Herpes Virus Injection|
62658315|NCT06197204||LCH patients|
62094762|NCT05851378|EXPERIMENTAL|Cohort 2: Hyperpolarized Carbon-13 Alpha-ketoglutarate (HP 13C-aKG)|Cohort 2 will be comprised 30 participants with recurrent IDH mutant glioma before receiving surgical resection. Participants will be injected with 0.67ml/kg actual body weight of 100 millimolar (mM) of α-KG solution and have a single imaging scan.
62094763|NCT01701765||Patients in residential facilities|All patients staying in September 2010 in 23 medium-long term RFs of the St John of God Order in Northern Italy with a primary psychiatric diagnosis and younger than 65 years recruited.
62094764|NCT01575860|EXPERIMENTAL|Phase I/II (Maintenance Lenalidomide in Lymphoma)|Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.
62465133|NCT02337218|ACTIVE_COMPARATOR|SENSUS Pain Management System|Electrical stimulation device worn on the leg delivering a dose of 50 volts.
62465134|NCT02337218|SHAM_COMPARATOR|SENSUS Pain Management System - Sham|Electrical stimulation device worn on the leg and programmed to deliver no stimulation.
62465135|NCT06370780|OTHER|Download the REMAIN App|All participants download the app
62465136|NCT02874300|NO_INTERVENTION|Control|The control arm will comprise the offer of an assessment by a standard community falls prevention service.
62465137|NCT02874300|OTHER|High intensity supervision arm|high-intensity supervision
62465138|NCT02874300|OTHER|Moderate intensity supervision arm|Moderate intensity supervision
62465139|NCT03739749|ACTIVE_COMPARATOR|Fascia lata autograft|Arthroscopic superior capsular reconstruction using a fascia lata autograft
62658316|NCT06197204||Control group|"* diffuse lung cystic disease~* pulmonary emphysema~* healthy smokers"
62465140|NCT03739749|ACTIVE_COMPARATOR|Fascia lata allograft|Arthroscopic superior capsular reconstruction using a fascia lata allograft
62465141|NCT03739749|ACTIVE_COMPARATOR|Achilles tendon allograft|Arthroscopic superior capsular reconstruction using an achilles tendon allograft
62658317|NCT03524001|ACTIVE_COMPARATOR|Bifocal stimulation|Active comparator is represented by programming bifocal stimulation (bifocal DDD mode). Every patients will undergo crossover randomization (from bifocal DDD mode to VVI and vice versa).
62465142|NCT03739749|ACTIVE_COMPARATOR|Bovine pericardium allograft|Arthroscopic superior capsular reconstruction using a bovine pericardium allograft
62465143|NCT03739749|ACTIVE_COMPARATOR|Swine dermal xenograft|Arthroscopic superior capsular reconstruction using a swine dermal xenograft
62658318|NCT03524001|PLACEBO_COMPARATOR|VVI 40|Placebo comparator is represented by programming the device in VVI mode 40/mins. Every patients will undergo crossover randomization (from VVI to bifocal DDD mode and vice versa).
62658319|NCT05271487|EXPERIMENTAL|Multi-Step Botanical Skin Care Regimen|The patient will be provided with and instructed to use a cleanser, toner, oil control cream, exfoliating facial scrub, clay mask, acne spot treatment, and body scrub for the duration of the study.
62094765|NCT05531370|EXPERIMENTAL|Breathing Retraining (BR)|"Patients will receive three sessions (60 min, 30 min, 30 min) of breathing retraining (BR), 1-to-1 with a trained physiotherapist.~As preferred by the patient:~* Hybrid delivery mode of BR (H-BR): First session on-site at hospital/clinic for initial assessment and introduction, and following sessions online (MedComs VDX platform or equal; participants access using web cam and sound on smart phone, tablet, or pc).~* Ordinary delivery of BR: Three sessions on-site at hospital/clinic."
62658320|NCT00964704|EXPERIMENTAL|Single Arm|
62658321|NCT02115152|ACTIVE_COMPARATOR|FEC|Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery.
62658322|NCT02115152|EXPERIMENTAL|XEC|Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery.
62658323|NCT00429247|EXPERIMENTAL|1|Her
62658324|NCT00429247|NO_INTERVENTION|2|Follow up
62658325|NCT01954615|EXPERIMENTAL|Group A 5 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
62658326|NCT01954615|EXPERIMENTAL|Group B 20 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
62658327|NCT01954615|EXPERIMENTAL|Group C ACT-281959 prodrug formulation I/placebo|Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
62094766|NCT03967561|EXPERIMENTAL|Progressive aerobic training|Water-based aerobic training performed with progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
62292292|NCT04223245|EXPERIMENTAL|exercise+MMSF|Group of PWPD who performed a base exercise program of speed and large amplitude stepping and standing balance exercises with Multimodal real-time sensory feedback
62465144|NCT03739749|ACTIVE_COMPARATOR|Collagen allograft|Arthroscopic superior capsular reconstruction using a collagen allograft
62658328|NCT01954615|EXPERIMENTAL|Group D ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.
62094767|NCT03967561|EXPERIMENTAL|Non-progressive aerobic training|Water-based aerobic training performed without progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
62094768|NCT02613780|ACTIVE_COMPARATOR|Sequential group|Photorefractive keratectomy will be performed 12-18 months after participants had crosslinking
62094769|NCT02613780|ACTIVE_COMPARATOR|Simultaneous group|Photorefractive keratectomy and crosslinking will be performed on the same day
62094770|NCT05201989||Atrial fibrillation|Subjects with symptomatic paroxysmal atrial fibrillation scheduled for AF ablation at Örebro University hospital
62094771|NCT05201989||Control|Sex and age-matched subjects without AF
62094772|NCT05472649||Participants exposed to Gene-Modified Cell Therapy|
62094773|NCT06697782|OTHER|Ondansetron group|Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
62292293|NCT04223245|ACTIVE_COMPARATOR|exercise only|Group PWPD who did the same exercise program without MMSF
62465145|NCT05634772|ACTIVE_COMPARATOR|the efficacy of dormia basket in management of proximal stent migration|
62465146|NCT05634772|ACTIVE_COMPARATOR|the efficacy of extraction biliary balloon in management of proximal stent migration|
62465147|NCT01003002||PD Cohort|The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
62465148|NCT01793194|NO_INTERVENTION|No Stocking Use|For pregnant women randomized to the no stocking use group, no compression stockings will be worn.
62658329|NCT01954615|EXPERIMENTAL|Group E ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.
62658330|NCT01954615|EXPERIMENTAL|Group F ACT-281959 prodrug formulation I/placebo|Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.
62094774|NCT06697782|OTHER|Arepitant group|Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
62094775|NCT06697782|EXPERIMENTAL|Combined treatment group|Patients in the combined group received 125 mg of oral aprepitant plus 8 mg of ondansetron 1 hour before anesthesia, with ondansetron followed by two oral doses of the drug at 8-hour intervals, and 80 mg of aprepitant once daily in the morning on postoperative days 2 and 3 (the day of the surgery was day 1)
62094776|NCT06613971||Patients diagnosed with dementia|Patients diagnosed with dementia including those caused by Alzheimer's, Vascular, Lewy body, Mixed, Parkinson's, Frontotemporal, Creutzfeldt-Jakob, Normal pressure hydrocephalus, Huntington's, Wernicke-Korsakoff Syndrome.
62094777|NCT06613971||Patients without cerebral pathology|Patients without cerebral pathology (no dementia)
62094778|NCT01890967|EXPERIMENTAL|20 mg LY3015014 Q4W|"20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
62094779|NCT01890967|EXPERIMENTAL|120 mg LY3015014 Q4W|"120 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
62094780|NCT01890967|EXPERIMENTAL|300 mg LY3015014 Q4W|"300 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
62094781|NCT01890967|EXPERIMENTAL|100 mg LY3015014 Q8W|"100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
62094782|NCT01890967|EXPERIMENTAL|300 mg LY3015014 Q8W|"300 mg LY3015014 given SC Q8W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
62292294|NCT01551745|EXPERIMENTAL|Vigil™ Vaccine|Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
62292295|NCT03775837|EXPERIMENTAL|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
62292296|NCT03775837|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 8 weeks
62292297|NCT01455974|EXPERIMENTAL|Dialysate sodium set at 136 mmol/L|
62292298|NCT05972512|PLACEBO_COMPARATOR|Placebo|The test treatment will be taken two times a day.
62465149|NCT01793194|EXPERIMENTAL|Compression Stocking Use|Patients who are randomized to the stocking use group (Treatment Subgroup A) will be formally measured for their stockings by a certified stocking fitter, given (at no charge) two pair of 20-30mmg Hg maternity pantyhose compression stockings, and will undergo a brief tutorial regarding how to put the stockings on. Each patient will be instructed to wear the stockings on a daily basis, during the day.
62465150|NCT02828904||Users of Chlormadinone Acetate (CMA) combined with Ethinylestradiol (EE)|"CMA/EE users are defined as~* aged 15 to 49 years~* Participation in one of the 4 observational studies conducted between 2000 and 2019 (LASS/EURAS-OC, INAS-OC, INAS-SCORE, INAS-FOCUS)~* COC new user (starters, switchers, and re-starters)"
62465151|NCT02828904||Users of Levonorgestrel (LNG) combined with Ethinylestradiol (EE)|"LNG/EE users are defined as~* aged 15 to 49 years~* Participation in one of the 4 observational studies conducted between 2000 and 2019 (LASS/EURAS-OC, INAS-OC, INAS-SCORE, INAS-FOCUS)~* COC new user (starters, switchers, and re-starters)"
62658331|NCT01954615|EXPERIMENTAL|Group G ACT-281959 prodrug formulation I & II/ACT-246475|9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.
62658332|NCT06290817|EXPERIMENTAL|Orelabrutinib combined with R-CDOP regimen|Participants will receive 150 mg of oral orelabrutinib once daily with R-CDOP on day 1 of each cycle (21 days)
62658333|NCT01176929|EXPERIMENTAL|Interventional group|Usual treatment + prevention program of recurrent suicidal acts
62658334|NCT01176929|ACTIVE_COMPARATOR|Control group|Usual treatment
62658335|NCT04376671||temporal lobe epilepsy|Group of patients with temporal lobe epilepsy
62658336|NCT04376671||Extra-temporal lobe epilepsy|Group of patients with extra-temporal lobe epilepsy
62292299|NCT05972512|EXPERIMENTAL|Botanical Extract of standardised for biotin (1250 mcg)|The standardised botanical extract of biotin is specially formulated for healthier hair and skin. Biotin promotes the hair growth.
62292300|NCT05972512|EXPERIMENTAL|Botanical Extract of standardised for biotin (1250mcg) + 10 mg Silica|The standardised botanical extract of biotin and silica is specially formulated for healthier hair. The combination of biotin and silica will helpful in hair growth, reduces shedding, and improves the health of hair.
62292301|NCT05243849||Ischemic Stroke|The diagnosis of ischemic stroke was obtained from previous diagnostic reports or electronic medical records, according to the diagnostic criteria from the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
62292302|NCT05243849||Control|Inclusion criteria for healthy controls were no history of ischemic stroke or other neurological and ocular diseases.
62292303|NCT01110187|EXPERIMENTAL|IV LCM (lacosamide)|Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
62292304|NCT01110187|ACTIVE_COMPARATOR|IV fPHT (fos-phenytoin)|Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin
62292305|NCT05722964|EXPERIMENTAL|SHR-1906，-Dose A|
62292306|NCT05722964|EXPERIMENTAL|SHR-1906，- Dose B|
62292307|NCT05722964|PLACEBO_COMPARATOR|Placebo|
62292308|NCT03093402|EXPERIMENTAL|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
62292309|NCT03093402|EXPERIMENTAL|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
62292310|NCT03093402|EXPERIMENTAL|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
62465152|NCT02219945|EXPERIMENTAL|Group 1 - 20 PTB patients aged >18yrs|Group 1 - 20 TB patients aged \> 18 yrs 5 min exhaled breath sampling with nose clamp
62465153|NCT02219945|EXPERIMENTAL|Group 2 - 20 TB suspects > 18 yrs|Group 2 - 20 non-TB patients \> 18 yrs (screened for TB - but appear to test negative for TB, and diagnosed with other conditions including bronchiectasis, etc) 5 min exhaled breath sampling with nose clamp
62658337|NCT01415076|PLACEBO_COMPARATOR|Insertion without CO2 insufflation|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
62658338|NCT01415076|EXPERIMENTAL|Insertion with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
62658339|NCT04057768|OTHER|Intervention|Device: Venus Viva
62658340|NCT01447966|NO_INTERVENTION|Treatment as Usual|Participants randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
62658341|NCT01447966|EXPERIMENTAL|Immediate CBT|Therapists will work with families for 12 twice weekly sessions, each lasting up to 60 minutes implementing a developmentally appropriate modulated cognitive behavioral therapy approach. A manualized CBT protocol will be followed.
62292311|NCT03093402|PLACEBO_COMPARATOR|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
62292312|NCT04209231||chronic periodontitis|
62292313|NCT04209231||chronic gingivitis|
62292314|NCT04209231||periodontally healthy|
62292315|NCT03780998||Group-1 (n: 50): Healthy cases|Control group
62292316|NCT03780998||Group-2 (n:50): Grade 1 hemorroid|With perianal examination diagnosed of grade 1 hemorroidal disease
62292317|NCT03780998||Group-3 (n:50): Grade 2 hemorroid|With perianal examination diagnosed of grade 2 hemorroidal disease
62292318|NCT03780998||Group-4 (n:50): Anal fissure cases|With perianal examination diagnosed of anal fissure cases
62292319|NCT03780998||Group-5 (n:50): Simple perianal fistula|With perianal examination diagnosed of uncomplicated, simple perianal fistula cases
61908090|NCT05705635|EXPERIMENTAL|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.
62658342|NCT05230732|EXPERIMENTAL|Experimental|Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks.
61908091|NCT05705635|ACTIVE_COMPARATOR|Taxotere|Taxotere will be administrated by intravenous infusion once every 3 weeks.
61908092|NCT00002501|EXPERIMENTAL|cyclophosphamide + filgrastim|Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.
61908093|NCT01671527||Cervical Dystonia: DBS Subjects|Subjects who have undergone or plan to undergo DBS surgery for cervical dystonia
61908094|NCT01671527||Cervical Dystonia: Control Subjects|Subjects who DO NOT plan to undergo DBS surgery for cervical dystonia
62292320|NCT03850821|EXPERIMENTAL|Connect Social Mechanisms Intervention|"The primary components of the intervention included: Get-to-know-you sessions aimed specifically at providing youth guided social opportunities to foster friendships, group belonging, and social skills, and novel socially-oriented 'PA sessions' infused within the daily time slot that ASPs' allocated towards recreation. Drawing from theoretical models of motivation, and the investigators' previous ASP studies, key essential elements were identified for facilitating improvements in targeted PA social mechanisms (i.e., friendships, group belonging, and staff connection) and included: 1) social-emotional goal-oriented support, 2) collaborative/cooperative play centered on friendship and informal fun; 3) equal treatment/access, and; 4) inclusive and engaging."
61908095|NCT01671527||Healthy Controls|Healthy control subjects who do not have dystonia.
61908096|NCT00361413|EXPERIMENTAL|1|Alefacept
61908097|NCT00361413|PLACEBO_COMPARATOR|2|
61908098|NCT00933218|ACTIVE_COMPARATOR|polyphenols (non-alcoholic beer)|
61908099|NCT00933218|PLACEBO_COMPARATOR|beverage without polyphenols|
61908100|NCT04453943|EXPERIMENTAL|Group A - SCI|Ten individuals with SCI at the T1-T10 level will be recruited (Group A). These individuals can have incomplete or complete paraplegia.
61908101|NCT04453943|EXPERIMENTAL|Group B - Subjects without disability|Twenty individuals without disability will be recruited (Group B). Individuals with SCI who have experience in using some kind of walking assistive devices in the recent past will be preferably recruited.
61908102|NCT00565929|EXPERIMENTAL|Group A: MVA-BN 1 X 10^7 TCID 50|10 participants to receive vaccine dose 1X10\^7 TCID 50; 2 participants to receive placebo.
61908103|NCT00565929|EXPERIMENTAL|Group B: MVA-BN 1 X 10^8 TCID 50|10 participants to receive vaccine dose 1X10\^8 TCID 50; 2 participants to receive placebo.
61908104|NCT06299410|EXPERIMENTAL|Cohort A1: 10 mg ITI-1284|
61908105|NCT06299410|EXPERIMENTAL|Cohort A2: 20 mg ITI-1284|
61908106|NCT02174588|EXPERIMENTAL|balanced propofol group|
61908107|NCT02174588|ACTIVE_COMPARATOR|propofol alone group|
61908108|NCT06047951|EXPERIMENTAL|SRS group|Participants in the SRS group will receive the intervention described earlier, consisting of a Gamma Knife radiosurgery, and undergo the same follow-up exams (radiological and clinical) as participants of the control group.
61908109|NCT06047951|NO_INTERVENTION|Control group|The medical care will consist of observation for any element that may indicate an increased risk of rupture, like aneurysm growth or instability in shape.
61908110|NCT02387476|EXPERIMENTAL|FRESCA mask first night|"FRESCA mask first night (experimental device) \| CPAP second night (active comparator)"
61908111|NCT02387476|EXPERIMENTAL|CPAP Mask first night|"CPAP Mask first night (active comparator)\| FRESCA mask second night (experimental device)"
61908112|NCT05880290|EXPERIMENTAL|gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful|
61908113|NCT05874570|ACTIVE_COMPARATOR|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 110mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
61908114|NCT05874570|EXPERIMENTAL|Doxycycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 110mg qid, Doxycycline 100mg bid, Metronidazole 400mg qid
61908115|NCT02094768|EXPERIMENTAL|Reduced Fat Milk|20 oz. reduced fat (2%) milk per day
62292321|NCT03850821|NO_INTERVENTION|Typical ASP curriculum wait-list control|No intervention was implemented within the active wait-list control condition, which served as the typical ASP curriculum control/comparison. After completion of the 8-week intervention (12 weeks including baseline and post-intervention data collection), the control condition received the social mechanisms curriculum as a token of appreciation for participating in measurement.
62292322|NCT03772327|EXPERIMENTAL|Routine counseling + AdhereTech bottle|"Participants will receive routine medication adherence counseling and be given the AdhereTech smart bottle with reminders."
62292323|NCT03772327|ACTIVE_COMPARATOR|Routine counseling|Participants will receive routine medication adherence counseling.
62292324|NCT03465033|NO_INTERVENTION|Usual Care|Patients will receive basic indications of rehabilitation consisting of daily mobilization of the jaw (perform several movements a day opening movements, laterotrusion and mouth protrusion).
62292325|NCT03465033|EXPERIMENTAL|Early Physiotherapy|
61908116|NCT02094768|EXPERIMENTAL|Sugar Sweetened Soda|24oz. soda per day
62465154|NCT02219945|EXPERIMENTAL|group 3 - 20 lung patients, non-TB|Group 3 - 20 patients with a lung disease - no TB suspects (recruited from Lung Clinics in Yogyakarta; lung cancer, COPD, etc) 5 min exhaled breath sampling with nose clamp
62465155|NCT02219945|EXPERIMENTAL|Group 4 - 20 healthy controls|Group 4 - 20 apparently healthy matched controls 5 min exhaled breath sampling with nose clamp
62465156|NCT02219945|EXPERIMENTAL|Group 5 - 7 newly diagnosedMDR PTB pts|Group 5 - 7 newly diagnosed MDRTB patients enrolled before start of treatment, to be followed 8 months, until after end of treatment 5 min exhaled breath sampling with nose clamp
62465157|NCT02219945|EXPERIMENTAL|group 6 - cohort of TB suspects|300 more individuals, suspected to have TB - final diagnosis by standard procedures plus sputum culture plus follow-up for \>2 years 5 min exhaled breath sampling with nose clamp
61908117|NCT02105753|EXPERIMENTAL|1210nm axillary laser treatments|two laser treatments right axilla and one treatment left axilla
62465158|NCT05693597|NO_INTERVENTION|Group I (control)|Patients will not receive any prophylactic intervention, as there is no standard of care for prophylaxis to the radiation induced dermatitis (RID).
62094783|NCT01890967|PLACEBO_COMPARATOR|Placebo Q4W|"Placebo given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
62465159|NCT05693597|EXPERIMENTAL|Group II (Topical intervention)|Patients will receive Imtenan ® N. sativa oil apply 1.5 mls; twice daily; not sooner than 2 hours before and after radiation therapy; from day 1 of radiation therapy till the end.
62465160|NCT05693597|EXPERIMENTAL|Group III (Oral intervention)|Patients will receive Baraka ® N. sativa gelatin capsules; 40-80 mg/Kg/day; from day 1 of radiation therapy till the end
62465161|NCT01138436|EXPERIMENTAL|MEBO Wound Ointment (MEBO)|Topical application once a day
62465162|NCT01138436|ACTIVE_COMPARATOR|Standard of Care|Application of Profore multilayer compression bandage system
62094784|NCT06689826||patient|Individuals diagnosed with unilateral rotator cuff
62094785|NCT04113837|EXPERIMENTAL|verum|"The food range is comprised of:~sausages (1100 g per week / exchange of saturated fatty acids by long-chain unsaturated omega-3 fatty acids from fish oil (Maris Oil ED0222N rich in docosahexaenoic acid (DHA)), partially exchange of fat by plant protein (sesame)), eggs (3 eggs per week / 2 µg vitamin D per egg), 100 g mushrooms per day (5 µg Vitamin D/d), one bread per week (5 µg Vitamin D/d), bread rolls (16 g dietary fibers/d), 100 ml ice cream per week (exchange of sugar by xylitol), 3x 70 g pasta per week (3 x 10 g dietary fibers per week)"
62292326|NCT04514263||Oral Biopsy|Patients with oral lesions undergoing diagnostic or therapeutic biopsies either for benign lesions or potentially malignant disorders or malignant lesions or salivary glands diseases.
62292327|NCT04513691||Sample|Asymptomatic newborns 35 weeks or greater GA born at Banner - University Medical Center Phoenix whose mothers were determined or suspected to have CAM.
62658343|NCT05230732|SHAM_COMPARATOR|Control arm|Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks.
62658344|NCT00858546|EXPERIMENTAL|Active repetitive transcranial Stimulation|Active repetitive transcranial Stimulation
62658345|NCT06030362|ACTIVE_COMPARATOR|Probiotic|
62658346|NCT06030362|PLACEBO_COMPARATOR|Placebo|
61908118|NCT02105753|EXPERIMENTAL|1210nm laser treatments to the axilla|two laser treatments left axilla and one treatment right axilla
62094786|NCT04113837|ACTIVE_COMPARATOR|control|In the placebo period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), eggs, mushrooms, bread, bread rolls, ice cream and pasta) with traditional nutrient profile.
62465163|NCT06149130|EXPERIMENTAL|treatment group|"1. Adebrelimab: 1200mg intravenously ,Q3W~2. dalpiciclib : 150mg once a day for 3 weeks, stop for 1 week, Q4W~3. Endocrine recommended drugs untreated: aromatase inhibitors (letrozole/anastrozole/exemestane), given orally once daily at a specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, exemestane 25mg/ day); first-line endocrine therapy failed: fluvestrant was given once every 28 days, 500mg intramuscular injection, and then 500mg intramuscular injection 2 weeks after the first administration;"
61908119|NCT00183729|EXPERIMENTAL|Memantine (1)|Memantine for 12 weeks
62094787|NCT05973669|EXPERIMENTAL|Remote cochlear implant support|Participants will use MED-EL Remote Care to test their hearing and device functionality. Participants and clinicians will complete user feedback surveys regarding their experience and time/cost-savings.
62292328|NCT03893045|EXPERIMENTAL|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
62292329|NCT03893045|ACTIVE_COMPARATOR|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL)
62658347|NCT01008644|EXPERIMENTAL|Saline|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min.
61908120|NCT00183729|PLACEBO_COMPARATOR|Placebo (2)|Placebo for 12 weeks
61908121|NCT04287543|EXPERIMENTAL|Melatonin group|Patients with PD who will receive 25 mg of melatonin gel at 12 hours a day and half an hour before sleeping for 12 months
61908122|NCT04287543|PLACEBO_COMPARATOR|Placebo group|Patients with PD who will receive 25 mg of placebo gel at 12 hours a day and half an hour before sleeping for 12 months
62292330|NCT04529291|OTHER|Group with walking disorder|This Group with walking disorder corresponds to patient reporting walking disorders due to his illness.
61908123|NCT05303662||ERCP-patients Netherlands|Patients undergoing ERCP in the study site in the Netherlands
61908124|NCT05303662||ERCP-patients Italy|Patients undergoing ERCP in the study site in Italy
61908125|NCT05303662||ERCP-patients United States|Patients undergoing ERCP in the study site in the Netherlands
61908126|NCT05303662||ERCP-patients India|Patients undergoing ERCP in the study site in India
61908127|NCT02847676||No previous surgery, adhesions present.|Patients have had no previous abdominal surgery. Inspection shows peritoneal adhesions.
62094788|NCT01562665||All Population|
62094789|NCT01562665||Sample of patients will be invited to complete Quality of Life|
62094790|NCT02646046|EXPERIMENTAL|Combi lone-CPR|"Intervention group~: Newly developed method"
62094791|NCT02646046|ACTIVE_COMPARATOR|Conventional lone-CPR|Conventional CPR group
62292331|NCT04529291|OTHER|Group without walking disorder|This Group without walking disorder corresponds to patients not reporting walking disorders due to his illness.
62292332|NCT03990129|OTHER|Study population|All participants
62465164|NCT03962348|EXPERIMENTAL|Specialized Early Engagement Support Service|The investigators will implement a Specialized Early Engagement Support Service (SEESS) in the same three jails. The SEESS will increase the likelihood that referred individuals found to have first-episode psychosis enroll in Coordinated Specialty Care upon release.
62094792|NCT06168604|EXPERIMENTAL|Pain Identification and Communication Toolkit|The Pain Identification and Communication Toolkit (PICT) components include: a) training using an observational assessment tool to detect pain in persons with Alzheimer's disease and related dementias (ADRD), b) coaching and feedback by a trained interventionist in effective strategies for communicating with providers about pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set through routine practice and homework exercises. A trained interventionist will deliver the PICT intervention following a manualized protocol to the caregiver participants. Patient participants will not receive any intervention.
62094793|NCT06168604|SHAM_COMPARATOR|Attention Control|The Attention Control (AC) condition, also known as the Health Promotion Program (HPP), focuses on caregiver health promotion topics, such as nutrition, exercise, and sleep. A trained interventionist will provide education on these topics using scripted material, use active listening and open questioning techniques, and provide the HPP participants with worksheets (e.g., meal plans) to complete between sessions to mirror the homework activities in the PICT condition for the caregiver participants. Patient participants will not receive any intervention.
62094794|NCT06479915||Stroke|Small cerebral vessel disease
62094795|NCT06479915||healthy people|MRI showed no signs of small cerebral vessel disease
62658348|NCT01008644|EXPERIMENTAL|Water|The subjects will drink tap water for 2 hours, the volume calculated as 20ml/kg/hour
62658349|NCT03735576|EXPERIMENTAL|LLD-adapted cognitive behavioural therapy (CBT)|manualized 15-session individually-delivered cognitive behavioural therapy (CBT) specific for late life depression (LLD)
62658350|NCT03735576|ACTIVE_COMPARATOR|supportive unspecific intervention (SUI)|manualized 15-session individually-delivered supportive unspecific intervention (SUI)
62658351|NCT02975596|OTHER|Youth|Youth between the ages beteen ages 13-18 will be offered awareness, education, empowerment and accessibility intervention components.
62658352|NCT02975596|OTHER|College|Age between 18-23 will be offered awareness, education, empowerment and accessibility intervention components.
62658353|NCT02975596|OTHER|Adult|parents of adolescents and young adults will be offered awareness, education, and accessibility intervention components.
62658354|NCT02975596|NO_INTERVENTION|Parent focus group|Parents discussed barriers and reviewed MenB education materials.
62658355|NCT02975596|NO_INTERVENTION|Provider focus groups|Providers discussed barriers and reviewed MenB education materials.
62658356|NCT04935632||Before implementation|Prior to the implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
62094796|NCT06462261||Group 1|Escherichia coli isolates
62094797|NCT00693030|ACTIVE_COMPARATOR|1|Device, Sirolimus drug-eluting stents implanted in overlap
62094798|NCT00693030|ACTIVE_COMPARATOR|2|Device, paclitaxel polymer drug eluting stent
62658357|NCT04935632||After implementation|After implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
62658358|NCT04935632||at a distance from the implementation|Approximately 8 months after implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia.
62658359|NCT04736875||Dialysis|Patients with hemodialysis-dependent end-stage renal disease and a newly created native arteriovenous fistula
62658360|NCT01456117|EXPERIMENTAL|Pioglitazone (Dose 1) QD|
62094799|NCT00693030|ACTIVE_COMPARATOR|3|Device, zotarolimus drug eluting stent
62658361|NCT01456117|EXPERIMENTAL|Pioglitazone (Dose 2) QD|
62658362|NCT01456117|EXPERIMENTAL|Pioglitazone (Dose 3) QD|
62658363|NCT01456117|PLACEBO_COMPARATOR|Placebo QD|
62658364|NCT04784689||Prospective - Cancer Patients that have received COVID-19 Vaccination|
62094800|NCT00693030|ACTIVE_COMPARATOR|4|bare metal coronary stents
62094801|NCT04541186|EXPERIMENTAL|Pegozafermin 9 mg QW|Participants received pegozafermin 9 mg QW as an SC injection for 8 weeks in the Main Study cohort.
62094802|NCT04541186|EXPERIMENTAL|Pegozafermin 18 mg QW|Participants received pegozafermin 18 mg QW as an SC injection for 8 weeks in the Main Study cohort.
62658365|NCT02818803|EXPERIMENTAL|Propolis|Standardized-propolis extract (EPP-AF®) oral gel formulation, 3 times a day, for 14 days
62658366|NCT02818803|ACTIVE_COMPARATOR|Miconazole|Miconazole 20mg/g oral gel,3 times a day, for 14 days
62658367|NCT00937196|ACTIVE_COMPARATOR|Histaminum hydrochloricum globuli|To allow double-blind administration of the placebo pills going along with verbal suggestions of a blood-pressure-lowering effect
62658368|NCT00937196|EXPERIMENTAL|Placebo globuli|
62658369|NCT00937196|NO_INTERVENTION|No treatment|
62465165|NCT04320849||Patients with protocol identified RV Leads|Medtronic model 6935M (Quattro Secure Single Coil Defibrillation Lead) Abbott model LDA 210Q (Optisure Single Coil Defibrillation Lead) Abbott model LDA 220Q (Optisure Dual Coil Defibrillation Lead) Boston Scientific model 4470/4471 (FINELINE II/FINELINE II Sterox); Positive Fixation Biotronik model Solia S (Active Fixation Leads)
62465166|NCT00585689|EXPERIMENTAL|Neoadjuvant ABI-007, Carboplatin, and Gemcitabine|Neoadjuvant ABI-007 (260 mg/m\^2) on day 1, Carboplatin (Target AUC \[Area under the curve\] =5) on day 1, and Gemcitabine (800 mg\^m2) on days 1 and 8, every 21 days.
62465167|NCT02068105|EXPERIMENTAL|ALKS 5461-A|
62465168|NCT02068105|EXPERIMENTAL|ALKS 5461-B|
62658370|NCT04336683|OTHER|Patient|Patients undergoing gynecological brachytherapy, will be imaged with a 3D ultrasound medical device for the purpose of efficacy testing.
62658371|NCT03217825|EXPERIMENTAL|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
62658372|NCT03217825|EXPERIMENTAL|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
62658373|NCT03217825|EXPERIMENTAL|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
62658374|NCT03217825|ACTIVE_COMPARATOR|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
62658375|NCT01081990|PLACEBO_COMPARATOR|Placebo Pill|
62658376|NCT01081990|EXPERIMENTAL|Flexeril|
62658377|NCT04252729|EXPERIMENTAL|Psychotherapy|Psychotherapy sessions based on the theoretical line of Psychoanalytic Psychosomatics for 1 year, every 10 days.
62658378|NCT04252729|NO_INTERVENTION|No psychotherapy|Follow-up according to institutional routine, without psychotherapy sessions.
62658379|NCT00989885||Obstructive Sleep Apnea|475 patients that sought the CESF to probable diagnosis of some sleep disorder, subsequently diagnosed with Obstructive Sleep Apnea.
62658380|NCT02912052|EXPERIMENTAL|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.
62658381|NCT02912052|ACTIVE_COMPARATOR|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.
62658382|NCT02628977|EXPERIMENTAL|OSA Health Education & Support Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer educator.
62658383|NCT02628977|ACTIVE_COMPARATOR|Attention Control Group|Participants in the attention control group will receive standard sleep literature, providing information about Obstructive Sleep Apnea and access to available sleep services.
62658384|NCT02631681|EXPERIMENTAL|Men with prostate cancer on androgen deprivation therapy|Group based supervised combined aerobic and resistance training for 12 weeks.
62658385|NCT01650376|EXPERIMENTAL|Olaparib plus carboplatin and paclitaxel|
62465169|NCT02068105|EXPERIMENTAL|ALKS 5461 Dose 1|
62465170|NCT02068105|EXPERIMENTAL|ALKS 5461 Dose 2|
62658386|NCT02521480|ACTIVE_COMPARATOR|Active Transcranial Magnetic Stimulation|During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression.
62465171|NCT02068105|EXPERIMENTAL|ALKS 5461 Dose 3|
62465172|NCT02068105|PLACEBO_COMPARATOR|Placebo|
62465173|NCT02550678|EXPERIMENTAL|Cohort 1|Study Participants will receive ASN-002 at a dose 5X 10(10) vp, weekly injection in tumor nodules for 3 weeks.
62465174|NCT02550678|EXPERIMENTAL|Cohort 2|Study Participants will receive ASN-002 at a dose of 1.5X 10(11) vp weekly injection in tumor nodules for 3 weeks
62465175|NCT02550678|EXPERIMENTAL|Cohort 4|Study Participants will receive ASN- 002 at a dose of 3.0X 10(11) vp weekly injections in tumor nodules for 3 weeks.
62465176|NCT02550678|EXPERIMENTAL|Cohort 5|Study Participants will receive ASN- 002 at a dose of 2.25X 10(11) vp weekly injections in tumor nodules for 3 weeks.
62658387|NCT02521480|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|During sham TMS, a coil will be placed on the left prefrontal area of the head. Sham TMS will simulate active treatment as described in active arm.
62658388|NCT01616927|NO_INTERVENTION|standard care|Subjects in this arm will receive standard care
62658389|NCT01616927|EXPERIMENTAL|Lanreotide|
62658390|NCT06384924||Raman Spectroscopy|
62658391|NCT02153281|EXPERIMENTAL|Phenelzine treatment|Subjects will undergo a PET and MRI scan before and after the treatment.
62658392|NCT06057857||Employees in Ahram Canadian university|
62094803|NCT04541186|EXPERIMENTAL|Pegozafermin 27 mg QW|Participants received pegozafermin 27 mg QW as an SC injection for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion pegozafermin 27 mg QW groups were pooled together due to low sample size in the expansion cohort.
62094804|NCT04541186|EXPERIMENTAL|Pegozafermin 36 mg Q2W|Participants received pegozafermin 36 mg Q2W as an SC injection for 8 weeks in the Main Study cohort.
62094805|NCT04541186|PLACEBO_COMPARATOR|Placebo|Matching placebo was injected at matching frequency per assigned cohort for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion placebo groups were pooled together due to low sample size in the expansion cohort.
62292333|NCT02834910||Case group|patients with Extended-Spectrum Beta-lactamase producing Enterobacteriaceae carrying a qnr gene isolate
62292334|NCT02834910||control-group|patients with Enterobacteriaceae isolate without qnr gene
62292335|NCT06331091|ACTIVE_COMPARATOR|Home exercise|This group performed the same exercises given to comprehensive physiotherapy group at home 3 times a week for 6 weeks.
62292336|NCT06331091|EXPERIMENTAL|Comprehensive physiotherapy|This group received comprehensive physiotherapy (manual therapy, neuromuscular electrical stimulation and exercises) 1 day a week, and did the exercises at home the other 2 days a week for 6 weeks.
62465177|NCT02550678|EXPERIMENTAL|Combination Cohorts|Study Participants will receive ASN- 002 at either dose of Cohorts II, IV or V in combination with a low dose 5-FU (1mg/2.5 mg/5mg/10mg or 25mg) weekly injections in tumor nodules for 3 weeks.
62465178|NCT02126137|EXPERIMENTAL|Ezetimibe|Ezetimibe administered by mouth 10 mg BID for 12 weeks
62465179|NCT05298267|EXPERIMENTAL|Monitoring phase|Participants will be monitored for 4 weeks. Halfway through the monitoring period, participants will be asked to turn on DNDWD.
62658393|NCT03943082|ACTIVE_COMPARATOR|Cohort A : Usual Care (FRP Only)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent.
62658394|NCT03943082|EXPERIMENTAL|Cohort A: Usual Care + Intervention (FRP + Follow-up)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent and a follow-up phone call on day 3 after iMPACT consent.
62658395|NCT03163966|EXPERIMENTAL|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
62658396|NCT03163966|EXPERIMENTAL|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
62292337|NCT02618369|OTHER|MR-HIFU treatment|"The interventional radiologist will locate the target lesion and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan."
62465180|NCT05165381||Contactless vital signs and stress measurement.|Contactless vital signs and stress measurement. Eligible participants will agree to have a 1.5-minute facial video recorded using an iPad. Video will be processed through a specialized algorithm to obtain BP, HR, RR, HRV and stress index. measurements.
62465181|NCT01482377|EXPERIMENTAL|Part A: RO5479599 Dose Escalation|Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
62465182|NCT01482377|EXPERIMENTAL|Part B: RO5479599 Dose Escalation + Cetuximab|Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
62465183|NCT01482377|EXPERIMENTAL|Part C: RO5479599 Dose Escalation + Erlotinib|Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599.
62658397|NCT03163966|EXPERIMENTAL|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
62658398|NCT03163966|EXPERIMENTAL|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
62658399|NCT02258061|EXPERIMENTAL|DDD-80 pacing|To investigate the impact of basal pacing rates of 80-bpm (DDD-80) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) and (iii) self-perceived quality of life (QoL).
62658400|NCT02258061|SHAM_COMPARATOR|DDD-60 pacing|To investigate the impact of basal pacing rates of 60-bpm (DDD-60) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) self-perceived quality of life (QoL).
62658401|NCT04609696|EXPERIMENTAL|Part 1: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 1 formulation under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
62658402|NCT04609696|EXPERIMENTAL|Part 1: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 1 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
62292338|NCT01085188|EXPERIMENTAL|Assertive Continuing Care (ACC)|Behavioral intervention comprised of the community reinforcement approach plus case management delivered in home and other community settings to youth and their caregivers.
62292339|NCT01085188|EXPERIMENTAL|Contingency Management (CM)|Using a prize drawing system (no, low, medium and large value prizes) with adolescents could earn escalating prize drawing opportunities by completing verifiable pro-social activities and providing negative urine test and breath alcohol test results.
62292340|NCT01085188|EXPERIMENTAL|ACC + CM|This arm is the combination of arms 1 and 2.
62292341|NCT01085188|ACTIVE_COMPARATOR|Usual Continuing Care (UCC)|UCC consists of a discharge recommendation to seek aftercare services at nearest treatment provider to where the patient lived. This service primarily consisted of outpatient group counseling.
62094806|NCT02641210|EXPERIMENTAL|Periodontal Treatment|The experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration.
62094807|NCT02641210|NO_INTERVENTION|No Periodontal Treatment|Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline.
62658403|NCT04609696|EXPERIMENTAL|Part 1: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fasted conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
62094808|NCT05219045|EXPERIMENTAL|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
62094809|NCT05219045|NO_INTERVENTION|Control|Medical providers who treat both treatment and control group enrollees receive training on stay-at-work/return-to-work best practices
62658404|NCT04609696|EXPERIMENTAL|Part 2: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 2 formulation under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
62094810|NCT06697327|EXPERIMENTAL|Treatment(Daunorubicin, Cytarabine, Ventoclax)|Treatment(Daunorubicin, Cytarabine, Ventoclax) See Detailed Description.
62094811|NCT06697327|ACTIVE_COMPARATOR|Control(Daunorubicin, Cytarabine)|Control(Daunorubicin, Cytarabine) See Detailed Description.
62094812|NCT01974232||Romiplostim group|
62094813|NCT01974232||Eltrombopag group|
62094814|NCT06191536|EXPERIMENTAL|Pilates Group (PG)|"Pilates exercises will be performed under the supervision of a certified pilates instructor.~Pilates exercises will be performed for 50 minutes, 2 days a week for 8 weeks."
62094815|NCT06191536|ACTIVE_COMPARATOR|Pelvic Floor Exercise Group (PFEG)|"It consists of voluntary pelvic floor muscle contractions applied in addition to pilates exercises.~Pelvic floor muscle contractions involve maximum contraction of the pelvic floor muscles alternately for five repetitions during exhalation.~Pelvic floor exercises will be applied under the supervision of a pelvic floor certified physiotherapist.~In addition to pilates exercises, pelvic floor exercises will be applied 2 days a week, 50 minutes, for 8 weeks."
62094816|NCT04995562|EXPERIMENTAL|Oxygen with nasal cannula|6 infants on oxygen with nasal cannula
62292342|NCT00260208|ACTIVE_COMPARATOR|Cyclosporin A|"The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges.~Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:~* Steroids administered and tapered as per local practice~* interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by the center was to be given to all patients enrolled in the trial from this center."
62308069|NCT02441803|EXPERIMENTAL|Haploidentical Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100."
62465184|NCT01482377|EXPERIMENTAL|Imaging (IMG) Substudy|RO5479599 will be administered with zirconium- 89-labeled RO5479599.
62094817|NCT04995562|EXPERIMENTAL|HFNC, CPAP, or RAM cannula|6 infants currently requiring respiratory support with high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) or RAM cannula
62094818|NCT01570777|EXPERIMENTAL|Renal denervation|
62094819|NCT01570777|OTHER|optimized medication regimen|optimized medication regimen
62094820|NCT04727775||Complications|Evaluathion
62094821|NCT04727775||Oxygen status|Evaluathion
62094822|NCT04727775||Oxugen support|Evaluathion
62094823|NCT06091930|EXPERIMENTAL|Part I: BI 765049|BI 765049 monotherapy - dose escalation
62094824|NCT06091930|EXPERIMENTAL|Part II: BI 765049|BI 765049 monotherapy - dose expansion
62094825|NCT06091930|EXPERIMENTAL|Part III: BI 765049 + ezabenlimab|BI 765049 + ezabenlimab combination therapy - dose escalation
62094826|NCT06091930|EXPERIMENTAL|Part IV: BI 765049 + ezabenlimab|BI 765049 + ezabenlimab combination therapy - dose expansion
62094827|NCT04106440|EXPERIMENTAL|Application Use|Participants will be asked to use applications to track food intake, carbohydrate counts, insulin delivered, and blood sugar values and share the data with the study team.
62736816|NCT05087433|NO_INTERVENTION|Control Group|No intervention was applied to the control group during the study. However, after the research was completed, the video of the application of the progressive relaxation exercises to the control group was shared on the WhatsApp group.
61908128|NCT02847676||No previous surgery, no adhesions present.|Patients have had no previous abdominal surgery. Inspection shows no peritoneal adhesions.
61908129|NCT02847676||Previous surgery, adhesions present.|Patients have had previous abdominal surgery. Inspection shows peritoneal adhesions.
62094828|NCT04106440|NO_INTERVENTION|Standard of Care|The control group will receive usual care during their hospitalizations at the time of diabetes diagnosis, and during the time between hospital discharge and first visit to the UCD Pediatric Diabetes clinic.
62094829|NCT04982380|EXPERIMENTAL|Experimental group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
62094830|NCT04982380|PLACEBO_COMPARATOR|Control group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
62292343|NCT00260208|ACTIVE_COMPARATOR|Tacrolimus|"Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges.~Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:~* Steroids administered and tapered as per local practice~* interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by center was to be given to all patients enrolled in trial from this center."
62292344|NCT05163704|OTHER|MRI Dexmedetomidine sedation|"Drug used: Dexmedetomidine. Given in increments of 0.2 ml at the time with atomizer (MAD Nasal™, Wayne Pennsylvania). Administered by radiology staff.~Dose 1 of nasal dexmedetomidine: 4 mcg/kg max 200 mcg Dose 2 of nasal dexmedetomidine: 2 mcg/kg max 100 mcg"
62094831|NCT04545593|EXPERIMENTAL|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) consists of 10 sessions focused on mental health (PM) and 36 sessions focused on physical health (SB), along with a group maintenance component.
62292345|NCT03182738|EXPERIMENTAL|Intervention|VIP app that delivers HIV-related symptom strategies
62292346|NCT03182738|SHAM_COMPARATOR|Control|VIP app without HIV-related symptom strategies
62292347|NCT05146141|EXPERIMENTAL|Intervention Group|The participants will have to perform a bent-arm throw program 5 minutes before each training session
62292348|NCT05146141|SHAM_COMPARATOR|Control group|No intervention. They will perform their usual warm-up.
62292349|NCT04646148|ACTIVE_COMPARATOR|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
62292350|NCT04646148|ACTIVE_COMPARATOR|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
61908130|NCT02847676||Previous surgery, no adhesions present.|Patients have had previous abdominal surgery. Inspection shows no peritoneal adhesions.
62094832|NCT04545593|ACTIVE_COMPARATOR|Enhanced Usual Care|The Enhanced Usual Care condition includes written materials on depression and anxiety and 4 calls to participants over the course of 6 months to assess symptoms and safety.
61908131|NCT05579951|ACTIVE_COMPARATOR|Conventional|Total knee replacement with conventional instrumentation
61908132|NCT05579951|ACTIVE_COMPARATOR|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
61908133|NCT03365388|EXPERIMENTAL|Sodium Hyaluronate group|Treatment of periarthritis of shoulder with Sodium Hyaluronate
61908134|NCT03365388|ACTIVE_COMPARATOR|Aerzhi group|Treatment of periarthritis of shoulder with Aerzhi
62094833|NCT06483022|PLACEBO_COMPARATOR|Pre-intervention|In the pre-intervention sequence(s), birthing people at participating hospitals will experience treatment-as-usual.
62094834|NCT06483022|ACTIVE_COMPARATOR|Post-intervention|In the post-intervention sequence(s), birthing people at participating hospitals will experience treatment by health care teams that have undergone the Building Equitable Linkages With Interprofessional Education Valuing Everyone interprofessional education (BELIEVE IPE) training.
62094835|NCT06494072|EXPERIMENTAL|Short course antibiotic duration|The participants in this group will receive a total antibiotic course of 5 days including the number of days received during their hospital admission and following hospital admission combined.
62094836|NCT06494072|ACTIVE_COMPARATOR|Standard of care antibiotic duration|Participants will receive the standard-of-care antibiotic course in this group. That is, the duration of antibiotics will be decided by the primary treating physician in this group. The antibiotic course will include the number of days received during the participant's hospital admission and following hospital admission combined.
62292351|NCT04646148|ACTIVE_COMPARATOR|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES recieve prompting Text messages,
62465185|NCT05136183|NO_INTERVENTION|Standard of care|"Patients randomized to this arm are treated with standard of care for patients with septic shock, including~* Fluid resuscitation and vasoactive agents~* Hemodynamic monitoring in intensive care units~* Antibiotics and infection source control, when applicable~* Supportive therapies and devices, including mechanical ventilation and renal replacement therapy~* Immunoregulatory medications, including systemic corticosteroids~All treatment provided are according to treating physicians"
62292352|NCT04646148|ACTIVE_COMPARATOR|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages, and financial Incentives to attend yoga classes
62292353|NCT04646148|ACTIVE_COMPARATOR|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
62465186|NCT05136183|EXPERIMENTAL|Standard of care, with hemoperfusion with HA-330|Patients randomized to this arm are treated with standard of care for patients with septic shock as described for 'Standard of care' arm, along with hemoperfusion with HA-330 Disposable Hemoperfusion Cartridge, as detailed under 'Interventions'
62292354|NCT04646148|ACTIVE_COMPARATOR|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes and One-on-One individual sessions with a Yoga Instructor
62465187|NCT03593980|EXPERIMENTAL|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
62465188|NCT04738084|EXPERIMENTAL|Meru Health Program|The Meru Health Program (MHP) is a 12-week online mobile digital mental health clinic delivered via Smartphone app that includes components of several evidence-based treatments (Cognitive Behavioral Therapy, Behavioral Activation Therapy, Mindfulness Meditation) and also several promising therapies (heart rate variability-biofeedback \[HRVB\], nutritional psychiatry, sleep training) and a group support component that is overseen by a licensed clinical therapist.
62094837|NCT01245413|ACTIVE_COMPARATOR|SenSura Adhesive (device)|Sensura is a commercially available adhesive, that is designed to collect output from a stoma.
62292355|NCT04646148|ACTIVE_COMPARATOR|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages and One-on-One individual sessions with a Yoga Instructor
62292356|NCT04646148|ACTIVE_COMPARATOR|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive financial Incentives to attend yoga classes, prompting Text messages and One-on-One individual sessions with a Yoga Instructor
62292357|NCT04646148|ACTIVE_COMPARATOR|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos
62292358|NCT04646148|ACTIVE_COMPARATOR|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive financial Incentives to attend yoga classes and Personal Practice Videos
62292359|NCT04646148|ACTIVE_COMPARATOR|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos and prompting Text messages
62465189|NCT04738084|NO_INTERVENTION|Waitlist|12 week waitlist
62465190|NCT01641380|NO_INTERVENTION|Control|Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment.
62094838|NCT01245413|EXPERIMENTAL|Athena adhesive|Athena = new test adhesive. The Athena baseplate is intended for collecting output from a stoma.
62465191|NCT01641380|EXPERIMENTAL|Text Messaging Intervention|Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication.
62465192|NCT01544361|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
62465193|NCT01544361|EXPERIMENTAL|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 milligram per kilogram (mg/kg) intravenous infusion over at least 60 minutes on Day 1.
62094839|NCT01423357|EXPERIMENTAL|Condom distribution and peer education|Youth peer educators distribute condoms and conduct condom demonstration in venues where people meet new sexual partners, i.e. bars, night clubs, sherbeens, guest houses
62094840|NCT01423357|NO_INTERVENTION|Business as usual|
62292360|NCT04646148|ACTIVE_COMPARATOR|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages and financial Incentives to attend yoga classes
62465194|NCT01544361|EXPERIMENTAL|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
62465195|NCT01544361|EXPERIMENTAL|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
62094841|NCT03571594|EXPERIMENTAL|ONO-5788 Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
62094842|NCT03571594|PLACEBO_COMPARATOR|ONO-5788 Placebo Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
62658405|NCT04609696|EXPERIMENTAL|Part 2: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 2 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
62658406|NCT04609696|EXPERIMENTAL|Part 2: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fasted conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
62658407|NCT05322486||Primary tumour resection group.|Surgical resection of the primary tumour followed by chemotherapy +/- targeted therapy regime.
62658408|NCT05322486||Chemotherapy group.|Chemotherapy +/- targeted therapy alone.
62658409|NCT03881787|EXPERIMENTAL|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
62658410|NCT03881787|ACTIVE_COMPARATOR|Cetuximab|Cetuximab,Erbitux 250mg/m2 single administration
62658411|NCT03847207|EXPERIMENTAL|Part 1 Single Ascending Dose|Eight subjects in up to 8 cohorts will be dosed. A single subcutaneous injection of HTL0030310 or placebo will be administered. In each cohort, 6 subjects will receive HTL0030310 and 2 subjects will receive placebo.
62658412|NCT03847207|EXPERIMENTAL|Part 2 Pasireotide PD Assessment|Sixteen subjects in 2 cohorts (8 subjects per cohort) will be dosed on 4 occasions. Within each cohort, 4 subjects will be randomised to active dosing with CRH with desmopressin, GHRH and OGTT challenge and 4 subjects will be randomised to placebo dosing with CRH with desmopressin, GHRH and OGTT challenge.
62658413|NCT03847207|EXPERIMENTAL|Part 3 Proof of Pharmacological Effect|Up to 80 subjects in 4 cohorts (up to 20 subjects per cohort) will be dosed in up to 3 study periods. In each period, subjects will receive active drug or placebo with GHRH, OGTT and CRH with desmopressin (optional).
62658414|NCT05213130|EXPERIMENTAL|Information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., as well as a clear reminder to inform donors that their blood has saved patient's life.
62658415|NCT05213130|NO_INTERVENTION|Non-information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., but there will be no reminder to inform donors that their blood has saved patient's life.
62658416|NCT03533933|ACTIVE_COMPARATOR|Autologous connective tissue graft|Soft tissue harvesting from patient palate
62658417|NCT03533933|EXPERIMENTAL|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
62658418|NCT02729233|OTHER|patients receiving biopsies|UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE).
62094843|NCT03571594|EXPERIMENTAL|ONO-5788 Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
62094844|NCT03571594|PLACEBO_COMPARATOR|ONO-5788 Placebo Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
62658419|NCT05542602|EXPERIMENTAL|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff to children with hfASD as part of their existing after-school program.
62658420|NCT05542602|NO_INTERVENTION|No-treatment control|Children in the no-treatment control condition will receive no after-school social programming during the active social intervention study phase.
62658421|NCT05320471||healthy young adults|between 20-40 years
62094845|NCT03571594|EXPERIMENTAL|ONO-5788 Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
62465196|NCT01544361|EXPERIMENTAL|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
62658422|NCT05320471||healthy older adults|between 50-75 years
62658423|NCT03799471||IBD with MSK pain|IBD patients with self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, MSK pain features, co-morbidity, and IBD features
62658424|NCT03799471||IBD without MSK pain|IBD patients without self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, co-morbidity, and IBD features
62658425|NCT03799471||Healthy Controls|Healthy controls. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, and co-morbidity.
62658426|NCT05946733|EXPERIMENTAL|Group A|subcostal TAP block
62094846|NCT03571594|PLACEBO_COMPARATOR|ONO-5788 Placebo Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
62094847|NCT03571594|EXPERIMENTAL|ONO-5788 Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
62094848|NCT03571594|PLACEBO_COMPARATOR|ONO-5788 Placebo Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
62658427|NCT05946733|EXPERIMENTAL|Group B|lateral TAP block.
62658428|NCT05946733|OTHER|GroupC|will receive postoperative morphine by patient-controlled analgesia (PCA).
62658429|NCT00580281|EXPERIMENTAL|blood, urine, and dexa scan|This study will involve venipuncture for obtaining blood samples; a spot second void (whenever possible) urine sample will be obtained at the same time. A Dexa scan to evaluate bone density will be obtained at the beginning, middle and end of the study.
62094849|NCT03571594|EXPERIMENTAL|ONO-5788 Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
62094850|NCT03571594|PLACEBO_COMPARATOR|ONO-5788 Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
62292361|NCT04646148|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
62094851|NCT03571594|ACTIVE_COMPARATOR|Octreotide Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
62658430|NCT02452190|EXPERIMENTAL|Reslizumab|Reslizumab
62658431|NCT02452190|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62658432|NCT01583361|EXPERIMENTAL|Arm A:Neoadjuvant sox|Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.
62658433|NCT01583361|ACTIVE_COMPARATOR|Arm B:Adjuvant SOX|Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
62658434|NCT06485505|ACTIVE_COMPARATOR|Itraconazole|all patients will be prescribed Itraconazole in the dose of 200mg twice daily for 1 week per month, for 3 consecutive months after screening of complete blood count, liver, and renal function tests. patients were advised to record any side effects
62658435|NCT06485505|EXPERIMENTAL|Itraconazole + Low dose Isotretinoin|patients will be given low dose of isotretinoin as an adjuvant to itraconazole in the same previously mentioned protocol. Treatment protocol consists of low dose isotretinoin (20mg, every other day for pediatrics) for a 3- month course. After completion of the course, treating dose of isotretinoin was maintained for 4-6 weeks to prevent recurrence, and to improve healing. During treatment, an infrequent application of the previous therapies was permitted.
62658436|NCT06485505|EXPERIMENTAL|Itraconazole +Excimer light|will be treated with excimer light as an adjuvant to itraconazole in the same previously mentioned protocol. Nails will be treated with XeCl2 excimer light (Eximal Elite Device).
62658437|NCT05136638|ACTIVE_COMPARATOR|Digital Sleep Hygiene and Self-Monitoring Control|Participants assigned to this condition will receive an app to track sleep and offers sleep hygiene recommendations
62658438|NCT05136638|EXPERIMENTAL|dCBTi without coaching|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with no coaching support
62658439|NCT05136638|EXPERIMENTAL|dCBTi with virtual coaching|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with a virtual coach in the form of a text-based force-choice conversation coach. The virtual coach will check participants' understanding of the treatment materials and lead them to come up with action plans to implement CBTi strategies.
62658440|NCT05136638|EXPERIMENTAL|dCBTi with non-therapist coaching support|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with the virtual coach. They will get additional support from a non-therapist support person who provides support after modules 1, 3, and 6 to address any questions or concerns.
62658441|NCT05136638|EXPERIMENTAL|dCBTi with therapist coaching support|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with the virtual coach. They will get additional support from a clinical psychology trainee who provides therapeutic support that aims to enhance the usage of CBTi treatment strategies.
62658442|NCT05166096|EXPERIMENTAL|Rho-11 administered in Period 1, oral aspirin administered in Period 2|
62658443|NCT05166096|EXPERIMENTAL|Oral aspirin administered in Period 1, Rho-11 administered in Period 2|
62658444|NCT03479827||Experimental|Subjects will undergo three Wavefront measurements, once with no contact lens, once with a monofocal contact lens and once with a bifocal contact lens.
62658445|NCT02556788|EXPERIMENTAL|CD5789 (Trifarotene) 50µg/g Cream|CD5789 (trifarotene) 50µg/g Cream
62658446|NCT02556788|PLACEBO_COMPARATOR|Placebo Cream|Placebo Cream
62658447|NCT04412187|OTHER|TSPO PET imaging|All study participants will receive \[18F\]-GE-180, i.e. TSPO PET imaging to assess microglia activation.
62658448|NCT02748993|EXPERIMENTAL|PAC-14028 Cream 0.1%|PAC-14028 Cream 0.1%, Twice daily for 4 weeks
62658449|NCT02748993|EXPERIMENTAL|PAC-14028 Cream 0.3%|PAC-14028 Cream 0.3%, Twice daily for 4 weeks
62658450|NCT02748993|EXPERIMENTAL|PAC-14028 Cream 1.0%|PAC-14028 Cream 1.0%, Twice daily for 4 weeks
62658451|NCT02748993|PLACEBO_COMPARATOR|PAC-14028 Cream Vehicle|PAC-14028 Cream Vehicle, twice daily for 4 weeks
62292362|NCT04646148|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages but DOES receive financial Incentives to attend yoga classes, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
62465197|NCT02975141|EXPERIMENTAL|Afatinib 40Mg Tab, Gemzar, Abraxane +1|Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
62658452|NCT00683137|ACTIVE_COMPARATOR|Arm 1|
62658453|NCT00683137|ACTIVE_COMPARATOR|Arm 2|
62094852|NCT03676556|ACTIVE_COMPARATOR|Topical lidocaine|23 patients will recieve lidocaine solution before wound treatment
62094853|NCT03676556|PLACEBO_COMPARATOR|Saline serum|23 patients will recieve saline solution before wound treatment
62094854|NCT00301379||1|Patients with unresectable cholangiocarcinoma.
62094855|NCT03035240|EXPERIMENTAL|Financial Education Intervention|
62094856|NCT03035240|NO_INTERVENTION|No Financial Education Intervention|
62658454|NCT00683137|ACTIVE_COMPARATOR|Arm 3|
62658455|NCT00608179|EXPERIMENTAL|1|
62658456|NCT00608179|EXPERIMENTAL|2|
61908135|NCT05373056|ACTIVE_COMPARATOR|Group 1- Control group|They will performer the conventional exercise program por epicondylar muscles.
62658457|NCT00608179|EXPERIMENTAL|3|control-euglycemia
62658458|NCT00608179|EXPERIMENTAL|4|control-hypoglycemia
62094857|NCT01388543|ACTIVE_COMPARATOR|CYP3A5 Expressors|A pre-screening genetic test determines CYP3A5 expressor status
62094858|NCT01388543|ACTIVE_COMPARATOR|CYP3A5 Non-expressors|A pre-screening genetic test determines CYP3A5 non-expressor status
62094859|NCT06476899|EXPERIMENTAL|Fixed regimen|orelabrutinib + FCR/BR
62094860|NCT06476899|ACTIVE_COMPARATOR|Control|BTKi chosen by doctors
62094861|NCT06615024||Newborns who are delivered in NEW VALLEY GOVERNORATE|Screening of coexistence between sickle cell anaemia and G6PD deficiency
62094862|NCT05489861|EXPERIMENTAL|Experimental group A The Group to which the Mother Applies Affirmation and Massage|"15 minutes of affirmation and massage practices, 3 days a week for 5 weeks, will be taught.~Affirmation and massage practices will be shown once in the practice hall of the center as an example for the mother to apply to their baby.~Afterward, affirmation and massage applications will be applied by the mother and father at the baby's home.~Parents will be informed about the importance of having the same characteristics of the practice room for each application.~In addition, the massage video material will be given to the mother with an affirmation note as a reminder."
62465198|NCT02975141|EXPERIMENTAL|Afatinib 30Mg Tab, Gemzar, Abraxane 0|Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
62465199|NCT02975141|EXPERIMENTAL|Afatinib 30Mg Tab, Gemzar, Abraxane -1|Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA
62465200|NCT02975141|EXPERIMENTAL|Afatinib 30Mg Tab, Gemzar, Abraxane -2|Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA
62465201|NCT04000815|ACTIVE_COMPARATOR|Reproductive age women|The healthy women between 18-40 years old.
62094863|NCT05489861|EXPERIMENTAL|Experimental group B The Group to which the Father Applies Affirmation and Massage|"15 minutes of affirmation and massage practices, 3 days a week for 5 weeks, will be taught.~Affirmation and massage practices will be shown once in the practice hall of the center as an example for the father to apply to their baby.~Afterward, affirmation and massage applications will be applied by the mother and father at the baby's home.~Parents will be informed about the importance of having the same characteristics of the practice room for each application.~In addition, the massage video material will be given to the father with an affirmation note as a reminder."
62094864|NCT05489861|NO_INTERVENTION|Control Group (C)|Parents will be asked to continue the implementation of routine sleeping techniques without being taught any practices.
62094865|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
62292363|NCT04646148|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive prompting Text messages, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
62292364|NCT04646148|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
62292365|NCT06546033|EXPERIMENTAL|1. Group (intermittent fasting)|Time Restricted Diet (10.00-18.00)
62292366|NCT06546033|EXPERIMENTAL|2. Group (mediterranean diet)|Diet based on the consumption of plant foods, cereals, oilseeds, etc.
62292367|NCT03651843||Healthy subjects|
62465202|NCT04000815|ACTIVE_COMPARATOR|Perimenopausal women|The healthy women between 40-49 years old.
62465203|NCT04000815|ACTIVE_COMPARATOR|Postmenopausal women|The healthy women that has been in to menopause more than a year
62094866|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
62094867|NCT00889382|EXPERIMENTAL|Phase 1 Arm A|Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)
62292368|NCT04329026|EXPERIMENTAL|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
62292369|NCT04329026|PLACEBO_COMPARATOR|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
62292370|NCT01145560|EXPERIMENTAL|1|AZD9773 250/50 units/kg
62292371|NCT01145560|EXPERIMENTAL|2|AZD9773 500/100 units/kg
62292372|NCT01145560|PLACEBO_COMPARATOR|3|
62292373|NCT03254173|ACTIVE_COMPARATOR|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
62465204|NCT05240495|EXPERIMENTAL|Internet-based Cognitive-behavioural therapy group (n=61)|TThe generic iCBT program was based on contemporary CBT techniques adapted for stress-related disorders, and recovery from work training inspired by Hahn et al. \[2011\]. The iCBT consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week. In the first module (introduction), the participants received information about the outline of the program, stress physiology and defined individual treatment goals. During the second week participants were introduced to different recovery techniques and applied relaxation. The third and fourth week contained exercises related to behavioral activation, work-home balance, and values-based action skills. Between weeks five and ten, participants were able to choose between different exposure-based exercises. In addition, participants with insomnia could choose to focus on sleep management.
62658459|NCT02664493|EXPERIMENTAL|SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Methylprednisolone 0.5 g daily for 3 days will be administered in (Steroid pulse therapy) SPT group."
62292374|NCT03254173|PLACEBO_COMPARATOR|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
62292375|NCT02601573|EXPERIMENTAL|Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks|TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.
62292376|NCT02601573|EXPERIMENTAL|Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks|TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
62292377|NCT02601573|EXPERIMENTAL|Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
62094868|NCT00889382|EXPERIMENTAL|Phase 1 Arm B1|Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)
62094869|NCT00889382|EXPERIMENTAL|Phase 1 Arm B2|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)
62094870|NCT00889382|EXPERIMENTAL|Phase 1 Arm B3|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)
62094871|NCT00889382|EXPERIMENTAL|Phase 2 Arm A|Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15
62465205|NCT05240495|EXPERIMENTAL|Internet-based Work-focused Cognitive-behavioural therapy group (n=61)|The internet-based and work-focused cognitive-behavioral therapy (W-iCBT) consisted of the generic treatment for stress-related disorders (iCBT), plus components focusing on work and return-to-work. These sections were integrated and represented in each of the ten modules. Work-focused CBT is built on the same conceptual framework as regular CBT. For example, CBT principles are used to change the appraisal of work stressors, change the dysfunctional behaviour, or increase health promoting behaviours. The CBT principal, exposure, is given special attention. Gradual exposure can help individuals develop more effective coping skills when dealing with work-related stressors (e.g., assertiveness) and stimulate gradual return to the work setting for individuals on a long-term sick leave \[27\].
62658460|NCT02664493|NO_INTERVENTION|non-SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Steroid pulse therapy (SPT) will not be applied and no additional treatment will be added in non-SPT group"
62292378|NCT02601573|EXPERIMENTAL|Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.
62292379|NCT02601573|EXPERIMENTAL|Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.
62094872|NCT00889382|EXPERIMENTAL|Phase 2 Arm B|Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15
62094873|NCT00889382|EXPERIMENTAL|Phase 2 Arm C|Paclitaxel on Days 1, 8, and 15
62094874|NCT00889382|EXPERIMENTAL|Phase 2 Arm C Roll-over|Continuous OSI-906 BID from Day 1 onwards
62094875|NCT02391909||Group A|Vivotif 6.9-10.0 x109 CFU/capsule
62094876|NCT02391909||Group B|Vivotif 4.0-6.8 x109 CFU/capsule
62094877|NCT00498537|OTHER|1|
62292380|NCT03566212|EXPERIMENTAL|conventional syringe|Individuals requiring local anesthesia for dental treatment were treated in first group by using conventional syringe.
62292381|NCT03566212|EXPERIMENTAL|camouflaged syringe|Individuals requiring local anesthesia for dental treatment were treated in second group by using camouflage syringe.
62094878|NCT00498537|OTHER|2|
62094879|NCT02636413|EXPERIMENTAL|LacTEST|0,45 g of gaxilose po, once, per diagnostic test performed.
62094880|NCT02636413|ACTIVE_COMPARATOR|Hydrogen Breath Test|25 to 50 g of lactose po, once, per diagnostic test performed.
62094881|NCT06696378|EXPERIMENTAL|Melatonin supplementation group|2 capsules distributed in a single daily oral intake at 9 p.m. or 30 minutes before bedtime, whichever came first, for 10 weeks.
62292382|NCT05530096||MRD level group|Participants will be defined as diagnosed with multiple myeloma
62292383|NCT04856592|EXPERIMENTAL|VICI Stent|
62292384|NCT04235387||Robotic prostatectomy|All patients undergoing robotic assisted prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
62292385|NCT04235387||Laparoscopic prostatectomy|All patients undergoing standard laparoscopic prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
62292386|NCT04572009|EXPERIMENTAL|Augmented physician|Medical decision assisted by the bio-mathematical model to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
62292387|NCT04572009|PLACEBO_COMPARATOR|Control|Unassisted medical decision to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
62292388|NCT05390216|EXPERIMENTAL|Partial capsule decortication|
62292389|NCT05390216|NO_INTERVENTION|Without partial capsule decortication|
62292390|NCT01431287|EXPERIMENTAL|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
62292391|NCT01431287|EXPERIMENTAL|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
62292392|NCT01431287|ACTIVE_COMPARATOR|olodaterol|Once daily 2 puffs solution for inhalation Respimat
62292393|NCT01431287|ACTIVE_COMPARATOR|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
62292394|NCT01431287|ACTIVE_COMPARATOR|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
62292395|NCT00793793|EXPERIMENTAL|20mg|patient to receive 20mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
62292396|NCT00793793|EXPERIMENTAL|48mg|patient to receive 48mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
62292397|NCT00793793|EXPERIMENTAL|120mg|patient to receive 120mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
62292398|NCT00793793|EXPERIMENTAL|240mg|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
62292399|NCT00793793|PLACEBO_COMPARATOR|Placebo|
62658461|NCT05255822|EXPERIMENTAL|INNA-051 arm 1|INNA-051 intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge
62658462|NCT05255822|EXPERIMENTAL|INNA-051 arm 2|NNA-051 intranasal spray high dose administered once on each of Days -4 and -2 prior to viral challenge
62658463|NCT05255822|PLACEBO_COMPARATOR|Placebo|Placebo intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge
62658464|NCT03061942|ACTIVE_COMPARATOR|Conventional|Arthroscopic rotator cuff repair without synovectomy
62465206|NCT05240495|NO_INTERVENTION|Wait-list control group (n=60)|Wait-list control group received equal and parallell assessment and eligibility procedure as the two experimental konditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
62094882|NCT06696378|PLACEBO_COMPARATOR|Placebo supplementation group|2 capsules distributed in a single daily oral intake at 9 p.m. or 30 minutes before bedtime, whichever came first, for 10 weeks.
62292400|NCT01148173|EXPERIMENTAL|Systemic and intrathecal chemotherapy|
62292401|NCT06330909|EXPERIMENTAL|Arm A - IMRT/IGRT/SBRT|"Prostate and seminal vesicles RT with 30 Gy in 6 Gy / fraction; prostate RT with 35 Gy in 7 Gy / fraction including a simultaneous integrated boost (SIB) on the intraprostatic tumour mass (ITM) with 40- 42 Gy in 8 - 8.4 Gy / fraction.~If the boost volume is ≥10 ml and/ or ≥ 1/3 of the prostate, the SIB on the ITM has to be restrained to 40 Gy in 8 Gy / fraction. SBRT will be performed twice a week, with at least 2 days between two RT fractions, 5 fractions in 3 weeks (technique: IMRT/IGRT/SBRT)."
62292402|NCT06330909|ACTIVE_COMPARATOR|Arm B - IMRT/IGRT|Prostate and seminal vesicles RT with 46.4 Gy in 2.32 Gy per fraction, prostate RT with 60 and 62 Gy in 3 and 3.1 Gy per fraction for unfavorable intermediate-risk and high-risk patients, respectively, 20 fractions, 5 fractions /week, (technique: IMRT/IGRT).
62292403|NCT01948492|EXPERIMENTAL|protein|varying protein intake in random order from deficient to excess
62292404|NCT04178148|EXPERIMENTAL|BestDose|Therapeutic drug optimization of amikacin using the BestDose software algorithm
62292405|NCT04178148|NO_INTERVENTION|Control|
62292406|NCT00663000||acromegalics|"1. Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to \< 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).~2. Written informed consent"
62465207|NCT01292720|PLACEBO_COMPARATOR|Placebo|Placebo (herbal oil)
62465208|NCT01292720|EXPERIMENTAL|Vitamin D|
62465209|NCT05651230|EXPERIMENTAL|Rhamnan sulfate|The subjects will take rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.
61908136|NCT05373056|EXPERIMENTAL|Group 2 - Experimental group|The experimental group will perform the conventional exercise program and also a scapular exercise program.
62094883|NCT02179645|EXPERIMENTAL|GRC 27864|Test Treatment GRC 27864
62094884|NCT02179645|ACTIVE_COMPARATOR|Celecoxib|Active Comparator Treatment
62094885|NCT02179645|PLACEBO_COMPARATOR|Placebo|Placebo Treatment
62292407|NCT01091961|ACTIVE_COMPARATOR|Continuing ACEi/ARB|Patients in this group will continue to take their chronic ACEi/ARB medications up to and including the day of surgery.
62292408|NCT01091961|ACTIVE_COMPARATOR|Holding ACEi/ARB|Patients in this arm will hold their chronic ACEi/ARB medication at least 24 hours prior to surgery.
62292409|NCT02734173|ACTIVE_COMPARATOR|Genotype 1a Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1a-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
62292410|NCT02734173|ACTIVE_COMPARATOR|Genotype 1b Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy without ribavirin
62292411|NCT02734173|ACTIVE_COMPARATOR|Genotype 1a/1b Compensated Cirrhotic Arm|• 8 compensated cirrhotic genotype 1a or 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
62292412|NCT01910792|ACTIVE_COMPARATOR|Group 2|Patients who have had gastric bypass surgery will be exposed to a Sperti Lamp 3x/week
62292413|NCT01910792|ACTIVE_COMPARATOR|Group 1|Patients with fat malabsorption syndromes will be exposed to a Sperti Lamp 3x/week
62465210|NCT05651230|PLACEBO_COMPARATOR|Placebo|The subjects will take placebo (Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.
62465211|NCT00086996|EXPERIMENTAL|Chemo Plus RT, Surgery, Chemo|neoadjuvant fluorouracil, oxaliplatin and radiation therapy followed by conventional surgery and adjuvant fluoruracil and oxaliplatin
62465212|NCT01591785|ACTIVE_COMPARATOR|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
62465213|NCT01591785|PLACEBO_COMPARATOR|Placebo ointment|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
62465214|NCT02616809|EXPERIMENTAL|Sitting|Participants will sit continuously for 8 hours in a simulated office environment
62658465|NCT03061942|EXPERIMENTAL|Synovectomy|Arthroscopic rotator cuff repair with synovectomy
62465215|NCT02616809|EXPERIMENTAL|slow cycling|Participants will cycle at regular hourly intervals during an 8-hr simulated office environment
62465216|NCT02616809|EXPERIMENTAL|standing|Participants will change posture (from sitting to standing) during hourly intervals for an 8-hr period in a simulated office environment
62465217|NCT02616809|EXPERIMENTAL|slow walking|Participants will transition from sitting to slow walking on a treadmill desk at regular hourly intervals during an 8-hr period in a simulated office environment
62465218|NCT02678286|EXPERIMENTAL|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
62465219|NCT02678286|PLACEBO_COMPARATOR|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
62465220|NCT00359905|EXPERIMENTAL|Silodosin|
62465221|NCT00359905|ACTIVE_COMPARATOR|Tamsulosin|
62465222|NCT00359905|PLACEBO_COMPARATOR|Placebo|
62465223|NCT02696694||P25-P75|serum progesterone between 25 and 75 percentile
62658466|NCT03600350|EXPERIMENTAL|Treatment Group|"* Nivolumab 240 mg IV every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~* pTVG-HP (100 µg) administered intradermally (i.d.) every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~* rhGM-CSF (208 µg) administered intradermally (i.d.) every two weeks x 4 beginning week 4, then every four weeks x 9 beginning week 12 NOTE: Only administered to patients for whom serum PSA obtained week 4 \> serum PSA obtained at day 1."
62292414|NCT02033356|EXPERIMENTAL|ACB with 30 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
62292415|NCT02033356|EXPERIMENTAL|ACB with 25 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
62292416|NCT02033356|EXPERIMENTAL|ACB with 20 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
62292417|NCT02033356|EXPERIMENTAL|ACB with 15 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
62292418|NCT02033356|EXPERIMENTAL|ACB with 10 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
62465224|NCT02696694||<P25 ó >P75|serum progesterone \<25 or \>75 percentile
62465225|NCT03020641|EXPERIMENTAL|Low pneumoperitoneum pressure.|Pneumoperitoneum pressure at 8 mmHg or lower.
62465226|NCT03020641|ACTIVE_COMPARATOR|standard pneumoperitoneum pressure|Pneumoperitoneum pressure at 12 mmHG or higher
62465227|NCT02722980|PLACEBO_COMPARATOR|Placebo|Capsules
62465228|NCT02722980|ACTIVE_COMPARATOR|Active|Capsules.
62465229|NCT00003528|EXPERIMENTAL|Arm I|Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.
62465230|NCT04836078|PLACEBO_COMPARATOR|Plain chitosan gel group|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement . Randomization will be performed and concealment from the assessors. For root conditioning purpose, Group (I) ; will be injected subgingivally with chitosan 2% gel .
62465231|NCT04836078|ACTIVE_COMPARATOR|Chitosan gels containing free Simvastatin|Will be injected subgingivally with simvastatin microsponges dispersed into chitosan 2% gel. .
62465232|NCT04836078|EXPERIMENTAL|Chitosan gels containing Simvastatin microsponges|This group will be injected subgingivally with free simvastatin dispersed into chitosan 2% gel containing .
62465233|NCT02263092|EXPERIMENTAL|15 minutes of physical exercise|the subjects will do physical exercise on a treadmill with 64 to 74% of maxHR
62465234|NCT02263092|EXPERIMENTAL|10 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 77 to 95% of maxHR.
62465235|NCT02263092|EXPERIMENTAL|30 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 57 to 63% of maxHR.
62465236|NCT02263092|EXPERIMENTAL|Rest/control|the subjects will be on 15 or 30 minutes seat without move the legs.
62658467|NCT00563173|OTHER|1|Low dose
62658468|NCT00563173|OTHER|2|Medium dose
62094886|NCT04404140|EXPERIMENTAL|Ipatasertib + Atezolizumab + Docetaxel|"Part A (Safety Run-In): 12 Participants will be administered Ipatasertib orally once a day \[QD\] from Day 1 to Day 14 in combination with Atezolizumab administered by intravenous (IV infusion) every 3 weeks (Q3W) on Day 1 of each cycle (a cycle being 21 days) and Docetaxel administered by IV infusion (Q3W) on Day 1 of each cycle. Docetaxel will be administered for a maximum of 10 cycles (approximately 7 months), after which Atezolizumab and Ipatasertib will be administered as a doublet until disease progression. During Part A, a staggered recruitment will be applied to the first and potentially first 6 participants to enrol a participant only once the former one has safely overcome the safety time window (Cycle 1).~Part B (Expansion): 38 Participants will be administered Ipatasertib, Atezolizumab and Docetaxel as described above, though without a staggered enrolment or safety assessment window."
62292419|NCT02033356|EXPERIMENTAL|ACB with 5 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
62292420|NCT02684071|EXPERIMENTAL|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
62292421|NCT02087332|EXPERIMENTAL|Prolonged release Torasemide (Britomar)|"Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and excipients - guar gum, maize starch, anhydrous colloidal silica, magnesium stearate, lactose.~Dosage scheme: per os, once a day, regardless of meals. The common starting dose in CHF - 10-20 mg once a day. If adequate diuretic effect is absent, the dose is increased approximately twofold up to adequate diuretic effect."
62292422|NCT02087332|ACTIVE_COMPARATOR|Torasemide (Diuver)|Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch, sodium glycolate starch, anhydrous colloidal silica, magnesium stearate. Dosage scheme: per os, once a day, after meals. Therapeutic dose - 5 mg a day. If necessary, a dose may be increased up to 20 mg a day, in some cases - up to 40 mg.
62465237|NCT02263092|EXPERIMENTAL|Anodal tDCS + physical exercise 1|the subjects will be undergo to anodal tDCS + physical exercise 1
62658469|NCT00563173|OTHER|3|High dose
61908137|NCT01606215|EXPERIMENTAL|mesenchymal stem cells|1-2 x106 MSCs/kg administered at Week 0
61908138|NCT01606215|SHAM_COMPARATOR|Placebo|Suspension media administered at Week 0
61908139|NCT01008241||Study Group|Convenience sample of adult residents of South Florida
61908140|NCT02929498|EXPERIMENTAL|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
62094887|NCT06187974||Study group|stroke patients
62292423|NCT05173129|EXPERIMENTAL|Haemophilic boys|Adolescent boys with haemophilia
62292424|NCT05173129|ACTIVE_COMPARATOR|Healthy boys|Healthy adolescent boys
62465238|NCT02263092|EXPERIMENTAL|Anodal tDCS + physical exercise 2|the subjects will be undergo to anodal tDCS + physical exercise 2
62658470|NCT03604003|EXPERIMENTAL|bedtime dosing ARB for hypertension|bedtime administration of potassium losartan has benefit for the isolated nocturnal hypertension
62658471|NCT03604003|EXPERIMENTAL|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
62094888|NCT06187974||Control group|healthy volunteers
62094889|NCT00341276||1|First, several hundred cases of esophageal cancer and gastric cancer (both cardia and body) ascertained in Taiyuan at the Shanxi Cancer Hospital.
62094890|NCT02862418||Pulmonary disease|UTE MRI
62292425|NCT02487875|EXPERIMENTAL|COPD patients -study group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme. The study group performs in addition to the standard programme, also a peripheric muscle strength training
62292426|NCT02487875|ACTIVE_COMPARATOR|COPD patients -control group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme
62658472|NCT00008697|EXPERIMENTAL|Phase 1|"Cohort 1 Arsenic trioxide = 0.1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 2 Arsenic trioxide = 0.15 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 3 Arsenic trioxide = 0.20 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 4 Arsenic trioxide = 0.25 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 5 Arsenic trioxide = 0.30 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)"
62094891|NCT02862418||Control|UTE MRI
62094892|NCT01952171||Congenital Heart Disease|Congenital Heart Disease
62094893|NCT01349855|EXPERIMENTAL|Cohort 1|Dose Level 1
62094894|NCT01349855|EXPERIMENTAL|Cohort 2|Dose Level 2
62658473|NCT00008697|EXPERIMENTAL|Phase 2|Arsenic trioxide = MTD found in Phase 1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
62658474|NCT02272270|EXPERIMENTAL|Treatment with Study Agent Combination|"Radiation Therapy 2.0GyX30fx, 5 days per week for a total of 60 Gy Temozolomide 75mg/m2 daily throughout radiation Minocycline begins one week prior to chemoradiation, and continues twice a day throughout radiation Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID~Followed by 28 day break followed by~Temozolomide 150-200mg/m2 on days 1-5 out of 28 for up to12 cycles~Minocycline taken twice a day throughout each 28 day cycle for up to 12 cycles:~Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID"
62658475|NCT03704077|EXPERIMENTAL|Cohort A: relatlimab + nivolumab + paclitaxel|
62094895|NCT06087692|OTHER|Aerobic Exercise|Patients in the aerobic exercise group will be included a medium intensity (%40-60 of the maximum heart rate or 4-6 intensity according to the Modified Borg Scala) aerobic exercise program with a horizontal bicycle ergometer, 2 days a week for 8 weeks, lasting an average of 30 minutes, accompanied by a physiotherapist.
62094896|NCT06087692|OTHER|Nintendo +aerobic exercise|Nintendo group will be included a medium intensity (40-60% of the maximum heart rate or 4-6 intensity according to the Modified Borg scale) aerobic exercise program with a horizontal bicycle ergometer 2 days a week for 8 weeks, lasting an average of 30 minutes, accompanied by a physiotherapist, and then they will be included in ''Wii Fit'' exercise program an average of 30 minutes.
62094897|NCT06087692|OTHER|Control|Physical activity recommendation and respiratory exercises
62094898|NCT06339918|EXPERIMENTAL|Kegel Exercise with4-7-8 Breathing technique group:|GroupAwill be given the intervention of kegel exercises as well as 4-7-8 breathing techniques for about 15 minutes per session for a total of 8 weeks with 4 sessions per week. To perform kegel exercises, tighten pelvic floor muscles like trying to hold in urine and stool. 4-7-8 breathing Technique can be performed by telling the participant to inhale to the count of 4. Hold their breath for 7 counts. To the count of 8, release air via their mouth.
62094899|NCT06339918|ACTIVE_COMPARATOR|4-7-8 Breathing Technique group|In this group, we only perform the 4-7-8 Breathing Technique by telling the participant to inhale to the count of 4. Hold their breath for 7 counts. To the count of 8, release air via their mouth.
62094900|NCT00335153|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances."
62094901|NCT03675711|ACTIVE_COMPARATOR|Midline Catheter|Pt. will receive midline catheters.
62292427|NCT00981526|EXPERIMENTAL|A: Telmisartan|(existing Clozapine or Olanzapine treatment) + (Telmisartan)
62292428|NCT00981526|PLACEBO_COMPARATOR|B: Placebo|(existing Clozapine or Olanzapine treatment) + (Placebo)
62465239|NCT02263092|EXPERIMENTAL|Cathodal tDCS + physical exercise 1|the subjects will be undergo to cathodal tDCS + physical exercise 1
62465240|NCT02263092|EXPERIMENTAL|Cathodal tDCS + physical exercise 2|- the subjects will be undergo to cathodal tDCS + physical exercise 2
62465241|NCT02263092|EXPERIMENTAL|Sham tDCS + physical exercise 1|the subjects will be undergo to sham tDCS + physical exercise 1
62658476|NCT03704077|EXPERIMENTAL|Cohort A: nivolumab + paclitaxel|
62658477|NCT03704077|ACTIVE_COMPARATOR|Cohort A: ramucirumab + paclitaxel|Standard-of-care
62658478|NCT03704077|EXPERIMENTAL|Cohort B: relatlimab + nivolumab|
62658479|NCT03704077|ACTIVE_COMPARATOR|Cohort B: nivolumab|Standard-of-care
62658480|NCT03704077|EXPERIMENTAL|Cohort C: relatlimab + nivolumab|
62094902|NCT03675711|ACTIVE_COMPARATOR|Standard Peripheral venous Catheter|Pt. will receive a standard Peripheral venous catheter
62094903|NCT06698237|EXPERIMENTAL|CWI_0|immediate cold-water immersion
62094904|NCT06698237|EXPERIMENTAL|CWI_3|3 hour delayed cold water immersion
62094905|NCT06698237|ACTIVE_COMPARATOR|THERM|immediate thermoneutral water immersion
62094906|NCT03289455|EXPERIMENTAL|AUTO3|Paediatric patients with relapse or refractory B-cell ALL
62292429|NCT01136551|ACTIVE_COMPARATOR|IR formulation|Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)
62292430|NCT01136551|EXPERIMENTAL|CR 1|"CR formulation~Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)"
62465242|NCT02263092|EXPERIMENTAL|Sham tDCS + physical exercise 2|the subjects will be undergo to sham tDCS + physical exercise 2
62465243|NCT03123471|EXPERIMENTAL|Apremilast 30 mg BID|Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
62465244|NCT03123471|PLACEBO_COMPARATOR|Placebo|Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
62465245|NCT01135797||Patients from phase I-II studies|
61908141|NCT02929498|EXPERIMENTAL|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
61908142|NCT06405971|EXPERIMENTAL|Drug Group|Patients in the drug group were given one oral tablet of metformin hydrochloride enteric capsule each day after breakfast and dinner at a dose of 250 mg per tablet.
62094907|NCT06420167|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg orally, daily for 6 months
62292431|NCT01136551|EXPERIMENTAL|CR 2|"CR formulation~Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)"
62465246|NCT02778165|NO_INTERVENTION|Usual Care|Patients receiving usual care are typically referred to CR at the time of discharge from the acute care center via paper or electronic systematic referral (completed by a physician or nurse practitioner). Additionally, a conversation with the patient regarding CR by a healthcare provider may occur, however this communication is not always a consistent occurrence. Once referred, patients will await contact from a CR program in their region/area and if actual program enrollment occurs, this usually happens between 8 to 10 weeks post discharge.
62465247|NCT02778165|EXPERIMENTAL|MyCaRe Android Application|The MyCaRe mobile application (education and symptom monitoring which includes pain, mood scales, wound monitoring) and Fitbit accelerometer (steps walked, distance) will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit Inspire 2 before leaving hospital. They will be asked to input data (pain, mood, wounds, activity, blood sugar, blood pressure) daily if possible in first 2 weeks and once weekly thereafter until 6 to 8 weeks or until entry to a cardiac rehabilitation program.
62465248|NCT03101995|EXPERIMENTAL|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
62465249|NCT04769648|PLACEBO_COMPARATOR|Vehicle|
62465250|NCT04769648|EXPERIMENTAL|Pro-ocular™ Topical Gel 1%|
62465251|NCT01333332|EXPERIMENTAL|Capecitabine, Radiation|
62658481|NCT03111433|EXPERIMENTAL|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
62094908|NCT06693999|OTHER|Adult stroke Survivors|This arm consists of stroke survivors with specified inclusion/exclusion criteria who will receive goal reminders and motivational, in addition to coping messages through Google Pixel Watches.
62465252|NCT01807793|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducation will include attending individual and group sessions.
62465253|NCT01807793|NO_INTERVENTION|Care as usual|Receive care as usual
62465254|NCT00857623|EXPERIMENTAL|1|
62465255|NCT00857623|PLACEBO_COMPARATOR|2|
62658482|NCT03111433|ACTIVE_COMPARATOR|Group II|this group of patients will receive their standard insulin treatment only
62658483|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
61908143|NCT06405971|PLACEBO_COMPARATOR|Placebo group|Patients in the placebo group were given one oral tablet of placebo (capsule filled with corn starch) each day after breakfast and dinner at a dose of 250 mg per tablet.
61908144|NCT01947062|ACTIVE_COMPARATOR|Standard intravenous chemotherapy|Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
61908145|NCT01947062|EXPERIMENTAL|Intravenous with metronomic chemotherapy|Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
62094909|NCT06157892|EXPERIMENTAL|Dose Escalation - Previously treated advanced GC/GEJC or breast cancer|disitamab vedotin + tucatinib
62094910|NCT06157892|EXPERIMENTAL|Cohort A monotherapy - HER2-low 2L or 3L breast cancer|disitamab vedotin monotherapy
62094911|NCT06157892|EXPERIMENTAL|Cohort A - HER2-low 2L or 3L breast cancer|disitamab vedotin + tucatinib
62094912|NCT06157892|EXPERIMENTAL|Cohort B monotherapy - HER2+ 3L or higher breast cancer|disitamab vedotin monotherapy
62292432|NCT05379751|EXPERIMENTAL|Patients diagnosed with Spigelian hernia who underwent prosthetic repair with the tentacle mesh|Patients diagnosed with Spigelian hernia who underwent prosthetic repair with the tentacle mesh Freedom Octomesh VHR XS
62292433|NCT02416869|ACTIVE_COMPARATOR|Intramuscular application|Intramuscular application of 4mg Dexamethasone
62292434|NCT02416869|EXPERIMENTAL|Submucosal application|Submucosal application of 4mg Dexamethasone
62292435|NCT02416869|ACTIVE_COMPARATOR|4mg Dexamethasone submucosal|4mg Dexamethasone submucosal application
62292436|NCT02416869|EXPERIMENTAL|8mg Dexamethasone submucosal|8mg Dexamethasone submucosal application
62292437|NCT02416869|ACTIVE_COMPARATOR|4mg Dexamethasone postoperative|4mg Dexamethasone postoperative application
62292438|NCT02416869|EXPERIMENTAL|4mg Dexamethasone preoperative|4mg Dexamethasone postoperative application
62292439|NCT05946967|ACTIVE_COMPARATOR|Biofeedback with TENS|Patients with constipation will undergo biofeedback treatment along with transcutaneous electrical stimulation (TENS)
62292440|NCT05946967|SHAM_COMPARATOR|Biofeedback only|Patients with constipation will undergo biofeedback treatment only
62658484|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
62658485|NCT02103842|EXPERIMENTAL|Omega-3 fatty acids|Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months
62658486|NCT06491758|EXPERIMENTAL|Total of 40 gastroparetic patients will be enrolled with diabetic and idiopathic patients.|"Investigators propose to study the effect on gastric hormone before, during and after auricular stimulation.~The proposal is to enroll 30 healthy volunteers with no gastric symptoms to undergo transcutaneous stimulation of the auricular branch of the vagus nerve and also undergo blood draw before, after stimulation and later a third draw after a period of no stimulation.~This is based upon the results obtained in our previous IRB approved study where blood was drawn in patients who had gastric electrical stimulation device implanted. Blood was drawn to study the effects of stimulation on gastric hormones. (Cardiac Vagal Effects of Gastric Electrical Stimulation and Vagal Nerve Action Potentials in Vagus nerve in Patients with Gastroparesis- IRB 1206008988)"
62094913|NCT06157892|EXPERIMENTAL|Cohort B - HER2+ 3L or higher breast cancer|disitamab vedotin + tucatinib
62094914|NCT06157892|EXPERIMENTAL|Cohort C monotherapy - HER2-low 2L GC/GEJC|disitamab vedotin monotherapy
62094915|NCT06157892|EXPERIMENTAL|Cohort C - HER2-low 2L GC/GEJC|disitamab vedotin + tucatinib
62094916|NCT00002784|ACTIVE_COMPARATOR|Standard chemotherapy|EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.
62094917|NCT00002784|EXPERIMENTAL|Dose-intensive EC|High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.
62094918|NCT06678789|EXPERIMENTAL|High Nicotine|High dosage nicotine pouches (6mg)
62465256|NCT04857697|EXPERIMENTAL|Supportive care (biospecimen collection, probiotic)|Patients undergo collection of blood samples at baseline and time of surgery, and collection of stool samples at baseline and after completion of probiotic regimen. Patients receive probiotics PO once on day 1, and then BID or TID for 2-4 weeks before standard of care surgery. Patients also undergo collection of tissue samples during standard of care surgery.
62292441|NCT02735213|EXPERIMENTAL|577-MPL|"577nm subthreshold micropulse laser(577-MPL) will be performed on the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein. Multiple laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT\>= 250um."
62292442|NCT02735213|ACTIVE_COMPARATOR|TLT|"Traditional laser will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT\>= 250um."
62465257|NCT01979341|ACTIVE_COMPARATOR|Dual trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)
62658487|NCT06491758|EXPERIMENTAL|Insulin, Glucose and C-peptide Blood Draw Group of Gastroparetic Patients|This arm part is also to enroll 40 gastroparetic subjects to undergo blood draw before, after transcutaneous stimulation of the auricular branch of the vagus nerve, and a third draw after a period of no stimulation. Blood Draws are to obtain levels of Insulin, Glucose, and C-peptide for: baseline, Experimental and Recovery.
62658488|NCT06491758|EXPERIMENTAL|GP subjects undergo vagal maneuver including food study with the bipolar EKG|This portion is to see if there is an effect on the stomach emptying after vagal nerve stimulation in Gastroparetic (GP)
62465258|NCT01979341|ACTIVE_COMPARATOR|hCG trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)
62292443|NCT01193686|EXPERIMENTAL|Peer Visitation Training (Peer Mentor)|Veteran Peer Visitors participated in a 2-day training program and then provide at 1-5 visits to at least 2 recipients.
62465259|NCT01979341|ACTIVE_COMPARATOR|agonist trigger|final oocyte maturation trigger using 0.2mg triptorelin acetate (GnRH agonist)
62465260|NCT02865356|EXPERIMENTAL|Cyclosporine 5% Solution|"SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
62465261|NCT02865356|PLACEBO_COMPARATOR|Placebo|"SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
62658489|NCT06491758|EXPERIMENTAL|25 subjects Healthy Subjects, but have undergone VNS Therapy|This portion is to see if there is an effect on the stomach emptying after vagal nerve stimulation (VNS) Therapy, for the treatment of partial or focal seizures will be recruited for the study.
62658490|NCT06491758|EXPERIMENTAL|The PENFS-percutaneous electrical field stimulation arm|Using percutaneous electrical field stimulation (PENFS) on vagal nerve in healthy volunteers and study the effect on the compound actions, parasympathetic and sympathetic vagal nerve activity and gastric myoelectrical (EGG) activity. A total of 24 healthy volunteers will be enrolled in this pilot study.
62658491|NCT06491758|EXPERIMENTAL|EDS- Ehlers Danlos Syndrome Arm|The PI and the research team would like to recruit subjects that have both the diagnosis of gastroparesis and EDS or EDS only to further study the effect of the stimulation on the heart rate variability. A total of 60 subjects will be enrolled. The next phase of the study would like to study the autonomic responses for EDS patients and matched controls using wearable watch device and transcutaneous stimulation of the auricular branch of the vagal nerve stimulation (TaVNS).
62658492|NCT00699751|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
62658493|NCT00699751|PLACEBO_COMPARATOR|Placebo|Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
62658494|NCT04081181|EXPERIMENTAL|CT_ guided percutaneous microwave ablation|The procedure will be done under anaesthesia by interventional radiologist
62292444|NCT01193686|EXPERIMENTAL|Peer Visitation|Veterans who received at least one visit from a Veteran Peer Visitor.
62658495|NCT01270659|EXPERIMENTAL|Low-FBT|Subject will receive FBT and placebo at a low dose
62658496|NCT01270659|EXPERIMENTAL|High-FBT|Subject will receive the high dose regimen of FBT and a high dose placebo
62658497|NCT01270659|ACTIVE_COMPARATOR|Low control|"Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl placebo"
62658498|NCT01270659|ACTIVE_COMPARATOR|High control|"Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl placebo"
62658499|NCT00977418|NO_INTERVENTION|No intervention|Seniors undergo all testing but remain current lifestyle
62658500|NCT00977418|EXPERIMENTAL|Training|Groups will undergo either physical or mental training. Physical training is 1 hour aerobic training 3 times per week for 12 weeks. Mental training is 1 hour Strategic Memory Advanced Reasoning Training 3 times per week.
62658501|NCT03436719|EXPERIMENTAL|Oral with Intravenous|Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
62658502|NCT03436719|ACTIVE_COMPARATOR|Intravenous|Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
62658503|NCT00025467|EXPERIMENTAL|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62658504|NCT02886351|EXPERIMENTAL|nitrous oxide|Administration of high concentration of nitrous oxygen in pediatric dentistry
62658505|NCT03175939|EXPERIMENTAL|CCRT alone|External beam radiotherapy \> 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
62292445|NCT05863715|EXPERIMENTAL|Within-subjects Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
62658506|NCT01604668||RevF vs RevG vs Pronto-7|Comparison of hemoglobin levels derived by continuous hemoglobin sensor RevF versus continuous hemoglobin sensor RevG versus an intermittent hemoglobin level derived from the Pronto-7 hand-held device versus a hemoglobin derived from a blood sample.
62658507|NCT06515353||GI Bleeding|"Patients administered to emergency department with GI bleeding will be scrrened and obtained retrospectively from hospital system.~Atmospheric pressure data will be obtained from Meteorology Directorate. Patients' data will be evaluated according to atmospheric pressure values."
62292446|NCT00127127|EXPERIMENTAL|Vorinostat 100 mg|During Cycle 1, participants receive a single oral dose of vorinostat 100 mg on Day 1 in a fasted state, Day 3 in a fed state, and Day 19 in a fed state. On Days 5-18, participants receive vorinostat 100 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
62094919|NCT06678789|EXPERIMENTAL|Low Nicotine|Low dosage nicotine pouches (3mg)
62094920|NCT00827944|ACTIVE_COMPARATOR|1|Parietex ProGrip
62292447|NCT00127127|EXPERIMENTAL|Vorinostat 200 mg|During Cycle 1, participants receive a single oral dose of vorinostat 200 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive vorinostat 200 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
62292448|NCT00127127|EXPERIMENTAL|Vorinostat 400 mg|During Cycle 1, participants receive a single oral dose of vorinostat 400 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 400 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
62292449|NCT00127127|EXPERIMENTAL|Vorinostat 500 mg|During Cycle 1, participants receive a single oral dose of vorinostat 500 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 500 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy on the Cycle 2 and subsequent cycles.(Each cycle will be 26 days.)
62292450|NCT02162862|OTHER|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
62292451|NCT02162862|OTHER|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
62292452|NCT02162862|NO_INTERVENTION|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
62292453|NCT01898156|EXPERIMENTAL|BIW-8962|"Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur~Phase 2 - Recommended dose determined in Phase 1"
62658508|NCT01680263|EXPERIMENTAL|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1 week interval"
62658509|NCT01680263|ACTIVE_COMPARATOR|NSAIDs/Physical therapy|treatment was done with NSAIDs and 10 sessions of daily physical therapy.
62658510|NCT02590783|EXPERIMENTAL|experimental intervention surgery|screw osteosynthesis of the sacrum and in certain cases additional plate osteosynthesis of dislocated pubic rami fractures, postoperative analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
62658511|NCT02590783|ACTIVE_COMPARATOR|control intervention conservative|analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
62658512|NCT01462942|EXPERIMENTAL|Aclidinium/Formoterol 400/6 μg|24 week, double blind treatment period
62658513|NCT01462942|EXPERIMENTAL|Aclidinium/Formoterol 400/12 μg|24 week, double blind treatment period
62658514|NCT01462942|EXPERIMENTAL|Aclidinium monotherapy 400 μg|24 week, double blind treatment period
62658515|NCT01462942|ACTIVE_COMPARATOR|Formoterol monotherapy 12 μg|24 week, double blind treatment period
62658516|NCT01462942|PLACEBO_COMPARATOR|Placebo|24 week, double blind treatment period
62094921|NCT00827944|ACTIVE_COMPARATOR|2|Low weight polypropylene mesh
62094922|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
62094923|NCT01542580||Vanguard SSK 360 with PS Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized (non-constrained) tibial bearing.
62094924|NCT01542580||Vanguard SSK 360 with PSC Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized Constrained tibial bearing.
62094925|NCT01542580||Vanguard DA 360|Patients enrolled using a Vanguard DA 360 component.
62094926|NCT01542580||Vanguard 360 TiNbN Femur with PS Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
62094927|NCT01542580||Vanguard 360 TiNbN Femur with PSC Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
62094928|NCT01805323||All Participants|Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX®) according to general clinical practice.
62094929|NCT04882462|EXPERIMENTAL|single arm|
62094930|NCT04607252|EXPERIMENTAL|Metformin plus megestrol acetate|Metformin 1500mg per day plus megestrol acetate 160mg per day.
62094931|NCT04607252|ACTIVE_COMPARATOR|Megestrol acetate|Megestrol acetate 160mg per day.
62094932|NCT05981677||NSSI|
62094933|NCT05981677||HC|
61908146|NCT02931708|EXPERIMENTAL|DFES group|"Diaphragm Functional Electrical Stimulation:~Each session will last 30 minutes. The parameters selected in the stimulator will be: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance.~The patient will be positioned supine, headboard 30º, knees extended. Furthermore, the electrodes used to perform the electrical stimulation will be adhesive, disposable and hypoallergenic. These will be placed at sixth, seventh and eighth intercostal spaces, axiliar medium line and paraxiphoid both chest sides."
61908147|NCT04042246|NO_INTERVENTION|Control|No intervention is implemented among Control
61908148|NCT04042246|EXPERIMENTAL|Treatment (Educational Information on Vaccination)|Provide general and tailored information on vaccination and vaccination schedule at the end of the baseline survey
62094934|NCT01587833||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
62094935|NCT01587833||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
62094936|NCT06263829|EXPERIMENTAL|Tappt App|Participants will download and utilize the Tappt app to record adherence to oral medication. For the purposes of this study, adherence for participants in the intervention arm will be measured using a modified medication possession ratio (MPR) measure called medication tag scan ratio (MTSR). MTSR is defined as a percentage of the number of times participants scanned their passive tags versus the total of expected tag scans based on that participant's medication regimen and treatment period.
62094937|NCT06263829|NO_INTERVENTION|Historical Control|Upon study completion, a retrospective matched control will be established for the intervention group. Historic data for the matched control's adherence, treatment completion, SVR assessment, and SVR rates will be compared to the intervention arm.
62094938|NCT00244257|EXPERIMENTAL|1|Cohort 1
62094939|NCT00244257|EXPERIMENTAL|2|Cohort 2
62094940|NCT00244257|EXPERIMENTAL|3|Cohort 3
62094941|NCT00244257|EXPERIMENTAL|4|Cohort 4
62094942|NCT00244257|EXPERIMENTAL|5|Cohort 5
62658517|NCT04228939|EXPERIMENTAL|Intervention group (IG)|
62658518|NCT04228939|ACTIVE_COMPARATOR|Control group (CG)|
62658519|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
62658520|NCT01539200|PLACEBO_COMPARATOR|Control|
62658521|NCT01539200|ACTIVE_COMPARATOR|Oral Nutritional Supplement (ONS) and JDR|
62658522|NCT02650583|EXPERIMENTAL|Supportive care (Enhancing Connections Program)|Patients participate in Enhancing Connections Program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. Patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.
62658523|NCT04245761|EXPERIMENTAL|Sonidor®|Application: following the summary of product characteristics (l tablet per day) At the 7-day phone call the Investigator can increase the dosage to 2 tablets per day only in non-responding subjects.
62658524|NCT06250114||retreatment|Voluntary patients with at least one previously treated tooth needing a retreatment
62658525|NCT06250114||dental implant|Voluntary patients with at least one previously treated tooth needing an extraction and implant placement
62658526|NCT06442358|OTHER|Single Arm home ultrasound in pregnant women require BPP|Pregnant participants will use Pulsenmore ES device to perform BPP while guided remotely by a clinician
62658527|NCT06493162|ACTIVE_COMPARATOR|FCV Group|Patients who will be ventilated with flow controlled ventilation following the intubation
61908149|NCT01317108|NO_INTERVENTION|A|Low uPA/PAI-1: Observation
61908150|NCT01317108|NO_INTERVENTION|B2|High uPA/PAI-1: Observation
61908151|NCT01317108|NO_INTERVENTION|B3|High uPA/PAI-1: refused randomization
61908152|NCT01317108|ACTIVE_COMPARATOR|B1|High uPA/PAi-1: CMF chemotherapy
61908153|NCT03377140|ACTIVE_COMPARATOR|Hesperidin|2 capsuls of Hesperidin
61908154|NCT03377140|PLACEBO_COMPARATOR|control|2 capsuls of placebo
61908155|NCT01512667|EXPERIMENTAL|Severe Renal Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency.
61908156|NCT01512667|EXPERIMENTAL|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
61908157|NCT04316403|EXPERIMENTAL|Laser-assisted corticotomy|Er:YAG laser beam was used to perform several perforations to the alveolar bone around the canine in one side of the mouth hoping that would accelerate canine retraction
61908158|NCT04316403|NO_INTERVENTION|Traditional treatment|Canines in this group were retracted by the conventional manner.
62658528|NCT06493162|ACTIVE_COMPARATOR|VCV Group|Patients who will be ventilated with volume controlled ventilation following the intubation
62658529|NCT02555878|EXPERIMENTAL|Rivaroxaban|Participants will be administered rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.
62658530|NCT02555878|EXPERIMENTAL|Placebo|Participants will be administered matching placebo tablet orally once daily for 180 days.
62658531|NCT04900272|EXPERIMENTAL|VIPA device and companion booklet|For Aim 2, we will recruit a total of 20-40 older adult homebound patients who are likely to be socially isolated, through the Geriatric and General Internal Medicine clinics at Northwestern (over 2,300 homebound older adults) to use the VIPA and accompanying instructional booklet focused on social-isolation. Either the study PI or Research Study Coordinator (RSC) will visit the participant's home, or assist the patient virtually, once consented, to set up the Google Home or Amazon Alexa device for them and review the companion VIPA booklet with them.
62658532|NCT04639440||Obese or overweight patients|
62658533|NCT04639440||Patients without overweight|
62658534|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
62658535|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
62658536|NCT03990974|EXPERIMENTAL|Postoperative antimicrobial prophylaxis|Patients will receive postoperative antimicrobial prophylaxis for 3 days in 24 hours after hepatectomy.
61908159|NCT06081088|EXPERIMENTAL|Group 1|"Study group: Graded Motor Imagery Training + Conventional Physiotherapy~In this group, each participant will be received a treatment protocol consisting of Graded Motor Imagery training, conventional physiotherapy, and home exercises.~* Graded Motor Imagery (GMI)~* Conventional Physiotherapy Program~* Home Exercise Program"
61908160|NCT06081088|ACTIVE_COMPARATOR|Group 2|"Control group: Conventional Physiotherapy~In this group, each participant will be received a treatment protocol consisting of conventional physiotherapy, and home exercises.~* Conventional Physiotherapy Program~* Home Exercise Program"
61908161|NCT00443196|EXPERIMENTAL|Experimental|
62094943|NCT01161017|ACTIVE_COMPARATOR|1 Amitriptyline.|Amitriptyline
62094944|NCT01161017|ACTIVE_COMPARATOR|2 Topiramate|Topiramate
62658537|NCT03990974|SHAM_COMPARATOR|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy, unless the clinicians suggest he/she need antibiotics to treat or prevent infection.
62094945|NCT05935267||control cohort|control cohort
62094946|NCT05935267||irrigation cohort|irrigation cohort
62094947|NCT05935267||standard cohort|standard cohort
62658538|NCT02122276|EXPERIMENTAL|SCI|SCI participated in a 4-month robot-assisted passive ankle exercise regimen.
62658539|NCT03803137|EXPERIMENTAL|VOC analysis|VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection
62658540|NCT06004960|EXPERIMENTAL|[14C]CCX168|Participants will receive a single oral dose of \[14C\]CCX168 100 mg containing 400 μCi of \[14C\] on Day 1.
62094948|NCT00953160|EXPERIMENTAL|RF treatment|Abdomen, flank or thigh treated with RF device
62292454|NCT04294485|EXPERIMENTAL|Experimental group|Physical therapy intervention Efficacy of electrostimulation intervention combined with lower limbs exercise.
62292455|NCT04294485|NO_INTERVENTION|Control group|Participants will no receive physical therapy intervention
62292456|NCT05255003|EXPERIMENTAL|Modified dose LMWH without platelet transfusion support|"Patients will be given modified dose LMWH as below based on the first platelet count of the day (daily in admitted patients or at least 2 times a week in outpatients), without empiric platelet transfusion:~I. Platelet count 25-50,000/µL: 50% dose LMWH~II. Platelet count \< 25,000/µL: hold anticoagulation"
62658541|NCT02061800|ACTIVE_COMPARATOR|Full intensity with TBI|Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
62094949|NCT02977156|EXPERIMENTAL|Combination PexaVec + Ipilimumab|"* PEXA-VEC (Pexastimogene devacirepvec): Oncolytic live replicating virus, Recombinant vaccinia virus GM-GCF of Classe 1, administered by Intra-tumoral injection with fixed-dosage regimen of 1x109 pfu (9.0 Log pfu)/ injection. Up to 5 IT injections, at Week 1 Day 1, Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed in case of disease progression following a documented objective response at W12. Provided by Transgene.~* IPILIMUMAB: Anti-CTLA-4 monoclonal antibody (IgG1k) produced in CHO cells by recombinant DNA technology, administered by Intra-tumoral injection. Up to 4 IT injections at Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed In case of disease progression following a documented objective response at W12. Four dose levels of ipilimumab will be tested in dose escalation step: 2.5mg, 5mg, 7.5mg, 10mg, 20mg or 40 mg."
62094950|NCT05477862|EXPERIMENTAL|Alzheimer Disease (AD)|
62094951|NCT05477862|EXPERIMENTAL|Cognitively Healthy (CH)|
62094952|NCT02644538|NO_INTERVENTION|nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) are still using the original treatment for 72 weeks
62094953|NCT02644538|ACTIVE_COMPARATOR|PegIFN alfa-2a + nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir), then will add PegIFN alfa-2a to the original nucleot(s)ides for 48 weeks, then follow up for 24 weeks
62094954|NCT05249998|EXPERIMENTAL|Interventional group|"Patients will receive the usual care, with the intervention of the multidisciplinary team which defines with the patient the objectives of the stay and the inter-stay period, without specific therapeutic education on adapted physical activity, nutrition and eating behaviour."
62094955|NCT05249998|NO_INTERVENTION|Standard care group|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
62094956|NCT06693739|ACTIVE_COMPARATOR|no scaffold|initiate bleeding using hand files size beyond apex with sharp strokes
62094957|NCT06693739|EXPERIMENTAL|platelets rich fibrin|PRF is used as Scaffold by placing the compressed PRF membrane into canal
62094958|NCT06693739|EXPERIMENTAL|hyaluronic acid|hyaluronic acid will be delivered by syringe into canal
62094959|NCT05061862||CIED Indicated Subjects|Subjects indicated to receive a cardiac implantable electronic devices (CIEDs)
62094960|NCT02420587|EXPERIMENTAL|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
62094961|NCT05349136|EXPERIMENTAL|Synchronous telerehabilitation group|Synchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
61908162|NCT00352573||Normal Volunteers|Adults over 21 years old
62292457|NCT05255003|ACTIVE_COMPARATOR|Higher dose LMWH with platelet transfusion support|"Patients assigned to higher dose LMWH (see below) will be given transfusion for 14 days when the first platelet count of the day falls below 50,000/uL (daily inpatient or at least 2 times a week in outpatients). Post-transfusion counts will not be routinely obtained unless clinically indicated~I. Platelet count 25-50,000/µL: platelet transfusion + 100% dose LMWH~II. Platelet count \< 25,000/µL: platelet transfusion + 50% dose LMWH~After Day 14, patients will be transitioned to modified dose LMWH as the other arm without platelet transfusion.~LMWH can include enoxaparin, dalteparin, or tinzaparin, with 100% as:~* Enoxaparin - 1mg/kg subcutaneously twice daily~* Dalteparin - 200 IU/kg subcutaneously daily for 1 month then 150 U/kg daily~* Tinzaparin - 175 units/kg subcutaneously daily"
62292458|NCT01746251|ACTIVE_COMPARATOR|Concise Afatinib|Afatinib oral daily dose for 3 months
62292459|NCT01746251|ACTIVE_COMPARATOR|Prolonged Afatinib|Afatinib oral daily dose for 2 years
62094962|NCT05349136|EXPERIMENTAL|Asynchronous telerehabilitation group|Asynchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
62094963|NCT05349136|NO_INTERVENTION|Control group|Conventional physiotherapy
62094964|NCT03946111|EXPERIMENTAL|Naltrexone/Bupropion|
62094965|NCT03946111|PLACEBO_COMPARATOR|Placebo|
62094966|NCT04768790|EXPERIMENTAL|Multidisciplinary Group|Description of the interventions of the multidisciplinary program: multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
62094967|NCT04768790|ACTIVE_COMPARATOR|General Group|Description of the interventions of the general program: exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
62094968|NCT01312506||Subjects undergoing a craniotomy|This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
61908163|NCT05668390|EXPERIMENTAL|STALORAL® Birch 300 IR|"1. Escalation Phase:~   The escalation phase starts with 10 IR/mL solution the first 5 days (daily increase from 1 to 5 actuations) and switching to 300 IR/mL solution the next 5 days (daily increase from 1 to 5 actuations).~2. Maintenance Phase:~The maintenance phase takes place with 5 actuations of the active 300 IR/mL solution from Day 11 onwards"
61908164|NCT05668390|PLACEBO_COMPARATOR|Placebo|"1. Escalation Phase:~   The escalation phase starts with 10 IR/mL Placebo solution the first 5 days (daily increase from 1 to 5 actuations) and switching to 300 IR/mL Placebo solution the next 5 days (daily increase from 1 to 5 actuations).~2. Maintenance Phase:~The maintenance phase takes place with 5 actuations of the active 300 IR/mL Placebo solution from Day 11 onwards"
61908165|NCT01724619|EXPERIMENTAL|Healthy Volunteers|F-18\] fluorinated dihydrotestosterone (FDHT) PET/CT
61908166|NCT01724619|EXPERIMENTAL|Prostate Cancer Patients|F-18\] fluorinated dihydrotestosterone (FDHT) PET/CT
62094969|NCT01312506||Metastases, no craniotomy|These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
62094970|NCT01312506||Healthy Volunteers|Subjects who do not have known melanoma or metastases.
62094971|NCT03892850|EXPERIMENTAL|nurse prescription|experimental group receiving pharmacological nurse prescription
62094972|NCT03892850|ACTIVE_COMPARATOR|medical prescription|control group receiving medical prescription
62094973|NCT03882515|EXPERIMENTAL|Experimental group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after myofascial release
62292460|NCT03751267|EXPERIMENTAL|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
62465262|NCT03410862|EXPERIMENTAL|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
61908167|NCT04121078|EXPERIMENTAL|Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg|TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
61908168|NCT04121078|EXPERIMENTAL|Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg|Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.
61908169|NCT04286997|EXPERIMENTAL|GRAIL population|patients are treated with 20 sessions of GRAIL rehabilitation, associated to 20 traditional physiotherapy sessions (1+1 a day, during a period of 30 days)
61908170|NCT04286997|ACTIVE_COMPARATOR|traditional population|subjects are treated with 40 sessions of traditional physiotherapy (2 a day, during a period of 30 days)
61908171|NCT00270842|PLACEBO_COMPARATOR|Education Control Group|Education group that is the control group for the study. Is a 10 week course with diverse health education topics.
62094974|NCT03882515|SHAM_COMPARATOR|Sham group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after continuous surface slip technique
62094975|NCT03882515|ACTIVE_COMPARATOR|Control group|Evaluation and reassessment of asymptomatic individuals
62094976|NCT00814489|EXPERIMENTAL|GSK2254233A Group|Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62094977|NCT00814489|EXPERIMENTAL|GSK2254232A Group|Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62094978|NCT00814489|ACTIVE_COMPARATOR|Engerix Group|Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62094979|NCT01819415|NO_INTERVENTION|Naive|Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.
62292461|NCT03751267|NO_INTERVENTION|Wait-list control|This group of patients will receive Tuina (massage) 4 weeks after baseline assessments.
62292462|NCT05699148||Children with cystic fibrosis aged 6 to 11 years|Group of children who have at least one copy of Phe508del gene mutation and are eligible for starting on the modulator elexacaftor/ tezacaftor/ ivacaftor (ETI). This group will have baseline MRI scans before starting ETI and aiming to have subsequent scans post starting ETI (6 months to 1 year post starting ETI)
62292463|NCT05699148||Control Group|Age and gender matched controls with no history of cystic fibrosis or gastrointestinal disease. This group will undergo one set of scans only.
62658542|NCT02061800|EXPERIMENTAL|Full intensity without TBI|Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
61908172|NCT00270842|EXPERIMENTAL|Functional Balance Training|Exercise group that participated in functional balance training
61908173|NCT00270842|EXPERIMENTAL|Tai chi|Exercise Group that participated in tai chi training classes
61908174|NCT00594711||1|Case-group
61908175|NCT00594711||2|Control-group
62658543|NCT02061800|EXPERIMENTAL|Reduced intensity|Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
61908176|NCT04865926|EXPERIMENTAL|Scapular and Neck Proprioceptive Neuromuscular Facilitation Group|Participants in the intervention group will be applied neck and scapular Proprioceptive Neuromuscular Facilitation exercises lasting 40 minutes for 3 sessions a week for 4 weeks.
61908177|NCT04865926|EXPERIMENTAL|Control Group|McKenzie and Kendall exercises will be given to the participants in the control group. Exercises will be done 3 sessions a week over a 4-week period.
62094980|NCT01819415|ACTIVE_COMPARATOR|Anti-VEGF plus AREDS-1 supplementation.|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.
62094981|NCT01819415|EXPERIMENTAL|Anti-VEGF plus AREDS-2|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).
61908178|NCT01071707||Confirmed Diagnosis of IPF|Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
62094982|NCT01819415|NO_INTERVENTION|Control|Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.
62094983|NCT05769582|EXPERIMENTAL|Anti-BK polyomavirus (AntiBKV)|1,000mg or 500mg Anti-BK polyomavirus (AntiBKV) per intravenous infusion every four weeks (four doses)
62094984|NCT05769582|PLACEBO_COMPARATOR|Placebo|Placebo intravenous infusion every 4 weeks (4 doses)
62094985|NCT03587194|EXPERIMENTAL|Otezla Enstilar|Otezla 30mg BID Enstilar QD
62094986|NCT05635266||Health Condition Group|
62292464|NCT06160102|OTHER|Framework for safe drug use in people with intellectual and/or developmental disabilities|"Optimizing medication management and medication therapy poses complex challenges related to the different groups, actors, and not least the data systems. To meet these challenges, we have chosen a method where the participants contribute actively in the research: participatory action research (PAR). This method involves both the action and the knowledge production being done in collaboration between all the participants, since neither the researcher nor others have exclusive right to the understanding of reality.~Normalization process theory offers an analytical tool that helps to understand and explain the dynamic processes that occur during the implementation of complex interventions and technological and organizational innovations in health care, which includes institutional and organizational contexts and focuses on what social processes can promote and inhibit it through the integration of new routines and work forms in established social structures."
62292465|NCT02945657|EXPERIMENTAL|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
62292466|NCT04768582|EXPERIMENTAL|Efient group|ACS patients who received oral Prasugrel after coronary angiography been done
62292467|NCT03244059|EXPERIMENTAL|Belimumab|"Subjects randomized to the experimental treatment arm will receive i.v. administrations of belimumab (10 mg/kg), consisting of three loading doses, two weeks apart, followed by five (5) more monthly infusions. The final assessment will be performed at month 8."
62292468|NCT03244059|PLACEBO_COMPARATOR|Placebo|"These subjects will be treated with identically appearing placebo i.v. on the same schedule as the experimental arm subjects (i.e., three loading doses, two weeks apart, followed by five more monthly infusions. Again, the final assessment will be performed at month 7 (210+10 days after treatment start)."
62658544|NCT01392937|ACTIVE_COMPARATOR|All-in-One Light multipurpose|Used All in One light multipurpose with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson \& Johnson).
62658545|NCT01392937|ACTIVE_COMPARATOR|Aquify care|Use Aquify care with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson \& Johnson).
62658546|NCT04892160|OTHER|Guided Imagery First/Virtual Reality Second|Patients will be played a guided imagery experience first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the virtual reality intervention.
62658547|NCT04892160|EXPERIMENTAL|Virtual Reality First/Guided Imagery Second|Patients will have the VR interactive experience played first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the guided imagery intervention.
62658548|NCT01069939|EXPERIMENTAL|Esomeprazole 20mg|Esomeprazole 20mg once daily oral
62658549|NCT01069939|PLACEBO_COMPARATOR|Placebo|Placebo once daily oral
62658550|NCT03173755||People with normal weight|
62658551|NCT03173755||people with overweight and obesity|
62658552|NCT05496764|ACTIVE_COMPARATOR|Group A|26 patients we planned to inject them local steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in (group A)
62658553|NCT05496764|ACTIVE_COMPARATOR|Group B|26 patients we planned to inject them local glucose 5% ( 10 ml glucose) directly into the carpal tunnel in (group A)
62094987|NCT05635266||Exceptive Condition Group|
62094988|NCT05635266||Control Group|
62094989|NCT06698068|EXPERIMENTAL|Experimental group|15 equine therapy sessions
62094990|NCT03845764||Rapid on-site evaluation (ROSE)|Evaluation, made by a pulmonologist, a pathologist and a molecular pathologist, of the tumor burden in ROSE slides produced from endoscopic procedures aimed at sampling intrathoracic lymphadenopathy and pulmonary nodules
62094991|NCT01642186|EXPERIMENTAL|Arm A everolimus|"Everolimus will be administered at the following doses:~* Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~* Patients with a BSA \> than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
62465263|NCT03410862|PLACEBO_COMPARATOR|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
62465264|NCT01423526|PLACEBO_COMPARATOR|Placebo|"Drug: Placebo tablets, oral administration, single administrations~Arms: Placebo"
62465265|NCT01423526|EXPERIMENTAL|DWP10292|"Drug: DWP10292 tablets, oral administration, single administrations~Arms: DWP10292"
62465266|NCT04697017|OTHER|Multiple births (twins and triplets)|Twins and triplets who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study
62465267|NCT04697017|OTHER|Singletons|Singletons who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study.
62465268|NCT00416520|EXPERIMENTAL|1|
62465269|NCT00416520|PLACEBO_COMPARATOR|2|
62465270|NCT00416520|ACTIVE_COMPARATOR|3|
62465271|NCT01415557|PLACEBO_COMPARATOR|Non-Fortified Control Product|Non-fortified control beverage
62465272|NCT01415557|ACTIVE_COMPARATOR|Micronutrient Fortified Test Product|Micronutrient fortified test beverage
62465273|NCT05310097|EXPERIMENTAL|Cognitive Processing Therapy + Memory Support (CPT + MS)|CPT + MS will involve the same treatment strategies as CPT while incorporating deliberate and frequent use of memory and learning support strategies. MS strategies are designed to enhance the memory of specific treatment points, defined as any insight, skill or strategy determined to be important for the patient to remember and/or implement. MS is not designed to enhance memory functioning generally, but rather improve the encoding, consolidation and retrieval of specific components of therapeutic learning.
62465274|NCT05310097|ACTIVE_COMPARATOR|Cognitive Processing Therapy (CPT)|CPT is a manualized, trauma-focused therapy for PTSD. Treatment consists of psychoeducation on the cognitive model of PTSD, identification of trauma-related stuck points (i.e. dysfunctional beliefs), and cognitive challenging techniques to help participants identify more realistic and adaptive ways of viewing their trauma, themselves, and the world.
62094992|NCT01642186|EXPERIMENTAL|Arm B letrozole plus leuprolide|"Day 1 of Cycle 1: Leuprolide 7.5 mg IM will be administered by a nurse in clinic.~Letrozole will be dispensed and will be taken at home. Patients will be instructed to take letrozole at the same time each day, consistently with food or without food, and swallowed whole with a glass of water. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
62094993|NCT01642186|EXPERIMENTAL|Arm C combination everolimus, letrozole and leuprolide|"* Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~* Patients with a BSA \> than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. Leuprolide 7.5 mg IM will be given every 4 weeks (+/- 7 days). Everolimus and letrozole will be administered continuously using the same dose, schedule and administration. Everolimus, letrozole and leuprolide should be administered concurrently at all times."
62094994|NCT06696482|EXPERIMENTAL|Escitalopram|Escitalopram tablets 10 mg once daily for 7 days
62465275|NCT03172351|EXPERIMENTAL|EDoF1|
62465276|NCT03172351|ACTIVE_COMPARATOR|Monofocal|
62465277|NCT03172351|ACTIVE_COMPARATOR|EDoF2|
62094995|NCT06696482|PLACEBO_COMPARATOR|Placebo|Lactose tablets 10 mg once daily for 7 days
62465278|NCT01942863|EXPERIMENTAL|water exchange single balloon enteroscopy|
62465279|NCT01942863|ACTIVE_COMPARATOR|CO2 insufflation single balloon enteroscopy|
62465280|NCT02236247|EXPERIMENTAL|ivabradine|I(f) inhibitor, heart rate controller
62465281|NCT02236247|PLACEBO_COMPARATOR|placebo|placebo pill will be administered orally twice daily
62465282|NCT01013025||Patients treated with Vantas implant|Patients were enrolled if they had had a Vantas implant placed for treatment of adenocarcinoma of the prostate, and if the patients were scheduled for explant of the implant, and the physician had difficulty locating the implant.
62465283|NCT01529060|ACTIVE_COMPARATOR|Phenylbutyrate|Study Drug
62094996|NCT05929651|EXPERIMENTAL|MenACYW conjugate vaccine|participants will receive a single booster dose of the MenACYW conjugate vaccine with an interval of at least 2 months after the last vaccination with Nimenrix® or Menveo® received during infancy before 12 months of age
62094997|NCT00540605|EXPERIMENTAL|1|4g tenofovir 1% gel applied vaginally 2 hours prior to expected time of cesarean delivery
62094998|NCT06615102|EXPERIMENTAL|Angiotensin II|Intravenous infusion through a central line according to the patient's situation. Target medium arterial pressure (MAP): \>65mmHg
62292469|NCT01150487|EXPERIMENTAL|Kidney recipients or kidney donors|Patients who have had a Kidney transplant or are undergoing a kidney transplant. Kidney donors.
62292470|NCT03683602|EXPERIMENTAL|PNF group|PNF techniques, patterns, re-education of postural control, once a day 10 days,
62292471|NCT03683602|ACTIVE_COMPARATOR|Manual therapy group|traction, joints mobilization, pos-isometric relaxation, once a day 10 days
62465284|NCT01529060|PLACEBO_COMPARATOR|Inactive Powder|Placebo powder
62465285|NCT04702828||Fallers group|1.60 years to 99 years old 2. have a recent fall within two months 3.can understand and answer the questions 4.can give their informed consent
62465286|NCT04702828||Non-fallers group|1.60 years to 99 years old 2. have any fall experiences in past year 3.can understand and answer the question 4.can give their informed consent
62465287|NCT01960569|ACTIVE_COMPARATOR|Arm 1 : active product (Thrombexx)|100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
62094999|NCT06615102|ACTIVE_COMPARATOR|Control|Intravenous infusion through a central line according to the patient's situation. Target medium arterial pressure (MAP): \>65mmHg
62095000|NCT04941417|EXPERIMENTAL|neoadjuvant PD-(L)1 inhibitor with chemotherapy followed by PD-(L)1 inhibitor for up to 1 year|
62095001|NCT06485297||Externs in 6th year|external in the 6th year working within the Riquier Institute of Oral Medicine at Nice University Hospital.
62095002|NCT06485297||Interns|interns working within the Riquier Institute of Oral Medicine at Nice University Hospital.
62095003|NCT06485297||Private practitioners|teachers working within the Riquier Institute of Oral Medicine at Nice University Hospital.
61908179|NCT01071707||No diagnosis of IPF|Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
62095004|NCT06485297||CHU practitioners|several categories of dental surgeons, on the basis of a list of addresses provided by the school of the faculty of dental surgery of Côte d'Azur University
62095005|NCT06431256|PLACEBO_COMPARATOR|Placebo Comparator|Matching placebo to HLD200 20 mg capsule (×2) for 3 weeks (prescribed at Visits 2, 3, and 4)
62095006|NCT06431256|EXPERIMENTAL|HLD200 20 mg|HLD200 20 mg placebo capsule (×1) and HLD200 20 mg active capsule (×1) for 3 weeks (prescribed at Visits 2, 3, and 4)
62095007|NCT06431256|EXPERIMENTAL|HLD200 40 mg|HLD200 20 mg placebo capsule (×1) and HLD200 20 mg active capsule (×1) for the first week (prescribed at Visit 2), with up-titration for the final 2 weeks to HLD200 20 mg active capsules (×2) (prescribed at Visits 3 and 4)
62095008|NCT03613584|ACTIVE_COMPARATOR|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
62095009|NCT03613584|PLACEBO_COMPARATOR|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
62095010|NCT03318913|NO_INTERVENTION|Health control|Health young subjects free of diabetes mellitus and nutritional intervention
62095011|NCT03318913|PLACEBO_COMPARATOR|DM Placebo|Sucralose
62465288|NCT01960569|PLACEBO_COMPARATOR|Arm 2 : Placebo|100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
61908180|NCT01768429|EXPERIMENTAL|Fatty fish|Four fatty fish meals per week
61908181|NCT01768429|EXPERIMENTAL|Lean Fish|Four lean fish meals per week
61908182|NCT01768429|EXPERIMENTAL|Alpha-linolenic acid|10 g of alpha-linolenic acid daily from camelina sativa oil
61908183|NCT01768429|EXPERIMENTAL|Control diet|Limited fish and alpha-linolenic acid intake
61908184|NCT03599375|EXPERIMENTAL|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
61908185|NCT03865888|ACTIVE_COMPARATOR|Cyclosporins 0.05 % treated eyes|Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
61908186|NCT03865888|ACTIVE_COMPARATOR|Tacrolimus 0.03% treated eyes|Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months
61908187|NCT01155167|PLACEBO_COMPARATOR|Placebo|
61908188|NCT01155167|EXPERIMENTAL|Topical dilator|
61908189|NCT06363266|EXPERIMENTAL|TEMPO|Using a stepped care approach, TEMPO will be provided across two intervention stages with variations on timing (initial vs. delayed) and intensity (self-directed vs. guided). All dyads will continue to access usual care (a co-intervention measure is included).
61908190|NCT06363266|ACTIVE_COMPARATOR|Actively Monitoring dyads' anxiety|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Dyads not responding to active monitoring will be stepped up to TEMPO; responders to active monitoring will only be invited to complete the follow-up measures.
61908191|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
61908192|NCT04933370|ACTIVE_COMPARATOR|Industry standard stimulation|Industry standard stimulation settings
62095012|NCT03318913|ACTIVE_COMPARATOR|DM FHP|Fish protein hydrolysates
62095013|NCT03990025|OTHER|Linked Color Imaging - White Light Imaging|Participant undergoes gastroscopy via Linked Color Imaging first, then followed by White Light Imaging
62095014|NCT03990025|OTHER|White Light Imaging - Linked Color Imaging|Participant undergoes gastroscopy via White Light Imaging first, then followed by Linked Color Imaging
62292472|NCT04196114|EXPERIMENTAL|All patients|All patients implanted.
62292473|NCT04531202||Patients with confirmed or suspected of coronavirus infe|Clinical and laboratory data will be collected throughout the acute illness period. Research data will be integrated with information available from hospital and regulatory files.
62465289|NCT04350086|EXPERIMENTAL|Experimental arm|
61908193|NCT04933370|SHAM_COMPARATOR|Experimental stimulation|Experimental stimulation settings
61908194|NCT00917644|OTHER|Reference|80 mg atorvastatin tablets
61908195|NCT00917644|EXPERIMENTAL|Test|New 80 mg atorvastatin tablets
61908196|NCT01297777|EXPERIMENTAL|Imatinib mesylate|Imatinib mesylate 300 or 400 mg daily for 12 months.
61908197|NCT00935155|EXPERIMENTAL|Acupuncture|Acupuncture in combination with exercise therapy
62658554|NCT00482144|ACTIVE_COMPARATOR|Treatment: PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
62465290|NCT01974297|ACTIVE_COMPARATOR|Atorvastatin 20mg, monotherapy|Atorvastatin 20mg/day PO for 12weeks
62095015|NCT05803824|EXPERIMENTAL|group A: Baduanjin Qigong exercise plus selected exercise|"Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks. The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Puls Selected Exercise Program~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises ."
62292474|NCT00472693|EXPERIMENTAL|Bevacizumab and ABI-007 (Abraxane)|Bevacizumab and ABI-007 (Abraxane)
62292475|NCT02533089|EXPERIMENTAL|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
62465291|NCT01974297|EXPERIMENTAL|Atorvastatin 10mg, Fenofibric acid 135mg|Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks
62658555|NCT00482144|ACTIVE_COMPARATOR|Treatment: PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
62658556|NCT00482144|NO_INTERVENTION|Control|The scar will be randomly divided into three equal fields. One third of the scar will not receive treatment
62658557|NCT04402242|SHAM_COMPARATOR|"SCS Group"|"Receiving anesthesia according to routine standard care, with the use of the hidden NOL (used to compare the data at the end of anesthesia with those of the classic BIS - without monitoring of the anesthesia by the NOL (without adjustment of treatments ))"
62658558|NCT04402242|EXPERIMENTAL|NOL Group|Receiving anesthesia monitored by the NOL
62658559|NCT04233684|EXPERIMENTAL|Study|"* Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~* Pathologic test for H. pylori by H\&E stain and Giemsa stain~* All tissues will be sent to immunohistochemistry as a gold standard"
62658560|NCT05273983|EXPERIMENTAL|Behavioural Activation Treatment|Two intervention sessions with a psychologist and an use of a mobile scheduling app over the course of 6 weeks.
62658561|NCT05024942||Severe aortic stenosis patients undergoing TAVR|Severe aortic stenosis patients undergoing TAVR will be stratified according to LUS evaluated pulmonary congestion before and after TAVR
62292476|NCT02533089|NO_INTERVENTION|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
62095016|NCT05803824|EXPERIMENTAL|Patients at group B: patients will receive selected exercise program|"Selected Exercise Program: Patients will receive~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises ."
62292477|NCT01592539||Case|Patients with Type 1 Diabetes Mellitus
62292478|NCT01592539||Control|Age and sex matched healthy controls.
62465292|NCT01661114|EXPERIMENTAL|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
62658562|NCT00417222|ACTIVE_COMPARATOR|Olmesartan medoxomil|olmesartan medoxomil
62658563|NCT00417222|NO_INTERVENTION|Standard therapy|Standard therapy
62658564|NCT06400810||Suicidal Adolescent|he study will enroll subjects aged 13-17 years admitted with a chief complaint of acute suicidality or attempt. Patients will undergo physiologic and biometric monitoring in the hospital with a wrist-wearable device and chest wall ECG leads. They will undergo serial assessment four times daily to gather data regarding their activities, affect, and suicidality.
62658565|NCT05604950||S group|underwent surgical treatment.
62658566|NCT05604950||NS group|underwent non-surgical treatment with RT and/or chemoradiotherapy.
62658567|NCT05319470||Study Group|100 patients with diagnosed glaucoma receiving travoprost without preservatives
62658568|NCT03785821|EXPERIMENTAL|BMSO|Bitter melon seed oil supplementation
62658569|NCT03785821|PLACEBO_COMPARATOR|OO|Olive oil supplementation
62465293|NCT02561793|ACTIVE_COMPARATOR|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
62658570|NCT03943485|ACTIVE_COMPARATOR|Uterien Manipulator Arm|Patients in this group will receive a uterine manipulator during abdominal hysterectomy.
62658571|NCT03943485|NO_INTERVENTION|Control|Patients in this group will receive standard abdominal hysterectomy without adoption of a uterine manipulator.
62095017|NCT05243056|EXPERIMENTAL|Arm I (Y-AMBIENT)|Patients receive three themed education sessions over 1 hour each, written materials, and videos at month 1. Patients also participate in 3, 20 minutes telephone reinforcement calls to discuss how they are doing and discuss any concerns that they are still managing at months 2, 3, and 4.
62292479|NCT03677193|EXPERIMENTAL|Experimental arm|
62465294|NCT02561793|PLACEBO_COMPARATOR|Placebo|Women will receive a placebo 12 weeks before starting IVF/ICSI
62292480|NCT03792048|EXPERIMENTAL|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
62292481|NCT03792048|NO_INTERVENTION|Manual Anastomosis|Manual Anastomosis for bilioenteric anastomosis and pancreaticojejunostomy
62292482|NCT05202457||Cirrhosis|Patients with cirrhosis undergoing urgent and elective surgery
62292483|NCT04790591|ACTIVE_COMPARATOR|Age <80 yrs. and ASA class <3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
62465295|NCT02336165|EXPERIMENTAL|Cohort A|Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
62465296|NCT02336165|EXPERIMENTAL|Cohort B|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
62658572|NCT02207608|ACTIVE_COMPARATOR|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
62658573|NCT02207608|EXPERIMENTAL|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
62658574|NCT00619463|EXPERIMENTAL|exercise then monitor|8 weeks of aerobic exercise followed by 16 weeks of monitoring
62658575|NCT00619463|EXPERIMENTAL|monitor than exercise|8 weeks of monitoring followed by 16 weeks of aerobic exercise
62658576|NCT04700943||Regional awake anesthesia|"In non-intubated patients, an epidural catheter was placed at T5-T6. An anesthetic load of 0,5 mg/kg of ropivacaine was administered to reach anesthesia of the thoracic wall. Adjunctive local anesthetic infiltration of the incision site was performed by the surgeon with 2% lidocaine and 7,5% Ropivacaine. The cumulative dose of anesthetics drugs was computed as not to exceed the recommended dosage.~To improve patient comfort through the procedure, sedation with Target Controlled Infusion of propofol (using Schnider algorithm) and low dose remifentanil (0,05 mcg/kg/min) was also administered."
62658577|NCT04700943||General anesthesia|"Either epidural block or an interfascial plane block of the thoracic wall, such as serratus anterior plane block or erector spinae plane block, were performed.~Patients were then anesthetized with Propofol plus opiates (usually remifentanil) and muscle paralysis was achieved with Rocuronium."
62658578|NCT00756301|ACTIVE_COMPARATOR|Traditional Technique|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
62658579|NCT00756301|EXPERIMENTAL|Alternative Technique|Local anesthetic (Lidocaine) injected using an alternative technique (inserting the numbing needle into the deeper tissues first and injecting numbing medication from there up to the skin).
62658580|NCT00756301|NO_INTERVENTION|No Anesthetic|No local anesthetic is used.
62465297|NCT02336165|EXPERIMENTAL|Cohort B2|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
62465298|NCT02336165|EXPERIMENTAL|Cohort B3|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
62465299|NCT02336165|EXPERIMENTAL|Cohort C|Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
62658581|NCT05073315|ACTIVE_COMPARATOR|Continued-use Group (Adalimumab)|Randomized participants will receive continuous injection of adalimumab Q2W until last dose at Week 28.
62095018|NCT05243056|ACTIVE_COMPARATOR|Arm II (enhanced usual care)|Patients receive usual care at month 1. Patients also participate in 3, 20 minutes telephone reinforcement calls to discuss their chemotherapy regimen at months 2, 3, and 4.
62095019|NCT06630819|EXPERIMENTAL|Group A|Buccal infiltration of 3.6 ml of 4% Articaine
62292484|NCT04790591|ACTIVE_COMPARATOR|Age ≥80 yrs. and/or ASA class ≥3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
62292485|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 1|Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
62292486|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 2|Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
62658582|NCT05073315|EXPERIMENTAL|Switching Group (Adalimumab - ABP 501)|Participants will initially receive adalimumab until Week 10 during the lead-in period. Thereafter, starting from Week 12, participants will switch between ABP 501 and adalimumab Q2W with last dose of ABP 501 at Week 28.
62095020|NCT06630819|ACTIVE_COMPARATOR|Group B|Buccal infiltration of 1.8 ml of 4% Articaine
62095021|NCT04960280|EXPERIMENTAL|Computerized Auscultation|Patients presenting to the echocardiogram laboratory for routine clinically indicated echocardiography or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures will undergo a computerized auscultation using the ©VoqX stethoscope and will have their heart sounds auscultated and recorded.
62095022|NCT01460992||Pacemaker therapy|Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.
61908198|NCT00935155|ACTIVE_COMPARATOR|exercises|Coordination, mobilizing, endurance, strength
62292487|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 3|Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
62292488|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 4|Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
62292489|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 5|Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
62292490|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 6|Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
62292491|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 7|Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
62292492|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 8|Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
62292493|NCT03530514|EXPERIMENTAL|Part A: Single dose cohort 9|Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
62292494|NCT03530514|EXPERIMENTAL|Part B: Repeated dose cohort 10|Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
62292495|NCT04297943|ACTIVE_COMPARATOR|3D Orthosis|See summary
62292496|NCT04297943|ACTIVE_COMPARATOR|Custom Thermoplastic Orthosis|See summary
62292497|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
62292498|NCT03173703|EXPERIMENTAL|Test Arm|Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
62292499|NCT03173703|ACTIVE_COMPARATOR|Control Arm|Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
62658583|NCT02756897|EXPERIMENTAL|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
62658584|NCT04415905|EXPERIMENTAL|group P|The participants in the group P are anesthetized with propofol.
62292500|NCT02104063||MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
62292501|NCT04095455|ACTIVE_COMPARATOR|pectoral nerves block group|modified pectoral nerves block was performed on the side of surgery
62658585|NCT04415905|ACTIVE_COMPARATOR|group S|The participants in the group S are anesthetized with sevoflurane.
62292502|NCT04095455|ACTIVE_COMPARATOR|Ktamine plus Magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump
62292503|NCT04095455|ACTIVE_COMPARATOR|Control Group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo
62465300|NCT05245357|EXPERIMENTAL|Lentil, then Control|Participants first received a meal with 140 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 0 g of lentils in the morning.
62658586|NCT01010178|EXPERIMENTAL|Macrolid, Theophylline, Corticosteroids|Approved drug in this setting
62658587|NCT02368392||Cardiac Arrest|Those who get in-hospital cardiac arrests
62658588|NCT02368392||Non Cardiac Arrest|Those who do not get in-hospital cardiac arrest
62465301|NCT05245357|EXPERIMENTAL|Control, then Lentil|Participants first received a meal with 0 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 140 g of lentils in the morning.
61908199|NCT04635605|EXPERIMENTAL|Methylene Blue|Methylene Blue 100 mg capsules. Patients will receive Methylene blue (MB) capsules of 100mg every 12 hours for a total of 5 days.
62095023|NCT03654989|EXPERIMENTAL|Treprostinil iontophoresis|"Gel of treprostinil 1 mg/mL (target concentration)~* Part 1: 1 administration/day, on separate days, with 72h between two doses. Ascending doses are 0.025 mg/mL, 0.05mg/mL, 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.7 mg/mL, and 1 mg/mL. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~* Part 2: 1 administration/day at the maximum tolerated dose (MTD) for 10 days; dressing will be changed by a trained nurse every 2 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
62465302|NCT00262223|ACTIVE_COMPARATOR|1) Seeking Safety + Sertraline|Seeking Safety + Sertraline
62658589|NCT02964871|ACTIVE_COMPARATOR|LTCF with RIDT|Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
62292504|NCT00213239|EXPERIMENTAL|Propofol 4 mg/kg group|First patient in this arm will receive a bolus of propofol 4 mg/kg followed by remifentanil 0.5 mcg/kg. Subsequent patients randomized to this arm will receive propofol 4 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
62465303|NCT00262223|PLACEBO_COMPARATOR|2) Seeking Safety + Placebo|Seeking Safety + Placebo;
62292505|NCT00213239|EXPERIMENTAL|Propofol 2 mg/kg group|First patient in this arm will receive a bolus of propofol 2 mg/kg followed by remifentanil 1 mcg/kg. Subsequent patients randomized to this arm will receive propofol 2 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
62292506|NCT06435390||3-5 year old 155 children with high caries risk and their parents|3-5 year old 155 children with high caries risk and their parents before and after COVID-19
62292507|NCT01136395|ACTIVE_COMPARATOR|LD kidney transplantation, ABOi|Living donor (LD) kidney transplantation, ABO incompatible (ABOi); Immunosuppressive treatment: Tacrolimus (Tacr)/ Mycophenolate sodium (MPS), Basiliximab induction, Rtx induction
61908200|NCT04635605|ACTIVE_COMPARATOR|control group|The control intervention would be the group receiving 100 mg placebo capsules twice a day for five consecutive days
61908201|NCT02342418|ACTIVE_COMPARATOR|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
61908202|NCT02342418|ACTIVE_COMPARATOR|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
61908203|NCT02254564||Positive Scrapings|Skin scrapings that are positive for scabies
61908204|NCT02254564||Negative Controls|collect negative controls from patients in whom tinea (superficial fungal infection) was clinically suspected. Samples from patients with demodex folliculitis (a mite that is commonly found in oil glands on the face) are also intended to be used as negative controls as well.
62095024|NCT03654989|PLACEBO_COMPARATOR|Remodulin® Placebo iontophoresis|Placebo will be made from the placebo of Remodulin® incorporated into hydrogel (Suprasorb® G). The route and frequency of administration will be the same as for the investigational drug (topical administration by iontophoresis).
62095025|NCT03654989|NO_INTERVENTION|Standard care|subjects randomized to the standard of care group (no iontophoresis) will only undergo standard blood test at visit 0 or 1, unless tests \<1 month before inclusion are available This group is not double blind Standard care consists on debridement and dressings
62292508|NCT01136395|ACTIVE_COMPARATOR|LD kidney transplantation, ABOc|Living donor (LD) kidney transplantation, ABO compatible (ABOc); Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
62292509|NCT01136395|ACTIVE_COMPARATOR|DD kidney transplantation|Deceased donor (DD) kidney transplantation, ABO compatible; Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
62292510|NCT02326948||Gallbladder cancer case group|Gallbladder cancer case group was defined as newly diagnosed gallbladder cancer diagnosed as GBC at the Department of Internal Medicine in Cheju Halla General Hospital, Jeju, Korea from 2009 to 2013.
62292511|NCT02326948||Age and sex matched control group|Age and sex matched control group was determined as age-sex matched subjects selected from the participants of Health Promotion Center in the same institute from 2009 to 2012.
62292512|NCT02358811||Eldery SAOS+|Patients with severe obstructive sleep apnea (AHI\>30) 70 years old and more
62292513|NCT02358811||Eldery SAOS-|People without obstructive sleep apnea (AHI\<10) 70 years old and more
62465304|NCT03733197|EXPERIMENTAL|Culture specific|"The culture-specific arm may entail FIT kits plus barbers as motivational interviewers."
62658590|NCT02964871|PLACEBO_COMPARATOR|LTCF Control|"Usual care.~Data will be collected from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns."
62658591|NCT01936155|EXPERIMENTAL|Oedema, Joint Mobility, Skin Oxygenation|Neuromuscular electrical stimulation (NMES) is to be applied using a custom-built, two-channel stimulator, Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 90 minutes. Its affect on oedema reduction, joint mobility and skin oxygenation will be assessed both before and after its application.
62658592|NCT04989933|ACTIVE_COMPARATOR|ESP 20 ml|Ultrasound-Guided erector spinae plane block with 20 ml of 0.25% bupivacaine
62658593|NCT04989933|ACTIVE_COMPARATOR|ESP 30 ml|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine
62095026|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
62292514|NCT02358811||Adult SAOS+|Patients with severe obstructive sleep apnea (AHI\>30) 18 \< Age \< 55 years old
62292515|NCT02358811||Adult SAOS-|People without obstructive sleep apnea (AHI\<10) 18 \< Age \< 55 years old
62465305|NCT03733197|EXPERIMENTAL|Control|Distribution of CRC screening brochures \& FIT (Fecal Immunochemical Test) kits by barbers
62658594|NCT00574639|EXPERIMENTAL|Arm 1|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
62095027|NCT02882503|EXPERIMENTAL|EUS-RFA|monopolar radiofrequency probe (1.2 mm Habib endoscopic ultrasound - radiofrequency ablation (EUS-RFA) catheter) and 19 or 22 gauge fine needle aspiration (FNA) needle
62095028|NCT00662909|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
62095029|NCT00662909|EXPERIMENTAL|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
62095030|NCT00662909|EXPERIMENTAL|Mirabegron 100 mg|Participants received mirabegron 100 m tablets, orally once a day for 12 weeks
62292516|NCT06213220||mood disorders group|Participants are requested to wear the wristbands throughout the experiment, and upload their data every three days. Additionally, the Hamilton Depression Rating Scale (HAMD) and the Young Mania Rating Scale (YMRS) are administered once a week for measurement.
62465306|NCT04448106|EXPERIMENTAL|Phase 2 Arm 1 - OA Knee|"50 subjects receive two doses of 2.0-2.86 x 10\^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10\^6 cells/kg via intra-articular injection into the injured joint."
62658595|NCT00574639|EXPERIMENTAL|Arm 2|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
62095031|NCT03728517||Subjects who undergo gynecologic surgery|Subjects who will undergo gynecologic surgery via vaginally, laparoscopic , or robotic who require observation or inpatient stay overnight. This group will receive pain medication in the hospital and will also be discharged home with pain medication.
62465307|NCT04448106|ACTIVE_COMPARATOR|Phase 2 Arm 2 OA Knee|Control group- 50 subjects receive three doses of 2.0-2.86 x 10\^6 cells/kg on day 0, 3, and 6 via intravenous infusion
62292517|NCT06213220||healthy control group|Participants are requested to wear the wristbands throughout the experiment, and upload their data every three days. Additionally, the Hamilton Depression Rating Scale (HAMD) and the Young Mania Rating Scale (YMRS) are administered once a week for measurement.
62658596|NCT00574639|EXPERIMENTAL|Arm 3|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
62658597|NCT00574639|EXPERIMENTAL|Arm 4|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
62095032|NCT06697834|EXPERIMENTAL|Patient with plantar fasciitis|
62095033|NCT04057833|EXPERIMENTAL|E-CEL UVEC|"Patients will receive an injection of the Cell therapy vehicle into their supraspinatus muscle and tendon at the time of rotator cuff repair.~E-CEL UVEC cells suspended in autologous plasma and combined with thrombin at the implantation site (tendon delivery).~E-CEL UVEC cells suspended in 6.0% Dextran 40 and 10.0% human serum albumin (HSA) (infusion solution) (muscle delivery)."
62095034|NCT01755286|EXPERIMENTAL|4 mg OTO-201|
62095035|NCT01755286|EXPERIMENTAL|12 mg OTO-201|
62095036|NCT01755286|PLACEBO_COMPARATOR|Vehicle for OTO-201|
62095037|NCT01755286|SHAM_COMPARATOR|Sham|
62095038|NCT06623292|NO_INTERVENTION|Control group|"Mothers in this group will not receive any treatment in the study. Mothers will fill out the Breastfeeding Self-Efficacy Scale and Breastfeeding Motivation Scale four times: on the first day of the baby's NICU admission, when their baby is discharged, 15 days after discharge and one month later discharge. In addition, a follow-up form will be completed."
62095039|NCT06623292|EXPERIMENTAL|Intervention group|"Mothers in this group will receive motivational interview-based breastfeeding education. Mothers will fill out the Breastfeeding Self-Efficacy Scale and the Breastfeeding Motivation Scale four times: on the first day of the baby's NICU admission, when their baby is discharged, 15 days after discharge and one month later discharge. In addition, a follow-up form will be completed."
62095040|NCT04029480|EXPERIMENTAL|Ertugliflozin 5 mg/5 mg|"All participants will initially receive ertugliflozin (ERTU) 5 mg once daily (QD) and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at Week 12 (WK12), all participants that do not meet the up-titration criteria will remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54. Approximately half the participants who meet the up-titration criteria at the second randomization at WK12 will also remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a fasting fingerstick glucose (FFSG) of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
62292518|NCT01624194|ACTIVE_COMPARATOR|Oxytocin nasal spray|Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
62292519|NCT01624194|PLACEBO_COMPARATOR|Placebo nasal spray|The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.
62658598|NCT01980758|EXPERIMENTAL|Surgery|Laparoscopic Gastric Plication
62658599|NCT00580840|ACTIVE_COMPARATOR|Certolizumab pegol 400 mg and placebo|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
62658600|NCT00580840|EXPERIMENTAL|Certolizumab pegol 200 mg and placebo|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
62658601|NCT00580840|PLACEBO_COMPARATOR|Placebo|Placebo administered as two injections every 2 weeks
62658602|NCT02903108|ACTIVE_COMPARATOR|Boric acid group|Oral prophylaxis followed by 0.75% boric acid drug in gel form placed in intrabony defects
62658603|NCT02903108|PLACEBO_COMPARATOR|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
62292520|NCT02000609|ACTIVE_COMPARATOR|CHF 1535 NEXThaler 800/48 ug|single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate
62292521|NCT02000609|PLACEBO_COMPARATOR|CHF 1535 NEXThaler PLACEBO|single dose administration of placebo via NEXThaler DPI
62465308|NCT04448106|EXPERIMENTAL|Phase 2 Arm 3 - OA Hip|"50 subjects receive two doses of 2.0-2.86 x 10\^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10\^6 cells/kg via intra-articular injection into the injured joint."
62465309|NCT04448106|ACTIVE_COMPARATOR|Phase 2 Arm 4 - OA Hip|Control group- 50 subjects receive three doses of 2.0-2.86 x 10\^6 cells/kg on day 0, 3, and 6 via intravenous infusion
62465310|NCT04448106|EXPERIMENTAL|Phase 2 Arm 5 - OA Shoulder|"50 subjects receive two doses of 2.0-2.86 x 10\^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10\^6 cells/kg via intra-articular injection into the injured joint."
62095041|NCT04029480|EXPERIMENTAL|Ertugliflozin 5 mg/15 mg|"All participants will initially receive ERTU 5 mg QD and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at WK12, approximately half the participants who meet the up-titration criteria at the second randomization will up-titrate to ERTU 15 mg and placebo to ERTU 5 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a FFSG of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
62292522|NCT02000609|ACTIVE_COMPARATOR|CHF 1535 pMDI 200/12|single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate
62292523|NCT02000609|ACTIVE_COMPARATOR|CHF 1535 100/6 pMDI 800/48|single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate
62292524|NCT02000609|ACTIVE_COMPARATOR|CHF 1535 NEXThaler 200/12|single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate
62465311|NCT04448106|ACTIVE_COMPARATOR|Phase 2 Arm 6 - OA Shoulder|Control group- 50 subjects receive three doses of 2.0-2.86 x 10\^6 cells/kg on day 0, 3, and 6 via intravenous infusion
62292525|NCT03975998||Aymptomatic patients with severe mitral regurgitation|Watchful waiting Early Surgery
61908205|NCT04208113|EXPERIMENTAL|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the eight week MBSR programme (2,5 hour group meeting once a week) and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b (48 hours) The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
61908206|NCT04208113|NO_INTERVENTION|Usual practice|Usual practice
62095042|NCT04029480|PLACEBO_COMPARATOR|Placebo|At the first randomization, participants receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD for 12 weeks. Participants in the placebo group with HbA1C ≥7.0% (53 mmol/mol) at WK12 will be mock titrated. Note: The up-titration criteria for participants on insulin will include a FFSG of ≥110 mg/dL (6.1 mmol/L) in addition to HbA1C ≥7.0% (53 mmol/mol) at WK12. Participants will continue to receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD from WK24 to WK54. Participants will remain on their background metformin with/without insulin treatment throughout the study.
62095043|NCT04107506|EXPERIMENTAL|Filming Interactions to Nurture Development (FIND)|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly sessions lasting 30-45 minutes. The process begins with an initial session in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
62292526|NCT04409678|EXPERIMENTAL|activity|
62292527|NCT04409678|NO_INTERVENTION|bed rest|
62292528|NCT01855256|EXPERIMENTAL|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
62292529|NCT01855256|PLACEBO_COMPARATOR|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
62292530|NCT01897909||HIV positive with H. pylori infection|HIV positive patients with H. pylori infection
62292531|NCT01897909||HIV positive without H. pylori infection|HIV positive patients without H. pylori infection
62292532|NCT01897909||HIV negative|HIV negative blood donors
62292533|NCT01180803|EXPERIMENTAL|oxygen-saving valves|
62292534|NCT01180803|ACTIVE_COMPARATOR|continuous oxygen supplementation|
62292535|NCT02119520|ACTIVE_COMPARATOR|Platelet rich fibrin + atorvastatin|In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD
62465312|NCT04607863||Low back pain|Patients with low back pain
61908207|NCT04950868|EXPERIMENTAL|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
61908208|NCT00448396|EXPERIMENTAL|Patupilone|
61908209|NCT05229861|EXPERIMENTAL|High-intensity Interval Training (HIIT)|Participants will complete seven HR-controlled HIIT sessions within their 3-week inpatient stay, corresponding to 3 exercise bouts per week.
61908210|NCT05229861|ACTIVE_COMPARATOR|Moderate Continuous Training (MCT)|MCT represents the standard treatment at Valens rehabilitation clinic. Participants will complete seven HR-controlled MCT sessions within their 3-week inpatient stay, corresponding to 3 exercise bouts per week.
61908211|NCT02753088|EXPERIMENTAL|BCD-063 (glatiramer acetate)|Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day
61908212|NCT02753088|ACTIVE_COMPARATOR|Copaxone-Teva (glatiramer acetate)|Subcutaneous injection of glatiramer acetate Copaxone-Teva subcutaneously every day
61908213|NCT02753088|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection of mannitol 40 mg, water for injections till 1 ml, every day
61908214|NCT01911910|NO_INTERVENTION|Standard care|Usual care that would be provided by the NHS Health Check or equivalent.
61908215|NCT01911910|EXPERIMENTAL|Electronic coaching plus standard care|Tailored coaching for participants randomised to use the HAPPY e-coaching tool. Access to lifestyle and heart health scores and personalised advice to improve suboptimal behaviour.
62292536|NCT02119520|SHAM_COMPARATOR|Platelet rich fibrin|In Platelet rich fibrin group PRF was inserted into the depth of the IBD.
62292537|NCT02119520|OTHER|Open flap debridement|open flap debridement was followed by no grafting or regenerative intervention.
62292538|NCT01335971|ACTIVE_COMPARATOR|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
62465313|NCT04607863||No low back pain|No low back pain patients
62095044|NCT04107506|ACTIVE_COMPARATOR|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 sessions each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
62095045|NCT03040219|ACTIVE_COMPARATOR|Treatment group|
62095046|NCT03040219|PLACEBO_COMPARATOR|Control|
62095047|NCT02500927|EXPERIMENTAL|ASP8273 group|Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
62095048|NCT04400708|SHAM_COMPARATOR|control group|normal saline injection
61908216|NCT02069067||Advanced cancer patients with pain|
61908217|NCT00909207||Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
62095049|NCT04400708|EXPERIMENTAL|test group|0.5% ropivacaine injection
62095050|NCT06259981|EXPERIMENTAL|GLY-200|Participants will receive 2.0 g GLY-200 orally twice daily for 16 weeks.
62095051|NCT06259981|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (identical in appearance to GLY-200) orally twice daily for 16 weeks.
62095052|NCT05355922|SHAM_COMPARATOR|Aussie current (placebo) and Exercises|
62095053|NCT05355922|EXPERIMENTAL|Aussie current and Exercises|
62095054|NCT06671483|EXPERIMENTAL|Zasocitinib Dose A|Participants will receive zasocitinib Dose A, tablets, orally, once daily (QD) for up to Week 52.
62095055|NCT06671483|EXPERIMENTAL|Zasocitinib Dose B|Participants will receive zasocitinib Dose B, tablets, orally, QD for up to Week 52.
62292539|NCT01335971|ACTIVE_COMPARATOR|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
62292540|NCT01335971|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose
61908218|NCT04631094|EXPERIMENTAL|Group 1|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken
62095056|NCT06671483|ACTIVE_COMPARATOR|Active Comparator Dose C|Participants will receive active comparator Dose C, capsules, orally, twice daily (BID) for up to Week 52.
62095057|NCT06671483|EXPERIMENTAL|Placebo + Zasoctinib|Participants will receive placebo, orally, QD for up to Week 16, followed by zasoctinib Dose A or Dose B, orally, QD, from Week 16 up to Week 52.
62095058|NCT05397015||postmenopausal women|A cohort of 200 postmenopausal women
62095059|NCT00423644|EXPERIMENTAL|Single Arm|
62095060|NCT04051619|EXPERIMENTAL|oxytocin|The oxytocin will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
62095061|NCT04051619|PLACEBO_COMPARATOR|matching placebo|The oxytocin-matched placebo will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
62095062|NCT01833975|OTHER|stem cell [ MNCs ]|transplantation of autologous stem cell \[MNCs \]
62292541|NCT01236391|EXPERIMENTAL|Participants received PCI-32765 560 mg daily|Participants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.
62292542|NCT00869297|ACTIVE_COMPARATOR|Control|
62292543|NCT00869297|EXPERIMENTAL|Intervention|These patients receive fluid boluses based on measurements from the FloTrac
62292544|NCT02351102|ACTIVE_COMPARATOR|Valacyclovir|Participants will receive Valacyclovir at a dose of 8g/d starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
62292545|NCT02351102|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo pills (same daily amount as the intervention group) starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
62292546|NCT03352245|EXPERIMENTAL|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
62292547|NCT03352245|NO_INTERVENTION|Control Group|Usual care group will receive standard of care management from their Oncologist.
62292548|NCT05547945|OTHER|health promotion program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
62292549|NCT05547945|NO_INTERVENTION|Control group|The control received as usual care.
62292550|NCT00755820||EXP-DCS/Exposure-D-cycloserine|Exposure Therapy + D-Cycloserine
62292551|NCT00755820||EXP-PBO|Exposure Therapy + Placebo
62292552|NCT00755820||SP|Supportive psychotherapy
62292553|NCT03311672|EXPERIMENTAL|Cohort 1 - Immunotherapy Alone|Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
62292554|NCT03311672|EXPERIMENTAL|Cohort 2 - Immunotherapy with Stereotactic Radiation|Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
62292555|NCT05352685|ACTIVE_COMPARATOR|Healthy volunteers|
62292556|NCT05352685|EXPERIMENTAL|supratentorial glioma patients|
62292557|NCT05946590|OTHER|Frenotomy|Frenotomy performed by a health care professional
62292558|NCT06334367|EXPERIMENTAL|CD25 treatment|The humanized CD25 antibody was administered at 1 mg/kg iv on days+4 and +7 after HSCT.
62095063|NCT05915130|EXPERIMENTAL|Virtual reality training program|In the VR group, participants will practice the training sessions in an experimental room. In one training session, participants will negotiate 60 trials. Participants will practice gait training sessions in a fully immersive virtual reality. They will negotiate virtual obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
62292559|NCT06334367|OTHER|control group|
62292560|NCT01871883|EXPERIMENTAL|Sensitive Skin|Subjects with sensitive skin, diagnosed by the lactic acid stinging test. Skin biopsy Oral mucosa specimen
62292561|NCT01871883|ACTIVE_COMPARATOR|Non-sensitive skin|Subjects without sensitive skin, determined by a negative lactic acid stinging test Skin biopsy Oral mucosa specimen
62292562|NCT06072014|EXPERIMENTAL|Head-mounted display (HMD)|The HMD system uses a commercially available virtual headset, the Oculus/Meta Quest 2, which allows a user to view a virtual environment in 360 degrees and to interact with the environment using hand-tracking technology (i.e., when a user's hand is projected into the virtual world to be used for interactions and gestures).
62095064|NCT05915130|EXPERIMENTAL|Nordic walking training program|Participants will be instructed to walk with poles continuously around the park. Each training session will consist of a warm-up (10 min), main exercise (40 min), and cool-down (5 min) periods. Participants will adapt their locomotion to uneven terrain. They will negotiate natural obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
62095065|NCT01305824|ACTIVE_COMPARATOR|PRT 201 (10 micrograms)|
62292563|NCT06072014|EXPERIMENTAL|Semi-cave automatic virtual environment (semi-CAVE)|The semi-CAVE system uses projectors and projector screens to provide a 270-degree view of the virtual environment. These projectors are connected to a powerful workstation (desktop computer), which uses HTC Vive trackers and base stations to track user movements and interactions
62292564|NCT03192904|EXPERIMENTAL|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
62292565|NCT03192904|EXPERIMENTAL|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
62292566|NCT02683369|EXPERIMENTAL|Iron Supplement|Participants will consume one tablet of Blood Builder®/Iron Response®, once per day, every day, for 8 weeks.
62292567|NCT05405829|ACTIVE_COMPARATOR|Control group|Conventional information received by caregivers. The speech therapist comes to the room to pass the Volume viscosity exploratory method test (V-VST) Test and after confirming dysphagia, informs the patient of the test result and delivers a booklet of recommendations.
62292568|NCT05405829|EXPERIMENTAL|Intervention group|A 45-minute session, hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
62292569|NCT05548036|ACTIVE_COMPARATOR|OPEP|Oscillatory Positive Expiratory Pressure OPEP is a technique aimed at loosening and mobilising secretions it can be achieved by using a device (AerobikaTM). The device provides pulses of resistance as you exhale acting to open airways and shake secretions, enabling expectoration using a huff and cough technique. Key factors to consider when completing a treatment session are body position, users should be seated, with good posture, in a comfortable position.
62292570|NCT05548036|ACTIVE_COMPARATOR|ACBT|Active Cycle of Breathing Technique ACBT is a method of breathing performed in a cycle, used to help loosen and clear secretions from within the lungs (Panaligan et al., 2012). It consists of three different phases.
62292571|NCT02529527|EXPERIMENTAL|MyFamilyPlan|Web-based health education tool (interactive self-assessment) provided for participant completion 7-10 days prior to a scheduled primary care visit.
61908219|NCT04631094|EXPERIMENTAL|Group 2|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.
61908220|NCT04631094|EXPERIMENTAL|Group 3|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken
62095066|NCT01305824|PLACEBO_COMPARATOR|Placebo|
62095067|NCT01305824|ACTIVE_COMPARATOR|PRT-201 (30 micrograms)|
62095068|NCT06697080|EXPERIMENTAL|Group A|Group A visited the clinic once each in the first, second, and third months for treatment with exosomes
62095069|NCT06697080|EXPERIMENTAL|Group B|Group B visited the clinic twice each in the first, second, and third months for treatment with exosomes.
62095070|NCT05586217|EXPERIMENTAL|Incentive Spirometry|12 weeks, 1 session per week; each session took about 1 hour.
62095071|NCT05586217|ACTIVE_COMPARATOR|Active Cycle of Breathing|Breathing Control Deep Breathing Exercises or Thoracic Expansion Exercises Huffing or Forced Expiratory Technique (FET)
62095072|NCT01426815|PLACEBO_COMPARATOR|Placebo|
62095073|NCT01426815|EXPERIMENTAL|Golimumab 50mg (Simponi ®)|
61908221|NCT04631094|EXPERIMENTAL|Group 4|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.
61908222|NCT04631094|NO_INTERVENTION|Group 5|The group that will undergo standard hospital blood collection procedure.
61908223|NCT03273218|EXPERIMENTAL|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
61908224|NCT03273218|ACTIVE_COMPARATOR|Judkins catheter|Judkins right and judkins left catheter
62095074|NCT01899209|EXPERIMENTAL|Group A|STARR
62095075|NCT01899209|EXPERIMENTAL|Group B|Laparoscopic ventral Rectopexy
62095076|NCT05169021|ACTIVE_COMPARATOR|Amlodipine folic acid 5.8mg+intensive antihypertensive therapy|This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) \<130 mmHg); with amlodipine folic acid 5.8mg.
62095077|NCT05169021|ACTIVE_COMPARATOR|Amlodipine folic acid 5.8mg+standard antihypertensive therapy|This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine folic acid 5.8mg.
62095078|NCT05169021|ACTIVE_COMPARATOR|Amlodipine+intensive antihypertensive therapy|This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) \<130 mmHg); with amlodipine 5.0mg.
62292572|NCT02529527|NO_INTERVENTION|Control|Standard preconception health education document provided for participant review 7-10 days prior to a scheduled primary care visit.
61908225|NCT01860183|EXPERIMENTAL|MMF 3g daily|
61908226|NCT01860183|ACTIVE_COMPARATOR|MMF 2 g daily|
62095079|NCT05169021|PLACEBO_COMPARATOR|Amlodipine+standard antihypertensive therapy|This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine 5.0mg.
62095080|NCT02883322||Initial|Patients answering the initial translation
62095081|NCT02883322||Committee-only|Patients answering the translation modified by an expert committee
62095082|NCT02883322||BT-only|Patients answering the translation modified with the use of a back-translation
62095083|NCT02883322||Both|Patients answering the translation modified by an expert committee with the use of a back-translation
62095084|NCT04011384|NO_INTERVENTION|Control Group|Participants in this arm will view the typical web-based ordering system platform (usual care group).
62292573|NCT01239407|NO_INTERVENTION|Treatment as usual|"The treatment as usual arm consists of two phone or in-person interviews:~1. Patients are asked questions about their mental health, their views of mental health, and how they cope with their mental health (including any treatment they might be receiving).~2. Patients are asked the same questions 6 months after the initial interview."
62095085|NCT04011384|EXPERIMENTAL|Behavioral Economic Intervention Group|Participants in this arm will be exposed to the web-based ordering system with multiple behavioral economic interventions applied, including healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
62095086|NCT03888365||Cohort A: Treprostinil|Participants who are currently prescribed and using inhaled treprostinil for the treatment of PAH.
62095087|NCT03888365||Cohort B: Non-Treprostinil PAH Medications|Participants who are taking other PAH medications (instead of inhaled treprostinil).
62095088|NCT00310713|EXPERIMENTAL|Group 1|
62095089|NCT00310713|EXPERIMENTAL|Group 2|
62095090|NCT00310713|EXPERIMENTAL|Group 3|
62095091|NCT00310713|EXPERIMENTAL|Group 4|
62095092|NCT00310713|EXPERIMENTAL|Group 5|
62465314|NCT00283699|ACTIVE_COMPARATOR|1|"1. albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy~2. placebo plus standard symptomatic therapy"
62465315|NCT00283699|PLACEBO_COMPARATOR|2|
62292574|NCT01239407|EXPERIMENTAL|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
62292575|NCT01541566||Home blood pressure telemonitoring|Patients regularly monitoring their blood pressure at home with an electronic validated upper arm device, transmitting blood pressure values at monthly intervals to the doctors office through the Internet.
62095093|NCT05806216||2a - Model Development|Enrollment for the purposes of training the EarliPoint system data models in children ages 31-84 months suspected of autism spectrum disorder or related developmental delays or those who are typically developing.
62095094|NCT05806216||2b - Model Testing|Enrollment for the purposes of testing/validating the EarliPoint system data models in children ages 31-84 months suspected of autism spectrum disorder or related developmental delays or those who are typically developing.
62095095|NCT04464941|EXPERIMENTAL|oral health promotion program|"The oral health promotion program was a composite intervention with both group and individual components. The group intervention consisted of:~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1. Instruction in the Bass tooth-brushing method 2. Individual behavioral modification method"
62292576|NCT01541566||Conventional blood pressure measurement|Blood pressure measured only in the doctor's office during quarterly visits, without regular home blood pressure monitoring.
62292577|NCT04070794|ACTIVE_COMPARATOR|FDC Zemimet® SR Tab. 50/1000(Fasting)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fasting condition
62292578|NCT04070794|ACTIVE_COMPARATOR|FDC Zemimet® SR Tab. 50/1000(Fed)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fed condition
62465316|NCT00537030|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive 6 doses of Erwinia asparaginase IM on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.
62465317|NCT00986245|ACTIVE_COMPARATOR|Ropinirole PR QD first, then BID|Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
62095096|NCT04464941|NO_INTERVENTION|Usual care group|
62095097|NCT02036060|EXPERIMENTAL|Arm A|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
62095098|NCT02036060|ACTIVE_COMPARATOR|Arm B|docetaxel 75 mg/m2 + prednisone 10 mg/d
62095099|NCT06697119|EXPERIMENTAL|FMT|Fecal microbiota transplantation: fecal suspension delivered to duodenal 3rd portion via esophagogastroduodenoscopy
62095100|NCT05254730|EXPERIMENTAL|micro-macroelectrodes|Patients will be implanted with usually the novel intracerebral micro-macroelectrodes (instead of the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
62095101|NCT02542514|EXPERIMENTAL|Ibrutinib|ibrutinib in monotherapy 28 days/cycles
62292579|NCT01216774|EXPERIMENTAL|Low load + fatigue|
62292580|NCT01216774|ACTIVE_COMPARATOR|High load|
62292581|NCT01216774|PLACEBO_COMPARATOR|Low load|
62292582|NCT05932719||Peritoneal Carcinosis|Patients hospitalized for peritoneal carcinosis between 2017 and 2020.
62292583|NCT05932719||Hepatocellular Carcinoma|Patients hospitalized for hepatocellular carcinoma between 2017 and 2020.
62465318|NCT00986245|ACTIVE_COMPARATOR|Ropinirole PR BID first, and then QD|Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing
62465319|NCT02389491|ACTIVE_COMPARATOR|normal density formula (Neocate)|In control group,infants intake normal density formula (Neocate,67kcal/100ml) when starting enteral nutrition after operation and continue for 7days
62465320|NCT02389491|EXPERIMENTAL|high density formula (Infatrini)|In the intervention group,infants intake high density formula (Infatrini, 100kcal/100ml) when starting enteral nutrition after operation and continue for 7days
62465321|NCT02189941|EXPERIMENTAL|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
62465322|NCT02189941|EXPERIMENTAL|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
62465323|NCT02189941|ACTIVE_COMPARATOR|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
62465324|NCT05267691||sun-protected|All patients with basal cell carcinoma in a sun protected body site
62465325|NCT05267691||sun-exposed|All patients with basal cell carcinoma in a sun exposed body site
62465326|NCT04700774|EXPERIMENTAL|mBA|Motor enhanced behavioral activation. 10 sessions.
62095102|NCT01631708|ACTIVE_COMPARATOR|Erythrocytapheresis|"Erythrocytapheresis is a procedure whereby whole blood is drawn from an individual and all elements except erythrocytes are returned to the donor. An automated filtration process removes the erythrocytes.~Those in arm 1 will have third weekly erythrocytapheresis until their SF is returned to the normal range."
62095103|NCT01631708|SHAM_COMPARATOR|Plasmapheresis|"In plasmapheresis, the plasma is removed by the automated filtration process whilst other blood elements including erythrocytes are returned to the subject.~Those in arm 2 will have plasmapheresis with the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm."
62095104|NCT05518513|EXPERIMENTAL|Continuous infusion|adductor canal block with continuous infusion of 0.25% bupivacaine 3.5 ml per hour for 2 days postoperatively
62095105|NCT05518513|ACTIVE_COMPARATOR|12hrs intermittent bolus|adductor canal block with intermittent bolus of 0.25% bupivacaine 21 ml every 12 hours for 2 days postoperatively
62095106|NCT05518513|EXPERIMENTAL|6hrs intermittent bolus|adductor canal block with intermittent bolus of 0.25% bupivacaine 21 ml every 6 hours for 2 days postoperatively
62095107|NCT05035212|EXPERIMENTAL|Efficacy Study: RSVpreF vaccine|RSVpreF
62095108|NCT05035212|PLACEBO_COMPARATOR|Efficacy Study: Placebo dose|Placebo
62095109|NCT05035212|EXPERIMENTAL|SSA: Vaccination of RSVpreF recipients with RSVpreF (Year 2 revaccination)|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive RSVpreF in SSA.
62095110|NCT05035212|PLACEBO_COMPARATOR|SSA: Vaccination of RSVpreF recipients with Placebo|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive Placebo in SSA.
62095111|NCT05035212|EXPERIMENTAL|SSB: Vaccination of RSVpreF recipients with RSVpreF (Year 1 revaccination)|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive RSVpreF in SSB.
62095112|NCT05035212|PLACEBO_COMPARATOR|SSB: Vaccination of RSVpreF recipients with Placebo|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive Placebo in SSB.
62095113|NCT05035212|EXPERIMENTAL|SSC: Vaccination of RSVpreF recipients with RSVpreF (Year 3 revaccination)|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive RSVpreF at the Year 3 vaccination followed by placebo at the Year 4 vaccination in SSC.
62095114|NCT05035212|EXPERIMENTAL|SSC: Vaccination of RSVpreF recipients with RSVpreF (Year 4 revaccination)|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive placebo at the Year 3 vaccination followed by RSVpreF at the Year 4 vaccination in SSC.
62095115|NCT05035212|PLACEBO_COMPARATOR|SSC: Vaccination of RSVpreF recipients with Placebo|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive placebo at both the Year 3 and Year 4 vaccination in SSC.
62095116|NCT02506387||Mitraclip patients|Patients with severe mitral regurgitation in whom decision for mitraclip implantation was made by the heart team.
62095117|NCT05509400|EXPERIMENTAL|Rimegepant|"Rimegepant - Double-blind (DB) Phase: One dose of rimegepant 75 mg Oral Disintegrating Tablet (ODT)~Rimegepant/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT as needed for a qualifying acute migraine. A qualifying migraine is an attack of moderate or severe headache pain intensity. Migraine headache pain intensity will be measured on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe)"
62292584|NCT01907165|EXPERIMENTAL|Maintenance Temozolomide + Disulfram|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses\* in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
62465327|NCT04700774|EXPERIMENTAL|BA|Standard behavioral activation. 10 sessions.
62658604|NCT03077776|EXPERIMENTAL|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:~1. (optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy~2. At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).~3. Biopsy of a metastatic site in the event of disease recurrence.~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
62465328|NCT04700774|NO_INTERVENTION|Waitlist|10 week waitlist.
62658605|NCT05026918|ACTIVE_COMPARATOR|Group A|all the components of Manual Chest Physiotherapy wer performed on the patients of this group. MCPT was done few hours before meals and it was made sure that nothing was in patient's mouth while doing chest physiotherapy. MCPT includes postural drainage, percussion and vibrations. Chest Physiotherapy was done thrice a day for 30 minutes and there were 21 sessions a week.
62658606|NCT05026918|EXPERIMENTAL|Group B|all the components of Active Cycle of Breathing techniques (ACBT) were performed on the patients of this group. ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique. These were performed thrice a day for 30 minutes and for 21 sessions a week.
62658607|NCT04755517|ACTIVE_COMPARATOR|A1|Frequent information of screening results for cytology and/or HPV DNA at the ages of 25 (cytology only) and 28 (cytology only) vs A2
62658608|NCT04755517|NO_INTERVENTION|A2|infrequent information of cytological screening/ HPV DNA results, only at the age 28 years.
62658609|NCT04755517|ACTIVE_COMPARATOR|C|The third arm with at 8000 participants devoid of herd effect protection and frequent screening at ages 25 and 28 is enrolled for comparative analyses between A1 vs. C and A2 vs. C.
62658610|NCT06199739|EXPERIMENTAL|Early-Weight bearing|Early Weight bearing was defined as starting Weight bearing within 48 h postoperatively, and WBAT referred to the adjustment of fracture site weight-bearing by pain tolerance.
62658611|NCT01909102|EXPERIMENTAL|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
62095118|NCT05509400|PLACEBO_COMPARATOR|Placebo|"Placebo - Double-blind (DB) Phase: One dose of matching placebo~Placebo/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT for a qualifying migraine"
62095119|NCT02752152|EXPERIMENTAL|Computer-assisted counseling|Computer-assisted informational/educational interactive session followed by an interactive face-to-face session to discuss personal issues with a counselor as needed
62658612|NCT01909102|ACTIVE_COMPARATOR|Usual care|Usual care is based on current guidelines for the long-term multi-disciplinary rehabilitation and prevention of cardiac patients.
62658613|NCT04546698||Multiple Sclerosis patients with an acute relapse|Multiple Sclerosis diagnosed according to Mc Donald's criteria with an acute relapse
62658614|NCT04546698||Multiple sclerosis pataients treated with Natalizumab|Multiple Sclerosis patients diagnosed according to Mc Donald's criteria and treated with Natalizumab since 6 cures
62658615|NCT04546698||Healthy people|
62095120|NCT02752152|EXPERIMENTAL|On-demand counseling|The counselor asks whether the participant has any questions
62465329|NCT01770938|ACTIVE_COMPARATOR|Effective light-emitting diode therapy and training|Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
62658616|NCT00909974|EXPERIMENTAL|Food supplement (FS)|Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
62658617|NCT00909974|ACTIVE_COMPARATOR|UNIMMAP|UNIMMAPin tablet form: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
62658618|NCT05836623|EXPERIMENTAL|Part A - Optimisation Phase|Following administration of 89Zr-CB307, patients will undergo PET scans The timing of the scans and CB307 dose administration will be determined by the Optimisation Review Committee (ORC)
62658619|NCT05836623|EXPERIMENTAL|Part B - Expansion phase|89Zr-CB307 PET scanning will be performed based on the optimal dosing and timing determined in Part A by the Optimisation Review Committee (ORC)
62095121|NCT02752152|ACTIVE_COMPARATOR|Standard counseling|Interactive face-to-face counseling session
62465330|NCT01770938|PLACEBO_COMPARATOR|Placebo light-emitting diode therapy and training|Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
62465331|NCT04225663|ACTIVE_COMPARATOR|Intervention group|The Intervention group will receive 30-minute sessions of guided meditation. During meditation, they will lie down with their backs and torsos elevated by a mat/soft blocks. They will undergo guided breath work.
62095122|NCT02752152|EXPERIMENTAL|Appointment + reminder|Make appointment and send SMS reminder
62095123|NCT02752152|EXPERIMENTAL|Reminder only|Send SMS reminder only
62095124|NCT02752152|ACTIVE_COMPARATOR|No appointment and no reminder|No appointment and no SMS reminder sent
62465332|NCT04225663|NO_INTERVENTION|Control group|The Control group will not have intervention. They will have quiet, independent study for 30-minute sessions.
62465333|NCT01516983|EXPERIMENTAL|Icotinib+WBRT|"Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to 3+3 until disease progression or intolerable toxicity."
62658620|NCT04050605|EXPERIMENTAL|somofilcon A toric (habitual), then fanfilcon toric (test)|Participants are habitual wearers of somofilcon A toric lens and refitted with fanfilcon A toric lens.
62658621|NCT01334099|EXPERIMENTAL|Radiation combined with CP-675,206|
62292585|NCT01907165|EXPERIMENTAL|Maintenance Temozolomide + Disulfiarm + Copper Gluconate|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months, disulfiram 500 mg PO QD (dose of disulfiram determined to be the MTD) on Days 1-28, and copper gluconate 6 mg PO QD on Days 1-28. Treatment repeats every 28 days for 6 courses\* in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
62658622|NCT03809585||Iris Tumors|This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
62292586|NCT02504255||Patients with Crohn's Disease|patients will have biological samplings (blood, urine and faecal sampling) and will fill questionnaires to assess their stress and adaptation
62465334|NCT03803800|EXPERIMENTAL|Classic training & beta-alanine|Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
62465335|NCT03803800|PLACEBO_COMPARATOR|Classic training & placebo|Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
62465336|NCT03803800|EXPERIMENTAL|Periodized training & beta-alanine|Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
62658623|NCT03809585||Healthy Controls|This group will consist of 50 adults age 18 and older who have healthy eyes.
62095125|NCT06317025||General anaesthetic patient|Monitoring depth of anaesthesia using PRST （P：pressure， T：tear，R：rate， S：sweat）score developed by Evans and bispectral index
62292587|NCT03766347||Pediatric Neuromyelitis Optica|Participants under the age of 18 that are positive for Aquaporin-4 antibody.
62292588|NCT04335487|EXPERIMENTAL|ICBT for PTSD Tailored for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy for PTSD tailored specifically for Canadian public safety personnel.
62658624|NCT00609505|OTHER|TM|Telemedicine genetic counseling group
62658625|NCT00609505|OTHER|FTF|Face-to-face genetic counseling group
62658626|NCT06244901|EXPERIMENTAL|Exoskeleton Walking|Walking with ankle exoskeleton assistance
62658627|NCT06244901|PLACEBO_COMPARATOR|Normal walking|Walking under normal conditions (no exoskeleton)
62658628|NCT05123924||POMS Group|Individuals in the POMS group will be evaluated in terms of respiratory capacity, respiratory muscle strength and fatigue.
62292589|NCT04335487|EXPERIMENTAL|Transdiagnostic ICBT Tailored for PSP|Therapist-guided, transdiagnostic Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
62292590|NCT01938157|EXPERIMENTAL|High Risk Breast Cancer Patients|High Risk Breast Cancer Patients (all subjects)
62292591|NCT05859087|EXPERIMENTAL|Bedside Family Planning Counseling|Patient is screened for pregnancy intention and then has a bedside family planning counseling session with the investigator taking into account pregnancy intention, medical conditions, medications, and previous contraception used. At the end of the conversation, if patient is desiring contraception, the patient is offered three contraception options (as appropriate for their medical conditions and paid for as part of the study) to be initiated prior to discharge: Etonogestrel implant, medroxyprogesterone 150 mg IM injection, or a year's supply of oral contraception pills.
62658629|NCT05123924||Control Group|Individuals in the control group will be evaluated in terms of respiratory capacity, respiratory muscle strength and fatigue.
62095126|NCT02860923|EXPERIMENTAL|Exenatide|Treatment with exenatide at the initial dose of 5 µg x 2/day (subcutaneously administered) during 4 weeks, and treatment with 10 µg x 2/day during 5 months.
62095127|NCT02860923|PLACEBO_COMPARATOR|Placebo|Patients will be maintained on placebo (injected subcutaneously, twice a day) with the same dose and frequency than exenatide arm.
62465337|NCT03803800|PLACEBO_COMPARATOR|Periodized training & placebo|Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
62465338|NCT05070260|EXPERIMENTAL|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to thrombolysis +/- mechanical thrombectomy
62465339|NCT05070260|PLACEBO_COMPARATOR|Intravenous Placebo|Intravenous Placebo to be added to thrombolysis +/- mechanical thrombectomy
62465340|NCT05044221||Interviews: Past ICU patients and caregivers|Former ICU patients and their families that meet the following criteria: Adults \> 18 years and above who required at least 48 hours of invasive mechanical ventilation and were in the ICU at least 4 days with an ICU admission in the past five years; and able to participate in a workshop in English.
62465341|NCT05044221||Interviews: Health care professionals|Active working health professionals with prior experience working directly in the ICU setting and/or care for ICU patients in their own clinical rea (acute, subacute and/or community settings).
62465342|NCT01975688|EXPERIMENTAL|Sativex: pre-treatment (Grade 0)|The PKs of a single dose of Sativex are investigated in subjects with mucositis of Radiation Therapy Oncology Group (RTOG) Grade 0 (i.e. at baseline, pre-induction of mucositis).
62658630|NCT04321395|EXPERIMENTAL|Vigabatrin|
62658631|NCT04256200|ACTIVE_COMPARATOR|Dienogest|Deinogest (Visanne) 2mg/day orally for 24 weeks
61908227|NCT02366533||Sites Implementing the LTC Program|This study will be conducted at the 15 ATN-funded clinical sites, known as the Adolescent Medicine Trial Units (AMTU). Each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the Strategic Multisite Initiative for the Identification, Linkage, and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) Project.
62465343|NCT01975688|EXPERIMENTAL|Sativex: mild mucositis (Grade 1)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 1 (mild).
61908228|NCT01239719|EXPERIMENTAL|Dexamethasone + Clemastine|Dexamethasone + clemastine fumarate cream
61908229|NCT01239719|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 0.5 mg
61908230|NCT06277453||AC ≥5|Patients with lymph node-negative gastric cancer who received neoadjuvant chemotherapy and underwent at least five cycles of adjuvant chemotherapy (AC ≥5) after surgery
61908231|NCT06277453||AC <5|Patients with lymph node-negative gastric cancer who received neoadjuvant chemotherapy and underwent at less five cycles of adjuvant chemotherapy (AC \<5) after surgery
61908232|NCT00883519|ACTIVE_COMPARATOR|IPT-A|
62658632|NCT04256200|ACTIVE_COMPARATOR|Oral Contraceptive Pills|Oral contraceptive pill (Yasmin, 0.03mg Ethinyl Estradiol and 3mg Drospirenone) orally daily for 24 weeks
62658633|NCT00396292|EXPERIMENTAL|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
62658634|NCT00396292|ACTIVE_COMPARATOR|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
62658635|NCT01136954|EXPERIMENTAL|1|
62658636|NCT03346343|EXPERIMENTAL|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
62658637|NCT03199105|EXPERIMENTAL|preoperative education and tetracaine|
62658638|NCT03199105|EXPERIMENTAL|tetracaine|
62658639|NCT06109298|EXPERIMENTAL|First study group|Before performing intravenous intervention, cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedure. After tourniquet fixation and subsequent skin disinfection for 60 seconds, the nurse researcher performed intravenous administration.
61908233|NCT00883519|ACTIVE_COMPARATOR|IPT-AP|
61908234|NCT04546828|EXPERIMENTAL|Gemcitabine, Cisplatin, and Nab-Paclitaxel|"* Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days"
61908235|NCT02129842||Atrial Fibrillation|
61908236|NCT04110652|ACTIVE_COMPARATOR|patient|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.(20-22) in addition to pulmonary rehabilitation program.
61908237|NCT04110652|PLACEBO_COMPARATOR|control group|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.
61908238|NCT03827915|NO_INTERVENTION|Third trial of DC cardioversion|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive a third trial of DC cardioversion (Standard of care)
62465344|NCT01975688|EXPERIMENTAL|Sativex: moderate mucositis (Grade 2)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 2 (moderate).
62465345|NCT01975688|EXPERIMENTAL|Sativex: severe mucositis (Grade 3)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 3 (severe).
62658640|NCT06109298|EXPERIMENTAL|Second study group|Before the intravenous intervention, refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated. After that, the nurse removed the gel ice from the procedure area, a tourniquet was applied, and skin disinfection was performed for 60 seconds. The nurse researcher performed intravenous administration.
62095128|NCT06434649|EXPERIMENTAL|the posterior approach extrafascial technique group|In 2010, Italian urologist Dr Bocciardi carried out the first clinical practice of separation and resection of the prostate via the vesicorectal fossa, and this new surgical procedure was called Retzius-sparing Robotic Assisted Radical Prostatectomy (RS-RARP). In recent years, the posterior approach extrafascial technique of RS-RARP which has been used to widely resect the prostate and its surrounding fascia and neurovascular bundles, compared with RS-RARP, has been proposed to provide more complete resection of the tumour and reduce the rate of positive margins. The patients are included into the posterior approach extrafascial technique group who undergo the posterior approach extrafascial technique of RS-RARP.
62095129|NCT06434649|ACTIVE_COMPARATOR|the anterior approach extrafascial technique group|Anterior approach extrafascial technique is the most traditional method of radical prostatectomy for prostate cancer, in which the prostate is tied ventrally to expose the prostate by cutting the deep dorsal penile vein complex and the surrounding ligaments and fascia, and intraoperatively extensive resection is required to remove the prostate and its surrounding fascia and neurovascular bundles. The patients are included into the anterior approach extrafascial technique group who undergo the anterior approach extrafascial technique robotic assisted radical prostatectomy.
62095130|NCT06232525|ACTIVE_COMPARATOR|transobturator tape operation group|Patients who are decided to undergo surgery due to stress urinary incontinence are the group who will undergo TOT surgery through a lottery system where the computer program will decide on the surgeon who will perform the surgery, without being told which surgery they will have (both surgeries will be performed through the mid-urethral approach and the patient will not be told whether mesh is used or not).
62095131|NCT06232525|ACTIVE_COMPARATOR|urethral ligament plication group|Patients who are decided to undergo surgery due to stress urinary incontinence are the group who will undergo urethral ligament plication surgery through a lottery system where the computer program will decide on the surgeon who will perform the surgery, without being told which surgery they will have (both surgeries will be performed through the mid-urethral approach and the patient will not be told whether mesh is used or not).
62095132|NCT06444529|EXPERIMENTAL|Apraclonidine Hydrochloride Ophthalmic Solution|One drop in each eye on Day 1, followed by 2 drops in each eye on Day 2 onward for approximately 8 weeks
62095133|NCT06444529|PLACEBO_COMPARATOR|Vehicle|One drop in each eye on Day 1, followed by 2 drops in each eye on Day 2 onward for approximately 8 weeks
62465346|NCT03499847|ACTIVE_COMPARATOR|Active Intervention|subjects will be given a pamphlet about the advanced medical directive, and a standardized face-to-face counselling session will be conducted with their healthcare provider
62465347|NCT03499847|ACTIVE_COMPARATOR|Passive Intervention|subjects will be given a pamphlet about the advanced medical directive
62465348|NCT03499847|NO_INTERVENTION|Control|
62465349|NCT00800137|ACTIVE_COMPARATOR|Bridging anti-coagulation|Low Molecular Weight Heparin or IV unfractionated Heparin
62465350|NCT00800137|EXPERIMENTAL|Continued oral anti-coagulation|Coumadin
62095134|NCT01747161|EXPERIMENTAL|botulin toxin|botulin toxin
62095135|NCT01747161|PLACEBO_COMPARATOR|physiological water|physiological water
62095136|NCT06481930||The cervical lesion was detected by fluorescence photoelectricity in the enrolled patients|The enrolled patients were detected with fluorescence photoelectric cervical lesion image detector.
62095137|NCT03422978|SHAM_COMPARATOR|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting after intubation.
62465351|NCT05730166|EXPERIMENTAL|Mechanical stimulation at moderate pain intensity|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 5/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
61908239|NCT03827915|EXPERIMENTAL|Double sequential external defibrillation|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive DSED
62095138|NCT03422978|EXPERIMENTAL|Dexmedetomidine 0.25 mcg/kg|0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
62465352|NCT05730166|ACTIVE_COMPARATOR|Mechanical stimulation at mild pain intensity|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 2/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
62465353|NCT05730166|ACTIVE_COMPARATOR|Painless mechanical stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 0/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
62465354|NCT00830232|ACTIVE_COMPARATOR|Closed-cell stent (Xact stent)|For patients randomized to the closed-cell stent group, the Xact closed-cell stents were used. The Xact stent is a FDA approved device.
62465355|NCT00830232|ACTIVE_COMPARATOR|Open-cell stent (Acculink carotid)|For patients randomized to the open-cell stent group, the Acculink carotid stent was used. The Acculink stent is a FDA approved device.
62465356|NCT04037969|EXPERIMENTAL|Nesofilcon A/Delefilcon A|Nesofilcon A was worn in right eye and delefilcon A worn in the left eye.
62465357|NCT04037969|EXPERIMENTAL|Delefilcon A/Nesofilcon A|Delefilcon A was worn in right eye and Nesofilcon A worn in the left eye.
62465358|NCT01306630|OTHER|tivozanib + capecitabine|
62658641|NCT06109298|NO_INTERVENTION|Control group|No pharmacologic or nonpharmacologic application was performed. The researcher performed intravenous access after skin disinfection by the nurse.
62658642|NCT00112229|EXPERIMENTAL|group 1|Melan-A analog peptide + CpG + Montanide
62658643|NCT00112229|EXPERIMENTAL|group 2|Melan-A natural peptide + CpG + Montanide
62095139|NCT03422978|EXPERIMENTAL|Dexmedetomidine 0.50 mcg/kg|0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
62658644|NCT00112229|EXPERIMENTAL|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
62658645|NCT00112229|EXPERIMENTAL|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
62095140|NCT03422978|EXPERIMENTAL|Dexmedetomidine 1.00 mcg/kg|1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
62292592|NCT05859087|EXPERIMENTAL|Flyer|Patient is given a flyer that recommends they discuss pregnancy intention and contraception with their OB/GYN or primary care physician.
62292593|NCT05859087|NO_INTERVENTION|Routine care|Patients receive a deception consent so as not to influence them by the consent process. Consent states that the purpose of the project is to study patterns of birth control usage of women admitted to the hospital. Patient is not given any further intervention.
62292594|NCT00891735|EXPERIMENTAL|Ranibizumab 0.5 mg monthly|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
62292595|NCT00891735|EXPERIMENTAL|Ranibizumab 2.0 mg monthly|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.
62292596|NCT00891735|EXPERIMENTAL|Ranibizumab 0.5 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
62292597|NCT00891735|EXPERIMENTAL|Ranibizumab 2.0 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.
62292598|NCT04580147|EXPERIMENTAL|Intervention (serial IAI)|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
62292599|NCT04580147|SHAM_COMPARATOR|Control|Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (+/-7 days) and at post-operative day 60 (+/-7 days)
62292600|NCT02100384|ACTIVE_COMPARATOR|Ultrasonics|Ultrasonic instrumentation for peri-implant maintenance
62292601|NCT02100384|ACTIVE_COMPARATOR|Scalers|Titanium Scalers instrumentation for peri-implant maintenance
62292602|NCT06541444|EXPERIMENTAL|Group A(low-dose group)|NK520: 3×10\^7NK/kg
62292603|NCT06541444|EXPERIMENTAL|Group B(medium-dose group)|NK520: 6×10\^7NK/kg
61908240|NCT02366364|PLACEBO_COMPARATOR|Drug: Placebo|Single oral administration on Day 1
61908241|NCT02366364|EXPERIMENTAL|Drug: NRX-1074 375 mg|Single oral administration on Day 1
62292604|NCT06541444|EXPERIMENTAL|Group C(high-dose group)|NK520: 9×10\^7NK/kg
62292605|NCT03846245||Young adults group|Cognitively unimpaired 18-25 years old
62292606|NCT03846245||Old adults group|Cognitively unimpaired \>= 70 years old
62292607|NCT05739773|EXPERIMENTAL|Study|the five-element music group
62292608|NCT05739773|PLACEBO_COMPARATOR|Control|binaural beats group
62292609|NCT05264220|EXPERIMENTAL|ACT Matrix|Participants will each receive the ACT Matrix intervention. Participants will be randomised to multiple start dates, producing different baseline durations.
62292610|NCT03700047|EXPERIMENTAL|GAL1704 (needle)|Subjects randomized (2:1) to GAL1704 or Control for cheek augmentation and the correction of midface contour deficiencies.
62292611|NCT03700047|EXPERIMENTAL|GAL1704 (cannula/needle)|GAL1704 treatment using a split face design - one cheek treated using cannula and the other cheek treated using needle.
62292612|NCT03700047|ACTIVE_COMPARATOR|Juvederm Voluma|Subjects randomized to control.
62292613|NCT04969055||patients with liver cirrhosis|cirrhosis based on either clinical/radiological parameters or liver histology
62658646|NCT05568290||Periodontitis|Individuals with Periodontitis
62658647|NCT05568290||Gingivitis|Individuals with Gingival Inflammation
62658648|NCT05568290||Healthy|Individuals with Periodontally Healthy
62658649|NCT00448149|EXPERIMENTAL|1|To establish the maximally tolerated dose (MTD) of RAD001 in combination with Nexavar®
62658650|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
62658651|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
62658652|NCT03743194|ACTIVE_COMPARATOR|Bupi HCl plus liposomal bupi|"Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.~An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic."
62658653|NCT03743194|PLACEBO_COMPARATOR|Control Group|Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.
62095141|NCT06207318|EXPERIMENTAL|ACT Intervention group|Participants in the ACT Intervention condition will receive a two-session intervention, with each session lasting 60-90 minutes. Intervention content will center around personal values and behaviors that align with participant goals and utilize the 'triflex' model of ACT, which indicates three core processes of psychological flexibility: be present, open up, and do what matters. Sessions will be facilitated by the PI, an advanced graduate student in the Clinical Science Ph.D. program at the University of Iowa trained in ACT psychotherapy and supervised by a licensed and highly experienced psychologist. Patients will receive a patient workbook and audio recordings of mindfulness exercises that mirror those completed during the session. The intervention will also focus on patients' health-related goals and objectives surrounding their surgery, and expectations for positive post-surgical functioning.
62095142|NCT06207318|NO_INTERVENTION|Control treatment as usual (TAU) group|The control condition will consist of treatment as usual. This includes a 1.5-hour preoperative appointment with the case-assigned cardiothoracic surgeon and a nurse practitioner. Patients are provided with workbooks that include orientation to the hospital and lifestyle factors information, which includes diet, physical activity, and stress management recommendations.
62095143|NCT03176745||healthy controls|"* no history of pulmonary disease~* absence of symptoms, smoking history \< 10 pack years~* normal lung function testing"
62095144|NCT03176745||chronic obstructive pulmonary disease|"* clinical history and/or specialist diagnosis of COPD and risk factor(s)~* persistent bronchial obstruction and/or hyperinflation and/or radiological sign of emphysema, each without alternative explanation~* dyspnea, cough and/or sputum production"
62095145|NCT03176745||bronchial asthma|"* clinical history and/or specialist diagnosis of bronchial asthma~* respiratory symptoms compatible with asthma varying over time~* variable and/or reversible obstructive ventilation disorder and/or airway hyperresponsiveness~* exclusion of alternative explanation"
62095146|NCT03176745||sarcoidosis|"* clinical history and/or specialist diagnosis of sarcoidosis~* lymphocytic alveolitis and CD4/CD8 \> 3.5 in bronchoalveolar lavage and/or noncaseating epithelioid granuloma~* exclusion of alternative explanation"
62095147|NCT00554164|ACTIVE_COMPARATOR|B1|Six cycles of the (R-)CHOP regimen.
62292614|NCT04969055||control group|Healthy ubjects without known heart disease
62292615|NCT01290926|EXPERIMENTAL|Capecitabine & Sorafenib|Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
62465359|NCT01021670||001|Dapoxetine hydrochloride One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
62292616|NCT05590572|ACTIVE_COMPARATOR|Etoposide plus Ifosfamide group|Children and adolescents with relapsed or refractory drug resistant osteosarcoma
62292617|NCT05590572|EXPERIMENTAL|Etoposide plus Ifosfamide Combined With Sulfatinib|Children and adolescents with relapsed or refractory drug resistant osteosarcoma
62465360|NCT01021670||002|Alternate care/non-dapoxetine hydrochloride treatment(s) As prescribed or directed
62658654|NCT00768053|EXPERIMENTAL|1|
62658655|NCT03317496|EXPERIMENTAL|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
61908242|NCT02366364|EXPERIMENTAL|Drug: NRX-1074 500 mg|Single oral administration on Day 1
61908243|NCT02366364|EXPERIMENTAL|Drug: NRX-1074 750 mg|Single oral administration on Day 1
62095148|NCT00554164|EXPERIMENTAL|B2|Six blocks of the B-ALL protocol.
62095149|NCT00554164|ACTIVE_COMPARATOR|A1|Four cycles of the (R-)CHOP regimen.
62095150|NCT00554164|ACTIVE_COMPARATOR|A2|Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.
62095151|NCT05373719||0-2 Years of Age|Patients from birth to 2 years of age at time of study entry
62095152|NCT05373719||3-5 Years of Age|Patients aged 3 to 5 years at time of study entry
62095153|NCT05373719||6-12 Years of Age|Patients aged 6 to 12 years at time of study entry
62292618|NCT06047704||All participants-cross sectional|All participants received the same data collection protocol. No intervention
62292619|NCT02486861||culprit plaque|correlation of OCT characteristics of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
62465361|NCT00699491|EXPERIMENTAL|Treatment (cixutumumab, temsirolimus)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 (cixutumumab is given on days 8, 15, and 22 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62465362|NCT00662740|EXPERIMENTAL|Tiotropium/Salmeterol quaque die (QD, once daily)|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
62465363|NCT00662740|ACTIVE_COMPARATOR|Tiotropium quaque die (QD, once daily)|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
62465364|NCT00662740|ACTIVE_COMPARATOR|Salmeterol bis in die (BID, twice daily)|Salmeterol Inhalation Powder, hard PE capsule
62465365|NCT00662740|ACTIVE_COMPARATOR|Tiotropium/Salmeterol quaque die (QD, once daily)+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
62465366|NCT00662740|PLACEBO_COMPARATOR|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
62658656|NCT03317496|EXPERIMENTAL|Group A Cohort A2|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
62465367|NCT03314298|EXPERIMENTAL|testosterone anastrozole implant|testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet
62465368|NCT00374335|OTHER|infants with cutaneous hemangiomas|
62465369|NCT03291925|EXPERIMENTAL|Selective invasive angiography based on CT/CCTA imaging|Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
62658657|NCT03317496|EXPERIMENTAL|Group A Cohort A3|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
61908244|NCT05775523||Patients on SKYTROFA (Lonapegsomatropin)Treatment|SKYTROFA (Lonapegsomatropin) administered once-weekly by subcutaneous injection
62095154|NCT05373719||13-55 Years of Age|Patients aged 13 to 55 years at time of study entry
62292620|NCT02486861||non culprit plaque|correlation of OCT characteristics of non culprit plaque of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
62292621|NCT01447394|EXPERIMENTAL|Arm 1: Pegylated Interferon Lambda + Ribavirin|
62095155|NCT03364816||TDR with Prodisc-C|participant underwent total disc replacement with Prodisc-C artificial disc
62095156|NCT03364816||TDR with Mobi-C|participant underwent total disc replacement with Mobi-C artificial disc
62095157|NCT03364816||TDR with Prestige-LP|participant underwent total disc replacement with Prestige-LP artificial disc
62095158|NCT02519556|EXPERIMENTAL|Probiatop|Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months
62095159|NCT02519556|PLACEBO_COMPARATOR|Placebo|Placebo of Maltodextrin in sachet
62095160|NCT06276595|EXPERIMENTAL|TODOS Intervention|"Participants in the TODOS Intervention Group will receive the intervention Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story. They will receive 11 intervention sessions of 60-90 minutes over 11 weeks."
62292622|NCT01447394|ACTIVE_COMPARATOR|Arm 2: Pegylated Interferon Alfa-2a + Ribavirin|
62292623|NCT03543813|EXPERIMENTAL|CX-2029 Escalation|Dose Escalation and Determination
62292624|NCT03543813|EXPERIMENTAL|CX-2029 Biomarker|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
62292625|NCT03543813|EXPERIMENTAL|CX-2029 Expansion|Evaluate antitumor activity of CX-2029
62658658|NCT03317496|EXPERIMENTAL|Group A Cohort A4|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
62658659|NCT02986776|ACTIVE_COMPARATOR|Inpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving inpatient treatment
62658660|NCT02986776|ACTIVE_COMPARATOR|Inpatient Care + No Need for Inpatient|Individuals with low alcohol involvement or mid-high cognitive functioning receiving inpatient treatment
62095161|NCT06276595|OTHER|Control condition - 3 Monthly Group Activities in the Community|Children and their female caregivers randomized to the control group will receive 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre. The third group session will consist of going bowling at the local bowling alley.
62095162|NCT04948073|EXPERIMENTAL|Experimental Group|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment. DNS group's protocol will involve 5 min warm-up, 40 min DNS movements (4 different parts, each part lasts for 10 min) accompanied with breathing exercises, and 5 min cool-down. DNS exercises will include diaphragmatic breathing, Baby Rock, Rolling, Side Lying, Oblique Sit, Tripod, Kneeling, Squat, Prone, and Czech Get Up (CGU). Week one specifically will involve training and practicing basic DNS exercises. The complexity of the exercises will increase gradually by adding a new task to an already practiced task every week. An increase in the complexity of a task will help the performer to automate performance. We will use the dual-task paradigm to examine if the task is automated or not (e.g. no new task should disturb the diaphragmatic breathing).
62095163|NCT04948073|ACTIVE_COMPARATOR|Control Group|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration). All patients will also continue their usual activities and receive advices related to the daily living activites in the form of a leaflet. Participants will be asked to refrain from seeking any other types of rehabilitation treatments during the trial. The conventional physical therapy program for both groups includes: TENS therapy for the low back (15 min 3 days/week), with a frequency of 100 Hz and fixed pulse; ultrasound for 5 minutes, 1 Hz, continuous mode of application 1.5 w/cm2. The exercise programs will consist strengthening, stretching exercises for the abdominal, back, pelvic, and lower limb muscles.
62095164|NCT06697886|EXPERIMENTAL|Antaiwei granules|
62095165|NCT06697886|PLACEBO_COMPARATOR|Antaiwei granules placebo|
62095166|NCT01627236|EXPERIMENTAL|glucocorticoid treatment group|
62095167|NCT01627236|NO_INTERVENTION|conventional treatment|
62095168|NCT01598987|EXPERIMENTAL|Everolimus based regimen|"Conversion at Baseline from an immunosuppressive regimen which contains either cyclosporine (CsA) or tacrolimus (TAC) with or without mycophenolic acid (MPA), with or without corticosteroids in a regimen which contains everolimus combined reduced dose of either cyclosporine (CsA) or tacrolimus (TAC).~The dosing schedule was twice daily, 12 hours apart."
62292626|NCT00716716|EXPERIMENTAL|rFIXFc|Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg
62658661|NCT02986776|ACTIVE_COMPARATOR|Outpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving outpatient treatment
62658662|NCT02986776|ACTIVE_COMPARATOR|Outpatient Care + No Need for Inpatient|Individuals with low alcohol involvement and or mid-high cognitive functioning receiving outpatient treatment
62658663|NCT06319118|PLACEBO_COMPARATOR|Placebo Comparator: placebo|control group patients, 40 cases
62658664|NCT06319118|EXPERIMENTAL|Experimental: dihydroergotine mesylate sustained-release tablets|treatment group patients, 80 cases
62658665|NCT03797053||Cohort 1 : metastatic cohort|Cohort1: Cohort of patients with stage III inoperable or IV metastatic melanoma This cohort will enable the achievement of objectives 1 (proof of concept) and 2 (establishment of prognostic and predictive value).
61908245|NCT06533995|EXPERIMENTAL|VISUPRIME|Patients receiving Visuprime eyedrop BID from Visit 1 (day -3 from surgery) to Visit 3 (day 7 from surgery).
61908246|NCT06533995|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo eyedrop (the vehicle of Visuprime, ie isotonic buffered saline solution) BID from Visit 1 (day -3 from surgery) to Visit 3 (day 7 from surgery).
61908247|NCT00513825|ACTIVE_COMPARATOR|1|1075 cc of 77 mEq/L solution of NaCl 0.45% , prepared by adding 75 cc of 77 mEq/L NaCl 0.45 % to 1000 cc of 77 mEq/L NaCl 0.45%
61908248|NCT00513825|ACTIVE_COMPARATOR|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate solution 8.4% to 1000 cc of NaCl 0.45%.
61908249|NCT05254145||Group A|This group will include participants without an arthritic knee. These participants will be recruited from the Orthopedic Sports Medicine consultation
61908250|NCT05254145||Group B|This group will include participants undergoing primary knee arthroplasty (KA).
61908251|NCT05254145||Group C|This group will include participants undergoing a surgical procedure whose opposite knee has no history of arthritis
61908252|NCT05254145||Group D|This group will include participants undergoing knee revision surgery with no suspicion of infection (aseptic knee revision replacement)
61908253|NCT05254145||Group E|This group will include participants undergoing knee revision with a known infection (septic knee revision replacements)
61908254|NCT02685059|EXPERIMENTAL|MEDI4736|part 1: MEDI4736 (with half dose as monotherapy for the first two weeks) part 2: MEDI4736 1.5 g total for 20 weeks
61908255|NCT02685059|PLACEBO_COMPARATOR|Placebo|part 1: Placebo (for the first two weeks) part 2: Placebo for 20 weeks
61908256|NCT02685059|ACTIVE_COMPARATOR|Taxane|Nab-Paclitaxel 125 mg/m² weekly for 12 weeks
61908257|NCT02685059|ACTIVE_COMPARATOR|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
61908258|NCT02685059|ACTIVE_COMPARATOR|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
62095169|NCT02742909|ACTIVE_COMPARATOR|rhBNP|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received rhBNP.
62292627|NCT03851510|ACTIVE_COMPARATOR|Resmon Pro|COPD participants will be first screened for Expiratory Flow Limitation using the Resmon Pro.
62292628|NCT03851510|EXPERIMENTAL|Vector Ventilator|COPD participants will be screened again for Expiratory Flow Limitation using the Vector device, participants with EFL will undergo 20 minute titration protocol for therapy.
62292629|NCT04847700|ACTIVE_COMPARATOR|Minimally invasive vestibular neurectomy|
62292630|NCT04847700|ACTIVE_COMPARATOR|Tenotomy of the stapedius and tensor tympani muscles|
62292631|NCT04653948||Cohort Study|Women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age seeking antenatal care at Kawempe National Referral Hospital in their first and second trimesters of pregnancy will be invited to participate in the study until a sample size of at least 4000 women is achieved. They will be followed-up along with their liveborn infants until a minimum of 14 weeks post-delivery.
62292632|NCT04653948||EMR Cohort|Anonymised data from the entire maternal and infant population that attend Kawempe Hospital for antenatal and/or delivery +/- post-partum care during the two-year study period will be analysed to describe maternal, obstetric and neonatal outcomes.
62465370|NCT03291925|ACTIVE_COMPARATOR|Invasive Cardiac Angiography|Patients will undergo systematic invasive angiography.
62465371|NCT02560194|ACTIVE_COMPARATOR|Flexible Sigmoidoscopy|People randomized to this arm are offered flexible sigmoidoscopy in addition to FOBT at the age of 60.
62658666|NCT03797053||Cohort 2 : adjuvant cohort|"Cohort 2: Cohort of patients with melanoma who are candidates for sentinel lymph node analysis.~This group includes patients with melanoma in whom sentinel lymph node testing is performed. According to current French recommendations, these are patients whose primary melanoma has a Breslow index (thickness) of more than 1 mm or ulcerated primary melanoma (loss of the epidermis)."
62658667|NCT05863949|EXPERIMENTAL|vitamin D +/- calcium supplementation|patients given Vitamin D 1000iu daily. Also given calcium 500mg BID daily if calcium deficient.
61908259|NCT03530709|EXPERIMENTAL|Experimental|videoconferencing
61908260|NCT03530709|NO_INTERVENTION|Control|Usual care
61908261|NCT05429775|EXPERIMENTAL|Budesonide: Formulation 1|single dose of 2 mg oral suspension formulation 1 administered orally under fasting conditions
62292633|NCT06071325||AID Group|We anticipate enrolling between 30 and 50 participants who will be recruited to participate in the Automated Insulin Delivery (AID) system study.
62658668|NCT05863949|PLACEBO_COMPARATOR|Placebo arm|patients given 3 pills of placebo daily.
62658669|NCT04375124|NO_INTERVENTION|non-peptide group|This group will receive routine treatment and care for COVID-19.
62658670|NCT04375124|ACTIVE_COMPARATOR|peptide group|This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
62658671|NCT00879853|EXPERIMENTAL|Interpersonal Therapy|
61908262|NCT05429775|EXPERIMENTAL|Budesonide: Formulation 2|single dose of 2 mg oral suspension formulation 2 administered orally under fasting conditions
62465372|NCT02560194|PLACEBO_COMPARATOR|FOBT only|People in this are offered fecal occult blood testing only.
62465373|NCT05853666|NO_INTERVENTION|Control Group with Standard Care|Consenting families in the NICU during the baseline control period will receive standard care as it is already provided at each site. Data collection procedures will mirror intervention groups to ensure comparable control data.
62465374|NCT05853666|EXPERIMENTAL|Intervention Group Receiving CNH+|Eligible consenting families (following enrollment) will be provided a secure login code and instructions to access the CNH+ educational modules and to send and receive virtual calls and text messages. Parents will be asked to use CNH+ during their entire NICU stay. To ensure equity, interested families without a personal device to access CNH+ will be offered a study-provided iPad for the duration of their infant's stay. Parents will have access to CNH+ while on the unit and 6 months post-discharge.
62465375|NCT04228744|EXPERIMENTAL|Bilateral surgical implantation of DBS system|All the participants will receive bilateral surgical implantation of DBS system to VIC and NAc. The experimenter will active the DBS system and adjust the parameters for all the participants after surgery.
61908263|NCT05429775|EXPERIMENTAL|Budesonide: Formulation 3|single dose of 2 mg oral suspension formulation 3 administered orally under fasting conditions
61908264|NCT05429775|EXPERIMENTAL|Budesonide: Formulation 4|single dose of 2 mg oral suspension formulation 4 administered orally under fasting conditions
62658672|NCT00879853|NO_INTERVENTION|Wait List Control|
62658673|NCT04888312|EXPERIMENTAL|Intravenously administered mitazalimab given in combination with chemotherapy|Mitazalimab, a human monoclonal antibody targeting CD40, administered intravenously every 14 days, in combination with standard of care chemotherapy modified FOLFIRINOX.
61908265|NCT05343468|EXPERIMENTAL|Experimental|Singe-arm: the assistive digital software was implemented as an intervention to all participants.
61908266|NCT00095147|ACTIVE_COMPARATOR|Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])|Days 1-365
61908267|NCT00095147|ACTIVE_COMPARATOR|Infliximab + MTX (DB)|Days 1-365
61908268|NCT00095147|PLACEBO_COMPARATOR|Placebo + MTX (DB)|Days 1-197
61908269|NCT00095147|EXPERIMENTAL|Placebo + MTX switched to abatacept + MTX (DB)|Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365
61908270|NCT00095147|EXPERIMENTAL|Abatacept (open-label)|Days 365 to 729 All participants receive Active Drug
62095170|NCT02742909|PLACEBO_COMPARATOR|Placebo|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received placebo.
62292634|NCT06071325||MDI + CGM Group|We anticipate that between 10 and 30 participants will be enrolled in the study and will be utilizing Multiple Daily Injections (MDI) therapy in conjunction with Continuous Glucose Monitoring (CGM). MDI therapy will be defined as administering three or more injections per day.
62292635|NCT02590029|EXPERIMENTAL|Mindfulness|15 minute mindfulness session
62658674|NCT05695313|PLACEBO_COMPARATOR|Placebo|Standard chemotherapy PACLITAXEL + placebo dietary supplement
62465376|NCT05491226|EXPERIMENTAL|Pembrolizumab with Radiation Therapy and Axatilimab|
62465377|NCT04593628|EXPERIMENTAL|All Participants|
62658675|NCT05695313|EXPERIMENTAL|OnLife®|Standard chemotherapy + OnLife® dietary supplement
62658676|NCT00976027|EXPERIMENTAL|Fluzone® High Dose Group|
62095171|NCT06024499|ACTIVE_COMPARATOR|PART 2 High-Dose|Active group selected for PART1 as a high-dose
62095172|NCT06024499|ACTIVE_COMPARATOR|PART 2 Low-Dose|Active group selected for PART1 as a Low-dose
62095173|NCT06024499|PLACEBO_COMPARATOR|PART 2 Placebo|Placebo group
62465378|NCT04327375||observational|observational
62465379|NCT01998217|ACTIVE_COMPARATOR|Rem group|Patients in this group receive single infusion of remifentanil with target concentration infusion.
62465380|NCT01998217|EXPERIMENTAL|Flur group|Patients in this group receive both infusion of flurbiprofen and remifentanil
62095174|NCT04484064|NO_INTERVENTION|Standard care|"Patients in the standard care arm will use an electronic adherence monitor (MEMS®) without any feedback (electronic data will be blinded to patients, clinicians and investigators until the analysis)"
62095175|NCT04484064|EXPERIMENTAL|Adherence program|"Patients in the adherence program will use the MEMS® and the pharmacist will provide an electronic feedback on medication adherence since the last visit. The identified determinants of medication adherence will be discussed with the patient."
62095176|NCT05585112|ACTIVE_COMPARATOR|A (Lidocaine 2%)|26 children will be injected with 1 ml of lidocaine 2% with epinephrine
62095177|NCT05585112|EXPERIMENTAL|B (Articaine 4%)|26 children will be injected with 1 ml of Articaine 4% with epinephrine.
62095178|NCT03545386|EXPERIMENTAL|FMT|
62292636|NCT02590029|EXPERIMENTAL|Suggestion|15 minute therapeutic suggestion session
62095179|NCT03545386|PLACEBO_COMPARATOR|Placebo|
62465381|NCT00727961|EXPERIMENTAL|Arm 1|Caelyx Intravenous, 50 mg/m\^2, given for 6 cycles
62465382|NCT01134848|ACTIVE_COMPARATOR|Morphine-neostigmine|
62465383|NCT01134848|ACTIVE_COMPARATOR|Secretin|
62465384|NCT03786965|OTHER|On-pump CABG.|On-pump CABG.
62095180|NCT06396845||robotic surgery with cci|
62095181|NCT06396845||laparoscopic surgery with cci|
62095182|NCT02963597|ACTIVE_COMPARATOR|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
62095183|NCT02963597|PLACEBO_COMPARATOR|Group B|Standard medical therapy only.
62292637|NCT02590029|ACTIVE_COMPARATOR|Psychoeducation|15 minute psychoeducation session
62465385|NCT03786965|OTHER|Off-pump CABG.|Off-pump CABG.
62465386|NCT03786965|OTHER|Pump-assisted CABG.|Pump-assisted CABG.
62465387|NCT03786965|OTHER|Heart Valve Procedure without CABG.|Heart Valve Procedure without CABG.
62465388|NCT03786965|OTHER|Heart Valve Procedure with CABG.|Heart Valve Procedure with CABG.
62658677|NCT00976027|ACTIVE_COMPARATOR|Fluzone® Group|
62658678|NCT01879436||Pregnant women|"Women during first trimester of pregnancy (age: 18-45)~Group contain 50 healthy pregnant women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.~The measure of outcome is composite and includes several changes:~Changes in:~* cell death (% from tested cells)~* cell cycle (% cells in G1, G2 and S phases)~* cell migration (% closure in Scratch test)~* cell invasion (% cells passing through membrane in Transwell assay)~* RNA repertoire (Fold change)~* miRNA repertoire (Fold change) Investigators will not treat the women with any drug."
62658679|NCT01879436||Non pregnant women|Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered women. Investigators will not treat the women with any drug.
62292638|NCT02823457|OTHER|VBMI intervention group|All patients will receive a 12 week VBMI intervention to promote treatment completion
62465389|NCT03115242|EXPERIMENTAL|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
62465390|NCT01732172|EXPERIMENTAL|Patient Group|Patient with urethritis
61908271|NCT05157802|EXPERIMENTAL|Physical Activity Coaching|Participants will receive up to 5 individualized coaching sessions delivered via telehealth to facilitate and optimize exercise uptake. The therapist will facilitate discussion on specific and measurable goals, and will provide options for tracking their progress, such as written or web-based exercise logs or an activity monitor. The recommended exercises will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. Balance and strengthening exercises will also be recommended as appropriate.
61908272|NCT00436540|ACTIVE_COMPARATOR|1|clobetasol propionate (Clobex®) spray
61908273|NCT00436540|ACTIVE_COMPARATOR|2|clobetasol propionate (Olux®) foam
61908274|NCT05873907|EXPERIMENTAL|AMG 592: Dose 1|Administered as a single dose subcutaneous (SC) injection.
61908275|NCT05873907|EXPERIMENTAL|AMG 592: Dose 2|Administered as a single dose SC injection.
61908276|NCT05873907|EXPERIMENTAL|AMG 592: Dose 3|Administered as a single dose SC injection.
61908277|NCT05873907|EXPERIMENTAL|AMG 592: Dose 4|Administered as a single dose SC injection.
61908278|NCT05873907|EXPERIMENTAL|AMG 592: Dose 5|Administered as a single dose SC injection.
61908279|NCT05873907|EXPERIMENTAL|AMG 592: Dose 6|Administered as a single dose SC injection.
61908280|NCT05873907|EXPERIMENTAL|AMG 592: Dose 7|Administered as a single dose SC injection.
61908281|NCT05873907|EXPERIMENTAL|AMG 592: Dose 8|Administered as a single dose SC injection.
61908282|NCT05873907|PLACEBO_COMPARATOR|Placebo|Administered as SC injection.
61908283|NCT01489813|PLACEBO_COMPARATOR|Sugar pill|Patients will be given placebo pills for 10 weeks.
61908284|NCT01489813|EXPERIMENTAL|Genistein supplement|30 mg of genistein supplement by mouth three times daily (PO TID) for 10 weeks.
61908285|NCT02361476|EXPERIMENTAL|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
61908286|NCT02361476|PLACEBO_COMPARATOR|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
61908287|NCT00510653|EXPERIMENTAL|Imatinib Mesylate|600 mg/day orally for 6 Weeks
61908288|NCT01046409||Main vessel, side branch vessel|
61908289|NCT04320030|EXPERIMENTAL|[18F]-DPA-714|pretherapeutic \[18F\]-DPA-714 PET/CT scan
62465391|NCT01732172|OTHER|Control group|Subjects with no urethritis and no history urogenital infection
62465392|NCT01392430|NO_INTERVENTION|Arm A|Continuation of prophylaxis of opportunistic infections
61908290|NCT02126475||Healthy volunteers|
61908291|NCT02126475||Park patients|
61908292|NCT01075191||HIV-infected participants|"HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.~Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (three 133 mg/33 mg capsules twice daily or two 200 mg/50 mg tablets twice daily)."
61908293|NCT05366400||Group I (CAT) ≥ 10|CAT is an eight-item questionnaire with a six-item Likert scale ranging from 0 to 5. The score ranges from zero (completely asymptomatic) to 40 (extremely symptomatic). A CAT score ≥10 is associated with a significantly impaired health status.
61908294|NCT05366400||Group II (CAT) < 10|CAT is an eight-item questionnaire with a six-item Likert scale ranging from 0 to 5. The score ranges from zero (completely asymptomatic) to 40 (extremely symptomatic). A CAT score \< 10 is associated with a significantly preserved health status.
61908295|NCT00330161|EXPERIMENTAL|Treatment (vorinostat)|"Patients receive oral vorinostat (SAHA) once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) after 4 courses receive an additional 3 courses. All other patients may continue treatment in the absence of disease progression or unacceptable toxicity.~Blood samples are taken on day 15 of course 1, day 1 of course 2, during the last week of course 4, and at completion of study treatment. Blood is examined for interleukin (IL)-6, IL-6 receptor, and gp130 levels."
61908296|NCT05412589|EXPERIMENTAL|intravenous mFOLFOX7 combined with Camrelizumab and apatinib|Combination of systemic chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX7) , targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
62292639|NCT05931783|ACTIVE_COMPARATOR|skeletonized harvesting technique|In skeletonized harvesting technique, only the left internal artery itself is harvested.
62292640|NCT05931783|ACTIVE_COMPARATOR|pedicled harvesting technique|In pedicled harvesting technique the left internal thoracic artery, it's accompanying veins and parts of the endothoracic fascia is harvested, creating a 1-2 cm broad pedicle.
62465393|NCT01392430|EXPERIMENTAL|Arm B|Discontinuation of opportunistic infections
62658680|NCT00970944|EXPERIMENTAL|Amantadine HCL|100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.
62292641|NCT01097044|EXPERIMENTAL|Afamelanotide|Dose: 16 mg implant; release of 16 mg over 7 to 10 days Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
62292642|NCT01097044|PLACEBO_COMPARATOR|Placebo|Dose: 16 mg implant; Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
61908297|NCT04486300|NO_INTERVENTION|Season of presentation|Comparison of number of presented cases in each season
62292643|NCT01930786||onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
62292644|NCT02812199|EXPERIMENTAL|pilot study group 1|Patients in pilot study group 1 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in pilot study group scheduled for 6 follow up visits at 1,2,3,4,6 and 12 weeks after implantation and for tampon removal at day 2 - 3 after FESS surgery. Stent will be removed between 14 and 28-day implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
62292645|NCT02812199|EXPERIMENTAL|study group 2|Patients in study group 2 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in 2nd study group scheduled for 4 follow up visits at 2, 4, 6 and 12 weeks after implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
62465394|NCT05138848|EXPERIMENTAL|Time in Bed Restriction|Time in Bed (TIB) restriction of 85% of habitual TIB.
62465395|NCT05138848|ACTIVE_COMPARATOR|Control|Participants will follow their typical sleep schedule consistent with measured average sleep and wake times.
62465396|NCT00815763|EXPERIMENTAL|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
62465397|NCT00815763|PLACEBO_COMPARATOR|placebo|infusion placebo (group B)once a day and continued for 14 days
62465398|NCT02780687|EXPERIMENTAL|Afatinib|
62658681|NCT00970944|PLACEBO_COMPARATOR|Placebo|
62658682|NCT03087032|EXPERIMENTAL|Liraglutide-bolus|'Liraglutide-bolus'(Liraglutide once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
62658683|NCT03087032|ACTIVE_COMPARATOR|Basal-bolus|'Basal-bolus' (insulin glargine once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
62658684|NCT04370496|EXPERIMENTAL|SOLUTION group|Patients enrolled in this clinical trial will undergo radical hysterectomy through minimally invasive surgery using an endoscopic stapler which both cuts and simultaneously sutures the open vaginal stump.
61908298|NCT04486300|ACTIVE_COMPARATOR|Intervention|Surgical intervention of failed Pneumatic cases is done
61908299|NCT05336604||General population, aged 15 years or more, living in France|Population-based ohort of general population, aged 15 years or more, living in France in May 2020, selected at random from national administrative sample frame
61908300|NCT02320201|EXPERIMENTAL|Electrical stimulation|Transcutaneous Electrical Nerve Stimulator (TENS) will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects. Subjects will be required to keep a daily voiding diary for one week before treatment to establish a control, during the treatment week and for one week after treatment. Subjects will also be asked to complete a validated questionnaire prior to treatment, during treatment week and one week after treatment. The primary outcomes of this study are improvement in objective measures of frequency as indicated by voiding diary and subjective symptom improvement based on questionnaire comparison.
61908301|NCT01062373|ACTIVE_COMPARATOR|TG-DHA|TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
61908302|NCT01062373|NO_INTERVENTION|Control|Control: lactating mothers and their newborn with no supplementation given to the mother
61908303|NCT01062373|EXPERIMENTAL|GPL-DHA|GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid
61908304|NCT03168958|ACTIVE_COMPARATOR|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
61908305|NCT03168958|SHAM_COMPARATOR|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
62658685|NCT03978767|EXPERIMENTAL|NSAID Analgesic bundle|Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery
62658686|NCT03978767|ACTIVE_COMPARATOR|NSAID free analgesic bundle|Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.
62095184|NCT03969602|EXPERIMENTAL|Experimental Group|Participants randomized will receive six individual 1-hour sessions of CBT: two sessions before the operation and four after, delivered by a psychologist trained in CBT for chronic pain. The CBT intervention is tailored to reduce pain catastrophizing. Main techniques are: pain education and the influence of cognitions, emotions and behavior on pain and pain disability; identification of catastrophizing cognitions and replacing them with more adaptive cognitions; stress/anxiety reduction by diaphragmatic breathing and progressive muscle relaxation; emotion regulation skills training; cognitive restructuring; coping skills training to combat helplessness and foster a sense of control and self-efficacy for dealing with acute post-operative pain. The four postoperative sessions build on and further extend the skills learned preoperatively. Each session ends with specific homework assignments. All patients receive a homework book and an individually tailored instruction manual.
62095185|NCT03969602|ACTIVE_COMPARATOR|Control Group|Participants will have six meetings with members of the research team (in person or through telephone). In a first preoperative meeting a member of the team provides verbal information on the preparation for surgery, surgery itself and recovery from surgery, stressing the importance of postoperative exercise. Any questions raised by the patient are discussed. A booklet is provided with information about: structure of the spinal column and spinal diseases; examinations before surgery; the operative environment; surgical procedures; anesthetic procedures; postoperative care and postoperative pain reduction. A second preoperative (telephone) meeting is scheduled to answer any remaining questions. During the postoperative phase, instructions and an exercise manual are provided, Patients keep a diary to record their training activity. Three, six and eight months after discharge patients are contacted by telephone and their training progress is discussed.
62095186|NCT03969602|NO_INTERVENTION|Observational Group (low catastrophizing)|Patients will be routinely prescribed medications for pain control and are referred for physical therapy on an out-patient basis in different sites or an in-patient basis in specialized rehabilitation centers following lumbar spinal fusion surgery, depending on the needs. Typically, a full rehabilitation regime starts 2-3 weeks after surgery. Usual programs involve active spinal mobilization aimed at gradually improving the range of motion, exercises to strengthen spinal deep muscles, and segmentary stretching involving the lower limb and back muscles, together with manual therapy. The patients are also given walking exercises and trained in how to change position.
62095187|NCT03229798|ACTIVE_COMPARATOR|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
62095188|NCT03229798|EXPERIMENTAL|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
62095189|NCT03229798|EXPERIMENTAL|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
62095190|NCT03229798|EXPERIMENTAL|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
62095191|NCT03229798|EXPERIMENTAL|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
62095192|NCT03229798|EXPERIMENTAL|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
62292646|NCT02812199|NO_INTERVENTION|control group 3|control group patients will undergo post-FESS bilateral Standard of Care (tampon) placement into middle meatus as standard of care. Frontal tampon will be placed to stop bleeding. Patients in control group scheduled for 3 follow up visits at 2, 6 and 12 weeks after surgery and for tampon removal at day 2 - 3 after FESS surgery.
62292647|NCT03831087|OTHER|TAVR-CMR|"All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D whole-heart coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA."
62465399|NCT04813705|EXPERIMENTAL|Reduced dose group|The patients achieving CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
62465400|NCT04813705|ACTIVE_COMPARATOR|Conventional dose group|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
62658687|NCT01947933|PLACEBO_COMPARATOR|Placebo IV|Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
62658688|NCT01947933|EXPERIMENTAL|Mirikizumab IV|Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
62658689|NCT01947933|EXPERIMENTAL|Mirikizumab SC|Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
62658690|NCT04801082|ACTIVE_COMPARATOR|EUS-CPB|Endoscopic Ultrasound Guided Coeliac Plexus Block
62658691|NCT04801082|ACTIVE_COMPARATOR|EUS-CPA|Endoscopic Ultrasound Guided Coeliac Plexus Radiofrequency Ablation
62095193|NCT04774406||parp inhibitors|All patients treated at least with 1 PARPi
62095194|NCT03570255|EXPERIMENTAL|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
61908306|NCT00668993|EXPERIMENTAL|A, B|A is treatment group B is waitlist group
62095195|NCT04471987|EXPERIMENTAL|Treatment|"The study will take place in two stages:~1. In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached.~2. Following successful identification of the RD, the study will proceed with a dose expansion part and 40 patients will be treated at the RD dose level."
62095196|NCT01517022|NO_INTERVENTION|Control arm|Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
62095197|NCT01517022|ACTIVE_COMPARATOR|Intervention arm|Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
62095198|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
62095199|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
62095200|NCT06454344|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|
62465401|NCT04819633||Study Group|30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
61908307|NCT01949467|OTHER|TDHS|20 Patients with Treated Dysmetabolic Hepatosiderosis (TDHS)
61908308|NCT01949467|OTHER|UDHS|20 patients with untreated Dysmetabolic Hepatosiderosis (UDHS)
62095201|NCT06454344|NO_INTERVENTION|Waitlist Control|
62095202|NCT05009485|EXPERIMENTAL|Intervention|Participants will be remotely monitored with the Current Health platform, respond to daily respiratory surveys, receive daily medication reminders and an action plan. Daily dashboard rounds and vital sign alarms from the continuously collected vital signs will be used to identify changes in health and escalated accordingly.
62658692|NCT01955304|EXPERIMENTAL|A-fasted dosing followed by fed dosing|Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
61908309|NCT01949467|OTHER|TFPD|20 patients with treated Ferroportin Disease (TFPD)
61908310|NCT01949467|OTHER|UFPD|20 patients with untreated Ferroportin Disease (UFPD)
61908311|NCT01949467|OTHER|HV|20 Healthy volunteers (HV) patients
61908312|NCT04516395|EXPERIMENTAL|Optimal antibiotic combination regimens|The patients in the groups will be given the optimal antibiotic combination regimens.
61908313|NCT04516395|OTHER|Standard antibiotic regimens|The patients in the groups will be given the standard antibiotic regimens.
62658693|NCT01955304|EXPERIMENTAL|B-fed dosing followed by fasted dosing|Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
62658694|NCT04764149||PFll Group|Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/ m2) on day 1 and day 28, every 60 days. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
62736817|NCT05906485|EXPERIMENTAL|Experimental Group: fNIRS Neurofeedback-VR Training Group|The experimental group will receive 16 sessions of training, 1 hour each, conducted twice per week over a period of 8 weeks. A classroom setting will be stimulated using VR and participants will be asked to complete some academic-related tasks during the stimulated lessons. The sensor on the neurofeedback device worn by the participants will detect changes in the blood oxy-hemoglobin level in brain cortical tissue and feedback to the participants via visual images or auditory sounds from the computer. Through practice, participants will learn to manipulate their attention, presumably by altering brain activities.
61908314|NCT05806489|EXPERIMENTAL|Intermittent Fasting|
61908315|NCT05806489|PLACEBO_COMPARATOR|Control Diet|
62095203|NCT06404762|ACTIVE_COMPARATOR|tSCTG+ CAF|Single, isolated gingival recessions; excluding molars; at maxilla will be treated with subepithelial connective tissue graft harvested from the maxillary tuberosity in conjunction with a coronally advanced flap
62095204|NCT06404762|ACTIVE_COMPARATOR|pSCTG+ CAF|Single, isolated gingival recessions; excluding molars; at maxilla will be treated with subepithelial connective tissue graft harvested from the lateral palate in conjunction with a coronally advanced flap
62095205|NCT06435299|EXPERIMENTAL|Cannabis oil|"Cannabis oil 50mg/mL arm :~An auto-titration phase will take place during the first 14 days of treatment: 0.2 ml on the first day then increase of 0.2 ml every 2 days in 2 daily doses, that is to say 1.4 ml/day maximum.~If any tolerable side-effects occurred, patients were advised not to increase the dose; if intolerable side-effects occurred, dose reduction was advised.~After initial titration, the dose will then be maintained for 4 consecutive weeks."
62292648|NCT03831087|OTHER|TAVR-CT|All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
62292649|NCT01975103|EXPERIMENTAL|Topcon Endpoint management|Active laser treatment
62292650|NCT01975103|SHAM_COMPARATOR|Control|Powerless (sham) laser treatment
62292651|NCT01903941|EXPERIMENTAL|Training|Aerobic
62292652|NCT01903941|PLACEBO_COMPARATOR|Control|Not exercise
62292653|NCT06028620|EXPERIMENTAL|Maltreated children|"The Maltreated Children group was assessed before and after a psychological intervention using clinical scales (anxiety, depression, post-traumatic stress disorder and Callous unemotional traits) and an emotion paradigm through functional magnetic resonance imaging (fMRI). The psychological intervention implemented with the maltreated group was the Trauma Focused-Cognitive Behavior Therapy.~For this study, 12 to 16 sessions of 60-90 min each, were implemented once a week for 4 months. 14 out of 15 maltreated children completed the TF-CBT units and one week after that, they underwent the post-treatment assessment."
62292654|NCT06028620|NO_INTERVENTION|Healthy Control group|This group did not have any records of maltreatment. They were assessed using clinical scales (anxiety, depression, post-traumatic stress disorder and Callous unemotional traits) and an emotion paradigm through functional magnetic resonance imaging (fMRI). Their scores and brain images were compared with the maltreatment group before this group underwent psychological treatment.
62292655|NCT05995444|EXPERIMENTAL|500 mg epetraborole|500 mg epetraborole
62292656|NCT05995444|EXPERIMENTAL|2000 mg epetraborole|2000 mg epetraborole
62292657|NCT05995444|PLACEBO_COMPARATOR|Epetraborole-matching placebo|Epetraborole-matching placebo
61908316|NCT01588756|EXPERIMENTAL|AcSDKP-NH2 inuline|AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less
61908317|NCT01588756|EXPERIMENTAL|AcSDKP-NH2 Cr-EDTA|AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less
61908318|NCT05132803|EXPERIMENTAL|Main Vaccination Arm|Participants will receive the HPV 16 TA-CIN vaccine.
61908319|NCT03350438||PTSD Patients|patients ranging 18-60, diagnosed with PTSD following a trauma that occured over one year before the current study and do not have other health problems that may affect their everyday participation.
61908320|NCT03350438||healthy adults|healthy adults, ranging 18-60, without any health problems that may affect their everyday participation.
62095206|NCT06435299|PLACEBO_COMPARATOR|PLACEBO|"Placebo arm :~An auto-titration phase will take place during the first 14 days of treatment: 0.2 ml on the first day then increase of 0.2 ml every 2 days in 2 daily doses, that is to say 1.4 ml/day maximum.~If any tolerable side-effects occurred, patients were advised not to increase the dose; if intolerable side-effects occurred, dose reduction was advised.~After initial titration, the dose will then be maintained for 4 consecutive weeks."
62292658|NCT05995444|ACTIVE_COMPARATOR|400 mg moxifloxacin|400 mg moxifloxacin
62292659|NCT01895530|NO_INTERVENTION|Control group|Conventional treatment with no probiotic supplementation
62095207|NCT04984356|EXPERIMENTAL|WU-CART-007|"A CD7-directed chimeric antigen receptor (CAR) T-cell product.~A single IV infusion of WU-CART-007 Cells on Day 1 after Lymphodepletion(LD) Therapy."
62292660|NCT01895530|EXPERIMENTAL|Probiotic group|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
62292661|NCT04801407|ACTIVE_COMPARATOR|radiofrequency group|it is the group that will be treated with Percutaneous Radiofrequency Rhizotomy
62465402|NCT04819633||Control Group|30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
61908321|NCT03872076|EXPERIMENTAL|Plyometric exercises|The subjects included in the experimental group will carry out an intervention using plyometric exercises and isometric exercises with elastic band for the quadriceps muscle. Each session will last 15 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
61908322|NCT03872076|ACTIVE_COMPARATOR|Isometric exercises|The subjects included in the experimental group will carry out an intervention of isometric exercises with elastic bands for the quadriceps muscle. Each session will last 8 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
61908323|NCT01120782|ACTIVE_COMPARATOR|etafilcon A toric new lens/etafilcon A toric lens|The lens worn first is a new etafilcon A toric contact lens and the lens worn second is a marketed etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
61908324|NCT01120782|ACTIVE_COMPARATOR|etafilcon A toric lens/etafilcon A toric new lens|The lens worn first is a marketed etafilcon A toric contact lens and the lens worn second is a new etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
62095208|NCT00908674||Group 1|
62095209|NCT05244421|EXPERIMENTAL|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
62292662|NCT04801407|ACTIVE_COMPARATOR|Microvascular decompression group|it is the group that will be treated with Microvascular decompression
62292663|NCT00691665|EXPERIMENTAL|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
62292664|NCT00691665|ACTIVE_COMPARATOR|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
62292665|NCT01517880|EXPERIMENTAL|6,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
62292666|NCT01517880|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).
62292667|NCT01517880|EXPERIMENTAL|3,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
62292668|NCT03757039|EXPERIMENTAL|Multifocal Contact Lenses|Multifocal soft contact lenses according to the subject's prescription and fitted using the Alcon multifocal fitting guide. Lenses were worn bilaterally (in both eyes) for up to 3 hours, 1 day only.
62095210|NCT05569655|EXPERIMENTAL|Subjects in group A|For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide: 20mg-40mg/d).
62095211|NCT05569655|ACTIVE_COMPARATOR|Subjects in group B|Subjects in group B receive standard therapy (including furosemide: 20mg-40mg/d).
62292669|NCT03757039|ACTIVE_COMPARATOR|PAL Spectacles|Progressive addition lens spectacles according to the subject's habitual prescription, with testing up to 3 hours, 1 day only.
62292670|NCT00693706|EXPERIMENTAL|GSK 1388442A Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of GSK 1388442A vaccine at Day 0. The GSK 1388442A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62292671|NCT00693706|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of Fluarix® vaccine at Day 0. The Fluarix® vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
62465403|NCT05926570|EXPERIMENTAL|35 children and adolescents with end stage renal disease on regular hemodialysis|All children will receive cinacalcet in a dose of 30 mg/day taken with food for 3 months
62095212|NCT01268059|ACTIVE_COMPARATOR|Carboplatin/Paclitaxel|Carboplatin/paclitaxel regimen (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\], and paclitaxel 200 milligram per square meter \[mg/m\^2\]) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal. Subjects were enrolled from North America/European Union (EU) and Japan regions.
62292672|NCT02335684|EXPERIMENTAL|CF-LVAD patients.|Patients are compared with themselves during submaximal exercise testing with baseline pump speed vs. submaximal exercise testing with increased pump speed.
62292673|NCT03010540|EXPERIMENTAL|Morphine Plus Fentanyl|
62465404|NCT01985308|EXPERIMENTAL|Magnetic Resonance Therapy (MRT)-Active|Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
62465405|NCT01985308|SHAM_COMPARATOR|Magnetic Resonance Therapy (MRT)-Sham|Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
61908325|NCT02617901|EXPERIMENTAL|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (\< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).~Bone age will be assessed according to the Greulich \& Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
62465406|NCT01561807|EXPERIMENTAL|787 low dose|VX-787 low dose capsule, taken orally for 5 days
61908326|NCT03579602|ACTIVE_COMPARATOR|Arm 1 (no tozuleristide)|Subjects randomized to Arm 1 (\~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
61908327|NCT03579602|EXPERIMENTAL|Arm 2 (tozuleristide treated)|Subjects randomized to Arm 2 (\~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m\^2 at least 1 hour and no more than 36 hours prior to surgery. They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
62095213|NCT01268059|EXPERIMENTAL|Carboplatin/Paclitaxel + MEDI-575|Carboplatin/paclitaxel regimen (carboplatin AUC = 6 mg/mL\*min, and paclitaxel 200 mg/m\^2) followed by MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575. Subjects were enrolled from North America/European Union (EU) and Japan regions.
62292674|NCT03010540|ACTIVE_COMPARATOR|Fentanyl only|
62465407|NCT01561807|EXPERIMENTAL|787 high dose|VX-787 high dose capsule, taken orally for 5 days
62292675|NCT04007159|EXPERIMENTAL|Developmental Serum|The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square \[mL/cm\^2\] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
62465408|NCT01561807|EXPERIMENTAL|Placebo low dose|Matching placebo low dose capsule, taken orally for 5 days
62736818|NCT05906485|ACTIVE_COMPARATOR|Active Control Group: Computerized Cognitive Training Group|The computerized cognitive training group will receive 16 sessions of training, 35 minutes each, conducted twice per week over a period of 8 weeks. Participants will be asked to complete a set of computerized tasks using Cogmed, a digital training programme which is proven to enhance working memory and attention level in children.
62292676|NCT04007159|EXPERIMENTAL|Developmental Lotion|The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm\^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
62292677|NCT04007159|EXPERIMENTAL|Developmental Cream|The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm\^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
62292678|NCT04007159|PLACEBO_COMPARATOR|Negative Control|The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm\^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
62292679|NCT04523662|EXPERIMENTAL|Carrelizumab treatment group started during radiotherapy|
62292680|NCT04523662|EXPERIMENTAL|Start the carrelizumab treatment group within 3 days after the|
62292681|NCT05462379|NO_INTERVENTION|Standard treatment|10 patients: Pelvic Chemoradiotherapy
62465409|NCT01561807|EXPERIMENTAL|Placebo high dose|Matching placebo high dose capsule, taken orally for 5 days
62465410|NCT00928525|EXPERIMENTAL|Imatinib Mesylate|Patients affected by Desmoid Tumor and Chondrosarcoma will receive Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
62465411|NCT06359132||TeleConvert-AF|Patients with presumed persistent AF, age ≥18 years, scheduled for ECV, and in possession of a smartphone will be included in this study from January 2022 to January 2025.
62465412|NCT00890981|OTHER|Arm 1|Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.
62465413|NCT01197339|EXPERIMENTAL|treatment|
62736819|NCT05906485|OTHER|Waitlist Control Group|The waitlist control group will not receive any intervention until the intervention arms complete their training. Depending on the availability, either the fNIRS Neurofeedback-VR Training or the Computerized Cognitive Training will be offered to this group.
62095214|NCT05365867|EXPERIMENTAL|iCAN Group|iCAN is comprised of text messaging, GPS technology, preloaded apps, and telephone case management integrated within a community-based navigation center. Participants will receive 3 - 5 messages daily regarding medication adherence and appointment reminders, general health messages, motivational messages, and as needed messages for local information (e.g., weather updates). Within 48 - 72 hours of enrollment, participants will be called on their study phone by the study case manager for an intake assessment that will take 30 - 45 minutes in duration. The purpose of the assessment is to identify relevant health and social needs that the case manager can assist the participant in addressing by connecting with other medical and social services in the community. Within 48 - 72 hours of notification of a ED or hospital visit the iCAN case manager will call the participant on the study phone to assess care coordination needs for managing discharge instructions.
62095215|NCT05365867|NO_INTERVENTION|Usual Care Control (UCC)|Participants randomized to the UCC group will have access to their personal phones and use it in the usual manner with no installment of apps, text messages, or case manager interventions. Since the majority of PEH have a cell phone of some type, this will allow us to compare the intervention to how PEH typically use their cell phones. Also, the UCC will have access to all of the services available at any of the enrollment sites but no formal interaction from the iCAN case manager and no option of text messaging with the iCAN case manager.
62095216|NCT04931095|PLACEBO_COMPARATOR|Placebo cannabis + placebo alcohol|Participants administer oral cannabis containing 0mg THC in combination with a placebo alcohol drink.
62095217|NCT04931095|EXPERIMENTAL|low dose cannabis with placebo alcohol|Participants administer oral cannabis containing 10mg THC in combination with a placebo alcohol drink.
62095218|NCT04931095|EXPERIMENTAL|high dose cannabis with placebo alcohol|Participants administer oral cannabis containing 25mg THC in combination with a placebo alcohol drink.
62292682|NCT05462379|EXPERIMENTAL|Ovarian Graft|10 patients: Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
62292683|NCT05383690|EXPERIMENTAL|Bright Light Arm|This is a one-arm study. Subjects will be provided with the LiteBook Edge™ (LiteBook Company LTD), which is a patented smart phone sized BLT device that provides 10,000 lux illumination at a recommended distance of 61 cm from an LED panel with peak spectral radiance in the blue color spectrum that closely corresponds to the peak spectral frequency (480 nm) of melanopsin photoreceptors that project to the suprachiasmatic nucleus and entrain the circadian clock (Hatori \& Panda, 2010).
62292684|NCT02960282||Ancillary-Correlative (gut microbiome analysis)|Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.
61908328|NCT05146102|EXPERIMENTAL|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~* The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method~* Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
62292685|NCT05684640|EXPERIMENTAL|Rodatristat ethyl|Part One: is 600 QD
62292686|NCT05684640|PLACEBO_COMPARATOR|Placebo|Part Two: Placebo match for Rodatristat ethyl
62292687|NCT00179959|ACTIVE_COMPARATOR|Treatment|Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths
62292688|NCT00179959|PLACEBO_COMPARATOR|Placebo|Intranasal petrolatum ointment treatment and plain water baths
62658695|NCT04764149||Non-PFLL Group|Patients were treated with other platinum-based chemotherapy every 21 days including: PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1. TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
62658696|NCT06291363|EXPERIMENTAL|Esmolol|"In the Esmolol group, intravenous esmolol will be given as a bolus (0.5mg.kg-1) over 5 minutes, and will be started simultaneously to the remifentanil initiation.~Once the bolus of esmolol is over, a perfusion of 20 mcg.kg-1.min-1 will be programmed and maintained until the end of the surgery and completion of skin sutures"
62292689|NCT02643095|EXPERIMENTAL|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
62292690|NCT05963503||Cystic Fibrosis|"Inclusion Criteria:~have a confirmed diagnosis of CF stable clinical condition 18-65 ages volunteering to participate~Exclusion Criteria:~having a serious comorbidity that limits mobilization or participation in physical activity being illiterate having cognitive problems being pregnant incomplete answers to surveys"
62658697|NCT06291363|PLACEBO_COMPARATOR|Standard of care|"In the standard of care group, intravenous saline bolus, equivalent to an esmolol bolus (0.5mg.kg-1) will be given over 5 minutes, and will be started simultaneously to the remifentanil initiation.~Once the bolus of saline is over, a saline perfusion equivalent to an esmolol infusion of 20 mcg.kg-1.min-1 will be programmed and maintained until the end of the surgery and completion of skin sutures"
62658698|NCT00316004|EXPERIMENTAL|7.5% hypertonic saline/6% dextran (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
62095219|NCT04931095|EXPERIMENTAL|low dose cannabis with low dose alcohol|Participants administer oral cannabis containing 10mg THC in combination with an alcohol drink (0.05 percent BAC).
62095220|NCT04931095|EXPERIMENTAL|high dose cannabis with low dose alcohol|Participants administer oral cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).
62095221|NCT04931095|EXPERIMENTAL|Placebo cannabis + low dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).
62095222|NCT04931095|EXPERIMENTAL|Placebo cannabis + high dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).
62095223|NCT04041310|EXPERIMENTAL|Cohort A - Dose-escalation|"Phase I. Part 1. Dose escalation cohort. Subjects treated with low dose or with high dose of GAd20-209-FSP prime and MVA-209-FSP boosts to define the RP2D, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors."
62465414|NCT01197339|SHAM_COMPARATOR|Controls|
62658699|NCT00316004|EXPERIMENTAL|7.5% hypertonic saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline
62658700|NCT00316004|PLACEBO_COMPARATOR|0.9% normal saline (NS)|250 ml intravenous bolus administration of 0.9% saline
62658701|NCT05688228||Abortion|Adult women performing a medical or surgical abortion
61908329|NCT05146102|NO_INTERVENTION|No organized ethics communication in group|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They have not being educated in the one to five-step method and organized interprofessional sessions are not planned at the wards."
61908330|NCT05052931|EXPERIMENTAL|treatment group|Nab-paclitaxel combined with oxaliplatin and S-1
62095224|NCT04041310|EXPERIMENTAL|Cohort B - Expansion Cohort Phase I|"Phase I. Part 1. Expansion cohort at RP2D. Subjects treated with RP2D dose of GAd20-209-FSP prime and MVA-209-FSP boosts, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic dMMR or MSI-H CRC, gastric, or G-E junction tumors."
62095225|NCT04041310|EXPERIMENTAL|Cohort C - Expansion cohort Phase II|Phase II. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who are eligible for anti-PD-1 1st line of treatment. Subjects will be randomized with an allocation ratio 2:1 to Nous-209 vaccine plus Keytruda® (pembrolizumab) combination therapy versus pembrolizumab monotherapy.
62465415|NCT01591122|EXPERIMENTAL|Abiraterone acetate and prednisone|
62465416|NCT01591122|ACTIVE_COMPARATOR|Placebo and prednisone|
62465417|NCT04825132|EXPERIMENTAL|Bacteremia and/or acute respiratory infection|Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards...) for with bacteraemia and/or acute respiratory infection
62658702|NCT02271178|EXPERIMENTAL|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
62658703|NCT02271178|OTHER|Conventional treatment|Usual therapy
62658704|NCT03695588|ACTIVE_COMPARATOR|Quadratus lumborum block|Bilateral posterior QLB with 20ml 0.25% L-Bupivacaine.
62736820|NCT03970876|EXPERIMENTAL|ATGC-100 (Phase I/II)|ATGC-100 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
62465418|NCT04825132|ACTIVE_COMPARATOR|Without suspicion of infection|The control patient will undergo the exact same procedures as the case patient described before except for the blood and respiratory sample part. • The typical control patient will be of the same age (+/- 3 years, but aged above 65 years), same sex, without suspicion of infection and hospitalized during the past or upcoming month in the same centre. There will be 2 controls for one case.
62465419|NCT00301366|EXPERIMENTAL|Alpha-1 Proteinase Inhibitor (Human), modified process|Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.
62658705|NCT03695588|SHAM_COMPARATOR|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle. Patient blinded due to residual spinal anaesthetic block.
62658706|NCT01159847|EXPERIMENTAL|Sitagliptin|Patients will receive insulin therapy with sitagliptin.
61908331|NCT05845697|EXPERIMENTAL|Actual dry needling group|Will receive actual dry needling of the lumbar multifidus with a 50-60mm filiform needle
62095226|NCT04041310|EXPERIMENTAL|Cohort D - Expansion cohort Phase II|Phase II. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who have had radiographic progression (PD) after having a best response of stable disease (SD) or better on/after anti-PD1 treatment. Nous-209 vaccine plus Keytruda® (pembrolizumab) combination therapy.
62095227|NCT02537444|EXPERIMENTAL|Regimen 1|Drug: acalabrutinib monotherapy
62095228|NCT02537444|EXPERIMENTAL|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
62095229|NCT06614764|PLACEBO_COMPARATOR|PG- Placebo gel|The PG group received the application of placebo gel for post tooth bleaching sensitivity.
62095230|NCT06614764|ACTIVE_COMPARATOR|GKF2- Potassium nitrate|The KF2 group received the application of potassium nitrate for post tooth bleaching sensitivity.
62095231|NCT06614764|EXPERIMENTAL|AG- Andiroba Gel|The AG group received the application of experimental gel of andiroba (Carapa guianensis) for post tooth bleaching sensitivity.
62095232|NCT05894759|EXPERIMENTAL|Music therapy|Patients will undergo music therapy, delivered online, for 1 month.
62095233|NCT05894759|SHAM_COMPARATOR|Relaxing stories|Patients will listen to relaxing stories, online, for 1 month.
62095234|NCT05894759|NO_INTERVENTION|Treatment as usual|Dermatological treatment as per national guidelines.
62095235|NCT03533855|EXPERIMENTAL|"CS plus FRFSE"|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
62095236|NCT00550732|EXPERIMENTAL|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
62292691|NCT05963503||Controls|"Inclusion Criteria:~18-65 ages volunteering to participate~Exclusion Criteria:~having any cardiopulmonary disease having cognitive problems being illiterate"
62292692|NCT00790517|EXPERIMENTAL|1|Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
62292693|NCT00790517|NO_INTERVENTION|2|Usual care
62292694|NCT04561349|EXPERIMENTAL|Task-oriented training (TOT)|Task-oriented training consisted of different functional tasks for lower limbs to improve balance and walk
62292695|NCT04561349|ACTIVE_COMPARATOR|Conventional rehabilitation treatment|Conventional rehabilitation treatment includes mat activities and range of motion (ROM) of all limbs, Lower limb strengthening and stretching, walking, cycling
62292696|NCT00595231|EXPERIMENTAL|SYN111|500 mg 1 week, followed by 1000 mg for 7 weeks
62292697|NCT00595231|PLACEBO_COMPARATOR|Placebo|0 mg tablets
62292698|NCT02844790|EXPERIMENTAL|IDegAsp|
62292699|NCT03870841|EXPERIMENTAL|PC945|PC945 5mg once daily
62658707|NCT01159847|ACTIVE_COMPARATOR|Insulin|Patients will receive insulin therapy without sitagliptin.
62658708|NCT02705170||left ventricle dilatation|The subjects of the investigation will be patients with recent diagnosis of unknown left ventricle dilatation. These subjects received coronary artery angiography as exam suggested by guidelines to discriminate the cause of left ventricle dilatation. In subjects without documentation of coronary artery lesions, the Authors will assess the index of microvascular resistance.
62658709|NCT05080985|EXPERIMENTAL|Group P : TPVB|Thoracic paravertebral block
62292700|NCT03215784|PLACEBO_COMPARATOR|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
62292701|NCT03215784|EXPERIMENTAL|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
62292702|NCT03215784|EXPERIMENTAL|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
62292703|NCT03215784|EXPERIMENTAL|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
62658710|NCT05080985|EXPERIMENTAL|Group E : ESPB|Erector spinae plane block
62658711|NCT00530166|EXPERIMENTAL|002|sham comparator 3(100 mg) tablets once daily for 12 weeks
62658712|NCT00530166|EXPERIMENTAL|001|JNJ-18054478 3(100 mg) tablets once daily for 12 weeks
62658713|NCT01721902|ACTIVE_COMPARATOR|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of autologous CD133+ cells in suspension.
62658714|NCT01721902|PLACEBO_COMPARATOR|Carrier Solution|Intra-myocardial inception of carrier solution.
62736821|NCT03970876|ACTIVE_COMPARATOR|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
62658715|NCT04040699|EXPERIMENTAL|KN026 combined with KN046|"KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.~KN046 is a PD-L1 - CTLA-4 bispecific antibody."
62095237|NCT02923895|EXPERIMENTAL|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
62095238|NCT02923895|ACTIVE_COMPARATOR|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
62658716|NCT05247320||Prospective|
62095239|NCT00427973|EXPERIMENTAL|AZD2171|Patients will receive AZD2171 (cediranib maleate) 30mg by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies. Laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, and pharmacological study will be performed.
62095240|NCT04858620|NO_INTERVENTION|No treatment|
62292704|NCT03288298|EXPERIMENTAL|luteolin|a natural extract derived flavinoids
62292705|NCT03288298|ACTIVE_COMPARATOR|nano-luteolin|nano-particles derived from a natural extract luteolin
62292706|NCT00000257|ACTIVE_COMPARATOR|Light drinkers|
62658717|NCT05247320||Retrospective|
62658718|NCT02049762|ACTIVE_COMPARATOR|P2Y12 inhibitors and aspirin|ACS patients on novel P2Y12 inhibitors and aspirin
62658719|NCT02049762|PLACEBO_COMPARATOR|P2Y12 inhibitors and placebo|ACS patients on novel P2Y12 inhibitors and placebo
62658720|NCT03846479|EXPERIMENTAL|Itacitinib|Itacitinib 200 mg administered orally daily
62658721|NCT03725553|EXPERIMENTAL|Intramyometrial Vasopressin|the experimental group received a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
62658722|NCT03725553|PLACEBO_COMPARATOR|Placebo|the placebo group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)immediately after delivery, as soon as the umbilical cord was clamped.
62658723|NCT02995148|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62658724|NCT01091259|EXPERIMENTAL|Irinotecan with Bevacizumab|Irinotecan is administered every 3 weeks at a dose of 175 mg/m\^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
62658725|NCT03073759|EXPERIMENTAL|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
62658726|NCT03073759|SHAM_COMPARATOR|Sham|Patients will receive a sham.
62658727|NCT01724593||Observational Cohort|No Intervention
62658728|NCT00204737|ACTIVE_COMPARATOR|Prednisone|Prednisone 20mg daily x 2 weeks
62658729|NCT00204737|PLACEBO_COMPARATOR|placebo|placebo
62658730|NCT00000935|EXPERIMENTAL|Intravenous Immune Globulin (Human)|
62658731|NCT00000935|PLACEBO_COMPARATOR|Intravenous Immune Globulin (Human) Placebo|
62095241|NCT04858620|EXPERIMENTAL|Treatment|
62095242|NCT04858620|PLACEBO_COMPARATOR|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
62292707|NCT00000257|ACTIVE_COMPARATOR|Moderate drinkers|
62292708|NCT05862389||Anorexia nervosa|Patients with anorexia nervosa.
62292709|NCT05862389||Bulimia nervosa|Patients with bulimia nervosa.
62292710|NCT05862389||Healthy control|The healthy control group
62292711|NCT04991831||Post Exablate Neuro Thalamotomy for Tremor Associated with Tremor Dominant Parkinson's Disease|This is a post Exablate Neuro Thalamotomy registry. No intervention is performed under this registry protocol.
62292712|NCT05305482|EXPERIMENTAL|DCS group|Drug-coated stent group
62658732|NCT02807259|EXPERIMENTAL|Multi-level intervention|This is a cluster-randomised controlled trial design. The unit of randomisation is village.
62658733|NCT02807259|OTHER|Control|The intervention will rolled out to all participating villages after 24 months.
62658734|NCT01723059|OTHER|Standard triple therapy|Gold standard for management of H pylori is amoxicillin 1 gm twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 10 days.
62658735|NCT01723059|ACTIVE_COMPARATOR|Sequential Therapy|Amoxicillin 1 gm twice daily and omeprazole 20 mg twice daily for 5 days followed by metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 5 days.
62658736|NCT05927415|EXPERIMENTAL|Mild renal impairment|Patients with 60 \<= eGFR \<90
62658737|NCT05927415|EXPERIMENTAL|Moderate renal impairment|Patients with 30 \<= eGFR \<60
62095243|NCT04107103|EXPERIMENTAL|Single Arm|A single-arm combining nivolumab with pemetrexed
62465420|NCT01799330|EXPERIMENTAL|Group 1:Active TCEMS|Transcutaneous Electrical Muscle Stimulation (TCEMS): Group 1 will undergo TCEMS using an Omnistim FX-2 with two surface patch electrodes (8 x 6 cm) applied to each quadriceps, hamstring and calf muscles. The knee angle will remain at 90 degrees during simultaneous muscle stimulation to prevent joint movement. Electrical stimulation will be performed for 20 minutes on each limb, 3 days/week for 8 continuous weeks on an outpatient basis. The stimulator will be set to generate brief bursts of electrical impulses at 50Hz lasting 200 ms every 1500 ms. Muscles will be stimulated with an asymmetrical square wave pulse with an initial intensity set to create a visible contraction ranging from 55 mA to 120 mA.
61908332|NCT05845697|SHAM_COMPARATOR|Sham dry needling group|Will receive needling from a sham needle that is blunted so it does not pierce the skin but has been shown to be valid for being indistinguishable from receiving an actual needle.
61908333|NCT04880902|EXPERIMENTAL|sleeve gastrectomy followed by volumetric assessment|
61908334|NCT02065427|EXPERIMENTAL|Social support|"Social support intervention~Intervention is performed by the health professionals working at the primary health care team responsible for the patient, and consisits of the following components:~a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support."
61908335|NCT02065427|NO_INTERVENTION|Usual home health care|Caregivers and dependent patients: usual home health care, consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request
61908336|NCT04036292|ACTIVE_COMPARATOR|OC-01 Low Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.6 mg/ML
61908337|NCT04036292|ACTIVE_COMPARATOR|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/ML
61908338|NCT04036292|PLACEBO_COMPARATOR|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
61908339|NCT01388556|EXPERIMENTAL|Tango|Twice weekly tango dance classes for 12 months.
61908340|NCT01388556|NO_INTERVENTION|Control Group|
61908341|NCT02248675|EXPERIMENTAL|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
61908342|NCT02248675|ACTIVE_COMPARATOR|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
62095244|NCT04746820|EXPERIMENTAL|Experimental (unconscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
62095245|NCT04746820|SHAM_COMPARATOR|Control group (healthy, conscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
62095246|NCT01851109|NO_INTERVENTION|Control|
62292713|NCT05305482|ACTIVE_COMPARATOR|DES group|Drug-eluting stent group
62292714|NCT05003115|NO_INTERVENTION|Standard of Care|Standard of Care
62292715|NCT05003115|EXPERIMENTAL|Intervention|Motivational interviewing intervention
62292716|NCT03646084|EXPERIMENTAL|Sleep Intervention Program (SCIP)|Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
62292717|NCT03646084|ACTIVE_COMPARATOR|Control|Rehabilitation according to current clinical practice.
62292718|NCT03044392|ACTIVE_COMPARATOR|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
62292719|NCT03044392|ACTIVE_COMPARATOR|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
62292720|NCT03044392|ACTIVE_COMPARATOR|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
62292721|NCT00507325||Blood Sample + Tumor Sample|Blood samples will be collected. Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
62292722|NCT01206569|EXPERIMENTAL|advagraf|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
62292723|NCT01737814|EXPERIMENTAL|MST-188|MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
62292724|NCT01737814|PLACEBO_COMPARATOR|Saline|Saline administered as a continuous infusion for up to 49 hours
62292725|NCT00382148|EXPERIMENTAL|1|
62292726|NCT03823391|EXPERIMENTAL|ABBV-3373 Followed by Placebo|Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
62292727|NCT03823391|EXPERIMENTAL|Adalimumab|Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.
62292728|NCT02620020|EXPERIMENTAL|Fasinumab 6 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
62292729|NCT02620020|EXPERIMENTAL|Fasinumab 9 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
62292730|NCT02620020|EXPERIMENTAL|Fasinumab 9 mg IV Q8W and Placebo SC Q4W|Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
62292731|NCT02620020|EXPERIMENTAL|Placebo SC Q4W and Placebo IV Q8W|Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.
62292732|NCT04964011|EXPERIMENTAL|Board game group|The Board game group was led by an occupational therapist who has been working for six years. The intervention comprised 1 week of board game instruction and 11 weeks of board game tasks (combined with daily tasks), for a total of 12 weeks, once a week for 2 hours, for a total of 24 hours of intervention.
62292733|NCT04964011|ACTIVE_COMPARATOR|Health promotion group|MCI seniors in the health promotion group received general health promotion and were led by instructors from the long-term care facility for 12 weeks, including 4 weeks of physical activities, 4 weeks of singing activities, and 4 weeks of art activities, once a week for 2 hours, for a total of 24 hours.
61908343|NCT01638442|EXPERIMENTAL|Treatment A|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
62292734|NCT03322358|NO_INTERVENTION|Control|No changes to normal sleep habits.
62292735|NCT03322358|EXPERIMENTAL|Naps only|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
62292736|NCT03322358|EXPERIMENTAL|Home sleep aids only|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
62292737|NCT03322358|EXPERIMENTAL|Home sleep aids + Sleep incentives|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful. In addition, they will be given a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
62095247|NCT01851109|EXPERIMENTAL|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
62095248|NCT03130036|EXPERIMENTAL|No risk of disease|Subjects with no identifiable risk of Alzheimer's Disease
62095249|NCT03130036|EXPERIMENTAL|Asymptomatic|Asymptomatic subjects with increased risk of Alzheimer's disease
62095250|NCT03130036|EXPERIMENTAL|Early Alzheimer's or Mild Cognitive Impairment|Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)
62095251|NCT01763736|EXPERIMENTAL|Music|Everyone enrolled with receive music sessions.
62095252|NCT06192706|EXPERIMENTAL|Tria Aortic Valve|Patients receiving the Foldax Aortic Valve
62292738|NCT03322358|EXPERIMENTAL|Naps + Home sleep aids|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
62292739|NCT03322358|EXPERIMENTAL|Naps + Home sleep aids + Sleep incentives|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish, and 3) a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period. The sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
62292740|NCT03078062|ACTIVE_COMPARATOR|Dexamethasone|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml. The study drug will be prepared by an independent assistant.
62292741|NCT03078062|PLACEBO_COMPARATOR|Normal Saline|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated. The infusion will be administered over 5 -10 minutes. The study drug will be prepared by an independent assistant.
62292742|NCT05206461||Hemiparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Hemiparetic CP
62292743|NCT05206461||Diparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Diparetic CP
62292744|NCT00500266|EXPERIMENTAL|1|13-valent Pneumococcal Conjugate Vaccine
62095253|NCT04609540||Pyrotinib and Trastuzumab group|Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
62292745|NCT04647110||Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients|
62292746|NCT04764942|EXPERIMENTAL|Arm A (selinexor, dexamethasone, carfilzomib, carfilzomib)|Patients receive selinexor PO and dexamethasone PO on days 1, 8 15, and 22, carfilzomib IV on days 1, 8, and 15, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT and bone marrow biopsy and aspiration during screening and on the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
62095254|NCT01594060|ACTIVE_COMPARATOR|sliding scale|
62658738|NCT05927415|EXPERIMENTAL|Severe renal impairment|Patients with eGFR \<30
62095255|NCT01594060|ACTIVE_COMPARATOR|basal bolus|
62292747|NCT04764942|EXPERIMENTAL|Arm B (selinexor, dexamethasone, pomalidomide)|Patients receive selinexor PO and dexamethasone PO on days 1, 8, 15, and 22, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT and bone marrow biopsy and aspiration during screening and on the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
62292748|NCT05841940|EXPERIMENTAL|[14C]HLX208|Single oral dose of 450mg \[14C\]HLX208 suspension.
62095256|NCT00371774||1|Dermatologic patients in Canada for which Amevive is clinically indicated
62095257|NCT01962064|EXPERIMENTAL|Semantic demantia|cognitive assessment and Brain imaging examination MRI of patient with the semantic variant of primary progressive aphasia
62658739|NCT05927415|EXPERIMENTAL|Normal renal function|Patients with eGFR \>=90
62095258|NCT01962064|EXPERIMENTAL|Frontotemporal dementia|cognitive assessment and Brain imaging examination MRI of patients with the behavioral variant of frontotemporal lobar degeneration
62095259|NCT01962064|EXPERIMENTAL|Elderly|cognitive assessment and Brain imaging examination MRI of healthy elderly subjects
62095260|NCT01962064|EXPERIMENTAL|Young|cognitive assessment and Brain imaging examination MRI of young subjects
62095261|NCT01027871|EXPERIMENTAL|LY2605541 Dosing Algorithm 1|Participants took both LY2605541 and their pre-study insulin for first several days
62095262|NCT01027871|EXPERIMENTAL|LY2605541 Dosing Algorithm 2|Participants took only LY2605541 with first dose doubled
62095263|NCT01027871|ACTIVE_COMPARATOR|Insulin glargine|
62658740|NCT02371811|EXPERIMENTAL|v care group|In this group we will use (v care) uterine manipulator during abdominal hysterectomy.
62658741|NCT02371811|NO_INTERVENTION|control group|In this group we will do abdominal hysterectomy without v care.
62658742|NCT05213091|EXPERIMENTAL|Otago Exercise Group|Otago Exercise program wil be applied to the elderly.
62658743|NCT05213091|NO_INTERVENTION|Control Group|The elderly wil be expected to continue their daily life.
62658744|NCT00878865|EXPERIMENTAL|Alprazolam 1 mg tablet|Alprazolam 1 mg tablet
62658745|NCT00878865|ACTIVE_COMPARATOR|Xanax 1 mg tablet|Xanax 1 mg tablet
62658746|NCT03188198|ACTIVE_COMPARATOR|Arm A - R-CHOP|"Patients receive the following treatment:Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy.Cyclophosphamide 750 mg/m\^2 IV on Day 1.Doxorubicin 50 mg/m\^2 IV on Day 1.Vincristine 1.4 mg/m\^2 IV (2 mg cap) on Day 1.Prednisone 40 mg/m\^2/day PO on Days 1-5.filgrastim or pegfilgrastim as defined in the protocol Required ancillary medications is administered during all cycles as defined in the protocol. Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.~Interventions:-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: filgrastim-Drug: pegfilgrastim"
61908344|NCT01638442|EXPERIMENTAL|Treatment B|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
62095264|NCT01348854|EXPERIMENTAL|Natural Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.
62095265|NCT01348854|EXPERIMENTAL|Post Cataract with Residual Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.
62095266|NCT04890145|EXPERIMENTAL|Mild to severe hearing loss|
62095267|NCT03498040||Patients with or at risk of carcinoid heart disease|"* Adult patients with well-differentiated metastatic ileum or bronchial neuroendocrine tumor~* Adult patients with carcinoid syndrome or elevated urinary 5HIAA regardless of primary site"
62292749|NCT02906800|EXPERIMENTAL|DIGHANC|Patients meeting all inclusion /exclusion criteria, will be given 3 cycles of the following regimen: 1) digoxin (0.25 mg/day) for a 7-day period (digitalization time) from Day 1 to Day 7; 2) chemotherapy regimen TPF protocol from Day 8 to D12 (continuous perfusion of fluorouracil for 120h, Cisplatin at Day 10 and Docetaxel at Day 11) administered in combination with digoxin 0.25 mg/day from Day 8 to Day 9; 3) a 15-day period off treatment.
62292750|NCT01147497|EXPERIMENTAL|misoprostol|Misoprostol 400mcg taken buccally 2 hours prior to IUD insertion visit
62292751|NCT01147497|PLACEBO_COMPARATOR|placebo|Pill that is identical to the study drug in appearance, taste, and smell, taken buccally 2 hours prior to IUD insertion visit
62292752|NCT02947919|EXPERIMENTAL|Intervention|Music in the perioperative period
62465421|NCT01799330|PLACEBO_COMPARATOR|Group 2: Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response.
62736822|NCT05368389||Healthdot Patients|This group represents the patient who have undergone a bariatric procedure and had the Healthdot device attached and had data collected from the device for 10 days.
62736823|NCT05368389||Healthdot providers|This group represents the providers or study/hospital staff who were involved in the attachment, recruitment, and enrollment of the Healthdot patients.
61908345|NCT03320876|EXPERIMENTAL|filgotinib|
61908346|NCT00830908|EXPERIMENTAL|LaserComb|Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
61908347|NCT01265264|EXPERIMENTAL|ulodesine Placebo + Allopurinol 300mg|Oral dose administered daily for 84 days.
61908348|NCT01265264|EXPERIMENTAL|ulodesine 5mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
62292753|NCT02947919|NO_INTERVENTION|Control|Usual treatment
62292754|NCT01250821|EXPERIMENTAL|Ovulation induction|
62465422|NCT00624065|EXPERIMENTAL|carvedilol CR + lisinopril|
62465423|NCT00624065|ACTIVE_COMPARATOR|lisinopril + placebo|
62465424|NCT02125370||Nicotine Replacement Therapy|
62465425|NCT00899483|ACTIVE_COMPARATOR|1|Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L
62465426|NCT00899483|NO_INTERVENTION|2|Normal departmental practice using dextrose insulin infusion
62736824|NCT01621256|EXPERIMENTAL|Ancrod|Ancrod
62736825|NCT01621256|PLACEBO_COMPARATOR|Saline solution|Saline solution
62465427|NCT00473486|ACTIVE_COMPARATOR|1|Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC
61908349|NCT01265264|EXPERIMENTAL|ulodesine 10mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
62292755|NCT02040688||Sleep Disorders|7-36 months old children with behavioral insomnia of childhood based on the International Classification of Sleep Disorders (ICSD) criteria will be recruited from the Pediatric Sleep Center at Dana Children's hospital
62465428|NCT00473486|PLACEBO_COMPARATOR|2|Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC
62095268|NCT03748771|EXPERIMENTAL|ApneaLink Air|Half of the participants will undergo HST no greater than one week prior to their in-laboratory PSG, while the other half will undergo HST no greater than one week following their in laboratory PSG. All participants will also undergo their HST concurrent to their in-laboratory PSG. The rational for splitting participants in these two groups is to equally distribute the effects of the first night evenly, in which the sleep architecture including reduced total rapid eye movement (REM) sleep time can vary during the first ever sleep study. As the HST will be compared to the in-lab PSG, we would like to evenly distribute this effect by having two groups of ten participants.
62095269|NCT06466668||Hyperacusis|participants with hyperacusis (or an increased sensitivity to sound)
62465429|NCT06425679|EXPERIMENTAL|Supervised synchronous online exercise intervention without motivational strategies|
61908350|NCT01265264|EXPERIMENTAL|ulodesine 20mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
62095270|NCT06466668||No hyperacusis|participants without hyperacusis (or an increased sensitivity to sound)
62292756|NCT02040688||Control|7-36 months old chidren of age who attend well-care clinics in the metropolitan of Tel Aviv for routine periodic medical examination.
62292757|NCT02040688||Feeding disorder|7-36 monthsold children with feeding disorders based on Chatoor criteria will be recruited from the clinic of feeding disorders at Dana Children's Hospital.
62292758|NCT02446587||Stroke with Mechanical Thrombectomy|Eligible patients will be adults ≥18 with the final diagnosis of an acute ischemic infarction and large artery occlusion in anterior circulation strokes who undergo endovascular therapy with mechanical thrombectomy utilizing stent retrievers
62292759|NCT02446587||Stroke without Mechanical Thrombectomy|Patients who would have large artery occlusion treated with best medical management (IV-tPA if eligible) and not receiving endovascular therapy will be collected for a secondary analysis as a comparison group and to evaluate the selection methods in them as well
62292760|NCT02976155|NO_INTERVENTION|Pre-intervention|enteral nutrition according routine practice
62292761|NCT02976155|EXPERIMENTAL|Post-intervention|The intervention in this arm is the application of a standard enteral nutrition protocol
62465430|NCT06425679|EXPERIMENTAL|Supervised synchronous online exercise intervention with motivational strategies|
62465431|NCT06425679|EXPERIMENTAL|Supervised face to face exercise intervention without motivational strategies|
61908351|NCT01265264|EXPERIMENTAL|ulodesine 40mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
61908352|NCT06334406||Cohort A|Patients treated with intravesical instillations for non-invasive bladder cancer
61908353|NCT06334406||Cohort B|Patients treated with radiotherapy (+/- concurrent chemotherapy) for invasive bladder cancer
61908354|NCT06334406||Cohort C|Patients treated with neo-adjuvant chemotherapy for invasive bladder cancer
61908355|NCT01887054|ACTIVE_COMPARATOR|Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~* Gait evaluation~* Neuropsychological testing~* Questionnaires and assessments~* Taught how to complete a visual problem-solving task (Tower of Hanoi)~* Given a diary to record training at home.~In-home~•For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1~Visit 2~* Gait evaluation~* Neuropsychological testing~* Questionnaires and assessments"
62095271|NCT05628662|EXPERIMENTAL|Automated Insulin Delivery System (SAFE-AP)|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFE-AP) based on blood glucose estimations from CGM.
62465432|NCT06425679|EXPERIMENTAL|Supervised face to face exercise intervention with motivational strategies|
62465433|NCT06425679|NO_INTERVENTION|Control group|Participants will be advised to maintain their usual lifestyle.
61908356|NCT01887054|PLACEBO_COMPARATOR|Non Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~* Gait evaluation~* Neuropsychological testing~* Questionnaires and assessments~Visit 2~* Gait evaluation~* Neuropsychological testing~* Questionnaires and assessments"
61908357|NCT06471387||Abstainers|Participants who achieve biochemically-verified smoking abstinence for at least 6 months following a cessation attempt aided by a computerized intervention program.
61908358|NCT06471387||Relapsers|Participants who do not achieve abstinence and relapse to smoking following the cessation attempt.
62095272|NCT02078830|PLACEBO_COMPARATOR|3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
62292762|NCT06353672|EXPERIMENTAL|Robotic liver resection|
62292763|NCT03312192|ACTIVE_COMPARATOR|Plate and Cage|ACDF with interbody cage and anterior plating.
62292764|NCT03312192|ACTIVE_COMPARATOR|Stand Alone Cage|ACDF with stand alone interbody cage without anterior plating
62292765|NCT05011084|EXPERIMENTAL|Game Ready Cryotherapy with Compression Group|Post-operative treatment will involve using a Game Ready ® unit
62292766|NCT05011084|ACTIVE_COMPARATOR|Control Cryotherapy Group|Post-operative treatment will involve using the standard of care cryotherapy (i.e., traditional ice packs without compression).
62292767|NCT02047084||Theraskin, Apligraf|Theraskin used every other week x 4 Apligraf used weekly x 8
62292768|NCT02047084||Venous leg ulcers|Theraskin and Apligraft
62292769|NCT03099733|EXPERIMENTAL|concussion|patients who present to ED with concussion
62292770|NCT04141371|ACTIVE_COMPARATOR|Molar Sodium Lactate|
62292771|NCT04141371|PLACEBO_COMPARATOR|physiological serum|
62465434|NCT03753425||PEG4L, four liters polyethylene glycol|PEG4L, four liters polyethylene glycol
62465435|NCT03753425||PEG2L, two liters polyethylene glycol with ascorbic acid|PEG2L, two liters polyethylene glycol with ascorbic acid
62465436|NCT03753425||Pico, sodium picosulfate|Pico, sodium picosulfate
62465437|NCT03753425||NaP, sodium phosphate|NaP, sodium phosphate
62465438|NCT03753425||MPS, sodium, magnesium and potassium sulphates|MPS, sodium, magnesium and potassium sulphates
62736862|NCT03693677|EXPERIMENTAL|Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively|"Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months~* Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.~* Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :~* Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~* Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
62292772|NCT03146286|PLACEBO_COMPARATOR|Control|Chocolate flavoured drink spiked with 15mg/kg \[2H31\]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with \[13C\]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
61908359|NCT02956590|ACTIVE_COMPARATOR|Pitavastatin|Study Drug
61908360|NCT02956590|PLACEBO_COMPARATOR|Placebo|Placebo
61908361|NCT03498053|OTHER|Cigarette brands smoked by participant|"The 3 experimental days per participant are exactly the same, except the cigarette brand they smoke.~The content of an experimental day is described in the study design."
62095273|NCT02078830|EXPERIMENTAL|3M™ Tegaderm™ CHG Securement Dressing|- CHG activity at EVD entry site
62095274|NCT02293707|EXPERIMENTAL|GX301 Regimen A (8 administrations)|Administration time frame: Day 1 to Day 63.
62095275|NCT02293707|EXPERIMENTAL|GX301 Regimen B (4 administrations)|Administration time frame: Day 1 to Day 63.
62095276|NCT02293707|EXPERIMENTAL|GX301 Regimen C (2 administrations)|Administration time frame: Day 1 to Day 63.
62095277|NCT03885037||Infliximab [infliximab biosimilar 3]|Patients with Rheumatoid Arthritis treated by Infliximab BS
62095278|NCT01824446|EXPERIMENTAL|Radiolabeled SPD602|
62292773|NCT03146286|EXPERIMENTAL|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg \[2H31\]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.7 g/kg bodyweight palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with \[13C\]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
62292774|NCT03146286|EXPERIMENTAL|Fish Oil|Chocolate flavoured drink spiked with 15mg/kg \[2H31\]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.45 g/kg bodyweight palm stearin and 0.25 g/kg bodyweight fish oil (n3PUFA). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with \[13C\]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
62292775|NCT03561727|EXPERIMENTAL|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
62465439|NCT03702894|EXPERIMENTAL|Clavamox,Coated Tablets, 875 mg + 125 mg|Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
62465440|NCT03702894|ACTIVE_COMPARATOR|Augmentin®, Coated Tablets, 875 mg + 125 mg|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
62095279|NCT02202356|EXPERIMENTAL|ALS-008176 Single Dose|Single dose of ALS-008176 administered orally as a suspension
62095280|NCT02202356|PLACEBO_COMPARATOR|Placebo Single Dose|Single dose of placebo administered orally as a suspension
62095281|NCT02202356|EXPERIMENTAL|ALS-008176 Multiple Doses|Multiple doses of ALS-008176 administered orally as a suspension
62095282|NCT02202356|PLACEBO_COMPARATOR|Placebo Multiple Doses|Multiple doses of placebo administered orally as a suspension
62095283|NCT05837026|EXPERIMENTAL|Enhanced Outreach Intervention plus Care as Usual (CAU)|Participants will receive the Enhanced Outreach Intervention (EOI) plus care as usual for 12 weeks after ED discharge.
62095284|NCT05837026|OTHER|Care as Usual (CAU)|Participants will receive the standard care (i.e., CAU) that the hospital provides to patients who present with suicidal thoughts.
62095285|NCT00372970|ACTIVE_COMPARATOR|Botulinum Toxin A|200 U of Botox injected endoscopically into pylorus
61908362|NCT03995329|OTHER|healthy non smokers|"Healthy non smokers males, aged 18-55years,receiving no medications~Intervention: the use of an IQOS Examination of pulmonary function, exhaled CO, blood pressure, heart rate and O2 saturation immediatly after IQOS"
61908363|NCT03645343|ACTIVE_COMPARATOR|Activator|Patients will be treated using the Activator appliance for one and a half year
61908364|NCT03645343|EXPERIMENTAL|Twin Block|Patients will be treated using the Twin Block appliance for 18 months on average
61908365|NCT03645343|NO_INTERVENTION|Control|Patients will be monitored until the last assessment times in the other groups. This group will serve as a control group
61908366|NCT00470509|EXPERIMENTAL|Adalimumab|adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
61908367|NCT00470509|PLACEBO_COMPARATOR|Placebo|2 placebo injections on day 0 and 7
61908368|NCT05661747|EXPERIMENTAL|Intervention Arm will use Vivos Grow/Vivos Way Device|This intervention will compare measurements prior to treatment with measurements post-treatment.
62095286|NCT00372970|PLACEBO_COMPARATOR|Placebo|saline into pylorus.
62095287|NCT05612776|EXPERIMENTAL|HIIT-based training|The HIIT group will train according to a predefined high intensity training program
62095288|NCT05612776|EXPERIMENTAL|HRV-based training|The training prescribed to the HRV group will depend on the subjects' diary HRV
62095289|NCT06378762|EXPERIMENTAL|Endurance|
62095290|NCT06378762|EXPERIMENTAL|Strength|
62095291|NCT06378762|EXPERIMENTAL|Concurrent|
62658747|NCT03188198|EXPERIMENTAL|Arm B - DA-EPOCH-R|"Patients receive the following treatment: Cycle 1 Doses:Rituximab 375 mg/m\^2 IV infusion on Day 1 prior to EPOCH chemotherapy. Doxorubicin 10 mg/m\^2/day CIVI on Days 1-4.Etoposide 50 mg/m\^2/day CIVI on Days 1-4. Vincristine 0.4 mg/m\^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours). Cyclophosphamide 750 mg/m\^2 IV on Day 5 (following completion of 96 hour infusions). Prednisone 60 mg/m\^2 PO BID on Days 1-5 Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC \> 5000 after the nadir (nadir usually between Days 10-12) Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.~Interventions:~-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: etoposide-Drug: filgrastim"
62658748|NCT01997450||Q/LAIV|FluMist Quadrivalent
62658749|NCT01997450||Inactivated Influenza Vaccine|Inactivated Influenza Vaccine
62292776|NCT03561727|ACTIVE_COMPARATOR|Layered closure technique|Abdominal cavity will be closed with two separate layers of continuous sutures. The first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia. In case of incisions not exceeding the lateral border of rectus abdominis muscle, the second layer will involve only the anterior layer of the rectus abdominis muscle fascia. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer will include internal oblique abdominal muscle fascia, external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
62292777|NCT01417130||Naproxen sodium (220 mg b.i.d)|Original assignment in the ADAPT trial
62292778|NCT01417130||Celecoxib (200 mg b.i.d.)|Original assignment in the ADAPT trial
62292779|NCT01417130||Placebo|Original assignment in the ADAPT trial
62292780|NCT04974788|ACTIVE_COMPARATOR|Low Intensity Respiratory Muscle Training Group|Low intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
62292781|NCT04974788|ACTIVE_COMPARATOR|Medium Intensity Respiratory Muscle Training Group|Medium intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
62292782|NCT04974788|ACTIVE_COMPARATOR|High Intensity Respiratory Muscle Training Group|High intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
62292783|NCT02185391|EXPERIMENTAL|fact-finding group|Intervention: Audience Response System and motivational telephone interview
62292784|NCT02185391|NO_INTERVENTION|control group|
62292785|NCT00763802||MNPDR|Type 2 diabetic patients with Mild non-prolipherative retinopathy.
62292786|NCT06246773|EXPERIMENTAL|Positive Parenting Program|
62292787|NCT06246773|ACTIVE_COMPARATOR|Usual Care|
62292788|NCT02021994||Arm Automatic Electronic BPM|
62292789|NCT02021994||mercury sphygmomanometer|
62292790|NCT02515513|ACTIVE_COMPARATOR|Pancreatic Cancer Patients|During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.
62292791|NCT02515513|ACTIVE_COMPARATOR|Surgical Patients with benign pathology|During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.
62658750|NCT03149770|EXPERIMENTAL|1|Naloxone, then placebo
62658751|NCT03149770|PLACEBO_COMPARATOR|2|Placebo, then Naloxone
62658752|NCT04131803|EXPERIMENTAL|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
62095292|NCT06044948|EXPERIMENTAL|DAILIES TOTAL1|Delefilcon A contact lenses worn in both eyes for the typical number of hours the subject wears his/her habitual contact lenses. The lenses will be worn in a daily disposable manner.
62095293|NCT00024635||Adult Healthy Volunteers|Adult Healthy Volunteers
62095294|NCT00024635||Adult Patients|Adult patients with mood and anxiety disorders
62095295|NCT00024635||Minor Healthy Volunteers|Minor Healthy Volunteers
62095296|NCT00024635||Minor Patients|Minor patients with mood and anxiety disorders
62095297|NCT00024635||Parents of Minor Healthy Volunteers|Parents and guardians of minor healthy volunteers
62095298|NCT00024635||Parents of Minor Patients|Parents and guardians of minor patients with mood and anxiety disorders
62095299|NCT03717545|EXPERIMENTAL|intervention arm|second allogeneic stem cell transplantation
62095300|NCT01555762||Cohort|
62292792|NCT04730518|EXPERIMENTAL|Yoga-based Group Therapy|"The yoga-based group therapy (YBGT) involves a four-week intervention with weekly group therapy sessions in addition to TAU. The fifty-minute session takes place with a group size of max. 10 participants and was held once a week by a psychologist who is experienced in yoga-based therapy.~A yoga session starts with breathing exercises (pranayama), followed by various exercises in standing, sitting and lying down (asanas), which are accompanied by mindful instructions from the psychologist. Every yoga session ends with a final relaxation (shavasana), which can take the form of a body scan, for example."
62658753|NCT04131803|EXPERIMENTAL|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
62658754|NCT02112201|EXPERIMENTAL|Integrated intervention for parents and adolescent girls|Twelve session parent education and support group; twelve session one-on-one adolescent skills training intervention
62658755|NCT02112201|NO_INTERVENTION|Treatment as usual|Treatment as usual
62658756|NCT03113097|ACTIVE_COMPARATOR|Good-quality embryo transfer|Women who had only good-quality embryo transfer
62658757|NCT03113097|ACTIVE_COMPARATOR|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
62658758|NCT00574314||Women|Women with varying backgrounds
62658759|NCT05175625|EXPERIMENTAL|SpikoGen COVID-19 Vaccine|
62658760|NCT05175625|PLACEBO_COMPARATOR|Saline Placebo|
62658761|NCT02440867|NO_INTERVENTION|Healthy subjects|Multimodal imaging data acquisitions Clinical data acquisitions
62658762|NCT02440867|EXPERIMENTAL|TBS-MPC|"* Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia~* Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~* Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~* Continuous actimetry acquisition"
62658763|NCT02440867|ACTIVE_COMPARATOR|TBS-CPDLF|"* Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia~* Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~* Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~* Continuous actimetry acquisition"
61908369|NCT05152225||Infective endocarditis|Infective endocarditis with systematic brain MRI and digital subtraction angiography (DSA) performed routinely.
62095301|NCT06603402|EXPERIMENTAL|low-dose involved-field radiotherapy combined with immunochemotherapy|low-dose involved-field radiotherapy combined with immunochemotherapy
62658764|NCT02440867|SHAM_COMPARATOR|TBS-Sham|"* Intervention with Sham TBS in 8 patients with schizophrenia~* Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~* Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~* Continuous actimetry acquisition"
62658765|NCT01741662|OTHER|group psychopathological|
62736863|NCT03693677|EXPERIMENTAL|Nal-IRI/5-FU/LV|Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
62736864|NCT03693677|ACTIVE_COMPARATOR|Nab-paclitaxel/Gemcitabine|"Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :~* Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~* Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
62736865|NCT00475553|OTHER|Group 2|Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
62736866|NCT00475553|OTHER|Group 1|Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
62736867|NCT01731340|ACTIVE_COMPARATOR|Supplemental Calcium|"* 750 mg Calcium Citrate per day~* 800 IU Vitamin D3 per day~* Low Dietary Calcium (450 mg per day)"
62095302|NCT04530344|EXPERIMENTAL|Cohort A : ruxolitinib cream|Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
62095303|NCT04530344|PLACEBO_COMPARATOR|Cohort A : Vehicle|Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
62095304|NCT04530344|EXPERIMENTAL|Cohort B : roxolitinib cream|Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.
62095305|NCT04484909|EXPERIMENTAL|Treatment (NBTXR3, radiation therapy)|Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity.
62292793|NCT04730518|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
62292794|NCT01427309|EXPERIMENTAL|High Dose Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
62292795|NCT01427309|ACTIVE_COMPARATOR|Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of the Trivalent Inactivated Influenza vaccine
62292796|NCT04187027|NO_INTERVENTION|the medical care and standard care only group|Group (A) received medical care and standard urotherapy only.
62292797|NCT04187027|EXPERIMENTAL|the medical care and standard care + P.E.M.F group|Group (B) which received the same medical care and standard urotherapy in addition to pulsed electromagnetic field therapy that applied for 20 min, ,three times / weak for three successful months.
62292798|NCT06351202|NO_INTERVENTION|No abdominal massage group|During 14 days, preterm infants with feeding intolerance will not be massed by physiotherapists.
62292799|NCT06351202|EXPERIMENTAL|Abdominal massage group|At least 10 abdominal massages will be performed on preterms, by a physiotherapist trained in this technique over a period of 14 days, at the rate of one massage per day.
62292800|NCT02144272|EXPERIMENTAL|LY3114062 (SC)|LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.
62292801|NCT02144272|EXPERIMENTAL|LY3114062 (IV)|LY3114062 given once intravenous (IV).
62292802|NCT02144272|PLACEBO_COMPARATOR|Placebo|Placebo (sodium chloride injection) given as a single SC dose.
62292803|NCT02595242|EXPERIMENTAL|Mitoxantrone 12 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
62292804|NCT02595242|EXPERIMENTAL|Mitoxantrone 16 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 16 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
62292805|NCT02595242|EXPERIMENTAL|Mitoxantrone 20mg/m2|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
61908370|NCT03162900|EXPERIMENTAL|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
62292806|NCT01878630|EXPERIMENTAL|Remote Patient Management|intervention group
62292807|NCT01878630|ACTIVE_COMPARATOR|Usual Care|control group
62292808|NCT02611713||Arm A: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
62292809|NCT02611713||Arm B: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries. Participants will be evaluated with a wearable device
62292810|NCT01995929||neurogenic dysphagia|Patients suffering from neurogenic dysphagia due to several reasons (e.g. Parkinson´s disease).
62292811|NCT04784962|SHAM_COMPARATOR|Control Arm|Sham device
62736868|NCT01731340|ACTIVE_COMPARATOR|Dietary Calcium|"* 400 IU Vitamin D3 per day~* High Dietary Calcium (1200 mg per day)"
62736869|NCT01731340|NO_INTERVENTION|Usual Diet|"* 400 IU Vitamin D3 per day~* Unrestricted Dietary Calcium"
61908371|NCT03162900|EXPERIMENTAL|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
61908372|NCT00724321|OTHER|Iloprost and placebo|Each participant will undergo testing at sea level and altitude after inhalation of iloprost and placebo, sequence is randomly assigned.
61908373|NCT01957670|EXPERIMENTAL|Treatment with Lacrima medical device|
61908374|NCT04708171||Awake mapping under local anesthesia|
61908375|NCT04708171||Asleep mapping under general anesthesia|
61908376|NCT04708171||Resection under general anesthesia without mapping|
62095306|NCT01210053|EXPERIMENTAL|Single arm|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
62292812|NCT04784962|EXPERIMENTAL|Intervention Arm|Standard rehabilitation care including physiotherapy + Adjunctive Neuromuscular Stimulation Device Usage
62292813|NCT03867630||Runoff Group|Runoff group are the patients whose images were shown root shadow by contrast media.
62465441|NCT04140188|ACTIVE_COMPARATOR|Axilla no touch|Volunteer patients who did not underwent to SLNB or axillary lymph node dissection during previous NSM
61908377|NCT05506228||Cerebral Palsy (CP) / Acquired Brain Injury (ABI)|Children and adolescents with cerebral palsy and acquired brain injury.
61908378|NCT05506228||TD (Typically Developed)|Typically developed children and adolescents.
62095307|NCT06565715|EXPERIMENTAL|Remazolam group|Remazolam group: remazolam is administered 0.3mg/kg intravenous for anesthesia induction.
62095308|NCT06565715|OTHER|Propofol group|Propofol group: propofol is administered 2mg/kg intravenous for anesthesia induction.
62095309|NCT06646926|EXPERIMENTAL|Body Tempering|Participant will be positioned prone on the Body Tempering Ab Mat with their feet hanging off the end of the mat. The body tempering intervention will be applied by the same investigator for all trials. The body tempering device will be applied dynamically to each participant for 4 minutes, with the device placed on both participants' lower extremities at the same time. First, the examiner will set a timer for two minutes and begin rolling one 80-pound body tempering device along the participant's gastrocnemius-soleus complex at a rate of 30 beats per minute, traveling from the Achilles tendon (medial malleolus) to the inferior aspect of the popliteal fossa, indicated by fibular head. The participant will then take thirty seconds to transition to a supine position and receive tempering with an 80-pound tempering device along their middle to distal quadriceps, set a timer for 2 minutes.
62095310|NCT06646926|ACTIVE_COMPARATOR|Foam rolling self-myofascial release|Participants will be instructed via standardized script to perform self-myofascial release (SMR) on their gastrocnemius-soleus complex and quadriceps muscles. The first SMR sequence will be performed by having the participant place the foam roller behind both calves, beginning the roll at the medial malleolus and ending at the inferior aspect of the popliteal fossa, indicated by the fibular head. The participant will perform this for two minutes, rolling at a tempo of 30 beats per minute. Next, the participant will take thirty seconds to transition to a prone position, placing the foam roller just distal to the hip crease, just inferior to the AIIS, and rolling inferiorly to the area just proximal to the most superior aspect of the patella. This self-release sequence will be performed for two minutes at a tempo of 30 beats per minute. The total time should be four minutes, matching the total time of the experimental intervention group.
62095311|NCT00551213|EXPERIMENTAL|Robatumumab→Robatumumab|Participants receive 1 dose of robatumumab 0.3 mg/kg intravenously (IV) followed by 1 dose of robatumumab 10 mg/kg IV once every 2 weeks (Q2W) until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
62095312|NCT00551213|ACTIVE_COMPARATOR|Chemotherapy→Robatumumab|Participants receive 1 cycle of standard colorectal cancer chemotherapy currently approved and available on the market for use in colorectal cancer (to be selected by the Investigator based on participant's prior treatment) followed by 1 dose of robatumumab 10 mg/kg IV Q2W until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
62292814|NCT03867630||Nonrunoff-Transforaminal group|Nonrunoff-Transforaminal group are the patients whose images are not shown root shadows by contrast media, so additional transforaminal blocks are done.
62292815|NCT03867630||Nonrunoff-NonTransforaminla group|Nonrunoff-NonTransforaminal group are the patients whose images are not shown root shadows by contrast media, but no additional transforaminal blocks are done.
62292816|NCT05407792|EXPERIMENTAL|Experimental group|Oral staphylococcus albicans tablet group.
62292817|NCT05407792|OTHER|Control group|On-demand treatment group
62292818|NCT02882256|EXPERIMENTAL|Intervention|Patients will receive video discharge instructions in addition to standard written discharge instructions.
62292819|NCT02882256|NO_INTERVENTION|Control|Patients will receive standard written discharge instructions.
62292820|NCT04755374||Group 1|Discharged from palliative care unit in equal or less than 21 days
62292821|NCT04755374||Group 2: Prolonged discharged in longer than 21 days|Discharged from palliative care unit in longer than 21 days
62292822|NCT05174091||With Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
62465442|NCT04140188|ACTIVE_COMPARATOR|Axilla with previous SLNB|Volunteer patients who has underwent to SLNB but not axillary lymph node dissection during previous NSM
62465443|NCT01382641|OTHER|Hoya AF-1 IOL|
62465444|NCT01382641|OTHER|Revital Vision|
62095313|NCT06433193|EXPERIMENTAL|PAK HD Sorbent Study|The study will be performed as a prospective, non-randomised, single arm two-period cross-over study comparing conventional CHD to PAK HD. All adverse events will be recorded and reviewed. Only one subject will enter each study period at a time.
62292823|NCT05174091||Without Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
62658766|NCT04386941|ACTIVE_COMPARATOR|Greenlight XPS Vaporization|Greenlight 532nm laser photoselective vaporization of the prostate (PVP) is an appealing treatment modality with hemoglobin as tissue target chromophore and relatively short learning curve. The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser. It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibres required in these situations.
62292824|NCT02314793|EXPERIMENTAL|Part 1: Single Ascending Dose ASP2205 (Fasting)|Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
62658767|NCT04386941|ACTIVE_COMPARATOR|Xpeeda Fibre Laser Vaporesection|Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue. Moreover, hemostasis would be improved by the pulse reshaping technology with a wider pulse width, activated by a dedicated footswitch. Therefore, the Lumenis Pulse™ 100W will make prostate vaporesection procedures more precise, faster and efficient, with excellent hemostasis. Consequently, bleeding is minimal, tissue is easier to remove and patients can have their catheter removed faster.
62658768|NCT00805688||Symptom Study|Questionnaires + Blood Draw + Pedometer used to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
62658769|NCT01558843||traumatic brain injury|
62095314|NCT02179918|EXPERIMENTAL|PF-05082566 +MK-3475|PF-05082566 +MK-3475
62095315|NCT02334943|EXPERIMENTAL|Treated HIV-1 infected patients|Treated HIV-1 infected patients for Blood test
62095316|NCT02334943|EXPERIMENTAL|No treated HIV-1 infected patients|No treated HIV-1 infected patients for Blood test
62095317|NCT02334943|EXPERIMENTAL|Healthy witness|Healthy witness for Blood test
62292825|NCT02314793|PLACEBO_COMPARATOR|Part 1: Single Ascending Dose Placebo (Fasting)|Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
62465445|NCT04135820|EXPERIMENTAL|Fasted|BPI-7711 following a period of fasting
62465446|NCT04135820|EXPERIMENTAL|High-fat meal|BPI-7711 following a high-fat meal.
62658770|NCT01558843||aneurysmal subarachnoid hemorrhage|
62658771|NCT01558843||intracerebral hematoma|
62658772|NCT01558843||brain tumor|
62658773|NCT01052415|NO_INTERVENTION|Standard care|Service providers and HIV patients, offered intervention at the end of study
62658774|NCT01052415|EXPERIMENTAL|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
61908379|NCT02087267||1- or 2-level spinal fusion|Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
61908380|NCT00660881|EXPERIMENTAL|EMAB|1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
61908381|NCT00170001|PLACEBO_COMPARATOR|Sugar pill|
61908382|NCT00170001|ACTIVE_COMPARATOR|Active Comparator|
61908383|NCT02176746|PLACEBO_COMPARATOR|non-cancer stem cell vaccine|This is no cancer stem cells vaccine in this group
61908384|NCT02176746|EXPERIMENTAL|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
61908385|NCT02176746|EXPERIMENTAL|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
61908386|NCT02176746|EXPERIMENTAL|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
61908387|NCT05631002||Patients with benign spinal tumor|
61908388|NCT05631002||Patients with intermediate spinal tumor|
61908389|NCT05631002||Patients with malignant spinal tumor|
61908390|NCT05258188|EXPERIMENTAL|Instrument-assisted Soft Tissue Mobilization|"1. Warm-up will be performed for 10 to 15 minutes by light jogging, elliptical machine, stationary cycle or an upper body ergometer~2. Instrument-assisted Soft Tissue Mobilization , will be applied at 30 to 60 degrees angle for 40 to 120 seconds~3. Stretching, for 30 seconds (3 rep)~4. Strengthening exercises, high repetitions with low intensity exercise~5. Cryotherapy for 10 to 20 min"
62095318|NCT06401577||CGM|Continuous Glucose Monitoring (CGM)
62095319|NCT06492486|EXPERIMENTAL|Stratum A (IDH-negative GBM)|Adaptive radiotherapy
62095320|NCT06492486|EXPERIMENTAL|Stratum B (IDH-mutant astrocytoma or oligodendroglioma)|Adaptive radiotherapy
62095321|NCT01161823||Nebivolol|2,5mg or maximum 5mg per day
62095322|NCT01161823||Menoflavon|2 times 1 pill at 40mg Isoflavone per day
62095323|NCT06054737||SPA THERAPY PROGRAM|3-week spa therapy program with Mineral Water of Royat in addition to standard of care for chronic venous insufficiency
62095324|NCT04308551|EXPERIMENTAL|Indobufen|200 mg Indobufen, bid po, 90 days
62095325|NCT04308551|ACTIVE_COMPARATOR|Aspirin|100 mg Aspirin, qd po, 90 days
62095326|NCT01496196|ACTIVE_COMPARATOR|tranexamic acid-500 mg/5 ml 3-4 times a day|tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
62095327|NCT01496196|PLACEBO_COMPARATOR|tranexamic|placebo arm
62292826|NCT02314793|EXPERIMENTAL|Part 1: Single Ascending Dose ASP2205 (Fed)|Young male and female subjects will receive a single dose of ASP2205
62292827|NCT02314793|EXPERIMENTAL|Part 2: Multiple Ascending Dose ASP2205, Young females|Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
62095328|NCT06696924|EXPERIMENTAL|Reciprocal inhibition|First Subjects will start doing baseline warmup exercises which are mentioned then they will perform reciprocal inhibition of the serratus muscle in supine or side-lying. After identifying the antagonist muscles of the serratus anterior, which are typically the rhomboids or the middle and lower trapezius. Athletes will perform a gentle contraction of the antagonist's muscles by retracting or squeezing their shoulder blades together. While the antagonist muscles are contracting, we will ask the athlete to simultaneously relax and lengthen the serratus anterior muscle. The patient can achieve this by protracting or pushing their shoulder blades forward and away from each other.
62095329|NCT06696924|EXPERIMENTAL|Static stretching:|"Subjects will perform 2 stretches~1. Standing Wall Stretch: Stand facing a wall with your feet about hip-width apart. Place their palms on the wall at shoulder height, slightly wider than shoulder-width apart. will Lean their body forward, keeping their arms straight, until feel a stretch in their serratus anterior. Hold the stretch for 15 to 30 seconds, then slowly release. Instead of using a wall or object, the athlete will use their opposite hand to hold the stretched arm in position.~2. Seated Cross-Body Stretch: Sit on the edge of a chair or bench. Cross one arm over your chest, placing your hand on the opposite shoulder. The athlete will use the other hand to gently pull the crossed arm closer to your body, feeling a stretch in the serratus anterior. Hold the stretch for 15 to 30 seconds or more, and then switch sides and repeat."
62658775|NCT05251870|EXPERIMENTAL|Intranodal TolDCB29 (low dose)|Two administrations of 5 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
62658776|NCT05251870|EXPERIMENTAL|Intranodal TolDCB29 (intermediate dose)|Two administrations of 10 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
62658777|NCT05251870|EXPERIMENTAL|Intranodal TolDCB29 (high dose)|Two administrations of 15 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
62658778|NCT05251870|EXPERIMENTAL|Intranodal TolDCB29 (recommended dose)|Two administrations of the recommended dose of autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). The recommended dose will be advised by the data safety monitoring board after data review of the first three arms. This cohort will consist of nine patients.
62292828|NCT02314793|PLACEBO_COMPARATOR|Part 2: Multiple Ascending Dose Placebo, Young females|Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
62292829|NCT02314793|EXPERIMENTAL|Part 2: Multiple Ascending Dose ASP2205, Elderly females|Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
62292830|NCT02314793|PLACEBO_COMPARATOR|Part 2: Multiple Ascending Dose Placebo, Elderly females|Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
62658779|NCT04948918|EXPERIMENTAL|Distal renal denervation|The arm comprises patients undergoing distal bilateral radiofrequency renal denervation performed using Symplicity Spyral renal denervation system.
62658780|NCT01169051||Thoracic sugery statins|
62658781|NCT01169051||Thoracic surgery non-statins|
62658782|NCT01339169|EXPERIMENTAL|YF476 treatment|
62658783|NCT02635035|EXPERIMENTAL|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
62292831|NCT01517035|EXPERIMENTAL|1|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
62292832|NCT00709826|EXPERIMENTAL|apricoxib + gemcitabine + erlotinib|400mg apricoxib + 1000mg/m2 gemcitabine + 100mg erlotinib
62292833|NCT00709826|PLACEBO_COMPARATOR|placebo + gemcitabine + erlotinib|placebo + 1000mg/m2 gemcitabine + 100mg erlotinib
62292834|NCT05305326||Control|Singleton pregnancies undergoing elective pre-labour CS at gestational age (37+0 to 40+0) that are healthy
62658784|NCT02635035|EXPERIMENTAL|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
62658785|NCT02508792|ACTIVE_COMPARATOR|LASER|"Subject will receive application of LASER before muscle fatigue protocol.~Note: this is a crossover study."
62658786|NCT02508792|PLACEBO_COMPARATOR|LASER PLACEBO|"Subject will receive application of LASER (now deactivated) before muscle fatigue protocol.~Note: this is a crossover study."
62292835|NCT05305326||Gestational diabetes|Singleton pregnancies complicated with gestational diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
62292836|NCT05305326||Type 1 diabetes with pregnancy|Singleton pregnancies complicated with Type 1 diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
62658787|NCT05068115||1|Young breast cancer patients in China from 2000 to 2015, of whom the clinical features, diagnosis and treatment models and survival status are described.
62658788|NCT03925155|EXPERIMENTAL|Chlorhexidine gluconate vaginal scrub|Use of chlorhexidine 4% vaginal scrub instead of current standard of care 10% povidone iodine vaginal scrub for cesarean sections
62658789|NCT03925155|ACTIVE_COMPARATOR|Povidone-iodine vaginal scrub|Current standard of care 10% povidone iodine vaginal scrub for cesarean sections
62658790|NCT02188134||65 and older|No intervention will be administered
62658791|NCT04428489||Idiopathic cytopenia of undetermined significance (ICUS)|
62658792|NCT04428489||Clonal cytopenia of unknown significance (CCUS)|
62658793|NCT03756675||haplotype PBSCT group|"Subjects in this group will receive haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system in the treatment of acute leukemia."
62658794|NCT01249196|PLACEBO_COMPARATOR|Placebo|
62658795|NCT01249196|EXPERIMENTAL|SK-PC-B70M 200mg bid|
62292837|NCT05305326||Type 2 diabetes with pregnancy|Singleton pregnancies complicated with Type 2 diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
62292838|NCT05707572|ACTIVE_COMPARATOR|steroid injection|1 injection of 1mL methylprednisolone \[40mg\]with 1 mL 2% lignocaine
62658796|NCT01249196|EXPERIMENTAL|SK-PC-B70M 300mg bid|
62658797|NCT01249196|OTHER|Donepezil|
62095330|NCT04129424|EXPERIMENTAL|Type 1 diabetes mellitus_7-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62292839|NCT05707572|EXPERIMENTAL|manual manipulation|weekly manipulations to the metatarsophalangeal joints of the forefoot for 6 weeks
62658798|NCT05488431|EXPERIMENTAL|Bempedoic acid (BA)|Patients randomized into the BA arm will receive 180 mg BA administered orally once daily without food for 52 weeks.
62658799|NCT05488431|PLACEBO_COMPARATOR|Placebo|Patients randomized into the placebo arm will receive 180 mg placebo administered orally once daily without food for 52 weeks.
62292840|NCT03793439|EXPERIMENTAL|Open-label treatment|All subjects will receive tofacitinib 5mg twice daily from week 0 to week 16, and a corticosteroid taper starting at week 16. Participants also undergo spirometry, RNA sequence testing, and laboratory evaluations.
62465447|NCT02248597|EXPERIMENTAL|Treatment (stem cell transplant with GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation"
62658800|NCT00849394||1|Shortened infusions of bevacizumab
62095331|NCT04129424|EXPERIMENTAL|Type 1 diabetes mellitus_14-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095332|NCT04129424|EXPERIMENTAL|Type 1 diabetes mellitus_28-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62465448|NCT05596877|NO_INTERVENTION|Control Group|Recieved pulmonary rehabilitation
62465449|NCT05596877|EXPERIMENTAL|Intervention Group|Recieved pulmonary rehabilitation with music therapy
62658801|NCT02607072|EXPERIMENTAL|Aspirin 200 mg daily|Aspirin 200 mg daily
61908391|NCT05258188|EXPERIMENTAL|Compressive Myofascial Release Technique|Compressive myofascial release technique will be applied 5 minutes, after a warmup of 10 to 15 minutes.
61908392|NCT03591770|EXPERIMENTAL|UC patients on tofacitinib monotherapy|Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
61908393|NCT03591770|ACTIVE_COMPARATOR|UC patients on anti-TNF monotherapy|Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
62658802|NCT02607072|EXPERIMENTAL|Aspirin 100 mg daily|Aspirin 100 mg daily
62658803|NCT02607072|PLACEBO_COMPARATOR|Placebo control|Placebo control
62658804|NCT02415985|OTHER|rifabutin 150|rifabutin 150 mg (1 capsule) once daily
62658805|NCT02415985|OTHER|rifabutin 300|rifabutin 150 mg (2 capsules) 300 mg 3 times a week
62658806|NCT05778539|EXPERIMENTAL|Lateral retinacular release group|During the implantation of a total knee arthroplasty a lateral retinacular release is performed
62658807|NCT05778539|NO_INTERVENTION|Non-release group|No aditional gesture in the lateral retinaculum is performed during the implantation of a total knee arthroplasty
62658808|NCT03382093|ACTIVE_COMPARATOR|Personalized Feedback Intervention|A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.
62658809|NCT03382093|ACTIVE_COMPARATOR|Smoking Information Control|Standard, computer-delivered smoking cessation treatment/information.
62658810|NCT02337582|ACTIVE_COMPARATOR|Intervention|
62658811|NCT02337582|OTHER|Control|
62658812|NCT00782067|EXPERIMENTAL|Midostaurin (PKC412)|Midostaurin was administered at a dose of 100 mg twice daily (bid) in continuous cycles of 28 days until disease progression, intolerable toxicity or withdrawal due to any cause, whichever occurred first.
62658813|NCT05998863|EXPERIMENTAL|EffCaMgCit|38 meq (760 mg) Ca, 20 meq (243 mg) Mg, and 100 meq total citrate per day; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing.
62658814|NCT05998863|PLACEBO_COMPARATOR|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing.
62658815|NCT05179629|ACTIVE_COMPARATOR|Group M = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
62095333|NCT04129424|EXPERIMENTAL|Type 2 diabetes mellitus_7-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62658816|NCT05179629|NO_INTERVENTION|Group C = Control group|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia."
62658817|NCT01379053||Staphylococcus Patients|Patients suspected of having Methicillin-resistant and/or methicillin-susceptible staphylococcus aureus.
62658818|NCT01379053||Control|Healthy volunteer
62658819|NCT03231176|EXPERIMENTAL|Varlitinib and Capecitabine|
62658820|NCT02525523|EXPERIMENTAL|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
62658821|NCT02525523|PLACEBO_COMPARATOR|Placebo|Placebo enema, once daily for 6 weeks
62658822|NCT03778632|EXPERIMENTAL|Study Group|Intensive stuttering group therapy which was included individualized desensitization exercises was applied with the study group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
62658823|NCT03778632|ACTIVE_COMPARATOR|Control Group|Standard intensive stuttering group therapy was applied with the control group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
62095334|NCT04129424|EXPERIMENTAL|Type 2 diabetes mellitus_14-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62292841|NCT05984446|EXPERIMENTAL|real-rTMS|4 daily 25-minutes high-frequency rTMS sessions over one week
62465450|NCT01645839|EXPERIMENTAL|Systemic treatment with Depocyte|Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.
62465451|NCT01645839|NO_INTERVENTION|Systemic treatment without Depocyte|No intrathecal injection.
62658824|NCT01039441|PLACEBO_COMPARATOR|instillation of normal saline 50ml under the diaphragm|
62658825|NCT01039441|EXPERIMENTAL|the instillation of 0.5% bupivacaine under the diaphragm|
62658826|NCT01039441|EXPERIMENTAL|CO2 removal by means of a pulmonary recruitment maneuver|
62658827|NCT01039441|EXPERIMENTAL|the instillation of bupivacaine + CO2 removal by maneuver|
62658828|NCT02419872||Patient Participants|Patients are confirmed to have either Persistent Asthma or COPD
62658829|NCT00514696|EXPERIMENTAL|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
62465452|NCT00567762|EXPERIMENTAL|1|FK506 ophthalmic suspension
62292842|NCT05984446|SHAM_COMPARATOR|sham-rTMS|4 daily 25-minutes sham-rTMS sessions over one week
62292843|NCT02800174|EXPERIMENTAL|Smart nitinol stent implantation group|The Smart nitinol stent system was used (import product registration number YZB/USA 0115-2008; Nitinol stent system, trade name SMART Control). The stent system comprises a self-expanding stent and a delivery system. The self-expanding stent is composed of a nickel titanium alloy and the ends of the stent are equipped with tantalum radiopaque markers. The Smart nitinol stent system is sterilized with ethylene oxide gas and is intended for single use only.
62465453|NCT00567762|PLACEBO_COMPARATOR|2|Base of eye drops
62465454|NCT03195374||Patients with chronic non-cancer pain|Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
62465455|NCT04350970|ACTIVE_COMPARATOR|Control|The cardiopulmonary exercise test was performed with patient breathing room air.
62465456|NCT04350970|ACTIVE_COMPARATOR|NIV|The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
62465457|NCT04350970|ACTIVE_COMPARATOR|HFNT|The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
62465458|NCT05016063|EXPERIMENTAL|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR T cells
62658830|NCT06392997||Symptomatic group|"Clinically symptomatic females with one or more of the following gynecological pathology:~* Endometriosis,~* Adenomyosis,~* Ovarian cysts,~* Fibroids,~* Ovarian cancer,~* Cervical cancer~* Uterine cancer."
62658831|NCT06392997||Asymptomatic group|"Asymptomatic females with:~* Cervical dysplasia or cancer~* A normal pap-smear (control)"
62658832|NCT03523637|EXPERIMENTAL|Pain Education/Interoceptive Exposure|This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks.
62658833|NCT04324320||outpatients (oncological rehabilitation)|the population studied in this cross-sectional study includes patients with malignant tumour diseases and benign CNS tumours who present to the Outpatient Clinic for Oncological Rehabilitation at the Department of Physical Medicine and Rehabilitation of the Medical University of Vienna
62658834|NCT06134388|NO_INTERVENTION|Control Group|This group will include 25 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks for 3 months.
62658835|NCT06134388|ACTIVE_COMPARATOR|Sulfasalazine Group|This group will include 25 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks plus sulfasalazine (1 gram orally twice daily) for 3 months.
62292844|NCT02800174|ACTIVE_COMPARATOR|Antiplatelet drug group|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
62292845|NCT03181113||peginterferon alfa 2b|
62658836|NCT04491487|EXPERIMENTAL|Experimental group|
62658837|NCT04491487|NO_INTERVENTION|Control group|
62658838|NCT04392804||0.1 ml 4% articaine|single dose of 0.1 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
62658839|NCT04392804||0.2 ml 4% articaine|single dose of 0.2 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
62658840|NCT04392804||0.3 ml 4% articaine|single dose of 0.3 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
62658841|NCT00577226||1 Shilla Technique|The patients whose data is observed are those who have undergone the shilla surgical technique.
62658842|NCT01055327||Infants/foetuses w/malformations registered in EUROCAT network|Pregnancies resulting in foetus/infant with malformation registered through participating registers within the EUROCAT network
62658843|NCT01348269|ACTIVE_COMPARATOR|Aclasta|
62658844|NCT01348269|PLACEBO_COMPARATOR|NaCl Solution|
62658845|NCT03618277|OTHER|Intra individual|Before and after being treated by a product (outside the study)
62658846|NCT00544882|EXPERIMENTAL|DR-1021|After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
62658847|NCT00544882|ACTIVE_COMPARATOR|Mircette|After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
61908394|NCT03591770|ACTIVE_COMPARATOR|UC patients on anti-TNF and a thiopurine|Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
61908395|NCT03591770|ACTIVE_COMPARATOR|UC pts. on aminosalicylates or off immunomodulatory therapy|Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.
61908396|NCT03287271|EXPERIMENTAL|Defactinib (VS-6063) +Carboplatin/Paclitaxel|Defactinib (VS-6063) +Carboplatin/Paclitaxel
62292846|NCT03181113||peginterferon alfa 2a|
62292847|NCT02357420|EXPERIMENTAL|Relamorelin 10 μg|Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
62465459|NCT03720262|EXPERIMENTAL|Mesh reinforcement|Retro muscular mesh at the stoma site.
62658848|NCT04163263|EXPERIMENTAL|Cohorts 1-3: BOS-356|Twice daily application of BOS-356 0.1%, 0.4%, and 0.7% gel in Cohorts 1, 2, and 3, respectively
62658849|NCT04163263|PLACEBO_COMPARATOR|Cohorts 1-3: Vehicle|Twice daily application of vehicle gel
62658850|NCT04163263|EXPERIMENTAL|Cohort 4: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
62658851|NCT04163263|PLACEBO_COMPARATOR|Cohort 4: Vehicle|Twice daily application of vehicle gel
61908397|NCT00679445|EXPERIMENTAL|A|Device: NeoVista Ophthalmic System A single procedure using the NeoVista Ophthalmic System plus an injection of Lucentis.
62292848|NCT02357420|EXPERIMENTAL|Relamorelin 30 μg|Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
62292849|NCT02357420|EXPERIMENTAL|Relamorelin 100 μg|Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
62292850|NCT02357420|PLACEBO_COMPARATOR|Placebo|Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.
62465460|NCT03720262|PLACEBO_COMPARATOR|No reinforcement|Standard closure of the abdominal wall
62465461|NCT01974141|EXPERIMENTAL|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
62465462|NCT01974141|PLACEBO_COMPARATOR|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
62465463|NCT00875030|EXPERIMENTAL|1.0|
62658852|NCT04163263|EXPERIMENTAL|Cohort 5: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
62658853|NCT04163263|PLACEBO_COMPARATOR|Cohort 5: Vehicle|Twice daily application of vehicle gel
62658854|NCT03320915|EXPERIMENTAL|Cholecalciferol|Cholecalciferol 5mg (200,000 IU)
62658855|NCT03320915|NO_INTERVENTION|Usual care|Usual care
62658856|NCT01286324|EXPERIMENTAL|Chamomile High Grade Extract|Each capsule contains 90 mg dry extract of chamomile flowering tops \[6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops\] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet
62658857|NCT01286324|PLACEBO_COMPARATOR|Placebo Tablet|Contained lactose
62095335|NCT04129424|EXPERIMENTAL|Type 2 diabetes mellitus_28-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095336|NCT04129424|EXPERIMENTAL|Gestational diabetes mellitus_7-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095337|NCT04129424|EXPERIMENTAL|Gestational diabetes mellitus_14-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095338|NCT04129424|EXPERIMENTAL|Gestational diabetes mellitus_28-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095339|NCT04129424|EXPERIMENTAL|Pregestational diabetes mellitus_7-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095340|NCT04129424|EXPERIMENTAL|Pregestational diabetes mellitus_14-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095341|NCT04129424|EXPERIMENTAL|Pregestational diabetes mellitus_28-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095342|NCT04129424|EXPERIMENTAL|Pancreatogenic diabetes mellitus _7-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095343|NCT04129424|EXPERIMENTAL|Pancreatogenic diabetes mellitus _14-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
61908398|NCT00894959|EXPERIMENTAL|1|Heparin Sodium Blausiegel 1
62095344|NCT04129424|EXPERIMENTAL|Pancreatogenic diabetes mellitus _28-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62292851|NCT00746174|ACTIVE_COMPARATOR|Rosiglitazone|Subjects in this arm will be randomly assigned to treatment with Rosiglitazone 4mg daily. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The dose will then be increased to Rosiglitazone 8mg daily (if indicated). The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, \& skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
62465464|NCT00875030|ACTIVE_COMPARATOR|2.0|
62465465|NCT05477030|ACTIVE_COMPARATOR|Study Group A (Intervention)|Group treated with automated insulin delivery (advanced hybrid closed-loop)
62465466|NCT05477030|ACTIVE_COMPARATOR|Study Group B (Control)|Group treated with predictive low glucose suspend (sensor augmented pump - PLGS)
61908399|NCT00894959|EXPERIMENTAL|Active Comparator|heparin sodium - APP 5.000 USP
62465467|NCT04006171|ACTIVE_COMPARATOR|women with polycystic ovary syndrome|36 patients with PCOS
62658858|NCT04954144|EXPERIMENTAL|Leap Motion Sensor|The Leap Motion Sensor is an optical hand tracking module that captures the movements of hands with unparalleled accuracy.
62095345|NCT04129424|EXPERIMENTAL|Diabetes patients in perioperative period _7-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
61908400|NCT01708096|ACTIVE_COMPARATOR|Modifast|treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass,
62095346|NCT04129424|EXPERIMENTAL|Diabetes patients in perioperative period _14-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095347|NCT04129424|EXPERIMENTAL|Diabetes patients in perioperative period _28-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
62095348|NCT06698172|EXPERIMENTAL|VR Study Group|Once the patient is included in the study, 12 weekly sessions of visual rehabilitation, each lasting 45 minutes, will be scheduled. A Virtual Reality device will be used along with the Visionary Sport visual therapy software.
62095349|NCT02759003|ACTIVE_COMPARATOR|inpatients group|"In-hospital nightime NIV initiation. For the inpatients Group, NIV was initiated in the respiratory wards of the two hospitals and continued during night for a minimum of 4 hours/night.~Inpatients had a 24-h availability of health staff care. During the night, they had nurses and physicians available on-hand."
62095350|NCT02759003|EXPERIMENTAL|outpatients group|"Home nightime NIV initiation. For the outpatients group, diurnal NIV was initiated during a scheduled visit in a hospital dedicated room(at least 4 hours/day of care), the trial proceeded at home during the night with a personal caregiver.~A minimum of 4 hours/night was required. No support during the night was provided to these patients."
61908401|NCT01708096|PLACEBO_COMPARATOR|Normal diet|normal diet 2 weeks before gastric by-pass surgery
61908402|NCT03997227|ACTIVE_COMPARATOR|Block group|
62095351|NCT03940469|PLACEBO_COMPARATOR|Control group|received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block.
62095352|NCT03940469|ACTIVE_COMPARATOR|Dexamethasone group|received 35ml levobupivacaine+8mg dexamethasone
62465468|NCT04006171|ACTIVE_COMPARATOR|Healthy women of reproductive age|30 patients with regular normal menstrual cycle
61908403|NCT03997227|NO_INTERVENTION|control group|
62095353|NCT03940469|ACTIVE_COMPARATOR|Dexmeteomidine group|received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.
62658859|NCT04954144|EXPERIMENTAL|Neurodevelopmental Treatment Approach|Neurodevelopment treatment approach is used to influence the quality of the motor response and is carefully matched to the patient's abilities to use sensory information and adapt movements.
61908404|NCT02594995|EXPERIMENTAL|NBP in thrombolysis group|NBP 25mg bid for 2 weeks administered after 24 hours after receiving recombinant plasminogenactivator(rt-PA) thrombolysis
61908405|NCT02594995|EXPERIMENTAL|NBP group|NBP 25mg bid for 2 weeks administered for the patients who do not receive rt-PA
62658860|NCT01561105|EXPERIMENTAL|IMPACT|
62658861|NCT01561105|NO_INTERVENTION|Care as Usual|Patients received all depression care available to them as part of care as usual in the participating primary care clinics.
62658862|NCT03421587||Individuals exposed to an intentional/non-intentional trauma|
62658863|NCT03421587||Healthy controls without trauma-exposure|
62095354|NCT06232499|EXPERIMENTAL|Red-Blue Arm|Participants in this arm first receive 10 sessions of vascular laser treatment with red light, followed by a two-month washout period, and then receive 10 sessions of vascular laser treatment with blue light.
62095355|NCT06232499|EXPERIMENTAL|Blue-Red Arm|Participants in this arm first receive 10 sessions of vascular laser treatment with blue light, followed by a two-month washout period, and then receive 10 sessions of vascular laser treatment with red light.
62095356|NCT01330355|EXPERIMENTAL|Besivance|Besifloxacin 0.6% ophthalmic suspension
62465469|NCT02475954|ACTIVE_COMPARATOR|TH-CBT + Standard Care|Cognitive-behavioral therapy delivered via telehealth with a focus on decreasing depressive symptoms in Parkinson's Disease (PD).
62095357|NCT01330355|ACTIVE_COMPARATOR|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution
62095358|NCT06577857||Inferonasal MIMS Surgery Cohort|Cohort that includes subjects that have undergone the MIMS® inferonasal surgery.
62095359|NCT03406429|EXPERIMENTAL|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
62095360|NCT06398626||Adult patients with ulcerative colitis taking etrasimod|
62095361|NCT06123858||NASH with fibrosis|NASH patients with fibrosis receiving routine treatment
62095362|NCT06556706|PLACEBO_COMPARATOR|Placebo|
62095363|NCT06556706|ACTIVE_COMPARATOR|Mitopure (Urolithin A)|
62095364|NCT02932150|EXPERIMENTAL|TAF (Cohort 1)|Participants (12 to \< 18 years) weighing ≥ 35 kg will receive TAF 25 mg tablet for 24 weeks
62465470|NCT02475954|OTHER|Standard Care|VA standard care depression in Parkinson's Disease (PD)
62465471|NCT04462926|EXPERIMENTAL|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
62465472|NCT00715377|EXPERIMENTAL|1|
62658864|NCT03275922|OTHER|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
62095365|NCT02932150|PLACEBO_COMPARATOR|Placebo (Cohort 1)|Participants (12 to \< 18 years) weighing ≥ 35 kg will receive placebo tablet for 24 weeks
62658865|NCT03275922|OTHER|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
62658866|NCT02006862||olanzapine, schizophrenia|
61908406|NCT02594995|NO_INTERVENTION|Control group|Control group not receiving rt-PA thrombolysis, receiving basic therapy for acute stroke, e.g. aspirin/clopidogrel and lipid-lowering therapy
61908407|NCT02594995|NO_INTERVENTION|Control in thrombolysis group|Control group receiving rt-PA thrombolysis
62658867|NCT02381691|EXPERIMENTAL|maternal breast milk odor|"In the first group breast milk, venipuncture was performed to the neonate while his mother's milk odor was being diffused."
62658868|NCT02381691|PLACEBO_COMPARATOR|no odor|In a second control group, venipuncture was performed to the neonate with an odorless diffusor.
61908408|NCT02801266|EXPERIMENTAL|Intervention|The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.
62095366|NCT02932150|EXPERIMENTAL|TAF (Cohort 2 Group 1)|Participants (6 to \< 12 years) weighing ≥ 25 kg will receive TAF 25 mg tablet for 24 weeks
62095367|NCT02932150|EXPERIMENTAL|TAF (Cohort 2 Group 2)|Participants (6 to \< 12 years) weighing ≥ 14 kg to \< 25 kg will receive TAF 15 mg oral granules for 24 weeks
62095368|NCT02932150|EXPERIMENTAL|TAF (Cohort 2 Group 3)|"Participants (2 to \< 6 years) will receive TAF for 24 weeks as follows:~* weight ≥ 10 kg to \< 14 kg (7.5 mg oral granules)~* weight ≥ 14 kg to \< 25 kg (15 mg oral granules)"
62095369|NCT02932150|PLACEBO_COMPARATOR|Cohort 2 Placebo|Participants will receive matching placebo of TAF (tablet or oral granules) for 24 weeks.
62095370|NCT02932150|EXPERIMENTAL|Open-Label TAF|Following 24 weeks of blinded randomized treatment, participants will be eligible to participate in an open-label extension phase to receive TAF for an additional 216 weeks.
61908409|NCT02801266|NO_INTERVENTION|No intervention|The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.
62095371|NCT02362035|EXPERIMENTAL|Acalabrutinib plus Pembrolizumab|"A nonrandomized study that will be conducted in 2 stages. In the first stage, (Safety), subjects will receive Acalabrutinib Dose A orally administered (PO) twice daily (BID) in combination with Pembrolizumab Dose B administered every 3 weeks (Q3W).~The second stage was an expansion of Cohorts with the same dose regimen as the first stage. An additional expansion in subjects with Myelofibrosis was planned but not conducted."
62095372|NCT06103565|OTHER|Active clinical decision support tool for pharmacists|In this single arm, pilot feasibility study, pharmacists with be exposed to a clinical decision support tool to facilitate monitoring adherence to GDMT for patients with heart failure with reduced ejection fraction
62095373|NCT05693662|EXPERIMENTAL|Session 1|Educational About Autism Spectrum Disorder
62095374|NCT05693662|EXPERIMENTAL|Session 2|Mindfulness Based Self-Compassion information
62095375|NCT05693662|EXPERIMENTAL|Session 3|How We Evolved - Threat, Impulse, and Soothing Systems
62095376|NCT05693662|EXPERIMENTAL|Session 4|Threat and Self-Compassion
62658869|NCT03206138|EXPERIMENTAL|GX-188E, GX-I7|GX-188E + GX-I7
61908410|NCT03550300||Participants with CMT|Participants with CMT1A, CMT1B, CMT2A or CMTX1
61908411|NCT03550300||Control participants|Control participants
62095377|NCT05693662|EXPERIMENTAL|Session 5|Untying the Knots of Desires and Patterns
62658870|NCT03206138|EXPERIMENTAL|GX-188E, Imiquimod|GX-188E + Imiquimod
62095378|NCT05693662|EXPERIMENTAL|Session 6|Internalize compassion
62095379|NCT05693662|EXPERIMENTAL|Session 7|Me and others - Widening the circle
62095380|NCT05693662|EXPERIMENTAL|Session 8|Growing happiness
62095381|NCT05693662|EXPERIMENTAL|Session 9|Weaving Wisdom and Compassion into Daily Life
62095382|NCT05693662|EXPERIMENTAL|Session 10|Living with Heart
62095383|NCT02788656|EXPERIMENTAL|Group A|Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
62292852|NCT00746174|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, \& skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
62292853|NCT06030934|EXPERIMENTAL|Patients who have failed previous standard chemotherapy|
62658871|NCT05084326||Mohamedabosena|
61908412|NCT06055738|EXPERIMENTAL|Zimberelimab combined with albumin-bound paclitaxel and cisplatin|Zimberelimab combined with albumin-bound paclitaxel and cisplatin in neoadjuvant treatment of locally advanced cervical cancer
61908413|NCT04493528|ACTIVE_COMPARATOR|Needle Infiltration anesthesia|Patients received one needle injection of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
62658872|NCT03931122|NO_INTERVENTION|Group A - Weight Based Method|"Body Weight Based method: This is the conventional method for LMA size selection. The patient will be weighed and LMA size corresponding to their weight will be used as follows.~(LMA Size - 1 for up to 5 kg of body weight) (LMA Size - 1.5 for 5 to 10 kg of body weight) (LMA Size - 2 for 10 to 20 kg of body weight) (LMA Size - 2.5 for 20 to 30 kg of body weight) (LMA Size - 3 for 30 to 50 kg of body weight)"
62658873|NCT03931122|EXPERIMENTAL|Group B - Ear Size Based Method|"Ear Size Based method: External ear size will be measured by using a paper ruler and will be recorded in cm as follows:~Vertical length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W )~Based on these ear measurements, nearest smaller LMA size will be selected."
61908414|NCT04493528|EXPERIMENTAL|Needle-free infiltration anesthesia|Patients received one NFLJI (needle-free liquid jet injection) of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
62658874|NCT03871413|ACTIVE_COMPARATOR|Manual repositioning maneuver|Diagnostics and treatment of BPPV with manual repositioning maneuvers. In case of posterior canal involvement, Epley's maneuver will be used. In case of horizontal canal involvement, the log roll maneuver will be used.
61908415|NCT04493528|ACTIVE_COMPARATOR|Needle mental nerve block|Patients received one needle injection of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
61908416|NCT04493528|EXPERIMENTAL|Needle-free mental nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
61908417|NCT04493528|ACTIVE_COMPARATOR|Needle mandibular nerve block|Patients received one needle injection of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
61908418|NCT04493528|EXPERIMENTAL|Needle-free mandibular nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
62658875|NCT03871413|EXPERIMENTAL|Treatment in mechanical rotational chair (TRV-chair)|"Diagnostics and treatment of BPPV with the use of a TRV chair. In case of posterior canal involvement, Epley's maneuver will be used with the addition of 10 kinetic impulses in each position.~In case of horizontal canal involvement, the log roll maneuver will be used with the addition of 10 kinetic impulses in each position."
61908419|NCT04493528|ACTIVE_COMPARATOR|Needle infraorbital nerve block|Patients received one needle injection of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
61908420|NCT04493528|EXPERIMENTAL|Needle-free infraorbital nerve block|Patients received one NFLJI (needle-free liquid jet injection) of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
61908421|NCT02316509|EXPERIMENTAL|Part I: Dose Escalation - GDC-0927|Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
61908422|NCT02316509|EXPERIMENTAL|Part II: Dose Expansion - GDC-0927|Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.
62095384|NCT02788656|ACTIVE_COMPARATOR|Group B|"Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device)."
62095385|NCT02633891|EXPERIMENTAL|Balance exercise program|Participants will attend weekly group training sessions and will keep an exercise log of home activity during a three month exercise program designed to improve balance. Balance exercises will be performed three times per week in a home-based training program.
62095386|NCT02633891|ACTIVE_COMPARATOR|standard care|Participants will meet in person on a weekly basis for a general education class regarding health and fall prevention but will not participate in an exercise class.
62095387|NCT00336921|ACTIVE_COMPARATOR|1|Alfuzosin 10mg
62095388|NCT00336921|PLACEBO_COMPARATOR|2|Placebo
62292854|NCT06030934|EXPERIMENTAL|Patients with SD or above obtained by previous first-line PD-1 antibody therapy|
62095389|NCT05510401|OTHER|SECURIDRAP® SELFIA®|Use of a SECURIDRAP® SELFIA® restraint system Monitoring with passage of an independent assessor
62095390|NCT00335556|EXPERIMENTAL|Surgery|Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
62658876|NCT03052036|OTHER|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
62658877|NCT03052036|OTHER|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
62292855|NCT02507479|EXPERIMENTAL|thiotepa|Thiotepa 5-10 mg/kg/d x 2 days
62465473|NCT05343637|EXPERIMENTAL|RT234 - Cohort 1|Participants will receive RT234 as 0.2 mg and 0.6 mg
62465474|NCT05343637|EXPERIMENTAL|RT234 - Cohort 2|Participants will receive RT234 as 0.6 mg and 1.2 mg
62465475|NCT05343637|EXPERIMENTAL|RT234 - Cohort 3|Participants will receive RT234 as 1.2 mg and 2.4 mg
62658878|NCT03201107|EXPERIMENTAL|Pilates group|This group receives physical training based on pilates exercises
61908423|NCT02518464|EXPERIMENTAL|Ticagrelor 90 mg twice per day|Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.
61908424|NCT04285840|OTHER|Single arm study|To establish a standardized procedure for venous ACT sampling during atrial fibrillation ablation. Analyses will examine the relationship and agreement between venous and arterial ACTs.
62095391|NCT00335556|EXPERIMENTAL|Treatment (UH-1)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
62095392|NCT00335556|EXPERIMENTAL|Treatment (window/UH-1)|Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
62095393|NCT00335556|EXPERIMENTAL|Treatment (UH-2)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
62095394|NCT00335556|EXPERIMENTAL|Treatment (regimen I)|Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
62095395|NCT00335556|EXPERIMENTAL|Treatment (regimen DD-4A)|Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
62095396|NCT02600156|EXPERIMENTAL|Single arm study|MR guided focal laser ablation of prostate cancer using the Visualase Thermal Therapy System.
62095397|NCT00918190|ACTIVE_COMPARATOR|Ondansetron-Dexa group|Use 2 different antiemetics
62095398|NCT00918190|ACTIVE_COMPARATOR|Midazolam, Dexa group|use of midazolam and dexamethasone
62095399|NCT00918190|PLACEBO_COMPARATOR|Placebo|Saline will be given
62095400|NCT02125513|ACTIVE_COMPARATOR|Arm A: 3 courses|Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
62095401|NCT02125513|EXPERIMENTAL|Arm B: 6 courses|Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
62658879|NCT03201107|NO_INTERVENTION|No intervention group|This group does not receive any treatment
62658880|NCT05055596|EXPERIMENTAL|Gentle Movement|
61908425|NCT03441217|EXPERIMENTAL|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
62095402|NCT01444976|ACTIVE_COMPARATOR|topical pharyngeal anesthesia|There were 26 patients who had the procedure under topical pharyngeal anesthesia.
62095403|NCT01444976|ACTIVE_COMPARATOR|midazolam|There were 25 patients who received midazolam.
62095404|NCT01444976|NO_INTERVENTION|hypnosis|There were 27 patients receiving hypnosis.
62095405|NCT06370351|EXPERIMENTAL|Dose escalation - Low dose group|Intracochlear administration of a Low dose of SENS-501 in one ear, with a dedicated administration system
62658881|NCT05055596|ACTIVE_COMPARATOR|Health Coaching|
62658882|NCT00958074|EXPERIMENTAL|Cohort I (>=65 years old)|200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
62658883|NCT00958074|EXPERIMENTAL|Cohort II (<65 years old)|400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
61908426|NCT03441217|PLACEBO_COMPARATOR|Saline solution|Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
62095406|NCT06370351|EXPERIMENTAL|Dose escalation - High dose group|Intracochlear administration of a High dose of SENS-501 in one ear, with a dedicated administration system
62292856|NCT06373874|EXPERIMENTAL|Experimental: group that practices in a high-reality simulation environment|The researcher showed the student how to take heel blood on the model. The researcher introduced both high-reality simulation environment. As a pre-test, the student was asked to fill out the Introductory Information Form, Self-Efficacy-Efficacy Scale and State and Trait Anxiety Scales surveys. Midwifery students in the experimental group were asked to take heel blood on a model in a high-reality simulation environment.Heel blood collection skill evaluation form was filled out by the researcher.As a post-test, the student was asked to fill out the Introductory Information Form, Self-Efficacy Scale and State and Trait Anxiety Scales surveys.
62292857|NCT06373874|NO_INTERVENTION|control group|They took heel blood on a newborn model in the simulation room as routine training.
62658884|NCT06215495|EXPERIMENTAL|reduced CTV (clinical target volume) and PTV (planning target volume)|
62658885|NCT06215495|ACTIVE_COMPARATOR|EORTC CTV (clinical target volume) and PTV (planning target volume)|
62658886|NCT01338389|EXPERIMENTAL|CITICOLINE|Daily oral administration of 800 mg citicoline
62658887|NCT01338389|PLACEBO_COMPARATOR|Placebo|Daily oral administration of placebo
62658888|NCT04681300||Patients with atopic Prurigo nodularis , non-atopic Prurigo nodularis or atopic dermatitis|
62658889|NCT04681300||Patients with plastic surgery interventions|
62658890|NCT05460884|SHAM_COMPARATOR|Control|Participants will consume 109 g of white bread
62658891|NCT05460884|EXPERIMENTAL|Experimental 1: Seaweed extract at lower dose (LD) and white bread|Participants will consume 109 g of white bread with 0.5g of seaweed extract
62658892|NCT05460884|EXPERIMENTAL|Experimental 2: Seaweed extract at higher dose (HD) and white bread|Participants will consume 109 g of white bread with 1g of seaweed extract
62658893|NCT00008177|EXPERIMENTAL|Treatment ( I 131 BC8, chemotherapy, TBI, PBSCT, CSP, MMF)|"CONDITIONING REGIMEN: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV BID on days -3 to 56 with taper to day 80 (for patients with a related donor) OR days -3 to 100 with taper to day 177 (for patients with an unrelated donor) in the absence of GVHD. Patients also receive mycophenolate mofetil PO or IV TID on days 0 to 27 (for patients with a related donor) OR on days 0 to 40 with taper to day 96 (for patients with an unrelated donor) in the absence of GVHD."
62658894|NCT04386785|EXPERIMENTAL|Single-arm: Endovascular thermal ablation in IPV|
62658895|NCT02760888|ACTIVE_COMPARATOR|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
62292858|NCT05564767|EXPERIMENTAL|B. adolescentis Bif-038|Probiotic capsule (single strain)
62095407|NCT06370351|EXPERIMENTAL|Dose expansion group|Intracochlear administration of SENS-501 in one ear, with a dedicated administration system, at the dose recommended following the Dose escalation phase
62095408|NCT02185664|ACTIVE_COMPARATOR|Landmark technique|The landmark technique is the standard technique used for internal jugular vein cannulation.
62292859|NCT05564767|EXPERIMENTAL|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®|Probiotic capsule (combination strain)
62095409|NCT02185664|EXPERIMENTAL|Static Ultrasound technique|Static ultrasound technique was used to assist internal jugular vein cannulation.
62095410|NCT00765089|EXPERIMENTAL|Pulmonary Vein isolation|Patients in this arm will receive pulmonary vein isolation during surgery
62095411|NCT00765089|NO_INTERVENTION|Standard of care|Subjects in this arm will receive standard of care and no pulmonary vein isolation
62292860|NCT05564767|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62292861|NCT05376917|EXPERIMENTAL|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50 Diopters (D) on the dominated eye
62292862|NCT05376917|EXPERIMENTAL|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
62292863|NCT05376917|EXPERIMENTAL|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
62292864|NCT05376917|EXPERIMENTAL|Zeiss AT Lara / Zeiss AT Lara|Micro-monovision with refractive target of -0.75 Diopters (D) on the non-dominant eye
62292865|NCT04507009|ACTIVE_COMPARATOR|Control|Traditional treatment group which alvogyl applied to the socket after irrigation
62658896|NCT02760888|ACTIVE_COMPARATOR|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
62658897|NCT02760888|PLACEBO_COMPARATOR|Placebo|Women will receive a placebo 1 hour before the procedure
62658898|NCT05651178|EXPERIMENTAL|Human CD19-CD22 Targeted T Cells Injection|Single administration: 1.0×10\^6 CAR+T cells/kg, 3.0×10\^6 CAR+T cells/kg, 5.0×10\^6 CAR+T cells/kg
62658899|NCT00542308|EXPERIMENTAL|Zalutumumab 4-16 mg/kg|Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
62658900|NCT01542281|EXPERIMENTAL|Nutritional supplementation and prehab|The first group (pre-hab) will receive both nutritional supplementation and a prehabilitation program.
62658901|NCT01542281|ACTIVE_COMPARATOR|Prehab exercise|
62658902|NCT04183478|EXPERIMENTAL|Best Support Care Plus K-001|Best support care including analgesic treatment, anti-infection therapy, biliary obstruction treatment, nutritional support, psychological support, reasonable advice from physicians, good communication with patients and etc. K-001 9,720mg per day which means that take K-001 capsule 18 tablets (270mg per tablet) orally twice a day (morning and evening), 56 days as a cycle.
62658903|NCT04183478|PLACEBO_COMPARATOR|Best Support Care Plus placebo|Best support care is the same as experimental arm. Placebo is take 18 placebo tablets which is the same as K-001 in appearance orally twice a day (morning and evening), 56 days as a cycle.
62658904|NCT05798312|EXPERIMENTAL|Intervention group|The intervention group will receive customizable support material.
62658905|NCT05798312|SHAM_COMPARATOR|Standard group|The standard group will receive a non-customizable support material.
62095412|NCT05787574|EXPERIMENTAL|Group A: Emapalumab (for isolated Interferongamma mediated disease)|Participants in this group will receive emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
62095413|NCT05787574|EXPERIMENTAL|Group B: Fludarabine and Dexamethasone (for generalized autoinflammation)|Participants in this group will receive fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.
62658906|NCT04118400||Experimental: NIN-NAVA|"* Premature\>30weeks with respiratory distress~* PI to determine eligibility or exclusion~* Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization~* PI will not be blinded to the intervention (not feasible)~* Place the catheter to optimize position~* ABG or VBG to be obtained at 2 hrs. post NIV-NAVA~* NIV-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
62658907|NCT04118400||Active Comparator: Nasal CPAP or NIMV|"* Premature\>30weeks with respiratory distress~* PI to determine eligibility or exclusion~* Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization~* PI will not be blinded to the intervention (not feasible)~* Place the catheter to optimize position~* ABG or VBG to be obtained at 2 hrs. post Nasal CPAP or NIMV~* NCPAP or NIMV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
62658908|NCT05679310|EXPERIMENTAL|Supplement|The supplement capsules were given to 12 healthy subjects, aged 26-52, once a day for 8 weeks
62095414|NCT06011967|ACTIVE_COMPARATOR|Group A : 90 degree|In this group patients were intubated using a 90 degree angled stylet with C-MAC D- Blade videolaryngoscope
62095415|NCT06011967|ACTIVE_COMPARATOR|Group B : 80 degree|In this group patients were intubated using a 80 degree angled stylet with C-MAC D- Blade videolaryngoscope
62095416|NCT06011967|ACTIVE_COMPARATOR|Group C: 60 degree|In this group patients were intubated using a 60 degree angled stylet with C-MAC D- Blade videolaryngoscope
62095417|NCT05501132|EXPERIMENTAL|tDCS group 1|In the first experimental group, the TDCS intervention protocol consists of 10 sessions of 20 minutes of 1 mA electrical stimulation on 5 consecutive days with two sessions per day.
62095418|NCT05501132|EXPERIMENTAL|tDCS group 2|In the second experimental group, the TDCS intervention protocol consists of 10 sessions of 20 minutes of 2 mA electrical stimulation on 5 consecutive days with two sessions per day.
62095419|NCT05501132|PLACEBO_COMPARATOR|Control group|In the placebo group, the TDCS intervention protocol consists of 10 sessions of 20 minutes of sham electrical stimulation on 5 consecutive days with two sessions per day.
62095420|NCT03283553|EXPERIMENTAL|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
62095421|NCT03283553|PLACEBO_COMPARATOR|Usual Care|Care as usual with the medical oncologist.
62095422|NCT02333851|EXPERIMENTAL|Premixed insulin|Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
62095423|NCT02333851|EXPERIMENTAL|Basal-bolus|'Lantus® once daily and Apidra® before meals
62095424|NCT06326047|EXPERIMENTAL|Dosing scheme A (NNC0519-0130)|Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner.
62095425|NCT06326047|PLACEBO_COMPARATOR|Dosing scheme A (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
62095426|NCT06326047|EXPERIMENTAL|Dosing scheme B (NNC0519-0130)|Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner.
62095427|NCT06326047|PLACEBO_COMPARATOR|Dosing scheme B (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
62095428|NCT06326047|EXPERIMENTAL|Dosing scheme C (NNC0519-0130)|Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.
62292866|NCT04507009|EXPERIMENTAL|Ozone|Ozone group which Ozone (O3) applied after irrigation of the socket
62658909|NCT05808959|EXPERIMENTAL|Education group|Structured training on sexual health will be given to patients in this group. After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health. It is anticipated that the training will take approximately 30 minutes. Immediately after the training, feedback will be received from the patient through a question-answer activity, and areas that are not understood will be repeated. It is thought that the training will take approximately 45-60 minutes in total.
62095429|NCT06326047|PLACEBO_COMPARATOR|Dosing scheme C (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
62095430|NCT06326047|EXPERIMENTAL|Dosing scheme D (NNC0519-0130)|Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.
62292867|NCT04507009|EXPERIMENTAL|CGF +Ozone|CGF + Ozone group which concentrated growth factor (CGF) after Ozone (O3) applied followed by irrigation of the socket.
62292868|NCT05381350|EXPERIMENTAL|Experimental group aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain）|400 participants aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
62292869|NCT05381350|ACTIVE_COMPARATOR|Control Group aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain）|200 participants aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
62658910|NCT05808959|NO_INTERVENTION|Control group|The clinic's routine discharge training will be applied to the participants in the control group.
62095431|NCT06326047|PLACEBO_COMPARATOR|Dosing scheme D (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
62095432|NCT06326047|EXPERIMENTAL|Dosing scheme E (NNC0519-0130)|Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner.
62095433|NCT06326047|PLACEBO_COMPARATOR|Dosing scheme E (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
62658911|NCT04120818||SIOL group|aphakic children diagnosed with congenital cataract who underwent secondary IOL implantation
62095434|NCT06326047|ACTIVE_COMPARATOR|Dosing scheme F (tirzepatide)|Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.
62095435|NCT06613503|EXPERIMENTAL|AI-supporter|Participants will use the AI-supporter for excretion detection, cleaning, and drying processes.
62095436|NCT06613503|NO_INTERVENTION|Traditional Diapers|Participants will use theTraditional Diapers for excretion detection, cleaning, and drying processes
62095437|NCT02684084|ACTIVE_COMPARATOR|Combination group (RBZ+DEX)|30 eyes will receive an intravitreal Lucentis (0.5 mg) injection followed by Ozurdex implant (0.7 mg) injection within 0 to 8 days.
62095438|NCT02684084|ACTIVE_COMPARATOR|Monotherapy group (DEX only)|30 eyes will receive Ozurdex implant (0.7 mg) injection only
62095439|NCT03766919|EXPERIMENTAL|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead)
62095440|NCT00898274||High risk for developing prostate cancer|Male subjects age 45-65 at high risk for developing prostate cancer.
62095441|NCT00898274||Healthy participants|Aged matched healthy participants
62095442|NCT00594932|ACTIVE_COMPARATOR|Arm I:|Participants randomly assigned to Arm I will receive mycophenolate mofetil in ascending doses during Month 1, and 3 grams/day (or less if there are tolerance issues) for Months 2 through 6. During Month 1 these participants receive the same number of pills as every other month, but with ascending doses of mycophenolate mofetil and descending numbers of placebo pills. Week one for a total of 1.5 gm/day of mycophenolate mofetil, Week two 2.0 gm/day, Week three 2.5 gm/day and Week 4 3 gm/day. Dose can be held or decreased for tolerance issues at any time.
62095443|NCT00594932|PLACEBO_COMPARATOR|Arm 2|Patients Randomly Assigned to Arm 2 will receive a placebo comparator. The placebo treatment will be structured so that they will undergo the same type of dosing in Month 1 that the ascending dose patient from Arm 1 undergo, but will have placebo in both bottles of pills. At the end of three months, after assessment of primary outcome, these patients enter open label treatment for three more months. During the fourth month this group continues to receive the same number of pills as they received before, with ascending doses of mycophenolate mofetil given vs descending placebo pills so that their induction is the same as those in Arm 1 at the first month.
62095444|NCT06128148|EXPERIMENTAL|50 mg qd|Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 50 mg qd. This arm evaluates the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of this dose level.
62095445|NCT06128148|EXPERIMENTAL|100 mg qd|Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 100 mg qd. This arm assesses safety, tolerability, and pharmacokinetics (PK) data for this dose level.
62465476|NCT05792774|EXPERIMENTAL|Phrenic nerve anesthetics infiltration|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
62658912|NCT04120818||PIOL group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and primary IOL implantation
62658913|NCT05651256|EXPERIMENTAL|TREATMENT|BEFORE TREATMENT/AFTER TREATMENT A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed with a total dose of 100 U (Type A toxinum botulinum, Allergan) in each patient, distributed at the different injection sites: 40 U in the masseter muscle, (0.1 cc=10 U), 20 U in the area of greatest hypertrophy (anterior inferior masseter), 10 U in the direction of the mandibular inferior border and 10 U in the area of the posterior inferior masseter; 20 U in the lateral pterygoid muscle (10 U extraorally between the zygomatic arch and sigmoid notch and 10 U intraorally, behind the maxillary tuberosity); 20 U in the TMJ, 10mm anterior to the tragus and 2mm below the zygomatic arch and 20 U in the anterior part of the temporalis muscle.
62095446|NCT06128148|EXPERIMENTAL|200 mg qd|Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 200 mg qd. This arm examines the safety, pharmacokinetics (PK), and preliminary efficacy of this dose level.
62095447|NCT06128148|EXPERIMENTAL|100 mg bid|Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 100 mg bid. The arm evaluates the safety, tolerability, and pharmacokinetics (PK) of this increased dosing frequency.
62095448|NCT06128148|EXPERIMENTAL|150 mg bid|Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 150 mg bid. This arm aims to determine the optimal dosing for safety, pharmacokinetics (PK), and efficacy.
62095449|NCT06128148|EXPERIMENTAL|200 mg bid|Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 200 mg bid. This arm focuses on evaluating safety, tolerability, and pharmacokinetics (PK) at this dose.
62095450|NCT03251144|EXPERIMENTAL|Switch to E/C/FTC/TAF daily|"Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be~1. If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months.~2. If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
62292870|NCT05381350|EXPERIMENTAL|Experimental group aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain）|100 participants aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
62292871|NCT05381350|ACTIVE_COMPARATOR|Control Group aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain）|50 participants aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
62658914|NCT03258242|EXPERIMENTAL|Experimental: Keluo Xin Capsule|
62658915|NCT03258242|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|
62095451|NCT06698094|ACTIVE_COMPARATOR|Healthy lifestyle group (HL)|"The control group will receive advice about a conventional healthy diet according to the Nordic Nutrition Recommendations (NNR 2014) and international physical activity recommendations from WHO. The participants will get information about the recommended distribution of energy from macronutrients i.e. energy coming from fat, protein, and carbohydrates, as well as general recommendations about the plate model, i.e. the combination of food on the plate to adhere to the recommended nutrient intake. Additionally, they will receive instructions to increase physical activity to reach 150 to 300 minutes of moderate aerobic activity per week or the equivalent vigorous activity."
62658916|NCT01626716|EXPERIMENTAL|case management|patients who assigned to the intervention group will take 7 times phone calls from case manager
62292872|NCT05381350|EXPERIMENTAL|Experimental group aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain）|400 participants aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
62465477|NCT05792774|PLACEBO_COMPARATOR|Physiological serum infiltration|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
62658917|NCT01626716|NO_INTERVENTION|control|usual care
62658918|NCT01027845|EXPERIMENTAL|10Pn Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of Synflorix (10Pn) vaccine, administered intramuscularly on alternating (left/right) sides of the anterolateral thigh and DPT KAKETSUKEN Syringe (DTPa) vaccine administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm. Both vaccines were administered at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
62658919|NCT01027845|ACTIVE_COMPARATOR|DTPa Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of the DPT KAKETSUKEN Syringe (DTPa) vaccine, administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
62658920|NCT02338830|ACTIVE_COMPARATOR|Progesterone group|Women received vaginal progesterone suppositories
62095452|NCT06698094|EXPERIMENTAL|Sustainable lifestyle group (SL)|The sustainable lifestyle group will receive instructions to increase the consumption of healthy organic plant-based foods that is carbon or environmentally friendly (i.e. fruits, vegetables, legumes, multigrain cereals, or labeled foods) and decrease consumption of beef and dairy products. We expect that the reduction of diet-related CO2e will be 50% as compared to the baseline, while the intake of nutrients such as fiber, vitamin C, and folate will increase. Additionally, they will receive instructions to increase active and emission-free transportation, i.e. walking and biking to and from work and meetings.
62095453|NCT06465186|EXPERIMENTAL|Efinopegdutide|Participants will start efinopegdutide once a week at the lowest dose level. Then, the dose level will go up every month for three months until they are getting the highest dose level. Efinopegdutide is given as an injection under the skin (subcutaneous injection) for 28 weeks.
62095454|NCT06465186|PLACEBO_COMPARATOR|Placebo|"Participants will receive placebo once a week. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.~Placebo is given as an injection under the skin (subcutaneous injection) for 28 weeks."
62095455|NCT00412516|OTHER|Group 1|JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month
62292873|NCT05381350|ACTIVE_COMPARATOR|Control Group aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain）|200 participants aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
62465478|NCT05502484|EXPERIMENTAL|4 weeks baseline followed by Integrative DBT|Integrative Dialectical Behavioural Therapy (DBT) consisting of 8 weeks outpatient pretreatment DBT, 40 weeks inpatient DBT, 24 weeks follow-up including 12 weeks after care DBT and 12 weeks no DBT.
62465479|NCT05502484|EXPERIMENTAL|6 weeks baseline followed by Integrative DBT|Integrative Dialectical Behavioural Therapy (DBT) consisting of 8 weeks outpatient pretreatment DBT, 40 weeks inpatient DBT, 24 weeks follow-up including 12 weeks after care DBT and 12 weeks no DBT.
62658921|NCT02338830|NO_INTERVENTION|No treatment group|Women received no treatment
62658922|NCT02625649||RYGB|RYGB-operated type 2 diabetic patients
62658923|NCT02625649||non-RYGB|non-RYGB-operated type 2 diabetic controls
62658924|NCT00589264|EXPERIMENTAL|1|iron + copper + zinc
62658925|NCT00589264|ACTIVE_COMPARATOR|2|iron + copper only
62095456|NCT00412516|EXPERIMENTAL|Group 2|JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently
62292874|NCT05381350|EXPERIMENTAL|Experimental group aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain）|100 participants aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
62292875|NCT05381350|ACTIVE_COMPARATOR|Control Group aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain）|50 participants aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
62292876|NCT05381350|ACTIVE_COMPARATOR|Historical control group|Backup serum samples will be selected from 250 healthy adult subjects aged 26-45 years who received two doses of inactivated COVID-19 vaccine(CZ strain)from clinical trial of lot-to-lot consistency of an inactivated SARS-CoV-2 Vaccine(Pro-NCOV-4001) to detect neutralizing antibodies against the CZ, Delta and Omicron strains.
62465480|NCT05502484|EXPERIMENTAL|8 weeks baseline followed by Integrative DBT|Integrative Dialectical Behavioural Therapy (DBT) consisting of 8 weeks outpatient pretreatment DBT, 40 weeks inpatient DBT, 24 weeks follow-up including 12 weeks after care DBT and 12 weeks no DBT.
62658926|NCT02716740|EXPERIMENTAL|Leucine-enriched amino acid : 2.16g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
62658927|NCT02716740|EXPERIMENTAL|Leucine-enriched amino acid : 4g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
62658928|NCT01925794|EXPERIMENTAL|COBRA PzF Stent|Single Arm study
62658929|NCT04433598|EXPERIMENTAL|Nutrition Education Intervention|the participants the intervention group under went to Nutrition Education Intervention program were received the developed educational materials (pamphlets).
62658930|NCT04433598|NO_INTERVENTION|Treatment as usual|the participants in the control group were received the usual medical care at their respective Center.The developed educational materials (pamphlets) were distributed at the end of the study.
62658931|NCT00576758|EXPERIMENTAL|Obinutuzumab|Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
62095457|NCT00412516|OTHER|Group 3|Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month
62292877|NCT04375306|ACTIVE_COMPARATOR|angiography guided CABG|angiography guided CABG
62292878|NCT04375306|EXPERIMENTAL|RFR guided CABG|RFR guided CABG
62292879|NCT00891514|EXPERIMENTAL|Aerobic Exercise|Treadmill training
62292880|NCT00891514|ACTIVE_COMPARATOR|Stretch Control|Stretching exercises
62465481|NCT04334798|EXPERIMENTAL|PFM&electro&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the pelvic floor muscles (PFM) will be performed using intravaginal palpation and electrostimulation, together with biofeedback (BFB).
62095458|NCT01434979||Controls|Active Duty,DoD Beneficiary, or civilian men and women between the ages of 18 and 45 years, with a waist circumference ≤ 39.4 inches (100 cm) will be asked to participate.
62292881|NCT04636905||Survivorship Wellness Group|Participants will be enrolled in a 15 week program to assess quality of life and general health outcomes
62292882|NCT05228366|EXPERIMENTAL|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
62465482|NCT04334798|EXPERIMENTAL|PFM&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with biofeedback (BFB).
62658932|NCT00576758|ACTIVE_COMPARATOR|Rituximab|Participants received 375 mg/m\^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m\^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
62736870|NCT03541889|EXPERIMENTAL|Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
62736871|NCT03541889|EXPERIMENTAL|Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
62736872|NCT01034644||PRISMS patients|This single group includes all the patients from the PRISMS study
62292883|NCT05228366|EXPERIMENTAL|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
62292884|NCT05228366|OTHER|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
62292885|NCT06258642|EXPERIMENTAL|Irinotecan Liposome and anlotinib|The treatment is continued until disease progression or intolerable toxicity
62292886|NCT01133145|EXPERIMENTAL|vascularized transplantation|allogeneic vascularized knee transplantation
62292887|NCT00351364|ACTIVE_COMPARATOR|Montelukast sodium|Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
62292888|NCT00351364|PLACEBO_COMPARATOR|2|No drug given - no placebo available. To compare with active drug.
62292889|NCT04396704||Botox|all eligible subjects, in a reverse consecutive order, initiated on onaBoNT-A from 01 March 2015 to 29 May 2017.
62292890|NCT04396704||Dysport|all subjects meeting inclusion/exclusion criteria and initiated on aboBoNT-A from 30 May 2017 to 30 March 2019.
62292891|NCT03691714|EXPERIMENTAL|Durvalumab and Cetuximab|Durvalumab 500mg as a 120-minute intravenous infusion every two weeks. Cetuximab 400mg/m2 IV loading dose followed by weekly Cetuximab 250mg/m2 IV Treatment with Durvalumab continues until progression and Cetuximab may continue as maintenance
62292892|NCT04874857|EXPERIMENTAL|Intervention group (Aromatherapy group)|With a mixture of Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L. essential oils, the foot and lower leg will be massaged for three sessions a week for 30 minutes in each session for four weeks.
62292893|NCT04874857|EXPERIMENTAL|Placebo group|The foot and lower leg will be massaged with baby oil for four weeks, three sessions a week, 30 minutes in each session.
62292894|NCT04874857|NO_INTERVENTION|Control group|No application will be made in addition to standard HD treatment.
62095459|NCT01434979||Exertional Heat Illness / Stroke|Active duty men and women between the ages of 18 and 45 years will be asked to participate. They must have a clinically documented heat stroke within the last year; they will not be tested any sooner than six weeks following the heat stroke. Heat stroke for the purpose of this study is defined as: a syndrome of hyperthermia, physical collapse or debilitation, and encephalopathy as evidenced by delirium, stupor, or coma, occurring during or immediately following exertion or significant heat exposure.
62095460|NCT05883800|EXPERIMENTAL|Intervention|Intervention: daily on-couch adaptive radiotherapy
62095461|NCT00249483|PLACEBO_COMPARATOR|Placebo|Placebo
62095462|NCT00249483|EXPERIMENTAL|Venlafaxine|Venlafaxine 300mg daily
62292895|NCT01969266|EXPERIMENTAL|PCI-32765|PCI-32765 840 mg will be administered as capsule (Treatment A in Period 1) and solution (Treatment B in Period 2) formulations. All participants will receive both treatments with a 7-day washout period between doses.
62292896|NCT04324853||S. haematobium positive|Pregnant women infected with Schistosoma hematobium alone
62292897|NCT04324853||geohelminths positive|pregnant women infected with geohelminths alone
62292898|NCT04324853||Helminth negative|Pregnant women free of anyn helminths infection
62095463|NCT06684743|EXPERIMENTAL|RSV prefusion F protein-based vaccine (RSV vaccine)|RSV vaccine single injection at day 0
62095464|NCT06684743|NO_INTERVENTION|No RSV vaccine (control)|Control arm, no RSV vaccine
62095465|NCT01008748|EXPERIMENTAL|Smoking Cessation Treatment|Nicotine replacement therapy (NRT), self-help materials, + brief in-person and telephone counseling, all conducted in Spanish. Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
62292899|NCT03851692|ACTIVE_COMPARATOR|60s (group E)|Intravenous cannulation was released either 60 s following loss of lid reflex in group E
62292900|NCT03851692|ACTIVE_COMPARATOR|90 or 120 s (groupe L)|Intravenous cannulation was released either 90 or 120 s following loss of lid reflex in group L
62292901|NCT02111005||Smoking Aggressive Periodontitis group|This group comprises 20 patients who are smokers and aged \< 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) \> 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (\>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
62292902|NCT02111005||Smoking Chronic Periodontitis group|This group comprises 20 patients who are smokers and aged \> 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
62095466|NCT06204666|EXPERIMENTAL|High Dose Hemp Fiber Bar|20% hemp hull powder
62095467|NCT06204666|EXPERIMENTAL|Low Dose Hemp Fiber Bar|5% hemp hull powder
62095468|NCT06204666|PLACEBO_COMPARATOR|Placebo|0% hemp hull powder
62095469|NCT02437851|EXPERIMENTAL|Treatment (surgery)|Participants undergo therapeutic conventional surgery to remove anal or perianal cancer (SISCCA). Any HSIL remaining is treated with the goal for complete eradication in accordance with clinician and participant preference.
62095470|NCT05720000|EXPERIMENTAL|PDO thread with active red LED photobiomodulation (PBM)|Participants will receive the PDO thread and the intervention with PBM using red light (Newskin, MMO) 150 mW, 2J per point, 4J/cm2, 10 points, twice a week.
62292903|NCT02111005||Non-smoking Aggressive Periodontitis grp|This group comprises 20 patients who are age- and sex- matched to the 'Smoking Aggressive Periodontitis group' and are non-smokers suffering from aggressive periodontitis.
62292904|NCT02111005||Non-smoking Chronic periodontitis grp|This group comprises 20 patients who are age- and sex-matched to the 'Smoking Chronic Periodontitis group' and are non-smokers suffering from chronic periodontitis.
62292905|NCT05996484|EXPERIMENTAL|Neoadjuvant Anlotinib Combined With Toripalimab and Chemotherapy|Toripalimab+ Anlotinib+Albumin-bound paclitaxel+Cisplatin
62292906|NCT00746499|EXPERIMENTAL|1|No control group, only one active arm with subjects taking Raltegravir.
61908427|NCT06518590|ACTIVE_COMPARATOR|Group(A)|Twenty five patients will receive unilateral limb training sequentially (counter weighted single limb cycling ) (dominant limb, then non-dominant limb) by bicycle for 20-30 minutes per session, three sessions per week for 2 months (8 weeks), in addition to health advices and their medications
62292907|NCT02150031|OTHER|Control|"* Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~* No prophylactic Chlorhexidine regimen.~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction."
62292908|NCT02150031|ACTIVE_COMPARATOR|CHX-Mouthwash|"* Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction."
62292909|NCT02150031|ACTIVE_COMPARATOR|CHX-MW/SUB_IR|"* Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction."
62292910|NCT02150031|ACTIVE_COMPARATOR|CHX-MW/SUPRA_IR|"* Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction."
62095471|NCT05720000|SHAM_COMPARATOR|PDO thread with sham photobiomodulation (PBM)|Participants will receive the PDO thread and the simulated intervention with PBM using Newskin, MMO.
62095472|NCT01890174||AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
62292911|NCT06252116||Neuropathic pain patients|Patients were randomized to pregabalin (group A) and duloxetine (group B). Those patients who did not have a 50% reduction in pain levels received duloxetine (group A) and pregabalin (group B). Then, those patients who did not have a 50% reduction in pain levels received tramadol.
62292912|NCT01523080|ACTIVE_COMPARATOR|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA.
62658933|NCT01349387|EXPERIMENTAL|Arm1|"During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry).~After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31."
62658934|NCT04650620|EXPERIMENTAL|Plenhyage® thin|Plenhyage® thin for the treatment of mild wrinkles;
62658935|NCT04650620|EXPERIMENTAL|Plenhyage® medium|Plenhyage® medium for the treatment of moderate wrinkles;
62658936|NCT04650620|EXPERIMENTAL|Plenhyage® strong|Plenhyage® strong for improving the skin tones and irregularities (atrophies) of the skin surface in neck, abdomen, thighs and buttocks
62658937|NCT01290809||Prophylactic Cranial Irradiation|NSCLC patients treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
62095473|NCT06693882|OTHER|Patients with glaucoma undergoing electrical stimulation of the optic nerve|Single arm study of patients with glaucoma undergoing electrical stimulation of the optic nerve
62095474|NCT05760755|EXPERIMENTAL|Intervention group (Stick Together)|Intervention group (all participants)
62095475|NCT05390645|EXPERIMENTAL|MFA-370|MFA-370 once daily for up to 8 x 21 days.
62658938|NCT01290809||no Prophylactic Cranial Irradiation|NSCLC patients not treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
61908428|NCT06518590|ACTIVE_COMPARATOR|Group(B)|Twenty-five patients will receive bilateral limbs training by bicycle for 20_ 30 minutes per session, three sessions per week for 2 months (8 weeks), in addition to health advices and their medications
61908429|NCT06518590|ACTIVE_COMPARATOR|Group(C)|Twenty five patients will receive medications in addition to health advices.
62095476|NCT06497491|EXPERIMENTAL|GNR-086|canakinumab biosimilar
62095477|NCT06497491|ACTIVE_COMPARATOR|Ilaris®|canakinumab
62095478|NCT03949322|EXPERIMENTAL|Adapted Physical Activity Program|Patients in the experimental group take part in a program of Adapted Physical Activity lasting 6 weeks, with 2 sessions per week.
62095479|NCT03864731|OTHER|Bone conduction device - ADHEAR|Patients will receive a hearing aid (ADHEAR). Hearing assessment will be carried out. Quality of life measurement will be carried out.
62292913|NCT01523080|EXPERIMENTAL|Acetaminophen extended release Gel tabs 650 mg|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
62095480|NCT04554498|EXPERIMENTAL|Hemodiafiltration with ATA filter|patients with clinical history of hypersensitivity to polisulfone/poliethersulfone dialysis filters or hypersensitivity to drugs or generic allergens.
62095481|NCT04554498|ACTIVE_COMPARATOR|Hemodiafiltration with Helixone filter|no history of hypersensitivity to polisulfone/poliethersulfone dialysis filters is assessed; no history of hypersensitivity to drugs or generic allergens is assessed.
62095482|NCT05205460|EXPERIMENTAL|Home-based telehealth exercise training|After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes). Then, the participants will start a home-based telehealth exercise training program (30minutes/session, 3 sessions/week for 12weeks, with a total of 36 sessions) combined with heart rate sensing clothes. Exercise type: brisk walking, jogging, or stationary ergometer exercise.
62095483|NCT05205460|ACTIVE_COMPARATOR|Education and self-exercise|"After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes).~Then, the patients will receive weekly reminders and monthly outpatient follow-ups during the exercise program."
62658939|NCT01334359|EXPERIMENTAL|Treatment Group|Participants randomized to the afterschool intervention
61908430|NCT05633303|EXPERIMENTAL|Patients with underlying LVZs (≥30% of LVZs in the LA body)|"Study 1- Developing a methodology and technique for sequential CV assessment. Twenty patients.~Study 2- Assess the mechanistic importance of RDCV slowing sites in AF. Twenty patients.~Study 3- Assess the impact autonomic modulation has on CV dynamics and RDCV slowing sites. Twenty patients.~Study 4- GP site ablation and substrate modification guided by RDCV slowing sites whereby substrate ablation is limited to substrate with these electrical properties and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~. Study 5- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients."
62292914|NCT04032340||Elderly with a companion dog|elderly living at home with a dog consulting his family doctor
62292915|NCT04032340||Elderly without a companion dog|elderly living at home without a dog consulting his family doctor
62292916|NCT03029832|EXPERIMENTAL|MOXR0916 plus Atezolizumab|
62292917|NCT03029832|ACTIVE_COMPARATOR|Atezolizumab|
62292918|NCT01449890|EXPERIMENTAL|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises they have learned during the initial treatment phase in order to cope with depression, e.g. integrating positive activities in their all day life or monitoring the interdependence of cognition, emotion and behaviour.
62292919|NCT01449890|NO_INTERVENTION|Treatment as usual|After having terminated inpatient CBT patients receive treatment as usual within routine care.
62292920|NCT00206726|EXPERIMENTAL|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.
62292921|NCT05573802|EXPERIMENTAL|Part 1 : Dose finding|"Belantamab mafodotin will be administered as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose:~• 1.4 mg/kg Q8W (i.e., on Day 1 of every other 28-day cycle)~* Dose Level +1: 1.9 mg/kg Q8W~* Dose Level -1: 1.0 mg/kg Q8W~* Dose Level -2: 1.0 mg/kg Q12W~Lenalidomide: 25 mg/d on day 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants \< 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years~Nirogacestat: 100 mg twice a day (BID) starting on day -3 and then each day of every other 28-day cycle (i.e., to be given only on cycles where belantamab mafodotin is administered)."
62292922|NCT04026984|EXPERIMENTAL|Rifamycin SV MMX plus ORT|One tablet contains 50 mg Rifamycin SV-MMX® plus standard of care Oral Rehydration Therapy (ORT). Two 50mg tablets will be administered twice daily.
62292923|NCT04026984|PLACEBO_COMPARATOR|Placebo tablets plus ORT|Matching placebo tablets plus standard of care Oral Rehydration Therapy (ORT)
61908431|NCT05633303|EXPERIMENTAL|Patients without underlying LVZs (<30% of LVZs in the LA body)|"Study 1- Mechanistic importance of GP site ablation. Twenty patients.~Study 2- GP site ablation in addition to PV isolation and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~Study 3- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients."
61908432|NCT00254267|EXPERIMENTAL|Arm One|AMG 706 125mg, oral, once a day
62292924|NCT02690701|EXPERIMENTAL|Secukinumab|Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
62292925|NCT02690701|PLACEBO_COMPARATOR|Placebo then Secukinumab|"Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8.~Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive."
62292926|NCT06351293|EXPERIMENTAL|Defyne Treatment|Defyne will be injected into the left or right nasolabial fold, per randomization.
62292927|NCT06351293|ACTIVE_COMPARATOR|RHA3 Treatment|RHA3 will be injected into the left or right nasolabial fold, per randomization.
62292928|NCT01508455|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
61908433|NCT04670627||Seasonal Allergic Rhinitics|"Non-smoking males and females aged 18-70 years, inclusive with history of Seasonal Allergic Rhinitis defined by:~Sensitization to at least one seasonal aeroallergen via skin prick testing (wheal =3 mm than negative control), AND History of physician-diagnosed seasonal allergic rhinitis, OR Symptoms consistent with seasonal allergic rhinitis, such as runny nose, nasal congestion, sneezing, or nasal pruritis."
61908434|NCT04670627||Control|Non-smoking males and females aged 18-70 years, inclusive with no history of physician-diagnosed allergic rhinitis and no history of seasonal runny nose, nasal congestion, sneezing or nasal pruritis. Negative results to a panel of aeroallergens via skin prick testing.
61908435|NCT00958438|PLACEBO_COMPARATOR|Placebo|Two subcutaneous injections of Placebo (for Rilonacept ) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
61908436|NCT00958438|EXPERIMENTAL|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
61908437|NCT00958438|EXPERIMENTAL|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
61908438|NCT01449942|EXPERIMENTAL|DZ1|DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
61908439|NCT01449942|PLACEBO_COMPARATOR|Saline|Placebo group receives saline injection in combination with radiation therapy.
61908440|NCT02929043||Dentine hypersensitivity subjects|
61908441|NCT04565327|EXPERIMENTAL|Cohort A: Single Dose/Image|Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than one minute then undergo MRI over 5 minutes at baseline
62658940|NCT01334359|PLACEBO_COMPARATOR|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
62736873|NCT04368299|EXPERIMENTAL|Telemedicine|Telemedicine group will receive scheduled follow-ups via videoconferencing.
62095484|NCT00350532|ACTIVE_COMPARATOR|Neuropathic Pain Subjects|Chronic Pain Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
62292929|NCT03445702|EXPERIMENTAL|Metformin intolerant & metformin|Metformin 1000mg once
61908442|NCT04565327|EXPERIMENTAL|Cohort B: Multiple Dose/Images|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute then undergo MRI over 5 minutes at baseline and 4 weeks after beginning treatment
61908443|NCT01239732|EXPERIMENTAL|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first). Participants will receive paclitaxel 175 mg/m\^2 IV on Day 1 every 3 weeks or 80 mg/m\^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first).
61908444|NCT02996058|ACTIVE_COMPARATOR|DEX I 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
62465483|NCT04334798|EXPERIMENTAL|PFM&electro&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation and electrostimulation, together with transabdominal ultrasound biofeedback (BFB).
61908445|NCT02996058|ACTIVE_COMPARATOR|DEX II 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale.
62095485|NCT00350532|ACTIVE_COMPARATOR|Healthy Subjects|Healthy Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
62292930|NCT03445702|PLACEBO_COMPARATOR|Metformin intolerant & placebo|Placebo 1000mg once
62292931|NCT03445702|ACTIVE_COMPARATOR|Metformin tolerant & metformin|Metformin 1000mg once
62292932|NCT03445702|PLACEBO_COMPARATOR|Metformin tolerant and placebo|Placebo 1000mg once
62292933|NCT00900003||pancreatic cancer patients|pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
62292934|NCT02964156|EXPERIMENTAL|Walking test using insoles|Supersole
62465484|NCT04334798|EXPERIMENTAL|PFM&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with transabdominal ultrasound biofeedback (BFB).
62465485|NCT06518785|EXPERIMENTAL|VS LIFU/ VPL LIFU|Participants will be assigned to receive VS LIFU during the first LIFU treatment session.
62465486|NCT06518785|ACTIVE_COMPARATOR|VPL LIFU/VS LIFU|Participants will be assigned to receive VPL LIFU during the first LIFU treatment session.
62292935|NCT02964156|EXPERIMENTAL|Walking test not using insoles|no intervention
62292936|NCT02457234|EXPERIMENTAL|Cultural Immersion Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons within a cultural immersion context as part of the camp program.
62292937|NCT02457234|ACTIVE_COMPARATOR|University Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons in addition to camp activities that did not include cultural immersion.
62292938|NCT02457234|NO_INTERVENTION|Recreational Children's Sports Day Camp|Participants in this group participated in existing camp activities that were exclusively physical activity.
62292939|NCT01380054||patients with pulmonary hypertension|
62292940|NCT05519631||subacute stroke|Participants were evaluated for clinical outcome before the electroencephalogram examination. They were evaluated with the National Institute of Health Stroke Scale (NIHSS) to quantify the severity and magnitude of neurological deficit after stroke and by the Montreal Cognitive Assessment (MoCA) to assess cognitive function.
62292941|NCT05519631||chronic stroke|Participants were evaluated for clinical outcome before the electroencephalogram examination. They were evaluated with the National Institute of Health Stroke Scale (NIHSS) to quantify the severity and magnitude of neurological deficit after stroke and by the Montreal Cognitive Assessment (MoCA) to assess cognitive function.
62292942|NCT05519631||healthy|Only the EEG will be collected
62292943|NCT02612909|PLACEBO_COMPARATOR|Phase 2: Placebo|Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
62095486|NCT01813955|EXPERIMENTAL|Papaverine|Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)
62095487|NCT06217068|EXPERIMENTAL|Sedentary Individuals - Acute Moderate-Intensity Exercise|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
62095488|NCT06217068|EXPERIMENTAL|Active Individuals - Acute Moderate-Intensity Exercise|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
62095489|NCT00928109|EXPERIMENTAL|Cognitive Behavioral Couples Therapy (CBCT)|CBCT is a 20-week program consisting of 1-hour sessions between a couple and a therapist. In this program, couples learn about ways to communicate about their relationship in the context of experiencing anorexia nervosa. CBCT focuses on couple-specific skills such as communication and targets relationship domains such as exercise, body image and sexuality, eating together as a couple, and broader relationship concerns outside of anorexia nervosa.
62095490|NCT00928109|ACTIVE_COMPARATOR|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
62095491|NCT06548035|NO_INTERVENTION|Control|The control condition will be a one-time, \~90-minute, didactic stress management session (with no interventionist follow-up). The session will provide information on the four-component model of stress and the energy battery exercise (asks participants to reflect on stressors and things that offset stress).
62292944|NCT02612909|ACTIVE_COMPARATOR|Phase 2: Vaccine (15 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
62292945|NCT02612909|ACTIVE_COMPARATOR|Phase 2: Vaccine (30 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
62292946|NCT02612909|PLACEBO_COMPARATOR|Phase 3: Placebo|Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
62292947|NCT02612909|EXPERIMENTAL|Phase 3: Vaccine|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
62658941|NCT01715285|EXPERIMENTAL|Abiraterone acetate + Prednisone + ADT|Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.
62658942|NCT01715285|PLACEBO_COMPARATOR|Placebo + Androgen Deprivation Therapy (ADT)|Participants will receive placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.
62465487|NCT04840797||Suspected Sudden Cardiac Arrest|All subjects with suspected of a circulatory arrest of any cause.
62465488|NCT00254644||Dyslexia|adults from 18-35 ans.
61908446|NCT03409978||In-Motion app for movement analysis|Participants will be recruited from infants referred to the high-risk follow-up clinic at the hospital. These at-risk children are included in the regular clinical follow-up program comprising a standard examination at 3 months corrected age (fidgety general movements period). Infant/families from St. Olavs Hospital (n= 15), in Norway, Lurie Children's Hospital (n=15), Chicago, USA, Christian Medical College (n=15), Vellore, India, University of Ghent (n=15), Belgium, and Hillerød Hospital (n=30), Copenhagen, Denmark will be invited to participate.
62465489|NCT00254644||Control|adults from 18-35 ans.
62465490|NCT04500353|ACTIVE_COMPARATOR|Routine face mask application|Routine application of a face mask shortly after birth to deliver continuous positive airway pressure (CPAP)
62465491|NCT04500353|EXPERIMENTAL|Selective face mask application|Selective application of a face mask to give positive pressure ventilation (PPV) for apnoea or bradycardia \[heart rate (HR) \< 100 beats per minute (bpm)\] at any time in the delivery room (DR); or to give CPAP for signs of respiratory distress after 5 minutes of life
62465492|NCT04649411|EXPERIMENTAL|Ferric citrate|Participants aged 12 to \<18 years and 6 to \<12 years will receive ferric citrate for 24 weeks at a starting dose based on body weight categories.
62465493|NCT04649411|ACTIVE_COMPARATOR|Standard of care|Participants aged 12 to \<18 years and 6 to \<12 years will receive standard of care treatment for 24 weeks.
62465494|NCT01474551|EXPERIMENTAL|vemurafenib|This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
62658943|NCT02780388|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
62658944|NCT02780388|EXPERIMENTAL|VIB4920 75 mg|Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
62658945|NCT02780388|EXPERIMENTAL|VIB4920 500 mg|Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
62292948|NCT00058461|EXPERIMENTAL|Treatment (chemotherapy, rituximab)|Patients receive ifosfamide IV over 2 hours and etoposide IV over 1 hour on days 3-5, rituximab IV on days 1 and 3, and carboplatin IV over 1 hour on day 3. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Patients also receive intrathecal (IT) chemotherapy comprising methotrexate and cytarabine. Patients with B-cell large cell lymphoma and negative CSF cytology receive IT chemotherapy on day 3 of the first course only. Patients with small non-cleaved cell lymphoma or B-cell acute lymphoblastic leukemia and negative CSF cytology receive IT chemotherapy on day 3. All patients with positive CSF cytology receive IT chemotherapy on days 3, 10, and 17 of the first and second courses. Treatment repeats every 23 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62292949|NCT03719235|OTHER|column|ultra-low dose CBCT versus digital panoramic radsiography
62465495|NCT02554370|EXPERIMENTAL|Psychoeducational programme|Psychoeducational programme
62465496|NCT02554370|NO_INTERVENTION|Usual care|No psychoeducational programme
62465497|NCT06158451|EXPERIMENTAL|Zinc-oxide Propolis (Zno-P)|Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed and added after minimal instrumentation until size 20 to remove all the accessible necrotic pulp and placed on the pulpal floor and intracanal.
62465498|NCT06158451|ACTIVE_COMPARATOR|Modified triple antibiotic paste|Metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt) will be mixed and added after minimal instrumentation until size 20 to remove all the accessible necrotic pulp and placed on the pulpal floor and intracanal.
62292950|NCT03195894|EXPERIMENTAL|Conventional treatment and TripleA|Conventional treatment and TripleA medical device consisting of alcoholometer, a Bluetooth mobile app on cell phone and information stored on computer for caregiver
62292951|NCT03195894|NO_INTERVENTION|Conventional treatment|Conventional treatment
62292952|NCT00570245|NO_INTERVENTION|A|Neither donors or recipients will receive NO
62292953|NCT00570245|ACTIVE_COMPARATOR|B|Donor will not receive NO, recipient will receive up to 48 hours of NO
62292954|NCT00570245|ACTIVE_COMPARATOR|C|The donor will receive NO for 3 hours and the recipient will receive NO for up to 48 hours
62292955|NCT01305499|EXPERIMENTAL|A: 5AC days 1-10 / entinostat days 3, 10|Arm A will be given an overlapping schedule of drugs with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle and entinostat given at a flat dose of 8 mg orally on days 3 and 10.
62658946|NCT02780388|EXPERIMENTAL|VIB4920 1000 mg|Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
62292956|NCT01305499|EXPERIMENTAL|B: 5AC days 1-10 / entinostat days 10,17|In Arm B the agents will be administered sequentially with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle followed by entinostat at a 8 mg flat dose on days 10 and 17.
62292957|NCT03716479|EXPERIMENTAL|0 fiber|0 grams fiber added to orange juice
62292958|NCT03716479|EXPERIMENTAL|low fiber|20 grams of acacia gum added to orange juice
62292959|NCT03716479|EXPERIMENTAL|high fiber|40 grams of acacia gum added to orange juice
62292960|NCT01472484|EXPERIMENTAL|lpa with high polyphenol|
62292961|NCT01472484|EXPERIMENTAL|lpa with low polyphenol|
62292962|NCT01472484|EXPERIMENTAL|control bean with low polyphenol|
62465499|NCT00846495|ACTIVE_COMPARATOR|topiramate|Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.
62465500|NCT00846495|ACTIVE_COMPARATOR|frovatriptan|Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).
62465501|NCT01371786|EXPERIMENTAL|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
62465502|NCT01371786|ACTIVE_COMPARATOR|mometasone|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
62658947|NCT02780388|EXPERIMENTAL|VIB4920 1500 mg|Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.
62658948|NCT04489368||Study Group|Patients undergoing NA-CCRT followed by Surgery
62292963|NCT01472484|EXPERIMENTAL|control bean with high polyphenol|
62292964|NCT00522392|EXPERIMENTAL|Arm A (VRD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
62292965|NCT00522392|ACTIVE_COMPARATOR|Arm B (VD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
62736874|NCT04368299|ACTIVE_COMPARATOR|Standard care|Standard care group patients will continue conventional standard in-person outpatient care.
62292966|NCT02204904||Allo-HSCT prospective|Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
62095492|NCT06548035|EXPERIMENTAL|Intervention|The intervention condition will consist of six one-hour group sessions. The sessions will provide information on topics including relaxation response, the components of stress, recuperative sleep, mindful awareness, resilience, and social support. Sessions will also include practice-based exercises (e.g., breathing exercises, mindfulness exercises). Participants will also have the option of accessing a closed WhatsApp group moderated by the interventionist. The interventionist will initiate chats in between group sessions to provide support to participants in practicing stress management skills. All intervention sessions will be delivered by a trained professional nurse, who will be trained and closely supervised by the study team members. Individual supervision will be provided at least bi-weekly, with opportunities for group supervision with US interventionists using the 3RP intervention in other studies as needed.
62736875|NCT02038777|EXPERIMENTAL|Monotherapy Cohort|PF-04449913 Monotherapy
62095493|NCT05391802|EXPERIMENTAL|Treatment group|Patients with PMR erolled in the trail will receive transcatheter mitral valve repair using the ValveClasp system
62095494|NCT04931680||Patients with treatment success|"Patients with diagnosis of confirmed or clinical scabies and treatment success"
62095495|NCT04931680||Patients with treatment failure|"Patients with diagnosis of confirmed or clinical scabies and treatment failure"
62095496|NCT04975581|EXPERIMENTAL|Rotator cuff repair Surgery with Augmentative patch|Open rotator cuff repair Surgery with additional application of augmentative human allograft patch
62095497|NCT04975581|ACTIVE_COMPARATOR|Rotator cuff repair surgery|Open Rotator cuff repair surgery
62095498|NCT03737253|ACTIVE_COMPARATOR|Follitropin alpha|Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
62095499|NCT03737253|ACTIVE_COMPARATOR|Menotropin|Menotropin (Menopur, Ferring GmbH, Kiel, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
62095500|NCT01884974||myeloproliferative disease|Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
62095501|NCT04236713|EXPERIMENTAL|Dietary intervention 1|
62095502|NCT04236713|EXPERIMENTAL|Dietary intervention 2|
62095503|NCT03670186|EXPERIMENTAL|V66V-HIIT|Val/Val carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
62095504|NCT03670186|EXPERIMENTAL|V66M-HIIT|Val/Met carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
62095505|NCT01444066|PLACEBO_COMPARATOR|dilation to 27 French|
62465503|NCT03642769|ACTIVE_COMPARATOR|Lactated Ringer|Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
62465504|NCT03642769|EXPERIMENTAL|Normal Saline|Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
62465505|NCT05427643|EXPERIMENTAL|study group|"patients need dental implants with narrow alveolar ridge of less than 6 mm horizontal width .~they will receive dental implants with I_PRF mixed with synthetic bone graft."
62095506|NCT01444066|EXPERIMENTAL|Dilation of the esophagus to 54 French|Esophagus will be dilated with a Savory dilator
62095507|NCT06696846|EXPERIMENTAL|CD70 CAR-NK for the treatment of CD70-positive relapsed/refractory T-cell lymphoma and AML|The first stage is a dose escalation study, with three CD70 CAR-NK dose levels. Each dose level is planned to recruit 3 to 6 subjects to evaluate safety and efficacy and determine the number of CD70 CAR-NK cells for treatment in the second stage. The second stage is the dose expansion stage, where 30 subjects are recruited to receive the number of CD70 CAR-NK cells recommended in the first stage.
62095508|NCT04602962||Fertility preservation performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
62095509|NCT04602962||Fertility preservation not performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
62095510|NCT02320253|ACTIVE_COMPARATOR|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
62095511|NCT02320253|EXPERIMENTAL|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
62095512|NCT02320253|EXPERIMENTAL|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
62736876|NCT02038777|EXPERIMENTAL|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
62292967|NCT02204904||Allo-HSCT partial prospective/retrospective|Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on study. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
62095513|NCT06351748||Participants with T2DM|Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023.
62095514|NCT05568719|OTHER|Hemophilia A / giroctocogene fitelparvovec|Participants have received treatment with giroctocogene fitelparvovec in a previous study and are not receiving any investigational product in this study
62095515|NCT05568719|OTHER|Hemophilia B / fidanacogene elaparvovec|Participants have received treatment with fidanacogene elaparvovec in a previous study and are not receiving any investigational product in this study
62095516|NCT05397106||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
62095517|NCT02998164|EXPERIMENTAL|Technology-assisted language intervention|This intervention will incorporate augmentative and alternative communication software delivered on iPads into speech-language therapy
62095518|NCT02998164|ACTIVE_COMPARATOR|usual care|This group will be usual care children are already receiving.
62095519|NCT03833011|NO_INTERVENTION|no intervention|
62095520|NCT03833011|EXPERIMENTAL|Osteopathic manipulation|
62095521|NCT06340854|EXPERIMENTAL|Insulin icodec|Participants will receive Insulin icodec subcutaneously once weekly.
62095522|NCT06340854|ACTIVE_COMPARATOR|Insulin glargine U100|Participants will receive Insulin glargine subcutaneously once daily.
62095523|NCT04302675|EXPERIMENTAL|Prevention, Maternal Immunization|
62095524|NCT01259687||Study group|
62095525|NCT06549309|ACTIVE_COMPARATOR|Experimental|JMKX003801
62095526|NCT06549309|PLACEBO_COMPARATOR|Placebo Comparator|Normal saline
62095527|NCT06583837|EXPERIMENTAL|Orelabrutinib followed by response-adapted ultra-low dose 4Gy radiation|Orelabrutinib was administrated for 12 weeks, followed by response-adapted ultra-low dose 4Gy radiation for local stage MALT EMZL
62095528|NCT02782988||CMV symptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
62095529|NCT02782988||CMV asymptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
62292968|NCT02204904||Allo-HSCT retrospective|Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.
62292969|NCT03172689|OTHER|CardioQ|CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor
62465506|NCT05427643|EXPERIMENTAL|control group|patients need dental implant with adequate horizontal bone with of more than 6 mm.
62465507|NCT03623230|SHAM_COMPARATOR|GCont|Only dressing will be applied to patients without actually nerve block performed
62465508|NCT03623230|ACTIVE_COMPARATOR|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
62095530|NCT02782988||Healthy controls|olfactory tests, otoacoustic emissions (OAE)
62095531|NCT04122924|EXPERIMENTAL|Intervention Group|A three months home-based abdominal muscle training program.
62095532|NCT04122924|NO_INTERVENTION|Control Group|The control group will have no intervention, and will be asked not to attend any specific supervised abdominal muscle training program during the 3 months intervention period.
62095533|NCT00315627|EXPERIMENTAL|islet transplantation|Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
62095534|NCT05090423|EXPERIMENTAL|Experimental: balance training alone|The subjects will receive the balance training twice a week for 6 weeks.
62095535|NCT05090423|EXPERIMENTAL|Experimental: balance training and neurodynamic intervention for the common peroneal nerve|The subjects will receive the balance training and neurodynamic intervention for the common peroneal nerve twice a week for 6 weeks.
62095536|NCT01653743|EXPERIMENTAL|MSJ-0011|
62095537|NCT01653743|ACTIVE_COMPARATOR|urinary hCG|
62095538|NCT04854486|EXPERIMENTAL|Treatment Group|Xylitol + GSE
62095539|NCT04854486|PLACEBO_COMPARATOR|Control placebo|Saline
62095540|NCT04293991|ACTIVE_COMPARATOR|High flow nasal cannula (HFNC) group|HFNC group will receive immediate connection to HFNC with a flow of 60L/min, and FIO2 adjusted to have SpO2 of 92% or more, through a heated humidifier and a oxygen blender of the same machine. In case of patient intolerance to high flow, flow will be diminished to the highest tolerated by the patient. Patients will be encouraged to have their mouth closed during HFNC to augment positive end expiratory pressure (PEEP) created by high flow.
62292970|NCT03185546|EXPERIMENTAL|Normal Nicotine Content (NNC) cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
62095541|NCT04293991|ACTIVE_COMPARATOR|Non invasive ventilation (NIV) group|NIV group, patients will be connected to ICU ventilatoron NIV mode for at least 4 hours, through a NIV continuous positive airway pressure (CPAP)mask with ventilator settings; pressure support (PS) level of 8 cmH2O and PEEP level of 5 cmH2O,which can be increased to 10 cmH2O to maintain tidal volume between 6-8 ml/Kg and FiO2 adjusted to keep SpO2 equal or more than 92%.At least patient will be on NIV for 12 hours during the day, alternating with Venturi mask 10-15 L/min to keep FiO2 equal or more than 92%.
62292971|NCT03185546|EXPERIMENTAL|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
62292972|NCT03185546|EXPERIMENTAL|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
62292973|NCT03185546|EXPERIMENTAL|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
62292974|NCT03185546|EXPERIMENTAL|Very Low Nicotine Content (VLNC) cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
62292975|NCT03185546|EXPERIMENTAL|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
62292976|NCT03185546|EXPERIMENTAL|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
62292977|NCT03185546|EXPERIMENTAL|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
62292978|NCT04326530||Persistent asthmatic children|"150 steroid-naive, persistent asthmatic children enrolled during their first consultation at the IRIB-CNR outpatient clinic.~They will underwent three visits:~1. screening visit (-2 days);~2. baseline visit (day 0);~3. last visit (+90 days).~They will be treated with controller medications according to GINA recommendations (http://ginasthma.org)."
62292979|NCT01994083|PLACEBO_COMPARATOR|Placebo|Placebo
61908447|NCT04592952|EXPERIMENTAL|Single-Arm|"Provocation Phase: Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.~Open-Label Treatment Phase: Erenumab packed in a SureClick® Autoinjector Pen (AI)"
61908448|NCT01278927|ACTIVE_COMPARATOR|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief (10 minute) personalized introduction to the home-based exercise intervention. On Day 30 post hematopoietic cell transplantation (HCT), participants will meet briefly with the same interventionist when possible. To minimize contamination across intervention conditions, participants randomized to Exercise will be provided with only general advice regarding stress management (i.e., to continue using any techniques they currently use to manage stress). The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant.
61908449|NCT01278927|ACTIVE_COMPARATOR|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief standardized introduction to the self-administered intervention. On Day 30 post HCT, the interventionist will meet with the participant to answer any questions about the intervention, encourage the continued use of stress management techniques as recommended, and monitor for any adverse reactions to use of the techniques. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
61908450|NCT01278927|ACTIVE_COMPARATOR|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions. On Day 30 post HCT, the same interventionist will meet with the participant briefly to answer any questions about the interventions, encourage the continued use of the interventions as recommended, and monitor for any adverse reactions. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
61908451|NCT01278927|OTHER|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive a digital video disc (DVD). The interventionist will briefly discuss the topics of the DVD and elicit questions. To minimize contamination across intervention conditions, participants randomized to the control group will be provided with only general advice about exercise and stress management during treatment (i.e., to maintain any usual patterns of exercise to the extent possible and to continue using any techniques they currently use to manage stress).
62095542|NCT00974298||Elbow replacement|There are no other arms other then an uncemented total elbow replacement.
62095543|NCT05578092|EXPERIMENTAL|Phase 1/1B Monotherapy|Dose Escalation/Evaluation
62292980|NCT01994083|EXPERIMENTAL|IX-01|Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
62292981|NCT04658602|ACTIVE_COMPARATOR|Direct composite restoration|Bulk-fill composite (Filtek bulk flow, 3M Espe ) will be used and covered using a nanohybrid copmosite (filtek XT, 3M Espe )
62465509|NCT03623230|ACTIVE_COMPARATOR|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
62658949|NCT02410330||Group I|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with Therapeutic ultrasound with 20 usec: custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 MI designed for the 1.7 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
62658950|NCT02410330||Group II|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with repeated diagnostic high mechanical index impulses (all \<2 usec pulse duration; MI=1.0) whenever very low MI perfusion imaging detected microbubbles within the microvasculature. Treatment will be applied while patient waits for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
62095544|NCT05578092|EXPERIMENTAL|Phase 1/1B Combination Therapy|Dose Escalation/Evaluation and Food Effect Assessment
62095545|NCT05578092|EXPERIMENTAL|Phase 2|MRTX0902 and adagrasib combination RP2D administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12C mutation to include the following: NSCLC, CRC, Other Solid Tumors
62095546|NCT00688688|EXPERIMENTAL|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
62095547|NCT00688688|EXPERIMENTAL|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
62095548|NCT00688688|ACTIVE_COMPARATOR|Tolterodine ER 4 mg|Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.
62095549|NCT02338037|EXPERIMENTAL|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62095550|NCT01237392|ACTIVE_COMPARATOR|Contact Ultrasonic Debridement Device|
62292982|NCT04658602|ACTIVE_COMPARATOR|Preformed metal crowns|Preformed stainless-steal crowns cemented by glass ionomer lutting cement (ketac cem. 3M Espe )
62095551|NCT01237392|ACTIVE_COMPARATOR|Standard Sharp Debridement|
62292983|NCT00140855|EXPERIMENTAL|ipilimumab|Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.
62292984|NCT01053429||observational cohort|
62292985|NCT04908995|EXPERIMENTAL|EC5026|Single 8 mg oral dose of EC5026
62292986|NCT04908995|PLACEBO_COMPARATOR|Placebo|Single dose of matching oral placebo
62292987|NCT05462184|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy (CBT)|CBT followed Craske \& Barlow´s (2007) manual, which contains a session-by-session description treatment of panic disorder with CBT. The treatment included the following components: (a) psychoeducation about the nature of anxiety and panic, (b) diaphragmatic breathing training, (c) identification and correction of maladaptive thoughts about anxiety and its consequences, (d) exposure to interoceptive sensations, and (e) exposure to feared situations.
62292988|NCT05462184|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|"ACT was conducted following Eifert \& Forsyth´s (2005) manual, which contains a session-by-session description of the application of ACT to anxiety disorders. In the current study, exercises were adapted to the panic disorder treatment. The treatment included the following components: (a) acceptance of internal experiences, (b) cognitive defusion, (c) work with the self as context, (d) contact with the present moment, (e) work with life values, and values, and (f) commitment to action."
62292989|NCT04720703|EXPERIMENTAL|Intervention Group|The Intervention Group will receive the Family-based Telehealth Intervention for the first three months of the study period. Once they have completed the intervention, there will be a two-week washout period. After the washout period, they will receive monthly newsletters, with similar information learned in the intervention, for three months until the end of the study period.
62465510|NCT04625348|EXPERIMENTAL|residents|daily care of 40 residents will be provided on the Ultracore Repose® mattress
62465511|NCT02962726||Patients|100 female patients between the age of 12 and 18 years suffering from anorexia nervosa.
62465512|NCT02962726||Age matched Controls|100 females volunteers between the age of 12 and 18 years old without eating disorder.
62658951|NCT02410330||Group III|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) while few limited diagnostic high MI impulses (n\<5 per patient) will be applied to assess myocardial perfusion before and after percutaneous coronary intervention (PCI).
62658952|NCT03186664|EXPERIMENTAL|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
62658953|NCT03186664|ACTIVE_COMPARATOR|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
62095552|NCT06256003|ACTIVE_COMPARATOR|UC-A|UC-0A is a digital mobile app intervention that uses cognitive control skills for task performance. The intervention is used once a day, 5 days a week, for 7 weeks.
62292990|NCT04720703|ACTIVE_COMPARATOR|Wait-list Control Group|The Waitlist Control Group will receive monthly newsletters, with similar information learned in the intervention, for the first three months of the study period while the Intervention Group receives the intervention. Then, there will be a two-week washout period. After the washout period, they will receive the Family-based Telehealth Intervention for 3 months until the end of the study period.
62292991|NCT03890809|EXPERIMENTAL|Normal liver function|Single dose
62292992|NCT03890809|EXPERIMENTAL|Mild liver impairment|Single dose
62292993|NCT03890809|EXPERIMENTAL|Moderate liver impairment|Single dose
62292994|NCT03890809|EXPERIMENTAL|Severe liver impairment|Single dose
62292995|NCT00575861|ACTIVE_COMPARATOR|1|Advair 250/50 (baseline) fluticasone/salmeterol 250/50
62292996|NCT04052737|ACTIVE_COMPARATOR|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, the same dosing regimen will be repeated every month for 6 months post randomization.
62292997|NCT04052737|EXPERIMENTAL|PMZ-1620 (sovateltide)|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1 (total dose/day: 0.9 µg/kg body weight), the same dosing regimen will be repeated every month for 6 months post randomization.
62292998|NCT02494570|EXPERIMENTAL|nab-Sirolimus|Patients with malignant PEComa received nab-sirolimus on Days 1 and 8 of every 21-day cycle, as a 30-minute IV infusion.
62292999|NCT04668560|EXPERIMENTAL|Intervention|Course intervention, six weeks wellbeing course
62293000|NCT04668560|NO_INTERVENTION|Control|Follow-up as usual
62465513|NCT00319735|EXPERIMENTAL|Investigational Treatment|"* Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose)~* Cetuximab 250 mg/m2 IV over 60 minutes Day -7~* Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36~* Combined with radiation therapy for six weeks.~* Surgery for esophageal resection after 6 to 8 week rest period.~Subjects who consent will provide tissue samples."
62465514|NCT00119015|PLACEBO_COMPARATOR|Fluticasone propionate + Placebo|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Placebo - 10 mg po daily for 2 weeks"
62095553|NCT06256003|ACTIVE_COMPARATOR|UC-N|UC-0N is a digital mobile app intervention that uses cog control skills for problem solving. The intervention is used once a day, 5 days a week, for 7 weeks.
62095554|NCT05457244|EXPERIMENTAL|Participant arm|
62095555|NCT05893043|EXPERIMENTAL|Cohort 1: GSBR-1290 or Placebo|Healthy Japanese participants will receive once daily doses of study drug (GSBR-1290 or placebo oral capsules) for up to 4 weeks.
62095556|NCT05893043|EXPERIMENTAL|Cohort 2: GSBR-1290|Healthy non-Japanese participants (Caucasians or African Americans) will receive once daily doses of study drug (GSBR-1290 oral capsules) for up to 4 weeks.
62095557|NCT02518906|EXPERIMENTAL|Adolescent Identity Treatment|Psychotherapeutic treatment performed routinely at the centres in Basel and Santiago de Chile
62293001|NCT05148871|ACTIVE_COMPARATOR|3 week arm|Subjects will receive two doses of vaccine 3 weeks apart
62293002|NCT05148871|ACTIVE_COMPARATOR|4 week arm|Subjects will receive two doses of vaccine 4 weeks apart
62293003|NCT05148871|ACTIVE_COMPARATOR|5 week arm|Subjects will receive two doses of vaccine 5 weeks apart
62293004|NCT05148871|ACTIVE_COMPARATOR|6 week arm|Subjects will receive two doses of vaccine 6 weeks apart
62293005|NCT06166836|EXPERIMENTAL|Phase 1b-Dose Escalation Part|To evaluate the safety and Recommended Phase 2 dose (RP2D) of D-1553 in combination with IN10018 in previously-treated solid tumors.
62293006|NCT06166836|EXPERIMENTAL|Phase II Cohort A-previously-treated CRC with KRAS G12C mutation（Treatmnt Group）|To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in previously-treated CRCs with KRAS G12C mutation.
62293007|NCT06166836|ACTIVE_COMPARATOR|Phase II Cohort A-previously-treated CRC with KRAS G12C mutation (Control Group)|To evaluate the safety and antitumor efficacy of D-1553 in previously-treated CRCs with KRAS G12C mutation.
62293008|NCT06166836|EXPERIMENTAL|Phase II Cohort B-treatment-naïve or previously-treated NSCLC with KRAS G12C mutation|To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in advanced NSCLCs with KRAS G12C mutation.
62465515|NCT00119015|ACTIVE_COMPARATOR|Fluticasone propionate + Montelukast|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Montelukast - 10 mg po daily for 2 weeks"
62465516|NCT02836847|EXPERIMENTAL|target therapy|The patients wil receive conventional chemotherapy(GEMOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
62465517|NCT02836847|OTHER|GEMOX|The patients wil receive conventional chemotherapy(GEMOX).
62293009|NCT06166836|EXPERIMENTAL|Phase II Cohort C-other previously-treated solid tumors with KRAS G12C mutation|To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in other solid tumors with KRAS G12C mutation
62293010|NCT01191814|ACTIVE_COMPARATOR|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
62293011|NCT01191814|ACTIVE_COMPARATOR|Plastic Stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a plastic stent
62293012|NCT00864760|EXPERIMENTAL|A|Gabapentin 800 mg tablets, single dose (1 tablet)
62293013|NCT00864760|ACTIVE_COMPARATOR|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
62293014|NCT01849926|ACTIVE_COMPARATOR|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
62293015|NCT01849926|ACTIVE_COMPARATOR|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
62293016|NCT02323022|EXPERIMENTAL|IAC regimen|Receive IAC induction therapy
62293017|NCT02323022|ACTIVE_COMPARATOR|IA regimen|Receive an IA induction therapy
62293018|NCT05177055|EXPERIMENTAL|n=15, sleep-school 6 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep-school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
62293019|NCT05177055|EXPERIMENTAL|n=15, sleep-school 6 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
62293020|NCT05177055|ACTIVE_COMPARATOR|n=30 Six-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
62293021|NCT05028621|EXPERIMENTAL|Genomic analysis|When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
62293022|NCT02452333|EXPERIMENTAL|Evidence-based Oncoplastic Algorithm|Oncoplastic Approach Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
62293023|NCT02452333|EXPERIMENTAL|Control|- Conventional Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
62293024|NCT02544555|EXPERIMENTAL|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
62293025|NCT02544555|ACTIVE_COMPARATOR|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
62293026|NCT04256967||Sport sciences|Bachelor and master students who study sport science or physical activity and health science
62293027|NCT04256967||Controls|Bachelor and master students who study other fields not related to sport or physical activity and health sciences.
62293028|NCT04178655|EXPERIMENTAL|Tranexamic Acid Treatment|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
62293029|NCT04178655|PLACEBO_COMPARATOR|Placebo|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
62293030|NCT00925600|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
62293031|NCT00925600|EXPERIMENTAL|Denosumab|Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
62293032|NCT02571348|ACTIVE_COMPARATOR|4 weeks and 8 weeks|Micro-osteoperforation will be done on either side of the maxilla at 4 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 8 weeks and the contralateral site will serve as the control
62293033|NCT02571348|ACTIVE_COMPARATOR|8 weeks and 12 weeks|Micro-osteoperforation will be done on either side of the maxilla at 8 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 12 weeks and the contralateral site will serve as the control
62293034|NCT02571348|ACTIVE_COMPARATOR|12 weeks and 4 weeks|Micro-osteoperforation will be done on either side of the maxilla at 12 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 4 weeks and the contralateral site will serve as the control
62293035|NCT01886118|EXPERIMENTAL|Autologous Endometrial Co-Culture|The embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5.
62293036|NCT01886118|ACTIVE_COMPARATOR|Conventional media culture|Patients in this arm will have their embryos cultured in conventional media
62293037|NCT04139122|EXPERIMENTAL|Cohort 1-4: SJP-0132|Each cohort will receive a single dose of 1 of 4 strengths of SJP-0132
62293038|NCT04139122|PLACEBO_COMPARATOR|Cohort 1-4: Placebo|Single dose of placebo
62293039|NCT04139122|EXPERIMENTAL|Cohort 5-6: SJP-0132|Cohort 5 SJP-0132 will receive the second maximum acceptable dose from Cohorts 1-4 for 4 weeks. Cohort 6 SJP-0132 will receive the maximum acceptable dose from Cohorts 1-4 for 4 weeks
62293040|NCT04139122|PLACEBO_COMPARATOR|Cohort 5-6: Placebo|Multiple dose placebo for 4 weeks
62293041|NCT01442298|ACTIVE_COMPARATOR|conventional treatment|the Standard method;tourniquet pressure based on systolic blood pressure, plus a safety margin.
62293042|NCT01442298|EXPERIMENTAL|limb occlusion pressure(LOP)|cuff pressure is based on limb occlusion pressure measurement
62293043|NCT01503216|EXPERIMENTAL|cholecalciferol|Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
61908452|NCT02061319|EXPERIMENTAL|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
61908453|NCT02061319|NO_INTERVENTION|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
61908454|NCT04203277|EXPERIMENTAL|Step Wedge Randomized Group 1|Includes two pediatric practices randomized to the first step of the step-wedge randomized trial
62293044|NCT01503216|EXPERIMENTAL|Ergocalciferol|Ergocalciferol 2000 IU per day for 8 weeks
62293045|NCT01503216|PLACEBO_COMPARATOR|Placebo|Placebo for 8 weeks
62465518|NCT03607097|EXPERIMENTAL|Secondary prevention of DRPs (medication code) (intervention)|The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence
61908455|NCT04203277|EXPERIMENTAL|Step Wedge Randomized Group 2|Includes two pediatric practices randomized to the second step of the step-wedge randomized trial
61908456|NCT04203277|EXPERIMENTAL|Step Wedge Randomized Group 3|Includes two pediatric practices randomized to the third step of the step-wedge randomized trial
61908457|NCT04203277|EXPERIMENTAL|Step Wedge Randomized Group 4|Includes two pediatric practices randomized to the fourth step of the step-wedge randomized trial
62095558|NCT02518906|EXPERIMENTAL|DBT-A|Psychotherapeutic treatment performed routinely at the centre in Heidelberg
62095559|NCT01096095|PLACEBO_COMPARATOR|Placebo|Placebo
62293046|NCT02507349|ACTIVE_COMPARATOR|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
62095560|NCT01096095|EXPERIMENTAL|Sodium phenylbutyrate|Active drug
62095561|NCT01141140|OTHER|M-NO-NR|Men (M) non-obese (NO) and non-restrained (NR).
62095562|NCT01141140|OTHER|M-NO-R|Men (M) non-obese (NO) and restrained (R).
62095563|NCT01141140|OTHER|M-O-NR|Men (M) overweight or obese (O) and non-restrained (NR).
62095564|NCT01141140|OTHER|M-O-R|Men (M) overweight or obese (O) and restrained (R).
62095565|NCT01141140|OTHER|W-NO-NR|Women (W) non-obese (NO) and non-restrained (NR).
62095566|NCT01141140|OTHER|W-NO-R|Women (W) non-obese (NO) and restrained (R).
62293047|NCT02507349|ACTIVE_COMPARATOR|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
62465519|NCT03607097|NO_INTERVENTION|Usual care (control group)|The patient is reviewed according to the standard procedure, consisting only on the review of the medical prescription in the emergency department by the pharmacist assisting the unit
62658954|NCT05901974|EXPERIMENTAL|Venetoclax Combined With azactidine in the Treatment of Acute Leukaemias of Ambiguous Lineage|Venetoclax combined with azacitidine regimen. Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
62658955|NCT03416179|EXPERIMENTAL|Arm A (Intensive Study)|Glasdegib + '7+3' Induction(s)
62293048|NCT04013126|EXPERIMENTAL|endometriosis|Women who undergoing surgery for removal of endometriosis implants
62293049|NCT04013126|ACTIVE_COMPARATOR|non-endometriosis|Women who undergoing surgery for removal of benign masses in the pelvis
62293050|NCT02786901|EXPERIMENTAL|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
62658956|NCT03416179|PLACEBO_COMPARATOR|Arm B (Intensive Study)|Placebo + '7+3' Induction(s)
62658957|NCT03416179|EXPERIMENTAL|Arm A (Non-intensive study)|Glasdegib + azacitidine
62658958|NCT03416179|PLACEBO_COMPARATOR|Arm B (Non-intensive study)|Placebo + azacitidine
62293051|NCT02786901|EXPERIMENTAL|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
62293052|NCT02786901|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle
62736877|NCT02038777|EXPERIMENTAL|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
62293053|NCT04537611|EXPERIMENTAL|dHb contrast compared to gadolinium contrast imaging|Subjects will be referred for a clinical gadolinium contrast perfusion exam. Gas manipulation will be supplied by a programmable computer-controlled gas delivery system while subjects are in the MRI scanner. In addition to their prescribed clinical scans, two additional scans will be obtained: 1) a structural sequence (, followed by 2) a BOLD-EPI sequence while inducing changes of PO2. PO2 will be held at a baseline of 45-50 mmHg for 60s. For 10 s, the lung PO2 will be transiently raised to peak PO2 of 90-120 mmHg (normoxia) within 2 s transition, and then returned to baseline. Alternatively, the baseline may be at normoxia and the gas challenges will target PO2 of 45-50 mmHg. A total of 4 such ventilatory challenges will be applied over 6 min while maintaining normocapnia.
62293054|NCT04035876|EXPERIMENTAL|Camrelizumab plus apatinib|
62293055|NCT01284881||OSAHS|
62293056|NCT01833871|EXPERIMENTAL|myometrial fibroid/adenomyoma|Patients scheduled for myomectomy or hysterectomy with preoperative diagnosis of uterine myoma, adenomyosis or both by ultrasound .Trans-vaginal 3D power Doppler and uterine artery doppler will be done for all participants prior to surgery.
62293057|NCT00801814|PLACEBO_COMPARATOR|1|White Bread
62293058|NCT00801814|PLACEBO_COMPARATOR|2|White Bread and Margarine Control
62293059|NCT00801814|PLACEBO_COMPARATOR|3|Glucose drink control
62293060|NCT00801814|EXPERIMENTAL|4|"White bread and margarine~or~Glucose drink"
62293061|NCT00801814|EXPERIMENTAL|5|"White bread and margarine~or~Glucose drink"
62293062|NCT00801814|EXPERIMENTAL|6|"White bread and margarine~or~Glucose drink"
62736878|NCT02038777|EXPERIMENTAL|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
62465520|NCT06265922|ACTIVE_COMPARATOR|High frequency cerebellar repetitive transcranial magnetic stimulation|Twenty patients will be treated by high frequency repetitive transcranial magnetic stimulation (Hf-rTMS) targeting the cerebellum beside a tailored physical therapy program designed for the ataxic manifestation The protocol of rTMS included 6 sessions over 2 weeks. MagPro R20 device will be applied over midline of cerebellum using circular coil. Ten repetition rate in 40 trains with one inter train interval will be applied two times within the same session, 5 minutes rest in between Tailored physiotherapy program for ataxic manifestation will be applied for 10 days in the same 2 weeks
61908458|NCT03359018|EXPERIMENTAL|apatinib plus anti-PD1 therapy arm|Every patients will received apatinib 250mg or 500mg orally daily and SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
62095567|NCT01141140|OTHER|W-O-NR|Women (W) overweight or obese (O) and non-restrained (NR).
62293063|NCT00828464|EXPERIMENTAL|clobetasol propionate foam|All subjects receive clobetasol propionate
62293064|NCT05395676|EXPERIMENTAL|Cognitive dual task training (CDT) Group|The CDT group (n = 20) will participate in games on Xbox one consoles that require a higher cognitive demand compared to those of the BDT group. The training sessions will include five different games that require participants to stand and use their hand reach function to interact with different cognitive (i.e. dual-tasking) skills, such as working memory, problem solving, Stroop effect, planning, attention and response time.
62465521|NCT06265922|SHAM_COMPARATOR|Sham cerebellar repetitive transcranial magnetic stimulation|"Twenty patients will be treated by sham cerebellar rTMS with the same parameters, same duration 6 sessions over 2 weeks except the coil will not be on the middle of the cerebellum instead it will be perpendicular away from it.~But the program of physiotherapy is the same"
62465522|NCT01813006|ACTIVE_COMPARATOR|Omega-3|Omega-3 fatty acids
62465523|NCT01813006|PLACEBO_COMPARATOR|Placebo|Placebo/olive oil
62465524|NCT05878730||good-responders (GR) to lithium in euthymic BD-1 individuals|
62465525|NCT05878730||non-responders (NR) to lithium in euthymic BD-1 individuals|
62465526|NCT01555411||No treatment|
61908459|NCT02683590|EXPERIMENTAL|sternum by a ceramic implant|The replacement of the sternum by a ceramic implant
61908460|NCT05139511|EXPERIMENTAL|Study group|IPL + laser refractive surgery
61908461|NCT05139511|PLACEBO_COMPARATOR|Control group|Laser refractive surgery without IPL
62095568|NCT01141140|OTHER|W-O-R|Women (W) overweight or obese (O) and restrained (R).
62095569|NCT02655653|EXPERIMENTAL|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
62095570|NCT02655653|EXPERIMENTAL|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
62095571|NCT01879878|EXPERIMENTAL|Verum, broccoli sprout grain|Active sulforaphane distributed in capsules each containing broccoli sprout grain
62095572|NCT01879878|PLACEBO_COMPARATOR|Placebo|Inactive substances (methylcellulose) with identical capsule and portion distribution
62095573|NCT06238466|ACTIVE_COMPARATOR|Part A1 (AZD1705)|Non-Asian participants will receive AZD1705 subcutaneously on Day 1.
62095574|NCT06238466|ACTIVE_COMPARATOR|Part A2 (AZD1705)|Japanese participants will receive AZD1705 subcutaneously on Day 1.
62095575|NCT06238466|ACTIVE_COMPARATOR|Part A3 (AZD1705)|Chinese participants will receive AZD1705 subcutaneously on Day 1.
62095576|NCT06238466|ACTIVE_COMPARATOR|Part B1 (AZD1705)|Non-Asian participants who may or may not be receiving moderate- or high-intensity statin therapy will receive AZD1705 subcutaneously on Day 1 and Day 29.
62095577|NCT06238466|ACTIVE_COMPARATOR|Part B2 (AZD1705)|Japanese participants not receiving statin therapy will receive AZD1705 subcutaneously on Day 1 and Day 29.
62095578|NCT06238466|ACTIVE_COMPARATOR|Part B3 (AZD1705)|Participants who may or may not be receiving moderate- or high-intensity statin therapy and with the additional diagnosis of type 2 diabetes will receive AZD1705 subcutaneously on Day 1 and Day 29.
62095579|NCT06238466|PLACEBO_COMPARATOR|Part A1 (Placebo)|Non-Asian participants will receive placebo on Day 1.
62095580|NCT06238466|PLACEBO_COMPARATOR|Part A2 (Placebo)|Japanese participants will receive placebo on Day 1.
62095581|NCT06238466|PLACEBO_COMPARATOR|Part A3 (Placebo)|Chinese participants will receive placebo on Day 1.
62095582|NCT06238466|PLACEBO_COMPARATOR|Part B1 (Placebo)|Non-Asian participants who may or may not be receiving moderate- or high-intensity statin therapy will receive placebo on Day 1 and Day 29.
62095583|NCT06238466|PLACEBO_COMPARATOR|Part B2 (Placebo)|Japanese participants not receiving statin therapy will receive placebo on Day 1 and Day 29.
62293065|NCT05395676|ACTIVE_COMPARATOR|Balance dual task (BDT) training Group|The BDT group (n = 20) will participate in the conventional training programme on Wii consoles that have been used by previous studies (Barcala et al. 2013; Chao et al. 2015; Kannan et al. 2019), to improve balance performance. The training sessions will include five different games that require participants to stand and use their weight shift to control the game while maintaining balance.
62293066|NCT00971308|EXPERIMENTAL|BMS-824393 (Panel 1)|
62293067|NCT00971308|EXPERIMENTAL|BMS-824393 (Panel 2)|
62293068|NCT00971308|EXPERIMENTAL|BMS-824393 (Panel 3)|
62293069|NCT00971308|EXPERIMENTAL|BMS-824393 (Panel 4)|
62293070|NCT00971308|EXPERIMENTAL|BMS-824393 (Panel 5)|
62293071|NCT02850848|EXPERIMENTAL|Entigin Film Coated Tablet 0.5mg|Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets
62736879|NCT02038777|EXPERIMENTAL|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
61908462|NCT03032302|EXPERIMENTAL|Multivitamin|Swisse Womens 50+ Ultivite Multivitamin. Once daily.
62095584|NCT06238466|PLACEBO_COMPARATOR|Part B3 (Placebo)|Participants who may or may not be receiving moderate- or high-intensity statin therapy and with the additional diagnosis of type 2 diabetes will receive placebo on Day 1 and Day 29.
62095585|NCT04872062||Chronic hypercapnic respiratory failure treated by home non-invasive ventilation (NIV)|
62095586|NCT05098015|EXPERIMENTAL|Intervention|8-session group intervention to train participants to engage in HIV prevention advocacy.
62095587|NCT05098015|NO_INTERVENTION|Usual care control|Participants will receive HIV usual care, and no added intervention.
62095588|NCT06697392||Prospective test set|
62293072|NCT02850848|ACTIVE_COMPARATOR|Baraclude 0.5mg Tablets|Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets
62293073|NCT02421861|EXPERIMENTAL|Anxiety Management (AM)|
62736880|NCT02038777|EXPERIMENTAL|Expansion Cohort of LDAC Combination for Efficacy|PF-04449913 in combination with LDAC to evaluate efficacy
61908463|NCT03032302|EXPERIMENTAL|Omega-3 Fatty Acids|Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
61908464|NCT03032302|NO_INTERVENTION|Control|Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
62095589|NCT04517591|EXPERIMENTAL|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
62293074|NCT02421861|PLACEBO_COMPARATOR|Usual Care (UC)|
62293075|NCT00882414|PLACEBO_COMPARATOR|ThromboVIT Placebo|Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.
62293076|NCT00882414|EXPERIMENTAL|ThromboVIT 1000|ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.
62293077|NCT00882414|EXPERIMENTAL|ThromboVIT 1500|Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).
62293078|NCT00882414|EXPERIMENTAL|ThromboVIT 500|ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.
62293079|NCT05792826|EXPERIMENTAL|BSZY Cream group|receiving BSZY Cream twice a day,in the morning and evening, for a period of four weeks.
62293080|NCT05792826|PLACEBO_COMPARATOR|emulsion matrix group|receiving the emulsion base twice a day, in the morning and evening, for a period of four weeks.
62293081|NCT00459030|EXPERIMENTAL|Print Communication|Cancer screening educational information mailed to patient's home one time after signing consent.
62465527|NCT06324682||Conventional right ventricular (RV) pacing|"The device (pace maker or implantable cardiac defibrillator) is implanted in the subcutaneous subclavian area (right or left) and it is connected to transvenous lead/leads (active or passive) implanted in the right cardiac chambers (atrium and ventricle or ventricle only), which detect intrinsic electrical activity and stimulate when needed. The ventricle pacing might be obtained with an apical or septal stimulation.~Vascular access might be from the cephalic, axillary or subclavian veins. Once positioned, lead's pacing threshold, sensing and impedance are measured. If the investigators find good and stable electrical parameters, the catheter(s) is(are) fixed and left in place."
62658959|NCT06075732|EXPERIMENTAL|ACTIVATE Leaders|This is a one group pretest-posttest design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by ACTIVATE triad leaders and researchers. The investigators will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention. PRISM, a Dissemination and implementation (D\&I) D\&I-based model can guide the implementation of the ACTIVATE program for successfully expansion and maintenance in community settings, especially for under-resourced populations.
62658960|NCT01687699|EXPERIMENTAL|spironolactone|
62095590|NCT04517591|NO_INTERVENTION|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels and health nutrition.
62658961|NCT05614076|EXPERIMENTAL|Conservation of the demineralized chalky white enamel margin of class V cavities|for cavity design in this arm we Conserved the demineralized chalky white enamel margin of class V cavities then application of resin composite restoration
62658962|NCT05614076|ACTIVE_COMPARATOR|Total removal of demineralized enamel margin of class V cavities|for cavity design in this arm is Total removal of demineralized enamel margin of class V cavities and restoration with resin composite
62095591|NCT04955587||Patients with longstanding complicated fatigue|The participants receive no intervention as part of this study.
62095592|NCT04955587||Healthy controls|The participants receive no intervention as part of this study.
62095593|NCT04955587||Controls with rheumatic disease|The participants receive no intervention as part of this study.
62658963|NCT04092764|EXPERIMENTAL|Participants Receiving Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks.
62095594|NCT04108910||Traditional Urine Culture|Patients treated based upon traditional urine culture
62095595|NCT04108910||Guidance PCR/Pooled Sensitivity|Patients treated based upon multiplex UTI PCR/pooled sensitivity results
62293082|NCT00459030|EXPERIMENTAL|Electronic communication|Cancer screening educational information delivered via a password protected internet site.
62293083|NCT00459030|ACTIVE_COMPARATOR|No Health Communication|No additional cancer screening education information sent to patient.
62658964|NCT03349463|EXPERIMENTAL|18F-Fluciclovine|
62658965|NCT01909271|EXPERIMENTAL|Intervention Group|Participants will receive education through a novel program called Stroke Education Film Viewing.
62658966|NCT01909271|OTHER|Usual Care Group|Participants will receive education through Stroke Education Pamphlet Exposure.
61908465|NCT03160313|EXPERIMENTAL|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
61908466|NCT03160313|ACTIVE_COMPARATOR|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
61908467|NCT01238627|EXPERIMENTAL|Nicotine Sublingual Tablet Mint (NSTM)-2|Experimental 2 mg NSTM
61908468|NCT01238627|ACTIVE_COMPARATOR|Microtab-2|2 mg Nicotine tablet
61908469|NCT01238627|EXPERIMENTAL|NSTM-4|Experimental 4 mg Nicotine Sublingual Tablet Mint
62293084|NCT04268134|EXPERIMENTAL|Omega 3 fatty acid supplement|Omega-3 ethyl esters orally daily (containing 465 mg eicosapentaenoic acid \[EPA\] and 375 mg docosahexaenoic acid \[DHA\] per capsule,supplied as 4 x 1gm capsule)
62293085|NCT02820961|ACTIVE_COMPARATOR|Cohort 1|Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
62658967|NCT02905708|ACTIVE_COMPARATOR|Forced Air Warming Device|"Active Comparator: Forced Air Warming Device first group will have the warming devices started in the pre-operative area. You will receive a full body forced air warming. Device is non experimental and FDA approved, used within the hospital to keep patients warm.You will then have your temperature taken and documented by the staff at various prescribed times.~Warming in the operating room: You will receive the same or a similar warming device known as a Bair Hugger and warmed IV fluids once you are in the operating room. Bair Paws or Bair Hugger will also be used in the post-anesthesia care area."
62658968|NCT02905708|ACTIVE_COMPARATOR|Air-Activated heating packs|The second group will receive the study warming device which consists of a jacket, pants, gloves and socks with integrated Air-Activated heating packs. Device is supplied vacuum packed, heat packs of iron powder/activated charcoal activated by air. Device applied at least twenty minutes prior to surgery. The same device will be maintained in place throughout the surgery and the post-anesthesia period.
61908470|NCT01238627|ACTIVE_COMPARATOR|Microtab-4|2 x 2 mg Nicotine tablet
61908471|NCT01447667|EXPERIMENTAL|Magnetic resonance elastography|Magnetic resonance elastography before radiofrequency ablation therapy will be performed.
61908472|NCT01576159|EXPERIMENTAL|High-Impact Loading|Performed high-impact running exercise during intervention period.
61908473|NCT01576159|EXPERIMENTAL|Moderate-Impact Loading|Performed moderate-impact cycling exercise during intervention period.
61908474|NCT01576159|EXPERIMENTAL|Non-Impact Loading|Performed low-impact swimming exercise during intervention period.
61908475|NCT01576159|NO_INTERVENTION|Control Group|Didn't participate any organized physical exercises
61908476|NCT04316910||Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
61908477|NCT04316910||Non-Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
61908478|NCT04249232|ACTIVE_COMPARATOR|abaloparatide prefilled syringe|Abaloparatide-SC is supplied as a liquid, 3120 micrograms per 1.56 milliliter (2000 mcg/mL) in a single patient multi-use prefilled pen. The prefilled pen delivers 30 doses of abaloparatide, each containing 80 mcg of abaloparatide in 40 microliters of a sterile, clear, colorless solution. To be administered subcutaneously daily.
62293086|NCT02820961|ACTIVE_COMPARATOR|Cohort 2|Cohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
61908479|NCT04249232|PLACEBO_COMPARATOR|Placebo prefilled syringe|For the placebo-SC a prefilled multi-use pen injector cartridge is designed to deliver 30 doses of placebo each in 40 microliters of sterile, clear, colorless solution to be administered subcutaneously daily.
62293087|NCT02016014|EXPERIMENTAL|Intervention group|Lifestyle counseling in physical activity and alimentation and add for three months a smartphopne with a app (EVIDENT) to improve alimentation and physical activity
62293088|NCT02016014|ACTIVE_COMPARATOR|Lifestyle counseling|Lifestyle counseling in physical activity and alimentation
62465528|NCT06324682||Conduction System Pacing|"The approach for the insertion of the device and of the transvenous leads is similar to the previous ones.~The ventricle activation might be obtained with the his bundle stimulation or with the left bundle branch area pacing downstream of the conduction block. Vascular access might be from the cephalic, axillary or subclavian veins.~Both selective and non-selective stimulation of the His bundle and the stimulation of the left bundle branch and left septum are considered successful. In both cases, attempts are made to locate the atrio-ventricular junction by fluoroscopic methods or with three-dimensional electroanatomical mapping system. The Hisian potential is sought and the catheter is positioned. In the LBBAP the investigators place the lead 1.5 cm below the His region and, with the pacemaking method, the investigators identify an area that electrocardiographically shows a W signal in V1 lead with D2 more positive than D3 - after checking the electrical parameters."
62658969|NCT03129646|EXPERIMENTAL|Arm 1 - MF/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
62293089|NCT05284695||TAP + RB|transversus abdominis plane block and rectus sheath block
62293090|NCT05284695||ESPB|Erector spinae plane block
62658970|NCT03129646|EXPERIMENTAL|Arm 2 - MF 28d/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
62658971|NCT03129646|ACTIVE_COMPARATOR|Arm 3 - SSG/PM 17d|Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
61908480|NCT04612608|NO_INTERVENTION|Control|Usual Care
61908481|NCT04612608|ACTIVE_COMPARATOR|Intervention|Intervention arm
61908482|NCT01215929|ACTIVE_COMPARATOR|Dextroamphetamine|
61908483|NCT01215929|PLACEBO_COMPARATOR|Placebo|
61908484|NCT04097951|EXPERIMENTAL|Montelukast|
61908485|NCT04097951|EXPERIMENTAL|Bepotastine|
61908486|NCT04097951|EXPERIMENTAL|Montelukast + Bepotastine|
61908487|NCT04363190||Cases|
61908488|NCT04363190||Controls|
61908489|NCT05680116|ACTIVE_COMPARATOR|Home based exercise group|Patients who will start radiotherapy after breast cancer surgery will be evaluated prior to treatment. During the radiotherapy process, all of the patients will be included in the home exercise program, 5 days a week, 2 sessions a day, each exercise will be 10x2 repetitions. Exercise follow-up of the patients will be provided with weekly routine face-to-face checks. After an average of 6 weeks of radiotherapy, the initial evaluations will be repeated.
61908490|NCT05680116|EXPERIMENTAL|Home based exercise plus vibration therapy group.|Patients who will start radiotherapy after breast cancer surgery will be evaluated prior to treatment. During the radiotherapy process, all of the patients will be included in the home exercise program, 5 days a week, 2 sessions a day, each exercise will be 10x2 repetitions. The study group continues their home based exercise, in addition they will receive 30 minutes of Myovolt (Myovolt TM, Myovolt Limited, Christchurch, New Zealand) device which is wearable vibration therapy 2 days a week. The vibration program will continue for 6 weeks, in the form of 2 sessions per week. Intermittent and sinusoidal modes between 20-100 Hz will be used for the vibration frequency.
61908491|NCT03489746|EXPERIMENTAL|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
61908492|NCT03489746|ACTIVE_COMPARATOR|Standard care|Patients will continue on their current recommended regimen including ICS.
62293091|NCT05284695||EOI|External oblique intercostal block
62293092|NCT01172067|EXPERIMENTAL|Quickopt Group|the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
62293093|NCT01172067|ACTIVE_COMPARATOR|Echocardiography group|the Echo Group patients will be optimized by Echo.
62293094|NCT05811065|EXPERIMENTAL|OPTIVF predicted drug dosage|This arm will use dosage, trigger predicted by Opt-IVF
62293095|NCT05811065|ACTIVE_COMPARATOR|Traditional drug treatment|This arm will use doctor specified treatment
62658972|NCT01134042|EXPERIMENTAL|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
62465529|NCT06324682||Cardiac resynchronization therapy (CRT) either -pacing (CRTP) or -defibrillation (CRTD)|"The approach for the insertion of the device and of the transvenous leads is similar to the previous ones.~The right ventricle pacing (with a pacing lead or a defibrillation coil) might be obtained with an apical or septal stimulation, while the left ventricular pacing is achieved by placing a catheter (active or passive) in the posterolateral area through a venous branch of the coronary sinus.~Cardiac resynchronisation therapy (CRT) delivers biventricular or left ventricular only pacing.~Vascular access might be from the cephalic, axillary or subclavian veins. Once positioned, lead's pacing threshold, sensing and impedance are measured. If the investigators find good and stable electrical parameters, the catheter(s) is(are) fixed and left in place - paying attention to the phrenic nerve capture threshold."
62465530|NCT06324682||Epicardial pacing|"The device is usually placed in the subcutaneous abdominal area and the lead(s) is(are) secured in the epicardial surface. It is often used in congenital heart defects or post-cardiac surgery scenarios.~Surgeons may access the epicardium during open-heart surgery or with minimally invasive techniques."
62658973|NCT01134042|ACTIVE_COMPARATOR|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
62658974|NCT01134042|ACTIVE_COMPARATOR|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks
62658975|NCT02081209|EXPERIMENTAL|Fat Reduction|
62658976|NCT03076879|EXPERIMENTAL|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
62658977|NCT03076879|NO_INTERVENTION|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
62658978|NCT04012645|EXPERIMENTAL|experimental group|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used during the surgeries.
62658979|NCT04012645|ACTIVE_COMPARATOR|control group|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
62658980|NCT02419950||No fixation of mesh in TEP|Patient having no mechanical fixation of the mesh in TEP. This will include both no fixation at all och glue fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
62658981|NCT02419950||Fixation of mesh in TEP|Patients having fixation of the mesh using mechanical, non absorbable fixating devices.This will include mechanical fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
62658982|NCT06439680|EXPERIMENTAL|experimental|Experimental: experimental This study was carried out with the women living in Tokat province. Trainings and measurement tools in the HASCV-R programme was implemented in the Hanımeli culture and art centers.
62658983|NCT06439680|OTHER|control|control
62658984|NCT04156529|EXPERIMENTAL|ESU position|Firstly, the semi-elevated supine position was given to participants during tube feeding
62658985|NCT04156529|EXPERIMENTAL|ESRL position|Firstly, the semi-elevated right lateral position was given to participants during tube feeding
62658986|NCT03844074|EXPERIMENTAL|bevacizumab|ONS-5010
62658987|NCT03844074|ACTIVE_COMPARATOR|ranibizumab|
62658988|NCT01995383|PLACEBO_COMPARATOR|Part 1: Placebo (PL)|
62658989|NCT01995383|EXPERIMENTAL|Part 1: Single Ascending Doses (SAD) of RO6836191|
62658990|NCT01995383|PLACEBO_COMPARATOR|Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet|
62658991|NCT01995383|PLACEBO_COMPARATOR|Part 2: PL: NS followed by LS diet|
62658992|NCT01995383|EXPERIMENTAL|Part 2: RO6836191: LS followed by NS diet|
62658993|NCT01995383|EXPERIMENTAL|Part 2: RO6836191: NS followed by LS diet|
62658994|NCT04148404|ACTIVE_COMPARATOR|Group NT|1.Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).
61908493|NCT05232409|EXPERIMENTAL|Zeaxanthin Monotherapy|Zeaxanthin administered orally on daily basis.
62658995|NCT04148404|ACTIVE_COMPARATOR|Group HT|2.Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
62658996|NCT01048424|EXPERIMENTAL|Paced respiration|Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
62658997|NCT01048424|PLACEBO_COMPARATOR|Control|Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
62658998|NCT01913184|ACTIVE_COMPARATOR|Continuous nebulization|Continuous nebulization with AKITA
62658999|NCT01913184|EXPERIMENTAL|Discontinuous nebulization|Discontinuous nebulization with AKITA
62293096|NCT01511731|EXPERIMENTAL|Famotidine|Famotidine tablets 40 mg of Dr. Reddy's
62293097|NCT01511731|ACTIVE_COMPARATOR|Pepcid|Pepcid 40 mg Tablets of Merck \& Co.,
62095596|NCT05613010|EXPERIMENTAL|Mobile health (mHealth) text messaging intervention|During baseline (4 weeks), adherence will be monitored daily via electronic pill boxes and no text messages will be sent. After baseline, participants will begin the 12-week micro-randomized trial of the intervention (a within-person study design). During this 12-week micro-randomized trial, daily adherence will be electronically monitored with the electronic pill boxes and participants will be randomized to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. For 12 months post-intervention, participants will keep using the electronic pill boxes (no text messages will be sent).
62095597|NCT00121199|EXPERIMENTAL|Treatment (CHOP, rituximab, bevacizumab)|Patients receive rituximab IV, bevacizumab IV over 30-90 minutes, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1. Patients also receive oral prednisone on days 1-5. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62095598|NCT04394819||experimental and control groups|"Task-oriented EMG-triggered ES treatment will be applied to the experimental group 2 days a week for 5 weeks and will continue with conventional physiotherapy.~The control group will only continue conventional physiotherapy treatment."
62095599|NCT06611137|EXPERIMENTAL|SBRT+Toripalimab Plus Docetaxel and Cisplatin|SBRT for gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin
62095600|NCT06552689|EXPERIMENTAL|Sutra Hemi-valve Transcatheter Mitral Valve Replacement (TMVR)|The Sutra Hemi-valve TMVR System is an innovative approach developed as a treatment for mitral regurgitation consisting of the Sutra Hemi-valve posterior leaflet replacement device, and the 32 Fr trans-septal delivery system.
62095601|NCT04707716|EXPERIMENTAL|conometric concept (Acuris system)|single implant crown retention using friction only
62293098|NCT02375867|ACTIVE_COMPARATOR|prednisolone|This group includes patients with FHF without encephalopathy
62293099|NCT02375867|ACTIVE_COMPARATOR|methylprednisolone|This group includes patients with FHF with encephalopathy
62293100|NCT02375867|NO_INTERVENTION|Non-intervention|FHF patients without any of the proposed intervention as controls
62659000|NCT01040819|EXPERIMENTAL|Pioglitazone 15 mg|Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
62659001|NCT01040819|EXPERIMENTAL|Pioglitazone 30 mg/d|Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
62659002|NCT02334189|EXPERIMENTAL|Letter|Patients receive a letter containing information on alternative healthcare options for non-emergency health concerns.
62659003|NCT02334189|NO_INTERVENTION|No letter|Patients receive no letter (this is the usual care).
62659004|NCT01477983|ACTIVE_COMPARATOR|ATP guide additional ablation - AAD|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: AAD for 90 days
62659005|NCT01477983|ACTIVE_COMPARATOR|Control - AAD|UNDER-ATP trial: Control, EAST-AF trial: AAD for 90 days
62659006|NCT01477983|ACTIVE_COMPARATOR|ATP guide additinal ablation - Control|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: Control
62659007|NCT01477983|ACTIVE_COMPARATOR|Control - Control|UNDER-ATP trial: Control, EAST-AF trial: Control
62659008|NCT00647816|EXPERIMENTAL|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
62659009|NCT00647816|ACTIVE_COMPARATOR|2|Inderal® LA Capsules 160 mg
62659010|NCT05257967|EXPERIMENTAL|Experimental arm|ddPCR and BC Cancer NGS panel completed on cerebral spinal fluid and blood circulating tumor DNA
62659011|NCT05062473|OTHER|Hypertension telemedicine curriculum|All participants participate in the 12-week telemedicine curriculum. All participants will be asked to record their steps via pedometer and their blood pressure measurements via automatic blood pressure arm cuff.
62659012|NCT05992727||Group 1( cases)|Galectin 3 will be measured in 30 Patients who are with active stage of pemphigus either newly diagnosed or in a relapse. The diagnosis of each patient is based on clinical examination and histopathological examination.
62659013|NCT05992727||Group 2( controls)|Galectin 3 will be measured in30 age and sex matched healthy controls
62659014|NCT00087802|ACTIVE_COMPARATOR|Stratum 1|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally
62659015|NCT00087802|ACTIVE_COMPARATOR|Stratum 2|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).
62659016|NCT00714818|EXPERIMENTAL|GC|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
62659017|NCT00714818|ACTIVE_COMPARATOR|EB|Educational Booklet: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants
62659018|NCT00714818|NO_INTERVENTION|WT|Waitlist
62659019|NCT05938738|EXPERIMENTAL|PEP-buddy|Patients will use the PEP-buddy as needed.
62659020|NCT00865605|EXPERIMENTAL|A|Halobetasol Propionate 0.05% Ointment, single exposure
62659021|NCT00865605|ACTIVE_COMPARATOR|B|Ultravate® 0.05% ointment, single exposure
62293101|NCT03490487|ACTIVE_COMPARATOR|A antiepileptic|will receive conventional antiepileptic drugs only
62293102|NCT03490487|EXPERIMENTAL|B steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs
62659022|NCT06407635|EXPERIMENTAL|Trauma-focused psychotherapy treatment condition|Individuals in this arm will undergo procedures related to trauma-focused psychotherapy (combined with standard psychological support) beginning after receipt of psilocybin.
62095602|NCT04707716|ACTIVE_COMPARATOR|screw retention|screw retained implant Crown fixation
62095603|NCT04707716|ACTIVE_COMPARATOR|cementation|cement retained implant Crown fixation
62465531|NCT06324682||Leadless pacing|"The leadless device is placed via a percutaneous approach through a large-calibre (femoral) vein inside the right ventricle. It is suitable for patients needing a single chamber pacing such as patients with permanent atrial fibrillation with slow ventricular response, in some cases of paroxysmal atrioventricular block, or patients with a history of CIED infections.~The only one currently available has a cardiac muscle fixation system consisting of 4 self-expanding barbs.~Once positioned, pacing threshold, sensing and impedance are measured. If the investigators find good and stable electrical parameters, the catheter is left in place."
62465532|NCT04690166||Cancer Patients|"In outpatients clinic, the first group consists of 60 head and neck cancer patients who were treated by ours. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
62659023|NCT06407635|ACTIVE_COMPARATOR|Standard psychological support treatment condition|This condition represents typical support following the experimental administration of psilocybin therapy.
62659024|NCT05648734||Group A|Patients received Corticosteroids only
62659025|NCT05648734||Group B|Patients received Corticosteroids in combination with Colchicine
62659026|NCT05648734||Group C|Patients received Corticosteroids in combination with Pirfenidone
61908494|NCT05232409|EXPERIMENTAL|Zeaxanthin plus Pembrolizumab|Zeaxanthin administered orally on daily basis in addition to intravenous pembrolizumab infused every 42 days at fixed dose of 400 mg.
62095604|NCT02331940|ACTIVE_COMPARATOR|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
62659027|NCT05648734||Group D|Patients received Corticosteroids in combination with Colchicine and Pirfenidone
62659028|NCT02661724|EXPERIMENTAL|Take Charge Burn - Pain (TCBR-Pain)|The TCBR-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress.
62095605|NCT02331940|ACTIVE_COMPARATOR|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
62095606|NCT04778371|EXPERIMENTAL|Almond supplement|Participants will consume 32 g dry roasted, unsalted almonds twice a day for 12 weeks
62095607|NCT04778371|PLACEBO_COMPARATOR|Placebo matched supplement|Participants will consume 100 g granola bar, calorie matched to Almond, twice a day for 12 weeks
62095608|NCT03222284|EXPERIMENTAL|Group 1|"N=10 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 7 Day 28"
62095609|NCT03222284|EXPERIMENTAL|Group 2|"N=20 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 28"
62095610|NCT06327113|NO_INTERVENTION|Control Group (Standard Wound Care)|The 'control' group will receive wound care treatment in accordance to standard of care procedures. The 'control' group will not receive study intervention.
62659029|NCT02661724|NO_INTERVENTION|Education attention control|The attention group receives an educational materials that is matched to the TCBR-Pain intervention in terms of session length and time on the web-based program. The web-based Education attention condition includes 7 sessions delivered over 7 weeks. The Education Attention Control is education materials commonly employed in rehabilitation centers and has been successfully used in several studies as a comparison to active rehabilitation interventions
62659030|NCT02094040|EXPERIMENTAL|Follow-up visit|Receive municipality-based follow-up visit including primary physician.
62659031|NCT02094040|NO_INTERVENTION|Usual care|Does not receive follow-up visit
62293103|NCT06299943|EXPERIMENTAL|Target Biofeedbak gait training|Patients in this group receive, in addition to conventional therapy, biofeedback gait training by selected biomechanical (Staince or single support phase, range of motion at joint or EMG amplitude) gait parameter. Training takes place 8-12 times over three weeks. The duration of each workout varies from 10 to 30 minutes.
62659032|NCT03122106|EXPERIMENTAL|Personalized neoantigen DNA vaccine|"* Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.~* Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.~* At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
62659033|NCT02236377|ACTIVE_COMPARATOR|ERRT - Enhanced Exposure|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced exposure techniques
62659034|NCT02236377|ACTIVE_COMPARATOR|ERRT - Sleep and Relaxation|Exposure, Relaxation, and Rescripting Therapy protocol, 5 sessions, focused on sleep and relaxation
62095611|NCT06327113|EXPERIMENTAL|Treatment Group (Tumescent Antibiotic Injection)|The 'treatment' group will receive wound care treatment in accordance to standard of care procedures along with the study intervention, a one-time tumescent antibiotic injection (TAI).
62095612|NCT04210856|EXPERIMENTAL|Sequence of Landscape exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
62095613|NCT02261415|EXPERIMENTAL|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
62095614|NCT02261415|PLACEBO_COMPARATOR|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
62095615|NCT02850627|EXPERIMENTAL|Tongguan capsule|Tongguan capsule (0.5 g tid. for 6 months)
62095616|NCT02850627|PLACEBO_COMPARATOR|placebo capsule|same volume/day of placebo capsule (0.5 g tid. for 6 months)
62095617|NCT03677947|ACTIVE_COMPARATOR|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning and overvalued ideas. IBCT does not include exposure, but aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
62095618|NCT03677947|ACTIVE_COMPARATOR|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, patients will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention).
62095619|NCT01409226|EXPERIMENTAL|MRI|
62095620|NCT05975996|EXPERIMENTAL|Experiemental|ALG/CsA(Cyclosporine) and herombopag and moderate-dose cyclophosphamide
62095621|NCT04377997|EXPERIMENTAL|Therapeutic Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation (LMWH for most subjects but UFH for those with morbid obesity or moderate to severe renal dysfunction as noted below) or standard of care anticoagulation. Those assigned to the therapeutic anticoagulation group will receive a higher dose of heparin."
62095622|NCT04377997|ACTIVE_COMPARATOR|Standard of Care Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation or standard of care anticoagulation. Those assigned to the standard of care anticoagulation group will receive the normal dose of heparin as per the Mass General guidelines."
62095623|NCT06614426|ACTIVE_COMPARATOR|Control group (C): Conventional open flap debridement|Conventional open flap debridement
62293104|NCT06299943|EXPERIMENTAL|Target Biofeedbak gait training-2|Patients in this group receive, in addition to conventional therapy, biofeedback gait training by selected biomechanical (Staince or single support phase, range of motion at joint or EMG amplitude) gait parameter. Training takes place 8-12 times over three weeks. The duration of each workout varies from 10 to 30 minutes.
62293105|NCT04219436|ACTIVE_COMPARATOR|periosteal suturing technique|periosteal suture is done to close the flap
62659035|NCT02236377|ACTIVE_COMPARATOR|ERRT-Rescription|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with rescription but no exposure
62095624|NCT06614426|EXPERIMENTAL|Test group 1 (T1): Open flap debridement using electrolysis decontamination|Open flap debridement using (GalvoSurge® - Straumann)
62095625|NCT06614426|EXPERIMENTAL|Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF|Open flap debridement using (GalvoSurge® - Straumann) combined with L-PRF application
62095626|NCT05932459|EXPERIMENTAL|BA Study|18 subjects were randomly divided into two sequences, TR and RT, with 9 subjects in each sequence, and were given in fasted condition once per period. In the first period of TR sequence, 100mg Deuremidevir Hydrobromide dry suspension was taken, and in the second period, 100 mg Deuremidevir Hydrobromide tablets were taken. In the first period of RT sequence, 100mg Deuremidevir Hydrobromide tablets were taken, and 100mg Deuremidevir Hydrobromide dry suspension was taken in the second period.
62095627|NCT05932459|EXPERIMENTAL|FE Study|12 subjects were randomly divided into two sequences, sequence 1 and sequence 2. There were 6 subjects in each sequence, and one dose per period. Sequence 1: Take Deuremidevir Hydrobromide dry suspension in fasted condition in period 1, and take Deuremidevir Hydrobromide dry suspension after taking infant formula for 10 minutes in period 2; Sequence 2: Take Deuremidevir Hydrobromide dry suspension after taking infant formula for 10 minutes in period 1, and take Deuremidevir Hydrobromide dry suspension in fasted condition in period 2.
62095628|NCT05932459|EXPERIMENTAL|PK Study|Fasting; PK study form is dry suspension, the doses are 25 mg, 100 mg, 300 mg, taken orally once in fasted condition. 8 subjects in 25 mg group; The 100 mg group used the data of 18 subjects with dry suspension in BA study, while the 300 mg group used the fasting condition data of 12 subjects with dry suspension in FE study.
62095629|NCT01537250|ACTIVE_COMPARATOR|Nemonoxacin 750 mg|Nemonoxacin 750 mg 2 tablets.
62095630|NCT01537250|ACTIVE_COMPARATOR|Nemonoxacin 500 mg|Nemonoxacin 500 mg 3 tablets
62095631|NCT01537250|ACTIVE_COMPARATOR|Levofloxacin 500 mg|Levofloxacin 500 mg
62293106|NCT04219436|ACTIVE_COMPARATOR|figure of eight suturing technique|figure of eight suture is done to close the flap
62293107|NCT06051630|EXPERIMENTAL|Lidocaine group|The group will receive 1.5 mg/kg lidocaine 2% bolus, followed by a continuous electric syringe dose of 1.5 mg/kg/hour intraoperatively, then 1.5 mg/kg/hour during the first 24 hours postoperatively
62293108|NCT06051630|PLACEBO_COMPARATOR|Saline group|The control group will receive an equivalent volume of saline: the volume of saline to be administered will be obtained by considering the dose of lidocaine 2% that the patient would have received if he/she had been in the interventional group.
62659036|NCT02236377|ACTIVE_COMPARATOR|ERRT-Sleep|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced sleep techniques
62659037|NCT02236377|ACTIVE_COMPARATOR|ERRT - Consensus Manual|Consensus Protocol, 6 sessions, includes components of ERRT and other nightmare protocols.
62659038|NCT00769769|EXPERIMENTAL|Telephone-based psychotherapy|
62659039|NCT00769769|ACTIVE_COMPARATOR|Face-to-face psychotherapy|
62659040|NCT02852759|EXPERIMENTAL|intervention group|Add Selective Cold and Electroacupuncture treatment to the existing treatment for patients with insulin resistance.
62659041|NCT02852759|NO_INTERVENTION|Intensive Care group|continue the existing management of insulin resistance in these patients. They will receive the same follow up, examinations etc as intervention group.
62659042|NCT02742688|EXPERIMENTAL|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|
62659043|NCT02742688|PLACEBO_COMPARATOR|Placebo|
62659044|NCT04148456|OTHER|Aortoiliac occlusive disease|This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
62659045|NCT00956189|EXPERIMENTAL|Amisulpride|A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
62659046|NCT00956189|EXPERIMENTAL|Aripiprazole|A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.
62659047|NCT01503424|EXPERIMENTAL|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
62659048|NCT01503424|ACTIVE_COMPARATOR|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
62659049|NCT03406676|EXPERIMENTAL|Methylene blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
62293109|NCT05485207|EXPERIMENTAL|Transvaginal Botulinum Toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
62293110|NCT04096534|EXPERIMENTAL|Normotonic partial nephrectomy|Performing a partial nephrectomy under normal body blood pressure
62293111|NCT04096534|ACTIVE_COMPARATOR|Hypotonic partial nephrectomy|Performing a partial nephrectomy under hypotonic body blood pressure
62659050|NCT03406676|NO_INTERVENTION|saline|50ml of saline is administrated I.V before anesthesia induction.
62659051|NCT06167057|EXPERIMENTAL|A|Single post-operative MMC 40mg or gemcitabine 2gr in Saline 0.9% 50cc bladder instillation
62659052|NCT06167057|PLACEBO_COMPARATOR|B|Single post-operative 50cc Saline 0.9% bladder instillation
62659053|NCT05428618|EXPERIMENTAL|e-BariS app Group|"Self-Monitoring Module and Patient Education Module"
62659054|NCT05428618|SHAM_COMPARATOR|Self-Monitoring Group|"Self-Monitoring Module"
62659055|NCT02657863||Healthy volunteer|Normal volunteers will be enrolled and informed consent obtained per study guidelines as described. Urine and plasma will be collected from each of 30 subjects with no prior history of prostate or other cancers.
62659056|NCT02657863||Prostate cancer patients being treat with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 25 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to the onset of therapy.
62659057|NCT02657863||Prostate cancer patients being treated with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
62659058|NCT01759927|NO_INTERVENTION|Control condition|Physically inactive employees are measured on anthropometrics, fitness and psycho-social variables.
62659059|NCT01759927|EXPERIMENTAL|Physical Activity Coaching|Physically inactive employees receiving a 12-week behavioural support intervention grounded in self-determination theory.
62659060|NCT02212067|EXPERIMENTAL|Semaglutide|Total of 12 visits
62659061|NCT02212067|PLACEBO_COMPARATOR|Placebo|Total of 12 visits
62659062|NCT02212067|NO_INTERVENTION|Healthy subjects|Total of 2 visits
62659063|NCT06397638|EXPERIMENTAL|Rescue carotid stenting|Rescue carotid stenting in tandem occlusions
62659064|NCT04150887|EXPERIMENTAL|Experimental: Cohort 2: Cusatuzumab + Venetoclax|Participants enrolled in this cohort will receive venetoclax ramp-up to 400 mg orally (as background therapy) starting on Cycle 1 Day 1 and followed by 400 mg daily dosing starting on Cycle 1 Day 4 plus cusatuzumab IV on Day 3 and Day 17 of each 28-day cycle. Cohort 2 will not be enrolled in the US.
62659065|NCT04150887|EXPERIMENTAL|Cohort 3: Cusatuzumab + Venetoclax + Azacitidine (CVA)|Participants enrolled at US sites will receive cusatuzumab 10 mg/kg and potentially escalate to 20 mg/kg IV in combination with azacitidine 75 mg/m\^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies). Participants enrolled from ex-US sites will receive cusatuzumab 20 mg/kg and potentially de-escalate to 10 mg/kg IV in combination with azacitidine 75 mg/m\^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies).
62659066|NCT02583269|EXPERIMENTAL|Arm 1 (muscadine grape skin extract) 1 pill 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
62659067|NCT02583269|EXPERIMENTAL|Arm 2 (muscadine grape skin extract) 2 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
62293112|NCT00707356|EXPERIMENTAL|WST11(TOOKAD® Soluble)|Treatment with WST11-mediated VTP
62293113|NCT03478384|EXPERIMENTAL|Coaching group|Patient coaching
62293114|NCT03478384|NO_INTERVENTION|Control group|Control group - no additional coaching provided
62293115|NCT04271761||Current adult recipients of Cochlear Carina System|Adults who are current recipients of the Cochlear Carina System. Participants will attend one scheduled visit where several acoustic measurements will be taken that do not require active participation by the participant.
62659068|NCT02583269|EXPERIMENTAL|Arm 3 (muscadine grape skin extract) 3 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
61908495|NCT05377697|EXPERIMENTAL|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
61908496|NCT05377697|NO_INTERVENTION|Control group|Participants in the control group will not receive any intervention.
61908497|NCT03355469|PLACEBO_COMPARATOR|LoEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
61908498|NCT03355469|PLACEBO_COMPARATOR|HiEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
61908499|NCT03355469|ACTIVE_COMPARATOR|LoEx+metformin|If subjects are assigned to this group they will participate in the same LoEx exercise program as outlined above. But, here they will be provided metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not be able to find out if you are on metformin until the study is done. If their doctor needs to know, the people doing this study can find out.
61908500|NCT03355469|ACTIVE_COMPARATOR|HiEx+metformin|If subjects are assigned to this group you will participate in the same HiEx exercise program and receive metformin as outlined above.
61908501|NCT06029257||Tildrakizumab|Participants who have been prescribed tildrakizumab in the treatment of plaque psoriasis with a manifestation in the genital area according to SmPC in routine clinical practice settings will be observed prospectively for up to 52 weeks.
61908502|NCT05027360||Acute heart Failure AHF|AHF diagnosis, defined as rapid onset or worsening of symptoms and/or signs of HF
61908503|NCT02929654|ACTIVE_COMPARATOR|Control|Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
61908504|NCT02929654|EXPERIMENTAL|OneTouch Verio®|Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
61908505|NCT02929654|EXPERIMENTAL|Intervention 02|Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
61908506|NCT00291213|EXPERIMENTAL|Levetiracetram Administration|
61908507|NCT00291213|PLACEBO_COMPARATOR|Placebo|
61908508|NCT02617485|EXPERIMENTAL|MabionCD20|"A course of MabionCD20 consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
61908509|NCT02617485|ACTIVE_COMPARATOR|MabThera|"A course of MabThera consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
61908510|NCT03254576||Children at high-risk for obesity|Healthy-weight children (5th-75thBMI%) with two overweight/obese parents (BMI\>25)
61908511|NCT03254576||Children at low-risk for obesity|Healthy-weight children (5th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
61908512|NCT05662670|EXPERIMENTAL|Experimental:WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
61908513|NCT05702346|EXPERIMENTAL|Intervention|Participants will receive the EPA intervention.
61908514|NCT05702346|ACTIVE_COMPARATOR|Control|This is the control group who will receive written information about health.
61908515|NCT00770380|EXPERIMENTAL|Hypnosis for relapse prevention|The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
61908516|NCT00770380|ACTIVE_COMPARATOR|Behavioral relapse prevention counseling|In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
61908517|NCT03014999|EXPERIMENTAL|High frequency rTMS|Volunteers will be submitted to high frequency of repetitive transcranial magnetic stimulation (10Hz)
62095632|NCT03791177|EXPERIMENTAL|Study Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
62293116|NCT02122627|EXPERIMENTAL|Vitamin D|colecalciferol 16.800 IU per week
62293117|NCT02122627|PLACEBO_COMPARATOR|Placebo|placebo
62293118|NCT00781365|NO_INTERVENTION|Control|Patients in the control group will receive usual care from their primary care physicians at HealthPartners Medical Group clinics.
62465533|NCT04690166||Healty Control|"In outpatients clinic, the control group consists of 60 patients who have not speech and hear impairments. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
62465534|NCT03116659|EXPERIMENTAL|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
62465535|NCT01856426|EXPERIMENTAL|1- EDP239|EDP239 given once a day.
62659069|NCT02583269|EXPERIMENTAL|Arm 4 (muscadine grape skin extract) 4 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
62659070|NCT02583269|EXPERIMENTAL|Arm 5 muscadine grape skin extract) 5 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
62659071|NCT02096913|ACTIVE_COMPARATOR|Dolormin® extra (Ibuprofen) 4 weeks|
62659072|NCT02096913|ACTIVE_COMPARATOR|Dolormin® extra (Ibuprofen) 12 weeks|
62659073|NCT04841291|EXPERIMENTAL|Virtual Simulation-Based Arm|Access virtual simulation-based diabetes foot care education once for 30 minutes plus the standard care.
62095633|NCT03791177|SHAM_COMPARATOR|Control Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
62095634|NCT01601743|ACTIVE_COMPARATOR|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
62095635|NCT01601743|ACTIVE_COMPARATOR|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
62095636|NCT01601743|ACTIVE_COMPARATOR|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
62095637|NCT05803486||experimental group|examined by ultrasound image to measure quadratus lumborum thickness, pelvic floor muscles force and diaphragm excursion in patients with urinary incontinence
62095638|NCT05803486||control group|examined by ultrasound image to measure quadratus lumborum thickness, pelvic floor muscles force and diaphragm excursion in patients with urinary incontinence
62095639|NCT04374877|EXPERIMENTAL|Part A Monotherapy Dose Escalation|The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of CHS-388 as monotherapy in up to 30 patients with advanced solid tumors.
62095640|NCT04374877|EXPERIMENTAL|Part B CHS-388 Monotherapy Expansion|Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of CHS-388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC, up to 40 patients with HCC, and up to 40 patients with NSCLC.
62659074|NCT04841291|NO_INTERVENTION|Standard Care Arm|Participants will continue utilizing the usual follow-up diabetes care which occurs every month.
62659075|NCT03595098|EXPERIMENTAL|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
62095641|NCT04374877|EXPERIMENTAL|Part C CHS-388 in Combination with Pembrolizumab|Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of CHS-388 in combination with pembrolizumab in patients with advanced RCC or HCC, or anti-PD(L)1 relapsed/refractory advanced NSCLC.
62465536|NCT01856426|PLACEBO_COMPARATOR|Placebo|1 treatment arm will be placebo, dose given once a day.
62659076|NCT03595098|ACTIVE_COMPARATOR|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
62659077|NCT05389267|EXPERIMENTAL|T4090|
62659078|NCT05389267|PLACEBO_COMPARATOR|Placebo|"named Vehicle in the study protocol."
62659079|NCT01431976|EXPERIMENTAL|Lamotrigine|No comparison
62095642|NCT04374877|EXPERIMENTAL|Part D CHS-388 in Combination with Toripalimab|Part D will evaluate the safety, preliminary efficacy, tolerability, and PK of CHS-388 in combination with toripalimab in patients with anti-PD(L)1 relapsed/refractory advanced NSCLC.
62095643|NCT02179463||Neoadjuvant Chemotherapy|undergo neoadjuvant chemotherapy before surgery
62465537|NCT01856426|EXPERIMENTAL|2- EDP239|EDP239 given once a day.
62465538|NCT01856426|EXPERIMENTAL|3-EDP239|EDP239 given once a day.
62465539|NCT01856426|EXPERIMENTAL|4-EDP239|EDP239 given once a day.
62465540|NCT04794322||Pelvic Mass Cohort (cohort #1)|200 participants scheduled for surgery for suspected ovarian cancer due to a pelvic mass but without a confirmed tissue or cytology diagnosis.
62465541|NCT04794322||BRCA1/2 Carriers Cohort (cohort #2)|50 participants with an inherited BRCA1 or BRCA2 deleterious mutation without suspected ovarian cancers who are scheduled for risk-reducing salpingo-oophorectomy (RRSO) to remove ovaries and fallopian tubes.
62659080|NCT02543411|EXPERIMENTAL|Lidocaine group|Administration of lidocaine 1%
62659081|NCT02543411|PLACEBO_COMPARATOR|Control group|Administration of normal saline
62659082|NCT04706338|EXPERIMENTAL|TMS treatment|Patients with TMS treatment
62659083|NCT02960451|EXPERIMENTAL|PRIME care|Specialized care in the PRIME clinic
62659084|NCT02960451|ACTIVE_COMPARATOR|Usual care|Usual care in the community
62659085|NCT05497128|EXPERIMENTAL|Ultrahigh-speed cut rate 27-gauge system|Patients will receive the pars plana vitrectomy in the macular disease with the 27-gauge vitrectomy systems with 20,000 cpm probes.
62659086|NCT05497128|ACTIVE_COMPARATOR|Standard cut rate 27-gauge system|Patients will receive the pars plana vitrectomy in the macular disease with the 27-gauge vitrectomy systems with 10,000 cpm probes.
62659087|NCT00471965|EXPERIMENTAL|A|Oxaliplatin + 5-Fluorouracil/Leucovorin
62659088|NCT00471965|ACTIVE_COMPARATOR|B|Doxorubicin
62465542|NCT01743547|NO_INTERVENTION|No Intervention; Arm A; Control Group|24 subjects who declined yoga but agreed to data collection
62465543|NCT01743547|ACTIVE_COMPARATOR|Active Comparator; Arm B; Intervention Group|24 subjects participating in 8 weeks of Yoga and agreed to data collection
62465544|NCT00757809|EXPERIMENTAL|QD|Once daily
62465545|NCT00757809|EXPERIMENTAL|BID|Twice daily
62465546|NCT01233505|EXPERIMENTAL|Treatment (veliparib, capecitabine, oxaliplatin)|Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62465547|NCT01155986|PLACEBO_COMPARATOR|Placebo Plaster|Active Comparator
62465548|NCT01155986|ACTIVE_COMPARATOR|Lidocaine Plaster|
62465549|NCT03341585|EXPERIMENTAL|Expiration Lente Prolongée|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of 'Expiration Lente Prolongée (ELPr)' . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
62465550|NCT03109977|EXPERIMENTAL|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
62465551|NCT00609830|EXPERIMENTAL|Tailored Materials|
62465552|NCT00609830|EXPERIMENTAL|Physician Feedback|
62465553|NCT00609830|ACTIVE_COMPARATOR|Generic Materials|
62465554|NCT00609830|PLACEBO_COMPARATOR|Placebo Comparator|Participants receive no information
62465555|NCT04471272|EXPERIMENTAL|RFA using gradual RF energy delivery mode|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
62465556|NCT03099538|EXPERIMENTAL|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
62465557|NCT03982485|EXPERIMENTAL|Arm I|Apatinib+Paclitaxel+Cisplatin
62095644|NCT02135783|EXPERIMENTAL|Decompressive Craniectomy|Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
62095645|NCT02135783|ACTIVE_COMPARATOR|non-Decompressive Craniectomy|non-Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
62095646|NCT02115854||bacteriologically confirmed tuberculosis|
62465558|NCT03982485|ACTIVE_COMPARATOR|Arm II|Paclitaxel+Cisplatin
62465559|NCT02332148|EXPERIMENTAL|3Vm1001|3VM1001 topical cream containing 10 mg/day of copper, for 30 days
62465560|NCT02332148|PLACEBO_COMPARATOR|Placebo|Placebo for 3VM1001, topical cream without 3VM1001
62095647|NCT02994550|EXPERIMENTAL|FSH/LH 2/1|dose: 300IU FSHrec and 150IU LHrec
62095648|NCT02994550|EXPERIMENTAL|FSH/LH 4/1|dose: 300IU FSHrec and 75IU LHrec
62465561|NCT03120117|EXPERIMENTAL|Cough Test following Sling Surgery|All subjects enrolled will undergo sling surgery for treatment of stress urinary incontinence and subsequently asked to do a standing cough test.
62465562|NCT03313349|OTHER|Usual Provision (UP)|"Usual Provision~Psychotherapy: 1. cognitive therapy 2.family intervention"
62465563|NCT03313349|OTHER|Enhanced/Need-Based Provision (ENP)|"Enhanced/need-based Provision~Psychotherapy: 1.cognitive therapy 2.family intervention"
62465564|NCT05333159||Experimental|Subjects will be treated with SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) with or without conventional hypoglycemic drugs .
62465565|NCT05333159||Control|Subjects will be only treated with conventional hypoglycemic drugs.
62465566|NCT04321850|PLACEBO_COMPARATOR|Group1|Control
62465567|NCT04321850|EXPERIMENTAL|Group 2|Intervention (Zinc)
62465568|NCT01301573||rAAV-GAD Treated Subjects|rAAV-GAD treated subjects who are being observed for long-term effects of the gene therapy product which they received from participating in a previous clinical study.
62465569|NCT02476799|EXPERIMENTAL|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
62465570|NCT02476799|SHAM_COMPARATOR|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
62465571|NCT01580384||Cohort|
62659089|NCT06544590||Control group|
62095649|NCT06174480|NO_INTERVENTION|Control Group|Participants will not undergo cryostimulation exposure but will only receive 2 1-hour hypoxia sessions at FiO2 13.5% for 1 hour, at 2-week interval
62095650|NCT06174480|EXPERIMENTAL|Cryostimulation Group|Participants will be exposed to cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks and will undergo 2 hypoxia sessions at FiO2 13.5% for 1 hour, at 2-week interval
62465572|NCT03550625||Routine Colonoscopy Cohort|Photographies of polyps for creation of computer program
62465573|NCT04355104|EXPERIMENTAL|Education+standard physical therapy|Consist of 37 patients will take education sessions in addition to standard physical therapy.
62465574|NCT04355104|ACTIVE_COMPARATOR|Standard physical therapy|Consist of 37 patients take just standard physical therapy.
62465575|NCT01358097||Patients with HPV positive tumors|
62465576|NCT01358097||Patients with HPV negative tumors|
62465577|NCT01358097||Control|
62659090|NCT06544590||taVNS group|
62659091|NCT06544590||sham taVNS group|
62659092|NCT05262179|EXPERIMENTAL|CTO0101|
62659093|NCT05262179|PLACEBO_COMPARATOR|Placebo (Vehicle)|
62659094|NCT00804271|OTHER|Memantine|
61908518|NCT03014999|EXPERIMENTAL|Low frequency rTMS|Volunteers will be submitted to low frequency of repetitive transcranial magnetic stimulation (1Hz)
62465578|NCT01533805|EXPERIMENTAL|Pilates with stabilization|This group will do pilates exercises with a focus on control of segmental stabilization of the lumbar spine neutral.
62293119|NCT00781365|EXPERIMENTAL|Telemonitors and pharmacy management|The telemonitoring intervention (TI) patients will receive a home blood pressure telemonitor and will work with a clinical pharmacist case manager to control elevated blood pressure. Patients will use their home telemonitors to read and send their blood pressures to their Pharmacist case manager, who will use phone meetings with the patient to make medication adjustments.
62293120|NCT02392260|EXPERIMENTAL|Vasculight prototype zero level|
62293121|NCT05728814||Case-only|The study population consists of adult female patients with diagnosis of dMMR/MSI-H recurrent or advanced endometrial cancer with progression to a previous platinum regimen, who were treated within the Spanish dostarlimab Expanded Access Program (EAP).
62293122|NCT04959123|ACTIVE_COMPARATOR|Ropivacaine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mL in each syringe) In the Ropivacaine only group, there is no adrenaline, the syringe loaded with ropivacaine is supplemented to 20 mL with a 0.9% sodium chloride solution"
62465579|NCT01533805|ACTIVE_COMPARATOR|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine.
62465580|NCT03316001||cases|patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed
62465581|NCT03316001||controls|"patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients"
62465582|NCT02506933|EXPERIMENTAL|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
62465583|NCT02506933|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
62465584|NCT02140060|EXPERIMENTAL|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
62465585|NCT02140060|EXPERIMENTAL|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
62465586|NCT02140060|EXPERIMENTAL|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
62465587|NCT02140060|ACTIVE_COMPARATOR|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
62465588|NCT02140060|ACTIVE_COMPARATOR|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
62465589|NCT02140060|ACTIVE_COMPARATOR|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
62465590|NCT04368624||Participants with PKU|"1. Patients with classical PKU phenotype (serum phenylalanine concentration \> 10 mg/dL on a normal diet at diagnosis) # \~25~2. Patients with hyperphenylalaninemia (serum phenylalanine concentration \< 10 mg/dL on a normal diet at diagnosis) # \~15~3. Patients with PKU on therapy with Kuvan # \~10"
62465591|NCT04368624||Non-PKU Control|Study Controls: Up to 50 children and adults without a known metabolic disorder.
62095651|NCT05111379||LEAD (Fontaine IIa)|Patients with mild intermittent claudication.
62095652|NCT05111379||Control|Healthy controls.
62465592|NCT00905840|ACTIVE_COMPARATOR|Titanium Zircon implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
62465593|NCT00905840|PLACEBO_COMPARATOR|Titanium Grade IV implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
62465594|NCT03606603||Surgical patients|Adult patients after elective major abdominal gastrointestinal surgery with pre-existing malnutrition or who are at significant risk for malnutrition or nutrition-related complications, with indications for nutritional support
61908519|NCT03014999|SHAM_COMPARATOR|Sham rTMS|Volunteers will be submitted to sham session of repetitive transcranial magnetic stimulation
61908520|NCT04645121||Hemodialysis group|Subjects receiving maintenance hemodialysis for at least three months
61908521|NCT04645121||Case group|Healthy subjects with eGFR above 60 ml/min/1.73m2
61908522|NCT05120063|EXPERIMENTAL|3D anatomical stem|3-D-Planing with anatomical stem (SPS monoblock stem, Symbios)
61908523|NCT05120063|EXPERIMENTAL|3D non-anatomical stem|3-D-Planing with non anatomical stem (Quadra-H, Medacta)
61908524|NCT05120063|EXPERIMENTAL|2D anatomical stem|2-D-Planing with anatomical stem (SPS monoblock stem, Symbios)
62095653|NCT04890756||Reliability Group|100 Healthy Adults
62095654|NCT04890756||Validity Group|45 Healthy Adults
62095655|NCT02469844||Patients with epilepsy having seizures in sleep|
62293123|NCT04959123|EXPERIMENTAL|Ropivacaine + Epinephrine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mLn each syringe) In the ropivacaine + epinephrine group, 0.1 mL of a 1 mg/mL ampoule of epinephrine is added to each syringe before making up to 20 mL (i.e., 100 µg of epinephrine for 20 mL of final solution, i.e., 5 µg/mL, i.e., 1 : 200000)."
62293124|NCT02986178|EXPERIMENTAL|Polio/Rhinovirus Recombinant (PVSRIPO)|Polio/Rhinovirus Recombinant (PVSRIPO)
62293125|NCT02924701||PBC patients|Patients diagnosed with primary biliary cholangitis
62293126|NCT00450944|EXPERIMENTAL|Combination Therapy with Immunotoxins Imtox 19 Plus Imtox 22|
62293127|NCT01983891|EXPERIMENTAL|Intervention|6-week nutrition education and cooking course
62293128|NCT05207475|EXPERIMENTAL|RIC group|RIC treatment and regular treatment.
62293129|NCT05207475|NO_INTERVENTION|Regular treatment|Regular treatment alone.
62293130|NCT01245673|EXPERIMENTAL|Prevnar, T Cells, Lenalidomide, MAGE A-3|All patients will receive a priming immunization with a MAGE-A3/GM-CSF vaccine with adjuvant Hiltonol® (Poly-ICLC) along with the pneumococcal conjugate vaccine/PCV control vaccine about 10 days before a steady-state mononuclear cell apheresis. Patients will then undergo hematopoietic stem cell mobilization. All patients will receive high-dose melphalan followed by hematopoietic stem cells on day 0. On day +2, patients will receive anti-CD3/anti-CD28-costimulated autologous T cells. At days 14, 42, and 90, patients will receive MAGEA3/GM-CSF (+Hiltonol® Poly-ICLC) and PCV booster immunizations followed by restaging studies and immune assessments at day +100. At day 100, after immunizations and restaging, patients will start Revlamid® (Lenalidomide) maintenance therapy followed by 2 additional MAGE-A3 and PCV immunizations at days 120 and 150.
62293131|NCT02673333|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
62293132|NCT03973450||Pituitary tumours|Patients affected by pituitary tumours and followed-up at the Neuroendocrinology Unit over a 5 yrs period (2014-2018)
62293133|NCT01776125||Dystrophic Scolisis and NF1|Patients with NF1 diagnosed with dystrophic scoliosis that have been clinically treated will be asked for a cheek swab for genetic testing
62293134|NCT01776125||Non-dystrophic scoliosis and NF1|NF1 patients with non-dystrophic scoliosis that have been treated clinically. will be asked for a cheek swab for genetic testing
62293135|NCT01691638||Periodontitis|
62095656|NCT06522672|EXPERIMENTAL|My Happy Flo Supplement|Participants will take two capsules of My Happy Flo daily, preferably in the morning with 8-10 oz of water and a meal, for three menstrual cycles.
62293136|NCT01691638||Control|
62293137|NCT03146364|EXPERIMENTAL|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
62293138|NCT03146364|EXPERIMENTAL|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
62293139|NCT03884686|EXPERIMENTAL|Web-based intervention|Patients allocated to intervention arm will have unlimited free access to a web-based education resource.
62293140|NCT03884686|NO_INTERVENTION|Usual care|Patients allocated to usual care will receive all usual care and education opportunities.
62293141|NCT06202248|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62293142|NCT00376961|EXPERIMENTAL|R-CHOP + Velcade|6 21-day cycles of standard R-CHOP with 1.3 mg/m\^2 Bortezomib given on days 1 and 4 of each cycle. This is followed by 8 3-month cycles of maintenance with 1.3 mg/m\^2 Bortezomib on days 1, 4, 8 and 11 of each cycle.
62293143|NCT04738955|EXPERIMENTAL|High dose group|micafungin sodium ≥ 200, ≤ 300 mg/time, once a day, intravenous drip
62293144|NCT01065584||Standard immunosuppression|Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
62095657|NCT06481501|EXPERIMENTAL|ONE Mindfulness-Oriented Recovery Enhancement|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
62293145|NCT01065584||Immunosuppression without calcineurininhibitors|Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors
62293146|NCT02876978|EXPERIMENTAL|CAR-GPC3 T cells|"Intravenous infusion with escalating dose is adopted in this study.~Total dosage: 1 x 10\^5 - 2 x 10\^9 CAR-GPC3 T cells/kg~The next dose and interval depends on the response of the subject to previous dose.~Lymphodepletion:~Fludarabine: 30 mg/m\^2/day x 4 days; Cyclophosphamide: 500 mg/m\^2/day x 2 days. Adjustment is in discretion of the investigator based on individual response."
62465595|NCT03343522|NO_INTERVENTION|Sedentarism|Patients assigned to this arm shall not perform regular exercise training.
62465596|NCT03343522|EXPERIMENTAL|Exercise Training|Patients assigned to this arm will be enrolled in exercise training program.
62465597|NCT02640183|EXPERIMENTAL|Group A (EMLA)|3 mL EMLA® cream 5% will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
62293147|NCT06657703|EXPERIMENTAL|HC022 5mg SC|Participants will receive single subcutaneous (SC) dose of 5 mg HC022 or matching placebo on Day 1.
62293148|NCT06657703|EXPERIMENTAL|HC022 50mg SC|Participants will receive single subcutaneous (SC) dose of 50 mg HC022 or matching placebo on Day 1.
62293149|NCT06657703|EXPERIMENTAL|HC022 150mg SC|Participants will receive single subcutaneous (SC) dose of 150 mg HC022 or matching placebo on Day 1.
62293150|NCT06657703|EXPERIMENTAL|HC022 450mg SC|Participants will receive single subcutaneous (SC) dose of 450 mg HC022 or matching placebo on Day 1.
62293151|NCT06657703|EXPERIMENTAL|HC022 900mg SC|Participants will receive single subcutaneous (SC) dose of 900 mg HC022 or matching placebo on Day 1.
62293152|NCT01573312|EXPERIMENTAL|Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.
62293153|NCT01573312|EXPERIMENTAL|Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.
61908525|NCT05120063|EXPERIMENTAL|2D non anatomical stem|2-D-Planning with non anatomical Stem (Quadra-H, Medacta)
62293154|NCT05025943|EXPERIMENTAL|Standard lifestyle intervention + omega-3 fatty acid enriched diet|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI) + omega-3 fatty acid enriched foods
61908526|NCT02449746|ACTIVE_COMPARATOR|Intravenous Immunoglobulin (IVIG)|"Intravenous Immunoglobulin IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
61908527|NCT02449746|ACTIVE_COMPARATOR|Plasma Pheresis / Plasma Exchange (PLEX)|Plasma Exchange (PLEX) is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and its use was first reported in myasthenia gravis in 1976, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects . PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice
61908528|NCT03328884|OTHER|nal-IRI|This is a single arm study. After signing the informed consent form, patients will start treatment with nal-IRI. nal-IRI will be administered at a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
61908529|NCT01688206|EXPERIMENTAL|Vanucizumab|Participants will receive escalating doses of vanucizumab and fixed dose of vanucizumab, intravenously every 2 weeks.
61908530|NCT01688206|EXPERIMENTAL|Vanucizumab + Atezolizumab|Participants will receive fixed dose of vanucizumab along with atezolizumab, intravenously every 2 weeks.
62095658|NCT06481501|NO_INTERVENTION|Treatment As Usual|In the Treatment as Usual (TAU) condition, participants will complete all study assessments (pre-treatment, post-treatment, 2-week, 4-week) without receiving any ONE MORE training. During their study involvement, TAU participants will be encouraged to continue any previously initiated treatment but discouraged from beginning any new form of treatment. Those in the TAU condition will not be sent any training materials.
62095659|NCT02509403|EXPERIMENTAL|Intervention|Essential oils infused Perineal Hygiene wipe
62095660|NCT04896255||interferon cohort|Patients who are going to take peginterferon alpha based regimen
62095661|NCT04896255||nucleos(t)ide cohort|Patients who are going to take nucleos(t)ide alone
62095662|NCT06615466|EXPERIMENTAL|Partial Breast Irradiation|
62095663|NCT04214860|EXPERIMENTAL|APR-246|APR-246 4.5 g/day
62095664|NCT03782948|ACTIVE_COMPARATOR|Controls|"In each session, the group will undergo standard gait training on BART without pelvic perturbations, i.e.,~* walk a virtual track on the BART without pelvic perturbations (i.e., the pelvic brace of the BART device will be set to follow the patient's motion) for 10 minutes;~* practise gait symmetry and take-off using visual feedback without pelvic perturbations in two 10-minute sessions."
62095665|NCT03782948|EXPERIMENTAL|Experimental|"In each session, the group will undergo robotised gait training with BART with pelvic perturbations, i.e.,~* walk a virtual track on the BART with pelvic perturbations during virtual uphill walk and virtual curved walk for 10 minutes;~* practise gait symmetry and take-off using visual feedback with pelvic perturbations for 10 minutes;~* practise dynamic gait balance using pelvic perturbations during treadmill walking for 10 minutes."
62465598|NCT02640183|PLACEBO_COMPARATOR|Group B (Placebo)|3 mL of ultrasonic gel will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
62659095|NCT06233656|EXPERIMENTAL|Acceptance and commitment therapy (ACT) group|The ACT group will receive eight weekly individual ACT sessions guided by a coach through videoconferencing with a booster session at 1-month follow-up.
62659096|NCT06233656|NO_INTERVENTION|Wait-list control group|The wait-list control group will maintain his or her own care as usual during the study period and receive eight individual ACT sessions after study participation ends.
62659097|NCT00932711|EXPERIMENTAL|Educational intervention|Subjects in this group will receive educational brochures about management of COPD
62659098|NCT03185078|EXPERIMENTAL|Active Comparator: Low density ESWT Application|ESWT application will be done at energy density of 0.12 mJ/mm2.
62659099|NCT03185078|EXPERIMENTAL|Active Comparator: High density ESWT Application|ESWT application will be done at an energy density of 0.3 mJ/mm2.
62659100|NCT03185078|SHAM_COMPARATOR|Control|The ESWT application will be executed when the ESWT application is in the off position. During application, pre-recorded sound beats will be played to the treatment group.
62659101|NCT03626896|EXPERIMENTAL|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
62095666|NCT03197311|EXPERIMENTAL|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
62095667|NCT03197311|NO_INTERVENTION|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
62095668|NCT06275880|EXPERIMENTAL|GROUP A|Patients who received intra-articular infiltration of PVP Collagen
62095669|NCT06275880|ACTIVE_COMPARATOR|GROUP B|Patients who received conservative treatment through rehabilitation with a home program for one month
62293155|NCT05025943|ACTIVE_COMPARATOR|Standard lifestyle intervention|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI)
62293156|NCT02601144|EXPERIMENTAL|VFS|variable frequency deep brain stimulation (VFS)
62293157|NCT02601144|ACTIVE_COMPARATOR|HFS|high frequency deep brain stimulation (HFS)
62293158|NCT02601144|ACTIVE_COMPARATOR|LFS|low frequency deep brain stimulation (LFS)
62293159|NCT02601144|NO_INTERVENTION|DBS off|deep brain stimulation off
62293160|NCT04796402|ACTIVE_COMPARATOR|Control|Standard of care
62465599|NCT00388024||cancer patients about to be treated with radiation therapy|Patienta with histologically confirmed squamous cell or lymphoepithelioma of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or unknown primary of the head and neck about to be treated with radiation therapy
61908531|NCT01022008|EXPERIMENTAL|Osteodistraction techniques|Osteodistraction techniques
61908532|NCT03877640|ACTIVE_COMPARATOR|Active EMSELLA treatment|6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology
61908533|NCT03877640|SHAM_COMPARATOR|Sham EMSELLA treatment|6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology
61908534|NCT00511940|EXPERIMENTAL|1|acamprosate
62095670|NCT04841044|EXPERIMENTAL|Intervention ( Cetoleic acid)|"6x mackerel oil (cetoleic acid: 16A%, estimated: 135 mg/g (FFA)) capsules every morning for 4 weeks~(A%= area percent)"
62095671|NCT04841044|PLACEBO_COMPARATOR|Control oil|"6x capsules control oil (Control oil= mix of anchovy oil, olive oil, high-oleic sunflower oil, rapeseed oil (cetoleic acid: 0,7 A% estimated: 6 mg/g (FFA)) every morning for 4 weeks~(A%= area percent)"
62095672|NCT03663387||Normal subjects|70
62095673|NCT00577447|ACTIVE_COMPARATOR|1|DHA supplemented group
62095674|NCT00577447|PLACEBO_COMPARATOR|2|Placebo group
62095675|NCT06087211|ACTIVE_COMPARATOR|Duloxetine and magnesium sulphate|this group will receive Duloxetine orally and magnesium sulphate intravenous infusion 1 hour before surgery.
62095676|NCT06087211|ACTIVE_COMPARATOR|Duloxetine|this group will receive Duloxetine orally and 200ml normal saline infusion
62095677|NCT06087211|PLACEBO_COMPARATOR|control|this will receive placebo capsule and an IV infusion of 200ml normal saline
62095678|NCT06423261|EXPERIMENTAL|Single Ascending Dose of GB002 Recombinant Peptide Inhalation Solution|Each subject will receive one single administration of GB002 recombinant peptide inhalation solution. The dosage of each group is 0.625mg, 1.25mg, 2.5mg, 5.0mg,7.5mg, respectively.
62095679|NCT06423261|EXPERIMENTAL|Multiple Ascending Dose of GB002 Recombinant Peptide Inhalation Solution|The subjects will receive multiple doses of GB002 recombinant peptide inhalation solution, administered twice a day for 6 consecutive days. The dosage for each group is 2.5mg, 5.0mg, and 6.5mg, respectively.
62095680|NCT04830514|EXPERIMENTAL|Recommended dietary allowance (RDA) for protein|(RDA; 0.8g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
62095681|NCT04830514|EXPERIMENTAL|Habitual protein intake consistent with population level norms|(NHANES; 1.0g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
62095682|NCT04830514|EXPERIMENTAL|Optimal protein intake (OPI)|(OPI; 1.5g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
62095683|NCT04236128|EXPERIMENTAL|Intervention Group|The intervention group will receive the same usual care as the control group plus be enrolled in the integrated discharge monitoring system.
62095684|NCT04236128|ACTIVE_COMPARATOR|Control Group|The control group will receive usual follow up care that is currently provided at the 3 participating centres.
61908535|NCT00511940|PLACEBO_COMPARATOR|2|sugar pill
62095685|NCT05450302||PURE EP|All patients from January 2022 till June 2022 in whom PURE EP was used at the Kansas City Heart Rhythm Institute, Overland Park, Kansas
62465600|NCT04176029||Children admitted with confirmed severe malaria|
62465601|NCT03496623|EXPERIMENTAL|Inhaled Treprostinil|Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms \[mcg\]) 4 times daily (QID)
62465602|NCT03496623|PLACEBO_COMPARATOR|Placebo|Placebo delivered via an ultrasonic nebulizer for QID administration
62465603|NCT04250064|EXPERIMENTAL|Concurrent low-dose Bevacizumab|Low-dose concurrent Bevacizumab with standard radiotherapy
61908536|NCT05595759|EXPERIMENTAL|Male patients with a diagnosis of alcohol and substance abuse|Male patients with a diagnosis of alcohol and substance abuse
61908537|NCT05595759|OTHER|Routine service operation|Male patients with a diagnosis of alcohol and substance abuse
61908538|NCT02901665|NO_INTERVENTION|Pre-FCC Intervention|Pre-intervention group. No intervention will be administered.
62095686|NCT06309043|EXPERIMENTAL|HLX05|
62095687|NCT06309043|ACTIVE_COMPARATOR|EU-sourced Erbitux|
62095688|NCT06309043|ACTIVE_COMPARATOR|US-sourced Erbitux|
62095689|NCT06309043|ACTIVE_COMPARATOR|CN-sourced Erbitux|
62095690|NCT00503074|EXPERIMENTAL|1|Parents receive tailored health-behavior change messages designed to reduce their child's exposure to televised food commercials. Intervention is delivered by a case manager, by a website, and by periodic newsletters.
62095691|NCT00503074|ACTIVE_COMPARATOR|Control|Parents of children ages 2-5 receive behavioral-change counseling around toddler \& preschooler safety and injury prevention.
62293161|NCT04796402|EXPERIMENTAL|Intervention|Administration of Bamlanivimab
62293162|NCT04558697|EXPERIMENTAL|Shepherd's Purse extractum oleosum vagitories|Vagitories containing Calendulae extractum oleosum 5,5% (w/w), Bursae pastoris extractum oleosum 5,5% (w/w), Matricariae extractum oleosum 5,5% (w/w), Hyperici extractum oleosum 5,5% (w/w) and Millefolii extractum oleosum 5,5% (w/w) as active component
62465604|NCT04250064|EXPERIMENTAL|Ultra-low-dose RT|Ultra-low-dose RT
61908539|NCT02901665|ACTIVE_COMPARATOR|Post-FCC Intervention|Following unit-wide implementation of FCC intervention consisting of communicating to families an expectation that they spend 4 hours per day in the NICU with their infants.
61908540|NCT03911102|EXPERIMENTAL|Cohort 1: DAXI 12 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
61908541|NCT03911102|EXPERIMENTAL|Cohort 2: DAXI 24 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
61908542|NCT03911102|EXPERIMENTAL|Cohort 3: DAXI 36 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
61908543|NCT03911102|EXPERIMENTAL|Cohort 4: DAXI 48 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
62095692|NCT02196012|EXPERIMENTAL|Lifestyle counseling|The intervention condition will contain multiple components: nutrition education, physical activity, social support, social media (Pinterest and Facebook), and smartphone applications for self-monitoring. Students in this condition will have access to the private study website, which will be the central platform for delivery of the program materials and social support. The website, developed using Wordpress.com, will include nutrition materials, exercise videos, a forum, and links to the study's Facebook and Pinterest pages
62095693|NCT02196012|ACTIVE_COMPARATOR|attention control condition|Students randomized to the attention control condition will receive educational emails three times per week. Nutrition materials will be sent once a week, and links to the YouTube exercise videos will be sent twice a week. At the start of the program, students will be emailed a link to the Pandora workout station. The materials sent to the control group will be the same materials posted on the website for the intervention group. Participants will access the emailed lessons and videos each week at their own convenience. Individuals in the attention control condition will not have access to the study website or social media pages.
62293163|NCT04558697|EXPERIMENTAL|Tea tree oil vagitories|Vagitories containing tea tree oil, 200 mg per each vagitorie as active component
62293164|NCT04558697|EXPERIMENTAL|Hyperici extractum oleosum vagitories|Vagitories containing Hyperici extractum oleosum 32% (w/w) as active component
62465605|NCT02592226|ACTIVE_COMPARATOR|Control group|
62465606|NCT02592226|EXPERIMENTAL|Protocol Group|
62293165|NCT04558697|ACTIVE_COMPARATOR|Vagitories - Probiotic|Commercially available vagitories with probiotic
62293166|NCT02151825|EXPERIMENTAL|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
62293167|NCT02151825|PLACEBO_COMPARATOR|Placebo|3 capsules of Maltodextrin per day
62293168|NCT01390545|ACTIVE_COMPARATOR|Veltuzumab 80 mg|
62293169|NCT01390545|ACTIVE_COMPARATOR|Veltuzumab 160 mg|
62293170|NCT01390545|ACTIVE_COMPARATOR|Veltuzumab 320 mg|
62293171|NCT01390545|PLACEBO_COMPARATOR|Placebo|
62293172|NCT00879450|EXPERIMENTAL|1 Booklet|
62293173|NCT00879450|ACTIVE_COMPARATOR|2 standard|
62293174|NCT00855439|EXPERIMENTAL|Exenatide|Subjects will take exenatide by subcutaneous injection twice daily for 18 months
62293175|NCT00855439|ACTIVE_COMPARATOR|glargine|Subjects will take 1 daily injection of insulin glargine for 18 months.
62293176|NCT04406571||"pancreatic adenocarcinoma before COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 16/03/2020.
62465607|NCT04044326|EXPERIMENTAL|microwave ablation (MWA)|20 patients with liver cancer, considered for local treatment of liver tumors of size measuring \<5 cm and without any signs of extra-hepatic metastasis, will be enrolled to be treated with microwave ablation (MWA)
62465608|NCT05723900|EXPERIMENTAL|Castor oil|Castor oil applied to one side of the selected primary canine
62465609|NCT05723900|EXPERIMENTAL|Formocresol|Formocresol applied to other side
62465610|NCT03931239|EXPERIMENTAL|Vaccination|DTPw-HB-Hib vaccine
62465611|NCT02511782|EXPERIMENTAL|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
62659102|NCT04144829|ACTIVE_COMPARATOR|HIFU|3 cycles of HIFU treatment in 6-week intervals
61908544|NCT00601952|EXPERIMENTAL|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
61908545|NCT00601952|PLACEBO_COMPARATOR|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
61908546|NCT03917524||no need for any adjuvant therapy|Patients with oral cavity squamous cell carcinoma post-surgery no need for any adjuvant therapy
62293177|NCT04406571||"pancreatic adenocarcinoma after COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 17/03/2020 and 31/10/2020.
61908547|NCT03917524||with risk factors|Patients with oral cavity squamous cell carcinoma post-surgery with major risk factor(s) or 2 minor risk factors Stratification by Risk factors, alcohol, betel nut chewing and cigarette use status
62095694|NCT04006795|EXPERIMENTAL|Developmental Serum|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square\[mL/cm\^2\] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm\^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
62293178|NCT03733652|NO_INTERVENTION|Tenofovir|Patents are treated with oral tenofovir 300mg once per day for 48 weeks. Then, tenofovir will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be continued if HBsAg is positive.
62293179|NCT03733652|ACTIVE_COMPARATOR|Interferon alfa|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
62293180|NCT04879615|EXPERIMENTAL|Alteplase with standard therapy|
62293181|NCT04879615|NO_INTERVENTION|Standard therapy|
62293182|NCT02606552|ACTIVE_COMPARATOR|Dabigatran plus aspirin|Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))
62293183|NCT02606552|EXPERIMENTAL|Dabigatran plus clopidogrel|medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)
62293184|NCT02606552|OTHER|Amplazter Cardiac Plug (ACP)|Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure
62465612|NCT02511782|EXPERIMENTAL|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
62659103|NCT04144829|ACTIVE_COMPARATOR|Fibrin|3 cycles of platelet-rich fibrin injection treatment in 6-week intervals
62659104|NCT06475976||Diagnostic cohort|Study participants will undergo the following diagnostic tests:
62659105|NCT01769586|ACTIVE_COMPARATOR|Diphenhydramine|Increments of 25 mcg to maximum of 3 times (total 75 mcg)
62659106|NCT01769586|ACTIVE_COMPARATOR|Midazolam|1.5 mg increments up to 3 times (maximum 4.5 mg)
62095695|NCT04006795|EXPERIMENTAL|Developmental Lotion|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm\^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm\^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
62293185|NCT03679403||ADHD Probands|Subjects with DSM-IV ADHD who received the same MRI and CANTAB+CPT assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at the estimated age of 15-25.
62293186|NCT03679403||Unaffected siblings of ADHD|The unaffected siblings received the MRI and CANTAB+CPT assessments during 2013.8-2015.7 (NCT01682915) will be recruited and assessed.
62659107|NCT03445429|EXPERIMENTAL|3D-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 3D-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 4 K-display system. After that again a NASA Task load index questionnaire is performed.
62659108|NCT03445429|EXPERIMENTAL|4K-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 4K-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 3D-display system. After that again a NASA Task load index questionnaire is performed.
62293187|NCT03679403||Neurotypicals Follow-up|Subjects without any lifetime diagnosis of DSM-IV ADHD or other psychiatric disorders as the control group of the ADHDFU group around 4-8 years ago when they received the same MRI and neuropsychological assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at their estimated age of 15-25.
62293188|NCT00666562|PLACEBO_COMPARATOR|Arm I (placebo)|Patients receive six oral placebo capsules once daily for 14-28 days.
62293189|NCT00666562|EXPERIMENTAL|Arm II (polyphenon E, placebo)|Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
62293190|NCT00666562|EXPERIMENTAL|Arm III (polyphenon E, trans-urethral resection or cystectomy)|Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
62293191|NCT06281392|EXPERIMENTAL|Colonoscopy assisted by CADe|
62293192|NCT06281392|ACTIVE_COMPARATOR|Virtual Colonoscopy with NBI|
62293193|NCT04879329|EXPERIMENTAL|Cohort A - DV monotherapy for HER2-positive tumor types|Disitamab vedotin monotherapy
62293194|NCT04879329|EXPERIMENTAL|Cohort B - DV monotherapy for HER2-low tumor types|Disitamab vedotin monotherapy
62293195|NCT04879329|EXPERIMENTAL|Cohort C - Non-randomized combination therapy|Disitamab vedotin + pembrolizumab
62293196|NCT04879329|EXPERIMENTAL|Cohort C - Randomized combination therapy|Disitamab vedotin + pembrolizumab
62293197|NCT04879329|EXPERIMENTAL|Cohort C - Randomized monotherapy|Disitamab vedotin monotherapy
62293198|NCT04879329|EXPERIMENTAL|Cohort D - DV monotherapy (Japan only)|Disitamab vedotin monotherapy
62293199|NCT04879329|EXPERIMENTAL|Cohort E - DV combination therapy (Japan only)|Disitamab vedotin + pembrolizumab
62293200|NCT01954823|EXPERIMENTAL|e-diary|The study group will have assess to an e-diary developed for people with MS, through the Internet and/or smart-phones. In addition, participants will continue to receive regular care at the MS clinic
62293201|NCT01954823|NO_INTERVENTION|no use of e-diary|Participants of the control group will receive regular care at the MS clinic and will and no use of the e-diary
62293202|NCT05658757|EXPERIMENTAL|Regular sweetened commercial foods (processed and high added sugar)|"This is the usual habits period. Participants consume the chosen, sweetened commercial products of their choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, they will eat regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as their usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, they will consume these regular sweetened beverages as they usually do."
62659109|NCT06361290||Patients|Patients under 18 years of age treated between 1986 and 2017 for malignant bone tumors of the lower limb (femur or tibia), diaphyseal or metaphyseal-diaphyseal and having benefited from diaphyseal resection of the tumor with biological reconstruction by either Membrane Induced, Fibula Vascularized and or Vascularized Fibula associated with an Allograft and having had a minimum follow-up of 5 years.
62293203|NCT05658757|EXPERIMENTAL|Allulose sweetened commercial foods (processed and low added sugar)|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
62293204|NCT05658757|EXPERIMENTAL|Whole and minimally processed and sweetened foods (low processed and low added sugar)|"This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines.~Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast food in place of usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If they eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as usual habits if more often~* If consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that usually do"
62293205|NCT05369819|EXPERIMENTAL|Group M|Patients of the Group M will be treated with midazolam premedication.
62659110|NCT06238726|NO_INTERVENTION|Passive control|Patients in this arm will not be sent any messages.
62293206|NCT05369819|PLACEBO_COMPARATOR|Group S|Group S patients are treated with 3 cc normal saline.
62659111|NCT06238726|ACTIVE_COMPARATOR|Active control|Patients in this arm will be sent messages encouraging them to ask about Shingrix at their upcoming appointment.
62659112|NCT06238726|EXPERIMENTAL|High risk|Patients in this arm will be sent messages informing them that they are at high risk for shingles because they are ages 50+, and encouraging them to ask about Shingrix at their upcoming appointment.
62095696|NCT04006795|EXPERIMENTAL|Developmental Cream|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm\^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm\^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
62659113|NCT06238726|EXPERIMENTAL|Multi-fact|Patients in this arm will be sent messages with facts about shingles and Shingrix, and encouraging them to ask about Shingrix at their upcoming appointment.
62659114|NCT06238726|EXPERIMENTAL|High risk + multi-fact|Patients in this arm will be sent messages informing them that they are at high risk for shingles because they are ages 50+, with additional facts about shingles and Shingrix, and encouraging them to ask about Shingrix at their upcoming appointment.
62659115|NCT03127059|EXPERIMENTAL|Breathing Exercises|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Three physiotherapist-sessions of Breathing Exercises (BrEX) with duration of 60 minutes (the initial) and 30 minutes (other sessions) at week 1, 4, and 9. The participant is expected to do 10 minutes of home exercise twice daily. The entire intervention combines elements of the Papworth method, and the Buteyko technique."
62659116|NCT03127059|OTHER|Usual care|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Besides the individual instruction described above, patients will receive only short information given initially at recruitment. They are allowed to receive instruction in positive expiratory pressure-treatment and physiotherapy targeting other problems than dysfunctional breathing (DB)."
62659117|NCT02263313||EGO-COMBO group|Previously enrolled into EGO-COMBO Pilot study and with combo stent
61908548|NCT03759808|EXPERIMENTAL|Persistent Post-Concussion Symptoms|Concussed participants with persistent post-concussion symptoms (PPCS) who receive the psychological intervention.
62293207|NCT03358914||Adolescents with psoriasis|No assigned intervention: completion of PsoTeenQOL and other instruments for assessment of psychometric properties and further refinement of the PsoTeenQOL.
62293208|NCT03358914||Parents of adolescents with psoriasis|No assigned intervention: completion of proxy-version of the PsoTeenQOL for validation purposes
62659118|NCT03453736||Robotic procedures|Experiences and practices in Robotic theatres will be studied via semi-structured interviews with staff as well as team observations during real time robotic surgery. As the study is a qualitative one, data collection will continue till we reach saturation of theoretical categories. We expect 20 interviews and 10 observations to suffice.
61908549|NCT03743077|EXPERIMENTAL|Individuals with spinal cord injury|Volunteers will participate in the the spinal mobility fitness training program which includes exercise training with inspiratory muscle training.
61908550|NCT02061527|EXPERIMENTAL|Breast reconstruction with ADM|Implant based Breast Reconstruction with ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implants. Patients in group B with ADM and partial submuscular coverage.
61908551|NCT02061527|ACTIVE_COMPARATOR|Breast reconstruction without ADM|Breast reconstruction without ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implant. Patients in group B will be reconstructed with implant and total submuscular coverage.
62293209|NCT03358914||Adolescents without psoriasis|No assigned intervention: completion of non-psoriasis control-version of the PsoTeenQOL for validation purposes
62659119|NCT03453736||Non-Robotic procedures|"Staff involved in robotic surgery will have almost definitely worked in non-robotic theatres ie major abdominal and laparoscopic. Staff interviews will explore differences in experiences and practices between these different theatre setups.~In addition, we aim to observe further 5 non-robotic procedures to evaluate staff teamwork and communication within the more regular theatre setup."
62659120|NCT03786393||Fibromyalgia|100 participants diagnosed with fibromyalgia according to ACR 1990 criteria.
62659121|NCT03786393||Control|
62659122|NCT06437171|OTHER|Open Label Injection of Omalizumab|Omalizumab dose and frequency based on baseline patient weight and total IgE
62659123|NCT00724945|ACTIVE_COMPARATOR|senofilcon A / balafilcon A|senofilcon A multifocal lenses worn first, balafilcon A multifocal lenses worn second
62659124|NCT00724945|ACTIVE_COMPARATOR|balafilcon A/senofilcon A|balafilcon A multifocal lenses worn first, senofilcon A multifocal lenses worn second
62659125|NCT00908700|EXPERIMENTAL|Occlusion arm|Surgical intervention: Occlusion of the left atrial appendage (LAA) using 'cut-and-sew' technique appendage occlusion.
62659126|NCT00908700|ACTIVE_COMPARATOR|Medical arm|Medical arm: The comparator is best medical practice for atrial fibrillation related stroke prevention as per guidelines.
62659127|NCT02842866|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.
62659128|NCT02842866|ACTIVE_COMPARATOR|Group 2: Menomune® Vaccine|Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.
62659129|NCT00917696|ACTIVE_COMPARATOR|1|ATP
62659130|NCT00917696|PLACEBO_COMPARATOR|2|Saline
62659131|NCT02052635|EXPERIMENTAL|Ticagrelor|90 mg oral tablet
62659132|NCT02052635|ACTIVE_COMPARATOR|Clopidogrel|300 mg oral tablet
62659133|NCT02833909|EXPERIMENTAL|HS|
62659134|NCT02833909|EXPERIMENTAL|Controls|
62659135|NCT02273947|EXPERIMENTAL|Arm 1 (ABDC): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
61908552|NCT01696162|ACTIVE_COMPARATOR|PDF exercise sheets|Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
62293210|NCT05850741|EXPERIMENTAL|Device|"The following procedure steps will take place:~* The study system is installed in the room before patient arrival~* The patient needs to fully undress the upper body before lying on the bed~* The 3 ECG electrodes are placed~* Ultrasound gel is applied on the ultrasound probe"
62293211|NCT05020379|SHAM_COMPARATOR|Group N|"The patients in Group N will not receive any intervention. Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol. The pain intensity will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS are the simple and most commonly used scales.11 The numerical scale is most commonly 0 to 10, with 0 being no pain and 10 being the worst pain imaginable."
62659136|NCT02273947|EXPERIMENTAL|Arm 2 (BCAD): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
62659137|NCT02273947|EXPERIMENTAL|Arm 3 (CDBA): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
62659138|NCT02273947|EXPERIMENTAL|Arm 4 (DACB): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
62659139|NCT02273947|EXPERIMENTAL|Arm 5 (EFHG): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
62659140|NCT02273947|EXPERIMENTAL|Arm 6 (FGEH): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
62659141|NCT02273947|EXPERIMENTAL|Arm 7 (GHFE): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
62659142|NCT02273947|EXPERIMENTAL|Arm 8 (HEGF): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
62659143|NCT02273947|EXPERIMENTAL|Arm 9 (IJK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659144|NCT02273947|EXPERIMENTAL|Arm 10 (JKI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659145|NCT02273947|EXPERIMENTAL|Arm 11 (KIJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659146|NCT02273947|EXPERIMENTAL|Arm 12 (IKJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659147|NCT02273947|EXPERIMENTAL|Arm 13 (JIK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659148|NCT02273947|EXPERIMENTAL|Arm 14 (KJI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659149|NCT02273947|EXPERIMENTAL|Arm 15 (LMN): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
61908553|NCT01696162|ACTIVE_COMPARATOR|Limited Exercise Videos|"Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks.~A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety."
62095697|NCT04006795|PLACEBO_COMPARATOR|Negative Control|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm\^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm\^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
62293212|NCT05020379|EXPERIMENTAL|Group ESPB|The patients in the group ESPB will be placed in sitting pozition. A convex probe ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS)
62293213|NCT02005055||Patients with recalcitrant keloid scars|All patients with keloids insensitive to other treatments
62293214|NCT03770403|EXPERIMENTAL|ARGX-113|
62465613|NCT02511782|ACTIVE_COMPARATOR|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
62293215|NCT00461175||1|Mirena®
62293216|NCT00461175||2|Copper IUD
62465614|NCT01110473|EXPERIMENTAL|Monotherapy, once daily|
62465615|NCT01110473|EXPERIMENTAL|Monotherapy, twice daily|
62465616|NCT01110473|EXPERIMENTAL|Combination with Azacitidine|
62465617|NCT01110473|EXPERIMENTAL|IV monotherapy, once daily|
62465618|NCT04407962|EXPERIMENTAL|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
62465619|NCT04407962|NO_INTERVENTION|Control group|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
62465620|NCT03289286|OTHER|Patients with breast cancer operated in ambulatory|
61908554|NCT01696162|EXPERIMENTAL|Algorithm based Exercise Videos|Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
61908555|NCT03561532|ACTIVE_COMPARATOR|FMT|50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum
62095698|NCT03186937|EXPERIMENTAL|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
62293217|NCT00277758|EXPERIMENTAL|1|Interventions: 12 weeks of interleukin-2 administration, followed by 48 weeks of interleukin-2 + Ribavirin + interferon-alpha therapy, followed by 24 weeks off therapy
62293218|NCT00277758|ACTIVE_COMPARATOR|2|48 weeks of therapy with Ribavirin + interferon-alpha, followed by 24 weeks off therapy
62293219|NCT06402409||Group 1: No treatment burden|Individuals scoring a total of 0 points on the Multimorbidity Treatment Burden Questionnaire, reflecting no perceived treatment burden.
62293220|NCT06402409||Group 2: Low treatment burden|Individuals scoring a total of below 10 points (but over 0) on the Multimorbidity Treatment Burden Questionnaire, reflecting low perceived treatment burden.
62659150|NCT02273947|EXPERIMENTAL|Arm 16 (OPQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659151|NCT02273947|EXPERIMENTAL|Arm 17 (PQO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659152|NCT02273947|EXPERIMENTAL|Arm 18 (QOP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659153|NCT02273947|EXPERIMENTAL|Arm 19 (OQP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
61908556|NCT03561532|PLACEBO_COMPARATOR|Placebo|50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.
61908557|NCT00205907|EXPERIMENTAL|single|BLVR treatment
62293221|NCT06402409||Group 3: Medium treatment burden|Individuals scoring a total of between 10 and 22 points on the Multimorbidity Treatment Burden Questionnaire, reflecting medium perceived treatment burden.
62293222|NCT06402409||Group 4: High treatment burden|Individuals scoring a total of over 22 points on the Multimorbidity Treatment Burden Questionnaire, reflecting high perceived treatment burden.
62293223|NCT03463772|ACTIVE_COMPARATOR|standard IVF|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group A will receive standard IVF procedure. Other standard assisted reproductive treatments are similar and parallel between two groups.
62659154|NCT02273947|EXPERIMENTAL|Arm 20 (POQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659155|NCT02273947|EXPERIMENTAL|Arm 21 (QPO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
62659156|NCT06444698|EXPERIMENTAL|Experimental group|the experimental group will receive two cookies that contain 50 grams of quinoa
62659157|NCT06444698|PLACEBO_COMPARATOR|Control group|control group will receive the same two cookies that but without quinoa
62659158|NCT04897243||Multidisciplinary model of care|The Chronic Viral Illness Service at the Glen hospital of the MUHC will provide care with a multidisciplinary assessment, according to local current standard practice. Each newly-referred patient at the CVIS will be first received by a dedicated nurse, who then orients referral to a physician and/or a social worker and/or a pharmacist.
61908558|NCT00796926|EXPERIMENTAL|Systane Ultra|Used four times a day topically to each eye
61908559|NCT00796926|ACTIVE_COMPARATOR|Refresh|Used four times a day topically to each eye
61908560|NCT03499964|EXPERIMENTAL|Optilume Treatment|The treatment arm will be the Urotronic Optilume Drug Coated Balloon (DCB).
61908561|NCT03499964|ACTIVE_COMPARATOR|Control Treatment|The control arm will be treated by a urethral dilation method considered to be best standard of care for the study site and subject. A control treatment may be either a rod, uncoated balloon or DVIU.
61908562|NCT04503187||Chronic Stroke|Participants who suffered a single event of cerebral vascular accident at least six months ago before study enrollment.
61908563|NCT04503187||Multiple Sclerosis|Participants who has been diagnosed with multiple sclerosis
61908564|NCT04503187||Healthy control|Age-matched healthy adults who are self-reported healthy and has no known musculoskeletal, neuromuscular, and cardiovascular diseases.
62659159|NCT04897243||Physician-only model of care|The Jewish General Hospital will provide care as per current local standard practice. Each newly-referred patient will be assessed by a clinician. Blood tests will be performed by central laboratory nurses who are not part of the HIV clinic.
62293224|NCT03463772|ACTIVE_COMPARATOR|In vitro maturation|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group B will receive IVM procedure.Other standard assisted reproductive treatments are similar and parallel between two groups.
62293225|NCT05320939|EXPERIMENTAL|Mepolizumab 100mg|The Investigators will recruit a total of 30 subjects for this study (all subjects for the mepolizumab treatment).
62293226|NCT00880750|EXPERIMENTAL|Lanthanum carbonate granules|Lanthanum carbonate granulated formulation crossover to chewable tablet formulation
62293227|NCT00880750|EXPERIMENTAL|Lanthanum carbonate chewable tablets (Fosrenol)|Lanthanum carbonate chewable table formulation crossover to granulated formulation
62293228|NCT03578835||Multi-center BSI cohort|Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
62659160|NCT02682121|PLACEBO_COMPARATOR|Placebo|Patients on placebo.
62659161|NCT02682121|ACTIVE_COMPARATOR|Active drug|Patients on Metformin, 850mg twice daily for 6mos.
61908565|NCT01337999||HE-4 levels, healthy premenopausal women|
61908566|NCT01604993|EXPERIMENTAL|High nitrate dietary source|556 grams of high nitrate spinach soup that is orally consumed as a single dose for 7 days.
61908567|NCT01604993|PLACEBO_COMPARATOR|No Nitrate dietary source|556g low nitrate asparagus soup; orally consumed as a single does for 7 days.
61908568|NCT05599477|EXPERIMENTAL|Endoscopic sutured gastroplasty|
61908569|NCT03310333|EXPERIMENTAL|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
62659162|NCT05445960|ACTIVE_COMPARATOR|Tourniquet|This arm will have a tourniquet placed around the thigh inflated to 250mmHg for the duration of surgery (until splint placed) or 2 hours, whichever is shorter, during ankle fracture surgery.
62659163|NCT05445960|NO_INTERVENTION|No Tourniquet|This arm will have a tourniquet placed around the thigh but NOT inflated for the duration of ankle fracture surgery.
62659164|NCT00594139|EXPERIMENTAL|1|Receipt of autologous neo-bladder construct
62659165|NCT04510168||MRI Only|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at least 50-60 people with dementia (as determined by the ongoing NOMAS procedures).
62659166|NCT04510168||MRI and PET|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study (NOMAS) participants. The investigators aim to include at 20 participants with dementia and 40 participants without (as determined by the ongoing NOMAS procedures). In addition to MRI, participants in this group will have three PET studies.
61908570|NCT03310333|ACTIVE_COMPARATOR|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
62659167|NCT05321784|EXPERIMENTAL|Self-skin exam (SSE), digital dermoscopy image (DDI), Sklip System, full body skin exam (FBSE).|This is a single-arm prospective trial. Participants perform self-skin exams using naked-eye criteria and will take smartphone clinical images (SCI) of each PSL of concern (PSLC). Participants will also take digital dermoscopy images (DDIs) and apply the Sklip System (integrating the Sklip Mole Scan Algorithm (SMSA) to each PSLC of concern in up to 14 days. Within up to 28 days of completing the at-home exams, participants will undergo an in-office visit full body skin exam (FBSE).
62659168|NCT05707208|EXPERIMENTAL|ST-01 70 mg/mL|
62659169|NCT05707208|EXPERIMENTAL|ST-01 140 mg/mL|
62659170|NCT05707208|ACTIVE_COMPARATOR|1% Lidocaine HCL|
62659171|NCT01307072||Never-treated group|The patients who had no previous ophthalmic examination until the first visit when vitreous surgery was prescribed
61908571|NCT00603642|PLACEBO_COMPARATOR|AMG 531|Double blinded placebo-controlled study
61908572|NCT00603642|PLACEBO_COMPARATOR|Placebo|
61908573|NCT03015480|EXPERIMENTAL|Remote counseling|This group of people will be asked to track dietary information on MyFitnessPal and receive remote dietary counseling with a dietitian.
62659172|NCT01307072||The non-compliant group|The patients with a history of missing ophthalmic examination over a one year period
62659173|NCT01307072||The compliant group|The patients who had ophthalmic examinations at least once a year
61908574|NCT00400803|EXPERIMENTAL|Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|Patients treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
61908575|NCT02143050|EXPERIMENTAL|Dabrafenib, Trametinib and Metformin|Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.
62659174|NCT01440920|EXPERIMENTAL|Cohort 1|0.3 mg
61908576|NCT00710762|EXPERIMENTAL|BIBF1120|
61908577|NCT00710762|PLACEBO_COMPARATOR|Placebo|
61908578|NCT03284918|EXPERIMENTAL|Plant stanol ester|Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar). Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
62465621|NCT02715622||Open Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia open repair surgical procedure
62659175|NCT01440920|EXPERIMENTAL|Cohort 2|1 mg
62659176|NCT01440920|EXPERIMENTAL|Cohort 3|3 mg
62659177|NCT04455932|EXPERIMENTAL|HCC surveillance with US and aNC-MRI|
61908579|NCT03284918|PLACEBO_COMPARATOR|Placebo|Cereal based snack bar without plant stanol ester. Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
61908580|NCT03725462|EXPERIMENTAL|Cardioskin|Subjects performed a monitoring with Cardioskin. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Cardioskin, either by an opinion of an expert.
61908581|NCT03725462|EXPERIMENTAL|Neuronaute|Subjects performed a monitoring with Neuronaute. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Neuronaute, either by an opinion of an expert.
61908582|NCT04564300|EXPERIMENTAL|Oral contraceptive users|
61908583|NCT04564300|ACTIVE_COMPARATOR|Non-oral contraceptive users|
62659178|NCT02587416|EXPERIMENTAL|Gemcabene 300 mg|Gemcabene 300 mg
62659179|NCT02587416|EXPERIMENTAL|Gemcabene 900 mg|Gemcabene 900 mg
62659180|NCT02587416|ACTIVE_COMPARATOR|Atorvastatin 80 mg|Atorvastatin 80 mg
62659181|NCT04607031||ischemic stroke patients|20 patients with ischemic stroke, onset within 24 hours, NIHSS≥8
62659182|NCT03570593|NO_INTERVENTION|Retrospective Group|
62659183|NCT03570593|EXPERIMENTAL|Prospective Group|
62659184|NCT03036943|EXPERIMENTAL|Fluciclovine (18F) PET/CT|
62659185|NCT01537588|ACTIVE_COMPARATOR|Standard|ACL reconstruction with autograft harvest of STG from ACL-deficient leg
62659186|NCT01537588|EXPERIMENTAL|Autograft harvest of STG from ACL-deficient leg|Autograft harvest of STG from leg contralateral to ACL-deficient leg
62659187|NCT01537588|NO_INTERVENTION|Normal matched|
62659188|NCT06452550||Crohn's disease patients with no-to-mild inflammation|On MR enterography, the Magnetic Resonance Index of Activity (MaRIA) and Magnetic Resonance Enterography Global Score (MEGS) were used to characterize intestinal inflammation by assessing intramural and extramural lesions in both the small and large intestines. In ileocolonoscopy, the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD) was used to quantify mucosal or luminal lesions from the terminal ileum to the colorectum. Both modalities were used to classify patients with no-to-mild or moderate-to-severe inflammation. We defined patients as having moderate-to-severe inflammation when at least two of the following criteria were met: (1) MaRIA≥11; (2) MEGS≥ 10 for the small bowel or MEGS≥12 for the colon; or (3) SES-CD≥11. Otherwise, patients were categorized as having no-to-mild inflammation.
62659189|NCT06452550||Crohn's disease patients with moderate-to-severe inflammation|On MR enterography, the Magnetic Resonance Index of Activity (MaRIA) and Magnetic Resonance Enterography Global Score (MEGS) were used to characterize intestinal inflammation by assessing intramural and extramural lesions in both the small and large intestines. In ileocolonoscopy, the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD) was used to quantify mucosal or luminal lesions from the terminal ileum to the colorectum. Both modalities were used to classify patients with no-to-mild or moderate-to-severe inflammation. We defined patients as having moderate-to-severe inflammation when at least two of the following criteria were met: (1) MaRIA≥11; (2) MEGS≥ 10 for the small bowel or MEGS≥12 for the colon; or (3) SES-CD≥11. Otherwise, patients were categorized as having no-to-mild inflammation.
62659190|NCT06043297|EXPERIMENTAL|Apixaban 5 mg Film Tablets|
62659191|NCT06043297|ACTIVE_COMPARATOR|Eliquis 5 mg Film tablets|
62659192|NCT01147445|EXPERIMENTAL|Cohort 1: 5 mcg dmLT|6 subjects to receive 5 micrograms (mcg) of dmLT vaccine.
62659193|NCT01147445|EXPERIMENTAL|Cohort 4: 100 mcg dmLT|6 subjects to receive 100 mcg of dmLT vaccine.
62659194|NCT01147445|EXPERIMENTAL|Cohort 2: 25 mcg dmLT|6 subjects to receive 25 mcg of dmLT vaccine.
62659195|NCT01147445|EXPERIMENTAL|Cohort 3: 50 mcg dmLT|6 subjects to receive 50 mcg of dmLT vaccine.
62659196|NCT01147445|EXPERIMENTAL|Cohort 5: 50 mcg or 100 mcg dmLT|12 subjects randomized, double-blinded, to receive either 50 mcg or 100 mcg of dmLT vaccine.
62659197|NCT05311865|EXPERIMENTAL|participating to the event|
62659198|NCT05311865|NO_INTERVENTION|Non partipating to the event|
62659199|NCT02978807||Pregnant women between 24 to 32 weeks|"Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.~All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c."
62659200|NCT06370819|EXPERIMENTAL|NNC0519-0130|Participants will receive single subcutaneous (s.c.) dose of NNC0519-0130.
62659201|NCT06293820|ACTIVE_COMPARATOR|TL-925 Arm|Subjects will be dosed in clinic and at home.
62659202|NCT06293820|PLACEBO_COMPARATOR|Placebo Arm|Subjects will be dosed in clinic and at home.
62659203|NCT03424642|EXPERIMENTAL|Interactive 4D-ultrasound examination|Pregnant women who are randomized to 4D-ultrasound intervention group will receive additional 4D-ultrasound examinations 2-3 times between gestational weeks 25-32. Patients in this group will also receive psychologist's interview twice and fill out questionaries.
62659204|NCT03424642|NO_INTERVENTION|Control group|Pregnant women who are randomized to control group will receive psychologist's interview twice twice and fill out questionaires.
62659205|NCT02860078|ACTIVE_COMPARATOR|Ultrasound|The group I will be subjected to epidural infiltration using methylprednisolone acetate diluted in ropivacaine 0.1%. Initially the sacral hiatus is identified by palpation. After, the ultrasound device is used (USG) for the puncture, with a linear transducer of high frequency. At the end of corticosteroid administration, the placement of the needle tip will be checked with fluoroscopy and noted.
62659206|NCT02860078|ACTIVE_COMPARATOR|Radioscopy|The group II will be subjected to infiltration using methylprednisolone acetate diluted in ropivacaine 0.1% . However, only radioscopy be used to guide the puncture.
61908584|NCT04951323|EXPERIMENTAL|Injection of anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Injection of two doses (at Day 1 and Day 21) of the anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
61908585|NCT02285062|EXPERIMENTAL|R2-CHOP|Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
61908586|NCT02285062|ACTIVE_COMPARATOR|R-CHOP|Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
61908587|NCT04043598|ACTIVE_COMPARATOR|high sodium infusion fluid|Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
61908588|NCT04043598|ACTIVE_COMPARATOR|low sodium infusion fluid|Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
61908589|NCT02581150|OTHER|Outpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during an ambulatory hospitalisation, with the use of an arterial closure device (ACD).~The patients treated for PAD (Peripheral Arterial Disease) are informed and prepared in the morning of D0. The surgical endovascular procedure is performed at D0 before 1:00 p.m. The patients leave the hospital in the evening at D0 after a systematic visit."
61908590|NCT02581150|OTHER|Conventional inpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during a conventional hospitalisation, with or without ACD (ACD will be used at the discretion of the interventionalist).~The patients treated for PAD arrive at the hospital the day before surgery (D-1). The surgical endovascular procedure takes place the next day (D0). The day after (D1), the patients leave the hospital after a systematic visit."
61908591|NCT00317278|EXPERIMENTAL|A,1|Massage therapy
61908592|NCT00317278|SHAM_COMPARATOR|A,2|
61908593|NCT00853996|EXPERIMENTAL|Prevention (acolbifene hydrochloride)|Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
61908594|NCT02074891||Persons prescribed PrEP|adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.
62659207|NCT00592293|EXPERIMENTAL|Proton Beam Radiation|Proton Beam Radiation
62659208|NCT06064240||Before operation, 1 month after operation, 3 months after operation and 6 months after operation.|Patients who underwent bariatric surgery were followed up regularly before and after surgery.
62659209|NCT00974870|EXPERIMENTAL|needling treatment|Needling treatment applied to half of the face at each study visit
62659210|NCT00974870|NO_INTERVENTION|Control|No treatment applied to half of the face
62659211|NCT04718701|EXPERIMENTAL|Experimental Group|Patients who failed first-line therapy with locally advanced or metastatic pancreatic cancer will be assigned to receive anlotinib plus toripalimab and nab-paclitaxel as second-line or maintenance treatment.
62659212|NCT02199587|ACTIVE_COMPARATOR|Endocrine test with medical clown|children who are referred to endocrine test will have the procedure with a medical clown, or without. The pain and anxiety perception of the child and caregivers will be compare between the two scenarios
62659213|NCT02199587|NO_INTERVENTION|Endocrine test without medical clown|
62659214|NCT01523197|OTHER|ventilator|The comparison of the curative effect on OS between BiPAP and auto-trilevel ventilations
62659215|NCT05759871|EXPERIMENTAL|FSH only (no GnRH antagonist)|Women receive only FSH starting on day 2 of the cycle. The starting dose of FSH is 225-300 IU s.c. for the first 4 days adjusted thereafter according to the ovarian response.
62293229|NCT00737529|EXPERIMENTAL|Lenalidomide|"Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but \< 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal."
62659216|NCT05759871|ACTIVE_COMPARATOR|FSH + GnRH antagonist|Women receive 225-300 IU s.c. FSH, and a GnRH antagonist from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day. The GnRH antagonist in group 2 is injected each time immediately after the injection of FSH.
62659217|NCT06268223|EXPERIMENTAL|Study Group|
62293230|NCT04233125|ACTIVE_COMPARATOR|Core Decompression (CD) Only|Participants in this group receive standard care
62293231|NCT04233125|EXPERIMENTAL|Added Polymethylmethacrylate (PMMA)|Participants in this group receive standard care with an additional treatment
62293232|NCT01118910|EXPERIMENTAL|Vusion ointment|
62293233|NCT06519656|EXPERIMENTAL|Mazdutide Treatment Arm|Subcutaneous injection of Mazdutide once weekly for 24 weeks.
62293234|NCT02300649|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
62659218|NCT06268223|ACTIVE_COMPARATOR|Control Group|
62659219|NCT01867255|OTHER|venlafaxine ER|venlafaxine ER (extended-release) 75 mg once
62659220|NCT03890965|EXPERIMENTAL|Experimental|Adult patients with chronic sequelae in the upper limb after neurological damage
62659221|NCT05726253|PLACEBO_COMPARATOR|Placebo|Randomization to receive either oral placebo or amoxicillin for a standard course (7 days)
62659222|NCT05726253|ACTIVE_COMPARATOR|Amoxicillin|Randomization to receive either oral amoxicillin or placebo for a standard course (7 days)
62659223|NCT00088855|EXPERIMENTAL|Treatment (bortezomib and pegylated liposomal doxorubicin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 4. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
61908595|NCT02586506|EXPERIMENTAL|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
62465622|NCT02715622||Laparoscopic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia laparoscopic repair surgical procedure
62659224|NCT03276143|ACTIVE_COMPARATOR|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
62659225|NCT03276143|ACTIVE_COMPARATOR|Apixaban|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
62659226|NCT03276143|EXPERIMENTAL|BAY1213790 0.3 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
62659227|NCT03276143|EXPERIMENTAL|BAY1213790 0.6 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
62659228|NCT03276143|EXPERIMENTAL|BAY1213790 1.2 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
62659229|NCT03276143|EXPERIMENTAL|BAY1213790 1.8 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
62659230|NCT03276143|EXPERIMENTAL|BAY1213790 0.3 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
62659231|NCT03276143|EXPERIMENTAL|BAY1213790 1.8 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.
62659232|NCT02827539|OTHER|Research|If the patient is randomized to the Research Arm, the physician will begin the procedure utilizing LessRay enhanced fluoroscopic images.
62659233|NCT02827539|OTHER|Control|For patients in the control arm standard fluoroscopy will be used with the C-arm set to the conventional full dose setting
62659234|NCT02617095|EXPERIMENTAL|T2762|One drop of T2762 in each eye 3 to 6 times daily
62659235|NCT02617095|ACTIVE_COMPARATOR|Optive|One drop of Optive in each eye 3 to 6 times daily
62659236|NCT05813561|EXPERIMENTAL|DWP14012|
62659237|NCT05813561|ACTIVE_COMPARATOR|Lansoprazole|
62659238|NCT06098547|EXPERIMENTAL|Study population|"Candidates will be evaluated by theMultidisciplinary Group after routine radiological studies (CT, MRI, PET-MR/CT).~Patients will receive 6 months of standard of care chemotherapy and undergo PET-MR with FDG to exclude the presence of extrahepatic disease.~Following completion of therapy, patients will undergo radiological restaging. If the disease is resectable, the patient will be considered for curative-intent surgical resection; if not, the patients will be evaluated by the Center's Multidisciplinary Transplantation Group.~Patients will continue chemotherapy until a compatible liver becomes available. If there are no further contraindications, exploratory laparotomy and surgical nodal staging of the tumor will be performed at the time of transplantation. If there are no signs of extrahepatic disease, transplantation will be conducted according to institutional protocols."
61908596|NCT04392700|EXPERIMENTAL|group A|drugs：tenofovir disoproxil fumarate, dose：300mg/d
62659239|NCT06358833|ACTIVE_COMPARATOR|Endodontic needle (EN)|In this group, the irrigation of root canals will be done with 2.5 % sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The tip of the needle will be pre-measured and positioned within 1 millimeter of the working length. No activation of the irrigant will be performed.
62659240|NCT06358833|EXPERIMENTAL|Endodontic activation (EA)|In this group, the irrigation of root canals will be done with 2.5% sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The irrigant will be activated with ultrasonic energy using the Endo-1 Ultrasonic Endo Activator (Guilin Woodpecker, Guilin, China). The tip of the Endo-1 Ultrasonic Endo Activator device will be pre-measured and kept within 1 mm from the working length. The manufacturer's instructions regarding irrigant activation will be followed.
61908597|NCT04392700|ACTIVE_COMPARATOR|group B|drugs：entecavir dose： 0.5 mg/d
61908598|NCT02184455|EXPERIMENTAL|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
62659241|NCT03112538|ACTIVE_COMPARATOR|Insulin pump|Medtronic Minimed Paradigm Veo Insulin Pump utilising rapid acting insulin Glulisine or Aspart
62659242|NCT03112538|ACTIVE_COMPARATOR|Multiple daily injections of insulin|Multiple daily injections consisting of a single basal insulin injection(Glargine) and 3 bolus insulin injections (rapid acting insulin Glulisine or Aspart) before each meal
61908599|NCT05981976|EXPERIMENTAL|Abatacept Treatment A|
61908600|NCT05981976|EXPERIMENTAL|Abatacept Treatment B|
62465623|NCT02715622||Robotic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia robotic-assisted laparoscopic repair surgical procedure
62465624|NCT01028469|EXPERIMENTAL|Artelon MTP Spacer|Metatarsophalageal hemi-implant
62659243|NCT01147458|EXPERIMENTAL|PF-04191834 followed by placebo|PF-04191834 600 mg BID dose followed by matched placebo plus naproxen placebo.
62293235|NCT02300649|PLACEBO_COMPARATOR|Control group|Saline will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
62293236|NCT05674448|EXPERIMENTAL|HH-003 20mg/kg|HH-003 20mg/kg, intravenously, Q2W
62659244|NCT01147458|EXPERIMENTAL|Placebo followed by PF-04191834|Placebo followed by 600 mg BID dose of PF-04191834 plus naproxen placebo.
62659245|NCT01147458|EXPERIMENTAL|PF-04191834+Naproxen followed by Naproxen|PF-04191834 600 mg BID + Naproxen 500 mg BID followed by Naproxen 500 mg BID plus PF-04191834 placebo
62659246|NCT01147458|EXPERIMENTAL|Naproxen followed by PF-04191834+Naproxen|Naproxen 500 mg BID followed by PF-04191834 600 mg BID + Naproxen 500 mg BID
62659247|NCT06340659|EXPERIMENTAL|Group 1|Subjects randomized to HbAEX
62659248|NCT06340659|EXPERIMENTAL|Group 2|Subjects randomized to HbExergame
62659249|NCT05500755||Patients DS Prime Taper|Patients who receive al least one DS Prime Taper on his dental implant treatment.
62293237|NCT05674448|EXPERIMENTAL|HH-003 3mg/kg|HH-003 3mg/kg, intravenously, Q2W
62659250|NCT02729857|EXPERIMENTAL|Familial hypercholesterolemia|Subjects diagnosed with familial hypercholesterolemia receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
62659251|NCT02729857|ACTIVE_COMPARATOR|Healthy|Subjects with no chronic diseases receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
62659252|NCT02750722|EXPERIMENTAL|Cycling in combination with Flutter® therapy|Participants perform 30 minutes of moderately intense cycling exercise in 4-min intervals at 75% of their maximal heart rate and interspersed with 2-min resting periods during which 6-8 breathing maneuvers are performed with the Flutter®.
62659253|NCT02750722|ACTIVE_COMPARATOR|Cycling without Flutter® therapy|Participants perform 30 minutes of continuous moderately intense cycling exercise at 75% of their maximal heart rate without additional Flutter® breathing maneuvers.
62659254|NCT03565289||All patients|All
62659255|NCT01481025|EXPERIMENTAL|Cimicifuga+Hiperico|80 + 450 mg / tablet
62659256|NCT01481025|ACTIVE_COMPARATOR|Cimicifuga Herbarium|80 mg / caps
62293238|NCT00642330|ACTIVE_COMPARATOR|I|
62293239|NCT00642330|ACTIVE_COMPARATOR|O|
62659257|NCT01481025|ACTIVE_COMPARATOR|Aplause®|20 mg / tablet
61908601|NCT03740893|NO_INTERVENTION|Cohort A (standard care reference cohort)|
61908602|NCT03740893|EXPERIMENTAL|Cohort B (AZD6738 monotherapy)|
61908603|NCT03740893|EXPERIMENTAL|Cohort C (olaparib monotherapy)|
62293240|NCT06217393|EXPERIMENTAL|Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals|Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)
62293241|NCT06217393|ACTIVE_COMPARATOR|Active Control group - Itopride Hydrochloride 50 mg film|
62293242|NCT01931046|EXPERIMENTAL|Part 1|Treatment at one of three dose levels of Ad5-SGE-REIC/Dkk-3 in a sequential dose-escalating design with 4 cycles of therapy at each dose level permitted.
62659258|NCT01812915|EXPERIMENTAL|Cylindrical-shape cuff ETT (Group C)|Control group: Mallinckrodt HiLo(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt Hi-Lo(TM) tube.
62293243|NCT01931046|EXPERIMENTAL|Part 2|Treatment with Ad5-SGE-REIC/Dkk-3 every 6-weeks for up to 4 cycles of therapy and may continue therapy if they have stable disease or are responding.
62293244|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
62659259|NCT01812915|EXPERIMENTAL|Tapered-shape cuff ETT (Group T)|Experimental group: Mallinckrodt TaperGuard(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt TaperGuard(TM) tube.
62659260|NCT02774083|ACTIVE_COMPARATOR|Feuerstein Program|The participants of the Intervention Group will participate in the Feuerstein mediated learning cognitive program.
62659261|NCT02774083|PLACEBO_COMPARATOR|Adler Program|The Control Group will participate in the program of the Adler Institute dealing with social and emotional development without specific cognitive skills training.
62095699|NCT04283409|EXPERIMENTAL|Motor Control Exercise|The primary goal of motor control exercises is to retrain optimal control and coordination of the spine. It uses principles of motor learning such as segmentation, simplification and task-specific practice to retrain control of trunk muscles activation, alignment and movement. The first stage of the treatment involves assessment of the postures, movement patterns and muscle activation associated with symptoms and a retraining program designed to improve activity of muscles assessed to have poor control (usually the deep trunk muscles). Participants are taught how to contract these muscles independently. During this stage additional exercises for breathing control, posture of spine and movement are performed. The second stage of the treatment involves the progression of the exercises towards functional activities, firstly using static then dynamic tasks. Education is also included.
62293245|NCT02901171|EXPERIMENTAL|Combined Treatment|ACT group treatment combined with smartphone application
62293246|NCT02901171|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy (ACT)|ACT group treatment
62293247|NCT02901171|ACTIVE_COMPARATOR|Behavioural Support Programme|Group based Behavioural Support Programme
62293248|NCT02126059|EXPERIMENTAL|Cognitive stimulation|One cognitive stimulation session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to cognitive stimulation.
62659262|NCT03342729|EXPERIMENTAL|Intervention Group|Immediate exposure to the 10-week Aging Mastery Program (AMP)
62659263|NCT03342729|PLACEBO_COMPARATOR|Wait-list Group|Class to start 3 months after the Intervention Group
62659264|NCT05983432|EXPERIMENTAL|BL-B01D1 administered Day 1 and Day 8 per cycle|BL-B01D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks
62659265|NCT05983432|EXPERIMENTAL|BL-B01D1 administered Day 1 per cycle|BL-B01D1 will be administered on Day 1 via by intravenous infusion every 3 weeks
62659266|NCT00117819|EXPERIMENTAL|[123I]ß CIT and SPECT imaging|To assess \[123I\]ß-CIT and SPECT imaging
62659267|NCT02716090|EXPERIMENTAL|Dalap Duo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.
62659268|NCT02716090|ACTIVE_COMPARATOR|Epiduo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.
62659269|NCT00737802||Normal Control|Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
62659270|NCT00737802||GERD Patients|GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
62659271|NCT00737802||Barrett's patients|Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.
62659272|NCT02151201|EXPERIMENTAL|Influenza vaccination video education|Influenza vaccination video education
62659273|NCT02151201|PLACEBO_COMPARATOR|Hand Washing video education|Hand Washing vaccination video education
62659274|NCT01668043|EXPERIMENTAL|Antibody UB-421 Cohort 1|10 mg/kg BW, 8 weekly doses for 8-week treatment period
62659275|NCT01668043|EXPERIMENTAL|Antibody UB-421 Cohort 2|25 mg/kg BW, 4 biweekly doses for 8-week treatment period
62659276|NCT04841265|ACTIVE_COMPARATOR|Vitamin D3|The Vitamin D3 (intervention) arm will receive a total of 800 IU vitamin D3 supplementation per day.
62659277|NCT04841265|NO_INTERVENTION|Control|The control arm will receive 400 IU vitamin D3 per day from routine antenatal multivitamin supplementation.
62659278|NCT03065660|ACTIVE_COMPARATOR|Mifepristone|A single dose of oral mifepristone 200mg, followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later
62659279|NCT03065660|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later.
62659280|NCT04626076||Aga Khan University|Pakistan
62659281|NCT04626076||African Medical and Research Foundation- Uganda|Uganda
62293249|NCT02126059|EXPERIMENTAL|Aroma-massage|One hand and shoulder massage session per week for a continuous 10 weeks, each session contains 30 minutes, totally 10 session massage.
62293250|NCT02126059|EXPERIMENTAL|reminiscence|One reminiscence session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to reminiscence.
62659282|NCT04626076||African Medical and Research Foundation- Kenya|Kenya
62293251|NCT02126059|NO_INTERVENTION|Control|Control group remain regular activities
62659283|NCT04626076||African Medical and Research Foundation- Zambia|Zambia
62293252|NCT00628186|EXPERIMENTAL|1|Pancreaticojejunostomy has a risk factor of pancreatic fistula. Type of stent tube (external stent vs. short stent)across pancreaticojejunostomy was randomized for the patients with pancreaticoduodenectomy.
62465625|NCT00540020|EXPERIMENTAL|Cognitive-Didactic|Developed by Sohlberg \& Mateer to target four cognitive domains often impaired by TBI: attention, memory, executive functions, and pragmatic communication. Subjects practiced progressively more difficult paper-and-pencil or computerized cognitive tasks in 1:1 cognitive therapy sessions (1.5-2.5 hours daily).
62659284|NCT04626076||African Medical and Research Foundation- Senegal|Senegal
62659285|NCT04626076||54Gene|Nigeria
62659286|NCT04626076||African Institute of Biomedical Science & Technology|Zimbabwe
62659287|NCT02463383|EXPERIMENTAL|Sequence 1|"1. Ibuprofen Tab 400MG~2. Placebo Tab"
62659288|NCT02463383|EXPERIMENTAL|Sequence 2|"1. Placebo tab~2. Ibuprofen Tab 400MG"
62659289|NCT06306703|EXPERIMENTAL|group1, verbal instruction|
62659290|NCT06306703|EXPERIMENTAL|group 2, digital vaginal palpation|
62659291|NCT06306703|EXPERIMENTAL|group 3, perineometer|
62659292|NCT02458417|ACTIVE_COMPARATOR|Full surface CO2 laser 200mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 209 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
62659293|NCT02458417|EXPERIMENTAL|Full surface CO2 laser 150mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
62659294|NCT02458417|EXPERIMENTAL|Fractional CO2 laser 7.5mJ 20% + ReCell|This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
62659295|NCT02458417|NO_INTERVENTION|Control|No intervention
62659296|NCT02214082|NO_INTERVENTION|Next day discharge|this group will be discharged as is the standard practice at our facility; i.e. the day after the PCI procedure
62659297|NCT02214082|EXPERIMENTAL|Same Day Discharge|Patients in this arm will be discharged on the same day as their angioplasty.
62659298|NCT04356651|EXPERIMENTAL|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
62659299|NCT04356651|ACTIVE_COMPARATOR|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
62659300|NCT06168214|ACTIVE_COMPARATOR|Rabeprazloe+bismuth+amoxicillin+clarithromycin 14days|14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
62659301|NCT06168214|EXPERIMENTAL|Vonoprazan+amoxicillin+clarithromycin 14 days|14D: V: vonoprazan 20mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
62659302|NCT06168214|EXPERIMENTAL|Vonoprazan+amoxicillin+clarithromycin 7 days|7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
62659303|NCT06168214|EXPERIMENTAL|Vonoprazan+tetracycline+furazolidone 14 days|14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
62659304|NCT06168214|EXPERIMENTAL|Vonoprazan+tetracycline+furazolidone 7 days|7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
62659305|NCT06168214|EXPERIMENTAL|Vonoprazan+amoxicillin+furazolidone 7 days|7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg tid; F: furazolidone 100mg bid.
62659306|NCT06168214|EXPERIMENTAL|Vonoprazan+amoxicillin+tetracycline 14 days|7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg tid; T: tetracycline 500mg tid.
62659307|NCT06168214|EXPERIMENTAL|Vonoprazan+amoxicillin 7 days|7D:V: vonoprazan 20mg bid; A:amoxicillin1000mg tid.
62659308|NCT06168214|EXPERIMENTAL|Vonoprazan+amoxicillin 14 days|14D:V: vonoprazan 20mg bid; A:amoxicillin1000mg tid.
62659309|NCT04905290|EXPERIMENTAL|Single Arm|On the date of implant, subjects will undergo Conduction System Pacing Optimized Therapy (CSPOT) lead placement, then Conduction System Pacing Optimized Therapy (CSPOT) acute pacing protocol, and then device implant. During the acute pacing protocol, all subjects will undergo three types of pacing configurations (defined in the intervention descriptions), and will serve as their own control. The subject will then be implanted with the cardiac resynchronization therapy defibrillator (CRT-D) or cardiac resynchronization therapy pacemaker (CRT-P) device will be implanted. Each subject's device will be programmed to conduction system pacing optimized therapy (CSPOT) configuration. Subjects will be followed for 6 months.
62659310|NCT00412620|PLACEBO_COMPARATOR|Sugar Pill|
62659311|NCT00412620|EXPERIMENTAL|Group 1 Part 1 - ABT-925|
62659312|NCT00412620|EXPERIMENTAL|Group 1 Part 2 - ABT-925|
62659313|NCT00412620|EXPERIMENTAL|Group 2 - ABT-925|
61908604|NCT03740893|EXPERIMENTAL|Cohort D (durvalumab monotherapy)|
62659314|NCT00983970|EXPERIMENTAL|Interactive video cycling|Interactive video cycling arm utilized the Gamebike that interfaced a Sony Play Station 2 with a stationary bicycle and a 42 inch flat screen TV. The Gamebike has a handle bar mounted game controller allowing the participant to play most Sony Play Station 2 raced-based video games. The Gamebike reads the participants' speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks.Participants were told that they could exercise at any intensity or duration that they desired, and reading materials were provided for those who did not chose to exercise for the full 60 minute session.
62659315|NCT00983970|ACTIVE_COMPARATOR|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device.
62659316|NCT03056053|OTHER|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
62659317|NCT02863042|EXPERIMENTAL|Deltoid Tendon Repaired|Repair Deltoid Tendon
62659318|NCT02863042|OTHER|Ankle Fracture Without Deltoid Tendon Repair|
62659319|NCT01402726|EXPERIMENTAL|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with heart failure.
62659320|NCT01402726|NO_INTERVENTION|Absolute medicine therapy|Maintenance of anti-heart failure medications only
62659321|NCT01164475|EXPERIMENTAL|Fixed Dose Plerixafor|10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by 20 milligram (mg) plerixafor SC injection (fixed dose) in evening of Day 4 (10 to 11 hours prior to first apheresis), and then 10 mcg/kg G-CSF SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of cluster of differentiation 34 (CD34+) stem cells (greater than or equal to \[\>=\] 5\*10\^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
62736881|NCT02794896|EXPERIMENTAL|Deep Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS 45 (group 1, deep anesthesia). Anesthesia depth was measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below or equal to a BIS level of 45 were counted.
61908605|NCT01974739|ACTIVE_COMPARATOR|hydrochloorthiazide|once a day 25 mg
62659322|NCT01164475|ACTIVE_COMPARATOR|Weight-Based Plerixafor|G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (\>=5\*10\^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
62659323|NCT03723824|EXPERIMENTAL|Zepatier therapy|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
62659324|NCT05267457||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
62293253|NCT05764369|EXPERIMENTAL|Parenting Wisely Residential Treatment (PWRT)|In the PWRT condition, parents will complete a total of ten web-based modules in an online parent training program called Parenting Wisely. Each week, parents will also attend a 90-minute facilitated discussion group via Zoom. Parents will complete assessments at baseline (T1), six weeks post-baseline (T2), and six months post-baseline (T3) via REDCap. While adolescents (n=60) will not directly receive the intervention, they will complete assessments at baseline, six weeks post-baseline (T2), and six months post-baseline (T3).
62465626|NCT00540020|EXPERIMENTAL|Functional-Experiential|The works of Giles and Clark-Wilson and Hartley guided the basic concepts and treatment of the functional-experiential arm (Functional). The objective of the functional protocol was to use real life performance situations and common tasks to remediate or compensate for functional deficits after brain injury. Functional protocol treatment interventions (1.5-2.5 hours daily) typically occurred in group settings and natural environments (hospital recreation areas, group rooms, simulated home environments in the dining room, community outings, etc.).
62659325|NCT05267457||Healthy pregnant women|Pregnant women with fasting glucose \< 5.1 mmol/L (92 mg/dL), 1 h glucose \< 10.0 mmol/L (180 mg/dL) and 2 h glucose \< 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
62659326|NCT02196129|EXPERIMENTAL|Sinbaro-3|1cc Harpagophytum Procumbens(freeze drying) pharmacoacupuncture adminstered to 6 acupoints at the site of pain Administered once and once only before any interventions
62659327|NCT02196129|PLACEBO_COMPARATOR|Hwangryun(distillation)|1cc Hwangryun(distillation) pharmaco-acupuncture administered to 6 acupoints at the site of pain Administered once and once only before any other intervention
61908606|NCT01974739|PLACEBO_COMPARATOR|placebo|once a day placebo
61908607|NCT04966858|EXPERIMENTAL|Individualized Caloric Refeeding (ICR)|Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal
62659328|NCT06281613||Case group|
62659329|NCT06281613||Control Headgear|
62659330|NCT04529174|ACTIVE_COMPARATOR|Active HDL supplement|25 subjects (ages 18-85 years old) will receive an active HDL supplement (CardioLux™HDL). They will take 2 capsules twice a day with food for 12 weeks. Total daily dosing is four (4) capsules.
61908608|NCT04966858|ACTIVE_COMPARATOR|Higher Calorie Refeeding (HCR)|Starting 2000 kcal/d, increasing by 200 kcal/d to goal
62293254|NCT05764369|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|The TAU condition is the standard of care offered to parents in RT settings. Parents in the TAU condition will receive traditional programming, including family therapy offered weekly during the RT admission. Parents will attend discharge planning meetings with caseworkers (if assigned) to discuss the adolescent's progress, continued treatment needs, safety plans, upcoming appointments, and medication needs. Following discharge, programs frequently recommend follow-up with an outpatient provider for medication management and therapy for the adolescent. Parents will complete assessments at baseline (T1), six weeks post-baseline (T2), and six months post-baseline (T3) via REDCap. While adolescents (n=60) will not directly receive the intervention, they will complete assessments at baseline, six weeks post-baseline (T2), and six months post-baseline (T3).
62293255|NCT02041962|ACTIVE_COMPARATOR|Educational Control|Patients will receive their usual care from providers at their clinic. They will also receive in the mail a self-guided workbook.
61908609|NCT02787486||Aneuploidy Arm|Includes pregnant women at high risk for fetal chromosome aneuploidy for serum screening
62095700|NCT04283409|EXPERIMENTAL|Graded Activity|The primary goal of graded activity is to address individual modifiable contextual factors associated with the pain experience such as self-efficacy, pain-related fear, kinesiophobia and unhelpful beliefs/behaviors about back pain while at the same time addressing physical impairments such as endurance, muscle strength and balance. A primary goal of the program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. Activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Cognitive-behavioral principles are used to help patients overcome the natural anxiety associated with pain and activities.
62293256|NCT02041962|EXPERIMENTAL|Chronic Care Model for Mood Disorders|Life Goals Collaborative Care
62293257|NCT01278290|ACTIVE_COMPARATOR|Triptorelin test AND LHRH test|Patients undergo two tests with a test interval of at least 15 days
62293258|NCT01278290|ACTIVE_COMPARATOR|LHRH test AND Triptorelin test|Patients undergo two test with a test interval of al least 15 days.
62659331|NCT04529174|PLACEBO_COMPARATOR|Placebo|25 randomly selected subjects (ages 18-85 years old) will receive a matching Placebo. They will take 2 capsules twice each day with food for 12 weeks. Total daily dosing is four (4) capsules.
62293259|NCT01253603|EXPERIMENTAL|1|QAW039 capsules once daily for 28 days
62465627|NCT04977245|EXPERIMENTAL|MBSR Intervention|The intervention group will take part in a group-based mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. This MBSR program will have a shortened session length of 1.5 hours compared to the traditional 2 hours, to reduce caregiver burden. Caregivers will be trained in meditation practices, like awareness of one's breath, body scan, and loving kindness meditation. Participants will also learn about mindfulness and stress theory, and have group discussions covering topics such as self-compassion.
62465628|NCT04977245|ACTIVE_COMPARATOR|Self-Guided Meditation eCourse|Participants in the active control group will participate in a self-guided, online program named GARDEN. The self guided material teaches skills about increasing the daily experience of positive emotion as a mechanism to assist with stress coping. The program consists of eight skills introduced and discussed over an eight week period.
62465629|NCT00531856|EXPERIMENTAL|1|5.97 mg/L of carbon monoxide in 30% oxygen
62659332|NCT01806493||obese subjects|One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);
62659333|NCT05342844|NO_INTERVENTION|Group-Control|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0.5% plus 10 mL normal saline 0.9% for each side
62659334|NCT05342844|ACTIVE_COMPARATOR|Group-Dexmedetomidine 0.5|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0.5% plus 10 mL normal saline containing 0.5 mcg/kg dexmedetomidine for each side
62659335|NCT05342844|ACTIVE_COMPARATOR|Group-Dexmedetomidine1|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0. 5% plus 10 mL normal saline containing 1 mcg/kg dexmedetomidine for each side
62095701|NCT00367237|EXPERIMENTAL|Infliximab + methotrexate (IFX + MTX)|Remicade (infliximab \[IFX\]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
62095702|NCT00367237|ACTIVE_COMPARATOR|Methotrexate (MTX)|Oral methotrexate (MTX) 15 mg/week
62293260|NCT01253603|EXPERIMENTAL|2|Placebo to QAW039 capsules once daily for 28 days
62293261|NCT01253603|EXPERIMENTAL|3|Fluticasone propionate inhaler twice daily for 28 days
62293262|NCT00928070|EXPERIMENTAL|Fesoterodine|
62293263|NCT00928070|PLACEBO_COMPARATOR|Placebo|
62465630|NCT00531856|PLACEBO_COMPARATOR|2|Oxygen 30% in Nitrogen
62465631|NCT04702178|EXPERIMENTAL|Group A-2|COVAC-2 25 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
62659336|NCT01796522|ACTIVE_COMPARATOR|Nifedipine (60 mg / day orally)|The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
62659337|NCT01796522|ACTIVE_COMPARATOR|Progesterone 200 mg / day vaginally|The name of this arm is Progesterone. Soft gelatin capsule vaginal use, used in clinical practice as maintenance tocolytic therapy after episode of threatened preterm labor. The 200mg capsule administered once daily to week 34 of gestation. The patients assigned to this arm will begin treatment while the patient assigned to the arm of nifedipine.
61908610|NCT02787486||TORCH Arm|Infectious disease arm: Toxoplasmosis, other viruses, rubella, cytomegalovirus, and herpes simplex virus (TORCH). Includes pregnant women at low-risk for fetal aneuploidy that may be at increased risk for fetal infection for serum screening
61908611|NCT00543244||1|Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)
61908612|NCT06427083||patient diagnosed with type2 diabetes mellitus|patient diagnosed with type2 diabetes mellitus
62095703|NCT01944943|EXPERIMENTAL|Vismodegib|Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
62293264|NCT01841632|EXPERIMENTAL|MultiStem|"Dose escalation~Cohort 1~Drug: MultiStem, Dose 1 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 2~Drug: MultiStem, Dose 2 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 3~Drug: MultiStem, Dose 3 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 4~Drug: MultiStem, Dose 4 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)"
62293265|NCT02190734|OTHER|wheelchair, walking on treadmill, walking overground|Sitting in wheel chair Gait training on treadmill Gait training overground
62465632|NCT04702178|PLACEBO_COMPARATOR|Group B-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
62465633|NCT04702178|EXPERIMENTAL|Group C-2|COVAC-2 50 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
62465634|NCT04702178|PLACEBO_COMPARATOR|Group D-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
62659338|NCT01104844|ACTIVE_COMPARATOR|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
62659339|NCT01104844|ACTIVE_COMPARATOR|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
62659340|NCT01104844|ACTIVE_COMPARATOR|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
62659341|NCT01104844|ACTIVE_COMPARATOR|ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
62659342|NCT01104844|ACTIVE_COMPARATOR|Ibuprofen high dose|Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
62659343|NCT01104844|PLACEBO_COMPARATOR|placebo|2 Placebo tablets
62095704|NCT06239974|ACTIVE_COMPARATOR|Control group|Patients will have no intervention and will continue to have optimised medical therapy and follow-up appointments (currently 1 appointment every 3 months).
62293266|NCT03871894|ACTIVE_COMPARATOR|Control arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy as per the standard enteral nutritional practice in a critical care setting in cirrhotics till the period admitted in ICU(Intensive care unit) 35-40 Kcal/Kg IBW/day; 1.5g protein per kg per day.
62293267|NCT03871894|EXPERIMENTAL|Intervention arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy based on indirect calorimetry measurements till the period admitted in ICU(Intensive care unit); 1.5g protein per kg per day.
62293268|NCT05589818|EXPERIMENTAL|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab (200mg IV every 3 weeks) for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV.
62293269|NCT04928014||Screening Mammogram|Individuals eligible for a screening mammogram.
62465635|NCT04702178|EXPERIMENTAL|Group E-2|COVAC-2 100 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
62465636|NCT04702178|PLACEBO_COMPARATOR|Group F-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
62465637|NCT04702178|EXPERIMENTAL|Group G-2|COVAC-2 25 µg: 8 or 9 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
62465638|NCT04702178|PLACEBO_COMPARATOR|Group H-2|Placebo Control: 4 or 5 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
62465639|NCT04702178|EXPERIMENTAL|Group I-2|COVAC-2 50 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
62465640|NCT04702178|PLACEBO_COMPARATOR|Group J-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
62465641|NCT02374996||APIGT|Bipolar subjects treated with antipsychotics and having impaired glucose tolerance
62465642|NCT02374996||APNGT|Bipolar subjects treated with antipsychotics and having normal glucose tolerance
62465643|NCT02374996||LINGT|Bipolar subjects treated with lithium and having normal glucose tolerance
62465644|NCT04597463|EXPERIMENTAL|Endometrial injury|Endometrial injury before the embryo transfer of a frozen cycle
62465645|NCT03122457|EXPERIMENTAL|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
62659344|NCT01104844|EXPERIMENTAL|Full Dose Strength|Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
62659345|NCT01926210|EXPERIMENTAL|mild ovarian stimulation|Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
62659346|NCT01926210|ACTIVE_COMPARATOR|controlled ovarian stimulation|Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
62465646|NCT02979015|EXPERIMENTAL|Alirocumab|Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
62465647|NCT02979015|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection of a single dose of matching placebo
62293270|NCT06500663||1|patients on haemodialysis themselves and their hospital records including the participant's information (name, age, sex, admission date, clinical procedures, medications administered...etc).
62293271|NCT05257122|EXPERIMENTAL|Arm A|Monotherapy of Fruquintinib
62095705|NCT06239974|EXPERIMENTAL|Intervention group|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
62293272|NCT03965143||3D talar group|Patients that will undergo a 3D custom talar augment
62293273|NCT04584177|EXPERIMENTAL|Arm-hand BOOST + Control|First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program
62465648|NCT01476085|NO_INTERVENTION|no treatment|no treatment
62465649|NCT03861845|ACTIVE_COMPARATOR|Standard off-the-shelf pillbox|Participants will engage in reflection on medication routines. Then they will receive a standard off-the-shelf pillbox. Finally, the participants will receive education \& training on how to use the pillbox.
62465650|NCT03861845|EXPERIMENTAL|Custom off-the-shelf|Participants will engage in reflection on medication routines. Then they will receive a custom off-the-shelf pillbox. Finally, the participants will receive education \& training on how to use the pillbox.
62465651|NCT03861845|EXPERIMENTAL|Custom designed and manufactured|Participants will engage in reflection on medication routines. Then they will receive a custom designed and manufactured pillbox. Finally, the participants will receive education \& training on how to use the pillbox.
62465652|NCT05172622|EXPERIMENTAL|JP-2266|Drug: JP-2266
62465653|NCT05172622|PLACEBO_COMPARATOR|JP-2266 Placebo|Drug: JP-2266 Placebo
62465654|NCT05063786|EXPERIMENTAL|Experimental Arm (Arm A) Cohort 1 (HER2+/HR-)|"Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~Alpelisib 300 mg oral once daily.~\*If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
62465655|NCT05063786|EXPERIMENTAL|Experimental Arm (Arm A) Cohort 2 (HER2+/HR+)|"Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~Alpelisib 300 mg oral once daily.~Fulvestrant 500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.~Males and females who are not post-menopausal must have been on a gonadotropin-releasing hormone (GnRH) agonist (e.g. goserelin or leuprorelin) for at least 28 days prior to starting study treatment, and should continue with this therapy.~\*If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
62659347|NCT04159064||Minimal Invasive Extracorporeal Circulation(MIECC)|"Monitoring coagulation using thromboelastometry and platelet function using impedance aggregometry. Samples at the following phases:~Time 0: Baseline, upon arrival at the operation room (samples for thromboelastometry and impedance aggregometry), Time 2: after aortic cross clamp off (only sample for thromboelastometry), Time 2': 20 minutes post protamine administration (only sample for impedance aggregometry )."
62095706|NCT03451292|EXPERIMENTAL|Standard Medical Treatment + Albutein 20%|Standard Medical Treatment plus Albutein 20% administrations
62095707|NCT03451292|ACTIVE_COMPARATOR|Standard Medical Treatment|The sites will follow the Standard Medical Treatment as per their Standard of Care.
62095708|NCT04758403|EXPERIMENTAL|Navigation Bronchoscopy ALONE|"This research study involves a screening period, a procedure and follow up visits~* Procedure Visit Navigation Bronchoscopy Alone~* Follow-Up Visits at Week 1, 4 and 12"
62095709|NCT04758403|EXPERIMENTAL|CBCT-GUIDED Navigation Bronchoscopy|"This research study involves a screening period, a procedure and follow up visits Procedure Visit- Cone Beam Computed Tomography - Guided Navigation Bronchoscopy for Peripheral Pulmonary Nodules~-Follow-Up Visits at Week 1, 4 and 12"
62095710|NCT06693986|EXPERIMENTAL|Level: -1 RGDCRAdcox2F (RGD)|"Patients given 3x10\^10 vp/d of RGD.~Safety arm. Enrollment begins at DL 1 in cohorts of 2 patients. A minimum of 28 days (DLT period) must separate the last patient treated in the current cohort and the 1st patient in the next cohort of 2 patients. A minimum of 21 days must separate the 1st and 2nd patient within a cohort."
62293274|NCT04584177|EXPERIMENTAL|Control + Arm-hand BOOST|First 4 weeks control program, afterwards 4 weeks arm-hand boost program
62659348|NCT01031290|EXPERIMENTAL|Group A|Active TMS
62659349|NCT01031290|SHAM_COMPARATOR|Group B|Sham TMS
62659350|NCT02157090|ACTIVE_COMPARATOR|Herpes Patch SOS (Hansaplast®)|
62293275|NCT05346107|EXPERIMENTAL|PldCHP---Nab-PHP|he patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
62465656|NCT05063786|ACTIVE_COMPARATOR|Control Arm (Arm B ) Cohorts 1 and 2|"Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~Chemotherapy (CT): vinorelbine, capecitabine or eribulin (according to investigator preference):~* Vinorelbine either oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.~* Capecitabine: 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.~* Eribulin: 1.23 mg/m2 IV on days 1 and 8, every 3 weeks.~  * If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
62095711|NCT06693986|EXPERIMENTAL|Level: 1 RGDCRAdcox2F (RGD)|"Patients given 3x10\^11 vp/d of RGD~Enrollment begins at DL 1 in cohorts of 2 patients. A minimum of 28 days (DLT period) must separate the last patient treated in the current cohort and the 1st patient in the next cohort of 2 patients. A minimum of 21 days must separate the 1st and 2nd patient within a cohort."
62659351|NCT02157090|ACTIVE_COMPARATOR|Herpes vesicle patch of Compeed®|
62659352|NCT03337412|EXPERIMENTAL|Patients|initial assessment of physical capacities, determination of personalized objectives on the occasion of 1 to 2 workshops during the hospital checkup. Telephone Contact by the APA educator at 6 months. One-year medical visit.
62095712|NCT06693986|EXPERIMENTAL|Level: 2 RGDCRAdcox2F (RGD)|"Patients given 9x10\^11 vp/d of RGD.~Enrollment begins at DL 1 in cohorts of 2 patients. A minimum of 28 days (DLT period) must separate the last patient treated in the current cohort and the 1st patient in the next cohort of 2 patients. A minimum of 21 days must separate the 1st and 2nd patient within a cohort."
62095713|NCT06693986|EXPERIMENTAL|Level: 3 RGDCRAdcox2F (RGD)|"Patients given 3x10\^12 vp/d of RGD.~Enrollment begins at DL 1 in cohorts of 2 patients. A minimum of 28 days (DLT period) must separate the last patient treated in the current cohort and the 1st patient in the next cohort of 2 patients. A minimum of 21 days must separate the 1st and 2nd patient within a cohort."
62293276|NCT05970692||Healthy Controls|Healthy individuals aged between 18-65 years old
62293277|NCT05970692||CTS Group|CTS patients aged between 18-65 years old
62293278|NCT00470496|EXPERIMENTAL|Treatment (intraoperative PDT)|Patients receive HPPH IV over 1 hour on day 1. Patients undergo surgery followed by laser light exposure to the entire tumor bed on day 2.
62293279|NCT05541783|ACTIVE_COMPARATOR|Laparoscopy-assisted distal gastrectomy|The patients who are assigned to LADG group undergo extracorporeal anasto- mosis for gastrointestinal reconstruction.
62465657|NCT05486780|EXPERIMENTAL|Digital window|The patients who will be assigned to the experimental group will sleep on the 1st, 2nd, and 3rd beds. Experimental group patients are in the field of view of the digital window. A digital window is a tool designed by the researcher to enable patients to differentiate between day and night.
62659353|NCT03337412|EXPERIMENTAL|Employees|"initial assessment of physical capacities, participation in 10 to 20 physical activity workshops over 6 months on working time, then employees oriented towards autonomous activities over the following 6 months.~Evaluation by computer-filled questionnaires."
62095714|NCT04411082|EXPERIMENTAL|Lower Dose IMR-687|Oral administration of once daily IMR-687
62095715|NCT04411082|EXPERIMENTAL|Higher dose IMR-687|Oral administration of once daily IMR-687
62095716|NCT04411082|PLACEBO_COMPARATOR|Placebo|Oral administration of once daily placebo
62659354|NCT03366584|EXPERIMENTAL|Intervention|"* beta carotene 25,000 IU~* vitamin D3 50,000 IU~* zinc 50 mg~* dexamethasone 6 mg"
62659355|NCT03366584|ACTIVE_COMPARATOR|Control|dexamethasone 6 mg
62095717|NCT05192824|NO_INTERVENTION|Single-vision glasses|Subjects wearing single-vision glasses CR-39
62095718|NCT05192824|EXPERIMENTAL|Orthokeratology lenses group 1|Subjects wearing orthokeratology lenses of 5mm optical zone.
62659356|NCT03188185|EXPERIMENTAL|ALKS 5461|Sublingual tablets
62659357|NCT03188185|PLACEBO_COMPARATOR|ALKS 5461 Placebo|Sublingual tablets
62659358|NCT05152784|EXPERIMENTAL|Octaray catheter|VT ablation guided by activation mapping using the Octaray catheter and integrated cardiac MRI data.
62659359|NCT05152784|ACTIVE_COMPARATOR|Standard of care|Identified retrospectively from registry data: propensity matched-controls undergoing VT ablation guided by substrate-modification alone.
62659360|NCT00141921|EXPERIMENTAL|Etanercept|Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
62659361|NCT02627716|EXPERIMENTAL|SOS Intervention Group|Subjects benefit from the SOS Plan in addition to the usual follow-ups
62659362|NCT02627716|NO_INTERVENTION|Control Group|Subjects receive no additional intervention (tracking the continuation of psychiatric care according to the standard care terms)
62659363|NCT05442112|EXPERIMENTAL|Wellness Smartphrase|This arm will receive a secure message after the conclusion of their standard clinic visit providing a set script containing information on a number of wellness-related topics in MS (sleep, diet, exercise).
62659364|NCT05442112|NO_INTERVENTION|No Intervention|This arm will not receive a secure message after their appointment, and will instead receive their standard care with their provider.
62659365|NCT02700841|EXPERIMENTAL|Arm I (vaccine, CD34 transplant, DLI)|ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.
62659366|NCT02700841|ACTIVE_COMPARATOR|Arm II (vaccine, stem cell transplant)|Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.
62659367|NCT00777842|EXPERIMENTAL|1|Device
62659368|NCT00095329|EXPERIMENTAL|sirolimus|
62095719|NCT05192824|EXPERIMENTAL|Orthokeratology lenses group 2|Subjects wearing orthokeratology lenses of 5.5mm optical zone.
62465658|NCT05486780|NO_INTERVENTION|Control group|the patients who will be assigned to the control group will sleep in the 4th, 5th, and 6th beds. Control group patients are not in the field of view of the digital window. Data collection will be completed by the researcher by completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the control group who are not in the field of view of the digital window.
62659369|NCT05700864|EXPERIMENTAL|Oxervate® (cenegermin)|OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj
62659370|NCT02908230|PLACEBO_COMPARATOR|Active Control|Active Control: exposure to a non-nutrition, physical activity, or mental health curriculum/program
62659371|NCT02908230|ACTIVE_COMPARATOR|Standard Care|Standard Care: exposure to a nutrition and physical activity curriculum/program
62659372|NCT02908230|EXPERIMENTAL|Enhanced Care|Enhanced Care: exposure to a nutrition, physical activity, and mental health curriculum/program
62659373|NCT05568004|EXPERIMENTAL|Combined exercise group|Aerobic plus resistance exercise intervention
62659374|NCT05568004|EXPERIMENTAL|Aerobic exercise group|Only aerobic exercise intervention
62659375|NCT05568004|NO_INTERVENTION|Control group|
62659376|NCT00070525|EXPERIMENTAL|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62659377|NCT03653741|EXPERIMENTAL|Healthy males|healthy males will undergo EEG, VEP, BAER, and SEP testing, then take a single dose of Perampanel 6 MG pill (intervention), then have blood drawn and undergo the 4 tests mentioned previously for a second time
62095720|NCT05192824|EXPERIMENTAL|Orthokeratology lenses group 3|Subjects wearing orthokeratology lenses of 6mm optical zone.
62095721|NCT05192824|EXPERIMENTAL|Orthokeratology lenses group 4|Subjects wearing orthokeratology lenses of 6mm optical zone and the increased height of peripheral reverse curve.
62293280|NCT05541783|EXPERIMENTAL|Totally laparoscopic distal gastrectomy|The patients who are allocated to TLDG group undergo intracorporeal anastomosis for the recovery of gastrointes- tinal continuity after gastrectomy.
62293281|NCT03184844|EXPERIMENTAL|thalidomide thalassemia|thalidomide:50mg/d p.o
62659378|NCT01418898|EXPERIMENTAL|Nutrient Fortified Beverage|
62659379|NCT01418898|PLACEBO_COMPARATOR|Control|
62659380|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
62659381|NCT03181997||TAVI patients without cancer|Patients with no active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
62659382|NCT01104285||Standard care|Treatment of pleural effusion with diuresis
62659383|NCT01104285||Chest tube|Treatment of pleural effusion with diuresis and chest tube
62659384|NCT06438003|EXPERIMENTAL|Laurel County|Specialized services
62659385|NCT06438003|ACTIVE_COMPARATOR|Pike County|Extension services as usual
62659386|NCT05272917|EXPERIMENTAL|head and neck cancer patients with radiotherapy AND chemotherapy|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) + chemotherapy
62465659|NCT01625065||pain patients|patients from a specific pain management department, patients with long duration of pain, mostly insufficiently treated pain
62465660|NCT01625065||pre-surgical patients|patients from a surgical outpatient department with current pain
62465661|NCT02753335|EXPERIMENTAL|GMI and Desensitization|Left/right judgement, imagine movements of the affected area, mirror treatment and tactile stimulation of the affected limb with different materials.
62465662|NCT02753335|EXPERIMENTAL|Desensitization|Tactile stimulation of the affected limb with different materials.
62465663|NCT03533270||Urethroplasty|Patients with traumatic urethral injury associated with pelvic fractures who underwent urethroplasty
62465664|NCT01924091|EXPERIMENTAL|Dapivirine Gel|"As outlined above, multiple gel formulations of dapivirine have been developed for vaginal use.~Three formulations, Dapivirine Gel-001 (Gel-001), Dapivirine Gel-002 (Gel-002), and Dapivirine Gel 4750 (Gel 4750) are no longer in development. Dapivirine Gel 4789, which has been tested in one clinical trial (IPM012), and Dapivirine Gel 4759 were recently evaluated in clinical trials, IPM 014A and IPM 020. This trial will use Dapivirine Gel 4759."
62659387|NCT05272917|EXPERIMENTAL|head and neck cancer patients with radiotherapy only|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) without chemotherapy
62659388|NCT05272917|ACTIVE_COMPARATOR|healthy volunteers|healthy volunteers paired with experimental patients on age (+/- 5 years), gender, tobacco status
62659389|NCT03060928|ACTIVE_COMPARATOR|Control|Arthroscopic Rotator Cuff Repair with standard treatment
62659390|NCT03060928|EXPERIMENTAL|Experimental 1|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with micro-perforations
62659391|NCT03060928|EXPERIMENTAL|Experimental 2|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with the combination of micro-perforations and use of Artelon® Tissue Reinforcement
62659392|NCT04089319|EXPERIMENTAL|Acupuncture + mindfulness|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen to a 15-minute mindfulness recording followed by music for 30 minutes. Acupuncture needles will then be removed.
61908613|NCT05297318|EXPERIMENTAL|hypotension prediction index guided|Patients receiving hypotension prediction index guided. In this group, they will be alerted when the index exceeded 85 (range 0 to 100) indicating the later occurrence of MAP\< 65mmHg for at least minutes and a treatment protocol based on advanced hemodynamic parameters recommended vasopressor or inotrope, fluid administration, or observation.
62465665|NCT01924091|EXPERIMENTAL|Dapivirine Film|Dapivirine film is formulated in a polyvinyl alcohol (PVA) based vaginal film containing hydroxypropyl methyl cellulose (HPMC) E5 (5 cp), polyethylene glycol 8000 (PEG), propylene glycol, and glycerin. PVA constituted 55.1% (w/w) of the film. The target loading dose for the film is 1.25 mg dapivirine per film based on phase I studies using dapivirine gels at concentrations of 0.01%, 0.02% and 0.05%30-33. The quantity of gel administered in these studies was 2.5 mL. Consequently the administered dose corresponds to 0.25, 0.5 and 1.25 mg dapivirine, respectively.
62659393|NCT04089319|OTHER|Acupuncture control|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen music for 45 minutes. Acupuncture needles will then be removed.
62659394|NCT04084704|OTHER|Cingal injection|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
62659395|NCT02687828||Subjects receiving adalimumab|The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.
62659396|NCT06232343|EXPERIMENTAL|Experimental|This group followed a resisted training programmed with a parachute
62659397|NCT06232343|OTHER|Controlled|This group perform sprinters with no external resistance training
62659398|NCT02691572|ACTIVE_COMPARATOR|Wound Infiltration|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
62659399|NCT02691572|EXPERIMENTAL|Transversus abdominis plane block|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
62659400|NCT00358488|EXPERIMENTAL|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
62659401|NCT00358488|EXPERIMENTAL|salbutamol|salbutamol
62659402|NCT00358488|EXPERIMENTAL|salmeterol 50mcg|salmeterol 50mcg
62659403|NCT00358488|PLACEBO_COMPARATOR|placebo|placebo
62659404|NCT03434262|EXPERIMENTAL|A: ribociclib + gemcitabine|"Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim.~Stratum A has completed all the necessary accrual"
61908614|NCT05297318|SHAM_COMPARATOR|without hypotesion prediction index guided|Patients will receive usual care during the operation without hypotension prediction index alerted.
61908615|NCT00858572|EXPERIMENTAL|Cohort|
62095722|NCT05094115|NO_INTERVENTION|Training as usual|Training as Usual for the 3rd SFAB is the U.S. Army Master Resilience Trainer (MRT). It focuses on teaching resilience skills and is one of the foundational pillars of the Comprehensive Soldier Fitness program. MRT course is intended to impart training resilience skills, designed to introduce other resilience concepts that soldiers will likely encounter through their careers. Key focus of course are (1) resilience, (2) building mental toughness, (3) identifying character strengths, and (5) strengthening relationships. The 3rd SFAB uses a a team training grounded in strengths-based leadership. The Small Team Development Consultant and Brigade Behavioral Health Provider serves as a consultant to units conducting their own resiliency training as usual. No booster sessions will be offered to Training as Usual.
62095723|NCT05094115|ACTIVE_COMPARATOR|Training as usual with psychological flexibility training|"Training as usual, with psychological flexibility training delivered during a 2-day workshop.~Day 1 provides an overview of the training and describes the posture or stance to prepare for response to challenging situations in a psychologically flexible manner.~Day 2 provides common coping strategies."
62095724|NCT04285086|EXPERIMENTAL|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
62659405|NCT03434262|EXPERIMENTAL|B: ribociclib + trametinib|"Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, \[sonic hedgehog (SHH)- or WNT-activated\];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.~Stratum B has completed all the necessary accrual"
62659406|NCT03434262|EXPERIMENTAL|C: ribociclib + sonidegib|"Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) \>6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.~Stratum C is being closed due to low accrual"
62659407|NCT04089722|OTHER|Open-Label: Deoxycholic Acid Injections|Deoxycholic Acid Injections (dose strength: 2 mg/cm2) via subcutaneous injections into posterior and/or anterior axillary roll adiposity. Patients will receive 10 mL or less (≤100 mg) of study drug per treatment administered in 0.2-mL injections with a 30-gauge, 0.5-in needle attached to a 1-mL syringe at 1.0-cm spacing using a customized grid. Up to 6 treatments (30 ± 7 days apart) will be permitted, but fewer can be allowed because of efficacy (insufficient BSF to inject, patient satisfaction with treatment) or safety/tolerability concerns.
62659408|NCT06018103|EXPERIMENTAL|Treatment|8-week online group learning course of the MBCT-vision programme
62095725|NCT04285086|ACTIVE_COMPARATOR|Anagrelide|Capsules, Daily, p.o.
62293282|NCT04351412|ACTIVE_COMPARATOR|Tactile stimulus|The tactile stimulus was examined using an explorer (# 17/23), passing at a right angle to the bucco-cervical tooth surface of concern. Contributors evaluated participants' pain score on a 10-point visual analogue scale (VAS). The stimulus was used to assess dentine hypersensitivity at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
61908616|NCT06272227|EXPERIMENTAL|alfacalcidol|alfacalcidol plus denosumab
61908617|NCT06272227|PLACEBO_COMPARATOR|placebo|placebo + denosumab
62293283|NCT04351412|ACTIVE_COMPARATOR|Air blast stimulus|For air blast stimuli, air was delivered by a three-way syringe from a typical dental unit air syringe at 40 psi (± 10 psi) and 70 °F (± 5 °F). The air flow was aimed at the tooth surface of concern, for 1 second, from a distance of 1 cm. The air blast stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for air blast stimuli at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
62465666|NCT01675232|ACTIVE_COMPARATOR|Soak and smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment immediately to wet skin once a day and dry skin once a day.
62465667|NCT01675232|ACTIVE_COMPARATOR|Dry smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment to dry skin twice a day.
62465668|NCT05353790|EXPERIMENTAL|Avocado mango meal plan|2 meals and snacks per day, including 1 avocado + 1 cup of mango, covering 75% of daily calories needs,
62465669|NCT05353790|OTHER|Control meal plan|2 meals and snacks per day, without avocado and mango, covering 75% of daily calories needs
62293284|NCT04351412|ACTIVE_COMPARATOR|Cold stimulus|For cold hypersensitivity assessment, the tooth was isolated using cotton rolls; then, a few drops of extremely cold water were delivered to the tooth from a syringe that had previously been cooled. The cold stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for cold stimulus at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
62293285|NCT05480969|EXPERIMENTAL|Intervention group 1|Heart failure educational sessions will be provided by the heart failure-trained nurse to patients and caregivers. These will be delivered through a combination of home visits and telephone calls performed at regular time intervals for a total period of 6 months.
62293286|NCT05480969|EXPERIMENTAL|Intervention group 2|Heart failure educational sessions will be provided by the heart failure-trained nurse to patients and caregivers. These will be delivered through telephone calls performed at regular time intervals for a total period of 6 months.
62293287|NCT05480969|NO_INTERVENTION|Control group|Control patients and caregivers will receive usual care for heart failure.
62293288|NCT00976014||Intensive Lipid-lowering therapy|Subjects on intensive long-term lipid lowering therapy (lowering LDL-C plus raising of HDL-C).
62465670|NCT01765114|EXPERIMENTAL|PEG-Formulation|PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
62465671|NCT04816838|EXPERIMENTAL|N/A(Single Arm)|
62465672|NCT02325531|OTHER|Low support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~EHR-based toolkit Basic webinar"
62465673|NCT02325531|OTHER|Medium support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~Support provided to the low support arm, PLUS Staff training Adaptive webinars"
62465674|NCT02325531|OTHER|High support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~Support provided to the low and medium support arms, PLUS Practice facilitation"
62465675|NCT02325531|OTHER|Comparison|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR."
62465676|NCT01532141|EXPERIMENTAL|Group 1|Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
62465677|NCT01532141|EXPERIMENTAL|Group 2|Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
62293289|NCT00976014||Usual Care|"Subjects with Atherosclerosis who have been on conventional standard of care treatment."
62293290|NCT02537678|EXPERIMENTAL|Stepped Care TF-CBT|Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
62465678|NCT01532141|EXPERIMENTAL|Group 3|Period 1: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone
62465679|NCT04222881||End To Side|End to Side Anastomosis
62465680|NCT04222881||Side To Side|Side To Side Anastomosis
62465681|NCT00183794|EXPERIMENTAL|Arm 1|Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks.
62465682|NCT01874756|EXPERIMENTAL|LY500307 150mg|LY500307 150mg
62465683|NCT01874756|PLACEBO_COMPARATOR|placebo|placebo 6 pills of inactive drug
62465684|NCT01874756|EXPERIMENTAL|LY500307 75mg|LY500307 75mg
62659409|NCT06018103|NO_INTERVENTION|Control|wait-list control (standard care, no research intervention)
62293291|NCT02537678|ACTIVE_COMPARATOR|Standard TF-CBT|Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.
62293292|NCT04410874|EXPERIMENTAL|Imvamune|Imvamune vaccine to be administered intratumorally at one of three doses on Days 0 and 4 of the study
62293293|NCT06657521|EXPERIMENTAL|OSTEOIMPLANT GROUP|patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
62293294|NCT06657521|PLACEBO_COMPARATOR|Placebo Group|30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
62293295|NCT05710432|EXPERIMENTAL|Quasi-Isometric Neck Flexion|"On minimal mechanical ventilation support (unassisted/assisted spontaneous breathing) via tracheostomy.~Quasi-Isometric Neck Flexion will be performed during mechanical ventilation. Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction. 30% will be the target intensity level for neck flexion. The patient will perform 2 sets of 6-10 quasi-isometric neck flexions."
62659410|NCT02485769|EXPERIMENTAL|PF-06650833|Active arm , PF-06650833 kinase.
62095726|NCT01386840|NO_INTERVENTION|Severe Pneumonia - Hospital Management|"Those randomized to hospital management will be monitored by health personnel for at least 48 hours for clinical deterioration and parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, Clinical deterioration, Other signs eg. comorbid conditions, Assessment of adherence, Adverse event.~Mothers, whose children are discharged after 48 hours, will be counseled to continue with oral treatment prescribed for a period of 7 days and will be advised to return to healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card"
62293296|NCT05710432|EXPERIMENTAL|Inspiratory Muscle Training|Perform 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load). The training device will be set at 30% of the highest value of three MIP maneuvers. A two-minute rest period with MV support will be provided between each set.
62465685|NCT01874756|EXPERIMENTAL|LY500307 25mg|LY500307 25mg
62659411|NCT02485769|PLACEBO_COMPARATOR|Placebo|Placebo arm
62659412|NCT06262867|EXPERIMENTAL|Intervention|Participants randomized to the intervention group will receive an early allergen introduction supplement.
62659413|NCT06262867|NO_INTERVENTION|Control|Participants randomized to the control group will follow the guidance of their pediatrician.
62659414|NCT01816607||Rectal cancer|
62659415|NCT04807413|EXPERIMENTAL|Study Arm: The balloon will be opened to deliver nitric oxide at 40 ppm.|Nitric oxide balloon will be connected to the CPB machine. Participants randomized to this group will receive 40 ppm nitric oxide through the pump.
62659416|NCT04807413|ACTIVE_COMPARATOR|Control Arm: The balloon will be closed and no nitric oxide will be delivered.|Participants in this group will receive standard of care treatment. Participation in the trial will not affect surgery management in any way.
62659417|NCT02490163|EXPERIMENTAL|CMNC|the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
62659418|NCT02490163|ACTIVE_COMPARATOR|MNC|The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure.
62659419|NCT00674297|EXPERIMENTAL|Fluvastatin|All patients will take Fluvastatin 40 mg daily for 3 months.
62293297|NCT02899169|EXPERIMENTAL|Oral Realgar-Indigo naturalis formula(RIF) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease \<10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
62293298|NCT02899169|ACTIVE_COMPARATOR|Intravenous Arsenic Trioxide(ATO) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease \<10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
62293299|NCT04532788|ACTIVE_COMPARATOR|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
62293300|NCT04532788|ACTIVE_COMPARATOR|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
62659420|NCT03345797|EXPERIMENTAL|Naive patients - ARM 1|TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel \[Natesto\] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
62659421|NCT03345797|EXPERIMENTAL|Non-naive patients - ARM 2|TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage \>/= 3, receiving Testosterone Nasal Gel \[Natesto\] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later
62659422|NCT05330949||case group|
62659423|NCT05330949||control|
62659424|NCT06066593||Ischemic Stroke|MRI suggests a new cerebral infarction.
62659425|NCT06066593||Hemorrhagic Stroke|CT suggests a new cerebral hemorrhage.
62659426|NCT06066593||Asymptomatic Group|Without new infarction or hemorrhage
62659427|NCT04454606|EXPERIMENTAL|Fit test|All the subjects will be tested for fit test
62659428|NCT02323009|ACTIVE_COMPARATOR|Esophageal balloon Arm|Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
62659429|NCT02323009|ACTIVE_COMPARATOR|Cstat Arm|Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
62659430|NCT02323009|NO_INTERVENTION|Historic Controls|These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.
62659431|NCT05926921|ACTIVE_COMPARATOR|music|Brahms lullaby at 50-60dB (depending on distance to speaker), played during the intravenous line procedure.
62659432|NCT05926921|NO_INTERVENTION|no music|No intervention, care as usual.
62736882|NCT02794896|EXPERIMENTAL|Shallow Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a inter scalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
61908618|NCT06261281|EXPERIMENTAL|The observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
62095727|NCT01386840|EXPERIMENTAL|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
62095728|NCT02466126|EXPERIMENTAL|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
62293301|NCT04795479|EXPERIMENTAL|Treatment Sequence 1|Participants will receive relacorilant 400 mg once daily (QD) for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62465686|NCT06402539|EXPERIMENTAL|receiving family-centered care|"IIn this randomized controlled clinical study, family-centered empowerment program (FCEM) will be implemented as an intervention. A total of 8 times (6 times face-to-face in the hospital; 2 times by phone) for 5 weeks. The content of face-to-face sessions consists of family-centered assessment, structured information booklet and bedside care skills training. Patients will be given a patient care booklet as part of this intervention.~The content of the booklet; TKA surgery, preoperative period, postoperative period postdischarge care (daily tasks, surgical site care, weight gain, diet, driving, exercises It will include information enriched with visual materials regarding prevention of complications at home.~The other part of the booklet consists of encouraging caregivers to actively participate in managing their own health and to maintain health-promoting behaviors such as nutrition, exercise, stress management and emotional management."
62465687|NCT06402539|NO_INTERVENTION|waiting care group|Patients and families in the control group will be cared for according to the routine of the clinic and no intervention will be made.This group will be given a booklet on what to do after the last follow-up measurement, that is, after the 1st month post-operative check-up.
62465688|NCT00323882|EXPERIMENTAL|MDX-010|
62465689|NCT06115889|EXPERIMENTAL|Smart Taiko Drumming Group|Smart Taiko Drumming
62465690|NCT06115889|NO_INTERVENTION|Usual Care Waitlist Control Group|Usual care
62465691|NCT06031857|EXPERIMENTAL|Group A|. Group A was given kinesio tape.Total six sessions of each intervention were given to each patient at a rate of two sessions per week along with the 10 minutes of interferential therapy and 10 minutes of moist packs to each patient
62465692|NCT06031857|ACTIVE_COMPARATOR|Group B|. Group A was given dry needling. Total six sessions of each intervention were given to each patient at a rate of two sessions per week along with the 10 minutes of interferential therapy and 10 minutes of moist packs to each patient
62465693|NCT04651803||Traumatic brain injury patients|Traumatic brain injury patients admitted in intensive care unit.
62736883|NCT00604318|PLACEBO_COMPARATOR|placebo|To receive the placebo treatment in connection with the primary RI therapy and the T3 tablets and rh-TSH injections prior to second RI uptake measurement
62736884|NCT00604318|ACTIVE_COMPARATOR|rh-TSH|To continue with L-T3 and to receive rh-TSH stimulation with 0,9 mg Thyrogen® (Genzyme) x 2 days minus 1 and 2 prior to RI therapy, and following this to have placebo tablets and placebo injections with isotone NaCl prior to the RI uptake measurement 4-6 months later
62736885|NCT02929199|ACTIVE_COMPARATOR|group A|Pressable E- max, an all ceramic crown
62736886|NCT02929199|EXPERIMENTAL|Group B|BIO-Hpp hybrid crown
62095729|NCT02466126|NO_INTERVENTION|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
62465694|NCT01225809||AD01with or without adjuvant|Patients who have received at least one immunization of AD01 with or without adjuvant during AFF001
62465695|NCT03004209|OTHER|EPO|Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
62293302|NCT04795479|EXPERIMENTAL|Treatment Sequence 2|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62095730|NCT01142999|ACTIVE_COMPARATOR|Intervention (moisturizer group)|One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.
62095731|NCT01142999|ACTIVE_COMPARATOR|Control group (no moisturizers)|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
62095732|NCT03768544|EXPERIMENTAL|Self-help guided by a lay provider|
62095733|NCT03768544|OTHER|Waiting list where participants wait for delayed treatment|
62095734|NCT06697314|EXPERIMENTAL|Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|Prospective single-arm trial reporting the efficacy, safety, and long-term functional outcomes of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for the treatment of acute pulmonary embolism.
62095735|NCT04071691||Active LVV|Patients with active LVV
62095736|NCT04071691||Stable LVV|Patients with inactive LVV
62095737|NCT01979055|EXPERIMENTAL|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
62293303|NCT04795479|EXPERIMENTAL|Treatment Sequence 3|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62293304|NCT04795479|EXPERIMENTAL|Treatment Sequence 4|Participants will receive relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62736887|NCT05827328||Patients eligible for lung surgery or mediastinal surgery|Patients with or without SARS-CoV-2 infection eligible for lung surgery or mediastinal surgery
62095738|NCT01979055|PLACEBO_COMPARATOR|Control group|3 telephone calls to assess any additional questions regarding asthma
62095739|NCT05210140||Standard dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram treatment resulted in optimal escitalopram exposure (25-50 ng/ml) as measured at VK. These patients will continue their treatment with 10 mg/day during the V1-V2 period.
62095740|NCT05210140||Adjusted dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram dose resulted in to high (\>50 ng/ml) or to low (\<25 ng/ml) escitalopram exposure, as measured at VK. These patients will be treated with the adjusted escitalopram dose, different from 10 mg/day, during the V1-V2 period.
62293305|NCT04795479|EXPERIMENTAL|Treatment Sequence 5|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62293306|NCT04795479|EXPERIMENTAL|Treatment Sequence 6|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62736888|NCT04624867|EXPERIMENTAL|HP-1050 patch|HP-1050 and Xulane will be administered simultaneously.
62736889|NCT05083884||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
62736890|NCT05083884||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
62736891|NCT05083884||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
62736892|NCT05083884||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
62736893|NCT03389412|EXPERIMENTAL|Treatment without evaluating the home recordings, medicin.|Children will receive desmopressin without evaluating the home recordings.
62736894|NCT03389412|EXPERIMENTAL|Treatment without evaluating the home recordings, alarm.|Children will receive conditional alarm without evaluating the home recordings.
62736895|NCT03389412|ACTIVE_COMPARATOR|Treatment based on home recordings, polyuria.|Children with polyuria based on the home recordings will receive desmopressin.
62736896|NCT03389412|ACTIVE_COMPARATOR|Treatment based on home recordings, reduced bladder capacity.|Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
62736897|NCT03389412|ACTIVE_COMPARATOR|Treatment based on home recordings, both.|Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
62736898|NCT03389412|ACTIVE_COMPARATOR|Treatment based on home recordings, none.|Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
62736899|NCT01899508|EXPERIMENTAL|Pain Coping Training with 3D viewer|All participants will receive a 1 and a half hour pain coping training while using the virtual reality viewer. We are testing the feasability of using the 3D viewer in collaboration with Pain Coping training to see if people who suffer from Osteoarthritis of the knee experience some pain relief.
62736900|NCT06107374|EXPERIMENTAL|Advanced non small cell lung cancer (NSCLC) patients undergoing PD-1/PD-L1 directed therapy|
62736901|NCT01032408|EXPERIMENTAL|HIV-1 Infected Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
61908619|NCT06261281|ACTIVE_COMPARATOR|The control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
61908620|NCT06492655|OTHER|Group 1|"* Period 1: CKD-383 two tablets(Fed)~* Period 2: CKD-383 two tablets(Fasted)"
62095741|NCT06575647|EXPERIMENTAL|Tafenoquine|"Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia).~Tafenoquine will be given as follows,~\>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)"
62095742|NCT02468505|EXPERIMENTAL|STEPS|structured psychosocial transition support that includes individual counseling, and education/training for parent and school personnel
62095743|NCT02468505|NO_INTERVENTION|TAU|typical transition services and supports
62095744|NCT05507008|EXPERIMENTAL|Ketone Supplementation|Subjects will ingest 2 daily doses of Kenetik ketone drink supplementation for 14 days.
62095745|NCT05453500|EXPERIMENTAL|Treatment (DA-EPOCH+/-R, tafasitamab)|Patients receive etoposide, doxorubicin, and vincristine IV continuously over 96 hours on days 1-4 of each cycle, cyclophosphamide IV over 1 hour on day 5 of each cycle, prednisone PO BID on days 1-5 of each cycle, and tafasitamab IV weekly on days 1, 8, and 15 of each cycle. CD20 positive patients also receive rituximab IV per guidelines on days 1 or 5 of each cycle. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration or biopsy, CT scan, lumbar puncture and undergo blood sample and cerebrospinal fluid collection.
62095746|NCT00811187|EXPERIMENTAL|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
62095747|NCT00811187|PLACEBO_COMPARATOR|Saline placebo injection|5cc Normal Saline injection in each paracervical region
62736902|NCT01032408|EXPERIMENTAL|HIV-1 Infected Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
62095748|NCT05350436|EXPERIMENTAL|Young adult non singers|
61908621|NCT06492655|OTHER|Group 2|"* Period 1: CKD-383 two tablets(Fasted)~* Period 2: CKD-383 two tablets(Fed)"
61908622|NCT02691871|EXPERIMENTAL|Apatinib + Docetaxel|Low, medium or high dose of Apatinib (days 3-19, q3w) and Docetaxel (60 mg/m2, day 1, q3w)
61908623|NCT03457779|EXPERIMENTAL|Non Glucose Arm|4 patients without glucose infusion
61908624|NCT03457779|EXPERIMENTAL|Glucose Arm|12 Patients with glucose infusion
61908625|NCT01213576|ACTIVE_COMPARATOR|albendazole 400mg and ivermectin 200mcg/kg|Annual treatment
61908626|NCT01213576|ACTIVE_COMPARATOR|Albendazole 800mg and ivermectin 400mcg/kg|Annual treatment
62095749|NCT05350436|EXPERIMENTAL|Young adult singers|
62095750|NCT05350436|EXPERIMENTAL|Older adult non singers|
62095751|NCT05350436|EXPERIMENTAL|Older adult singers|
62095752|NCT05356026|EXPERIMENTAL|Online follow up group|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
62095753|NCT05356026|NO_INTERVENTION|Routine follow up group|The women in the control group received the routine follow-up and care provided by the hospital.
62095754|NCT03700255|EXPERIMENTAL|Group A|Group A will undergo the PickUpSimTM simulation training program
62095755|NCT03700255|NO_INTERVENTION|Group B|Group B will only have the classic training with no simulation.
62095756|NCT02095704|EXPERIMENTAL|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
62465696|NCT01772030|OTHER|Recurrent Atrial Fibrillation|
62736903|NCT01032408|EXPERIMENTAL|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
62736904|NCT01032408|EXPERIMENTAL|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
62736905|NCT06660082|EXPERIMENTAL|Experimental Group|"Participants included in this group will undergo experimental treatment as described below.~Head movements"
61908627|NCT01213576|ACTIVE_COMPARATOR|Albendazole 400mg and ivermectin 200mcg/kg|albendazole 400mg and ivermectin 200mcg/kg given twice a year
61908628|NCT01213576|ACTIVE_COMPARATOR|Albendazole 800mg and ivermectin 400mcg /kg bi-annually|Albendazole 800mg and ivermectin 400mcg/kg given twice a year
61908629|NCT03741478|EXPERIMENTAL|Metabolic Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility.~This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 3. Visits 1 to 3 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.~Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.~On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure."
61908630|NCT03741478|EXPERIMENTAL|Cognitive and MRI Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing."
62095757|NCT02095704|EXPERIMENTAL|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
62095758|NCT04697784|EXPERIMENTAL|Subjects who receive the TREO Abdominal Stent-Graft System|Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.
62293307|NCT04795479|EXPERIMENTAL|Treatment Sequence 7|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62293308|NCT04795479|EXPERIMENTAL|Treatment Sequence 8|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62293309|NCT04795479|EXPERIMENTAL|Treatment Sequence 9|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62293310|NCT04795479|EXPERIMENTAL|Treatment Sequence 10|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
61908631|NCT01287182|PLACEBO_COMPARATOR|Placebo|
61908632|NCT01287182|ACTIVE_COMPARATOR|Ateronon|
61908633|NCT04329624|ACTIVE_COMPARATOR|Levosimendan|Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours. Infusion will be started with surgical skin incision.
61908634|NCT04329624|PLACEBO_COMPARATOR|Placebo|Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours. Infusion will be started with surgical skin incision.
61908635|NCT01680198|PLACEBO_COMPARATOR|Placebo|Placebo capsules daily for 12 weeks.
62095759|NCT03177187|EXPERIMENTAL|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
62095760|NCT03177187|EXPERIMENTAL|Phase II|"The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.~RECRUITING"
62095761|NCT06132776|EXPERIMENTAL|Verum group|
62095762|NCT06132776|PLACEBO_COMPARATOR|Placebo group|
62095763|NCT05780736||Cohort 1|
62736906|NCT06660082|SHAM_COMPARATOR|Control Group|"Participants included in this group will undergo sham-treatment as described below.~Eye movements without head movements"
62736907|NCT02191878|EXPERIMENTAL|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.~Phase 2 - dose expansion at the MTD."
62736908|NCT00617058|EXPERIMENTAL|1|metformin, 250mg-2000 mg/day, in BID to TID doses for 26 weeks. Open, flexibly adjusted.
62736909|NCT00617058|EXPERIMENTAL|2|Healthy lifestyle intervention. Additional meeting at each psychiatric visit to review weight changes, level of physical activity and healthy eating behaviors
62736910|NCT00617058|NO_INTERVENTION|3|Self-selected patients will be followed at major timepoints to assess weight and related measures.
62736911|NCT01204983||Observational|"This is a quality improvement project to evaluate the current standard of care of nutritional management for very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.~There is no randomization, there are no control subjects, and therefore there is no probability of group assignment."
62736912|NCT01270880|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62736913|NCT02525484|EXPERIMENTAL|Pirfenidone ACBD treatment sequence|Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.
62095764|NCT04018092|EXPERIMENTAL|Active NIR-PBM|"For transcranial stimulation, the study team will use two MedX units (1116 Rehab Console, MedX Health), whereas intranasal stimulation is delivered using the 810 Intranasal device (Vielight Inc). During each lab session, six transcranial LED clusters will be placed on the scalp in two distinct configurations guided by 10-20 EEG system. Total transcranial stimulation time is 40 minutes, 20 min per cluster. Concurrently, two 810 intranasal devices will be placed in each nostril for 25 min of total dose per nostril. For at home sessions, participants will use the standalone 810 Intranasal device only.~Total amount of sessions:~1. 16 sessions of stimulation will occur in the laboratory. Each session will last approximately 90 minutes and will include two 20-minute segments of NIR stimulation.~   AND~2. 44 sessions of intranasal stimulation in the home. Each session will last 25 minutes and will occur on weekdays when there is no in-lab session."
61908636|NCT01680198|EXPERIMENTAL|Paracalcitol|"see Intervention description for details."
61908637|NCT01402336|EXPERIMENTAL|GnRH antagonist, SD #1 starting group|Start GnRH antagonist from stimulation day 1 during ovulation induction cycles
61908638|NCT01402336|EXPERIMENTAL|GnRH antagonist, SD #6 starting group|Start GnRH antagonist from stimulation day 6 during ovulation induction cycles
61908639|NCT01402336|ACTIVE_COMPARATOR|Conventional GnRH agonist long group|Conventional GnRH agonist long protocol
61908640|NCT05446831|EXPERIMENTAL|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
61908641|NCT03775538|EXPERIMENTAL|CDNF mid-dose (400 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
62095765|NCT04018092|SHAM_COMPARATOR|Sham NIR-PBM|"Participants randomized to the Sham control group will undergo identical procedures as the Active group. The only difference is that the sham NIR devices are modified not to deliver stimulation. Because NIR is invisible, participants are unable to detect whether NIR is being delivered."
61908642|NCT03775538|EXPERIMENTAL|CDNF high-dose (1200 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to high-dose (1200 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
62095766|NCT05550974||LC|laparoscopic surgery using conventional laparoscopic instruments
62095767|NCT05550974||LW|Using wristed laparoscopic instruments (Artisential Maryland dissector, Artisential Fenestrated gasper)
62095768|NCT05550974||RC|Conventional robotic surgery
61908643|NCT05857553|EXPERIMENTAL|Treatment Group|Participants in the treatment group will receive $500 per month for 12 months
62095769|NCT05550974||RSS|Use of singlesite system for reduced port robotic surgery
62095770|NCT05550974||RSP|Use of da Vinci SP system for reduced port robotic surgery
62095771|NCT05550974||RRI|A new surgical robot Revo-i developed by Meerae company in Korea
62095772|NCT03889899|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62293311|NCT04795479|EXPERIMENTAL|Treatment Sequence 11|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62293312|NCT04795479|EXPERIMENTAL|Treatment Sequence 12|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
62293313|NCT04397484|ACTIVE_COMPARATOR|Levobupivacaine|0.5% levobupivacaine (0.5% Chirocaine) 30ml (150mg) will be injected once for regional anaesthesia before surgery
62293314|NCT04397484|ACTIVE_COMPARATOR|Xylocaine + adrenaline|2% Xylocaine with adrenaline 1:200,000 30ml (450mg) will be injected once for regional anaesthesia before surgery
62293315|NCT04899479|EXPERIMENTAL|SGLT-2 inhibitor|The SGLT-2 inhibitor group will receive SGLT-2 inhibitor once daily until the end of the study period.
61908644|NCT05857553|ACTIVE_COMPARATOR|Control Group|Participants in the control group will not receive monthly cash benefits.
61908645|NCT02185976|ACTIVE_COMPARATOR|cartoon|paediatric patients undergoing general anesthesia. This group will choose a cartoon movie to watch throughout the preparation until the induction of anesthesia
61908646|NCT02185976|NO_INTERVENTION|routine|paediatric patients undergoing general anesthesia
61908647|NCT04241978|EXPERIMENTAL|Intervention group|The participants will complete the baseline assessment and will be asked to read the project information sheet. Then, patients allocated to the intervention group will review the PtDA accompanied by the researcher and will complete the questionnaires assessing the outcome measures, in the same web interface.
61908648|NCT04241978|ACTIVE_COMPARATOR|Control group|Patients in the control group will follow the same procedure, but they will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
62095773|NCT04901728||Target Population|People living with HIV and following a DTG/3TC drug regimen
62095774|NCT04901728||Control Group on Dual Regimens|The first control population will include a group on dual regimens other than DTG/3TC and a group on triple therapy. In the control group of patients receiving dual therapies, we will include patients (i) on Juluca (DTG/rilpivirine\[RPV\]), (ii) on boosted darunavir plus lamivudine (DRV/r or DRV/c + 3TC), and (iii) on boosted darunavir plus raltegravir (DRV/r or DRV/c + RAL).
62293316|NCT04899479|PLACEBO_COMPARATOR|Control|The control group will not receive any additional drugs.
62293317|NCT03156036|EXPERIMENTAL|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
62095775|NCT04901728||Control Group on Triple Regimens|The second control population will include a group on triple regimens including: 2 NRTIs + 1 NNRTI; 2 NRTIs + 1 INSTI, and 2 NRTIs + 1 PI/b.
62293318|NCT03156036|ACTIVE_COMPARATOR|MGMT hypermethylated Cohort B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
62293319|NCT03156036|ACTIVE_COMPARATOR|MGMT unmethylated Cohort A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
62293320|NCT03156036|ACTIVE_COMPARATOR|MGMT unmethylated Cohort B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.~(n=37)"
62465697|NCT01122147|ACTIVE_COMPARATOR|chamomilla tincture mouthwash|Chamomile comprises bisaboloids, matricine and chamazulene, flavonoids, and cumarins having therapeutical anti-inflammatory, analgesic, musculotropic, and spasmolytic action
62465698|NCT01122147|PLACEBO_COMPARATOR|placebo mouth wash|placebo mouthwash is produced with the same taste and smell for using in placebo/ control group.
62465699|NCT01949662|EXPERIMENTAL|Lorazepam + Haloperidol|Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
62465700|NCT01949662|ACTIVE_COMPARATOR|Placebo + Haloperidol|Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
62465701|NCT03834870|EXPERIMENTAL|Elder adults in emergency department setting|Elder mistreatment in an Emergency Department setting.
62465702|NCT01461850|ACTIVE_COMPARATOR|Primary debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted to an attempt of primary debulking surgery in order to obtain RT \< 1 cm, followed by adjuvant chemotherapy.
62465703|NCT01461850|EXPERIMENTAL|Interval debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted only to diagnostic laparoscopy followed by neoadjuvant chemotherapy and subsequent Interval Debulking Surgery, followed by further cycles of chemotherapy.
62465704|NCT01612871|EXPERIMENTAL|hormone therapy treatment|Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
62465705|NCT03766620||Tube Fed Participants|Individuals with diabetes and malnutrition receiving tube feed as sole source nutrition.
62465706|NCT02933931||vaccinated with 5 x 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV
62465707|NCT02933931||vaccinated with 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV
62465708|NCT02933931||vaccinated with 3 x 10E5 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV
62465709|NCT03380377|EXPERIMENTAL|Clazakizumab (Anti-IL-6 Monoclonal)|All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months. Then patients will be scheduled for six month protocol biopsy. If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months. All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit. If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
62465710|NCT03141840|EXPERIMENTAL|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
62465711|NCT03141840|PLACEBO_COMPARATOR|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
62465712|NCT05194839|EXPERIMENTAL|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
62465713|NCT05194839|EXPERIMENTAL|RIST4721 200 mg|RIST4721 200 mg: 2 active (100 mg) tablets + 2 placebo tablets once daily for 12 weeks
62465714|NCT05194839|PLACEBO_COMPARATOR|Placebo|Placebo: 4 placebo tablets once daily for 12 weeks
62465715|NCT06354166|EXPERIMENTAL|Divomed digital tool combined with human coordination|A digital tool combined with human coordination (Divomed) to organise discharge home from the start of hospitalisation. The digital application will be interconnected with the patient's medical file.
62293321|NCT01569633|PLACEBO_COMPARATOR|Placebo|This group of infant will not receive any medication but sugar water or placebo
61908649|NCT01073046||Place Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is placed (Rusch® distributed by Teleflex Medical Srl)
61908650|NCT01073046||No Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is not placed
62095776|NCT05831046|EXPERIMENTAL|Study Arm|Patients who undergo use of the software prior to being re-evaluated by a physician
62095777|NCT05831046|NO_INTERVENTION|Healthy Control|Patients undergo care without using the software
62293322|NCT01569633|ACTIVE_COMPARATOR|Metclopramide|This group of infants will receive Metoclopramide at 0.1mg/kg q8 hrs.
62293323|NCT01569633|ACTIVE_COMPARATOR|Erythromycin|mediaction used to treat feeding disorder
62293324|NCT04911621|EXPERIMENTAL|Stratum A (newly diagnosed)|Dendritic cell vaccination plus temozolomide-based chemoradiotherapy
62095778|NCT03422302|EXPERIMENTAL|Treatment (CT simulation, CPAP, DIBH, SBRT, BiPAP)|Patients undergo free-breathing, DIBH, and CPAP CT simulation scans. If patient has difficulty exhaling on CPAP, then patient undergo BiPAP CT simulation. The attending physician then compares all 3 simulation treatment plans (free-breathing, DIBH, and CPAP/BiPAP) and determines which method to use during SBRT. If CPAP/BiPAP is chosen as preferred method, patients wear CPAP/BiPAP over 1 hour prior to SBRT, then again during SBRT over 30-60 minutes. All other patients complete free-breathing or DIBH during SBRT over 30-60 minutes.
62095779|NCT03558113|OTHER|visual tactile method|visual tactile method using the modified USHPS critiria
62095780|NCT00747279|EXPERIMENTAL|1|Carbohydrate restrictive strategy
62095781|NCT00747279|ACTIVE_COMPARATOR|2|Intensive insulin therapy
62095782|NCT01220531|EXPERIMENTAL|#1: Typical cDGA No Immunosuppression|Subjects receive thymus transplant. Subjects do not receive any pre or post-transplantation immunosuppression.
62095783|NCT01220531|EXPERIMENTAL|#2:Typ & Atyp cDGA Immunosuppression|"Group two subjects receive three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV pre- transplantation.~Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin."
62659433|NCT04684316|NO_INTERVENTION|Care-as-usual: all consult physician|All employees at risk are invited to attend screening. Upon arrival, several biometrics are measured (weight, length, Body Mass Index, blood pressure), along with spirometries, a vision test, and a blood and urine test. The OP then investigates the general health status and systems of the employee, which includes an anamnesis with questions about new health burdens or changes in occupational risks, follow-up questions on previous complaints, medical advice, referral to a healthcare provider, or booking another appointment with an occupational health specialist. After the PHS, a (employee-unique) link to an online questionnaire is sent by email to gather information on final (health, health care use, absenteeism and presenteeism) and intermediary (health literacy, help-seeking behaviour) outcomes.
62293325|NCT04911621|EXPERIMENTAL|Stratum B (prior treatment)|Dendritic cell vaccination plus optional conventional anti-glioma treatment (in line with standard-of-care practice, at the investigator's discretion)
62095784|NCT01220531|EXPERIMENTAL|#3: Atypical cDGA Immunosuppression|Pre-transplant cyclosporine (Csa) as soon as complete DiGeorge anomaly is diagnosed. Csa continues with target trough levels of 180 to 220 ng/ml. When trough levels are outside of range, dosing is modified appropriately. If subject cannot tolerate Csa, the Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of this target range, dosing will be modified appropriately. Pre-transplant steroids are used for atypical subjects if pre-transplant T cells \>4,000/mm3. Three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV are given pre-transplant. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
62095785|NCT01220531|EXPERIMENTAL|#4: Atypical cDGA Additional Suppression|Pre-transplant cyclosporine (Csa) and steroids are started after atypical complete DiGeorge anomaly is diagnosed. After PHA response is documented \>40,000 cpm on suppression, peri-transplant Csa is maintained at target levels 250 to 300 ng/ml. (When levels outside of range, dose modified.) If subject cannot tolerate Csa then may be changed to tacrolimus (FK506) with target level 10 to 15 ng/ml. When levels are outside of range, dosing is modified. Three doses of 2 mg/kg rabbit anti-thymocyte globulin IV are given pre-transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin. Additional immunosuppression: Basiliximab, 5 mg/kg single dose IV; Mycophenolate Mofetil (MMF), 15 mg/kg/dose every 8 hours IV or enteral.
62095786|NCT05577962|NO_INTERVENTION|C group|The routine anesthesia group
62095787|NCT05577962|EXPERIMENTAL|T group|Opioid-free Anesthesia
62293326|NCT05957705|ACTIVE_COMPARATOR|Bilateral Sinus Augmentation|Split-mouth bilateral sinus augmentation of xenogeneic bone graft associated or not with platelet-rich fibrin produced by horizontal centrifugation.
62293327|NCT05957705|ACTIVE_COMPARATOR|Early dental implant placement by Guided Surgery|
62293328|NCT05957705|ACTIVE_COMPARATOR|Dental implants reopening surgery for implant load|
62308070|NCT02441803|EXPERIMENTAL|Matched Unrelated Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0."
62095788|NCT02359058|OTHER|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m\^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m\^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
62095789|NCT02359058|OTHER|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m\^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m\^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
62095790|NCT02359058|OTHER|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m\^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m\^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62095791|NCT06362837|EXPERIMENTAL|Intervention|Includes multiple activities, depending on country, including support of school-based iron-folic acid supplementation program; promotion of bio-fortified crops (sweet potatoes, beans, rice, corn); training on nutrition, water \& sanitation, gender equity for rural communities through community groups and for health facility staff; support to improve gender-sensitive health services for nutrition, sexual and reproductive health,
62095792|NCT06362837|NO_INTERVENTION|Comparison|No intervention will take place. Standard of care will be available in the health facilities and schools.
62095793|NCT02286856|OTHER|control group|Usual care followed bij diet intervention after 6 months
62095794|NCT02286856|ACTIVE_COMPARATOR|intervention group|diet intervention
62095795|NCT04437108|ACTIVE_COMPARATOR|Li-SWT|Patients will be treated by 8 sessions of Li-SWT with one week interval. This group is subdivided into 3 subgroups according to the approach through which Li-SWT is applied; suprapubic, perineal and combined approaches
62465716|NCT06354166|ACTIVE_COMPARATOR|Control Group|"The control group corresponds to the organisation of conventional hospital discharge from the geriatric short-stay department.~The digital application will be interconnected with the patient's medical file."
62465717|NCT03764748|EXPERIMENTAL|Washed microbiota transplantation|WMT
62465718|NCT01592578|ACTIVE_COMPARATOR|Ligation and Cyanoacrylate Group|
62465719|NCT01592578|EXPERIMENTAL|Ligation plus Sclerotherapy and Cyanoacrylate Group|
62465720|NCT00587470|EXPERIMENTAL|1|Atacand treatment.
62465721|NCT00587470|PLACEBO_COMPARATOR|2|Placebo
62465722|NCT02661295|OTHER|Ferric Citrate|Ferric citrate at a starting dose of 2 tablets with each meal will be given to all participants.
62465723|NCT05125601||Patients with bilateral deafness|Patients aged 2 to 10 years with bilateral deafness, wearing an amplifier device and / or a cochlear implant.
61908651|NCT04273880|EXPERIMENTAL|10 mg Psychostimulant|Drug: Methylphenidate (MPH) Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 10mg of MPH an hour and a half before the testing session is set to begin, to account for the time taken for the effects of the drug to start.
62308071|NCT01666522|EXPERIMENTAL|Vitamin D|vitamin D-oral cholecalciferol 2000 IU/day for 4 months
62659434|NCT04684316|EXPERIMENTAL|Intervention: Electronic survey with selective consultations|In the intervention group, all employees at risk receive a (employee-unique) link to an online health screening questionnaire by email. Dependent upon their answers, 20% of the employees (i.e. the 20% of the employees that mostly need contact with the OP) are referred to the occupational physician for a discussion of the results. The OP then gives medical advice, refers to a healthcare provider (e.g. general practitioner or specialist), or books a (follow-up) appointment with an occupational health specialist (OP, occupational nurse, etc.).
62095796|NCT04437108|SHAM_COMPARATOR|Sham treatment|Patients will be treated by 8 sessions of sham treatment with one week interval, applied through suprapubic and perineal approaches.
62095797|NCT04437108|ACTIVE_COMPARATOR|antimuscarinics|Patients will be treated by solifenacin 10 mg once daily for 6 months.
62095798|NCT01471262||Elderly|Patients more or equal to 70 years old
62308072|NCT01666522|ACTIVE_COMPARATOR|Physical activity|A 3-day/week exercise programme lasting 60 minutes each day for 4 months was instigated.
62308073|NCT01666522|EXPERIMENTAL|Vitamin D and Physical activity|Vitamin D -oral cholecalciferol 2000 IU/day and Physical activity-60-minute 3-day/week exercise programme
62659435|NCT03310047|EXPERIMENTAL|Right-low, left-high|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.~This will be repeated after 24 hours."
62095799|NCT01471262||Young|Patients less than 70 years old
62095800|NCT02028975|OTHER|Patients with type 2 diabetes|
62095801|NCT02028975|OTHER|Obese patients without diabetes|
62095802|NCT02028975|OTHER|Healthy volunteers|
62095803|NCT03570749|EXPERIMENTAL|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
62095804|NCT03570749|EXPERIMENTAL|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
62095805|NCT03570749|PLACEBO_COMPARATOR|Placebo|Participants administered orally.
62095806|NCT03570749|EXPERIMENTAL|Open-Label Addenda Baricitinib High Dose|Baricitinib will be administered orally during the open-label addenda.
62095807|NCT00561574|EXPERIMENTAL|Esmirtazapine 1.5 mg|Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
62095808|NCT00561574|EXPERIMENTAL|Esmirtazapine 3.0 mg|Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
62095809|NCT00471640|ACTIVE_COMPARATOR|1|dexamethasone
62095810|NCT00471640|PLACEBO_COMPARATOR|2|Placebo
62095811|NCT02316314||Individuals diagnosed with FRDA|Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
62095812|NCT02316314||Healthy controls|Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
62293329|NCT04931602||Model A|"Patients will be followed-up at bone, endocrine and rheumatology clinic after discharge depending upon availability of the consultant. Multifaceted risk-factor assessment for identifying patients at risk will be conducted including formal future fracture risk assessment/life style/medication review and fall risk assessment.~Comprehensive laboratory designed package including calcium (Ca), albumin (ALB), phosphate (P), bone alkaline phosphatase (BAP), C terminal peptide of type 1 collagen (CTx), vitamin D (25OHD) and intact parathyroid hormone (iPTH) will be performed at first clinic visit for all patients between 6-8 weeks post fracture. Screening for secondary causes of osteoporosis will be conducted for those identified in need. BMD testing as per guidelines for patients with fragility fractures will be conducted at clinic visit and recorded with risk assessment form (12)."
62293330|NCT04931602||Model B|All routine intervention except treatment initiation-the responsibility of patient's general practitioner for prevention of secondary fracture. Those included in this intervention arm, will be identified and risk assessment will be performed at hospital admission. Recommendations for the treatment will be made to be initiated by the patient's general physician. Patients will be followed at 6 months on telephone, and a questionnaire related to treatment compliance \&/or non-compliance will be filled by the coordinator.
62293331|NCT04931602||Model C|Health education only provided at the time of admission with handover to family physician for follow-up. Patients will be given an appointment to follow-up at community health center of Aga Khan University
62659436|NCT03310047|EXPERIMENTAL|Right-high, left-low|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.~This will be repeated after 24 hours."
62659437|NCT01755299|ACTIVE_COMPARATOR|Active ingredient|"Regular 5-hour Energy"
62659438|NCT01755299|ACTIVE_COMPARATOR|Active ingredient-2|"5-hour Energy Decaf"
62659439|NCT01755299|ACTIVE_COMPARATOR|Active ingredient-3|Compounded caffeine product 135 mg/2 ounces
62659440|NCT01755299|PLACEBO_COMPARATOR|Placebo|Flavored placebo
62659441|NCT04244539|EXPERIMENTAL|Experimental group|a received routine physical therapy program, in addition to HILT. Patients in the study group received pulsed Nd: YAG laser treatment, produced by a HIRO 3 device (ASA Laser, Arcugnano, Italy). The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2),
62659442|NCT04244539|ACTIVE_COMPARATOR|Control group|The control group received traditional physical therapy program in the form of strengthening exercise, stretching , and range of motion exercise.for the affected digits and wrists. for one hour, three sessions per week for 8 weeks.
62659443|NCT03829384|EXPERIMENTAL|mRNA-1944|Escalating dose levels
62659444|NCT03829384|PLACEBO_COMPARATOR|Placebo|Saline
62659445|NCT04674956|EXPERIMENTAL|Treatment arm|Regimens：anti-PD1 antibody and AG regimens.
62659446|NCT04674956|PLACEBO_COMPARATOR|Control arm|Regimens：Placebo and AG regimens.
62659447|NCT03658772|EXPERIMENTAL|Cohort 1|Single Agent run-in with grapiprant and then combination treatment of grapiprant and pembrolizumab.
62659448|NCT03658772|EXPERIMENTAL|Cohort 2|Participants will be treated with grapiprant in combination with pembrolizumab.
62659449|NCT01887808|EXPERIMENTAL|Cetaphil DermaControl Oil Control Moisturizer SPF 30|All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30
62659450|NCT04764890|EXPERIMENTAL|Electroacupuncture and manual therapy|Electroacupuncture in several points and manual therapy in the lumbar spine
62659451|NCT04764890|ACTIVE_COMPARATOR|Manual therapy|Manual therapy in the lumbar spina
62659452|NCT03777501|EXPERIMENTAL|non-random whole body vibration group|Each participant will receive the non-random type whole body vibration treatment about one hour after the administration of medicine.
62659453|NCT03777501|ACTIVE_COMPARATOR|conventional therapy group|For the conventional therapy group, participants will receive the occupational therapy including dynamic balance training and functional ambulatory training. Each session is 10 minutes.
62659454|NCT03542383|ACTIVE_COMPARATOR|Active HD tDCS|Administer 10 20-minute sessions of 1 mA anodal High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
62659455|NCT03542383|SHAM_COMPARATOR|Sham HD tDCS|Administer 10 20-minute sessions of sham High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
62659456|NCT06424353|EXPERIMENTAL|lentilospiral group|Obturation of primary molars with calcium hydroxide, eugenol and iodoform paste using paste carrier files(lentiospiral files)
62659457|NCT06424353|ACTIVE_COMPARATOR|pressure seringe group|Obturation of primary molars with calcium hydroxide, eugenol and iodoform paste using pressure seringe
62659458|NCT05098561|EXPERIMENTAL|Music treatment group|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
62659459|NCT05098561|NO_INTERVENTION|Control Group|No music treatment will be used. Standard pain and comfort measure only.
62659460|NCT05953727|EXPERIMENTAL|Low level laser therapy with proprioceptive stimulation|Patients will be treated with low level laser therapy and proprioceptive stimulation will also be given.
62659461|NCT05953727|ACTIVE_COMPARATOR|Low level laser therapy without proprioceptive stimulation|Patients will be treated with low level laser therapy only.
62659462|NCT02705430|NO_INTERVENTION|A|Group A will continue their actual therapy (control).
62659463|NCT02705430|EXPERIMENTAL|B|Group B will continue their standard therapy with additional stress management application only using a mobile phone (Eco Fusion Mentally) for 3 months of the study
62659464|NCT02705430|EXPERIMENTAL|C|Group C will continue their standard therapy with additional life style program using a mobile phone (Eco Mentally and NewMe) for 3 months of the study
62659465|NCT02705430|EXPERIMENTAL|D|Group D will continue their standard therapy plus additional life style program using a mobile phone with additional supplemental EPA and DHA capsules of 2 g/day to be taken daily for the 3 months of the study
62659466|NCT04419259|EXPERIMENTAL|Erenumab|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
62659467|NCT03479554|EXPERIMENTAL|Early antihypertensive treatment group|BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
62095813|NCT02353611|EXPERIMENTAL|6% bleaching agent|One upper hemiarch will be bleached with 6% hydrogen peroxide with titanium oxide nanoparticles, activated by a led/laser hybrid light. Whitening compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of one upper hemiarch. In each bleaching session the gel will be applied twice for 12 minutes each and activated with continuous irradiance using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
62095814|NCT02353611|ACTIVE_COMPARATOR|35% bleaching agent|Together with the experimental agent application, the other upper hemiarch will be bleached with 35% hydrogen peroxide whitening compound. The compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of the corresponding hemiarch. The gel will be applied twice for 12 minutes each and irradiated using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
62095815|NCT05793398||Endomyocardial biopsy-positive Cardiac sarcoidosis|
62095816|NCT05793398||Endomyocardial biopsy-negative non ischemic cardiomyopathy|
62095817|NCT02338622|EXPERIMENTAL|Schedule A: 4 days on, 3 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 4 days on, 3 days off~Schema for dose escalation in schedule A (4-days-on, 3-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 240mg~1. Olaparib: 300mg, AZD5363 320mg~2. Olaparib: 300mg, AZD5363 400mg~3. Olaparib: 300mg, AZD5363 480mg"
62095818|NCT02338622|EXPERIMENTAL|Schedule B: 2 days on, 5 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 2 days on, 5 days off~Schema for dose escalation in schedule B (2-days-on, 5-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 400mg~1. Olaparib: 300mg, AZD5363 480mg~2. Olaparib: 300mg, AZD5363 560mg~3. Olaparib: 300mg, AZD5363 640mg"
62659468|NCT03479554|ACTIVE_COMPARATOR|Delayed antihypertensive treatment group|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization.
62659469|NCT03881371|EXPERIMENTAL|Safinamide|Patient will receive film-coated Safinamide tablets orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
62095819|NCT00824785|ACTIVE_COMPARATOR|Arm A EOX|EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
62095820|NCT00824785|ACTIVE_COMPARATOR|Arm B EOX + panitumumab.|EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
62095821|NCT01055782|EXPERIMENTAL|With endoguide|Colonoscopy completed with endoguide
62095822|NCT01055782|NO_INTERVENTION|Without endoguide|Colonoscopy completed without endoguide
62095823|NCT04783935|EXPERIMENTAL|Mavenclad®|
62095824|NCT05004779|EXPERIMENTAL|human stem cell media apply lesion|human media apply after non ablative laser treatment
62095825|NCT05004779|SHAM_COMPARATOR|control condition lesion|normal saline apply after non ablative laser treatment
62659470|NCT03881371|PLACEBO_COMPARATOR|Placebo|Patient will receive matching placebo orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
62659471|NCT00932256|EXPERIMENTAL|STAHIST for seasonal allergic rhinitis|STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
62659472|NCT03838874|ACTIVE_COMPARATOR|Low-Dose Bupivacaine|Subjects in this group will be given 10mg of Low-Dose Bupivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
62659473|NCT03838874|ACTIVE_COMPARATOR|Mepivacaine|Subjects in this group will be given 70mg of Mepivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
62095826|NCT01409174|EXPERIMENTAL|Ipilimumab + Chemotherapy|Ipilimumab starting 1 mg/kg by vein (IV) Day 1 each cycle; Temozolomide 200 mg/m\^2 orally Days 2-5 of Induction; Cisplatin 25 mg/m\^2 IV for Days 2-4 of Induction; Interferon alfa-2b 5 million U/m2 subcutaneously on Days 1-5 of each cycle Induction + Consolidation; and Interleukin-2 9 million IU/m\^2 IV as a continuous infusion on Days 2-5 of Induction + Consolidation.
62095827|NCT06453109|OTHER|LIFU/Sham|double-blind, sham-controlled, crossover study in N=25 individuals with opiate use disorder, anxiety, and chronic back pain
62095828|NCT06453109|OTHER|Sham/LIFU|double-blind, sham-controlled, crossover study in N=25 individuals with opiate use disorder, anxiety, and chronic back pain
62659474|NCT01118923|NO_INTERVENTION|Washout|
62659475|NCT01118923|ACTIVE_COMPARATOR|Mablet|
62659476|NCT01118923|PLACEBO_COMPARATOR|Placebo|
62659477|NCT01188447|EXPERIMENTAL|Eligible low-risk trauma patients|Paramedics will use the Canadian C-Spine Rule to evaluate low-risk trauma patients meeting the study inclusion criteria in order to determine the need for spinal immobilization for transport to the hospital.
62659478|NCT05856487|EXPERIMENTAL|NVP-2203|NVP-2203 Plus other Placebo for up to 8 weeks, oral dose
62659479|NCT05856487|ACTIVE_COMPARATOR|NVP-2203-R1|NVP-2203-R1 Plus other Placebo for up to 8 weeks, oral dose
61908652|NCT04273880|PLACEBO_COMPARATOR|90 mg Vitamin C|Placebo: Vitamin C Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 90mg of Vitamin an hour and a half before the testing session is set to begin, to follow the exact protocol that is used for MPH.
62293332|NCT04931602||Model D|Health Education provided. There is no physician contact with the person's general practitioner for prevention of secondary fracture. Education material for the patient have been prepared and will be provided to patient along with counselling by the nurse at the time of discharge
62293333|NCT01559103|EXPERIMENTAL|MEDI5117|Intravenous infusion administered over 60 minutes
62659480|NCT05856487|ACTIVE_COMPARATOR|NVP-2203-R2|NVP-2203-R2 Plus other Placebo for up to 8 weeks, oral dose
62659481|NCT05856487|ACTIVE_COMPARATOR|NVP-2203-R3|NVP-2203-R3 Plus other Placebo for up to 8 weeks, oral dose
62659482|NCT01271855|PLACEBO_COMPARATOR|Glycerin suppository|Women assigned to this arm receive a glycerin suppository (placebo) every 8 hours after delivery during the first 24 hours postpartum
62659483|NCT01271855|EXPERIMENTAL|Belladonna and opioid suppository|Women assigned to this arm receive a belladonna and opioid (B\&O) suppository every 8 hours after delivery during the first 24 hours postpartum
62659484|NCT00144885|NO_INTERVENTION|1|
62659485|NCT06374719||Prospective|Participants in the prospective cohort are enrolled during early infancy, shortly after diagnosis, and followed longitudinally with repeated assessments until reaching the primary study outcome.
62659486|NCT06374719||Cross-Sectional|Participants in the cross-sectional cohort enroll at any time after diagnosis and all study data are collected at a single time point.
62659487|NCT02871102|EXPERIMENTAL|Intervention Arm|
62659488|NCT02994680|EXPERIMENTAL|Intervention arm|"Will receive:~1. Three-burner LPG stove (at enrollment)~2. Delivery of LPG tanks (beginning at enrollment for one year)~The study will be conducted over three years, with staggered enrollment over one year, one year of observations during the intervention period, and one year of follow-up observations after the intervention period for each participant.~Participants in the intervention arm will receive an LPG stove upon enrollment and the research team will deliver fuel twice monthly to their homes during the first year. Participants in the intervention arm will not receive fuel during the second year, but researchers will encourage these participants to continue using LPG fuel for cooking."
62659489|NCT02994680|ACTIVE_COMPARATOR|Control arm|"Will receive:~1. Three-burner LPG stove (one year after enrollment)~2. Vouchers for LPG tanks (one year after enrollment)~Participants in the control arm but will not receive an LPG stove or fuel during the first year. Instead, participants will receive an LPG stove at the end of the first year and vouchers to obtain free fuel at distribution centers during the course of the second year."
62659490|NCT02441647|EXPERIMENTAL|Experimental group|
62659491|NCT00961415|EXPERIMENTAL|Part 1|
62659492|NCT00961415|EXPERIMENTAL|Part 2A|
62659493|NCT00961415|ACTIVE_COMPARATOR|Part 2B|
62659494|NCT00313170|EXPERIMENTAL|1|Fulvestrant 250 mg (intramuscular injection 250 mg)
61908653|NCT03224559||Sham Stimulation|subject receives minimal transcranial electrical stimulation
61908654|NCT03224559||Left Side Stimulation|transcranial electrical stimulation on the left side of the head.
61908655|NCT04276558|EXPERIMENTAL|Dose 1 - 0.5 µg/day|Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID
61908656|NCT04276558|EXPERIMENTAL|Dose 2 - 2.5 µg/day|Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID
61908657|NCT04276558|EXPERIMENTAL|Dose 3 - 5 µg/day|Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID
61908658|NCT04276558|PLACEBO_COMPARATOR|Vehicle|Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID
61908659|NCT04118257|EXPERIMENTAL|Fruit Juice|Participants consumed 2 bottles of 100% fruit juice daily for 3 weeks.
62293334|NCT01559103|PLACEBO_COMPARATOR|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
62293335|NCT04545957|EXPERIMENTAL|Phase I MRI Simulation|"This research study involves a screening period to determine eligibility.~- Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data."
62293336|NCT04545957|EXPERIMENTAL|Phase II MR Simulation Protocol: Track A|MR-only Radiation Therapy Simulation MRI-simulation and synthetic CT to plan treatment
62659495|NCT00313170|EXPERIMENTAL|2|Fulvestrant 250 mg (+ 250 mg loading regimen)
62659496|NCT00313170|EXPERIMENTAL|3|Fulvestrant 500 mg (intramuscular injection 500 mg)
62659497|NCT04364256|ACTIVE_COMPARATOR|Active NMES|"asymmetric biphasic waveforms at 71 pulses per second frequency (Hz), 400 s pulse duration, 5:10s on:off time (50% duty cycle), and 1.5s ramp-up time. Participants will be in control of the muscle stimulator devices at all times and will be instructed to perform all sessions in the supine position. Bilateral NMES will be delivered via asymmetric, biphasic using four cutaneous parallel channels delivered simultaneously using 2x4 or 3x5 self-adhesive electrodes. For the active NMES group, participants will be encouraged to increase the amplitude to a level of moderate discomfort, such as that experienced during conventional exercise, but not to induce pain. At minimum, the amplitude should induce visible muscle contraction."
62659498|NCT04364256|SHAM_COMPARATOR|Sham NMES|The amplitude of the muscle stimulators for the Sham group will be capped at 15 milliamperes so patients will only feel cutaneous sensation without achieving muscle contraction.
62659499|NCT05970458||Ethioperm|All patients with a permanent ostomy visiting the stoma center in Addis Abeba
61908660|NCT04118257|EXPERIMENTAL|Soda|Participants consumed 2 cans of caffeine-free Coca Cola daily for 3 weeks.
61908661|NCT04118257|OTHER|Water|Participants consumed 2 bottles of water daily for 3 weeks.
61908662|NCT03707275|EXPERIMENTAL|Alexa+ Arm|
61908663|NCT03707275|OTHER|Standard of Care Arm|
61908664|NCT02651909||Rivaroxaban Cohort|Evidence of Rivaroxaban use with-in the last 48hours Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
62095829|NCT02929069|EXPERIMENTAL|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
62095830|NCT02929069|ACTIVE_COMPARATOR|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
62465724|NCT05385679|ACTIVE_COMPARATOR|Envelop Flap|An envelope flap designs involves a sulcular incision from the first to the second molar and a distal relieving incision to the mandibular ramus.
62293337|NCT04545957|EXPERIMENTAL|Phase II MR Simulation Protocol: Track B|Adjusted Margin or / Dose Painted RT Based on Imaging of MR Simulator (e.g. biological imaging or higher resolution imaging)
62293338|NCT02285829||T4/T1=0.1-0.25|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.1-0.25, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
62659500|NCT05970458||EthioTemp|All patients waiting for ostomy reversal at Tikur Anbessa Specialized Hospital
62095831|NCT02929069|ACTIVE_COMPARATOR|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
62095832|NCT06566586|EXPERIMENTAL|TQB3702 tablets+Chemotherapy regimen|"TQB3702 tablets 200mg, every 4 weeks for a treatment cycle.~Chemotherapy regimen：Every 3 or 4 weeks is a treatment cycle, with 6 or 12 cycles of combination therapy"
62095833|NCT05113589|EXPERIMENTAL|PBM TREATMENT|REAL PBM TREATMENT
62095834|NCT05113589|PLACEBO_COMPARATOR|PLACEBO PBM|PLACEBO PBM TREATMENT
62465725|NCT05385679|ACTIVE_COMPARATOR|Triangular flap|Triangular flap involves incision from the mandibular ramus to the distobuccal crown edge of the second molar, followed by a perpendicular incision obliquely into the mandibular vestibulum, with a length of about 10 mm.
62465726|NCT04934917||Patients with disc degenerative disease (DDD)|Patients suffering from disc degenerative disease, age 30-60 years that are on the waiting list for surgery (fusion/disc implants) at Stockholm Spine Center, Stockholm, Sweden.
62465727|NCT04934917||Healthy controls (HC)|Healthy controls matched according to age and sex, no chronic pain conditions.
62659501|NCT05970458||SweSto|All patients visiting the stoma clinic at South General Hospital
62659502|NCT03542760||Primary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia that is symptomatic (eg, exhibiting sleepiness, cyanosis, dizziness, etc) or with measured methemoglobin levels \> 30%.
62659503|NCT03542760||Secondary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia with measured methemoglobin levels ≤ 30 and lack of clinical symptoms
61908665|NCT02651909||Control cohort not taking Rivaroxaban|Not taking Rivaroxaban - matched to Rivaroxaban group by age gender, type of injury or illness requiring urgent surgery Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
61908666|NCT04097587|OTHER|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
61908667|NCT01499368|EXPERIMENTAL|Lafutidine|Lafutidine 20mg/day
61908668|NCT01499368|ACTIVE_COMPARATOR|Famotidine|Famotidine 40mg/day
61908669|NCT01499368|OTHER|Omeprazole|Omeprazole 20mg/day
61908670|NCT03483064|NO_INTERVENTION|Control group|Subjects without low back pain to whom the electric current is put but it is not activated.
61908671|NCT03483064|EXPERIMENTAL|Healthy group|Subjects without low back pain to whom the electric current is put but it is activated.
61908672|NCT05991544|EXPERIMENTAL|Experimental|Training and Follow-up According to the Neuman Systems Model
62293339|NCT02285829||T4/T1=0.25-0.50|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.25-0.50, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
62095835|NCT02065245|EXPERIMENTAL|Pilot phase - Group 1|Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
62095836|NCT02065245|EXPERIMENTAL|Pilot Phase - Group 2|Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
62659504|NCT00218959|EXPERIMENTAL|Narrative Exposure Therapy|carried out according to the manual as outlined by Schauer et al. (2005) (second revised edition 2011) 10 sessions of 90 min duration
62659505|NCT00218959|ACTIVE_COMPARATOR|treatment as usual|mainly help with such as sleep problems, depressive symptoms, problems related to asylum status, and other practical matters. Focus on everyday issues and the limited focus on the traumatic events, in line with reports from the National Center on Violence and Traumatic Stress.
62308074|NCT01666522|PLACEBO_COMPARATOR|Control|The control group was provided with health education using videotaped presentations, physician talks on topics concerning bone and muscle health.
62308075|NCT00599651|EXPERIMENTAL|1|Surfactant by LMA
62659506|NCT03213236|EXPERIMENTAL|OSA Homemonitoring|Homemonitoring diagnostic system
62659507|NCT01733953|EXPERIMENTAL|Atorvastatin|6-Months Atorvastatin Therapy; 40mg oral, once daily
62659508|NCT01733953|PLACEBO_COMPARATOR|Sugar Pill (Placebo)|6-Months Placebo (sugar pill); oral, once daily
62659509|NCT05578547|EXPERIMENTAL|combined Kndell and McKenzie group|patients receivee combined Kndell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
61908673|NCT05991544|NO_INTERVENTION|Control|only procedure will be applied
61908674|NCT05195060||COVID-19|Patients diagnosed with COVID-19
62308076|NCT00599651|OTHER|2|Standard of care
62308077|NCT00097266|PLACEBO_COMPARATOR|A|
62659510|NCT05578547|ACTIVE_COMPARATOR|Conventional therapy group|patients receive ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
62659511|NCT00662259|EXPERIMENTAL|alprazolam|Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.
62659512|NCT00662259|PLACEBO_COMPARATOR|placebo|A placebo comparator will be administered to 12 patients with generalized anxiety disorder
61908675|NCT00945906|EXPERIMENTAL|FXIII|Subjects were administered FXIII Concentrate (Human) by intravenous (IV) infusion approximately every 28 days to maintain a trough FXIII level of approximately 5 to 20%.
61908676|NCT03540251|ACTIVE_COMPARATOR|Therapeutic auricular points treatment|Therapeutic auricular points treatment including auricular points:CO18、TF2、TF4、AT4、CO15（with complaint of sweating）or CO12(with symptom of heart palpitation)in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets. In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points.
62659513|NCT00901641|EXPERIMENTAL|cognitive training|CogniFit Personal Coach® computer cognitive training program. The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®). The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
62659514|NCT04809753|EXPERIMENTAL|Eustachian tube dilation|Eustachian tube dilation with an endovascular balloon
62308078|NCT00097266|EXPERIMENTAL|B|
62308079|NCT00097266|ACTIVE_COMPARATOR|C|
62293340|NCT02285829||T4/T1=0.50-0.75|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.50-0.75, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
62659515|NCT06086249|EXPERIMENTAL|Regeneration using Injectable platelet-rich fibrin|A 10-mL sample of whole venous blood will be drawn from the patient's forearm (median cubital vein). It will be centrifuged immediately by a tabletop centrifuge at 700 rpm for 3 minutes at room temperature. Injectable platelet-rich fibrin (I-PRF) will be collected. After that, the I-PRF will be injected inside the canals using a plastic syringe needle that will be placed 1mm short of the working length and withdrawn gradually while injecting till reaching the orifices of the canals. After that, a Collagen membrane matrix will be placed above the canal orifice and will left for 5 minutes to partially harden, then a 3 mm thick layer of MTA will be placed directly over it. The cavity will be sealed with composite and covered with a stainless steel crown.
62659516|NCT06086249|ACTIVE_COMPARATOR|Root canal treatment|The root canal will be obturated with gutta-percha by the cold lateral condensation technique with epoxy resin-based root canal sealer, the cavity will be sealed with composite and covered with a stainless steel crown.
62659517|NCT05312203|OTHER|the App first group (fAPP)|Participants assigned to fAPP group will use the App initially for 28 consecutive days (T1). After T1, during the next 28 consecutive days (T2) without washout period, fAPP will only maintain the usual treatment.
62659518|NCT05312203|OTHER|wait list crossover group (dAPP)|During T1, participants assigned to the dAPP arm will maintain the usual treatment. After T1, during the next 28 consecutive days (T2) without washout period, dAPP will use the APP.
62659519|NCT00124319||1|Incoming cadets at the U.S. Naval, Air Force, or Military Academies
62659520|NCT04065308|EXPERIMENTAL|Experimental arm|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
62659521|NCT00714480|OTHER|Group I|Administration of anti-thymocyte globulin post-operative days -6,-4,-2, and 0
62659522|NCT00714480|OTHER|Group II|Administration of anti-thymoglobulin post-operative days -2, 0, 2 and 4
62659523|NCT00714480|OTHER|Group III|Administration of anti-thymocyte globulin post-operative days 0, 2, 4 and 6
62659524|NCT00910975|ACTIVE_COMPARATOR|Standard of care|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment is given for 24, 48 or 72 weeks depending on the time point (week 4, 12 or 24) when HCV RNA becomes undetectable by the Cobas Taqman assay. If HCV RNA has not declined 2 logs by week 12 or is detectable at week 24, treatment is stopped.
62659525|NCT00910975|EXPERIMENTAL|Tailored treatment|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment duration is flexible, 24-72 weeks, depending on the time point when the HCV RNA level is calculated to be 1 copy/mL. If the decline between day 14 and 28 is poor, treatment is stopped after 5 weeks.
62659526|NCT06439069||Normal Weight (BMI 18.5-24.9)|Participants with a BMI between 18.5 and 24.9. This group will serve as a reference for normal weight individuals, providing baseline data for comparison with higher BMI categories regarding the tolerability and efficacy of Entresto.
62659527|NCT06439069||Overweight (BMI 25-29.9)|Participants with a BMI between 25 and 29.9. This group will assess the impact of being overweight on the tolerability and efficacy of Entresto in heart failure patients.
62659528|NCT06439069||Obese (BMI 30-34.9)|Participants with a BMI between 30 and 34.9. This group will evaluate the effects of obesity on the tolerability and efficacy of Entresto, providing insights into how increased body weight influences treatment outcomes.
62308080|NCT05751525||Early SU treatment|Patients with permanent neonatal diabetes (PNDM) due to the V59M mutation in the KCNJ11 gene who commenced sulfonylurea therapy in the first twelve months of life.
62465728|NCT03097783|EXPERIMENTAL|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
62659529|NCT06439069||Very Obese (BMI ≥ 35)|Participants with a BMI of 35 or higher. This group will explore the challenges and potential benefits of Entresto uptitration in very obese individuals, focusing on the highest BMI category.
62659530|NCT05499936|EXPERIMENTAL|68Ga-FAPI PET/CT|Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer
62659531|NCT03991975|EXPERIMENTAL|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62659532|NCT06254313||Influenza-related ARDS group|Person with influenza virus infection proven by a positive polymerase chain reaction test for the influenza ARDS group. Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
62659533|NCT06254313||Bacterial-related ARDS group|A person with a proven bacterial infection (105 colony-forming units/mL for tracheal aspirates and more than 104 colony-forming units/mL for BAL). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
62659534|NCT06254313||Extra-pulmonary (digestive inflammation) ARDS group|"Person presenting with acute pancreatitis according to the 2013 international recommendations (typical pain, lipasemia above 3 times normal and/or abnormality on imaging).~Or Person presenting with acute bacterial peritonitis based on a clinical diagnosis and bacteria isolated on peritoneal samples (RFE SFAR 2018). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample."
62659535|NCT06009874|ACTIVE_COMPARATOR|Dapagliflozin group|patients with MI will be treated with DAPA 10 mg once daily for three months.
62465729|NCT03097783|NO_INTERVENTION|No intervention arm|No treatment
62293341|NCT02285829||T4/T1=0.75-0.90|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.75-0.90, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
62293342|NCT03388814|ACTIVE_COMPARATOR|Bupivacaine Group|Those patients randomized to surgeon infiltration will have a skin wheal performed with lidocaine at the site where an actual pectoralis nerve block would be performed as visualized using ultrasound. Surgeons performing infiltration techniques will be blinded to the contents of the injectate and those patients randomized to surgeon infiltration will receive pharmacy study drug labeled bupivacaine injected in the same fashion and volume as the saline group for oncologic and plastic surgery.
62095837|NCT02065245|EXPERIMENTAL|Pilot Phase - Group 3|Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
62095838|NCT02065245|EXPERIMENTAL|Randomized Phase - Group A|Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
62465730|NCT03124966|EXPERIMENTAL|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all will receive the pulse oximeter sensor.
62659536|NCT06009874|PLACEBO_COMPARATOR|Placebo group|patients with MI will be treated with a matching placebo once daily for three months.
62659537|NCT00689832|EXPERIMENTAL|A|
62659538|NCT00689832|ACTIVE_COMPARATOR|B|
62095839|NCT02065245|EXPERIMENTAL|Randomized phase - Group B|Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
62095840|NCT02065245|EXPERIMENTAL|Randomized Phase - Group C|Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.
62095841|NCT02065245|EXPERIMENTAL|Addendum B - Antibiotic free cell Group|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
62659539|NCT01676662|EXPERIMENTAL|Treatment on Day 0|Subjects who are treated with the Solace Bladder Control System upon entry into the trial.
62659540|NCT01676662|SHAM_COMPARATOR|Sham Treatment on Day 0|Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.
62659541|NCT02557997||ART-naive (primary infection)|ART-naive (primary infection) HIV infected adults
62659542|NCT02557997||ART-naïve (chronic infection)|ART-naïve (chronic infection) HIV infected adults
62659543|NCT02557997||ART-controlled|ART-controlled HIV infected adults
62659544|NCT02557997||ART-failing|ART-failing HIV infected adults
62659545|NCT04323475|ACTIVE_COMPARATOR|Standard of Care|Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
62659546|NCT04323475|EXPERIMENTAL|Cocktail-SPK and standard of care|The experimental drug consists of Cocktail-SPK used as an adjunct to the standard of care. Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
62659547|NCT03238534|ACTIVE_COMPARATOR|Omeprazole 20mg|"Patients will be provided with enough amount of 20 mg omeprazole \[30' before meal\] and Neobianacid® placebo \[30' after meal\] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole + Neobianacid® placebo; Lunch: Neobianacid® placebo; Midafternoon: Neobianacid® placebo; Dinner: Neobianacid® placebo; Before going to bed: Neobianacid® placebo.~Day14-27 Breakfast: Omeprazole+ Neobianacid® placebo on demand Lunch: Neobianacid® placebo on demand Dinner: Neobianacid® placebo on demand Any other time: Neobianacid® placebo on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
62659548|NCT03238534|EXPERIMENTAL|Neobianacid®|"Patients will be provided with enough amount of Omeprazole placebo \[30' before meal\] and Neobianacid® \[30' after meal\] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole placebo + Neobianacid® Lunch: Neobianacid® Midafternoon: Neobianacid® Dinner: Neobianacid® Before going to bed: Neobianacid®~Day14-27 Breakfast: Omeprazole placebo + Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
62659549|NCT02826096|EXPERIMENTAL|biofeedback group|biofeedback therapy
62659550|NCT02826096|NO_INTERVENTION|medication group|only medication treament
62659551|NCT06551012|EXPERIMENTAL|Nitrate-rich beetroot juice|Participants will consume 2 x 70 ml bottles of nitrate-rich beetroot juice for a 7 day period prior to exercise testing
62659552|NCT06551012|PLACEBO_COMPARATOR|Beetroot juice with nitrate extracted|Participants will consume 2 x 70 ml bottles of beetroot juice with nitrate extracted for a 7 day period prior to exercise testing
62659553|NCT02907372|OTHER|cognitive tests|
62293343|NCT03388814|EXPERIMENTAL|Pectoralis Nerve block Group|Those patients who are randomized to pectoralis nerve block will have randomization immediately preoperatively and will undergo the nerve block procedure using local anesthetic in the standard fashion. Those patients randomized to pectoralis block will have a standard volume of normal saline injected for oncologic and plastic surgery.
62293344|NCT01145235||Females previously treated with Macrolane in their breasts.|
62293345|NCT03180814|ACTIVE_COMPARATOR|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
62293346|NCT03180814|EXPERIMENTAL|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
62293347|NCT03106532|EXPERIMENTAL|PHP-201 0.25% ophthalmic solution|PHP-201 0.25% ophthalmic solution, TID
62095842|NCT06526728|EXPERIMENTAL|Treatment Arm|"Participants will be subjected to seven once-daily sessions of hyperbaric oxygen therapy.~Generic Name: Oxygen Dosage: 100% Frequency: Once-daily Duration per treatment session: 115-120 minutes"
62095843|NCT04307979|EXPERIMENTAL|Bulletproof Coffee|A black coffee (bullet proof coffee keurig pod) with 29 grams of added fat (1 tablespoon bullet proof brain octane medium chain triglyceride oil, and 1 tablespoon bullet proof grass fed ghee) blended for 20 seconds with butter scent that is added to the lid.
62095844|NCT04307979|PLACEBO_COMPARATOR|Black Coffee|Black coffee that is blended for 20 seconds with butter scent added to the top of the lid.
62095845|NCT05362578|EXPERIMENTAL|Treatment group|Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
62095846|NCT05362578|SHAM_COMPARATOR|Sham group|Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
62293348|NCT03106532|EXPERIMENTAL|PHP-201 0.5% ophthalmic solution|PHP-201 0.5% ophthalmic solution, TID
62293349|NCT03106532|PLACEBO_COMPARATOR|Placebo ophthalmic solution|Placebo ophthalmic solution, TID
62293350|NCT01991561|EXPERIMENTAL|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
62293351|NCT01991561|EXPERIMENTAL|Med dose H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
62095847|NCT06068738||Newly diagnosed|Newly diagnosed ovarian carcinoma patients presenting with ascites and/or pleural effusions before start of their initial therapy.
62095848|NCT06068738||Relapsed/refractory|Relapsed/refractory (r/r) ovarian carcinoma patients presenting with ascites before start of their next therapy line (for r/r patients).
62293352|NCT01991561|EXPERIMENTAL|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
62293353|NCT01991561|EXPERIMENTAL|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
62659554|NCT05997589|EXPERIMENTAL|Health Services Research (educational program)|Participants attend financial health educational program over 60 minutes. Patients also receive educational materials on study.
62293354|NCT01991561|EXPERIMENTAL|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
62293355|NCT01991561|PLACEBO_COMPARATOR|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
62293356|NCT05456750|EXPERIMENTAL|treatment group|The treatment group receive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The laser power is set between 2.5 \~ 3.0Mw, 60 minutes each time, once a day for five consecutive days each week, for 2 weeks (total 10 times in one course)
62465731|NCT04132908|EXPERIMENTAL|Sclerocarya birrea|
62465732|NCT04132908|PLACEBO_COMPARATOR|Placebo|
62659555|NCT03815305|ACTIVE_COMPARATOR|Topical CA and Placebo Oral Drug|Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
62095849|NCT00350181|EXPERIMENTAL|Regimen Treatment 1|For subjects 18-60 years old with lymphoma: (BCNU+ VP-16 +CY) BCNU 15 mg / kg (maximum dose 550 mg/m² actual body weight) on day -6. VP 60 mg / kg on day 4 and CY 100 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
62095850|NCT00350181|EXPERIMENTAL|Regimen Treatment 2|For subjects 18-50 years old with AML, ALL or CML: (VP-16 +CY+ FBI) Patients aged 18-50 years with AML, ALL or CML: FTBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days -8 through -5. VP 60 mg / kg on day -4 and CY 60 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
62095851|NCT00350181|EXPERIMENTAL|Regimen Treatment 3|For subjects 51-60 years with MDS, AML or ALL or 18-60 with MDS, secondary AML pr non-CML myeloproliferative disease: (BU+ VP-16 +CY) BU 1 mg/kg every 6 hours X 14 doses on days -9 through -6 with target concentration at steady state of X 800 ng / ml based on first dose pharmacokinetics. VP 60 mg / kg on day -5 and CY 45 mg / kg per day -2 days on day -3 and day -2. Followed by Sirolimus and MMF as prophylaxis
62095852|NCT01876043|EXPERIMENTAL|plitidepsin|plitidepsin
62095853|NCT06319144|ACTIVE_COMPARATOR|Experimental group|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
62293357|NCT05456750|SHAM_COMPARATOR|control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
62293358|NCT01113151|NO_INTERVENTION|Washout|
62095854|NCT06319144|ACTIVE_COMPARATOR|Control group|Patients in the control group were infused intravenously with 0.9% Normal Saline (500 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
62095855|NCT05488782|EXPERIMENTAL|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
62095856|NCT05488782|OTHER|Enhanced Waitlist (eWL)|After the week 12 follow up visit, subjects in the Waitlist group will receive the TEAM Red intervention
62095857|NCT03193567|EXPERIMENTAL|HEKT cell|Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
62293359|NCT01113151|ACTIVE_COMPARATOR|Mablet|
62293360|NCT01113151|PLACEBO_COMPARATOR|Placebo|
62293361|NCT03496701|EXPERIMENTAL|Stenfilcon A / Test lens|All subjects will first wear stenfilcon A contact lenses for one week, then refitted with test contact lenses to wear for one week.
62293362|NCT05104944|EXPERIMENTAL|Arm A (Intervention - Standard Care and Serial MRIs)|Immobilisation discontinued on the basis of MRI defined disease resolution at 3, 6, 9 or 12 months. In the intervention arm participants will receive additional MRIs at 3, 6, 9 and 12 months. Patients randomised to serial MRI will not undergo further MRI once remission has been diagnosed i.e. if remission is diagnosed at 6 months the MRI at 9 and 12 months will not occur.
62095858|NCT06239662|EXPERIMENTAL|Therapeutic group intervention|Patients will be called in groups every 3 months for a total of 10 meetings. At each meeting they will be weighed and measured. Each meeting will focus on a topic of nutritional/lifestyle interest and will see the co-presence of the figures of the dietician and the psychologist, in order to allow an emotional declination for all the participants.
62095859|NCT06239662|ACTIVE_COMPARATOR|Usual care|Patients will be called individually every 3 months for a total of 10 meetings. At each meeting they will be weighed and measured. Each meeting will focus on a topic of nutritional/lifestyle interest. The meetings will be conducted by a dietician.
62095860|NCT04795102|EXPERIMENTAL|L-PRF with ATBG around implant|L-PRF clots to cover ATBG around immediately placed dental implants in the extraction sockets
62308081|NCT05751525||Late SU treatment|Patients with permanent neonatal diabetes (PNDM) due to the V59M mutation in the KCNJ11 gene who commenced sulfonylurea older than the age of twelve months.
62659556|NCT03815305|PLACEBO_COMPARATOR|Petroleum Jelly and placebo oral drug|Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
62095861|NCT04795102|ACTIVE_COMPARATOR|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
62095862|NCT05092932||Normal Control Data|"Normal adults with no history of neuromusculoskeletal disease will be recruited for this study. Participants will be independent walkers (no walking aid needed) and will not have needed a walking aid for injury over the past 5 years.~Participants will walk 200 m under 4 randomized conditions: non-weightbearing ambulation using crutches, a walker, a wheeled knee walker, and unaided walking. An in-shoe sensor will measure stance limb plantar force, a stopwatch will time each walk, perceived exertion will be reported using the BORG CR-10 scale, and device preference will be identified."
62095863|NCT03098264|EXPERIMENTAL|Simultaneous surgery|to perform surgery both on biliary stone and portal hypertension
62659557|NCT03815305|EXPERIMENTAL|Centella asiatica extract and Topical CA|Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
62293363|NCT05104944|NO_INTERVENTION|Arm B (Control - Standard Care and one additional MRI)|Immobilisation discontinued on the basis of clinical remission determined by skin temperature measurement and MRI. In the standard care arm participants will receive one additional MRI when the temperature measurements, X-ray and/or signs and symptoms indicate to the clinical team that the foot is in remission. A temperature difference of ≤ 2ºC which is maintained or improves on two separate consecutive occasions for a period of ≥4weeks will be the indicator to arrange the second MRI, to confirm the diagnosis of remission. If participants in either arm of the trial have not reached remission at the end of the 12 month active phase of the study they will exit the study. Ongoing standard care will be provided by their clinical team.
62095864|NCT03098264|ACTIVE_COMPARATOR|Staged surgery|to perform surgery on biliary stone and portal hypertension by staged surgery
62095865|NCT05793099|EXPERIMENTAL|Aqueous propolis 5% gum|The children will be given aqueous propolis gums to chew for 15 minutes.
62293364|NCT02241473|EXPERIMENTAL|CH training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion.
62095866|NCT05793099|PLACEBO_COMPARATOR|Placebo gum|The children will be given placebo gums gums to chew for 15 minutes.
62095867|NCT03505645|ACTIVE_COMPARATOR|Treatment group 1: Periarticular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 1.
62095868|NCT03505645|ACTIVE_COMPARATOR|Treatment Group 2: Intra-articular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 2.
62293365|NCT02241473|ACTIVE_COMPARATOR|CN training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) condition in a single-blind fashion.
62293366|NCT03478241|ACTIVE_COMPARATOR|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system.
62293367|NCT03478241|ACTIVE_COMPARATOR|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system.
62293368|NCT03478241|ACTIVE_COMPARATOR|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system.
62659558|NCT02363491|EXPERIMENTAL|OPN-305|OPN-305
62293369|NCT00222105|EXPERIMENTAL|1|Doxil, Thalidomide, Dexamethasone
62659559|NCT03780192||Treatment|Bifurcation lesion treatment using provisional stent technique
62659560|NCT04335864|ACTIVE_COMPARATOR|Group A|39 patients with hydrosalpinx will have laparoscopic salpingectomy
62659561|NCT04335864|ACTIVE_COMPARATOR|Group B|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
62659562|NCT05775653|EXPERIMENTAL|ADAPT program|The ADAPT program is a structured and individualized group-based program.
62659563|NCT05775653|ACTIVE_COMPARATOR|Usual Occupational Therapy (UOT)|UOT is delivered by one occupational therapist. .
62659564|NCT02955693|OTHER|Sequence A (n=8)|Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
62659565|NCT02955693|OTHER|Sequence B (n=8)|LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
62659566|NCT02955693|OTHER|Sequence C (n=8)|Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
62659567|NCT02955693|OTHER|Sequence D (n=8)|LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
62095869|NCT04859556|EXPERIMENTAL|10k 25G cutter|New cutter, with a 10,000 cut per minute blade
62095870|NCT04859556|ACTIVE_COMPARATOR|5k 25G cutter|Traditional cutter, with a 5,000 cut per minute blade
62095871|NCT05419492|EXPERIMENTAL|Part 1|Part 1 will follow an open-label, rule-based, dose-escalation design and will evaluate 3 dose levels of ETX101.
62095872|NCT05419492|SHAM_COMPARATOR|Part 2|"Part 2 is a dose-selection study, which will follow a double-blind (up through Week 52), randomized, sham delayed-treatment control design.~There will be up to 3 cohorts in Part 2. If it is determined two dose levels of ETX101 will be evaluated in Part 2, participants will be randomized 1:1:1 to study treatment or sham procedure with delayed treatment. If Part 2 proceeds with a single dose level of ETX101, participants will be randomized 2:1 to study treatment or sham procedure with delayed treatment."
62095873|NCT00438971|EXPERIMENTAL|Duloxetine|
62095874|NCT04488653|EXPERIMENTAL|Oligopin®|Oligopin® contains French Maritime Pine Bark Extract
62095875|NCT04488653|PLACEBO_COMPARATOR|Placebo|Placebo is a mixture of different inert compounds
62095876|NCT04036240|EXPERIMENTAL|Finger feeder|HMF supplementation will be given by finger feeder
62095877|NCT04036240|NO_INTERVENTION|Control|HMF supplementation will be given by mother preference such as cup, bottle.
62095878|NCT05870930|EXPERIMENTAL|Carob beverage|
62095879|NCT06497985|EXPERIMENTAL|tucidinostat+sintilimab+bevacizumab|
62095880|NCT06497985|ACTIVE_COMPARATOR|fruquintinib|
62659568|NCT05662618|EXPERIMENTAL|Rapamycin coated peripheral balloon catheter|Rapamycin coated peripheral balloon catheter of Bomaian Company.
62095881|NCT06668207||adult athletes|This study aimed to evaluate the effect of carbohydrate quality on enjoyment of physical activity and burnout in athletes. Data were collected from 139 active athletes aged 19 to 35 years using a Demographic Structure Questionnaire, the Athlete Burnout Questionnaire (ABQ), and the Physical Activity Enjoyment Scale (PACES). Carbohydrate quality was assessed using food frequency data, and the results were analyzed with SPSS 24 software.
62095882|NCT05379686|EXPERIMENTAL|150 ug glucagon before exercise|150 ug glucagon will be administered subcutaneously just before exercise
62308082|NCT01809236|EXPERIMENTAL|0.5 mg Conbercept|patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
62659569|NCT05662618|ACTIVE_COMPARATOR|Drug eluting peripheral balloon catheter|Paclitaxel eluting balloon catheter
62659570|NCT01035788|EXPERIMENTAL|Mindfulness-Based CBCT|Mindfulness Based Cognitive Behavioral Conjoint Therapy for PTSD
62308083|NCT04776343|EXPERIMENTAL|Telemedecine follow-up|
62095883|NCT05379686|NO_INTERVENTION|Control|No glucagon will be administered before exercise
62095884|NCT04344990|ACTIVE_COMPARATOR|Group E- Epidural analgesia|Continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure. The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The epidural catheter is placed preoperatively.
62095885|NCT04344990|ACTIVE_COMPARATOR|Group F- Femoral blockade|Continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The femoral catheter is placed preoperatively.
62095886|NCT04344990|ACTIVE_COMPARATOR|Group I- Intraarticular infusion|Continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The intraarticular catheter is placed before the closure of the incision.
62095887|NCT01649726|OTHER|Standard strategy|Apnea test according to recommendations
62095888|NCT01649726|EXPERIMENTAL|CPAP strategy|Apnea test with CPAP connection
62095889|NCT06569953|EXPERIMENTAL|intervention (liposomal bupivacaine）|Participants randomized to the intervention arm received liposomal bupivacaine for paravertebral block before surgery.
62308084|NCT04776343|NO_INTERVENTION|Hospital follow-up|
62308085|NCT04508309|EXPERIMENTAL|Cecolin® at 0 and 6 months|Two doses of Cecolin® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
62659571|NCT01035788|ACTIVE_COMPARATOR|CBCT Communication Skills|CBCT for PTSD - Communication Skills
62095890|NCT06569953|ACTIVE_COMPARATOR|control (bupivacaine hydrochloride)|Participants randomized to the intervention arm received bupivacaine hydrochloride for paravertebral block before surgery.
62095891|NCT06224075|EXPERIMENTAL|Task-specific training|
62095892|NCT06224075|OTHER|Usual care|
62659572|NCT05665998|EXPERIMENTAL|ARC-BSI Cervical Rehabilitation|Implantation of a neuroprosthetics system composed of an electrocorticography acquisition system (WIMAGINE) and a cervical epidural electrical spinal cord stimulation system (ARC-IM) to restore voluntary arm movements in participants with SCI.
62659573|NCT02413762||NGT, no insulin resistance|Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
62659574|NCT02413762||IFG/IGT/T2DM|Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
62659575|NCT02413762||Insulin resistance without IGT|e.g. polycystic ovarian syndrome. No intervention.
62659576|NCT02413762||IGT, no insulin resistance|e.g. T1DM. No intervention.
62659577|NCT02413762||Previous metabolic surgery|Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
62659578|NCT03007940|EXPERIMENTAL|NIATx Strategy|"The implementation intervention, NIATx, will be deployed by the first cohort of programs in a 1-year active implementation phase. Each program is assigned an expert quality improvement coach. The coach will help the staff identify ways to improve and integrate services for individuals with co-occurring substance use and mental health disorders. Supports include an in-person coach site visit, coaching including monthly coaching calls and peer to peer coaching calls and learning sessions which promote peer-to-peer sharing about specific goals and objectives and to receive guidance on how to implement organizational level changes to improve integrated treatment services. A walk-through will allow the provider to understand the co-occurring treatment process from a customer perspective."
62095893|NCT05182437|EXPERIMENTAL|LINAC-based Stereotactic Radiotherapy|The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone (EZ) with the neurologist, radiologist and neurosurgeon.
62095894|NCT05182437|OTHER|Randomised waitlist-controlled trial|The first 2 years after randomization stardard treatment (AED continuation and neuromodulation). After 2-year follow up the waitlist-control group, patients are offered the intervention (LINAC-based Stereotactic Radiotherapy). This intervention is optional
62095895|NCT03880656|EXPERIMENTAL|Autologous BM-MNCs High Dose|Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
62659579|NCT03007940|PLACEBO_COMPARATOR|Wait List Control|The wait-list control group will receive the NIATx strategy at the end of the twelve month implementation period for the initial cohort. During the first year of the study, they will follow a business as usual approach to the integration of co-occurring substance use and mental health services.
62659580|NCT03217097|EXPERIMENTAL|Unmethylated MGMT NET - OX|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
62095896|NCT03880656|NO_INTERVENTION|Observational Control|Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome. No autologous bone marrow mononuclear cells will be administered.
62659581|NCT03217097|ACTIVE_COMPARATOR|Unmethylated MGMT NET - ALKY|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
62095897|NCT03880656|EXPERIMENTAL|Autologous BM-MNCs Low Dose|Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
62095898|NCT04559932|EXPERIMENTAL|Intervention|The knowledge and self-efficacy pre-tests will be completed at the start of the course and the post-test will be completed after the course at the end of the day. Study participants will complete tests independently using paper and pencil. Six weeks and six months post course completion, the knowledge and self-efficacy tests will be completed using REDcap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases or via telephone as per participant preference. Study participants will be sent a link to complete the tests online for the subsequent study visits. Study participants will receive 2 reminder emails (1 week apart) and 1 reminder phone call after the email reminders (if applicable) to complete the tests. Monthly telephone calls by the RA will be made to review the HCP experience logs.
62293370|NCT05011591|EXPERIMENTAL|swimming economy|This is a study based on a comparative clinical trial (effect of an imposed V and/or SR on the swimming economy of swimmers or para-swimmers). This longitudinal study is carried out on a representative sample of swimmers and para-swimmers selected for their potential at the Paris 2024 Olympic and Paralympian Games. Following a standardized warm-up, all swimmers will perform intermittent swimming tests of progressive velocity in a 50 m indoor pool in their swimming specialty with or without an imposition of the SR to adopt. During the trials, the swimmers and para-swimmers will be equipped with inertial measurement units, as well as a heart rate monitor and tissue oximeters. The swimming and non-swimming phases will also be filmed continuously. Gas exchanges will be recorded 2 minutes after the warm-up and during the 7 minutes of passive recovery. Micro blood samples will be taken from the earlobe at the end of the warm-up and at 1, 3, 5 and 7 minutes of recovery between each trial.
62659582|NCT03217097|EXPERIMENTAL|Methylated MGMT NET - OX|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
61908677|NCT03540251|SHAM_COMPARATOR|Placebo auricular points treatment|Placebo auricular points treatment including auricular points AH9、AH11、TG3、AT2、LO4 in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing placebo auricular points treatments.
62659583|NCT03217097|ACTIVE_COMPARATOR|Methylated MGMT NET - ALKY|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
61908678|NCT04458324|EXPERIMENTAL|NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
61908679|NCT04458324|PLACEBO_COMPARATOR|NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
62095899|NCT04559932|NO_INTERVENTION|Control|Study participants in the control arm will be offered complementary attendance in the Health Tech Junior enterostomy and vascular access competency based training course while awaiting their session. This is being done to minimize the potential confound of generalized improvements in self-efficacy that may occur as a result of participating in an 8 hour learning opportunity at SickKids. The control group will also complete the tracheostomy course during session 3 and 4 but this will occur outside the window of data collection for the study procedures. Data collection intervals as described above for the intervention group will be followed for the control group.
62095900|NCT00907686||LBWIs of CMV-positive mother|LBWIs born to CMV-positive mothers
62095901|NCT00907686||CMV Sero-negative & Sero-postive LBWIs|LBWIs of CMV sero-negative \& sero-positive mothers
62095902|NCT06494774|EXPERIMENTAL|SRD part: low dose|Single-rising dose (SRD)
62095903|NCT06494774|EXPERIMENTAL|SRD part: medium dose followed by MD part|Single-rising dose (SRD) Multiple dose (MD)
62095904|NCT06494774|EXPERIMENTAL|SRD part: high dose|
62095905|NCT06494774|PLACEBO_COMPARATOR|Placebo|
62659584|NCT05891275||Patients with a Geographic Atrophy diagnosis|
62659585|NCT00556959|EXPERIMENTAL|1|CLONICEL High Dose
62659586|NCT00556959|EXPERIMENTAL|2|CLONICEL Low Dose
62659587|NCT00556959|PLACEBO_COMPARATOR|3|Placebo
62659588|NCT06038630|ACTIVE_COMPARATOR|Transfusion and Phlebotomy Patients|Individuals receiving treatment for their blood hemoglobin levels or are a healthy volunteer who is planning to donate blood.
62659589|NCT06038630|ACTIVE_COMPARATOR|Oxygen Administration Patients|Individuals diagnosed with a chronic blood clot in their lungs and are planning on having surgery to remove it (CTEPH), or have an interstitial lung disease (ILD), or have dyspnea, or are a healthy volunteer.
62659590|NCT06038630|ACTIVE_COMPARATOR|Acute or Chronic Pulmonary Embolism Patients|Individuals recently diagnosed with a blood clot in their lungs.
62659591|NCT04507321|EXPERIMENTAL|GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension|Participants will receive a single oral dose of GSK3640254 200 milligram (mg) (2×100 mg) tablets with a moderate fat meal. Participants will then be administered a 100 microgram (mcg) dose (approximately 3.7 kilobecquerel; 100 nano Curie) of \[14C\]-GSK3640254 as an IV infusion for 1 hour on Day 1 in treatment Period 1, On Day 1 in treatment Period 2, participants will receive a single oral dose of 85 mg (approximately 3.15 megabecquerel; 85 micro Curie) \[14C\]-GSK3640254 administered as an oral suspension with a moderate fat meal. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
62659592|NCT01737086|EXPERIMENTAL|ORS with probiotic and zinc|Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
62659593|NCT01737086|PLACEBO_COMPARATOR|Standard ORS|Standard oral rehydration solution
62659594|NCT06061419|ACTIVE_COMPARATOR|Huel Powder|This arm of the study will receive Huel as their first study meal with cornflakes and milk as their second
62659595|NCT06061419|ACTIVE_COMPARATOR|Cornflakes and Milk|This arm of the study will receive cornflakes and milk as their first study meal with Huel as their second
61908680|NCT04458324|SHAM_COMPARATOR|sham NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
61908681|NCT04458324|ACTIVE_COMPARATOR|sham NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
61908682|NCT03970356|EXPERIMENTAL|intervention|The antibiotic stewardship intervention will encourage to prescribe according to the latest relevant UTI guidelines which promote more restrictive use of antibiotics in case of non-specific symptoms.
61908683|NCT03970356|NO_INTERVENTION|control|Usual care
62095906|NCT04660435||Women with ER+/Her2 negative metastatic breast cancer|Patients with ER+/HER2-negative metastatic breast cancer candidate to first-line treatment with a CDK4/6 inhibitor and an aromatase inhibitor as per standard clinical practice
62095907|NCT05282459|EXPERIMENTAL|Enasidenib mesylat|Participants will self administer the enasidenib orally everyday.
62308086|NCT04508309|EXPERIMENTAL|Cecolin® at 0 and 12 months|Two doses of Cecolin® given at 0 and 12 months with blood draw at baseline, prior to second dose and one-month post second dose
62659596|NCT03754647|NO_INTERVENTION|Patients receiving SSRIs|This group will be receive SSRIs only
61908684|NCT02842034|ACTIVE_COMPARATOR|Active rTMS|Active treatment will be delivered at an intensity that is 120% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 50 stimuli each (i.e., 3000 stimuli) and an intertrain interval of 10 sec. Treatment will be applied in sequential order to the dorsomedial prefrontal cortices (DMPFC).
61908685|NCT02842034|SHAM_COMPARATOR|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the same site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
61908686|NCT05406193|EXPERIMENTAL|Intervention (CIM2)|An extended overview consultation, lasting 45 minutes, with the general practitioner, the patient (and maybe a relative), and the care coordinator. An individual care plan is developed, covering planned activities in the three sectors (general practice, municipality, and hospital) that will take place within the 12-month intervention period. General practice coordinates the planned patient care between general practice, the municipality, and the hospital, and follow-up on the execution of planned healthcare activities. The individual care plan is shared electronically with the healthcare center in the municipality and with the outpatient clinics using the standard IT-communication tool provided by MedCom and a routinely used national standard in general practice, hospitals, and municipalities.
61908687|NCT05406193|NO_INTERVENTION|Usual care|Patients with a general practitioner allocated to the control group will receive usual care.
62659597|NCT03754647|ACTIVE_COMPARATOR|Patients receiving Vitamin C with SSRIs|This group will be receive vitamin C (500mg) twice daily with SSRIs for 8 weeks
62095908|NCT03924245|EXPERIMENTAL|Treatment (entinostat, olaparib)|Patients receive entinostat PO 1 week before starting combination therapy (day -7). Patients then receive entinostat PO on days 1, 8, 15, and 22, olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity
62095909|NCT06268210|EXPERIMENTAL|Experimental|"Patients will receive a combination therapy of Lazertinib and Pemed-S + Carboplatin as neoadjuvant treatment before surgery, followed by post-surgery maintenance with Lazertinib at a dosage of 240 mg once daily for a duration of 3 years.~Dosages:~Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)"
62095910|NCT06268210|ACTIVE_COMPARATOR|Comparator|Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
62095911|NCT02098031|NO_INTERVENTION|control|
62293371|NCT06656143|EXPERIMENTAL|Diaphragmatic Myofascial release|Myofascial release of the diaphragm is an intervention intended to indirectly stretch the diaphragm muscle fibers to reduce muscle tension, normalize fiber length, and promote the efficiency of muscle contraction.
62293372|NCT06656143|ACTIVE_COMPARATOR|Traditional Physical therapy|Strengthening Deep Cervical Flexors Strengthening Shoulder Retractors Stretch Cervical Extensors Stretch Pectoralis Muscle
62308087|NCT04508309|EXPERIMENTAL|Cecolin® at 0 and 24 months|Two doses of Cecolin® given at 0 and 24 months with blood draw at baseline, prior to second dose and one-month post second dose
62659598|NCT03108690|EXPERIMENTAL|TDM and CI.|Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.
62659599|NCT03108690|NO_INTERVENTION|Control|Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.
62659600|NCT05514119|EXPERIMENTAL|Recipients of DCD liver transplants|Subjects that have undergone transplant of a liver donation after circulatory death (DCD) in the last 21-35 days will receive a 12 week fenofibrate (Lofibra) for a duration of 12 weeks
62659601|NCT04739709|EXPERIMENTAL|APP13007 0.05% BID|1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
62659602|NCT04739709|PLACEBO_COMPARATOR|Matching Vehicle Placebo|1 drop matching vehicle place twice daily for 14 days to study (operated) eye
62659603|NCT06126978|EXPERIMENTAL|Vibration Therapy|Vibration Therapy uses vibration as a physical tool during the treatment. It can be applied with different devices that transmit mechanical vibration throughout the whole or a part of the body. Focal Muscle Vibration (FMV) is a safe, well-tolerated and non-invasive technique, which may be an efficient intervention in reducing the upper extremity spasticity, whereas Whole Body Vibration (WBV) can provide proper somatosensory stimulation, and improve muscle strength and postural control in stroke patients (Oliveira et al., 2018).
62659604|NCT06126978|EXPERIMENTAL|Mirror Therapy|Mirror Therapy is a structured, inexpensive, simple and patient-directed treatment. The principle of Mirror Therapy is the use of a mirror to create a reflective illusion of an affected limb, in order to trick the brain into thinking the movement has occurred without pain. It has shown to improve movements of the affected upper limb and the ability to carry out daily activities, in addition to reducing pain (Dhami et al., 2019).
62659605|NCT03040531|EXPERIMENTAL|Genistein|"Each tablet will contain 27 mg of 98% pure genistein + 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will receive a tablet containing only 500mg Calcium + 200 IU Vit. D3."
62659606|NCT03040531|ACTIVE_COMPARATOR|Alendronate|"Each tablet will contain 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will take one tablet containing 70mg alendronate."
61908688|NCT04119271|OTHER|Breathe Easy at Home Kit Products|"Families will be provided with a Breathe Easy at Home Kit. These kits will include:~a HEPA filtered upright vacuum cleaner, a HEPA-filtered Air Purifier, a Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control, and a combination of safe products to locate and kill roaches."
61908689|NCT00345332|PLACEBO_COMPARATOR|1|Placebo
61908690|NCT00345332|EXPERIMENTAL|2|Botox
61908691|NCT05291169|EXPERIMENTAL|OCM™ plus Standard of Care|Omeza® OCM™ is an FDA cleared 510(K) medical combination drug/device which is applied directly to the wound bed. Treatment, followed by compression management, is applied on a weekly basis.
61908692|NCT05291169|NO_INTERVENTION|Standard of Care|Cleaning and debridement of the ulcers with compression management on a weekly basis.
61908693|NCT02817399|ACTIVE_COMPARATOR|Neuro-muscular electrical stimulation|Active exercises \& Neuro-muscular electrical stimulation in a stationary position (lying and/or sitting).
61908694|NCT02817399|EXPERIMENTAL|Functional electrical stimulation|Active exercises \& Functional electrical stimulation while walking.
62095912|NCT02098031|EXPERIMENTAL|intervention|Nutritional intervention (nutrition education)
62095913|NCT05192512|EXPERIMENTAL|TQB2928 injection|weekly intravenous (IV) infusions for four times (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle
62659607|NCT04452175|EXPERIMENTAL|HIGH 5%|
62659608|NCT04452175|ACTIVE_COMPARATOR|LOW 1.7%|
61908695|NCT02081248|ACTIVE_COMPARATOR|Standard Consent|This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
61908696|NCT02081248|EXPERIMENTAL|Easy-to-Read Informed Consent|This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
61908697|NCT01467687|ACTIVE_COMPARATOR|1|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
61908698|NCT01467687|ACTIVE_COMPARATOR|2|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
61908699|NCT00984620|EXPERIMENTAL|short arm|patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
61908700|NCT00984620|EXPERIMENTAL|long arm|patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
61908701|NCT00522925|PLACEBO_COMPARATOR|1|Matching Placebo
61908702|NCT00522925|EXPERIMENTAL|2|
61908703|NCT00522925|EXPERIMENTAL|3|
61908704|NCT00533793|ACTIVE_COMPARATOR|SoC|Standard of Care
61908705|NCT00533793|ACTIVE_COMPARATOR|SoC plus 0.133 mg/mL|
61908706|NCT00533793|ACTIVE_COMPARATOR|SoC plus 0.4 mg/mL|
61908707|NCT00533793|ACTIVE_COMPARATOR|SoC plus 1.0 mg/mL|
61908708|NCT05062954|EXPERIMENTAL|Polyphenol-rich cranberry extract supplement standardized in PACs|Supplementation with polyphenol-rich cranberry extract standardized in PACs (1 capsule / day)
61908709|NCT05062954|PLACEBO_COMPARATOR|Placebo supplement|Supplementation with placebo (1 capsule / day)
62095914|NCT03569813|EXPERIMENTAL|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits, behavioral surveillance, and telemedicine visits as needed.
62095915|NCT03569813|ACTIVE_COMPARATOR|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
62095916|NCT02814760||Pre-intervention group (Control group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included before the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
62465733|NCT03337386|EXPERIMENTAL|Inferior Vena Cava Collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
62659609|NCT00038610|EXPERIMENTAL|Hyper-CVAD + Imatinib|Imatinib 600 mg orally days 1-14, course 1, \& 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m\^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m\^2 IV day 4; Vincristine 2 mg IV days 4 \& 11; \& Dexamethasone 40 mg IV or orally daily days 1-4 \& 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m\^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m\^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
62659610|NCT04568109|EXPERIMENTAL|Exposure-based cognitive-behavior therapy|Patients are treated in accordance with a manualized protocol (Gloster et al., 2011)
62659611|NCT04568109|NO_INTERVENTION|Wait-List control condition|Patients are assessed prior to and after a 12-week waiting period. Patients are treated after this 12-week delay.
61908710|NCT03351101|EXPERIMENTAL|Senofilcon C|Senofilcon C Contact Lens
61908711|NCT03351101|EXPERIMENTAL|Samfilcon A|Samfilcon A Contact Lens
62095917|NCT02814760||Post-intervention group (Training course group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included after the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
62095918|NCT00198874|ACTIVE_COMPARATOR|Psychoeducation|
62095919|NCT00198874|EXPERIMENTAL|Conitive Behavorial Therapy|
62465734|NCT03337386|EXPERIMENTAL|Subclavian Vein Collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
61908712|NCT04235413|EXPERIMENTAL|Real-Time Incentives Group|Each participant will be randomized using a blocking procedure (SNAP participant or not). The intervention will last 6 months and consist of receiving real-time financial incentives at the point of purchase for eligible fruits and vegetables purchases.
61908713|NCT04235413|NO_INTERVENTION|Control Group|No intervention administered. Each participant will be randomized using a blocking procedure (SNAP participant or not).
61908714|NCT01193257|EXPERIMENTAL|Orteronel + prednisone|
61908715|NCT01193257|PLACEBO_COMPARATOR|Placebo + prednisone|
61908716|NCT02490020|EXPERIMENTAL|iv of BMSC to prevent rejection|Routine treatment protocol(ATG 50mg\*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2\*10\^6cell/kg, 48h before op)
62095920|NCT00198874|EXPERIMENTAL|Family Therapy|
62095921|NCT00198874|EXPERIMENTAL|Intergrated Family|
62095922|NCT02651558|EXPERIMENTAL|OBPM 2015-MD-0022 - CHEST|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the chest
62293373|NCT01237951|EXPERIMENTAL|GemBuMel|"Gemcitabine 1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.~Busulfan 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan area under curve (AUC) 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.~Melphalan 60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.~Palifermin 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~Palifermin 60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.~Dexamethasone 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.~Stem Cell Transplant: On Day 0, stem cells returned to body by vein over 30-60 minutes."
62659612|NCT02143648|EXPERIMENTAL|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
61908717|NCT02490020|NO_INTERVENTION|routine treatment protocol to prevent rejection|Routine treatment protocol(ATG 50mg\*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
62095923|NCT02651558|EXPERIMENTAL|OBPM 2015-MD-0022 - CHEST & FINGER|Cohort of 10 patients undergoing general anesthesia, monitored by optical signals at the chest and at the fingertip
62095924|NCT02651558|EXPERIMENTAL|OBPM 2015-MD-0022 - FINGER|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the fingertip
62095925|NCT05697965|EXPERIMENTAL|Vancomycin loaded group|applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty operations
62095926|NCT05697965|EXPERIMENTAL|Non vancomycin loaded group|Total knee \& hip arthroplasty done without applying local vancomycin powder comparing the results with vancomycin loaded group
62095927|NCT00508443|EXPERIMENTAL|Radiation Therapy|Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
62095928|NCT03969329|EXPERIMENTAL|Etelcalcetide|Patients will receive etelcalcetide in addition to standard of care
62095929|NCT03418779|EXPERIMENTAL|Control Group|Optimized supportive care, YQF placebo (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
62095930|NCT03418779|EXPERIMENTAL|YQF Group|Optimized supportive care, YQF (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
62095931|NCT01650337|EXPERIMENTAL|Smartphone Application|Patients will be given access to a smartphone application for weight loss and instructed on how to use it.
62095932|NCT01650337|NO_INTERVENTION|Usual primary care|
62095933|NCT01065415||control group|routine staging work-up with chest CT, PET/CT, and brain MRI
62095934|NCT01065415||study group|routine staging work-up plus whole body MRI for Coregistered MRI/PET
62095935|NCT06629766|EXPERIMENTAL|Oocytes inseminated by sperm prepared by a microfluidic (Zymot) sperm preparation device|Half of the mature oocytes will be randomly allocated to receive sperm prepared by the microfluidic (Zymot) sperm preparation device. This sperm will be used by the embryologist for the ICSI procedure.
62095936|NCT06629766|OTHER|Oocytes inseminated by sperm prepared via density grade centrifugation|The other half of the mature oocytes will be allocated to receive sperm prepared by DGC. This sperm will be used by the embryologist for the ICSI procedure.
62095937|NCT01929993|EXPERIMENTAL|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode.
62095938|NCT01929993|ACTIVE_COMPARATOR|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth.
62095939|NCT06498453|EXPERIMENTAL|Knee treatment|Use of TRAK platform as a treatment metodology on knee patients
62095940|NCT06498453|ACTIVE_COMPARATOR|Knee control|They did not have access to the platform and were instructed to continue with the standard care program through exercise.
62465735|NCT03337386|ACTIVE_COMPARATOR|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
62659613|NCT02143648|EXPERIMENTAL|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
62659614|NCT02143648|PLACEBO_COMPARATOR|Sugar pill|Placebo tablets BID
61908718|NCT02490020|EXPERIMENTAL|ia and iv of MSC to prevent rejection|Routine treatment protocol(ATG 50mg\*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2\*10\^6cell/kg + ia 5\*10\^6cell, 48h before op)
61908719|NCT02490020|NO_INTERVENTION|routine treatment to prevent rejection|Routine treatment protocol(ATG 50mg\*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
61908720|NCT02490020|EXPERIMENTAL|Routine CMR treatment plus MSC to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2\*10\^6cell/kg at d1,d7)
61908721|NCT02490020|NO_INTERVENTION|Routine CMR treatment to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)
61908722|NCT02490020|EXPERIMENTAL|Routine AMR treatment plus MSC to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2\*10\^6cell/kg at d1,d7)
61908723|NCT02490020|NO_INTERVENTION|Routine AMR treatment to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)
61908724|NCT06082973|EXPERIMENTAL|Dual-hormone configuration system (insulin and glucagon)|12-hour inpatient study that will include an unannounced 30-min aerobic exercise session and a meal challenge. Automated insulin and glucagon delivery will be performed using a dual-hormone configuration system for glucose control .
61908725|NCT06082973|ACTIVE_COMPARATOR|Single-hormone configuration (insulin) with carbohydrate recommendations system|12-hour inpatient study that will include an unannounced 30-min aerobic exercise session and a meal challenge. Automated insulin delivery will be performed using a single-hormone configuration system with carbohydrate recommendations if needed for glucose control .
62095941|NCT06498453|EXPERIMENTAL|Shoulder treatment|Use of TRAK platform as a treatment metodology on shoulder patients
62095942|NCT06498453|ACTIVE_COMPARATOR|Shoulder control|They did not have access to the platform and were instructed to continue with the standard care program through exercise.
62095943|NCT05652608||Particpants|participating in Immune Strength, a multi-week wellness program
62095944|NCT04017884|EXPERIMENTAL|Remin Pro Forte.|intervention
62095945|NCT04017884|ACTIVE_COMPARATOR|Remin pro.|comparator
62095946|NCT02380274||Patients with CRPC|Patients with CRPC
62095947|NCT05287932|EXPERIMENTAL|Intervention|Brief physical activity intervention including an initial 45-minute physical activity consultation, telephone support after 2 weeks (approx. 15-minute call), and provision of a pedometer, written information, and a physical activity diary. Embedded behaviour change techniques will include goal setting, self-monitoring, building self-efficacy and social support, and overcoming barriers.
62293374|NCT02505256||case group|cases who presented as breast pain or breast lumps, and no intervention will be administered.
62659615|NCT01934179||Ancillary-correlative (real-time PCR)|Patients undergo blood collection for analysis via real-time PCR at baseline, 3 months, and 6 months.
62659616|NCT05844046|EXPERIMENTAL|Arm A|Durvalumab (1500 mg q4w) plus tremelimumab (300 mg x 1) followed by addition of bevacizumab (15mg/kg) upon detection of radiological progression or in the absence of objective response after the second staging.
62659617|NCT05844046|EXPERIMENTAL|Arm B|Durvalumab plus tremelimumab followed by maintenance treatment with durvalumab and bevacizumab.
62293375|NCT01856101|EXPERIMENTAL|BEZ235, powder|"* Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.~* Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
62293376|NCT06444438||Ruptured aneurysm|Patients with aneurysmal subarachnoid hemorrhage
62659618|NCT04796974|EXPERIMENTAL|Cention|Alcasite restorative material
62293377|NCT06444438||Unruptured aneurysm|Patients with unruptured aneurysm
61908726|NCT03077087|EXPERIMENTAL|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
62095948|NCT05287932|NO_INTERVENTION|Wait-list control|The control group will not receive any active or placebo intervention during the 4-week study period. They will also not receive any trial contacts during this period. They will however continue to be able to access their usual care from primary, secondary, community, and social services. After the final (4-week) follow-up assessment, this group will receive the full physical activity intervention.
61908727|NCT03636841|EXPERIMENTAL|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
61908728|NCT03636841|ACTIVE_COMPARATOR|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
61908729|NCT02447627||Part A|Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (\<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
61908730|NCT02447627||Part B|Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
62095949|NCT05418010|ACTIVE_COMPARATOR|Tysabri® 300mg|Tysabri® 300mg, administered via intravenous infusion in a 4 week cycle, for a total of 6 cycles
62293378|NCT05195788|EXPERIMENTAL|Intervention|Participants assigned to the Intervention group will undergo a cardiac rehabilitation program. The program will combine individualized aerobic and muscle strengthening exercises, comprising three sessions per week to be conducted in person at the EPIC center and at home, for a duration of three months. All sessions will be prepared by a certified kinesiologist.
62293379|NCT05195788|NO_INTERVENTION|Control|Participants assigned to the control group will be encouraged to remain at the usual level of physical activity for the duration of the study. At the end of the study, they will gain free access to the same cardiac rehabilitation program provided to the intervention group.
62293380|NCT03041311|EXPERIMENTAL|trilaciclib+etoposide/carboplatin/atezolizumab|"Induction: Patients received trilaciclib 240 mg/m² administered intravenously (IV) once daily prior to E/P/A on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m² was administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin was administered on Day 1 of each 21-day cycle using the Calvert formula with a target area under the concentration-time curve (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg was administered as an IV infusion on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients received maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or discontinuation by the patient or investigator."
62293381|NCT03041311|EXPERIMENTAL|placebo+etoposide/carboplatin/atezolizumab|"Induction: Patients received placebo administered IV once daily prior to E/P/A on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m² was administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin was be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 mg/mL/min to calculate the dose. Atezolizumab 1200 mg was administered as an IV infusion on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients received maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or discontinuation by the patient or investigator."
62659619|NCT01697046|EXPERIMENTAL|Isentress+Truvada|All participants will receive the intervention
62659620|NCT04792892||Patients with a new diagnosis of anal cancer|All patients identified at our national tumour board will be offered to participate
62659621|NCT04568200|EXPERIMENTAL|durvalumab and neoadjuvant therapy|durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
61908731|NCT05292547|ACTIVE_COMPARATOR|Arm 1|Subjects receive 20 rTMS sessions in 2 weeks
61908732|NCT05292547|ACTIVE_COMPARATOR|Arm 2|Subjects receive 20 rTMS sessions in 4 weeks
61908733|NCT05292547|ACTIVE_COMPARATOR|Arm 3|Subjects receive 20 rTMS sessions in 5 weeks
61908734|NCT01306929|EXPERIMENTAL|pridopidine|45mg bid
61908735|NCT01836276|EXPERIMENTAL|African American (AA) Smokers|AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
61908736|NCT01836276|ACTIVE_COMPARATOR|White Smokers|White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
61908737|NCT00385476||Patient Medication Knowledge Tool|Assessment of Cancer patients' knowledge of their medications in an outpatient acute care setting
61908738|NCT01710540|OTHER|Metformin GSK 850mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 850mg
61908739|NCT01710540|OTHER|Glucophage 850mg|open label, crossover, two period, two treatment, two sequence, single dose
61908740|NCT02508558|OTHER|Measurements under different gravity states|motion perception and locomotor operation performance under different gravity states
61908741|NCT06470568|EXPERIMENTAL|Intervention group|Participants assigned to the intervention group will perform a supervised Progressive Resistance Exercise Training program for the whole body three times per week for 12 weeks.
62095950|NCT05418010|PLACEBO_COMPARATOR|Placebo|Placebo, administered via intravenous infusion in a 4 week cycle, for 3 cycles, followed by Tysabri® 300mg, administered via intravenous infusion for a total of 3 cycles
62095951|NCT04903002|OTHER|Crossover sequence 1: Oxytocin first|Patients receive 2-weeks courses of 24-IU oxytocin, placebo, 48-IU oxytocin.
62095952|NCT04903002|OTHER|Crossover sequence 2: placebo first|Patients receive 2-weeks courses of placebo, 24-IU oxytocin, 48-IU oxytocin.
62095953|NCT00836810|EXPERIMENTAL|Timed Release Tablet Prednisone|12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
62095954|NCT00836810|ACTIVE_COMPARATOR|Standard Prednisolone|12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
62095955|NCT02491411|EXPERIMENTAL|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
62095956|NCT04992442|EXPERIMENTAL|TAK-935 300 mg + [14C]TAK-935 50 μg + [14C]TAK-935 300 mg|TAK-935 3×100 mg, tablets, orally, once on Day 1, followed by \[14C\]TAK-935 50 micrograms (μg) \[approximately 1 μCi\], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by \[14C\]TAK-935 300 mg (approximately 100 μCi) solution, orally, once on Day 1 of Treatment Period 2.
62095957|NCT00865956|EXPERIMENTAL|Care Management|Care Management plus voucher incentives for adherence to primary care appointments.
62095958|NCT00865956|NO_INTERVENTION|Usual care|Usual care
62659622|NCT04568200|PLACEBO_COMPARATOR|normal saline and neoadjuvant therapy|normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
62095959|NCT06103461|EXPERIMENTAL|Fat Grafting|It is an experimental study for effect of fat grafting on pigmentation of skin
62095960|NCT06204185|ACTIVE_COMPARATOR|1% Metformin|1% Metformin Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 months and 6 months.
62095961|NCT06204185|PLACEBO_COMPARATOR|Control Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 months and 6 months.
62095962|NCT02339727|ACTIVE_COMPARATOR|Omega-6/omega-3=2/1 milk formula|Preterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
62095963|NCT02339727|ACTIVE_COMPARATOR|Omega-6/omega-3=1/1 milk formula|preterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
62095964|NCT00618358|EXPERIMENTAL|Vascular Sealant)|
62095965|NCT00618358|ACTIVE_COMPARATOR|Gelfoam/Thrombin|
62095966|NCT02219594|EXPERIMENTAL|Gemstone CT|Gemstone CT ：Discovery CT750 HD（high definition） ，GE（General Electric Co.） Healthcare, Milwaukee； CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient
62095967|NCT02219594|ACTIVE_COMPARATOR|320-detector row spiral CT|320-detector row spiral CT：Aquilion One, Toshiba, Nasu, Japan. CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient .
62095968|NCT01878695|EXPERIMENTAL|IV and oral n-acetylcysteine|"50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.~600mg n-acetylcysteine orally twice daily except on day of infusion"
62095969|NCT06697145|EXPERIMENTAL|Cardioneuroablation|
62095970|NCT02618629|EXPERIMENTAL|14C-Z-215|
62095971|NCT05674643||Cohort 1 - ultrasound and acetaminophen|Cohort 1 will include subjects who have a peripheral intravenous line placed in the pre-op area per routine care. This cohort is on average age 7 years and older. Procedures for cohort 1 will include: (a) gastric US measurement of the antral CSA and gastric volume using the Perlas US qualitative grading assessment by an expert and a novice operator to determine the inter-rater class reliability and repeat measurements by each operator to assess the intra-rater reliability (Aim 1), and (b) serial abdominal ultrasounds for gastric assessment and the acetaminophen absorption test to determine the correlation between gastric US and a gold-standard for gastric emptying (Aim 2). The acetaminophen absorption test requires administering a single weight-based enteral dose of acetaminophen with 6 oz of water and drawing of blood samples through a peripheral intravenous line.
62095972|NCT05674643||Cohort 2 - ultrasound only|Cohort 2 will include subjects for whom a peripheral intravenous line placement is not part of routine pre-operative care. Average age for cohort 2 is age less than 7 years old. Procedures for Cohort 2 will include a gastric US measurement of the antral CSA and gastric volume using Perlas US qualitative grading assessment by an expert and a novice operator to determine the inter-rater class reliability and repeat measurements by each operator for the intra-rater reliability (Aim 1). This cohort is included to examine the reliability of measurements across age groups.
62095973|NCT02775617|OTHER|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
62095974|NCT02775617|OTHER|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
62095975|NCT06606613|EXPERIMENTAL|Intraurethral injection group|Intraurethral Cross-linked hyaluronic acid/dextranomer injection was performed in female patients with Stress Urinary incontinence
62095976|NCT06606613|ACTIVE_COMPARATOR|Mid-urethral sling group|Mid-urethral sling procedure was performed in female patients with Stress Urinary incontinence
62095977|NCT04215744|EXPERIMENTAL|Ice water immersion group|Ice water immersion of the left hands(30 minutes before the infusion, during the infusion, and 30 minutes after the end of infusion).
62095978|NCT04215744|NO_INTERVENTION|Control group|No intervention of the right hands as control.
62095979|NCT04937075||Before period without multiplex PCR identification|
62659623|NCT06238960|EXPERIMENTAL|Telerehabilitation|"the patients who will be randomized and subjected to the experimental treatment will undergo a physiotherapy treatment with a biweekly frequency which will be started at the same times as the standard group.~After the sixth session, the process will continue through telerehabilitation until the end of outpatient treatment."
62659624|NCT06238960|ACTIVE_COMPARATOR|traditional physiotherapy|Patients who will be randomized and subjected to standard treatment (usual care at our clinic) will undergo physiotherapy treatment on a bi-weekly basis in person.
62659625|NCT03053011|EXPERIMENTAL|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
62659626|NCT02880176|EXPERIMENTAL|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.~Subjects will use Fitbit Zip to track step counts"
62095980|NCT04937075||After period with multiplex PCR identification|
62095981|NCT06202937|EXPERIMENTAL|mother baby yoga|Mother-baby yoga will be held with the babies discharged from the neonatal intensive care unit and their mothers
62095982|NCT06202937|EXPERIMENTAL|control|the control group received the usual care
62095983|NCT04900870||Neck pain|Diagnostic Test: A self-administered questionnaire A self-administered questionnaire will be used to screen VAS scores, bournemouth neck questionnaire, demographic information and for temporomandibular pain Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments Axis I TMD Pain Screener, Symptom questionnaire and Axis II PHQ-4, Oral Behaviors Checklist .
62095984|NCT04900870||Neck pain with temeporomandibular pain|Diagnostic Test: A self-administered questionnaire A self-administered questionnaire will be used to screen VAS scores, bournemouth neck questionnaire, demographic information and for temporomandibular pain Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments Axis I TMD Pain Screener, Symptom questionnaire, Clinical Examination Form, Axis II Pain Drawing Graded Chronic Pain (version 2), JFLS-8 ,PHQ-4 Oral Behaviors Checklist.
62293382|NCT03670576||Case|A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.
62293383|NCT03670576||Control|Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.
62293384|NCT05634902|EXPERIMENTAL|Group 1: Pre-CME with Patient Education|"Physicians in hospitals that have not received the DIZZTINCT educational intervention.~Patients have received the DIZZTINCT educational intervention"
62293385|NCT05634902|NO_INTERVENTION|Group 2: Pre-CME with Standard Patient Care|"Physicians in hospitals that have not received the DIZZTINCT educational intervention.~Patients have not received the DIZZTINCT educational intervention"
62659627|NCT02880176|NO_INTERVENTION|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
62659628|NCT05920265|EXPERIMENTAL|Quadratus Lumborum Block|
62659629|NCT05920265|EXPERIMENTAL|Fascia Iliac Block|
62659630|NCT05920265|ACTIVE_COMPARATOR|control|
61908742|NCT06470568|NO_INTERVENTION|Control Group|Participants assigned to the control group will receive the usual therapy, medical monitoring, and educational lectures. They will be instructed to maintain their current physical condition.
62095985|NCT00690469||Observational (biomarker analysis)|"Participants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology.~Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available.~For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened."
62095986|NCT02061306||Infants with a first-degree relative with celiac disease|Infants who have a first-degree relative diagnosed with celiac disease.
62095987|NCT01104103|EXPERIMENTAL|BOA(R)|Nurse or paramedic uses the BOA(R)-Constricting IV Band to attempt placement of an upper extremity IV in an adult
62095988|NCT01104103|ACTIVE_COMPARATOR|Standard care|Nurse or paramedic uses standard IV starting technique in the upper extremity of adults
62293386|NCT05634902|NO_INTERVENTION|Group 3: Pre-CME with Chart Review Only|"Physicians in hospitals that have not received the DIZZTINCT educational intervention.~Eligible patient will have their medical records abstracted to assess the main study outcome"
62659631|NCT04341051||Case|we will observe the regional saturation of O2 through NIRS at the following time: T0(before peripheral anesthesia); T1 (5 minutes from the block); T2 (15 minutes from the block); T3 (30 minutes from the block); T4 (after revascularization); At each interval PA, SpO2 and NIRS were also recorded in the contralateral limb as control data.
62659632|NCT00564980|ACTIVE_COMPARATOR|1|Wafer Procedure
62659633|NCT00564980|ACTIVE_COMPARATOR|2|Ulnar shortening osteotomy
62659634|NCT06322303|PLACEBO_COMPARATOR|Placebo (CBD 0%)|Participants are required to vaporize a placebo at 0% CBD concentration
62659635|NCT06322303|EXPERIMENTAL|CBD 15%|Participants are required to vaporize CBD at a concentration of 15%.
62659636|NCT06322303|EXPERIMENTAL|CBD 30%|Participants are required to vaporize CBD at a concentration of 30%.
62659637|NCT01295411|OTHER|schizophrenia PATIENTS|
62095989|NCT00180687|SHAM_COMPARATOR|Control|No intraperitoneal therapeutics (No nebulised Bupivacaine)
62293387|NCT05634902|EXPERIMENTAL|Group 4: Post-CME with Patient Education|"Physicians in hospitals that have received the DIZZTINCT educational intervention.~Patients have receive the DIZZTINCT educational intervention"
62293388|NCT05634902|EXPERIMENTAL|Group 5: Post-CME with Standard Patient Care|"Physicians in hospitals that have received the DIZZTINCT educational intervention.~Patients have not receive the DIZZTINCT educational intervention"
62659638|NCT01913353|EXPERIMENTAL|Group 1|Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).
62659639|NCT01913353|ACTIVE_COMPARATOR|Group 2|A single vaccination of ACAM2000® will be administered at Day 0.
62659640|NCT03991143|EXPERIMENTAL|ATH3G10|Phosphorylcholine human monoclonal antibody (ATH3G10)
62095990|NCT00180687|PLACEBO_COMPARATOR|IP Aerosolized Normal Saline|Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
62095991|NCT00180687|EXPERIMENTAL|Nebulised Bupivacaine intraperitoneally|Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
62095992|NCT00180687|ACTIVE_COMPARATOR|Injected Bupivacaine intraperitoneally|Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
62095993|NCT00202397|PLACEBO_COMPARATOR|2|placebo bid for 8 weeks
62095994|NCT00202397|EXPERIMENTAL|1|Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks
62095995|NCT00079937|EXPERIMENTAL|Omalizumab|Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
62095996|NCT00079937|PLACEBO_COMPARATOR|Placebo|Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
62293389|NCT05634902|EXPERIMENTAL|Group 6: Post-CME with Chart Review Only|"Physicians in hospitals that have received the DIZZTINCT educational intervention.~Eligible patient will have their medical records abstracted to assess the main study outcome"
62293390|NCT03709992|ACTIVE_COMPARATOR|Trospium|Patients will receive 30 mg of Trospium chloride tablet twice daily
62293391|NCT03709992|ACTIVE_COMPARATOR|Tamsulosin|Patients will receive 0.4 mg of Tamsulosin tablet once daily
62659641|NCT03991143|PLACEBO_COMPARATOR|Placebo|Placebo to ATH3G10, 0.9% sodium chloride
62659642|NCT06518759|ACTIVE_COMPARATOR|Traditional chest techniques|the patients will receive traditional chest techniques only
62659643|NCT06518759|EXPERIMENTAL|Traditional chest techniques +Glossopharyngeal breathing exercise|the patients will receive traditional chest techniques and glossopharyngeal breathing exercise
62659644|NCT06518759|EXPERIMENTAL|Traditional chest techniques +diaphragmatic breathing exercise|the patients will receive traditional chest techniques and diaphragmatic breathing exercise
62659645|NCT03315364|EXPERIMENTAL|Liporaxel® (oral paclitaxel)|"* 28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.~* Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration."
61908743|NCT05613712||Patients|Patients followed by the rheumatology department of the CHU Grenoble Alpes, constituting the SCORIC group
62293392|NCT05148884|EXPERIMENTAL|NLX-112|Patients will self-administer NLX-112 2 times each day, once in the morning and once in the evening. Up-titration over 4 weeks, maximal dose of 2 mg/day during 2 weeks, down-titration over 2 weeks.
62293393|NCT05148884|PLACEBO_COMPARATOR|Placebo|Patients will self-administer placebo 2 times each day, once in the morning and once in the evening. Up-titration of number of tablets over 4 weeks, number of tablets equivalent to maximal dose of 2 mg/day NLX-112 during 2 weeks, down-titration over 2 weeks.
62308088|NCT04508309|ACTIVE_COMPARATOR|Gardasil® at 0 and 6 months|Two doses of Gardasil® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
62659646|NCT03315364|ACTIVE_COMPARATOR|Taxol® (IV paclitaxel)|"* 28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.~* Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL."
62659647|NCT02050100||Lung Cancer|Early-late stage primary lung cancer
62659648|NCT02050100||Lung Neoplasm|Benign non-calcified pulmonary nodules
62659649|NCT03990753||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and microbiome/peptidome examination.
62659650|NCT02392910|OTHER|Group A|Placebo
61908744|NCT05613712||Referring physician|Physicians identified as the referring physician for patients in the SCORIC group
61908745|NCT01650870|ACTIVE_COMPARATOR|Evening Only (full-dose)|The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
61908746|NCT01650870|EXPERIMENTAL|Split-dose|The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.
62659651|NCT02392910|OTHER|Group B|Iron Sucrose
62659652|NCT01289977||Phlebotomus group|Those in the Phlebotomus group will have exposure to P. duboscqui sand fly
62659653|NCT01289977||Lutzomyia group|Those placed in this group will receive exposure to L. longipalpis sand fly bites.
62659654|NCT01530919||Parathyroid surgery|Database of patients who have undergone minimally invasive radioguided parathyroidectomy
62659655|NCT02242344|EXPERIMENTAL|telmisartan - low dose|
62659656|NCT02242344|EXPERIMENTAL|telmisartan - high dose|
62659657|NCT02242344|PLACEBO_COMPARATOR|Placebo|
62659658|NCT03564262|EXPERIMENTAL|Cerebrovascular Reactivity|"Cerebrovascular reactivity (CVR) will be assessed using transcranial Doppler ultrasound with carbon dioxide as the vasoactive stimuli.~The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. The CVR test will be performed prior to soup consumption as well as after soup consumption."
62659659|NCT03564262|EXPERIMENTAL|Blood Pressure Reactivity|Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
62659660|NCT05104125|EXPERIMENTAL|Experimental group 1|ASC40 25mg for 12 weeks
61908747|NCT01306578|ACTIVE_COMPARATOR|IVIG group|20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
61908748|NCT01306578|ACTIVE_COMPARATOR|Plasma Exchange|21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
61908749|NCT05168501|EXPERIMENTAL|Lead-In|Multiple rebreathing procedures using methodology developed by Duffin (referred to as Duffin's rebreathing procedure) will be conducted under hyperoxic and hypoxic conditions over the course of a day to confirm feasibility and gather reproducibility data using the procedure.
61908750|NCT05403398|EXPERIMENTAL|BSCU1|B. subtilis CU1 at 2 billion CFUs daily for 4 weeks
61908751|NCT00523263|ACTIVE_COMPARATOR|Dacron|Patients receiving polyester above-knee femoro-popliteal bypass
61908752|NCT00523263|ACTIVE_COMPARATOR|HUV|patients receiving HUV femoro-popliteal bypass
61908753|NCT04175119|EXPERIMENTAL|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses.
61908754|NCT05763745|EXPERIMENTAL|Point of Care Ultrasound|
61908755|NCT01496937|EXPERIMENTAL|GLPG0974 oral solution|GLPG0974 oral solution
61908756|NCT01496937|PLACEBO_COMPARATOR|Placebo oral solution|Placebo oral solution
61908757|NCT02242422||transobturator tape|
61908758|NCT04328207|OTHER|No financial incentive|This group will receive standard of care eye health education alone and no financial incentive for completing a referral visit.
62095997|NCT04036799||Hypertrophic Cardiomyopathy|
62659661|NCT05104125|EXPERIMENTAL|Experimental group 2|ASC40 50mg for 12 weeks
62659662|NCT05104125|EXPERIMENTAL|Experimental group 3|ASC40 75mg for 12 weeks
62659663|NCT05104125|PLACEBO_COMPARATOR|Placebo group|Placebo for 12 weeks
62659664|NCT00738088|EXPERIMENTAL|1|Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c
61908759|NCT04328207|EXPERIMENTAL|Financial incentive|This group will receive a financial incentive once the referral visit is completed (if one was required) as well as eye health education.
62095998|NCT04925050|ACTIVE_COMPARATOR|Drug VB0004|Experimental, Single Ascending dose , Multiple Ascending dose in healthy subjects and naive patients with mild or moderate hypertension with low cardiovascular risk
62095999|NCT04925050|PLACEBO_COMPARATOR|Placebo|Matching Placebo for VB0004
62096000|NCT02987829|EXPERIMENTAL|Dose Level 1: TRC253 40 mg daily|40 mg of single-agent TRC253 to be administered as oral capsules once daily
62096001|NCT02987829|EXPERIMENTAL|Dose Level 2: TRC253 80 mg|80 mg of single-agent TRC253 to be administered as oral capsules once daily
62096002|NCT02987829|EXPERIMENTAL|Dose Level 3: TRC253 160 mg|160 mg of single-agent TRC253 to be administered as oral capsules once daily
62096003|NCT02987829|EXPERIMENTAL|Dose Level 4: TRC253 240 mg|240 mg of single-agent TRC253 to be administered as oral capsules once daily
62096004|NCT02987829|EXPERIMENTAL|Dose Level 5: TRC253 280 mg|280 mg of single-agent TRC253 to be administered as oral capsules once daily
62096005|NCT02987829|EXPERIMENTAL|Dose Level 6: TRC253 320 mg|320 mg of single-agent TRC253 to be administered as oral capsules once daily
62096006|NCT03812289|EXPERIMENTAL|Treatment (SBRT)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
62293394|NCT03135392|ACTIVE_COMPARATOR|Breast Reconstruction with Artificial Implant|Participants undergoing unilateral reconstruction: patient will serve as internal control with contralateral breast and reconstructed breast will be compared to all other reconstructed breasts. Participants undergoing bilateral reconstruction: reconstructed breasts will be compared to all other reconstructed breasts
62293395|NCT03135392|ACTIVE_COMPARATOR|Autologous Breast Reconstruction without Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which do not have their nerves reconstructed during surgery
62293396|NCT03135392|EXPERIMENTAL|Autologous Breast Reconstruction with Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which have a nerve connected (neurotized) during surgery.
62293397|NCT05408689|EXPERIMENTAL|T1 TENS|In this study, participants will be treated 30 min per day, 3 days per week, for 10 consecutive weeks
62293398|NCT05408689|EXPERIMENTAL|Concha TENS|In this study, participants will be treated 30 min per day, 3 days per week, for 10 consecutive weeks
62659665|NCT02806076|EXPERIMENTAL|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
62659666|NCT02806076|ACTIVE_COMPARATOR|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
61908760|NCT03387488|EXPERIMENTAL|Treatment|StingrayTM, Medtronic®
62659667|NCT00232882|ACTIVE_COMPARATOR|1|Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
62096007|NCT01438099||normal subjects|parturients admitted to the labor ward who request epidural analgesia with BMI \< 30
62096008|NCT01438099||obese subjects|parturients admitted to the labor ward who request epidural analgesia with BMI \> 30
62096009|NCT01495780|EXPERIMENTAL|Remote Health Monitoring|Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
62096010|NCT00919438||Dialysis|
62096011|NCT04217421|ACTIVE_COMPARATOR|Allopurinol|
62096012|NCT04217421|PLACEBO_COMPARATOR|Placebo|
62096013|NCT01518257|EXPERIMENTAL|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
62096014|NCT01518257|PLACEBO_COMPARATOR|Placebo|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
62096015|NCT00764868|EXPERIMENTAL|LDX|Lisdexamfetamine Dimesylate (LDX)
62096016|NCT01734811|PLACEBO_COMPARATOR|Placebo|The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
62096017|NCT01734811|EXPERIMENTAL|Biological vaccine|The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation
62096018|NCT05433948||Liver cirrhosis with normal cognition|Liver cirrhosis and performs normally in all psychometric tests. n=100
62293399|NCT05408689|PLACEBO_COMPARATOR|Control|In this study, participants will be treated 30 min per day, 3 days per week, for 10 consecutive weeks
62293400|NCT06158243||0-2|children aged 0 to 2 years
62293401|NCT06158243||2-4|children aged 2 to 4 years
61908761|NCT02337231|OTHER|GG genotype|Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
61908762|NCT02337231|OTHER|GT genotype|Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
61908763|NCT02337231|OTHER|TT genotype|Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
61908764|NCT01255748||Treatment with Radiation Therapy|Includes 16 different arms to capture patient data by disease site
61908765|NCT05299853|EXPERIMENTAL|Robotic Rehabilitation|
62293402|NCT06158243||4-6|children aged 4 to 6 years
62293403|NCT06158243||6-8|children aged 6 to 8 years
62293404|NCT06158243||8-10|children aged 8 to 10 years
61908766|NCT05299853|ACTIVE_COMPARATOR|Conventional Rehabilitation|
62659668|NCT00232882|ACTIVE_COMPARATOR|2|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
62659669|NCT00232882|ACTIVE_COMPARATOR|3|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
61908767|NCT02603263||Workplace Restaurant Customers|"1 Group (Workplace Restaurant Customers) across 3 sites (data to be combined at end of study)~Study consists of three phases:~1. Pre Intervention~2. Intervention~3. Post Intervention~All phases lasted two weeks and included monitoring till receipts for meals (these were automatically generated and held on the tills electronically). The intervention phase consisted of posters being displayed in the restaurants, featuring a Social Norms Poster."
61908768|NCT02843997|OTHER|Healthy volunteers|Members of a family
61908769|NCT01030081|EXPERIMENTAL|Amlodipine (Norvasc®)|
62096019|NCT05433948||Liver cirrhosis with minimal hepatic encephalopathy|Liver cirrhosis and performs abnormally en 2 or more psychometric test. n=100
62096020|NCT05433948||Liver cirrhosis and overt hepatic encephalopathy|West Haven grade 2 or more. n=50
62096021|NCT05433948||Healthy control persons|Completely healthy persons, age, and gender-matched to cirrhosis patients. n=100
62096022|NCT05433948||Sick control persons|Persons with other chronic diseases than liver disease. n=100
62096023|NCT05433948||Pre-cirrhotic liver disease|Not yet cirrhosis. Will primarily be NAFLD patients. n=100
62465736|NCT02076763||Acute intermittent porphyria|Patient diagnosed of AIP (by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation). The patient must have a severe AIP condition, with at least two hospitalizations during the previous year due to acute attacks (clinical manifestations of acute porphyria), or at least four hospitalizations during the previous year due to the requirement of hospital treatment administration (including day-hospital and home hospital program).
61908770|NCT01030081|ACTIVE_COMPARATOR|Nifedipine GITS (Adalat® XL 30)|
61908771|NCT00366093|EXPERIMENTAL|1|eszopiclone 3 mg
61908772|NCT00366093|PLACEBO_COMPARATOR|2|Placebo tablet
62096024|NCT03106376|EXPERIMENTAL|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
62096025|NCT02831400|EXPERIMENTAL|IFABP assessment (1 study group)|30 elderly volunteers
62096026|NCT02060097|ACTIVE_COMPARATOR|Cocoa flavanol beverage|flavanol 320mg/day
62096027|NCT02060097|PLACEBO_COMPARATOR|Placebo beverage|no flavanol
62659670|NCT02359708|EXPERIMENTAL|OR nurse group|OR nurses (14) who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. When surgery were completed and before disposal of gloves and gown the fourth culture were taken where the glove cuff meets the gown sleeve, under and above, the inner glove of all OR nurses.When gloves were removed cultures were taken again at three sites on the hand, approximately 2-3 hours.
62659671|NCT02359708|EXPERIMENTAL|Non-hospital group|Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
61908773|NCT01561898|EXPERIMENTAL|Paliperidone extended-release (JNS007ER)|
61908774|NCT05273502|EXPERIMENTAL|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the project, and participants will be assessed at baseline and end-of-study.
61908775|NCT05273502|NO_INTERVENTION|Control group|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
61908776|NCT02451371|EXPERIMENTAL|tDCS|Patients with schizophrenia to receive tDCS treatment
61908777|NCT00329849|EXPERIMENTAL|MenACWY-CRM|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)
62096028|NCT04436029|EXPERIMENTAL|Descartes 11|
62096029|NCT01258361||The study population|Patients will be recruited during anesthesia consultations carried out before programmed pelvic or visceral surgeries.
62096030|NCT00740519||A|
62096031|NCT02452229||Burn patients|The included patient are burn victims who sustained a burn of at least 1 % total body surface are (TBSA); with no restriction on age.
62096032|NCT06613802||2013-2014|Patients in 2013-2014. All fall patient charts will be included depending on the prevalence of gabapentionoid prescriptions. It is expected that the prevalence in 2013 is twice (6%) that of the background population (3%). Sample size calculations at 80% power and 5% significance based on differences in population between 2023 (estimated 20%, which is twice that of 2023 background population of 10%) shows that 90 participants are required. Thus it is expected to include the whole of 2013. However, if the prevalence is lower than expected, 2014 will also be included. The sample size required prevalences of 3% in 2013 and 10% in 2023 is 194, which would be met by expanding the sampling frame to encompass 2014.
62096033|NCT06613802||2018-2019|All patients in 2018 will be included. If it is necessary to also include 2014 as described above, then 2019 will also be included to ensure approximately equal group sizes.
61908778|NCT00329849|ACTIVE_COMPARATOR|MenACWY-PS|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)
61908779|NCT02224196|EXPERIMENTAL|manual ventilation|
61908780|NCT02224196|ACTIVE_COMPARATOR|pressure-controlled ventilation|
62096034|NCT06613802||2023|More patients were seen in 2023, with a total of 254 available. If only 2013 is included based on the prevalence as stated above, then every second patient from 2023 will be included. If 2014 is also included then all patient from 2023 will be included to ensure approximately equal group sizes.
62659672|NCT01422109|EXPERIMENTAL|Group A|
62659673|NCT01422109|ACTIVE_COMPARATOR|Group B|
62659674|NCT02060162||HIV/HBV co-infected|150-200 patients in Zambia and 250-300 across all sites
62659675|NCT02060162||HIV mono-infected|700-750 patients in Zambia and 1600-1700 across all sites
62659676|NCT02412943|EXPERIMENTAL|PAPP-A2 Enzyme Replacement|A 20 cc/kg transfusion of Fresh Frozen Plasma will be given over 3 hours on day 0.
62659677|NCT06510127||training cohort|Data of patients treated in the North Ward of Sun Yat-sen Memorial Hospital of Sun Yat-sen University from January 1, 2002 to August 31, 2023 were retrospectively collected for the training cohort
61908781|NCT04704362|ACTIVE_COMPARATOR|Training and Supervision as Usual|Non-specialists are trained in a psychological intervention under standard conditions. No feedback from competency-based evaluations is provided to modify the training or supervision curriculum.
61908782|NCT04704362|EXPERIMENTAL|Competency-based Training and Supervision|Non-specialists are trained and supervised in a competency-based approach in which trainers and/or supervisors are provided with the competency scores of trainees in order to modify the training and supervision content and approach as needed.
61908783|NCT00392145|ACTIVE_COMPARATOR|1|
61908784|NCT00392145|EXPERIMENTAL|2|
61908785|NCT02452931|EXPERIMENTAL|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
61908786|NCT05985460|EXPERIMENTAL|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
61908787|NCT05985460|PLACEBO_COMPARATOR|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
61908788|NCT01331252|EXPERIMENTAL|supine body position|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
61908789|NCT01331252|EXPERIMENTAL|semi-recumbent|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
61908790|NCT00907452|ACTIVE_COMPARATOR|melphalan-prednisone-thalidomide|
61908791|NCT00907452|ACTIVE_COMPARATOR|lenalidomide-dexamethasone|
61908792|NCT05330910|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
61908793|NCT05330910|EXPERIMENTAL|Laparoscopic sleeve gastrectomy with hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
61908794|NCT03853824|OTHER|Intervention arm|Patients randomised to increased postoperative surveillance.
61908795|NCT03853824|OTHER|Control arm|Patients randomised to usual postoperative care.
61908796|NCT04935645|EXPERIMENTAL|Experimental Group|The experimental group was informed about progressive muscle relaxation (PMR) before colonoscopy. PMR audio recordings were given to the patients. Abdominal pain and distention scores were determined after colonoscopy. PMR was applied to the patients for 30 minutes. These scores were determined again after exercise and at the 2nd, 4th, 8th, 12th, 16th, and 24th hours.
61908797|NCT04935645|NO_INTERVENTION|Control Group|VAS pain and VAS distension scores of the control group were determined after colonoscopy and 30 minutes later. VAS form was given to all patients to determine VAS abdominal pain and VAS distension scores at the 2nd, 4th, 8th, 12th, 16th and 24th hours after the procedure. The day after the colonoscopy, post test data were collected.
61908798|NCT04662970|EXPERIMENTAL|Device programming|according to different settings from the SyncAV algorithm
62096035|NCT01456663|EXPERIMENTAL|AFQ056|
62293405|NCT05212025|EXPERIMENTAL|Adavosertib and Gemcitabine|"Participants will receive:~* Adavosertib 1x per day on days 2, 3, 9, 10, 16, and 17 of every 28 day study cycle.~* Gemcitabineon on days 1,8, and 15 of every 28-day cycle"
62293406|NCT05664620|NO_INTERVENTION|Low risk|Standard of care to treat post-concussion symptoms in the community
62659678|NCT06510127||internal validation cohort|Data of patients treated in the South Ward of Sun Yat-sen Memorial Hospital of Sun Yat-sen University from January 1, 2002 to August 31, 2023 were retrospectively collected for the internal validation cohort
62659679|NCT06510127||external validation cohort|Data on patients treated at external centers between January 1, 2002 and August 31, 2023 were retrospectively collected for the external validation cohort
62659680|NCT06510127||test cohort|Data on patients admitted to Sun Yat-sen Memorial Hospital of Sun Yat-sen University after January 1, 2024 were prospectively collected for the test cohort
62659681|NCT01685554|ACTIVE_COMPARATOR|normothermic CPB|cardiopulmonary bypass with maintenance of normal body temperature
62659682|NCT01685554|ACTIVE_COMPARATOR|hypothermic CPB|cardiopulmonary bypass using mild hypothermia
62096036|NCT02458846|EXPERIMENTAL|Screened Schools|25 schools. Screening involved: crowded HOTV acuity test, Preschool Randot Stereoacuity Test, and Plusoptix autorefractor. Referral criteria followed AAPOS guidelines for screening for amblyopia and amblyopia risk factors. Children who fail any one of the three tests (including uncooperative/unable children) will be given a referral letter, which includes an assigned appointment time for a comprehensive eye exam at school with a licensed optometrist. Any needed glasses will be dispensed at no cost to the parents. 6 months after the eye exam, we will follow up with a phone call to parents to offer any additional support (such as replacing broken/lost glasses)
62096037|NCT02458846|NO_INTERVENTION|Care As Usual Schools|"25 schools were randomly allocated to the care as usual schools. No intervention was provided by the research team, however, children may have received optometry/ophthalmology care via regular referral channels (e.g., family physicians, teachers)"
62096038|NCT06474806|EXPERIMENTAL|100 MBq 64Cu-DOTA-AE105|For Part 1 of the trial, 9 patients will receive 100 MBq 64Cu-DOTA-AE105 Day 1 and Day 8
62096039|NCT06474806|EXPERIMENTAL|150 MBq 64Cu-DOTA-AE105|For Part 1 of the trial, 9 patients will receive 150 MBq 64Cu-DOTA-AE105 Day 1 and Day 8
62096040|NCT06474806|EXPERIMENTAL|200 MBq 64Cu-DOTA-AE105|"For Part 1 of the trial, 9 patients will receive 200 MBq 64Cu-DOTA-AE105 Day 1 and Day 8.~For Part 2 of the trial, additional 141 patients will receive 200 Mbq 64Cu-DOTA-AE105"
62096041|NCT02889042|EXPERIMENTAL|Volunteers repeated drug poisoning|performing MRI and a biological assessment
62465737|NCT03247920|ACTIVE_COMPARATOR|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
62096042|NCT02889042|OTHER|Volunteers single drug poisoning|performing MRI and a biological assessment
62096043|NCT02889042|OTHER|alcoholic|performing MRI and a biological assessment
62293407|NCT05664620|NO_INTERVENTION|Medium risk|Patients who are assigned to the medium risk group will receive the same treatment as the low risk group for one month, after which they will be reassessed. If improving they will go into the low risk group, and if not improving they will go into the high risk group
62096044|NCT02889042|OTHER|volunteers|performing MRI and a biological assessment
62096045|NCT04392258||Status post resuscitation|Patients or dataset that underwent resuscitation
62096046|NCT02181699|EXPERIMENTAL|KHK2823|single agent KHK2823 administered at selected dose levels
62096047|NCT03882463|EXPERIMENTAL|insulin pump function|continuous glucose monitoring and then continuous glucose monitoring with the stop insulin pump function
62096048|NCT00599677|EXPERIMENTAL|group 1|specific acupoints of Stomach meridians
62096049|NCT00599677|EXPERIMENTAL|group 2|Non-specific acupoints of Stomach meridians
62293408|NCT05664620|OTHER|High risk|"A multidisciplinary individualized treatment (personalized medicine) model of treating all post-concussion symptoms simultaneously including the following:~Headache therapy, balance therapy, vestibular therapy, exercise therapy\* mental health support e.g. CBT and/or mindfulness meditation\* (with more specialized diagnosis and care where required), cognitive assessment and therapy, vision therapy, sleep assessment and therapy, physiotherapy, education sessions\*, occupational therapy These patients will be treated through the Altum Health Neurology Specialty Program~\*Offered to all high risk patients"
62293409|NCT02440750|EXPERIMENTAL|Dienogest|Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
62465738|NCT03247920|ACTIVE_COMPARATOR|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
62465739|NCT04068441||Regular treatment|no intervention
62465740|NCT04068441||Treatment interruption|no intervention
62659683|NCT02474368|EXPERIMENTAL|Cohort 1|"* Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~* Cohort 1 (patients who have received prior radiation in the head and neck with gross unresectable disease)~  * Intensity Modulated Radiation Therapy (IMRT) : daily for 6 weeks~ * Cisplatin will be administered intravenously on predetermined days~ * Stereotactic Body Radiotherapy (SBRT)"
62096050|NCT00599677|EXPERIMENTAL|group 3|alarm and transport points
62096051|NCT00599677|EXPERIMENTAL|group 4|acupoints of the other meridian
62096052|NCT00599677|SHAM_COMPARATOR|group 5|non-acupoints
62096053|NCT00599677|ACTIVE_COMPARATOR|group 6|Itopride
62096054|NCT02373813|EXPERIMENTAL|Open Label Run-In: Etanercept plus Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
62096055|NCT02373813|EXPERIMENTAL|Double-Blind Treatment: Methotrexate Monotherapy|"Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
62293410|NCT02440750|EXPERIMENTAL|Ulipristal acetate|Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
62293411|NCT01812902|EXPERIMENTAL|Extended LND|Radical Prostatectomy with extended lymphadenectomy
62293412|NCT01812902|ACTIVE_COMPARATOR|Limited LND|Radical Prostatectomy with Limited lymphadenectomy
62293413|NCT06400992|EXPERIMENTAL|Bilaterally implanted patients|patient with two cochlear implant in each ear
62293414|NCT06400992|EXPERIMENTAL|Bimodal patients|patient with cochlear implant in one ear and fitted with hearing aid audio in the other ear
62293415|NCT04417257|EXPERIMENTAL|LAU-7b|Active drug as LAU-7b capsules
62293416|NCT04417257|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
62293417|NCT00564993|ACTIVE_COMPARATOR|A|"necessary re-intervention (pulmonary valve replacement) after repair of Fallot:~2 Visits with cardiac imaging under rest and stress (Dobutamin) before and after pulmonary valve replacement"
62096056|NCT02373813|EXPERIMENTAL|Double-Blind Treatment: Etanercept Monotherapy|"Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
62293418|NCT00564993|ACTIVE_COMPARATOR|B|"comparison group: with a good result of repair of tetralogy of fallot and good ventricular function:~1 Visit with cardiac imaging under rest and stress (Dobutamin)"
62293419|NCT03339895|EXPERIMENTAL|pvı-guided|pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery
62293420|NCT03339895|EXPERIMENTAL|traditional-guided|4-8 ml/kg/h infusion during surgery
62293421|NCT00341328|EXPERIMENTAL|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
62293422|NCT00341328|PLACEBO_COMPARATOR|2|In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
62293423|NCT04826900|EXPERIMENTAL|Robotic Group|Training session included 45 minutes Robotic Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
62293424|NCT04826900|EXPERIMENTAL|Robotic Mirror Group|Training session included 45 minutes Robotic Mirror Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
62293425|NCT00981994|EXPERIMENTAL|Electronic Decision Support|Use of electronic decision support to provide the treatment algorithm for providers managing patients with acute respiratory infections.
62465741|NCT04355468|ACTIVE_COMPARATOR|Control group|General anesthesia was induced with midazolam 0.1 mg∙kg-1, propofol 2 mg∙kg-1, and cisatracurium 0.15 mg∙kg-1. The patients were intubated with a left-sided double-lumen tube in adequate size and positioned laterally. Anesthesia was maintained with 1 minimum alveolar concentration (MAC) sevoflurane. The patients awoke from anesthesia in a post-anesthesia care unit, and were extubated after the administration of adequate doses of atropine and neostigmine as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
62465742|NCT04355468|EXPERIMENTAL|Opioid Free Aneasthesia group|General anesthesia was induced with midazolam 0.1 mg∙kg-1, propofol 2 mg∙kg-1, and cisatracurium 0.15 mg∙kg-1. The patients were intubated with a left-sided double-lumen tube in adequate size and positioned laterally. Anesthesia was maintained with 1 minimum alveolar concentration (MAC) sevoflurane. The patients awoke from anesthesia in a post-anesthesia care unit, and were extubated after the administration of adequate doses of atropine and neostigmine as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
62465743|NCT01457053|ACTIVE_COMPARATOR|Ultrafiltration|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
62465744|NCT01457053|ACTIVE_COMPARATOR|Diuretic Therapy|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.
62465745|NCT01822847||catheterization|patients undergoing elective heart catheterization
62465746|NCT04969757|EXPERIMENTAL|Predigraft|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
62465747|NCT04091256|EXPERIMENTAL|Clinical trials with a single arm|: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
62465748|NCT04058288||Stroke|People suffering from upper-limb motor dysfunction due to stroke
62465749|NCT03668704||Medial Bicompartmental Knee Arthroplasty|Patient who have received a robotic-arm assisted medial and patellofemoral knee arthroplasty.
62465750|NCT00803491|EXPERIMENTAL|Problem based learning program|PBL intervention - a self-promoting PBL program for patients with rheumatic diseases.
62465751|NCT00803491|ACTIVE_COMPARATOR|Control group|Traditional rheumatological care.
62096057|NCT02373813|EXPERIMENTAL|Double-Blind Treatment: Etanercept plus Methotrexate|"Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment)."
62096058|NCT00964717|ACTIVE_COMPARATOR|Chiropractic|Real Chiropractic treatment
62096059|NCT00964717|SHAM_COMPARATOR|Sham Chiropractic|stimulation utilizing 'activator' thumper
62096060|NCT00964717|NO_INTERVENTION|No treatment|No add on therapy - patients lay down for a period of 15 minutes without any treatment or intervention
62293426|NCT00981994|EXPERIMENTAL|Paper Decision Support|Use of paper based tools to provide the treatment algorithm for providers managing patients with acute respiratory infections.
62293427|NCT00981994|NO_INTERVENTION|Usual Care|Usual Care
62293428|NCT01238120|ACTIVE_COMPARATOR|Placebo and Home-Based Exercise|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
62096061|NCT04333836|EXPERIMENTAL|Aligners group|Receiving full set of aligners ( Clear Removable Orthodontic appliance) until complete canine retraction
62096062|NCT04333836|ACTIVE_COMPARATOR|Conventional Brackets group|leveling and alignment of lower followed by complete canine retraction
62096063|NCT01687192|EXPERIMENTAL|Girls and young womens receiving immunosuppressive treatment|
62096064|NCT01369355|PLACEBO_COMPARATOR|001|Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
62096065|NCT01369355|EXPERIMENTAL|002|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
62096066|NCT01369355|EXPERIMENTAL|003|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
62096067|NCT01369355|EXPERIMENTAL|004|Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
62096068|NCT01369355|EXPERIMENTAL|005|Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
62465752|NCT04067180|EXPERIMENTAL|Haplo SCT|Allogeneic stem cell transplantation with a haplo-identical family donor graft.
62465753|NCT04067180|ACTIVE_COMPARATOR|URD SCT|Allogeneic stem cell transplantation with a matched unrelated donor graft.
62465754|NCT00233194||Cohort 2|Children scheduled for adenotonsillectomy and healthy subjects, for comparison, not scheduled for such surgery.
62465755|NCT03257722|EXPERIMENTAL|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
62465756|NCT03257722|EXPERIMENTAL|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
62465757|NCT02822820|ACTIVE_COMPARATOR|Advanced bipolar (Ligasure-Covidien)|Devices with advanced bipolar energy (Ligasure-Covidien) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
62465758|NCT02822820|ACTIVE_COMPARATOR|Conventional bipolar (RoBi forceps-Karl Storz)|Devices with conventional bipolar energy (RoBi rotating bipolar forceps-Karl Storz) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
62465759|NCT01838720|EXPERIMENTAL|zero ischemia laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
62465760|NCT01838720|ACTIVE_COMPARATOR|conventional laparoscopic partial nephrectomy|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
62465761|NCT02152332|EXPERIMENTAL|Treatment Sequence Group ADBC|Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
62465762|NCT02152332|EXPERIMENTAL|Treatment Sequence Group BACD|Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen).
62659684|NCT02474368|EXPERIMENTAL|Cohort 2|"* Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~* Cohort 2 (patients with metastatic solid tumors of any histology who have targetable lesions within the head and neck) -- Stereotactic Body Radiotherapy (SBRT)"
62096069|NCT01369355|PLACEBO_COMPARATOR|006|Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.
62096070|NCT01904357|ACTIVE_COMPARATOR|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and \< 50 kg will receive the 1g dose.
62096071|NCT01904357|ACTIVE_COMPARATOR|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
62293429|NCT01238120|ACTIVE_COMPARATOR|Ibuprofen 200mg BID, Home-Based Exercise|200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
62293430|NCT01238120|PLACEBO_COMPARATOR|Placebo|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
62096072|NCT06180798|ACTIVE_COMPARATOR|cold snare endoscopic mucosal resection (C-EMR)|All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
62096073|NCT06180798|SHAM_COMPARATOR|Hot snare endoscopic mucosal resection (H-EMR)|All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
62096074|NCT01101165|EXPERIMENTAL|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
62096075|NCT01101165|ACTIVE_COMPARATOR|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
62096076|NCT00518752|ACTIVE_COMPARATOR|A|Standard Oral Care
62096077|NCT00518752|EXPERIMENTAL|B|Comprehensive Oral Care
62096078|NCT05930756|ACTIVE_COMPARATOR|Three-target GNRFA technique (T1)|Radiofrequency ablation will target three of the genicular nerves: the superolateral genicular nerve, the superomedial genicular nerve, and the inferomedial genicular nerve.
62096079|NCT05930756|ACTIVE_COMPARATOR|Six-target GNRFA technique (T2)|Radiofrequency ablation will target six of the genicular nerves: the superolateral genicular nerve, the superomedial genicular nerve, the inferomedial genicular nerve, two branches from the nerve of vastus intermedius, and the recurrent fibular nerve
62096080|NCT01121874|ACTIVE_COMPARATOR|LRTI|These patients will undergo ligament reconstruction with tendon interposition (LRTI) surgery. They will serve as a control group, against which to compare the investigational surgical technique.
62659685|NCT01176175|EXPERIMENTAL|50 mg|Progesterone microspheres injectable suspension 50 mg
62659686|NCT01176175|EXPERIMENTAL|100 mg|Progesterone microspheres injectable suspension 100 mg
62096081|NCT01121874|EXPERIMENTAL|Suture fixation system|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system.
62096082|NCT01121874|EXPERIMENTAL|Suture fixation system + 2 week immobilization|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system, and with a decreased immobilization time from 6 to 2 weeks post-surgery.
62096083|NCT06233630|PLACEBO_COMPARATOR|Placebo|Only spinal anaesthesia - No peripheral nerve block
62096084|NCT06233630|ACTIVE_COMPARATOR|Erector Spinae Plane Block|spinal anaesthesia and unilateral ultrasound guided erector spinae plane block - 20ml 0.2% ropivacaine
62096085|NCT06233630|ACTIVE_COMPARATOR|Infiltration Popliteal Artery and Capsule of the Knee and Adductor Canal Block|"spinal anaesthesia and ultrasound guided Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee (iPACK) block - 20ml 0.2% ropivacaine~+ ultrasound guided Adductor Canal Block - 10ml 0.2% ropivacaine"
62096086|NCT06232161|EXPERIMENTAL|red-light therapy group|The red-light therapy group would be treated with red-light therapy twice daily including the single focus spectacles during the follow-up.
62096087|NCT06232161|OTHER|control group|The control group including both the stopping red-light therapy group from the first 12 months (who obtained red-light therapy but stopped during the second 12-month follow-up) and those never use red-light therapy.
62096088|NCT05064761|EXPERIMENTAL|Treatment group|PLLA new dilution for treatment to improve appearance of cellulite.
62096089|NCT01903382||Adult patients|All patients undergoing general anesthesia between January 2006 and December 2013
62096090|NCT03089619|ACTIVE_COMPARATOR|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
62096091|NCT03089619|ACTIVE_COMPARATOR|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
62659687|NCT01176175|EXPERIMENTAL|200 mg|Progesterone microspheres injectable suspension 200 mg
62659688|NCT01176175|EXPERIMENTAL|300 mg|Progesterone microspheres injectable suspension 300 mg
62659689|NCT00435942|EXPERIMENTAL|1|Endovascular Treatment arm to be implanted with Relay device
62659690|NCT00435942|ACTIVE_COMPARATOR|2|Surgical Control, underwent open repair
62659691|NCT00102973|EXPERIMENTAL|TLK286 in Combination with Carboplatin|
62659692|NCT00102973|ACTIVE_COMPARATOR|Doxorubisin HCl Liposome Injection|
62659693|NCT02242630|ACTIVE_COMPARATOR|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
61908799|NCT02154828||Integrative practices|"Children included in this project are children 3 to 6 years with diagnosis F84.0 F84.1 according to CIM-10.~these children must be supported in care units that meet the criteria defined integrative practices."
62293431|NCT01238120|ACTIVE_COMPARATOR|Ibuprofen 200 mg BID|200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
61908800|NCT06146270||Cohort A|A cohort in which the incidence of the primary outcomes in the study population will be assessed.
62096092|NCT05661526|EXPERIMENTAL|Bloodpoly board game|Students in the Bloodpoly board game group; In the designated classroom and common time frame and under the supervision of researchers, they will be provided with an average of 50 minutes of board games per day for three days. For this, four groups of five students will be formed and students will be randomly assigned to these groups. Students will then be asked to move on to the four areas where the board game takes place. Four groups will start playing Bloodpoly simultaneously. The game will continue until all questions are finished.
62096093|NCT05661526|ACTIVE_COMPARATOR|Text-to-speech group|Students in the text-to-speech group; 50 minutes of reading time will be organized per day for three days in the designated classroom and common time and under the supervision of the researchers During the reading time, the content of the topic related to blood transfusion described by the researchers will be given to the students and they will be provided with reading. At the end of the period, the documents given will be taken back by the researchers.
62293432|NCT02351362|EXPERIMENTAL|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
61908801|NCT06146270||Cohort B|A cohort in which risk factors for primary outcomes will be identified, and a risk calculator for their development will be developed and validated
61908802|NCT01027806|ACTIVE_COMPARATOR|Montelukast|
62293433|NCT02351362|NO_INTERVENTION|Control Group|Standard of care
62293434|NCT03124459|EXPERIMENTAL|Part 1 Cohort 1|ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
62293435|NCT03124459|EXPERIMENTAL|Part 1 Cohort 2|ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
62293436|NCT03124459|EXPERIMENTAL|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
62293437|NCT03124459|EXPERIMENTAL|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
62293438|NCT03124459|EXPERIMENTAL|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
62659694|NCT02242630|ACTIVE_COMPARATOR|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
61908803|NCT01027806|PLACEBO_COMPARATOR|Placebo|
61908804|NCT01357850|EXPERIMENTAL|GSK716155 (3.75mg)|GSK716155 (3.75mg)
61908805|NCT01357850|EXPERIMENTAL|GSK716155 (15mg)|GSK716155 (15mg)
61908806|NCT01357850|EXPERIMENTAL|GSK716155 (30mg)|GSK716155 (30mg)
61908807|NCT01357850|PLACEBO_COMPARATOR|GSK716155-matched placebo|GSK716155-matcued placebo
61908808|NCT02191215||Nevirapine (Viramune®)|
62659695|NCT02242630|ACTIVE_COMPARATOR|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
62659696|NCT02242630|ACTIVE_COMPARATOR|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
62659697|NCT05220735|EXPERIMENTAL|Experimental|Participants will receive three fish oil capsules daily for 14 weeks, and fractional iron absorption from test meals provided without and with ascorbic acid will be determined at baseline and endpoint.
62096094|NCT06087068|EXPERIMENTAL|test group|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
62659698|NCT00000142|EXPERIMENTAL|treatment deferral|"IV (in the vein) treatment deferred until retinitis progressed, either:~5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks, or~5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
62659699|NCT00000142|EXPERIMENTAL|Cidofovir (low dose)|5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks
62659700|NCT00000142|EXPERIMENTAL|Cidofovir (high dose)|5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
62096095|NCT02998489|EXPERIMENTAL|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
62096096|NCT02998489|ACTIVE_COMPARATOR|Traditional milk advancement|20 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
62096097|NCT03746275||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Europe, Asia, Latin America and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid to prevent atherothrombotic events
62096098|NCT05526508|EXPERIMENTAL|Rebound once-weekly|This group will undergo 12 weeks of rebound exercise training once weekly, for 30 minutes per session.
62096099|NCT05526508|EXPERIMENTAL|Rebound twice-weekly|This group will undergo 12 weeks of rebound exercise training twice weekly, for 30 minutes per session.
62096100|NCT02409160|EXPERIMENTAL|Bariatric Surgery|Standard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
62096101|NCT02409160|NO_INTERVENTION|Control Group|
62096102|NCT04934462|OTHER|non-surgical treatment|All participants will undergo 6 months of non-surgical treatment.
62293439|NCT05756192|EXPERIMENTAL|Video and physician counseling arm|This groups will complete a pre survey and will then watch the 10-minute educational video on cervical cancer screening and prevention prior to seeing their provider. Patients will then see the provider and will complete a post survey following appointment.
62659701|NCT02749734|EXPERIMENTAL|hESC-RPE|Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums
62096103|NCT04934462|OTHER|arthroscopic treatment|Those participants with failed non-surgical treatment at 6 months will undergo arthroscopic treatment.
62096104|NCT04602364||Miga-Fab patients|Miga-Fab is a French prospective, observational cohort study of patients with Fabry disease treated with migalastat
62096105|NCT01313598|EXPERIMENTAL|GLPG0187|GLPG0187 for infusion
62096106|NCT03207425|EXPERIMENTAL|Mild hepatic impairment group|
62096107|NCT03207425|EXPERIMENTAL|Moderate hepatic impairment group|
62096108|NCT03207425|EXPERIMENTAL|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
62096109|NCT02794116|ACTIVE_COMPARATOR|Control group: Sound teeth|"20 first permanent molars sound, that not affected by MIH will be included.~The teeth were treated with conventional sealants to prevent caries lesion"
62096110|NCT02794116|EXPERIMENTAL|Test: Hypomineralized teeth|"20 first permanent molars affected by MIH will be included.~The MIH teeth were treated with a resin sealants."
62096111|NCT00340340||Cases|Newly diagnosed lung cancer cases
62096112|NCT00340340||Controls|Population-based controls
62096113|NCT03848481|EXPERIMENTAL|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
62096114|NCT03848481|PLACEBO_COMPARATOR|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
62096115|NCT00248287|ACTIVE_COMPARATOR|Arm 1|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle (Arm 1, ICb)
62096116|NCT00248287|EXPERIMENTAL|Arm 2|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 Week 1 and then 250 mg/m2 weekly thereafter, (Arm 2, ICb+Erbitux)
62659702|NCT01717508|OTHER|Cognitive Behavioral Therapy|12 weekly sessions of cognitive behavioral therapy
62659703|NCT01717508|NO_INTERVENTION|Healthy Controls|
62659704|NCT04278313|EXPERIMENTAL|PRP group|Platelet RICH Plasma prepared using RegenLab FDA approved device.
62096117|NCT00814853||Extubation readiness testing|Patients who pass the ERT.
62096118|NCT06698146|EXPERIMENTAL|RAPID- Deceased Donor Transplant|RAPID-Deceased Donor Transplant
62096119|NCT06698146|EXPERIMENTAL|RAPID Living Donor Liver Transplant|RAPID Living Donor Liver Transplant
62659705|NCT04278313|PLACEBO_COMPARATOR|PPP group|Platelet POOR Plasma prepared using RegenLab FDA approved device.
62659706|NCT04214782|NO_INTERVENTION|Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images without the help of Artificial Intelligence (AI) algorithm
62659707|NCT04214782|EXPERIMENTAL|AI enabled Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images with the help of Artificial Intelligence algorithm
62659708|NCT00566033|EXPERIMENTAL|1|
62659709|NCT00566033|NO_INTERVENTION|2|Patients in this arm (arm 2) will undergo to standard care.
62659710|NCT00479232|EXPERIMENTAL|Cohort 1: Vorinostat (sequential)|"Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.~Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
62659711|NCT00479232|EXPERIMENTAL|Cohort 2: Vorinostat (concurrent)|"Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.~Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
62293440|NCT05756192|NO_INTERVENTION|Physician counseling arm|This group will complete a pre survey and will then see their provider. Following provider visit patients will complete a post survey.
61908809|NCT01325662||Continuous drip sampling|Sampling at \~0.6 cc / hour (\~1.2 cc / 2 hours, or lowest feasible rate given technical requirements and volume requirements for core analytes assays)
61908810|NCT01325662||Intermittent sampling|Sampling at 4 cc every 2 hours (+ 2 cc dead space clearance, total = 6 cc / 2 hours)
62293441|NCT06033729|EXPERIMENTAL|"Group 1 REMIFENTANIL TCI (Experimental Group)"|the patients performed the EBUS-TBNA procedure under conscious sedation with infusion of Remifentanil TCI with a target between 3 and 6 ng/ml;
62293442|NCT06033729|ACTIVE_COMPARATOR|"Group 2 STANDARD (Control Group)"|the patients performed the EBUS-TBNA procedure in conscious sedation with the association of midazolam and/or fentanyl and/or propofol in refracted boluses based on clinical needs (agitation, unsatisfactory level of sedation or not collaborative patient) and according to the anesthesiologist's clinical judgement.
62293443|NCT05623566|EXPERIMENTAL|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
62293444|NCT03987750|EXPERIMENTAL|Safinamide 100mg|Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide
62293445|NCT03987750|EXPERIMENTAL|Safinamide 150mg|Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study
62293446|NCT03987750|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)
62293447|NCT05335889||Type 2 Diabetes group|Participants with Type 2 Diabetes will wear eButton and Continuous Glucose Monitoring (CGM) for 2 weeks and complete food diaries to record carb grams.
62659712|NCT05709080|EXPERIMENTAL|family-professional collaboration practice model|"Physical therapists in the family-professional collaboration practice model group will receive instructions in the collaborative intervention, following the process and the strategies of the family-professional collaboration practice model to enhance the collaboration during physical therapy sessions.~The instruction conducted online in two sessions for six hours (3 hours per session).~the therapists in this group will treat the children according to steps of family-professional collaboration practice model: Step 1: Mutually agreed-upon goals, Step 2: shared planning, Step 3:Shared implementation, and Step 4: Shared evaluation of child and family outcomes."
62659713|NCT05709080|NO_INTERVENTION|conventional therapy|"Physical therapists in the conventional therapy group will not receive any instructions related to the collaborative intervention process.~the therapists in this group will treat the children as conventional therapy"
62659714|NCT02814019|EXPERIMENTAL|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
62659715|NCT02814019|PLACEBO_COMPARATOR|placebo|matching placebo tablets
62659716|NCT01644929|EXPERIMENTAL|1 tDCS-Sham|tDC stimulation for 3 weeks, then cross-over to sham stimulation
62659717|NCT01644929|EXPERIMENTAL|2 Sham-tDCS|Sham stimulation for 3 weeks, then cross over to tDCS stimulation
62659718|NCT01644929|SHAM_COMPARATOR|3 Sham-Sham|Treatment for 6 weeks daily with sham stimulation
61908811|NCT04621383|EXPERIMENTAL|whey protein plus collagen group|Participants received a dose of 30 grams of whey protein plus 20 grams of collagen seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
62659719|NCT01529268|ACTIVE_COMPARATOR|DR cysteamine bitartrate capsule|Active DR cysteamine bitartrate capsule
62659720|NCT01529268|PLACEBO_COMPARATOR|DR cysteamine bitartrate placebo|Placebo DR cysteamine bitartrate capsule
62096120|NCT06698146|NO_INTERVENTION|Standard of Care/Conventional Living Donor Liver Transplant|Standard of Care/Conventional Living Donor Liver Transplant
62293448|NCT06124079|PLACEBO_COMPARATOR|standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
62096121|NCT06698146|NO_INTERVENTION|Standard of Care/Conventional Deceased Donor Whole Liver Transplant|Standard of Care/Conventional Deceased Donor Whole Liver Transplant
62096122|NCT06615492|EXPERIMENTAL|Routine ECMO|Routine ECMO during lung tansplant
62096123|NCT06615492|ACTIVE_COMPARATOR|On-demand ECMO|Selective, indication-based intraoperative cardiopulmonary support.
62096124|NCT04558086|EXPERIMENTAL|Reduce pain and fear|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
62096125|NCT04558086|EXPERIMENTAL|control group|To develop the intervention strategies of hospitalized school-age children with IV placement, using photo book to further examine the effectiveness of reducing IV pain and fear.
61908812|NCT04621383|PLACEBO_COMPARATOR|whey protein plus maltodextrin group|Participants received a dose of 30 grams of whey protein plus 20 grams of maltodextrin seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
61908813|NCT05895526|EXPERIMENTAL|5% Sodium Fluoride Varnish|71 patients will be in 5% Sodium Fluoride Varnish
61908814|NCT05895526|EXPERIMENTAL|Self Etch Dentin Adhesive|71 patients will be in Self Etch Dentin Adhesive
61908815|NCT03648866||Physicians|interview physicians who have conducted compassion rounds
62096126|NCT03672760|ACTIVE_COMPARATOR|IMT PowerBreath|"Participants will have PowerBreath device for IMT adjusted for 30% of maximal inspiratory pressure and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will provide re-adjustment of load through maximal inspiratory pressure performance"
62659721|NCT02706496||young adults (20-35yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
61908816|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
61908817|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
62096127|NCT03672760|PLACEBO_COMPARATOR|IMT PowerBreath Placebo|"Participants will have PowerBreath device for IMT with no load and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will not re-adjustment the load though maximal inspiratory pressure performance will be performed"
62096128|NCT03672760|ACTIVE_COMPARATOR|CardioBreathApp|CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 10 minutes for five weeks An once a week meeting will provide re-adjustment of respiratory rate to perform exercises
62096129|NCT01878890|EXPERIMENTAL|Efavirenz: 600 mg|Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.
62293449|NCT06124079|EXPERIMENTAL|Interactive messaging service|Participants will be randomized to one of 3 specific versions of OPY.
62293450|NCT01479608|EXPERIMENTAL|A: Transplantation or resection (randomized)|Liver transplantation or liver resection by 1:1 randomization (open label)
62293451|NCT01479608|EXPERIMENTAL|B: Liver transplantation|For non-resectable patients metachronous disease.
62293452|NCT01479608|EXPERIMENTAL|C:Liver transplantation|For non-resectable patients synchronous disease.
62293453|NCT01479608|EXPERIMENTAL|D:Liver transplantation|For non-resectable patients synchronous disease.
62096130|NCT01878890|EXPERIMENTAL|Efavirenz: 1200 mg|Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.
62096131|NCT01878890|EXPERIMENTAL|Efavirenz: 1800 mg|Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.
62096132|NCT01878890|EXPERIMENTAL|Efavirenz: 2200 mg|Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.
62293454|NCT00302393|ACTIVE_COMPARATOR|IR-MPH|Immediate Release Methylphenidate administered before PET Scan
62293455|NCT00302393|ACTIVE_COMPARATOR|Concerta|OROS Methylphenidate (Concerta) administered before PET Scan
62096133|NCT05397808|EXPERIMENTAL|pilates group|Pilates training will be held for eight weeks, two days a week for 1 hour. The investigators divided the individuals in the pilates exercise group into groups of 12 or 13 to verify whether they did the exercises correctly. A program including 15 minutes of warm-up, 30 minutes of Pilates exercises, and 15 minutes of cooling and stretching exercises was arranged for the pilates group. The activities were performed in ten repetitions. The exercise program recommended by the Australian Pilates and Physiotherapy Institute during postpartum will be used in the training.
62293456|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
62293457|NCT02770807|EXPERIMENTAL|EryDex Low Dose DSP|"EDS-EP dose range of \~5-10 mg DSP/infusion. This study treatment was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment).~Other Names:~EryDex System end product Low dose DSP"
62293458|NCT02770807|EXPERIMENTAL|EryDex High Dose DSP|"EDS-EP dose range of \~14-22 mg DSP/infusion. This study treatment was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period). Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment).~Other Names:~EryDex System end product High dose DSP"
62293459|NCT02770807|PLACEBO_COMPARATOR|Placebo|"Patients were treated with autologous erythrocytes prepared with the EDS process using a placebo solution. Placebo was to be administered by IV infusion once per month for 12 consecutive months (6 months Initial Treatment Period + 6 months Extension Treatment Period).~Each patient underwent a 30-day Screening Period, during which any previous treatments with other corticosteroid compounds were withdrawn (washout from previous treatment)."
62308089|NCT04508309|OTHER|Gardasil® at 0 and Cecolin® at 24 months|One dose of Gardasil® at 0 months and one dose of Cecolin® at 24 months with blood draw at baseline, prior to second dose and one-month post second dose.
62465763|NCT02152332|EXPERIMENTAL|Treatment Sequence Group CBDA|Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
62465764|NCT02152332|EXPERIMENTAL|Treatment Sequence Group DCAB|Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen).
62465765|NCT05776303|EXPERIMENTAL|Good Bowls + App Nudges, followed by Good Bowls alone|Participants in this arm will be exposed to Good Bowls + App Nudges throughout the first four months followed by four months of Good Bowls alone.
62659722|NCT02706496||middle age(45-60yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
62096134|NCT05397808|ACTIVE_COMPARATOR|control group|The control group was given breathing and relaxation exercises, which they would do two days a week for eight weeks, in the form of a home program. Diaphragmatic breathing and respiratory control were given as breathing exercises.
62096135|NCT01842243|ACTIVE_COMPARATOR|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
62096136|NCT01842243|ACTIVE_COMPARATOR|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
62096137|NCT05669833|EXPERIMENTAL|Guselkumab 100mg q4w|Guselkumab (GUS) 100mg every 4 weeks
62096138|NCT05669833|EXPERIMENTAL|Guselkumab 100mg q8w|Guselkumab (GUS) 100mg every 8 weeks
62659723|NCT02706496||elderly(65-74yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
62096139|NCT05669833|ACTIVE_COMPARATOR|Golimumab 50mg q4w|Golimumab (GOL) 50mg every 4 weeks
62096140|NCT03681340|EXPERIMENTAL|Hydroxyapatite toothpaste|4 weeks toothbrushing with a hydroxyapatite toothpaste
62659724|NCT01373619|EXPERIMENTAL|IVABRADINE, HEART FAILURE WITH NORMAL EF|Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
62659725|NCT02387112|EXPERIMENTAL|Early VAD implantation|The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
62659726|NCT02387112|NO_INTERVENTION|Emergency VAD implantation|The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.
62659727|NCT03081169|ACTIVE_COMPARATOR|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
62659728|NCT03081169|ACTIVE_COMPARATOR|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
62659729|NCT01571375||FinnHEMS10|Patients Treated by Helsinki HEMS.
62659730|NCT01571375||FinnHEMS30|PAtients Treated by Tampere HEMS.
62096141|NCT03681340|ACTIVE_COMPARATOR|Fluoridated toothpaste|4 weeks toothbrushing with a fluoridated toothpaste
62096142|NCT05550298||Hematopoietic Cell Transplantation (HCT)|Early and accurate diagnosis of respiratory viral infections (RVIs) in children and adolescents who have undergone HCT is important for improving outcomes. The investigators are doing this study to understand more about how RVIs affect children who receive a transplant.
62096143|NCT05550298||Solid Organ Transplant (SOT)|Early and accurate diagnosis of respiratory viral infections (RVIs) in children and adolescents who have undergone SOT is important for improving outcomes. The investigators are doing this study to understand more about how RVIs affect children who receive a transplant.
62096144|NCT01459315|EXPERIMENTAL|GSK1349572|
62308090|NCT03855254|EXPERIMENTAL|Positive communication|
62096145|NCT01657318||Chronic Wound Group|Treatment with Olivamine containing wound care products
62096146|NCT05696808|EXPERIMENTAL|Indian hepatoprotective diet (IHPD)|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
62096147|NCT05696808|ACTIVE_COMPARATOR|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
62308091|NCT03855254|NO_INTERVENTION|Control (neutral communication)|
62096148|NCT02239185|OTHER|Hernial sac ligation in continuity|laparoscopic closure of hernia sac in continuity using 3 - 0 non-absorbable purse-string suture. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying.
62659731|NCT02660099|EXPERIMENTAL|Internet-delivered CBT|12 weeks of internet-delivered cognitive behavior therapy provided through a secure internet platform and online clinician contact
62096149|NCT02239185|OTHER|Hernial sac disconnection|circumferential incision on the peritoneum at internal inguinal ring (IIR) with separation of hernia sac from the peritoneum. The proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
62293460|NCT01305447|EXPERIMENTAL|Exercise Maintenance|"Randomization and Group-Mediated Cognitive Behavioural therapy (GMCB) sessions will begin on week 8 of the program. Topics of self-regulation related to exercise (Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the GMCB principles on how to maintain exercise behavior."
62096150|NCT05336123|EXPERIMENTAL|Hatha Yoga|Participants will be invited to attend one 60-75 minute yoga class for 10 weeks in the prison facility where they reside. Each class will consist of: breathing exercises, brief guided centering meditation, warm-ups, standing postures, floor postures, an inversion, relaxation, and between-class practice assignments. Classes will emphasize mindfulness, including noticing emotions, thoughts, and physical sensations related to anger, and moderate physical activity. Classes will include some teaching of a relevant yoga theme, such as nonviolence (ahimsa).
62096151|NCT05336123|ACTIVE_COMPARATOR|Health Education|To match for attention, the control condition will be a 10-week program that consists of weekly 60-75 minute group classes. In classes, instructors will provide information about general health topics through a variety of means such as slides and handouts. There will be an emphasis on group discussion of relevant topics; instructors do not just lecture. The core rationale for this course is that good physical health is important for good mental health. Instructors will provide information and encourage questions but avoid psychotherapeutic techniques or personalized goal-setting. Instructors will give participants readings to explore on their own.
62096152|NCT03008343|EXPERIMENTAL|Electroporation and natural killer|In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62096153|NCT03008343|ACTIVE_COMPARATOR|Electroporation|In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62096154|NCT00748969|EXPERIMENTAL|Growth hormone treatmen|Growth hormone treatment arm. Somatropin (DNA origin)
62096155|NCT00748969|NO_INTERVENTION|No growth hormone treatment in year 1|No growth hormone treatment in year 1; option for treatment in year 2 open-label period.
62293461|NCT01305447|EXPERIMENTAL|Ex. Maintenance + relapse prevention|"The same topics of self-regulation related to exercise maintenance(Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the Group-Mediated Cognitive Behavioural therapy (GMCB) principles on how to maintain exercise behavior.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
62293462|NCT01305447|ACTIVE_COMPARATOR|relapse prevention|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
62308092|NCT03855254|EXPERIMENTAL|Negative communication|
62465766|NCT05776303|ACTIVE_COMPARATOR|Good Bowls, followed by Good Bowls + App Nudges|Participants in this arm will be exposed to Good Bowls alone throughout the first four months followed by four months of Good Bowls + App Nudges.
62465767|NCT03328676|EXPERIMENTAL|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
62659732|NCT03279315|EXPERIMENTAL|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
62659733|NCT00327093|EXPERIMENTAL|1|Bevacizumab
61908818|NCT03648866||Patients|interview patients who have participated in compassion rounds
62659734|NCT00327093|EXPERIMENTAL|2|Cetuximab
62659735|NCT00469547|EXPERIMENTAL|1|62% ethanol in emollient gel
62659736|NCT00469547|PLACEBO_COMPARATOR|2|15% ethanol in emollient gel
62659737|NCT00707200||1|Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.
61908819|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
61908820|NCT04220593|EXPERIMENTAL|aETCC before TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
61908821|NCT04220593|EXPERIMENTAL|aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
62659738|NCT00707200||2|Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.
62293463|NCT01305447|ACTIVE_COMPARATOR|Contact Control|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time."
62465768|NCT03328676|PLACEBO_COMPARATOR|placebo oil|Patients in the control group will receive placebo.
62659739|NCT03698461|EXPERIMENTAL|Atezolizumab, Bevacizumab, FOLFOX|Atezolizumab 1200mg IV Once, Atezolizumab (840mg IV D1 of C1-12) + Bevacizumab (5mg/kg IV D1 of C1-12) + FOLFOX(Oxaliplatin 85mg/m2 IV D1 of C1-12, Levoleucovorin 200mg/m2 IV D1 of C1-12, 5-FU - bolus 400mg/m2 IV D1 of C1-12, - infusional 2400mg/m2 IV continuous(46 hours) D1-3 of C1-12)
61908822|NCT04220593|EXPERIMENTAL|aETCC after TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
62293464|NCT06085183|PLACEBO_COMPARATOR|Saline|48 subjects treated with 5 ml of saline then crossover to treatment arm
61908823|NCT04220593|SHAM_COMPARATOR|Simulated aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
61908824|NCT00681356|EXPERIMENTAL|1|4975 - 15 mg
61908825|NCT00681356|PLACEBO_COMPARATOR|2|Placebo
61908826|NCT00681356|EXPERIMENTAL|3|4975 - truncated for Phase 3
62293465|NCT06085183|EXPERIMENTAL|High Dose|24 subjects randomly treated with 5 mL of drug
62293466|NCT06085183|EXPERIMENTAL|Low Dose|24 subjects randomly treated with 2.5 mL of drug
62293467|NCT04651634|EXPERIMENTAL|20 mg|MIT-001 20 mg
62293468|NCT04651634|EXPERIMENTAL|40 mg|MIT-001 40 mg
61908827|NCT02687867||Dabigatran|Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention.
61908828|NCT02687867||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention.
61908829|NCT00862797||endotracheal tube|Patients intubated with cuffed endotracheal tubes
62293469|NCT04651634|EXPERIMENTAL|60 mg|MIT-001 60 mg
62293470|NCT04651634|PLACEBO_COMPARATOR|Placebo|Matching placebo
62308093|NCT02367612|EXPERIMENTAL|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
62308094|NCT02367612|PLACEBO_COMPARATOR|Placebo|Placebo
62465769|NCT01861379|EXPERIMENTAL|Ghost Ileostomy|The patients were subjected to laparoscopic anterior rectal resection with performance of ghost ileostomy
62465770|NCT01861379|PLACEBO_COMPARATOR|No protective stoma|The patients were subjected to laparoscopic anterior rectal resection without simultaneous construction of any protective stoma.
62465771|NCT02468258|ACTIVE_COMPARATOR|endometrial flushing (A)|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected in a sterile container and was centrifuged at 600 rpm for 10 min at room temperature and a 5-ml sample of the supernatant was obtained for laboratory workup, while the remaining amount of supernatant was used to flush the endometrium through an applied uterine catheter in FF group and was discarded in the other group.
62096156|NCT00006221|EXPERIMENTAL|Arm I|"Patients receive BMS-247550 IV over 1 hour once weekly on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients treated at the MTD receive treatment once weekly on weeks 1-3 of each 4-week course."
62659740|NCT02503046||Arthritis with Periodontitis|"Patients aged between 30-65 years with 6 positive diagnostic criteria for Rhematoid Arthritis. Patients should have Clinical attachment loss \>6mm, and Probing pocket depth\>5mm in more than 6 teeth to satisfy criteria for periodontitis.~5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA) Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels."
62096157|NCT05737563|EXPERIMENTAL|Experimental|PD-1 Antibody Combined With mXELIRI
62096158|NCT05737563|ACTIVE_COMPARATOR|Control|mXELIRI
62096159|NCT02288858|ACTIVE_COMPARATOR|Test product|Viviscal Oral Supplement Tablets (as 512mg coated red-brown tablets in unbranded blister packs)
62096160|NCT02288858|PLACEBO_COMPARATOR|Placebo|Placebo Tablets (as 512 coated red-brown tablets in unbranded blister packs)
62096161|NCT01101542||Cervarix Group|Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.
62659741|NCT02503046||Periodontitis group|"Patients aged between 30-65 years with Periodontal findings being presence of atleast 20 teeth in the mouth .More than 6 teeth with Clinical attachment loss \>6mm and Probing pocket depth\>5mm to satisfy criteria for periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
62293471|NCT00316264|EXPERIMENTAL|Motavizumab followed by Palivizumab|2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
62659742|NCT02503046||Healthy Subjects|"Subjects aged between 30-65 years with no systemic diseases and periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
62659743|NCT02358629|EXPERIMENTAL|Prospective, non-randomized|use the NovaCross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal Chronic Total Occlusion (CTO) lesion
62659744|NCT04808037|EXPERIMENTAL|Cohort 1, First Part|12 patients are anticipated to receive Belantamab Mafodotin 2.5 Q8W = 2.5 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
62659745|NCT04808037|EXPERIMENTAL|Cohort 2, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
62659746|NCT04808037|EXPERIMENTAL|Cohort 3, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
62659747|NCT04808037|EXPERIMENTAL|Group A, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose Modification Guidelines for Corneal-Related Adverse Events Associated with belantamab mafodotin"
62659748|NCT04808037|EXPERIMENTAL|Group B, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose modification guidance based on visual acuity"
62293472|NCT00316264|EXPERIMENTAL|Palivizumab followed by motavizumab|2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
62659749|NCT01344564|OTHER|ADT|All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot.
62659750|NCT04877964||pediatric patients with scoliosis|Patients aged 3-14 years with scoliosis and who request epidural analgesia
62659751|NCT02988609|EXPERIMENTAL|Concussion Group|Players with a recent (\<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
62659752|NCT02988609|ACTIVE_COMPARATOR|Control Group|a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
62293473|NCT00316264|EXPERIMENTAL|Motavizumab control|5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
62293474|NCT03843047|OTHER|Dual cigarette smokers/e-cigarette users|Dual cigarette smokers/e-cigarette users will be recruited.
62293475|NCT03843047|OTHER|Exclusive cigarette smokers|Exclusive cigarette smokers with minimal prior e-cigarette experience will be recruited.
62293476|NCT05071898|EXPERIMENTAL|Open label administration of semaglutide|Semaglutide: 0.25 mg, sc, q.week for 4 weeks followed by 0.5 mg, sc, q.week for 2 weeks
62293477|NCT04057209|ACTIVE_COMPARATOR|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|Transoral CO2-Laser Microsurgical Cordectomy defined by European Laryngological Society (Remacle M, Eckel HE, Antonelli A, et al. Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol. 2000;257(4):227-231.)
62308095|NCT03697239|EXPERIMENTAL|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
62308096|NCT05159765|PLACEBO_COMPARATOR|Control|Contact lens with refractive correction, single vision optic
62308097|NCT05159765|EXPERIMENTAL|Treatment|Contact lens with refractive correction, multifocal optic
62659753|NCT00952913|EXPERIMENTAL|1|Bosutinib
62659754|NCT00952913|EXPERIMENTAL|2|bosutinib + lansoprazole
62659755|NCT00439439|SHAM_COMPARATOR|A|Sham Procedure
62659756|NCT00439439|ACTIVE_COMPARATOR|B|Verum Beamer ablation of heterotopic gastric mucosa
61908830|NCT03283605|EXPERIMENTAL|Durvalumab + tremelimumab and SBRT|All subjects will receive durvalumab (1500 mg IV q4week) and tremelimumab (75mg q4week) for 4 doses, followed by durvalumab alone (1500 mg IV q4week) until disease progression, unacceptable toxicity or patient withdrawal. SBRT will be administered between cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
61908831|NCT03483129|EXPERIMENTAL|Consultation|The consultation will provide the participant with one to one information regarding the benefits of physical activity and healthy eating. Emphasis will placed on the importance of achieving at least 150 minutes of moderate physical activity each week as well as adhering to healthy dietary habits, based on the NHS Eatwell Guide (Eatwell Guide, 2016). Furthermore, participants will have the opportunity to discuss pre-diabetes with a trained practice nurse and ask any questions they may have.
61908832|NCT03483129|NO_INTERVENTION|Control|All participants will receive an information leaflet detailing pre-diabetes, the associated risks and steps that can be taken to avoid developing diabetes.
61908833|NCT05397782|EXPERIMENTAL|Pilot Group: Flourish HEC|All women in the study will use the Flourish HEC Vaginal Care System for 6 months. Flourish HEC consists of 3 products: 1) Balance, an external feminine wash; 2) BioNourish, a vaginal moisturizing gel; and 3) BiopHresh, a homeopathic vaginal suppository with probiotics. Products are pH-balanced to match healthy vaginal pH (3.5-4.5). BioNourish is formulated to be iso-osmotic with vaginal fluid. Balance and BioNourish contain lactic acid. BiopHresh contains 7 strains of lactobacilli, including Lactobacillus crispatus and other species found in healthy vaginas or shown to be effective probiotics strains.
61908834|NCT04316975|OTHER|Biopsy: Barrett's Esophagus, Intramucosal adenocarcinoma|"Subjects will undergo standard of care (SOC) standard esophagogastroduodenoscopy (EGD) for the treatment of their condition (BE or IMC). Four (4) research biopsies will be taken from the midpoint of current disease. In cases where EMR (Endoscopic Mucosal Resection) is performed clinically, no research biopsies will be taken. Following CEIM, four (4) additional research biopsies will be collected, from the midpoint of previous BE site.~Laboratory Biomarker Analysis: Correlative studies~Esophagogastroduodenoscopy: Standard of care, research biopsies will be collected if clinical biopsies are taken"
61908835|NCT02079818|EXPERIMENTAL|Penumbra Ruby Coil System|
61908836|NCT06385067||Experimental group|Use at least one Biolimus coated coronary balloon dilation catheter (BioAscend) to treat primary in situ coronary artery vascular disease with a diameter of 2.0 mm-2.75 mm regardless of the number of blood vessels, the length and number of treated lesions.
62659757|NCT05994417||Non-Hispanic Black|Infants born to mothers identifying as Non-Hispanic Black
62659758|NCT05994417||Non-Hispanic White|Infants born to mothers identifying as Non-Hispanic White
61908837|NCT00307008|EXPERIMENTAL|Group A|
61908838|NCT05282056|EXPERIMENTAL|CAD analysis|The XVision COVID-19 computer aided diagnostic software is used by radiologist at CT analysis time
62308098|NCT03303430||Surgery group|This patient's group will benefit from a endarteriectomy in order to treat their carotid stenosis.
62659759|NCT05994417||Infants across the spectrum of melanin index and ITA-based skin color classification|
62659760|NCT00916734|EXPERIMENTAL|Spinal Manipulation Group|Subjects who received spinal thrust manipulation as an intervention.
62659761|NCT00916734|ACTIVE_COMPARATOR|McKenzie MDT Group|
62659762|NCT02820389||Optical colonoscopy|Patients with suspected colorectal cancer will undergo optical colonoscopy as the initial imaging modality.
62659763|NCT02820389||CT Colonography|Patients with suspected colorectal cancer will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan.
62659764|NCT05166876|EXPERIMENTAL|Brequinar monotherapy|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
62659765|NCT05166876|PLACEBO_COMPARATOR|Placebo|Placebo matching brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
62096162|NCT05949372|EXPERIMENTAL|Experimental Group : (Biological Breastfeeding Position)|The first breastfeeding after birth will take place within the first half hour - two hours. The second breastfeeding will be performed 2 hours after the first breastfeeding, and the third breastfeeding will be performed at the 24th hour. Three measurements will be made in total.The mother is half-sitting, in the most comfortable position where she can make eye contact with her baby. The baby's head is placed on the mother's chest with her legs on the mother's stomach. With this position, gravity fixes the baby's whole body to that of its mother. The breastfeeding duration will be measured with a chronometer in the breastfeedings at these measurement hours. In order to determine the breastfeeding time, after the mother and baby are positioned, the stopwatch will be started when the baby takes the first breast into his mouth. Data collection forms will be filled.
62096163|NCT05949372|EXPERIMENTAL|Experimental ( armpit / football breastfeeding position):|The first breastfeeding after birth will take place within the first half hour - two hours.The second breastfeeding will be performed 2 hours after the first breastfeeding, and the third breastfeeding will be performed at the 24th hour.Three measurements will be made in total.The baby's head is placed on the breast that is breastfed and the feet are laid flat so that they pass under the armpit of the breastfed side.While the mother's hand on the breastfeeding side holds the baby's head, the other hand directs the breast towards the baby and breastfeeding is initiated.The breastfeeding duration will be measured with a chronometer in the breastfeedings at these measurement hours.In order to determine the breastfeeding time, after the mother and baby are positioned, the stopwatch will be started when the baby takes the first breast into his mouth. Data collection forms will be filled.
62096164|NCT06629025||esophageal motility disorder|Pediatric patients (0-20 years old) with clinically diagnosed abnormal esophageal motility
62096165|NCT06217029||Effective Group of Cervical Spondylotic Pain|"VAS reduction rate is used to evaluate clinical efficacy. The reduction rate = (baseline value - end value)/baseline value. The clinical efficacy is divided into four levels: cured, significant effect, slight effect, ineffective or recurrent. cured: reduction rate ≥ 75%; significant effect: 50% ≤ reduction rate \< 75%; slight effect: 25% ≤ reduction rate \< 50%; ineffective: reduction rate \< 25%. The cured + significant effect group was classified as the treatment effective group,"
62096166|NCT06217029||Ineffective Group of Cervical Spondylotic Pain|"The slight effect + ineffective group and the recurrent group were classified as the treatment ineffective group"
62096167|NCT04093128|EXPERIMENTAL|adults aged 19-57|adults aged 19-57 years old living in Amman Jordan, body mass index between 19-57
62096168|NCT04077684|PLACEBO_COMPARATOR|Placebo|placebo s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
62096169|NCT04077684|ACTIVE_COMPARATOR|IL-2 at 0.2MIU|0.2 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
62096170|NCT04077684|ACTIVE_COMPARATOR|IL-2 at 0.5MIU|0.5 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
62096171|NCT04077684|ACTIVE_COMPARATOR|IL-2 at 1.0MIU|1.0 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
62096172|NCT02679651||Control group|Healthy Adults without foot pain
62659766|NCT05166876|EXPERIMENTAL|Brequinar-Dipyridamole Combination|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met. All subjects assigned to this arm will also receive dipyridamole 75 mg tablets TID.
61908839|NCT05282056|NO_INTERVENTION|No CAD analysis|No CAD analysis is shown to radiologist.
61908840|NCT05580445|EXPERIMENTAL|Dose-escalation and dose-expansion|Dose-escalation study is designed to determine the dose-limiting toxicity (DLTs) and recommended phase II dose (RP2D). Dose-expansion study is designed to evaluate the antitumor activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer.
61908841|NCT00802113|EXPERIMENTAL|Arm A - Family Donor|Fludarabine and Busulfan: Patients who have a matched family (allogeneic) donor will go on to receive non-ablative therapy, followed by an infusion of donor stem cells; this is called an allogeneic peripheral blood stem cell transplant. The non-ablative therapy will be busulfan and ﬂudarabine, Usually large (myeloablative) doses of these drugs are used for an allogeneic transplant. However, in this study lower doses (non-ablative) of chemotherapy will be given. In patients who still have evidence of disease after allogeneic transplant, additional donor immune cells (donor lymphocyte infusion) (DLI) will be given twice to further treat the lymphoma.
62096173|NCT02679651||DIsease group|Adults diagnosed with fat pat atrophy and report symptoms of foot pain and have participated in clinical trial to treat fat pad atrophy.
62096174|NCT06546449|EXPERIMENTAL|SAD Cohort 1|Participants will be administered a single 12.5 mg dose of LH-001
62096175|NCT06546449|EXPERIMENTAL|SAD Cohort 2|Participants will be administered a single 25 mg dose of LH-001
62096176|NCT06546449|EXPERIMENTAL|SAD Cohort 3|Participants will be administered a single 50 mg dose of LH-001
62659767|NCT06348043|EXPERIMENTAL|LVAD support with the Jarvik 2015|Children implanted with the Jarvik 2015 LVAD as a bridge to heart transplant
62659768|NCT02936765|EXPERIMENTAL|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
62659769|NCT02936765|ACTIVE_COMPARATOR|Squale|Patients, who receive Squale (TM) as cervical disc prosthesis after ventral discectomy.
62736914|NCT02525484|EXPERIMENTAL|Pirfenidone BADC treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.
62293478|NCT04057209|EXPERIMENTAL|Arm B: Single Vocal Cord Irradiation (SVCI)|Single Vocal Cord Irradiation defined by Kwa et al. and Al-Mamgani et al. (Kwa SLS, Al-Mamgani A, Osman SOS, Gangsaas A, Levendag PC, Heijmen BJM. Inter- and Intrafraction Target Motion in Highly Focused Single Vocal Cord Irradiation of T1a Larynx Cancer Patients. Int J Radiat Oncol Biol Phys. 2015;93(1):190-195. Al-Mamgani A, Kwa SLS, Tans L, et al. Single Vocal Cord Irradiation: Image Guided Intensity Modulated Hypofractionated Radiation Therapy for T1a Glottic Cancer: Early Clinical Results. Int J Radiat Oncol Biol Phys. 2015;93(2):337-343.)
62293479|NCT05300087|EXPERIMENTAL|Test Group|Albuterol Sulfate Inhalation Aerosol
62293480|NCT05300087|ACTIVE_COMPARATOR|Reference Group|Proair HFA (albuterol sulfate) Inhalation Aerosol
62293481|NCT06216093|EXPERIMENTAL|RSV-1|
62293482|NCT06216093|EXPERIMENTAL|RSV-2|
62293483|NCT06216093|PLACEBO_COMPARATOR|Normal Saline|
62293484|NCT05865184||Passive monitoring|No intervention
62293485|NCT04059744|EXPERIMENTAL|Experimental arm|"Device: Fun-Knee Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
62293486|NCT00997971|EXPERIMENTAL|Modilac Rose 1|Infant formula with partially hydrolysed rice protein
61908842|NCT00802113|EXPERIMENTAL|Arm B - Unrelated Cord Blood or Adult|Fludarabine, Busulfan and ATG: For patients who don't have a matched family donor, a cord blood search and unrelated adult search will be done at all of the cord blood banks and adult donor registries in the world. If a closely matched cord blood donor or unrelated adult donor is found, non-ablative chemotherapy with busulfan, ﬂudarabine and antithymocyte globulin (ATG) followed by the infusion of matched unrelated cord blood cells or adult donor stem cells or bone marrow to restore the bone marrow will be given.
62293487|NCT02583984||Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic Surgery with Lung Resection, such as lobectomy, segmentectomy
62293488|NCT02583984||Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic Surgery without Lung Resection, such as esophageal surgery, mediastinal surgery
62293489|NCT00730340|ACTIVE_COMPARATOR|1|Patients will receive closure of the tonsillar fossae following tonsillectomy.
62293490|NCT00730340|ACTIVE_COMPARATOR|2|Patients will not receive closure to one or both tonsillar fossa following a tonsillectomy
62293491|NCT03669978||Patients with chronic occlusive arthritis of the Lower Limbs|"Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.~Creation of a bone and arterial panorama using EndoNaut® software."
62293492|NCT02193789|EXPERIMENTAL|Anastomosis site stricture|anastomosis site stricture after subtotal gastrectomy with Billroth-I anastomosis
62293493|NCT04399382||Non-radiographic group|Participants with non-radiographic axial SpA
61908843|NCT02610101|ACTIVE_COMPARATOR|Traditional SCD Diet|7 subjects will be randomized to a traditional SCD diet
61908844|NCT02610101|ACTIVE_COMPARATOR|Modified SCD Diet|"7 subjects will be randomized to a modified SCD diet, which includes oatmeal and rice"
62293494|NCT04399382||Radiographic group|Participants with radiographic axial SpA (a.k.a. ankylosing spondylitis)
62293495|NCT02006576|PLACEBO_COMPARATOR|COPD, Placebo|Placebo three times daily
62293496|NCT02006576|NO_INTERVENTION|Control subject|Control subjects, no intervention
62293497|NCT02006576|EXPERIMENTAL|COPD, ibuprofen|600 mg ibuprofen three times daily for 48 weeks
62293498|NCT03859284|ACTIVE_COMPARATOR|flowable resin-composite|"3M flowable composite is a conventional restoration to treat anterior carious cervical lesions. considered to be the gold standard of the flowable composites.~other names: ''flowable composite ''"
62293499|NCT03859284|EXPERIMENTAL|self-adhering flowable|intervention one is moist bonding self adhering flowable composite that binds to tooth without an adhesive system
62659770|NCT06044870|EXPERIMENTAL|Modified laterally stretched technique with a connective tissue graft.|"After the administration of local anesthesia, root planing of the exposed root surfaces will be performed by means of hand instruments.~A partial thickness envelope is performed with tunneling instruments involving one or two teeth adjacent to the tooth, in case of a very thin biotype a complete thickness envelope could be done.~Two horizontal incisions are done at the base of the papillae, allowing to place the graft in a more coronal position and improving access and visibility."
61908845|NCT02610101|ACTIVE_COMPARATOR|Whole Foods Diet|"7 subjects will be randomized to a Whole foods diet without added sugars"
62293500|NCT03859284|EXPERIMENTAL|self-adhering flowable with adhesive|intervention two moist bonding self adhering flowable composite that binds to tooth with the aid of adhesive system to improve the clinical performance
62293501|NCT03501979|EXPERIMENTAL|Tucatinib + Trastuzumab + Capecitabine|Tucatinib will be taken orally at 300 mg twice a day starting with Cycle 1, Day 1. A cycle consists of 21 days. Capecitabine will be taken orally at 1000 mg/m2 twice a day on Days 1-14 starting with cycle 1. Trastuzumab is given intravenously as a loading dose of 8 mg/kg on Cycle 1, Day 1 and then at 6 mg/kg for all subsequent cycles.
62293502|NCT06070428|ACTIVE_COMPARATOR|PAC Intervention Arm|"Participants randomized to the interventional arm will be given 2 PAC units with HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor.~Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed.~Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters."
61908846|NCT04658940|EXPERIMENTAL|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
62308099|NCT03303430||Stenting group|This patient's group will benefit from a stenting of their carotid in order to treat their stenosis.
61908847|NCT03697135||Seed Contacts|Initial participants who will invite previous injecting contacts to take a hepatitis C test using a respondent driven sampling method
61908848|NCT03697135||Initial Nominations for Testing|Contacts of initial participants who consent to be tested and enrol in the study using a respondent driven sampling method
62096177|NCT06546449|EXPERIMENTAL|SAD Cohort 4|Participants will be administered a single 100 mg dose of LH-001
62096178|NCT06546449|EXPERIMENTAL|MAD Cohort 1|Participants will be administered multiple 25 mg doses of LH-001
62096179|NCT06546449|EXPERIMENTAL|MAD Cohort 2|Participants will be administered multiple 50 mg doses of LH-001
62096180|NCT06546449|EXPERIMENTAL|MAD Cohort 3|Participants will be administered multiple 100 mg doses of LH-001
62096181|NCT06546449|PLACEBO_COMPARATOR|SAD Placebo cohorts 1, 2, 3 and 4|Participants will be administered a single dose of placebo
62096182|NCT06546449|PLACEBO_COMPARATOR|MAD Placebo cohorts 1, 2 and 3|Participants will be administered multiple doses of placebo
62096183|NCT06107621|EXPERIMENTAL|Internet-based iCBT targeting Gambling Disorder and comorbidities|An 8 module internet-based iCBT program targeting Gambling Disorder and comorbidities, administered with treatment support.
62096184|NCT06696833|EXPERIMENTAL|Patients with relapsed/refractory B cell Acute lymphoblastic Leukemia|In this study, we adopted a 3+3 design with dose escalation. A conditional chemotherapy regimen of fludarabine and cyclophosphamide will be administered, and each dose group received treatment on Days 0 through i.v. injection, with bone marrow examination performed on Days 14 and 28 to assess tumor burden. Upon assessment by the investigators and discussion with the Safety Review Committee (SRC), it will be determined that whether patients may benefit from additional infusions. With SRC approval, the number of administrations could be increased. At the end of dose escalation, the SRC may decide to adjust the number of participants in the designated dose group as deemed appropriate.
62096185|NCT05685758|EXPERIMENTAL|Intervention group|Individuals with Major Depressive Disorder who have access to an FTP-based mobile phone application for eight weeks.
62096186|NCT05685758|NO_INTERVENTION|Control group|Individuals with Major Depressive Disorder who are on an 8-week waitlist (delayed intervention) before being offered to use the app. During the eight weeks, they will be subjected to the same questionnaires and assessments as the intervention arm.
62096187|NCT02692235|EXPERIMENTAL|carnitine|24 weeks l-carnitine-l-tartrate supplementation
62096188|NCT02692235|PLACEBO_COMPARATOR|placebo|24 weeks isonitrogenous supplementation
62096189|NCT04986215||Benign pancreatic space occupying group|
62096190|NCT04986215||Malignant pancreatic space occupying group|
62096191|NCT04284748|EXPERIMENTAL|Plyometric training with blood flow restriction|Routine physiotherapy program + Plyometric training with blood flow restriction, 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
62096192|NCT04284748|ACTIVE_COMPARATOR|Plyometric training|Routine physiotherapy program + Plyometric training 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
62293503|NCT06070428|SHAM_COMPARATOR|Control non-interventional Arm|"Participants randomized to the non-interventional arm will be given 2 PAC units without HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor.~Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed.~Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters."
62096193|NCT00797225|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
62736915|NCT02525484|EXPERIMENTAL|Pirfenidone CDAB treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.
62736916|NCT02525484|EXPERIMENTAL|Pirfenidone DBCA treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.
61908849|NCT03697135||Second Level Nominations for testing|Contacts of wave one participants who consent to be tested and enrol in the study using a respondent driven sampling method
61908850|NCT01352260||Cardiac Disease|Total Aortic Arch Replacement
61908851|NCT02086643|EXPERIMENTAL|Retroclavicular block|Retroclavicular block
61908852|NCT00838864|ACTIVE_COMPARATOR|1|ceftrioxone 500mg q12h for 3 days
61908853|NCT00838864|ACTIVE_COMPARATOR|2|ceftrioxone 500 mg q12h for 7 days
61908854|NCT06129617|ACTIVE_COMPARATOR|Hemodialysis|Patients receiving hemodialysis therapy mit Fresenius 5008
61908855|NCT06129617|EXPERIMENTAL|ADVOS|Patients receiving ADVOS therapy with ADVOS multi
61908856|NCT03680235|ACTIVE_COMPARATOR|Group I: (standard information about pregnancy, breastfeeding)|Participants receive standard information about pregnancy and breastfeeding. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
61908857|NCT03680235|EXPERIMENTAL|Group II (information about breastfeeding and cancer)|Participants receive standard information about pregnancy and breastfeeding as well as information about breastfeeding and breast cancer. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
61908858|NCT05084729||Imagio OA/US|Imagio optoacoustic
61908859|NCT02762227|EXPERIMENTAL|gallbladder polyps patients|"All patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal US, were enrolled in this study.~Of these patients, we excluded: (1) gallbladder polyp with a diameter less than 10 mm. (2) lesions highly suspected to be cancer due to visible metastasis. (3) allergy to contrast agents and cannot received CT or CEUS examination. (4) women in pregnancy or lactation.~All patients received transabdominal US, abdominal high resolution CT and contrast-enhanced ultrasonography (CEUS) before the cholecystectomy."
61908860|NCT05205473|ACTIVE_COMPARATOR|SN blockade under ultrasound control with a peripheral nerve stimulator 12.5 ml 1% lidocaine|Patients undergoing surgery on the knee, shin, ankle or foot
61908861|NCT05205473|EXPERIMENTAL|SN blockade under ultrasound control without a peripheral nerve stimulator|Patients undergoing surgery on the knee, shin, ankle or foot
61908862|NCT02250001||Treatment with DCV/ASV|Patients who are beginning to receive the treatment with DCV/ASV under the approved indications, dosage, and administration will be included in this study
61908863|NCT01982968|NO_INTERVENTION|Control|Subjects to receive standard anti-reflux treatment per clinical discretion
61908864|NCT01982968|ACTIVE_COMPARATOR|Surgery|Subjects will receive laparoscopic fundoplication surgery
61908865|NCT02057588|OTHER|LV Paced sites|LV pacing sites : Patients will be paced from various left ventricular origin, defined by their 3D localization.
61908866|NCT04678076|EXPERIMENTAL|ketoprofen 25mg/5ml oral gel stick pack|Single dose of ketoprofen 25mg/5ml oral gel stick pack will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
62736917|NCT01471769|EXPERIMENTAL|pain management video|Experimental
62736918|NCT01471769|PLACEBO_COMPARATOR|falls prevention video|placebo
62736919|NCT01334385||OEF/OIF Veterans through VA ECHCS|
62736920|NCT03855046|EXPERIMENTAL|Xeomin|Complex treatment of chronic anal fissure with drug-induced relaxation of the internal sphincter with Botulinum Toxin Type A. (IncobotulinumtoxinA 50 U Intramuscular Powder for Solution).
62736921|NCT03855046|ACTIVE_COMPARATOR|Xeomin control|Complex treatment of chronic anal fissure with lateral subcutaneous sphincterotomy.
62736922|NCT02658552|EXPERIMENTAL|HIFU treatment|To collect the data after HIFU treatment
62736923|NCT00868972|ACTIVE_COMPARATOR|Embolic protection|Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
62736924|NCT00868972|SHAM_COMPARATOR|No embolic protection|Percutaneous renal stenting intervention without embolic protection
62465772|NCT02468258|NO_INTERVENTION|B|no intervention Control group included 40 women would not have FF endometrial flushing.
62465773|NCT01303549|EXPERIMENTAL|Anidulafungin|Anidulafungin IV once a day: initial dose 200 mg/day, following doses 100 mg/day.
62659771|NCT06044870|ACTIVE_COMPARATOR|Tunneling technique with connective tissue graft.|Immediately before surgery, contact point composite stops were placed to prevent the collapse of the suspended sutures in the inter-proximal spaces.• The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva. The anchorage in the lingual gingiva will be placed far apically. The suture must capture the buccal flap and graft to avail optimal stabilization (Aroca et al., 2010, 2013; Azzi et al, 2002).
62659772|NCT01197066|OTHER|Certolizumab Pegol|Single Arm
62659773|NCT04553315|EXPERIMENTAL|intervention group|Intervention group was received Chest mobility exercises with Incentive spirometer and segmental breathing exercise and breath stacking technique . The patient in the intervention group was instructed to perform the exercises 3 times per day, 7-8 times per session for one week. Ensure that the patient fully hydrated by maintaining normal daily water requirement in the form of (30-35ml/kg/day) with restriction of intravenous fluids.
62659774|NCT04553315|EXPERIMENTAL|control group|control group will receive only routine hospital care
62659775|NCT04129541|ACTIVE_COMPARATOR|SDD|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
62659776|NCT04129541|ACTIVE_COMPARATOR|OH|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
62096194|NCT00797225|EXPERIMENTAL|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
62096195|NCT00797225|EXPERIMENTAL|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
62096196|NCT00797225|OTHER|Leuprorelin|Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
62096197|NCT02461238|ACTIVE_COMPARATOR|Vouchers|Families included in the Voucher arm will receive vouchers for fruits and vegetables by mail every month for a period of 1 year coupled to nutritional education from a dietician
62096198|NCT02461238|OTHER|Control|Families included in the control arm will only receive nutritional education
62096199|NCT01084161|EXPERIMENTAL|N1539 5 mg|
62659777|NCT02661971|ACTIVE_COMPARATOR|FLOT alone|"Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT~* Docetaxel 50 mg/m², d1~* Oxaliplatin 85 mg/m², d1~* Calciumfolinat 200 mg/m², d1~* 5-Fluorouracil 2600 mg/m², d1"
62096200|NCT01084161|EXPERIMENTAL|N1539 7.5 mg|
62659778|NCT02661971|EXPERIMENTAL|FLOT + Ramucirumab|"Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab~* Ramucirumab 8mg/kg, d1~* Docetaxel 50 mg/m², d1~* Oxaliplatin 85 mg/m², d1~* Calciumfolinat 200 mg/m², d1~* 5-Fluorouracil 2600 mg/m², d1"
62659779|NCT03661918|OTHER|Group 1|In-person first session, no second caregiver, no wifi-enabled scale
62659780|NCT03661918|OTHER|Group 2|In-person first session, no second caregiver, wifi-enabled scale
62096201|NCT01084161|EXPERIMENTAL|N1539 15 mg|
62096202|NCT01084161|EXPERIMENTAL|N1539 30 mg|
62096203|NCT01084161|EXPERIMENTAL|N1539 60 mg|
62096204|NCT01084161|PLACEBO_COMPARATOR|Placebo|
62096205|NCT01084161|ACTIVE_COMPARATOR|morphine|
62096206|NCT02424344|EXPERIMENTAL|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
62096207|NCT02424344|PLACEBO_COMPARATOR|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
62096208|NCT05753293|EXPERIMENTAL|Bhastrika pranayama|"done in sitting posture and the following instructions: The back must be kept straight and shoulder muscles should be kept relaxed, patient was asked to close the right nostril with right thumb and to bring right elbow to the level of right shoulder.~To close the eyes, inhale and exhale through left nostril-first slowly, then a little faster, The subject was asked to do the above steps about 20-25 times, (Then the subject was asked to take a long breath in and retain it for as long as possible, This is one cycle of Bhastrika pranayama. The subject has to repeat this cycle by closing left nostril and breathing through right nostril."
62293504|NCT00333216|EXPERIMENTAL|15 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
62465774|NCT01303549|ACTIVE_COMPARATOR|Liposomal Amphotericin B|Liposomal amphotericin B once a day: 3 mg/kg/day
62465775|NCT04910126|EXPERIMENTAL|experiment group|adriamycin and Camrelizumab
62465776|NCT04910126|ACTIVE_COMPARATOR|control group|adriamycin
62465777|NCT01707134|EXPERIMENTAL|insulin aspart|
62465778|NCT01707134|ACTIVE_COMPARATOR|human insulin|
62465779|NCT02380807|EXPERIMENTAL|Dry Needling Therapy|Dry Needly Therapy will be assesses in trigger points on latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourum muscle.
62465780|NCT02380807|ACTIVE_COMPARATOR|Cross Tape Therapy|Cross Tape is a grid-shaped bandage easy aplicacionen different parts of the body that regulates the tension.
62659781|NCT03661918|OTHER|Group 3|In-person first session, second caregiver, no wifi-enabled scale
62659782|NCT03661918|OTHER|Group 4|In-person first session, second caregiver, wifi-enabled scale
62659783|NCT03661918|OTHER|Group 5|No in-person first session, no second caregiver, no wifi-enabled scale. 10 core coaching calls only
62659784|NCT03661918|OTHER|Group 6|No in-person first session, no second caregiver, wifi-enabled scale
62659785|NCT03661918|OTHER|Group 7|No in-person first session, second caregiver, no wifi-enabled scale
62659786|NCT03661918|OTHER|Group 8|No in-person first session, second caregiver, wifi-enabled scale
62659787|NCT05690516|EXPERIMENTAL|Face masks|Participants in the experimental arm are asked to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
62659788|NCT05690516|NO_INTERVENTION|Not face masks|Participants in the no intervention arm arm are asked not to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
62659789|NCT04201600||Middle-aged and Older adults with Prediabetes|Middle-aged and Older adults with Prediabetes
62659790|NCT05714761|OTHER|Postpartum glucose sensor|Will wear glucose sensor for 10 days postpartum and at time of glucose tolerance test.
62659791|NCT01677793||Child and adolescent population|
62659792|NCT02772731|EXPERIMENTAL|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
62096209|NCT05753293|EXPERIMENTAL|Buteyko breathing exercise|"Step 1 beginning control pause (CP) the patient inhales and then exhales through the nose and then holds their breath until the point they feel either the first clear and distinct desire to breath or involuntary movement or jerk coming from diaphragm.Step 2 three to five minutes of relaxed reduced-volume breathing or slow breathing the patient gradually reduced their breathing until they feel a light lack of air. they sustain these while staying relaxed.~Step 3 maximum pause (MP) the maximum pause begins with gentel inhalation and exhalation. Then the breath is held as long as possible but not to the point of severe discomfort.~Step 2 and step 3 are then repeated up to 5 times. Final control pause: same as step 1."
62096210|NCT05832723||650 nm low-level red-light|Children who are exposed to the 650 nm low-level red-light will be recruited into the cohort, the exposure factor is red-light irradiation. The study does not give interventions, but only recruit children who received or who is receiving the 650 nm low-level red-light intervention for observation.
62096211|NCT01416909|ACTIVE_COMPARATOR|Dose Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on the dose of the opioid pain medication they are receiving.
62293505|NCT00333216|EXPERIMENTAL|30 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
62293506|NCT00333216|SHAM_COMPARATOR|Anecortave Acetate Vehicle|Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months
62465781|NCT03597711|ACTIVE_COMPARATOR|IVCannulation 24G non-safety cannula|Peripheral Intravenous cannulation using 24G non-safety cannula
62659793|NCT02772731|ACTIVE_COMPARATOR|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
62659794|NCT03018730|EXPERIMENTAL|PRX-102|PRX-102 infusion every 2 weeks
62659795|NCT02641041|EXPERIMENTAL|Cohort 1|A single IV dose of 10 mg/kg BIIB033 or placebo given on Day 1
61908867|NCT04678076|ACTIVE_COMPARATOR|OKi 80 mg granules for oral solution (bipartite sachet)|Single dose of half sachet containing 40 mg of ketoprofen lysine salt (corresponding to 25 mg as ketoprofen) will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
61908868|NCT04582123|OTHER|comparison of two cross pin fixation methods|Fixation of supracondylar humerus fractures with 2 crossed pins and 3 crossed pins are compared in terms of Flynn's criteria
62659796|NCT02641041|EXPERIMENTAL|Cohort 2|A single IV dose of 30 mg/kg BIIB033 or placebo given on Day 1
62659797|NCT02641041|EXPERIMENTAL|Cohort 3|One IV dose of 100 mg/kg BIIB033 or placebo given on Days 1 and 15
62659798|NCT04000724|EXPERIMENTAL|Text+Step|The TechStep Text+Step messaging intervention is a six-month technology-based culturally competent theory-based text messaging intervention that sends three automated text messages to participants daily to reduce HIV risk and increase PrEP uptake and adherence.
62659799|NCT04000724|EXPERIMENTAL|WebApp+Step|The TechStep WebApp+Step website intervention is a six-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV sexual risk reduction and PrEP uptake and adherence.
62659800|NCT04000724|EXPERIMENTAL|Information|The Information/No Step intervention includes nothing more than access to a website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
62659801|NCT02373072|EXPERIMENTAL|Cohort 1|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
62659802|NCT02373072|EXPERIMENTAL|Cohort 2|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
62659803|NCT03176199|EXPERIMENTAL|Control-released oxycodone|Control-released oxycodone Q12H, initial daily dose is 20 mg + immediate-released oxycodone for PRN
61908869|NCT02925416|EXPERIMENTAL|Oritavancin/Oritavancin|On Day 1, participants were administered a single 1200-mg IV dose of oritavancin in 1000 milliliters (mL) diluted in 5% dextrose in water (D5W). On Day 7, an additional 1200-mg IV dose of oritavancin in 1000 mL of D5W was administered.
61908870|NCT02925416|OTHER|Oritavancin/Placebo|On Day 1, participants were administered a single 1200-mg IV dose of oritavancin in 1000 mL of D5W. On Day 7, a placebo was administered IV in 1000 mL of D5W.
61908871|NCT02726542|EXPERIMENTAL|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
61908872|NCT02726542|NO_INTERVENTION|No treatment|(no study treatment - observation only)
62659804|NCT03176199|ACTIVE_COMPARATOR|Immediate-released oxycodone|Immediate-released oxycodone Q6H, initial daily dose is 20mg + immediate-released oxycodone for PRN
62659805|NCT04521803|NO_INTERVENTION|Arm 1: Standard of care (RIF10)|Dosing of the daily oral RHZE fixed dose combination (FDC) will be according to WHO weight bands
62293507|NCT03506503|EXPERIMENTAL|processed Nanofat grafting|processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia.
62293508|NCT03537040|OTHER|Method of Levels|Talking therapy- duration and frequency of sessions to be determined by participant
62293509|NCT06546865|ACTIVE_COMPARATOR|22F Sheath Size|Comparator arm for procedures using 22F sheath size
62293510|NCT06546865|ACTIVE_COMPARATOR|26F Sheath Size|Comparator arm for procedures using 26F sheath size
62293511|NCT01083914||OPCAB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
62736925|NCT03742310|EXPERIMENTAL|identical supplement group|"Take vitamin D supplements according to genotype. If the genotype result is high risk, we will give vitamin d 800 international unit(IU)/d, when the result is middle risk, we will give 600 international unit(IU)/d, when the result is low risk, we will give 400 international unit(IU)/d."
62096212|NCT01416909|ACTIVE_COMPARATOR|Assessment Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be determined based on their severity of constipation.
62096213|NCT01416909|OTHER|Control Group - Opioid|Standard of Care: Participants Receiving Opioids for the Treatment of Pain will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
62096214|NCT01416909|ACTIVE_COMPARATOR|Assessment Intervention - Vinca Alkaloid|Laxative Treatment: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on their level of constipation.
62096215|NCT01416909|OTHER|Control Group - Vinca Alkaloid|Standard of Care: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Patients will receive standard of care while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
62293512|NCT01083914||CPB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
62293513|NCT01083914||MECC|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
62293514|NCT02359786||Genetic Testing Subjects undergoing genetic testing|
62293515|NCT02359786||Topicals Subjects using topical compounds|
62293516|NCT02359786||Patients undergoing Spinal Surgery using IOM|
62293517|NCT02359786||Spine Patients undergoing cervical or lumbar surgery|
62293518|NCT02359786||Total Joint Patients undergoing knee and hip replacement|
62293519|NCT02359786||UDT (unrinary drug test) Patients who are given a UDT|
62293520|NCT01057277|EXPERIMENTAL|RAD001(Afinitor)|Radiation 47 days Cisplatin day 1,8,15,22,29,36,43 RAD001 Day 1 according to assigned group to day 47
62293521|NCT03069651|ACTIVE_COMPARATOR|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
62293522|NCT03069651|PLACEBO_COMPARATOR|Routine Care|Usual clinical care.
62293523|NCT02968355||Subjects/Specimens|Subjects/Specimens that meet the eligibility criteria
62293524|NCT04680650|EXPERIMENTAL|Group DS|Anesthesia was maintained with sevoflurane and target-controlled infusion of remifentanil in the group DS
62293525|NCT04680650|ACTIVE_COMPARATOR|Group DP|Anesthesia was maintained with propofol and target-controlled infusion of remifentanil in the group DP
62293526|NCT03461055|EXPERIMENTAL|Lavender|Lavandula angustifolia aromatherapy. 1 drop on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
62293527|NCT03461055|PLACEBO_COMPARATOR|Water|1 drop of water on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
61908873|NCT02653703|PLACEBO_COMPARATOR|Vehicle, topical ethanol 96%|Exposure: 10 % topical trans-cinnamaldehyde \[CAS Number: 14371-10-9\] Vehicle: 96% ethanol
62096216|NCT00708279|EXPERIMENTAL|A|After establishing a baseline for the first 4 weeks of trial involvement, thereby providing their own control group, all participants begin the intervention phase of osteopathic manipulation.
62096217|NCT01095224|EXPERIMENTAL|rAd35 Env A and rAd5 Env A|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
62096218|NCT01095224|EXPERIMENTAL|rAd35 Env A and rAd5 Env B|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
62096219|NCT01095224|EXPERIMENTAL|rAd35 Env A and rAd35 Env A|Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
62096220|NCT01095224|EXPERIMENTAL|rAd5 Env A and rAd5 Env A|Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
62293528|NCT02429999|ACTIVE_COMPARATOR|Letrozole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75 international unit(IU) /day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till human chorionic gonadotrophin (hCG) injection.
62293529|NCT02429999|ACTIVE_COMPARATOR|Standered protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225 international unit/day) from day 2. We will give them at first 225 international unit FSH for 5 days.
62293530|NCT05410990||mortality, MACE (+)|patients with all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
62293531|NCT05410990||mortality, MACE (-)|patients without all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
62465782|NCT03597711|ACTIVE_COMPARATOR|IVCannulation 26G safety cannula|Peripheral Intravenous cannulation using 26G safety cannula
62096221|NCT01095224|EXPERIMENTAL|rAd5 Env A and rAd5 Env B|Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
62096222|NCT03770377|EXPERIMENTAL|Stroke without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
62096223|NCT03770377|EXPERIMENTAL|Stroke with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
62293532|NCT03205579|EXPERIMENTAL|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
62293533|NCT03205579|ACTIVE_COMPARATOR|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
62293534|NCT04003714|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation Group|Patients in r-TMS group received r-TMS 20-min (1000 pulses) daily session, 5 days per weeks, for a total of 10 sessions.
62293535|NCT04003714|SHAM_COMPARATOR|Sham Group|Control group received sham r-TMS with the same protocol.
62096224|NCT03770377|EXPERIMENTAL|SCA6 without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
62096225|NCT03770377|EXPERIMENTAL|SCA6 with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
62096226|NCT03770377|ACTIVE_COMPARATOR|Age-Matched Controls|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
62293536|NCT01126346|EXPERIMENTAL|Arm I|Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
62293537|NCT01724892|ACTIVE_COMPARATOR|Loteprednol etabonate|Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks
62293538|NCT01724892|ACTIVE_COMPARATOR|Dexamethasone|Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks
62293539|NCT03978273|EXPERIMENTAL|Night-time brace + virtual-brace|Patients are conventionally treated with night-time brace. Additionally, they use the new developped virtual-brace (MD).
62293540|NCT03978273|ACTIVE_COMPARATOR|Night-time brace only|Patients are conventionally treated with night-time brace only.
62293541|NCT04495660|EXPERIMENTAL|Severe/profoundly deaf children 10-24 months old|The cohort 1 includes patients aged 10-24 months old about to be implanted
62293542|NCT04495660|EXPERIMENTAL|Severe/profoundly deaf children 3-7 years old|The cohort 2 includes 3-7 years old cochlear implanted patients (implanted before 24 months of age)
62659806|NCT04521803|EXPERIMENTAL|Arm 2: High-dose RIF (RIF35)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used39
61908874|NCT02653703|EXPERIMENTAL|Topical L-menthol 40%|Exposure: 10 % trans-cinnamaldehyde \[CAS Number: 14371-10-9\] Intervention: 40% l-menthol \[CAS Number: 2216-51-5\] Vehicle: 96% ethanol
62096227|NCT06613919|EXPERIMENTAL|Six months|Six months anti-TB therapy
62465783|NCT03597711|ACTIVE_COMPARATOR|IVCannulation 24G safety cannula|Peripheral Intravenous cannulation using 24G safety cannula
62096228|NCT06613919|ACTIVE_COMPARATOR|Nine months|Nine months anti-TB therapy
62096229|NCT02249481|ACTIVE_COMPARATOR|Group F|Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
62096230|NCT02249481|EXPERIMENTAL|Group A|Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
62293543|NCT04495660|OTHER|Normally hearing children 10-24 months old|The cohort 1 includes patients aged 10-24 months matched in age and sex with normally hearing children
62096231|NCT06342258|EXPERIMENTAL|Heads|Heads indicates the RIGHT side of mouth WILL be cured prior to sealant placement. The left side of the mouth will have bond and sealant cured together after.
62096232|NCT06342258|EXPERIMENTAL|Tails|Tails indicates the LEFT side of the mouth WILL be cured prior to sealant placement. The right side of the mouth will not have bond cured prior to sealant placement.
62096233|NCT03840070|EXPERIMENTAL|Potenfill|
62096234|NCT03810885|EXPERIMENTAL|Salt reduced bread|Bread with reduced salt content
62293544|NCT04495660|OTHER|Normally hearing children 3-7 years old|The cohort 2 includes 3-7 years old matched in sex and age with cochlear implanted patients
62293545|NCT04210726|ACTIVE_COMPARATOR|Active Group - 25% Saline Bath|The Active group's patients will separately have an immersion bath in 25% Sea Salt in Water solution (made by adding pure Sodium Chloride in the form of Sea Salt to Tap Water Bath) at a temperature comfortable to every participant (please note that Solubility of Sodium Chloride in Water does not change significantly with change in temperature, therefore the concentration will remain the same regardless of water temperature), whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers.
62293546|NCT04210726|PLACEBO_COMPARATOR|Control Group - 0.9% Saline Bath|The Control group's patients will separately have a bath in 0.9% Sea Salt in Water (Isotonic solution, made by adding Sodium Chloride in form of Sea Salt to Tap Water) at a comfortable temperature whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers
62293547|NCT01708031|EXPERIMENTAL|stress inducing task|Normal subjects without history medication presently will be participated. Stress induced through stress inducing task (mental arithmetic task), the physiological signals collected before and during the task simultaneously. All the subjects will be participating only once in this MAT based study. Because, the stress will not be possible to induce when the subject is more familiar with the stress inducing task.
62293548|NCT01883037||Laboratory blood glucose|Blood glucose value from Lab
62293549|NCT01883037||HemoCue Glucose 201 RT|Blood glucose value from HemoCue Glucose 201 RT
62293550|NCT02983604|EXPERIMENTAL|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
62308100|NCT02682329|ACTIVE_COMPARATOR|CP 10% + HP 40%|Carbamide Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. CP at home and HP at office
62465784|NCT04403997|ACTIVE_COMPARATOR|Chromoendoscopy with methylene blue 0.1%|Once the cecum is reached, a spray catheter is introduced through the working channel and the dye, a 0.1% methylene blue solution, is applied.
62465785|NCT04403997|EXPERIMENTAL|Virtual Chromoendoscopy with NBI with HQ190 endoscopes|Intubation is done with normal white light. Once the cecum is reached, the removal will be done in NBI mode
62465786|NCT01126125|EXPERIMENTAL|Iodized oil to mother|400 mg iodine as iodized oil to breastfeeding mother
62659807|NCT06022055|EXPERIMENTAL|epileptic patients|All patients will be enrolled in the same arm. Patients can be enrolled during the pre-surgical evaluation (group 1) or in the days preceding the surgery (group 2).
61908875|NCT01369329|PLACEBO_COMPARATOR|001|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
62096235|NCT03810885|EXPERIMENTAL|Dietary advice and Salt reduced bread|bread with reduced salt content, dietary advice
62096236|NCT03810885|PLACEBO_COMPARATOR|Normal bread|Bread with standard salt content
62096237|NCT00578695|EXPERIMENTAL|Active|Lixivaptan
62096238|NCT00578695|PLACEBO_COMPARATOR|Placebo|Placebo
62096239|NCT04034238|EXPERIMENTAL|1. Dose escalation|LMB-100 at escalating doses plus tofacitinib
62096240|NCT04034238|EXPERIMENTAL|2. Dose expansion|LMB-100 at optimal dose plus tofacitinib
62659808|NCT05559541|EXPERIMENTAL|AK119+AK104|AK119 and AK104 IV every 2 or every 3 weeks.
62096241|NCT04990687|EXPERIMENTAL|Intervention Group|Treatment effects will be measured using standard rating scales including the HDRS-17, MADRS, SF-36, CSSR-S, CGI-I, CGI-S, which will be completed at each visit. The following scales will be completed at every other visit following the screening visit: Social Anhedonia Scale, the Motivation and Energy Inventory and the Physical Anhedonia Scale. At each study visit safety assessments including vital sign assessment and adverse event assessment will be completed. Subjects will also undergo physical examination and an ECG for safety during screening, after 8 weeks of treatment and at the end of 12 weeks of treatment.
62659809|NCT05181384|EXPERIMENTAL|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
61908876|NCT01369329|EXPERIMENTAL|002|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
61908877|NCT01369329|EXPERIMENTAL|003|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg) 390 mg (weight \> 55 kg and \<= 85 kg) and 520 mg (weight \> 85 kg).
61908878|NCT01552798|EXPERIMENTAL|Arm 1|
61908879|NCT01552798|ACTIVE_COMPARATOR|Arm 2|
61908880|NCT01552798|PLACEBO_COMPARATOR|Arm 3|
61908881|NCT01788410||Cryoablation under image guidance|Patients with facet joint disease, or compressed or damaged nerve roots causing pain in the head, neck or spine. Procedures performed with MRI Seednet Cryotherapy System (Galil Medical).
62096242|NCT02582203|ACTIVE_COMPARATOR|Ceftaroline|600 mg IV (over 1 hour) every 12 hours for renal function \> 50 mL/min, adjusted for renal function based on package insert for no more than 14 days.
62465787|NCT01126125|ACTIVE_COMPARATOR|Iodized oil to infant|100 mg of iodine as iodized oil to infant
62659810|NCT05181384|ACTIVE_COMPARATOR|Exercise group|pelvic floor muscle training
62659811|NCT05181384|PLACEBO_COMPARATOR|Control group|pelvic girdle education
62659812|NCT02552602|ACTIVE_COMPARATOR|Group A|Study participants in this arm will be given Multivitamin A
62465788|NCT03064880|ACTIVE_COMPARATOR|SV maximization|Dynamic fluid responsiveness parameters, such as stroke volume (SV) response to fluid therapy, are precise fluid indicators that specifically determine patient volume status and are helpful for clinicians to determine the appropriate time for fluid bolus. For SV maximization, the investigators maximize SV after anesthetic induction by fluid therapy up to achieve maximized SV maintained.
62096243|NCT02582203|ACTIVE_COMPARATOR|Vancomycin|Dosed by institutional pharmacy protocol to reach goal trough level of 10 - 20 mg/L steady state concentration for no more than 14 days.
62096244|NCT03409718||Biomet Comprehensive Shoulder System|Subjects in need of a total shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Shoulder System.
62659813|NCT02552602|ACTIVE_COMPARATOR|Group B|Study participants in this arm will be given Multivitamin B
62096245|NCT04100356|EXPERIMENTAL|Normal diet|The group ingests normal diet, recommended by the health authorities
62659814|NCT02552602|ACTIVE_COMPARATOR|Group C|Study participants in this arm will be given Multivitamin C
62096246|NCT04100356|EXPERIMENTAL|LCHF diet|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat
62096247|NCT04100356|EXPERIMENTAL|Normal diet + exercise|The group ingests normal diet, recommended by the health authorities in addition to exercise program 3x week.
62096248|NCT04100356|EXPERIMENTAL|LCHF diet + exercise|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat, in addition to exercise program 3x week.
62659815|NCT01927588|EXPERIMENTAL|Everolimus+Tacrolimus+Prednisone|Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
61908882|NCT02600871|EXPERIMENTAL|Provodine|"Provodine patients will have standard care including incision and drainage. The contents of 1 packet of Provodine applied with a Q-tip to the walls and floor of the abscess cavity. The contents of a 2nd packet will be applied to the surrounding skin within 5 cm around the incision.~Provodine patients will return within 48-72 hours for a follow-up visit, have the packing removed and the contents of the packet reapplied to the abscess cavity and surrounding skin.~Provodine patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will wash their hands with soap and water, pat dry, and apply the contents of 1 packet of Provodine to dorsum and palmar aspects of hands and fingers and rub together for 1 minute. They will apply the contents of a 2nd packet to the abscess cavity, and a 3rd packet to the surrounding skin. They will be then rinse their hands with water, pat dry, and cover the wound with 4x4 gauze."
62096249|NCT04610684|EXPERIMENTAL|Study Treatment Arm|4 cycles of induction treatment with Atezolizumab (1200 mg on Day 1) combined with carboplatin (5-6 AUC on Day 1) and etoposide (80-100 mg/m2 on Days 1-3). After 4 cycles of induction treatment, subjects will receive atezolizumab maintenance 1200 mg on Day 1 of each 3-week cycle.
62096250|NCT05196594||Affected group by transthyretinal amyloidosis with cardiac involvement|collection of stools
62465789|NCT03064880|NO_INTERVENTION|SV normalization|NO active fluid therapy.
62096251|NCT05196594||Affected group by transthyretinal amyloidosis without cardiac involvement|collection of stools
62096252|NCT05196594||healthy control group|collection of stools
62096253|NCT04544540|EXPERIMENTAL|One-Unit|Patients will be randomized to receive 1-unit of red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 1-unit
62096254|NCT04544540|EXPERIMENTAL|Two-Unit|Patients will be randomized to receive 2-unit sof red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 2-units
62659816|NCT01927588|ACTIVE_COMPARATOR|Mycophenolate+Tacrolimus+Prednisone|Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
62659817|NCT05047926|EXPERIMENTAL|Cohort 1 (surveys, CT, blood samples)|Patients undergoing primary surgical intervention complete surveys, undergo CT, and undergo collection of blood samples at baseline.
62659818|NCT05047926|EXPERIMENTAL|Cohort 2 (exercise, supplement, Resilient Living)|Patients undergoing neoadjuvant chemotherapy complete physical activity for 30 minutes per day 3 times a week. Patients receive nutritional supplement drink up to 4.5 times daily, and complete Resilient Living program in-person or remotely over 60 minutes. Patients also undergo CT scans throughout the trial.
62659819|NCT05047926|EXPERIMENTAL|Cohort 3 (exercise, supplement, coaching, Resilient Living)|Patients undergoing neoadjuvant chemotherapy complete physical activity remotely for 30 minutes per day 3 times a week. Patients receive nutritional supplement drink up to 4.5 times daily. Patients also undergo health coaching remotely for 60 minutes weekly, complete Resilient Living program remotely over 60 minutes, and may wear a FitBit throughout the study.
62659820|NCT02019069|EXPERIMENTAL|Liposomal cytarabine-daunorubicin CPX-351|"* 1st INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV at a dose of 65 units/m2/day over 90 minutes on days 1, 3, and 5.~* 2nd INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3.~* CONSOLIDATION: Beginning on day 28, patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3."
62659821|NCT02328105|EXPERIMENTAL|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m\^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
62096255|NCT06486935||Time period prior to & after the implementation of IoT sensors|Since our study involves a single group of 19 participants, we will evaluate their quality of life at two different times: before and after the introduction of IoT sensors.
62096256|NCT05476822||Adults who received a full course of COVID-19 vaccine and booster|Adults at Travis Air Force Base who are Active Duty, DoD beneficiaries, and civilian employees who present with a vaccination card verifying they have received a full course of mRNA spike protein COVID vaccine (Moderna, Pfizer, or Johnson \& Johnson) and booster will have antibody titers performed from blood drawn at time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
62096257|NCT02941146|EXPERIMENTAL|Zeltiq Dual Sculpting Treatment Group|All subjects treated with CoolSculpting System using the CoolAdvantage and CoolAdvantage Plus applicators simultaneously on the abdomen.
62096258|NCT01799408||betamethasone|Patients who had intra-articular injection of betamethasone
62293551|NCT02983604|EXPERIMENTAL|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
62659822|NCT00687518|EXPERIMENTAL|1|erythropoietin
62096259|NCT01799408||Hyaluronic acid|Patients who had intra-articular injection of hyaluronic acid
62659823|NCT00687518|PLACEBO_COMPARATOR|2|Saline serum
62659824|NCT03991039|ACTIVE_COMPARATOR|Gamma knife group|Patients selected to be treated with gamma knife radiosurgery
62096260|NCT00002556|ACTIVE_COMPARATOR|ARM A (VBMCP)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive VBMCP as in the induction phase. Courses repeat every 35 days in the absence of disease progression or unacceptable toxicity."
62293552|NCT02983604|EXPERIMENTAL|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
62293553|NCT02983604|ACTIVE_COMPARATOR|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
62293554|NCT00618722|EXPERIMENTAL|Deoxycholic Acid Injection 1 mg/cm²|Participants received 0.5% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (1 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62293555|NCT00618722|EXPERIMENTAL|Deoxycholic acid Injection 2 mg/cm²|Participants received 1.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (2 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62293556|NCT00618722|EXPERIMENTAL|Deoxycholic acid Injection 4 mg/cm²|Participants received 2.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (4 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62293557|NCT00618722|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered in 0.2 mL injections, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62293558|NCT03872492|EXPERIMENTAL|Patients with Major Depressive Disorder|"Patients will be followed for 12 weeks. Hospital visits will be made at week 2 and week 6 (Phase1) as well as week 8 and week 12 (Phase 2).~At the end of phase 1 if the patient is considered as an responder he will make one more visit at week 12.~If the patient is considered as non-responder, he will make 2 other visits: at week 8 and week 12.~Between each visit, the patient will perform REDRESS application assessments every day for My daily survey and every 3 days for the other assessments."
62293559|NCT05699655|EXPERIMENTAL|Tislelizumab combined with apatinib and oxaliplatin plus S1|
62293560|NCT05699655|ACTIVE_COMPARATOR|oxaliplatin plus S1|
62293561|NCT01055509|EXPERIMENTAL|Cognitive Adaptation Training|Cognitive adaptation training and treatment as usual
62465790|NCT04305782|EXPERIMENTAL|Release/Relock Socket - In Lab|The test socket will be operated by the participant in lab, following a structured protocol. This arm focuses on the order effects on the re-lock panel and pin mechanisms on limb volume.
62659825|NCT03991039|ACTIVE_COMPARATOR|MVD Group|Patients treated with microvascular decompression
62659826|NCT03399084|EXPERIMENTAL|Ferric carboxymaltose (test)|Patients will receive a single dose of Ferric carboxymaltose
62659827|NCT03399084|ACTIVE_COMPARATOR|Ferric carboxymaltose (reference)|Patients will receive a single dose of Ferric carboxymaltose
62736926|NCT03742310|NO_INTERVENTION|control group|General dose. Whatever the result is, we all give 400 international unit(IU)/d.
62736927|NCT05773807|EXPERIMENTAL|BIS group|In the BIS group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ml every two minutes to maintain the BIS value at 45-60.
62096261|NCT00002556|EXPERIMENTAL|Arm B (VBMCP, high dose cyclophosphamide, r alpha 2b IFN)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive vincristine sulfate, carmustine, and melphalan as in the induction phase, high-dose cyclophosphamide IV on days 1-4 and prednisone PO on days 1-4 during courses 3 and 5. Patients receive VBMCP as in the induction phase during even numbered courses. Patients receive recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22 during odd courses beginning course 7. Treatment repeats every 35 days for courses 3-5, every 21 days for even courses beginning course 6, and every 22 days for odd courses beginning course 7 in the absence of disease progression or unacceptable toxicity."
62659828|NCT02711137|EXPERIMENTAL|Part1/Treatment Group A : 8mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
62659829|NCT02711137|EXPERIMENTAL|Part1/Treatment Group A : 12mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
62096262|NCT04737590|ACTIVE_COMPARATOR|Bioactive glass|20 bone cysts (in 20 patients) are filled with bioactive glass
62659830|NCT02711137|EXPERIMENTAL|Part1/Treatment Group A : 16mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
62096263|NCT04737590|ACTIVE_COMPARATOR|Allogenic bone|20 bone cysts (in 20 patients) are filled with allogenic bone
62096264|NCT04968587|OTHER|Group 1: RACD - RCA|First period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED and second period of treatment with Regional Citrate Anticoagulation SLED
62096265|NCT04968587|OTHER|Group 2 : RCA - RACD|First period of treatment with Regional Citrate Anticoagulation SLED and second period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED
62096266|NCT03037060|EXPERIMENTAL|Experimental|"5 experimental sessions per participant:~(1) \[11C\]-(+)-PHNO PET scan, (2), Alcohol Self-Administration, (3) Craving Task, (4) MRI scan and (5) Neuropsychological Assessment."
62096267|NCT05744128|OTHER|Single Arm|"Eligible subjects will receive up to two zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 2.0 mCi ± 20% and 3.0 mg API) as an IV infusion or slow bolus injection.~PET/CT imaging is performed 24hrs ± 3hrs post administration. The two scans are performed a minimum 2 weeks apart."
62096268|NCT02055209||1|Adults only, all genders, US born African American
62096269|NCT06576908|EXPERIMENTAL|HyperSight Imaging arm|Subjects have both HyperSight and conventional CBCT imaging.
62096270|NCT06156007|EXPERIMENTAL|progressive muscle relaxation exercises|Women will be given one-time progressive muscle relaxation exercise training prepared by the researcher. In the training, the exercise will be demonstrated through demonstration method. Following training, women will be asked to perform progressive relaxation exercise at least 3 times a week (every other day). Women will be followed for 8 weeks with a progressive muscle relaxation exercise daily follow-up chart prepared by the researcher, and weekly reminders will be made (via WhatsApp® or text message). The final test will be administered to women online at the end of 8 weeks. RLS Severity Rating Scale form, Johns Hopkins Restless Legs Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used in the pre-test and post-test applications.
62096271|NCT06156007|NO_INTERVENTION|no intervention|No intervention will be applied to women. Posttest application to women; It will be conducted online 8 weeks after the pre-test application. RLS Severity Rating Scale form, Johns Hopkins Restless Legs Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used in the pre-test and post-test applications.
62096272|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
62659831|NCT02711137|EXPERIMENTAL|Part1/Treatment Group B : 8mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF
62659832|NCT02711137|EXPERIMENTAL|Part1/Treatment Group B : 12mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF.
62659833|NCT02711137|EXPERIMENTAL|Part1/Treatment Group C : 8mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group C (TGC), based on protocol-specific criteria. Treatment Group C includes subjects with MM
61908883|NCT02600871|ACTIVE_COMPARATOR|Standard Care|"Standard care patients will have standard care including incision and drainage.~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
61908884|NCT04375319|EXPERIMENTAL|OCT guided 3-month follow-up group|OCT guided the operation, and OCT reexamined 3 months after the operation to evaluate the vascular repair
62096273|NCT06313723|EXPERIMENTAL|İntervention group (n:52)|Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure.Pregnant women in the intervention group will be made to listen to 3 podcasts consisting of 3 modules lasting an average of 5-6 minutes during the Non-Stress Test. After the podcast is prepared, it will be edited in line with expert opinion and its final version will be given.
62096274|NCT06313723|NO_INTERVENTION|Control group (n:52)|"Pregnant women assigned to the control group were given T.R. treatment within the scope of routine care. The Ministry of Health's Pregnancy and Birth Process booklet will be given and the pregnant woman's questions will be answered on the topics she wants to get information about."
62659834|NCT02711137|EXPERIMENTAL|Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort|Initial cohort dose of INCB054763 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group A (TGA), based on protocol-specific criteria. Part 2 Treatment Group A expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
62096275|NCT02724267|ACTIVE_COMPARATOR|transcatheter arterial chemoembolization|Patients will be treated with TACE only.
62096276|NCT02724267|EXPERIMENTAL|internal radiation group|Patients will be treated with TACE combined with internal radiation.
62096277|NCT02429609|EXPERIMENTAL|Keratoconic subjects|"1. Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~2. Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~3. Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~4. Anterior eye examination (approx. 4 minutes)~5. Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~6. Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~1. Standard ETDRS logMAR acuity measurement (5 minutes)~2. Vanishing Optotype logMAR acuity measurement (5 minutes)"
62096278|NCT02429609|EXPERIMENTAL|Healthy subjects|"1. Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~2. Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~3. Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~4. Anterior eye examination (approx. 4 minutes)~5. Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~6. Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~1. Standard ETDRS logMAR acuity measurement (5 minutes)~2. Vanishing Optotype logMAR acuity measurement (5 minutes)"
62096279|NCT00647413|NO_INTERVENTION|1|
62293562|NCT01055509|NO_INTERVENTION|Treatment as ususal|Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives.
62308101|NCT02682329|ACTIVE_COMPARATOR|CP 15% + HP 40%|Carbamide Peroxide 15% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
62659835|NCT02711137|EXPERIMENTAL|Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort|Initial cohort dose of INCB057463 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group B (TGB), based on protocol-specific criteria. Part 2 Treatment Group B expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
62659836|NCT02711137|EXPERIMENTAL|Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg|Initial cohort dose of INCB057643 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Gemcitabine) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies where Gemcitabine is relevant
62465791|NCT04305782|EXPERIMENTAL|Release/Relock Socket - Out of Lab|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the effects of the re-lock panel and pin mechanisms on participant comfort.
62659837|NCT02711137|EXPERIMENTAL|Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Paclitaxel) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
62659838|NCT02711137|EXPERIMENTAL|Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Rucaparib) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
62659839|NCT02711137|EXPERIMENTAL|Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Abiraterone + Prednisone) in Castration Resistant Prostrate Cancer
62659840|NCT02711137|EXPERIMENTAL|Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Ruxolitinib) in Myelofibrosis.
62465792|NCT04305782|EXPERIMENTAL|Release/Relock Socket & Control|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the comparing participant experience using the novel mechanism versus traditional socket mechanisms.
62465793|NCT01532297|ACTIVE_COMPARATOR|HD treated with standard dialysate|
62465794|NCT01532297|ACTIVE_COMPARATOR|post-dilution oHDF with standard dialysate|
61908885|NCT04375319|NO_INTERVENTION|3-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 3 months after operation to evaluate vascular repair
62659841|NCT02711137|EXPERIMENTAL|Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Azacitidine) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
61908886|NCT04375319|NO_INTERVENTION|6-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 6 months after operation to evaluate vascular repair
62096280|NCT00647413|EXPERIMENTAL|2|expert system intervention on smoking behaviour + feedback of a biomarker
62096281|NCT01230034|EXPERIMENTAL|Imidapril|10 and 20 mg/day, pill
62096282|NCT01230034|ACTIVE_COMPARATOR|Ramipril|5 and 10 mg/day, pill
62096283|NCT05714553|EXPERIMENTAL|Module 1 (NUC-3373 + LV + pembrolizumab)|"This Module is designed to evaluate the tolerability and the overall safety profile of NUC-3373 (1875 mg/m2) + LV (400 mg/m2) + pembrolizumab (200 mg) in the treatment of patients with advanced solid tumours (dose validation phase).~NUC-3373 and LV will be administered on Days 1, 8 and 15 and pembrolizumab will be administered on Day 1 of 21-day cycles. The dosing schedule may be adjusted based on emerging data with agreement from the Safety Review Committee. Following completion of the dose validation phase, expansion cohorts may be initiated at the selected dose level."
62096284|NCT05714553|EXPERIMENTAL|Module 2 (NUC-3373 + LV + docetaxel)|"This Module is designed to assess NUC-3373 (750 mg/m2) + LV (400 mg/m2) + docetaxel (55 mg/m2) for the treatment of patients with advanced/metastatic NSCLC or pleural mesothelioma who have progressed on, or were unable to tolerate, 1 or 2 prior lines of cytotoxic chemotherapy-containing regimens for advanced/metastatic disease (dose validation phase).~NUC-3373 and LV will be administered on Days 1 and 22 and docetaxel will be administered on Day 8 of 28-day cycles. The dosing schedule may be adjusted based on emerging data with agreement from the Safety Review Committee. Following completion of the dose validation phase, expansion cohorts may be initiated at the selected dose level."
62096285|NCT02333773|EXPERIMENTAL|Group A|irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
62293563|NCT06494579|EXPERIMENTAL|Participants with Relapsed Refractory Solid Tumors|Participants with Solid Tumors which are typically treated with cancer immunotherapy (PD-1 or PD-L1 blocking antibodies) and their cancer has progressed on immunotherapy will be candidates for the trial. This is a single-arm trial.
62293564|NCT03421015||case group|patients with biochemical recurrence and positive imaging (case group)
62293565|NCT03421015||Control Group|patients without biochemical recurrence (control group)
62293566|NCT02335502||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
62465795|NCT01532297|EXPERIMENTAL|pre-dilution oHDF with citrate dialysate|
62659842|NCT05066529|EXPERIMENTAL|dry-needling group|"32 participants in this group Dry-needling treatment will be applied once a week for three weeks. Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
62659843|NCT05066529|OTHER|exercise group|"32 participants in this group Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
62096286|NCT02333773|EXPERIMENTAL|Group B|irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
62096287|NCT02333773|EXPERIMENTAL|Group C|irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
62293567|NCT02428504||End of life decision|
62293568|NCT01642212|EXPERIMENTAL|Oral Budesonide Suspension|Taken once or twice daily for up to 40 weeks
62293569|NCT01642212|PLACEBO_COMPARATOR|Matching Placebo|Taken once or twice daily for 20 weeks
62659844|NCT03860688|EXPERIMENTAL|Teduglutide + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
61908887|NCT04925856|EXPERIMENTAL|Experimental|"4 différents cohorts:~* Paclitaxel cohort (N=30)~* Epirubicine - cyclophosphamide cohort (N=30)~* Eribuline cohort (N=30)~* Palbociclib (N=20) ou Abemaciclib (N=20) ou Ribociclib cohort (N=21)~Study diagram :~* Inclusion and screening visite~* Visit 1: J1C1~* Visit 2 : J8C1 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C1 to Palbociclib ou Abemaciclib ou Ribociclib cohort~* Visit 3 :J21C1~* Visit 4 : J8C3 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C3 to Palbociclib ou Abemaciclib ou Ribociclib cohort~During these visits, we collect, before the start of treatment administration ;~* Vital signs,~* Concomitant treatments,~* Blood sample:~  * 1 heparinized tube (4 mL) for collection of plasma and storage~ * 1 heparinized tube (4 mL) for immunophenotyping,~ * 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
61908888|NCT04874051|EXPERIMENTAL|Experimental Group (EG)|In the EG the subjects will perform balance exercises using the OAK system under the supervision of a trained physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
61908889|NCT04874051|ACTIVE_COMPARATOR|Control Group (CG)|In the CG the subjects will be asked to perform conventional balance exercises under the supervision of a physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
61908890|NCT01605500||Medtronic ICDs|Patients with Generation 2 Medtronic ICDs
62465796|NCT01532297|EXPERIMENTAL|HD treated with citrate dialysate|
62465797|NCT01532297|EXPERIMENTAL|post-dilution oHDF with citrate dialysate|
62659845|NCT01549509|EXPERIMENTAL|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
62659846|NCT05374928||Cohort 1: Newly Diagnosed Idiopathic Generalized Epilepsy (IGE)|Cohort 1 will have IGE that was diagnosed within the prior year. We will follow these participants for a minimum of two years.
62659847|NCT05374928||Cohort 2: Longstanding Treatment Responsive|Cohort 2 will consist of subjects with established IGE who have been responsive to treatment.
62659848|NCT05374928||Cohort 3: Longstanding IGE, Treatment Resistant|Cohort 3 will consist of patients with established treatment-resistant IGE.
62659849|NCT01403584|EXPERIMENTAL|AutoVPAP with addition of AutoEPAP|This arm will receive conventional device modified to enable algorithm for automatically applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
62659850|NCT01403584|ACTIVE_COMPARATOR|AutoVPAP without addition of AutoEPAP|This arm will receive conventionally applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
62659851|NCT02959268|OTHER|Single arm Al-Sense diagnostic|Investigator blinded to subject assessments
62659852|NCT05515419|EXPERIMENTAL|Allogeneic cord blood therapy|Allogeneic cord blood therapy
62659853|NCT01801254|EXPERIMENTAL|STRIDES|Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
62659854|NCT01801254|SHAM_COMPARATOR|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior. Stimuli used and durations of training sessions for this protocol are identical to those used in the treatment condition.
62659855|NCT03033888|OTHER|Intervention Group|Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
62659856|NCT03033888|NO_INTERVENTION|Control Group|
62659857|NCT02411955|EXPERIMENTAL|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% (Taro Pharmaceuticals Inc.)
61908891|NCT01167387|EXPERIMENTAL|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
61908892|NCT01167387|PLACEBO_COMPARATOR|water|The control group will receive plain water with the same volume and timing of treatment.
61908893|NCT04218565|EXPERIMENTAL|Golimumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
61908894|NCT02802046||FFR≦0.8|FFR is a score of 0 to 1, FFR \< 0.75, has proved almost always accompanied by myocardial ischemia.
62465798|NCT01532297|ACTIVE_COMPARATOR|pre-dilution oHDF with standard dialysate|
62659858|NCT02411955|ACTIVE_COMPARATOR|Tazorac®|Tazorac® (tazarotene cream 0.1%) (Allergan LLC)
62659859|NCT02411955|PLACEBO_COMPARATOR|Placebo|Placebo (Vehicle of the test product) (Taro Pharmaceuticals Inc.)
62659860|NCT04664309||Participants|Adults who are receiving a COVID-19 vaccine
62659861|NCT01143792|EXPERIMENTAL|CRA + HIV prevention|
61908895|NCT02802046||FFR>0.8|FFR \> 0.80 almost never associated with myocardial ischemia.
62096288|NCT01941316|EXPERIMENTAL|Phase II|"Phase II: Stratified, single arm trial using a starting dose of 20/36 mg/m\^2 of carfilzomib and 125 mg/m\^2 of irinotecan, in small cell lung cancer patients who have relapsed on a prior platinum regimen.~Stratification for phase II component:~1. Platinum sensitive disease: initial response to platinum-based chemotherapy with progression \> 90 days after last treatment.~2. Platinum refractory disease: No response to platinum-based chemotherapy or progression within 90 days of completing platinum-based therapy. Subjects that progressed during or within one month of completion of platinum-based chemotherapy will be excluded."
62096289|NCT01941316|EXPERIMENTAL|Phase Ib Cohort 1: 20/27 mg/m^2 Carfilzomib, 125 mg/m^2 Irinotecan|"Cohort 1 of Phase Ib run-in to determine maximum tolerated dose (MTD) of Carfilzomib (Day 1,2,8,9, 15, and 16) in combination with Irinotecan (Days 1, 8, 15) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers.~Cohort 1 used a starting dose of 20/27 mg/m\^2 of carfilzomib in combination with 125 mg/m\^2 of irinotecan."
62096290|NCT01941316|EXPERIMENTAL|Phase Ib Cohort 2: 20/36 mg/m^2 Carfilzomib, 125 mg/m^2 Irinotecan|"Cohort 2 of Phase Ib run-in to determine maximum tolerated dose (MTD) of Carfilzomib (Day 1,2,8,9, 15, and 16) in combination with Irinotecan (Days 1, 8, 15) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers.~Cohort 2 used a starting dose of 20/36 mg/m\^2 of carfilzomib in combination with 125 mg/m\^2 of irinotecan."
62096291|NCT01941316|EXPERIMENTAL|Phase Ib Cohort 1: 20/45 mg/m^2 Carfilzomib, 125 mg/m^2 Irinotecan|"Cohort 3 of Phase Ib run-in to determine maximum tolerated dose (MTD) of Carfilzomib (Day 1,2,8,9, 15, and 16) in combination with Irinotecan (Days 1, 8, 15) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers.~Cohort 3 used a starting dose of 20/45 mg/m\^2 of carfilzomib in combination with 125 mg/m\^2 of irinotecan."
62096292|NCT06004167|EXPERIMENTAL|5-5-5 Adaptive Bridging Radiation Therapy (ABRT)|5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion
62096293|NCT04592237|EXPERIMENTAL|Group I (niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62096294|NCT04592237|EXPERIMENTAL|Group II (cetrelimab, niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62096295|NCT05492474|EXPERIMENTAL|Cranial Point of Care Ultrasound|Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane
62096296|NCT03830775|EXPERIMENTAL|Experimental - PRP injection|2cc of PRP is injected into the ulnocarpal joint
62096297|NCT03830775|PLACEBO_COMPARATOR|control - Saline injection|2cc of 0.9% sterile saline is injected into the ulnocarpal joint
62659862|NCT01143792|ACTIVE_COMPARATOR|Case Management + HIV prevention|
62659863|NCT01143792|ACTIVE_COMPARATOR|MET + HIV prevention|
62659864|NCT06115980|EXPERIMENTAL|1 - An open label study|"This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~A total of 15 patients, who are scheduled for lead extraction, will be recruited in order to ensure a total of at least 10 patients finishing the study procedures and follow up."
62659865|NCT03144999|EXPERIMENTAL|Low Dose|AAVCAGsCD59
62659866|NCT03144999|EXPERIMENTAL|Mid Dose|AAVCAGsCD59
62096298|NCT06697418||Active Group|The average daily physical activity measured by the fitness tracker is above 5,000 steps.
62096299|NCT06697418||Sedentary Group|The average daily physical activity measured by the fitness tracker is below 5,000 steps.
62096300|NCT06170060|EXPERIMENTAL|Laparoscopic Sleeve Gastrectomy|
62659867|NCT03144999|EXPERIMENTAL|High Dose|AAVCAGsCD59
62465799|NCT02963025|OTHER|THE HIGHER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 10 cmH2O with lung recruitment maneuvers
62659868|NCT06054425|EXPERIMENTAL|Arm 1|Participants will receive risankizumab manufactured with using the current process (CMC2).
62659869|NCT06054425|ACTIVE_COMPARATOR|Arm 2|Participants will receive risankizumab manufactured with using the new process (CMC3).
62659870|NCT02761538|EXPERIMENTAL|AVIITAM Group|Utilization of the web platform Aviitam
62659871|NCT02761538|NO_INTERVENTION|Control group|No utilization of web-platform Aviitam
62659872|NCT00820534|EXPERIMENTAL|Penciclovir|Penciclovir
62659873|NCT00820534|PLACEBO_COMPARATOR|Placebo|Placebo
62659874|NCT00747513|EXPERIMENTAL|I|intervention group
62659875|NCT00884442|ACTIVE_COMPARATOR|1|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state
62659876|NCT00884442|ACTIVE_COMPARATOR|2|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state
62659877|NCT00884442|ACTIVE_COMPARATOR|3|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state
62659878|NCT00884442|ACTIVE_COMPARATOR|4|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state
62659879|NCT02701491|EXPERIMENTAL|Ginger|Ginger
62659880|NCT02701491|PLACEBO_COMPARATOR|Placebo|Placebo-no intervention
62659881|NCT04351815|EXPERIMENTAL|Short prehabilitation|This arm will benefit from a 2 weeks prehabilitation program including a personalized dietetic and physical training program as well as psychological support.
62659882|NCT04351815|OTHER|No prehabilitation|This arm will not benefit from a prehabilitation program before surgery. Patients will be told to maintain a regular physical activity without support.
62096301|NCT05513521|EXPERIMENTAL|High-velocity interval training|Subjects will be provided high-speed, low-load training to target improvements in velocity.
62659883|NCT02872441|EXPERIMENTAL|diagnosis of disease associated with IgG4|patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
62659884|NCT05841576|EXPERIMENTAL|COMET monitoring device|Anaesthetists for patients allocated to the intervention group were asked to strive and maintain the intraoperative mitoPO2 to the individualised preoperative baseline mitoPO2 with a minimum of 66 mmHg
62659885|NCT05841576|NO_INTERVENTION|Control group|Patients allocated to the control group were treated as per anaesthetist preference and followed our institution's conventional care
62659886|NCT04999787|EXPERIMENTAL|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
62659887|NCT04999787|PLACEBO_COMPARATOR|Placebo|
62659888|NCT01785316|EXPERIMENTAL|IHP|Isolated Hepatic Perfusion
62659889|NCT01785316|NO_INTERVENTION|BAC|Best alternative care
62096302|NCT05513521|EXPERIMENTAL|Resistance training|Subjects will be provided low-speed, high-load training to target improvements in velocity
62096303|NCT00620581|PLACEBO_COMPARATOR|Paroxetine 10mg;paroxetine 20mg; Placebo|
62465800|NCT02963025|OTHER|THE LOWER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 5 cmH2O without lung recruitment maneuvers
62465801|NCT04315662|EXPERIMENTAL|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
62659890|NCT02859012|EXPERIMENTAL|axitinib|Axitinib 5 mg twice (10mg) daily po medication until progression or development of unacceptable toxicity (4 weeks is considered as one cycle).
62096304|NCT02876146|OTHER|Hepatic alveolar echinococcosis|"Follow-up of standardized clinical, biological, and imaging characteristics (according to the WHO-expert consensus). Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)~Standardized earlier withdrawal of benzimidazole :~* Patients with non operable hepatic AE lesion : Withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after at least 4 years when viability markers became negative (PET-CT, serological markers)~* Curative hepatectomy : Earlier withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after one year (WHO guidelines : 2 years), if viability markers became negative. Close prospective follow-up after withdrawal (PET-CT, serological markers)"
62293570|NCT05448118|EXPERIMENTAL|Virtual POC Toxicology Testing|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
62308102|NCT02682329|ACTIVE_COMPARATOR|CP 20% + HP 40%|Carbamide Peroxide 20% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
62659891|NCT02859012|ACTIVE_COMPARATOR|observation|Observation. if disease progression is detected, cross-over will be permitted.
62659892|NCT02103075|EXPERIMENTAL|The SCA|
62659893|NCT02103075|EXPERIMENTAL|The age-matched control|
62659894|NCT02103075|EXPERIMENTAL|The young control|
62659895|NCT03010501|EXPERIMENTAL|100% Food Energy Density|Baseline Food Energy Density
62659896|NCT03010501|EXPERIMENTAL|80% Food Energy Density|Lower Food Energy Density
62659897|NCT03010501|EXPERIMENTAL|120% Food Energy Density|Higher Food Energy Density
62659898|NCT06006455|EXPERIMENTAL|Erchonia LunulaLaser|The Erchonia LunulaLaser emits red light (635 nm) and violet light (405 nm) to the affected toenail for 12 minutes per treatment. The treatment phase involves an initial weekly treatment administration phase, 1 treatment a week for 4 weeks, followed by an every two-month maintenance treatment administration phase, months 3, 5, 7, 9, and 11.
62659899|NCT04186273|SHAM_COMPARATOR|Donor Site Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
62659900|NCT04186273|EXPERIMENTAL|Donor Site Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
62659901|NCT04186273|EXPERIMENTAL|Donor Site Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested)
62659902|NCT04186273|SHAM_COMPARATOR|Skin Graft Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the skin grafted wound site.
62659903|NCT04186273|EXPERIMENTAL|Skin Graft Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the skin grafted wound site.
62659904|NCT04186273|EXPERIMENTAL|Skin Graft Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the skin grafted wound site.
62659905|NCT01800370|EXPERIMENTAL|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
61908896|NCT03842982|EXPERIMENTAL|Arm A (PDS or IDS + HIPEC)|"Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy)~Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).~Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care."
61908897|NCT03842982|NO_INTERVENTION|Arm B (PDS or IDS)|"Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC)~Patients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).~Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care."
61908898|NCT04870697|EXPERIMENTAL|ACT group|In addition to usual care, participants in the ACT group will receive ACT intervention. ACT intervention will be conducted in an individual-based format with four weekly sessions. The first session is a face-to-face format and the other three sessions are online live format.
61908899|NCT04870697|OTHER|Control group|Participants in the control group will receive usual care in the study setting delivered by clinical staff. The rationale for adopting usual care as a control group is not only because it is more commonly used but also for practical and ethical considerations, as usual care is what is already being delivered clinically, therefore the results of the study can support any necessity of changes to clinical practice or not.
62659906|NCT01800370|PLACEBO_COMPARATOR|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
61908900|NCT05885308|ACTIVE_COMPARATOR|Group training|
61908901|NCT05885308|EXPERIMENTAL|Online training|
61908902|NCT00998244|EXPERIMENTAL|Very Low Carbohydrate Diet|Very Low Carbohydrate Diet
61908903|NCT00998244|ACTIVE_COMPARATOR|Low Fat Diet|Low Fat Diet
61908904|NCT04821505|EXPERIMENTAL|Meditation|The Transcendental Meditation program is described as a simple natural technique practiced for 20 minutes twice daily for deep rest and relaxation. Previous studies have shown its feasibility, validity, and reliability in Blacks at risk for CVD.
62659907|NCT01800370|EXPERIMENTAL|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.~Includes blood draws and fasting requirements."
62096305|NCT01070056|ACTIVE_COMPARATOR|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
62308103|NCT02682329|ACTIVE_COMPARATOR|HP 10% + HP 40%|Hydrogen Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. HP at Home and HP at office
62659908|NCT04727008|EXPERIMENTAL|CXCR4 modified anti-BCMA CAR T cell therapy|CAR T cell therapy
62659909|NCT05174624||FAMILY Cohort|This Cohort was part of a prospective population-based study in 2007, consisting of 46,001 participants in Hong Kong. It was the first large-scale programme to understand the determinants of physical, mental, and social wellbeing in Hong Kong. The Cohort has an excellent (99.8%) coverage of the neighbourhoods in Hong Kong and represents roughly 1% of all households, which enables detailed studies linking the social environment to physical and mental health.
62659910|NCT04344444|NO_INTERVENTION|Arm A|Supportive Care only
62659911|NCT04344444|EXPERIMENTAL|Arm B|Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5
62659912|NCT04344444|EXPERIMENTAL|Arm C|Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5
62659913|NCT03477981|OTHER|Study cohort|Participants will receive standard white bread for two weeks and then alginate bread for two weeks. All participants will receive the bread in the same order.
62659914|NCT01776489||food allergic|positive reaction during DBPCFC
62659915|NCT01776489||Non-food allergic|no reaction during DBPCFC
62293571|NCT04531384|EXPERIMENTAL|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 weekly individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants.
62293572|NCT04531384|OTHER|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions, which consisted of weekly group and/or individual therapy, as determined by the clinical team.
62659916|NCT01136590|EXPERIMENTAL|tranexamic acid|tranexamic acid will be administered as a bolus (10-mg/kg dose ) or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery
62659917|NCT01136590|PLACEBO_COMPARATOR|placebo|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
61908905|NCT04821505|ACTIVE_COMPARATOR|Health Education|Health education program matched to the experimental intervention for time, attention, and other non-specific factors.
62293573|NCT02612870|ACTIVE_COMPARATOR|Sienna+ retro and Technetium 1|"Sienna+® is administered retro-mamillary 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
62293574|NCT02612870|ACTIVE_COMPARATOR|Sienna+ peri and Technetium 1|"Sienna+® is administered peri-tumorally 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
62659918|NCT03930433|ACTIVE_COMPARATOR|Nebivolol group|Oral Nebivolol 5mg / day (2 weeks) -\> 10mg / day (10 weeks)
62659919|NCT03930433|PLACEBO_COMPARATOR|Diltiazem group|Oral Diltiazem 90mg / day (2 weeks) -\> 180mg / day (10 weeks)
62659920|NCT03930433|PLACEBO_COMPARATOR|Nebivolol+Diltiazem group|Oral Nebivolol 2.5mg / day + Oral Diltiazem 45mg / day (2 weeks) -\> Oral Nebivolol 5mg / day + Oral Diltiazem 90mg / day (10 weeks)
62659921|NCT00306488|EXPERIMENTAL|OT-551 antioxidant eye drop|The fellow eye was treated with OT-551 antioxidant eye drops over the course of the study.
62659922|NCT02466503|EXPERIMENTAL|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
62659923|NCT02466503|ACTIVE_COMPARATOR|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
62659924|NCT05524129|EXPERIMENTAL|Interventional (Group I)|It will be a hybrid form of rehabilitation, i.e. home exercises according to brochures in combination with regular visits to the ambulance for check-ups according to a precisely set schedule, the authorized physiotherapist will also contact the patients by phone at regular weekly intervals, thereby maintaining their motivation.
62659925|NCT05524129|ACTIVE_COMPARATOR|Control (Group II)|These patients will undergo regular rehabilitation only in the outpatient center with the normally indicated frequency visits twice a week for 4 weeks.
62659926|NCT03233217|EXPERIMENTAL|Cohort 1: QIV-HD by IM|Participants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0.
62293575|NCT02612870|ACTIVE_COMPARATOR|Sienna+ retro 4-6 and Technetium 1|"Sienna+® is administered retro-mamillary 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
62096306|NCT01070056|EXPERIMENTAL|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
62293576|NCT02612870|ACTIVE_COMPARATOR|Sienna+ peri 4-6 and Technetium 1|"Sienna+® is administered peri-tumorally 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
62293577|NCT04952623|EXPERIMENTAL|E-learning Group|Participants will enroll in a 4-week e-learning program immediately after completing the pre-intervention assessment measures.
62293578|NCT04952623|ACTIVE_COMPARATOR|Wait-list Control Group|Participants will enroll in a 4-week e-learning program, 4-5 weeks after completion of the pre-intervention assessment measures.
62659927|NCT03233217|EXPERIMENTAL|Cohort 1: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
62659928|NCT03233217|EXPERIMENTAL|Cohort 2: QIV-HD by IM|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0.
62659929|NCT03233217|EXPERIMENTAL|Cohort 2: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
62659930|NCT03233217|ACTIVE_COMPARATOR|Cohort 2: QIV-SD by SC|Participants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0.
62293579|NCT02550899|ACTIVE_COMPARATOR|Bulkamid injection treatment group 1|Injection at four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
62293580|NCT02550899|ACTIVE_COMPARATOR|Bulkamid injection treatment group 2|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
62293581|NCT02550899|ACTIVE_COMPARATOR|Bulkamid injection treatment group 3|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
62293582|NCT03813030|EXPERIMENTAL|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 6 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
62293583|NCT03813030|EXPERIMENTAL|Pivotal Study|"Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 20 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.~Clearance Visit: Clearance of lidocaine will be evaluated after intravenous infusion of lidocaine."
62293584|NCT02427282|ACTIVE_COMPARATOR|MS. Frog|miniscrew-supported frog molar distalizing appliance
62293585|NCT02427282|EXPERIMENTAL|Stand. Frog|Standard Frog appliance
62293586|NCT06199466|EXPERIMENTAL|Dose Escalation|Participants will be assigned to a dose level of YL-13027 in combination with gemcitabine and nab-paclitaxel based on when you join this study.
62293587|NCT06199466|EXPERIMENTAL|Dose Expansion|Participants will receive YL-13027 in combination with gemcitabine and nab-paclitaxel at the recommended dose that was found in the Dose Escalation part.
62659931|NCT00523575|NO_INTERVENTION|C|Usual nurse and dietetic care
62659932|NCT00523575|EXPERIMENTAL|I|Intensive nutritional support composed of oral dietary supplement combined with dietetic counselling.
62659933|NCT04174261|EXPERIMENTAL|Ticagrelor - Remote Ischemic Preconditioning|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
62659934|NCT04174261|OTHER|Ticagrelor - Control|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. BP-cuff uninflated around the non-dominant arm
62659935|NCT04174261|ACTIVE_COMPARATOR|Clopidogrel - Remote Ischemic Preconditioning|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
62293588|NCT05504109|ACTIVE_COMPARATOR|Group A|patients who will undergo mitral valve replacement through full sternotomy approach
62293589|NCT05504109|ACTIVE_COMPARATOR|Group B|patients who will undergo mitral valve replacement through right mini thoracotomy approach
62293590|NCT04866927||Adults|"Inclusion criteria: Healthy, non-pregnant women, adults aged 18-65 years, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range.~Exclusion criteria: Children and elderly (over 65), pregnant women, individuals diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study."
62659936|NCT04174261|OTHER|Clopidogrel - Control|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. BP-cuff uninflated around the non-dominant arm
61908906|NCT01044329|ACTIVE_COMPARATOR|Intravitreal bevacizumab|
61908907|NCT01044329|ACTIVE_COMPARATOR|Intravitreal triamcinolone|
62096307|NCT03666429|ACTIVE_COMPARATOR|Bulb suction|Patients in this arm will be given bulb suction to treat nasal congestion. This group will contain participants who have used bulb suction in the past.
62293591|NCT02920125|ACTIVE_COMPARATOR|Trial: Ayurvedic SUVED, REIMMUGEN|"Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.~Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I \& II \& Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals."
62293592|NCT02920125|PLACEBO_COMPARATOR|Control: grain flour|Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
62293593|NCT06574633|ACTIVE_COMPARATOR|In-person therapy|
62659937|NCT05424055|EXPERIMENTAL|Multicomponent Exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance training, and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening).
62659938|NCT05424055|NO_INTERVENTION|Usual care|Participants randomly assigned to the usual care group will receive normal hospital care, including physical rehabilitation when needed
62096308|NCT03666429|EXPERIMENTAL|NoseFrida|Patients in this arm will be given the NoseFrida to treat nasal congestion. This group will contain participants who will trial the NoseFrida in the emergency department.
62293594|NCT06574633|EXPERIMENTAL|Telehealth|
62293595|NCT02300493|EXPERIMENTAL|Experimental|weigh themselves daily
62293596|NCT02300493|ACTIVE_COMPARATOR|Control|Weigh themselves every six months
62293597|NCT01596101||acute burns|
62293598|NCT01596101||rehab patients|
62293599|NCT00844493|EXPERIMENTAL|H10407 challenge 1|7 or 8 logs of E. coli strain H10407 with CeraVacx buffer
62293600|NCT00844493|EXPERIMENTAL|H10407 challenge 2|7 or 8 logs of E. coli strain H10407 with bicarbonate buffer
62293601|NCT00844493|EXPERIMENTAL|H10407 challenge 3|6 logs of E. coli H10407 with bicarbonate buffer
61908908|NCT04810780|EXPERIMENTAL|1st arm|Wearing the Duo infusion set for up to 1 month or up to 4 infusion set failures.
62293602|NCT00844493|EXPERIMENTAL|H10407 challenge 4|5 logs of E. coli H10407 with bicarbonate buffer
62293603|NCT06428903|EXPERIMENTAL|ADC189 tablet Group A|16 patients.
62293604|NCT06428903|EXPERIMENTAL|ADC189 granules Group B|16 patients.
62293605|NCT06428903|EXPERIMENTAL|ADC189 180mg Group|8 patients.
62293606|NCT04320836||Cervical epidural steroid injection|This group will receive an interlaminar cervical ESI at C6-7 or C7-T1 with 1 mL steroid (depo-methylprednisolone 40 mg at Johns Hopkins and the DC VA Hospital or dexamethasone 10 mg at Seoul National University) and 2 mL normal saline.
62293607|NCT02536248|EXPERIMENTAL|Sitagliptin first, then Placebo|"Sitagliptin 100 mg/d for 6 weeks~Wash-out 14 days~Placebo for 6 weeks"
62293608|NCT02536248|PLACEBO_COMPARATOR|Placebo first, then Sitagliptin|"Placebo for 6 weeks~Wash-out 14 days~Sitagliptin 100 mg/d for 6 weeks"
62293609|NCT01661322|ACTIVE_COMPARATOR|Intensive antiplatelet therapy|Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
62659939|NCT06535568|EXPERIMENTAL|Single antiplatelet therapy|
62659940|NCT06535568|ACTIVE_COMPARATOR|Dual antiplatelet therapy|
61908909|NCT02967757||liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg|
61908910|NCT00771589|EXPERIMENTAL|Prosthesis|Motorized External Knee prosthesis for above knee amputees. Comprised of agonist and antagonist actuators to mimic behavior of knee joint during locomotion.
61908911|NCT04215757|EXPERIMENTAL|Intervention group|"Patient received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.~For L4 radiculopathy Saphenous nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For S1 radiculopathy Sural nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%)"
62096309|NCT05037994|PLACEBO_COMPARATOR|Control Group (C Group)|Patients will receive continuous US suprascapular nerve block only.
62096310|NCT05037994|EXPERIMENTAL|Gabapentin Group (G Group)|Patients will receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.
62096311|NCT01043731||Ginven indication for laparoscopic anterior resection|
62096312|NCT05799560|NO_INTERVENTION|control group|no intervention
62096313|NCT05799560|EXPERIMENTAL|intervention|Reiki touch and terapotic touch will be done
62096314|NCT04056156|NO_INTERVENTION|Control|Standard of care (no specific intervention)
62293610|NCT01661322|NO_INTERVENTION|Guideline antiplatelet therapy|This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.
62293611|NCT06294600|PLACEBO_COMPARATOR|Placebo|These patients will be treated with 1 placebo tablet every 12 hours and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.
62308104|NCT03077295|EXPERIMENTAL|High Fibre to High-Protein (HF-HP)|"* Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~* Phase 2: consumption of HF meals for 4 weeks~* Phase 3: washout for 1 week, controlled maintenance diet~* Phase 4: consumption of HP meals for 4 weeks"
62293612|NCT06294600|ACTIVE_COMPARATOR|Clarithromycin|These patients will be treated with oral clarithromycin 500 mg twice daily for seven days and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.
62465802|NCT04315662|ACTIVE_COMPARATOR|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
62465803|NCT01012934|EXPERIMENTAL|1|Alendronate Sodium Tablets, 70 mg
62465804|NCT01012934|ACTIVE_COMPARATOR|2|Fosamax Tablets, 70 mg
62465805|NCT03146130|ACTIVE_COMPARATOR|Patient treated with N-acetylcysteine|Patients randomise in the drug group
62659941|NCT06121674|EXPERIMENTAL|Shaeer-II|"SHAEER-II targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated."
62659942|NCT06121674|ACTIVE_COMPARATOR|PPI|Penile prosthesis implantation (PPI) will be performed
62659943|NCT01139879|EXPERIMENTAL|P400 support surface|All patients will receive the P400 mattress
62659944|NCT06208332|EXPERIMENTAL|Photo-Narrative|
62659945|NCT06208332|NO_INTERVENTION|Usual Care|
62659946|NCT05203016||caesarean sections|
62659947|NCT05203016||Plastic surgery|
62659948|NCT05203016||Maxillofacial surgery|
62293613|NCT04402047|EXPERIMENTAL|Electroacupuncture group|
62293614|NCT04402047|ACTIVE_COMPARATOR|Topical DSG group|
62659949|NCT00574652|OTHER|1|it is a single arm study
62659950|NCT03864432|EXPERIMENTAL|25mg SAD|
61908912|NCT04215757|PLACEBO_COMPARATOR|Control group|"Patients received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.~For L4 radiculopathy Saphenous nerve block with 10ml distilled water For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 10ml distilled water For S1 radiculopathy Sural nerve block with10ml distilled water"
62293615|NCT02822456|EXPERIMENTAL|Individual 3D-printed guided tube|IOE tube feeding using individual 3D-printed guided tube and nelaton tube whenever they eat
62465806|NCT03146130|PLACEBO_COMPARATOR|Patient treated with placebo|Patients randomise in the placebo group
62465807|NCT04419311|EXPERIMENTAL|Ultra-congruent insert group|Ultra-congruent inserts were used during total knee arthroplasty in patients randomized to this group.
62659951|NCT03864432|EXPERIMENTAL|50mg SAD|
62465808|NCT04419311|EXPERIMENTAL|Posterior cruciate ligament-stabilized insert|Posterior cruciate ligament-stabilized inserts were used during total knee arthroplasty in patients randomized to this group.
62465809|NCT05179993||Study Group|Proof of principle Study group: detection of microplastics in human granulosa cells and in the follicular fluid of women undergoing intracytoplasmic sperm injection (ICSI) treatment
62659952|NCT03864432|EXPERIMENTAL|100mg SAD|
62659953|NCT03864432|EXPERIMENTAL|50mg Multiple dosing|
62659954|NCT05632991|ACTIVE_COMPARATOR|External oblique intercostal plane block|Ultrasound-guided External oblique intercostal plane block before surgery
62659955|NCT05632991|ACTIVE_COMPARATOR|Subcostal Transversus Abdominis Plan Block Group|Ultrasound-guided Subcostal Transversus Abdominis Plan Block Group
62659956|NCT01095770|ACTIVE_COMPARATOR|Ablation Frontiers Ablation|This group will undergo AF ablation using Ablation Frontiers Technology.
62659957|NCT01095770|ACTIVE_COMPARATOR|LASSO ablation|This group will undergo atrial fibrillation ablation with traditional LASSO technology
62659958|NCT01095770|ACTIVE_COMPARATOR|Reveal XT monitoring|This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.
62659959|NCT01095770|ACTIVE_COMPARATOR|Permanent Pacemaker - dual chamber|This group will be monitored pre and post ablation with a dual chamber permanent pacemaker
62659960|NCT04024137|EXPERIMENTAL|ZSP1273-200 mg BID|Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
62659961|NCT04024137|EXPERIMENTAL|ZSP1273-400 mg BID|Subjects will receive 10 doses of ZSP1273 400mg（200mg\*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
62659962|NCT04024137|EXPERIMENTAL|ZSP1273-600 mg QD|Subjects will receive 5 doses of ZSP1273 600mg （200mg \*3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .
62659963|NCT04024137|PLACEBO_COMPARATOR|Placebo|Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
62659964|NCT00146471|ACTIVE_COMPARATOR|2|
62659965|NCT00146471|PLACEBO_COMPARATOR|1: Diazepam plus Placebo|
62659966|NCT05941936|EXPERIMENTAL|Intravenous of LM103|≥5×10\^9 cells (LM103) will be infused i.v. to patients after NMA lymphodepletion treatment with Cyclophosphamide for Injection and Fludarabine Phosphate for Injection.
62659967|NCT00652041|EXPERIMENTAL|1|Induction: 6 alternating cycles Bortezomib-Melfalan-Prednisone or Bortezomib- Adriamycine-Melfalan-Prednisone and Thalidomide-Cyclophosphamide-Dexamethasone, followed by other 6 maintenance cycles
62736928|NCT05773807|PLACEBO_COMPARATOR|OAAS/S group|In the OAAS/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ml every two minutes maintain the OAA/S value at 1 point.
61908913|NCT00813540|EXPERIMENTAL|1|Exercise
62293616|NCT02822456|ACTIVE_COMPARATOR|traditional IOE tube|classic IOE tube feeding using nelaton tube only whenever they eat
62659968|NCT05907265|EXPERIMENTAL|Immersive Virtual Reality group|"The intervention will be group-based, with 5 participants per group, and will consist of a total of 24 sessions of 60 minutes. These 24 sessions are organized over 12 weeks, 2 sessions per week. The sessions will consist of a group program of multimodal stimulation using immersive MK360 technology to train cognitive, emotional, and physical areas.~Each session will have a different content, although they will follow the following outline:~1. Welcome and awareness of the here and now.~2. Mindfulness techniques~3. Cognitive stimulation~4. Physical activation~5. Feedback and end of session.~The visual material used for each session will be specific and adapted to the group."
62659969|NCT05907265|ACTIVE_COMPARATOR|Active Comparator: Active control program|In paper or pdf format, patients in the active control group will receive guidelines for physical and cognitive stimulation to do autonomously at home. Patients in the active control group will receive guidelines for cognitive and physical stimulation and meditation exercises in paper or pdf format, to be done independently at home. They will be encouraged to do physical exercises, meditation, and cognitive activities two times a week.
62293617|NCT02822456|ACTIVE_COMPARATOR|nasogastric tube|nasogastric tube feeding using levin tube always
62293618|NCT05946343||Small Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Small tear: Less than 1 cm.
62659970|NCT00866320|EXPERIMENTAL|Sorafenib|Chemotherapy single agent systemic. Sorafenib given up to 600mg orally every 12 hours for up to 10 months (40 weeks).
62293619|NCT05946343||Medium Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Medium tear: 1-3 cm
61908914|NCT00813540|OTHER|2|Usual Care, no intervention
61908915|NCT00843778|EXPERIMENTAL|Certolizumab Pegol|Certolizumab Pegol 200 mg every two weeks at the hospital by a nurse. Certolizumab Pegol 200 mg every two weeks at the patient's home done by patient (self-injection).
61908916|NCT01392651||Women with urinary stress incontinence|
61908917|NCT01922401|EXPERIMENTAL|inverse ratio ventilation|in one group change the I:E ratio during pneumoperitoneum 1:2-1:2-2:1
61908918|NCT03229343|EXPERIMENTAL|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
62293620|NCT05946343||Large Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Large tear: 3-5 cm
62293621|NCT05946343||Massive Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Massive tear: Greater than 5 cm
62659971|NCT06467734||Infection group|Joint puncture to extract joint fluid
62659972|NCT06467734||None infection group|Joint puncture to extract joint fluid
62659973|NCT00496457|EXPERIMENTAL|1|TRO19622
62659974|NCT00496457|PLACEBO_COMPARATOR|2|
62659975|NCT04239664|EXPERIMENTAL|Acceptance Based Telephone Support (ABS+UC)|One face-to-face session to be informed of the group they have been randomised into and Acceptance Based Support, followed by five 30-minute telephone sessions of Acceptance Based Support. Usual care continues as normal.
62659976|NCT04239664|NO_INTERVENTION|Usual Care (Control Group) (UC)|One face to face session to be informed of the group they have been randomised into and encouraged to ask any questions, and will be informed they will be contacted again in 8 weeks. Usual care continues as normal.
62736929|NCT01774669|EXPERIMENTAL|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
61908919|NCT03229343|NO_INTERVENTION|standard|pneumological consultation performed at M0, M3 and M6
61908920|NCT02025153|OTHER|Cohort|pain testing. All 444 subjects enrolled in the study. Subjects will receive preoperative physical (tonic heat stimulation, mechanical temporal summation and wound hyperalgesia), psychological (State Trait Anxiety Inventory, Pain Catastrophizing Scale), and genetics test; postoperative pain score assessment at 24, 48 hours; postoperative wound hyperalgesia in open abdominal hysterectomy at 72 hours; and phone survey for CPSP at 4 months.
61908921|NCT02025153|OTHER|Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
61908922|NCT02025153|OTHER|No Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
61908923|NCT05370703||Standard of Care (SOC) group|This group will continue their current lipid-lowering therapy and will not need to download any mobile application.
61908924|NCT05370703||SOC + My A:Care group:|This group will continue their current lipid-lowering therapy along with access to the mobile application My A:Care that supports medication adherence through motivational messages and challenges, health insights, and medication reminders.
62293622|NCT04237493|EXPERIMENTAL|Low-dosage therapy|
62293623|NCT04237493|ACTIVE_COMPARATOR|Regular-dosage therapy|
62293624|NCT01382615||Healthy Volunteers|Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
62293625|NCT01382615||Patients with multiple myeloma|Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.
62659977|NCT03509090|ACTIVE_COMPARATOR|ESP block group|Unilateral ESP block will be applied as postoperative regional analgesia technique in addition to the multimodal therapy. Then she is positioned in a right lateral position to perform ESP blocks. The skin will be disinfected and ESP block at one side will be performed in the lateral decubitus position and at T4 transverse process level by using 10-MHz linear ultrasound probe (Logic Ebook XP General Electrics, USA). The probe will be located 3 cm lateral to T4 spinous process in longitudinal parasagittal orientation. An 8 cm 21 gauge needle (BRAUN Stimuplex A®, Germany) will be inserted by using out of the plane technique. The ESP blocks proceed with 15 ml of 0,25% bupivacaine, 7,5 ml 1 % lidocaine, ,7,5 ml 0,9 % NaCl as total 30 ml . The injections will be applied after the confirmation of location by hidrodisection developed anterior to erector spinae muscle with 1-2 ml of local anesthetic solution.
62659978|NCT03509090|ACTIVE_COMPARATOR|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia prepared with tramadol. Patient-controlled analgesia (PCA) with tramadol at 3mg/cc concentration is programmed with no basal infusion, demand dose 10 mg and 20-minute lock-out interval. Also, patients received 1 gr paracetamol in every 6 hours.
62659979|NCT01730196|EXPERIMENTAL|Fit Body and Soul|Faith-based adaptation of the Group Life Style Program
62096315|NCT04056156|EXPERIMENTAL|Level 1: Online dissemination of the HIV screening advice|General practitioners included at the first level receive the HIV-testing advice through a personal electronic mail by their local GP-organization coordinator containing an information message with the printer-friendly screening advice attached. The message also provides a link to the website of the Flemish umbrella organization for GPs (https://domusmedica.be), where the tool is available for download for all Flemish GPs. A reminder is sent out to all participants after 13 months.
62096316|NCT04056156|EXPERIMENTAL|Level 2: additional group-level training session|At the second intervention level, GPs first receive intervention condition 1 and additionally the face-to-face group-level training session. These sessions are organized as part of regular 'continuous medical education' provided by the GP organizations ('quality circles') at their usual venues and are organized a few months after receiving intervention level 1. A reminder of the advice is sent out 13 months after the initiation of intervention level 1.
62293626|NCT03803527|EXPERIMENTAL|EST|"All subjects enrolled into the study will:~* Complete a clinical history~* Have vitals obtained~* Complete Patient-reported outcomes~* Have Esophageal mucosal biopsies collected as part of standard of care at the time of the most recent endoscopy to report the peak eosinophilia per hpf.~* Complete the Esophageal String test"
62465810|NCT06363747|NO_INTERVENTION|Standard of Care|"Patients in the control group will attend four in-person visits with the study coordinator at baseline, week 12, week 24, and week 48 to measure study outcomes.~Patients will get medical drug management (endocrinologist), nutritional/behavioral counseling (dietician, psychologist) and will be maintained on once weekly GLP-1 agonist +/- other diabetic medicines."
62465811|NCT06363747|EXPERIMENTAL|Very Low Calorie Diet|"Patients in the experimental group will attend 4 in-person visits with the study coordinator at baseline, week 12, week 24, and week 48 to measure study outcomes. Additionally, they will undergo a 2 week run-in phase before baseline with weekly meetings to ensure that they are able to tolerate and comply with Optifast.~Patients will get medical drug management (endocrinologist), nutritional/behavioral counseling (dietician, psychologist) and will be maintained on Optifast + once weekly GLP-1 agonist +/- other diabetic medicines."
62465812|NCT05558930|EXPERIMENTAL|iTBS stimulation|Participants receive iTBS stimulation of bilateral cerebellar one session per day for 5 consecutive days.
62659980|NCT01730196|ACTIVE_COMPARATOR|Wellness education|A health education program developed from the list of topics provided by the Centers for Disease Control and Prevention (CDC) Guide to Community Prevention Services
62736930|NCT01774669|ACTIVE_COMPARATOR|Conventional therapy|Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
62736931|NCT03932318|EXPERIMENTAL|Phase I and Phase II|"Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles.~Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
62096317|NCT03670381||ASD group|ASD patients with HDAC4 CNVs
62096318|NCT03670381||TD group|Typically developing controls without lifetime ASD or a family history of ASD
62096319|NCT06008067||Survivors|Patients who survived after day 28.
62096320|NCT06008067||Non-survivors|Patients who died at or before day 28.
62096321|NCT04730947|EXPERIMENTAL|Dapagliflozin Group|Subjects with HFpEF will take the study drug dapagliflozin daily
62736932|NCT03485261||Group A|patient group include 50 female patients with chronic renal failure (eGFR \<15ml/min/1.7m2 )
62096322|NCT04730947|PLACEBO_COMPARATOR|Placebo Group|Subjects with HFpEF will take a placebo daily
62096323|NCT05125861|ACTIVE_COMPARATOR|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. RIC will be conducted twice within 6 to 24 hours from thrombolysis.
62096324|NCT05125861|PLACEBO_COMPARATOR|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis.
62096325|NCT05504694|EXPERIMENTAL|Ofatumumab|The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.
62096326|NCT05972616||NMP|"Have clinical or radiological evidence of degenerative disc disease of the lumbar spine.~Have been treated with NMP™ during a lumbar spinal fusion procedure."
62096327|NCT03929731||Polypoidal Choroidal Vasculopathy RCT|Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T\&E studies
62096328|NCT01156415|EXPERIMENTAL|Agomelatine (AGO178) 0.5 mg|
62096329|NCT01156415|EXPERIMENTAL|Agomelatine (AGO178) 1 mg|
62096330|NCT06128551|EXPERIMENTAL|RMC-6291 and RMC-6236|Dose escalation and Dose expansion
62096331|NCT02263885|EXPERIMENTAL|ExAblate Transcranial System|Transcranial ExAblate MRgFUS
62736933|NCT03485261||Group B|the control group including 50 healthy females age matched with the patient group
62736934|NCT00118248|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62736935|NCT03017690||lanreotide group (Somatuline Depot®)|
62736936|NCT03017690||octreotide LAR group (Sandostatin LAR®)|
62736937|NCT05109429|EXPERIMENTAL|No Craving|Each participant will attend three sessions where the participant will experience three distinct cue-induced craving tasks in a randomized fashion.
62736938|NCT02831855|EXPERIMENTAL|CP-690,550 and methotrexate|Open-label tofacitinib tablet and blinded methotrexate capsule
62736939|NCT02831855|PLACEBO_COMPARATOR|CP-690,550 and placebo|open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
62736940|NCT02769364||Participants treated with eribulin for at least 7 months|
62736941|NCT02445105|ACTIVE_COMPARATOR|Autism Navigator Enhanced Practice|A 6-hour training will be provided to community service providers with the Autism Navigator for Primary Care professional development course and use of a web-based platform that includes an automated communication and autism screening and monthly electronic monitoring.
62736942|NCT02445105|EXPERIMENTAL|Family Engagement plus Autism Navigator|A 6-hour training will be provided to community service providers on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler, in addition to Autism Navigator Enhanced Practice.
62736943|NCT06182098|EXPERIMENTAL|Bolus|Will receive a normal saline bolus
62736944|NCT06182098|PLACEBO_COMPARATOR|Control|Will receive 1/2 maintenance normal saline
62736945|NCT05072860|EXPERIMENTAL|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid or placebo
62736946|NCT05072860|PLACEBO_COMPARATOR|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
62736947|NCT01053104||capecitabine 2000mg/m2 (Colorectal)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
62736948|NCT01053104||capecitabine 2500mg/m2 (Colorectal)|capecitabine 2500mg/m2 d 1-14, q 3 weekly
62736949|NCT01053104||capecitabine 2000mg/m2 (Breast)|capecitabine 2000mg/m2d 1-14, q 3 weekly
62736950|NCT01053104||docetaxel 75mg/m2 (Breast)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
62736951|NCT06263608|OTHER|Symptomatic AF patients|Eligible participants will use the NOX T3s polygraphy device for one night at home. If they have a positive obstructive sleep apnea diagnosis, they will be referred to a polysomnography examination, and subsequently treatment. Participants will also receive 3 to 6 months of semi-continuous heart rhythm monitoring with the Fitbit smartwatch (depending on whether they get treatment after obstructive sleep apnea diagnosis via polysomnography).
62736952|NCT05420961|EXPERIMENTAL|Cohort 1: V116|Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
62736953|NCT05420961|ACTIVE_COMPARATOR|Cohort 1: PCV15|Participants will receive a single 0.5 mL IM injection of PCV15 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
62736954|NCT05420961|EXPERIMENTAL|Cohort 2: V116|Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
62736955|NCT05420961|ACTIVE_COMPARATOR|Cohort 2: PPSV23|Participants will receive a single 0.5 mL IM injection of PPSV23 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
62736956|NCT05420961|EXPERIMENTAL|Cohort 3: V116|Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV15, PCV20, PCV13+PPSV23, PCV15+PPSV23, or PPSV23+PCV13 prior to the enrollment.
62659981|NCT05360264|EXPERIMENTAL|Experimental group|"A fresh, mandatory, tumor biopsy will be performed at baseline to assess KRAS mutational status and functional dependency and determine the patient's eligibility for the trial. KRAS dependency will be assessed based on computational score and inferred by a transcriptional signature of tumor cells. Transcriptomic data will be generated by using RNAseq data. Sample RNA processing and generation of the gene expression profile will be guaranteed within a maximum of 10 working days from the biopsy.~Patients with high L-, S- or both L/S- scores of KRAS-dependency will receive DACOGEN.~DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.~Patients will continue to receive study treatment until objective radiological disease progression per modified RECIST 1.1, as assessed by the investigator, unacceptable toxicity, physician's decision, patient's refusal, or until they meet any other discontinuation criteria."
62659982|NCT01405573|ACTIVE_COMPARATOR|A: Best Supportive Care|best supportive care
62659983|NCT01405573|EXPERIMENTAL|B: Sorafenib 400 mg, twice a day + Best Supportive Care|sorafenib + best supportive care
62659984|NCT04426656|NO_INTERVENTION|Part 2 Standard of Care|Participants will receive written HIV prevention materials including basic facts of PrEP, recommendations for HIV/STI(sexually transmitted infections) testing and referrals to local HIV/STI testing sites and prevention services.
62659985|NCT04426656|EXPERIMENTAL|Part 2 mini-app|In addition to the standard of care, participants in the mini-app arm will have access to the mini-app (i.e. the intervention) during the whole study period.
62659986|NCT01834794|EXPERIMENTAL|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
62659987|NCT01949987|ACTIVE_COMPARATOR|2 hours after surgery|the investigators permit the patients to resume oral intake two hours after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
62659988|NCT01949987|EXPERIMENTAL|1 hour after surgery|the investigators permit the patients to resume oral intake one hour after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
62659989|NCT01803542|EXPERIMENTAL|SBRT|High dose of radiation will be used to treat tumours.
62659990|NCT04294823||FRANCE - CHU creteil|An internal physical examination including vital signs measurements and a 13C-UBT with the standard test meal (Helicobacter Test INFAI) will be performed. Patients with a positive UBT will undergo upper endoscopy. All biopsy samples will be analysed in the local laboratory of the centre. Patients with a negative UBT will undergo also upper endoscopy. Endoscopic procedures and subsequent investigations will be identical in patients with a positive and with a negative UBT. H. pylori positive and negative patients will perform the 13 C-UBT breath tests with new test meal on Day 30. The study will be conducted in outpatients. Starting on Day 1, H. pylori positive and negative patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast. Patients will return to the hospital/medical practice for UBT breath tests with new test meal on Day 30. Patients will be followed-up for 7 days after discontinuation of PPI treatment.
62659991|NCT04596423||A|Extended fetal heart examination
62659992|NCT04596423||B|Modified extended heart examination
62659993|NCT04596423||C|Sief_Twist sign only examination
62659994|NCT01731496|EXPERIMENTAL|Telephone reminder|Telephone message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
62659995|NCT01731496|EXPERIMENTAL|Text Message reminder|Text message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
62659996|NCT01731496|NO_INTERVENTION|Control: Telephone|
62659997|NCT01731496|NO_INTERVENTION|Control: Text Message|
62659998|NCT05951686|ACTIVE_COMPARATOR|Group inhalation|Patients will receive desflurane as an inhalation anesthetic and remifentanil infusion for general anesthesia maintenance during the surgery. The doses of desflurane and remifentanil will be adjusted according to the Patient State Index (PSI) where the goal score is 25-50.
62659999|NCT05951686|ACTIVE_COMPARATOR|Group tiva|Patients will receive total intravenous anesthesia with an infusion of propofol and remifentanil for general anesthesia maintenance during the surgery. The infusion doses will be changed according to the Patient State Index (PSI) where the goal score is 25-50.
62660000|NCT05564117|EXPERIMENTAL|Oral semaglutide 25 mg|Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 64 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), and 25 mg (weeks 13 to 64).
62660001|NCT05564117|PLACEBO_COMPARATOR|Oral semaglutide placebo|Participants will receive placebo tablets matched to semaglutide orally once daily for 64 weeks.
62660002|NCT02072616|EXPERIMENTAL|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done after Pancreatic adenocarcinoma diagnosis
62660003|NCT01091610||1|all emergency medical staff having suffered an accident during work
62660004|NCT01091610||2|non emergency medical personnel having suffered an injury due to a medical mission, e.g. transported patient having suffered additional injury due to an ambulance accident or collision of an ambulance with another vehicle.
62660005|NCT03738215|EXPERIMENTAL|Cariprazine 1.5 mg/Day + ADT|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
62660006|NCT03738215|EXPERIMENTAL|Cariprazine 3 mg/Day + ADT|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2).
62660007|NCT03738215|PLACEBO_COMPARATOR|Placebo + ADT|During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
62660008|NCT05229900|EXPERIMENTAL|SGN-ALPV|SGN-ALPV monotherapy
62660009|NCT03748524|EXPERIMENTAL|Single Influenza Vaccine|Single Influenza Vaccine,Quadrivalent
62660010|NCT03585543|EXPERIMENTAL|Single group intervention arm|
62736957|NCT00418600|OTHER|1|Hectorol capsules at 1.0 times current injection dose
62736958|NCT00418600|OTHER|2|Hectorol capsules at 1.5 times current injection dose
62660011|NCT02714153|EXPERIMENTAL|Bridge Occlusion Balloon|Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
62660012|NCT05190432|EXPERIMENTAL|Taxifolin/Dihydroquercetin|250mg/day Taxifolin (also known as Dihydroquercetin). One capsule in the morning for 8 weeks.
61920124|NCT04447872|ACTIVE_COMPARATOR|Luteal phase ovarian stimulation (LPOS)|Patients will present in the luteal phase, and will begin 150 IU hMG and 300 IU recombinant FSH daily, as well as oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH can then be titrated per patient response. Gonadotropin releasing hormone antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started per criteria. Once patients are ready for ovulation trigger, 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU), will be administered. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
62096332|NCT02744274|EXPERIMENTAL|Verum acupuncture|16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
62096333|NCT02744274|PLACEBO_COMPARATOR|Sham acupuncture|16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
62465813|NCT05558930|SHAM_COMPARATOR|sham stimulation|Participants receive sham stimulation of bilateral cerebellar one session per day for 5 consecutive days.
62660013|NCT05190432|EXPERIMENTAL|Ergothioneine|80mg/day Ergothioneine. One capsule in the morning for 8 weeks.
62660014|NCT05190432|PLACEBO_COMPARATOR|Control|One capsule in the morning for 8 weeks.
62096334|NCT01716832|EXPERIMENTAL|Mindfulness walking|
62096335|NCT01716832|NO_INTERVENTION|No intervention (waiting list)|
62293627|NCT03622281|EXPERIMENTAL|Colonoscopists who received quality intervention|
62293628|NCT03622281|NO_INTERVENTION|Colonoscopists who did not received quality intervention|
62465814|NCT01165385|EXPERIMENTAL|Pazopanib and Cisplatin|"* Steady state period:Pazopanib will be given 8 days prior to cisplatin~* Then pazopanib will be given 400 mg, 600 mg or 800 mg/day, daily and cisplatin 60, 75 or 100 mg/m2 , day 1 - 3 weekly, depending of the dose level"
62465815|NCT05232877|EXPERIMENTAL|tDCS combined with simultaneous cognitive training|
62465816|NCT05232877|SHAM_COMPARATOR|cognitive training with a combined sham tDCS|
62465817|NCT00873132||Data Collection|Collect data both retrospectively and prospectively on subjects seen at the Preston Robert Tisch Brain Tumor Center
62465818|NCT00144534|EXPERIMENTAL|1|
62465819|NCT00674505|OTHER|Treatment, Open label, Single Group Assignment|
62465820|NCT03269409|SHAM_COMPARATOR|Hip Decompression with lactated ringers|Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
62660015|NCT04286880|EXPERIMENTAL|TEST GROUP|Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle.
62660016|NCT04286880|ACTIVE_COMPARATOR|CONTROL GROUP|In control group, dry needling will be performed.
62660017|NCT05770310|EXPERIMENTAL|JS015|
62660018|NCT05579704|ACTIVE_COMPARATOR|Web-based wellness platform|Participants will receive access to a web-based wellness platform focused on nutrition, physical activity, and mindfulness. Interactions with the platform will be fully self-guided (without weekly group video conferencing sessions healthcare professionals and peers).
62736959|NCT00418600|OTHER|3|Hectorol capsules at 2.0 times current injection dose
62293629|NCT03481270|PLACEBO_COMPARATOR|Discordant|Does not receive the concordant provider.
62293630|NCT03481270|EXPERIMENTAL|Concordant|The intervention is that the subject receives the concordant provider.
62293631|NCT06292078|EXPERIMENTAL|Wave 1 Instructional Skill-Building Learning Approach (ISLA)|Following a baseline year for data collection, school staff in 15 schools will be trained and supported in implementing ISLA schoolwide for two consecutive years.
62465821|NCT03269409|EXPERIMENTAL|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
62465822|NCT01496183|PLACEBO_COMPARATOR|Placebo|
62465823|NCT01496183|EXPERIMENTAL|Olanzapine|
62465824|NCT01938339|EXPERIMENTAL|PET/MR|Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
62465825|NCT02225301|EXPERIMENTAL|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
62736960|NCT06510803||Control is GE Ohmeda|The control group will utilize the GE Ohmeda workstation for induction of anesthesia with sevoflurane.
62465826|NCT03637556|EXPERIMENTAL|DST-0509|DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets. DST-0509 is taken once daily with food; the first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
62660019|NCT05579704|EXPERIMENTAL|Web-based wellness platform with healthcare professional-facilitated online support|Participants will receive access to a web-based wellness platform focused on nutrition, physical activity, and mindfulness. In addition to the platform access, participants will take part in weekly group video conferencing sessions with various healthcare professionals (registered dietitian, mental health therapist, and exercise professional). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
62465827|NCT03637556|ACTIVE_COMPARATOR|Jadenu|Jadenu is commercially available as tablets and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. Jadenu is taken once daily with or without a light meal. However, Jadenu can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
62465828|NCT03637556|ACTIVE_COMPARATOR|Exjade|Exjade is commercially available as tablets and Exjade as tablets for oral suspension and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. If converting from Exjade, the dose will be scaled for each treatment by 28 mg/40 mg (treatment/Exjade). Jadenu and Exjade are taken once daily, Jadenu is taken with or without a light meal, and Exjade is recommended to be taken without food. However, either Jadenu or Exjade can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
62465829|NCT02724462|EXPERIMENTAL|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
62660020|NCT01022580|ACTIVE_COMPARATOR|Infasurf surfactant (ONY, Inc.)|Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.
62660021|NCT01022580|SHAM_COMPARATOR|Sham (No Treatment)|"Infants already receiving inhaled nitric oxide will receive Sham (no treatment) doses on study days 0,2,4,6, and 8."
62660022|NCT02655341||Consecutive STEMI Patients|All patients with AMI referred for primary PCI in a single centre
62660023|NCT01809652|EXPERIMENTAL|Remote Implant Support|Implant supported through remote implant support capability
62660024|NCT02819817|EXPERIMENTAL|Aloe Vera Gel|Experimental gel placed in identical opaque tube as placebo gel.
62660025|NCT02819817|PLACEBO_COMPARATOR|Ultrasound Gel|Placebo placed in identical opaque tube as experimental gel.
62660026|NCT02819817|NO_INTERVENTION|Standard care|Standard care
62660027|NCT04120779|EXPERIMENTAL|The EMPOWER-SUSTAIN e-Health Intervention|The EMPOWER-SUSTAIN intervention is a multifaceted chronic disease management strategies based on the Chronic Care Model (CCM) and persuasive technology (PT) theory. It consists of training physicians and patients to use the EMPOWER-SUSTAIN web-based self-management intervention mobile apps, strengthening patient-physician relationship and reinforcing the use of relevant clinical practice guidelines for management and prescribing.
62096336|NCT06491095|OTHER|No Flax Product|175 g yogurt containing no flax product
62096337|NCT06491095|EXPERIMENTAL|40 g whole ground flaxseed|175 g yogurt with 40 g whole ground flaxseed
62465830|NCT02724462|ACTIVE_COMPARATOR|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
62660028|NCT04120779|NO_INTERVENTION|Control|The control group will continue to receive usual care at the university primary care clinic. They will be given the EMPOWER-SUSTAIN Global CV Risks Self-Management Booklet©, as this is considered as usual care at the university primary care clinic. The EMPOWER-SUSTAIN web-based self-management tool will be made available to the control group at the end of the study. During the course of the study, there will be no limit to the number of clinic visits that a patient is allowed to make in either the intervention or control groups.
62660029|NCT06166797||No NAFLD|individuals with \<5 percent hepatic fat fraction on magnetic resonance spectroscopy
62660030|NCT06166797||Simple Steatosis|individuals with at least 10% fat fraction on magnetic resonance spectroscopy without any history of nonalcoholic steatohepatitis or evidence of fibrosis
62096338|NCT06491095|EXPERIMENTAL|40 g roasted then ground whole flaxseed|175 g yogurt with 40 g roasted then ground whole flaxseed
62096339|NCT06491095|EXPERIMENTAL|40 g of whole intact flaxseeds|175 g yogurt with 40 g of whole intact flaxseeds
62096340|NCT06491095|EXPERIMENTAL|28 g flax hulls|175 g yogurt with 28 g flax hulls
62096341|NCT05971641|ACTIVE_COMPARATOR|intervention group|The experimental group is the one in which progressive relaxation exercises will be taught, and we will monitor the results in patients.
62096342|NCT05971641|NO_INTERVENTION|control group|The control group is the one in which the service routine is implemented, and progressive relaxation exercises are not taught but monitored.
62096343|NCT00534755|OTHER|Breast database|Database
62096344|NCT02849262|EXPERIMENTAL|Omiganan (CLS001)|CLS001 Topical Gel, 2.5%
62096345|NCT02849262|PLACEBO_COMPARATOR|Vehicle|Vehicle Topical Gel
62096346|NCT03601728|EXPERIMENTAL|Enhanced Monitoring Program|Four weeks prior to the scheduled (elective) surgery, participants will receive a 60-minute in person education session how to increase the level of physical activity. This will be followed by 4 weeks of keeping this level of physical activity, which will be monitored and supported by personalized interactive prompts delivered by a smartwatch. This approach is called personalized prehabilitation.
62096347|NCT03601728|NO_INTERVENTION|Regular Monitoring Program|Participants randomized to this arm will receive standard perioperative care.
62465831|NCT04873011|EXPERIMENTAL|Quinine hydrochloride|The bitter tastant, quinine hydrochloride, will be acutely infused via a nasogastric feeding tube into the stomach. 320 mg of quinine hydrochloride is dissolved in 10 mL of water and all is infused.
62660031|NCT06166797||Nonalcoholic Steatohepatitis|individuals with biopsy confirmed nonalcoholic steatohepatitis and stage 2 or 3 fibrosis
62660032|NCT02887001|OTHER|BMO|
62660033|NCT01245751|EXPERIMENTAL|Group 1: Booster Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
62660034|NCT01245751|EXPERIMENTAL|Group 2: First Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
62660035|NCT01245751|EXPERIMENTAL|Group 3: First Dose Participants ≥60 and <70 years of age|Herpes zoster history-negative participants ≥60 and \<70 years of age who have never received Zoster Vaccine, Live
62660036|NCT01245751|EXPERIMENTAL|Group 4: First Dose Participants ≥50 and <60 years of age|Herpes zoster history-negative participants ≥50 and \<60 years of age who have never received Zoster Vaccine, Live
62660037|NCT01798290|EXPERIMENTAL|Behavioral: narrative medicine: reading workshop|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading patients' diaries or nurses'diaries. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
62096348|NCT00816582|EXPERIMENTAL|PET/CT Guided FES Therapy|All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.
62096349|NCT01113515|PLACEBO_COMPARATOR|Placebo|Placebo gel
62096350|NCT01113515|EXPERIMENTAL|Galnobax 20% QD|Esmolol Hydrochloride (Galnobax) 20% gel once daily
62096351|NCT01113515|EXPERIMENTAL|Galnobax 20% BID|Esmolol Hydrochloride (Galnobax) 20% gel twice daily
62096352|NCT01113515|EXPERIMENTAL|Galnobax 14% BID|Esmolol Hydrochloride (Galnobax) 14% gel twice daily
62096353|NCT05018273|EXPERIMENTAL|VB10.NEO 3 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 3 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
62096354|NCT05018273|EXPERIMENTAL|VB10.NEO 6 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 6 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
62293632|NCT06292078|NO_INTERVENTION|Wave 1 Waitlist Control|These 15 schools will receive no intervention while wave 1 intervention schools undergo training and coaching on ISLA.
62293633|NCT06292078|EXPERIMENTAL|Wave 2 Instructional Skill-Building Learning Approach (ISLA)|Delayed one year after wave 1: Following a baseline year for data collection, school staff in 15 schools will be trained and supported in implementing ISLA schoolwide for two consecutive years.
62293634|NCT06292078|NO_INTERVENTION|Wave 2 Waitlist Control|These 15 schools will receive no intervention while wave 2 intervention schools undergo training and coaching on ISLA.
62293635|NCT00914875||group tramadol plus ketorolac|
62096355|NCT05018273|EXPERIMENTAL|VB10.NEO 9 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 9 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
62465832|NCT04873011|PLACEBO_COMPARATOR|Placebo|10 mL of water is infused via a nasogastric feeding tube into the stomach.
62465833|NCT01878825|EXPERIMENTAL|Fluviral 18-60 Years Group|Subjects aged between 18 and 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
61908925|NCT05370703||SOC + Smart Coach group:|"This group will continue their current lipid-lowering therapy along with access to the mobile application Smart Coach that supports medication adherence through personalized motivational messages and challenges, health insights, and medication reminders. Personalization of the messages and challenges will be based on a behavioral profiling Social, Psychological, Usage, Rational (SPUR™) questionnaire that is completed at randomization to the Smart Coach application.~Study site will guide the subjects on how to use these mobile applications. Eligibility assessment will be based on information collected at screening/baseline visit (Visit 1) and assessment of Part 1 of MARS 5VA questionnaire. Adherence at baseline (Visit 1) and after 12 weeks of observation (Visit 2), will be evaluated by the complete MARS 5VA (Part 1 and 2) questionnaire. Each subject will be followed up for approximately 12 weeks from randomization at Visit 1."
62096356|NCT05535582||Patients with SMuRFs|Patients with acute myocardial infraction with a history of at least one standard modifiable risk factor (SMuRF; smoking, diabetes mellitus, dyslipidemia, hypertension)
62096357|NCT05535582||SMuRF-less Patients|Patients with acute myocardial infraction without history of any SMuRF
62660038|NCT01798290|ACTIVE_COMPARATOR|Behavioral: critical reading|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading literature. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
62660039|NCT06055582|OTHER|Treatment - Mango|Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.
62096358|NCT06452836|PLACEBO_COMPARATOR|Translucent Glasses Group|
62096359|NCT06452836|EXPERIMENTAL|Green Colored Glasses Group|
62096360|NCT06452836|EXPERIMENTAL|Red Colored Glasses Group|
62096361|NCT06452836|EXPERIMENTAL|Blue Colored Glasses Group|
62096362|NCT04633889|EXPERIMENTAL|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
62660040|NCT06055582|OTHER|Controlled- Bread|Subjects in bread group were given 81g (3 slices) harvest gold white bread as standard food in raw form.
62660041|NCT03424304|OTHER|Excel V™ Laser With Green Genesis|Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area
62293636|NCT00914875||group tramadol plus dypirone|
62660042|NCT02476162||Group 1: Daily for 3 Months|Participants randomly assigned to this group will be instructed to measure their blood pressure (BP) every day during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
62660043|NCT02476162||Group 2: Daily for 1 Week/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
62660044|NCT02476162||Group 3: 3 Consecutive Days Once/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
62660045|NCT06050772|EXPERIMENTAL|STUDY GROUP|Groups who will receive virtual reality reminiscence versus traditional reminiscence therapy to determine its effect on cognitive function and psychological wellbeing.
62660046|NCT06050772|NO_INTERVENTION|Control group|Groups who will not receive any intervention
62660047|NCT00564356|OTHER|A|patients under coumadin and antiaggregants operated by phacoemulsification
62660048|NCT04526054|OTHER|anosmic or normosmic COVID-19 patients|Patients will undergo ENT exams, olfactometry and MRI.
62660049|NCT00867880|EXPERIMENTAL|1|
62660050|NCT00867880|ACTIVE_COMPARATOR|2|
62660051|NCT04695678||residents and staff of all nursing homes in Solingen|each study participant receives a single nasal/pharyngeal swab
62660052|NCT04695678||staff of one single nursing home in Solingen|each study participant receives a weekly nasal/pharyngeal swab for six months
62660053|NCT05323851||Surgeon|Any Resident, Fellow, PhD candidate, consultant or attending surgeon in any surgical specialty in Italy
62660054|NCT04490707|EXPERIMENTAL|Azacitidine plus Lenalidomide (AZA+LEN)|"Arm 1(AZA+LEN): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA combined with LEN: AZA 50mg/m² per day for days 1-5 and LEN 10mg per day orally for days 6-26 , every 28 days for up to 12 cycles or progression.~AZA -Azacitidine, LEN- Lenalidomide"
61908926|NCT03372759|ACTIVE_COMPARATOR|study group air|airtamponade
61908927|NCT03372759|SHAM_COMPARATOR|study group saline|saline
62096363|NCT04633889|PLACEBO_COMPARATOR|Placebo|Normal saline (240mL) intravenous infusion over 12 hours
62096364|NCT06614166|EXPERIMENTAL|Synbiotic Medical Food SBD111|Probiotic comprised of three lactic acid bacteria and one yeast
62096365|NCT06614166|EXPERIMENTAL|Synbiotic Medical Food SBD121|Probiotic comprised of three lactic acid bacteria and one bacillus
62096366|NCT04517851|EXPERIMENTAL|Treatment (elotuzumab)|Patients receive elotuzumab IV over 1-4 hours on days 1, 8, 15, and 22 of cycles 1-2. Beginning in cycle 3, patients receive elotuzumab IV over 1-4 hours on day 1. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
62096367|NCT05236543|EXPERIMENTAL|Treatment Arm|Subjects will receive AZD4831 on Day 1; Itraconazole only on Days 8 through 10 , and AZD4831 and Itraconazole on Day 11 oral dosing of Itraconazole only on Days 12 through 17.
62096368|NCT03163511|EXPERIMENTAL|Cohort 1|"VC-02 Combination Product:~Up to ten (10) VC-02-20 implants and up to two (2) VC-02-300 implants"
62096369|NCT03163511|EXPERIMENTAL|Cohort 2|VC-02 Combination Product; Up to twelve units implanted of which up to ten (10) are VC-02-300 implants and the rest are VC-02-20 implants.
62293637|NCT01608334|EXPERIMENTAL|group A|Fentanyl
62293638|NCT01608334|ACTIVE_COMPARATOR|Group B|Sufentanil
62293639|NCT04026568|EXPERIMENTAL|Single dose 4AP|15mm opaque capsule containing 10mg of 4-AP
62293640|NCT04026568|PLACEBO_COMPARATOR|Placebo|Opaque capsule identical looking to the 4AP placebo pill
62660055|NCT04490707|EXPERIMENTAL|Azacitidine(AZA)|"Arm 2 (AZA): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA 50mg/m² per day for days 1-5, every 28 days for up to 12 cycles or progression.~AZA -Azacitidine"
62096370|NCT06614673|EXPERIMENTAL|Non-Narrative Text|A short text, consisting of 504 words, that addresses the preventability of cancer cases. It highlights the impact of lifestyle factors such as smoking, unhealthy diet, obesity, and physical inactivity, which contribute to approximately 40% of cancer cases. The text also provides recommendations for reducing the risk of cancer through behavioral changes in these areas, with a particular emphasis on nutrition and physical activity. The text was developed based on the Protection Motivation Theory.
62096371|NCT06614673|EXPERIMENTAL|Narrative Text|The narrative text contains the same information as the non-narrative text, but it is presented as a story. It is slightly longer at 737 words and features a main character and two work colleagues sharing their personal experiences about nutrition and physical activity.
62465834|NCT01878825|EXPERIMENTAL|Fluviral >60 Years Group|Subjects aged \> 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm
62465835|NCT01792635|NO_INTERVENTION|Part A (Pilot Study)|
62465836|NCT01792635|EXPERIMENTAL|Monotherapy (Part B)|
62465837|NCT06278077|EXPERIMENTAL|Neurexan|Two tablets taken sublingually 3 times daily for a period of 14 consecutive days, at approximately midday, evening and bedtime and not to be taken with meals.
62660056|NCT04490707|NO_INTERVENTION|Observation|Arm 3(Observation): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter observation.
62660057|NCT06549543|EXPERIMENTAL|High-Intensity Laser Therapy|This group (n = 21) received transcutaneous electrical nerve stimulation (TENS), hotpack (HP), exercises, and high-intensity laser therapy (HILT) for 10 consecutive sessions.
62660058|NCT06549543|SHAM_COMPARATOR|Control|This group (n = 22) received TENS, HP, exercises, and placebo HILT for 10 consecutive sessions.
62660059|NCT05193487|ACTIVE_COMPARATOR|inferior alveolar nerve block|Conventional inferior alvoelar nerve block anaesthesia will be given using a traditional metal syringe
62660060|NCT05193487|EXPERIMENTAL|intra-osseous mandibular anaesthesia|Computerized intraosseous anesthesia administration using the Quick Sleeper 5TM system (Dental Hi TecTM, Cholet, France)
62660061|NCT06356493||Group1|Patients treated by caesarean hysterectomy without prior placement of prophylactic occlusion balloons of both internal iliac arteries
62660062|NCT06356493||Group2:|Patients treated by caesarean hysterectomy with prior placement of prophylactic occlusion balloons of both internal iliac arteries
62660063|NCT01837342|OTHER|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
62660064|NCT01837342|EXPERIMENTAL|Control arm|laproscopic drainage and washing
62660065|NCT03704688|EXPERIMENTAL|Phase I: Dose Level -3|Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily
62660066|NCT03704688|EXPERIMENTAL|Phase I: Dose Level -2|Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily
62660067|NCT03704688|EXPERIMENTAL|Phase I: Dose Level -1|Trametinib 1.5 mg PO q daily 15mg PO q daily
62660068|NCT03704688|EXPERIMENTAL|Phase I: Dose Level 1|Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily
62660069|NCT03704688|EXPERIMENTAL|Phase I: Dose Level 2|Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily
62660070|NCT03704688|EXPERIMENTAL|Phase II|Maximum tolerated dose as established in Phase I portion
62660071|NCT00757900|ACTIVE_COMPARATOR|1|To receive a sub-unit influenza vaccine
61908928|NCT04712240|OTHER|Respiration rate monitor (concurrently measured with standard of care capnography)|Single group study whereupon participants will be fitted with portable respiration rate monitor around their chest for duration of surgery. Respiration rates acquired by the respiration rate monitor will be compared to capnography, which is standard of care and applied to all surgical cases
62660072|NCT00757900|NO_INTERVENTION|2|
62293641|NCT06363162|EXPERIMENTAL|Perform two different tests on the same sample|Perform the diagnosis of Raman analyzer and immunohistochemistry or genetic test on the same sample.
62465838|NCT06278077|PLACEBO_COMPARATOR|Placebo|Two tablets taken sublingually 3 times daily for a period of 14 consecutive days as for Neurexan
62660073|NCT01334047|EXPERIMENTAL|DC vaccine|Dendritic cells loaded with amplified ovarian cancer stem cell mRNA, hTERT and Survivin.
62660074|NCT05398588|EXPERIMENTAL|Cyriax Deep Friction Massage|Cyriax Deep Friction Massage on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
62660075|NCT05398588|EXPERIMENTAL|Spencer Muscle energy technique|"The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/weeK"
61908929|NCT02358356|ACTIVE_COMPARATOR|PRRT|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.
62465839|NCT01667679|EXPERIMENTAL|OPTINOSE SUMATRIPTAN and Placebo|20 mg OPTINOSE SUMATRIPTAN Powder Delivered Intranasally With the Bi-directional Device nasally and Placebo Tablet
61908930|NCT02358356|ACTIVE_COMPARATOR|CAPTEM|Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
62465840|NCT01667679|ACTIVE_COMPARATOR|100mg Sumatriptan and OPTINOSE Placebo|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
62465841|NCT02301325|OTHER|0.03 mg Nicotine Cigarette|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes
62465842|NCT02301325|OTHER|0.03 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
62465843|NCT02301325|OTHER|0.80 mg Nicotine Cigarette|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.
62465844|NCT02301325|OTHER|0.80 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
62660076|NCT05856435|OTHER|Chicago Parent Program for Foster Care|Caregiver parent training sessions.
62660077|NCT01949272||ARDS|ARDS patients achieving stades II and III of Berlin 2011 Classification
62660078|NCT04044508|ACTIVE_COMPARATOR|Interventional diet|A modified ketogenic diet (with the composition found in the pilot study, 75%fat, 15% protein, 10% carbohydrates)
62660079|NCT04044508|PLACEBO_COMPARATOR|Placebo diet|A placebo diet (over 100 g of carbohydrates per day)
62660080|NCT03797729|PLACEBO_COMPARATOR|Normal saline|
62660081|NCT03797729|EXPERIMENTAL|Tirofiban|
62660082|NCT02758470|EXPERIMENTAL|Acetazolamide|Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.
62660083|NCT02758470|EXPERIMENTAL|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.
62660084|NCT02758470|PLACEBO_COMPARATOR|Placebo|Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.
61908931|NCT02358356|EXPERIMENTAL|PRRT/CAPTEM|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.
61908932|NCT04944056|ACTIVE_COMPARATOR|Control Group|It includes ultrasound therapy, glides, exercises and home plan.
61908933|NCT04944056|EXPERIMENTAL|Experimental Group|It includes ultrasound therapy, glides, exercises, compression mobilization and home plan.
61908934|NCT02632123||Development cohort|Patients newly diagnosed with idiopathic pulmonary fibrosis
62096372|NCT06614673|EXPERIMENTAL|Non-Narrative Animation|The animation with a total duration of 3:35 min is based on the text in non-narrative form and aims to be as fully comparable as possible.
62096373|NCT06614673|EXPERIMENTAL|Narrative Animation|The animaion (4:04 min) is based on the text in narrative form and aims to be as fully comparable as possible.
62096374|NCT06614673|NO_INTERVENTION|Control Group|After completing all the questionnaires (i.e. after completing participation in the study), the control group will be given the opportunity to view all the information material that was created.
62293642|NCT00803114|EXPERIMENTAL|Epidural Morphine|2.5 mg dose of epidural morphine given within one hour following vaginal delivery
62293643|NCT00803114|PLACEBO_COMPARATOR|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
62293644|NCT02345798|ACTIVE_COMPARATOR|Arm I (standard care)|Patients and caregivers receive standard care during routine clinic visits.
62465845|NCT06171360||Metastatic HR-positive HER2-negative breast cancer|"Patients with metastatic HR+ HER2- BC starting a first line treatment with a CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib).~Investigators will regularly collect blood and fecal samples for correlative translational research."
61908935|NCT02632123||Validation cohort|Patients newly diagnosed with idiopathic pulmonary fibrosis
62096375|NCT04370093|EXPERIMENTAL|Pioglitazone Drug (including Placebo)|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
62096376|NCT04370093|EXPERIMENTAL|Weight Loss, Behavioral|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
62096377|NCT04370093|OTHER|Pioglitazone + Weight Loss|Pioglitazone 45 mg/day + Weight Loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
62096378|NCT01743651|PLACEBO_COMPARATOR|Placebo|Placebo
62096379|NCT01743651|ACTIVE_COMPARATOR|Baclofen|80 mg/day of Baclofen Tablets, USP
62096380|NCT01743651|EXPERIMENTAL|Arbaclofen|40 mg/day of Arbaclofen Tablets
62096381|NCT06235879|OTHER|Group A (Control Group|Patients will receive ultrasound guided Interscalene brachial plexus (ISB) block after induction of general anesthesia.
62096382|NCT06235879|EXPERIMENTAL|Group B (Pericapsular nerve group (PENG) block)|Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia
62293645|NCT02345798|EXPERIMENTAL|Arm II (video-assisted intervention)|Patients view Parts 1 and 2 of the video program, which focus on what to expect before surgery and after surgery in the hospital, on a tablet over approximately 8 minutes at a scheduled pre-operative visit. Patients then receive an educational handbook and discuss the video with a nurse. After surgery and before hospital discharge, patients view Part 3 of the video over approximately 6 minutes, which focuses on what to expect after going home.
62293646|NCT03396328|ACTIVE_COMPARATOR|Conventional education|
62293647|NCT03396328|EXPERIMENTAL|Low salt dietary education by smartphone application|
62293648|NCT01393093|ACTIVE_COMPARATOR|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
62660085|NCT02949934|PLACEBO_COMPARATOR|Placebo/rs4680 val/val|"Placebo three times per day for eight days~Individuals with the rs4680 val/val genotype"
62660086|NCT02949934|ACTIVE_COMPARATOR|Tolcapone/rs4680 val/val|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/val genotype"
62660087|NCT02949934|PLACEBO_COMPARATOR|Placebo/rs4680 val/met|"Placebo three times per day for eight days~Individuals with the rs4680 val/met genotype"
62660088|NCT02949934|ACTIVE_COMPARATOR|Tolcapone/rs4680 val/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/met genotype"
62660089|NCT02949934|PLACEBO_COMPARATOR|Placebo/rs4680 met/met|"Placebo three times per day for eight days~Individuals with the rs4680 met/met genotype"
61908936|NCT00266786|EXPERIMENTAL|Intranasal Ketorolac Tromethamine|
61908937|NCT00266786|PLACEBO_COMPARATOR|Intranasal Placebo|
62096383|NCT02622425|ACTIVE_COMPARATOR|PD01|Carotenoid-producing Bacillus strain PD01
62096384|NCT02622425|PLACEBO_COMPARATOR|Placebo|Maltodextrin
61908938|NCT05461378||Outpatients|Outpatients who have not yet received EVUSHELD but who plan on receiving it in the future.
62465846|NCT06171360||Early HR-positive HER2-negative breast cancer at high risk of relapse|"Patients with early HR+ HER2- BC at high risk of relapse, starting adjuvant treatment with a CDK4/6 inhibitor (abemaciclib, ribociclib).~Investigators will regularly collect blood and fecal samples for correlative translational research."
62660090|NCT02949934|ACTIVE_COMPARATOR|Tolcapone/rs4680 met/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 met/met genotype"
61908939|NCT05461378||Select inpatients (SOT/HCT/CAR-T)|Newly transplanted adult solid organ transplant and HCT recipients, as well as CAR-T-cell therapy recipients, during their hospitalization to undergo SOT/HCT/CAR-T-cell therapy
61908940|NCT05461378||Individuals who have received EVUSHELD|Individuals who have received EVUSHELD within 9 months of enrollment.
62096385|NCT01442168|EXPERIMENTAL|Sevuparin/DF02|Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
62096386|NCT01442168|ACTIVE_COMPARATOR|Control|Anti-malarial regimen (Malanil®) alone
62096387|NCT06630312|PLACEBO_COMPARATOR|Yellow beans|Yellow beans, cooked in spaghetti sauce
62465847|NCT03995420|EXPERIMENTAL|Virtual Reality Therapy (V-NeST)|Participants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
62465848|NCT03995420|OTHER|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) only.
61908941|NCT00653432|EXPERIMENTAL|Monovisc®|Injectable Hyaluronic Acid Gel
61908942|NCT00653432|PLACEBO_COMPARATOR|Saline|0.9% Sterile Saline
62096388|NCT06630312|EXPERIMENTAL|Yellow beans with AGS|Yellow beans, cooked in spaghetti sauce, with AGS treatment
62096389|NCT06630312|PLACEBO_COMPARATOR|Yellow bean pasta|Yellow bean pasta with spaghetti sauce
62096390|NCT06630312|EXPERIMENTAL|Yellow bean pasta with AGS|
62096391|NCT02658721|EXPERIMENTAL|lidocaine+adjunct tramadol|In the first group (LDC+TRA group), IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation.
62096392|NCT02658721|EXPERIMENTAL|lidocaine+systemic tramadol|In the second group (LDC+SysTRA group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation.
61908943|NCT02068898|EXPERIMENTAL|XS003 Dose-level 1|Capsule formulation
61908944|NCT02068898|EXPERIMENTAL|XS003 Dose-level 2|Capsule formulation
61908945|NCT02068898|EXPERIMENTAL|XS003 Dose-level 3|Capsule formulation
61908946|NCT02068898|EXPERIMENTAL|Tasigna|Marketed capsule
61908947|NCT04954248|EXPERIMENTAL|Covid-19 Negative/Uninfected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
61908948|NCT04954248|EXPERIMENTAL|Covid-19 Positive/Infected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
62096393|NCT02658721|ACTIVE_COMPARATOR|lidocaine|In the third group (LDC group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL.
62096394|NCT06183164|EXPERIMENTAL|Mindfulness|The program lasts eight weeks, with face-to-face group meetings for 2-2.5 hours per week and applications requested from the patient. It is a program in which various mindfulness practices are used consecutively for eight weeks and completed with a six-hour silence (retreat) day at the end of the eight weeks.
62096395|NCT06183164|NO_INTERVENTION|Control group|Routine main tenance will be applied.
62293649|NCT01393093|EXPERIMENTAL|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
62293650|NCT01393093|EXPERIMENTAL|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
62293651|NCT01393093|EXPERIMENTAL|TACE-KMG(withou chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
62293652|NCT01682005||Complete RV vaccination|Subjects had received 2 doses of Rotarix or 3 doses of Rotateq/mixed within the vaccination window and the observation time is from the end of the vaccination window (8 months old) to end of observation.
62660091|NCT03880565|EXPERIMENTAL|ECMO Facilitated Resuscitation|Regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, patients will enter the Cardiac Catheterization Laboratory (CCL) for expeditious VAECMO initiation, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
62660092|NCT03880565|OTHER|Standard ACLS Resuscitation|Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI, and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
62660093|NCT06551558|EXPERIMENTAL|RéGlo arm|Innovative support with global warming strategy.
62293653|NCT01682005||Incomplete RV vaccination|Subjects received at least one vaccination but less than complete vaccination has been received within the vaccination window and the observation time from 8 months old (if still observed) to end of observation.
62096396|NCT06611644|ACTIVE_COMPARATOR|Erector Spinae Plane (ESP) block group|This group will include patients who undergo the Erector Spinae Plane (ESP) block. The ESP block will be performed under ultrasound guidance, with a needle placed on the transverse process of the vertebra to inject local anesthetic into the erector spinae muscle.
62096397|NCT06611644|ACTIVE_COMPARATOR|Serratus Posterior Superior Intercostal Plane (SPSIP) block|This group will include patients who undergo the Serratus Posterior Superior Intercostal Plane (SPSIP) block. The SPSIP block will be performed under ultrasound guidance, injecting local anesthetic into the plane between the serratus posterior superior muscle and the intercostal muscles.
62293654|NCT01682005||Any RV vaccination before 8 months|Subjects received any vaccination within the vaccination window and the observation time from 6 weeks old to earliest of end of observation or 8 months old.
62293655|NCT01682005||Historical unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and the observation time is from 6 weeks old (if still observed and on/before 12/31/06) to earliest of: 12/31/2006, end of observation, or 8 months old.
62293656|NCT01682005||Historical unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 8 months old (if still observed and on/before 12/31/2006) to earliest of: 12/31/2006 or end of observation.
62293657|NCT01682005||Contemporary unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 6 weeks old (if on/after 01/01/2007) to earliest of: end of observation, or 8 months old.
62293658|NCT01682005||Contemporary unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window observation time is from 8 months old (if on/after 01/01/2007) to end of observation.
62293659|NCT05696938|ACTIVE_COMPARATOR|Wonderlab Nicotinamide Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~* Nicotinamide 0.39 mg~* Vitamins C 300 mg~* Hyaluronic acid 50 mg~* Tomato powder 120 mg"
62465849|NCT03880266|ACTIVE_COMPARATOR|Group 1 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
62660094|NCT06551558|OTHER|Control arm|Support according to recommendations
62096398|NCT06611644|OTHER|Control Group|Patients in this group will receive standard postoperative pain management. This management will be provided through systemic analgesics (e.g., paracetamol, nonsteroidal anti-inflammatory drugs, and opioids if necessary) based on the patient's pain level during the postoperative period. This group will consist of patients who do not receive regional blocks, and pain management will be conducted according to the standard procedure of the surgery.
62293660|NCT05696938|PLACEBO_COMPARATOR|Ordinary Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~* Litchi juice 0.7 g~* Erythritol 2 g~* Pectin 0.25 g"
62096399|NCT03022266|EXPERIMENTAL|Intervention Arm|Participants receiving the Financial Incentive and Mobile Phone App will be given an smartphone app offering pill reminders and $50/month financial incentives for three months to upload photos of medication each day for 90 days. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
62293661|NCT04994925|ACTIVE_COMPARATOR|Control ready meal|Control supermarket brand ready meal with high energy density
62293662|NCT04994925|EXPERIMENTAL|Test ready meal with low energy density|Slimming world test ready meal with low energy density
62293663|NCT04552470|PLACEBO_COMPARATOR|Placebo|
62293664|NCT04552470|EXPERIMENTAL|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
62293665|NCT04552470|EXPERIMENTAL|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
62293666|NCT04552470|EXPERIMENTAL|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
62293667|NCT00717730|PLACEBO_COMPARATOR|A|Placebo dietary supplement
62293668|NCT00717730|EXPERIMENTAL|B|Folic acid
62293669|NCT00717730|EXPERIMENTAL|C|Vitamin B12
62293670|NCT00717730|EXPERIMENTAL|D|Folic acid and Vitamin B12
62293671|NCT02995434|EXPERIMENTAL|Intervention Group|Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the immersive virtual reality application with a Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 30 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
62293672|NCT02995434|ACTIVE_COMPARATOR|Control Group|The control group will be exposed to 2D PC equivalent versions of the same multimedia experiences but on their PC screen (without the Virtual Reality headset use). These will be functionally similar to the VR experiences.
62293673|NCT05005884|ACTIVE_COMPARATOR|oral phenolics intake|Prescription of oral phenolics 250 mg two times daily
62293674|NCT05005884|PLACEBO_COMPARATOR|placebo caplet intake|Prescription of oral phenolics 250 mg two times daily
62293675|NCT03545139|EXPERIMENTAL|NeoMTA (intervention group)|Revascularization with NeoMTA as coronal plug.
62293676|NCT03545139|ACTIVE_COMPARATOR|White MTA (Control group)|Revascularization with Conventional white mineral trioxide aggregate (White MTA) as coronal plug.
62293677|NCT01498133|EXPERIMENTAL|skin-to-skin contact|Newborns in the study group had skin-to-skin contact with their mothers in the NICU, twice a day (morning and evening) for 60 minutes, for seven days (including weekends).
62465850|NCT03880266|PLACEBO_COMPARATOR|Group 1 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
62293678|NCT01498133|NO_INTERVENTION|control group|The control group (n = 49) received routine care without skin-to-skin contact.
62293679|NCT05432531|EXPERIMENTAL|Baracetinib|oral tablet 4 mg baricitinib and placebo IV infusion/ month
62293680|NCT05432531|ACTIVE_COMPARATOR|Cyclophosphamide|IV cyclophosphamide 0.7mg/m2 every month and placebo tablet daily
62293681|NCT05338008|EXPERIMENTAL|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 20ml of normal saline was injected directly into the joint.
62293682|NCT05338008|EXPERIMENTAL|Intrawound Administration of Vancomycin combined with epsilon-aminocaproic acid (EACA)|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 4g (20ml) of epsilon-aminocaproic acid (EACA) was injected directly into the joint.
62293683|NCT01504802||Growth hormone deficient|Children with short stature, a peak growth hormone response on stimulation testing of less than 7 ng/ml, and no other identifiable cause of short stature
62293684|NCT01504802||Idiopathic short stature|Children with short stature, a peak growth hormone response on stimulation testing of greater than or equal to 7 ng/ml, and no identifiable cause for the short stature
62293685|NCT06393283|EXPERIMENTAL|the intervention group|Diaphragm Training will be given twice a day and 30min per time.
62293686|NCT06393283|NO_INTERVENTION|the blank group|No intervention will be applied.
62293687|NCT01743430|EXPERIMENTAL|telerehabilitation|telerehabilitation via internet
62293688|NCT01743430|NO_INTERVENTION|conventional|conventional therapy
62293689|NCT01053910|EXPERIMENTAL|Ramipril|Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)
62465851|NCT03880266|ACTIVE_COMPARATOR|Group 2 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
62096400|NCT03022266|NO_INTERVENTION|Usual Care Control Arm|Participants in the usual care control arm will receive the usual education about medications provided by hospital staff. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
62096401|NCT04644861|OTHER|Elders aged 70|Program of adapted physical activity
62096402|NCT04671628|EXPERIMENTAL|Relaxing music|
62096403|NCT04671628|NO_INTERVENTION|Control|
62096404|NCT00578227|EXPERIMENTAL|Cervarix™ & Twinrix™ Group|Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A \& Hepatitis B (HAB) vaccine (Months 0, 1 \& 6).
62465852|NCT03880266|PLACEBO_COMPARATOR|Group 2 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
62465853|NCT03880266|ACTIVE_COMPARATOR|Group 3 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes
62096405|NCT00578227|EXPERIMENTAL|Cervarix™ Group|Subjects received 3 doses of HPV vaccine (Months 0, 1 \& 6).
62096406|NCT00578227|ACTIVE_COMPARATOR|Twinrix™ Group|Subjects received 3 doses of HAB vaccine (Months 0, 1 \& 6).
62096407|NCT00788424|EXPERIMENTAL|AS101 Cream|Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.
62096408|NCT00788424|EXPERIMENTAL|Placebo|Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.
62096409|NCT03722303|ACTIVE_COMPARATOR|Steroid Injection|Subjects with CTS will receive steroid injection.
62465854|NCT03880266|PLACEBO_COMPARATOR|Group 3 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes
62465855|NCT03880266|ACTIVE_COMPARATOR|Group 4 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes
62096410|NCT03722303|EXPERIMENTAL|Fat Injection|Subjects with CTS will receive fat injection.
62096411|NCT06391203|EXPERIMENTAL|Long-term Drainage|The drainage catheter is indwelling continuously and keeps to drainage for 7 days.
62096412|NCT06391203|ACTIVE_COMPARATOR|Short-term Drainage|The drainage catheter is indwelling continuously and keeps to drainage for 2 days.
62096413|NCT05489224|EXPERIMENTAL|CT-P47|CT-P47(Tocilizumab)
62096414|NCT05489224|ACTIVE_COMPARATOR|EU-approved RoActemra|EU-approved RoActemra(Tocilizumab)
62096415|NCT04642053|EXPERIMENTAL|Immediate Treatment|Participants in the Immediate Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin between 1-3 weeks following the diagnostic evaluation.
62660095|NCT04677257|EXPERIMENTAL|STEMI acute myocardial infarction treated with effective primary PCI|STEMI patients treated with effective primary PCI to assess the ability of coronary physiology parameters (CFR and IMR) measured soon after recanalization to predict myocardial tissue characterization assessed with cardiac magnetic resonance (CMR) within a week of the acute event.
62660096|NCT01063907|EXPERIMENTAL|Phase 1: Cohort 1|Cohort 1: KW 2478 130 mg/m\^2 and Bortezomib 1.0 mg/m\^2
62660097|NCT01063907|EXPERIMENTAL|Phase 1: Cohort 2|Cohort 2: KW 2478 130 mg/m\^2 and Bortezomib 1.3 mg/m\^2
62660098|NCT01063907|EXPERIMENTAL|Phase 1: Cohort 3|Cohort 3: KW 2478 175 mg/m\^2 and Bortezomib 1.0 mg/m\^2
62660099|NCT01063907|EXPERIMENTAL|Phase 1: Cohort 4|Cohort 4: KW 2478 175 mg/m\^2 and Bortezomib 1.3 mg/m\^2
62660100|NCT01063907|EXPERIMENTAL|Phase 2|KW 2478 175 mg/m\^2 and Bortezomib 1.0 mg/m\^2
62660101|NCT04648176|ACTIVE_COMPARATOR|HoLEP|Conventional laser
62660102|NCT04648176|EXPERIMENTAL|m-HoLEP|Moses technology
61908949|NCT02251548|EXPERIMENTAL|Ibrutinib|"- Ibrutinib-~* Oral, daily during each cycle~* fludarabine-administered at standard dosing for up to 6 cycles~* cyclophosphamide-administered at standard dosing for up to 6 cycles~* rituximab-administered at standard dosing for up to 6 cycles"
61908950|NCT04634045|EXPERIMENTAL|Web-Based Treatment|A web-based treatment for pediatric overweight or obesity will be piloted with 10 caregiver and child pairs. Assessments will take place pre (0 months), post intervention (3.5 months) and at six months post-intervention (9.5 months) to evaluate patient outcomes, acceptability and feasibility.
62096416|NCT04642053|EXPERIMENTAL|Delayed Treatment|The Delayed Treatment Group serves as a control during the period in which participants are waiting to begin treatment. A delayed treatment onset is employed to control for maturation effects. Participants in the Delayed Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin after an 8-week delay following the diagnostic evaluation.
62096417|NCT06340880||ultrasound vs anatomical landmark SAPB|Forty subjects presenting for gynecomastia surgery will receive ultrasound guided block in one side (US group) and landmark guided block in the other side (LM group) with the same volume (25) ml and concentration (0.25 %) of bupivacaine.
62096418|NCT02250144|EXPERIMENTAL|Morpho-specific foot orthoses|"Morpho-specific thermo-molded foot orthoses are designed according to the patient's morphotype.~Orthoses are custom-molded from different materials such as BIOFLUX resin, Covercuir MF, EVA300/60, EVA400/70, PE255/55, ABSORB Dur and CAPITON PU."
62096419|NCT02250144|PLACEBO_COMPARATOR|Placebo foot orthoses|The placebo foot orthoses will be made with the same principle of molding and with the same materials as for the experimental group. The only difference is that they involve no active corrective insert element : they will be made without morphotype correction.
62096420|NCT06376019|PLACEBO_COMPARATOR|group CD (conventional complete denture group)|patients will receive a conventional complete denture with no implant placement
62096421|NCT06376019|ACTIVE_COMPARATOR|group IB (implant-supported overdenture with ball attachment)|patients will receive an implant-supported overdenture with ball attachment. The overdenture will be relined by a soft liner.
62660103|NCT01137786|ACTIVE_COMPARATOR|IOPAMIDOL 370|
62660104|NCT01137786|ACTIVE_COMPARATOR|IODIXANOL 320|
62660105|NCT05426525|EXPERIMENTAL|Empagliflozin|Participants will be provided 10-25mg empagliflozin per day for 13 weeks.
62660106|NCT05426525|PLACEBO_COMPARATOR|Multivitamin-Placebo|Participants will be provided 1 multivitamin-placebo per day for 13 weeks.
62660107|NCT06373510|OTHER|Observational arm|
61908951|NCT01517360|ACTIVE_COMPARATOR|Placebo+Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
62293690|NCT04747405|NO_INTERVENTION|A standard|standard of care
62293691|NCT04747405|EXPERIMENTAL|B therapy group|standard of care and therapy group
62660108|NCT03236389|EXPERIMENTAL|Collar Wearing|subjects will wear collar during MRI testing
62660109|NCT06310863|EXPERIMENTAL|test group|The test device, LASBEAU Strong, was developed for the purpose of temporary improvement of facial nose and lip wrinkles, which is the same indication as the control device, and has a hyaluronic acid structure similar to that of Restylane® Lyft Lidocaine, and was developed using the same crosslinker, 1,4-butanediol diglycidyl ether. The test device, LASBEAU Strong, has a higher content of hyaluronic acid than the control device, Restylane® Lyft Lidocaine, but the clinical efficacy cannot be evaluated as superior because of the high content of hyaluronic acid. This is because, in addition to the content of hyaluronic acid, differences in the manufacturing process can affect the physicochemical properties and decomposition period.
62660110|NCT06310863|ACTIVE_COMPARATOR|control group|Restylane® Lyft Lidocaine, a previously licensed product with the same ingredients as the test group, was selected as the control group. Restylane® Lyft Lidocaine is a representative filler formulation that has been recognized for the temporary improvement of facial nose and lip wrinkles, and it was selected as a control group because it is similar to the clinical trial medical device in the test group, and the application site and application method are the same. The control device, Restylane® Lyft Lidocaine, is a product imported and sold by Galderma Korea, which is a bacterial fermentation product and is known as non-animal hyaluronic acid. The purpose of use is to temporarily improve the wrinkles of the nose and lips of the face.
62660111|NCT05268289|ACTIVE_COMPARATOR|Iptacopan + standard of care (part 1)|Iptacopan + standard of care
62660112|NCT05268289|PLACEBO_COMPARATOR|Placebo matching iptacopan + standard of care (part 1)|Placebo matching iptacopan standard of care
62660113|NCT05268289|ACTIVE_COMPARATOR|Iptacopan + standard of care (part 2)|Iptacopan + standard of care
62660114|NCT05268289|ACTIVE_COMPARATOR|Iptacopan + placebo (part 2)|Iptacopan + placebo standard of care
62660115|NCT05268289|ACTIVE_COMPARATOR|Placebo matching iptacopan + standard of care (part 2)|Placebo matching iptacopan + standard of care
62660116|NCT03690544|EXPERIMENTAL|Single Arm|Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
62660117|NCT01684800|ACTIVE_COMPARATOR|A. Desmopressin 10 microgram|
62660118|NCT01684800|ACTIVE_COMPARATOR|B. Desmopressin 25 microgram|
62660119|NCT01684800|PLACEBO_COMPARATOR|C. Placebo|
62293692|NCT06008548||TACE group|Incorporated HCC patients underwent TACE therapy.
62660120|NCT00705419||Previous vicriviroc 30 mg QD|Subjects who previously received vicriviroc 30 mg daily in a Phase 2 or 3 clinical trial.
62660121|NCT00705419||Previous vicriviroc 20 mg QD|Subjects who previously received vicriviroc 20 mg daily in a Phase 2 or 3 clinical trial.
62660122|NCT00705419||Control Group|Subjects who previously received active control or placebo in a Phase 2 or 3 clinical trial involving vicriviroc.
62660123|NCT01056536|EXPERIMENTAL|Structured intervention + free condoms|The subjects will receive a structured intervention on STI's and will be offered free condoms
62660124|NCT01056536|ACTIVE_COMPARATOR|Free condoms|Subjects will be offered free condoms at the end of the pre-travel consultation
62660125|NCT01056536|NO_INTERVENTION|No intervention|The topic of STI's will not be actively discussed during the pretravel consultation
62660126|NCT00309179|EXPERIMENTAL|1|
61908952|NCT01517360|EXPERIMENTAL|Oxytocin+Social Cognitive Skill Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
62660127|NCT02508389|EXPERIMENTAL|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
62660128|NCT02508389|EXPERIMENTAL|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
62660129|NCT02508389|PLACEBO_COMPARATOR|Placebo|Placebo daily, prior to IMRT
62660130|NCT04213131|OTHER|Rehabilitation control group|Routine rehabilitation treatment for chronic spinal cord injury and Intravenous injection of 100 mL 0.9% saline solution.
62660131|NCT04213131|EXPERIMENTAL|hUC-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUC-MSCs
62660132|NCT04213131|EXPERIMENTAL|hUC-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUC-MSCs and 5 mL of cerebrospinal fluid
62660133|NCT04213131|EXPERIMENTAL|hUC-MSCs local administration group|hUC-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUC-MSCs/point.
62660134|NCT04213131|EXPERIMENTAL|hUCB-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUCB-MSCs
61908953|NCT02718170|EXPERIMENTAL|Buried Intramedullary K-wire Fixation|Patients randomized to buried intramedullary k-wire fixation will undergo a standardized antegrade open reduction and fixation procedure with an intramedullary k-wire.
61908954|NCT02718170|ACTIVE_COMPARATOR|Plate and Screw Fixation|Patients randomized to Plate and Screw Fixation will undergo a standardized open reduction and internal fixation with plate and screws. Brand of plate will be left to the operating surgeon's discretion.
61908955|NCT04184388|EXPERIMENTAL|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng extract for 1g/day
61908956|NCT04184388|PLACEBO_COMPARATOR|Placebo|Hydrolysed Red Ginseng extract for 0g/day
62660135|NCT04213131|EXPERIMENTAL|hUCB-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUCB-MSCs and 5 mL of cerebrospinal fluid
62660136|NCT04213131|EXPERIMENTAL|hUCB-MSCs local administration group|hUCB-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUCB-MSCs/point.
62660137|NCT02662543||Hospitalized AGE patients|Children less than 18-years-old hospitalized due to acute gastroenteritis to seven Estonian hospitals participating in this study
62660138|NCT02136589|EXPERIMENTAL|Dicrofenac|
62660139|NCT03518944||occult premature ovarian insufficiency|Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion \>4 weeks apart
62660140|NCT02617251||neonatology patients|neonatology patients
62660141|NCT02617251||paediatric patients|paediatric patients
62660142|NCT01706627|PLACEBO_COMPARATOR|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
62660143|NCT01706627|ACTIVE_COMPARATOR|Drug: 10 mg Melatonin|10 mg melatonin gelatin capsule
62293693|NCT06008548||Liver resection group|Incorporated HCC patients underwent liver resection therapy.
62308105|NCT03077295|EXPERIMENTAL|High Protein to High-Fibre (HP-HF)|"* Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~* Phase 2: consumption of HP meals for 4 weeks~* Phase 3: washout for 1 week, controlled maintenance diet~* Phase 4: consumption of HF meals for 4 weeks"
62308106|NCT04600999|EXPERIMENTAL|Group Avigan|Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.
62660144|NCT01706627|ACTIVE_COMPARATOR|Drug: 20 mg Melatonin|20 mg melatonin gelatin capsule
62660145|NCT06125665|EXPERIMENTAL|Aminophylline-Dexmedetomidine Group|10 minutes after endotracheal intubation, patients will receive IV bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.
61908957|NCT05516563|ACTIVE_COMPARATOR|EDucation and eXercise intervention (EDX)|EDX-Ireland will involve 6 face-to-face education and exercise sessions on a individualised basis with a physiotherapist, delivered over eight weeks. This will be supplemented by a home based exercise programme.
61908958|NCT05516563|NO_INTERVENTION|Usual Care|"Participants will continue to follow what they have done so far for their hip pain, or what their doctor has suggested/prescribed. If a participant is referred to physiotherapy as part of the usual care treatment, waiting time will be recorded.~Participants will receive a written information leaflet on the pathology of gluteal tendinopathy and general advice on symptom management."
62096422|NCT06376019|ACTIVE_COMPARATOR|group II (implant-supported overdenture with an intraoral welded bar)|patients will receive an implant-supported overdenture with an intraoral welded bar. The overdenture will be relined by a soft liner.
62293694|NCT06220695|EXPERIMENTAL|Mediterranean Diet Group|"The Mediterranean diet includes high amounts of olive oil, olives, fruits, vegetables, whole grains, legumes, nuts, a high intake of fish, moderate consumption of eggs, poultry, and dairy, and low consumption of red meat and products. The targeted macronutrient distribution is 40% of total energy from carbohydrates, approximately 20% from protein, and 40% from fats. The share of saturated fats in total energy will not exceed 10%. Participants will be provided with written resources, brochures explaining the Mediterranean diet, and information about the Mediterranean diet pyramid. A weekly menu will be planned for all participants, along with cooking tips.~Participants in this group will receive a weekly food support package for 12 weeks, including essential elements of the Mediterranean diet such as olive oil, fish, nuts, and legumes."
62308107|NCT04600999|NO_INTERVENTION|Group Control|Supportive care (symptomatic therapy)
62465856|NCT03880266|PLACEBO_COMPARATOR|Group 4 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes
62465857|NCT03080597|EXPERIMENTAL|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
62465858|NCT03471078|EXPERIMENTAL|Avatrombopag|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
62465859|NCT03471078|PLACEBO_COMPARATOR|Placebo|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
62465860|NCT05380895||SVT group|Varicose vein patients complicated with superficial thrombophlebitis
62465861|NCT05380895||Non-SVT group|Patients had varicose vein only
62465862|NCT02281305|EXPERIMENTAL|Colchicine Active treatment group|Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
62465863|NCT02281305|PLACEBO_COMPARATOR|Control group|Drug: Placebo
62465864|NCT02702102|EXPERIMENTAL|11C-PBR28 PET scans|Participants will receive one IV injection of up to 20 millicuries of 11C-PBR28.
62465865|NCT03182114|PLACEBO_COMPARATOR|supine position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in supine position
61908959|NCT01311635|EXPERIMENTAL|Treatment A|
61908960|NCT01311635|EXPERIMENTAL|Treatment B|
61908961|NCT01311635|EXPERIMENTAL|Treatment C|
61908962|NCT01311635|EXPERIMENTAL|Treatment D|
61908963|NCT04367051|EXPERIMENTAL|Withdrawal group|Spironolactone will be discontinued in patients who were receiving optimal medical therapy including angiotensin-converting enzyme or angiotensin receptor blocker or angiotensin receptor neprilysin, beta-blocker, and spironolactone.
61908964|NCT04367051|ACTIVE_COMPARATOR|Continuation group|Spironolactone will be continued during the study period with other medical therapy in combination.
61908965|NCT03746288|EXPERIMENTAL|Treatment Group|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
62096423|NCT06401850|EXPERIMENTAL|Education Group|Training for women with Polycystic Ovary Syndrome (POS) can play an important role in improving quality of life and managing symptoms. These trainings may cover topics such as healthy lifestyle choices, nutritional habits, exercise, stress management and strategies to support hormone balance. Acquiring these knowledge and skills can help women cope with POS, promote psychosocial recovery, and improve their overall quality of life.
62465866|NCT03182114|EXPERIMENTAL|Left lateral tilted position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in left lateral tilted position
62465867|NCT01049607|ACTIVE_COMPARATOR|Clamp-Crush technique|
62465868|NCT01049607|EXPERIMENTAL|Stapler hepatectomy|
62465869|NCT03503422|EXPERIMENTAL|tDCS (anodal) + therapeutic exercises|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
62293695|NCT06220695|ACTIVE_COMPARATOR|Low Fat Diet Group|"The type of diet to be followed in this group is based on the recommendations of the American Heart Association, the American Diabetes Association guidelines, and the Specific Nutrition Guide for Turkey. The targeted macronutrient distribution will be 50% of total energy from carbohydrates, approximately 20% from protein, and less than 30% from fats. The share of saturated fats in total energy will not exceed 10%. Participants will be provided with information notes and brochures explaining the low-fat diet. A weekly menu will be planned for all participants, and cooking tips will be provided.~Participants in this group will receive a weekly food support package for 12 weeks, including low-fat dairy products, whole grains, and legumes, which are the essential elements of a low-fat diet."
61908966|NCT03746288|ACTIVE_COMPARATOR|Control Group|The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.
62096424|NCT06401850|EXPERIMENTAL|Control Group|Since there was no training given to the control group, its effect on the participants' quality of life could not be evaluated. However, considering the potential of regularly provided training for women with polycystic ovary syndrome to improve quality of life, it may be important to provide similar training to the control group and compare the results. In this way, the effectiveness of training can be understood more clearly and the relationship between POS and quality of life can be evaluated more comprehensively.
62293696|NCT04574843|EXPERIMENTAL|Embolization arm|Intervention: Embolization of middle meningeal artery Device: Onyx, squid, Phil
62660146|NCT06125665|ACTIVE_COMPARATOR|Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive IV bolus of dexmedetomidine 0.5 microgm/kg LBW over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
62660147|NCT00303953|EXPERIMENTAL|Arm I|"Patients will receive an infusion of PXD101 once a day for 5 days. Treatment may repeat every 3 weeks for up to 2 years. Some patients will also undergo core biopsy and blood collection for laboratory studies before and after treatment.~After finishing treatment, patients will be evaluated every 3-6 months for up to 3 years."
62660148|NCT04463706||COVID19 REDISSEC|Patients admitted (confirmed cases) by CoVid-19, excluding paediatric population. No losses are expected. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene \[RdRp or S gene\] or PCR positive for at least 2 genes used for screening \[E or N gene\].
62660149|NCT04463706||COVID19 Basque Country|All people from thw Basque Country positive to CoVid-19. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene \[RdRp or S gene\] or PCR positive for at least 2 genes used for screening \[E or N gene\], or, as well and in the general population of the Basque Country, by detection of COVID-19 IgM or IgG antibodies.
61908967|NCT03265964|ACTIVE_COMPARATOR|Uridine|Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks
61908968|NCT03265964|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.
61908969|NCT03721029|EXPERIMENTAL|Intraoperative nerve monitoring|Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
61908970|NCT03721029|ACTIVE_COMPARATOR|Control Cohort|Patients that undergo standard of care robotic-assisted radical prostatectomy.
62096425|NCT00755755|EXPERIMENTAL|A (PGL4001 5mg)|PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
62096426|NCT00755755|EXPERIMENTAL|B (PGL4001 10mg)|PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
62096427|NCT00755755|PLACEBO_COMPARATOR|C (placebo)|PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
62096428|NCT04939428|EXPERIMENTAL|Molnupiravir|Participants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.
62096429|NCT04939428|PLACEBO_COMPARATOR|Placebo|Participants take placebo Q12H on Days 1 to 5.
62293697|NCT01705691|ACTIVE_COMPARATOR|Arm 1: Paclitaxel then AC|Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
62293698|NCT01705691|EXPERIMENTAL|Arm 2: Eribulin then AC|Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles, followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
62308108|NCT04205422|ACTIVE_COMPARATOR|BIPAP group|Biphasic Intermittent Positive Airway Pressure group
62465870|NCT03503422|SHAM_COMPARATOR|tDCS (sham) + therapeutic exercises|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
62660150|NCT05526768|EXPERIMENTAL|VITLS Device|The remote monitoring device (VITLS) will be placed onto the chest of consented patients in a manner that will not interfere with standard in-patient monitoring devices. Subjects will simultaneously be monitored with conventional inpatient methods per the unit routine. The providers caring for participating patients will be blinded to the data being collected by the remote monitoring system and no patient care decisions will be made based on the remote monitoring system. The remote monitoring device will automatically monitor and store the data for each subject by subject ID number. Once at least 6, but up to 72 hours of data have been recorded, the investigational device will be removed. Researchers will then retrospectively obtain the corresponding data from the current standard of care inpatient monitoring devices.
62660151|NCT01980888|EXPERIMENTAL|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
62660152|NCT01980888|PLACEBO_COMPARATOR|Placebo+bendamustine+rituximab|Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
62660153|NCT04675879|EXPERIMENTAL|Velpau bandage (Group 1)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with velpau bandage.
62660154|NCT04675879|EXPERIMENTAL|Shoulder arm sling (Group 2)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with shoulder arm sling.
61908971|NCT02412813|ACTIVE_COMPARATOR|LEGION OXINIUM femoral component|
61908972|NCT02412813|ACTIVE_COMPARATOR|LEGION Cobalt Chrome femoral components|
62293699|NCT06322758|EXPERIMENTAL|ΔP-guided VT group|During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
62465871|NCT04298177|EXPERIMENTAL|QDOT-LAWT|"A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used.~The primary ablation mode for PVI will depend on the calculated LAWT at each atrial point, as follows:~\*\*\< 3.5-mm LAWT (red, and yellow colors): vHPSD ablation will be performed. If \<1-mm LAWT (red color): Power 90 W; the duration of RF applications will be reduced to 2 seconds. If 1-3.5 mm LAWT (yellow color): Power 90 W; the duration of RF applications will be 4 seconds, according to the QDOT-FAST protocol.~\*\*\> 3.5-mm LAWT (green color): QMODE ablation will be performed. 50 W with AI target = 500"
62660155|NCT04675879|EXPERIMENTAL|Padded shoulder arm sling (Group 3)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with padded shoulder arm sling with 30 degree abduction.
62660156|NCT03077867|EXPERIMENTAL|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
62660157|NCT03077867|EXPERIMENTAL|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
62660158|NCT03077867|EXPERIMENTAL|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
62096430|NCT04654351|EXPERIMENTAL|TAK-667|TAK-667, single SC administration on the abdomen on Day 1. The dose of TAK-667 will be dependent on the participant's body weight (Up to 30 mg; 10 mg for 12 kg to 25 kg, 15 mg for 26 kg to 40 kg, 20 mg for 41 kg to 50kg, 25 mg for 51 kg to 65 kg, 30 mg for \>65 kg).
62293700|NCT06322758|ACTIVE_COMPARATOR|PBW-guided VT group|The VT will be kept at 6 mL/kg of PBW. If the plateau pressure threshold is reached (30 cm H2O), the VT will be decreased down to a minimal value of 4 mL/kg of PBW.
62096431|NCT06141564||Early stage HCC|
62096432|NCT06141564||Compensated cirrhosis|
62096433|NCT06141564||Chronic hepatitis without cirrhosis|
62096434|NCT04879355|EXPERIMENTAL|Spinal needle|Fine needle aspiration from thyroid nodules using af spinal needle.
62096435|NCT04879355|ACTIVE_COMPARATOR|Conventional fine needle|Fine needle aspiration from thyroid nodules using af conventional fine needle, which is traditionally used.
62660159|NCT03077867|ACTIVE_COMPARATOR|control|anorganic bovine bone sinus floor augmentation with bone graft
62660160|NCT02131883|EXPERIMENTAL|Group-Cognitive Behavioral Therapy|Group-Cognitive Behavioral Therapy for 7 patients and 2 therapists, 3 hours sessions a week in 12 weeks and a 3 hours booster session 12 weeks after
62660161|NCT02131883|OTHER|Wait-List with treatment as usual|Wait-List with treatment as usual waiting in 9 months for the intervention with group-CBT
62096436|NCT03604835||Patients with MPS VII receiving vestronidase-alfa|via prescription, or early access/ compassionate use program
62293701|NCT02278783|EXPERIMENTAL|Regorafenib Treatment arm, all patients|
62308109|NCT04205422|ACTIVE_COMPARATOR|APRV group|Airway Pressure Release Ventilation group:
62293702|NCT04807959||20Lighter Program Participants|All enrolled subjects will have completed a 20Lighter anti-obesity program prior to enrollment.
62660162|NCT01807455|EXPERIMENTAL|Restylane Vital Lidocaine|
61908973|NCT00727441|EXPERIMENTAL|Arm A|Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.
61908974|NCT00727441|EXPERIMENTAL|Arm B|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..
62096437|NCT03604835||Patients with MPS VII not receiving vestronidase-alfa|no treatment or treatment other than vestronidase alfa
62096438|NCT01991717|EXPERIMENTAL|Victus Group|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
62096439|NCT01991717|OTHER|Conventional Group|The Conventional Group acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually
62096440|NCT05709002|EXPERIMENTAL|MASP+ app & NRT|"MASP+ is an intervention designed to assist Black smokers with HIV who experience elevated anxiety sensitivity to quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal.~Nicotine patches will be made available to provide adjunctive support."
62293703|NCT05083520||critical care patients|
62096441|NCT05709002|ACTIVE_COMPARATOR|QuitGuide app + NRT|"The QuitGuide app is a standard-of-care app that allows users to track nicotine cravings and provides motivational messages.~Nicotine patches will be made available to provide adjunctive support."
62096442|NCT04216160|EXPERIMENTAL|Verum|Patients with mild to moderate acne using ACN Cream
62096443|NCT04216160|EXPERIMENTAL|Placebo|Patients with mild to moderate acne using the placebo cream
62096444|NCT01732575|EXPERIMENTAL|Enrichment|Enrichment with meaning-generating activities
62293704|NCT03881709|EXPERIMENTAL|The intervention group|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
62293705|NCT03881709|NO_INTERVENTION|The control group|The control group will receive a health education about prostate biopsy.
62660163|NCT02545192|EXPERIMENTAL|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
62660164|NCT02545192|SHAM_COMPARATOR|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
62660165|NCT00912119|EXPERIMENTAL|Group A|Group A - Low Dose
62660166|NCT00912119|EXPERIMENTAL|Group B|Group B - Intermediate Dose
62660167|NCT00912119|EXPERIMENTAL|Group C|Group C - High Dose
62660168|NCT00912119|EXPERIMENTAL|Group D|Group D - Extra Low
61908975|NCT00727441|EXPERIMENTAL|Arm C|Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.
61908976|NCT01410617|ACTIVE_COMPARATOR|dialysis|the patients who undergo 3 sessions prophylactic hemodialysis
61908977|NCT01410617|NO_INTERVENTION|control group|the patients who do not undergo hemodialysis
61908978|NCT01819285|ACTIVE_COMPARATOR|Immediate Endocrine Therapy|Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
61908979|NCT01819285|EXPERIMENTAL|Delayed Endocrine Therapy|Orchiectomy or LHRH Therapy plus (initially) Antiandrogen Therapy. BSRL; CPTR. Treatment delayed until onset of symptoms.
61908980|NCT06394362|EXPERIMENTAL|Experimental monitoring group with BIS|Subjects who meet the study criteria and has signed the inform consent will be randomized in a 1:1 ratio into 2 groups, namely Group A undergoing general anesthesia with additional BIS monitoring. When the patient arrives in the preparation room approximately 1 hour before surgery, MMSE evaluation is conducted to obtain preoperative MMSE data. Before anesthesia induction, monitoring and BIS sensor placement are performed
62465872|NCT04298177|ACTIVE_COMPARATOR|CLOSE|"In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. A ThermoCool® SmartTouch® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA) will be used. The ablation will be performed using a proprietary RF generator (SMARTABLATE®; Biosense Webster, Diamond Bar, CA, USA).~Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of ≥ 400 at the posterior wall/roof and ≥ 550 at the anterior wall are reached."
61908981|NCT06394362|NO_INTERVENTION|Control monitoring group without BIS|Subjects who meet the study criteria and has signed the inform consent will be randomized in a 1:1 ratio into 2 groups, Group B undergoing general anesthesia with standard monitoring according to ASA. When the patient arrives in the preparation room approximately 1 hour before surgery, MMSE evaluation is conducted to obtain preoperative MMSE data. The BIS monitor for patients in Group B is then covered (hidden BIS), so that the data cannot be viewed by the anesthesia team performing the anesthesia
61908982|NCT01698307|ACTIVE_COMPARATOR|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
61908983|NCT01698307|OTHER|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Index (HBI).
61908984|NCT02470637|EXPERIMENTAL|SAR439065 + insulin lispro|1 of 6 sequences with single administration of 3 dose levels of SAR439065 (Afrezza Technosphere insulin) and 3 dose levels of insulin lispro with a washout duration between dosing days (7 to 28 days)
61908985|NCT03189056||Single cohort|"single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography~If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure."
61908986|NCT02631382|EXPERIMENTAL|wet cupping : double cupping|wet cupping: (traditional cupping technique): cupping (suction) - Scarification - cupping (suction)
61908987|NCT02631382|EXPERIMENTAL|wet cupping: single cupping|wet cupping:(Asian cupping): Puncture by needles then cupping (suction):
61908988|NCT01375075|EXPERIMENTAL|30 milligrams (mg) LY2484595|Administered orally once daily for 12 weeks
61908989|NCT01375075|EXPERIMENTAL|100 mg LY2484595|Administered orally once daily for 12 weeks
61908990|NCT01375075|EXPERIMENTAL|500 mg LY2484595|Administered orally once daily for 12 weeks
61908991|NCT01375075|PLACEBO_COMPARATOR|Placebo|Administered orally once daily for 12 weeks
62293706|NCT04222829||Megadose Shinbaro Pharmacopuncture Group|"The Megadose Shinbaro Pharmacopuncture group who are treated with korean medical treatment including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
62660169|NCT00775034|EXPERIMENTAL|1|Study group (Tisseel®)
61908992|NCT01375075|ACTIVE_COMPARATOR|10 mg Atorvastatin|Administered orally once daily for 12 weeks
61908993|NCT01375075|EXPERIMENTAL|100 mg LY2484595 + 10 mg Atorvastatin|Administered orally once daily for 12 weeks
62660170|NCT00775034|OTHER|2|Control group
62096445|NCT01732575|NO_INTERVENTION|Rehabilitation as usual|The ongoing, normal day center program.
62096446|NCT04424485|ACTIVE_COMPARATOR|Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy|"Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC)~Standard TT+CLND procedure only"
61908994|NCT02571907|EXPERIMENTAL|Zenith® Branch Endovascular Graft-Iliac Bifurcation|Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the Atrium iCAST™ and the Zenith® Flex AAA Endovascular Graft
61908995|NCT00628043|EXPERIMENTAL|EPOCH|
61908996|NCT00628043|PLACEBO_COMPARATOR|placebo|
61908997|NCT00435253|EXPERIMENTAL|BLVR Treatment|BLVR Treatment
62660171|NCT02901860||Traditional workers|"Individuals who work 'traditional work hours, i.e., 9a-5p."
62096447|NCT04424485|EXPERIMENTAL|Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node|"Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND).~TT+CLND with NIR fluorescence ICG"
62096448|NCT03411811|ACTIVE_COMPARATOR|Usual Care|
62096449|NCT03411811|EXPERIMENTAL|Dextrose|
61908998|NCT00745589|ACTIVE_COMPARATOR|higher dose sevelamer|first-line higher dose sevelamer hydrochloride
61908999|NCT00745589|ACTIVE_COMPARATOR|low dose sevelamer|second-line fixed low-dose sevelamer hydrochloride added to calcium carbonate
61909000|NCT01090895|ACTIVE_COMPARATOR|Vitamin C|Vitamin C infusion
61909001|NCT01090895|PLACEBO_COMPARATOR|Placebo|Saline solution
61909002|NCT03343418|ACTIVE_COMPARATOR|desmopressin|Patients randomized to this group receive desmopressin 0,3 microgram.kg-1 as an intravenous infusion given during 20 min.
61909003|NCT03343418|PLACEBO_COMPARATOR|Placebo|Patients randomized to the control group will receive the infusion of 100 mL 0.9% saline (SF0,9%).
62660172|NCT02901860||Non-traditional workers|Individuals who have work hours outside the usual daytime period
62660173|NCT03243019|EXPERIMENTAL|SIROLIMUS|
61909004|NCT06270758||Fractured subjects|Post-menopausal women who have been hospitalised because of a femur fracture.
61909005|NCT06270758||Control subjetcs|Post-menopausal women without history of fracture
61909006|NCT02219802|ACTIVE_COMPARATOR|Drug-eluting stent|Treatment of infarct related laesion with a drug-eluting stent
61909007|NCT02219802|EXPERIMENTAL|Drug-coated balloon|After treatment of the infarct related artery with a drug-coated ballon, an additional BMS is advised to be used in case of residual stenosis \> 50% or coronary artery dissection type \> B.
61909008|NCT04130308|EXPERIMENTAL|ACL-R|
61909009|NCT04130308|NO_INTERVENTION|Control|
62660174|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
61909010|NCT03001271|EXPERIMENTAL|Healthy Subjects|Placebo and Angiotensin-(1-7) acute infusion
61909011|NCT03001271|EXPERIMENTAL|Hypertensive Subjects|Placebo and Angiotensin-(1-7) acute infusion
61909012|NCT01286961||outpatient colonoscopy, bowel preparation, split dose PEG|adult outpatients who undergo colonoscopy
61909013|NCT00300742|EXPERIMENTAL|Topiramate|Drug: Topiramate Other Name for Topiramate: Topamax
61909014|NCT02289716|PLACEBO_COMPARATOR|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
61909015|NCT02289716|EXPERIMENTAL|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
61909016|NCT02289716|EXPERIMENTAL|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
61909017|NCT01624311|EXPERIMENTAL|Adjunct Hypothermia Arm|Patients that receive adjunct therapeutic hypothermia in addition to standard of care therapy
61909018|NCT01624311|OTHER|Historic Controls|Patients that were treated with standard of care therapy for the same conditions at the sponsoring institution over the past 10 years.
61909019|NCT04763681|EXPERIMENTAL|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
61909020|NCT04763681|NO_INTERVENTION|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
62096450|NCT02899637|EXPERIMENTAL|Spinal Cord Injury (Active Group)|Active high-frequency Transcranial Magnetic Stimulation
62096451|NCT02899637|SHAM_COMPARATOR|Spinal Cord Injury (Control group)|Sham high-frequency Transcranial Magnetic Stimulation
62096452|NCT05359900|EXPERIMENTAL|Pain neuroscience education|Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
61909021|NCT06370715|EXPERIMENTAL|Insulin Lispro-aabc + Insulin Glargine|Participants will receive insulin lispro-aabc in combination with insulin glargine administered by subcutaneous (SC) injection.
62465873|NCT01885455|ACTIVE_COMPARATOR|Usual Care Arm|Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
62096453|NCT05359900|ACTIVE_COMPARATOR|Red flag education|Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
62096454|NCT05860881|EXPERIMENTAL|Topical Sirolimus|Topical 1% sirolimus cream applied daily to the face for 24 weeks
62096455|NCT05860881|PLACEBO_COMPARATOR|Placebo|Topical placebo cream applied daily to the face for 24 weeks
62096456|NCT03415022|EXPERIMENTAL|4-week computer-based treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
62096457|NCT03415022|EXPERIMENTAL|8-week computer-based treatment|An 8-week (12-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks, and then once a week for the subsequent four weeks.
62465874|NCT01885455|EXPERIMENTAL|Intervention Arm|"The PN will provide each patient with a copy of the NCI's What You Need to Know About Lung Cancer booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options.~The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first).~During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum)."
62465875|NCT01705522||IBD patients|patients with ulcerative colitis or crohn's disease, in remission
62465876|NCT05253105|EXPERIMENTAL|TAB006 60mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62465877|NCT05253105|EXPERIMENTAL|TAB006 240mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62465878|NCT05253105|EXPERIMENTAL|TAB006 600mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62465879|NCT05253105|EXPERIMENTAL|TAB006 1800mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62465880|NCT05253105|EXPERIMENTAL|Dose Expansion / TAB006 RP2D and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62096458|NCT05032235|EXPERIMENTAL|Group A|
62096459|NCT05032235|EXPERIMENTAL|Group B|
61909022|NCT01666847|EXPERIMENTAL|Cord Milking|Infant receiving cord milking intervention before umbilical cord clamped.
62096460|NCT05032235|EXPERIMENTAL|Group C|
62096461|NCT01513356|EXPERIMENTAL|CBKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days
62096462|NCT04493437|EXPERIMENTAL|Telerehabilitation group A|Device: Telerehabilitation Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
62465881|NCT05253105|EXPERIMENTAL|Indication Specific / TAB006 RP2D and Torpalimab 240mg repeat dose every 21 days up to 2 years|
62465882|NCT00237003|ACTIVE_COMPARATOR|1) assessment plus motivational interview|Participants are assigned, in this 6 month study, to an assessment-only condition or an assessment plus motivational interview condition. Two motivational interview sessions are conducted during the first month of study participation.
62465883|NCT03322111|EXPERIMENTAL|Cyclofusion|
62096463|NCT04493437|EXPERIMENTAL|Telerehabilitation group B|"Device: Telerehabilitation + rehabilitation at health care center Telerehabilitation: Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).~Rehabilitation at health care center: The rehabilitation will consist of four closed group sessions focusing on patient education. The groups will consist of both patients and relatives. The program at the health care center will not include any psychological tests or data control. Duration is 4 x 2 hours sessions over a period of 1 month."
62096464|NCT03841708|ACTIVE_COMPARATOR|Pleth Variability Index|In the experimental group patients will be hemodynamically resuscitated in the early phases after ROSC based on the pleth variability index on top of standard non invasive monitoring
62096465|NCT03841708|PLACEBO_COMPARATOR|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG.
62096466|NCT06283238||Cohort A|Participating subjects will be enrolled prior to initiating treatment with a regimen that includes an immune checkpoint inhibitor or chemotherapy alone in the case of the immunotherapy ineligible cohort. Archived formalin fixed paraffin embedded (FFPE) tumor tissue will be collected for all subjects if available. Patients will have an optional fresh research only biopsy if there is a lesion amenable to safe biopsy which will be frozen for further studies.
62096467|NCT06283238||Cohort B (Melanoma Cohort)|Melanoma samples were previously collected and analyzed under Pro00059349, NCT02694965. Data will continue to be collected from participant's electronic medical records.
62660175|NCT05749419||study group and control group|"Study group - children with chronic diseases, disabilities, or congenital anomalies.~Control group - their siblings."
61909023|NCT01666847|NO_INTERVENTION|Immediate Cord Clamping|Infant whose umbilical cord is immediately clamped after delivery.
61909024|NCT01564056|OTHER|Arm A: ENDOCRINE TREATMENT|HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
62096468|NCT06283238||Cohort C|Retrospective portion that will allow for collection of data and archived tissue The Duke Enterprise Data Unified Content Explorer (DEDUCE) software tool will be utilized to identify patients with gastroesophageal adenocarcinoma or squamous cell or melanoma initiated on anti-PD-1 antibody immunotherapy at Duke University Medical Center and the Duke Cancer Institute between January 1, 2011 and August 31, 2023, and patients ineligible for immunotherapy that received chemotherapy during the same time period.
62096469|NCT03457922||Group Therapy|Patients in the Stanford Department of Psychiatry and Behavioral Sciences who are enrolling in a trans-diagnostic anxiety therapy group will be invited to participate in research on group processes and outcomes.
62096470|NCT02377219|EXPERIMENTAL|couples|couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis
62096471|NCT05876585|EXPERIMENTAL|Ondansetron 8 mg ampoule|A clear, colorless, sterile solution for injection or infusion. Each 1 ml of the solution contains 2 mg of ondansetron as hydrochloride dihydrate.
62096472|NCT05876585|ACTIVE_COMPARATOR|Metoclopramide 10 mg ampoule|Metoclopramide 10 mg/ 2 ml solution for injection in ampoules. Each 2 ml of the solution contains 10 mg of metoclopramide hydrochloride equivalent to 10 mg of anhydrous metoclopramide
62660176|NCT00697164|PLACEBO_COMPARATOR|1|Patients in group I received intravenous quinine followed by oral ACT for a total period of 6 days.
62660177|NCT00697164|EXPERIMENTAL|2|Patients in group II received antimalarial drug as in group I and in addition 1500U/kg/day of rHUEPO for the initial 3 days.
62660178|NCT01767415|EXPERIMENTAL|Indigo Carmine|Intraoperative stereotactic injection of Indigo Carmine
62660179|NCT01741818||Group B|CVP less than 8cmH2o
62660180|NCT05924932||group 1 with Control IQ system|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6
62660181|NCT05924932||Group 2 with SmartGuard system|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4
62096473|NCT06099015||Cera Vascular Plug Subjects|Patients who need arterial or venous embolization in the peripheral vasculature.
62096474|NCT02632916|ACTIVE_COMPARATOR|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg
62096475|NCT02632916|EXPERIMENTAL|Denosumab|Subcutaneous denosumab 1.0mg/kg
62096476|NCT03937687|PLACEBO_COMPARATOR|Placebo|300 mg cellulose
62096477|NCT03937687|EXPERIMENTAL|Caffeine|300 mg caffeine
61909025|NCT01564056|EXPERIMENTAL|Arm B: CHEMOTHERAPY + ENDOCRINE TREATMENT|"HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).~CHEMOTHERAPY regimen will be chosen amongst the following ones:~* TC (docetaxel + cyclophosphamide)~* AC (doxorubicin + cyclophosphamide)~* MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)"
61909026|NCT01456624|ACTIVE_COMPARATOR|Megace / Fasting condition|800mg
61909027|NCT01456624|EXPERIMENTAL|DW-ES(B) / Fasting condition|625mg
62096478|NCT03937687|EXPERIMENTAL|Caffeine Combination|150 mg caffeine with 100 mg Dynamine and 50 mg TeaCrine
62096479|NCT06649851|EXPERIMENTAL|Standard Chemoradiation combined with G-CSF|"Per standard of care, participants undergo a 6-week chemoradiation (chemo-RT) cycle followed by a 4-week break. During this 4-week break after chemo-RT, participants receive granulocyte colony stimulating factor (G-CSF) once per day for 5 days (Days 7-11).~After the 4-week break, as a part of standard care, participants may then receive up to 6 additional 4-week cycles of chemotherapy (temozolomide (TMZ)). During these additional TMZ cycles, participants will receive G-CSF once per day for 3 consecutive days (Days 14-16). G-CSF is injected under the skin (subcutaneously injected) by a study staff member, or self-administered (or a caregiver) can be trained by a study staff member to administer it at home.~The chemo-RT (radiation therapy and chemotherapy (TMZ)) are standard of care in this study."
62096480|NCT06649851|OTHER|Standard Chemoradiation|Participants receive standard of care chemoradiation (chemo-RT) which includes an initial 6-week chemo-RT cycle followed by a 4-week break, and up to 6 additional 4-week chemotherapy (temozolomide (TMZ)) cycles.
62096481|NCT01600703|EXPERIMENTAL|Sitagliptin|sitagliptin, 100mg, oral, single dose
62096482|NCT01600703|PLACEBO_COMPARATOR|Placebo|Placebo, oral, single dose
61909028|NCT01456624|ACTIVE_COMPARATOR|Megace / Fed condition|800mg
62660182|NCT01067300|ACTIVE_COMPARATOR|Double unit unrelated cord blood transplantation|Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
62660183|NCT01067300|ACTIVE_COMPARATOR|single unit unrelated cord blood transplantation|Transplantation of a single unrelated cord blood unit at least 24 hours after last chemotherapy
62660184|NCT05485090||Test Phase : Test-Retest Reliability|Caregivers will complete the questionnaire twice with the same investigator. The interval between the two questionnaires is 3 to 10 days.
62660185|NCT05485090||Test Phase : Inter-rater Reliability|Caregivers will complete the questionnaire twice with two different investigators. The interval between the two questionnaires is 3 to 10 days.
62660186|NCT03033615|ACTIVE_COMPARATOR|Chest CT|Conventional processing vs. PixelShine processing
62660187|NCT03033615|ACTIVE_COMPARATOR|Abdominal CT|Conventional processing vs. PixelShine processing
62660188|NCT04641637|OTHER|Selective catheterization of segmental or more peripheral arteries in TACE|From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders.
62660189|NCT02237664|ACTIVE_COMPARATOR|Patient-controlled paravertebral analgesia (PC-PVB)|Patient-controlled paravertebral analgesia
61909029|NCT01456624|EXPERIMENTAL|DW-ES(B) / Fed condition|625mg
61909030|NCT04075812|EXPERIMENTAL|Neuromuscular Stimulator|Neuromuscular Stimulator is setup and calibrated, various spatial and temporal stimulation patterns will be tested to evoke wrist/hand movements in various sequences of individual and combined movements.
62096483|NCT00629512|EXPERIMENTAL|1|20mg oral daily
62096484|NCT00629512|EXPERIMENTAL|2|40mg oral daily
62096485|NCT00629512|PLACEBO_COMPARATOR|3|
62096486|NCT01289743|EXPERIMENTAL|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice weekly
62465884|NCT04165239|EXPERIMENTAL|Treatment A|Oral administration of 50 mg KH176 twice daily
62465885|NCT04165239|EXPERIMENTAL|Treatment B|Oral administration of 100 mg KH176 twice daily
62465886|NCT04165239|PLACEBO_COMPARATOR|Treatment C|Oral administration of matching placebo twice daily
62465887|NCT03992586|EXPERIMENTAL|Pink lenses|Pink-colored lenses
62465888|NCT03992586|PLACEBO_COMPARATOR|Clear lenses|Clear lenses
62660190|NCT02237664|PLACEBO_COMPARATOR|Continuous paravertebral analgesia (C-PVB)|Continuous paravertebral analgesia
62660191|NCT01255020|ACTIVE_COMPARATOR|α-Keto Acid plus restricted protein diet|Participants randomized to this group will receive 12 months treatment of α-Keto Acid. The dose of α-Keto Acid is 100mg/kg per day and will divided into three times per day, and the α-Keto Acid will be asked to be taken during the meal. In addition, the participants will be asked to restrict the protein intake. The protein intake is restricted as 1g/kg/d.
62660192|NCT01255020|PLACEBO_COMPARATOR|Placebo plus restricted protein diet|All participants will receive 12 months treatment of placebo, at the same time they will be asked to restrict the protein intake.The dose of placebo is 100mg/kg per day, and the protein intake is restricted as 1g/kg/d.
62660193|NCT00915525|EXPERIMENTAL|botulinum toxin Type A 100U|Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
62660194|NCT00915525|EXPERIMENTAL|botulinum toxin Type A 150U|Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
62660195|NCT02135289||IMID patients|Patients with IMID
62660196|NCT02135289||Control - subjects without IBD|Patients without IBD
62660197|NCT02943759|EXPERIMENTAL|Neem leaf extract|Neem leaf extract (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
62660198|NCT02943759|ACTIVE_COMPARATOR|Chlorhexidine gluconate|2% chlorhexidine gluconate intracanal irrigant solution used as an antibacterial chemical mean for canal irrigation
62660199|NCT05743582||COPD patients|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
62660200|NCT05743582||Healthy controls - smokers|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
62660201|NCT05743582||Healthy controls - non-smokers|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
62660202|NCT00818272||Remicade (infliximab)|Participants with confirmed diagnosis of active Crohn's disease.
62660203|NCT04324840|EXPERIMENTAL|Part A|
61909031|NCT00952380|OTHER|Single Arm|Single arm open-label
61909032|NCT01057875|EXPERIMENTAL|coffee with caffeine|
61909033|NCT01057875|PLACEBO_COMPARATOR|decaffeinated coffee|Starbuck's Grande Pike Roast Decaf
61909034|NCT03841747|EXPERIMENTAL|Pembrolizumab + Paclitaxel|200 mg Pembrolizumab IV Q3W plus 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
61909035|NCT03841747|ACTIVE_COMPARATOR|Paclitaxel|80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
61909036|NCT05188157|OTHER|control group|conventional physiotherapy
61909037|NCT05188157|EXPERIMENTAL|mirror therapy group|conventional physiotherapy and mirror therapy
61909038|NCT03207373|EXPERIMENTAL|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
61909039|NCT00583713|EXPERIMENTAL|Renal Group|Patients with moderate renal impairment
61909040|NCT00583713|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers
61909041|NCT00583713|EXPERIMENTAL|Hepatic Group|Patients with mild/moderate hepatic impairment.
61909042|NCT01718340|EXPERIMENTAL|Metformin|The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive
61909043|NCT02162407|EXPERIMENTAL|Insulin detemir 60 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
61909044|NCT02162407|EXPERIMENTAL|Insulin detemir 120 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
61909045|NCT02162407|ACTIVE_COMPARATOR|Human insulin 6 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
61909046|NCT02083549||Trauma 1 massively transfused|Trauma 1 massively transfused patients are identified as a Trauma level one patient by triage through guidelines from the Kessler Regional Trauma Center Trauma Triage Guidelines.
61909047|NCT03554811|EXPERIMENTAL|Functional electrical stimulation assisted supine cycling|Patients will start functional electrical stimulation assisted supine cycling (FESC) within 48 hours of ICU admission and will undergo up to 1 hour of supine cycling daily, 5 days per week for 28 days, or until discharge from ICU.
61909048|NCT03554811|ACTIVE_COMPARATOR|Conventional early exercise and mobility interventions|Patients will undergo standard ICU exercise and mobility interventions.
61909049|NCT05449015|EXPERIMENTAL|1% atropine|1% atropine eye drops, in the conjunctival sac, once a night, for 7 days
61909050|NCT05449015|PLACEBO_COMPARATOR|tropicamide|tropicamide eye drops, in the conjunctival sac, once every 5 minutes, after 3 consecutive doses, close eyes for 20 minutes
61909051|NCT01253954||ICU patients with IFI|1
61909052|NCT02126345||MASTER SL|
61909053|NCT03940183|EXPERIMENTAL|Trelagliptin succinate 100 mg|Tablets,100mg per tablet,oral, once a week, 100mg each time, continuous medication for a total of 24 weeks
61909054|NCT03940183|PLACEBO_COMPARATOR|Placebo Oral Tablet|Tablets,N/A,oral, once a week, one tablet each time, continuous medication for a total of 24 weeks
61909055|NCT00532675|EXPERIMENTAL|PAN 5 mg|Panobinostat 5 mg
62096487|NCT05766670|OTHER|Intramedullary calcium sulfate antibiotic depot prior to Intramedullary nailing (IMN) placement (CS)|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
62096488|NCT05766670|OTHER|Standard of care intramedullary nail (SN)|Standard of care intramedullary nail
62465889|NCT01307722|EXPERIMENTAL|Patients under LA distensibility-guiding management|The management of guide group will be adjusted by LA distensibility, including the adjustments of inotropic agents, diuretics, beta-blocker, ACEI, and AIIB.
62660204|NCT04324840|EXPERIMENTAL|Part B - CC-90010 + Temozolomide (TMZ) + Radiotherapy (RT)|
62660205|NCT04324840|OTHER|Part B - Standard TMZ + RT|Control
62660206|NCT05363176|EXPERIMENTAL|CBT for Treatment Seeking|CBT delivered over the course of 1, \~45 minute session delivered via telehealth.
62660207|NCT05363176|ACTIVE_COMPARATOR|Pain Treatment Education|Pain treatment education is delivered over the course of 1, \~45 minute session delivered via telehealth
62660208|NCT03044561|EXPERIMENTAL|Sildenafil citrate|
62660209|NCT03044561|PLACEBO_COMPARATOR|placebo|
62660210|NCT00975923|EXPERIMENTAL|Collaborative Group|Quality Improvement Virtual Learning Collaborative with Interactive Teleconferences and Tool Kit
61909056|NCT00532675|EXPERIMENTAL|PAN 10 mg|Panobinostat 10 mg
62096489|NCT01970943|NO_INTERVENTION|No Intervention|PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
62096490|NCT01970943|PLACEBO_COMPARATOR|Saline Injection (Placebo)|PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
62096491|NCT05989737|EXPERIMENTAL|AEBT online program|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT). Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
62293707|NCT04222829||Control Group|"The control group who are treated with Korean medical treatment not including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
62293708|NCT00759603|EXPERIMENTAL|Lenalidomide + Rituximab|Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m\^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
62293709|NCT01154608|EXPERIMENTAL|pancreatic enzymes|
62293710|NCT01154608|PLACEBO_COMPARATOR|control|
61909057|NCT00532675|EXPERIMENTAL|PAN 20 mg|Panobinostat 20 mg
62293711|NCT03933943|EXPERIMENTAL|LY3361237|LY3361237 administered subcutaneously (SC)
62293712|NCT03933943|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62293713|NCT02252367|EXPERIMENTAL|Tadalafil|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to tadalafil 5 mg - 1 film-coated tablet orally once daily for 12 weeks.
62465890|NCT01307722|NO_INTERVENTION|patients under conservative monitor and management|This group will be treated by conventional management and traditional echocardiography can be performed as in-charge doctor request. Renal function will be checked 1 time per 3 months.
62465891|NCT04940962|EXPERIMENTAL|Non-diabetic obese|
62465892|NCT04940962|EXPERIMENTAL|Diabetic obese|
62465893|NCT04940962|ACTIVE_COMPARATOR|Witnesses|
62660211|NCT00975923|ACTIVE_COMPARATOR|Tool Kit Group|Tool Kit of Evidence-Based Guidelines, Education Seminars, and Aide for Quality Improvement Methods
62660212|NCT01965795|PLACEBO_COMPARATOR|Nutrim|"Nutrim will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottle will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
62660213|NCT01965795|EXPERIMENTAL|Whole Coffee Fruit Concentrate (WCFC)|"WCFC is in powder form, and will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottles will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
62660214|NCT04611217|EXPERIMENTAL|High Fiber diet|Group receiving a high fiber diet
62660215|NCT04611217|OTHER|Low Fiber diet|Control group receiving a low fiber diet
62660216|NCT05781802||Adult mechanically ventilated patients with ARDS|Adult mechanically ventilated patients with ARDS (see inclusion/exclusion criteria)
62660217|NCT03724344||Dimensions with Behavioral and psychological symptoms|
61909058|NCT00532675|EXPERIMENTAL|PAN 25 mg|Panobinostat 25 mg
61909059|NCT02431260|EXPERIMENTAL|INCB054329 Monotherapy|
61909060|NCT03538171|ACTIVE_COMPARATOR|ARM Entinostat+Exemestane|Patients receive Exemestane orally (PO) once daily (QD) on days 1-28 and Entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61909061|NCT03538171|PLACEBO_COMPARATOR|ARM Placebo+Exemestane|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61909062|NCT01237483|OTHER|Erbitux Radiotherapy|Radiotherapy during 5 weeks and concurrent Erbitux once a week.
61909063|NCT02880696|EXPERIMENTAL|Test (Regular)|Regular stimulation sequence \& DCS
61909064|NCT02880696|ACTIVE_COMPARATOR|Control (Random)|Random stimulation sequence \& DCS
61909065|NCT02585661|ACTIVE_COMPARATOR|Dairy product + Salt 1|Dairy product fortified with enriched Fe-54 salt (1)
62096492|NCT05989737|NO_INTERVENTION|Waitlist control|Waitlist condition; only assessment
62465894|NCT04389320||Rheumatoid patients receiving hydroxychloroquine|immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics
62465895|NCT03497897|EXPERIMENTAL|LYS006 20 mg BID|LYS006, 20 mg, orally, twice daily (BID), for 12 weeks
62465896|NCT03497897|EXPERIMENTAL|LYS006 2 mg BID|LYS006, 2 mg, orally, BID, for 12 weeks
62465897|NCT03497897|PLACEBO_COMPARATOR|Placebo BID|Matching placebo, orally, BID, for 12 weeks
62465898|NCT03334825|EXPERIMENTAL|Enhanced housing placement assistance|
62465899|NCT03334825|ACTIVE_COMPARATOR|Standard housing placement assistance|
62465900|NCT01579357|OTHER|A|Capecitabine in week 1,2,4,5,7 and 8 Cetuximab in week 3 to 9 Oxaliplatin in week 7
62096493|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
62465901|NCT01579357|OTHER|B|Capecitabine in weeks 1,2,4,5,7, and 8 Cetuximab in weeks 1,8 and 9 Oxaliplatin in week 7
62465902|NCT02420444|PLACEBO_COMPARATOR|BCG SSI prime with Placebo|"All subjects received BCG Vaccine SSI, 2-8 x 10\^5 CFU (BCG) on Study Day -42.~Placebo containing 0,8 mL sterile buffer consisting of 10 mmol Tris and 169 mmol NaCl aqueous solution was administered on Study Days 0, 56, and 231."
62465903|NCT02420444|EXPERIMENTAL|BCG SSI prime with Placebo and AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10\^5 CFU (BCG) on Study Day -42.~Placebo on Study Day 0 followed by AERAS-404 50/500 on Study Days 56 and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~* H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~* IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
62465904|NCT02420444|EXPERIMENTAL|BCG SSI prime with AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10\^5 CFU (BCG) on Study Day -42.~AERAS-404 50/500 on Study Days 0, 56, and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~* H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~* IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
62096494|NCT06615362|EXPERIMENTAL|Autogenous Dentin Derived Barrier Membrane|Autogenous Dentin Derived Barrier Membrane + Xenogeneic bone graft material+ immediate implant
62465905|NCT02003547|EXPERIMENTAL|AMA0076 Formulation A|Topical Ocular Drop BID X 1 wk
62465906|NCT02003547|EXPERIMENTAL|AMA0076 Formulation B|Topical Ocular Drop BID X 1wk
62465907|NCT02003547|EXPERIMENTAL|AMA0076 Formulation C|Topical Ocular Drop BID X 1 wk
62660218|NCT05550519|EXPERIMENTAL|Discontinuation of Nucleos(t)ide (NA) Treatment|Participants will receive standard of care NA treatment (Entecavir \[ETV\], Tenofovir Disoproxil Fumarate \[TDF\], Tenofovir Alafenamide \[TAF\]) in screening phase (up to 6 weeks) and in baseline visit (Day -1). NA treatment will be discontinued on Day 1 up to 96 weeks (Post-NA discontinuation off-treatment phase). Off-treatment refers to the phase after baseline, in which NA treatment will be discontinued.
62660219|NCT00250484|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation|Active treatment with TMS for 10 days.
62660220|NCT00250484|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Patients will receive no active TMS/treatment.
62660221|NCT03442062|EXPERIMENTAL|AFIX|Clinics randomly assigned to this arm will receive an Assessment Feedback Incentives and eXchange (AFIX) consultation delivered in-person by a state health department immunization specialist.This arm includes \~ 90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
62660222|NCT03442062|EXPERIMENTAL|Physician-to-physician engagement|Clinics randomly assigned to this arm will receive physician-to-physician (P2P) consultations delivered remotely to providers by physician educators. This arm includes \~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
62293714|NCT02252367|PLACEBO_COMPARATOR|Placebo|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to placebo.
62465908|NCT02003547|PLACEBO_COMPARATOR|Placebo|Topical Ocular Drop BID X 1 wk
62465909|NCT05832996|EXPERIMENTAL|Cooled artificial tear group|Stored at 4 degree Celsius
62465910|NCT05832996|ACTIVE_COMPARATOR|Room temperature artificial tear group|Stored at 25 degree Celsius
62465911|NCT00550537|EXPERIMENTAL|Treatment|Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
62465912|NCT00004562|ACTIVE_COMPARATOR|Optimal Medical Therapy Only (MED)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification
62465913|NCT00004562|EXPERIMENTAL|Percutaneous Coronary Intervention (PCI)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting
62465914|NCT05214560||All participants|Participants who require a BD Spinal needle
61909066|NCT02585661|EXPERIMENTAL|Dairy product + Salt 2|Dairy product fortified with enriched Fe-57 salt (2)
62096495|NCT06615362|EXPERIMENTAL|Collagen Membrane|Collagen Membrane + Xenogeneic bone graft material + immediate implant
62096496|NCT05649332|EXPERIMENTAL|Subjects presenting pressure ulcers or burn wounds|Subjects will be treated with the medical device Argogen® adsorbing spray powder. The dosage will depend on the patient's skin condition and the extent of the areas to be treated. The medical device will be used twice a day without interruption for the duration of the study (4 weeks) or until complete healing.
62096497|NCT06613568|EXPERIMENTAL|Professional Care and At Home|Participants will receive dialysis therapy using the Moda-Flx Hemodialysis System™ in a Professional Care setting and At-Home setting
62293715|NCT02886702|EXPERIMENTAL|Test|Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)
62465915|NCT01926821|EXPERIMENTAL|sonifilan|Group who get sonifilan
62465916|NCT01926821|NO_INTERVENTION|control|No Sonifilan administered
62465917|NCT04452656|ACTIVE_COMPARATOR|bilateral erector spinae plane block|The patient WILL receive bilateral erector spinae plane block.
62465918|NCT04452656|NO_INTERVENTION|NO BLOCK|The patient will not receive Erector spinae plane block
62465919|NCT01026363|EXPERIMENTAL|ergocalciferol|Ergocalciferol intervention arm
62096498|NCT02825043|EXPERIMENTAL|High Flow Nasal Cannula Participants|High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
62096499|NCT06346145|ACTIVE_COMPARATOR|Bariatric surgery|Gastric bypass or gastric sleeve
62096500|NCT06346145|ACTIVE_COMPARATOR|Standard care|Standard obesity treatment offered in Swedish regions
62660223|NCT03442062|EXPERIMENTAL|AFIX + P2P|Clinics randomly assigned to this arm will receive both an Assessment Feedback Incentives and eXchange (AFIX) consultation and a physician-to-physician (P2P) consultation.This arm includes \~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
62660224|NCT03442062|OTHER|Active Intervention Control|Clinics randomly assigned to this arm will receive a brief non-HPV vaccine related quality improvement consultation. This arm includes \~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
62293716|NCT02886702|ACTIVE_COMPARATOR|Reference|TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)
62293717|NCT02886702|PLACEBO_COMPARATOR|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
62660225|NCT01044498|EXPERIMENTAL|Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)|Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
62293718|NCT02241486|EXPERIMENTAL|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
62660226|NCT01044498|OTHER|Ortho-Novum® 1/35 (Group 2)|Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
62660227|NCT04226677|EXPERIMENTAL|aerobic exercise group|Aerobic exercise group is received treadmill training.
62660228|NCT04226677|EXPERIMENTAL|Video based exercise group|Video based exercise group is received exergame training.
62660229|NCT04226677|EXPERIMENTAL|Control group|Control group
62096501|NCT05136742|EXPERIMENTAL|aerobic exercise and diet program|aerobic exercise with balanced restricted diet
62096502|NCT05136742|ACTIVE_COMPARATOR|diet program|balanced restricted diet
62465920|NCT01026363|EXPERIMENTAL|calcitriol|calcitriol intervention arm
62737008|NCT03097523|EXPERIMENTAL|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:~* Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed~* Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)~* Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
62096503|NCT04582175||group A|patients who received complete revascularization by angioplasty during the PPCI
62096504|NCT04582175||Group B|patients who underwent complete revascularization by angioplasty in a staged procedure
62096505|NCT02562014|OTHER|Lean|Participants with body mass index \<=25
62096506|NCT02562014|OTHER|Overweight|Participants with body mass index \>25
62096507|NCT06528977|EXPERIMENTAL|Western Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
62293719|NCT01908348|EXPERIMENTAL|Erythritol|Orange-flavored beverage containing 6, 12, or 18 grams of erythritol
62293720|NCT01591070|NO_INTERVENTION|vehicle twice weekly|
62096508|NCT02985697|EXPERIMENTAL|IN DEX|Group IN DEX will receive a placebo dose of flavored water followed by 3 mcg/kg intranasal dexmedetomidine in conjunction with 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or placebo will not be given.
62096509|NCT02985697|EXPERIMENTAL|MIDDEX|Group MIDDEX will receive 3 mcg/kg intranasal dexmedetomidine and 0.5 mg/kg oral midazolam and 100% oxygen at a calculated flow rate (oxygen administration to function as placebo for nitrous oxide). If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
62293721|NCT01591070|EXPERIMENTAL|tacrolimus once weekly|
62293722|NCT01591070|EXPERIMENTAL|tacrolimus twice weekly|
62293723|NCT04030000|OTHER|Paclitaxel/Carboplatin and radiation|"Paclitaxel 135 mg/m2 over 3 hrs on day 1 Carboplatin IP (AUC= 6.0) on day 1 Paclitaxel 60 mg/m2 IP on Day 8 Repeat q 21 days x 6 cycles~Pelvic 6MV Photon Beam Energy, or IMRT where appropriate 1.8 Gy Dose/FX Total Dose 45 Gy~High Dose Radiation (HDR) x 3, or IMRT where appropriate 5 Gy to 0.5cm Depth from the Vaginal Cylinder Surface Total Dose 15 Gy"
62293724|NCT04621903|EXPERIMENTAL|Ayurveda|
62293725|NCT02471690|ACTIVE_COMPARATOR|Oritavancin|IV -Single Dose - 1200 mg Oritavancin
62293726|NCT02471690|PLACEBO_COMPARATOR|Placebo|250 mL Dextrose 5% in Water
62293727|NCT05191043|EXPERIMENTAL|Group A/ kinesio taping group|Routine physical therapy along with Kinesio Taping
62293728|NCT05191043|ACTIVE_COMPARATOR|Group B/ routine physical therapy|routine physical therapy
62465921|NCT02527278||Laparoscopic tubal ligation (no pain)|Women who have laparoscopic tubal ligation, with no previous diagnosis of pain at baseline
62293729|NCT00756548|EXPERIMENTAL|1|multi-dose preparation for oral administration prior to colonoscopy
62293730|NCT00756548|ACTIVE_COMPARATOR|2|multi-dose preparation for oral administration prior to colonoscopy
62293731|NCT02862691|ACTIVE_COMPARATOR|Oral analgesic|2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once
62737009|NCT06040684||Level of antibodies in kidney transplant recipients|Patients with kidney transplant with a severe acute infection will be enrolled in the study. Levels of antibodies in these patients will be analyzed.
62096510|NCT02985697|EXPERIMENTAL|NOMIDDEX|Group NOMIDDEX will receive 3 mcg/kg intranasal dexmedetomidine, 0.5 mg/kg oral midazolam, and 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
62293732|NCT02862691|EXPERIMENTAL|Injectable local anesthetic|local injection or nerve block with bupivicaine 0.5%
62293733|NCT04992416|EXPERIMENTAL|SMV with ATBG around implant|SMV mixed with ATBG around immediately placed dental implants in the extraction sockets
62293734|NCT04992416|ACTIVE_COMPARATOR|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
62293735|NCT00623831|EXPERIMENTAL|Cohort 1|Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
62293736|NCT00623831|EXPERIMENTAL|Cohort 2|Subjects received MBV twice weekly at the fixed dose (60,800 EU \[dose level 6\]) that was determined to be the pyrogenic dose level in Cohort 1.
62293737|NCT03495492|EXPERIMENTAL|Participants|Group receiving dermal chelation and nutritional therapy
62465922|NCT02527278||Laparoscopic tubal ligation (pain)|Women who have laparoscopic tubal ligation, with a previous diagnosis of pain at baseline
61909067|NCT06076291|EXPERIMENTAL|SG1827|SG1827 monotherapy intravenous (IV) infusion - administered every three weeks (Q3W)
61909068|NCT00348608|EXPERIMENTAL|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
61909069|NCT01816451|EXPERIMENTAL|interval|The running training for interval group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine. The interval training group intensities ranged between 84-87% of maximal heart rate (HRmax) (vigorous intensity), 88-93%HRmax (near maximum intensity) and 94-99% HRmax (maximum intensity).
62465923|NCT02527278||Hysteroscopic sterilization (no pain)|Women who have hysteroscopic sterilization, with no previous diagnosis of pain at baseline
62465924|NCT02527278||Hysteroscopic sterilization (pain)|Women who have hysteroscopic sterilization, with a previous diagnosis of pain at baseline
62465925|NCT00002804|EXPERIMENTAL|Chemotherapy Regimen|Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
62293738|NCT05381506|EXPERIMENTAL|Orelabrutinib and Gemox|Orelabrutinib and Gemox for 6 cycles
62293739|NCT01841619|ACTIVE_COMPARATOR|IVIg as a monotherapy|IVIg will be used as a first line treatment. Topical treatment will be stopped at the beginning of IVIg therapy.
62293740|NCT04302506||Patients with drug-induced liver injury|Patients who underwent liver biopsy and were diagnosed with drug-induced liver injury were diagnosed as DILI.
62465926|NCT02092805|SHAM_COMPARATOR|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce some of subjective sensation of rTMS.
61909070|NCT01816451|EXPERIMENTAL|continuous|The running training for continuous group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine.The continuous group ran at an intensity of \~87% of maximal heart rate (HRmax)
61909071|NCT01816451|NO_INTERVENTION|control|The control group did not do the running training program. Control did their normal physical activities.
61909072|NCT04685239|ACTIVE_COMPARATOR|Unipolar cup|Patients randomized to receive a conventional unipolar acetabular cup
62293741|NCT02489214|EXPERIMENTAL|donafenib tosilate tablets|200mg bid
62293742|NCT01443013||Cohort of Renal Transplant recipients|
62293743|NCT06184438|EXPERIMENTAL|Daflon group|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day 0 to day 7.
62293744|NCT06184438|PLACEBO_COMPARATOR|Placebo group|Received placebo after surgery from day 0 to day 7.
62293745|NCT01977287||Functional Electrical Stimulation|The Functional Electrical Stimulation (FES) group will be asked to use their clinically prescribed FES unit (either ODFS III or Pace) to the dorsiflexors to treat foot drop for a period of 12 weeks.
62293746|NCT01977287||Ankle Foot Orthosis|The people in the Ankle Foot Orthosis group (AFO) will be asked to use their clinically prescribed AFO to treat drop foot for a period of 12 weeks.
62293747|NCT03934645||Not In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)=0
62293748|NCT03934645||In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)≥4
62293749|NCT03251326|EXPERIMENTAL|Nabilone|Nabilone capsules (4 mg)
62293750|NCT03251326|ACTIVE_COMPARATOR|Propranolol|Propranolol capsules (40mg)
61909073|NCT04685239|ACTIVE_COMPARATOR|dual mobility cup|Patients randomized to receive a double mobility acetabular cup
62096511|NCT02985697|ACTIVE_COMPARATOR|CTRL|The control group, Group CTRL, will receive a placebo dose of normal saline and 0.5 mg/kg oral midazolam and 50/50 nitrous oxide/oxygen at a calculated flow rate. Midazolam was chosen as the control due to its well documented history of use in pediatric procedural sedations. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
62096512|NCT05627765|EXPERIMENTAL|Standard treatment (ST) arm|Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
62096513|NCT05627765|EXPERIMENTAL|Integrated Intervention (II) arm|Participants in the II arm will receive brief advice on alcohol use based on the FRAMES model in addition to the brief smoking cessation intervention at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
62096514|NCT05627765|NO_INTERVENTION|Control arm|Participants will be provided with two leaflets designed by Department of health: one for smoking cessation and another for alcohol abstinence.
62096515|NCT02484365||single arm study|No treatment or intervention will given to the patients
62096516|NCT03737734|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62096517|NCT04621071|EXPERIMENTAL|Probiotics|Two probiotic strains will constitute the experimental arm (Probiotics). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
62096518|NCT04621071|PLACEBO_COMPARATOR|Placebo|Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
62096519|NCT04280029|EXPERIMENTAL|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal coronary angioplasty (PTCA) balloon catheter coated with a drug (Sirolimus).
62096520|NCT04280029|ACTIVE_COMPARATOR|Control Treatment|POBA or FDA-approved -limus DES
62096521|NCT05464589|EXPERIMENTAL|Transcutaneous Tibial Nerve Stimulation + Pelvic Floor Muscle Strengthening|"Pelvic floor muscle strengthening through Kegel exercises along with the transcutaneous tibial nerve stimulation.~Pelvic Floor Muscle-strengthening exercises - Kegels' exercises 15 repetitions, 3 times a day For 6 weeks, daily.~Transcutaneous Tibial Nerve Stimulation for 30 minutes on the right lower limb 6 sessions, one per week."
62096522|NCT05464589|ACTIVE_COMPARATOR|Pelvic Floor Muscle Strengthening|"Pelvic floor muscle strengthening through Kegel exercises.~Pelvic floor muscle exercises - Kegels; exercises 15 repetitions, 3 times a day For 6 weeks, daily."
62096523|NCT00647140|EXPERIMENTAL|1|18F-L6DOPA PET
62096524|NCT06614140|EXPERIMENTAL|Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors|"Participants will receive a personalized neoantigen peptide vaccine based on tumor-specific mutations identified through genomic analysis. The treatment has three phases:~Preparation Phase: Poly-ICLC, an immune adjuvant, is given intramuscularly twice weekly for four weeks before the first vaccine dose to enhance immune readiness.~Treatment Phase: The neoantigen vaccine is administered with Poly-ICLC on days 1, 4, 8, 15, and 22. A checkpoint inhibitor (e.g., anti-PD-1 or anti-PD-L1) will be introduced after neoantigen-specific T cell responses are detected to counteract immune exhaustion. Booster injections are given at weeks 12 and 20.~Follow-up Phase: Checkpoint inhibitors (per standard regimen) and Poly-ICLC (twice monthly) will be continued to maintain the immune response. Safety, immune activity, and clinical outcomes will be closely monitored."
62465927|NCT02092805|ACTIVE_COMPARATOR|Real rTMS|The active group recieved real-rTMS over the motor cortical area corresponding to the hand of painful side. Each train consist of 2000 pulses at 20 Hz and 80% RMT (total duration 10s). The treatment was repeated every day for 5 consecutive days in week for two weeks (the total number of sessions had be given was 10 sessions).
62465928|NCT02039908|ACTIVE_COMPARATOR|Methylphenidate 7-day dosing|During the school year, children in this arm will receive 7-day dosing of medication.
61909074|NCT00275132|EXPERIMENTAL|Erlotinib|Tarceva (OSI-774, erlotinib) PO 150mg daily
61909075|NCT00275132|PLACEBO_COMPARATOR|Matched placebo|Matched placebo PO daily
61909076|NCT00985829|EXPERIMENTAL|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
61909077|NCT04209985|EXPERIMENTAL|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach will call patients up to five times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
61909078|NCT04209985|NO_INTERVENTION|Usual care|Patients assigned to usual care have access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
61909079|NCT03643536|EXPERIMENTAL|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
62096525|NCT00748254||Rheumatoid Arthritis|Patients who have active disease affecting the joints in the hand will have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound
62096526|NCT00748254||Normal controls|Healthy volunteers who do not have arthritis will also have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound on the joints of their hand
62096527|NCT05213403||Patient G1|Correlation between surgery and scoring system
62096528|NCT05213403||Patients G2|Incongruence between surgery and scoring system
62096529|NCT00082485|ACTIVE_COMPARATOR|1|
62096530|NCT00082485|PLACEBO_COMPARATOR|2|
62096531|NCT03405298|ACTIVE_COMPARATOR|Educational Material with Collaborative Care available|In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.
62096532|NCT03405298|ACTIVE_COMPARATOR|Educational Material Only|Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.
62096533|NCT04880213|EXPERIMENTAL|Japanese: M5049 Dose A (low dose)|
62096534|NCT04880213|EXPERIMENTAL|Japanese: M5049 Dose B (medium dose)|
62096535|NCT04880213|EXPERIMENTAL|Japanese: M5049 Dose C (high dose)|
62096536|NCT04880213|EXPERIMENTAL|Caucasian: M5049 Dose A (low dose)|
62096537|NCT04880213|EXPERIMENTAL|Caucasian: M5049 Dose B (medium dose)|
62293751|NCT03251326|EXPERIMENTAL|Smoked cannabis|(0.0 and 5.6% THC)
62293752|NCT03251326|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62293753|NCT05994170|EXPERIMENTAL|Reduction CTVp1|CTVp1=GTVp+5mm
62293754|NCT05994170|PLACEBO_COMPARATOR|Non-reduction CTVp1|CTVp1=GTVp+5mm+whole nasopharynx
62465929|NCT02039908|ACTIVE_COMPARATOR|Methylphenidate 5-day dosing|During the school year phase, these children will receive 5-day dosing with weekend holidays.
61909080|NCT03643536|ACTIVE_COMPARATOR|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
61909081|NCT04477278|EXPERIMENTAL|Audio-Guided Mindfulness Intervention|Brief, 8-minute, audio-guided mindfulness intervention delivered prior to osteopathic manipulation.
62293755|NCT01454804|EXPERIMENTAL|Arm A: Pazopanib + Lapatinib|Oral Pazopanib 200 mg every other day starting on day 1 and oral Lapatinib 500 mg daily starting day 1, both for 28 days.
62293756|NCT01454804|EXPERIMENTAL|Arm B: Pazopanib + Trastuzumab|Oral Pazopanib 200 mg daily for 28 day cycle and Trastuzumab (Herceptin®) 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1, with a maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
62293757|NCT04576312|EXPERIMENTAL|Cohort 1|Single dose of UNI911 inhalation (4 mL 0.1% \~ 3,4 mg) and intranasal spray (2 x 150 µL, 1% \~ 2,5 mg)
62465930|NCT01672515|EXPERIMENTAL|RIPC group|RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
61909082|NCT04477278|ACTIVE_COMPARATOR|History of Osteopathy|Brief, 8-minute, audio-guided history of osteopathy delivered prior to osteopathic manipulation.
62096538|NCT04880213|EXPERIMENTAL|Caucasian: M5049 Dose C (high dose)|
62096539|NCT05623202|EXPERIMENTAL|Capacity-oriented behavior-change intervention|
62096540|NCT04174807||Cohort|
62096541|NCT03270020|EXPERIMENTAL|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML \[Xgeva\]
62293758|NCT04576312|EXPERIMENTAL|Cohort 2|Single dose of UNI911 inhalation (1 mL 1% \~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% \~ 2,5 mg)
62293759|NCT04576312|EXPERIMENTAL|Cohort 3|Single dose of UNI911 inhalation (3 mL 1% \~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% \~ 2,5 mg)
62465931|NCT01672515|SHAM_COMPARATOR|Control group|RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
62096542|NCT03541603|EXPERIMENTAL|Levosimendan 2.5mg/mL Injectable Solution|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
62096543|NCT03541603|PLACEBO_COMPARATOR|Matching Placebo|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
62096544|NCT03033732|OTHER|Methadone|Opioid agonist treatment for opioid use disorder. Ingested in liquid oral form via strict initial daily witnessed ingestion as per local guidelines.
62096545|NCT03033732|OTHER|Buprenorphine/Naloxone|Opioid agonist treatment for opioid use disorder. Ingested orally via sublingual tablet form, flexible take home dosing.
62096546|NCT02144324|EXPERIMENTAL|Tandem Appliance|This group of patients will receive the new appliance which is called the Tandem Appliance
62096547|NCT02144324|NO_INTERVENTION|Traditional Treatment|Patients in this group will be treated by the traditional Face Mask appliance.
62096548|NCT06343441|EXPERIMENTAL|digital impression|intraoral scan
62096549|NCT06343441|ACTIVE_COMPARATOR|conventional impression|open tray
62293760|NCT04576312|EXPERIMENTAL|Cohort 4|Single dose of UNI911 inhalation (6 mL 1% \~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% \~ 2,5 mg)
62293761|NCT04576312|EXPERIMENTAL|Cohort 5|UNI911 inhalation (6 mL 1% \~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% \~ 2,5 mg) BID for 2,5 days.
62293762|NCT04576312|EXPERIMENTAL|Cohort 6|UNI911 inhalation (1 mL 1% \~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% \~ 2,5 mg) BID for 6,5 days.
62293763|NCT04576312|EXPERIMENTAL|Cohort 7|UNI911 inhalation (3 mL 1% \~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% \~ 2,5 mg) BID for 6,5 days.
62465932|NCT03189173|EXPERIMENTAL|All patients|"Patients will receive all four interventions in randomized order.~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:~Interventions: Oral appliance \| Oral appliance plus oxygen \| Oxygen \| No treatment"
62096550|NCT04301388|EXPERIMENTAL|TVCL-based|Monitor progression of labor by shortening of cervix examined by transvaginal cervical length
62096551|NCT04301388|ACTIVE_COMPARATOR|Conventional-based|Monitor progression of labor by per vaginal exam to detect cervical change
62096552|NCT05407194|EXPERIMENTAL|Supplement + progressive tendon loading therapy|The intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C, in comparison to a placebo supplement consisting of maltodextrin. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
62096553|NCT05407194|PLACEBO_COMPARATOR|Placebo + progressive tendon loading therapy|The placebo consists of maltodextrin. In comparison the intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
62096554|NCT00764179|EXPERIMENTAL|1|hyperproteinic milk
62096555|NCT00764179|ACTIVE_COMPARATOR|2|Normoproteinic milk
62096556|NCT02759198|EXPERIMENTAL|YH23537|YH23537 750/1500/3000mg
62096557|NCT02759198|ACTIVE_COMPARATOR|Celebrex|Celecoxib 200mg
62096558|NCT02759198|PLACEBO_COMPARATOR|Placebo|YH23537 Placebo
62096559|NCT04531683|EXPERIMENTAL|electroacupuncture|patients will receive electroacupuncture at 3 acupoints (Bladder meridian of foot-taiyang 33 and 35（BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 8 weeks(24 times in total), followed with 24-weeks follow up. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 × 40 mm at SP 6. Standardised electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
61909083|NCT02489929|EXPERIMENTAL|patient suffering of MDS or Myeloid leukemia|The patients suffering of MDS or Acute myeloid leukemia will be the object of 8 sampling of blood (on tube EDTA) distributed as this: the first day of the usual treatment (azacytidine) at T0, T30 MIN, T60 MIN, T90 MIN, T120 MIN, then a second series of taking in the 5th day of treatment at T0, T30 MIN, T90 MIN to determine cytidine deaminase (CDA) activities by following its plasmatic dosage
62096560|NCT04531683|SHAM_COMPARATOR|sham electroacupuncture|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
62096561|NCT04531683|OTHER|life style counselling group|patients randomised to this group will receive a one-time life style counselling at the enrolment to improve their daily behaviour to expedite the recovery of their mixed urinary incontinence. Then the patients will be followed up for 20 weeks.
62096562|NCT03682354|ACTIVE_COMPARATOR|Intercostal Nerve Block with PCIA|Intercostal Nerve Block with patient-controlled intravenous analgesia
62096563|NCT03682354|EXPERIMENTAL|Erector Spinae Plane Block (ESPB)|Continuous Erector Spinae Plane Block
61909084|NCT02058524|EXPERIMENTAL|fecal microbiota transplantation|
61909085|NCT04133207||Patients with advanced HR-positive breast cancer|patients with histologically confirmed HR-positive, HER2-negative advanced (recurrent or metastatic) breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
62293764|NCT04576312|PLACEBO_COMPARATOR|Placebo (applicable for cohorts 1-5)|Placebo, administered in a double-blinded fashion (except for the first subjects of cohorts 1-4) at the same dose and frequency as UNI911 inhalation and intranasal spray.
62293765|NCT00737139|ACTIVE_COMPARATOR|1|Intra-articular Injection of Marcaine/Epinephrine
62293766|NCT00737139|ACTIVE_COMPARATOR|2|Intra-articular Injection of Marcaine alone
62293767|NCT01475734|ACTIVE_COMPARATOR|albiglutide|single dose of albiglutide
62293768|NCT01475734|PLACEBO_COMPARATOR|placebo|single dose of placebo
62293769|NCT06379334||HCC|Urine samples from patients with chronic hepatitis B related hepatocellular carcinoma were collected and their proteomes were analyzed via liquid chromatography with tandem mass
62293770|NCT06379334||CHB|Urine samples from patients with chronic hepatitis B were collected and their proteomes were analyzed via liquid chromatography with tandem mass
61909086|NCT01699347|EXPERIMENTAL|OK432|Intracystic injection of OK432 under US guiding
61909087|NCT02365142|ACTIVE_COMPARATOR|Platelet Rich Plasma (PRGF)|Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.
61909088|NCT02365142|ACTIVE_COMPARATOR|BMMSC with Platelet Rich Plasma (PRGF)|Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.
61909089|NCT03337789|EXPERIMENTAL|Polygonatum sibiricum|
61909090|NCT03337789|PLACEBO_COMPARATOR|Placebo|
61909091|NCT04590833|EXPERIMENTAL|Aerobic exercise group|
61909092|NCT04590833|PLACEBO_COMPARATOR|Attention control group|
61909093|NCT00842413||1|The study compares brain-damaged patients with healthy ones on two psychophysical tasks.
61909094|NCT00842413||2|The study does not intervene on the brain-damaged patients, it merely compares their behaviour with that of healthy patients on a range of psychophysical tasks.
62096564|NCT00341900||Case|Male pilots with high cosmic radiation exposure
62096565|NCT06094920|OTHER|A. Good albuminuria response after 2 weeks empagliflozin 10 mg/day|Albuminuria reduction \>30% and the remaining albuminuria level is \<30 mg/g: continue empagliflozin 10 mg/day for an additional four weeks.
62465933|NCT05149118|EXPERIMENTAL|PDRN injected group|The participants in treatment group had received two consecutive injections of PDRN one day and two days after the surgery. A total 1mL of PDRN was injected along the suture line at distance of 1cm in each session.
62660230|NCT05766748|EXPERIMENTAL|Treatment Group|"Azeliragon will be orally administered to 5 groups of 6 subjects, with escalation of dosing occurring with each subsequent group.~Dose Level 1 is a loading dose of 15mg once daily for 6 days, followed by a dose of 5mg once daily for the rest of the study.~Dose Level 2 is a loading dose of 15mg twice daily for 6 days, followed by a dose of 10mg once daily for the rest of the study.~Dose Level 3 is a loading dose of 30mg twice daily for 6 days, followed by a dose of 20mg once daily for the rest of the study.~Dose Level 4 is a loading dose of 30mg twice daily for 6 days, followed by a dose of 15mg twice daily for the rest of the study.~Dose Level 5 is a loading dose of 30mg twice daily for 6 days, followed by a dose of 25mg twice daily for the rest of the study.~Escalation will continue until stopping rules are met or the highest defined dose level is reached. The trial will be closed to accrual if the first dose level is deemed intolerable."
62660231|NCT06490315|EXPERIMENTAL|Intervention group|The intervention group will receive a one-month mobile psychoeducation program (OkeyMind), which includes both psychoeducation and meditation components, with all content fully automated.
62660232|NCT06490315|EXPERIMENTAL|Waiting list control group|Participants in the waiting list control group will withhold access to the OkeyMind intervention until after the 3-month follow-up assessment.
62465934|NCT05149118|NO_INTERVENTION|Control group|The participants in control group were left untreated.
62465935|NCT03351335|EXPERIMENTAL|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
62465936|NCT03351335|EXPERIMENTAL|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
62465937|NCT03351335|EXPERIMENTAL|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
62465938|NCT05820685|ACTIVE_COMPARATOR|Treatment Strategy #1|
62465939|NCT05820685|EXPERIMENTAL|Treatment Strategy #2|
62465940|NCT01832259|PLACEBO_COMPARATOR|Placebo arm|Participants receiving placebo
62465941|NCT01832259|EXPERIMENTAL|Pazopanib arm|Participants receiving Pazopanib
61909095|NCT03647189|EXPERIMENTAL|Treatment Arm|Subjects will be treated with hybrid fractional laser
61909096|NCT03647189|PLACEBO_COMPARATOR|Control Arm|
61909097|NCT04552145|ACTIVE_COMPARATOR|surgery|Decompression surgery
61909098|NCT04552145|ACTIVE_COMPARATOR|physiotherapy|Physical therapy program
61909099|NCT03661879|EXPERIMENTAL|NNC9204-1706|Participants will receive NNC9204-1706 for 10 weeks. There will be a 2-week follow-up period after the treatment period.
61909100|NCT03661879|PLACEBO_COMPARATOR|Placebo (NNC9204-1706)|Participants will receive placebo (NNC9204-1706) for 10 weeks. There will be a 2-week follow-up period after the treatment period.
62293771|NCT06379334||HC|Urine samples from healthy controls were collected and their proteomes were analyzed via liquid chromatography with tandem mass
62293772|NCT06379334||Other cancer|Urine samples from other cancer controls were collected and their proteomes were analyzed via liquid chromatography with tandem mass
62465942|NCT01319123|OTHER|wound dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers.
61909101|NCT00790309||Weight loss surgery|This group will be comprised of people having weight loss surgery: Roux-en Y gastric bypass, vertical sleeve gastrectomy, or adjustable gastric banding
61909102|NCT00790309||Abdominal surgery|This group will be comprised of people having abdominal surgeries such as nissen fundoplication or cholecystectomy.
61909103|NCT00790309||Lean|This group will be comprised of normal weight healthy volunteers.
61909104|NCT01578824|ACTIVE_COMPARATOR|Healthy Control|
61909105|NCT01578824|ACTIVE_COMPARATOR|Vitamin D resistant Rickets|Vitamin D resistant Rickets patients
62096566|NCT06094920|OTHER|B. Moderate albuminuria response after 2 weeks empagliflozin 10 mg/day|Albuminuria reduction \>30% or \>0 and ≤30%, and the remaining albuminuria level is \>30 mg/g: continue empagliflozin 10 mg/day for an additional four weeks and intensify treatment by adding finerenone 10 or 20 mg/day for four weeks (dosage depends on eGFR levels).
62096567|NCT06094920|OTHER|C. No albuminuria reduction after 2 weeks empagliflozin 10 mg/day|No albuminuria reduction or increase: discontinue empagliflozin and switch to finerenone 10 or 20 mg/day for four weeks (dosage depends on eGFR levels).
62293773|NCT04272593|EXPERIMENTAL|Simultaneous Control|Simultaneous pattern recognition style of control allows prosthetic users to actuate more than one hand/arm function on their device at the same time.
62293774|NCT04272593|ACTIVE_COMPARATOR|Conventional Control|Conventional, seamless sequential pattern recognition style of control allows prosthetic users to actuate a single hand or arm functions on their device at a time.
62293775|NCT02318758|ACTIVE_COMPARATOR|Comparison 1|UT-15C 1 mg alone
62465943|NCT04705714|EXPERIMENTAL|Frankincense Extract|the anti-bacterial and antibiofilm activity of frankincense extract against Porphyromonas gingivalis clinical isolates were studied
62465944|NCT05956366||Anorexia nervosa|Children and adolescents presenting for treatment for anorexia nervosa typica or atypica (ICD-10: F50.0 or F50.1)
62465945|NCT05956366||Bulimia nervosa|Children and adolescents presenting for treatment for bulimia nervosa typica or atypica (ICD-10: F50.2 or F50.3)
62465946|NCT05956366||Other eating disorders|Children and adolescents presenting for treatment for other eating disorders (ICD-10: F50.8)
62465947|NCT03610113|NO_INTERVENTION|CONSERVATIVE TREATMENT|Conservative treatment is conceived to the use of sling for three weeks, followed by rehabilitation protocol
62096568|NCT02806895|PLACEBO_COMPARATOR|Placebo|Once daily dosing
62096569|NCT02806895|ACTIVE_COMPARATOR|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
62293776|NCT02318758|ACTIVE_COMPARATOR|Comparison 2|UT-15C 1 mg plus ethanol (simultaneously)
62096570|NCT00766857|EXPERIMENTAL|1. Exenatide|
62096571|NCT00766857|ACTIVE_COMPARATOR|2. Insulin glargine|
62096572|NCT02843022|ACTIVE_COMPARATOR|Usual care|Participant will receive the usual care provided by the nursing staff at Catholic Medical Center. A lactation consultant or childbirth educator attempts to call each patient within 2-3 weeks prior to discharge. Only one call is made, and a message left if the patient would like to call back.
62293777|NCT02318758|ACTIVE_COMPARATOR|Comparison 3|UT-15C 1 mg administered 1 hour before ethanol
62293778|NCT02318758|ACTIVE_COMPARATOR|Comparison 4|UT-15C 1 mg administered 1 hour after ethanol
62293779|NCT05246540||Patients|
62293780|NCT03502187|ACTIVE_COMPARATOR|Primary Care Management (PCM)|Non-specific LBP, where the cause for the pain cannot be determined, accounts for ninety percent of LBP cases.(Koes, et al, 2006) Reducing pain and continuing daily activity to prevent deconditioning are the primary therapy goals of PCM. Traditional PCM treatment of LBP will include advice/information on self-care options, over-the-counter analgesics, heat application, and remaining active.(Chou, et al., 2007; Koes, et al, 2010) Despite evidence that physical activity is effective, limiting activity remains common; individuals cite pain or re-injury fear as a limiting factor.( Lethem, et al., 1983; Poirandeau, et al., 2006; Steenstra, et al., 2016)
62293781|NCT03502187|EXPERIMENTAL|NeuromuscularElectricalStimulation(NMES)|Rehabilitation requires activation of deep stabilizing muscle groups in the lumbopelvic region. Traditional exercises specific for these muscles are hard to teach with poor compliance. NMES is effective in stimulating these muscles, (Porcari, et al., 2005; Glaser, et al., 2001) resulting in enhanced activation, and improved performance. (Coghlan, et al., 2011) NMES devices are programmed to exercise core muscles through a series of stimulated muscle contractions. Concurrent muscle stimulation of the abdominal wall and lumbar paraspinal area has been shown to be most effective to maximally activate deep lumbar stabilizers in LBP patients. (Baek, et al., 2016) NMES provides as much pain relief as transcutaneous electric nerve stimulation (TENS) in LBP subjects. (Moore SR, Shurman J, 1997)
61909106|NCT05627778|EXPERIMENTAL|68Ga-PSMA-11 and 68Ga-P15-041 PET/ CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a PET/ CT scan after intravenous administration of 68Ga- PSMA-11 and 68Ga-P15-041, respectively.
62293782|NCT03502187|EXPERIMENTAL|Progressive Exercise Plan (PEP)|The literature suggests that this intervention may be of benefit in military personnel with subacute LBP. (Chou, et al., 2007;Marshall PW, Murphy BA, 2006) Meta-analysis showed evidence that graded-activity exercise improved patient outcomes in subacute LBP; however, evidence for other exercise programs were inconsistent. (Hayden, et al., 2005) A strengthening program involving the trunk and abdomen muscles showed clinical reductions in low back pain and disability with high adherence. (Kendall, et al., 2015) Systematic reviews were unable to support any one type of exercise over another. The use of pain-relieving modalities combined with muscle strengthening, such as home-based electrotherapy or progressive exercise, could reduce pain and improve function more rapidly.
62293783|NCT00624221|ACTIVE_COMPARATOR|1|An Eye bank pre-cut the donor grafts used for the corneal transplant procedures.
62293784|NCT00624221|ACTIVE_COMPARATOR|2|The surgeon dissected the donor grafts used for the transplant procedures.
62293785|NCT01412853|EXPERIMENTAL|MR-spectroscopy|
62465948|NCT03610113|EXPERIMENTAL|REVERSE ARTHROPLASTY TREATMENT|"This group receives a surgical intervention by the use of reverse shoulder arthroplasty through deltopectoral approach and tuberosities reattachment.~It is followed by the same rehabilitation protocol than conservative treatment"
62660233|NCT02189824|EXPERIMENTAL|Infusion of partially matched unrelated donor cells|
62465949|NCT05641064|PLACEBO_COMPARATOR|Saline|Continuous infusion of saline starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
62465950|NCT05641064|EXPERIMENTAL|Dexmedetomidine 0.5|Continuous infusion of dexmedetomidine in dose 0.5 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
62660234|NCT00568243||Normal Volunteer|Healthy subjects without neurodegenerative diseases
62660235|NCT00568243||Patients|Subjects with neurodegenerative diseases
62660236|NCT04235855|EXPERIMENTAL|Endoscopic USG guided Liver biopsy|Olympus linear echo endoscope (GF -UCT 180, Olympus Ltde, Tkyo, Japan) will be used. 19 Gz EUS Acquire needle Boston ©Scientific Corp will be used for liver tissue acquisition.
61909107|NCT02458937||Osteonecrosis|"Observational measures of functional outcomes will be obtained from all participants who consent to and complete the study.~Interventions: Functional Mobility Assessment (FMA), GAITRite® System, and Range of Motion."
61909108|NCT06125470|EXPERIMENTAL|Intervention areas|Health facilities and other service delivery points including outreach health workers receiving FP supplies, trainings and renovations to create enabling environment at health and Family planning facilities Community engagement and creating creating adolescents friendly spaces roll out of Gender responsive strategies
61909109|NCT02811523|EXPERIMENTAL|Doxorubicin 5 mcg/ml|Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
62096573|NCT02843022|EXPERIMENTAL|Message Only|Participant will receive the usual care, and in addition, will receive four standardized electronic messages weekly for six months postpartum. These will be one-way messages without the option to respond.
61909110|NCT02811523|EXPERIMENTAL|Doxorubicin 7 mcg/ml|Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
62096574|NCT02843022|EXPERIMENTAL|Message and Nurse|"Participant will receive the usual care as well as the four standardized electronic messages/week for 6 months. Two of these weekly messages will be two-way, providing the option for the participant to respond yes to an offer to have a nurse call them. A nurse phone call if requested will be provided with a week."
62096575|NCT02763553|EXPERIMENTAL|Ketogenic Feed|A low-carbohydrate, high-fat enteral feed (Nutrison KetoCal 4:1) containing 0.4g of carbohydrate and 10g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
62096576|NCT02763553|ACTIVE_COMPARATOR|Standard Feed|Standard enteral feed (Nutrison ProteinPlus MF 1.28) containing 11.1g of carbohydrate and 3.8g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
62293786|NCT01625806|ACTIVE_COMPARATOR|RO4602522|
61909111|NCT02811523|EXPERIMENTAL|Doxorubicin 9 mcg/ml|Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
62096577|NCT05377099|ACTIVE_COMPARATOR|Laser In situ Keratomileusis (LASIK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after LASIK
62096578|NCT05377099|ACTIVE_COMPARATOR|Femto-second assisted LASIK (FS-LASIK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after Femto LASIK
62293787|NCT01625806|EXPERIMENTAL|RO4602522 + ketoconazole|
62293788|NCT03333473|EXPERIMENTAL|Intervention|The intervention will be applied to health facilities in one district in Indonesia and one county in Kenya. The intervention package will work within existing public and private health facilities to strengthen and assess the effectiveness of facility and provider level PPFP service provision and counseling, and expand method choice for women during antenatal, early labor, and post-pregnancy pre-discharge periods. Training within the intervention package include provider-lever PPFP counseling and service provision (PPFP Clinical and Counseling Skills), as well as provider and facility-level leadership management and governance training (Facility-Level Leadership Management and Governance Training).
62293789|NCT03333473|NO_INTERVENTION|Control|The health facilities control district in Indonesia and county in Kenya will continue with their standard counseling and service provision throughout the study period. At the conclusion of the study period, the facilities in these areas will receive the same intervention that Intervention facilities received prior to study startup.
62293790|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
62293791|NCT02272790|EXPERIMENTAL|Arm A (adavosertib + gemcitabine)|Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
62465951|NCT05641064|EXPERIMENTAL|Dexmedetomidine 1|Continuous infusion of dexmedetomidine in dose 1 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
62465952|NCT01352663|EXPERIMENTAL|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
62096579|NCT05377099|ACTIVE_COMPARATOR|Photorefractive Keratectomy (PRK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after PRK
62465953|NCT01352663|ACTIVE_COMPARATOR|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
62465954|NCT03789019|EXPERIMENTAL|BP-C1|"Dose-response part: patients who have completed the first 32-day treatment period with BP-C1 under Protocol BMC2011-1/Protocol MBC-BPC1/IIB or Protocol BMC2012-4, and having a maximum of moderate toxicity at the end of treatment are offered to continue in the second 32-day treatment period with BP-C1 under the protocol BMC2011-02. Patients completing 64-day treatment period with BP-C1 will be followed up for 28 days.~Follow-up study: the patients will be given BP-C1 as long as they obtain benefit from the treatment (i.e. until disease progression or increase in toxicity not above moderate grade)."
62465955|NCT00501345|EXPERIMENTAL|Aspirin|
62465956|NCT00808171|EXPERIMENTAL|EMLA and Livopan|Administered EMLA and Livopan
62465957|NCT00808171|EXPERIMENTAL|EMLA and gas placebo|Administered EMLA and oxygen
62465958|NCT00808171|EXPERIMENTAL|Livopan and placebo cream|Administered Livopan and placebo cream
62465959|NCT02129426|EXPERIMENTAL|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
62465960|NCT02129426|ACTIVE_COMPARATOR|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
62465961|NCT02209428|ACTIVE_COMPARATOR|IDH wild type|Patients with IDH wild type, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
61909112|NCT02811523|EXPERIMENTAL|Doxorubicin 7 mcg/ml - expansion|Expansion group at ideal dose
61909113|NCT05925543||all neonates diagnosed with biliary atresia and managed by Kasai portoenterostomy.|all neonates diagnosed with biliary atresia in the previous period 2019 and managed by Kasai portoenterostomy.
62293792|NCT02272790|EXPERIMENTAL|Arm B (adavosertib + paclitaxel)|Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
62293793|NCT02272790|EXPERIMENTAL|Arm C/C2 (adavosertib + carboplatin)|"Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.~Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
62293794|NCT02272790|EXPERIMENTAL|Arm D (adavosertib + PLD)|Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
62293795|NCT03519048|ACTIVE_COMPARATOR|Conventional follow-up|clinical examination with nasofibroscopy every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter. Low Dose Chest CTscan every year in patients with tobacco consumption history of \> 20 pack-year. Panendoscopy plus CT-scan are performed in case of clinical symptoms or abnormal clinical exam.
61909114|NCT05056428|EXPERIMENTAL|Intervention group|8-week mindfulness program
62308110|NCT05863936|OTHER|Belimumab and multi-target therapy group|Patients with severe lupus nephritis will be enrolled and received pulse methylprednisolone at a dose of 1.5 to 3.0g, followed by intravenous belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks thereafter. Multitarget therapy will be also administered during the induction phase. Induction therapy will last for 24 weeks.
62308111|NCT05513976|EXPERIMENTAL|treatment group A|
62465962|NCT02209428|EXPERIMENTAL|IDH mutation|Patients with IDH mutations, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
62465963|NCT04277325|EXPERIMENTAL|Intervention|Couples will receive 19-21 free sessions of Emotionally-Focused Therapy.
62465964|NCT04277325|NO_INTERVENTION|Waitlist|Couples will receive no intervention during the trial. After the trial is ended, they will be invited to participate in a weekend intervention meeting.
62465965|NCT04601792|EXPERIMENTAL|Individualized Decoction|"It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For subjects with lung and spleen qi deficiency syndrome, the investigators added Radix Codonopsis Pilosulae, Pericarpium Citri Reticulatae, and Atractylodes Macrocephala Koidz. The investigators can adjust the individualized decoction in accordance with the change in the patient's condition throughout the whole study duration.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
62465966|NCT04601792|PLACEBO_COMPARATOR|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
62465967|NCT04601792|ACTIVE_COMPARATOR|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
62465968|NCT04987619|EXPERIMENTAL|BJR|70 mL of beetroot juice (BEET It Sport®; James White Drinks Ltd., Ipswich, UK)
62096580|NCT04869657|ACTIVE_COMPARATOR|Sustainment 1: Coaches with CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by Children's Hospital of Philadelphia (CHOP) research consultants. In Year 2, schools in Sustainment 1 will receive reduced support for Tier 2 interventions provided by school district coaches. The coaches will in turn receive diminished support from research consultants. In Year 3, schools in both conditions will implement Tier 2 interventions with support from school district coaches; coaches will not receive direct assistance from research consultants.
62308112|NCT05513976|EXPERIMENTAL|treatment group B|
62308113|NCT05513976|PLACEBO_COMPARATOR|treatment group C|
62465969|NCT04987619|PLACEBO_COMPARATOR|PLA|70 mL of blackcurrant beverage Capri-Sun.
62465970|NCT00889109||1|Open Capsular Shift
62465971|NCT00889109||2|Arthroscopic Bankart Repair
62465972|NCT00889109||3|Healthy controls
62660237|NCT04235855|ACTIVE_COMPARATOR|Percutaneous Liver biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
61909115|NCT05056428|NO_INTERVENTION|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after experimental group completed the intervention.
62096581|NCT04869657|ACTIVE_COMPARATOR|Sustainment 2: Coaches without CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by CHOP research consultants. In Years 2 and 3, schools in Sustainment 2 will receive support from school district coaches but coaches will not receive help from research consultants.
62096582|NCT00558753|PLACEBO_COMPARATOR|1 Placebo|Half of the patients will receive PO placebo for 14 days
61909116|NCT02142387|ACTIVE_COMPARATOR|New DA-BLS training program|A one-hour training course that includes a 30-minute video-based self-instruction (VSI) training session, a short role-play, and a debriefing. The video consists of a bystander CPR simulation with dispatcher instructions using the trainee's own phone and practice session following demonstration by a simulated layperson. After watching the video clip, all trainees are divided into two groups and conduct a role-play as dispatchers and laypersons for 15 minutes. Finally, there is a 15-minute debriefing session with several assignments. The HEROS program focuses on cooperation with a dispatcher, from recognition of cardiac arrest to performing DA-CPR, with hands-on practice so that laypersons can provide bystander CPR immediately in a real situation. Moreover, the HEROS program emphasizes practice for providing the correct address of the scene and switching to speakerphone mode, especially for the elderly.
61909117|NCT02142387|NO_INTERVENTION|Current Basic Life Support (BLS) training program|A one-hour training program that was developed by the Korea Center for Disease Control and Prevention (CDC) and it was based on the American Heart Association (AHA) guideline (http://www.cdc.go.kr/board.es?mid=a20503050000\&bid=0021\&tag=\&act=view\&list_no=127655). The program consists of a 30-minute VSI, and a 30-minute practice debriefing session. It focuses on detailed techniques for performing high-quality chest compressions including the correct hands and body position of the bystanders.
61909118|NCT06476054|OTHER|early interval|Both arms involve interventions, but participants in the early interval arm will undergo treatment (laparoscopic cholecystectomy) within 2 weeks after diagnosis, preferably within 10 days after the onset of symptoms of acute cholecystitis.
62660238|NCT03402412|EXPERIMENTAL|Study Arm|Narrow-band UVB will be given to a small part of the patients skin with eczema. The rest of the skin surface serves as control.
62096583|NCT00558753|EXPERIMENTAL|2 Pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
62096584|NCT02498613|EXPERIMENTAL|Treatment (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.
62096585|NCT06613438|EXPERIMENTAL|Active|Participants in the active arm will be using a functional version of the investigational device for 28 days.
61909119|NCT06476054|OTHER|late interval|Both arms involve interventions, but participants in the late interval arm will undergo treatment (laparoscopic cholecystectomy) after the 6th week of diagnosis, ideally between week 6 and week 8 following the diagnosis of acute cholecystitis.
61909120|NCT01414920|PLACEBO_COMPARATOR|Placebo QD|
61909121|NCT01414920|EXPERIMENTAL|TAK-875 25 mg QD|
61909122|NCT01414920|EXPERIMENTAL|TAK-875 50 mg QD|
61909123|NCT01414920|EXPERIMENTAL|Sitagliptin 100 mg QD|
61909124|NCT01414920|EXPERIMENTAL|TAK-875 25 mg QD + Sitagliptin 100 mg QD|
62096586|NCT06613438|SHAM_COMPARATOR|Control|Participants in the control arm will be using a sham version of the investigational device for 28 days.
62660239|NCT04298853|ACTIVE_COMPARATOR|Standard|Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.
62660240|NCT04298853|EXPERIMENTAL|Study|Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.
61909125|NCT01414920|EXPERIMENTAL|TAK-875 50 mg QD + Sitagliptin 100 mg QD|
61909126|NCT04135105||Normal hearing group|Right-handed, normal hearing, no reported neurological disorders
61909127|NCT02997241|OTHER|high genetic risk and high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
62096587|NCT03679702|OTHER|Active treatment|
62660241|NCT03180372|EXPERIMENTAL|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
62660242|NCT04638244|EXPERIMENTAL|BOMI Group (Intervention Group)|Listening to an expert-selected, theory-guided and self-chosen song each day actively in a personalized and focused way (Brief Online Music Intervention: BOMI) for 3 months
62660243|NCT04638244|ACTIVE_COMPARATOR|POM Group (Control Group)|Receiving psychoeducational online message (POM) (for focused reading for 5 minutes) daily for 3 months
62660244|NCT03578913|ACTIVE_COMPARATOR|porcelain fused to metal crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
62660245|NCT03578913|EXPERIMENTAL|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading
62660246|NCT03606824|PLACEBO_COMPARATOR|Pivastatin and placebo|After randomization, patients in Pivastatin + placebo group will receive pitavastatin and placebo.
62096588|NCT05661942|ACTIVE_COMPARATOR|Calcium pre-treatment|Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl
62096589|NCT05661942|PLACEBO_COMPARATOR|Placebo|diluent (NS) vials
62096590|NCT03869853|EXPERIMENTAL|intervention|Entrepreneurial stimulation and integrated education
62660247|NCT03606824|EXPERIMENTAL|Pivastatin and LT-4|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
62660248|NCT02603133|OTHER|Cohort 1|The intervention will begin for all NICUs, with baseline surveys as necessary pre-work. For those unable to attend, a link to the baseline survey will be emailed with site champion instructions to complete in groups at staff meetings and during shift change. Two weeks later, three randomly (random number generator) assigned NICUs (block 1) included in the first block webinar will then receive Module 1 of the intervention with Modules 2-6 being rolled out monthly. The second block of three NICUs starts approximately six-month later.
62660249|NCT02603133|OTHER|Cohort 2|This second block of 3 NICUs will start approximately six-months after roll-out of group 1. At time point 0 this NICUs in this group will receive a lecture on safety culture, unrelated to the burnout intervention.
62737010|NCT01047137|PLACEBO_COMPARATOR|Control|Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.
62737011|NCT01047137|EXPERIMENTAL|Intervention|Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.
62096591|NCT03869853|EXPERIMENTAL|control|no intervention
62096592|NCT01192295|EXPERIMENTAL|Oxycodone HCl controlled-release|Oxycodone hydrochloride (HCl) controlled-release (CR)
62096593|NCT03906747||Patients|Patients at their end-of-life (EOL) phase attending the emergency department
62096594|NCT03906747||Family members and next-of-kin of (EOL) patients|Family members and next-of-kin of EOL patients in the emergency department
62096595|NCT03906747||Healthcare workers|Comprised of doctors in the emergency department, nurses and general practitioners
62737012|NCT01266109|EXPERIMENTAL|CM-FAM|
62737013|NCT01266109|ACTIVE_COMPARATOR|US|
61909128|NCT02997241|ACTIVE_COMPARATOR|low genetic risk but high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
61909129|NCT02997241|ACTIVE_COMPARATOR|high genetic risk but low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
61909130|NCT02997241|OTHER|low genetic risk and low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
61909131|NCT01453387|EXPERIMENTAL|Part 1 - MSC2015103B (Schedule 1)|
62096596|NCT03618303|EXPERIMENTAL|Interventional|All patients will undergo the same intervention of having a PET-MRI scan and optical coherence tomography.
62096597|NCT01941264|ACTIVE_COMPARATOR|community based screening and treatment|CHWs will identify pregnant women in the village and encourage to go to the antenatal care clinic, furthermore, once a month the community health worker will screen the pregnant women for malaria with a rapid diagnostic test and treat with artemether-lumefantrine in case of a positive test result.
62096598|NCT01941264|NO_INTERVENTION|Control|All pregnant women will be identified in the study area and asked for participation to the study. No intervention will take place.
62660250|NCT02603133|EXPERIMENTAL|Cohort 3 (July cohort) WISER 2.0|"Individually randomized to one of two cohorts. Cohort 1 to start will serve as the waitlist control 1 before starting their version of the intervention. Each cohort will experience modified versions of WISER, which only differ by the spacing of intervention. Participants will receive 10-day sequential or 10-day non-sequential rollout of the resilience tools. Seq will receive the tools on ten consecutive days. NSeq will receive messages daily noThursdays, Fridays and Saturdays.~Days 1 through 3 will be offered 3GT. Day 4 will continue with 3GT but add a single day activity for Gratitude. Day 5 adds a single activity for Awe. Day 6 adds a single day activity for RAK. Days 7 -10 the participant is offered the choice of Gratitude, Awe or RAK to accompany their daily 3GT. At 1 month follow-up time point, participants will receive 8 days of the 1 Good Chat tool, as a booster. At 6 month follow-up, participants will receive a gratitude exercise."
62660251|NCT05285969|EXPERIMENTAL|Motivational interview|Motivation Interview program with standard care
62660252|NCT05285969|ACTIVE_COMPARATOR|Standard care group|Standard care
62660253|NCT01251458|EXPERIMENTAL|Torisel|
62660254|NCT04785729|EXPERIMENTAL|almonertinib|
62660255|NCT06355973|EXPERIMENTAL|Using tablets and workbooks.|Using tablets and workbooks Cognitive and physical function training self-programming for 6 weeks.
62660256|NCT06355973|EXPERIMENTAL|Only self-programming of physical function training.|Only self-programming of physical function training is provided Implemented for 6 weeks.
61909132|NCT01453387|EXPERIMENTAL|Part 1 - MSC2015103B (Schedule 2)|
61909133|NCT04598191|PLACEBO_COMPARATOR|Control group|Participants in this group are administered inhaled normal saline.
61909134|NCT04598191|EXPERIMENTAL|iloprost group|Participants in this group are administered inhaled iloprost.
61909135|NCT06530472||Fondazione Don Carlo Gnocchi|All patients diagnosed with ischaemic heart disease established by angiography; attained age of majority; Score \>= 26 on the Montreal Cognitive Assessment (MoCA) test. At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
61909136|NCT06530472||Ospedale Valduce|All patients diagnosed with ischaemic heart disease established by angiography; attained age of majority; Score \>= 26 on the Montreal Cognitive Assessment (MoCA) test. At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
62096599|NCT04956692|EXPERIMENTAL|Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy|Participants receive pembrolizumab subcutaneous (SC) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for squamous non-small cell lung cancer (NSCLC); PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for non-squamous NSCLC.
62660257|NCT00470613|EXPERIMENTAL|SGT-53|SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 \& 7 when it will be administered biweekly on days 1 \& 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 \& 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
62737014|NCT04193904|EXPERIMENTAL|MRx0518 with hypofractionated preoperative radiation|Subjects will take one capsule of MRx0518 twice daily from one week prior to radiation therapy until surgical resection (6 to 9 weeks approx.) Radiation therapy will be delivered as 30Gy/10 fractions over 2 weeks.
62737015|NCT01924039|EXPERIMENTAL|Brief Motivational Enhancement Therapy|
62660258|NCT06201325|ACTIVE_COMPARATOR|VR group|VR-based exercise program for half an hour a day, 5 days a week for a total of 3 weeks, in addition to home exercise programs for half an hour a day, 5 days a week for a total of 3 weeks. These individuals will use the Microsoft Kinect for Azure VR system in the virtual environment. They will play the registered games. These games will include purpose-oriented activities such as lying on the shelf and using bilaterally, which are intended to use the upper extremities of individuals with AC in daily life.
62660259|NCT06201325|ACTIVE_COMPARATOR|Conventional group|Individuals in the second group, who will be included in the traditional exercise group, will be included in the stretching and strengthening exercise program for half an hour a day, 5 days a week for a total of 3 weeks, in addition to home exercise programs for half an hour a day, 5 days a week for a total of 3 weeks. The exercises will be performed by a physiotherapist working in the clinic and blind to the study.
61909137|NCT06530472||Ospedale Cà Granda Niguarda|All patients diagnosed with ischaemic heart disease established by angiography; attained age of majority; Score \>= 26 on the Montreal Cognitive Assessment (MoCA) test. At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
61909138|NCT04434846||1|Healthy Cambodian Adults aged 18-55 were screened for antibodies to ZIKV, DENV, and CHIKV at a single time point at Amphae Phnom, Chbar Mon, Cambodia.
62308114|NCT01625169|OTHER|HIV + pregnant women|Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
62308115|NCT01855555||sedation group|Children requiring sedation for MRI/CT
62660260|NCT06201325|OTHER|Control group|In the third group, who will be included in the home exercise group, exercises will be taught to the patient and will be applied for half an hour a day, 5 days a week for a total of 3 weeks.
62737016|NCT01924039|OTHER|treatment as usual|
62660261|NCT05546762|EXPERIMENTAL|Antiseptic irrigation arm|250 ml solution of 2% povidone-iodine (i.e. 50 ml betadine in 200 ml saline) will be attached to the chest tube via a giving set and a 3-way tap and irrigated into the pleural space with gravity. The chest tube will be clamped for 10-20 minutes after irrigation and then will be unclamped and left to drain freely. The first dose will be applied 24-48 hours after tube insertion. This will be repeated every 12 hours for a total of four to six applications.
62660262|NCT05546762|ACTIVE_COMPARATOR|Saline irrigation arm|250 ml solution of normal saline will be attached to the chest tube via a giving set and a 3-way tap and irrigated into the pleural space with gravity. The chest tube will be clamped for 10-20 minutes after irrigation and then will be unclamped and left to drain freely. The first dose will be applied 24-48 hours after tube insertion. This will be repeated every 12 hours for a total of four to six applications.
62660263|NCT04403139|OTHER|Cohort 1: 30-40 year of age|
62660264|NCT04403139|OTHER|Cohort 2: 70 years of age or older|
62660265|NCT02321904||Diabetic cases|Children with Type 1 Diabetes 8 to 18 years old followed at the Alberta Children's Hospital Diabetes Clinic with duration of diabetes for at least 5 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
62660266|NCT02321904||Normal controls|Healthy children aged 8 to 18 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
62660267|NCT02705703|EXPERIMENTAL|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
62660268|NCT05180058|EXPERIMENTAL|Wrapping + Breastmilk Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of breast milk will be given by the researcher with a sterile syringe 2 minutes before the OGT insertion to the same newborn. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
62660269|NCT05180058|EXPERIMENTAL|Wrapping + Oral Sucrose Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of 20% oral sucrose will be given to the same newborn by the researcher with a sterile syringe 2 minutes before OGT insertion. Oral sucrose will be slowly introduced into the mouth of the preterm newborn on the upper part of the tongue through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at 1 minute before the procedure, during and after the procedure at 1 minute and 2 minutes (4 measurements).
62737017|NCT06005532|EXPERIMENTAL|Adalimumab (manufactured by Mabscale, LLC)|In the main period, patients will begin Visit 1 receiving Adalimumab therapy at an initial dose (80 /0, 16 ml) on Visit 1, from Visit 2 Adalimumab therapy at a maintenance dose (40 /0, 8 ml) for up to Visit 9 of therapy. Each visit is conducted every two weeks ± 2 days. In additional period (from Visit 11 until Visit 28), eligible patients will continue to receive treatment after additional randomization (Adalimumab or Humira® (40 /0, 8 ml)) every 2 weeks until the end of a trial.
62465973|NCT04269460|ACTIVE_COMPARATOR|subcostal transversus abdominis plane block (sTAP)|patients will be in the supine position; after preparing the skin with with povidone iodine, a high frequency (5-10 MHz) ultrasound probe will be used tp identify the rectus abdominis muscle, then 1 mL/Kg of bupivacaine 0.25% will be injected in the plane between rectus abdominis and transversus abdominis muscles.The patient will then be positioned for the procedure if other than supine position is chosen.
62465974|NCT04269460|ACTIVE_COMPARATOR|quadratus lumborum block (QLB)|patients will be positioned in the lateral decubitus position so that the blocked side will be the uppermost one. After skin sterilization with povidone iodine the ultrasound probe will be positioned to identify the quadratus lumborum muscle. then 1 mL/Kg of bupivacaine 0.25% will be injected behind the QL muscle on the lateral border of the erector spinae muscle.The patient will then be positioned for the procedure if other than lateral decubitus position is chosen.
62096600|NCT04956692|ACTIVE_COMPARATOR|Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy|Participants receive pembrolizumab intravenous (IV) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for squamous non-small cell lung cancer (NSCLC); PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for non-squamous NSCLC.
62465975|NCT06131853|EXPERIMENTAL|prostate group|
62465976|NCT06131853|ACTIVE_COMPARATOR|control group|
62465977|NCT01363765|EXPERIMENTAL|Xpert MTB/Rif|Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
62660270|NCT05180058|EXPERIMENTAL|Fetal Position + Breastmilk Group|The fetal position will be given to the preterm newborn immediately after 2 ml of breast milk is given by the researcher 3 minutes before OGT insertion. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure. Newborns will be recorded with a video camera before, during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
62660271|NCT05180058|EXPERIMENTAL|Fetal Position + Oral Sucrose Group|The fetal position will be given to the preterm newborn immediately after 2 ml of oral sucrose is given by the researcher 3 minutes before OGT insertion. Oral sucrose will be slowly injected into the mouth of the preterm newborn on the upper part of the tongue by means of an injector. At the end of the 3rd minute, the clinic nurse will insert the OGT as part of the treatment. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure.
62660272|NCT05143502|EXPERIMENTAL|Montelukast Group|Patients in group A (interventional group) will be treated with fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 monthes and oral Prednisolone 40 mg/day for two weeks.
62660273|NCT05143502|ACTIVE_COMPARATOR|Control Group|Subjects in treatment group B will receive topical and systemic steroids in an identical regimen only.
62660274|NCT02471183|EXPERIMENTAL|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
62096601|NCT03486340|EXPERIMENTAL|Cardiological assessment|a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment
62096602|NCT03486340|NO_INTERVENTION|Standard treatment|Standard chemotherapeutic treatment
62096603|NCT05981456|EXPERIMENTAL|Flipped Educational Model|Giving the subject of patient safety education with the flipped education model
62096604|NCT05981456|ACTIVE_COMPARATOR|Traditional Educatıonal Model|Giving the subject of patient safety education with the traditional education model
62096605|NCT01124617|EXPERIMENTAL|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
62096606|NCT01124617|PLACEBO_COMPARATOR|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
62096607|NCT05504343|OTHER|Single Arm|This study is a prospective, single arm single center, open label study.
62096608|NCT01023919|ACTIVE_COMPARATOR|Group B:|Coronary artery disease without diabetes mellitus
62096609|NCT01023919|ACTIVE_COMPARATOR|Group A:|Coronary artery disease with diabetes mellitus
62096610|NCT02467374|ACTIVE_COMPARATOR|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
62096611|NCT02467374|ACTIVE_COMPARATOR|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
62096612|NCT01528124|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride given as a single subcutaneous injection
62096613|NCT01528124|EXPERIMENTAL|LY3025876|Single escalating doses of LY3025876 given as subcutaneous injections
62096614|NCT02307123||HEMS treated patients|Patients whose airways were secured by the HEMS physician.
62660275|NCT01500083|EXPERIMENTAL|Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with CLL will receive bendamustine at a dose of 100 mg/m2 on Days 1 and 2 in treatment cycles of 28 days for up to six cycles.
62293796|NCT03519048|EXPERIMENTAL|Intensive follow-up strategy|adding to the conventional follow-up strategy , an annual head\&neck and thoracic injected CT-scan and Lugol upper gastrointestinal endoscopy (the first performed 12 months after inclusion), annual whole body PET-CT (the first at 6 months after inclusion). These 3 exams are performed every year during 3 years after inclusion (i.e. 3 CT-scan, 3 digestive endoscopies and 3 PET-CT per patient). Clinical follow up will be conducted as in the conventional follow up group and panendoscopy or bronchoscopy will be performed if needed. After 3 years, patients will be followed by conventional follow-up.
62293797|NCT04203901|EXPERIMENTAL|Combination Arm|CMN-001 dosing (1x10\^7 DC/dose) is initiated at Visit 2 during 1st line therapy and through 2nd line therapy. CMN-001 is administered as 1 dose every 3 weeks for 3 doses (Induction phase), followed by maintenance doses, 1 every 4 weeks for 7 doses (Maintenance phase), followed by booster doses, 1 dose every 12 weeks (Booster phase). 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression, 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
62660276|NCT01500083|EXPERIMENTAL|Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)|Patients with iNHL will receive bendamustine at a dose of 120 mg/m2 on Days 1 and 2 in treatment cycles of 21 or 28 days for up to eight cycles.
62660277|NCT02504164|EXPERIMENTAL|No premedication|No premedication before sedation
62293798|NCT04203901|ACTIVE_COMPARATOR|Standard Treatment|1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
62293799|NCT05527951|EXPERIMENTAL|Enhanced MBC Implementation(eMBC)|The eMBC implementation arm use our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
62293800|NCT05527951|ACTIVE_COMPARATOR|Standard MBC Implementation|The standard MBC implementation arm use paper and pencil questionnaires.
62293801|NCT00797433||Mechanical ventilation|All male patients with acute respiratory failure requiring mechanical ventilation
62660278|NCT02504164|ACTIVE_COMPARATOR|Midazolam|Premedication with midazolam before sedation
62293802|NCT03823664||Type 2 Diabetic|"Fasting Plasma Glucose ≥126 mg/dL (7.0 mmol/L). OR \* A1C ≥6.5% (48 mmol/mol). OR \* Patients with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).OR\* 2-h Plasma Glucose ≥200 mg/dL (11.1 mmol/L) during oral glucose tolerance test\*~\* American Diabetes As. (ADA) type 2 diabetes diagnosis criteria"
62293803|NCT03823664||Prediabetic|"Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (Impaired Fasting Glucose)\* OR A1C 5.7-6.4% (39-47 mmol/mol)\* OR 2-h Plasma Glucose during 75-g Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (Impaired Glucose Tolerance)\*~\* ADA prediabetes criteria"
62293804|NCT03823664||Healthy|Healthy glucose metabolism and according to endocrinology visit no health problems related or affect cardiorespiratory fitness and other parameters examined in this study.
62293805|NCT05925608|ACTIVE_COMPARATOR|Study Treatment|Phase I of the study will utilize a dose escalation study design with three patients at 20 million MSCs, three patients at 100 million MSC, and three patients at 200 million MSC to identify dose for Phase II. The study treatment (active comparator) is comprised of left ventricular catheterization and treatment with allogeneic hMSC using the Helix transendocardial delivery catheter.
62293806|NCT05925608|SHAM_COMPARATOR|Control|In Phase II of the study, the control group will undergo left ventricular catheterization with introduction of an iliofemoral sheath but no introduction of the Helix transendocardial delivery catheter but no administration of allogeneic hMSC with the Helix transendocardial delivery catheter.
62465978|NCT01363765|ACTIVE_COMPARATOR|Sputum smear|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining
62660279|NCT03120273|EXPERIMENTAL|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd in dexlansoprazole treatment arm for 5 days
62660280|NCT03120273|ACTIVE_COMPARATOR|Lansoprazole Injection|30 mg q12h in lansoprazole treatment arm for 5 days.
62660281|NCT02115386|EXPERIMENTAL|Nilotinib|Dosage was 300 mg BID daily taken orally without food.
62660282|NCT02395770|EXPERIMENTAL|Subacromial pain group|Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
62660283|NCT00090103|ACTIVE_COMPARATOR|dutasteride|dutasteride 0.5mg once daily
62465979|NCT02817841|EXPERIMENTAL|15 mg E4/3 mg DRSP|15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive
62660284|NCT00090103|EXPERIMENTAL|Combo|Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily
62660285|NCT00090103|ACTIVE_COMPARATOR|tamsulosin|tamsulosin 0.4mg once daily
62660286|NCT04168489|ACTIVE_COMPARATOR|active rTMS|
62660287|NCT04168489|SHAM_COMPARATOR|sham rTMS|
62096615|NCT05687890|EXPERIMENTAL|SC0062 low dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
62096616|NCT05687890|EXPERIMENTAL|SC0062 medium dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
62096617|NCT05687890|EXPERIMENTAL|SC0062 high dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
62096618|NCT05687890|PLACEBO_COMPARATOR|Placebo of SC0062 group|Subjects will take two capsules daily for 24 weeks during the treatment period
62096619|NCT04929379|EXPERIMENTAL|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
62096620|NCT04929379|PLACEBO_COMPARATOR|Placebo|Inactive tablets identical to fenofibrate
62096621|NCT01452672|ACTIVE_COMPARATOR|RT to chest wall and S/C|Irradiation of the chest-wall and supraclavicular fossa
62096622|NCT01452672|EXPERIMENTAL|RT to chest wall|Irradiation of the chest-wall alone
62096623|NCT03131141|EXPERIMENTAL|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
62096624|NCT03131141|EXPERIMENTAL|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
62096625|NCT06613607|EXPERIMENTAL|Experimental group|"The group will receive strengthening treatment protocol. Strengthening will be divided into following phases~1. Warm up phase:~2. Strengthening phase:~3. Cool down phase:"
62096626|NCT06648824|EXPERIMENTAL|Mitapivat and Midazolam|Participants will receive single oral dose of 2 milligram (mg) midazolam on Day 1 followed by 100 mg mitapivat, orally, twice daily (BID) from Day 3 to 13. On Day 14, participants will receive single oral dose of 2 mg midazolam and 100 mg mitapivat orally, BID. Midazolam will be co-administered with morning mitapivat dose.
62096627|NCT06697548|ACTIVE_COMPARATOR|Usual Care|Usual Care Group will receive their current medical management care along with study-specific patient education and progressive home exercise.
62096628|NCT06697548|EXPERIMENTAL|Emerging Field-expedient Care|Emerging Field-expedient Care Group will receive a combination of emerging nonvaginal interventions aimed at normalizing sensory, motor, and autonomic nervous system dysfunction including pain neuroscience education, diaphragmatic breathing training, and lumbopelvic manual therapy and dry needing treatment
62465980|NCT01639222|EXPERIMENTAL|Calcium 500 mg and Vitamin D3 800 IU|"Period 1: Low calcium meals for up to 3 days.~Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals."
62660288|NCT05067270|EXPERIMENTAL|Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh|Participants had cannulas inserted into each of the designated infusion sites (6 millimeter (mm) for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated subcutaneously (SC) with 15 millimolar (mM) sodium citrate and 1 microgram per milliliter (μg/mL) treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 unit per hour (U/h). The same procedure occurred at subsequent infusion sites with an approximately 30-minute (min) interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
62096629|NCT06697548|ACTIVE_COMPARATOR|Gold-standard Intravaginal Specialist Care|Gold-standard Intravaginal Specialist Care Group will receive tailored intravaginal and intrarectal manual therapy and biofeedback intervention by a pelvic-health specialist.
62096630|NCT03351829|EXPERIMENTAL|Gene-modified autologous stem cells|Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo
62096631|NCT02030210||cardiologists|
62096632|NCT02030210||study coordinators|
62096633|NCT02030210||registred nurses|
62096634|NCT01668485|EXPERIMENTAL|Islet transplant recipients|Hypoglycemic and euglycemic glucose clamp
62096635|NCT01668485|PLACEBO_COMPARATOR|Type 1 diabetic subjects|Hypoglycemic and euglycemic glucose clamp.
62096636|NCT01668485|ACTIVE_COMPARATOR|Non-diabetic subjects|Hypoglycemic and euglycemic glucose clamp
62096637|NCT01955382|EXPERIMENTAL|AS + oAC|All children will receive Artesunate (AS) 2.4 mg/kg IV at 0 and 12 h, 24 h, and 48 h. Children in the AS+oAC group will be given weight-based doses of oAC (Actidose Aqua) (Table 1) at 0, 6, 12, and 18 h. All children will then receive amodiaquine.
62096638|NCT01955382|PLACEBO_COMPARATOR|AS only (water)|Children in the AS only group will receive a weight-based volume of clean water (Bottled Water) to drink rather than the oAC.
62096639|NCT04234243||HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis treated with cytoreduction and HIPEC
62096640|NCT04234243||No HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis, treated with systemic chemotherapy only
62096641|NCT05843565|EXPERIMENTAL|Cobalt group: Cobalt blade then Miller blade|Patients enrolled in the study will receive sevoflurane 6% for induction of general anesthesia followed by rocuronium 0.6 mg/kg to facilitate tracheal intubation. In patients allocated to the Cobalt group, the POGO and C\&L classification will be recorded using video laryngoscopy with a Cobalt blade followed by an assessment using the Miller blade. Intubation will then be attempted during the second assessment. Endotracheal tube size will be selected according to body weight and a guiding stylet will be used. If the first attempt at intubation fails, the subsequent attempts will be left at the discretion of the attending anesthesiologist.
62293807|NCT02036229|EXPERIMENTAL|0.5% ivermectin cream|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
62293808|NCT02036229|PLACEBO_COMPARATOR|vehicle cream|Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
62096642|NCT05843565|PLACEBO_COMPARATOR|Miller group: Miller blade then cobalt blade|Patients enrolled in the study will receive sevoflurane 6% for induction of general anesthesia followed by rocuronium 0.6 mg/kg to facilitate tracheal intubation. In patients allocated to the Miller group, the POGO and C\&L classification will be recorded using video laryngoscopy with a Miller blade followed by an assessment using the Cobalt blade. Intubation will then be attempted during the second assessment. Endotracheal tube size will be selected according to body weight and a guiding stylet will be used. If the first attempt at intubation fails, the subsequent attempts will be left at the discretion of the attending anesthesiologist.
62096643|NCT03605329|OTHER|Type 1 diabetic patients with OSAS|to explore the severity of NAC in case of OSAS
62096644|NCT03752320||POP+ and POP-|POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia
62465981|NCT04324580|ACTIVE_COMPARATOR|Delayed mobilization/Formal physical therapy group|Participants will be placed into a volar-based plaster splint post-operatively. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. After that, participants will be placed into a custom thermoplastic splint by a therapist. This will be worn for 5 weeks. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks. The splint will be removed only for formal and home physical therapy and hygiene.
62465982|NCT04324580|ACTIVE_COMPARATOR|Immediate mobilization/self guided physical therapy group|Participants will be placed into a soft dressing after surgery. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. This group will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
62465983|NCT05226923|EXPERIMENTAL|KSP-1007 single ascending dose|Single, ascending intravenous dose of KSP-1007
62465984|NCT05226923|PLACEBO_COMPARATOR|Placebo single dose|Single dose of placebo (0.9% normal saline)
62465985|NCT05226923|EXPERIMENTAL|KSP-1007 multiple ascending dose|Multiple, ascending, intravenous doses of KSP-1007
62465986|NCT05226923|PLACEBO_COMPARATOR|Placebo multiple dose|Multiple doses of placebo (0.9% saline)
62660289|NCT05067270|EXPERIMENTAL|Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
62096645|NCT06614517|EXPERIMENTAL|Birdwatching Intervention Arm|The intervention arm will involve participants, divided into four subgroups, taking part in field trips for visual and auditory birdwatching. These trips will take place every 15 days over three sessions, guided by an expert in the subject. Students will be provided with binoculars and guidance on the use of apps to identify observed birds. Additionally, WhatsApp groups will be created for each subgroup, where videos and audios of birds will be shared, along with weekly challenges to reinforce exposure to the intervention. The outings will take place in natural environments such as coffee farms and forests near Bucaramanga.
62096646|NCT06614517|NO_INTERVENTION|Control Arm|The control group will not receive any intervention related to birdwatching. Participants in this group will continue with their usual activities without taking part in the field trips or complementary activities such as watching videos or listening to bird sounds.
62096647|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
62096648|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
62096649|NCT04672460|EXPERIMENTAL|Sequence 1|Participants receive Treatment B for 28 days, followed by Treatment A for 21 days, followed by Treatment C for 21 days.
62096650|NCT04672460|EXPERIMENTAL|Sequence 2|Participants receive Treatment A for 28 days, followed by Treatment B for 21 days, followed by Treatment C for 21 days.
62096651|NCT01575145|EXPERIMENTAL|Quitline facilitation intervention|brief quitline facilitation intervention given
62465987|NCT05226923|EXPERIMENTAL|KSP-1007 multiple ascending dose + Meropenem multiple dose|Multiple, ascending intravenous doses of KSP-1007 and multiple doses of meropenem (fixed dose)
62465988|NCT05226923|PLACEBO_COMPARATOR|Placebo + Meropenem multiple dose|Multiple doses of placebo (0.9% normal saline) plus multiple doses of meropenem (fixed dose)
62465989|NCT02903888||BAY86-5028|Women aged 18 to 29 years that use Jaydess for contraception
62465990|NCT02254174|EXPERIMENTAL|Tiotropium/Salmeterol|
62465991|NCT02254174|ACTIVE_COMPARATOR|Serevent® Diskus®|
62465992|NCT02254174|ACTIVE_COMPARATOR|Spiriva®|
62465993|NCT02254174|ACTIVE_COMPARATOR|Spiriva® and Serevent® Diskus®|
62096652|NCT01575145|ACTIVE_COMPARATOR|Stop-smoking intervention|brief review of tips to maintain smoking abstinence, using brochure
62465994|NCT01725698|EXPERIMENTAL|Stemcell|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
62465995|NCT02006160|ACTIVE_COMPARATOR|treatment|dalfampridine
62465996|NCT02006160|PLACEBO_COMPARATOR|control|placebo
62465997|NCT05220683|EXPERIMENTAL|Verion and Callisto|Alignment axis will be analysed with both, the Verion and the Callisto, digital marking system in the same eye of the same patient
62096653|NCT03452111|EXPERIMENTAL|Nestorone (NES) + testosterone (T) combined gel|A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally (NES/T gel). The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day).
62096654|NCT00696904|OTHER|1|Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose
62096655|NCT00696904|OTHER|2|HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID
62096656|NCT00696904|OTHER|3|Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect
62096657|NCT06615284|EXPERIMENTAL|Arm 1|Drug- Atorvastatin 40mg Dosage form- Oral tablet Frequency and duration- once daily for 28 days
62096658|NCT06615284|EXPERIMENTAL|Arm 2|Drug- Atorvo+™ Low (40 mg Atorvastatin and 100 mg CBD) Dosage form- Oral tablet Frequency and duration- once daily for 28 days
62096659|NCT06615284|EXPERIMENTAL|Arm 3|Drug- Atorvo+™ High (40 mg Atorvastatin and 200 mg CBD) Dosage form- Oral tablet Frequency and duration- once daily for 28 days
62096660|NCT00684970|OTHER|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118 (single arm)
62096661|NCT01827228|EXPERIMENTAL|Primary Recent infection network tracing|"Subjects: LAg+ recent HIV infection testees \& referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues. We'll network trace direct contacts of Index Cases \& network/venue members of contacts; and maybe 3rd ring as exploratory part of project. We'll test network/venue members for recent \& acute HIV. If they have recent/acute HIV infection, their network/venue contacts will be traced. We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management. We will distribute community alerts to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected."
62096662|NCT01827228|ACTIVE_COMPARATOR|Contact tracing of long-term HIV+ people|We will start with 50 subjects in each city who test HIV+ but LAg negative-and who report they have just learned they are HIV+. We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm. HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
62096663|NCT01827228|ACTIVE_COMPARATOR|HIV negative comparison arm|This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
62096664|NCT02920944|EXPERIMENTAL|EUS-FNB with 20-gauge|EUS-FNB with 20-gauge procore needle
62465998|NCT04329988||Primary care patients aged 18 or more|All patients consulting in a general practitioner office, aged 18 or more, who completed the questionnaire
62465999|NCT01364194|ACTIVE_COMPARATOR|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
62466000|NCT01364194|PLACEBO_COMPARATOR|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
62096665|NCT02920944|ACTIVE_COMPARATOR|EUS-FNB with 22-gauge|EUS-FNB with 22-gauge procore needle
62096666|NCT00519779|PLACEBO_COMPARATOR|2|Placebo oral Omega-3 fish oil supplementation
62096667|NCT00519779|EXPERIMENTAL|1|oral Omega-3 fish oil supplementation
62096668|NCT01218828|ACTIVE_COMPARATOR|Standard therapy|Hydration with 0.9% saline per a standard protocol (control group)
62096669|NCT01218828|EXPERIMENTAL|LVEDP-based hydration strategy|LVEDP guided hydration with 0.9% saline (treatment group)
62096670|NCT04942470|EXPERIMENTAL|Experimental:Intervention Arm|For the experimental group patients, sponges prepared by impregnating cream containing Aloe Vera and Propolis will be sterilized in the sterilization device. If any contamination occurs in the wound area of the patient (in the presence of feces, discharge), the product is applied to the wound bed after cleaning the wound with 0.9% isotonic sodium chloride washing solution. And the effects of the product on the wound will be monitored. The solution will be applied 2 times a day for the first 10 days. The second 10 days will be applied daily 1x1. Application results will be recorded and wound healing status will be monitored. In order to prevent and maintain pressure injury, the experimental group patients will be given an in-bed position every 2 hours. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure, etc.), necessary treatment and care is performed.
62293809|NCT04900402||Individuals with physical disabilities continuing rehabilitation after COVID-19|International Physical Activity Questionnaire Short Form (IPAQ) and Child Quality of Life Scale (PedsQL) questionnaires will be applied to individuals who continue their rehabilitation after the COVID-19 pandemic is declared.
62466001|NCT00756080|EXPERIMENTAL|1|After receiving a 7-day oral supplementation with citrulline, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with placebo, as a cross-over study design will be used.
62737018|NCT06005532|ACTIVE_COMPARATOR|Humira®|"In the main period, patients will begin Visit 1 receiving Humira® therapy at an initial dose (80 /0, 8 ml) on Visit 1, from Visit 2 Humira® therapy at a maintenance dose (40 /0, 4 ml) for up to Visit 9 of therapy. Each visit is conducted every two weeks ± 2 days.~In additional period (from Visit 11 until Visit 28), eligible patients will continue to receive treatment after additional randomization (Adalimumab or Humira® (40 /0, 4 ml)) every 2 weeks until the end of a trial."
62737019|NCT05052463||sodium (hypo-hyper-normonatremia)|
62737020|NCT05052463||potassium (hypo-hyper-normokalemia)|
62737021|NCT05052463||calcium (hyper-hypo-normocalcemia)|
62096671|NCT04942470|NO_INTERVENTION|No Intervention:Control Arm|In control group patients, if any pollution occurs in the wound area (feces, discharge) in the sterile dressing performed in the morning and evening at 10-22 hours, the wound area will be cleaned with the help of 0.9% isotonic sodium chloride washing solution and the clinical routine application of the pressure injury of the hospital will be carried out according to the physician's order. In patients in the control group, the results of the application will be recorded and wound healing status will be observed. An in-bed position will be given every 2 hours for the prevention and care of pressure injury patients of the control group patients. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure and other), the necessary treatment and care will be performed.
62096672|NCT06560840|EXPERIMENTAL|intervention group|The intervention group will receive the gut microbiota targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly healthy diet guidance for the same duration. The intervention will span three months, followed by a three-month follow up period
62096673|NCT06560840|NO_INTERVENTION|control group|The control group will continue routine follow-up and health education practices.
62096674|NCT04296162|EXPERIMENTAL|Single arm|6 cycle of oral vinorelbine or capecitabine combined with trastuzumab (21 days per cycle), followed by sequential single trastuzumab to 1 year
62096675|NCT03647319|EXPERIMENTAL|Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
62096676|NCT03647319|EXPERIMENTAL|Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
62096677|NCT03647319|ACTIVE_COMPARATOR|Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
62293810|NCT04900402||Individuals with physical disabilities not continuing rehabilitation after COVID-19|International Physical Activity Questionnaire Short Form (IPAQ) and Child Quality of Life Scale (PedsQL) questionnaires will be applied to individuals who do not continue rehabilitation after the COVID-19 pandemic is declared.
62293811|NCT05422092|EXPERIMENTAL|Canagliflozin treatment group|Canagliflozin 100mg were given to the patients for 24 weeks
62293812|NCT05422092|PLACEBO_COMPARATOR|Pioglitazone treatment group|Pioglitazone 30mg were given to the patients and the dosage will be increased to 45mg 2 weeks later
62466002|NCT00756080|PLACEBO_COMPARATOR|2|After receiving a 7-day oral supplementation with placebo, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with citrulline, as a cross-over study design will be used.
62466003|NCT05397093|EXPERIMENTAL|Phase 1a: Dose Escalation|Various doses will be tested in participants with EOC, NSCLC and RCC.
62466004|NCT05397093|EXPERIMENTAL|Phase 1b: Expansion|"Cohort 1: Participants with epithelial ovarian cancer (EOC)~Cohort 2: Participants with non-small cell lung cancer (NSCLC)~Cohort 3: Participants with renal cell carcinoma (RCC)"
62466005|NCT03314870|OTHER|Retrospective study|Tumoral tissue of 100 patients with breast cancer treated with neoadjuvant chemotherapy.
62293813|NCT03058744|EXPERIMENTAL|IDP-118 Lotion|8 Weeks
62293814|NCT03058744|EXPERIMENTAL|HP Monad Lotion|8 Weeks
62293815|NCT03058744|ACTIVE_COMPARATOR|Ultravate Cream|2 Weeks
62293816|NCT03058744|ACTIVE_COMPARATOR|Tazorac Cream|4 Weeks
62466006|NCT03314870|OTHER|Prospective study|Tumoral tissue and plasma of 120 patients with breast cancer treated with neoadjuvant chemotherapy.
62737022|NCT05052463||magnesium (hyper-hypo-normocalcemia)|
62466007|NCT00893386||Non-4195 Lead, 181 days|Patients with a Medtronic LV Lead, other than Model 4195, implanted at least 181 days
62096678|NCT05992480|EXPERIMENTAL|Ebola Virus Disease (EVD) survivors|Participants with a history of admission and discharge from an Ebola Treatment Unit as registered by the Sierra Leone Association of Ebola Survivors (SLAES), and Anti-EBOV GP IgG positive by ELISA at the time of screening.
62096679|NCT05992480|ACTIVE_COMPARATOR|Community control|Age- and sex-matched controls who are Anti-EBOV GP IgG negative by ELISA at the time of screening.
62096680|NCT03863717|EXPERIMENTAL|Arm Endurance Exercise Training Group|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
62096681|NCT03863717|ACTIVE_COMPARATOR|Control Group|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
62096682|NCT00589862|EXPERIMENTAL|1|
62096683|NCT02022462|EXPERIMENTAL|Health Navigation|151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, were recruited to participate in a 12-month study of Bridge navigation. Participants were randomly assigned to either waitlist control (6 month waitlist with treatment as usual) or immediate intervention with the Bridge. Participants in the immediate treatment group completed three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group completed three assessments (baseline, 6 months, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
62096684|NCT02022462|OTHER|Waitlist Control|151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, were recruited to participate in a 12-month study of Bridge navigation. Participants were randomly assigned to either waitlist control (n = 75, 6-month waitlist with treatment as usual then they received the intervention) or immediate intervention with the Bridge (n = 76). Participants in the immediate treatment group completed three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group completed three assessments (baseline, 6 months, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
62737023|NCT05052463||phosphor (hypo-hyper-normophosphatemia)|
62096685|NCT06588322|OTHER|Patient with an epithelial ovarian cancer.|
62096686|NCT00189020|EXPERIMENTAL|2-dose|PCV7 at age 2 and 4 months
62096687|NCT00189020|EXPERIMENTAL|2+1-dose|PCV7 at age 2, 4 and 11 months
62096688|NCT00189020|NO_INTERVENTION|Control|Control group
62096689|NCT01244984|EXPERIMENTAL|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
62096690|NCT01244984|EXPERIMENTAL|Fluticasone Furoate|Inhaled corticosteroid
61909139|NCT06172985||Suspected patients with coronary heart disease.|The coronary CT angiography (CCTA) images collected by each center within a certain period of time will be desensitized after the screening is successful. The final CCTA images were sent to an independent judgment expert group for diagnosis, the results of the test group and the independent judgment expert group were compared, and the clinical application of the coronary artery CT angiography image vascular stenosis auxiliary triage software developed by Keya Medical Technology Co., Ltd. was evaluated. Validity and Accuracy
61909140|NCT04113369|SHAM_COMPARATOR|TENS group|30 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training program, patients will receive 30 minutes of conventional antalgic TENS (100 Hz) program as controls with electrostimulation device to the non-paretic wrist flexors.
61909141|NCT04113369|ACTIVE_COMPARATOR|EMS group|0 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training, the patients will receive 20 minutes of electrical stimulation to their non-paretic forearm upon wrist flexors by an intermittent maximum strength program (6 seconds of contraction, 10 seconds of rest) along with 5 minutes of pre and post warm-up with the same device.
61909142|NCT06411171|EXPERIMENTAL|Pembrolizumab plus chemotherapy (FLOT)|Pembrolizumab plus chemotherapy (FLOT)
61909143|NCT06411171|ACTIVE_COMPARATOR|chemotherapy (FLOT)|chemotherapy (FLOT)
62096691|NCT03850444|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stop the initial course of pembrolizumab due to complete response or complete the initial course of pembrolizumab and have stable disease, but progress after discontinuation, are eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles).
62096692|NCT03850444|ACTIVE_COMPARATOR|SOC Treatment|Participants receive carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies receive optional additional maintenance treatment with pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W.
62293817|NCT04992988|EXPERIMENTAL|Toripalimab+CCRT|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy.~Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 3 weeks after CCRT"
61909144|NCT04891393|EXPERIMENTAL|Caffeine|Single-dose, orally ingested, instant coffee.
62096693|NCT05027971||Lithotripsy Cohort|Subjects in this cohort will undergo lithotripsy procedure for the treatment of urinary calculi.
62096694|NCT05027971||Benign Prostatic Hyperplasia (BPH) Cohort|Subjects in this cohort will undergo Holmium Laser Enucleation of the Prostate (HoLEP) procedure for the treatment of BPH.
62096695|NCT02321540|EXPERIMENTAL|Ibrutinib|"Participants in Part 1 receive dose level of Ibrutinib depending on study joined. First group of participants receive lowest dose level of Ibrutinib. Each new group receives a higher dose of Ibrutinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Ibrutinib is found.~Participants in Part 2 receive Ibrutinib at highest dose that was tolerated in Part 1 or 840 mg daily.~Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle."
62096696|NCT00843362|EXPERIMENTAL|1|24-hours vaginal dinoprostone pessary
62096697|NCT00843362|ACTIVE_COMPARATOR|2|Vaginal dinoprostone gel
62293818|NCT01485978|ACTIVE_COMPARATOR|Ramipril blinded|oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years
62293819|NCT01485978|PLACEBO_COMPARATOR|placebo to ramipril|Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.
61909145|NCT04891393|PLACEBO_COMPARATOR|Inactive Placebo|Single-dose, orally ingested, instant decaffeinated coffee (equal weight to intervention dose).
62293820|NCT01485978|OTHER|open label ramipril|Open label treatment with ramipril as per protocol, if randomization is refused.
62660290|NCT05067270|EXPERIMENTAL|Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
62660291|NCT05067270|EXPERIMENTAL|Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 units per U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
62737024|NCT03213132|EXPERIMENTAL|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
62096698|NCT04550039|EXPERIMENTAL|Body-weight-supported treadmill training|Participants complete prescribed gait training program for at least three weeks or until they discharge.
62096699|NCT04550039|EXPERIMENTAL|EksoNR exoskeleton|Participants complete prescribed gait training program for at least three weeks or until they discharge.
62096700|NCT02958228|EXPERIMENTAL|Positive Mental Imagery Training (PMIT)|Computerized Positive Mental Imagery Training (PMIT), a form of mental imagery-based cognitive bias modification adapted from previous experimental (e.g. Holmes, Lang, \& Shah, 2009) and clinical (e.g. Blackwell \& Holmes, 2010) work. The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
62096701|NCT02958228|ACTIVE_COMPARATOR|Cognitive Control Training (CCT)|An adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015). The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
62096702|NCT02958228|ACTIVE_COMPARATOR|Treatment as Usual|Participants will receive their treatment as usual (TAU) within the inpatient setting, which may include group/individual psychological therapy, a range of therapeutic activities, and pharmacological treatment.
62096703|NCT03301922|EXPERIMENTAL|Work-focused metacognitive therapy|Work-focused metacognitive therapy
62096704|NCT03301922|OTHER|Waiting list|Waiting list
62096705|NCT04341298|EXPERIMENTAL|Avulux® device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
61909146|NCT03140358|ACTIVE_COMPARATOR|Premyopia atropine|On Atropine 0.01%
62096706|NCT04341298|SHAM_COMPARATOR|Control/sham device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
62096707|NCT06613646|EXPERIMENTAL|Intervention Arm|Patients presenting to the outpatient clinic with shoulder pain on the hemiplegic side will first undergo a diagnostic subacromial bursa injection, followed by a pectoralis minor muscle block.
62096708|NCT02116387|ACTIVE_COMPARATOR|Routine Physical Therapy|"Patients randomized to this arm will follow a classic, routine, physical therapy program.~Intervention: Routine Physical Therapy"
62466008|NCT00893386||4195 Lead, 181 days|Patients with a Medtronic Model 4195 LV Lead implanted at least 181 days
61909147|NCT03140358|PLACEBO_COMPARATOR|Premyopia placebo|On placebo
61909148|NCT03140358|ACTIVE_COMPARATOR|Low myopia atropine|On Atropine 0.01% daily or every other day
61909149|NCT03140358|PLACEBO_COMPARATOR|Low myopia placebo|On placebo
61909150|NCT02557477|ACTIVE_COMPARATOR|Active|Participants received 3 capsules of Omega 3/6 fatty acids twice daily
61909151|NCT02557477|PLACEBO_COMPARATOR|Placebo|Participants received 3 capsules of identical placebo (palm oil) twice daily
61909152|NCT06138730|EXPERIMENTAL|Appa Complete|Participants in this arm will be granted access to Appa Complete (i.e., weekly mentorship + CBT videos).
61909153|NCT06138730|ACTIVE_COMPARATOR|Appa Lite|Participants in this arm will be granted access to Appa Lite (i.e., CBT videos without weekly mentorship).
62096709|NCT02116387|EXPERIMENTAL|I-Moove Physical Therapy|"Patients randomized to this arm will follow a physical therapy program using the I-Moove device.~Intervention: I-Moove Physical Therapy"
62096710|NCT03353272|NO_INTERVENTION|Impairment Based Treatment|an impairment-based conservative intervention that has been created by compiling the evidence associated with established, effective treatment interventions for rotator cuff related shoulder pain.
62096711|NCT03353272|EXPERIMENTAL|Impairment Based Treatment PLUS PEERC|Participants assigned to the impairment-based care plus PEERC condition will also receive the PEERC protocol. This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
61909154|NCT06138730|NO_INTERVENTION|Waiting List Control|Participants in this arm will be given a mental health resources packet. In 12 weeks (after the study period), they will be granted access to Appa Lite.
62096712|NCT05683262|ACTIVE_COMPARATOR|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection is applied to patients in this group
62096713|NCT05683262|ACTIVE_COMPARATOR|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection with coccygeal nerve block|Ultrasound-guided coccygeal nerve blockade is done before the application of ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection to patients in this group
62096714|NCT03246672|EXPERIMENTAL|maintenance|behavioral intervention to increase adherence to lifestyle recommendations
62096715|NCT06238648|EXPERIMENTAL|Arm A (epcoritamab)|Patients receive epcoritamab SC on days 1, 8, 15, and 22 of cycles 1-3, days 1 and 15 of cycles 4-9, and day 1 of cycles 10-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI at screening, undergo PET/CT and collection of blood samples throughout the trial, and undergo biopsy at screening and end of treatment. Patients may undergo CT or MRI during follow up.
62293821|NCT02197325|ACTIVE_COMPARATOR|PICSO|Participants enrolled in the PICSO treatment Group will be treated with PICSO concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction
62293822|NCT02197325|NO_INTERVENTION|Parallel control|Participants enrolled in will receive treatment based on the standard guidelines for treatment of a myocardial infarction.
62466009|NCT00893386||4195 Lead, 90-180 days|Patients with Medtronic Model 4195 LV Lead implanted for 90-180 days
62466010|NCT03748303|EXPERIMENTAL|Allo IM cohort|Allopregnanolone 4-18mg IM, weekly, for 12 weeks.
62466011|NCT05088252|EXPERIMENTAL|Desflurane Inhalational Anesthesia|
61909155|NCT06505733|EXPERIMENTAL|attendants in the postnatal period|In the guide, the needs of the postpartum mother and baby, postpartum depression (definition, symptoms, risk factors, complications, care), the role and responsibilities of the companion in supporting the postpartum mother are included.
62096716|NCT06238648|ACTIVE_COMPARATOR|Arm B (observation)|Patients undergo observation per standard care. Patients also undergo MRI at screening, undergo PET/CT and collection of blood samples throughout the trial, and undergo biopsy at screening and end of treatment. Patients may undergo CT or MRI during follow up.
62096717|NCT02939183|EXPERIMENTAL|Part 1 Oprozomib Immediate-release (IR) + Dexamethasone|Oprozomib IR plus dexamethasone
62096718|NCT02939183|EXPERIMENTAL|Part 1 Oprozomib Gastro-retentive (GR) + Dexamethasone|Oprozomib GR plus dexamethasone
62096719|NCT02939183|EXPERIMENTAL|Part 2 Oprozomib IR + Pomalidomide + Dexamethasone|Oprozomib IR plus pomalidomide and dexamethasone
62096720|NCT02939183|EXPERIMENTAL|Part 2 Oprozomib GR + Pomalidomide + Dexamethasone|Oprozomib GR plus pomalidomide and dexamethasone
62096721|NCT02939183|EXPERIMENTAL|Open-label Roll-over|Oprozomib GR monotherapy, or oprozomib GR plus dexamethasone
62096722|NCT03519321|EXPERIMENTAL|Treatment|MID-C EOS implant will be implanted for the correction of the spine deformity in children found eligible for the study
62293823|NCT06657040|ACTIVE_COMPARATOR|INTERVENTION|The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first).
62293824|NCT06657040|PLACEBO_COMPARATOR|STANDARD TREATMENT|IN THIS ARM, PATIENTS WILL UNDERGO STANDARD TREATMENT IN THE ICU WHERE THEY ARE ADMITTED AND FOR 45 MINUTES, TWICE A DAY, NOISE-CANCELLING HEADPHONES WILL BE USED WITHOUT PLAYING MUSIC.
62293825|NCT01152606||Cohort|
62293826|NCT03148210|ACTIVE_COMPARATOR|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
62466012|NCT05088252|ACTIVE_COMPARATOR|Propofol Total Intravenous Anesthesia|
62466013|NCT02127450||Case: NS-CARB positive|Patient with a clinical sample positive for a NS-CARB Enterobacteriaceae
62466014|NCT02127450||Control 1: non-NS-CARB positive|Patient with clinical sample positive for a non-NS-CARB Enterobacteriaceae
62466015|NCT02127450||Control 2 : negative sample|Patient having had clinical sample(s) being stayed negative since the beginning of his admission and up to 3 days after the detection of the case
62466016|NCT03018249|ACTIVE_COMPARATOR|Arm I (medroxyprogesterone acetate, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.
62466017|NCT03018249|EXPERIMENTAL|Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.
62466018|NCT01713465|EXPERIMENTAL|1 CBMP|CBMP: Computer based Metabolic syndrome program
62466019|NCT02499718|EXPERIMENTAL|Noninvasive ventilator|noninvasive positive pressure ventilation combined with long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
62466020|NCT02499718|NO_INTERVENTION|LTOT|long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
62466021|NCT06248853|EXPERIMENTAL|Garston technique|the patients will receive graston technique with exercise program three times aweek for six weeks
61909156|NCT06505733|NO_INTERVENTION|non-intervention group|the group will not be trained
61909157|NCT00973297|EXPERIMENTAL|Falls prevention|
61909158|NCT00973297|NO_INTERVENTION|Control group|Routine rehabilitation treatment
61909159|NCT04985344|EXPERIMENTAL|Propranolol|Patient will receive oral propranolol
61909160|NCT04985344|PLACEBO_COMPARATOR|Placebo|Patient will receive oral placebo
61909161|NCT02776202|EXPERIMENTAL|Reduced-intensity conditioning regimen|"The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
61909162|NCT02593136|EXPERIMENTAL|Home Fortification and Counseling|Participants aged 6 to 18 months will receive a daily supplement of vitamins and minerals in dry powder form to be taken once daily for up to nine months or up to 240 sachets. Participant caregivers will also receive improved young child feeding practices (IYCF) counseling from a front line worker.
61909163|NCT02593136|EXPERIMENTAL|Improved Child Feeding Practices (IYCF) Counseling|Participants ages 6 to 18 months will receive improved young child feeding practices (IYCF) counseling from a front line worker.
61909164|NCT01012674|EXPERIMENTAL|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
61909165|NCT03005873|EXPERIMENTAL|TLC599 LD group|12 mg DSP with 100 µmol PL (1.0 mL)
62293827|NCT03148210|PLACEBO_COMPARATOR|Standard of Care|Spirometry result sent to family MD
62293828|NCT02539706|EXPERIMENTAL|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
62293829|NCT02539706|ACTIVE_COMPARATOR|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
62293830|NCT00511420|PLACEBO_COMPARATOR|1|Cocoa and other ingredients (product type 1). This product is a control of type 2.
62293831|NCT00511420|PLACEBO_COMPARATOR|2|Cocoa plus hazelnuts and other ingredients (product type 2). This product is a control of type 3 and 4.
62293832|NCT00511420|ACTIVE_COMPARATOR|3|Cocoa plus hazelnuts and other ingredients (cocoa product type 3).
62293833|NCT00511420|ACTIVE_COMPARATOR|4|Cocoa, hazelnuts and other ingredients called LMN (cocoa product type 4).
62293834|NCT00486486|ACTIVE_COMPARATOR|Bimatoprost/Timolol AM therapy|
62293835|NCT00486486|ACTIVE_COMPARATOR|Bimatoprost/Timolol PM therapy|
61909166|NCT03005873|EXPERIMENTAL|TLC599 HD group|18 mg DSP with 150 µmol PL (1.5 mL)
61909167|NCT03005873|PLACEBO_COMPARATOR|Placebo group|1.5 mL normal saline
61909168|NCT00043550|EXPERIMENTAL|1 Sertraline/Venlafaxine|Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8
62096723|NCT04925180||Physicians|Physicians who have recently prescribed (e.g., within previous 12 months) CPA monotherapy will be invited to complete a brief web-based questionnaire regarding their knowledge of the revised summary of product characteristics (SmPC) and the direct healthcare professional communication (DHPC).
62293836|NCT01906437||Cardiac Magnetic Resonance|Cardiac Magnetic Resonance scan at visits 1 and 2
62293837|NCT06273995|EXPERIMENTAL|Behavioral Activation (BA)|Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms
62293838|NCT01689038|EXPERIMENTAL|Tested product|
61909169|NCT00043550|ACTIVE_COMPARATOR|2 Supportive Expressive Therapy|Participants will receive supportive-expressive psychotherapy.
62096724|NCT02926937|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 400 milligrams (mg) administered as two 200 mg tablets, once daily (QD), before the first meal of the day in the double-blind treatment period for up to 26 weeks.
62293839|NCT01781949|OTHER|A: Nontargeted rapid HIV screening|Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
62293840|NCT01781949|OTHER|B: Enhanced targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
62466022|NCT06248853|ACTIVE_COMPARATOR|exercise program|the patients will receive an exercise program three times a week for six weeks
62466023|NCT03938402|EXPERIMENTAL|PEEP 5|
62466024|NCT03938402|EXPERIMENTAL|PEEP 10|
61909170|NCT00043550|PLACEBO_COMPARATOR|3 Pill Placebo|Participants receive placebo.
61909171|NCT04646564|ACTIVE_COMPARATOR|control arm|standard of care
62660292|NCT05067270|EXPERIMENTAL|Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
62660293|NCT02388009|ACTIVE_COMPARATOR|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
62293841|NCT01781949|OTHER|C: Traditional targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions related to HIV risk using a traditional behavioral risk screening tool to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
62660294|NCT02388009|ACTIVE_COMPARATOR|Flexyn2a plus adjuvant|2 doses of 10 μg of Flexyn2a plus adjuvant will be injected intramuscularly 4 weeks apart
62660295|NCT02388009|PLACEBO_COMPARATOR|Placebo|2 doses of saline buffer plus adjuvant will be injected intramuscularly 4 weeks apart
62660296|NCT03561207||Tumor tissue tested with EV3D Assay|Cancer tissue from multiple sites in the body, to include ovarian, brain, and other rare tumors.
62660297|NCT03729284|EXPERIMENTAL|Duloxetine Hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
62660298|NCT03729284|ACTIVE_COMPARATOR|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
62660299|NCT01006629|EXPERIMENTAL|palivizumab|palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections
62096725|NCT02926937|EXPERIMENTAL|Sotagliflozin 200 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 Sotagliflozin tablet and 1 matching placebo tablet, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
62293842|NCT01913782||patients with low back pain|"1. Patients with disc herniation or radiculitis who are over 18 years of age.~2. Patients with a history of chronic function-limiting low back pain and lower extremity pain for at least one months' duration.~3. Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
62660300|NCT00690651|ACTIVE_COMPARATOR|2|this group will rest in bed with operated leg well elevated for 48 hour and then mobilize with physiotherapist with aim for discharge home when safe.
62660301|NCT00690651|EXPERIMENTAL|1|mobilize with physiotherapist within 24 hours of surgical fixation of fractured ankle
62096726|NCT02926937|PLACEBO_COMPARATOR|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
62293843|NCT05068856|EXPERIMENTAL|HRS2543|
62293844|NCT00539019||A, observed|measure REE via indirect calorimetry at various time points post burn
62466025|NCT03938402|EXPERIMENTAL|PEEP 15|
62466026|NCT00795015|ACTIVE_COMPARATOR|leuven|these patients had their IV insulin controlled by using the protocol adapted from van den Berghe et al. University of Leuven, Belgium, NEJM Nov. 2001
62466027|NCT00795015|ACTIVE_COMPARATOR|glucommander|these subjects had IV insulin controlled by a computer program called the glucommander described by Davidson, P et al Diabetes Care Oct. 2005
62466028|NCT00556790|OTHER|1|Standard Care
62660302|NCT01890993||Liraglutide|
62660303|NCT01890993||DPP-4|
62660304|NCT05219890|EXPERIMENTAL|OBESE PATIENTS|Obese patients will be recruited from the outpatient Clinic of Obesity at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
62660305|NCT05219890|ACTIVE_COMPARATOR|CONTROL GROUP|Healthy normal volunteers will be recruited from friends and family of the investigators, and staff at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
62660306|NCT04136132|EXPERIMENTAL|Biological collection|"Biological collection~For all the patients include in the study :~blood and tissue samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database"
62660307|NCT02588508|EXPERIMENTAL|Warm packs|The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
62660308|NCT02588508|EXPERIMENTAL|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
62660309|NCT02588508|NO_INTERVENTION|Hands off|Hands off group does not receive any perineal manipulation and they are only observed.
62660310|NCT02760303|EXPERIMENTAL|Cognitive Behavioral Therapy|Hains' adaptation of cognitive behavioral therapy for adolescents and young adults with type 1 diabetes
62660311|NCT02760303|EXPERIMENTAL|Mindfulness Based Stress Reduction|Sabinga's adaptation of Mindfulness Based Stress Reduction for adolescents and young adults with type 1 diabetes
62660312|NCT02760303|ACTIVE_COMPARATOR|Diabetes Support and Education|Investigator developed peer support group and diabetes education
61909172|NCT04646564|EXPERIMENTAL|study arm|radiotherapy + standard of care
61909173|NCT06225908|NO_INTERVENTION|Group Control|
61909174|NCT06225908|ACTIVE_COMPARATOR|Group SPSİPB|
61909175|NCT03355547||no URI (upper respiratory tract infection) symptoms|Patients without upper respiratory tract infection symptoms
62096727|NCT03233165|EXPERIMENTAL|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er:YAG laser"
62096728|NCT03233165|EXPERIMENTAL|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er,Cr:YSGG laser"
62293845|NCT01211912|EXPERIMENTAL|Arm 1 (20 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.
62293846|NCT01211912|EXPERIMENTAL|Arm 2 (34 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.
62293847|NCT01036399|EXPERIMENTAL|Revlimid|"Oral Revlimid is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~After this induction phase, the CR, PR and SD will continue Revlimid with the same schedule for other 8 months."
62660313|NCT04225156|EXPERIMENTAL|efgartigimod|patients receiving efgartigimod
61909176|NCT03355547||URI (upper respiratory tract infection) symptoms|Patients with upper respiratory tract infection symptoms
61909177|NCT05269121|EXPERIMENTAL|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotics.
61909178|NCT05163015||with oncogeriatric consultation|"with oncogeriatric consultation group: patients aged 75 and more with cancer with oncogeriatric consultation"
61909179|NCT05163015||without oncogeriatric consultation|"without oncogeriatric consultation group: patients aged 75 and more with cancer without oncogeriatric consultation"
61909180|NCT02152644||amyloid|unique cohort of Adult patients older than 21 years with carpal tunnel syndrome with surgical indication (moderate to severe symptoms that do not respond to conservative treatment physiotherapy, splinting, activity modification) for more than 6 months.
61909181|NCT04690439|EXPERIMENTAL|Group A|Group A will receive first PBM + manual lymphatic drainage for 9 weeks (2 sessions/week), followed by 9 weeks only manual lymphatic drainage.
61909182|NCT04690439|ACTIVE_COMPARATOR|Group B|Group B will first receive only manual lymphatic drainage for 9 weeks, followed by the combination of PBM and manual lymphatic drainage for 9 weeks (2x/week).
61909183|NCT04978519|EXPERIMENTAL|Cryotherapy|Cryotherapy achieves a temperature averaging -40°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.
62293848|NCT05740150|EXPERIMENTAL|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|
62293849|NCT05740150|ACTIVE_COMPARATOR|Heparin lock (heparin 100 IU/mL)|
62293850|NCT03945279|EXPERIMENTAL|Cohort 1: BIIB100 Dose 1|Participants will receive single oral dose of BIIB100 on Day 1.
62293851|NCT03945279|EXPERIMENTAL|Cohort 2: BIIB100 Dose 2|Participants will receive single oral dose of BIIB100 on Day 1.
62293852|NCT03945279|EXPERIMENTAL|Cohort 3: BIIB100 Dose 3|Participants will receive single oral dose of BIIB100 on Day 1.
62293853|NCT03945279|EXPERIMENTAL|Cohort 4: BIIB100 Dose 4|Participants will receive single oral dose of BIIB100 on Day 1.
62293854|NCT03945279|EXPERIMENTAL|Cohort 5: BIIB100 Dose 5|Participants will receive single oral dose of BIIB100 on Day 1.
62293855|NCT03945279|EXPERIMENTAL|Cohort 6: BIIB100 Dose 6|Participants will receive single oral dose of BIIB100 on Day 1.
62293856|NCT03945279|PLACEBO_COMPARATOR|Cohort 1-6: Matching Placebo|Participants will receive single oral dose of matching placebo on Day 1.
62466029|NCT00556790|OTHER|2|Fast Track Care
61909184|NCT04105478|EXPERIMENTAL|Un-cemented Comprehensive Nano stemless shoulder arthroplasty|"By using a stemless humeral component stem-related complications can be reduced. Furthermore, the canal preserving design may also facilitate further surgery should the need of a revision prosthesis arise.~Currently, little is known about the results of the stemless design. The initial results have been promising, but as with the stemmed design migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
61909185|NCT04105478|ACTIVE_COMPARATOR|Un-cemented Comprehensive stemmed total shoulder arthroplasty|A design with a metal stem in the humeral bone canal is currently regarded as the best treatment option, but complications related to the stem including humeral fractures can have devastating consequences.
61909186|NCT02245425|ACTIVE_COMPARATOR|Supine Thoracic Spine Manipulation|Supine (lying face-up on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
61909187|NCT02245425|ACTIVE_COMPARATOR|Prone Thoracic Spine Manipulation|Prone (lying face down on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
61909188|NCT04634305||Total elbow arthroplasty|Total elbow arthroplasty, all indications combined
61909189|NCT00510432||s.c. anticoagulant therapy|All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)
61909190|NCT03608150|EXPERIMENTAL|Therapeutic Group|Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
61909191|NCT03608150|ACTIVE_COMPARATOR|Control Group|Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
61909192|NCT05120921|ACTIVE_COMPARATOR|standard osteopathic manual treatment|Pragmatic individualised osteopathic manual treatment which is a system of diagnosis and treatment for a wide range of musculoskeletal conditions. Osteopaths take a detailed case history and perform a thorough clinical examination to help understand the nature of patients' pain and symptoms so that they can arrive at a diagnosis. Practitioners use touch, physical manipulation, stretching and massage to help increase the mobility of joints, to relieve muscle/joint tension and pain. Osteopaths often combine a range of other treatment techniques in their approach, such as rehabilitative exercises, advice about how patients can self-manage their condition and educational approaches to help them understand their pain. Osteopathy is a regulated profession (regulated by the General Osteopathic Council) in the UK
61909193|NCT05120921|ACTIVE_COMPARATOR|biopsychosocially informed osteopathic manual treatment|As for the active comparator + biopsychosocial management: after having a completed a 8-10 hour e-learning on the biopsychosocial model for the management of low back pain, osteopaths will use the same approaches as in the active comparator group, plus techniques to help patients making sense of their symptoms, to develop patients' self-efficacy, and psychosocial management skills.
62096729|NCT04305912|EXPERIMENTAL|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to verofilcon A daily disposable lenses for one week.
61909194|NCT04896970|EXPERIMENTAL|Concert|Participants will go to a concert in a closed hall.
62096730|NCT04305912|ACTIVE_COMPARATOR|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
61909195|NCT04896970|NO_INTERVENTION|Control|Participant will stay at home.
61909196|NCT06068426|EXPERIMENTAL|TUS SWE|"This arm includes two cohorts:~1. Children with confirmed diagnosis of ARP or CP~2. Controls (Children without a history of pancreatic disease)"
61909197|NCT00390026|EXPERIMENTAL|Avastin|
61909198|NCT00390026|ACTIVE_COMPARATOR|Visudyne|
61909199|NCT03997292||Alteplase group|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion
61909200|NCT03997292||Urokinase group|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End
61909201|NCT03206788|EXPERIMENTAL|Losartan group|Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
61909202|NCT03206788|PLACEBO_COMPARATOR|Placebo group|Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.
62096731|NCT02863159|ACTIVE_COMPARATOR|Treatment Group 1|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +3.25D (ZLB00) in their non-dominant eye.
62096732|NCT02863159|ACTIVE_COMPARATOR|Treatment Group 2|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +4.00D (ZMB00) in their non-dominant eye.
62293857|NCT03772912||Total Knee Arthroplasty Patients|Patients undergoing primary or revision total knee arthroplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
62096733|NCT06395363||Tension Band Wiring (TBW) group|Patients had The fixation method that involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Following surgery, the operated shoulder was supported with a triangular sling for a period of 4 to 6 weeks. Gentle mobilization was permitted once pain subsided, although full range of motion was limited due to pin impingement until implant removal.
62096734|NCT06395363||In the Hook plate group|Patients had The fixation method that involved creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel. If necessary, the plate was contoured to match the clavicle's shape, with careful consideration given to the appropriate depth of the hook. Dynamic compression was utilized to secure the plate in place. Following surgery, the shoulder was supported with a triangular sling for a period ranging from 2 to 4 weeks. Mobilization commenced at the earliest opportunity, typically resulting in full range of motion within three to four weeks. It is worth mentioning that across both groups, heavy manual labor was prohibited until evidence of solid fracture union was observed.
62293858|NCT04284293|EXPERIMENTAL|Group 1A|"Visual acuity of 20/200 or worse~Single, unilateral, subretinal injection of 300,000 CNS10-NPC (n=3)"
62293859|NCT04284293|EXPERIMENTAL|Group 1B|"Visual acuity of 20/200 or worse~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=3)"
62660314|NCT03734341|EXPERIMENTAL|EZ START Titration|"CPAP titration test performed with an auto CPAP device preset on incremental fixed pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with EZ START pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: auto-adjusting pressure (no wash-out period)."
62660315|NCT03734341|ACTIVE_COMPARATOR|APAP Titration|"CPAP titration test performed with an auto CPAP device preset on auto-adjusting pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with APAP pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: incremental fixed pressure (no wash-out period)."
62660316|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
62660317|NCT01697241|EXPERIMENTAL|Supervised exercise and patient education|The entire duration of the intervention is 12 weeks, and consists of 24 sessions each lasting 60-70 minutes. Patients will receive two types of exercises, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX) in groups with progression guided by the patient's neuromuscular function (12 sessions). The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load (12 sessions).
62660318|NCT01697241|OTHER|Patient Education|The patient education program is designed to educate the patients about hip OA during 3 sessions of 90 min. duration
62660319|NCT05420740|EXPERIMENTAL|COPD patients with Small Airway Disease|Subjects will be given Aerobika OPEP and IOS, CAT score, Spirometry, 6MWT and Exacerbation were assessed at Week 0, Week 12 and Week 24
62660320|NCT04363814|EXPERIMENTAL|Bactek-R|Subject included in the experimental group will receive Bactek- R.The dose consists on 3 spray puff every 6 hours for 2 weeks.
61909203|NCT03936452|EXPERIMENTAL|Treatment arm|Sintilimab 200mg ivdrip D1 Peg-aspargase 2500U/m2 im D1 Anlotinib 12 mg po D1-14 repeat every three weeks When patients obtained an CR or PR after the second dose of the combined regimen, they woud undergo radiotherapy after the third dose of the combined regimen. Subsequently, another three cycles of the combined regimen would be administered to these patients.
61909204|NCT04363151||Hydatid cyst patients|patients who underwent surgery for liver hydatid cyst from 2004 to 2018 in two major university-affiliated hospitals in Fars Province, southern Iran
61909205|NCT03618589|PLACEBO_COMPARATOR|opioid only|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
61909206|NCT03618589|EXPERIMENTAL|pregabalin add-on|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
61909207|NCT03219710|ACTIVE_COMPARATOR|Arm A|"Patient on control group (ODA) with weight category of 15-40 kg will receive:~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;~The patient on control group with weight category of \> 40 kg will receive:~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
62293860|NCT04284293|EXPERIMENTAL|Group 2|"Visual acuity between 20/80 and 20/200~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=10)"
62293861|NCT06642974|EXPERIMENTAL|Experimental - Education module on Learning disabuilities|A total of 67 samples will receive the education module delivery on early identification of learning disabilities
62293862|NCT06642974|OTHER|Control|A total of 67 samples will receive education pamphlets on early identification of learning disability
62293863|NCT04807894|EXPERIMENTAL|Vaginal Testosterone Cream Arm|Women enrolled in this arm will receive vaginal testosterone cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
62660321|NCT04363814|NO_INTERVENTION|Control|Subject included in the control group will receive standard therapy for COVID-19.
62096735|NCT00601965|EXPERIMENTAL|CBT/Escitalopram|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
62466030|NCT01607645|EXPERIMENTAL|Arm1: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
62096736|NCT00601965|ACTIVE_COMPARATOR|No CBT/escitalopram|12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.
62096737|NCT00601965|PLACEBO_COMPARATOR|CBT/placebo|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
62096738|NCT00601965|PLACEBO_COMPARATOR|No CBT/placebo|"12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo~12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks."
62096739|NCT03458897|EXPERIMENTAL|MRI arm|Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
62096740|NCT00117611|ACTIVE_COMPARATOR|1|Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
62096741|NCT00117611|PLACEBO_COMPARATOR|2|placebo administered subcutaneously once or twice monthly
62096742|NCT05864768|EXPERIMENTAL|Patients with a vegan/vegetarian diet|"After excluding patients with clinical signs of periodontitis, the patients recruited at baseline underwent prophylaxis and home oral hygiene instructions were given with brushing and flossing in order to reduce the parameters of inflammation and the presence of plaque (FMPS and FMBS). The use of antiseptics (chlorhexidine mouthwash 0.20%) was prescribed twice a day for 15 days.~After 15 days from baseline (T0) all patients were recorded the parameters of FMPS, FMBS, PPD and Eastman Interdental Bleeding Index (EIBI) and were asked to stop using dental floss and mouthwash. All patients were recalled weekly 4 times after T0 (T1, T2, T3, T4) in order to monitor the parameters of inflammation and plaque accumulation by recording FMBS, FMPS and EIBI."
62096743|NCT05864768|ACTIVE_COMPARATOR|Patients with an omnivorous diet|"After excluding patients with clinical signs of periodontitis, the patients recruited at baseline underwent prophylaxis and home oral hygiene instructions were given with brushing and flossing in order to reduce the parameters of inflammation and the presence of plaque (FMPS and FMBS). The use of antiseptics (chlorhexidine mouthwash 0.20%) was prescribed twice a day for 15 days.~After 15 days from baseline (T0) all patients were recorded the parameters of FMPS, FMBS, PPD and Eastman Interdental Bleeding Index (EIBI) and were asked to stop using dental floss and mouthwash. All patients were recalled weekly 4 times after T0 (T1, T2, T3, T4) in order to monitor the parameters of inflammation and plaque accumulation by recording FMBS, FMPS and EIBI."
62660322|NCT06280677||GnRH Antagonist & hr-FSH|Patients stimulated with GnRH Antagonist \& hr-FSH with GnRH Agonist trigger
62096744|NCT00186810|OTHER|1|
62096745|NCT01354938||Acute Exacerbation of Chronic Bronchitis (AECB)|Participants with a diagnosis of chronic bronchitis and signs and symptoms of an acute exacerbation who were prescribed Klaricid XL (500 mg of modified release clarithromycin) at a dose of one tablet once a day or two tablets once a day based on physician's decision of severity of symptoms per routine clinical care.
62466031|NCT01607645|EXPERIMENTAL|Arm2: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
62466032|NCT00987948|EXPERIMENTAL|Maraviroc|
62660323|NCT06280677||Progesterone & hr-FSH|Patients stimulated with Progesterone \& hr-FSH with GnRH Agonist trigger
62660324|NCT01151436|EXPERIMENTAL|hyaluronic acid|
62660325|NCT05658549|EXPERIMENTAL|N-acetylcysteine injection 1200 mg|N-acetylcysteine injection 1200 mg per day
62293864|NCT04807894|PLACEBO_COMPARATOR|Vaginal Placebo Cream Arm|Women enrolled in this arm will receive vaginal placebo cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
62293865|NCT01815645|ACTIVE_COMPARATOR|Standard treatment Alone|Participants in the Standard Treatment Alone group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted
62293866|NCT01815645|EXPERIMENTAL|ST+CM|Participants in the Standard treatment plus Contingency Management (ST+CM) group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted plus CM.
62293867|NCT00450580|EXPERIMENTAL|Arm A|Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
62293868|NCT00450580|ACTIVE_COMPARATOR|Arm B|Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
62466033|NCT02993991|EXPERIMENTAL|Mocetinostat and Durvalumab|"Patients will start therapy with mocetinostat within 10 days of study enrollment. Mocetinostat will be given in 2 dose levels (n = 6 evaluable patients each) of 70mg three-times weekly and 90mg three-times weekly for 2 weeks.~Durvalumab will be given as a single infusion at a dose of 1500mg, over a period of 1-hour, on day 8 of the study."
62466034|NCT05170009|ACTIVE_COMPARATOR|Active and standard of care|Active Baloxavir Marboxil and standard of care Oseltamivir
62466035|NCT05170009|PLACEBO_COMPARATOR|Placebo and standard of care|Placebo-matched Baloxavir Marboxil and standard of care Oseltamivir
62466036|NCT03084822|EXPERIMENTAL|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
62466037|NCT03893318|EXPERIMENTAL|Study Group|will receive intravenous lidocaine during and after posterior spinal fusion for AIS
62660326|NCT05658549|EXPERIMENTAL|N-acetylcysteine pill 1200 mg|N-acetylcysteine pill 1200 mg orally per day
62096746|NCT03992911|EXPERIMENTAL|FOLFSIM Plus Teripalimab|Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab
62096747|NCT03992911|ACTIVE_COMPARATOR|EP/EC|Etoposide plus Cisplatin or Carboplatin
62096748|NCT03279198|PLACEBO_COMPARATOR|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
62096749|NCT03279198|ACTIVE_COMPARATOR|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
62293869|NCT00289640|EXPERIMENTAL|1|
62293870|NCT00289640|EXPERIMENTAL|2|
62293871|NCT00289640|EXPERIMENTAL|3|
62293872|NCT05502497|OTHER|Control Group|Which leg of the individuals will be treated will be determined by tossing a coin. After the toss, the right leg will be applied when the tail comes, and the left leg will be applied when it comes to the heads. The leg to be treated, the treatment group of the individuals; the other leg (the untreated leg) will form the control group of the individuals.
62466038|NCT03893318|PLACEBO_COMPARATOR|Control Group|will receive saline placebo during and after surgery.
62466039|NCT00155545|NO_INTERVENTION|Metformin|
62466040|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
62660327|NCT05658549|EXPERIMENTAL|N-acetylcysteine pills 600 mg per day|N-acetylcysteine pills 600 mg per day orally
62660328|NCT05658549|PLACEBO_COMPARATOR|placebo|Capsule with shape and appearance similar to N-acetylcysteine
62293873|NCT05502497|EXPERIMENTAL|IASTM Treatment Group|Which leg of the individuals will be treated will be determined by tossing a coin. After the toss, the right leg will be applied when the tail comes, and the left leg will be applied when it comes to the heads. The leg to be treated, the treatment group of the individuals; the other leg (the untreated leg) will form the control group of the individuals.
62293874|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
62293875|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
62293876|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
62293877|NCT01400932|EXPERIMENTAL|GI148512 (Benzoyl Peroxide 3% Gel)|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
62293878|NCT01400932|PLACEBO_COMPARATOR|vehicle gel|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
62660329|NCT06378970|EXPERIMENTAL|Audio Book Application Group|Patients were made to listen to audio books.
62660330|NCT06378970|NO_INTERVENTION|Control Group|No Intervention
62660331|NCT00367458|EXPERIMENTAL|Atorvastatin, then Placebo|Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.
62096750|NCT03279198|ACTIVE_COMPARATOR|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
62096751|NCT03279198|ACTIVE_COMPARATOR|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
62096752|NCT06434428||IV DEX|Patients treated intravenously receives a bolus of DEX (2 mcg/kg over ten minutes), followed by continuous infusion (1-2 mcg/kg/hour), stopped at the end of the procedure. The bolus could be repeated up to three times to reach the optimal target level of sedation before starting the continuous infusion.
62096753|NCT06434428||IN DEX|For the IN administration, after a first bolus of 4 mcg/kg it is possible to repeat boluses of 1-2mcg/kg of DEX (maximum dose for each administration is 200mcg). The drug dose is divided into two equal aliquots, with one aliquot administered into each nostril by a nurse using an atomizer device.
62096754|NCT00508885|EXPERIMENTAL|1|Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily
62096755|NCT00508885|PLACEBO_COMPARATOR|2|Placebo
62096756|NCT05151861|EXPERIMENTAL|Experimental|Complete removal of pharmacological treatment
62096757|NCT05151861|ACTIVE_COMPARATOR|Control|Maintenance of pharmacological treatment
62096758|NCT05542680|EXPERIMENTAL|Group 1|In the intervention group, the special cushion for semi recumbent position was used
62096759|NCT05542680|NO_INTERVENTION|Group 2|Routine nursing intervention
62096760|NCT03000712|EXPERIMENTAL|Autologous Adipose Tissue derived MSCs|Biological: Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)
62096761|NCT03000712|NO_INTERVENTION|No treatment|No treatment (after high tibial osteotomy)
62096762|NCT02542735||Spanish di@bet.es cohort|Representative of Spanish population
62096763|NCT06400056|EXPERIMENTAL|Terbinafine|"Patients will be treated by systemic terbinafine alone for 6 weeks~• Dosage: 25 kg for 125 mg 25-35 kg for 187.5 mg 35 for 250 mg"
62293879|NCT03939013|EXPERIMENTAL|Xpert HCV VL, sof/dac (local standard of care therapy)|Use of Cepheid GeneXpert HCV VL device as diagnostic tool to test for HCV RNA for diagnosis of chronic hepatitis C infection, for assessment of sustained virological response at 12 weeks post treatment completion
62293880|NCT04116099||Conservative care alone|Conservative care alone which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
62293881|NCT04116099||Flexitouch Plus and conservative care|Flexitouch Plus and conservative care which includes Flexitouch Plus treatment as well as conservative care measures which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
62293882|NCT02633176|ACTIVE_COMPARATOR|cisplatin and docetaxel|"Induction chemotherapy: Patients receive cisplatin and docetaxel intravenously on day 1 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cisplatin 30mg/m\^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m\^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
62096764|NCT06045637|EXPERIMENTAL|Group included in a psychoeducational program based on cognitive behavioral approach (experiment)|"Emerging adults between the ages of 18-29 who experienced the Kahramanmaraş 2023 earthquake in Turkey constitute the experimental group.~The cognitive behavioral approach-based psychoeducation program will be implemented in 9 sessions, two days a week and 90 minutes a day.In the psychoeducation program, based on the cognitive behavioral approach, trauma and trauma symptoms, emotion-thought-behavior analysis, cognitive errors, automatic thoughts, alternative thought generation, mentality and distorted thoughts that reveal feelings of depression, anxiety, stress, anger, guilt, inadequacy, helplessness, The cognitive aspect of hopelessness and methods of coping with negative emotions will be discussed.The training program includes verbal expression, visual material (projection), question and answer, homework, sample stories, entertaining activities, warm-up games, etc. It will be continued and feedback will be shared."
62293883|NCT02633176|EXPERIMENTAL|cetuximab, cisplatin, and docetaxel|"Induction chemotherapy: Patients receive cetuximab 400mg/m\^2 intravenously over at least 120 minutes on day 1 followed by 250 mg/m\^2 intravenously over at least 60 minutes every week. Cisplatin and docetaxel will be administered intravenously on day 2 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cetuximab 250mg/m\^2 intravenously followed by cisplatin 30mg/m\^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m\^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
62660332|NCT00367458|EXPERIMENTAL|Placebo, Then Atorvastatin|Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.
62660333|NCT05361837|ACTIVE_COMPARATOR|Single level serratus anterior plane block|the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics only
62660334|NCT05361837|EXPERIMENTAL|Single level serratus anterior plane block with dexmedetomidine|the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics and dexmedetomidine
62293884|NCT02547727|EXPERIMENTAL|Four-site intradermal vaccination|0.1 ml of rabies vaccine is distributed to 4 sites over both arms and thigh intradermally on day 0. Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
62466041|NCT03141047|EXPERIMENTAL|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
62466042|NCT03141047|NO_INTERVENTION|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
62660335|NCT05361837|EXPERIMENTAL|Bilevel serratus anterior plane block|the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics only
62293885|NCT02547727|ACTIVE_COMPARATOR|Intramuscular vaccination|0.5 ml of rabies vaccine is injected to one arm on day 0 and 3.Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
62466043|NCT06209567|EXPERIMENTAL|Participants with high-grade glioma|Participants with newly diagnosed or recurrent high-grade glioma/HGG or brain metastases
62096765|NCT06045637|NO_INTERVENTION|Group not included in the psychoeducation program based on cognitive behavioral approach (Control)|No intervention will be made to this group.
62466044|NCT02374853|EXPERIMENTAL|Vancomycin|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
62466045|NCT02374853|PLACEBO_COMPARATOR|Control|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
62466046|NCT01303848||Healthy probands|Healthy probands, age between 18 and 40 years
62466047|NCT01678066||Bilateral cardiac output|This is a prospective, non-randomized study to collect data from two noninvasive FDA-approved cardiac output monitors simultaneously in pediatric patients under general anesthesia in the operating room from age 1 month old to 8 years old with all types of medical conditions. We will enroll 50 male and female pediatric patients who are having lower abdominal and lower extremity surgery in this study so that the additional 8 EKG leads placed on the patients do not interfere with the surgical site or patient positioning.
62466048|NCT05605301|EXPERIMENTAL|Sequential ascending dose cohort|Cohort 1 will receive single 40 mg dose once. Cohort 2 will receive single 60 mg dose once. Cohort 3 will receive (2) 60 mg dose on one occasion.
62466049|NCT03701256|EXPERIMENTAL|TAP Group|Bilateral ultrasound TAP bloc performed via 20 ml of 2.5% bupivacaine without neuromuscular blocking agents
62293886|NCT04698928|EXPERIMENTAL|Theta burst stimulation group|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
62660336|NCT05361837|EXPERIMENTAL|Bilevel serratus anterior plane block with dexmedetomidine|the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics and dexmedetomidine
62660337|NCT02797730|EXPERIMENTAL|art-therapy sessions|Caregivers will receive 6 art-therapy sessions
62660338|NCT02797730|NO_INTERVENTION|no art-therapy sessions|Caregivers will not receive 6 art-therapy sessions during the evaluation period
62660339|NCT01986998|ACTIVE_COMPARATOR|oMP 1250 mg: Group A|Methylprednisolone 1250 mg/24h x3 days
61909208|NCT03219710|EXPERIMENTAL|Arm B|"weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)~Weight category of \> 40 kg in study group will receive:~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant \& Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
62660340|NCT01986998|ACTIVE_COMPARATOR|oMP 625 mg: Group B|Methylprednisolone oral 625 mg/24h x3 days
62096766|NCT05656365||Patients|Patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome and other tonsil disorders.
62660341|NCT00486967||Heart Failure|CHF patients were identified from inpatients as well as patients attending outpatient clinics and from the general practice in the community. Diagnosis of CHF was based on the European Society of Cardiology guidelines for CHF. All patients with stable CHF were included in the study. Inpatients with CHF who were hospitalized were also included, except patients with acutely decompensated CHF requiring intravenous therapy. CHF patients with a previous diagnosis of diabetes mellitus were excluded from the study.
62096767|NCT01571089|EXPERIMENTAL|DBT-inspired exposure treatment|DBT-inspired exposure treatment.
62293887|NCT01962779|EXPERIMENTAL|Continuous positive airway pressure|Moderate to severe SDB subjects will be offered a 6-month therapy with continuous positive airway pressure (CPAP).
62293888|NCT01962779|NO_INTERVENTION|No intervention|Subjects that refuse treatment with CPAP or that have a poor long-term compliance will be considered controls.
62293889|NCT03067090|EXPERIMENTAL|Intra-articular Aquamid Reconstruction|Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
62293890|NCT00308724|EXPERIMENTAL|1|Cognitive Behavior Therapy
62293891|NCT00308724|ACTIVE_COMPARATOR|2|Usual Care
62293892|NCT00902837|ACTIVE_COMPARATOR|oxycodone Tablet|OxyCodone Prolonged release tablets
62293893|NCT00902837|EXPERIMENTAL|oxycodone naloxone tablet|Oxycodone naloxone prolonged release tablets (OXN)
62293894|NCT01947829||Chronic Hemodialysis|
62466050|NCT03701256|ACTIVE_COMPARATOR|TRAC Group|Neuromuscular blocking agent: Atracurium 0.1 mg/kg per bolus
62096768|NCT03788291|EXPERIMENTAL|Acalabrutinib and Rituximab treatment|"Rituximab: administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, Then 50 mg SQ thereafter.~Acalabrutinib: 100 mg po BID starting on day 8 of cycle 1.~* Patients who have attained a complete response who are also MRD negative at cycle 12 will undergo a BM biopsy to confirm CR and MRD negatively. If confirmed, the patient will stop therapy and be followed until disease progression.~* Patients not in a MRD negative CR, will continue acalabrutinib.~* Repeat response assessments (CTs, MRD testing in blood) will be performed at 24 cycles of therapy for those continuing on acalabrutinib. If both negative the patient will undergo a BM biopsy to confirm CR and MRD negativity. If confirmed, the patient will stop therapy and be followed until disease progression. In the absence of a CR or if MRD +, acalabrutinib may be continued until disease progression, unacceptable toxicity or physician/patient discretion."
62096769|NCT00607035|EXPERIMENTAL|A|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
62096770|NCT00607035|EXPERIMENTAL|H|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
62466051|NCT02413320|ACTIVE_COMPARATOR|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
61909209|NCT05874206|EXPERIMENTAL|TEVAR|Thoracic Endovascular Repair (TEVAR) provides a minimally invasive treatment option for descending thoracic aorta (DTA) pathologies.
61909210|NCT00853970|EXPERIMENTAL|Bromfenac ophthalmic solution 0.09%|dosed 1 drop daily in study eye for 2 weeks
61909211|NCT00853970|PLACEBO_COMPARATOR|Placebo|dosed 1 drop daily in study eye for 2 weeks
62096771|NCT02913196|EXPERIMENTAL|All patients|Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
62096772|NCT06071104|EXPERIMENTAL|UNITY VCS|Anterior segment ophthalmic surgery performed with UNITY VCS
62096773|NCT04623723|SHAM_COMPARATOR|Perio Slim (PS)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with PS (DS-016A, EMS® Piezon, Switzerland) scaler tip
62096774|NCT04623723|ACTIVE_COMPARATOR|Conventional scaler tip|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with conventional (FS-407, EMS® Piezon, Switzerland) scaler tip
62096775|NCT03427229|EXPERIMENTAL|Multiple-infusion FMT|Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
62096776|NCT03427229|ACTIVE_COMPARATOR|Single-infusion FMT|Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
62096777|NCT06042387||IBD Subjects|"Self-identify as:~Black, African, African American, Afro-Caribbean, Afro-Latino/a/x, or Hispanic/Latinx, Afro-Latino/a/x or any other Black or Latin or Indigenous ancestry~Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) Any age"
62096778|NCT06042387||Controls|"Self-identify as:~Black, African, African American, Afro-Caribbean, Afro-Latino/a/x, or Hispanic/Latinx, Afro-Latino/a/x or any other Black or Latin or Indigenous ancestry No personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss Any age"
62096779|NCT03241498|NO_INTERVENTION|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
62096780|NCT03241498|EXPERIMENTAL|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
62096781|NCT04694560||CLL/SLL|Diagnosis of CLL or SLL confirmed by the enrolling institution
62096782|NCT03351309|EXPERIMENTAL|Telephone-based cognitive behavioral therapy|Telephone-based cognitive behavioral therapy (CBT) intervention - Four session protocol plus routine perioperative management.
62466052|NCT02413320|ACTIVE_COMPARATOR|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
62466053|NCT04763005|NO_INTERVENTION|Healthy controls|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry.
61909212|NCT01901796|EXPERIMENTAL|Screening and CBT|Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
61909213|NCT01901796|NO_INTERVENTION|Usual care|Usual prenatal care
61909214|NCT02890108|EXPERIMENTAL|Sugar sweetened beverages|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a sugar sweetened beverage, that contain 38,7 grams of carbs and 154 kcal, separated by at least 1 week each one
62096783|NCT03351309|NO_INTERVENTION|Treatment as Usual|Treatment as Usual (TAU) - Routine perioperative management.
62293895|NCT04672083|EXPERIMENTAL|Cohort 1|6 subjects receiving a single subcutaneous injection of CPT31 (0.01 mg/kg) and 2 subjects receiving matching placebo SC injection
62096784|NCT06589414|OTHER|DAMeGe protocol|
62293896|NCT04672083|EXPERIMENTAL|Cohort 2|6 subjects receiving a single subcutaneous injection of CPT31 (0.04 mg/kg) and 2 subjects receiving matching placebo SC injection
62096785|NCT00250224|EXPERIMENTAL|Stent|
62096786|NCT04795141|EXPERIMENTAL|#1: Cohort 1-High Dose Q2W|Cohort 1: ABY-035 High Dose, every 2 weeks, subcutaneous injection
62096787|NCT04795141|EXPERIMENTAL|#2: Cohort 1-High Dose Q4W|Cohort 1: ABY-035 High Dose, every 4 weeks, subcutaneous injection
62096788|NCT04795141|EXPERIMENTAL|#3: Cohort 1-Low Dose Q2W|Cohort 1: ABY-035 Low Dose, every 2 weeks, subcutaneous injection
62096789|NCT04795141|EXPERIMENTAL|#4: Cohort 2-Low Dose QW|Cohort 2: ABY-035 Low Dose, every week, subcutaneous injection
62096790|NCT04795141|EXPERIMENTAL|#5: Cohort 2-High Dose QW|Cohort 2: ABY-035 High Dose, every week, subcutaneous injection
62096791|NCT04795141|PLACEBO_COMPARATOR|#1: Cohort 1-Placebo Q2W|Cohort 1: Placebo, every 2 weeks, subcutaneous injection
62096792|NCT04795141|PLACEBO_COMPARATOR|#2: Cohort 2-Placebo QW|Cohort 2: Placebo, every week, subcutaneous injection
62096793|NCT05557019|EXPERIMENTAL|Booster Balloon Therapy|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
62293897|NCT04672083|EXPERIMENTAL|Cohort 3|6 subjects receiving a single subcutaneous injection of CPT31 (0.12 mg/kg) and 2 subjects receiving matching placebo SC injection
62293898|NCT04672083|EXPERIMENTAL|Cohort 4|6 subjects receiving a single subcutaneous injection of CPT31 (0.24 mg/kg) and 2 subjects receiving matching placebo SC injection
62096794|NCT05441280|ACTIVE_COMPARATOR|Pimavanserin 34mg PO at bedtime|Pimavanserin 34mg is taken by mouth at bedtime for 8 weeks .
62096795|NCT05441280|PLACEBO_COMPARATOR|Placebo PO at bedtime|The active study medication listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it
62096796|NCT06441773|NO_INTERVENTION|Control|Maintenance of chemotherapy and immunotherapy alone: without respiratory rehabilitation (control group)
62096797|NCT06441773|EXPERIMENTAL|Respiratory rehabilition|Maintenance of chemotherapy and immunotherapy combined with a respiratory rehabilitation program of 2 sessions per week for 8 weeks (respiratory rehabilitation group) = 16 sessions
62096798|NCT03738358|EXPERIMENTAL|Trehalose|
62293899|NCT04133077|OTHER|Succeed PDX|Genetic analysis will be performed in patients who got a successful PDX
62293900|NCT02818699|PLACEBO_COMPARATOR|Placebo Capsule|Participants assigned to this group will receive placebo capsules identical in appearance to EMIQ capsules.
62096799|NCT03738358|PLACEBO_COMPARATOR|Placebo|
62096800|NCT03326479||Retrospective|Subject who have previously had MI Profiling performed prior to 11/11/2016 are eligible for this study. No drug intervention is required for this study.
62293901|NCT02818699|EXPERIMENTAL|EMIQ Capsule|Participants assigned to this group will receive EMIQ capsules identical in appearance to placebo capsules.
62293902|NCT03979976|ACTIVE_COMPARATOR|ramipril group|Use of ramipril 10mg/day per 12 weeks
62096801|NCT02922413|EXPERIMENTAL|Hemin for injection|Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
62096802|NCT02922413|PLACEBO_COMPARATOR|Placebo|A double blind dose of saline.
62096803|NCT04445844|EXPERIMENTAL|Treatment (pelareorep, retifanlimab)|Patients receive pelareorep IV over 60 minutes on days 1, 2, 15, and 16. Patients also receive INCMGA00012 IV over 60 minutes on day 3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62096804|NCT00660166|EXPERIMENTAL|1|
62096805|NCT02742051|EXPERIMENTAL|Everolimus+Letrozole|everolimus 10mg/d,po + letrozole 2.5mg/d,po \* 18 weeks
62096806|NCT02742051|ACTIVE_COMPARATOR|Fluorouracil+epirubicin+cyclophosphamide|Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 \* 6 cycles (every 21 days per cycle)
62096807|NCT03537885|EXPERIMENTAL|TMS, EEG, and tDCS Group|"Participants will wear a cap fitted with Electroencephalography (EEG) electrodes to detect the brain's activity during the task. Transcranial Magnetic Stimulation will be used to evaluate the brain's responsiveness to Transcranial Direct Current Stimulation.~All study participants will receive the same study procedures - TMS, tDCS, and EEG."
62293903|NCT03979976|NO_INTERVENTION|Control Group|Without ramipril
62293904|NCT00499109|EXPERIMENTAL|E. Dual Agent Chemotherapy|"Experimental Arm E.~Patients received treatment according to gene expression strata with four doublet regimens.~Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.~Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.~High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.~High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group."
62660342|NCT00486967||Controls|A group of healthy subjects were also studied. They were recruited from the community and were clinically healthy based on history, physical examination, and blood laboratory results and were not taking any medication.
62096808|NCT04227535||Rheumatoid arthritis - Interstitial lung disease patients|"Assessment are as follows :~1. Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~2. Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~3. Radiologic: chest HRCT scan~4. Genetic: DNA, mRNA~5. Biologic: serum"
62096809|NCT04227535||Rheumatoid arthritis - no Interstitial lung disease patients|"Assessment are as follows :~1. Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~2. Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~3. Radiologic: chest HRCT scan~4. Genetic: DNA, mRNA~5. Biologic: serum"
62096810|NCT03145077|EXPERIMENTAL|Cohort 1 (DCE-MRI)|Patients with newly diagnosed tumors undergo DCE-MRI within 4 weeks prior to the first radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation. Patients who were previously irradiated and are at various stages of oncologic follow-up undergo DCE-MRI for a total of 2-5 times at baseline and at 6, 12, 24, 36, and/or 48 months post radiation. Patients in the third or subsequent years post treatment may undergo subsequent yearly imaging studies.
62096811|NCT03145077|EXPERIMENTAL|Cohort 2 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to the first re-radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation.
62096812|NCT03145077|EXPERIMENTAL|Cohort 3 (DCE-MRI)|Patients undergo DCE-MRI before and at 2 and 6 months post ORN treatment. Patients may undergo DCE-MRI during the mid-ORN treatment.
62096813|NCT03145077|EXPERIMENTAL|Cohort 4 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to and at 5-10 weeks and 12 months post surgery.
62096814|NCT05541419|EXPERIMENTAL|Maximum clinical treatment + Budesonide diluted|"The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.~In this study, the investigator wishes to add to the maximum clinical treatment a daily wash with high volume diluted budesonide."
62096815|NCT05541419|PLACEBO_COMPARATOR|Maximum clinical treatment + Placebo|To compare the efficacy of adding diluted budesonide lavage to maximal clinical treatment, the placebo group is used. The placebo formula is composed of 1% glycerin diluted in water.
62096816|NCT00710164|EXPERIMENTAL|A|
62096817|NCT00710164|PLACEBO_COMPARATOR|B|
62096818|NCT00790062|ACTIVE_COMPARATOR|Oxytocin 10 units/500cc|1 dose only for prophylaxis given over 1 hour
62096819|NCT00790062|EXPERIMENTAL|Oxytocin 40 units/500cc|One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
62096820|NCT00790062|EXPERIMENTAL|Oxytocin 80U/500cc|1 dose only given over 1 hour
62096821|NCT06613932|EXPERIMENTAL|hydroxyapatite|using hydroxyapatite as a pulpotomy agent and reviewing its clinical and radiographic performance compared to the other groups
62096822|NCT06613932|EXPERIMENTAL|L-PRF|using L-PRF as a pulpotomy agent and assessing the clinical and radiographic result compared to other groups
62466054|NCT04763005|EXPERIMENTAL|Hypertensive Patients|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry. In addition, randomization to an eight-week high-intensity interval intervention or control condition with physical activity recommendations.
61909215|NCT02890108|EXPERIMENTAL|Artificially sweetened beverage|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a artificially sweetened beverage, that contain 84 mg of Aspartame, 56 mg of Acesulfame K and 0,7 kcal, separated by at least 1 week each one
62660343|NCT03407586|OTHER|Diagnostic STI care|All participants underwent point-of-care STI testing, and if diagnosed with a STI were offered immediate therapy, and expedited therapy if indicated.
62660344|NCT05733299|ACTIVE_COMPARATOR|Standard Care|
61909216|NCT02889744|ACTIVE_COMPARATOR|36-TH|Core temperature 36℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
62096823|NCT06613932|EXPERIMENTAL|L-PRF combined with Nano-hydroxyapatite|using the combined material (nanohydroxyapatite mixed to L-PRF ) and assessing the clinical and radiographic result compared to other groups
61909217|NCT02889744|ACTIVE_COMPARATOR|33-TH|Core temperature 33℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
62293905|NCT00499109|ACTIVE_COMPARATOR|C. Standard of Care Control Arm|"Control Arm C: Gemcitabine and Carboplatin (GCb).~All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed."
62293906|NCT02198950||ICU patients|all patients admitted into the ICU
62660345|NCT05733299|EXPERIMENTAL|aflo™ digital respiratory management platform with standard care|The new aflo™ digital respiratory management platform will provide automated inhaler technique direction, with real time quantitative personalised feedback on inhaler technique and timing.
62660346|NCT00986141||laser trabeculoplasty|Subjects with POAG and on medical treatment who are undergoing SLT
61909218|NCT06401629|EXPERIMENTAL|National Priorities Research Program (NPRP) diagnostic criterion|Interventional diagnostic strategy
61909219|NCT06401629|ACTIVE_COMPARATOR|International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criterion|Control diagnostic strategy
61909220|NCT03815578|EXPERIMENTAL|Rheumatoid Arthritis (RA) patients|RA according to the ACR/EULAR 2010 classification criteria
61909221|NCT05446337||Patients and Informal Care Givers|Individuals living with diabetes who are receiving or have received care through the Diabetes Foot Care and Limb Preservation Pathway at various stages of the care pathway including screening \& prevention, wound care treatment, surgery and monitoring.
62293907|NCT04971525||Darvadstrocel Cohort|Participants diagnosed with CPF-CD, who administered at least one dose of darvadstrocel in fistula tract tissue under surgical environment will be observed.
62293908|NCT04971525||Matched Control Cohort: Standard of Care (SoC)|Participants diagnosed with CPF-CD with no history of administration of darvadstrocel, matched age at index date (within 3 years), sex and if feasible, complex perianal fistula (CPF) diagnosis (within 1 year) to individuals in the darvadstrocel cohort who received the alternative Standard of Care (SoC), which varies from country to country and according to local centre expertise will be observed.
62293909|NCT01085682|ACTIVE_COMPARATOR|Lifestyle counseling|
62293910|NCT01085682|ACTIVE_COMPARATOR|Standard care|
62293911|NCT02119715|EXPERIMENTAL|Pegylated rhG-CSF 100μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K） 100µg/kg in cycle 2 to 4
62293912|NCT02119715|EXPERIMENTAL|Pegylated rhG-CSF 150μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K)150 μg/kg in cycle 2 to 4
62293913|NCT02119715|ACTIVE_COMPARATOR|G-CSF 5 μg/kg/d|Chemotherapy naive patients receiving chemotherapy and rhG-CSF 5μg/kg/day in cycle 2 to 4
62660347|NCT00986141||Surgery|Glaucoma laser treatment
62660348|NCT03956875|ACTIVE_COMPARATOR|yoga|Yoga treatment
61909222|NCT05446337||Healthcare Providers|Medical, Nursing, and other allied healthcare providers including chiropodists, physiotherapists, occupational therapists, social workers, and nutritionists.
62096824|NCT04438785|EXPERIMENTAL|INTERVENTION (AirwayGym) GROUP|Patients newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the AirwayGym app for 20 min a day for 90 days.
62096825|NCT04438785|NO_INTERVENTION|CONTROL GROUP|Patients newly diagnosed with severe OSAHS do no therapy for 90 days.
62466055|NCT01757600||Macular Hole|
62660349|NCT03956875|PLACEBO_COMPARATOR|massage|massage
62660350|NCT01027156|EXPERIMENTAL|High Intensity Exercise|
62660351|NCT00167271|EXPERIMENTAL|Experimental|Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
62660352|NCT00167271|ACTIVE_COMPARATOR|Control|Subjects given pamphlets from the Arthritis Foundation
62660353|NCT01928849|PLACEBO_COMPARATOR|Cherry syrup|"Cherry Syrup: Patients randomized to the Control arm of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo."
61909223|NCT05446337||Stakeholders|Individuals external and internal involved in clinical care, continuity of care, and policy-making including but not limited to senior hospital leadership, decision support, and researchers and policy decision-makers.
62096826|NCT02051439|OTHER|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava before balloon assisted Valsava. The second group performed balloon assisted Valsava before conventional Valsava for venous reflux examination by duplex scan.
62096827|NCT05648955|EXPERIMENTAL|Test product|An enriched high protein and high energy oral nutrition supplement (ONS)
62660354|NCT01928849|EXPERIMENTAL|Valproic Acid|"Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid."
62660355|NCT01531179|EXPERIMENTAL|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
62660356|NCT01531179|PLACEBO_COMPARATOR|Control|Placebo for 3 months
62096828|NCT05648955|ACTIVE_COMPARATOR|Control product|standard isocaloric high energy normal protein isocaloric ONS
62096829|NCT02843087||NW vaginal deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62096830|NCT02843087||NW C-section deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62293914|NCT01869335|ACTIVE_COMPARATOR|radiography|Arm1: patients undergo mammographic localizations and radiography of the specimen after surgical resection.
62660357|NCT06256276|EXPERIMENTAL|Whey protein powder and L-carnitine capsules|Subjects will daily consume whey protein powder to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) L-carnitine for 16 weeks.
61909224|NCT02642224|EXPERIMENTAL|Social work intervention|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
62096831|NCT02843087||Ob vaginal deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62096832|NCT02843087||Ob C-section deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62293915|NCT01869335|ACTIVE_COMPARATOR|MRI (magnetic resonance imaging)|Arm2: patients undergo MRI localization and ex vivo MRI after surgical resection.
62293916|NCT05524883|EXPERIMENTAL|Placebo-Controlled MAD Period - DYNE-251|DYNE-251 will be administered once every 4 weeks (Q4W) or once every 8 weeks (Q8W) over 24 weeks.
62293917|NCT05524883|EXPERIMENTAL|Placebo-Controlled MAD Period - Placebo|Placebo will be administered Q4W or Q8W over 24 weeks.
62466056|NCT04608253||All enrolled subjects received an 11C-choline PET/CT prior to enrollment.|Patients with biochemically proven primary hyperparathyroidism who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging
62466057|NCT00649753|NO_INTERVENTION|A|
62466058|NCT00649753|EXPERIMENTAL|B|
62466059|NCT00649753|EXPERIMENTAL|C|
62466060|NCT00649753|EXPERIMENTAL|D|
62660358|NCT06256276|PLACEBO_COMPARATOR|Maltodextrin placebo powder and Psyllium Husk capsules|Subjects will daily consume maltodextrin powder as if to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) psyllium husk for 16 weeks.
62660359|NCT05076500||Cervical cancer|Cervical cancer patients receiving standard of care radiotherapy
62096833|NCT02843087||GDM vaginal deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62466061|NCT01321190||Low Back Pain|Individuals who experience bothersome low back pain.
62466062|NCT01321190||Headache|Individuals who experience bothersome headaches.
62660360|NCT05076500||Rectal cancer|Rectal cancer patients receiving standard of care radiotherapy
62660361|NCT05076500||Head and neck cancer|Head and neck cancer patients receiving standard of care radiotherapy
62660362|NCT05076500||nodal non-Hodgkin lymphoma|Patients with nodal NHL receiving standard of care radiotherapy
62660363|NCT05076500||cutaneous lymphoma|Patients with cutaneous lymphoma receiving standard of care radiotherapy
62660364|NCT05076500||cutaneous squamous cell carcinoma and basal cell carcinoma|Patients with cSCC and cBCC receiving standard of care radiotherapy
62660365|NCT02222324|PLACEBO_COMPARATOR|Treatment A|Placebo
62660366|NCT02222324|EXPERIMENTAL|Treatment B|E2609 Low dose
62660367|NCT02222324|EXPERIMENTAL|Treatment C|E2609 High dose
62660368|NCT02222324|ACTIVE_COMPARATOR|Treatment D|Moxifloxacin
62096834|NCT02843087||GDM C-section deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62096835|NCT02843087||T2D vaginal deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62293918|NCT05524883|EXPERIMENTAL|Open-Label and Long-Term Extension Period - DYNE-251|DYNE-251 will be administered Q4W or Q8W for up to 192 weeks after participants complete the Placebo-Controlled MAD Period of the study.
62293919|NCT03744455||End of training|Anesthesia residents at the end of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
62293920|NCT03744455||Begin of training|Anesthesia residents at the begin of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
62466063|NCT01321190||Fibromyalgia|Individuals who experience bothersome fibromyalgia-related pain.
62466064|NCT00282048|EXPERIMENTAL|AG-013736 (axitinib)|AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity
62466065|NCT01564511|EXPERIMENTAL|Gait trainer treatment|Roboti gait training by mean of Gangtrainer I
62466066|NCT01564511|SHAM_COMPARATOR|Conventional group|Convetional physical gait training
62466067|NCT02424266||Healthy subjects|None invasive imaging of the tear film for subjects with no eye disease
62466068|NCT02424266||keratoconjunctivits sicca (KCS) and Dry Eye Syndrome (DES)|None invasive imaging of the tear film for KCS and DES patients as confirmed by a cornea specialist
62466069|NCT05647031||20 participants were interviewed on a voluntary basis|A total of 20 participants were interviewed on a voluntary basis (7 competitive athletes with 17 physical disabilities, 4 physiotherapists, 5 coaches and 4 psychologists)
62466070|NCT05689762|EXPERIMENTAL|Health counselling plus E-health platform|Receive same information as controls plus health counseling and access to E-health platform
62466071|NCT05689762|NO_INTERVENTION|Standard care|Receive (1) standard care advice based on general health benefits of healthy lifestyle habits (benefits of adherence to national guidelines about physical activity and dietary habits as well as limiting alcohol intake and smoking withdrawal), (2) feedback about current lifestyle habits and health status. Tobacco users and subjects with high alcohol consumption will be referred to specialized care.
62660369|NCT06294353|EXPERIMENTAL|WELT-ED (CBT based DTx)|"Participants in this group will receive a shortened version of the standard treatment plus access to the DTx app for 8 weeks.~The DTx app is designed to provide therapeutic interventions based on CBT principles, aiming to help participants manage and reduce their eating disorder symptoms.~Participants are expected to engage with the app, completing tasks such as self-monitoring food diaries. The app will collect data on adherence, including diary completion rates and app login frequency.~Additional Support: Aside from app usage, participants will receive counseling and support therapy during visits at baseline, the 4-week mark, and the 8-week mark.~They will continue any pre-existing medication for eating disorders."
62660370|NCT06294353|OTHER|Standard Treatment|"Participants will receive the standard treatment protocol for eating disorders, which includes regular counseling and support therapy at all scheduled visits.~This treatment is comprehensive and follows the conventional approach to managing eating disorders, without the use of the DTx app.~Participants will continue any pre-existing medication for eating disorders."
62660371|NCT05415878|OTHER|Tall RCW|
62660372|NCT05415878|OTHER|Short RCW with contralateral lift|
62660373|NCT06327594||Lung cancer patients with sarcopenia|
62660374|NCT06327594||Lung cancer patients without sarcopenia|
62660375|NCT04249778|EXPERIMENTAL|Dapagliflozin|Patients admitted with exacerbation of chronic heart failure by clinical and radiologic features randomized to receive 10 mg of dapagliflozin, once daily for 26 weeks.
62660376|NCT04249778|PLACEBO_COMPARATOR|Placebo|Patients admitted with exacerbation of chronic heart failure by clinical and radiologic features randomized to receive a placebo to match 10 mg of dapagliflozin, once daily for 26 weeks.
62660377|NCT01223677|ACTIVE_COMPARATOR|rumination focused CBT|RFCBT-group. This group training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, group discussion, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
62096836|NCT02843087||T2D C-section deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62096837|NCT02843087||T1D vaginal deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62096838|NCT02843087||T1D C-section deliveries|Normal weight (NW; pre-pregnant BMI \<25.0 kg/m2), obese (Ob; pre-pregnant BMI \>30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
62096839|NCT03661190|OTHER|Grammatical Reasoning|This group will complete a short-term Intensive Grammatical Reasoning cognitive task delivered online by Wesnes Cognition Ltd (START). Participants will be encouraged to complete the START training once a day for six-weeks.
62096840|NCT03661190|OTHER|Control - Card Pairs|The control group will complete a basic picture-matching task that will provide the same level of engagement, but without the learning effects.
62293921|NCT01490593||Patients with Eye Injuries|The database is being established to record the number and types of eye injuries occurring in Canada. Thus there is only one cohort group, individuals who have sustained an eye injury.
62293922|NCT01950819|EXPERIMENTAL|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
62293923|NCT01950819|ACTIVE_COMPARATOR|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
62293924|NCT00332202|EXPERIMENTAL|A|
62660378|NCT01223677|ACTIVE_COMPARATOR|rumination focused CBT (online)|The online training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
62660379|NCT01223677|NO_INTERVENTION|No training control group|No training control group. Participants within this condition received no treatment, but only filled out the outcome measures at each measurement period.
62660380|NCT01655160|EXPERIMENTAL|mirror therapy treatment|Three groups will be involved in this part of the whole project:MT with low-intensity group (MT-LI), MT with moderate-intensity group (MT-MI), MT with high-intensity group (MT-HI)
62466072|NCT06327243|EXPERIMENTAL|Kineso taping group|
62466073|NCT06327243|SHAM_COMPARATOR|Sham group|
62660381|NCT01655160|ACTIVE_COMPARATOR|control intervention group|The part of this project will involve 1 treatment groups:control intervention group (CI)
62660382|NCT02213536||VMAT WBRT|Patients requiring whole brain radiotherapy as part of their cancer managment.
62660383|NCT04490915|EXPERIMENTAL|Crinecerfont|Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.
62660384|NCT04490915|PLACEBO_COMPARATOR|Placebo|Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.
62660385|NCT02546570|EXPERIMENTAL|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
62737025|NCT03213132|ACTIVE_COMPARATOR|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
62293925|NCT00332202|PLACEBO_COMPARATOR|B|
62293926|NCT05646810|ACTIVE_COMPARATOR|Lidocaine|Nerve block
62293927|NCT05646810|PLACEBO_COMPARATOR|Isotonic saline|Nerve block
62293928|NCT03217851||Patients Presenting P. falciparum Malaria|
62466074|NCT03538405|EXPERIMENTAL|all participants|All participants received the same interventions, there were no subgroups interventions: supporting cushions and harmonic techniques
62096841|NCT02135393|EXPERIMENTAL|13C5-folic acid or 13C5-6S-5-FormylTHF|Physiological 500 nmol (220 µg folic acid equivalent) dose of dietary supplement 13C5-folic acid or 13C5-6S-5-FormylTHF given to subjects with in situ transjugular intrahepatic portosystemic stent at the time of routine venography patency check followed by regular portal venous sampling for 85 minutes at pre determined intervals and then physiological 500 nmol dose of 13C-6S-5-FormylTHF or 13C5-folic acid respectively at the next annual routine venography patency check followed by portal venous sampling for 85 minutes
62096842|NCT02857764||Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users|Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
62096843|NCT02857764||Canagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.
62096844|NCT02857764||Dapagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
62096845|NCT02857764||Empagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
62096846|NCT02857764||First-time Non-SGLT2i AHA New Users|Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
62096847|NCT02635659|EXPERIMENTAL|Encapsulated nutrients|The investigational product will be a shot of sterile water (80 ml) mixed with a total of 21.6 grams encapsulate consisting of 13 grams of sucrose (60% of the total) encapsulated whey protein (\<5% of total). On top of the encapsulated sucrose, 6.44 grams of casein (30% of total) encapsulated in whey protein (\<5% of total) will be mixed with the shot of water. The micro-beats of encapsulated sucrose and casein are 150 µm and the ratio active (sucrose and casein) : whey is 95:5%, this means that the shot of water contains 13 grams of encapsulated sucrose, 6.44 grams of encapsulated casein and 1.3 grams of whey protein required for the encapsulation.
62096848|NCT02635659|PLACEBO_COMPARATOR|Placebo|The placebo has the same nutrient composition (e.g. 13 grams of sucrose and 6.44 grams of casein) as the active and will be equicaloric, and will also be mixed with a shot of sterile water (80 ml). The main difference of the placebo is that this nutrient mixture will be immediately released in the stomach, instead of being delivered to the ileum (active). This immediate release of the nutrient mixture is possible by using a different micro-encapsulation technique.
62096849|NCT03765697|EXPERIMENTAL|Lidocaine 5% medicated plaster|Up to 3 plasters were applied per day.
62096850|NCT00076141||Older, Racially Diverse Males|Racially Divers Males over 50, expected to live more than 5 years
62096851|NCT02206685|ACTIVE_COMPARATOR|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
62096852|NCT02206685|PLACEBO_COMPARATOR|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
62096853|NCT04135495|EXPERIMENTAL|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
62096854|NCT00783692|EXPERIMENTAL|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
62096855|NCT00783692|PLACEBO_COMPARATOR|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
62096856|NCT02398838|EXPERIMENTAL|Home administration of mifepristone|Home administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
62096857|NCT02398838|ACTIVE_COMPARATOR|Clinic administration of mifepristone|Clinic administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
62096858|NCT04087772|ACTIVE_COMPARATOR|Mental Health-Enhanced PBIS|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
62293929|NCT03378570|ACTIVE_COMPARATOR|5.5cm Rule Group|rTMS will be targeted at a left prefrontal target 5.5cm anterior to the primary motor strip identified on the scalp during motor threshold testing.
62293930|NCT03378570|ACTIVE_COMPARATOR|F3 Group|rTMS will be targeted at the left prefrontal scalp target identified as F3 according to the 10-20 EEG system.
62660386|NCT02546570|EXPERIMENTAL|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
62466075|NCT04384978|ACTIVE_COMPARATOR|Control Group|Control Group: Group 2 users will play solitary games (word puzzles) and activities but will have no interaction with Ryan.
62466076|NCT04384978|EXPERIMENTAL|Active Group|Active Group: Group 1 users will play games with and administered by Ryan, 2-3 times a week and 30-minutes per day.
62466077|NCT01327690|NO_INTERVENTION|Wait List|Wait Period corresponding in length to treatment period
62096859|NCT04087772|EXPERIMENTAL|Mental Health-Enhanced PBIS + RED|PBIS-MH+RED involves the components of PBIS-MH integrated with racial/ethnic discrimination interventions (RED) to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
62096860|NCT06419946|EXPERIMENTAL|treatment arm|"arm with temozolomide (TMZ) plus lomustine (LOM) treatment.~6 cycles of LOM/TMZ Start day 1 of RT. Cycle length of 42 days. Duration 9 months."
62096861|NCT06419946|ACTIVE_COMPARATOR|standard arm|"arm with standard of care treatment with temozolomide only.~Oral TMZ 75 mg/m2 daily during RT and with start day 1 of RT. This is followed by 6 cycles of TMZ with start 4 weeks after the end of RT. Cycle length 28 days. Duration 8,5 months."
62096862|NCT00002569|ACTIVE_COMPARATOR|Radiation therapy (RT) alone|Radiation therapy (RT) alone - External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume.
62293931|NCT03492593|EXPERIMENTAL|lycopene|A dose of lycopene (20 mg) is provided as part of an emulsified liquid meal (with or without 160 mg powdered ferrous sulfate). Samples from the upper digestive tract (gastric or duodenal) are aspirated over 4 hours, and blood collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 3 additional visits with 2 weeks between each visit. The same protocol is followed, with the subject receiving all combinations of meal (w/ and w/o iron) and upper digestive tract sampling (gastric or duodenal)
61909225|NCT05885178||Endovascular therapy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.
61909226|NCT05885178||Best medical management|Patients enrolled in this group received the best medical management.
61909227|NCT04922047|EXPERIMENTAL|Experimental: Intravenous tislelizumab / Intravesical BCG|"Drug: tislelizumab / BCG~Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).~Other Name: BGB-A317"
62466078|NCT01327690|EXPERIMENTAL|EFT (Emotional Freedom Techniques)|EFT group therapy sessions.
62466079|NCT01327690|ACTIVE_COMPARATOR|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
62466080|NCT02461823|EXPERIMENTAL|Z Crown|A Zirconia crown will be provided to patients.
62466081|NCT02461823|ACTIVE_COMPARATOR|PFM Crown|A Porcelain metal crown will provided to patients.
62660387|NCT02546570|EXPERIMENTAL|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
62466082|NCT01488786|EXPERIMENTAL|BrainPort Vision Device|Single Arm
62466083|NCT00818545|PLACEBO_COMPARATOR|2|
62466084|NCT00818545|EXPERIMENTAL|hydroxypropyltetrahydropyrantriol|
62466085|NCT05859841|EXPERIMENTAL|Music listening|Music listening under instruction by music therapist, min 3 hours daily
62466086|NCT05859841|PLACEBO_COMPARATOR|Control|Standard treatment, care and rehabilitation
61909228|NCT01213667|OTHER|ranibizumab as needed|
61909229|NCT04623125|EXPERIMENTAL|Spaced Repetition|Two weeks (10 sessions) of online picture-naming training with 60 words.
61909230|NCT05779371|ACTIVE_COMPARATOR|Experimental group|Experiment group A accepted the Integrated-based Laughing Qigong Program (IB-LQP) During the intervention, the participants formed a standing circle and could make eye contact. The time was divided into 10 minutes of warm-up (deep breathing, stretching of muscles, expressing various emotions on the face, stretching of limbs) and 30-40 minutes of main exercise (Breathing and Laughing Qigong practice). The main exercise included using the natural breath of laughter to activate the body, turning a fake smile into a real smile and laughter, using different body movements at the same time, producing a variety of types of laughter, and conducting self-emotional awareness and emotional transformation drills to reduce the backlog.
61909231|NCT05779371|NO_INTERVENTION|control group|The control group received no intervention and was asked to maintain their current lifestyle for 6 weeks following the baseline test.
61909232|NCT01101308|EXPERIMENTAL|Reformulated OXY 10 mg (Totowa)|Reformulated OXY 10 mg (Totowa) x 1 dose
61909233|NCT01101308|ACTIVE_COMPARATOR|Reformulated OXY 10 mg (Wilson)|Reformulated OXY 10 mg (Wilson) x 1 dose
61909234|NCT00935090|EXPERIMENTAL|3'-deoxy-3'-[18F]fluorothymidine|The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
61909235|NCT04656899|ACTIVE_COMPARATOR|Pillsy arm|Participants in the Pillsy arm will receive a prescription for buprenorphine-naloxone with an ''active'' Pillsy smart cap that will continuously collect data on pill bottle openings, missed doses, text messages sent, automated phone calls made. A participant who misses an entire day of buprenorphine-naloxone will automatically receive a survey about cravings and risk of relapse.
61909236|NCT04656899|NO_INTERVENTION|Service as usual arm|Participants in the Service As Usual arm will receive a prescription for buprenorphine-naloxone with an ''inactive'' Pillsy smart cap that will track openings but will not provide reminders or any other messaging. They will receive a basic application that can deploy patient satisfaction surveys.
61909237|NCT02336126|EXPERIMENTAL|Biopsychological intervention|
61909238|NCT05012670|EXPERIMENTAL|[14C]-Paxalisib Capsule|Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).
62466087|NCT00723476|ACTIVE_COMPARATOR|A|Participants will receive three 60- to 90-minute health education control sessions.
62466088|NCT00723476|EXPERIMENTAL|B|Participants will receive three 60- to 90-minute Family Centered Advanced Care Planning sessions.
62466089|NCT01835093|EXPERIMENTAL|A single-arm study|
62466090|NCT05789238|NO_INTERVENTION|Control|No labels for products high in added sugar, saturated fat, or sodium
62096863|NCT00002569|EXPERIMENTAL|Intensive pre-treatment chemotherapy and radiation therapy|Intensive pre-treatment chemotherapy (Day 1 CCNU 130 mg/m2 p.o., Day 8 - Vincristine 1.4 mg/m2 i.v., Days 8-21 - Procarbazine 75 mg/m2 p.o., Day 29 - Vincristine 1.4 mg/m2 i.v.) followed by radiation therapy (External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume).
62096864|NCT01141660|EXPERIMENTAL|Endotracheal Tube|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
62096865|NCT01141660|EXPERIMENTAL|Laryngeal Mask Airway|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
62293932|NCT03492593|EXPERIMENTAL|13C beta-carotene|A dose of 13C beta-carotene (20 mg) is provided as part of an emulsified liquid meal. Samples from the upper digestive tract (gastric or duodenal) are aspirated over 5 hours, blood collected over 7 hours, and urine collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 1 additional visit with a minimum of 4 weeks between each visit. The same protocol is followed, with sampling taken from the remaining upper digestive tract compartment (gastric or duodenal)
62293933|NCT03492593|PLACEBO_COMPARATOR|control|The same procedure is followed (as detailed in the experimental arms) but the subject receives an emulsified liquid meal without carotenoids or vitamin E.
62466091|NCT05789238|EXPERIMENTAL|ANVISA|Levels of added sugars, saturated fat, and sodium, if exceeded according to the Brazil Nutrient Profile Model, will require the magnifying glass FOPL below on the front of the package for either solid food or liquid food.
62466092|NCT05789238|EXPERIMENTAL|PAHO|PAHO Model is not based on thresholds (cut-off limits), but by percentage of regulated nutrient values in total calories amount and by NOVA categories. Therefore, the Brazil team has classified products from the dataset into NOVA categories and created calculations to apply the PAHO model to PdeA products.
62660388|NCT04539704|EXPERIMENTAL|Healthy Adults-magnet|Healthy adults with magnet and/or sham
61909239|NCT01024725||Not (yet) vaccinated persons|The participants do not want to take the vaccine (available only in the national vaccination campaign) or have not received it yet
62096866|NCT03812666||Severe stroke|Patients with severe (defined as NIHSS score of \> 10) acute stroke, either ischemic or hemorrhagic. (n= 150)
62096867|NCT03812666||Moderately stroke|Patients with moderately severe (defined as NIHSS score of \> 5 but \< 11) acute stroke, either ischemic or hemorrhagic. (n= 25)
62293934|NCT00452803|ACTIVE_COMPARATOR|study arm|pre-operative chemotherapy (Pac/Cis)
62293935|NCT00452803|ACTIVE_COMPARATOR|study arm 2|Pre-operative concurrent chemoradiation therapy
62466093|NCT04624412|EXPERIMENTAL|Continuous Aerobic Moderate Intensity Exercise|(Treadmill walking exercise) 50% - 70% of max Heart Rate (HR) (3-6 METS)
61909240|NCT01024725||Vaccinated persons|The participants have taken the vaccine according to the national vaccination campaign
62096868|NCT03812666||Mild stroke|Patients with mild (defined as NIHSS score of \<6) acute stroke, either ischemic or hemorrhagic. (n= 25)
62096869|NCT05868499|EXPERIMENTAL|EXG34217|single autologous CD34+ cells contacted ex vivo with EXG-001
62096870|NCT02862782|EXPERIMENTAL|hCG|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono)
62096871|NCT02862782|EXPERIMENTAL|hCG + GnRH agonist|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono) and GnRH agonist - Gonadotropin - releasing hormone (Decapeptyl 0.2mg - Ferring Gmgh)
62466094|NCT04624412|EXPERIMENTAL|Continuous Aerobic (Mild intensity Exercise)|(Treadmill walking exercise) 30% -50 % of max HR (1-3 METS)
62466095|NCT04004091|EXPERIMENTAL|24-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 24 days of pregnancy. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
62466096|NCT04004091|EXPERIMENTAL|26-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
62466097|NCT04004091|EXPERIMENTAL|28-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 28 days of pregnancy. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
62096872|NCT06527105|ACTIVE_COMPARATOR|Interventional group|Eye masks and Ear plugs given during sleep
62466098|NCT04004091|NO_INTERVENTION|24-Day Non Spermine Group|Subjects are not given any intervention. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
62466099|NCT04004091|NO_INTERVENTION|26-Day Non Spermine Group|Subjects are not given any intervention. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
62466100|NCT04004091|NO_INTERVENTION|28-Day Non Spermine Group|Subjects are not given any intervention. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
62466101|NCT03195491|EXPERIMENTAL|Monotherapy|Nivolumab administered every two weeks
62660389|NCT04539704|SHAM_COMPARATOR|Healthy Adults-sham|Healthy adults with magnet and/or sham
62096873|NCT06527105|NO_INTERVENTION|Control group|Routine care given without any intervention
62096874|NCT05267977|ACTIVE_COMPARATOR|cephalosporin|cephalosporin
62096875|NCT05267977|ACTIVE_COMPARATOR|cephalosporin and aminoglycoside|the combination of cephalosporin and aminoglycoside.
62096876|NCT05079217|EXPERIMENTAL|Experimental Group|600 participants will receive one dose of booster vaccination with high-dosage inactivated SARS-CoV-2 vaccine .
62096877|NCT05079217|ACTIVE_COMPARATOR|Control Group|600 participants will receive one dose of booster vaccination with medium-dosage inactivated SARS-CoV-2 vaccine .
62096878|NCT02099539|EXPERIMENTAL|Cohort 1: N-803 - IV 1 ug/kg|
62096879|NCT02099539|EXPERIMENTAL|Cohort 2: N-803 - IV 3 ug/kg|
62096880|NCT02099539|EXPERIMENTAL|Cohort 3: N-803 - IV 6 ug/kg|
62096881|NCT02099539|EXPERIMENTAL|Cohort 4: N-803 - IV 10 ug/kg|
62096882|NCT02099539|EXPERIMENTAL|Cohort 5: N-803 - SQ 10 ug/kg|
62096883|NCT02099539|EXPERIMENTAL|Cohort 6: N-803 - SQ 15 ug/kg|
62096884|NCT02749708|EXPERIMENTAL|Dose level 1|IRX5183 50 mg daily
62096885|NCT02749708|EXPERIMENTAL|Dose level 2|IRX5183 75 mg daily
62096886|NCT05063331|ACTIVE_COMPARATOR|Sacrocolpopexy|Minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP)
62096887|NCT05063331|ACTIVE_COMPARATOR|Uterosacral Ligament Suspension|Total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
62096888|NCT05071573|EXPERIMENTAL|Intervention arm|"Quality improvement package Identification of a viral load champion whose role will include tracing and recalling patients who need further assessments of their VL or switch to second-line regimen.~QIP to address process and clinic impediments to VLM as well as training in antiretroviral treatment monitoring guidelines Training in the use of enhanced TIER.Net technology developed as part of the trial and how to access reports on the dashboard system.~Augmentation of TIER.Net with a dashboard system VL results will be imported into TIER.Net daily from the National Health Laboratory Service which will be linked to patients in TIER.Net based on multiple exclusive and linked deterministic rules using a combination of variables such as name, surname, sex, date of birth, date of visit, NHLS lab number, facility and folder number. The information contained in TIER.Net will be used to develop a dashboard which summarises viral load data at individual and clinic level."
62096889|NCT05071573|NO_INTERVENTION|Control arm|Viral load results are manually captured on to the TIER.Net system with filing of the paper results in patients' clinical notes for nurses' review during routine appointments. This is used to produce a monthly enrolment and quarterly cohort reports for the central monitoring of the ART programme.
62096890|NCT00562393|EXPERIMENTAL|Overfeeding|4 weeks of 1250 kcal added daily
62096891|NCT02639962||NSTEMI|patients hospitalized with NSTEMI diagnosed according to the national Danish guidelines, and are scheduled to coronary angiography.
62096892|NCT02639962||patients with stable angina pectoris|Patients in this group have stable angina symptoms and had verified plaques by earlier CAG or Cardiac CT
62096893|NCT02387203|EXPERIMENTAL|PrevPac|"Study intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)twice daily x 14 days for 2 courses (preoperative and post-operative).~All eligible patients with a PMP diagnosis, undergoing CRS/HIPEC treatment, who consent to study participation will have a urea breath test prior to the first course of PrevPac.~After surgery, when tolerated, each patient will take a second course of PrevPac. Patients will be seen for follow-up as clinically indicated until year 5."
62096894|NCT02387203|NO_INTERVENTION|PMP Historical Control|The historical control group will consist of all PMP patients who did not receive perioperative antibiotic treatment.
62096895|NCT02911272|ACTIVE_COMPARATOR|2-hour group|Augmentation of labour at 2-hour action line on the labour partograph
62096896|NCT02911272|EXPERIMENTAL|4-hour group|Augmentation of labour at 4-hour action line on the labour partograph
62096897|NCT04892667|OTHER|Patients with lymphoma (Hodgkin's or non Hodgkin's)|
62096898|NCT02081768|EXPERIMENTAL|90yttrium colloid|90 Yttrium colloid will be inserted into the cystic cavity. Based on clinical expertise, the treating neurosurgeon will determine the appropriate surgical procedure for each patient on an individual basis which will be reflected in the surgical consent the patient is presented and signs.
62096899|NCT05254509|ACTIVE_COMPARATOR|Occupational Therapy (OT)|Subjects in this treatment group will receive outpatient occupational therapy geared towards people with chronic pain conditions. After obtaining consent, an occupational therapist will meet with the participant to begin their occupational therapy sessions targeted for those who have chronic pain. Additionally, subjects will complete online surveys administered by the therapist before and after each therapy session. There is a total of six 1-hour visits during the 3-month study duration involving occupational therapy. They will also receive online surveys every two weeks and will be asked to complete them at home.
62096900|NCT05254509|EXPERIMENTAL|Occupational Therapy + Virtual Reality (OT+VR)|Subjects in this treatment group will receive outpatient occupational therapy intervention geared towards people with chronic pain conditions followed by active, immersive virtual reality sessions. Participants in this treatment group will have 10-30minutes of usual care while receiving 10-30 minutes of virtual reality (e.g. exercises, games, and activities in the virtual world) during each study visit. Subjects will complete online surveys before and after each virtual reality session, along with debriefing from a therapist after each VR session to review what happened and why. Debriefing will include questions to obtain thoughts and narrative information about the participant's experience, as well as overall take-aways from the session. The therapist and subject will also watch a video recording of the subject's VR experience as a method to provide them feedback on their performance. Subjects will receive online surveys every two weeks and will be asked to complete them at home.
62096901|NCT06610799|EXPERIMENTAL|Cohort 1|IBI363 combination with oxaliplatin and capecitabine (XELOX) for first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma
62466102|NCT01944800|EXPERIMENTAL|Ticagrelor|
62466103|NCT01944800|ACTIVE_COMPARATOR|Prasugrel|
62096902|NCT05992233|EXPERIMENTAL|Dual wavelength low dose laser|Immediately after suturing the patient, a low-dose laser application was performed on the laser group using the square probe (16 J/min) of the locally produced GRR laser device (Ankara, Turkey) for 5 minutes. The device combines a 22 mW GaAlAs infrared laser with a wavelength of 904 nm and a 10 mW red laser with a wavelength of 650 nm. The square probe contains 5 red lasers and 4 infrared lasers, covering an area of 30mm X 30mm.
62096903|NCT05992233|PLACEBO_COMPARATOR|Plasebo|Laser probe will be applied to the control group patients, but the device was not operated.
62096904|NCT00917189|EXPERIMENTAL|Computerized Cognitive Skills Training|Participants will receive the Challenging Our Minds intervention, delivered in-person in Phase 1 and remotely in Phases 2 and 3.
62096905|NCT04189328|ACTIVE_COMPARATOR|control group|conventional macrosurgical implant placement
62660390|NCT05555017|ACTIVE_COMPARATOR|Arm A: ADT|Patients in arm A will receive standard 6 months of ADT according to current clinical guidelines.
62660391|NCT05555017|EXPERIMENTAL|Arm B: ADT + PSMA radioguided surgery|Patients in arm B will receive standard 6 months of ADT according to current clinical guidelines, and will undergo 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery.
62096906|NCT04189328|EXPERIMENTAL|test group|microsurgical implant placement
62096907|NCT01608893|ACTIVE_COMPARATOR|Metoprolol|The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.
62096908|NCT01608893|ACTIVE_COMPARATOR|Carvedilol|The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.
62096909|NCT05724212||Control Group (healthy subject)|
62293936|NCT04794335||Patients undergoing resection of intestine for therapeutic purposes|Tissue will be accepted from all eligible donors who consent to having their intestine removed for therapeutic purposes. This tissue would normally be disposed of as medical waste, used for research purposes. The tissue will be studied in the lab in a series of experiments involving GABA agonists and antagonists. Each GABA agonist and/or agonists/antagonist combination will be studied on intestine tissue randomly assigned to one of four groups defined by patient sex (m/f) and the application of inflammatory mediators (+/-). Thus, four groups are needed per GABA agonist and agonist/antagonist combination and seven agonist/antagonist combinations will be tested for a total of 28 experimental groups. But all of these groups will be generated from all patients recruited for the study.
62293937|NCT03584763|ACTIVE_COMPARATOR|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
62293938|NCT03584763|EXPERIMENTAL|Weekly Umbilical Artery Doppler|will undergo Doppler every week
62293939|NCT04331041|EXPERIMENTAL|Adaptive SBRT + Defactinib|"* Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT) and seventeen 21-day cycles of defactinib (beginning on Day 2 of radiation).~* Participants who are candidates for surgical resection will undergo standard of care surgery at 2 weeks post-end of SBRT (+/- 1 weeks) or 12 weeks post-end of SBRT (+/- 1 week). These participants will discontinue defactinib the day prior to the operation and will resume taking it for the remainder of the 17 cycles 4 to 6 weeks after surgery. Participants who are not candidates for surgical resection will continue to receive defactinib uninterrupted. All participants should receive 17 cycles of defactinib unless they experience disease progression or intolerable toxicity."
62293940|NCT04331041|ACTIVE_COMPARATOR|Adaptive SBRT|-Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT)
62293941|NCT03926143|EXPERIMENTAL|Cancer patients|Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
62293942|NCT06544278|EXPERIMENTAL|Probiotic group|Participants in the probiotic group received 1 sachet probiotic product per day.
62293943|NCT06544278|PLACEBO_COMPARATOR|Placebo group|Participants in the placebo group received 3g of maltodextrin per day.
62293944|NCT06147024|ACTIVE_COMPARATOR|historical control group|conventional preoperative assessment
62293945|NCT06147024|EXPERIMENTAL|3D printed lesion model group|using 3D printed lesion models for preoperative planning
62466104|NCT02404662|EXPERIMENTAL|Supportive text messages intervention|Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
62466105|NCT02404662|ACTIVE_COMPARATOR|Control group|Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
62096910|NCT05724212||Subject with Pulmonary Tuberculosis (PTB)|
62096911|NCT05078385|EXPERIMENTAL|AGLE-102|AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
62096912|NCT05205447|EXPERIMENTAL|Part 1 Period 1 (LY3410738 Alone)|Single dose of LY3410738 administered orally.
62096913|NCT05205447|EXPERIMENTAL|Part 1 Period 2 (LY3410738 + Itraconazole)|Single dose of LY3410738 administered orally with multiple doses of itraconazole orally.
62096914|NCT05205447|EXPERIMENTAL|Part 2 Period 1 (LY3410738 Alone)|Single dose of LY3410738 administered orally.
62096915|NCT05205447|EXPERIMENTAL|Part 2 Period 2 (LY3410738 + Carbamazepine)|Single dose of LY3410738 administered orally with multiple doses of carbamazepine orally.
62096916|NCT00916006|EXPERIMENTAL|PEP005 gel|PEP005 gel, 0.015% applied once daily for three consecutive days
62096917|NCT00916006|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel applied once daily for three consecutive days
62096918|NCT06022809|ACTIVE_COMPARATOR|Individual-level intervention|Virtual one-on-one session
62096919|NCT06022809|EXPERIMENTAL|Group-level intervention|Virtual group sessions
62096920|NCT04865562|EXPERIMENTAL|testosterone|7mg testosterone propionate
62096921|NCT04865562|PLACEBO_COMPARATOR|placebo|125 mg 0.5% cholorbutanol, 50mg saline, pH5
62096922|NCT01576315|EXPERIMENTAL|itraconazole|"* itraconazole 10 mg/mL oral solution~* patients \> 40 kg body weight : 200 mg morning and evening.~* patients \< 40 kg body weight : 100 mg morning and evening.~* dosage out of meal.~* Without a loading dose"
62096923|NCT01576315|EXPERIMENTAL|voriconazole|"* voriconazole 40 mg/mL oral suspension :~* patients \> 40 kg body weight : 200 mg morning and evening.~* patients \< 40 kg body weight : 100 mg morning and evening.~* dosage out of meal.~* Without a loading dose"
62096924|NCT02768805|EXPERIMENTAL|15 µg/strain of Quadrivalent VLP Vaccine|
62096925|NCT02768805|EXPERIMENTAL|30 µg/strain of Quadrivalent VLP Vaccine|
62096926|NCT02768805|ACTIVE_COMPARATOR|15 µg/strain of the licensed quadrivalent vaccine|
62096927|NCT06613724|EXPERIMENTAL|Magnet System, DI Biofragmentable|GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System)
62096928|NCT02347917|EXPERIMENTAL|BBI608 puls pemetrexed and cisplatin|
62096929|NCT06298630||BRL-101|All patients who have received BRL-101
62096930|NCT06613594|ACTIVE_COMPARATOR|Conventional Physical Therapy Group|Patients in this group will recieve conventional physical therapy including Hot pack and Tens for 10 to 15 minutes.Broomstick ROM exercises such as Internal \& external rotation,Extension,flexion,abduction,these are Low intensity, short duration, 1-5 sec, 2-3 times/day, pain free passive, 3 sets of 10 reps with 1 minute rest in between will be given, Codman circular motion exercises(1time clockwise ,1 time anticlcock wise) 2-3 times/day with 10reps .Strengthening exercises include Isometric in all planes, 5 second holds, 1 set of 10 each direction, against wall.Every session will be given for 30 minutes and a total of 10 sessions would be conducted over a period of 2 weeks.
62096931|NCT06613594|EXPERIMENTAL|Conventional physical therapy+kaltenborn traction Group|Patients will recieve kaltenborn traction mobiliztion in addition to conventional physical therapy including Hot pack and tens for 10 to 15 minutes , Broomstick ROM exercises such as Flexion, Internal \& external rotation,Extension, Abduction,these are Low intensity, short duration, 1-5 sec, 2-3 times/day with 10 reps, pain free passive, AAROM.Codman circular motion exercises (1time clockwise ,1 time anticlockwise) 2-3 times/day with 10 reps. kaltenborn direction non specific traction mobilization for (1 minute), 3 sets of 10 reps with 1 minute rest in between will be given. Strengthening exercises include Isometric in all planes, 5 second holds, 1 set of 10 each direction, against wall.Every session will be given for 30 minutes and a total of 10 sessions would be conducted over a period of 2 consecutive weeks.
62096932|NCT06613594|EXPERIMENTAL|Conventional physical therapy+kaltenborn translatoric glides Group|Patient will recieve kaltnborn linear translatoric glides in addittion to Conventional physical therpay including Hot packs and tens for 10-15 minutes. Broomstick ROM exercises such as flexion,Exention,Internal rotation,External roation and Abuction,these are low intensity,short duration,1- 5sec,2-3 times/ day with10 reps,pain free passive, AAROM.Codman exercises circular motion exercises (1time clock wise ,1Time anticlockwise), 2-3 times/day with 10reps. Kaltenborn direction specific linear tranlatoric glides, rhtymic 5reps of each glide,such anterior glide for extension and external rotation,caudal glide for abduction,post glide for flexion and internal roation,these3 sets of painless glides will perfromed with 10 reps,rest of 1 minutes between these sets. Strengthening exercises including Isometric in all planes,5sec hold,1 sets of 10 each direction against wall. Every session will be given for 30 minutes and a total of 10 session would be conduted over a period of 2 weeks.
62096933|NCT05895773|EXPERIMENTAL|Treatment group|Nasal and oropharyngeal Povidone Iodine plus Glycyrrhizin sprays will be applied 4 times daily after tooth cleaning with a brush.
62096934|NCT05895773|PLACEBO_COMPARATOR|Placebo group|Nasal and oropharyngeal saline sprays will be applied 4 times daily after teeth cleaning with a brush.
62660392|NCT00729586|EXPERIMENTAL|Arm I (temsirolimus)|Patients receive temsirolimus IV over 30 minutes once weekly for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62660393|NCT00729586|EXPERIMENTAL|Arm II (temsirolimus, megestrol acetate, tamoxifen citrate)|Patients receive temsirolimus as in Arm I and megestrol acetate PO BID for 3 weeks alternating with tamoxifen citrate PO BID for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62660394|NCT03831997||Historical Controls|The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.
62096935|NCT04614077||A( saline)|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
62660395|NCT03831997||Prospective Arm|The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.
62096936|NCT04614077||B specific solution|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
62466106|NCT03370549|EXPERIMENTAL|AWARE intervention|Group psychotherapy intervention for Asian-American women
62466107|NCT03370549|OTHER|Waitlist control|Delayed AWARE intervention for Asian-American women
62660396|NCT04076683|EXPERIMENTAL|Algorithm (arm A)|Frequency and volume for apherisis proposed by algorithm and validated by the physician
62660397|NCT04076683|NO_INTERVENTION|Usual care (arm C)|Frequency and volume for apherisis only decided by the physician (usual care)
62660398|NCT02697045|OTHER|ARIPIPRAZOLE|ABILIFY MAINTENA 400 MG LAI Aripiprazole 400mg, IM, Once a month
62660399|NCT01143012|ACTIVE_COMPARATOR|Group eczema education session|One group will attend a group eczema education session. All subjects will answer quality of life questions two times.
62660400|NCT01143012|ACTIVE_COMPARATOR|Control group|The other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
62660401|NCT05246748|EXPERIMENTAL|Intervention group|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
62466108|NCT03393728|EXPERIMENTAL|Intervention|72-hour propanolol before specific treatment of hyperthyroidism
62660402|NCT05246748|ACTIVE_COMPARATOR|Control group|The control group received solely standard education program for one sessions in prenatal period.
62660403|NCT05963659|EXPERIMENTAL|Group N|
62096937|NCT01616719|OTHER|DTRAX graft|
62096938|NCT02370732|OTHER|Roux en Y Gastric Bypass|"Participants recruited for this protocol will be those planning to undergo Roux-en-Y Gastric Bypass (RYGB). Upon study screening completion, participants will take part in a total of 4 laboratory assessment days where a fixed dose of alcohol will be given.~* 2 pre-surgery research appointments where participants will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day.~* 2 post-surgery (1 year) research appointments where you will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day."
62096939|NCT04038476|OTHER|Standard monitoring|"When assigned to the group Standard monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. The examiner (doctor or physicians involved in the study) are blinded to the transcutaneous CO2 measurement. An adjustment of the sedation management therefore takes place on the basis of the monitoring measures mentioned above. Transcutaneous CO2 monitoring is recorded in the background (Excel table of all registered values) and also monitored by the sedation assisting nurse and integrated into the standard sedation protocol."
62293946|NCT06295055|EXPERIMENTAL|semi-rigid shell barrier system|"The semi-rigid shell barrier system is based on polycaprolactone (PCL) and biphasic calcium phosphate (BCP) in a 70:30 ratio.~In vitro study, Tunthasen Pripatnanont et al. demonstrated that the semi-rigid shell barrier system exhibits suitable physical characteristics and mechanical properties, including appropriate morphology, hydrophilicity, adequate porosity, and a small pore size of less than 40 µm, facilitating angiogenesis and vascular penetration into the defect area. The semi-rigid shell demonstrates high resistance to compressive force, while the semi-resorbable covering membrane exhibits high elastic strength.~In vivo studies have confirmed the effectiveness of the semi-rigid shell barrier system, showing bone and tissue integration after function, good stability, biocompatibility, and property as a barrier due to space-making and maintenance. The system also exhibits limited susceptibility to complications and ease of clinical handling during surgery."
62466109|NCT01163825|EXPERIMENTAL|Nerve Growth Factor|Dose 1
62466110|NCT01163825|EXPERIMENTAL|Nerve Growth Factor 2|Dose 2
62466111|NCT00482794||1|Individuals with APS who also have one or more of their family members affected specifically by APS
62096940|NCT04038476|OTHER|Standard monitoring + transcutaneous CO2 monitoring|"When assigned to the group Standard monitoring + transcutaneous CO2 monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. In this group, the values of transcutaneous, continuous CO2 monitoring, including an alarm sound, are accessible to the treating physicians. Moreover, sedation management is adjusted on the basis of transcutaneous CO2 measurement. The above-mentioned measurements of the standard monitoring are carried out as described, in addition there is the the transcutaneous CO2 monitoring."
62096941|NCT02112929|EXPERIMENTAL|Inhalation of hyperpolarized xenon|One litre of hyperpolarized xenon to be inhaled during MRI scan of the lungs
62096942|NCT05838560|EXPERIMENTAL|Dasatinib + quercetin|open label dasatinib plus quercetin combined as a drug therapy
62096943|NCT02688361|EXPERIMENTAL|Fluimucil® (reference) then Acetylcysteine (test) 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Acetylcysteine (test).
62466112|NCT00482794||2|Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
62466113|NCT00482794||3|Individuals with APS and no family or no family affected with APS or another autoimmune disorder
62466114|NCT03049384|ACTIVE_COMPARATOR|Traditional Exercise|A classical exercise intervention based on current guidelines for cancer survivors.
62660404|NCT05963659|PLACEBO_COMPARATOR|Group P|
62660405|NCT00974454|ACTIVE_COMPARATOR|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
62660406|NCT00974454|PLACEBO_COMPARATOR|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
62660407|NCT02842021|ACTIVE_COMPARATOR|S2G6T-1|Topical cream
62660408|NCT02842021|ACTIVE_COMPARATOR|S2G6T-2|Topical Cream
62660409|NCT02842021|ACTIVE_COMPARATOR|S2G6T-3|Topical Cream
62660410|NCT02842021|PLACEBO_COMPARATOR|S2G6T-4|Topical Cream
62660411|NCT04857710|ACTIVE_COMPARATOR|Control (CONT)|A control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations
62660412|NCT04857710|EXPERIMENTAL|Conventional neuromuscular electrostimulation (CONV)|The CONV (conventional) modality allows us to compare with the current clinical application and the majority of the literature on the adaptations induced by NMES (neuromuscular electrostimulation) training.
62660413|NCT04857710|EXPERIMENTAL|Wide-pulse neuromuscular electrostimulation (WP)|The use of wide-pulse (WP) stimulations allows, in addition to the direct activation of the muscle fibers, the use of sensory pathways. This more global solicitation of the neuromuscular system (i.e. information going back to the spinal cord and even to the brain) prejudges more nervous adaptations and therefore a greater functional benefit.
62660414|NCT01094093|EXPERIMENTAL|Part B|Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).
62293947|NCT00550160|ACTIVE_COMPARATOR|1|The Home Management of Malaria (HMM) is a strategy aimed at improving access to prompt and effective antimalarial treatment of all fevers in children under 5 years. Community Drug Distributors (CDD) have been trained and equipped for this task.
62293948|NCT00550160|EXPERIMENTAL|2|An Intermittent Preventive Treatment (IPTc) schedule for asymptomatic pre-school children during high malaria transmission seasons alongside an ongoing Home Management of Malaria programme
62293949|NCT02151513||Cancer Pain|Placement of an intrathecal pump
62293950|NCT04145466|EXPERIMENTAL|Fat responders (1)|receiving high-fat diet
62293951|NCT04145466|EXPERIMENTAL|Carbohydrate responders (1)|receiving high-fat diet
62293952|NCT04145466|EXPERIMENTAL|Fat responders (2)|receiving high-carbohydrate diet
62660415|NCT01094093|EXPERIMENTAL|Part A|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.
62096944|NCT02688361|EXPERIMENTAL|Acetylcysteine (test) 2% solution then Fluimucil® (reference)|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Fluimucil® (reference).
62096945|NCT02819193||exposed group : early raw mother's own milk|"The use of raw MOM is considered as early when it begins before day 7."
62096946|NCT02819193||unexposed group : no use of raw mother's own milk|Neonates who receive, or not, raw MOM before day 7.
62293953|NCT04145466|EXPERIMENTAL|Carbohydrate responders (2)|receiving high-carbohydrate diet
62293954|NCT03190525||Multiple Myeloma patients|
62293955|NCT01953952|EXPERIMENTAL|Arm I (surgery, risk-based adjuvant therapy)|Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
62293956|NCT01953952|ACTIVE_COMPARATOR|Arm II (chemoradiotherapy)|Patients undergo IMRT QD five days a week for 7 weeks. Patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
62293957|NCT02503605|ACTIVE_COMPARATOR|Biosimilar recombinant FSH|Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
62293958|NCT02503605|ACTIVE_COMPARATOR|Urinary FSH|Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
62293959|NCT00976430|EXPERIMENTAL|Therapy for Parkinson's disease|Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
62293960|NCT02644408|EXPERIMENTAL|Megestrol and chemoradiotherapy|"Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before chemoradiotherapy and one week after chemoradiotherapy.~chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w."
62660416|NCT01046942|EXPERIMENTAL|Clopidogrel+Aspirin, hypercoagulabel|
62660417|NCT01046942|ACTIVE_COMPARATOR|Aspirin,hypercoagulabel control|
62660418|NCT02036918|ACTIVE_COMPARATOR|Arm A|Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy.
62660419|NCT02036918|EXPERIMENTAL|Arm B|Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy.
62660420|NCT03417414||B-CLL|Patients with B-Cell CLL
62660421|NCT03417414||B-NHL|Patients with B-Cell NHL
62096947|NCT01498874|PLACEBO_COMPARATOR|Placebo|
62096948|NCT01498874|EXPERIMENTAL|low dose gevokizumab|
62096949|NCT01498874|EXPERIMENTAL|high dose gevokizumab|
62293961|NCT02644408|ACTIVE_COMPARATOR|chemoradiotherapy|chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.
62293962|NCT06544239|EXPERIMENTAL|Virtual reality basketball asymmetric training|
62293963|NCT06544239|EXPERIMENTAL|Traditional basketball asymmetric training|
62293964|NCT00433888|EXPERIMENTAL|1|
62293965|NCT00433888|EXPERIMENTAL|2|
62096950|NCT05611606||DanFunD baseline|"Data from the DanFunD baseline cohort will be included (11). It comprises a total of 9,656 (33.7% of the invited participants) men and women aged 18-76 years born in Denmark and living in the Western part of greater Copenhagen.~Individuals with FSD are identified by means of self-reported questionnaires (n=9,656) (2) and diagnostic research interviews (n=1,590) (12).~Participants with FSD will be defined as follows:~* FSD operationalised by the Bodily Distress Syndrome single- and multi-organ type will be defined with both self-reported questionnaires (14) and diagnostic interviews (3)~* Three functional somatic syndromes, i.e. irritable bowel (15), chronic widespread pain (16), and chronic fatigue (17) will be defined with questionnaires.~Severe physical disease will be defined as having received at least one of the following five diagnoses: Cancer, stroke, myocardial infarction, other heart disease, and obstructive pulmonary disease."
62096951|NCT05518110|EXPERIMENTAL|PaTcH|All eligible patients will be treated with trametinib 2mg and hydroxychloroquine 1200mg daily (600mg twice a day (BID)) orally. Treatment will be continuous in treatment cycles lasting 28 days, and will continue until radiological or clinical progression of disease, unacceptable toxicity or consent withdrawal.
62737026|NCT03213132|PLACEBO_COMPARATOR|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
61909241|NCT03255629|OTHER|Study drug (glucagon) first, placebo second|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. A participant could receive 2 doses of the study drug or placebo at each study visit. The opposite treatment will be given during the second testing session after a 1-2 week washout period. Both participants and the study team will be blinded to the intervention being used during each session.
62096952|NCT05497869|EXPERIMENTAL|Experimental interventional group|Active Release Technique (ART)
62096953|NCT05497869|ACTIVE_COMPARATOR|active control group|conventional group
62096954|NCT05576662|EXPERIMENTAL|Nirmatrelvir plus ritonavir|Participants receive nirmatrelvir plus ritonavir (Paxlovid) for 15 days, and attend follow-up visits through week 15.
62096955|NCT05576662|PLACEBO_COMPARATOR|Placebo plus ritonavir|Participants receive placebo to match nirmatrelvir plus ritonavir for 15 days, and attend follow-up visits through week 15.
62096956|NCT04765202|EXPERIMENTAL|All participants|"Each participant will receive both treatments.~On each participant, similar wounds will be identified as treatment sites.~Treatment sites will be randomized to receive either AG Tx (control) or SOMA Tx (experimental)."
62096957|NCT06280729||T1DM cohort|A. T1DM label attached in the EHR OR B. patients with at least a record of Glycated Hemoglobin level of \>6.5% (48 mmol/mol) AND \< 45 years old AND no use of oral antidiabetic drug AND positivity of ≥2 anti-islet antibodies
62096958|NCT06280729||T2DM cohort:|A. T2DM label attached in the EHR OR B. patients with at least a record of Glycated Hemoglobin level of \>6.5% (48 mmol/mol) AND Medication history of antidiabetic drug comprising insulin or not
62466115|NCT03049384|EXPERIMENTAL|Tailored Exercise|A tailored and individualized exercise intervention based on the results of pre-intervention testing.
62096959|NCT02398825|EXPERIMENTAL|Ponatinib|
62096960|NCT04393103|OTHER|Follow up|Follow Up of 30 patients after administration of atropine.
62096961|NCT04393103|EXPERIMENTAL|intralipid 20% adjuvant|30 patients will receive atropine and intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart.
62096962|NCT06481774|EXPERIMENTAL|Patient Navigation Services|Following the consent process, participant will have access to a Patient Navigator, who will serve as a resource for during the time in the study to help navigate and get connected to local resources. The Patient Navigator will keep track of the kinds of support services and referrals provided. The Patient Navigator will contact the participant in 4 months to reassess current needs, quality of life, and areas where additional support is needed.
62096963|NCT02530151|EXPERIMENTAL|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
62466116|NCT01201460||Glucose testing|Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health.
62466117|NCT00716248|EXPERIMENTAL|1|
62096964|NCT02530151|PLACEBO_COMPARATOR|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
62293966|NCT03369795|EXPERIMENTAL|Study Drug|Methotrexate 10mg
62293967|NCT03369795|PLACEBO_COMPARATOR|Placebo|Pills equivalent to other study arm (10 mg)
62293968|NCT04381234|EXPERIMENTAL|ATA plus citrate|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan) in combination with citrate (1 mM) containing dialysate
62293969|NCT04381234|ACTIVE_COMPARATOR|ATA plus predilution hemodiafiltration|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan), in combination with high volume predilution hemodiafiltration
62293970|NCT06129630|ACTIVE_COMPARATOR|Control Group (CG)|Control Group (CG), which received their usual sessions of conventional occupational therapy.
62293971|NCT06129630|EXPERIMENTAL|Experimental Group (EG)|Experimental Group (EG), which received therapy with Nintendo Switch, plus their conventional occupational therapy sessions.
62293972|NCT00622193|EXPERIMENTAL|1 Active 50 mg|
62293973|NCT00622193|EXPERIMENTAL|2 Active 100 mg|
62293974|NCT00622193|PLACEBO_COMPARATOR|3 Placebo|
62293975|NCT02377102|NO_INTERVENTION|Observational|Patients will be asked to continue for 12 weeks of nonoperative medical management without physical therapy. At 12 weeks they will be reevaluated regarding the need for total knee arthroplasty.
62293976|NCT02377102|ACTIVE_COMPARATOR|Physical Therapy|Patients will be provided a prescription for 12 weeks of physical therapy at a location of their choice. No set protocol will be issued to allow for adjustments based on patient activity level and the therapist's professional choice. The physical therapy techniques, consisting of active and passive physiological and accessory movements and soft tissue mobilization, active range of motion exercises, muscle strengthening, muscle stretching, and exercises such as riding a stationary bicycle will be applied at the discretion of the treating physical therapist primarily to the knee and surrounding structures.
62293977|NCT06413004|OTHER|Positive food item during CLE or COLAP|The food item(s) which were positive during CLE (fluorescein leakage and cell shedding) or COLAP (swelling).
62293978|NCT00341263||Cases - twin pregnancies|Maternal and cord hormones in twins
62293979|NCT00341263||Controls - singleton pregnancies|Maternal and cord hormones in singletons
62293980|NCT01228747|PLACEBO_COMPARATOR|Placebo|Matching placebo for 28 weeks
61909242|NCT03255629|OTHER|Placebo first, study drug (glucagon) second|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. A participant could receive 2 doses of the study drug or placebo at each study visit. The opposite treatment will be given during the second testing session after a 1-2 week washout period. Both participants and the study team will be blinded to the intervention being used during each session.
61909243|NCT03251131|EXPERIMENTAL|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
62096965|NCT02888158|ACTIVE_COMPARATOR|Pelvic Trainer without robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart.~Intervention: Pelvic Trainer"
62293981|NCT01228747|EXPERIMENTAL|Levetiracetam|Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks
62293982|NCT04249882|PLACEBO_COMPARATOR|Placebo|Matched to active medications
62293983|NCT04249882|ACTIVE_COMPARATOR|Varenicline|1 mg twice a day
62293984|NCT04249882|ACTIVE_COMPARATOR|Naltrexone|50 mg once a day
62293985|NCT03609255|ACTIVE_COMPARATOR|Control group (C)|
62293986|NCT03609255|EXPERIMENTAL|Sedentary behavior group (SB)|
62293987|NCT03609255|EXPERIMENTAL|Stress management group (SR)|
62293988|NCT01096394||Ovarian cancer|Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.
62293989|NCT00648401|EXPERIMENTAL|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
62293990|NCT00648401|ACTIVE_COMPARATOR|2|Verelan® PM Extended-Release Capsules, 300 mg
62293991|NCT01688869||Mild TBI|Patients who have been diagnosed with a mild brain injury.
62293992|NCT03314805|PLACEBO_COMPARATOR|Control|Placebo
62293993|NCT03314805|EXPERIMENTAL|Treatment|Astragalus polysaccharides 500 mg
62293994|NCT02059824|EXPERIMENTAL|Eyelid|The selection of the laterality of the eyelid will be randomized
62466118|NCT00716248|ACTIVE_COMPARATOR|2|
62466119|NCT03507335||Atrial fibrillation|Patients with atrial fibrillation during measurements
62293995|NCT04213651||Diabetes Mellitus|Patients with diabetes mellitus
62293996|NCT01129193|EXPERIMENTAL|Arm I (Hematologic Malignancies)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
62293997|NCT01129193|EXPERIMENTAL|Arm II (Solid Tumors)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
62293998|NCT05121402|EXPERIMENTAL|Low dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
62293999|NCT05121402|EXPERIMENTAL|Middle dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
62294000|NCT05121402|EXPERIMENTAL|High dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
62294001|NCT05121402|PLACEBO_COMPARATOR|Placebo|Placebo twice daily for 8 weeks.
62294002|NCT01372319||Glaucoma Patients (OAG, Aulhorn stages II - IV)|Manifest glaucoma (OAG, Aulhorn stages II - IV) with advanced binocular visual loss, as obtained by semi-automated kinetic perimetry (SKP), no study medication
62294003|NCT01372319||Normal subjects|male+female \> 18 years
62294004|NCT01678274||Turner syndrome|Females with Turner syndrome
62294005|NCT01678274||Control group|age matched females acting as controls
62294006|NCT04924426||Patients with AMI|Patients with AMI
62294007|NCT04924426||Patients with no AMI|Patients with no AMI
62294008|NCT06162884||STP >=30%|STP score is 30% or greater than 30% in whole lung at baseline inspirational HRCT scan. STP score is an AL/ML derived score using radiomic patterns of lung parenchyma to identify the spatial location of likely progressed in the short-term follow up. The higher score is the worse expected outcome.
62466120|NCT03507335||Sinus|Patients with sinus rhythm during measurements
62096966|NCT02888158|EXPERIMENTAL|Pelvic Trainer with robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart but with robotic assistance.~Intervention: Robotic assistance~Intervention: Pelvic Trainer"
62096967|NCT02060279|EXPERIMENTAL|Lifestyle intervention and carotenoid supplement|
62096968|NCT02060279|EXPERIMENTAL|Lifestyle intervention and placebo|
62096969|NCT03118752|EXPERIMENTAL|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
62096970|NCT03118752|NO_INTERVENTION|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
62096971|NCT03759171|EXPERIMENTAL|Immediate Entry Group|Following the baseline interview, veterans randomized to the immediate entry group directly engaged in the Guitars for Vets Intervention and were interviewed at the end of the intervention period, roughly 6 weeks later. The intervention content and duration (6 weeks) was the same across both groups.
62096972|NCT03759171|EXPERIMENTAL|Delayed Entry Group|Those randomized to the delayed entry group had their baseline interview repeated at the end of the delayed entry period (4 weeks) prior to receiving the 6-week Guitars for Vets Intervention as well as after intervention completion. The intervention content and duration (6 weeks) was the same across both groups.
62096973|NCT06479980|EXPERIMENTAL|Single Session Narrative Therapy Intervention|A single 60-75 minute narrative therapy session with a trained licensed behavioral health provider will be offered to patients on the psychotherapy waitlist of an HIV primary care clinic.
62294009|NCT06162884||STP < 30%|STP score is less than 30% in whole lung at baseline inspirational HRCT scan.
62294010|NCT01746433|ACTIVE_COMPARATOR|Hanging Triangle Bar|"The patients randomized to this group will use a hanging triangle bar for aid in sitting up exercises.~No particular brand of hanging bar is targeted."
62294011|NCT01746433|EXPERIMENTAL|Ergonome|"The patients randomized to this group will use the l'ERGONOME device for aid in sitting up exercises.~Commercial name of the device: SAM ERGONOM (TM)~Manufacturer: Medicatlantic groupe Winncare, Le Pas du Château, 85680 Saint-Paul-Mont-Penit"
62660422|NCT05508802|OTHER|State Counselor-Coordinated Services|In this program, services are coordinated by a counselor employed by the New Jersey State Division of Vocational Rehabilitation Services (NJDVRS), a state-based agency that assists people with disabilities who are interested in pursuing employment. While the participant is in inpatient rehabilitation or soon after their discharge, a member of the research team will assist them in completing the necessary documentation to apply for services from this agency. Services for which they are eligible will be provided directly through NJDVRS.
62737027|NCT06477003|EXPERIMENTAL|Arm 1 - surgery patients|70 patients with clinically confirmed metastatic head and neck squamous cell carcinomas (N+ HNSCC) planned for definitive surgery will be imaged using the MSOT device prior to surgery. Skin temperature will be measured prior to and after MSOT imaging to assess for safety.
61909244|NCT03251131|NO_INTERVENTION|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
61909245|NCT00813943|EXPERIMENTAL|Cilengitide (2-times weekly) + Temozolomide + Radiotherapy|
61909246|NCT00813943|EXPERIMENTAL|Cilengitide (5-times weekly) + Temozolomide + Radiotherapy|
61909247|NCT00813943|ACTIVE_COMPARATOR|Temozolomide + Radiotherapy|
61909248|NCT00368290|EXPERIMENTAL|1|modafinil plus CBT
61909249|NCT00368290|PLACEBO_COMPARATOR|2|placebo plus CBT
61909250|NCT01403948|EXPERIMENTAL|Patients with relapsed or refractory NHL|Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
61909251|NCT03141996|EXPERIMENTAL|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
61909252|NCT03141996|ACTIVE_COMPARATOR|Standard of care|Regular occupational therapy session
61909253|NCT04445389|EXPERIMENTAL|GX-19: Dose A|Dose A of GX-19 will be intramusculary administered via EP on day 1 and day 29.
61909254|NCT04445389|EXPERIMENTAL|GX-19: Dose B|Dose B of GX-19 will be intramusculary administered via EP on day 1 and day 29.
61909255|NCT04445389|PLACEBO_COMPARATOR|GX-19: Dose C|Dose C of GX-19 will be intramusculary administered via PharmaJet® Needle Free Delivery on day 1 and day 29.
61909256|NCT04445389|PLACEBO_COMPARATOR|Placebo: Dose A, B, or C|Placebo will be intramusculary administered on day 1 and day 29 via EP or PharmaJet® Needle Free Delivery
61909257|NCT03262311|EXPERIMENTAL|Hypoxia marker|Administration of a single dose of the hypoxia marker Pimonidazole
61909258|NCT02973373|EXPERIMENTAL|MRI with HF-NIV|Intervention: Acquisition of MRI with High-Frequency non-invasive ventilation (HF-NIV)
61909259|NCT02973373|ACTIVE_COMPARATOR|MRI without HF-NIV|Intervention: MRI without High-Frequency non-invasive ventilation (HF-NIV)
61909260|NCT02121665|EXPERIMENTAL|Probiotic (Inersan) Arm|Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
61909261|NCT02121665|PLACEBO_COMPARATOR|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
61909262|NCT04552678|EXPERIMENTAL|Healthy Eating, Active Play, Self-Regulation, Parent Education|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum) and Parent Education
61909263|NCT04552678|EXPERIMENTAL|Healthy Eating, Active Play, Self-Regulation|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum), but no Parent Education
62096974|NCT04138940|EXPERIMENTAL|Distributed, Short Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 5 sentence-long script.
62096975|NCT04138940|EXPERIMENTAL|Distributed, Long Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 10 sentence-long script.
62096976|NCT04138940|EXPERIMENTAL|Massed, Short Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 5 sentence-long script.
62096977|NCT04138940|EXPERIMENTAL|Massed, Long Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 10 sentence-long script.
62096978|NCT02785055|ACTIVE_COMPARATOR|Ultrasound-Assisted|Ultrasound assisted marking of the thoracic spine on the skin for Thoracic Epidural Placement
62096979|NCT02785055|ACTIVE_COMPARATOR|Palpation|Palpation marking of the thoracic spine on the skin for Thoracic Epidural Placement
62096980|NCT04185519|EXPERIMENTAL|AI (model)|This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
62096981|NCT04185519|NO_INTERVENTION|DR1|Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl.
62096982|NCT05626283|ACTIVE_COMPARATOR|lumbar disc prolapse group|44 patients diagnosed as having symptomatic lumbar disc prolapse
62096983|NCT05626283|PLACEBO_COMPARATOR|Control|44 age and sex matched healthy controls
62294012|NCT05314673|ACTIVE_COMPARATOR|Preoperative intralesional injection of bevacizumab + pterygium excision+ autograft|Patients receiving intralesional injection of 0.05 ml (1.25 mg) of Bevacizumab, one month before surgical treatment. Surgical treatment consisted of lesion excision and conjunctival autograft performed by a single trained surgeon.
62294013|NCT05314673|ACTIVE_COMPARATOR|pterygium excision+ autograft|Patients undergoing only pterygium surgical treatment.
62466121|NCT02047071|NO_INTERVENTION|Standard Care|Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
62660423|NCT05508802|OTHER|Center Facilitator-Coordinated Services|In this program, services are coordinated by a facilitator who is employed by Kessler Institute for Rehabilitation and works cooperatively with NJDVRS. The facilitator will begin working with the participant during inpatient rehabilitation, or soon after discharge, depending on when they enroll in the study. Some services for which they are eligible will be provided through NJDVRS and others will be provided to them by the facilitator.
62660424|NCT01024595||Without treatment|
62660425|NCT01571349||chronic ITP group|ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography
62660426|NCT01571349||acute ITP group|ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography
62660427|NCT05045183|NO_INTERVENTION|Treatment A: Uncovered Wound (Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as a negative control.
62660428|NCT05045183|ACTIVE_COMPARATOR|Treatment B: Standard of Care (SoC) Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, SoC adhesive bandage will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
62660429|NCT05045183|EXPERIMENTAL|Treatment C: Antibiotic Ointment|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment will be applied. This treatment will be applied daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
62660430|NCT05045183|EXPERIMENTAL|Treatment D: Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
62660431|NCT05045183|EXPERIMENTAL|Treatment E: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 0 through Day 2 and all wound sites will be uncovered after Day 3 to Day 16 for assessments.
61909264|NCT04552678|EXPERIMENTAL|Healthy Eating, Active Play, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, and Parent Education
61909265|NCT04552678|EXPERIMENTAL|Healthy Eating + Active Play|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, but no Parent Education
62466122|NCT02047071|EXPERIMENTAL|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
62096984|NCT03795974|ACTIVE_COMPARATOR|MNC & MSC with Control|One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity
62096985|NCT03795974|EXPERIMENTAL|MNC & MSC|Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients
62096986|NCT04612075||All patients referred to fast track clinical pathway for HNC cancer|MRI as part of staging, including a 5-minute additional sequence.
62096987|NCT04612075||Patients with locally advanced HNC|FDG-PET/MRI
62294014|NCT00733902|EXPERIMENTAL|Tanezumab 10 mg|
62294015|NCT00733902|EXPERIMENTAL|Tanezumab 5 mg|
62294016|NCT00733902|EXPERIMENTAL|Tanezumab 2.5 mg|
62294017|NCT00733902|PLACEBO_COMPARATOR|Placebo|
62294018|NCT06428890|EXPERIMENTAL|Dietary Supplementation with Grape Seed Extract|Participants received the supplement (600 mg, capsules) via cross-over design for 7 days
62294019|NCT06428890|PLACEBO_COMPARATOR|Placebo|Participants received the placebo (600 mg, capsules) via cross-over design for 7 days
62294020|NCT01348230||prior preterm delivery at 24-32 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
62466123|NCT03608722|EXPERIMENTAL|BrainCheck vs Pen and paper tests|Compare patient performance on BrainCheck neurocognitive test vs pen and paper dementia tests (SLUMS, MMSE, MoCA), as well as an exploratory analysis comparing BrainCheck performance to aid in identifying patients with MCI and dementia vs physician diagnosis
62466124|NCT03608722|EXPERIMENTAL|BrainCheck performance in ESRD patients|Assess BrainCheck test performance in patients with ESRD and how undergoing hemodialysis treatment can impact cognitive performance.
62466125|NCT02620891|ACTIVE_COMPARATOR|experimental group|Using helium oxygen mixture
62466126|NCT02620891|NO_INTERVENTION|matched group|Using air oxygen mixture
62294021|NCT01348230||prior preterm delivery at 32-34 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
62294022|NCT01348230||prior preterm delivery at 34-36 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
62294023|NCT06190587|NO_INTERVENTION|Control Group|In control group participants had 8-weeks follow-up without any intervention.
62294024|NCT06190587|EXPERIMENTAL|Interventional Group|In interventional group participants had 8-weeks follow-up with 20 g/day goji berry consumption intervention.
62294025|NCT04963829|ACTIVE_COMPARATOR|Study Group (SG)|Participants who used the abovementioned gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration.
62466127|NCT05792397|EXPERIMENTAL|treatment group|The arm contains patients with acute pulmonary embolism who undergoing interventional therapy with transcatheter pulmonary embolectomy system which named 'TwiFlow-Thrombectomy Catheter System'
62466128|NCT03846765|EXPERIMENTAL|Phenylephrine continuous infusion|
62466129|NCT03846765|EXPERIMENTAL|Dobutamine continuous infusion|
62660432|NCT05045183|EXPERIMENTAL|Treatment F: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
62294026|NCT04963829|ACTIVE_COMPARATOR|Control Group 1 (CG1)|Participants who were subjected to a standardized treatment (collagenase ointment was selected for this treatment),
62294027|NCT04963829|ACTIVE_COMPARATOR|Control Group 2 (CG2)|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum)
62294028|NCT04934826|EXPERIMENTAL|Hydrolized proteins|Group receiving hydrolyzed proteins in the postprandial metabolic test
62294029|NCT04934826|ACTIVE_COMPARATOR|Intact proteins|Group receiving intact proteins in the postprandial metabolic test
62294030|NCT06432738|EXPERIMENTAL|600mg ZL-82|The subjects in the single-dose group were fasted and water-free for at least 10 hours the night before the administration. On the first day of the study (D1), the subjects were given ZL-82 tablets or placebo according to the requirements of the random table, and were followed as per the study. Schedule safety inspections and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; complete a series of safety inspections, PK, and PD sample collection on the 3rd day and leave the clinical trial facility on the 7th day Safety follow-up.
62466130|NCT03699020|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|The intervention will consists of eight weekly two hour group ACT sessions led by trained lay personnel and followed by homework. ACT is a behavioral therapy.
62466131|NCT03699020|EXPERIMENTAL|Education Control|Consists of eight weekly two hour group chronic pain education sessions led by trained lay personnel and followed by homework.
62466132|NCT06346730|EXPERIMENTAL|Virtual reality glasses to intervention group|Virtual reality glasses to intervention group, randomized pretest-posttest
62466133|NCT06346730|NO_INTERVENTION|control|Non-intervention
62466134|NCT04699747|EXPERIMENTAL|Multiple sclerosis|F-18 3F4AP PET Scan
62466135|NCT04699747|ACTIVE_COMPARATOR|Healthy controls|F-18 3F4AP PET Scan
62466136|NCT06036082|EXPERIMENTAL|Conventional physical therapy group|It consisted of 20 children received conventional physical therapy program
62466137|NCT06036082|EXPERIMENTAL|isokinetic training group|It consisted of 20 children received conventional physical therapy program and isokinetic training
62466138|NCT06036082|EXPERIMENTAL|Treadmill training group|It consisted of 20 children received conventional physical therapy program and treadmill training
62294031|NCT06432738|PLACEBO_COMPARATOR|600mg ZL-82 placebo|The subjects in the single-dose group were fasted and water-free for at least 10 hours the night before the administration. On the first day of the study (D1), the subjects were given ZL-82 tablets or placebo according to the requirements of the random table, and were followed as per the study. Schedule safety inspections and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; complete a series of safety inspections, PK, and PD sample collection on the 3rd day and leave the clinical trial facility on the 7th day Safety follow-up.
62096988|NCT03912103|ACTIVE_COMPARATOR|Interdiciplinary medication review intervention|The clinical pharmacist perform medication review and presents medication interventions orally and written to the physician. The physician perform the changes and inform the patient about the changes. 7 days after intervention the patient receives a follow up phone call from the pharmacist about the medication interventions. If the pharmacist during the follow up phone call identify any complications due to compliance/add on/deprescribing the pharmacist uses motivational conversation to come to a solution.14 days after the beginning of the intervention the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire and measured on a Likert scale (1-5). 30 days after the beginning of the intervention the pharmacist collect an updated medication history. Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group.
62096989|NCT03912103|NO_INTERVENTION|Control group|Standard treatment without a medication review and follow up related to medication changes (standard treatment).14 days after the enrollment the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire measured on a Likert scale (1-5). 30 days after the enrollment the pharmacist collect an updated medication history.Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group
62096990|NCT06501118|OTHER|Educational intervention|SP02 target ranges will be 90-96%. Education about the specific oxygen targets will be provided to the clinical teams. Real time feedback on adherence to the Sp02 target range will be provided by virtual respiratory therapists.
62096991|NCT06612606||Experienced robot surgeons|Robot surgeons with 100 or more performed robot surgical cases.
62096992|NCT06612606||Novice robot surgeons|Robot surgeons with less than 100 performed robot surgical cases.
62096993|NCT02797483|EXPERIMENTAL|Test Fat Blue|16 weeks interventions
62096994|NCT02797483|EXPERIMENTAL|Test Fat Green|16 weeks interventions
62096995|NCT02797483|EXPERIMENTAL|Test Fat Red|16 weeks interventions
62096996|NCT04548622|EXPERIMENTAL|Non-randomized bilateral rTMS|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
62096997|NCT00955461|EXPERIMENTAL|Laser treatment|Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
62466139|NCT04720638|EXPERIMENTAL|Short fiber reinforced flowable resin composite restorations|(everX Flow, GC Europe) + (Gaenial posterior, GC Europe
62466140|NCT04720638|ACTIVE_COMPARATOR|Conventional resin composite restoration.|(Gaenial posterior, GC Europe)
62466141|NCT01933373|ACTIVE_COMPARATOR|Toupet|Laparoscopic Myotomy + Toupet 180 degree partial posterior fundoplication.
62466142|NCT01933373|EXPERIMENTAL|Dor|Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
62660433|NCT05045183|EXPERIMENTAL|Treatment G: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
62660434|NCT05045183|EXPERIMENTAL|Treatment H: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
61909266|NCT04552678|EXPERIMENTAL|Healthy Eating, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, and Parent Education
62096998|NCT05780047|EXPERIMENTAL|Mobile EDC reduction program|Million Marker's (MM) first-of-its-kind mobile endocrine disrupting chemical (EDC) reduction program will be tested and validated in a prospective longitudinal cohort intervention trial. 50 women in reproductive age and their partners will be recruited from the Healthy Nevada Project, an existing state-wide health monitoring effort. Using MM's services, participants' urine samples will be collected two times (at pre- and post-intervention) to measure changes in EDC levels. Changes in participants' environmental health literacy, attitudes, knowledge, and behaviors will be assessed after using MM's products and services. Validated surveys on environmental health literacy and readiness to change and analyses of participants' lifestyle behaviors and product use will be conducted at baseline (first test) and upon completion of the second test. The investigators will evaluate the MM app and platform usability to improve the user experience, using the System Usability Score (SUS) survey.
62096999|NCT03950908|OTHER|Single bite|The single bite technique involved removing the forceps with its specimen after each individual biopsy.
62466143|NCT05778422|ACTIVE_COMPARATOR|Pulsed Radiofrequency|The investigators performed pulsed radiofrequency in the suprascapular nerve
62466144|NCT05778422|ACTIVE_COMPARATOR|Bupivacaine|The investigators performed a blocade with bupivacaine in the suprascapular nerve.
62466145|NCT05487547|EXPERIMENTAL|Study arm|Subjects will receive 4 treatments at 2-weeks intervals. Each treatment will consist of IPL administered on the malar region, followed by RF administered around the eye, followed by Meibomian gland expression (MGX). Follow-up will be conducted at 4 weeks after the 4th treatment session.
62466146|NCT00524264|EXPERIMENTAL|1|
62466147|NCT00524264|PLACEBO_COMPARATOR|2|
62466148|NCT06034119|EXPERIMENTAL|Stroke participants|Researchers will assess muscle control in participants post-stroke during different types of walking modifications
62466149|NCT06034119|ACTIVE_COMPARATOR|Neurotypical participants|Researchers will compare muscle control to neurotypical participants during the same types of walking modifications to assess stroke-induced changes in muscle control vs. intervention-induced changes in muscle control
62097000|NCT03950908|OTHER|Double bite|The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
62097001|NCT04785183|EXPERIMENTAL|Melatonin Group|
62097002|NCT04785183|PLACEBO_COMPARATOR|Control Group|
62097003|NCT05983692|EXPERIMENTAL|Mg Wire group|Intervention: Magnesium-based wire as braiding suture to braid the tendon graft.
62097004|NCT05983692|NO_INTERVENTION|control group|2-0 vicryl suture as control, size and length matched Mg wire
62097005|NCT05545462|EXPERIMENTAL|COMPARISON OF DOXYCYCLINE AND COMMON SALT FOR TREATMENT OF UMBILICAL GRANULOMA IN CHILDREN|to study the comparison of doxycycline and common salt for the treatment of umbilical granuloma to check which is more effective safe timesaving and can be performed by even parents it showed that common salt is more effective than doxycycline
62097006|NCT05545462|EXPERIMENTAL|COMPARISON BETWEEN COMMON SALT AND SOXYCYLIN FOR TREATMENT OF UMBILICAL GRANULOMA|to study the comparison of doxycycline and common salt for the treatment of umbilical granuloma to check which is more effective safe timesaving and can be performed by even parents it showed that common salt is more effective than doxycycline
62097007|NCT06126146||Risankizumab|Participants will receive risankizumab on-body injector (OBI) as prescribed by their physician according to local label.
62097008|NCT01974921|EXPERIMENTAL|Bronchial thermoplasty|ALAIR Catheter. Radiofrequency system.
62097009|NCT00448864|EXPERIMENTAL|Ecallantide - Low Dose Regimen|Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
62097010|NCT00448864|EXPERIMENTAL|Ecallantide - High Dose Regimen|Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 milliliters per hour (mL/hr) for 4 hours.
62097011|NCT00448864|PLACEBO_COMPARATOR|Placebo|Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
62097012|NCT03935828|EXPERIMENTAL|Topical Sinonasal Antibiotics|For topical antibiotics, the compounding pharmacy will use pre-determined doses using data extrapolated from oral and intravenous doses and data that has detailed the effect of the medication on solubility, pH, and particle properties. Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml, and Amphotericin B 20mcg/ml, all to be prescribed for 21 days, applied twice a day. Although the dosing schedule for these topical antibiotics has not been definitively studied, the majority of the data supports a range from two to three times daily for three to four weeks. Patients will be instructed by the pharmacist how to dissolve the cream, powder, or vial of antibiotic in saline, and to irrigate each nostril with 120 ml total. Doses will not be varied during the study period.
62097013|NCT03935828|ACTIVE_COMPARATOR|Oral Antibiotics|Oral antibiotics will be prescribed for 21 days, as available (albeit limited) evidence recommends antimicrobial therapy in CRS for at least 3 weeks. For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours, Levofloxacin 500 mg once daily, or Clindamycin 300 mg every 6 hours, as these are standard of care for treatment of Chronic Rhinosinusitis.
62097014|NCT06504264|EXPERIMENTAL|LPA: Letters-phonemes-articulatory gestures|This group will receive training for phonemic segmentation that includes using printed letters, sounds (phonemes) while simultaneously learning the articulation placements of the letters/sounds.
62097015|NCT06504264|EXPERIMENTAL|LPM: Letters-phonemes-general mouth awareness|This group will receive training for phonemic segmentation that includes using printed letters, sounds (phonemes) while simultaneously learning about the mouth in general.
62466150|NCT05611216||Third-line (3L) Cohort|patients with Chronic Myeloid Leukemia - Chronic Phase (CML-CP) who initiated 3L for CML-CP
62466151|NCT05611216||T315I Cohort|patients with CML-CP with T315I mutation
62466152|NCT01416584|NO_INTERVENTION|Usual Care Control|Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
62466153|NCT01416584|EXPERIMENTAL|Methadone Contingency Group|Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
62097016|NCT06504264|EXPERIMENTAL|LP: Letters-phonemes|This group will receive training for phonemic segmentation that includes using printed letters and sounds (phonemes) only.
62097017|NCT03453385|NO_INTERVENTION|Control|Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
62097018|NCT03453385|EXPERIMENTAL|Sampling|Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
62097019|NCT01616563|EXPERIMENTAL|Diet and exercise|A combined diet and exercise program tailored to individuals incorporating behavioural modification support
62097020|NCT00503568|EXPERIMENTAL|DS-1: gp96-ig Dose Schedule 1|Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient;
62466154|NCT01416584|EXPERIMENTAL|Methadone & Abstinence Contingency|Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).
62294032|NCT06432738|EXPERIMENTAL|50mg ZL-82|Subjects in the multiple-dose group were fasted and water-free for at least 10 hours the night before dosing, and were given ZL once a day according to the random table requirements from day 1 (D1) to day 10 (D10) of the study. -82 tablets or placebo, and undergo safety inspections according to the study schedule and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; after completing a series of safety inspections, PK, and PD sample collection on day 12 Safety follow-up was conducted on day 16 after leaving the clinical trial facility.
62466155|NCT02363634|ACTIVE_COMPARATOR|Magnesium threonate (Magtein)|Those randomized to receive the Magtein
62466156|NCT02363634|PLACEBO_COMPARATOR|Placebo|Those randomized to placebo
62466157|NCT00633399|EXPERIMENTAL|1|Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.
62466158|NCT00633399|PLACEBO_COMPARATOR|2|Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.
62294033|NCT06432738|PLACEBO_COMPARATOR|50mg ZL-82 placebo|Subjects in the multiple-dose group were fasted and water-free for at least 10 hours the night before dosing, and were given ZL once a day according to the random table requirements from day 1 (D1) to day 10 (D10) of the study. -82 tablets or placebo, and undergo safety inspections according to the study schedule and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; after completing a series of safety inspections, PK, and PD sample collection on day 12 Safety follow-up was conducted on day 16 after leaving the clinical trial facility.
62294034|NCT06432738|EXPERIMENTAL|100mg ZL-82|Subjects in the multiple-dose group were fasted and water-free for at least 10 hours the night before dosing, and were given ZL once a day according to the random table requirements from day 1 (D1) to day 10 (D10) of the study. -82 tablets or placebo, and undergo safety inspections according to the study schedule and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; after completing a series of safety inspections, PK, and PD sample collection on day 12 Safety follow-up was conducted on day 16 after leaving the clinical trial facility.
62466159|NCT03002597|EXPERIMENTAL|Blind Children|Children between the ages of 4 and 17 who are blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
62466160|NCT03002597|EXPERIMENTAL|Sighted Children|Children between the ages of 4 and 17 who are sighted in both eyes.
62466161|NCT03497247|EXPERIMENTAL|Mindfulness-Based Cognitive-Behavioral Therapy|
62466162|NCT03497247|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy|
62466163|NCT02687074|EXPERIMENTAL|Intubation rate on 28 days|patients with respiratory failure treat with HFNC or NIV and intubation rate on 28 days
62466164|NCT00184600|EXPERIMENTAL|Insulin detemir (basal insulin)|Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.
62466165|NCT00184600|ACTIVE_COMPARATOR|Insulin aspart (prandial insulin)|Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.
62660435|NCT05177744||allergic (Zagreb, urban)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Zagreb (urban)"
62097021|NCT00503568|EXPERIMENTAL|DS-2: gp96-ig Dose Schedule 3|Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10\^7 cells weekly, maximum 18 vaccines/patient;
62660436|NCT05177744||healthy subjects (Zagreb, urban)|"Healthy subjects that will be recruited from continental region in Croatia - Zagreb (urban).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
61909267|NCT04552678|EXPERIMENTAL|Healthy Eating + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, but no Parent Education
61909268|NCT04552678|EXPERIMENTAL|Healthy Eating + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, and Parent Education
62097022|NCT00503568|EXPERIMENTAL|DS-3: gp96-ig Dose Schedule 3|Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
62097023|NCT05892575|EXPERIMENTAL|experimental:educt|"Training on improving the quality of life, coping with incontinence and kegel exercises will be given to obese elderly people over 65 years of age with urinary incontinence in the experimental group.~Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months."
62097024|NCT05892575|NO_INTERVENTION|active comparator, control group|The elderly in the control group will not be interfered with.
62097025|NCT03932617||fluid responders|
62466166|NCT00184600|ACTIVE_COMPARATOR|Biphasic insulin aspart 30 (biphasic insulin)|Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.
62097026|NCT03932617||fluid non responders|
62466167|NCT06214364|ACTIVE_COMPARATOR|Active transcranial direct current stimulation|"Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
62660437|NCT05177744||allergic (Slavonia, urban and rural)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Slavonia (urban and rural)"
62660438|NCT05177744||healthy subjects (Slavonia, urban and rural)|"Healthy subjects that will be recruited from continental region in Croatia -(Slavonia, urban and rural).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
61909269|NCT04552678|EXPERIMENTAL|Healthy Eating Only|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, but no Parent Education
62097027|NCT01188317|EXPERIMENTAL|1|
62097028|NCT01188317|PLACEBO_COMPARATOR|2|
61909270|NCT04552678|EXPERIMENTAL|Active Play, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, and Parent Education
62097029|NCT02408965|EXPERIMENTAL|methergine|Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
61909271|NCT04552678|EXPERIMENTAL|Active Play + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, but no Parent Education
62097030|NCT02408965|PLACEBO_COMPARATOR|saline placebo|Placebo group saline single injection when manual cervical dilation begins the day before the procedure
62097031|NCT03815916|EXPERIMENTAL|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62097032|NCT03815916|EXPERIMENTAL|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62097033|NCT03815916|EXPERIMENTAL|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62097034|NCT03815916|EXPERIMENTAL|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62097035|NCT01414036|ACTIVE_COMPARATOR|Enhanced Traditional Care control|This arm will receive a low literacy smoking cessation educational brochure, a list of hospital and community resources for smoking cessation, in addition to usual care.
62097036|NCT01414036|EXPERIMENTAL|Patient Navigation|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
62097037|NCT01571778|EXPERIMENTAL|Donning Gloves without Hand Hygiene|In this arm, healthcare workers will be assigned to don non-sterile gloves prior to patient contact WITHOUT first performing hand hygiene. Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
62294035|NCT06432738|PLACEBO_COMPARATOR|100mg ZL-82 placebo|Subjects in the multiple-dose group were fasted and water-free for at least 10 hours the night before dosing, and were given ZL once a day according to the random table requirements from day 1 (D1) to day 10 (D10) of the study. -82 tablets or placebo, and undergo safety inspections according to the study schedule and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; after completing a series of safety inspections, PK, and PD sample collection on day 12 Safety follow-up was conducted on day 16 after leaving the clinical trial facility.
62660439|NCT05177744||allergic Mediterranean region (urban and rural population)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from mediterranean region in Croatia - urban and rural"
62294036|NCT06432738|EXPERIMENTAL|200mg ZL-82|Subjects in the multiple-dose group were fasted and water-free for at least 10 hours the night before dosing, and were given ZL once a day according to the random table requirements from day 1 (D1) to day 10 (D10) of the study. -82 tablets or placebo, and undergo safety inspections according to the study schedule and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; after completing a series of safety inspections, PK, and PD sample collection on day 12 Safety follow-up was conducted on day 16 after leaving the clinical trial facility.
62660440|NCT05177744||healthy subjects Mediterranean region (urban and rural population)|"Healthy subjects that will be recruited from mediterranean region in Croatia -urban and rural.~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
62660441|NCT01346150||Stratum A -Typical SCID|Typical Severe Combined Immunodeficiency (SCID), Adenosine Deaminase-Deficient ADA SCID, and X-linked SCID (XSCID) who received a transplant
62660442|NCT01346150||Stratum B - Atypical SCID|Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant
62660443|NCT01346150||Stratum C - SCID w/Non-HCT Treatments|SCID who received Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) or gene therapy
62660444|NCT04976257|EXPERIMENTAL|Ga-PSMA-11, PET/CT, Angiogram, and Prostatic Arterial Catheterization|Patients receive 68Ga-PSMA-11 IV over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after on day 1. One to 14 days later, patients undergo pelvic angiogram and prostatic arterial catheterization. Patients then receive 68Ga-PSMA-11 IA over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after.
62660445|NCT02317549|EXPERIMENTAL|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
62660446|NCT02317549|PLACEBO_COMPARATOR|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
62660447|NCT02378181|EXPERIMENTAL|Toolkit (TK)|Patients in the TK condition will receive counseling sessions from participating counselors who have been trained to use the Health Education Toolkit (TK).
62660448|NCT02378181|ACTIVE_COMPARATOR|Treatment-as-usual (TAU)|Patients in the treatment-as-usual (TAU) condition will receive the same number of counseling sessions as patients in the TK condition from participating counselors who have not been trained to use the Health Education Toolkit. Counselors working with patients in this condition will receive a control training of the same length and intensity on recovery topics that are covered in the Health Education Toolkit, but will not be equipped with the Toolkit.
62660449|NCT03139201|EXPERIMENTAL|OxyAqua|OxyAqua (olifilcon D) daily disposable
62660450|NCT03139201|ACTIVE_COMPARATOR|Si-Hy|Si-Hy (olifilcon B) daily disposable
62660451|NCT02202616|OTHER|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
61909272|NCT04552678|EXPERIMENTAL|Active Play + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, and Parent Education
61909273|NCT04552678|EXPERIMENTAL|Active Play Only|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, but no Parent Education
62097038|NCT01571778|NO_INTERVENTION|Hand Hygiene before donning Non-Sterile Gloves|In this arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (This is usual,expected practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
62097039|NCT01145144|EXPERIMENTAL|DHEA supplementation|DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
62097040|NCT01145144|NO_INTERVENTION|only induction of ovulation by same long protocol without DHEA|
62097041|NCT04942054|EXPERIMENTAL|SCO-120|
62097042|NCT01055587||major abdominal surgery|The investigators compare the levels of biomarkers in patients with and without complications in the early postoperative course following major abdominal surgery
62097043|NCT01055587||severe burn injury|The investigators compare levels of biomarkers within the first 20 days in patients with and without complications following severe burn injury
62097044|NCT06488599||1- hybrid prosthesis|Patients having fixed hybrid prosthesis over 4 implants in the mandible for 5 years
62097045|NCT06488599||2- over denture|Patients having removable overdenture with locators over 2 implants in the mandible for 5 years
62660452|NCT06049342|EXPERIMENTAL|NCR100 injection|Cohort1:Low dose NCR100 injection; Cohort2:Mid-low dose NCR100 injection; Cohort3:Mid-high dose NCR100 injection; Cohort4:High dose NCR100 injection.
61909274|NCT04552678|EXPERIMENTAL|Self-Regulation + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, and Parent Education
62097046|NCT06523725|EXPERIMENTAL|Part A and Part B|"Interventions:~Drug: BRC-003 (High Cannabidiol Botanical Extract) 100 mg/mL"
62097047|NCT06523725|PLACEBO_COMPARATOR|Part B|"Placebo Comparator: 1 Placebo Half of the patients will receive PO placebo~Interventions:~Drug: Placebo"
62097048|NCT03756194|EXPERIMENTAL|Experimental|"Participants will utilize the socially-assistive robot with a CARESSES cultural competence solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
62660453|NCT01405859||TS controls|10
62660454|NCT01405859||Non TS Controls|11
62660455|NCT01405859||TS remission|0
62660456|NCT06327061|EXPERIMENTAL|Experimental: Peer education and network support|During sessions 1 and 2, participants will be taught information and skills pertaining to overdose prevention and response. During the 3rd session, participants will trained to talk to their non drug using network members in overdose prevention and response.
62660457|NCT06327061|ACTIVE_COMPARATOR|comparison: Standard of care of health education|In one session, participants will receive the standard of care for overdose prevention.
61909275|NCT04552678|EXPERIMENTAL|Self-Regulation Only|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, but no Parent Education
61909276|NCT04552678|EXPERIMENTAL|Food Literacy + Parent Education|Classrooms receive the core Food Literacy Curriculum, and parents are invited to complete web-based education modules.
61909277|NCT04552678|EXPERIMENTAL|Food Literacy Only|Classrooms only receive the core Food Literacy Curriculum, and no other intervention materials or parent education.
62097049|NCT03756194|OTHER|Control arm 1|"Participants will utilize the socially-assistive control robot with an alternative CARESSES solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
62097050|NCT03756194|NO_INTERVENTION|Control arm 2|"Participants will be receiving conventional human care with no robot intervention.~Baseline assessments will be conducted as soon as participants are recruited and allocated to the study arm. Follow-up assessments will be conducted in two weeks after the baseline data collection."
62097051|NCT04960618|EXPERIMENTAL|Participants with confirmed mycosis fungoides/Sezary syndrome|Participants will have confirmed mycosis fungoides/Sezary syndrome, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher.
62097052|NCT06120361||Patients in primary care with cognitive symptoms|
62097053|NCT02201030|EXPERIMENTAL|NBP606|13-valent pneumococcal conjugate vaccine
62097054|NCT02201030|ACTIVE_COMPARATOR|Prevnar13|13-valent pneumococcal conjugate vaccine
62097055|NCT02379364|EXPERIMENTAL|Intervention group|Diacutaneous Fibrolysis treatment
61909278|NCT01065324||Anally inserted enteroscopy group|Anally inserted enteroscopy group
61909279|NCT01065324||Orally inserted enteroscopy group|Orally inserted enteroscopy group
61909280|NCT04204070|EXPERIMENTAL|Group I Accuro|epidural catheter insertion using the Accuro ultrasound imaging assisted technique
62660458|NCT04124965|EXPERIMENTAL|Rozanolixizumab dosage regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
61909281|NCT04204070|EXPERIMENTAL|Group II APAD|epidural catheter insertion using the real time ultrasound guided technique combined with the use of the acoustic puncture assist device (APAD) technique.
61909282|NCT05905744||patients with unexplained bile duct stenosis|Patients with unexplained bile duct stenosis undergo cholangioscopy examination and ERCP
61909283|NCT03105466|EXPERIMENTAL|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
61909284|NCT04668261||Neurosurgical patients|"• Neurosurgical diseases with the potential to alter blood flow to the brain:~* Cerebrovascular disease~* Brain tumors~* Normal Pressure Hydrocephalus"
61909285|NCT04668261||Healthy subjects|"* Male and Female subjects \>18 years of age~* Written Informed Consent by the participant after information about the project. Foreign speaking healthy subjects should be accompanied by a person with sufficient German language proficiency to act as a translator"
61909286|NCT01230177||Etanercept (genetical recombination)|Among the patients with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy), the patients who will have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
61909287|NCT02108340|EXPERIMENTAL|Microwave radiometry|Patients diagnosed with acute appendicitis will undergo a measurement of the temperature of the appendix with the use of microwave radiometry in a room temperature of 20 -24 degrees celsius.
61909288|NCT04458688||African Americans with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as African American.
61909289|NCT04458688||Caucasian American with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as Caucasian American.
61909290|NCT05262348|ACTIVE_COMPARATOR|Phase 1a - conventional stimulation|Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.
62097056|NCT00592748|ACTIVE_COMPARATOR|Group 1|40-44 Treatments
62097057|NCT00592748|ACTIVE_COMPARATOR|Group 2|37-40 Treatments
62097058|NCT03743922|EXPERIMENTAL|Oral calciferol group|Subjects will receive oral calciferol 20,000 iu per week during pregnancy until delivered
62097059|NCT03743922|PLACEBO_COMPARATOR|oral placebo group|Subjects will receive oral placebo 1 tab per week during pregnancy until delivered
62097060|NCT04021043|EXPERIMENTAL|Group I (ipilimumab, BMS-986156, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
62097061|NCT04021043|EXPERIMENTAL|Group II (ipilimumab, BMS-986156, SBRT, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
62097062|NCT04021043|EXPERIMENTAL|Group III (nivolumab, BMS-986156, SBRT)|Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
62097063|NCT05543369|EXPERIMENTAL|Cohort 1 : Healthy Japanese Participants|Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.
62097064|NCT05543369|EXPERIMENTAL|Cohort 2: Healthy Non-Asian Participants|Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.
62097065|NCT05574634|EXPERIMENTAL|Older adult participants|Older adult participants in the study will complete one of two variants of an attention practice program and that will be preceded by, and followed by, an fMRI scan session featuring an attention task
61909291|NCT05262348|EXPERIMENTAL|Phase 1b - adaptive stimulation|Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.
62097066|NCT05574634|NO_INTERVENTION|Younger adult participants|Younger adult participants in the study will complete one fMRI scan session featuring an attention task
62097067|NCT05682261|EXPERIMENTAL|Multiple micronutrient supplement arm|The participants in this arm will receive United Nations International Multiple Micronutrient-Multiple Micronutrient Supplements. The recommended doses of UNIMMAP-MMS are vitamin A as retinol acetate (800 µg RAE), vitamin D as cholecalciferol (5 µg), vitamin E as alpha-tocopherol succinate (10 mg), vitamin C as ascorbic acid (70 mg), vitamin B1 as thiamin mononitrate (1.4 mg), vitamin B2 as riboflavin (1.4 mg), vitamin B3 as nicotinamide (18 mg), vitamin B6 as pyridoxine hydrochloride (1.9 mg), vitamin B12 as cyanocobalamin (2.6 µg), folic acid (680 µg), iron as ferrous fumarate (30 mg), zinc as zinc oxide (15 mg), copper as copper oxide (2 mg), selenium as sodium selenite (65 µg), iodine as potassium iodide (150 µg). The UNIMMAP-MMS in the tablet form will be used. We will give the supplementation twice a week and follow the study participants for 17 weeks.
62097068|NCT05682261|EXPERIMENTAL|Iron-folic acid supplement arm|The participants in this arm will receive Iron-Folic Acid (IFA) supplements. The recommended doses of iron-folic acid are 30-60 mg of elemental iron and 400 µg of folic acid combined. In this trial, we will use ferrous sulfate with 30 mg of iron and 400 µg of folic acid in the form of capsule. The supplementation will be given to the study subjects twice a week for 17 weeks.
62097069|NCT05682261|PLACEBO_COMPARATOR|Control arm|The participants in this arm will receive placebos made of sugar (lactose anhydrous). There is no active ingredient in the placebos. The placebos are lactose powder filled in the capsule. We will give placebos twice a week and will follow the study subjects for 17 weeks. The study subjects in this arm will be compensated with UNIMMAP-MMS at the end of the intervention.
62097070|NCT04394871||ALS4 Patients|Patients with ALS4 inherited defect in the senataxin (SETX) gene.
62660459|NCT04124965|EXPERIMENTAL|Rozanolixizumab dosage regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
62660460|NCT05417113|ACTIVE_COMPARATOR|Bupivacaine only|bupivacaine 0.25% in ESP blocks
62097071|NCT04394871||Disease Control Participants|Disease control participants with mutation in other genes which alter RNA processing (e.g., RNASEH1+2 and loss of function SETX mutations in patients with ataxia and oculomotor apraxia type 2\[AOA2\]).
62660461|NCT05417113|EXPERIMENTAL|Liposomal Bupivacaine and Bupivacaine|liposomal bupivacaine in addition to 0.25% bupivacaine in ESP blocks
62660462|NCT06090240|EXPERIMENTAL|Motivational Interview|Older adult-family member dyads in this arm will receive an MI-based education intervention our team developed.
62097072|NCT04394871||Gain of Function|patients with gain of function mutations in genes that result in other forms of neurological disease, as well as select patients with mutation in the SETX gene (select ALS4 patients), will be enrolled and followed annuallt for 5 years.
62097073|NCT04394871||Related, Unaffected Healthy Controls|Unrelated, unaffected healthy relatives of the ALS4 and disease control groups enrolled as controls.
62097074|NCT04394871||Unrelated, Healthy Controls|Unrelated, healthy volunteers who are age and sex matched to the affected ALS4 and disease control participants.
62097075|NCT00264589|OTHER|Study Population|"non-diabetic obese subjects and type 2 diabetic subjects~Intervention: 8 weeks individualized training program"
62097076|NCT05331495|EXPERIMENTAL|Hemoperfusion and CPB and DHCA surgery|The experimental group was treated with hemoperfusion simultaneously with CPB and DHCA.
62660463|NCT06090240|NO_INTERVENTION|Self-learning|Older adult-family member dyads in this arm will receive a self-learning ACP educational material developed by the Hong Kong Hospital Authority.
62660464|NCT05208320|EXPERIMENTAL|intervention ward|"Patients received interventions as follow:~* The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~* Home health education by Community Health Workers every month for 6 months"
62660465|NCT05208320|NO_INTERVENTION|control ward|Patients received usual care, consisted of existing services in the community
62660466|NCT01136915|ACTIVE_COMPARATOR|IOPAMIDOL injection 370|
62097077|NCT05331495|NO_INTERVENTION|traditional CPB and DHCA surgery|The control group was treated with intraoperative CPB and DHCA surgery.
62660467|NCT01136915|ACTIVE_COMPARATOR|Iodixanol 320|
62097078|NCT04812470|EXPERIMENTAL|Autologous tumor infiltrating lymphocytes (TIL)|Autologous TIL administered via hepatic arterial infusion followed by low dose Interleukin-2 after preconditioning chemotherapy with Melphalan.
62660468|NCT04572815|EXPERIMENTAL|Arm I (ustekinumab)|Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive ustekinumab IV. Beginning 8 weeks after receiving IV ustekinumab, patients receive ustekinumab SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
62660469|NCT04572815|PLACEBO_COMPARATOR|Arm II (placebo)|Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive a placebo IV. Beginning 8 weeks after IV placebo, patients receive a placebo SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse, or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
62660470|NCT05407896|NO_INTERVENTION|Comparison arm|Patients and caregivers in this arm will receive existing counselling by trained counsellors.
62660471|NCT05407896|EXPERIMENTAL|Intervention arm|Patients and caregivers in this arm will receive counselling with the newly developed web-based decision aid (myKIDNEY) by trained counsellors.
62660472|NCT01695746||C.E.R.A.|Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months). Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information. Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
62294037|NCT06432738|PLACEBO_COMPARATOR|200mg ZL-82 placebo|Subjects in the multiple-dose group were fasted and water-free for at least 10 hours the night before dosing, and were given ZL once a day according to the random table requirements from day 1 (D1) to day 10 (D10) of the study. -82 tablets or placebo, and undergo safety inspections according to the study schedule and complete PK, PD, and Holter collection according to the PK, PD, and Holter collection schedule; after completing a series of safety inspections, PK, and PD sample collection on day 12 Safety follow-up was conducted on day 16 after leaving the clinical trial facility.
62097079|NCT06613828|EXPERIMENTAL|RAPIDO Strategy Arm|Participants in this arm receive educational training based on the RAPIDO strategy, an acronym developed to raise awareness of stroke symptoms among the Spanish-speaking community. This strategy is modeled after the English FAST mnemonic and focuses on the rapid identification of stroke symptoms.
62097080|NCT06613828|EXPERIMENTAL|CORRE Strategy Arm|Participants in this arm are trained using the CORRE strategy, created by a Colombian neurologist. It mirrors the structure of other mnemonic-based interventions and emphasizes the importance of quickly recognizing and acting upon early stroke symptoms.
62097081|NCT06613828|EXPERIMENTAL|DALE Strategy Arm|Participants in this arm are educated using the DALE strategy, developed in 2012 by researchers at the University of Guadalajara. Similar to the RAPIDO strategy, DALE adapts the FAST mnemonic for the Spanish-speaking population, promoting quick recognition and response to cerebrovascular symptoms.
62097082|NCT06613828|EXPERIMENTAL|CAMALEON Strategy Arm|In this arm, participants receive training based on the CAMALEON strategy, a mnemonic created in Costa Rica with the support of the pharmaceutical industry. The approach is designed to facilitate the recognition of early stroke symptoms by adapting the FAST mnemonic to Spanish.
62294038|NCT03358472|EXPERIMENTAL|Pembrolizumab + Epacadostat|
62294039|NCT03358472|EXPERIMENTAL|Pembrolizumab|
62294040|NCT03358472|ACTIVE_COMPARATOR|EXTREME|EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.
62294041|NCT03306654|ACTIVE_COMPARATOR|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
62294042|NCT03306654|PLACEBO_COMPARATOR|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
62294043|NCT03306654|SHAM_COMPARATOR|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
62294044|NCT02824484|EXPERIMENTAL|Guided Written Disclosure Protocol|GWDP consists of three 20-minutes writing sessions. Participants write every two weeks at home following the specific instructions for each session.
62294045|NCT02824484|PLACEBO_COMPARATOR|Control|Control condition consists of three 20-minutes writing sessions. Participants write every two weeks at home following the instructions. Their task is constructed to be emotionally neutral.
62294046|NCT03467906||Weight loss < median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
62660473|NCT02827968|EXPERIMENTAL|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1, 2.5, 5 and 10 mg/kg weekly.
62097083|NCT06613828|EXPERIMENTAL|ICTUS 911 Strategy Arm|Participants in this arm are educated using the ICTUS 911 strategy, which differs from the other four in that it is not directly based on a literal translation of FAST. Instead, it focuses on recognizing stroke symptoms and immediately calling emergency services (911) upon suspicion of a stroke.
62097084|NCT03942419|EXPERIMENTAL|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser
62097085|NCT03942419|EXPERIMENTAL|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser
62097086|NCT03942419|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser
62097087|NCT05062590|EXPERIMENTAL|Group Intervention|Experimental: Group 1 The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
62097088|NCT05062590|NO_INTERVENTION|Group control|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations
62097089|NCT00445627||Healthy Lean Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
62097090|NCT00445627||Overweight Obese Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
62097091|NCT00445627||Type 1 Diabetes|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
62097092|NCT03286205|ACTIVE_COMPARATOR|Weekly Dosage|weekly dose of 100mg
62097093|NCT03286205|ACTIVE_COMPARATOR|3 week dosage|every 3 week dosage.
62097094|NCT06443047|NO_INTERVENTION|ESD with clips|Closure of the defect will be performed at the end of the Endoscopic Submucosal Dissection procedure with clips (Boston scientific®). Pictures or movies of the closing defect will be necessary to independently confirm the complete closure.
62097095|NCT06443047|EXPERIMENTAL|TTS suturing system|Closure of the defect will be performed at the end of the ESD procedure with a new TTS suturing system (X-Tack Boston scientific®). Pictures or movies of the closing defect will be necessary to independently confirm the complete closure.
62097096|NCT01162655|EXPERIMENTAL|Telehealth|Complete CBT group via telehealth
62097097|NCT01162655|EXPERIMENTAL|Internet|Complete Internet-based CBT program
62294047|NCT03467906||Weight loss > median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
62294048|NCT01574534|EXPERIMENTAL|Drug eluting balloon|paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany
62466168|NCT06214364|SHAM_COMPARATOR|Sham Transcranial Direct Current Stimulation|"Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes.~The electrodes will be placed in the same positioned as for M1 stimulation in the experimental group, but the current will only be applied ramping for 30 seconds in the beginning and at the end of the procedure to secure the blinding.~While the sham tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the sham tDCS stimulation."
62737028|NCT06477003|EXPERIMENTAL|Arm 2 - radiotherapy patients|30 patients with clinically confirmed metastatic head and neck squamous cell carcinomas (N+ HNSCC) planned for definitive radiotherapy (RT) (+/- chemo) will be imaged using the MSOT device before, during, and after radiotherapy. 15 patients will be treated with photon RT and 15 patients will be treated with proton therapy. Skin temperature will be measured prior to and after MSOT imaging to assess for safety.
62097098|NCT05123716|EXPERIMENTAL|Experimental: Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 100 mg MDMA.
62097099|NCT05123716|EXPERIMENTAL|Experimental: MDMA Then Placebo|Participants first receive 100 mg MDMA at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
62097100|NCT04136236||esophageal mucosal lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy or IEE.
62294049|NCT01574534|ACTIVE_COMPARATOR|Drug eluting stent|paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA
62294050|NCT02943395|EXPERIMENTAL|dual cure amine free adhesive resin cement|resin cement that get activated by both light and chemicals
62294051|NCT02943395|ACTIVE_COMPARATOR|light cured adhesive resin cement|resin cement that only get activated by light
62294052|NCT03906825|ACTIVE_COMPARATOR|dietary supplement CEAG|The dietary supplements consists of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG).
62466169|NCT01346007|ACTIVE_COMPARATOR|patients|Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A
62294053|NCT03906825|PLACEBO_COMPARATOR|Placebo|The Placebo does not contain any CEAG.
62294054|NCT06316479|EXPERIMENTAL|Treatment group|All participants will receive PTMC Dermal Filler.
62294055|NCT00914693|EXPERIMENTAL|Arm 1|
62466170|NCT01346007|ACTIVE_COMPARATOR|controls|
62466171|NCT00099047|EXPERIMENTAL|Arm I (celecoxib)|Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
62097101|NCT03631147|EXPERIMENTAL|Rifaximin treatment group|Rifaximin 400mg bid for 8 weeks
62097102|NCT03631147|NO_INTERVENTION|The control group|
62097103|NCT04296240|EXPERIMENTAL|Neoadjuvant chemotherapy|Oxaliplatin 130mg/m2 d1 and Capecitabine 1250mg/m2 bid1-14 or other fluorouracils, every 21 or 14 days for 2 to 4 cycles, and efficacy evaluation every 2 cycles;
61909292|NCT03946722|OTHER|Standard downregulation with GnRH analogue|"Participants in this arm will be assigned to the routine IVF protocol currently being used in the investigators' IVF unit, as outlined below, with one week of downregulation. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Start progesterone (Norethisterone 5mg twice daily orally) on day 14 of downregulation cycle and continue for 11 days. Start GnRH analogue (Buserelin 0.5ml subcutaneously once daily) on day 21 of downregulation cycle and reduce to 0.2ml on day 1 of bleed. Baseline scan on day 1 - 5 of bleed and start oestrogen (Progynova 2mg three times daily orally). Serial scanning from day 10 until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
61909293|NCT03946722|EXPERIMENTAL|Prolonged downregulation with GnRH analogue|"Participants in this arm will be exposed to an additional five weeks of downregulation using a GnRH analogue. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Baseline scan on day 1-5 of bleed and administer GnRH analogue (Leuprorelin acetate 3.75 mg subcutaneously single injection). 28 days later administer second dose of GnRH analogue (Leuprorelin acetate 1.875 mg subcutaneously), and 21 days later start oestrogen (Progynova 2 mg three times daily orally). Serial scanning from day 10 of oestrogen until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
62097104|NCT01477229||Abdominoperineal resection|Patients with low rectal cancers
62097105|NCT01477229||Anterior resection|Patients where it is possible to perform an anterior resection
62466172|NCT00099047|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
62466173|NCT05941403|EXPERIMENTAL|Enhanced Produce Prescription Implementation|The study team will develop an enhanced implementation blueprint to support uptake of the produce prescription (VeggieRx) intervention that is informed by advisory board input and includes multiple implementation strategies to address identified barriers to implementation.
62466174|NCT04953832|EXPERIMENTAL|Cognitive Training + exposure|Participants will complete adaptive computerized cognitive training plus a series of speech tasks
62466175|NCT04953832|ACTIVE_COMPARATOR|No training + exposure|Participants will complete a low-dose computerized cognitive program plus a series of speech tasks
62466176|NCT03536130|EXPERIMENTAL|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter.
62097106|NCT01477229||Preoperative chemo-radiation treatment|Patients with locally advanced rectal cancer
62097107|NCT01477229||Palliative treatment|Patients with systemic disease
62294056|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 1 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62466177|NCT03536130|NO_INTERVENTION|Traditional device|Patients in the no intervention (traditional) arm are connected to traditional drain system with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with traditional devices (requiring connection to wall suction) are managed by applying suction (-20 cmH2O) until the morning of POD 1 and are subsequently disconnected from suction thereafter.
62466178|NCT03079050|EXPERIMENTAL|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
62466179|NCT01387022|EXPERIMENTAL|Tenofovir, lamivudine and efavirenz|
61909294|NCT02536261||Withdrawal group|Withdrawal observation after reaching the withdrawal standard
61909295|NCT02536261||Continue treatment group|Continue treatment obsevation after reaching the withdrawal standard
62097108|NCT05838612|EXPERIMENTAL|Heat Acclimation|Participants will undergo an exercise heat stress test prior to and following seven consecutive days of warm-water immersion (\~40°C) of 1-hour duration with core temperature clamped at 38.5°C. During the exercise-heat stress test participants will perform three, successive 30-minute bouts of semi-recumbent cycling performed at increasing fixed loads of metabolic heat production of 150, 200 and 250 W/m2 (i.e., exercise bout 1, exercise bout 2 and exercise bout 3, respectively), each separated by 15-minute of rest break with the final recovery extended to 1-hour.
62466180|NCT01387022|ACTIVE_COMPARATOR|Zidovudine, lamivudine and efavirenz|
62660474|NCT04100057|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomina (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
62660475|NCT04100057|ACTIVE_COMPARATOR|Desensitization Therapy for Insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
62660476|NCT01708603|EXPERIMENTAL|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
62660477|NCT01708603|EXPERIMENTAL|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
62660478|NCT01708603|ACTIVE_COMPARATOR|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
62660479|NCT01708603|PLACEBO_COMPARATOR|Placebo|Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
62660480|NCT01014091|EXPERIMENTAL|GSK2340272A F1 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
62660481|NCT01014091|EXPERIMENTAL|GSK2340272A F1 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
62660482|NCT01014091|EXPERIMENTAL|GSK2340272A F2 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
62660483|NCT01014091|EXPERIMENTAL|GSK2340272A F2 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
62660484|NCT01014091|EXPERIMENTAL|GSK2340272A F3 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
62660485|NCT01014091|EXPERIMENTAL|GSK2340272A F3 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
62660486|NCT01474187|EXPERIMENTAL|Irinotecan|irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week
61909296|NCT03740984|EXPERIMENTAL|Hypnosis / Hypnotherapy|Hypnosis intervention has been created by a certified hypnosis therapist (Prof. Reinhard) has been audio-recorded. The hypnosis intervention is based on the patient's happy place as well as many other interventions which all focus on support and wellbeing (total recording time ca. 4 ½ hours). All patients are advice to start with the beginning, however during the course of chemotherapy they are allowed to skip mp3 files, if they prefer to listen to a new intervention.
62097109|NCT02228603|EXPERIMENTAL|high-intensity exercise|community-based group program: weekly supervised high-intensity exercise training during 8 weeks, followed by group counselling every third month for 12 months
62660487|NCT03882099||Pregnant women with pre-eclampsia|
62660488|NCT03882099||Pregnant women with eclampsia|
62660489|NCT03882099||Normotensive pregnant women|
62097110|NCT02228603|ACTIVE_COMPARATOR|web-based follow-up|web-based follow-up program: home-based group will be followed up by mail and telephone calls the first 8 weeks, then every third month for 12 months
62660490|NCT04525820|EXPERIMENTAL|High Dose Vitamin D|"Patient will receive a single high dose of vitamin D (140'000) in addition to daily 800 IU of vitamin D.~The medication be administered orally"
62097111|NCT02228603|OTHER|control|control group will receive usual care: information about recommended physical activity and healthy lifestyle
62097112|NCT00038792|EXPERIMENTAL|aGvHD|
62097113|NCT05191797|EXPERIMENTAL|Treatment (bomedemstat, atezolizumab)|Patients receive bomedemstat PO QD on days 1-21 and atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62097114|NCT03975387|EXPERIMENTAL|ASTX295|
62097115|NCT01542619|EXPERIMENTAL|rVIIa-FP|
62097116|NCT01542619|PLACEBO_COMPARATOR|Placebo (0.9% normal saline)|
62466181|NCT00938834|ACTIVE_COMPARATOR|CFQ Qigong training group|"Qigong training con- sisted of an initial workshop conducted over three con- secutive half-days by a qualified CFQ instructor. Participants received training in level 1 CFQ; this con- sisted of instruction in seven key movements known as the hexagram and ancillary exercises. Hexagram move- ments consist of choreographed movements that emphasize softness, relaxation, downward releases and full body distribution of qi. Once initial training was complete, participants were asked to practice CFQ at home for 45 to 60 minutes per day for eight weeks; time could be broken up into shorter sessions during the day. Participants returned for a 60 minute weekly review/group practice sessions for these eight weeks."
61909297|NCT03740984|EXPERIMENTAL|Music therapy|"For the music therapy the following music recordings have been used. All patients were allowed to skip tracks if they did not like to listen to that particular track.~Purple Waves - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Black Garden View - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Sunset Destination - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Crystal Tree - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Best nature sounds / Ocean Volume 2 - Best Relaxation Music - Deep Sleep Top 10 Serse: Aria Ombra mai Fu - Andreas Scholl, Akademie für Alte music Berlin - Händel Johann Sebastian Bach: Jesus Bleibet Meine Freude (Studio) - Eduard Stan - Piano Recital Mozart: Concerto pour violon no 4 en re majeur, KV (Köchel listing) 218 - Christian Ferras; Pietro Argento; Orchestra Scarlatti di Nap - La fete a Stradivarius~... etc."
61909298|NCT03740984|PLACEBO_COMPARATOR|Standard therapy|In this standard therapy the patient listens to a short explanation that they were randomized into the control arm and that they are allowed to listen to silence (tracks with no music or intervention).
61909299|NCT02588001|EXPERIMENTAL|Enzalutamide Group|
61909300|NCT03276169|EXPERIMENTAL|Left atrial appendage closure group|
61909301|NCT03276169|OTHER|Radiofrequency ablation group|
62466182|NCT06283186|EXPERIMENTAL|Lower limb cycle ergometer|The participants in the lower limb cycle ergometer group will undergo a 30-minute aerobic exercise intervention comprising a 5-minute warm-up, 20 minutes of training at 70-80% of the heart rate reserve, and a 5-minute cool-down.
62466183|NCT06283186|EXPERIMENTAL|Upper limb cycle ergometer|The participants in the upper limb cycle ergometer group will undergo a 30-minute aerobic exercise intervention comprising a 5-minute warm-up, 20 minutes of training at 70-80% of the heart rate reserve, and a 5-minute cool-down.
61909302|NCT03276169|EXPERIMENTAL|LAAC combined with radiofrequency ablation group|
61909303|NCT03073551|NO_INTERVENTION|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
62097117|NCT02656940|EXPERIMENTAL|Group 1 - diet rich in n-3 and n-6 PUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 1 received diet rich in n-3 and n-6 polyunsaturated fatty acids (PUFA). The volunteers were asked to consume daily a mixture of virgin olive oil and soybean oil, totaling 35.2g to 52.8g, and 2 g of fish oil."
62097118|NCT02656940|EXPERIMENTAL|Group 2 - diet rich in MUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 2 received diet rich in monounsaturated fatty acids (MUFA). The volunteers were asked to consume daily virgin olive oil, totaling 35.2g to 50.6g, and 1 capsule of 1g of soybean oil."
62097119|NCT02656940|EXPERIMENTAL|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming 1 sachet of 2g of soybean oil and 1 capsule of 1g of soybean oil by day.
62097120|NCT01065272|ACTIVE_COMPARATOR|Ventolin - Dexamethasone group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
62097121|NCT01065272|PLACEBO_COMPARATOR|Ventolin - Placebo group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
62097122|NCT01726959||Methotrexate|Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly
62097123|NCT06408246|EXPERIMENTAL|Sertraline + Guanfacine|We will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-). We will enrich for C+, the signature of interest, at a 2:1 ratio. Participants will be randomly assigned to receive guanfacine (shown to ameliorate cognitive control deficits in our preliminary data) plus sertraline or placebo plus sertraline.
62097124|NCT06408246|EXPERIMENTAL|Sertraline + Placebo|We will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-). We will enrich for C+, the signature of interest, at a 2:1 ratio. Participants will be randomly assigned to receive guanfacine (shown to ameliorate cognitive control deficits in our preliminary data) plus sertraline or placebo plus sertraline.
62097125|NCT02336893|NO_INTERVENTION|Pre-intervention|Family members of patients admitted to the ICU from August to December 2013 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
62097126|NCT02336893|EXPERIMENTAL|Post-intervention|Family members of patients admitted to the ICU from March to August 2014 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
62660491|NCT04525820|PLACEBO_COMPARATOR|Placebo|Patient will receive a single dose of placebo, orally administered and then treatment as usual (daily 800 IU of vitamin D, orally administered)
62097127|NCT02516774|EXPERIMENTAL|Dose escalation|Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
62097128|NCT00266097|EXPERIMENTAL|Part I|Oxaliplatin + Gemcitabine + Radiation
62097129|NCT00266097|EXPERIMENTAL|Part II|Erlotinib + Oxaliplatin + Gemcitabine + Radiation
62097130|NCT03975660|EXPERIMENTAL|Part 1 Device Calibration|50 patients requesting epidural labor analgesia will have pain levels monitored during labor.
62097131|NCT03975660|EXPERIMENTAL|Part 2 Device Validation|60 patients requesting epidural labor analgesia will have pain levels monitored during labor.
62097132|NCT04497584|EXPERIMENTAL|Afatinib + Prednisone|"Afatinib 40 mg PO daily~Prednisone 40 mg PO daily starting 7 days after Afatinib"
62660492|NCT02787291|OTHER|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
62660493|NCT03205631|SHAM_COMPARATOR|Sham Natural Frequency Patch|
62660494|NCT03205631|ACTIVE_COMPARATOR|Active Natural Frequency Patch|
62097133|NCT03424928|EXPERIMENTAL|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
62097134|NCT03424928|EXPERIMENTAL|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
62097135|NCT03397914|EXPERIMENTAL|Group A Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 2.5 mg/kg of colistimethate sodium intravenous as loading dose followed by 1.25 mg/kg every 12 hours as maintenance dose
62097136|NCT03397914|EXPERIMENTAL|Group B Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 5 mg/kg of colistimethate sodium intravenous as loading dose followed by 2.5 mg/kg every 12 hours as maintenance dose
62097137|NCT05122403||FUS Thalamotomy|The cohort includes patients with neuropathic pain who underwent MRgFUS central lateral thalamotomy.
62466184|NCT06283186|NO_INTERVENTION|Control|Participants in the control group will remain seated for the entire 30-minute duration of the experiment without receiving any form of distraction.
62466185|NCT02809469|EXPERIMENTAL|Dose reduction|Eligible patients with apixaban levels persistently above 170ng/mL on two occasions, 2 weeks apart, will undergo apixaban dose reduction.
62660495|NCT03547570|EXPERIMENTAL|Heavy shoulder resistance training|Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.
62660496|NCT02226900|EXPERIMENTAL|Hybrid Revascularization|The hybrid myocardial revascularization group will be accomplished by a two-step scheme, comprised by off-pump LIMA-to-left anterior descending grafting, followed by percutaneous coronary interventions with Promus Element (everolimus second generation drug eluting stent) for the remaining coronary lesions.
62660497|NCT02226900|OTHER|Conventional Surgical Coronary Bypass Grafting|Conventional Coronary Artery Bypass Grafts with in pump technique.
62660498|NCT03027934|ACTIVE_COMPARATOR|Group 1|
62097138|NCT05122403||Sham Procedure|The cohort includes patients with neuropathic pain who underwent sham MRgFUS central lateral thalamotomy.
62097139|NCT00234143|ACTIVE_COMPARATOR|Aranesp and Neupogen|solution for subcutaneous injection , syringe 500 mcg and 300 mcg respectively
62660499|NCT03027934|ACTIVE_COMPARATOR|Group 2|
62294057|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 2 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62466186|NCT03707912|EXPERIMENTAL|Anaferon|"1 tablet per administration. Day 1: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals through the rest of the day.~Days 2-5: 1 tablet 3 times a day. The drug is taken out of the meal (in the interval between meals or 15-30 minutes before eating), keep the tablet in the mouth, without swallowing, until completely dissolved."
62466187|NCT03707912|PLACEBO_COMPARATOR|Placebo|Placebo using Anaferon regimen until the end of the study.
62660500|NCT05672056|EXPERIMENTAL|Intervention|The intervention will be modifying stock reconstruction plates to mimic patient specific plates in mandibular reconstruction with free fibula flaps
61909304|NCT03073551|ACTIVE_COMPARATOR|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
61909305|NCT05288907||Pruritus ani patients|Adult patients with pruritus ani (rectal itch) treated with lidocaine ointment
61909306|NCT05062434|EXPERIMENTAL|Intervention Arm|VA cardiac electrophysiologists receiving the intervention
61909307|NCT05453734|EXPERIMENTAL|Experimental Group: The group applied Progressive Muscle Relaxation Exercises|Introductory information form and EPDS were completed by the mothers before the PMR exercises. PMR exercises were applied and training was given to the mothers by the researcher in the milking room (a quiet room) located on the NICU floor (approximately 40 minutes). The application was continued until the mother was able to do the PMR exercises on her own. After the application and training, the mother was given guidance on PMR. The mother was asked to perform the exercises twice a day, in the morning and evening, and record them on the follow-up form. The researcher's contact number was given to the mother for counseling in case she had difficulty following the steps of the PMR exercises. During the follow-ups, the mother was called by the researcher and a message was sent to ensure her continuity in the exercises. At the end of the 1st and 2nd weeks of the follow-up, BSES, EPDS and patient follow-up forms were filled when the mother came for routine controls.
61909308|NCT05453734|NO_INTERVENTION|Control group: The group without any ıntervention|Introductory information form, the BSES, and the EPDS were initially applied to the mothers. At the end of the 1st and 2nd weeks of the follow-up, the BSES and the EPDS were applied to the mothers. At the end of the 2nd week, it was told the mothers how to practice the PMR exercises and the guideline on the PMR exercises was given to them.
61909309|NCT04698577|EXPERIMENTAL|Attention Training|"Engaged in sustained updating by mentally keeping score during an interactive game without written or verbal aids.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
61909310|NCT04698577|ACTIVE_COMPARATOR|Active Control|"Played the same interactive game as the attention training group without the requirement of mentally keeping score.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
61909311|NCT02905396|EXPERIMENTAL|Spinal cord stimulation|implantation of spinal cord stimulator
61909312|NCT05974462|EXPERIMENTAL|Pulsed corticosteroid therapy|IV methylprednisolone 125 mg daily for 3 days diluted in saline solution 250 ml on top of standard therapy.
61909313|NCT05974462|PLACEBO_COMPARATOR|Placebo|IV saline solution 250 mL daily for 3 days on top of standard therapy.
61909314|NCT04197453||Consented Arm|Subjects with a recent (within 18 months) hospitalization for myocardial infarction, unstable angina, ischemic stroke, or critical limb ischemia, and subjects undergoing coronary, peripheral, or carotid revascularization, including surgical and percutaneous revascularization, with an LDL-C greater than or equal to 70 mg/dL who may be eligible for PCSK9 inhibitor therapy.
62097140|NCT00234143|ACTIVE_COMPARATOR|Aranesp|solution for subcutaneous injection, 500 mcg
62660501|NCT05393219|EXPERIMENTAL|Cardiac Biofeedback|Relaxing breathing exercise coupled with cardiac biofeedback
62660502|NCT05393219|EXPERIMENTAL|Mindfulness|Mindfulness guided through a video tape
62660503|NCT05393219|EXPERIMENTAL|Inner resource mobilization|Resources and inner strength mobilization guided through a video tape
62097141|NCT00234143|NO_INTERVENTION|Best supportive care|Red cell transfusion support
62097142|NCT00478556|ACTIVE_COMPARATOR|1|Gastroview
62660504|NCT05393219|SHAM_COMPARATOR|Control|Standardized video tape
62660505|NCT01816269||Patients with scaling and patients without scaling|No drug
62097143|NCT00478556|EXPERIMENTAL|2|Omnipaque
62660506|NCT01816269||Helicobacter eradicated or non-eradicated|
61909315|NCT04197453||Electronic Health Record (EHR) arm|Subjects with an inpatient or outpatient diagnosis of clinical ASCVD within the prior 12 months including coronary heart disease, ischemic cerebrovascular disease, atherosclerotic peripheral arterial disease, or prior coronary or peripheral or carotid revascularization.
61909316|NCT04837352||Multiple sclerosis patients|Patients with multiple sclerosis over 18 years old who have already started a long-term treatment and consent to participate to the study
61909317|NCT02447224|EXPERIMENTAL|Antibiotics|Once-a-day dose of IV/IM ertapenem for at least two days and cefdinir and metronidazole, to complete 10 days total antibiotic therapy.
62466188|NCT02134834|EXPERIMENTAL|Ascending single dose of OP0595|
62660507|NCT00368550|EXPERIMENTAL|1|Oral sertraline, cognitive-behavioral counseling to maintain abstinence from alcohol
61909318|NCT02447224|ACTIVE_COMPARATOR|Appendectomy|Patients in the surgery therapy arm will only receive one dose of IV ertapenem prior to surgery.
62466189|NCT02134834|PLACEBO_COMPARATOR|Normal Saline|
62466190|NCT01467765|ACTIVE_COMPARATOR|Elemental diet|
62466191|NCT01467765|PLACEBO_COMPARATOR|Liquid nutrient|
62660508|NCT00368550|PLACEBO_COMPARATOR|2|Placebo, cognitive-behavioral counseling to maintain abstinence from alcohol
62660509|NCT04795349|EXPERIMENTAL|NAC Patients.|Breast cancer patients after NAC completion, prior to surgery
62660510|NCT03692962|SHAM_COMPARATOR|Sleep restriction without acoustic stimulation|
61909319|NCT03149367|EXPERIMENTAL|Fixed suture|
61909320|NCT03149367|EXPERIMENTAL|Adjustable suture|
61909321|NCT01037088|EXPERIMENTAL|Mild dose cannabis|3.53% THC by weight
61909322|NCT01037088|EXPERIMENTAL|Low dose cannabis|1.29% THC by weight
61909323|NCT01037088|PLACEBO_COMPARATOR|Placebo cannabis|placebo marijuana
62466192|NCT02305706|EXPERIMENTAL|Right|patients will be positioned on the right-lateral position at the start of colonoscopy
62466193|NCT02305706|ACTIVE_COMPARATOR|Left|patients will be positioned on the left-lateral position at the start of colonoscopy
62660511|NCT03692962|EXPERIMENTAL|Sleep restriction with acoustic stimulation|
62466194|NCT02698982|EXPERIMENTAL|Monitoring|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring accessible to the anesthesia provider.
62660512|NCT02469909|OTHER|immediate decannulation|In the immediate decannulation group - the tracheostomy tube is removed and the patient would be monitored overnight in an intermediate monitored unit. On the next day a clinical evaluation would be held, and the patient would be discharge or transferred to his department according to the clinical course of the patient
62660513|NCT02469909|OTHER|Gradual tracheostomy tube decrease|In the gradual decannulation group The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
62660514|NCT02588365|EXPERIMENTAL|Brain Training (Active)|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
62660515|NCT02588365|EXPERIMENTAL|Brain Training (Passive)|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent level."
62660516|NCT02588365|EXPERIMENTAL|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
62097144|NCT03743012|EXPERIMENTAL|Integrated cardiac rehabilitation|Participants enrolled in integrated cardiac rehabilitation plus usual care
62097145|NCT03743012|ACTIVE_COMPARATOR|Usual Care|Participants receiving usual care only
62097146|NCT01112735|EXPERIMENTAL|ARTISS|ARTISS will be used as an adjuvant to standard of care.
62466195|NCT02698982|SHAM_COMPARATOR|Sham|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring blinded to the anesthesia provider
62466196|NCT02698982|NO_INTERVENTION|Control|elderly non scheduled for surgery
62466197|NCT06314737||Neoadjuvant therapy group|The primary tumor received neoadjuvant therapy before surgical treatment.
62466198|NCT06314737||Surgical treatment group|The primary tumor did not receive neoadjuvant therapy before surgical treatment.
62660517|NCT01115231||Group 1 (Control)|Case control subjects without AMD diagnosis
62660518|NCT01115231||Group 2 (Age-related Macular Degeneration)|Case (i.e., within 5 years) subjects will be recruited. Cases are defined as subjects with diagnosed AMD.
62660519|NCT02078037|EXPERIMENTAL|Arctic Sun cooling device|The Arctic Sun device pads will be placed on the patient as per manufacturer's instructions. Patients, who cannot tolerate placement of all the pads for any given reason, will still be included in the study if they can maintain normothermia (normal body temperature). The total normothermia time for the study is five days. After 5 days, the attending physician will make clinical decisions based on the patient needs.The temperature goal for this study is 36.5 degree Celsius, but normothermia for the purpose of this study will be defined as a temperature of 35.5 - 37.5 degree Celsius. A thermometer mounted urinary catheter will be used for temperature monitoring and feedback to the Arctic Sun.
62466199|NCT02134080|ACTIVE_COMPARATOR|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
62660520|NCT02078037|ACTIVE_COMPARATOR|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician) initiated at a temperature of 38.5 degrees Celsius
62660521|NCT00679198|EXPERIMENTAL|1|We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers
62660522|NCT00679198|NO_INTERVENTION|2|Standard care
62660523|NCT03137004|EXPERIMENTAL|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
62660524|NCT01809067|ACTIVE_COMPARATOR|Lavender Aromatherapy Inhalers|Lavender Aromatherapy Inhalers
62097147|NCT01112735|OTHER|Standard of care|Standard of care
62097148|NCT06615089|EXPERIMENTAL|balance training|thirty elderly patients will receive balance training and orthotic prescription for four months
62097149|NCT06615089|ACTIVE_COMPARATOR|orthotic prescription|thirty elderly patients will receive orthotic prescription for four months
62097150|NCT00825474|EXPERIMENTAL|survival rate|therapeutic effect of partial hepatectomy or TACE plus PEI for small hepatocellular carcinoma
62660525|NCT01809067|NO_INTERVENTION|No aromatherapy|No aromatherapy
62660526|NCT03846232||Cognitive impairment. Alzheimer's disease|Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers)
62660527|NCT03846232||Cognitively unimpaired, preclinical Alzheimer's disease|Normal cognition as defined by the ALFA study cognitive workup Positive amyloid PET in the last 30 months
62660528|NCT03846232||Cognitively unimpaired, control|Normal cognition as defined by the ALFA study cognitive workup Negative amyloid PET in the last 30 months
62097151|NCT04926324|EXPERIMENTAL|Cohort 1 (starting)|niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
62466200|NCT02134080|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill) will be administered orally at 4mg daily for four weeks.
62466201|NCT01219322|EXPERIMENTAL|intravenous bicarbonate|Intravenous bicarbonate(05meq/cc ) 50 cc will be injected.
62466202|NCT01219322|PLACEBO_COMPARATOR|Intravenous injection of 50 cc normal saline|Injection of volume equivalent of normal saline to compare the establish the effect of same volume as the experimental drug
62466203|NCT03447262|EXPERIMENTAL|VX-659/TEZ/IVA TC|Participants from parent studies VX17-659-102 (NCT03447249) or VX17-659-103 (NCT03460990) were administered VX-659 240 milligrams (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the TC treatment period for up to 96 weeks in the current study VX17-659-105.
62660529|NCT05926713|EXPERIMENTAL|nutritional supplements and supervised exercise on Sarcopenia group and Severe Sarcopenia group|The intervention consisted of providing nutritional supplements and supervised exercise for 12 weeks. After the intervention (the 12th week), the trial commissioned company provides nutritional supplements with a market price of about NT$4,000 per month for three months free to participants who are willing to continue taking the products. Those participants will be tracked for one year.
62097152|NCT04926324|EXPERIMENTAL|Cohort 2|niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
62466204|NCT05813340|EXPERIMENTAL|vascularized interpositional periosteal connective tissue flap|Vascularized inter-positional periosteal connective tissue flap (VIPCTF) may have many advantages over traditional collagen membranes such as; high vascularity, decreased cost (as it may substitute membrane), providing an increase in soft tissue thickness, and reusability.
62660530|NCT00844519|ACTIVE_COMPARATOR|Maraviroc|For subjects assigned to the maraviroc group, subjects will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medication. For subjects on ritonavir, the dose of maraviroc will be 150mg by mouth twice daily.
62660531|NCT00844519|PLACEBO_COMPARATOR|Placebo|
62660532|NCT02996786|EXPERIMENTAL|Danggui Buxue Tang group|Danggui Buxue Tang group receive orally supplementation of 7.5 g/day of Danggui Buxue Tang for 10 days
62660533|NCT02996786|PLACEBO_COMPARATOR|Placebo group|Placebo group receive orally supplementation of 7.5 g/day of placebo for 10 days
62660534|NCT06023290|OTHER|Study population (single arm)|
62660535|NCT05289882|EXPERIMENTAL|PASS Program Condition|Participants in this condition will take part in weekly physical activity, augmented with built-in opportunities to socially connect, and be directed to veteran-specific support services and resources.
62660536|NCT05289882|NO_INTERVENTION|Waitlist Control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 6-month assessment period (following randomization). They will be asked to complete the same measures (and will be remunerated in the same way as those in the PASS program condition, based on the completion of study measures). At the end of the 6-month trial, participants in this condition will have the opportunity to participate in the PASS program.
62660537|NCT02715557|EXPERIMENTAL|Full Access to the relapse prevention program|The participants will receive access to the relapse prevention program throughout the entire 6-week trial period.
62660538|NCT02715557|EXPERIMENTAL|TAU|The participants will receive treatment as usual (TAU) for 6-weeks, and will receive access to the relapse prevention program after the completion of the 6 month follow-up.
62660539|NCT02076841||interferon beta-1a|30 μg intramuscularly once a week using an injection device (Avonex Pen).
62660540|NCT01886560|PLACEBO_COMPARATOR|Placebo|Adding eatable flour into the pills
62660541|NCT01886560|EXPERIMENTAL|Doxycycline treatment|Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
62660542|NCT05104346|PLACEBO_COMPARATOR|Patients in group I (G1) had AA prior to the era of COVID|Patients in group I (G1) had AA prior to the era of COVID
62660543|NCT05104346|ACTIVE_COMPARATOR|patients in group II (G2) had AA during COVID|patients in group II (G2) had AA during COVID
62660544|NCT04475510|EXPERIMENTAL|Antiplatelet treatment discontinuation|At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
62660545|NCT02394275|EXPERIMENTAL|Single arm:|Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
62660546|NCT01372956||Dyslipidemia|
62660547|NCT02235740|EXPERIMENTAL|Afuresertib 125 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive Afuresertib 125 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m\^2: Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg (increased dosage of 27 mg/meter (m)\^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
61909324|NCT01583556||Standard treatment|This study will employ a prospective, non-randomized design. After the questionnaires are filled the patients choose whether or not to schedule a second appointment for evaluation of their fracture: The first group will be scheduled for a second visit (standard treatment) as our daily practice after 1-3 months. They will be contacted after 2-6 months either by phone or email and will complete again some questionnaires (Quick DASH, satisfaction, return to work).
61909325|NCT01583556||Optional follow-up group|The alternative (Optional follow-up group) will be to take a handout describing the recovery and providing instructions for how to contact us should they get off course. The questionnaires will be repeated either by phone or email in 2-6 months.
61909326|NCT05874167|EXPERIMENTAL|Sequence A|Period 1: Linagliptin and Metformin / Period 2: DW6013
62097153|NCT03836664|EXPERIMENTAL|Group 1: Timolol|Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
62466205|NCT05813340|ACTIVE_COMPARATOR|collagen membrane|Collagen membranes are the most commonly used and can inhibit soft tissue growth in bone defects, They achieve better wound healing and bone regeneration.
62466206|NCT02845739|EXPERIMENTAL|kidney transplanted patient|
62466207|NCT02133105|ACTIVE_COMPARATOR|Levosimendan|Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
62660548|NCT02235740|EXPERIMENTAL|Afuresertib 150 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive oral Afuresertib 150 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m\^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m\^2 (increased dosage of 27 mg/m\^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
61909327|NCT05874167|EXPERIMENTAL|Sequence B|Period 1: DW6013 / Period 2: Linagliptin and Metformin
62097154|NCT03836664|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
62294058|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 3 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62466208|NCT02133105|ACTIVE_COMPARATOR|Dobutamine|Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.
62466209|NCT04963491|EXPERIMENTAL|3D printed personalized TKA prosthesis|Design：Personalized TKA prosthesis Manufacture：3D
61909328|NCT04441190|EXPERIMENTAL|Digital Action Observation Therapy (Digital AOT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
61909329|NCT04441190|EXPERIMENTAL|Digital Mirror Therapy (Digital MT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
62466210|NCT04963491|ACTIVE_COMPARATOR|Zimmer NexGen TKA prostheses|Prosthesis has been widely used in clinic
61909330|NCT04441190|ACTIVE_COMPARATOR|Conventional Occupational Therapy|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
61909331|NCT00812760|EXPERIMENTAL|1|
61909332|NCT04427332||Covid19 infection related patients|"All subjects that had access to the nasopharyngeal swabs service of the hospital for the detection of the Sars-CoV-2 virus, both hospitalized and discharged from the hospital and not hospitalized, from mid-May to the end of June 2020, will be consecutively enrolled. It is assumed that 500 people will be recruited."
61909333|NCT00833417|EXPERIMENTAL|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
61909334|NCT03717272|EXPERIMENTAL|AEF0117|AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
61909335|NCT03717272|PLACEBO_COMPARATOR|Placebo oral capsule|corn oil capsules once a day for 5 consecutive days.
61909336|NCT01484288|EXPERIMENTAL|Device group|Barostim Neo system
61909337|NCT00622271|OTHER|Wait List Control|Patients and their families will be enrolled into either a treatment group or a wait list control (WLC) group to receive the group therapy intervention.
62466211|NCT03365115|ACTIVE_COMPARATOR|intrathecal fentanyl|
62466212|NCT03365115|ACTIVE_COMPARATOR|intrathecal morphine|
62466213|NCT03365115|EXPERIMENTAL|intrathecal morphine and fentantyl|
62097155|NCT05708417|EXPERIMENTAL|Weight neutral intervention|"The intervention is based on the concept of Acceptance and Commitment Therapy (ACT) and is conducted by specially trained physiotherapist and a dietician. The intervention in SDOI has the predominantly focus on each individual reflection and realization and is built upon ACT' six core processes. Specific focus on teach participant with different narrative and background and on coaching and back-and-forth dialogue with physiotherapist and dietician. The program is based on up to 13 times attendance within the 12 months intervention period. Part 1: Three to five individual coaching, Part 2: six group sessions and Part 3: one or two individual coaching.~Compliance to the intervention is classified as 'good' if the participants participate for a minimum four out of six group sessions, a minimum three out of five initial individual coaching and a minimum one out of two individual coaching post intervention."
62466214|NCT01163591||Case|Patients with overt diabetic nephropathy as evidenced by ACR greater than or equal to 30mg/mmol on urinalysis and eGFR greater than or equal to 15ml/min/1.73m2 and less than 60ml/min/1.73m2
62466215|NCT01163591||Control|Patients without diabetic nephropathy as defined by the absence of albuminuria (defined by a random spot urinary ACR \<2.5 mg/mmol in women or ACR\<3.5 mg/mmol in men)and eGFR greater or equal to 90 ml/min/1.73m2
62466216|NCT00971256||Bladder cancer patients|Bladder cancer patients from one Beaumont Urologist.
62466217|NCT03004820|EXPERIMENTAL|Remote Ischemic Conditioning|RIC (remote ischemic conditioning) consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
62660549|NCT02235740|EXPERIMENTAL|Afuresertib 100 mg+ Carfilzomib (Part 1)|An additional arm with 100 mg of afuresertib may be evaluated if the other 2 arms are not tolerated. Approximately 8 subjects will receive Afuresertib 100 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m\^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m\^2 (increased dosage of 27 mg/m\^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
62660550|NCT02235740|EXPERIMENTAL|Afuresertib/carfilzomib (Part 2)|Approximately 50 subjects will receive Afuresertib Recommended Phase 2 Dose (RP2D) daily starting Cycle 1 Day 1 + Carfilzomib 20 mg/m\^2 Cycle 1, Day 1, 2. Carfilzomib 27 mg (increased dosage of 27 mg/m\^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15 and 16; Cycle Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9 and 15 and 16 of each cycle.
61909338|NCT03970408||Carpal tunnel syndrome|"Patients with CTS who fulfill the following eligibility criteria:~Inclusion criteria~* Females and male patients referred with a CTS diagnosis confirmed by nerve conduction studies and positive Tinel and Phalen tests.~* Age ranging from 30-50 years old.~* The selected patient will be able to tolerate the entire standard neurodynamic technique.~Exclusion criteria~* Symptoms referred to the neck.~* Sever CTS~* More than 10% limitation of neck flexion, rotation, and side bending ranges.~* History of disease, trauma, or surgery to neck, thorax, or upper limbs.~* Presence of peripheral neuropathy or cervical radiculopathy.~* History of systemic disease associated with neuropathies such as diabetes mellitus, connective tissue diseases, thyroid disease, or obesity."
61909339|NCT03970408||Healthy control|Asymptomatic healthy age-matched control with no symptoms or history of upper quadrant disease, dysfunction, trauma or surgery.
61909340|NCT03756493|EXPERIMENTAL|OFD+ABG+L-PRF treated patients|Periodontal surgery with Leukocyte and Platelet Rich Fibrin (L-PRF) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous bone graft mixed with cutted L-PRF will be applied to the furcation defects; then, a L-PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures.
61909341|NCT03756493|ACTIVE_COMPARATOR|OFD+ABG treated patients|Periodontal surgery with Autogenous Bone Graft (ABG) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. ABG will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
61909342|NCT03756493|ACTIVE_COMPARATOR|OFD treated patients|Periodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
62097156|NCT05708417|PLACEBO_COMPARATOR|Reference group|The reference group will not receive the intervention in the study and only participate in the test/data collection. The reference group will established consisting of participants participating in the SDOI program but, who of some reasons have refused participating in the lifestyle program. In case of insufficient recruitment of participants to the reference group, individuals meeting inclusion criteria such as age and BMI will be recruited via advertising in local newspapers and social media.
62097157|NCT06119191|EXPERIMENTAL|Control Lenses|Participants will wear Control Lenses for 4 weeks
61909343|NCT05934058||StoP Consortium + UK Biobank|"In the PRS development 338,480 cases and controls from the UK Biobank + 3,650 cases and controls from the StoP consortium studies are going to be enrolled.~Cases are defined as primary gastric carcinoma patients, with histological confirmation.~Controls are selected from cancer-free patients matched with the cases."
61909344|NCT05934058||StoP Consortium|"In the analysis on the aetiology of Gastric Cancer 13,500 cases and 32,000 controls from the StoP consortium studies will be enrolled.~Cases are defined as primary gastric carcinoma patients, with histological confirmation.~Controls are selected from cancer-free patients matched with the cases."
61909345|NCT04844151||Acute myocarditis|Patients hospitalized for an acute myocarditis.
62660551|NCT02235740|ACTIVE_COMPARATOR|Carfilzomib (Part 2)|Approximately 50 subjects will receive Carfilzomib 20 mg/m\^2: Cycle 1, Day 1, 2. Carfilzomib 27 mg/m\^2 (increased dosage of 27 mg/m\^2 will be administered only if tolerated): Cycle 1, Days 8, 9 15, and 16; Cycle 2, Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9, 15 and 16 of each cycle.
61909346|NCT02783079|ACTIVE_COMPARATOR|Arm 1|Cognitive Behavioral Therapy (CBT)
61909347|NCT02783079|ACTIVE_COMPARATOR|Arm 2|Mindfulness Based Stress Reduction (MBSR)
61909348|NCT04226170|ACTIVE_COMPARATOR|treatment|ondansetron + pyridostigmine
61909349|NCT04226170|PLACEBO_COMPARATOR|Placebo|placebo+ pyridostigmine
61909350|NCT02043340|EXPERIMENTAL|Indocyanine green (ICG)|The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
61909351|NCT05090176|EXPERIMENTAL|povidone-soaked suture|"The patient is randomized, those with povidone-soaked suture group will be prepared for povidone-soaked suture during wound closure.~The absorbable suture will be soaked into povidone for 3 mins before the wound closure."
61909352|NCT05090176|ACTIVE_COMPARATOR|ordinary suture|the patient is randomized, those with ordinary suture group will proceed with wound closure as usual manner following the standard practice.
61909353|NCT00787904||Surgical Menopause|Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
62097158|NCT06119191|EXPERIMENTAL|Test Lenses|Participants will wear Test Lenses for 4 weeks
62097159|NCT06522035|EXPERIMENTAL|Stage 1|Stage 1 will include patients who have been treated with standard PsA therapies, and are insufficiently responsive to treatment in one or more involved joints.
62294059|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 4 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62294060|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 5 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62294061|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 6 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62294062|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 7 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62294063|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 8 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62294064|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 9 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62466218|NCT03611374|EXPERIMENTAL|Erector Spinae Plane Block|All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
62466219|NCT04645615|EXPERIMENTAL|CURE AF|
62466220|NCT01856205|PLACEBO_COMPARATOR|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) \[ImmunoRel™ (batch 20081217)\] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
62660552|NCT01303497|OTHER|Arm A : Paclitaxel|administration of paclitaxel drug during cycle of 28 days (6 cycles Max) + blood sample on day 1, 8, 15, 29 and 57
62660553|NCT01303497|OTHER|Arm B : Paclitaxel + Bevacizumab|"administration of paclitaxel drug during per cycle of 28 days (6 cycles Max) + Bevacizumab every two weeks during paclitaxel cycles then every 3 weeks during P cycles until disease progression or inacceptable toxicity~+ blood sample on day 1, 8, 15, 29 and 57"
61909354|NCT00787904||Surgical Control|Pre-menopausal women undergoing abdominal surgery but without ovary removal
61909355|NCT00787904||Healthy|Healthy matched pre-menopausal controls
62097160|NCT06522035|EXPERIMENTAL|Stage 2|Stage 2 will include patients with oligoarticular PsA (1-4 joints involved), who have received at least one injection of corticosteroids to the target joint with insufficient response.
62097161|NCT01639443|EXPERIMENTAL|Fast-tracked|"'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots."
62097162|NCT01639443|NO_INTERVENTION|Control|Patients who are scheduled routinely
62097163|NCT06030089|EXPERIMENTAL|AML patients ineligible for intensive chemotherapy and treated with azacitidine and venetoclax|Newly diagnosed AML patients
62097164|NCT02538640|EXPERIMENTAL|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
62097165|NCT02538640|ACTIVE_COMPARATOR|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
62097166|NCT03583437|EXPERIMENTAL|Healthy male volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
62097167|NCT03583437|EXPERIMENTAL|Healthy female volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
62097168|NCT02531438|EXPERIMENTAL|Omadacycline|Omadacycline IV; Omadacycline tablets
61909356|NCT04645433||Favipiravir therapy|Favipiravir was advised to all patients with severe pneumonia and progressing pneumonia findings or worsening clinical manifestations except pregnant, breast feeding, postpartum woman. PCR results were not waited to start favipiravir in this group of patients and continued if it would be negative but tomography findings were consistent with COVID-19. Loading dose was 1600 mg twice a day. Maintenance dose was 600 mg per 12 hours for four days.
62097169|NCT02531438|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
62097170|NCT02248454|EXPERIMENTAL|Insulin bolus dose/type|Lispro insulin, dose calculated by modeling analysis
62097171|NCT06614257|EXPERIMENTAL|LG-TAP|The laparoscopic guided TAP Block was performed at the beginning of surgery, injecting 15 ml of Local Anesthetic (Ropivacaine Hydrochloride 0.5%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
62097172|NCT06614257|PLACEBO_COMPARATOR|PLACEBO|The laparoscopic guided TAP Block was performed at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
62097173|NCT03293862|ACTIVE_COMPARATOR|Suture group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture only, without mesh, aiming a suture length to wound length ratio higher than four. Randomization occurs after fascial closure.
62294065|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 10 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62097174|NCT03293862|EXPERIMENTAL|Prophylactic mesh group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture aiming a suture length to wound length ratio higher than four AND further polypropilene onlay mesh. Randomization occurs after fascial closure.
62097175|NCT05675631|EXPERIMENTAL|Experimental Group|This group will perform training using suspension elements.
62097176|NCT05675631|ACTIVE_COMPARATOR|Control Group|This group will perform training using weights and elastic bands.
62466221|NCT01856205|PLACEBO_COMPARATOR|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) \[ImmunoRel™ (batch 20081217)\] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
62466222|NCT05187949||Patients|"Quantitative study: Surveys: 1,067 out of a total of 1,389,725 people of residents of the Valencian Community, Spain. Three groups with quota control: proportional to age (40-50; 50-70; \> 70 years) of men aged 40 and over who have not had prostate cancer from each stratum (geographical area and population habitat).~Qualitative study: general population focus groups: 3"
62466223|NCT05187949||General Practitioners|"Quantitative study: 369 General Practitioners working in two Health Departments in the Valencian Community, Spain (Dept of Health Alicante, General Hospital 19, 255,439 habitants) and (Dept of Health Alicante, S Juan Alicante 17, 233,115 habitants).~Qualitative study: general practitioners focus groups: 2."
62097177|NCT01556841|EXPERIMENTAL|TroVax®|TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
62097178|NCT01556841|PLACEBO_COMPARATOR|Placebo|
62097179|NCT01268566|EXPERIMENTAL|MEDI-575, 25 mg/kg|MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
62097180|NCT02214459|EXPERIMENTAL|mhealth counseling|DASH Mobile mhealth enhanced coaching
62097181|NCT06040645|EXPERIMENTAL|Electronic Consult (E-consult)|In Arm 1, the investigators will implement an electronic referral system (electronic co-management), in which specialists will electronically review referrals and make additional recommendations if appropriate primary UI care was not provided.
62097182|NCT06040645|EXPERIMENTAL|Advanced Practice Provider (APP) Co-management|In Arm 2, Advanced Practice Provider (APP) co-management will reduce the burden of care on the PCPs by providing UI care, patient education, and assisting with patient self-management through dedicated televisits (APP co-management).
62097183|NCT04140058|ACTIVE_COMPARATOR|group O4|Patients received 4mg ondansetron.
62097184|NCT04140058|ACTIVE_COMPARATOR|group O6|Patients received 6mg ondansetron.
62097185|NCT04140058|PLACEBO_COMPARATOR|group C|Patients received normal saline.
62466224|NCT05187949||Urologists|Quantitative study: 345 Urologists working in Valencian Community, Spain Qualitative study: urologists focus groups: 1.
62097186|NCT02519179|EXPERIMENTAL|Conventional vs. Opaque, Weighted Bottle|This is a within-subject experiment; mothers will be asked to feed their infants from a clear, conventional bottle during one visit and an opaque, weighted bottle during the other visit. Order of conditions will be counterbalanced.
62294066|NCT06142084|EXPERIMENTAL|Dietary Intervention Sequence 11 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~* Protein meal: pea protein, low bioavailability~* Protein meal: pea protein, high bioavailability~* Protein meal: oat protein, low bioavailability~* Protein meal: oat protein, high bioavailability~* Protein-free meal"
62097187|NCT01049139|NO_INTERVENTION|No Supplemental Information|Participants will be administered a standard HIV vaccine trial consent form but no additional information.
62097188|NCT01049139|EXPERIMENTAL|Supplemental information with 1-sided message|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
62097189|NCT01049139|EXPERIMENTAL|Supplemental information with 2-sided messages|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
62097190|NCT01525979|EXPERIMENTAL|Task-Related UAT|Therapist conducted unilateral arm training Task-related unilateral arm training
62097191|NCT01525979|EXPERIMENTAL|Task-Related BAT|Therapist conducted bilateral arm Training Task-related bilateral arm training
62097192|NCT01525979|EXPERIMENTAL|Task-Related UAT coupling BAT|Therapist conducted task-related unilateral training for 45 minutes, followed by task-related bilateral arm training for another 45 minutes during each training session
62097193|NCT01525979|EXPERIMENTAL|Robot-assisted UAT|Robot-assisted unilateral arm training
62097194|NCT01525979|EXPERIMENTAL|Robot-assisted BAT|Robot-assisted bilateral arm training
62097195|NCT01353235|SHAM_COMPARATOR|usual care|
62097196|NCT01353235|ACTIVE_COMPARATOR|Prednisolone|1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
62097197|NCT04968782||Patients with acute appendicitis|
62097198|NCT01495507||Patellofemoral Instability|Patients with diagnosis of patellofemoral instability receiving MPFL-reconstruction as part of the clinical routine
62097199|NCT04664777||Group1|"Living liver donors who operated between 1 August and 15 november:~After anesthesia induction and surgical field sterilization, before surgical incision; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded.~After the surgical procedure is over and before the patient is awakened from anesthesia; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded."
62466225|NCT01980693|OTHER|bone age assessment by ultrasound|The aim of this phase is to collect the ultrasound reading values of Speed of Sound (SOS) and Distance (DIS) of all participants by performing a one time measurement of the left hand by the SonicBone's BA device. Each measurement will be performed on three sites of the hand: the wrist the phalanx and the metacarpal bones.
62466226|NCT03600376|EXPERIMENTAL|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
62466227|NCT03600376|OTHER|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
62466228|NCT03723395|EXPERIMENTAL|Part A|Tucatinib plus Itraconazole
62097200|NCT05323929|EXPERIMENTAL|deep ESD group|Performed according to the ESD standard procedure, the depth of dissection includes the SM3 layer (submucosa 1/3 layer)
62097201|NCT05323929|EXPERIMENTAL|shallow ESD group|Performed according to the ESD standard procedure, the depth of dissection does not include the SM3 layer (submucosa 1/3 layer)
62097202|NCT02513914|EXPERIMENTAL|Dural Venous Sinus Stenting|Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
62294067|NCT01313130||blast-related TBI|100 active duty US military personnel identified clinically as having suffered blast-related TBI
62294068|NCT01313130||non-blast-related TBI|100 active duty US military personnel identified clinically as having suffered non-blast-related TBI. TBI caused by other mechanisms such as motor vehicle crashes, falls, struck by blunt objects etc.
62294069|NCT01313130||other blast-related injuries|100 active duty US military personnel with blast-exposure and other blast-related injuries but no clinical evidence of TBI
62294070|NCT01313130||other non-blast injuries|100 active duty US military personnel with other non-blast injuries and no clinical evidence of TBI
62294071|NCT01330901|EXPERIMENTAL|Ustekinumab|Ustekinumab 90 mg subcutaneously at week 0, 4 and 16
62294072|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
62294073|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
62294074|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
62294075|NCT02887911||Healthy, atopic non-asthmatic|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
62294076|NCT01422330|EXPERIMENTAL|Etravirine|
62294077|NCT01167296|ACTIVE_COMPARATOR|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.removed uterine stent was sent for bacterial culture too.
62466229|NCT03723395|EXPERIMENTAL|Part B|Tucatinib plus Rifampin
62466230|NCT03723395|EXPERIMENTAL|Part C|Tucatinib plus Gemfibrozil
62097203|NCT02513914|ACTIVE_COMPARATOR|Cerebrospinal Fluid Shunting|Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.
62097204|NCT06041997|EXPERIMENTAL|Smartphone restriction|"Patients with headache with history of high smartphone use will be randomized into restriction and no-restriction arm.~Restriction method:~In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment."
62097205|NCT06041997|NO_INTERVENTION|Control|"Comparison:~In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. In the non-intervention group only the smartphone usage data will be collected in the study period. The non-smartphone users will be as another control arm."
62097206|NCT01820819||Registered or not on the transplantation national waiting list|
62097207|NCT02725203|EXPERIMENTAL|Intervention: Activate intervention|Participants in the intervention arm will visit their primary care nurse four times in a three-month period for structured and comprehensive support in achieving an improved level of physical activity.
62097208|NCT02725203|NO_INTERVENTION|Control|Patients in the control arm will receive care as usual.
62097209|NCT05787652|EXPERIMENTAL|ARTEMIS mobile app|Intervention participants will be asked to download the ARTEMIS app in the Apple or Google Play app stores. The app will comprise of daily self-weighing, daily weight-recording, daily action-planning, and weekly reports and reflection. Daily weight loss action plans will predominantly relate to diet, physical activity and sleep, and comprise of eight categories, to be chosen by participants and rotated on a weekly basis, each with 5-10 actions, to be chosen by participants and rotated on a daily basis. Participants can explore and engage in all of these actions for as long as they wish within the 26-weeks of the intervention but will be recommended to continue within the 'active exploratory phase' of the intervention for at least four weeks, before moving to a 'maintenance phase', where participants continue with the actions which worked best for them in the 'active exploratory phase'.
62097210|NCT05787652|NO_INTERVENTION|Control|Control group participants will receive no intervention. They will be thanked for taking part in the study, advised that they may want to lose weight on their own and reminded of the next assessment at 12 weeks. The investigators will explain the value of control groups in randomised trials and the impact that remaining in follow-up has for the impact of the trial. They will also be reminded that they will receive equal financial reimbursement.
62097211|NCT06615180|OTHER|Transcultural Nursing Course (new curriculum)|The Transcultural Nursing Course is a 25-hour elective designed to promote cultural competence in nursing students. It consists of 8 hours of theoretical instruction and 17 hours of practical training. The course is based on Madeleine Leininger's Culture Care Theory and incorporates models such as the Purnell, Campinha-Bacote, and Papadopoulos Models of Cultural Competence. It is aimed at enabling students to provide culturally appropriate nursing care for individuals, families, and communities.
62097212|NCT06136806||Multisite Artery Disease (MAD) Group|Participants in MAD group mean these patients are suspected with multisite artery disease, like coronary artery disease accompany with renal artery stenosis or lower extremity atherosclerosis.
62097213|NCT06136806||Venous Thromboembolism （VTE）Group|Participants in VTE group mean these patients are suspected with deep vein thrombosis or pulmonary embolism.
62097214|NCT05463120||IFED-2|Children who participated in the IFED study as infants (2010-2014) and a parent/guardian will be enrolled in this follow-up study in childhood and followed for at least one year.
62097215|NCT05292963|EXPERIMENTAL|Fatherhood Works Program delivered in-person|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
62097216|NCT04991025|EXPERIMENTAL|Participants with resectable stage II-III lung cancers (Adenocarcinoma)|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
62097217|NCT04991025|EXPERIMENTAL|Participants with resectable stage II-III lung cancers (squamous cell carcinoma)|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
62097218|NCT04730180|ACTIVE_COMPARATOR|No neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.
62097219|NCT04730180|ACTIVE_COMPARATOR|Mixed reality neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.
62294078|NCT01167296|EXPERIMENTAL|without Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
62466231|NCT03723395|EXPERIMENTAL|Part D|Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
62466232|NCT03723395|EXPERIMENTAL|Part E|Tucatinib plus Digoxin
62466233|NCT01918397|ACTIVE_COMPARATOR|Dose 1|Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
62466234|NCT01918397|EXPERIMENTAL|Dose 2|Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
62466235|NCT01918397|EXPERIMENTAL|Dose 3|Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
62466236|NCT01918397|EXPERIMENTAL|Dose 4|Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
62466237|NCT03469505|ACTIVE_COMPARATOR|data from veterans using COPES|Data from veterans using COPES for chronic pain
62466238|NCT03469505|ACTIVE_COMPARATOR|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
62466239|NCT01886326|EXPERIMENTAL|Consumption of 42 g of salted peanuts|Consumption of 42 grams of peanuts daily
62097220|NCT05000775|EXPERIMENTAL|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
62097221|NCT05000775|PLACEBO_COMPARATOR|Placebo|Placebo
62097222|NCT04198961|EXPERIMENTAL|Electronic Intervention|Individualized opioid taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
62097223|NCT06226025|EXPERIMENTAL|Melatonin|Oral medication will be taken for 28 days on the afternoon or evening of the participants first intervention session and continue daily for the remainder of the treatment period.
62097224|NCT06226025|PLACEBO_COMPARATOR|Placebo|Oral medication will be taken for 28 days on the afternoon or evening of the participants first intervention session and continue daily for the remainder of the treatment period.
62660554|NCT03301714|NO_INTERVENTION|Control: Standard of Care|Regular dental care under the standard clinic operation
62660555|NCT03301714|EXPERIMENTAL|Intervention 1: Group-based oral health education|Group based oral health education
62097225|NCT01445756|ACTIVE_COMPARATOR|Topical Lidocaine|Topical Lidocaine
62097226|NCT01445756|PLACEBO_COMPARATOR|Placebo|Placebo
62097227|NCT04651738|EXPERIMENTAL|Study group|All eligible participants consenting to participate the study.
62097228|NCT00895024||Caregivers|
62294079|NCT05011396|EXPERIMENTAL|PH94B|3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time
62294080|NCT05011396|EXPERIMENTAL|Placebo|Placebo intranasal spray (100 microliters to each nostril) one time
62294081|NCT03200951|EXPERIMENTAL|Bolus group|
62097229|NCT03564938|EXPERIMENTAL|Regorafenib (Stivarga, BAY 73-4506)|Patients with metastatic colorectal cancer
62097230|NCT05396495|EXPERIMENTAL|Treatment arm|Treatment arm using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
62097231|NCT04792983||Older (≥ 65 years of age)|Older surgical patients presenting for elective spine surgery.
62097232|NCT06613620|EXPERIMENTAL|Post Facilitation Stretching and Strengthening|"Group A will recieve standard treatment of post facilitation stretching and strengthening.~Strengthening will be divided into following phases~1. Warm up phase:~2. Strengthening phase:~3. Cool down phase:"
62294082|NCT03200951|ACTIVE_COMPARATOR|Infusion group|
62294083|NCT03793543|EXPERIMENTAL|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
62294084|NCT00827190|EXPERIMENTAL|1|ILS-920
62660556|NCT03301714|EXPERIMENTAL|Intervention 2: Individual-based oral health education|Individual-based motivational interviewing
62660557|NCT00178373|EXPERIMENTAL|Modafinil|Modafinil 200 mg taken by mouth once a day. Subjects will take 2 100 mg tablets each morning.
62660558|NCT00178373|PLACEBO_COMPARATOR|placebo|Inactive sugar pill, 2 are taken once a day in the morning
62097233|NCT06613620|EXPERIMENTAL|Visual and auditory biofeeback|Group B will receive surface EMG biofeedback(visual and auditary) in addition to standard treatment.
62466240|NCT01886326|EXPERIMENTAL|Consumption of 42 g of unsalted peanuts|Consumption of 42 grams of peanuts daily
62466241|NCT01886326|EXPERIMENTAL|Consumption of 42 g of spicy peanuts|Consumption of 42 grams of peanuts daily
62466242|NCT01886326|EXPERIMENTAL|Consumption of 42 g of honey peanuts|Consumption of 42 grams of peanuts daily
62466243|NCT01886326|EXPERIMENTAL|Consumption of 42 g of 3 diff. varieties|Consumption of 42 grams of peanuts daily
62466244|NCT01886326|EXPERIMENTAL|Consumption of 42 g of var. of types|Consumption of 42 grams of peanuts daily
62097234|NCT06613620|EXPERIMENTAL|Electrical stimulation along with visual and auditory feedback|Group C will receive 3 types of feedbacks (electrical, visual and auditory) in addition to standard treatment
62097235|NCT00874796|EXPERIMENTAL|GS-9450 10 mg/day|GS-9450 taken as one 10 mg capsule by mouth once daily
62097236|NCT00874796|EXPERIMENTAL|GS-9450 40 mg/day|GS-9450 taken as one 40 mg capsule by mouth once daily
62466245|NCT03161405|EXPERIMENTAL|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
62097237|NCT00874796|PLACEBO_COMPARATOR|Placebo|Placebo taken as one placebo capsule by mouth once daily
62466246|NCT01273805|EXPERIMENTAL|Hydroxychloroquine 400 mg b.i.d.|Patients received 400 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
62466247|NCT01273805|EXPERIMENTAL|Hydroxychloroquine 600 mg b.i.d.|Patients received 600 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
62466248|NCT00721305|EXPERIMENTAL|1|In this arm, subjects will receive 40 mg of Lovastatin (2 tablets of 20 mg each, p.o.), in a daily doses, during twelve months
62466249|NCT00721305|PLACEBO_COMPARATOR|2|In this arm, subjects will receive placebo (2 tablets which will look externally identical to lovastatin: wrapped in the same way, with the same size, shape and color)
62660559|NCT04214015||Patients with metastatic mesothelioma|Patients who have been diagnosed with metastatic mesothelioma
62660560|NCT02891824|PLACEBO_COMPARATOR|Arm A: Placebo + Avastin + platinum-based chemotherapy|"The placebo arm:~Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression"
62660561|NCT02891824|EXPERIMENTAL|Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy|"The atezolizumab arm:~Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression~."
62660562|NCT00805532|EXPERIMENTAL|Behavioral Activation|Behavioral Activation (BA), modified to be delivered in 6-8, 60 minute sessions to address PTSD-related problems.
62466250|NCT03743753|NO_INTERVENTION|Control|The control group will receive the current standard educational information from the surgeon along with an information package.
62466251|NCT03743753|EXPERIMENTAL|Experimental|The experimental group will receive an additional educational session before their operation about what to expect during their reconstructive journey, in addition to the current standard educational information from the surgeon along with an information package.
62660563|NCT00805532|ACTIVE_COMPARATOR|Treatment as Usual|Treatment As Usual for PTSD (TAU) within VA PTSD specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system.
62097238|NCT04870164|EXPERIMENTAL|ensovibep dose 1 (infusion)|
62097239|NCT04870164|EXPERIMENTAL|ensovibep dose 2 (infusion)|
62097240|NCT04870164|EXPERIMENTAL|ensovibep dose 3 (infusion)|
62097241|NCT04870164|PLACEBO_COMPARATOR|placebo (infusion)|
62097242|NCT04870164|EXPERIMENTAL|ensovibep dose 4 (IV bolus)|
62097243|NCT04870164|EXPERIMENTAL|ensovibep dose 5 (IV bolus)|
62097244|NCT04870164|EXPERIMENTAL|ensovibep dose 6 (SC injection)|
62097245|NCT04870164|EXPERIMENTAL|ensovibep dose 7 (SC injection)|
62466252|NCT04915534|OTHER|Women - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
62660564|NCT03642314|EXPERIMENTAL|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
62660565|NCT03642314|NO_INTERVENTION|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
62660566|NCT01850329|NO_INTERVENTION|control|No computed-assisted information program will be administered.
62660567|NCT01850329|EXPERIMENTAL|intervention|computed-assisted information program will be administered.
62660568|NCT01059851|EXPERIMENTAL|Participants with Severe Renal Impairment (Part I)|"Participants with severe renal impairment will receive a~single dose of 20 mg open-label suvorexant during Part I of the~study."
62660569|NCT01059851|EXPERIMENTAL|Healthy Participants (Severe Impairment Controls) (Part I)|Healthy participants matched to participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
62660570|NCT01059851|EXPERIMENTAL|Participants with Moderate Renal Impairment (Part II)|Participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
62660571|NCT01059851|EXPERIMENTAL|Healthy Participants (Moderate Impairment Controls) (Part II)|Healthy participants matched to participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
62660572|NCT01059851|EXPERIMENTAL|Participants with Mild Renal Impairment (Part II)|Participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
61909357|NCT04645433||Lopinavir-ritonavir therapy|Lopinavir-ritonavir therapy was used in selected ICU patients before widespread availability of favipiravir (23 March 2020) and/or if favipiravir was contraindicated. Combination of lopinavir 200 mg-ritonavir 50 mg tablet was the given form. It was given as double tablets twice daily for 10-14 days. Patients were accepted as under favipiravir therapy if they had incomplete course of lopinavir-ritonavir therapy (less than 5 days) and followed by favipiravir for 5 days.
61909358|NCT02412514|ACTIVE_COMPARATOR|Arm A|Infants assigned to Arm A will receive bOPV at 6, 10, and 14 weeks of age and IPV at 6 weeks of age.
61909359|NCT02412514|ACTIVE_COMPARATOR|Arm B|Infants assigned to Arm B will receive bOPV at 10 and 14 weeks of age and IPV at 6 weeks of age.
61909360|NCT00732004|EXPERIMENTAL|1|Group 1
61909361|NCT00732004|EXPERIMENTAL|2|Group 2
61909362|NCT00732004|EXPERIMENTAL|3|Group 3
61909363|NCT06243523|OTHER|Action group|The action intervention of this research is the implementation of a stress management psychoeducation program based on Neuman's Systems Model for the spouses of patients hospitalized in the intensive care unit.
61909364|NCT05481957|EXPERIMENTAL|vortioxetine|participants given 5\~10mg per day for 16 weeks
61909365|NCT05481957|ACTIVE_COMPARATOR|Sodium valproate|participants given 500\~1000mg per day for 16 weeks
61909366|NCT05293392|EXPERIMENTAL|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|
61909367|NCT05293392|ACTIVE_COMPARATOR|Standard Care|
61909368|NCT03452748|EXPERIMENTAL|FTIR arm|all excised membranes are examined with FTIR spectroscopy
61909369|NCT05322044|NO_INTERVENTION|Control (no financial incentive)|No incentive. Usual care (plus EMD with reminders) for 12-weeks.
61909370|NCT05322044|EXPERIMENTAL|Intervention (financial incentive)|Financial incentive dependent upon daily medication adherence (plus EMD with reminders) for 12-weeks.
61909371|NCT02805504|EXPERIMENTAL|Exparel|This arm will receive intraoperative local Liposomal Bupivacaine injection (Exparel) at the port placement site.
61909372|NCT02805504|ACTIVE_COMPARATOR|Marcaine|This group will receive will local bupivacaine HCl (Marcaine) injection at the port placement site.
61909373|NCT06342739||Benign thyroid nodules group|Participants with benign thyroid nodules involved in a consultation with endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid nodules
61909374|NCT05712486|EXPERIMENTAL|Lateral distraction group|High force lateral distraction of affected hip.
61909375|NCT05712486|SHAM_COMPARATOR|Placebo distraction group|Placebo lateral traction of affected hip.
61909376|NCT01147627|ACTIVE_COMPARATOR|Exenatide|
61909377|NCT01147627|ACTIVE_COMPARATOR|Premixed insulin analog|
61909378|NCT01147627|ACTIVE_COMPARATOR|pioglitazone|
62097246|NCT04870164|EXPERIMENTAL|ensovibep dose 8 (SC injection)|
61909379|NCT04717830|EXPERIMENTAL|Gamezumab 1/10 therapeutic dose|1/10 therapeutic dose (5 volunteers)
61909380|NCT04717830|EXPERIMENTAL|Gamezumab 1/2 therapeutic dose|1/2 therapeutic dose (5 volunteers)
61909381|NCT04717830|EXPERIMENTAL|Gamezumab full therapeutic dose|therapeutic dose (10 volunteers)
61909382|NCT05832775|EXPERIMENTAL|MRx0029 Treatment Sequence 1|Patients will receive MRx0029 in the first treatment period and then placebo in the second treatment period
61909383|NCT05832775|EXPERIMENTAL|MRx0029 Treatment Sequence 2|Patients will receive placebo in the first treatment period and then MRx0029 in the second treatment period
61909384|NCT05832775|EXPERIMENTAL|MRx0005 Treatment Sequence 1|Patients will receive MRx0005 in the first treatment period and then placebo in the second treatment period
61909385|NCT05832775|EXPERIMENTAL|MRx0005 Treatment Sequence 2|Patients will receive placebo in the first treatment period and then MRx0005 in the second treatment period
62097247|NCT04870164|EXPERIMENTAL|ensovibep dose 9 (SC injection)|
62097248|NCT04870164|EXPERIMENTAL|ensovibep dose 10 (IM injection)|
62097249|NCT04870164|EXPERIMENTAL|ensovibep dose 11 (IM injection)|
62097250|NCT04870164|EXPERIMENTAL|ensovibep dose 12 (IM injection)|
62097251|NCT04870164|EXPERIMENTAL|ensovibep dose 13 (IM injection)|
62466253|NCT04915534|OTHER|Men - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
62466254|NCT04915534|OTHER|Women - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
62466255|NCT04915534|OTHER|Men - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
62097252|NCT05298670|EXPERIMENTAL|Metformin (Cidophage®) and Interferon Beta 1 a (Rebiff ® 44mcg or Avonex ®)|Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet twice daily for 6 months as add on therapy with Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®).
62097253|NCT05298670|ACTIVE_COMPARATOR|Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)|Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)
62097254|NCT06611020||treatment of HPV-related disease with or without vaccination|
62097255|NCT01913756|EXPERIMENTAL|Gouda-type cheese|80 g/day Gouda-type cheese
62097256|NCT01913756|NO_INTERVENTION|Low cheese intake|
62097257|NCT01913756|EXPERIMENTAL|Gamalost (Norwegian traditional cheese)|50 g/day Gamalost
62097258|NCT05969561|ACTIVE_COMPARATOR|Ultrasound-guided femoral nerve block|Patients with hip fractures had underwent Ultrasound-guided femoral nerve block performed by emergency physicians.
62097259|NCT05969561|SHAM_COMPARATOR|The liberal use of pain medication|Patients with hip fractures had given intravenous or intramuscular opioids or NSAID at the emergency department.
62466256|NCT04414072|ACTIVE_COMPARATOR|laparoscopic sleeve gastrectomy|
62097260|NCT05387928|EXPERIMENTAL|Dose Escalation|KL340399 weekly on Days 1, 8 and 15 on repeated 21-day cycles in escalating doses.
62097261|NCT00495469|EXPERIMENTAL|GSK189075|Participants will receive GSK189075 for 12 weeks
62097262|NCT00495469|PLACEBO_COMPARATOR|Placebo|Participants will receive GSK189075 matching Placebo for 12 weeks
62097263|NCT03116282|EXPERIMENTAL|Intervention|Conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of therapy where participants are not required to show up at a clinic.
62097264|NCT03116282|NO_INTERVENTION|Control|Treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic.
62097265|NCT01085617|ACTIVE_COMPARATOR|B1 - Standard therapy|Standard chemotherapy for precursor B-cell ALL
62466257|NCT04414072|ACTIVE_COMPARATOR|mini gastric bypass|
62466258|NCT04414072|ACTIVE_COMPARATOR|sleeve gastrectomy with loop bipartition|
62466259|NCT04166552|EXPERIMENTAL|EHP-101 low dose once a day|
62097266|NCT01085617|EXPERIMENTAL|B2 - Rituximab|Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction
62097267|NCT01085617|ACTIVE_COMPARATOR|T1 - Standard therapy|Standard chemotherapy for T-cell ALL
62097268|NCT01085617|EXPERIMENTAL|T2 - Nelarabine|Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction
62097269|NCT01085617|ACTIVE_COMPARATOR|P1 - standard palifermin|6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)
62097270|NCT01085617|EXPERIMENTAL|P2 - collapsed palifermin|1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)
62660573|NCT01059851|EXPERIMENTAL|Healthy Participants (Mild Impairment Controls) (Part II)|Healthy participants matched to participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
62097271|NCT06580951|EXPERIMENTAL|RPNI|Subjects will complete BREAST-Q Pre-Op (Qol) survey and Pain Distribution survey prior to Surgery. Subjects will in the RPNI arm will undergo mastectomy with breast reconstruction surgery with regenerative peripheral nerve interface. Subjects will complete BREAST-Q Post-Op (QoL) survey and Pain Distribution Survey at Months 1, 3, 6, and 12 post-surgery. Information about the patient and course of care will be collected from electronic medical records.
62097272|NCT06580951|NO_INTERVENTION|No RPNI (Control)|Subjects will complete BREAST-Q Pre-Op (Qol) survey and Pain Distribution survey prior to Surgery. Subjects undergo mastectomy with breast reconstruction surgery without regenerative peripheral nerve interface. Subjects will complete BREAST-Q Post-Op (QoL) survey and Pain Distribution Survey at Months 1, 3, 6, and 12 post-surgery. Information about the patient and course of care will be collected from electronic medical records.
62097273|NCT03886181|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62466260|NCT04166552|EXPERIMENTAL|EHP-101 low dose twice a day|
62466261|NCT04166552|EXPERIMENTAL|EHP-101 high dose once a day|
62466262|NCT04166552|EXPERIMENTAL|EHP-101 high dose twice a day|
62466263|NCT02414152|EXPERIMENTAL|anakinra|100mg of Anakinra administered as a daily subcutaneous injection
62466264|NCT03895957|EXPERIMENTAL|Group 1: VR Mind+|Virtual Reality Exposure Therapy VR Mind+
62466265|NCT03895957|EXPERIMENTAL|Group 2: VR Mind|Virtual Reality Exposure Therapy VR Mind
62466266|NCT03895957|ACTIVE_COMPARATOR|Control group: CBT|Cognitive Behavioral Therapy
62466267|NCT01310647|EXPERIMENTAL|Testosterone|Transdermal testosterone (20µg/day) from day 24 of the previous cycle until day 2 of the ICSI cycle
62466268|NCT01310647|EXPERIMENTAL|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
62466269|NCT01310647|EXPERIMENTAL|CombEq|"* (150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI~* Estradiol valerate 4 mg/day during 10 days, starting the second day of the cycle prior to the ICSI cycle."
62466270|NCT01448057|EXPERIMENTAL|Combination Product|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
62097274|NCT00354393|EXPERIMENTAL|Induction Combination Chemotherapy|"Induction chemotherapy: Patients get MVP chemo. Treatment repeats every 28 days for 2 courses.~Patients w/ unresectable disease may get up to 2 add'l courses of induction chemo. Patients requiring palliative radiotherapy or have PD are removed from study. Patients w/ resectable disease or sarcomatoid histology \& T1-3, N1-2 disease w/ a CR or PR to induction chemo go to surgery.~Surgery: Patients w/ extensive disease get palliative debulking pleurectomy and decortication \& are taken off study. Other patients undergo a thoracotomy w/ extrapleural pneumonectomy \& proceed to chemoradiotherapy.~Chemoradiotherapy: At 6-10 weeks post-op, patients get 3-dimensional conformal or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients receive cisplatin IV over 30-60 minutes days 1 \& 22. Patients w/ responding disease proceed to adjuvant chemotherapy.~Adjuvant chemotherapy: Patients get 2 more courses of MVP chemotherapy"
62097275|NCT04223362|EXPERIMENTAL|Pulmonary rehabilitation + Community-based physical activity programme|After pulmonary rehabilitation, the experimental group will integrate a community-based physical activity programme.
62097276|NCT04223362|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates physical activity recommendations.
62097277|NCT04029740|OTHER|Healthy controls|40 Healthy controls matched on gender and age with no current psychopathology will have exosomal microRNAs measured twice over a 3 month period.
62097278|NCT04029740|EXPERIMENTAL|panic disorder receiving CBT|40 adult patients diagnosed with primary panic disorder will have their exosomal microRNAs measured 2x over 3 months.
62097279|NCT05126602|EXPERIMENTAL|High Dose Vitamin D3|A chewing tablet of 5000 IU of vitamin D3 is given twice daily, orally in the morning and evening for two weeks
62097280|NCT05126602|ACTIVE_COMPARATOR|Low Dose Vitamin D3|A chewing tablet of 1000 IU of vitamin D3 is given once daily, orally in the morning for two weeks
62097281|NCT06217731|ACTIVE_COMPARATOR|Group1 laser + clonazepam|Group 1 (n=20) were treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril ( clonazepam) 0.25mg once every 24 hours for a month.
62097282|NCT06217731|SHAM_COMPARATOR|group 2 Laser Sham|Group 2 (n=19) were treated with the same laser once a week for a month, but with the tip deactivated
62097283|NCT06217731|EXPERIMENTAL|group3 laser|Group 3 (n=21) were treated with the Helbo® laser once a week for a month.
62097284|NCT06217731|EXPERIMENTAL|group 4 clonazepam|Group 4 (n=18) were treated with Rivotril 0.25mg once a day for a month.
62097285|NCT06510283|EXPERIMENTAL|Taitacept treatment group|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
62097286|NCT05805059|EXPERIMENTAL|Control Contact Lens, Then Test Contact Lens|Participants will wear control contact lenses for one week and then crossover to test contact lenses for one week.
62097287|NCT05805059|EXPERIMENTAL|Test Contact Lens, Then Control Contact Lens|Participants will wear test contact lenses for one week and then crossover to control contact lenses for one week.
62097288|NCT03959709|EXPERIMENTAL|Prepectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
62097289|NCT03959709|ACTIVE_COMPARATOR|Subpectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
62097290|NCT02303119|ACTIVE_COMPARATOR|Am A : Rituximab IV|4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22
62097291|NCT02303119|EXPERIMENTAL|Arm B: Rituximab SC|1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
62097292|NCT02303119|EXPERIMENTAL|Arm C : Rituximab SC first cycle|8 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
62097293|NCT02710383||Participants genetically diagnosed with Cystic fibrosis|Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years
62660574|NCT00090428|EXPERIMENTAL|1|Participants will follow a gluten-free and casein-free diet for 18 weeks. The compliance with the diet was monitored with 24 hour dietary recall and nutritional sufficiency with diet diary analysis.
62097294|NCT05879120|EXPERIMENTAL|Neoadjuvant pembrolizumab|
62097295|NCT05879120|EXPERIMENTAL|Exablate MRgFUS + neoadjuvant pembolizumab|
62097296|NCT06376890|EXPERIMENTAL|Red Chili Pepper|2.4 grams/day of red chili will be given to the red chili group for 10 weeks.
62466271|NCT01448057|ACTIVE_COMPARATOR|Paracetamol tablets|Paracetamol (500 mg) tablets
62097297|NCT06376890|EXPERIMENTAL|Green Chili Pepper|2.4 grams/day of green chili will be given to the green chili group for 10 weeks.
62097298|NCT06376890|PLACEBO_COMPARATOR|Placebo|2.4 grams/day of corn start will be given to the placebo group for 10 weeks.
62097299|NCT04285996|OTHER|All patients|Pilot study: All registered patients will undergo a PET scan using \[18F\]-FBA-A20FMDV2.
62097300|NCT05300464|OTHER|Single arm|All patients perform standard breast screening and also MammoWave exam.
62097301|NCT02777983|EXPERIMENTAL|Education Group|This will consist of a 6-minute educational video app created and delivered within an application (mobile app) that will be interactive in nature, asking multiple-choice questions at the end to help reinforce key points of the video message. It will include self-management guidance based on evidence related to activity, exercise, and other behavioral components known to influence the prognosis of low back pain. Subjects will also receive the 1-page general conditioning handout that the usual care group will receive.
62097302|NCT02777983|NO_INTERVENTION|Usual Care Group|Subjects randomized to usual care will receive a 1-page generic informational handout on general conditioning recommended for low back pain, in addition to whatever education the subject's PCP decides to provide.
62466272|NCT05029297|EXPERIMENTAL|CAPSAICIN 0.75 mg/g topical solution applicable in roll-on|CAPSAICIN 0.75 mg / g topical solution applicable in roll-on: 4 applications per day for 8 weeks.
62466273|NCT05029297|ACTIVE_COMPARATOR|CAPSAICIN 0.075% cream|CAPSAICIN 0.075% cream (ARAFARMADOL® 0.075% cream): 4 applications per day for 8 weeks.
62097303|NCT04127344|EXPERIMENTAL|Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients randomised to a music therapy intervention will receive an individualised music therapy intervention."
62097304|NCT04127344|NO_INTERVENTION|Non-Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients allocated to Non-Music Therapy Intervention received standard treatment."
62097305|NCT04327596|NO_INTERVENTION|Conventional Treatment|Subjects will receive management of AF consisting of either rate or rhythm control.
62097306|NCT04327596|ACTIVE_COMPARATOR|AF Ablation|Subjects will undergo early RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter
62097307|NCT05510687|EXPERIMENTAL|Glasses to correct presbyopia and digital financial training|The intervention is the provision of glasses to correct presbyopia plus digital financial training to use bKash, a popular mobile banking application that is becoming the preferred mode of transferring payments to the bank accounts of OAA and WA beneficiaries in Bangladesh.
62097308|NCT05510687|NO_INTERVENTION|Control-No treatment|"Mobile phone with preloaded bank transaction tracking app: Participants will be provided a basic mobile phone handset. The bank transaction tracking application that is being developed to measure the primary outcomes for this trial will be installed on these phones before giving them to the participants. A mobile data pack will also be remotely loaded on the mobile phone to facilitate internet access for mobile banking.~Eyeglasses: These participants will receive a free pair of eyeglasses at the conclusion of the study to correct refractive errors, unless they have obtained such glasses on their own during the study."
61909386|NCT02907476|EXPERIMENTAL|Iyengar Yoga|Twelve-week Iyengar Yoga protocol with two 90-minute classes per week and three 30-minute homework assignments. Classes consist of approximately 60-minutes of yoga postures, 10-minutes of rest and transition, and 20-minutes of Coherent Breathing at 5 breaths per minute. Homework consist of 15-minutes of yoga postures and 15-minutes of Coherent Breathing. Coherent Breathing is CD guided. Yoga classes are taught by certified Iyengar Yoga instructors.
62097309|NCT04777071|EXPERIMENTAL|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/CT, PET/MR)|Patients receive gallium Ga 68-labeled PSMA-11 IV then undergo PET/CT or PET/MR scan over 2-4 minutes per bed position at baseline. Patients receiving systemic therapy undergo an additional 68Ga-PSMA-11 PET/CT or PET/MR scan 12 weeks after initiating therapy. Patients may also undergo CT and bone scan during screening.
62097310|NCT01268761|EXPERIMENTAL|GnRH antagonist|• GnRH antagonist (Cetrorelix 0.25)
62097311|NCT01268761|PLACEBO_COMPARATOR|Placebo (saline solution)|• Placebo (saline solution)
62097312|NCT05633771||Hyrimoz|Patients prescribed with Hyrimoz
62097313|NCT06614621|EXPERIMENTAL|Extensive-stage small cell lung cancer|Therapeutic medications
62097314|NCT03716167|EXPERIMENTAL|Laser Treatment|Summus Laser treatment with infrared light
62097315|NCT03716167|SHAM_COMPARATOR|Sham treatment|Sham Summus Laser treatment with no infrared light
62097316|NCT02760862|ACTIVE_COMPARATOR|Group (I) (N=25)|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours (Hydrocortisone as sodium succinate, vial, equivalent to hydrocortisone 100mg, Egyptian INT, Pharmaceutical Industries CO. ARE,EIPICO.EGYPT).
62097317|NCT02760862|ACTIVE_COMPARATOR|Group (II) (N=25)|group (II), received mannitol 20% intravenous fluid (100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis for 48 hours) (Manufactured by Allmed Middle East, Egypt).
62660575|NCT00090428|ACTIVE_COMPARATOR|2|After established on a gluten free and casein free diet for at least 6 weeks, participants received double blind, placebo controlled challenges containing gluten, casein, gluten+casein, or placebo in a random order. Data was collected on behavioral and physiologic responses relative to the challenges. Children remained on the gluten free and casein free diet throughout this period.
62660576|NCT04831658|EXPERIMENTAL|Orelabrutinib combined with PD-1 and fotemustine|To observe the efficacy and safety of a new generation of BTK inhibitor abutinib combined with PD-1 and formustine in the treatment of newly-treated patients with primary central nervous system lymphoma (PCNSL)
61909387|NCT02907476|ACTIVE_COMPARATOR|Walking|Twelve-week walking intervention will consist of two 60-minute group-walking sessions per week and three 15-minute homework walking sessions at 2.5 miles per hour on flat surface. Walking classes are conducted by research staff.
62097318|NCT04332276|EXPERIMENTAL|Cerebroventricular administration of A- dopamine|Cerebroventricular administration of dopamine prepared and stored in anaerobia
61909388|NCT02278523|EXPERIMENTAL|Inspiratory muscle training group|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
61909389|NCT02278523|ACTIVE_COMPARATOR|control group|normal volunteers use Inspiratory muscle trainer(Threshold IMT®)
62097319|NCT04332276|ACTIVE_COMPARATOR|Optimized oral dopaminergic treatment|Optimized oral dopaminergic treatment with L-dopa (at least 5 doses a day) with dopaminergic agonist, monoamine B inhibitor and catechol-o-methyl inhibitor (if tolerated) (A-dopamine replaced by saline un the pump during optimized oral dopaminergic treatment)
62097320|NCT00875628|OTHER|Cohort 1|PF-00868554 100 mg or placebo
62097321|NCT00875628|OTHER|Cohort 2|PF-00868554 300 mg or placebo
62097322|NCT00875628|OTHER|Cohort 3|PF-00868554 600 mg or placebo
61909390|NCT00734747|EXPERIMENTAL|Medigus SRS Endoscopic Stapling System|Endoluminal fundoplication for the treatment of GERD
62097323|NCT01395264||Episodic Migraine.|
62097324|NCT01395264||menstrual migraine|
62097325|NCT01395264||Cluster Headache patients|
62097326|NCT01395264||control (non-headache group)|
62466274|NCT01061866|EXPERIMENTAL|Thalidomide|Open-labeled preliminary trial
62097327|NCT03554187|EXPERIMENTAL|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Interventions :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
62097328|NCT03554187|PLACEBO_COMPARATOR|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Intervention(s) :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
62097329|NCT03465111|EXPERIMENTAL|Twice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U twice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria.
61909391|NCT02536183|EXPERIMENTAL|Part A|LTLD will be administered intravenously in combination with MR-HIFU ablation on day 1 of every 21 day cycle. There will be two potential dose escalation of LTLD with highest dose not to exceed the adult recommended MTD. Patients may receive up to a total of 6 cycles.
61909392|NCT02536183|EXPERIMENTAL|Part B|LTLD at dose determined from Part A will be administered intravenously on day 1 of every 21 day cycle. MR-HIFU induced MHT will follow immediately post LTLD infusion for one hour to target area with target temperatures of 40-45°C. Patients may receive up to a total of 6 cycles
62097330|NCT03465111|EXPERIMENTAL|Thrice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U thrice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 16, the treatment will be administered on as needed basis, based on the retreatment criteria.
62294085|NCT05629039|EXPERIMENTAL|Wave 1-Experimental Group|The experimental group in Wave 1 will complete the baseline questionnaires (the socio-demographic, FTND, and COM-B questionnaires) followed by both the if-then list and the if-then link from the Volitional-Help Sheet as manipulations. The if-then list consists of several situations and solutions linked to smoking uptake in the volitional help sheet and the group will be informed that the activity will help to stop smoking. In addition, the if-then link consists of the situations in which people are urged to smoke and then link them to solutions that are most likely to help them abstain from starting smoking
61909393|NCT02006095||Neuroimaging Correlates|
61909394|NCT00205270||Pre-transplant Vaccine|Cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
61909395|NCT00205270||0-6 Months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 0-6 months post transplant.
61909396|NCT00205270||13-60 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 13-60 months post transplant.
61909397|NCT00205270||Greater than 110 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine greater than 110 months post transplant.
61909398|NCT00205270||Healthy Controls|Healthy controls to measure normal immune response to the influenza vaccine
61909399|NCT02536404|EXPERIMENTAL|Etrasimod 2 mg|
61909400|NCT02536404|ACTIVE_COMPARATOR|Placebo|
61909401|NCT03430076|EXPERIMENTAL|Revascularization by (Propaten)®|Revascularization by PTFE with heparin bonded luminal surface (Propaten)®
61909402|NCT03430076|ACTIVE_COMPARATOR|Revascularization by Crude PTFE|
61909403|NCT00852514|EXPERIMENTAL|Monthly BIA|monthly BIA to monitor fluid status
61909404|NCT05050591|EXPERIMENTAL|Single-Arm Study|This is a prospective trial of the clinical utility of a patient-specific silicone stent implant for patients with complex airway disease, requiring an airway stent. The aim of this study is to observe the outcomes associated with the implants. Current stents have been suboptimal for treating benign stenosis of the airway and we are seeking to create a better treatment option. We hypothesize, based on the previous compassionate-use cases, that placing a patient-specific silicone stent will effectively alleviate symptoms associated with stenosis of the airway. The main measure of effectiveness will be patient-reported outcomes.
61909405|NCT02623231|EXPERIMENTAL|escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
61909406|NCT02623231|PLACEBO_COMPARATOR|placebo|Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
61909407|NCT04013243|ACTIVE_COMPARATOR|Magnesium Sulfate group|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
61909408|NCT04013243|PLACEBO_COMPARATOR|Placebo group|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
61909409|NCT00458224|EXPERIMENTAL|Parental counseling|Life style counseling
61909410|NCT03016143|ACTIVE_COMPARATOR|Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
61909411|NCT03016143|ACTIVE_COMPARATOR|Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
61909412|NCT03016143|EXPERIMENTAL|Group #3 (Vaccine VAXIGRIP)|50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
61909413|NCT03016143|EXPERIMENTAL|Group #4 (Vaccine VAXIGRIP)|50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
61909414|NCT01737229|EXPERIMENTAL|Direct pulp capping/carious exposure|symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
61909415|NCT01737229|EXPERIMENTAL|Direct pulp capping/dental trauma|• Permanent mature or immature single-root tooth having suffered traumatic injury \< 72 hours, with amelodentinal coronal fracture causing pulp exposure.
62097331|NCT03281343|EXPERIMENTAL|MI-NAV|A study therapist will deliver a motivational interviewing session with participants while they are incarcerated and serve as a role of patient navigator post-release.
61909416|NCT01737229|EXPERIMENTAL|Repairing root canals/pulp chamber floor|"* Iatrogenic perforation of the pulpal floor, with or without LEO.~* Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.~* Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO."
61909417|NCT01737229|EXPERIMENTAL|Retrograde endodontic surgery - adults|"* Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.~* Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option"
61909418|NCT01737229|EXPERIMENTAL|Pulpotomy in primary molars - children (3 to 12 years )|"* Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.~* Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years."
61909419|NCT01737229|EXPERIMENTAL|Apexification - children (7 to 18 years) + adults|"* Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.~* Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.~* Apical Root Resorption"
62097332|NCT03281343|ACTIVE_COMPARATOR|Standard of Care (SOC)|Approximates care currently provided at the prison.
62097333|NCT01702896|EXPERIMENTAL|Interleukin-2|Interleukin-2 will be used in this group
62097334|NCT01671475|EXPERIMENTAL|Routine care plus microEEG|Subjects allocated to this group will undergo an EEG using microEEG device in addition to their routine care. The microEEG device will be used with commercially available electrodes in a headpiece configuration.
62097335|NCT01671475|NO_INTERVENTION|Routine care only (control group)|Subjects allocated to the control group will receive routine care without microEEG. The treating physician may request a standard EEG, which will be performed by the hospital EEG laboratory, if available.
62097336|NCT03978117|EXPERIMENTAL|Freeze Dried Powder Preparation|
62097337|NCT03978117|PLACEBO_COMPARATOR|Placebo|
62097338|NCT04864561|EXPERIMENTAL|VLA2001|\<30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222
62097339|NCT04864561|ACTIVE_COMPARATOR|AZD1222|\<30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222
62097340|NCT04864561|EXPERIMENTAL|VLA2001 - adolescent part|≥12 to \< 18 years will be randomized 1:1 to receive VLA2001 or Placebo
62097341|NCT04864561|PLACEBO_COMPARATOR|Placebo|≥12 to \< 18 years will be randomized 1:1 to receive VLA2001 or Placebo
62097342|NCT00530777|EXPERIMENTAL|1|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
62466275|NCT04811183||Experimental group|Adult patients hospitalized with diabetes and polymedicated. Selected to benefit from a pharmaceutical consultation before their return home.
62466276|NCT01734265|EXPERIMENTAL|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
62097343|NCT00530777|PLACEBO_COMPARATOR|2|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
62097344|NCT06508099|EXPERIMENTAL|Vitamin supplementation|vitamin A 300 000 IU and vitamin D 100 000 IU on days -14 to -8 before transplantation
62466277|NCT01734265|EXPERIMENTAL|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
62466278|NCT02937701|EXPERIMENTAL|ABP 710|"Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46."
62097345|NCT06508099|NO_INTERVENTION|Routine care|Routine care
62097346|NCT00823589|EXPERIMENTAL|pathological group|pathological group
62097347|NCT00823589|EXPERIMENTAL|healthy aged|healthy aged
62097348|NCT04209387||Control|No PTSD, TBI, and Depression
62097349|NCT04209387||PTSD|Veterans with PTSD
62097350|NCT00051311|OTHER|Donor|Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
62097351|NCT00051311|EXPERIMENTAL|Recipient|Recipients will receive induction chemotherapy (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.
62097352|NCT04391309|EXPERIMENTAL|anti-CD14 + SOC|"Anti-CD14: Anticipated 150 participants randomized to 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 intravenously.~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
62097353|NCT04391309|PLACEBO_COMPARATOR|Placebo + SOC|"Anticipated 150 participants randomized to Placebo diluent on Days 1-4 intravenously.~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
62097354|NCT06052982|OTHER|Drain|At the end of the knee arthroplasty, a drain is placed at the surgical site
62097355|NCT06052982|OTHER|Without drain|At the end of the knee arthroplasty, a drain is not placed at the surgical site
62097356|NCT02493790||Volunteers|Cognitive and motor performances were measured in a single and dual task situations.
62097357|NCT02493790||COPD patients|Cognitive and motor performances were measured in a single and dual task situations, before rehabilitation, and compared to those of healthy subjects. Then, Chronic Obstructive Pulmonary Disease patients were re-evaluated after rehabilitation.
62097358|NCT04559308|EXPERIMENTAL|metformin arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.
62097359|NCT04559308|ACTIVE_COMPARATOR|control arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel followed by surgery.
62294086|NCT05629039|NO_INTERVENTION|Wave 1-Control Group|The control group participants will complete the baseline questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
62294087|NCT05629039|NO_INTERVENTION|Wave 2-Control group|This group will complete the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
62097360|NCT02476643||Integrative Therapy|"This group receives and integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.~Patients are admitted to the hospital ward for 14 days."
62097361|NCT05435885|EXPERIMENTAL|Tele-rehabilitation group|The Tele-rehabilitation group performs 12 training sessions during four weeks. (3 sessions/week)
62097362|NCT05435885|OTHER|Control group|The control group receives usual care with only one educational session.
62294088|NCT05629039|EXPERIMENTAL|Wave 2-Delayed VHS Group|This group will receive the (delayed) Volitional Help Sheets intervention after completing the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire).
62294089|NCT05629039|EXPERIMENTAL|Wave 2-Early VHS Group|This group will complete the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
62294090|NCT05629039|EXPERIMENTAL|Wave 2-Repeated VHS group|This group will complete the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire), and receive a repeated, booster VHS intervention.
62294091|NCT05629039|NO_INTERVENTION|Wave 3-Control Group|This group will complete the six-month follow-up questionnaires. Due to ethical consideration, in wave three the control group will be offered the opportunity to complete the VHS form after they complete the follow-up assessments and the scores will not be included in the analysis.
62294092|NCT05629039|EXPERIMENTAL|Wave 3-Delayed VHS Group|This group will complete the six-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
62294093|NCT05629039|EXPERIMENTAL|Wave 3-Early VHS Group|This group will complete the six-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
62294094|NCT05629039|EXPERIMENTAL|Wave 3-Repeated VHS Group|This group will complete the six-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
62294095|NCT02688517||Ancillary-Correlative (genomic analysis)|Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.
62294096|NCT03291314|EXPERIMENTAL|Axitinib + Avelumab|On day 1 of the treatment phase, patients recruited to this arm will initiate concomitant continuous daily treatment with axitinib (InlytaTM, 5 mg comp BID) in combination with avelumab (10 mg/kg IV Q2 weeks)
62097363|NCT03967743||Infants with rare genetic disorders|This is a prospective, registry study of infants with genetic disorders being seen clinically in the NICU GraDS program.
62097364|NCT03024541||LASA study|
62097365|NCT03024541||InterRAI consortium|
62097366|NCT06330402|EXPERIMENTAL|Painful condition|Hypertonic saline injection to the infrapatellar fat pad.
62097367|NCT06330402|PLACEBO_COMPARATOR|Control condition|Isotonic saline injection to the infrapatellar fat pad.
62097368|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
62097369|NCT02729324|EXPERIMENTAL|FORRAD group|This group of patients will receive Medical Radiation Protectants (FORRAD®) during study for prevention and treatment of acute radiation-induced dermatitis. This is the experimental group.
62097370|NCT02729324|ACTIVE_COMPARATOR|Biafine group|This group of patients will receive Trolamine (Biafine) during study for prevention and treatment of acute radiation-induced dermatitis. This is the active comparator group.
62097371|NCT01113229|EXPERIMENTAL|Misoprostol|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two misoprostol tablets taken orally (400µg) following cord clamp
62097372|NCT01113229|PLACEBO_COMPARATOR|PLACEBO|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two placebo tablets taken orally following cord clamp.
62097373|NCT05997979|ACTIVE_COMPARATOR|QUTENZA|"The experimental product is QUTENZA®, a cutaneous patch which contains 179 mg of capsaicin (capsaicin 8%).The patch measures 14 cm x 20 cm.~The second application takes place three months after the first application."
62097374|NCT05997979|PLACEBO_COMPARATOR|Placebo|"The placebo comparator is a hydrocolloid dressing: COMFEEL PLUS TRANSPARENT, a medical device class IIb commercialized by Coloplast. The patch measures 15 cm x 15 cm.~The second application takes place three months after the first application."
62097375|NCT06359002|EXPERIMENTAL|Dose Escalation|Escalating dose cohorts of BYON4413 for patients with AML or MDS.
62097376|NCT01577043|ACTIVE_COMPARATOR|Racecadotril|intestinal antisecretory
62097377|NCT01577043|PLACEBO_COMPARATOR|cornstach solution|Cornstarch powder diluted in distilled water
62097378|NCT01288638|EXPERIMENTAL|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
62097379|NCT01288638|PLACEBO_COMPARATOR|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
62097380|NCT05047094|EXPERIMENTAL|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds in Combination with Standard Treatment of Pembrolizumab
62097381|NCT06302062|EXPERIMENTAL|Cohort A|Three patients were planned to be enrolled, and each subject received one to two cell transfusions.
62097382|NCT06302062|EXPERIMENTAL|Cohort B|14 to 20 patients were enrolled, and each subject received one to two cell transfusions. In this group, Tumor Associated Lymph node T cells were combined with Serplulimab Injection.
62097383|NCT06403644|ACTIVE_COMPARATOR|Active Photobiomodulation Full Body Light Bed Therapy|Active treatment will be provided via a specialized full body light bed equipped with light-emitting diodes (LEDs) emitting specific wavelengths of light. The participant will be asked to lay in the bed for a 20-minute session. Treatment will be provided 3 times a week for 3 weeks.
62097384|NCT06403644|SHAM_COMPARATOR|Sham Photobiomodulation Full Body Light Bed Therapy|Sham-PBMT will be delivered in the same manner as indicated for the Active treatment process, but the devices will not be turned on. The participant will be asked to lay in a specialized full body light bed equipped with light-emitting diodes (LEDs) for a 20-minute session. Sham-PBMT Treatment will be provided 3 times a week for 3 weeks.
62097385|NCT04543344|EXPERIMENTAL|Low Dose|Repeated multiple doses
62097386|NCT04543344|PLACEBO_COMPARATOR|placebo|Repeated multiple doses
62097387|NCT04543344|EXPERIMENTAL|High Dose|Repeated multiple doses
62097388|NCT03269396|EXPERIMENTAL|Larynx Allograft Transplantation|Cadaveric laryngotracheal transplantation
62097389|NCT04880070|EXPERIMENTAL|Shockwave Device|The Shockwave device will be used on multiple areas of the body for the purpose of treating connective tissue.
62097390|NCT02955862|OTHER|Assigned Interventions Antifungals Patients with symptoms|"Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.~For CrAg-positive patients, the initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 \>200 cells/µL for at least 6 months."
62097391|NCT06615674|EXPERIMENTAL|Dapagliflozin|The intervention group will have dapagliflozin 10mg once a day every morning besides standard treatment of Acute Coronary Syndrome for 14 days before further evaluation
62097392|NCT06615674|EXPERIMENTAL|Control|The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
62097393|NCT01217580|EXPERIMENTAL|20 ml per side of 0.5% ropivacaine|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
62660577|NCT05297708||All Participants|he population would be pediatric patients 6 years to \<19 years of age who were referred for elevated blood pressure. At the initial clinic visit, the participant will be consented and a thorough history will be taken. An ECHO and non-invasive vascular measurements will be taken (central BP, augmentation index, pulse wave velocity). Patients will have an ambulatory blood pressure monitor (ABPM) placed and be trained to use a home blood pressure monitor (HBP) which will be sent home with them. The monitors in this study are FDA-approved and are being used as indicated. After one day at home, patients will return the ABPM via mail and continue to take measurements with the HBP for 20 days.
62097394|NCT01217580|PLACEBO_COMPARATOR|20 ml per side of 0.9% sodium chloride|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
62097395|NCT01567059|EXPERIMENTAL|Arm I (tosedostat and cytarabine)|Patients receive tosedostat PO QD on days 1-35 and cytarabine IV on days 1-5.
62097396|NCT01567059|EXPERIMENTAL|Arm II (tosedostat and decitabine)|Patients receive tosedostat PO QD on days 1-35 and decitabine IV on days 1-5.
62097397|NCT00347659|EXPERIMENTAL|Single Treatment|Experimental Treatment
62097398|NCT06614023||underweight|BMI \<20.0 kg/m2
62097399|NCT06614023||normal weight|BMI 20.0-24.9 kg/m2
62097400|NCT06614023||overweight|BMI 25-29.9 kg/m2
62097401|NCT06614023||obesity class I|BMI 30-34.9 kg/m2
62660578|NCT01931605|EXPERIMENTAL|Embolization procedure|selective prostatic arterial embolization using BeadBlock (Terumo) particules
61909420|NCT01811264|EXPERIMENTAL|Intervention|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. Then they will be helped through the Patient-Participation Aid (PPA) by the research assistant (RA). Then they will meet with their doctor while the visit is video-recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication. Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
61909421|NCT01811264|NO_INTERVENTION|Usual Care|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. They will have their doctor's visit video recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication.Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
61909422|NCT01827683|ACTIVE_COMPARATOR|Hyperbaric oxygen therapy group|hyperbaric oxygen therapy during the first 2 months
61909423|NCT01827683|OTHER|Crossed group|no active intervention during the first 2 months.After 2 months will be crossed to HBOT
61909424|NCT06449274|EXPERIMENTAL|DCB treatment|Non-flow limited vulnerable plaque will be treated by drug-coated balloon when the enrolled individual is randomized into DCB treatment group. The individual located in DCB treatment will receive guideline-directed medical treatment.
61909425|NCT06449274|ACTIVE_COMPARATOR|Guideline-directed medical treatment|Non-flow limited vulnerable plaque will be left with no intervention when the individual is randomized into guideline-directed medical treatment group. The individual will receive guideline-directed medical treatment alone.
61909426|NCT01495312|EXPERIMENTAL|SLT|
61909427|NCT03459391|EXPERIMENTAL|XC221 60 mg|Cohort 1:16 subjects were randomized in a 3:1 ratio to be treated either with 60 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
61909428|NCT03459391|EXPERIMENTAL|XC221 200 mg|Cohort 2: 16 subjects were randomized in a 3:1 ratio to be treated either with 200 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
61909429|NCT03459391|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm consists of 8 subjects (4 subjects from each cohort).
61909430|NCT01873521|ACTIVE_COMPARATOR|NIV PS|The patients in this arms will received non invasive ventilation in PS mode.
62097402|NCT06614023||obesity class II|BMI 35-39.9 kg/m2
62097403|NCT06614023||obesity class III|BMI \>40 kg/m2
62097404|NCT01792609|ACTIVE_COMPARATOR|Maximum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
62097405|NCT01792609|ACTIVE_COMPARATOR|Minimum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
62097406|NCT02425319||patients with CapFlex-PIP© implant|
61909431|NCT01873521|ACTIVE_COMPARATOR|NIV NAVA|The patients in this arm will received non invasive ventilation in NAVA mode.
62097407|NCT02425319||patients with silicone implant|
62097408|NCT02425319||patients with healthy PIP joints|
62097409|NCT06020417|ACTIVE_COMPARATOR|O-Arm neuronavigator|The O-ARM imaging system can help surgeons to view the spine in real time and verify the placement of implants such as screws or rods. Primarily, therefore, in image acquisition, during surgery, the O-ARM is activated and generates real-time images of the patient's spine, so that these images are displayed on a screen, allowing the surgeon to visualize the anatomical structures and check that implant placement is proper. Therefore, when analyzing these images, the surgeon can, for example, analyze and verify the placement of the implants and ensure that the arthrodesis is performed correctly, in such a way that, if necessary, the surgeon can make adjustments and then acquire new images for verification.
62097410|NCT06020417|PLACEBO_COMPARATOR|Conventional|The conventional procedure for spinal arthrodesis will involve the intervertebral disc removal step between the vertebrae that will be fused. This is done precisely to create space for the bone graft that will be placed later. Then, there is bone surface preparation, where you prepare the bone surfaces of the vertebrae that will be fused, removing any soft tissue that might interfere with bone fusion. Then, there is bone graft placement, where the surgeon places a bone graft between the vertebrae that will be fused together. This graft can be obtained from another part of the patient's body (such as the pelvis) or from a deceased donor. Then, in the spinal column fixation step, rods, screws and/or plates are used to fix the vertebrae that will be fused.
62097411|NCT05235061|EXPERIMENTAL|PTE Participant Group 1|"PTE Participant Group 1 will receive the HOBSCOTCH-PTE intervention consisting of 1:1 sessions delivered once per week including:~* 1 pre-HOBSCOTCH Session (on webcam)~* 1 educational session (on webcam)~* 6 telephone sessions~* 1 wrap-up session (webcam or telephone)"
62097412|NCT05235061|OTHER|PTE Participant Group 2|"PTE Participant Group 2 will be on a 3-month wait list after which they will receive HOBSCOTCH-PTE consisting of 1:1 sessions delivered once per week including:~* 1 pre-HOBSCOTCH Session (on webcam)~* 1 educational session (on webcam)~* 6 telephone sessions~* 1 wrap-up session (webcam or telephone)"
62097413|NCT05235061|EXPERIMENTAL|PTE Caregiver Group 1|Caregiver Group 1 will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 1 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
62466279|NCT02937701|ACTIVE_COMPARATOR|Infliximab|"Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46."
62466280|NCT03872947|EXPERIMENTAL|Arm A: TRK-950 + FOLFIRI|"* Colorectal Cancer~* TRK-950 will be administered intravenously (IV) on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
62466281|NCT03872947|EXPERIMENTAL|Arm B: TRK-950 + Gemcitabine/Cisplatin|"* Cholangiocarcinoma or Bladder Cancer~* TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Cisplatin will be administered by infusion. Then, Gemcitabine will be administered as an IV infusion."
62466282|NCT03872947|EXPERIMENTAL|Arm C: TRK-950 + Gemcitabine/Carboplatin|"* Ovarian Cancer~* TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Gemcitabine will be administered as an intravenous infusion. On day 1, following the administration of TRK-950 and Gemcitabine, Carboplatin will be administered IV."
62466283|NCT03872947|EXPERIMENTAL|Arm D: TRK-950 + Ramucirumab/Paclitaxel|"* Gastric Cancer~* TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Ramucirumab will be administered as an IV infusion. Paclitaxel will be dosed on days 1, 8 and 15, after the Ramucirumab on days 1 and 15 and after the TRK-950 on day 8."
62660579|NCT05406089||The short-term antiviral therapy (STAT) group|The short-term antiviral therapy (STAT) group was defined as individuals who received HBV antiviral ( antiviral treatments consisted of adefovir (10 mg/day), entecavir (0.5 mg/day), and lamivudine (100 mg/day) )at least 24 weeks before hepatectomy (antiviral therapy still continued during perioperative period). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
62466284|NCT03872947|EXPERIMENTAL|Arm E: TRK-950 + PD1 inhibitors|"•Solid Tumors~E-1: TRK-950 + Nivolumab~•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.~E-2: TRK-950 + Pembrolizumab~•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
62466285|NCT03872947|EXPERIMENTAL|Arm F: TRK-950 + Imiquimod Cream|"* Palpable subcutaneous malignant lesions~* TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. Imiquimod cream is to be applied 5 of 7 days in a row with 2 days rest for a maximum of 2 cycles (total 6 weeks)."
62466286|NCT03872947|EXPERIMENTAL|Arm G: TRK-950 + Bevacizumab|"* Renal Cell Carcinoma~* TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Bevacizumab will be administered as an IV infusion."
62660580|NCT05406089||The perioperative antiviral therapy (PAT) group|The perioperative antiviral therapy (PAT) group was defined as individuals who received antiviral treatment perioperatively ( antiviral treatments consisted of adefovir (10 mg/day), entecavir (0.5 mg/day), and lamivudine (100 mg/day) ). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
62466287|NCT03872947|EXPERIMENTAL|Arm H: TRK-950 + PD1 inhibitors|"•Melanoma~H-1: TRK-950 + Nivolumab~•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.~H-2: TRK-950 + Pembrolizumab~•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
62466288|NCT03872947|EXPERIMENTAL|Arm J: TRK-950 + FOLFIRI|"* Colorectal Cancer~* TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
62466289|NCT03872947|EXPERIMENTAL|Arm K: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab|"* Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer~* TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. Gemcitabine will be administered as an intravenous infusion on days 1 and 8. On day 1, following the administration of Gemcitabine, Carboplatin will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next. After 6 cycles of chemotherapy the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease."
62660581|NCT04142827|EXPERIMENTAL|Therapy with high flow humidification|The patients will be activated after enrollment with myAirvo2 device at home for 6 months before first observations
62660582|NCT04142827|NO_INTERVENTION|Therapy with usual care|The patients will be under usual care for observational
61909432|NCT03986931|EXPERIMENTAL|Pharmacist-Bidirectional Texting Group|Patients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.
61909433|NCT03986931|ACTIVE_COMPARATOR|Control Group|Patients randomized to the control group will also return 7 morning and 7 evening blood pressure measurements. The report will be shared with a pharmacist who will call the patient to discuss the measurements and possibly recommend follow up with a physician, but no other pharmacist intervention or monitoring will occur during the 12 months.
61909434|NCT03838809|EXPERIMENTAL|INTERVENTION|A group that underwent a neurological physiotherapy program with electromyography-biofeedback on the hand and the foot
62660583|NCT05283837|EXPERIMENTAL|Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)|Pertuzumab (ZRC-3277) will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
62466290|NCT03872947|EXPERIMENTAL|Arm O: TRK-950 + PLD|"* Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer~* TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. PLD will be dosed as IV on Day 1 of each cycle. On days that TRK-950 and PLD are both dosed, PLD will be dosed first."
62466291|NCT03872947|EXPERIMENTAL|Arm Q: TRK-950 + Ramucirumab/Paclitaxel|"* Gastric cancer~* TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. On days 1 and 15, ramucirumab will be administered IV. Paclitaxel will be dosed on days 1, 8 and 15, after ramucirumab on days 1 and 15, before TRK-950 on day 8."
62466292|NCT03872947|EXPERIMENTAL|Arm R: TRK-950 + Bevacizumab|"* Renal cell carcinoma cancer~* TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. Bevacizumab will be dosed as IV on Day 1 and 15 of each cycle. On days that TRK-950 and Bevacizumab are both dosed, Bevacizumab will be dosed first."
62660584|NCT05283837|ACTIVE_COMPARATOR|Pertuzumab (Perjeta®, a product of Genentech, Inc.,)|Perjeta® will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
62660585|NCT00487591||Simva+Omacor|
62660586|NCT00487591||Simva + Placebo|
62660587|NCT03043781|EXPERIMENTAL|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
62660588|NCT03043781|ACTIVE_COMPARATOR|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
62660589|NCT06305039|EXPERIMENTAL|Bilateral Cochlear Implant Users|
62660590|NCT06305039|EXPERIMENTAL|Unilateral Cochlear Implant Users with Single-Sided Deafness|
62660591|NCT06305039|OTHER|Non-Implanted Listeners with Acoustic Hearing|
62660592|NCT00591799|EXPERIMENTAL|Jarvik 2000 Ventricular Assist System|Jarvik 2000 Ventricular Assist System
61909435|NCT03838809|ACTIVE_COMPARATOR|CONTROL|A group that underwent a conventional physiotheraphy intervention
61909436|NCT02338908|EXPERIMENTAL|Experimental group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
61909437|NCT02338908|ACTIVE_COMPARATOR|Control group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
61909438|NCT05088473||Mutliple sclerosis|
61909439|NCT05088473||CIS/RIS|
61909440|NCT05088473||Other CNS inflammatory diseases|
61909441|NCT05088473||Non inflammatory CNS diseases|
61909442|NCT02604537|ACTIVE_COMPARATOR|Betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone (Celestone)
61909443|NCT02604537|EXPERIMENTAL|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac (Toradol)
61909444|NCT03601234|EXPERIMENTAL|laparoscopic surgery|This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.
61909445|NCT03601234|EXPERIMENTAL|laparoscopic and endoscopic combined surgery|LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy.
61909446|NCT02683746|EXPERIMENTAL|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
62097414|NCT05235061|OTHER|PTE Caregiver Group 2|Caregiver Group 2 will be on a 3 month wait list with their PTE patient after which time they will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 2 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
62097415|NCT03796494|ACTIVE_COMPARATOR|Control Group|The control group is considered, using the company's classic multi-position straight anti-rotational abutment
62660593|NCT00226655|EXPERIMENTAL|I|All patients will receive hCRF (XERECEPT) 2mg/day
62097416|NCT03796494|EXPERIMENTAL|Test group|The test group is considered, where the new multi-position straight esthetic anti-rotational slim abutment is used
62097417|NCT02005666|EXPERIMENTAL|Test-Cadila healthcare limited|Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
62097418|NCT02005666|ACTIVE_COMPARATOR|Reference|Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
62097419|NCT02005666|PLACEBO_COMPARATOR|Placebo|Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
62097420|NCT06614413|ACTIVE_COMPARATOR|Mother-child binomial with nutritional intervention|Interventions will be based on dietary-nutritional advice, derived from scientific evidence: nutrition based on the Mediterranean diet (MD) and usual treatment
62097421|NCT06614413|PLACEBO_COMPARATOR|Mother-child binomial as a control group (with follow-up without intervention).|Mother-child binomial as a control group, with follow-up without intervention.
62097422|NCT04848909|EXPERIMENTAL|Men with prostate cancer post-prostatectomy|Men with localized prostate cancer who are considered candidates for post-prostatectomy radiation.
62097423|NCT01939860|NO_INTERVENTION|Usual pharmacy care|Participants will not receive any structured written education on hypertension and its treatment
62097424|NCT01939860|EXPERIMENTAL|usual pharmacy care plus structured information|Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
62097425|NCT06614530|EXPERIMENTAL|Chilipad Docker Pro Interventional Arm|Users will receive a Chilipad Docker Pro.
62097426|NCT05153915|EXPERIMENTAL|Tacrolimus granules (Modigraf)|"The first dose of Modigraf should be administered within 24 hours after reperfusion. Participants will be treated with a Modigraf-based immunosuppressive regimen.~The initial daily dose of Modigraf is given in two divided doses (recommended interval 12 hours) postoperatively. Subsequent oral Modigraf doses will be adjusted by the investigator based on clinical evidence of efficacy, occurrence of AEs, and tacrolimus whole blood trough level."
62097427|NCT06711471|EXPERIMENTAL|trifluridine/tipiracil, bevacizumab, camrelizumab|TAS-102 35mg/m² twice daily, orally on Days 1-5; Bevacizumab 5mg/kg intravenous infusion on Day 1; Camrelizumab 200mg intravenous infusion on Day 1; Repeat every 14 days.
62660594|NCT00147238|EXPERIMENTAL|Ferumoxtran-10 MRI|MR lymphangiography using Ferumoxtran-10 contrast agent.
62660595|NCT00147238|ACTIVE_COMPARATOR|MRI|MR lymphangiography before injecting Ferumoxtran-10 contrast agent.
62660596|NCT05410067|EXPERIMENTAL|Cervicothoracic Junction Mobilization Technique|"It is a part of manual therapy technique. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given.For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7.~Dosage:~Glide would be given according to the nature, intensity and severity of the patient's pain. 30 sec bouts with 3 sets \&amp; 2 reps. Total 2-3 min duration. 2 sessions per week for 3 weeks."
62660597|NCT05410067|EXPERIMENTAL|Eccentric Muscle Energy Technique|"Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.~Dosage:~The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch. This is applied for generalized cervical movements in each plane like Flexion, Extension, Side Bending~\&amp; Rotation. 3-5 repetitions with 2-3 sets were performed. Total duration: 3-5 min 2 sessions per week for 3 weeks."
62660598|NCT00762905|ACTIVE_COMPARATOR|1|LiquiBand Laparoscopic
61909447|NCT02683746|EXPERIMENTAL|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
61909448|NCT00879008||Group 1|
62660599|NCT00762905|ACTIVE_COMPARATOR|2|Dermabond
62660600|NCT00839137||no exercise program group|group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit
61909449|NCT05551247|EXPERIMENTAL|Envafolimab plus recombinant human endostatin (endostatin)|Envafolimab:300mg,sc,d3,Q3W; endostatin:210mg,civ,d1-3,Q3W.
61909450|NCT06097390|EXPERIMENTAL|Sequence 1: Semaglutide J then Semaglutide K|Oral semaglutide J will be administered in treatment period 1 followed by semaglutide K in treatment period 2.
62097428|NCT03361592|EXPERIMENTAL|Spinal Manipulative Therapy|The participants assigned to the intervention group received the procedure Lumbar (SMT) was performed after baseline measurements, using Diversified techniques, aiming to correct vertebral dysfunctional segments after clinical assessment. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was performed in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
62097429|NCT03361592|SHAM_COMPARATOR|Sham pre-load positioning SMT|"The participants assigned to the control group received the procedure Sham (pre-load positioning MVT). The Sham (SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained for approximately 1 minute in total, 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
62097430|NCT05490043|EXPERIMENTAL|ATG-101|"Dose Escalation Phase:~Will be conducted with an enhanced PDx cohort.~Dose Expansion Phase:~Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled."
62097431|NCT05328505|EXPERIMENTAL|Molecular Imaging Informed Radiation Dose Escalation and De-escalation|Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas.
62097432|NCT03332966||Participants|"The adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients are enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder.~The participants fill in psychiatric self-report questionnaires, and their structured diagnostic interview data are collected with their permission."
62097433|NCT05597098|EXPERIMENTAL|Female|The participant will initially attend either in person or virtually for a screening visit for eligibility. Cantharidin will be applied on the second visit to the forearm, back or abdomen (depending on patient preference) via 1cm2 cantharidin soaked filter paper. The particpant will then attend for two further cantharidin applications (24 hr and 48 hr after the first application). 72 hours after initial cantharidin application the blister fluid will be collected.
62097434|NCT05597098|EXPERIMENTAL|Male|The participant will initially attend either in person or virtually for a screening visit for eligibility. Cantharidin will be applied on the second visit to the forearm, back or abdomen (depending on patient preference) via 1cm2 cantharidin soaked filter paper. The particpant will then attend for two further cantharidin applications (24 hr and 48 hr after the first application). 72 hours after initial cantharidin application the blister fluid will be collected.
62097435|NCT05157334|EXPERIMENTAL|Deep breathing|"Sub-project 1: To compare the effect of one session of DB and one session of non-invasive auricular tVNS on vagal nerve tone measured by HRV in healthy participants and in patients with RA and SLE.~Sub-project 2: A dose-response study in healthy participants comparing the effect of 5, 15 and 30 minutes of DB on HRV.~Sub-project 3: To investigate the effect of the optimal dose found in sub-project 2 in patients with RA and SLE measured by HRV, and to investigate its reproducibility by doing it twice."
62660601|NCT00839137||exercise group|will meet three times a week for 12 weeks, following specific exercise program
62660602|NCT02363660|EXPERIMENTAL|Arm I|will receive standard dose (0.5mL) delivered by standard intramuscular injection using a needle and syringe.
62660603|NCT02363660|EXPERIMENTAL|Arm II|will receive standard dose (0.5mL) delivered by intramuscular injection using the Pharmajet needle-free Stratis device.
62660604|NCT02363660|EXPERIMENTAL|Arm III|will receive a reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device
62660605|NCT03630900|EXPERIMENTAL|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
62660606|NCT03630900|NO_INTERVENTION|5% O2 culture|
62660607|NCT00870142|EXPERIMENTAL|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
62660608|NCT00870142|ACTIVE_COMPARATOR|B|Norvasc® 10 mg Tablets, single dose
62097436|NCT06614283|EXPERIMENTAL|Intervention arm|Ae mobile application tailored for patients with Type 2 diabetes, aiming to enhance their self-management practices will be used for the intervention arm. The app includes features such as medication tracking, appointment scheduling, patient data storage, advice for treatment and follow-ups, health education and promotion, and real-time health monitoring.
62097437|NCT06614283|NO_INTERVENTION|Control arm|The control arm will be given no intervention except usual care
62097438|NCT06018129|EXPERIMENTAL|R/R CD30+ cHL Cohort|
62097439|NCT06018129|EXPERIMENTAL|R/R CD30+ TCL Cohort|
62097440|NCT03342924|EXPERIMENTAL|Flanker test and physical fitness test|Participants performed a computer-based Flanker Task measuring cognitive control and physical fitness tests: two-minute walk, vertical jump, one-minute curl-ups, and handgrip strength. Body composition variables included: body mass index, percent body fat, waist circumference, and sagittal abdominal height. General linear models were performed to evaluate impacts of physical fitness and body composition on cognition, adjusting for age and sex.
61909451|NCT06097390|EXPERIMENTAL|Sequence 2: Semagultide K then Semaglutide J|Oral semaglutide K will be administered in treatment period 1 followed by semaglutide J in treatment period 2.
61909452|NCT03507114|EXPERIMENTAL|Rumination-Focused CBT (RFCBT)|RFCBT seeks to change the process of thinking as opposed to the content of thoughts as in standard CBT. The underlying idea is that shifting individuals repetitive negative thinking into the concrete mode will reduce unconstructive ruminations and worries.
61909453|NCT03507114|NO_INTERVENTION|Wait List Control Group|This arm represents the wait-list comparison group.
62097441|NCT05057754|EXPERIMENTAL|Experimental Group|A total of 50 participants are estimated to be recruited, each completing six conditions in the following order: 1) wrist cooling, 2) wrist heating, 3) exercising, 4) typing, 5) using a mouse, 6) cooking, with an observation of intraneural blood flow assessed with Doppler sonography before and after each condition.
62097442|NCT00126113|EXPERIMENTAL|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
62660609|NCT04632719|EXPERIMENTAL|Covid-19 Study Group|The Study Group will be the group that was remiss for COVID-19 and has some of the mentioned comorbidities as asthma, cardiovascular disease, cancer even if controlled by drugs or treatments.
62660610|NCT04632719|ACTIVE_COMPARATOR|Covid-19 Control Group|The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen cognitive functions' impairment after the remission of the symptoms of COVID-19.
61909454|NCT03837522|ACTIVE_COMPARATOR|Procurement Biopsy: Frozen section|In the routine care condition, biopsies will be processed immediately as a frozen section.
61909455|NCT03837522|ACTIVE_COMPARATOR|Procurement Biopsy: Permanent section|In the intervention group, the biopsy processing will be delayed to permanent section, and therefore not available until allocation is complete.
61909456|NCT04125251|ACTIVE_COMPARATOR|BISP,CT & LSB to Couples|In this arm 1, the LSB intervention will be offered to the BISP-CT beneficiary women and their spouses
61909457|NCT04125251|ACTIVE_COMPARATOR|BISP,CT & LSB to Women|In this arm, the LSB intervention will be offered to the BISP-CT beneficiary women only.
62097443|NCT00126113|OTHER|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
62097444|NCT05091762|NO_INTERVENTION|Blank control group|
62097445|NCT05091762|EXPERIMENTAL|Exercise group|
62097446|NCT05091762|NO_INTERVENTION|Hyperlipidemia group|
62660611|NCT04493177|EXPERIMENTAL|Gestational diabetes intervention|All mothers with gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
62660612|NCT04493177|EXPERIMENTAL|No diabetes intervention|Mothers without gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
62660613|NCT04493177|ACTIVE_COMPARATOR|No diabetes no intervention|Mothers without gestational diabetes will receive the conventional care for 18 months post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
61909458|NCT04125251|NO_INTERVENTION|BISP,CT & No LSB|This is the control group, where neither BISP-CT beneficiary women nor their spouses will be offered the LSB intervention
61909459|NCT02621840|EXPERIMENTAL|Intervention|Patients in the intervention group will be mandated to complete the PAT with Dr. Koka. After scheduling the surgery with the surgical coordinator, intervention patients will be required to go directly to Dr. Koka's office, to complete all necessary pre-operative steps.
61909460|NCT02621840|NO_INTERVENTION|Usual Care|Patients in the usual care group will be treated with the standard protocol that is currently utilized in the Wills Eye Hospital Cataract and Primary Eye Care (CPEC) Service. After scheduling the surgery with the surgical coordinator, the patient will be given pre-admission testing (PAT) paperwork to be completed. The patient schedules the PAT on his or her own with the primary care physician.The patient will be given the information for Dr. Koka's cardiology office if he or she has any problem getting the PAT done.
61909461|NCT01055652|EXPERIMENTAL|1|
61909462|NCT06066229||Lung transplant patients|Adult lung transplant patients followed at Hôpital Bichat (Paris) or Hôpital Foch (Suresnes)
61909463|NCT06066229||Relatives of lung transplant patients|Close relatives of lung transplant patients (spouse; partner; first-degree parent) followed at Bichat Hospital (Paris) or Foch Hospital (Suresnes).
61909464|NCT06066229||Physicians from lung transplant|Physicians from lung transplant centers in France, or French-speaking experts identified in the professional network of investigators
61909465|NCT06066229||Paramedical staff|Nurses, psychologists, physiotherapists, etc.) from the same French center or French-speaking centers whose primary focus is on caring for lung transplant patients
61909466|NCT06376903|ACTIVE_COMPARATOR|Study group ; of pilates exercises,Kegel exercises,and home care advices.advices|•study group : It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.
62097447|NCT05091762|NO_INTERVENTION|Hyperlipidemia and medication group|
62097448|NCT05091762|EXPERIMENTAL|Hyperlipidemia and exercise group|
62097449|NCT05091762|EXPERIMENTAL|Hyperlipidemia and medication and exercise group|
62660614|NCT03752827|EXPERIMENTAL|Adipose Derived Regenerative Cells|Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear
62660615|NCT03752827|ACTIVE_COMPARATOR|Corticosteroid|Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.
61909467|NCT06376903|ACTIVE_COMPARATOR|Controlled group;Kegel exercises,and home care advices.|Controlled group : It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A).
61909468|NCT06435065|SHAM_COMPARATOR|BIODENTINE|DIRECT PULP CAPPING WILL BE DONE USING BIODENTINE AS DIRECT PULP CAPPING AGENT
62097450|NCT05091762|NO_INTERVENTION|Routine treatment group|
62097451|NCT05091762|EXPERIMENTAL|Routine treatment and exercise group|
62097452|NCT04847648|ACTIVE_COMPARATOR|Control - Mechanical instrumentation of implant surface|The control group will be subjected to non-surgical decontamination including the use of hand instruments and polishing cups aiming at the removal of all supra-mucosal soft and hard deposits from the implant surfaces.
62097453|NCT04847648|EXPERIMENTAL|Test - Mechanical instrumentation and air-polishing of implant surface|In the test group the mechanical instrumentation will be supplemented by the use of an air-polishing device during non-surgical therapy.
62097454|NCT03032159|NO_INTERVENTION|Control Group|Participants randomized to the control group will receive their usual asthma care from their provider. Additionally, participants in the control group will receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment.
62660616|NCT05456672|EXPERIMENTAL|Dietary intervention|Dietary intervention using standardized test meals
62660617|NCT02139319|EXPERIMENTAL|Botulinum toxin|Single intra-articular injection
62097455|NCT03032159|EXPERIMENTAL|Text2Breathe Study Group|"The study group spends about 10-20 minutes learning about ways to have better communication with their child's primary care provider about his/her asthma. Additionally this group is enrolled in the Text2Breathe messaging program which sends asthma related educational text messages 2 times a week for 3 months. Participants randomized to the study group will also receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment."
62097456|NCT06055075|EXPERIMENTAL|Dose Exploration Phase: Forimtamig (Dose 1) + Carfilzomib|Participants will receive Dose 1 of forimtamig, subcutaneous (SC) injection in combination with carfilzomib, intravenous (IV) infusion until disease progression.
62097457|NCT06055075|EXPERIMENTAL|Dose Exploration Phase: Forimtamig (Dose 2) + Carfilzomib|Participants will receive Dose 2 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.
61909469|NCT06435065|SHAM_COMPARATOR|MINERAL TRIOXIDE AGGREGATE|DIRECT PULP CAPPING WILL BE DONE USING MTA AS DIRECT PULP CAPPING AGENT
61909470|NCT06435065|SHAM_COMPARATOR|THERACAL LC|DIRECT PULP CAPPING WILL BE DONE USING THERACAL LC AS DIRECT PULP CAPPING AGENT
62097458|NCT06055075|EXPERIMENTAL|Dose Exploration Phase: Forimtamig (Dose 3) + Carfilzomib|Participants will receive Dose 3 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.
62097459|NCT06055075|EXPERIMENTAL|Dose Exploration Phase: Forimtamig (Dose 1) + Daratumumab|Participants will receive Dose 1 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
61909471|NCT06435065|ACTIVE_COMPARATOR|TRISTRONTIUM ALUMINATE|DIRECT PULP CAPPING WILL BE DONE USING TRISTRONTIUM ALUMINATE AS DIRECT PULP CAPPING AGENT
61909472|NCT03455790|EXPERIMENTAL|Wheelchair Basketball|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
61909473|NCT03455790|EXPERIMENTAL|20 Meters Sprint Test|It will be done to evaluate the speed of sportsmen's wheelchair use. The sportsman will be prompted to take the chair as fast as possible after the wheelchair has been positioned so that the front bar is on the field edge. The 2 meter slow-down distance will also be counted in seconds and the completion time of the 20 meter track will be measured.
61909474|NCT03455790|OTHER|Slalom test|It will be done to measure the ability of sportsmen to use wheelchairs. Five cones will be placed starting 1.5 meters from the starting line of the Sahara, with a distance of 1.5 meters between them. Sportsmen will be required to complete the course by making a slalom between these topics and making a slalom in the same way by turning back and passing through the starting line. Track completion times will be recorded in seconds.
61909475|NCT03455790|OTHER|Zone Shot Test|Zone Shot test will be applied to evaluate the shooting skills of the athletes. In the starting position the athlete will be asked to shoot the pot from the athlete with the warning given while on the foul shooting line and then to take their own rebounds. They will have to shoot again from the point where they have taken the rebound and rebound and go back to the foul line. The test will continue for 2 minutes in this manner. At the end of the 2-minute training period, the athletes will score the correct shot 2, the missed shot 1 point and the total score will be recorded.
62097460|NCT06055075|EXPERIMENTAL|Dose Exploration Phase: Forimtamig (Dose 2) + Daratumumab|Participants will receive Dose 2 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
62097461|NCT06055075|EXPERIMENTAL|Dose Exploration Phase: Forimtamig (Dose 3) + Daratumumab|Participants will receive Dose 3 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
62097462|NCT06055075|EXPERIMENTAL|Dose Expansion Phase: Forimtamig|Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase until disease progression or completion of 12 months of treatment, whichever occurs first.
62097463|NCT06055075|EXPERIMENTAL|Dose Expansion Phase: Forimtamig + Carfilzomib|Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with carfilzomib, IV infusion until disease progression.
62097464|NCT06055075|EXPERIMENTAL|Dose Expansion Phase: Forimtamig + Daratumumab|Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with daratumumab, SC injection until disease progression.
62097465|NCT00601640|EXPERIMENTAL|Eflornithine HCL|Patients apply Eflornithine HCL ointment to their left forearm twice daily on days 1-90.
62097466|NCT00601640|ACTIVE_COMPARATOR|Diclofenac Na|Patients apply topical Diclofenac Na gel to their left forearm once daily on days 1-90.
62097467|NCT00601640|EXPERIMENTAL|Eflornithine HCL and Diclofenac Na|Eflornithine HCl ointment and Diclofenac Na gel applied twice and once daily, respectively on days 1-90.
62097468|NCT03315221|EXPERIMENTAL|Test product|Human Milk Fortifier (HMF) with added lipids.
62097469|NCT03315221|ACTIVE_COMPARATOR|Control product|Commercially available HMF (without lipids).
62097470|NCT05898139||Assisting (caregiver) / aided (patient with Parkinsonian syndrome) dyad|The dyad will be filmed during a meal had during a hospitalization, and an interview with the sick person and his caregiver will be carried out independently. Between 15 days and a month after the first visit, excerpts from the film will be presented and commented by the dyad according to the technique of self-confrontation
62097471|NCT04438915|NO_INTERVENTION|Average weight .control group|Average weight BMI (18.5_25)
62097472|NCT04438915|ACTIVE_COMPARATOR|Overweight|Overweight BMI ( 25_30 )
62097473|NCT04438915|ACTIVE_COMPARATOR|Mild obese|Mild obese BMI (30_35 )
62097474|NCT00288769|OTHER|2|
62097475|NCT00660374|ACTIVE_COMPARATOR|A|
62097476|NCT00660374|EXPERIMENTAL|B|
62097477|NCT06384053|EXPERIMENTAL|Hyperthermia -Experimental Group A|The study arm in which hyperthermia and radiotherapy are administered. The RT Dose: 6 fractions of 5 Gy each, delivered twice per week and with a minimum interval of 48 hours, preferably 72 hours, between each fraction over three weeks.
62097478|NCT06384053|ACTIVE_COMPARATOR|Radiotherapy - Control Group|The study arm in which only radiotherapy is administered. RT Dose: 12 fractions of 4 Gy each, delivered 3 times per week, with sessions scheduled every other day (exceptions can be made in weeks with holidays) over four weeks.
62660618|NCT02139319|PLACEBO_COMPARATOR|Placebo|Single intra-articular injection
62097479|NCT00624104||1|Lean male
62097480|NCT00624104||2|Males with type 2 diabetes
62097481|NCT03057561|EXPERIMENTAL|3.0 Tesla Cardiac MRI using Dotarem contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Dotarem
62097482|NCT03057561|EXPERIMENTAL|3.0 Tesla Cardiac MRI using a Gadovist contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Gadovist
62660619|NCT02331732|ACTIVE_COMPARATOR|Control|Patients receive DOT as normal - involves patient going to polyclinic to be observed taking treatment every day
62660620|NCT02331732|EXPERIMENTAL|Treatment|Patients receive VOT - involves patient sending a video of themselves taking their treatment over M-health app which will be reviewed remotely by observers
62660621|NCT03518606|EXPERIMENTAL|Breast cancer cohort|Patients presenting advanced refractory breast cancer
62097483|NCT06630416|EXPERIMENTAL|Treatment (pemetrexed)|Patients receive pemetrexed IV over 10 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and urine sample collection on study as well as CT throughout the trial.
62097484|NCT02600429|EXPERIMENTAL|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
62097485|NCT02600429|PLACEBO_COMPARATOR|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
62097486|NCT01649427|EXPERIMENTAL|Prograf|Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
62097487|NCT01649427|EXPERIMENTAL|Tacroliums Hexal|Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
62097488|NCT05823636||uninvestigated dyspepsia|Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.
62097489|NCT04282746|EXPERIMENTAL|JNJ-54135419|Participants will receive a single oral dose of JNJ-54135419-AAA oral solution for sublingual administration in 1 of 3 serial dose escalating cohorts in fasted conditions.
62097490|NCT04661215||Symptoms of gastroparesis|Participants with symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0 (18/45 x 5)
62097491|NCT04661215||Control participants|Participants undergoing endoscopy for evaluation but without gastroparesis symptoms or gastroesophageal reflux symptoms. Score 1.0 or less (≤ 1 ) on the GCSI of Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) questionnaire
62097492|NCT03979742|EXPERIMENTAL|MC001 before locomotor training|Transplant UCBMNC (MC001) first and then perform locomotor training
62294097|NCT03291314|EXPERIMENTAL|Axitinib (+Avelumab)|"On day 1 of the treatment phase, patients recruited to this arm will initiate treatment with continuous daily axitinib (InlytaTM, 5 mg comp BID).~Patients who tolerate treatment with axitinib and are able to taper the dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone (or an equivalent dose of another oral corticosteroid) will initiate combination therapy with avelumab (10 mg/kg IV Q2 weeks) on day 43, following the the first MRI-based tumor response evaluation in week 6.~Patients who do not tolerate monotherapy with axitinib, or cannot decrease their daily dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone will not be allowed to initiate avelumab treatment."
62097493|NCT03979742|EXPERIMENTAL|Locomotor training before MC001|Locomotor training first and then transplant UCBMNC (MC001)
62660622|NCT03518606|EXPERIMENTAL|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
62660623|NCT03518606|EXPERIMENTAL|Cervix cohort|Patients presenting advanced refractory cervix cancer
62660624|NCT03518606|EXPERIMENTAL|Prostate cohort|Patients presenting advanced refractory prostate cancer
62097494|NCT06001684|EXPERIMENTAL|IBR854 Cell Injection|The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
62294098|NCT00323661|EXPERIMENTAL|1|Rate-adaptation by Closed Loop Stimulation
62660625|NCT03518606|EXPERIMENTAL|Miscellaneous cohort|Patients presenting advanced refractory solid tumour with high mutational load
62660626|NCT01766284|EXPERIMENTAL|Niris 1300e OCT imaging|OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.
62660627|NCT00877864|ACTIVE_COMPARATOR|High volume combined aerobic/resistance exercise|
62660628|NCT00877864|ACTIVE_COMPARATOR|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
62660629|NCT00877864|ACTIVE_COMPARATOR|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
62466293|NCT03872947|EXPERIMENTAL|Arm S: TRK-950 + Carboplatin / PLD/ Bevacizumab|"* Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer~* Treatment Phase: TRK-950 will be administered IV on days 1 and 15 of a 28-day cycle. Carboplatin will be administered as an intravenous infusion on day 1. On day 1, following the administration of Carboplatin, PLD will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next.~On days 1 and 15, TRK-950 will be administered IV after the Bevacizumab infusion.~• Maintenance Phase: After 6 cycles of chemotherapy, the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Following the Bevacizumab administration, TRK-950 will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease."
62660630|NCT00877864|ACTIVE_COMPARATOR|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
62097495|NCT03506490|EXPERIMENTAL|Experimental|The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.
62097496|NCT02939001|EXPERIMENTAL|Ophthalmic surgery group|Ophthalmic surgery group (refractive surgery, phakic Intraocular Lens implantation, and cataract surgery)
62097497|NCT03591289|ACTIVE_COMPARATOR|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
62097498|NCT03591289|ACTIVE_COMPARATOR|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
62466294|NCT03872947|EXPERIMENTAL|Arm T: TRK-950 + Paclitaxel|"* Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer~* TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On days 1, 8 and 15 of each cycle, Paclitaxel will be dosed on IV"
62466295|NCT05565664|ACTIVE_COMPARATOR|Ketamine group|"After preoperative assessment, participants will receive IM midazolam (0.1 mg/kg) and atropine (0.02 mg/kg) 30 min. before surgery as premedication.~Inhalation induction of GA will be done using 8% sevoflurane in 100% oxygen. After insertion of a peripheral IV cannula, IV fentanyl 1 mcg/kg and atracurium 0.5 mg/kg will be given. Direct laryngoscopy will be attempted to insert an age-appropriate cuffed ETT.~Patients will be maintained on controlled mechanical ventilation with a mixture of isoflurane in 60% oxygen in air, using a tidal volume of 8cc/kg and a frequency of 16-20 cycle/min. to maintain an ETCO2 35-40 mmHg and to keep an ET isoflurane concentration of 1.5-2%. All patients will receive 10 ml/kg of IV Ringer's solution in the operating room. A single dose of paracetamol 15 mg/kg IV drip will be administered for all patients once they arrive at the PACU.~Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg."
62466296|NCT05565664|ACTIVE_COMPARATOR|Magnesium group|"After preoperative assessment, participants will receive IM midazolam (0.1 mg/kg) and atropine (0.02 mg/kg) 30 min. before surgery as premedication.~Inhalation induction of GA will be done using 8% sevoflurane in 100% oxygen. After insertion of a peripheral IV cannula, IV fentanyl 1 mcg/kg and atracurium 0.5 mg/kg will be given. Direct laryngoscopy will be attempted to insert an age-appropriate cuffed ETT.~Patients will be maintained on controlled mechanical ventilation with a mixture of isoflurane in 60% oxygen in air, using a tidal volume of 8cc/kg and a frequency of 16-20 cycle/min. to maintain an ETCO2 35-40 mmHg and to keep an ET isoflurane concentration of 1.5-2%. All patients will receive 10 ml/kg of IV Ringer's solution in the operating room. A single dose of paracetamol 15 mg/kg IV drip will be administered for all patients once they arrive at the PACU.~Patients will receive IV magnesium sulphate in a dose of 40 mg/kg."
62466297|NCT00763763|EXPERIMENTAL|1|imatinib in combination with chemotherapy by vincristin and dexamethasone
62466298|NCT02495545|EXPERIMENTAL|CSFD with elevation of MAP|Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
62466299|NCT02495545|ACTIVE_COMPARATOR|Maintenance of MAP|Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
62660631|NCT00877864|ACTIVE_COMPARATOR|Printed PA information, pedometers and step log group|Printed physical activity information, pedometers and step log group
62660632|NCT00877864|PLACEBO_COMPARATOR|Control|
62097499|NCT04695080|ACTIVE_COMPARATOR|Cladribine (MAVENCLAD®)|
62097500|NCT04695080|PLACEBO_COMPARATOR|Placebo|
62097501|NCT06505837|EXPERIMENTAL|Arm1:JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy|
62097502|NCT06505837|ACTIVE_COMPARATOR|Arm 2:JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy|
62294099|NCT00323661|ACTIVE_COMPARATOR|2|Accelerometer based pacing rate adaptation
62097503|NCT05067192||Parkinson's Disease|Patients with Parkinson's Disease. Patients will undergo \[18F\]ACI-3847 PET, \[18F\]DOPA PET and MRI. Up to 20 patients will be scanned
62097504|NCT05067192||Dementia with Lewy Bodies|Patients with Dementia with Lewy Bodies. Patients will undergo \[18F\]ACI-3847 PET, \[18F\]DOPA PET and MRI. Up to 10 patients will be scanned
62097505|NCT05067192||Multiple System Atrophy|Patients with Multiple System Atrophy. Patients will undergo \[18F\]ACI-3847 PET, \[18F\]DOPA PET and MRI. Up to 10 patients will be scanned
62097506|NCT05067192||Corticobasal Syndrome|Patients with Corticobasal Syndrome. Patients will undergo \[18F\]ACI-3847 PET, \[18F\]DOPA PET and MRI. Up to 10 patients will be scanned
62097507|NCT05067192||Progressive Supranuclear Palsy|Patients with Progressive Supranuclear Palsy. Patients will undergo \[18F\]ACI-3847 PET, \[18F\]DOPA PET and MRI. Up to 10 patients will be scanned
62097508|NCT05067192||Healthy controls|Healthy contols. Contols will undergo \[18F\]ACI-3847 PET, \[18F\]DOPA PET and MRI. Up to 20 patients will be scanned
62097509|NCT00917254|EXPERIMENTAL|YM150 group-1|YM150 low dose group
62097510|NCT00917254|EXPERIMENTAL|YM150 group-2|YM150 high dose group
62097511|NCT00917254|PLACEBO_COMPARATOR|Placebo group|
62097512|NCT00917254|ACTIVE_COMPARATOR|Enoxaparin group|
62097513|NCT02669225|EXPERIMENTAL|Rested Wakefulness|RW PET/MR Scanning Sessions
62097514|NCT02669225|EXPERIMENTAL|Sleep Deprivation|SD PET/MR Scanning Sessions
62466300|NCT05644340|ACTIVE_COMPARATOR|Automated Gas Flow Group using speed 8 to reach targeted end-tidal sevoflurane concentration|Pediatric patients who are operated under general anesthesia using automated gas flow which is set to speed 8 to achieve targeted end-expiratory sevoflurane concentration (MAC 1.2) will be included in the study. Automated gas flow provides a gas mixture in different proportions which is automatically generated and consists of sevoflurane, oxygen and air. Inspired and end-tidal concentrations of sevoflurane, oxygen and air will be available on the anesthesia ventilator screen which will be recorded accordingly in15-minute intervals.
62466301|NCT05644340|ACTIVE_COMPARATOR|Automated Gas Flow Group using speed 4 to reach targeted sevoflurane concentration|Pediatric patients who are operated under general anesthesia using automated gas flow which is set to speed 4 to achieve targeted end-expiratory sevoflurane concentration (MAC 1.2) will be included in the study. Automated gas flow provides a gas mixture in different proportions which is automatically generated and consists of sevoflurane, oxygen and air. Inspired and end-tidal concentrations of sevoflurane, oxygen and air will be available on the anesthesia ventilator screen which will be recorded accordingly in15-minute intervals.
62466302|NCT04000464|EXPERIMENTAL|Single Arm|24 Week Lifestyle Modification intervention
62097515|NCT03985579|EXPERIMENTAL|Standard care and Kinesiology taping Group|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders.
62097516|NCT03985579|NO_INTERVENTION|Standard care Group|Assistance in baby feeding, manual of device-assisted (lactator) milk expression, cold compress, ibuprofen, gentle breast massage, breathing and shoulder girdle exercise.
62097517|NCT04340115||Participants treated with RINVOQ|Participants treated with upadacitinib in accordance with approved local label. Decision to treat with upadacitinib was made prior to offering participation in this study.
62097518|NCT05896306||Term neonates|
62097519|NCT05896306||Preterm neonates|
62097520|NCT05203055|EXPERIMENTAL|monotherapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 48 consecutive weeks. Patients will stop the treatment whenever HBsAg is eliminated, and those without HBsAg elimination after 48 dosages will enter the group of best treatment. The patients will be followed up for another 24 weeks after treatment.
62097521|NCT05203055|EXPERIMENTAL|continuous combination therapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 48 consecutive weeks, plus continuous oral NA. Patients will stop the treatment whenever HBsAg is eliminated, and those without HBsAg elimination after 48 dosages will enter the group of best treatment. The patients will be followed up for another 24 weeks after treatment.
62294100|NCT02874911|EXPERIMENTAL|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
62097522|NCT05203055|EXPERIMENTAL|pulse combination therapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 8 consecutive weeks and cessation for 4 weeks,plus continuous oral NA. Patients will discontinue the treatment at any time if they are recovery, and those without HBsAg elimination after 48 dosages will enter the group of best treatment.The patients will be followed up for another 24 weeks after treatment.
62097523|NCT05654649|PLACEBO_COMPARATOR|Group C|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
62097524|NCT05654649|ACTIVE_COMPARATOR|Group D|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
62097525|NCT06444347|EXPERIMENTAL|Biosynthetic Mesh|The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture. This is a biosynthetic mesh that completely reabsorbs in 12-18 months after surgery. The mesh is designed to provide strength during the initial healing phase after hernia repair, allowing for rapid tissue ingrowth and vascularization, gradually transferring the load to native tissue as it resorbs1. This mesh has been FDA approved for procedures involving soft tissue repair, such as hernia defects.
62097526|NCT06444347|ACTIVE_COMPARATOR|No Mesh|The non-mesh group will undergo repair with permanent suture only.
62097527|NCT03647475|EXPERIMENTAL|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfilled the inclusion criteria and none of the exclusion criteria were treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal was evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
62097528|NCT06493929||Paients with Successful weaning from Mechanical Ventilation|The criteria for successful extubation: successful extubation was defined as the ability to maintain spontaneous breathing for at least 48 h, without any ventilatory support.
62097529|NCT06493929||Patients with failed weaning from Mechanical Ventilation|failure extubation was defined as the reconnection to ventilator (invasive or noninvasive) within 48 h due to respiratory failure or other reasons. Extubation and the reconnection to ventilator were all based on SBT results and physicians' decision (5,9).
62097530|NCT02096003|ACTIVE_COMPARATOR|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
62097531|NCT02096003|EXPERIMENTAL|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
62097532|NCT05365386|EXPERIMENTAL|Tixel Treatment|All subjects will undergo 1-3 treatments (determined by the investigator assessment), 3-4 weeks apart with the Tixel device.
62097533|NCT01262495|OTHER|orchidectomy|as specified in the summary
62097534|NCT06613945|ACTIVE_COMPARATOR|Combined EUS-HGS and ERCP biliary drainage|unilateral metallic stent will be inserted on right side through ERCP and a hepaticogastrostomy transmural stent will be inserted on left side by EUS to secure biliary drainage
62097535|NCT06613945|ACTIVE_COMPARATOR|ERCP biliary drainage|bilateral metallic stents insertion will be attempted through ERCP to secure biliary drainage
62097536|NCT01151254|ACTIVE_COMPARATOR|PA-Intravenous Sedation|Propofol based total intravenous anesthesia and postoperative sedation
62097537|NCT01151254|ACTIVE_COMPARATOR|Volatile sedation|Total inhalational anesthesia and postoperative sedation with the AnaConda device
62097538|NCT03984747||Adult Transplant Patients|Adult subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
62097539|NCT03984747||Pediatric Transplant Patients|Pediatric subjects between ages 2-17 who have undergone at least one organ transplant prior to enrollment and are willing to provide assent/LAR is willing to provide consent.
62097540|NCT03984747||Pregnant Transplant Patients|Pregnant subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
62097541|NCT06704217|EXPERIMENTAL|Other|Patients with total hip arthroplasty (THA)
62097542|NCT06614244|EXPERIMENTAL|DOPA group|Children affected by acute persistent FPIES subjected to OIT for the offending food
62097543|NCT06614244|ACTIVE_COMPARATOR|Diet group|Children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet for the offending food
62097544|NCT03381391|EXPERIMENTAL|Feedback intervention condition|
62097545|NCT03381391|NO_INTERVENTION|Assessment-only control condition|
62097546|NCT03422510|EXPERIMENTAL|Regimen 1 - CXA-10 75 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm stays at 75 mg.
62097547|NCT03422510|EXPERIMENTAL|Regimen 1 - CXA-10 150 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm increases to 150 mg.
62097548|NCT03422510|EXPERIMENTAL|Regimen 2 - CXA-10 150 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.
62097549|NCT03422510|EXPERIMENTAL|Regimen 2 - CXA-10 300 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm increases to 300 mg.
62097550|NCT06690398|EXPERIMENTAL|Lumateperone high dose|Lumateperone 42 mg for patients ages 13-17 years old
62097551|NCT06690398|EXPERIMENTAL|Lumateperone low dose|Lumateperone 21 mg for patients ages 13-17 years old
62097552|NCT06690398|PLACEBO_COMPARATOR|Placebo|Placebo
62097553|NCT01796665|EXPERIMENTAL|Test product|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.
62097554|NCT01796665|ACTIVE_COMPARATOR|Reference product|Acanya Gel applied to the affected areas of the face once daily.
62097555|NCT01796665|PLACEBO_COMPARATOR|Placebo product|Placebo of the Test product applied to the affected areas of the face once daily.
62466303|NCT02157636|EXPERIMENTAL|CPI-0610|
62097556|NCT05708820|ACTIVE_COMPARATOR|Standard care|Group in face-to-face session
62097557|NCT05708820|EXPERIMENTAL|Online education programme|Group in online sessions
62097558|NCT06298188|EXPERIMENTAL|Risankizumab|Induction regimen: 0,4,8 IV and then every 8 weeks sc
62097559|NCT05897788|NO_INTERVENTION|Augmented Usual Care (AUC)|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6."
62097560|NCT05897788|ACTIVE_COMPARATOR|Augmented usual care + text-message check-ins|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Text check-in: Patients will also receive incentives for engagement with treatment and~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6."
62097561|NCT05897788|ACTIVE_COMPARATOR|Augmented Usual care + Contingency Management (CM)|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6.~CM: Patients will also receive incentives for engagement with treatment."
62097562|NCT05897788|ACTIVE_COMPARATOR|Augmented usual care + text-message check-ins + contingency management|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Text check-in: Patients will also receive incentives for engagement with treatment and~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6.~CM: Patients will also receive incentives for engagement with treatment."
62097563|NCT06458101|ACTIVE_COMPARATOR|Group 1: Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter
62097564|NCT06458101|EXPERIMENTAL|Group 2: Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter
62097565|NCT00577629|EXPERIMENTAL|Induction + Consolidation + Bexxar|Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
62097566|NCT03433274|EXPERIMENTAL|Randomized Cohort - Treatment Group|Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
62097567|NCT03433274|ACTIVE_COMPARATOR|Randomized Cohort - Control Group|Treatment of mitral regurgitation within commercially approved MitraClip system indications
62097568|NCT03433274|EXPERIMENTAL|Non-repairable Cohort|Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
62097569|NCT03433274|EXPERIMENTAL|Severe Mitral Annular Calcification (MAC) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System
62294101|NCT06016478|EXPERIMENTAL|L-citrulline|6 grams/day
62294102|NCT06016478|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose
62097570|NCT03433274|EXPERIMENTAL|Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System after the completion of enrollment in the Severe MAC Cohort
62294103|NCT06119880|EXPERIMENTAL|PERT Group|After surgery, resume diet and begin receiving standard PERT treatment (2 capsules per meal, 1 capsule per snack, taken with meals, starting at a dose of 40000 to 50000 units of lipase) for 8 weeks.
62294104|NCT06119880|PLACEBO_COMPARATOR|Placebo Group|Follow the routine treatment plan for pancreatic tumors during the perioperative period.
62294105|NCT01409928|EXPERIMENTAL|Lap-Band|Placement of the LAP-BAND® system will be performed laparoscopically under general anesthesia, using the pars flaccida technique. The device will be placed by surgeons from the University of Texas Southwestern Medical Center Obesity Management Program at Children's Medical Center Dallas. Surgeons will be fully trained in the placement of the LAP-BAND® device, in accordance with FDA approval of the device for the placement in adults. As is current practice in adults undergoing the procedure, incidentally discovered hiatal hernias are repaired at the time of band placement, to reduce the incidence of post-operative reflux. Children receive prophylactic antibiotics, and are observed overnight after surgery. Patients are generally discharged from the hospital the next day. The band will initially be left empty at the end of the placement procedure.
62294106|NCT00704470|ACTIVE_COMPARATOR|1|Classic one-day simulator training for intensivists.
62294107|NCT00704470|EXPERIMENTAL|2|Crew resource management training
62294108|NCT00962715|EXPERIMENTAL|TIV|TIV (Influenza Vaccine Trivalent Inactivated) alone
62660633|NCT03243799|EXPERIMENTAL|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.~Group psychoeducation."
62660634|NCT03243799|NO_INTERVENTION|Control Group|Usual clinical care
62660635|NCT00332397|ACTIVE_COMPARATOR|A|Rapamycin-eluting Stent (Cypher)
62660636|NCT00332397|ACTIVE_COMPARATOR|B|Zotarolimus-eluting Stent (Endeavor)
62660637|NCT00332397|ACTIVE_COMPARATOR|C|Rapamycin-eluting Stent
62660638|NCT00392041|EXPERIMENTAL|Eszopiclone|
62660639|NCT00392041|PLACEBO_COMPARATOR|Placebo|
62660640|NCT04593602|EXPERIMENTAL|Early Mobilization Intervention|The bedside nurse determines the prehospital Level of Function based on patient and family report and current Level of Function based on nursing mobility assessment. Each Level of Function has 3 primary activities designed to promote the patient to the next level. The nurse leads mobility activities based on the patient's current Level of Function once per shift, twice daily (AM+PM). If a patient is able to complete each of the 3 activities, the nurse on the subsequent shift will assess whether the Level of Function can be advanced. Physiotherapy consultation is available if required, although not obligatory. Patients are encouraged to spend as much time in the chair and ambulatory as possible.
62660641|NCT04593602|ACTIVE_COMPARATOR|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
62097571|NCT04071080|EXPERIMENTAL|100mg Fluorescein disodium|100mg Fluorescein disodium will be mixed with 500mL of Gatorade and taken orally by the participant
62097572|NCT04071080|PLACEBO_COMPARATOR|Placebo|500mL of Gatorade taken orally by the participant
62660642|NCT02013414|EXPERIMENTAL|3D ultrasound-guided biopsy|Participants will have a 3D ultrasound-guided biopsy of the prostate rather than the standard of care 2D ultrasound-guided biopsy.
62660643|NCT00230737|EXPERIMENTAL|A|Melatonin 0.4 mg
62660644|NCT00230737|EXPERIMENTAL|B|Melatonin 4.0 mg
62660645|NCT00230737|PLACEBO_COMPARATOR|C|
62660646|NCT01805336|OTHER|Arm A|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by traditional tests + executive function by virtual reality tests.~One week later, Assessment 2 : attentional function by virtual reality tests + executive function by traditional tests."
62097573|NCT03687385|ACTIVE_COMPARATOR|ASA I / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62097574|NCT03687385|ACTIVE_COMPARATOR|ASA II / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62294109|NCT00962715|EXPERIMENTAL|TIV + PEGrIFN-α|TIV + Pegylated Interferon
62294110|NCT00962715|EXPERIMENTAL|TIV + IFNα|TIV + Interferon
62660647|NCT01805336|OTHER|Arm B|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by virtual reality tests + executive function by traditional tests.~One week later, Assessment 2 : attentional function by traditional tests + executive function by virtual reality tests."
62660648|NCT04655872|EXPERIMENTAL|[14C]TPN171H|
62660649|NCT05759832|EXPERIMENTAL|Modified HFNC oxygen therapy group|
62660650|NCT05759832|OTHER|Face mask group|
62660651|NCT04445649||ICU patients|Patients with impaired consciousness admitted to intensive care unit after severe brain injury
62660652|NCT00113139|EXPERIMENTAL|Telephone-based coping skills|Telephone-based coping skills intervention
62660653|NCT00113139|ACTIVE_COMPARATOR|Usual Care|
62660654|NCT00962767|EXPERIMENTAL|a|2 doses of gemtuzumab ozogamicn administered at monthly intervals
62660655|NCT00962767|ACTIVE_COMPARATOR|b|2 years maintenance therapy with intermittent ATRA plus 6-Mercaptopurine (6-MP) and methotrexate (MTX)
62097575|NCT03687385|ACTIVE_COMPARATOR|ASA III / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
62294111|NCT01442467||Mild to Severe MAC|
62660656|NCT03067415|EXPERIMENTAL|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
62660657|NCT03067415|ACTIVE_COMPARATOR|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
62660658|NCT02963324|EXPERIMENTAL|Ivermectin|Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
62660659|NCT01670006|EXPERIMENTAL|Cochlear Implantation|Cochlear Nucleus Cochlear Implant System
62660660|NCT03965650|EXPERIMENTAL|Intervention group: video coaching exercises|Video coaching exercises group: patients will perform physical exercises according to a video coaching program 3 times weekly during 6 months. The on-line program has been designed especially for this study.
62660661|NCT03965650|ACTIVE_COMPARATOR|Control group: routine exercises|Routine method advising and encouraging patients to perform physical activities according to the WHO recommendations during 3 months then to follow the video coaching physical exercises program during 3 months.
62660662|NCT02886663|EXPERIMENTAL|immediate rehabilitation|
62097576|NCT03687385|EXPERIMENTAL|ASA I / HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62097577|NCT03687385|EXPERIMENTAL|ASA II/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62097578|NCT03687385|EXPERIMENTAL|ASA III/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
62294112|NCT01442467||No to mild MAC|
62294113|NCT01287754|EXPERIMENTAL|Single Arm|
62294114|NCT03971188|EXPERIMENTAL|Internal Brace|Patients will undergo Internal Brace procedure for thumb CMC OA.
62294115|NCT03971188|ACTIVE_COMPARATOR|LRTI|Patients will undergo ligament reconstruction tendon interposition (most commonly performed surgery for thumb CMC OA) and serve as control group.
62294116|NCT00018902|EXPERIMENTAL|1|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI.
62294117|NCT00018902|EXPERIMENTAL|2|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant.
62660663|NCT02886663|OTHER|delayed rehabilitation|
62660664|NCT00042978|EXPERIMENTAL|Arm I (oblimersen sodium, carboplatin, and etoposide)|Patients receive oblimersen sodium IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 60 minutes on days 6-8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
61909476|NCT03455790|OTHER|Aerobic Capacity|To measure aerobic capacity values, it shall be measured with Cosmed K5® device and Cosmos-Saturn branded treadmill using TS which is used in routine workout with customized ramp protocol. Before starting the test, the athlete's TS walking belt at a speed of 1 mph (1.7 km / h) at 0% incline for 3 min. and it will be checked whether or not the gas measuring equipment is disturbing the participant. If the athlete is unable to continue, the time at which the test will end will be determined. Time min. . The air that the individual exposes during the test will be collected using a breath by breath method.
61909477|NCT03455790|OTHER|Anaerobic Capacity|Using the Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement, TS basketball athletes will be subjected to a Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions.
62097579|NCT06231082|ACTIVE_COMPARATOR|Group one - percutaneous (P)|Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
62097580|NCT06231082|ACTIVE_COMPARATOR|Group two - EUS FNB (E)|"EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique"
62097581|NCT06169241|PLACEBO_COMPARATOR|Placebo|The placebo group will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
62660665|NCT00042978|ACTIVE_COMPARATOR|Arm II (carboplatin and etoposide)|Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62660666|NCT04652648|ACTIVE_COMPARATOR|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID for 10 days
62660667|NCT04652648|NO_INTERVENTION|Control|No Intervention
62294118|NCT00018902|EXPERIMENTAL|3|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI and receive cognitive behavioral therapy (CBT).
62466304|NCT05728385|EXPERIMENTAL|Modified SPD as adjunct to asthma medications in children|Explore if the modified specific carbohydrate diet has an effect on asthma control in children and if it will affect the frequency, severity, and duration of asthma and thus provide it as a potential complementary treatment option for them.
62660668|NCT03874962|EXPERIMENTAL|Routine oral cleaning and professional oral care group|"The subjects in Routine oral cleaning and professional oral care group were received about routine oral cleaning and professional oral care."
62660669|NCT03874962|NO_INTERVENTION|Routine oral cleaning group|"The subjects in Routine oral cleaning group were received only routine oral cleaning, just maintain daily condition."
62660670|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
62660671|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
62660672|NCT00898807|EXPERIMENTAL|Citalopram and psychosocial intervention|Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
62660673|NCT00898807|PLACEBO_COMPARATOR|Placebo and psychosocial intervention|Matching placebo, oral, and psychosocial intervention
62660674|NCT04659187||All hospitalized COVID-19 patients|All consecutive hospitalized patients, tested positive for SARS-CoV-2 at 45 Asklepios hospitals in Germany
62466305|NCT05728385|NO_INTERVENTION|Usual asthma medications only in children with moderate asthma|Assess control based on the usual asthma medications only
62466306|NCT01545830|ACTIVE_COMPARATOR|Regular Dose|Intervention: 600 IUs of cholecalciferol taken by mouth daily.
62660675|NCT04659187||Subgroup: Detailed cohort of 7 hospitals|Cohort of 7 hospitals with detailed data set
62660676|NCT04659187||Subgroup with cardiovascular events|Definition: Patients hospitalized to COVID-19, who developed a cardiovascular event, defined as (1) cardiopulmonary resuscitation in cardiac arrest, (2) cardiogenic shock, (3) acute coronary artery syndrome, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), (4) acute myocarditis, (5) denovo cardiac arrhythmia, (6) arterial or venous thrombosis, (7) pulmonary artery embolism, (8) worsening of prior or new onset heart failure, (9) ischemic stroke
62660677|NCT04659187||Subgroup with oncological patients|Definition: Patients hospitalized to COVID-19 with prior or preexisting oncological disease
61909478|NCT03455790|OTHER|Isokinetic shoulder muscle strength|Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer.
61909479|NCT04669418||Group 1|70 children with cancer and a positive blood culture.
62660678|NCT04659187||Subgroup with critical ill COVID-19 patients|Definition: Patients hospitalized to COVID-19 with intensive care treatment
62660679|NCT03602001|EXPERIMENTAL|attentive eating smartphone app group|Participant's received the intervention 'Attentive eating smartphone application'. This is a smartphone application that encourages a more attentive eating style. Participants also received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
62660680|NCT03602001|ACTIVE_COMPARATOR|control group|Participants received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
62660681|NCT02211651||ObeseDYS|Obese subjects with dysfunctional vascularization and inflammation of placenta.
62660682|NCT02211651||ObeseNL|Obese subjects with normal vascularization and inflammation of placenta
62660683|NCT02211651||LeanNL|Lean subjects with normal vascularization and inflammation of placenta.
62097582|NCT06169241|ACTIVE_COMPARATOR|Beetroot extract|Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
61909480|NCT04669418||Group 2|50 children with cancer and no positive blood culture.
62097583|NCT04401722|ACTIVE_COMPARATOR|PD in normal altitude|PD underwent in the area at the level of the sea, normal altitude region
62097584|NCT04401722|ACTIVE_COMPARATOR|PD in high altitude region.|PD underwent in high altitude region.
62097585|NCT04955795|ACTIVE_COMPARATOR|Alcohol Brief Intervention (BI)|At the time of trial enrollment, participants will receive a session of alcohol brief intervention (BI) via telephone.
62097586|NCT04955795|EXPERIMENTAL|Common Elements Treatment Approach (CETA) via Telemedicine|Participants will be provided with 6 to 12 weekly CETA sessions via telephone.
62097587|NCT06592443|EXPERIMENTAL|LvL UP|Downloading and using the LvL UP app
62097588|NCT06592443|EXPERIMENTAL|LvL UP + MI|Downloading and using the LvL UP app + taking part in motivational interviewing support sessions
62097589|NCT06592443|ACTIVE_COMPARATOR|Comparison|Receiving healthy lifestyle and mental well-being resources from Singapore's Health Promotion Board
62097590|NCT02091063|EXPERIMENTAL|Phase Ib and II: ACY-1215|Participants will receive Phase Ib Arm A: ACY-1215 QD or Arm B: ACY-1215 BID. Once Phase I dosing schedule has been determined. 160 mg BID dosing will be administered for Phase II.
62097591|NCT05201248|EXPERIMENTAL|Cohort 1 Part 1: Epcoritamab Monotherapy|Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
62660684|NCT02757014|EXPERIMENTAL|Coppertone (BAY987517)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61909481|NCT03430453|EXPERIMENTAL|Patient with ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed.
61909482|NCT01943357|EXPERIMENTAL|Diabetes Self-Management Program|Behavioral: Diabetes Self Management Program. Consists of either a six-week small-group face-to-face program with two peer leaders or an six-week peer-facilitated Internet-based program.
62097592|NCT05201248|EXPERIMENTAL|Cohort 1 Part 2: Epcoritamab Expansion|Participants will receive SC epcoritamab in 28 day cycles.
62097593|NCT05201248|EXPERIMENTAL|Cohort 2: Epcoritamab + RCHOP|Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)\] in 21 day cycles followed by 28 day cycles.
62660685|NCT00446875|EXPERIMENTAL|Sucrose|Participants received oral sucrose (0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
61909483|NCT02384057|EXPERIMENTAL|C8 sciences|cognitive rehabilitation with C8 sciences
61909484|NCT02384057|ACTIVE_COMPARATOR|Conventional cognitive rehabilitation|cognitive rehabilitation with conventional methods
62097594|NCT05201248|EXPERIMENTAL|Cohort 3: Epcoritamab + R2|Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, and oral lenalidomide (R2)\] in 28 day cycles.
62097595|NCT06268925|EXPERIMENTAL|Study group|single arm group exercises will be given to the patients
62097596|NCT03494738||Newborn infants|Neonates born from consented women at the study hospital
62097597|NCT03971357|EXPERIMENTAL|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
62097598|NCT03971357|PLACEBO_COMPARATOR|Placebo|Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.
62097599|NCT06452407|EXPERIMENTAL|Implementation of elleFA smartphone application|Implementation of the elleFA smartphone application to track symptoms, lifestyle, treatments and any patient-defined endpoints.
62097600|NCT06221774|EXPERIMENTAL|Phase Ib: dose optimization phase|"Approximately 12 participants will be enrolled and randomized 1:1 into two different dosage groups:~* Dose Group A (N=6): TT-00420 tablets 10mg QD + Toripalimab 240mg Q3W.~* Dose Group B (N=6): TT-00420 tablets 8mg QD + Toripalimab 240mg Q3W."
62097601|NCT06221774|EXPERIMENTAL|Phase II|"Based on the safety and efficacy data from Phase Ib, further cohorts will enroll participants with specific tumor types at the optimal dose of TT-00420 tablets:~* Cohort 1 (N=10): Metastatic or unresectable advanced renal clear cell carcinoma (RCC).~* Cohort 2 (N=10): Metastatic or unresectable advanced urothelial carcinoma (UC).~* Cohort 3 (N=10): Metastatic castration-resistant prostate cancer (mCRPC)."
62660686|NCT00446875|PLACEBO_COMPARATOR|Placebo|Participants received Placebo (sterile water, 0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
62660687|NCT02497014|EXPERIMENTAL|1 Stent|Patients who are going to receive 1 stent in the main vessel and the side vessel will be treated with kissing ballon inflation
62660688|NCT02497014|EXPERIMENTAL|2 Stents|Patients who are going to receive 2 stents in both vessels
61909485|NCT06102330|NO_INTERVENTION|Usual Care|No alteration in care. Will interview families and clinicians at 1 month, and families again at 6 and 12 months
61909486|NCT06102330|EXPERIMENTAL|Intervention|Will review a web-based decision-making tool with families and simultaneously interview family regarding website topics. Will interview families and clinicians at 1 month, and families again at 6 and 12 months
61909487|NCT03763565||Vaccinated group|Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old
61909488|NCT03763565||Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
62097602|NCT06614556|EXPERIMENTAL|Young Training Group|Ages 18-35. Performed 4 weeks of an at-home, hand grip resistance training intervention.
62097603|NCT06614556|NO_INTERVENTION|Young Control Group|Ages 18-35. Did not perform the training intervention
62097604|NCT06614556|EXPERIMENTAL|Older Training Group|Ages 60+. Performed 4 weeks of an at-home, hand grip resistance training intervention.
62097605|NCT06614556|NO_INTERVENTION|Older Control Group|Ages 60+. Did not perform the training intervention
62097606|NCT01338064||exposed workers|At least six months of occupational exposure to Caesar stone
62097607|NCT04978363|NO_INTERVENTION|Arm 1. NONE|Participants will be tested while wearing no boot and no assistive device.
62294119|NCT00018902|EXPERIMENTAL|4|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant and receive CBT.
62294120|NCT03864692||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
61909489|NCT01556412||Chronic hepatopathy suspicious of PSC|"All patients with chronic hepatopathy of unknown origin and a high risk of primary sclerosing cholangitis as the underlying disease for chronic hepatopathy.~This group includes all patients with cholestatic hepatopathy (predominantly elevated gamma-glutamyltransferase and alkalic phosphatase) and positive ANCAs (Anti-neutrophil cytoplasmic antibodies) and/or inflammatory bowel disease in medical history.~Other explanations of cholestatic hepatopathy (like pancreatic tumor or cholelithiasis) must not be apparent in patients eligible for this study.~Furthermore, infection oder extrahepatic cholestasis already proven by laboratory results or percutaneous ultrasound, which make endoscopic retrograde cholangiography necessary, are exclusion criteria in this study."
61909490|NCT02208063|EXPERIMENTAL|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
62097608|NCT04978363|EXPERIMENTAL|Arm 2. BOOT|The first intervention condition tested is a walking boot only on the subject's right lower extremity.
62294121|NCT03864692||Normotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
62660689|NCT03793153|NO_INTERVENTION|Control|Standard Lower Segment Cesarean Section (LSCS) will be done.
62097609|NCT04978363|EXPERIMENTAL|Arm 3. HFC+BOOT|The second intervention condition tested is a Hands Free Crutch (HFC) with the walking boot, both worn on the subject's right lower extremity.
62660690|NCT03793153|ACTIVE_COMPARATOR|Study|Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
62660691|NCT06404528|EXPERIMENTAL|Blood glucose stress combined with low-dose chemotherapy|By controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
62097610|NCT04978363|EXPERIMENTAL|Arm 4. SAC+BOOT|The third intervention condition tested is standard axillary crutches (SAC) with the walking boot worn in non-weight bearing on the subject's right lower extremity.
62097611|NCT04978363|EXPERIMENTAL|Arm 5. HFC|The fourth intervention condition tested is the Hands Free Crutch worn on the subject's right lower extremity without the walking boot.
62097612|NCT04978363|EXPERIMENTAL|Arm 6. SAC|The fifth and last intervention condition tested is standard axillary crutches with the subject non-weight bearing on the right lower extremity without the walking boot.
62660692|NCT03135795|EXPERIMENTAL|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
62097613|NCT05513690|EXPERIMENTAL|Amnioinfusion at room temperature (intervention arm)|Routine amnioinfusion will be administered via an intrauterine catheter inserted through the cervix. Normal saline at room temperature will be infused per hospital protocol at a rate of 600 milliliters/hour for the first hour followed by 180 milliliters/hour. A plastic applicator will be used to introduce a flexible disposable general-purpose temperature probe into the uterus. The probe will be guided to the contralateral side of the uterus from the intrauterine pressure catheter. Intrauterine temperature will then be measured by DataThermII continuous temperature monitor. This monitor has accuracy of 0.1 °C and will store temperature measurements every 10 minutes until delivery. The temperature data will be downloaded into a computer software. The DataThermII has been previously used in prior research to measure intrauterine temperature.
62097614|NCT05513690|NO_INTERVENTION|Standard of care (control arm)|Women in this group will have the temperature probe placed and temperate measured as described in experimental arm. They will otherwise receive current standard of care (i.e. no amnioinfusion).
62660693|NCT06122545|EXPERIMENTAL|Greater Occipital Nerve Block|"Patients will receive greater occipital nerve block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided Greater Occipital Nerve Block (GONB) will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery"
62660694|NCT06122545|EXPERIMENTAL|Medical Treatment|Patients who will receive medical treatment
62660695|NCT00859118|EXPERIMENTAL|Schedule A Cohort 1|"Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
62660696|NCT00859118|EXPERIMENTAL|Schedule A: Cohort 2|"Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
62660697|NCT05318326|PLACEBO_COMPARATOR|Placebo control group|Placebo control group
62097615|NCT03680014||1|Capable of independent of daily activities and able to mobilise unaided. No previous of falls.
62294122|NCT02631720||Adult Lung Transplant Recipients|Adult lung transplant recipients undergoing lung transplant at each of the participating centers.
62660698|NCT05318326|EXPERIMENTAL|Yogliptin 200mg group|Yogliptin 200mg group
62660699|NCT05318326|EXPERIMENTAL|Yogliptin 400mg group|Yogliptin 400mg group
62660700|NCT02331420|EXPERIMENTAL|Bariatric Surgery|Gastric bypass
62660701|NCT02331420|ACTIVE_COMPARATOR|Optimal Medical Therapy|planned visits, optimized hypoglycemic treatment, diet and lifestyle modification
62660702|NCT06310629|ACTIVE_COMPARATOR|High Flow Nasal Cannula|High Flow Nasal Cannula
62660703|NCT06310629|EXPERIMENTAL|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"
62097616|NCT03680014||2|Capable of independent of daily activities and able to mobilise unaided. With a previous of atleast one fall.
62097617|NCT03680014||3|Requires help with most daily activities, mobilises with a single walking stick. No previous falls.
62097618|NCT03680014||4|Requires help with most daily activities, mobilises with a single walking stick. With a previous of atleast one fall.
62294123|NCT00260221|EXPERIMENTAL|1|Arm one uses Virtual Reality Hypnosis post hypnotic suggestions to reduce pain durng wound care procedures.
61909491|NCT02208063|ACTIVE_COMPARATOR|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
62097619|NCT03680014||5|Requires help with most daily activities. Mobilise with frame or roller frame. No previous falls.
62097620|NCT03680014||6|Requires help with most daily activities. Mobilise with frame or roller frame. Previous history of at least one fall.
62294124|NCT00260221|EXPERIMENTAL|2|Arm two uses Virtual Reality distraction that is administered at times other than during burn care procedure to control for both for attention and high technology.
62660704|NCT01627717|EXPERIMENTAL|Maraviroc Boceprevir|
62660705|NCT03797612|EXPERIMENTAL|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the active treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
62660706|NCT03797612|PLACEBO_COMPARATOR|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal injection of placebo as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
61909492|NCT02876250|EXPERIMENTAL|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
62097621|NCT03917212||Patients|Patients with propionic acidemia, isovaleric acidemia, methylmalonic acidemia
61909493|NCT02876250|PLACEBO_COMPARATOR|Control|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
61909494|NCT04479319||COVID-19 Pneumonia|"COVID-19 patients who have pneumonia on thorax CT~either Thorax CT + SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +"
62097622|NCT03917212||Controls|Healthy humans
62097623|NCT06193330|EXPERIMENTAL|antibiotic-coated plate|participants will receive antibiotic-coated plate for treatment of their type III open long bone fractures
62097624|NCT06193330|ACTIVE_COMPARATOR|External Fixator|participants will receive external fixator for treatment of their type III open long bone fractures
62097625|NCT05792046||Normal|Subjects with normal visual function
62097626|NCT04151121|EXPERIMENTAL|Intervention|The participants will receive MBCT (Mindfulness-Based Cognitive Therapy) as 2-hourly sessions over 8-weeks including a 6-hour session at the end of 6th week. The MBCT will be adapted for chest pain.
62097627|NCT04151121|NO_INTERVENTION|Control group|These participants will continue to receive any treatment (or no treatment) by their primary care physicians.
62097628|NCT05707182|EXPERIMENTAL|Prostate Cancer|18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
62097629|NCT02743663||Wheezing subjects|Two study visits will be completed with wheezing subjects. The baseline visit will be completed within a 5 day window from the child's discharge from the emergency department. The follow-up visit will be completed 3 months after the baseline visit. At both visits, participants will provide a nasal swab and urine sample, complete three breathing tests: multiple-breath washout, forced oscillation technique, and Spirometry. In addition, at the follow-up visit, children will have an allergy skin test done, a nasal brush to collect epithelial cells and provide a blood sample. Whole blood will be used for basophil activation test (BAT). Children age 4+ will also complete post-bronchodilator testing using Salbutamol to capture information about bronchodilator response.
62097630|NCT02743663||Healthy cohort|One study visit will be completed with healthy participants. At this visit, three breathing tests will be performed: multiple-breath washout, forced oscillation technique, and spirometry. As well, an allergy skin test will be performed at the visit.
62097631|NCT02697721|EXPERIMENTAL|Powerful Tools for Caregivers|A 6-week psycho-educational program
62294125|NCT00260221|EXPERIMENTAL|3|Arm three use Audio administered Hypnosis without the visual technology.
62294126|NCT02013544|PLACEBO_COMPARATOR|Placebo|Placebo vaginal ovule daily for 12 weeks
62294127|NCT02013544|EXPERIMENTAL|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
62294128|NCT05525663|EXPERIMENTAL|Rehabilitation Intervention|The Rehabilitation Intervention is a novel, progressive, multi-domain rehabilitation and exercise training intervention. The intervention will include strength, balance, endurance, and mobility training and the specific training exercises will be tailored based on participant performance in each of these domains. The intervention will begin as soon as possible after randomization during the hospitalization and will continue 3 times per week in an outpatient setting for 12 weeks.
62294129|NCT05525663|NO_INTERVENTION|Attention Control|Attention control participants are contacted bi-weekly by study staff to maintain contact, collect information regarding health status, clinical events, and physical activity/exercise, and ensure retention; they do not receive any specific exercise recommendations.
62294130|NCT02103686|ACTIVE_COMPARATOR|Immediate release capsule|Immediate release capsule treatment under fasted condition
62466307|NCT01545830|EXPERIMENTAL|High Dose D|Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
62466308|NCT03495622|EXPERIMENTAL|Motivational Interviewing/Text messaging|Home visits by community health worker to deliver motivational interviewing and set up a structured text messaging strategy designed around a pre-determined quit date for smoking cessation.
62466309|NCT03495622|NO_INTERVENTION|Control|All participants will receive brief verbal advice about the hazards of smoking and the benefits of smoking cessation.
62660707|NCT03963388|EXPERIMENTAL|Intervention group|Speech therapy, right after T0 (baseline measurement).
62660708|NCT03963388|NO_INTERVENTION|Control group|Patients will be on a waiting list for 8 weeks. After the primary endpoint (T1), patients will receive speech therapy.
62660709|NCT02525978|EXPERIMENTAL|Healthy Controls|Healthy controls will complete the video task and imaginal task in one session
61909495|NCT04479319||COVID-19, without Pneumonia|"COVID-19 patients who have not pneumonia on thorax CT~Thorax CT - SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-"
62097632|NCT02697721|OTHER|Control group, delayed intervention|Control group with delayed intervention
62097633|NCT01197885|EXPERIMENTAL|IMAB362|Two different doses (antibody / body surface area) of IMAB362 will be administered sequentially.
62097634|NCT05077631|EXPERIMENTAL|ACD856|
62097635|NCT05077631|PLACEBO_COMPARATOR|Placebo|
62097636|NCT01759121|ACTIVE_COMPARATOR|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
62294131|NCT02103686|EXPERIMENTAL|sustained release tablet|sustained release tablet treatment under fasted condition
62294132|NCT02103686|EXPERIMENTAL|sustained release tablet (high fat meal)|sustained release tablet under high fat meal condition.
62294133|NCT01912755|EXPERIMENTAL|Articaine|injection of 1.8 mL buccal infiltrations of 4% articaine with 1:100,000 epinephrine in one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
62294134|NCT01912755|ACTIVE_COMPARATOR|Lidocaine|1.8 mL 2% lidocaine with 1:100,000 epinephrine injected as inferior alveolar nerve block in the mandible side with one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
61909496|NCT04479319||Non COVID-19|"Patients with viral infection symptoms who is not diagnosed with COVID-19~either Thorax CT - SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 -"
61909497|NCT05099094|EXPERIMENTAL|BD311 Adults single group|Administered by suprachoroidal injection. Dosage form: injection solution. Dose: 500uL. Frequency of administration: one time injection.
61909498|NCT00725842||Peg-IFN alfa-2b + ribavirin|Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).
62097637|NCT01759121|EXPERIMENTAL|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
62097638|NCT01824836|EXPERIMENTAL|Supportive care (anastrozole)|Patients receive anastrozole PO QD for 12 months.
62097639|NCT01218919||Brio DBS System|Eligible subjects in this study will be screened to confirm that they meet the strict guidelines for advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication followed by bilateral surgery to implant the Brio™ deep brain stimulation system
62097640|NCT05806138|EXPERIMENTAL|Vericiguat plus optimal medical therapy|For patients randomized to vericiguat, a starting dose of 2.5mg will be initiated at the randomization visit. At pre-specified titration visits, subjects will be up-titrated to vericiguat 5mg and then to the target dose of vericiguat 10mg using titration criteria based on mean systolic blood pressure and evaluation for clinical symptoms. Vericiguat will be administered in the background of optimal medical therapy for cardiomyopathy/heart failure.
62097641|NCT05806138|ACTIVE_COMPARATOR|Optimal medical therapy|For patients randomized to the control group, optimal medical therapy for cardiomyopathy/heart failure will be instituted throughout the study period.
62294135|NCT06247969||Patients intubated under general anesthesia via nasotracheal route.|Patients intubated under general anesthesia via nasotracheal route successfully.
61909499|NCT00479271|ACTIVE_COMPARATOR|Home Care|"A flexible home-care program tailored to the needs of the individual and the family. The components of the intervention will include:~1. Basic education about dementia (what is the disease, its course, its features etc)~2. Education about common behaviour problems and how they can be managed~3. Support to the carer, for example for an elderly carer living alone with the patient, in activities of daily living~4. Referral to specialists when behaviour problems are severe and warrant medication intervention (sedatives)."
61909500|NCT00479271|OTHER|Wait-list|This group will be put on a waiting list to receive the intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
61909501|NCT01397734|EXPERIMENTAL|Cohort 1|Patients who are receiving Imatinib as part of their standard of care therapy for CML.
61909502|NCT01397734|EXPERIMENTAL|Cohort 2|Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
61909503|NCT01397734|EXPERIMENTAL|Cohort 3|Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
62097642|NCT02485964|OTHER|Blood Draw Only|One time blood draw at time of consent; No treatment
62097643|NCT05039619|EXPERIMENTAL|Blinded Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1, Day 14, Week 24, Week 26 and Week 52. Participants with a body weight of 45 kg or more will receive the 1000 mg dose. Participants with a body weight below 45 kg will receive a weight adjusted dose of 20 mg/kilogram (kg).
62294136|NCT00080847|EXPERIMENTAL|Arm I (closed to accrual as of 9/21/04)|Patients receive rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1 and oral prednisone on days 1-5.
62294137|NCT00080847|EXPERIMENTAL|Arm II|Patients receive oblimersen IV continuously on days 1-7; rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 5; and oral prednisone on days 5-10.
62294138|NCT06030180|OTHER|Single Arm Study|
62294139|NCT06053021|EXPERIMENTAL|Intervention|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
61909504|NCT04605367|EXPERIMENTAL|100% PP, a-TDCS|"After the pre-test:~repetition of the correct sequence as many times as possible (12 blocks of 30s).~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
61909505|NCT04605367|EXPERIMENTAL|100% PP, sham TDCS|"After the pre-test :~physical repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
62097644|NCT05039619|PLACEBO_COMPARATOR|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1, Day 14, Week 24, Week 26 and Week 52.
62097645|NCT05039619|EXPERIMENTAL|Open-Label Obinutuzumab|Younger participants aged 5 to \<12 will receive obinutuzumab 1000 mg IV infusions on Days 1, 14, Week 24, Week 26 and Week 52.
62097646|NCT04707794||Elderly|Patients \> 65 years age undergoing non-cardiac surgery will be administered general anesthesia maintained with sevoflurane or desflurane titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
62097647|NCT06406140|EXPERIMENTAL|Experimental Niacin group|patients will receive niacin-tablets 500 mg per day with their standard therapy for 3 months.
62097648|NCT06406140|NO_INTERVENTION|control group|patients will receive their standard therapy only
62097649|NCT04529057|EXPERIMENTAL|Tooth-borne (Hyrax) expander|
62097650|NCT04529057|EXPERIMENTAL|Tooth tissue-borne (KBME) expander|
62097651|NCT04529057|EXPERIMENTAL|Bone-borne (MIDME) expander|
62097652|NCT04474600|EXPERIMENTAL|TIVA group|Patients receiving the total intravenous anesthesia using propofol
62097653|NCT04474600|ACTIVE_COMPARATOR|Inhalation group|Patients receiving inhalation anesthesia using desflurane
62097654|NCT06152783||A group|The sequence of endoscopy in group A was as follows: white light endoscopy, ME-NBI endoscopy,Confocal laser endomicroscopy.
62097655|NCT06152783||B group|The sequence of endoscopy in group B was as follows: white light endoscopy, Confocal laser endomicroscopy, ME-NBI endoscopy.
62097656|NCT04414722|PLACEBO_COMPARATOR|Concurrent control yogurt and amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
62466310|NCT05311501|EXPERIMENTAL|Immediate periodontal treatment|Right after the execution of a complete periodontal chart, non-surgical periodontal treatment (NST) was performed, according to the most recent clinical guidelines. NST was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period.
62466311|NCT05311501|NO_INTERVENTION|Delayed Periodontal treatment|Right after the execution of a complete periodontal chart, the patient is informed regarding their group allocation, according to which they are asked to delay NST for 10 weeks. 10 weeks after baseline examination, NST was performed according to the most recent clinical guidelines. NST was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments.
62466312|NCT00189956|ACTIVE_COMPARATOR|Group 1|healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
62466313|NCT00189956|ACTIVE_COMPARATOR|Group 2|healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
61909506|NCT04605367|EXPERIMENTAL|100% MP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm².)"
61909507|NCT04605367|EXPERIMENTAL|100% MP, sham TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
61909508|NCT04605367|EXPERIMENTAL|50% MP and 50% PP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 6 blocks of 30s. Then physical repetition of the correct sequence as many times as possible, during 6 blocks of 30s.~After the post-test : they will receive the real stimulation. Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
61909509|NCT04605367|EXPERIMENTAL|50% MP and 50% PP, sham TDCS|For both tasks, the training modalities are the same. After the pre-test, this group will have to mentally repeat the correct sequence as many times as possible, during 6 blocks of 30s. Then they will have to physically repeat the correct sequence as many times as possible, during 6 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the sham stimulation. The sham stimulation will be consisted of a gradual increase in current for 30 seconds until 1mA, immediately followed by gradual decrease for 30 s until 0mA.
61909510|NCT04605367|NO_INTERVENTION|No practice, No stimulation|After the pre-test, this group will read an article for 12 minutes. After this training, they will perform the post-test. Immediately after this, they will read another article during 15 minutes.
61909511|NCT02188901|OTHER|single arm|
62466314|NCT00189956|ACTIVE_COMPARATOR|Group 3|"healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous"
62097657|NCT04414722|PLACEBO_COMPARATOR|Control yogurt taken 4 hours after amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
62097658|NCT04414722|ACTIVE_COMPARATOR|Concurrent BB-12 yogurt and amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
62294140|NCT05563493|EXPERIMENTAL|Treatment group, Chair-Based Exercise Training|Treatment group will receive chair-based exercise training. Chair-based exercise training consisting of 20 different exercises will be applied in 2-3 sets with an average of 8-15 repetitions. Rest between sets will average 45-60 seconds.
62294141|NCT05563493|OTHER|Control group, Breathing exercise|Control group will receive breathing exercises.
62097659|NCT04414722|ACTIVE_COMPARATOR|BB-12 yogurt taken 4 hours after amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
62097660|NCT04414722|OTHER|Amoxicillin-clavulanate|Amoxicillin-clavulanate 875 mg-125 mg oral tablet
62294142|NCT00686816|PLACEBO_COMPARATOR|1|
62294143|NCT00686816|EXPERIMENTAL|2|
61909512|NCT00796445|EXPERIMENTAL|MAGE-A3 Group|Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of ASCI product at 3-week intervals, followed by 8 doses of ASCI product at 12-week intervals.
62097661|NCT02487719|ACTIVE_COMPARATOR|Iron sulfate|"Iron sulfate (or) is given if randomly asigned in this group and Ferritin at inclusion \< 50 mcg/L.~intervention: oral iron sulfate 1 tbl daily until birth"
62097662|NCT02487719|ACTIVE_COMPARATOR|Iron polymaltose|"Iron polymaltose (or) is given if randomly asigned in this group and Ferritin at inclusion \< 50 mcg/L.~intervention: oral iron polymaltose 1 tbl daily until birth"
62097663|NCT02487719|NO_INTERVENTION|Multimineral|"Routine supplementation of multivitamin. multimineral only. Ferritin level \> 50 mcg/L at inclusion. No additional iron supplementation.~oral multivitamin- multimineral preparation 1 tbl daily until birth as done in daily clinic routine"
62097664|NCT06484140|EXPERIMENTAL|Financial Navigation|"Participants will receive financial navigation service, including~* Needs Assessment: provide a brief introduction of cancer-related FT and assess patients' information needs using a self-made cost-related health literacy questionnaire;~* Cost-Related Health Education: mainly include topics regarding communication of cost, treatment-related cost, health insurance policies, and family support;~* Resource and Service Referral: promote timely referral to financial assistance programs and clinical professionals when identify unaddressed problems;~* Personalized Counseling Module: provide one-on-one counseling for symptom management, cost-related issues, and coping strategies."
62294144|NCT00136864|EXPERIMENTAL|1|PET Imaging
62294145|NCT00136864|NO_INTERVENTION|2|Standard Imaging
62294146|NCT02319902|PLACEBO_COMPARATOR|Standard cold carbon dioxide gas|Standard cold carbon dioxide gas
62294147|NCT02319902|ACTIVE_COMPARATOR|Heated humidified carbon dioxide gas|Heated humidified carbon dioxide gas
62294148|NCT01238003||Hospitalized patients|
62466315|NCT04715477||Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
62466316|NCT05397028|EXPERIMENTAL|Intervention Group|Replace meals with a plant-based meal replacement and self-prepared Meditteranean meals for a max 1200 calorie per day. Enroll in a 12 week intensive lifestyle intervention program.
62466317|NCT05397028|NO_INTERVENTION|Standard of Care Group|
61909513|NCT00796445|PLACEBO_COMPARATOR|Placebo Group|Patients who received up to 13 doses of placebo. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of placebo at 3-week intervals, followed by 8 doses of placebo at 12-week intervals.
61909514|NCT04769180||Patients affected with NCWS|100 patients with a definitive diagnosis of NCWS, based on DBPC gluten/wheat challenge.
61909515|NCT04769180||Patients affected with CD|50 patients affected with CD, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
62097665|NCT06484140|ACTIVE_COMPARATOR|Usual Care|Participants will receive usual care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support. When participants actively inquire about cancer treatment-related costs or financial planning strategies, financial navigators will answer their questions.
62097666|NCT00920374|EXPERIMENTAL|Fluarix Adult Group|Subjects who are 18-60 years of age received one dose of Fluarix™
62097667|NCT00920374|EXPERIMENTAL|Fluarix Elderly Group|Subjects who are \> 60 years of age received one dose of Fluarix™
62294149|NCT03900195|EXPERIMENTAL|Bottle PEP|Bottle PEP is a positive expiratory system that is applied via a tube of more than 5 mm of thickness and a bottle filled with water about 10 cms.
62294150|NCT03900195|NO_INTERVENTION|Control|No interventions will be applied.
62294151|NCT05601700|EXPERIMENTAL|Experimental arm|Letrozole 2.5 mg daily, per os, until progression or up to 60 months, whichever comes first
62294152|NCT05601700|ACTIVE_COMPARATOR|Control arm|Carboplatin AUC 5 + Paclitaxel 175 mg/mq, IV, on day 1 every 21 days, for 6-8 cycles.
62294153|NCT01644877|EXPERIMENTAL|DAS181|DAS181-F02, 4.5 mg qd x 10 days
62294154|NCT01644877|PLACEBO_COMPARATOR|Lactose Placebo|placebo, 4.5 mg qd x 10 days
62294155|NCT02902094|EXPERIMENTAL|Experimental|Drug eluting angioplasty balloons
62294156|NCT02902094|ACTIVE_COMPARATOR|Control|Non-drug eluting balloons
62294157|NCT02912364|EXPERIMENTAL|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
62294158|NCT02912364|EXPERIMENTAL|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
62294159|NCT01383031|ACTIVE_COMPARATOR|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
62097668|NCT05370989|EXPERIMENTAL|Technology-Based Parent School Program.|Technology-Based Parent School Program. This program, developing parents' self-efficacy and parenting skills in child care with the Parent School Program
62097669|NCT05370989|ACTIVE_COMPARATOR|Control group|the control group will continue to receive routine check-ups.
62097670|NCT02138916|EXPERIMENTAL|Benralizumab Arm A|Benralizumab administered subcutaneously
62097671|NCT02138916|EXPERIMENTAL|Benralizumab Arm B|Benralizumab administered subcutaneously
62097672|NCT02138916|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62097673|NCT02153788|ACTIVE_COMPARATOR|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
62294160|NCT01383031|ACTIVE_COMPARATOR|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC（conventional laparoscopic cholecystetomy）by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
62294161|NCT02209766|EXPERIMENTAL|D5884|D5884 capsule, Per oral(po)
62097674|NCT02153788|PLACEBO_COMPARATOR|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
62097675|NCT04095923|EXPERIMENTAL|Social media game|Private Facebook group with weekly walking challenges, Fitbit wearable activity monitor, and brief counseling
62097676|NCT04095923|ACTIVE_COMPARATOR|Standard self-regulation|Fitbit wearable activity monitor and brief counseling
62097677|NCT05104762|ACTIVE_COMPARATOR|Arm 1 plasmapheresis|Arm 1 (plasmapheresis): This study will be conducted at Assiut University at Neurology and psychiatry department as Group 1 of patients presented with Guillian Barrie syndrome (54 patients) will be subjected to plasmapheresis after assessment of clinical state and scales including MRC, Erasmus Guillain-Barre respiratory insufficiency score and Overall neuropathy limitation scale and Neurophysiological studies. Each patient was evaluated at baseline and at Follow up assessment points (one month and 3 months, one year follow up)
62294162|NCT02209766|PLACEBO_COMPARATOR|Placebo|Placebo capsule, po
62294163|NCT00935883|PLACEBO_COMPARATOR|Saline|Randomized patients in the drusen or the GA cohort will receive placebo saline infusions as a comparator
62294164|NCT00935883|ACTIVE_COMPARATOR|Eculizumab|Randomized patients in the drusen or the GA cohort will receive active treatment with eculizumab
62294165|NCT00190060|ACTIVE_COMPARATOR|1|Transdermal testosterone gel (Testogel 1% )
62294166|NCT00190060|PLACEBO_COMPARATOR|2|Matched transdermal placebo gel
62294167|NCT03560973|EXPERIMENTAL|Gemcitabine + Ramucirumab|Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
62294168|NCT03560973|PLACEBO_COMPARATOR|Gemcitabine + Placebo|Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
62294169|NCT00518349|ACTIVE_COMPARATOR|Prototype colonoscope|Colonoscopy using prototype colonoscope with passive bending function
62294170|NCT00518349|PLACEBO_COMPARATOR|Standard colonoscope|Colonoscopy using standard colonoscope with no passive bending function
62294171|NCT05653375|EXPERIMENTAL|mindfulness-based psychoeducation program|The group in which the mindfulness-based psychoeducation program was applied.
62294172|NCT05653375|ACTIVE_COMPARATOR|control group|The group in which no intervention was made and only the pre-test and post-test were applied for comparison.
62097678|NCT05104762|ACTIVE_COMPARATOR|Arm 2: Intravenous injection of immunoglobulin|This study will be conducted at Assiut University at Neurology and psychiatry department as Group 2 of patients presented with Guillian Barrie syndrome (27 patients) will be subjected to intravenous injection of immunoglobulin after assessment of clinical state and scales including MRC, Erasmus Guillain-Barre respiratory insufficiency score, and Overall neuropathy limitation scale and Neurophysiological studies. Each patient was evaluated at baseline and at Follow up assessment points (one month and 3 months, one year follow up).
62097679|NCT06617065|EXPERIMENTAL|Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice|The physician will add 1 mL of 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) to the usual local anesthetic solution of choice for each patient. Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio.
62097680|NCT02942056|EXPERIMENTAL|Study Drug|Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile
62097681|NCT02942056|PLACEBO_COMPARATOR|Placebo|Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile
62097682|NCT03968887||Case group|Patients with postoperative delirium.
62097683|NCT03968887||Control group|Patients who have not had postoperative delirium.
62097684|NCT05119933|EXPERIMENTAL|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
62097685|NCT05736367|EXPERIMENTAL|Metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer|"Administration of U-13C-glucose to participants with early-stage HR+/Her2- breast cancer fitting criteria, will be done intraoperatively at the time of resection, as well as blood sample collection.~This will allow for in depth evaluation of glycolysis as well as TCA cycle, lipid and amino acid metabolism and comprehensive genomic analyses to complement the metabolic assays that will be done by the Ludwig Institute of Cancer Research. HR+/Her2- breast cancer subtype is chosen for this feasibility pilot study given that metabolic studies have not been done in this subtype of breast cancer and it makes up the majority of breast cancer cases."
62097686|NCT05980793|ACTIVE_COMPARATOR|Surgical treatment|PIP joint denervation is performed through a volar approach.
62097687|NCT05980793|ACTIVE_COMPARATOR|Non-surgical treatment|An education and exercise program.
62097688|NCT04382677|EXPERIMENTAL|Promoting First Relationships|The PFR program designed for birth families being reunited after foster care placement consists of a manualized 12-session intervention delivered in the home by trained providers.
62466318|NCT06455579|EXPERIMENTAL|Sleep Health Education Program for Healthcare Providers|The BTS-HP is an online sleep health education program supported by the Boston Children's Hospital Department of Education (CE Courses - BCH Education (childrenshospital.org). The provider will also receive access to an educational webinar on Melatonin. The provider can participate all modules and the webinar in one sitting or overtime.
62097689|NCT04382677|OTHER|Resource & Referral|The service consists of a needs assessment conducted by phone, followed by a personalized resource packet and referrals, and 3 monthly check-in phone calls.
62466319|NCT01623726|EXPERIMENTAL|tDCS active|Active tDCS as foreseen in research protocol: daily sessions for 10 days with 2mA intensity stimulation during 20 minutes.
62097690|NCT04555330|EXPERIMENTAL|Visual Feedback|Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level and motivation to move. This information will be visible to the health personnel, the patients and visitors.
62097691|NCT04555330|OTHER|Control Group|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.No feedback on physical activity is provided.
62660710|NCT02525978|EXPERIMENTAL|Depressed + Ketamine|Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
62097692|NCT02215798||Cymbalta|
62294173|NCT03501862|EXPERIMENTAL|Mindfulness-based intervention|Intervention: a twelve 1.5 weekly program on mindfulness-based cognitive therapy (psychosis)
62294174|NCT03501862|ACTIVE_COMPARATOR|Psychoeducation|Intervention: a twelve 1.5 hours weekly program on psychoeducation (psychosis)
62660711|NCT01961492|ACTIVE_COMPARATOR|Fecal microbiota transplantation|A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
62097693|NCT03783455|ACTIVE_COMPARATOR|Non arthroscopic joint lavage (NAJL)|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper.
62097694|NCT03783455|ACTIVE_COMPARATOR|Non arthroscopic joint lavage plus corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the NAJL plus corticosteroid group was given an intra-articular injection containing 40 mg of triamcinolone acetonide.
62097695|NCT03783455|ACTIVE_COMPARATOR|Non arthroscopic joint lavage plus hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the patients were given an intra-articular injection containing 4 ml of a bioengineered hyaluronic acid.
62097696|NCT03783455|ACTIVE_COMPARATOR|Intraarticular injection of hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
62097697|NCT03783455|ACTIVE_COMPARATOR|Intraarticular injection of corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 40 mg of triamcinolone acetonide.
62097698|NCT03107702||Melatonin and bariatric surgery|the relationship between melatonin level and analgesia requirement.
62097699|NCT03161522|EXPERIMENTAL|Group I (maintenance chemotherapy)|Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
62097700|NCT03161522|EXPERIMENTAL|Group II (local therapy)|Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
62097701|NCT00797862|EXPERIMENTAL|Aliskiren + Amlodipine|Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
62097702|NCT00797862|EXPERIMENTAL|Aliskiren Start - Amlodipine Add-On|Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
62294175|NCT05983640|NO_INTERVENTION|Control|Assessment without training or video prompt
62294176|NCT05983640|EXPERIMENTAL|Just in time video|Assessment with JiT video available
62294177|NCT05983640|ACTIVE_COMPARATOR|AHA Course|Assessment after completion of CPR training course
62466320|NCT01623726|PLACEBO_COMPARATOR|tDCS sham|Sham tDCS : as foreseen in research protocol: sham stimulation with initial stimulation followed by turning off the device during the same time of intervention as to guarantee blinding
62660712|NCT01961492|NO_INTERVENTION|Standard medical treatment|Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
62660713|NCT00151515|EXPERIMENTAL|1|Topical 5% minoxidil foam formulation used twice daily
62660714|NCT04113993|EXPERIMENTAL|Oral Bazedoxifene|Oral Bazedoxifene dosed at 40 mg daily
62660715|NCT04113993|PLACEBO_COMPARATOR|Placebo|Identically packaged placebo capsule daily
62660716|NCT01017250|EXPERIMENTAL|Stereotactic Radiosurgery|Avastin and Radiosurgery
62660717|NCT02859116||Collection of digestive tissues|Digestive tissues will be collected from participants undergoing scheduled (non-emergent) gastrointestinal surgery.
62660718|NCT01779661|ACTIVE_COMPARATOR|Infant Aquatics|
62660719|NCT01779661|ACTIVE_COMPARATOR|Infant Massage|Infant Massage
62660720|NCT00274456|EXPERIMENTAL|ABI-007 300 mg/m^2 q3w|ABI-007 300 mg/m\^2 administered once every third week (q3w).
62660721|NCT00274456|EXPERIMENTAL|ABI-007 100 mg/m^2 weekly|ABI-007 100 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest
62466321|NCT00985257|OTHER|Subjects with diabetes|Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
62660722|NCT00274456|EXPERIMENTAL|ABI-007 150 mg/m^2 weekly|ABI-007 150 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest
62660723|NCT00274456|ACTIVE_COMPARATOR|Docetaxel 100 mg/m^2, q3w|Docetaxel (Taxotere) 100 mg/m\^2 administered once every third week (q3w).
62097703|NCT00797862|EXPERIMENTAL|Amlodipine Start- Aliskiren Add-On|Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
62097704|NCT06356142|EXPERIMENTAL|Intervention Group|
62097705|NCT06356142|PLACEBO_COMPARATOR|Control|
62097706|NCT03597308|ACTIVE_COMPARATOR|Opioid Group|
62097707|NCT03597308|ACTIVE_COMPARATOR|NSAID group|
62097708|NCT03597308|ACTIVE_COMPARATOR|Acetaminophen|
62097709|NCT06711523|EXPERIMENTAL|PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)|A single subcutaneous injection of 6 mg PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.) was administered 24h+2h after the end of chemotherapy administration on day 1 of each chemotherapy cycle; Inject at least 1 cycle of chemotherapy with PEG-G-CSF injection, and up to 4 cycles of chemotherapy.
62097710|NCT06711523|ACTIVE_COMPARATOR|PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)|Single subcutaneous injection of 6 mg PEG-G-CSF injection ( Neulasta®, Amgen Europe B.V.) 24h+2h after the end of chemotherapy administration on day 1 of each chemotherapy cycle in the abdomen (5 cm beyond the umbilicus); Inject at least 1 cycle of chemotherapy with PEG-G-CSF injection, and up to 4 cycles of chemotherapy.
62294178|NCT04278794|EXPERIMENTAL|Transitional Care Stroke Intervention (TCSI)|Participants randomly assigned to the intervention group will be offered the intervention in addition to usual care provided by in-patient and outpatient stroke rehabilitation services. The TCSI is a 6-month stroke transitional care intervention, provided in addition to usual stroke care, that includes four core components: comprehensive hospital discharge plan, structured home visits and telephone support, monthly intraprofessional case conferences, and linkages to primary care and other healthcare and community services. The TCSI will be delivered by an interprofessional team of care providers at the study site, including an occupational therapist, registered nurse, speech language pathologist, physical therapist, and social worker from a hospital-based outpatient stroke rehabilitation setting.
62294179|NCT04278794|NO_INTERVENTION|Control|Usual care provided by in-patient and out-patient stroke rehabilitation services.
62294180|NCT02022826|EXPERIMENTAL|SmartPill Monitoring System|patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test
62097711|NCT05008341|EXPERIMENTAL|Solriamfetol|Participants will receive a single oral dose of solriamfetol 150 mg with 240 mL water at 0 hour on the morning of Day 1, 2 hours after completion of a light breakfast.
62466322|NCT06080321|EXPERIMENTAL|WhatsApp messages|
62466323|NCT06080321|EXPERIMENTAL|Instagram messages|
62466324|NCT06080321|EXPERIMENTAL|Phone calls|
62466325|NCT06080321|ACTIVE_COMPARATOR|App alerts|
62466326|NCT06080321|NO_INTERVENTION|No active reminders|
62466327|NCT02597101|PLACEBO_COMPARATOR|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
62466328|NCT02597101|EXPERIMENTAL|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
62660724|NCT00739167||Y90 Group|Patients receiving treatment with radioembolization.
62097712|NCT05201768||INDIVIDUALS WITH ALZHEIMER|balance and gait will be evaluated survey questions will be asked
62660725|NCT00739167||TACE Group|Patients receiving treatment with transcatheter arterial embolization
62660726|NCT00739167||RFA Group|Patients receiving treatment with radiofrequency ablation.
62097713|NCT05201768||HEALTHY INDIVIDUALS|balance and gait will be evaluated survey questions will be asked
62097714|NCT05052411|EXPERIMENTAL|Expanded beta testing of the JomPrEP app|App usage assessments and analytics over a 1-month period.
62294181|NCT03283631|EXPERIMENTAL|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
62294182|NCT05731921|EXPERIMENTAL|Experimental group|The exercise program with the 'Empathy Dress'
62294183|NCT05731921|NO_INTERVENTION|Control group|No intervention
62294184|NCT03140319|EXPERIMENTAL|Fibroblast|Injection of Fibroblast
62294185|NCT03140319|PLACEBO_COMPARATOR|Placebo|the patient receive placebo injection
62466329|NCT03596372|EXPERIMENTAL|Patients with Solid tumors|Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme.
62466330|NCT03596372|EXPERIMENTAL|Patients with Gastric cancer|"Expansion with patients having gastric and/or gastroesophageal adenocarcinoma:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
62466331|NCT03596372|EXPERIMENTAL|Patients with Colorectal cancer|"Expansion with patients having colorectal cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
62466332|NCT03596372|EXPERIMENTAL|Patients with Non-small-cell-lung cancer|"Expansion with patients having adeno Non-small-cell-lung cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
62660727|NCT04852822||Observational (biospecimen collection, medical record review)|"For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical records are also reviewed.~For patients enrolled after vaccination, they will undergo collection of blood samples at 1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose."
62660728|NCT04601506|NO_INTERVENTION|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
62660729|NCT04601506|EXPERIMENTAL|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
62660730|NCT04601506|EXPERIMENTAL|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration \& Nudge intervention.
62466333|NCT03596372|EXPERIMENTAL|Low-dose expansion|Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD).
62660731|NCT04601506|EXPERIMENTAL|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration \& nudge interventions.
62660732|NCT01318434|EXPERIMENTAL|EB-1010 25 mg BID|Experimental Active
62660733|NCT01318434|EXPERIMENTAL|EB-1010 50 mg BID|Experimental Active
62660734|NCT01318434|ACTIVE_COMPARATOR|SSRI/SNRI|Active Comparator
62660735|NCT01318434|PLACEBO_COMPARATOR|EB-1010 0 mg BID|Placebo comparator
62660736|NCT03954210|EXPERIMENTAL|Six-Week CBT-I Program|"CBT-I, six sessions, forty-five to sixty minutes in duration.~Session 1: set up sleep restriction and stimulus control, discuss strategies for how to stay awake to a prescribed hour and what to do with wake after onset sleep time, provide sleep hygiene education.~Session 2: determine if upward titration of total sleep time is warranted, review sleep hygiene.~Session 3: continue upward titration of total sleep time, cognitive therapy for negative sleep beliefs if indicated.~Session 4: continue upward titration of total sleep time, follow-up regarding negative sleep beliefs.~Session 5: continue upward titration of total sleep time, discuss relapse prevention.~Session 6: assess global treatment gains, discuss questions regarding relapse prevention."
62660737|NCT03954210|ACTIVE_COMPARATOR|Six-Week Sleep and Lifestyle Education Program|"Sleep and Lifestyle Education, six sessions, forty-five to sixty minutes in duration.~Session 1: Sleep education, Instruction/demonstration on stretching exercises.~Session 2: Education on environmental factors \& sleeping positions that impact sleep.~Session 3: Education on lifestyle factors that impact sleep.~Session 4: Education on diet and sleep.~Session 5: Education on exercises and sleep.~Session 6: Discus maintaining achievements \& preventing relapses."
62660738|NCT05311592|EXPERIMENTAL|In Person|Participants will receive all services in person, including participating in the initial intake process, and attending all workshops.
62660739|NCT05311592|EXPERIMENTAL|Virtual (Zoom)|Participants will complete their intake process in person, but will complete all workshops virtually through Zoom.
62660740|NCT00632359|EXPERIMENTAL|Lenalidomide|Lenalidomide 10 mg daily given for 12 months.
62660741|NCT01614223|ACTIVE_COMPARATOR|ACP treatment|
62660742|NCT01614223|ACTIVE_COMPARATOR|Corticosteroid treatment|
62097715|NCT04094012|ACTIVE_COMPARATOR|3-months weekly RPT plus INH (3HP)|weekly RPT (900 mg for participants with body weight \>50.0 kg; 750 mg for 32.1-50.0 kg; 600 mg for 25.1-32.0 kg; and 450 mg for 14.1-25.0 kg) plus INH (dose: 15 mg/kg, rounded up to nearest 150 mg; maximum 900 mg) for a total of 12 doses.
62097716|NCT04094012|EXPERIMENTAL|1-month daily RPT plus INH (1HP)|daily RPT (dose: 600 mg for participants with body weight ≥45.0 kg; 450 mg for \<45.0 kg) plus INH (dose: 300 mg) for a total of 28 days.
62660743|NCT04978779|EXPERIMENTAL|Monotherapy of VIP152|Investigating VIP152 in a monotherapy cohort in patients with high-risk CLL and Richter Syndrome
62660744|NCT04978779|EXPERIMENTAL|VIP152 in combination with BTKi|Investigating VIP152 in combination with a BTKi in patients with CLL
62097717|NCT01439425|EXPERIMENTAL|weight loss|balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
62466334|NCT03762564|EXPERIMENTAL|Arm A (Paclitaxel + Ramucirumab)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 plus Ramucirumab 8 mg/kg as 1 hour intravenous infusion on day 1 and 15 qd 28
62466335|NCT03762564|ACTIVE_COMPARATOR|Arm B (control arm)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 qd 28
62466336|NCT04901377||Combined oral contraception: Estradiol valerate / Dienogest|Young women (18-35 years of age) using estradiol valerate / dienogest in real clinical practice.
62660745|NCT00564239|EXPERIMENTAL|A|
62660746|NCT00564239|ACTIVE_COMPARATOR|B|
62660747|NCT00564239|NO_INTERVENTION|C|
62660748|NCT02072044|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62660749|NCT05486728|EXPERIMENTAL|SHJ002|SHJ002 Ophthalmic Solution will be topically administered to each eye BID for 84 days
62660750|NCT05486728|PLACEBO_COMPARATOR|Vehicle|Vehicle will be topically administered to each eye BID for 84 days
62097718|NCT00868205|EXPERIMENTAL|low coffee dose|3 cups of coffee daily for 8 weeks
62097719|NCT00868205|EXPERIMENTAL|high coffee dose|5 cups of coffee daily for eight weeks
62097720|NCT00868205|NO_INTERVENTION|Control|Consumption of water instead of coffee daily for eight weeks
62097721|NCT06038071|ACTIVE_COMPARATOR|Control Group|nutrition, IYCF, and WASH education at discharge, followed by regular community-based screenings led by health extension workers, with one final visit scheduled at 6 months after discharge
62097722|NCT06038071|ACTIVE_COMPARATOR|scheduled followup|standard of care plus scheduled follow-up visits at 1 month, 3 months, 6 months after discharge
62466337|NCT04681703|EXPERIMENTAL|Intervention group|In addition to usual care: a 1-h educational and training program conducted by the family nurse (FN) in a dedicated room of the ambulatory care centers. During the program, the nurse instructed patients on how to self-measure blood pressure (BP) using the BP self-measurement device and on the importance of adequate device maintenance. The intervention was carried out by the FN on a daily basis during outpatient visits of the participants to the general practitioner (GP).
62097723|NCT06038071|EXPERIMENTAL|family MUAC|standard of care plus Family MUAC training for the primary caregiver present at the time of recovery, with one final visit scheduled at 6 months after discharge
62097724|NCT04440228|EXPERIMENTAL|Schools implementing TeamSTEPPS|Select schools will take a participatory approach to collaboratively identify solutions to challenges in collocated school-based mental health services based upon the feedback of stakeholders and use TeamSTEPPS to support mental health team-school collaboration.
62097725|NCT06054789|EXPERIMENTAL|68Ga-PSMA-33|For the injection, subjects will receive a target dose of 3-7mCi 68Ga-PSMA-33 as a bolus injection. Among them, 3\~4 subjects will additionally inject with 68Ga-PSMA-617 (3-7mCi).
62097726|NCT00462943|EXPERIMENTAL|OMA|"Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.~Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months."
62466338|NCT04681703|NO_INTERVENTION|Conrol group|Management of hypertensive patients, usual care: verbal and written instructions during which the family nurse (FN) or general practitioner (GP) advised the patient to follow the recommendations regarding correct HBPM. A written summary of the recommendations was given to all participants by the GP or FN at the end of the training program.
62466339|NCT05633485|EXPERIMENTAL|Experimental|An animation-supported training based on the health promotion model for COVID-19 disease and prevention measures was given to the participants.
62466340|NCT05633485|NO_INTERVENTION|Control|No intervention was applied to the participants in the control group.
62466341|NCT00759447||3D investigational imaging|Patients enrolled will be imaged with a 3D mammogram in one of 3 speeds of acquisition
62466342|NCT00759447||3D Imaging with commercial Mammography Device|
62466343|NCT01666470||Drug allergy patients|Patients with a history of drug allergy in Thailand
62466344|NCT04997122|EXPERIMENTAL|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
62466345|NCT04997122|ACTIVE_COMPARATOR|High-oleic sunflower oil|Intake of 45 g/d of high-oleic sunflower oil as the only source of oil in the diet
62466346|NCT00881322|EXPERIMENTAL|BC-130|Active Arm
62466347|NCT00881322|PLACEBO_COMPARATOR|Sugar Pill|Placebo
62466348|NCT03288883|ACTIVE_COMPARATOR|Fractional Microablative CO2-laser|
62466349|NCT03288883|ACTIVE_COMPARATOR|Photothermal Non-ablative Erbium:YAG-laser|
62466350|NCT03601637|EXPERIMENTAL|Part A: LUM/IVA|Participants weighing 7 to less than (\<)10 kilograms (kg) at screening received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 10 to \<14 kg at screening received LUM 100 mg/IVA 125 mg q12h for 15 days. Participants weighing greater than or equal to (\>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 15 days.
62466351|NCT03601637|EXPERIMENTAL|Part B: LUM/IVA|Participants weighing 7 to \<9 kg at screening received LUM 75 mg/IVA 94 mg FDC q12h and those weighing 9 to \<14 kg received LUM 100 mg/IVA 125 mg q12h for 24 weeks. Participants weighing \>=14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 24 weeks. Doses were adjusted upwards for changes in weight.
62097727|NCT06421974|EXPERIMENTAL|Robotic surgery for right colon cancer|Robot-assisted right colon cancer radical resection group, referred to as robotic surgery group
62097728|NCT06421974|ACTIVE_COMPARATOR|laparoscopic surgery for right colon cancer|Laparoscopic right colon cancer radical resection group, referred to as laparoscopic surgery group
62097729|NCT04002362|EXPERIMENTAL|Children receiving triamcinolone acetonide|Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks.
62466352|NCT04566848||Gastrointestinal cancers|Patients with advanced stage colorectal cancer, gastric cancer and pancreatic cancer who develop malignant ascites
62466353|NCT04566848||Control|Patients with intraabdominal ascites with benign reasons (liver cirrhosis, Congestive heart failure, etc.) .
62466354|NCT05343078|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10mg P.O.
62466355|NCT01987011|EXPERIMENTAL|MG1109|MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
62466356|NCT01987011|PLACEBO_COMPARATOR|Placebo|Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
62466357|NCT01556308|EXPERIMENTAL|DM-EBS|
62466358|NCT05074030|ACTIVE_COMPARATOR|PNF|Participants in the PNF condition will receive normative feedback only on their alcohol use.
62466359|NCT05074030|EXPERIMENTAL|PFIcope+EMI|The 6-week PFIcope+EMI includes: 1) an in-person personalized feedback session to present feedback on problems with drinking to cope, discuss the individual's use of alcohol to cope, and generate coping skills messages to be used in the EMI intervention; 2) EMA to monitor affect, intention to drink, coping skills usage, alcohol use, drinking to cope post-discharge; 3) tailored text messages (EMI) based on EMA (individualized coping skills messages when NA and intention to drink are reported).
62466360|NCT00194753|EXPERIMENTAL|1|Weekly doxorubicin (24 mg/m2 IV) with daily oral cyclophosphamide (60 mg/m2 PO) for 12 weeks with G-CSF support days 2 - 7 of each week followed by weekly paclitaxel (80 mg/m2 IV) for 12 weeks.
62466361|NCT01109862|EXPERIMENTAL|THA|Total hip arthroplasty
62466362|NCT01109862|ACTIVE_COMPARATOR|HAP|Bipolar Hemiarthroplasty
62466363|NCT05225597|ACTIVE_COMPARATOR|epinephrine|In the epinephrine group, 0.2 mL of epinephrine (1:5000 solution) was used immediately after making the clear corneal incision during cataract surgery
62097730|NCT03701464|EXPERIMENTAL|Endoscopic naso-gallbladder drainage|After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
62097731|NCT03701464|ACTIVE_COMPARATOR|Percutaneous gallbladder drainage|Ultrasound guided，an 18-gauge needle is inserted into the gallbladder，0.035 inch guidewire is coiled into the gallbladder and 9Fr dilator expands the skin,then 8Fr-20cm catheter is placed.
62097732|NCT01576510|EXPERIMENTAL|Prolonged Exposure (PE) treatment.|
62097733|NCT01576510|NO_INTERVENTION|Trauma exposed healthy controls|Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
62097734|NCT04378179||HFpEF|HF patients with preserved ejection fraction (HFpEF)
62097735|NCT04378179||HFrEF|HF patients with reduced ejection fraction (HFrEF)
62466364|NCT05225597|ACTIVE_COMPARATOR|carbachol|In the carbachol group, a 0.5 ml dose of 0.01% carbachol solution (Miostat®, Alcon Laboratories, Inc., Fort Worth, TX) was given intracamerally immediately after viscoelastic matter removal following IOL implantation
62097736|NCT04378179||PH|Patients with Pulmonary hypertension (PH)
62097737|NCT04378179||Control|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria.
62097738|NCT04378179||Controls with suspected CAD|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria, and may have a diagnosis of Coronary Artery Disease (CAD) or may be suspected to have CAD.
62097739|NCT06613997|EXPERIMENTAL|Albendazole 21 days|Participants randomized in this arm will receive 21 days of albendazole 400mg/days .
62097740|NCT06613997|PLACEBO_COMPARATOR|Placebo 21 days|Participants randomized in this arm will receive 21 days of placebo.
62294186|NCT06657014|EXPERIMENTAL|Mind-Mindedness Training Group|"The Mind-Mindedness Training Group will involve 50 caregivers of preschool-aged children (ages 4 to 7) with social anxiety. Participants will attend three one-hour online sessions over three consecutive weeks.~The training focuses on enhancing caregivers' ability to recognize and respond to their children's thoughts and emotions. Each session includes:~* Session 1:\*\* Introduction to mind-mindedness, its importance, and caregiver roles in managing social anxiety.~* Session 2:\*\* Practical strategies for emotion coaching, including role-play exercises.~* Session 3:\*\* Advanced strategies addressing common challenges, with discussions and video examples.~Participants will receive materials to support their learning. Effectiveness will be assessed through evaluations of mind-mindedness, child social anxiety, and related areas at baseline, post-intervention, and three months later."
62308116|NCT01826669|ACTIVE_COMPARATOR|Stretching|"The respiratory muscle stretching were developed bilaterally as follows:~* Upper trapezius: head lateral flexion with a hand therapist supports the the occipital region and his shoulder, promotes the stretching;~* Sternocleidomastoid: was stretched with flexion lateral and rotation of the head to the side which hands on the occipital region and in the sternal region;~* Scalene: with one hand on the occipital region and the other in the sternum, the two points was stretched;~* Pectoralis major: the arm was abducted, flexed the forearm and hand was in the occipital region the therapist hands in the arm and in the side of the upper chest, which was stretched craniocaudal direction;~* Intercostal: therapist performs with both hands to mobilize and stretch the ribs in cranial-caudal directions."
62466365|NCT05225597|NO_INTERVENTION|control|The control group was given neither epinephrine nor carbachol. Standard cataract surgery was performed
62466366|NCT02324725|EXPERIMENTAL|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
62466367|NCT03295474||Rehabilitation using telehealth technology|
62466368|NCT02336854|EXPERIMENTAL|Tacrobell tab. 2mg|2mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
62097741|NCT03350321|EXPERIMENTAL|Molidustat (BAY85-3934)|Molidustat group
62097742|NCT03350321|ACTIVE_COMPARATOR|Darbepoetin alfa|Darbepoetin alfa group
62097743|NCT00699933||1|Evaluation of one study cohort
62097744|NCT01947075||Adults with fever|Every adult with fever will be screened for different infectious diseases and for nasopharyngeal respiratory viruses and bacteria
62097745|NCT01947075||Healthy volonteers|For every adult with fever included with a diagnosis of pneumonia, a healthy volunteer will be included. These healthy volunteers will be screened for nasopharyngeal respiratory viruses and bacteria.
62097746|NCT06714331|EXPERIMENTAL|Caffeine|"Caffeine supplement is consumed at 3 time points (120, 90 and 45 minutes prior to testing) with participants drinking 300mL of a caffeine and water solution at each time for a total consumed volume of 900mL .~Caffeine concentration - 3mg/kg or 0.003g/kg~Each solution has MiO Liquid Water Enhancer to mask the taste."
62097747|NCT06714331|EXPERIMENTAL|Sodium bicarbonate|"Sodium bicarbonate supplement is consumed at 3 time points (120, 90 and 45 minutes prior to testing) with participants drinking 300mL of sodium bicarbonate solution at each time for a total consumed volume of 900mL.~Sodium bicarbonate concentration - 0.3g/kg (Arm and Hammer brand)~Each solution has MiO Liquid Water Enhancer to mask the taste."
62097748|NCT06714331|SHAM_COMPARATOR|Control|Control solution is MiO + 300mL water at 3 time points (120, 90 and 45 minutes prior to testing) with participants drinking 300mL of control solution at each time for a total consumed volume of 900mL.
62097749|NCT06470204|ACTIVE_COMPARATOR|Ropivacaine|iPACK Block + ACB with Ropivacaine
62097750|NCT06470204|ACTIVE_COMPARATOR|Ropivacaine + Dexamethasone|iPACK Block + ACB with Ropivacaine + Dexamethasone
62097751|NCT03516149|EXPERIMENTAL|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
62097752|NCT03516149|NO_INTERVENTION|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
62097753|NCT04783415|EXPERIMENTAL|Treatment (ublituximab, acalabrutinib, umbralisib)|"Patients receive ublituximab IV over 90 minutes-4 hours on days 1, 8, and 15 of cycle 1 and days 1 of cycles 2-6. Patients also receive acalabrutinib PO BID and umbralisib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ublituximab IV on day 1 on cycles 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30. Patients also receive acalabrutinib Po BID and umbralisib PO QD on day 1-28. Treatment repeats every 28 days for 24 cycles in the absence of disease progression of unacceptable toxicity."
62097754|NCT01151033|EXPERIMENTAL|stent implantation|ProNOVA XR Polymer Free Drug Eluting Stent implantation - single arm
62466369|NCT02336854|ACTIVE_COMPARATOR|Prograf cap. 2mg|1mg/capsule, PO, 2 capsule once daily for Period I \& II D1(crossover)
62466370|NCT02403791|EXPERIMENTAL|Lung Ultrasound|In infants allocated to this arm Lung ultrasound for detection of ARDS will be performed before chest radiography.
62660751|NCT01498549|ACTIVE_COMPARATOR|Atomoxetine|Atomoxetine compared to the sugar pill
62660752|NCT01498549|PLACEBO_COMPARATOR|Sugar Pill|Sugar pill compared to atomoxetine
62660753|NCT05173636|EXPERIMENTAL|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
62660754|NCT05173636|EXPERIMENTAL|thoracic mobilization|A posteroanterior unilateral pressure will be applied over the transverse processes at T2-T5 on the ipsilateral side of pain in prone position.
62660755|NCT02290418|ACTIVE_COMPARATOR|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass and routine care.
62097755|NCT04895306|EXPERIMENTAL|Testosterone|Weekly intramuscular administration at a dose of 3 mg
62097756|NCT04895306|PLACEBO_COMPARATOR|Placebo|Weekly intramuscular administration of placebo
62097757|NCT05380232||Individuals with type 2 diabetes at the baseline examination|"UK Biobank: Prevalent type 2 diabetes is determined by the algorithm of Eastwood et al. (6) or from measured Hba1c ≥48 mmol/mol.~China Kadoorie Biobank: prevalent type 2 diabetes is based on self-reported current diabetes with a diagnosis age above 30 years, a random plasma blood glucose ≥11.1 mmol/L, or fasting plasma blood glucose ≥7.0 mmol/L."
62097758|NCT02824289|EXPERIMENTAL|Sun Safe Workplaces Program|Program promoting the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers and in-person training of outdoor workers by research staff over two years.
62308117|NCT01826669|NO_INTERVENTION|Rest|COPD patients were not submitted to any intervention, remaining at rest in the same place, position and time period to the treatment group.
62308118|NCT06244966|EXPERIMENTAL|Any client attending clinic for venous blood sampling|Any client attending clinic for venous blood sampling for sexually transmitted disease diagnostics will also collect capillary blood using a finger prick
62466371|NCT02403791|ACTIVE_COMPARATOR|Chest Radiography|In infants allocated to this arm chest radiography will be performed for the detection of indirect signs of ARDS without ultrasound evaluation.
62660756|NCT02290418|ACTIVE_COMPARATOR|Omega-Loop Gastric Bypass|Laparoscopic Omega-Loop Gastric Bypass and routine care.
62660757|NCT04656665|EXPERIMENTAL|75mg|Take 75mg of aspirin daily in tihis group
62660758|NCT04656665|ACTIVE_COMPARATOR|100mg|Take 100mg of aspirin daily in this group
62097759|NCT02824289|ACTIVE_COMPARATOR|Attention Control|Program promoting occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff.
62097760|NCT06439576||Cohort 1: Patients with nAMD|
62097761|NCT06439576||Cohort 2: Patients with DME|
62097762|NCT06439576||Cohort 3: Patients with RVO|
62097763|NCT04018664|PLACEBO_COMPARATOR|Placebo|"Placebo~150 mL flavored beverage"
62097764|NCT04018664|EXPERIMENTAL|90 mg nalbuphine HCl solution|"90 mg nalbuphine HCl solution~9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage"
62308119|NCT01243476|EXPERIMENTAL|lenalidomide|Experimental treatment branch with Lenalidomide 5 mg/day (oral use)
62308120|NCT01243476|PLACEBO_COMPARATOR|placebo|Placebo branch (oral use)
62466372|NCT04125576||Burn patients|The subjects complaine of severe neuropathic pain that is rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
62466373|NCT04125576||Healthy controls|age and sex matched healthy controls
62097765|NCT04018664|EXPERIMENTAL|120 mg nalbuphine HCl solution|"120 mg nalbuphine HCl solution~12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage"
62097766|NCT04018664|EXPERIMENTAL|150 mg nalbuphine HCl solution|"150 mg nalbuphine HCl solution~15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage"
62466374|NCT05854602|NO_INTERVENTION|Condition 1: 000|Families in this condition will not receive any of the intervention components during study period (T0-T2, T2-T4, T4-T6). Target n = 35.
62660759|NCT04656665|NO_INTERVENTION|blank|Not taking aspirin in this group
62097767|NCT04018664|EXPERIMENTAL|180 mg nalbuphine HCl solution|"180 mg nalbuphine HCl solution~18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage"
62097768|NCT04018664|EXPERIMENTAL|270 mg nalbuphine HCl solution|"270 mg nalbuphine HCl solution~27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage"
62097769|NCT04018664|EXPERIMENTAL|Up to 405 mg nalbuphine HCl solution|"Up to 405 mg nalbuphine HCl solution~Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage"
62097770|NCT04018664|EXPERIMENTAL|Up to 540 mg nalbuphine HCl solution|"Up to 540 mg nalbuphine HCl solution~Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage"
62097771|NCT05696730|EXPERIMENTAL|Communication intervention about sexuality in people with COPD|Communication intervention. Individual counselling to improve holistic well-being by addressing sexuality and to increase adherence for long-term physical activity given the correlation with sexual activity.
62097772|NCT05696730|NO_INTERVENTION|30 minutes counselling and intervention material per request after the RCT|Usual care. Participants will have the possibility to receive a brief version of the intervention on request (30 minutes counselling and intervention material) at the end of the 3-months follow-up assessment visit.
62097773|NCT06649604|EXPERIMENTAL|PRP with the Vibration Anesthesia Device|Laser for PRP treatment as usual, but with the addition of the Vibration Device in one of the two eyes of a patient (The other eye receiving the same laser treatment without the device).
62660760|NCT04623151|EXPERIMENTAL|Online leaflet in narrative format|
62660761|NCT04623151|ACTIVE_COMPARATOR|Online leaflet in non-narrative format|
62660762|NCT04623151|NO_INTERVENTION|No leaflet (control)|
62097774|NCT06649604|ACTIVE_COMPARATOR|PRP without the Vibration Anesthesia Device|Laser for PRP treatment as usual in one of the two eyes of a patient (other eye receiving the same treatment, but with the Vibration Device).
62097775|NCT05060471|EXPERIMENTAL|Intervetional group|Neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and concurrent toripalimab
62097776|NCT00607516|ACTIVE_COMPARATOR|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
62097777|NCT00607516|ACTIVE_COMPARATOR|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
62097778|NCT04953910|EXPERIMENTAL|Group B: Moderate hepatic impairment|Cancer participants with moderate hepatic impairment \[total bilirubin \>1.5X - 3X upper limit of normal (ULN); any aspartate aminotransferase (AST) level\]
62097779|NCT04953910|EXPERIMENTAL|Group C: Severe hepatic impairment|Cancer participants with severe hepatic impairment (\>3X ULN; any AST level)
62660763|NCT04892407|EXPERIMENTAL|Algeness DF 3.5%|This arm is with the Sponsor's product. The product is already CE Marked and sold for this indication for the majority of participating countries.
62660764|NCT04892407|ACTIVE_COMPARATOR|Juvéderm Voluma|This arm is with a Control product that is already CE Marked and sold for this indication.
62660765|NCT03155698|EXPERIMENTAL|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side~Intervention:~* Combination Product: microneedling and Platelet rich plasma.~* radiation : NB-UVB phototherapy"
61909516|NCT04769180||Patients affected with IBS not related to NCWS or other food allergies/intolerances|50 patients affected with IBS, according to the Rome IV criteria, not related to NCWS or other food allergies/intolerances, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
62097780|NCT04953910|ACTIVE_COMPARATOR|Group A: Normal hepatic function|Cancer participants with normal hepatic function (total bilirubin ≤ULN; AST ≤ULN)
62097781|NCT06154226|EXPERIMENTAL|Pantoprazole group|Pantoprazole (40 mg iv every 12 hours/q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on postoperative (POD) 1 for a total of 4 doses over 2 days. There will be no other modifications in patient care.
62097782|NCT06154226|ACTIVE_COMPARATOR|Famotidine Group|Famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days. There will be no other modifications in patient care.
62097783|NCT02443792|EXPERIMENTAL|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
62097784|NCT02443792|ACTIVE_COMPARATOR|Open Surgical|Open surgical circumcision under local anesthetic with suturing
62097785|NCT00630864|EXPERIMENTAL|1|Fx-1006A 20mg soft gelatin capsules once daily for 12 months
62466375|NCT05854602|EXPERIMENTAL|Condition 2: 0A0|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62660766|NCT05401851|OTHER|Body surface mapping|With the Insite Vest, activation of the epicardium will be performed.
62097786|NCT06542250|EXPERIMENTAL|Module 1: AZD5492 Monotherapy|AZD5492 monotherapy for Relapsed or Refractory B-Cell Malignancies.
62097787|NCT03569969|EXPERIMENTAL|control group|Step1. Under local anesthesia and sedation , the temporal muscle fascia was removed, Step2. After the preparation on the tympanic membrane embedded , foam gel smeary with Dexamethasone was worn.Step3. Then the wound dressing was done with a gas number and a Surgifix. Step4. Patients were discharge from the operating room with an oral administration of Cephalexin capsules.
62097788|NCT03569969|EXPERIMENTAL|Test group|Step1. After sedation and conducting local anesthesia with Lidocaine 2% and inserting the edges of the tympanic membrane and inserting the foam gel into the middle ear, amniotic membranes (produced in Iran tissue product) with a thickness of 100 microns on the tympanic membrane and the foam gel embedded. Step2. Under-layered and short-lived foam gel (manufactured by Ethicon Company) smeary with dexamethasone was covered.
62097789|NCT06120751|EXPERIMENTAL|Tetanus Vaccine, Adsorbed (TTVA)|1 dose of (TTVA) (0.5ml)
62097790|NCT06120751|ACTIVE_COMPARATOR|Tetanus Vaccine, Adsorbed (TT)|1 dose of (TT) (0.5ml)
62097791|NCT05617339|EXPERIMENTAL|"Personalised internet-based treatment I am."|Need-based internet-based treatment
62097792|NCT05617339|NO_INTERVENTION|Treatment As Usual|Control group, Treatment in primary care which is medical treatment
62308121|NCT02207387|EXPERIMENTAL|MCW|Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold.
62308122|NCT02207387|EXPERIMENTAL|NCMW|Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size.
62466376|NCT05854602|EXPERIMENTAL|Condition 3: 00A|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
62097793|NCT05372003|EXPERIMENTAL|Subjects on Dupilumab|"individuals with atopic dermatitis placed on dupilumab for more than 6 months will be eligible to this study. Their metabolic profile will be compared to the group of Subjects on Phototherapy"
62097794|NCT05372003|ACTIVE_COMPARATOR|Subjects on Phototherapy|"individuals with atopic dermatitis placed on phototherapy for more than 6 months will be eligible to this study to serve as an active comparator to the Subjects with Dupilumab"
62097795|NCT06707935|EXPERIMENTAL|Descriptive social norm nudges|Participants receive messages with social norm nudges presented in the word form.
62097796|NCT06707935|EXPERIMENTAL|Pictorial social norm nudges|Participants receive messages with social norm nudges presented in graphic form.
62097797|NCT06707935|ACTIVE_COMPARATOR|Active control|Participants receive messages with generic mental health knowledge or information.
62097798|NCT00870350|ACTIVE_COMPARATOR|Td5ap|Group 1 receiving Td5ap as a single intramuscular injection.
62097799|NCT00870350|ACTIVE_COMPARATOR|Td1aP|Group 2 receiving Td1aP as a single intramuscular injection
62097800|NCT00001532||1|Subjects with pulmonary disease or possible pulmonary disease and Relatives
62097801|NCT00001532||2|Healthy
62097802|NCT01872611|EXPERIMENTAL|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
62097803|NCT01872611|PLACEBO_COMPARATOR|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
62097804|NCT04318080|EXPERIMENTAL|Cohort 1|Participants with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after autologous hematopoietic stem cell transplantation (HSCT)
62097805|NCT04318080|EXPERIMENTAL|Cohort 2|Participants with relapsed or refractory cHL who have received at least 1 prior systemic regimen and are not candidates for autologous or allogeneic HSCT
62097806|NCT05806554||T1DM|Participants with type 1 diabetes mellitus
62466377|NCT05854602|EXPERIMENTAL|Condition 4: 0AB|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
62466378|NCT05854602|EXPERIMENTAL|Condition 5: 0AC|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
62097807|NCT05806554||T2DM|Participants with type 2 diabetes mellitus
62097808|NCT03742843||Group of adenomyosis|Patients with adenomyosis with or without endometriosis
62097809|NCT03742843||Group of endometriosis|Patients with endometriosis without adenomyosis
62097810|NCT03742843||Group of control|Patients without adenomyosis or endometriosis
62466379|NCT05854602|EXPERIMENTAL|Condition 6: 0B0|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62660767|NCT05533190|EXPERIMENTAL|Wysa AI chatbot mental health app|Wysa is a guided self-help and triaging tool delivered to patients via an app or widget. It uses Natural Language Processing to understand individuals' written inputs but not to generate responses. Wysa makes use of a wide range of clinically underpinned modules whilst gamification, clinical outcome measures and AI promotes engagement, improving efficacy and triage and reducing the cost of scale.
62097811|NCT06614205||Patients treated with 177Lu-DOTATATE for meningioma|Patients treated with 177Lu-DOTATATE for meningioma at the Nancy's hospital who met the treatment criteria of the Compassionate Prescribing Framework and received a scintigraphy at D1, D4 and D7 (± 1 day)
62097812|NCT03477110|EXPERIMENTAL|Treatment (temozolomide, radiation, NovoTTF-200A device)|Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62097813|NCT03123640|EXPERIMENTAL|Intervention group|Pharmacist conducts medication reconciliation and medication review while the patient is admitted to the emergency Department. The pharmacist present results from medication reconciliation to physicians at the emergency Department before the Medical history is obtained. Further the pharmacist will discuss drug related problems obtained during the medication review with the physicians to customize and optimize the medication treatment for each patient.
62097814|NCT03123640|NO_INTERVENTION|Control group|Standard treatment without pharmacist intervention in the emergency department
62308123|NCT02207387|EXPERIMENTAL|NMW|Non-music walking (NMW/silent) group: no music on at all regardless of step size.
62097815|NCT03918577|EXPERIMENTAL|right cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their right external ear canal, with before and after measures of OCRD symptom severity and insight.
62097816|NCT03918577|EXPERIMENTAL|left cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their left external ear canal, with before and after measures of OCRD symptom severity and insight.
62097817|NCT06630793|EXPERIMENTAL|Radical CTRT with IMPT (Intensity Modulated Proton Therapy)|Patients randomized to proton therapy arm will receive radiotherapy with IMPT technique along with concurrent chemotherapy for a duration 6-8 weeks.
62097818|NCT06630793|ACTIVE_COMPARATOR|Radical CTRT with IMRT (Intensity Modulated Radiation Therapy)|Patients randomized to photon arm will receive radiotherapy with IMRT technique along with concurrent chemotherapy for a duration 6-8 weeks.
62097819|NCT06112704|EXPERIMENTAL|Phase IIa: Cohort 1|Participants with advanced esophageal squamous cell carcinoma will be administered HS-20093.
62097820|NCT06112704|EXPERIMENTAL|Phase IIa: Cohort 2|Participants with advanced esophageal adenocarcinoma and gastroesophageal junction adenocarcinoma will be administered HS-20093.
62097821|NCT06112704|EXPERIMENTAL|Phase IIa: Cohort 3|Participants with other advanced solid tumor will be administered HS-20093.
62097822|NCT06112704|EXPERIMENTAL|Phase IIb|Participants with advanced esophageal squamous cell carcinoma will be administered HS-20093.
62097823|NCT06701825|ACTIVE_COMPARATOR|Standard of care|Patients in this control group will receive treatment with any formulation of Tacrolimus authorized and commercialized in Spain. They will be administered tacrolimus according to clinical practice and the drug's product labeling.
62660768|NCT05533190|NO_INTERVENTION|Waitlist control|The intervention will be compared against a waitlist group. This comparator was selected to compare Wysa to the current standard of care for patients waiting for standard IAPT assessment and treatment.
62660769|NCT03695835||Adenocarcinoma treated with MyVaccx|MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
62660770|NCT02278354|EXPERIMENTAL|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
62660771|NCT02278354|EXPERIMENTAL|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
62097824|NCT06701825|EXPERIMENTAL|Dose adjusted by guidelines|Participants in this experimental group will receive treatment with any formulation of Tacrolimus authorized and commercialized in Spain. They will be administered the specific dosage of tacrolimus recommended by the Clinical Pharmacogenetics Consortium's genotype guidelines, utilizing the patient's pharmacogenetic information and characteristics.
62097825|NCT06712069|EXPERIMENTAL|Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) Arm|"This arm involves the application of Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) during neurosurgical procedures. Participants in this arm undergo continuous intraoperative monitoring using a combination of:~Somatosensory Evoked Potentials (SSEP): Monitoring sensory pathway integrity. Motor Evoked Potentials (MEP): Assessing motor pathway functionality. Electromyography (EMG): Detecting nerve irritation and monitoring cranial and limb muscles.~The intervention is designed to enhance surgical precision by providing real-time feedback to the surgical team, aiming to prevent postoperative neurological deficits and improve patient outcomes. Pre- and postoperative clinical assessments are conducted to evaluate the effectiveness of MIONM."
62097826|NCT04452591|EXPERIMENTAL|Cohort C(All Countries):Enrollment Closed|Patients with CIS with or without HG Ta/T1 papillary disease. Cretostimogene will be administered intravesically following a series of bladder washes with 5% DDM and normal saline. Cretostimogene will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has disease recurrence at Week 13, they will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 then the patient will receive 3 weekly treatments. Cohort C(All Countries):Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 51 then every 6 months and then a last treatment at Weeks 73, 74, and 75 until the tumor returns or study treatment is completed at Week 97. Cohort C Extension( Japan and the US) At Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 51 then every 6 months starting at Weeks 73, 74, and 75 through Weeks 157, 158, and 159 until the tumor returns or study treatment is completed at Week 159.
62308124|NCT02207387|EXPERIMENTAL|MCW+rasagiline|"Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
62308125|NCT02207387|EXPERIMENTAL|MMW+rasagiline|"Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
62660772|NCT04766333|ACTIVE_COMPARATOR|Healthcare Worker Focused Outreach Intervention Strategy|Healthcare Worker Focused Outreach Intervention Strategy
62660773|NCT04766333|ACTIVE_COMPARATOR|Community Organization Led Outreach|Community Organization Led Outreach
62660774|NCT01178931|ACTIVE_COMPARATOR|Oral dydrogesterone|Study group receiving 2x10mg of oral dydrogesterone until a pregnancy test or in the case of pregnancy until 10 week.
62660775|NCT01178931|ACTIVE_COMPARATOR|Crinone 8% vaginal gel|Control group is receiving vaginal gel, 1x90mg, until a pregnancy test or in the case of pregnancy until 10 week.
62660776|NCT06214390|ACTIVE_COMPARATOR|Single strategy|A single strategy based only on urine output
62660777|NCT06214390|EXPERIMENTAL|Combined strategy|A strategy based on combined criteria (urine output + urinary parameters)
62660778|NCT04760626|EXPERIMENTAL|Insulin icodec with DoseGuide|Participants randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their titration.
62660779|NCT04760626|ACTIVE_COMPARATOR|Once daily basal insulin analogues|Participants randomised to basal insulin analogue injections once daily
62660780|NCT04942600|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation (rTMS)|1 session (3,000 pulses) of high-frequency (10Hz) repetitive stimulation applied over the right temporal parietal junction (TPJ) gyrus in individuals with Functional Neurological Disorder using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
62660781|NCT01199614|EXPERIMENTAL|open-label PTH(1-84)|open-label PTH(1-84) / variable dosing: 25mcg every other day, 25mcg every day, 50mcg every day, 75mcg every day, 100mcg every day
62097827|NCT04452591|EXPERIMENTAL|Cohort P(Japan and United States Only) :Open to Enrollment|"HG Ta/T1 papillary disease bladder cancer patients.~In Cohort P, cretostimogene will be administered at a dose of 1 × 1012vp IVE following instillation of 5% DDM. Cretostimogene will be administered every week for 6 treatments on Weeks 1, 2, 3, 4, 5, and 6. If the patient has recurrence at Week 13 or any timepoint, the patient will receive a second induction of 6 weekly treatments (Weeks 13, 14, 15, 16, 17, and 18.). If the tumor has not returned they will receive 3 weekly treatments every 12 weeks (approximately 3 months) starting Weeks 13, 14, and 15 through Week 51 (approximately 12 months), and then every 6 months starting at Weeks 73, 74, and 75 (approximately 18 months) through Month 36."
62097828|NCT06091436|EXPERIMENTAL|GenSci094|Participants received a single subcutaneous (SC) injection of 150 µg or 100µg GenSci094 on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 150 IU or225IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles \>= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
62097829|NCT06091436|ACTIVE_COMPARATOR|recFSH|Participants received a single SC injection of placebo GenSci094 on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 150 IU or 225IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles \>= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
62097830|NCT06058637|NO_INTERVENTION|Care as usual|
62660782|NCT01968317|EXPERIMENTAL|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62097831|NCT06058637|EXPERIMENTAL|Eye screening on top of care|
62097832|NCT06614946|EXPERIMENTAL|Electronic safety plan (ESP) + Text-Based Support|Participants who are randomized to this arm will receive ESP during ED care and receive a text-based support program for 4 weeks after discharge, with up to 2 messages per day. The text-based program includes a microrandomized trial (MRT), where participants are randomized twice daily to receive or not receive a message.
62097833|NCT06614946|EXPERIMENTAL|Enhanced electronic safety plan (ESP) enhanced with 2 reminder text messages with ESP link|
62097834|NCT06382142|EXPERIMENTAL|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62097835|NCT06382142|EXPERIMENTAL|Eribulin or Vinorelbine or Gemcitabine or Capecitabine|Participants receive Eribulin or Vinorelbine or Gemcitabine or Capecitabine in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62466380|NCT05854602|EXPERIMENTAL|Condition 7: 00B|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
62466381|NCT05854602|EXPERIMENTAL|Condition 8: 0BA|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
62660783|NCT01968317|EXPERIMENTAL|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62660784|NCT02871596|EXPERIMENTAL|Placebo,Flavonoids,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
62466382|NCT05854602|EXPERIMENTAL|Condition 9: 0BC|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
62660785|NCT02871596|EXPERIMENTAL|Placebo,Flavonoids+Prebiotics,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
62660786|NCT02871596|EXPERIMENTAL|Flavonoids,Placebo,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
62660787|NCT02871596|EXPERIMENTAL|Flavonoids,Flavonoids+Prebiotics,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
62660788|NCT02871596|EXPERIMENTAL|Flavonoids+Prebiotics,Placebo,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
62660789|NCT02871596|EXPERIMENTAL|Flavonoids+Prebiotics,Flavonoids,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
62097836|NCT05452941||Case|Cases will be defined as participants hospitalized for RAD+CAP in whom the 7 additional serotypes in 20vPnC beyond 13vPnC plus 15C are identified.
62097837|NCT05452941||Control|All other participants who meet study inclusion criteria but for whom 20vPnC serotypes are not identified from any source and all other RAD+CAP of non-pneumococcal etiologies will serve as test-negative controls.
62097838|NCT05318014|EXPERIMENTAL|Intervention group|Regular nutrition education and supply one serving per day of 6% low protein formula.
62097839|NCT05318014|PLACEBO_COMPARATOR|Regular nutrition education|Regular nutrition education
62097840|NCT02058914|EXPERIMENTAL|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage (sweetened with 50 g fructose and 15 g glucose)
62097841|NCT02058914|ACTIVE_COMPARATOR|High Glucose sweetened beverage|HG-sweetened beverage (sweetened with 50 g glucose and 15 g fructose)
62097842|NCT01642264|NO_INTERVENTION|Control (Delayed Training) Condition|Participants in this condition were assessed at 1 week, 1 month and 3 months post-enrollment, and were provided access to the WeBREATHe training website upon completion of their 3-month assessment.
62097843|NCT01642264|EXPERIMENTAL|Intervention (Training) Condition|In this condition, participants used the WeBREATHe training program website for 1 week, and completed assessments at 1 week, 1 month, and 3 months post-training.
62097844|NCT06365554|EXPERIMENTAL|Intervention Group|Group undergoing intervention with the Remedy Robot.
62097845|NCT00006265|EXPERIMENTAL|Cohort I|Immunotherapy with gemtuzumab
62097846|NCT00006265|EXPERIMENTAL|Cohort II|Gemtuzumab + ara-C
62097847|NCT00006265|EXPERIMENTAL|Cohort IA|Gemtuzumab + ara C
62097848|NCT00006265|EXPERIMENTAL|Cohort IV|Gemtuzumab + ara-C
62097849|NCT01461356|EXPERIMENTAL|Minimally Invasive Surgical approach|Minimally invasive surgical approach for total knee replacement.
62097850|NCT01461356|ACTIVE_COMPARATOR|Medial Parapatellar surgical approach|Standard medial parapateller surgical approach for total knee replacement.
62097851|NCT06631573|EXPERIMENTAL|Fixed all-on-four prosthesis reinforced with PEEK framework.|
62097852|NCT06631573|ACTIVE_COMPARATOR|Fixed all-on-four prosthesis reinforced with Co-Cr framework|
62097853|NCT00112723|EXPERIMENTAL|Treatment (alvocidib)|"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive flavopiridol\* as in phase I at the MTD determined in phase I."
62097854|NCT03084861|EXPERIMENTAL|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
62097855|NCT03084861|ACTIVE_COMPARATOR|Conventional treatment|"Conventional treatment:~1. Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~2. Therapeutic Contact lens Description: Air Optix Night\&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
62097856|NCT06360718|NO_INTERVENTION|Control|Parents in this group will receive the standard child life interventional support for explaining the leukemia diagnosis to the school-aged patient/sibling. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey (about 1 week following the child life intervention), and the (3) Parenting Stress Index-4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later).
62660790|NCT00704353|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
62097857|NCT06360718|EXPERIMENTAL|Intervention (Storybook) Group|"Parents in this group will receive the Who is Luke Eemia? storybook, and will receive guidance from the child life specialist on how to utilize the storybook with their school-aged child. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey and (3) Storybook Assessment survey to review the parent's impression of the storybook intervention tool (about 1 week following the child life intervention), and the (4) Parenting Stress Index -4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later)."
62097858|NCT00852475|PLACEBO_COMPARATOR|MUFA|Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program
62097859|NCT00852475|ACTIVE_COMPARATOR|PUFA|Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program
62097860|NCT04155892||URI group|This group includes participants \<8 years of age undergoing elective procedures with a score of at least 3 on our pre-operative URI survey.
62097861|NCT04155892||non-URI group|This group includes participants \<8 years of age undergoing elective procedures with no URI symptoms or recent URI.
62097862|NCT06500572|ACTIVE_COMPARATOR|Landmark Guided Intercostobrachial Nerve Block|In addition to the supraclavicular plexus block, the intercostobrachial nerve block block will be performed without ultrasound guidance and based on the traditional method using superficial anatomy and nerve pathway by subcutaneous injection of 20 mL of bupivacaine 0.25% at the site of the pulse.
62466383|NCT05854602|EXPERIMENTAL|Condition 10: 0C0|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62660791|NCT00704353|ACTIVE_COMPARATOR|Standard Medical Care|Per product label
62660792|NCT00840125|EXPERIMENTAL|1|docetaxel + erlotinib
62660793|NCT05649371|EXPERIMENTAL|Prehabilitation|
62466384|NCT05854602|EXPERIMENTAL|Condition 11: 00C|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
62466385|NCT05854602|EXPERIMENTAL|Condition 12: 0CA|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
62466386|NCT05854602|EXPERIMENTAL|Condition 13: 0CB|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
62466387|NCT05854602|EXPERIMENTAL|Condition 14: A00|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62466388|NCT05854602|EXPERIMENTAL|Condition 15: A0B|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
62097863|NCT06500572|EXPERIMENTAL|Ultrasound Guided Intercostobrachial Nerve Block|The patient's head will be turned to the opposite side while the patient is in the supine position and the shoulder to be treated will be elevated 5- 10 cm. The high-frequency linear ultrasound probe (12-4 MHz) and the region to be treated will be prepared in sterile conditions and placed transversely across the external jugular vein at 3-4 cm above the clavicle. Between the anterior and middle scalene muscles, the imaging of the brachial plexus showed three to five hypoechoic circles. The entry will be in-plane technique using an 80-mm block needle from lateral to medial. After confirming the needle insertion site with 2 mL saline solution, a 20 mL bupivacaine 0.25% will be administered.
62097864|NCT06500572|EXPERIMENTAL|Serratus Plane Block|The patient will be placed in the lateral decubitus position with the area to be treated on the upper side. The high-frequency linear ultrasound probe and the region to be treated will be sterilized. The ultrasound probe will be placed on the anterior line at the level of fourth and fifth ribs. Images of the muscle's latissimus dorsi and serratus anterior, the ribs, and the pleura will be obtained. Subsequently, with the in-plane technique, an 80-mm block needle will be advanced between the latissimus dorsi and the serratus muscles planes in a caudal to the cranial direction. There is no blood or air in aspiration. After confirming the location of the needle with 2 mL of saline solution, (20 mL of bupivacaine 0.25%) will be administered between the two muscles.
62097865|NCT04892810||RFA|Patient with HCC and decision of treatment with ablation
62097866|NCT04892810||MWA|Patient with HCC and decision of treatment with ablation
62097867|NCT06427603|EXPERIMENTAL|activity group|
62097868|NCT06427603|NO_INTERVENTION|control group|
62097869|NCT04750629||SARS-Cov-2 RT-PCR AND CoviDx Rapid Antigen Testing|Sequentially enrolled symptomatic patients who present for COVID-19 testing and have a swab collected for high-sensitive, SARS-CoV-2 RT-PCR testing per Standard of Care AND a swab for CoviDx™ Rapid Antigen testing.
62294187|NCT06657014|ACTIVE_COMPARATOR|Peer Support Control Group|"The Peer Support Control Group will consist of 50 primary caregivers of preschool-aged children (ages 4 to 7) exhibiting signs of social anxiety. Participants will not receive Mind-Mindedness training but will have access to a private online peer support platform.~This group aims to provide a supportive environment for caregivers to share experiences, concerns, and coping strategies. Key features include:~Peer Support Platform:A moderated online group for discussions and emotional support among caregivers.~Resource Sharing: Opportunities for caregivers to share helpful articles, tips, and resources.~Facilitated Discussions: Occasional prompts to encourage conversations about common challenges.~Participants will complete assessments of mind-mindedness, social anxiety, attachment, and theory of mind at baseline, post-intervention, and three months later, similar to the Mind-Mindedness Training Group. This control group allows for comparisons of the effectiveness"
62294188|NCT02500537|EXPERIMENTAL|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
62294189|NCT02500537|EXPERIMENTAL|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
62466389|NCT05854602|EXPERIMENTAL|Condition 16: A0C|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
62466390|NCT05854602|EXPERIMENTAL|Condition 17: AB0|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62466391|NCT05854602|EXPERIMENTAL|Condition 18: ABC|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
62466392|NCT05854602|EXPERIMENTAL|Condition 19: AC0|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62097870|NCT04311203|EXPERIMENTAL|Mental Health First Aid Intervention|Two-day MHFA training provided by MHFA England. Organisations will raise awareness of the presence of MHFA in the workplace, with delivery of MHFA by trained members to participants in the workplace.
62097871|NCT04311203|NO_INTERVENTION|Control|A brief consultation from MHFAE on the promotion of mental health and well-being in the workplace.
62097872|NCT05759221|EXPERIMENTAL|Peripheral airway biopsy arm|All patients with clinical and radiological suspicion of sarcoidosis will be submitted to biopsy of peripheral airways (\> 6th branching generation).
62097873|NCT03208556|EXPERIMENTAL|iPD1 CD19 eCAR T cells|patients will receive a lymphodepletion chemotherapy prior to CAR T cell infusion
62097874|NCT05515367|EXPERIMENTAL|Desidustat oral tablet|Oral administration of Desidustat from baseline (week 0) to Week 52
62097875|NCT03344289|EXPERIMENTAL|Linked color imaging|When the patient is randomized for LCI, the imaging mode is switched to LCI and colonoscopic inspection will take place during withdrawal of the endoscope
62097876|NCT03344289|ACTIVE_COMPARATOR|High definition white light|When the patient is randomized for HD-WLE, the imaging mode is switched to HD-WLE and colonoscopic inspection will take place during withdrawal of the endoscope.
62097877|NCT04374318|ACTIVE_COMPARATOR|IT intrathecal|administration of intrathecal dexmedetomidine in addition to bupivacaine for lower limb surgeries
61909517|NCT01109732|EXPERIMENTAL|Systematic physical training|Hospital-based SET two days per week for 12 weeks and one home-based exercise session every week. The group-based SET was based on The Norwegian Ullevaal Model, a modified cardiac rehabilitation program, and was slightly adjusted to be applicable to this patient group. Each SET session lasted for 60 minutes and consisted of warm-up exercises, three high-intensity, two moderate-intensity and cool-down exercises, including stretching. The exercises were generally simple aerobic dance movements and walking and involved the use of both upper and lower extremities. The warm-up exercises included large muscle movements that were repeated later in the higher-intensity intervals, but with greater force and a larger range of movement.
62097878|NCT04374318|ACTIVE_COMPARATOR|IV intravenous|administration of intravenous dexmedetomidine in addition to spinal anaesthesia for lower limb surgeries
62466393|NCT05854602|EXPERIMENTAL|Condition 20: ACB|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
62466394|NCT05854602|EXPERIMENTAL|Condition 21: B00|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62660794|NCT05986318|ACTIVE_COMPARATOR|NAC + Corticosteroids|"Participants will take 600 mg of active NAC orally, three times daily, for 60 days.~Participants will also take 4 mg of active dexamethasone, orally, once daily for 10 days, then 2 mg, orally, once daily for 5 days, then 1 mg, orally, once daily for 5 days.~All participants will be treated with radical pulmonary radiation therapy."
62097879|NCT03218956|EXPERIMENTAL|Protein intake|Dietary supplement: Protein intake
62097880|NCT04028674|EXPERIMENTAL|Early Activation of Laryngeal Pacing device|Early Activation of the laryngeal pacing device (n=4) at one-month post-implantation.
62097881|NCT04028674|SHAM_COMPARATOR|Delayed Activation of Laryngeal Pacing device|Delayed activation of the laryngeal pacing device (n=4) at two months post-implantation.
62097882|NCT04426487|PLACEBO_COMPARATOR|Control|Receiving conventional management for traumatic subarachinoid hemorrhage
62097883|NCT04426487|ACTIVE_COMPARATOR|progesterone group|Intramusculer progesterone therapy before and after craniotomy
62466395|NCT05854602|EXPERIMENTAL|Condition 22: B0A|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
61909518|NCT01109732|NO_INTERVENTION|Treatment as of today|The control group did not receive any additional follow-up regarding exercise at discharge beyond the general advice about the importance of exercise that is routinely provided at the hospital.
62097884|NCT05425797|ACTIVE_COMPARATOR|In-Person|Standard Prevention Practitioner visit that will take place in-person
62097885|NCT05425797|EXPERIMENTAL|Video|Prevention Practitioner visit that will take place through video call
62097886|NCT05425797|EXPERIMENTAL|Phone|Prevention Practitioner visit that will take place through phone call
62097887|NCT06481735|EXPERIMENTAL|Patients with refractory or relapsed B-ALL|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T.
62097888|NCT03871998|EXPERIMENTAL|Interventional arm|Skin barrier protection in the first 2 months of life.
62294190|NCT06383494|ACTIVE_COMPARATOR|LMA Supreme group|Patient in LMA supreme group received device of LMA supreme for airway management (one of supraglottic airway device for airway management during general anesthesia)
62294191|NCT06383494|ACTIVE_COMPARATOR|I-gel group|Patient in I-gel group group received device of I-gel for airway management (one of supraglottic airway device for airway management during general anesthesia)
62466396|NCT05854602|EXPERIMENTAL|Condition 23: B0C|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
62466397|NCT05854602|EXPERIMENTAL|Condition 24: BA0|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62097889|NCT03871998|NO_INTERVENTION|Control arm|Standard skincare advice. No moisturiser in the first 2 months.
62097890|NCT04708821|EXPERIMENTAL|DEXTENZA|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
62097891|NCT04708821|ACTIVE_COMPARATOR|Antihistamine|PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.
62097892|NCT04708821|ACTIVE_COMPARATOR|Topical Steroid|ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.
62097893|NCT03625921|EXPERIMENTAL|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
62097894|NCT03625921|ACTIVE_COMPARATOR|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
62097895|NCT05239702|EXPERIMENTAL|Crohn Disease|
62097896|NCT05239702|EXPERIMENTAL|Ulcerative Colitis|
62097897|NCT05239702|EXPERIMENTAL|Dermatomyositis|
62097898|NCT05239702|EXPERIMENTAL|Still Disease|
62097899|NCT05239702|EXPERIMENTAL|Autoimmune Diseases|
62097900|NCT06329869|EXPERIMENTAL|Sacituzumab govitecan|
62097901|NCT00810303|EXPERIMENTAL|whole study group|A study with a duration of 34 days with 4 periods (= 4 pharmakokinetics) on 12 healthy subjects.
62097902|NCT00828945||Hyperlipidemic Patients|
62097903|NCT00658411|EXPERIMENTAL|All patients|Deferoxamine for \>=2 weeks prior to stem cells
62097904|NCT03329833|EXPERIMENTAL|Motivational Interviewing|Participants will talk to a coach on the phone who will employ Motivational Interviewing as a coaching style.
62097905|NCT03329833|EXPERIMENTAL|Web-Based Application|Participants will use a Web-Based Application to track their daily physical activity.
62466398|NCT05854602|EXPERIMENTAL|Condition 25: BAC|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
62097906|NCT03329833|EXPERIMENTAL|Combination MI and App|Participants will have both a coach by phone who will employ Motivational Interviewing as a coaching style and use a Web-Based Application to track their daily physical activity.
62097907|NCT03329833|NO_INTERVENTION|Educational Program|Participants will get to use a website that contains information relevant to patients with Parkinson's Disease.
62097908|NCT03677726|EXPERIMENTAL|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
62097909|NCT03677726|ACTIVE_COMPARATOR|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise of eight weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
62097910|NCT00248612|EXPERIMENTAL|Venlafaxine & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
62097911|NCT00248612|ACTIVE_COMPARATOR|Placebo & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
62097912|NCT00248612|ACTIVE_COMPARATOR|Venlafaxine & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
62097913|NCT00248612|PLACEBO_COMPARATOR|Placebo & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
62097914|NCT06214806|EXPERIMENTAL|Instacart|Voucher for grocery purchase and delivery via Instacart
62097915|NCT06214806|ACTIVE_COMPARATOR|Rouses Market|Voucher for grocery purchase in-person at Rouses Market in New Orleans
62097916|NCT05561855|EXPERIMENTAL|lifestyle intervention|"1. Weight monitoring: Participants are required to record the weighting data in the WeChat official account at least once a week to lose 5% or more of their initial body weight in 3 months.~2. Goals record: At baseline, the participants need to complete a behavioral goals questionnaire. All these behaviors are then ranked for each participant based on an algorithm that determines the participants'self-reported necessity, self-efficacy, and estimated caloric deficit from performing that behavior. The top six goals are assigned to each participant with two for every 4-week cycle.~3. Exercise: The form is the combination of aerobic exercise (3d/w) and resistance exercise(2d/w). Each participant will be equipped with a Huami watch as a means of monitoring.~4. Health education: Participants are provided with T2DM-related knowledge. They can also contact the endocrinologist online and offline."
62097917|NCT05561855|NO_INTERVENTION|usual-care control|Participants assigned to the control group will receive routine medical care and diabetes education, and be treated with hypoglycemic drugs under the guidance of endocrinologists according to the patient's condition and clinical treatment standards throughout their participation in the trial. After finishing the study, they will be offered healthy management as the participants in the multi-component lifestyle intervention group.
62097918|NCT02190838|EXPERIMENTAL|Dacarbazine with Metformin|32 patients will receive Dacarbazine 1000 mg/m\^2 once every 28 days with Metformin 850 mg BID.
62097919|NCT02190838|EXPERIMENTAL|Dacarbazine and Melatonin|32 patients will receive Dacarbazine 1000 mg/m\^2 once every 28 days with Melatonin 3 mg before sleep daily.
62097920|NCT02190838|ACTIVE_COMPARATOR|Dacarbazine|32 patients will receive Dacarbazine 1000 mg/m\^2 once every 28 days
62097921|NCT03494699|EXPERIMENTAL|Intervention group|
62097922|NCT03494699|NO_INTERVENTION|Control group|
62097923|NCT04542824|EXPERIMENTAL|arm 1: epcoritamab|In subjects with DLBCL/FL
62097924|NCT04542824|EXPERIMENTAL|arm 2: epcoritamab + rituximab + lenalidomide|In subjects with relapsed/refractory FL
62097925|NCT04542824|EXPERIMENTAL|arm 3: epcoritamab + rituximab + cyclophosphamide+ doxorubicin+ vincristine + prednisone|In subjects with previously untreated DLBCL
62097926|NCT04542824|EXPERIMENTAL|arm 4: epcoritamab + gemcitabine + oxaliplatin|In subjects with relapsed/refractory DLBCL
62466399|NCT05854602|EXPERIMENTAL|Condition 26: BC0|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62097927|NCT04542824|EXPERIMENTAL|arm 5: epcoritamab maintenance|In subjects with FL in complete response (CR) or in partial response (PR) following first line or second line SOC treatment
62466400|NCT05854602|EXPERIMENTAL|Condition 27: BCA|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
62097928|NCT01464294||nano-composite|crowns and onlays
62097929|NCT01464294||ceramic|crowns \& onlays
62466401|NCT05854602|EXPERIMENTAL|Condition 28: C00|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62097930|NCT02047786||General Hospital Patients|Those patients undergoing appendicectomy in a general (non-specialised) surgical centre.
62097931|NCT02047786||Paediatric Hospital Patients|Those patients undergoing appendicectomy in specialised paediatric centres.
62097932|NCT06615336|EXPERIMENTAL|Intensive Sleep retraining|
62097933|NCT06615336|EXPERIMENTAL|Total Sleep deprivation|
61909519|NCT00947505|ACTIVE_COMPARATOR|HairMax LaserComb 2009, 7 Beam|Lower level laser phototherapy medical device with 7 laser beams
61909520|NCT00947505|ACTIVE_COMPARATOR|Control Device|Identical to the Active device, but with 7 LED's instead of lasers
61909521|NCT05617495|ACTIVE_COMPARATOR|15-Minute mbNF|Participants receiving mindfulness training and 15-minute session of mbNF
62097934|NCT06615336|NO_INTERVENTION|Control|The control condition consisted of one night of habitual sleep in the laboratory
62097935|NCT06347315|ACTIVE_COMPARATOR|BrainXpert|15 g kMCT + B-vitamins (B3, B6, B9/folic acid, and B12) will be provided in powder format
62097936|NCT06347315|PLACEBO_COMPARATOR|Placebo|"high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will be provided in a powder format~."
62294192|NCT06383494|EXPERIMENTAL|GMA-Tulip group|Patient in GMA-Tulip group group received device of GMA-Tulip for airway management (one of supraglottic airway device for airway management during general anesthesia)
62097937|NCT00875641||HRV cohort|HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).
62466402|NCT05854602|EXPERIMENTAL|Condition 29: C0A|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
62660795|NCT05986318|ACTIVE_COMPARATOR|Corticosteroids + NAC Placebo|"Participants will take 4 mg of active dexamethasone, orally, once daily for 10 days, then 2 mg, orally, once daily for 5 days, then 1 mg, orally, once daily for 5 days.~Participants will also take matching NAC placebo orally, three times daily, for 60 days.~All participants will be treated with radical pulmonary radiation therapy."
62660796|NCT05986318|ACTIVE_COMPARATOR|NAC + Dexamethasone Placebo|"Participants will take 600 mg of active NAC orally, three times daily, for 60 days.~Participants will also take matching dexamethasone placebo (4 mg for 10 days, then 2 mg for 5 days, then 1 mg for 5 days), orally, once daily.~All participants will be treated with radical pulmonary radiation therapy."
62097938|NCT00875641||Concurrent Control cohort|Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).
62097939|NCT00875641||Recent Historical Control cohort|Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.
62660797|NCT05986318|PLACEBO_COMPARATOR|NAC Placebo + Dexamethasone Placebo|"Participants will take matching NAC placebo orally, three times daily, for 60 days.~Participants will also take matching dexamethasone placebo (4 mg for 10 days, then 2 mg for 5 days, then 1 mg for 5 days), orally, once daily.~All participants will be treated with radical pulmonary radiation therapy."
62660798|NCT01802047|EXPERIMENTAL|Electric Pump Modality|Each mother follows all 3 electric pump modalities in a randomized order.
62097940|NCT05978661|EXPERIMENTAL|Treatment arm|
62097941|NCT05822440|EXPERIMENTAL|Period 1|The treatment arm includes a single dose of PF-07817883 (Period 1 Day 1)
62097942|NCT05822440|EXPERIMENTAL|Period 2|This treatment arm includes 7-day dosing of itraconazole with a single dose of PF-07817883 Co-administered on Day 4 (Period 2 Day 4)
62097943|NCT04390464|ACTIVE_COMPARATOR|Standard of care|Standard of care
62097944|NCT04390464|EXPERIMENTAL|Ravulizumab + Standard of care|Ravulizumab IV (adjusted to weight, Day 1 only)
62466403|NCT05854602|EXPERIMENTAL|Condition 30: C0B|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
62466404|NCT05854602|EXPERIMENTAL|Condition 31: CA0|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62466405|NCT05854602|EXPERIMENTAL|Condition 32: CAB|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
62466406|NCT05854602|EXPERIMENTAL|Condition 33: CB0|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
62660799|NCT05721313|EXPERIMENTAL|Patients with advanced periodontal furcation involvement|
62097945|NCT04390464|EXPERIMENTAL|Baricitinib + Standard of care|Baricitinib PO OD (4mg, Days 1-14)
62097946|NCT03116204||Patients hospitalized in a FRC department|
62097947|NCT01304147|EXPERIMENTAL|Ketamine|Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
62097948|NCT01304147|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive intranasal saline.
62097949|NCT05724173|OTHER|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
62294193|NCT05043584|EXPERIMENTAL|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted total thyroidectomy
62466407|NCT05854602|EXPERIMENTAL|Condition 34: CBA|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
62466408|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
62466409|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
62466410|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
62097950|NCT04609293||Camrelizumab+apatinib+Hypofractionated radiation therapy|"Camrelizumab:200mg every 2 weeks for 1 years or until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Apatinib:250mg everyday until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Radiation: one week following completion of the second immunotherapy, hypofractionated radiotherapy with marginal dose of 50Gy/2Gy/25f and tumor center dose of local hyperfraction increase 24-32Gy/8-12Gy/3-4f will be performed 3-5 times. The routine radiotherapy will be started at the same time as the third immunotherapy and 25 times routine radiotherapy will be completed before the fifth or sixth immunotherapy."
62097951|NCT05974709||Office Workers|The study will document the sociodemographic attributes of the participants, encompassing variables such as age, gender, height, weight, educational attainment, marital status, occupation, daily working hours, and professional experience. The data pertaining to the variables in question were obtained through employment of a structured questionnaire.
62097952|NCT06712277|EXPERIMENTAL|Patients and caregivers who underwent percutaneous endoscopic gastrostomy for the first time|
62097953|NCT05874791|EXPERIMENTAL|Goal management training|Cognitive rehabilitation:14 hours of GMT in groups of 4-6 participants, administered following a script with accompanying PowerPoint slides and participant workbooks, over the course of 7 weeks (one 2-hour session per week). In addition, the participants receive Treatment as Usual
62097954|NCT05874791|NO_INTERVENTION|Treatment as Usual|Norway has established clinical guidelines for ADHD assessment and treatment in public health, emphasizing psychoeducation, parent management training, school counseling, and pharmacological treatment adapted to the needs of each patient
62097955|NCT04774718|EXPERIMENTAL|ALK-Fusion Positive|Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle
62097956|NCT03614234|EXPERIMENTAL|Experimental open label|Pegunigalsidase alfa
62097957|NCT05423080|EXPERIMENTAL|Bolus group|Participants in this group are administered remimazolam via the bolus injection method during anesthesia induction.
62097958|NCT05423080|ACTIVE_COMPARATOR|Infusion group|Participants in this group are administered remimazolam via the continuous infusion method during anesthesia induction.
62660800|NCT02595749|EXPERIMENTAL|Placebo then Intranasal Oxytocin (40 IU)|Participants received a single placebo nasal spray (consisting of 4ml sterile saline \[Ocean Nasal Spray Solution\]) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
61909522|NCT05617495|ACTIVE_COMPARATOR|30-Minute mbNF|Participants receiving mindfulness training and 30-minute session of mbNF
62097959|NCT04215913||Normal lung tissue|Normal lung tissue from PSC patients
62466411|NCT01889498|NO_INTERVENTION|control group with no acetazolamide|Treatment as usual without acetazolamide treatment
62466412|NCT01889498|ACTIVE_COMPARATOR|Acetazolamide|Treatment arm
62466413|NCT03928886|EXPERIMENTAL|Senographe Pristina patient-assisted compression model|Senographe Pristina is a commercial mammography medical device consisting of the Senographe Pristina FFDM system (2D) and Senographe Pristina DBT option (3D). Senographe Pristina includes the hardware and software components required for multi-modality functioning and is designed to improve patient experience, patient throughput, and radiographer experience. The system offers two compression modes - standard mode and the optional patient-assisted compression. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
62097960|NCT04215913||PSC tissues|PSC tissues from PSC patients
62294194|NCT04587115|PLACEBO_COMPARATOR|Oxycodone|This arm will be considered the control arm, containing oxycodone as the placebo.
61909523|NCT04424329|EXPERIMENTAL|Nutrition intervention|Ingestion of fibers and probiotics daily for 22 days
61909524|NCT04424329|NO_INTERVENTION|No intervention|No intervention
62097961|NCT04215913||Metastasis tissues|Metastasis tissues from PSC patients
62294195|NCT04587115|EXPERIMENTAL|Oxycodone and Risperidone|Administration of oxycodone plus risperidone in a single capsule
62294196|NCT04587115|EXPERIMENTAL|Oxycodone and Ziprasidone|Administration of oxycodone and risperidone in a single capsule
62294197|NCT04045067||Group 1|A group of patients who have pulmonary vein isolation alone, without low-voltage areas identified.
62097962|NCT06211140|EXPERIMENTAL|Depressive disorders|"Three conductive electrodes will be placed overhead. Based on the 10/20 international placement system, a 4.45 x 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 x 3.81 cm electrodes are placed on the mastoid region of each side.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~All participants with major depression disorder will receive a total of 20 sessions in four weeks, once daily on weekdays, with tACS stimulation at 77.5 Hz and 15 mA.~From Monday to Friday, each session will last 40 min at a fixed daytime interval."
62097963|NCT06211140|OTHER|Healthy controls|Without the tACS stimulation in this group
62097964|NCT05321069|EXPERIMENTAL|BI 1015550 low dose|
62097965|NCT05321069|EXPERIMENTAL|BI 1015550 high dose|
62097966|NCT05321069|PLACEBO_COMPARATOR|Placebo|
62097967|NCT00846781|EXPERIMENTAL|Denufosol tetrasodium Inhalation Solution|
62097968|NCT01282099||Cardiac patients|Postoperative congenital heart disease patients requiring stay in the PICU
62097969|NCT01282099||non-cardiac patients|non-cardiac patients requiring stay in the PICU
62097970|NCT05833360||Control Cohort|Participants without cancer, with general medical comorbidities
62097971|NCT05833360||Cancer Predisposition Cohort|Participants without cancer, with comorbidities that induce cancer predisposition.
62097972|NCT05833360||Pre-Malignant Condition Cohort|Participants without cancer, with pre-malignant conditions
62097973|NCT05833360||Cancer Patients Cohort|Participants with a cancer diagnosis.
62097974|NCT04173845|EXPERIMENTAL|Tianqi Pingchan Granule group|Tianqi Pingchan Granule were manufactured according to Good Manufacturing Practice (GMP) by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. , granule, twice a day, for six months.
62097975|NCT04173845|PLACEBO_COMPARATOR|Tianqi Pingchan Granule Placebo group|placebo, granule, twice a day, for six months.
62097976|NCT00800124|NO_INTERVENTION|1|Cemented hemiprosthesis
62097977|NCT00800124|ACTIVE_COMPARATOR|2|Non-cemented hemiprosthesis
62097978|NCT03921528|EXPERIMENTAL|Cohort 1|Ambulatory Type 3 SMA
62097979|NCT03921528|EXPERIMENTAL|Cohort 2|Type 2 SMA / Non-Ambulatory Type 3 SMA
62097980|NCT03921528|EXPERIMENTAL|Cohort 3|Type 2 SMA
62097981|NCT02013232|PLACEBO_COMPARATOR|placebo|risperidone plus placebo
62097982|NCT02013232|EXPERIMENTAL|aripiprazole 5mg|risperidone treatment plus aripiprazole 5mg/day
62097983|NCT02013232|EXPERIMENTAL|aripiprazole 10mg|risperidone plus aripiprazole 10mg/day
62097984|NCT02013232|EXPERIMENTAL|aripiprazole 20mg|risperidone plus aripiprazole 20mg/day
62097985|NCT02222415|PLACEBO_COMPARATOR|Training + placebo drink|Exercise + non-caloric placebo drink
62097986|NCT02222415|EXPERIMENTAL|Exercise + Protein drink|exercise + Drink containing Protein, Carbohydrates and Fat
62097987|NCT05588674|EXPERIMENTAL|Probiotic Supplement|1 billion CFU per capsule of a multistrain probiotic formulation including one Bifidobacterium and two Lactobacilli strains with maltodextrin as a carrier
62466414|NCT03928886|ACTIVE_COMPARATOR|Senographe Pristina standard compression mode (usual care)|Senographe Pristina standard mode
62097988|NCT05588674|PLACEBO_COMPARATOR|Placebo capsule|418mg maltodextrin
61909525|NCT02292901|ACTIVE_COMPARATOR|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope
62097989|NCT04163666|EXPERIMENTAL|Mirror therapy group|The mirror therapy group will receive a treatment based on this therapy, combined with task-oriented motor learning.
62097990|NCT04163666|EXPERIMENTAL|Cognitive therapeutic exercise group|The cognitive therapeutic exercise group will receive a treatment based on this therapy, combined with task-oriented motor learning.
62097991|NCT04163666|NO_INTERVENTION|Control Group|No additional intervention with the participants of this group will be completed.
62097992|NCT00626847||1|Primary Open Angle Glaucoma (POAG)
62097993|NCT00626847||2|Controls (Normals, patients without glaucoma)
62097994|NCT06713512||People with physician-diagnosed disease (Asthma and/or COPD).|People with physician-diagnosed disease (Asthma and/or COPD).
62097995|NCT06713512||Healthy controls|People with no physician-diagnosed disease (Asthma and/or COPD).
62097996|NCT04129762|EXPERIMENTAL|Diet without NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
62097997|NCT04129762|ACTIVE_COMPARATOR|Diet with NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS
62097998|NCT04129762|EXPERIMENTAL|Diet without NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
62097999|NCT04129762|ACTIVE_COMPARATOR|Diet with NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS
62098000|NCT05583617|EXPERIMENTAL|Substudy 2: Dose Escalation and Expansion|"In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on Day(D)1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 and D15 for cycles 1-6 and D1 of cycle 7 onwards. Each cycle is 28 days. Lenalidomide will be administered by mouth (PO) on a 28-day cycle.~During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Lenalidomide will be administered PO on a 28-day cycle."
62294198|NCT04045067||Group 2|A group of patients who have pulmonary veins isolation alone, with low-voltage areas identified but the complementary defragmentation will not be carried out.
62466415|NCT04535843||myasthenia gravis|300 MG patients are anticipated for precision diagnosis and disease monitoring.
61909526|NCT02292901|EXPERIMENTAL|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope
62098001|NCT05583617|EXPERIMENTAL|Substudy 4: Dose Escalation and Expansion|"In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on D1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 of each cycle, every 3 weeks (Q3W). Each cycle is 21 days. Iberdomide will be administered PO on a 21-day cycle.~During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Iberdomide will be administered PO on a 21-day cycle."
62098002|NCT06601907|EXPERIMENTAL|alivis + TAU|Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
62098003|NCT06601907|NO_INTERVENTION|TAU|Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
62098004|NCT03288350|EXPERIMENTAL|mDCF + Avelumab|"Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil, followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of docetaxel, cisplatin, 5-fluorouracil and avelumab.~Docetaxel as a one-hour 40 mg/m2 IV infusion on day 1. Cisplatin 40 mg/m2 IV infusion on day 1. 5-FU 1000 mg/m2/day over 2 days. Avelumab 10 mg/kg following the completion of the mDCF regimen."
62098005|NCT05934773|EXPERIMENTAL|Gait Rehabilitation|12-16 gait rehabilitation sessions on a robotic treadmill, emphasizing gait scaffolds: endurance, strength, speed, and balance. 3-4 sessions of training for each.
62098006|NCT02487290|EXPERIMENTAL|Treatment|Aneufix ACP-T5
62098007|NCT06170489|EXPERIMENTAL|JS004 plus Toripalimab|JS004 200mg plus Toripalimab 240mg IV on day 1 of each cycle, every 3 weeks for up to 2 years
62098008|NCT06170489|ACTIVE_COMPARATOR|Investigator-Selected Chemotherapy|Bendamustine or gemcitabine
62098009|NCT00809224||ALS|ALS group should have ALS.
62098010|NCT00809224||Control|The control group should not have ALS or any other neurological/psychiatric disorder, and must be over the age of 40.
62098011|NCT04502927|OTHER|Stroke patients with hand spasticity (n=20)|
62098012|NCT04502927|OTHER|Healthy volunteers (n=10)|
62098013|NCT03668067||Photoscreener (2WIN)|Accommodation, refraction and ocular alignment are estimated by infrared photoscreener using the photoscreener device. Photoscreener screening makes use of light crescent quantification from off-axis flash-to-lens in a camera.
62098014|NCT03668067||school bus skiascopy|Refractive error estimated by child-friendly skiascopy rack holding lenses from +1.00 D to +10.00 D and -5.00 D. Skiascopy is a common, old-fashioned form of retinoscopy.
62098015|NCT04068194|ACTIVE_COMPARATOR|Arm A (hypofractionated RT, avelumab)|Patients undergo 8 fractions of hypofractionated RT QD on days -17 to -7. Patients also receive avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, CT, and collection of blood on the trial.
62660801|NCT02595749|EXPERIMENTAL|Intranasal Oxytocin (40 IU) then Placebo|Participants received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single placebo nasal spray (consisting of 4ml sterile saline \[Ocean Nasal Spray Solution\]) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
62660802|NCT02077699|EXPERIMENTAL|1|Treatment with Lactobacillus casei DG (24 billion of live cells per pill) 2 pills b.i.d. for 4 weeks
62098016|NCT04068194|EXPERIMENTAL|Arm B (hypofractionated RT, peposertib, avelumab)|Patients undergo 8 fractions of hypofractionated RT QD on days -17 to -7. Patients also receive peposertib PO BID on days 1-28, and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, CT, and collection of blood on the trial.
62098017|NCT04398459|EXPERIMENTAL|iBRIAN|
62098018|NCT03381430|EXPERIMENTAL|Gefitinib + Radiotherapy|Experimental: Gefitinib Gefitinib 250 mg/day oral daily Radiotherapy Total dose 50-54Gy, divided dose 1.8-2Gy
62098019|NCT01324882|EXPERIMENTAL|Study Arm|This is the group who will have a colonoscopy with the Olympus Technically Improved Colonoscope.
62098020|NCT01324882|ACTIVE_COMPARATOR|Control|This is the group who will have a colonoscopy with the traditional colonoscope Olympus CF-H180.
62098021|NCT00694811|EXPERIMENTAL|A|1 week of re-feeding
62098022|NCT00694811|EXPERIMENTAL|B|6 weeks of re-feeding
62098023|NCT05205941|OTHER|MMV533 (single, oral doses).|Approximately 12 volunteers in 1 cohort, Up to six dose levels between 10 and 160mg
62098024|NCT03556826|EXPERIMENTAL|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
62098025|NCT05705401|ACTIVE_COMPARATOR|Standard of Care Adjuvant Breast Radiation|Patients continue to receive their current planned adjuvant breast radiation and systemic HER2-targeted therapies
62098026|NCT05705401|ACTIVE_COMPARATOR|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|Patients continue to receive their current systemic HER2-targeted therapy without breast adjuvant radiation
62098027|NCT04467463|EXPERIMENTAL|GPN|administrated bilateral greater palatine nerve block using levobupivacaine 0.25%
62098028|NCT04467463|EXPERIMENTAL|SMN|administrated bilateral suprazygomatic nerve block using levobupivacaine 0.25%.
62098029|NCT04669613|EXPERIMENTAL|Patients|
62660803|NCT05783973||bile group|bile samples from 20 resectable BTC patients with 520 Panel sequencing (bile10000X)
62294199|NCT04045067||Group 3|A group of patients who have pulmonary veins isolation, with low-voltage areas identified and the complementary defragmentation will be carried out.
62098030|NCT00986271|OTHER|With and without MODS developement|EVLI was determinated by PiCCO plus system.
62098031|NCT03597321|EXPERIMENTAL|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
62098032|NCT03597321|NO_INTERVENTION|Arm B- No intervention|
62098033|NCT03318120|EXPERIMENTAL|Progressive Resistance Training|Participants assigned to this arm will receive progressive resistance training under the supervision of a personal trainer at a gym facility close to their home. They will be required to perform these exercises twice a week for the first six months. They will be monitored with an activity monitor.
62098034|NCT03318120|NO_INTERVENTION|Control Arm|The control arm offered to subjects with dystonia and other involuntary muscle disorders, participants will be followed at baseline and 6 months similar to what will be done in active exercise arm but this arm will not receive exercise. They will be monitored with an activity monitor.
62098035|NCT05835466|EXPERIMENTAL|Reparixin|Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.
62098036|NCT03487666|EXPERIMENTAL|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
62098037|NCT03487666|ACTIVE_COMPARATOR|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
62098038|NCT03487666|EXPERIMENTAL|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
62098039|NCT02579512||Extra-corporeal ECG Signal Analysis|
62098040|NCT03211598|OTHER|TACE with Surefire|Subjects enrolled in the study will have their TACE procedure with the Surefire Infusion System.
62098041|NCT06640894|EXPERIMENTAL|Intervention (MegaPower training)|"MegaPower training is a twelve-week long functional power training program in which children will perform functional power training three times a week together with a personal trainer. During the intervention, training volume will be influenced by training weight, velocity of movement, and amount of repetitions. The training program has the following characteristics:~1. (Weighted) functional exercises like walking, running, and walking stairs.~2. High velocity movements.~3. Progressive overload.~Prior to and during the training, a physiotherapist makes a personalized participation plan for the child. This plan is used to tackle participation barriers related to their goal (not directly related to mobility; e.g. beliefs or behaviours) encountered by the child (e.g. involving parents, a sports consultant, a psychologist).~Both at twelve and twenty-four weeks during the follow-up, parent and child will visit again to measure whether the effects on participation are long-lasting."
62098042|NCT06640894|ACTIVE_COMPARATOR|Control (Usual Care)|The control group will receive their usual care for twelve weeks (non-intervention group). This usual care consists of physiotherapy appointments, for example.
62098043|NCT04571073|EXPERIMENTAL|Treatment arm|The only arm in the study was the intervention arm as this is a pilot study.
62098044|NCT00232011|EXPERIMENTAL|1|
62098045|NCT06121570|EXPERIMENTAL|Chemotherapy + LNL treatment|Participants receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by neoadjuvant LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.
62294200|NCT01755169|EXPERIMENTAL|Ketamine 0.25 mg/kg/dose|A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
62294201|NCT01755169|EXPERIMENTAL|Ketamine 0.5 mg/kg/dose|A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
62294202|NCT01755169|EXPERIMENTAL|Ketamine 1 mg/kg/dose|A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
62294203|NCT01755169|PLACEBO_COMPARATOR|Placebo|
62294204|NCT04851184|ACTIVE_COMPARATOR|Usual Vestibular Rehabilitation Care|Participants in this arm will perform typical PT in the clinic and home environment. They will be asked to keep a log to track their HEP.
62294205|NCT04851184|EXPERIMENTAL|Home Exercises Using Virtual Reality Device|Participants in this arm will perform typical PT in the clinic, but will use the virtual reality device as part of their HEP.
62660804|NCT05783973||Tissue group|tissue samples from 20 resectable BTC patients with 520 Panel sequencing (tissue1000X)
62660805|NCT05783973||Plasma group|plasma samples from 20 resectable BTC patients with 520 Panel sequencing (plasma 10000X)
62660806|NCT02756520||Chronic kidney disease (pre-dialysis)|Observational study: supplemented protein-restricted diet
62098046|NCT03109288|EXPERIMENTAL|Combination Therapy|Any two-drug combination of study interventions
62098047|NCT03109288|EXPERIMENTAL|Monotherapy|Any of the study Interventions
62660807|NCT04448301|EXPERIMENTAL|PointCheck Cohort|
62098048|NCT06714435|EXPERIMENTAL|Groupe 1|Group with non-hypoxique endurance trial first
62098049|NCT06714435|EXPERIMENTAL|Groupe 2|Group with hypoxique endurance trial first
62466416|NCT02357732|EXPERIMENTAL|Nivolumab and Dabrafenib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV every 2 weeks (q2 weeks); Dabrafenib 100mg by mouth (PO) twice a day(BID) every day (QD); Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD;
62660808|NCT00448045|EXPERIMENTAL|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough peak flow. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough peak flow. Subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
62660809|NCT00448045|ACTIVE_COMPARATOR|Incentive spirometry|The active control group will consist of individuals assigned to the oximetry with incentive spirometry group. These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
62660810|NCT01522053|EXPERIMENTAL|Catheter-over-needle|Patients will receive a catheter placed by a catheter-over-needle method.
62660811|NCT01522053|ACTIVE_COMPARATOR|Catheter-through-needle|Patients will receive a catheter placed by the traditional catheter-though-needle method.
62098050|NCT03881254|EXPERIMENTAL|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
62098051|NCT03881254|ACTIVE_COMPARATOR|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
62098052|NCT05247489|EXPERIMENTAL|Group A: Ruxolitinib + Narrow-Band Ultraviolet B Phototherapy (NB-UVB)|Participants will initially apply ruxolitinib 1.5%mg cream as a monotherapy. At week 12, those who have \< 25% improvement in total body Vitiligo Area Scoring Index (T-VASI25) will have NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen. NB-UVB will be given 3 times per week starting at Week 12 through Week 48 (36 weeks). For participants who receive combination therapy, NB-UVB machines will be supplied by the sponsor for at home use during the study.
62660812|NCT04488952|EXPERIMENTAL|nerve block combined with general anesthesia group|Patients in this group receive nerve block combined with general anesthesia.
62098053|NCT05247489|EXPERIMENTAL|Group B: Ruxolitinib Monotherapy|Participants will apply ruxolitinib 1.5% cream BID as monotherapy. Participants who have ≥ T-VASI25 at Week 12 will continue on ruxolitinib 1.5% cream BID alone.
62098054|NCT00828620||PET-CT|Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
62098055|NCT04920214||Experimental group|"1. patients with hepatic focal lesions~2. patients with non-high risk factors for hepatocellular carcinoma"
62098056|NCT06028048|EXPERIMENTAL|PLACES intervention|Participants in the intervention group will receive the PLACES intervention during 12-months after randomization.
62098057|NCT06028048|NO_INTERVENTION|Care as usual|Participants in the control group will receive usual care from the SSA.
62098058|NCT04082637|EXPERIMENTAL|MABT* + Medication Treatment|Mindful Awareness in Body-oriented Therapy + Medication Treatment
62098059|NCT04082637|NO_INTERVENTION|Treatment as Usual|Treatment as Usual is medication for the treatment of opioid use disorder
62098060|NCT02967692|EXPERIMENTAL|Part 1: Safety run-in Cohort|In Part 1, participants are treated at different dose levels to determine the recommended Phase 3 regimen of spartalizumab in combination with dabrafenib and trametinib. The starting dose of spartalizumab is 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD).
62294206|NCT04851184|NO_INTERVENTION|Healthy Control|Age-matched healthy control subjects will perform all balance, gait, vestibular, and patient reported outcome measure assessments, including performing 30 seconds of each level of gaze stability exercise for an active comparison to outcomes obtained to those with vestibular disorders.
62660813|NCT04488952|EXPERIMENTAL|spinal anesthesia group|Patients in this group receive spinal anesthesia.
62660814|NCT04488952|PLACEBO_COMPARATOR|control group|This group is used to obtain the learning effect.
62660815|NCT02702856||Men screened for prostate cancer|
62098061|NCT02967692|EXPERIMENTAL|Part 2: Biomarker cohort|In Part 2, participants are treated with spartalizumab 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD).
62294207|NCT01917123|ACTIVE_COMPARATOR|Stimol, Brachial Index, Powder agent|L-Citrulline malate,1gr,twice a day,2weeks
62294208|NCT01917123|PLACEBO_COMPARATOR|Placebo, Brachial Index, Powder agent|Placebo,1gr,twice a day,2weeks
62098062|NCT02967692|EXPERIMENTAL|Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib|In Part 3, participants are randomized to receive spartalizumab at the RP3R identified in Part 1 (400 mg Q4W) in combination with approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD)
62098063|NCT02967692|PLACEBO_COMPARATOR|Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib|In Part 3, participants are randomized to receive matching placebo in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD)
61909527|NCT04948931|EXPERIMENTAL|Lavender aromatherapy|As an intervention to this group, lavender application will be made by inhalation. Participants will apply lavender oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
62098064|NCT03549806||Prospective Cohort|No study intervention. Patients referred for ablation of atrial arrhythmias will be treated as per operator preference with no study intervention. Data will be collected in de-identified fashion.
62098065|NCT00623246|ACTIVE_COMPARATOR|1|Participants will receive motivational enhancement therapy (MET) for 12 weeks.
62098066|NCT00623246|ACTIVE_COMPARATOR|2|Participants will receive educational therapy (ED) for 12 weeks.
62098067|NCT00623246|NO_INTERVENTION|3|Participants will receive standard clinical care.
62098068|NCT02978456|EXPERIMENTAL|quantitative coronary angiography guided|
62098069|NCT02978456|ACTIVE_COMPARATOR|Intravascular ultrasound guided|
62098070|NCT06527768|EXPERIMENTAL|Theory-based health behaviour change intervention group|Participants will be enrolled via WeChat and undergo 8 intervention sessions over 12 weeks. The 8 intervention sessions contain two online individual education sessions, two online group music-paced brisk walking training, two group discussions, and two telephone follow-ups. Besides, participants in the intervention group will be required to perform self-music-paced brisk walking 150 minutes/week for three months.
62098071|NCT06527768|NO_INTERVENTION|Control group|Usual care.
62098072|NCT06180356|EXPERIMENTAL|Niraparib|
62466417|NCT02357732|EXPERIMENTAL|Nivolumab and Trametinib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Trametinib 2mg PO QD;
62660816|NCT01898078|EXPERIMENTAL|Alisertib 50 mg Fed + Fasted|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
62660817|NCT01898078|EXPERIMENTAL|Alisertib 50 mg Fasted + Fed|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
61909528|NCT04948931|EXPERIMENTAL|Rosemary aromatherapy|As an intervention to this group, rosemary application will be made by inhalation. Participants will apply rosemary oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
61909529|NCT04948931|PLACEBO_COMPARATOR|Control|Distilled water will be used for the application to this group. The application will be made every night for a month, half an hour before going to bed, under the supervision of a relative. Participants will apply distilled water by dropping three drops on cotton, holding it 5-10 cm away from the nose, for five minutes and breathing normally.
61909530|NCT00885820|EXPERIMENTAL|1|Protocol biopsies at 1, 2 and 3 months
61909531|NCT00885820|ACTIVE_COMPARATOR|2|No protocol biopsies
62660818|NCT01402856||Southern Lehigh HS, PA School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
61909532|NCT04271644|EXPERIMENTAL|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
61909533|NCT01328366||Participants with severe psoriasis|The participants had severe disease as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and had not responded to standard systemic therapies.
61909534|NCT05828927|OTHER|Caregiver of subject with cancer|Adults who identify as a primary unpaid caregiver for a rural-dwelling adult with cancer.
61909535|NCT05828927|NO_INTERVENTION|Subject with Cancer|Subjects is with cancer and receive care from caregivers.
61909536|NCT01765478|EXPERIMENTAL|Treatment A Period 2|40mg HM71224 single dose
61909537|NCT01765478|EXPERIMENTAL|Treatment B Period1|20mg HM71224 single dose
61909538|NCT01765478|EXPERIMENTAL|Treatment A Period1|10mg HM71224 single dose
61909539|NCT01765478|EXPERIMENTAL|Treatment B Period2|80mg HM71224 single dose
61909540|NCT01765478|EXPERIMENTAL|TreatmentA Period3|160mg HM71224 single dose
61909541|NCT01765478|EXPERIMENTAL|TreatmentB Period3|200mg HM71224 single dose
61909542|NCT01765478|EXPERIMENTAL|Food effect period1|active 4subjects + placebo 4subjects
61909543|NCT01765478|EXPERIMENTAL|Food effect period2|active 4subjects + placebo 4subjects
61909544|NCT01765478|EXPERIMENTAL|TreatmentC|HM71224 Xmg multiple dose for 14days
61909545|NCT01765478|EXPERIMENTAL|TreatmentD|HM71224 Ymg 14days multiple dose
61909546|NCT01765478|EXPERIMENTAL|TreatmentE|HM71224 Zmg 14days multiple dose
61909547|NCT02004288|EXPERIMENTAL|Lactobacillus reuteri Protectis DSM17938|One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)
61909548|NCT02004288|PLACEBO_COMPARATOR|Placebo|One chewable tablet twice per day with placebo per day
61909549|NCT02965768|ACTIVE_COMPARATOR|LDN arm|Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
62098073|NCT03174938|OTHER|COHORT A: Cognitively healthy younger individuals (40-65 y)|"We will recruit 300 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline.~An auxiliary cohort (termed Cohort A2) of 40 healthy individuals aged 20-40 years of age will also be included."
62098074|NCT03174938|OTHER|COHORT B: Cognitively healthy elderly individuals (66-100 y)|"We will recruit 300 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline. Motor assessments (Motor-ACT) are performed at baseline and afte"
62098075|NCT03174938|OTHER|COHORT C: SCD and MCI|"\>750 patients with either subjective cognitive decline (SCD) or mild cognitive impairment (MCI) will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio).~FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET, Amyloid PET and MRI will be done every 2 years. Motor assessment (Motor-ACT) at year 1, year 3 and year 5.~A auxiliary cohort (Cohort C2) \>150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y.~In total, 1000 patients with SCD or MCI will be included."
62294209|NCT06427512||COVID patients|Patients with long COVID-19 and experiencing cardiovascular symptoms at 24 weeks post-acute illness or post-COVID without cardiovascular symptoms by 8 weeks after illness.
62294210|NCT04372095||group 1: Exposed to CPA + Meningioma|"Meningioma diagnosed in women by medical imaging examination and confirmed histologically if surgery is performed.~Cyproterone acetate taken for at least 6 months."
62294211|NCT04372095||group 2: Exposed to CPA without Meningioma|Women exposed to Cyproterone acetate without developing any meningioma Absence of meningioma assessed by a normal cerebral MRI . Cyproterone acetate taken for at least 5 years.
62294212|NCT04372095||group 3: Not exposed to CPA, Meningioma diagnosed|"Meningioma in women not exposed to cyproterone acetate. Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery was necessary.~Never exposed to cyproterone acetate."
62660819|NCT01402856||Bethlehem HS, PA Area School District|Freedom \& Liberty HS's in Bethlehem, PA will serve as the study's control group.
62660820|NCT01402856||Phillipsburg HS, NJ Area School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
62660821|NCT00968487|EXPERIMENTAL|Lyophilized Plasma|
62660822|NCT00968487|ACTIVE_COMPARATOR|Fresh Frozen Plasma|
62660823|NCT03276416||150 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
61909550|NCT02965768|OTHER|Placebo/LDN arm|"Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo~Individuals will be switched between drugs as per approved schedule during the 24 weeks."
61909551|NCT02085031|EXPERIMENTAL|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed for the patients assigned to this arm.
61909552|NCT02085031|ACTIVE_COMPARATOR|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed for the patients assigned to this arm.
61909553|NCT05767567|EXPERIMENTAL|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
61909554|NCT05767567|NO_INTERVENTION|Control|
62098076|NCT03174938|OTHER|COHORT D: Dementia due to Alzheimer's disease|"400 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include at least 50 cases aged 40-65 years of age, at least 200 cases aged 66-79 years of age and at least 50 cases aged 80-100 years of age.~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET and MRI will be done at baseline and after 2 years. Amyloid PET is performed at baseline for a subset of this group."
62098077|NCT03174938|OTHER|COHORT E: Other dementias|"Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited:~1. 160 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD), Progressive nonfluent aphasia (PNFA), semantic dementia (SD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD).~2. 50 cases with subcortical Vascular dementia (VaD).~3. 200 cases with either Parkinson's disease (PD), Parkinson's disease with dementia (PDD), Dementia with Lewy Bodies (DLB), Multiple system atrophy (MSA).~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group. Motor assessments (Motor-ACT) are performed at baseline and a 2-year follow-up since 7th Oct 2019."
62098078|NCT06092710||study group with PSG and sleep survey|the study group will be recruited after their polysomnography but before its results, so patients and investigators will not have any data about Apnea Hypopnea Index (AHI) and sleep survey. they will experiment their subjective perception of air flow through their airways with the guidance of a manual therapist during a 15 minutes protocol
62098079|NCT06092710||control group with sleep survey|the control group will be recruited after a sleep survey with no sleep disorder. they will experiment their subjective perception of air flow through their airways with the guidance of a manual therapist during a 15 minutes protocol
62466418|NCT02357732|EXPERIMENTAL|Nivolumab, Dabrafenib and Trametinib Combination (triplet)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD;
61909555|NCT05186415|EXPERIMENTAL|diagnostic arm|The echocardiography team will perform baseline echocardiographic views of the right ventricle without contrast. The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations. Dosages and timing of administration as well as patient size and transducer type will be recorded for each patient. The total cumulative dose of Lumason from the clinical study and the research study will not exceed the maximum recommended dose by the manufacturer, 4.8 mL. A single injection will not exceed the maximal FDA-recommended dose of 2.4 mL per single injection. These echocardiographic views of the right ventricle with ultrasound enhancing agent will be compared to the measurements made without the use of ultrasound enhancing agents, and the measurements made in MRI.
62660824|NCT02421211|EXPERIMENTAL|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
62660825|NCT02421211|EXPERIMENTAL|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
62660826|NCT04026425|EXPERIMENTAL|ME/CFS|Adults with ME/CFS
62660827|NCT04026425|ACTIVE_COMPARATOR|Healthy controls|Healthy, low-active adults
62660828|NCT06076590|EXPERIMENTAL|multiple electrolytes solution group|Experimental group drugs: Multiple Electrolytes Injection(II) Manufacturer: B.Braun Melsungen AG Dosage Form: Liquid Specification: 500ml/ bag Ingredients: Per 1000ml contains: sodium chloride 6.799g, potassium chloride 0.2984g, calcium chloride 0.3675g, magnesium chloride 0.2033g, sodium acetate 3.266g, L-malic acid 0.671, sodium hydroxide 0.200g Duration :36 months Storage conditions: airtight storage, storage temperature shall not exceed 25, can not be refrigerated or frozen
62098080|NCT05946798|PLACEBO_COMPARATOR|local lactated Ringer's perfusion|lactated Ringer's is perfused through the microdialysis fiber to serve as the vehicle control
62098081|NCT05946798|EXPERIMENTAL|local apocynin perfusion|local apocynin is perfused through the microdialysis fiber to serve as the NADPH oxidase inhibited experimental treatment
62098082|NCT05946798|EXPERIMENTAL|local L-NAME perfusion|local L-NAME is perfused through the microdialysis fiber to inhibit nitric oxide synthase
62098083|NCT05946798|EXPERIMENTAL|local apocynin + L-NAME perfusion|local apocynin and L-NAME are perfused through the microdialysis fiber for dual inhibition of NADPH oxidase and nitric oxide synthase
62098084|NCT00611637|EXPERIMENTAL|1|
62098085|NCT04940390|EXPERIMENTAL|STS101|STS101 (dihydroergotamine nasal powder)
62098086|NCT04940390|EXPERIMENTAL|STS101 Placebo|STS101 Placebo
62098087|NCT00832780|EXPERIMENTAL|Stereotactic Body Radiation (SBRT)|60 Gy using 12 Gy per fraction over 5 fractions, to be given within 10 calendar days
62466419|NCT00940810|EXPERIMENTAL|PDD procedure|
62466420|NCT00940810|ACTIVE_COMPARATOR|Conservative Care|
62660829|NCT06076590|ACTIVE_COMPARATOR|saline group|Control group drug: Sodium chloride injection Manufacturer: Hua Run Shuang He Pharmaceutical Co., LTD. Dosage Form: Liquid Specification: 500ml:4.5g Ingredients: Per 1000ml contains sodium chloride 9.0g Duration: 36 months Storage conditions: airtight storage
62098088|NCT04373135|EXPERIMENTAL|Experimental|Subjects will be provided a brief educational intervention prior to completing follow up survey about SRA attitudes and knowledge
62098089|NCT04373135|NO_INTERVENTION|Control|Subjects will not be provided any prior to completing follow up survey about SRA attitudes and knowledge
62098090|NCT03966716|EXPERIMENTAL|Arthroplasty|Arthroplasty, hemi or total depending on patient characteristics and surgeon's choice
62098091|NCT03966716|ACTIVE_COMPARATOR|Internal Fixation|Internal fixation with 2-3 screws or pins, or sliding hip screw device, depending on each hospital's routine
62098092|NCT00884611|EXPERIMENTAL|Predictive Low Glucose Suspend|The pump suspension system consists of the Revel CGM device communicating with a laptop computer that contains the hypoglycemia prediction algorithm. During the 21 night study period, the laptop is placed at the bedside and turned on by the participant at bedtime and off on arising in the morning.The laptop contains a randomization schedule (2:1) that indicats whether the hypoglycemia prediction algorithm will be in operation that night (Predictive Low Glucose Suspend Algorithm ON) or will not be activated (Predictive Low Glucose Suspend Algorithm OFF), to which the participant is blinded.
62098093|NCT02763020|PLACEBO_COMPARATOR|Food bar without fruit|snack bar without fruit
62098094|NCT02763020|EXPERIMENTAL|Food bar with cranberry extract (0.5%)|Snack bar with cranberry extract (0.5% total weight)
62098095|NCT02763020|EXPERIMENTAL|Food bar with cranberry extract (1.0%)|Snack bar with cranberry extract (1.0% total weight)
62098096|NCT02763020|EXPERIMENTAL|Food bar w/ dried black raspberry (10%)|Snack bar with freeze-dried black raspberry(10% total weight)
62098097|NCT02763020|EXPERIMENTAL|Food bar w/ dried black raspberry (20%)|Snack bar with freeze-dried black raspberry (20% total weight)
62098098|NCT06466499|NO_INTERVENTION|Control|The control group will receive the standard treatment, which is oral and written information about the characteristic symptoms after head trauma, specific signals to be aware of, when to contact the general practitioner and guidance of gradual return to daily activities
62098099|NCT06466499|EXPERIMENTAL|Intervention|"The intervention will cover an interdisciplinary 5-week program with sessions from both psychologists and physiotherapists. The psychologist sessions will focus on topics regarding cognitive behavioural therapy, psychoeducation, occupational rehabilitation and work activity. The physiotherapeutic sessions will include a combination of exercises on neck tensions, relaxation therapies and advises on, how to return gradually to daily activities (social, cognitive, and physical activities, such as reading, working by the computer, house cleaning, exercising, and going out with friends). Furthermore, patients will get exercise handouts to do at home between sessions.~Both psychologist and physiotherapist sessions will be group-based with 6-8 patients in each group. Once every week, the groups receive psychologist sessions lasting 90 minutes and afterwards physiotherapist sessions of 60 minutes."
62098100|NCT06310239||Study subjects|Individuals with a limb amputation who are undergoing an osseointegration surgery
62098101|NCT06343155|EXPERIMENTAL|Therapeutic Exercises|Participants will be planned to participate in therapeutic lumbar exercises in groups of 5, in the morning and at noon, via the Zoom Platform in 40-minute sessions, 3 days a week, with a physiotherapist, for 6 weeks. Additionally, participants will do Rocabado's exercise at home. All exercises will be taught face to face in the first session. Online sessions with the physiotherapist will continue. A 5-minute warm-up and cool-down period and a 30-minute exercise period are planned. Patients will be asked to perform the exercises in 3 sets of 10-15 repetitions and will be allowed to rest for 10 seconds. Every exercise performed unilaterally will be performed bilaterally.
62098102|NCT06343155|ACTIVE_COMPARATOR|Rocabado's Exercises|Each exercise will consist of 6 sets and 6 repetitions.
62098103|NCT02400190|EXPERIMENTAL|Endocrine therapy alone|Patients receive endocrine therapy alone without radiotherapy
62098104|NCT05341167|ACTIVE_COMPARATOR|Intervention group:|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
62098105|NCT05341167|OTHER|Control group:|Hypotensive episodes will be treated with vasoactive agents and fluids according to the standard clinical practice. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
62098106|NCT03750656|ACTIVE_COMPARATOR|Hyoscyamine|Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort
62098107|NCT03750656|ACTIVE_COMPARATOR|Tamsulosin|0.4 mg tab orally daily
62294213|NCT04372095||group 4: General population|Subjects (women) never diagnosed with meningioma and not exposed to cyproterone acetate.
62294214|NCT01082276|OTHER|Rifampin/Lurasidone|Healthy Normal Subject
62294215|NCT01193335|ACTIVE_COMPARATOR|Group 1: Preterm infants|Infant born at \< 37 weeks of gestation.
62294216|NCT01193335|ACTIVE_COMPARATOR|Group 2: Term infants|Infants born at ≥ 37 weeks of gestation
62294217|NCT00864734|EXPERIMENTAL|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
62098108|NCT05015478|ACTIVE_COMPARATOR|Active Tailored Rhythmic Lighting then Inactive Placebo Rhythmic Lighting|"1. hour intervention period where active lighting is experienced by participants. then 1 hour intervention period where an inactive, placebo lighting condition is experienced by participants.~2. sessions, 1 week apart"
62294218|NCT00864734|ACTIVE_COMPARATOR|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
62294219|NCT04489654|ACTIVE_COMPARATOR|study|Test group will receive immediate implant with modified socket shield and deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) put in the buccal gap
62660830|NCT05296278|EXPERIMENTAL|Cohort A|patients with only 3'ALK confirmed by NGS
62660831|NCT05296278|EXPERIMENTAL|Cohort B|patients with 3'ALK with retention of 5'ALK
61909556|NCT03234140||"Group Genome Wide Association Studies"|"Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :~* PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396~* RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441~* FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229~* MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178~* MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321~Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data."
62098109|NCT05015478|PLACEBO_COMPARATOR|Inactive Placebo Rhythmic Lighting then Active Tailored Rhythmic Lighting|"1. hour intervention period where an inactive, placebo lighting condition is experienced by participants. then 1 hour intervention period where active lighting is experienced by participants.~2. sessions, 1 week apart"
62098110|NCT05805345|OTHER|DT1fA/T30fA/AOHGfA/P1fA|DT1fA worn first, followed by T30fA, as randomized, during the first wear period, with AOHGfA worn first, followed by P1fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
62098111|NCT05805345|OTHER|T30fA/AOHGfA/P1fA/DT1fA|T30fA worn first, followed by AOHGfA, as randomized, during the first wear period, with P1fA worn first, followed by DT1fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
62098112|NCT05805345|OTHER|AOHGfA/P1fA/DT1fA/T30fA|AOHGfA worn first, followed by P1fA, as randomized, during the first wear period, with DT1fA worn first, followed by T30fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
62098113|NCT05805345|OTHER|P1fA/DT1fA/T30fA/AOHGfA|P1fA worn first, followed by DT1fA, as randomized, during the first wear period, with T30fA worn first, followed by AOHGfA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
62098114|NCT05067959||IBD patients|patients with IBD (Chron's disease, Ulcerative colitis, IBD-Unspecify). patients will be divided into two sub-groups: IBD patients on anti-TNF therapy IBD patients on any other therapy
62098115|NCT05067959||Controls|healthy volunteers
62098116|NCT01149135|ACTIVE_COMPARATOR|Standard light treatment|standard light treatment 5000K; 10 000 lux
62098117|NCT01149135|EXPERIMENTAL|blue enriched light|Blue enriched light with a low intensity (750 lux)
62098118|NCT06083714|EXPERIMENTAL|Group 1|Participants in this group will receive scapular stabilization exercises in addition to Schroth exercises specific to scoliosis.
62098119|NCT06083714|ACTIVE_COMPARATOR|Group 2|Participants in this group will receive Schroth exercises specific to scoliosis only.
62098120|NCT06364410|EXPERIMENTAL|Dose escalation (T-DXd, azenosertib)|Patients receive T-DXd IV over 30-90 minutes on day 1 of each cycle and azenosertib PO QD on days 1-5, 8-12, and 15-19 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA and collection of blood samples at screening and on study and undergo CT or MRI throughout the trial.
62098121|NCT06364410|EXPERIMENTAL|Dose expansion, Cohort 1 (T-DXd, azenosertib)|Patients receive T-DXd IV over 30-90 minutes on day 1 of each cycle and azenosertib PO QD on days 8-12 and 15-19 of cycle 1 and days 1-5, 8-12, and 15-19 in subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA and collection of blood samples at screening and on study and undergo CT or MRI throughout the trial. Patients also undergo biopsy at screening and on study.
62098122|NCT06364410|EXPERIMENTAL|Dose expansion, Cohort 2 (T-DXd, azenosertib)|Patients receive treatment as in the dose escalation arm. Patients also undergo ECHO or MUGA and collection of blood samples at screening and on study and undergo CT or MRI throughout the trial. Patients also undergo biopsy at screening and on study.
62098123|NCT00255021|EXPERIMENTAL|1|
62294220|NCT04489654|NO_INTERVENTION|control|Control group will receive an immediate implant with modified socket shield technique but without deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) in the buccal gap
62466421|NCT02148484|EXPERIMENTAL|1|Prolonged exposure for adolescents
62660832|NCT00153842|EXPERIMENTAL|Bexarotene|Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
62737029|NCT02840318|EXPERIMENTAL|Compassion Intervention|Coordinated by the ICL who co-ordinates key activities at each site to address the two core components of the Intervention. Component 1 activities include: (a) person-centred assessment of residents, focussing on their physical, psychological, emotional and social needs, (b) meetings of the core care team (General practitioner, care home nurse and/or manager and ICL) and (c) meetings of the wider multidisciplinary care teams (including care home staff, ICL, and external healthcare professionals such as geriatrician, palliative care, mental health etc). Activities to facilitate component 2 include: (d) staff training sessions, education and support for staff and family carers. Training sessions are run by the ICL and logistics of training is planned at core meetings.
62737030|NCT00906178|EXPERIMENTAL|CyberSenga|6-module HIV prevention program tailored for adolescents in Uganda
62466422|NCT02148484|ACTIVE_COMPARATOR|2|Client centered therapy
62466423|NCT00318812|EXPERIMENTAL|Heme Iron|Heme Iron Polypeptide 11mg PO tid for 6 months
62660833|NCT04728256|EXPERIMENTAL|İntervention group|A six-session antenatal care program included both music listening and laughter therapy, and was designed for those in the study group as a session every week. The program was carried out by arranging a session of music listening for one week and a laughter therapy session over the following week. Also, the notes uttered by pregnants women were discussed at the week laughter listening sessions were performed. Data from the intervention group was collected four times as pretest (after providing informed contest), first-interval measurement (fourth week of the intervention), second-interval measurement (the first month following the birth) and post-test (the third month following the birth).The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
62660834|NCT04728256|NO_INTERVENTION|Control group|Mothers receiving standard antenatal care in the prenatal period, giving birth, and having a three-month-old baby constituted the control group. The Control group was created after the procedures were completed for those in the intervention group. Only the post test was applied to the control group.The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
62660835|NCT05115253|EXPERIMENTAL|mHealth HAPA Intervention Group|This intervention group will receive a single one-on-one online behavioural counselling session and daily personalized SMS text message boosters with the aim of increasing the breaking of consecutive work related sedentary behaviour. Counselling strategies will be grounded in the HAPA model, specifically focusing on the creation of an action plan and the development of coping strategies to increase sedentary behaviour breaks. The SMS text message boosters will be personalized based on participant's preferences of timing, type, frequency, and length. The boosters will framed through HAPA principles with content focusing on risk awareness, outcome expectancy, action and coping planning, barriers and resources, and self-efficacy. The intervention will last for three weeks.
62660836|NCT05115253|EXPERIMENTAL|JITAI Group|This intervention group will receive push notifications from a EMA behaviour monitoring mobile application that will be downloaded to each participants' mobile phones. The application will measure and monitor a participant's sedentary behaviour and once a pre-set condition of 30 consecutive sedentary minutes has been reached, the application will administer a push notification notifying the participant to break their sedentary behaviour. The push notifications will ask the participants to stand up, stretch, or lightly walk around to break their current behaviour. The intervention will last for three weeks.
61909557|NCT03234140||"Group EPIC"|"Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).~The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals."
61909558|NCT04040491|EXPERIMENTAL|Newly diagnosed PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
61909559|NCT04040491|OTHER|Relapse/refractory PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
61909560|NCT04404218|EXPERIMENTAL|Açaí palm berry extract|Açaí palm berry extract is a powerful antioxidant with no known side-effects and is widely consumed in Brazil. Açaí palm berry chemical composition has been established and includes several antioxidants - gallic acid, catechin, chlorogenic acid, caffeic acid, p-coumaric acid, epicatechin, orientin, cyanidin-3-0-glucoside, luteolin and apigenin. Orientin is the most concentrated compound (7,96mg/g) and this compound is able to modulate the NLRP3 inflammasome.
61909561|NCT04404218|PLACEBO_COMPARATOR|Placebo arm|This study will be double-blinded and placebo-controlled. To ensure double-blinding, placebo and active compound capsules will be over-encapsulated with DBCAPS® capsules, which were developed with a tamper-evident design to address the clinical trial challenges of testing without bias. These capsules are made of gelatin and have no interaction with bioavailability.
62098124|NCT01853358|EXPERIMENTAL|NK Cell infusion|"* Cell collection~  o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation~* NK Cell selection~  o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)~* NK Cell ex-vivo activation~  o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)~* NK Cell infusion (60 to 90 days after transplantation)"
62098125|NCT02803294|EXPERIMENTAL|Aortic Stenosis/regurgitation|Transcatheter aortic valve replacement
62466424|NCT00318812|ACTIVE_COMPARATOR|Venofer|Venofer q month IV x 6 months
61909562|NCT04049409|EXPERIMENTAL|CMAB809|
61909563|NCT04049409|ACTIVE_COMPARATOR|Trastuzumab|
62098126|NCT04574245||Resectable group|
62098127|NCT04574245||Potentially resectable group|
62098128|NCT04574245||Unresectable group|
62098129|NCT05491317|EXPERIMENTAL|Radiotherapy + GEN1042|
62098130|NCT05491317|EXPERIMENTAL|Radiotherapy + GEN1042 + Pembrolizumab|
62466425|NCT01916317|NO_INTERVENTION|Arm B:Control|: No peritumoral Local Anesthesia prior to excision
62098131|NCT03771326|EXPERIMENTAL|obese men|To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
62098132|NCT03771326|EXPERIMENTAL|Normal men|To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
62098133|NCT02342912|EXPERIMENTAL|Social Media Targeted Treatment|Participants randomly assigned to this treatment arm will receive weight loss materials via text messages, Facebook postings, on-line videos, and weekly reports. The topics relate to relate to behavioral and lifestyle changes associated with weight-loss (e.g., nutrition, exercise, social support, and self-monitoring). Calorie and physical activity targets also are set. Participants will receive a suggestion to track diet, physical activity, and weight.
62098134|NCT02342912|EXPERIMENTAL|Social Media Tailored Treatment|Participants randomly assigned to this treatment arm receive all of the same weight loss materials (as well as weight, calorie, and physical activity targets) as the Targeted group above. Weekly reports will be more personalized to help participants track diet, physical activity, and weight. Additionally, participants will be asked to report on their weight, exercise and calorie goals, and receive feedback.
62098135|NCT02342912|ACTIVE_COMPARATOR|Social Media Contact Control|Participants randomly assigned to this treatment arm receive health information via text messages, Facebook postings, on-line videos, and weekly reports. Topics relate to having a healthy body weight through a healthy mind, body, and energy. Some topics include stress management, importance of sleep, and importance of accepting one's body. Participants will receive a suggestion to track stress, body image, and energy levels.
62098136|NCT04701502|EXPERIMENTAL|Interventional|"A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip, plus standard care of the hospital.~Treatment duration: 21 days."
62098137|NCT04701502|OTHER|Control|"A total of 60 subjects will be randomized 2: 1 in this study. 20 control patients will be assigned to standard care of the hospital only.~Treatment duration: 21 days."
61909564|NCT04290728|EXPERIMENTAL|High flow|Apply high-flow nasal oxygenation during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
62098138|NCT03115346|EXPERIMENTAL|decision aid|the experimental group will receive the decision aid
62098139|NCT03115346|NO_INTERVENTION|control|the control group will only receive the survey
62098140|NCT03829280|EXPERIMENTAL|Cognitive Adaptation Training|Psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology and the organization of belongings established in a person's home or work environment to bypass the cognitive and motivational difficulties associated with schizophrenia, and support habits for functional behavior to promote recovery.
62098141|NCT03829280|ACTIVE_COMPARATOR|Community Treatment|Medication follow-up and case management as provided by the community mental health center according to usual care.
62098142|NCT05785897|EXPERIMENTAL|Potent P2Y12 receptor inhibitor-based single antiplatelet therapy (SAPT)|"* P2Y12 receptor inhibitor-based SAPT with ticagrelor (90 mg bd) or prasugrel (10 mg od, or 5 mg in patients ≥75 years or with a body weight \<60 kg), at the discretion of the investigator, during 12 months after the index procedure.~* Clopidogrel-based SAPT will not be allowed.~* Aspirin will be discontinued after primary PCI, or at latest at hospital discharge."
62098143|NCT05785897|ACTIVE_COMPARATOR|Conventional dual antiplatelet therapy (DAPT)|"* DAPT combining aspirin (≥75 mg od) and a potent P2Y12 receptor inhibitor, either ticagrelor (90 mg bd) or prasugrel (10 mg od, or 5 mg in patients ≥75 years or with a body weight \<60 kg), at the discretion of the investigator, during 6 or 12 months after the index procedure, followed by aspirin-based SAPT.~* Clopidogrel (75 mg od orally) will be allowed if ticagrelor or prasugrel are contra-indicated or not available."
62294221|NCT05798988|EXPERIMENTAL|Experimental group|Experimental group will follow 8 weeks of neurophysiology-based exercise program.
62294222|NCT05798988|NO_INTERVENTION|Control group|Control group will receive no intervention. They will not change the movement habits.
62466426|NCT01916317|ACTIVE_COMPARATOR|Arm A: Intervention|Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
62466427|NCT01140581|EXPERIMENTAL|Group A|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks followed by dronedarone 400 mg twice daily for 8 weeks
62466428|NCT01140581|EXPERIMENTAL|Group B|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Two weeks wash-out followed by dronedarone 400 mg twice daily for 6 weeks
62660837|NCT05115253|NO_INTERVENTION|Control Group|The control group will receive no intervention or further instruction past the letter of information.
61909565|NCT04290728|ACTIVE_COMPARATOR|Control|Apply nothing during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
61909566|NCT03640780||cataract extraction (CE)|Patients received CE without IOL implantation in the first surgical stage, and received IOL implantation at secondary surgical stage.
62098144|NCT05971381|OTHER|Study Treatment|Skin cell suspension prepared using the RECELL System will be applied to a prepared treatment area, followed by at-home NB-UVB phototherapy.
61909567|NCT03640780||cataract extraction and IOL implantation|Patients received CE and IOL implantation in the first surgical stage.
61909568|NCT02735889|OTHER|No carbonation (control)|No carbonation (NC, control): Potable water + sugar
61909569|NCT02735889|ACTIVE_COMPARATOR|Low carbonation|Low carbonation (LC): Potable water + sugar + little CO2
62098145|NCT05756439||Control|Participants having dental surgery
62098146|NCT05756439||Intravenous sedation|Participants having dental surgery
62098147|NCT02087033|EXPERIMENTAL|ritmonutra|ritmonutra 2 tablets/day by mouth for 4 weeks sugar pill manufatured to simulate ritmonutra: 2 tablets/day by mouth for 4 weeks
62098148|NCT02087033|PLACEBO_COMPARATOR|placebo|placebo
62098149|NCT01238029|EXPERIMENTAL|Capecitabine, Lapatinib, Vinorelbine|
62098150|NCT02862704|EXPERIMENTAL|MG7-CART|A single dose of MG7-CART cells will be administered by intra-tumor injection under ultrasound guidance. The dose is 1-6x108 MG7-CAR positive T cells. The infusion will be scheduled to occur 2 days after two doses of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. The cells perfusion process would lasts 1min to 2min, and an interventional radiologist would operate the cell infusion.
62098151|NCT02391662|EXPERIMENTAL|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 \& 15 in a 28 days cycle
62098152|NCT05996146||hoarseness group|"This study recruited all patients admitted at Seoul National University Hospital.~Age range is 20 to 80 years old. Patients who require surgical treatment for degenerative spine conditions. Patients who voluntarily consent to participate in the study."
62098153|NCT05209542|ACTIVE_COMPARATOR|Hysterosalpingo-Foam Ultrasonography|3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
62098154|NCT05209542|ACTIVE_COMPARATOR|laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
62098155|NCT02275936|EXPERIMENTAL|Group 1 - 50 mg|Every 12 hour oral dosing of N91115 for 28 days
61909570|NCT02735889|ACTIVE_COMPARATOR|High carbonation|High carbonation (HC): Potable water + sugar+ high CO2
61909571|NCT05277337|EXPERIMENTAL|Group 1 (Alluzience)|Single treatment at the baseline visit with Alluzience. Glabellar lines will be treated with 10 U/0.05 mL per injection point. In total 50 s.U in 0.25 mL for 5 injection points.
62098156|NCT02275936|EXPERIMENTAL|Group 2 - 100 mg|Every 12 hour oral dosing of N91115 for 28 days
62098157|NCT02275936|EXPERIMENTAL|Group 3 - 200 mg|Every 12 hour oral dosing of N91115 for 28 days
62098158|NCT02275936|PLACEBO_COMPARATOR|Group 4 - Placebo|Every 12 hour oral dosing of placebo comparator for 28 days
62098159|NCT06629623||Patients with IPF|
62294223|NCT04921215|ACTIVE_COMPARATOR|0 hours of sleep restriction|Bedtime will be the same as baseline.
62098160|NCT02256969|OTHER|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
62098161|NCT02256969|OTHER|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
62098162|NCT02256969|ACTIVE_COMPARATOR|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
62098163|NCT00073957|EXPERIMENTAL|Y-90 Ibritumomab Tiuxetan|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab and central nervous system prophylaxis with Cytarabine or liposomal cytarabine
62660838|NCT03393572|ACTIVE_COMPARATOR|Group BM|bupivacaine 0.25% plus magnesium sulphate.
62660839|NCT03393572|ACTIVE_COMPARATOR|Group BN|bupivacaine 0.25% plus nalbuphine
62660840|NCT00876395|EXPERIMENTAL|Everolimus + Paclitaxel + Trastuzumab|Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
61909572|NCT05277337|ACTIVE_COMPARATOR|Group 2 (powder BoNT-A: BOTOX/Vistabel)|Single treatment at the baseline visit with powder BoNT-A (BOTOX/Vistabel). Glabellar lines will be treated with 4 U/0.1 mL per injection point. In total 20 U in 0.5 mL for 5 injection points.
62098164|NCT06696079|EXPERIMENTAL|Early resumption|Oral anticoagulation therapy is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma.
62098165|NCT06696079|ACTIVE_COMPARATOR|Late resumption|Oral anticoagulation therapy is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma.
62098166|NCT04863898|OTHER|Staff (Study Participants) Working in HIV Care and Treatment Clinics|"Single arm, Pre-post with staff (study participants) working in HIV care and treatment clinics~Drug use stigma reduction training intervention for staff (study participants) working in HIV care and treatment clinics. The intervention consists of five-2.5 hour participatory training sessions. We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building."
62098167|NCT02312440|PLACEBO_COMPARATOR|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
62098168|NCT02312440|EXPERIMENTAL|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' prior to skin incision and the second dose at 180' after the first dosage.
62098169|NCT02312440|EXPERIMENTAL|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
62098170|NCT05826548|EXPERIMENTAL|Telerehabilitation group|The TR group will perform 4 weeks of cogntiive training using the FINAGE tablet. The rehabilitation tasks will train the patients on the detected FA deficits, but also on the cognitive domains underlying such abilities. FINAGE TR program will have a modular structure, with 8 different packages including AF and: language, attention, memory, numbers, logical reasoning, executive functions, theory of mind and testamentary capacities. Every package will involve exercises of increasing difficulty. Reaction times, number of stimuli presented and other parameters will be customizable, in order to be adaptable to different patients' cognitive conditions and/or to their achievements from one session to the other.
62098171|NCT05826548|ACTIVE_COMPARATOR|Conventional treatment group|The CT group will perform 4 weeks of the standard cognitive training offered by IRCCS San Camillo Hospital.
62660841|NCT00876395|PLACEBO_COMPARATOR|Placebo + Paclitaxel + Trastuzumab|Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
62660842|NCT04697706|ACTIVE_COMPARATOR|"Study period Water"|Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.
62098172|NCT05499585|OTHER|Arm One|Habitual diet for 12 weeks followed by experimental diet for 12 weeks
62466429|NCT01140581|EXPERIMENTAL|Group C|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Four weeks wash-out followed by dronedarone 400 mg twice daily for 4 weeks
62466430|NCT00377416|EXPERIMENTAL|1|rAAV2-CB-hAAT Gene Vector
62466431|NCT02877147|EXPERIMENTAL|$60 SEBTC Benefit Group|Households received $60 per summer month when school was not in session for each eligible child (Summers 2011-2013).
62660843|NCT04697706|EXPERIMENTAL|"Study period Moonstone"|Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.
62660844|NCT03854227|EXPERIMENTAL|Dose Escalation|Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis
61909573|NCT00307320|NO_INTERVENTION|1|
61909574|NCT00307320|EXPERIMENTAL|2|Relaxation techniques
61909575|NCT03495609|EXPERIMENTAL|Ovitrelle|
61909576|NCT00167297|EXPERIMENTAL|Atomoxetine|Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.
62294224|NCT04921215|EXPERIMENTAL|1.5 hours of sleep restriction|Bedtime will be 1.5 hours later than baseline.
61909577|NCT04933643||well prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that the stomach is well prepared when GCS ≥ 18
62098173|NCT04751383|EXPERIMENTAL|Arm A (magrolimab, dinutuximab)|Patients receive magrolimab IV and dinutuximab IV on study. Patients also undergo CT, MRI, and blood sample collection on study, as well as bone marrow aspiration and biopsy throughout the trial.
62098174|NCT04751383|EXPERIMENTAL|Arm B (magrolimab, dinutuximab, surgery)|Patients receive magrolimab IV and dinutuximab IV on study. Patients with pulmonary osteosarcoma may undergo surgical resection of tumor after cycle 1. After surgery, these patients continue receiving magrolimab and dinutuximab on study. Patients also undergo CT, MRI, and collection of blood samples on study, as well as bone marrow aspiration and biopsy throughout the trial.
62098175|NCT05180240|EXPERIMENTAL|CardiolRx|"* Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~* Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~* Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~* Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
62294225|NCT04921215|EXPERIMENTAL|3 hours of sleep restriction|Bedtime will be 3 hours later than baseline.
62294226|NCT04921215|EXPERIMENTAL|4.5 hours of sleep restriction|Bedtime will be 4.5 hours later than baseline.
62294227|NCT01021566|EXPERIMENTAL|Combined hemoperfusion-hemodialysis|On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
62466432|NCT02877147|EXPERIMENTAL|$30 SEBTC Benefit Group|Households received $30 per summer month when school was not in session for each eligible child (Summer 2013 only).
62466433|NCT02877147|NO_INTERVENTION|No Intervention Group|Households with eligible children were not issued SEBTC benefits (Summers 2011 and 2012)
62660845|NCT03854227|EXPERIMENTAL|Non small cell lung cancer monotherapy|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
62660846|NCT03854227|EXPERIMENTAL|Urothelial carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
61909578|NCT04933643||inadequate prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that GCS \< 18 is inadequate.
61909579|NCT00545129|EXPERIMENTAL|Tanezumab 10 mg IV + opioids|
61909580|NCT00545129|PLACEBO_COMPARATOR|Placebo + opioids|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
61909581|NCT02841878|OTHER|analysis on colorectal biopsy|"* Proteases activity (cystein and serin proteases)~* Proteases inhibitors genes expression (Serpins A1 / E1)~* Colonic biopsies permeabilityTight junctions genes expression~* Cytokines genes expression (TNFalpha, interleukines)~* Cellularity on histologic sections"
61909582|NCT01984762|ACTIVE_COMPARATOR|RYGBP|Roux-en-Y gastric bypass
61909583|NCT01984762|ACTIVE_COMPARATOR|SG|sleeve gastrectomy
61909584|NCT02805270|EXPERIMENTAL|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
61909585|NCT02805270|NO_INTERVENTION|usual care|Usual care provided by ward pharmacist, nurses and doctors in the ward
61909586|NCT05577520|EXPERIMENTAL|Small particle group (SPG)|SPG (n=10): MSA using 250 to 1000 µm size ABBM particles (Osteodens®, Pharmatrix, Argentina) as bone substitute.
61909587|NCT05577520|EXPERIMENTAL|Large particles group (LPG)|LPG (n=10): MSA using 1000 to 2000 µm size ABBM particles (Osteodens®, Pharmatrix, Argentina) as bone substitute.
61909588|NCT04233918|EXPERIMENTAL|Evinacumab|Part A: Single intravenous (IV) dose Part B: IV dose every 4 weeks (Q4W) until week 20 Part C: IV dose Q4W
61909589|NCT00220779|EXPERIMENTAL|Group 1|IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
61909590|NCT00220779|EXPERIMENTAL|Group 2|IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
61909591|NCT00220779|PLACEBO_COMPARATOR|Group 3|placebo (0.1% albumin) 4 ml/kg bw/infusion
61909592|NCT04124497|EXPERIMENTAL|Daratumumab Pomalidomide dexamethasone|"Therapy consists in cycles of the DPd combination as follows:~* Pomalidomide 4 mg once daily on days 1-21;~* Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22;~* Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1."
62294228|NCT01021566|ACTIVE_COMPARATOR|Methadone, conventional treatment for opiate detoxification|On admission thirty patients receive the 10-day methadone treatment regimen.
62294229|NCT06193473|NO_INTERVENTION|Control Group: Group in which only observation is made by the clinical pharmacist|For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded. Follow-up was performed to determine whether the patients had a re-admission within 3 months.
61909593|NCT04272112|ACTIVE_COMPARATOR|Glass-ceramic|30 dental crowns of lithium-disilicate glass-ceramic
61909594|NCT04272112|ACTIVE_COMPARATOR|Zirconia|30 dental crowns of high translucent zirconia
61909595|NCT04272112|ACTIVE_COMPARATOR|Zirconia with mini-veneer|30 dental crowns of high translucent zirconia with a mini-veneer of porcelain
61909596|NCT04348968||Patient who received a Maxera Cup of large diameter|Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm between Nov 2011 and Feb 2018.
61909597|NCT05223153||Amblyopic eye group|
61909598|NCT05223153||Sound eye group|
61909599|NCT04783688|EXPERIMENTAL|Experimental Group|All subjects will snorkel using the same FFSMs.
61909600|NCT06005324|OTHER|Induction Treatment Arm|All participants will receive 3 cycles (9 weeks) of chemotherapy with paclitaxel, carboplatin, and cetuximab.
61909601|NCT06005324|EXPERIMENTAL|De-Escalation CRT Cohort|After completing induction chemotherapy, participants that have significant disease response by imaging will receive low dose radiation treatment with additional chemotherapy (CRT). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
62098176|NCT05180240|PLACEBO_COMPARATOR|Placebo|"* Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~* Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~* Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~* Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
62098177|NCT04500821|EXPERIMENTAL|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
62098178|NCT03502668|EXPERIMENTAL|Phase 1 Stage A|3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD
62098179|NCT03502668|EXPERIMENTAL|Phase 1 Stage B|3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD
62098180|NCT03502668|EXPERIMENTAL|Phase 2|80 additional subjects randomized in a 1:1 ratio studying two different doses
62466434|NCT03521856|EXPERIMENTAL|shoulder exercise intervention|A home exercise intervention for strengthening and stretching the shoulders - Strengthening and Optimal Movement for Painful Shoulders (STOMPS) - performed 3 times per week for 12 weeks.
62098181|NCT01093534|PLACEBO_COMPARATOR|Placebo|Participants received 2 placebo tablets once daily for 12 weeks.
62098182|NCT01093534|EXPERIMENTAL|Solifenacin 5 mg|Participants received one 5 mg solifenacin tablet and one placebo tablet, once daily for 12 weeks.
62466435|NCT03521856|ACTIVE_COMPARATOR|education-only control|Subjects watched a 1 hour educational video on shoulder anatomy, mechanisms of shoulder injury and pain, and hints for managing shoulder pain
62466436|NCT01054027|EXPERIMENTAL|0 Drop|Left eye dose
62466437|NCT01054027|EXPERIMENTAL|1 Drop|Left eye dose
62098183|NCT01093534|EXPERIMENTAL|Solifenacin 10 mg|Participants received two 5 mg solifenacin tablets once daily for 12 weeks.
62098184|NCT06441331|EXPERIMENTAL|Three sequential age cohorts|"Arms are based upon age at enrollment. The opening of the 2nd and 3rd cohort will depend on the recruitment of at least four participants with dosimetry and safety data for cycle 1, in the previous cohort.~1. ≥ 12 to \< 18 years old~2. ≥ 6 years to \< 12 years old~3. ≥ 2 to \< 6 years old"
62098185|NCT06492603||20 Women in the Postpartum Diastasis Recti Group|
62466438|NCT01054027|EXPERIMENTAL|2 drop|Left eye dose
62466439|NCT01054027|ACTIVE_COMPARATOR|3 drops|Right eye dose for all groups
62466440|NCT01029340|EXPERIMENTAL|Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS|Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
62466441|NCT01029340|EXPERIMENTAL|Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)|Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
62466442|NCT01029340|EXPERIMENTAL|Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ|Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
62660847|NCT03854227|EXPERIMENTAL|Head and neck squamous cell carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
62660848|NCT03854227|EXPERIMENTAL|Non small cell lung cancer PF-06939999 plus docetaxel|Participants will receive PF-06939999 on a continuous basis in combination with docetaxel
62098186|NCT06492603||20 Women in the Control Group (Postpartum Without Diastasis Recti)|
62098187|NCT06712797|EXPERIMENTAL|Physical Activity (PA) and Nutrition (N)|"Physical Activity: Participants will perform 150 minutes/week of moderate to vigorous Physical Activity per week. Participants will self-monitor physical activity using active minutes that approximate moderate to vigorous physical activity via a Fitbit device.~Nutrition: Participants will undergo counseling appointments to address nutritional symptoms and will be given targets for daily calorie and protein intake following a Mediterranean diet."
62098188|NCT01789203|ACTIVE_COMPARATOR|Ciprofloxacin|Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
62098189|NCT01789203|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
62098190|NCT06360926|EXPERIMENTAL|SuperSonic® Ultrasound System equipped with new software iterations used with a new probe|
62466443|NCT01029340|EXPERIMENTAL|Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP|Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
62466444|NCT01029340|EXPERIMENTAL|Arm 5: Recombinant Factor VIII by CS/EP|Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
62466445|NCT03024918||MCDA cohort|Unselected monochorionic diamniotic (MCDA) twin pregnancies, included between 11 and 14 weeks of gestation
62466446|NCT03024918||TTTS cohort|Pregnancies complicated by twin-twin transfusion syndrome (TTTS) undergoing laser treatment, included at the time of diagnosis or referral
62466447|NCT03024918||sIUGR cohort|Pregnancies complicated by selective intrauterine growth restriction (sIUGR), included at the time of diagnosis or referral. We define sIUGR as a discordance in estimated fetal weight of ≥ 20%.
62466448|NCT02238678||Deep endometriosis patients|
62466449|NCT05757765|EXPERIMENTAL|deprescribing pharmacotherapy approach (DPA)|A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible
62660849|NCT03854227|EXPERIMENTAL|Non small cell lung cancer dose finding|Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel
62098191|NCT02911571|EXPERIMENTAL|MMprofiler SKY92|Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature
62737031|NCT00906178|NO_INTERVENTION|Control|"treatment as usual - the sexual health education adolescents currently receive in secondary school"
62098192|NCT03047733|ACTIVE_COMPARATOR|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
62098193|NCT03047733|EXPERIMENTAL|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
62098194|NCT00932919|EXPERIMENTAL|Thought field therapy|24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
62098195|NCT00932919|ACTIVE_COMPARATOR|Cognitive therapy|Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
62660850|NCT04254211||EVAR|Patinets with AAA, treated electively by EVAR. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively. Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause
62098196|NCT00932919|OTHER|Wait list|24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
62098197|NCT01021644|EXPERIMENTAL|aerobic exercise-training|
62098198|NCT01021644|ACTIVE_COMPARATOR|stretch exercise|
62098199|NCT06714279|OTHER|Study Group - Tap Block|"Study Group: Study group: Laparoscopic Transversus Abdominis Plane in four points: above the umbilicus on the left side; dose calculation 2.5mg per body weight.~After the cholecystectomy is done and just before withdrawing port and deflating the abdomen, the operating surgeon will advance a needle into the abdominal wall to the level of the preperitoneal space. Once the needle tip is seen, it is withdrawn slowly and gently about 0.5cm above/superficial to the transversus abdominis (TA) muscle. The surgeon then infiltrates the local anaesthetic into the plane, and the right plane is confirmed by visualising a uniform protrusion downwards of the TA muscle fibres (Doyle's bulge). Seeing a preperitoneal or muscle blister laparoscopically indicates that the infiltration is deeper to this plane, and the needle should be withdrawn more superficially."
62098200|NCT06714279|PLACEBO_COMPARATOR|Control Group - Intraperitoneal Local Anesthetic onto Liver|Administration of local anesthetic to the liver using, dose calculation 2.5mg per body weight.
62098201|NCT02283645|EXPERIMENTAL|Minoxidil|3% Minoxidil lotion is applied twice daily to the chest.
62098202|NCT02283645|PLACEBO_COMPARATOR|Placebo|Placebo lotion is applied twice daily to the chest.
62098203|NCT05763251|EXPERIMENTAL|Short-course therapy|pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy will receive no additional antifungal therapy
62098204|NCT05763251|NO_INTERVENTION|Standard-course therapy|pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy will receive 7 additional days of systemic antifungal therapy
62098205|NCT05322161|NO_INTERVENTION|Control|Parents will experience usual care including all available parental support as practiced in the specific site NICU.
62098206|NCT05322161|EXPERIMENTAL|Yoga Group|In addition to usual care, the parents randomized to the intervention group will be provided a yoga mat and participate in 30-min online led yoga sessions done at least twice weekly at the parent's pace using a secure, virtual platform (website).
62466450|NCT05757765|ACTIVE_COMPARATOR|STOPP-START deprescribing approach (SSA)|The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
62466451|NCT06132074|EXPERIMENTAL|Intervention-arm|Immediate scheduling and participation of Uppsala Tjej- och Transjour's intervention.
62466452|NCT06132074|ACTIVE_COMPARATOR|Wait-list control-arm|Wait-listed group, will await intervention for 6-8 months. After follow-up measurements, this group will receive the intervention.
62466453|NCT00576056|EXPERIMENTAL|Tace and Sorafenib|Patients with unresectable HCC will be treated with TACE in combination with oral sorafenib administration. TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin. Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment.
62660851|NCT05191784|EXPERIMENTAL|GX-I7 and bevacizumab|Bevacizumab at a dose of 10 mg/kg intravenously, and GX-I7 intramuscularly.
62098207|NCT05366387|SHAM_COMPARATOR|Aerosol delivery without intrapulmonary percussive ventilation (Control condition)|"A radiolabelled 99mTc-DTPA aerosol is generated with a jet nebuliser and is inhaled by the subject through a device (connecting tubes, filters) connecting the nebuliser with 1) a mouthpiece and 2) an intrapulmonary percussive ventilation device which is turned off.~Aerosol deposition in fibrotic lung regions is characterized by SPECT imaging."
62098208|NCT05366387|ACTIVE_COMPARATOR|Aerosol delivery with intrapulmonary percussive ventilation (IPV condition)|"A radiolabelled 99mTc-DTPA aerosol is generated with a jet nebuliser and is inhaled by the subject through a device (connecting tubes, filters) connecting the nebuliser with 1) a mouthpiece and 2) an intrapulmonary percussive ventilation device which is turned on (frequency=1 Hz, pressure to be determined in phase 1 for each patient, in the 5-40 cm H2O range).~Aerosol deposition in fibrotic lung regions is characterized by SPECT imaging."
62098209|NCT02187653||Lumbar|Patients undergoing lumbar surgery
62098210|NCT02187653||Cervical|Patients undergoing cervical surgery
62098211|NCT01685580|EXPERIMENTAL|Manufacturer VPAP ST|7 days minimum non-invasive ventilation at 2 levels of pressure (BPAP) to the intervention.
62098212|NCT01685580|NO_INTERVENTION|No intervention|usual advice
62098213|NCT06250075|EXPERIMENTAL|G1 Intervention Group|In group 1, the intervention will take place with intake from the 1st day Post-OP when releasing the diet (Orally or ENT) and up to 7 days post-operatively with probiotic capsules.
62098214|NCT06250075|NO_INTERVENTION|Non-Intervention Group G2|Group G2 followed general nutritional guidelines. This group will not take probiotics, it will be the surgical comparator.
62098215|NCT06250075|SHAM_COMPARATOR|G3 Negative Control Group|Group G3 (guest employees) will follow the intake of probiotic capsules for 7 days during follow-up, without surgical intervention, these will be chosen at random and standardized by social level paired with G1
62466454|NCT03063814|EXPERIMENTAL|APP|In the APP group, a video sequence of each exercise, supported by short written descriptions (in accordance to 'Get set - Train smarter', (9) on how to perform the exercise correctly, was shown to the participants on an iPad. The video-recorded exercises were performed by the same physiotherapist who supervised PHY participants. If required, the participants in the APP group were allowed to watch the video and description several times between trials of the same exercise. The participants approved their own trials when they believed that the exercises had been performed as described.
62466455|NCT03063814|ACTIVE_COMPARATOR|PHY|In PHY, a physiotherapist demonstrated and explained the focus areas of each of the five exercises before the participant performed the exercises. If needed, verbal feedback was given between trials to correct the performance of the exercise. The physiotherapist approved trials that were performed with proper technique.
62466456|NCT00553228|EXPERIMENTAL|group I|Tdap
62466457|NCT00553228|ACTIVE_COMPARATOR|group 2|Td
62466458|NCT00698230|EXPERIMENTAL|Treatment A - INCB013739 & Metformin|INCB013739 5 mg QD and Metformin
62466459|NCT00698230|EXPERIMENTAL|Treatment B - INCB013739 & Metformin|INCB013739 15 mg QD and Metformin
62466460|NCT00698230|EXPERIMENTAL|Treatment C - INCB013739 & Metformin|INCB013739 50 mg QD and Metformin
62466461|NCT00698230|EXPERIMENTAL|Treatment D - INCB013739 & Metformin|INCB013739 100 mg QD and Metformin
62660852|NCT05475158||Dementia|"Patients with Alzheimer disease dementia (ADD) fulfilled the NIA-AA core clinical criteria for probable ADD and Aβ positive according to ATN classification scheme.~Aβ positive refers to Aβ pathology (CSF Aβ1-42 \< 631.8 pg/ml or positive amyloid deposits on 18F-flutemetamol PET by visual inspection)."
62660853|NCT05475158||MCI (Mild cognitive impairment)|Patients with mild cognitive impairment (MCI) met the Petersen's criteria.
62098216|NCT06250075|ACTIVE_COMPARATOR|Intervention for Clinical Outcomes -G4|The G4 and G5 groups will be recruited and randomized in the second stage of the research after the end of the collection of the G1 and G2 groups, for analysis of clinical outcomes in the 7-day postoperative period.
62098217|NCT06250075|PLACEBO_COMPARATOR|Non-intervention for Clinical Outcomes -G5|G5 will use placebo capsules with 0.5g calcium carbonate to test the power of the intervention in reducing postoperative surgical complications or not.
62294230|NCT06193473|EXPERIMENTAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|For patients in this group, intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. Through medication reviews, evaluations were made to identify drug-related problems and provide solutions to these problems. The clinical pharmacist provided recommendations to the physicians regarding significant clinically important problems. Additionally, follow-up was performed to determine whether the patients had a re-admission within 3 months.
62660854|NCT05475158||CU (Cognitively unimpaired control)|CU consisted of cognitively unimpaired subjects whose cognition (as defined by the Seoul Neuropsychological Screening Battery (SNSB)) was within normal limits.
62660855|NCT05475158||Aβ positive|Aβ positive refers to Aβ pathology (CSF Aβ1-42 \< 631.8 pg/ml or positive amyloid deposits on 18F-flutemetamol PET by visual inspection).
62660856|NCT05475158||Aβ negative|Aβ negative was within normal limits.
62466462|NCT00698230|EXPERIMENTAL|Treatment E - INCB013739 & Metformin|INCB013739 200 mg QD and Metformin
62466463|NCT00698230|PLACEBO_COMPARATOR|Treatment F - Placebo|Matching placebo
62466464|NCT05934071||patients affected by HFrEF on ARNI|patients affected by HFrEF in optimized medical therapy including ARNI, eligible for glyphozine
62466465|NCT05946460|EXPERIMENTAL|Neoadjuvant Aumolertinib|Single Arm
62466466|NCT05087524|EXPERIMENTAL|BinaxNOW Surveillance|Participants will agree to the performance of nasal swabs samples to be used for diagnosis or screening. Samples will be obtained by research staff in the school setting. Madison Metropolitan School District (MMSD) has obtained a Clinical Laboratory Improvement Amendments (CLIA) waiver for collection of samples. When there is a positive test, a saliva sample will be collected for testing with a standard polymerase chain reaction (PCR) method. The standard PCR samples will be processed at University of Wisconsin (UW) Clinical Laboratory.
62466467|NCT04605094|EXPERIMENTAL|Benralizumab|
62466468|NCT04605094|EXPERIMENTAL|Placebo / Benralizumab|
62660857|NCT04800796||Intervention Group|Intervention Group with audiovisually blended learning concept
62660858|NCT04800796||Standard group|Standard Group receiving the Standard operating procedures via E-Mail and Confirmation when reading.
62660859|NCT03785028|EXPERIMENTAL|Experimental Arm|Only arm of this basic science study, participants will undergo working memory and attention tasks
62098218|NCT02977143|EXPERIMENTAL|Fluid responsiveness test|"First, apply 10 cmH2O positive endexpiratory pressure (PEEP) and measure the increase in central venous pressure (CVP) as well as other preload indexes (central venous pressure, mean arterial pressure, stroke volume variation).~Second, measure the increase in cardiac index after administration of volulyte 300 ml.~If cardiac index increase more than 10%, fluid responsiveness is confirmed."
62098219|NCT05120869|EXPERIMENTAL|Treatment|A tailored HPV education and professional skills intervention.
62098220|NCT05120869|ACTIVE_COMPARATOR|Control|General/publicly available educational materials on HPV and communication skills.
62098221|NCT01532050|OTHER|Mandibular Advancement Device (MAD)|Mandibular Advancement Device (MAD)
62098222|NCT05039736|EXPERIMENTAL|cabozantinib|cabozantinib by mouth every day for 6 weeks
62466469|NCT01054898|EXPERIMENTAL|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
62466470|NCT01054898|ACTIVE_COMPARATOR|Usual community services|Standard care for abused women in the community
62737032|NCT04970823|EXPERIMENTAL|The somatosensory interactive game|The somatosensory interactive game, an independent nursing intervention, promotes pain relief on the experimental group.
62737033|NCT04970823|EXPERIMENTAL|A VR (virtual reality) game|A VR (virtual reality) game promotes pain relief on the experimental group.
62098223|NCT05039736|EXPERIMENTAL|nivolumab|nivolumab by vein every 4 weeks for up to 2 years
62294231|NCT04130815|ACTIVE_COMPARATOR|Slow/Deep/Large|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration
61909602|NCT06005324|ACTIVE_COMPARATOR|Standard Treatment Cohort|After completing induction chemotherapy, participants that have limited disease response by imaging will receive standard dose radiation treatment with additional chemotherapy (CRT). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
61909603|NCT06361342|EXPERIMENTAL|General decrease in smartphone use.|Subjects will limit their time on smartphone.
61909604|NCT06361342|EXPERIMENTAL|Avoid certain social media apps|Subjects will limit time on smartphone, in particular avoiding use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest.
61909605|NCT00755300||1|Standard Total Knee Replacement
61909606|NCT00755300||2|Computer Guided Knee Replacement
61909607|NCT01209104|EXPERIMENTAL|Cohort 1-PK and and safety of GSK1325756 in subjects 40-64y|This arm assesses the pharmacokinetics and safety of a single oral ose of 100mg of GSK1325756 administered to subjects in the age range 40y-64y when administered in the fasted state, in the presence of a high-fat meal and in the presence of a proton-pump inhibitor.
61909608|NCT01209104|EXPERIMENTAL|Cohort 2- PK and safety of GSK1325756 in subjects aged 65y-80y|This arm assesses the pharmacokinetics and safety of a single dose of 100mg of GSK1325756 administered to a group of subjects in the 64y-80y age range in the fasted state
61909609|NCT05059288|EXPERIMENTAL|Investigation Mask|Non invasive ventilation mask
61909610|NCT01970904|EXPERIMENTAL|200 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 200 mg twice daily (BID) and Ribavirin (RBV) for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
61909611|NCT01970904|EXPERIMENTAL|300 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 300mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
61909612|NCT01970904|EXPERIMENTAL|400 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
62098224|NCT04460443|EXPERIMENTAL|Sofosbuvir and ledipsavir|Sofosbuvir and ledipsavir plus standard of care treatment.
62098225|NCT04460443|EXPERIMENTAL|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir plus standard of card treatment..
62294232|NCT04130815|ACTIVE_COMPARATOR|Slow/Deep/Small|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
61909613|NCT02247648|EXPERIMENTAL|treatment|treatment: tramadol group
61909614|NCT02247648|PLACEBO_COMPARATOR|control|control: placebo group
61909615|NCT02603965|EXPERIMENTAL|Diagnostic (Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT at 30 minutes and 2 hours post-injection. Patients then undergo radical prostatectomy within 1 to 3 weeks after scans.
61909616|NCT01203852|EXPERIMENTAL|Metoprolol + Chlorthalidone|Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) \> 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.
61909617|NCT01100957|ACTIVE_COMPARATOR|Conventional flexible videoscope for intubation|
61909618|NCT01100957|EXPERIMENTAL|Single-patient flexible endoscope|Single-patient flexible video-endoscope used for tracheal intubation in this intervention-arm
61909619|NCT02856360|EXPERIMENTAL|Moderate Stiffness|Shoe condition that has moderate stiffness
62098226|NCT04460443|NO_INTERVENTION|Standard treatment|Standard treatment alone
62737034|NCT03955783|EXPERIMENTAL|Treatment (venetoclax, selinexor)|Patients receive venetoclax PO QD on days 1-28. Patients with DLBCL receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Venetoclax naïve AML patients receive selinexor on days 8, 15, and 22 of cycle 1, followed by days 1, 8, 15, and 22 of subsequent cycles. Venetoclax refractory AML patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62098227|NCT06336746||Patients with Preoperative EF: 50% or higher|Patients included will be examined with Transthoracic Echocardiography preoperatively and Ejection Fraction (EF) measured.
62294233|NCT04130815|ACTIVE_COMPARATOR|Fast/Shallow/Large|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration.
61909620|NCT02856360|ACTIVE_COMPARATOR|High Stiffness|Shoe condition that has high stiffness
61909621|NCT04137107|EXPERIMENTAL|Phase II, Arm I (duloxetine hydrochloride, placebo)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
61909622|NCT04137107|EXPERIMENTAL|Phase II, Arm II (duloxetine hydrochloride)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 60 mg (2 duloxetine capsules) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
62294234|NCT04130815|ACTIVE_COMPARATOR|Fast/Shallow/Small|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
61909623|NCT04137107|PLACEBO_COMPARATOR|Phase II, Arm III (placebo)|Patients in Phase II receive placebo (1 placebo capsule) orally (PO) once daily (QD) during week 1, placebo (2 placebo capsules) PO QD weeks 2-16, followed by placebo (1 placebo capsule) PO QD during week 17 in the absence of unacceptable toxicity.
61909624|NCT04137107|EXPERIMENTAL|Phase III, Arm I (duloxetine hydrochloride)|Patients in Phase III receive most promising dose of duloxetine hydrochloride from Phase II PO QD in the absence of unacceptable toxicity.
61909625|NCT04137107|PLACEBO_COMPARATOR|Phase III, Arm II (placebo)|Patients in Phase III receive placebo PO QD in the absence of unacceptable toxicity.
61909626|NCT05667415|EXPERIMENTAL|disulfiram and cisplatin|Cisplatin combined with disulfiram chemotherapy
61909627|NCT05667415|ACTIVE_COMPARATOR|standard cisplatin|Cisplatin chemotherapy alone
61909628|NCT02819232|OTHER|Patient with a prescription of a microbiologic diagnostic of|Patient with a prescription of a microbiologic diagnostic of keratitis
61909629|NCT05411575|PLACEBO_COMPARATOR|Placebo|continuous intravenous infusion for 7 days of Placebo
61909630|NCT05411575|EXPERIMENTAL|Plerixafor|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
61909631|NCT00275821|EXPERIMENTAL|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|
61909632|NCT00275821|EXPERIMENTAL|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|
61909633|NCT00275821|ACTIVE_COMPARATOR|Ranibizumab 0.3 mg monthly|
61909634|NCT06121245|EXPERIMENTAL|Esomeprazol|On the day before the study visits participants will ingest a capsule in the morning on a capsule in the evening containing Esomperazol
61909635|NCT06121245|PLACEBO_COMPARATOR|Placebo|On the day before the study visits participants will ingest a capsule in the morning on a capsule in the evening containing a placebo
61909636|NCT04686058|ACTIVE_COMPARATOR|TCI propofol|Target controlled infusion propofol titrated by the investigator intra-procedure, based on the Modified Observer's Assessment of Alertness and Sedation Scale
62294235|NCT01321047|ACTIVE_COMPARATOR|Propofol group|the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age \> 70 or ASA class III-IV).
61909637|NCT04686058|ACTIVE_COMPARATOR|PCS propofol|Patient-controlled sedation titrated by the patient to comfort level
61909638|NCT04686058|ACTIVE_COMPARATOR|midazolam and pethidine|Midazolam and pethidine bolus doses administered by the investigator based on clinical parameters and observation
61909639|NCT04604132|EXPERIMENTAL|Substudy 1: Cohort 1.1 Derazantinib 300 mg once daily|Patients with FGFR2 fusions or amplifications were treated with 300 mg Derazantinib monotherapy once daily
61909640|NCT04604132|EXPERIMENTAL|Substudy 1: Cohort 1.2 Derazantinib 300 mg once daily|Patients with FGFR1-3 mutations were treated with 300 mg Derazantinib monotherapy once daily
62098228|NCT06336746||Patients with Preoperative EF: 45% or lower|Patients included will be examined with Transthoracic Echocardiography preoperatively and Ejection Fraction (EF) measured.
62466471|NCT04109417|EXPERIMENTAL|osteotomy filled with PRP-gel and covered with PRP-biomembrane|the defect was filled with the previously activated autologous Platelet-rich plasma (PRP) gel and its supernatant. The site was then externally covered with the prepared bio-membrane composed of activated PRP which acted as an adjunct to the mucoperiosteal flap to stimulate tissue regeneration
62466472|NCT04109417|SHAM_COMPARATOR|osteotomy site left empty|osteotomy site following the surgical intervention was left empty
61909641|NCT04604132|EXPERIMENTAL|Substudy 1: Cohort 1.3 Derazantinib 200 mg twice daily|Patients with FGFR fusions, amplifications or mutations were treated with 200 mg Derazantinib monotherapy twice daily
62098229|NCT06336746||Patients without intrathecal bupivacain and morphine.|The routine is that all patient receive an intrathecal injection of morphine and bupivacain before start of anesthesia. Patients who have contraindications for spinal anesthesia will be collected in this group.
62098230|NCT02728986|ACTIVE_COMPARATOR|Compression1|Multilayer compression bandage (Profore)
61909642|NCT04604132|EXPERIMENTAL|Substudy 2: Derazantinib 200 mg once daily +Paclitaxel+ Ramucirumab|Patients with FGFR fusions, amplifications or mutations were treated with 200 mg Derazantinib once daily in combination with Paclitaxel and Ramucirumab
61909643|NCT04604132|EXPERIMENTAL|Substudy 2: Derazantinib 300 mg once daily+Paclitaxel+ Ramucirumab|Patients with FGFR fusions, amplifications or mutations were treated with 300 mg Derazantinib once daily combination with Paclitaxel and Ramucirumab
61909644|NCT03625908|ACTIVE_COMPARATOR|OCT-guided PCI|Patients will receive PCI under OCT-guidance.
61909645|NCT03625908|ACTIVE_COMPARATOR|Angiography-guided PCI|Patients will receive PCI under Angiography-guidance.
61909646|NCT02858700|EXPERIMENTAL|umbilical cord blood procalcitonin|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP
62098231|NCT02728986|EXPERIMENTAL|Compression2|Coban2 compression system
62098232|NCT06118619||Experimental|Ingaron 500,000 IU intramuscularly 1 time per day daily or every other day for 2 months (60 days) - a total of 30 or 60 injections + basic anti-tuberculosis therapy
62098233|NCT06118619||No Intervention|only basic anti-tuberculosis therapy
62466473|NCT01185548|EXPERIMENTAL|Tasisulam and Tolbutamide|"Three study periods and continued access to tasisulam every 28 days (except Period 1 which was tolbutamide only and lasted 4 days) until disease progression:~Period 1: 500 milligram (mg) tolbutamide administered on Day 1.~Period 2: 500 mg of tolbutamide and individualized tasisulam dose \[based on area under the curve albumin-corrected threshold (AUCalb)\]. The AUCalb is a surrogate marker for unbound tasisulam, and this dosing approach represents the maximum level of unbound tasisulam which may be achieved clinically, administered on Day 1.~Period 3: Individualized tasisulam dose (based on AUCalb) administered on Day 1 and 500 mg tolbutamide administered on Day 4."
62466474|NCT04937101|EXPERIMENTAL|Antihistamine treatment group|Chlorpheniramine, the concentration is 10mg/ml per unit point, the highest dose is 1ml
62466475|NCT04937101|NO_INTERVENTION|Control group|
62466476|NCT01423006|EXPERIMENTAL|Focal Prostate Radio-Frequency Ablation|Treatment is performed under a spinal or general anesthetic and will include the one to three regions of the prostate containing cancer based on the mapping biopsy.
61909647|NCT02585570|EXPERIMENTAL|Low dose phenylephrine|phenylephrine 0.5 mcg/kg/min
61909648|NCT02585570|EXPERIMENTAL|High dose phenylephrine|phenylephrine 1.0 mcg/kg/min .
61909649|NCT02585570|NO_INTERVENTION|Normal saline|normal saline for 5minutes
61909650|NCT05173545|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection（12 mg/m2）|itoxantrone Hydrochloride Liposome Injection（12 mg/m2）
61909651|NCT05173545|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection（16 mg/m2）|itoxantrone Hydrochloride Liposome Injection（16 mg/m2）
61909652|NCT05173545|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection（20mg/m2）|itoxantrone Hydrochloride Liposome Injection（20 mg/m2）
62098234|NCT03921905||Patients with CAD|In this study will be included patients with stable CAD
62098235|NCT05152628|EXPERIMENTAL|Tacrolimus granules (Modigraf)|Participants will receive the first dose of Modigraf in the morning within 24 hours after reperfusion. Total initial dose will be received in two divided doses post operatively. Subsequent oral Modigraf doses will be adjusted by the investigator and will be received in two doses (recommended interval 12 hours)
62098236|NCT01572077|EXPERIMENTAL|FTHA/GDF PET imaging|"This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.~Both groups will undergo FTHA/FDG PET imaging."
62098237|NCT06331962|EXPERIMENTAL|remote home-based exercise therapy group|"Location and Frequency: Four times per week at the individual's own home. Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistance training, sensory exercises.~Note: The participant will receive a customized exercise plan based on their capabilities, including guidelines and exercise instructions (exercise names, required equipment, movement sequences, repetitions, precautions)."
62098238|NCT06331962|ACTIVE_COMPARATOR|supervised exercise therapy group|"Exercise Location and Frequency: Physiotherapy Center (twice a week) and individual's home (twice a week).~Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistance training, sensory training exercises. The home-based exercise training content is partially the same as the remote home-based exercise group."
62098239|NCT06331962|OTHER|regular care group|Perform regular care for eight consecutive weeks. After the tracking period ends (8 weeks), provide home-based education on resistance exercises, cardiovascular endurance exercises, and sensory training exercises.
62098240|NCT06614088||Group A|Eligible patients with CPIRO 0-2
62098241|NCT06614088||Group B|Eligible patients with CPIRO \>3
62098242|NCT06614088||Group C|Control group (elective surgical patients without any source of intra-abdominal infection)
62098243|NCT03127345|EXPERIMENTAL|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
62098244|NCT03127345|ACTIVE_COMPARATOR|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
62098245|NCT05847764|EXPERIMENTAL|Arm 1: RC48+PD-1/PD-L1 inhibitor|
62098246|NCT05847764|EXPERIMENTAL|Arm 2: RC48+Furmonertinib, 1L|
62098247|NCT05847764|EXPERIMENTAL|Arm 3: RC48+Furmonertinib, 2L+|
62098248|NCT05536466|EXPERIMENTAL|doravirine treatment|patients stable on doravirine and candidate for bariatric surgery
62098249|NCT04523181|ACTIVE_COMPARATOR|Antroquinonol with SOC|Antroquinonol in a dose of 100 mg (1 capsule) administered twice daily (BID) orally, for 14 days.
62466477|NCT03475030|NO_INTERVENTION|Usual Care|Patients receive usual care and can continue using their existing pharmacy.
61909653|NCT00484744|EXPERIMENTAL|Acetaminophen|
61909654|NCT00484744|EXPERIMENTAL|Ibuprofen|
61909655|NCT00484744|PLACEBO_COMPARATOR|Avicel|
62098250|NCT04523181|PLACEBO_COMPARATOR|Placebo with SOC|Placebo (1 capsule) administered twice daily (BID) orally, for 14 days.
62098251|NCT01312662||normal ophthalmological status|
62098252|NCT01312662||opacity of the refractive media|
62098253|NCT01312662||maculopathy|
62098254|NCT01312662||optic neuropathy|
62098255|NCT01312662||chiasmal and postchiasmal visual pathway pathologies|
62098256|NCT01312662||amblyopia (deprivation)|
62098257|NCT01312662||amblyopia (strabism)|
62098258|NCT01981161||Fingolimod|patients treated by Fingolimod will have biological samples and clinical data
62466478|NCT03475030|EXPERIMENTAL|Smart Pillbox|Patients receive pre-filled medication trays from Curant Health Pharmacy or the Brigham and Women's Hospital Outpatient Pharmacy. The smart pillbox in which pre-filled medication trays are housed provide automated medication reminders.
62098259|NCT01981161||Natalizumab|patients treated by Natalizumab will have biological samples and clinical data
62098260|NCT04500743|ACTIVE_COMPARATOR|Dienogest|
62098261|NCT04500743|ACTIVE_COMPARATOR|GnRH analogue|
62098262|NCT04463082|EXPERIMENTAL|Weight category 10-20kg|Pediatric patients with a weight of 10-20kg will be enrolled in this arm.
62466479|NCT03447860|ACTIVE_COMPARATOR|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress.
62466480|NCT03447860|EXPERIMENTAL|PAACC|A mindfulness-based multi-component caregiver intervention to reduce caregiver stress.
62098263|NCT04463082|EXPERIMENTAL|Weight category 20-30kg|Pediatric patients with a weight of 20-30kg will be enrolled in this arm.
62466481|NCT06396026|EXPERIMENTAL|Arm 1|TLL018 tablets,1piece,BID
62466482|NCT06396026|PLACEBO_COMPARATOR|Arm 2|Placebo tablets,1piece,BID
62466483|NCT01684241|EXPERIMENTAL|RBL001/RBL002 intranodal administration|"All participants will be treated with RBL001/RBL002 after allocation to one of the four escalating dose cohorts:~* Cohort-1 50 µg RBL001 and 50 µg RBL002~* Cohort-2 100 µg RBL001 and 100 µg RBL002~* Cohort-3 300 µg RBL001 and 300 µg RBL002~* Cohort-4 600 µg RBL001 and 600 µg RBL002"
62098264|NCT04463082|EXPERIMENTAL|Weight category 30-50kg|Pediatric patients with a weight of 30-50kg will be enrolled in this arm.
62098265|NCT06650696|ACTIVE_COMPARATOR|Psychoeducation group （PsyE）|Psychoeducation consists of parent and adolescent psychoeducation. The content includes an introduction to stress, emotional distress and mental disorders.
62098266|NCT06650696|EXPERIMENTAL|Psychoeducation + Emotional Skills (PsyE+EmoS)|Psychoeducation includes sessions for both parents and adolescents, offering the same content as the control group, which introduces stress, emotional distress, and mental disorders via online programe. In addition, the emotional skills enhancement sessions provide online materials focused on emotional awareness and emotion regulation strategies, along with tasks related to the content. Participants will also be required to complete a weekly writing assignment, upload their written contents, and assess their level of subjective discomfort following each writing exercise.
62098267|NCT06650696|EXPERIMENTAL|Psychoeducation + emotional skills + PCE (PsyE+EmoS+PoCE)|In comparison to the PsyE+EmoS group, this group additionally requires parents to complete a weekly parent-child communication task via online programe aimed at fostering positive childhood experiences. Parents are also expected to document and upload the details of these tasks each week.
62098268|NCT00990756|EXPERIMENTAL|PF-03526299 1.396 mg|
62098269|NCT00990756|EXPERIMENTAL|PF-03526299 4mg|
62098270|NCT01368120|EXPERIMENTAL|IV Clear™|
62098271|NCT01368120|ACTIVE_COMPARATOR|Tegaderm CHG™|
62098272|NCT01368120|PLACEBO_COMPARATOR|Vehicle Control Dressing|
62098273|NCT06651658|NO_INTERVENTION|Lung ablation only|Patients proceed to standard of care treatment with lung ablation as deemed clinically appropriate
62466484|NCT03985865|EXPERIMENTAL|Intragastric quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
62466485|NCT03985865|EXPERIMENTAL|intragastric denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
62466486|NCT03985865|PLACEBO_COMPARATOR|Intragastric placebo|0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
62466487|NCT03985865|EXPERIMENTAL|Intraduodenal quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
62466488|NCT03985865|EXPERIMENTAL|Intraduodenal denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
61909656|NCT04643600|ACTIVE_COMPARATOR|Smokers|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients who are smokers will have recorded : the age of onset of smoking, the year of smoking experience and the average number of cigarettes smoked per day. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
62098274|NCT06651658|EXPERIMENTAL|Lung ablation with pleural embolisation|In addition of standard of care lung ablation, patients undergo pleural blood patch embolisation during withdrawal of the ablation probe
62098275|NCT03683355||Edwards Sapien 3|Patients who underwent transcatheter aortic valve replacement with the Edwards Sapien 3 valve
62098276|NCT03683355||Core Valve Evolut R|Patients who underwent transcatheter aortic valve replacement with the Core Valve Evolut R valve
62098277|NCT00331162|ACTIVE_COMPARATOR|1|Alemtuzumab
62098278|NCT00331162|ACTIVE_COMPARATOR|2|Anti-Thymocyte Globulin
62098279|NCT04835584|EXPERIMENTAL|Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.
62098280|NCT04835584|EXPERIMENTAL|Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.
62098281|NCT04835584|EXPERIMENTAL|Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.
62098282|NCT04835584|EXPERIMENTAL|Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.
62294236|NCT01321047|ACTIVE_COMPARATOR|BPS group|the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.
62294237|NCT00686543|EXPERIMENTAL|POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15|POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.
62466489|NCT03985865|PLACEBO_COMPARATOR|Intraduodenal placebo|0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
62660860|NCT05469490|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT) + NLG802 and navoximod|"SBRT - Initial Starting Dose:~Lung - Peripheral - 45 Gy (3 fractions) Lung - Central OR Mediastinal/Thoracic/Axillary/Cervical Lymph Node - 50 Gy (5 fractions) Liver - 45 Gy (3 fractions) Spinal/Paraspinal OR Osseous - 30 Gy (3 fractions) Abdominal/Pelvic (including Adrenal Gland) - 45 Gy (3 fractions)~SBRT - Decreased DLT Dose:~Lung - Peripheral - 42 Gy (3 fractions) Lung - Central OR Mediastinal/Thoracic/Axillary/Cervical Lymph Node - 47.5 Gy (5 fractions) Liver - 42 Gy (3 fractions) Spinal/Paraspinal OR Osseous - 27 Gy (3 fractions) Abdominal/Pelvic (including Adrenal Gland) - 42 Gy (3 fractions)~NLG802 - 1452mg BID (no dose decrease)~navoximod - Starting dose: 1000mg BID, Dose decrease 1: 800mg BID, Dose decrease 2: 600mg BID"
62660861|NCT04085016||meibography of statin group|patients with regular HMG CoA reductase inhibitor (statin) treatment
62660862|NCT04085016||meibography of non-statin group|patients with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy
62660863|NCT04959513|EXPERIMENTAL|GBR with L-PRF bone block|Guided bone regeneration using Leukocyte and platelet-rich fibrin
62098283|NCT00375856|NO_INTERVENTION|1|DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee
62098284|NCT00375856|EXPERIMENTAL|2|Rotating Platform Knee
62098285|NCT00052962|OTHER|Arm 1 Surgery + post op chemotherapy|"* Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~* Post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-fluorouracil (5-FU), every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
62294238|NCT00686543|EXPERIMENTAL|POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.
62294239|NCT00686543|EXPERIMENTAL|POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.
62294240|NCT01795651||Take-Home message|
62466490|NCT02063841|ACTIVE_COMPARATOR|sterile identical sham drape|Sham drape and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
62098286|NCT00052962|OTHER|Arm 2 Surgery + HIPEC|"Arm 2 Surgery + Continuous hyperthermic peritoneal perfusion (CHPP/HIPEC) + post op dwell + post op chemotherapy~* Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~* followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin~* post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluorouracil (5FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2~* post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-FU, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
62660864|NCT01635140|EXPERIMENTAL|Hypofractionated arm|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
62098287|NCT03323840|EXPERIMENTAL|Incentivized Care|Patients will meet with the pharmacist up to 2 times/month for blood pressure measurement. Patients will receive a $10 gift card for each measurement.
62098288|NCT03356015|EXPERIMENTAL|4L Polyethylene Glycol|4L-group received 4 bags of PEG and were instructed to drink 2L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
62098289|NCT03356015|ACTIVE_COMPARATOR|3L Polyethylene Glycol|3L-group received 3 bags of PEG and were instructed to drink 1L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
62294241|NCT02956811|ACTIVE_COMPARATOR|Active|Dapagliflozin 10mg once daily for 12 months
62098290|NCT06045806|EXPERIMENTAL|Arm A|
62294242|NCT02956811|PLACEBO_COMPARATOR|Placebo|Placebo 10mg once daily for 12 months
62466491|NCT02063841|EXPERIMENTAL|lead-free protective drape containing bismuth and antimony|lead-free protective drape containing bismuth and antimony (RADPAD®) hung around the fluoroscopy image intensifier to prevent scatter radiation, and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
62660865|NCT01635140|OTHER|Conventional arm|The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.
62660866|NCT02522845|ACTIVE_COMPARATOR|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
62660867|NCT02522845|NO_INTERVENTION|No Compression|Patients randomised to this group will not be provided with any compression
62098291|NCT06045806|ACTIVE_COMPARATOR|Arm B|
62098292|NCT03825393||Fibromyalgia|Non-anemic FMS patients who were diagnosed based on 2011 FMS diagnostic criteria of the American Rheumatology College
62098293|NCT03825393||Control|Non-anemic women without a FMS diagnosis
62660868|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
62660869|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of \>30%. This will include patients scheduled for carotid endarterectomy (\>50% for men and \>70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
62098294|NCT00555581|EXPERIMENTAL|400 mg daily of Imatinib Mesylate|All patients were treated with imatinib mesylate at a target dose of 400 mg daily by mouth for 12 months. Dose modifications and interruptions were made for AE and were recorded. After 12 months of treatment, imatinib was stopped for 3 months. Patients were reassessed and offered entrance to an extension phase of the trial.
62660870|NCT01687803|EXPERIMENTAL|Physical Activity|Physical activity intervention will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to \~60 min/day for 6 days/week (\~360 minutes per week).
62660871|NCT01687803|OTHER|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
62098295|NCT05843500||Chronic thromboembolic disease|Patients with chronic thromboembolic disease/pulmonary hypertension
62098296|NCT06392360|EXPERIMENTAL|Betaine|3 grams per day in 6 capsules, white crystalline betaine powder produced from beet molasses
62098297|NCT06392360|PLACEBO_COMPARATOR|Placebo|3 grams per day in 6 capsules, white cellulose powder
62098298|NCT02947711|EXPERIMENTAL|E2027 100 mg alone and in combination with diltiazem ER 300 mg|E2027 100 milligrams (mg) will be administered orally on Days 1 and 12. Diltiazem extended release (ER) 300 mg will be administered alone on Days 7 to 24; however, on the morning of Day 12 it will be coadministered with E2027 100 mg.
62098299|NCT03364179||young onset dementia|
62098300|NCT03364179||late onset dementia|
62098301|NCT04399707|ACTIVE_COMPARATOR|Active TENS Unit|
62098302|NCT04399707|PLACEBO_COMPARATOR|Placebo TENS Unit|
62098303|NCT04399707|NO_INTERVENTION|No TENS Unit|
62098304|NCT03310528||Obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
62098305|NCT03310528||Did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
62660872|NCT03619525|ACTIVE_COMPARATOR|recruitment group|will receive intermittent lung recruitment during CPB
62660873|NCT03619525|NO_INTERVENTION|control group|will recieve no intervention
62098306|NCT03310528||Trauma - obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
62098307|NCT03310528||Trauma - did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
62098308|NCT01675830|EXPERIMENTAL|Head Retention Head Wrap device|All subjects recieved the experimental intervention with the Heat Retention Head Wrap device for during the rewarming phase of cardiopulmonary bypass surgery.
62098309|NCT05536427|EXPERIMENTAL|IPM001|A neoantigen/ tumor-specific antigen sencitized autoimmune cell injection
62098310|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
62098311|NCT04699448|ACTIVE_COMPARATOR|High-protein hypocaloric diet|Composition of hypocaloric diet: protein:40%,carbohydrates:30% and fat:30%.
62098312|NCT04699448|ACTIVE_COMPARATOR|High-carbohydrate hypocaloric diet|Composition of hypocaloric diet: carbohydrate 60%, protein:18% and fat:22%
62098313|NCT00816335|EXPERIMENTAL|Arm 1|F-FDG-directed surgery for known or suspected malignancy using gamma detection probes.
62098314|NCT00490555|PLACEBO_COMPARATOR|1|Placebo gel + Placebo pill + placebo injection
62098315|NCT00490555|ACTIVE_COMPARATOR|2|Testosterone 1% transdermal gel 10 g + placebo pill + placebo injection
62098316|NCT00490555|ACTIVE_COMPARATOR|3|Testosterone 1% transdermal gel 10 g + dutasteride 0.5 mg Orally + placebo injection
62660874|NCT02686411||Observational (survey)|Patients and caregivers complete surveys over 5-10 minutes before and after care in the PCU.
61909657|NCT04643600|ACTIVE_COMPARATOR|Non - smokers|All patients will be maesured: body weight, height, BMI (body mass index), waist circumference, pulse (cp), saturation (SpO2), blood pressure, respiratory index and thoracic spine mobility index measured. All patients will do a 6-minute walk test and test on a bicycle erogometer. The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
61909658|NCT04951167|ACTIVE_COMPARATOR|PB: prophylactic bolus|an IV bolus of 4 mcg Norepinephrine will be administered immediately after spinal anesthesia, and then SF infusion will be started at 1 ml/min.
62098317|NCT00490555|ACTIVE_COMPARATOR|4|Testosterone 1% transdermal gel 10 g + placebo pill + DMPA 300 mg injection (IM)
62308126|NCT02584985|OTHER|ETAP : Endoscopic Transanal Proctectomy|"1. Primary transanal approach :~   Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).~2. Secondary transabdominal approach :~Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction."
62660875|NCT05727644|ACTIVE_COMPARATOR|Participants with normal renal function|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
62660876|NCT05727644|EXPERIMENTAL|Participants with impaired renal function|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
62660877|NCT05981105|EXPERIMENTAL|Adductor Canal Catheter (ACC) - Interventional|"Patients will received the an adductor canal catheter that continuously infuses numbing medication to their operative leg for 50 hours post-surgery.~Patients will also communicate with their pain doctor via the Diagnotes application while the catheter is in place."
62660878|NCT05981105|SHAM_COMPARATOR|Adductor Canal Block (ACB) - Control|"Patients will received the a sham adductor canal catheter that is attached to their operative leg for 50 hours post-surgery.~Patients will also communicate with their pain doctor via the Diagnotes application while the catheter is in place."
62660879|NCT05882136||Patients with acute intermittent porphyria (AIP)|Patients aged 18-65 (men and women) with acute intermittent porphyria and at least one episode of exacerbation of this disease requiring admission to the hospital
62660880|NCT05882136||Control group|People recruited from the general population and matched by age, sex and body mass index.
62660881|NCT02327481|EXPERIMENTAL|3D Laparoscopic Surgery|3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
62660882|NCT02327481|ACTIVE_COMPARATOR|2D Laparoscopic Surgery|2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
62660883|NCT01065168||endometrioma|ovarian endometrioma undergoing cystectomy
62660884|NCT03144232|EXPERIMENTAL|Active rTMS|10 Hz rTMS applied to the left DLPFC
62660885|NCT03144232|SHAM_COMPARATOR|Sham rTMS|Sham rTMS applied to the left DLPFC
62660886|NCT03154606|EXPERIMENTAL|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
62660887|NCT03154606|ACTIVE_COMPARATOR|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
62660888|NCT02098551||Four (4)|"Group 1: Birch pollen-related atopic dermatitis (AD) (n=15) Group 2: Birch pollen allergic patients without AD (n=5) Group 3: Allergic individuals without birch pollen allergy (n=5) Group 4: Non-allergic individuals (n=5)~Patients will be tested by SPT and APT:~SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, and equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~APT: birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, equimolar mix of rBet v 1 fragments (160 μg/application); negative control with vaseline"
62660889|NCT06109740|EXPERIMENTAL|Lactobacillus GG|Probiotic nutritional supplement
62660890|NCT06109740|PLACEBO_COMPARATOR|Placebo capsule|Matching placebo capsule
62660891|NCT04403282|ACTIVE_COMPARATOR|Paired(right and left neck) comparison group eflornithine|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
62660892|NCT04403282|PLACEBO_COMPARATOR|Paired(right and left neck) comparison group placebo|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
61909659|NCT04951167|ACTIVE_COMPARATOR|PI:prophylactic infusion|1ml of saline is administered immediately after spinal anesthesia, and then infusion will be started with the study drug at 1 ml/min.(4mcg/min)
62660893|NCT06447051||Biliary Atresia|Subject undergoing Kasai Surgery at Institute of Liver and Biliary Sciences would be enrolled and will include retrospective historical cohort (Jan 2015 to Dec 2017) and retrospective + prospective cohort with new protocol (Jan 2018 till June 2024).
62308127|NCT02584985|OTHER|Standard Transabdominal Laparoscopic proctectomy|Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
62660894|NCT01416051|ACTIVE_COMPARATOR|Test|Subjects consumed a vegetable oil emulsion in yogurt at a food intake test and were asked to consume the product twice daily for 12 weeks.
61909660|NCT04951167|ACTIVE_COMPARATOR|TB:therapeutic bolus|immediately after spinal anesthesia, 1 ml of saline, followed by 1 ml/min infusion of SF, and when the blood pressure decreases by 20%, 1 ml of working solution and then 1 ml/min of saline infusion will be started.
61909661|NCT04951167|ACTIVE_COMPARATOR|TBI:therapeutic bolus-infusion|1 ml of study drug and 1 ml/min of study drug infusion will be started immediately after spinal anesthesia, after 1 ml of saline followed by 1 ml/min of SF infusion when blood pressure decreases by 20% of the entry
61909662|NCT06343857||Anatomical site|Subjects who have requested an orthopaedic specialist examination for the knee, or ankle or shoulder
61909663|NCT04232969|ACTIVE_COMPARATOR|Exenatide|Exenatide extended release 2mg (Bydureon) once weekly for 96 weeks n=100
61909664|NCT04232969|PLACEBO_COMPARATOR|Placebo|Exenatide extended release placebo once weekly for 96 weeks n=100
61909665|NCT04319497|OTHER|Refraction reproducibility and agreement|Subjective and objective refraction will be performed in all patients
61909666|NCT02439359|PLACEBO_COMPARATOR|Placebo|Placebo
61909667|NCT02439359|EXPERIMENTAL|CF-301|CF-301
61909668|NCT06393335|EXPERIMENTAL|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
61909669|NCT05536128|EXPERIMENTAL|Olaparib,Fulvestrant|"Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.~Fulvestrant should be administered on days 1, 15, 29, and then once monthly at 500 mg per dose."
61909670|NCT06046742|EXPERIMENTAL|M1-c6v1 intravenous injection|M1-c6v1 will be administered through IV drip
61909671|NCT04988191|EXPERIMENTAL|Toripalimab combined with bevacizumab and chemotherapy|
61909672|NCT01252667|EXPERIMENTAL|Part 1 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m\^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
61909673|NCT01252667|EXPERIMENTAL|Part 1 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m\^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
62098318|NCT05551403|EXPERIMENTAL|rest-EEG, TMS-EEG/TMS-electromyography(EMG) and photic stimulation|
62308128|NCT01466114|EXPERIMENTAL|Group A: Estriol|Standard MS Treatment + Estriol
62308129|NCT01466114|PLACEBO_COMPARATOR|Group B: Placebo|Standard MS Treatment + Placebo
62660895|NCT01416051|PLACEBO_COMPARATOR|Control Group|Subjects were given a placebo of milk fat in yogurt at food intake tests and asked to consume the placebo twice daily for 12 weeks.
62660896|NCT01949259||Retrospective collection|Retrospective collection of data from included lung cancer patients.
62660897|NCT05084456|EXPERIMENTAL|Control|ModraDoc006/r will be administered in a continuous weekly dose of 30-20 mg without dose escalation. This is the established recommended phase II dose for patients with normal liver function based on previous phase I trials.
62660898|NCT05084456|EXPERIMENTAL|Child-Pugh class A|ModraDoc006/r administration will start treatment with a weekly BID dose of 20-10mg ModraDoc006 in combination with ritonavir. If toxicity is acceptable, after 4 weeks an intra-patient dose-escalation will be initiated, followed by the second dose escalation after another 4 weeks.
62660899|NCT05084456|EXPERIMENTAL|Child-Pugh class B|ModraDoc006/r administration will start treatment with a weekly QD dose of 20mg ModraDoc006 in combination with ritonavir. If toxicity is acceptable, after 4 weeks an intra-patient dose-escalation will be initiated, followed by the second dose escalation after another 4 weeks.
62660900|NCT01784263|EXPERIMENTAL|Individual Cognitive Behavioral Therapy|
62660901|NCT01784263|ACTIVE_COMPARATOR|Standard Community Treatment|
62660902|NCT02232347|EXPERIMENTAL|ketamine|ketamine 5 mg/kg/h, continuous infusion for 48 hours
62660903|NCT02232347|ACTIVE_COMPARATOR|sufentanil|sufentanil 0,5 mcg/kg/h, continuous infusion for 48 hours
62660904|NCT05820438|EXPERIMENTAL|Patients requiring orthopedic treatment with Rapid Maxillary Expander|Patients will be treated with Rapid Maxillary Expander with two bands on the upper first permanent molars or upper second primary molars (depending on the eruptive stage of the patient). The screw will be activated according to clinitian's indication until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with a metal legature and the patient will wear the cemented RME for retentions at least for six months.
62660905|NCT01017315|EXPERIMENTAL|No application of baby talcum|control
62660906|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
62660907|NCT05461495|EXPERIMENTAL|Treatment Group|"Treatment group will receive 6 counseling sessions, participate in local support group and on-line chat group, and receive ad hoc' counseling."
62660908|NCT05461495|NO_INTERVENTION|Control Group|Control group will participate in on-line chat group, and call the counselor for resource information and support as needed.
62660909|NCT00578526|ACTIVE_COMPARATOR|Arm 1|SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks
62660910|NCT00578526|PLACEBO_COMPARATOR|Arm 2|1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment.
62660911|NCT05521373|ACTIVE_COMPARATOR|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
62660912|NCT05521373|ACTIVE_COMPARATOR|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
62660913|NCT04350502|EXPERIMENTAL|complicated pleural infection patients|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
62098319|NCT06197672|EXPERIMENTAL|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
62098320|NCT05180474|EXPERIMENTAL|GEN1047|
62308130|NCT06459752|EXPERIMENTAL|Group A|This group received three sessions a week for six weeks, with 30 minutes per session given to visceral manipulation and noble technique (15 minutes each technique).
62308131|NCT06459752|ACTIVE_COMPARATOR|Group B|This group receives three sessions a week for six weeks, with 15 minutes per session in which noble technique is applied.
62098321|NCT03063307|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment|
62098322|NCT03063307|EXPERIMENTAL|Silver Diamine Fluoride|
62098323|NCT01822158|OTHER|vaginal delivery debrief checklist|Utilization of a Vaginal Delivery Debrief Checklist after vaginal deliveries for a period of three months, by team members who have consented to be a part of this study and who are present at vaginal deliveries. The Vaginal Delivery Debrief checklist consists of 2 levels. The first level includes a list of 6 key elements, such as APGAR scores,estimated blood loss, perineal repair, etc. The second level,or extended debrief, occurs whenever unanticipated outcomes, such as low APGAR scores, postpartum hemorrhage or a difficult delivery occurs. Team members complete the checklist after each delivery they attend.
62098324|NCT04210024|OTHER|Rural-Dwelling Community Members/Residents|Rural-dwelling adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. A subset of participants (\~4) will be identified as Community Health Workers and will receive training with the Diabetes Empowerment Education Program (DEEP).
62098325|NCT06713772|ACTIVE_COMPARATOR|Group A - Adhesive glue|Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
62098326|NCT06713772|ACTIVE_COMPARATOR|Group B - Adhesive tape|Steri-StripsTM (3M, St. Paul, Minnesota, USA
62098327|NCT06713772|ACTIVE_COMPARATOR|Group C - Suture|Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
62098328|NCT06454292|EXPERIMENTAL|Intervention group：Oliceridine Fumarate|
62098329|NCT06454292|EXPERIMENTAL|Control group: Remifentanil|
62098330|NCT04912557||Patients|Open major abdominal surgery patient (predicted operative time ≥ 2 hours) with Peridural Analgesia accepted
62660914|NCT04729712|ACTIVE_COMPARATOR|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive an erector spinae block with catheter insertion under ultrasound guidance under general anaesthesia. This regional anaesthesia procedure will be performed by an Anaesthesiologist with experience in performing this block.
62098331|NCT05417698|EXPERIMENTAL|Exercise only (Ex only)|"Participants in the Exercise only group will be performing home-based, equipment-free HIIT exercise for 20 minutes, 3 times a week for the duration of the 8-weeks, achieving ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals. Participants are also required to exercise at least 17 out of 20 on the Rate of Perceived Exertion (RPE) scale."
62098332|NCT05417698|EXPERIMENTAL|Exercise and Mediterranean Diet (Ex + MedDiet)|"Participants in Ex+MedDiet arm will be required to adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks according to a Mediterranean diet booklet provided by the researcher. In brief, diet encompasses a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants in this group will also be performing home-based, equipment-free HIIT exercise for 20 minutes, 3 times a week for the duration of the 8-weeks, achieving ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals. Participants are also required to exercise at least 17 out of 20 on the Rate of Perceived Exertion (RPE) scale."
62098333|NCT05417698|NO_INTERVENTION|Control|Participants will be asked to maintain their diet and physical activity levels throughout the 8 weeks.
62098334|NCT06713837|EXPERIMENTAL|Low intensity treatment|"Low intensity treatments are based on the single agent use of innovative and target drugs or their combination with other target drugs and less-toxic agents in doublets or triplets.~Administration of low intensity therapies in combination with antibodies or target agents would be included in this cohort"
62098335|NCT06713837|ACTIVE_COMPARATOR|High intensity treatment|"Intensive treatment of leukemia is based on high dose of chemotherapy agents.~Administration of high-dose chemotherapy in combination with antibodies or target agents would be included in this cohort."
62098336|NCT04908163|ACTIVE_COMPARATOR|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one month. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured."
62308132|NCT00201851|ACTIVE_COMPARATOR|Immediate surgery|Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
62308133|NCT00201851|EXPERIMENTAL|Scheduled surgery|Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
62660915|NCT04729712|EXPERIMENTAL|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive a paravertebral block with catheter insertion under under thoracoscopic guidance. This regional anaesthesia procedure will be performed at the start of the operation by a surgeon with experience in performing this block.
62660916|NCT01414296|EXPERIMENTAL|Arm 1|
62660917|NCT02065557|EXPERIMENTAL|Adalimumab Induction Standard Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
62660918|NCT02065557|EXPERIMENTAL|Adalimumab Induction High Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
62660919|NCT02065557|EXPERIMENTAL|Adalimumab Induction High Dose - Open Label|(After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
62660920|NCT02065557|PLACEBO_COMPARATOR|Maintenance Placebo|(Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.
62660921|NCT02065557|EXPERIMENTAL|Adalimumab Maintenance Standard Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg \[maximum dose of 40 mg\] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
62660922|NCT02065557|EXPERIMENTAL|Adalimumab Maintenance High Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg \[maximum dose of 40 mg\] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
61909674|NCT01252667|EXPERIMENTAL|Part 1 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m\^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
61909675|NCT01252667|EXPERIMENTAL|Part 2 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m\^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
61920125|NCT04447872|ACTIVE_COMPARATOR|Luteal estradiol priming protocol|In the luteal phase, the patient will begin Estradiol patches 0.1mg QOD. She will also take daily Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) for three days. With menses, she will begin 150 IU hMG, 300 IU recombinant FSH daily, and oral Clomiphene citrate 100mg qd (for five days). FSH can be titrated per patient response. GnRH antagonist will be started per criteria. 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU) will be administered for ovulation trigger. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
62308134|NCT00201851|OTHER|Immediate Surgery - nonrandomized|Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
62660923|NCT01965873|EXPERIMENTAL|Enteral nutrition|In the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
62660924|NCT01965873|NO_INTERVENTION|Nil-by-mouth treatment|The nil-by-mouth treatment consists intravenous fluid replacement according to assessed needs via peripheral veins. This will include crystalloid (0.9% saline and 5% glucose), and colloid (10% hydroxyethyl starch and 3.5% plasma expander - haemaccel) solutions.
62660925|NCT01113749|EXPERIMENTAL|Decision support|Structured decision aid with prompting to share information in discussion with primary treating health care providers.
62660926|NCT01113749|NO_INTERVENTION|Control|Usual care
62660927|NCT01432327|PLACEBO_COMPARATOR|Control group|This group receives no kind of feedback during the intervention period. The participants wear the SenseWear Armband for 4 weeks and results of the intervention are discussed after the 4 week intervention period.
62660928|NCT01432327|EXPERIMENTAL|Step Group|This group receives feedback about the daily amount of steps by means of a pedometer.
61920126|NCT05405127|ACTIVE_COMPARATOR|Traditional physical therapy|breathing exercises
61920127|NCT05405127|EXPERIMENTAL|Core stability exercise|core stability exercise along with breathing exercises and pain pressure algometer is used
61920128|NCT06322290||pneumococcal, meningococcal, and hemophilus Invasive Bacterial Diseases|Pediatric and adult patients diagnosed with pneumococcal, meningococcal, and hemophilus Invasive Bacterial Diseases, as defined in the Italian Superior Institute of Health (ISS) protocol.
61920129|NCT05242861||Cervix radical BT|
61920130|NCT05242861||Cervix adjuvant BT|
61920131|NCT05242861||Cervix palliative BT|
61920132|NCT05242861||Uterus BT|
62660929|NCT01432327|EXPERIMENTAL|Display Group|Participants receive real time feedback on their energy expenditure, minutes of physical activity and step count by means of the SenseWear Display
62660930|NCT01432327|EXPERIMENTAL|Coaching Group|Participants receive real-time feedback on their energy expenditure, step count and minutes of physical activity by means of the SenseWear Display and weekly meet with a Personal Coach to discuss their progress
62660931|NCT04443829|EXPERIMENTAL|CD19CAR T-cells|Treatment with the ATIMP: CD19CAR T-cells
62660932|NCT05892198|ACTIVE_COMPARATOR|primary closure|The group in which the pits location were in midline ,underwent excision with primary closure
62660933|NCT05892198|ACTIVE_COMPARATOR|Rhomboid flap group|in which more lateral pits and pits located \<2cm from mid line natal cleft
61909676|NCT01252667|EXPERIMENTAL|Part 2 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m\^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
62098337|NCT04908163|EXPERIMENTAL|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group will receive a written nutrition educational information as well as eight online nutritional and cooking classes during the one-month intervention period. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Participants will receive 8 culinary workshops between visit 2 and visit 3. In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Volunteers will be also contacted by phone after 6 months of the end of the intervention to collect information about food and culinary habits."
62098338|NCT02616263|EXPERIMENTAL|Foot Intervention|The intervention is a progressive, home based exercise program aimed to increase ankle and foot plantarflexion muscle strength, increase ankle dorsiflexion and toe flexion range of motion, and to retrain individuals to dorsiflex the ankle while keeping the toes in a neutral position. A trained physical therapist with experience working with older adults with diabetes and foot specific complications will monitor and progress the exercise program assuring participant safety and maximizing exercise benefit.
62660934|NCT05892198|ACTIVE_COMPARATOR|Rotational flap group|in which more lateral pits and pits located \>2cm from mid line natal cleft
62660935|NCT05969691|EXPERIMENTAL|Validation of IDH1 mutations from the radiomics model|In this experiment, we validate the accuracy of radiomics model for IDH1 prediction by puncturing typical targets of gliomas, gene sequencing and quantitative gene analysis.
62660936|NCT01067235|EXPERIMENTAL|BF2.649 + Modafinil placebo|
62660937|NCT01067235|EXPERIMENTAL|BF2.649 + Modafinil|
62660938|NCT04007900|EXPERIMENTAL|Positive Affect Treatment|Individuals randomized to the intervention will participate in 20 therapy visits. Before each therapy visit, the participant will meet briefly with a member of the research staff, who will measure weight (blind to the participant) and administer the CHEDS, PANAS, and a pre-session feedback form that will assess how helpful the skills learned in the prior session had been over the past week. After the session, the participant will complete the post-session feedback form, which will assess how helpful the skills he or she perceived the skills from this session to be. These procedures will take approximately 10 minutes. Each intervention session will take approximately 50 minutes to complete. Therefore, each intervention visit will be approximately 1 hour long. Therapy sessions will take place either in the private office of a study therapist or in a consultation room of the Ambulatory Research Center.
61920133|NCT05242861||Other GO cancer BT|
62660939|NCT04007900|NO_INTERVENTION|Waitlist|For participants randomized to the waitlist control, the opportunity will be offered to participate in the intervention following the second assessment (20 weeks following their Baseline assessment).
62660940|NCT00896259||THA control|those with THA not participating in exercise and education program
62660941|NCT00896259||THA exercise|those with THA and participating in exercise and education program
62466492|NCT02770820|EXPERIMENTAL|Treatment (autologous CD8 T cells)|Beginning 4 weeks after completion of last course of consolidation chemotherapy, patients receive autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes IV over 1-4 hours on day 0 and again after a minimum of 3 weeks. Beginning 6 hours after the second infusion of T cells, patients also receive aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity. Patients who have clinically benefitted from T cell therapy may receive additional infusions of T cells and aldesleukin at the discretion of the PI and the attending physician.
62466493|NCT04383431|EXPERIMENTAL|Standard CXL|Standard epithelium-off CXL, 30 minutes soaking time with riboflavin, 30 minutes UVA corneal irradiation continuous mode.
62466494|NCT04383431|EXPERIMENTAL|Accelerated CXL|Accelerated epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation continuous mode.
62466495|NCT03552250|OTHER|Parenting for Lifelong Health|"Parenting Programme Parenting for Lifelong Health for Young Children (PLH) for parents of children aged 2-9, 12 sessions"
62660942|NCT00896259||healthy control|Healthy control, people with no lower limb gait abnormalities
62660943|NCT03834298|EXPERIMENTAL|Four Food Elimination Diet (FFED)|There is one arm to the study. All participants meeting eligibility will be assigned to intervention / treatment with a previously defined four food elimination diet (FFED) (Aim 1). This is a longitudinal study in which outcome measures including symptoms, QOL and inflammation at baseline and at 2, 4 and 6 weeks after starting stand of care (SOC) FFED will be measured. Participants meeting eligibility for Aim 2 will have foods added back to the diet using a specified protocol.
61909677|NCT01252667|EXPERIMENTAL|Part 2 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m\^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
62098339|NCT02616263|ACTIVE_COMPARATOR|Shoulder Intervention|Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation and a tailored dose of active shoulder motion.
62098340|NCT06708832|EXPERIMENTAL|SIMBA ingestion|Participants will be prescreened for eligibility prior to obtaining informed consent. After informed consent is signed the participant will be screened and requested to complete a set of questionnaires prior to the ingestion of the SIMBA capsules. Then, a saliva and fecal sample will be collected and SIMBA capsules are ingested. The participant will be instructed on capsule ingestion. Retrieval of capsules occurs in their home environment. The participant is expected to continue searching their stool until both capsules are found. A fecal sample will be collected upon retrieval of first SIMBA capsule. After both capsules are collected the participants schedules an appointment to deliver the capsules to the study center and complete the second set of questionnaires. Additionally, saliva sample will be collected again.
62098341|NCT01636362|EXPERIMENTAL|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
62098342|NCT06575517||Group 1|The Group 1 in this trial will consist of a multifaceted bundle of instructions to sites about optimal management of bleeding.
62098343|NCT06575517||Group 2|The Group 2 will be randomized to the standard of care. Standard of care will be left to the discretion of the sites (clusters) participating in the study.
62098344|NCT04550650|NO_INTERVENTION|Controll|No intervention
62098345|NCT04550650|EXPERIMENTAL|Training grp|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
62098346|NCT04550650|EXPERIMENTAL|PNF|2 years long, You have only treated patients with the PNF technique.
62098347|NCT04550650|EXPERIMENTAL|Spinning group|Patients developed endurance for 2 years. They worked using a spinning bike.
62098348|NCT04550650|EXPERIMENTAL|Balance|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance
62098349|NCT06581926||Female|Healthy young women aged 18-30 years
62098350|NCT06581926||Male|Healthy young men aged 18-30 years
62098351|NCT04213846|EXPERIMENTAL|Mobile Alcohol Expectancy Intervention|Participants randomized to the intervention condition will receive twice daily intervention messages for three weeks and have access to other psycho-educational alcohol information.
62098352|NCT04213846|NO_INTERVENTION|Assessment-only Control|Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.
62466496|NCT03929822||Contrast-Enhanced Spectral Mammography (CESM)|Women called back from an abnormal screening mammogram/tomosynthesis exam will be offered CESM as part of their diagnostic work up. The radiologist will interpret the low energy images and record their findings.
62466497|NCT04386759||Healthcare workers|"Up to protocol v2.0: Filling when including a first self-survey concerning the period of the last fifteen days. The following questionnaires will be completed online every week until the end of the study. For healthcare worker who have already presented a symptomatic infection at the time of inclusion, only the self-survey inclusion will be completed, it will relate to the period of fifteen days preceding the diagnosis.~From protocol v3.0: After performing a RT-PCR or an antigenic test for COVID diagnosis, the healthcare workers will complete a unique self-questionnaire about individual and contextual risks factors during the 15 days preceding the test."
62098353|NCT05536284|EXPERIMENTAL|Acute coronary syndrome patients|Acute coronary syndrome patients that are prescribes bisoprolol
62098354|NCT00555347|ACTIVE_COMPARATOR|Armnodafinil|Armodafinil
62098355|NCT00555347|PLACEBO_COMPARATOR|Placebo|
62098356|NCT03165383|ACTIVE_COMPARATOR|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
62098357|NCT03165383|PLACEBO_COMPARATOR|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
62098358|NCT01394770|EXPERIMENTAL|Aliskiren|
62098359|NCT01394770|ACTIVE_COMPARATOR|Amlodipine|
62098360|NCT01886469|EXPERIMENTAL|Adolescents (12-17yrs)|
62098361|NCT01886469|EXPERIMENTAL|Children (6-11 yrs)|
62098362|NCT05931484|ACTIVE_COMPARATOR|Active|Active
62466498|NCT02479893||cold snare polypectomy|CSP: In this group polyps will be removed with the cold snare polypectomy technique, as a single piece. Additionally, a 1-2mm of normal tissue around the small polyp will also be ensnared in the CSP.
62466499|NCT02479893||hot snare polypectomy|HSP: In this group polyps will be removed with the hot snare polypectomy technique as a single piece with a electrosurgical snare and monopolar current with a setting of 30-35 W in the endocut function.
62660944|NCT03591419|EXPERIMENTAL|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
62660945|NCT03591419|ACTIVE_COMPARATOR|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
62660946|NCT04717440||Patients accepting palliative care|Patients included in an early phase trial and accepting palliative care
62660947|NCT04717440||Patients refusing palliative car|Patients included in an early phase trial but refusing palliative care
62660948|NCT02666599|EXPERIMENTAL|18F-FDG PET/CT|18F-FDG radiotracer All patients will undergo a 18F-FDG PET/CT and a surgery with probe detection of β+''
62660949|NCT03831724|EXPERIMENTAL|EndoFLIP™ System|Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
62660950|NCT03132896||Patients with moderate or severe ARDS|
62660951|NCT01363622||SGA|SGA (small for gestational age)
62660952|NCT01363622||LGA|LGA (large for gestational age)
62660953|NCT01363622||AGA|AGA (appropriate-for-gestational-age)
61909678|NCT01337102|OTHER|Physician to receive results|Arm 1 Physician to receive the results of the Lung QoL scale
61909679|NCT01337102|OTHER|Physician Does Not Receive Results|Arm 2 Physician does not receive the results of the Lung QoL scale
62098363|NCT05931484|PLACEBO_COMPARATOR|Placebo|Placebo
62098364|NCT03917381|EXPERIMENTAL|Dose Escalation|Acasunlimab will be administered as monotherapy.
62098365|NCT03917381|EXPERIMENTAL|Expansion|Acasunlimab will be administered as monotherapy or in combination with either docetaxel, pembrolizumab, or pembrolizumab + standard chemotherapy in separate expansion cohorts.
62098366|NCT03371108|EXPERIMENTAL|Gan & Lee Insulin Glargine Injection|Gan \& Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan \& Lee injector pen. Subjects randomized to the Gan \& Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
62466500|NCT02479893||APC polyp destruction-polypectomy|APC: In APC group polyps will be cauterized by application of high power argon plasma coagulation on small waves at 50-60W and flow at 2lt/min,as result the polyp destruction.
62466501|NCT00718926||Sjogren|Sjogren syndrome with dry eye
62466502|NCT00718926||non-Sjogren|dry eye without Sjogren syndrome
61909680|NCT01762020|ACTIVE_COMPARATOR|3M Cavilon No Sting Barrier Film|Two of four regions of the breast will be randomly chosen to receive 3M Cavilon No Sting Barrier Film treatment twice per week.
61909681|NCT01762020|PLACEBO_COMPARATOR|Standard preparations|Standard treatment
61909682|NCT00395343|EXPERIMENTAL|1|sitagliptin
61909683|NCT00395343|PLACEBO_COMPARATOR|2|Placebo
61909684|NCT01479283|ACTIVE_COMPARATOR|Short-Arm Antibiotic Regimen|"Intervention: 24-Hour Prophylactic Cefazolin\* Antibiotic Regimen~\*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
61909685|NCT01479283|EXPERIMENTAL|Long-Arm Antibiotic Regimen|"Intervention: 5-Days Prophylactic Cefazolin\* Antibiotic Regimen~\*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
61909686|NCT06403488|EXPERIMENTAL|femara 1x3|Femara 2.5 mg (Novartis pharma ) 3 tablets per day starting from the second day of the menstrual cycle for 5 days
61909687|NCT06403488|EXPERIMENTAL|femara 2x2|(Femara 2.5 mg (Novartis pharma )2 tablets twice daily for 5 days starting from the second day of the cycle
61909688|NCT03387111|EXPERIMENTAL|NANT Squamous Cell Carcinoma (SCC) Vaccine|Combination of agents were administered in this study: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.
62098367|NCT03371108|ACTIVE_COMPARATOR|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
62098368|NCT00418847|EXPERIMENTAL|1|
62098369|NCT03034733|EXPERIMENTAL|dexamethasone 0,15 mg/kg|single-dose intravenous dexamethasone 0,15 mg/kg, intraoperative
62098370|NCT03034733|EXPERIMENTAL|dexamethasone 0,25 mg/kg|single-dose intravenous dexamethasone 0,25 mg/kg, intraoperative
62098371|NCT03034733|PLACEBO_COMPARATOR|Sodium Chloride, (24)NaCl 0,9%|single-dose intravenous saline, intraoperative
62098372|NCT00589732|EXPERIMENTAL|Valsartan treatment gorup|Valsartan 160mg per day group
62098373|NCT00589732|NO_INTERVENTION|No Valsartan treatment group|No valsartan treatment
62466503|NCT00718926||Short-BUT|Dry eye by shortened tear break up time
62466504|NCT00718926||control|normal patients
62098374|NCT05245656|EXPERIMENTAL|RB/RBAC alternating|"Every 4 weeks for 6 cycles~RB (1st, 3rd, and 5th cycles)~* Rituximab + Bendamustine~RBAC (2nd, 4th, and 6th cycles)~* Rituximab + Bendamustine + Cytarabine"
62098375|NCT05245656|ACTIVE_COMPARATOR|RB|"Every 4 weeks for 6 cycles~- Rituximab + Bendamustine"
62098376|NCT03905135|EXPERIMENTAL|1- Experimental Treatment: Dose Escalation|Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at escalating doses of 1, 2, 3 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with avelumab by intravenous (IV) infusion at a dose of 10mg/kg on Day 8 and 22 of each cycle, to determine maximum tolerated dose (MTD)
62098377|NCT03905135|EXPERIMENTAL|2- Experimental Treatment: Dose Expansion|Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at the maximum tolerated dose (MTD) on days 1-5 of cycles 1-6 with avelumab at 10mg/kg on Day 8 and 22 of each cycle
62660954|NCT02056678|ACTIVE_COMPARATOR|IV acetaminophen, OSA, laparoscopic cholecystectomy|IV acetaminophen 1000mg to be administered to obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy
62098378|NCT03136276|ACTIVE_COMPARATOR|IPS Empress CAD|Leucite Based glass Ceramics which is etchable ceramics and proved to have good success rate if used for laminate veneers
62098379|NCT03136276|EXPERIMENTAL|polished Celtra Duo|Zirconia reinforced lithium silicate, it is a recent material with glass ceramics enriched with 10% zirconia that offers high strength properties
62098380|NCT04699799|EXPERIMENTAL|record brain activity while smelling odors|Record brain activity while smelling odors
62660955|NCT02056678|NO_INTERVENTION|OSA, laparoscopic cholecystectomy, narcotics|No IV acetaminophen in obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy; patients will receive other modalities for pain control primarily including IV narcotics
62098381|NCT02487641||Moderat Obesity|60 persons with BMI between 30-34.49 kg/m2
62098382|NCT02487641||Sever Obesity|60 persons with BMI above 34.49 kg/m2
62098383|NCT02487641||Normal weighted|60 persons with BMI between 18.5-24.49 kg/m2
62098384|NCT05630339|EXPERIMENTAL|Intervention group|Will receive 1.2 g of magnesium chloride (equivalent to 360 mg of magnesium elemental) + 4000 IU of vitamin D once a day, for four months.
62098385|NCT05630339|PLACEBO_COMPARATOR|Control group.|Will receive inert placebo for four months.
61909689|NCT01517191||Influenza Positive Case|Influenza cases are hospitalized adults who have tested positive for influenza.
61909690|NCT01517191||Influenza Negative Control|Control Controls are hospitalized adults who have tested negative for influenza.
61909691|NCT05145270|ACTIVE_COMPARATOR|Escitalopram|The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.
61909692|NCT05145270|EXPERIMENTAL|Escitalopram plus Sulforaphane|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
61909693|NCT05145270|EXPERIMENTAL|Escitalopram plus rTMS|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day."
61909694|NCT05323825|EXPERIMENTAL|Experimental group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
61909695|NCT05323825|PLACEBO_COMPARATOR|Control group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
62098386|NCT05804396|EXPERIMENTAL|Active stimulation|Relivion® device- Active stimulation
62098387|NCT06300398|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Single oral doses (6 dose cohorts) of IAMA-6 liquid suspension or placebo-to-match IAMA-6 liquid suspension in fasted participants
61909696|NCT03894371|OTHER|Thermage|Subjects will undergo treatment with the Thermage FLX system using a 900 pulse, 4cm2 Total Tip to treat the face and neck and a 450 pulse, 0.25cm2 tip to treat the upper and lower eyelids.
61909697|NCT02491229|OTHER|"Hepafast"|"This group consumes three portions of Hepafast and additionally 200 kcal of vegetables for two weeks. In the following ten weeks, they consume two portions of Hepafast and one meal which follows the instructions of the Low Glycemic and Insulinemic Diet (LOGI)."
61909698|NCT02491229|OTHER|Control|This group follows the instruction of the LOGI diet for the entire 12 weeks
61909699|NCT03339297|EXPERIMENTAL|Defibrotide Prophylaxis|Standard of Care Immunoprophylaxis + Defibrotide
61909700|NCT03339297|ACTIVE_COMPARATOR|Standard of Care|Standard of Care Immunoprophylaxis Alone
62098388|NCT06300398|EXPERIMENTAL|Part B: Food Effect (FE)|Single oral dose (1 dose cohort) of IAMA-6 liquid suspension in fed participants
62098389|NCT06300398|EXPERIMENTAL|Part C: Multiple Ascending Dose (MAD)|Multiple oral doses (3 dose cohorts) of IAMA-6 liquid suspension or placebo-to-match IAMA-6 liquid suspension for 7 days in fasted or fed participants
62098390|NCT03566680|EXPERIMENTAL|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
62660956|NCT01680913|EXPERIMENTAL|Spinal with ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
62660957|NCT01680913|ACTIVE_COMPARATOR|Spinal by palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
62660958|NCT01047501|PLACEBO_COMPARATOR|Placebo|
62660959|NCT01047501|EXPERIMENTAL|AMR101 (ethyl icosapentate) - 2 g/day|
62660960|NCT01047501|EXPERIMENTAL|AMR101 (ethyl icosapentate) - 4 g/day|
62660961|NCT04155554|EXPERIMENTAL|Bictegravir/emtricitabine/tenofovir alafenamide|Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD
61909701|NCT05270447|EXPERIMENTAL|Total laparoscopic hysterectomy (TLH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
62098391|NCT03861455|EXPERIMENTAL|dupilumab group|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
62098392|NCT03861455|PLACEBO_COMPARATOR|placebo group|patient receive placebo
62294243|NCT03721068|EXPERIMENTAL|iC9.GD2.CAR.IL-15 T-cells|The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10\^6 cells/kg, 1.0 x 10\^6 cells/kg, 1.5 x 10\^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10\^6 cells/kg.
62294244|NCT04766866|NO_INTERVENTION|Non-intervention or non-reveal group|Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery
61909702|NCT05270447|OTHER|Total laparoscopic hysterectomy (TLH) control group|routine care+ advising
61909703|NCT05270447|EXPERIMENTAL|Total abdominal hysterectomy (TAH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
61909704|NCT05270447|OTHER|Total abdominal hysterectomy (TAH) control group|routine care+ advising
61909705|NCT00819793|EXPERIMENTAL|CentriMag Ventricular Assist System|All patients meeting the patient selection criteria will be treated with the CentriMag Ventricular Assist System.
61909706|NCT00494767|EXPERIMENTAL|GW869682 1000 mg thrice daily (TID)|Subjects will be randomized to receive GW869682 1000 mg TID
62098393|NCT03382743|ACTIVE_COMPARATOR|Group A (Lidocaine group)|5 sprays of endocervical Lidocaine 10% spray ( AstraZeneca, bedforshire) are used 3 minutes before office hysteroscopy
62098394|NCT03382743|NO_INTERVENTION|Group B (control group)|office hysteroscopy is done without analgesia
62098395|NCT06271356|EXPERIMENTAL|BC-Navi|Apply TCI's patient navigation-and-coaching program and its website/mobile app (Breast Cancer-Navigate) platform to improve timely initiation to patient adjuvant chemotherapy treatment among diverse breast cancer patients.
62294245|NCT04766866|EXPERIMENTAL|Intervention group or reveal group|A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
62294246|NCT04022486||Children admitted in the PICU for severe bronchiolitis|Children admitted in the Pediatric Intensive Care Unit (PICU) for severe bronchiolitis between January 1st, 2010 and April 30th, 2018
62660962|NCT04155554|ACTIVE_COMPARATOR|Dolutegravir/lamivudine/abacavir|Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD
62660963|NCT00445718||Observational|Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.
62660964|NCT04329455||Intervention group|
62660965|NCT02713620|PLACEBO_COMPARATOR|Healthy|"the Healthy group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
62660966|NCT02713620|ACTIVE_COMPARATOR|HIV-Group1|"the Standard doses group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
61909707|NCT00494767|EXPERIMENTAL|GSK189075 250 mg TID|Subjects will be randomized to receive GSK189075 250 mg TID
61909708|NCT00494767|PLACEBO_COMPARATOR|GW869682-Placebo TID|Subjects will be randomized to receive Placebo matching GW869682 for TID
61909709|NCT00494767|PLACEBO_COMPARATOR|GSK189075-Placebo TID|Subjects will be randomized to receive Placebo matching GSK189075 for TID
61909710|NCT04769999|EXPERIMENTAL|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
62098396|NCT05546099|EXPERIMENTAL|Self-management|Patients monitor their home BP and self manage their BP medications based on a predesigned titration protocol and under the guidance of the clinical pharmacist.
62098397|NCT05546099|ACTIVE_COMPARATOR|Self-monitoring|Patients monitor their home BP and contact their provider if the BP is above the goal.
62098398|NCT03794778|EXPERIMENTAL|study group|pegylated liposomal doxorubicin 30 mg/m2, i.v.,d1; carboplatin AUC 5,i.v.,d1; once every 21days, 3\~6 cycles for early stage patients and 6 cycles for late stage.
62098399|NCT03794778|ACTIVE_COMPARATOR|chemotherapy|paclitaxel 175 mg/m2, i.v.,d1; carboplatin AUC 5, i.v.,d1; once every 21days, 3\~6 cycles for early stage patients and 6 cycles for late stage.
62098400|NCT02775435|EXPERIMENTAL|Pembrolizumab + Chemotherapy Combo|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (\~ 2 years) PLUS Investigator's choice of paclitaxel (200 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m\^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin area under the curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
62098401|NCT02775435|ACTIVE_COMPARATOR|Placebo + Chemotherapy|Participants receive normal saline as placebo by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles (\~ 2 years) PLUS Investigator's choice of paclitaxel (200 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m\^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
62098402|NCT03040193|EXPERIMENTAL|Nebulized Lignocaine|4% Lignocaine administered as nebulization for topical anaesthesia during bronchoscopy procedure
62098403|NCT03040193|PLACEBO_COMPARATOR|Nebulized Saline|Normal Saline administered as nebulization for topical anaesthesia during bronchoscopy procedure
62098404|NCT00854139|EXPERIMENTAL|Bone marrow and renal transplant|Cyclophosphamide, anti-thymocyte globulin, thymic irradiation conditioning and kidney transplant and bone marrow transplant from a related donor for patients with multiple myeloma and end stage renal disease with cyclosporine for graft versus host disease prophylaxis
62098405|NCT04516811|EXPERIMENTAL|Arm 1|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
62098406|NCT04516811|PLACEBO_COMPARATOR|Arm 2|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines.
62098407|NCT06378879|ACTIVE_COMPARATOR|Continuous infusion (CI group) of propofol|CI was defined by continuous propofol infusion at a 3 mg/ kg/h rate with induction using benzodiazepine (2 mg dormicum i.v.) to evaluate the effect of the drug and assess sedation induction time, total dose of propofol, recovery time, quality of sedation.
62098408|NCT06378879|ACTIVE_COMPARATOR|Intermittent bolus injection (BI group) of propofol|BI was defined by intermittent use of 20 mg propofol boluses on demand, with a minimum period of 30 seconds between boluses to evaluate the effect of the drug and assess sedation induction time, total dose of propofol, recovery time, quality of sedation.
62294247|NCT00928811|OTHER|Control|Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
62294248|NCT00928811|EXPERIMENTAL|Simulect|"Simulect (basiliximab) intravenously day of transplant and day 4.~Chronic Simulect (basiliximab) administration monthly for one year duration.~Concomitant decrease in Prograf administration."
62294249|NCT03399383|OTHER|Patient education (longitudinal analysis)|Patients with adrenal insufficiency complete a questionnaire before and 6 months after participation in a standardised patient education.
61909711|NCT03565367|EXPERIMENTAL|Healthy Volunteers|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes.
62098409|NCT02871765|EXPERIMENTAL|education group|In education group, each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department by researchers. Three months later, participants in the education group received a follow-up phone call in order to clarify any questions related to the brochure. All participants completed posttest at 6-month follow-up.
62098410|NCT02871765|NO_INTERVENTION|control group|The control group received the brochure only.
62098411|NCT06311227|EXPERIMENTAL|Treatment (venetoclax)|Patients receive venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection throughout the study. Patients may undergo bone marrow biopsy and/or aspiration on study.
62098412|NCT00893217|ACTIVE_COMPARATOR|Arm 1|
62098413|NCT00893217|EXPERIMENTAL|Arm 2|
62098414|NCT05939947|EXPERIMENTAL|ALE.F02|Patients will receive 3 doses of ALE.F02 administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.
62098415|NCT05939947|PLACEBO_COMPARATOR|Placebo|Patients will receive 3 doses of matching placebo administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.
62294250|NCT03240900|EXPERIMENTAL|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
62294251|NCT03240900|PLACEBO_COMPARATOR|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
62294252|NCT02314806|EXPERIMENTAL|Irrigation with Gentamicin solution|The surgical bed is irrigated with a gentamicin solution
62294253|NCT02314806|EXPERIMENTAL|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
62294254|NCT02314806|PLACEBO_COMPARATOR|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
62098416|NCT06711224|EXPERIMENTAL|Digital intervention|The digital intervention includes a mobile app and weekly phone calls with a therapist.
62098417|NCT01111890|EXPERIMENTAL|Azarga|Azarga (brinzolamide 1% / timolol 0.5%)
62660967|NCT02713620|ACTIVE_COMPARATOR|HIV-Group 2|"the Four doses group receiving four intramuscular doses of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
62098418|NCT01111890|ACTIVE_COMPARATOR|Cosopt|Cosopt (dorzolamide 2% / timolol 0.5%)
62098419|NCT05913323||COPD sub-group: GOLD 1 COPD|"A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD.~Thus, there will be a 'mild' (GOLD 1) COPD sub-group."
62098420|NCT05913323||COPD sub-group: GOLD 4 COPD|"A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD.~Thus, there will be a 'very severe' (GOLD 4) COPD sub-group."
62098421|NCT02386371|EXPERIMENTAL|surgery and Intra Operative Radiotherapy|"Surgery :~Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.~Intra Operative Radiotherapy (IORT):~After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure."
62098422|NCT05814640|EXPERIMENTAL|Fluoxetine|"Dosage form: po Dosage: 10-60mg Frequency: qn Course of treatment: 8 weeks. At week 8, patients will be evaluated as in remission or not in remission. Patients who are not in remission will be randomized to phase II treatment based on the patient's wishes."
62098423|NCT05814640|EXPERIMENTAL|group cognitive behavioral therapy（GCBT）|"GCBT was administered in addition to fluoxetine and consisted of 11 sessions for 8 weeks. It lasts 90 to 120 minutes, once or twice a week. At week 8, patients will be evaluated as in remission or not in remission. Patients who are not in remission will be randomized to phase II treatment based on the patient's wishes."
62098424|NCT05814640|EXPERIMENTAL|Sertraline|dosage form: po dosage:25-200mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given Sertraline as a switching treatment to fluoxetine.
62098425|NCT05814640|EXPERIMENTAL|Votioxetine|dosage form: po dosage: 10-20mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given votioxetine as a switching treatment to fluoxetine.
62098426|NCT05814640|EXPERIMENTAL|Duloxetine|dosage form: po dosage: 60-120mg frequency: qn duration: At Week 8, patients assessed as 'non-remission' will be given duloxetine as an add-on treatment to fluoxetine.
62098427|NCT05814640|EXPERIMENTAL|Aripiprazole|dosage form: po dosage: 2.5-15mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given aripiprazole as an add-on treatment to fluoxetine.
62098428|NCT05814640|EXPERIMENTAL|Lithium carbonate|dosage form:po dosage: 125-500mg frequency: qn duration: At Week 8, patients assessed as 'non-remission' will be given lithium carbonate as an add-on treatment to fluoxetine.
62098429|NCT05814640|EXPERIMENTAL|Olanzapine|dosage form:po dosage: 1.25-10mg frequency:qn duration: At Week 8, patients assessed as 'non-rremission' will be given olanzapine as an add-on treatment to fluoxetine.
62098430|NCT06713148|EXPERIMENTAL|Oncolytic Virus injection(IDOV-SAFETM)|"Intratumoral administration of IDOV-SAFETM every 2 weeks for patients with advanced solid tumors.~Dose cohorts: 1x10\^8 PFU、3x10\^8 PFU、7x10\^8 PFU 、1x10\^9 PFU and 3x10\^9 PFU"
62294255|NCT02978937||Metabolically healthy and abnormal obese|Obese patients divided into two groups according to their metabolic profile (healthy vs unhealthy)
62294256|NCT04360265|OTHER|Cohort 1|Participants who have completed a prior clinical trial involving the administration of ABO-102 and are able to comply with onsite scheduled visits and assessments. Select participants may receive adjuvant IS therapy.
62660968|NCT02713620|ACTIVE_COMPARATOR|HIV-Group 3|"the Four double doses group receiving four intramuscular double doses (40 μg) of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
62294257|NCT04360265|OTHER|Cohort 2|Participants who have completed a prior clinical trial involving the administration of ABO-102 and who cannot participate in Cohort 1. Participants will partake in a reduced number of assessments, performed either onsite or at home via a combination of telehealth and home healthcare visits.
62294258|NCT01938287|EXPERIMENTAL|SENSIMED Triggerfish|
62660969|NCT04383678||COVID-19 positive patients|
62660970|NCT05542641|EXPERIMENTAL|real rTMS|verum rTMS to the DLPFC, 1500 1Hz pulses at 120% RMT, 25 minutes total
62660971|NCT05542641|SHAM_COMPARATOR|sham rTMS|sham rTMS to the DLPFC, 1500 1Hz pulses at 120% RMT, 25 minutes total
62466505|NCT01060618|EXPERIMENTAL|Maraviroc + Trofile ESTA®|the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response
62660972|NCT04664114|EXPERIMENTAL|Experimental group|Both the evaluation of the fetus and the ultrasound for visual purposes took 15-20 minutes in total. These pregnant women were asked to bring their mobile phones with them during delivery. When the birth of the pregnant woman started, she was hospitalized by the third researcher. The follow-up and deliveries during the labor were carried out by the 3rd and 4th researchers. With an application installed on the pregnant woman's phone, these two-dimensional images were transformed into three-dimensional images and the pregnant women were watched consecutively with the VR Box 3D virtual reality glasses. In cases where the program was not compatible with the phone of the pregnant woman, the researcher was watched by the midwife. The total image viewing time was recorded.
62660973|NCT04664114|NO_INTERVENTION|Control Group|Only one pregnant woman was included in the study at the same time in order to avoid any interruption in the follow-up of the pregnant women. VAS was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale and the Perinatal Anxiety Screening Scale were applied.
62098431|NCT05976854|EXPERIMENTAL|Pain neuroscience education (PNE)|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 PNE lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler \& Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
62098432|NCT05976854|OTHER|Prenatal education (PE)|Patients assigned to the PE group will receive different content on standard PE based on the Pregnancy and Postpartum Clinical Practice Guide, consisting of general information about pregnancy (visits and monitoring of pregnancy, diet, phases of delivery, lactation, etc.), as well as specific recommendations for lumbopelvic pain associated with pregnancy. These contents will be developed by midwives from the participating hospitals. Participants will receive 12 educational sessions, with an estimated duration of 10 minutes each.
62098433|NCT01796977|ACTIVE_COMPARATOR|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing is a closed-cell foam wound dressing enriched with gaseous and dissolved oxygen for use in the management of wounds.
62098434|NCT01796977|PLACEBO_COMPARATOR|Standard Gauze Dressing|A sterile 4x4 covered by an adhesive Tegaderm will serve as the comparator for this study.
62098435|NCT04141163|EXPERIMENTAL|Metformin|Subjects randomized to metformin will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
62098436|NCT04141163|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
62098437|NCT05908448||13-17 year old participants|13-17 year old participants
62098438|NCT05908448||7-12 year old participants|7-12 year old participants
62098439|NCT05908448||2-6 year old participants|2-6 year old participants
62098440|NCT04729543|EXPERIMENTAL|Adoptive therapy with autologous MC2 TCR T cells|"* Accelerated titration phase I design and a subsequent single arm phase II study~* Prior to T cell transfer (day 0), patients will be treated with valproic acid (dose 50 mg/kg/d, 7d; days -9 to day -3) and 5' azacytidine (dose 75mg/m2/d, 7d; days -9 to day -3)~* Phase I: patients will be treated with one single intravenous administration of MC2 TCR T cells at 5 different escalated doses of 5x10E7, 5x10E8, 5x10E9,1.0x10E10, and the total number of cultured TCR T cells (i.e., usually 1.0-5.0 x10E10 TCR T cells). MC2 TCR T cell infusions will be supported by low dose of IL-2 administrations (s.c. 5x10E5 IU/m2 2qd for 5 days)~* T cells will be processed using IL-15 and IL-21 to generate young T cells"
62294259|NCT05073185||Children with healthy weight status|100 child-parent dyads (200 total) will be followed for 1 year to determine the behavioral and neural impact of food and toy advertising exposure. Children will be 7-9 years old, with body mass index \< 85th % for age and sex, and either with a mother who has BMI of 30 kg/m-sq or over or a BMI of 25 kg/m-sq or less.
62294260|NCT00521781|EXPERIMENTAL|1|Treatment will be Abraxane/hormonal therapy (LHRH Agonist) for four nine-week cycles, followed by Total androgen blockade therapy (LHRH Agonist+ Anti-androgen) for 2 years from the time the hormonal therapy was started.
62098441|NCT05207787|EXPERIMENTAL|Multiple doses of HS-10365 and 160mg BID (recommended Phase 2 dose)|Phase 1 : Multiple doses of HS-10365 for oral administration. Phase 2 : 160 mg BID of HS-10365
62098442|NCT04467762||Meningoencephalitis (ME-PED)|"* pediatric patients between 0 and 17 years of age~* admission to hospital with suspected meningoencephalitis~* confirmed meningoencephalitis within 24 hours after admission"
62098443|NCT04467762||Sepsis-associated encephalopathy (SAE-PED)|"* pediatric patients between 0 and 17 years of age~* admission to hospital with suspected sepsis~* confirmed sepsis within 24 hours after admission or time of diagnosis"
62660974|NCT01926535|EXPERIMENTAL|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
62098444|NCT04467762||Control group (CON-PED)|"* pediatric patients between 0 and 17 years of age~* exclusion of neurocognitive impairment~* admission to hospital for minor surgery (e.g. herniotomy, adenoidectomy, fractures treated by osteosynthesis) or for hemangioma treated by propranolol"
62098445|NCT06371482|EXPERIMENTAL|D with CRT|The patients with limited stage small cell lung cancer receive durvalumab combined with chemoradiotherapy.
62098446|NCT00945477|EXPERIMENTAL|Advanced prostate cancer, treatment, pazopanib|Pazopanib
62660975|NCT01926535|ACTIVE_COMPARATOR|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
62660976|NCT00696527||1|
62660977|NCT02805491||with hypospadias|parent-child triads as cases (male newborns with hypospadias)
62660978|NCT02805491||without hypospadias|parent-child triads as controls (male newborns without hypospadias)
62660979|NCT05415007|EXPERIMENTAL|GOLD Psychosocial Program|Participant will receive a 2-hour interventional session. Its content will consist of two modules: (1) psychoeducation and coping, providing information in content areas such as side effects of cancer treatments, fever protocols, role disruption and (2) stress, triggers, and self care, where caregivers will be briefed on symptoms of and reactions to traumatic stress in order to help parents accurately label thoughts and emotions related to their child's cancer diagnosis.
62660980|NCT05415007|ACTIVE_COMPARATOR|Treatment-as-Usual (TAU)|
62660981|NCT03787407|EXPERIMENTAL|Mindfulness training with neurofeedback|mindfulness training with neurofeedback using mobile application instruction and review of the application will be provided
62660982|NCT03787407|ACTIVE_COMPARATOR|Mindfulness training|mindfulness training using mobile application instruction and review of the application will be provided
62660983|NCT03787407|NO_INTERVENTION|Self-care|
62660984|NCT00580086||1|
62660985|NCT02456064|EXPERIMENTAL|Lifestyle counseling|"In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions."
62660986|NCT02456064|NO_INTERVENTION|Normal group|In this group will be controlled as usual in the consultations.
62660987|NCT03834012|EXPERIMENTAL|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 ug per day Daily dose of Beclomethasone 800 ug 4 inhalations 100 μg ex-valve 2 times a day for 6 weeks
62660988|NCT03834012|ACTIVE_COMPARATOR|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day 4 inhalations 80 μg ex-actuator 2 times a day for 6 weeks
62660989|NCT03834012|PLACEBO_COMPARATOR|Placebo|Intervention: Drug: placebo 4 inhalations 2 times a day for 6 weeks
62098447|NCT03623646|OTHER|Arm A (standard arm): Chemoradiotherapy arm|
62098448|NCT03623646|EXPERIMENTAL|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
62098449|NCT05166343|NO_INTERVENTION|Standard of Care|All POHCA events will be handled per standard of care of epinephrine administration via intravenous or intraosseous (IV/IO) based on patient estimated weight.
62294261|NCT01495988|ACTIVE_COMPARATOR|Vemurafenib/Cobimetinib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
62660990|NCT03834012|EXPERIMENTAL|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 6 weeks Intervention: Drug: Placebo 2 inhalations 2 times a day for 6 weeks
62660991|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
61909712|NCT03565367|EXPERIMENTAL|Known CNS Malignancy|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).
62660992|NCT06249971|ACTIVE_COMPARATOR|Split thickness skin graft alone|"Intra-individual approach Patient has 2 comparable (near) full thickness skin defects or 1 (near) full thickness skin defect that can be divided into 2 comparable regions.~Randomization: the defect randomized in this arm receives only a skin graft."
62660993|NCT06249971|EXPERIMENTAL|Split thickness skin graft + Glyaderm|"Intra-individual approach Patient has 2 comparable (near) full thickness skin defects or 1 (near) full thickness skin defect that can be divided into 2 comparable regions.~Randomization: the defect randomized in this arm receives a skin graft combined with Glyaderm"
62660994|NCT02517788|EXPERIMENTAL|Part A: Interferon beta-1a in HSA-free solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a without albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
62660995|NCT02517788|EXPERIMENTAL|Part A: Interferon beta-1a combined with HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
62660996|NCT02517788|ACTIVE_COMPARATOR|Part A: Interferon beta-1a in marketed HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU original interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
62660997|NCT02517788|EXPERIMENTAL|Part B: Interferon beta-1a in HSA-free solution|Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU biosimilar interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose \[i.e. dose 1 and 3\] and left side for even dose \[i.e. dose 2 and 4\]).
62660998|NCT02517788|ACTIVE_COMPARATOR|Part B: Interferon beta-1a in marketed HSA+ solution|Part B: Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU original interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose \[i.e. dose 1 and 3\] and left side for even dose \[i.e. dose 2 and 4\]).
62660999|NCT06530329|EXPERIMENTAL|Group 1|Classical massage group
62661000|NCT06530329|EXPERIMENTAL|Group 2|Classical massage + ischemic compression group
62661001|NCT05548907|EXPERIMENTAL|Sleep restriction treatment|In this condition participants receive a behavioral sleep restriction intervention for six weeks
62661002|NCT05548907|PLACEBO_COMPARATOR|Sleep monitoring|In this control condition people fill out a sleep diary for six weeks
62661003|NCT06544538||AKI Group|AKI 1-3 in the first 48 hours after cardiac arrest according to KDIGO 2012 criteria
62661004|NCT06544538||Non-AKI Group|Those who did not develop AKI in the first 48 hours after cardiac arrest according to KDIGO 2012 criteria
62661005|NCT00923312|EXPERIMENTAL|CV9201|CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.
62661006|NCT02556450|EXPERIMENTAL|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
62661007|NCT02556450|NO_INTERVENTION|Control group|Only background treatment
62661008|NCT03817983||MRE review for axSpA|Review of MRE scan for evidence of axSpA in Crohn's disease patients
62661009|NCT05893641|ACTIVE_COMPARATOR|A regular training volume|They will maintain their training volume of 35 h/week
62661010|NCT05893641|ACTIVE_COMPARATOR|A lower exercise volume group|They will conduct 85% of the control group weekly training volume (i.e., 30h/week)
62661011|NCT05893641|ACTIVE_COMPARATOR|A longer rest group|They will maintain the 35 h/week of exercise training, but with longer rest between exercise sessions
62661012|NCT04581512|EXPERIMENTAL|Module 1 EP0042|Establishing the safety of EP0042 as a monotherapy and establishing an appropriate dose to take forward into subsequent modules.
62661013|NCT02558569|EXPERIMENTAL|Levobupivacaine|Scalp nerve block with 0.5% Levobupivacaine adds up to intravenous fentanyl for intraoperative pain control during supratentorial craniotomy with brain tumor removal. The scalp block includes 4-6 nerves which give sensory supply to related location with the use of total 10-15 ml of 0.5% Levobupivacaine. Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given. is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
62661014|NCT02558569|SHAM_COMPARATOR|NSS|Scalp nerve block with 10-15 ml of 0.9% sodium chloride(NaCl), or normal saline (NSS) includes 4-6 nerves which give sensory supply to related location (sham block). Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
62661015|NCT06134700|EXPERIMENTAL|Low pressure pneumoperitoneum laparoscopic nephrectomy|Pneumoperitonuem Pressure of 8 - 10 mmHg
62661016|NCT06134700|ACTIVE_COMPARATOR|Standard pressure pneumoperitoneum laparoscopic nephrectomy|Pneumoperitonuem Pressure of 12 - 15 mmHg
62661017|NCT02520973|EXPERIMENTAL|Universal screening|All HIV + pregnant women will be asked to give a sputum sample for TB prior to TB symptom screen
62661018|NCT02520973|ACTIVE_COMPARATOR|Symptom- directed screening|Only symptomatic HIV+ pregnant women will be asked to give a sputum sample for TB
62466506|NCT04786080|EXPERIMENTAL|Parent Positive|This is an app developed for use on a smartphone providing a flexible digital space where parents can get support and advice to help them manage their children's behaviour. The app will be free and parents will be able to access the information when needed and in the order they choose. Parents in the intervention group will receive access during the immediate post-randomisation period.
62661019|NCT01288430|EXPERIMENTAL|DS-2248|"Study Part 1: DS-2248 oral capsule(s) of increasing strength in a dose escalation study in subjects with advanced solid tumors, administered once daily in 21-day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression is observed.~Study Part 2: DS-2248 oral capsule(s) dose of 4.5 mg/m\^2, in subjects with non-small cell lung cancer who have developed acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors or whose tumors carry an ALK translocation and are resistant to ALK inhibitor therapy, administered once daily in 21 day-cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed."
62661020|NCT03801252|EXPERIMENTAL|Cefazolin + Azithromycin|Women will be randomized 1:1 to receive cefazolin 2 grams intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and azithromycin 500 mg intravenously once at the start of the labor induction
62661021|NCT03801252|PLACEBO_COMPARATOR|Placebo + Placebo|Women will be randomized 1:1 to receive placebo intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and placebo intravenously once at the start of the labor induction
61909713|NCT00709709|EXPERIMENTAL|1|Scan
61909714|NCT05796830|ACTIVE_COMPARATOR|Intervention Group|Before the operation, the rules of the puzzle will be explained to the patients in the intervention group and how it will be applied will be shown. Then, Patient Diagnosis Form, Mini-Mental State Test and Quality of Life Scale will be administered.On the 1st, 2nd and 3rd days after the surgery, the rules of the puzzle will be reminded again and the puzzle will be applied to the patients once a day. After the puzzle application on the 1st, 2nd and 3rd days after the surgery, the Mini-Mental State Test will be applied to the patients. Postoperative Recovery Index and Quality of Life Scale will be applied on the 3rd postoperative day.
61909715|NCT05796830|NO_INTERVENTION|Control Group|Patients in the control group will be followed according to routine clinical procedure. Since there are no procedures or interventions in clinical procedures, only patient monitoring will be performed. The patients in the control group will also be followed and evaluated with the same forms at the same time.
61909716|NCT02396160|ACTIVE_COMPARATOR|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
62098450|NCT05166343|OTHER|Intramuscular Epinephrine Dose|"POHCA events will be handled per standard of care, however, first dose epinephrine administration will be via intramuscular (IM) autoinjector and/or pre-filled syringes. Dosing will be dependent on weight as follows:~* 3-\<5kg=0.3mg IM epinephrine~* 5-\<10kg=0.5mg IM epinephrine~* 10-\<20kg=1.0mg IM epinephrine~* 20-\<30kg=2.0mg IM epinephrine~* 30kg=3.0mg IM epinephrine"
62098451|NCT04413279|ACTIVE_COMPARATOR|Lipiflow Only Group|Patients with dry eye disease Lipiflow only
62098452|NCT04413279|EXPERIMENTAL|Lipiflow + Dextenza Group|Patients with dry eye disease Lipiflow + Dextenza
62661022|NCT00485303|EXPERIMENTAL|Abiraterone|Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
62661023|NCT01940588||Neuropsychoanalytic treatment|Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach.
62661024|NCT06265025|EXPERIMENTAL|Treatment (GM103): Part A_Dose escalation|"Multiple escalating dose levels of GM103~(1 x 10\^11 vp, 3 x 10\^11 vp, 1 x 10\^12 vp, 3 x 10\^12 vp)"
61909717|NCT02396160|PLACEBO_COMPARATOR|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
62098453|NCT05167747|ACTIVE_COMPARATOR|Active Comparator|Dietary supplement
62098454|NCT05167747|PLACEBO_COMPARATOR|Placebo comparator|Placebo
62098455|NCT00117377|EXPERIMENTAL|1|Pimecrolimus
62098456|NCT00117377|PLACEBO_COMPARATOR|2|Placebo control twice daily application
62098457|NCT00359957|EXPERIMENTAL|1|ADDED condition - behavioral intervention for modifying diet and physical activity, with greater emphasis on physical activity than the STANDARD condition
62308135|NCT03478683|EXPERIMENTAL|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
62098458|NCT00359957|ACTIVE_COMPARATOR|2|STANDARD condition - behavioral intervention for modifying diet, with little emphasis on physical activity
62661025|NCT06265025|EXPERIMENTAL|Treatment (GM103): Part B_Dose expansion|"Dose expansion study of GM103 as monotherapy~(GM103 RP2D for HNC, GM103 RP2D for CRC)"
61909718|NCT05212857|EXPERIMENTAL|systemic treatment combined with radical treatment and radiotherapy|"All recruited participants would receive long-term and unified systemic treatment. Systemic treatment is defined as chemical castration plus new-generation anti-androgen therapy.~For the primary lesion:~The preferred local treatment for primary lesion is radical prostatectomy. Patients who refuse surgery or whose tumors cannot be surgically resected after 3 months' systemic treatment could receive radical radiotherapy.~For the metastatic lesion:~Radiotherapy for metastatic lesions would be performed between 4 weeks and 24 weeks after the local treatment for primary lesion. Stereotactic body radiation therapy (SBRT) is preferred, which could treat all the detected lesions at once or in stages."
62098459|NCT05566405|ACTIVE_COMPARATOR|General Anaesthesia|Patients undergoing open retropubic radical prostatectomy under general anaesthesia
62294262|NCT01495988|EXPERIMENTAL|Vemurafenib/Cobimetinib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Bevacizumab will be administered at the MTD (determined by phase Ib safety lead-in), intravenously, every 2 weeks. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
62661026|NCT06265025|EXPERIMENTAL|Treatment (GM103 and pembrolizumab): Part C_Dose escalation and dose expansion|"Dose-escalation and dose-expansion of GM103 in combination with pembrolizumab~* Safety run in cohorts (GM103 1 dose level below RP2D + Pembrolizumab 200mg, GM103 RP2D + Pembrolizumab 200mg)~* Dose expansion (GM103 RP2D\*+ Pembrolizumab 200mg for HNC, GM103 RP2D\* + Pembrolizumab 200mg for CRC)~  * \*Recommended dose based on previous safety run in cohorts"
61909719|NCT02694757|EXPERIMENTAL|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
61909720|NCT05240443|EXPERIMENTAL|Bariatric Surgery + Medical Management for Chronic Kidney Disease|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
62098460|NCT05566405|ACTIVE_COMPARATOR|Combined (Epidural and Spinal) Anaesthesia|Patients undergoing open retropubic radical prostatectomy under combined (epidural and spinal) anaesthesia
62098461|NCT04144985|ACTIVE_COMPARATOR|Eyelid Speculum|Eyelid retraction was performed with an eyelid speculum.
62098462|NCT04144985|EXPERIMENTAL|Cotton Tipped Applicator|Eyelid retraction was performed with the cotton tipped applicator eyelid retraction technique.
62098463|NCT04144985|EXPERIMENTAL|Unimanual Eyelid Retraction|Eyelid retraction was performed with the unimanual eyelid retraction method.
62098464|NCT01031693|ACTIVE_COMPARATOR|Group A|Active TMS
62098465|NCT01031693|SHAM_COMPARATOR|Group B|Sham TMS
62661027|NCT02826473|EXPERIMENTAL|Intervention-Group|
62661028|NCT02826473|NO_INTERVENTION|Control-Group|
62661029|NCT05411978|PLACEBO_COMPARATOR|Idebenone 30 mg+ Placebo 60 mg|Idebenone 30 mg+ placebo 60 mg TID Oral ,for 12 weeks
62661030|NCT05411978|EXPERIMENTAL|Idebenone 90 mg|Idebenone 90 mg TID Oral ,for 12 weeks
62661031|NCT05411978|PLACEBO_COMPARATOR|Placebo 90 mg|Placebo 90 mg TID Oral,for 12 weeks
62661032|NCT02249325|EXPERIMENTAL|Probiotic dietary supplement|Florajen3 oral probiotic (\>7.5 x10\^9 L. acidophilus, \>6.0 x10\^9 .B. lactis, and \>1.5 x10\^9 B .longum) taken daily beginning at 28 weeks gestation.
62661033|NCT02249325|NO_INTERVENTION|Placebo|Women in the comparison group did not take a placebo.
62661034|NCT03100747|ACTIVE_COMPARATOR|Bilamellar 3 mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
62661035|NCT03100747|ACTIVE_COMPARATOR|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
62661036|NCT03100747|ACTIVE_COMPARATOR|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
62661037|NCT03514797|EXPERIMENTAL|Combined technique|A single session of in-office tooth bleaching will be performed with 35% hydrogen peroxide for 45 minutes. Following, the teeth will be further bleached with customized trays filled with 10% carbamide peroxide and used for 1h per day.
62661038|NCT03514797|ACTIVE_COMPARATOR|At-home bleaching|The teeth will be bleached only with customized trays filled with 10% carbamide peroxide and used for 1h per day.
62661039|NCT03003468|EXPERIMENTAL|Arm A - Phase Ib|"Dose Escalation Cohort Cohort 1 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 of each 21 day cycle. Imprime PGG will be administered at 2mg/kg on Day 1,8, and 15 of cycles 1-4, and on Day 1 of cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab.~Experimental: Arm A - Phase II Investigational Treatment The maximum safe dose of Imprime PGG in combination with pembrolizumab (as determined in the phase Ib cohort) will be given on Day 1,8, and 15 for cycles 1-4, and on Day 1 of cycles 5-16.~Cohort 2 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 4mg/kg on Day 1,8, and 15 for Cycles 1-4 and on Day 1 only for Cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab."
62661040|NCT03846375|EXPERIMENTAL|Participants in DBT|Psychotherapy: The participants will be given standard DBT treatment.
62661041|NCT03846375|OTHER|Control Group|Control Group at preintervention.
62661042|NCT01194310||phaco alone|patients w/ diagnosis of open angle glaucoma underwent phaco alone
62661043|NCT01194310||phaco-ELT|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus ELT
62661044|NCT01194310||phaco-Trabectome|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus Trabectome
62098466|NCT06708962|ACTIVE_COMPARATOR|Group A|Will receive mulligan's mobilization plus corticosteroid injection for shoulder joint
62294263|NCT01495988|ACTIVE_COMPARATOR|Vemurafenib|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
62661045|NCT03456323|EXPERIMENTAL|Palliative Care Consultation|After enrollment the palliative care consultation team will meet with the patient-surrogate pair one or more times to (1) assess symptoms, (2) provide supportive counseling, (3) make symptom treatment recommendations to the primary team of physicians, and (4) will address goals of care.
62661046|NCT03456323|PLACEBO_COMPARATOR|Usual Care|Patient-surrogate pairs randomized to usual care will continue to receive care by their primary physicians without having a palliative care consultation intervention offered.
62661047|NCT02110693|OTHER|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
62661048|NCT03474575|OTHER|COPD patient|Prevention of re-hospitalization rate for Early supported discharge and enhanced homecare to patient admited for COPD exacerbation
62661049|NCT04135534|ACTIVE_COMPARATOR|group A|mutonpain 0.05 mg/kg
62098467|NCT06708962|SHAM_COMPARATOR|corticosteroid injection for rotator cuff tendinopathy only|patients will receive corticosteroid injection for rotator cuff muscle only which helps in resolving inflammation at the shoulder joint
62098468|NCT05567159|EXPERIMENTAL|Donanemab|Participants received a 350 milligrams (mg) intravenous (IV) infusion of donanemab every two weeks for six treatment periods (1 to 6), each lasting two weeks. Treatments were administered on the first day of each period, i.e., days 1, 15, 29, 43, 57, and 71.
62661050|NCT04135534|ACTIVE_COMPARATOR|Group B|mutonpain 0.1 mg/kg
62661051|NCT04135534|ACTIVE_COMPARATOR|Group C|mutonpain 0.2 mg/kg
61909721|NCT05240443|ACTIVE_COMPARATOR|Medical Management for Chronic Kidney Disease|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
61909722|NCT02011139|ACTIVE_COMPARATOR|Group A|12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
61909723|NCT02011139|ACTIVE_COMPARATOR|Group B|12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
62098469|NCT06584513|EXPERIMENTAL|Physician and patient intervention|Patients in the intervention group will be treated by physicians, who received informative and educative materials (including videos) and training, including guidelines and implementation recommendations on how to deprescribe, on shared-decision making with patients, on how to manage sleep problems using alternative methods other than BSH. Patients receive brochures and access to videos. Communication forms are implemented to ensure continuity of care.
62098470|NCT06584513|NO_INTERVENTION|Control/Usual care|Participants in the control group receive treatment according to standard care of the prescribing physician, who did not receive any training or additional material.
62098471|NCT01203553||Control Group|The main operation will be performed as planned. For the closure of the abdominal wall, a standard technique will be applied using a running suture of PDS 1 loop. The distance of the sutures to the fascial border is 1cm and the distance between two stitches is not more than 1cm. The total length of suture is at least 4 times the total length of the abdominal incision
62294264|NCT01495988|EXPERIMENTAL|Vemurafenib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients assigned to the combination arm will also receive bevacizumab 15 mg/kg every IV every 3 weeks. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
62661052|NCT01146483|ACTIVE_COMPARATOR|Pantoprazole|two-arm study: 2-period, 2-sequence, cross-over study.Volunteers will be administered either sequence 1 or sequence 2 randomly.
62294265|NCT04782791|EXPERIMENTAL|Nivo + SOX|Nivolumab plus SOX
62294266|NCT04782791|ACTIVE_COMPARATOR|Nivo|Nivolumab
62294267|NCT02069691|EXPERIMENTAL|virtual reality-cycling training system|
62294268|NCT03709563|ACTIVE_COMPARATOR|Oral Nutraceutical Supplement|
62661053|NCT01146483|PLACEBO_COMPARATOR|Placebo|
61909724|NCT02682979||Geriatric patients|100 consecutive geriatric patients admitted in the Emergency Department of the Brugmann Hospital, Horta site, from 01/04/2015.
61909725|NCT05488756|ACTIVE_COMPARATOR|Group 1|Conventional training plus isometric neck exercises
61909726|NCT05488756|EXPERIMENTAL|Group 2|Conventional training plus deep cervical flexor exercises
61909727|NCT05488756|EXPERIMENTAL|Group 3|Conventional training plus stabilization exercises of the neck and core region
61909728|NCT05873660||People with established CVD|Adults diagnosed with established CVD, attending routine medical care or follow-up in a cardiology clinic.
61909729|NCT02346890|EXPERIMENTAL|AZD1722 alone|15 mg BID
61909730|NCT02346890|EXPERIMENTAL|AD1722 with Renvela|AZD1722 15 mg BID and Renvela 800 mg TID
61909731|NCT00680238|NO_INTERVENTION|A|Embryo selection for transfer based on a Day 3 score only.
61909732|NCT00680238|ACTIVE_COMPARATOR|B|Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
61909733|NCT02331901||MTBI SYMP|Mild Traumatic Brain Injury subjects with symptoms
62098472|NCT01203553||Treatment Group|The main operation will be performed as planned. Prior to the closure of the abdominal wall a mesh will be implanted in a standardized fashion: A Dynamesh IPOM mesh will be used for the present study. The mesh has a width of 15cm and is tailored to overlap lateral and cranial boarders at least 5cm. The mesh will be placed intra-abdominally and fixed using intra-abdominal stitches using Prolene 2/0 in all four corners. After the initial fixation of the mesh in all quadrants, the boarders of the mesh will be adapted using Prolene 2/0 running sutures. The fixation aims to prevent any intestinal structures to herniate onto the mesh. Afterwards, the abdominal wall is closed as described in the control group.
62098473|NCT06714357|ACTIVE_COMPARATOR|STUDY PART 1 - ARM A - control arm|Patients will continue to receive standard rechallenge with irinotecan and panitumumab until treatment failure, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria.
62294269|NCT03709563|PLACEBO_COMPARATOR|Placebo|
62661054|NCT04501692|EXPERIMENTAL|VivaSight|Intubated with a VivaSight-SL endotracheal tube.
62661055|NCT04501692|ACTIVE_COMPARATOR|Conventional|Intubated by videolaryngoscopy.
62098474|NCT06714357|EXPERIMENTAL|STUDY PART 1 - ARM B - experimental arm|Patients will continue to receive standard rechallenge with irinotecan and panitumumab in combination with VPA until treatment failure, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria.
62098475|NCT06711614|OTHER|Intervention Diet First, then Control Diet|Participants will complete \~4 weeks of the Intervention Diet, followed by a washout period of at least 4 weeks, then \~4 weeks of the Control Diet. At the end of each Diet period, participants will undergo a 2 hour controlled wood smoke exposure, following which outcome measures will be assessed.
62098476|NCT06711614|OTHER|Control Diet First, then Intervention Diet|Participants will complete \~4 weeks of the Control Diet, followed by a washout period of at least 4 weeks, then \~4 weeks of the Intervention Diet. At the end of each Diet period, participants will undergo a 2 hour controlled wood smoke exposure, following which outcome measures will be assessed.
62294270|NCT06079216|EXPERIMENTAL|MCTM Intervention|Activity sessions will be led by activity volunteers
62294271|NCT06079216|ACTIVE_COMPARATOR|Control|Activity sessions will be led by activity professionals
62098477|NCT02758262|ACTIVE_COMPARATOR|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the duration of the experimental session.
62098478|NCT02758262|PLACEBO_COMPARATOR|Noninvasive brain stimulation: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of the experimental session.
62098479|NCT00852228|EXPERIMENTAL|chronomodulated HAI chemotherapy|
62098480|NCT00852228|EXPERIMENTAL|conventional HAI chemotherapy|
62294272|NCT00609622|EXPERIMENTAL|A|Treatment arm A - sunitinib plus mFOLFOX6
62294273|NCT00609622|ACTIVE_COMPARATOR|B|Treatment arm B - bevacizumab plus mFOLFOX6
62294274|NCT01516827|EXPERIMENTAL|TF-CBT|"12 Sessions Trauma-focused Cognitive Behavioral Therapy including the child/adolescents and a non-abusive caregiver according to the treatment manual:~Cohen JA, Mannarino AP, and Deblinger E (2006) Treating Trauma and Traumatic Grief in Children and Adolenscents. Guilford, N.Y."
62294275|NCT01516827|NO_INTERVENTION|Wait-list|Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
62098481|NCT04706013|EXPERIMENTAL|Single Arm Active|Pyridoxal 5'-Phosphate
62098482|NCT01250951|EXPERIMENTAL|Deferasirox|
62098483|NCT06551584|EXPERIMENTAL|ORCA-T + (tacrolimus and ruxolitinib)|Dual-agent tacrolimus starting on the day after Tcon infusion (Day +3 or Day +4) and ruxolitinib starting on the day after tacrolimus (Day +4 or Day +5).
62098484|NCT03186807||low risk pregnancy|"Inclusion criteria - Women aged 18-45 years old ,Pregnant women between 14+0 and 34+0 weeks.speaking Hebrew language and eligible for obtaining informed consent.~Gestation who had a singleton fetus in cephalic presentation, with well documented gestational age by first trimester US scan CRL.~Biometric measurement within 10th to 90th percentile.and low risk for fetal brain developmental disorders."
62098485|NCT01174550|ACTIVE_COMPARATOR|Functional diagnostic tests|Stress Echocardiogram Nuclear Stress Test Exercise Electrocardiogram
62294276|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
62294277|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
62294278|NCT00359892|EXPERIMENTAL|Obatoclax Mesylate|Obatoclax Mesylate 60mg
62294279|NCT03752125|EXPERIMENTAL|Flavonoid, caffeine|Flavonoid, caffeine capsules
62661056|NCT03830606|EXPERIMENTAL|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area\<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area\>1.5 m2; D1-14, q3w)
61909734|NCT02331901||MTBI NO SYMP|Mild Traumatic Brain Injury subjects without symptoms
62098486|NCT01174550|ACTIVE_COMPARATOR|Anatomic diagnostic test|Coronary Angiography
62098487|NCT04844099|EXPERIMENTAL|Intervention arm|The intervention will be oral dihydroartemisinin (20mg) and piperaquine (160 mg) and administered once weekly at approximate doses of dihydroartemisinin 2.5mg/kg/day and piperaquine 20mg/kg/day based on participants' weight categories
62098488|NCT04844099|ACTIVE_COMPARATOR|Comparator|The active control will be Sulphadoxine-Pyrimethamine (SP), the current standard of care for malaria chemoprevention for SCA in Uganda and Malawi. This will also be provided by Guilin Pharmaceutical Co. Ltd as their generic World Health Organization-approved sulphadoxine-pyrimethamine 500/25mg tablets. It will be administered as monthly single-day courses of SP at approximate doses of S=25mg/kg and P=1.25mg/kg.
62098489|NCT00070954|PLACEBO_COMPARATOR|2|look-alike placebo
62098490|NCT00070954|ACTIVE_COMPARATOR|Ginkgo Biloba|Compared to placebo
62098491|NCT02892409|ACTIVE_COMPARATOR|Clarithromycin + Amoxicillin + Bismuth + Lansoprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
62098492|NCT02892409|EXPERIMENTAL|Clarithromycin + Amoxicillin + Bismuth + TAK-438|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
62098493|NCT05777057|OTHER|Extracted teeth|Extracted teeth with intial caries without cavitation is examined by diagnodent and digital imaging and then by light microscope
62098494|NCT05917717|NO_INTERVENTION|Control (usual care)|Usual care for a cardiac arrest patient with no deviation.
62294280|NCT03752125|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62294281|NCT04493047|EXPERIMENTAL|Counselling on pneumonia prevention|Recruited caregivers will be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject.
62294282|NCT01577862|ACTIVE_COMPARATOR|Colistin|Colistin alone, 2 million units every 8 hours intravenously or according to renal function
62294283|NCT01577862|EXPERIMENTAL|Colistin plus Rifampicin|Colistin, 2 million units every 8 hours intravenously or according to renal function, plus Rifampicin, 600 mg every 12 hours intravenously
62294284|NCT01035190|EXPERIMENTAL|inhaled Budesonide|
62661057|NCT00884988|ACTIVE_COMPARATOR|Lymphomyosot|homeopathic remedy
62661058|NCT00884988|PLACEBO_COMPARATOR|Placebo remedy|identical in color, constituency and taste to true remedy
62661059|NCT01732900|ACTIVE_COMPARATOR|Morphology|Embryos selected for transfer will be based on morphology alone.
62661060|NCT01732900|EXPERIMENTAL|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
61909735|NCT03023839||Severe trauma patients|Severe Trauma patients (ISS \>15) admitted to Intensive Care Unit (ICU)
61909736|NCT00265148|EXPERIMENTAL|Rosiglitazone|4 mg once a day for 1 month increasing to 8 mg once a day (Extended Released Tablets)
61909737|NCT00265148|OTHER|Placebo|Placebo dummy to match
62661061|NCT04736433||ACE Inhibitors|Reference group
62661062|NCT04736433||Sacubitril/Valsartan|Exposure group
61909738|NCT00642889|EXPERIMENTAL|High Dose|150-200mg/day
62294285|NCT03112811|EXPERIMENTAL|Intubated infant|
62294286|NCT03112811|EXPERIMENTAL|Extubated infant|
62661063|NCT01859819|EXPERIMENTAL|Group B|"De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH \<2 X ULN.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine"
62098495|NCT05917717|EXPERIMENTAL|Intervention 'bundle of care'|The clinical team will follow a specific sequence of actions using three devices (Elegard, Lucas-3, and ITD-16), in addition to standard CPR. Firstly, they will place the ITD onto the i-gel) or ETT, followed by the Elegard device and the LUCAS-3. The team will also place a cerebral saturation monitor on (Near-Infrared Spectroscopy (NIRS)) (if they have access to one). After 2 minutes of CPR via the LUCAS-3 with the ResQPOD-16 (ITD), the Elegard device will be turned on and activated to gradually elevate the head approximately 22cm from the ground to the back of the occiput. If necessary, the clinical team may choose to intubate the trachea at this point. Resuscitation will continue for at least 30 minutes or until ROSC is achieved. If ROSC is achieved, standard post ROSC guidelines will be followed.
62098496|NCT01648283|EXPERIMENTAL|Methadone arm|"1. Intravenous racemic methadone HCl, 6.0 mg bolus~2. Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)"
62466507|NCT04786080|NO_INTERVENTION|Follow-Up as Usual|FAU was selected as a comparator because of the pragmatic nature of the trial. Individuals randomised to FAU will receive no intervention for the first 10 weeks while the data for baseline (T1), T2 and T3 are collected. They will then be given access to all three zones of the app.
62661064|NCT01859819|EXPERIMENTAL|Group C, CNS negative|"De-novo Mature CD 20 + B-ALL (\> 25% Bone marrow blasts) without CNS involvement.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine"
62098497|NCT06711068||Taxanes combined with cyclophosphamide chemotherapy|Taxanes (paclitaxel, liposomal paclitaxel, docetaxel, albumin paclitaxel), cyclophosphamide chemotherapy, combined with targeted therapy with trastuzumab, for a total of 4 cycles, followed by targeted therapy maintenance for 1 year
62098498|NCT06711068||Taxanes chemotherapy|Taxanes (paclitaxel, liposomal paclitaxel, docetaxel, albumin paclitaxel) combined with trastuzumab and pertuzumab targeted therapy, for a total of 4 cycles, followed by targeted therapy maintenance for 1 year
62098499|NCT02652494||Patients receiving Apremilast per daily clinical practice|Dutch patients receiving Apremilast according to daily clinical practice
62098500|NCT03256682|EXPERIMENTAL|Mobile Video Counseling|Utilize mobile imaging equipment, receive a total of 4 stress management consultations every 50 minutes at a time, once a week.
62098501|NCT03256682|ACTIVE_COMPARATOR|Offline Counseling|Receive a total of 4 stress management counseling, once a week for 50 minutes each session.
62098502|NCT03256682|NO_INTERVENTION|Selfcare|Use stress management materials to manage yourself.
62098503|NCT03115775|ACTIVE_COMPARATOR|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
62098504|NCT03115775|ACTIVE_COMPARATOR|Vitamin D|Vitamin D3 (2000 IU per day)
62466508|NCT02209922|ACTIVE_COMPARATOR|Transcranial direct current stimulation|"ARM1: Transcranial direct current stimulation (tDCS) intervention and simultaneous balance training.~Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week."
62661065|NCT01859819|EXPERIMENTAL|Group C, CNS Positive|"De-novo Mature CD 20 + B-NHL with CNS involvement:~1. Any L3 blasts in CSF~2. Cranial nerve palsy (if not explained by extracranial tumor)~3. Clinical spinal cord compression~4. Isolated intracerebral mass~5. Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,"
62661066|NCT01073475||Pregnant women|Pregnant women in the MNH cluster
62466509|NCT02209922|SHAM_COMPARATOR|ARM 2|ARM2: Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
62466510|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
61909739|NCT00642889|EXPERIMENTAL|Low dose|50-100mg/day
61909740|NCT00642889|PLACEBO_COMPARATOR|Placebo|
62098505|NCT03115775|ACTIVE_COMPARATOR|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
62098506|NCT03115775|PLACEBO_COMPARATOR|Placebo|Corn oil (4000 mg per day)
62098507|NCT06711055||Taxanes combined with trastuzumab|Taxane with trastuzumab. Taxane drugs allow the selection of paclitaxel, liposomal paclitaxel, albumin paclitaxel, or docetaxel. Chemotherapy is administered in a single week regimen with 12 cycles or a 3-week regimen with 4 cycles, with target therapy for 1 year
62098508|NCT01944982|EXPERIMENTAL|Activated natural killer cells|Activated natural killer cells
62466511|NCT01409278|EXPERIMENTAL|Ropivacaine infiltration and infusion.|Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
62466512|NCT01409278|EXPERIMENTAL|Ropivacaine and Saline|Ropivicaine infiltration followed by normal saline infusion.
61909741|NCT06058988|EXPERIMENTAL|Cohort A|Participants with Her2-expressing or solid tumors with activating ERBB2 mutations with 1 or more CNS metastases requiring neurosurgical resection/biopsy with no prior T-DXd
61909742|NCT06058988|EXPERIMENTAL|Cohort B|Participants with Her2-expressing or solid tumors with activating ERBB2 mutations with 1 or more CNS metastases requiring neurosurgical resection/biopsy with no prior T-DXd and prior T-DXd exposure and with documented radiological CNS progression while on T-DXd, requiring neurosurgical resection/biopsy of 1 or more recurrent metastases, with continuation of T-DXd until prior to surgery
61909743|NCT06058988|EXPERIMENTAL|Cohort C|Participants with recurrent glioblastoma requiring neurosurgical resection/biopsy
61909744|NCT01264575|EXPERIMENTAL|BPV6E1|
61909745|NCT01264575|EXPERIMENTAL|BPV7E1|
61909746|NCT01264575|EXPERIMENTAL|BPV8E1|
61909747|NCT01264575|EXPERIMENTAL|BPV9E1|
61909748|NCT01264575|EXPERIMENTAL|BPV10E1|
61909749|NCT01264575|EXPERIMENTAL|BPV11E1|
61909750|NCT01264575|EXPERIMENTAL|BPV6E2|
61909751|NCT01264575|EXPERIMENTAL|BPV7E2|
61909752|NCT01264575|EXPERIMENTAL|BPV8E2|
61909753|NCT01264575|EXPERIMENTAL|BPV9E2|
61909754|NCT01264575|EXPERIMENTAL|BPV10E2|
61909755|NCT01264575|EXPERIMENTAL|BPV11E2|
61909756|NCT06449365|ACTIVE_COMPARATOR|midazolam delivery via intravenous|normal sedation given via Intravenous route
61909757|NCT06449365|ACTIVE_COMPARATOR|midazolam delivery via nasal atomizer|normal sedation given via nasal atomizer
61909758|NCT04718545|ACTIVE_COMPARATOR|Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a conventionally prepared recipient site and sutured to cover the mucosal recession
61909759|NCT04718545|EXPERIMENTAL|Modified Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a modified recipient site and sutured to cover the mucosal recession
62098509|NCT02321358|EXPERIMENTAL|Two-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention and a booster again six weeks following.
62098510|NCT02321358|ACTIVE_COMPARATOR|One-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention.
62098511|NCT02321358|SHAM_COMPARATOR|Sham Comparator Group|Group will receive Canada's Food Guide which contains a small amount of physical activity information.
62098512|NCT01641276|EXPERIMENTAL|hepatitis|hepatitis B carriers patients
62466513|NCT01409278|PLACEBO_COMPARATOR|Saline infiltration and infusion.|Normal saline infiltration followed by saline infusion.
62466514|NCT03586726|EXPERIMENTAL|Balovaptan + Rifampicin|Participants received the study drugs in 2 periods. There was a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
62466515|NCT04564482|OTHER|Neoadjuvant Chemoradiotherapy (CRT)|
61909760|NCT03619967|EXPERIMENTAL|Multispectral imaging device|Bio-inspired multispectral imaging device will be used to record fluorescence signals emited by dyes (Indocyanine green and methylene blue) routinely used for visual identification of sentinel lymph nodes per current standard of care worldwide.
61909761|NCT04966910|EXPERIMENTAL|Stay Connected|Menu-driven set of strategies to combat loneliness, anxiety and depression in older adults
61909762|NCT04966910|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual in these practice settings typically includes regular check-in calls and offering resources and referrals
61909763|NCT05365945|EXPERIMENTAL|The study group|
61909764|NCT05365945|ACTIVE_COMPARATOR|The control group|
61909765|NCT04805489|EXPERIMENTAL|stress test with masks|Within the framework of this research, an additional stress test is performed. This stress test, consisting of 3 periods, will follow a cardiovascular assessment requested as part of a health check-up, a license application, for risk factor assessment.
62098513|NCT01641276|EXPERIMENTAL|hepatocellular carcinoma patients|hepatites B carriers patients with associated hepatocellular carcinoma
62466516|NCT04564482|OTHER|Short-course preoperative radiotherapy (SCPRT)|
61909766|NCT04879147||Syncope|Subjects admitted immediately after syncopation.
61909767|NCT04879147||Seizre|Subject admitted immediately after cerebarl seizure
61909768|NCT00536029||A|Subject with pigmented skin lesion suspect for malignant melanoma
61909769|NCT01156064||Case (subjects with digestive diseases)|The investigators cases are subjects with confirmed digestive diseases.
61909770|NCT01156064||Control|Healthy individuals aged between 18 and 90 years who are asymptomatic for digestive diseases.
61909771|NCT01794195|EXPERIMENTAL|apathetic patients with Parkinson's disease|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
61909772|NCT01794195|EXPERIMENTAL|non apathetic paired patients|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
61909773|NCT01794195|EXPERIMENTAL|healthy paired control|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
61909774|NCT02776748|OTHER|FTC-TDF|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) PrEP: 200mg FTC /300 mg TDF
61909775|NCT02521896|EXPERIMENTAL|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
61909776|NCT03473548|EXPERIMENTAL|Unmonitored Polysomnography|All eligible subjects will be asked to conduct an unattended, overnight sleep study performed in their home prior to in-laboratory polysomnography, using a standard Type III portable monitor. The type III portable sleep monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
62098514|NCT06518187||Anesthesiology Healthcare providers/professionals|Investigating whether needle tip movement during catheter advancement is affected by whether the individual performing the insertion pushes the catheter off the needle themselves (either one handed or two handed) or if the catheter is advanced off the needle by another person.
62294287|NCT06226402|NO_INTERVENTION|Control group|Patients will receive the standard pharmacotherapy of Acute Respiratory Distress Syndrome (ARDS) patients.
62466517|NCT04564482|OTHER|Neoadjuvant Chemoradiotherapy (CROSS protocol)|
62466518|NCT00006226|EXPERIMENTAL|Treatment (thalidomide)|Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
62661067|NCT01073475||Male and Female Infants|Male and Female Infants delivered in the clusters
62098515|NCT04178005|OTHER|Cladribine|"All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI.~Each treatment course is divided into 2 treatment cycles:~* Administration of first treatment course (year 1 treatment):~* First cycle: Starts on Day 1 of the study~* Second cycle: Administered 23 to 27 days after the last dose of first cycle.~* Administration of second treatment course (year 2 treatment):~* First cycle: Administered at least 43 weeks after the last dose of year 1 treatment~* Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment.~The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days."
62098516|NCT01784380||the case group|
62098517|NCT01784380||the control group|
62098518|NCT01784380||the treatment group|Patients of the treatment group recieved drugs,then we observed drugs' treatment effect.
62098519|NCT01565538|EXPERIMENTAL|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression.
62098520|NCT01565538|EXPERIMENTAL|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.
62098521|NCT00362752|PLACEBO_COMPARATOR|Placebo|
62098522|NCT00362752|EXPERIMENTAL|Norfloxacin 400 mg bid|
62661068|NCT04179682|ACTIVE_COMPARATOR|4-week 2-hours/day CIMT program|a 4-week 2-hours/day constraint program, total 40 hours CIMT, in preschool education.
62661069|NCT04179682|ACTIVE_COMPARATOR|2-week 4-hours/day CIMT program|one was a 2-week 4-hours/day constraint program, total 40 hours CIMT, in preschool education.
62661070|NCT06520280|OTHER|GroupI|First, patients will receive maxillary and mandibular complete dentures constructed by polyamide thermoplastic resin.
62661071|NCT06520280|OTHER|Group II|First, patients will receive maxillary and mandibular complete dentures constructed by 3D printed
61909777|NCT03473548|ACTIVE_COMPARATOR|In-laboratory Polysomnography|All eligible subjects will have in-laboratory polysomnography as is routinely performed in the diagnostic work up for suspected sleep disordered breathing.
61909778|NCT05681559|ACTIVE_COMPARATOR|Medi for All|"Participants randomized to the USDA Mediterranean-style Food Pattern Arm (called Medi for all) will have access to a toolbox that includes education materials (e.g., food pattern tables according to daily caloric intake), recipes, grocery lists, group-based online dietary support, feedback, and reminders to encourage dietary change. Recipes and grocery lists can be individualized to a participant's food budget and preferences. Materials will be available in print and Web-based. This state-of-the art intervention will then use electronic feedback in the form of nudge messages designed to motivate participants to sustain or improve adherence to the Med-style Food Pattern."
61909779|NCT05681559|ACTIVE_COMPARATOR|Fiber Supplementation|Participants randomized to the High Fiber Diet Arm will be given commonly used patient education pamphlet,149 describing fiber and high-fiber foods, the rationale for increasing fiber intake, and ways patients can promote greater intake. Based on prior observational studies of incident diverticulitis, at least 25 grams/day of fiber will be recommended for participants.
61909780|NCT03527342||Dilated Cardiomyopathy|
61909781|NCT03527342||Myocarditis|
61909782|NCT03527342||Sarcoidosis Heart|
61909783|NCT03527342||Giant Cell Myocarditis|
61909784|NCT03527342||Amyloidosis Heart|
61909785|NCT03527342||Hypertrophic Cardiomyopathies|
61909786|NCT03527342||Left Ventricular Myocardial Noncompaction Cardiomyopathy|
61909787|NCT03527342||Arrhythmogenic Right Ventricular Cardiomyopathies|
61909788|NCT00436501|EXPERIMENTAL|Treatment (VEGF Trap, Docetaxel)|"Phase I (closed to accrual as of 3/14/2008): Patients receive VEGF Trap IV over 1 hour on day 1 of course 1. Patients then receive VEGF Trap IV over 1 hour and docetaxel IV over 1 hour on day 1 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 or 6 patients experience dose-limiting toxicity."
61909789|NCT00436501|EXPERIMENTAL|Phase II Treatment (VEGF Trap, Docetaxel)|Phase II (opened to accrual as of 5/9/2008): Patients receive VEGF Trap at the MTD determined in phase I and docetaxel as in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62098523|NCT03079375|NO_INTERVENTION|usual care|no pharmaceutical intervention.
62098524|NCT03079375|SHAM_COMPARATOR|basic intervention|Medication review
62098525|NCT03079375|SHAM_COMPARATOR|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
62098526|NCT01143077|EXPERIMENTAL|Lurasidone Open-Label Arm A|
62098527|NCT01143077|EXPERIMENTAL|Lurasidone Open-Label Arm B|
61909790|NCT00300430|ACTIVE_COMPARATOR|A|20 mg drug and ABT-335
61909791|NCT00300430|ACTIVE_COMPARATOR|B|40 mg drug and ABT 335
61909792|NCT00300430|ACTIVE_COMPARATOR|C|40 mg drug and ABT-335
61909793|NCT03907839|ACTIVE_COMPARATOR|Endurance Training (ET)|endurance training for control group
61909794|NCT03907839|EXPERIMENTAL|ET+cognitive training(CT)|endurance training added to cognitive training for exprimental COPD group
61909795|NCT03929094|EXPERIMENTAL|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m\^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m\^2 on days 1, 8, and 15
62098528|NCT01143077|EXPERIMENTAL|Lurasidone Open-Label Arm C|
62098529|NCT02601703|EXPERIMENTAL|Tacrolimus Ointment 0.1%|
62098530|NCT02601703|ACTIVE_COMPARATOR|Protopic® ointment, 0.1%|
62098531|NCT02601703|PLACEBO_COMPARATOR|Placebo of Tacrolimus Ointment|
62098532|NCT00462553|EXPERIMENTAL|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.
62098533|NCT05967689|EXPERIMENTAL|"Cohort A (prior ex20ins treatment)"|"Cohort A (prior ex20ins treatment) participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first."
62466519|NCT03569761|EXPERIMENTAL|Decision Aid Video Intervention|Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer.
61909796|NCT01594801|NO_INTERVENTION|Control|Subject continue their routine therapy
62098534|NCT05967689|EXPERIMENTAL|"Cohort B (1st line treatment)"|Cohort B participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
62098535|NCT05967689|EXPERIMENTAL|"Cohort C (active brain mets)"|Cohort C participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
62098536|NCT05967689|EXPERIMENTAL|"Cohort D (other uncommon EGFRmt)."|Cohort D participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
62294288|NCT06226402|EXPERIMENTAL|Inhalational group|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
62737035|NCT01626586|EXPERIMENTAL|Group Therapy|"This study includes having an initial assessment completed; participating in a 6 session group therapy intervention over a 7 week time period; and returning at 2 and 4 months after group therapy intervention for booster follow-up sessions. During the group intervention sessions, the parent group and the youth group will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
62294289|NCT06226402|EXPERIMENTAL|Intravenous group|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
61909797|NCT01594801|EXPERIMENTAL|Test|Subjects using the InsuPad device
62098537|NCT04221035|EXPERIMENTAL|phase induction-R-I|"R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.~Patients with insufficient metastatic response at the end of induction chemotherapy, defined as SIOPEN score \> 3 or less than 50% reduction in mIBG score (or \> 3 bone lesions or less 50% reduction in number of FDG-PET-avid bone lesions for mIBG-non avid tumours), have a poorer prognosis.~Chemoimmunotherapy arm Metastatic response rate after 4 courses of irinotecan-temozolomide (TEMIRI) combined with dinutuximab beta (DB) in patients with insufficient metastatic response at the end of induction chemotherapy (TEMIRI/DB)."
62098538|NCT04221035|EXPERIMENTAL|Phase high dose chemotherapy consolidation|R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).
62098539|NCT04221035|EXPERIMENTAL|Phase of radiotherapy|R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease
62098540|NCT03793855|EXPERIMENTAL|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
62098541|NCT03793855|ACTIVE_COMPARATOR|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
62098542|NCT04739423|EXPERIMENTAL|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
62098543|NCT04739423|EXPERIMENTAL|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 co-administered with matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
62294290|NCT02717156|EXPERIMENTAL|Treatment (EphB4-HSA and pembrolizumab)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, and 15 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62294291|NCT02518555|EXPERIMENTAL|Arm A (concurrent vaccines and ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 3 and 5 and trivalent influenza vaccine IM and DTaP vaccine IM on day 1 of course 4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62294292|NCT02518555|EXPERIMENTAL|Arm B (sequential vaccines and ibrutinib)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 1 and 3 and trivalent influenza IM and DTaP vaccine IM on day 1 of course 2. Beginning in course 4, patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity.
62294293|NCT01019564|EXPERIMENTAL|Easy Rub MPS|Complete Easy Rub Formula MPS
62294294|NCT01019564|ACTIVE_COMPARATOR|Aquify MPS|
61909798|NCT02433431|ACTIVE_COMPARATOR|Mindfulness Training|14-lesson audio-guided mindfulness training program instructing present-moment attention and an orientation of acceptance
61909799|NCT02433431|ACTIVE_COMPARATOR|Mindful Attention Only Training|14-lesson audio-guided mindfulness training program instructing present-moment attention only
61909800|NCT02433431|ACTIVE_COMPARATOR|Analytic Thinking Training|14-lesson audio-guided analytic thinking program encouraging reflection on one's thoughts, feelings, and behaviors, but not instructing mindfulness
61909801|NCT04598256||Children who underwent endoscopic procedures|"* Children between the ages of 1-18 who were underwent endoscopic procedures~* Patients who can be questioned about COVID-19 infection before and on the 7th and 14th days after the procedure~* Patients who volunteered to study"
61909802|NCT03472547|EXPERIMENTAL|Single cohort (Healthy Volunteers)|diacerein 1% ointment
61909803|NCT05520164|NO_INTERVENTION|Control Group|Routine heel blood was taken from the control group. At the same time, the behaviors of newborns were recorded on camera throughout the procedure. At the end of the study, the camera recording was watched and scored by two midwives who had training in the Neonatal Pain Scale.
61909804|NCT05520164|EXPERIMENTAL|Experimental Group|The newborns in the experimental group listened to the recorded heart sounds of their mothers for 1 minute before the heel blood procedure, during the procedure and for 1 minute after the procedure. At the same time, the behaviors of newborns were recorded on camera throughout the procedure. At the end of the study, the camera recording was monitored and scored by two midwives trained in the Neonatal Pain Scale.
61909805|NCT03713177||Ministry of health - Cairo|Dentists working for Egyptian ministry of health - Cairo
61909806|NCT03713177||Interns|Dental interns of Cairo University
61909807|NCT01446614|EXPERIMENTAL|MSC|Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.
61909808|NCT01324518|EXPERIMENTAL|Low dose of ORM-12741|
61909809|NCT01324518|EXPERIMENTAL|High dose of ORM-12741|
61909810|NCT01324518|PLACEBO_COMPARATOR|Placebo|
61909811|NCT04752644|EXPERIMENTAL|Group1: MVA-BN-RSV|"Participants will receive one intramuscular injection of MVA-BN-RSV (nominal titre 5 x 10\*8 Inf.U per 0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
62466520|NCT03569761|ACTIVE_COMPARATOR|Control|Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer. The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm. The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
62098544|NCT05360732|EXPERIMENTAL|Experimental: FOLFIRINOX|FOLFIRINOX: Oxaliplatin, Leucovorin and 5-Fluorouracl, Irinotecan,
62466521|NCT05437744|EXPERIMENTAL|Study group|
62466522|NCT05437744|ACTIVE_COMPARATOR|Control group|
62098545|NCT06610864||Women with uterine malformations|Women with uterine malformations who underwent hysteroscopic correction.
61909812|NCT04752644|PLACEBO_COMPARATOR|Group 2: Placebo|"Participants will receive one intramuscular injection of Tris-Buffered-Saline (0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
61909813|NCT06158529|ACTIVE_COMPARATOR|spinal cord stimulation|
61909814|NCT06158529|EXPERIMENTAL|high frequency spinal cord stimulation|
61909815|NCT02702297||Single arm|daily multimodal monitoring during pregnancy after PPROM, Analysis of neonatal routine parameters and histologic examination of placenta
61909816|NCT01491438|EXPERIMENTAL|PRGF and conventional treatment|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
61909817|NCT01491438|ACTIVE_COMPARATOR|Conventional treatment alone|Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
61909818|NCT03457441|OTHER|Near visual acuity +1.0 and +0.7 logMAR|Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
61909819|NCT03457441|OTHER|Near visual acuity +0.6 and +0.3 logMAR|Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
61909820|NCT03457441|OTHER|Near visual acuity +0.2 and +0.0 logMAR|Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
62294295|NCT02132442|EXPERIMENTAL|Vitamin D supplementation|Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo
62294296|NCT02132442|PLACEBO_COMPARATOR|Placebo|Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.
61909821|NCT02031328|EXPERIMENTAL|Stereotactic Ablative Radiation|Stereotactic Ablative Radiation 26 Gy in 2 fractions, once weekly to prostate
61909822|NCT03249662|EXPERIMENTAL|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
61909823|NCT03249662|ACTIVE_COMPARATOR|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
61909824|NCT03356704||General anaesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had general anesthesia
61909825|NCT03356704||continued spinal anesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had continued spinal anesthesia
61909826|NCT03356704||peripheral nerve blocks|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had peripheral nerve blocks
61909827|NCT04613843|ACTIVE_COMPARATOR|Water stirring|
61909828|NCT04613843|EXPERIMENTAL|No water stirring|
62098546|NCT06150885|EXPERIMENTAL|CAR001|CAR001 cells mixed with normal saline will be administered to patients.
62098547|NCT06016556||Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)|Adult COVID-19 patients' HCRU within the 30-day period following nirmatrelvir, ritonavir prescription.
62098548|NCT04580407|EXPERIMENTAL|TAK-672|TAK-672 was administered at an initial dose of 200 U/kg with IV infusion at a rate of 1-2 mL/min at Day 1. Subsequent doses were determined based on the post-infusion FVIII:C achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer.
62294297|NCT05148026|ACTIVE_COMPARATOR|Anticoagulation sequence 1 (UFH+ RCA)|UFH+ RCA first
62294298|NCT05148026|ACTIVE_COMPARATOR|Anticoagulation sequence 2 (UFH)|UFH first
62294299|NCT03724448|EXPERIMENTAL|ALEOZEN group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
62294300|NCT03724448|PLACEBO_COMPARATOR|placebo group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
62294301|NCT03151889|EXPERIMENTAL|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
62294302|NCT03151889|NO_INTERVENTION|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
62294303|NCT01560351|EXPERIMENTAL|rTMS|Session of repeated low-frequency Transcranial Magnetic Stimulation
62294304|NCT01560351|SHAM_COMPARATOR|Placebo|Sessions of sham rTMS
62294305|NCT00990171||PD-BCM|"1. Patients at National Taiwan University Hospital (NTUH)~2. Patients who have received PD more than 3 months~3. Patients who sign the informed consents~4. Patients who aged between 20-90 years"
62294306|NCT03429868|EXPERIMENTAL|integrated PET/MRI|The participants receive an integrated 18F-FDG PET/MRI during tumor staging.
61909829|NCT05302453|EXPERIMENTAL|Basic Body Awareness Therapy Group|BBAT exercises to the participants in the study group, were performed under the leadership of two physiotherapists with internationally valid training certificates. In the face-to-face training, BBAT exercises were taught to the participants. Then the training went on via Google Meet. The lying exercises were shown on one participant before each group study and participants were asked to do lying exercises at home. Sitting and lying exercises were performed as a hybrid at one hour/in a week for 12 weeks. At the beginning and end of each group training, feedback was received from the participants' own experiences of the effects of the exercises on the body, emotions, and thoughts.
61909830|NCT05302453|NO_INTERVENTION|Control Group|The Control group was warned to continue with daily routines and not to take any training that includes body-mind approaches such as yoga or Tai chi for 12 weeks.
61909831|NCT02030431|ACTIVE_COMPARATOR|Cancellous screws|Patients in this group are having osteosynthesis with three screws
61909832|NCT02030431|ACTIVE_COMPARATOR|Dynaloc|Patients in this group are having osteosynthesis with Dynaloc (three screws fixed in a small plate)
61909833|NCT04835831|EXPERIMENTAL|adapted physical activity + Dietetic advice|
62294307|NCT06121128|SHAM_COMPARATOR|Female Control Group (FCON)|female endurance trained athletes between 18 and 44 years old
62466523|NCT00761020|EXPERIMENTAL|Mefloquine|Mefloquine 250 mg orally daily x 3 days beginning 2 days prior to challenge and then weekly for 4 weeks post challenge.
62466524|NCT00761020|SHAM_COMPARATOR|Control|
61909834|NCT04835831|NO_INTERVENTION|Dietetic advice only|
61909835|NCT02624947|PLACEBO_COMPARATOR|Treatment Group A|Formulation buffer (0.5mL injection)
61909836|NCT02624947|ACTIVE_COMPARATOR|Treatment Group|RSV F vaccine with adjuvant (0.5mL injection)
61909837|NCT01214057|EXPERIMENTAL|Total Intravenous Anesthesia|Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
62294308|NCT06121128|EXPERIMENTAL|Female Training Group (FTRAIN)|female endurance trained athletes between 18 and 44 years old
62294309|NCT06121128|SHAM_COMPARATOR|Male Control Group (MCON)|male endurance trained athletes between 18 and 44 years old
62294310|NCT06121128|EXPERIMENTAL|Male Training Group (MTRAIN)|male endurance trained athletes between 18 and 44 years old
62294311|NCT01530243|PLACEBO_COMPARATOR|Placebo|
62294312|NCT01530243|ACTIVE_COMPARATOR|Terazosin|
62294313|NCT01530243|ACTIVE_COMPARATOR|Tolterodine|
62294314|NCT01530243|ACTIVE_COMPARATOR|Tolterodine + Terazosin|
61909838|NCT01214057|ACTIVE_COMPARATOR|Inhaled Anesthesia|Inhaled anesthesia with sevoflurane and remifentanyl.
61909839|NCT03897140|EXPERIMENTAL|Patients scheduled for an echocardiogram|Patients ≥18 years scheduled for an echocardiographic examination. This is a non-randomized, un-blinded, study in patients with an indication for an echocardiographic examination. Enrolled patients will be stratified into two groups based on known cardiac abnormalities to ensure a sufficient number of patients with cardiac abnormalities and into 3 strata of BMI: normal, overweight and obese.
61909840|NCT00832832|EXPERIMENTAL|Eyelid closure|Eyelids will be closed after administration of eye drop
61909841|NCT00832832|ACTIVE_COMPARATOR|No eyelid closure|Eyelids will not be closed after eye drop instillation
62294315|NCT02670876|EXPERIMENTAL|Anti-bullying intervention|An anti-bullying intervention target to perpetrators of school bullying was conducted. The program consisted of 8 sessions over 4 weeks and was conducted by a board-certified psychiatrist and a therapist with previous training in psychosocial treatments. The intervention was based on cognitive-behavioral therapy (CBT) principles and addressed various factors that have been associated with perpetrators of school bullying, including impulse control, perspective taking (empathy), and the enhancement of communication skills.
62294316|NCT03661684|EXPERIMENTAL|Prednisone in subjects with Diabetes|Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
62294317|NCT03661684|EXPERIMENTAL|Prednisone in control subjects|Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
61909842|NCT02578719|PLACEBO_COMPARATOR|drug: bupivacaine|Placebo comparator: bupivacaine first 3 months 0.5% 1 cc bupivacaine diluated with 1.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
62098549|NCT04836195|EXPERIMENTAL|PCLX-001 intervention|"The Dose-Escalation phase will follow a standard 3+3 cohort design. Three patients will be treated at each dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level. Escalation will terminate as soon as two or more patients experience any DLT attributable to study drugs, at a given dose level.~Oral PCLX-001 will be provided as continuous daily dosing on a 28-day cycle."
62737036|NCT01626586|ACTIVE_COMPARATOR|Individual Arm|"This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the booster follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
61909843|NCT02578719|PLACEBO_COMPARATOR|placebo|first 3 months 2.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
61909844|NCT03386045|ACTIVE_COMPARATOR|Optimal SBRT|Participants in this group will be randomised to either SBRT ( 36 to 45 GY in 5 fractions) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the SBRT (5 treatments) and one third will get the standard fractions.
61909845|NCT03386045|ACTIVE_COMPARATOR|Optimal Booster|Participants in this group will be randomised to either standard radiotherapy plus SBRT (45 Gy in 20 fractions plus 20-30 Gy in 2 fractions-Booster) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the Booster arm and one third will get the standard fractions.
62294318|NCT04143633|EXPERIMENTAL|FODMAP diet in Irritable Bowel Syndrome|Patients with IBS will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
62294319|NCT04143633|EXPERIMENTAL|FODMAP diet in Ulcerative Colitis|Patients with UC will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
62294320|NCT04143633|ACTIVE_COMPARATOR|FODMAP diet in healthy patients|Healthy patients will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
62098550|NCT00438425|EXPERIMENTAL|Intensive Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 7 visits during a 6-month period with the study dietitian.
62098551|NCT00438425|EXPERIMENTAL|Routine Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 2 visits during a 6-month period with the study dietitian.
62661072|NCT00891397|EXPERIMENTAL|1|Pregabalin group is made up of 20 patients. Patients will receive 150mg/day in two divided does. The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain. The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain. This is also the maximum permissible does that will be given to the patient. If patient reports any side effects then the dose can be decreased once. The time period of 2 to 5 weeks will be the dose adjustment period. After which the drug maintenance period extends from week 5 to 12. All doses will be given in two divided doses/day.
62098552|NCT00438425|ACTIVE_COMPARATOR|Control|Advice focused on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
62098553|NCT00968331|EXPERIMENTAL|REVLIMID plus RITUXIMAB|"Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles."
62098554|NCT06196710|EXPERIMENTAL|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
62466525|NCT01416246|EXPERIMENTAL|Fractionated Stem Cell Infusions|A single arm, open-label, single institution pilot trial is planned. Patients with chemosensitive MM and at least 7 x 10\^6 CD34+ stem cells/kg (+/- 0.5 x 10\^6 CD34+ stem cells/kg)available for use will be enrolled following initial induction or salvage therapy.
62661073|NCT00891397|PLACEBO_COMPARATOR|2|Ten patients will be be in the placebo group.
62661074|NCT04612400|EXPERIMENTAL|Low|Low dose (6.3g) EAA/whey protein supplement
62661075|NCT04612400|EXPERIMENTAL|High|High dose (12.6g) EAA/whey protein supplement
62661076|NCT00872118|EXPERIMENTAL|1|Brief Intervention for Socially Anxious Drinkers
62661077|NCT00872118|ACTIVE_COMPARATOR|2|Enhanced Alcohol Skills and Education Program
62098555|NCT06196710|ACTIVE_COMPARATOR|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine \<=20 clips or pulse
62098556|NCT02680769|EXPERIMENTAL|Magnesium|300 mg of citrate Mg/daily
62466526|NCT02058498|EXPERIMENTAL|Liver Transplant Patients|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log.
62466527|NCT03037372|EXPERIMENTAL|ART-Atorvastatin adjunct therapy|ART, atorvastatin
62466528|NCT03037372|EXPERIMENTAL|ART-Rosuvastatin adjunct therapy|ART, rosuvastatin
62466529|NCT03037372|EXPERIMENTAL|ART-without statin adjunct therapy|ART, no statin
62661078|NCT01682525|EXPERIMENTAL|Ovarian tissue cryopreservation|The ovarian tissue is cryopreserved and stored at Boston IVF, which is an FDA compliant and American Association of Tissue Banks accredited long term storage facility for reproductive tissue.
62098557|NCT02680769|PLACEBO_COMPARATOR|Placebo|placebo group
62098558|NCT03200743||Hpertension|
62466530|NCT03037372|EXPERIMENTAL|Healthy-HIV-negative|Age-matched HIV-negative, healthy volunteers from the same community
62466531|NCT06460025||slough|slough as the wound specimen for microbiology cultivation
62098559|NCT03200743||Health|
62098560|NCT02790606|EXPERIMENTAL|Covera(TM) Vascular Covered Stent|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
62098561|NCT04591899|EXPERIMENTAL|CAD/CAM SS|
62098562|NCT04591899|ACTIVE_COMPARATOR|Conventionally manufactured SS|
62098563|NCT01986244||STAR Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the STAR
62098564|NCT01986244||Salto Talaris Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the Salto Talaris
62294321|NCT02547623|ACTIVE_COMPARATOR|dexamethasone depot|dexamethasone depot 517 mcg
62294322|NCT02547623|ACTIVE_COMPARATOR|standard of care|prednisolone drops 1%
62294323|NCT00541983|ACTIVE_COMPARATOR|1|
62661079|NCT05399771|EXPERIMENTAL|Thermofield temperature controlled radiofrequency device|Participants will serve as their own control, by heating one leg and not the other. The radiofrequency device consists of a 4 by 6 inch heating pad connected to a temperature controller. The pad will be applied to the back of the leg and will covered using a compression stocking. The other leg will receive a pad and compression stocking, but radiofrequency will not be applied (no heating).
62661080|NCT01155141|EXPERIMENTAL|No arms|There are no arms to this study. All patients receive drug (H.P. Acthar Gel)
62466532|NCT06460025||swap|swap as the wound specimen for microbiology cultivation
62098565|NCT01986244||In-Bone Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the In-Bone
62098566|NCT05355805|EXPERIMENTAL|Part A (Open-label) izokibep every week|Participants will receive izokibep every week from Day 1 through Week 31
62098567|NCT05355805|EXPERIMENTAL|Part B (Double-blind) izokibep every week|Participants will receive izokibep every week for 31 weeks.
62098568|NCT05355805|EXPERIMENTAL|Part B (Double-blind) izokibep every other week|Participants will receive izokibep every other week for 30 weeks.
62098569|NCT05355805|PLACEBO_COMPARATOR|Part B (Double-blind) placebo every week|Participants will receive placebo every week up to Week 15, then izokibep from Week 16 to Week 31.
62098570|NCT05355805|PLACEBO_COMPARATOR|Part B (Double-blind) placebo every other week|Participants will receive placebo every other week up to Week 14, then izokibep from Week 16 to Week 30.
62098571|NCT01810445||1|Patients undergoing a surgical bladder procedure in the main O.R.
62098572|NCT06102343|EXPERIMENTAL|acne scars treatment using the Alma Harmony platform with the ClearSkin applicator.|treatment of acne scars using the ClearSkin non-ablative ER:Glass 1540nm laser Module.
62098573|NCT06323525|EXPERIMENTAL|Patients with refractory or relapsed B-cell lymphoma|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, Power3 gene knock-out allogeneic CD19-targeting CAR-T.
62098574|NCT06478654|EXPERIMENTAL|PECS II group|"PECS II group will receive Bilateral Modified Pectoral Nerve Block (PECS II) Group Under all aseptic precautions and sonar guided.~10 mL of 0.25% bupivacaine will be injected. Then, the needle will be advanced to the interfascial plane between the pectoralis minor and serratus anterior muscle, and 20 mL of 0.25% bupivacaine will be administered with the same procedure. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine."
62098575|NCT06478654|EXPERIMENTAL|ESP group|"ESP group will receive Bilateral Thoracic Erector spinae plane block (ESPB) Group.~Under all aseptic precautions and sonar guided. We will inject 20ml of bupivacaine 0.25% into interfacial plane below to erector spinae, a manifest linear pattern will be visualized uplifting the muscle. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine"
62294324|NCT00541983|PLACEBO_COMPARATOR|2|
62294325|NCT00667706|ACTIVE_COMPARATOR|1|Patients who will undergo Laparoscopic Sleeve Gastrectomy
62294326|NCT00667706|ACTIVE_COMPARATOR|2|Patients who will undergo Laparoscopic Roux-en-Y Gastric Bypass
62294327|NCT05057364|EXPERIMENTAL|Heart Smart Group|Receives Heart Smart Intervention
62294328|NCT05548478|ACTIVE_COMPARATOR|TransEpi single step PRK|
62294329|NCT05548478|ACTIVE_COMPARATOR|alcohol assisted PRK|
62294330|NCT06054529||Participants in surgery|Surgical removal of the GBM tumor.
62294331|NCT02698189|EXPERIMENTAL|Birabresib 20 mg AML Cohort|Participants in the AML cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
62294332|NCT02698189|EXPERIMENTAL|Birabresib 20 mg DLBCL Cohort|Participants in the DLBCL cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
62294333|NCT01306760|EXPERIMENTAL|Ketamine|Ketamine used as the anaesthetic during ECT.
62294334|NCT01306760|ACTIVE_COMPARATOR|Propofol|Propofol, the standard anaesthetic, used during ECT.
62294335|NCT00469079|ACTIVE_COMPARATOR|1|Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
62466533|NCT04035603|EXPERIMENTAL|D-Cycloserine Augmentation|D-cycloserine (DCS) augmentation of CET sessions
62466534|NCT04035603|PLACEBO_COMPARATOR|Placebo Augmentation|Placebo (PBO) augmentation of CET sessions
62466535|NCT05160350|ACTIVE_COMPARATOR|Probiotic|Familact 2 plus (Zist takhmir pharmaceutical company, Iran), one capsule per day
62466536|NCT05160350|PLACEBO_COMPARATOR|Placebo|Similar capsule in shape and size (Zist takhmir pharmaceutical company, Iran), one capsule per day
62466537|NCT00422747|EXPERIMENTAL|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
62466538|NCT02392000|EXPERIMENTAL|WatchPAT and CBT-i Coach mobile app|Individuals use the WatchPAT sleep monitor and the CBT-i Coach app to self-manage insomnia
62466539|NCT05868564|EXPERIMENTAL|Atherectomy+Drug-coated balloon|The lesion treated by atherectomy + UltrafreeTM drug-coated balloon.
62466540|NCT05868564|ACTIVE_COMPARATOR|Drug-coated balloon|The lesion treated by UltrafreeTM drug-coated balloon only.
62661081|NCT04585542|EXPERIMENTAL|Polyethylene glycol 3350 (MiraLax)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~One study arm is the nonspecific laxative MiraLax (one dose of 17g). Since constipation can contribute to hyperkalemia, this arm will study the effect of treating constipation instead of direct cation exchange for potassium in the gut."
61909846|NCT02270996||NO Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) BEFORE the implementation of the Antimicrobial Stewardship Program.
61909847|NCT02270996||WITH Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) WITH the implementation of the Antimicrobial Stewardship Program.
61909848|NCT03163602|ACTIVE_COMPARATOR|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
62098576|NCT04927052|ACTIVE_COMPARATOR|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine is a clear, colorless gel in 1.2 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
62294336|NCT00469079|EXPERIMENTAL|2|Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
62294337|NCT00469079|EXPERIMENTAL|3|Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
62466541|NCT03148886|EXPERIMENTAL|PA intervention|The intervention consisted in a home-based adapted PA program defined at the inclusion, according to patient's capacities.
62661082|NCT04585542|EXPERIMENTAL|Sodium polystyrene sulfonate (Kayexalate)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
62661083|NCT04585542|EXPERIMENTAL|Patiromer (Veltassa)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
61909849|NCT03163602|ACTIVE_COMPARATOR|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
62098577|NCT04927052|ACTIVE_COMPARATOR|Juvederm Voluma with Lidocaine|Juvederm Voluma with Lidocaine is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine.
62466542|NCT01814462|EXPERIMENTAL|6 months CPAP|Application of continuous positive airway pressure (CPAP) therapy as established per routine clinical treatment. Home use of therapy for a period of 6 months.
61909850|NCT01785173|EXPERIMENTAL|Endoscopic-guided gauze pledgetting|All patients in the study group receive endoscopic-guided gauze pledgetting (EGGP) nasal anesthesia. Each patient will receive an anterior rhinoscopy to select the most patent meatus for gauze pledegetting by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up the acute angle between the shorter leg and hypotenuse of a right-angled gauze strip (already soaked with anesthesia/decongestant) and retract back just into the biopsy channel. When the transnasal endoscope tip is set in the nasal vestibule, the preloaded biopsy forceps is protruded slowly into the desired meatus under endoscope monitoring. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
62098578|NCT06167655|ACTIVE_COMPARATOR|High Dose|
62661084|NCT04585542|EXPERIMENTAL|Sodium zirconium cyclosilicate (Lokelma)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
62466543|NCT04274114|EXPERIMENTAL|Experimental group|Patients in this group will receive flexible doses of L-glutamine ranging from 5 to 25 grams once daily for 8 weeks. L-glutamine is administered as a powder dissolved in water.
62661085|NCT01186406|EXPERIMENTAL|Gliadel, Radiation Therapy, Avastin, Temodar|Single arm study where patients with newly diagnosed Grade IV malignant glioma will receive Gliadel at the time of resection, followed by radiation therapy (XRT), Avastin, and Temodar for approximately 6 1/2 weeks, followed by Avastin and Temodar post-radiation
62661086|NCT03757923|EXPERIMENTAL|metformin|TAB METFORMIN 500mg TDS
62661087|NCT03757923|EXPERIMENTAL|pioglitazone|TAB PIOGLITAZONE 30 mg OD
62661088|NCT00927472|EXPERIMENTAL|Malathion Gel|Malathion gel 0.5% 30 minute application
62661089|NCT00927472|ACTIVE_COMPARATOR|Nix Creme Rinse|Nix applied to scalp for 10 minutes
62661090|NCT01750502||coronary-artery-disease group|Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
62661091|NCT01750502||non-coronary-artery-disease group|Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
62661092|NCT05112133|PLACEBO_COMPARATOR|Control|Water administrated just before a meal
62661093|NCT05112133|EXPERIMENTAL|Mulberry leaf extract before|250 mg of Mulberry leaf extract was administered before a standard meal
62661094|NCT05112133|EXPERIMENTAL|Mulberry leaf extract during|250 mg of Mulberry leaf extract was administered during a standard meal
62661095|NCT03987048||Cirrhotic patients with septic shock|All consecutive adult cirrhotic patients admitted to the ICU with septic shock from 2002 to 2013.
62661096|NCT03625674|OTHER|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
62661097|NCT03625674|OTHER|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
62661098|NCT03625674|OTHER|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
62661099|NCT03625674|OTHER|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
62661100|NCT05311969|EXPERIMENTAL|groups/cohort|participants will perform the various neuropsychological tests provided for in the protocol
62098579|NCT06167655|SHAM_COMPARATOR|Low Dose|
62661101|NCT06398587|EXPERIMENTAL|Group 1 (onvansertib, GnP)|Patients receive onvansertib PO QD on days 1-5, 8-12, and 15-19 and gemcitabine IV and nab-paclitaxel IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo electrocardiography at baseline, as well as blood sample collection, tumor biopsy, CT, MRI, and/or PET throughout the trial.
62661102|NCT06398587|EXPERIMENTAL|Group 2 (onvansertib monotherapy lead-in, GnP)|Patients receive onvansertib PO QD on days 1-10. Patients then receive onvansertib, gemcitabine, and nab-paclitaxel as in Group 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo electrocardiography at baseline, as well as blood sample collection, tumor biopsy, CT, MRI, and/or PET throughout the trial.
62661103|NCT04503005|ACTIVE_COMPARATOR|Effect of fasting duration|study the effect of different daily fasting duration on body composition and blood lipid and inflammatory markers in healthy adults.
62661104|NCT04503005|OTHER|Effect of time restricted eating protocol on chronotype|study the effect of 2 month of time restricted eating on the chronotype profile of healthy adults.
62098580|NCT06081855||Repaired TOF|
62098581|NCT06081855||Unrepaired TOF|
62098582|NCT03980756|EXPERIMENTAL|Group A1|Period 1: Test Drug(AD-206 20mg) Period 2: Reference Drug(Esomeprazole 20mg)
62098583|NCT03980756|EXPERIMENTAL|Group A2|Period 1: Reference Drug(Esomeprazole 20mg) Period 2: Test Drug(AD-206 20mg)
62661105|NCT00118287|EXPERIMENTAL|Treatment (chemotherapy, chemoprotection)|Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
62661106|NCT01750346|ACTIVE_COMPARATOR|0.05% AH-8|Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
62661107|NCT01750346|ACTIVE_COMPARATOR|0.025% AH-8|Participants in the 0.025% AH-8 arm received the lower dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
62661108|NCT01750346|PLACEBO_COMPARATOR|Placebo|Participants in the Placebo arm received the placebo.
62661109|NCT03907436|SHAM_COMPARATOR|USDA diet arm|Participants will receive dietician counseling based on the USDA guidelines for Americans, 2010. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the Mediterranean arm.
62661110|NCT03907436|EXPERIMENTAL|Mediterranean diet arm|Participants will receive dietician counseling on a standard Mediterranean diet although they will not be told this diet is labelled as a Mediterranean diet. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the USDA diet arm.
62661111|NCT05534672|EXPERIMENTAL|Rapamycin arm|Each patient randomized to the rapamycin arm will receive rapamycin in liquid. The rapamycin will be administered in individually calculated doses depending on the body surface of participants
62661112|NCT05534672|PLACEBO_COMPARATOR|Placebo arm|The patients assigned to the placebo arm will receive placebo in liquid, analogically to the rapamycin group.
62661113|NCT02641821|EXPERIMENTAL|Nifedipine GITS|
62661114|NCT03881774|EXPERIMENTAL|experimental arm|cord blood derived CAR T cells group
62661115|NCT00350285|EXPERIMENTAL|1|Motivational enhancement therapy
62661116|NCT00350285|ACTIVE_COMPARATOR|2|Marijuana education
62661117|NCT00350285|NO_INTERVENTION|3|Delayed treatment control condition
62661118|NCT02311478|EXPERIMENTAL|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
62661119|NCT02325778|EXPERIMENTAL|CTI First|CTI ablation prior to left atrial ablation
62661120|NCT02325778|EXPERIMENTAL|CTI second|CTI ablation after left atrial ablation
62661121|NCT00533988|NO_INTERVENTION|5592|Standard triple lumen catheter
62661122|NCT00533988|ACTIVE_COMPARATOR|5593|Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
62661123|NCT04911504||Questionnaire survey group|All nurses were recruited from 3 tertiary hospitals in central China from 3rd October, 2019 to 15th December, 2019. A total of 992 clinical nurses from different nursing departments were recruited through convenience sampling. Data were collected using General information questionnaire, the Professional Quality of Life Scale, the Connor-Davidson Resilience Scale and General Perceived Self-Efficacy Scale.
62661124|NCT05518552|EXPERIMENTAL|manual Lumbar Traction|The subjects consist of 25 patients with chronic low back pain. They underwent a manual lumbar traction with Physiotherapist pulling the patients while lying prone on a couch
62661125|NCT05518552|EXPERIMENTAL|Prone traction|This group consist of patients with non specific chronic low back pain that were put on prone traction.
62661126|NCT01374386|NO_INTERVENTION|Usual Physical Activity|Participants in this arm are do not have access to Exergames, only usual physical activity at the gym
62661127|NCT01374386|EXPERIMENTAL|Exergaming|Participants in this arm will have access to usual physical activity at the gym as well as access to Exergaming equipment (video games that require physical activity)
62661128|NCT06105437|OTHER|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
62661129|NCT01613391||RYGBP|Patients underwent Roux-en-Y Gastric Bypass for morbid obesity.
62661130|NCT01613391||LAGB|Patients underwent Laparoscopic Adjustable Gastric Banding for morbid obesity.
62661131|NCT01218178||Sodium bicarbonate plus NAC|Sodium bicarbonate plus NAC
62661132|NCT01218178||Saline hydration plus NAC|Saline hydration plus NAC
62661133|NCT05052281|EXPERIMENTAL|Intervention group|"The first MB course session and technology training will take place in-person, prior to 23 weeks gestation. The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress. Sessions are delivered 1-on-1 with a trained facilitator and are based on principles of cognitive-behavioral therapy (CBT) and attachment theory. The MB course is divided into 3 sections: 1) Pleasant Activities; 2) Thoughts; 3) Contact with Others. Throughout each module, mindfulness skills training will be integrated as a strategy to help center participants. All participants will receive a Participant Manual for Families, containing worksheets that correspond to the 12 sessions."
62661134|NCT05052281|ACTIVE_COMPARATOR|Stress monitoring (control) group|This group will not receive any additional intervention but will engage in stress monitoring via biosensors and EMA text messages through the 14 week period
62098584|NCT03980756|EXPERIMENTAL|Group B1|Period 1: Test Drug(AD-206 40mg) Period 2: Reference Drug(Esomeprazole 40mg)
62661135|NCT01756755|NO_INTERVENTION|Control|Treat with severe sepsis / septic shock practice guideline
62661136|NCT01756755|EXPERIMENTAL|PMX HP|Treat with severe sepsis / septic shock practice guideline Treat with PMX-20R Hemoperfusion \[Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood\].
62661137|NCT01659905|ACTIVE_COMPARATOR|Montelukast|5 mg Chewable Tablet
62661138|NCT01659905|ACTIVE_COMPARATOR|Singulair|5 mg Chewable Tablet
62661139|NCT01976208|EXPERIMENTAL|Omalizumab|During the 4\~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
62661140|NCT01976208|PLACEBO_COMPARATOR|placebo|During the 4\~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
62098585|NCT03980756|EXPERIMENTAL|Group B2|Period 1: Reference Drug(Esomeprazole 40mg) Period 2: Test Drug(AD-206 40mg)
62098586|NCT05226481||TF-CBT|Trauma-focused cognitive-behavioral therapy (TF-CBT), an evidence-based method for the treatment of posttraumatic stress among youth, was provided to children and adolescents referred to CAMHS.
62098587|NCT04167891||Patients admitted in the intensive care unit|Patients with return of spontaneous circulation after cardiac arrest regardless of initial rhythm, and admitted in intensive care unit for post cardiac arrest care
62098588|NCT02860091||Ropivacaine infusion|Patients receiving continuous ropivacaine infusion for approximately 7 days via paravertebral nerve block or erector spinae catheter managed according to existing institutional protocols.
62098589|NCT03239210|ACTIVE_COMPARATOR|Ondansetron (OND)|24 mg/day for 4 weeks
62098590|NCT03239210|PLACEBO_COMPARATOR|Placebo (PL)|Placebo pill
62098591|NCT06038851|EXPERIMENTAL|Para-Sartorial Compartment (PACS) Block + Femoral Triangle Block (FTB) + IPACK block|"In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment).~For all patients, an infiltration between popliteal artery and capsule of the knee block (IPACK) will be performed concomitantly, in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000."
62098592|NCT06038851|ACTIVE_COMPARATOR|Femoral Triangle Block (FTB) + IPACK block|"This block is currently the most used in practice and is considered a standard of care. It consists of a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle~For all patients, an infiltration between popliteal artery and capsule of the knee block (IPACK) will be performed concomitantly, in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000."
62098593|NCT04938817|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
62098594|NCT04938817|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
62098595|NCT04938817|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab + MK-4830|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS MK-4830 800 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. MK-4830 will be administered by IV infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
62098596|NCT04938817|EXPERIMENTAL|Coformulation Favezelimab/Pembrolizumab|Participants receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) administered by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
62294338|NCT00902629|EXPERIMENTAL|Intervention|Intervention group contains the patients randomized for early treatment of their epiretinal fibrosis.
62294339|NCT00902629|NO_INTERVENTION|Control|Control contains patients not randomized for early surgery.
62294340|NCT05292755|EXPERIMENTAL|Carboxymethylcellulose (CMC) Artificial Tears|Refresh brand artificial tears containing 0.5% carboxymethylcellulose will be self-administered three times a day in each eye by the participants for 1 week in the experimental arm.
62294341|NCT05292755|PLACEBO_COMPARATOR|Preservative-free, CMC-free Artificial Tears|Systane brand artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be self-administered three times a day in each eye by the participants for 1 week in the control arm.
62294342|NCT04216173|EXPERIMENTAL|Acupuncture|
62661141|NCT03286894||1264 healthy schoolchildren|There is only one study group consisting of 1264 children recruited at school.
62294343|NCT00502840|EXPERIMENTAL|1|
62294344|NCT05072444|EXPERIMENTAL|QPX7728|Drug: QPX7728 beta lactamase inhibitor Other names: IV
62294345|NCT05072444|EXPERIMENTAL|QPX2014|Drug: QPX2014 antibiotic Other names: IV
62294346|NCT04328506|EXPERIMENTAL|T-R cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (test product) under fasted state, after a wash period of 5 days, the subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state.
62661142|NCT05202951||Patients with hemophilia|all adult patients follow-upin Hospital for hemophilia
62098597|NCT04938817|EXPERIMENTAL|R-DXd|Participants receive 5.6 mg/kg R-DXd via IV infusion every three weeks (Q3W) until progressive disease or discontinuation.
62098598|NCT06383884|EXPERIMENTAL|Patritumab deruxtecan treatment arm|Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
62098599|NCT05638659|EXPERIMENTAL|Experimental group|Twice a week for 8 weeks, total of 16 sessions course of computerized dual-task balance and home program.
62294347|NCT04328506|EXPERIMENTAL|R-T cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (test product) under fasted state.
62294348|NCT04328506|EXPERIMENTAL|T-R cohort after meal|Subjects will be administered with one single dose of CM082 tablet (test product) after meal, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (reference product) after meal.
62294349|NCT04328506|EXPERIMENTAL|R-T cohort after meal|Subjects will be administered with one single dose of CM082 tablet (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of CM082 tablet (test product) after meal
62661143|NCT01025895|ACTIVE_COMPARATOR|single bundle|acl reconstruction - single bundle technique
62661144|NCT01025895|EXPERIMENTAL|double bundle|acl reconstruction - double bundle technique
62098600|NCT05638659|ACTIVE_COMPARATOR|Control group|Medical consultation and traditional balance training, and assessed after 8 weeks.
62466544|NCT04274114|PLACEBO_COMPARATOR|Placebo group|Patients in this group will receive flexible doses of placebo ranging from 5 to 25 grams once daily for 8 weeks. Placebo is administered as a powder dissolved in water.
62661145|NCT03557944|EXPERIMENTAL|TAPER|"The intervention is medication reduction. This arm is comprised of:~1. Medication reconciliation~2. Identification of patient priorities for care~3. Identification of medications that are potentially appropriate for discontinuation/dose reduction~4. Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~5. Identification of medications for trial of discontinuation/dose reduction (shared decision making)~6. Pause of medication and clinical monitoring"
62661146|NCT05367999||Patients presenting with TLOC|A concurrent nested qualitative-quantitative design is used. Patients first presenting to an ED with TLOC (and witnesses) who have contributed to the quantitative part of this project will be offered participation in a qualitative interview study after completion of the iPEP during the initial study procedure. Capturing variation based on diagnosis, gender, age and participant/witness role, a purposive sample of participating participants and witnesses will be invited to semi-structured interviews in which they will be prompted to discuss their experiences of using the iPEP and their views on the accuracy in describing their peri-episodal experiences.
62098601|NCT04679584||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, SUEP).
62098602|NCT04679584||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (POP, SUEP).
62098603|NCT04679584||Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, POP).
62098604|NCT02846818|EXPERIMENTAL|Low mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were randomized to usual range MAP (40 to 60 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
62098605|NCT02846818|EXPERIMENTAL|High mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to intervention group MAP (60 to 80 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
62098606|NCT03437668|EXPERIMENTAL|Withania Somnifera Extract (WSE)|WSE 500 mg bid for 12 weeks
62098607|NCT03437668|PLACEBO_COMPARATOR|Placebo tablets|Placebo oral tablet bid for 12 weeks
62294350|NCT00624234|EXPERIMENTAL|NF-Tutoring Program 1|Tutoring Program I
62466545|NCT01038856|EXPERIMENTAL|+JAK2V61F mutation|Patients with MPN diagnoses and polycythemia vera who also have a confirmed JAK2V617F mutation
62466546|NCT00750594||1|
62294351|NCT00624234|EXPERIMENTAL|NF-Tutoring Program 2|Tutoring Program II
62466547|NCT00750594||2|
62466548|NCT01606540|EXPERIMENTAL|Reposition and immobilism|"The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain.~After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition."
62098608|NCT04831775|EXPERIMENTAL|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice over 8 weeks. Classes 1 \& 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 \& 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on. The intervention group will be asked to practice 20 minutes, 7 days a week.
62098609|NCT04831775|ACTIVE_COMPARATOR|Brain Games Only|An active control group will be used. The differing variable between the two groups is the class sessions. Those randomized to the control group will only receive a link to the BrainHQ games site. A specific amount of practice will not be prescribed, but the frequency and duration of participant's practice will be obtained from BrainHQ. Participants will receive a weekly phone call to maintain connection to the study. Data collection will be on the same schedule as the intervention group.
62098610|NCT01588704|EXPERIMENTAL|Neoadjuvant Bevacizumab|Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.
62098611|NCT01746394|EXPERIMENTAL|Parents as Teachers Enhanced|Participants in the Parents as Teachers Enhanced (PaTE) intervention arm will receive the enhanced diet and activity maternal, infant, and early childhood home visiting program
62294352|NCT00624234|NO_INTERVENTION|Typically Developing Readers|Control group
62661147|NCT04688788|EXPERIMENTAL|Rituximab|Intravenous biosimilar rituximab (Ruxience®, Rixathon® or other biosimilar rituximab) 1000 mg given every 6th month (first 2 infusions 1000mg/1000 mg given 2 weeks apart).
62661148|NCT04688788|ACTIVE_COMPARATOR|Ocrelizumab|Intravenous ocrelizumab (Ocrevus®) 600 mg every 6th month (first 2 infusions 300 mg/300 mg given 2 weeks apart).
61909851|NCT01785173|ACTIVE_COMPARATOR|Cotton-tipped applicator pledgetting|"Another randomized group of patients will receive cotton-tipped applicator gauze pledgetting (CTGP) method of nasal anesthesia. Two cotton-tippled applicators help determine the following: (a) right or left side, (b) inferior or middle nasal meatus (INM or MNM) and (c) the need of local epinephrine. The investigators apply gently in parallel two sterile 3 x 1/10, double-ended, plastic shaft cotton-tipped applicators, pretreated with minimal amount of 2% viscous lidocaine plus 4% liquid lidocaine, to lubricate and anesthetize the more patent meatus One cotton-tipped applicator is re-used to deliver a triangular gauze strip to the selected meatus during the gauze pledgetting procedure."
61909852|NCT03250364|EXPERIMENTAL|Multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + multilayer bandage consisting of three layers. The first was a 100% cotton tubular bandage which will be directly placed on the skin to prevent any injury (Tubinylex TM). The second layer is a paddle with the purpose of unify and increase pressure (Emulsified Latex FoamTM 8mm, Thuasne, France); and the third layer of inelastic bandages (6, 8 and/or 10 cm Rosidal K Short Stretch Bandage, Germany). All the bandage layers will be placed from caudal to cranial in a circular disposition, overlapping in one third the previous layer for a correctly cover of the limb and not to leave open spaces. The cotton tubular bandage and the short-stretch bandage could be cleaned without losing their material properties."
62098612|NCT01746394|ACTIVE_COMPARATOR|Parents as Teachers|Participants in the Parents as Teachers (PaT) control arm will receive the standard maternal, infant, and early childhood home visiting program
62098613|NCT05646511|ACTIVE_COMPARATOR|Control arm SCRT+CAPOX|The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, q3wks).
62098614|NCT05646511|EXPERIMENTAL|Experimental arm SCRT+CAPOXIRI|The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOXIRI (capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, and irinotecan 150 mg/m2 intravenously on day 1\*, q3wks). If the initial dose of irinotecan 150 mg/m2/day is tolerated, the dose can be increased to 200 mg/m2/day from the second cycle.
62098615|NCT05464927||Participants pre CDT|"* Participants with lipedema~* Biologically Female~* Age range = 18-80 years~* BMI range = 18 to 40 kg/m2~* BMI range = 18 to 40 kg/m2"
62294353|NCT00624234|EXPERIMENTAL|IRD-Tutoring Program 1|Tutoring Program I
62294354|NCT00624234|EXPERIMENTAL|IRD-Tutoring Program 2|Tutoring Program II
62294355|NCT00624234|NO_INTERVENTION|Waitlist Control|Intervention Control Group (RD)
62294356|NCT02021721||Cohort|Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
62294357|NCT02309047||WHO anovulation|WHO I, II. III anovulation. See inclusion criteria
62294358|NCT01596179|EXPERIMENTAL|Interactive navigational support|Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
62294359|NCT01596179|ACTIVE_COMPARATOR|control arm|Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
62294360|NCT01026584|OTHER|drug|
62466549|NCT01606540|ACTIVE_COMPARATOR|Surgery|"The method of surgery is type bridging.~After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation."
62466550|NCT01275586|EXPERIMENTAL|Tasigna|Following enrollment each subject will initially receive the drug Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily.
62661149|NCT05491967||Continuous Positive Airway Pressure (CPAP)|Obstructive Sleep Apnea/Hypopnea Syndrome treated with Continuous Positive Airway Pressure (CPAP
62661150|NCT05491967||Mandibular Advancement Orthosis|Obstructive Sleep Apnea/Hypopnea Syndrome treated with Mandibular Advancement Orthosis
62098616|NCT05464927||Controls|"* Participants without lipedema~* Biologically Female~* Age range = 18-80 years~* BMI range = 18 to 40 kg/m2"
62294361|NCT00940277|EXPERIMENTAL|Enhanced Couples Group|Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
62098617|NCT05464927||Participants post CDT|"* Participants with lipedema~* Biologically Female~* Age range = 18-80 years~* BMI range = 18 to 40 kg/m2~* BMI range = 18 to 40 kg/m2"
62098618|NCT05180045|EXPERIMENTAL|LINKED-BP Program|"Patients in the LINKED-BP Program will be trained to measure their BP with an Omron 10 series device. Patients who have smartphones will download the patient facing app and receive a unique link from the study team. Patients who do not own a smartphone will be provided one with a data plan for the duration of the study. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal.~CHWs will support patients by: (1) providing education on how to manage BP through self-monitoring and practicing dietary modification and exercise; (2) reinforcing positive BP self-management through follow-up encounters; (3) assisting with linkages to existing clinical and administrative services; and (4) link participants with community resources to address health-related social needs.~The staff in each participating community health center practice will be trained in blood pressure measurement best practices."
62098619|NCT05180045|NO_INTERVENTION|Enhanced Usual Care|Patients in the Enhanced Usual Care Arm, will receive care as usual from thier primary care provider and will be trained to measure their BP with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
62294362|NCT00940277|EXPERIMENTAL|Support Group|Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
62661151|NCT01768273|EXPERIMENTAL|Midazolam and 824|2 mg midazolam (oral syrup) Day 1 and Day 17. 400 mg PA-824 once daily Day 4 - 17.
62661152|NCT02253498|EXPERIMENTAL|Deep Brain Stimulation|Deep Brain Stimulation is on
62661153|NCT02253498|SHAM_COMPARATOR|Sham Stimulation|placebo
62661154|NCT00759096|EXPERIMENTAL|Acrysof ReSTOR IOL|AcrySof ReSTOR Intraocular lens (IOL) implanted
62661155|NCT03784495|PLACEBO_COMPARATOR|Placebo (P)|Placebo.
62661156|NCT03784495|EXPERIMENTAL|Melatonin (M)|1 mg/day of melatonin.
62661157|NCT03784495|EXPERIMENTAL|Essential Aminoacids (eAA)|4 g/day of essential aminoacids
62661158|NCT03784495|EXPERIMENTAL|Essential Aminoacids + Melatonin (eAAM)|4 g/day of essential aminoacids and 1 mg/day of melatonin
62661159|NCT02929004|EXPERIMENTAL|Vibrasens|"In addition of classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction, this group will follow a local vibration training, using small and portable vibrator device.~Training programme: vibration training 3/week from Day 1 to Day 60"
62661160|NCT02929004|NO_INTERVENTION|Usual activities|Usual activities from day 1 to Day 60 during their classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction.
62661161|NCT04593472|EXPERIMENTAL|SHARE|"SHARE components include: 1) a letter from the practice introducing the initiative, 2) access to a designated person (medical assistant, social worker, nurse, or lay person) trained to lead advance care planning discussions, 3) person-family agenda-setting to align perspectives about the role of the caregiver and stimulate discussion about goals of care, and 4) education about communication and available resources, including a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor, a blank easy to complete advance directive, and facilitated registration to the patient portal (for patient and caregiver participants) to extend electronic interactions and information access to family."
62661162|NCT04593472|PLACEBO_COMPARATOR|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
62661163|NCT01039675|EXPERIMENTAL|GSK573719/GW642444|
62661164|NCT01039675|PLACEBO_COMPARATOR|Placebo|
62098620|NCT02967666|EXPERIMENTAL|FDG PET/MRI, DOTANOC PET/MRI|FDG PET/MRI and DOTANOC PET/MRI will be performed.
62098621|NCT03686384|EXPERIMENTAL|SVT-15652|1 vial twice daily
62098622|NCT03686384|PLACEBO_COMPARATOR|Placebo|1 vial twice daily
62098623|NCT05798104|EXPERIMENTAL|Collaborative nurse-pharmacist counseling|Collaborative nurse-pharmacist counseling - At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
62661165|NCT01180777|OTHER|etafilcon A (A)/etafilcon A (B)/etafilcon A (C)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
62661166|NCT01180777|OTHER|etafilcon A (A)/etafilcon A (C)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
62098624|NCT02861573|EXPERIMENTAL|Pembrolizumab+Olaparib|Participants with adenocarcinoma (AC) mCRPC in Cohort A will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week dosing cycle (Q3W) and olaparib 400 mg capsules or 300 mg tablets by mouth (PO) twice a day (BID) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with olaparib will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
62098625|NCT02861573|EXPERIMENTAL|Pembrolizumab+Docetaxel+Prednisone|Participants with AC mCRPC in Cohort B will receive pembrolizumab 200 mg IV on Day 1 Q3W, docetaxel 75 mg/m\^2 IV on Day 1 Q3W, and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Participants will only be permitted to receive a maximum of 10 cycles of docetaxel and prednisone. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
62098626|NCT02861573|EXPERIMENTAL|Pembrolizumab+Enzalutamide|Participants with AC mCRPC in Cohort C will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with enzalutamide will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
62098627|NCT02861573|EXPERIMENTAL|Pembrolizumab+Abiraterone+Prednisone|Participants with AC mCRPC in Cohort D will receive pembrolizumab 200 mg IV on Day 1 Q3W, abiraterone acetate 1000 mg PO QD and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
62098628|NCT02861573|EXPERIMENTAL|Pembrolizumab+Lenvatinib: AC|Participants with AC mCRPC in Cohort E will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
62098629|NCT02861573|EXPERIMENTAL|Pembrolizumab+Lenvatinib:t-NE|Participants with neuroendocrine (t-NE) mCRPC in Cohort F will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
62098630|NCT02861573|EXPERIMENTAL|Pembrolizumab/Vibostolimab coformulation|Participants with AC mCRPC in Cohort G will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
62098631|NCT02861573|EXPERIMENTAL|Pembrolizumab/Vibostolimab coformulation:t-NE|Participants with t-NE mCRPC in Cohort H will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
62098632|NCT02861573|EXPERIMENTAL|Pembrolizumab+Carboplatin+Etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 1 will receive pembrolizumab 200 mg IV on Day 1 Q3W + carboplatin titrated to an area under the plasma drug concentration-time curve \[AUC\] 5 IV on Day 1 Q3W + etoposide 100 mg/m\^2 IV on Days 1, 2, and 3 Q3W. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 or 2 of the 3 drugs due to adverse events in the combination may continue the study with the other combination drug/drugs.
62098633|NCT02861573|EXPERIMENTAL|Carboplatin+Etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 2 will receive carboplatin titrated to an area under the plasma drug concentration-time curve \[AUC\] 5 IV on Day 1 Q3W + etoposide 100 mg/m\^2 IV on Days 1, 2, and 3 Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
62294363|NCT02661594|EXPERIMENTAL|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
62294364|NCT02661594|EXPERIMENTAL|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
62294365|NCT02661594|EXPERIMENTAL|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
62294366|NCT02661594|ACTIVE_COMPARATOR|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
62294367|NCT02508155|EXPERIMENTAL|MEDI7352 IV|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
62294368|NCT02508155|PLACEBO_COMPARATOR|IV Placebo|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
62294369|NCT02508155|EXPERIMENTAL|MEDI7352 Subcutaneous Injection|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
62098634|NCT02861573|EXPERIMENTAL|Belzutifan|Participants with AC mCRPC in Cohort J will receive belzutifan 120mg QD in the initial cohort. If an efficacy signal is detected in this arm based on a totality of evidence, Cohort J may be expanded further where participants will be randomized 1:1 to receive either belzutifan 120 mg QD or belzutifan 120 mg QD and pembrolizumab 200 mg Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
62294370|NCT02508155|PLACEBO_COMPARATOR|Subcutaneous Placebo|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
62661167|NCT01180777|OTHER|etafilcon A (C)/etafilcon A (A)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
62661168|NCT01180777|OTHER|etafilcon A (B)/etafilcon A (C)/etafilcon A (A)|Printed etafilcon A Lens with PVP (B) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
62661169|NCT01180777|OTHER|etafilcon A (C)/etafilcon A (B)/etafilcon A (A)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
62661170|NCT01180777|OTHER|etafilcon A (B)/etafilcon A (A)/etafilcon A (C)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
62661171|NCT01200914|ACTIVE_COMPARATOR|'PTA without use of the GORE VIABAHN'|Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
62661172|NCT01200914|EXPERIMENTAL|PTA with covered stent|Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
62661173|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
62661174|NCT03543995||Enuresis nocturna|Patients aged 6 to 15 years with at least one night-time wetting weekly
62661175|NCT03543995||Normal population|Patients who were admitted to the urology clinic with a complaint of abdominal or lateral pain, who had no NE and had a direct abdominal x-ray examination
62661176|NCT00788333|EXPERIMENTAL|A|Combination
62661177|NCT06059859|EXPERIMENTAL|Augmented reality robot-assited radical prostatectomy|Robot-assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
62661178|NCT06059859|ACTIVE_COMPARATOR|Robot-assited radical prostatectomy|Robot-assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction
62661179|NCT02502500|ACTIVE_COMPARATOR|Celecoxib|Celecoxib
62661180|NCT02502500|EXPERIMENTAL|AKB-6548 and Celecoxib|AKB-6548; celecoxib
62661181|NCT01516125||Screening only - no intervention|
62294371|NCT04278911||Participates|This is an observational study
62294372|NCT04514614|EXPERIMENTAL|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62294373|NCT02276261|EXPERIMENTAL|Vertical|Vaginal cuff closure performed in a vertical manner.
62294374|NCT02276261|ACTIVE_COMPARATOR|Horizontal|Vaginal cuff closure performed in a horizontal manner.
62294375|NCT02760290|EXPERIMENTAL|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
62294376|NCT02760290|ACTIVE_COMPARATOR|Intraperitoneal group|Conventional transperitoneal cesarean will perform
62661182|NCT00182819|OTHER|radiotherapy|Radiotherapy (control arm), 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
62661183|NCT00182819|EXPERIMENTAL|Temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles (experimental arm)
62661184|NCT03956706|EXPERIMENTAL|Dose Escalation (18Gy)|Receive additional dose of 18Gy to the subventricular zone
62661185|NCT03956706|EXPERIMENTAL|Dose Escalation (20Gy)|Receive additional dose of 20Gy to the subventricular zone
62661186|NCT03956706|EXPERIMENTAL|Dose Escalation (22Gy)|Receive additional dose of 22Gy to the subventricular zone
62661187|NCT06217549|EXPERIMENTAL|healthy participants|healthy, physically active people will be included the study.
62661188|NCT04359212||Medical|subject with a confirmed infection for COVID-19 and needing admission to a medical division for a non-severe clinical disease
62661189|NCT04359212||Intensive|subject with a confirmed infection for COVID-19 and needing admission to an Intensive Cure Unit for a severe to critical disease
62294377|NCT02850302|OTHER|FDG PET + exome analysis before treatment and after|Participants will performed one PET with FDG an tumor exome analysis before treatment is started.After 6 cycles of chemotherapy a second PET with FDG and a second tumor exome analysis will be performed
62294378|NCT05995535|EXPERIMENTAL|LFX/PGB|"PGB/day 1=400mg, day 2-7=600mg each day, day 8=400mg, day 9=200mg, day 10=100mg~LFX/day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg"
62466551|NCT00770718|EXPERIMENTAL|Recombinant Activated Factor VII|The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is \>1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given. If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
62294379|NCT05995535|ACTIVE_COMPARATOR|LFX/PLA-PGB|"PLA-PGB/day 1-7= 0mg each day, day 8, 9, and 10 =0mg each day~LFX/ day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg"
62294380|NCT05245123||Families of rare diseased children|Clinical study participants are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Centre Mannheim due to the rare disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
62661190|NCT01181479|EXPERIMENTAL|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel. Type of intervention is drug.
62661191|NCT01181479|ACTIVE_COMPARATOR|Lessina crossover to AG200-15|Lessina containing ethinyl estradiol and levonorgestrel for 6 cycles followed by AG200-15 for 6 cycles. Type of intervention is drug.
62661192|NCT00672009|EXPERIMENTAL|One|
62098635|NCT02861573|EXPERIMENTAL|Pembrolizumab+Belzutifan|Participants with AC mCRPC in Cohort J will receive belzutifan 120mg QD in the initial cohort. If an efficacy signal is detected in this arm based on a totality of evidence, Cohort J may be expanded further where participants will be randomized 1:1 to receive either belzutifan 120 mg QD or belzutifan 120 mg QD and pembrolizumab 200 mg Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
62294381|NCT05245123||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
62294382|NCT04004052|ACTIVE_COMPARATOR|Group 1|Blockade of the LFCN is performed for therapeutic management of MP in group 1.
62294383|NCT04004052|ACTIVE_COMPARATOR|Group 2|Ten sessions of conventional TENS were applied to the group 2 daily 20 minutes per session, 5 days per week, for 2 weeks.
62661193|NCT03602781|PLACEBO_COMPARATOR|Cohort 1: Placebo 99.999% Nitrogen|"Randomized Withdrawal Treatment Period Week 1-8:~Placebo at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
62098636|NCT06615323|EXPERIMENTAL|Polyphonic Lullaby Group|After discharge, mothers will be asked to listen to the Dandini Dandini Dastana lullaby by singer Mircan Kaya, which they downloaded from the YouTube application, from a distance of one meter (away from the baby's head to minimize radioactive effects) and by turning the phone to airplane mode just before sleep. In case of active sleep transition (signs of sleep transition such as slowing down muscle movements and closing eyes), the polyphonic lullaby volume will be gradually reduced. The polyphonic lullaby will be lowered to 55 decibels for the first 5 minutes after falling asleep and then to 25 decibels and then turned off. In order to reduce the effect of confounding factors, mothers in the polyphonic lullaby group who used another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the scope of the study.
62294384|NCT04004052|SHAM_COMPARATOR|Group 3|Sham TENS was applied to the group 3 with the same protocol.
62294385|NCT03941002|PLACEBO_COMPARATOR|Clinical pressure support|The level of inspiratory pressure support will be selected by the attending physician
62294386|NCT03941002|ACTIVE_COMPARATOR|Reduced pressure support|The level of inspiratory pressure support will be reduced by 25%
62294387|NCT03941002|ACTIVE_COMPARATOR|Lowest pressure support|The level of inspiratory pressure support will be reduced by 50%
62294388|NCT04502615|EXPERIMENTAL|Sand|Participants perform 5 single leg hops onto a Sand surface from a 30cm height
62294389|NCT04502615|ACTIVE_COMPARATOR|Artificial grass|Participants perform 5 single leg hops onto a grass surface from a 30cm height
61909853|NCT03250364|EXPERIMENTAL|Simplified multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + double compression bandage consisting of two layers, made up of a first rigid cotton bandage (11 cm Bande coton Short Stretch; Thuasne, France) and a second elastic bandage (BiflexTM 16 light; Thuasne, France). The two layers will be placed caudal to cranial in a circular manner, overlapping in one third the previous layer. The elastic bandage have squares drawn to help to the physiotherapist to control the stretch they given to the bandage. The two bandages could be cleaning without losing their properties. If there was any oedema concentration or a fibrous place, a paddle pad will be put in these places (Mobiderm TM, Thuasne, France)."
62294390|NCT04502615|ACTIVE_COMPARATOR|Firm Ground|Participants perform 5 single leg hops onto a firm ground surface from a 30cm height
62294391|NCT06423248|ACTIVE_COMPARATOR|Ginger|Participants consumed 3g of dried powdered Ginger (Zingiber officinale) daily for 12 weeks.
62294392|NCT06423248|ACTIVE_COMPARATOR|Cinnamon|Participants consumed 3g of dried powdered Cinnamon (Cinnamomum) daily for 12 weeks.
62294393|NCT06423248|ACTIVE_COMPARATOR|Black Seed|Participants consumed 3g of dried powdered Black Seed (Nigella sativa) daily for 12 weeks.
62294394|NCT06423248|PLACEBO_COMPARATOR|Placebo|Participants consumed 3g of powdered corn starch daily for 12 weeks.
62294395|NCT01696357||Adolescents with asthma|Ages 13-17 with an asthma diagnosis-both symptomatic and non-symptomatic- and with currently prescribed asthma medication.
62098637|NCT06615323|EXPERIMENTAL|Pish Pish Sound Group|After discharge, mothers will be asked to turn on the Piş Piş sound downloaded from the YouTube application and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by turning the phone to airplane mode just before sleep. In case of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the piş piş sound will be gradually reduced. The polyphonic lullaby played will be at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effect of confounding factors, mothers in the piş piş sound group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the scope of the research.
62098638|NCT06615323|NO_INTERVENTION|Model Group|The mothers in the control group will be given general sleep education on ensuring sleep hygiene before discharge, and brochures containing information on ensuring sleep hygiene will be distributed, and no other application will be made. In order to reduce the effect of confounding factors, the mothers in the control group will be asked at each interview whether they used any assistive methods to facilitate the transition to sleep, and newborns in the control group who were determined to use piş piş sounds or polyphonic lullabies will be excluded from the scope of the study.
62294396|NCT01696357||Adolescents without asthma|Ages 13-17 without an asthma diagnosis and without any other respiratory condition that presents with asthma-like symptoms.
62466552|NCT00770718|EXPERIMENTAL|Prothrombin Complex Concentrate (PCC)|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is \>1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
62466553|NCT00770718|ACTIVE_COMPARATOR|Fresh Frozen Plasma (FFP)|The last five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is \>4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to \>1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
61909854|NCT03250364|EXPERIMENTAL|Cohesive bandage group|Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + cohesive bandage consisting of a single short-stretched layer that will be put directly on the subject skin and stick on itself (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States). It will be placed in a circular manner distal to cranial with a paddle pad in the elbow fold not to damage this moving part. This bandage will be reused twice in the same subject.
62466554|NCT00003040|EXPERIMENTAL|Transoral CO2 laser laryngectomy and RT|Transoral CO2 laser supraglottic laryngectomy and irradiation
62466555|NCT01311245|EXPERIMENTAL|Stage-tailored|At baseline and three months later
62294397|NCT02201758|PLACEBO_COMPARATOR|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
62466556|NCT01311245|EXPERIMENTAL|Non-stage-tailored|At baseline and three months later
62466557|NCT01311245|NO_INTERVENTION|Control group|Assessment only
62466558|NCT04720664|EXPERIMENTAL|oral SM-88|SM-88 taken with three conditioning agents: methoxsalen, phenytoin, and sirolimus
62466559|NCT04567147|EXPERIMENTAL|Probiotic|Formula probiotic contains freeze-dried Lactobacillus casei, Bafidobacterium animals, Bifidobacterium longum, Bifidobacterium bidium and Lactobacillus plantarum, each at a dosage of 3.0E+10 CFU per 2g sachet.
62466560|NCT04567147|PLACEBO_COMPARATOR|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
61909855|NCT03250364|EXPERIMENTAL|Adhesive compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + adhesive compression bandage consisting of an elastic bandage (BiplastTM Thuasne, France. Measures: 10cm x 2,5 m) which will put over a pre-tape bandage not to damage the skin. It will be placed in a circular disposition from distal to cranial. In each physiotherapy session, the bandage has to be replaced with a new one."
62294398|NCT02201758|EXPERIMENTAL|flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
62294399|NCT02095301|EXPERIMENTAL|Control plus herbal extract|Control plus herbal extract
62294400|NCT02095301|PLACEBO_COMPARATOR|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
62294401|NCT03386084|EXPERIMENTAL|direct application of microwave diathermy and motor control|
62294402|NCT03386084|PLACEBO_COMPARATOR|application of microwave diathermy without therapeutic effects|
62294403|NCT03760588|EXPERIMENTAL|Sacubitril/valsartan|Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: Sacubitril/valsartan 24/26 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure \> 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by sacubitril/valsartan 49/51 mg b.i.d. for 2-4 weeks. Provided blood pressure \> 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to sacubitril/valsartan 97/103 mg b.i.d. will be performed.
62294404|NCT03760588|PLACEBO_COMPARATOR|Placebo|Matched to the comparator.
62294405|NCT02479347|EXPERIMENTAL|Chloraprep|Preoperative skin preparation with chlorhexidine 2% in alcohol 70% solution
62294406|NCT02479347|ACTIVE_COMPARATOR|Povidone-iodine|Preoperative skin preparation with povidone-iodine 10% solution
62294407|NCT06343090|EXPERIMENTAL|Arm-1: CD19 CAR T and CD22 CAR T-cell sequential treatments (Sequential CAR)|
62294408|NCT06343090|EXPERIMENTAL|Arm-2: CD19 CAR T-cell treatment bridging to HSCT (CAR+HSCT)|
61909856|NCT03250364|EXPERIMENTAL|Kinesiotaping bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + kinesiotaping bandage consisting of K-Active Tape. The k-tape will be pasted directly on the skin and put longitudinally in thin bands in a cranio-caudal disposition. The width of the bandage will be of 5cm, and will be cut in four bands that will cover all the upper limb cranial to caudal in a spiral way surrounded it. The bandage will be placed moving the limb into internal and external rotation for putting the skin in a little stretch without lengthen the tape."
61909857|NCT01886027|EXPERIMENTAL|Emotional Awareness and Expression|Emotional awareness and expression training (EAET) is an emotional processing intervention.
61909858|NCT01886027|ACTIVE_COMPARATOR|Relaxation|Relaxation training will teach patients different relaxation training skills.
62098639|NCT01495637|EXPERIMENTAL|GM-CSF|GM-CSF is given in one of four treatment regimens (three days at a dose of 30, 62, or 125 mcg/m2/day, or extended dosing at 125 mcg/m2 through post-trauma day 6) to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
62098640|NCT04572295|EXPERIMENTAL|Part 1 Dose Escalation: E7090 + Fulvestrant or Exemestane|Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 milligram (mg), intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later, or along with exemestane 25 mg tablet, orally, once daily in 28 days cycle. Each cycle length equals to (=) 28 days.
62294409|NCT03115996|EXPERIMENTAL|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
62294410|NCT03115996|EXPERIMENTAL|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
62294411|NCT03115996|EXPERIMENTAL|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
62294412|NCT03115996|EXPERIMENTAL|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
62294413|NCT03809624|EXPERIMENTAL|Single Agent Escalation|INBRX-105 will be escalated in patients with locally advanced or metastatic solid tumors.
62294414|NCT03809624|EXPERIMENTAL|Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
62294415|NCT03809624|EXPERIMENTAL|Expansion Cohort Melanoma|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
62294416|NCT03809624|EXPERIMENTAL|Expansion Cohort PD-L1 Positive Basket|Patients with gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
62294417|NCT03809624|EXPERIMENTAL|Expansion Cohort Nasopharyngeal or Oropharyngeal Carcinoma|Patients with head and neck squamous cell carcinoma (NPC or OPC) will be treated with single-agent INBRX-105 at either the MTD or RP2D.
62294418|NCT03809624|EXPERIMENTAL|INBRX-105 Escalation in Combination with Pembrolizumab|INBRX-105 will be escalated in combination with Pembrolizumab in pateitns with locally advanced or metastatic solid tumors.
62294419|NCT03809624|EXPERIMENTAL|Combination Expansion Cohort Non-small Cell Lung Cancer|CPI relapsed/refractory patients will be treated with INBRX-105 in combination with Pembrolizumab.
62294420|NCT03809624|EXPERIMENTAL|Combination Expansion Cohort Melanoma|CPI relapsed/refractory patients will be treated with INBRX-105 in combination with Pembrolizumab.
62294421|NCT03809624|EXPERIMENTAL|Combination Expansion Cohort Cohort PD-L1 Positive Basket|CPI-relapsed/refractory patients with head and neck squamous cell carcinoma, gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-105 in combination with Pembrolizumab.
62294422|NCT03809624|EXPERIMENTAL|Combination Expansion Cohort CPI Naive Non-small Cell Lung Cancer|CPI naive patients (PD-L1 IHC between 1 and 49%) will be treated with INBRX-105 in combination with Pembrolizumab.
62294423|NCT03809624|EXPERIMENTAL|Combination Expansion Cohort CPI Naive HNSCC|CPI naive patients (PD-L1 IHC \>50%) will be treated with INBRX-105 in combination with Pembrolizumab.
61909859|NCT01886027|NO_INTERVENTION|Wait-list control|Standard medical care until the 3-month follow-up is completed
61909860|NCT00402233|OTHER|Placebo|
61909861|NCT00402233|OTHER|Pramipexole 0.5 mg Tid|Pramipexole 0.5 mg tid (three times a day)
61909862|NCT00402233|OTHER|Pramipexole 0.5 mg Bid|Pramipexole 0.5 mg bid (bis in die (two times a day))
61909863|NCT00402233|OTHER|Pramipexole 0.75 mg Bid|Pramipexole 0.75 mg bid (bis in die (two times a day))
62294424|NCT05740241||Healthy participants aged more than 65 years old|Participation in 8 physical activity sessions, lasting 45 minutes, at the rate of 2 sessions per week
62661194|NCT03602781|ACTIVE_COMPARATOR|Cohort 2: iNO 75 mcg/kg IBW/hr|"Randomized Withdrawal Treatment Period Week 1-8:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
62661195|NCT00562341||bariatric surgery|description of enrollees
61909864|NCT04887376|ACTIVE_COMPARATOR|Mirror Therapy|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors. In addition to this application, mirror therapy was applied simultaneously with NMES.
61909865|NCT04887376|PLACEBO_COMPARATOR|Control|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors.
61909866|NCT01151943|EXPERIMENTAL|Transversus Abdominis Plane (TAP) Block|Patients will receive a bilateral transversus abdominis plane block
61909867|NCT01151943|ACTIVE_COMPARATOR|Incisional Infiltration of Local Anesthetic|Patients will receive an incisional infiltration with local anesthetic (continuous administration of levobupivacaïne during 48 hours)
61909868|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
61909869|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
61909870|NCT04468529|EXPERIMENTAL|Investigational drug group|Injectable Neucardin + standard basic therapeutic medication
62098641|NCT04572295|EXPERIMENTAL|Part 2 Monotherapy: E7090|Participants will receive E7090 tablets, orally, once daily in 28 days cycle. Each cycle length =28 days.
62661196|NCT00962962|OTHER|Low-Amount/Moderate Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
61909871|NCT04468529|PLACEBO_COMPARATOR|Placebo group|placebo + standard basic therapeutic medication
61909872|NCT03037645|EXPERIMENTAL|Dose escalating cohorts of SNS-062|Sequential groups, 25, 50, 100, 200, 300, 400 and 500 mg twice daily to determine maximum tolerated dose and recommended dose (RD) in the treatment of various hematological cancers followed by expansion of the recommended dose cohort in Phase 2 of the study treating hematological cancers.
61909873|NCT02108678|EXPERIMENTAL|ACT-ME|ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
62294425|NCT01823809|OTHER|Imaging arm|There is one study arm only. The imaging modalities will be performed in all patients.
62294426|NCT03651076|EXPERIMENTAL|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
62294427|NCT03651076|NO_INTERVENTION|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
62098642|NCT04572295|EXPERIMENTAL|Part 3 Dose Expansion: E7090 + Fulvestrant|"Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 mg, intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later. Each cycle length =28 days.~The dose of E7090 for Part 3 in combination with fulvestrant will be determined based on the safety, tolerability, pharmacokinetic (PK), and biomarker data obtained from Part 1."
62098643|NCT06431698|ACTIVE_COMPARATOR|Control group|Correction of deformation using the adjustable Earwell device
62098644|NCT06431698|EXPERIMENTAL|Intervention group|Correction of deformation using the custom-made silicone device
62661197|NCT00962962|OTHER|High-Amount/Moderate-Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
62098645|NCT03395587|EXPERIMENTAL|Experimental intervention|Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
62294428|NCT05304364|EXPERIMENTAL|DLP-160 alpha-10|One time single Naltrexone Implant for a duration of 123 days
62661198|NCT00962962|OTHER|High-Amount/Vigorous-Intensity Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
62661199|NCT00962962|OTHER|Low-Amount/Moderate-Intensity Exercise + Diet|"* Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~* Diet - The CLI sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
62661200|NCT03877809|EXPERIMENTAL|Open label trial|Sirolimus 0.5 mg tablets
62661201|NCT01609972|EXPERIMENTAL|Test|Subjects randomized to this arm will be trialed and implanted with the Nevro Senza System
62098646|NCT03395587|OTHER|Control intervention|"Standard therapy:~Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)"
62098647|NCT01363479|EXPERIMENTAL|Oral palonosteron plus dexamethasone|Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
62294429|NCT04947202||Safil Mesh|
62661202|NCT01609972|ACTIVE_COMPARATOR|Control|Subjects randomized to this arm will be trialed and implanted with a commercially available SCS system.
62661203|NCT01277419||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist
62098648|NCT01363479|ACTIVE_COMPARATOR|I.V. palonosetron plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
62661204|NCT01277419||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist
62661205|NCT01277419||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
62661206|NCT01277419||Crohn's disease|Patients with Crohn's disease
62661207|NCT01277419||Acute anterior uveitis|Patients with acute anterior uveitis
62661208|NCT01277419||Axial psoriatic arthritis|Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)
62661209|NCT05306288||Individuals with elevated-risk lung cancer (screening population)|
62661210|NCT00528151|PLACEBO_COMPARATOR|2|"1. curcumin~2. placebo"
62661211|NCT01814085|EXPERIMENTAL|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
62737037|NCT01626586|ACTIVE_COMPARATOR|Recently Diagnosed Arm|"This study includes enrolling patients with Type 1 Diabetes, who are recently diagnosed (\<1 year) to participate in a 4 session group therapy intervention over a 4 week time period; and returning at 2 months after the last group session for the booster follow-up session. During the group sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15-20 minutes."
62737038|NCT01473199|EXPERIMENTAL|BioPoly RS Implant|BioPoly RS Implant
62098649|NCT01202864||Cases|3000 Cases
62098650|NCT01202864||Controls|3000 Controls
62098651|NCT04252820|NO_INTERVENTION|Control|No prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer and zero-heat-flux temperature sensor will be used to measure the temperature throughout the perioperative period.
62294430|NCT01412229|EXPERIMENTAL|Treatment|"* nab-paclitaxel 100mg/m2~* Carboplatin area under curve (AUC)2 (IV)~* Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks"
62294431|NCT06329050|EXPERIMENTAL|Losartan group|Losartan tablet(50 mg)
62294432|NCT06329050|PLACEBO_COMPARATOR|Placebo group|Placebo tablet
62294433|NCT02964637||Progressive supranuclear palsy|Observational Study
62294434|NCT02964637||Corticobasal syndrome|Observational Study
62294435|NCT02964637||Behavoral variant FTD|Observational Study
62294436|NCT02964637||Semantic variant PPA|Observational Study
62294437|NCT02964637||Non-fluent variant PPA|Observational Study
62294438|NCT02964637||FTD-motor neuron disease|Observational Study
62294439|NCT02964637||Healthy controls|Observational Study
62737039|NCT01927523|NO_INTERVENTION|Control group|These youth will not receive the non-academic cognitive behavioral programming nor the intensive academic mathematics tutoring.
61909874|NCT02108678|EXPERIMENTAL|Migraine Education Only|The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine. The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic. If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement. However, information on coping practices will be omitted.
61909875|NCT02907190|EXPERIMENTAL|Bean Type|Beans (black; cranberry; great northern; navy; pinto; red) soaked overnight and boiled. 1/2 cup serving eaten by participants at study visit
62098652|NCT04252820|EXPERIMENTAL|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
61909876|NCT02907190|ACTIVE_COMPARATOR|Starchy Foods|1/2 cup serving of rice or paste or potato or corn will be eaten by participants on different study visit
61909877|NCT01648556|OTHER|patients with a thrombopenia isolated|Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet \< 100 G/l Blood tests and bone marrow biopsy repeated
62098653|NCT04252820|EXPERIMENTAL|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
62098654|NCT04252820|EXPERIMENTAL|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
62098655|NCT03813056|EXPERIMENTAL|Glanatec|Glanatec eye drops will be administered 6x per day for 2-4 weeks
62098656|NCT03813056|PLACEBO_COMPARATOR|Placebo Control|Optive artificial tears will be administered 6x per day for 2-4 weeks
61909878|NCT04918056||beta thalassemia patients|
61909879|NCT00793273||A|
62098657|NCT05515796|EXPERIMENTAL|Gastric cancer:CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative)|"CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative):~Cycle 1 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy Cycle: Day 1 through Day 21"
62098658|NCT05515796|EXPERIMENTAL|Gastric cancer:CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive )|"CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive ):~Cycle 1 up to Cycle 3 CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) Cycle: Day 1 through Day 21"
61909880|NCT00593242|EXPERIMENTAL|infusions|infants who arrive at the study site within the first 14 postnatal days and had a history of moderate to severe hypoxic ischemic encephalopathy, and have cells available for infusion that pass Carolinas Cord Blood Bank Quality checks Outcomes will be measured at 22-26 months fby neurodevelopment assessment
61909881|NCT00593242|OTHER|historical control|Infants who had moderate to severe hypoxic ischemic encephalopathy in the neonatal period but did not receive autologous cord blood cells.
61909882|NCT01375855|ACTIVE_COMPARATOR|Polimeric-PES|Arm receiving polimeric stent (Taxus)
62098659|NCT05515796|EXPERIMENTAL|Rectal cancer:Radiotherapy with CapeOx+ Terelizumab (aka Tislelizumab)|"Rectal cancer:~Cycle 1:25 Gy/5 fractions (Day 1 through Day 7) Cycle 2 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy(Day 1 through Day 21)"
62098660|NCT03768245|EXPERIMENTAL|Behaviour|Physical activity and the Health Education programs are applied.
62737040|NCT01927523|EXPERIMENTAL|BAM Group Therapy & Match Math Tutoring|These youth will receive both the non-academic cognitive behavioral programming and the intensive academic mathematics tutoring.
62098661|NCT03768245|ACTIVE_COMPARATOR|Nutrition|In this Arm, the the Physical activity, the Health education and Nutrition program are applied.
62098662|NCT06593314|EXPERIMENTAL|EHR Alert Group|Provider will receive a computer-based alert notifying them that the patient has subclinical HFpEF as determined by the Ultromics EchoGo algorithm and associated guideline recommendations for the management of these patients. The alert will include guideline-based and standard-of-care recommendations for the use of SGLT-2 inhibitors and/or GLP-1 RA (if obesity is present). Providers will have the option for referring for cardiometabolic e-consult to manage HF risk. The purpose of the alert is to inform the providers about the risk of heart failure and provide them guidance regarding the guideline-recommended standard of care. The providers can choose to provide care as deemed fit based on the information provided
62098663|NCT06593314|NO_INTERVENTION|Control Group|No alert will be provided to providers in the control group. We will monitor the practice pattern in this group as well over the study period.
62098664|NCT00114881||Inner-city children with asthma|Children at high risk for developing allergic diseases and asthma, on the basis of a parental history of asthma, allergic rhinitis or atopic dermatitis, and residence in the inner city
62098665|NCT02676297|EXPERIMENTAL|Test product A|tiotropium
62098666|NCT02676297|EXPERIMENTAL|Test product B|tiotropium
62098667|NCT02676297|ACTIVE_COMPARATOR|reference product|tiotropium
62098668|NCT01781910|EXPERIMENTAL|Branch Chain Amino Acid supplement|A drink supplement containing 1.22 grams of branched chain amino acids, plus glucose.
62098669|NCT01781910|PLACEBO_COMPARATOR|Placebo supplement|The placebo was formulated to match both the taste and color of the test supplement. Crystal Light Lemonade powder (Kraft Foods, Northfield, IL, USA) was mixed with 5.6g of powdered dextrose (Now Foods, Bloomingdale, IL, USA) to match the amount of dextrose present in the BCAA supplement.
62098670|NCT05091424|EXPERIMENTAL|Arm A|Participants with R/R CLL who have failed two prior lines of therapy and who have had prior exposure to BTKi and/or venetoclax will receive mosunetuzumab subcutaneous (SC) monotherapy
62098671|NCT05091424|EXPERIMENTAL|Arm B|Participants with R/R CLL who have failed two prior lines of therapy, who are currently progressing on BTKi therapy, and who require salvage therapy as assessed by their treating physician will receive mosunetuzumab SC with BTKi overlap therapy for the first two cycles of mosunetuzumab SC
62661212|NCT04194970|EXPERIMENTAL|Group I (monitoring with live-feedback system)|WBM smart insole system is a product that can monitor the pressure under the foot and provide live feedback (if this option activated) to the user in case of exceeding the specified limits. Its components are insole with pressure sensors and mobile applications (IOS, Android). Post-operative patients (osteochondral lesion of the talus) will be monitored with the WBM smart insole system in case live feedback is turned on. We aimed to ensure the compliance of patients to specified weight bearing limits. We will follow up this grup for 6 weeks periods with WBM smart insole system. Pre-op. and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot \& Ankle Society (AOFAS) Scoring. Also we will monitor the compliance success of patients with WBM smart insole system during 6 week. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate.
62098672|NCT05091424|EXPERIMENTAL|Arm C (non-US participants only)|Participants with R/R CLL who have failed two prior lines of therapy and who have had prior exposure to BTKi and/or venetoclax will receive mosunetuzumab SC with venetoclax (this arm is open only to participants outside of the US)
62661213|NCT04194970|ACTIVE_COMPARATOR|Group II (monitoring without live feedback)|"The post-operative patients (osteochondral lesion of talus), follow-up with product in live-feedback closed condition.~After surgery, we will educate the patients about weight bearing protocol on post-op first day and post op 3 week. The protocol is  first 3 weeks, %0 body weight bearing (BWB), second 3 weeks between %10-%20 BWB. Patients' compliance to BWB protocol will be monitored daily with the WBM smart insole system in case live-feedback is turned off. Pre-op and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot \& Ankle Society (AOFAS) Scoring. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate."
62661214|NCT05510453|EXPERIMENTAL|Intervention|
62661215|NCT05510453|OTHER|Wait-list control|
62661216|NCT03411551|ACTIVE_COMPARATOR|Forearm Bier's block|Forearm intravenous regional anesthesia (Bier's block)
61909883|NCT01375855|ACTIVE_COMPARATOR|Non-Polimeric PES|Arm receiving non-polimeric PES (axxion)
62661217|NCT03411551|EXPERIMENTAL|Peripheral Nerve Block|Ultrasound-guided peripheral nerve block (regional anesthesia)
62661218|NCT04115059|EXPERIMENTAL|Dasatinib|"-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.~Dasatinib: Oral Study Drug(s):~* Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.~* This will continue for up to 24 cycles."
62661219|NCT01414309||Observational patients|Heart Failure patients with moderate to severe central sleep apnea
62661220|NCT00080106|EXPERIMENTAL|1|Participants in the experimental arm will receive the MRK Ad5 HIV-1 gag vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
62661221|NCT00080106|PLACEBO_COMPARATOR|2|Participants in Arm 2 will receive a placebo vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
62661222|NCT05347355|EXPERIMENTAL|Spencer technique along with conventional treatment|
62661223|NCT05347355|EXPERIMENTAL|Gongs Mobilization along with conventional treatment|
62661224|NCT06392087|ACTIVE_COMPARATOR|Control standard care|The patients who meet the indications of the study trauma-related pain Moderate/Severe (\>4 verbal numeric pain score), are provided current standard of care for pain (Advil or Ketorolac/Tylenol, opioids (for Advanced Care paramedics)
61909884|NCT01431209|EXPERIMENTAL|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62661225|NCT06392087|EXPERIMENTAL|Intervention|The patients who meet the indications of the study trauma-related pain Moderate/Severe (\>4 verbal numeric pain score) and receive methoxyflurane
62661226|NCT00832806|ACTIVE_COMPARATOR|1|Extended IVR (integrated voice response technology) vs. no extended IVR
62661227|NCT00832806|ACTIVE_COMPARATOR|2|Extended IVR (integrated voice response technology) vs. no extended IVR
62661228|NCT01942512||ARETA|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
62661229|NCT06189950|EXPERIMENTAL|Experimental group|Microport NeuroTech Intracranial Visualized Stent
62661230|NCT06189950|ACTIVE_COMPARATOR|Control group|LVIS™ and LVIS™ Jr
61909885|NCT02333864||PWD testing POGO® BGMS|All enrolled persons with diabetes
62661231|NCT05862701|ACTIVE_COMPARATOR|Permethrin|Group A treated with application of topical 5% permethrin cream twice with one week interval. Follow-up at 1, 2 and 4 weeks
62661232|NCT05862701|ACTIVE_COMPARATOR|Sulfur|Group B treated with 10% sulfur ointment for two or three weeks. Follow-up at 1, 2 and 4 weeks
62661233|NCT04585594|EXPERIMENTAL|Mi Propio Camino (MPC; My Own Way)|Participants will complete the MPC intervention alongside usual care for hypertension
62661234|NCT04585594|ACTIVE_COMPARATOR|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|Participants will complete the HCP intervention alongside usual care for hypertension.
62098673|NCT02286440|EXPERIMENTAL|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on test results
62466561|NCT05645471|EXPERIMENTAL|Together After Cancer Intervention|Couples randomized into the intervention will participate in the program which is approximately 8-10 hours of web-based online content to be delivered over the course of 5-8 weeks. The online program can be done on a smartphone, tablet, or computer. In this program, partners complete the majority of the program on their own (to make it more flexible) and come together for 2-3 key conversations with their partner. In addition to the online content, couples will receive up to 100 minutes of scheduled research check-in/coaching calls from a research assistant to check-in. These coach calls will occur via a video chat via Zoom or, if not possible given a couple's technology limitations, over the phone. The coach calls serve several purposes: a) helping couples stay accountable to staying on the recommended schedule of activity completion; b) addressing any technical or program questions the couple has; and c) collecting research data as couples move through the program.
61909886|NCT01892384|EXPERIMENTAL|BI 409306 dose 1|low dose, once daily
62098674|NCT02286440|ACTIVE_COMPARATOR|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
62098675|NCT00717613||1|Observational cohort study
62098676|NCT04159506|EXPERIMENTAL|The Equus Effect (TEE)|TEE is a 4-session intervention. Each session is 4 hours and includes: 1) mindfulness-based activities; 2) didactics about emotion regulation and interpersonal skills; and 3) experiential learning activities with horses that provide opportunities to practice emotion regulation and interpersonal skills. At the end of each session, Veterans debrief about what they learned and identify how they might apply this knowledge to manage their mental health concerns and function better socially.
61909887|NCT01892384|EXPERIMENTAL|BI 409306 dose 2|medium dose, once daily
61909888|NCT01892384|EXPERIMENTAL|BI 409306 dose 3|high dose, once daily
62098677|NCT04159506|ACTIVE_COMPARATOR|Attention Control (AC)|AC will exclude equine-related activities or discussions but maintain mindfulness-based activities, emotion regulation and interpersonal skills didactics, and experiential learning activities with between-session application. Instead of experiential equine activities, AC will rely on team-building activities, which aim to enhance social relations by involving participants in collaborative tasks and providing opportunities for emotion regulation and interpersonal skills practice.
62098678|NCT05460130|OTHER|Study Participants|Persons infected with the hepatitis C virus who meet the study inclusion criteria and do not meet one or more of the exclusion criteria.
62098679|NCT05717335||Patients with ventricular entry during surgery (vascular, tumoral and epilepsy).|Group of patients operated on for periventricular lesions with ventricular entry and placement of TachoSil directly over the area of ventricular opening in order to avoid complications.
62661235|NCT03036631||Conscious Sedation/Monitored Anesthesia Care|
62661236|NCT03036631||General Anesthesia|
61909889|NCT01892384|PLACEBO_COMPARATOR|Placebo|placebo, once daily
61909890|NCT00639652||1. 3D-histology|Nodular, micronodular, or sclerosing BCCs
62737041|NCT01927523|EXPERIMENTAL|BAM Group Therapy|These youth will receive the non-academic cognitive behavioral programming.
61909891|NCT00639652||2. Shave excision|Superficial BCCs
62737042|NCT01927523|EXPERIMENTAL|Match Math Tutoring|These youth will receive the intensive academic mathematics tutoring.
61909892|NCT00947791|EXPERIMENTAL|Ketamine/Midazolam|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
61909893|NCT00947791|EXPERIMENTAL|Midazolam/Ketamine|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
61909894|NCT01122264|EXPERIMENTAL|Tadalafil on demand|10 milligrams (mg) or 20 mg on demand
61909895|NCT01122264|EXPERIMENTAL|Tadalafil once a day|5 mg or 2.5 mg once a day
62098680|NCT06340347|EXPERIMENTAL|Group 1|Participants with moderate hepatic impairment will receive a single dose of osivelotor, administered orally under fasted conditions.
62098681|NCT06340347|EXPERIMENTAL|Group 2|Participants with mild hepatic impairment will receive a single dose of osivelotor, administered orally under fasted conditions.
62098682|NCT05005169|EXPERIMENTAL|intrapartum streptococcal B detection by PCR|The automatons will be installed by the laboratory in the delivery rooms and used delocalized by the obstetrical teams. Verification and validation of results will be ensured by the microbiology laboratory team, according to the recommendations and procedures already in use for off-site biology.
62098683|NCT05005169|ACTIVE_COMPARATOR|"intrapartum streptococcal B detection by SGB culture strategy"|
62098684|NCT01348321|EXPERIMENTAL|Azithromicine plus levamisole|
62098685|NCT01348321|EXPERIMENTAL|Azithromicin|
62098686|NCT01383083||iloprost|In the adult patient group, iloprost acceptable target dose is 2.5 ug 4-6 times/day according to the patient's compliance. Because of the concern of safety and tolerability, during the first 4 weeks of treatment, patients receive 2.5 ug twice daily. After 4 weeks, this is increased to the target dose, if iloprost is well tolerated.
62098687|NCT04004000|EXPERIMENTAL|Treatment|FSHD1 subjects with genetic confirmation with receive 15 mg of losmapimod twice daily given by mouth; for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or study termination.
62098688|NCT06615115|EXPERIMENTAL|External Attention Focus Instructions Group|All participants will perform a total body stretching exercise for 10 minutes, followed by 10 minutes of obstacle course navigation, 10 minutes of balance training (including tandem walking, balance board exercises, single-leg balance, and two-legged reaching exercises), and will conclude with 10 minutes of strength training exercises. Throughout these activities, the physiotherapist will guide the participants using only external focus of attention instructions.
62098689|NCT06615115|EXPERIMENTAL|Combined Attention Focus Instructions|The exercise program given to the External Focus of Attention group will also be administered to this group. While guiding the exercises, the physiotherapist will use the combination of both external and internal focus of attention instructions to direct the participants.
62098690|NCT06615115|EXPERIMENTAL|Control Group|The same exercise program given to the other groups will also be administered to this group but no instruction will be given to this group.
62098691|NCT03238729|EXPERIMENTAL|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
62098692|NCT03238729|ACTIVE_COMPARATOR|Standard of Care|Patients will be provided standard literature on heart failure management.
62098693|NCT05341544|EXPERIMENTAL|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 10 days.
62098694|NCT05341544|SHAM_COMPARATOR|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 10 days.
62098695|NCT04438811|OTHER|Consultant Anesthetist|Patients who are randomized to this arm will receive their spinal anesthesia froma consultant anesthetist
62737043|NCT04033081|EXPERIMENTAL|CivaSheet Treatment|Implanted with CivaSheet during tumor removal
62737044|NCT05606848|ACTIVE_COMPARATOR|Control product|Nutrition Emulsion (TPF-T) is a tumor-specific enteral nutrition therapy
62737045|NCT05606848|EXPERIMENTAL|Study prodcut|Foods for special medical purposes \[FSMP\] for patients with tumors
62737046|NCT00780767|EXPERIMENTAL|Thrombectomy arm|
62098696|NCT04438811|OTHER|Medical Officer|Patients randomized to this arm will receive their spinal anesthetic from a medical officer. There will be a consultant anesthetist immediately available if needed but they will not be a direct participant in this arm. Any involvement by the consultant will result in the label of failure for this patient.
62098697|NCT02949271|ACTIVE_COMPARATOR|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
62294440|NCT01892722|EXPERIMENTAL|Fingolimod|Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
62294441|NCT01892722|ACTIVE_COMPARATOR|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
62294442|NCT01892722|EXPERIMENTAL|Fingolimod-Younger Cohort|The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage \<2)
61909896|NCT01122264|ACTIVE_COMPARATOR|Sildenafil Citrate|50 mg, 100 mg, or 25 mg on demand
62294443|NCT00881660|EXPERIMENTAL|Fetal Endotracheal Occlusion|Placement and retrieval of the GoldBAL4 or GoldBal2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
62294444|NCT01137214|ACTIVE_COMPARATOR|CPAP|Continuous Positive Airway Pressure
62294445|NCT01137214|ACTIVE_COMPARATOR|Adaptive Servo-Ventilator|Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
61909897|NCT00972140|EXPERIMENTAL|Formoterol-HFA|Formoterol-HFA pMDI 12µg twice daily
61909898|NCT00972140|ACTIVE_COMPARATOR|Formoterol-DPI|Formoterol-DPI 12µg twice daily
62294446|NCT03689218|NO_INTERVENTION|Control|The control arm will receive routine public and private health services available in the area.
62737047|NCT03029039||patients with severe sepsis|Blood samples will be collected at inclusion.
62737048|NCT03029039||patients with inflammatory syndrome without sepsis|Blood samples will be collected at inclusion.
61909899|NCT06072898|EXPERIMENTAL|Staged Active Treatment Arm (Psilocybin-Psilocybin)|This group will receive psilocybin (25mg) at the first and second treatment visit, along with supportive psychotherapy.
61909900|NCT06072898|EXPERIMENTAL|Placebo to Active Delayed-Start Treatment Arm (MCC-Psilocybin)|This group will receive microcrystalline cellulose (25mg) at the first treatment visit and psilocybin (25mg) at the second treatment visit, along with supportive psychotherapy.
61909901|NCT01928745||CABG patients|15 patient who underwent a CABG will be submitted in this study
61909902|NCT01928745||Sepsis patients|15 patients with a severe sepsis will be admitted in this study
62098698|NCT02949271|ACTIVE_COMPARATOR|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
62098699|NCT06536036|EXPERIMENTAL|High-fat meal group（Group1）|Eight subjects were enrolled and administered single dose of 60mg SIM0270 under fasting condition in the first cycle, and administered single dose of 60mg SIM0270 under high-fat diet condition in the second cycle.
62294447|NCT03689218|EXPERIMENTAL|Intervention|Pregnant women in intervention arm will receive 30 sachets of Maamta (Nutritious Food Supplement) during pregnancy and first six months of lactation. Children 6-24 months of age will receive 30 sachets of Wawamum (Lipid-Based Nutrient Supplement) every month during the study.
62294448|NCT05439616|EXPERIMENTAL|Cariprazine|Participants will receive age-and weight dependent flexible doses of cariprazine once daily for 8-weeks.
62294449|NCT05439616|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once daily for 8-weeks.
62294450|NCT01851967|EXPERIMENTAL|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
62294451|NCT03996967||BA Group|The bacterial group: Patients will be assorted to this group if he/she has a bacterial pathogen culture of fluid from a normally sterile site (e.g. blood, pleural fluid)
62294452|NCT03996967||VI Group|"The viral group: Patients will be assigned to this group if they have negative bacteria microbiological tests, negative malaria blood slides, X-rays without endpoint pneumonia, no evidence of fungal infection, and positive PCR for a viral pathogen from nasopharyngeal swabs."
62466562|NCT05645471|NO_INTERVENTION|Usual Care|"Participants randomized into UC, will consist of primary referral sources for breast cancer survivorship. At AdventHealth, Moffitt, and Sylvester Cancer centers, usual care consists of screening items assessing relationship/intimacy issues as a practical need. If these items are endorsed, referrals are provided to supportive oncology. At Sylvester, the Cancer Support Services offers caregiver support groups, mental well-being services (i.e., individual therapy), and an online support community for patients, caregivers, and survivors. At Moffitt, Support Services offers psychotherapy, support groups for patients, support groups for family/caregivers of cancer patients, and a program to help patients talk with their children about their diagnosis. At AdventHealth, patients are offered referrals to social services and psychoeducational programs like HEAL. However, none of the sites have services designed to focus on issues specific to patients' romantic relationships."
62466563|NCT02222805|OTHER|Early cord clamping (ECC)|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
62466564|NCT02222805|OTHER|Delayed cord clamping (DCC)|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
62466565|NCT06000280|ACTIVE_COMPARATOR|Study group|The Study group refers to patients who are using topical prostaglandins analogues
62466566|NCT06000280|PLACEBO_COMPARATOR|Control group|The Control group refers to patients who discontinued the use of topical prostaglandins analogues
62466567|NCT00527657|EXPERIMENTAL|Lomustine + Temozolomide + Thalidomide|Lomustine starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m\^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m\^2 by mouth daily.
62466568|NCT05304481|EXPERIMENTAL|Treatment|ATL administration
62466569|NCT04904861|EXPERIMENTAL|Videoconference Intervention group|Brief group videoconferencing attachment-based intervention (sessions once a week for 4 weeks)
62466570|NCT04904861|ACTIVE_COMPARATOR|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks)
62466571|NCT03764709|EXPERIMENTAL|Vital signs wireless monitoring system GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The experimental arm will wear wireless monitoring for 5 days after transfer in subacute care unit"
62466572|NCT03764709|ACTIVE_COMPARATOR|Control arm GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The active comparator arm will be monitored by nursing staff."
62737049|NCT03029039||blood donor voluntary|Blood samples will be collected.
62737050|NCT05466084|EXPERIMENTAL|tissue glue|mesh fixed using tissue glue
62098700|NCT06536036|EXPERIMENTAL|High-fat meal group（Group2）|Eight subjects were enrolled and administered single dose of 60mg SIM0270 under high-fat diet condition in the first cycle, and administered single dose of 60mg SIM0270 under fasting condition in the second cycle.
62098701|NCT06536036|EXPERIMENTAL|Standard meal group（Group3）|Eight subjects were enrolled and administered single dose of 60mg SIM0270 under fasting condition in the first cycle, and administered single dose of 60mg SIM0270 under standard meal condition in the second cycle.
62098702|NCT06536036|EXPERIMENTAL|Standard meal group（Group4）|Eight subjects were enrolled and administered single dose of 60mg SIM0270 under standard meal condition in the first cycle, and administered single dose of 60mg SIM0270 under fasting condition in the second cycle.
62098703|NCT04790344|EXPERIMENTAL|Treatment Arm|All study subjects belong to Treatment Arm, which is receiving investigational LUX-Dx ICM device.
62294453|NCT03996967||MA Group|The malarial group: Patients will be assigned to this group if they have normal X-rays, no bacterial infection and \>0 asexual P. falciparum parasites if they are aged \< 1 year, or \> 2,500 asexual parasites/µl of blood if they are aged \> 1 year
61909903|NCT06005129|EXPERIMENTAL|Personality-based treatment 2 week baseline|Participants will receive treatment tailored to 1 of 3 personality dimensions after a 2 week baseline assessment
61909904|NCT06005129|EXPERIMENTAL|Personality-based treatment 4 week baseline|Participants will receive treatment tailored to 1 of 3 personality dimensions after a 4 week baseline assessment
62098704|NCT06472089|EXPERIMENTAL|BMT-CARE|"Participants randomized to BMT-CARE plus usual care will complete the following:~* Questionnaires at baseline, and days 60, 90 and 180 post HCT.~* Receive the BMT-CARE intervention from enrollment up to 60 days post-HCT. BMT-CARE is a -6-session caregiver-directed cognitive behavioral therapy (CBT)-based psychosocial intervention that integrates HCT-related education with CBT strategies to enhance caregiver knowledge and skills.~* Receive usual care as per HCT practice which entails meeting a transplant social worker prior to HCT and as needed for extra visits."
61909905|NCT02610504|EXPERIMENTAL|Durolane 3ml|Single intra-articular injection into shoulder
62098705|NCT06472089|ACTIVE_COMPARATOR|Usual Care|"Participants randomized to usual care will complete the following~* Questionnaires at baseline, and days 60, 90 and 180 post HCT.~* Receive usual care as per HCT practice which entails meeting a transplant social worker prior to HCT and as needed for extra visits."
62466573|NCT03764709|EXPERIMENTAL|Vital signs wireless monitoring system GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The experimental arm will wear wireless monitoring for 5 days after discharge at home"
62466574|NCT03764709|ACTIVE_COMPARATOR|Control Arm GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The active comparator arm will perform usual checks by caregivers at home."
62098706|NCT05144217|PLACEBO_COMPARATOR|Placebo|1 capsule twice per day
62098707|NCT05144217|ACTIVE_COMPARATOR|oral administration of 2x 140 mg per day|1 capsule twice per day
62098708|NCT05144217|ACTIVE_COMPARATOR|oral administration of 3x 280 mg per day|2 capsules three times a day
62098709|NCT05144217|ACTIVE_COMPARATOR|oral administration of 1x 1120 mg per day|8 capsules once per day
62098710|NCT00933296||A Patients with the Schnitzler syndrome|Patients with the Schnitzler syndrome
62098711|NCT00933296||B Control subjects:|B1 healthy B2 other diseases
62466575|NCT02816788|EXPERIMENTAL|Equine Assisted Therapy (EAT)|Equine Assisted Therapy (EAT) treatment group
61909906|NCT00835731|EXPERIMENTAL|1|400mcg buccal misoprostol
61909907|NCT00835731|EXPERIMENTAL|2|Dilapan-S, control: vitamin B-12 administered sublingually
61909908|NCT00875589||Control|Control subjects with no Mild Traumatic Brain Injury (MTBI) and no Post-Traumatic Stress Disorder (PTSD)
61909909|NCT00875589||MTBI|Subject with a diagnosis for Mild Traumatic Brain Injury (MTBI)
62098712|NCT01597518|EXPERIMENTAL|Riluzole|
62098713|NCT01597518|PLACEBO_COMPARATOR|Placebo|
62098714|NCT04028492|EXPERIMENTAL|Tradipitant|Oral Capsule
62098715|NCT04028492|PLACEBO_COMPARATOR|Placebo|Oral Capsule
61909910|NCT03610529|EXPERIMENTAL|ECG monitoring system CardioSenseSystem group|
61909911|NCT03610529|ACTIVE_COMPARATOR|ECG monitoring system Philips Intellivue|
61909912|NCT02358317|EXPERIMENTAL|Video Game Motor Training|Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
61909913|NCT02358317|ACTIVE_COMPARATOR|Sedentary Video Game Training|Participants randomly assigned to this condition will come to the lab for six weeks to play sedentary video games 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes. Pre-and post assessments will be done identically to the Experimental group.
61909914|NCT01409343|EXPERIMENTAL|TrasGEX|A total of 37 patients with advanced HER2-positive carcinomas and progressive disease.
61909915|NCT03970044|EXPERIMENTAL|Exenatide 2 mg plus Dapagaliflozin 10 mg|Exenatide extended release, 2 mg weekly, injected Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
62466576|NCT05492630|EXPERIMENTAL|HEC73077 tablets|Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts.
61909916|NCT03970044|ACTIVE_COMPARATOR|Exenatide 2 mg|Exenatide extended release, 2 mg weekly, injected 14 weeks of treatment
62098716|NCT04028492|EXPERIMENTAL|Open Label Tradipitant|Oral Capsule
62098717|NCT06055556|EXPERIMENTAL|Partial Heart Transplantation|Participants will receive a partial heart transplantation to replace the pulmonary valve with fresh donor graft(s). This is an investigational procedure. This means this procedure is not done as a routine treatment for patients with congenital heart defects. Partial heart transplantation involves surgical replacement of the semilunar heart valve with the heart valve and supporting blood vessels and tissue from an organ donor. No other parts of the heart are transplanted besides the heart valve, blood vessel, and tissue surrounding the valve.
62098718|NCT00984178|NO_INTERVENTION|Control group|standard treatment
62098719|NCT00984178|EXPERIMENTAL|Bone marrow mononuclear progenitors|intracoronary transplantation of bone-marrow mononuclear progenitor cells
62098720|NCT00984178|EXPERIMENTAL|GCSF|progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
62098721|NCT00984178|EXPERIMENTAL|GCSF plus bone marrow mononuclear cells|combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
62098722|NCT03748160|NO_INTERVENTION|Control|There is no intervention (letter) in the control arm. There is no control arm in the city of Espoo. 1/3 of subjects in all other municipalities are assigned to the control arm.
62466577|NCT05492630|PLACEBO_COMPARATOR|HEC73077 placebo tablets|Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts.
61909917|NCT03970044|ACTIVE_COMPARATOR|Dapagaliflozin 10 mg|Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
61909918|NCT05798468|OTHER|Control group|There will be two control groups. One control group will belong to the University of Malaga and the other will belong to the University of Cadiz. This group will follow the traditional teaching method. The total sample of the group will be approximately 96 students, ensuring a homogeneous distribution between the two groups.
62098723|NCT03748160|ACTIVE_COMPARATOR|Mailing|This treatment arm consists of a standard letter reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
62466578|NCT01887262|EXPERIMENTAL|Intervention|Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.
62098724|NCT03748160|ACTIVE_COMPARATOR|Herd|This treatment arm consists of a letter that highlights the herd immunity effects of vaccination and reminds elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
62098725|NCT02232763|EXPERIMENTAL|Losartan|12 weeks of losartan or placebo with crossover to the other
62098726|NCT02232763|EXPERIMENTAL|Placebo|12 weeks of losartan or placebo with crossover to the other
62737051|NCT05466084|EXPERIMENTAL|metallic tackers|mesh fixed using metallic tackers
62098727|NCT00597883||Patients having CEA|Patients undergoing carotid endarterectomy (CEA) for treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
62737052|NCT01017042|EXPERIMENTAL|colchicine|colchicine 1.2mg by mouth initially then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
61909919|NCT05798468|EXPERIMENTAL|Experimental group|There will be two experimental groups. One experimental group will belong to the University of Malaga and will use augmented reality using Zapworks software while the other experimental group will belong to the University and will use the Aumentaty platform. The sample will be made up of approximately 107 students, ensuring a homogeneous distribution between the two groups. Both the software and the platform mentioned above will work with augmented reality in the educational field, in this case in the university environment.
61909920|NCT01193296|EXPERIMENTAL|Vildagliptin|
62098728|NCT01688973|EXPERIMENTAL|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28.
62098729|NCT01688973|EXPERIMENTAL|Arm II (tivantinib and erlotinib hydrochloride)|Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
61909921|NCT01193296|ACTIVE_COMPARATOR|Sitagliptin|
61909922|NCT02516540|NO_INTERVENTION|Control|Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer
62098730|NCT02288715||SAE|patient who develop encephalopathy in the progress of sepsis
62098731|NCT02288715||non-SAE|patient who do not develop encephalopathy in the progress of sepsis
62098732|NCT03773965|EXPERIMENTAL|Baricitinib|Baricitinib given orally.
62098733|NCT01644773|EXPERIMENTAL|Chemotherapy|Research participants with high grade glioma or diffuse intrinsic pontine glioma will receive crizotinib and dasatinib.
62098734|NCT05310721|EXPERIMENTAL|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window. The first meal will be before 10 am (last meal before 18h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
62098735|NCT05310721|EXPERIMENTAL|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window. The first meal will be at 13h or later (last meal not before 21h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
62098736|NCT05310721|EXPERIMENTAL|Self-selected time-restricted eating|Participants will self-selecte an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
62098737|NCT05310721|NO_INTERVENTION|Usual-care group|Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
62098738|NCT06440109|EXPERIMENTAL|EFT intervention|The application will be carried out in line with EFT application protocols. In this regard, women's home visits will be completed with 6 meetings, once every week. Each EFT session will last 15 minutes
62098739|NCT06440109|EXPERIMENTAL|TD intervention|The application will be carried out in line with TD application protocols. In this regard, women's home visits will be completed with 6 meetings, once every week. Each TD session will last 15 minutes
62661237|NCT05967468|EXPERIMENTAL|Family-Based Internet-Based CBT Group (iCBT)|One third of participants will be randomized to receive iCBT. Each week of treatment, the parent will be encouraged to read the corresponding materials on the Baylor College of Medicine (BCM) webpage, complete accompanying worksheets, and guide their child through completing activities in the child-facing materials, with support from a therapist (6 30-minute supportive videoconferencing via Zoom, 6 emails on alternating weeks). One core aspect of treatment will be parents leading their child through graduated exposure. Exposures, a hallmark of CBT for anxiety, are used to gradually and repeatedly confront feared stimuli. For example, exposure therapy for a child fearful of dogs may begin with looking at pictures of dogs and standing across the park from a dog on a leash, to eventually petting a dog. All relevant information regarding parent-led exposures will be detailed in the treatment materials, and therapists will review with parents via email and/or video-conferencing sessions.
62098740|NCT06440109|NO_INTERVENTION|Control grup|No intervention will be made. Women in the intervention groups will be followed for 6 weeks and receive standard care. The final test will be administered at the end of the sixth week
62098741|NCT06711081|NO_INTERVENTION|• Group I: Conventional complete Pulpotomy using MTA (control group).|MTA putty material will be placed using premixed capsule which will be triturated according to manufacturer's instructions. MTA will be placed in a 2-3 mm layer above the pulp tissue using an amalgam carrier and gently packed to the canal orifice using a condenser, then it will be covered by moistened cotton pellet for 2 minutes to achieve the initial setting, then the cotton pellet will be removed. A layer of resin modified glass ionomer cement will be placed and the tooth will be restored using light cured composite filling material .
62294454|NCT02207114|NO_INTERVENTION|Observational|9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.
62466579|NCT01887262|ACTIVE_COMPARATOR|Control|BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.
62466580|NCT00987805|EXPERIMENTAL|Banhasasim-tang|
62466581|NCT00987805|PLACEBO_COMPARATOR|Placebo drug|The placebo of this study is corn-starch granules. It has the same form, color, flavor and amount like experimental herbal extracted formula
62466582|NCT00705536|ACTIVE_COMPARATOR|Humalog first, then Humalog + rHuPH20|"Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days"
61909923|NCT02516540|EXPERIMENTAL|Intervention|Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet.
61909924|NCT05145218|EXPERIMENTAL|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 21 days, 1200mg each time, intravenous infusion. The longest administration time should not exceed 24 months.~Anlotinib Hydrochloride capsules: once a day, 12mg each time, oral administration on an empty stomach before breakfast for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment."
62466583|NCT00705536|ACTIVE_COMPARATOR|Humalog + rHuPH20 first, then Humalog|"Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog~A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days"
62098742|NCT06711081|ACTIVE_COMPARATOR|• Group II: LLLT following complete pulpotomy.|after achieving homeostasis, LLLT will be applied using diode laser of 810 nm wave length with energy of 2 J/cm2 under a continuous mode with power output of 100 mW for about 10 sec with laser tip size 600 μm and 2 mm away from the canal orifice, Then MTA will be placed and the tooth will be restored as in group I.
62098743|NCT06711081|ACTIVE_COMPARATOR|• Group III: Cryotherapy following complete pulpotomy.|after achievement of homeostasis, the cryotherapy will be applied using small piece of shaved sterile ice wrapped with sterile piece of gauze (0° Celsius) which will be placed over the pulpal tissue in the pulp chamber. After approximately 60 seconds, the molten ice will be removed, then MTA will be placed and the tooth will be restored as in group I.
62098744|NCT06712160|EXPERIMENTAL|CBCT, Clinical using DOM|Comparing the three methods for the detection of the number of canals of maxillary and mandibular molars
62098745|NCT03028948|EXPERIMENTAL|Arm I (ITW)|Patients access ITW and complete each module over 30-40 minutes. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
62098746|NCT03028948|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
62098747|NCT01454362|EXPERIMENTAL|Electronic cigarette|We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
62098748|NCT01454362|ACTIVE_COMPARATOR|Nicotine Inhalator|The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
62098749|NCT05630495|EXPERIMENTAL|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns of South-East Asian ethnicity and skin type.
62098750|NCT00353145|EXPERIMENTAL|Gemcitabine + Oxaliplatin|Gemcitabine 1000 mg/m\^2, infused at 10 mg/m\^2/min on Day 1 and Oxaliplatin 100 mg/m\^2 by vein infused on Day 2 over two hours. Repeated every 14 days (one cycle).
62098751|NCT04477798|EXPERIMENTAL|PCT-DIA/MS|PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules
62308136|NCT03478683|ACTIVE_COMPARATOR|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
62466584|NCT00705536|ACTIVE_COMPARATOR|Humulin-R first, then Humulin-R + rHuPH20|"Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days"
62466585|NCT00705536|ACTIVE_COMPARATOR|Humulin-R + rHuPH20 first, then Humulin-R|"Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R~A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days"
62466586|NCT03012178||Mitral Valve Surgery|Patients undergoing ACC/AHA guideline directed mitral valve surgery for mitral insufficiency.
62466587|NCT05481840|EXPERIMENTAL|Intervention group|Receiving smart continence care by the use of continence material with sensor, in which their care professionals receive a notification when change is needed.
61909925|NCT05145218|ACTIVE_COMPARATOR|Paclitaxel injection|80mg/m2, intravenous drip, once a week (D1, D8, D15 of 21 days), 21 days as a course of treatment.
61909926|NCT06316999|OTHER|Patients with Pouchitis|Transabdominal and transperineal ultrasounds of the pouch will be performed by an experienced sonographer for each patient and interpreted by a board-certified radiologist specializing in IUS.
61909927|NCT04148144||Adolescents with low back pain|Adolescents aged 8-19 with low back pain.
62098752|NCT05273801|EXPERIMENTAL|Observational HR monitoring|"Participants will receive 2 intervention conditions: HR monitoring with visual feedback, and HR monitoring without visual feedback. Observed condition will alternate by session. The investigators will monitor overall HR response, mean time HR and time in target zone, Rate of perceived exertion (RPE), and provider behavior to HR monitoring prior to HR monitoring, with visual feedback and without visual feedback.~Visual Feedback of Multiple Participant Heart Rates: Visual feedback of HR is provided through a television (TV) monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity."
62098753|NCT05153954||Colorectal cancer patients|Patients who can be treated with either PME or TME and receive a primary anastomosis during surgery.
62098754|NCT01665729||artery-artery embolus|There is no hypoperfusion ( contralateral compensatory is good )
62098755|NCT01665729||Hypoperfusion|Contralateral compensatory not sufficient
62098756|NCT01665729||Hypoperfusion and embolus amotic|Hypoperfusion and embolus amotic
62098757|NCT06211075|EXPERIMENTAL|Intervention Group|The intervention will be delivered remotely via zoom or google meets, guided by Overcome coaches. Coaches are trained over two days via training slides, role plays and feedback. The intervention includes CBT-I and Motivational Interviewing.
62098758|NCT06211075|NO_INTERVENTION|Waitlist Control Group (WLC/WLCG)|Participants will receive the same benefits from the intervention after the end of the main study or after the last participant in the experimental group is interviewed at the post-intervention interview.
62098759|NCT06089629|NO_INTERVENTION|Control group|Nonsurgical intervention with speech and myofunctional therapy
62098760|NCT06089629|EXPERIMENTAL|Intervention group|Surgical intervention with frenuloplasty followed by speech and myofunctional therapy
62466588|NCT05481840|NO_INTERVENTION|Waiting list group|Will continue regular continence care as received by their care professionals. After data collection is finalized, they will receive smart continence care.
62661238|NCT05967468|EXPERIMENTAL|Parent Training Bibliotherapy (SPACE)|One third of participants will be randomized to the SPACE group. Families will receive 4 45-minute supportive video calls with a therapist over the course of 12-14 weeks. Participating families will receive a copy of the book 'Breaking Free of Child Anxiety and OCD' to use at home and in session with the therapist. During each of the video-conferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
62098761|NCT03861273|EXPERIMENTAL|PF-06838435/ fidanacogene elaparvovec|
62466589|NCT02154997||Type 1 and Type 2 Diabetes|pregnant women which have a known condition of type 1 or type 2 diabetes
62466590|NCT02154997||Gestational diabetes|pregnant women which have developed Gestational diabetes
62466591|NCT02154997||Control group|Pregnant women whom do not suffer from any altered glucose metabolism
62466592|NCT01367457||Patients that received treatment with Temsirolimus|Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
62466593|NCT01493635|ACTIVE_COMPARATOR|Standard 3 Step approach.|Standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
62098762|NCT05924893|EXPERIMENTAL|Naltrexone group|25 eyes with refractory non infective corneal ulcer were subjected to daily insertion of a NTX film in the lower conjunctival fornix for 2 weeks
62098763|NCT05924893|EXPERIMENTAL|Control|25 eyes with refractory non infective corneal ulcer were treated by carboxymethyl cellulose sodium 0.5 % eye drops
62098764|NCT05392764|EXPERIMENTAL|Empagliflozin|Patients will be randomized 1:1 to either empagliflozin or placebo.
62098765|NCT05392764|PLACEBO_COMPARATOR|Placebo|Placebo matching empagliflozin
62098766|NCT05305911|ACTIVE_COMPARATOR|Treatment Group|Treatment group will receive SGLT2 inhibitor in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
62308137|NCT01581411|EXPERIMENTAL|IA t-PA|intra-ophthalmic artery injection of tissue plasminogen activator
62308138|NCT00950417|EXPERIMENTAL|Esophageal Cancer|
62466594|NCT01493635|EXPERIMENTAL|2 Step approach.|2 Step approach of the WHO analgesic ladder (Step 1 - Step 3).
62466595|NCT00629590|EXPERIMENTAL|1|
62466596|NCT00629590|NO_INTERVENTION|2|
62466597|NCT00539266|ACTIVE_COMPARATOR|1|non diabetic patients with Fontaine IIb-IV peripheral artery disease
62466598|NCT00539266|PLACEBO_COMPARATOR|2|non diabetic patients with Fontaine IIb-IV peripheral artery disease
62466599|NCT00539266|ACTIVE_COMPARATOR|3|diabetic patients with Fontaine IIb-IV peripheral artery disease
62098767|NCT05305911|PLACEBO_COMPARATOR|Placebo Group|Placebo Group will receive placebo in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
62098768|NCT03669042|EXPERIMENTAL|Treatment|All patients will undergo a vascular repair or reconstruction surgery, which requires the use of PhotoFix. The surgical procedures will vary by patient and by underlying etiology. Therefore, PhotoFix implant sites will also vary. In all cases, PhotoFix will be implanted per the Instructions for Use (IFU).
62098769|NCT06494553|ACTIVE_COMPARATOR|control group|Received traditional treatment program in the form of US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors .
62098770|NCT06494553|EXPERIMENTAL|cervical stabilization exercises group|Received cervical stabilization exercises (included the following: Chin tuck, cervical extension, Shoulder shrugs, Shoulder rolls, Scapular retraction) was given in 3 sets with 10 repetitions for 24 sessions (3 sessions per week for 8 weeks) plus traditional treatment program in the form of US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.
62466600|NCT00539266|PLACEBO_COMPARATOR|4|diabetic patients with Fontaine IIb-IV peripheral artery disease
62466601|NCT00995241|EXPERIMENTAL|Raltegravir 800 mg / 24 hours|Raltegravir 800 mg / 24 hours
62466602|NCT04414605|EXPERIMENTAL|Chinese herbal medicine in combination with secukinumab|Oral Chinese herbal medicine (Gu Ben Hua Yu Fang decoction) and secukinumab will be used concurrently. The treatment duration for both secukinumab and oral Chinese herbal medicine is up to 16 weeks. Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg). Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice a day. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
62466603|NCT02576730||Fratures|patient with foot and ankle fractures and surgery with ORIF
62466604|NCT02576730||healthy subjects|patients without foot and ankle fracture s
61909928|NCT04148144||Parents of included adolescents|Parents recruited for the parallel cohort, are required to be a parent or a legal guardian of the included adolescent. Siblings, grandparents or a similar person are not eligible for inclusion in the parallel cohort.
61909929|NCT00746200|EXPERIMENTAL|A|
61909930|NCT00746200|SHAM_COMPARATOR|S|
61909931|NCT04124744|EXPERIMENTAL|Intervention|Will receive the Health Champion intervention
61909932|NCT04124744|ACTIVE_COMPARATOR|Control|Treatment as usual
61909933|NCT04831632||people aged 50-75|men and women aged 50-75 who belong to Hospital El Cruce's coverage area and do not have personal history of colorectal cancer or inflammatory bowel disease, personal or family history of syndromes of predisposition to known cancers, or family history of colorectal cancer in a first-degree relative aged less than 60
61909934|NCT04982003|EXPERIMENTAL|Single Group|A single group of subjects with pretest, posttest, and one-month follow-up testing relative to 10-week drumming exercise classes
61909935|NCT04138225||Healthy|Healthy participants are those without IBS, IBD or any other gastrointestinal disorder
61909936|NCT04138225||Irritable bowel syndrome (IBS)|Participants with Rome IV diagnosed IBS
61909937|NCT04138225||Inflammatory bowel disease (IBD)|Patients with IBD - either ulcerative colitis (UC) or Crohn's disease (CD)
61909938|NCT02213406|EXPERIMENTAL|intervention group|Fat detection threshold test, intake of high and low fat yogurt, fMRI-measurements
61909939|NCT00435045|ACTIVE_COMPARATOR|atorvastatin arm|atorvastatin + placebo
61909940|NCT00435045|EXPERIMENTAL|Lovaza arm|Lovaza + atorvastatin
61909941|NCT03445156|EXPERIMENTAL|Pilot Study|After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
61909942|NCT03445156|EXPERIMENTAL|Experiment Proper|"After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed."
61909943|NCT02000908|EXPERIMENTAL|Realief Therapy|Each patient will be given 15-18 treatments depending on response of 30-minute duration of photobiomodulation with the Realief Therapy system, scheduled every three times weekly for 5-6 weeks. The treatments will include laser exposure of any or all of 27 differentiated areas of the legs, feet, cervical spine region and lumbar spine region, for durations of 3 to 30 minutes, based on the symptom presentation at the time. Power densities will vary from 5 to 12 watts, based on the symptom presentations through the course of therapy.
62661239|NCT05967468|ACTIVE_COMPARATOR|Active Comparator|One third of participants will be randomized to receive a Relaxation and Mentorship. This involves attending 4 45-minute sessions with a therapist over the course of 12-14 weeks. Topics covered include breathing slowly and deeply, coloring activities, and releasing muscle tension to reduce stress levels.
62466605|NCT02712827|EXPERIMENTAL|Progrip|The Progrip group is the intervention group. Patients will undergo laparoscopic total extraperitoneal repair of inguinal hernia. The surgeon will use a self-gripping mesh to repair the hernia. No fixation is required for the mesh.
62661240|NCT04167800|NO_INTERVENTION|Control group|All patients will be instructed to wear the device for 23 weeks for 12 weeks after being instructed on how to use the appropriate compression orthosis. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
62098771|NCT06622941|EXPERIMENTAL|ONO-4538|
62098772|NCT01408680|ACTIVE_COMPARATOR|Coenzyme Q10 600 mg|
62661241|NCT04167800|ACTIVE_COMPARATOR|Exercise Group|In addition to the applications to the first group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PC. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
62661242|NCT04552093|EXPERIMENTAL|Colorectal liver metastases|Patients with potentially resectable colorectal liver metastases will undergo hepatic artery infusion pump placement. Subsequent hepatic artery infusion of floxuridine via the HAIP as well as standard of care Dutch systemic chemotherapy (FOLFOX or FOLRIRI) will be administered in a combined chemotherapy schedule.
62661243|NCT04916678|NO_INTERVENTION|Control|The control period is a 5-day period during which no psychologist is available. ER cares will be provided as usual.
62098773|NCT01408680|ACTIVE_COMPARATOR|Coenzyme Q10 1200 mg|
62098774|NCT01408680|PLACEBO_COMPARATOR|Placebo|
62098775|NCT06176144|ACTIVE_COMPARATOR|Sevoflurane group|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil, sufentanil. Sevoflurane inhalation will be stopped at the end of surgery.
62098776|NCT06176144|EXPERIMENTAL|Desflurane group|Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil, sufentanil. Desflurane inhalation will be stopped at the end of surgery.
62098777|NCT01756365|EXPERIMENTAL|ACCE (Autologous Cultured Corneal Epithlium) graft for the treatment of corneal lesions|Surgical transplantation of Autologous Cultured Corneal Epithelium
62098778|NCT03897998|ACTIVE_COMPARATOR|Naloxone|NARCAN® Naloxone Nasal Spray will be used to block placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
62466606|NCT02712827|ACTIVE_COMPARATOR|Non-Progrip|"The Non-Progrip group is the control group.~Operation is performed under general anesthesia. A standard three-trocar technique is used: one infra-umbilical camera trocar (1cm) and two 5mm trocars placed at midline between the umbilicus and pubic bone (or one at the side of inguinal hernia). A laparoscope is inserted to the preperitoneal space through the incision. The space is insufflated with carbon dioxide. Dissection is performed, hernia content (if any) is reduced.~A non self-gripping synthetic mesh is placed. Fibrin glue is used for fixation."
62466607|NCT06309901||Control Group|A progressive home exercise program consisting of 3 phases was applied.
61909944|NCT02000908|SHAM_COMPARATOR|Sham Treatment|"The placebo group will receive sham treatment, during which a heat probe will be guided over both lower extremities over a period of 30 minutes, consistent with the treatment arm. The laser device will be activated during the treatment so that the visual and auditory environment prior to therapy will be the same for both treatment and sham control.~After 8 weeks of sham treatment the subjects in this arm will be offered the photobiomodulation combined with physiotherapy."
62098779|NCT03897998|SHAM_COMPARATOR|Saline|Saline will be used as a sham comparator for blocking placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
62098780|NCT05079698|EXPERIMENTAL|Stereotactic Body Radiotherapy and 177Lu-PSMA-617|
62098781|NCT00406809|EXPERIMENTAL|Phase 1a and 1b|Relapsed or refractory lymphoid malignancies
62098782|NCT00406809|EXPERIMENTAL|Arm A (Phase 2a)|Relapsed or refractory follicular lymphoma
62294455|NCT02207114|EXPERIMENTAL|Biomarker Algorithm Intervention|"The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics.~The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs."
62294456|NCT01805648|EXPERIMENTAL|rhTPO|Active investigational product
62294457|NCT04117321||Pregnant women|Women who are being pregnant and plan to give birth in local hospital. Pregnant women who plan to stay in the same local area for at least 7 years post-delivery.
62294458|NCT04117321||New Born Baby|new born baby of an enrolled pregnant woman.
62294459|NCT04117321||Father of new born baby|Biological father of an enrolled new born baby.
62294460|NCT06318936||Older adults with RSV infection|Adults aged ≥60 years attending primary care with acute respiratory tract infecion
62661244|NCT04916678|EXPERIMENTAL|Intervention|The intervention period is a 5-day period during which trained psychologists are available in the ER and will provide a R-TEP EMDR intervention for patients selected with high risk of PCLS and who may provide psychotherapeutic care or reassurance to other patients should they be identified in need of help.
62098783|NCT00406809|EXPERIMENTAL|Arm B (Phase 2a)|Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
62098784|NCT00406809|EXPERIMENTAL|Extension Study|Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
62098785|NCT01417000|EXPERIMENTAL|Cy/GVAX + CRS-207|200 mg per square meter (mg/m\^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units \[CFU\]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
61909945|NCT04910308|EXPERIMENTAL|Dose painting|Dose painting
61909946|NCT03526588|EXPERIMENTAL|Autologous umbilical cord blood|
62098786|NCT01417000|EXPERIMENTAL|Cy/GVAX|200 mg/m\^2 Cy administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16; GVAX (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1, 4, 7, 10, 13, 16.
62098787|NCT03383211||HIV+|Pregnant women diagnosed with HIV infection during pregnancy. No intervention beyond the standard care provided for such cohort.
62098788|NCT03383211||LTBI|Pregnant women diagnosed with Latent form of TB infection (LTBI). No intervention beyond the standard of care provided for such cohort.
62294461|NCT03696329|EXPERIMENTAL|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
62294462|NCT03696329|ACTIVE_COMPARATOR|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
62294463|NCT00640094|EXPERIMENTAL|A: Melatonin|Melatonin: intravenous infusion and intracoronary bolus
62294464|NCT00640094|PLACEBO_COMPARATOR|B: Placebo of melatonin|Placebo: intravenosus infusion and intracoronary bolus
62294465|NCT04022746|EXPERIMENTAL|Diagnostic (MRI/MRE)|Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
62308139|NCT01703312|EXPERIMENTAL|QGE031|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.
62466608|NCT06309901||FDM Group|In addition to the progressive home exercise program consisting of 3 phases, the trigger band technique of the fascial distortion model was applied around the knee.
62661245|NCT01813643|EXPERIMENTAL|Aripiprazole|Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
62098789|NCT03383211||HV+/LTBI|Pregnant women diagnosed with HIV and LTBI co-infection. No intervention beyond the standard of care provided for such cohort.
62098790|NCT03383211||Healthy Control|Healthy pregnant women without HIV or LTBI. No intervention beyond the standard of care provided for such cohort.
62098791|NCT00602160|ACTIVE_COMPARATOR|1|2 different dosages
62098792|NCT00602160|PLACEBO_COMPARATOR|2|
62098793|NCT04533217|ACTIVE_COMPARATOR|Vertebroplasty|Patients treated with vertebroplasty in addition to regular medical treatment.
62098794|NCT04533217|NO_INTERVENTION|Regular treatment|Patients treated with regular medical treatment.
62098795|NCT00740272|EXPERIMENTAL|1|AF ablation + pacemaker
62098796|NCT00740272|ACTIVE_COMPARATOR|2|Pacemaker
62308140|NCT01703312|ACTIVE_COMPARATOR|omalizumab|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.
62661246|NCT01813643|ACTIVE_COMPARATOR|Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.
61909947|NCT01779219|ACTIVE_COMPARATOR|iMRI-guided|Intervention: iMRI-guided brain tumour biopsy. The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet imager will be used in all cases. After the patient's positioning, the preoperative reference examination is routinely carried out. The entry point, target and optimal biopsy trajectory are then defined by the operator on the basis of the obtained iMRI images. Serial tissue samples are collected. Following each operation, a control iMRI (T1-weighted, axial, 4 mm scan examination) is routinely performed to confirm and document the proper targeting and to exclude postoperative hyperacute intraparenchymal bleeding.
61909948|NCT01779219|ACTIVE_COMPARATOR|non-iMRI|Intervention: Stereotactic frameless brain tumour biopsy. A frameless STx biopsy is performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory are defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
62098797|NCT03243760|EXPERIMENTAL|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62098798|NCT03243760|EXPERIMENTAL|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62098799|NCT03243760|EXPERIMENTAL|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62098800|NCT03243760|EXPERIMENTAL|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
62098801|NCT03243760|EXPERIMENTAL|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62098802|NCT03243760|EXPERIMENTAL|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62098803|NCT03243760|EXPERIMENTAL|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62098804|NCT03243760|EXPERIMENTAL|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62308141|NCT01703312|PLACEBO_COMPARATOR|placebo|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).
62661247|NCT01449487|ACTIVE_COMPARATOR|PPC-5650|
62661248|NCT01449487|PLACEBO_COMPARATOR|Placebo|
62661249|NCT04424901|PLACEBO_COMPARATOR|Standard Care|"Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 \& 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
62098805|NCT03243760|EXPERIMENTAL|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
62661250|NCT04424901|EXPERIMENTAL|Standard Care with Dipyridamole|"For this arm, Dipyridamole 100 mg, tid is given for 7 days. Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 \& 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
62661251|NCT01651585|EXPERIMENTAL|Valacyclovir arrow|Experimental : Valacyclovir arrow 500mg give Valacyclovir arrow to all participants (open phase)
62098806|NCT03243760|EXPERIMENTAL|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =\< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
62098807|NCT03243760|EXPERIMENTAL|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
62098808|NCT01452490|EXPERIMENTAL|Diode Laser Treatment|
62098809|NCT03454932||Rheumatoid Arthritis|Patients with Rheumatoid Arthritis
62098810|NCT03454932||Psoriatic Arthritis|Patients with Psoriatic Arthritis
62098811|NCT03454932||Spondylarthritis|Patients with Spondylarthritis
62294466|NCT03420976|EXPERIMENTAL|Novel Supplement-based Therapy|"Low FODMAP diet + supplements outlined below:~Product Name: Liver-G.I. Detox Active Ingredients: Alpha lipoic acid, n-acetyl-l-cystine, turmeric root extract, milk thistle seed extract, broccoli sprout concentrate, artichoke leaf extract, taurine, glycine, l-glutamine, l-methionine, and chlorella.~Product Name: l-Glutamine Active Ingredients: l-glutamine~Product Name: MicroDefense Active Ingredients: berberine sulfate, olive leaf extract, sweet wormwood, clove bud powder, and grapefruit seed and fruit extract.~Product Name: A.C. Formulla II Active Ingredients: calcium and magnesium undecylenate, calcium and magnesium caprylate, bromelain, grapefruit seed and fruit extract, and berberine sulfate~Product Name: Probiotic-5 (Pure Encapsulations) Active Ingredients: Probiotic blend~Product Name: Digestive Enzymes Ultra with Betaine HCl Active Ingredients: Digestive enzyme blend and betaine HCl"
62098812|NCT06473480|NO_INTERVENTION|PERIOD 1: Fingerstick glucose monitoring = Standard care|Subjects' blood glucose levels are monitored using point-of-care fingerstick capillary glucose monitoring (standard care). which is conducted by surgical ward nurses. Diabetes treatment management is overseen by specific in-house diabetes nurses. Treatment decisions are based on point-ofcare fingerstick capillary glucose values.
62661252|NCT02596087|NO_INTERVENTION|Normal Use of EHR|Sites will configure their EHR systems so that alerts will not be triggered for providers in the control arm if the patient does not have the condition on her/his problem list.
62661253|NCT02596087|EXPERIMENTAL|Intervention Arm|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. Each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
62661254|NCT04820504|PLACEBO_COMPARATOR|Blinded to visual feedback from AIR device|Providers did not receive AIR device feedback during newborn mannequin ventilation
62661255|NCT04820504|EXPERIMENTAL|Not blinded to visual feedback from AIR device|Providers did receive AIR device feedback during newborn mannequin ventilation
62098813|NCT06473480|ACTIVE_COMPARATOR|PERIOD 2: Fingerstick glucose monitoring = standard care + blinded sensor|Same as for period 1, but with a blinded sensor (FreeStyle Libre Pro). The data from the blinded sensors are concealed from both participants and nurses and will be used for comparison with the experimental arm.
62294467|NCT04114981|ACTIVE_COMPARATOR|Arm I (SSRS)|Patients undergo SSRS over 1 session.
62661256|NCT04585360||Patient with Behcet disease|adult patient with Behcet's disease followed regularly in the internal medicine department of Bicetre
61909949|NCT05299983|EXPERIMENTAL|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
62294468|NCT04114981|EXPERIMENTAL|Arm II (FSRS)|Patients undergo FSRS over 3 or 5 daily sessions.
62294469|NCT04378166|EXPERIMENTAL|Smart glasses|Application of smart glasses for ultrasound-guided central venous catheterization
61909950|NCT05299983|ACTIVE_COMPARATOR|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
62098814|NCT06473480|EXPERIMENTAL|PERIOD 3: Continuous glucose monitoring system = study Intervention|"PERIOD 3: Continuous glucose monitoring system = study intervention, involving 140 participants.~The sensor from the continuous glucose monitoring system is scanned by surgical nurses as point-of-care according to the predefined schedule, as in standard care. Monitoring is conducted by surgical ward nurses. Diabetes treatment management is overseen by specific in-house diabetes nurses. Diabetes nurses' treatment decisions are based on the continuous glucose monitoring system values"
62098815|NCT02049437|ACTIVE_COMPARATOR|Arm A: TCZ, then placebo|ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
62098816|NCT02049437|PLACEBO_COMPARATOR|Arm B: Placebo, then TCZ|ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
62098817|NCT05841784|ACTIVE_COMPARATOR|MBCT-T (Reference)|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T).
62466609|NCT06309901||IASTM Group|In addition to the progressive home exercise program consisting of 3 phases, the IASTM was applied with Graston technique around the knee.
62661257|NCT02684175|ACTIVE_COMPARATOR|In-Person CI Counseling Session|Participants (n=6) randomized to receive an in-person CI counseling session will receive what normally occurs with patients pursuing cochlear implantation. The counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, an explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
62661258|NCT02684175|EXPERIMENTAL|Remote CI Counseling Session|Participants (n=6) randomized to receive a remote CI counseling session will be receiving the counseling session remotely. The participants will be counseled remotely by the audiologist located in Lexington, KY via the telemedicine system (intervention). This counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
62661259|NCT00971828||Idiopathic inflammatory myopathy|IIM patients will be recruited via the Adult Onset Myositis clinic, Salford Royal NHS Foundation Trust. Suitable patients will be asked if they are willing to partake in the study, via a letter, including a patient information leaflet. If willing, they will contact our study co-ordinator, who will facilitate the visit to the WTCRF. The patient will then sign a consent form and be able to enter the study.
61909951|NCT01917656|EXPERIMENTAL|Liraglutide+Metformin|Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
61909952|NCT01917656|ACTIVE_COMPARATOR|Sulphonylurea and Metformin|Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
61909953|NCT01883856|ACTIVE_COMPARATOR|Silicone Plate Ahmed Glaucoma Valve|Silicone plate Ahmed Glaucoma Valve
62098818|NCT05841784|EXPERIMENTAL|MBCT-T + Booster Mindfulness Sessions|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T), in addition to booster mindfulness sessions.
62098819|NCT05841784|EXPERIMENTAL|MBCT-T + Website Support|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T), in addition to website support.
62098820|NCT05841784|EXPERIMENTAL|MBCT-T + Website Support + Booster Mindfulness Sessions|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T), in addition to both booster sessions and website support.
62294470|NCT04378166|NO_INTERVENTION|Control|Conventional ultrasound-guided central venous catheterization
62098821|NCT05801042|EXPERIMENTAL|Encapsulated probiotic|
62098822|NCT05801042|ACTIVE_COMPARATOR|Non-encapsulated probiotic|
62466610|NCT01043380|EXPERIMENTAL|LZ group|
62466611|NCT01043380|ACTIVE_COMPARATOR|L group|
62466612|NCT02795000||Primary Ovarian insufficiency group|"1. amenorrhea one year or more than one year~2. amenorrhea more than 4 months and FSH≥40IU/L~3. ≤42 years old and AMH≤0.071"
62466613|NCT02795000||The normal group|"1. normal regular menorrhea~2. ≤42 years old~3. normal FSH and AMH level"
62098823|NCT05801042|PLACEBO_COMPARATOR|Placebo|
62098824|NCT05191901|EXPERIMENTAL|stress ball group|
62098825|NCT05191901|NO_INTERVENTION|control group|
62098826|NCT04638387|EXPERIMENTAL|PB125|Twice daily oral administration of 1 capsule of PB125 (Pathways Bioscience). Treatment will last 12 weeks.
62294471|NCT04840121|ACTIVE_COMPARATOR|Study Group - AdhesioRT|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the study group will proceed with frozen embryo transfer cycle according window of implantation determined by AdhesioRT.
62308142|NCT00003565|EXPERIMENTAL|docetaxel|OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
62308143|NCT06367270|EXPERIMENTAL|PIPAC|
62098827|NCT04638387|PLACEBO_COMPARATOR|Placebo|Twice daily oral administration of 1 capsule of rice flour placebo (Pathways Bioscience). Treatment will last 12 weeks. Because of pandemic restricting study time frame, enrollment will favor the experimental arm in this pilot study
62098828|NCT06613815||(scopic group, N=19)|comparing the analgesic effectiveness of conventional radiofrequency of the geniculate nerves performed in a cohort of patients with a scopy-guided technique (scopic group, N=19)
61909954|NCT01883856|EXPERIMENTAL|Porous Plate Ahmed Glaucoma Valve|Porous Plate Ahmed Glaucoma Valve
62294472|NCT04840121|ACTIVE_COMPARATOR|Control Group - Standard of Care|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the control group will proceed with the first frozen embryo transfer cycle as per standard of care. In the event of unsuccessful implantation (negative serum pregnancy test), participants will proceed with subsequent frozen embryo transfer cycle according to window of implantation determined by AdhesioRT.
62294473|NCT01892488|PLACEBO_COMPARATOR|lactose pill|Placebo for 5 days as supplement to standard of care for patients with AE-COPD
61909955|NCT01029405|ACTIVE_COMPARATOR|1. AN2728 Ointment B|2%, administered twice daily
62098829|NCT06613815||the ultrasound-guided technique (US group, N=38)|, comparing the analgesic effectiveness of conventional radiofrequency of the geniculate nerves performed in a cohort of patients with a scopy-guided technique (scopic group, N=19) versus the ultrasound-guided technique
62098830|NCT05311475|EXPERIMENTAL|Mometasone + Azelastine|Mometasone + Azelastine (50 + 140 mcg per actuation)
62098831|NCT05311475|ACTIVE_COMPARATOR|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
62098832|NCT05311475|ACTIVE_COMPARATOR|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
62098833|NCT05311475|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
62294474|NCT01892488|EXPERIMENTAL|Sultamicillin|Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
62098834|NCT02896608||Dravet syndrome - HCN1 channel mutation|early infantile epileptic encephalopathy with HCN1 channel mutation
62294475|NCT01604746|NO_INTERVENTION|Safety assessment|Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.
62294476|NCT00642642|EXPERIMENTAL|Double blinded active|Subject will receive autologous fibroblast treatment on either their left or right side of their face
62466614|NCT05928481|EXPERIMENTAL|İntervention group (n:39)|Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
62466615|NCT05928481|NO_INTERVENTION|Control group (n:39)|Postpartum hemorrhage management practices were applied to the students in the control group on a standard adult patient model in the basic skills laboratory.
61909956|NCT01029405|PLACEBO_COMPARATOR|2. AN2728 Ointment B Vehicle|
61909957|NCT01029405|ACTIVE_COMPARATOR|3. AN2728 Ointment B|2%, administered once daily
62098835|NCT02896608||control with epilepsy|
62098836|NCT02896608||control without epilepsy|
62098837|NCT05453682|EXPERIMENTAL|Hypo IMRT|in muscle invasive bladder cancer, hypofractionated IMRT with chemotherapy
62098838|NCT06712472|NO_INTERVENTION|Standard arm|
62098839|NCT06712472|EXPERIMENTAL|Experimental arm|
62294477|NCT00642642|PLACEBO_COMPARATOR|Double blinded placebo|Subject will receive placebo treatment on the opposite side of the face from active treatment
61909958|NCT01029405|ACTIVE_COMPARATOR|4. AN2728 Ointment B|0.5%, administered twice daily
61909959|NCT01029405|ACTIVE_COMPARATOR|5. AN2728 Ointment B|0.5%, administered once daily
61909960|NCT00782470||Group 1|
61909961|NCT00782470||Group 2|
61909962|NCT00782470||Group 3|
62098840|NCT02919085|EXPERIMENTAL|Mobilization|
62098841|NCT06447142|EXPERIMENTAL|Open Kinetic Chain Exercise Group|Each subject in Open Kinetic Chain Exercise Group will receive a treatment protocol consisting of stretching exercises, open kinetic chain strengthening exercises, and functional exercises for the knee and hip.
62098842|NCT06447142|ACTIVE_COMPARATOR|Closed Kinetic Chain Exercise Group|Each subject in Closed Kinetic Chain Exercise Group will receive a treatment protocol consisting of stretching exercises, closed kinetic chain strengthening exercises, and functional exercises for the knee and hip.
62098843|NCT04018729|EXPERIMENTAL|Endobronchial valve + marrow-derived mesenchymal stromal cell|
62098844|NCT04018729|ACTIVE_COMPARATOR|Endobronchial valve|
62098845|NCT03377036|EXPERIMENTAL|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
62098846|NCT03377036|ACTIVE_COMPARATOR|2D-FFDM|2D full-field digital mammography
62294478|NCT06654557|PLACEBO_COMPARATOR|Placebo beverage (Part 1 and Part 2)|
62294479|NCT06654557|EXPERIMENTAL|0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|
62294480|NCT06654557|EXPERIMENTAL|0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)|
62294481|NCT06654557|EXPERIMENTAL|1% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|
62294482|NCT06654557|EXPERIMENTAL|6% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|
62098847|NCT06095206|EXPERIMENTAL|GenSci094|Participants received a single subcutaneous (SC) injection of 150 µg GenSci094 on day 1 pre-meal，PK and immunogenicity blood collection to day18， safety call follow-up completed at day 25
62098848|NCT04618016||With Vitamin E|
62098849|NCT04618016||Without Vitamin E|
62098850|NCT05407220|EXPERIMENTAL|group1|Period1: HCP1904-1
62466616|NCT03802682|EXPERIMENTAL|Treatment Sequence AB|Participants will receive a single dose of apalutamide 240 milligram (mg) (4\*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A \[reference\]) followed by a single dose of apalutamide 240 mg (4\*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B \[test\]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
62661260|NCT03179267|EXPERIMENTAL|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
62661261|NCT05869747|ACTIVE_COMPARATOR|Blood Donation|
62661262|NCT05869747|ACTIVE_COMPARATOR|Plasma Donation|
62661263|NCT05869747|PLACEBO_COMPARATOR|Blood/Plasma Control|
62098851|NCT05407220|EXPERIMENTAL|group2|Period1: HCP1904-3
62098852|NCT04776434|EXPERIMENTAL|SELUTION SLR™ DEB|Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
62098853|NCT04476043|EXPERIMENTAL|INCB054707 15 mg|Participants will receive INCB054707 15 milligrams (mg) for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
62098854|NCT04476043|EXPERIMENTAL|INCB054707 45 mg|Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
62098855|NCT04476043|EXPERIMENTAL|INCB054707 75 mg|Participants will receive INCB054707 75 mg for 52 weeks in the Placebo-controlled Treatment Period (16 weeks) plus the Open-label Extension Period (36 weeks). Participants will have the option to continue open-label treatment for an additional 48 weeks.
62098856|NCT04476043|PLACEBO_COMPARATOR|Placebo followed by INCB054707 75 mg|Participants will receive placebo for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
62098857|NCT06152198|EXPERIMENTAL|Hip arthroplasty|Operative treatment with hip arthroplasty i.e cemented total- or hemiarthroplasty.
62098858|NCT06152198|ACTIVE_COMPARATOR|Internal fixation|Operative treatment with internal fixation i.e screws, pins, hook pins, sliding hip device.
62098859|NCT06106945|EXPERIMENTAL|AZD0305 monotherapy|"Module 1:~Phase Ia: Dose Escalation Phase Ib: Dose Expansion/Optimization AZD0305 will be prescribed at specified dose levels."
62098860|NCT06401993|EXPERIMENTAL|"The dao qi tong luo group"|"Subjects in the dao qi tong luo group will undergo acupuncture treatment, which is administered 10 times"
62294483|NCT06654557|EXPERIMENTAL|6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|
62294484|NCT06654557|EXPERIMENTAL|6% carbohydrate electrolyte solution with glycerol beverage (Part 2 only)|
62294485|NCT02662478||primary gastric GIST|Consisted of all consecutive cases of primary gastric stromal tumors (PGST) that underwent laparoscopic surgery (LS).
62661264|NCT05869747|ACTIVE_COMPARATOR|Zone 2 Training|
62661265|NCT05869747|ACTIVE_COMPARATOR|Intermittent Fasting|
61909963|NCT05383001|EXPERIMENTAL|Arm A: tremelimumab /durvalumab (1 cycle), subsequently Durvalumab maintenance therapy|
62294486|NCT01678976|EXPERIMENTAL|Group 1 BIA 2-093 + Oxcarbazepine|Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
62294487|NCT01678976|ACTIVE_COMPARATOR|Group 2 Oxcarbazepine + BIA 2-093|Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
62294488|NCT02628587|EXPERIMENTAL|Generic clopidogrel|Patients are assigned to take generic clopidogrel
62661266|NCT05869747|PLACEBO_COMPARATOR|Zone 2 Control|
61909964|NCT05383001|OTHER|Arm B: platinum-based chemotherapy (SoC)|
61909965|NCT00382642|EXPERIMENTAL|Ondansetron|Arm 1 = Ondansetron 4 mcg/kg b.i.d.+ Cognitive behavioral therapy
61909966|NCT00382642|PLACEBO_COMPARATOR|Placebo|Arm 2 = Placebo + Cognitive behavioral therapy
61909967|NCT02181270|EXPERIMENTAL|high intensity exercise|High-intensity interval exercise (HIIE): Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes
61909968|NCT02181270|EXPERIMENTAL|Continuous moderate exercise group|Continuous moderate exercise group (CME): Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
61909969|NCT01198522|OTHER|Therapy of L19IL2 and Gemcitabine|Dose escalation study. Part A) Gemcitabine dose escalation. Part B) L19IL2 dose escalation.
61909970|NCT02821663|EXPERIMENTAL|Vocal intervention|Vocal intervention
61909971|NCT03561688|SHAM_COMPARATOR|Standard insole|a flat insole
61909972|NCT03561688|EXPERIMENTAL|Foot orthotics|Custom-made foot orthoses
62661267|NCT05869747|PLACEBO_COMPARATOR|Intermittent Fasting Control|
62661268|NCT02639533|EXPERIMENTAL|Pregabalin|Pregabalin 150 mg PO single dose
62661269|NCT02639533|PLACEBO_COMPARATOR|Placebo|Placebo (a pill of same physical characteristics as the one used for the experimental arm, containing starch) PO single dose
62661270|NCT04753112|EXPERIMENTAL|Treatment|"All the subjects will receive sacubitril/valsartan from weeks 6 to 12. From weeks 1-6 and 12-18 patients will be treated with standard therapy for HFpEF according to PA pressures (diuretics and systemic vasodilators if concomitant hypertension).~All the subjects will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).~Device: Patients eligible for this study are those with an already implanted CardioMEMS device.~Drug: Sacubitril/Valsartan Target dose:97/103mg bid"
62098861|NCT06401993|SHAM_COMPARATOR|The acupuncture group|Subjects in the acupuncture group will undergo acupuncture treatment, which is administered 10 times
62098862|NCT05718219|EXPERIMENTAL|Part 1 (dose escalation and dose expansion)|Cohorts of at least 3 participants each will be treated with escalating doses of SIM0348. Dose expansion part will be decided based on the findings of dose escalation part.
62098863|NCT05718219|EXPERIMENTAL|Part 2 (cohort expansion)|Participants will be treated with SIM0348 at a recommended dose (RD) in the study.
62098864|NCT04721392|EXPERIMENTAL|Mental fatigue - No Robot|During a 15 minute trial, the participant will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will perform a 60- minute Stroop task and is asked to repeat this abovementioned physical dual-task.
62098865|NCT04721392|EXPERIMENTAL|Mental fatigue - Exoskeleton|During a 15 minute trial, the participant will wear the Laevo exoskeleton and will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will perform a 60- minute Stroop task and is asked to repeat this abovementioned physical dual-task.
62098866|NCT04721392|PLACEBO_COMPARATOR|No Mental fatigue - No Robot|During a 15 minute trial, the participant will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will watch a 60- minute neutral documentary and is asked to repeat this abovementioned physical dual-task.
62098867|NCT04721392|PLACEBO_COMPARATOR|No Mental fatigue - Exoskeleton|During a 15 minute trial, the participant will wear the Laevo exoskeleton and will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will watch a 60- minute neutral documentary and is asked to repeat this abovementioned physical dual-task.
62098868|NCT01838551|EXPERIMENTAL|Levoketoconazole DL0|Levoketoconazole Tablets Dose Level 0 Once Daily
62661271|NCT04286646||Pupil diameter before/after cataract|The investigators measure the pupil diameter before and after (3 months) cataract. Mesopic and photopic conditions
62098869|NCT01838551|EXPERIMENTAL|Levoketoconazole DL1|Levoketoconazole Tablets Dose Level 1 Twice Daily
62098870|NCT01838551|EXPERIMENTAL|Levoketoconazole DL2|Levoketoconazole Tablets Dose Level 1 Twice Daily
62098871|NCT01838551|EXPERIMENTAL|Levoketoconazole DL3|Levoketoconazole Tablets Dose Level 3 Twice Daily
62098872|NCT01838551|EXPERIMENTAL|Levoketoconazole DL4|Levoketoconazole Tablets Dose Level 4 Twice Daily
61909973|NCT05095012|OTHER|Clinical Pathway Participation|Patients that are seen in an emergency department participating in the clinical pathway will not be aware of any changes, other than be given a specific education handout at discharge and be advised to visit the recoverconcussion.ca web portal. Specialty referrals for high risk patients will automatically be made during the emergency visit, through the clinical pathway.
62098873|NCT01838551|EXPERIMENTAL|Levoketoconazole DL5|Levoketoconazole Tablets Dose Level 5 Twice Daily
61909974|NCT05566483|EXPERIMENTAL|Exercise|
61909975|NCT05566483|NO_INTERVENTION|Control|
61909976|NCT02486341|EXPERIMENTAL|Human Neutral Protamine Hagedorn (NPH)|The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
62098874|NCT01838551|EXPERIMENTAL|Levoketoconazole DL6|Levoketoconazole Tablets Dose Level 6 Twice Daily
62098875|NCT01838551|EXPERIMENTAL|Levoketoconazole DL7|Levoketoconazole Tablets Dose Level 7 Twice Daily
62098876|NCT06555419|EXPERIMENTAL|Nusinersen Via LP and ThecaFlex DRx System|Participants will receive a nusinersen maintenance dose via LP in the PIERRE-PK study, followed by implantation of the ThecaFlex DRx System and the subsequent nusinersen maintenance dose via the system in the PIERRE study.
62098877|NCT06641778|EXPERIMENTAL|experimental group|This group of patients received conventional antibiotic therapy and fecal microbiota transplantation.
62098878|NCT06641778|NO_INTERVENTION|control group|Patients in this group were treated with conventional antibiotics.
62098879|NCT04717882|NO_INTERVENTION|Control arm|Patients in the control arm will receive the usual treatment
62661272|NCT01922011|EXPERIMENTAL|Daptomycin|Intravenous (IV) daptomycin was dosed as follows: age 12 years to \<18 years (7 mg/kg); age 7 years to \< 12 years (9 mg/kg); age 24 months to \<7 years (12 mg/kg); age 12 months to \<24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
61909977|NCT02486341|EXPERIMENTAL|Long-acting basal insulin analogues|
61909978|NCT04223492|OTHER|Neoadjuvant systemic treatment|All patients undergo standard neoadjuvant treatment and additional multi-parametric MRI and liquid biopsies during neoadjuvant treatment.
62098880|NCT04717882|EXPERIMENTAL|Intervention arm|After crossing over to the intervention period, attending physicians will receive medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
62098881|NCT06384430||Patients with subacromial impingement syndrome|Patients with subacromial impingement syndrome: Being between 18-70 years old Clinical evaluation positive for subacromial impingement syndrome (Neer's test, Hawkins Kennedy, supraspinatus palpation test)
62294489|NCT02628587|ACTIVE_COMPARATOR|Patent clopidogrel|Patients are assigned to take patent clopidogrel (Plavix)
61909979|NCT00849316||A|
62098882|NCT00049114|EXPERIMENTAL|Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)|"PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection."
62098883|NCT00082719|EXPERIMENTAL|Arm I|Low-dose interferon alfa subcutaneously (SC) twice daily.
61909980|NCT01517971||Ancillary-correlative (whole-genome expression)|RNA extracted from archived tumor tissue samples are analyzed for whole-genome expression profiling by Gene Profiling Array cGMP U133 P2 and RT-PCR.
61909981|NCT01952483||vitamin D deficient,|Vitamin D deficiency (serum level \<20ng/ml)
61909982|NCT01952483||Vitamin D normal|Serum level \>35 ng/ml
61909983|NCT05309876|EXPERIMENTAL|Usage of tool|Participants get access to the tool and use it regularly
61909984|NCT05309876|NO_INTERVENTION|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease is followed via clinical registries.
62294490|NCT01339455|EXPERIMENTAL|AHSCT|All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.
62294491|NCT03720314||IBS|Irritable bowel syndrome patients
62294492|NCT03720314||control|healthy controls
62294493|NCT03781557|EXPERIMENTAL|High-concentrated DHA|High-concentrated DHA fish oil softgels
62661273|NCT01922011|ACTIVE_COMPARATOR|Vancomycin or Nafcillin|IV vancomycin (or equivalent), 10 to 15 mg/kg, was infused over 60 (± 10) minutes q6h (± 1 hour) or IV nafcillin (or β-lactam equivalent) at 100-200 mg/kg/day, in divided doses was infused over 60 (± 10) min q6h (± 1 hour)
62661274|NCT01054248|EXPERIMENTAL|MAS3|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
62661275|NCT01054248|ACTIVE_COMPARATOR|ALN+|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet)
62661276|NCT01054248|EXPERIMENTAL|DP|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
62661277|NCT03860480|ACTIVE_COMPARATOR|ESP with Bupivacaine 0.5%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of bupivacaine at a concentration of 0.5% with epinephrine 1:200 000 will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
62661278|NCT03860480|SHAM_COMPARATOR|ESP with Saline 0.9%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of a placebo solution (normal saline) will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
62661279|NCT00661440|OTHER|1|
61909985|NCT03229174|EXPERIMENTAL|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
61909986|NCT03229174|OTHER|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
61909987|NCT04057716|EXPERIMENTAL|Sleep restriction followed by extension|Children will spend 8 hours in bed for one week, engage in one week of wash-out, and then spend 11 hours in bed for one week.
62098884|NCT00082719|EXPERIMENTAL|Arm II|Interferon alfa as in arm I at a higher dose.
62098885|NCT00082719|EXPERIMENTAL|Arm III|Interferon alfa SC once daily.
62294494|NCT03781557|EXPERIMENTAL|High-concentrated EPA|High-concentrated EPA fish oil softgels
62294495|NCT03781557|PLACEBO_COMPARATOR|Olive Oil|Olive Oil softgels
62294496|NCT05199584|EXPERIMENTAL|200 mg ENV-101|ENV-101 (taladegib) tablets, 200 mg once-daily in 28-day cycles
62294497|NCT05199584|EXPERIMENTAL|300 mg ENV-101|ENV-101 (taladegib) tablets, 300 mg once-daily in 28-day cycles
62661280|NCT00661440|OTHER|2|
62661281|NCT04543864|EXPERIMENTAL|electric welded metal framework|
61909988|NCT04057716|EXPERIMENTAL|Sleep extension followed by restriction|Children will spend 11 hours in bed for one week, engage in one week of wash-out, and then spend 8 hours in bed for one week.
61909989|NCT04479371|EXPERIMENTAL|Liposomal bupivacaine|a penile block administered with novel liposomal bupivacaine during hypospadias repair
62098886|NCT00082719|EXPERIMENTAL|Arm IV|Interferon alfa as in arm III at a higher dose.
62098887|NCT06323174|ACTIVE_COMPARATOR|CagriSema Dose 2|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.
62098888|NCT06323174|PLACEBO_COMPARATOR|Placebo Dose 2|Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.
62294498|NCT00317044|EXPERIMENTAL|Esomeprazole 40 mg twice daily|
62294499|NCT00317044|EXPERIMENTAL|Esomeprazole 40 mg once daily|
62294500|NCT00317044|PLACEBO_COMPARATOR|Placebo|
62294501|NCT01012908|EXPERIMENTAL|Norzyme|Pancreatic Enzymes - Norzyme (Bergamo)
62294502|NCT01012908|ACTIVE_COMPARATOR|Creon (Solvay)|Pancreatic Enzymes - Creon (Solvay)
62294503|NCT03569267|EXPERIMENTAL|OLX10010|OLX10010, an siRNA therapeutic, with four different doses by Groups (dose ascending manner with 1, 4, 10, 20 mg)
62294504|NCT03569267|PLACEBO_COMPARATOR|Placebo|placebo
62294505|NCT02832089|EXPERIMENTAL|active arm|single arm study with one group given oral carvedilol.
61909990|NCT04479371|ACTIVE_COMPARATOR|Standard Penile Block|Standard weight based bupivacaine penile block during hypospadias repair
61909991|NCT00265356|EXPERIMENTAL|1|PET diagnostic imaging
62294506|NCT05501925|EXPERIMENTAL|GlideSheath Slender®|Placement of 6 French GlideSheath Slender® for cardiovascular intervention via distal radial artery
61909992|NCT00265356|NO_INTERVENTION|2|No PET
61909993|NCT01837576|EXPERIMENTAL|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
62294507|NCT05501925|ACTIVE_COMPARATOR|Conventional Sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II ) for cardiovascular intervention via distal radial artery
62661282|NCT04543864|EXPERIMENTAL|conventional casted metal framework|
62661283|NCT03528031|EXPERIMENTAL|Intervention Daily Avocado|Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
62466617|NCT03802682|EXPERIMENTAL|Treatment Sequence BA|Participants will receive a single dose of apalutamide 240 mg (4\*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 1 (Treatment B \[test\]) followed by a single dose of apalutamide 240 mg (4\*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 2 (Treatment A \[reference\]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
62661284|NCT03528031|NO_INTERVENTION|Control Usual Diet and Lifestyle|Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
62661285|NCT06492694|EXPERIMENTAL|Fish oil + wild orange essential oil supplement|Participants in this arm will take three capsules of a fish oil + wild orange essential oil supplement daily for approximately six weeks.
62661286|NCT06492694|ACTIVE_COMPARATOR|Fish oil supplement|Participants in this arm will take three capsules of a fish oil essential oil supplement daily for approximately six weeks.
62661287|NCT03220789|EXPERIMENTAL|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
62661288|NCT03220789|ACTIVE_COMPARATOR|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
62661289|NCT01341470|EXPERIMENTAL|Single IV dose LY2495655|Single 70 milligram (mg) dose LY2495655 administered intravenously (IV)
62661290|NCT01341470|EXPERIMENTAL|Multiple SC dose 17.5 mg LY2495655|17.5 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
62661291|NCT01341470|EXPERIMENTAL|Multiple SC dose 140 mg LY2495655|140 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
62661292|NCT01341470|EXPERIMENTAL|Multiple SC dose 420 mg LY2495655|420 mg dose of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
62661293|NCT01341470|PLACEBO_COMPARATOR|Single IV dose placebo|Single Placebo dose administered intravenously (IV)
62661294|NCT01341470|PLACEBO_COMPARATOR|Multiple SC dose placebo|Placebo dose administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
62661295|NCT04713683|ACTIVE_COMPARATOR|Amplatzer PFO Occluder|Patients randomized in this arm will be implanted with Amplatzer PFO Occluder.
62661296|NCT04713683|ACTIVE_COMPARATOR|Gore Cardioform Septal|Patients randomized in this arm will be implanted with Gore Cardioform Septal Occluder.
62661297|NCT03783806||Osteoarthrosis (OA)|Patients with primary osteoarthrosis, waiting for a total hip replacement. Determination of functional status, posturography measurements, postural tests.
62661298|NCT03783806||Rheumatoid arthritis (RA)|Patients with rheumatoid arthritis affecting hip joint. Determination of functional status, posturography measurements, postural tests.
62661299|NCT03783806||Control (C)|The healthy reference group was matched with the patient groups for age, gender and body mass index (BMI). Determination of functional status, posturography measurements, postural tests.
62661300|NCT05009420|EXPERIMENTAL|Avocado|Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
62661301|NCT03168724|EXPERIMENTAL|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
62661302|NCT03168724|NO_INTERVENTION|Control|Group not getting the intervention
62661303|NCT01204515||Girls with IBS|Girls ages 7-12 years who meet Rome III criteria for IBS
62661304|NCT01204515||Healthy Girls (controls)|Girls ages 7-12 years who are otherwise healthy and have no complaints of stomach pain
62661305|NCT05608655|EXPERIMENTAL|DKutting|DKutting LL Scoring Balloon, DK Medtech Co Ltd
61909994|NCT02930980|EXPERIMENTAL|Investigational Software|Investigational Software loaded on Micra device
61909995|NCT02612831|OTHER|Early bariatric surgery|patient receive their procedure early (within 3 months)
61909996|NCT02612831|OTHER|Delayed bariatric surgery|Patient receive their procedure later (in 12 - 15 months), following a year of optimal medical treatment
61909997|NCT00760799|ACTIVE_COMPARATOR|1|Standard discectomy without anular repair
61909998|NCT00760799|EXPERIMENTAL|2|Standard Discectomy with anular repair
61909999|NCT01336361||Physical Therapists|Physical Therapists who are members of the American Physical Therapy Association (APTA) and live in the United States .
61910000|NCT03978793||MyTPill|Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill.
62294508|NCT04125537||Dialysis Centers - Seriously Ill patients - pre-implementation cohort|Dialysis center patients who screened positive as seriously ill in month 1 of the collaborative activities (the preimplementation period).
62294509|NCT04125537||Dialysis Centers - Seriously Ill patients - post-intervention cohort|Dialysis Center patients who screened positive as seriously ill in month 15 of the intervention (the post-implementation period).
62308144|NCT05421377||lymph node dissection for treatment of urogenital, gynaelogical or skin cancer|Patients with any type of skin melanoma (at the level of the lower limb), urogenital or gynaecological cancer scheduled for lymph node dissection
62661306|NCT05608655|ACTIVE_COMPARATOR|Chocolate|Chocolate Balloon, TriReme Medical LLC
62098889|NCT06323174|ACTIVE_COMPARATOR|Cagrisema Dose 1|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.
62098890|NCT06323174|PLACEBO_COMPARATOR|Placebo Dose 1|Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.
62098891|NCT02459964|EXPERIMENTAL|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
62098892|NCT02459964|ACTIVE_COMPARATOR|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
62098893|NCT05495711|EXPERIMENTAL|stem cell and collagen transplantation group|Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-UT)
62098894|NCT05495711|ACTIVE_COMPARATOR|control group|collagen transplantation
62098895|NCT04639947|EXPERIMENTAL|EyeCheck|EyeCheck pressures will be measured with contact lens in place
62098896|NCT04639947|ACTIVE_COMPARATOR|Traditional Tonometer (Goldmann and Tonopen)|Pressures will be measured with both Goldmann and Tonopen (both traditional tonometers to take the intraocular pressure (IOP) measurements of the eye).
62098897|NCT04000893|EXPERIMENTAL|Resistance exercise session|Acute isometric session, about 20 minutes.
62098898|NCT04000893|ACTIVE_COMPARATOR|Aerobic exercise session|Acute aerobic session, about 20 minutes.
62098899|NCT02341313||Newborns at risk of hypoglycaemia|Measurement of ketones
62466618|NCT02683837|ACTIVE_COMPARATOR|Standard practice|"Remifentanil infusion guided by usual clinical signs (heart rate, blood pressure).~Pupillometry blindly recorded. Anesthesia maintenance with sevoflurane."
61910001|NCT05154968|EXPERIMENTAL|Sequence 1 (ABCD)|Participants will receive 1 millilitre (ml) subcutaneous (SC) injection of treatment A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at the potential of hydrogen (pH) 5.7) followed by treatments B (higher pain Room Temperature \[RT\] solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), C (lower pain refrigerated solution contains mannitol), and D (lower pain RT solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
62098900|NCT04541225|EXPERIMENTAL|Phase 1 Dose Escalation|NUV-422 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.
62098901|NCT06610357||Children with diparetic serebral palsy|42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
62098902|NCT04267146|EXPERIMENTAL|newly diagnosed high-grade glioma|"Phase I : Open label, non-randomized, safety run study in nine patients. In case of safety issue a -1 dose level will be tested.~Phase II : Open label, non randomized, efficacy study of nivolumab in addition to radiotherapy and temozolomide. This phase will start when the RP2D has been defined after the last patients evaluable for DLT achieved the first 6 weeks of treatment (the radio-chemotherapy period) with a DLT rate below 30% during the the phase I study."
62098903|NCT01238497||Registry 1 - SOURCE XT|Registry 1: All patients implanted with a SAPIEN XT valve, via Transfemoral access using NovaFlex (for 23mm and 26mm valve), or via Transapical access using Ascendra2 (23mm, 26mm and 29mm valve)
62098904|NCT01238497||Registry 2 - Ascendra+|Registry 2: All patients implanted with a SAPIEN XT Valve, via Transapical or Transaortic access using Ascendra+ delivery system (23mm, 26mm and 29mm valve)
62098905|NCT01238497||Registry 3 - NovaFlex+ 29 mm|Registry 3: All patients implanted with a SAPIEN XT valve, 29mm only, via Transfemoral access using NovaFlex+
62098906|NCT06659289|NO_INTERVENTION|Baseline therapy|Patients will be treated according to the standard protocol for cardiac surgery with cardiopulmonary bypass without hemoperfusion.
62098907|NCT06659289|EXPERIMENTAL|Basic therapy + Efferon LPS|Patients will be treated according to the standard protocol for cardiac surgery with cardiopulmonary bypass and will receive hemoperfusion with Efferon LPS.
62098908|NCT03296579|ACTIVE_COMPARATOR|Conventional asthma therapy.|Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 \> 92%.
62098909|NCT03296579|EXPERIMENTAL|Non-invasive ventilation (CPAP).|Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 \> 92%.
62308145|NCT05121246|EXPERIMENTAL|MB05 (Proposed palivizumab biosimilar)|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1.
62098910|NCT03296579|EXPERIMENTAL|Non-invasive ventilation (BiPAP)|Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.
62098911|NCT02309840|NO_INTERVENTION|control|Students received standard meals in a standard cafeteria environment
62098912|NCT02309840|EXPERIMENTAL|Chef|Students were exposed to chef-enhanced meals
62098913|NCT02309840|EXPERIMENTAL|choice architecture|"Students were exposed to modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
62098914|NCT02309840|EXPERIMENTAL|Chef and choice architecture|"Students were exposed to both chef-enhanced meals and modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
62098915|NCT05947513|EXPERIMENTAL|Concurrent Curcumin Palliative Radiotherapy|Daily 1000 mg oral CGM Curcumin in four divided doses for seven days prior to the start of and for three to five weeks concurrently with palliative radiotherapy.
62098916|NCT02595307|EXPERIMENTAL|Pamphlet|Participant group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
62294510|NCT01672957||Renal Transplant Participants|Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
62661307|NCT00512668|EXPERIMENTAL|Treatment (hormone therapy, temsirolimus)|"Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90.\* Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. Treatment with temsirolimus continues for up to 36 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry."
62661308|NCT01549197||ICU staff and relatives|
62661309|NCT03947723|EXPERIMENTAL|Low power|"These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of low."
62661310|NCT03947723|EXPERIMENTAL|1 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.
62661311|NCT03947723|EXPERIMENTAL|1.5 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5
62661312|NCT03947723|EXPERIMENTAL|2 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.
62661313|NCT01432951|EXPERIMENTAL|Enzastaurin|"Enzastaurin 500 mg, four 125-mg tablets administered orally once daily for 14 days. Dosing is held for 3 days, and resumes on Day 18. Participants may continue receiving optional enzastaurin for an additional 2 to 4 weeks.~Safety Extension: Participants had the option to continue receiving enzastaurin until disease progression or discontinuation criteria are met, as per the investigator's assessment."
62661314|NCT03791931|OTHER|Patients|Oxidative stress measurement in cleavage state embryos
62737053|NCT02057640|EXPERIMENTAL|Combination therapy: Panobinostat, dexamethasone, MLN9708|Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28
62737054|NCT04254653|EXPERIMENTAL|Immediate Intervention|Participants receive diabetes nutrition education classes immediately.
61910002|NCT05154968|EXPERIMENTAL|Sequence 2 (BDAC)|Participants will receive 1 ml SC injection of treatment B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) followed by treatments D (lower pain RT solution contains mannitol), A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), and C (lower pain refrigerated solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
62294511|NCT03704337|EXPERIMENTAL|Commercially Available Food Bar|62 g. Food Bar
62294512|NCT03704337|PLACEBO_COMPARATOR|Placebo|25 g. Dextrose
62737055|NCT04254653|EXPERIMENTAL|Wait list intervention|Participants wait listed (control) for 3 months and then receive the diabetes nutrition education classes.
62098917|NCT02595307|NO_INTERVENTION|No Pamphlet|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
62098918|NCT04108338||CCRT-randomized clinical trial|Trial patients receiving CCRT
62098919|NCT04108338||CCRT-real-world database|Patients receiving CCRT from real-world database
62098920|NCT04108338||IC+CCRT-randomized clinical trial|Trial patients receiving IC+CCRT
62098921|NCT04108338||IC+CCRT-real-world database|Patients receiving IC+CCRT from real-world database
62098922|NCT02886988|EXPERIMENTAL|Botulinum toxin type A|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
62294513|NCT04301414|OTHER|Safety lead-in|The first 4 subjects enrolled will be given degarelix plus BMS-986218.
62294514|NCT04301414|ACTIVE_COMPARATOR|Arm A|Degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy
62294515|NCT04301414|EXPERIMENTAL|Arm B|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy.
62294516|NCT01417676|EXPERIMENTAL|Radiation|
62294517|NCT02370121|PLACEBO_COMPARATOR|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
62661315|NCT01373229|EXPERIMENTAL|Lenalidomide + Plerixafor+ Rituximab|"1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression."
62661316|NCT05303285|EXPERIMENTAL|Secukinumab 300mg|Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 300 mg s.c. every 4 weeks for an additional 48 weeks.
62661317|NCT05303285|ACTIVE_COMPARATOR|Secukinumab 150 mg|Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks for an additional 48 weeks.
62098923|NCT02886988|PLACEBO_COMPARATOR|Normal Saline|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.
62098924|NCT04813211|EXPERIMENTAL|Trial group|20 patients with cervical spondylosis undergoing mobile artificial cervical vertebrae replacement
62098925|NCT04813211|EXPERIMENTAL|Control group|20 patients with cervical spondylosis undergoing anterior cervical corpectomy and fusion
61910003|NCT05154968|EXPERIMENTAL|Sequence 3 (CADB)|Participants will receive 1 ml SC injection of treatment C (lower pain refrigerated solution contains mannitol) followed by treatments A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), D (lower pain RT solution contains mannitol), and B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
62098926|NCT06711016|EXPERIMENTAL|multimodal monitoring strategy|These include TCD to monitor cerebral blood perfusion levels, NIRS to monitor oxygen saturation levels in brain regions, ONSD to evaluate cerebral edema, and continuous quantitative EEG to monitor brain function to assess prognosis. Among them, The Vm will maintained between 56-85 cm/s, Vd\>30cm/s，PI\<1.2, the cerebral oxygen saturation (rSO2) in the brain region will maintained at 55%-75%, ONSD \<5.5mm, and the pathological state will be monitored with EEG.
62661318|NCT01237730|ACTIVE_COMPARATOR|Cefuroxime group|Use the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
61910004|NCT05154968|EXPERIMENTAL|Sequence 4 (DCBA)|Participants will receive 1 ml SC injection of treatment D (lower pain RT solution contains mannitol) followed by treatments C (lower pain refrigerated solution contains mannitol), B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), and A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
61910005|NCT04518995|EXPERIMENTAL|Placebo|Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
61910006|NCT04518995|EXPERIMENTAL|CTP-543 8 mg BID|Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
61910007|NCT04518995|PLACEBO_COMPARATOR|CTP-543 12 mg BID|Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
61910008|NCT02265198||PC Group|patients with Pulmonary Contusion on chest computed tomography (CT)
61910009|NCT02265198||Control Group 1|Uninjured patients undergoing elective surgical procedures that will require intubation and mechanical ventilation
62098927|NCT06711016|ACTIVE_COMPARATOR|control|SPO2 between 92 and 98%, MAP ≥ 65 mmHg, Hb ≥ 7 g/dL, pH 7.35 to 7.45, Pco2 between 40-45 mmHg， Routine fluid resuscitation, dehydration and intracranial pressure reduction, ECMO circulatory flow adjustment, temperature management, ventilator-supported ventilation, coronary angiography if coronary causes are suspected.
62098928|NCT06713161||NIR-II probe incubation|The fresh excision breast tissues or SLN will be completely soaked in the NIR-II probe (i.e:ICG-POL6326) incubation solution (12.5,25,50,100 ug/mL) for1, 3, 5,7 or 10 min, followed by 5 min of rinsing with PBST buffer and drying with absorbent paper.The NIR-II fluorescence imaging will be then performed under the DPM NIR-II system. And the correlation between pathological characterization and fluorescent information will be further analyzed.
62294518|NCT02370121|EXPERIMENTAL|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
61910010|NCT02265198||Control Group 2|Trauma patients without chest injury who are mechanically ventilated
61910011|NCT02265198||MICU group|Patients in the Medical ICU who are mechanically ventilated with acute respiratory failure
61910012|NCT02848443|EXPERIMENTAL|S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)|
61910013|NCT01642875|EXPERIMENTAL|EN|early enteral nutrition with standard enteral formulas administered through a nasojejunal tube
61910014|NCT01642875|ACTIVE_COMPARATOR|PerOs|early oral nutrition with hospital diets and oral formulas
61910015|NCT04311593||group 1|control group with normal platelet count
62098929|NCT05067283|EXPERIMENTAL|Arm 1|Participants will receive daily oral escalating doses of up to 800 mg of MK-1084 until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
62294519|NCT03534037|EXPERIMENTAL|Febuxostat 40mg|Febuxostat 40mg orally per day
61910016|NCT04311593||group 2|patients with acute ITP
61910017|NCT04311593||group 3|patients with chronic ITP
61910018|NCT05055089||new-generation bioprostheses|Patients undergoing surgical aortic valve replacement with new-generation bioprostheses
62098930|NCT05067283|EXPERIMENTAL|Arm 2|Participants will receive MK-1084 daily oral escalating dose of up to 800 mg plus pembrolizumab given as a 200 mg intravenous infusion once every 21-day cycle up to a total of 35 cycles (up to \~24 months). Treatment with MK-1084 will continue until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
62294520|NCT03534037|ACTIVE_COMPARATOR|Benzbromarone 50mg|Benzbromarone 50mg orally per day
62661319|NCT01237730|EXPERIMENTAL|Tailored antibiotics group|Tailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
62098931|NCT05067283|EXPERIMENTAL|Arm 3|Participants will receive alternate formulation of MK-1084 until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
62098932|NCT05067283|EXPERIMENTAL|Arm 4|Participants will receive MK-1084 daily oral dose plus an intravenous infusion of pembrolizumab (200 mg) once every 21-day cycle for up to 35 cycles (up to \~24 months). Participants will also receive carboplatin (per label) and pemetrexed (per label) once every 21-day cycle for the first 4 cycles.
62098933|NCT05067283|EXPERIMENTAL|Arm 5|Participants will receive MK-1084 daily oral dose plus an intravenous infusion of cetuximab (per label) every 2 weeks of each 28-day cycle.
62294521|NCT03534037|OTHER|Control|Dietary control only
62661320|NCT05091827||Pregnant women with pre-eclampsia|Pre-eclamptic pregnant women with singleton uncomplicated ≥ 20 week old pregnancies will be recruited in this group of the study.
62661321|NCT05091827||Normotensive pregnant women|Normotensive pregnant women with singleton uncomplicated ≥ 20 week old pregnancies will be recruited in this group of the study
62661322|NCT05091827||Offspring of pre-eclamptic women|Both male and female offspring of pre-eclamptic women recruited in this study will be recruited into this study group.
62098934|NCT05067283|EXPERIMENTAL|Arm 6|Participants will receive MK-1084 daily oral dose. Additionally, participants receive an intravenous infusion of cetuximab (per label) every 2 weeks of each 28-day cycle, oxaliplatin (per label) for first 6 cycles, and leucovorin (per label) and 5-fluorouracil (per label) once every 14-days.
62098935|NCT06161883|EXPERIMENTAL|Soffritto group|After a two-week run-in phase, participants (N=20) were randomly assigned to the Soffritto group. For 6 weeks, volunteers received soffritto (100 g/day). After the initial six-week phase, there was a two-week washout period, followed by a second six-week period in which participants were placed in the control group.
62294522|NCT01778244|EXPERIMENTAL|metformin|metformin
62294523|NCT01778244|PLACEBO_COMPARATOR|placebo|placebo
62294524|NCT02001545||Patients with STEMI and NSTEMI|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.
62294525|NCT06227130|EXPERIMENTAL|Intervention|Experimental: Intervention A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work. Each session lasts for about 20 minutes and the participant is encouraged to perform the session at least 3 times/week.
62308146|NCT05121246|ACTIVE_COMPARATOR|EU-Synagis®|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1
62661323|NCT05091827||Offspring of normotensive pregnant women|Both male and female offspring of from normotensive pregnant women recruited in this study will be recruited into this study group.
62661324|NCT00689936|EXPERIMENTAL|Lenalidomide / Dexamethasone until disease progression|Lenalidomide plus low-dose dexamethasone given until disease progression
62661325|NCT00689936|EXPERIMENTAL|Lenalidomide / Dexamethasone for 18 cycles|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
62661326|NCT00689936|ACTIVE_COMPARATOR|Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles|Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
62661327|NCT05071404||Cases|Patients treated with infliximab sc.
62661328|NCT03917888|EXPERIMENTAL|Lung ultrasound|Patients will be monitored for ventilator associated pneumonia using lung ultrasound combined with clinical features
62661329|NCT03917888|NO_INTERVENTION|Chest x-ray|Patients will be monitored for ventilator associated pneumonia using chest x-ray and clinical features.
62661330|NCT05075772|EXPERIMENTAL|100 mg BI 765080 SC injection (T)|
62661331|NCT05075772|EXPERIMENTAL|100 mg BI 765080 IV infusion (R)|
62661332|NCT02845804||Alpine|The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
62661333|NCT05408988||Patients with subarachnoid haemorrhage|Patients aged 18 or older hospitalized in the Intensive Care Unit with Subarachnoid Haemorrhage.
62098936|NCT06161883|EXPERIMENTAL|Control group|After a two-week run-in phase, the participants (N=20) were randomly assigned to the control group. For 6 weeks, the volunteers did not receive any product. After the initial six-week run-in phase, there was a two-week washout period, followed by a second six-week period in which participants were switched to the Soffritto group (100g/day).
62098937|NCT05687123|EXPERIMENTAL|Treatment (sunitinib malate, lutetium Lu 177 dotatate)|Patients receive sunitinib malate PO QD from day 1 of lutetium 177 dotatate therapy to 28 days after the last dose of lutetium 177 dotatate in the absence of unacceptable toxicity. Patients also receive lutetium Lu 177 dotatate IV over 30 minutes on day 1 of each cycle. Cycles repeat Q8W for 4 cycles in the absence of unacceptable toxicity. Patients undergo a CT scan and/or MRI throughout the trial. Patients also undergo a SSR PET/CT scan during screening and blood sample collection on study.
62098938|NCT03364959|EXPERIMENTAL|Flixotide|Patients inhale first Flixotide and then Qvar
62098939|NCT03364959|EXPERIMENTAL|Qvar|Patients inhale first Qvar and then Flixotide
62098940|NCT04486638||Pregnant women and their offspring(s)|Women and their offspring(s) exposed to Dengvaxia during pregnancy
62098941|NCT03236233|EXPERIMENTAL|Single dose - healthy subjects|
61910019|NCT05055089||traditional bioprosthesis|patients who received a traditional bioprosthesis
61910020|NCT01689428||IVF treatment EmbryoGen|Embryo culture in EmbryoGen medium
61910021|NCT01689428||IVF treatment ISM1|Embryo culture in ISM1 medium
61910022|NCT02878057|EXPERIMENTAL|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
61910023|NCT05519293|EXPERIMENTAL|20 mg QD, oral|H002 20mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62098942|NCT03236233|EXPERIMENTAL|Repeat dose - healthy subjects|
62098943|NCT03236233|EXPERIMENTAL|Single dose - subjects with asthma|
62098944|NCT03818061|EXPERIMENTAL|HPV +|Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
62294526|NCT06227130|ACTIVE_COMPARATOR|Waiting list|The first 6 weeks of the study, the participants will be controls. During week 6-12 they will then perform the intervention according to the description above.
62294527|NCT04772248||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
61910024|NCT05519293|EXPERIMENTAL|40 mg QD, oral|H002 40mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
61910025|NCT05519293|EXPERIMENTAL|80 mg QD, oral|H002 80mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
61910026|NCT05519293|EXPERIMENTAL|150 mg QD, oral|H002 150mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
61910027|NCT05519293|EXPERIMENTAL|250 mg QD, oral|H002 250mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
61910028|NCT05519293|EXPERIMENTAL|350 mg QD, oral|H002 350mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
62098945|NCT03818061|EXPERIMENTAL|HPV -|Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.
62098946|NCT04478175|OTHER|Patients with advanced gastrointestinal (GI) cancers|"All patients will receive usual care including:~* Chemotherapy at the investigator's choice,~* Outpatient clinical visits according to the regular schedule,~* Tumor evaluation based on tumor marker serum levels, as appropriate, and TAP-CT with intravenous contrast injection every 8 weeks.~Nutritional support will consist of:~* A nutrition assessment by a dieticianat W4 and W8 (plus additional visits if required),~* Nutritional intervention ± oral supplementation, enteral tube feeding, and/or parenteral nutrition).~Physical activity support will consist of:~* A physical condition assessment by a APA profesional including physical tests (6-minute walking test, handgrip test, chair stand fitness test, get-up and go test, balance in single-leg and bipodal stance) at baseline, W4 and W8,~* Personalized counselling for unsupervised home-based exercises"
62098947|NCT06291701||Other|adolescent tennis player
62098948|NCT03504449|EXPERIMENTAL|surgery without neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.
62098949|NCT03504449|EXPERIMENTAL|surgery with neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.
62294528|NCT04772248||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
62294529|NCT00559091|EXPERIMENTAL|I|Ribavirin
62294530|NCT06156527|ACTIVE_COMPARATOR|single arm|lazertinib single arm
62661334|NCT05436288|EXPERIMENTAL|Single arm active|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S), up to 6 times a day for 4 weeks.
62661335|NCT03600129|EXPERIMENTAL|QLB with 0,375% ropivacaine|
62661336|NCT03600129|PLACEBO_COMPARATOR|QLB with 0,9% NaCl|
62661337|NCT01246167|ACTIVE_COMPARATOR|Conservative|Active physiotherapy and self-training
62661338|NCT01246167|ACTIVE_COMPARATOR|Philos locking plate|After operative treatment active physiotherapy and self-training
62661339|NCT01246167|ACTIVE_COMPARATOR|Epoca prosthesis|After operative treatment active physiotherapy and self-training
62098950|NCT06228742|EXPERIMENTAL|Immobilized Leg|One leg of a young, healthy adult will be randomly assigned to undergo 5 days of immobilization using a rigid knee brace.
62098951|NCT06228742|EXPERIMENTAL|Non-immobilized leg|One leg of a young, healthy adult will remain active and not immobilized for 5 days.
62466619|NCT02683837|EXPERIMENTAL|Pupillometry|Remifentanil infusion guided by changes in pupillary diameter. Anesthesia maintenance with sevoflurane.
62661340|NCT02821559|EXPERIMENTAL|triweekly then biweekly|The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks).
62661341|NCT02821559|EXPERIMENTAL|biweekly then triweekly|The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen.
62661342|NCT05793944|ACTIVE_COMPARATOR|Intervention: SmartMom messaging|Participants receive three text messages per week with evidence-based information to promote healthy behaviours during pregnancy.
62661343|NCT05793944|PLACEBO_COMPARATOR|Control messaging|Participants receive one text message per week with general information about pregnancy but not about making healthy choices.
62661344|NCT05735470|EXPERIMENTAL|Antibacterial bone traction needle|The bone traction needle with an antibacterial coating.
62661345|NCT05735470|NO_INTERVENTION|bone traction needle|The bone traction needle without an antibacterial coating.
62661346|NCT04464460|EXPERIMENTAL|Cohort 1: TAK-671 Low Dose|TAK-671 low dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
62661347|NCT04464460|EXPERIMENTAL|Cohort 2: TAK-671 High Dose|TAK-671 high dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
62661348|NCT03156140|EXPERIMENTAL|motion|Right hand performs three different motion types
62661349|NCT02588287|EXPERIMENTAL|Tenofovir PK before and after SOF/LDV|
62098952|NCT05237193||malignant biliary obstruction|Pre-surgery patients with malignant biliary obstruction will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology.
62098953|NCT05237193||Benign biliary obstruction|Patients being treated for other biliary diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
62098954|NCT05727059|EXPERIMENTAL|HR-PCI patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions
62661350|NCT00407875|ACTIVE_COMPARATOR|Permanent interstitial prostate brachytherapy (PIPB)|patient will undergo permanent interstitial prostate brachytherapy (PIPB) using a transperineal approach to deliver 125Iodine Rapidstrand® seeds at the facilities of the British Columbia Cancer Agency (BCCA) by one or more of the certified prostate brachytherapists in the BCCA Prostate Brachytherapy Program. The minimum peripheral dose (MPD) to the prostate gland of the implant will be 144 Gy as per TG 43 protocol. A modified peripheral loading technique will be utilized in an effort to maintain the periurethral dose to \< 150% of the MPD. Within 48 hours of the implant, the patient will undergo a day 0 CT scan of the pelvis to assess post implant dosimetry using the standard BCCA protocol.
62661351|NCT00407875|EXPERIMENTAL|Intensity modulated external beam radiation therapy (IMRT)|patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) to a volume encompassing the prostate gland. The total radiation dose will be 70 Gy delivered in 28 fractions, so that the minimum dose to the PTV is 70 Gy, with CT simulation used for planning the treatment. Prior to starting the course of IMRT, fiducial markers will be placed in the prostate to assist in localization of the prostate for planning and quality assurance during treatment.
62661352|NCT01026597|EXPERIMENTAL|Cohort 1|Dose 1 versus placebo
62661353|NCT01026597|EXPERIMENTAL|Cohort 2|Dose 2 versus placebo
62661354|NCT01026597|EXPERIMENTAL|cohort 3|Dose 3 versus placebo
62661355|NCT01026597|EXPERIMENTAL|cohort 4|Dose 4 versus placebo
62661356|NCT01026597|EXPERIMENTAL|cohort 5|Dose 5 versus placebo
62661357|NCT04314089|EXPERIMENTAL|GT103|Participants will receive GT103 every 3 weeks. GT103 will be escalated from .3mg/kg up 10 to mg/kg or until MTD is found
62661358|NCT00622518|ACTIVE_COMPARATOR|1|homeopathic ear drops in addition to standard care for otitis media
62098955|NCT02883504|EXPERIMENTAL|Echocardiography|
62098956|NCT06480422|EXPERIMENTAL|segmental breathing technique + Autogenic drainage|"For Segmental Breathing instruction, the therapist's hand is placed on the chest area to be expanded. The patient is encouraged to deeply breath and to preferentially Send Airto that area of chest where tactile stimulation is being applied by the therapist. On full expiration moderate compression is applied. To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow patient's nose and huff, cough to clear your upper airways to mucus. This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways (Evacuation) Take in a deep breath. Hold the breath for three seconds. With some gentle force exhale all the air out of your lungs. Repeat three times. Do not cough untill after the third breath. Repeat sessions 3 times in a week for 4 almost weeks."
62466620|NCT01199848|PLACEBO_COMPARATOR|Placebo|Pbo
62466621|NCT01199848|EXPERIMENTAL|10G STRB powder|Dose 1
62466622|NCT01199848|EXPERIMENTAL|20G STRB powder|Dose 2
62466623|NCT01199848|EXPERIMENTAL|40G STRB powder|Dose 3
62466624|NCT01199848|PLACEBO_COMPARATOR|PlacebonoFiber|Placebo without fiber
62466625|NCT05403684|NO_INTERVENTION|Usual-volume breastfeeding (UV Group)|Infants will receive cup-feeding (to standardize the volume at each feeding) per standard of care guidelines (SOC: 140-180 mL/kg/day) with volumes adjusted for weight and infant age.
62661359|NCT00622518|NO_INTERVENTION|2|No ear drops, standard care for otitis
62661360|NCT02993809|EXPERIMENTAL|BM-ECs and PRPE|Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
62466626|NCT05403684|EXPERIMENTAL|High-volume breastfeeding (HV Group)|Along with SOC volume provided via cup-feeding, the mother will continue to express and feed the baby hind-milk reaching 240 mL/kg/day with volumes adjusted for weight and infant age (200-240 ml/kg/day).
62661361|NCT02993809|ACTIVE_COMPARATOR|BM-ECs|Intramuscular injection of bone marrow derived endothelial cells only.
62661362|NCT01258868|EXPERIMENTAL|1|Celebrex+ tumor cell vaccine
62661363|NCT00610948|EXPERIMENTAL|Group 1|Patients receive oral everolimus once daily on days 1-28. Patients also receive leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62661364|NCT00610948|EXPERIMENTAL|Group 2|Patients receive oral everolimus once daily on days 1-28 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62661365|NCT00610948|EXPERIMENTAL|Group 3|Patients receive oral everolimus once daily on days 1-28, leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1, and oxaliplatin IV over 2-4 hours on day 1. Some patients may also receive panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62661366|NCT03542799|EXPERIMENTAL|3|anti-tumor response of EGFR IL12 CART
62098957|NCT06480422|ACTIVE_COMPARATOR|Autogenic drainage|"To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks."
62098958|NCT01492309|ACTIVE_COMPARATOR|Active Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive active 1 Hz right-sided dorsolateral prefrontal cortex (DLPFC) TMS.
62466627|NCT03821545|ACTIVE_COMPARATOR|Lidocaine Group|
62661367|NCT01771926|EXPERIMENTAL|High Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
62661368|NCT01771926|EXPERIMENTAL|Low Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
62661369|NCT01771926|PLACEBO_COMPARATOR|Other Carbohydrate Source|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
62661370|NCT05627115|EXPERIMENTAL|Tislelizumab Response-Adapted Treatment|"All patients will receive 3 cycles of tislelizumab 200 mg (IV) every 21 days. They will then undergo a PET-CT scan (PET1).~Subsequent treatment with further tislelizumab, radiotherapy, and between 2-6 cycles of chemotherapy (Doxorubicin, Vinblastine, and Dacarbazine - AVD) is determined by the patient's stage and response at PET1."
62661371|NCT01285089||A|
61910029|NCT03005210|EXPERIMENTAL|T test|Test drug (Magicbuvir Plus)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
61910030|NCT03005210|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
61910031|NCT03005210|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
62098959|NCT01492309|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive sham transcranial magnetic stimulation.
62466628|NCT03821545|ACTIVE_COMPARATOR|Ketamine Group|
62466629|NCT03821545|ACTIVE_COMPARATOR|Lidocaine and Ketamine Group|
62466630|NCT03821545|PLACEBO_COMPARATOR|Placebo (0.9% NaCl) Group|
62466631|NCT04385771|EXPERIMENTAL|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
62466632|NCT04385771|OTHER|vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
62661372|NCT02208440|SHAM_COMPARATOR|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
62661373|NCT02208440|ACTIVE_COMPARATOR|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
62661374|NCT01653886|EXPERIMENTAL|Pilot Group 1|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
62661375|NCT01653886|EXPERIMENTAL|Pilot Group 2|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
62661376|NCT01653886|EXPERIMENTAL|Pilot Group 3|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
62661377|NCT01653886|EXPERIMENTAL|Pilot Group 4|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
62661378|NCT05225831|EXPERIMENTAL|SL19+22 CAR-T|Eligible patients will be treated with SL19+22 CAR-T.
62661379|NCT00969189||Children|between 10 and 30 kgs
62098960|NCT03453632|EXPERIMENTAL|Botulinic toxin|Injections of botulinic toxin (Dysport®, Allergan) 200 UI
62098961|NCT03453632|PLACEBO_COMPARATOR|Placebo|Injections of physiological serum
62294531|NCT06156527|EXPERIMENTAL|combination arm|Lazertinib plus bevacizumab
61910032|NCT05779774|EXPERIMENTAL|WayToServe Plus In-service Component|Intervention group of servers to participate in Facebook group.
62098962|NCT05210842||Lumen apposing metal stent|All patients who had a lumen-proximating stent implanted are included.
61910033|NCT05779774|EXPERIMENTAL|WayToServe Training Only|Control group of servers who do not participate in Facebook group and receive WayToServe Training only.
62098963|NCT02065011|OTHER|Long-term follow up|Long-term follow up of patients who received SAR421869 in a previous study TDU13600
61910034|NCT05622409||Arm 1|Newly diagnosis arm (N=150): The study aims to obtain clinical information to correlate with genetic characterization of ATDGs of all types. Only patients with primary tumors that have recently received surgery are applicable.
62098964|NCT06711432|EXPERIMENTAL|Strict Blood Pressure Management Group (MAP > 80 mmHg)|Management strategy: For patients assigned to strict blood pressure management, stop taking ACEI (angiotensin converting enzyme inhibitors) or ARB (angiotensin receptor blockers) on the day of surgery. Other antihypertensive drugs can be given selectively depending on the patient's blood pressure level. Intraoperative use of norepinephrine or phenylephrine (norepinephrine 0.01-0.1μg/kg/min or phenylephrine 0.15-1.1 ug/kg/min). The actual infusion speed depends on achieving the target MAP.
62098965|NCT06711432|NO_INTERVENTION|Management strategy of the conventional blood pressure management group (MAP>65mmHg|For patients assigned to the conventional blood pressure management group, ACEI, ARB or calcium antagonists can be used until the morning of the day of surgery if the anesthesiologist deems it necessary. Intraoperative blood pressure management is based on routine, and it is not necessary to use pressor drugs prophylactically, which can be used according to the actual clinical situation. In general, intraoperative MAP should not be lower than 65mmHg. If there is no contraindication of hypotension, oral antihypertensive drugs can be resumed as soon as possible after surgery.
62098966|NCT04045119|EXPERIMENTAL|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the longterm effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study
61910035|NCT05622409||Arm 2|Post treatment arm 1 for training set (IDH-wild type ATDGs, N=50; IDH-mutant ATDGs, N=50): The study aims to compare the genetic differences of ATDGs in terms of IDH mutation status. Samples of primary tumors are preferred but can be replaced with recurrent ones. Paired samples are both eligible for typing if the recurrent diseases of IDH-mutant tumors possess potential altered genes (such as up grading per histology features).
62294532|NCT02740309|EXPERIMENTAL|Integrated Brief Behavior Therapy (IBBT) Intervention|4-sessions of IBBT for youth anxiety and depression.
62294533|NCT02740309|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual
61910036|NCT05622409||Arm 3|Post treatment arm 2 (recurrent ATDGs; N=25): The study will focus on recurrent diseases of ATDGs to study the consistency of genetic difference of the primary and the recurrent tumors. Tumor free is mandatory and needs to be documented after resection of the primary tumor. Patients remain eligible if IDH statuses are uncertain.
62098967|NCT04990674|EXPERIMENTAL|REMOTION + TAU|
62098968|NCT04990674|ACTIVE_COMPARATOR|TAU|
62098969|NCT00990678|EXPERIMENTAL|"Strong vitamin D"|Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily
62098970|NCT00990678|ACTIVE_COMPARATOR|Vitamin D|calcium 400 mg + 10 microgram Vitamin D3, 3 times daily
62098971|NCT00990678|PLACEBO_COMPARATOR|Calcium|Tablet Calcium 400 mg x 3 daily
62098972|NCT01618331|ACTIVE_COMPARATOR|Protein supplementation|Patients consume a drink after each exercise session. The drink consist of whey protein, maltodextrin, and flavors mixed in water.
62098973|NCT01618331|PLACEBO_COMPARATOR|Placebo supplement|Patients consume a drink after each exercise session. The drink consist of flavors mixed in water.
62098974|NCT01618331|NO_INTERVENTION|Control|Patients will be tested before and after a none-intervention period of 12 weeks.
62294534|NCT04172090|OTHER|Control|2 consecutive days of standardised daily levels of moderate physical activity (PAL=1.85 reflecting their habitual levels), and matched energy (food) intake
62294535|NCT04172090|EXPERIMENTAL|SIT+E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst maintaining the level of food intake prescribed in the Control trial, thus creating a positive energy balance
62308147|NCT05121246|ACTIVE_COMPARATOR|US-Synagis®|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1
61910037|NCT03086564|EXPERIMENTAL|ADCC & TACE|"The first course :~Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2\*10\^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.~The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
62098975|NCT06712004|EXPERIMENTAL|Routine maintenance dose group|Undergoing bevifibatide citrate injection with intravenous bolus of 220μg/kg (0.11ml/kg) over 1 to 2 minutes, followed by continuous intravenous bolus at a rate of 2.5μg/kg/min (0.075ml/kg/h) for 24 hours.
62098976|NCT06712004|EXPERIMENTAL|Low maintenance dose group|Undergoing bevifibatide citrate injection with intravenous bolus of 220μg/kg (0.11ml/kg) over 1 to 2 minutes, followed by continuous intravenous bolus at a rate of 2.0μg/kg/min (0.06ml/kg/h) for 24 hours.
62098977|NCT03771235|EXPERIMENTAL|Mindfulness-based Intervention for Tics|8-week group-based mindfulness-based program
62466633|NCT05633745|EXPERIMENTAL|NEU-723|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)
62098978|NCT03771235|ACTIVE_COMPARATOR|Tic Information and Coping Strategies|8-week group-based educational and supportive therapy program
62294536|NCT04172090|EXPERIMENTAL|SIT=E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst reducing food intake to match the reduction in energy expenditure induced by inactivity, thus maintaining energy balance
62661380|NCT00969189||Infants|between 5 - 10 kg
62661381|NCT01370915|EXPERIMENTAL|Pregabalin|Patients receive oral placebo 150 mg 1hour prior to septal surgery, and 12 hours later
62661382|NCT01370915|PLACEBO_COMPARATOR|Placebo|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
62661383|NCT03483753|EXPERIMENTAL|Vasopressin group|Blinded vasopressin
62661384|NCT03483753|ACTIVE_COMPARATOR|Norepinephrine group|Blinded norepinephrine
62661385|NCT02341469|NO_INTERVENTION|Standard-of-care|
62661386|NCT02341469|EXPERIMENTAL|integrated ediagnostic approach|
62661387|NCT01900314|ACTIVE_COMPARATOR|Active rTMS|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain. After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period.
62661388|NCT01900314|SHAM_COMPARATOR|Sham rTMS|20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS). After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period.
62098979|NCT06554964|EXPERIMENTAL|Patients undergoing laparoscopic salpingectomy for tubal ectopic pregnancy.|Patient undergoing laparoscopic salpingectomy due to ectopic tubal pregnancy will be offered chromotubation as the same tome in order to asess the potency of the remaining fallopian tube. Data will be recorded.
62098980|NCT00774111|EXPERIMENTAL|Sequence 1|
62098981|NCT05047354||1|Subjects with Smith-Lemli-Opitz syndrome
62294537|NCT01524380|ACTIVE_COMPARATOR|Ginkgo biloba extract, antioxidant|Active treatment with Ginkgo biloba extract
62661389|NCT01125748|EXPERIMENTAL|Omalizumab|Participants received omalizumab subcutaneously at the same dose and dosing interval as administered prior to enrollment in this study. The dose of omalizumab was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
62098982|NCT05047354||2|Subjects with Disorders of cholesterol synthesis and metabolism
62098983|NCT04816526|EXPERIMENTAL|Descartes 08|
62098984|NCT05341661|ACTIVE_COMPARATOR|Active|The active arm patients undergo the Butterfly device procedure.
62098985|NCT05341661|SHAM_COMPARATOR|Sham Comparator|The sham control arm patients undergo a rigid cystoscopy procedure.
62098986|NCT05341661|OTHER|Cross over|Sham arm patient is allowed to crossover and undergo the Butterfly procedure
62098987|NCT02008292|EXPERIMENTAL|physostigmine and amphetamine|There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
62098988|NCT01906229||Acute respiratory distress syndrome (ARDS)|
62098989|NCT01906229||Systemic inflammatory response syndrome (SIRS)|
62098990|NCT01906229||ARDS+SIRS|
62098991|NCT06525246|EXPERIMENTAL|ONO-7475+Osimertinib|
62294538|NCT01524380|PLACEBO_COMPARATOR|Placebo|Treatment with placebo
62308148|NCT00949650|EXPERIMENTAL|BIBW 2992|BIBW 2992 tablet once daily until progression
62466634|NCT05633745|PLACEBO_COMPARATOR|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)
62661390|NCT01125748|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneously at the same dosing interval as omalizumab was administered prior to enrollment in this study.
62466635|NCT03667183|EXPERIMENTAL|Pilates Group|Female adolescents with eating disorders who receive Pilates for 10 weeks.
62661391|NCT01592838||Hospitalized Group|Data collection for changes in hospital pattern pre- versus post-rotavirus vaccination, in children ≤15 years old hospitalised for any reason between June 2004 and May 2010.
62661392|NCT01460472|EXPERIMENTAL|Racotumomab plus Best Support Treatment|Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.
62661393|NCT01460472|ACTIVE_COMPARATOR|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC including onco-specific therapies when disease progresses.
62661394|NCT01454284|EXPERIMENTAL|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
62737056|NCT05083611|NO_INTERVENTION|Control group|The control group will receive an information session on phantom limb pain (1 hour) and will continue with the usual treatment received.
62661395|NCT01454284|ACTIVE_COMPARATOR|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
62098992|NCT06713681||TTP-ICG incubation|The fresh excision breast masses or lymph nodes will be completely soaked in the TTP-ICG incubation solution (5, 10, 20 μg/mL) for 3, 5, or 10 min, followed by 5 min of rinsing with PBST buffer and drying with absorbent paper.The NIR-II fluorescence imaging will be then performed under the DPM NIR-II system. And the correlation between pathological characterization and fluorescent information will be further analyzed.
62098993|NCT03686683|EXPERIMENTAL|Treatment Group: Sipuleucel-T|Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion. Participants randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals.
62661396|NCT01486433|EXPERIMENTAL|Epanova and Simvastatin|
62661397|NCT01486433|ACTIVE_COMPARATOR|Simvastatin|
62661398|NCT02150005|EXPERIMENTAL|Periodontal treatment|The test group received oral hygiene instructions, supragingival and subgingival scaling and root planning using curettes and an ultrasonic appliance.
62661399|NCT02150005|NO_INTERVENTION|Control|
62098994|NCT03686683|NO_INTERVENTION|Control Arm: Active Surveillance|Participants randomized to the control arm will be followed on Active Surveillance described in the schedule of events.
62661400|NCT01937338|EXPERIMENTAL|AZD7624|
62098995|NCT05471726|EXPERIMENTAL|Prospective audit-and-feedback at discharge|When hospitals are in the intervention arm, they will perform the audit-and-feedback process focused on patients receiving antimicrobials who have an anticipated discharge.
62661401|NCT01937338|PLACEBO_COMPARATOR|Placebo|
62098996|NCT05471726|NO_INTERVENTION|Standard of care|When hospitals are in the control arm, they will not perform a stewardship process that focuses on hospital discharge.
62661402|NCT02939664|ACTIVE_COMPARATOR|Banded Gastric Bypass|The patient will have done a laparoscopic Roux-en-Y banded (with polypropylene mesh) gastric bypass at the time of the surgical procedure.
62661403|NCT02939664|ACTIVE_COMPARATOR|Gastric Bypass.|The patient will have done a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
62661404|NCT00677287|EXPERIMENTAL|A|
62661405|NCT02749929|EXPERIMENTAL|Low-Level Laser therapy|"After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the laser to make skin contact. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. The light from the laser is not visible to the eye, and will not give any perceptible stimulus.~Low-Level Laser therapy (LLLT) will be given according to the recommended dosage from World Association of Laser Therapy (WALT). A LLLT dose of 3.6 Joules will be administered at two points over the fracture site."
62661406|NCT02749929|PLACEBO_COMPARATOR|Placebo Low-Level Laser therapy|After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the placebo laser to make skin contact. The placebo laser is identical in apperance to a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Since the light from the laser is invisible, neither the participant nor the therapist will know whether the laser is a placebo. The treatment time and number of treated points will be identical to group 1.
62661407|NCT01695772|EXPERIMENTAL|Bevacizumab|
62661408|NCT02540304|EXPERIMENTAL|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
62661409|NCT02540304|NO_INTERVENTION|Business as Usual|Business as usual
62661410|NCT02336503|EXPERIMENTAL|BBI-4000 Gel, 5%|Low concentration of BBI-4000; BBI-4000 Gel, 5%
62661411|NCT02336503|EXPERIMENTAL|BBI-4000 Gel, 10%|Middle concentration of BBI-4000; BBI-4000 Gel, 10%
62661412|NCT02336503|EXPERIMENTAL|BBI-4000 Gel, 15%|High concentration of BBI-4000; BBI-4000 Gel, 15%
62661413|NCT02336503|PLACEBO_COMPARATOR|Vehicle|Vehicle (placebo); BBI-4000 Gel, 0%
62661414|NCT06255548|EXPERIMENTAL|Immersive virtual reality group|During the circumcision operation, the IVR group received both routine care and VR game. The children were allowed to play the virtual reality game of their choice. The children in the IVR group had an interactive gaming experience for 10 minutes with the game of their choice, using the remote controls while lying on their backs on the operating table during circumcision.
62098997|NCT01719289|EXPERIMENTAL|PROGRAVIDA|All women in this arm receive a stepped-care program for depression based on psycho-education and problem solving techniques.
62098998|NCT01719289|NO_INTERVENTION|Treatment as usual|Primary health care professionals in charge of prenatal care are notified by the research team about all women with depression receiving pre-natal care and included in the trial. Primary health care professionals decide how to treat these women without any interference from the research team.
62098999|NCT04046575|EXPERIMENTAL|IMRT + Carboplatin + Paclitaxel|Concurrent chemoradiation will consist of hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) for 3 weeks with carboplatin and paclitaxel for 3 cycles every 7 days. Endoscopy and (optional) PET/CT within 6-8 weeks post-completion of chemoradiation.
62099000|NCT02905513|EXPERIMENTAL|Intervention|App plus the contraceptive instant messages
62099001|NCT02905513|PLACEBO_COMPARATOR|Control|App only
62661415|NCT06255548|EXPERIMENTAL|Music group|The researcher explained the use of music headphones to the children in the music group. Each child in the music group was allowed to choose the music he wanted to listen to during the circumcision. In the interview with the children in the music group, the type of music they listened to in their daily lives was asked and the music they wanted to listen to during circumcision was determined.
62661416|NCT06255548|NO_INTERVENTION|Control group|Children in the control group received routine care and no intervention was performed.
62661417|NCT03676829|EXPERIMENTAL|Arterial Embolization of the Shoulder (AES)|Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.
62661418|NCT03692806|EXPERIMENTAL|Stablor|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
62661419|NCT03692806|PLACEBO_COMPARATOR|placebo|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
62661420|NCT01251432||chronic otitis media|adults who have had tympanostomy tube(s) inserted for chronic otitis media
62661421|NCT01251432||Eustachian tube dysfunction|adults who have had tympanostomy tube(s) inserted for the clinical diagnosis of Eustachian tube dysfunction
62661422|NCT01990781|EXPERIMENTAL|Group LD: Lidocaine and Dexamethasone|lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
62661423|NCT01990781|ACTIVE_COMPARATOR|Group L: Lidocaine|Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
62661424|NCT01990781|ACTIVE_COMPARATOR|D: Dexamethasone|Dexamethasone 8 mg iv prior to induction of anesthesia
62661425|NCT01990781|PLACEBO_COMPARATOR|N: normal saline|N: normal saline (placebo): 2 ml
62661426|NCT05359068|EXPERIMENTAL|Stage 1 Arm A|1 SPH3127 tablet，3 SPH3127 matching placebo tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
62661427|NCT05359068|EXPERIMENTAL|Stage 1 Arm B|2 SPH3127 tablets，2 SPH3127 matching placebo tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
61910038|NCT03086564|ACTIVE_COMPARATOR|TACE|"Every course:~In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.~The 31th day is the same as the first day in the second course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
61910039|NCT06240767|EXPERIMENTAL|Clinical study of human granulocyte in the treatment of advanced recurrent tumor|"Experimental: Anticancer mouse characteristic human granulocyte treatment of advanced recurrent tumors.~A single infusion of human granulocytes with anti-cancer mouse characteristics was performed for 5 consecutive transfusions at a interval of 2±1 day, and the safety and efficacy were clinically observed."
61910040|NCT01244490|EXPERIMENTAL|Extended-release Guanfacine Hydrochloride|
62661428|NCT05359068|EXPERIMENTAL|Stage 1 Arm C|4 SPH3127 tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
62661429|NCT05359068|EXPERIMENTAL|Stage 1 Arm D|4 SPH3127 matching placebo tablets, 1 valsartan capsule, once daily for 12 weeks.
62661430|NCT05359068|EXPERIMENTAL|Stage 2 Arm A|2 SPH3127 tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
62661431|NCT05359068|EXPERIMENTAL|Stage 2 Arm B|2 SPH3127 matching placebo tablets, 1 valsartan capsule, once daily for 12 weeks.
62661432|NCT05359068|EXPERIMENTAL|Stage 3|2 SPH3127 tablets, once daily for 40 weeks.
62661433|NCT02295319|EXPERIMENTAL|Individual discharge|Discharge based on the patients individual needs and conditions. The discharge focus on information, communication, follow-up plans and collaboration, as well as the patients understanding and accept of the discharge plan. In addition, it includes a telephone interview 2 days after discharge to home.
62661434|NCT02295319|NO_INTERVENTION|Control|Usual discharge procedures
62661435|NCT02210195|ACTIVE_COMPARATOR|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
62661436|NCT02210195|PLACEBO_COMPARATOR|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
62661437|NCT02734667|EXPERIMENTAL|CGM at diagnosis of T1D|Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
62661438|NCT02734667|NO_INTERVENTION|Usual Care|Participants receive usual care for T1D for 6 months post diagnosis.
62661439|NCT05141994|EXPERIMENTAL|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: about once every 4 weeks, taking 3 times after continuous use, effective observation to Week 48.
61910041|NCT01244490|OTHER|Atomoxetine Hydrochloride|Active Reference
62661440|NCT05141994|EXPERIMENTAL|4.0mg of BAT5906|16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4.0mg/eye/time, 50μl; duration of administration: once every 4 weeks, 3 times after continuous administration , The effectiveness was observed to the 48th week.
62661441|NCT02574208|ACTIVE_COMPARATOR|"HIV testing by ELISA"|Patients enrolled in this arm will be tested by usual HIV Elisa
61910042|NCT01244490|PLACEBO_COMPARATOR|Placebo|
61910043|NCT03994029|EXPERIMENTAL|Polyphenol supplementation|120mg per day of powder polyphenol for 60 days
61910044|NCT03994029|PLACEBO_COMPARATOR|Placebo|1 tab PO QD per day of placebo for 60 days
61910045|NCT03720392|EXPERIMENTAL|FMT Capsules|"* Two doses of FMT: one standard dose starting within four (4) days from the start of the conditioning regimen prior to HCT and one non-standard dose starting within 4 weeks after engraftment after HCT.~* A standard dose of oral FMT is 15 capsules per day for two consecutive days,"
62308149|NCT00949650|ACTIVE_COMPARATOR|Cisplatin/Pemetrexed|Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles
62661442|NCT02574208|EXPERIMENTAL|"HIV testing by rapid test"|Patients enrolled in this arm will be tested by the new rapid HIV test
62661443|NCT06290999||patient with pulsatile tinnitus|
62661444|NCT02734147|ACTIVE_COMPARATOR|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
62661445|NCT02734147|PLACEBO_COMPARATOR|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
62661446|NCT01424852|ACTIVE_COMPARATOR|Probiotics in milk formula|B. lactis BB-12 and L. rhamnosus GG delivered in milk formula during the first year of infancy
62661447|NCT01424852|PLACEBO_COMPARATOR|Control milk formula|The children received milk formula with no probiotics
62661448|NCT02450136|EXPERIMENTAL|pazopanib|pazopanib 800 mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
62661449|NCT01369303|EXPERIMENTAL|Daily dosing|Tenofovir 1% gel will be inserted each day or evening at about the same time with the last study-sex 12 hours after the final dose
62661450|NCT01369303|EXPERIMENTAL|BAT24 dosing|Tenofovir 1% gel will be inserted 1 hour before and 1 hour after sex
62661451|NCT01369303|EXPERIMENTAL|Pericoital dosing|Tenofovir 1% gel will be inserted either 1 hour before sex OR 1 hour after sex
62661452|NCT05891327|EXPERIMENTAL|Maca group|
62661453|NCT05891327|PLACEBO_COMPARATOR|Placebo group|
62661454|NCT03011853||Non-invasive only|Non-invasive ventilation as first and only respiratory support
62661455|NCT03011853||Invasive|Invasive ventilation with intubation as first respiratory support
61910046|NCT03720392|PLACEBO_COMPARATOR|Placebo Capsules|"* Two doses of placebo, instead of FMT: one starting within four (4) days from the start of the conditioning regimen prior to HCT and the second one starting within 4 weeks after engraftment after HCT.~* A standard dose of oral Placebo is 15 capsules per day for two consecutive days,"
62099002|NCT01963026|EXPERIMENTAL|ToCUEST (constant or variable practice)|After therapy as usual (intervention A), the Task-oriented Client-centred Upper Extremity Skill Training (ToCUEST) module (Spooren et al., 2011) will be given. In this program individual goals will be extracted using the COPM (Canadian Occupational Performance Measure) and the training program is based on a task-analysis and uses principles of training physiology and motor learning. Intervention B will consist of the ToCUEST program, including the component 'practice variability' (ToCUEST variability). Intervention C will consist of a modified ToCUEST program in which the component 'practice variability' will be replaced by 'constant practice' (ToCUEST constant) in order to evaluate the contribution of these components. Intervention A' will be therapy as usual.
62099003|NCT05108051|EXPERIMENTAL|sequence 1|Period 1: study of ZSP1273's pharmacokinetics at steady state； Period 2: study of Oseltamivir's pharmacokineticsat at steady state； Period 3: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state.
62099004|NCT05108051|EXPERIMENTAL|sequence 2|Period 1: study of Oseltamivir's pharmacokineticsat at steady state; Period 2: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 3: study of ZSP1273's pharmacokinetics at steady state.
62099005|NCT05108051|EXPERIMENTAL|sequence 3|Period 1: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 2: study of ZSP1273's pharmacokinetics at steady state; Period 3: study of Oseltamivir's pharmacokineticsat at steady state.
62099006|NCT02828930|EXPERIMENTAL|Idasanutlin|On Day 1, 300 milligram (mg) idasanutlin tablet orally and 100 mg \[14C\]-radiolabeled idasanutlin capsule orally (2, 50 mg capsules containing approximately 100 microcurie of radioactivity). After 5 hours and 45 minutes of the oral dose, 100 microgram (mcg) of \[13C\]-radiolabeled idasanutlin will be administered over a 15-minute intravenous (IV) infusion. On Day 11, idasanutlin matching placebo aqueous dispersion orally and approximately after 1 hour, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. On Day 19, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days, and no treatment during 23 days of 28-day cycle, until the development of progressive disease, unacceptable toxicity, consent withdrawal or any other criteria for removal.
62099007|NCT05916560|EXPERIMENTAL|LY3437943 (Normal Hepatic Function)|LY3437943 administered subcutaneously (SC).
62099008|NCT05916560|EXPERIMENTAL|LY3437943 (Severe Hepatic Impairment)|LY3437943 administered SC.
62099009|NCT05916560|EXPERIMENTAL|LY3437943 (Moderate Hepatic Impairment)|LY3437943 administered SC.
62099010|NCT05916560|EXPERIMENTAL|LY3437943 (Mild Hepatic Impairment)|LY3437943 administered SC.
62099011|NCT06303986|OTHER|Observational Group|These are the neonates enrolled in the study to collect data and aid in establishing continuous monitoring advantages.
62099012|NCT03768661||SILC Group|patients with symptomatic cholelithiasis submitted to a single-incision laparoscopic cholecystectomy
62099013|NCT03768661||Laparoscopy Group|patients with symptomatic cholelithiasis submitted to a standard three trocar laparoscopic cholecystectomy
62099014|NCT03834844|NO_INTERVENTION|Usual Care|patient receives same care as patients not enrolled in study intervention
62099015|NCT03834844|EXPERIMENTAL|AF education|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week.
62099016|NCT03834844|EXPERIMENTAL|Mindfulness Meditation Practice|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
62099017|NCT03834844|EXPERIMENTAL|Weekly Phone Calls|Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
62661456|NCT03011853||NIV+Inv|Non-invasive ventilation as first respiratory support followed by invasive ventilation with intubation
62661457|NCT04307394|EXPERIMENTAL|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
62661458|NCT00460798||Non-Interventional Study|
62661459|NCT03588520|EXPERIMENTAL|Home BP Monitoring Group|Patients allocated to this group will receive a home blood pressure monitoring device and decisions to modify the hypertension treatment will be based on the results of the home blood pressure monitoring in accordance with the current guidelines of the European Society for Hypertension for the Treatment of Hypertension.
62661460|NCT03588520|NO_INTERVENTION|Office BP Monitoring Group|Patients allocated to this group will act as controls. They will receive no home blood pressure monitoring device and decisions to modify the hypertension treatment will be based exclusively on blood pressure measurements in office visits.
62308150|NCT03750162|EXPERIMENTAL|Passive Ultrasonic irrigation|Irrigation solution was ultrasonically activated in the canal for 1 minute by using IrriSafe tip coupled to an ultrasonic device with VDW Ultra .
62661461|NCT04680585|OTHER|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
62661462|NCT04680585|EXPERIMENTAL|MOVIN|Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
61910047|NCT04246931||Pulmonologists|Interviews with pulmonologists
61910048|NCT04246931||General practitioners|Interviews with general practitioners
61910049|NCT04246931||Patients|Survey with COPD patients
61910050|NCT00450008|OTHER|A|Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
61910051|NCT04022733|PLACEBO_COMPARATOR|Moderate NMB group|
61910052|NCT04022733|EXPERIMENTAL|Deep NMB group|
61910053|NCT00797966|EXPERIMENTAL|1|OPC-34712 + ADT
62294539|NCT05195528|EXPERIMENTAL|Vonoprazan 10 mg|Participants will be administered vonoprazan at a dose of 10 mg QD in the 4 week Placebo-controlled Treatment Period. Participants randomized to vonoprazan 10 mg in the Placebo-controlled Treatment Period will continue to take the same dose in the 20 week Extension Period.
62466636|NCT02321566|EXPERIMENTAL|Treatment Arm|A craniotomy will be performed for the placement of an epidural motor cortex stimulation lead in the context of subjects with chronic facial, upper extremity, and throat pain. If the stimulation is successful during a trial period with externalized lead cabling, the system cabling will be internalized and connected to an internal implantable pulse generator to power and control the system for the duration of the trial.
62466637|NCT04374448|OTHER|Sinus Tumor Resection|Those who are undergoing endoscopic sinonasal surgery for benign and malignant tumor removal.
62099018|NCT03834844|EXPERIMENTAL|AF Education and Mindfulness Meditation|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
62099019|NCT03834844|EXPERIMENTAL|AF Education and Weekly Phone Calls|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
62099020|NCT03834844|EXPERIMENTAL|Mindfulness Meditation and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
62099021|NCT03834844|EXPERIMENTAL|Meditation and Education and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
62099022|NCT05711940|EXPERIMENTAL|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
62294540|NCT05195528|EXPERIMENTAL|Vonoprazan 20 mg|Participants will be administered vonoprazan at a dose of 20 mg QD in the 4 week Placebo-controlled Treatment Period. Participants randomized to vonoprazan 20 mg in the Placebo-controlled Treatment Period will continue to take the same dose in the 20 week Extension Period.
62099023|NCT05711940|EXPERIMENTAL|10 mg COMP360 Psilocybin|10 mg COMP360 Psilocybin
62099024|NCT05711940|ACTIVE_COMPARATOR|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin, active comparator
62099025|NCT05190185|EXPERIMENTAL|TAA06 injection|T cell injection targeting B7-H3 chimeric antigen receptor
62099026|NCT00765661|EXPERIMENTAL|LCP-Tacro|The initial dose starting at 0.14 mg/kg (the starting daily dose for African-American patients was 0.17 mg/kg), will be administered orally in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
62294541|NCT05195528|PLACEBO_COMPARATOR|Placebo|Participants will be administered the placebo QD in the 4 week Placebo-controlled Treatment Period. Participants randomized to placebo in the Placebo-controlled Treatment Period will be re-randomized to receive either vonoprazan 10 mg QD or vonoprazan 20 mg QD in the 20 week Extension Period.
62294542|NCT01309737|EXPERIMENTAL|Active Treatment 10 mg BID|
62294543|NCT01309737|EXPERIMENTAL|Active Treatment 5 mg BID|
62294544|NCT01309737|PLACEBO_COMPARATOR|Placebo Treatment|
62466638|NCT04374448|OTHER|Skull Base Surgery|Those who are receiving Endoscopic Skull Base Surgery (ESBS) for minimally-invasive access for removal of skull base tumors, most commonly for ones of pituitary origin.
62466639|NCT04374448|OTHER|Endoscopic Sinus Surgery|Individuals with chronic rhinosinusitis (CRS) with or without polyposis that are to have endoscopic sinus surgery, a minimally invasive procedure to open the sinuses.
62466640|NCT04374448|OTHER|Epistaxis Management|Those who have severe nose bleeds and requires going into the operating room for management.
62466641|NCT05286203|ACTIVE_COMPARATOR|Standard of Care|Patients enrolled in the trial and randomized to the standard of care (SOC) arm will undergo standard of care testing.
62466642|NCT05286203|EXPERIMENTAL|MDS|Patients enrolled in the trial and randomized to the MDS arm will undergo standard of care testing and MDS testing.
62466643|NCT03368755|EXPERIMENTAL|Cases (IUGR)|50 school-aged children (7-10 years old) exposed to IUGR (birth weight \<10th percentile \& fetal ultrasound documentation) and of comparable gestational age with controls Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance
62466644|NCT03368755|ACTIVE_COMPARATOR|Controls|"100 school-aged children (7-10 years old) not exposed to IUGR (birth weight \<10th percentile \& fetal ultrasound documentation) and of comparable gestational age with cases.~Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance"
62466645|NCT02651753|EXPERIMENTAL|A|"Period 1: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.~Period 2: Test drug(CKD-337), 1 capsule administered under fed conditions."
61910054|NCT00797966|PLACEBO_COMPARATOR|2|Placebo + ADT
62294545|NCT00866437|EXPERIMENTAL|Healthy Control group|
62294546|NCT00866437|EXPERIMENTAL|PMS|
62294547|NCT02029976|ACTIVE_COMPARATOR|attention control condition|Child and parent participants randomized to the attention control condition will receive a Newsletter Program or mailed monthly newsletter with general family-focused health information.
62661463|NCT02744456|OTHER|N-of-1 trial|Patients with hypertension who are taking none or one BP medication will be will be provided with prescriptions for up to 3 BP medications representative of different BP medication classes (i.e., losartan, an angiotensin system blocking agent; amlodipine, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic). Patients will be asked to take each medication for 2 weeks at a low dose, 2 weeks at a medium dose, and then 2 weeks at a high dose; provide health information and identify which medication they prefer to remain on following the N-of-1 trial (i.e., for long-term use).
62099027|NCT00765661|ACTIVE_COMPARATOR|Prograf (tacrolimus)|"Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
62661464|NCT03569462|EXPERIMENTAL|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
62661465|NCT03569462|ACTIVE_COMPARATOR|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
62661466|NCT01890577||Study population|Single cohort of dialysis patients
62661467|NCT04645108|EXPERIMENTAL|Coached|
62661468|NCT04645108|ACTIVE_COMPARATOR|No Coach|
62661469|NCT04328194|EXPERIMENTAL|Study Group|80 patients with breast cancer
62099028|NCT02547805|PLACEBO_COMPARATOR|Placebo|Five (5) capsules of placebo by mouth (PO) three times per day (TID) with meals
62099029|NCT02547805|EXPERIMENTAL|ALLN-177|Five (5) capsules of ALLN-177 (1,500 units per capsule) PO TID with meals
62099030|NCT03129035|ACTIVE_COMPARATOR|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
62099031|NCT03129035|ACTIVE_COMPARATOR|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
62099032|NCT06297980|EXPERIMENTAL|Personalized treatment|We will test an intervention that includes up to four personalized adjustments to food intake, insulin dose and glycemic algorithms by menstrual cycle phase, based on the three months of observational data collected.
62099033|NCT06297980|NO_INTERVENTION|Standard Care|In this arm, women will continue with their usual insulin dose, food intake and glycemic algorithms as determined by their provider
62661470|NCT04328194|PLACEBO_COMPARATOR|Control Group|20 healthy controls aged ( 19 to 69 years ) from healthy volunteers after informed consent.
62661471|NCT03323463|EXPERIMENTAL|Arm A: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia. This arm is closed to accrual.
62099034|NCT04863105|EXPERIMENTAL|Conference-Abiraterone acetate tablet|Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)
62099035|NCT04863105|EXPERIMENTAL|test-Abiraterone acetate tablet|Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd)
62661472|NCT03323463|EXPERIMENTAL|Arm B: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia.
61910055|NCT04320862||Duke Health region and beyond|Individuals in the Duke Health region as well as individuals beyond the Duke Health region who have flu-like symptoms, a viral test order for COVID-19, confirmed COVID-19, or concern for exposure to COVID-19.
62099036|NCT03983343|NO_INTERVENTION|control group|Standard technique: Suturing the perineal skin with fast-absorbable running sutures (Vicryl Rapide 3-0).
62099037|NCT03983343|ACTIVE_COMPARATOR|intervention group|Closing the perineal skin using adhesive glue- exofin® (Octyl-2-cyanoacrylate)
62099038|NCT05214794|EXPERIMENTAL|nemolizumab|
62099039|NCT03297983|EXPERIMENTAL|First M7583 Tablet:Fasted, Then PiC:Fasted, Then Tablet:Fed|
62099040|NCT03297983|EXPERIMENTAL|First M7583 PiC:Fasted, Then Tablet:Fasted, Then Tablet:Fed|
62099041|NCT04887272|ACTIVE_COMPARATOR|Exercise Training (EXT)|Research participants will complete six weeks of supervised progressive aerobic and resistance exercise training (EXT). Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post EXT.
62099042|NCT04887272|EXPERIMENTAL|Inspiratory Muscle and Exercise Training (IMET)|Research participants will complete six weeks of supervised aerobic and resistance exercise training in addition to supervised respiratory muscle training (IMET). IMET sessions will be performed similar to EXT, with the exception of having sessions of at-home IMT training. On these days, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle, and end of the session. Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post IMET.
62099043|NCT03867864|EXPERIMENTAL|Group A|Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
62099044|NCT03867864|OTHER|Group B|The group B will wear the necklace without essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace with essential oil for last 4 weeks (the sixth to ninth weeks).
62661473|NCT02623764||MCI due to Alzheimer´s disease|Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
62661474|NCT02623764||Mild dementia due to Alzheimer´s disease|Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
62099045|NCT05238779||End Stage Liver Disease (ESLD)|Patients with ESLD
62661475|NCT02623764||Mild dementia due to Lewy body disease|Individuals with mild Lewy body dementia. The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
62661476|NCT05185856|SHAM_COMPARATOR|Start with: Concentric (normal) cycling|Patients that are allocated to this arm will start with normal cycling
62661477|NCT05185856|EXPERIMENTAL|Start with: Eccentric cycling|Patients that are allocated to this arm will start with eccentric cycling
62661478|NCT03673358|EXPERIMENTAL|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
62099046|NCT04816682|ACTIVE_COMPARATOR|LAGOSA ARM|Consecutively admitted patients will be allocated silymarin tablets (150 mg each) T.I.D. 3-2-2
62099047|NCT04816682|NO_INTERVENTION|Control arm|Consecutive patients with the same inclusion/exclusion criteria as in active arm, hospitalised at the same department before the initiation of the study (historical controls)
62099048|NCT05169281|NO_INTERVENTION|Control|Usual care consisted of a text message hyperlink to nearby disposal locations.
62099049|NCT05169281|EXPERIMENTAL|Intervention|Intervention participants were mailed an at-home disposal packet timed to arrive between post-operative days four and seven based on prior data collection on reported use.
62099050|NCT04902742|ACTIVE_COMPARATOR|Ganglion impar block group|Fluoroscopy-guided ganglion impar block is applied to patients in this group.
62099051|NCT04902742|ACTIVE_COMPARATOR|Caudal epidural steroid injection group|Fluoroscopy-guided caudal epidural steroid injection is applied to patients in this group.
62099052|NCT00819234|PLACEBO_COMPARATOR|1|
62099053|NCT00819234|EXPERIMENTAL|2|Pramlintide and 1.25mg Metreleptin
62099054|NCT00819234|EXPERIMENTAL|3|Pramlintide and 2.5mg Metreleptin
62099055|NCT00819234|EXPERIMENTAL|4|Pramlintide and 5.0mg Metreleptin
62099056|NCT04348370|EXPERIMENTAL|BCG Group|FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing \~1x10\^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (\~2x10\^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area.
62099057|NCT04348370|PLACEBO_COMPARATOR|Placebo Group|A single dose will consist of 0.1 mL saline
62099058|NCT05266261|ACTIVE_COMPARATOR|Non-diabetes|postmenopausal women with normal glucose tolerance
62099059|NCT05266261|EXPERIMENTAL|diabetes|postmenopausal women with type 2 diabetes
62099060|NCT04939207|EXPERIMENTAL|CT-derived FFR|In this study arm, the need for coronary revascularization will be determined by CT-derived Fractional Flow Reserve (FFR) calculations
62099061|NCT04939207|EXPERIMENTAL|Angiography-derived FFR|In this study arm, the need for coronary revascularization will be determined by FFR-calculations derived from angiographic images
62099062|NCT04939207|ACTIVE_COMPARATOR|Routine Care|In this study arm, the need for coronary revascularization will be determined by angiography and invasive FFR-measurements
62099063|NCT00568503|ACTIVE_COMPARATOR|1|QAX028 high dose
62099064|NCT00568503|PLACEBO_COMPARATOR|2|Placebo
62099065|NCT00568503|ACTIVE_COMPARATOR|3|Tiotropium bromide
62099066|NCT00568503|ACTIVE_COMPARATOR|4|QAX028 medium dose
62466646|NCT02651753|EXPERIMENTAL|B|Period 1: Test drug(CKD-337), 1 capsule administered under fed conditions. Period 2: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
62466647|NCT05035355|EXPERIMENTAL|weaning protocol group|spontaneous breathing trial (SBT)-based protocol-directed weaning combined with the high-flow nasal cannula group
62661479|NCT03673358|NO_INTERVENTION|No intervention- - control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
61910056|NCT02728427|EXPERIMENTAL|Suprapubic Catheterization|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients in this group.
61910057|NCT02728427|ACTIVE_COMPARATOR|Transurethral Catheterization|Transurethral catheterization using Foley catheter will be performed for patients in this group.
62099067|NCT00568503|ACTIVE_COMPARATOR|5|QAX028 low dose
62099068|NCT01051778|EXPERIMENTAL|enoxaparin 40 mg plus low dose aspirin|
62466648|NCT05035355|NO_INTERVENTION|routine SBT weaning group|
62466649|NCT03283345|ACTIVE_COMPARATOR|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
62466650|NCT03283345|ACTIVE_COMPARATOR|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
62099069|NCT01051778|ACTIVE_COMPARATOR|Heparin calcium 5,000 U twice daily plus low dose aspirin|
62099070|NCT02485353|OTHER|Vosaroxin and Cytarabine|
62099071|NCT00421902|EXPERIMENTAL|Acupuncture|Acupuncture of the patients
62099072|NCT05592613|EXPERIMENTAL|PrEP Participants|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total, while using the next-generation Reader and ID-Cap System.
62099073|NCT05592613|EXPERIMENTAL|ART Participants|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total, while using the next-generation Reader and ID-Cap System.
62099074|NCT04709731|EXPERIMENTAL|Total Patients|Intolerant Group Ponatinib 15 mg tablet, taken orally once daily (QD) Resistant Group Ponatinib 30 mg tablet, taken orally once daily (QD) The dose will be reduced to 15mg once daily (QD) as soon as a Complete Cytogenetic Response will be obtained. In those patients showing Major Molecular Response or better, the dose could be further reduced to 15MG every other day (EOD), due to the prolonged half-life of the drug.
62099075|NCT00721864||Affected Population|Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
62099076|NCT05247853||Group 1|HPV-vaccinated women living with HIV
62466651|NCT03546205|EXPERIMENTAL|Group 1: JNJ-64565111|Participants with normal renal function and no evidence of kidney damage (estimated glomerular filtration rate \[eGFR\] greater than or equal to \[\>=\] 90 milliliter/minute \[mL/min\]) will be enrolled. Participants will receive a single subcutaneous (SC) dose of JNJ-64565111 on Day 1.
62466652|NCT03546205|EXPERIMENTAL|Group 2: JNJ-64565111|Participants with mild renal impairment (eGFR 60 to less than \[\<\] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
62466653|NCT03546205|EXPERIMENTAL|Group 3: JNJ-64565111|Participants with moderate renal impairment (eGFR 30 to \<60 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
62466654|NCT03546205|EXPERIMENTAL|Group 4: JNJ-64565111|Participants with severe renal impairment (eGFR \<30 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
62466655|NCT03546205|EXPERIMENTAL|Group 5: JNJ-64565111|Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
62466656|NCT05683730|EXPERIMENTAL|Intermittent caloric restriction|Intermittent caloric restriction during 16 weeks.
62466657|NCT05683730|NO_INTERVENTION|Routine practice|Routine practice
62099077|NCT05247853||Group 2|HPV-unvaccinated women living with HIV
62099078|NCT05247853||Group 3|HIV\[-\] women who are HPV-vaccinated
62466658|NCT02388620|EXPERIMENTAL|Normal Hepatic Function|Normal hepatic function; matched demography to hepatic impairment cohorts
62466659|NCT02388620|EXPERIMENTAL|Mild Hepatic Impairment|Child-Pugh Classification A (score 5-6)
62466660|NCT02388620|EXPERIMENTAL|Moderate Hepatic Impairment|Child-Pugh Classification B (score 7-9)
62466661|NCT02388620|EXPERIMENTAL|Severe Hepatic Impairment|Child-Pugh Classification C (score 10-15)
62466662|NCT05735639|NO_INTERVENTION|Compression therapy alone|
62466663|NCT05735639|EXPERIMENTAL|Compression therapy + single dose of low-molecular weight heparin at time of procedure|A single prophylactic dose of low molecular weight heparin (LMWH) (e.g., dalteparin sodium, tinzaparin sodium, enoxaparin sodium) will be prescribed as per standard practice and administered in accordance with the relevant Summary of Product Characteristics (SmPC), manufacturer's recommendations and instructions for use.
62466664|NCT05735639|EXPERIMENTAL|Compression therapy + single dose of LMWH at time of procedure + extended course of LMWH or DOAC|An extended duration of LMWH (e.g., dalteparin sodium, tinzaparin sodium, enoxaparin sodium) or an extended duration of a direct oral anticoagulant (DOAC) (e.g., rivaroxaban, apixaban, dabigatran etexilate) will be prescribed as per current local practice and administered in accordance with the relevant SmPC, manufacturer's recommendations and instructions for use. The duration of this must be at least 7 days, but can be in line with local practice i.e., 7, 10 or 14 days.
62466665|NCT00414765|EXPERIMENTAL|Aldesleukin|All participants were treated with aldesleukin 600,000 international units per kilogram \[IU/kg\] (0.037 milligram (mg)/kg) administered as a 15-minute intravenous (IV) infusion every 8 hours for a maximum of 14 doses for the first cycle (5-day cycle). Following 9 days of rest from therapy, the cycle was repeated for up to 14 doses (i.e., a total of up to 28 doses), if tolerated.
62466666|NCT01546545||Insulin Sensitivity in Pre-Diabetic Population|Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.
62466667|NCT04550065|EXPERIMENTAL|Intervention arm|Digital game
62466668|NCT04759885|EXPERIMENTAL|Phase II: NTC015 low dose (Mannitol 50 g)|One day single dose preparation same day of colonoscopy
62466669|NCT04759885|EXPERIMENTAL|Phase II: NTC015 medium dose (Mannitol 100 g)|One day single dose preparation same day of colonoscopy
62466670|NCT04759885|EXPERIMENTAL|Phase II: NTC015 high dose (Mannitol 150 g)|One day single dose preparation same day of colonoscopy
62466671|NCT04759885|EXPERIMENTAL|Phase III: NTC015 selected dose|One day single dose preparation same day of colonoscopy
62466672|NCT04759885|ACTIVE_COMPARATOR|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC) (Moviprep®)|Two litres of Moviprep® taken according to split-dose regimen (to commence in the evening before colonoscopy)
62466673|NCT01513434|ACTIVE_COMPARATOR|transtibial technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via tibial tunnel.
62466674|NCT01513434|ACTIVE_COMPARATOR|Transportal technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via anteromedial portal.
62466675|NCT02329197|EXPERIMENTAL|Group A|women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure.
62099079|NCT06616506||Highly myopic cataract patients without fundus defects|Highly myopic cataract patients with fundus defects
62099080|NCT06616506||Highly myopic cataract patients with fundus defects|
62099081|NCT06616506||Highly myopic cataract patients with lens grading of NC2-3|
62099082|NCT06616506||Highly myopic cataract patients with lens grading of NC4-5|
62099083|NCT03770624|EXPERIMENTAL|200 mg QD|Tablet QL-007 will be administered orally daily (200 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
62099084|NCT03770624|EXPERIMENTAL|400 mg QD|Tablet QL-007 will be administered orally daily (400 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
62099085|NCT03770624|EXPERIMENTAL|600 mg QD|Tablet QL-007 will be administered orally daily (600 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
62099086|NCT03770624|EXPERIMENTAL|100 mg BID|Tablet QL-007 will be administered orally daily (100 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
62099087|NCT03770624|EXPERIMENTAL|200 mg BID|Tablet QL-007 will be administered orally daily (200 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
62099088|NCT03770624|ACTIVE_COMPARATOR|TDF 300 mg QD|TDF will be administered orally daily (300 mg QD) over the 28 days not request fast .
62099089|NCT01334541||SAFE VET|
62099090|NCT01334541||E-CARE|
62099091|NCT02846415|EXPERIMENTAL|PID group|Experimental group receiving the Play Intervention for Dementia
62661480|NCT00238290|EXPERIMENTAL|Arm A|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
62099092|NCT02846415|NO_INTERVENTION|Wait-list control group|Participants will receive usual care offered by the day care centre, including health and social services, and meals, etc.
62661481|NCT03505775|OTHER|23Na-MRI|A 23Na magnetic resonance imaging of the calf (muscle and skin) was performed in every participating patient after clinical and laboratory examinations.
62661482|NCT06061913|ACTIVE_COMPARATOR|Breast Pump Suction Pattern 1|
62099093|NCT01110174|EXPERIMENTAL|HD PET/CT|utilization of PET/CT for diagnostic of breast cancer progression.
62099094|NCT06416085|EXPERIMENTAL|Psilocybin|
62294548|NCT02029976|EXPERIMENTAL|after school weight management program|The 9-month after school weight management program called SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), with a focus on healthy food and activity practices will be directed by a school nurse and will include: 1) quarterly parent/child coaching sessions with the school nurse held in the participant's home; 2) 14 child group sessions led by the school nurse, held in a school setting 1-2 times a month; 3) 5 parent group sessions led by a school nurse held in a school setting.
62294549|NCT06237881|EXPERIMENTAL|Arm 1: Phase 1- Safety Lead-in (Cohort 1)|Approximately 6 patients with melanoma, NSCLC or HNSCC will be enrolled in the Safety Lead-in phase of the study with a KSQ-001EX dose.
62294550|NCT06237881|EXPERIMENTAL|Arm 2: Phase 1- Safety Lead-in (Cohort 2)|Patients in Cohort 2 will receive IL-2 dosing (600,000 international units \[IU\]/kg administered every 8 to 12 hours for up to 6 doses, as tolerated).
62294551|NCT06237881|EXPERIMENTAL|Arm 3: Phase 2- Expansion Phase|It is expected that approximately 20 participants will be enrolled in each of the 3 indication specific cohorts.
62294552|NCT01130506|EXPERIMENTAL|Treatment (decitabine, vorinostat, cytarabine)|"INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; vorinostat PO on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.~MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and vorinostat PO on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity."
62661483|NCT06061913|ACTIVE_COMPARATOR|Breast Pump Suction Pattern 2|
62661484|NCT06061913|SHAM_COMPARATOR|Breast Pump Suction Pattern 3|
62661485|NCT03731143|EXPERIMENTAL|study arm|surgical opening the lower punctum using the pig tail probe and a scalpel followed by insertion of self retaining bicanalicular stent (FCI®; Paris, France).
62661486|NCT05574985|EXPERIMENTAL|Research Group|People 6 to 15 months after the completion of basic immunization with inactivated COVID-19 vaccine were vaccinated one dose of the study vaccine
62661487|NCT05574985|ACTIVE_COMPARATOR|Control Group|People 6 to 15 months after the completion of basic immunization with inactivated COVID-19 vaccine were vaccinated with one dose of control vaccine
62661488|NCT05574985|EXPERIMENTAL|Observation group ①|People 6 to 9 months after the completion of the inactivated COVID-19 vaccine booster immunization were vaccinated one dose of the study vaccine
62661489|NCT05574985|EXPERIMENTAL|Observation group ②|People 6 to 15 months after the completion of basic immunization with COVID-19 recombinant vaccine were vaccinated one dose of the study vaccine
62661490|NCT01577121|PLACEBO_COMPARATOR|placebo|
62661491|NCT01577121|EXPERIMENTAL|indomethacin|50 mg/ 6 hours of indomethacin oral use
61910058|NCT03492008|ACTIVE_COMPARATOR|Conventional technique|Nasogastric tube
62099095|NCT06711978|EXPERIMENTAL|Mirogabalin Group|
62099096|NCT06711978|ACTIVE_COMPARATOR|Duloxetine Group|
62099097|NCT05168969||Patient carrying a CTNNB1 syndrome|Recruitment of subjects with CTNNB1 syndrome will be done through health care providers, but also by contacting families through social media and specialized databases.
62099098|NCT06429410|EXPERIMENTAL|fortified formula milk powder group|Fortified formula milk powder is supplemented with whey protein, calcium, vitamin D, colostrum basic protein, β-hydroxy-β-methylbutyrate, and sodium hyaluronate, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day, for a duration of 24 weeks.
62661492|NCT05162092|EXPERIMENTAL|Group A|training duration for each session is 30 mints with 5 mints rest and it includes passive soft tissue elogation of tight muscles,lower limb resistance exercises,movement transition,balance board standing ,walking and stair climbing
62099099|NCT06429410|EXPERIMENTAL|formula milk powder group|Formula milk powder is supplemented with whey protein, calcium, vitamin D, colostrum basic protein, and sodium hyaluronate, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day, for a duration of 24 weeks.
62099100|NCT06429410|PLACEBO_COMPARATOR|regular milk powder group|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
62099101|NCT06429410|NO_INTERVENTION|observation group|Participants in the observation group did not receive any supplementation.
62099102|NCT03429309|OTHER|Anesthesia-induction with propofol|
62099103|NCT03425292|ACTIVE_COMPARATOR|1 SOC (closed to enrollment)|Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide
62099104|NCT03425292|EXPERIMENTAL|2 Nivo|Nivolumab
62099105|NCT03425292|EXPERIMENTAL|3 Nivo-Ipi (closed to enrollment)|Nivolumab plus Ipilimumab
62661493|NCT05162092|EXPERIMENTAL|Group B|It included passive soft tissue elongation of tight muscles,lower limb resistance exercises,movement transition,balance board standing ,walking and stair climbing and Vestibular Stimulation exercises such as Swinging in standing in all directions, trampoline jumps, rocking movement in rocking chair, gaze stabilization exercises and visual pursuit exercises under supervision.
62661494|NCT01932606|EXPERIMENTAL|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
62661495|NCT01932606|PLACEBO_COMPARATOR|Saline|Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.
62099106|NCT03425292|EXPERIMENTAL|4 Nivo-Ipi-CCNU-TMZ|Nivolumab plus Ipilimumab plus Lomustine (CCNU) plus 5-day Temozolomide
62099107|NCT03425292|EXPERIMENTAL|5 Nivo-Ipi-TMZ|Nivolumab plus Ipilimumab plus 5-day Temozolomide
62661496|NCT01246323|ACTIVE_COMPARATOR|combined anesthesia|Patients will receive spinal and general anesthesia for benign laparoscopy gynecological surgery
62661497|NCT01246323|NO_INTERVENTION|Control|
62661498|NCT03597867|PLACEBO_COMPARATOR|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
62661499|NCT03597867|EXPERIMENTAL|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
62661500|NCT03597867|EXPERIMENTAL|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
62661501|NCT03597867|EXPERIMENTAL|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
62661502|NCT03597867|EXPERIMENTAL|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
62661503|NCT04093999||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction with additional sensory nerve coaptation.
62661504|NCT04093999||Noninnervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction without sensory nerve coaptation.
62661505|NCT01983930|ACTIVE_COMPARATOR|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
62661506|NCT01983930|EXPERIMENTAL|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 20 minute meditation
62661507|NCT02208622|EXPERIMENTAL|Study 1: Whey Supplement Day 1|Children in this arm received the whey supplement as part if their diet on day 1.
62661508|NCT02208622|EXPERIMENTAL|Study 1: Whey Supplement Day 2|Children in this arm received whey supplement as part of their diet on day 2.
62661509|NCT02208622|EXPERIMENTAL|Study 2: Whey Supplement|Children in this arm received a whey supplement as part of their diet.
62661510|NCT02208622|NO_INTERVENTION|Study 2: Control|Children in this arm did not receive a whey supplement as part of their diet.
62661511|NCT03697590|EXPERIMENTAL|PDT with no curettage|
62661512|NCT03697590|ACTIVE_COMPARATOR|Standard PDT|
62661513|NCT06275399||Patients with chronic coronary syndrome and coronary stenosis (30% - 90%) amenable to OCT imaging|"Patients with chronic coronary syndrome and coronary stenosis (30% - 90%) amenable to OCT imaging. The groups will be assessed at the time of angiography with:~* OCT for evaluation of plaque morphology within the coronary stenosis~* Computational fluid dynamics with vFFR and estimation of value and distribution of shear rate and shear stress~* Impedance aggregometry based platelet reactivity~* Single-particle high-resolution flow cytometry analysis of pMVs and sEVs as well as additional platelet activation and inflammatory biomarkers~* Proteomic and metabolomic characterization - in the subset of patients~Biomarker assessment will be done in the blood sampled directly from coronary artery (proximal and distal segment) arteries. Shear rate/shear stress distribution and biomarkers profile will be compared between the stenotic vessel and the non-stenotic vessel (stenoses \<30%) in the same patient."
62099108|NCT03425292|EXPERIMENTAL|6 Nivo-Ipi-Bev-TMZ|Nivolumab plus Ipilimumab plus Bevacizumab plus 5-day Temozolomide
61910059|NCT03492008|EXPERIMENTAL|Contralateral cricothyroid pressure|Nasogastric tube
62099109|NCT05540990|EXPERIMENTAL|Robotic assisted gait training (RAGT) + conventional physiotherapy (CPt) group|This group will receive 15 sessions of robot-assisted gait training (two or three times per week with a maximum of 45 minutes each) and conventional physiotherapy, which is individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
62099110|NCT05540990|ACTIVE_COMPARATOR|Conventional physiotherapy (CPt) group|This group will receive conventional physiotherapy, which is individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
62294553|NCT06162455|ACTIVE_COMPARATOR|Control group|Oxygen-air mixture without NO after extubation within 5 days after surgery 2 times a day for 30 min
62294554|NCT06162455|EXPERIMENTAL|200 ppm|NO will be supplemented at 200-ppm concentration after extubation within 5 days after surgery 2 times a day for 30 min
62661514|NCT02383849||Arm 1|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
62661515|NCT02383849||Arm 2|Breastfeeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
62661516|NCT02383849||Arm 3|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
62661517|NCT02383849||Arm 4|Breast or formula feeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
62661518|NCT02383849||Arm 5|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 4000 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
61910060|NCT03492008|EXPERIMENTAL|Ipsilateral head turning|Nasogastric tube
62099111|NCT06060418|EXPERIMENTAL|Intervention Group|After deciding on the participant of the intervention group the researcher will start the protocol of intervention The researcher will soak a 4×4 cm sterile gauze pad with 0.2 ml equivalent to 2 drops of 10% Lavender essential oil and will suspend the soaked gauze at a distance of 10cm from the patient's nose with the help of forceps, and he or she will have asked to inhale its scent for 5 min. 15 and 40 minutes after the beginning of the aromatherapy treatment, the researcher will measure the nausea and vomiting scores by using the standardized tool. During this entire 40 minutes, the researcher will strictly monitor the participant's condition. If the nausea score is still higher than 1 or the vomiting persists the participants will be noted as failure of treatment and move to standard care.
62099112|NCT06060418|NO_INTERVENTION|Control group|The control group received standard care against the complain of nausea and vomiting.
62099113|NCT05035836|EXPERIMENTAL|Zanidatamab|zanidatamab by vein every 2 weeks (+/- 3 days) for up to 6 doses (3 study cycles
62099114|NCT03298087|EXPERIMENTAL|Experimental Arm|Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.
62466676|NCT02329197|NO_INTERVENTION|Group B|women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG.
62466677|NCT04507425|ACTIVE_COMPARATOR|Not Intubated|Patients admitted with a trauma injury who do not need to be intubated to receive treatment. Intubated means putting a tube down your throat to keep your airway from collapsing. Participants will be randomized to receive one of the three interventions in this arm.
62466678|NCT04507425|ACTIVE_COMPARATOR|Intubated Patients Undergoing Extubation|Patients admitted with a trauma injury who had to be intubated for treatment of their injury. Interventions administered after the tube is extubated (removed from throat). Participants will be randomized to receive one of the three interventions in this arm.
62466679|NCT02743130|EXPERIMENTAL|Blackcurrant nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
62466680|NCT02743130|EXPERIMENTAL|Lingonberry nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
62466681|NCT02743130|ACTIVE_COMPARATOR|Reference|Sugar control, contains 17.5 g glucose and 17.5 g fructose in water
62099115|NCT01729871|EXPERIMENTAL|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
62099116|NCT01729871|EXPERIMENTAL|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
62099117|NCT06051162|EXPERIMENTAL|HPI|Managing intraoperative hemodynamic condition under the HPI guidance
62099118|NCT06051162|NO_INTERVENTION|Control|Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
62099119|NCT06583590|OTHER|Group 1|32 patients will be injected single intracavernosal injection of 100 unit of Botulinum toxin A accompained by oral daily tadalafil 5 mg for 3 months.
62466682|NCT01281501|ACTIVE_COMPARATOR|Conventional|Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
62661519|NCT02383849||Arm 6|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)
62294555|NCT00908284|ACTIVE_COMPARATOR|Control Group|Participants will take part in a 12-week control group.
62294556|NCT00908284|EXPERIMENTAL|Exercise Program|Participants will take part in a 12-week exercise program.
62294557|NCT02395549|EXPERIMENTAL|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
62294558|NCT02395549|EXPERIMENTAL|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
62661520|NCT01287247||Cervical Dystonia|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.
62661521|NCT01287247||Blepharospasm|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.
62661522|NCT02998112|PLACEBO_COMPARATOR|control|5-ASA 4g/day enema through TET for 1 week; 200ml saline infusion through TET for 3 times every other day in one week
62294559|NCT02395549|EXPERIMENTAL|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
62294560|NCT02395549|PLACEBO_COMPARATOR|Vehicle Control Gel|Vehicle Control Gel will be applied bid to the whole face for 12 weeks.
62466683|NCT01281501|EXPERIMENTAL|Pantoprazole|Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
62466684|NCT02215161|EXPERIMENTAL|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62466685|NCT00038675|EXPERIMENTAL|Imatinib|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily.
62466686|NCT00737490|ACTIVE_COMPARATOR|1|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm"
62466687|NCT00737490|ACTIVE_COMPARATOR|2|"Simultaneous BiV pacing. Simultaneous Arm"
62099120|NCT06712394||IPACK|IPACK block involves ultrasound-guided local anesthetic infiltration of the space between the popliteal artery and the posterior knee joint capsule.
62099121|NCT01133613|EXPERIMENTAL|Cohort 1|0.03 mg/ml BMP-7 or placebo via intraarticular knee injection
62099122|NCT01133613|EXPERIMENTAL|Cohort 2|0.1 mg/ml BMP-7 or placebo via intraarticular knee injection
62099123|NCT01133613|EXPERIMENTAL|Cohort 3|0.3 mg/ml BMP-7 or placebo via intraarticular knee injection
62099124|NCT06601387|OTHER|group 1 of patients|recurrent CBD Stones.
62099125|NCT06601387|OTHER|group 2 of patients|recurrent CBD stones
62099126|NCT06100939|EXPERIMENTAL|Active Treatment|Epithelium-on corneal cross-linking
62099127|NCT06100939|PLACEBO_COMPARATOR|Control Treatment|Placebo and sham for epithelium-on corneal cross-linking
62099128|NCT06713720|EXPERIMENTAL|Remote Ischemic Conditioning Group|Participants in this group will receive remote ischemic conditioning (RIC) therapy. This involves five cycles of 5-minute inflation at 200 mmHg followed by 5-minute deflation, twice daily, for at least five days per week over a one-year period.
62466688|NCT01030848||Patients with knee osteoarthritis|
62466689|NCT02575222|EXPERIMENTAL|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
62661523|NCT02998112|EXPERIMENTAL|Study group|5-ASA 4g/day enema through TET for 1 week; 200ml fecal microbiota suspension infusion through TET for 3 times every other day in one week
62099129|NCT06713720|SHAM_COMPARATOR|Sham Remote Ischemic Conditioning Group|Participants in this group will receive sham remote ischemic conditioning therapy. This involves the same device with inflation pressure set at 60 mmHg, following identical timing and frequency as the intervention group.
62099130|NCT04657081|EXPERIMENTAL|Oral administration of ASTX727 and Venetoclax combination|"Cycle 1: ASTX727 according to a prescribed dosing regimen and venetoclax on day 1 (100 mg daily), day 2 (200 mg daily), and days 3-28 (400 mg daily) of a 28-day cycle.~Cycle 2 and beyond: ASTX727 according to a prescribed dosing regimen and venetoclax on days 1-28 (400 mg daily) of a 28-day cycle."
62099131|NCT06456554|EXPERIMENTAL|Acellular Dermal Matrix|Breast reconstruction with Cortiva Tissue Matrix
62099132|NCT06456554|NO_INTERVENTION|no Acellular Dermal Matrix|Breast reconstruction only with no ADM
62099133|NCT06652763||HFpEF with T2D|Participants with heart failure with preserved ejection fraction and type 2 diabetes
62099134|NCT06652763||HFpEF without T2D|Participants with heart failure with preserved ejection fraction but without type 2 diabetes
62099135|NCT06652763||Controls|Healthy volunteers without heart failure or type 2 diabetes
62294561|NCT00342355|ACTIVE_COMPARATOR|AZT+DDI+EFV|Zidovudine,Didanosine,Efavirenz ( Zidovudine 600 mg once daily,Didanosine \<60 kg/125 mg twice daily or \>60kg/200 mg twice daily,Efavirenz 600 mg once daily)
62294562|NCT00342355|ACTIVE_COMPARATOR|AZT+DDI+r/LPV|Zidovudine,Didanosine,Lopinavir/Ritonavir(AZT 600 mg once daily,DDI 100 mg twice daily,r/LPV 400mg/100mg twice daily)
62466690|NCT02372305|ACTIVE_COMPARATOR|FlexHD|Patients randomly assigned to receive FlexHD for breast reconstruction.
62661524|NCT04994236|EXPERIMENTAL|Hepatic Artery Infusion Chemotherapy|Subjects assigned to this arm will receive chemotherapy via catheterizations placed into the hepatic artery.
62099136|NCT04895345|EXPERIMENTAL|TQB2450+Intensity modulated radiotherapy|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day；The total dose of radiotherapy should meet PTVnx: 60Gy/27Fr/2.22Gy, PTVnd: 60-64Gy/27Fr/2.22-2.37Gy, PTV1: 54Gy/27Fr/2.00Gy, once a day, 5 times/week.
62661525|NCT01860404|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally twice daily for 21 days
62099137|NCT03908047||healthy volunteers|
62099138|NCT06465316|EXPERIMENTAL|Treatment (iberdomide, teclistamab)|Patients receive teclistamab SC on days 1, 4, 7, 15 and 22 for cycle 1 and days 1, 8, 15 and 22 for remaining cycles. Patients also receive iberdomide PO QD on days 1-21 for cycle 2 and beyond. Cycles repeat every 28 days for up to 4 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood and urine sample collection, bone marrow aspiration and biopsy and CT, PET/CT or MRI throughout the trial.
62099139|NCT06712433|EXPERIMENTAL|BD + Intranasal Mupirocin + Chlorhexidine|"Bacterial Decolonization with 2% intranasal mupirocin ointment twice daily (BID) and 4% chlorhexidine gluconate body cleanser, once daily (QD) for 5 consecutive days prior to RT, and this will be repeated for 5 days every 2 weeks throughout Radiation Therapy.~The treatment will also be administered for 5 consecutive days prior to index surgery. RT can be prescribed in one of three dose/fractionation regimens at the investigator's discretion: 50 Gy in 25 fractions, 42.75 Gy in 15 fractions, or 36 Gy in 18 fractions"
62099140|NCT03820986|EXPERIMENTAL|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
62294563|NCT00342355|ACTIVE_COMPARATOR|d4T+3TC+EFV|Stavudine,Lamivudine,Efavirenz(d4T 40 mg twice daily,3TC 300 mg once daily,EFV 600 mg once daily)
62661526|NCT01860404|EXPERIMENTAL|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
62294564|NCT00342355|ACTIVE_COMPARATOR|d4T+3TC+r/LPV|Stavudine,Lamivudine,Lopinavir/Ritonavir(d4T 40m mg twice daily,3TC 300 mg once daily,r/LPV 400mg/100mg twice daily)
62466691|NCT02372305|ACTIVE_COMPARATOR|Alloderm|Patients randomly assigned to receive Alloderm for breast reconstruction.
62466692|NCT00465764|EXPERIMENTAL|Protein formula|Feed as per HCP direction
62466693|NCT00465764|ACTIVE_COMPARATOR|Standard infant formula|Feed as per HCP instructions
62466694|NCT04132622|EXPERIMENTAL|Experimental therapy group|Besides Traditional therapy，patients in this group will also receive thyroid replacement therapy.
62466695|NCT04132622|SHAM_COMPARATOR|Traditional therapy group|Patients in Standard therapy group will receive treatments according to guideline worldwide.
62466696|NCT04758130|EXPERIMENTAL|App Group|Patients in this group are provided with a link to download the application and their application usage is tracked by the clinic.
62466697|NCT04758130|PLACEBO_COMPARATOR|Placebo Group|Patients in this group are not provided with the clinic link to the application.
62466698|NCT03627091|EXPERIMENTAL|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous (SC) injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]).
62466699|NCT03627091|EXPERIMENTAL|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]).
62466700|NCT03627091|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched with ontamalimab SC injection using prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 \[NCT03559517\] or SHP647-306 \[NCT03566823\]).
62466701|NCT02380989|EXPERIMENTAL|Ayurveda|
62466702|NCT02380989|PLACEBO_COMPARATOR|Placebo|
62466703|NCT01114022|ACTIVE_COMPARATOR|Active comparator|cylindrical PVC cuff
62466704|NCT01114022|EXPERIMENTAL|Experimental 1|cylindrical polyurethane cuff
62466705|NCT01114022|EXPERIMENTAL|Experimental 2|conic PVC cuff
62466706|NCT01114022|EXPERIMENTAL|Experimental 3|conic polyurethane cuff
62466707|NCT00877032|EXPERIMENTAL|Arm 1|
62466708|NCT03783793|EXPERIMENTAL|Mindfulness Training App|
62099141|NCT03820986|ACTIVE_COMPARATOR|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
62099142|NCT05549024|EXPERIMENTAL|68Ga-RM26-RGD and 18F-FDG PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 18F-FDG, respectively.
62099143|NCT05549024|EXPERIMENTAL|68Ga-RM26-RGD and 68Ga-RM26 PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RM26, respectively.
62466709|NCT03783793|ACTIVE_COMPARATOR|Cognitive Training With 2048|
62466710|NCT02692547|OTHER|Hybrid-logic closed loop system|All patients get to wear the pump. only 1 arm. There is no comparator in this study, as all patients wear the pump.
62466711|NCT01037114|EXPERIMENTAL|Twinrix Group|"Subjects who received 2 doses of Twinrix (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the first long-term follow-up NCT00289718 and this long-term follow-up.~A challenge dose of the Havrix or Engerix-B vaccines can be administered in this study based on serology results at each time point."
62466712|NCT02881385||E5 Esense 10%|PSV mode using E5 ventilator with Esense 10%
62466713|NCT02881385||E5 Esense 30%|PSV mode using E5 ventilator with Esense 30%
62466714|NCT02881385||E5 Esense 50%|PSV mode using E5 ventilator with Esense 50%
62466715|NCT02881385||Servo-I Esense 10%|PSV mode using Servo-I ventilator with Esense 10%
62466716|NCT02881385||Servo-I Esense 30%|PSV mode using Servo-I ventilator with Esense 30%
62466717|NCT02881385||Servo-I Esense 50%|PSV mode using Servo-I ventilator with Esense 50%
62466718|NCT02881385||E5 Esense autocycle|PSV mode using E5 ventilator with Esense Auto cycle
62466719|NCT03452501||Naïve group|Newly diagnosed patients
62661527|NCT01860404|EXPERIMENTAL|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
62466720|NCT03452501||Switched group|Patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®
62466721|NCT00890422|EXPERIMENTAL|1FSME vaccination|2 vaccination on day 0
62466722|NCT00890422|EXPERIMENTAL|2 FSME vaccination|1 vaccination on day 0 and one vaccination on day 4
62466723|NCT00890422|EXPERIMENTAL|3 FSME vaccination|2 vaccinations on day 0 and 1 vaccination on day 4
62099144|NCT05549024|EXPERIMENTAL|68Ga-RM26-RGD and 68Ga-RGD PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RGD, respectively.
62099145|NCT04069546|EXPERIMENTAL|AIS-RIC|RIC is a physical strategy performed through cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times. This group of patients received regular therapy of acute ischemic stroke plus unilateral arm of RIC intervention.
62099146|NCT04069546|NO_INTERVENTION|AIS|This group of patients received regular therapy of acute ischemic stroke.
62099147|NCT01420367|EXPERIMENTAL|Single dose of antibiotics|This group will receive one dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) in the pre-operative period and two post-operative IV 'doses' of normal saline 8 and 16 hours after the pre-operative dose, which will act as a placebo and facilitate blinding.
62099148|NCT01420367|ACTIVE_COMPARATOR|Three doses of antibiotics|This group will receive one pre-operative dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) and two post-operative doses of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) 8 and 16 hours after the pre-operative dose.
62466724|NCT03402503|EXPERIMENTAL|Group A|Montelukast buccal film, administered 10-mg once or 30-mg twice daily (once in the morning and once in the evening) for 26 weeks.
62466725|NCT03402503|PLACEBO_COMPARATOR|Group B|Placebo buccal film, administered once or twice daily (once in the morning and once in the evening) for 26 weeks.
62466726|NCT05231837|EXPERIMENTAL|Fee Waiver|Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment.
62099149|NCT04784065|ACTIVE_COMPARATOR|Treatment arm with control orthosis|
62099150|NCT04784065|EXPERIMENTAL|Treatment arm with experimental orthosis|
62294565|NCT04409847||COVID+ PCR|Subjects who are SARS-CoV-2 PCR+ve and/or have diagnostic CXR or CT chest features of COVID -19
62661528|NCT01860404|EXPERIMENTAL|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
62661529|NCT01860404|EXPERIMENTAL|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
62661530|NCT00874133|ACTIVE_COMPARATOR|Motillium|20 mg motilium thrice daily for 12 weeks.
62099151|NCT06388187|EXPERIMENTAL|CagriSema Dose 1|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 60 weeks.
62099152|NCT06388187|PLACEBO_COMPARATOR|Placebo Dose 1|Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 1 (cagrilintide and semaglutide) for 68 weeks.
62661531|NCT00874133|ACTIVE_COMPARATOR|Acupuncture|Acupuncture treatment.
62661532|NCT05525468|EXPERIMENTAL|SAD Cohorts 1-4 TDM-180935 topical ointment|Single dose administration of TDM-180935 topic ointment, 0.25% or 0.5% or 1.0% or 2.0%
62661533|NCT05525468|PLACEBO_COMPARATOR|SAD placebo for TDM-180935 topical ointment|Single dose administration of placebo for TDM-180935 topic ointment
62661534|NCT05525468|EXPERIMENTAL|MAD Cohorts 1-4 TDM-180935 topical ointment|Multiple dose administration of TDM-180935 topic ointment, 0.25% or 0.5% or 1.0% or 2.0%
62661535|NCT05525468|PLACEBO_COMPARATOR|MAD placebo for TDM-180935 topical ointment|Multiple dose administration of placebo for TDM-180935 topic ointment
62661536|NCT01988415|OTHER|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile in one eye (active comparator \[i.e., control\]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).
62661537|NCT03510936|NO_INTERVENTION|blue light phototherapy|the patients in this arm will not receive probiotics.
62661538|NCT03510936|EXPERIMENTAL|probiotics concurrent with phototherapy|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks
62661539|NCT01617213|EXPERIMENTAL|Maintenance Lenalidomide After Melphalan|
62661540|NCT03740490|EXPERIMENTAL|Smart-T + NRT|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT).
62661541|NCT03740490|ACTIVE_COMPARATOR|NCI QuitGuide + NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT).
62661542|NCT04889274|EXPERIMENTAL|Part A: Male healthy volunteers|
62661543|NCT04889274|EXPERIMENTAL|Part A: Female healthy volunteers|
62661544|NCT04889274|ACTIVE_COMPARATOR|Part B: Nitrate-rich beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) containing \~5mmol of inorganic nitrate
62661545|NCT04889274|PLACEBO_COMPARATOR|Part B: Nitrate-deplete beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) which is nitrate-depleted
62661546|NCT03669471||FAIS group|Subjects who have had a hip arthroscopy for femoroacetabular impingement during the preceding 6-30 months
62661547|NCT04604860|EXPERIMENTAL|EL-FIT|Patients using the EL-FIT app
62661548|NCT01805050||New Technique|All patients who underwent surgical repair of the anterior instability due an HAGL lesion.
62661549|NCT06119529|EXPERIMENTAL|Part A: LY3872386|Single doses of LY3872386 administered either intravenously (IV) or subcutaneously (SC) in healthy participants.
62661550|NCT06119529|EXPERIMENTAL|Part B: LY3872386|Multiple doses of LY3872386 administered either IV or SC in participants with atopic dermatitis.
62661551|NCT06119529|EXPERIMENTAL|Part C: Prednisone|Prednisone administered orally in healthy participants.
62661552|NCT06119529|PLACEBO_COMPARATOR|Placebo|Placebo administered either IV or SC.
62294566|NCT04409847||COVID- PCR|subjects admitted with COVID-19 like symptoms but are SARS-CoV-2 PCR-ve and have CXR or CT chest that show low probability of COVID-19 will form the control group
62661553|NCT05312112||Venetoclax|Venetoclax in newly diagnosed AML
62661554|NCT05312112||FLT3 inhibitors|FLT3 inhibitors including gilteritinib in relapsed AML
62661555|NCT03437954|OTHER|Standard soft diet|
62661556|NCT03437954|OTHER|Non-restricted diet|
62661557|NCT06554236|EXPERIMENTAL|Chronic low back pain|18-64 years with low back pain duration \> 3 months.
62661558|NCT02602327|EXPERIMENTAL|Tas-102 and radioembolization|Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
62661559|NCT04826731||Incentive Spirometer Group|"Patients who would use an incentive spirometer, in addition to standard care provided to COVID-19 patients, will be categorized under Incentive Spirometer Group."
62661560|NCT04826731||Standard Care Group|"Patients who did not use an incentive spirometer despite being suggested to do so will be categorized under Standard Care Group."
62661561|NCT03296683|EXPERIMENTAL|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
62661562|NCT04248179|ACTIVE_COMPARATOR|Active|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Ropivacaine 5mg/ml corresponding to 3 \* 10ml \* 5mg/ml Ropivacaine = 150mg Ropivacaine.
62661563|NCT04248179|PLACEBO_COMPARATOR|Placebo|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Sodium chloride 9mg/ml corresponding to 3 \* 10ml \* 9mg/ml Sodium chloride = 189mg Sodium chloride.
62661564|NCT03818568|EXPERIMENTAL|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
62661565|NCT03818568|ACTIVE_COMPARATOR|Control|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).
62294567|NCT04753125|ACTIVE_COMPARATOR|compliance treatment|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance for 3, 6. 9 and 12 months
62294568|NCT04753125|ACTIVE_COMPARATOR|compliance for blood test|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance, follow-up via a game in a smartphone app through an interactive game with stimuli to pass the phase as the treatment was completed and blood tests were performed in 3,6,9 and 12 months.
62099153|NCT06388187|ACTIVE_COMPARATOR|CagriSema Dose 2|Participants will receive once-weekly s.c injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 12-week dose escalation period until target dose (dose 2) of CagriSema(cagrilintide and semaglutide) is achieved and maintained up to 56 weeks.
62099154|NCT06388187|PLACEBO_COMPARATOR|Placebo Dose 2|Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 2 (cagrilintide and semaglutide) for 68 weeks.
62099155|NCT06212921|OTHER|Patient with suspicion of acute mesenteric ischaemia|Bolld samples is the only intervention. All patients with suspicion of AMI will be included and blood samples collected
62099156|NCT00715806|EXPERIMENTAL|1|
62099157|NCT00715806|ACTIVE_COMPARATOR|2|
62099158|NCT06566664|EXPERIMENTAL|Ultrasound-guided brachial plexus block with peripheral nerve stimulation|Patients will receive a single shot brachial plexus block with ultrasound guidance as per standard of care, with additional use of the B. Braun HNS 12 nerve stimulator for duration of block placement.
62099159|NCT06566664|SHAM_COMPARATOR|Ultrasound-guided brachial plexus block without peripheral nerve stimulation|Patients will receive the single shot brachial plexus block in the same way the first arm would, and the B Braun nerve stimulator will be placed in the same way, but not turned on.
62099160|NCT06607965|EXPERIMENTAL|experimental group|"Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed."
62661566|NCT06342141|EXPERIMENTAL|Empagliflozin|The patients included in this group will receive a loading dose of 25 mg of Empagliflozin at the time of enrollment in the study, prior to percutaneous coronary intervention. Over the following three days, they will receive a daily maintenance dose of 10 mg of Empagliflozin.
62099161|NCT06607965|NO_INTERVENTION|control group|Patients fasted for 12 hours before surgery, and after surgery, intravenous fluids were administered. Fat-free diet began after 24 hours post-surgery.
62099162|NCT06536517|EXPERIMENTAL|Methadone|Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
62099163|NCT06536517|OTHER|Short-Acting Opioid|Standard intra-operative IV shorter acting opioids
62099164|NCT04620239|EXPERIMENTAL|padeliporfin VTP|"Induction Treatment phase:1-3 padeliporfin VTP treatments provided 4 weeks (28 +/-3 days) apart.~Maintenance Treatment Phase: Repeated maintenance VTP treatments during this period will be provided for patients who show evidence of tumor recurrence that is deemed treatable."
62099165|NCT06251908|EXPERIMENTAL|Active intervention arm|Participants allocated to active intervention arm will receive Rewritalize in addition to standard mental health care
62099166|NCT06251908|ACTIVE_COMPARATOR|Control arm|Participants allocated to the control arm will receive standard mental health care.
62099167|NCT03563781|OTHER|SENTINEL NODE|Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)
62099168|NCT03214887|EXPERIMENTAL|RV-P1501-4|Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
62294569|NCT04753125|PLACEBO_COMPARATOR|demographic socio-economic and sexuality questionnaire|Questionnaire applied to all patients with positive VDRL
62099169|NCT03214887|EXPERIMENTAL|RV-P1501-5|Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
62294570|NCT02575430||Subjects with IRD|IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
62661567|NCT06342141|NO_INTERVENTION|Standar Treatment|The patients included in this group will receive standar treatment according to the current guidelines
62661568|NCT03727867|PLACEBO_COMPARATOR|Drug group|Participants were under prescription of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) at the beginning and continued until disease progressed.
62099170|NCT03214887|EXPERIMENTAL|RV-P1501-6|Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution
62099171|NCT05211284|EXPERIMENTAL|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks)
62099172|NCT05211284|PLACEBO_COMPARATOR|Placebo Arm|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 weeks).
62099173|NCT05626660||Right Radial Group|
62099174|NCT05626660||Left Radial Group|
62099175|NCT06185985|EXPERIMENTAL|Open-Label Treatment|SPN-812 (200mg to 600mg once daily) for up to 14 weeks
62661569|NCT03727867|EXPERIMENTAL|Drug plus SBRT group|After the first month of EGFR TKI orally, participants were given Stereotactic Body Radiation Therapy (SBRT) in dose of 50 Gy/5 F or 60 Gy/8 F for peripheral and central primary tumor, respectively, combined with oral EGFR TKI continually until the primary end point.
62661570|NCT00643253|EXPERIMENTAL|1|Receipt of behavioral interventions to encourage breastfeeding.
62099176|NCT05283720|EXPERIMENTAL|Arm 1: Dose Escalation|Participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) will receive escalating doses of subcutaneous (SC) epcoritamab in combination with oral lenalidomide in 28 day cycles.
62099177|NCT05283720|EXPERIMENTAL|Arm 2: Dose Escalation|Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
62099178|NCT05283720|EXPERIMENTAL|Arm 3: Dose Escalation|Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
62099179|NCT05283720|EXPERIMENTAL|Arm 4: Dose Escalation|Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
62099180|NCT05283720|EXPERIMENTAL|Arm 5: Dose Escalation|Participants with R/R follicular lymphoma (FL) will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
62661571|NCT00643253|NO_INTERVENTION|2|Standard of Care
62661572|NCT03148340||VIPS monitoring group|The study population will consist of adult patients presenting for evaluation of acute brain pathology,
62661573|NCT01822990||Atherosclerotic patients|Male patients with intermittent claudication.
62661574|NCT01822990||Control subjects|healthy male subjects with normal results on vascular examination and no cardiovascular risk factors, who are not in receipt of any pharmacological treatment, matched by age within two years with peripheral arterial disease patients
62661575|NCT04256408|EXPERIMENTAL|Treatment group|Treatment group
62661576|NCT02930070||qSOFA(+)SOFA(+)|Infection patients who has a qSOFA\>=2 and SOFA\>=2 in a same day within 28 day of hospital stay.This group has the greatest priority in the competition of inclusion of groups.
62661577|NCT02930070||qSOFA(-)SOFA(+)|Infection patients who has a qSOFA\<2 and SOFA\>=2 in a same day within 28 day of hospital stay.This group has the secondary priority in the competition of inclusion of groups.
62099181|NCT05283720|EXPERIMENTAL|Arm 6A: Dose Escalation|Participants with R/R mantle cell lymphoma (MCL) will receive escalating doses of SC epcoritamab in combination with oral ibrutinib in 28 day cycles.
62294571|NCT05855161|EXPERIMENTAL|Rebound therapy|The group that will perform exercises on a trampoline.
61910061|NCT06092125||Alzheimer's Disease (AD)|The study will collect PET/MR multimodal imaging data, including brain structure, cerebral perfusion, brain function, glucose metabolism, and Aβ deposition, from 100 healthy volunteers, 250 patients with MCI, and 300 patients with AD. Abnormal changes in imaging biomarkers will be analyzed quantitatively, specifically for AD, to determine the specific quantitative threshold for diagnosing AD using 18F-FDG PET and 18F-AV-45 PET and establish imaging biomarkers for early diagnosis of AD. Longitudinal follow-up will be conducted to analyze multimodal imaging data dynamically and discover imaging biomarkers for early prediction of subjective cognitive decline (SCD), MCI, and AD progression.
61910062|NCT06092125||Parkinson's Disease (PD)|The study aims to collect PET/MR multimodal imaging data from 250 patients with rapid eye movement sleep behavior disorder (RBD) and 300 patients with Parkinson's disease (PD) across multiple centers. The imaging data will include brain structure, brain iron deposition, brain function, glucose metabolism, and vesicular monoamine transporter levels, among other imaging biomarkers. Abnormal changes in these imaging biomarkers will be analyzed quantitatively to determine the specific quantitative threshold for diagnosing PD using 18F-FDG PET and 18F-AV-133 PET and establish imaging biomarkers for early diagnosis of PD. Longitudinal follow-up will be conducted to dynamically analyze the multimodal imaging data and discover imaging biomarkers for early prediction of RBD and PD progression.
62466727|NCT05231837|EXPERIMENTAL|Fee Waiver Plus Intensive Outreach|"Parks randomly assigned to the Intensive Outreach and Fee Waiver:~Intensive Outreach consists of the formation and activity of a community advisory group who will engage with neighborhood community partners to support parents in the neighborhood to enroll their child and support the child's participation in the park youth sports programs offered at the neighborhood park and recreation center. Program marketing and materials and registration will be offered in both Spanish and English. Program coaches will be supported with technical assistance from study staff to implement the park youth sports program with high fidelity and with high communication and engagement with enrolled youth and their parents.~Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment."
62466728|NCT01029379||200 patients,ASA 1|
62466729|NCT01846845|ACTIVE_COMPARATOR|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
62466730|NCT01846845|EXPERIMENTAL|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
62466731|NCT03756272|EXPERIMENTAL|Stellate ganglion bupivacaine block|Nervus Sympathicus block. Stellate ganglion anaesthetic block in which 7 ml of 0.5% bupivacaine will be injected next to the stellate ganglion
62466732|NCT03756272|PLACEBO_COMPARATOR|Placebo ganglion block|Sham Nervus Sympathicus block. Stellate ganglion sham anaesthetic block using 7 ml of 0.9 % natrium chloride (NaCl)
62466733|NCT04924868|ACTIVE_COMPARATOR|UDCA (Ursodeoxycholic Acid) group|"Patients receiving Ursodeoxycholic Acid, capsules containing 300 mg, 10 mg/Kg per day:~Patients 40 to 70 kg: 2 capsules/day \>70 to 100 Kg: 3 capsules/day \>100 kg: 4 capsules/day"
62466734|NCT04924868|PLACEBO_COMPARATOR|Placebo group|Capsules containing placebo, indistinguishable from active treatment.
62661578|NCT02930070||qSOFA(+)SOFA(-)|Infection patients who has a qSOFA\>=2 and SOFA\<2 in a same day within 28 day of hospital stay.This group has the third priority in the competition of inclusion of groups.
62661579|NCT02930070||qSOFA(-)SOFA(-)|Infection patients who has a qSOFA\<2 and SOFA\<2 in a same day within 28 day of hospital stay.This group has the least priority in the competition of inclusion of groups.
62294572|NCT05855161|EXPERIMENTAL|Control group|The group that will perform exercises on a stable surface.
62661580|NCT00339560||Cases will bile duct CA|Patients with bile duct cancer
62661581|NCT00339560||Cases with Gallbladder CA|Patients with gallbladder cancer
62661582|NCT00339560||Controls with gall stones|Patients undergoing cholecystectomy for gall stones
62661583|NCT00339560||Controls without cancer|Hospital controls with cancer
62466735|NCT05786274|OTHER|Cardiac surgery with cardiopulmonary bypass patients|Patients will be enrolled before cardiac surgery with cardiopulmonary bypass (CPB) and monitored until after the surgery. Patients enrolled will undergo diffusion weighted magnetic resonance imaging and will be administered with cognitive tests one day before surgery and within one week after surgery. Cerebral blood flow velocity as derived from transcranial Doppler recordings will be acquired from the middle cerebral artery synchronously with arterial pressure, invasively derived from the radial artery, and with the electrocardiogram as derived from patient's monitor. Signals will be acquired before anesthesia induction (BASAL), after anesthesia induction and intubation of the chest (ANESTH) and during CPB (CPB). Each acquisition will last at least 5 minutes and will be prolonged to the maximum possible length in keeping with clinical scheduling. Partial pressure of carbon dioxide and other clinical parameters will be acquired too during the intervention.
62466736|NCT05352087|ACTIVE_COMPARATOR|early cholecystectomy|In early cholecystectomy group after antibiotherapy was started with ceftriaxone and metronidazole, laparoscopic cholecystectomy was performed in the first 7 days following the hospitalization.
62466737|NCT05352087|ACTIVE_COMPARATOR|delayed cholecystectomy|Patients who accepted delayed surgery were also given the same antibiotherapy and operated after 6 weeks following their discharge
62099182|NCT05283720|EXPERIMENTAL|Arm 6B: Dose Escalation|Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
62099183|NCT05283720|EXPERIMENTAL|Arm 7: Dose Escalation|Participants with newly diagnosed treatment-naïve MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
62294573|NCT02469129|EXPERIMENTAL|Dosimetry Studies Arm|Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of \[18F\]FluorThanatrace.
62099184|NCT05283720|EXPERIMENTAL|Arm 8: Dose Escalation|Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral pirtobrutinib in 28 day cycles in the first year and then 56 day cycles thereafter.
62099185|NCT05283720|EXPERIMENTAL|Arm 1: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral lenalidomide in 28 day cycles.
62099186|NCT05283720|EXPERIMENTAL|Arm 2: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
62099187|NCT05283720|EXPERIMENTAL|Arm 3: Dose Expansion|Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
62099188|NCT05283720|EXPERIMENTAL|Arm 4: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
62099189|NCT05283720|EXPERIMENTAL|Arm 5: Dose Expansion|Participants with R/R FL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
62294574|NCT02469129|EXPERIMENTAL|Kinetic Studies Arm|An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of \[18F\]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images. When possible these subjects will also undergo 18F-FDG imaging for comparison to tumor metabolism
62294575|NCT05564559|EXPERIMENTAL|MFGP intervention|This group will provide 8 weeks of multi-family psychoeducation to the families of people living with a diagnosis of substance abuse disorder.
62294576|NCT05564559|NO_INTERVENTION|Wait list-control group|This group will provide 8 weeks of multi-family psychoeducation to the families of people living with a diagnosis of substance abuse disorder after the intervention group is completed. This group is the control group on the waiting list.
62294577|NCT03115190|OTHER|General practitioner diagnosis with Heart score|Patients with chest pain who are reviewed by the general practitioner (GP) at the GP cooperation will be evaluated with the Heart score to support the GP with the diagnosis.
62466738|NCT00661596|EXPERIMENTAL|Arm 1|
62466739|NCT00661596|PLACEBO_COMPARATOR|Arm 2|
62099190|NCT05283720|EXPERIMENTAL|Arm 6: Dose Expansion|Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib in 28 day cycles.
62099191|NCT05283720|EXPERIMENTAL|Arm 7: Dose Expansion|Participants with newly diagnosed treatment-naïve MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
62099192|NCT05283720|EXPERIMENTAL|Arm 8: Dose Expansion|Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral pirtobrutinib in 28 day cycles in the first year and then 56 day cycles thereafter.
62099193|NCT06423781|EXPERIMENTAL|BHV-7000|
62466740|NCT05205759|EXPERIMENTAL|Bamlanivimab Etesevimab|Bamlanivimab 700 mg + Etesevimab 1400 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
62099194|NCT06710977|EXPERIMENTAL|Safety of Intracameral levofloxacin in cataract surgery|Eligible and recruited patients are randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery
62099195|NCT06710977|ACTIVE_COMPARATOR|Use of intracameral cefazolin in cataract surgery|Eligible and recruited patients were randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery
62099196|NCT03057132|EXPERIMENTAL|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
62099197|NCT00354029|PLACEBO_COMPARATOR|Placebo|Saline 0,9%
62099198|NCT00354029|ACTIVE_COMPARATOR|S (+) Ketamine|
62099199|NCT03523702|EXPERIMENTAL|PembroRT|"Subjects with PD-L1 expression ≥ 50%:~Combination of sequential pembrolizumab (200mg every 3 weeks) and accelerated, dose-painted radiotherapy for locally advanced NSCLC patients with high (≥ 50%) PD-L1 expression.~Subjects with PD-L1 expression \< 50%:~Patients with PD-L1 expression \< 50% will also be enrolled and treated with standard concurrent chemoradiotherapy"
62099200|NCT06609876|EXPERIMENTAL|Thermal ablation|Patients only accepted thermal ablation (microwave ablation,radiofrequency ablation)
62099201|NCT06609876|EXPERIMENTAL|Microwave ablation plus Donafenib|Patients accepted thermal ablation (microwave ablation,radiofrequency ablation) plus Donafenib (100mg, bid)
62466741|NCT05205759|EXPERIMENTAL|Sotrovimab|Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
62466742|NCT05205759|ACTIVE_COMPARATOR|Casirivimab Imdevimab|Casirivimab 600 mg + Imdevimab 600 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
62466743|NCT05328180|OTHER|Non-buffered local anaesthetic|The investigators allocate 58 patients in this arm. It serves as the control group, who receives currently used local anaesthetic solution.
61910063|NCT06092125||Epilepsy(EP)|The study aims to collect PET/MR multimodal imaging data from 550 patients with epilepsy across multiple centers. The imaging data will include brain structure, brain function, glucose metabolism, and microglial cell activity, among other imaging biomarkers, to identify abnormal changes characteristic of epilepsy. Key features will be quantitatively analyzed to determine the specific quantitative threshold for diagnosing epilepsy using 18F-FDG PET and 18F-DPA714 PET and establish imaging biomarkers for epilepsy diagnosis. Using pathological results as the gold standard, the analysis of imaging data from lesions and surrounding brain tissue aims to discover imaging biomarkers that differentiate lesions from normal brain tissue and establish imaging markers for precise localization of epilepsy lesions.
62294578|NCT03115190|NO_INTERVENTION|Triage Nurse education|The general practitioner cooperation employs nurses for (telephone) triage. They are aided by a computer based triage system, the Netherlands triage system (NTS), a 6-level urgency triage system. With this study we aim to educate the nurses in the signs and symptoms of chest pain patients. The training program will aim to educate the triage nurses in acute coronary syndrome, including pathophysiology, symptoms and risk factors. The NTS will be incorporated within the training. The triage nurses will receive a training session by Cardiologists with information about acute coronary syndrome, the symptoms and the risks.
62466744|NCT05328180|EXPERIMENTAL|Buffered local anaesthetic|The investigators allocate 58 patients in this arm. It serves as the experimental group, who receives currently used anaesthetic solution that has been buffered.
62466745|NCT04487132|ACTIVE_COMPARATOR|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan provided to the controlled group
62466746|NCT04487132|ACTIVE_COMPARATOR|Recess or lunch time activities|Preparing the playground by offering adequate spaces and games provided to the experimental group
62099202|NCT04805346|EXPERIMENTAL|Therapeutic Group|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada). The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol).
62099203|NCT04805346|NO_INTERVENTION|Control Group|A control group will undergo a similar procedure, but the cuff will not be inflated.
62099204|NCT06309992|EXPERIMENTAL|Treatment arm|
62099205|NCT06309992|PLACEBO_COMPARATOR|Placebo arm|
62099206|NCT00731042|EXPERIMENTAL|Avagard|3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers
62099207|NCT00731042|ACTIVE_COMPARATOR|Purell|Purell Surgical Scrub with Moisturizers
62099208|NCT06711289||Hypotensive patients|Patients who developed hypotension after the induction of spinal anesthesia.
62099209|NCT06711289||Normotensive patients|Patients who did not develop hypotension after the induction of spinal anesthesia.
62099210|NCT03332797|EXPERIMENTAL|Dose Escalation: GDC-9545|During dose escalation, postmenopausal participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).
62099211|NCT03332797|EXPERIMENTAL|Dose Escalation: Cohort B0: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose lower than the MTD or MAD determined in single-agent dose escalation, in combination with the label-recommended dose of palbociclib.
62099212|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort A1: GDC-9545 Dose 1|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 1).
62099213|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 1) in combination with an approved LHRH agonist.
62099214|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort A3: GDC-9545 Dose 2|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 2).
62099215|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort A4: GDC-9545 Dose 2 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 2) in combination with an LHRH agonist.
62099216|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort A5: GDC-9545 Dose 3|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 3).
62099217|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort B1: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib.
62099218|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib and an approved LHRH agonist.
62099219|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort C1: GDC-9545 Dose 2 +/- Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2) as a single agent for 14 days, followed by treatment with either GDC-9545 (Dose 2) plus palbociclib or GDC-9545 (Dose 2) alone for the duration of the study, as determined by the investigator.
62099220|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort C2: GDC-9545 Dose 2 + Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2), in combination with the label-recommended dose of palbociclib.
62099221|NCT03332797|EXPERIMENTAL|Dose Expansion: Cohort X: GDC-9545 Dose 3|GDC-9545 will be administered at a pre-defined dose level (Dose 3) to postmenopausal participants currently receiving clinical benefit with GDC-0927 or GDC-0810 on Studies GO29656 (NCT02316509) or GO29642 (NCT01823835), respectively, upon completion of their studies.
62099222|NCT06203626||participant|we will collect an ULF-MRI from all participants.
62099223|NCT01580943|ACTIVE_COMPARATOR|Antiplaque Efficacy|"This study was designed as a randomized, two group parallel, double-blind, 3-day non-brushing clinical trial. The sample size (50 participants) was determined using similar studies, making it a convenience sample.~Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds."
62099224|NCT01580943|ACTIVE_COMPARATOR|Taste and Side Effects|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
62099225|NCT05186454|ACTIVE_COMPARATOR|Morphine|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 200 µg of morphine intrathecally.
62099226|NCT05186454|ACTIVE_COMPARATOR|Multimodal|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam intrathecally
62466747|NCT05479383||Tobacco users|"Tobacco users~Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers.~Never snus users (reference group) will also compare with never users, former users and current users."
62466748|NCT03101540|EXPERIMENTAL|Supplementation|Subjects received Omega-3 PUFA supplementation
62099227|NCT04209881||Patients with Ankylosing spondylitis|"Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
62099228|NCT04209881||Healthy women as controls|"Regular menstruation with intervals of 21-35 days; cycle length variations \<4 days; and both ovaries still present healthy women will create the control group.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.~Amh will be looked for. (pmol / l). Antral folukul census in the overin folukular stage will be valued as number. Fsh (iu / l) and Estradiol (pmol / l) values will also be recorded."
62099229|NCT06713421|EXPERIMENTAL|A1:Dimeticone+Pronase+Postural Exercise group|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3. Then the patients are asked to take a 3-minute postural exercise.
62099230|NCT06713421|EXPERIMENTAL|A2:Dimeticone+Pronase group|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3. Then the patients sit quietly awaiting examination.
62099231|NCT06713421|ACTIVE_COMPARATOR|B1:Dimeticone+Postural Exercise group|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder. Then the patients are asked to take a 3-minute postural exercise.
62099232|NCT06713421|ACTIVE_COMPARATOR|B2:Dimeticone group|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder. Then the patients sit quietly awaiting examination.
62099233|NCT04670575||Vivity|Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.
62099234|NCT06510517||Paients with Successful weaning|"The procedure of weaning from mechanical ventilation will be considered as early as possible. Patients who will be mechanically ventilated \>24 h will be underwent daily screen of subjective and objective indices for assessment of readiness to wean. Weaning will be conducted according to European Respiratory Society guidelines (ERS) (5).~The criteria for successful extubation: successful extubation was defined as the ability to maintain spontaneous breathing for at least 48 h, without any ventilatory support."
62099235|NCT06510517||Patients with failed weaning|the reconnection to ventilator (invasive or noninvasive) within 48 h due to respiratory failure or other reasons. Extubation and the reconnection to ventilator were all based on SBT results and physicians' decision (5,9).
62099236|NCT06714526|EXPERIMENTAL|Point-of-Care CYP2C19 Testing|Patients will undergo point-of-care CYP2C19 testing with the Research Use Only (RUO) Genomadix Cube to inform the choice of P2Y12 inhibitor (i.e. clopidogrel vs ticagrelor).
62099237|NCT06714526|NO_INTERVENTION|Standard of Care|Patients will receive standard-of-care ASA + clopidogrel.
62099238|NCT06713382|NO_INTERVENTION|Standard of care|Patients will receive the current standard of care, which includes antibiotics, chest tube placement, and intrapleural tPA/DNase therapy based on their clinical criteria
62099239|NCT06713382|EXPERIMENTAL|Standard Care + Saline Irrigation|In addition to the standard care, patients in this group will receive pleural saline irrigation through the chest tube immediately after IPFT. The amount of saline will be determined by free-flow saline infusion up to 250 mL. This maneuver will be repeated every time that IPFT is administered, based on treating physician's criteria
62099240|NCT06711887|NO_INTERVENTION|Study Treatment Withdrawal (cohort 1)|(Cohort 1): Study Treatment-Withdrawal group. Participants who received blinded study treatment in the core study and achieve CRR or PRR at Week 140 in the core study will enter the extension study and discontinue study treatment while maintaining standard of care (SoC) medication, as required. If renal flare criteria are met, participants will be eligible to receive open-label ianalumab.
62099241|NCT06711887|EXPERIMENTAL|Open-Label Ianalumab (cohort 2)|(Cohort 2): Open-Label Ianalumab group: Participants who received blinded study treatment throughout the core study and did not achieve CRR or PRR at Week 140 of the core study, or who had switched to open-label ianalumab during the core study, will be eligible or will continue to receive open-label ianalumab in the extension study.
62466749|NCT00358449|EXPERIMENTAL|Mepolizumab 0.55 mg/kg|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
62099242|NCT01979978|EXPERIMENTAL|Healthy Buddies Curriculum|Healthy buddies curriculum delivered by older peers weekly covering three components of healthy living: Physical activity, healthy eating and a healthy body image.
62099243|NCT01979978|NO_INTERVENTION|Control|This group received standard school curriculum.
62294579|NCT03115190|NO_INTERVENTION|Baseline registry as comparison|"All patients referred to the emergency department (ED) with suspected acute coronary syndrome (ACS) will be evaluated. They will receive a questionnaire to evaluate the accuracy of referral and the delays of ACS patients. This will be compared to the registry at baseline. Some patients will either have not contacted the general practitioner cooperation (GPC) at all, or will have been referred to the ED directly through the GPC nurse triage.~The 30 day, 6 months and one year follow-up of all patients will be via medical records, or in case of no or not enough information, by telephone."
62466750|NCT00358449|EXPERIMENTAL|Mepolizumab 2.5 mg/kg|Participants received mepolizumab 2.5 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
62466751|NCT00358449|EXPERIMENTAL|Mepolizumab 10 mg/kg|Participants received mepolizumab 10 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
62466752|NCT04767477|OTHER|Face-to-face rehabilitation and Telerehabilitation|The Face-to-face rehabilitation and Telerehabilitation protocol will consist of flexibility exercises, aerobic and resistance training, with two sessions per week.
62466753|NCT04121286|EXPERIMENTAL|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
62466754|NCT03222817|EXPERIMENTAL|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
62466755|NCT00725998||1|"The ECAP characteristics have been analyzed in 13 children implanted younger than three years old.~Series Study Results:~During the first year of CI use there was a significant statistical growth for the amplitude of N1 peak, in basal electrodes, between the second and third returns. There were not any significant differences obtained for N1 peak, latency, slope, neither for p-NRT nor recovery time, among the returns."
62466756|NCT05291702|OTHER|Multitract PCNL patients|Assessment of the multitract PCNL procedure in removal of large renal stones using pneumatic or laser lithotripsy.
62466757|NCT02804945|EXPERIMENTAL|Mesenchymal Stem Cells|"Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).~Participants receive a maximum dose of 3 x 10\^6 cell/Kg by vein one time on Day 1."
61910064|NCT06092125||Malignant Brain Tumors(MBT)|A total of 550 patients with malignant brain tumors (gliomas, metastatic tumors, and lymphomas) were collected from multiple centers for PET/MR multimodal imaging of brain structure, brain function, glucose metabolism, and amino acid metabolism, analyzing the characteristic abnormal changes in imaging markers. Using pathological results as the gold standard, specific quantitative threshold values for diagnosing different pathological types of malignant brain tumors using 18F-FDG PET and 18F-FET PET were determined, establishing imaging biomarkers for the diagnosis of malignant brain tumor pathology. Analysis of imaging data of the tumor and surrounding brain tissue revealed imaging markers for distinguishing tumors from surrounding normal brain tissue, enabling precise localization of malignant brain tumors.
61910065|NCT05950152|EXPERIMENTAL|meloxicam injection 30 mg|meloxicam injection 30mg every 24 hours for up to 2 doses.
61910066|NCT05950152|EXPERIMENTAL|meloxicam injection 60 mg|meloxicam injection 60mg every 24 hours for up to 2 doses
61910067|NCT05950152|PLACEBO_COMPARATOR|IV Placebo|IV Placebo every 24 hours for up to 2 doses
62294580|NCT01668368|OTHER|Esophageal balloon group|"Esophageal balloon will be inserted, and esophageal pressure will be measured in patients with acute respiratory failure.~Intervention - PEEP and Inspiratory pressure will be adjusted according to the measured esophageal pressure."
62466758|NCT02670005||FFR-PCI group|patients with ST-segment elevation myocardial infarction (STEMI) who received fractional flow reserve (FFR)-guided selective percutaneous coronary intervention (PCI)
61910068|NCT02527200|EXPERIMENTAL|Liraglutide|
61910069|NCT02527200|PLACEBO_COMPARATOR|Placebo|
61910070|NCT05258370||incident patients with chronic respiratory failure|adult patients with untreated chronic respiratory failure
61910071|NCT05370183|EXPERIMENTAL|Hyperambulatory tenotomy|regarding randomization result, patient wil have a tenotomy of biceps' long head by mini-optics in consultation
62294581|NCT01468649|EXPERIMENTAL|Breast Cancer SLN Mapping|Fifty participants consented who will be undergoing standard of care for breast cancer SLN mapping with Tc-99m will be enrolled in this study.
62466759|NCT02670005||angiography-PCI group|patients with STEMI who received angiography-guided selective PCI
62466760|NCT06349967|EXPERIMENTAL|Nab-paclitaxel+Cadonilimab (AK104)|Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;
62466761|NCT01938066|ACTIVE_COMPARATOR|Negative Pressure with Procellera|Arm 2 is Negative Pressure Therapy and Procellera Dressing under the sponge dressing of the Negative Pressure Therapy. The dressing will be changed at the end of 5 days. This is the intervention arm of the study.
62466762|NCT01938066|SHAM_COMPARATOR|Negative Pressure Therapy only|Arm 1 is Negative Pressure Therapy only with no Procellera Dressing and the dressing is changed every other day per standard of care when you use Negative Pressure Therapy with no dressing underneath the sponge.
62466763|NCT01029470|EXPERIMENTAL|Luveris|Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.
61910072|NCT05370183|ACTIVE_COMPARATOR|Operating room tenotomy|regarding randomization result, patient wil have a tenotomy of biceps' long head upon arthroscopy under normal operating condition
61910073|NCT00774176||1|Phase 1 \& Gene Expression:Hospitalized COPD exacerbators
62294582|NCT00956930|EXPERIMENTAL|Arm I (radioembolization)|Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
62466764|NCT04016532|OTHER|Patient malnourished or at risk of undernutrition|Dietary follow-up at home: 4 visits (D15, D30, D60, D90)
62466765|NCT04016532|OTHER|Not undernourished patients|Dietary follow-up at home: 3 visits ( D30,D60, D90)
62466766|NCT04175379|EXPERIMENTAL|group 40|In group 40, target PaCO2 is 40 during surgery
62466767|NCT04175379|EXPERIMENTAL|group 50|In group 50, target PaCO2 is 50 during surgery
61910074|NCT00774176||2|Phase 2: COPD group
61910075|NCT00774176||3|Genetic Association Studies: COPD and Healthy Controls
61910076|NCT04592484|EXPERIMENTAL|CDK-002|
61910077|NCT02228616|EXPERIMENTAL|Prucalopride plus Polyethylene glycol or lactulose|
62466768|NCT04175379|EXPERIMENTAL|group 60|In group 60, target PaCO2 is 60 during surgery
62466769|NCT04033471|ACTIVE_COMPARATOR|MI|Bupivacaine 0.25% + midazolam 5mg in total volume 10m1
61910078|NCT01584544|EXPERIMENTAL|1000mg|capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.
62466770|NCT04033471|ACTIVE_COMPARATOR|MM|Bupivacaine 0.25% + midazolam 5mg and morphine 5mg in total volume 10ml
62466771|NCT04033471|ACTIVE_COMPARATOR|MO|bupivacaine 0.25% + morphine 5 mg in total volume 10 ml
62661584|NCT04032223|EXPERIMENTAL|3D printed metal copings|3D printed primary and secondary metal copings inderctly from 3D printed resin in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
62661585|NCT04032223|ACTIVE_COMPARATOR|Cast metal copings|Cast metal primary and secondary metal copings in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
61910079|NCT01584544|EXPERIMENTAL|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
61910080|NCT01584544|EXPERIMENTAL|1350mg|capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
61910081|NCT01584544|EXPERIMENTAL|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
62661586|NCT03906994|EXPERIMENTAL|Subjects with Amblyopia|Adult amblyopia subjects will play the video game Mario Kart Wii
62661587|NCT03329001|EXPERIMENTAL|Stage 1: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase
61910082|NCT01584544|EXPERIMENTAL|1650mg|capecitabine 1650mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
61910083|NCT01577290|EXPERIMENTAL|Mindfulness training|Group receives mindfulness training.
62466772|NCT00306462|ACTIVE_COMPARATOR|1|Intravenous magnesium sulfate or placebo
62466773|NCT00306462|ACTIVE_COMPARATOR|2|Oral nifedipine or placebo
62466774|NCT03878719|EXPERIMENTAL|Safety Run-in Phase|"* binimetinib taken twice daily (BID) and~* encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol."
61910084|NCT01577290|ACTIVE_COMPARATOR|Discussion group|Group has access to a discussion group.
61910085|NCT03995251|EXPERIMENTAL|Standard Medical Treatment +Intramuscular Testosterone + Exerc|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
62466775|NCT03878719|EXPERIMENTAL|Expansion Phase|"* binimetinib taken twice daily (BID) and~* encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol."
62466776|NCT03433430|OTHER|truSculpt|truSculpt treatment
62661588|NCT03329001|EXPERIMENTAL|Stage 1: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
62661589|NCT03329001|EXPERIMENTAL|Stage 2: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase.
62661590|NCT03329001|EXPERIMENTAL|Stage 2: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
62661591|NCT03329001|EXPERIMENTAL|Stage 3: High fat meal-fasted sequence|Single dose niraparib tablet with a high fat meal followed by single dose of niraparib tablet in a fasted state.
61910086|NCT03995251|ACTIVE_COMPARATOR|Standard Medical Treatment+Exercise|Standard Medical Treatment +Exercise
61910087|NCT03643978|EXPERIMENTAL|Decision Aid Group|These patients review a decision aid.
61910088|NCT03643978|NO_INTERVENTION|Control Group|These patients do not review a decision aid.
61910089|NCT00289523||Escitalopram|
61910090|NCT00289523||Bupropion XL|
61910091|NCT00289523||Combination Therapy|Escitalopram and Bupropion XL
61910092|NCT05726877|EXPERIMENTAL|Experimental arm|All patients will be enrolled in the same arm.
62466777|NCT02903901|PLACEBO_COMPARATOR|Placebo|Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
62466778|NCT02903901|ACTIVE_COMPARATOR|Melatonin|Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
62466779|NCT00216983||1|"Fasting condition to measure:~1. quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients~2. Evaluating the rate of proline de novo synthesis from glutamate or ornithine in burn patients"
62466780|NCT00216983||2|We will study the quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients. When the patients are receiving regular TPN or TPN depleted with proline - arginine - glutamate.
62661592|NCT03329001|EXPERIMENTAL|Stage 3: Fasted-high fat meal sequence|Single dose niraparib tablet in a fasted state followed by single dose Niraparib tablet with a high fat meal.
62661593|NCT04398134|EXPERIMENTAL|ABI-H2158 plus ETV|ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
62661594|NCT04398134|PLACEBO_COMPARATOR|Placebo plus ETV|Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
62661595|NCT01952951|EXPERIMENTAL|chemoradiation followed by CapOx|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by 2 cycles of chemotherapy (Capecitabine Oxaliplatin - CapOx) and surgery (total mesorectal excision)
61910093|NCT02618356|EXPERIMENTAL|combined use Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA(body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d"
61910094|NCT06162390|EXPERIMENTAL|Remifentanil for NIM tube intubation|
61910095|NCT05624047|EXPERIMENTAL|Experimental Group|Breastfeeding education using the hybrid simulation method
61910096|NCT05624047|OTHER|Control Group|Routine verbal breastfeeding education
61910097|NCT05015985|ACTIVE_COMPARATOR|MUSIC-CARE Group|"In the Music-Care group, a program of music therapy was administered through a hardware and software provided to the investigative team by the Music-Care Company. The standardized techniques include three sequences in which the relaxing, maintenance and simulating times differ.~Music-Care utilizes the U technique designed to gradually relax the listener. In the current study, music sequences during patients' sessions were based on the mount U, and instrumental musical works were selected for a varying numbers styles (classical, jazz, world music, etc.) and adapted to the patient's style via patient request."
61910098|NCT05015985|SHAM_COMPARATOR|CONTROL group|In the control group, a music program from an established playlist with various instrumental music is chosen by the patient and delivered by the same tablet.
61910099|NCT02976220|EXPERIMENTAL|Digital Education|1 month digital education program
61910100|NCT06491966||viral sepsis group|The viral sepsis group comprises patients with sepsis secondary to viral infections, specifically COVID-19. Patients in this group were admitted to the ICU of Sichuan Provincial People's Hospital between July 2021 and December 2023 and diagnosed with viral sepsis based on positive RT-PCR results for SARS-CoV-2.
61910101|NCT06491966||bacterial sepsis group|The bacterial sepsis group includes patients with sepsis resulting from bacterial infections. These patients were admitted to the ICU of Sichuan Provincial People's Hospital during the same period and diagnosed with bacterial sepsis based on positive bacterial cultures.
61910102|NCT03678870|EXPERIMENTAL|Education|Opioid Education
61910103|NCT03678870|NO_INTERVENTION|Control|standard discharge instructions, which lists medications prescribed at discharge
61910104|NCT03453372|EXPERIMENTAL|Active|MRgFUS treatment of pain caused by knee osteoarthritis
62661596|NCT01952951|ACTIVE_COMPARATOR|chemoradiation|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by rest for 8 weeks and surgery (total mesorectal excision)
61910105|NCT03453372|PLACEBO_COMPARATOR|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
61910106|NCT03859973|EXPERIMENTAL|BI 425809 10 mg + Computerized Cognitive Training|
62099244|NCT06054828|EXPERIMENTAL|mHELP@ICU|Participants will receive cognitive engagement twice daily, have physical activity once daily, and be monitored for their feeding. The intervention will be administered for 14 days or until hospital discharge or death.
62294583|NCT00956930|EXPERIMENTAL|Arm II (transarterial chemoembolization [TACE])|Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
62661597|NCT00933933|EXPERIMENTAL|ARCHITECT HIV Ag/Ab Combo Specificity|Specimens collected from normal apparently healthy individuals at low risk for HIV infection will be tested by the investigational HIV test and FDA-licensed HIV test.
62661598|NCT00933933|NO_INTERVENTION|ARCHITECT HIV Ag/Ab Combo Sensitivity|Specimen with confirmed positive HIV Antigen, HIV-1 antibody, or HIV-2 antibody will be tested by the investigational HIV test.
62661599|NCT00933933|EXPERIMENTAL|ARCHITECT HIV Ag/Ab Combo Reactivity|Specimen collected from individuals at risk for HIV infection will be tested by the investigational HIV test.
62661600|NCT02818543|EXPERIMENTAL|Cohort 1|LYC-30937 25 mg single oral dose
62661601|NCT02818543|EXPERIMENTAL|Cohort 2|LYC-30937 100 mg single oral dose
62661602|NCT03270488|EXPERIMENTAL|Laser Group|Laser application three times a week for 4 weeks.
62661603|NCT03270488|PLACEBO_COMPARATOR|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
62099245|NCT06054828|NO_INTERVENTION|Control group|Participants in the control group will receive the usual care.
62661604|NCT02783625|EXPERIMENTAL|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15\* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
61910107|NCT03859973|PLACEBO_COMPARATOR|Placebo + Computerized Cognitive Training|
61910108|NCT00005862|EXPERIMENTAL|Arm I|atients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
61910109|NCT00558688|EXPERIMENTAL|1|Light Therapy
61910110|NCT00558688|EXPERIMENTAL|2|Light Therapy
61910111|NCT03782831|EXPERIMENTAL|TACE plus PD-1 antibody|Patients received hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
61910112|NCT03782831|ACTIVE_COMPARATOR|TACE alone|Patients received hepatic intra-arterial infusion with lipiodol mixed with hemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received placebos intravenously every 2 weeks
62294584|NCT01349348|EXPERIMENTAL|Tolvaptan 15mg|Tablet;15mg/tab
62294585|NCT01349348|EXPERIMENTAL|Tolvaptan 7.5mg|Tablet;7.5mg/tab
62294586|NCT01349348|PLACEBO_COMPARATOR|Placebo|Tolvaptan 0mg/tab
62661605|NCT02783625|EXPERIMENTAL|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11\* Bortezomib subcutaneous injection, days 1, 4, 8, 11\*\* duvelisib by mouth twice daily, days 1-28
62661606|NCT04288791|EXPERIMENTAL|Equia Forte Fil|
62661607|NCT04288791|EXPERIMENTAL|Zirconomer Improved|
62661608|NCT03759184|EXPERIMENTAL|Arm 1 -DOSE ESCALATION|DOSE ESCALATION: Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at escalating doses of 0.5, 1, and 2 mcg/kg/day on days 1-5 of each 4-week cycle (max 6 cycles), with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle, to determine the maximum tolerated dose (MTD)
62099246|NCT05565521|EXPERIMENTAL|Treatment Arm|Concurrent dose-escalated chemoradiation with temozolomide (TMZ) on the MR-Linac with weekly adaptation
62661609|NCT03759184|EXPERIMENTAL|Arm 2 - DOSE EXPANSION|DOSE EXPANSION: 3 to 6 patients to receive interleukin-15 (IL-15) by continuous intravenous (civ) infusion at the maximum tolerated dose (MTD) on days 1-5 of cycles 1-6 with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle (Total 9 patients at MTD)
62661610|NCT05508256|ACTIVE_COMPARATOR|Catheter Ablation|Symptomatic HFmrEF or HFpEF patients with AF that meet I/E criteria will be randomized 1:1 to receive either CA or usual medical care without the aim of CA. Patients assigned to rhythm control group will be treated with catheter ablation as first line therapy to restore and maintain sinus rhythm, additionally to the therapeutic recommendations of the current ESC guidelines for the management of atrial fibrillation (AF) and the current ESC Heart Failure (HF) guidelines.
62099247|NCT02553382|EXPERIMENTAL|Dietary, Herbal|
62294587|NCT04144621||Normal SDF|Couples with male partners having SDF lower than 20% using TUNEL assay
62294588|NCT04144621||Abnormal SDF|Couples with male partners having SDF greater than 20% using TUNEL assay
62661611|NCT05508256|NO_INTERVENTION|Usual Medical Care|Symptomatic HFmrEF or HFpEF patients with AF that meet I/E criteria will be randomized 1:1 to receive either CA or usual medical care without the aim of CA. Subjects randomized to usual care will be treated according to current ESC guidelines for the management of AF and current ESC HF guidelines. Usual care of AF in the context of CABA-HFPEF consists of an initial treatment limited to rate control in addition to adequate antithrombotic therapy, typically oral anticoagulation.
62661612|NCT00539474|ACTIVE_COMPARATOR|1|Wireguided localisation
62661613|NCT00539474|EXPERIMENTAL|2|Radioguided occult lesion localisation
62661614|NCT03354377|EXPERIMENTAL|Vegan Diet|"Participants in this group will follow a plant-based vegan diet. The vegan group diet will be based on investigators' pilot work, which instructs participants to favor a diet built around whole grains, fruits, vegetables, and legumes. This group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course.~Interventions include intervention meetings, physical activity, and podcasts/mailings."
62661615|NCT03354377|EXPERIMENTAL|Omnivorous (Omni) Diet|"Participants in this group will follow a low-fat omni diet. The diet intervention for the omni group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide, A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course).~Interventions include intervention meetings, physical activity, and podcasts/mailings."
62661616|NCT04447365||control|10 patients who have had no device-monitored for ventricular tachycardia/ ventricular fibrillation the 3 months prior to recruitment will comprise a group of controls
62661617|NCT04447365||high burden of ventricular arrhythmias|20 patients will comprise a group of patients with high burden of ventricular arrhythmias, defined as patients with at least one sustained episode of VT/VF requiring ICD therapies in the 3 months preceding study enrollment.
62661618|NCT00895713|EXPERIMENTAL|im HBIG Grifols|
62661619|NCT00262379|NO_INTERVENTION|Group A|HCV treatment with peginterferon plus ribavirin during 48 weeks
62661620|NCT00262379|ACTIVE_COMPARATOR|Groupb|HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions
62661621|NCT01417962||Fetuses|Still birth and Termination of pregnancies
62661622|NCT01417962||Children|Includes Newborns, Infants and Children
62661623|NCT01332162|EXPERIMENTAL|Biventricular pacing|All patients will be pacing during two years
62661624|NCT01332162|ACTIVE_COMPARATOR|No Pacing during the first year|No Pacing during the first year. In the second year all patients will be pacing
62661625|NCT00709670|EXPERIMENTAL|whole population who receive both tests|this arm includes the whole study population who will receive both tests: MSCT and stress echocardiography
62661626|NCT00005849|EXPERIMENTAL|Arm A|Paclitaxel (90 mg/m2, days 1, 8 and 15 of every 28 day cycle), Bryostatin-1 (50 mcg/m2, days 2, 9 and 16 of every 28 day cycle)
62661627|NCT05439564|PLACEBO_COMPARATOR|Group morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
62661628|NCT05439564|ACTIVE_COMPARATOR|Group morphine-Dex|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
61910113|NCT04860908||covid exposed|women who were exposed to covid 19 during pregnancy
62661629|NCT05439564|ACTIVE_COMPARATOR|Group Dex|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
62661630|NCT05619341|PLACEBO_COMPARATOR|inulin|20g inulin in 500ml water
62661631|NCT05619341|ACTIVE_COMPARATOR|inulin + psyllium|Inulin 20g + 20g psyllium in 500 ml water
62661632|NCT05619341|ACTIVE_COMPARATOR|inulin divided doses|2.5 g inulin in 62.5ml water given at 45 minute intervals
62661633|NCT05804903|EXPERIMENTAL|TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|
61910114|NCT04860908||covid vaccinated|women who were vaccinated to covid 19 during pregnancy
61910115|NCT06299254||Participants with obesity|Participants affected by obesity (the level of body mass index (BMI) higher or equal to 30).
62099248|NCT02553382|PLACEBO_COMPARATOR|Positive Control|
62099249|NCT05198453||vaccinated patients with COVID-19|
62099250|NCT05198453||unvaccinated patients with COVID-19|
62294589|NCT05872048|EXPERIMENTAL|periodontal distractor with interseptal bone cuts|
62294590|NCT05872048|EXPERIMENTAL|periodontal distractor without interseptal bone cuts|
62294591|NCT05796479|EXPERIMENTAL|Group 1 (Part1)|Participants will receive a single SC dose of amlitelimab DP1 on Day 1.
62294592|NCT05796479|EXPERIMENTAL|Group 2 (Part 2)|Participants will receive a single SC dose of amlitelimab DP1 on Day 1.
62294593|NCT05796479|EXPERIMENTAL|Group 3 (Part 2)|Participants will receive a single SC dose of amlitelimab DP2 on Day 1.
61910116|NCT06299254||Healthy-weight participants|As controls, not-hospitalized participants with a healthy weight
62099251|NCT01097655||HIV-infected Participants|"HIV-infected participants starting with Kaletra tablets.~Participants included 3 subgroups:~* antiretroviral therapy (ART) treatment-naïve participants starting with Kaletra tablets~* participants receiving their first protease inhibitor (PI)-containing regimen (apart from Kaletra) pretreated with any non nucleoside reverse transcriptase inhibitor (NNRTI)-containing or nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen~* participants pretreated with a PI-containing regimen (apart from Kaletra)."
62099252|NCT04159155|EXPERIMENTAL|Early Stage Cohort - Arm A|Pelvic EBRT at 45Gy in 25 fractions, in 1.8Gy fractions daily, 5 days per week
62099253|NCT04159155|EXPERIMENTAL|Early Stage Cohort - Arm B1|Vaginal high-dose rate brachytherapy 21 Gy in 3 fractions, prescribed to 5mm (i.e. 100% isodose at 5mm) from the cylinder/applicator surface and top along the upper third to half of the vagina (minimum 3cm, maximum 4cm).
62099254|NCT04159155|ACTIVE_COMPARATOR|Advanced Stage Cohort Arm C|Observation
62099255|NCT04159155|EXPERIMENTAL|Advanced Stage Cohort Arm D1|Investigational agent (niraparib), orally, at a dose of 200 mg, or 300 mg, once daily, based on baseline platelet count and weight.
62099256|NCT00657774|EXPERIMENTAL|1|FlutiForm 250/10 ug
62099257|NCT00657774|EXPERIMENTAL|2|FlutiForm 100/10 ug
61910117|NCT03391193|EXPERIMENTAL|Multi-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal containing) in multi-dose presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
61910118|NCT03391193|ACTIVE_COMPARATOR|Single-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal free) in single-dose syringe presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
62099258|NCT00657774|ACTIVE_COMPARATOR|3|Oral Prednisone 10 mg
62099259|NCT00657774|PLACEBO_COMPARATOR|4|Placebo inhaler and/or placebo tablets
62099260|NCT05835024||Participants phase 1|Phase 1: patients enrolled for a right heart catheterization procedure as part of their standard of care.
62099261|NCT05835024||Participants phase 2|Phase 2: patients enrolled for a right heart catheterization procedure as part of their standard of care.
62099262|NCT05343455|EXPERIMENTAL|DFD-29|DFD-29 (40 mg) extended release capsules
62099263|NCT05343455|ACTIVE_COMPARATOR|Doxycycline 40 mg|Doxycycline 40 mg modified release capsules
62099264|NCT05343455|PLACEBO_COMPARATOR|Placebo|Placebo capsules matching DFD-29
62099265|NCT03981549|ACTIVE_COMPARATOR|Immediate Cellular Therapy / Deferred Sham Therapy|"At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.~At 6 months: Sham bone marrow aspiration and sham intravitreal injection."
62099266|NCT03981549|SHAM_COMPARATOR|Immediate Sham Therapy / Deferred Cellular Therapy|"At baseline: Sham bone marrow aspiration followed by sham intravitreal injection.~At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells."
62099267|NCT06589986|EXPERIMENTAL|RO7790121|Participants will receive RO7790121 intravenously (IV) followed by RO7790121 subcutaneous (SC) injection.
62099268|NCT06589986|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo IV followed by placebo SC.
61910119|NCT03717428|EXPERIMENTAL|Daily Weighing Group|This group will be weighed and height measured in our metabolic unit at the beginning and end of the two year experimental period. In addition, the intervention in Daily Weighing Group is that they will be given an internet based scale and asked to weigh themselves immediately after rising from bed every morning for the duration of the two year experimental period.
61910120|NCT03717428|ACTIVE_COMPARATOR|Control Group|The only intervention for the control group is that they will be weighed and height measured at the beginning and end of the experimental period in our metabolic unit.
61910121|NCT05767879|EXPERIMENTAL|Neo adjuvant BRAF/MEK inhibition in pN1c Melanoma|"Neo adjuvant BRAF/MEK inhibition (encorafenib/binimetinib).~Patients receive encorafenib 450 mg once daily for a period of 8 weeks. Patients receive 45 mg binimetinib twice daily for a period of 8 weeks. After the neo-adjuvant therapie, patients will receive encorafenib 450 mg once daily fand binimetinib 45mg twice daily for 44 weeks."
61910122|NCT02375789|ACTIVE_COMPARATOR|Active RhinoChill|"Following the initial 30 days (and minimum of 2 separate migraine attacks) of data collection the patient will be trained in the use and self administration of the RhinoChill device.~At the onset of an acute migraine, the patient will insert the RhinoChill Migraine Intranasal catheters and commence a 10 minute treatment on the Low Flow setting of the device.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
62099269|NCT05499481|ACTIVE_COMPARATOR|Long Antibiotic Arm|"Without implant material in place:~6 weeks of systemic post-surgical antibiotic therapy~With mateial in place 12 weeks of systemic post-surgical antibiotic therapy"
62099270|NCT05499481|EXPERIMENTAL|Short Antibiotic Arm|"Without implant material in place:~3 weeks of systemic post-surgical antibiotic therapy~With mateial in place 6 weeks of systemic post-surgical antibiotic therapy"
62099271|NCT06613399|EXPERIMENTAL|Multi-Technology Integrated Total Mesorectal Excision，MTI-TME|
62099272|NCT06613399|PLACEBO_COMPARATOR|Conventional Total Mesorectal Excision，C-TME|
62099273|NCT03194893|EXPERIMENTAL|Alectinib|Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
62099274|NCT03194893|EXPERIMENTAL|Crizotinib|Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
61910123|NCT02375789|PLACEBO_COMPARATOR|Placebo RhinoChill|"The same procedure will be followed for the placebo comparator as in the active comparator. The RhinoChill device looks identical and functions in a very similar way to the active device however through some minor design changes the device has been altered to provide a sufficient placebo treatment.~At the onset of an acute migraine headache the patient will insert the RhinoChill Migraine Intranasal catheters and the 10 minute treatment is commenced on Low Flow.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
61910124|NCT04090775|OTHER|Single arm. Subjects receiving treatment.|Cryosurgical freezing and intratumoral combination immunotherapy as determined by the proportion of patients achieving serum PSA decline from baseline of at least 50%.
61910125|NCT05254743|EXPERIMENTAL|Pirtobrutinib|Administered orally.
62099275|NCT03923101||Patients with Keratoconus|Aim is to include as many Keratoconus patients as possible with the intention to elucidate how the disease begins and develops during lifetime.
62294594|NCT01322906|OTHER|Group A|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
62294595|NCT06606028||Cohort A: Non-investigational Radiation therapy|Participants will have tumor tissue collected at screening and blood samples (approximately 20ml x 3) will be obtained during non-investigational, standard of care radiation and after care for up to 2 years.
61910126|NCT05254743|ACTIVE_COMPARATOR|Ibrutinib|Administered orally.
62661634|NCT04682613|EXPERIMENTAL|"Prevention Program young In Favor of Myself, active teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers will also participate by delivering planned activities to do with their pupils in addition to each week's topic, parallel to the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62661635|NCT04682613|ACTIVE_COMPARATOR|"Prevention Program young In Favor of Myself, passive teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers won't participate in the program, they will only be present in the classroom during the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
62661636|NCT04366804||Patients with neuropsychiatric fluctuations|PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)
62661637|NCT04366804||Patients without neuropsychiatric fluctuations|PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)
62661638|NCT01823900|EXPERIMENTAL|Test and reference formulations|Test formulation and reference formulation given orally 7 days apart in a fasted state
62661639|NCT04079959||women who are undergoing frozen embryo transfer|endometrial biopsy will be done one cycle before the frozen embryo transfer
62661640|NCT06190366|EXPERIMENTAL|Bloodletting acupuncture at the fossa poplitea|
62661641|NCT06190366|EXPERIMENTAL|Bloodletting acupuncture at the regio glutaea|
62661642|NCT06190366|NO_INTERVENTION|Waiting list control group|
61910127|NCT02027129|OTHER|Low frequency HFO/HFO-TGI vs high frequency HFO|Total study population for the testing of the ventilatory strategies
61910128|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection \[Japanese Pharmacopoeia\]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
62661643|NCT01580644|EXPERIMENTAL|Period 1: formulation 1 oral solution|
62661644|NCT01580644|EXPERIMENTAL|Period 2: formulation 2 capsule|
61910129|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
62294596|NCT06606028||Cohort B: Non-investigational Surgery|Participants will have tumor tissue collected at screening and blood samples (approximately 20ml x 3) will be obtained during non-investigational, standard of care surgery and after care for up to 2 years.
62661645|NCT01580644|EXPERIMENTAL|Period 3: Selected formulation + food|
62661646|NCT01580644|EXPERIMENTAL|Period 4: Selected formulation at higher dose|
62661647|NCT02142543|PLACEBO_COMPARATOR|placebo|placebo powder containing zinc oxide, karaya gum, and yellow dye, which was added to imitate the color of the original powder, applied twice a day until the ulcer had resolved, an expected average of 3-5 days
62661648|NCT02142543|EXPERIMENTAL|2-DeNT powder|2-DeNT powder containing dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum, applied twice a day until the ulcer had resolved, applied twice a day until the ulcer had resolved, in an expected average of 3 to 5 days
62661649|NCT03589703|ACTIVE_COMPARATOR|T-APA|Patients with active points related to cLBP. Will receive acupressure within the two zones for cLBP located on the front and back of the ear and three points known for alleviating stress and pain.
62661650|NCT03589703|ACTIVE_COMPARATOR|NT-APA|"The same procedure for APA will be applied but the tapes/seeds will be placed on five different ear points, comprising mouth, stomach, duodenum, internal ear, and tonsil.~These points are chosen for the non-target ear points of APA treatment for two reasons. First, they are distinct from the zones of the ear (and the points therein) associated with the lower back, and correspond to body regions in which the participant is usually pain-free. Second, they are equivalent in number to those points used in the APA treatment group."
61910130|NCT05532423|EXPERIMENTAL|Metabolic Syndrome Older Adult|Participants with metabolic syndrome will be drinking nitrate rich beetroot juice from the James White Beet It company. Participants will drink one dose of 140mL beetroot juice for two visits of either a nitrate rich juice or a nitrate depleted placebo drink. Both drinks taste and smell the same, just with the active component removed. Following these visits, participants will drink 70ml of nitrate rich beetroot juice daily for 4 weeks to investigate long term effects of the juice on study outcomes.
61910131|NCT05532423|EXPERIMENTAL|Metabolic Syndrome Older Adult - Placebo juice condition|Participants with metabolic syndrome will be drinking nitrate rich beetroot juice from the James White Beet It company. Participants will drink one dose of 140mL beetroot juice for two visits of either a nitrate rich juice or a nitrate depleted placebo drink. Both drinks taste and smell the same, just with the active component removed. Following these visits, participants will drink 70ml of nitrate rich beetroot juice daily for 4 weeks to investigate long term effects of the juice on study outcomes.
61910132|NCT04465201|EXPERIMENTAL|Subjects receiving the Impella/Impella® Hemodynamics platform|
62099276|NCT02477943||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
62099277|NCT02477943||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
62294597|NCT02706938|OTHER|Head of bed elevation - Control|Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
62308151|NCT03750162|EXPERIMENTAL|Manuel dynamic activation|Irrigation solution was activated with a well-fitting a ProtaperNext X3 gutta-percha point placed to working length was then moved in push - pull motions at a rate of 100 strokes/per minute
62661651|NCT03589703|OTHER|Enhanced Educational Control Group (CG-2)|Participants in the enhanced educational control group will be given the cLBP educational booklet and visit the office weekly for assessment (i.e., blood draws and questionnaires), which is the same schedule as that for the APA groups.
62661652|NCT01567410|OTHER|traditional Classroom training|one group of nurses receive traditional classroom training to learn about the braden scale and pressure ulcer classification
62099278|NCT06714149|OTHER|Allergic subjects|All subject with positive skin prick testing for grass and/or birch pollen are assigned to this group.
62099279|NCT06714149|OTHER|Healthy controls|Subjects with negative skin prick testing for grass and/or birch pollen are assigned to this group and used for as negative controls in our experiments.
62099280|NCT02042443|EXPERIMENTAL|Trametinib|Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62099281|NCT02042443|EXPERIMENTAL|Chemotherapy|Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
62099282|NCT05724550|ACTIVE_COMPARATOR|Neostigmine|The use of neostigmine 0.02mg/kg for reversal of neuromuscular blocking agent.
62099283|NCT05724550|EXPERIMENTAL|Sugammadex|The use of sugammadex 2mg/kg for reversal of neuromuscular blocking agent.
62099284|NCT00716079|OTHER|Intensive BP lowering|Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
62099285|NCT00716079|OTHER|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the American Heart Association (AHA) in 2007 and 2010. The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
62294598|NCT02706938|OTHER|Control - Head of bed elevation|Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
62308152|NCT03750162|EXPERIMENTAL|Photodynamic Therapy|Root canal was filled by 0.5 mL of 0.01% methylene blue (MB) solution for 5 minutes, then radiated by the light supply of a diode laser AMD picasso with a wavelength of 810 nm for 40 seconds (0.2 W).
62099286|NCT06711029|ACTIVE_COMPARATOR|Control Group|In the final irrigation, 6 ml of 5.252% NaOCI will be applied with needle irrigation for a total of 60 seconds.
62099287|NCT06711029|ACTIVE_COMPARATOR|Passive Ultrasonic Irrigation 3*20 sec|In the final irrigation, 6 ml of 5.25% NaOCI will be applied as 3\*20 seconds with PUI for a total of 60 seconds.
62099288|NCT06711029|ACTIVE_COMPARATOR|Passive Ultrasonic Irrigation 6*10 sec|In the final irrigation, 6 ml of 5.25% NaOCI will be applied as 6\*10 seconds with PUI for a total of 60 seconds.
61910133|NCT06215768|EXPERIMENTAL|Dexemedetomidine group A|Patients aged( 2_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous dexmedetomidine 0.5 μg/kg
62099289|NCT06613425|EXPERIMENTAL|Experimental group|Combined platelet
62099290|NCT06713564|EXPERIMENTAL|LS301-IT Cohort -1|0.0125 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery
62099291|NCT06713564|EXPERIMENTAL|LS301-IT Cohort 1|0.025 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery
62661653|NCT01567410|OTHER|e-learning|one group of nurses receive e-learning as a training method to learn about the braden scale and classification of pressure ulcer
61910134|NCT06215768|EXPERIMENTAL|Midazolam group B|Patients aged( 2_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous midazolam 0.1 mg/kg
62099292|NCT06713564|EXPERIMENTAL|LS301-IT Cohort 2|0.05 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery
62308153|NCT01821248|EXPERIMENTAL|Gemcitabine, Cisplatin, S-1|1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7
62661654|NCT00585182|EXPERIMENTAL|1|
62661655|NCT03527602|EXPERIMENTAL|Intervention|Endodontic treatment will be performed in maxillary anterior teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with rotary files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
62661656|NCT03527602|NO_INTERVENTION|Control|In the control group, no foraminal enlargement will be performed.
62661657|NCT04681378|ACTIVE_COMPARATOR|Classical double layer closure|a holding Vicryl 1-0 was placed in the in the left corner to stabilize and define the demarcation of the suture line. A continuous unlocked stitch beginning at the right corner was used, closing the whole thickness of the uterine wall, including the decidual layer. The second unlocked stitch was performed by Vicryl 1-0 in a lateral -lateral (horizontal) position, adapting the first layer. Up to three additional single sutures were added for hemostasis if required.
62661658|NCT04681378|ACTIVE_COMPARATOR|Turan technique|beginning in one corner, the incision is closed using Vicryl 1-0 stitch. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously in the form of a purse string closure. With this technique, the original string is returned to the starting point and tied with a knot. Following the double layered purse-string closure, the aperture left in the middle of the uterine incision is closed with one separate figure of eight suture
62661659|NCT04681378|ACTIVE_COMPARATOR|Double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
62661660|NCT05595434|EXPERIMENTAL|active stress group|20 healthy subjects will be subject to the active condition of a standardized stress protocol
62661661|NCT05595434|PLACEBO_COMPARATOR|placebo stress group|20 healthy subjects will be subject to the placebo condition of a standardized stress protocol.
62661662|NCT04230070|EXPERIMENTAL|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
62661663|NCT04230070|ACTIVE_COMPARATOR|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
62661664|NCT00063622|ACTIVE_COMPARATOR|1|Pioglitazone
62661665|NCT00063622|ACTIVE_COMPARATOR|2|Vitamin E
62661666|NCT00063622|PLACEBO_COMPARATOR|3|Placebo Pioglitazone or Placebo Vitamin E
62661667|NCT05593458|EXPERIMENTAL|Arterial infusion group|"1. 3 cycles of neoadjuvant chemotherapy: Oxaliplatin arterial infusion+S-1~2. 3 cycles of immunotherapy: sintilimab~3. surgery and 3 cycles of adjuvant chemotherapy using SOX regimen plus sintilimab.~4. S-1 administration till 1 year after surgery"
62661668|NCT05593458|ACTIVE_COMPARATOR|SOX group|"1. 3 cycles of neoadjuvant chemotherapy: SOX regimen~2. 3 cycles of immunotherapy: sintilimab~3. surgery and 3 cycles of adjuvant chemotherapy using SOX regimen plus sintilimab.~4. S-1 administration till 1 year after surgery"
62661669|NCT01626313|ACTIVE_COMPARATOR|Immediate intervention|Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT
62661670|NCT01626313|ACTIVE_COMPARATOR|Waitlisted|Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT
62661671|NCT03834116|EXPERIMENTAL|Inspiratory muscle training group|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
62661672|NCT03834116|NO_INTERVENTION|Control group|The control group will receive standard treatment in a fast-track design.
62661673|NCT04624243|EXPERIMENTAL|MK-8189 8 mg (Acute) - MK-8189 8 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 8 mg once daily (QD) in the acute treatment period from Week 1-6 followed by MK-8189 8 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12. Enrollment of participants in the MK-8189 8 mg arm was closed with Amendment 4. Participants enrolled before Amendment 4 that have been assigned to 8 mg MK-8189 will remain on 8 mg MK-8189 per protocol.
62099293|NCT06713564|EXPERIMENTAL|LS301-IT Cohort 3|0.075 mg/kg LS301-IT administered by IV infusion over approximately 15 minutes the day before surgery
62099294|NCT03530280|ACTIVE_COMPARATOR|pregabalin (lyrica)|pregabalin (lyrica) 150 mg preoperative 1 hour before and the postoperative sham block will perform.
62099295|NCT03530280|PLACEBO_COMPARATOR|placebo group|a placebo capsule 1 hour before surgery and the postoperative sham block will perform.
62099296|NCT03530280|ACTIVE_COMPARATOR|adductor channel block group|A preoperative placebo capsule will be given.This group will receive postoperative adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
62308154|NCT03126227|ACTIVE_COMPARATOR|AR101 Powder Provided in Capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
62661674|NCT04624243|EXPERIMENTAL|MK-8189 16 mg (Acute) - MK-8189 16 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 16 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 16 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
62099297|NCT05376488|ACTIVE_COMPARATOR|Meal type A|Meal type A: equicaloric meal as meal type B and C with differing constituents
62099298|NCT05376488|ACTIVE_COMPARATOR|Meal type B|Meal type B: equicaloric meal as meal type A and C with differing constituents
62099299|NCT05376488|EXPERIMENTAL|Meal type C|Meal type C: equicaloric meal as meal type B and A with differing constituents
62099300|NCT03634189|EXPERIMENTAL|HF- ACC/AHA stage A-C + CBD|Patients with HF stages A-C + Cannabidiol
62661675|NCT04624243|EXPERIMENTAL|MK-8189 24 mg (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 24 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
62661676|NCT04624243|ACTIVE_COMPARATOR|Risperidone 6 mg (Acute) - Risperidone 6 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive risperidone 6 mg QD in the acute treatment period from Week 1-6 followed by risperidone 6 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive MK-8189-matching placebo QD from Week 1-12.
62661677|NCT04624243|EXPERIMENTAL|Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189-matching placebo QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
62661678|NCT04360720|NO_INTERVENTION|Dual Antiplatelet Therapy|"Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months.~Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)"
62661679|NCT04360720|EXPERIMENTAL|Antiplatelet Monotherapy|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone for 12 months.~Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)"
62661680|NCT01334515|EXPERIMENTAL|Disease measured by standard radiographic criteria|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC \[preferred\]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
62737057|NCT05083611|EXPERIMENTAL|Experimental group|The experimental group will receive an educational session on phantom limb pain and the previously designed GraMI protocol through a systematic review and validation through a study with Delphi methodology. This protocol contains the three techniques with their defined intensity, frequency, duration and progression.
62737058|NCT00005699||Hypertensive|described as hypertensive according to AHA guidelines at time of trial
61910135|NCT00430183|EXPERIMENTAL|Arm A: docetaxel + LHRH agonist + surgical intervention|"Patients receive six cycles of docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.~Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol.~Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery."
61910136|NCT00430183|OTHER|Arm B: surgical intervention|All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery.
61910137|NCT01733212|EXPERIMENTAL|Ginger|2 gm powder of ginger filled in a capsule
61910138|NCT01733212|PLACEBO_COMPARATOR|Placebo|2 gm of placebo pill (A capsule)
62099301|NCT06705491|EXPERIMENTAL|TIPPI-R|
62099302|NCT06705491|NO_INTERVENTION|Standard of Care|Participants and families in this arm will receive the standard treatment for pain and distress during cancer treatment at each respective institution, which may include psychoeducation and support implementing pain coping skills from mental health providers within the healthcare system.
62099303|NCT06705491|EXPERIMENTAL|Delayed Intervention Delivery|Participants will be moved into this arm if they are initially randomized into the intervention arm, but they receive the TIPPI-R intervention outside of the window dictated in the protocol. According to the protocol, consented participants should receive the interventions within 2 weeks of consent. If they do not, the TIPPI-R intervention will still be delivered and the participant will be moved to this arm of the study.
62099304|NCT06524583|NO_INTERVENTION|Arm A|Standard of care : Active surveillance
62099305|NCT06524583|EXPERIMENTAL|Arm B|Experimental treatment: 4 cycle of Doxorubicine + trabectedin
62099306|NCT06524583|NO_INTERVENTION|Prospective Cohort|Standard of care : Active surveillance
62099307|NCT05986487||Patients with nocturnal hypertension and/or non-dipper pattern and diagnosed with OSA|Patients with nocturnal hypertension and/or non-dipper pattern who undergo a sleep test, obtaining the diagnosis of obstructive sleep apnea, will be treated following the clinical practice standards.
62308155|NCT03126227|PLACEBO_COMPARATOR|Placebo powder|Placebo formulation in pull-apart capsules containing only excipients color-matched to AR101 study product.
61910139|NCT04672707|EXPERIMENTAL|Group A|Bromhexine Hydrochloride Tablet, 32 mg, 8 mg 4 tablets, three times a day, for 2 days
62099308|NCT05986487||Patients with nocturnal hypertension and/or non-dipper pattern and without OSA|Patients with nocturnal hypertension and/or non-dipper pattern undergoing a sleep test, the result of which is negative for obstructive sleep apnea disease.
62099309|NCT06329804|NO_INTERVENTION|No Intervention Control|Participants allocated to this group will maintain their usual lifestyle for 4-weeks
62099310|NCT06329804|EXPERIMENTAL|Two Sessions/Week|Participants allocated to this group will complete 4-weeks of isometric handgrip exercise training with a frequency of two sessions/week
62661681|NCT01334515|EXPERIMENTAL|Disease evaluable only by I-MIBG or BM histology|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC \[preferred\]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
62661682|NCT05010967|EXPERIMENTAL|High intensity interval training|High intensity interval training will be administered three days a week for 8 weeks. six series with 3 minutes rest period between series. For first 4 weeks the series would consist of 30 seconds of exercise and 30 seconds rest. exercises will consist of burpees, skipping, lunges, 1-legged squat, leg lever, push ups. for next four weeks the duration of exercise will be 45 seconds followed by 30 seconds recovery.
62661683|NCT05010967|ACTIVE_COMPARATOR|Yoga Training|Yoga will be administered 3 days a week for 8 weeks. the session would be of 30-50 minutes with 5 minutes breathing followed by 15-35 minutes yoga and 10 minutes supine meditation. cat-cow stretch, child's pose, downward dog, plank, cobra pose will be used.
62661684|NCT04571034|SHAM_COMPARATOR|Control Group|Healthy adults receiving sham comparator.
62661685|NCT04571034|EXPERIMENTAL|Medium-Intensity Roller Massage|Healthy adults receiving medium-intensity roller massage.
62661686|NCT04571034|EXPERIMENTAL|High-Intensity Roller Massage|Healthy adults receiving high-intensity roller massage.
62661687|NCT04154345|EXPERIMENTAL|Painful exercises|The pain allowed during exercises ranges between 4 and 7 on NPRS (Numeric Pain Rating Scale)
62661688|NCT04601376|EXPERIMENTAL|Mobile monitoring group|
62661689|NCT02825602||Vietnam War Theater Veterans|Vietnam War Theater Veterans are defined for this protocol as those who served in the U.S. Armed Forces on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos between February 28, 1961 and May 7, 1975, inclusive. The investigators based this definition on legal dates of service set forth in 38 Code of Federal Regulations (CFR) 3.2 - Periods of war, but broadened the definition of sites of military service that constituted war zones based on written historical accounts and input from Vietnam Veterans.
62661690|NCT02825602||Blue Water Navy Vietnam Veterans|Blue Water Navy Veterans are defined as Veterans who served aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975 and who never served ashore or on inland waterways of Vietnam.
62099311|NCT06329804|ACTIVE_COMPARATOR|Four Sessions/Week|Participants allocated to this group will complete 4-weeks of isometric handgrip exercise training with a frequency of four sessions/week
62099312|NCT03014687|PLACEBO_COMPARATOR|Standard Nasal Care|One dose of preoperative intravenous (iv) antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Postoperative antibiotics: Study participants will receive one dose only of postoperative intravenous antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg \[cephalosporin allergic patients\]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Placebo PO BID (twice daily) will commence on the morning of postoperative day 1 and continue for 7 days.
62294599|NCT05424393||RA Patients receiving routine treatment|During the induction phase, the dose of YISAIPU is 50mg/wk. Patients who achieved clinical remission or low activity after 24 weeks of induction treatment can enter the maintenance phase. Those who fail to succeed in induction treatment will not be followed up. During the maintenance phase, the dose of YISAIPU could be either 50mg/wk or 25mg/wk. Patients will be followed up regularly for 2.5 years.
61910140|NCT04672707|EXPERIMENTAL|Group B|Bromhexine Hydrochloride Tablet, 48 mg, 8 mg 6 tablets, three times a day, continuous service within 2 days
61910141|NCT04672707|EXPERIMENTAL|Group C|Bromhexine Hydrochloride Tablet, 64 mg ,8 mg spec 8 tablets ,3 times daily ,2 days in succession)
61910142|NCT04672707|EXPERIMENTAL|Group D|Bromhexine Hydrochloride Tablets, 80 mg ,8 mg Standard preparation 10 tablets ,3 times a day ,2 day
61910143|NCT04337710|EXPERIMENTAL|Exclusive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 60-80 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
61910144|NCT04337710|ACTIVE_COMPARATOR|Progressive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 20-30 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
61910145|NCT04721561||Chronic stroke patients|Patients who are at least 6 months after a first unilateral stroke
61910146|NCT04721561||Healthy controls|Healthy subjects with no history of any neurological condition and who are in the same age group as the chronic stroke patients
62294600|NCT03381443||ERC|all students assessed by the methods used by the European Resuscitation Council
62294601|NCT03381443||AHA|all students assessed by the methods used by the American Heart Association
62661691|NCT02825602||Vietnam era Veterans|Vietnam era Veterans served in locations around the world OTHER than on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos or aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975.
62661692|NCT02825602||Non-military U.S. public|Non-military U.S. public are individuals who were born before 1958, never served in the U.S. military, and are age- and gender-matched (by the study investigators) to Vietnam War Theater Veterans.
62661693|NCT01021384|OTHER|Problem Solving Education|
62661694|NCT02162563|EXPERIMENTAL|Arm B: FOLFOXIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.~Intervention: FOLFOXIRI with bevacizumab"
62661695|NCT02162563|ACTIVE_COMPARATOR|Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
62661696|NCT02162563|EXPERIMENTAL|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.~Intervention: FOLFOX/FOLFIRI with panitumumab"
61910147|NCT03137667|NO_INTERVENTION|Control|No school-located influenza vaccination clinic
61910148|NCT03137667|EXPERIMENTAL|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
61910149|NCT06036004|ACTIVE_COMPARATOR|Study Product Intervention: intranasal OXT|Intranasal OXT spray of 40 IU per ml (Syntocinon®).
61910150|NCT06036004|PLACEBO_COMPARATOR|Control Intervention: placebo nasal spray|The placebo nasal spray will be identical in volume, labelling, container system, and other features.
62294602|NCT04080011|EXPERIMENTAL|NP-PWD application|All patients enrolled into the study will have the negative pressure- platform wound device applied to their surgical incision.
61910151|NCT01235598|OTHER|Placebo followed by Certolizumab Pegol (CZP)|Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
61910152|NCT01235598|EXPERIMENTAL|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40
62308156|NCT02604719|EXPERIMENTAL|tanexamic acid and Ethamsylate|10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth
62308157|NCT02604719|PLACEBO_COMPARATOR|placebo|10 ml normal saline will be administered intravenously just after birth
62308158|NCT02124850|EXPERIMENTAL|Motolimod plus cetuximab|Cohort 1: motolimod plus cetuximab
62661697|NCT02162563|ACTIVE_COMPARATOR|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
62661698|NCT02229604|EXPERIMENTAL|EA group|Patients choose this group will receive EA as a combination. Beside of EA, participants could receive oral medicine as the same as that of the drug group. The EA regimen has two point formulae, i.e. A (BL33) and B (ST25, EX-CA1 and RN4). The two formulae will be used alternatively. One session will last for 20 minutes, 5 sessions per week for the first 4 weeks and 3 sessions per week later (44 sessions in all).
62661699|NCT02229604|ACTIVE_COMPARATOR|drug group|Hormone replacement therapy (HRT), DHEA and herb decoction are allowed to be used for this group. Treatment course is not fixed. Immunosuppressive agents are not allowed.
62308159|NCT02124850|EXPERIMENTAL|Motolimod, cetuximab, and nivolumab|Cohort 2: motolimod, cetuximab, and nivolumab
62661700|NCT06454539|EXPERIMENTAL|F-IMT Group|Participants in this group will apply functional IMT as a supervised program 3 days a week, and IMT as a home program on 2 different days. In functional IMT, participants will perform breathing exercises with the device while simultaneously performing exercises based on the neurodevelopmental treatment approach given below.
62661701|NCT06454539|ACTIVE_COMPARATOR|IMT Group|Participants in this group will perform supervised neurodevelopmental treatment approach-based exercises and IMT 3 days a week, and IMT as a home program on 2 different days.
62661702|NCT01177176|OTHER|Standard Care|Standard tobacco counseling provided to hospital inpatients as part of routine, clinical-guideline compliant care in the study hospital. No post-discharge treatment is offered in this arm.
62661703|NCT01177176|EXPERIMENTAL|Extended Care Management|In addition to Standard Care, subjects in this arm receive Extended Care Management intervention to facilitate the continued use of smoking cessation treatment (counseling and medication use) after hospital discharge. This consists of 3 months of telephone-based contact after discharge.
62661704|NCT05911568||Stroke patients with moderate-to-severe pre-stroke disability|Patients with pre-stroke modified Rankin scale score 3 or 4, presenting with a anterior circulation large vessel occlusion stroke within 24 hours of last known well
62661705|NCT06398288|EXPERIMENTAL|Test group (Oracell group)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health) + dermal matrix on the buccal aspect (Oracell, Lifenet Health)
62661706|NCT06398288|EXPERIMENTAL|Control group (no Oracell group)|Control group: Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health)
62661707|NCT02505061|EXPERIMENTAL|Program|"The participants performance is indicative of the extent to which early power mobility training is feasible for both young infants and up to 3-year-old child with mobility Disabilities.Parents/caregivers and occupational therapists will be responsible for theHospital-based Program and Regular Therapy Program service respectively"
62661708|NCT02593864|EXPERIMENTAL|Variable-Stiffness Shoe|Subjects will wear a load-modifying variable-stiffness shoe for 6 months
62661709|NCT03412032|OTHER|ERC|Assessment as used by the European Resuscitation Council
62661710|NCT03412032|OTHER|AHA|Assessment as used by the American Heart Association
62661711|NCT01130402||Neck masses|Patients with previously untreated neck masses
62661712|NCT02194075|ACTIVE_COMPARATOR|Fluvoxamine+Methylphenidate Hydrochloride|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks."
62661713|NCT02194075|PLACEBO_COMPARATOR|Fluvoxamine+sugar pill|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~sugar pill: tablet, 1-2 tablets/d, were treated with a course of 8 weeks."
62661714|NCT04808921|EXPERIMENTAL|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
62661715|NCT04810962|EXPERIMENTAL|APP13007 0.05% BID|1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
62661716|NCT04810962|PLACEBO_COMPARATOR|Matching Vehicle Placebo|1 drop matching vehicle placebo twice daily for 14 days to study (operated) eye
62661717|NCT00800540|OTHER|AZARGA/COMBIGAN|AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
62661718|NCT00800540|OTHER|COMBIGAN/AZARGA|COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
62661719|NCT05791110|OTHER|Pancreatic exocrine function|Strict clinical diagnosis and fecal pancreatic elastase 1 test were performed for each subject (including PEI patients (n=525) and non-PEI patients (n=528))
62661720|NCT03390660||birth cohorts|born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014
62661721|NCT03816917||topical treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: only topical/UV therapy (no systemic therapy)
62308160|NCT05552638|EXPERIMENTAL|Senior Center Members|Participants who are using the provided telehealth stations in senior centers.
62661722|NCT03816917||systemic treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy, but no biologicals. Topical therapy is permitted.
62661723|NCT03816917||biologics|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy with biologics. Other systemic and topical therapy is permitted.
62661724|NCT02115698|ACTIVE_COMPARATOR|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
62661725|NCT02115698|EXPERIMENTAL|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
62661726|NCT02115698|ACTIVE_COMPARATOR|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
62661727|NCT02115698|ACTIVE_COMPARATOR|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
62661728|NCT02115698|PLACEBO_COMPARATOR|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
62661729|NCT03185351|ACTIVE_COMPARATOR|BUPIVACAINE|"patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.~."
62737059|NCT00005699||Controls|described as non-hypertensive according to AHA guidelines at time of trial
61910153|NCT00545870|EXPERIMENTAL|A|Bevacizumab treatment
61910154|NCT00545870|ACTIVE_COMPARATOR|B|Ranibizumab treatment
61910155|NCT01515020|ACTIVE_COMPARATOR|vancomycin monotherapy|vancomycin monotherapy: standard therapy
62661730|NCT03185351|ACTIVE_COMPARATOR|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
61910156|NCT01515020|EXPERIMENTAL|daptomycin monotherapy|daptomycin monotherapy: experimental therapy
61910157|NCT00104598|ACTIVE_COMPARATOR|Gain Framed Absitnence Program|Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
61910158|NCT00104598|ACTIVE_COMPARATOR|Loss Framed Abstinence Program|Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
61910159|NCT01236547|EXPERIMENTAL|Arm I (paclitaxel, pazopanib hydrochloride, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
61910160|NCT01236547|ACTIVE_COMPARATOR|Arm II (paclitaxel, placebo, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and placebo PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
62099313|NCT03014687|EXPERIMENTAL|Standard Nasal Care + Oral Antibiotics|One dose of preoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg) will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Participants will receive 1 dose only of postoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg \[cephalosporin allergic patients\]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Oral antibiotics will commence on the morning of postoperative day 1; this group will receive oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.
62099314|NCT01441778|ACTIVE_COMPARATOR|NSS irrigation salt|
62099315|NCT01441778|EXPERIMENTAL|BHS nasal irrigaiton salt|
62294603|NCT02226341|ACTIVE_COMPARATOR|CellCept daily & ACTHar gel biw|Patients will be treated with CellCept 3 grams daily and ACTHar gel 80 U biw for 3 months per Aim 1. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
62308161|NCT01635569|ACTIVE_COMPARATOR|OCD-affected subjects (Group 1)|OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
61910161|NCT03844711|EXPERIMENTAL|Transcutaneous electrical diaphragmatic stimulation (TEDS)|For transcutaneous electrical diaphragmatic stimulation, surface electrodes will be used that will be positioned at the transcutaneous motor points of the diaphragm.
61910162|NCT03844711|EXPERIMENTAL|Inspiratory Muscle training (IMT)|The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax.
61910163|NCT03844711|ACTIVE_COMPARATOR|Conventional physiotherapy|The protocol of physiotherapy by the physiotherapists of HCPA will be twice a day and consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
61910164|NCT00816023|EXPERIMENTAL|Ecallantide Low Dose|target steady state concentration of 0.15 mg/L
61910165|NCT00816023|EXPERIMENTAL|Ecallantide Medium Dose|target steady state concentration of 0.75 mg/L
62099316|NCT03412838|ACTIVE_COMPARATOR|Cortico-Cancellous|Graft surgery with cortico-cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
62661731|NCT03185351|ACTIVE_COMPARATOR|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
62661732|NCT04393948|EXPERIMENTAL|No irradiation|
62661733|NCT04393948|EXPERIMENTAL|100 cGy single lung irradiation|100 cGy single lung radiation
62661734|NCT04393948|EXPERIMENTAL|100 cGy bilateral lung irradiation|100 cGy bilateral lung radiation
62661735|NCT01435941||Respondents who report episodic migraines (EM)|Survey respondents whose headaches meet the diagnostic criteria for migraine and report that they experienced between 1 and 14 headache days in the month prior to the survey administration
62661736|NCT04375046|EXPERIMENTAL|Experimental: rbACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
62661737|NCT04375046|NO_INTERVENTION|No Intervention: Control group|Standard of care; no placebo
62661738|NCT01089595|ACTIVE_COMPARATOR|Nilotinib|Nilotinib 400 mg po bid
62661739|NCT01089595|ACTIVE_COMPARATOR|Nilotinib + Imatinib|Nilotinib 400 mg BID with Imatinib 400 mg daily
62661740|NCT06255483|OTHER|Osteoperiosteal clavicular flap|Harvesting of a pedicled osteoperiosteal clavicular flap and clarification of its vascular supply
62661741|NCT04017455|EXPERIMENTAL|bevacizumab and atezolizumab|1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy
62661742|NCT01502852||OEF/OIF Veterans with TBI|
62661743|NCT01502852||Family Members and Friends|Family Members and Friends of OEF/OIF Veterans with TBI
62661744|NCT01502852||Community Mental Health Center Providers|Community Mental Health Center providers working with OEF/OIF Veterans with TBI
62661745|NCT02468453|EXPERIMENTAL|Cohort 1 -facial skin disorders|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of facial skin disorders including photo-damage, age spots, lentigos, solar telangiectasia and general facial telangiectasia
62661746|NCT02468453|EXPERIMENTAL|Cohort 2 - leg veins|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of leg veins of diameter of at least 1mm, i.e., venulectasia and reticular leg veins.
61910166|NCT00816023|EXPERIMENTAL|Ecallantide High Dose|target steady state concentration of 2.25 mg/L
61910167|NCT00816023|PLACEBO_COMPARATOR|Placebo|placebo
61910168|NCT03830905|EXPERIMENTAL|XC221|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
61910169|NCT03830905|PLACEBO_COMPARATOR|Placebo|Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
62661747|NCT02468453|EXPERIMENTAL|Cohort 3-general skin rejuvenation|Pulsed dye laser/bipolar radiofrequency (Velos) treatment treatment of general skin rejuvenation including Rosacea, erythematous scars (including acne), and erythematous striae (subjects enrolled in this group must have at least two of the above mentioned treatment indications.
62661748|NCT02468453|EXPERIMENTAL|Cohort 4-improving skin laxity|Velos (Bipolar radiofrequency only) treatment for improving skin laxity or skin tightness/firmness
62661749|NCT04051801|EXPERIMENTAL|Dose Escalation of VU319 - Dose 1|
62661750|NCT04051801|PLACEBO_COMPARATOR|Dose Escalation of Placebo - Dose 1|
62661751|NCT04051801|EXPERIMENTAL|Dose Escalation of VU319 - Dose 2|
62661752|NCT04051801|PLACEBO_COMPARATOR|Dose Escalation of Placebo - Dose 2|
62661753|NCT04051801|EXPERIMENTAL|Dose Escalation of VU319 - Dose 3|
62661754|NCT04051801|PLACEBO_COMPARATOR|Dose Escalation of Placebo - Dose 3|
62661755|NCT02382302|EXPERIMENTAL|Telemedicine system|Telemedicine system
62737060|NCT05415267|ACTIVE_COMPARATOR|Group 1 Arm A|Immediate SARS-CoV-2 booster at week 0 and booster of combined diphtheria toxoid/tetanus toxoid (dT vaccine) at week 24.
62737061|NCT05415267|ACTIVE_COMPARATOR|Group 1 Arm B|dT vaccine at week 0 and SARS-CoV-2 deferred booster at week 24.
62737062|NCT05415267|ACTIVE_COMPARATOR|Group 2 Arm C|Immediate SARS-CoV-2 booster at week 0.
62737063|NCT05415267|ACTIVE_COMPARATOR|Group 2 Arm D|Delayed SARS-CoV-2 booster at week 24
62737064|NCT05284500||Pediatric cardiac surgery patients|Patients undergoing pediatric cardiac surgery with cardiopulmonary bypass between 2008 and 2018 at our institution.
62737065|NCT02792764||Port|Subjects receiving chemotherapy through a port
62737066|NCT02792764||Peripheral Intravenous (PIV) Lines|Subjects receiving chemotherapy through a peripheral IV
62737067|NCT06643858||Nationwide retrospective neuroimaging data collection (5,000 participants)|The primary imaging modalities include 3D T1-weighted imaging (3D T1WI) and 3D fluid-attenuated inversion recovery (3D FLAIR), along with basic demographic information, health status, and neuropsychological assessments.
62737068|NCT06643858||Nationwide prospective neuroimaging cohort of the Chinese normal population (5,000 participants).|This cohort will include multimodal imaging sequences (3D T1-weighted imaging, 3D FLAIR, diffusion kurtosis imaging \[DKI\], arterial spin labeling \[ASL\], vascular water exchange imaging \[VEXI\], and resting-state functional MRI \[rest-fMRI\]). Detailed demographic information, neuropsychological assessments, standardized questionnaires, and basic physical examinations will also be collected. Multimodal neuroimaging data and neuropsychological assessments will be followed up twice (at 1 year and 2 years).
62737069|NCT00585988|OTHER|1|
62737070|NCT00585988|OTHER|2|
62737071|NCT06140368|EXPERIMENTAL|Experimental group|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
62737072|NCT06140368|NO_INTERVENTION|Control group|Patients will not use virtual reality glasses during trigger point injection.
62737073|NCT03572569||Index patients|Patients ≤18 years with primary cardiomyopathy
62737074|NCT03572569||First-degree family members|Parents and siblings of index patients
62737075|NCT02805465|EXPERIMENTAL|HBP Group|CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.
62099317|NCT03412838|ACTIVE_COMPARATOR|Cancellous|Graft surgery with cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
62099318|NCT04635111||Symptomatic TGCT Participants|Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).
62294604|NCT02226341|ACTIVE_COMPARATOR|CellCept daily & ACTHar gel qod|Patients will be treated with CellCept 3 grams daily for 3 months, and ACTHar gel 80 U qod for the first month and ACTHar gel 80 U biw for the following 2 months per Aim 2. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
62294605|NCT04159090|EXPERIMENTAL|Prostate cancer patients|
62661756|NCT04304703||Internal Medicine resident subjects|Subjects who are categorical Internal Medicine residents at Penn State Hershey Medical Center (PGY1-PGY3), and meet inclusion/exclusion criteria, will be enrolled in this study and wear the WHOOP strap 3.0 for real-time measurement of physiologic metrics.
62661757|NCT01699828|EXPERIMENTAL|Buspirone 120 mg|Buspirone 120 mg (encapsulated).
62661758|NCT01699828|EXPERIMENTAL|Buspirone 60 mg|Buspirone 60 mg (encapsulated)
62661759|NCT01699828|PLACEBO_COMPARATOR|Placebo|Placebo (encapsulated)
62661760|NCT01699828|EXPERIMENTAL|Buspirone 30 mg|Buspirone 30 mg (encapsulated).
62661761|NCT04908033||myocardial pacing group|patients with the pacing lead placed into the right ventricle to obtain myocardial capture
62661762|NCT04908033||physiological pacing group|patients with the pacing lead placed into the His bundle or left bundle branch area
62661763|NCT02530242|OTHER|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
62661764|NCT02530242|OTHER|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
62661765|NCT02082951|EXPERIMENTAL|Group 2: empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
62661766|NCT02082951|EXPERIMENTAL|Group 1: empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
62661767|NCT02909426||Women aged 40-59|"Asymptomatic women aged 40-59 who participate in the National Cancer Screening Program in Korea and agreed with participating in this study will be the cohort.~The participants' digital mammography and ultrasonography will be interpreted combinedly by radiologists who perform the screening sonography and the participants' digital mammography will be interpreted independently by other radiologists who do not perform the screening sonography."
62661768|NCT01986712||Intron A, HDI|High-dose interferon alfa (Intron A, HDI)
62661769|NCT01986712||Sylatron|Pegylated alfa-interferon 2b (Sylatron, PEG IFN)
62661770|NCT02286674|EXPERIMENTAL|Tablet for watching movie|The study group will receive standard of care in addition to a tablet to watch movies and/or TV
62661771|NCT02286674|NO_INTERVENTION|Standard of care - no tablet|The control group will receive standard of care only.
62661772|NCT01410253|EXPERIMENTAL|Group 1|
62661773|NCT01410253|EXPERIMENTAL|Group 2|
62661774|NCT01410253|EXPERIMENTAL|Group 3|
62661775|NCT01410253|PLACEBO_COMPARATOR|Group 4|
62661776|NCT04837170|EXPERIMENTAL|S (+)-Ketamine group|"Drug: Conventional therapy + S (+)-Ketamine In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection,but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Bolus intravenous injection before skin incision, the dose is 0.1\~0.5 mg/kg;~2. Bolus intravenous injection (dose 0.1\~0.5 mg/kg) before skin incision +continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation;~3. Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h."
61910170|NCT04962256||Study group|Patients with degenerative CSM or OPLL undergoing C3-7 open-door laminoplasty
61910171|NCT01416597||Cross-Protection Studies|
62661777|NCT04837170|ACTIVE_COMPARATOR|Control group|Drug: Conventional therapy Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
62661778|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
62661779|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
62661780|NCT02210754|EXPERIMENTAL|E-cigarette 1|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
62661781|NCT02210754|EXPERIMENTAL|E-cigarette 2|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/propylene glycol (PG) vehicle)
61910172|NCT00384683||Endothelial Dysfunction|Participants are scheduled for major chest (lung or esophagus) surgery or are a healthy volunteer. A blood test will quantify the number of cells that are destined to become endothelial cells.
62099319|NCT04887285|EXPERIMENTAL|Virtual reality (VR)|Subjects in the VR group will be fitted with an HTC headset and headphones with disposable ear covers. They will choose from a menu of 6 different programs. They will also receive 1% superficial anesthesia.
62099320|NCT04887285|ACTIVE_COMPARATOR|Sedation|Conscious sedation will be accomplished by the use of midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). All medications will be titrated to conscious sedation by a board-certified anesthesiologist. Subjects will also receive 1% superficial anesthesia.
62099321|NCT04887285|OTHER|Standard care|Patients in this arm will be administered only 1% lidocaine as superficial anesthesia, similar to the other 2 arms.
62099322|NCT01919619|EXPERIMENTAL|Treatment (lenalidomide and ipilimumab)|Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62661782|NCT02210754|EXPERIMENTAL|E-cigarette 3|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
61910173|NCT04049682||Pre Time-change|Daily activity, sleep duration, subjective sleepiness, and response time before change in school start time
62099323|NCT06565988|OTHER|Investigational Medical Device|All eligable subjects desiring correction of cheek volume will receive intradermal injection of Decoria Voluma on either one or both sides of the face.
62661783|NCT02210754|EXPERIMENTAL|E-cigarette 4|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
62099324|NCT05825417|ACTIVE_COMPARATOR|Arm A (selexipag/riociguat)|Baseline - established PDE/ERA therapy Week 1 - initiate OPA (PDE/ERA/OPA therapy) Weeks 2-12 - uptitration of OPA to maximal therapy (PDE/ERA/OPA therapy) Weeks 13-14 - reduce OPA (PDE/ERA/OPA therapy) Week 15 - washout OPA (PDE/OPA therapy) Week 16 - washout PDE (ERA therapy) Week 17 - initiate sGCS (ERA/sGCS therapy) Weeks 18-27 - uptitration of sGCS to maximal therapy (ERA/sGCS therapy)
62099325|NCT05825417|ACTIVE_COMPARATOR|Arm B (riociguat/selexipag)|Baseline - established PDE/ERA therapy Week 1 - washout PDE (ERA therapy only) Week 2 - initiate sGCS (ERA/sGCS therapy) Weeks 3-12 - uptitration of sGCS to maximal therapy (ERA/sGCS therapy) Week 13 - reduce sGCS (ERA/sGCS therapy) Week 14 - reduce and washout sGCS (ERA therapy) Week 15 - initiate PDE (PDE/ERA therapy) Week 16 - initiate OPA (PDE/ERA/OPA therapy) Weeks 17-27 - uptitration of OPA to maximal therapy (PDE/ERA/OPA therapy)
62099326|NCT04459832|EXPERIMENTAL|15 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 15 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
62099327|NCT04459832|EXPERIMENTAL|30 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 30 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
62099328|NCT04459832|EXPERIMENTAL|60 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 60 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
62099329|NCT04459832|SHAM_COMPARATOR|control|The control group followed the same procedures except that no stretching force was applied at the end
62099330|NCT03867617|EXPERIMENTAL|Study group|Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients
62099331|NCT03867617|ACTIVE_COMPARATOR|Control group|Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients
62294606|NCT05397236|ACTIVE_COMPARATOR|Bupivacaine Magnesium sulphate group|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
61910174|NCT04049682||Post Time-change|Daily activity, sleep duration, subjective sleepiness, and response time after change in school start time
61910175|NCT04120103|EXPERIMENTAL|Doll therapy|"Experimental: Doll Therapy Intervention A total of 30 patients were included in the study. All patients that meet the study inclusion criteria will be included in the study The patients in the intervention group will have Doll therapy for 60 days and weekly patient visits. The study will be started with control group patients. At the beginning of the study and after 60 days, Introductory Information Form, Mini Standard Mini Mental Test and Cohen-Mansfield Agitation Inventory will be applied to patients in intervention and control groups for data collection. Dementia patients will be given a baby, patients will be followed for two months. There will be monitoring once a week."
62661784|NCT02210754|EXPERIMENTAL|E-cigarette 5|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
62661785|NCT02210754|ACTIVE_COMPARATOR|Combustible Cigarette|Marlboro Cigarette
62661786|NCT01939392|EXPERIMENTAL|Renal Denervation|Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
62661787|NCT01939392|NO_INTERVENTION|Optimal Medical Therapy|Subjects randomized to the control arm will be maintained on antihypertensive medications.
62661788|NCT01301092|EXPERIMENTAL|Part A: LY2189265 intravenous|Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.
62737076|NCT02805465|ACTIVE_COMPARATOR|BiVP Group|CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.
62737077|NCT03999099|PLACEBO_COMPARATOR|Placebo|
62661789|NCT01301092|EXPERIMENTAL|Part B: LY2189265 subcutaneous, intravenous|Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
62661790|NCT01301092|EXPERIMENTAL|Part C: LY2189265 subcutaneous, intramuscular|Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
62661791|NCT05967091|EXPERIMENTAL|Targeted Lung Denervation|Targeted lung denervation (TLD) with the Ryme Medical Lung Denervation System
62661792|NCT06099483|ACTIVE_COMPARATOR|action observation and motor imegary|The motor imagery and action observation group was asked to watch a previously recorded breathing exercise video and imagine it as if they were doing it themselves.
62661793|NCT06099483|ACTIVE_COMPARATOR|Active Breathing Exercise Group|Respiratory control, diaphragmatic breathing and thoracic expansion exercises were actively performed for 10 repetitions each.
62099332|NCT04308447|EXPERIMENTAL|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
62099333|NCT04083599|EXPERIMENTAL|Monotherapy - Dose Escalation and Dose Expansion Parts|
62099334|NCT04083599|EXPERIMENTAL|Combination Therapy - Safety Run-in and Expansion Parts|
62099335|NCT06615453|EXPERIMENTAL|Tixel treatment|
62099336|NCT06615453|SHAM_COMPARATOR|Sham treatment|
62099337|NCT04389255||Healthy people|65 people will be included.
62294607|NCT05397236|ACTIVE_COMPARATOR|Bupivacaine Dexamethasone group|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
62294608|NCT05397236|ACTIVE_COMPARATOR|bupivacaine saline group|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
62661794|NCT06099483|ACTIVE_COMPARATOR|Control group|Participants will remain in a sitting position throughout the entire experimental group application. Participants were prevented from making physical movements and were asked to keep their minds closed by closing their eyes and not thinking about anything.
62099338|NCT04676347||Eligible population|All patients admitted in the semi-intensive care units attending the study. Be basing on the average number of patients yearly treated in those units, we expect to have at least 39000 patients during the 5 years of the study.
62099339|NCT06711146|EXPERIMENTAL|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
62099340|NCT01365338|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo as a single oral dose.
62099341|NCT01365338|EXPERIMENTAL|Cohort 1|Participants will receive 0.075 milligrams (mg) of PF-04958242 as a single oral dose.
61910176|NCT04120103|ACTIVE_COMPARATOR|Routine nursing care|"The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.~There was no intervention other than routine care. The patients were followed up for two months.The patients were followed up for two months.Data collection forms were applied at the beginning, first and second months of the study."
62099342|NCT01365338|EXPERIMENTAL|Cohort 2|Participants will receive 0.15 mg of PF-04958242 as a single oral dose.
62661795|NCT00886236|ACTIVE_COMPARATOR|1 Preoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
62661796|NCT00886236|EXPERIMENTAL|2 Preoperative and Postoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)
62661797|NCT00886236|PLACEBO_COMPARATOR|3 Preoperative and Postoperative Placebo Liquid|Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
62099343|NCT03023059|EXPERIMENTAL|Escalating dose of carbidopa-levodopa|The intervention is that patients will receive open label, commercially available Carbidopa-Levodopa 25 Mg-100 Mg oral tablet, once daily hs for one month, followed by one tablet dosed three times daily, in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg).
62466781|NCT00216983||3|We wull evaluate the rate of proline de novo synthesis from glutamate or ornithine in burn patients when the patients are receiving regular TPN or TPN depleted proline-arginine-glutamate.
62661798|NCT00498550|EXPERIMENTAL|Clozapine|Clozapine, Clozaril
62661799|NCT00498550|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual with any antipsychotic other than Clozapine.
62661800|NCT03286504|NO_INTERVENTION|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
62661801|NCT03286504|EXPERIMENTAL|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take \~ 2 hours.
62661802|NCT04302285|EXPERIMENTAL|Exercise trial|In this trial, participants were asked to exercise for one hour under controlled laboratory conditions. Participants were exercising on the treadmill at speed and grade corresponding to 60% of their V̇O2max. Participants were wearing a HR monitor and a face mask while exercising, connected to indirect calorimetry equipment. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
62661803|NCT04302285|EXPERIMENTAL|Control trial|In this trial, participants were asked to rest for one hour. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
62661804|NCT01617109|PLACEBO_COMPARATOR|Placebo|
62661805|NCT01617109|EXPERIMENTAL|Ca/Vit D|
62661806|NCT01967277|PLACEBO_COMPARATOR|Incandescent red light source|A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
62661807|NCT01967277|ACTIVE_COMPARATOR|Handi-Dome Laser|Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.
62661808|NCT06196359|EXPERIMENTAL|Combined Femoral and Popliteal nerve block|Patients who receive a Patients undergoing total knee arthroplasty received a combined femoral and popliteal nerve block (single-shot of each) during the surgical procedure.
62661809|NCT06196359|NO_INTERVENTION|Control group|Patients undergoing total knee arthroplasty and didn\&#39;t receive pain block.
62661810|NCT01233830|EXPERIMENTAL|1|
62661811|NCT01233830|PLACEBO_COMPARATOR|2|
61910177|NCT00853216|EXPERIMENTAL|A|Oxycodone hydrochloride tablet 30 mg
62099344|NCT02718469|EXPERIMENTAL|Ebola Vaccine - low dose|Low Dose Zaire Ebola Vaccine
62099345|NCT02718469|EXPERIMENTAL|Ebola Vaccine - mid dose|Mid Dose Zaire Ebola Vaccine
62099346|NCT02718469|EXPERIMENTAL|Ebola Vaccine - high dose|High Dose Zaire Ebola Vaccine
62099347|NCT02718469|PLACEBO_COMPARATOR|Placebo|Placebo
62099348|NCT03378479|OTHER|SOC + 'Posaconazole 18 MG/ML'|standard of care (SOC) treatment for influenza pneumonia +posaconazole 2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)
62099349|NCT03378479|OTHER|Standard of Care|standard of care treatment for influenza pneumonia (at the investigators discretion)
62466782|NCT01533298|EXPERIMENTAL|CombiflexOmega peri|
62466783|NCT01533298|ACTIVE_COMPARATOR|SmofKabiven peripheral|
62466784|NCT01019889|EXPERIMENTAL|Placebo|Placebo (encapsulated starch + lactose)
62661812|NCT06293144|EXPERIMENTAL|ciprofol-assisted sedation 1|Adjusting the dose of ciprofol-assisted sedation in knee arthroplasty on a case-by-case basis
62661813|NCT03620279|EXPERIMENTAL|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
62661814|NCT04073277|EXPERIMENTAL|SCF-N-treated needle acupuncture|For each participant, one hand was randomly assigned to the experimental group with SCF-N-treated needle acupuncture .
62661815|NCT04073277|SHAM_COMPARATOR|untreated needle acupuncture|The other hand of participant in experimental group was assigned to the control group with untreated needle acupuncture.
62661816|NCT05370482|EXPERIMENTAL|MRI-guided focal laser ablation|
62661817|NCT04125459||Individuals with Gout|This arm will be getting a biopsy as well as a blood draw
61910178|NCT00853216|ACTIVE_COMPARATOR|B|Roxicodone™ tablet 30 mg
61910179|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
62661818|NCT04125459||Controls|These individuals will not be getting a joint biopsy and will just get a blood draw
61910180|NCT00344890|EXPERIMENTAL|Preservon|
62099350|NCT05588141|EXPERIMENTAL|1|Escalation/de-escalation dose levels of zotiraciclib given in 28 day cycles
62099351|NCT05588141|EXPERIMENTAL|2|Estimated RP2D of zotiraciclib given in 28 day cycles
62099352|NCT05588141|EXPERIMENTAL|3|One RP2D dose of zotiraciclib given on the day prior to brain tumor biopsy or resection, a continuation of treatment with estimated RP2D of zotiraciclib given in 28 days cycles following the recovery of the surgery
62099353|NCT06713057|EXPERIMENTAL|Organoid-guided chemotherapeutic group|Patients who take the recommended chemothetapy drugs regularly based on sensitivity analysis.
62099354|NCT03660917|EXPERIMENTAL|Riluzole|Riluzole 50 mg twice daily for 12 months in the treated group. In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (RHDD; 100 mg).
62099355|NCT03660917|PLACEBO_COMPARATOR|Placebo + riluzole|Placebo twice daily for 6 months and riluzole 50 mg twice daily for the following 6 months in the comparison group
62099356|NCT02727621|ACTIVE_COMPARATOR|Dexmedetomidine group|
62099357|NCT02727621|ACTIVE_COMPARATOR|Propofol group|
62099358|NCT03530553|EXPERIMENTAL|Treatment arm|The treatment arm will receive the HMS as well as standard of care of the weight management program.
62099359|NCT03530553|NO_INTERVENTION|Control arm|The control arm will not receive the HMS and will receive standard of care.
62099360|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
62099361|NCT05484726|EXPERIMENTAL|Intervention group (Group 1)|"* Maternal involvement shall be in three stages for the intervention group as~  * Observer status~ * Performing under supervision~ * Independent~* Study groups for sensory motor stimulation (5 minutes) + pacifier (2 minutes)~Intervention group (Group I): by mothers~1. T1: Nurses performing all steps while mother observer status~2. T2: Nurses perform all steps in front of the mother and a pacifier will be offered by the mother~3. D1: Mother performs all steps and oral milk shall be offered by the nurse while the mother observes.~4. D2: Mother performing all steps and offering oral milk while the nurse is supervising~5. D3: Mother performing all steps independently"
62099362|NCT05484726|SHAM_COMPARATOR|Control group (Group 2)|All steps will be the same as the intervention group and shall be performed by staff nurses
62294609|NCT04268888|ACTIVE_COMPARATOR|TACE/TAE Alone|Transarterial Chemoembolisation (TACE) and/or Transarterial Embolisation (TAE) Alone.
61910181|NCT00344890|ACTIVE_COMPARATOR|Control|
62661819|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
62661820|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
62661821|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
62661822|NCT01149967|EXPERIMENTAL|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
61910182|NCT01975324|EXPERIMENTAL|dalfampridine (ampyra)|Dalfampridine (ampyra) 10mgs twice a day (b.i.d.)for two weeks
61910183|NCT01975324|PLACEBO_COMPARATOR|Placebo|placebo (sugar Pill) twice a day (b.i.d.)for two weeks
61910184|NCT02512627|ACTIVE_COMPARATOR|Cognitive training group (Cog)|The BrainHQ program will be used to train different cognitive functions of the participants. The participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions. The tasks will become more difficult as the participants progress in their abilities.
61910185|NCT02512627|ACTIVE_COMPARATOR|Physical exercise group (PE)|The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
62099363|NCT03571243||smokers|no intervention
62099364|NCT03571243||never-smokers|no intervention
62099365|NCT05929807|EXPERIMENTAL|TransCon CNP 100 mcg|TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
62099366|NCT04269850|EXPERIMENTAL|FMT+ruxolitinib+steroids|ruxolitinib 10 mg bid, fecal microbiota transplantation 2 caps/kg single dose, methylprednisone 0.5 mg/kg bid
62099367|NCT06622408|EXPERIMENTAL|Scheduled caesarean delivery|Use of virtual reality headset during patient admission to the OR for cesarean section.
62099368|NCT02121704|NO_INTERVENTION|Controll Group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL NOT BE USED during the investigation.
62294610|NCT04268888|EXPERIMENTAL|TACE/TAE and Nivolumab|As above for TACE/TAE. Nivolumab adminstered as a flat dose of 480mg IV.
62661823|NCT01149967|ACTIVE_COMPARATOR|Celexa|Celexa 40 mg Tablets of Forest Labs
61910186|NCT02512627|EXPERIMENTAL|Sequential training group (Seq)|The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
61910187|NCT02512627|EXPERIMENTAL|Dual-task training group (Dual)|In this group, the participants will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance.
61910188|NCT02032043||Annual MDA treated Group|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
61910189|NCT02032043||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
61910190|NCT03706547|EXPERIMENTAL|anti-CD19/BCMA CAR-T cells|"1. Chemotherapy with a classic combination with fludarabine and cyclophosphamide;~2. Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients."
61910191|NCT02728713|EXPERIMENTAL|Cranial manipulation|"Assessment for cranial strain patterns, followed by indirect cranial manipulation to treat dysfunctions found on assessment, followed by reassessment.~Repeated for a total of eight visits no less than one week apart."
62099369|NCT02121704|ACTIVE_COMPARATOR|Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL BE USED during the investigation.
62099370|NCT06121544||Cognitively unimpaired individuals with preclinical Alzheimer's disease|75% of the recruited population will be cognitively unimpaired individuals with preclinical Alzheimer's disease.
62099371|NCT06121544||Cognitively unimpaired individuals without preclinical Alzheimer's disease.|25% of the recruited population will be cognitively unimpaired individuals without preclinical Alzheimer's disease.
62099372|NCT03038256|EXPERIMENTAL|4 Cycles XELOX pre- TME|experimental group (arm B): concurrent capecitabine-based long-term radiotherapy, 4 cycles of XELOX as neoadjuvant chemotherapy and TME surgery
62099373|NCT03038256|ACTIVE_COMPARATOR|6 Cycles XELOX post- TME|control group (arm A): concurrent capecitabine-based long-term radiotherapy, TME surgery and 6 cycles of XELOX as adjuvant chemotherapy.
62099374|NCT06071468||Ultrasound Guided Carpal Tunnel Release (CTR-US)|Carpal Tunnel Release using CTR-US technique
62099375|NCT06071468||Open Carpal Tunnel Release (OCTR)|Carpal Tunnel Release Using Open Carpal Tunnel Release (OCTR)
61910192|NCT02728713|SHAM_COMPARATOR|Sham/placebo|Assessment for cranial strain patterns, followed a laying on of hands, followed by reassessment. Repeated for a total of eight visits no less than one week apart.
62099376|NCT06071468||Endoscopic Carpal Tunnel Release (ECTR)|Carpal Tunnel Release Using Endoscopic Carpal Tunnel Release (ECTR)
62099377|NCT04515797|EXPERIMENTAL|Treatment with Direct Acting Antiviral for HCV|4 week treatment period with glecaprevir and pibrentasvir (G/P) within 24 hours of transplant
62099378|NCT06080958|ACTIVE_COMPARATOR|High negative pressure group|A high negative pressure amplitude, (75- 125 mmHg) on continuous mode, is applied over the flaps
62099379|NCT06080958|ACTIVE_COMPARATOR|Low negative pressure group|A low negative pressure amplitude, (50- \<75 mmHg) on intermittent mode, is applied over the flaps
62099380|NCT06080958|PLACEBO_COMPARATOR|Control group|Conventional dressing is applied over the flaps
62308162|NCT01635569|ACTIVE_COMPARATOR|OCD-affected subjects (Group 2)|Waitlist affected-controls awaiting a treatment spot.
62661824|NCT01107015|NO_INTERVENTION|Group 1: Usual Care|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
62737078|NCT03999099|EXPERIMENTAL|Suvorexant 10mg|Suvorexant 10mg oral dose
62737079|NCT03999099|EXPERIMENTAL|Suvorexant 20mg|Suvorexant 20mg oral dose
62737080|NCT02688504||serious road accidents|Drivers involved in serious road accidents (hospitalization \> 24 hours)
62737081|NCT02688504||non-serious road accidents|drivers involved in non-serious road accidents (hospitalization \< 24 hours).
62737082|NCT03809078|EXPERIMENTAL|68Ga RM2 first followed by 68Ga PSMA11|Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
62737083|NCT03809078|EXPERIMENTAL|68Ga PSMA11 first followed by 68Ga RM2|Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2
62737084|NCT03910790|EXPERIMENTAL|19 Gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle
62737085|NCT05351840|EXPERIMENTAL|Period I|Subject will receive Drug(LivaloV), then take it by oral, once-daily form Day 1 to Day 7
62737086|NCT05351840|EXPERIMENTAL|Period II|Subject will receive Drug(A), then take it by oral, once-daily form Day 14 to Day 23
62737087|NCT05351840|EXPERIMENTAL|Period III|Subject will receive Drug(LivaloVA), then take it by oral, once-daily form Day 24 to Day 30
62737088|NCT04094493|EXPERIMENTAL|A1|vit D + no hypocalcemia
62737089|NCT04094493|EXPERIMENTAL|A2|Vit D + hypocalcemia
62737090|NCT04094493|NO_INTERVENTION|B1|NO vit D + no hypocalcemia
62737091|NCT04094493|NO_INTERVENTION|B2|NO vit D + hypocalcemia
61910193|NCT04248725|EXPERIMENTAL|E-TIPS|The E-TIPS intervention is based upon a cognitive-behavioral intervention for pain that was developed for and shown to be effective in people with chronic pain and a physical disability such as the conditions of interest in this study. Eight, 45-minute telephone sessions will be delivered by a clinician. A patient workbook will be used to facilitate skill acquisition and rehearsal in and outside of sessions. The intervention includes education about the role of unhelpful thoughts, particularly pain catastrophizing, and unhelpful pain coping behaviors; instruction in how to identify and change unhelpful or negative thinking about pain; utilization of helpful coping strategies; relaxation techniques; behavioral activation including setting goals for physical activation, activity pacing and scheduling; and coping with pain flare-ups. Each session includes a brief relaxation exercise. Participants receive digital audio recordings of relaxation exercises to practice at home.
61910194|NCT04248725|NO_INTERVENTION|Usual care|Participants assigned to the control intervention will continue to pursue standard care (a waitlist). Waitlist control subjects will be offered the opportunity to receive the intervention following completion of the final 6-month follow up outcome assessment.
61910195|NCT02649829|EXPERIMENTAL|Single Arm|dendritic cell vaccination plus chemotherapy
61910196|NCT01503671|EXPERIMENTAL|Atorvastatin|Atorvastatin 40 mg/day for high inflammation CAPD patient
61910197|NCT01503671|NO_INTERVENTION|No intervention arm|Placebo arm without intervention
61910198|NCT03965000||Patients|Patients carrying one or both mutations.
62099381|NCT03013842|EXPERIMENTAL|Administration of Fetal Oximetry Probe|Administration of Raydiant Oximetry Sensor System on 36 weeks or greater pregnant women
62099382|NCT05304390|EXPERIMENTAL|Health services research (patient navigation intervention)|Participants receive a patient navigation intervention consisting of a series of points of contact (mostly via telephone) between the PN/TTS and includes: 1) An introduction and enrollment in LCS, 2) facilitation of a SDM visit with the LCS-dedicated nurse practitioner, 3) individual assessment of barriers and facilitators to in-person low-dose CT screening, 4) explanation of results and needed follow-up, and 5) follow-up reminders. Participants also undergo carbon monoxide measurement by exhaling into a disposable monitor for 10 seconds at the initial visit and the post-intervention visit. The PN may also provide an intervention for smoking cessation.
62099383|NCT04248829|EXPERIMENTAL|Lazertinib + Gefitinib-matching placebo|Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule
62099384|NCT04248829|ACTIVE_COMPARATOR|Gefitinib + Lazertinib-matching placebo|Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule
62661825|NCT01107015|ACTIVE_COMPARATOR|Group 2: patient intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
61910199|NCT03965000||Controls|Patients not carrying a mutation Familial renal glucosuria causing mutation in the SLC5A2 gene and without impaired glucose tolerance and type 1 or 2 diabetes mellitus.
61910200|NCT02213133|EXPERIMENTAL|Cohort 1: Head and Neck-SCC|Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than \[\<\] 100\*10\^9 per litre \[/L\]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
61910201|NCT02213133|EXPERIMENTAL|Cohort 2: Lungs-SCC|Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets \<100\*10\^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
62099385|NCT05800964|EXPERIMENTAL|Part A: Dose Exploration|Participants will receive escalating doses of AMG 305.
62099386|NCT05800964|EXPERIMENTAL|Part B: Dose Expansion|Participants with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and other solid tumors will receive the RP2D identified in Part A.
62099387|NCT02687243|EXPERIMENTAL|Interactive Virtual Application|Online application
62099388|NCT02687243|NO_INTERVENTION|Standard of Care|No intervention and Hospital Standard of Care
62099389|NCT02943382|EXPERIMENTAL|Fingerprick Autologous Blood (FAB)|Assigned treatment with FAB
62099390|NCT05926960|EXPERIMENTAL|Triplet|encorafenib and binimetinib in combination with pembrolizumab
61910202|NCT02213133|EXPERIMENTAL|Cohort 3: Esophagus-SCC|Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets \<100\*10\^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
61910203|NCT05319873|EXPERIMENTAL|Phase Ib (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib PO BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
61910204|NCT05319873|EXPERIMENTAL|Phase II, Arm C (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
61910205|NCT05319873|EXPERIMENTAL|Phase II,Arm A(ribociclib,tucatinib, trastuzumab, fulvestrant)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, trastuzumab IV over 30-90 minutes every 7 days and fulvestrant subcutaneously (SC) on days 1 and 15 of cycle 1 and day 1 of every subsequent cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
61910206|NCT05319873|ACTIVE_COMPARATOR|Phase II,Arm B(docetaxel,carboplatin,trastuzumab,pertuzumab)|Patients receive docetaxel IV over 1 hour on day 1, carboplatin IV on day 1, trastuzumab IV over 30-90 minutes on day 1, and pertuzumab IV over 1 hour on day 1. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
61910207|NCT02787239|EXPERIMENTAL|HLX01|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
61910208|NCT02787239|ACTIVE_COMPARATOR|Rituximab|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
61910209|NCT05349201||Adult R/R DLBCL cohort: KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
61910210|NCT05349201||Adult R/R DLBCL cohort: YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
61910211|NCT05349201||ALL pediatric and young adult cohort: KYMRIAH|Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) ( refractory, in relapse post transplant or in second or later relapse
61910212|NCT03364829|EXPERIMENTAL|COPD on Indacaterol/Glycopyrronium|COPD on indacaterol/glycopyrronium for 1 month
61910213|NCT02031965|EXPERIMENTAL|Treatment (oncolytic HSV-1716)|Patients receive oncolytic HSV-1716 IT and peritumorally after undergoing surgical tumor resection. Patients also receive dexamethasone IV prior to and 6 and 12 hours after surgery.
62099391|NCT05926960|ACTIVE_COMPARATOR|Doublet|ipilimumab and nivolumab
62099392|NCT00912041|OTHER|BrainGate|BrainGate Neural Interface System
62099393|NCT06696092|EXPERIMENTAL|WoundClot Surgical|If the pre- and intra-operative eligibility criteria are fulfilled, WoundClot Surgical will be applied to the index bleeding site and success in achieving hemostasis will be evaluated within 5 minutes following the application.
62099394|NCT02240875|EXPERIMENTAL|Group 1|Single dose of cAd3-EBO Z at 1 x 10\^10 vp intramuscularly
62099395|NCT02240875|EXPERIMENTAL|Group 1b|Single dose of cAd3-EBO Z at 1 x 10\^10 vp intramuscularly, followed by 4.4x10\^8 TCID50s MVA-BN® Filo
62099396|NCT02240875|EXPERIMENTAL|Group 1c|Single dose of cAd3-EBO Z at 1 x 10\^10 vp intramuscularly, followed by 2.2x10\^8 TCID50s MVA-BN® Filo
62099397|NCT02240875|EXPERIMENTAL|Group 2|Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly
62099398|NCT02240875|EXPERIMENTAL|Group 2b|Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly, followed by 4.4x10\^8 TCID50s MVA-BN® Filo
62099399|NCT02240875|EXPERIMENTAL|Group 2c|Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly, followed by 2.2x10\^8 TCID50s MVA-BN® Filo
62099400|NCT02240875|EXPERIMENTAL|Group 3|Single dose of cAd3-EBO Z at 5 x 10\^10 vp intramuscularly
62099401|NCT02240875|EXPERIMENTAL|Group 3b|Single dose of cAd3-EBO Z at 5 x 10\^10 vp intramuscularly, followed by 4.4x10\^8 TCID50s MVA-BN® Filo
62099402|NCT02240875|EXPERIMENTAL|Group 3c|Single dose of cAd3-EBO Z at 5 x 10\^10 vp intramuscularly, followed by 2.2x10\^8 TCID50s MVA-BN® Filo
62099403|NCT02240875|EXPERIMENTAL|Group 4|Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 2.2 x 10\^8 TCID50s MVA-BN® Filo at day 7
62099404|NCT02240875|EXPERIMENTAL|Group 5|Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 2.2 x 10\^8 TCID50s MVA-BN® Filo at day 14
62099405|NCT02240875|EXPERIMENTAL|Group 6|Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 4.4 x 10\^7 TCID50s MVA-BN® Filo at day 7
62099406|NCT02240875|EXPERIMENTAL|Group 7|Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 4.4 x 10\^7 TCID50s MVA-BN® Filo at day 14
62099407|NCT06712771|EXPERIMENTAL|VSA003|subcutaneous injections
62099408|NCT06712771|PLACEBO_COMPARATOR|Placebo|subcutaneous injections
62294611|NCT01835184|EXPERIMENTAL|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62661826|NCT01107015|ACTIVE_COMPARATOR|Group 3: patient-physician intervention|Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
62661827|NCT01107015|ACTIVE_COMPARATOR|Group 4: data analyzed intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations
61910214|NCT00711516|EXPERIMENTAL|1|Armodafinil treatment (200 mg/day) - Study drug was supplied as 50 mg tablets and the dose was titrated from a starting dose of 50 mg taken once daily in the morning (before 0800), increasing to 100 mg/day on Day 2, 150 mg/day on day 5, and then 200 mg/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
61910215|NCT00711516|PLACEBO_COMPARATOR|2|Placebo comparator - Placebo tablets matching the armodafinil 50 mg tablets drug were supplied and the dose was titrated from a starting dose of one tablet taken once daily in the morning (before 0800), increasing to two tablets/day on Day 2, three tablets/day on day 5, and then four tablets/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
62099409|NCT06224426|EXPERIMENTAL|Normobaric high-concentration oxygen (NBHO) group|After preoxygenating (FiO2=100%, 6 L/min) with a face mask for 3 min, patients will be sequentially administered intravenous sufentanil 0.2 µg/kg followed by propofol 2 mg/kg. Once the eyelash reflex was absent, all patients received 0.6 mg/kg rocuronium, with an endotracheal tube inserted approximately 90 seconds later. Mechanical ventilation is set to volume-controlled ventilation (VCV) mode, fresh gas flow 4 L/min, tidal volume (Vt) 6-8 ml/kg, respiratory rate (RR) 12-14 breaths/min, and positive end-expiratory pressure (PEEP) 5 cmH2O. End-tidal carbon dioxide (PetCO2) will be continuously monitored, maintaining it between 35-40 mmHg. Based on group allocation, the NBHO group will adjust the FiO2 at 80% throughout the surgery. Anesthesia will be maintained through total intravenous anesthesia, continuously infusing remifentanil 0.05-0.1 µg/kg/min and propofol 4-6 mg/kg/min, with intermittent 10 mg rocuronium as needed.
62661828|NCT05548374|EXPERIMENTAL|Acupucnture|Treatment will start 2 weeks before the onset of menstruation in 3 consecutive menstrual cycles, three sessions per week (ideally every other day) in the first two menstrual cycles and two sessions per week in the last menstrual cycle, 16 sessions in total.
62661829|NCT05548374|SHAM_COMPARATOR|Sham Acupuncture|Treatment will start 2 weeks before the onset of menstruation in 3 consecutive menstrual cycles, three sessions per week (ideally every other day) in the first two menstrual cycles and two sessions per week in the last menstrual cycle, 16 sessions in total.
62661830|NCT00168298|EXPERIMENTAL|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
62661831|NCT00168298|EXPERIMENTAL|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
61910216|NCT01210417||Trauma victims|All prehospital traumatic patients enrolled by our Helicopter Emergency Medical System (HEMS)
62661832|NCT00168298|SHAM_COMPARATOR|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
62661833|NCT00207688||Infliximab 5 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
62661834|NCT00207688||Infliximab 10 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
62661835|NCT00207688||Placebo|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
62661836|NCT04666298|EXPERIMENTAL|300 mg inclisiran sodium|Subcutaneous injection
62661837|NCT04666298|EXPERIMENTAL|200 mg inclisiran sodium|Subcutaneous injection
62661838|NCT04666298|EXPERIMENTAL|100 mg inclisiran sodium|Subcutaneous injection
62661839|NCT04666298|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection
62661840|NCT02329288|ACTIVE_COMPARATOR|Triamcinolone Acetonide|40mg/1ml
62661841|NCT02329288|PLACEBO_COMPARATOR|placebo|1ml
62661842|NCT03647007|NO_INTERVENTION|Standard group|The Standard programme on the Christmas Seal Homes.
62661843|NCT03647007|EXPERIMENTAL|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
62661844|NCT04547920|EXPERIMENTAL|12 Weeks Followed by Optional 12 Month Continuation|"Initial 12 Weeks: Patients were instructed to completed one (1) 30 minute session per week or three (3) 30 minute sessions per week.~Optional Months 4-12: Subjects who qualified for the long-term follow up and elected to enroll, signed a new informed consent and were instructed to taper down their treatment frequency to twice (2) monthly 30 minute treatment sessions."
62661845|NCT02173951|ACTIVE_COMPARATOR|arm 1 iron chelation|Active Comparator arm : iron chelation Included 32 thalassemia major patients with low serum ferritin (≥500) . They will receive low dose Deferiprone( DFP )on 50 mg/kg/d.
62661846|NCT02173951|PLACEBO_COMPARATOR|arm 2 blood transfusion|Placebo Comparator arm: blood transfusion only Included 32 thalassemia patients with low serum ferritin (≥500). They receive blood transfusion with no chelation. Patients will start deferiprone 75 mg/kg/d when reaching Primary end point which is elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6
62661847|NCT00699725||1|NSAID patients with risk factors treated with gastroprotective drugs
62661848|NCT00308776|EXPERIMENTAL|Cholecystokinin|Participants will receive intravenous saline plus cholescystokinin.
62661849|NCT00308776|PLACEBO_COMPARATOR|Saline|Participants will receive intravenous saline only.
62661850|NCT02421510|PLACEBO_COMPARATOR|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
62661851|NCT02421510|EXPERIMENTAL|Sotagliflozin 200 mg|Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
62661852|NCT02421510|EXPERIMENTAL|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
62661853|NCT05788380|OTHER|The Scapular Muscles Endurance (SME|The Scapular Muscles Endurance (SME) test was used to assess the endurance of the Serratus Anterior muscles.
62661854|NCT05788380|OTHER|Vizual Analog Scale|The VAS for pain, measures pain severity in the affected shoulder from 0 to 10 points, with 0 points representing no pain at all and 10 points representing pain as bad as it can be
62661855|NCT01260051||Epidural Recipients|
62661856|NCT01260051||Non-Epidural Recipients|
62661857|NCT02852044|ACTIVE_COMPARATOR|Rest|Remain rested prior to the oral glucose tolerance test
62661858|NCT02852044|EXPERIMENTAL|Exercise|Complete exercise prior to the oral glucose tolerance test
62661859|NCT03506126|EXPERIMENTAL|Leucine Adults > 60|In this arm, all subjects will receive all 8 of the leucine test levels, assigned in random order.
62661860|NCT01199770|EXPERIMENTAL|experimental pasta B, small|small portion experimental pasta B
62661861|NCT01199770|EXPERIMENTAL|experimental pasta C, small portion|small portion experimental pasta C
62661862|NCT01199770|PLACEBO_COMPARATOR|Control pasta, small|small portion Control pasta
62661863|NCT01199770|OTHER|No Load|Only water
62661864|NCT01199770|ACTIVE_COMPARATOR|Control pasta, medium|medium portion Control pasta
62661865|NCT01199770|EXPERIMENTAL|experimental pasta B, medium portion|medium portion experimental pasta B
62661866|NCT01199770|EXPERIMENTAL|experimental pasta C, medium portion|medium portion experimental pasta B
62661867|NCT02489201|EXPERIMENTAL|donafenib tosilate tablets|200mg bid
62661868|NCT00198120|EXPERIMENTAL|1|Participants will receive D-Cycloserine for 8 weeks.
62661869|NCT00198120|PLACEBO_COMPARATOR|2|Participants will receive placebo for 8 weeks.
62661870|NCT05123417|EXPERIMENTAL|Intervention Group|Intervention group students will be educated with educational materials (lecture presentation, video) will be uploaded through the system in accordance with the flipped learning model, and students will be asked to come prepared to the planned lesson. No classical presentations will be made to the students, but the education will be carried out in the form of question and answer discussion, in line with the Flipped Learning model. After the lesson, the questions of the students who have questions will be answered.
62661871|NCT05123417|NO_INTERVENTION|Control Group|The training, consisting of control group students will be trained with Powerpoint presentation, which will last 20-30 on average, will be given in accordance with the traditional education model. After the lesson, the questions of the students who have questions will be answered.
62661872|NCT05743855|PLACEBO_COMPARATOR|Placebo|Participants consume 1 serving of Placebo daily and attend weekly chiropractor sessions for 12 weeks.
62661873|NCT05743855|EXPERIMENTAL|Treatment Group|Participants consume 1 serving of the Nutrional supplement daily and attend weekly chiropractor sessions for 12 weeks.
62661874|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
62099410|NCT06224426|EXPERIMENTAL|Normobaric low-concentration oxygen (NBLO) group|After preoxygenating (FiO2=100%, 6 L/min) with a face mask for 3 min, patients will be sequentially administered intravenous sufentanil 0.2 µg/kg followed by propofol 2 mg/kg. Once the eyelash reflex was absent, all patients received 0.6 mg/kg rocuronium, with an endotracheal tube inserted approximately 90 seconds later. Mechanical ventilation is set to volume-controlled ventilation (VCV) mode, fresh gas flow 4 L/min, tidal volume (Vt) 6-8 ml/kg, respiratory rate (RR) 12-14 breaths/min, and positive end-expiratory pressure (PEEP) 5 cmH2O. End-tidal carbon dioxide (PetCO2) will be continuously monitored, maintaining it between 35-40 mmHg. Based on group allocation, the NBLO group will adjust the FiO2 at 30% throughout the surgery. Anesthesia will be maintained through total intravenous anesthesia, continuously infusing remifentanil 0.05-0.1 µg/kg/min and propofol 4-6 mg/kg/min, with intermittent 10 mg rocuronium as needed.
62099411|NCT06098586|ACTIVE_COMPARATOR|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
62099412|NCT06098586|ACTIVE_COMPARATOR|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
62099413|NCT06713369|EXPERIMENTAL|Primary Treatment Arm - AZD5305|"Part A will assess absolute bioavailability via oral administration of Saruparib (AZD5305) and IV \[14C\]-saruparib microtracer.~Part B will assess ADME via IV \[14C\]-saruparib administration"
62737092|NCT02223052|EXPERIMENTAL|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1|Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
62099414|NCT05513300|EXPERIMENTAL|HIIT group|Participants randomized in this group will be assigned to 12 weeks high intensity interval training.
62737093|NCT02223052|EXPERIMENTAL|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1|One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
62737094|NCT02223052|EXPERIMENTAL|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
62737095|NCT02223052|EXPERIMENTAL|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
62737096|NCT01001767|ACTIVE_COMPARATOR|Lovaza|Lovaza 1 gram by mouth twice a day for 24 weeks.
62737097|NCT01001767|PLACEBO_COMPARATOR|Placebo|Placebo capsule by mouth twice a day x 24 weeks.
62737098|NCT01657968||Acute tonsillitis|Patients with acute tonsillitis aged 15 to 40 years meeting at least two of Centors criteria.
62737099|NCT01657968||Healthy control patients|Control patients aged 15 to 40 years.
62737100|NCT00783835|EXPERIMENTAL|Methylphenidate|
61910217|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS\> 2 or intracranial tumor progression.
61910218|NCT04307342||Posterior MIPO|Patients treated with posterior MIPO for Humerus Diaphyseal Fractures With Extra-articular Distal Humeral Anatomical Plate
61910219|NCT00281658|EXPERIMENTAL|Paclitaxel and Lapatinib (Blinded)|Paclitaxel and Lapatinib (Blinded)
61910220|NCT00281658|ACTIVE_COMPARATOR|Paclitaxel and Placebo (Blinded)|Paclitaxel and Placebo (Blinded)
61910221|NCT00281658|OTHER|Open Label - Monotherapy (Extension Phase)|Open Label - Monotherapy (Lapatinib)
61910222|NCT00281658|OTHER|Open Label - Combination Therapy (Extension Phase)|Open Label - Combination Therapy (Lapatinib and Paclitaxel)
61910223|NCT05170776|EXPERIMENTAL|Pilates and postural correction exercise|pilates and postural correction exercise will be received three times a week for 10 weeks
61910224|NCT05170776|ACTIVE_COMPARATOR|Pilates exercises|pilates exercise will be received three times a week for 10 weeks
61910225|NCT05170776|ACTIVE_COMPARATOR|postural correction exercises|postural corrections exercise will be received three times a week for 10 weeks
61910226|NCT02284932||COPD patients|Group : COPD patients No specific intervention for this study
61910227|NCT02284932||Healthy controls|Group : healthy volunteers No specific intervention for this study
61910228|NCT06105671|EXPERIMENTAL|Symbicort - usual care|Participants are administered Formoterol + Budesonide from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
61910229|NCT06105671|EXPERIMENTAL|Formoterol - inhalation|Participants are administered Formoterol from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
62099415|NCT05513300|EXPERIMENTAL|MICT group|Participants randomized in this group will be assigned to 12 weeks of moderate-intensity continuous training.
62099416|NCT05513300|NO_INTERVENTION|Control group|
61910230|NCT06105671|EXPERIMENTAL|Formoterol - oral|Participants are administered a Formoterol capsule, which is taken orally. In addition, participants are administered placebo from an inhaler device.
62099417|NCT06713759||primigravida women|This group will include 20 primigravida pregnant woman with low back pain. They will undergo balance and low back pain assessment (at 2 different time points: one at their second trimester (22-24) weeks and the other one in their third trimester (34th) week
62099418|NCT06713759||Multigravida women|This group will include 20 pregnant women with low back pain. They will undergo balance and low back pain assessment (at 2 different time points: one at their second trimester (22-24) weeks and the other one in their third trimester (34th) week
62099419|NCT05877547|EXPERIMENTAL|Efinopegdutide 4mg|Efinopegdutide administered by subcutaneous (SC) injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks and 4mg for 48 weeks.
62099420|NCT05877547|EXPERIMENTAL|Efinopegdutide 7mg|Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, and 7 mg for 44 weeks.
62099421|NCT05877547|EXPERIMENTAL|Efinopegdutide 10mg|Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for 40 weeks.
61910231|NCT06105671|PLACEBO_COMPARATOR|Placebo|Participants are administered placebo from an inhaler device testing and a placebo capsule.
62099422|NCT05877547|PLACEBO_COMPARATOR|Placebo|Placebo administered by SC injection once weekly for 52 weeks
62099423|NCT05877547|ACTIVE_COMPARATOR|Semaglutide 2.4 mg|Semaglutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and 2.4 mg for 36 weeks.
62099424|NCT05004610|NO_INTERVENTION|standard of care|Patients will receive the standard of care infusion (balanced crystalloids)
62099425|NCT05004610|EXPERIMENTAL|treatement group|Sodium lactate infusion 15 µmol/Kg/min
62099426|NCT06711757||QMH&DKCH cohort|A total of 1,950 whole spine posteroanterior X-rays collected from two local hospitals (QMH and DKCH) were utilized for the development and internal validation of our model.
61910232|NCT06105671|EXPERIMENTAL|Mannitol-test|Participants are administered Bronchitol from an inhaler device testing.
61910233|NCT01488123|EXPERIMENTAL|Ayurvedic Intervention|
61910234|NCT01428947||Coronary angiography|Patents scheduled for elective coronary angiography
61910235|NCT02995369|EXPERIMENTAL|Cotton Roll Isolation (left), then DryShield Isolation (right)|"Cotton rolls (CRI) will be used to isolate the maxillary and mandibular teeth on the left side of the mouth, followed by sealants placement using Dryshield (DS) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
62099427|NCT06711757||PUMCH cohort|314 whole spine posteroanterior X-rays from Peking Union Medical College Hospital, Beijing, China
62099428|NCT06711757||NFH cohort|94 whole spine posteroanterior X-rays from Nanfang Hospital, Guangzhou, China
62099429|NCT06711757||JSTH cohort|187 whole spine posteroanterior X-rays from Jishuitan Hospital, Beijing, China
62099430|NCT06711757||RJH cohort|294 whole spine posteroanterior X-rays from Ruijin Hospital, Shanghai, China
62099431|NCT06711757||HSH cohort|176 whole spine posteroanterior X-rays from Huashan Hospital, Shanghai, China
62099432|NCT06649344|EXPERIMENTAL|Treatment group A|HRS953-low dose
62099433|NCT06649344|EXPERIMENTAL|Treatment group B|HRS9531-high dose
62099434|NCT06649344|ACTIVE_COMPARATOR|Treatment group C|Semaglutide-1mg
62099435|NCT03575962|EXPERIMENTAL|GSK3640254 Bis-hydrochloride followed by GSK3640254 mesylate|The subjects in this arm will receive an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsules(reference), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1, during Period 2 of the study. The drug will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
62099436|NCT03575962|EXPERIMENTAL|GSK3640254 Mesylate followed by GSK3640254 Bis-hydrochloride|The subjects in this arm will receive an oral administration of 200 mg as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsule, 100 mg (reference), as single oral dose, on the morning of Day 1 during Period 2, of the study. The drug, will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
62099437|NCT01462019|NO_INTERVENTION|Control|
62099438|NCT01462019|EXPERIMENTAL|Photobiomodulation|
62099439|NCT06675357|EXPERIMENTAL|Fibroblast activation protein inhibitor (FAPI)|FAPI radiotracer will be used during PET
62099440|NCT00902447||Human Blood Cell Disorders|Human Blood Cell Disorders Tissue Bank
62099441|NCT06713187|ACTIVE_COMPARATOR|group 1|Patients with systemic lupus erythematosus without interstial lung disease.
62099442|NCT06713187|ACTIVE_COMPARATOR|group2|Patients with systemic lupus erythematosus with interstial lung disease.
62099443|NCT06713187|ACTIVE_COMPARATOR|group3|healthy control groups
62294612|NCT03339804|EXPERIMENTAL|Chemotherapy|Infusion of doxorubicin and cyclophosphamide
62099444|NCT01879904|EXPERIMENTAL|Endoscopic submucosal dissection (ESD)|Endoscopic submucosal dissection (ESD)
62099445|NCT06711731||spinal CSF leak|"Patients with suspected spinal CSF leak based on one of the following:~1. History of new orthostatic symptoms with or without prior spinal procedure~2. Imaging suggestive for spinal CSF leak"
62099446|NCT06533254||Patients who have Chronic Kidney Disease (Phase 1)|Patients who have Chronic Kidney Disease attending clinics managed by Dallas Renal Group in Texas USA, Leeds Teaching Hospitals NHS Trust UK and Suffolk and North East Essex NHS Trust UK will be contacted via their health care provider to invite them to participate.
62099447|NCT06533254||Patients who have Chronic Kidney Disease (Phase 2)|Patients who have Chronic Kidney Disease and are attending the units managed by Dallas Renal Group in Texas USA, Leeds Teaching Hospitals NHS Trust UK and Suffolk and North East Essex NHS Trust UK.
62099448|NCT01026662||Abdominoplasty|Subjects scheduled for abdominoplasty surgery
62099449|NCT06707792||Kidney transplant recipients|
62294613|NCT05548686|EXPERIMENTAL|Adapted Physical Activity|Patients benefiting from adapted physical activity
62294614|NCT04995094|EXPERIMENTAL|Imprime PGG + Pembrolizumab (Investigational ARM)|Imprime PGG + Pembrolizumab (Investigational ARM)
62294615|NCT04995094|ACTIVE_COMPARATOR|Pembrolizumab (Control ARM)|Pembrolizumab (Control ARM)
62308163|NCT04064710|OTHER|Allograft Tissue|Allograft tissue product for patients with painful vertebral compression fractures
62099450|NCT00910702|EXPERIMENTAL|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
62099451|NCT04604782|EXPERIMENTAL|adolescents aged 12 to <18 years|
61910236|NCT02995369|EXPERIMENTAL|Cotton Roll Isolation (right), then DryShield Isolation (left)|"Cotton rolls (CRI) will be used to isolate the maxillary and mandibular teeth on the right side of the mouth, followed by sealants placement using DryShield (DS) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
62099452|NCT04604782|EXPERIMENTAL|children aged 2 to <12 years|
62294616|NCT04057001||Patients who received a HCV+ liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C+ virus positive tested liver transplant.
62294617|NCT04057001||Patients who received a HCV- liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C- virus positive tested liver transplant.
62294618|NCT03404648|EXPERIMENTAL|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
62294619|NCT01578902|EXPERIMENTAL|Hypofractionated radiotherapy using SABR|Stereotactic radiation: 35Gy in 5 fractions over 29 days
62294620|NCT01070420|ACTIVE_COMPARATOR|FFR via central venous line|
62294621|NCT01070420|EXPERIMENTAL|FFR via peripheral vein|
62294622|NCT01769105|ACTIVE_COMPARATOR|Standard Lid Hygiene Regime|Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
61910237|NCT02995369|EXPERIMENTAL|DryShield Isolation (left), then Cotton Roll Isolation (right)|"DryShield (DS) will be used to isolate the maxillary and mandibular teeth on the left side of the mouth, followed by sealants placement using cotton rolls (CRI) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
61910238|NCT02995369|EXPERIMENTAL|DryShield Isolation (right), then Cotton Roll Isolation (left)|"DryShield (DS) will be used to isolate the maxillary and mandibular teeth on the right side of the mouth, followed by sealants placement using cotton rolls (CRI) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
62099453|NCT04604782|EXPERIMENTAL|infants aged 1 to <24 months and who weigh at least 3 kg|
62099454|NCT06479564|EXPERIMENTAL|Group A|20 participants will be in control group, they will only perform free weight training and machine training and will not perform aerobic exercises
62099455|NCT06479564|EXPERIMENTAL|Group B|20 participants will be in experimental group, they will perform aerobic exercises along with free weight training and machine training
62099456|NCT05435963|EXPERIMENTAL|COPD undergoing pulmonary rehabilitation|45 individuals with COPD will complete the UCLA-LS scale, CRQ, HADS, and 6 minute walk test before and after pulmonary rehabilitation.
62099457|NCT06188559|EXPERIMENTAL|Part 1, Dose Optimization, Cohort 1|HER2-positive or HER2-low, unresectable or metastatic BC.
62099458|NCT06188559|EXPERIMENTAL|Part 1, Dose Optimization, Cohort 2|HER2-positive or HER2-low, unresectable or metastatic BC.
62099459|NCT06188559|EXPERIMENTAL|Part 1, Dose Optimization, Cohort 3|HER2-positive or HER2-low, unresectable or metastatic BC.
62099460|NCT06188559|EXPERIMENTAL|Part 2, Dose Expansion|HER2-positive or HER2-low, unresectable or metastatic BC.
62294623|NCT01769105|ACTIVE_COMPARATOR|Lipiflow|Patients receive a singe Lipiflow-treatment
62099461|NCT04644016|EXPERIMENTAL|Participants with malignant hematologic disorders|Patients with malignant disorders receive clofarabine intravenously (IV) over 2 hours, fludarabine phosphate (fludarabine) IV over 30 minutes, and busulfan IV over 3 hours on days -5 to -2. Beginning on day -3, patients receive tacrolimus IV or orally (PO) and mycophenolate mofetil IV over at least 2 hours in the absence of unacceptable toxicity. Patients may begin to taper tacrolimus at approximately 3 months post-transplant and mycophenolate mofetil at approximately 60 days post-transplant in the absence of ongoing graft versus host disease (GVHD) requiring systemic immune suppression. TRANSPLANT: Patients undergo cord blood transplantation (CBT) on day 0.\*\*Subgroup will get rATG (day -12 to -10) POST-TRANSPLANT: Beginning on day 7, patients receive filgrastim subcutaneously (SC) or IV over 15-30 minutes until absolute neutrophil count (ANC) recovery. Additionally, patients undergo blood sample collection, computed tomography (CT) and positron emission tomography (PET) on study.
62099462|NCT04644016|EXPERIMENTAL|Participants with non-malignant hematologic disorders|"Patients with non-malignant disorders receive rituximab IV on day -12 and rabbit anti-thymocyte globulin (rATG) over 12 hours on day -12 to -9. Patients then receive clofarabine IV over 2 hours, fludarabine IV over 30 minutes, and busulfan IV over 3 hours on days -5 to -2. Beginning on day -3, patients receive tacrolimus IV or PO and mycophenolate mofetil IV over at least 2 hours. Patients may begin to taper tacrolimus at approximately 6 months post-transplant and mycophenolate mofetil at approximately 60 days post-transplant in the absence of ongoing GVHD requiring systemic immune suppression.~TRANSPLANT: Patients undergo CBT on day 0. POST-TRANSPLANT: Beginning on day 7, patients receive filgrastim SC or IV over 15-30 minutes until ANC recovery. Patients also receive rituximab IV on day 30.~Additionally, patients undergo blood sample collection, CT and PET on study."
62099463|NCT05603026|ACTIVE_COMPARATOR|TAVR using the self-expanding valve Evolut FX|Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Medtronic Evolut FX supra-annular self-expanding valve
62099464|NCT05603026|ACTIVE_COMPARATOR|TAVR using the balloon-expandable valve Sapien 3 Ultra|Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Edwards Sapien 3 Ultra valve
62099465|NCT00703482|PLACEBO_COMPARATOR|1|
62099466|NCT00703482|ACTIVE_COMPARATOR|2|
62466785|NCT01019889|EXPERIMENTAL|SCRT(Socheongryong-tang )|encapsulated Socheongryong-tang extract
62466786|NCT01019889|EXPERIMENTAL|YPS (Yeongyopaedok-san)|Encapsulated Yeongyopaedok-san extract
62466787|NCT04166032|EXPERIMENTAL|ANICGM|non-invasive continuous glucose monitoring device
62466788|NCT00360997|OTHER|Behavioural|Conventional UK physical therapy (Con UK PT)
62466789|NCT00360997|EXPERIMENTAL|Con UK PT + MTS|Con UK PT + 30/60 or 120 minutes MTS
61910239|NCT00528970|EXPERIMENTAL|MOA-728 12 mg|Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
61910240|NCT00528970|EXPERIMENTAL|MOA-728 24 mg|Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
62466790|NCT03726151|NO_INTERVENTION|Usual Care|
62466791|NCT03726151|EXPERIMENTAL|Parent Reminders|
62466792|NCT03726151|EXPERIMENTAL|Multicomponent clinic-system strategies|
61910241|NCT00528970|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to MOA-728 as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
61910242|NCT04858971||Control|No source will be indicated on information provided for review
62099467|NCT00703482|ACTIVE_COMPARATOR|3|
62099468|NCT00703482|EXPERIMENTAL|4|
62099469|NCT00703482|EXPERIMENTAL|5|
62099470|NCT00703482|EXPERIMENTAL|6|
62099471|NCT00703482|EXPERIMENTAL|7|
62466793|NCT03726151|EXPERIMENTAL|Combined Condition|
62466794|NCT04682145||Haemophilia A patients|All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.
62099472|NCT06360601|ACTIVE_COMPARATOR|Labetalol group|
62099473|NCT06360601|ACTIVE_COMPARATOR|Hydralazine group|
62099474|NCT06626074|EXPERIMENTAL|Open label|
62466795|NCT05867095|EXPERIMENTAL|Navigation|Patients will get the standard of care in the Netherlands with the addition of surgical navigation
62466796|NCT05867095|OTHER|Conventional|Patients will get the standard of care in the Netherlands
62466797|NCT04441463|EXPERIMENTAL|cohort|Mother-child couple
62466798|NCT04834271|ACTIVE_COMPARATOR|Exercise without blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) without blood flow restriction.
62466799|NCT04834271|EXPERIMENTAL|Exercise with 40% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% of arterial occlusion pressure blood flow restriction.
62466800|NCT04834271|EXPERIMENTAL|Exercise with 80% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% of arterial occlusion pressure blood flow restriction.
62466801|NCT03127631|ACTIVE_COMPARATOR|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label statins, ACE-I, and other antihypertensive medications where appropriate.
61910243|NCT04858971||Government source|A government logo will be shown on information provided for review
62099475|NCT05820074||Young, healthy control|"Young healthy participants below 45 years will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section.~During the protocol, neural activity is recorded using EEG."
62099476|NCT05820074||Age-matched healthy control|"Age-matched healthy participants above 45 years will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section.~During the protocol, neural activity is recorded using EEG."
62099477|NCT05820074||Parkinson's patients|"Parkinson's patients will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section. Additionally, a neuromodulation set-up will be tested.~During the protocol, neural activity is recorded using EEG and signals from the DBS-electrodes."
62099478|NCT05927480|EXPERIMENTAL|Audio Distraction|Those included in this study and randomized into the treatment arm will be given an mp3 device and headphones to listen to genre of music of their choosing in addition to be treated to the routine care with the skeletal traction pin.
62099479|NCT05927480|NO_INTERVENTION|Control|Those randomized into this arm will receive the current routine care which is treatment with a skeletal traction pin and no audio distraction.
62099480|NCT06714604|ACTIVE_COMPARATOR|Standard|8 cycles of neoadjuvant mFOLFIRINOX or 4 cycles of neoadjuvant gemcitabine-nab-paclitaxel
62099481|NCT06714604|EXPERIMENTAL|Prolonged|12 cycles of neoadjuvant mFOLFIRINOX or 6 cycles of neoadjuvant gemcitabine-nab-paclitaxel
61910244|NCT04858971||Medical source|A medical logo will be shown on information provided for review
61910245|NCT04858971||Social media source|A social media logo will be shown on information provided for review
61910246|NCT04136444|EXPERIMENTAL|Healthy participants|Participants will receive assigned single and multiple doses of padsevonil.
62099482|NCT06270719||Cohort 1: Delandistrogene Moxeparvovec|"Participants in Cohort 1 will have a plan for prescription of delandistrogene moxeparvovec commercially as part of clinical care prior to entry into this study.~Cohort 1a includes participants who are ambulatory and aged 4 years or greater at baseline prescribed delandistrogene moxeparvovec commercially and recruited by treating physicians before infusion is administered.~Cohort 1b includes non-ambulatory DMD participants aged 4 years or greater at baseline prescribed delandistrogene moxeparvovec commercially and recruited by treating physicians before infusion is administered."
62099483|NCT06270719||Cohort 2: Standard of Care|Cohort 2 includes ambulatory DMD participants aged 4 years or greater at baseline unexposed to DMD gene therapy and receiving standard of care therapy (chronic glucocorticoid treatment) at study entry with or without baseline use of other DMD approved therapies.
62099484|NCT01982019|OTHER|Obese patients with type 2 diabetes|Meal test taking and hormones measure including 26RFa
62099485|NCT01982019|OTHER|Obese patients witout diabetes|Meal test taking and hormones measure including 26RFa
62099486|NCT01982019|OTHER|healthy volonteers|Meal test taking and hormones measure including 26RFa
61910247|NCT04136444|EXPERIMENTAL|Hepatically impaired participants|Participants will receive assigned single and multiple doses of padsevonil.
61910248|NCT02539056|EXPERIMENTAL|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
62099487|NCT03618472|EXPERIMENTAL|metformin|The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
61910249|NCT04401020|EXPERIMENTAL|Dose escalation|SAR442257 will be given intravenously with lead-in doses (LID) in the first-week, followed by once weekly until week 4 (Cycle 1) and once weekly for each subsequent cycle(s).
61910250|NCT01625260|EXPERIMENTAL|0.06 mg/kg ALT-801 with 1000 mg/m^2 Gemcitabine|ALT-801 at 0.06 mg/kg with Gemcitabine at 1000 mg/m\^2
61910251|NCT01625260|EXPERIMENTAL|0.08 mg/kg ALT-801 with 1000 mg/m^2 Gemcitabine|ALT-801 at 0.08 mg/kg with Gemcitabine at 1000 mg/m\^2
62099488|NCT03618472|PLACEBO_COMPARATOR|placebo|The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
61910252|NCT02101697|EXPERIMENTAL|HIV Stigma Reduction Intervention|The HIV stigma reduction arm group will participate in a promising intervention designed to reduce HIV stigma among health professionals. The intervention builds on results of our previous research, identifying prevalence and drivers of stigma and discrimination in Indian healthcare settings among PLHIV, health care providers, and uninfected patients.The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
62661875|NCT03870386|EXPERIMENTAL|EUS-BD with LAMS|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts \< 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts \> 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
62099489|NCT04191551||Precursor lesions|Subjects with precursor lesions detected on endoscopy.
62661876|NCT03870386|ACTIVE_COMPARATOR|Traditional transpapillary metal stent via ERCP|A duodenoscope is advanced orally to the papilla. The bile duct is then cannulated with a sphincterotome using the guidewire-assisted technique. A cholangiogram is then performed followed by insertion of a self-expanding metal biliary stent. The performance of a biliary sphincterotomy prior to stent insertion and the choice of stent size (10x 40 mm, 10 x 60 mm, 10x 80 mm) will be at the discretion of the endoscopist.
62099490|NCT05962125|EXPERIMENTAL|periodic alveolar recruitment maneuvers (PARM) alone|Alveolar recruitment maneuvers \[ARM\] repeated every 30 min after tracheal intubation and after any disconnection from the ventilator.
62099491|NCT05962125|ACTIVE_COMPARATOR|positive end-expiratory pressure (PEEP) alone|PEEP was routinely set at 6 cm H2O. If it was in a state of Trendelenburg position or carbon dioxide pneumoperitoneum, PEEP was set to 8 cm H2O.
62099492|NCT05962125|ACTIVE_COMPARATOR|a combination of PEEP and PARM|Alveolar recruitment maneuvers \[ARM\] repeated every 30 min after tracheal intubation and after any disconnection from the ventilator. PEEP was routinely set at 6 cm H2O. If it was in a state of Trendelenburg position or carbon dioxide pneumoperitoneum, PEEP was set at 8 cm H2O.
62099493|NCT04495894|EXPERIMENTAL|Preoperative Ketorolac|Participants randomized to receive ketorolac prior to surgery for stage I/II NSCLC and stage III RCC. Participants will receive standard-of-care surgery. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered.
62099494|NCT04495894|NO_INTERVENTION|Control Group|Participants randomized to the control group receiving the standard of care during surgery for stage I/II NSCLC and stage III RCC. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered. The concurrent control group is to obtain untreated biologic samples for biologic correlative studies and secondary endpoints.
62294624|NCT02617355|OTHER|Prototype vs Covidien magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs Covidien magnetic drape
62661877|NCT02896023|ACTIVE_COMPARATOR|pregnant|women with positive pregnancy test after induction of ovulation and ICSI
62661878|NCT02896023|ACTIVE_COMPARATOR|Not pregnant|women with negative pregnancy test after induction of ovulation and ICSI
62661879|NCT02448108|EXPERIMENTAL|i-IPSRT|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer.
62661880|NCT02448108|EXPERIMENTAL|i-IPSRT + CH|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
61910253|NCT02101697|PLACEBO_COMPARATOR|Time Matched Control Group|The time-matched control group will also receive three sessions; two administered by computers and one in small group format to control for attention effects. However, rather than AIDS stigma, the content will be focused on diabetes management (a disease not considered to be stigmatized).
61910254|NCT00473122|OTHER|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Reconstruction: If radiation therapy (XRT) not needed, immediate reconstruction. If XRT is needed, delayed reconstruction until XRT complete.
61910255|NCT00002952|EXPERIMENTAL|Arm A|Melan-A peptide loaded PBMCs (sc, q3wk x 3), rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
61910256|NCT03587285|EXPERIMENTAL|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
61910257|NCT03587285|EXPERIMENTAL|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
61910258|NCT03131427||Wilson's Disease|Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.
62294625|NCT02617355|OTHER|Prototype vs 4 commercial drapes|"New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs 4 commercially available magnetic drapes:~Green Covidien Magnetic Drape Jac-Cell Medic Reusable Magnetic Pad DeRoyal Magnetic Pad size 10 x 16 DeRoyal Magnetic Pad size 20 x 16"
62294626|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
62294627|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
62294628|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
62661881|NCT02448108|OTHER|CC (Controlled Condition)|Participants randomized to this arm will receive brief written psychoeducational material that includes information about social rhythm regularity. This information will be either mailed or e-mailed to them.
62661882|NCT03331081|EXPERIMENTAL|Group Bladder Training|Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.
62661883|NCT03331081|ACTIVE_COMPARATOR|Group TMAP|In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.
62661884|NCT03331081|ACTIVE_COMPARATOR|Group Bladder Training + TMAP|In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.
62661885|NCT01651884|EXPERIMENTAL|High-Definition tDCS|
62661886|NCT01651884|EXPERIMENTAL|Sponge tDCS|
61910259|NCT03131427||Hereditary Hemochromatosis|Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.
61910260|NCT03131427||Hereditary Hyperbilirubinemias|Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).
61910261|NCT03131427||Inherited Cholestatic Liver Disease|Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).
61910262|NCT03131427||Other genetic/metabolic liver diseases|Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.
62661887|NCT01136122|ACTIVE_COMPARATOR|CPAP Arm|Receive effective CPAP treatment for one month
62661888|NCT01136122|NO_INTERVENTION|Control Arm|Receive no treatment for one month
61910263|NCT05275361|EXPERIMENTAL|Patient: Scheduled for mammogram|"* Will be asked to choose 2 social contacts (adult family member or friend identified by the participant as someone who could be engaged by the research team to encourage the participant to attend her mammogram appointment)~* Will receive reminder(s) from social contact about the screening mammogram appointment~* Will receive reminder from Breast Health Center about screening mammogram appointment~* Will be contacted to provide experience with the study"
61910264|NCT05275361|NO_INTERVENTION|Social Contact of Patient|"* Facilitate enrolled patient to complete the screening mammogram.~* Will receive information about screening mammograms and resources available at the Breast Imaging Center.~* Will be contacted approximately 3 days prior to the patient's mammogram appointment.~* Will be contacted to provide experience with the study"
61910265|NCT00668356|EXPERIMENTAL|1|
61910266|NCT00668356|ACTIVE_COMPARATOR|2|
61910267|NCT03632486||Suspected Dengue|Children with fever and two of the following criteria: anorexia and nausea, rash, aches and pains, warning signs, leukopenia, positive tourniquet test will all receive a diagnostic bedside ultrasound.
61910268|NCT01872325||Training site|All emergency medical dispatchers at a central ambulance communication centre in Ontario will participate in an educational program designed to improve cardiac arrest diagnostic accuracy.
61910269|NCT01872325||Control site|All emergency medical dispatchers at a central ambulance communications centre geographically remote from the Training Site and has a similar rate to the Training Site for cardiac arrests, bystander CPR rate, and survival
62661889|NCT01817478|EXPERIMENTAL|medical staff|
61910270|NCT00353470|EXPERIMENTAL|1|Participants will receive panic focused psychodynamic psychotherapy for 12 weeks
62099495|NCT06518837|EXPERIMENTAL|Tirzepatide|Tirzepatide will be administered subcutaneously in the stomach, upper arm, or thigh, rotating injection sites with each dose. Administer once weekly at any time of day, with or without meals. Start with an initial dosage of 2.5 mg. After 4 weeks, increase to 5 mg weekly. Further increases may be made in 2.5 mg increments after at least 4 weeks on the current dose, aiming for a target of 15 mg (i.e., 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). Consider treatment tolerability when selecting the maintenance dose. If not tolerated, consider the next lower maintenance dose. Recommended maintenance doses are 5 mg, 10 mg, or 15 mg, with 5 mg as the lowest evaluable dose. The 2.5 mg dose is not a maintenance dose. The maximum allowed dosage is 15 mg once weekly.
62099496|NCT02725281|NO_INTERVENTION|Control group|"The patients in Group 1 didn't receive any intervention during ESWL."
62099497|NCT02725281|ACTIVE_COMPARATOR|Stress ball|"The patients in Group 2 were given stress ball into both their palms 5 minutes before ESWL. Participants were instructed to squeeze the balls twice after counting up to ten and repeat it until the end of the procedure. This ball was medium hard and it was made of high quality silicon."
62099498|NCT02725281|ACTIVE_COMPARATOR|Music|"The patients in Group 3 were listened to the music chosen by them with a headset as a nonpharmacological method during lithotripsy."
62099499|NCT04910022|EXPERIMENTAL|NMS-03305293 +TMZ|"Phase 1 Dose Escalation: All patients will receive NMS-03305293 and temozolomide (TMZ) administered orally (NMS-03305293 once or twice daily on days 1-7 or 28 consecutive days from Day 1 to Day 28; TMZ once daily on days 1-5;) in repeated 4-week cycles aimed at defining the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Doses (RP2Ds) of NMS-03305293 in combination with TMZ. Each cycle is 28 days.~Phase 2: Once the RP2D is defined, the patients will receive TMZ daily on days 1-5 in combination with NMS-03305293 at the RP2D on days 1-7 or on days 1-28 every 28 days.~Backfill cohorts: additional patients may be treated with TMZ daily on days 1-5 and NMS-03305293 at different dose levels/schedules that have been previously assessed and determined to be safe, in order to properly characterize the exposure relationship over a range of doses/schedules. The backfill cohorts may run in parallel."
62099500|NCT05896189|ACTIVE_COMPARATOR|Arm 1: Computerized Cognitive Training-Global Stimulation Games|The global stimulation games active attention control intervention is composed of computerized games. These games are fully developed and are rated E (for everyone) by the Entertainment Software Rating Board. The program will present 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku.
62294629|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
62294630|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
62661890|NCT03208452|PLACEBO_COMPARATOR|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
61910271|NCT00353470|ACTIVE_COMPARATOR|2|Participants will receive cognitive behavioral therapy-panic control treatment for 12 weeks
61910272|NCT00353470|ACTIVE_COMPARATOR|3|Participants will receive applied relaxation training for 12 weeks
61910273|NCT00357591|ACTIVE_COMPARATOR|Control|
61910274|NCT04861493||Smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL\>5 mm and PD\>5 mm in one or more sites and bleeding on probing \>30% and smoking at least 10 cigarettes /day for a minmum of 5 years.
61910275|NCT04861493||Non-smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL\>5 mm and PD\>5 mm in one or more sites and bleeding on probing \>30% and they are never smoked before.
61910276|NCT04861493||Healthy patients|patients free from periodontitis or any systemic disease and never smoked before.
61910277|NCT06021860|EXPERIMENTAL|Part 1: multiple doses spironolactone oral suspension (Group 1)|Patients aged ≥12 to ≤17 years of age in Part 1 of the study, administered spironolactone oral suspension QD for 10 days
61910278|NCT06021860|EXPERIMENTAL|Part 1: multiple doses spironolactone oral suspension (Group 2)|Patients aged ≥6 to \<12 years of age in Part 1 of the study, administered spironolactone oral suspension QD for 10 days
61910279|NCT06021860|EXPERIMENTAL|Part 1: multiple doses spironolactone oral suspension (Group 3)|Patients aged ≥2 to \<6 years of age in Part 1 of the study, administered spironolactone oral suspension QD for 10 days
61910280|NCT06021860|EXPERIMENTAL|Part 1: single and multiple doses spironolactone oral suspension (Group 4)|Patients aged from birth to \<2 years of age in Part 1 of the study, administered spironolactone oral suspension as a single dose, and then QD for 10 days
62099501|NCT05896189|EXPERIMENTAL|Arm 2: Computerized Cognitive Training-Neuroplasticity Games|The neuroplasticity games provide core elements necessary for inducing neuroplasticity. The five core elements include the principles of speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. Importantly, all of the exercises adapt to user skill and ability. Behavioral tracking built within the program is used to monitor individual performance and ensure that the person is training at their uppermost threshold level. Specifically, we will use eight of these exercises which are designed to address cognitive concerns most noted in BCS including exercises to improve attention and working memory, processing speed, and executive function.
62099502|NCT01079598|OTHER|Treatment|RF ablation with ClosureRFS Stylet
62099503|NCT04826224|EXPERIMENTAL|Subjects with Osteoarthritis of the shoulders|Subjects diagnosed with Osteoarthritis of the shoulders will be injected with concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
61910281|NCT06021860|EXPERIMENTAL|Part 2: multiple doses spironolactone oral suspension (Group 1)|Patients aged ≥12 to ≤17 years of age in Part 2 of the study, administered low or high dose spironolactone oral suspension QD for 10 days
61910282|NCT06021860|EXPERIMENTAL|Part 2: multiple doses spironolactone oral suspension (Group 2)|Patients aged ≥6 to ≤12 years of age in Part 2 of the study, administered low of high dose spironolactone oral suspension QD for 10 days
61910283|NCT06021860|EXPERIMENTAL|Part 2: multiple doses spironolactone oral suspension (Group 3)|Patients aged ≥2 to ≤6 years of age in Part 2 of the study, administered low or high dose spironolactone oral suspension QD for 10 days
61910284|NCT06021860|EXPERIMENTAL|Part 2: single and multiple doses spironolactone oral suspension (Group 4)|Patients aged from birth to \<2 years of age in Part 2 of the study, administered low or high dose spironolactone oral suspension as a single dose, and then QD for 10 days
61910285|NCT03317301|EXPERIMENTAL|Experimental|Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
61910286|NCT03317301|ACTIVE_COMPARATOR|Active comparator|Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
62466802|NCT03127631|NO_INTERVENTION|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
61910287|NCT03938753|EXPERIMENTAL|Phonak Audéo M90-T|The Phonak Audéo M90-T is a Receiver-in-the-canal Hearing aid with direct connectivity functionality and a T-Coil from Phonak which will be fitted to the participants individual Hearing loss.
61910288|NCT01863589||Subjects prescribed adefovir tablets|Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
61910289|NCT05800431|EXPERIMENTAL|Non-invasive Neuromodulation|The non-invasive neuromodulation experimental group, made up of 20 participants, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
62099504|NCT06707883|EXPERIMENTAL|TQC2731 injection|TQC2731 injection, 28days as a treatment cycle.
62466803|NCT02683083|EXPERIMENTAL|[131I]-SGMIB Anti-HER2 VHH1|
62466804|NCT03462654|ACTIVE_COMPARATOR|individual LiFE (iLiFE)|In iLiFE, LiFE activities to increase strength, improve balance, and promote physical activity as well as habitualization strategies are introduced and taught in 7 highly individualized, one-to-one home visits.
62466805|NCT03462654|EXPERIMENTAL|group LiFE (gLiFE)|In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
62099505|NCT06707883|PLACEBO_COMPARATOR|TQC2731 Placebo|TQC2731 Placebo, 28days as a treatment cycle.
62099506|NCT05284422|ACTIVE_COMPARATOR|Traditional technique|Peripheral venous catheters inserted to the participants in this arm are inserted with a palpation/visualization guided technique in their hand, arm, foot or head.
62099507|NCT05284422|EXPERIMENTAL|Ultrasound-guided technique|Peripheral venous catheters inserted to the participants in this arm are inserted with an ultrasound-guided technique in their forearm.
62099508|NCT06713603|EXPERIMENTAL|Technology Assisted Motivational Interviewing (TAMI)|"Individuals randomized to TAMI will interact with the fully automated, web-based MI-chatbot for the 6-month study period. Patients who continue to smoke will receive up to two text messages per week with the chatbot URL link to initiate additional conversations always beginning with an assessment of readiness to change but remembering prior conversations much like a clinician. Individuals in the preparation stage will move directly to EBP education, tailoring a quit plan and boosting both self-efficacy and outcome expectancies. Patients with sufficient confidence will be encouraged to set a quit date. Patients will be encouraged to include their PCP and/or state quitline. TAMI will provide support proximal to the quit date including guidance through common obstacles. TAMI will check back to assess treatment initiation, treatment sustainment (and/or cessation), or relapse. Patients who are unable to quit (or who relapse) will be encouraged to restart conversations with TAMI."
62099509|NCT06713603|NO_INTERVENTION|Usual Care|"Individuals randomized to the Usual Care (UC) condition will receive a detailed educational handout on the health risks associated with smoking and information on Evidence Based Practice's (EBP) for cessation using the standard Kick-It California materials. Additional materials and referral resources regarding depression, stress, and other common barriers will be provided to all UC participants. Any UC individual can choose to quit at any time but they will not have access to TAMI. While this is not an active treatment condition, the handout and recurring assessments (at 3 and 6mo) may serve as reminders about the importance of quitting and may assist with finding support for co-occurring conditions or social needs."
62099510|NCT03070392|EXPERIMENTAL|IMCgp100 (tebentafusp, Kimmtrak)|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
62099511|NCT03070392|ACTIVE_COMPARATOR|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine~1 of 3 Investigator's Choice options: Systemic Ipilimumab~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
62099512|NCT05098600||Cases|Patients with a confirmed histologic/dermatoscopic diagnosis of Alopecia areata within the study period will be included for analysis.
61910290|NCT05800431|NO_INTERVENTION|Control group (CG)|Conventional care will be performed without interrupting their normal activity.
62661891|NCT03208452|ACTIVE_COMPARATOR|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
61910291|NCT02386189|NO_INTERVENTION|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
61910292|NCT02386189|ACTIVE_COMPARATOR|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
62294631|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
62099513|NCT03898687|OTHER|MAGMEN arm|Patients with melanoma of the extremities included in the protocol. SLNB will be performed with the addition of magtrace (SPIO) injection, 0.2 ml around previous scar. The patients will undergo MRI of the involved basin (Axilla-groin)and receive the SpIO injection the day before SLN biopsy. A separate SPIO MRI will be performed before the operation. All patients will receive all 3 methods for SLN identification as described in the protocol.
62099514|NCT04107519|EXPERIMENTAL|Immediate GRIT (ImT) training intervention|
61910293|NCT05099224|EXPERIMENTAL|Experimental group receiving mindfulness meditation|The ABC standardized version of mindfulness meditation was used, which includes 5 30-minute weekly sessions of mindfulness meditation. An additional 3-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. The intervention was supervised by PI is an experienced practitioner who received stress-management training at the Psychology Department at Kent State University The participants were asked to sit upright in a comfortable position, place their feet on the floor, and quietly observe and reflect on internal and external stimuli such as breathing, thought, feeling, physical sensation, and sound, without reactions, judgments, or evaluations.
61910294|NCT05099224|NO_INTERVENTION|Control group|Each of the control group subgroups had 10 participants. The participants were instructed to sit with their eyes closed and relax during the intervention sessions, in order to control for the nonspecific effects of trainer interaction, social interaction, attention, environment, time, and closed eyes. The timings of the control group interventions were similar to those of the experimental groups, whereby if a given experimental group intervention lasted for 30 minutes, the control group participants would be asked to sit with their eyes closed and relax for 30 minutes also.
61910295|NCT04456231||QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. In Addition, this Group will receive a health app for better preparation and more Information regarding preparation and endoscopy itself.
61910296|NCT04456231||no QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. This Group will have no app and will have to receive Information in traditional ways.
61910297|NCT03131830||Staff of the University Clinic of Tuebingen|Online-based questionnaire
61910298|NCT03131830||Participants of the 9th German Urogynecological Congress|Online-based questionnaire
61910299|NCT03131830||All members of the German Society of Obsetrics and Gynecology|Online-based questionnaire
61910300|NCT03131830||Pregnant women from Tübingen and Heidelberg|Online-based questionnaire
61910301|NCT03893890||No Treatment|Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in the EN3835-201 study, will be eligible for this study. The study will consist of up to two evaluations approximately 3 years after the first dose of study drug was received in the EN3835-201 study.
61910302|NCT03848299|EXPERIMENTAL|Experimental: Single Arm|All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.
61910303|NCT03679442|EXPERIMENTAL|Healthy individuals|Healthy individuals received intravenous N-acetylcysteine (NAC) treatment to investigate its actions on macrophage activation assessed by the markers soluble CD163 and CD206
61910304|NCT01513200|PLACEBO_COMPARATOR|UFH + Placebo|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
61910305|NCT01513200|EXPERIMENTAL|UFH + Bendavia|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
61910306|NCT03616223|EXPERIMENTAL|FX-322 Low Dose|Cohort of 8. Single intratympanic injection
61910307|NCT03616223|EXPERIMENTAL|FX-322 High Dose|Cohort of 8. Single intratympanic injection
61910308|NCT03616223|PLACEBO_COMPARATOR|Placebo-Low Dose|Cohort of 4. Single intratympanic injection
62099515|NCT04107519|NO_INTERVENTION|Delayed Training (DeT) control|
62099516|NCT06008678|OTHER|Treatment|RXiBreeze PAP System, Model RXiBreeze 20A
62099517|NCT03507309||Unselected cohort of patients who had a troponin measured|Patients who presented to hospital during the study period (2010-17) and had at least one troponin blood test measured.
61910309|NCT03616223|PLACEBO_COMPARATOR|Placebo-High Dose|Cohort of 4. Single intratympanic injection
62099518|NCT06713252|EXPERIMENTAL|Art therapy|Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
62099519|NCT06713252|ACTIVE_COMPARATOR|Regular therapy|Standard treatment
62099520|NCT01631903|EXPERIMENTAL|Arm 2 (3mg)|
62099521|NCT01631903|EXPERIMENTAL|Arm 3 (6 mg)|
62099522|NCT01631903|EXPERIMENTAL|Arm 4 (12 mg)|
62099523|NCT01631903|EXPERIMENTAL|Arm 5 (24 mg)|
62099524|NCT01631903|EXPERIMENTAL|PK arm (12 mg)|PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
62099525|NCT05451108|EXPERIMENTAL|Insertion of PCL Pectus scaffold|Insertion of a custom-made 3D printed medical-grade polycaprolactone (PCL) Pectus scaffold with autologous fat graft for pectus excavatum defect correction.
62099526|NCT02823743|EXPERIMENTAL|Low dose aspirin|75 mg aspirin orally daily from gestational week 7-35
62099527|NCT02823743|PLACEBO_COMPARATOR|Placebo|Placebo pill orally daily from gestational week 7-35
62661892|NCT05235607|EXPERIMENTAL|Tumor antigen-sensitized vaccine and their sensitized T cells|"Tumor antigen-sensitized vaccine is administrated, 1- week interval, totally 2 times.~Then, Neo-antigen DC vaccine and their sensitized T cells are administrated, 2-week interval, totally 5 times."
61910310|NCT01038869|EXPERIMENTAL|Azelaic acid 15% (Finacea)|Open label pilot study, Topical gel to be appiled twice daily for 16 weeks
62099528|NCT03134456|EXPERIMENTAL|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
62099529|NCT02820051|ACTIVE_COMPARATOR|Midazolam|"In the group of midazolam, the initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
62099530|NCT02820051|EXPERIMENTAL|Propofol|"In the group of propofol, the starting dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
62099531|NCT05893121||Control|subjects who received information about MRI examination
62099532|NCT05893121||Experimental|Subjects who received information about MRI examination and one cardiac coherence session
62099533|NCT05196633|EXPERIMENTAL|Conventional physiotherapy, visual feedback training, rESWT|conventional physiotherapy (5 times/week), visual feedback training (5 times/week), radial extracorporeal shock wave therapy (once/week for 2 weeks)
62099534|NCT05196633|SHAM_COMPARATOR|Conventional physiotherapy, visual feedback training, sham rESWT|conventional physiotherapy (5 times/week), visual feedback training (5 times/week), sham radial extracorporeal shock wave therapy (once/week for 2 weeks)
62099535|NCT02887651|NO_INTERVENTION|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
62099536|NCT02887651|ACTIVE_COMPARATOR|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
62099537|NCT01371201|EXPERIMENTAL|Sunitinib|sunitinib 37.5 mg per day
62099538|NCT01371201|PLACEBO_COMPARATOR|Placebo|Placebo 37.5 mg per day
62099539|NCT04238715|EXPERIMENTAL|E7090 140 mg|Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.
62099540|NCT04889118|EXPERIMENTAL|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
62099541|NCT04889118|ACTIVE_COMPARATOR|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
62099542|NCT00651677|ACTIVE_COMPARATOR|HAL Proctectomy|Hand-assisted laparoscopic proctectomy
62099543|NCT00651677|ACTIVE_COMPARATOR|SL Proctectomy|"straight laparoscopic proctectomy"
62099544|NCT00483262|EXPERIMENTAL|CCI779 and Bortezomib Phase I/II|In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.
62099545|NCT06565390|EXPERIMENTAL|Babies in the Owlet monitor group|The Owlet group will be given an Owlet OSS 3.0 monitor to wear when sleeping. The Owlet alarms if the baby has a very low heart rate or very low oxygen levels. In addition, caregivers in the Owlet group with a smart phone and Wi-Fi access will be able to use an application to monitor the baby's vital signs and sleep state. Will complete a survey or questionnaire every month until 6 months after discharge.
62661893|NCT05998447|EXPERIMENTAL|GEN-001 with pembrolizumab or GEN-001 with pembrolizumab and mFOLFOX|"Drug: GEN-001~Drug: pembrolizumab~Drug: mFOLFOX"
62661894|NCT01026766||Non obese/ Warming blankets|
62661895|NCT01026766||Non obese/ Warming intravenous fluids|
62661896|NCT01026766||Obese/ Warming intravenous fluids|
62661897|NCT01026766||Obese/ Warming blankets|
62661898|NCT05124548||Post-COVID condition|
62661899|NCT05124548||Healthy controls|
62466806|NCT02923635|ACTIVE_COMPARATOR|Standard Wide Local Excision group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
62466807|NCT02923635|ACTIVE_COMPARATOR|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
62099546|NCT06565390|NO_INTERVENTION|Babies in the Usual Care Group|The usual care group will not be given an Owlet vital sign monitor. Will complete a survey or questionnaire every month until 6 months after discharge.
62466808|NCT01739959||Necrotizing fasciitis proven|Histological evidence of necrotizing fasciitis at initial surgical debridement
62466809|NCT01739959||Not necrotizing fasciitis|A composite of those with no histological tissue necrosis at initial surgical debridement, and those clinically judged not to be a necrotizing infection who therefore did not undergo surgery.
62466810|NCT03552692|EXPERIMENTAL|ARM1 - Venetoclax (ABT-199)|"Venetoclax (ABT-199) will be administered orally at the dose of 800 mg once daily.~Response evaluation will be performed initially after 3 cycles from the beginning of treatment with ABT-199 and then every 3 cycles during the first 12 cycles, every 4 cycles from cycle 13 to 24; for those patients still on therapy after 24 cycles, the response evaluation, after this time, will be performed every 6 cycles."
62466811|NCT01540760|EXPERIMENTAL|MCAF5352A|
62466812|NCT01540760|PLACEBO_COMPARATOR|Placebo|
62099547|NCT06711185|EXPERIMENTAL|Dapagliflozin|Standard chemotherapy treatment + Dapagliflozin 10mg/day.
62099548|NCT06711185|PLACEBO_COMPARATOR|Placebo Group|Standard chemotherapy treatment + Placebo.
62099549|NCT06630273||Enrollment|Correlative Collection until time of disease progression of protocol specific IO therapy
62099550|NCT05933122|SHAM_COMPARATOR|"Cohort called elsewhere"|cohort without specific care by a sexologist
62099551|NCT05933122|EXPERIMENTAL|"Cohort called here"|cohort with an intervention by a sexologist
62099552|NCT02682355||Study cohort|Patients receiving IV polymyxin B for treatment of bacteremia and/or urinary tract infection and/or respiratory tract infection (including tracheobronchitis) or sepsis
62099553|NCT05492890||Dexcom CGM|Continuous glucose monitoring
62099554|NCT05492890||Point of care testing|Finger poke glucose measure
62099555|NCT00071643|EXPERIMENTAL|1 Problem Solving Therapy|Participants will receive problem solving therapy.
62099556|NCT00071643|EXPERIMENTAL|2. Escitalopram|Participants will receive escitalopram.
62099557|NCT00071643|PLACEBO_COMPARATOR|3 Placebo|Participants will receive placebo.
62099558|NCT06644014|EXPERIMENTAL|AI-instructed group|Participants in this group will receive Oura Rings and access to AI-based exercise guidance. They are instructed to follow received instructions, but they are blinded to their outcome measure (CVA).
62099559|NCT06644014|ACTIVE_COMPARATOR|Supervised exercise group|Participants in this group receive Oura Rings and are instructed to attend supervised HIIT-cycling sessions twice a week. They are blinded to their outcome measure (CVA).
62099560|NCT06644014|OTHER|Ring-only group|Participants in this group receive Oura Rings but no AI-advice or supervised training. They are blinded to the outcome measure (CVA).
62099561|NCT06540118|EXPERIMENTAL|15 Medically Tailored Meals (MTM) + snacks|Participants will receive 15 medically tailored meals (MTM) per week, plus snacks, for 12 weeks.
62099562|NCT06540118|EXPERIMENTAL|14 Medically Tailored Meals (MTM)|Participants will receive 14 medically tailored meals (MTM) per week for 12 weeks.
62099563|NCT06711341|ACTIVE_COMPARATOR|Whole-body Vibration (WBV) Training Group|Participants undergo WBV training as outlined in the WBV intervention, 3 days per week for 3 weeks. The sessions begin with a duration of 10 minutes in the first week, with the duration increasing each week thereafter. They also perform the home exercises assigned to the Control group on the same days as their PRE sessions.
62099564|NCT06711341|ACTIVE_COMPARATOR|Progressive Resistance Exercise (PRE) Group|Participants undergo PRE training as outlined in the PRE intervention, 3 days per week for 3 weeks. The training focuses on strengthening the quadriceps muscles using ankle weights. The load is determined using the DeLorme principle at the start of each week. They also perform the home exercises assigned to the Control group on the same days as their PRE sessions.
62099565|NCT06711341|ACTIVE_COMPARATOR|Control Group (Home-Based Exercise)|Participants perform home exercises three days per week for 3 weeks. The exercises consist of range of motion (ROM) and isometric strengthening exercises as detailed in the intervention section.
62099566|NCT04852887|ACTIVE_COMPARATOR|Arm 1: Breast Radiation Therapy + Endocrine Therapy|Radiation therapy to the breast and hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
62099567|NCT04852887|ACTIVE_COMPARATOR|Arm 2: No Breast Radiation Therapy + Endocrine Therapy|No radiation therapy, only hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
62099568|NCT03230565|ACTIVE_COMPARATOR|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
62099569|NCT03230565|ACTIVE_COMPARATOR|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
62099570|NCT06253325||Patients presenting to the Emergency Department with suspected sepsis|Patients who present with potential sepsis. This is characterised by their illness suspected to be from an infection and significantly unwell defined by one of two scoring systems, either the National Early Warning Score or quick Sequential Organ Failure Assessment
62099571|NCT05904106|EXPERIMENTAL|Ven+Aza arm|non-intensive treatment: venetoclax plus azacitidine
62099572|NCT05904106|ACTIVE_COMPARATOR|SOC arm|standard of care treatment: intensive chemotherapy plus gemtuzumab ozogamicin
61910311|NCT03207165|ACTIVE_COMPARATOR|Left ventricular [LV] +/- Biventricular dysfunction|Assessment of left ventricular \[LV\] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
62099573|NCT06644651||Participants with type 2 diabetes mellitus|The study population consists of participants with type 2 diabetes mellitus who are cardiac asymptomatic and have no known coronary heart disease. Participants underwent a baseline examination and CCTA scan, followed by a 12-month visit with repeated examinations and a second CCTA scan. A journal audit will be conducted for all participants approximately 7 years after the baseline CCTA scan.
62099574|NCT02774356||Native Chinese speakers|
62099575|NCT02774356||Native English speakers without experience of a tonal language|
62099576|NCT06712537||Renal allograft futility|This refers to the group meeting the primary outcome, which is the need for dialysis or occurrence of death at 3 months after simultaneous liver-kidney transplantation. This group defines the absence of renal function recovery post-transplant and thus renal graft failure, termed renal futility.
62099577|NCT06712537||Control group|
62099578|NCT06323330|EXPERIMENTAL|Intervention|The intervention arm will be given the Music Therapy, the Indian language adapted module
61910312|NCT03207165|ACTIVE_COMPARATOR|Right ventricular [RV] dysfunction|Assessment of right ventricular \[RV\] dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
62294632|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
62099579|NCT06323330|ACTIVE_COMPARATOR|Active comparator|The active comparator arm will be given the standard speech rehabilitation.
62099580|NCT01061905|EXPERIMENTAL|Calorie information only|Posting calorie information of sugar-sweetened and zero-calorie beverages prominently on a poster.
62099581|NCT01061905|EXPERIMENTAL|Exercise Equivalent Information|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
62099582|NCT01061905|EXPERIMENTAL|Calorie and Exercise Equivalent information|Posting of both calorie and exercise equivalent information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
62099583|NCT06712355|EXPERIMENTAL|Arm 1 - Atezolizumab + Etoposide + Carboplatin|
62099584|NCT06712355|EXPERIMENTAL|Arm 2 - BNT327 Dose 1 + Etoposide + Carboplatin|
62099585|NCT06712355|EXPERIMENTAL|Arm 3 - BNT327 Dose 2 + Etoposide + Carboplatin|
62099586|NCT05829681|EXPERIMENTAL|Medial Prefrontal Cortex (MPFC)|Intermittent theta-burst stimulation (iTBS) of MPFC at up to 100% resting motor threshold (RMT), with lower extremity RMT established for the MPFC target.
61910313|NCT03478436|OTHER|fed group|14 once daily oral doses of doxycycline 40 mg, preceded by a standardized high-fat, high-calorie breakfast
62099587|NCT05829681|ACTIVE_COMPARATOR|Right Prefrontal Cortex (rPFC)|Continuous theta-burst stimulation (cTBS) of rPFC at up to 110% of RMT, with upper extremity RMT established for the rPFC target.
62099588|NCT06713824||neo-adjuvant radiotherapy and surgery|receive radiation therapy before surgery
62099589|NCT04001504|EXPERIMENTAL|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV during index ACS hospitalization
61910314|NCT03478436|OTHER|fasting group|14 once daily oral doses of doxycycline 40 mg in fasting conditions (no food allowed 8 hours prior to dosing)
62099590|NCT04001504|ACTIVE_COMPARATOR|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV 30 days after randomization
62099591|NCT06611358|EXPERIMENTAL|Kinesiology Taping Group|Individuals meeting the inclusion criteria will have kinesio tape applied to the temporomandibular joint by a physiotherapist every three days for a duration of two weeks. In addition to the kinesio taping, participants will perform an at-home exercise program prescribed three days a week. This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). As part of the treatment protocol, each movement will be performed in 3 sets of 15 repetitions.
62099592|NCT06611358|ACTIVE_COMPARATOR|Conventional Group|Individuals meeting the inclusion criteria will not receive kinesio taping but will follow the same exercise protocol as the Kinesio Taping + Exercise Group. Participants will perform an exercise program prescribed three days a week, including isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). As part of the treatment protocol, each movement will be performed in 3 sets of 15 repetitions.
62099593|NCT02518243|EXPERIMENTAL|Alzheimer's Disease|
61910315|NCT02402725|EXPERIMENTAL|Ultra-high dose dexamethasone|Ultra-high dose dexamethasone administered intravenously and orally
62099594|NCT06709846||Patients with Metabolic Diseases|
62099595|NCT06709846||Healthy Control Participants|
62099596|NCT02858323||1|Previously selected HLA-alloimmunized platelet refractory, clinical, patients.
62099597|NCT02122848|EXPERIMENTAL|Bilevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
62099598|NCT01796093||Digoxin cross-over ivabradine|Digoxin 0,125 mg once a day 5 days per week during 3 months. Ivabradine, 7,5 mg b.id. during 3 months.
62099599|NCT00507637|EXPERIMENTAL|NT 201 (IncobotulinumtoxinA/Xeomin®)|
62099600|NCT00809874|ACTIVE_COMPARATOR|Casein|
61910316|NCT03105544|EXPERIMENTAL|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
62099601|NCT00809874|ACTIVE_COMPARATOR|Whey Isolate|
62099602|NCT00809874|ACTIVE_COMPARATOR|Whey Hydrolysate|
61910317|NCT03105544|NO_INTERVENTION|Control|No intervention.
61910318|NCT03751254|EXPERIMENTAL|Myopic patients|In myopic patients with axial length over 25.0 mm during surgery of the first eye the Stellaris platform will be used and during surgery of the second eye the Stellaris Elite platform will be used
61910319|NCT05101200|EXPERIMENTAL|High Dose Neural Mobilization Technique|Patients in this Group will receive High Dose Neural Mobilization Technique
61910320|NCT05101200|EXPERIMENTAL|Low Dose Neural Mobilization Technique|Patients in this Group will receive Low Dose Neural Mobilization Technique
62099603|NCT00809874|ACTIVE_COMPARATOR|Alphalact-Albumin|
62099604|NCT05844423|EXPERIMENTAL|VAX-24 Low|Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
62099605|NCT05844423|EXPERIMENTAL|VAX-24 Mid|Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
62099606|NCT05844423|EXPERIMENTAL|VAX-24 Mixed|Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
62099607|NCT05844423|ACTIVE_COMPARATOR|PCV20|Participants will receive 4 doses of PCV20 administered as an intramuscular injection of the standard dose at 2, 4, 6, and 12-15 months of age.
62099608|NCT05842850|EXPERIMENTAL|LBW individuals with NAFLD|LBW individuals with NAFLD
62099609|NCT05842850|PLACEBO_COMPARATOR|NBW controls without NAFLD|Age-, gender- and body mass index-matched NBW controls without NAFLD
62099610|NCT06712316|EXPERIMENTAL|Substudy A Phase 2 - BNT327 Dose 1 + Carboplatin + Pemetrexed|
62099611|NCT06712316|EXPERIMENTAL|Substudy A Phase 2 - BNT327 Dose 2 + Carboplatin + Pemetrexed|
62099612|NCT06712316|EXPERIMENTAL|Substudy A Phase 3 - BNT327 + Carboplatin + Pemetrexed|BNT327 selected dose for Phase 3
62099613|NCT06712316|ACTIVE_COMPARATOR|Substudy A Phase 3 - Pembrolizumab + Carboplatin + Pemetrexed|
62099614|NCT06712316|EXPERIMENTAL|Substudy B Phase 2 - BNT327 Dose 1 + Carboplatin + Paclitaxel|
62099615|NCT06712316|EXPERIMENTAL|Substudy B Phase 2 - BNT327 Dose 2 + Carboplatin + Paclitaxel|
62099616|NCT06712316|EXPERIMENTAL|Substudy B Phase 3 - BNT327 + Carboplatin + Paclitaxel|BNT327 selected dose for Phase 3
62099617|NCT06712316|ACTIVE_COMPARATOR|Substudy B Phase 3 - Pembrolizumab + Carboplatin + Paclitaxel|
62099618|NCT05978609|EXPERIMENTAL|Candonilimab in combination with cisplatin and gemcitabine|"This study is a single-arm study to evaluate the safety and efficacy of candonilimab combined with cisplatin and gemcitabine in advanced biliary tract tumors~Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；~Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；~gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；"
62099619|NCT01585181|PLACEBO_COMPARATOR|Placebo|
62099620|NCT01585181|EXPERIMENTAL|PXVX0200|
62099621|NCT04315220|EXPERIMENTAL|Experimental group (Core stability training (CST))|"Core stability training (CST) consists of two levels: level 1- Mat exercises (includes abdominal muscle contraction, bridging,cat stretch,single leg circle and superman) and level 2- Swiss ball exercises (includes abdominal muscle contraction, bridging and squatting by using therapy ball).~There will be three sets of 15 repetitions of each exercises. The first set will consist of 10 seconds hold period, follow by 12 seconds hold in second set and 15 seconds hold in third set respectively. The entire session will last for approximately 30 minutes."
62099622|NCT04315220|ACTIVE_COMPARATOR|Control group|Will not receive any kind of training.
62099623|NCT06712511|EXPERIMENTAL|water|The participants will drink 200 ml water four times at 1 hour intervals.
62099624|NCT06712511|EXPERIMENTAL|coffee|The participants will drink 200 ml coffee four times at 1 hour intervals.
62099625|NCT06713018|EXPERIMENTAL|Three cannulated compression screws by navigation system|
62099626|NCT06713018|PLACEBO_COMPARATOR|Traditional three cannulated compression screws|
62099627|NCT06582628|ACTIVE_COMPARATOR|Control|Enzalutamide 160 mg orally daily continuously in 28-day cycles.
62099628|NCT06582628|EXPERIMENTAL|Enzalutamide and Talazoparib|Enzalutamide 160 mg and Talazoparib 0.5 mg both orally daily and continuously in 28-day cycles.
62099629|NCT05173571|EXPERIMENTAL|Nutritional and physical activity program|Homecare IPF patient educational, nutritional and physical activity training based on patient's needs
62099630|NCT05945823|EXPERIMENTAL|Cohort A|Patients with Esophageal cancer (Adenocarcinoma or Squamous cell cancer) will receive Futibatinib administered once daily on a continuous dosing regimen in combination with pembrolizumab plus investigator choice of SoC chemotherapy (FP or mFOLFOX6) for 6 cycles (induction phase) following by Futibatinib combination with pembrolizumab (consolidation phase).
62099631|NCT05945823|EXPERIMENTAL|Cohort B|Patients with PDAC will receive Futibatinib administered once daily on a continuous dosing regimen in combination with pembrolizumab plus mFOLFIRINOX for 6 cycles (induction phase) following by Futibatinib combination with pembrolizumab (consolidation phase) .
62099632|NCT00583089||1|Algorithm Test Set
62099633|NCT00583089||2|Algorithm Development Set
62099634|NCT06511934|EXPERIMENTAL|BrainGate Neural Interface System|Device: BrainGate Neural Interface System
62099635|NCT05761067|EXPERIMENTAL|Percutaneous Coronary Intervention (PCI)|Patients will be revascularized by PCI
62099636|NCT05761067|NO_INTERVENTION|Coronary artery bypass grafting (CABG)|Patients will be revascularized by CABG
62466813|NCT02867280|EXPERIMENTAL|Sorafenib|Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
62466814|NCT02867280|NO_INTERVENTION|Control|No use of Sorafenib (Nexavar). Regular treatment.
62099637|NCT06265168||Physicians|Volunteering intensivists, emergency physicians, internists, and neurologists.
62099638|NCT02999217|ACTIVE_COMPARATOR|Treatment|1 g of intravenous iron isomaltoside given postoperatively for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin\<100 mkg/l).
62099639|NCT02999217|PLACEBO_COMPARATOR|Control|The same amount of intravenous saline for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin\<100 mkg/l).
62099640|NCT01304706|EXPERIMENTAL|Fluocinolone Acetonide|
62099641|NCT05800665|EXPERIMENTAL|Stage 1: Dose Escalation|Participants will receive RO7656594 administered at a specified dose on specific days in each 28-day cycle. The dose will be increased in successive cohorts until a study-specific threshold is reached.
62099642|NCT05800665|EXPERIMENTAL|Stage 2: Expansion|Participants will receive RO7656594 at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD).
62099643|NCT02973919|EXPERIMENTAL|Eye movements|Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
62099644|NCT02973919|ACTIVE_COMPARATOR|Control|virtual reality exposure therapy
62099645|NCT06629467|EXPERIMENTAL|1) CBT for smoking cessation + personalized PA plan + Fitbit Versa 3 ®.|"The intervention will be delivered in groups (maximum 4 participants) for a total of 6 weeks. Sessions (1.5 hours) will take place once per week. Personalized PA objectives will be set during the treatment.~Participants in this arm will wear the Fitbit Versa 3® during the treatment (6 weeks)."
62099646|NCT06629467|ACTIVE_COMPARATOR|2) CBT for smoking cessation + personalized PA plan|This intervention include the same components as described above. The exception will be that participants will not be requested to wear the Fitbit Versa 3®.
62099647|NCT03673202||UC monitoring patients|Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.
62099648|NCT02392156||rFVIIIFc for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
62099649|NCT02392156||non-Fc (fusion protein) replacement products for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
62099650|NCT02392156||rFIXFc for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
62099651|NCT02392156||non-Fc factor replacement products for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
62099652|NCT06556212|EXPERIMENTAL|Feedback|This arm will have the smart swim goggles display on and receive real-time metrics and guided workouts via the goggles throughout the study training period.
62099653|NCT06556212|NO_INTERVENTION|Non-feedback|This arm will have the smart swim goggles display turned on but will only have the workout timer visible during rest. They will not receive real-time metrics or guided workouts via the goggles.
62099654|NCT06712667|PLACEBO_COMPARATOR|Water|The participants will drink 200 ml water.
62099655|NCT06712667|EXPERIMENTAL|Decaffeinated coffee|The participants will drink 200 ml decaffeinated coffee.
62099656|NCT06712667|EXPERIMENTAL|Coffee|The participants will drink 200 ml coffee, the caffeine content is 200 mg.
62099657|NCT03155204|EXPERIMENTAL|Test Product 1|tiotropium pMDI 2 inhalations
62099658|NCT03155204|EXPERIMENTAL|Test Product 2|tiotropium pMDI 2 inhalations
62099659|NCT03155204|EXPERIMENTAL|Test Product 3|tiotropium pMDI 2 inhalations
62099660|NCT03155204|EXPERIMENTAL|Test Product 4|tiotropium pMDI 2 inhalations
62099661|NCT03155204|ACTIVE_COMPARATOR|Commercial Product|tiotropium Respimat 2 inhalations
62099662|NCT04974489|EXPERIMENTAL|Emotion-based messages about the harm of VLNC|
62099663|NCT04974489|EXPERIMENTAL|Continued-harm-framed messages about the harm of VLNC|
62099664|NCT04974489|EXPERIMENTAL|Myth-refuting messages about the harm of VLNC|
62099665|NCT04974489|ACTIVE_COMPARATOR|Control messages about littering|
62099666|NCT04893421|NO_INTERVENTION|Standard of Care WGS or RSL|Patients will undergo the institutional standard of care approach (WGS or RSL) for BCS. For WGL, a hooked wire will be implanted to mark the center or outer edges of the lesion under imaging guidance. For RSL, patients will be implanted with a radioactive seed using an impregnated needle under imaging guidance. A special handheld probe will be used to find the radioactive seed during the lumpectomy surgery.
62294633|NCT02162888|OTHER|Eagle-BDM; Teva-BDM; Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
61910321|NCT03497598|EXPERIMENTAL|mannose|"2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
62661900|NCT03121274|ACTIVE_COMPARATOR|Early pushing during vaginal delivery|patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not
62099667|NCT04893421|EXPERIMENTAL|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
62099668|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
62099669|NCT06364423|EXPERIMENTAL|1/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose escalation|Escalating dose of anti-CD19 CAR T- cells/kg + rituximab and conditioning chemotherapy
62099670|NCT06364423|EXPERIMENTAL|2/Rituximab, conditioning chemotherapy plus CAR T-cells- Dose expansion|MTD dose or Optimal dose of Anti-CD19 CAR T- cells/kg + rituximab and conditioning chemotherapy
62099671|NCT05214365|ACTIVE_COMPARATOR|Conventional stimulation|An electrode (in the apical or septal portion) will be implanted at the discretion of the implanter physician. Parameters of (sensing, impedance and threshold) will be measured as is usually done in our center.
62294634|NCT02162888|OTHER|Teva-BDM; Eagle-BDM;Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
62294635|NCT02162888|OTHER|Teva-BDM, Teva-BDM, Eagle-BDM|Eagle-BDM: IV Teva-BDM: IV
62294636|NCT00398112|EXPERIMENTAL|Arm I|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62294637|NCT04366999||SG|In this group, the bariatric procedure is sleeve gastrectomy (SG), all operations follow the same standard operating procedure.
62294638|NCT04366999||RYGB|In this group, the bariatric procedure is Roux-en-Y gastric bypass (RYGB), all operations follow the same standard operating procedure.
62294639|NCT04366999||OAGB|In this group, the bariatric procedure is one anastomosis gastric bypass(OAGB), all operations follow the same standard operating procedure.
62661901|NCT03121274|ACTIVE_COMPARATOR|Delayed pushingduring vaginal delivery|patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible
62661902|NCT02184156|EXPERIMENTAL|AMPION™ 4 mL dose|4 mL injection of Ampion
61910322|NCT03497598|PLACEBO_COMPARATOR|placebo|"2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
61910323|NCT02397018|EXPERIMENTAL|Allogeneic Umbilical Cord Blood Infusion|All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.
62099672|NCT05214365|ACTIVE_COMPARATOR|Physiological stimulation|Pacing the his-purkinje system.
62099673|NCT06369129|EXPERIMENTAL|Orbital floor reconstruction with Patient Specific Zirconia Implant|Orbital floor reconstruction with Patient Specific Zirconia Implant will be done
62099674|NCT06369129|ACTIVE_COMPARATOR|Orbital floor reconstruction with Patient Specific Titanium Implant|Orbital floor reconstruction with Patient Specific Titanium Implant will be done.
62099675|NCT02460887|EXPERIMENTAL|Experimental|Induction chemotherapy+IMRT gemcitabine and cisplatin regimen Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT).
62099676|NCT02460887|ACTIVE_COMPARATOR|Active Comparator|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with weekly cisplatin 40 mg/m² up to 7cycles.
62661903|NCT02184156|PLACEBO_COMPARATOR|Placebo 4 mL dose|4 mL injection of placebo
62661904|NCT03948490|OTHER|Arm 1 Cohort 1: Interventional arm/In-person rehab (CLOSED)|"The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.~n = 20 patients"
62661905|NCT03948490|EXPERIMENTAL|Arm 1 Cohort 2: Interventional arm/ReMind iPad app (CLOSED)|"The ReMind iPad-based cognitive rehabilitation was developed with collaborators at Tilburg University, The Netherlands, and is an evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors. Brain plasticity-based computerized cognitive training is a newly developing field of therapeutics for neurological and psychiatric disorders that uses frequent game-like training sessions to drive improvements in cognitive functions.~n = 20 patients"
62661906|NCT03948490|EXPERIMENTAL|Arm 1 Cohort 3: Interventional arm/Healthy SMS texting (CLOSED)|"The mobile phone texting intervention was developed with collaborators at Zuckerberg San Francisco General Hospital and is currently being studied in individuals with depression and traumatic brain injury. Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.~n = 20 patients"
62661907|NCT03948490|NO_INTERVENTION|Arm 2 Cohort 4: Longitudinal arm/Upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
62099677|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
62099678|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
62099679|NCT05310084|EXPERIMENTAL|Coadministration Group|BNT162b2 and SIIV followed by placebo a month later
62099680|NCT05310084|EXPERIMENTAL|Separate Administration Group|Placebo and SIIV followed by BNT162b2 a month later
62099681|NCT02840448||Case|Subjects with WS/SVAS/WS gene region variation
62099682|NCT02840448||Controls|Healthy volunteers
62099683|NCT06667414||Participants Who Are Huntington Disease Gene Expansion Carriers|
62099684|NCT05800821||Patients with reduced cerebrovascular reserve|
62661908|NCT03948490|NO_INTERVENTION|Arm 1 Cohort 5: Longitudinal arm/No upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
62661909|NCT03948490|OTHER|Arm 1 Cohort 1A: Telehealth Cognitive Rehabilitation|"The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning. During treatment implementation, patients acquire, apply, and adapt evidenced based strategies based on neuropsychological testing and conjointly developed treatment planning goals.~N=20"
62099685|NCT05800821||Patients with sufficient cerebrovascular reserve|
62661910|NCT04257864||Erlotinib followed by docetaxel|Erlotinib given for twelve consecutive days before docetaxel
62661911|NCT04257864||Docetaxel followed by erlotinib|Erlotinib given for twelve consecutive days after docetaxel
62661912|NCT04257864||Bevacizumab treated|Bevacizumab treated patients
62661913|NCT04373733|EXPERIMENTAL|Favipiravir & Standard of Care|Favipiravir: Day 1 1800mg twice per day, Days 2-10 800mg twice per day
62661914|NCT04373733|OTHER|Standard of care|No trial intervention
62661915|NCT00393367|PLACEBO_COMPARATOR|Saline Placebo|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.
62661916|NCT00393367|EXPERIMENTAL|Budesonide Inhalaiton Suspension|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.
62661917|NCT01642160|ACTIVE_COMPARATOR|Standard of care|Participants randomized to this arm will have the usual follow up care without any additional information.
62661918|NCT01642160|ACTIVE_COMPARATOR|Additional Education|This arm will receive a weekly text message or e-mail asking participants to sign on to the web page that we will provide. Once they sign on, they will see additional educational materials and questions regarding their CPAP use. Based on their response, they will be directed to suggestion or sites to help improve their compliance with their CPAP.
62661919|NCT01245062|EXPERIMENTAL|GSK1120212|MEK inhibitor
62661920|NCT01245062|ACTIVE_COMPARATOR|Chemotherapy|Investigator Choice of DTIC or paclitaxel
62661921|NCT01245062|EXPERIMENTAL|Crossover|MEK inhibitor after documented progression on Chemotherapy Arm
62661922|NCT05699681||Study cohort|Children aged below 12 years undergoing elective cardiac surgery for congenital heart disease with left to right shunt with prior evidence of pulmonary arterial hypertension on preoperative echocardiography
62661923|NCT00464464|ACTIVE_COMPARATOR|1|cognitive-behavioral therapy
62661924|NCT00464464|NO_INTERVENTION|2|standard medical care
62661925|NCT05949840|EXPERIMENTAL|Expressive Interviewing + Survey|Intervention with Expressive Interviewing computer system. Participants spent roughly 10-15 minutes each in conversation with an automated computer chat system. Participants answered a survey about mental health and social outcomes immediately before the intervention and two weeks after the intervention.
62661926|NCT05949840|NO_INTERVENTION|Survey Only|No intervention. Participants answered a survey about mental health and social outcomes at time of recruitment and two weeks afterward.
62661927|NCT00637897|EXPERIMENTAL|Paricalcitol (Zemplar)|Paricalcitol (Zemplar)
62661928|NCT00004055|EXPERIMENTAL|topotecan + paclitaxel + filgrastim|Patients receive oral topotecan on days 1-5 followed by paclitaxel IV over 3 hours on day 5. Beginning 24-48 hours after chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily for up to 10 days until blood counts recover. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression. Patients who develop CNS progressive disease only should receive whole brain radiotherapy before continuing study treatment.
62661929|NCT03841292|ACTIVE_COMPARATOR|Active tDCS+Varenicline|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
62661930|NCT03841292|SHAM_COMPARATOR|Sham tDCS+Varenicline|Sham tDCS (Nuraleve, Canada)(30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
62661931|NCT03983109|EXPERIMENTAL|Detection by EpiFaith syringe with air|Fill the EpiFaith Syringe with air for LOR detection
62099686|NCT05367674|EXPERIMENTAL|Summer Harvest Adventure (SHA)|Remote nutrition counseling, weekly produce harvesting, group nutrition education
62099687|NCT05367674|ACTIVE_COMPARATOR|My Summer Plate (MSP)|Nutrition education packet
62661932|NCT03983109|EXPERIMENTAL|Detection by EpiFaith syringe with saline|Fill the EpiFaith Syringe with saline for LOR detection
62661933|NCT01819662|PLACEBO_COMPARATOR|Standard management|No echocardiogram
62661934|NCT01819662|ACTIVE_COMPARATOR|Enhanced standard management|Echocardiogram performed, with results to GP
62308164|NCT01803165||Single shot femoral and sciatic nerve block|Prospective patient study group who present for infrainguinal bypass grafting and will receive single shot femoral and sub gluteal sciatic nerve blocks.
62099688|NCT04380844|ACTIVE_COMPARATOR|Beprevent|10 will become part of the intervention group. Each of the participants in the intervention group is selected. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
62099689|NCT04380844|NO_INTERVENTION|patients only evaluated|10 will be included in the control group. During the period of the study, we will pass the same questionnaires in the participants assigned to the control group, also leaving a time interval of two weeks, and no device will be installed, nor will any monitoring be carried out in their homes.
62099690|NCT05300555|EXPERIMENTAL|Rivaroxaban group|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
62099691|NCT05300555|EXPERIMENTAL|Warfarin group|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
62099692|NCT06393634|ACTIVE_COMPARATOR|Testosterone group one|"The participant will receive a single injection of one of three types of testosterone in phase one.~In phase two the participant will receive two weeks of either a daily skin cream or a twice-daily pill to swallow."
62099693|NCT06393634|ACTIVE_COMPARATOR|Testosterone group two|"The participant will receive a single injection of one of three types of testosterone in phase one.~In phase two the participant will receive two weeks of either a daily skin cream or a twice-daily pill to swallow."
62099694|NCT03367364|ACTIVE_COMPARATOR|Patient education bundle (PEB)|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
62099695|NCT03367364|PLACEBO_COMPARATOR|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
62099696|NCT03910465||1/Cohort 1|Subjects with confirmed chordoma.
62099697|NCT06712888|ACTIVE_COMPARATOR|Induction GP+placebo group|"GP + Placebo Induction Therapy:~Gemcitabine: 1000 mg/m² on days 1 and 8 DDP (cisplatin): 80 mg/m² on day 1 Placebo: 240 mg on day 1 Total of 3 cycles.~Concurrent Chemoradiotherapy (CCRT):~DDP (cisplatin): 100 mg/m² on day 1 of radiation, then every 3 weeks during radiotherapy.~Total of 3 cycles (administered on D1, D22, and D43).~Adjuvant Metronomic Capecitabine Therapy:~Starts 4-6 weeks after the completion of radiotherapy and continues for up to 1 year.~Adjuvant metronomi capecitabine is administered at the physician's discretion: Capecitabine: 650 mg/m², administered BID (twice daily)."
62099698|NCT06712888|EXPERIMENTAL|Induction GP+toripalimab group|"Induction GP + Toripalimab Therapy:~Gemcitabine: 1000 mg/m² on days 1 and 8 DDP (cisplatin): 80 mg/m² on day 1 Toripalimab: 240 mg on day 1 Total of 3 cycles.~Concurrent Chemoradiotherapy (CCRT):~DDP (cisplatin): 100 mg/m² on day 1 of radiation, then every 3 weeks during radiotherapy.~Total of 3 cycles (administered on D1, D22, and D43).~Adjuvant Metronomic Capecitabine Therapy:~Starts 4-6 weeks after the completion of radiotherapy and continues for up to 1 year.~Adjuvant metronomic capecitabine therapy is administered at the physician's discretion: Capecitabine: 650 mg/m², administered BID (twice daily)."
62099699|NCT05737628|EXPERIMENTAL|BYON4228 + Rituximab|"BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.~Rituximab IV infusion (375 mg/m2) starts after first BYON4228 cycle. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles."
62099700|NCT04077281|EXPERIMENTAL|Intervention Arm|Clinical Pharmacology specialist team approach starting in hospital and following up with the patient at home using telemedicine and detailed communication with them, their caregiver, family physician, community pharmacist and other specialists.
62099701|NCT04077281|NO_INTERVENTION|Control Arm (Usual care)|Patients will receive a best possible medication history (BPMH) as do the intervention patients, then usual care by their primary team.
62099702|NCT05417204|EXPERIMENTAL|Correction of abnormal somatic response to a meal|Biofeedback in patients with functional dyspepsia and abnormal somatic response to a probe meal
62099703|NCT05417204|ACTIVE_COMPARATOR|Sham intervention in patients with normal somatic response to a meal|Biofeedback in patients with functional dyspepsia and normal somatic response to a probe meal
62099704|NCT03111095|EXPERIMENTAL|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
62661935|NCT01819662|ACTIVE_COMPARATOR|Optimised heart failure management|Echocardiogram, followed by referral to comprehensive heart failure program for those with left ventricular dysfunction
62661936|NCT04726904|OTHER|Conventional lead placement|The cadaver is placed in the prone position. The exact location for insertion of the needle is defined with the conventional technique.
62661937|NCT02560467|EXPERIMENTAL|Patients with HCM|This is a prospective, non-blinded single center study. Subjects with known HCM with variant will be recruited. MCE at rest and during vasodilator stress will be performed. Full echocardiography including for diastolic function and regional strain imaging will also be performed. Patient history and questionnaires will be used for evaluation of symptoms and arrhythmias.
62661938|NCT02507284|EXPERIMENTAL|SRX246 120mg BID|SRX246 capsules, administered orally, in divided doses twice daily
62661939|NCT02507284|EXPERIMENTAL|SRX246 160mg BID|SRX246 capsules, administered orally, in divided doses twice daily
62661940|NCT02507284|PLACEBO_COMPARATOR|Placebo|Placebo capsules, administered orally, in divided doses twice daily
61910324|NCT02270853|OTHER|sleep apnea screening with ApneaLinkTM|This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.
61910325|NCT03657771|ACTIVE_COMPARATOR|DED|Diet eliminating dairy
62099705|NCT03111095|NO_INTERVENTION|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
62099706|NCT05403138|EXPERIMENTAL|Daratumumab|Induction Period: Participants received daratumumab (8mg/kg) via intravenous (IV) every 2 weeks for two cycles. This was followed by the Maintenance Period: Participants received daratumumab (4mg/kg) via IV infusion every 4 weeks from the third dose (Week 4) onwards.
62099707|NCT05403138|PLACEBO_COMPARATOR|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles. This was followed by the Maintenance Period: Participants received matching placebo (4mg/kg) via IV infusion every 4 weeks from the third dose (Week 4) onwards.
62099708|NCT06351904|EXPERIMENTAL|RAG-01|The starting dose of RAG-01 is 30 mg, and there are 4 dose cohorts, including 30 mg, 100 mg, 300 mg and 600 mg, respectively. Each eligible subject will be distributed into one dose cohort.
62099709|NCT04107337|EXPERIMENTAL|Experimental group|Experimental group (N=10): this group will conduct a vocal work session based on semi-occluded vocal-tract exercises with a straw.
62099710|NCT04107337|OTHER|Control group|Control group (N=10): the second group acting as control group will perform a vocal work session based on open mouth exercices (vocalizations).
62099711|NCT01969890|EXPERIMENTAL|G-CSF administration|Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days
62099712|NCT01969890|NO_INTERVENTION|standard therapy|Standard therapy
62099713|NCT02588222||Healthy children|Healthy children, aged 6-18 years old.
62099714|NCT04123002|EXPERIMENTAL|Interventional group|Miswak chewing sticks would be provided to the participants and they would be explained the method of use
62099715|NCT04123002|NO_INTERVENTION|Comparison group|They would use only tooth brush and paste
61910326|NCT03657771|ACTIVE_COMPARATOR|FREE|Diet eliminating dairy and food additives
61910327|NCT03505398|EXPERIMENTAL|central vision disorder|
61910328|NCT03505398|EXPERIMENTAL|peripheral vision disorder|
61910329|NCT03505398|OTHER|control|
61910330|NCT00649597|EXPERIMENTAL|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
62099716|NCT06713785|OTHER|Amlodipine 0mg|amlodipine dose 0mg Week 0 → 1mg Week 2 → 2mg Week 4 → 3mg Week 6 → 4mg Week 8 → 5mg Dose escalation to continue in 1mg increments to a maximum of 5mg
62099717|NCT06713785|OTHER|Amlodipine 5mg|amlodipine dose 5mg Week 0 → 6mg Week 2 → 7mg Week 4 → 8mg Week 6 → 9mg Week 8 → 10mg Dose escalation to continue in 1mg increments to a maximum of 10mg
61910331|NCT00649597|ACTIVE_COMPARATOR|2|Lotensin HCT® Tablets 20 mg/25 mg
61910332|NCT03726385||Group I|Group I: The control group. Participants in this group received only NDT based upper extremity rehabilitation. Number of the participants were 19.
61910333|NCT03726385||Group II|Group II: The study group. Participants in this group received NDT based upper extremity rehabilitation + Cogniboard® Light Trainer training. Number of the participants were 19.
61910334|NCT04619160|ACTIVE_COMPARATOR|propofol|
61910335|NCT04619160|ACTIVE_COMPARATOR|sevoflurane|
61910336|NCT03786627|EXPERIMENTAL|Combined NMES and motor control|This group will receive combined 15-minute neuromuscular electrical stimulation and 30-minute motor control training based on movement system impairment concept.
61910337|NCT03786627|PLACEBO_COMPARATOR|Motor control and placebo NMES|This group will receive placebo NMES for 15 minutes followed by 30 minutes motor control training based on movement system impairment concept.
61910338|NCT03642704|EXPERIMENTAL|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
61910339|NCT05355493|EXPERIMENTAL|Mental Fatigue condition|"A Stroop task, of approximately 60 min, partitioned in 6 blocks of 336 stimuli, will be used as the mentally fatiguing task. In this task, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself. If, however, the ink color is red, the button to be pressed will be the button linked to the real meaning of the word, not the ink color. The word presented and its ink color will be randomly selected by the computer (100% incongruent), with all incongruent word-color combinations being equally common (meaning, in each block 84 words will be presented in the color red, yellow, green and blue). Subjects will be instructed to respond as quickly and accurately as possible. To assess performance accuracy (ACC) and reaction time (RT) will be collected and averaged every block."
62099718|NCT05909943|EXPERIMENTAL|Ruxolitinib|Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
62099719|NCT03526120|EXPERIMENTAL|Pistachio diet|Incorporates 44 g (1 serving) of pistachios into a daily diet
62099720|NCT03526120|NO_INTERVENTION|Control|No pistachio consumption
62099721|NCT06714110||Precice IMLL System|Patients 12 years of age or younger received Precice IMLL for correction of limb length discrepancy.
62099722|NCT06714110||External Fixator|Patients 12 years of age or younger received an external fixator for correction of limb length discrepancy.
62099723|NCT06712927|EXPERIMENTAL|Cohort A: Asymptomatic|
62099724|NCT06712927|EXPERIMENTAL|Cohort B: Symptomatic|
62099725|NCT06356181|EXPERIMENTAL|Experimental|Participants in this group will undergo 6 weeks of high-intensity functional training using the respiratory muscle training device.
62099726|NCT06356181|ACTIVE_COMPARATOR|Control|Participants in this group will undergo 6 weeks of high-intensity functional training without using the respiratory muscle training device.
62099727|NCT06714292|EXPERIMENTAL|Clip group|Patients who are underwent localization of colon lesion with fluorescent clip
62099728|NCT06714292|ACTIVE_COMPARATOR|ICG group|Patients who are underwent localization of colon lesion with ICG(indocyanine green) through tattooing method
62099729|NCT05676996|EXPERIMENTAL|attachment-based support group|"In addition to the routine follow-ups and trainings that the pregnant women in the intervention group can receive from the hospital, they will be included in the Attachment Based Support Program. Within the scope of the 1st stage of this support; A mobile application. There are 12 videos on connecting in the mobile application. These videos were shot by the researcher in a professional studio. 22nd-26th of pregnancy. The participants included in the study during the weeks of participation installed this mobile application on their phones during participation. It was requested to complete watching the videos by 36 weeks. In the second phase of Attachment-Based Support, breastfeeding and skin-to-skin contact support are provided to mothers on postpartum day 0."
62099730|NCT05676996|NO_INTERVENTION|routine follow-up control group|The control group pregnants were left to the routine follow-up of the hospitals during their pregnancy and postpartum period. In this follow-up; When pregnant women apply to the outpatient clinic services of the hospital, appointments are made for their monthly routine follow-up. Information and practices that support mother-infant attachment in attachment-based support modules are not included in these trainings.
62099731|NCT06538181|EXPERIMENTAL|Safety Run-in: Pacritinib|Assigned dose of pacritinib by mouth twice per day. Each cycle is 28 days and participants can receive up to 12 cycles of treatment.
62099732|NCT06538181|EXPERIMENTAL|Expansion: Pacritinib|Recommended phase II dose of pacritinib by mouth twice per day. Each cycle is 28 days and participants can receive up to 12 cycles of treatment.
62099733|NCT03956173||Clamp group|24 patients with type 1 diabetes.
62099734|NCT04427098|ACTIVE_COMPARATOR|a phase II single-arm interventional prospective study|"Patients included in the interventional study will receive subcutaneous enoxaparin in a single daily dose of:~* 60 mg once daily in case of body weight of 45 to 60 kg~* 80 mg per day in case of weight from 61 to 100 kg or~* 100 mg once daily in case of bodyweight \>100 kg~Enoxaparin will be started on the first day of COVID19 diagnosis and continued for 14 days."
62099735|NCT04427098|EXPERIMENTAL|observational cohort study|Patients included in the observational cohort will will receive standard thrombo-prophylaxis with subcutaneous enoxaparin 40 mg/die
62099736|NCT06698367|EXPERIMENTAL|Standard rehabilitation plus unilateral high-intensity strength exercise|Participants will undergo progressive strength training based on eccentric contractions during the mobilization and strengthening phases of standard rehabilitation.
62099737|NCT06698367|ACTIVE_COMPARATOR|Standard rehabilitation plus unilateral mobility exercises|Participants will undergo active mobility training of the pronation-supination movements during the mobilization and strengthening phases of standard rehabilitation
62099738|NCT06714539|EXPERIMENTAL|Patient Specific Virtual Reality Stimulation|Physician participants will engage with the patient specific virtual reality simulator through multi-player teaching and individual practice modes.
62099739|NCT05199688|EXPERIMENTAL|Cohort 1: Participants with body weight ≥10kg to <20kg|Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients
62099740|NCT05199688|EXPERIMENTAL|Cohort 2 Participants with body weight ≥20kg to <40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
62661941|NCT04223037|ACTIVE_COMPARATOR|Day 0，7 immunization shedule|Japanese Encephalitis Vaccine produced by Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) and Japanese Encephalitis Vaccine produced by Liaoning Chenda CO.,LTD Dosage form: 0.5mL/vial Two Dose injection with 7 days interval
62661942|NCT04223037|EXPERIMENTAL|Day 0，28 immunization shedule|Japanese Encephalitis Vaccine produced by IMBCAMS Dosage form: 0.5mL/vial Two Dose injection with 28 days interval
62099741|NCT05199688|EXPERIMENTAL|Cohort 3 Participants with body weight ≥40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
62661943|NCT02612155|EXPERIMENTAL|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
62661944|NCT02612155|PLACEBO_COMPARATOR|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
62661945|NCT05694585|EXPERIMENTAL|esmolol group|esmolol group: esmolol 50 μg/kg /min were intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg /min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
62661946|NCT05694585|PLACEBO_COMPARATOR|Saline solution|Saline group: saline 50 μg/kg /min were intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg /min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
62661947|NCT05592691||Study Cohort|Patients undergoing fascial blocks in elective cardio-thoracic and abdominal surgery.
62661948|NCT05540899|EXPERIMENTAL|Hypofractionated Postoperative Radiotherapy (H-PORT)|H-PORT of 50 Gy given over 4 weeks.
62661949|NCT00767871|EXPERIMENTAL|Escitalopram|escitalopram (10-20mg) to panic patients
62661950|NCT00918307|EXPERIMENTAL|Varenicline|Varenicline titrated to 2 x 0.5 mg twice daily for 12 weeks
62661951|NCT00918307|PLACEBO_COMPARATOR|Placebo|placebo titrated to 2 pills twice daily for 12 weeks
62661952|NCT00748800|EXPERIMENTAL|1|
62661953|NCT00748800|ACTIVE_COMPARATOR|2|
61910340|NCT05355493|ACTIVE_COMPARATOR|Control condition|"In the control task subjects will have to watch a documentary during 60 min on the same computer screen as that used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several episodes (One Planet, Frozen Worlds, Jungles, Costal Seas, From Desserts to Grasslands, The High Seas, Fresh Water and Forests) of the Netflix documentary Our Planet, 2019 as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial."
61910341|NCT03127098|EXPERIMENTAL|ETBX-011 in combination with ALT-803|A combination of agents were administered to subjects in this dose-escalation study
62099742|NCT01106287|EXPERIMENTAL|Treatment Sequence 1|Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg
62099743|NCT01106287|EXPERIMENTAL|Treatment Sequence 2|Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo
62099744|NCT01106287|EXPERIMENTAL|Treatment Sequence 3|Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg
62099745|NCT01106287|EXPERIMENTAL|Treatment Sequence 4|Period 1: 60 mg - Period 2: 80 mg - Period 3: Placebo - Period 4: 120 mg - Period 5: 140 mg
62099746|NCT03720340|ACTIVE_COMPARATOR|Recombinant human interleukin-11|Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.
62099747|NCT03720340|PLACEBO_COMPARATOR|Saline|Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.
62099748|NCT02416635||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
62099749|NCT02416635||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
62099750|NCT02416635||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
62099751|NCT02416635||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
62661954|NCT01723605|EXPERIMENTAL|insitu repair|insitu repair of the uterine incision during caeserean section
62099752|NCT06711991|EXPERIMENTAL|TQC3927 powder for inhalation|TQC3927 powder for inhalation is administered as a single administration for 1 day and continuous administration for 6 days.
61910342|NCT00045942|EXPERIMENTAL|PKC412 (Core)|Participants received 75 mg PKC412 three time daily (tid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
62099753|NCT06711991|ACTIVE_COMPARATOR|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo is administered as a single administration for 1 day and continuous administration for 6 days.
62099754|NCT06713889||Group A|Patients with symptomatic severe aortic stenosis, with indication for TAVI. They are followed at inclusion, during hospitalisation of the TAVI procedure, at 1-month follow-up, at 1-year follow-up and by phone at 2 years follow-up.
62099755|NCT06713889||Group B|Patients with asymptomatic severe aortic stenosis, without indication for TAVI. They are followed at inclusion, at 1-month follow-up, at 1-year follow-up and at 2 years follow-up.
62099756|NCT06713889||Group C|Patients with asymptomatic middle aortic stenosis, without indication for TAVI. They are followed at inclusion, at 1-month follow-up, at 1-year follow-up and at 2 years follow-up.
62099757|NCT03342079|EXPERIMENTAL|Group 1|local anesthetic + placebo
62099758|NCT03342079|EXPERIMENTAL|Group 2|local anesthetic + nitrous oxide
62099759|NCT03342079|PLACEBO_COMPARATOR|Group 3|Placebo + nitrous oxide
62099760|NCT05066451|EXPERIMENTAL|%5 dextrose prolotherapy|A total of 3 sessions of prolotherapy solution containing 5% dextrose will be applied at the beginning, 3rd week, and the 6th week.
62099761|NCT05066451|ACTIVE_COMPARATOR|%15 dextrose prolotherapy|A total of 3 sessions of prolotherapy solution containing 15% dextrose will be applied at the beginning, 3rd week, and the 6th week.
62099762|NCT06668740|OTHER|Intervention|A pretest was conducted with a group of elderly residents from three different nursing homes. Following this, participants watched 360-degree VR videos featuring nature walks, trips, and similar experiences for 10 minutes, once a week, over a period of four weeks. After completing the VR sessions, a posttest was administered. The results will be used to assess the participants' Quality of Life and their Satisfaction with the intervention.
62099763|NCT03097211|EXPERIMENTAL|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
62661955|NCT01723605|ACTIVE_COMPARATOR|exteriorisation of the uretus|uterine closure during caeserian section with exteriorisation of the uterus
61910343|NCT00045942|EXPERIMENTAL|FLT3 mutated PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
61910344|NCT00045942|EXPERIMENTAL|FLT3 mutated PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
62099764|NCT03097211|EXPERIMENTAL|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
62661956|NCT04832217|EXPERIMENTAL|Pyrenees' beef group|"In the first period, 24 participants were randomly assigned to a beef (Pyrenees' beef group).~In the second period, 23 participants were randomly assigned to a beef (Pyrenees' beef group)."
61910345|NCT00045942|EXPERIMENTAL|FLT3 wild type PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
62099765|NCT03097211|EXPERIMENTAL|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
62099766|NCT03097211|EXPERIMENTAL|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
62099767|NCT03813407|EXPERIMENTAL|Active Arm ( Sodium Zirconium Cyclosilicate SZC)|Dosage formulation: 5 g sachets 2.5 g sachets 0.25 g sprinkle capsules 0.125 g sprinkle capsules (can be manufactured to support participants \<2 years of age) Route of administration: Oral Dosing instructions: SZC is provided as a powder. At the time of dosing SZC is mixed with a quantity of water or sprinkled onto semi-solid food (eg, milk, baby food, yogurt, or ice cream) within an hour of drug administration. Packaging and labelling: Study treatment will be provided in sachets packed in cartons or sprinkle capsules in high density polyethylene bottles, as appropriate for the dose. Each carton of sachets, individual sachets, and bottle of capsules will be labelled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement. Participant-specific dosing cards (diary) will be provided.
62294640|NCT01963494|EXPERIMENTAL|Dyadic planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, randomly selected target persons form action plans to increase daily physical activity together with their partners.
62308165|NCT01803165||Retrospective study group|Retrospective chart review will be performed and data collected on patients who have undergone infrainguinal bypass grafting under general anesthesia and without the use of regional or neuraxial anesthesia.
62661957|NCT04832217|NO_INTERVENTION|Conventional Chicken group|"In the first period, 23 participants were randomly assigned to a conventional chicken-based group (control group).~In the second period, 24 participants were randomly assigned to a conventional chicken-based group (control group)."
61910346|NCT00045942|EXPERIMENTAL|FLT3 wild type PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
62099768|NCT06628401|PLACEBO_COMPARATOR|Group 1 (Control)|Participants will be asked to maintain their habitual diet throughout the intervention. They will be provided with a brief document outlining the importance of a control group in research studies to maximise compliance. They will also receive £10/week vouchers during the intervention period and a further £60 on completion of the study to replicate voucher provision in the two intervention groups. Mimicking the voucher provision structure of the intervention groups will help to minimise participant drop out and will avoid any bias associated with differential financial remuneration between groups.
62466815|NCT03885362|EXPERIMENTAL|Dexcom G6 and Abbott Freestyle Libre|"Participants will have a Dexcom G6 sensor and Abbott FreeStyle Libre sensor inserted in the abdomen and upper arm respectively. Participants will be asked to swipe the FreeStyle Libre reader across the sensor a minimum of every 8 hours. Participants will be asked to continue their usual regimen of self-monitoring capillary blood glucose (SMBG).~During haemodialysis, a dialysis circuit blood sample will be drawn at 0 (pre-dialysis) 30, 60, 90, 120, 150, 180, 210 and 240 minutes and immediately after dialysis. Samples from the circuit will be analysed on the YSI glucose analyser. Participants will be asked to change the FreeStyle Libre sensors at day 14. The blinded CGM data will be uploaded at the time of each sensor change by the research team."
62099769|NCT06628401|ACTIVE_COMPARATOR|Group 2 (Whole F&V)|Participants will be provided with educational material to increase their fruit and vegetable intake to meet 5-a-day guidelines via exclusive intake of whole fruits/vegetables . They will receive £10/week supermarket vouchers during the intervention period to support fruit/vegetable purchase. They will receive a further £60 on completion of the study.
62099770|NCT06628401|EXPERIMENTAL|Group 3 (Whole F&V + Juice)|Participants will be provided with educational material to increase fruit and vegetable intake to meet 5-a-day guidelines, with recommendations to consume one portion per day via fruit juice/smoothies. Participants will receive the same financial support as group 2.
62099771|NCT04318444|EXPERIMENTAL|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
62099772|NCT04318444|PLACEBO_COMPARATOR|Placebo|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
62099773|NCT06704945|EXPERIMENTAL|No SLNB group|The study arm - BCS without SLNB
62099774|NCT06704945|OTHER|SLNB group|The control arm - BCS with SLNB(+/-ALND)
62099775|NCT02744508|ACTIVE_COMPARATOR|P group|Palonosetron group
62099776|NCT02744508|EXPERIMENTAL|PD group|Palonosetron and dexamethasone group
62099777|NCT06534983|EXPERIMENTAL|Autogene Cevumeran + Nivolumab|Participants will receive autogene cevumeran along with nivolumab intravenously (IV) at a recommended dose at specified timepoints.
62099778|NCT06534983|ACTIVE_COMPARATOR|Saline+Nivolumab|Participants will receive saline solution along with 480 milligrams (mg) of nivolumab, IV, once every 4 weeks (Q4W) for 1 year.
62099779|NCT05281471|EXPERIMENTAL|Olvi-Vec + Platinum-doublet & bevacizumab|"Olvi-Vec: A total of 2 consecutive days of intraperitoneal catheter infusions in Week 0~Platinum-doublet \& bevacizumab (or biosimilar) administered beginning in Week 4 (preferred), but no later than Week 5"
62099780|NCT05281471|ACTIVE_COMPARATOR|Physician's Choice of Chemotherapy & bevacizumab|Physician's Choice of chemotherapy \& bevacizumab (or biosimilar) administered beginning in Week 0. Physician's Choice of chemotherapy includes either a single agent non-platinum chemotherapy, or as platinum chemotherapy is allowed as an option, a platinum-doublet (i.e., platinum agent combined with a non-platinum agent).
62099781|NCT05767073|EXPERIMENTAL|Intervention|Lifestyle intervention
62099782|NCT05905458|EXPERIMENTAL|Treatment group A: HRS9950 tablets (Low dose)|
62099783|NCT05905458|EXPERIMENTAL|Treatment group B: HRS9950 tablets (High dose)|
62099784|NCT05905458|PLACEBO_COMPARATOR|Placebo Comparator: Treatment group C|
62099785|NCT06508658|EXPERIMENTAL|Arm A: Epcoritamab Plus Lenalidomide (E-Len)|Participants will receive E-Len for up to 12 cycles (each cycle is 28 days).
62099786|NCT06508658|EXPERIMENTAL|Arm B: Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx)|Participants will receive R-GemOx for up to 4 cycles (each cycle is 28 days)
62661958|NCT02894138|EXPERIMENTAL|Alteplase|40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel
62661959|NCT02894138|PLACEBO_COMPARATOR|Placebo|40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel
61910347|NCT00045942|EXPERIMENTAL|FLT3 mutated PKC412 dose escalation|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
61910348|NCT00045942|EXPERIMENTAL|FLT3 mutated PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
62099787|NCT06015646|EXPERIMENTAL|Lifestyle Coaching and Educational Handout|Lifestyle coach-led 30-minute focused, personalized session in addition to educational handout containing lifestyle tips for fatigue mitigation in night shift workers, which will be given to all participants at the beginning of the study.
62099788|NCT06015646|ACTIVE_COMPARATOR|Educational Handout Control|An educational handout containing lifestyle tips for fatigue mitigation in night shift workers will be given to all participants at the beginning of the study. Personalized coaching will not be offered to participants in this arm.
62099789|NCT03870945|EXPERIMENTAL|Dose level 1 with 1x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10\^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least \>2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
62099790|NCT03870945|EXPERIMENTAL|Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10\^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least \>2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
62099791|NCT05346692|ACTIVE_COMPARATOR|Arm I (Pain Survey)|Patients complete pain survey via text message daily for 10 days after surgery. Patients also complete telephone interview 2 weeks after surgery.
62099792|NCT05346692|EXPERIMENTAL|Arm 2 (Mindfulness Intervention)|Patients complete mindfulness intervention via text message daily for 10 days after surgery. Patients also complete telephone interview 2 weeks after surgery.
62099793|NCT01779375|ACTIVE_COMPARATOR|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
62661960|NCT02894138|NO_INTERVENTION|Observational|10 patients with IMR \<30 will undergo the same follow-up as the randomised patients
62661961|NCT01360476|ACTIVE_COMPARATOR|Vitamin D|
62661962|NCT01360476|PLACEBO_COMPARATOR|placebo|
62661963|NCT06005376|ACTIVE_COMPARATOR|No additive|This arm was served 2 reference wheat bread rolls (a 40 g) a day.
62661964|NCT06005376|EXPERIMENTAL|E304i/zinc additive|This arm was served 2 wheat bread rolls (a 40 g) a day containing a E304i/zinc additive.
62661965|NCT03572218|EXPERIMENTAL|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
61910349|NCT00045942|EXPERIMENTAL|FLT3 wild type PKC412 dose escalation (E2)|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
61910350|NCT00045942|EXPERIMENTAL|FLT3 wild type PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
61910351|NCT01801371|EXPERIMENTAL|68Ga-BNOTA-PRGD2|In patients in suspicion of glioma, single bolus of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be intravenously injected 30 minutes before brain PET/CT to determine 68Ga-BNOTA-PRGD2 uptake in tumor and brain.
61910352|NCT03190044|EXPERIMENTAL|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
61910353|NCT03190044|PLACEBO_COMPARATOR|Migranineurs (placebo)|One pill per day of placebo: Cellulose
62099794|NCT01779375|ACTIVE_COMPARATOR|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.
62099795|NCT02741843|EXPERIMENTAL|Patient Education|
62099796|NCT02741843|NO_INTERVENTION|Control|
62099797|NCT01214902|EXPERIMENTAL|Experimental CIMT|Two month home program that includes restricting the non hemiplegic hand an hour a day during play
62099798|NCT01214902|ACTIVE_COMPARATOR|Active Play|Two month home program that includes active use of hemiplegic hand during play one hour a day
62099799|NCT03316456||AL Patients Undergoing Induction Chemotherapy|Adults undergoing inpatient induction chemotherapy for newly diagnosed/relapsed acute leukemia.
62099800|NCT01040663|OTHER|Dash Diet|Subjects receive DASH diet for 4 weeks
62099801|NCT01040663|OTHER|Low GI Diet|Subjects will receive Low GI diet for 4 weeks
62099802|NCT01040663|OTHER|Western Style Diet|Subjects will receive western style diet for 4 weeks
62099803|NCT05345821||primary augmentation group|Women undergoing primary breast augmentation with Silimed® smooth surface Breast Implant.
62099804|NCT05345821||secondary (revision) augmentation group|Women undergoing secundary or revision breast augmentation with Silimed® smooth surface Breast Implant.
62099805|NCT05586321|EXPERIMENTAL|GEN1056 Monotherapy|
62099806|NCT06463171|EXPERIMENTAL|combination therapy|"Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off."
62099807|NCT02377206|EXPERIMENTAL|Alzheimer Disease|Alzheimer Disease People ADAS-Cog evaluation PET imaging with \[18F\]DPA-714
62661966|NCT03572218|ACTIVE_COMPARATOR|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
62099808|NCT06461741|EXPERIMENTAL|Integrated Dual-task EMG Biofeedback Training (EMG-BF)|"Participants will engage in EMG-BF for 30 minutes 3 times per week for 6 weeks for a total of 18 sessions. Our novel EMG Biofeedback training system can be adapted to a training objective by planning 3 to 5 movements and placing sensors over muscles that must be active when the user adheres to the correct movement form. For our training we use right or left torso shift with knee bend, and right or left hand opening, and place sensors over left and right vastus lateralis and left and right extensor digitorum superficialis muscles.~Each movement corresponds to a specific videogame command. To introduce cognitive challenge, we randomly shuffle the game command assigned to each movement at the beginning of every session. This will require the user to choose the appropriate movement to trigger the intended game input while suppressing incorrect movements. We use the puzzle game, Tetris, which requires spatial reasoning and planning under increasingly tight time constraints."
62099809|NCT06461741|ACTIVE_COMPARATOR|Traditional Balance Exercise Training (BAL-EX)|Participants will perform 7 balance exercises traditionally prescribed by physiotherapists. The first is a heel/toe square exercise where the trainee lifts their right toe and left heel, then their left toe and right heel, then both heels, then both toes. The 2nd exercise involves maintaining tandem stance while static, then moving the arms, then looking up and down, then looking left and right. The 3rd exercise is lateral stepping where the individual steps with one foot out to the side and then bring the foot back to the starting stance. The 4th exercise is a golfer's lift where the person slowly leans forward while extending one leg straight behind and touches the seat of a chair placed opposite. The 5th exercise is extended-duration single leg stands and exercises 6 and 7 are back and side leg raises, respectively. The exercise sequence will repeat until 30 minutes has expired. Sessions are repeated 3 times per week for 6 weeks, for 18 sessions.
62099810|NCT05278988|ACTIVE_COMPARATOR|Group A|Treatment according to WHO MDR-TB treatment guidelines (2019).
61910354|NCT06449937|EXPERIMENTAL|Group I (Radical local treatment combined with systematic treatment)|Patients undergo radical local treatment of liver metastases (hepatectomy, ablation) combined with systematic treatment.
62099811|NCT05278988|EXPERIMENTAL|Group B(PRS Regimen V)|bedaquiline, delamanid, clofazimine, pyrazinamide
62099812|NCT06245226||Fibromyalgia group|50 female fibromyalgia patients
62099813|NCT06245226||Control group|50 pain-free female volunteers
62099814|NCT06615297||central facial paralysis|70 stroke patients with central facial paralysis who were included in the rehabilitation program at Istanbul Physical Therapy and Rehabilitation Training and Research Hospital will be included
62099815|NCT04531540|EXPERIMENTAL|Repeated Insult Patch Test|During the Induction Phase, participants received 0.2 g Butenafine HCl 1% covered by an occlusive patch on the upper back skin test site three times a week for a total of 9 applications. Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system. After 14 days of Rest Phase, on the first day of Challenge Phase, participants received same procedure on original Induction Phase test site and on a virgin test site. The patches were removed and the sites scored 48 hours after application and scored again at 96 hours after application. The test sites were evaluated using the Induction Phase scoring system.
62099816|NCT02563600|EXPERIMENTAL|Pre-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
61910355|NCT06449937|ACTIVE_COMPARATOR|Group II (systematic treatment only or combined with local interventional therapy)|Patients undergo systemic therapy only or combined with local interventional therapy (TACE, HAIC).
61910356|NCT04240795|EXPERIMENTAL|Low lubricity (LL) hydrogels containing fibre-based beads|"Participants are given a preload of 30 g of low lubricity hydrogels (alginate beads in kappa-carrageenan hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
62099817|NCT02563600|EXPERIMENTAL|Post-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
62099818|NCT02563600|NO_INTERVENTION|No telephone call|No telephone call made to patient.
62099819|NCT06628531||Subarachnoid Hemorrhage (SAH)|
62661967|NCT01972828|EXPERIMENTAL|PRELOAD DEPENDENCE|in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).
62099820|NCT06714006|PLACEBO_COMPARATOR|Part A (SAD - Healthy)|Part A will be conducted as a randomized, double-blend, placebo-controlled, Single Ascending Dose Study to assess the safety, tolerability, Pharmacokinetic, Pharmacodynamic, and immunogenicity of PYC-003 in healthy adult participants
62099821|NCT06714006|NO_INTERVENTION|Part B (Control MRI - Healthy)|Part B will be conducted to qualify the local imaging vendor at each CRU participating in Part C and will enrol healthy participants who have not previously received the IP.
61910357|NCT04240795|ACTIVE_COMPARATOR|High lubricity (HL) hydrogels containing no fibre-based beads|"Participants are given a preload of 30 g of high lubricity hydrogels (no beads in kappa-carrageenan and alginate mixed hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
61910358|NCT04240795|PLACEBO_COMPARATOR|Water|"The water containing the same watermelon flavor, color and sweetness was given as control to match the gels. Participants receive the same amount of water like hydrogels - 30 g after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
61910359|NCT03231683|ACTIVE_COMPARATOR|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
61910360|NCT03231683|PLACEBO_COMPARATOR|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
61910361|NCT04514783|OTHER|Group 2|Use of scalpel and a spoon-shaped metal instrument (curette).
61910362|NCT04514783|EXPERIMENTAL|Group 1|Use of Debritom+ micro water jet technology
61910363|NCT03174002|EXPERIMENTAL|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
62099822|NCT06714006|ACTIVE_COMPARATOR|Part C (SAD - ADPKD)|Part C will be conducted as an open-label Single Ascending Dose study to assess the safety, tolerability, Pharmacokinetic, Pharmacodynamic, and immunogenicity of PYC-003 in adult participants with confirmed PKD1 mutation-associated ADPKD.
62099823|NCT04866407|EXPERIMENTAL|Mentha x piperita|A diluted solution of Mentha x piperita in carrier oil will be applied to the subject's interventional extremity.
62099824|NCT04866407|EXPERIMENTAL|Eucalyptus globulus|A diluted solution of Eucalyptus globulus in carrier oil will be applied to the subject's interventional extremity.
62099825|NCT04866407|NO_INTERVENTION|No intervention|Each participant will have one extremity that receives no essential oil intervention.
62099826|NCT00507611|OTHER|Single-arm|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
62099827|NCT01380119|EXPERIMENTAL|V7|Oral pill containing heat-killed Mycobacterium vaccae
62099828|NCT01380119|PLACEBO_COMPARATOR|Placebo pill|Identically appearing placebo pills
62099829|NCT03519451|EXPERIMENTAL|Group I (KickAsh smartphone mobile application)|Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.
62099830|NCT03519451|EXPERIMENTAL|Group II (Breathe2Relax smartphone mobile application)|Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.
62099831|NCT06360640|EXPERIMENTAL|50 mg of APC148 and placebo|Cohort 1: 4 participants receives 3 hours IV administration of 50 mg APC148, and 2 participants placebo.
62099832|NCT06360640|EXPERIMENTAL|150 mg of APC148 and placebo|Cohort 2: 6 participants receives 3 hours IV administration of 150 mg APC148 and 2 participants placebo.
62099833|NCT06360640|EXPERIMENTAL|300 mg of APC148 and placebo|Cohort 3: 6 participants receives 3 hours IV administration of 300 mg APC148 and 2 participants placebo.
61910364|NCT03174002|ACTIVE_COMPARATOR|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
61910365|NCT02168387|ACTIVE_COMPARATOR|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
61910366|NCT02168387|ACTIVE_COMPARATOR|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
62661968|NCT01972828|ACTIVE_COMPARATOR|CONTROL|
62661969|NCT00820300|EXPERIMENTAL|Punctal plug|
62661970|NCT05468307|EXPERIMENTAL|Membrane Bound Cytokine Modified TIL|2x10\^8-1x10\^10 in vitro expanded autologous TIL engineered with membrane-binding cytokine (GC203 TIL) will be infused i.v. to patients with advanced gynecologic tumors after NMA lymphodepletion treatment with cyclophosphamide.
62661971|NCT00694161|EXPERIMENTAL|Fx-1006A|
61910367|NCT02769897|EXPERIMENTAL|Intervention group|The exercise program, nutritional counseling and oral health will last for five to six months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC). The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
61910368|NCT02769897|NO_INTERVENTION|Control group|The control group did not receive the intervention.
62099834|NCT06360640|EXPERIMENTAL|450 mg of APC148 and placebo|Cohort 4: 6 participants receives 3 hours IV administration of 450 mg APC148 and 2 participants placebo.
62099835|NCT06360640|EXPERIMENTAL|600 mg of APC148 and placebo|Cohort 5: 6 participants receives 3 hours IV administration of 600 mg APC148 and 2 participants placebo.
61910369|NCT02914028|ACTIVE_COMPARATOR|Tramadol and paracetamol|subjects were administered intravenous analgesia (control group) Tramadol 100 mg and paracetamol 1000 mg at the end of the surgery
62661972|NCT02695459|EXPERIMENTAL|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
62661973|NCT05548894|ACTIVE_COMPARATOR|stabilization splint|acrylic splint in the maxillary arch with flat surface
62661974|NCT05548894|ACTIVE_COMPARATOR|laser therapy|laser beam directed to the affected part cause activation of blood circulation
62099836|NCT06360640|EXPERIMENTAL|900 mg of APC148 and placebo|Cohort 6: 6 participants receives 3 hours IV administration of 900 mg APC148 and 2 participants placebo.
62661975|NCT05548894|ACTIVE_COMPARATOR|stabilization splint and laser therapy|using both laser therapy and stabilization splint for more improvement
62661976|NCT01940861||Traumatic brain injury|
62661977|NCT06419166|EXPERIMENTAL|Refractory gMG subjects|Refractory Generalized Myasthenia Gravis
62661978|NCT01310283|NO_INTERVENTION|control group|Conventional pediatric dental care.
62661979|NCT02015156|EXPERIMENTAL|PF-05280014|
62661980|NCT02015156|ACTIVE_COMPARATOR|Trastuzumab-US|
62099837|NCT06032234||Omnivorous|Participants following an omniviours diet
62661981|NCT03360968|EXPERIMENTAL|Treatment A-B|Patient is treated with 1 hour SPN-CPAP/PS followed by 1 hour of Variable-PS ventilation mode
62661982|NCT03360968|EXPERIMENTAL|Treatment B-A|Patient is treated with 1 hour Variable-PS followed by 1 hour of SPN-CPAP/PS ventilation mode
62661983|NCT06023407|EXPERIMENTAL|Heat therapy Group|40.5°C water
62661984|NCT06023407|SHAM_COMPARATOR|Thermoneutral Control Group|36°C water
62661985|NCT01034423|EXPERIMENTAL|omega-3 high quality|
62661986|NCT01034423|EXPERIMENTAL|omega-3 low quality|
62661987|NCT01034423|PLACEBO_COMPARATOR|placebo|
62661988|NCT00859846|EXPERIMENTAL|Long Axis arterial line placement|Twenty four patients will undergo arterial line placements using long axis arterial line placement under ultrasound.
62661989|NCT00859846|EXPERIMENTAL|Short Axis arterial line placement|Twenty four patients will undergo arterial line placements using short axis arterial line placement under ultrasound.
62661990|NCT00859846|ACTIVE_COMPARATOR|Palpation arterial line placement|Twenty four patients will undergo arterial line placements using Traditional palpation arterial line placement.
62661991|NCT01713517|ACTIVE_COMPARATOR|Universal coverage of Long Lasting Insecticidal Nets (LLIN)|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons
62661992|NCT01713517|EXPERIMENTAL|LLIN Plus Indoor Residual Spraying|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons plus indoor residual spraying with insecticide of interior walls of all houses twice yearly.
62661993|NCT02896842|NO_INTERVENTION|Control Arm|cohort 3: Imatinib through dosage ≥ 1000 ng/ml
62099838|NCT06032234||Vegan|Participants following a vegan diet
62661994|NCT02896842|ACTIVE_COMPARATOR|Active comparator|Cohort 2 : Imatinib standard dose Imatinib through dosage \< 1000 ng/ml
62661995|NCT02896842|EXPERIMENTAL|Experimental arm|Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage \< 1000 ng/ml
62661996|NCT04018001||Truven Health MarketScan Research Database|individuals who are privately insured and with Medicare Supplemental insurance
62661997|NCT04649723|EXPERIMENTAL|Rifampicin 600 mg + SHR1459 Tablets 200 mg|
62661998|NCT04649723|ACTIVE_COMPARATOR|SHR1459 tablets 200 mg|
62661999|NCT03611062|EXPERIMENTAL|VR Executive Functions Training|Participants will receive training of executive functions in a virtual reality environment.
62662000|NCT03611062|PLACEBO_COMPARATOR|Control|Participants will play a virtual reality game using the same hardware and similar environments, but without the training of executive functions.
62662001|NCT03117270|EXPERIMENTAL|oral filgotinib tablets|
62662002|NCT03117270|PLACEBO_COMPARATOR|placebo tablets|
62662003|NCT04426032||Patients with RRI between 0.6 and 0.7|Normal renal resistive index
62662004|NCT04426032||Patients with RRI more than 0.7|High renal resistive index
62662005|NCT03090295|EXPERIMENTAL|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
62662006|NCT02006654|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to base treatment with an AChEI
62662007|NCT02006654|EXPERIMENTAL|Idalopirdine 60 mg (or 30 mg)|Idalopirdine adjunct to base treatment with an AChEI
62662008|NCT06263491|EXPERIMENTAL|Cohort A|If participants show that they have no MRD, participants will be in Cohort A and will stop taking pirtobrutinib. Participants will continue to be observed and tested for MRD, and participants will be able to continue receiving the drug if you test positive.
61910370|NCT02914028|ACTIVE_COMPARATOR|transversus abdominis plane block|patients that applied transversus abdominis plane block at the end of the surgery after given intravenous analgesia
61910371|NCT05045937||COVID-19 patients treated with Ivermectin|This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
62099839|NCT06714227||Patients diagnosed with prostate carcinoma before the age of 55|Exome sequencing (WES) of genomic DNA
62466816|NCT05281822|EXPERIMENTAL|Experimental group|The BMI (kg/m2) was calculated by measuring the height and weight of the women in the experimental groups. Then, the women in the experimental group were provided with stress management training to help cope with stress conditions, how to use positive coping in conditions in case of stress and tension. In terms of the reliability of the training, each woman was interviewed face-to-face, which lasted for 30-40 minutes.
62662009|NCT06263491|EXPERIMENTAL|Cohort B|If participants test positive for MRD at the 24 month time point, participants will be in Cohort B and the participant will continue taking pirtobrutinib.
62662010|NCT02393755|EXPERIMENTAL|Treatment (capecitabine, nintedanib)|Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
62662011|NCT02393755|EXPERIMENTAL|Treatment (capecitabine , nintendanib)|Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
62662012|NCT01125553|EXPERIMENTAL|IDegAsp B|
62662013|NCT01125553|EXPERIMENTAL|IDegAsp F|
62662014|NCT03229811|NO_INTERVENTION|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
62662015|NCT03229811|ACTIVE_COMPARATOR|ESRD education + ACP|Standard ESRD education + conservative kidney management and advance care planning education
62662016|NCT01610193||Right sided abdominal pain|Patients that present at the Emergency Department with abdominal pain and a clinical suspicion of appendicitis.
62662017|NCT06357767|EXPERIMENTAL|Healing Within|A culturally-tailored, trauma-informed group intervention to support smoking cessation by leveraging Lakota values, mindfulness, and a storytelling approach.
62662018|NCT04256499||Water load test|Patients experiencing a syndrome of inappropriate antidiuresis who had an acute water load test
62662019|NCT04256499||Control group|Patients who had an acute water load test and who did not experience any water homeostasis anomalies
62662020|NCT06305325|NO_INTERVENTION|Control Group|control group received the standard care. It included antenatal classes offered at the CC clinic, which comprised of four face-to-face sessions in clinic. These classes focus on pregnancy and postpartum care including baby growth in each trimester, minor discomforts, diet, exercise, personal hygiene, complications during pregnancy, labour and delivery stages, breastfeeding, care of newborn baby, and family planning methods. The 2-3 hour long face-to-face classes are offered every week on Saturdays in the clinic
62662021|NCT06305325|EXPERIMENTAL|eHealth antenatal Coparenting Intervention|This intervention focuses on developing conflict management, problem solving, communication, and mutual support to foster positive joint parenting of an infant. A modification in the delivery of this intervention was made in the current study in order to make it deliver online. The eACoP intervention included eight antenatal videos from Feinberg's Family Foundation intervention. A website for the eACoP intervention was developed, and all the videos were uploaded to the website. These videos were 30-40 minutes each. The videos were in English and subtitles in Urdu were added to the videos. These videos were accompanied by an activity-based coparenting workbook. The coparenting workbook includes a worksheet and homework for each video and was also translated into Urdu
62662022|NCT02806167|EXPERIMENTAL|Clinical algorithm|This is a single arm study. All eligible patients will be subject to our clinical algorithm.
62737101|NCT00862368|EXPERIMENTAL|PAM -Enhanced/Asthma|The PAM-Enhanced/Asthma group: 2 in-home visits that included asthma education consistent with NIH recommendations (NIH, NAEPP, 1997) and smoking cessation counseling. Consistent with Motivational Interviewing (MI), smoking was broached in a non-judgmental manner and as another trigger for asthma. Feedback was given on expired air Carbon Monoxide (CO) levels of the smoker (to increase personal perception of risk) and the amount of smoke exposure to the child (to increase risk perception to the child). 6 phone calls were then provided over the next 4 months that focused on asthma education, a second round of feedback on the child's ETS exposure, and smoking cessation counseling. MI was used at all contacts. Free nicotine patch tx was given if they were ready to quit within 30 days.
62099840|NCT06614634|EXPERIMENTAL|Tele-cardiac rehabilitation group|Patients in the tele-cardiac rehabilitation group initially underwent a similar trial exercise session as those in the hospital-based rehabilitation group. During this session, patients were informed about exercise duration and intensity, using the heart rate monitor (Polar H9) and elastic bands, and transferring data to the web application (Polar Flow web). Subsequently, patients were instructed to perform aerobic and strengthening exercises at home/outdoors at least 3 days a week for four weeks. During the program, the researcher called them once a week for reinforcement. Phone calls included symptom inquiry and encouraging feedback regarding exercise parameters recorded on the Polar H9 website in the previous week. In the second week, patients underwent an interim exercise session under supervision in our CPR unit and a similar face-to-face interview was conducted. The program was concluded at the end of four weeks.
62099841|NCT06614634|ACTIVE_COMPARATOR|Hospital-based rehabilitation group|Participants in the hospital-based rehabilitation group performed aerobic and strengthening exercises under the supervision of a physiotherapist/nurse/research doctor three days a week for four weeks in the cardiopulmonary rehabilitation unit. Aerobic exercise included 30-minute treadmill walking at 60-80% of the peak VO2 value obtained in the cardiopulmonary exercise test. After the end of the aerobic exercise, upper and lower extremity muscle strengthening exercises were performed with warm-up and cool-down periods using medium-tension elastic bands under the supervision of a physiotherapist. At the end of four weeks, the program was terminated and a follow-up evaluation was conducted.
62662023|NCT04542564|EXPERIMENTAL|telemedicine group|The HT app (HealthCap) allows patients to record their home BP measurements (HBPM) and can automatically provide mean BP values from the previous 7 or 30 days. 1-2 week prior to a scheduled physician, HealthCap and a research assistant will remind patients to take dual BP readings both in the morning and evening for 1 week for doctors' management. The mean values of the 7-day home BP will be checked before the index consultation. If the home BP control was optimal (i.e. ≤135/85 mmHg), other important parameters will be checked automatically by a questionnaire in the app: (i) if they have good drug compliance and if they experienced any side effects,(ii) if they have symptoms suggestive of target organ damages such as chest pain or hemiplegia, and (iii) if they have any problem(s) that need to consult a physician. If no complaints are identified, the patient can collect medications directly from the clinic and the physician appointment will be deferred for 3 months
62099842|NCT04056221|EXPERIMENTAL|acupuncture|Acupuncture at the selected points.
62099843|NCT04056221|SHAM_COMPARATOR|Sham acupuncture|Similar appearance to conventional acupuncture, however, without needles skin penetration.
62099844|NCT06104657||Observational Patient Group|Patients take part in interview on study.
62099845|NCT06104657||Observational Patient Advocate Group|Patient advocate participants take part in an interview on study.
62099846|NCT01287156||1|Subjects with diagnosed or suspected TBI or postconcussive syndrome
62099847|NCT03970447|ACTIVE_COMPARATOR|Control Arm|"Newly Diagnosed GBM: Radiation therapy (XRT) 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 2-6 weeks from the last day of radiation, and the start of the first cycle of Maintenance Therapy 2-6 weeks after the last day of radiotherapy. The start of all subsequent maintenance therapy cycles (2-12) every 4 weeks + 7 days after the first daily dose of temozolomide of the preceding cycle. Total number of cycles should comply with institutional or country standards. During maintenance therapy, the first cycle of temozolomide will be at 150 mg/m2 for Days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for Days 1-5 of a 28-day cycle.~Recurrent GBM: Lomustine started at 110 mg/m2/day on Day 1 of a 42-day cycle as per local standards. Treatment will continue for up to 6 total cycles."
62099848|NCT03970447|EXPERIMENTAL|Regorafenib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).~Recurrent GBM: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)."
62099849|NCT03970447|EXPERIMENTAL|Paxalisib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles.~Recurrent GBM: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 21 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 21 days for all subsequent cycles."
62099850|NCT03970447|EXPERIMENTAL|VAL-083 Treatment Arm|"Newly Diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle.~Recurrent GBM: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle."
62662024|NCT04542564|PLACEBO_COMPARATOR|usual care|Patients in the usual care group will be asked to refrain from downloading or using any health care apps related to HT
62662025|NCT05900154|EXPERIMENTAL|standard dose in 5 to <18 years olds, healthy|standard dose (120 µg)
62099851|NCT03970447|EXPERIMENTAL|VT1021 Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Rolling 6 design. Treatment as outlined in section Experimental: VT1021 Treatment Arm with the first 6 patients receiving VT1021 at 12 mg/kg twice weekly in combination with temozolomide and radiation therapy. If there are two dose limiting toxicities reported, the dose will be de-escalated to 9 mg/kg two times a week. 6 patients will then be receiving 9 mg/kg two times a week and observed for DLTs for 4 weeks.~Recurrent GBM: Dose Finding Phase is not applicable for patients with Recurrent GBM in the VT1021 treatment arm."
62662026|NCT05900154|EXPERIMENTAL|standard dose in 5 to < 18 years olds, with chronic high risk conditions|standard dose (120 µg)
62662027|NCT05900154|EXPERIMENTAL|standard dose in 2 to < 5 years olds|standard dose (120 µg)
62662028|NCT05900154|EXPERIMENTAL|low dose in 5 to <18 years olds, healthy|low dose (60 µg)
62099852|NCT03970447|EXPERIMENTAL|VT1021 Treatment Arm - Enhanced Safety Management (ESM)|"Experimental: VT1021 Treatment Arm - Enhanced Safety Management (ESM) Newly diagnosed MGMT Methylated and Unmethylated GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. PK and PD assessments are done for patients as a part of ESM. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data.~Recurrent GBM: ESM is not applicable for patients with Recurrent GBM in the VT1021 treatment arm."
62099853|NCT03970447|EXPERIMENTAL|VT1021 Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily and VT1021 (Dosage Form: Infusion for intravenous administration; Strength: 10 mg/mL; Dose: As confirmed through the dose finding phase) twice weekly during radiation therapy. Rest period: 2-6 weeks from last day of radiation. VT1021 dosing will continue during the rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with VT1021. After 6 cycles, VT1021 only.~Recurrent GBM: VT1021 (Dosage Form: Infusion for intravenous administration; Strength: 10 mg/mL; Dose: 12mg/kg) twice weekly."
62099854|NCT03970447|EXPERIMENTAL|Troriluzole Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Rolling 6 design. The first 6 patients will receive troriluzole at 100 mg BID for the first two weeks followed by 200 mg BID for the next two weeks in combination with temozolomide and radiation therapy. If there are two dose limiting toxicities (DLTs) reported, the dose will be de-escalated to 100 mg in the morning and followed by 200 mg in the evening. 6 patients will receive this dose and observed for 4 weeks. If there are two DLTs reported, then this dose will be de-escalated to 100 mg BID. 6 patients will then be receiving this dose and observed for DLTs for 4 weeks.~Recurrent GBM: Rolling 6 design. The first 6 patients receiving troriluzole 100 mg twice a day (BID) for the first two weeks followed by 200 mg BID for the next two weeks in combination with lomustine. The dose de-escalation is similar to that of newly diagnosed patients during the rolling 6 design."
62099855|NCT03970447|EXPERIMENTAL|Troriluzole Treatment Arm - Enhanced Safety Management (ESM)|Newly diagnosed MGMT Methylated and Unmethylated GBM and Recurrent GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data.
62662029|NCT05900154|EXPERIMENTAL|low dose in 5 to <18 years olds, with chronic high risk conditions|low dose (60 µg)
62662030|NCT05900154|EXPERIMENTAL|low dose in 2 to < 5 years olds|low dose (60 µg)
62662031|NCT02709902|EXPERIMENTAL|Adapalene/BP gel, 0.3%/2.5%|Topical, once daily, for 84 days.
62662032|NCT02709902|ACTIVE_COMPARATOR|EPIDUO® FORTE|Topical, once daily, for 84 days.
62662033|NCT02709902|PLACEBO_COMPARATOR|Placebo|Topical, once daily, for 84 days.
62662034|NCT02194465|EXPERIMENTAL|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
62662035|NCT02194465|EXPERIMENTAL|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
62662036|NCT02194465|EXPERIMENTAL|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
62662037|NCT02194465|EXPERIMENTAL|13 mg LY2623091 + 20 mg tadalafil|13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
62662038|NCT02194465|EXPERIMENTAL|20 mg tadalafil|20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
62662039|NCT02194465|ACTIVE_COMPARATOR|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
62662040|NCT02194465|PLACEBO_COMPARATOR|Placebo|Placebo for blinding administered orally once daily for 4 weeks.
62662041|NCT00598403|EXPERIMENTAL|1|Cefditoren pivoxil
62662042|NCT00598403|ACTIVE_COMPARATOR|2|Ciprofloxacin
62662043|NCT01653418|EXPERIMENTAL|V-BEAM + Stem Cell Infusion|Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
62662044|NCT06417047|EXPERIMENTAL|Hand Holding Group|In the experimental group, hand holding will be done by the researcher, and intramuscular injection will be done by the clinical nurse. All intramuscular injections will be performed by a single nurse and the ventrogluteal region will be used as the injection site. Patients will first fill out the Voluntary Information and Consent Form, and then the Descriptive Characteristics Form and State Anxiety Scale. After the injection site is evaluated, the researcher will hold the patient's hand, the nurse will enter the tissue at a 90-degree angle and administer the drug slowly (1 ml/10 seconds). After removing the needle from the tissue, the nurse will apply pressure with dry cotton, and then the researcher will stop holding the patient's hand. After the procedure, the Numerical Pain Scale and State Anxiety Scale will be filled in within 1 minute.
62099856|NCT03970447|EXPERIMENTAL|Troriluzole Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily and troriluzole (Dosage Form: Capsule for oral administration; Strength: 100 mg; Dose: As confirmed by dose finding phase) BID. Rest period: 2-6 weeks from last day of radiation. Troriluzole dosing will continue during the rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with troriluzole. After 6 cycles, troriluzole only.~Recurrent GBM: Lomustine 100 mg/m2 orally on day 1 of a 42-day cycle in combination with troriluzole (Dosage Form: Capsule for oral administration; Strength: 100 mg; Dose: As confirmed by dose finding phase) BID. After 6 cycles, troriluzole only."
62099857|NCT03970447|EXPERIMENTAL|ADI-PEG 20 Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Dose Finding Phase is not applicable for newly diagnosed patients on the ADI-PEG 20 treatment arm.~Recurrent GBM: Rolling 6 design. The first 6 patients will receive ADI-PEG 20 at 36 mg/m2 once a week in combination with lomustine 100 mg/m2 orally on day 1 of a 42-day cycle. 6 patients will receive this dose and be observed for 4 weeks. If there are two dose limiting toxicities (DLTs) reported, the dose will be de-escalated to 18 mg/m2 once a week. 6 patients will receive this dose and be observed for 4 weeks."
62099858|NCT03970447|EXPERIMENTAL|ADI-PEG 20 Treatment Arm - Enhanced Safety Management (ESM)|"Newly diagnosed MGMT Methylated and Unmethylated GBM: ESM is not applicable for newly diagnosed patients on the ADI-PEG 20 treatment arm.~Recurrent GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data."
62099859|NCT03970447|EXPERIMENTAL|ADI-PEG 20 Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy over 6 weeks. Temozolomide (75 mg/m2 orally daily and ADI-PEG 20 (Dosage Form: Solution for intramuscular injection; Strength: 11.5 ± 1.0 mg/ml; Dose: 36 mg/m2) once a week. Rest period: 2-6 weeks from last day of radiation. ADI-PEG 20 dosing will continue during rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Subsequent cycles will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with ADI-PEG 20. After 6 cycles, ADI-PEG 20 only for up to 104 weeks of total treatment.~Recurrent GBM: Lomustine 100 mg/m2 orally on day 1 of a 42-day cycle in combination with ADI-PEG 20 (Dosage Form: Solution for IM injection; Strength: 11.5 ± 1.0 mg/ml; Dose: As confirmed by dose finding phase, once a week. After 6 cycles, ADI-PEG 20 only for up to 104 weeks of total treatment."
62099860|NCT00689156|ACTIVE_COMPARATOR|Regimen 1|Epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times three followed by docetaxel 100 mg/m2 intravenously day 1 every 3 weeks times three
62099861|NCT00689156|EXPERIMENTAL|Regimen 2|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
62099862|NCT05413928|EXPERIMENTAL|Intervention|Participants will undergo a baseline phase for 20 days, where they will follow their regular dietary intake, physical activity, and sleep. They will be wearing a CGM and an activity monitor and for a couple of nights, they will use a sleep monitor. That will be followed by 4 interventional phases where they will be asked to limit their daily eating to 10 hours or less (Time Restricted Eating, TRE), with the eating window and the caloric distribution will be shifted during each of the next 3 phases, each phase lasting 20 days. The last phase will last 8 days and participants will be asked to consume provided meals with a determined amount of protein, carbohydrates, and fat. Their body temperature will be measured using a continuous temperature device and a heart rate monitor to capture dynamic rage of the sympathetic response during and after the meal consumption (thermotyping).
62099863|NCT05603962|ACTIVE_COMPARATOR|Stop training group|Home-base prism training during week 1-6 --\> then stop training during week 7-12 --\> endpoint data collected at week 12
62099864|NCT05603962|EXPERIMENTAL|Continune training group|Home-base prism training during week 1-12 --\> endpoint data collected at week 12
62099865|NCT03379415|EXPERIMENTAL|Meniscus Injured|These meniscus patients will be recruited to participate in a single session to wear 4 different pairs of shoes
62099866|NCT03379415|EXPERIMENTAL|Footwear|4 Different types of trainers will be used to see the difference in gait in meniscectomy patients
62099867|NCT06356272||Observational|Patients undergo blood sample collection, saliva sample collection, complete questionnaires and have their medical records reviewed on study.
62099868|NCT06652984|ACTIVE_COMPARATOR|Exercisers with a mobile breathing apparatus|The mobile device will be given to the patient for use. The exercise programme will be taught by the physiotherapist with face-to-face training before the study. The settings of the device will be started at the beginner level in breathing and exhalation exercises.
62099869|NCT06652984|ACTIVE_COMPARATOR|Pursed Lip Breathing Exercisers|'Pursed lip breathing' will be taught to the patients in this group. The programme will be taught by the physiotherapist with face-to-face training before the study. The patient will be taught to take a deep breath through the nose as much as he/she can and then to empty the air in the lungs in a controlled manner without applying any force by pursing the lips as if whistling.
62099870|NCT06711770|OTHER|Patients receiving G-CSF|
62099871|NCT06711770|OTHER|Patients without G-CSF|
62099872|NCT05867121|EXPERIMENTAL|Cohort A: NSCLC|Participants with NSCLC will receive RO7496353, and atezolizumab, given as an intravenous (IV) infusion at an assigned dose on Day 1 of each 21-day cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.
61910372|NCT05045937||COVID-19 patients declining Ivermectin and wanting traditional treatment|This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
62466817|NCT04520464|ACTIVE_COMPARATOR|Self-test for cervical sample|First sequence will start with self-test. Second sequence will start with traditional method.
62099873|NCT05867121|EXPERIMENTAL|Cohort B: GC|Participants with GC will receive RO7496353, nivolumab, and oxaliplatin, given as an IV infusion at an assigned dose on Day 1 of each 21-day cycle along with either capecitabine or S-1, orally, twice daily on Days 1 to 14 of each cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.
62099874|NCT05867121|EXPERIMENTAL|Cohort C: PDAC|Participants with PDAC will receive RO7496353, and atezolizumab, given as an IV infusion at an assigned dose on Days 1 and 15 of each 28-day cycle along with nab-paclitaxel, and gemcitabine, also given as an IV infusion on Days 1, 8, 15 of each 28-day cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.
61910373|NCT00329901|EXPERIMENTAL|Tdap + MenACWY-CRM|Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
61910374|NCT00329901|EXPERIMENTAL|Tdap + saline|Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
61910375|NCT00329901|EXPERIMENTAL|MenACWY-CRM + saline|Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms
61910376|NCT02229656|EXPERIMENTAL|radiotherapy and olaparib|Radiotherapy will be given with accelerated fractionation following the DAHANCA schedule Olaparib: dose escalation
61910377|NCT05917431|EXPERIMENTAL|SBRT plus Tislelizumab and Regorafenib|Participants will receive SBRT (8 Gy × 3-5 fractions) to all visible lesions. Systemic treatment (tislelizumab and regorafenib) will start concurrently and last for 2 years, or until disease progression, intolerable side-effects or death. Tislelizumab will be delivered every 21 days at a dose of 200mg, and regorafenib will be given at a dose of 120mg for the first 21 days of a 28-day cycle. Appropriate dose adjustments of regorafenib will be made if side-effects are intolerable, while the dose of tislelizumab should not be adjusted, but could be paused.
61910378|NCT06272175|EXPERIMENTAL|Open Kinetic Chain Activity Group|Open kinetic chain activity will involve Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns from the Proprioceptive Neuromuscular Facilitation (PNF). During the application, participants will lie on their back, and the pattern will be initiated from the opposite direction of the targeted movement. Participants will be encouraged to perform the movement as actively as possible. Assistance will be provided if the participant cannot complete the pattern. No other PNF techniques will be applied. Both patterns will be practiced for 10 repetitions. Resting periods will be provided as needed to prevent fatigue. The entire application is planned to last approximately 5 minutes.
61910379|NCT06272175|EXPERIMENTAL|Closed Kinetic Chain Activity Group|For closed kinetic chain activity of the upper extremity, an activity involving weight shifting onto the hands on a table while standing with the elbows in extension will be used. Participants will be asked to shift weight onto the hemiplegic upper extremity for 30 seconds. After a 30-second rest period, the weight shifting will be repeated for a second time.
61910380|NCT01802918|EXPERIMENTAL|Cohort 1|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): ABCD, BACD, BCAD, or BCDA. Where A=Placebo, B= GSK2838232 5mg, C=GSK2838232 10mg, and D=GSK2838232 20mg
61910381|NCT01802918|EXPERIMENTAL|Cohort 2|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
61910382|NCT00732901|EXPERIMENTAL|A (escitalopram)|Escitalopram
61910383|NCT00732901|EXPERIMENTAL|B (placebo)|Placebo
61910384|NCT05184010|EXPERIMENTAL|arthroscopic release with ulnar nerve mini open release|
61910385|NCT05184010|PLACEBO_COMPARATOR|arthroscopic release alone without ulnar nerve mini open release|
61910386|NCT02310009|EXPERIMENTAL|Control (CON)|Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
61910387|NCT02310009|EXPERIMENTAL|Anakinra (AN)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
61910388|NCT02310009|EXPERIMENTAL|Exercise (EX)|1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
61910389|NCT02310009|EXPERIMENTAL|Anakinra + Exercise (ANEX)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
61910390|NCT03518476|EXPERIMENTAL|Intervention arm|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
61910391|NCT03518476|ACTIVE_COMPARATOR|Control arm|Non-tobacco related training or education sessions will delivered to pharmacists in the control group.
61910392|NCT02650921|EXPERIMENTAL|Restylane Lyft with Lidocaine|
61910393|NCT02650921|NO_INTERVENTION|No Intervention|
61910394|NCT04571528|EXPERIMENTAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
61910395|NCT04571528|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
62099875|NCT04874610||BMI > 95|Cohort 1: greater than or equal to 95%ile body mass index
62099876|NCT04874610||BMI < 95|Cohort 2: less than 95%ile body mass index
62099877|NCT04680910|EXPERIMENTAL|Propofol infusion|Serial propofol infusions to maximally and safely induce unconsciousness and EEG slow waves while minimizing burst suppression.
62099878|NCT03514368|OTHER|Patients treated with immune checkpoint blockade|
62099879|NCT05176353|EXPERIMENTAL|VAP diagnostic stewardship|Intervention group - all patients hospitalized in study ICUs who were mechanically ventilated Feb 17 2022 - Feb 17 2023.
62099880|NCT05176353|NO_INTERVENTION|Pre-VAP diagnostic stewardship|"Pre-intervention historical control group - all patients hospitalized in study ICUs who were mechanically ventilated Feb 17 2017-Feb 16 2022.~While these patients were all mechanically ventilated, their treatment took place prior to the beginning of the study, under what standard or standards of care existed at the time. They received no treatment during the course of the study. No interventions could be assigned because their treatment was performed prior to study start date."
62099881|NCT05610410||Patients with angina and no obstructive coronary arteries|
62099882|NCT05610410||Patients with HFpEF|
62099883|NCT05178394|EXPERIMENTAL|Male recreational weightlifters|
62099884|NCT05422924|NO_INTERVENTION|Control Arm|No use of My Viva Plan
62099885|NCT05422924|EXPERIMENTAL|Intervention Arm|Use of My Viva Plan
62662045|NCT06417047|NO_INTERVENTION|Control Group|In the control group, intramuscular injection will be performed by the clinic nurse. All intramuscular injections will be performed by a single nurse and the ventrogluteal region will be used as the injection site. Patients will first fill out the Voluntary Information and Consent Form, and then the Descriptive Characteristics Form and State Anxiety Scale. After the injection site is assessed, the nurse will enter the tissue at a 90-degree angle and administer the medication slowly (1 ml/10 seconds). After removing the needle from the tissue, the nurse will apply pressure with dry cotton. After the procedure, the Numerical Pain Scale and State Anxiety Scale will be filled in within 1 minute.
62662046|NCT02296697|ACTIVE_COMPARATOR|Low-level laser therapy AlGaInP|AlGaInP 660 nm laser and dose of 6 J / cm 2 with point application on the edges of the lesion and sweep up application in the center.
62662047|NCT02296697|ACTIVE_COMPARATOR|High-frequency therapy with O3 formation|High frequency generator, spherical electrode. Direct spark technique will be used, in which the electrode is positioned millimeters away from the skin of the patient, causing the formation of sparks, with increasing intensity up to 80 to 100% for ozone formation.
62662048|NCT02296697|PLACEBO_COMPARATOR|Wound dressing with saline solution|Wound dressing with hygiene of the pressure ulcer with warm saline and after applying the bandage will be held will be held.
62662049|NCT02403271|EXPERIMENTAL|Phase 1b|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
62099886|NCT06401005|EXPERIMENTAL|TNBC patients|
62099887|NCT01071694||Group 1|
62099888|NCT05555485|SHAM_COMPARATOR|tAN stimulation - sham|Active or sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved.
62099889|NCT05555485|ACTIVE_COMPARATOR|tAN stimulation - active|Active or sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
62099890|NCT06706505|EXPERIMENTAL|Mindfulness based art therapy|Prior to the MBAT intervention, data collection forms were administered and randomization was performed. Following the pre-test, participants in this group will attend weekly MBAT sessions for five weeks. Post-intervention, data collection forms will be administered again. Subsequent follow-up assessments will be conducted at 3 and 6 months.
62099891|NCT06706505|NO_INTERVENTION|Therapy waiting list|Following the pre-test and randomization, the control group will receive follow-up assessments concurrently with the intervention group at predetermined intervals (post-intervention, 3 months, and 6 months). Upon completion of the research, the participants assigned to the control group will undergo the MBAT intervention.
62099892|NCT02513433|ACTIVE_COMPARATOR|Bupivacaine & Levobupivacaine|Bupivacaine 15 ml 0.5% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
62099893|NCT02513433|ACTIVE_COMPARATOR|Bupivacaine & Ropivacaine|Bupivacaine 15 ml 0.5% and Ropivacaine 15 ml 0.75% in epidural route before surgery
62099894|NCT02513433|ACTIVE_COMPARATOR|Ropivacaine & Levobupivacaine|Ropivacaine 15 ml 0.75% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
62099895|NCT05879926|ACTIVE_COMPARATOR|Arm 1: Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist (gonadotropin releasing hormone) for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
62294641|NCT01963494|ACTIVE_COMPARATOR|Individual planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons form action plans individually to increase daily physical activity and partners receive a distraction task.
62294642|NCT01963494|ACTIVE_COMPARATOR|No-planning control condition|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons do not receive instructions for action planning, but perform a distraction task together with their partners.
62099896|NCT05879926|ACTIVE_COMPARATOR|Arm 2 Adjuvant Chemotherapy + Ovarian Function Suppression + Aromatase Inhibitor|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
62099897|NCT05507697|EXPERIMENTAL|Experimental|MSCs Participants will received i. m. HUC-MSCs both lower extremities
62099898|NCT05507697|PLACEBO_COMPARATOR|Comparator|The control group will receive i.v Lipoic Acid Injection
62099899|NCT00274989|EXPERIMENTAL|Bendamustine plus Rituximab|
62099900|NCT06355817|ACTIVE_COMPARATOR|Group A: Tap then Vibrate|Tapping for the first eye/side during infiltration of local anesthetic, then vibration for the second eye.
62099901|NCT06355817|EXPERIMENTAL|Group B: Vibrate then Tap|Vibration first, then tapping
62099902|NCT05468333|EXPERIMENTAL|Main arm|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time.
62099903|NCT04952272|EXPERIMENTAL|Intratumor CpG-ODN Injection|CpG-ODN will be Injected into the tumor.
62099904|NCT06612554|PLACEBO_COMPARATOR|Placebo|Placebo tablets will be administered. Three Tablets will be with the same shape and size that Zn supplement tablets during 16 weeks
62099905|NCT06612554|EXPERIMENTAL|Zn Supplementation|16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet)
62099906|NCT03381794||Patients with corneal transplantation|Aim is to include all patients in Germany treated with the different types of corneal transplantation.
62099907|NCT05379868|ACTIVE_COMPARATOR|Posterior column osteotomy|Apical 3-5 posterior column osteotomies in addition to standard treatment
62099908|NCT05379868|PLACEBO_COMPARATOR|No osteotomies|Standard treatment
62099909|NCT06478199||Group A :normal semen|
62099910|NCT06478199||Group B : abnormal semen|
62099911|NCT03387917|EXPERIMENTAL|TLD-1|"Duration of treatment~* 1 cycle: 21 days~* 1 cycle: 28 days (only comparative PK part, in cycle 1 or 2)~* until progression or occurrence of unacceptable toxicity or withdrawal, but~  * maximum 9 cycles for patients previously not treated with anthracyclines~ * maximum 6 cycles for patients previously treated with anthracyclines.~* Dose: i.v., according to DL on day 1 of each cycle or tentative MTD"
62099912|NCT03387917|EXPERIMENTAL|Caelyx (only for comparative PK part)|"Duration of treatment~* 1 cycle: 28 days~* Caelyx is given only in one cycle (cycle 1 or 2)~* Dose: i.v., 40mg/m2"
62099913|NCT04910347|EXPERIMENTAL|Single Arm|Nivolumab
62466818|NCT04520464|ACTIVE_COMPARATOR|Traditional provider for cervical sample|First sequence will start with traditional method. Second sequence will start with self-test method.
62662050|NCT02403271|EXPERIMENTAL|Phase 2|Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.
62662051|NCT04678102|EXPERIMENTAL|Cohort 1 (PHI-101 40mg/day)|In the starting dose cohort 1 subject will be administered 40mg/day PHI-101 and will be assessed for DLT ('single subject cohort'), and until an ADR ≥ \[CTCAE version 5.0\] grade 2 occurs, higher doses will be explored in single subject cohorts in a stepwise fashion. If an ADR ≥ \[CTCAE version 5.0\] grade 2 occurs, the accelerated 3+3 design will be immediately switched to the standard 3+3 scheme.
62662052|NCT04678102|EXPERIMENTAL|Cohort 2 (PHI-101 80mg/day)|In cohort 2, the subject will be administered 80mg/day PHI-101.
62662053|NCT04678102|EXPERIMENTAL|Cohort 3 (PHI-101 120mg/day)|In cohort 3, the subject will be administered 120mg/day PHI-101.
62099914|NCT04624230|EXPERIMENTAL|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
62099915|NCT06702839|EXPERIMENTAL|Cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY)|3 days a week for 3 months
62099916|NCT06702839|ACTIVE_COMPARATOR|Home exercise program|For 3 months
62099917|NCT03698136|EXPERIMENTAL|Stimulation of denervated muscle|direct muscle stimulation 5 times a week for 33 minutes 3 minutes warm up 30 minutes treatment
62099918|NCT06268301|EXPERIMENTAL|Sequence 1: BOS 2 mg Fasted, then Fed|Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fasted condition (Treatment A). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fed condition (Treatment B).
62099919|NCT06268301|EXPERIMENTAL|Sequence 2: BOS 2 mg Fed, then Fasted|Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fed condition (Treatment B). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fasted condition (Treatment A).
62099920|NCT06624059|EXPERIMENTAL|Cohort B1|Participants will receive alectinib in combination with platinum-based chemotherapy for up to 4 cycles (cycle length = 3 weeks), followed by alectinib monotherapy for up to 5 years.
62099921|NCT06624059|EXPERIMENTAL|Cohort B2|Participants will receive alectinib and platinum-based chemotherapy for up to 3 cycles (cycle length = 3 weeks) prior to surgery, and alectinib monotherapy after surgery for up to 5 years after surgery.
62099922|NCT06125028|EXPERIMENTAL|[68Ga]Ga-PTF PET/CT|150 (+/-50) MBq \[68Ga\]Ga-PTF will be administered intravenously and PET/CT will be performed
62099923|NCT06125028|ACTIVE_COMPARATOR|[18F]FDG PET/CT|\[18F\]FDG will be administered once intravenously according to the SMPC and PET/CT will be performed
62099924|NCT02392338|NO_INTERVENTION|Thoracoscopic ablation group|Patients who will undergo thoracoscopic ablation only
62466819|NCT02017223|EXPERIMENTAL|Knowme Device Wear|Participants wear KNOWME devices and use mobile phone interface for three days outside of school. This is a pre-post design with no control group
62466820|NCT02170311|EXPERIMENTAL|Z-213 100mg|Group/Cohort Label: 100 mg iron Z-213 will be administered by intravenous infusion.
62466821|NCT02170311|EXPERIMENTAL|Z-213 500mg|Group/Cohort Label: 500 mg iron Z-213 will be administered by intravenous infusion.
62099925|NCT02392338|ACTIVE_COMPARATOR|Hybrid procedure|Patients who will undergo hybrid procedure (thoracoscopic ablation and eletrophyologic study with or without additional ablation)
62099926|NCT01546571|PLACEBO_COMPARATOR|POL-103A without API|
62662054|NCT04678102|EXPERIMENTAL|Cohort 4 (PHI-101 160mg/day)|In cohort 4, the subject will be administered 160mg/day PHI-101.
62099927|NCT01546571|EXPERIMENTAL|POL-103A|
62099928|NCT01066260|EXPERIMENTAL|Probiotic|
62099929|NCT01066260|PLACEBO_COMPARATOR|Placebo|
62662055|NCT04678102|EXPERIMENTAL|Cohort 5 (PHI-101 200mg/day)|In cohort 5, the subject will be administered 200mg/day PHI-101.
62662056|NCT04678102|EXPERIMENTAL|Cohort 6 (PHI-101 240mg/day)|In cohort 6, the subject will be administered 240mg/day PHI-101.
62662057|NCT03284554|ACTIVE_COMPARATOR|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
62662058|NCT03284554|SHAM_COMPARATOR|Non-encapsulated nutrients|"Nutrients known to be able to stimulate GLP-1 and PYY release if they are encapsulated to provide release at pH ≈7.0 (in the distal part of the ileum). The same capsules in a non-coated form will be provided in order to study the effect of the coating.~The non-encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
62662059|NCT03284554|PLACEBO_COMPARATOR|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The placebo capsules will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
62662060|NCT01143324||MAST™ procedure|
62662061|NCT03439839|EXPERIMENTAL|Cohort 1: LNP023 200mg bid + SoC|Orally administered iptacopan 200 mg b.i.d. in Part 1 and Part 2
62662062|NCT03439839|EXPERIMENTAL|Cohort 2: LNP023 50mg/200mg bid + SoC|Orally administered iptacopan 50 mg b.i.d. for a minimum of 2 weeks in addition to SoC; this could be increased to iptacopan 200 mg b.i.d. at study day 15 or at any time later in the study if LDH was not within limit of normal or reduced by at least 60% as compared to baseline values.
62662063|NCT02401295|EXPERIMENTAL|ATRA/celecoxib/itraconazole|"All maintenance drugs will be given on days 1-21 of each cycle, followed by 14 days off treatment. Cycles will be repeated every 35 days (+/- 3 days) for a total of five cycles.~Each patient enrolled will receive ATRA 20mg twice per day by mouth. Dose modifications are not allowed unless excessive toxicity occurs. In this case, ATRA will be de-escalated by 50% to 10mg twice per day by mouth.~The dose of celecoxib for all patients enrolled will be 400 mg twice per day by mouth. If creatinine level increases to more than 2 mg/dl and cannot be corrected by increased oral fluid intake or other measures, the dose of celecoxib will be decreased by 50%. If creatinine level does not drop below 2 mg/dl on the reduced dose, celecoxib will be discontinued.~The dose of itraconazole for all patients enrolled will be 200 mg twice per day by mouth. Dose modifications are not allowed."
62662064|NCT00149643|ACTIVE_COMPARATOR|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
62662065|NCT00149643|PLACEBO_COMPARATOR|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
62662066|NCT02935387|EXPERIMENTAL|Taper methotrexate, then golimumab|Taper methotrexate 25\>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50\>0mg/month during 24 weeks.
62662067|NCT02935387|ACTIVE_COMPARATOR|Taper golimumab, then methotrexate|Taper golimumab 50\>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25\>0mg/wk during 24 weeks.
62662068|NCT05141799|ACTIVE_COMPARATOR|high-intensity laser therapy (HILT)|"we will apply the HILT device to the most painful area of the wrist in two phases. In both phase I and phase II, the laser will be applied using continuous circular movements.~The first three sessions (phase I) will be used to provide analgesic effects at an intermittent phase, applying a 75 sec, 8 W, 6 J/cm2 treatment for a total of 150 J of energy. The subsequent six sessions (phase II) will provide a biostimulatory effect at a continuous phase, applying a 30 sec, 6 W, 120 to 150 J/cm2 treatment. The HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks."
62662069|NCT05141799|SHAM_COMPARATOR|sham HILT|We will apply the HILT device to the most painful area of the wrist by using continuous circular movements, but the laser instrument will switched off during applications. The sham HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks.
62662070|NCT04597450|EXPERIMENTAL|Lu AG06466|
61910396|NCT04571528|ACTIVE_COMPARATOR|Physiotherapy part of VIRTUA FIBROWALK|The physiotherapy part of the VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE) and therapeutic exercise.
61910397|NCT03886545||caregivers with shoulder pain|
62099930|NCT06316297|EXPERIMENTAL|Experimental 1|Two administrations of the Acne mRNA vaccine will be injected in three increasing doses
62099931|NCT06316297|EXPERIMENTAL|Experimental 2|One administration of the Acne mRNA vaccine in three increasing doses and one administration of placebo will be injected
62099932|NCT06316297|PLACEBO_COMPARATOR|Placebo 1|Two administrations of placebo will be injected
61910398|NCT03886545||Healthy subjects|
62099933|NCT06384131|ACTIVE_COMPARATOR|ABI-4334|
62099934|NCT06384131|PLACEBO_COMPARATOR|Placebo|
62099935|NCT01709292|EXPERIMENTAL|Vemurafenib - (Presurgery)|All Groups: Vemurafenib 960 mg by mouth 2 times a day for 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56 +/- 7 days).
62099936|NCT01709292|EXPERIMENTAL|Vemurafenib (Post Surgery) - Group A|Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
62099937|NCT01709292|NO_INTERVENTION|Post Surgery - Group B|Post Surgery - Group B: Patients discontinue vemurafenib after surgery but will be restaged with CT neck 8 weeks after surgery.
62099938|NCT01709292|EXPERIMENTAL|Vemurafenib - Group C|Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56, Vemurafenib 960 mg by mouth twice a day unless there is evidence of progressive disease on day 56 CT scan. Patients evaluated for resectability after each CT scan is performed. If scheduled for resection, patient continues vemurafenib until surgery and follows same treatment schema as patients in Groups A and B.
62099939|NCT01149603|EXPERIMENTAL|Implantation of the HeartMate II VAD|Consenting patients who meet the study inclusion and exclusion criteria will be implanted with a HeartMate II ventricular assist device.
62099940|NCT06435312|EXPERIMENTAL|Zilucoplan Arm|Study participants will receive Zilucoplan at a pre-defined dose based on their weight.
62099941|NCT04749693||Patient with HbA1c >= 8% despite the use of insulin pump and frequent glycemic control|only group included in the study
62099942|NCT06712212|ACTIVE_COMPARATOR|Inguinal hernia|
62099943|NCT06711965|EXPERIMENTAL|Intraoperative Use of 3D Printed Breast Mold|Participants will be randomized using a 1:1 ration to 1 of 2 conditions
62099944|NCT06711965|EXPERIMENTAL|Standard of Care Reconstruction|Participants will be randomized using a 1:1 ration to 1 of 2 conditions
62662071|NCT04597450|PLACEBO_COMPARATOR|Placebo|
61910399|NCT04308031|EXPERIMENTAL|Ivabradine|Subject will be randomly assigned to either Ivabradine or Digoxin group. Ivabradine starting dose is 2.5 mg twice daily(BID). ECG will be performed at each visit during the treatment phase and dose will be adjusted based on the heart rate result from the ECG. Total treatment phase is 16 weeks ( 4 months).
62099945|NCT06687460|EXPERIMENTAL|nerve electrical stimulation|During the process of nerve microsurgical reconstruction, a 30-minute electric stimulation is applied to the distal end of the damaged nerve.
62099946|NCT06687460|PLACEBO_COMPARATOR|nerve microsurgical reconstruction|no nerve electrical stimulation
62099947|NCT06641076|EXPERIMENTAL|sonelokimab dose with an induction regimen|Subjects randomized to this arm will receive sonelokimab subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dosing starting at Week 8.
62099948|NCT06641076|EXPERIMENTAL|sonelokimab dose without an induction regimen|Subjects randomized to this arm will receive sonelokimab subcutaneously every 4 weeks.
62099949|NCT06641076|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo subcutaneously.
62466822|NCT02170311|EXPERIMENTAL|Z-213 800mg|Group/Cohort Label: 800 mg iron Z-213 will be administered by intravenous infusion.
62662072|NCT04137549||Nocturnal controlled hypertension|Nocturnal blood pressure was controlled under 120/70 mmHg after aggressive anti-hypertensive therapy.
62662073|NCT04137549||Nocturnal uncontrolled hypertension|Nocturnal blood pressure was still over 120/70 mmHg after aggressive anti-hypertensive therapy.
62099950|NCT04268264|EXPERIMENTAL|Treatment arm|Will receive trial intervention, Incremental haemodialysis (n=20)
62099951|NCT04268264|OTHER|Control arm|Historical controls. Matched controls from database of historical patients receiving conventional, three times weekly haemodialysis treatment (n=40)
62099952|NCT06713044|EXPERIMENTAL|Arm 1: Murottal Therapy|"Arm 1: Murottal Therapy~Intervention: Participants in this group will listen to selected recitations of Islamic verses (murottal) as a non-pharmacological intervention during their postoperative recovery."
62466823|NCT02170311|EXPERIMENTAL|Z-213 1000mg|Group/Cohort Label: 1000 mg iron Z-213 will be administered by intravenous infusion.
62466824|NCT01196260|EXPERIMENTAL|5-fluorouracil plus oxaliplatin|patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin
61910400|NCT04308031|ACTIVE_COMPARATOR|Digoxin|Subject will be randomly assigned to either Ivabradine or Digoxin group. Digoxin starting dose is 0.125mg once daily(QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60. Dose adjustment will be based on heart rate result from ECG performed at each treatment visit and Digoxin level from blood sample collected from each visit during treatment phase. Total treatment phase is 16 weeks ( 4 months).
61910401|NCT00839033|EXPERIMENTAL|1|patients treated with standard treatment and a mechanical insufflation-exsufflation
62099953|NCT06713044|EXPERIMENTAL|Arm 2: Classical Music Therapy|Intervention: Participants in this group will listen to selected classical music compositions during their recovery from lower extremity orthopedic surgery with spinal anesthesia.
62099954|NCT06713044|EXPERIMENTAL|Arm 3: Standard Care|Participants in this group will receive standard postoperative care following their surgery, without any additional interventions.
62099955|NCT02467582|EXPERIMENTAL|Aspirin 100 mg|Asprin 100 mg daily for maximum 3 years standard chemo if indicated
62099956|NCT02467582|ACTIVE_COMPARATOR|Placebo|Placebo daily for maximum 3 years standard chemo if indicated
62099957|NCT03621553|EXPERIMENTAL|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
62099958|NCT03621553|PLACEBO_COMPARATOR|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
62099959|NCT03621553|OTHER|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
62099960|NCT02360345|EXPERIMENTAL|q1week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.
62099961|NCT02360345|EXPERIMENTAL|q2week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1 and 15 of repeated 28-day treatment cycles.
62466825|NCT04092751|EXPERIMENTAL|Treatment A|Single oral 20-mg dose of PRA on Day 1 AM
62099962|NCT06534463||Observational Cohort|Including newly diagnosed marginal zone lymphoma (MZL) and relapse/refractory MZL participants who meet the treatment indications for MZL and are about to undergo MZL treatment.
62099963|NCT02741479|EXPERIMENTAL|K Tape Group|
62099964|NCT02741479|ACTIVE_COMPARATOR|Sham Group|
62099965|NCT02741479|EXPERIMENTAL|No Tape|
62099966|NCT04327037|EXPERIMENTAL|NK cells + IL-2|After cycle of chemotherapy patient receive one intravenous infusion of expanded haploidentical NK cells on day 0. On alternate days, 6 doses of subcutaneous IL-2 is administered with start on day -1.
62099967|NCT03199469|EXPERIMENTAL|1.3 × 10^14 vg/kg (Low dose)|Participants received 1.3 x 10\^14 viral genomes per kilogram (vg/kg) of body weight resamirigene bilparvovec as a single dose intravenously on Day 1. A sentinel dose was given to first participant and if there were no safety concerns, subsequent participants received either resamirigene bilparvovec at the same dose or control with delayed treatment after at least 4 weeks of post-dose data from the sentinel participant.
62099968|NCT03199469|EXPERIMENTAL|3.5 × 10^14 vg/kg (High dose)|Participants received 3.5 × 10\^14 vg/kg of body weight resamirigene bilparvovec as a single dose intravenously on Day 1. A sentinel dose was given to first participant and if there were no safety concerns, subsequent participants received either resamirigene bilparvovec at the same dose or control with delayed treatment after at least 4 weeks of post-dose data from the sentinel participant.
62099969|NCT04736056|EXPERIMENTAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|"Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills (MBTI+)~The MBTI+ intervention will train participants in mindfulness-based sleep strategies and behavioral symptom management techniques. The MBTI+ intervention will consist of 6 weekly sessions that will last between 60 and 75 minutes."
62099970|NCT06712576||patients with placenta accrete spectrum|patients with placenta accrete spectrum secondary to previous cesarean section will be recruited from the outpatient clinic and reception unit, Assiut, Egypt.
62099971|NCT04401436||COVID 19 patients|Study participants will be adults who either have COVID-19 or who have recently recovered from the disease(recovered per Centers for Disease Control and Prevention guidelines).
62099972|NCT05995782|EXPERIMENTAL|FB418|"Part A - Single ascending oral doses of FB418 in healthy adult subjects and healthy elderly subjects.~Part B - Multiple ascending oral doses FB418 in healthy adult subjects."
62099973|NCT05995782|PLACEBO_COMPARATOR|FB418-Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
62099974|NCT00358306||a|those with previous history of Acute kidney injury
62099975|NCT06636253||SCC students|Healthy adults attending and actively enrolled in the Scotland College of Chiropractic's degree program and who were without health issues or mental disorders.
62099976|NCT05754333|EXPERIMENTAL|White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354.
62099977|NCT05754333|EXPERIMENTAL|White Light - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354.
62099978|NCT05754333|EXPERIMENTAL|White Light/near-infrared fluorescence - Adolescents|Adolescent participants will receive a single dose of ASP5354.
62099979|NCT05754333|EXPERIMENTAL|White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment|Adult participants with moderate or severe renal impairment will receive a single dose of ASP5354.
62099980|NCT02929108|NO_INTERVENTION|Enhanced Usual Care|The family caregivers in his group will receive usual hospice care which has been enhanced as the staff have been trained in shared decision making.
62099981|NCT02929108|EXPERIMENTAL|Facebook|The family caregivers in this group only participates in the Facebook groups, not in the shared decision making
62099982|NCT02929108|EXPERIMENTAL|ACCESS|The family caregivers in this group participates in Facebook and web conferencing for shared decision making
62099983|NCT06712381|ACTIVE_COMPARATOR|1|Carac
62099984|NCT06712381|ACTIVE_COMPARATOR|2|Photodynamic Therapy
62099985|NCT06712381|ACTIVE_COMPARATOR|3|Carac combined with Photodynamic Therapy
62099986|NCT01244100|EXPERIMENTAL|PL2200|
62099987|NCT01634919||Chronic hepatitis C|Chronic hepatitis C
62099988|NCT06688214|EXPERIMENTAL|Kinesio Taping|Kinesio Taping treatment
62099989|NCT06688214|ACTIVE_COMPARATOR|Scapular Stabilization Exercises|Scapular Stabilization Exercises
62099990|NCT02812966|ACTIVE_COMPARATOR|Lutonix Drug Coated Balloon|Lutonix 035 Drug coated Balloon Percutaneous Transluminal Angioplasty Catheter
62099991|NCT02812966|ACTIVE_COMPARATOR|IN.PACT Drug Coated Balloon|IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter
62099992|NCT05164666|EXPERIMENTAL|TAK-103, Dose Escalation|TAK-103, Chimeric antigen receptor (CAR) (+) cells, intravenous infusion, will be administered at approximately 5 mL/min. There are 5 planned dose levels: 1x10\^6, 3x10\^6, 1x10\^7, 1x10\^8 and 5x10\^8 CAR (+) cells/body. The level of dose in dose escalation will be guided by dose escalation schema based on the observed dose limiting toxicities (DLT) rate at each dose level.
62099993|NCT04771273|EXPERIMENTAL|Survodutide 2.4 mg - planned maintenance treatment|
62099994|NCT04771273|EXPERIMENTAL|Survodutide 4.8 mg - planned maintenance treatment|
62099995|NCT04771273|EXPERIMENTAL|Survodutide 6.0 mg - planned maintenance treatment|
62099996|NCT04771273|PLACEBO_COMPARATOR|Placebo - planned maintenance treatment|
62099997|NCT06711380|OTHER|Peer Ambassador|There is one arm of the trial which includes the Patient Ambassador intervention.
62099998|NCT06711497|EXPERIMENTAL|global postural reeducation exercise|the patients will receive global postural reeducation and active neck flexor exercises twice a week for four weeks
62099999|NCT06711497|EXPERIMENTAL|deep neck flexor activation exercise|the patients will receive deep neck flexor activation with active neck exercises
62100000|NCT01456780|ACTIVE_COMPARATOR|Zylet|Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
62100001|NCT01456780|ACTIVE_COMPARATOR|Lotemax|Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
62100002|NCT01456780|PLACEBO_COMPARATOR|B+L Advanced Eye Relief Lubricant Drop|Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.
62100003|NCT06713525||Patients with PC are referred to Comprehensive Pancreatic Cancer Center at Herlev Hospital|
62100004|NCT06713863|EXPERIMENTAL|Intervention first|Participant directly enrolled to the intervention
62100005|NCT06713863|NO_INTERVENTION|Waitlist first|Participant spends amount of time similar to completing the intervention in a waitlist after which gets enrolled into the intervention after post-waitlist measures have been completed.
62100006|NCT02993029|EXPERIMENTAL|99Tc-MDP|99Tc-MDP group:15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
62100007|NCT02993029|ACTIVE_COMPARATOR|celecoxib|celecoxib capsule 200mg qd by mouth.
62100008|NCT01784289||normal|Patients with no overweight and no type 2 diabetes
62100009|NCT01784289||lipodystrophy|patients with a lipodystrophy, most are diabetics
62662074|NCT04940221|EXPERIMENTAL|Phone-delivered decision-counseling program for shared decision making in lung cancer screening|All individuals who are eligible for lung cancer screening according to USPSTF criteria were invited to participate in the study and all patients who accepted the invitation and consented were slated to receive the intervention which was a phone-delivered on line decision-counseling program (DCP) and there was no one randomized or enrolled into a control group, nor was anyone randomized or enrolled into a usual care group.
62662075|NCT06460129|EXPERIMENTAL|Brugger's Exercises|Participants will receive Burger Exercise
62100010|NCT01784289||obese non diabetics|Patients with obesity (BMI \<30kg/m2), without diabetes
62100011|NCT01784289||obese diabetics|Patients with obesity (BMI \<30 kg/m2), with diabetes
62100012|NCT01387256|OTHER|mifepristone+misoprostol|200 mg mifepristone + 800 mcg buccal misoprostol
62100013|NCT01387256|EXPERIMENTAL|buccal misoprostol|2 doses of 800 mcg buccal misoprostol
62100014|NCT06108492|EXPERIMENTAL|SHR-2005|Only one arm with SHR-2005
62100015|NCT02552550||Ability to swallow, speak and quality of life|This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.
62100016|NCT06132321||Patients operated for vulvar cancer without reconstruction|
62100017|NCT06132321||Patients operated for vulvar cancer with reconstruction|
62100018|NCT06713551|EXPERIMENTAL|Big amplitude calisthenic group exercises with music|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
62100019|NCT06713551|ACTIVE_COMPARATOR|Big amplitude calisthenic group exercises|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
62100020|NCT05202080|EXPERIMENTAL|Opioid Counseling and PCS Video Group|This arm of the study will receive the opioid counseling and pain coping skills video 2 weeks prior to their surgery in addition to the conventional information provided to all patients undergoing total joint arthroplasty.
62100021|NCT05202080|NO_INTERVENTION|Standard of Care Group|This arm of the study will the conventional information provided to all patients undergoing total joint arthroplasty.
62662076|NCT06460129|ACTIVE_COMPARATOR|KENDALL EXERCISE|Participants will receive Kendal Exercise
62100022|NCT04196985|EXPERIMENTAL|Patients with HNSCC|Patients who have histologically confirmed HNSCC and have received CRT for it
62100023|NCT01619254|EXPERIMENTAL|Hand hygiene|Hand washing with soap measures will be carried out as an intervention activity
62100024|NCT01619254|EXPERIMENTAL|Hand finger nail hygiene|Hand finger nail clipping activities
62100025|NCT01619254|EXPERIMENTAL|Hand and finger nails hygiene|Both hand washing with soap and hand finger nail clipping activities will be implemented
62662077|NCT03295916|EXPERIMENTAL|Systemic therapy plus SBRT to OM|Stereotactic Body Radiotherapy (SBRT) up to 5 OM sites
62100026|NCT01619254|PLACEBO_COMPARATOR|Customary practice|No hand washing with soap and nail clipping activities. House holds and children assigned to the control group will not have the interventions (hand washing with soap and nail clipping activities)
62662078|NCT01902069|EXPERIMENTAL|Phosholean dietary supplement|Subjects in the PhosphoLean group will receive two capsules of PhosphoLEAN orally daily (total of 55 mg of NOPE and 100 mg of EGCG), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
62662079|NCT01902069|PLACEBO_COMPARATOR|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
62662080|NCT00408954|PLACEBO_COMPARATOR|Placebo|
62662081|NCT00408954|ACTIVE_COMPARATOR|UK-369,003|
62662082|NCT02724436|EXPERIMENTAL|TACE|transcatheter arterial chemoembolization
62662083|NCT02724436|EXPERIMENTAL|TACE+radioembolization|TACE plus radioembolization with Y-90: 100
62100027|NCT05930041|EXPERIMENTAL|CSP|
62100028|NCT05930041|ACTIVE_COMPARATOR|HS-EMR|
62100029|NCT06458738|EXPERIMENTAL|Printable denture base material|
62100030|NCT03444779|ACTIVE_COMPARATOR|Control group|The patients will be treated with an open technique: cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope. The reduction will be performed using a spatula, a bone tamp or open reduction internal fixation. The osteosynthesis and filling of the cavity will be performed by the same surgical access.
62662084|NCT05457543||Adult|A venous blood and capillary blood collection is taken from each participant and tested with investigative diagnostic tests.
62662085|NCT00261040|ACTIVE_COMPARATOR|Minimally Invasive Surgery (MIS)|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
62662086|NCT00261040|SHAM_COMPARATOR|Standard Surgery|The standard way an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision
62662087|NCT06047327|EXPERIMENTAL|EUS Guided Liver Biopsy|Procedure will be done by 19G Franseen needle in EUS guided liver biopsy.
62662088|NCT06047327|ACTIVE_COMPARATOR|Percutaneous Liver Biopsy|Procedure will be done by 18G BioPince Needle in percutaneous liver biopsy.
62466826|NCT04092751|EXPERIMENTAL|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later.
62466827|NCT05315739|ACTIVE_COMPARATOR|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the gammaCore device (electroCore)
62662089|NCT05339074|EXPERIMENTAL|Ketamine|Open-label ketamine infusions will be provided on a flexible schedule (every 2-4 weeks) with flexible dosing (0.5-1.0mg/kg over 40 minutes) titrated to optimize benefits, while minimizing the dosage and frequency over a 12-week extension period
62662090|NCT00742677|EXPERIMENTAL|Group 1 (early feeding)|Patients are offered a liquid diet on day 1 for 24 hours following surgery. Beginning on day 2, patients who tolerate a liquid diet are offered a light regular diet until hospital discharge.
62100031|NCT03444779|EXPERIMENTAL|Experimental group|"The patients will be treated with the Tibial Tuberoplasty technique under fluoroscopic guidance with or without arthroscopy. The reduction will be performed by an anterior approach using a kyphoplasty balloon. The combined osteosynthesis including cannulated screws and cementoplasty will both be performed by a percutaneous technique."
62662091|NCT00742677|ACTIVE_COMPARATOR|Group 2 (traditional feeding)|Patients are offered nothing by mouth on days 1 and 2 following surgery. Beginning on day 3, patients are offered a liquid diet for 24 hours. Beginning on day 4, patients who tolerate a liquid diet (absence of nausea and vomiting) are offered a semi-solid diet for 24 hours. Beginning on day 5, patients who tolerate a semi-solid diet are offered a light regular diet until hospital discharge.
62100032|NCT01688544|EXPERIMENTAL|Ilaprazole|"Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.~After 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed"
62100033|NCT04633343|EXPERIMENTAL|Small Volume Breath Group (5mlKg)|Small volume breath and fast breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation
62100034|NCT04633343|EXPERIMENTAL|Large Volume Breath Group (10mL/kg)|Large volume breath and slow breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation.
62100035|NCT06044649|EXPERIMENTAL|Cognitive Behavioral Therapy|8-session, individual, Cognitive Behavioral Therapy delivered remotely by skilled CBT therapists
62100036|NCT06044649|EXPERIMENTAL|Acceptance and Commitment Therapy|8-session, individual, Acceptance and Commitment Therapy delivered remotely by skilled ACT therapists
62100037|NCT06044649|EXPERIMENTAL|Emotional Awareness and Expression Therapy|8-session, individual, Emotional Awareness and Expression Therapy delivered remotely by skilled EAET
62100038|NCT06044649|OTHER|Treatment As Usual|In this control condition, participants will engage in their usual care for neck/back pain with no additional experimental intervention
62100039|NCT06712199|PLACEBO_COMPARATOR|Opioid Anesthesia Group (OBA Group)|In OBA group, propofol, rocuronium bromide and sufentanil were induced by combined anesthesia, tracheal intubation was performed through a visual laryngeal mask, propofol and remifentanil were injected into the intraoperative pump to maintain anesthesia, and sufentanil was brided to 10μg 30 minutes before the end of the operation. PCA administration regimen in OBA group: Sufentanil + dexmedetomidine + Ondansetron.
62100040|NCT06712199|EXPERIMENTAL|Less opioid anesthesia Group (OFA group)|In OFA group, propofol, rocuronium bromide and esketamine were induced by combined anesthesia, and endotracheal intubation was performed through visual laryngeal mask. Intraoperative pump propofol and esketamine to maintain anesthesia; Oxeridine was bridged-1.5 mg 30min before the operation and administered in two doses, 0.75mg/ time, with an interval of 10min.
62100041|NCT06610526|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg once daily
62100042|NCT05058794|EXPERIMENTAL|Resistance exercise group|"During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and LOP was calculated in the body position that the blood flow restriction (BFR) stimulus would be applied. BFR pressure was set at 50% occlusion.Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.~Secondly, Rest between sets (1 min) Therapist will help these positions to maintain Knee extension and Wall Squatting.~The study includes interventional protocol of 6 weeks. Total sessions will be 12 and in each week there will 2 sessions with alternative days and follow up."
62100043|NCT05058794|ACTIVE_COMPARATOR|Conventional Therapy Group|Patients in this group will receive treatment via Knee extension,Wall squatting Each training session includes 3 minutes warm-up.First, participants will perform 2 sets with 15 repetitions in (0 to 90 degree.) Secondly, Rest between sets (1 min) Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. The study includes interventional protocol of 6 weeks. The sessions will be given on 2 alternate days making it a total of 12 sessions and then follow up.
62100044|NCT02749331|EXPERIMENTAL|AdVince|"Dose escalation, minimum 3 patients per dose in Phase I. Dose levels:~1. 10 000 000 000 virus particles~2. 100 000 000 000 virus particles~3. 300 000 000 000 virus particles~4. 1000 000 000 000 virus particles~Maximum tolerated dose will be confirmed by 12 additional patients treated at this dose level in Phase IIa."
62466828|NCT05315739|SHAM_COMPARATOR|Sham treatment|Inactive sham vagus nerve stimulation applied by the gammaCore sham device (electroCore)
62662092|NCT05231967||Atrial fibrillation recurrence|Atrial fibrillation recurrence one month after cardioversion
62662093|NCT05231967||Sinus rhythm continue|Sinus rhythm continue one month after cardioversion
62662094|NCT03006679|EXPERIMENTAL|Meropenem-Vaborbactam HABP|Participants with a clinical diagnosis of HABP will be treated with meropenem 2 grams (g) and vaborbactam 2 g in 250 milliliters (mL) infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
62662095|NCT03006679|ACTIVE_COMPARATOR|Piperacillin/Tazobactam HABP|Participants with a clinical diagnosis of HABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
62662096|NCT03006679|EXPERIMENTAL|Meropenem-Vaborbactam VABP|Participants with a clinical diagnosis of VABP will be treated with meropenem 2 g and vaborbactam 2 g in 250 mL infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
62662097|NCT03006679|ACTIVE_COMPARATOR|Piperacillin/Tazobactam VABP|Participants with a clinical diagnosis of VABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
62662098|NCT04056026|EXPERIMENTAL|Fecal Microbiota Transplant|The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
62100045|NCT01723774|EXPERIMENTAL|Arm 1: PIK3CA Wild Type Cohort|"* Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~* Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~* Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~* Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~* Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
62100046|NCT01723774|EXPERIMENTAL|Arm 2: PIK3CA Mutant Type Cohort|"* Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~* Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~* Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~* Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~* Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
62100047|NCT01723774|EXPERIMENTAL|Arm 3: Endocrine Resistant Cohort|"* Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~* Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~* Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~* Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
62100048|NCT05037656|NO_INTERVENTION|Control|Students in the control group will receive the standard health education curriculum.
62100049|NCT05037656|EXPERIMENTAL|Experimental|Students in the treatment group will receive the school-based classroom curriculum.
62100050|NCT01123161|ACTIVE_COMPARATOR|Group1: IV t-PA and normothermia|IV tpa and normothermia
62100051|NCT01123161|ACTIVE_COMPARATOR|Group 2 : IV t-PA and hypothermia and anti-shivering treatment|IV tpa and hypothermia and anti-shivering treatment
62662099|NCT03603704|EXPERIMENTAL|LY3209590|"Insulin naïve participants with Type 2 Diabetes Mellitus received 5 mg and 10 mg LY3209590 administered subcutaneously (SC) in Cohort 1 and 2 respectively.~Participants with T2DM received 20 mg LY3209590 administered subcutaneously in Cohort 3."
62662100|NCT03603704|ACTIVE_COMPARATOR|Placebo|Participants from Cohort 1 and 2 received Placebo administered SC.
62662101|NCT03483103|EXPERIMENTAL|Treatment|Lisocabtagene maraleucel at a dose of 100×10\^6 CAR+ T cells (50×10\^6 CD8+ CAR+ T cells and 50×10\^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).
62662102|NCT01875237|EXPERIMENTAL|Stem Cell Transplant + Modified T-Cells + Chemotherapy|The first component is stem cell transplant. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC). The second component is the planned DLI infusion. iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10\^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64. The transplant day is referred to as day zero (D0), treatment plan activities prior or after D0 are denoted as day minus (D-) or day plus (D+). Patients receive standard reduced intensity regimen using fludarabine, melphalan, and alemtuzumab to achieve engraftment with a low risk of GVHD. At approximately 60 days post transplant patients who are alive and without GVHD, receive DLI to enhance graft-vs.-malignancy and immune reconstitution.
62662103|NCT05169905|EXPERIMENTAL|RSV_dTpa-P Group|Healthy non-pregnant girls 9-17 years of age received a single dose of RSV MAT vaccine at Day 1 and were scheduled to receive a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). Participants who were enrolled and were due to receive the dTpa vaccine at Day 31, did no longer receive the dTpa as part of this study, but they were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.
61910402|NCT00839033|ACTIVE_COMPARATOR|2|Patients with standard treatment and standard respiratory physiotherapy
61910403|NCT01165762|EXPERIMENTAL|Immune Tolerance, Kidney transplantation|Induction of immune tolerance in Haplotype matched living donor kidney transplantation.
61910404|NCT02788162|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61910405|NCT04992858|EXPERIMENTAL|CT053PTSA|60 mg/d, starting on the first day
61910406|NCT03062254|EXPERIMENTAL|Radium-223|
62100052|NCT06711783|EXPERIMENTAL|Family based treatment|Family based treatment including the whole chain of care, such as day care and in patiant care when necessary. The interventions includes consultation with dietician, psyciotherapist, LEAP-Y and Skills training based on an individual plan.
62100053|NCT05660850|EXPERIMENTAL|Part A: CRC Asthma atopic|Patients with CRC atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
62100054|NCT05660850|EXPERIMENTAL|Part A: CRC Asthma non-atopic|Patients with CRC non-atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
62662104|NCT05169905|EXPERIMENTAL|dTpa_RSV-P Group|Healthy non-pregnant girls 9-17 years of age were scheduled to receive a single dose of dTpa vaccine at Day 1 and a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration), but there were no participants assigned to this study group, and hence, there was no vaccine administered in this study group.
62100055|NCT05660850|EXPERIMENTAL|Part A: Unexplained Chronic Cough|Patients with Unexplained Chronic Cough will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
62100056|NCT05660850|EXPERIMENTAL|Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease|Patients with Chronic Obstructive Pulmonary Disease will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
62100057|NCT05660850|EXPERIMENTAL|Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis|Patients with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
62100058|NCT03749291|EXPERIMENTAL|Obemat2.0 Intervention Group|Obese children (BMI \>97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
62100059|NCT03749291|ACTIVE_COMPARATOR|Control Group|Obese children (BMI \>97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
62100060|NCT06585540|EXPERIMENTAL|Group Barhemsys|Interventional arm receiving Barhemsys during surgery
62100061|NCT06585540|PLACEBO_COMPARATOR|Group Placebo|Placebo arm receiving Placebo during surgery
62466829|NCT04764214|EXPERIMENTAL|3rd generation EGFR-TKI+ SRT|Patients were treated with the intent to ablate all residual disease with consolidative SRT. EGFR-TKI treatment was continued during and after consolidative SRT until disease progression or intolerable toxicity.
62662105|NCT05169905|EXPERIMENTAL|RSV_dTpa-A Group|Healthy non-pregnant adult women 18-49 years of age received a single dose of RSV MAT vaccine at Day 1 and were scheduled to receive a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). Participants who were enrolled and were due to receive the dTpa vaccine at Day 31, did no longer receive the dTpa as part of this study, but they were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.
62662106|NCT05169905|EXPERIMENTAL|dTpa_RSV-A Group|Healthy non-pregnant adult women 18-49 years of age received a single dose of dTpa vaccine at Day 1 and were scheduled to receive a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). RSV MAT vaccine was no longer administered to participants at Day 31.
62662107|NCT03399344|OTHER|DW-MRI|Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
62662108|NCT02627807|EXPERIMENTAL|Individualized CTV|Patients receive IMRT using individualized CTV based on disease extension risk atlas and computer-aided delineation. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
62662109|NCT02627807|ACTIVE_COMPARATOR|Traditional CTV|Patients receive IMRT using traditional CTV. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
62662110|NCT03181555|OTHER|Pregnant Obese African American Women|Exploratory
62662111|NCT02984137|EXPERIMENTAL|idiopathic RBD group|A group of patients diagnosed as idiopathic RBD that is confirmed by polysomnography. Interventions as testing, evaluation, samplings at baseline, then repeat at 2 years and 4 years of prospective follow-up. thereafter only clinical observations until Lewy body disease is diagnosed.
62662112|NCT02984137|ACTIVE_COMPARATOR|incident PD group|A group of patients who are newly diagnosed as Parkinson's disease, and never been treated with prolonged history of probable RBD. Interventions as testing, evaluation, sampling at baseline and then evaluations only at 3 year follow-up after anti-parkinsonian treatment.
62662113|NCT02984137|PLACEBO_COMPARATOR|Control|Control group includes elderly controls without neurodegerative diseases examined by neurologists. Interventions as testing, evaluation, sampling at baseline only.
62466830|NCT01049334|EXPERIMENTAL|flurbiprofen 8.75 mg lozenge|Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
62100062|NCT06585540|EXPERIMENTAL|Group Placebo Barhemsys|Of patients who are members of Group Placebo they will be able to receive Barhemsys in the Post Anesthesia Care Unit if they experience nausea or emesis
62100063|NCT06585540|PLACEBO_COMPARATOR|Group Placebo Placebo|Of patients who are members of Group Placebo they will be able to receive Placebo in the Post Anesthesia Care Unit if they experience nausea or emesis
62100064|NCT05991505|NO_INTERVENTION|1- Control|Volunteers with no physical activity during 10 weeks
62100065|NCT05991505|ACTIVE_COMPARATOR|2 - Training|Volunteers with supervised home physical activity, twice a week, during 10 weeks
62466831|NCT01049334|PLACEBO_COMPARATOR|Placebo lozenge|Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
62466832|NCT01794065||Cypher|100 patients who have received a Cypher stent during their coronary intervention
62466833|NCT01794065||Taxus Express|100 patients who have received a Taxus Express stent during their coronary intervention
62662114|NCT05883488|EXPERIMENTAL|Robotic rehabilitation group|The robotic rehabilitation group will receive a robot-assisted upper extremity rehabilitation program in addition to the conventional rehabilitation program.The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes.
62662115|NCT05883488|ACTIVE_COMPARATOR|Conventional rehabilitation group|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
62662116|NCT05580120|EXPERIMENTAL|Online-supervised exercise group|After the pre-tests (The Brief Resilience Scale, Quality of Life) , the patients were given online-supervised exercise education for 6 weeks.
62662117|NCT05580120|EXPERIMENTAL|The unsupervised-exercise training group|After the pre-tests (The Brief Resilience Scale, Quality of Life) , the patients were given unsupervised exercise education for 6 weeks.
61910407|NCT03843346||Cohort 1: Postoperative group|"Consists of 75 patients who have completed definite surgery for their primary breast cancer as determined by a Consultant Surgeon and have been referred to a Medical Oncologist for consideration of adjuvant chemotherapy.~* Tumours of any size will be eligible~* Between 1 and 3 lymph nodes involved by tumour as assessed by Consultant Pathologist~* Micro metastases (\<=0.2mm) will be eligibile~* Isolated tumour cells only (node negative i+/i-) are excluded"
61910408|NCT03843346||Cohort 2: Preoperative group|"Consists of 75 patients who have been referred by a Consultant Surgeon to a Medical Oncologist for consideration of neoadjuvant (preoperative) chemotherapy.~* Min tumour size 2.1mm (T2)~* Histological proof of involvement of at 1 lymph node, including micrometastases (\<=0.2mm)"
61910409|NCT03753581|EXPERIMENTAL|Care protocol plus microcurrents|"* Standardized protocol of nursing care: postural treatment plus standardized cure.~* Intervention with microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer."
61910410|NCT03753581|PLACEBO_COMPARATOR|Care protocol plus placebo microcurrents|"* Standardized protocol of nursing care: postural treatment plus standardized cure.~* Placebo microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer previously handled that do not emit current."
61910411|NCT04620798|EXPERIMENTAL|Intervention|Participants will be given their results of their antibody test immediately (within 24 hours) and will be followed and surveyed to see if having this knowledge changes their engagement with SARS-CoV-2 prevention behaviors.
61910412|NCT04620798|NO_INTERVENTION|Control (Delayed)|Participants will be given their results of their antibody test after 4 weeks. Their engagement with SARS-CoV-2 prevention behaviors will also be assessed following testing.
61910413|NCT00948584|EXPERIMENTAL|insulin titration by specialized system|Insulin dose titration system by using a SMS automatically produced by a knowledge matrix
61910414|NCT00322621|EXPERIMENTAL|Duloxetine|All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.
61910415|NCT02278536||Multiple high risk gestation pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
61910416|NCT02278536||Multiple low risk gestation pregnancies|women pregnant with twins or triplets at low risk for aneuploidy
62100066|NCT06595030|ACTIVE_COMPARATOR|Active Lighting Intervention|Combining spectrum and light level, the active TLI will allow the researchers to use a light source that will stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.
62100067|NCT06595030|PLACEBO_COMPARATOR|Control Lighting Intervention|The control TLI will allow the researchers to use a light source that will not stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.
62100068|NCT04763317||AFFECTED|"1. Affected with PrCa \< 70 years~2. Affected with metastatic castration resistant PrCa (mCRPC) at any age~3. Affected with PrCa and a family history defined as~   1. two or more cases in family with one case \< 70~  2. three or more cases any age (FDR or SDR)"
62466834|NCT01794065||Endeavor|100 patients who have received an Endeavor stent during their coronary intervention
62466835|NCT01794065||Promus/Xience V|100 patients who have received a Promus/Xience V stent during their coronary intervention
62466836|NCT01794065||Promus Element|100 patients who have received a Taxus Element stent during their coronary intervention
62466837|NCT05507801|EXPERIMENTAL|High Physically Active Group|Based on accelerometer data, women with 162 ≥ min/per day moderate and vigorous activity or men 133.25 ≥ min/per day moderate and vigorous activity.
62100069|NCT04763317||UNAFFECTED|"- Aged \>30 and with a family history defined as::~1. FDR diagnosed \< 70~2. 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years~3. 3 or more cases at any age (on same side of family)"
62100070|NCT06266650|EXPERIMENTAL|Pelvic Muscle Energy - One sided|Receives pubic abduction/adduction somatic dysfunction combinations one sided
62662118|NCT00867932|EXPERIMENTAL|Eculizumab|Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.
62662119|NCT03339362|ACTIVE_COMPARATOR|Active Procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided intra-articular facet-joint injections via a spinal needle at 2 bilateral lumbar levels, using 0.5ml 0.5% bupivacaine + 20mg methylprednisolone per joint"
62100071|NCT06266650|ACTIVE_COMPARATOR|Pelvic Muscle Energy - two sided|Receives pubic abduction/adduction somatic dysfunction combinations two sided
62100072|NCT06657768|EXPERIMENTAL|LY4006895 of Part A (SAD)|Single-ascending doses of LY4006895 administered intravenously (IV)
62100073|NCT06657768|PLACEBO_COMPARATOR|Placebo Part A|Placebo administered IV
62100074|NCT06657768|EXPERIMENTAL|LY4006895 of Part B (MAD)|Multiple-ascending doses of LY4006895 will be administered IV
62662120|NCT03339362|SHAM_COMPARATOR|Sham procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml normal saline per injection"
62100075|NCT06657768|PLACEBO_COMPARATOR|Placebo Part B|Placebo administered IV
62100076|NCT06644430||Ablation+system group|Participants received ablation of plumonary combined systemic therapy
62100077|NCT06644430||System group|Participants received systemic therapy
62100078|NCT01386424||Healthy Volunteers|Healthy Volunteers
62100079|NCT05866016|EXPERIMENTAL|Skill birth attendants who trained on new modular training package|"Maternal and child health service providers (skilled birth attendants) will be trained using modular training that covers both theory and practical sessions on midwifery skills.~Auxiliary nurse midwives should complete modules 1, 2, and 3 whereas nurses will get modules 1, 2, 3, and 4.~The training will be implemented in National Health Training Center-accredited training sites/ hospitals."
62100080|NCT05866016|ACTIVE_COMPARATOR|Skill birth attendants who trained on existing standard training package|"Maternal and child health service providers (auxiliary nurse midwives and nurses) get training based on the existing standard skilled birth attendant training curriculum of Nepal. This is a two-month-long integrated skill birth attendant package implemented in National Health Training Center-accredited training sites.~The midwifery competencies of these service providers will be assessed and compared with the competencies of experimental groups."
62100081|NCT03317392|EXPERIMENTAL|Arm I (radium Ra 223 dichloride, olaparib)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
62100082|NCT03317392|EXPERIMENTAL|Arm II (radium Ra 223 dichloride)|Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
62100083|NCT06714383|EXPERIMENTAL|Trilaciclib Arm|Neoadjuvant therapy of adding Trilaciclib to Pirarubicin and Lobaplatin
62100084|NCT06714383|SHAM_COMPARATOR|Control Arm|Neoadjuvant therapy of Pirarubicin and Lobaplatin
62100085|NCT06389786|EXPERIMENTAL|Screening (18F-rhPSMA-7.3 PET/MRI)|Patients receive 18F-rhPSMA-7.3 IV and undergo PET/MRI up to 30 days prior to SOC robotic radical prostatectomy with bilateral pelvic lymph node dissection. Patients also undergo CT or MRI, bone scan and tissue collection during screening.
62100086|NCT06711120|EXPERIMENTAL|Radiofrequency ablation for the treatment of varicose veins of the small saphenous vein|After radiofrequency ablation, patients' postoperative length of stay, time out of bed, and visual analogue scoring (VAS) scores were used to count the occurrence of postoperative complications, and all patients were followed up with colour Doppler ultrasound at 2 weeks, 1 month, and 3 months postoperatively to determine whether there was recurrence or not, and the use of the Venous Clinical Criticality Score (VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ), and Chronic Venous Disease Quality of Life Scale (CIVIQ) to evaluate the treatment effect.
62662121|NCT04640896|SHAM_COMPARATOR|Lidocaine skin wheal|They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
62308166|NCT02066662|EXPERIMENTAL|Rivaroxaban|Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing
62662122|NCT04640896|ACTIVE_COMPARATOR|Trigger point injection with normal saline|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
62662123|NCT04640896|EXPERIMENTAL|Trigger point injection with bupivacaine|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
62308167|NCT02066662|ACTIVE_COMPARATOR|Marcumar|Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
62466838|NCT05507801|EXPERIMENTAL|Low Physically Active Group|Based on accelerometer data, women with 108.25 ≤ min/per day moderate and vigorous activity or men 100.1 ≤ min/per day moderate and vigorous activity.
62662124|NCT06478095|NO_INTERVENTION|The conventional oral education group|Patients were only orally educated about glaucoma, preoperative preparation, surgical procedures, anaesthesia methods, and precautions during the preoperative visit.
62100087|NCT06711120|EXPERIMENTAL|Microwave ablation for the treatment of varicose veins of the small saphenous vein|After Microwave ablation, patients' postoperative length of stay, time out of bed, and visual analogue scoring (VAS) scores were used to count the occurrence of postoperative complications, and all patients were followed up with colour Doppler ultrasound at 2 weeks, 1 month, and 3 months postoperatively to determine whether there was recurrence or not, and the use of the Venous Clinical Criticality Score (VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ), and Chronic Venous Disease Quality of Life Scale (CIVIQ) to evaluate the treatment effect.
62100088|NCT06395311||COPD subjects|"Diagnosis of COPD established by a qualified healthcare professional (e.g., pulmonologist, general practitioner) based on:~Post-bronchodilator spirometry demonstrating airflow obstruction (FEV1/FVC \< 0.70) following GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines.~Age: 18 years or older. Adequate visual and/or auditory abilities to read and understand study materials/questionnaires or receive instructions verbally"
62466839|NCT06340256|ACTIVE_COMPARATOR|Group !|Continuous spinal anesthesia
62662125|NCT06478095|EXPERIMENTAL|The Visual aids plus conventional oral education group|Patients were orally educated about glaucoma, preoperative preparation, surgical procedures, anaesthesia methods, and precautions with pictures and videos during the preoperative visit.
61910417|NCT06235255|EXPERIMENTAL|Guided Imagery Intervention|Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs. The Guided Imagery Programs include: 1.Relaxation and Wellness; 2. Immune System Imagery and 3. Healing Trauma. The study measures are completed upon entry and 21 days post entry into the study and include: PKPCT and 21 days post entry into the study and include: PKPCT and the SF-36v2.
61910418|NCT06235255|EXPERIMENTAL|Cognitive Power Intervention|The participant is randomly assigned to this group completes The Power as Knowing Participation in Change (PKPCT) to determine: 1. Freedom to Act Intentionally; 2. Involvement in creating change; 3.Freedom to act intestinally and 4. My involvement in creating change. The study measures are completed upon entry and 21 days post entry into the study and include: PKPCT and the SF-36v2.
62466840|NCT06340256|ACTIVE_COMPARATOR|Group 2|Continuous epidural anesthesia
62466841|NCT04005859|ACTIVE_COMPARATOR|CONTROL: IV Lido|CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)
62466842|NCT04005859|EXPERIMENTAL|EXPERIMENTAL: Exparel|EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)
62466843|NCT00420238|EXPERIMENTAL|A|
62662126|NCT02772588|EXPERIMENTAL|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
62100089|NCT06371417|EXPERIMENTAL|RAY121|All enrolled patients will receive RAY121 multiple dose
62100090|NCT05036772|NO_INTERVENTION|Standard Practice|The control arm is supported according to the usual practice. The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography
62100091|NCT05036772|EXPERIMENTAL|Interventionnal|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
62100092|NCT05974605|EXPERIMENTAL|Combined mindfulness meditation and cognitive training|"Participants train at home for 20 hours over 8 weeks, splitting the time between mindfulness meditation and cognitive training. Participants train for 30 minutes per day, for 5 days a weeks on a provided tablet computer. The participants are to keep a paper log of dates and durations.~The mindfulness meditation portion of the training is a commercially available mobile app. Participants listen to guided meditations and follow the instructions. The program includes common mindfulness meditation exercises such as body scan or breath awareness.~The cognitive training portion of the intervention uses a highly demanding attentional control training program BirdWatch game (BWGU). BWGU is a gamified n-back paradigm where participants randomly switch the focus of attention to update or maintain an adaptively growing set of bird stimuli in their working memory and are sometimes required to inhibit their response."
62100093|NCT06174896|ACTIVE_COMPARATOR|Group 1|Placement with standard technique
62100094|NCT06174896|ACTIVE_COMPARATOR|Group 2|Placement with direct laryngoscopy
62100095|NCT06174896|ACTIVE_COMPARATOR|Group 3|Placement with the aid of video laryngoscopy
62100096|NCT06712056|EXPERIMENTAL|Arm and İnterventional|"MBSR training will be given to this experimental group. To assess the cognitive status of the elderly, the Standardized Mini-Mental State Examination was used for those with primary or higher education levels, and the Standardized Mini-Mental State Examination for the Uneducated for those without primary education. Only elderly individuals scoring 23 or above on the Mini-Mental State Examination were included in the study. The elderly participants received mindfulness training (8 sessions), and personal questionnaire forms, the Spiritual Well-Being Scale, and the Meaning in Life Scale were administered before the intervention and post-intervention (at the 1st and 3rd months).The training is include awareness, staying in the moment, awareness of body, emotion, thought and environment, and breathing exercise techniques."
62100097|NCT06712056|NO_INTERVENTION|İnterventional|MBRS training will not be given to this control group
62100098|NCT05968508|EXPERIMENTAL|BAT1806 prefilled subcutaneous injection|
62100099|NCT05968508|ACTIVE_COMPARATOR|RoActemra® (from EU)|
62100100|NCT04601857|EXPERIMENTAL|futibatinib and pembrolizumab (Cohort A)|Patients with UC and FGFR3 mutation or FGFR1-4 fusion/rearrangement.
62100101|NCT04601857|EXPERIMENTAL|futibatinib and pembrolizumab (Cohort B)|All other patients than in Cohort A with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type \[non-mutated\] tumors).
62100102|NCT05437471|ACTIVE_COMPARATOR|Group A (GnRH analogue with Aromatase Inhibitor|This group of candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) followed by Letroloze 10mg OD for 3 months
62100103|NCT05437471|ACTIVE_COMPARATOR|Group B (GnRH analogue with Progesterone|This group of candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) followed Duphaston 10mg BD by for 3 months
62100104|NCT05437471|PLACEBO_COMPARATOR|Group C (GnRH analogue alone)|This is a control group. The candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) only.
62100105|NCT00097474|EXPERIMENTAL|Combination|Both HC 30 and ML 5 will be administered
62100106|NCT00097474|EXPERIMENTAL|Hydrocortisone|30mg Hydrocortisone will be administered
62100107|NCT00097474|EXPERIMENTAL|Melatonin|5 mg Melatonin will be administered
62100108|NCT00097474|PLACEBO_COMPARATOR|Placebo|Placebo
62466844|NCT00420238|PLACEBO_COMPARATOR|B|
62466845|NCT06370182|EXPERIMENTAL|ANA Funnel Catheter Group|Mechanical thrombectomy using a stent retriever delivered by the ANA device.
62662127|NCT01800760|EXPERIMENTAL|No groups|
62662128|NCT05167539||Mechanical aortic valve replacement|simple procedure but need long term of anticoagulant
62662129|NCT05167539||Aortic root replacement|complicated procedure but without anticoagulant
62662130|NCT02984345|ACTIVE_COMPARATOR|Mycoprotein beverage|
62100109|NCT02124460|NO_INTERVENTION|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
62100110|NCT02124460|EXPERIMENTAL|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
62100111|NCT05450783||Patients group|Patients and their relatives affected with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20
62100112|NCT01218503|EXPERIMENTAL|CHOICES - obese|behavioral weight loss treatment - overweight/obese females
62100113|NCT06593054|EXPERIMENTAL|CTB-AVP Capsules, fasted|Reference formulation of CTB-AVP in capsules, administered under fasted conditions
62100114|NCT06593054|EXPERIMENTAL|CTB-AVP Tablet , fasted|Test formulation of CTB-AVP in tablets, administered under fasted conditions
62100115|NCT06593054|EXPERIMENTAL|CTB-AVP Tablet , fed|Test formulation of CTB-AVP in tablets, administered under fed conditions
62100116|NCT05825820|EXPERIMENTAL|Enhanced Outreach Intervention plus Care as Usual|Participants will receive the Enhanced Outreach Intervention (EOI) plus care as usual for 12 weeks after ED discharge.
62100117|NCT05767450|EXPERIMENTAL|Treated|Probiotic name: Vivomixx® Form: powder Dosage: 4,4g/sachet with 450 billion of lactobacilli and bifidobacteria in a base of maltose Frequency: 1 sachet/day for children \<10 year old or 2 sachets/day for children \>10 year old Duration: 90 days
62100118|NCT05767450|PLACEBO_COMPARATOR|Untreated|Product name: Placebo Form: powder Dosage: 4,4g/sachet containing maltose Frequency: 1 sachet/day for children \<10 year old or 2 sachets/day for children \>10 year old Duration: 90 days
62100119|NCT02527850|EXPERIMENTAL|treatment with real laser|10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle.
62100120|NCT02527850|SHAM_COMPARATOR|sham laser|10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle.
62100121|NCT06711419|EXPERIMENTAL|GROUP A|Thirty-five patients (to compensate dropouts) will be subjected to Combined caudal neuroplasty using epidural catheter (Perifix® Complete Set 16 G) combined with Pulsed Radiofrequency (PRF) targeting the dorsal root ganglion In patients with lumbosacral radicular pain
62100122|NCT06711419|EXPERIMENTAL|GROUP B|Thirty-five patients (to compensate dropouts) will be subjected to Pulsed Radiofrequency (PRF) alone targeting the dorsal root ganglion In patients with lumbosacral radicular pain
62100123|NCT04274179|EXPERIMENTAL|Diet therapy|Modified Atkins Diet - high fat, low carbohydrate, outpatient initiated approach. Parents will check urine ketones twice weekly and follow by email, phone and clinic. Labs at baseline and 3 months. Dietitian support.
62100124|NCT04274179|ACTIVE_COMPARATOR|Drug therapy|Families will have the usual care for absence epilepsy at the discretion of the family's neurologist and the family choice. Typically ethosuximide bis in die (BID), however, if convulsions have occurred or other factors are involved, the child may be started on valproate or lamotrigine. The child will continue medications with dose adjustment and antiseizure drug levels checked as usual. \*\*OF NOTE, THIS ARM IS COMPLETED
62466846|NCT06370182|ACTIVE_COMPARATOR|Control Group|Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter.
62662131|NCT02984345|PLACEBO_COMPARATOR|Milk protein beverage|
62662132|NCT01952860|EXPERIMENTAL|Hatha Yoga|Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
62100125|NCT06350123|EXPERIMENTAL|Balcinrenone/dapagliflozin 15 mg/10 mg|Patients will be randomized 1:1:1 to either balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
62100126|NCT06350123|EXPERIMENTAL|Balcinrenone/dapagliflozin 40 mg/10 mg|Patients will be randomized 1:1:1 to either balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
62466847|NCT05899855||Group 1|30 subjects with rigid flatfoot and chronic ankle instability
62466848|NCT05899855||Group II|30 subjects with flexible flatfoot and chronic ankle instability
62466849|NCT05689905||Common HLA antigens with the lung donor|Children who have common HLA antigens with the lung donor of their mother
62737102|NCT00862368|ACTIVE_COMPARATOR|PAM-Asthma|The PAM-Asthma arm received the same in-home counseling visits as PAM-Enhanced/Asthma. The 6 counseling phone calls were different from those received by PAM-Enhanced/Asthma, and included only an asthma follow-up and discussion of a child wellness topic. Smoking cessation was not discussed and additional feedback on ETS samplers was not provided. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
62100127|NCT06350123|ACTIVE_COMPARATOR|Dapagliflozin 10 mg|Patients will be randomized 1:1:1 to either balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
62100128|NCT06122415||Patients in secondary care with cognitive symptoms|
62100129|NCT06293963|EXPERIMENTAL|Numerical label|
62100130|NCT06293963|EXPERIMENTAL|Interpretive text-only label|
62100131|NCT06293963|EXPERIMENTAL|Interpretive magnifying glass icon label|
62100132|NCT06293963|EXPERIMENTAL|Separated interpretive magnifying glass icon label|
62100133|NCT06505980|OTHER|Behavioral Parent Training Program|The behavioral parent training intervention is delivered briefly through telehealth. It will be the only arm. It will be the only intervention received by participants in the context of this study.
62100134|NCT00971009|EXPERIMENTAL|OPPC service|A practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
62100135|NCT00971009|EXPERIMENTAL|WebChoice IHCA|WebChoice is an interactive health communications application (IHCA) that in addition to offer a practice-integrated nurse administered online patient-provider communication (OPPC) service, allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
62100136|NCT00971009|NO_INTERVENTION|Control group|The control group receives usual care
62100137|NCT06711367|ACTIVE_COMPARATOR|tell show do behavior management technique|
62466850|NCT05689905||No common HLA antigens with the lung donor|Children without common HLA antigens with the lung donor of their mother.
39441224|NCT06442839||training cohort|for training the model, from Sun Yat-sen Memorial Hospital of Sun Yat-sen University.
39441225|NCT06442839||internal validation cohort|used to evaluate the model's performance, is from Sun Yat-sen Memorial Hospital of Sun Yat-sen University.
62466851|NCT02303808|NO_INTERVENTION|USUAL CARE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
62466852|NCT02303808|ACTIVE_COMPARATOR|INHALATION WITH PEP DEVICE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) combined with a PEP device (Acapella Duet) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
62466853|NCT06391606|ACTIVE_COMPARATOR|Coenzyme Q10|2 pills of 150 mg CoQ10 phytosome (i.e. 300 mg CoQ10 phytosome per day)
39441226|NCT06442839||external validation cohort 1|used to evaluate the model's performance, is from the Third Affiliated Hospital of Sun Yat-sen University.
39441227|NCT06442839||external validation cohort 2|used to evaluate the model's performance, is from the Second Affiliated Hospital of Dalian Medical University.
39441228|NCT06442839||external validation cohort 3|used to evaluate the model's performance, is from the First Affiliated Hospital of Chongqing Medical University.
39441229|NCT06442839||external validation cohort 4|used to evaluate the model's performance, is from the Yan'an Hospital Affiliated to Kunming Medical University.
62466854|NCT06391606|PLACEBO_COMPARATOR|Placebo|2 pills of placebo per day
62100138|NCT06711367|EXPERIMENTAL|a costume-designed dental storybook|
62100139|NCT00444574|ACTIVE_COMPARATOR|Methylphenidate Transdermal System|Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
62100140|NCT00444574|PLACEBO_COMPARATOR|Placebo|Placebp matching MTS and Concerta for 7 weeks
62100141|NCT00444574|ACTIVE_COMPARATOR|Concerta|Methylphenidate HCL 18mg tablet 7 weeks
62100142|NCT06480968|EXPERIMENTAL|CTH120|Hard capsules of two strengths, 10 mg and 75 mg of CTH120 to be administered with 200 mL of water. CTH120 will be supplied by CONNECTA Therapeutics. Within each dose cohort group subjects (n=8) will be randomly assigned to the CTH120 dose or to the matching placebo in a 6 to 2 randomization ratio (placebo=2 and CTH120=6 per dose).
62100143|NCT06480968|PLACEBO_COMPARATOR|Placebo|Hard capsules of placebo to be administered with 200 mL of water. Placebo will be supplied by CONNECTA Therapeutics. Within each dose cohort group subjects (n=8) will be randomly assigned to the CTH120 dose or to the matching placebo in a 6 to 2 randomization ratio (placebo=2 and CTH120=6 per dose).
62100144|NCT03593317|EXPERIMENTAL|Spironolactone group|
62100145|NCT03593317|PLACEBO_COMPARATOR|Placebo group|
62100146|NCT03528954|ACTIVE_COMPARATOR|Propofol|Received intravenous 0.5mg/kg propofol
62100147|NCT03528954|NO_INTERVENTION|Control|Do not received intravenous 0.5 mg/kg propofol
62466855|NCT01090713|ACTIVE_COMPARATOR|Lisdexamfetamine|drug
62466856|NCT01090713|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62466857|NCT03050944||Cases|Lifestyle behaviour and dietary habits assessment in couples achieving pregnancy after in vitro fertilization process.
62466858|NCT03050944||Controls|Lifestyle behaviour and dietary habits assessment in couples failed to achieve pregnancy after in vitro fertilization process.
62100148|NCT06516887|EXPERIMENTAL|Pharmacokinetic Phase 1b (PK) Study Cohort|"Patients will receive bemcentinib and pacritinib in combination from Days 1 to Day 28. PK samples will be collected on Day 1 (pre-dose, 4, 6h), pre-dose Day 2, Day 7 (pre-dose, 4h and 6h post-dose), pre-dose Day 8, pre-dose Day 14, and Day 22 (pre-dose and 6h post-dose) samples. The Day 22 sample will cover the steady state values for both compounds.~Six dose levels of combination treatments will be considered:~* Dose level -1: pacritinib 100 mg oral dose (p.o.) daily + bemcentinib 50 mg p.o. daily;~* Dose level 1: pacritinib 100 mg oral dose (p.o.) twice daily (BID) + bemcentinib 50 mg p.o. daily;~* Dose level 2: pacritinib 100 mg p.o. BID + bemcentinib 75 mg p.o. daily;~* Dose level 3: pacritinib 100 mg BID + bemcentinib 100 mg p.o. daily;~* Dose level 4: pacritinib 200 mg BID + bemcentinib 100 mg p.o. daily;~* Dose level 5: pacritinib 200 mg BID + bemcentinib 125 mg p.o. daily."
62662133|NCT04572035|EXPERIMENTAL|Exercise only|Undergraduate peer-facilitators part of a curricular kinesiology program will facilitate a personalized group-based exercise program adapted to the participant's abilities, teach participants how to exercise, and gauge exercise intensity in a safe manner (26). The CANMAT guidelines will be implemented, with the program consisting of supervised group-based moderate-intensity exercise sessions lasting 30-minutes (plus 10-minutes for warm-up and cool-down), 3 times weekly, for a period of 10-weeks. Participants will start exercising at a low intensity and progressively increase until they are consistently exercising at a moderate intensity. As a result of the uncertainty surrounding the pandemic, the intervention will be conducted either via a virtual platform or in-person at the Exercise and Health Psychology Lab, depending on the health and safety restrictions applicable to when the student enrolls and begins their program.
62100149|NCT06516887|EXPERIMENTAL|Phase II Cohort|Of these participants taking the Maximum tolerated dose, up to 15 will undergo a biopsy. Progression free survival will be the primary objective of this study phase.
62100150|NCT05580146|ACTIVE_COMPARATOR|Zynamite® 15% 150mg|Mango leaf extract (Mangifera indica)
62100151|NCT05580146|ACTIVE_COMPARATOR|Zynamite® 15% 300mg|Mango leaf extract (Mangifera indica)
62100152|NCT05580146|ACTIVE_COMPARATOR|Zynamite® 15% 600mg|Mango leaf extract (Mangifera indica)
62662134|NCT04572035|EXPERIMENTAL|Exercise + Self-compassion|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks).
62662135|NCT04572035|EXPERIMENTAL|Exercise + Behavioural Coaching|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting).
62662136|NCT01750437|EXPERIMENTAL|YH1885L 33.3 mg|TID, Subject takes it for 4 week.
62466859|NCT04544878||Pediatric patients|All term children from birth to 18 years of age admitted in the PICU
62466860|NCT04544878||Adult patients|All patients \>18 years of age
62662137|NCT01750437|EXPERIMENTAL|YH1885L 50mg|BID, Subject takes it for 4 week.
62662138|NCT01750437|EXPERIMENTAL|YH1885L 66.6 mg|TID, Subject takes it for 4 week.
62662139|NCT01750437|EXPERIMENTAL|YH1885L 100mg|BID, Subject takes it for 4 week.
62662140|NCT01750437|ACTIVE_COMPARATOR|Esomeprazole 20mg|QD, Subject takes it for 4 week.
61910419|NCT06235255|EXPERIMENTAL|Combined Guided Imagery and Cognitive Power Intervention|The participants are randomly assigned to this group completes The Power as Knowing Participation in Change (PKPCT) and the Guided Imagery Intervention as described above. The study measures are completed upon entry and 21 days after entry and include the PKPCT and the SF-36v2.
61910420|NCT06235255|NO_INTERVENTION|Control Group (No intervention)|The participants are randomly assigned to this group complete all study measures PKPCT and the SF-36v2 measures upon entry into the study and 21 days after entry.
61910421|NCT04087330|EXPERIMENTAL|Group 1 Experimental group|Stretching, facilitation exercises with whole body vibration
61910422|NCT04087330|ACTIVE_COMPARATOR|Group 2 Control group|Stretching and facilitation exercises
61910423|NCT01976039|OTHER|RRC|rhinopharyngeal retrograde clearance (RRC) isolated: First patient sits in a chair. Second: patient inhales air deeply and exhales making noise and vibration in the upper airway to facilitate swalling. Third patients finishes with another deep inhalation. This technique is new, simple to use and with no cost. No need of any material or equipment.
62100153|NCT05580146|PLACEBO_COMPARATOR|Placebo|Placebo matched for appearance
62466861|NCT05977049|OTHER|Takotsubo Support Group|Participants diagnosed with Takotsubo Syndrome will be enrolled into the study.
62100154|NCT03142789|ACTIVE_COMPARATOR|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
62466862|NCT00485472|EXPERIMENTAL|Lacosamide|lacosamide (LCM)
62466863|NCT00485472|PLACEBO_COMPARATOR|Placebo|Placebo
62466864|NCT00007852|EXPERIMENTAL|Arm I|Rituxan and BEAM with autologous stem cell transplant
62466865|NCT00465270|EXPERIMENTAL|Device|AMPLATZER PFO Occluder
62466866|NCT00465270|ACTIVE_COMPARATOR|Standard or Care - Medical Management|Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
62466867|NCT00978822|EXPERIMENTAL|Clevidipine butyrate injectable emulsion|
62466868|NCT01790347|EXPERIMENTAL|Exercise group|
62466869|NCT01790347|NO_INTERVENTION|Control group|Sedentary pregnant women
62466870|NCT01796886|EXPERIMENTAL|patient's neurological status|
62662141|NCT00784875|EXPERIMENTAL|Period A|2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.
62662142|NCT00784875|EXPERIMENTAL|Period B|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.
62662143|NCT00784875|EXPERIMENTAL|Period C|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.
62100155|NCT03142789|ACTIVE_COMPARATOR|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
62100156|NCT03142789|ACTIVE_COMPARATOR|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
62100157|NCT05044130|ACTIVE_COMPARATOR|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD~MR spectroscopy verified steatosis"
62100158|NCT05044130|ACTIVE_COMPARATOR|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD~MR spectroscopy verified no steatosis"
62100159|NCT06712251|EXPERIMENTAL|Velocity Percutaneous Arterio-Venous Fistula System|
62100160|NCT05049382|EXPERIMENTAL|Low Difficulty|Classified as low difficulty according to Escoda's classification
62100161|NCT05049382|EXPERIMENTAL|Modarate Difficulty|Classified as modarate difficulty according to Escoda's classification
62466871|NCT06291792|EXPERIMENTAL|Telerehabilitation Otago Exercise Group (TOEG)|"The use of Otago Exercise Program in the home environment using the telerehabilitation method. Telerehabilitation was performed with video and audio interviews 3 times a week for 45 minutes.~The study will take 12 weeks. An 8-week treatment protocol will be applied. 4 weeks after the treatment protocol, the last measurement will be made and the study will be terminated."
62466872|NCT06291792|EXPERIMENTAL|Face to face Otago Exercise Group (FOEG)|"Otago Exercise Program was applied in a face-to-face clinical setting. Interviews were held 3 times a week for 45 minutes.~The study will take 12 weeks. An 8-week treatment protocol will be applied. 4 weeks after the treatment protocol, the last measurement will be made and the study will be terminated."
62662144|NCT00784875|EXPERIMENTAL|Period D|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.
62662145|NCT06229938||Elderly perioperative population|All patients included in the study (minimum 70 years of age on day of surgery)
62662146|NCT02401230|ACTIVE_COMPARATOR|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
62662147|NCT02401230|ACTIVE_COMPARATOR|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
62662148|NCT02401230|ACTIVE_COMPARATOR|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
61910424|NCT01976039|EXPERIMENTAL|RRC+S|retrograde rhinopharyngeal retrograde clearance combined with saline instillation (RRC+S): patient sits in a chair and inhaled air and make noise and vibrate the upper airway at the same instills saline into the nare to facilitate nose washing and swalling. This technique is new, simple to use and with low cost (only saline).
62662149|NCT02257151|EXPERIMENTAL|Group 1: BMS-986142 or placebo|BMS-986142 or placebo Single dose oral Solution or spray dried dispersion as specified
61910425|NCT03593473|EXPERIMENTAL|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
62100162|NCT05049382|EXPERIMENTAL|High Difficulty|Classified as high difficulty according to Escoda's classification
62100163|NCT06419621|EXPERIMENTAL|PM8002 Plus Nab-Paclitaxel|Patients will receive both PM8002 and Nab-Paclitaxel.
62100164|NCT06419621|PLACEBO_COMPARATOR|Placebo Plus Nab-Paclitaxel|Patients will receive both Placebo and Nab-Paclitaxel.
62100165|NCT06043700||All Participants|Participants with or without symptoms of AD will be enrolled and observed in this study.
62100166|NCT01227356|EXPERIMENTAL|imatinb + pegIntron|
62308168|NCT03084159|EXPERIMENTAL|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys (for feasibility and feedback prior to actual trial enrollment). Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
62662150|NCT02257151|EXPERIMENTAL|Group 2: BMS-986142 or placebo|BMS-986142 or placebo Multiple dose oral Solution as specified
62662151|NCT05134818|EXPERIMENTAL|group OT +|In this group (OT +), the resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
62662152|NCT05134818|NO_INTERVENTION|group OT-|In this group (OT-), the resident will not use the observer tool and will observe other residents to insert a CVC on the simulator without any physical support.
62662153|NCT02597114|EXPERIMENTAL|AGT-181|AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase) administered once weekly x 26 weeks at same dose level as subject received in core study
62100167|NCT06625762|OTHER|observation of the change in biological age after bariatric surgery|"Patients over 18 years of age suffering from obesity and requiring bariatric surgery.~Evolution of biological age 1 year after surgery, defined by the difference between age biological at TPO and TAC 1 year, estimated by measuring the phenotypic age, itself determined from the following eight variables: albumin; creatinine; fasting blood sugar; CRP~; lymphocyte count; mean corpuscular volume of red blood cells; Anisocytosis index of red blood cells; alkaline phosphatases; leukocyte rate."
62100168|NCT03983161|EXPERIMENTAL|Fedratinib in moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to subjects with moderate hepatic impairment
62100169|NCT03983161|EXPERIMENTAL|Fedratinib in severe hepatic impairment subjects|A single dose of 200 mg of fedratinib will be given to subjects with severe hepatic impairment
62100170|NCT03983161|EXPERIMENTAL|Fedratinib in healthy vs moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to healthy subjects with normal hepatic function.
61910426|NCT03593473|PLACEBO_COMPARATOR|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
62100171|NCT03983161|EXPERIMENTAL|Fedratinib in healthy vs severe hepatic impairment subjects|A single oral dose of 200 mg of fedratinib will be given to healthy subjects with normal hepatic function.
62100172|NCT03628079|EXPERIMENTAL|Single arm study|"ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole."
62100173|NCT06707272||delayed graft function|Delay graft function (DGF) was defined as the need for dialysis treatment within the first week following transplantation or Scr at post-transplant 1 week (POW1) ≥ 4.52 mg/dL.
62100174|NCT06707272||Immediate graft function|Immediate graft function (IGF) was defined as Scr at POW1 \< 2.50 mg/dL, and slow graft function (SGF) was defined as Scr at POW1 ≥ 2.50 mg/dL.
62100175|NCT03302065|EXPERIMENTAL|Test Product 1 Tiotropium|4 inhalations
62100176|NCT03302065|EXPERIMENTAL|Test Product 2 Tiotropium|4 inhalations
62100177|NCT03302065|EXPERIMENTAL|Test Product 3 Tiotropium|4 inhalations
62100178|NCT03302065|ACTIVE_COMPARATOR|Reference Tiotropium|2 inhalations
62100179|NCT06614569||Subjects previously treated with AXO-AAV-GM2 gene therapy for Tay-Sachs or Sandhoff Disease|All subjects have previously received gene therapy and will be followed for the collection of clinical information, especially pertaining to de novo cancer, neurologic, rheumatologic, and hematologic/immunologic disorders following AAV gene therapy.
62100180|NCT03681639|EXPERIMENTAL|Patients who received Metasul Monoblock in hip resurfacing|Patients who received the Zimmer Hip Resurfacing System utilising the Metasul Monoblock Component Cup in a Hip Resurfacing Application with the Durom Hip Resurfacing Femoral Component and whose Serum metal ion levels is being measured.
62100181|NCT01875835|ACTIVE_COMPARATOR|DES|Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
62100182|NCT01875835|ACTIVE_COMPARATOR|BMS|Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
62100183|NCT05447923|EXPERIMENTAL|Screening (FIT, education, questionnaire, patient navigation)|Participants receive free FIT tests in conjunction with education on colorectal cancer screening. Participants undergo self-collect FIT and mail the sample to Mayo Clinic Lab for processing. Participants also complete a questionnaire about colorectal cancer screening and healthcare. Participants receive FIT test results through Mayo Clinic nursing support and participants with a positive test are followed up by a patient navigator to discuss next steps and consultation with a gastroenterologist to review their results.
62100184|NCT06703892|EXPERIMENTAL|GF-CART01|CAR-positive viable T cells
62100185|NCT02887378|EXPERIMENTAL|hot clamps|reusable hot biopsy forceps
62100186|NCT02887378|ACTIVE_COMPARATOR|normal clamps|normal clamps
62100187|NCT03511248|EXPERIMENTAL|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing \~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
62100188|NCT03511248|PLACEBO_COMPARATOR|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
62466873|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
62466874|NCT05551780|EXPERIMENTAL|SoundBite Crossing System - PAD|Use of the SoundBite Crossing System to cross calcified chronic total occlusions (above-the-knee or below-the-knee)
62662154|NCT00590473|ACTIVE_COMPARATOR|1|Unilateral Placement of Interstim IPG
62662155|NCT00590473|ACTIVE_COMPARATOR|2|Bilateral Placement of Interstim IPG
61910427|NCT01809470|EXPERIMENTAL|Watching TV|Watching TV (comedy, 'Friends') for 1 hour
61910428|NCT01809470|EXPERIMENTAL|FIFA2013|Playing the video game 'FIFA2013' for 1 hour
62100189|NCT02735252|EXPERIMENTAL|Group A: Androgen Signaling Inhibition|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving treatments that inhibit androgen signaling to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62466875|NCT05551780|EXPERIMENTAL|SoundBite Crossing System - BTK|Use of the SoundBite Crossing System to cross calcified chronic total occlusions (below-the-knee)
62662156|NCT00683995|EXPERIMENTAL|1|KW-2246 (fentanyl citrate)
62662157|NCT03394573||OCT guided treatment arm|OCT guided aflibercept injection
62662158|NCT03394573||VA guided treatment arm|VA guided aflibercept injection
62662159|NCT01017497|EXPERIMENTAL|1mm margin|GTV expanded by 1 mm
62100190|NCT02735252|EXPERIMENTAL|Group B: Immunotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving immunotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100191|NCT02735252|EXPERIMENTAL|Group C: Radiotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving radiotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100192|NCT02735252|EXPERIMENTAL|Group D: Targeted Therapy Not Otherwise Specified|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving targeted therapy and investigational therapeutics to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100193|NCT02735252|EXPERIMENTAL|Group E: DNA Damage Response|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100194|NCT02735252|EXPERIMENTAL|Group F: Aggressive Variant Disease|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients with variants of disease that display aggressive behavior to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100195|NCT02735252|EXPERIMENTAL|Group G1: Castration Sensitive, ADT naïve and ADT < 3 months|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100196|NCT02735252|EXPERIMENTAL|Group G2:Castration Sensitive,Pre-treated w/ sub-optimal PSA|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100197|NCT02735252|EXPERIMENTAL|Group R: Advanced Renal Cell Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100198|NCT02735252|EXPERIMENTAL|Cohort U: Advanced Urothelial Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
62100199|NCT01390857||Pediatric patients prescribed valaciclovir|Pediatric patients with chickenpox prescribed valaciclovir during study period.
62100200|NCT06613698|EXPERIMENTAL|GSK4532990 Dose 1|
62100201|NCT06613698|EXPERIMENTAL|GSK4532990 Dose 2|
62100202|NCT06613698|EXPERIMENTAL|GSK4532990 Dose 3|
62100203|NCT06613698|EXPERIMENTAL|GSK4532990 Dose 4|
62100204|NCT06613698|PLACEBO_COMPARATOR|Placebo|
62100205|NCT05475470|EXPERIMENTAL|group a|the group we used our new blade-finger technique
62662160|NCT01017497|EXPERIMENTAL|3mm margin|GTV expanded by 3 mm
62100206|NCT05475470|EXPERIMENTAL|group b|the group we used Hasson's technique
62100207|NCT05475470|EXPERIMENTAL|group c|the group we used veress needle technique
62100208|NCT05700123|EXPERIMENTAL|Video|
62466876|NCT03443986|EXPERIMENTAL|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes.
62662161|NCT02413268|PLACEBO_COMPARATOR|Placebo|Patient receives an antibiotic ointment with no vasoactive drug as a placebo for comparison.
62662162|NCT02413268|ACTIVE_COMPARATOR|Nitropaste|Nitroglycerin 2% ointment is applied above the compression surface on the skin, to evaluate its efficacy in reducing radial artery occlusion.
62662163|NCT05877105|NO_INTERVENTION|pre-experimental|assessment of MV patients for VAP incidence and severity ICU staff for will be assessed for Compliance with implementing VAP prevention EBP
62662164|NCT05877105|EXPERIMENTAL|experimental|"The intervention group of patients will receive the proposed VAP prevention EBP which consists of ten items bundle.~also, assessment of MV patients for VAP incidence and severity ICU staff for will be assessed for Compliance with implementing VAP prevention EBP"
62662165|NCT00886457|EXPERIMENTAL|Decitabine plus PEG Interferon-alfa 2B|3.7 mg/m\*\*2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
62100209|NCT05700123|EXPERIMENTAL|Music|
62100210|NCT05700123|ACTIVE_COMPARATOR|Vocal-Local|
62100211|NCT02890693|EXPERIMENTAL|interdisciplinary lifestyle/psychosocial|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions.
62100212|NCT02890693|NO_INTERVENTION|treatment as usual|Usual clinical follow-up and treatment is based on the current American Diabetes Association, the Endocrine Society guidelines, and the NICE guidelines.
62100213|NCT02552277|EXPERIMENTAL|PDA-002 Dose Level 1: 3 x 10^6 cells|3 x 10\^6 PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
62100214|NCT02552277|EXPERIMENTAL|PDA-002 Dose Level 2: 30 x 10^6 cells|30 x 10\^6 PDA-002 cells administered IM on study Days 1, 29, and 57.
62100215|NCT02552277|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo administered IM on study days 1, 29, and 57.
62100216|NCT04230694|ACTIVE_COMPARATOR|Control Group|Control Group subjects will wear the CGM device during their hospitalization, up to 10 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.
62100217|NCT04230694|EXPERIMENTAL|Treatment Group|Treatment Group subjects will wear the CGM device during their hospitalization, up to 10 days, and glucose readings WILL be continuously monitored. Treatment Group subjects will have their glucose management guided by readings from the CGM device and standard of care finger sticks.
62100218|NCT02652130|EXPERIMENTAL|Safety population|All participants who were enrolled and had received at least 1 dose of remestemcel-L in Study MSB-GVHD001.
62100219|NCT06714175|NO_INTERVENTION|Control Group|This group will not receive any specific muscle power intervention.
62100220|NCT06714175|EXPERIMENTAL|Lower Limb Strength Training Program with Visual Feedback|This lower limb explosive strength training system integrates visual feedback games and is equipped with angle and force sensors to simultaneously output the power of the left and right legs, as well as maximum explosive force and pushing force. Users can immediately understand the balance of leg strength and make adjustments, making it particularly suitable for the elderly to improve lower limb strength or for rehabilitation training. The gamification of the system enhances the fun of training, while data quantification allows progress tracking, making the training more precise and effective. Additionally, after the game ends, data can be exported to Excel for further analysis to identify issues in the pushing process and optimize the training plan.
62100221|NCT06613464||ICU patients|Patients over the age of 18 who are admitted to intensive care unit and who have been in intensive care for \>5 days
62100222|NCT00232193||IFNβ+DS group|IFNβ+DS group received lyophilized Avonex 30mcg IM weekly plus dexamethasone 160 mg IV every 4 weeks for 52 weeks and was treated with Avonex 30mcg IM weekly from week 53 to 104
62662166|NCT06153550||Patients who have sternotomy|Patients who have sternotomy wll be included. They will have preparation in Respiratory Physiotherapy before sternotomy.
62662167|NCT00979511|EXPERIMENTAL|1 Hi-Calcium milk & exercise|
62100223|NCT00232193||IFNβ group|IFNβ group received lyophilized Avonex 30mcg IM weekly for 104 weeks
62100224|NCT02606292|EXPERIMENTAL|Arm 1: PAE assessment|-The PAE-EUS assessment will be performed in the operating room by the after induction of general anesthesia and following strict sterile technique while the patient is being positioned and prepped for esophageal surgery.
62100225|NCT06711601||T group|Intercristal line was defined as an Tuffier's line drawn between the tops of both iliac crests. It was considered to intersect the body of L4 or the L4-L5 intervertebral space. The L3-L4 intervertebral space was determined by counting down the level from this line
62100226|NCT06711601||P group|The patient also was palpated the The Posterior Superior Iliac Spine (PSIS), and confirmed the L3-4 intervertebral space position based on the average PI calculated in the first experiment.
62100227|NCT06711601||TP group|confirmed the L3-4 intervertebral space position based on the average PI calculated in the first experiment and Intercristal line.
62100228|NCT04074954||Cataracts present, no surgery|Adult patients undergoing bilateral cataract surgery
62662168|NCT00979511|EXPERIMENTAL|2 Hi-calcium milk with passive exercise|
62662169|NCT00979511|EXPERIMENTAL|3Low-Calcium with exercise|
62662170|NCT00979511|EXPERIMENTAL|4 Low-calcium milk with passive exercise|
62662171|NCT01055912|EXPERIMENTAL|Lixivaptan|Capsule, 100mg Lixivaptan or matching placebo once daily.
62662172|NCT01055912|PLACEBO_COMPARATOR|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
62662173|NCT04770974||Urothelial Carcinoma|"Patients over the age of 18 known for urological interventions for the following pathologies will be considered for enrollment in the group of cases:~- Bladder cancer~The exclusion criteria will be:~* Age under 18~* Pregnancy~* Lack of informed consent~* Inability to provide informed consent~Patients included in the study, who meet the inclusion criteria, have an operative note for:~* Transurethral Resection of Bladder Neoplasia (TURBT)~* Radical Cystectomy for Bladder Neoplasia"
62100229|NCT04074954||Cataracts present, yes surgery|adult patients who have cataracts but are not undergoing cataract surgery
62100230|NCT02739568|EXPERIMENTAL|Pitolisant (BF2.6449|Histamine H3 receptor H3R antagonist/ inverse agonist
62100231|NCT02739568|PLACEBO_COMPARATOR|Placebo|Placebo
62466877|NCT03443986|SHAM_COMPARATOR|Resistance training associated with sham|"The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown. The vibration sham; will be held with the disconnected platform. A device will be connected producing a noise similar to the sound of the connected platform for a time equivalent to the treatment protocol, since it will not be possible to distinguishing noticeably stimulate vibrator. Participants that will undergo false vibration will not have contact with those who carry out the real treatment."
62100232|NCT04651361|ACTIVE_COMPARATOR|Naldebain group|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
62100233|NCT04651361|PLACEBO_COMPARATOR|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
62100234|NCT03547999|ACTIVE_COMPARATOR|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
62100235|NCT03547999|EXPERIMENTAL|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
62100236|NCT05502380|ACTIVE_COMPARATOR|Standard prophylaxis arm|"The standard prophylaxis consists of one to three intravenous doses of cefuroxime 1.5 g intravenously; or cefuroxim 3g if obesity \> 120 kg or a BMI \> 35 kg/m2; or vancomycin 1 g or clindamycin 600 mg in case of intolerance to cephalosporins~In patients alrady under current therapuetic antibiotic therapy, continuation of that therapuetic antibiotic regimen"
62466878|NCT03443986|NO_INTERVENTION|Control group|Will not be submitted to any physical intervention. It continues in your daily life with only monitoring via phone callings. Guidelines about foot care.
62466879|NCT05745870|EXPERIMENTAL|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
62100237|NCT05502380|EXPERIMENTAL|Innovative prophylaxis arm|Additional single-shot perioperative antibiotic prophylaxis with Broad-spectrum prophylaxis: vancomycin 1 g \& gentamicin 5 mg/kg.
62100238|NCT06635824|EXPERIMENTAL|Arm A|Acasunlimab, 100 mg and pembrolizumab, 400 mg will be administered via intravenous (IV) infusion, once every 6 weeks (Q6W) (Cycle length=42 days).
62100239|NCT06635824|ACTIVE_COMPARATOR|Arm B|Docetaxel, 75 mg/m\^2 will be administered via IV infusion, once every 3 weeks (Q3W) (Cycle length=21 days).
62100240|NCT01695343|EXPERIMENTAL|KB001-A|KB001-A administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.
62100241|NCT01695343|PLACEBO_COMPARATOR|Placebo Comparator|Placebo administered up to 5x intravenously
62100242|NCT02394834||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
62100243|NCT02394834||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
62466880|NCT05745870|PLACEBO_COMPARATOR|Placebo Supplementation|Participants will consume 10g/d maltodextrin for 42 consecutive days
62466881|NCT01017848||Adults, nondiabetics|adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction
62100244|NCT06055777|ACTIVE_COMPARATOR|Single intravenous doses of SZEY-2108|Single escalating doses of SZEY-2108
62100245|NCT06055777|PLACEBO_COMPARATOR|Single intravenous doses of placebo|Single intravenous doses of placebo to match SZEY-2108
62100246|NCT06055777|ACTIVE_COMPARATOR|Multiple intravenous doses of SZEY-2108|Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.
62100247|NCT06055777|PLACEBO_COMPARATOR|Multiple intravenous doses of placebo|Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.
62100248|NCT05279963|ACTIVE_COMPARATOR|medication group|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of participants will be recorded on diary cards.
62100249|NCT05279963|EXPERIMENTAL|EA group|Patients allocated to this group will receive treatment with electroacupuncture. The location of acupoints will be determined based on the National Standard Nomenclature and Location of Acupoints. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks.
62466882|NCT02071875||Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording
62466883|NCT01854008|EXPERIMENTAL|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
62100250|NCT05279963|SHAM_COMPARATOR|SA group|Patients allocated to this group will receive acupuncture in non-meridian and non-acupoints regions. The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the EA group.
62100251|NCT03034382|EXPERIMENTAL|Morphine|5 mg morphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
62100252|NCT03034382|EXPERIMENTAL|Nalbuphine|5 mg nalbuphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
62100253|NCT03034382|EXPERIMENTAL|Morphine and Nalbuphine|"5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.~combination of 5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block"
62100254|NCT03034382|PLACEBO_COMPARATOR|Bupivacaine 0.5%|10 ml of lidocaine 1% and epinephrine 1:400,000 and 5 ml of Bupivacaine 0.5% in interscalene block.
62100255|NCT06599021|EXPERIMENTAL|Muscular strengthening training|"The muscular strengthening training is permformed 3 times daily as head-ups where the participant lies down and lifts their head anf then holds it upright during 60 seconds. This is repeated x 3 followed by 30 head-lifts. The duration of the training programme is 6 weeks."
62100256|NCT06599021|EXPERIMENTAL|Skill-based training|During the skill-based training programme, food and beverages are used as swallowing training material based on a pre-determined food-hierarchy. The training starts at the highest level that the participant can safely swallow and then progresses as strength and coordination of swallowing improves. This training is comprised of 15 speech- and language pathologist lead training sessions during 3 weeks.
62100257|NCT06599021|NO_INTERVENTION|Compensatory treatment|The control group will receive information about dysphagia and advise on compensatory strategies.
62466884|NCT01854008|EXPERIMENTAL|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
62466885|NCT04807374|EXPERIMENTAL|Single arm- HCL Therapy|Single arm study with all participants being treated with HCL for 6 months given the non-randomized interrupted time series study design.
62466886|NCT01358422||In Patients|
62466887|NCT02945891|EXPERIMENTAL|Study group|Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.
62466888|NCT06493266|NO_INTERVENTION|control|pain evaluation by questionnaire in colposcopy patients
61910429|NCT01809470|EXPERIMENTAL|Call of Duty|Playing the video game 'Call of duty' for 1 hour
62100258|NCT06188260|EXPERIMENTAL|Dry eye participants|Participants aged 20 years or above, with OSDI score between 12-32, and with either of the following positive signs: 1) corneal staining; 2) NITBUT\<10s; 3) osmolarity \>=308, or difference \>8
62100259|NCT06582251|EXPERIMENTAL|High Intensity Functional Training|Training will include power and strength movements, then 30 minutes of metabolic conditioning training comprised of whole-body multi-joint movements.
62100260|NCT06582251|ACTIVE_COMPARATOR|Traditional Resistance Training|This group will perform traditional resistance training.
62100261|NCT06582251|ACTIVE_COMPARATOR|Concurrent Training|This group will perform traditional resistance training followed by 20 minutes of running, high intensity intervals.
62100262|NCT05139056|EXPERIMENTAL|Treatment (NSC-CRAd-S-pk7)|Patients undergo standard of care surgical resection. Patients then receive NSC-CRAd-S-pk7 intracerebrally over 10 minutes QW for up to 4 doses in the absence of disease progression or unacceptable toxicity.
62100263|NCT06711900|EXPERIMENTAL|SKB264+Pembrolizumab|Participants will receive SKB264 on Day 1、Day 15 and Day 29 of each 6-week cycle,Pembrolizumab on Day1 of each 6-week cycle.
62100264|NCT06711900|ACTIVE_COMPARATOR|Pembrolizumab+Chemotherapy|Participants will receive Pembrolizumab on Day1 of each 6-week cycle,Chemotherapy on Day1 and Day 22 of each 6-week
62100265|NCT06626685||Acute Heart Failure|Patients hospitalized with acute HF classified according to LVEF.
62100266|NCT06626685||Chronic Heart Failure|Ambulatory patients with chronic HF classified according to LVEF.
62466889|NCT06493266|EXPERIMENTAL|intervention|pain evaluation by questionnaire in colposcopy patients after NLP
62662174|NCT06026306|EXPERIMENTAL|Problem Management Plus (PM+)|The experimental group will receive a 5-session individual PM+.
62662175|NCT06026306|NO_INTERVENTION|Enhanced Care as Usual|The control (enhanced care as usual) group will receive the information about freely available psychological support options. E-CAU ranges from standard community care which may include any existing mental health support services available to earthquake survivors in container cities. The participants will be given flyers which include information about the services provided by the government and by non-governmental organizations. After completion of the post and follow-up assessment of experimental group, those in the E-CAU condition will be offered with PM+.
62662176|NCT02281877|EXPERIMENTAL|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) 48 hours after TKA, 5x/week, 2x/day, for 45 minutes/session.~Standard Rehabilitation Protocol"
62662177|NCT02281877|ACTIVE_COMPARATOR|Control|Standard Rehabilitation Protocol
62662178|NCT03720847|EXPERIMENTAL|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
62662179|NCT03720847|PLACEBO_COMPARATOR|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
62662180|NCT00355641|EXPERIMENTAL|Open Label|All subjects will receive ropinirole XR in this study. The total daily dose range of ropinirole XR will be 0.5mg to 6.0mg daily
62662181|NCT01475773||Adults (starting from age 17)|adults seeking orthodontic treatment at the university of Leuven
62662182|NCT01127360|EXPERIMENTAL|Bevacizumab|Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
62662183|NCT01127360|ACTIVE_COMPARATOR|Ranibizumab|Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
62662184|NCT02232698|EXPERIMENTAL|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
62662185|NCT02232698|ACTIVE_COMPARATOR|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
62100267|NCT04913649|EXPERIMENTAL|Intravenous iron (ferric derisomaltose)|The intervention consists of a single dose of ferric derisomaltose (Monofer®) 100 mg/mL solution for infusion (Monofer® is a registered product with a marketing authorization in the Netherlands (RVG number: 103070). Manufacturer: Pharmacosmos A/S, Denmark. Dutch marketing authorization holder: Cablon Medical B.V). The method of administration and dosage of the investigational medication are standard treatment. The ferric derisomaltose dose will calculated for each patient depending on body weight (20mg/kg) and diluted in 250 ml NaCl 0.9%. Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
62100268|NCT04913649|PLACEBO_COMPARATOR|Placebo|Single dose of sodium chloride 0.9% (250ml). Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
62100269|NCT00903045|EXPERIMENTAL|1|
62100270|NCT00903045|PLACEBO_COMPARATOR|2|
62662186|NCT02568423|EXPERIMENTAL|Mirikizumab IV|Participants received 200mg Mirikizumab by intravenously.
62662187|NCT02568423|EXPERIMENTAL|Mirikizumab SC|Participants received single dose of either 60mgor 200mg 0r 600mg or 1200mg or 2400mg Mirikizumab by subcutaneously.
62662188|NCT02568423|PLACEBO_COMPARATOR|Placebo IV|Participants received placebo by intravenously.
62662189|NCT02568423|PLACEBO_COMPARATOR|Placebo SC|Participants received placebo by subcutaneously.
62662190|NCT02190058|EXPERIMENTAL|DS-1971a|DS-1971a suspension, up to 4650mg/day
62662191|NCT02190058|PLACEBO_COMPARATOR|placebo|matching DS-1971a suspension
62662192|NCT02891330|EXPERIMENTAL|Dietary and nutritional recommendations|Postoperative personalized approach based on dietary and nutritional recommendations conducted by a nurse
62662193|NCT02891330|NO_INTERVENTION|Standard of care|Postoperative standard of care
62662194|NCT02957448|EXPERIMENTAL|BMS 986141 and Rifampin|
62662195|NCT04999969|EXPERIMENTAL|AZD0171 + Durvalumab + chemotherapy|Participants will receive AZD0171 (intravenous \[IV\]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel).
62662196|NCT01044667|OTHER|Patients taking Myfortic|Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
62662197|NCT02326883|EXPERIMENTAL|Care Management|The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
61910430|NCT00158132|EXPERIMENTAL|Propranolol|Propranolol 100mg/day in 3 divided doses
61910431|NCT00158132|EXPERIMENTAL|Amantadine|Amantadine 100mg three times daily
61910432|NCT00158132|EXPERIMENTAL|Propranolol and Amantadine|Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
62662198|NCT02326883|EXPERIMENTAL|Skills Training|The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
62662199|NCT02326883|ACTIVE_COMPARATOR|Usual Care|Those assigned to the Usual Care group will not be approached or contacted.
62100271|NCT06031441|EXPERIMENTAL|Dose Escalation Cohort|Participants in successive cohorts will receive escalating doses of RO7566802, as an intravenous (IV) infusion on Day 1 of each 21-day cycle followed by RO7566802 in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
62100272|NCT06031441|EXPERIMENTAL|Dose Expansion Cohort|Participants with select solid tumors will receive a recommended dose of RO7566802, determined in Dose Escalation phase, as an IV infusion in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
61910433|NCT00158132|PLACEBO_COMPARATOR|Placebo|Identical Placebo pills
61910434|NCT03848871|EXPERIMENTAL|Enstilar foam|Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
62100273|NCT05398120|EXPERIMENTAL|Skills Group|There will be one condition which is the group and participants will complete feasibility and outcome measures at baseline, at midpoint, and at the end of the group.
62100274|NCT02915809|EXPERIMENTAL|GC3110B Vaccine Group|Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).
62100275|NCT02915809|ACTIVE_COMPARATOR|GCFLU Quadrivalent Inj.|Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).
62100276|NCT06391775|EXPERIMENTAL|Dose Escalation|GEN1055 will be administered as monotherapy and in combination with a fixed dose of pembrolizumab.
62100277|NCT06391775|EXPERIMENTAL|Expansion|GEN1055 will be administered as monotherapy or in combination with pembrolizumab or in combination with pembrolizumab and standard chemotherapy in separate expansion cohorts, at a dose level selected from the Dose Escalation part.
62100278|NCT00991276|EXPERIMENTAL|pregabalin|
62100279|NCT00991276|PLACEBO_COMPARATOR|placebo|
62100280|NCT00991276|ACTIVE_COMPARATOR|pramipexole|
62466890|NCT05619783|EXPERIMENTAL|Active|All participants will be treated with oral (or feeding tube) AMX0035 (a fixed-dose combination of Sodium Phenylbutyrate (PB) and taurursodiol). All participants will take 2 sachets daily (one morning dose and one evening dose) starting on Day 1, for the duration of the study (if twice a day dosing is poorly tolerated, dosing interruptions and reductions are further discussed in section 6.3) AMX0035 will be supplied by Amylyx as a carton box containing approximately 1 month supply of single use sachets. Each AMX0035 sachet contains active ingredients in a powder formulation with 3 g PB and 1 g taurursodiol. AMX0035 powder is mixed with water and taken orally (or via feeding tube).
62466891|NCT02964260|EXPERIMENTAL|TAE combined ablation simultaneously|TAE simultaneously combined with ablation.The treatment interval is 1-3 days between two procedures. TAE using embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
62466892|NCT02964260|OTHER|TACE combined ablation sequentially|TACE sequentially combined thermal ablation.The treatment interval is 1 month between two procedures. TACE using chemotherapy drug(Doxorubicin/platinum agents) and embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
62466893|NCT05961423|NO_INTERVENTION|Laparoscopic surgery|The patients will undergoing laparoscopic surgery for the treatment of locally advanced colorectal cancer
62466894|NCT05961423|ACTIVE_COMPARATOR|Robotic group|The patients will undergoing robotic surgery for the treatment of locally advanced colorectal cancer
62662200|NCT05279079||Group 1|Drug-associated AP: patients aged 18 or more years undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
62662201|NCT05279079||Group 2|Other cause AP: patients aged 18 or more years not undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
62662202|NCT05279079||Group 3|Chronic pancreatitis: patients aged 18 or more years with symptomatic chronic pancreatitis confirmed by CT or MRI
62662203|NCT05279079||Group 4|Pancreas cancer: patients aged 18 or more years with biopsy proven pancreas cancer
62662204|NCT05279079||Group 5|Diabetes mellitus: patients aged 18 or more years with type 1 or type 2 diabetes mellitus in receipt of insulin or oral hypoglycaemics
61910435|NCT02658591|ACTIVE_COMPARATOR|Control|Crackers/pasta with no faba bean fraction
61910436|NCT02658591|EXPERIMENTAL|Faba bean protein concentrate|Crackers/pasta with added faba bean protein concentrate
61910437|NCT02658591|EXPERIMENTAL|Faba bean protein isolate|Crackers/pasta with added faba bean protein isolate
62100281|NCT04338529||Group Alendronate 6m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of \> -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 6 months and then followed for another 6 months without medication. In case serum P1NP levels are \> 35μg/L and/or serum CTX levels are \> 280 ng/L at 9 months (3 months following alendronate discontinuation) the patients would be strongly advised to restart alendronate treatment.
62662205|NCT05279079||Group 6|Healthy volunteers
62662206|NCT01400048|ACTIVE_COMPARATOR|Aloe vera effervescent tablet (AVH200)|
62662207|NCT01400048|PLACEBO_COMPARATOR|Placebo|
62100282|NCT04338529||Group Alendronate 12m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of \> -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 12 months.
62100283|NCT01750957|PLACEBO_COMPARATOR|Placebo|
62100284|NCT01750957|EXPERIMENTAL|RO4917523 Dose A|
62100285|NCT01750957|EXPERIMENTAL|RO4917523 Dose B|
62100286|NCT03990038|ACTIVE_COMPARATOR|Group C|"Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter.~They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery"
62466895|NCT03064334||one medium of focus groups|"The present study aims to understand patient experiences and outcomes post- Total Knee Arthroplasty(TKA). Therefore, a qualitative approach will be most appropriate to facilitate the collection of in-depth experiences and perceptions of patients post-TKA.~The medium of focus groups (with 8-10 patients) is preferred to allow a group of patients to share their perceptions and experiences post-surgery, with sufficient quantity and diversity of views while balancing the facilitator's ability to manage all patients' participation for 90-120 minutes (Bloor, 2006)."
62100287|NCT03990038|ACTIVE_COMPARATOR|Group U|"Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down.~They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total"
62100288|NCT06711328|EXPERIMENTAL|Using a new oropharyngeal airway set|Study participants entered the examination room to establish intravenous access, using 2% lidocaine gel 5ml containing mouth cavity and pharynx.Heart rate (HR), pulse oxygen saturation (SpO2), end-expiratory carbon dioxide, ECG monitoring, and non-invasive blood pressure (measured every 2.5 minutes) were routinely monitored before anesthesia induction.Study participants were asked to lie on their left side.In this study, the relevant staff of the undergraduate department participating in this clinical trial planned to implement simple randomization using SAS: The group using the new oropharyngeal airway (trial group) : Oxygen was continuously supplied through a catheter partially connected to the endoscopic mouth before induction of anesthesia until the end of gastroenteroscopy
62100289|NCT06711328|NO_INTERVENTION|The conventional endoscopic bite group|Study participants entered the examination room to establish intravenous access, using 2% lidocaine gel 5ml containing mouth cavity and pharynx.Heart rate (HR), pulse oxygen saturation (SpO2), end-expiratory carbon dioxide, ECG monitoring, and non-invasive blood pressure (measured every 2.5 minutes) were routinely monitored before anesthesia induction.Study participants were asked to lie on their left side.In this study, the relevant staff of the undergraduate department participating in this clinical trial planned to implement simple randomization using SAS:In the conventional endoscopic bite group (control group), oxygen was continuously supplied through a common nasal catheter before induction of anesthesia until the end of gastroenteroscopy.
62100290|NCT05799222||Adults with overweight/obesity and pre-diabetes/diabetes and low income|Adults with overweight or obesity and pre-diabetes or type 2 diabetes who earn a low income.
62100291|NCT02782182|EXPERIMENTAL|FOLFIRINOX+surgery|4 cycles of pre-operative FOLFIRINOX, followed by surgery, followed by 2 more cycles of FOLFIRINOX
62466896|NCT04504526|EXPERIMENTAL|68Ga-Pentixafor, PET/CT|PET/CT perform after injecting 68Ga-Pentixafor
62466897|NCT04115332|EXPERIMENTAL|Interventional|"EEG Recording The one-channel EEG sensor was recorded from Cz with linked-ear reference based on the International 10-20 system. EEG signals were recorded using BioGraph Infiniti software (Version 6.0.4, n.d.) with a band-pass between 1-30 Hz. The sample rate was 256 Hz with 60-Hz notch filters, and the electrode impedances were lower than 5 kΩ.~A lead II electrocardiogram (ECG) was collected for 5 minutes at baseline using the ProComp InfinitiTM system (Thought Technology Ltd., Montreal, Canada), which was installed on a laptop. A sampling rate of 2,048/second was set in order to acquire real-time interbeat intervals."
62466898|NCT00724542|NO_INTERVENTION|Control|Placebo with lifestyle intervention
62466899|NCT00724542|EXPERIMENTAL|Drug|Voglibose tablets with lifestyle intervention
62466900|NCT01916408|ACTIVE_COMPARATOR|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
62662208|NCT06425614|EXPERIMENTAL|Autotransfusion by filtration|new filtration-based autotransfusion (SAME I-SEP device)
62662209|NCT06425614|OTHER|Autotransfusion by centrifugation|centrifugation-based autotransfusion (routinely used in cardiac surgery centers)
62100292|NCT06055985|EXPERIMENTAL|UCB0022-Dose A|Study participants randomized to this arm will receive UCB0022 Dose A orally administered as tablet during the Treatment Period.
62100293|NCT06055985|EXPERIMENTAL|UCB0022-Dose B|Study participants randomized to this arm will receive UCB0022 Dose B orally administered as tablet during the Treatment Period.
62100294|NCT06055985|PLACEBO_COMPARATOR|Placebo|Study participants randomized to this arm will receive matching placebo orally administered as tablet during the Treatment Period.
62466901|NCT01916408|PLACEBO_COMPARATOR|Placebo PL1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
62466902|NCT02272556|ACTIVE_COMPARATOR|Subjects with Type 2 Diabetes|Type 2 DM subjects with HbA1C \> 7.5% treated with metformin, sulfonylurea, insulin or combination
62466903|NCT02272556|ACTIVE_COMPARATOR|Non-Diabetic Obese|Age-matched, non-diabetic obese (BMI \> 30 kg/m\^3) individuals
62466904|NCT02272556|ACTIVE_COMPARATOR|Lean, healthy control subjects|Age-matched, lean, healthy control subjects (BMI \< 25 kkg/m\^3)
62662210|NCT04575012|EXPERIMENTAL|Deferred invasive strategy|
62662211|NCT04575012|OTHER|Early invasive strategy|
62100295|NCT05750095|EXPERIMENTAL|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
62100296|NCT05750095|ACTIVE_COMPARATOR|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
62100297|NCT03286725|NO_INTERVENTION|Control Group|The Control Group will be asked to continue with their normal PE lessons.
62100298|NCT03286725|EXPERIMENTAL|Intervention Group|'Physical Education (PE) Programme'
62100299|NCT03049696|NO_INTERVENTION|Control Group (Standard of Care)|All patients will receive the Centre for Metabolic and Bariatric Surgery (CMBS) standard of care including two to four multidisciplinary visits over six months, exercise counseling (kinesiologist), completion of a the CMBS behavior modification program (Craving ChangeTM), and achievement of lifestyle and dietary modification goals in order to be scheduled for surgery. The standard of care will be used as the control group (n=24). Matched historical controls (1:1) will be selected (based on age, gender, and body mass index) from the existing CMBS database.
62100300|NCT03049696|EXPERIMENTAL|Intervention Group-ENCOURAGEING START|Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
62100301|NCT06094205|EXPERIMENTAL|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
62100302|NCT02259413|EXPERIMENTAL|Exercise Rehabilitation|"Participants will receive baseline exercise counselling as per Standard Care group. Participants will then participate in a 26-week exercise rehabilitation program incorporating 3 components:~1. One-to-one self-management/resistance education once per week during the first 4 weeks of intervention. Participants will subsequently receive resistance training material to allow for home exercise for the remaining 22 weeks of the intervention.~2. Intradialytic aerobic exercise on a cycle ergometer 3 times weekly for 26 weeks at their usual hemodialysis sessions.~3. Four additional one-to-one standardized education sessions will be completed during the intervention period."
62100303|NCT02259413|NO_INTERVENTION|Standard Care|Participants will receive one exercise counseling session as part of their baseline assessment. Participants in the control group will not undergo any other exercise counseling or formal exercise intervention, but will not be prohibited from participating in exercise outside of the study protocol.
62100304|NCT04220229|EXPERIMENTAL|Treatment (cabozantinib S-malate, radiation therapy)|Patients receive cabozantinib S-malate PO QD on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression or unacceptable toxicity. Beginning cycle 1 day 8, patients also undergo standard of care radiation therapy for 5-6 weeks.
62662212|NCT03520010|ACTIVE_COMPARATOR|Internally-driven implementation|
62100305|NCT04344158|EXPERIMENTAL|AK105 combined with Anlotinib|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62100306|NCT04344158|ACTIVE_COMPARATOR|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
62100307|NCT06241664|EXPERIMENTAL|AEYE-DS Software Device|Eligible participants will undergo the following procedures: photographic imaging of each eye using various fundoscopy camera devices. Images obtained will be sent to the AEYE-DS software for analysis. Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second fundoscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. All study subjects will have their pupils dilated using dilation drops.
62100308|NCT05727176|EXPERIMENTAL|Treatment Arm A|TAS-120 (20mg) tablets, oral; 21-day cycle
62100309|NCT05727176|EXPERIMENTAL|Treatment Arm B|TAS-120 (16mg) tablets, oral; 21-day cycle
62100310|NCT05033067|NO_INTERVENTION|Usual Care|
62466905|NCT04386278|EXPERIMENTAL|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
62466906|NCT04386278|EXPERIMENTAL|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
62466907|NCT04386278|EXPERIMENTAL|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
62662213|NCT03520010|EXPERIMENTAL|Externally-facilitated implementation|
62662214|NCT03318068|EXPERIMENTAL|Yoga intervention arm|The group will receive a weekly yoga session for the duration of 10 weeks. The yoga sessions will be delivered in person for 3 weeks during the intervention, coordinated with existing clinic visits. The other 7 sessions will be delivered via skype. The participant will be asked to fill out questionnaires during each of the three in-person yoga visits asking about psychological symptoms and quality of life.
62100311|NCT05033067|EXPERIMENTAL|Intervention (P3-BC) Usual Care|intervention + usual care group. In addition to receiving usual care, patients will have access to the aid and related materials before consultation with the physician about cystectomy and urinary diversion.
62100312|NCT03794804|ACTIVE_COMPARATOR|ColdZyme|"ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~* Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~* A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
62100313|NCT03794804|PLACEBO_COMPARATOR|Placebo|"Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~* Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~* A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
62100314|NCT06713291|EXPERIMENTAL|Sliding compression locking plate|Patients with femoral neck fracture were treated with sliding compression locking plate internal fixation.
62100315|NCT06713291|PLACEBO_COMPARATOR|Three cannulated compression screws|The patients with femoral neck fracture were treated with three cannulated compression screws.
62100316|NCT03066596|EXPERIMENTAL|PRAGMATIC|Intervention practices will receive guideline information and assess children's asthma severity and control. For children with persistent/uncontrolled asthma, academic detailing and prompt in EHR following asthma guidelines will guide asthma management; outreach worker will follow up with patients referred to the by providers to receive care coordination to assure that provider management plan is followed by patient at home.
62100317|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(good perfusion)
62662215|NCT05658991|ACTIVE_COMPARATOR|Intermittent fasting healthy group|Healthy participants with intermittent fasting dietary habit.
62100318|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(middle perfusion)
62100319|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(poor perfusion)
62100320|NCT01024179|ACTIVE_COMPARATOR|Group B: CTO|Chronic total occlusion
62100321|NCT01024179|ACTIVE_COMPARATOR|Group A : Non-CTO|"Non-chronic total occlusion :~1. Fibrous plaque+fibro-calcific plaque + Lipid plaque(\<2 quadrants )~2. Lipid-rich plaque ( ≥2 quadrants )"
62100322|NCT06704633|OTHER|Symptomatic adult particiopants with HFrEF, under heart failure therapy|Symptomatic adults with HFrEF, under heart failure medication
62100323|NCT05262972|EXPERIMENTAL|Group I|The subject will obtain a conservative treatment for this type of pathology consisting of the development of a personalized plantar orthosis
62100324|NCT05262972|EXPERIMENTAL|Group II|The subjects belonging to this group, in addition to providing their corresponding personalized plantar orthosis, will receive a complementary treatment consisting of the application of ultrasound-guided percutaneous electrolysis
62100325|NCT03683472|NO_INTERVENTION|Treatment as usual (TAU)|Individuals will receive treatment as usual
62100326|NCT03683472|ACTIVE_COMPARATOR|TAU and Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals unlearn/extinguish worry at a core mechanistic level."
62100327|NCT05601583|EXPERIMENTAL|CP-CGMH|"CP-CGMH: Care Partner-Assisted Intervention through linking continuous glucose monitoring and Mobile Health.~Participants will receive a CGM device and asked to share CGM data with their care partners for daily decision-making for diabetes self-management for two weeks. The LibreLinkup mHealth app will be used to share data."
62100328|NCT05975294|ACTIVE_COMPARATOR|Group(E):|including 30 patients with multiple fracture ribs will undergo ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
62100329|NCT05975294|ACTIVE_COMPARATOR|Group (C)|including 30 patients with multiple fracture ribs will be given intravenous PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
62100330|NCT06712966|EXPERIMENTAL|EngageRx_SMBP|Integrated SMBP monitoring using EngageRx_SMBP.
62100331|NCT00690456|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily on top of metformin
62100332|NCT00690456|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily on top of metformin
62100333|NCT00946192|EXPERIMENTAL|Estrogen Patch|17Beta-estradiol transdermal patch twice weekly application for 12 months
62100334|NCT00946192|ACTIVE_COMPARATOR|Estrogen Pill|One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
62466908|NCT04386278|EXPERIMENTAL|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
62466909|NCT04386278|EXPERIMENTAL|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
62662216|NCT05658991|ACTIVE_COMPARATOR|Obesity group|Subjects with body mass index more than 30.
62662217|NCT00985374|EXPERIMENTAL|1|
62100335|NCT00946192|SHAM_COMPARATOR|Control|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
62100336|NCT01663610|EXPERIMENTAL|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
62100337|NCT01663610|NO_INTERVENTION|Wait List Control (CONT)|Weekly registrations only. After 6 weeks the Internet-based course without therapist support well be offered (SelfSMART)
62100338|NCT00819910|ACTIVE_COMPARATOR|Rosiglitazone + Placebo|Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
62100339|NCT00819910|ACTIVE_COMPARATOR|Fenofibrate + Placebo|Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks
62100340|NCT00819910|EXPERIMENTAL|Rosiglitazone +Fenofibrate|Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks
62100341|NCT00819910|PLACEBO_COMPARATOR|Placebo Therapy Daily|Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
62100342|NCT04423393|EXPERIMENTAL|VIR-3434|
62100343|NCT04423393|PLACEBO_COMPARATOR|Placebo|
62100344|NCT03484182|ACTIVE_COMPARATOR|Standard Home Exercise Program|
62100345|NCT03484182|EXPERIMENTAL|Web-based Home Exercise Program|
62100346|NCT05669794||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
62100347|NCT02755922|EXPERIMENTAL|Fractures with Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.
62100348|NCT02755922|NO_INTERVENTION|Fractures without Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site.
62100349|NCT05792540|ACTIVE_COMPARATOR|Control Group|Control group ( fluoxetine 20 mg, n =25 ) who will receive fluoxetine (20 mg) once daily for 3 months
62662218|NCT05391152|EXPERIMENTAL|robotic-arm assisted modified kinematic alignment total knee replacement|The patients in this group receive robotic-arm assisted total knee replacement. And these patients achieve modified kinematic alignment.
62662219|NCT05391152|ACTIVE_COMPARATOR|traditional manual total knee replacement|The patients in this group receive traditional manual total knee replacement. And these patients achieve traditional alignment.
62662220|NCT02990962|EXPERIMENTAL|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (5cc) between carpal tunnel and median nerve.
62100350|NCT05792540|ACTIVE_COMPARATOR|Dapagliflozin group|Patients will receive fluoxetine (20 mg) once daily plus dapagliflozin 10 mg once daily for 3 months
62100351|NCT05792540|ACTIVE_COMPARATOR|Atorvastatin group|Patients will receive fluoxetine (20 mg) once daily plus atorvastatin 80 mg once daily for 3 months
62100352|NCT03969277|EXPERIMENTAL|Graded Motor Imagery|Each subject in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, and home exercises.
62294643|NCT00486603|EXPERIMENTAL|Phase 1: RT+TMZ+HCQ 200 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT. Starting dose of HCQ is 200mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
62466910|NCT04386278|EXPERIMENTAL|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
62466911|NCT04386278|EXPERIMENTAL|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
62466912|NCT04386278|EXPERIMENTAL|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
62662221|NCT02990962|ACTIVE_COMPARATOR|Perineural injection with steroid|Ultrasound-guided perineural injection with 1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and median nerve.
62662222|NCT04549441||WALANT|The participants undergo distal radius plating surgery via wide-awake local anesthesia no tourniquet technique. In this group, mean arterial pressure, heart rate, and numeric rating scale for pain were measured by nursing staff in the operation theatre seven times perioperatively, namely before surgery (T0) and at the time of injection of local anesthesia (T1), skin incision (T2), fracture reduction (T3), plating and screwing (T4), skin closure (T5), surgery completion (T6).
61910438|NCT02658591|EXPERIMENTAL|Faba bean flour|Crackers/pasta with added faba bean flour
62100353|NCT03969277|ACTIVE_COMPARATOR|Standard Rehabilitation|Each subject in the Standard Rehabilitation group will receive a treatment protocol consisting of stretching and strengthening exercises, cold therapy, and home exercises.
62100354|NCT05350202||Cohort receiving empagliflozin|Patients will receive first prescription of empagliflozin as routine therapy for Heart Failure with reduced Ejection Fraction (HFrEF).
62100355|NCT05350202||Cohort receiving drugs with another mechanism of action|Patients will receive Heart Failure therapy with drugs with another mechanism of action.
62100356|NCT05305040|EXPERIMENTAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
62100357|NCT05305040|PLACEBO_COMPARATOR|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
62100358|NCT03529019|EXPERIMENTAL|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
62100359|NCT02708862|EXPERIMENTAL|Preoxygenation|All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 15 L/min for 3 min 3) Non-rebreather at 60 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
62100360|NCT06470776|EXPERIMENTAL|Chatbot counselling|Smoking cessation counselling delivered by chatbot
62100361|NCT06470776|ACTIVE_COMPARATOR|Peer counselling|Smoking cessation counselling delivered by peer counsellors
62308169|NCT03084159|EXPERIMENTAL|Intervention Only|This arm include new patients at the initial site that also received the intervention of using an education worksheet during their appointment and filled out post intervention surveys. Some of these providers/staff were not involved in the initial design of the intervention.
62466913|NCT03229018|OTHER|voxel size|200 μm and 300 μm Voxel Sizes
62466914|NCT03478397|ACTIVE_COMPARATOR|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
62466915|NCT03478397|NO_INTERVENTION|Usual Care|Women with HPV self-collected tests receive usual care. Upon opting for the HPV self-collected test, women will be instructed to go to the health care center in 30 days to pick up the results.
62466916|NCT01552447|OTHER|1 application of EpiFix|1 x dehydrated human amnion/chorion membrane
62466917|NCT01552447|OTHER|2 applications of EpiFix|2 x dehydrated human amnion/chorion membrane
62100362|NCT06528457|EXPERIMENTAL|Cohort A|The first cohort (Cohort A) allows examination of prophylaxis as well as treatment, as ISLA101 will be taken prior to inoculation and for 21 days thereafter. Subjects will be randomized 3:1 (active:control), enrolling in a single group three days prior to inoculation. Following the morning dose on the 4th day of dosing, all subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL).
62466918|NCT01552447|OTHER|Standard of care|Compression bandaging
62466919|NCT02918877|EXPERIMENTAL|Inhaled Anesthesia|Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.
62662223|NCT04549441||GA|The participants undergo distal radius plating surgery via general anesthesia induced by an anesthesiologist. The anesthesia team continuously monitored patients' intraoperative physiological status. MAP and HR in group B were marked after induction (T1) and at the other six same time points as in the group WALANT.
62662224|NCT04301284|EXPERIMENTAL|CAD-1883|"Capsules of 150 mg of CAD-1883 will be administered orally, twice daily (BID). The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.~The initial dose regimen evaluated will be 150 mg BID. Additional dose regimens up to 600 mg BID will be determined based on forthcoming clinical data."
62100363|NCT06528457|PLACEBO_COMPARATOR|Cohort B|The first cohort (Cohort B) allows examination of prophylaxis as well as treatment, as placebo will be taken prior to inoculation and for 21 days thereafter. Subjects will be randomized 3:1 (active:control), enrolling in a single group three days prior to inoculation. Following the morning dose on the 4th day of dosing, all subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL).
62100364|NCT06528457|EXPERIMENTAL|Cohort C|The second cohort (Cohort C) is planned to enroll in two groups of five subjects each, using 4:1 randomization (active:control). All subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL) on Day 1. After the inoculation, subjects will be evaluated in the clinic daily through day 18 (eighteen consecutive daily clinic visits). Dosing with ISLA101 will commence on the morning of Day 8 and continue with a total of 28 doses taken twice daily through Day 21.
62294644|NCT00486603|EXPERIMENTAL|Phase 1: RT+TMZ+HCQ 400 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 400 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
62294645|NCT00486603|EXPERIMENTAL|Phase 1: RT+TMZ+HCQ 600 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 600 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
62294646|NCT00486603|EXPERIMENTAL|Phase 1: RT+TMZ+HCQ 800 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 800 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
62294647|NCT00486603|EXPERIMENTAL|Phase 2: RT + TMZ + HCQ MTD|"Phse 2: daily hydroxychloroquine (HCQ) (MTD 600mg) on 1st day of RT and concomitant temozolomide for 6wks during RT. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~Other: pharmacological study (PK)~Pts will continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 2~Radiation (RT)"
62466920|NCT02918877|ACTIVE_COMPARATOR|Intravenous Anesthesia|Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.
62466921|NCT05082779|EXPERIMENTAL|Cohort A1: 0.2 mg|Participants in fasted state will receive CS0159 0.2 mg or placebo once on Day 1.
62466922|NCT05082779|EXPERIMENTAL|Cohort A2: 0.6 mg|Participants in fasted state will receive CS0159 0.6 mg or placebo once on Day 1.
62466923|NCT05082779|EXPERIMENTAL|Cohort A3: 1 mg|Participants in fasted state will receive CS0159 1 mg or placebo once on Day 1 followed by a 7-day washout period then given in 1 mg tablet (in fed state) on Day 8.
61910439|NCT02658591|EXPERIMENTAL|Faba bean starch|Crackers/pasta with added faba bean starch
62466924|NCT05082779|EXPERIMENTAL|Cohort A4: 2 mg|Participants in fasted state will receive CS0159 2 mg or placebo once on Day 1.
62662225|NCT04301284|PLACEBO_COMPARATOR|Placebo|Matching placebo will be provided in capsules, to be administered orally, twice daily. The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
62662226|NCT01182363|NO_INTERVENTION|Control|Usual early intervention services
62662227|NCT01182363|EXPERIMENTAL|Problem Solving Education|
62662228|NCT04490356|EXPERIMENTAL|Legacy Intervention|Older adults who have successfully completed a lifestyle intervention (lost at least 3% body weight and increased short physical performance battery (SPPB) score by 1 point or 6-minute walk test (6MWT) by 50 meters) will be enrolled in a tele-nutrition and tele-exercise intervention.
62662229|NCT03362320|EXPERIMENTAL|double layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with double layer fixation
61919803|NCT04174014|EXPERIMENTAL|Recruitment manoeuvre|"1. Volume control (VC) ventilation mode with a tidal volume of 6 mL/kg of ideal body weight~2. P/V tool assessment~3. Baseline measurements~4. CT scan of chest without EIT belt~5. Re-establishment of EIT belt, continuous EIT and transpulmonary pressure measurement during the recruitment and de-recruitment manoeuvre.~   increment phase:~  * constant volume settings~  * increasing PEEP with 4 cmH2O following each 10 consecutive controlled breath until reaching a peak pressure of 40 cmH2O~   decrement phase:~  * constant volume settings~  * decreasing PEEP with 4 cmH2O following each 10 consecutive controlled breath not lower than 2 cmH20 from target PEEP~  * target PEEP level is defined where the end-expiratory transpulmonary pressure is 0-1 cmH2O~6. P/V recruitment with target end-PEEP level~7. Removal of EIT belt, CT scan of chest~8. Continuous EIT and transpulmonary pressure measurement with the initial FiO2 and the new PEEP settings"
62100365|NCT06528457|PLACEBO_COMPARATOR|Cohort D|The second cohort (Cohort D) is planned to enroll in two groups of five subjects each, using 4:1 randomization (active:control). All subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL) on Day 1. After the inoculation, subjects will be evaluated in the clinic daily through day 18 (eighteen consecutive daily clinic visits). Dosing with placebo will commence on the morning of Day 8 and continue with a total of 28 doses taken twice daily through Day 21.
62100366|NCT05391126|EXPERIMENTAL|Genocare Guided|
62100367|NCT05391126|NO_INTERVENTION|Usual Care|
62100368|NCT06712238|ACTIVE_COMPARATOR|Group A: (Narrow Band Ultraviolet B)|About 12 patients will expose to 24 sessions of Narrow Band Ultraviolet B (NB-UVB) radiation (initial dose of 130 - 400 mJ / cm2 ) selected according to skin for 3 month.
62100369|NCT06712238|ACTIVE_COMPARATOR|Group B: (Methotrexate )|About 12 patients will receive Methotrexate tablets (MTX) in dose of (0.3 mg/kg/week) along with folic acid (5 mg/day) for 3 month.
62100370|NCT06712238|ACTIVE_COMPARATOR|Group C: (Methotrexate and Narrow Band Ultraviolet B)|About 12 patients will undergo the treatment by both Methotrexate tablets (MTX) and Narrow Band Ultraviolet B( NB-UVB) radiation.for 3 month.
62100371|NCT06712238|ACTIVE_COMPARATOR|Group D (Control Group)|About 12 patients apparently healthy individuals as control group.and will not take any medication
62100372|NCT05974202|ACTIVE_COMPARATOR|Active (high-frequency) rTMS|Daily high-frequency (10 Hz) repetitive transcranial magnetic brain stimulation for 3 weeks (15 sessions).
62100373|NCT05974202|PLACEBO_COMPARATOR|Sham (placebo) rTMS|Sham rTMS uses the same device and mimics the auditory and scalp sensations without stimulating the brain.
62100374|NCT02576418|EXPERIMENTAL|Partosure TTD Test|PartoSure TTD test will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
62466925|NCT05082779|EXPERIMENTAL|Cohort A5: 4 mg|Participants in fasted state will receive CS0159 4 mg or placebo once on Day 1.
62662230|NCT03362320|EXPERIMENTAL|single layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with single layer fixation
62662231|NCT04714671|EXPERIMENTAL|Euthymics patients with history of suicide attempt (suicide attempters)|Euthymics patients with a lifetime history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
62466926|NCT05082779|EXPERIMENTAL|Cohort A6: 8 mg|Participants in fasted state will receive CS0159 8 mg or placebo once on Day 1.
62466927|NCT05082779|EXPERIMENTAL|Cohort B1: 0.4 mg|Participants in fasted state will receive CS0159 0.4 mg or placebo once daily for a consecutive 14 days.
61910440|NCT04541277|EXPERIMENTAL|Tislelizumab with DAN hypmethylation agent +/- chemotherapy|"Decitabine, 20 mg/m2/d, IV, on days 1-5; or Azacitidine, 75 mg/m2/d,SC, on days 1-7.~Aclamycin hydrochloride, 20 mg/d, IV, on day 1, 3, and 5 (For relapse/resistance AML, on days 1-5.); or idarubicin hydrochloride,10 mg/d, IV, on day 1, 3, and 5.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cytarabine,100 mg, IV, q12h/d. For patients with one of the following conditions, cytarabine,10 mg, SC, q12h/d: (1) There are obvious heart, lung, and kidney complications; (2) Bone marrow is hypoproliferative; (3) Age\> 75 years old; (4) Age\> 60 years old who are unfit for standard-dose chemotherapy.~Recombinant human granulocyte colony stimulating factor injection, 5 μg/kg, SC, from day 0 to stop of chemotherapy after the WBC count exceeds 10.0×10\^9/L; or Pegylated recombinant human granulocyte stimulating factor injection Liquid, 100 μg/kg, SC, on day 0.~Tislelizumab,200 mg, IV, on the next day after chemotherapy was stopped."
61910441|NCT02975362|EXPERIMENTAL|Acupuncture combined rehabilitation|Acupuncture Treatment Rehabilitation Treatment
61910442|NCT02975362|EXPERIMENTAL|Rehabilitation|Rehabilitation Treatment
62100375|NCT03520075|EXPERIMENTAL|Phase 1 Regimen 1|"Dose escalation and expansion:~Regimen 1: ASTX029 orally once a day for 21 days of each 21-day cycle."
62100376|NCT03520075|EXPERIMENTAL|Phase 1 Regimen 2|"Dose escalation and expansion:~Regimen 2: ASTX029 orally once a day for 14 days of each 21-day cycle."
62100377|NCT03520075|EXPERIMENTAL|Phase 2|ASTX029 at the RP2D of the selected dosing regimen identified in Phase 1 to subjects with tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029.
62100378|NCT06645249|EXPERIMENTAL|Amiodarone orally impregnation starting one month before ECV|Treatment impregnation with amiodarone starting one month before ECV (600 mg/day 1st week, 400 mg/day 2nd week and 200 mg/day thereafter until ECV).
61910443|NCT02014870|EXPERIMENTAL|Cohort 1|1:1000 dilution of neat virus
61910444|NCT02014870|EXPERIMENTAL|Cohort 2|1:100 dilution of neat virus
61910445|NCT02014870|EXPERIMENTAL|Cohort 3|1:10 dilution of neat virus
62100379|NCT06645249|ACTIVE_COMPARATOR|Amiodarone orally impregnation started 5 days before ECV|Treatment impregnation with amiodarone 800 mg/day started 5 days before ECV.
62100380|NCT04759339|EXPERIMENTAL|AG-920|Subjects will receive a single dose of articaine sterile topical ophthalmic solution in one eye only. The study eye will be randomized. The single dose will be administered by the clinic staff as two drops in study eye 30 seconds apart.
62100381|NCT04954430||fatigue|After enrollments, subjects were assigned to perform mental fatigue-inducing experiment-a 90 min of monotonous simulated driving task. They underwent repeated measurements of quantitative pupillary light reflex (PLR) using an automated quantitative pupillometer at baseline and at an interval of 30 min during the task. Subjective ratings, heart rate variability (HRV), and electroencephalography (EEG) were performed simultaneously.
62294648|NCT05591781|EXPERIMENTAL|Vest Airway Clearance System|Thirty patients (Group A) received high frequency chest wall oscillation with vest system in addition to their prescribed medication, 3 times per week for three successive weeks and the total duration of each session was 15-30 minutes
61910446|NCT02104037|EXPERIMENTAL|Liraglutide treated patients|
61910447|NCT02328053|EXPERIMENTAL|Collagen crosslinking group|patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
61910448|NCT02328053|ACTIVE_COMPARATOR|standard medical therapy|patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
61910449|NCT01546272|EXPERIMENTAL|Resorbable staples|Suture using Insorb Resorbable staples
61910450|NCT01546272|ACTIVE_COMPARATOR|Resorbable wires|Suture using Monocryl resorbable wire
61910451|NCT00423787|EXPERIMENTAL|Ragweed MATA MPL|modified Ragweed pollen allergen absorbed to Tyrosine and containing MPL adjuvant
61910452|NCT00423787|PLACEBO_COMPARATOR|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
61910453|NCT00830778|EXPERIMENTAL|PG anastomosis|Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
62100382|NCT01144949|ACTIVE_COMPARATOR|silodsosin|
62100383|NCT01144949|PLACEBO_COMPARATOR|placebo|
62294649|NCT05591781|ACTIVE_COMPARATOR|Lung flute (OPEP)|Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day
62294650|NCT05621356||allergen-specific immunotherapy (AIT)|Adults with birch pollen allergy, who are treated with allergen-specific immunotherapy (AIT)
62294651|NCT05621356||control|Adults with birch pollen allergy, who are treated with immunosuppressive medication
62466928|NCT05082779|EXPERIMENTAL|Cohort B2: 1 mg|Participants in fasted state will receive CS0159 1 mg or placebo once daily for a consecutive 14 days.
62466929|NCT05082779|EXPERIMENTAL|Cohort B3: 2 mg|Participants in fasted state will receive CS0159 2 mg or placebo once daily for a consecutive 14 days.
62294652|NCT00365989|EXPERIMENTAL|ExAblate Enhanced Sonication Test Arm|The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.
61910454|NCT00830778|ACTIVE_COMPARATOR|PJ anastomosis|Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
61910455|NCT02012868||bariatric surgery, obstructive sleep apnoea|bariatric surgery
61910456|NCT03516474||St. Michael's Hospital|"St. Michael's Hospital is an Acute care centre for the diabetic lower extremity.~n=100"
61910457|NCT03516474||South Riverdale Community Health Centre|South Riverdale is a Community Health Centre focused on prevention. n=100
61910458|NCT03516474||Westpark|Westpark is a rehabilitation site focused on post-operative/amputation care and preservation of the opposite limb. n=100
61910459|NCT03516474||Women's College Hospital|Women's College Hospital is an outpatient wound clinic focused on the management of DFUs. n=100
62466930|NCT05082779|EXPERIMENTAL|Cohort B4: 4mg|Participants in fasted state will receive CS0159 4 mg or placebo once daily for a consecutive 14 days.
61910460|NCT00770146|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once a week for 26 weeks.
61910461|NCT00770146|EXPERIMENTAL|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
61910462|NCT00708084|EXPERIMENTAL|A|CL184 combined with rabies vaccination
61910463|NCT00708084|ACTIVE_COMPARATOR|B|HRIG combined with rabies vaccination
61919804|NCT04496934|EXPERIMENTAL|Intervention|Exercise intervention
61919805|NCT04496934|ACTIVE_COMPARATOR|Control|The control group is a waiting list group. The participants will receive exercise intervention after twelve weeks of treatment as usual.
62100384|NCT05395208|EXPERIMENTAL|Therapeutic touch group accompanied by white noise|"* Camera recording was started 5 minutes before intravenous catheter intervention, vital signs and pain were evaluated.~* Therapeutic touch application with white noise was started.~* Vital signs and pain were evaluated during intravenous catheterization.~* Vital signs and pain were evaluated when the intravenous catheter intervention was terminated and 5 minutes later, and the camera recording was stopped."
62100385|NCT05395208|NO_INTERVENTION|Control group|"* Camera recording was started 5 minutes before the intravenous catheter intervention, vital signs and pain were evaluated.~* No application was made other than intravascular catheter intervention.~* Vital signs and pain were evaluated during intravenous catheterization.~* Vital signs and pain were evaluated when the intravenous catheter intervention was terminated and 5 minutes later, and the camera recording was stopped."
62662232|NCT04714671|EXPERIMENTAL|Euthymics patients without any history of suicide attempt (affective controls)|Euthymics patients without history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
61910464|NCT02523469|EXPERIMENTAL|ALT-803 + Nivolumab dose escalation|"Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
61910465|NCT02523469|EXPERIMENTAL|Arm A: ALT-803 + Nivo naive|"Patients who have not received PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
61910466|NCT02523469|EXPERIMENTAL|Arm B: ALT-803 + Nivolumab progressor|"Patients who have had PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
61910467|NCT02523469|EXPERIMENTAL|ALT-803 + Nivolumab Exploratory Arm 1|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
61910468|NCT02523469|EXPERIMENTAL|ALT-803 + Nivolumab Exploratory Arm 2|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
61910469|NCT04395950|ACTIVE_COMPARATOR|PF-0522130|PF-05221304 10 mg daily (two 5mg tablets daily in the morning).
61910470|NCT04395950|PLACEBO_COMPARATOR|Placebo|Placebo (two tablets daily in the morning).
61910471|NCT05014061|EXPERIMENTAL|Adenosine|Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours
61910472|NCT05014061|NO_INTERVENTION|Controll|Standard of care
61910473|NCT00672659|ACTIVE_COMPARATOR|1|Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
61910474|NCT00672659|PLACEBO_COMPARATOR|2|Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
61910475|NCT00588159|EXPERIMENTAL|Gabapentin preoperatively|Preoperative gabapentin 600 mg orally within 2 hours prior to surgery.
61910476|NCT00588159|PLACEBO_COMPARATOR|Active placebo|Diphenhydramine 12.5 mg orally 2 hours preoperatively.
61910477|NCT01128023||PET Rb-82 perfusion imaging|Patients diagnosed with or suspected coronary artery disease requiring evaluation and/or risk stratification will undergo PET Rb-82 perfusion imaging.
61910478|NCT01128023||SPECT perfusion imaging|Patients diagnosed with or suspected coronary artery disease who have undergone SPECT myocardial perfusion imaging.
62100386|NCT06708312|EXPERIMENTAL|ear acupuncture|"Placement of pressure needles on the MA-TF1 Shenmen, MA-IC4 Heart and ear points MA-IC4 Sympathetic is carried out 30 minutes before starting the running session. Aseptic and antiseptic measures are carried out with alcohol wipe. Stimulation is carried out at the acupuncture points determined by press for 1 minute, using a press needle measuring 0.22 mm x 15 mm.~Press the needle removed 15 minutes after the run"
62466931|NCT05618405||Children who undergo anesthesia because of surgery|Children, aged between 1-11 years, who undergo general anesthesia because of surgery.
62662233|NCT02811107||Patients in preoperative area|Patients in preoperative area before surgery or interventional procedure will complete questionnaires on tablet computers
62662234|NCT03510000|EXPERIMENTAL|Main arm|Single arm open-label cross-over study with random order of SGLT-2 inhibitor intervention (Empagliflozin 25mg po qd), in which each cross-over phase includes different meal strategies (carbohydrate counting, meal announcement, no meal announcement) on separate days in the setting of single hormone artificial pancreas
61910479|NCT04081259|EXPERIMENTAL|Arm B: Dose Escalation LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients with inhibitors for fungal prophylaxis/treatment
61910480|NCT04081259|EXPERIMENTAL|Arm A: Dose Expansion LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients without inhibitors for fungal prophylaxis/treatment
62100387|NCT06708312|SHAM_COMPARATOR|sham ear acupuncture|Placement of adhesive plaster on the MA-TF1 Shenmen, MA-IC4 Heart ear points and MA-IC4 Sympathetic is carried out 30 minutes before starting the running session. Aseptic and antiseptic measures are carried out with alcohol swab. At acupuncture points, pressure stimulation is not carried out, only rubbing. The adhesive plaster is removed 15 minutes after running.
62100388|NCT05133167|EXPERIMENTAL|GROUP A|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage.
62100389|NCT05133167|EXPERIMENTAL|GROUP B|In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage.
62100390|NCT06713811|NO_INTERVENTION|standard|
62100391|NCT06713811|EXPERIMENTAL|experimental|
62100392|NCT04577183|EXPERIMENTAL|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
62662235|NCT02703363|EXPERIMENTAL|Minocycline with TAU|
62662236|NCT02703363|EXPERIMENTAL|Celecoxib with TAU|
62662237|NCT02703363|EXPERIMENTAL|Minocycline and celecoxib with TAU|
62662238|NCT02703363|ACTIVE_COMPARATOR|Placebo with TAU|
62662239|NCT02323334|PLACEBO_COMPARATOR|Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg|"Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626."
62662240|NCT02323334|EXPERIMENTAL|Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626."
62662241|NCT02323334|EXPERIMENTAL|Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO."
62662242|NCT02323334|EXPERIMENTAL|Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole."
62662243|NCT02323334|EXPERIMENTAL|Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
62662244|NCT02323334|EXPERIMENTAL|Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra|"Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
62662245|NCT02323334|EXPERIMENTAL|Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.
62662246|NCT02323334|EXPERIMENTAL|Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.
62662247|NCT02323334|EXPERIMENTAL|Part B Cohort 4: 1.6mg|Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.
62662248|NCT02323334|EXPERIMENTAL|Part B Cohort 5: 10mg|Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.
62662249|NCT02323334|EXPERIMENTAL|Part B Cohort 6: 26mg|Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.
62662250|NCT02323334|PLACEBO_COMPARATOR|Part B Cohort 4, 5, 6: Placebo Comparator|Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.
62662251|NCT02323334|EXPERIMENTAL|Part C Cohort 7: 1mg|Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.
62662252|NCT02323334|EXPERIMENTAL|Part C Cohort 8: 6mg|Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
62662253|NCT02323334|EXPERIMENTAL|Part C Cohort 9: 26mg|Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
62662254|NCT02323334|PLACEBO_COMPARATOR|Part C Cohort 7, 8 ,9: Placebo Comparator|Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.
62662255|NCT02323334|EXPERIMENTAL|Part D Cohort 10: 6mg|Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
61910481|NCT01406405||PEEK cages|Patients will have fusion surgery performed using polyetheretherketone (PEEK) cages
61910482|NCT01406405||Allograft spacers|Patients will have fusion surgery performed using allograft spacers
61910483|NCT03719534|ACTIVE_COMPARATOR|Haplo-HCT|people enrolled in this arm will receive a typical haploidentical donor HCT
62466932|NCT05618405||Children who undergo anesthesia because of an MRI|Children, aged between 1-11 years, who undergo general anesthesia because of an MRI.
62466933|NCT01733511||admitted to emergency department|
61910484|NCT03719534|EXPERIMENTAL|Haplo-cord HCT|people enrolled in this arm will receive a coinfusion of cord blood unit in addition to a typical haploidentical donor HCT
61910485|NCT03493932|EXPERIMENTAL|Nivolumab and BMS-986016|Recurrent Glioblastoma patients
61910486|NCT06306872|OTHER|Sequence A|Subjects in sequence A will be given ABSK-011 old formulation 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) on an empty stomach in the morning of the first day of cycle 1 (C1D1) and ABSK-011 new formulation 200 mg (100 mg capsule \*2) on an empty stomach in the morning of the first day of cycle 2 (C2D1).
61910487|NCT06306872|OTHER|Sequence B|Subjects in sequence B will be given ABSK-011 new formulation 200 mg (100 mg capsule \*2) on an empty stomach in the morning of Cycle 1 day (C1D1) and ABSK-011 old formulation 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) on an empty stomach in the morning of the first day of cycle 2 (C2D1).
61910488|NCT06436664|OTHER|Control group|In patients receiving fixed orthodontic treatment, the orthodontic plaque index, Turesky modified index and gingival index will be recorded at the beginning, 1st and 3rd months. No special instructions will be given to these patients regarding the tooth brushing process.
61910489|NCT06436664|EXPERIMENTAL|Group 1|Patients will receive a standard brochure and oral presentation on tooth brushing in the Group 1. The orthodontic plaque index, Turesky modified index and gingival index will be recorded at the beginning, 1st and 3rd months. These patients will receive a standardized brochure for tooth brushing.
62100393|NCT04132505|EXPERIMENTAL|Treatment (binimetinib, hydroxychloroquine)|Patients receive binimetinib PO BID and hydroxychloroquine PO BID on days 1-14. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62466934|NCT01733511||patients admitted to surgical ward|
61910490|NCT06436664|EXPERIMENTAL|Group 2|Patients will receive a standard tooth brushing on a dental model in the Group 2. The orthodontic plaque index, Turesky modified index and gingival index will be recorded at the beginning, 1st and 3rd months.
61910491|NCT06436664|EXPERIMENTAL|Group 3|In patients undergoing fixed orthodontic treatment, the orthodontic plaque index, Turesky modified index and gingival index will be recorded at the beginning, 1st and 3rd months. Patients will be taught standard tooth brushing with a video in Group 3.
61910492|NCT03706924|EXPERIMENTAL|VM-1500FDC|VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
61910493|NCT03706924|ACTIVE_COMPARATOR|Elpida® & Truvada®|Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
61910494|NCT04083729|ACTIVE_COMPARATOR|Patients with persistent pulmonary hypertension|Patients with persistent pulmonary hypertension after balloon mitral comisseruotomy
62100394|NCT05861986|EXPERIMENTAL|Risdiplam|Participants will receive risdiplam orally once daily for 72 weeks (Treatment Period). The Treatment Period will be followed by a 1-year Treatment Extension Period for a total study duration of 120 weeks (approximately 2.5 years) for each participant enrolled.
62100395|NCT06450210|EXPERIMENTAL|1.2 mg psilocybin trihydrate microdose|Participants will receive a single microdose of 1.2 mg psilocybin trihydrate via oral capsule in the laboratory in double-blind fashion.
62100396|NCT06450210|EXPERIMENTAL|2.0 mg psilocybin trihydrate microdose|Participants will receive a single microdose of 2.0 mg psilocybin trihydrate via oral capsule in the laboratory in double-blind fashion.
62466935|NCT05119270|EXPERIMENTAL|Femtosecond laser assisted cataract surgery with Active Sentry handpiece|Participants suffering from cataract who are candidates for femtosecond laser assisted cataract surgery
62466936|NCT05119270|EXPERIMENTAL|Standard phacoemulsification with the Active Sentry handpiece|Participants suffering from cataract who are candidates for standard phacoemulsification with the new Active Sentry handpiece
62466937|NCT05119270|EXPERIMENTAL|Standard phacoemulsification with the OZil handpiece|Participants suffering from cataract who are candidates for standard phacoemulsification with the traditional OZil handpiece
62466938|NCT04567056||Cancer group|Patients with verified head and neck squamous cell carcinomas
62466939|NCT04567056||Control group|Matched control group without active or earlier cancer and a normal ENT examination.
61910495|NCT04083729|ACTIVE_COMPARATOR|Patients without persistent pulmonary hypertension|Patients without persistent pulmonary hypertension after balloon mitral comisseruotomy
61910496|NCT05721807|EXPERIMENTAL|functional magnetic stimulation|functional magnetic stimulation for stress urinary incontinence
61910497|NCT05721807|EXPERIMENTAL|pelvic floor muscle training program|exercise program for pelvic floor muscle
61910498|NCT04371874|NO_INTERVENTION|Control|Hypertension of patients in the control group was managed with the original protocol including lifestyle by doctors in village clinic.
62294653|NCT05827159|EXPERIMENTAL|SBIRT|Participants will receive the Brief Negotiation Interview (BNI) and Referral to Treatment. The BNI has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
62294654|NCT05827159|EXPERIMENTAL|SBIRT+ED-MAUD|Participants with receive BNI, Referral to Treatment, and MAUD. In the MAUD component, either XR-NTX or oral naltrexone will be provided, supplemented by ancillary treatment with gabapentin. Participants will receive their first doses of XR-NTX (injection) and gabapentin in the ED and will receive 7 days of gabapentin take-home doses. Those who prefer to initiate treatment in ED with oral naltrexone receive their first doses of naltrexone and gabapentin in the ED and receive 29-day take-home doses of naltrexone and 7 days of gabapentin.
62466940|NCT01675622|EXPERIMENTAL|Oxycodone Capsules for cancer pain|
61910499|NCT04371874|EXPERIMENTAL|Treatment with Ten Dollars Project (TDP)|"Hypertension of patients in the TDP group were managed with the protocol of Ten Dollars Project (TDP) by doctors in village clinic."
61910500|NCT02226744|ACTIVE_COMPARATOR|Focused breathing|Focused deep breathing techniques used to produce specific physiological and psychological states
61910501|NCT02226744|ACTIVE_COMPARATOR|Focused breathing 2|Focused deep breathing techniques used to produce specific physiological and psychological states
61910502|NCT04253886|ACTIVE_COMPARATOR|Group A|The Ovassapian Fibreoptic Intubating Airway has a flat lingual surface that widens distally. This provides better retraction of the tongue to prevent it and the soft tissues of the anterior pharyngeal wall from herniating around the side of the airway. The airway has a pair of vertical sidewalls and two pairs of curved guide walls at its proximal section. These walls are separated by a gap which allows removal of the airway after intubation has been completed
61919806|NCT03535571|EXPERIMENTAL|Salmon Protein Hydrolysate (CollaGo®)|Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
61919807|NCT03233269|EXPERIMENTAL|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association \[AMTA\], 2013, para 1 and 2).
62294655|NCT05426421||No actigraphy|Participants will receive viral load testing at transition from LPV/r-based to DTG-based ART, and subsequent routine viral load data will be analysed. Questionnaires will be filled in and dried blood spots collected at transition and at four weeks. Medical history as well as clinical and socio-demographic data will be collected.
62466941|NCT01675622|ACTIVE_COMPARATOR|Morphine tablets for cancer pain|
62100397|NCT06450210|EXPERIMENTAL|3.0 mg psilocybin trihydrate microdose|Participants will receive a single microdose of 3.0 mg psilocybin trihydrate via oral capsule in the laboratory in double-blind fashion.
62100398|NCT06450210|EXPERIMENTAL|4.2 mg psilocybin trihydrate microdose|Participants will receive a single microdose of 4.2 mg psilocybin trihydrate via oral capsule in the laboratory in double-blind fashion.
62294656|NCT05426421||With actigraphy|Participants will receive viral load testing at transition from LPV/r-based to DTG-based ART, and subsequent routine viral load data will be analysed. Baseline actigraphy data will be collected for two weeks prior to transition (actigraphy period 1), and for four weeks after transition (actigraphy period 2 from 0-2 weeks after transition; actigraphy period 3 from 2-4 weeks after transition). Sleep diaries will be filled in during all actigraphy periods. Questionnaires will be filled in and dried blood spots taken at transition as well as two and four weeks after transition. Medical history as well as clinical and socio-demographic data will be collected.
62466942|NCT05213273|EXPERIMENTAL|Group A: Fresh/frozen fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish), excluding the consumption of canned fish.
62662256|NCT00764517|EXPERIMENTAL|Previously untreated|"Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) \[Group I\].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
61910503|NCT04253886|ACTIVE_COMPARATOR|Group B|"Fekry airway:~● It has two parts are: Airway body\& Special connector~1. Airway body consists of:~   1. Flange → it is the buccal end it is 7 cm wide to prevent it from~  2. moving deeper into mouth \& may also serve to fix airway in place.~  3. Bite Portion → it is straight \& fits between teeth \&oral cavity.~  4. Oral straight part → open anterior lingual part; it varies in length according to size~  5. Pharyngeal curved part → extends backwards to correspond the shape oropharynx and ends below laryngeal inlet.~2. The connector: it is a special type (two sizes: adult and pediatric) can attach to all ventilating machines\& it has a teeth rest act as a bite block."
62100399|NCT06450210|PLACEBO_COMPARATOR|Placebo|Participants will receive a single placebo oral capsule in the laboratory in double-blind fashion.
62100400|NCT04363515|NO_INTERVENTION|Usual Pre-Transplant Counseling Intervention|Subjects in the control arm will undergo usual pre-transplant counseling as per the standard of care.
61910504|NCT02815280|EXPERIMENTAL|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
61910505|NCT02815280|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
61910506|NCT00959400|EXPERIMENTAL|Fentanyl Transdermal|
61910507|NCT04518189|EXPERIMENTAL|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
61910508|NCT04518189|PLACEBO_COMPARATOR|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
62294657|NCT06428214|EXPERIMENTAL|Restylane Shaype|Participants will receive Restylane Shaype in the chin area only.
61910509|NCT00691119|EXPERIMENTAL|A|Relaxation and Visualization Therapy group
61910510|NCT00691119|ACTIVE_COMPARATOR|B|Health education group
62100401|NCT04363515|EXPERIMENTAL|Social Support Network Counseling Intervention|Subjects in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks between 2-12 weeks after their initial transplant evaluation and counseling
62100402|NCT04506086|EXPERIMENTAL|Blinatumomab|
62100403|NCT01793740|EXPERIMENTAL|Cogmed|These children are enrolled in the Cogmed intervention.
62100404|NCT01793740|NO_INTERVENTION|Waitlist|These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
62100405|NCT06712173|EXPERIMENTAL|linperlisib combined with SHR2554|
62100406|NCT04356066|OTHER|Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise|"* History taking: age, sex, disease duration, history of present illness, drug intake, past and family history.~* Physical examination including thorough clinical examination.~* Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018)."
62100407|NCT04844866|EXPERIMENTAL|CAR T-cell MB-CART2019.1|Single infusion of 2.5 × 10\^6 CAR-transduced autologous T cells per kg/body weight.
62100408|NCT04844866|ACTIVE_COMPARATOR|Standard of Care|"Immunochemotherapy will be administered from the following 2 predefined regimens: R-GemOx (8 cycles of 14 days each) or BR plus polatuzumab vedotin (6 cycles of 21 days each). BR plus polatuzumab vedotin will be capped at a maximum of 10% of participants; i.e. a maximum of 8 participants will be randomised to the BR plus polatuzumab vedotin regimen.~Participants from the SoC arm are allowed to be treated with CAR T-cell MB-CART2019.1 upon request by the investigator if at least one of the following criteria is confirmed by the IRC:~* Relapse or progression occurring at any time within 1 year after randomisation.~* Failure to achieve PR or CR at or beyond Week 8 after randomisation (after 4 cycles of R-GemOx or 3 cycles of BR plus polatuzumab vedotin) and the start of a new anti-lymphoma therapy is warranted."
61910511|NCT00691119|NO_INTERVENTION|C|Control group
61910512|NCT06421129||good prognosis|A good prognosis within 1-year post-surgery was defined as healing of the internal and external openings of the fistula, no recurrence of the fistula, no secondary perianal infection, no symptoms of incontinence, no persistent pain, and the ability of the patient to perform activities independently
61910513|NCT06421129||poor prognosis|outcomes that did not meet good prognosis criteria indicated a poor prognosis
61910514|NCT05926375|EXPERIMENTAL|first intervention group (Supp-Con sequence)|The first intervention group used HINEX Jelly as daily breakfast during the first to 8th weeks of the experiment, the 9th to 12th week is the wash out period, the 13th to the 20th week is the selfcontrol period.
61910515|NCT05926375|EXPERIMENTAL|post intervention group (Con-Supp sequence)|the post-intervention group is in the first to the 8th week of self-control period,the 9th to 12th week is the wash out period, and the 13th to the 20th week is used HINEX Jelly as daily breakfast.
61910516|NCT04645277||Patients with MRI using two dimensional reconstruction|
61910517|NCT04645277||Patients with MRI using three dimensional reconstruction|
61910518|NCT05094973|EXPERIMENTAL|Canine and molar distalization and molar derotation|Evaluating the canine and molar distalization and molar derotation in dental Class II patients who where submitted to Carriere Motion Appliance® for a mean of 4 months.
61910519|NCT06506591|EXPERIMENTAL|WD-890 1mg|Take a fixed dose of WD-890 tablets orally
61910520|NCT06506591|EXPERIMENTAL|WD-890 3mg|Take a fixed dose of WD-890 tablets orally
61910521|NCT06506591|EXPERIMENTAL|WD-890 6mg|Take a fixed dose of WD-890 tablets orally
61910522|NCT06506591|EXPERIMENTAL|WD-890 9mg|Take a fixed dose of WD-890 tablets orally
61910523|NCT06506591|PLACEBO_COMPARATOR|WD-890 Tablets Placebo|Take a fixed dose of WD-890 tablets Placebo orally
61910524|NCT01676467||Smoking asthma on steroids|Smokers with persistent asthma on background steroid therapy
61910525|NCT01676467||Smoking asthma steroid naïve|Smokers with persistent asthma, steroid naive
61910526|NCT01676467||asthma on steroids|Non-Smokers with persistent asthma on background steroid therapy
61910527|NCT01676467||asthma, steroid naïve|Non-smokers with persistent asthma, steroid naive
61910528|NCT01676467||Healthy smoking|Healthy smoking control subjects
61910529|NCT01676467||Healthy non-smoking|Healthy non-smoking control subjects
61910530|NCT00736515|EXPERIMENTAL|Combination therapy|The subjects allocated into this arm will receive the combination therapy of oral administration of 60\~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
61910531|NCT00736515|ACTIVE_COMPARATOR|monotherapy|The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.
62100409|NCT01021930|ACTIVE_COMPARATOR|Group A: DM|Coronary artery disease with diabetes mellitus
62100410|NCT01021930|ACTIVE_COMPARATOR|Group B: Non-DM|Coronary artery disease without diabetes mellitus
62100411|NCT02550054|EXPERIMENTAL|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
62100412|NCT02550054|PLACEBO_COMPARATOR|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
62100413|NCT05508360|EXPERIMENTAL|Lumbar Disc Nucleus Replacement|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
61910532|NCT02242591|ACTIVE_COMPARATOR|ACB_active/placebo|"Patients will receive the first ACB with a active drug, 30 ml bolus Ropivacaine 7,5 mg/ml at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60 (60 minutes after T0), patients will receive their second ACB with the placebo drug, 30 ml bolus Saline and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
62100414|NCT06345443|ACTIVE_COMPARATOR|830 mg Nicotinamide and Placebo|830 mg Nicotinamide supplement capsule and 1 identical Placebo capsule twice a day for 12 weeks
62100415|NCT06345443|ACTIVE_COMPARATOR|1660 mg Nicotinamide|1660 mg Nicotinamide supplement; 2 of the 830 mg capsules twice a day for 12 weeks
62100416|NCT06345443|PLACEBO_COMPARATOR|Placebo|2 identical Placebo capsules twice a day for 12 weeks
62100417|NCT06040476|EXPERIMENTAL|A group: hUCB treatment|Human cord blood infusion
62100418|NCT06040476|NO_INTERVENTION|B group: Placebo treatment|Placebo infusion
62100419|NCT06144684|PLACEBO_COMPARATOR|Placebo|placebo solution
62100420|NCT06144684|ACTIVE_COMPARATOR|GUB014295|GUB014295 solution 5 mg/mL
62466943|NCT05213273|EXPERIMENTAL|Group B: Canned fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish where at least 1-2 servings will be in the form of canned fish). A selection of canned fish (tuna, sardine, salmon and mackerel) will be administered to each volunteer for the duration of the study.
62466944|NCT02062580|ACTIVE_COMPARATOR|Delayed BCG|BCG delayed to 8 weeks of age
62466945|NCT02062580|OTHER|Early BCG|BCG at birth; standard of care
62466946|NCT04200014||Syncope and Implantable loop recorder|Patients implanted with a subcutaneous Loop Recorder after syncope in Nancy University Hospital
62466947|NCT01548248||Levemir® users|
62466948|NCT04256122||Responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.~* Patient treated with adjuvant MMC or BCG that did not experience recurrence for at least 42 months after TURBT~* Patients are tumor-free at the moment of the analysis"
62466949|NCT04256122||Non responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.~o Patient treated with adjuvant MMC or BCG that experienced recurrence in the first 24 months after TURBT."
61910533|NCT02242591|PLACEBO_COMPARATOR|ACB_placebo/active|"Patients will receive the first ACB with placebo, 30 ml isotonic saline at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60(60 minutes after T0), patients will receive their second ACB with the ropivacaine 7,5 mg/ml 30 ml and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
61910534|NCT01954927|ACTIVE_COMPARATOR|Gabapentin|Patients will be randomized to receive one dose of gabapentin.
61910535|NCT01954927|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to receive one dose of placebo.
62466950|NCT01629069|ACTIVE_COMPARATOR|Participant in MBRT|6 sessions of Mindfulness Based Resilience Training
62466951|NCT01162603|EXPERIMENTAL|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
61910536|NCT01150344|ACTIVE_COMPARATOR|Malarone|"Malarone (atovaquone + proguanil combination):~patients treated with Malarone®"
61910537|NCT01150344|ACTIVE_COMPARATOR|Riamet|"RIAMET (artemether + LUMEFANTRIN combination):~patients treated with Riamet®"
61910538|NCT01779271|EXPERIMENTAL|Pelubiprofen|
61910539|NCT01779271|ACTIVE_COMPARATOR|Loxoprofen|
61910540|NCT04045418||COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
61910541|NCT04045418||Healthy control group|This group will include 40 healthy volunteers.
61910542|NCT04045418||Healthy intervention group|This group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
61910543|NCT02984943|EXPERIMENTAL|Hyperbaric Oxygen|Hyperbaric Oxygen
62100421|NCT02979483|OTHER|Integrative Supportive Care|All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)
62100422|NCT05403450|EXPERIMENTAL|Phases 1 and 2: Tolinapant + Oral Decitabine/Cedazuridine|"Tolinapant, orally, once daily (QD) on Days 1 to 7 and 15 to 21 of each 28-day cycle in combination with oral decitabine/cedazuridine fixed-dose combination (FDC) tablet, QD on days determined by the Lead-in Phase during each 28-day cycle. The starting dose of tolinapant will be escalated stepwise in successive cohorts until the RP2D is determined.~Based on RP2D and results determined from Phase 1 participants would receive tolinapant at the identified RP2D in combination with decitabine/cedazuridine, FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle in Phase 2."
62662257|NCT00764517|EXPERIMENTAL|Relapsed|"Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) \[Group II\].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
62662258|NCT03719664|EXPERIMENTAL|Cohort 1: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
62662259|NCT03719664|EXPERIMENTAL|Cohort 2: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
61910544|NCT00538785|EXPERIMENTAL|Motavizumab|Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
61910545|NCT00538785|ACTIVE_COMPARATOR|Pailvizumab|Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
61910546|NCT02236351|PLACEBO_COMPARATOR|Control|Patients assigned to the Control Arm will be taught to apply their patches using the standard technique -- applying the patch evenly and flatly around the orbit.
62100423|NCT05403450|EXPERIMENTAL|Phase 1: Oral Decitabine/Cedazuridine|Decitabine/cedazuridine FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle.
62100424|NCT04940546|EXPERIMENTAL|Sintilimab + XELOX + Bevacizumab|"Patients receive Sintilimab + XELOX regimen every 3 weeks for 4 cycles and Bevacizumab every 3 weeks for 2 cycles.~Details are as follows:~Sintilimab: 200mg intravenously, d1 Oxaliplatin: 135mg/m2 intravenously, d1 Capecitabine: 2g/m2 orally, d1-14 for Bevacizumab: 7.5mg/kg intravenously, d1~After neoadjuvant treatment, if there are no new lesions upon radiological and Multidisciplinary Team (MDT) assessment, radical surgery is performed within 6 weeks. If there are new lesions the surgical team will assess the optimal time for surgery.~After surgery 4 cycles of XELOX regimen is advised for adjuvant therapy."
62100425|NCT06440850|EXPERIMENTAL|Treatment (vemurafenib and cobimetinib)|Patients receive vemurafenib PO BID for 6 weeks and cobimetinib PO QD for 3 weeks, followed by 1 week off, and then continuing for 2 weeks. Patients then receive iodine 131 PO followed by 3 additional days of vemurafenib PO BID and cobimetinib PO QD. Patients receive thyrogen IM daily for 2 days followed by I-123 diagnostic scan during screening and on study. Patients also undergo MRI during screening, PET scan or CT scan and blood sample collection throughout the study and ultrasound imaging and I-131 whole body scan during follow up.
62100426|NCT05854992||Cardiovascular Risk Group Treated with Triptans|Subjects with diagnosis of migraine and cardiovascular disease, cerebrovascular disease and/or two or more cardiovascular risk factors who received Triptans as part of clinical care.
62100427|NCT05854992||Cardiovascular Risk Control Group Treated with No Triptans|Subjects with who did not received Triptans as part of clinical care.
61910547|NCT02236351|EXPERIMENTAL|Pinched Patch|Patients assigned to the Pinched Patch Arm will be taught to apply their patches after pinching the middle of the superior and inferior edges of the patch so that the patch is convex and the center is raised above the eye.
62662260|NCT03719664|ACTIVE_COMPARATOR|Control Arm 1: Baseline ART|Subjects continuing on baseline ART
61910548|NCT02434471|NO_INTERVENTION|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
61910549|NCT02434471|ACTIVE_COMPARATOR|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
61910550|NCT03489954||Non-specific chronic neck pain group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
62100428|NCT05854992||Pregnant Women Group Treated with Triptans|Subjects diagnosed with migraine that received Triptans as part of clinical care during pregnancy.
62100429|NCT05854992||Pregnant Women Control Group Treated with No Triptans|Subjects that did not receive Triptans as part of clinical care during pregnancy.
62662261|NCT03719664|EXPERIMENTAL|Cohort 3: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
62100430|NCT05166174||Pregnant women who underwent previous cesarean section with barbed suture|"This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed by using barbed suture (Fish-bone suture)."
62100431|NCT05166174||Pregnant women who underwent previous cesarean section with conventional smooth suture|This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed conventional smooth suture.
62100432|NCT06096129||Spy PTC|People who had Spy PTC performed
62100433|NCT03192085|OTHER|SITA FAST then SITA STANDARD|SITA FAST and SITA STANDARD
61919808|NCT02810353|EXPERIMENTAL|Expander with differential opening group|The experimental group will comprise 25 patients who will be submitted to rapid maxillary expansion using the expander with differential opening. The expander will be composed by two 11-mm screws, one anteriorly and the other posteriorly positioned on the palate (Great lakes Orthodontics Ltd, NY, EUA).
62100434|NCT03192085|ACTIVE_COMPARATOR|SITA STANDARD then SITA FAST|SITA FAST and SITA STANDARD
62100435|NCT03374072|EXPERIMENTAL|Siblings FORWARD|Siblings who participate in the Siblings FORWARD program will participate in telehealth sessions with a community provider. The Siblings FORWARD program includes 6-7 sessions, depending upon whether the autistic adult participates. Siblings work with a program facilitator to develop a future plan of action. They learn communication and problem-solving skills, and about adult service systems.
62100436|NCT03374072|ACTIVE_COMPARATOR|Information Only Condition|We will create an online learning module for siblings in the control condition. Siblings in the control condition will be provided with access to the same information about resources for autistic adults provided to participants in the Siblings FORWARD program.
62294658|NCT06428214|OTHER|Restylane Shaype with Restylane Defyne|Participants will receive Restylane Shaype in the chin area and Restylane Defyne in the marionette line areas laterally to the chin.
62294659|NCT06428214|OTHER|Restylane Shaype with Restylane Defyne and Restylane Lyft Lidocaine|Participants will receive Restylane Shaype in the chin area and Restylane Defyne in the marionette line areas laterally to the chin. Participants in this group will be treated with Restylane Lyft lidocaine in the midface, nasolabial folds (NLF) and /or jawline.
62294660|NCT04321161|EXPERIMENTAL|AML relapse under DLI and Bicanorm treatment|Analysis of T cell metabolism, immune phenotype and serum pH before and after Bicanorm (Sodium bicarbonate) treatment.
62100437|NCT05218915|EXPERIMENTAL|GLP1-ra plus basal insulin (BGLP)|Dulaglutide and insulin degludec in combination with CGM
62100438|NCT05218915|ACTIVE_COMPARATOR|Basal bolus insulin (BB)|Insulin aspart/lispro and insulin degludec in combination with CGM
62100439|NCT02800161|ACTIVE_COMPARATOR|Trehalose|Trehalose 70g/die
62100440|NCT02800161|PLACEBO_COMPARATOR|Placebo|Maltose 70g/die
62294661|NCT05381909|EXPERIMENTAL|Phase 1a: Dose Escalation Part A|Participants will receive escalating doses of BGB-24714 as monotherapy
62294662|NCT05381909|EXPERIMENTAL|Phase 1a: Dose Escalation Part B|Participants will receive increasing dose levels of BGB-24714 in combination with paclitaxel
62100441|NCT03939520|EXPERIMENTAL|Combined therapy|
62100442|NCT03939520|ACTIVE_COMPARATOR|Switch monotherapy|
62100443|NCT03939520|OTHER|Control group|
62100444|NCT05496049|EXPERIMENTAL|Triburter|The intervention group will receive a triburter device for training, the patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day.
62100445|NCT05496049|ACTIVE_COMPARATOR|Incentive spirometry|For the control group (incentive spirometry) they will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks.
62100446|NCT06613776|EXPERIMENTAL|intervention group (Antibiotic)|4 amoxicillin 500 mg capsules (2 grams)
62100447|NCT06613776|PLACEBO_COMPARATOR|Control group (Placebo)|4 empty amoxicillin 500mg capsules
62100448|NCT06711211||Biliary Tract Cancer (BTC)|Patients diagnosed with cholangiocarcinoma or gallbladder carcinoma from 01-01-2017.
62100449|NCT06711211||Hepatocellular Carcinoma (HCC)|Patients with hepatocellular carcinoma primary diagnosed from 01-01-2017 and treated with systemic therapy.
62100450|NCT06711211||MSI-High Colorectal Cancer (MSI-H CRC)|Patients with MSI-High colorectal cancer (by PCR or IHQ) and primary pathological diagnosis from 01-01-2017.
62100451|NCT06711211||Pancreatic Cancer|Patients with exocrine pancreatic cancer diagnosed from 01-01-2019.
62100452|NCT06711211||Rectal Cancer|Patients diagnosed with rectal cancer from 01-01-2019.
62100453|NCT01928940|EXPERIMENTAL|dabrafenib + trametinib|Combination therapy of dabrafenib and trametinib
62100454|NCT04139694|EXPERIMENTAL|Cinnamon with Food Plan|Group of ladies who will undergo testing, receive dietary intervention, and take cinnamon supplements.
62294663|NCT05381909|EXPERIMENTAL|Phase 1a: Dose Escalation Part C|Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation
62294664|NCT05381909|EXPERIMENTAL|Phase 1a: Dose Escalation Part D|Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation
62100455|NCT04139694|ACTIVE_COMPARATOR|Food Plan Only|Group of ladies who will undergo testing, receive dietary intervention, but will not get cinnamon supplements.
62466952|NCT01162603|ACTIVE_COMPARATOR|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.
61910551|NCT03489954||Healthy group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
62100456|NCT01257503|EXPERIMENTAL|Homeopathic cold remedy|5 ml of homeopathic cold remedy given by mouth up to 6 times per day as needed for cold symptoms
62100457|NCT01257503|PLACEBO_COMPARATOR|placebo|5 ml of placebo given by mouth up to 6 times per day as needed for cold symptoms
62100458|NCT05228860|EXPERIMENTAL|Food and Lifestyle Intervention Group|The Food and Lifestyle Intervention Group will receive weekly household deliveries of healthy food as well as a lifestyle intervention (called Vida Sana) that will be delivered via Zoom and facilitated by a trained bilingual/bicultural health coach.
62100459|NCT05228860|EXPERIMENTAL|Waitlist Control Group|The waitlist control will continue usual care with no intervention for 6 months. To balance rigor with ethical considerations, they will receive the healthy food box deliveries after a 6 month waiting period.
62100460|NCT05555264|EXPERIMENTAL|Self-Guided Alcohol Change Course Enhanced|"Clients who select or are assigned the self-guided condition will receive access to 6 ICBT core lessons, 6 associated worksheets to enhance skill acquisition, and 8 additional resources addressing potential co-morbid concerns (e.g., Addressing Anger, Improving Assertiveness and Communication, Changing Cannabis Use, Developing Cognitive Coping, Coping with Grief, Understanding PTSD, Improving Sleep Quality, and Managing Worry). The 6 lessons and 6 associated worksheets are released at a rate of 1 per week over 7 weeks, with no new content being released to participants in Week 4. The 8 additional resources are available at any time during the course.~Clients will not receive therapist support/guidance during the 8-week intervention."
62100461|NCT05555264|EXPERIMENTAL|Therapist-Guided Alcohol Change Course Enhanced|"Clients who select the therapist-guided condition will receive access to 6 ICBT core lessons, 6 associated worksheets to enhance skill acquisition, and 8 additional resources addressing potential co-morbid concerns (e.g., sleep quality, cannabis use). The 6 lessons and 6 associated worksheets are released at a rate of 1 per week over 7 weeks, with no new content being released to participants in Week 4. The 8 additional resources are available at any time during the course.~Clients will receive therapist support/guidance during the 8-week intervention."
62466953|NCT01552499|OTHER|Control|
62100462|NCT02471365||Healthy Volunteers|Non-pregnant and non-nursing females between 35 and 74 who usesa high number (e.g., 15 or more products a day) of consumer products.
62294665|NCT05381909|EXPERIMENTAL|Phase 1a: Dose Escalation Part A-CN|Participants will receive escalating doses of BGB-24714 as monotherapy in Chinese participants
62294666|NCT05381909|EXPERIMENTAL|Phase 1a: Dose Escalation Part E|Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation in Chinese participants
62294667|NCT05381909|EXPERIMENTAL|Phase 1b: Dose Expansion|BGB 24714 will be administered in combination with paclitaxel or docetaxel in participants with selected solid tumors.
62294668|NCT01116050|PLACEBO_COMPARATOR|Placebo|
62294669|NCT01116050|EXPERIMENTAL|MISOPROSTOL|
62308170|NCT03084159|NO_INTERVENTION|Usual Care|A second site included usual care, which did not include the intervention. Participants were given post visit surveys similar to those in the two other study / intervention arms. This site served as a usual care comparison.
62466954|NCT01552499|EXPERIMENTAL|Treatment|
62466955|NCT02438722|EXPERIMENTAL|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61910552|NCT03373227|EXPERIMENTAL|Prospective|25 adult male or female recipients of a heart transplant will be prospectively enrolled to once-daily therapy with Envarsus tablets. Time of initiation will follow current standard of care.
61910553|NCT03373227|NO_INTERVENTION|Retrospective|25 age/gender-matched subjects who are receiving twice daily dosing with Prograf will be identified from the transplant center database and contacted to be consented, after which their results will be analyzed retrospectively.
62100463|NCT01251614|EXPERIMENTAL|Adalimumab 0.4 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.
62100464|NCT01251614|EXPERIMENTAL|Adalimumab 0.8 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
62100465|NCT01251614|ACTIVE_COMPARATOR|Methotrexate|Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
62100466|NCT06711744|ACTIVE_COMPARATOR|TISSUE LEVEL X|Implants with aggressive macro design
62100467|NCT06711744|EXPERIMENTAL|TISSUE LEVEL C|Implants with less aggressive macro design
61910554|NCT02884700||Severe legionellosis cases|Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.
61910555|NCT03862508|EXPERIMENTAL|Experimental|Five Plyometric exercises
61910556|NCT03862508|NO_INTERVENTION|Control|Subjects included in the control group will not receive any intervention
61919809|NCT02810353|ACTIVE_COMPARATOR|Hyrax group|The control group will be comprised by 25 patients who will undergo rapid maxillary expansion using the conventional Hyrax expander. The expander will be composed by one 11-mm screw centrally positioned on the palate (Dentaurum, Ispringen, Germany).
62466956|NCT02438722|ACTIVE_COMPARATOR|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62466957|NCT01448798|EXPERIMENTAL|gelatine-thrombin matrix|Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix.
62662262|NCT03719664|EXPERIMENTAL|Cohort 4: albuvirtide & 3BNC117|albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
62662263|NCT03719664|EXPERIMENTAL|Optimal Dose: albuvirtide & 3BNC117|albuvirtide and 3BNC117 every 2 or 4 weeks
62100468|NCT03649555|EXPERIMENTAL|[18F]-FTC-146|\[18F\]-FTC-146
62100469|NCT06489249|EXPERIMENTAL|Placebo then Salsalate|Placebo oral table twice daily for 4 days prior to experimental testing followed by 14 day washout period and then salsalate oral tablet 1500mg twice daily for 4 days prior to experimental testing.
62100470|NCT06489249|EXPERIMENTAL|Salsalate then Placebo|Salsalate oral tablet 1500mg twice daily for 4 days prior to experimental testing followed by 14 day washout period and then placebo oral tablet twice daily for 4 days prior to experimental testing.
62100471|NCT03656133|EXPERIMENTAL|Radiotherapy Fractionation|"Investigators will use an individual patient proliferation saturation index (PSI) to select radiotherapy fractionation (conventional fractionation or hyperfractionation) to improve the likelihood of a rapid response (defined as ≥ 32% reduction in volume at 4 weeks).~Radiotherapy fractionation: Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)"
62100472|NCT03132454|EXPERIMENTAL|Arm I (palbociclib, sorafenib)|Patients receive palbociclib PO QD on days 1-28. Patients also receive sorafenib PO QD on days 1-28 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62100473|NCT03132454|EXPERIMENTAL|Arm II (palbociclib, decitabine)|Patients receive palbociclib as in Arm I. Beginning cycle 2, patients receive palbociclib PO QC on days 1-7 and decitabine IV QD over 1 hour on days 8-17 of cycle 2 and days 8-12 of cycles 3-8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62100474|NCT03132454|EXPERIMENTAL|Arm III (palbociclib, dexamethasone)|Patients receive palbociclib as in Arm I. Patients also receive dexamethasone PO QD or IV over 15-30 minutes on days 1-4 and 15-18 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62100475|NCT05251259|EXPERIMENTAL|Lead-in PK Cohort (Atuliflapon)|Randomised participants will receive Atuliflapon
62100476|NCT05251259|EXPERIMENTAL|Part 1: Atuliflapon|Randomised participants will receive Atuliflapon
62100477|NCT05251259|PLACEBO_COMPARATOR|Lead-in PK, Part 1 Placebo|Randomised participants will receive placebo
62100478|NCT06554444|EXPERIMENTAL|Dental implant placement in the posterior mandible|In this study, patients who have tooth loss in the posterior mandible and meet the inclusion criteria will receive dental implants under local anesthesia
62294670|NCT05873712|EXPERIMENTAL|Treatment (zanubrutinib, liso-cel)|Patients receive zanubrutinib PO, undergo leukaphereis, and receive fludarabine IV, cyclophosphamide IV, and liso-cel IV on study. Patients also undergo BM biopsy and lymph node biopsy at screening and follow up, and undergo collection of blood samples and CT, PET/CT, and/or MRI throughout the trial.
62294671|NCT05029557|NO_INTERVENTION|Control group patients|The patients in the Control Group will continue their routine procedures.
62308171|NCT03894540|EXPERIMENTAL|IPN60090|"Part 1: Dose escalation of IPN60090, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle"
62466958|NCT01448798|SHAM_COMPARATOR|Control|Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping.
62662264|NCT03719664|ACTIVE_COMPARATOR|Control Arm 2: Baseline ART|Subjects continuing on baseline ART
62662265|NCT06364527|EXPERIMENTAL|Participants with fractioned exhaled nitric oxide ≥ 45 ppb|Group 1 consists of 59 participants with a fractioned exhaled nitric oxide ≥ 45 ppb and ≥ 3 exacerbations / year (biologic eligible). Group 2 consists of 59 participants with a fractioned exhaled nitric oxide ≥ 45 ppb and \< 3 exacerbations / year (biologic ineligible).
62662266|NCT02342730|EXPERIMENTAL|Weight Loss Referral|Patients are referred to a weight loss specialist for assistance with weight loss and medical chart reviews are performed at baseline and every 3 months for 24 months. Patients complete Quality-of-Life Assessment (EORTC- QLQ-C30 and EORTC-QLQ-EN24) at baseline, 12, and 24 months. Patients are also contacted at 90 days to determine whether they have initiated any weight loss interventions.
62662267|NCT06390215|EXPERIMENTAL|School Readiness Coaching Intervention|Two 1-hr individualized parent-child School Readiness Coaching Sessions conducted with Community Health Worker to assess child and parent school readiness skills and behaviors and provide parents with modeling, tools, and resources to support parent early math and literacy skills for home practice and connect them to preschool and community resources.
62662268|NCT00627978|EXPERIMENTAL|Ixabepilone|Participants are treated with Ixabepilone.
62662269|NCT00627978|NO_INTERVENTION|Control|
62662270|NCT02133963||women with no history of depression|Non-Probability Sample of women with no history of depression
62662271|NCT02133963||women with a past depression history|Non-Probability Sample of women with a past history of depression
62100479|NCT02096289|EXPERIMENTAL|Thioridazine|Up to 3 dose levels of thioridazine will be assessed sequentially: 25 mg Q6H (Level I), 50 mg Q6H (Level II) and 100 mg Q6H (Level III). The duration of thioridazine therapy is for a total of 21 days (Days 1-22 on study). All patients will receive cytarabine 1 g/m2 administered as a 2 hour infusion for 5 consecutive days (Days 6-10 on study).
62100480|NCT02583074|EXPERIMENTAL|Stimulation Group|Patients in 'Neurostimulation Group' will receive subthalamic nucleus deep brain stimulation for 3 months.
62294672|NCT05029557|EXPERIMENTAL|Education and telephone follow ups based on the Chronic Care Model|Intervention Group will be given training (0 months) with the training booklet, which is prepared by the researcher based on the Chronic Care Model, and which includes information and suggestions about self-management strategies. The training will be organized in one single session in a way not to exceed approximately 45-50 minutes. The patients, who will be included in the Intervention Group, will be followed up by phone every two weeks. Also, reminders and informative information based on the training booklet will be sent to patients every week in the form of a short message.
62294673|NCT05569135||Debridement only|Debridement of the pilonidal cyst through pits was performed in this group. After the removal of hair and necrotic tissues through pits, the surgical site was covered with a simple gauze dressing for 1 day. Patients were allowed to return to work and sit freely on the day of surgery.
62662272|NCT05814835|EXPERIMENTAL|68Ga/64Cu-FAPI-XT117 PET/CT|Each patient will receive 2-4 mCi, 4-6 mCi or 6-8 mCi 68Ga/64Cu-FAPI-XT117 intravenously (IV), and then PET/CT scanning within the specified time. On another day, patients receive 18F-FDG and then undergo PET/ CT.
62100481|NCT02583074|SHAM_COMPARATOR|Sham-stimulation Group|Patients in 'Sham-stimulation Group' will receive sham stimulation of subthalamic nucleus for 3 months.
62100482|NCT06527027|SHAM_COMPARATOR|Lymph node assessment according to RECIST 1.1|
62100483|NCT06527027|EXPERIMENTAL|Lymph node assessment according to LN-RADS|
62100484|NCT06527027|EXPERIMENTAL|Lymph node assessment according to Node-RADS|
62100485|NCT06678516|EXPERIMENTAL|Intermittent fasting|One month of intermittent fasting.
62100486|NCT06678516|NO_INTERVENTION|Ad libitum diets|One month of ad libitum diets (no fasting and/or restriction).
62100487|NCT06707987||Non-immunogenic staphylokinase|Drug: non-immunogenic staphylokinase
62100488|NCT05295225|ACTIVE_COMPARATOR|Green Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a green light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
62100489|NCT05295225|PLACEBO_COMPARATOR|White Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a white light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
62100490|NCT06707675||MPS|Patients aged between 18-65 who applied to the AFSÜ PTR Polyclinic and had complaints of neck and back pain for at least 3 months and were diagnosed with myofascial pain syndrome based on anamnesis and physical examination.
62100491|NCT05783817|EXPERIMENTAL|MDMA-assisted cognitive behavioral therapy|Administration of 80mg MDMA HCl (with a supplemental dose offered 1.5 to 2 hours later of 40 mg MDMA HCl) in combination with cognitive behavioral therapy (CBT).
62100492|NCT05783817|ACTIVE_COMPARATOR|Methamphetamine-assisted cognitive behavioral therapy|Administration of 10mg methamphetamine (with a supplemental dose offered 1.5 to 2 hours later of 5 mg methamphetamine) in combination with cognitive behavioral therapy (CBT).
62100493|NCT04773002||Group P|Total intravenous anesthesia (TIVA)
62100494|NCT04773002||Group S|Volatile anestesia
62100495|NCT03417843|EXPERIMENTAL|EUSRA RF electrode|new ablation catheter RFA (RADIOFREQUENCY under EUS), developed by TAEWOONG company for the treatment of pancreatic premalignant and early malignant cystic lesion.
62100496|NCT06390488|EXPERIMENTAL|T-MPNS|In this study, the stimulation device will be connected to the patient via channel 1, and active stimulation will be performed. Channel 2 will not be connected to the patient, thus no stimulation will be given through this channel. Both channels will utilize a stimulation protocol set to continuous mode with a frequency of 20 Hz and a pulse width of 200 ms. The intensity of the current for channel 1 (ranging from 0 to 50 mA) will be determined based on the comfort level of the patient after ensuring correct positioning. Correct positioning will be confirmed by observing a hallux reaction (plantar flexion of the big toe or, rarely, fanning of the fingers). T-MPNS sessions will be conducted twice a week for 6 weeks, with each session lasting 30 minutes. The intervention will consist of a 12-session T-MPNS treatment program.
62294674|NCT05569135||Debridiment with laser ablation|This group underwent the same procedure as the debridement group. After the removal of hair and necrotic tissues through pits, a diode laser at 1470 wavelength was inserted and the pilonidal cavity was ablated in a continuous fashion. The surgical site was covered with a simple gauze dressing for 1 day. Patients were allowed to return to work and sit freely on the day of surgery.
62294675|NCT03912584|OTHER|Optical Coherence Tomographer|
62294676|NCT02495337||TIssue Collection|Only one arm will be used to collect tissue from Esophageal Adenocarcinoma
62294677|NCT04116021|ACTIVE_COMPARATOR|PECS block|Ultrasound-guided pectoral nerve block with bupivacaine 0.5 % 30 mL before surgical incision
62294678|NCT04116021|ACTIVE_COMPARATOR|Wound infiltration|Wound infiltration with bupivacaine 0.5 % 30 mL at the end of surgery
62294679|NCT05922202||COPD outpatients|Outpatients with COPD. COPD diagnosis confirmed by spirometry and according to Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines.
62294680|NCT00887952|EXPERIMENTAL|1|Partial removal of carious dentine. Carious dentine partial removal plus restoration in one session. The group is divided according to the filling material: amalgam or resin.
62466959|NCT03478748|ACTIVE_COMPARATOR|one-to-one dental health education|Conventional oral health education programme that mainly focuses at child level, which has been the normal practice at the Ministry of Health, were provided to the control participants.
62466960|NCT03478748|EXPERIMENTAL|anticipatory guidance technique|Anticipatory guidance technique were applied where appropriate dental health education (according to the children's milestones) were provided to mothers and their children.
62466961|NCT03567174|EXPERIMENTAL|Integrated care van (ICV)|ICV visits neighborhoods served by the mobile syringe service program weekly. ICV provides a range of services targeted to people who inject drugs - HIV testing, HCV testing, PrEP, MAT, wound care, case work services, on-site medical management and linkage.
62466962|NCT03567174|NO_INTERVENTION|Control|No additional services provided.
62466963|NCT00825110||No treatment|confirmed diagnosis of colorectal carcinoma
61919810|NCT02779387|EXPERIMENTAL|GnRH-a|"patients treated with GnRH-a after surgery and Outpatient guidance~."
61919811|NCT02779387|NO_INTERVENTION|non GnRH-a|patients treated with outpatient guidance only.
61919812|NCT00075439|EXPERIMENTAL|Arm I|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61919813|NCT01070797|EXPERIMENTAL|Group A|Group A is for CMV seropositive donors.
61919814|NCT01070797|EXPERIMENTAL|Group B|Group B is for CMV seronegative donors.
61919815|NCT01475071|EXPERIMENTAL|Metvix and daylight|
61919816|NCT01475071|ACTIVE_COMPARATOR|Metvix and lamp|
61919817|NCT05588804|EXPERIMENTAL|Group 1: Broncho-munal®|Participants will receive the study drug Broncho-munal®, capsules, 7 mg (Sandoz dd, Slovenia), 1 capsule per day in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
61919818|NCT05588804|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive a placebo, 1 capsule per day in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
61919819|NCT02482207|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 10 mg qd for 1 year and life style modification
61919820|NCT02482207|PLACEBO_COMPARATOR|Placebo|Life style modification alone
61919821|NCT00644644||1|monitored
61919822|NCT00644644||2|control
61919823|NCT04341753|EXPERIMENTAL|Pulmonary rehabilitation|"In addition to the usual evaluation, other tests will be carried out in addition and specifically for this study:~* the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~* 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
61919824|NCT02021656|EXPERIMENTAL|LDV/SOF|Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.
61919825|NCT03475875|EXPERIMENTAL|TEST/CONTROL/CONTROL|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
61919826|NCT03475875|EXPERIMENTAL|CONTROL/TEST/TEST|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
61919827|NCT05202470|EXPERIMENTAL|Telehealth Education (TE)|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
61919828|NCT05202470|ACTIVE_COMPARATOR|Conventional Education (CE)|Paper-based education forms will be given to the patients in the first group. Face-to-face conventional diabetes education will be carried out.
61919829|NCT03905447|EXPERIMENTAL|PC945|
61919830|NCT03905447|OTHER|Standard of Care|Standard of care anti-fungal medication
61919831|NCT02402842|EXPERIMENTAL|DCF regimen|docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days
62662273|NCT06532773|EXPERIMENTAL|Nite2Day+|During inpatient treatment, Nite2Day+ will be delivered via a self-paced mobile app. Participants will use the app to access: 1) mindfulness meditations (e.g., Body Scan, 3-Minute Mini-Meditation) from Mindfulness Based Therapy for Insomnia (MBTI); 2) brief, 3-5 minute sleep education videos (i.e., 3-P Model of Insomnia, sleep hygiene, sleep drive, circadian rhythm) specifically tailored to the inpatient setting; and 3) brief, 3-5 minute videos teaching behavioral strategies (e.g., stimulus control, daytime activity, light exposure, communication with medical team) to improve sleep quality in the hospital. After inpatient treatment, Nite2Day+ will deliver a six session (45-60 minutes), therapist-led, Zoom protocol. Participants will learn new mindfulness-based sleep strategies (e.g., sleep consolidation, sleep reconditioning), meditations (e.g., Sitting Meditation), and behavioral symptom coping skills.
62662274|NCT06532773|NO_INTERVENTION|Usual Care|Participants will receive written materials describing free services (e.g., legal and financial assistance, counseling) available through the Duke Cancer Patient Support Program.
62662275|NCT02187055|EXPERIMENTAL|Tofacitinib 5 mg twice daily with methotrexate|
62662276|NCT02187055|EXPERIMENTAL|Tofacitinib 5 mg twice daily monotherapy|
62662277|NCT02187055|ACTIVE_COMPARATOR|Adalimumab with methotrexate|
62662278|NCT02847767|EXPERIMENTAL|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution.
62662279|NCT04598113|ACTIVE_COMPARATOR|Effective Traction/Sham Traction|Group of patients treated firstly with Effective Traction then with Sham Traction
62662280|NCT04598113|SHAM_COMPARATOR|Sham Traction/Effective Traction|Group of patients treated firstly with Sham Traction then with Effective Traction
62100497|NCT06390488|SHAM_COMPARATOR|Sham T-MPNS|In the Sham T-MPNS group, patients will receive stimulation with the same electrotherapy device, same patient and electrode positioning, and identical current characteristics as the T-MPNS group. Channel 2 of the device will be connected to the patient without delivering stimulation, while channel 1 will not be connected but will display current intensity and treatment duration on the device screen. The current intensity on channel 1 will only be able to be increased up to 2-3 mA to prevent patients from exceeding this level. Patients will be advised that higher stimulations might negatively affect treatment outcomes. All patients, including those in the placebo group, will be informed that the absence of motor or sensory responses during treatment does not imply ineffectiveness, alleviating concerns about lack of sensation. Sham T-MPNS sessions will be conducted twice weekly for 6 weeks, with each session lasting 30 minutes, totaling 12 sessions.
62100498|NCT06055621|EXPERIMENTAL|DASATINIB|
62100499|NCT03875690|EXPERIMENTAL|Experimental group|
62662281|NCT06545864||patients who received systemic thrombolysis|patients have been diagnosed with acute intermediate-high pulmonary embolism received I.V. streptokinase if there are no contraindications.
62100500|NCT03875690|PLACEBO_COMPARATOR|Control group|
62662282|NCT06545864||patients who underwent catheter-based intervention|patients have been diagnosed with acute intermediate-high pulmonary embolism underwent catheter-based intervention including thrombus aspiration or catheter directed thrombolysis using Penumbra System
62662283|NCT02130141|EXPERIMENTAL|Dark chocolate, dietary counselling|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
62662284|NCT02130141|ACTIVE_COMPARATOR|Dietary counselling|Usual snacks are limited.
62662285|NCT02262871|EXPERIMENTAL|CF patients HFN|CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.
62662286|NCT02262871|EXPERIMENTAL|CF patients NIV|CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.
62662287|NCT03022448||Treatment Group|Trabectedin will be used according to the local SmPC. Modification of the treatment schedule should follow the standard medical practice at the discretion of the treating physician and is not part of this Observational Plan.
62662288|NCT02689778|EXPERIMENTAL|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.
62662289|NCT02689778|PLACEBO_COMPARATOR|Placebo|Oral placebo with breakfast and with dinner for 12 months.
62662290|NCT02961660|EXPERIMENTAL|Cohort 1 (Severe Renal Impairment): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
62294681|NCT00887952|ACTIVE_COMPARATOR|2|Stepwise excavation: Carious dentine removal performed in 2 steps: partial removal of carious dentine, indirect pulp capping (calcium hydroxide cement); temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling (amalgam or resin).
62294682|NCT04151108||Old medical patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.~Will be assessed at admission"
62466964|NCT00696020|EXPERIMENTAL|BI 1744 CL low dose/tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
62662291|NCT02961660|EXPERIMENTAL|Cohort 2 (Normal Renal Function): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
62662292|NCT03669679|ACTIVE_COMPARATOR|Group A|"participants undergoing superomedial pedicle breast reduction Hall-Findlay technique"
62662293|NCT03669679|ACTIVE_COMPARATOR|Group B|"participants undergoing inferior pedicle breast reduction Robbins technique"
62662294|NCT05422885|EXPERIMENTAL|Arm 1|Dasatinib and Quercetin
62662295|NCT04871113|EXPERIMENTAL|Part 1:GSK3810109A 40milligram(mg)/kilogram intravenously (IV)|Participants with human immunodeficiency viruses-1 (HIV-1) received GSK3810109A as a single intravenous (IV) infusion of 40 milligrams per kilogram (mg/kg) dose based on individual bodyweight on Day 1 in part 1.
62662296|NCT04871113|EXPERIMENTAL|Part 1: GSK3810109A 280 mg IV|Participants with HIV-1 received GSK3810109A as a single IV infusion of 280 mg dose on Day 1 in part 1.
62662297|NCT04871113|EXPERIMENTAL|Part 2: GSK3810109A 700 mg IV|Participants with HIV-1 received GSK3810109A as a single IV infusion of 700 mg dose on Day 1 in part 2. This included dose level determined based on the data of part 1.
62100501|NCT05473520|EXPERIMENTAL|Doxycycline + standard anti-tuberculous treatment|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
62100502|NCT05473520|PLACEBO_COMPARATOR|Placebo + standard anti-tuberculous treatment|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15-20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician.
62100503|NCT05366361||Patients Undergoing Clinically-Indicated Maze Surgery|This group includes patients with persistent AF who will be undergoing clinically-indicated Maze surgery.
62100504|NCT05366361||Patients Undergoing Clinically-Indicated Ablation|This groups includes patients with persistent AF who will be undergoing clinically-indicated ablation.
62100505|NCT06562608|EXPERIMENTAL|Anticholinergic Deprescription|In this arm, clinically determined unneeded benztropine or trihexyphenidyl will be deprescribed, per routine care by clinical providers.
62100506|NCT06562608|ACTIVE_COMPARATOR|No Anticholinergic Deprescription|In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
62100507|NCT06562608|NO_INTERVENTION|Healthy Controls|In this arm, a healthy control group with minimal anticholinergic burden will be examined longitudinally.
62100508|NCT06696300|ACTIVE_COMPARATOR|Classical Physiotherapy Group|
62100509|NCT06696300|EXPERIMENTAL|Foundation Inspiratory Muscle Training|
62466965|NCT00696020|EXPERIMENTAL|BI1744CL medium dose/tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
62662298|NCT04871113|EXPERIMENTAL|Part 2: GSK3810109A 70 mg IV|Participants with HIV-1 received GSK3810109A as a single IV infusion of 70 mg dose on Day 1 in part 2. This included dose level determined based on the data of part 1.
62662299|NCT04871113|EXPERIMENTAL|Part 2: GSK3810109A 700 mg subcutaneously (SC)|Participants with HIV-1 received GSK3810109A as a subcutaneous (SC) injection of total 700 mg dose administered as three equally divided SC injections of 2.33 mL each (approximately 7 mL) in quick succession at same time on Day 1 in part 2. This included dose level determined based on the data of part 1.
62662300|NCT04871113|EXPERIMENTAL|Standard of care (SOC) - GSK3810109A 40mg/kg IV|Participants who completed the monotherapy phase of treatment of GSK3810109A 40mg/kg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
62100510|NCT06696300|EXPERIMENTAL|Functional Inspiratory Muscle Training Group|
62294683|NCT04151108||Geriatric patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, gait-speed, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.~Blood tests, physical function measures and body composition will be assessed at both admission and discharge."
62294684|NCT03533166|EXPERIMENTAL|Chlorhexidine|Mechanical treatment + 0.03% chlorhexidine + 0.05% CPC mouthrinse
62466966|NCT00696020|EXPERIMENTAL|BI 1744 CL high dose/tiotropium bromide|BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
62466967|NCT00696020|EXPERIMENTAL|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
62466968|NCT01932086|EXPERIMENTAL|White rice|
62466969|NCT01932086|EXPERIMENTAL|Brown rice|
61919832|NCT01369485|ACTIVE_COMPARATOR|Active Treatment group|VERV™ System
61919833|NCT01369485|SHAM_COMPARATOR|Sham Treatment Group|Sham version of (VERV™ System)
62294685|NCT03533166|PLACEBO_COMPARATOR|Placebo|Mechanical treatment + Placebo mouth rinse
62294686|NCT04816240|EXPERIMENTAL|Midodrine + Albumin +Standard Medical Treatment|SMT + Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).
62294687|NCT04816240|ACTIVE_COMPARATOR|Albumin + Standard Medical Treatment+ Placebo|80grams/week for 2 weeks followed by 40gram/week + Placebo
62466970|NCT01932086|EXPERIMENTAL|Black rice|
62466971|NCT01932086|ACTIVE_COMPARATOR|Bread|
62466972|NCT01932086|ACTIVE_COMPARATOR|Glucose solution|
62466973|NCT03982862|ACTIVE_COMPARATOR|control group|0.9% Normal saline 0.1 ml +Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1cm2 scar volume
62662301|NCT04871113|EXPERIMENTAL|SOC - GSK3810109A 280 mg IV|Participants who completed the monotherapy phase of treatment of GSK3810109A 280 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
61910557|NCT04800952|OTHER|To establish the appropriate dosing regimens of newly available antibiotics during CRRT|High dose (world standard dose) and low dose CRRT (Japan local) CRRT protocol Vascular access will be obtained by inserting a double-lumen dialysis catheter into the internal jugular or femoral veins. High dose CRRT in Australia, Blood flow through the extracorporeal circuit will be maintained at 150 ml/min. The CVVHF replacement volume will be set at 25ml/kg/hour and bicarbonate-buffered replacement fluids will be added in post-dilutional mode. Low dose CRRT in Japan, Blood flow through the extracorporeal circuit will be maintained at 80 ml/min. CVVHF replacement volume will be set at 15ml/kg/hour and bicarbonate-buffered replacement fluids will be added in the post-dilutional mode. Fluid balance, volume removal and the duration of CVVHF will be determined by the ICU physician based on the patient's individual clinical status.
62100511|NCT04753996||Primary Sclerosing Cholangitis (PSC)|Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
61910558|NCT00634738|EXPERIMENTAL|one|
61910559|NCT04023929||Term babies|Babies who are born at or after 37 gestational weeks.
61910560|NCT04023929||Preterm babies|Babies who are born between 32 and 36+6 gestational weeks.
61910561|NCT04023929||Very preterm babies|Babies who are born before 32 gestational weeks.
61910562|NCT05951465|EXPERIMENTAL|eskatemine 0.3mg/kg + propofol|eskatemine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
62100512|NCT04753996||Control (non-PSC)|Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
62100513|NCT01021332|EXPERIMENTAL|Total Group|Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
62100514|NCT06711705|EXPERIMENTAL|Elranatamab|Treatment with elranatamab
62100515|NCT05154799|EXPERIMENTAL|Dyspraxic children|Children with Developmental coordination disorder
62100516|NCT05154799|EXPERIMENTAL|Control children|Healthy children
62100517|NCT05154799|EXPERIMENTAL|Dyspraxic adults|Adults with with Developmental coordination disorder
62100518|NCT05154799|EXPERIMENTAL|Control adults|Control adults
62100519|NCT00372216|ACTIVE_COMPARATOR|1|Pre-hospital loading dose of 600 mg Clopidogrel as early as possible (in addition to standard infarction therapy)
62466974|NCT03982862|EXPERIMENTAL|botox group|4U Botox® diluted to 0.1 ml + Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1 cm2 scar volume
62466975|NCT04441970|ACTIVE_COMPARATOR|Neutral position|General anesthesia will be induced and nasotracheal tube will be placed through the patient's nose. After 30 seconds, the cuff pressure will be measured using a cuff manometer. Inspiratory tidal volume, expiratory tidal volume, peak inspiratory pressure, and end-tidal carbon dioxide waveform will be recorded three times according to breathing. Whether ventilation is not adequate and air is leaking will be recorded.
62100520|NCT00372216|NO_INTERVENTION|2|Standard infarction therapy (without study-specific additions, no Clopidogrel before angiography)
61910563|NCT05951465|EXPERIMENTAL|eskatemine 0.6mg/kg + propofol|eskatemine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
61910564|NCT05911594|EXPERIMENTAL|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
61910565|NCT05911594|EXPERIMENTAL|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
62100521|NCT00088465|EXPERIMENTAL|Intramuscular Olanzapine Depot|Intramuscular (IM) olanzapine depot flexible dosing and flexible interval
62294688|NCT06340919|NO_INTERVENTION|Control|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to OFF.
62466976|NCT04441970|EXPERIMENTAL|Head extension position|After changing the posture of the head and neck into head extension, cuff pressure will be recorded.
61910566|NCT05911594|EXPERIMENTAL|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after the failure of medical therapy
61910567|NCT05911594|EXPERIMENTAL|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after the failure of medical therapy
61910568|NCT02762773|EXPERIMENTAL|Experimental|Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
61910569|NCT02762773|PLACEBO_COMPARATOR|Control|Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery
61910570|NCT01643031|EXPERIMENTAL|Ticagrelor|Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).
61910571|NCT01643031|ACTIVE_COMPARATOR|Continued Clopidogrel|Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
62100522|NCT02734004|EXPERIMENTAL|Arm 1|Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1
62100523|NCT02734004|EXPERIMENTAL|Arm 2|Includes 2nd stage cohorts (modules 5 \& 7): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1
62294689|NCT06340919|EXPERIMENTAL|Low Sudden Sound Reduction|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low.
62294690|NCT06340919|EXPERIMENTAL|High Sudden Sound Reduction|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to High.
62466977|NCT04441970|EXPERIMENTAL|Head flexion position|After changing the posture of the head and neck into head flexion, cuff pressure will be recorded.
62662302|NCT04871113|EXPERIMENTAL|SOC - GSK3810109A 700 mg IV|Participants who completed the monotherapy phase of treatment of GSK3810109A 700 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
62662303|NCT04871113|EXPERIMENTAL|SOC - GSK3810109A 70 mg IV|Participants who completed the monotherapy phase of treatment of GSK3810109A 70 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
61910572|NCT00998218|EXPERIMENTAL|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) for 4 weeks
61910573|NCT00998218|PLACEBO_COMPARATOR|Sugar pill|Placebo comparator BID for 4 weeks.
61910574|NCT02819908|ACTIVE_COMPARATOR|Imprimis Dropless|TriMoxiVanc 0.2cc intravitreal one time
62100524|NCT02734004|EXPERIMENTAL|Arm 3|Includes 2nd stage cohort (module 6): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1
62100525|NCT01841840|NO_INTERVENTION|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
62100526|NCT01841840|EXPERIMENTAL|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
62100527|NCT01841840|EXPERIMENTAL|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
61910575|NCT02819908|ACTIVE_COMPARATOR|Imprimis Less Drops|Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
61910576|NCT06071728|ACTIVE_COMPARATOR|Endocalyx Pro|Subjects will receive 6 capsules per day (3,712mg) of Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572), a commercially available supplement that includes a proprietary blend of glycocalyx precursors and antioxidants
62100528|NCT05877560|ACTIVE_COMPARATOR|NIBS-OBVAT|8 sessions of non-invasive brain stimulation with 8 weeks of office-based vergence/accommodative therapy.
62100529|NCT05877560|ACTIVE_COMPARATOR|NIBS|8 sessions of non-invasive brain stimulation only.
62662304|NCT04871113|EXPERIMENTAL|SOC - GSK3810109A 700 mg SC|Participants who completed the monotherapy phase of treatment of GSK3810109A 700 mg SC entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
62662305|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
61910577|NCT06071728|PLACEBO_COMPARATOR|Placebo|Subjects will ingest placebo pills
61910578|NCT01520428|ACTIVE_COMPARATOR|Motivational Interviewing, CBT and E-mail support|
62100530|NCT05877560|SHAM_COMPARATOR|OBVAT|8 sessions of sham stimulation with 8 weeks of office-based vergence/accommodative therapy.
62100531|NCT04692714|EXPERIMENTAL|Experimental knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented without additional cement using the MAKO robot
62100532|NCT04692714|ACTIVE_COMPARATOR|Conventional knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented with additional cement using the MAKO robot
61910579|NCT01520428|ACTIVE_COMPARATOR|E-Mail-support|
62100533|NCT06712030|EXPERIMENTAL|Sacubitril/Valsartan|Sacubitril/valsartan up to maximum tolerated dose
62100534|NCT06712030|NO_INTERVENTION|No treatment|No initiation of Sacubitril/valsartan
62294691|NCT06340919|EXPERIMENTAL|Maxiumum Sudden Sound Reduction|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Maximum.
62294692|NCT02829879|EXPERIMENTAL|arginine|25 volunteers with dentin sensitivity
62294693|NCT02829879|ACTIVE_COMPARATOR|potassium nitrate|25 volunteers with dentin sensitivity
62466978|NCT04441970|EXPERIMENTAL|Head rotation position|After changing the posture of the head and neck into head rotation, cuff pressure will be recorded.
62466979|NCT04738071||Sex|Female and male patients
62662306|NCT03097263||Patients|Patients included for rehabilitation program
61910580|NCT02980952|PLACEBO_COMPARATOR|Energy-balanced diet|Forearm immobilization whilst consuming an energy-balanced diet
61910581|NCT02980952|EXPERIMENTAL|High-fat overfeeding|Forearm immobilization whilst consuming a high-fat diet, 50% energy excess
62100535|NCT06341374||Participants who have had severe COVID-19 infection with sleep disturbance|"This cohort of participants will be recruited from participants in ongoing study in our institution (CEIm 2021/5096) where exploring contributions of sleep disorders on severity of COVID-19.~To explore present sleep status participants will be asked to fill out sleep questionnaires referred to their sleep characteristics since COVID-19 episode until present moment. As objective evaluation of sleep participants will perform a night home sleep study with WatchPAT® 300 sleep recording, Itamar Medical Ltd.~Cohort 1 will be those participants who have had a severe COVID19 infection and have been diagnosed with a sleep disorder."
62100536|NCT06341374||Participants who have had severe COVID-19 infection without sleep disorder|Participants with severe COVID19 infection and no currently diagnosed sleep disorders
62100537|NCT06341374||Participants who have had mild COVID-19 infection with sleep disturbance|Participants who have had a mild COVID19 infection and have been diagnosed with a sleep disorder
62100538|NCT06341374||Participants who have had mild COVID-19 infection without sleep disorder|Participants who have had a mild COVID19 infection and have not been diagnosed with a sleep disorder
62100539|NCT06030427|EXPERIMENTAL|Supportive care (virtual mindfulness and weight management)|Patients participate in a virtual behavioral weight management program with an integrated mindfulness component consisting of 12, 75-minute virtual group sessions over 12 weeks to help improve mood, coping strategies, stress management, and weight loss. Patents also receive patient education handouts, view behavioral educational PowerPoint presentations over 30 minutes, and wear a Fitbit on study.
62100540|NCT05855226|NO_INTERVENTION|Care as usual|Care as usual, consist of GR rehabilitation when a patient is back at home.
62100541|NCT05855226|EXPERIMENTAL|OTHER-intervention|The OTHER-intervention is part of the OT care. Start during inpatient GR rehabilitation and goes on 12 weeks after discharge when a patient is home or starts after discharge from hospital going home. The OT will coach a patient and use a activity monitoring system. Also videoconferencing will be used.
62100542|NCT05882032|EXPERIMENTAL|LY3502970 (Mild Hepatic Impairment)|LY3502970 administered orally.
62100543|NCT05882032|EXPERIMENTAL|LY3502970 (Moderate Hepatic Impairment)|LY3502970 administered orally.
62100544|NCT05882032|EXPERIMENTAL|LY3502970 (Severe Hepatic Impairment)|LY3502970 administered orally.
62662307|NCT02749825|EXPERIMENTAL|Trelstar|Per prescribing information
61910582|NCT05292300|NO_INTERVENTION|Control Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group.
61910583|NCT05292300|EXPERIMENTAL|Cornelian Cherry Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 20 g/day Cornelian Cherry powder.
61910584|NCT05292300|EXPERIMENTAL|Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
61910585|NCT05292300|EXPERIMENTAL|Cornelian Cherry and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 20 g/day Cornelian Cherry powder for their one portion fruit a day.
61910586|NCT01204723|EXPERIMENTAL|Behavioral Condition 1|Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
61910587|NCT01204723|EXPERIMENTAL|Behavioral Condition 2|Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
62100545|NCT05882032|EXPERIMENTAL|LY3502970 (Normal Hepatic Function)|LY3502970 administered orally.
62294694|NCT05464017|NO_INTERVENTION|Standard mHealth screening tool|This is a tested standard phone screening tool which determines the need for in-person follow-up after a patient has been discharge. Consenting trauma patients will be contacted via mobile phone at 0.5, 1, 3, and 6 months post-discharge by a research assistant to complete the screening which will guide whether or not the patient should seek follow-up care based on the number of flagged responses to ≥1 question on the 7-item screening survey.
62466980|NCT04738071||Age >60 years of age|Patients younger or oder than 6o years of age
62466981|NCT04738071||World region|Patients from different world regions: North America, Europe, Asia, Latin America
62466982|NCT04738071||Stroke vs. TIA|Index event: stroke vs. TIA
62466983|NCT04738071||Neurocardiology Teams|Patients assessed by a neurocardiology team
62466984|NCT02078986|EXPERIMENTAL|Whole Body Electromyostimulation|
62662308|NCT02749825|ACTIVE_COMPARATOR|Lupron|Per prescribing information
62662309|NCT02749825|ACTIVE_COMPARATOR|Zoladex|Per prescribing information
62662310|NCT00243321|EXPERIMENTAL|HDR brachytherapy -> IMRT|Radiotherapy
62662311|NCT01002105|EXPERIMENTAL|Baclofen|The study was a double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations.
62466985|NCT02078986|EXPERIMENTAL|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise 2-3 session/week/14 weeks
61910588|NCT01204723|EXPERIMENTAL|Behavioral Condition 3|Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
61910589|NCT02122783|EXPERIMENTAL|Conventional then Experimental brace resistance|Participants received the Default intervention for a period of a month, were evaluated in the lab and then the novel intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
62466986|NCT01486147|EXPERIMENTAL|Visual|Group provided with nutrition information using visual nutrient profiling tool
62466987|NCT01486147|OTHER|Table|Group provided nutrition information using table format
62466988|NCT05883943|EXPERIMENTAL|Cook® Venous Valve System|
62466989|NCT01012635||Neurofeedback, tDCS (2 levels), Self-hypnosis, Meditation|
62466990|NCT01876875|EXPERIMENTAL|Intervention group|The patients of this group were randomized to receive an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d).
61910590|NCT02122783|EXPERIMENTAL|Experimental then Conventional brace resistance|Participants received the the novel elastomer to provide brace support intervention for a period of a month, were evaluated in the lab and then the conventional intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
61919834|NCT03127800|EXPERIMENTAL|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
62466991|NCT01876875|ACTIVE_COMPARATOR|Control group|The participants of this group are randomized to receive drug therapy alone, continuing their usual diet
62466992|NCT03860415|EXPERIMENTAL|Probiotic|Vivomixx
62466993|NCT03860415|PLACEBO_COMPARATOR|Placebo|
62466994|NCT00267644||Hydrated patients|Group 1 (n=63) were pediatric patiens that wer hydrated.
62466995|NCT00267644||Dehydrated Group|Group 2 (n=13) were pediatric patients that were dehydrated.
62466996|NCT06064422|EXPERIMENTAL|BeatIt-MV Treatment Group|Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
62100546|NCT06308653|EXPERIMENTAL|Psilocybin 25 mg|"During the Double-blind Period, participants randomized to receive Psilocybin 25 mg will receive a single dose administered orally as a capsule and taken with water, along with the Set and Setting (SaS) Protocol.~The Set and Setting (SaS) Protocol includes preparatory meetings with two Facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two Facilitators, and 4 hours of post-dose integration sessions with Facilitators. During the dosing session, participants are encouraged to wear eyeshades and listen to a curated playlist on headphones."
62100547|NCT06308653|ACTIVE_COMPARATOR|Psilocybin 5 mg|"During the Double-blind Period, participants randomized to receive Psilocybin 5 mg will receive a single dose administered orally as a capsule and taken with water, along with the Set and Setting (SaS) Protocol.~The Set and Setting (SaS) Protocol includes preparatory meetings with two Facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two Facilitators, and 4 hours of post-dose integration sessions with Facilitators. During the dosing session, participants are encouraged to wear eyeshades and listen to a curated playlist on headphones."
61910591|NCT03810729|ACTIVE_COMPARATOR|Modified Allen's Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on the participant's hand. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
62100548|NCT06308653|PLACEBO_COMPARATOR|Inactive Placebo|"During the Double-blind Period, participants randomized to receive inactive placebo will receive a single dose of Microcrystalline Cellulose (MCC) 25 mg administered orally as a capsule and taken with water, along with the Set and Setting (SaS) Protocol.~The Set and Setting (SaS) Protocol includes preparatory meetings with two Facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two Facilitators, and 4 hours of post-dose integration sessions with Facilitators. During the dosing session, participants are encouraged to wear eyeshades and listen to a curated playlist on headphones."
62100549|NCT06308653|OTHER|Long-Term Follow-Up|"After the initial 6-week Double-blind Period, all participants will proceed to a 1-year Follow-up Period. Participants will be followed via in-clinic visits and telephone visits during which clinic staff will assess changes in MDD symptom severity and safety measures including concomitant medications, adverse events (AEs), and suicidal ideation and behavior.~Participants will also engage in group psychosocial support sessions, including psychoeducation, throughout this period.~Participants may also be eligible to receive open-label re-administration(s) of Psilocybin 25 mg under the Set and Setting (SaS) Protocol if re-administration eligibility criteria are met."
62294695|NCT05464017|EXPERIMENTAL|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|This arm will receive an improvement to the mHealth triage tool using a machine learning approach. Patients will be called using the optimized tool at outcome timepoints (3 months, 6months and 12months). At each call, research assistants will complete the GOSE survey and the mHealth triage tool, entering call outcomes and patient responses directly into the mHealth system. If follow-up care is indicated, the research assistant will share that information with the patient and offer to schedule an appointment.
62294696|NCT05888025|EXPERIMENTAL|MBCT-T|Participants with high pain catastrophizing who are scheduled for spine surgery will receive four weekly sessions of preoperative telephone-delivered mindfulness-based cognitive therapy (MBCT-T). They will then be followed for two weeks postoperatively.
62294697|NCT05495048|EXPERIMENTAL|NOSES VIIIA|totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction
62294698|NCT05495048|ACTIVE_COMPARATOR|laparoscopic surgery with mini-laparotomy|laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
62294699|NCT02006134||PEDIATRIC VASCULITIS/PROSPECTIVE|Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.
61910592|NCT03810729|ACTIVE_COMPARATOR|Smartphone assessment|The smartphone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's index finger and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
61910593|NCT05507359|EXPERIMENTAL|Clove Gel|"Group 1: a. The heart rate will be measured using the pulse oximeter before topical application of clove gel.~b. The site where the rubber dam\\ matrix band will be applied will be dried, then topically anesthetized with 4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel for 30-60 seconds.~c. During rubber dam clamp\\ matrix band application, the pain will be evaluated using the Sounds, Eyes, Motor scale.~d. After the rubber dam clamp\\ matrix band application, the child will be asked to choose a face from the Wong-Baker FACES pain rating scale to assess subjective pain.~e. The heart rate will be measured again using the pulse oximeter to evaluate the child's dental anxiety."
61910594|NCT05507359|ACTIVE_COMPARATOR|Benzocaine Gel|"1. The heart rate will be measured using the pulse oximeter before topical application of benzocaine gel.~2. The site where the rubber dam\\ matrix band will be applied will be dried, then topically anesthetized with 20% benzocaine gel for 30-60 seconds (Opahl Gel).~3. During rubber dam clamp\\ matrix band application, the pain will be evaluated using the Sounds, Eyes, Motor scale.~4. After the rubber dam clamp\\ matrix band application, the child will be asked to choose a face from the Wong-Baker FACES pain rating scale to assess subjective pain.~5. The heart rate will be measured again using the pulse oximeter to evaluate the child's dental anxiety."
62100550|NCT02266420|OTHER|TNBC pT1a/b with size < or = 10 mm|Patients with pN0 triple negative breast tumor with size \< or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit
62662312|NCT01002105|OTHER|Psychosocial intervention|Intervention of the addition of placebo to low-intensity psychosocial intervention program. This was the control group
62662313|NCT03892733|EXPERIMENTAL|Intervention|CHEKS (calorie health, education, knowledge and skills) intervention will educate participants about calories in fast-food and teach skills to select lower calorie fast-food items.
61910595|NCT02232880|ACTIVE_COMPARATOR|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those \>100 kg will receive 1000 mg abatacept by intravenous infusion at 0 \[randomization\], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
61910596|NCT02232880|PLACEBO_COMPARATOR|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 \[randomization\], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
62100551|NCT02266420|OTHER|TNBC pT1c T2 with size <or = 30 mm|Patients with pN0 triple negative breast tumor with size \< or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit
62100552|NCT04228276|EXPERIMENTAL|Active rTMS|Receive active rTMS
62100553|NCT04228276|SHAM_COMPARATOR|Sham rTMS|Receive sham rTMS
62100554|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
62662314|NCT03892733|NO_INTERVENTION|Control|Participants will receive a brochure about healthier choices in fast-food restaurants.
62662315|NCT01415674|EXPERIMENTAL|Arm A: Afatinib 40mg per os daily|Patients randomized to the arm A will take a single oral dose of Afatinib from Day 1, for 14 to 28 days, depending on the date of surgery. The number of dosing days will be chosen so that patients are off treatment for a maximum of 7 days before surgery.
62662316|NCT01415674|NO_INTERVENTION|Arm B : No pre operative treatment|
62100555|NCT06191744|EXPERIMENTAL|Arm A: Epcoritamab + Lenalidomide and Rituximab (R2)|Participants will receive epcoritamab in combination with R2 during the 120 week treatment duration.
62466997|NCT01460147|OTHER|DXA scan + MRI|
62662317|NCT03012776|EXPERIMENTAL|TOPS System|Investigational surgical treatment using TOPS System
62466998|NCT00318461|EXPERIMENTAL|Lira 0.6 + Met|Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
62662318|NCT03012776|ACTIVE_COMPARATOR|Transforaminal Lumbar Interbody Fusion (TLIF)|Control surgical treatment using interbody fusion and placement of posterolateral instrumentation
62662319|NCT01843231|EXPERIMENTAL|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
62662320|NCT01843231|ACTIVE_COMPARATOR|Diet and exercise Control Group|Diet and Exercise only control group
62662321|NCT00809198|EXPERIMENTAL|Sodium Hyaluronate|Sodium Hyaluronate (Kynex)
62662322|NCT00809198|ACTIVE_COMPARATOR|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium (Refresh Plus)
61910597|NCT05382000|OTHER|Intervention|"Inclusion in the study will be proposed to all patients who come to the Emergency Department of the Gynecology and Obstetrics Service~The planned procedures for this group are as follows:~1. Obtaining informed consent.~2. Sequential triage - Patients will be evaluated sequentially using the MAT system according to standard practice. Next, another professional from the center, trained in the use of the Mediktor Hospital ® tool, will perform the advanced triage in the same space, both professionals being blind to the result of each of the tools.~3. Once the sequential triage is finished, the patient's care will be carried out according to usual clinical practice, following the triage assessment carried out with the MAT system.~4. Retrieval and introduction of data in DRF - Data of the study variables will be retrieved from the emergency report issued in the Gynecology and Obstetrics Emergency area and will be entered into an electronic DRF for subsequent analysis and processing."
61910598|NCT01014923|EXPERIMENTAL|Intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
61910599|NCT01014923|NO_INTERVENTION|Control|Parents receive a Department of Transportation booklet on teen driving
61910600|NCT03739229|ACTIVE_COMPARATOR|H7N9 LAIV|H7N9 live influenza vaccine at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of study vaccine (total dose 0.50 ml at each study vaccine administration).
62100556|NCT06191744|EXPERIMENTAL|Arm B: Chemoimmunotherapy (CIT) Option A|Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration.
62100557|NCT06191744|EXPERIMENTAL|Arm B: Chemoimmunotherapy (CIT) Option B|Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration.
62662323|NCT05652842||Day workers|Includes people working from 9 a.m. to 5 p.m./8 a.m. to 4 p.m. We will be recruiting 15 day workers.
62662324|NCT05652842||Shift workers|Includes those involved in any arrangement of daily working hours other than the standard daylight hours, 8 a.m. - 5 p.m. It also includes on-call or casual workers. We will be recruiting 15 shift workers.
62100558|NCT06191744|EXPERIMENTAL|Arm C: Lenalidomide and Rituximab (R2)|Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration.
62100559|NCT06712524|EXPERIMENTAL|Breast-conserving plastic surgery group|Breast-conserving plastic surgery
62100560|NCT06712524|ACTIVE_COMPARATOR|Traditional breast surgery group|Traditional breast surgery
62662325|NCT05652842||Rotational workers|Includes those who work on a set schedule and whose working hours are rotating on a set schedule. We do not include offshore workers here. We will be recruiting 15 rotational workers.
62662326|NCT04735302||Sarcoidosis, Nonsarcoidosis|
62100561|NCT02560103||Single group|No treatment
62100562|NCT06062888|NO_INTERVENTION|Standard of Care|Standard of Care Control Group
62100563|NCT06062888|EXPERIMENTAL|Standard of Care + FFP|Standard of Care + Experimental Treatment
62662327|NCT04735302||Malign, benign|
61910601|NCT03739229|PLACEBO_COMPARATOR|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of placebo (total dose 0.50 ml at each placebo administration).
62100564|NCT06622031|EXPERIMENTAL|Transjugular intrahepatic portosystemic shunt|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the participants received a diuretic treatment and a salt-limited diet.
62662328|NCT01320449|PLACEBO_COMPARATOR|No training + placebo|10 young men being investigated with 10 weeks apart. The will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
61910602|NCT02822547|EXPERIMENTAL|Peginterferon alfa-2a|
61910603|NCT01822314|ACTIVE_COMPARATOR|Paclitaxel|"Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
61910604|NCT01822314|EXPERIMENTAL|Abraxane|"Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
61910605|NCT00282347|EXPERIMENTAL|Rituximab|Participants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
62100565|NCT06080711|NO_INTERVENTION|Workflow 1|Standard of care
62100566|NCT06080711|EXPERIMENTAL|Workflow 2|Consult with AI assistance
62100567|NCT06080711|EXPERIMENTAL|Workflow 3|First workflow 1, then workflow 2
62100568|NCT02655692|PLACEBO_COMPARATOR|Placebo|Saline dose
62294700|NCT02006134||PEDIATRIC VASCULITIS/RETROSPECTIVE|Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA \& serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
61910606|NCT00282347|PLACEBO_COMPARATOR|Placebo|Participants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
62294701|NCT04439786|PLACEBO_COMPARATOR|control group|the control group will be given the same volume of saline as the experimental group
62294702|NCT04439786|EXPERIMENTAL|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
62294703|NCT01128387|EXPERIMENTAL|Dose Level -1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
62294704|NCT01128387|EXPERIMENTAL|Dose Level 1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)
62294705|NCT05097625||High Risk Pathway|Risk-stratified surveillance pathway, including non-invasive methods of surveillance such as blood and saliva tests; to monitor for relapse, with any abnormalities triggering imaging
62662329|NCT01320449|ACTIVE_COMPARATOR|No training + EPO|10 young men being investigated with 10 weeks apart. During the 10 weeks participants will receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-mas tests will be obtained during the 10 weeks.
61910607|NCT03430713|EXPERIMENTAL|Dental colour measurement|Comparison of dental colour measurement between two shade guides VITA Classical and VITA Toothguide 3D-Master and two spectrophotometers VITA Easyshade and Spectroshade Micro
61910608|NCT00002975|EXPERIMENTAL|PDT|4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
62100569|NCT02655692|EXPERIMENTAL|Low Dose Ketamine|Low Dose Ketamine (.20 mg/kg)
62100570|NCT02655692|EXPERIMENTAL|High Dose Ketamine|High Dose Ketamine (.50 mg/kg)
62100571|NCT06554652|EXPERIMENTAL|Selective neck dissection|
62100572|NCT06554652|ACTIVE_COMPARATOR|Modified neck dissection|
62100573|NCT06712043|EXPERIMENTAL|Intervention group|An individualized exercise program consisting of aerobic exercises, strength exercises and balance exercises. The exercises will be prescribed via the Physitrack app.
62100574|NCT06712043|ACTIVE_COMPARATOR|Historical control group|Aerobic training (see study Voet 2024, Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD)
62100575|NCT02197234|EXPERIMENTAL|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
62100576|NCT00531479|ACTIVE_COMPARATOR|Voriconazole|Voriconazole monotherapy
62100577|NCT00531479|EXPERIMENTAL|Voriconazole and Anidulafungin|Combination therapy with voriconazole and anidulafungin
62100578|NCT06680479|EXPERIMENTAL|Study Arm 1: CH505 TF chTrimer (300 mcg) admixed with 3M-052-AF (3 mcg) and Alum (500 mcg)|
62100579|NCT06680479|PLACEBO_COMPARATOR|Study Arm 2: Placebo (sodium chloride for injection, 0.9% USP)|
62294706|NCT05097625||Low Risk Pathway|Risk-stratified surveillance pathway, including non-invasive methods of surveillance such as blood and saliva tests; to monitor for relapse, with any abnormalities triggering imaging
62466999|NCT00318461|EXPERIMENTAL|Lira 1.2 + Met|Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
62662330|NCT01320449|ACTIVE_COMPARATOR|Training + placebo|10 young men will be trained for 10 weeks and investigated before and after. They will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
61910609|NCT04444830|NO_INTERVENTION|Standard|"To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed a standard postoperative regimen of Acetaminophen 650 mg PO q 6-8 hours + Ibuprofen 600 mg PO q 6-8 hours + rescue narcotics (Oxycodone 5-10 mg PO q 4-6 hours or if allergic to Oxycodone, Norco 5-10mg/325mg PO q 4-6 hours) for breakthrough pain"
61910610|NCT04444830|EXPERIMENTAL|Sprix|To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed regimen of Sprix 30.5mg Intranasal q 6-8 hour up to 4 times daily + Acetaminophen 650 mg PO q 6- 8 hours + rescue narcotics (as above) for breakthrough pain during the day of surgery and the following 4 postoperative days.
62100580|NCT02286661|ACTIVE_COMPARATOR|Short Arm Cast|Short arm cast below the elbow
62308172|NCT03894540|EXPERIMENTAL|IPN60090 in combination with pembrolizumab|"Part 1: Dose escalation of IPN60090 in combination with pembrolizumab, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose, starting with pharmacologically active dose identified in 1dose escalation of IPN60090 as a single agent, over a 21-day cycle in combination with 200 mg pembrolizumab given every 21 days (Day 1 of every cycle) as IV infusion"
61910611|NCT02181517|EXPERIMENTAL|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
61910612|NCT02181517|EXPERIMENTAL|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
61910613|NCT02181517|ACTIVE_COMPARATOR|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
61910614|NCT00557817|NO_INTERVENTION|1|No medication given
61910615|NCT00557817|ACTIVE_COMPARATOR|2|Aranesp 300 µg/15 days
61910616|NCT00557817|ACTIVE_COMPARATOR|3|Aranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.
61910617|NCT05661188|EXPERIMENTAL|atezolizumab and tiragolumab in concomitancy with standard chemoradiotherapy|"TIRANUS is a Phase II, single-arm, open-label, non-randomized, multicenter clinical trial of atezolizumab and tiragolumab in concomitance with standard chemoradiotherapy as first-line in treatment-naïve, localized squamous cell carcinoma of the anal canal who are candidates for radical chemoradiotherapy. Patients with well differentiated stage I anal margin cancer or previously treated with immunotherapy are not eligible.~All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase)."
62100581|NCT02286661|ACTIVE_COMPARATOR|Long Arm Cast|Long arm cast above the elbow
62100582|NCT02867839|EXPERIMENTAL|A: postoperative Oxaliplatin plus S-1|"Patients in arm A will receive standard distal gastrectomy with D2 lymphadenectomy first, and 8 cycles of adjuvant Oxaliplatin plus S-1 (SOX) later.~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3W S-1: 40\~60mg bid, po, d1\~14, q3W (6 months)"
62100583|NCT02867839|ACTIVE_COMPARATOR|B: postoperative S-1 only|"Patients in arm B will receive standard distal gastrectomy with D2 lymphadenectomy first, and 16 cycles of adjuvant S-1 later.~S-1: 40\~60mg bid, po, d1\~14, q3W (12 months)"
62100584|NCT05174169|ACTIVE_COMPARATOR|Cohort A - Arm 1 (ctDNA-ve)|"Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles~OR~Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles"
62100585|NCT05174169|EXPERIMENTAL|Cohort A - Arm 2 (ctDNA-ve)|Serial ctDNA monitoring no treatment
62662331|NCT01320449|ACTIVE_COMPARATOR|Training + EPO|10 young men will be investigated with 10 weeks apart. During the ten weeks they will train 3 times a week and receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
62662332|NCT03590470|EXPERIMENTAL|Experimental_INTERCARE intervention|Implementation of a nurse-led model of care adapted to the Swiss context, comprising a geriatric nurse expert with specific training in multidimensional clinical assessment and quality improvement tools.
62662333|NCT03590470|NO_INTERVENTION|Control|The design used for the INTERCARE intervention is a non-randomized stepped wedge design, therefore all nursing homes will receive the intervention but at different time points. All nursing homes will be in a control phase before receiving the intervention, and switch to the intervention phase, once the intervention is implemented.
61910618|NCT00815854|EXPERIMENTAL|Folate|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
61910619|NCT00815854|PLACEBO_COMPARATOR|Placebo|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
61910620|NCT02248688|OTHER|Embolic Agent - BeadBlock|Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
62100586|NCT05174169|ACTIVE_COMPARATOR|Cohort B - Arm 3 (ctDNA+ve)|"Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles~OR~Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles"
62662334|NCT00296335|ACTIVE_COMPARATOR|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
62662335|NCT00296335|EXPERIMENTAL|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
62662336|NCT04192344|EXPERIMENTAL|ABSK021|"Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by3+3 escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles."
61910621|NCT00986284|EXPERIMENTAL|Gefitinib, Neoadjuvant therapy|Patients with EGFR mutation will be recruited and treated with gefitinib.
61910622|NCT05441878|EXPERIMENTAL|20% Albumin arm|20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h
62100587|NCT05174169|EXPERIMENTAL|Cohort B - Arm 4 (ctDNA+ve)|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
62308173|NCT03894540|EXPERIMENTAL|IPN60090 in combination with paclitaxel|"Part 1: Dose escalation of IPN60090 in combination with paclitaxel, Part 2: Dose expansion~IPN60090 given as a BID oral dose, starting with pharmacologically active dose identified in dose escalation of IPN60090 as a single agent over a 21-day cycle in combination with 175 mg/m2 or 135 mg/m2 paclitaxel given every 21 days (Day 1 of every cycle) as IV infusion"
62662337|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
62100588|NCT05373901|EXPERIMENTAL|Dinutuximab Beta + 13-cis-Retinoic Acid|The study recruited participants who were hospitalized (with full resuscitation equipment) on Day 1 of each cycle and received continuous infusion of dinutuximab beta for 10 consecutive days in 35-day cycles. Participants could be discharged from the hospital at the investigator's discretion. Participants continued to receive 13-cis-retinoic acid orally for 14 days after completion of dinutuximab beta infusion (day 12-25 in each cycle).
62100589|NCT05534945|EXPERIMENTAL|F5 ml PIEB|Female patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62662338|NCT05563857|NO_INTERVENTION|Placebo|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert or inactive ingredients. Participants may need to use a mobile app in order to participate in the trial.
61910623|NCT05441878|ACTIVE_COMPARATOR|Balanced salt solution arm|Fluid resuscitation protocol includes use of an immediate 500 ml bolus of crystalloid i.e., balanced salt solution (BSS) or 0.9% normal saline (Rescue phase), followed by 20 ml/kg fluid in the first 6 hours titrated to target MAP of \> 65mmHg.The second phase of fluid resuscitation (Optimization phase) will be performed as per IVC targets, attainment of lactate clearance, and LUS score to prevent overload.
61910624|NCT05181280|EXPERIMENTAL|Intervention|"Treatment: Standardized body image messaging targeting mothers. Following a similar model that has been used in previous studies testing the effect of traditional media exposure on body image and disordered eating behaviour, participants randomized to the treatment condition will have 1 exposure session per day over 5 days. Each exposure session will consist of 15 social media body message posts. Body image messaging targeting mothers will consist of mothers with ideal postpartum bodies and captions trending over the past 24 months."
62100590|NCT05534945|EXPERIMENTAL|F6 ml PIEB|Female patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100591|NCT05534945|EXPERIMENTAL|F7 ml PIEB|Female patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100592|NCT05534945|EXPERIMENTAL|F8 ml PIEB|Female patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62662339|NCT05563857|ACTIVE_COMPARATOR|Viome's Precision Nutrition Program (VPNP)|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
61910625|NCT05181280|PLACEBO_COMPARATOR|Control|Control: Standardized infant feeding tips messaging. Participants randomized to the control will have 1 exposure session/day over 5 days. Each exposure will consist of 15 social media posts on infant feeding tips.
62662340|NCT05563857|ACTIVE_COMPARATOR|Viome's condition-based supplements|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
62100593|NCT05534945|EXPERIMENTAL|F9 ml PIEB|Female patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100594|NCT05534945|EXPERIMENTAL|F10 ml PIEB|Female patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100595|NCT05534945|EXPERIMENTAL|M5 ml PIEB|Male patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100596|NCT05534945|EXPERIMENTAL|M6 mL PIEB|Male patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100597|NCT05534945|EXPERIMENTAL|M7 mL PIEB|Male patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100598|NCT05534945|EXPERIMENTAL|M8 mL PIEB|Male patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100599|NCT05534945|EXPERIMENTAL|M9 mL PIEB|Male patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62100600|NCT05534945|EXPERIMENTAL|M10 mL PIEB|Male patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
62662341|NCT04029597|EXPERIMENTAL|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the Remote Patient Monitoring System.
62662342|NCT00869180|EXPERIMENTAL|Diclofenac Sodium Patch|
62662343|NCT00869180|PLACEBO_COMPARATOR|Topical Placebo Patch|
62662344|NCT02107898|PLACEBO_COMPARATOR|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
62662345|NCT02107898|EXPERIMENTAL|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.~* ≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)~* ≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
62662346|NCT03033706|ACTIVE_COMPARATOR|Study group|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 13%.
62308174|NCT03894540|EXPERIMENTAL|IPN60090 food effect|"Part 1: Food Effect of IPN60090~IPN60090 given as a single oral dose as a single agent at the recommended dose (RD) under fasting and fed conditions followed by IPN60090 given as a BID oral dose administered at the RD over a 21-day cycle."
62308175|NCT01483404||Patient with fracture of femural neck|All patient with fracture of the femural neck in the listed period of time
62662347|NCT03033706|PLACEBO_COMPARATOR|Control group|Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
62662348|NCT05190133|EXPERIMENTAL|Treatment A|
62100601|NCT06085950|EXPERIMENTAL|Transcranial Ultrasonic Stimulation with Personalized Acoustic Lens|Low-intensity transcranial focused ultrasound stimulation of deep brain target, using a personalized acoustic lens to correct the aberrations induced by the skull
62294707|NCT06044324|ACTIVE_COMPARATOR|Repetitive Transcranial Magnetic Stimulation|Stimulation site: According to the localization of neural orientation navigation system, magnetic resonance data was read in Brainsight software, and three-dimensional brain reconstruction was carried out. The stimulation target was located in the coordinates of Montreal Neurological Institute (MNI), which was located in the left middle temporal (-43, -73, 10). Treatment intensity was 100% exercise threshold, continuous 10Hz stimulation, repeated 75 times, that is, 3000 pulses per treatment, 2 times a day, stimulation lasted for 4 seconds with a 26-second interval for 37.5 minutes, continuous stimulation for 5 days, 2 days rest interval, and 5 days of continuous stimulation.
62294708|NCT06044324|NO_INTERVENTION|HC observation|Collect data on healthy controls without stimulation. The subjects get clinical evaluation, blood sample collection, positron emission tomography-magnetic resonance scanning, and electrophysiological monitoring.
62662349|NCT05190133|EXPERIMENTAL|Treatment B|
62662350|NCT02290093|ACTIVE_COMPARATOR|Standard full-volume PEG|
62662351|NCT02290093|EXPERIMENTAL|Split-dose full-volume PEG|
62662352|NCT02290093|EXPERIMENTAL|Split-dose low-volume PEG|
62662353|NCT01334775|EXPERIMENTAL|Experimental - Cousin Biotech Adhesix|Placement of a self-adhering (sutureless) surgical mesh in open anterior inguinal hernia repair
62662354|NCT01334775|ACTIVE_COMPARATOR|Conventional - Cousin Biotech Biomesh P8|Placement of the conventional (sutured) surgical mesh in open anterior inguinal hernia repair
62662355|NCT01325766|ACTIVE_COMPARATOR|Yoga (immediate start) group|This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks. This group will then continue with home yoga for an additional 8 weeks.
62662356|NCT01325766|ACTIVE_COMPARATOR|Yoga (waitlist) group|This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
62662357|NCT02967887|EXPERIMENTAL|cisplatin and 5-fluorouracil|Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.
61910626|NCT02390791|EXPERIMENTAL|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
61910627|NCT02390791|ACTIVE_COMPARATOR|treatment as usual standard portal|Standard version of myADHDportal.com web software
61910628|NCT02870023|EXPERIMENTAL|Balance training|"All sessions will start with a ten minute warm-up on either a treadmill or a cycle.~The balance intervention will be conducted in stations/domains where balance is challenged in the five different functions: standing, walking, sit to stand, stepping, and a station that exercises vestibular and gaze control.~Progression is achieved by adding exercises with increased balance requirements and by adding additional motoric and cognitive tasks to the exercises-dual-tasking.~Intensity of the exercises is defined from an error-rate where an adequate level is 20-40 percent.~The intervention is conducted according to a standardized framework that describes examples of exercises and progressions."
61910629|NCT02870023|EXPERIMENTAL|Strength training|"All sessions will start with a ten minute warm-up on a stationary bicycle, followed by strength training of primary muscle synergies in the lower extremities. All exercises will be performed on machines with patients sitting or lying, adequately supported. The exercises are leg press, knee extension, hip flexion, hamstring curl, and hip extension. Exercises are performed with a fast concentric phase and a slow eccentric phase..~Set, repetition, and load:~* Weeks 1 and 2, 3 sets of 10 repetitions at a load of 15 repetitions maximum (RM)~* Weeks 3 and 4, 3 sets of 12 repetitions at a load of 12RM~* Weeks 5 and 6, 4 sets of 12 repetitions at a load of 12RM~* Weeks 7 and 8, 4 sets of 10 repetitions at a load of 10RM~* Weeks 9 and 10, 4 sets of 8 repetitions at a load of 8RM."
62100602|NCT06391177|EXPERIMENTAL|Vonoprazan 20 mg Once Daily|Participants will be administered once-daily doses of vonoprazan 20 mg for 4 consecutive days (Days 1 through 4).
61910630|NCT02870023|NO_INTERVENTION|Control group|On a waitlist. After ten weeks of waiting, and intervention that contains 50 percent strength training and 50 percent balance training begins.
62100603|NCT06391177|EXPERIMENTAL|Vonoprazan 20 mg Twice Daily|Participants will be administered twice-daily doses of vonoprazan 20 mg for 4 consecutive days (Days 1 through 4).
62100604|NCT05708261|EXPERIMENTAL|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
62100605|NCT05708261|OTHER|Be Well|Attention match control arm. Participants will receive standard of care for HIV treatment and one-way SMS with video content about general health. This will occur once per week during the first 5 weeks after enrollment.
62100606|NCT01735929|EXPERIMENTAL|Neck Liposuction and Ultrasound Treatment|Subject will receive neck liposuction and ultrasound treatment.
62100607|NCT01735929|SHAM_COMPARATOR|Sham|Subject will receive sham treatment
62100608|NCT03361735|EXPERIMENTAL|Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)|Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
62100609|NCT06713980|SHAM_COMPARATOR|sham acupuncture group|In the SA group, non-penetrating sham acupuncture was applied at 14 specific non-acupuncture points on the back. A pedestal was affixed to each non-acupuncture point. Blunt-tip needles were then inserted into the pedestal at a depth of 3-5 mm, and it was ensured that they only touched the skin without penetration
62100610|NCT06713980|EXPERIMENTAL|acupuncture group|the choice of acupoints was based on the theory of traditional Chinese medicine (TCM), as follows: Ashi point, Tanzhong (CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong (SI11), Geshu (BL17), Ganshu (BL18), Hegu (LI4), Sanyinjiao (SP6), and Taichong (LR3).
62467000|NCT00318461|EXPERIMENTAL|Lira 1.8 + Met|Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
62467001|NCT00318461|ACTIVE_COMPARATOR|Met Mono|Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
62467002|NCT00318461|ACTIVE_COMPARATOR|Met + Glim|Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo
61910631|NCT02647450||GIANT Clinic Group|Patients are required to have been refereed to the GI and Nutrition team Clinic at the Royal Marsden Hospital. In the clinic they will be assessed for their symptoms using the Gastrointestinal Symptom Rating Scale (GSRS).
61910632|NCT01361061||patients with liver cirrhosis|
61910633|NCT02224118|EXPERIMENTAL|CNTO 3649 10 mcg/kg (single dose)|A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
61910634|NCT02224118|EXPERIMENTAL|CNT0 3649 30 mcg/kg (single dose)|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
61910635|NCT02224118|EXPERIMENTAL|CNTO 3649 100 mcg/kg (single dose)|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
61910636|NCT02224118|EXPERIMENTAL|CNTO 3649 300 mcg/kg (single dose)|A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
62100611|NCT04083183|EXPERIMENTAL|Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)|Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365. Patients undergo blood sample collection and may undergo bone marrow aspiration throughout the study.
62100612|NCT06711107||SBO patients|"After adhesive SBO diagnosis is performed through clinical examination, blood tests, and abdominal CT-scan, and need for urgent surgical exploration excluded, patients are admitted to the General/Digestive Surgery Department for NOM. NOM consists in fasting, analgesics, antiemetics, and fluids administration, with or without electrolytes correction. Nasogastric tube positioning and/or hyperosmolar water-soluble contrast administration is not deemed necessary for the patient to be included in this study, thus allowing us to evaluate different management strategies for adhesive SBO.~After at least 24 hours of NOM, patients are re-evaluated for NOM prosecution or surgical treatment.~NOM is considered effective when patients achieved symptoms remission, flatus and stools evacuation, and realimentation without symptoms recurrence for at least 90 days.~NOM failure is defined as need for surgery, both laparoscopic or laparotomic, to treat adhesive SBO. Surgical management depends on single"
62100613|NCT04228770|EXPERIMENTAL|Warfarin patients|Patients on high risk medication - warfarin
62467003|NCT04043884|EXPERIMENTAL|sEmg Biofeedback training|8-week exercise program, twice a week, with emg biofeedback training.
62467004|NCT04043884|ACTIVE_COMPARATOR|Exercises|8-week exercise program, twice a week.
62467005|NCT04089735|EXPERIMENTAL|APP13007 0.05% twice daily (BID) [Part A]|1 drop 0.05% APP13007 twice daily for 21 days to the operated eye
62467006|NCT04089735|EXPERIMENTAL|APP13007 0.05% Placebo twice daily (BID) [Part A]|1 drop matching vehicle placebo for 0.05% APP13007 twice daily for 21 days to the operated eye
62467007|NCT04089735|EXPERIMENTAL|APP13007 0.05% twice daily (BID) and once daily (QD) [Part B]|1 drop 0.05% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
62662358|NCT06157424|EXPERIMENTAL|Acupuncture + Standard treatment|Standard treatment plus thread embedding acupuncture and auricular acupuncture
62100614|NCT04228770|EXPERIMENTAL|Parkinson's patients|Patients with high risk disease - parkinson's
62467008|NCT04089735|EXPERIMENTAL|APP13007 0.05% Placebo twice daily (BID) and once daily (QD) [Part B]|1 drop matching vehicle placebo for 0.05% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
62467009|NCT04089735|EXPERIMENTAL|APP13007 0.1% twice daily (BID) and once daily (QD) [Part B]|1 drop 0.1% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
62467010|NCT04089735|EXPERIMENTAL|APP13007 0.1% Placebo twice daily (BID) and once daily (QD) [Part B]|1 drop matching vehicle placebo for 0.1% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
62467011|NCT05357898|EXPERIMENTAL|Part 1A Monotherapy Dose Escalation Phase|"In Part 1A, SQZ-eAPC-HPV as a monotherapy is administered every 3 weeks for up to a year.~There are 3 groups (Cohorts) in this Phase as follows:~* Cohort 1: low dose SQZ-eAPC-HPV~* Cohort 2: intermediate dose SQZ-eAPC-HPV~* Cohort 3: high dose SQZ-eAPC-HPV~Additional provisional cohorts may be opened prior to starting Part 1B."
62467012|NCT05357898|EXPERIMENTAL|Part 1B Combination Phase|In Part 1B, SQZ-eAPC-HPV is administered in combination with immune checkpoint inhibitor pembrolizumab. SQZ-eAPC-HPV will be administered on Day 1 of Cycle 1 and 200 mg of pembrolizumab will be administered on Day 8 of Cycle 1. In future cycles, patients will be first administered SQZ-eAPC-HPV and then pembrolizumab on the first day of each cycle, every 3 weeks for a maximum of 1 year for SQZ-eAPC-HPV, and 2 years for pembrolizumab.
62467013|NCT05357898|EXPERIMENTAL|Part 2 Lead-in Combination Phase|In Part 2, SQZ-eAPC-HPV will be administered on Day 1 of each treatment cycle. Treatment with 200 mg of pembrolizumab will begin in Cycle 3. Starting at Cycle 3, patients will be administered SQZ-eAPC-HPV and then pembrolizumab every 3 weeks for a maximum of 1 year for SQZ-eAPC-HPV, and 2 years for pembrolizumab.
62662359|NCT06157424|ACTIVE_COMPARATOR|Standard treatment|Standard treatment
62662360|NCT03897621|EXPERIMENTAL|tranexamic acid|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
62662361|NCT03897621|PLACEBO_COMPARATOR|Normal saline|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
62662362|NCT01177410|PLACEBO_COMPARATOR|Placebo|
62662363|NCT01177410|EXPERIMENTAL|Mesalamine Granules 750 mg|
62100615|NCT05776706|EXPERIMENTAL|Single arm|"We will set up 2 navigation systems, newly developed AR-based navigation and conventional navigation system, to surgeries of all participants.~Surgeons will perform all surgical planning and operations with reference to the conventional navigation system. In this process, the errors of the existing navigation and the newly developed navigation will be measured and compared in 3D at several points, and the points are as follows:~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)"
62100616|NCT04071522||LBP|110 literate Turkish speaking patients suffering from low back pain (LBP) for over 3 months, within the age range 18-65 were included in the study.
62294709|NCT03751332|OTHER|Conversion from either CSA or TAC|Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily. In patients treated with ciclosporin A, the initial dose will be 0.1 - 0.12 mg tacrolimus MR4 per kg of body weight per day with oral morning administration. In patients who are already treated with Prograf, the conversion to Advagraf will be performed in a 1:1 ratio.
62294710|NCT02532049|ACTIVE_COMPARATOR|Group 1|ChAd63 Pfs25-IMX313 (5x10\^9 vp)
61910637|NCT02224118|EXPERIMENTAL|CNT0 3649 30 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
62100617|NCT06708325|EXPERIMENTAL|Exercise group|The 12-week resistance training program consisted of three supervised sessions per week, each lasting approximately 55-60 minutes. Sessions were structured as follows: 5-7 minute dynamic warm-up, 35-40 minutes of resistance training, and 4-5 minutes of stretching for active recovery. Participants were paired based on similar strength fitness levels and progressed according to the principle of periodized progressive overload.
62294711|NCT02532049|ACTIVE_COMPARATOR|Group 2A|ChAd63 Pfs25-IMX313 (5x10\^10 vp)
62294712|NCT02532049|ACTIVE_COMPARATOR|Group 2B|ChAd63 Pfs25-IMX313 (5x10\^10) and MVA Pfs25-IMX313 (1x10\^8 pfu) 8 weeks later
62662364|NCT01177410|EXPERIMENTAL|Mesalamine Granules 1500 mg|
62662365|NCT00077194|EXPERIMENTAL|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
62662366|NCT04189523|ACTIVE_COMPARATOR|Standard of Care Pain Management|
62662367|NCT04189523|EXPERIMENTAL|Early Administration of US Guided Nerve Blocks|
62662368|NCT03404375|OTHER|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
62662369|NCT06049537||Young children|"Children aged 1-5 years old attending school or day care. Follow-up for 28 days using minimally-invasive nasosorption sampling and questionnaires relating to symptoms.~No intervention administered"
62662370|NCT06049537||Parents|"Parents of enrolled children, if it is a one-child family. Follow-up for 28 days using minimally-invasive saliva sampling.~No intervention administered"
62662371|NCT00868556||1 episodic migraine sufferers|
61910638|NCT02224118|EXPERIMENTAL|CNTO 3649 100 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
61910639|NCT02224118|PLACEBO_COMPARATOR|Placebo|Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
62100618|NCT06708325|NO_INTERVENTION|control group|did not participate in any structured exercise program during the 12-week study period. The participants were asked to maintain their usual lifestyle habits.
62100619|NCT05560399|EXPERIMENTAL|Iberdomide, Elotuzumab and Dexamethasone|Dose-Finding: Patients will be enrolled in a 3+3 dose escalation cohort. Dose-Expansion: additionally enrolled patients at the recommended maximum tolerated dose of Iberdomide as was determined in Part 1 (Dose-Finding Phase).
62100620|NCT03869710|EXPERIMENTAL|Dry-Needling|Ultrasound-Guided Dry-Needling Therapy focused on the active and latent myofascial trigger points.
62100621|NCT06507969||Healthy young adults aged 18-30 years|Sociodemographic information of all participants will be obtained within the scope of the evaluations. Body composition parameters will be measured with Tanita DC360 Body Analysis Scale. In pulmonary function test, Forced vital capacity (FVC), Forced expiratory volume in 1st second (FEV1), Tiffeneau ratio (FEV1/FVC), peak expiratory flow rate (PEF) values will be evaluated with COSMED Pony FX (COSMED; Italy) spirometer. Respiratory muscle endurance will be assessed by Maximum Minute Ventilation will be determined. Pittsburg Sleep Quality, a reliable questionnaire that assesses sleep quality The index will be filled in by the participants. 6 Minutes to assess functional capacity A walking test will be performed and the distance travelled by individuals will be recorded.
62100622|NCT01078233||Raltegravir Cohort|Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.
62100623|NCT01078233||Historical Cohort|Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.
62100624|NCT01078233||Concurrent Cohort|Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.
62100625|NCT01649102|EXPERIMENTAL|Palindroom catheter|Insertion of Palindroom catheter
62100626|NCT01649102|EXPERIMENTAL|Hemoglide Bard Catheter|Insertion of Hemoglide Bard Catheter
62100627|NCT04377633|SHAM_COMPARATOR|Pre-intervention|Anesthesia handover during surgery will be performed as usual, i.e., a verbal exchange of pertinent clinical information.
62100628|NCT04377633|EXPERIMENTAL|Post-intervention|Anesthesia handover during surgery will be performed according to a structured checklist.
62294713|NCT02532049|ACTIVE_COMPARATOR|Group 2C|ChAd63 Pfs25-IMX313 (5x10\^10) and MVA Pfs25-IMX313 (2x10\^8 pfu) 8 weeks later
62662372|NCT00868556||2 chronic migraine sufferers|
62662373|NCT00868556||3 non migraine sufferers (controls)|
61910640|NCT00729469|EXPERIMENTAL|Ospemifene 60 mg/day and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
61910641|NCT00729469|PLACEBO_COMPARATOR|Placebo and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
61910642|NCT04882969|EXPERIMENTAL|Fractionated Thulium Laser and KeraFactor|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied KeraFactor every 2 weeks for 12 week period.
61910643|NCT00980161||Peg-IFN + RBV with SVR|HCV patients receiving peginterferon alfa-2a and ribavirin with sustained virologic response
61910644|NCT00980161||Peg-IFN + RBV without SVR|HCV patients receiving peginterferon alfa-2a and ribavirin without sustained virologic response
61910645|NCT00407381|EXPERIMENTAL|Ranibizumab|Ranibizumab (RBZ) intravitreal injection alone
61910646|NCT00407381|ACTIVE_COMPARATOR|Laser|Laser photocoagulation
61910647|NCT00407381|EXPERIMENTAL|Laser with Ranibizumab|Laser following intravitreal injection of RBZ
61910648|NCT04600011|OTHER|TELEREHABILITATION ARM|ARM 1: The TELEREHABILITATION ARM where participants receive the full originally-intended protocol that includes one initial in-person PT/OT evaluation, four virtual PT/OT visits, and one final in-person (or virtual, if in-person is not possible) PT/OT evaluation. The study duration for Arm 1 is about 10 weeks of the primary intervention as described with 3- and 6-month follow-up calls. The mobile virtual platform for Arm 1 is comprised of a tablet on a height-adjustable rotating tablet floor stand with a gooseneck and wheels.
61910649|NCT04600011|OTHER|VIRTUAL HOME SAFETY EVALUATIONS (HSE)-ONLY ARM|ARM 2: The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
61910650|NCT02744742|EXPERIMENTAL|G-CSF + Decitabine + BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
61910651|NCT02744742|ACTIVE_COMPARATOR|BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
62100629|NCT05308836|EXPERIMENTAL|Adipose-derived messenchymal stem cell (AD-MSC)|Intervention: Intravenousling (IV) AD-MSC in 10 patients with type 1 diabetes mellitus.
62100630|NCT06711653|EXPERIMENTAL|Different Test Conditions|one test group with different test conditions
62100631|NCT03390556|EXPERIMENTAL|Asthma education|
62100632|NCT06705023|EXPERIMENTAL|UA-ADRCs group|"Patients in the UA-ADRC (uncultured, autologous, adipose-derived regenerative cells) group will be treated as follows:~1. Patients will have an outpatient liposuction procedure from the abdomen, bilateral flanks, and/or medial thigh (at least 100 mL of adipose tissue) to get cell product.~2. Oral sedation and local anesthesia with tumescent solution will be used. Patients' vitals will be monitored and recorded during the procedure and in 1 to 2 hours post-procedure.~3. Each patient in the UA-ADRC group will have cells isolated using the Transpose RT/Matrase system (InGeneron).~4. Cell product testing will be assessed with the following acceptance criteria: total nucleated cell count is \> 35 million cells, b) cell viability is \> 75%. AE status will be monitored for 30 days post-liposuction procedure.~5. The i.cv injection of UA-ADRCs will be given using an aseptic technique. This group will include 24 patients."
61910652|NCT04095585||Patients presenting with WBS and ASD|patients with WBS and ASD. The diagnosis of WBS was confirmed by fluorescent in situ hybridization. All patients met formal ASD criteria.
62100633|NCT06705023|ACTIVE_COMPARATOR|Control group|Patients will receive continuation of their best guideline based medical treatment. This group will include 12 patients.
62100634|NCT00662064||1|Patients with lower urinary tract dysfunction
62100635|NCT00662064||2|Controls with normal lower urinary tract function
62100636|NCT03478579||Emergency physicians|The observational group will be composed of emergency physicians working in the French Midi-Pyrenees region. Physicians must work since 2 years in emergency service
62100637|NCT01965080|EXPERIMENTAL|Exemestane|Exemestane 25 mg daily
61910653|NCT02775019|ACTIVE_COMPARATOR|Lactobacillus reuteri lonzenges|2x daily repeated intake of lozenges containing 10E9 CFU Lactobacillus reuteri each for 42 days
62100638|NCT06614231|EXPERIMENTAL|Tislelizumab|Tislelizumab 200mg Q3W
62100639|NCT02356029||EMS Healthcare Providers|Healthcare Providers working in Emergency Medical Services and directly involved in treatment of cardiac arrest patients (out-of-hospital or in the Emergency Department)
62100640|NCT04257279|EXPERIMENTAL|Robotic|Patients receiving spine surgery with posterior stabilization placed by ExcelsiusGPS
62100641|NCT05963776||case|cases are cirrhotic with hepatocellular carcinoma
62100642|NCT05963776||control|patients with cirrhosis
62100643|NCT04135144|ACTIVE_COMPARATOR|Group 1 (printed materials),|Group 1 was given home exercise method with printed materials
62100644|NCT04135144|ACTIVE_COMPARATOR|Group 2 (video phone reminder)|Group 2 was given exercise with home exercise method with video phone reminder
62100645|NCT06713629|EXPERIMENTAL|PICO arm|PICO vacuum system for post-sternotomy wound
62100646|NCT06713629|ACTIVE_COMPARATOR|Control arm|usual commercial wound dressing
62294714|NCT04790942|EXPERIMENTAL|berberine hydrochloride group|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets
62294715|NCT04790942|PLACEBO_COMPARATOR|lifestyle intervention group|Lifestyle intervention group (CON) refers to healthy lifestyle education
61910654|NCT02775019|PLACEBO_COMPARATOR|Placebo lozenges|2x daily repeated intake of lozenges being void of Lactobacillus reuteri for 42 days.
61910655|NCT05808634|EXPERIMENTAL|BA3182|All Patients will receive BA3182
61910656|NCT05563038|EXPERIMENTAL|Scrambler Therapy Group 5 sessions|Patients undergoing treatment by Scrambler Therapy will begin by describing the areas and levels of pain along the Numerical Rating Scale (NRS) from 0-10. After the Scrambler treatment, patients will again be asked to describe the areas and levels of pain using the NRS. Each patient undergoing Scrambler Therapy will undergo this process for 5 consecutive days, following the same procedure every day of treatment. After completion of treatment, participants will be asked to complete monthly ratings of their pain for three months, and to follow-up in clinic at 3-6 month intervals (standard of care).
61910657|NCT05563038|ACTIVE_COMPARATOR|Scrambler Therapy Group 10 sessions|Patients undergoing treatment by Scrambler Therapy will begin by describing the areas and levels of pain along the Numerical Rating Scale (NRS) from 0-10. After the Scrambler treatment, patients will again be asked to describe the areas and levels of pain using the NRS. Each patient undergoing Scrambler Therapy will undergo this process for 10 consecutive days, following the same procedure every day of treatment. After completion of treatment, participants will be asked to complete monthly ratings of their pain for three months, and to follow-up in clinic at 3-6 month intervals (standard of care).
61910658|NCT00855270|PLACEBO_COMPARATOR|saline|An IV injection of saline will be administered to the control group in a double blind, randomized manner.
61910659|NCT00855270|EXPERIMENTAL|Hydrocortisone|IV hydrocortisone will be given in a double blind random manner as the active treatment group
61910660|NCT00940472|EXPERIMENTAL|Experimental Drug|DMMET-01 + Diet
61910661|NCT00940472|ACTIVE_COMPARATOR|Metformin|Metformin + Diet
61910662|NCT04538209||canditates for variceal eradication|patients with documented liver cirrhosis (Based on clinical, laboratory and ultrasonographic findings) undergoing either primary or secondary prophylaxis variceal eradication at endoscopy unit of El-Rajhi hospital, Assuit University
61910663|NCT01718418|EXPERIMENTAL|+ ind.CHO + prebiotics|test meal: intrinsic indigestible carbohydrates in combination with a combined probiotic supplement.
61910664|NCT01718418|EXPERIMENTAL|+ ind.CHO - prebiotics|test meal: intrinsic indigestible carbohydrates in combination with placebo probiotic supplement.
61910665|NCT01718418|EXPERIMENTAL|- ind.CHO - prebiotics|reference: no ind. carbohydrates and no probiotic supplement
61910666|NCT03970980|EXPERIMENTAL|FIO2 >90% group|This group receives FIO2 \>90% during the surgery.
61910667|NCT03970980|ACTIVE_COMPARATOR|FIO2 <70% group|This group receives FIO2 \<70% during the surgery.
61910668|NCT00619320|EXPERIMENTAL|Safer Sex Skill Building (SSB)|Safer Sex Skill Building Intervention (SSB) A five session behavioral intervention focused on HIV/STD prevention and safer sex negotiation skills
62100647|NCT06339905|EXPERIMENTAL|Sonic Activation with EndoActivator|Sonic irrigation was performed using an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA). A suitable-size activator tip was selected and loosely placed at 2 mm from working length, and the device was operated at 10,000 cycles/min using a pumping action to move the tip to produce vertical strokes of 2-3 mm.
62100648|NCT06339905|ACTIVE_COMPARATOR|Conventional needle irrigation (control)|Conventional needle irrigation was performed with short, in-and-out vertical strokes of 2-3 mm at a rate of approximately 100 strokes per minute.
62100649|NCT06712225|ACTIVE_COMPARATOR|Arm A: Anomia Therapy alone|
61910669|NCT00619320|ACTIVE_COMPARATOR|2|one group session focused on standard HIV/STD education
61910670|NCT04842032|EXPERIMENTAL|KRN23|KRN23 0.8 mg/kg starting dose, administered Q2W by SC injection up to Week 64. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
61910671|NCT02898285|ACTIVE_COMPARATOR|Personal time condition|"People randomized to this group will be asked to go on a night out with no kids (i.e. dinner, or a movie) once a month."
61910672|NCT02898285|EXPERIMENTAL|Individual sport condition|People randomized to this group will select an individual sport. They will be asked to participate in this individual sport for three months.
62662374|NCT04790201|EXPERIMENTAL|Friendship Bench Delivered by Professional Counselor|Participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a professional counselor. Individuals enrolled in this arm will receive 6 weekly counseling sessions per the adapted FB protocol (Aim 1).
61910673|NCT02898285|EXPERIMENTAL|Team sport condition|People randomized to this group will select a team sport. They will be asked to participate in the team sport for three months (length of the team sport season).
61910674|NCT00289055|EXPERIMENTAL|1|Cordis SMART™ Nitinol Stent
61910675|NCT00289055|ACTIVE_COMPARATOR|2|balloon angioplasty
62662375|NCT04790201|EXPERIMENTAL|Friendship Bench Delivered by Lay Counselor|Participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a trained lay counselor. Individuals enrolled in this arm arm will receive 6 weekly counselling sessions per the adapted FB protocol (Aim 1).
62467014|NCT01596166|EXPERIMENTAL|Metoclopramide, Ketorolac|"1. 10 mL/kg IV 0.9% sodium chloride~2. Metoclopramide 0.2 mg/kg (max 10 mg) IV~3. Ketorolac 0.5 mg/kg (max 30 mg) IV"
61910676|NCT03154229|ACTIVE_COMPARATOR|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
61910677|NCT03154229|ACTIVE_COMPARATOR|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
61910678|NCT04929717|EXPERIMENTAL|Intervention|The personal information form and BSES-SF were administered to women in the hospital before the intervention. Breastfeeding education and counseling were provided via social media (WhatsApp) to support women for breastfeeding and to ensure the continuity of breastfeeding in the postpartum period. Breastfeeding education was given to women in the first four weeks after discharge from the hospital. After the breastfeeding education was completed via social media, the counseling process started. Counseling was conducted via social media with a question-answer method between the first and 6th months of postpartum.
61910679|NCT04929717|OTHER|Control|The women in the control group were pre-tested at the hospital before discharge. The BSES-SF was re-administered by phone at the 3rd and 6th postpartum months. The control group received the routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures. Except for routine breastfeeding training, no intervention was applied to the control group.
61910680|NCT01634256|EXPERIMENTAL|Fermented turmeric|
61910681|NCT01634256|PLACEBO_COMPARATOR|Placebo|
61910682|NCT03438721|EXPERIMENTAL|Infant Obesity Prevention|The infant obesity prevention arm will provide parents with education on optimal infant feeding, sleep, and screen time practices.
61910683|NCT03438721|EXPERIMENTAL|Financial Coaching|The financial coaching arm will provide parents with education on basic financial literacy topics and coaching to help parents achieve financial goals.
61910684|NCT02727530|EXPERIMENTAL|GROUP RECEIVING VISCERAL MANUAL THERAPY-ADVICES|Subjects will receive 2 manual therapy sessions and advices.
61910685|NCT02727530|EXPERIMENTAL|GROUP RECEIVING ADVICES|Subjects will receive advices.
61910686|NCT04180384|EXPERIMENTAL|Oraxol (paclitaxel capsules+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
61910687|NCT04180384|ACTIVE_COMPARATOR|Oraxol (paclitaxel tablets+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg tablets~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
61910688|NCT02943083|EXPERIMENTAL|Coached Intervention|Perform prenatal relaxation exercise in the lab with a coach and at home
62467015|NCT01596166|PLACEBO_COMPARATOR|Metoclopramide, Placebo|"1. 10 mL/kg IV 0.9% sodium chloride~2. Metoclopramide 0.2 mg/kg (max 10 mg) IV~3. Placebo (normal saline)"
62467016|NCT02436057|NO_INTERVENTION|Usual care|Individuals in this arm will undergo usual care with their physician.
61910689|NCT02943083|ACTIVE_COMPARATOR|Home Intervention|Only perform relaxation exercise at home
61910690|NCT02943083|NO_INTERVENTION|Control Group|Never performs relaxation routine, attends prenatal assessment sessions
61910691|NCT02943083|NO_INTERVENTION|Postpartum Only|Only attends visits postpartum, never receives prenatal assessments
61910692|NCT04645498||Metabolism, Inborn Errors|Patient affected by an inherited metabolic disease
61910693|NCT04109339|NO_INTERVENTION|group 1 with no oxytocin|
61910694|NCT04109339|EXPERIMENTAL|group 2 with oxytocin 10 U IM + oxytocin 10 U IV|
61910695|NCT04109339|EXPERIMENTAL|group 3 with oxytocin 20 U IM + oxytocin 0 U IV|
61910696|NCT04109339|EXPERIMENTAL|group 4 with oxytocin 0 U IM + oxytocin 20 U IV|
61910697|NCT04851093|EXPERIMENTAL|TCM granule plus conventional drug|The experimental group will receive three types of TCM granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
61910698|NCT04851093|PLACEBO_COMPARATOR|TCM placebo granule plus conventional drug|The control group will receive three types of TCM placebo granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
61910699|NCT00928590|EXPERIMENTAL|DuoTrav APS|Travoprost/Timolol Maleate Fixed Combination solution, 1 drop in the study eye(s) once daily, at 9 AM, for 12 months
61910700|NCT00617669|ACTIVE_COMPARATOR|Placebo + Docetaxel|placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
61910701|NCT00617669|EXPERIMENTAL|ZD4054 + Docetaxel|ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
61910702|NCT04002518||Small Screws|Patients who have surgically been treated with a 3.0mm or 4.0mm screw.
61910703|NCT04002518||Large Screws|Patients who have surgically been treated with a 5.0mm, 6.5mm or 8.0mm screw.
61910704|NCT00923364|EXPERIMENTAL|Recipients and Healthy Related Donors|Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
62294716|NCT05920213|EXPERIMENTAL|Lactulose AND LOLA|Lactulose which is the standard of care treatment will be administered with the experimental drug L-ornithine L-aspartate (LOLA).
62294717|NCT05920213|EXPERIMENTAL|Lactulose and PEG|Lactulose which is the standard of care treatment will be administered with the experimental drug polyethylene glycol (PEG).
61910705|NCT02685475||Diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
62294718|NCT05920213|ACTIVE_COMPARATOR|Lactulose|This group will receive Lactulose only which is the standard of care treatment.
62294719|NCT04695509|EXPERIMENTAL|moderate sedation|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with moderate propofol sedation
61910706|NCT02685475||Non-diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
61910707|NCT02491359|EXPERIMENTAL|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
61910708|NCT02747979|EXPERIMENTAL|hemodialysis+hemoperfusion (HA330)|Combination of hemodialysis and hemoperfusion (HA330) therapy All subjects in the study phase will receive hemodialysis plus hemoperfusion(HA330) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
61910709|NCT02747979|EXPERIMENTAL|hemodialysis+hemoperfusion (HA130)|Combination of hemodialysis and hemoperfusion (HA130) treatment All subjects in the study phase will receive hemodialysis and hemoperfusion(HA130) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
61910710|NCT02747979|ACTIVE_COMPARATOR|hemodialysis only|hemodialysis only All subjects in the study phase will receive regular hemodialysis treatment three times per week.
61910711|NCT02872220|EXPERIMENTAL|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products compared to that of a negative control \[0.9% NaCl\] were tested simultaneously on each subject.
61910712|NCT02216812|EXPERIMENTAL|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
61910713|NCT02216812|PLACEBO_COMPARATOR|Placebo|Arm will take 1 placebo pill per day for 6 weeks
61910714|NCT06208956|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reach 3, colonoscope will be inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
61910715|NCT06208956|OTHER|Propofol group|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
62100650|NCT06712225|EXPERIMENTAL|Arm B: Anomia Therapy + Executive Function Training|
62100651|NCT04549051|EXPERIMENTAL|Tenex plus local anesthetic|Use of the TENEX device for sectioning of the CHL
62294720|NCT04695509|EXPERIMENTAL|deep sedation|Arm Description: patients with American Society of Anesthesiologists (ASA I-II), Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with deep propofol sedation
62308176|NCT01498510|NO_INTERVENTION|treatment-as-usual (TAU)|The standard medical treatment provided to chronic pain patients at the study site pain specialty practice
61910716|NCT00910624|EXPERIMENTAL|BOC + PEG/RBV|Participants who enrolled within 2 weeks after the last dose of PEG/RBV in previous protocol received boceprevir (BOC) + peginterferon/ribavirin (PEG/RBV) for up to 44 weeks followed by 24 weeks post-treatment follow-up. Participants who did not enroll within 2 weeks after the last dose of PEG/RBV in previous protocol received PEG/RBV for 4 weeks followed by BOC + PEG/RBV for up to 44 weeks, with 24 weeks post-treatment follow-up.
61910717|NCT02222025|EXPERIMENTAL|Injury Prevention Programme|see intervention prescription
61910718|NCT02222025|NO_INTERVENTION|Control|The coaches of the control group will receive the instruction to regularly perform a common warm-up consisting of running and ball-based exercises (sham treatment, no neuromuscular and stability exercises).
62100652|NCT04549051|OTHER|Local Anesthetic|Only Local anesthetic will be injected into the CHL. This arm will have the option to cross over into Tenex arm at 1 month
62100653|NCT01049620|EXPERIMENTAL|Xelox+RAD001|
61910719|NCT05266573|EXPERIMENTAL|Exercise Participants with Limited Mobility|"The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components:~Warm Up: Walking which is progressively increased from 6 to 15 minutes. Dual task activity is introduced as tolerated by the participants. Participants are able to utilize assistive devices and there were additional supports provided.~Stretching, Strengthening and Balance Activities: Gradual progression of activities and repetitions for 30 minutes that are tailored by the exercise instructor to each participant. Exercises are led by the trainer and performed at the balance bar, in a chair, or in standing. Task oriented activities included items such as: weight shifting, forward/backward/side stepping, squats, forward/backward/side leg raises, toe raises, seated trunk rotations, sit to stand, forward trunk bending, arm rotations, and marching.~Walk/Obstacle Course: The final 6 to 15 minutes included challenged walking through an obstacle course."
62100654|NCT06630962|EXPERIMENTAL|Financial Navigation Arm|A financial navigator will educate these participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies.
62467017|NCT02436057|EXPERIMENTAL|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
61910720|NCT02848729|EXPERIMENTAL|Treatment A: Oral Acetaminophen|Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6
62100655|NCT06630962|NO_INTERVENTION|Routine Care Arm|Participants will not have access to the services of the financial navigator. Financial counseling and assistance will be limited to what is routinely provided by the cancer center.
62100656|NCT02214251|EXPERIMENTAL|PK-16CH EXG system|PK-16CH EXG is a wireless physiological signal acquisition system for monitoring the bio-signals, such as EEG, ECG, and EMG. The system can concomitant EEG and EMG recording during ambulation.
61910721|NCT02848729|EXPERIMENTAL|Treatment B: IV Acetaminophen|Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.
61910722|NCT01986777|ACTIVE_COMPARATOR|lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 10 weeks.
61910723|NCT01986777|PLACEBO_COMPARATOR|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
62100657|NCT00753987|EXPERIMENTAL|1|
62467018|NCT03363503|EXPERIMENTAL|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
62467019|NCT03363503|ACTIVE_COMPARATOR|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
61910724|NCT03345966|EXPERIMENTAL|Immunohistochemistry|"In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.~The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units."
62100658|NCT06220474|EXPERIMENTAL|Radiofrequency treatment (RF), followed by meibomian gland expression (MGX)|Before treatment, a thermage return pad will be applied to subject's skin to help prevent electrical burns. The return pad is a rubber, non-active electrode that creates a return path for radiofrequency energy back to the thermage comfort pulse technology (CPT) system. The upper and lower lid of both eyes are marked with skin marking paper (Thermage ® Skin Marking Paper TK-3.00). Coupling fluid is then applied to the external surface of the upper and lower lids of both eyes. All subjects then receive 225 applications to each eye over the upper and lower eyelids. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.
62100659|NCT06220474|SHAM_COMPARATOR|Sham treatment, followed by meibomian gland expression (MGX)|The training mode is used in the Thermage FLX, which simulates treatment without dissipation of radiofrequency energy. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.
62100660|NCT01234194|ACTIVE_COMPARATOR|Group 1|
62100661|NCT01234194|ACTIVE_COMPARATOR|Group 2|
62294721|NCT02226666||Patients having MRI with Eovist|Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
61910725|NCT03345966|EXPERIMENTAL|Polymerase Chain Reaction PCR|"Calculation of Relative Quantification (RQ) (relative expression):~After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:~Finally, RQ was calculated according to the following equation:~1. ∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene~2. ∆∆ Ct = ∆ Ct sample - Ct control gene~3. RQ = 2-(∆∆Ct)"
61910726|NCT00317291|EXPERIMENTAL|Acupuncture/Moxibustion|Acupuncture/Moxibustion for Peripheral Neuropathy in HIV
61910727|NCT00317291|SHAM_COMPARATOR|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion for Peripheral Neuropathy in HIV
61910728|NCT06200025|EXPERIMENTAL|Virtual Reality Group|visual and auditory cue-based aphasia rehabilitation program in full immersive virtual reality
61910729|NCT06200025|ACTIVE_COMPARATOR|Conventional Group|visual and auditory cue-based aphasia rehabilitation program
61910730|NCT02226133|EXPERIMENTAL|Exclusion of Left Atrial Appendage|Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,
61910731|NCT06492837|EXPERIMENTAL|Mosunetuzumab in combination with Zanubrutinib|"Pre-phase: Zanubrutinib 320 mg daily by mouth (D-15 to D-1)~Induction phase cycle 1 (Q21 days):~* Zanubrutinib 320 mg daily by mouth (D1-21)~* Mosunetuzumab 5 mg, SC (D1)~* Mosunetuzumab 45 mg, SC (D8)~* Mosunetuzumab 45 mg, SC (D15)~Induction phase cycles 2-12 (Q28 days):~* Zanubrutinib 320 mg daily by mouth (D1-28)~* Mosunetuzumab 45 mg, SC (D1)~Maintenance phase cycles 13-24 (Q28 days): Zanubrutinib 320 mg daily by mouth (D1-28)~Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events."
61910732|NCT04868630||Outpatients; Atlantic Sleep Centre & SJRH Respiratory Clinic|The study population consists of approximately 80 adult, outpatient participants recruited from the Atlantic Sleep Centre and the Respiratory Clinic at the Horizon Health Network, Saint John Regional Hospital.
61910733|NCT02826720||HP+|Subjects with plasma Triglyceride or Total cholesterol levels \> 200 mg/dl and low density lipoprotein-cholesterol levels \> 130 mg/dl were included in the hyperlipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
62100662|NCT02257866||Healthy Volunteers|Patients without known auto immune diseases
61910734|NCT02826720||HP-|Subjects with plasma Triglyceride or Total cholesterol levels \> 200 mg/dl and low density lipoprotein-cholesterol levels \> 130 mg/dl were included in the hyperlipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
62100663|NCT02257866||Vasculitis|Patients with known or suspected vasculitis age 5 or older
62100664|NCT02953275|EXPERIMENTAL|vedolizumab plus pentoxifylline|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.
62100665|NCT02953275|PLACEBO_COMPARATOR|vedolizumab plus placebo|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.
62100666|NCT06687668|EXPERIMENTAL|Short Leg Walking Plaster Cast|Participants in this group will receive a short leg walking plaster cast, extending from the metatarsal heads up to the mid-calf. This cast limits mobility at the fracture site while allowing partial weight-bearing as tolerated. Participants will use this cast for six weeks, with follow-up for fracture healing and functional outcome at the end of the treatment period.
61910735|NCT02826720||NP+|Subjects with plasma Triglyceride or Total cholesterol levels \< 200 mg/dl and low density lipoprotein-cholesterol levels \< 130 mg/dl were included in the normolipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
61910736|NCT02826720||NP-|Subjects with plasma Triglyceride or Total cholesterol levels \< 200 mg/dl and low density lipoprotein-cholesterol levels \< 130 mg/dl were included in the normolipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
62467020|NCT05235321|ACTIVE_COMPARATOR|Standard GAT|This is the standard method for IOP measurement in clinical practice
61910737|NCT04548843|EXPERIMENTAL|Cohort 1 & Cohort 2|"3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells).~3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells)."
61910738|NCT04803123|EXPERIMENTAL|Copanilisib|
61910739|NCT01090583||Cesarean Delivery Patients|
61910740|NCT06139042||liver, biliary tract, and pancreatic cancers|participants with liver, biliary tract, and pancreatic cancers
61910741|NCT06139042||liver, biliary tract, and pancreatic benign diseases|participants with liver, biliary tract, and pancreatic benign diseases
62662376|NCT04790201|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Enhanced usual care will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care.
61910742|NCT06139042||non-liver, biliary tract, and pancreatic diseases|Participants with no known presence of malignancies or benign diseases
61910743|NCT04012489|ACTIVE_COMPARATOR|Breath Stacking|Breath stacking: patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
61910744|NCT04012489|EXPERIMENTAL|Air Stacking|Air stacking: the same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
62100667|NCT06687668|ACTIVE_COMPARATOR|Walking Foot Plaster Cast|Participants in this group will receive a walking foot plaster cast, which provides support to the foot while allowing more flexibility around the ankle. This cast restricts movement to avoid further injury while enabling weight-bearing activities as tolerated. The cast will be worn for six weeks, with follow-up assessments for fracture healing and functional outcome after this period.
62662377|NCT03395964|ACTIVE_COMPARATOR|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
62662378|NCT03395964|EXPERIMENTAL|Hybrid Dyna-CT guided localization|Patients will be brought into the Hybrid OR, and placed in the lateral decubitus position. A C-arm CT scan of the pre-determined ﬁeld of view that included the nodule position will be acquired during an end-inspiratory hold maneuver using a 5 sec scan protocol with 0.36mGy/projection and 248 projections acquired over 200°. The radiologist reviewed the C-arm CT scan to localize the nodule and plan trajectories for percutaneous hook-wire placement using Syngo iGuide needle guidance software. The planned needle pathways will be integrated into the C-arm fluoroscopic imaging system, which provided laser crossbar and guidance markers on fluoroscopy images to direct the needle pathway for hook wire placement.
62662379|NCT06068400|EXPERIMENTAL|BCMA/GPRC5D double CAR-T|The study plans to enroll 40 subjects, with a sample size based on actual occurrence and a dosage of 3 × 106/kg ± 20%\~1 × 107/kg ± 20% CAR positive T cells
62662380|NCT01644838|EXPERIMENTAL|Promethazine|25 mg of promethazine
62662381|NCT01644838|EXPERIMENTAL|Hyoscine|20 mg of hyoscine
61910745|NCT03660137|EXPERIMENTAL|MOLLI Localization|All patients will be implanted with a MOLLI magnetic seed in addition to the standard-of-care RSL seed. Both systems will be use to localize the respective seeds during the lumpectomy surgery.
61910746|NCT00164697|EXPERIMENTAL|1|Parenting group
61910747|NCT00164697|NO_INTERVENTION|2|"Families in this usual care comparison group were not prevented from utilizing any service that would otherwise be available to them, even if the service was similar to the services received in the intervention arm of the study."
61910748|NCT01606657|ACTIVE_COMPARATOR|Irrigation|THE PATIENT IS TO HAVE IRRIGATION OF THE ABSCESS WITH NORMAL SALINE AS PART OF THE I\&D PROCEDURE
61910749|NCT01606657|PLACEBO_COMPARATOR|No Irrigation|THE PATIENT IS NOT TO HAVE IRRIGATION OF THE ABSCESS AS PART OF THE I\&D PROCEDURE
61910750|NCT05448820|EXPERIMENTAL|P1 Cohort 1A: Dose 1 YH001 + Dose 1 Envafolimab Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 Envafolimab every 3 weeks.
62100668|NCT01281761|EXPERIMENTAL|cetuximab/irinotecan/simvastatin|"D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily)~* every 2weeks"
62100669|NCT01147549|EXPERIMENTAL|1|\[C14\]AZD9668
62662382|NCT05375305|EXPERIMENTAL|Treatment group A：SHR8554 Injection|
61910751|NCT05448820|EXPERIMENTAL|P1 Cohort 2A: Dose 2 YH001 + Dose 1 Envafolimab Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 Envafolimab every 3 weeks.
62662383|NCT05375305|EXPERIMENTAL|Treatment group B：SHR8554 Injection|
62662384|NCT05375305|PLACEBO_COMPARATOR|Treatment group C：Saline Solution|
61910752|NCT05448820|EXPERIMENTAL|P1 Cohort 1B: Dose 1 YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 of Envafolimab with Doxorubicin every 3 weeks.
61910753|NCT05448820|EXPERIMENTAL|P1 Cohort 2B: Dose 2 YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 of Envafolimab with Doxorubicin every 3 weeks.
61910754|NCT05448820|EXPERIMENTAL|P2: Sarcoma Subtype 1 RP2D YH001 + Dose 1 Envafolimab Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks
62662385|NCT05375305|ACTIVE_COMPARATOR|Treatment group D：Morphine|
61910755|NCT05448820|EXPERIMENTAL|P2: Sarcoma Subtype 2 RP2D YH001 + Dose 1 Envafolimab Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks
62308177|NCT01498510|EXPERIMENTAL|TAU plus web-based intervention|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that teaches chronic pain patients with aberrant behavior self-management skills to reduce pain severity and medication misuse and improve functioning
62308178|NCT01070355|PLACEBO_COMPARATOR|Placebo|2 capsules twice daily
61910756|NCT05448820|EXPERIMENTAL|P2: Sarcoma Subtype 3 RP2D YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks and Doxorubicin every 3 weeks for a maximum of 6 doses
61910757|NCT05448820|EXPERIMENTAL|P2: Sarcoma Subtype 4 RP2D YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks and Doxorubicin every 3 weeks for a maximum of 6 doses
61910758|NCT00028145||1|Pregnant, HIV-infected women
61910759|NCT05375773|NO_INTERVENTION|Control group|Participants in the Control group accept standard treatment for the management of their symptoms according to the diagnosis and treatment for novel coronavirus pneumonia (Trial Nine Edition).
62308179|NCT01070355|ACTIVE_COMPARATOR|Eicosapentaenoic acid free fatty acid|2g daily (2 x 500mg capsules twice daily)
62308180|NCT00906789||Radiologists|Radiologists who have certification by the American Board of Radiology
62100670|NCT06713902||Fifty-one m/f patients matching the inclusion and exclusion criteria|Six patients undergoing plastic surgery procedures for the removal of adipose tissue from which waste material (adipose tissue) will be taken to obtain MSCs for EVs production. Five patients undergoing hip or knee joint replacement surgery from which waste material (osteo-cartilaginous material) will be taken to obtain chondrocytes for functional tests. Forty patients undergoing regenerative medicine treatments with PRP from which a waste aliquot (obtained during PRP preparation) will be taken to obtain plasma for fibrin gel production.
62100671|NCT06224595|EXPERIMENTAL|CS32582 Cohort 1|Subjects receive a single dose of 3 mg CS32582 or matching placebo
62100672|NCT06224595|EXPERIMENTAL|CS32582 Cohort 2|Subjects receive a single dose of 6 mg CS32582 or matching placebo
62467021|NCT05235321|EXPERIMENTAL|Fixed-force GAT|From the patient perspective, this method will feel identical to the standard GAT. The eye is given topical fluorescein/anesthetic. The GAT dial is set at 1.8 or 2.0, a C-MOS camera is connected to one of the oculars of the slit lamp machine and under blue light illumination, the GAT prism contacts the eye while the CMOS camera makes a video of the mire appearance through the ocular. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
62100673|NCT06224595|EXPERIMENTAL|CS32582 Cohort 3|Subjects receive a single dose of 12 mg CS32582 or matching placebo
62100674|NCT06224595|EXPERIMENTAL|CS32582 Cohort 4|Subjects receive a single dose of 24 mg CS32582 or matching placebo
62100675|NCT06224595|EXPERIMENTAL|CS32582 Cohort 5|Subjects receive a single dose of 36 mg CS32582 or matching placebo
62100676|NCT06224595|EXPERIMENTAL|CS32582 Cohort 6|Subjects receive a single dose of 54 mg CS32582 or matching placebo
62294722|NCT02226666||Patients having MRI with Multihance|Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
62100677|NCT06224595|EXPERIMENTAL|CS32582 Cohort 7|Subjects receive a single dose 12 mg CS32582 in either the fasted or fed state for two periods
62100678|NCT06224595|EXPERIMENTAL|CS32582 Cohort 8|Subjects receive 3 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.
62100679|NCT06224595|EXPERIMENTAL|CS32582 Cohort 9|Subjects receive 6 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.
62100680|NCT06224595|EXPERIMENTAL|CS32582 Cohort 10|Subjects receive 12 mg CS32582 or matching placebo for 10 days, once daily from Day 1 to Day 10.
62100681|NCT06224595|EXPERIMENTAL|CS32582 Cohort 11|Subjects receive 12 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.
62100682|NCT06712420|EXPERIMENTAL|upfront surgery|after staging workup and biopsy, patient being taken up for upfront surgical exploration will undergo staging laparoscopy followed by exploration and interaortocaval lymphnode sampling. After ruling out distant metastasis, local resectability will be reassessed and curative surgery will be performed. . Post-operative complications were recorded and graded according Clavien Dindo classification
62100683|NCT06712420|EXPERIMENTAL|Neoadjuvant chemotherapy followed by surgery|NACT group will receive gemcitabine and platinum combination. Most common regimen comprised of gemcitabine (1000 mg/ m2 intravenously over 30-60 min) on days 1 and 8, and cisplatin (75 mg/ m2 intravenously over 2 h) on day 1, every 21 days. In case of renal compromise, carboplatin was used. Response was assessed using CECT abdomen and PET scan. Chemotherapy related toxicity will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 5 .0.
62100684|NCT04824131|EXPERIMENTAL|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or join an open-label extension CAB study in their area, if available.
62294723|NCT06657690|EXPERIMENTAL|Irinotecan liposome group|Irinotecan liposome injection combined with S-1 every 4 weeks for up to 6 cycles, until intolerable toxicity, subject withdrawal of informed consent, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
61910760|NCT05375773|EXPERIMENTAL|PVP-I Nasal Irrigation and gargling|Participants in the intervention arm will be required to perform Nasal Irrigation and gargling 4 times daily. They will also accept standard treatment for the management of their symptoms according to the diagnosis and treatment for novel coronavirus pneumonia (Trial Nine Edition).
61910761|NCT05940454|EXPERIMENTAL|Pericapsular nerve group block (Group P)|Pericapsular nerve group block will be performed with 20 ml of 0.5% bupivacaine hydrochloride before general anesthesia is applied to the patients in Group P.
61910762|NCT05940454|NO_INTERVENTION|control group (Group C)|No block will be applied to patients in Group C.
62100685|NCT05599633|EXPERIMENTAL|Intervention Arm|Subjects who are randomised to Intervention Arm will be taking a drink containing 25g of Sarawak sago starch in 200mL of plain water. The subjects will take the drink twice daily i.e., within 30 minutes before lunch and dinner. On top of that, they will be counselled on diet recommendations for diabetes by a study dietitian at Visit 1 or baseline.
62100686|NCT05599633|PLACEBO_COMPARATOR|Control Arm|Subjects who are randomised to Control Arm will be taking a drink containing 25g of corn starch in 200mL of water. The subjects will take the starch suspension twice daily i.e., within 30 minutes before lunch and dinner. On top of that, they will be counselled on diet recommendation for diabetes by a study dietitian at Visit 1 or baseline.
62100687|NCT06711198|NO_INTERVENTION|Control group (application with calf tongue)|Control group (application with calf tongue): In Sakarya University Midwifery Department, while teaching episiotomy application within the scope of Normal birth and postpartum period course, laboratory application is routinely performed on calf tongue. Therefore, the application group to be performed on calf tongue was accepted as the control group. The instructor will first provide theoretical training on episiotomy to the group coming to the laboratory. The theoretical training period will consist of 50 minutes. The content of the training will include the importance of episiotomy, risks, indications, contraindications, episiotomy application time, materials used, episiotomy types, episiotomy repair and time, suture techniques and midwifery care in episiotomy. While explaining suture techniques within the scope of this course, videos about suture techniques on social media platforms will be watched by students. Immediately after the training, episiotomy repair (suture techniques) ap
62294724|NCT04526184|ACTIVE_COMPARATOR|healthy group|25 healthy individuals between the ages of 40-70 will be contacted by phone and included in the initiative.
61910763|NCT06394934||Home BP Monitoring Cohort|Participants in this cohort are hypertensive adults who will use the Healthscan mobile application to monitor and record their blood pressure at home.
61910764|NCT00918073||HIV positive smokers|50 HIV infected patients who enroll in a parent protocol to quit smoking and elect to participate in this sub-study.
62294725|NCT04526184|ACTIVE_COMPARATOR|patient group|25 individuals will be selected randomly from 103 patients with COPD from hospital records.
62294726|NCT00456703|ACTIVE_COMPARATOR|restriction|In this group, the fluids will be restricted compared to a standard procedure
62294727|NCT01106924|EXPERIMENTAL|Probiotic|daily probiotic consumption
61910765|NCT02866955|OTHER|GROUP E (Estramustine)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by estramustine
61910766|NCT02866955|OTHER|GROUP T (Tamoxifen)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by tamoxifen
61910767|NCT06226532|EXPERIMENTAL|Group SL|10%lidocaine spray total 8 puffs at laryngoscopes blade and endotracheal tube cuff, 4 puffs each.
61910768|NCT06226532|ACTIVE_COMPARATOR|Group IL|2% lidocaine intravenous 1.5 mg/kg, not exceed 80 mg equally to spray group.
62294728|NCT01106924|PLACEBO_COMPARATOR|Placebo|daily placebo consumption
62308181|NCT03939910|ACTIVE_COMPARATOR|Control arm|bupivacaine 0.25% for pudendal block
61910769|NCT04583709|EXPERIMENTAL|ECG Belt|ECG belt will be used to record ECG during baseline rhythm, LBBP in unipolar and bipolar configurations and / or during HOT-CRT using HBP or LBBP. These ECG belt characteristics would then be compared with baseline and existing data on RV pacing and traditional Biventricular pacing.
61910770|NCT02296138|EXPERIMENTAL|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
61910771|NCT02296138|ACTIVE_COMPARATOR|tiotropium|Once daily 2 puffs solution for inhalation Respimat
61910772|NCT02642497|ACTIVE_COMPARATOR|local ketamine group|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
62308182|NCT03939910|EXPERIMENTAL|Intervention arm|ropivacaine 0.2 % for the pudendal block
62662386|NCT03991767|EXPERIMENTAL|period 1|"Period 1: Retrospective period:~Collection of data from the 12 months preceding the start of the research of hospitalized patients:~* number of hospitalizations,~* number of HIV serologies performed,~* number of patients with socio-demographic criteria justifying HIV screening.~Start of research: Implementation of the POP-UP electronic alert~Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.~Six possibility to answer:~1. Patient accept to participate: patient is include and receive HIV serology during their hospitalization.~2. Not time to answer to the alert~3. Patient already has a serology less than 3 months old~4. Patient followed for a known HIV infection.~5. Patient who refused the test~6. Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization."
62662387|NCT03191968|EXPERIMENTAL|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
61910773|NCT02642497|PLACEBO_COMPARATOR|control group|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
61910774|NCT02642497|ACTIVE_COMPARATOR|systemic ketamine group|Intra-muscular injection of ketamine at a dose of 1 mg/kg before wound closure.
61910775|NCT00766753|EXPERIMENTAL|Single|All consenting, eligible subjects receive the intervention
61910776|NCT06450119|EXPERIMENTAL|dual-task training|walking and cognition training
61910777|NCT06450119|ACTIVE_COMPARATOR|walking training alone|walking training
61910778|NCT06450119|ACTIVE_COMPARATOR|cognition training alone|cognition training
61910779|NCT06450119|NO_INTERVENTION|waiting list group|no intervention
61910780|NCT03964558|OTHER|100 mg [14C]-acebilustat|a single oral dose of 100 mg \[14C\]-acebilustat
61910781|NCT02248558|ACTIVE_COMPARATOR|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
61910782|NCT02248558|EXPERIMENTAL|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
61910783|NCT03910920||Cystic fibrosis patients with PA|All the children with acute or chronic Pseudomonas aeruginosa infection and followed-up in our cystic fibrosis center will be included in this study.
61910784|NCT00243607|EXPERIMENTAL|immediate treatment group (SBG)|immediate start of hydrotherapy (self treatment) in immediate treatment group (SBG)
62308183|NCT04760548||Train dataset|This group is dedicated to developing an automated algorithm
62308184|NCT04760548||Test dataset|This group is dedicated to testing the semantic performance of an automated algorithm
62308185|NCT04760548||Clinical Validations|Patients groups are dedicated to assessing the clinical validity of the measurement in independent validation cohorts, with or without longitudinal evaluations such as monitoring of a treatment effect
62308186|NCT04577768|EXPERIMENTAL|HD-tDCS 2 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 2 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
61910785|NCT00243607|NO_INTERVENTION|waiting group (WG)|start of hydrotherapy (self treatment) after waiting period of 12 weeks
61910786|NCT05145738|EXPERIMENTAL|C-Raven + Avatar|Computer delivered intervention with Avatar as virtual counselor plus linkage to community health worker
61910787|NCT05145738|ACTIVE_COMPARATOR|C-Raven|Computer-delivered intervention without virtual counselor, with linkage to community health worker
62294729|NCT04848493||HEMATOLOGICAL MALIGNANCIES|"1a. Newly diagnosed patients with ANY haematological malignancy requiring treatment (No.=100).~1b. Patients with ongoing treatments or with treatments completed within 6 months (chemotherapy and target therapies) other than antibodies. More specifically: patients with ongoing or completed chemotherapy (No.=50) or patients with ongoing or completed Ibrutinib (No.=50) or patients with ongoing or completed ruxolitinib (No.=50)~1c. Patients treated with anti-CD19 or CD20 or CD22 or CD30 or anti-PD1 antibodies with or without chemotherapy OR patients receiving CAR-T cells: patients treated anti-B-cell (No.=50) or patients treated anti-CD30 (No.=50) or patients treated anti-PD1 (No.=50).~1d. Patients at three months after autologous or allogeneic transplantation without active immune suppressive therapy: after autologous transplantation (No.=50) or after allogenic transplantation (No.=50)."
62308187|NCT04577768|EXPERIMENTAL|HD-tDCS 1.5 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 1.5 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
61910788|NCT02066987|EXPERIMENTAL|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
61910789|NCT02066987|EXPERIMENTAL|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
61910790|NCT02066987|ACTIVE_COMPARATOR|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
61910791|NCT01094392||treatment every 6th week during 6 months|
61910792|NCT01094392||treatment every 2nd week during 6 months|
61910793|NCT03253419|OTHER|Home Safety Application|Use of Home Safety application as part of assessment for home safety. The only intervention is the use of the home safety application and identification of home safety issues by the patient using this application.
61910794|NCT00957125|EXPERIMENTAL|Epirubicin Docetaxel Bevacizumab|"Epirubicin and docetaxel i.v. infusion q 3 weeks for 2 cycles.~* If complete response this treatment continues for 4 cycles, totally 6 cycles.~* If partial response or stable disease, epirubicin and docetaxel and bevacizumab i.v. infusion q 3 weeks for 4 cycles.~* If progressive disease after the first 2 cycles individualized treatment."
62308188|NCT04577768|SHAM_COMPARATOR|Control|Single session of 20-min of sham HD-tDCS. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
62308189|NCT01746602|EXPERIMENTAL|healthy subjects I|20 healthy subjects
62308190|NCT01746602|EXPERIMENTAL|healthy subjects II|20 healthy subjects
62308191|NCT01746602|EXPERIMENTAL|healthy subjects III|20 healthy subjects
62308192|NCT01746602|EXPERIMENTAL|healthy subjects IV|20 healthy subjects
62308193|NCT01746602|EXPERIMENTAL|healthy subjects V|20 healthy subjects
62662388|NCT03191968|ACTIVE_COMPARATOR|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
62662389|NCT04077359|EXPERIMENTAL|nephrographic phase CT|the nephrographic phase will be evaluated alone by a radiologist blinded to the remaining series
62662390|NCT04077359|ACTIVE_COMPARATOR|gold standard|all series (unenhanced, corticomedullary, nephrographic and excretory phase) will be evaluated by a radiologist not involved in the experimental arm
62662391|NCT00839826|ACTIVE_COMPARATOR|Arm 2|
62662392|NCT00839826|EXPERIMENTAL|Arm 1|
62662393|NCT03034928|OTHER|Test 1/Control 1, then Control 2/Test 2|Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
62662394|NCT03034928|OTHER|Test 2/Control 2, then Control 1/Test 1|Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
62662395|NCT03034928|OTHER|Control 1/Test 1, then Test 2/Control 2|Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
61910795|NCT05947292||Nerve Block|Patients with femur fractures who receive a fascia-iliaca compartment nerve block as part of their care in the Emergency Department.
61910796|NCT05947292||No Nerve Block|Patients with femur fractures who receive only intravenous analgesia in the Emergency Department.
62662396|NCT03034928|OTHER|Control 2/Test 2, then Test 1/Control 1|Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
62662397|NCT03003689|ACTIVE_COMPARATOR|Scaling and Root Planing|"Hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
62662398|NCT03003689|EXPERIMENTAL|Scaling and Root Planing + Er:YAG Laser|"Er:YAG Laser, hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
62662399|NCT01060488|ACTIVE_COMPARATOR|Group 1:|
62662400|NCT01060488|ACTIVE_COMPARATOR|Group 2:|
61910797|NCT03154892|EXPERIMENTAL|Intracameral injection|Intracameral injection of conbercept for the treatment of NVG
61910798|NCT03154892|ACTIVE_COMPARATOR|Intravitreal injection|Intravitreal injection of conbercept for the treatment of NVG
62308194|NCT01746602|NO_INTERVENTION|healthy subjects VI|20 healthy subjects
62308195|NCT01372891||Patients underging PCI|
62308196|NCT01224899|EXPERIMENTAL|Surgery|
62662401|NCT00932854|EXPERIMENTAL|EBUS|All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
62662402|NCT02937922|ACTIVE_COMPARATOR|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: \[(HR max - HR rest) x desired intensity\] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
62308197|NCT01224899|NO_INTERVENTION|Control|
61910799|NCT03346473||Adolescents aged 12-15 years in LMICs|No interventions administered
61910800|NCT01265654||All patients|Patients with ABC and two lines of hormonal treatment
62100688|NCT06711198|EXPERIMENTAL|1. Experimental group (Application with virtual reality simulation)|The instructor will first provide theoretical training to the group coming to the laboratory on episiotomy. The theoretical training will consist of 50 minutes. The content of the training will include the importance of episiotomy, risks, indications, contraindications, episiotomy application time, materials used, episiotomy types, episiotomy repair and time, suture techniques and midwifery care in episiotomy. While explaining suture techniques within the scope of this course, videos on suture techniques on social media platforms will be watched by the students. Immediately after the training, the episiotomy repair (suture techniques) application will be started. Students will be taken to the laboratory one by one. The student who is taken to the application will be put on the Meta Quest 3 virtual reality glasses and the episiotomy application will be started via the computer integrated with the glasses. The episiotomy application will start with the image of a woman who has given bir
62100689|NCT06711198|EXPERIMENTAL|2. Experimental group (Both calf tongue and virtual reality simulation)|Students in this group will first receive theoretical training as in other groups. The theoretical training will consist of 50 minutes. The content of the training will include the importance of episiotomy, risks, indications, contraindications, episiotomy application time, materials used, episiotomy types, episiotomy repair and time, suture techniques and midwifery care in episiotomy. While suture techniques are explained in this course, videos about suture techniques on social media platforms will be watched by students. Immediately after the training, an application will be made in a virtual reality simulation for episiotomy repair, and then the application will be repeated on the calf tongue.
62100690|NCT05218603||Maintenance with V-Dara after receiving VMP-Dara as induction regimen|Maintenance with bortezomib plus daratumumab (V-Dara) after induction with bortezomib, melphalan, prednisone plus daratumumab (VMP-Dara)
62100691|NCT02248142||RLS patients|
62100692|NCT06219213|EXPERIMENTAL|Group A: Cream of formulation A|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation A on both targeted skin area. The skin areas must be clean and dry. Subjects may proceed with additional product applications if needed. However, for each additional application, both targeted areas must be treated with the Serum and the cream. Subjects must proceed with at least one application of products each day for 14 consecutive days.
62100693|NCT06219213|EXPERIMENTAL|Group B: Cream of formulation B|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation B on both targeted skin area. The skin areas must be clean and dry. Subjects may proceed with additional product applications if needed. However, for each additional application, both targeted areas must be treated with the Serum and the cream. Subjects must proceed with at least one application of products each day for 14 consecutive days.
61910801|NCT01328444|EXPERIMENTAL|GSK 573719 + GW642444 125/25|125mcg/25mcg nDPI
61910802|NCT01328444|EXPERIMENTAL|GSK 573719 +GW642444 62.5/25|62.5mcg/25mcg nDPI
61910803|NCT01328444|EXPERIMENTAL|GSK 573719 125|125mcg nDPI
61910804|NCT01328444|EXPERIMENTAL|GSK 573719 62.5|62.5 mcg nDPI
61910805|NCT01328444|EXPERIMENTAL|GW 642444 25|25mcg nDPI
61910806|NCT01328444|PLACEBO_COMPARATOR|Plb|Plb nDPI
61910807|NCT04163289|EXPERIMENTAL|Fecal Microbiota Transplantation|Fecal microbiota transplantation combined with approved standard of care treatment with nivolumab and ipilimumab.
61910808|NCT03879343||Clinical group|Children aged six to eleven with clinical diagnosis of attention deficit / hyperactivity disorder were recruited for interview and completion of questionnaires
61910809|NCT03879343||Control group|Normally developing children aged six to eleven studying in local mainstream primary schools were recruited for completion of questionnaires
61910810|NCT05946304|EXPERIMENTAL|Standard care + moderate-intensity continuous exercise training (MICT)|Supervised virtual MICT exercise sessions for 12 weeks (2x/wk) using the platform Zoom Care.
61910811|NCT05946304|EXPERIMENTAL|Standard care + high-intensity interval training (HIIT)|Supervised virtual HIIT exercise sessions for 12 weeks (2x/wk) using the platform Zoom Care.
61910812|NCT06299371|EXPERIMENTAL|neoadjuvant immuno-chemotherapy|Adebrelimab plus paclitaxel for injection (albumin bound) and platinum chemotherapy
61910813|NCT03446144|EXPERIMENTAL|IONIS-FB-Lrx|
61910814|NCT03446144|PLACEBO_COMPARATOR|Placebo (sterile saline 0.9%)|
61910815|NCT01800175|EXPERIMENTAL|Formulation C|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
62662403|NCT02937922|ACTIVE_COMPARATOR|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60% of a maximum repetition (1-RM) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
62100694|NCT06219213|EXPERIMENTAL|Group C: Cream of formulation C|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation C on both targeted skin area. The skin areas must be clean and dry. Subjects may proceed with additional product applications if needed. However, for each additional application, both targeted areas must be treated with the Serum and the cream. Subjects must proceed with at least one application of products each day for 14 consecutive days.
62100695|NCT06709339|EXPERIMENTAL|Faricimab|This open-label, single-arm study will evaluate the efficacy, safety, and durability of Faricimab Injection \[Vabysmo\] 6 mg anti-VEGF IVT in Caucasian patients with symptomatic macular PCV.
62100696|NCT05206357|EXPERIMENTAL|Epcoritamab|Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
62100697|NCT05458102|EXPERIMENTAL|Cohort 1: Vesatolimod + Cobicistat + Voriconazole|Participants will receive a single dose of vesatolimod (VES) 2 mg on Day 1 of Period 1. In Period 2, participants will receive cobicistat (COBI) 150 mg once daily on Days 1 to 5 along with a single dose of VES 2 mg on Day 2. In Period 3, participants will receive a loading dose of voriconazole (VOR) 400 mg twice daily on Day 1, then VOR 200 mg twice daily on Days 2 to 6, and a single dose of VES 2 mg in the morning on Day 3. There will be a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1 and a washout period of 14 to 21 days between treatments in Period 2 Day 5 and Period 3 Day 1.
62662404|NCT02937922|ACTIVE_COMPARATOR|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
62662405|NCT01482221|EXPERIMENTAL|1|
62662406|NCT01482221|EXPERIMENTAL|2|
62662407|NCT01482221|PLACEBO_COMPARATOR|3|
62662408|NCT06310135|EXPERIMENTAL|Unfiltered Monocular|Unfiltered monocular with the non-dominant eye occluded.
62662409|NCT06310135|EXPERIMENTAL|Filtered Binocular|Filtered binocular with both eyes filtered.
62662410|NCT06310135|EXPERIMENTAL|Filtered Monocular|Filtered monocular with non-dominant eye filtered, the other non-filtered.
62662411|NCT06310135|EXPERIMENTAL|Unfiltered Binocular|Unfiltered binocular - neither eye will be filtered.
62662412|NCT06310135|PLACEBO_COMPARATOR|Dim Light Control|Dim light with no filters.
62100698|NCT05458102|EXPERIMENTAL|Cohort 2: Vesatolimod + Rifabutin|Participants will receive a single dose of VES 6 mg on Day 1. In Period 2, participants will receive Rifabutin (RFB) 300 mg once daily on Days 1 to 9 along with a single dose of VES 6 mg on Day 6. There will be a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1.
62100699|NCT01473628|EXPERIMENTAL|Arm I (radiation therapy and rituximab)|Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
62100700|NCT01473628|EXPERIMENTAL|Arm II (radiation therapy and observation)|Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
62662413|NCT03593629|NO_INTERVENTION|Standard of Care|Participants receive standard of care for PrEP, including 3-months of PrEP supply and HIV testing at clinic every three months
62662414|NCT03593629|EXPERIMENTAL|Blood-based HIV self-testing|Participants receive 6-months of PrEP supply and blood-based HIV self-tests for quarterly HIV testing.
62662415|NCT03593629|EXPERIMENTAL|Oral fluid HIV self-testing|Participants receive 6-months of PrEP supply and oral fluid HIV self-tests for quarterly HIV testing.
62662416|NCT02019537|ACTIVE_COMPARATOR|Steroid group|Triamcinolone injection group
62662417|NCT02019537|EXPERIMENTAL|PRP group|Allogeneic PRP injection group
62662418|NCT00260442|PLACEBO_COMPARATOR|Placebo|\< 200 mg/day dietary cholesterol, resistance training, sedentary
62662419|NCT00260442|EXPERIMENTAL|Average intake|400 mg/day dietary cholesterol, resistance training, sedentary
62662420|NCT00260442|EXPERIMENTAL|High intake|800 mg/day dietary cholesterol, resistance training, sedentary
62662421|NCT03912636|ACTIVE_COMPARATOR|Diaphragmatic breathing in healthy volunteers in study1|Healthy volunteers will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
62662422|NCT03912636|ACTIVE_COMPARATOR|Diaphragmatic breathing in rumination patients in study1|Rumination patients will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
62662423|NCT03912636|ACTIVE_COMPARATOR|Deep slow breathing in healthy volunteers in study1|Healthy volunteers will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
62662424|NCT03912636|ACTIVE_COMPARATOR|Deep slow breathing in rumination patients in study1|Rumination patients will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
62662425|NCT03912636|PLACEBO_COMPARATOR|Normal breathing in healthy volunteers in study1|healthy volunteers will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
62662426|NCT03912636|PLACEBO_COMPARATOR|Normal breathing in rumination patients in study1|rumination patients will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
62662427|NCT03912636|ACTIVE_COMPARATOR|Diaphragmatic breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
62662428|NCT03912636|ACTIVE_COMPARATOR|Deep slow breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
61910816|NCT01800175|EXPERIMENTAL|Formulation D|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
62100701|NCT05892289|EXPERIMENTAL|Robotic assisted proximal gastrectomy with double-flap technique|
62100702|NCT00818025|NO_INTERVENTION|Standard of Care|All subjects will receive standard care to prepare for discharge that consists of a one-on-one, pre-discharge educational session delivered by the transplant coordinator prior to hospital discharge and provision of a reference binder for each lung transplant recipient to take home.
62662429|NCT03915899|EXPERIMENTAL|WIN Intervention|WIN Intervention
62662430|NCT03915899|NO_INTERVENTION|Standard of Care|No WIN intervention.
62662431|NCT02333032|EXPERIMENTAL|hemiplegic patient|
62662432|NCT02596672|EXPERIMENTAL|Intervention|They will complete a 12-week peer-led walking programme. Participants will be paired together as walking partners and will be given a pedometer and step count logs for self-monitoring. The walking co-ordinators will facilitate walking groups two times a week in the local areas, lasting for 30 minutes. The nature of the walks will be tailored to the participants stated preferences of types of activity. Participants will also receive local walking route maps. After 12 weeks, the formal peer-led component will finish and participants will be encouraged to continue walking with their walking partners other activity programmes organised in the fold in order to maintain activity levels.
62662433|NCT02596672|NO_INTERVENTION|Control|"Folds assigned to the control group will not receive any additional support to change their physical activity behaviour over the course of the intervention period.~At the six-month data collection point they will be offered a referral to a local walking group in their area or advice on beginning a self-directed walking programme (similar to Public Health Agency www.choosetolivebetter.com/content/getting-active). They will be asked to complete outcome measures at baseline and follow up time-points. Post-study a sample of control participants will be asked to attend a focus group, exploring their views on social activity as form of physical activity for older adults in folds."
62662434|NCT02534961|ACTIVE_COMPARATOR|prophylactic antibiotics group|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy.
62662435|NCT02534961|NO_INTERVENTION|on-demand antibiotics group|Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.
62662436|NCT03084484|EXPERIMENTAL|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
62662437|NCT03084484|ACTIVE_COMPARATOR|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the control group didi not receive any dietary advice."
62662438|NCT06117137|EXPERIMENTAL|Control group|Control group (stander treatment of Type two diabetes mellitus without SGLT2-I )
61910817|NCT02654964|EXPERIMENTAL|Treatment Arm|"A Drug Combination Treatment will be determined through High Throughput Screening. The classes of drugs this combination therapy will be comprised from are:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
61910818|NCT01482390|EXPERIMENTAL|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
62100703|NCT00818025|EXPERIMENTAL|Pocket PATH hand-held device|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
62662439|NCT06117137|EXPERIMENTAL|Group dapa|Dapa group: (stander treatment of type two diabetes mellitus plus Dapagliflozin)
62100704|NCT00867347|ACTIVE_COMPARATOR|Arm I|"Patients undergo a radical cystectomy, including pelvic lymphadenectomy,~between 4 and 6 weeks after initiating course 4 of chemotherapy."
62662440|NCT06117137|EXPERIMENTAL|Group empa|Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin
62662441|NCT03104803|EXPERIMENTAL|Long-term PAS|The intervention is given to one hand only
62100705|NCT00867347|EXPERIMENTAL|Arm II|Patients with no visible residual tumor (cT0 or pT0) or residual but superficial tumor (pTa, pT1) undergo radiotherapy beginning within 4-6 weeks of day 1 of course 4 and continuing for 6.5 weeks.
62100706|NCT06022848|EXPERIMENTAL|Quantitative sensory testing|
62662442|NCT03104803|NO_INTERVENTION|No intervention|Contralateral hand of the same patient
62662443|NCT04925323|EXPERIMENTAL|a plastic or repair surgery indication generating surgical waste|
62100707|NCT06552234|EXPERIMENTAL|Repotrectinib treatment|patient treated by Repotrectinib until progression or unacceptable toxicity
62308198|NCT05533554|EXPERIMENTAL|Experimental group with intervention|The experimental group will receive the intervention. First, the group will undergo a pre-intervention evaluation lasting 120 minutes. The intervention will consist of two synchronized virtual sessions of brief intervention with a cognitive-behavioral approach where various persuasive communication strategies will be implemented, definition of hazardous alcohol consumption, establishment of a consumption goal, social skills to deal with pressure to consume and plan of pleasant activities alternative to consumption, each session will last 120 minutes. Four weeks after the end of the intervention, the experimental group will carry out the post-intervention evaluation session in a virtual synchronized manner with a duration of 120 minutes.
62662444|NCT02957643|PLACEBO_COMPARATOR|pregnant women|iron dosage 1 per day for 3 months
62662445|NCT02957643|EXPERIMENTAL|pregnant women with anemia|iron dosage 1 per day for 6 months
61910819|NCT01482390|EXPERIMENTAL|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
61910820|NCT01482390|EXPERIMENTAL|TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
61910821|NCT01482390|ACTIVE_COMPARATOR|TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
61910822|NCT03480464|EXPERIMENTAL|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
61910823|NCT03480464|NO_INTERVENTION|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
61910824|NCT03562767|EXPERIMENTAL|Group-based Cognitive Behavioral Intervention|Subjects receiving the group-based CT-CB intervention
61910825|NCT03562767|EXPERIMENTAL|Web-based Cognitive Behavioral Intervention|Subjects receiving the web based CT-CB intervention
62294730|NCT04848493||SOLID TUMORS|"2a. Chemotherapy in adjuvant therapy. All patients with a diagnosis of solid tumors apart resected basal-cell or squamous-cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, and carcinoma in situ of the Breast. Under curative surgery (stage II-III) for the solid tumor or hemotherapy alone or in combination with target therapies or radiotherapy (No.=100).~2b. Chemotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing chemotherapy alone or in combination with immunotherapy or target therapy (No.=100).~2c. Immunotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing immunotherapy alone (No.=100).~2d. Target therapies in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), Undergoing target therapy alone (No.=100)"
62308199|NCT05533554|NO_INTERVENTION|Control group|The control group will participate in a pre-intervention evaluation session. Four weeks after the end of the last intra-session evaluation session, the control group will participate in the post-intervention evaluation in a virtual synchronized manner with a duration of 120 minutes.
62662446|NCT01397747||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
62662447|NCT03070652|EXPERIMENTAL|NBO, Newborn behavioral observation|In the intervention group new parents will receive the NBO delivered in connection with the examination of the newborn in a shared observation with the parents in the homevisit of the health visitor 3 weeks post partum
62662448|NCT03070652|EXPERIMENTAL|Practice as usual|In the comparison group new parents will receive practice as usual due to the examination of their newborn in the homevisit of the health visitor 3 weeks post partum
62662449|NCT00699127|EXPERIMENTAL|1|The group that will have lecture of information regarding infants in NICU.
62662450|NCT00699127|NO_INTERVENTION|2|The group that will not have lecture of information regarding NICU hospitalization
61910826|NCT03562767|PLACEBO_COMPARATOR|Usual Care|Subjects receiving usual care from their primary care providers
61910827|NCT02217774|EXPERIMENTAL|MGUIDE assisted implant placement|Implant placement, using MGUIDE MORE system for implant planning and placement
62662451|NCT00248547|ACTIVE_COMPARATOR|Aprepitant|
62662452|NCT00248547|PLACEBO_COMPARATOR|sugar pill|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
62662453|NCT04115722||Agroup of IBD patients in activity|
62662454|NCT04115722||Normal controlled group|
61910828|NCT02188693||Gemcitabine, Experimental|Gemcitabine 1250 mg/m2, IV on day 1 of 21 day cycle,with a follow up for every 12 weeks until disease progression or the date of first documented death from any cause
62662455|NCT02487836|OTHER|First attempt stenting (T0 = date of the first act)|Efficacy of laying of a biliary stent for chemotherapy realization
62467022|NCT05235321|EXPERIMENTAL|Upright applanating prototype|With this prototype, an applanating prism (custom manufactured with medical grade acrylic in an ISO-13485 certified facility) is attached to a fixed-force spring that creates a force equivalent to 1.8 or 2.0 on the GAT dial. Blue LED lights on the prototype are used to create the blue illumination similar to the blue light used in clinical practice on the slit lamp or Perkins tonometer. A C-MOS camera is aligned with the GAT prism to image the applanation mires. The eye is given topical fluorescein/anesthetic. Like fixed-force GAT, the GAT prism contacts the eye while the CMOS camera makes a video of the mire appearance. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
61910829|NCT02188693||Observational|Observation for every 12 weeks until disease progression or the date of first documented death from any cause
61910830|NCT05725759||Rehabilitation Arm|Participants will participate in outpatient physical and/or occupational therapies while participating in the tofersen early access program (EAP)
62467023|NCT05235321|EXPERIMENTAL|Supine Applanating Prototype|With this method, a 5 gram clear acrylic cylinder (custom manufactured with medical grade acrylic in an ISO-13485 certified facility) is aligned with the lens of the CMOS camera and the distal tip of the cylinder is illuminated with blue light using an LED similar to the blue light used in clinical practice on the slit lamp or Perkins tonometer. The eye is given topical fluorescein/anesthetic. While the CMOS camera is recording, the 5 gram weight will rest upon the eye and circular applanation mires are recorded. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
62662456|NCT01379612||Rectal cancer patients in chemoradiation|
62662457|NCT02691338||patients undergoing thrombectomy|150 anesthetized patients undergoing intra-arterial catheterization for thrombectomy after CVA. The patients will be recruited at the Rambam Health Center, Haifa, Israel. The patients will undergo EEG recording during the procedure, without changing patient's standard treatment care. The EEG recording will continue after the procedure for four hours approximately, while the patients are admitted to intensive care unit (ICU).
62662458|NCT02691338||Control - healthy individuals|20 health individuals under general anesthesia or sedation for other surgery or procedures. They will undergo EEG recording during the surgery/ procedure, to validate the sensitivity of the EEG to the effect of the anaesthetic medications.
62662459|NCT03942731||Experimental|83 adult outpatients at CHR Metz-Thionville with penicillin allergy label
62662460|NCT03748667||Patients with colorectal polyps|Patients with non-pedunculated type 0 lesions in Paris classification (not obvious cancers) larger than 10 mm
62308200|NCT02924753|EXPERIMENTAL|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
62662461|NCT01508897|EXPERIMENTAL|Phase 2 formulation|
62662462|NCT01508897|EXPERIMENTAL|Phase 3 formulation|
61910831|NCT05153889|OTHER|Intensive care unit|systematic intensive care unit (ICU) monitoring
61910832|NCT05153889|EXPERIMENTAL|General cardiology ward|Group without ECG monitoring
61910833|NCT06321367||elderly COVID-19 patients with coinfection|
61910834|NCT06321367||elderly COVID-19 without coinfection|
62662463|NCT03365245|OTHER|study arm|Microperimetry and automated visual field are performed at three different days
62662464|NCT03743818|EXPERIMENTAL|dry needling|dry needling in trigger point in vastus medialis of quadriceps
62662465|NCT03743818|ACTIVE_COMPARATOR|standardized treatment protocol|in the standardized treatment protocol the investigators including ultrasound, tens, and isometric quadriceps contractions
62662466|NCT03743818|ACTIVE_COMPARATOR|hialuronic acid|infiltration of hyaluronic acid in the affected knee
61910835|NCT01814280|OTHER|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
62308201|NCT06073314||Original cohort|This cohort will have a maximum of 10 minutes of quantitative MRI sequences added on to the end of the clinical standard MRI scan
62308202|NCT06073314||Reproducibility cohort|This group will be invited back for a second MRI scan to test reproducibility of quantitative scans and the machine learning algorithms developed to interpret them.
62308203|NCT05951127|EXPERIMENTAL|Additional Local Consolidative Esophagectomy Group|The patient in this arm will go on esophagectomy base on tracitional systemic therapy.
62100708|NCT05468658|EXPERIMENTAL|Experimental Group (A): Feng Shui Birth Unit|"1. The cabinets will be painted using salmon and pastel green.~2. It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~3. Live nature videos and sounds will be projected onto the wall.~4. Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~5. Natural plants will be placed.~6. Lighting will be used.~7. Bed linen will be designed according to the Feng Shui.~8. Wooden bell will be used.~9. Turtle, elephant and Wu Lou objects will be placed.~10. The Bagua mirror will be placed.~11. Crystals will be placed.~12. Natural stones will be placed.~13. The fountain will be placed in the east compass direction of the unit.~14. Straw bamboo separator will be used."
62100709|NCT05468658|NO_INTERVENTION|Control Group (B): Routine Birth Unit|The delivery unit of the institution consists of a small corridor, a labor room, a delivery room and a baby room. In the small corridor, there is a desk, document cabinets, vaccine cabinet and medicine cabinet for the midwife to work. The institution's routine delivery unit is equipped with standard medical devices and supplies. However, there are medical devices that are not used in the unit. White bed linens designed with the standard hospital logo are used in the unit. However, the curtains are plain cream, the walls are light blue, and the ceilings are white.
62100710|NCT05944237|EXPERIMENTAL|Phase 1 Part A HTL0039732 (Dose Escalation Monotherapy)|Groups of participants will receive increasing doses of HTL0039732 Capsules as a single agent to find a safe dose and a dose that best targets cancer cells.
62662467|NCT03334097|EXPERIMENTAL|Experimental arm|There will only one experimental arm in order to study test-retest validity after having validate the questionnaire. The beginning of the maternal education takes place between 26 and 30 weeks of gestation and ends between 32 and 36 weeks of gestation. Hence, to study responsiveness, questionnaires will be filed at the beginning of the maternal education and after the two educational sessions related to childbirth.
62100711|NCT05944237|EXPERIMENTAL|Phase 1 Part B HTL0039732 and Atezolizumab (Dose Escalation Combination)|Groups of participants will receive increasing doses of HTL0039732 Capsules in combination with a fixed 1200 mg dose of atezolizumab to find a recommended Phase 2 dose (RP2D) for HTL0039732.
62100712|NCT05944237|EXPERIMENTAL|Phase 2a HTL0039732 and Atezolizumab (Dose Expansion Combination)|An expansion cohort will receive the RP2D of HTL0039732 Capsules in combination with a fixed 1200 mg dose of atezolizumab.
62100713|NCT02298374|EXPERIMENTAL|Homecare reablement|Receives comprehensive assessment and individualized follow-up according to a plan with short and longterm goals.
62100714|NCT02298374|ACTIVE_COMPARATOR|Usual care|Receives normal care
62100715|NCT01021878|EXPERIMENTAL|icodextrin|glucose sparing alternative dialysis solution
62662468|NCT01320540||Breast Center Patients|Patients newly diagnosed with breast cancer who did or did not have genetic testing (retrospectively and prospectively).
62662469|NCT01320540||Staff from the Lynn Sage Comprehensive Breast Cancer Center|Members of the Northwestern staff to include but not limited the Lynn Sage Comprehensive Breast Cancer Center and/or Breast Cancer Genetics Program provider staff (including physicians, nurses, schedulers, physician assistants and/or genetic counselors).
62100716|NCT01021878|ACTIVE_COMPARATOR|dextrose|dianeal, Control group, standard treatment
62100717|NCT06622499|ACTIVE_COMPARATOR|Cold - Room temperature|Trial day 1: Participants receive Ringer's lactate cold (10°C, 50°F), Trial day 2: Participants receive Ringer's lactate at room temperature (22°C, 71.6°F)
62100718|NCT06622499|ACTIVE_COMPARATOR|Room temperature - Cold|Trial day 1: Participants receive Ringer's lactate at room temperature (22°C, 71.6°F), Trial day 2: Participants receive Ringer's lactate cold (10°C, 50°F)
62100719|NCT04304729||Diabetics|Girls and boys living with Type 1 Diabetes.
62100720|NCT04304729||Control|Age and sex matched participants without any type of diabetes
62100721|NCT00196170|EXPERIMENTAL|1|8mm tip ablation catheter for ablation of cavotricuspid isthmus
62100722|NCT00196170|EXPERIMENTAL|2|irrigated tip ablation catheter for ablation of cavotricuspid isthmus
62100723|NCT00196170|EXPERIMENTAL|3|cryo 10mm tip ablation catheter for ablation of cavotricuspid isthmus
62100724|NCT00196170|EXPERIMENTAL|4|Cryo 6.5mm tip ablation catheter for ablation of cavotricuspid isthmus
62308204|NCT05951127|NO_INTERVENTION|Traditional Systemic Therapy Group|The patients in this arm will receive traditional therapy, including chemotherapy, immunotherapy, radiotherapy, ect.
62308205|NCT01775566||Eperisone SR tablet 75mg, Myonal 50mg|Eperisone SR tablet 75mg Myonal 50mg
62662470|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
62662471|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
62662472|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
62662473|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
62662474|NCT01499511||ASCOT participants amlodipine|It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
61910836|NCT05814276|EXPERIMENTAL|San Rocco group|The San Rocco study encompasses a training on the non-pharmacological therapies' methodology.
62100725|NCT01598025|EXPERIMENTAL|REGIMEN 1|"REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
62294731|NCT04848493||IMMUNORHEUMATOLOGICAL DISEASES|3a. Patients with ANCA-associated vasculitis classified according to Chapel Hill Consensus Conference nomenclature, treated with immunodepressants agents with/without glucocorticoids (No.=50) or treated with RTX with/without glucocorticoids (No.=50) 3b. Interstitial Lung Disease in Autoimmune Conditions. Patients with a diagnosis of a specific CTD, myositis or rheumatoid arthritis based on validated classification criteria, and clinically significant ILD defined as disease treated with traditional immunodepressants or rituximab and fibrotic and/or inflammatory changes on chest CT not attributable to infection, and no evidence of obstructive lung disease. Patients treated with traditional immunodepressive agents with/without glucocorticoidspatients (No.=50) or patients treated with rituximab with/without glucocorticoids (No.=50)
62467024|NCT06349538||Essential tremor patients|"Essential tremor patients will undergo a detailed clinical examination incl. motor/non motor scoring systems and questionnaires, blood draw, sonography, tremor analysis and cerebral MRI. Additionally, essential tremor patients will undergo optic coherence tomography and olfcatory mucosa swab for alpha-synuclein.~All tests are conducted at baseline as well as at a follow-up examination 5 years later.~No drugs or other interventions are to be administered"
61910837|NCT05814276|NO_INTERVENTION|As usual control group|Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training.
61910838|NCT02572739||haemodynamics measuring|those with already implemented PICCO device get impedance device (NICCOMO) attached
61910839|NCT00715143|OTHER|All subjects will be receive the Novation Ceramic on Ceramic Articulating Hip System|All subjects will receive the Novation Ceramic on Ceramic Articulating Hip System.
62100726|NCT01598025|EXPERIMENTAL|Regimen 2|"To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
62308206|NCT05426044|PLACEBO_COMPARATOR|Patients will receive oral metformin|twice daily, oral metformin 750mg (i.e. 1500mg/day)
62662475|NCT01499511||ASCOT participants atenolol|It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.
61910840|NCT00918996|EXPERIMENTAL|No Bladder Flap Group|Uterine incision made 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
61910841|NCT00918996|NO_INTERVENTION|Bladder Flap Group|Standard cesarean section technique with incision and dissection of a bladder flap prior to uterine incision.
61910842|NCT04036123|EXPERIMENTAL|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
61910843|NCT05410756||FIBROMYALGIA GROUP|Patients diagnosed with Fibromyalgia Syndrome (n=25) who volunteered to be undergone voice analysis.
61910844|NCT05410756||HEALTHY CONTROL GROUP|Healthy volunteers (n=25) without any chronic disease not under any medication volunteered to be undergone voice analysis.
62467025|NCT00550563|EXPERIMENTAL|Oral Cholecalciferol|Patients receive oral cholecalciferol 2000 IU once daily for 1 year
62662476|NCT04602650||Type 2 Diabetic|Type 2 diabetic individuals of Mexican descent.
62662477|NCT04602650||Non-diabetic Controls|Non-diabetic individuals of Mexican descent.
62100727|NCT06711939||Control (Healthy)|"At least 240 healthy controls for both phases of the study, of both sexes, aged between 20 and 75 years, who do not suffer from the diseases under investigation will be selected for participation in the study at the same time as the patients. The same healthy controls will participate in both phases of the study, and the breath samples obtained will be analyzed using both methods.~The prospective controls will fill in a questionnaire with demographic and medical-history data after having been informed in detail about the study by the VOCORDER team of MITERA. The questionnaire will be analyzed by the project team, and if it is concluded that the person can participate in the study, a consent form will be signed by the participant."
62100728|NCT06711939||Patients|"A total of 275 patients, 55 for each disease, aged 18-75 years of both genders, selected according to the following inclusion criteria:~1. Patients\>18 years of age of both genders~2. They must be able to communicate and understand the information given to them by the MITERA staff.~3. Suffer from the disease under investigation.~4. The disease must be at the earliest possible stage, i.e., the patients must not yet have started treatment.~5. Patients should have no other serious comorbidities that affect the derived measurements. Patients will be selected in collaboration with the clinicians responsible for the treatment and/or hospitalisation of patients with the diseases under investigation.~Criteria 1, 2, and 3 are mandatory for enrollment in the study."
62662478|NCT03268863|EXPERIMENTAL|Virtual Reality|Google Cardboard Virtual Reality headset running an interactive game
62662479|NCT03268863|SHAM_COMPARATOR|Control|Powered down Google Cardboard Virtual Reality headset
62662480|NCT04867148|EXPERIMENTAL|Gait analysis|Gait analysis of patients with ankylosing spondylitis, patients with adoldescent idiopathic scoliosis and control group.
62662481|NCT01963806|EXPERIMENTAL|Smartphone-supplemented iCBT with therapist support|n = 50
62100729|NCT06712979|ACTIVE_COMPARATOR|adapted Lee Silverman Method|The individuals will perform the Lee Silverman methods adapted to voice professionals. They will do a 14-day protocol, with three sets of 5 repetitions daily.
62308207|NCT05426044|EXPERIMENTAL|Patients will receive oral placebo.|twice daily, oral metformin 750mg (i.e. 1500mg/day)
62308208|NCT00927680||Colorectal cancer cases|
62308209|NCT00927680||Controls|
62662482|NCT01963806|EXPERIMENTAL|Smartphone-supplemented iCBT without therapist support|n = 50
62662483|NCT01963806|ACTIVE_COMPARATOR|Active waiting list control group with delayed treatment|n = 50
62662484|NCT00957710|OTHER|langauge therapy|Naming therapy
62467026|NCT01880593|EXPERIMENTAL|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study
62467027|NCT01880593|PLACEBO_COMPARATOR|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
62467028|NCT01470482|OTHER|No Tourniquet|We compare tourniquet or not in knee surgery
62467029|NCT01470482|ACTIVE_COMPARATOR|Tourniquet|We compare tourniquet or not in knee surgery
62467030|NCT02146495|EXPERIMENTAL|Simultaneous EEG/ fMRI Recordings during Amyg-EFP-NF|Patients with FM will undergo concurrent EEG and fMRI recordings. During the fMRI scans, they will engage in Amyg-EFP NF training.
62294732|NCT04848493||NEUROLOGICAL DISEASES|"4a. Patients with a diagnosis of multiple sclerosis, age \< 60 years with relapsing-remitting MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50) or with secondary/primary progressive MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50).~4b. Generalized Myasthenia Gravis, on immunosuppressive polytherapies or on B-cell targeted biological treatments, with lymphocytes count \< 1 cell/microliter, or with thymoma (No.=100)"
62294733|NCT05960565|EXPERIMENTAL|Glucagon|Micro dose of glucagon is aded at the insulin injection site
62294734|NCT05960565|NO_INTERVENTION|Control|Insulin injected without any glucagon
62467031|NCT02146495|ACTIVE_COMPARATOR|Amyg-EFP-NF Trial|The EFP-NF procedure will include a multisession NF trial (10 sessions) using feedback driven by the Amyg-EFP model.
62467032|NCT02146495|SHAM_COMPARATOR|Amyg-EFP-NF Sham Trial|The sham NF procedure will include a multisession NF trial (10 sessions) using sham feedback; in this condition, the feedback will be provided based on a randomized Amyg-EFP signal.
62467033|NCT02146495|NO_INTERVENTION|Treatment As Usual|Patients in this group will continue their usual treatment without any intervention. Patients in this control group will undergo a complete clinical and neural evaluation at the beginning and end of a defined period, similar to the NF intervention period, and a clinical follow-up (after 10-12 months).
62467034|NCT06387771|EXPERIMENTAL|Tolcapone|Tolcapone (Film-coated tablet) 200 mg orally every 8 hours for 7 days
62467035|NCT04038801|ACTIVE_COMPARATOR|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed over four visits at 1-weekly intervals using an assortment of manual periodontal curettes.
62467036|NCT04038801|EXPERIMENTAL|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
62467037|NCT04038801|EXPERIMENTAL|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
62467038|NCT03857061||COPD Patients|This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.
62467039|NCT05599438||Current users anabolic steroids|Current users of anabolic steroids with a use of more than 4 weeks
62467040|NCT05599438||Former users of anabolic steroids|Former users of anabolic steroids with a use of more than 4 weeks
62467041|NCT05599438||Healthy controls|"100 participants with no former use of anabolic steroids~* 80 Male~* 20 Female"
62467042|NCT05495997|EXPERIMENTAL|Mental Imagery|
62467043|NCT05495997|ACTIVE_COMPARATOR|Psychoeducation|
62467044|NCT01182415|EXPERIMENTAL|High-dose chemotherapy with autologous stem cell transplant|
62467045|NCT05054348|EXPERIMENTAL|IO-108 Monotherapy|Treatment of patients with advanced solid tumors with IO-108 monotherapy
62467046|NCT05054348|EXPERIMENTAL|IO-108 + pembrolizumab combination therapy|Treatment of patients with advanced solid tumors with IO-108 in combination with a fixed dose of pembrolizumab
62294735|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
62294736|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
62100730|NCT06712979|EXPERIMENTAL|Lung volume recruitment Technique - LVRT|In the LVRT intervention, the same exercises as in the adapted LEE Silverman intervention will be performed, however, a bag-mask ventilation system (Lumiar, Brazil) will be attached during the emission with an inflated oro-nasal mask (Lumiar, Brazil) connected to a pressure gauge (Illife device, Brazil) that will monitor the inspiratory pressure level between 30 and 40 cmH2O during phonatory emissions. it will be performed 3 sets with 5 repetitions.
62100731|NCT06555965||STXBP1 cohort|
62100732|NCT06555965||SYNGAP1 cohort|
62100733|NCT02544282|ACTIVE_COMPARATOR|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
62100734|NCT02544282|PLACEBO_COMPARATOR|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
62100735|NCT06141239|NO_INTERVENTION|primary closure +Collagen plug +Bone graft|Placement of bone graft and collagen plug
62100736|NCT06141239|EXPERIMENTAL|primary closure + Collagen plug +Bone graft +Vit.D3|Placement of bone graft, collagen plug and local administration of Vit.D3
62100737|NCT06141239|EXPERIMENTAL|primary closure +Collagen plug+Bone graft+Autologous Tooth Root|Placement of bone graft, collagen plug and placement of autologous root slices
62100738|NCT06141239|EXPERIMENTAL|primary closure +Collagen plug+Bone graft+Autologous Tooth Root+Vit.D3|Placement of bone graft, collagen plug and local administration of Vit.D3, and placement of autologous root slices
62100739|NCT06488365|EXPERIMENTAL|Cytophone application|It is anticipated that Cytophone diagnostic procedure will start with 30-min preparation including ultrasound imaging of an examined vessel, photo of a skin area above the vessel and quick navigation of the PAFC probe on the vessel using near-infrared viewer. After completion, the Cytophone monitoring will be conducted for 30-60 min and will include noninvasive irradiation of the vessel by a laser beam(s) using a safe for human laser energy level.
62100740|NCT05424198|ACTIVE_COMPARATOR|Trident Cervical Medial Branch Radiofrequency Ablation|During this procedure a 50 mm or 100 mm long (dependent on body habitus), 18-gauge insulated cannula with a 5 mm active tip will be placed perpendicularly at targeted medial branches (the nerves carrying pain signals from the facet joints).
62100741|NCT05424198|ACTIVE_COMPARATOR|Conventional Cervical Medial Branch Radiofrequency Ablation|During this procedure a 50 mm or 100 mm long (dependent on body habitus), 18-gauge conventional cannula with a straight 5 mm active tip will be placed parallel and oblique to the targeted medial branch branches (the nerves carrying pain signals from the facet joints). At each location, one lesion will be made to accommodate anatomic variation.
62662485|NCT01422902|EXPERIMENTAL|Plasticity-based Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 130 hours
62100742|NCT06297590|EXPERIMENTAL|LY3954068 (Part A)|Single ascending dose of LY3954068 administered intrathecally (IT)
62662486|NCT01422902|ACTIVE_COMPARATOR|Non-plasticity-based Training|Commercially available computerized training, up to 130 hours
62662487|NCT00870701|EXPERIMENTAL|Absence of Radiotherapy|No Radiotherapy; Simple monitoring without active treatment
62100743|NCT06297590|PLACEBO_COMPARATOR|Placebo (Part A)|Single ascending dose of placebo administered IT
62662488|NCT00870701|ACTIVE_COMPARATOR|Radiotherapy|Radiotherapy
62662489|NCT00624260|ACTIVE_COMPARATOR|2|Usual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)
62662490|NCT00624260|EXPERIMENTAL|1|Semi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)
62662491|NCT02602951|EXPERIMENTAL|Control|Pilot subjects
62100744|NCT06297590|EXPERIMENTAL|LY3954068 (Optional Part B)|Multiple ascending dose of LY3954068 administered IT
62100745|NCT06297590|PLACEBO_COMPARATOR|Placebo (Optional Part B)|Multiple ascending dose of placebo administered IT
62100746|NCT02295475|EXPERIMENTAL|Apixaban|Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.
62100747|NCT02295475|ACTIVE_COMPARATOR|Warfarin|Subjects will receive warfarin for the duration of the study, with the dose and frequency adjusted per clinician discretion to achieve an INR (International Normalized Ratio) between 2 and 4.
62662492|NCT02602951|EXPERIMENTAL|Patients|Patients with an intracranial disorder or needing a supraaortic trunk MRA
62662493|NCT01564407|EXPERIMENTAL|Safety Cohort|"Stable restrictive scar contractures resulting from abdominal surgical incision, not transversing a joint. The minimum scar length of 7 cm and a maximum scar area size of 80cm². The scar is divided into five injection areas with a minimum of 0.5 cm uninjected areas between the 5 sites.Drug Dosing for Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4 Subjects in Cohort 1 will undergo elective surgeries, at which time the treated scars will be removed, at week 6-8 post-treatment of the first dosed subject."
62662494|NCT01564407|ACTIVE_COMPARATOR|2.5M cells/cm2|Participants receive intervention treatment of 2.5 million cells/ cm2, single administration injected into the scar.
62662495|NCT01564407|ACTIVE_COMPARATOR|5M cells/cm2|Participants receive intervention treatment of 5 million cells /cm2, single administration
62100748|NCT06541041||Arm A: Standard nerve transfer surgery without electrical stimulation|This is a retrospective group that has already undergone standard nerve transfer surgery targeting hand function without intraoperative or postoperative electrical stimulation. No additional patients will be enrolled in this group.
62294737|NCT02216136||Mastectomy Only Cohort|Mastectomy Only Cohort: This group will have mastectomy without reconstruction. They may or may not require chemotherapy and radiation.
62294738|NCT04265066||Measurement of sublingual microcirculation|
62294739|NCT01865734|EXPERIMENTAL|Early Physical Therapy|Physical therapy after initial podiatry visit
62294740|NCT01865734|ACTIVE_COMPARATOR|Usual Podiatric Care|Usual care provided by podiatry
62662496|NCT01564407|ACTIVE_COMPARATOR|2.5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 2.5 million cells/ cm2, repeat dose administration @ 4 weeks
62662497|NCT01564407|ACTIVE_COMPARATOR|5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 5 million cells / cm2 repeat dose administration @ 4 weeks
62662498|NCT06237491|EXPERIMENTAL|Experimental: 177Lu-LNC1003 Injection group 1|"177Lu-LNC1003 Injection, a single dose of 30mCi will be administered every 6 weeks, for a total of 2 cycles.~Interventions:~Drug: 177Lu-LNC1003 Injection group 1 radionuclide therapy"
62662499|NCT06237491|EXPERIMENTAL|Experimental: 177Lu-LNC1003 Injection group 2|"177Lu-LNC1003 Injection, a single dose of 50mCi will be administered every 6 weeks, for a total of 2 cycles.~Interventions:~Drug: 177Lu-LNC1003 Injection group 2 radionuclide therapy"
62662500|NCT06237491|EXPERIMENTAL|Experimental: 177Lu-LNC1003 Injection group 3|"177Lu-LNC1003 Injection, a single dose of 70mCi will be administered every 6 weeks, for a total of 2 cycles.~Interventions:~Drug: 177Lu-LNC1003 Injection group 3 radionuclide therapy"
62662501|NCT01211249|EXPERIMENTAL|GLPG0259 (Part A)|
62662502|NCT01211249|PLACEBO_COMPARATOR|Placebo (Part A)|
62662503|NCT01211249|EXPERIMENTAL|GLPG0259 (Part B)|
62662504|NCT01211249|PLACEBO_COMPARATOR|Placebo (Part B)|
62662505|NCT00694746|EXPERIMENTAL|Fish oil|Omega-3-acid ethyl esters in the form of fish oil capsules with ram up from 1g to 4 g/day (capsules 1g)
62662506|NCT00694746|PLACEBO_COMPARATOR|Placebo|Placebo
62662507|NCT02478788|EXPERIMENTAL|LR-MAS - Low-risk ADHD adolescents|ADHD adolescents without any first or second degree-relatives with bipolar disorder. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
62662508|NCT02478788|EXPERIMENTAL|HR-MAS - High-risk ADHD adolescents|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). The subjects in this group will receive mixed amphetamine salts-extended release( MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD."
62662509|NCT02478788|PLACEBO_COMPARATOR|HR-P - High-risk ADHD on Placebo|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). Following initiation of treatment, the ADHD adolescents will have regularly scheduled visits during which symptom and tolerability ratings will be performed."
62662510|NCT02478788|NO_INTERVENTION|HC (Healthy Controls)|Healthy subjects (n=60) will be recruited from the community and will not receive medication but will undergo MR scans at the same intervals to assess normal variability in imaging parameters between time points as well as to adjust and interpret comparisons within patients (i.e., whether patient values are changing toward or away from those of healthy adolescents). Neuroimaging evaluations will be performed at baseline and Week 12 (or termination).
62662511|NCT05183620|OTHER|Nocturnal erection measurement|Overnight measurements of the temperature of the penile skin and outer thigh will be performed, while simultaneously the penile circumference and rigidity is determined by RigiScan measurements
62662512|NCT02475447|PLACEBO_COMPARATOR|Placebo|Placebo-matched tablets twice daily for 4 weeks.
62662513|NCT02475447|EXPERIMENTAL|Asimadoline|Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.
62662514|NCT04575324|EXPERIMENTAL|Intervention Arm|Participants will receive the telemedicine linkage intervention.
62662515|NCT04575324|NO_INTERVENTION|Control Arm|Participants will receive a standard referral to an in-person MOUD treatment appointment, which typically occurs within 24-72 hours. They also receive a bus pass to cover transportation (both directions), as well as an appointment reminder card.
62294741|NCT02918084|SHAM_COMPARATOR|ARM A|Adjuvant chemotherapy → Aromatase inhibitors x 5 yrs (sequential arm)
62662516|NCT00515190|ACTIVE_COMPARATOR|A|(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
62662517|NCT00515190|ACTIVE_COMPARATOR|B|(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
62662518|NCT04687722|EXPERIMENTAL|High Intensity Aerobic Training Group.|The experimental group will receive High Intensity Aerobic Training at 80-90% of Heart Rate Maximum calculated using karvonen rule.
62662519|NCT04687722|ACTIVE_COMPARATOR|Control Group|The control group will receive routine low Intensity aerobic Training at 40-60% of Heart Rate Maximum calculated using karvonen rule.
62662520|NCT04913298|OTHER|Cytosorb therapy|blood samples are taken before and after the cytokine adsorber at given times
62662521|NCT01845857|EXPERIMENTAL|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
62662522|NCT00303043||1|
62662523|NCT05708651|EXPERIMENTAL|Use of investigational device during sedation|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterisation \[IV\].
62662524|NCT05708651|ACTIVE_COMPARATOR|Use of comparator during sedation|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock \[I-II\] or no device \[II-IV\]) in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterisation \[IV\].
62662525|NCT05382728|EXPERIMENTAL|TY-9591+placebo Osimertinib|TY-9591 (160mg orally, once daily) plus placebo Osimertinib (80mg orally, once daily), in accordance with the randomization schedule.
62662526|NCT05382728|ACTIVE_COMPARATOR|Osimertinib+placebo TY-9591|Osimertinib (80mg orally, once daily) plus placebo TY-9591 (160mg orally, once daily), in accordance with the randomization schedule.
62662527|NCT05362084|ACTIVE_COMPARATOR|Oblique group|medial branch block with oblique group
61910845|NCT00927940|EXPERIMENTAL|Drug Eluting Stent|All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. A patient with one or two lesions treated with stents of diameter 2.5mm - 3.5mm will be designated in this study.
62100749|NCT06541041||Arm B: Standard nerve transfer surgery plus intraoperative and postoperative electrical stimulation|This is a prospectively enrolled group that will undergo standard nerve transfer surgery targeting hand function plus brief intraoperative electrical stimulation of the donor nerves and placement of a temporary peripheral nerve stimulator to allow postoperative electrical stimulation of the donor nerves for up to 60 days. All care provided, including the surgery, intraoperative electrical stimulation, postoperative electrical stimulation, and postoperative hand therapy, will be provided according to standard of care and is not considered experimental.
62100750|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-negative and middle-aged adults (55-64) with a low dose of QTP101|"This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative adults aged 55-64. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. The target population includes individuals without prior TB infection as indicated by the QFT-negative status.~The primary objective is to assess safety, focusing on adverse events (AEs), and to explore immunogenicity through antibody titers and cytokine responses. Findings will provide critical insights into the vaccine's effects in middle-aged, previously uninfected individuals."
61910846|NCT03090048|EXPERIMENTAL|Vitamin A|retinyl palmitate USP
62100751|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-negative and middle-aged adults (55-64) with a high dose of QTP101|"This study arm evaluates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative adults aged 55-64. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. This group focuses on individuals without prior TB infection, as indicated by their QFT-negative status.~The primary objective is to assess the safety profile, including adverse events (AEs), and to evaluate the immune response, such as antibody titers and cytokine production. The findings will help determine the vaccine's suitability for middle-aged individuals and guide future dose optimization."
62100752|NCT06714513|PLACEBO_COMPARATOR|BCG-vaccinated, HIV-negative, QFT-negative and middle-aged adults (55-64) with the placebo|"This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-negative adults aged 55-64. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56.~The purpose of this arm is to provide a baseline for evaluating the safety and immunogenicity outcomes of QTP101 by comparing the incidence of adverse events (AEs) and immune responses against those observed in the experimental groups. This group includes individuals without prior TB infection, as indicated by their QFT-negative status, and is essential for assessing the specific effects of the investigational vaccine."
62294742|NCT02918084|EXPERIMENTAL|ARM B|Adjuvant chemotherapy + Aromatase inhibitors x 5 yrs (concurrent arm)
61910847|NCT03090048|EXPERIMENTAL|Azithromycin with Vitamin A|USP grade ingredients
61910848|NCT03090048|ACTIVE_COMPARATOR|Azithromycin|azithromycin monohydrate
62662528|NCT05362084|PLACEBO_COMPARATOR|Anteroposterior group|medial branch block with anteroposterior group
62662529|NCT01426126|EXPERIMENTAL|Genexol PM|Genexol PM intravenous infusion every 3 weeks
62662530|NCT05316467|EXPERIMENTAL|overweight 24kg/m2≤BMI<28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
62662531|NCT05316467|EXPERIMENTAL|BMI≥28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
62662532|NCT03594838|EXPERIMENTAL|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
62662533|NCT03594838|EXPERIMENTAL|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
61910849|NCT00665314|EXPERIMENTAL|AMD3100 added to a G-CSF Mobilisation regimen|AMD3100 added to a G-CSF Mobilisation regimen
61910850|NCT00665314|ACTIVE_COMPARATOR|G-CSF plus placebo|G-CSF plus placebo
61910851|NCT01797406|ACTIVE_COMPARATOR|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
61910852|NCT01797406|EXPERIMENTAL|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
61910853|NCT03676101|EXPERIMENTAL|9-valent HPV Recombinant Vaccine|
61910854|NCT03676101|PLACEBO_COMPARATOR|Placebo|
61910855|NCT04657107|PLACEBO_COMPARATOR|Saline group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous normal saline before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
61910856|NCT04657107|EXPERIMENTAL|K1 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.2mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
62100753|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-negative and older adults (65-74) with a low dose of QTP101|"This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative older adults aged 65-74. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56.~This arm focuses on individuals without prior TB infection, as indicated by their QFT-negative status. The primary objective is to assess the safety profile, including adverse events (AEs), and to explore the vaccine's immunogenicity through antibody titers and cytokine responses. The findings will provide key data on the vaccine's effects in older, previously uninfected populations."
62294743|NCT05427474|NO_INTERVENTION|standard protocol of manaegement|traumatic brain injury protocol in Emergency ICU without adding propranolol or gabapentin
62294744|NCT05427474|ACTIVE_COMPARATOR|propranolol group|addding propranolol to the traumatic brain injury protocol in Emergency ICU
62308210|NCT03088605|EXPERIMENTAL|Active|TOP1630 Ophthalmic Solution
62662534|NCT03594838|NO_INTERVENTION|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
62662535|NCT02189447|EXPERIMENTAL|Refractive surgery|Patients with keratoconus treated with simultaneous photorefractive keratectomy and Corneal collagen cross-linking.
62662536|NCT03336970|ACTIVE_COMPARATOR|Single visit root canal treatment|The teeth were treated in single-visit (SV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
62662537|NCT03336970|ACTIVE_COMPARATOR|Multiple visit root canal treatment|The teeth were treated in multiple visit (MV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
62467047|NCT05054348|EXPERIMENTAL|IO-108 + cemiplimab combination therapy|Treatment of patients with advanced solid tumors with IO-108 in combination with a fixed dose of cemiplimab
62662538|NCT02679105|PLACEBO_COMPARATOR|ALK diluent|Human albumin
62662539|NCT02679105|ACTIVE_COMPARATOR|ALK Alutard birch or 5-grasses|Grass pollen suspension or birch pollen suspension
62662540|NCT03908853||Patients|Subjects with painful bone metastases caused by primary breast cancer.
62662541|NCT03908853||Controls|Gender and age matched healthy volunteers.
62662542|NCT01562691|EXPERIMENTAL|Nasopore only|Packing using nasopore without airway integrated
62662543|NCT01562691|ACTIVE_COMPARATOR|nasopore with airway integrated|packing using airway integrated nasopore
62662544|NCT01562691|ACTIVE_COMPARATOR|airway-integrated Vaseline gauze|Nasal packing using airway-integrated Vaseline gauze
62662545|NCT03848468|ACTIVE_COMPARATOR|CH(conventional Hemorrhoidectomy)|conventional hemorrhoidectomy
62662546|NCT03848468|EXPERIMENTAL|LH (Ligasure Hemorrhoidectomy)|Ligasure hemorrhoidectomy
61910857|NCT04657107|EXPERIMENTAL|K2 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.3mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
62100754|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-negative and older adults (65-74) with a high dose of QTP101|"This study arm investigates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative older adults aged 65-74. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56.~The arm focuses on individuals without prior TB infection, as indicated by their QFT-negative status. The primary aim is to evaluate the safety profile, including adverse events (AEs), and to assess the immunogenicity of the high-dose vaccine through antibody titers and cytokine production. The findings will help determine the vaccine's suitability and dose optimization for older populations."
62294745|NCT05427474|ACTIVE_COMPARATOR|combined propranolol and gabapentin|adding propranolol and gabapentin to the traumatic brain injury protocol in Emergency ICU
62294746|NCT01305512|EXPERIMENTAL|SPARC1028|
62294747|NCT02531815|EXPERIMENTAL|Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo|
62294748|NCT02531815|EXPERIMENTAL|Cohort 2 (SC) PF-06741086, Placebo|
62294749|NCT02531815|EXPERIMENTAL|Cohort 3 (SC) PF-06741086, Placebo|
62294750|NCT02531815|EXPERIMENTAL|Cohort 4 (Intravenous [IV]) PF-06741086, Placebo|
62294751|NCT02531815|EXPERIMENTAL|Cohort 5 (IV) PF-06741086, Placebo|
62662547|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
62662548|NCT02126332|OTHER|Conventional group|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
62662549|NCT02126332|EXPERIMENTAL|EA group (Epidural anesthesia )|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
62662550|NCT01991951|EXPERIMENTAL|Short term warfarin group|taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
62662551|NCT01991951|ACTIVE_COMPARATOR|Conventional therapy arm|conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
62662552|NCT03691532|EXPERIMENTAL|Seated control (CON)|Participants remain seated in their habitual wheel chair for \~60 min (duration of exercise performed in other arm). Following the intervention they are fed a liquid meal.
62662553|NCT03691532|EXPERIMENTAL|Arm cycle exercise (ACE)|Participants complete continuous arm cycle exercise (ACE) for \~60 min. Following the intervention they are fed a liquid meal.
62662554|NCT04697901|EXPERIMENTAL|Active Stimulation|Active tDCS stimulation will be applied.
62662555|NCT04697901|SHAM_COMPARATOR|Sham Stimulation|Sham tDCS stimulation will be applied.
62662556|NCT03863912|ACTIVE_COMPARATOR|Disney|watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
62662557|NCT03863912|OTHER|Control|fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
61910858|NCT03547115|EXPERIMENTAL|voruciclib monotherapy and voruciclib in combination with venetoclax|"voruciclib monotherapy - Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level and disease type (AML or B-cell malignancies)~voruciclib and venetoclax - Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level for AML subjects"
62100755|NCT06714513|PLACEBO_COMPARATOR|BCG-vaccinated, HIV-negative, QFT-negative and older adults (65-74) with the placebo|"This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-negative older adults aged 65-74. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56.~The purpose of this arm is to establish a baseline for safety and immunogenicity assessments by comparing the incidence of adverse events (AEs) and immune responses against those observed in the experimental groups. This group includes individuals without prior TB infection, as indicated by their QFT-negative status, and plays a crucial role in evaluating the specific effects of the investigational vaccine."
62467048|NCT05223426|EXPERIMENTAL|Cognitive training followed by usual care|Usual care and cognitive training for 6 weeks, followed by usual care (only) for 6 weeks.
62662558|NCT03667716|EXPERIMENTAL|P1a Arm A (Monotherapy Dose Escalation).|COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
61910859|NCT04391985|ACTIVE_COMPARATOR|Cirrhotic Participants|The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
62100756|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-positive and middle-aged adults (55-64) with a low dose of QTP101|"This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive middle-aged adults aged 55-64. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56.~This arm targets individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary objective is to assess the safety profile, focusing on adverse events (AEs), and to explore the vaccine's immunogenicity through antibody titers and cytokine responses. The results will provide valuable data on the vaccine's performance in previously exposed middle-aged adults."
62294752|NCT02531815|EXPERIMENTAL|Cohort 6 (IV) PF-06741086, Placebo|
62294753|NCT02531815|EXPERIMENTAL|Cohort 7 (IV) PF-06741086, Placebo|
62294754|NCT02531815|EXPERIMENTAL|Cohort 8 (subcutaneous [SC]) PF-06741086|
62294755|NCT02598414|EXPERIMENTAL|Bowel Anastomosis Under ICG Guidance|Patients undergo robotic colon/rectal resection and anastomosis with near-infrared ICG fluorescence imaging.
62308211|NCT03088605|PLACEBO_COMPARATOR|Placebo|Placebo (Vehicle) Ophthalmic Solution
62467049|NCT05223426|EXPERIMENTAL|Usual care followed by cognitive training|Usual care (only) for 6 weeks, followed by cognitive training and usual care for 6 weeks.
62467050|NCT00771485|EXPERIMENTAL|1|
62467051|NCT00771485|OTHER|2|
62467052|NCT01397630|EXPERIMENTAL|Accelerated Oxytocin Titration|
62467053|NCT01397630|ACTIVE_COMPARATOR|Gradual Oxytocin Titration|
62467054|NCT02411552||Intervention schools|These schools were promoting 4 strategies to increase physical activity in students.
62467055|NCT02411552||Control schools|These schools continued with standard programming for activity during year 1, and implemented intervention during years 2 and 3.
62467056|NCT00830206|EXPERIMENTAL|Azithromycin (test)|Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
62467057|NCT00830206|ACTIVE_COMPARATOR|Zithromax® (reference)|Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in second period
62294756|NCT02598414|ACTIVE_COMPARATOR|Standard Bowel Anastomosis|Patients undergo robotic colon/rectal resection and anastomosis without near-infrared ICG fluorescence imaging.
62294757|NCT02866344|EXPERIMENTAL|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
61910860|NCT04391985|ACTIVE_COMPARATOR|Non-cirrhotic Participants|The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.
62467058|NCT00481338|EXPERIMENTAL|Study specific procedure|X-rays, biological samples and medical information about osteoarthritis
62100757|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-positive and middle-aged adults (55-64) with a high dose of QTP101|"This study arm investigates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive middle-aged adults aged 55-64. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56.~This arm focuses on individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary goal is to assess the safety profile, including adverse events (AEs), and to evaluate the immunogenicity of the high-dose vaccine by measuring antibody titers and cytokine responses. The findings will inform dose optimization and vaccine effectiveness in previously exposed middle-aged adults."
62100758|NCT06714513|PLACEBO_COMPARATOR|BCG-vaccinated, HIV-negative, QFT-positive and middle-aged adults (55-64) with the placebo|"This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-positive middle-aged adults aged 55-64. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56.~The purpose of this arm is to establish a baseline for evaluating the safety and immunogenicity outcomes of QTP101 in individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. This comparison will help identify the specific effects of the investigational vaccine by contrasting it with the placebo group in terms of adverse events (AEs) and immune responses."
62100759|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-positive and older adults (65-74) with a low dose of QTP101|"This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive older adults aged 65-74. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56.~This arm targets individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary objective is to assess the safety profile, focusing on adverse events (AEs), and to explore the vaccine's immunogenicity through antibody titers and cytokine responses. The findings will provide critical insights into the vaccine's safety and effectiveness in previously exposed older populations."
62662559|NCT03667716|EXPERIMENTAL|P1a Arm B (Combination Dose Escalation).|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
62662560|NCT03667716|EXPERIMENTAL|P1a Arm A (Monotherapy Expansion).|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
62662561|NCT03667716|EXPERIMENTAL|P1b (Combination Cohort Dose Expansion).|COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer).
61910861|NCT05424432|EXPERIMENTAL|short course neoadjuvant chemoradiotherapy plus toripalimab|"Paclitaxel, carboplatin and toripalimab every 3 weeks for two cycles. Concurrent short course neoadjuvant radiotherapy (30 Gy in 12 fractions, 5 days per week, D3-D18).~Surgery will be performed within 8-10 weeks after the completion of preoperative therapy described above."
62294758|NCT02866344|ACTIVE_COMPARATOR|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
62662562|NCT05494918|EXPERIMENTAL|Dose escalation|It's a dose escalation to identify the Maximum Tolerated dose (MTD) , recommended dose for expansion (RDE) or recommended Phase II dose (RP2D) of JSKN003, guided by the modified ADT design and BOIN design.
61910862|NCT03030742||Post-cesarean delivery|Women who have undergone cesarean delivery
62308212|NCT03000738||non-hodgekin lymphoma|100 non-hodgekin lymphoma patients (age \>=18y) without previous treatment would be administered, including 50 DLBCLs and 50 PTCLs.
62662563|NCT02649699|OTHER|Additional 3D MRI scans|Participating patients will receive additional 3D MRI scans during pre and post RT planning for their primary brain tumors.
62662564|NCT00577408|EXPERIMENTAL|Depot Naltrexone|Depot Naltrexone. Vivitrol (380 mg)given monthly
62662565|NCT00577408|ACTIVE_COMPARATOR|Oral Naltrexone|Oral Naltrexone. For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday).
62662566|NCT03559309|OTHER|Alirocumab|Medical Treatment (Clinical Routine)
62662567|NCT01355367|EXPERIMENTAL|Arm 1|
61910863|NCT03030742||Post-vaginal delivery|Women who have undergone vaginal delivery
62100760|NCT06714513|EXPERIMENTAL|BCG-vaccinated, HIV-negative, QFT-positive and older adults (65-74) with a high dose of QTP101|"This study arm investigates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive older adults aged 65-74. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56.~This arm focuses on individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary goal is to assess the safety profile, including adverse events (AEs), and to evaluate the vaccine's immunogenicity through antibody titers and cytokine responses. The results will inform dose optimization and effectiveness of the vaccine in older adults with prior TB exposure."
62100761|NCT06714513|PLACEBO_COMPARATOR|BCG-vaccinated, HIV-negative, QFT-positive and older adults (65-74) with the placebo|"This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-positive older adults aged 65-74. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56.~The purpose of this arm is to establish a baseline for evaluating the safety and immunogenicity of QTP101 in individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. Comparing this group to the experimental arms will help identify the specific effects of the investigational vaccine in terms of adverse events (AEs) and immune responses."
62100762|NCT04345523|EXPERIMENTAL|Treatment Arm|Pathogen-reduced CP from patients recovered from COVID-19, whom, for the purpose of this trial, are herein designated as donors.
62100763|NCT04345523|ACTIVE_COMPARATOR|Control Arm|Standard of Care (SOC) for COVID-19
62100764|NCT06042725|EXPERIMENTAL|Arm A (Ven-Dd)|Patients receive venetoclax PO QD on days 1-28 of each cycle, daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7+, and dexamethasone PO on days 1, 8, 15, 22 of cycles 1-12. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo chest x-ray and optional collection of blood samples during screening. In addition, patients undergo x-rays, WBLDCT, PET/CT or MRI scans during screening and on study, and bone marrow aspiration and biopsy during screening, and during follow-up.
62100765|NCT06042725|EXPERIMENTAL|Arm B (Ven-Rd)|Patients receive venetoclax PO QD on days 1-28 of each cycle, lenalidomide PO QD on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, 22 of cycles 1-12. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo chest x-ray and optional collection of blood samples during screening. In addition, patients undergo x-rays, WBLDCT, PET/CT or MRI scans during screening and on study, and bone marrow aspiration and biopsy during screening, and during follow-up.
62100766|NCT06042725|EXPERIMENTAL|Arm C (Ven-DRd)|Patients receive venetoclax PO QD on days 1-28 of each cycle, daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7+, lenalidomide PO QD on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo chest x-ray and optional collection of blood samples during screening. In addition, patients undergo x-rays, WBLDCT, PET/CT or MRI scans during screening and on study, and bone marrow aspiration and biopsy during screening, on study, and during follow-up.
62100767|NCT03614130|OTHER|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
62100768|NCT03614130|OTHER|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
62100769|NCT03588975|EXPERIMENTAL|MACI|autologous cultured chondrocytes on porcine collagen membrane
62100770|NCT03588975|ACTIVE_COMPARATOR|microfracture|surgical procedure
62100771|NCT05129800||PRP 1|This is the group of patients who were injected with 5 ml of PRP prepared using a tube from a company 1
62100772|NCT05129800||PRP 2|This is the group of patients who were injected with 5 ml of PRP prepared using a tube from a company 2
62100773|NCT05129800||Mesotherapy 1|This is the group of patients who were injected with mesotherapy from a company 1
62100774|NCT05129800||Mesotherapy 2|This is the group of patients who were injected with mesotherapy from a company 2
62100775|NCT05988203|EXPERIMENTAL|SSA - BNT166a Dose Level (DL)1|One dose level
62100776|NCT05988203|EXPERIMENTAL|SSA - BNT166a DL2|One dose level
62467059|NCT00662571||A|"Our hypothesis is that effective acamprosate response in alcohol dependent subjects may be influenced by genetically controlled variation in the functionality of the N-methyl-D-aspartate receptor (NMDA) and/or the type 5 metabotropic glutamate receptor (mGluR5). Hypothesis confirmation could lead to development of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations.~There will be no placebo drug given. Just measurement of genetic response."
62467060|NCT01330186||Anal cancer|
62100777|NCT05988203|EXPERIMENTAL|SSA - BNT166a DL3|One dose level
62100778|NCT05988203|EXPERIMENTAL|SSB - BNT166a DL2|One dose level
62100779|NCT05988203|EXPERIMENTAL|SSD - BNT166a|One dose level based on SSA and SSB data
62100780|NCT02292394|EXPERIMENTAL|Multicomponent Cognitive Behavioral Telephone Intervention|In this study, we will apply a telephone intervention that is a modified version of a brief prevention intervention for depressed caregivers that previously was applied in person in a group format during five 90-minute sessions (Vazquez et al., 2014). During the intervention, participants will be trained in various behavioral and cognitive abilities such as increasing pleasant activities, self-reinforcement, relaxation techniques, assertive communication, strategies to increase social contacts and social skills, and strategies to increase positive thoughts and decrease depressive ones.
62308213|NCT02569489|EXPERIMENTAL|HBI-8000, Paclitaxel, Trastuzumab|HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles)
61910864|NCT00713310|EXPERIMENTAL|Low-Dose|1.2 - 2.4 g/day Asacol dependent on body weight
62308214|NCT02862912|EXPERIMENTAL|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
62100781|NCT02292394|EXPERIMENTAL|Telephone Intervention Pleasant Activities|This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
62100782|NCT02292394|NO_INTERVENTION|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms. The use of such treatments will be recorded.
62100783|NCT06714422|ACTIVE_COMPARATOR|no apple group|No apples during night shift
62100784|NCT06714422|EXPERIMENTAL|apple group|Doctors will bring apples during night shift
62100785|NCT06056050|EXPERIMENTAL|Experimental vaccine group 1A,≥18 years old|1 dose of Tdcp vaccine
62100786|NCT06056050|ACTIVE_COMPARATOR|Control vaccine group 1B,≥18 years old|1 dose of PPV23 vaccine
62100787|NCT06056050|EXPERIMENTAL|Experimental vaccine group 2A,12~17 years old|1 dose of Tdcp vaccine
62100788|NCT06056050|ACTIVE_COMPARATOR|Control vaccine group 2B,12~17 years old|1 dose of PPV23 vaccine
62100789|NCT06056050|EXPERIMENTAL|Experimental vaccine group 3A,6~11 years old|1 dose of Tdcp vaccine
62100790|NCT06056050|ACTIVE_COMPARATOR|Control vaccine group 3B,6~11 years old|1 dose of DT vaccine
62100791|NCT06713694|EXPERIMENTAL|CBT|
62100792|NCT06713694|EXPERIMENTAL|CBT-II|
62100793|NCT06713694|OTHER|Wait-list|
62100794|NCT06713694|OTHER|Wait-list-II|
62100795|NCT06713408|EXPERIMENTAL|Experimental (Music)|Audio recordings consisting of pentatonic music and neva makam will be uploaded to the patients' phones by the researcher. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
62294759|NCT02581709|EXPERIMENTAL|Countering cognitive impairment|Each participant will complete neuropsychological assessments at baseline (prior to chemotherapy) and after chemotherapy. Patients identified as experiencing cognitive decline measured using Reliable Change Index on at least one cognitive function measure from before until after chemotherapy will be offered the intervention. Participants in the interventions will complete a neuropsychological assessment after completion of the intervention. Questionnaires to assess other non-cognitive factors e.g. quality-of-life will be administered at the end of chemotherapy to all participants and after the intervention to participants in the intervention.
62467061|NCT02739997|EXPERIMENTAL|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
62467062|NCT01689181||chronic schizophrenic patients|
62467063|NCT01689181||healthy volunteers|
62662568|NCT01905072|EXPERIMENTAL|Education Home Visits|The intervention group will receive the full intervention delivered by community health workers (CHWs) through home visits. CHWs will deliver the intervention in the subjects' homes. Home visits will be arranged at subjects' convenience and occur on a planned schedule. The intervention content will be based on the Institute of Medicine recommendations.
62662569|NCT01905072|NO_INTERVENTION|Control Group|The control group will receive only measurement visits, with no intervention or interaction during the home visits. They will receive only support from their WIC clinic.
62100796|NCT06713408|EXPERIMENTAL|Experimental (Affirmation)|Patients in this group will be asked to listen to the audio recording with pentatonic music and neva makam in the background, along with the affirmation sentences provided in the appendix. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
62100797|NCT06713408|NO_INTERVENTION|Control|No application will be made to these patients, and standard care practices will be continued.
62100798|NCT05306418|EXPERIMENTAL|Mim8|52-week treatment period with a part 1 and part 2, where all participants receive Mim8 prophylaxis
62100799|NCT03655483|EXPERIMENTAL|GLS-010|GLS-010
62467064|NCT05283070||Control|Volunteers without preexisting chronic pain and/or mental health issues
62467065|NCT05283070||Patients with chronic pain|Patients with chronic pain and/or mental health issues
62467066|NCT01273974|EXPERIMENTAL|intradermal influenza vaccine|
62467067|NCT01273974|ACTIVE_COMPARATOR|intramuscular influenza vaccine|
62662570|NCT03237754|EXPERIMENTAL|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
62100800|NCT03899805|EXPERIMENTAL|Liposarcomas|"* Participants will receive eribulin intravenously on Day 1 and Day 8~* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
62100801|NCT03899805|EXPERIMENTAL|Leiomyosarcomas|"* Participants will receive eribulin intravenously on Day 1 and Day 8~* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
62100802|NCT03899805|EXPERIMENTAL|Undifferentiated Pleomorphic sarcomas|"* Participants will receive eribulin intravenously on Day 1 and Day 8~* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
62100803|NCT06711913|ACTIVE_COMPARATOR|Intervention group|Received intravenous dexmedetomidine
62100804|NCT06711913|PLACEBO_COMPARATOR|Control group|control group receive normal saline
62100805|NCT06306274|EXPERIMENTAL|Active|
62100806|NCT06306274|PLACEBO_COMPARATOR|Placebo|
62100807|NCT05334082|EXPERIMENTAL|FIFA 11+ Group|Teams will replace regular warm-up with the intervention protocol - FIFA11+ injury prevention program - during training sessions
62662571|NCT03237754|SHAM_COMPARATOR|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
62100808|NCT05334082|NO_INTERVENTION|Control Group|Teams will maintain regular warm-up during training sessions
62100809|NCT05428436|EXPERIMENTAL|BI 1015550 TF2 fasted/BI 1015550 iCF fasted/BI 1015550 iCF fed|
62100810|NCT05428436|EXPERIMENTAL|T1 BI 1015550 iCF fasted/BI 1015550 iCF fed/BI 1015550 TF2 fasted|
62100811|NCT05428436|EXPERIMENTAL|BI 1015550 iCF fed/BI 1015550 TF2 fasted/BI 1015550 iCF fasted|
62100812|NCT06015737|EXPERIMENTAL|Stage 1: Anifrolumab|The participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to and including week 51.
62100813|NCT06015737|PLACEBO_COMPARATOR|Stage 1: Placebo|The participant will receive placebo as a SC injection from Week 0/Day 1 to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.
62100814|NCT06015737|EXPERIMENTAL|Stage 2: Anifrolumab|The participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to and including week 51.
62100815|NCT06015737|PLACEBO_COMPARATOR|Stage 2: Placebo|The participant will receive placebo as a SC injection from Week 0/Day 1 to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.
62294760|NCT06228157|EXPERIMENTAL|the experimental group|"The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.~Based on the invention above, the patients in the experimental group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
61910865|NCT00713310|EXPERIMENTAL|High-Dose|2.0 - 4.8 g/day Asacol dependent on body weight
61910866|NCT06506487|EXPERIMENTAL|Doll Therapy plus Routine Nursing Care|Participants in this arm will receive doll therapy sessions in addition to routine nursing care. Doll therapy involves the use of lifelike dolls to provide comfort and reduce behavioral and psychological symptoms in people with dementia. The therapy includes activities such as holding, dressing, and interacting with the dolls under the guidance of trained caregivers. Routine nursing care will include standard care practices without additional non-pharmacological interventions.
61910867|NCT06506487|NO_INTERVENTION|Routine Nursing Care|Participants in this arm will receive routine nursing care without any additional interventions. Routine nursing care includes standard care practices as provided in the residential care facilities, focusing on the overall well-being and daily needs of the participants.
61910868|NCT04504058||UFACH|Unsaturated Fatty Acid in Clinical High-risk
61910869|NCT01439815|PLACEBO_COMPARATOR|Placebo Nasal Spray|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
61910870|NCT01439815|ACTIVE_COMPARATOR|Fluticasone Propionate|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
61910871|NCT02565134|EXPERIMENTAL|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
61910872|NCT02565134|EXPERIMENTAL|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
61910873|NCT02565134|EXPERIMENTAL|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
61910874|NCT02565134|PLACEBO_COMPARATOR|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
61910875|NCT05373069|EXPERIMENTAL|Group intervention|PIM - DIEP
61910876|NCT03265223|NO_INTERVENTION|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
61910877|NCT03265223|ACTIVE_COMPARATOR|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
61910878|NCT03265223|ACTIVE_COMPARATOR|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
62100816|NCT00477412|EXPERIMENTAL|Treatment (combination chemotherapy)|"Participants receive Drug Combination I during courses 1, 3, 5, and 7 (if needed) and Drug Combination II during courses 2, 4, 6, and 8 (if needed) in the absence of disease progression or unacceptable toxicity.~Drug Combination I: Participants receive rituximab IV over 6 hours on day 1, cyclophosphamide IV over 3 hours BID on days 2-4, doxorubicin IV over 15-30 minutes on day 5, vincristine IV over 15-30 minutes on days 5 and 12, dexamethasone PO or IV on days 2-5 and 12-15, and bortezomib IV over a few seconds after the first dose of cyclophosphamide and immediately after vincristine and doxorubicin have been given on day 5.~Drug Combination II: Participants receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours every 12 hours on days 3-4."
62100817|NCT06684314||Efanesoctocog alfa|Participants observed receiving treatment with efanesoctocog alfa for hemophilia A
62100818|NCT01895257|ACTIVE_COMPARATOR|A: systemic chemotherapy LV5FU2 alone|Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab or cetuximab or panitumumab (according its previous use) every 2 weeks
62100819|NCT01895257|ACTIVE_COMPARATOR|B:SIR-spheres+systemic chemotherapy LV5FU2|ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab or cetuximab or panitumumab according its previous use (refer to protocol).
62100820|NCT02482493|ACTIVE_COMPARATOR|All-polyethylene Tibial component|Sigma PFC All polyethylene Tibial component will be implanted
62100821|NCT02482493|ACTIVE_COMPARATOR|Metal Backed Tibial component|Sigma PFC metal-backed tibial component will be implanted
62100822|NCT06227338|EXPERIMENTAL|0.125 mg/kg|Patients who will be injected with 0.125 mg/kg Indocyanine green before their tumorectomy
62100823|NCT06227338|EXPERIMENTAL|0.25 mg/kg|Patients who will be injected with 0.25 mg/kg Indocyanine green before their tumorectomy
62100824|NCT06227338|EXPERIMENTAL|0.5 mg/kg|Patients who will be injected with 0.5 mg/kg Indocyanine green before their tumorectomy
62662572|NCT06278649|EXPERIMENTAL|Relaxation and Guided Imagery Intervention|During the RGI sessions, the participant will be told to lie down on an exercise mat while a 15 minute relaxation and guided imagery audio recording is played. During the relaxation portion of the script, the participant will be instructed to let go of tension they might feel in individual parts of their body (starting with their feet and working their way up). The second portion is the guided imagery portion, which includes asking each participant to imagine themselves in a peaceful place. The participant will then be guided to imagine healing in the specific bronchial tubes and lungs, asking them to imagine themselves doing a favorite activity in which they have no trouble with their asthma, and asking them to visualize breathing in a colored air that would clear the airways and lungs.
62662573|NCT02632942|EXPERIMENTAL|HAQ Criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~1. 60% or greater diameter of the main AVF~2. 50% diameter of AVF with at least one more av\>40% in diameter.~3. 50% in diameter and divides into branches of same size.~4. av likely to interfere with cannulation on physical examination.~5. \>30% in diameter and associated with stenosis at site of origin."
62662574|NCT02632942|ACTIVE_COMPARATOR|Current Recommendation|Obliteration of accessory vein which satisfy the current recommendations only defined as accessory vein with a diameter greater than 25% of the AVF diameter.
62100825|NCT06227338|EXPERIMENTAL|1 mg/kg|Patients who will be injected with 1 mg/kg Indocyanine green before their tumorectomy
62100826|NCT06227338|EXPERIMENTAL|2 mg/kg|Patients who will be injected with 2 mg/kg Indocyanine green before their tumorectomy
61910879|NCT05785481||Patients with early diagnosis (within 6 hours of life) of mild HIE|
61910880|NCT05003271|EXPERIMENTAL|Small group zoom meeting|Group one: participants were asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a Zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants; e.g., questions, perceptions, etc.).
62100827|NCT06713473|EXPERIMENTAL|Rehumanized Intervention|This self-rehumanization intervention will involve a set of multi-sensory activities (i.e., reading, writing, and speaking) to prompt body and soul awareness, agency, connection, and creativity.
62100828|NCT06713473|ACTIVE_COMPARATOR|Control Intervention|Control Intervention about political attitudes
62100829|NCT06668818||Nurses employed at IRCCS-CRO Aviano|
62100830|NCT06668818||Patients admitted to the IRCCS-CRO Aviano as in-patients|
62100831|NCT05154916|EXPERIMENTAL|Experimental:|Bronchoscopy of Virtual Reality Based Relaxation Program Will Be Applied
62100832|NCT05154916|NO_INTERVENTION|No Intervention|Bronchoscopy of Virtual Reality Based Relaxation Program Will Not Be Applied
62294761|NCT06228157|ACTIVE_COMPARATOR|the control group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.
62294762|NCT00850252|EXPERIMENTAL|Lifeline blood vessel|
62662575|NCT01588275|ACTIVE_COMPARATOR|MRA therapy|During 12 months patients will be treated with a bibloc MRA (SomnoDent® MAS, SomnoMed Australia/Europe AG). The MRA will be customized by certified dentists or dental-specialists experienced in the field of dental sleep medicine.
62662576|NCT01588275|ACTIVE_COMPARATOR|CPAP therapy|"During 12 months patients will be treated with Continuous positive airway pressure (CPAP).Treatment with CPAP prevents upper airway collapse by pneumatically splinting the upper airway during sleep."
62100833|NCT05487586||ceftazidime avibactam group|Receive ≥1 dose of ceftazidime avibactam in routine practice; Aged ≥ 18 years old at the time of the informed consent signature.
62100834|NCT05784155|OTHER|Group 1|Test Drug for Period I Reference Drug for Period II
62100835|NCT05784155|OTHER|Group 2|Reference Drug for Period I Test Drug for Period II
62100836|NCT02831153|ACTIVE_COMPARATOR|normal coronary anatomy|coronary angiography will be performed by transfemoral or transradial route.
62100837|NCT02831153|ACTIVE_COMPARATOR|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
62100838|NCT02831153|ACTIVE_COMPARATOR|slow coronary flow|coronary angiography will be performed by transfemoral or transradial route.
62100839|NCT02831153|ACTIVE_COMPARATOR|nonobstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
62100840|NCT02831153|ACTIVE_COMPARATOR|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
62100841|NCT06426082|PLACEBO_COMPARATOR|Thermoneutral condition|n=10; receiving a thermoneutral exposure 2 hours/day at 32ºC; 5 days/week; Total 4 weeks
62100842|NCT06426082|EXPERIMENTAL|Cold condition|n=10; receiving 2 hours/day at 18ºC; 5 days/week; Total 4 weeks
62100843|NCT06426082|EXPERIMENTAL|Salbutamol|n=10; salbutamol 12 mg/day. 7 days week. Total 4 weeks
62100844|NCT06426082|EXPERIMENTAL|Aerobic exercise|n=10; receiving 5 days/week at 65% heart rate reserve for 60 minutes each training session. Total 4 weeks
61910881|NCT05003271|EXPERIMENTAL|YouTube pre-recorded video|Group two: participants were asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
62100845|NCT06631547|PLACEBO_COMPARATOR|patients with main lines of management without progesterone|patients with main lines of management without progesterone
62100846|NCT06631547|ACTIVE_COMPARATOR|Patients taking progesterone plus the main lines of management of traumatic brain injury|taking progesterone IM 1mg/kg twice for 5 days plus the main lines of management of traumatic brain injury
62100847|NCT06631001|EXPERIMENTAL|Abdominal Massage Group|This group consists of patients receiving abdominal massage. Abdominal massage will be administered twice a day for 15 minutes. This intervention is conducted to assess its effects on defecation frequency, gastric residual volume, and abdominal distension.
62100848|NCT06631001|NO_INTERVENTION|Control Group|This group will receive standard care without abdominal massage. Measurements for bowel excretion frequency, gastric residual volume, and abdominal distension will also be conducted.
62100849|NCT01328587|EXPERIMENTAL|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
62100850|NCT05954871|EXPERIMENTAL|Dose-Finding Stage: Non-Small Cell Lung Cancer (NSCLC)|Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at an assigned dose, orally, once daily (QD), on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 milligrams (mg), orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
62662577|NCT04790799|EXPERIMENTAL|Intervention group|Treatment in a hospital setting at Gentofte Hospital skin department with patient education, glove counselling, personal product screening by a chemistry engineer, extended allergy testing and the standard treatment of hand eczema.
62100851|NCT05954871|EXPERIMENTAL|Dose-Finding Stage: Colorectal Cancer (CRC)|Participants with metastatic CRC will receive GDC-1971, at an assigned dose, orally, QD, on Days 1 to 28 days of each 28-day cycle in combination with cetuximab, 500 milligrams per square meter (mg/m\^2), given by IV infusion on Days 1 and 15 of each cycle, until disease progression or unacceptable toxicity.
62100852|NCT05954871|EXPERIMENTAL|Dose Expansion Stage: NSCLC|Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 mg, orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
62100853|NCT05954871|EXPERIMENTAL|Dose Expansion Stage: CRC|Participants with metastatic CRC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with cetuximab, 500 mg/m\^2, given by IV infusion on Days 1 and 15 of each cycle until disease progression or unacceptable toxicity.
62100854|NCT04746859|EXPERIMENTAL|Intervention|Patients will have a prevention visit with a Prevention Practitioner (a healthcare provider who has received additional training), complete the baseline survey then be invited to receive ongoing support from a trained, volunteer peer health coach, for up to six months. The coach will support the patient as she works towards achieving personalized health goals to reduce her risk of chronic diseases, including cancer. Patients will be administered additional surveys at 3 and 6 months and a final survey at 12 months.
62100855|NCT04746859|OTHER|Wait-list Control|Patients will have a prevention visit with a Prevention Practitioner (a healthcare provider who has received additional training) and complete a baseline survey, after which they will receive usual care from their healthcare providers. Patients will be administered another survey at 3 months and a final survey at 6 months. After study completion (about 6-months after the initial prevention visit), patients will be invited to receive ongoing support from a trained, volunteer peer health coach, for up to six months. The coach will support the patient as she works towards achieving personalized health goals to reduce her risk of chronic diseases, including cancer.
62662578|NCT04790799|NO_INTERVENTION|Control group|Treatment as usual (at a dermatologist office).
62100856|NCT04960709|EXPERIMENTAL|Durvalumab + Tremelimumab + Enfortumab vedotin|Participants will receive 3 preoperative 21-day cycles of Durvalumab + Tremelimumab + Enfortumab Vedotin, followed by radical cystectomy, followed by 1 cycle of postoperative Tremelimumab and 9 cycles of Durvalumab. Each postoperative cycle is 28 days.
62100857|NCT04960709|EXPERIMENTAL|Durvalumab + Enfortumab vedotin|Participants will receive 3 preoperative 21-day cycles of Durvalumab + Enfortumab Vedotin, followed by radical cystectomy, followed by 9 cycles of Durvalumab. Each postoperative cycle is 28 days.
62100858|NCT04960709|ACTIVE_COMPARATOR|Cystectomy with or without approved Adjuvant Therapy.|Participants may receive SoC (nivolumab approved as adjuvant treatment for MIBC based on high risk criteria) per approved label in the country OR Participants receive standard of care surgery (radical cystectomy) alone.
62100859|NCT03529864|EXPERIMENTAL|Exercise therapy|The participants took part in a progressive exercise therapy program for 9 consecutive weeks, once a week. This consisted of group sessions with 8 or 9 students, with each session lasting 60 minutes, supervised by the principal researcher
62100860|NCT03529864|NO_INTERVENTION|Control|The CG did not receive any type of information or instructions apart from the general information sheet on the progress of the study, attached to the informed consent form
62100861|NCT04364880|EXPERIMENTAL|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
62100862|NCT04364880|SHAM_COMPARATOR|Sham controlled intervention|The sham-TBS coil produced a similar sound without a magnetic pulse.
62100863|NCT06599879|OTHER|Patients with a brain tumour treated with radiotherapy in the first line 2 years prior to inclusion.|
62100864|NCT01660295|EXPERIMENTAL|Certoparin control|Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.
62100865|NCT01660295|EXPERIMENTAL|Certoparin Renal|"Participants receive dose escalation upon medical criteria qualification at each period:~Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4."
62100866|NCT06268613|EXPERIMENTAL|SB27|SB27 will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
62100867|NCT06268613|ACTIVE_COMPARATOR|EU sourced Keytruda|EU sourced Keytruda will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
62100868|NCT06268613|ACTIVE_COMPARATOR|US sourced Keytruda|EU sourced Keytruda will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
62100869|NCT03137914|EXPERIMENTAL|autologous chondrocyte transplantation|Autologous transplant of chondrocytes diluted in hyaluronic acid after orthognathic surgery. The transplantation will be performed through an intra-articular injection into the TMJ (arthrocentesis). Hyaluronic acid is used only as a soluble medium to dilute the chondrocytes, so it is not considered as another experimental group, or as part of interest in this investigation.
62100870|NCT06711679|EXPERIMENTAL|Neonatal group|From birth to 28 days
61910882|NCT03841084|ACTIVE_COMPARATOR|Conservative Oxygen Management Strategy|Patients allocated to the conservative strategy will have the ECMO blender oxygen fraction (FbO2) will be titrated to achieve a post-oxygenator saturations of 92-96% (the FbO2 cannot be reduced to lower than 0.5). Post-oxygenator arterial blood gases (ABG's) will be taken to ensure safety and to allow for adjustments to be made. The ventilator FiO2 will be titrated to patient oxygen saturations (SpO2) of 92-96%.
61910883|NCT03841084|ACTIVE_COMPARATOR|Liberal Oxygen Management Strategy|Patients allocated to the liberal strategy will have the FbO2 set at 1.0 at all times. The ventilator FiO2 will be titrated to achieve a patient oxygen saturations (SpO2) of 97-100% (but not lower than 0.5).
62662579|NCT05707169|EXPERIMENTAL|Two Centimeters from Saphenofemoral Junction|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture. Using 1470 nm laser and a radial fibre for less discomfort. The catheter is placed 2-2.5 cm distal to the sapheno-femoral junction. Tumescence with a mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
62662580|NCT05707169|EXPERIMENTAL|Zero point Ablation|The catheter is positioned exactly at the terminal valve of the SFJ (kissing the valve).
61910884|NCT05828641|ACTIVE_COMPARATOR|Supination-flexion|Supination-flexion maneuver will be applied in the treatment of patients in this group.
61910885|NCT05828641|ACTIVE_COMPARATOR|Hyperpronation|Hyperpronation maneuver will be applied in the treatment of patients in this group.
62662581|NCT00561327||A|Patients chronically treated with drug losartan
61910886|NCT05568940||Pre-menopausal women >18 years old with endometriosis and/or uterine fibroids|GnRH-a depot (11.25mg IM x 1) and daily Tibolone 2.5mg orally once a day for 2-3 months.
62100871|NCT06711679|EXPERIMENTAL|Infant group|1 month to 1 year
62100872|NCT06711679|EXPERIMENTAL|Toddler Group|1-3 years
62100873|NCT06711679|EXPERIMENTAL|Child Group|3-7 years
62100874|NCT06711393|EXPERIMENTAL|Exergaming group|Exergaiming group plaing games during intervention period
62100875|NCT06711393|ACTIVE_COMPARATOR|Control group|Regular exercise without exergaming
62100876|NCT05975931||"Cohort 1 (new insertions cohort)"|Subjects who have had Aspire SR® implanted as their first VNS model.
62100877|NCT05975931||"Cohort 2 (battery change cohort)"|Subjects who have had their VNS battery changed from a previous model to Aspire SR®.
62294763|NCT00352703|EXPERIMENTAL|Kepivance (palifermin) 60 μg/kg/day IV|60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
62294764|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
62294765|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
62294766|NCT02842931|ACTIVE_COMPARATOR|R-DA-EPOCH-21|Protocol involves 6 cycles.
62662582|NCT00561327||B|Patients not chronically treated with losartan
62662583|NCT04825522|NO_INTERVENTION|Control|Participants will not be receiving vancomycin.
62662584|NCT04825522|ACTIVE_COMPARATOR|Vancomycin|For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
62100878|NCT06614985|ACTIVE_COMPARATOR|Group A|"After completing the induction treatment period, patients undergo an efficacy evaluation to determine if complete remission or partial remission has been achieved. Patients who have not achieved complete or partial remission are classified as non-responders. Patients who have achieved complete or partial remission are then randomly assigned to either Group A or Group B at a 1:1 ratio.~Medication regimen of Group A： Prednisone：the maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation； Cyclophosphamide injection：an intravenous injection of 0.4 g is administered twice a month."
62100879|NCT06614985|EXPERIMENTAL|Group B|Medication regimen of Group B： Prednisone：the maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation； Telitacicept injection：an intravenous injection of 0.4 g is administered twice a month.
62100880|NCT06614985|ACTIVE_COMPARATOR|Group C|"After completing the induction treatment period, patients undergo an efficacy evaluation to determine if complete remission or partial remission has been achieved. Patients who have not achieved complete or partial remission are classified as non-responders. Non-responders are randomly assigned to either Group C or Group D at a 1:1 ratio.~Medication regimen of Group C： Prednisone：the maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation； Cyclophosphamide injection：an intravenous injection of 0.4 g is administered twice a month."
62100881|NCT06614985|EXPERIMENTAL|Group D|Medication regimen of Group D： Prednisone：the maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation； Telitacicept injection：an intravenous injection of 0.4 g is administered twice a month.
62100882|NCT05931835|EXPERIMENTAL|Catheter-ablation and closure procedures arm|Subjects entitled to undergo a catheter-based ablation treatment for typical atrial flutter or atrial fibrillation and subjects entitled to undergo a left atrial appendage/atrial septal defect closure procedure
62100883|NCT05667753|ACTIVE_COMPARATOR|Basic|The MINISTOP app will be offered to all parents of children at the 2.5/3-year routine visit at primary child healthcare. The child healthcare centers randomly allocated to the basic group will receive the basic implementation strategy package.
62100884|NCT05667753|EXPERIMENTAL|Enhanced|The MINISTOP app will be offered to all parents of children at the 2.5/3-year routine visit at primary child healthcare. The child healthcare centers randomly allocated to the enhanced group will receive the enhanced implementation strategy package.
62100885|NCT06426654|EXPERIMENTAL|sintilimab+LDRT|"Laparoscopic exploration is required in all patients to detect occult peritoneal metastases.~All patients will start with one cycle of neoadjuvant therapy of sintilimab: 200 mg, iv drip, d1, q3w.~Then, LDRT will be performed in the target area (including the primary gastric lesion and positive/suspected positive lymph nodes).~After radiotherapy, patients will receive another three cycles of sintilimab. Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles."
62100886|NCT05061524|EXPERIMENTAL|YH35324|"* Part A: A single dose of the YH35324 will be administered subcutaneously in 5 dose groups (0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses~* Part B: A single dose of the YH35324 will be administered subcutaneously. The dose of YH35324 will be determined after the safety, tolerability, PK, and PD data in Part A are reviewed"
62100887|NCT05061524|PLACEBO_COMPARATOR|Placebo|"* Part A: A single dose of the Placebo will be administered subcutaneously in 5 Cohorts(Dose groups=0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses~* Part B: Placebo is not administered in Part B"
62100888|NCT05061524|ACTIVE_COMPARATOR|Xolair® for injection (Omalizumab)|"* Part A: A single fixed dose of the Omalizumab 300mg will be administered subcutaneously in 4 Cohorts(Dose groups of YH35324=1, 3, 6, and 9 mg/kg)~* Part B: A single dose of the Omalizumab 300mg will be administered subcutaneously."
62100889|NCT02825654||Post-9/11 Gulf War Era Veterans|Military personnel who deployed to Central Asia, Southwest Asia, and Africa during the Post-9/11 Gulf War Era
62100890|NCT02960776|NO_INTERVENTION|Habitual Sleep (HS)|Participants will be asked to follow a fixed bedtime routine based on the participant's regular bed- and wake-times during the habitual sleep (HS) phase.
62100891|NCT02960776|EXPERIMENTAL|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time during the sleep restriction (SR) phase.
62294767|NCT02842931|ACTIVE_COMPARATOR|R-DA-EPOCH-21 + auto-SCT|Protocol involves 6 cycles. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
62294768|NCT02842931|ACTIVE_COMPARATOR|R-mNHL-BFM-90|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 25 mg/m2/day IV 1, 2 days, Vincristine 2 mg IV 1 day, Cytarabine 100 mg/m2/day IV 1 h 4, 5 days.~Course B:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Cyclophosphamide 200 mg/m2/day IV 1 h 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Doxorubicin 25 mg/m2/day IV 4, 5 days, Vincristine 2 mg IV 1 day. Protocol involves 6 cycles : A-B-A-B-A-B. One cycle continues 21 days."
62662585|NCT02197156|EXPERIMENTAL|10 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 10 mg
62100892|NCT05829174|EXPERIMENTAL|Cognitive Behavioral Therapy with Techniques of Starting on Time and Planning Realistically|5 session (one session a week) online group therapy including several psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention) and a behavioral module: realistic planning, timely beginning.
62100893|NCT05829174|EXPERIMENTAL|Cognitive Behavioral Therapy with Technique of Working Time Restriction|5 session (one session a week) online group therapy including several psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention) and a behavioral module: working time restriction.
62100894|NCT05829174|ACTIVE_COMPARATOR|Cognitive Behavioral Intervention with Time Management Technique|5 session (one session a week) online group therapy including several psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention) and a behavioral module: pomodoro technique.
62100895|NCT05829174|NO_INTERVENTION|Wait-list control group|No intervention
62100896|NCT06611176|NO_INTERVENTION|No levobupivacaine|ESD without local levobupivacaine
62100897|NCT06611176|EXPERIMENTAL|Levobupivacaine|levobupivacaine submucosally injected during esopahgeal esd
62100898|NCT06042127|EXPERIMENTAL|Per-oral endoscopic myotomy with fundoplication|The detail of the procedure has been reported in the literature. After completion of myotomy as per conventional anterior POEM, a serosal incision would be made at the level of the GE junction below the diaphragmatic crus. The peritoneal cavity would then be entered and the anterior gastric wall could be identified. A detachable endoloop would be introduced alongside the endoscope with the guidance of endoscopic clip. Three to four clips would be applied to the anterior gastric fundus while additional 3-4 clips would be applied to the edge of the submucosal tunnel, all anchoring to the endoloop. Upon tightening of the endoloop the anterior fundus would be approximated to the esophagogastric junction and thus completing the partial anterior fundoplication. Abdominal paracentesis to treat capnoperitoneum would be performed as required based on patient's clinical condition.
62100899|NCT06042127|ACTIVE_COMPARATOR|Conventional POEM|Conventional per-oral endoscopic myotomy An anterior POEM would be performed per usual manner described in the literature. The procedure would be performed under general anaesthesia by expert endoscopists with at least 50 case experience of conventional POEM and 5 cases experience of POEM-F. The requirement of POEM experience is based on a recent multicenter study of learning curve by Fujiyoshi Y, et al. The procedure would follow the current recommendations from expert panel in reducing GER, including avoidance of excessive gastric myotomy and preservation of the sling fibers are the gastric cardia. The length of the esophageal and gastric myotomy is standardized at 5cm and 2cm respectively
62100900|NCT04928157|EXPERIMENTAL|CPAP|Use of CPAP, a device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
62100901|NCT04928157|NO_INTERVENTION|Control|No CPAP use, otherwise usual care
62100902|NCT04547543|OTHER|Video consultation|Patients in this group will have a continuous positive pressure follow-up visit by videoconsultation
62662586|NCT02197156|EXPERIMENTAL|20 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 20 mg
61910887|NCT00319267|EXPERIMENTAL|Bosentan|The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
62100903|NCT04547543|NO_INTERVENTION|Face-to-face consultation|Patients in this group will have a continuous positive pressure follow-up visit by face-to-face consultation
62100904|NCT02107001||Patients with pleuritic chest pain|Study investigators will perform lung ultrasound in each patient with pleuritic chest pain at inclusion
62662587|NCT02197156|EXPERIMENTAL|30 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 30 mg
62100905|NCT06713122|EXPERIMENTAL|İntervention Group- Group receiving Symptom Management Training with Mobile Application|Mobile application intervention will be applied to the intervention group. The evaluation tests will be repeated after the first cycle of chemotherapy treatment, at the 3rd and 5th cycles.
62662588|NCT02197156|EXPERIMENTAL|40 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 40 mg
62662589|NCT02197156|ACTIVE_COMPARATOR|10 mg HC / 325 mg APAP|10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)
61910888|NCT06189235|NO_INTERVENTION|System development: Validation for patients|No intervention. The patients will receive one time of MRI and three times of ultrasound evaluation on the injured area, each evaluaitons will be done by two to three days interval.
61910889|NCT06189235|NO_INTERVENTION|System development: Building dataset from healthy subjects|No intervention. The healthy subjects will receive one time of ultrasound evaluation on the dominant hand, the different part and different axis in dominant hand will be assessed in types of images or films for building the dataset.
61910890|NCT06189235|NO_INTERVENTION|System application: Understanding the recovery patterns in patients|No intervention. The patients will receive three times of ultrasound evaluation on the injured area and hand function assessments, each evaluaitons will be done by two weeks interval.
61910891|NCT06189235|EXPERIMENTAL|System application: Biofeedback training|"The program last for one month. In this program, the patients receive traditional rehabilitation protocol assigned from original hospital or therapist. Also, ultrasound evaluation and hand function assessment will be performed at pre-test, one follow-up test and post-test, which will be done with two weeks interval.~For this biofeedback training group, the therapist and patients will be asked to use the hint recommanded by modular system to assist the rehabilitation excepting the traditional routine at least two times a week."
62662590|NCT02197156|PLACEBO_COMPARATOR|Placebo|Matching placebo
62662591|NCT01025050|EXPERIMENTAL|Group A|In this group the smallest ring diameter will be applied.
62662592|NCT01025050|EXPERIMENTAL|Group B|In this group the intermediate ring diameter will be applied.
62662593|NCT01025050|EXPERIMENTAL|Group C|In this group the biggest ring diameter will be applied.
62100906|NCT06713122|NO_INTERVENTION|Control Group|No intervention will be applied to the control group. The evaluation tests will be repeated after the first cycle of chemotherapy treatment, at the 3rd and 5th cycles.
62100907|NCT06132737|EXPERIMENTAL|[90Y]Y-PTT|The study will be performed in three cohorts with different dose levels. Eligible patients will receive one cycle of 90Y-PTT, which will be administered intravenously.
62100908|NCT04143646|ACTIVE_COMPARATOR|Web-based prevention program|"Patients after myocardial infarction participate in a 12-months program with telemetric risk factor control, e-learning and E-Mail/App-contacts.~In a substudy patients are further randomly assigned to disclosure of genetic risk vs. no disclosure."
62100909|NCT04143646|NO_INTERVENTION|Usual Care|Patients after myocardial infarction are treated following the standard of care (clinical practice as offered by general practitioners, cardiologists, etc.).
62100910|NCT04362319||Anaesthesiology clinicians|Including Consultants, Specialists and Medical officers serving in the Department of Anaesthesiology and Intensive Care
62100911|NCT03398135|PLACEBO_COMPARATOR|Substudy 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
62100912|NCT03398135|EXPERIMENTAL|Substudy 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
62100913|NCT03398135|EXPERIMENTAL|Substudy 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
62100914|NCT03398135|EXPERIMENTAL|Substudy 2: Open-label (OL) Clinical Assessment Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
62100915|NCT03398135|EXPERIMENTAL|Substudy 2: OL Therapeutic Drug Monitoring Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
62100916|NCT03398135|EXPERIMENTAL|Substudy 3: OL Extension Risankizumab|Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
62100917|NCT03398135|EXPERIMENTAL|OL Continuous Treatment Extension - Dose 1|Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection.
62100918|NCT03398135|EXPERIMENTAL|OL Continuous Treatment Extension - Dose 2|Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection.
62662594|NCT05852288||Individuals with carpal tunnel syndrome|This study will follow a group of individuals with carpal tunnel syndrome (CTS) according to Bland's grading scale (grades 1-3) to assess the role of inflammation in CTS. Participants will undergo clinical and biochemical evaluations to assess inflammatory markers and CTS severity. The study will follow participants over time to determine the relationship between inflammation and CTS, which can inform the choice of transdermal drug administration.
62662595|NCT04972721||Questionnaire survey|Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.
62100919|NCT05426291||Group I|At least two of the preoperative biomarkers (Mg\<0.85 mmol/L, Hgb\<8.5 mmol/L, proBNP\>480 pg/mL, CRP\>5 mg/L) that are thought to be closely related to acute kidney injury after cardiac surgery Group I,
62100920|NCT05426291||Group II|Patients who meet at least two of the preoperative biomarkers (Mg\>0.85 mmol/L, Hgb\>8.5 mmol/L, proBNP\<480 pg/mL, CRP\<5 mg/L) Group II .
62100921|NCT03986606|EXPERIMENTAL|Open-label Dose Escalation and Expansion Study of PSB205|"Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts."
62100922|NCT05120440|EXPERIMENTAL|Breakfast Omission|This arm will consist of omission of breakfast and consumption of standardized food items solely at lunch preceding afternoon resistance exercise.
62662596|NCT02738515|ACTIVE_COMPARATOR|Group 1|Scaling and Root Planing (SRP) with 0.75% BORIC ACID GEL for treating furcation defect
62662597|NCT02738515|PLACEBO_COMPARATOR|Group 2|Scaling and Root Planing (SRP) with PLACEBO GEL for treating furcation defect.
62662598|NCT05482789|EXPERIMENTAL|Exenatide|Participant receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
62662599|NCT03016637|EXPERIMENTAL|EUS biopsy|EUS guided SharkCore (TM) biopsy of pancreatic lesions suspected of malignancy
62662600|NCT04176523||Methylmalonic_acidemia|Patients with confirmed diagnosis of methylmalonic acidemia, and treated with carglumic acid, at any dose form, any dosage,
62662601|NCT04176523||Propionic_Acidemia|Patients with confirmed diagnosis of propionic acidemia, and treated with carglumic acid, at any dose
62662602|NCT00478036|ACTIVE_COMPARATOR|Acular LS|Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
62100923|NCT05120440|ACTIVE_COMPARATOR|Breakfast Consumption|This arm will consist of consumption of standardized food items at breakfast and lunch preceding afternoon resistance exercise.
62100924|NCT05819827||Patients with genitourinary cancers|Genitourinary medical oncologists and study coordinators will identify patients with genitourinary cancers (i.e., bladder cancer, prostate cancer, and testicular cancer) who will receive moderate to high emetogenic chemotherapy regimen.
62662603|NCT00478036|ACTIVE_COMPARATOR|Pred Forte|Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
62662604|NCT00478036|PLACEBO_COMPARATOR|Refresh Tears|Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
62100925|NCT01096056|EXPERIMENTAL|Influenza vaccine GSK2186877A formulation 1 Group|Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.
62100926|NCT01096056|EXPERIMENTAL|Influenza vaccine GSK2186877A formulation 2 Group|Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.
62100927|NCT03952481|EXPERIMENTAL|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
62100928|NCT06042114|EXPERIMENTAL|Listening to Surah Inshirah|Experimental group patients; A patient descriptive characteristics form will be applied, pretest VAS pain score and state anxiety scale will be applied. Then, the Surah al-Inshirah will be listened to and the final test VAS pain score and state anxiety scale will be applied.
62100929|NCT06042114|NO_INTERVENTION|control group|Control group patients; A patient descriptive characteristics form will be applied, pretest VAS pain score and state anxiety scale will be applied. The posttest VAS pain score and state anxiety scale will be applied 10 minutes later, without any intervention.
62100930|NCT05650411|EXPERIMENTAL|P2Y12 inhibitor-based single antiplatelet therapy after a short DAPT strategy arm|"Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).~P2Y12 inhibitor SAPT with any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, or prasugrel 10 mg) after a short DAPT course during 2 years after the index LMCA procedure.~In patients with intended clopidogrel use, a platelet function or genetic test is mandatory before hospital discharge for patients with intended treatment with clopidogrel. In case of high on-treatment platelet reactivity or an ABCD-GENE score =/\>10, patients treated with clopidogrel should be switched to either ticagrelor or prasugrel with corresponding on-label loading dose regimens, at the investigator's discretion.~At the discretion of the investigator, aspirin will be discontinued after LMCA PCI, or continued during the hospital stay. In all cases, aspirin will be discontinued at latest at hospital discharge."
62662605|NCT00845000|EXPERIMENTAL|SCH 420814 10 mg→SCH 420814 100 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
62294769|NCT02842931|ACTIVE_COMPARATOR|R-mNHL-BFM-90 + auto-SCT|Protocol involves 6 cycles R-mNHL-BFM-90: A-B-A-B-A-B. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
62294770|NCT04233489|EXPERIMENTAL|Family Nurture Intervention (FNI)|This arm contains the combined GDM+FNI and control+FNI cohort.
62294771|NCT04233489|NO_INTERVENTION|Non-FNI|This arm contains the combined GDM+no FNI and control+no FNI cohort.
62294772|NCT00632580|ACTIVE_COMPARATOR|1|intraarticular injection with local anesthetic
62294773|NCT00632580|EXPERIMENTAL|2|intracapsular injection with local anesthetic
62662606|NCT00845000|EXPERIMENTAL|SCH 420814 100 mg→Placebo→ SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
62662607|NCT00845000|EXPERIMENTAL|Placebo→SCH 420814 10 mg→SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
62737103|NCT00862368|ACTIVE_COMPARATOR|PAM-Healthy|The PAM-Healthy arm received the same in-home counseling visits as PAM and PAM Enhanced but asthma information was replaced with child wellness topics. The 6 counseling phone calls were the same timing and duration as the other two groups (six, 15 minutes calls, over four months) focused on a child wellness topic. Smoking cessation or sampler feedback was not discussed. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
61910892|NCT06189235|NO_INTERVENTION|System application: Traditional training|The program last for one month. In this program, the patients receive traditional rehabilitation protocol assigned from original hospital or therapist. Also, ultrasound evaluation and hand function assessment will be performed at pre-test, one follow-up test and post-test, which will be done with two weeks interval.
61910893|NCT03253562|NO_INTERVENTION|Healthy control|healthy volunteers not suffering from diabetes or hypertension
61910894|NCT03253562|NO_INTERVENTION|diabetic hypertensive recently diagnosed patients|recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
61910895|NCT03253562|OTHER|Metformin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
61910896|NCT03253562|OTHER|Vildagliptin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
61910897|NCT00266864|EXPERIMENTAL|Testosterone Replacement Therapy|Subjects with Low Testosterone (Hypogonadal) Receive Testosterone Transdermal System (Androderm 5 mg patch)
62100931|NCT05650411|ACTIVE_COMPARATOR|Conventional DAPT strategy arm|"Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland) DAPT combining aspirin and any of the commercially available oral P2Y12 receptor inhibitors (clopidogrel, ticagrelor, or prasugrel) during 6 or 12 months followed by aspirin-based SAPT.~In patients with index ACS presentation and who have tolerated DAPT for 12 months without bleeding complications, a prolonged DAPT course with aspirin and ticagrelor 60 mg bd (clopidogrel or prasugrel allowed, if patient not eligible for treatment with ticagrelor) beyond 12 months may be considered in those patients with high thrombotic risk and without an increased risk for major or life-threatening bleeding, and those with moderately elevated thrombotic risk."
62467068|NCT01852617|EXPERIMENTAL|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
62662608|NCT00845000|EXPERIMENTAL|SCH 420814 10 mg→ Placebo→ SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
62662609|NCT00845000|EXPERIMENTAL|SCH 420814 100 mg→ SCH 420814 10 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
62662610|NCT00845000|EXPERIMENTAL|Placebo→ SCH 420814 100 mg→SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
62662611|NCT05201001|ACTIVE_COMPARATOR|Standard of Care|"Carboplatin AUC = 5, IV day 1 and pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks~Total:6 cycles or until progressive disease or unacceptable toxicity."
62662612|NCT05201001|EXPERIMENTAL|APX005M|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 \& 15 IV q4 wks x concomitant with chemotherapy~Total:6 cycles or until progressive disease or unacceptable toxicity."
62737104|NCT01646541||Asymptomatic|No dyspnea with exertion greater than 6 months after mitral valve surgery \[New York Heart Association (NYHA) Functional Class I\]
62100932|NCT05628727|EXPERIMENTAL|5:2 Fasting Group|This group will use the 5:2 method and fast for two non-consecutive days of the week.
62100933|NCT05628727|EXPERIMENTAL|Time-Restricted Feeding Group|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
62100934|NCT05628727|NO_INTERVENTION|Control Group|This group will not fast.
62100935|NCT04311619|EXPERIMENTAL|Major Depression Disorder Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the \[11C\]UCB-J radiotracer before and after Repetitive Transcranial Magnetic Stimulation (rTMS) treatment
62100936|NCT02921230|EXPERIMENTAL|ELUVIA Stent Implantation|Peripheral stenting
62662613|NCT05201001|EXPERIMENTAL|APX005M+RT|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 \& 15 IV q4 wks x concomitant with chemotherapy External beam radiation therapy; a dose of 0.5 Gy per fraction, administered as single fractions prior to APX005M administration; days 1 \& 15 q4 wks x 6 cycles. Maximum 24 wks of therapy; total dose 6 Gy.~Total:6 cycles or until progressive disease or unacceptable toxicity."
62662614|NCT06398691|ACTIVE_COMPARATOR|CPAP group|A Babylog 8000 neonatal ventilator (Dräger, Lübeck, Germany) for nasal CPAP support was used support . The nasal CPAP support had been applied through short binasal prongs (Optiflow Junior 2 nasal cannula) used as an interface. PEEP pressure was set to 6-8 cmH2O for nasal CPAP. The FiO2 was regulated to keep the oxygen-saturation value between 92% and 95%.
62662615|NCT06398691|ACTIVE_COMPARATOR|HHHFNC group|A Vapotherm® device (Vapotherm Inc., Stevensville, MD) for HHHFNC support was used. The airflow rate was set to 6-8 L/min for HHHFNC (heat: 37 °C). The HHHFNC support had been applied through the small bore cannula in the Vapotherm as an interface. The FiO2 was regulated to keep the oxygen-saturation value between 92% and 95%.
62662616|NCT01966783|EXPERIMENTAL|Budesonide dosage 1|Budesonide 2 mg suppository
61910898|NCT00266864|NO_INTERVENTION|No Intervention|Subjects with normal testosterone levels (eugonadal) participated in identical outcome measurements at parallel time points.
61910899|NCT01246908|EXPERIMENTAL|CX157 (TriRima)|CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)
61910900|NCT01246908|PLACEBO_COMPARATOR|Placebo|
61910901|NCT04858178|EXPERIMENTAL|Individuals with spinal cord injury|
61910902|NCT04858178|EXPERIMENTAL|Individuals without spinal cord injury|
61910903|NCT03355482|ACTIVE_COMPARATOR|Depomedrol arm|Patients are treated with new or ascending doses of subcutaneous methotrexate, and receive a single intramuscular dose of Depomedrol (160mg) at baseline.
61910904|NCT03355482|SHAM_COMPARATOR|Placebo arm|Patients are treated with new or ascending doses methotrexate, and receive a single intramuscular placebo injection at baseline.
61910905|NCT06113380|EXPERIMENTAL|Rehabilitation by rehabilitation robot|"Rehabilitation therapists will determine the training mode based on the subject's movement ability.~Passive training mode Active-assistive training mode"
62467069|NCT01852617|NO_INTERVENTION|No implementation of the intervention|Standard in-service activities
61910906|NCT06113380|ACTIVE_COMPARATOR|Traditional rehabilitation|Traditional upper limb physical therapy is performed by the therapist.
61910907|NCT02454361|EXPERIMENTAL|KBP-7072 cohort 1|KBP-7072 by mouth once
61910908|NCT02454361|EXPERIMENTAL|KBP-7072 cohort 2|KBP-7072 by mouth once
61910909|NCT02454361|EXPERIMENTAL|KBP-7072 cohort 3|KBP-7072 by mouth once
61910910|NCT02454361|EXPERIMENTAL|KBP-7072 cohort 4|KBP-7072 by mouth once
61910911|NCT02454361|EXPERIMENTAL|KBP-7072 cohort 5|KBP-7072 by mouth once
61910912|NCT02454361|EXPERIMENTAL|KBP-7072 Fed Group|KBP-7072 by mouth once to the fed group
61910913|NCT03661476|EXPERIMENTAL|Oculo-Motor Exercises (OME)|10 repetitive four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
62662617|NCT01966783|EXPERIMENTAL|Budesonide dosage 2|Budesonide 4 mg suppository
62662618|NCT01966783|ACTIVE_COMPARATOR|Mesalazine|Mesalazine 1g suppository
61910914|NCT00717704|EXPERIMENTAL|1|All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.
61910915|NCT01900912|EXPERIMENTAL|CLTS communities|Assigned to a community led total sanitation (CLTS) intervention, carried out by the government with support from Unicef (n=60 communities). The CLTS intervention includes a triggering session facilitated by the government to encourage community members to build their own latrines and stop open defecation. Regular monitoring is conducted by government program staff until the community is declared open defecation free.
61910916|NCT01900912|NO_INTERVENTION|Rural communities|No intervention will be delivered (n=61 communities)
61910917|NCT01781273|PLACEBO_COMPARATOR|Cranberry juice alone|500 mL of cranberry juice
61910918|NCT01781273|EXPERIMENTAL|BAC 0.5 g/L|Cranberry juice with ethanol to rise BAC to 0.5 g/L
61910919|NCT01781273|EXPERIMENTAL|BAC 0.65 g/L|Cranberry juice with ethanol to rise BAC to 0.65 g/L
61910920|NCT01781273|EXPERIMENTAL|BAC 0.8 g/L|Cranberry juice with ethanol to rise BAC to 0.8 g/L
61910921|NCT01271582|EXPERIMENTAL|FOLFIRI|Patients with colorectal cancer or gastric cancer will be treated with FOLFIRI(Irinotecan, 5FU, leucovorin) regimen upto 12 cycles. (Single arm study)
61910922|NCT00535288|PLACEBO_COMPARATOR|Placebo|Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
61910923|NCT00535288|EXPERIMENTAL|Esmirtazapine 2.25 mg|Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
61910924|NCT00535288|EXPERIMENTAL|Esmirtazapine 4.5 mg|Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
61910925|NCT00535288|EXPERIMENTAL|Esmirtazapine 9 mg|Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
62467070|NCT01253590||post op cancer patients experiencing atrial fibrillation|This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
61910926|NCT00535288|EXPERIMENTAL|Esmirtazapine 18 mg|Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.
61910927|NCT06190054|EXPERIMENTAL|MERAMIRT|Patients with diagnosis of moderate to severe dry eye disease with asthenopia and accommodative effort will receive MERAMIRT®, 1-2 drop per eye 3 times a day for 90 days.
61910928|NCT04043624|EXPERIMENTAL|Lidocaine group|First group (lidocaine group) will include those who receive a intraoperative lidocaine infusion.Induction bolus dose of 1.5 mg/kg body weight ( 30 minutes before incision)followed by a continous lidocaine infusion of 2mg/kg/h，until 1 hours after skin closure.
61910929|NCT04043624|PLACEBO_COMPARATOR|Saline group|The second group（saline group） will include those who receive a intraoperative placebo.The same dosage of saline was given according to the same method of administration in the lidocaine group.
61910930|NCT02789267|NO_INTERVENTION|Control|"Group of patients with standard of care: the nutritional support is conducted by physicians.~No systematic dietary support"
62294774|NCT01996787|ACTIVE_COMPARATOR|Air Optix Aqua|Compare safety and efficacy of the lens using OptiFree Replenish solution
62294775|NCT01996787|ACTIVE_COMPARATOR|Clariti with Handling Tint|Compare safety and efficacy of the lens using OptiFree Replenish solution
62294776|NCT04920409|EXPERIMENTAL|FAWGT Diet|Composed of fruit, avocado, whole grains and trout
62100937|NCT02921230|ACTIVE_COMPARATOR|control Bare Metal Stent Implantation|Peripheral stenting
62294777|NCT04920409|ACTIVE_COMPARATOR|Usual diet (UD)|Based on the food which the participants usually consumed prior to the study in their normal lifestyle.
62100938|NCT05913739|ACTIVE_COMPARATOR|Oxygen Therapy|Participants received nocturnal oxygen therapy (minimum 6 hours) for 6 months.
62100939|NCT05913739|NO_INTERVENTION|No Oxygen Therapy|Participants will not received oxygen therapy
62100940|NCT01268891|PLACEBO_COMPARATOR|Placebo|
61910931|NCT02789267|EXPERIMENTAL|Regular dietary support|Group of patients will benefit from a systematic and regular dietary support. Patients will be followed by a dietitian 1 month and 3 month after radiotherapy in hospital. Then, dietitian will realize a telephon interview 2 and 5 months after radiotherapy
61910932|NCT06257602||Endoscopic tympanoplasty group|Endoscopc tympanoplasty group: rigid endoscope 3 mm diameter/14 cm long/0 angle of view will be used together with a high-definition camera head and monitor and using tragal graft to reconstruct perforations of tympanic membrane.
61910933|NCT06257602||Microscopic tympanoplasty group|Microscopic tympanoplasty group: operating microscope and microscopic instruments will be used, and using tragal graft to reconstruct tympanic membrane perforations.
61910934|NCT03354793||endometriosis|Survey on first pregnancy after endometriosis diagnosis
61910935|NCT03354793||non endometriosis|Survey on first pregnancy
61910936|NCT04224688|EXPERIMENTAL|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
62100941|NCT01268891|EXPERIMENTAL|Azilect®|
23526589|NCT05996224|EXPERIMENTAL|Mesenchymal progenitor cells|Mesenchymal progenitor cells group
62100942|NCT03744117|EXPERIMENTAL|Intervention Arm|There is a single arm in this study. All patients will be assigned to receive the intervention, which is a palliative care consultation delivered by telemedicine.
62100943|NCT05121207|OTHER|Dry skin condition|2. The second arm will consist of 50 patients with benign dry skin conditions (eczema, psoriasis, skin grafts, scars etc.) and will compare the water content of their skin before and after application of a propriety emollients in common usage (e.g. E45®, Aveeno®, Doublebase®). This will add to the existing dataset that has been recorded from healthy non-patient volunteers (unpublished data, University of Warwick). This may help to guide patient-specific emollient selection in the future.
62294778|NCT04525703|EXPERIMENTAL|Pathways for Parents|
23526590|NCT05996224|ACTIVE_COMPARATOR|Sodium hyaluronate|Sodium hyaluronate injection group
62294779|NCT01361711|EXPERIMENTAL|Treatment (monoclonal antibody therapy)|Patients receive alemtuzumab SC three times a week in weeks 1-18 and ofatumumab IV over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and 17.
62294780|NCT02426307||Transcatheter Aortic Valve Replacement|TAVR: Portico (St Jude Medical), CoreValve (Medtronic), Lotus (Boston Scientific), Edwards Sapien 3 (Edwards LifeSciences),
62294781|NCT02426307||Surgical aortic valve replacement|SAVR: Perimount (Edwards), Epic (St Jude Medical), Trifecta (St Jude Medical)
62294782|NCT05971849|EXPERIMENTAL|kisspeptin|IV administration of kisspeptin 112-121; 24-hour infusion, up to 2 boluses.
62294783|NCT01578915||Cases|Women with 4 or more sexual partners during the past year
62294784|NCT01578915||Controls|Women with only one sexual partner during the past year
62294785|NCT03906266|ACTIVE_COMPARATOR|nutric score|\> 5 indicates high risk for malnutrition \< 4 indicates low risk for malnutrition
62294786|NCT03906266|PLACEBO_COMPARATOR|adductor pollicis|\< 20 mm indicates high high risk for malnutrition \> 20 mm indicates low risk for malnutrition
62294787|NCT03906266|PLACEBO_COMPARATOR|SGA score|SGA 1 indicates no malnutrition SGA 2 indicates good diet SGA 3 indicates high risk for malnutrition
62294788|NCT03906266|PLACEBO_COMPARATOR|NRS 2002 score|\> 3 indicates high risk for malnutrition
61910937|NCT04224688|PLACEBO_COMPARATOR|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
61910938|NCT05736575||Chronic Pain Patient|A blood draw is to be performed to analyze peripheral BDNF.
61910939|NCT05736575||Asymptomatic subject|A blood draw is to be performed to analyze peripheral BDNF.
61910940|NCT00811213|EXPERIMENTAL|1|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
61910941|NCT00811213|ACTIVE_COMPARATOR|2|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
61910942|NCT06305884|EXPERIMENTAL|Diagnostic (BI, PPG)|"Participants undergo BIA and wear watch-like sensors and undergo PPG at rest and while active (pedaling an exercise bike) on study."
61910943|NCT04641689|ACTIVE_COMPARATOR|Desk Only|Participants will receive a height-adjustable desk to use in their home work environment.
61910944|NCT04641689|ACTIVE_COMPARATOR|Program Only|Participants will receive 12 weeks of online content to support reductions in sedentary behavior while working from home. Content will be based on social cognitive theory.
61910945|NCT04641689|EXPERIMENTAL|Desk + Program|Participants will receive a height-adjustable desk to use in their home work environment AND 12 weeks of online content to support reductions in sedentary behavior while working from home.
61910946|NCT04641689|NO_INTERVENTION|Waitlist Control|Participants will receive the intervention (desk + program) after all follow-up data have been collected.
61910947|NCT05024292||rapid local ischemic postconditioning (RL-IPostC) group|RL-IPostC is performed immediately after successful reperfusion with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation.
61910948|NCT05024292||control group|no intervention was provided after successful reperfusion
61910949|NCT03997045|EXPERIMENTAL|Intervention group|Pregnant women receiving usual care and participating in supervised physical exercise program.
61910950|NCT03997045|NO_INTERVENTION|Control group|Pregnant women that are receiving usual care but are not participating in supervised physical exercise program.
61910951|NCT02294760|ACTIVE_COMPARATOR|Subsensory, OFF, subsensory|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then turned OFF for the next 4 weeks and finally set subsensory for the last 4 weeks.
62100944|NCT05121207|OTHER|Skin cancer|1. One arm will consist of 100 patients with known or suspected skin cancer (skin cancer defined as: incompletely excised BCC with histologically proven radial margin involvement; biopsy proven BCC, or pigmented lesions suspicious of malignant melanoma). Images will be taken in the clinic prior to planned skin surgery and later compared to the formal histology results after the primary (melanoma) or residual (BCC) tumour has been removed.
61910952|NCT02294760|ACTIVE_COMPARATOR|Subsensory, subsensory, OFF|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then set subsensory for another 4 weeks and finally turned OFF for the last 4 weeks.
62100945|NCT06713499|EXPERIMENTAL|SHR-1819 injection|Dose 1, dose 2 and dose 3.
62100946|NCT05642000|EXPERIMENTAL|SASEA HUB|Access to online COVID-19 information tool hub to support testing access
61910953|NCT01765309|EXPERIMENTAL|Bilateral mastectomy with reconstruction|The trial was a comparison between each breast in a single patient undergoing bilateral mastectomy with reconstruction
61910954|NCT02535572|EXPERIMENTAL|FEAST|Patients will receive the FEAST form of ECT
61910955|NCT02535572|ACTIVE_COMPARATOR|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
61910956|NCT05933109|EXPERIMENTAL|TMR group|Patients will receive a sound S1 while they generate a positive outcome of imagery rehearsal therapy (IRT). They will also receive the sound S1 during REM sleep.
61910957|NCT05933109|ACTIVE_COMPARATOR|Control group|Patients will not receive the sound S1 while they generate a positive outcome of imagery rehearsal therapy (IRT). During REM sleep, they will receive the same sound as the experimental group (S1) under the same conditions.
61910958|NCT00875134|EXPERIMENTAL|Verbal prompt, cutaneous stimulation|Patient receives either or both a verbal stimulus or cutaneous stimulus
61910959|NCT01075633|EXPERIMENTAL|Fecal occult blood testing|Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
61910960|NCT01075633|ACTIVE_COMPARATOR|Colonoscopy|Colonoscopy with sedation.
61910961|NCT01088607|EXPERIMENTAL|UDCA Withdrawal and Reinstitution|Each study subject will undergo serial UDCA withdrawal and reinstitution.
61910962|NCT01675089|EXPERIMENTAL|Zoledronic acid|Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
61910963|NCT01675089|NO_INTERVENTION|Control|The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
61910964|NCT06119958|EXPERIMENTAL|DWC202313|DWC202313
61910965|NCT06119958|EXPERIMENTAL|DWC202314|DWC202314
61910966|NCT01612845|EXPERIMENTAL|PRF|the group in which the PRF was administered
61910967|NCT01612845|ACTIVE_COMPARATOR|Control|repair without PRF
62100947|NCT05642000|NO_INTERVENTION|Control|
62100948|NCT06570759|EXPERIMENTAL|OMI/NOMI arm|Any clinical or ECG evidence of acute total or near-total coronary occlusion will be intervened immediately. Other patients will be managed as standard NSTEMI guidelines.
62294789|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
62100949|NCT06570759|ACTIVE_COMPARATOR|STEMI/NSTEMI arm|The patients fulfilling STEMI ECG criteria will be intervened immediately. Other patients will be managed as standard NSTEMI guidelines.
61910968|NCT05772351|EXPERIMENTAL|Experimental group|Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery
61910969|NCT05772351|NO_INTERVENTION|Control group|Patients of the control group received a tablet containing starch.
61910970|NCT02211911|EXPERIMENTAL|Bisacodyl|
61910971|NCT02211911|EXPERIMENTAL|Sodium picosulfate|
62100950|NCT04465890|EXPERIMENTAL|cohort1: Single dose ASC22 injection 0.3mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,0.3mg/kg dose of the drug once.
62100951|NCT04465890|EXPERIMENTAL|cohort2:Single dose ASC22 injection 1.0mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,1.0mg/kg dose of the drug once.
62100952|NCT04465890|EXPERIMENTAL|cohort3:Single dose ASC22 injection 2.5mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,2.5mg/kg dose of the drug once.
62100953|NCT04465890|EXPERIMENTAL|cohort4: Multiple dose ASC22 injection 1.0mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 1.0mg/kg, up to 24 weeks
62100954|NCT04465890|EXPERIMENTAL|cohort5: Multiple dose ASC22 injection 2.5mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 2.5mg/kg, up to 24 weeks
62100955|NCT04465890|PLACEBO_COMPARATOR|cohort4: Placebo sodium chloride injection A|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (1.0mg/kg).
62294790|NCT03766243|EXPERIMENTAL|Brochure and DVD plus nursing training|"In addition to the control intervention, see below, the experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. The nurse provided theoretical explanations on the exercises, watched the explanatory DVD with the patients, answering questions and commenting relevant points, and then had the patients repeat the exercises in front of a mirror under direct observation, so that any errors could be pointed out and corrected."
61910972|NCT00315757|ACTIVE_COMPARATOR|A|Bortezomib
61910973|NCT00315757|EXPERIMENTAL|B-10|Bortezomib and Mapatumumab 10 mg/kg
61910974|NCT00315757|EXPERIMENTAL|B-20|Bortezomib and Mapatumumab 20 mg/kg
61910975|NCT06472986|EXPERIMENTAL|ABT-TCSCS|The participants will receive activity-based therapy combined with transcutaneous spinal cord stimulation.
61910976|NCT02946931||Prizbind® for Intravenous Solution|Patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
61910977|NCT01410851|EXPERIMENTAL|Pasta, tomato sauce & added chickpeas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (\~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
61910978|NCT01410851|EXPERIMENTAL|Pasta, tomato sauce and added lentils|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (\~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
61910979|NCT01410851|EXPERIMENTAL|Pasta, tomato sauce and added navy beans|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (\~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
61910980|NCT01410851|EXPERIMENTAL|Pasta, tomato sauce with yellow peas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (\~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
61910981|NCT01410851|EXPERIMENTAL|Pasta and tomato sauce|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (\~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
61910982|NCT00721253|ACTIVE_COMPARATOR|ReSTOR Aspheric +4|ACRYSOF ReSTOR Aspheric +4 Model SN6AD3
61910983|NCT00721253|ACTIVE_COMPARATOR|Tecnis MF|Abbott Medical Optics Tecnis Multifocal Intraocular Lens (IOL) Model ZM900
61910984|NCT00721253|ACTIVE_COMPARATOR|Acri.LISA|Meditec Acri.LISA Intraocular Lens (IOL) Model 366D
61910985|NCT01114230|EXPERIMENTAL|Dose Level 1|
61910986|NCT01114230|EXPERIMENTAL|Dose Level 2|
61910987|NCT01114230|EXPERIMENTAL|Dose Level 3|
61910988|NCT01114230|EXPERIMENTAL|Dose Level 4|
61910989|NCT01114230|EXPERIMENTAL|Dose Level 5|
61910990|NCT01114230|EXPERIMENTAL|Dose Level 6|
61910991|NCT01114230|EXPERIMENTAL|Dose Level 7|
61910992|NCT01114230|EXPERIMENTAL|Dose Level 8|
62100956|NCT04465890|PLACEBO_COMPARATOR|cohort5: Placebo sodium chloride injection B|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (2.5mg/kg).
62100957|NCT04465890|EXPERIMENTAL|cohort6: Multiple dose ASC22 injection 1.0mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 1.0mg/kg, up to 24 weeks
62662619|NCT01966783|EXPERIMENTAL|Combination|Budesonide 2 mg suppository/Mesalazine 1 g suppository
62662620|NCT04278352|EXPERIMENTAL|Mindfulness Based Relapse Prevention|MBRP is a group aftercare program that integrates mindfulness skills training with cognitive-behavioral relapse prevention strategies. The intervention consists of eight weekly two-hour group therapy sessions, delivered by two facilitators with 6-12 people. The experimental group will complete the intervention in weeks 1-8. They will continue treatment as usual for weeks 9-16.
61910993|NCT01114230|EXPERIMENTAL|Dose Level 9|
61910994|NCT05308940|EXPERIMENTAL|Single-dose of TB001|In the SAD stage, participants will receive subcutaneous injection of TB001 once on Day 1, planning to ascend from 20 μg, 60 μg，150 μg，300 μg，600μg to 900 μg or higher dose (whether to proceed to the next higher cohort based on dose escalation criteria). Actual dose of TB001 may vary based on safety, tolerability and PK data from previous cohorts.
61910995|NCT05308940|EXPERIMENTAL|Multiple-dose of TB001|In the MAD stage, participants will receive subcutaneous injection of TB001 once daily for 7 days, planning to ascend from 60 μg，150ug to 300 μg or higher dose (whether to proceed to the next higher cohort based on dose escalation criteria). Actual dose of TB001 may vary based on safety, tolerability and PK data from previous cohorts.
61910996|NCT05308940|PLACEBO_COMPARATOR|Single-dose of placebo|In the SAD stage, participants will receive subcutaneous injection of placebo once on Day 1.
61910997|NCT05308940|PLACEBO_COMPARATOR|Multiple-dose of placebo|In the MAD stage, participants will receive subcutaneous injection of placebo once daily for 7 days.
61910998|NCT01106092|EXPERIMENTAL|GSK2036874A GROUP 1|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0.
61910999|NCT01106092|EXPERIMENTAL|GSK2036874A GROUP 2|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0.
62100958|NCT04465890|PLACEBO_COMPARATOR|cohort6: Placebo sodium chloride injection A|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (1.0mg/kg).
62100959|NCT06548009||SeHCAT confirmed bile acid diarrhea|Patients referred to a SeHCAT scan due to suspected bile acid diarrhea, who afterwards turned out to be suffering from SeHCAT confirmed bile acid diarrhea
62662621|NCT04278352|NO_INTERVENTION|Control|The waitlist control group will not receive the MBRP program during weeks 1-8 and will continue treatment as usual. During weeks 9-16, the control group will receive MBRP.
62737105|NCT01646541||Symptomatic|Dyspnea with exertion greater than 6 months after mitral valve surgery \[New York Heart Association (NYHA) Functional Class II, III, or IV\]
62100960|NCT06548009||SeHCAT negative patients|Patients referred to a SeHCAT scan due to suspected bile acid diarrhea, who afterwards turned out to be SeHCAT negative
61911000|NCT01106092|EXPERIMENTAL|GSK2036874A GROUP 3|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0.
62100961|NCT06377228|EXPERIMENTAL|TAK-007- 800 × 10^6 CD19-CAR+ Viable NK Cells|Participants will receive IV LDC, for 3 days in conditioning phase (Days -5, -4, and -3), followed by a single dose of IV 800 × 10\^6 TAK-007 on Day 1.
61911001|NCT01106092|ACTIVE_COMPARATOR|ZILBRIX/HIB/POLIORIX GROUP|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively.
61911002|NCT00773045||pain training program|ICU Patients treated with or without pain management protocol
62100962|NCT06705530|EXPERIMENTAL|Hem101 Arm|The investigational product (Hem101) will be administered as an intravenous infusion twice to each patient, on Day 1 and Day 2 of the dose if the first dose is well tolerated
62100963|NCT06711796||Study cohort|Patients undergiong surgery with no need for muscle relaxation
62100964|NCT06706518||Paroxysmal or persistent AF diagnosis and a PVI clinical indication|Patients \>18 years old, with a diagnosis of paroxysmal or persistent AF and a clinical indication to undergo PVI
62100965|NCT06352294|ACTIVE_COMPARATOR|Core stability training|A total of 18 sessions of core stabilization training will be given to the participants in 6 weeks.
62100966|NCT06352294|EXPERIMENTAL|Basic stability training and myofascial relasing method|Core stabilization training and myfacial relaxation application will be performed to the participants for 6 weeks and 18 sessions.
62467071|NCT01875952|OTHER|one arm|All patients with response to positive purified protein derivative (PPD) test are treated
62100967|NCT05912816|EXPERIMENTAL|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
62100968|NCT03015831|ACTIVE_COMPARATOR|Colchicine|Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
62100969|NCT03015831|PLACEBO_COMPARATOR|Placebo Oral Tablet|Identical tablet (placebo) administered in a similar way as that in the active comparator arm
62308215|NCT02862912|ACTIVE_COMPARATOR|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to \~ 2 ml
62100970|NCT05349877|EXPERIMENTAL|Expressive writing|Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.
62100971|NCT05349877|EXPERIMENTAL|Self-affirmation|Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination.
62100972|NCT05349877|PLACEBO_COMPARATOR|Placebo|Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week.
62100973|NCT06630221|EXPERIMENTAL|Eltrombopag (EPAG)|Enrolled participants will receive EPAG 100 mg daily, 2h prior to or after meals for 4 weeks
62100974|NCT05653037|EXPERIMENTAL|RBD4059 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD4059 on Day 1.
62100975|NCT05653037|PLACEBO_COMPARATOR|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
62100976|NCT06030687||Free-Living|
62100977|NCT06706882|EXPERIMENTAL|Experimental Training: VIRTRAEL/LUCCIDY|The neuropsychological rehabilitation program VIRTRAEL/LUCCIDY is designed for cognitive assessment and stimulation, shown to improve verbal learning, memory, attention, reasoning, and planning. It consists of 11 exercises over 9 sessions, each lasting 60 minutes. The platform adapts the difficulty of exercises based on performance through an algorithm, focusing on cognitive functions like attention, memory, and planning. To maintain motivation, the program includes varied exercises, avatars, and rewards. The exercises are ecologically designed to simulate daily activities for real-life application. Sessions involve tasks like shopping lists, puzzles, and memory challenges. Link: http://www.everyware.es/webs/virtrael/#home
62308216|NCT01857986|EXPERIMENTAL|Study group|Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
62100978|NCT06706882|ACTIVE_COMPARATOR|Standard Training: Reflection Group (TAU)|"It is a group work offered to survivor women of IPV in municipal and provincial centers (CIMs) of the Women's Institute. The objective of this intervention is to provide women with a space for group reflection, as well as a series of skills and tools. Concrete topics are presented, including those related to intervention in crisis situations from a gender perspective. It lasts for 9 sessions (60 minutes per session) with a frequency of one session per week.~The sessions cover themes such as the idealization of women as caregivers (Session 1), gender conflicts (Session 2), guilt when deviating from gender expectations (Session 3), dependence on others for self-worth (Session 4), and romantic love as a tool to fulfill men's needs over women's (Session 5). They explore intimate partner violence (IPV) as a conflict strategy (Session 6), family's role in socialization (Session 7), fears of abandonment (Session 8), and life skills for independence (Session 9)."
62100979|NCT05096117|EXPERIMENTAL|ASP8062 (25 mg once daily)|
61911003|NCT02230488|ACTIVE_COMPARATOR|Intensive Diabetes Case Management|Intensive Case Diabetes Management : A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
62100980|NCT05096117|PLACEBO_COMPARATOR|Matching Placebo|
62662622|NCT04883853|EXPERIMENTAL|Mild -Moderate Ptosis with good levator function (more than 8 mm)|The upper eyelid crease was marked for the incision site, up to 5-7 mm from the lid margin, guided by the fellow eyelid crease position. The skin incision was done and the orbicularis occuli muscle was dissected to the tarsus. The anterior surface of the tarsal plate was then identified with the aponeurosis at its insertion, the orbital septum was then opened with a resultant fat prolapse, and the levator aponeurosis exposed until Whitnall's ligament. Three double-armed 5/0 polyester white braided, non-absorbable sutures, with spatulated needle 1/4 circle (Astralen, Assut Medical Sàrl, Pully-Lausanne, Switzerland) were passed between the levator aponeurosis near Whitnall's ligament and the anterior surface of the tarsus in a mattress form
62662623|NCT04393012|EXPERIMENTAL|Noddle Group|Patients who received noddle to allow access to the nurse call system.
62100981|NCT04914676|EXPERIMENTAL|Prospective HiDAC Treatment (HiDAC 123)|Subject on this arm will be treated with HiDAC prospectively.
62100982|NCT04914676|OTHER|Historical HiDAC Treatment (HiDAC 135)|Subjects on this arm will be historical controls who have previously received treatment with HiDAC.
61911004|NCT02230488|NO_INTERVENTION|Control :Standard/ usual care|
61911005|NCT03381534|PLACEBO_COMPARATOR|stent assisted angioplasty|patient randomly assigned to this group would be undergone stenting of vertebral artery origin without embolic protection device
62467072|NCT01929642|EXPERIMENTAL|Sirolimus or Everolimus|Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)
62467073|NCT01511939|OTHER|Pennsaid, warfarin|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months
62467074|NCT01511939|OTHER|Pennsaid, dabigatran|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months
61911006|NCT03381534|EXPERIMENTAL|stenting with EPD|patient randomly assigned to this group would be undergone stenting of vertebral artery origin with embolic protection device
61911007|NCT00650481|EXPERIMENTAL|1|Oxybutynin Chloride Extended-release Tablets 5 mg
61911008|NCT00650481|ACTIVE_COMPARATOR|2|Ditropan XL® Tablets 5 mg
61911009|NCT00456144||Group 1|GnRH agonist for 24 months
61911010|NCT00456144||Group 2|GnRH agonist for 6 months
61911011|NCT00606047||Asymptomatic patients|Asymptomatic, healthy patients (without hip pain or prior hip disease) will be recruited. Patients will undergo a magnetic resonance imaging (MRI) of the hip joints to evaluate for the prevalence of femoroacetabular impingement (FAI).
61911012|NCT02307253|EXPERIMENTAL|patients with solid lesions|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
61911013|NCT00627952|ACTIVE_COMPARATOR|amlodipine 10 mg|
61911014|NCT00627952|ACTIVE_COMPARATOR|manidipine 20 mg|
62100983|NCT06614686|EXPERIMENTAL|U87 autologous CAR T-cell injection|Two stages: dose escalation and dose expansion
62294791|NCT03766243|ACTIVE_COMPARATOR|Brochure and DVD only|"After recruitment, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use. At the same time, she contacted the research nurse to obtain the random allocation to one of the study groups for that patient.~These exercises had to be done every day for the entire duration of the program (12 months) and registered in the diary with any comments."
62294792|NCT03417440|OTHER|PA App+ On Your Feet+ CoachMe+ Proof Pos|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 3 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (3) Proof Positive (explicit and implicit messaging to promote positive aging views)."
62662624|NCT05075369|NO_INTERVENTION|baseline Intraocular pressure|The participants will have their intraocular pressure measured with Goldmann Application Tonometry immediately prior to beginning the water drinking test.
61911015|NCT06165458|EXPERIMENTAL|HP6V|6% hydrogen peroxide gel + violet LED
62100984|NCT04074499||Group-1|"The patients were classified based on the frequency of falls in the last 12 months.~Group-1 consists of COPD patients whose have at least one fall (fallers)"
62100985|NCT04074499||Group-2|"The patients were classified based on the frequency of falls in the last 12 months.~Group-2 consists of COPD patients whose have no history of falls (non-fallers)."
62100986|NCT06028841|EXPERIMENTAL|VLA1553|
62294793|NCT03417440|OTHER|PA App + On Your Feet + Coach Me|"Participants in this arm will use a basic physical activity (PA) app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
62662625|NCT05075369|ACTIVE_COMPARATOR|Change in Intraocular pressure with Water drinking test|The participants will undergo the water drinking test as previously described, i.e. after drinking 800 mls of water over a 5 minute period, the intraocular pressure will be measured immediately after completion of ingestion, followed by intraocular pressure measurements every 15 minutes for 60 minutes, using etc Goldmann apllantion tonometer.
62662626|NCT02530840|EXPERIMENTAL|medical team|personal meetings and follow-up of un-balanced diabetic patients by trained medical team (nurse and doctor), which designed to promote adherence to healthy life style and medical therapy.
62100987|NCT02931396|EXPERIMENTAL|FES intervention|Study participants who are randomized into the intervention group will be fitted with a portable commercially available surface FES device and instructed in its use by a study investigator. Participants will be directed to use the FES 30 minutes a day for the first week, one hour a day during the next week, 90 minutes a day during the third week, and then a minimum of 2 hours per day or 10 hours per week for the next three months at home.
62100988|NCT02931396|NO_INTERVENTION|Control|Participants will be asked to continue their activities of daily living as usual.
62100989|NCT02507310|ACTIVE_COMPARATOR|Control|The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
62100990|NCT02507310|EXPERIMENTAL|Warm Environment|The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
62100991|NCT06711718||Patients qualitative interviews|"1. Patients reviewed by their GP as a result of Stage 1 (running of tool) are invited to a qualitative interview.~2. Consenting participants interviewed by the research team.~3. Information used to assess the impact and potential benefit of using the diabetes classification tool in general practice."
62100992|NCT06711718||Practice staff qualitative interviews|"1. Practice staff (clinical and administrative) who have been involved in Stage 1 (running of tool) are invited to a qualitative interview.~2. Consenting participants interviewed by the research team.~3. Information used to assess the impact and potential benefit of using the diabetes classification tool in general practice."
62100993|NCT06572462|EXPERIMENTAL|targeted dosing ATG cohort|The targeted dosing ATG cohort received the same dose of medication at -5 days and -4 days as the traditional administration method (-5days, 1.5mg/kg; -4days 2.5mg/kg), Two individual doses were given on -3days and day -2days according to the dose adjustment strategy.
62100994|NCT04893135|NO_INTERVENTION|G1A|Uncontrolled diabetes (HbA1c\> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, without the practice physical activity
61911016|NCT06165458|EXPERIMENTAL|HP6B|6% hydrogen peroxide gel + blue LED
61911017|NCT06165458|EXPERIMENTAL|HP35V|35% hydrogen peroxide gel + violet LED
62100995|NCT04893135|EXPERIMENTAL|G1B|Uncontrolled diabetes (HbA1c\> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, with the practice physical activity
62100996|NCT04893135|NO_INTERVENTION|G2|Controlled diabetes (HbA1c level \<7%). This group will study the natural course of RANKL levels in balanced diabetic patients.
62467075|NCT01511939|OTHER|Pennsaid, aspirin and/or clopidogrel|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months
62100997|NCT05565742|EXPERIMENTAL|LY3819469 Dose 1|Participants will receive LY3819469 subcutaneously (SC).
62100998|NCT05565742|EXPERIMENTAL|LY3819469 Dose 2|Participants will receive LY3819469 SC.
62467076|NCT04054232|EXPERIMENTAL|EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to have their primary care physician receive an electronic health record message regarding their high risk of having PAD and a recommendation will be made to have the participant referred for non-invasive testing called Ankle Brachial Index (ABI) testing to confirm diagnosis. For individuals who undergo ABI testing and are confirmed to have PAD, they and their physicians will be provided with American Heart Association Guidelines for the management of PAD. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications.
61911018|NCT06165458|EXPERIMENTAL|HP35B|35% hydrogen peroxide gel + blue LED
62100999|NCT05565742|EXPERIMENTAL|LY3819469 Dose 3|Participants will receive LY3819469 SC.
62101000|NCT05565742|EXPERIMENTAL|LY3819469 Dose 4 + Placebo|Participants will receive LY3819469 SC and placebo.
62101001|NCT05565742|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62101002|NCT06712147|EXPERIMENTAL|Mental health use, education, and skill-building|"Participants randomly assigned to this arm will attend a 6 week educational series that will cover topics around mental health.~Data will be collected form participants at baseline (before the start of the first session), 1 week after the last session, and at 3- and 6- months after the sessions (follow ups)."
61911019|NCT04111562|OTHER|polymethyl methacrylate Cranioplasty|The Cranioplastic kit used (Teknimed, Biomaterials Innovation, Gentafix 1 ®, France) a biocompatible material that is composed of powder and liquid form of polymethyl methacrylate.
61911020|NCT01743001|EXPERIMENTAL|Macitentan|Subjects receive macitentan 10 mg oral tablet once daily
61911021|NCT01743001|PLACEBO_COMPARATOR|Placebo|Subjects receive macitentan-matching placebo oral tablet once daily
61911022|NCT03127982|EXPERIMENTAL|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
62662627|NCT02530840|EXPERIMENTAL|peers group|group meetings and follow-up of un-balanced diabetic patients by trained peers (peers: balanced diabetic patients),which designed to promote adherence to healthy life style and medical therapy.
62662628|NCT02530840|EXPERIMENTAL|SMS notifications|un-balanced diabetic patients receiving daily SMS with content,which designed to promote adherence to healthy life style and medical therapy.
62662629|NCT02530840|NO_INTERVENTION|control|un-balanced diabetic patients will get the basic and regular treatment for diabetic patients according to Clalit Health Services. In addition, the patients will have the same check-ups like all the patients in the experimental arms.
62662630|NCT06493747|EXPERIMENTAL|Combined Low- and High-Frequency rTMS Intervention|Participants will receive a combined intervention of low-frequency rTMS (1Hz) and high-frequency rTMS (5Hz) using an 8-shaped coil, with each frequency's treatment duration and pulse count aligning with the protocol provided.
62101003|NCT06712147|ACTIVE_COMPARATOR|Resources in the community|"Participants randomly assigned to this arm will attend a 6 week educational series that will cover topics on resources in the community.~Data will be collected form participants at baseline (before the start of the first session), 1 week after the last session, and at 3- and 6- months after the sessions (follow ups)."
62662631|NCT06493747|EXPERIMENTAL|Combined High- and Low-Frequency rTMS Intervention|Similar to Arm A, but the order of interventions is reversed, starting with high-frequency rTMS followed by low-frequency rTMS.
62101004|NCT03936062||2nd Generation SUs|Reference group
62662632|NCT06493747|EXPERIMENTAL|rTMS Experimental Group: Individualized Precision rTMS Therapy|Participants will undergo individualized precision rTMS therapy based on integrated analysis of assessment data, with a continuous two-week intervention, 10-25 minutes per session, at an intensity of 80% of the active motor threshold (AMT).
62662633|NCT06493747|EXPERIMENTAL|"rTMS + Acupuncture Group: rTMS Combined with Kaiqiao Jieyan Acupuncture Therapy"|"Participants will receive both the aforementioned rTMS therapy and Kaiqiao Jieyan acupuncture therapy, including specific acupoint selection and manipulation techniques."
62662634|NCT06493747|ACTIVE_COMPARATOR|rTMS Control Group: Conventional rTMS Intervention|Participants will receive conventional rTMS intervention according to the guidelines' recommended strategies.
62662635|NCT06493747|ACTIVE_COMPARATOR|"Acupuncture Group: Kaiqiao Jieyan Acupuncture Therapy Alone"|"Participants will receive only Kaiqiao Jieyan acupuncture therapy, without rTMS intervention."
62662636|NCT06430528||Observational cohort|Participants with Cushing syndrome consented to participate in block-and-replace osilodrostat therapy.
62662637|NCT02560805|EXPERIMENTAL|Veterans|Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.
62662638|NCT02560805|EXPERIMENTAL|Control|Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.
62662639|NCT00744835|EXPERIMENTAL|1|Ablation Management
62662640|NCT06467019||Before intervention|This group will consist of patients who attended the primary care center before the implementation of the intervention.
62662641|NCT06467019||After intervention|This group will consist of patients who will attend the primary care center after the implementation of the intervention.
62662642|NCT04557644|ACTIVE_COMPARATOR|medical staff treating patients with scabies|
62101005|NCT03936062||Sitagliptin|Exposure group
62101006|NCT06714240|ACTIVE_COMPARATOR|Normal protein amount|Tube feed with 1.0 g of protein/kg body weight/day
62662643|NCT04557644|ACTIVE_COMPARATOR|family infested with scabies|
62662644|NCT00177671|EXPERIMENTAL|1|"escitalopram plus donepezil (DNP)in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation donepezil.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
62662645|NCT00177671|PLACEBO_COMPARATOR|2|"escitalopram plus placebo (PBO) in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of venlafaxine or duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
62662646|NCT00843973||iliac crest bone graft|Bone graft harvested via iliac crest bone graft procedure
62662647|NCT00843973||Reamer Irrigator Aspirator|Bone graft harvested via the Reamer Irrigator Aspirator (RIA) Procedure
62662648|NCT01985659||open thoracotomy|In the first cohort(20007-2009) almost all patients where operated through a thoracotomy.
62662649|NCT01985659||Early VATS|In a second cohort, (2010-2011) the experience with vats was early.
62662650|NCT01985659||Standardized VATS|In the third period (2012-2013), a standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy was used.
62101007|NCT06714240|EXPERIMENTAL|Elevated protein amount|Tube feed with 1.5 g of protein/kg body weight/day
62101008|NCT02820857|EXPERIMENTAL|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
62101009|NCT02820857|ACTIVE_COMPARATOR|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
62101010|NCT04817254|EXPERIMENTAL|Arm 1|Nivolumab + Ipilimumab 1mg/kg + TMZ
62101011|NCT04817254|EXPERIMENTAL|Arm 2|Nivolumab + Ipilimumab 3mg/kg + TMZ
62101012|NCT01224678|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo once daily for 12 months.
62101013|NCT01224678|EXPERIMENTAL|Vitamin D|Patients receive oral vitamin D (2000 IU) once daily for 12 months.
62101014|NCT01101919|EXPERIMENTAL|CP-690,550 Dose Group|
62101015|NCT02516176|EXPERIMENTAL|Treadmill Training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
62101016|NCT00049517|EXPERIMENTAL|Standard Daunorubicin Then Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
62101017|NCT00049517|EXPERIMENTAL|High-dose Daunorubicin Then Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
62101018|NCT00049517|EXPERIMENTAL|Standard Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
62294794|NCT03417440|OTHER|PA App + On Your Feet + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
62294795|NCT03417440|OTHER|PA App + On Your Feet|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions)."
62467077|NCT04054232|NO_INTERVENTION|No EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to the control arm and they nor their physicians will be alerted of their status for 6 months. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications. At the end of 6 months of observation, the primary care physician's of control participants will receive the same alert as participants in the intervention arm.
62467078|NCT02058797|EXPERIMENTAL|Coherence Therapy|Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
62467079|NCT02058797|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.
62467080|NCT05752734||Group D|Patients who used/applied dexamethasone before bariatric surgery were included in this group.
62467081|NCT05752734||Group C|Patients who did not use dexamethasone or steroid-derived drugs were included in this group.
62737106|NCT02672189|NO_INTERVENTION|Waiting list control group|Women in the waiting list control group will receive usual care. They will complete questionnaires during a period of 6 months. After completion of the last questionnaire they will be offered the opportunity to follow the EVA-Online program.
61911023|NCT03127982|ACTIVE_COMPARATOR|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
61911024|NCT03206164|EXPERIMENTAL|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
61911025|NCT03206164|ACTIVE_COMPARATOR|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
62101019|NCT00049517|EXPERIMENTAL|High-dose Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
62101020|NCT00049517|ACTIVE_COMPARATOR|Standard Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count \> 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
62101021|NCT00049517|EXPERIMENTAL|High-dose Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count \> 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
62101022|NCT05506930|ACTIVE_COMPARATOR|Intrathecal Morphine|Intrathecal Morphine: spinal (neuraxial) dose of preservative free morphine (duramorph), usually about 4-5mcg/kg
62101023|NCT05506930|ACTIVE_COMPARATOR|quadratus lumborum block|Quadratus Lumborum Block: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per kg per side (total dose approximately 1mL/kg).
62101024|NCT03331328|SHAM_COMPARATOR|Control/sham|The CO2 laser will not be activated but the same procedure of moving the probe inside the vagina in a systematic manner including depressing the foot pedal at similar frequency will be performed. The smoke evacuator will also be activated, laser eye glasses and masks worn by the laser team and the subject. However, the laser will remain in the standby mode.
62101025|NCT03331328|ACTIVE_COMPARATOR|Treated|Active arm subjects will be treated intravaginally with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm and the smart stack parameter from 1 to 3. For the vulva, the dot power will be reduced to 26 watts, dwell time 800 μs, dot spacing 800 μm and the smart stack parameter of 1.
62101026|NCT03688854|PLACEBO_COMPARATOR|Placebo|Placebo are capsules containing cellulose.
62101027|NCT03688854|EXPERIMENTAL|SCFA mixture low dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 10 grams of fiber.
62294796|NCT03417440|OTHER|PA App + Coach Me + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
62294797|NCT03417440|OTHER|PA App + Coach Me|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
62294798|NCT03417440|OTHER|PA App + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Proof Positive (explicit and implicit messaging to promote positive aging views)."
61911026|NCT01715597|EXPERIMENTAL|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 2hours before the operation
62294799|NCT03417440|OTHER|PA App|Participants in this arm will use a basic physical activity (PA) tracker app without any additional features.
62294800|NCT01129947|EXPERIMENTAL|DHEA|
62294801|NCT06144008||Medical experts in departments at risk|Expert healthcare workers at the Munich University Hospital within departments potentially affected by a major medical incident that could benefit from student surge capacity workforce. The following departments are included: Emergency Department, Intensive Care Units, Intermediate Care Units, Medical and Surgical wards, Department for Microbiology, Department for Infectious Diseases, Department for Laboratory Medicine, Antibiotic Stewardship Team, Department for Tropical Medicine, Max-von-Pettenkofer Institute, Institute for Emergency Medicine, Faculty Dean's office.
62294802|NCT06144008||Students|Medical students from all medical faculties in Germany to be questioned on their willingness to partake in clinical work as surge capacity work force in the context of a potential major medical incident.
62467082|NCT04990817|EXPERIMENTAL|Average American Diet With SoFAS Replaced With Avocado|Average American diet with foods that provide the equivalent of 1 medium to large avocado per day. It is anticipated that energy from avocado would replace 12-15% of daily energy, roughly half from solid fats and half from added sugars (SoFAS).
62467083|NCT04990817|PLACEBO_COMPARATOR|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
62467084|NCT02220166|EXPERIMENTAL|Triticum monococcum|60 days of daily administration of 100 grams of water biscuits of Triticum monococcum
62467085|NCT00864097|EXPERIMENTAL|Tanezumab 10 mg + diclofenac|IV tanezumab 10 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
62467086|NCT00864097|EXPERIMENTAL|Tanezumab 5 mg + diclofenac|IV tanezumab 5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
62467087|NCT00864097|EXPERIMENTAL|Tanezumab 2.5 mg + diclofenac|IV tanezumab 2.5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
61911027|NCT01715597|PLACEBO_COMPARATOR|Control|Normal saline 500ml IV infusion for 2hour
62101028|NCT03688854|EXPERIMENTAL|SCFA mixture high dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 20 grams of fiber.
62101029|NCT06615609|EXPERIMENTAL|"Smart family doctor assisted management"|"Smart family doctor, an AI-assisted applications with personalized interactions."
62101030|NCT06615609|PLACEBO_COMPARATOR|Usual care: health managers|2-hour health management guidance from a health manager once a week.
62101031|NCT06713083|EXPERIMENTAL|Exercise group|Pregnant women admitted in the Maternal Intermediate Care Unit who will follow the standard management for its complication and will follow a specific designed exercise program.
62101032|NCT06713083|NO_INTERVENTION|Non-exercise group|Pregnant women admitted in the Maternal Intermediate Care Unit who will follow the standard management for its complication
62101033|NCT02019706|EXPERIMENTAL|Imaging|All subjects will be imaged
62101034|NCT00881335|NO_INTERVENTION|control group|
62101035|NCT00881335|EXPERIMENTAL|intervention|Intervention group were given flutter valve mucus clearance devices to do pulmonary function exercise
62101036|NCT03904719|EXPERIMENTAL|CM082 plus JS001|CM082 tablets 150mg is orally given once daily in a 28-day cycle, combinational JS001 240mg was given intravenously on day 1 once every 21 days.
62101037|NCT05931198|EXPERIMENTAL|Upper limb amputee population|
62101038|NCT06435572|EXPERIMENTAL|Experimental and A control group|Each patient will be evaluated as both the experimental and control group. In line with the patient's aspiration needs, two different suction methods will be applied and the effects of the methods will be evaluated on the same patient. In the study, open suction applied to the patient will be considered as the control group, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be performed as open suction, and the second suction will be performed as closed suction. Pain and physiological parameters will be evaluated before, during and 30 minutes after each sucking session.
62101039|NCT04982926|EXPERIMENTAL|TAS2940 Dose Escalation|Dose escalation will assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of TAS2940 administered orally.
62101040|NCT04982926|EXPERIMENTAL|Dose Expansion Non-small Cell Lung Cancer|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
62467088|NCT00864097|PLACEBO_COMPARATOR|IV placebo + diclofenac|IV placebo to match tanezumab every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
62467089|NCT05831462|ACTIVE_COMPARATOR|Standard dose ticagrelor with aspirin in patients post PPCI for 1 year.|Drug: Ticagrelor 90 mg until 1 year after PPCI (other name: Brillique). Drug: Aspirin 75 mg until 1 year after PPCI.
62467090|NCT05831462|EXPERIMENTAL|Low-dose Ticagrelor with aspirin in patients post PPCI|"Patients will recieve the following antiplatlet therapy:~1. Ticagrelor 2x90 mg + aspirin 1x 75 during the first three months post PPCI.~2. Ticagrelor 2x60 mg + aspirin 1x 75 after the first three months post PPCI until one year post PPCI."
62467091|NCT01826409|EXPERIMENTAL|Fermented red ginseng|
62467092|NCT01826409|PLACEBO_COMPARATOR|Placebo|
62662651|NCT04454502|EXPERIMENTAL|Experimental|"In the first stage of data collection, the information in the Mother-Preterm Introductory Information Form study and control groups before colostrum administration, and the information in Preterm Follow-up Form including questions related to physiological parameters, body measurements and nutrition will be obtained. In the second stage, oral colostrum, will be administered once every 3 hours and for at least 5 days until the newborn begins oral feeding. In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered in approximately 1 minute for infants weighing between 1001-1500 g. The third stage, the effectiveness of the first breastfeeding will be evaluated by the observers in experimental group using the Bristol Breastfeeding Assessment Tool. In the last stage, one week after the first breastfeeding sucking / breastfeeding experience will be evaluated again."
62662652|NCT04454502|NO_INTERVENTION|Control Groups|The infants in the control group will be followed up by oral care with sterile physiological saline in routine care of the service
61911028|NCT00362180|EXPERIMENTAL|Cohort A: mipomersen|Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
62467093|NCT00373217|EXPERIMENTAL|Group 1|Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
61911029|NCT00362180|PLACEBO_COMPARATOR|Cohort A: placebo|Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
61911030|NCT00362180|EXPERIMENTAL|Cohort D: mipomersen|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
61911031|NCT00362180|PLACEBO_COMPARATOR|Cohort D: placebo|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
61911032|NCT00362180|EXPERIMENTAL|Cohort E: mipomersen|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.
61911033|NCT00362180|PLACEBO_COMPARATOR|Cohort E: placebo|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.
61911034|NCT00362180|NO_INTERVENTION|Cohort F: no intervention|A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.
61911035|NCT00362180|EXPERIMENTAL|Cohort G: mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
62662653|NCT04232137|EXPERIMENTAL|Coffee ceremony|Antenatal care patients will be told on their first antenatal care visit that a postpartum coffee ceremony will be organized for them and up to 4 relatives
62662654|NCT04232137|NO_INTERVENTION|NO Coffee ceremony|Antenatal care patients will be told that they will NOT receive a postpartum coffee ceremony, as is the current status quo
62662655|NCT02768181|EXPERIMENTAL|Arm 1: BCC+PNS+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with a lipid-based nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with a lipid-based nutrient supplement for children (CNS) aged 6m to 2 years.
61911036|NCT00362180|PLACEBO_COMPARATOR|Cohort G: placebo followed by mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
61911037|NCT05628259|EXPERIMENTAL|Intervention Group|A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
61911038|NCT05628259|NO_INTERVENTION|Control Group|The control group received routine nursing care in the diabetes policlinic.
61911039|NCT00626470|ACTIVE_COMPARATOR|-TSP|Patients operated without TSP
61911040|NCT00626470|ACTIVE_COMPARATOR|+TSP|Patients operated with TSP
61911041|NCT01143805|EXPERIMENTAL|Treatment A: Tasocitinib 10 mg oral tablet|
61911042|NCT01143805|EXPERIMENTAL|Treatment B: Tasocitinib 10 mg IV Infusion|
61911043|NCT04118452|EXPERIMENTAL|Intervention + Usual Care + Developmental Screening Results|Intervention group families will receive usual care and developmental screening results will be shared with each child's primary care provider. In addition, they will be connected via telephone to 2-1-1 prior to their scheduled well-child visit for the telephone-based early childhood development care coordination intervention.
61911044|NCT04118452|NO_INTERVENTION|Usual Care + Developmental Screening Results|This group will receive usual care. In addition, developmental screening results will be shared with each child's primary care provider.
61911045|NCT00745849|EXPERIMENTAL|1|esomeprazole 40mg po bid
61911046|NCT00745849|PLACEBO_COMPARATOR|2|
61911047|NCT00736047|ACTIVE_COMPARATOR|1|
61911048|NCT00736047|PLACEBO_COMPARATOR|2|
61911049|NCT04676256|EXPERIMENTAL|Early Vitrectomy|Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis
61911050|NCT04676256|ACTIVE_COMPARATOR|Comparator|"Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed.~Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up"
61911051|NCT05939778|EXPERIMENTAL|TH-SC01 local injection treatment group|"The trial was conducted in a non-randomized, single-center, single-arm, dose-escalation design. Three dose groups were preset, which were as follows:~Low dose group: 3×10\^7 live cells/person (6mL); Medium dose group: 6×10\^7 live cells/person (12mL) ; High dose group: 1.2×10\^8 live cells/person (24mL); Each subject should receive only one corresponding dose. Three subjects were enrolled in the low-dose group,If the safety of the subjects was good, the researchers evaluated the safety and efficacy data and entered the next dose group for treatment. The medium and high-dose groups were enrolled according to the 5+7 principle.~For the first 3 dose groups, after safety evaluation by the investigators, the maximum dose could reach 2.4×10\^8 live cells/person (48mL). If the MTD group is not identified by the highest dose group, it is up to the investigator to decide whether to continue with dose escalation."
61911052|NCT05433623||Vascular Surgery Admissions|Patients who present and/or are admitted to University Hospital Limerick under the care of a Vascular Consultant.
61911053|NCT04693143|OTHER|Parenteral Nutrition for Critically Ill Children|Total Parenteral Nutrition for critically ill children
61911054|NCT05265780|EXPERIMENTAL|kinesiotape|kinesiotaping group
61911055|NCT05265780|SHAM_COMPARATOR|control|sham group
61911056|NCT01857596|EXPERIMENTAL|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
61911057|NCT06016023||Group 1: 30 periodontally healthy individuals.|Group 1 comprises of 30 periodontally healthy individuals who have never been clinically diagnosed with periodontitis.
61911058|NCT06016023||Group 2: 30 individuals with generalized gingivitis|Group 2 comprises of 30 participants diagnosed with generalized gingivitis according to the WWP 2017 classification.
61911059|NCT06016023||Group 3: 30 participants with generalised mild/moderate (STAGE I/II) periodontitis|Group 3 comprises of 30 participants, diagnosed with generalized mild/moderate (STAGE I/II) periodontitis, according to the WWP 2017 classification of periodontal disease.
62101041|NCT04982926|EXPERIMENTAL|Dose Expansion Breast Cancer|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
61911060|NCT06016023||Group 4: 30 participants with generalized severe/very severe (STAGE III/IV) periodontitis|Group 4 comprises of 30 participants, diagnosed with generalized severe/very severe (STAGE III/IV) periodontitis, according to WWP 2017 classification of periodontal disease.
62294803|NCT03880877|EXPERIMENTAL|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followed by Leucovorin (400 mg/m2 IV infusion over 2 hours), and fluorouracil (5-FU) (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle."
62662656|NCT02768181|EXPERIMENTAL|Arm 2: BCC+PNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
62662657|NCT02768181|EXPERIMENTAL|Arm 3: BCC+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with nutrient supplement to children (CNS) 6m to 2 years.
62662658|NCT02768181|EXPERIMENTAL|Arm 4: BCC only|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
62662659|NCT02768181|NO_INTERVENTION|Arm 5: comparison|No intervention will be provided by the study. The existing services delivered though government health systems will be continued. Government /NGO-led routine counseling and supplementary services available at Upazila and union levels, which include prenatal counseling, exclusive breastfeeding counseling, and maternal iron-folic acid supplementation and vitamin-A supplementation for children will continue. However, assessment of outcomes will be conducted in same frequency and schedule, alike in intervention arms, described in data collection section.
62662660|NCT00657566|ACTIVE_COMPARATOR|1|antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function
62662661|NCT00657566|EXPERIMENTAL|2|4 +/- 1 days of antibiotics
62662662|NCT04307563|OTHER|Mindfulness group|Participants will attend 6 weekly educational and mindfulness sessions.
62662663|NCT02719795|EXPERIMENTAL|Ropivacaine|Ropivacaine hydrochloride injection； Generic name：Naropin； Dosage form：Liquid、Injectable formulation； Dosage：105mg；30ml； Frequency：Once.
61911061|NCT03104816|EXPERIMENTAL|Acetaminophen IV Soln 10 MG/ML (A)|Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
61911062|NCT03104816|EXPERIMENTAL|PO acetaminophen (B)|Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
61911063|NCT03104816|ACTIVE_COMPARATOR|Hydromorphone (control arm) (C)|Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.
61911064|NCT04717206|EXPERIMENTAL|Plyomtric training to male badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to male badminton players.
61911065|NCT04717206|EXPERIMENTAL|Plyomtric training to female badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to female badminton players.
61911066|NCT02811276|NO_INTERVENTION|Control Group|Those assigned to the Control Group will receive a eucaloric diet (a diet designed to meet the person's energy needs and maintain body weight) composed of 55% of carbohydrate, 15% of protein, and 30% of lipid.
61911067|NCT02811276|EXPERIMENTAL|High-Protein Diet Group|Those assigned to the High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®).
61911068|NCT05555173|EXPERIMENTAL|Buzzy|Buzzy will be applied 5 to 10 cm proximal (toward the subject's head) to the dorsum of the hand site immediately prior and throughout the intravenous catheter insertion attempt.
61911069|NCT05555173|NO_INTERVENTION|No Buzzy|Subjects will have a 20g intravenous catheter inserted either in the left or right dorsum side of the hand without the Buzzy device.
61911070|NCT00965965|EXPERIMENTAL|Experimental patient education document|
61911071|NCT00965965|ACTIVE_COMPARATOR|Traditional patient education document|
61911072|NCT03843619||Non-E-referral|Patients who are referred in the traditional manner between two separate organizations.
61911073|NCT03843619||E-referral|Patients who are referred in an automated manner between two separate organizations.
61911074|NCT04884451|EXPERIMENTAL|Intervention|Participants will receive nutritional counselling from the researcher based on Stage-Based, Nutrition Education Package for Childhood Obesity (ST-NEPCO). Nutritional advice and educational tools will be provided according to participants' stages of change.
61911075|NCT04884451|NO_INTERVENTION|Control|Participants will receive counseling from dietitians based on the routine care for the management of childhood obesity.
61911076|NCT06229171|NO_INTERVENTION|usual practice|
61911077|NCT06229171|EXPERIMENTAL|vocal assistant|
61911078|NCT01613170|EXPERIMENTAL|Toviaz and Premarin Vaginal Cream|Toviaz 4 mg PO q day and premarin cream 1 g per vagina 2 times a week.
61911079|NCT01613170|PLACEBO_COMPARATOR|Toviaz , Placebo Premarin Vaginal Cream|Toviaz 4 mg PO q day and placebo cream 1 g per vagina 2 times a week.
62101042|NCT04982926|EXPERIMENTAL|Dose Expansion Gliblastoma|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
62101043|NCT04982926|EXPERIMENTAL|Dose Expansion Solid tumors|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
62101044|NCT05882318|EXPERIMENTAL|Sensory|
62101045|NCT05882318|EXPERIMENTAL|Subsensory|
62101046|NCT01619943||Patients with minor head injury|MHI is defined as a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.
62101047|NCT06573762||Recently Referred for Possible Parkinson's Disease|Patients referred to the University of Iowa Hospitals and Clinics (UIHC) Movement Disorders Clinic for possible Parkinson's disease.
62101048|NCT06573762||Recently Diagnosed with Parkinson's Disease|Patients of the UIHC Movement Disorders Clinic with a recent (less than 6 months) diagnosis of Parkinson's disease.
62101049|NCT01264718|NO_INTERVENTION|Control|After randomization to the control group, minority low-income parents of uninsured, Medicaid/CHIP-eligible children received only traditional Medicaid/Children's Health Insurance Program (CHIP) outreach and enrollment.
62101050|NCT01264718|EXPERIMENTAL|Parent Mentors|After randomization to the Parent Mentor group, minority low-income parents of uninsured Medicaid/CHIP-eligible children received face-to-face instruction and guidance from Parent Mentors on obtaining and keeping Medicaid/CHIP for their child; getting a doctor, dentist, and pharmacist; and addressing social determinants of health.
62101051|NCT04737720||1|This is an expanded use protocol for a named subject.
62101052|NCT06411132||Full Analysis set|"The full analysis set includes all patients who meet all the inclusion criteria and none of the exclusion criteria at the end of the screening procedure. All the analyses on the primary and secondary endpoints will be provided on this population. The screened population consists of all patients who sign the ICF and are assigned a patient identification number.~Please note that the sample size may vary depending on feasibility."
62101053|NCT06714409|EXPERIMENTAL|Intervention arm|Patients in the intervention arm will undergo VExUS examinations at 1st day of inclusion, every other day while hospitalized and at discharge. The results from the VExUS examination (VExUS score) will be provided to the treatment team and the treatment team decides the individual treatment regime based on available information, with the overall goal to optimize decongestionand HF treatment according to current hospital standards. Safety issues and AEs will be assessed.In both gropus echocardiography will be performed at least once during the hospital stay.
62101054|NCT06714409|NO_INTERVENTION|Standard of care|Patients will undergo VExUS examinations at 1st day of inclusion and at discharge. The results from the VExUS examinations (VExUS score) will NOT be provided to the treatment team. They will be treated and followed up according to standard of care. In both gropus echocardiography will be performed at least once during the hospital stay.
62101055|NCT06351631|EXPERIMENTAL|Bomedemstat|Participants will receive oral capsules of bomedemstat once daily for up to 10 years, with the starting dose as the same dose that the participant was on at the time of transition from the feeder study.
62101056|NCT03446508|EXPERIMENTAL|Active frontal|Active HD-tDCS
62101057|NCT03446508|EXPERIMENTAL|Active parietal|Active HD-tDCS
62467094|NCT00373217|EXPERIMENTAL|Group 2|Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.
62101058|NCT03446508|SHAM_COMPARATOR|Sham control|Sham HD-tDCS
62101059|NCT06526663|ACTIVE_COMPARATOR|Vignette1|abbb
62101060|NCT06526663|ACTIVE_COMPARATOR|Vignette2|aabb
62101061|NCT06526663|ACTIVE_COMPARATOR|Vignette3|aaab
62101062|NCT06526663|ACTIVE_COMPARATOR|Vignette4|aaaa
62101063|NCT06526663|ACTIVE_COMPARATOR|Vignette5|babb
62101064|NCT06526663|ACTIVE_COMPARATOR|Vignette6|baab
62101065|NCT06526663|ACTIVE_COMPARATOR|Vignette7|baaa
62101066|NCT06526663|ACTIVE_COMPARATOR|Vignette8|abaa
62101067|NCT06526663|ACTIVE_COMPARATOR|Vignette9|abba
62101068|NCT06526663|ACTIVE_COMPARATOR|Vignette10|bbab
62101069|NCT06526663|ACTIVE_COMPARATOR|Vignette11|bbaa
62101070|NCT06526663|ACTIVE_COMPARATOR|Vignette12|bbba
62101071|NCT06526663|ACTIVE_COMPARATOR|Vignette13|bbbb
62101072|NCT06526663|ACTIVE_COMPARATOR|Vignette14|baba
62101073|NCT06526663|ACTIVE_COMPARATOR|Vignette15|abab
62101074|NCT06526663|ACTIVE_COMPARATOR|Vignette16|aaba
62101075|NCT06460818||benign|tissue collection from women with benign reproductive conditions
62101076|NCT06460818||malignant|tissue collection from women with suspected and malignant reproductive conditions
62101077|NCT05440929||Clinicans|Participants will include: physicians, nurse practitioners, physician assistants, and nurse navigators. Participants will be recruited from the UNC Medical Center breast oncology group as well as other practices identified by the Principal Investigator based on existing professional networks (referring physicians, other UNC oncology entities, collaborative groups).
62101078|NCT03278197|EXPERIMENTAL|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:~* Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~* Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~* Questionnaires"
62294804|NCT03880877|ACTIVE_COMPARATOR|Regorafenib|Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.
62294805|NCT03871491|EXPERIMENTAL|Intervention|The study intervention is a single 2 g dose of directly observed oral azithromycin.
62294806|NCT03871491|PLACEBO_COMPARATOR|Placebo|By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.
62101079|NCT03278197|OTHER|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses~* Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~* Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~* Questionnaires"
62101080|NCT03278197|OTHER|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
62101081|NCT01032850|EXPERIMENTAL|Arm 1: Sorafenib & Capecitabine|Intervention: Sorafenib \& Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)
61911080|NCT04044144|EXPERIMENTAL|Probiotic Dietary Supplement|Subjects will be asked to take 1 capsule per day of the dietary supplement for a period of 10 days
62101082|NCT05296629|EXPERIMENTAL|DFD-29|DFD-29 (40 mg) extended release capsules
62101083|NCT05296629|ACTIVE_COMPARATOR|Doxycycline 40 mg|Doxycycline 40 mg modified release capsules
62101084|NCT05296629|PLACEBO_COMPARATOR|Placebo|Placebo capsules matching DFD-29
62101085|NCT06165679|ACTIVE_COMPARATOR|Prilocaine group|
62101086|NCT06165679|ACTIVE_COMPARATOR|Bupivacaine GROUP|
62101087|NCT05474664|EXPERIMENTAL|protein-losing enteropathy after Fontan operation|single-arm with protein-losing enteropathy after Fontan operation
62101088|NCT01821911|EXPERIMENTAL|Zagreb2-1-1|Injection on day 0、7、21
62467095|NCT05134220||Chronic Kidney Disease (CKD) patients with acute coronary syndrome|"The CKD patients with or without dialysis who admitted to coronary care unit with chest pain consistent with ACS with any of following features :~1. Electrocardiogram (ECG) changes:~   * ST elevation.~  * ST depression.~  * T wave inversion.~  * recent left bundle branch block.~2. Troponin elevation."
62467096|NCT05134220||Chronic Kidney Disease (CKD) patients without acute coronary syndrome|The CKD patient with or without dialysis with no previous history of ACS.
62467097|NCT01845870||urinary albumin >300mg/24h|none extra intervention was given by the investigator
62467098|NCT01845870||urinary albumin <30mg/24h|none extra intervention was given by the investigator
62467099|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
62101089|NCT01821911|ACTIVE_COMPARATOR|Essen|Injection on day 0、3、7、14、28
62101090|NCT04162509|EXPERIMENTAL|Exposure|The experimental intervention in the experimental group consists of six 30-minutes AR exposures as home training (total duration in AR: 3 hours) within two weeks.
62101091|NCT04162509|NO_INTERVENTION|Control|The control group will not receive any active treatment (untreated comparison group).
62308217|NCT01857986|ACTIVE_COMPARATOR|Control group|Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
62308218|NCT03180762|EXPERIMENTAL|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
62308219|NCT03180762|EXPERIMENTAL|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
62467100|NCT02755714|NO_INTERVENTION|No Atrovent ®|NO INTERVENTION: The patient will not receive Ipratropium bromide spray (MDI) 20 μg ,(Atrovent ®) prior to CLE testing
62467101|NCT02755714|EXPERIMENTAL|Atrovent ®|INTERVENTION: Ipratropium bromide spray (MDI) 20 μg (Atrovent ®) prior to CLE testing
62467102|NCT06312488|OTHER|Septic patients|
62467103|NCT06312488|OTHER|Healthy volunteers|
62467104|NCT06016894|ACTIVE_COMPARATOR|Nanocrystalline hydroxyapatite|Nanocrystalline hydroxyapatite loaded in PRF+ coronally advanced flap
62467105|NCT06016894|ACTIVE_COMPARATOR|Nanocrystalline tricalcium phosphate (NcTCP)|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF+ coronally advanced flap
62467106|NCT05380024|EXPERIMENTAL|Ensaritinib|
62467107|NCT04795154|NO_INTERVENTION|Pre-test group|pregnant women\> 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg without treatment.
62467108|NCT04795154|EXPERIMENTAL|Post-test group|pregnant women \> 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg got yoga exercise, and post group was got yoga exercise was 30 minutes every 2 weeks for two months (4 times treatment). Yoga exercises technique used stretching and posture exercises (asanas) combined with deep breathing (pranayama) and meditation, to unify body, mind, and spirit (Babbar S, Parks-Savage AC, Chauhan SP, 2012).
62467109|NCT01864174|ACTIVE_COMPARATOR|Arm 1: Metformin XR and Placebo matching with Metformin XR|"Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
62467110|NCT01864174|ACTIVE_COMPARATOR|Arm 2: Metformin IR and Placebo matching with Metformin IR|"Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
62662664|NCT02719795|PLACEBO_COMPARATOR|Normal saline|Medical Normal saline Generic name：Normal saline； Dosage form：Liquid、Injectable formulation； Dosage：30ml； Frequency：Once.
62662665|NCT02693418|EXPERIMENTAL|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
61911081|NCT01529801|EXPERIMENTAL|Roughness group A|Osseotite Certain Tapered Group A
61911082|NCT01529801|EXPERIMENTAL|Roughness Group B|Osseotite Certain Tapered Group B
62101092|NCT03553615|EXPERIMENTAL|Oral treatment|12mg oral ivermectin treatment taken once a week for four weeks
62101093|NCT03293667|OTHER|Exploratory arm|
62101094|NCT03493178|ACTIVE_COMPARATOR|MCI-active|30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. ll subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks.
61911083|NCT01529801|EXPERIMENTAL|Roughness Group C|Osseotite Certain Tapered Group C
61911084|NCT01889381|EXPERIMENTAL|Treatment (Transplantation)|Face transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
62467111|NCT04314505|EXPERIMENTAL|Opioid Sparing Protocol|Preemptive(before incision): Parecoxib sodium 40 mg Postoperative: Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses.
62662666|NCT02693418|EXPERIMENTAL|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
62662667|NCT02693418|EXPERIMENTAL|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
62101095|NCT03493178|PLACEBO_COMPARATOR|MCI-placebo|30 subjects will received alanine for 12-weeks. All subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks
62467112|NCT04314505|ACTIVE_COMPARATOR|Opioid Based Patient Controlled Analgesia|Preemptive(before incision) and Postoperative: the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours; adjusted by the PCA staff
62101096|NCT05144386|EXPERIMENTAL|EBT-101 Dose-Level 1|Cohort A: Participants will be administered dose-level 1 of EBT-101
62101097|NCT05144386|EXPERIMENTAL|EBT-101 Dose-Level 2|Cohort B: Participants will be administered dose-level 2 of EBT-101
62101098|NCT05165238|EXPERIMENTAL|Coaching program|Participants will complete a 4-week coaching program in an on-line group setting. The purpose of the program will be to help participants change dietary behaviors via a small changes approach.
62467113|NCT05872217|PLACEBO_COMPARATOR|control group|"• This group will receive conventional UE therapeutic program for 60 minutes each session including:~* Exercises based on neurodevelopment technique .~* Gentle manual stretching~* Weight-bearing exercises for 10minutes for UE from prone lying, side sitting and quadriped position .~* Strengthening exercises for 10 minutes for muscles of UE as push-up from prone lying position, quadriped position, 3 point exercise, walk on hand, climbing, hanging on a bar, squeeze stress balls, cutting usescissors to strengthen hand .~* Goal directed training for 10 minutes the child will practice specific tasks that are needed for everyday life and which they find a challenge like (3 daily tasks as cleaning mirror, dressing and undressing, using pen and ruler to draw shapes, brushing teeth .~* Fine motor activities as reach, grasp, carry and release activities."
62467114|NCT05872217|EXPERIMENTAL|study group|Children in this group will receive the same conventional UE therapeutic program as control group for 60 minutes in addition to virtual reality session using VRapeutic software gaming technology, Archeeko module (figure 3) for 30 min/3 sessions/week for 8 weeks
62662668|NCT02693418|PLACEBO_COMPARATOR|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
62662669|NCT02693418|NO_INTERVENTION|No intervention, Group E|No vaginal product administered
62662670|NCT02832999|EXPERIMENTAL|sub cutaneous liraglutide|once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week
62662671|NCT02832999|ACTIVE_COMPARATOR|Oral Vildagliptin|Once daily oral 100mg of Vildagliptine for two weeks
62662672|NCT04806451|EXPERIMENTAL|Crinecerfont|Crinecerfont solution or capsule, administered orally, twice daily for 28 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 24 weeks.
62101099|NCT05598528||EGFR-positive lung patients recieving 3rd generation EGFR-TKIs as first-line therapy|Stage III-IV EGFR-positive lung patients receiving 3rd generation EGFR-TKIs (Osimertinib 80mg/Qd or Almonertinib 110mg/Qd or Furmonertinib 80mg/Qd) as first-line therapy.
62101100|NCT06607484|EXPERIMENTAL|SR-878|Solution for infusion, administered intravenously once
62101101|NCT06607484|PLACEBO_COMPARATOR|Placebo|Solution for infusion, administered intravenously once
62101102|NCT01997840|EXPERIMENTAL|ACY-1215 in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
62101103|NCT05668091|EXPERIMENTAL|Nirmatrelvir / Ritonavir|Participants receive nirmatrelvir plus ritonavir (Paxlovid) for 15 days. All 3 tablets (2 of nirmatrelvir and 1 of ritonavir) must be taken twice daily by mouth for 15 days.
62101104|NCT05668091|PLACEBO_COMPARATOR|Placebo / Ritonavir|Participants receive placebo to match nirmatrelvir plus ritonavir for 15 days. The control formulation includes 2 placebo tablets and 1 ritonavir tablet.
62101105|NCT06565481|OTHER|Single Test-Re Test Arm|"This study, including two time points, is performed to determine validity and reliability of performance based assessments using a one-arm sample.~A test retest design is used to determine reliability and a cross-sectional design to determine validity.~For each participant, the measures will be performed on two time points with a minimal recovery break of 2 days in one single centre in the Canton of Zurich (University Hospital Zurich)."
62101106|NCT03531905|EXPERIMENTAL|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
62101107|NCT03531905|ACTIVE_COMPARATOR|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
62101108|NCT03531905|PLACEBO_COMPARATOR|Placebo|Placebo Oral Tablet, Placebo oral capsule
62662673|NCT04806451|PLACEBO_COMPARATOR|Placebo|Placebo solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment with crinecerfont for at least 24 weeks.
62662674|NCT05117476|EXPERIMENTAL|Module A Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619
62662675|NCT05117476|EXPERIMENTAL|Module A Cohort Expansion|Patients with select solid tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module A Escalation arm
62662676|NCT05117476|EXPERIMENTAL|Module B Combination Therapy Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619 in combination with pembrolizumab
62101109|NCT00723294|EXPERIMENTAL|Treatment (cryoablation)|A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
62101110|NCT06714123|ACTIVE_COMPARATOR|Senicapoc|Senicapoc 30 mg per day, administered as 3 tablets of 10 mg,.
62101111|NCT06714123|PLACEBO_COMPARATOR|Placebo|Tablets similar in size, color and composition, as the active comparator, administered as 3 tablets a day.
62101112|NCT03610477|ACTIVE_COMPARATOR|Medium Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.
62294807|NCT03059290|ACTIVE_COMPARATOR|protaper next file|the PROTAPER NEXT™ X1 (017/04) file, in one or more passes until the working length is reached. Use PROTAPER NEXT X2 (025/06), exactly as described for PROTAPER NEXT X1 file, until the working length is passively reached. Gauge the foramen with a size 025 hand file and, if this file binds at length, the canal is shaped and ready for disinfection. If the size 025 hand file is loose at length, then continue shaping with the PROTAPER NEXT X3 (30/07) and, when necessary, the PROTAPER NEXT X4 (040/06) or PROTAPER NEXT X5 (050/06), gauging after each instrument with the 030, 040 or 050 hand files, respectively. During canal shaping, irrigate, recapitulate with a small-sized hand file after each sequential PROTAPER NEXT instrument, then re-irrigate. in an endodontic motor according to the manufacturer instructions (X-Smart, Dentsply Maillefer, USA.), with torque 2.0 N.cm and speed 300 rpm.
62467115|NCT02609295|PLACEBO_COMPARATOR|Placebo|Individuals who consumed 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil daily
62467116|NCT02609295|EXPERIMENTAL|ALA group|Individuals who consumed 1.2 g (two capsules) of perilla oil daily
62467117|NCT05835622|OTHER|Arm A|8 weeks of using keeogo at home (experimental phase) followed by 8 weeks of wash-up and then followed by 8 weeks of recommended home practise (control phase).
62467118|NCT05835622|OTHER|Arm B|8 weeks of recommended home practise (control phase) followed by 8 weeks of wash-up and then followed by 8 weeks of using keeogo at home (experimental phase)
62467119|NCT01616498||Lean|Comparison data from this lean cohort will be compared to the obese older adults are already being collected in an R01-funded study (Improving Muscle for Functional Independence Trial; IRB00009098; NCT01049698)
62467120|NCT05005494|ACTIVE_COMPARATOR|Magnesium sulfate IV|10 patients scheduled for thyroidectomy
62467121|NCT05005494|PLACEBO_COMPARATOR|Placebo|10 patients scheduled for thyroidectomy
61911085|NCT01975857|EXPERIMENTAL|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP) to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
62101113|NCT03610477|PLACEBO_COMPARATOR|Long Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.
62101114|NCT02611427|ACTIVE_COMPARATOR|Education/Self-efficacy|Booklet about physical activity, movement monitoring device, encouragement
62101115|NCT02611427|ACTIVE_COMPARATOR|Education|Booklet about physical activity
62101116|NCT04244591|PLACEBO_COMPARATOR|standard care|standard care
62101117|NCT04244591|EXPERIMENTAL|standard care + methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
62101118|NCT05263141|EXPERIMENTAL|RASSET group|Patients in the retro-auricular single-site endoscopic thyroidectomy (RASSET) group will receive endoscopic thyroid lobectomy and central lymph node dissection.
62101119|NCT05263141|ACTIVE_COMPARATOR|traditional open thyroid lobectomy group|Patients in the traditional open thyroid lobectomy group will receive thyroid lobectomy and central lymph node dissection.
62101120|NCT06714474|EXPERIMENTAL|Virtual Simulation Game Group|Participants in this arm will receive traditional training on venous blood sampling (VBS), including theoretical instruction and hands-on practice in a laboratory setting. Additionally, they will use a Virtual Simulation Game (VSG) platform (http://www.hemsirelab.com) to enhance their learning through interactive, scenario-based training. After logging into the VSG platform with unique credentials, participants will complete the training scenarios to refine their skills before performing the procedure on peers under supervision.
62101121|NCT06714474|ACTIVE_COMPARATOR|Traditional Education Group|Participants in this arm will receive traditional training on venous blood sampling (VBS) in a laboratory setting. They will observe demonstrations and practice the procedure on peers without the use of virtual simulation
62101122|NCT06712485||AN|Patients with Anorexia Nervosa diagnosed according to the DSM-V criteria.
62101123|NCT06712485||AN-R|Patients recovered from Anorexia Nervosa
62101124|NCT06712485||CON|Healthy subjects of the same age and gender as all other groups
62467122|NCT01004237|ACTIVE_COMPARATOR|pravastatin|
62294808|NCT05267626|EXPERIMENTAL|AU-007 Monotherapy|AU-007 (Q2w) will be administered as a monotherapy sequential ascending doses with each Dose Escalation Cohort
62294809|NCT05267626|EXPERIMENTAL|AU-007 combined with an aldesleukin loading dose|AU-007 (Q2w) will be administered in combination with a single dose of aldesleukin with the initial AU-007 dose.
62294810|NCT05267626|EXPERIMENTAL|AU-007 combined with aldesleukin given concomitantly|AU-007 will be administered in combination with aldesleukin, both administered Q2w.
62467123|NCT01004237|ACTIVE_COMPARATOR|valsartan|
62467124|NCT01004237|ACTIVE_COMPARATOR|pravastatin combined with valsartan|
61911086|NCT01975857|ACTIVE_COMPARATOR|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
61911087|NCT05128422|EXPERIMENTAL|NBO+EVT group|Normobaric hyperoxia Combined with Endovascular therapy group were given 100% oxygen via a face mask initiated before vascular recanalization (10L/min for 4h) . In addition, the patient will be given endovascular therapy surgery.
62101125|NCT03593759|ACTIVE_COMPARATOR|Prednisone (or Prednisolone)|"\[Dose everywhere except Japan\] Prednisone 0.5 mg kg/day for 6 months (max dose 30 mg)~\[Dose in Japan\] Prednisone or prednisolone 0.5 mg/kg po (max 30mg) for one month then reduce by 5 mg per month for five months"
62101126|NCT03593759|EXPERIMENTAL|Methotrexate|"\[Dose everywhere except Japan\] Methotrexate 15-20 mg orally, sc, or IM once a week for 6 months + Prednisone 20 mg po daily for one month then 10 mg po daily for one month then 5 mg po daily for one month and then stop. Also Folic Acid OD (exact dose and directions at physicians discretion) for 6 months.~\[Dose in Japan\] Methotrexate 5-20mg mg orally, sc, or IM once a week for 6 months+ Prednisone or Prednisolone 20mg OD for 1 month then 10mg OD for 1 month then 5 mg OD one month. Also Folic Acid 2 mg po daily for 6 months."
62101127|NCT06613737|EXPERIMENTAL|Dose 1|Medium dose, expected to be approximately 10\^5.5 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
62101128|NCT06613737|EXPERIMENTAL|Dose 2|High dose, expected to be approximately 10\^4 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
62101129|NCT06613737|EXPERIMENTAL|Dose 3|Optional: TBD, depending on outcome of Part A
62101130|NCT04684342|EXPERIMENTAL|cirrhotic ICU Patients|about 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.
62101131|NCT06629753|EXPERIMENTAL|DSD arm for stable clients|PPHIV who meet the following criteria will be considered stable clients: on current antiretroviral therapy ≥6 months; no active illness in the past 6 months; retained in care; viral load \<50 copies/mL within the last 6 months; age ≥18 years; not primigravida; not high-risk pregnancy. PPHIV meeting these criteria will be offered postnatal clinic visits monthly for the first 6 months followed by visits every 2-3 months, flexible ART refills, and encounters with a clinician at each visit and mentor mother as needed. Clients who do not meet these criteria will continue to receive standard-of-care services which include monthly visits and ART refills during pregnancy through 18 months postpartum.
62294811|NCT05267626|EXPERIMENTAL|AU-007 combined with aldesleukin and avelumab given concomitantly|AU-007 and avelumab will be administered Q2w, with either a single loading dose or Q2w aldesleukin.
62467125|NCT05068648|ACTIVE_COMPARATOR|MWC Configuration 1|"standard upholstery back that promotes posterior pelvic tilt set at or below cushion level and 1 above inferior angle"
61911088|NCT05128422|NO_INTERVENTION|EVT group|The Endovascular therapy group were given room air. And the patient will also be given endovascular therapy surgery.
61911089|NCT04357288|EXPERIMENTAL|Patient Decision Aid|Participants in this arm will use the Patient Decision Aid (PDA), an online education tool about atrial fibrillation designed for patient use, prior to the encounter with their provider.
61911090|NCT04357288|EXPERIMENTAL|Encounter Decision Aid|Participants in this arm will use the Encounter Decision Aid (EDA), an online educational tool about atrial fibrillation designed for patient-provider use, during the encounter with their provider.
61911091|NCT04357288|EXPERIMENTAL|Patient & Encounter Decision Aids|Participants in this arm will use both the PDA \& EDA as described above.
61911092|NCT04357288|NO_INTERVENTION|Standard Care|Participants in this arm will receive standard care, that is they will not use either the PDA or EDA.
62101132|NCT05988489|EXPERIMENTAL|Dynamic Deconstructive Psychotherapy (DDP)|53 participants will meet with an assigned DDP therapist in-person or through televideo for 50 to 60 minutes on a weekly basis for 12 months. Participants will also meet with a psychiatric provider for a 60-minute psychiatric consultation with at least monthly 30-minute follow-up visits. In addition, participants in this arm will have the option of attending family and group therapy if interested and indicated. At baseline, 3, 6, 9, and 12 months, participants will meet with a research coordinator for 60-minute visits to complete outcome measures.
62101133|NCT05988489|ACTIVE_COMPARATOR|Brief Intervention and Contact (BIC)|53 participants will meet with an assigned BIC therapist in-person or through televideo for an initial 60-minute visit with eight 30-minute follow-up contacts at 1, 2, 4 weeks and 2, 3, 4, 6 and 12 months after study entry. Participants will also meet with a psychiatric provider for a 60-minute psychiatric consultation with at least monthly 30 minute follow-up visits. In addition, participants in this arm will be encouraged to receive services in the community, such as weekly individual psychotherapy, family and group therapy. At baseline, 3, 6, 9, and 12 months, participants will meet with a research coordinator for 60-minute visits to complete outcome measures.
62294812|NCT00843570|NO_INTERVENTION|1|Natural FER (frozen embryo replacement)
62294813|NCT00843570|ACTIVE_COMPARATOR|2|HRT-FER (Down regulated frozen embryo replacement)
62294814|NCT05237557|EXPERIMENTAL|Interventional group|
62294815|NCT05237557|NO_INTERVENTION|Control group|
62294816|NCT03898648|EXPERIMENTAL|Depressed patients with history of suicide attempt|Depressed patients with a lifetime history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
62294817|NCT03898648|EXPERIMENTAL|Depressed patients without any history of suicide attempt|Depressed patients without history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
62294818|NCT02521129|EXPERIMENTAL|Ablation|Intervention: ablation of biopsy needle track with a new device
62467126|NCT05068648|ACTIVE_COMPARATOR|MWC Configuration 2|active contour back positioned with seat gap and with free scapulae
62467127|NCT05068648|ACTIVE_COMPARATOR|MWC Configuration 3|active contour back positioned with seat gap and with blocked scapulae
62467128|NCT05068648|ACTIVE_COMPARATOR|MWC Configuration 4|deep contour back positioned with seat gap and with free scapulae
62467129|NCT05068648|ACTIVE_COMPARATOR|MWC Configuration 5|deep contour back positioned without seat gap and with free scapulae
62662677|NCT05117476|EXPERIMENTAL|Module B Combination Therapy Cohort Expansion|Patients with select tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module B Escalation arm, in combination with pembrolizumab
62662678|NCT05276700||case with hcv|
62101134|NCT05242458||Participants with Crohn's Disease (CD)|Participants with moderate-to-severe active CD enrolled in ImproveCareNow (ICN) pediatric Inflammatory bowel disease (IBD) registry will be observed who are being treated with ustekinumab under real world setting and will be divided into 9 cohorts. Cohorts 1-6 for age group \>=2 to \<18 years (pediatric), cohorts 7-9 for young adults within age group \>=18 to \<26 years. Cohort 1: participants with moderate-severe CD and body weight \>=40 kg, cohort 2: participants with moderate-severe CD and body weight \<40 kg, cohort 3: all participants with moderate-severe CD, cohort 4: participants with active disease and body weight \>=40 kg, cohort 5: participants with active disease and body weight \<40 kg, cohort 6: all participants treated with ustekinumab, cohort 7: young adults with moderate-severe CD, cohort 8: young adults with active-disease; and cohort 9: all young adults treated with ustekinumab. Only data available per routine clinical practice will be collected within this study.
62101135|NCT05604391|ACTIVE_COMPARATOR|Free gingival grafts to be placed apical to the gingival recession.|It is the application of free gingival graft to the apical part of the recession area of mandibular anterior teeth with gingival recession and keratinized gingival height deficiency.
62101136|NCT05604391|ACTIVE_COMPARATOR|Free gingival grafts to be placed coronal to the gingival recession.|It is the application of free gingival graft to the coronal part of the recession area of mandibular anterior teeth with gingival recession and keratinized gingival height deficiency.
62101137|NCT06629857||Group 1: HCC Patients with Elevated AFP Levels Description: This group includes patients diagnosed|
62101138|NCT05610696|EXPERIMENTAL|Low impact immersion|This intervention will use the principles of Ai Chi, a model defined as a low-intensity aquatic exercise strategy
62101139|NCT05610696|EXPERIMENTAL|Conventional aquatic physiotherapy|In this intervention, medium impact exercises will be performed, with a comfortable movement speed.
62101140|NCT05610696|EXPERIMENTAL|High intensity aquatic physiotherapy|In this intervention, high-impact exercises will be performed, with maximum movement speed, twice time of the medium-intensity protocol
62662679|NCT05276700||control without hcv|
62662680|NCT03875417||Group A|Patients who developed HCC recurrences after surgery and treated with re-resection, or microinvasive non-surgical means.
62101141|NCT06209359|ACTIVE_COMPARATOR|Ammonium chloride|"Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily.~On Day 2, the participant will take ammonium chloride 150 mmol or placebo once"
62294819|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
62294820|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
62294821|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
62467130|NCT05439109|EXPERIMENTAL|Topographical landmark technique|Surface anatomic landmarks of an individual's trachea will be measured from the mid-thyroid level (corresponds to vocal cords) to manubriosternal joint (corresponds to carina) in the sagittal plane to estimate tracheal length. Three centimeters will be deducted from the estimated tracheal length to provide the length of the endotracheal tube from the tube tip to be inserted inside the trachea.
62467131|NCT05439109|ACTIVE_COMPARATOR|Intubation guide mark technique|Already established and commonly practiced technique, in this technique, the guide mark present above the proximal end of the endotracheal tube cuff will be placed just beyond the vocal cords.
62467132|NCT03518905|SHAM_COMPARATOR|sham-treatment|Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation
62467133|NCT03518905|ACTIVE_COMPARATOR|treatment arm|Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
62662681|NCT03875417||Group B|Patients who did not develop recurrences after surgery.
62662682|NCT05413642|EXPERIMENTAL|'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
62662683|NCT05413642|ACTIVE_COMPARATOR|Usual care|COVID-19 patients treated at home by their family doctors according to their usual clinical practice expected to be in accordance with AIFA recommendations
62662684|NCT04615507|EXPERIMENTAL|Test/Control/Control|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Test/Control/Control)
62662685|NCT04615507|EXPERIMENTAL|Control/Test/Test|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Control/Test/Test)
62662686|NCT03406468|EXPERIMENTAL|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
62467134|NCT04050930|EXPERIMENTAL|Normal weight, normo-dented|healthy young male presenting a good oral health ad a normal weight
62662687|NCT06023797||MAICT|chemotherapy that included at one application of PD-1 inhibitor
62467135|NCT04050930|EXPERIMENTAL|Obese, normo-dented|healthy young male presenting a first level of obesity, and a good oral health
62467136|NCT01585259|ACTIVE_COMPARATOR|Anfibatide|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
62467137|NCT01585259|PLACEBO_COMPARATOR|Placebo|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
62662688|NCT05443854|EXPERIMENTAL|Aminoglycosides intervention|"Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
62101142|NCT06209359|PLACEBO_COMPARATOR|Placebo|"Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily.~On Day 2, the participant will take ammonium chloride 150 mmol or placebo once"
62101143|NCT02817373|OTHER|transvaginal ultrasound study|Patients with a well established infertility requiring IVF treatment and who are \<40. Cohort will consist of patients going through a fresh day 5 transfer with a planned transfer of a single good quality embryo. Patients will go thorough a Ultrasound scan performed through a vaginal probe on the morning of the embryo transfer.
62101144|NCT05887557|OTHER|Low-barrier drop-in and mobile care|This is a single-arm trial of a set of implementation strategies to encourage uptake of drop-in and mobile HIV care for people living with HIV who experience barriers to engage in usual scheduled appointments.
62101145|NCT03547505|EXPERIMENTAL|R-Pilot®|"R-Pilot® was operated by an endomotor (VDW Silver, Munich, Germany) at Reciproc All setting."
62101146|NCT03547505|EXPERIMENTAL|ProGlider®|ProGlider® was operated by an endodontic motor (X-Smart, Dentsply Sirona, Ballaigues, Switzerland) with 16:1 contra angle at the suggested settings (300 rpm on display, 5 Ncm).
62101147|NCT03547505|EXPERIMENTAL|Manual preparation|"In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with push and pull motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan)."
62662689|NCT05443854|EXPERIMENTAL|Lack of protective isolation intervention|Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.
62101148|NCT00450892|OTHER|arm 1|
62294822|NCT04047888||Intervention Group|Mothers and children in this group will have measurements, questionnaire administration. The children will have routine child care at their health center and mothers will have a 60 minute nutrition-based and non-nutrition based educational message
62662690|NCT05443854|OTHER|No systematic aminoglycosides intervention|Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines - standard arm
62662691|NCT05443854|OTHER|Protective isolation intervention|Protective isolation will be provided systematically as currently practiced in participating centers - standard arm
62662692|NCT04582071|EXPERIMENTAL|Arm 1 (Psychotherapy, Intervention arm)|Subjects undergoing a 3 step IPAA will receive the four sessions of psychotherapy preceding and following their first surgery only, and receive an additional set of questionnaires again after their third surgery.
62662693|NCT04582071|NO_INTERVENTION|Arm 2 (Non-Therapy, Control Arm)|Subjects will receive questionnaires which will be administered remotely via telemedicine if patient and psychologist/ research team member are unable to meet in person.
62101149|NCT00450892|OTHER|arm 2|
62101150|NCT00450892|EXPERIMENTAL|arm 3|
62101151|NCT06712368|ACTIVE_COMPARATOR|Designed cardiac physical therapy program ( study group )|Designed cardiac physical therapy program
62101152|NCT06712368|EXPERIMENTAL|virtual reality group (study group)|virtual reality glasses Designed cardiac physical therapy program applied through virtual reality glasses for study group
62101153|NCT03961256|EXPERIMENTAL|Exenatide SR Intervention Group|Subjects will receive, in addition to standard care, Exenatide SR 2 mg subcutaneous (SQ) weekly for 24 months.
62294823|NCT04047888||Control Group|Mothers and babies will have measurements and questionnaire administration and children will receive routine child care at their health centers. These mothers will receive a non-nutrition based educational message only.
62101154|NCT03961256|NO_INTERVENTION|Standard of Care|Subjects will receive standard post-transplant care as per Mayo Clinic usual practice.
62101155|NCT06029660|EXPERIMENTAL|Treatment|Treatment Arm: Subjects in the treatment arm will have both an EVAR device and IMPEDE-FX RapidFill implants inserted.
62101156|NCT06029660|ACTIVE_COMPARATOR|Control|Control Arm: Subjects in the control arm will only have an EVAR device implanted.
62101157|NCT00552734||Control|The other half of the patients were randomized to the control group who were followed for their routine diabetes care and had to visit the clinic on the same schedule as the experimental group.
62101158|NCT00552734||Experimental|Half of the subjects were randomized to this group using insulin guidance software on a PDA to adjust their insulin dose at home based on the prescription provided by the provider.
62101159|NCT00003311|EXPERIMENTAL|Regimen A|Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
62101160|NCT00003311|EXPERIMENTAL|Regimen B|Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.
62294824|NCT01164878||Before|ELBW infants before change of feeding policy
62294825|NCT01164878||After|ELBW infants after change of feeding policy
62101161|NCT06392256|ACTIVE_COMPARATOR|PM-NS: Peri-implant mucositis-Non-surgical therapy|Professional mechanical plaque removal and submarginal instrumentation using titanium curettes will be performed in the non-surgical treatment of peri-implant mucositis with KMW \< 2 mm.
62101162|NCT06392256|ACTIVE_COMPARATOR|PM-NS-FGG: Peri-implant mucositis-Non-surgical therapy-Free Gingival Grafting|Professional mechanical plaque removal and submarginal instrumentation using titanium curettes will be performed in the non-surgical treatment of peri-implant mucositis with KMW \< 2 mm. Free gingival grafting will be done one month after the non-surgical treatment.
62101163|NCT06392256|NO_INTERVENTION|HC: Peri-implant healthy controls|Professional mechanical plaque removal will be applied to patients with healthy implants with sufficient KMW (i.e., ≥ 2 mm) as a routine procedure in supportive peri-implant care.
62101164|NCT00441675||Salmeterol/Fluticasone|Previous Salmeterol/Fluticasone treatment
62101165|NCT00441675||Fluticasone|Previous Fluticasone propionate treatment
62662694|NCT03886623|EXPERIMENTAL|4-day systematic oral hygiene|The intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
61911093|NCT03712423|EXPERIMENTAL|Patients [89Zr]-Df-CriPec® docetaxel|Day 1 of the Run-in a low dose of \[89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed \< 2 h by a second low dose of \[89Zr\]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of \[89Zr\]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).
62662695|NCT03886623|OTHER|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
62662696|NCT04015063|OTHER|Primary Subjects|Women subjects 40-65 years of age that meet the specified inclusion/exclusion criteria taking P29429-01 as a skin care product per the protocol.
62101166|NCT05916885|EXPERIMENTAL|experimental group|an experimental group receiving short-intensity modified CIMT and conventional therapy
62101167|NCT05916885|ACTIVE_COMPARATOR|control group|a control group receiving conventional therapy alone.
62101168|NCT00009958|EXPERIMENTAL|Stage I|Patients receive fCEA-TRI vaccine SC once daily on days 1, 29, 57, and 85.
62662697|NCT06476730|EXPERIMENTAL|Telerehabilitation exercise group|This group will receive a structured tele rehabilitation exercise protocol (of low to moderate intensity warm up ,aerobic ,resistance and cool down exercises for 3 times a week progressively increased for 8 weeks) in addition to routine medical care for GDM.
62662698|NCT06476730|ACTIVE_COMPARATOR|Routine medical care|The control group will receive routine medical care including oral medication, diet and regular walk.
62101169|NCT00009958|EXPERIMENTAL|Stage II|Patients receive vCEA-TRI vaccine intradermally once on day 1 and fCEA-TRI vaccine SC at the MTD determined in stage I once daily on days 29, 57, and 85.
62101170|NCT00009958|EXPERIMENTAL|Stage III|A single cohort of 6-10 patients receive both vaccines as in stage II, at the MTDs determined in stages I and II, and sargramostim (GM-CSF) SC once daily on days 1-4, 29-32, 57-60, and 85-88.
62101171|NCT05478863|PLACEBO_COMPARATOR|Oral placebo|Acute administration of oral placebo three times in study session (Time 0, 60, and 120).
62101172|NCT05478863|EXPERIMENTAL|Oral administration of 2.5 mg THC|Acute administration of oral THC (2.5 mg) three times in study session (Time 0, 60, and 120).
61911094|NCT01855373|OTHER|Placebo|No active ingredient
61911095|NCT01855373|ACTIVE_COMPARATOR|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
61911096|NCT01855373|ACTIVE_COMPARATOR|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
62101173|NCT05478863|EXPERIMENTAL|Oral administration of 2.5 mg THC + 60 mg caffeine|Acute administration of oral THC (2.5 mg) and oral caffeine (60 mg) three times in study session (Time 0, 60, and 120).
62101174|NCT05478863|EXPERIMENTAL|Oral administration of 2.5 mg THC + 60 mg caffeine + 35 mg CBD|Acute administration of oral THC (2.5 mg), oral caffeine (60 mg), and oral CBD (35 mg) three times in study session (Time 0, 60, and 120).
62294826|NCT04028037|EXPERIMENTAL|FTPGT treated patients|"The recipient site will be prepared according to Langer\&Langer modified technique, raising a split-thickness flap without vertical incisions. The harvest of palatal graft will be done using FTPG technique ant it will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central U shaped part.The palatal graft will be adapted to the recipient site and sutured."
61911097|NCT01855373|ACTIVE_COMPARATOR|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
62662699|NCT04248361|EXPERIMENTAL|TEM-PCR Diagnosis|The TEM-PCR diagnostic technology will be used to assess for a source pathogen involved in the subject's acute respiratory illness. Results of the TEM-PCR URI Panel will be used by the physician to guide treatment decisions. If indicated, the investigator may also utilize rapid strep testing and rapid influenza testing for diagnosis. In the event a lower respiratory infection is suspected a chest x-ray or complete blood count (CBC) with differential may also be performed.
61911098|NCT02428127|EXPERIMENTAL|Test|20g Carbohydrate powder fortified with multiple micronutrients, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
62101175|NCT06268028|EXPERIMENTAL|EXPERIMENT GROUP|"The individual identification form was first filled out using the face-to-face interview technique. An explanation given regarding filling out the scale and they will be asked to fill it out by self-reporting method under observation. When the mothers in the training group feel good and ready; discharge training gave using the discharge training brochure prepared by the researchers by reviewing the literature. We provided discharge training in the mother's own room and in an average of 30-45 minutes with a one-on-one training method. Mothers asked to fill out the RHD-NMF themselves again, close to postnatal discharge."
61911099|NCT02428127|ACTIVE_COMPARATOR|Calorie matched protein powder|20g Calorie matched protein powder with 80% protein, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
61911100|NCT02428127|PLACEBO_COMPARATOR|Control|200mL lukewarm water given twice a day
61911101|NCT05930015|EXPERIMENTAL|Music intervention only|Music only (the fast tempo of 120-130 bpm music will be selected) The effect was achieved by playing music selected by the researchers during originally physical education classes in school.
61911102|NCT05930015|EXPERIMENTAL|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice.
61911103|NCT05930015|EXPERIMENTAL|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class.
61911104|NCT00321646|EXPERIMENTAL|chemotherapy|docetaxel and bevacizumab prior to prostatectomy
61911105|NCT05599568|OTHER|Exercise challenge|At baseline, subjects will perform the selected exercise challenge followed by blood samples collected at rest and 0, 2, 4, 24 hours and 4 days after end of exercise. Muscle soreness will be measured by asking the participant how sore their muscles in their thighs are on a visual-analog scale (1-10) at the same timepoints. After 4 weeks (+/- 3 days) of normal daily activity, the same test will be performed including blood samples.
62101176|NCT06268028|NO_INTERVENTION|CONTROL GROUP|"Starting from the first (smallest number) room in the clinic, the individual identification form was filled out initially by face-to-face interview technique for mothers who meet the appropriate conditions and agree to participate in the study, according to the randomization order. An explanation given regarding filling out the scale and they will be asked to fill it out by self-reporting method under observation. Mothers asked to fill out the RHD-NMF themselves again, close to postnatal discharge."
62101177|NCT01065454|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) up to 2 mg|Participants received riociguat up to 2 mg three times per day (tid) (increasing from 0.5 to 1 to 2 mg).
62294827|NCT04028037|ACTIVE_COMPARATOR|CAF+SCTG treated patients|A tension-free trapezoidal flap will be elevated by the split-full-split technique. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap by 5-0 silk sutures.
62294828|NCT06075303|EXPERIMENTAL|Easier Targets|"All participants will participate in a modified Cycles approach where speech targets are worked on for a short period of time and switched within a cycle. During the Easier Targets arm, children will work on target sounds that are easier based on their pre-treatment scores of 8, 9, 10, or 11 on the Glaspey Dynamic Assessment of Phonology. Children will complete 8 sessions in this arm that are each 50-minutes long and occur two times per week with each target addressed for 2 sessions."
61911106|NCT06173115|ACTIVE_COMPARATOR|Double Perclose device|Double Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures
62294829|NCT06075303|EXPERIMENTAL|Harder Targets|"All participants will participate in a modified Cycles approach where speech targets are worked on for a short period of time and switched within a cycle. During the Harder Targets arm, children will work on target sounds that are harder based on their pre-treatment scores of 15, 14, 13, or 12 on the Glaspey Dynamic Assessment of Phonology. Children will complete 8 sessions in this arm that are each 50-minutes long and occur two times per week with each target addressed for 2 sessions."
61911107|NCT06173115|EXPERIMENTAL|Single Perclose device|Single Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures
61911108|NCT03865797|EXPERIMENTAL|Experimental|Before carrying out each session of the intervention, each subject included in the experimental group will have a sports bandage on both ankles. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
61911109|NCT03865797|ACTIVE_COMPARATOR|Control|The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
62101178|NCT01065454|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) up to 1 mg|Participants received riociguat up to 1 mg tid (increasing from 0.5 to 1 mg).
62101179|NCT01065454|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) fixed 0.5 mg|Participants received riociguat 0.5 mg tid (fixed dose).
62662700|NCT04248361|ACTIVE_COMPARATOR|SOC/Empiric Diagnosis|The Standard of Care for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
61911110|NCT05441657||dyspnoeic patients with post-acute COVID-19 syndrome|Patients with persisting dyspnoeic symptoms after COVID-19 disease were examined by Electric Impedance Tomography (EIT).
61911111|NCT05441657||control group|Healthy volunteers with no lung disease and non-smokers were voluntarily examined by Electric Impedance Tomography.
61911112|NCT01180179|ACTIVE_COMPARATOR|Lansoprazole 30mg once daily|Lansoprazole 30mg once daily
61911113|NCT01180179|ACTIVE_COMPARATOR|Famotidine 40mg once daily|Famotidine 40mg once daily
61911114|NCT06237192|EXPERIMENTAL|MRD-positive with Target therapy|MRD-positive patients after induction therapy in target therapy group (for B-ALL- blinatumomab, for T-ALL - venetoclax+ChT)
61911115|NCT01716962||ARDS with acute circulatory failure|acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
61911116|NCT00814216|EXPERIMENTAL|QAV680|
61911117|NCT00814216|PLACEBO_COMPARATOR|Placebo|
61911118|NCT00814216|ACTIVE_COMPARATOR|Fluticasone Propionate Inhaler|
61911119|NCT02823639|ACTIVE_COMPARATOR|Transcranial direct current stimulation|tDCS with varying intensity, location and polarity
61911120|NCT02823639|PLACEBO_COMPARATOR|Sham stimulation|Double blind sham stimulation with sham mode of neuroConn device
61911121|NCT03985878|EXPERIMENTAL|Eteplirsen|Participants will receive eteplirsen via IV infusions, once weekly, for up to 284 weeks.
61911122|NCT03207438|EXPERIMENTAL|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
61911123|NCT03207438|PLACEBO_COMPARATOR|Placebo 1|Placebo OD for 6 weeks
61911124|NCT03207438|EXPERIMENTAL|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
61911125|NCT03207438|PLACEBO_COMPARATOR|Placebo 2|Placebo OD for 6 weeks
61911126|NCT04742413||A|Patients who are prescribed to switch to lurasidone (lurasidone cohort)
61911127|NCT04742413||B|Patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort)
61911128|NCT03458598|EXPERIMENTAL|Single shot rectus sheath block|The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.
62101180|NCT01065454|PLACEBO_COMPARATOR|Placebo|Participants received placebo tid.
62662701|NCT00782444|ACTIVE_COMPARATOR|Computer navigated knee replacement|Computer navigation system from Brainlab, vector vision, kolibri.
62101181|NCT04222244||Headache Attributed to Rhinosinusitis Group (HAR)|No interventions will be provided.
62294830|NCT02987855|EXPERIMENTAL|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
62662702|NCT00782444|PLACEBO_COMPARATOR|Conventional knee replacement|Conventional total knee replacement is performed with intramedullary guides in the traditional way.
61911129|NCT03458598|SHAM_COMPARATOR|Placebo Control|The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.
61911130|NCT04880330|EXPERIMENTAL|Experimental: Cryo-Auriculotherapy|Patients benefit from 1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
61911131|NCT04880330|SHAM_COMPARATOR|Sham Comparator: Control group|Patients benefit from 1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points..
61911132|NCT04963842|NO_INTERVENTION|Conventional phase (use of conventional food packaging material)|During the conventional phase, participants are asked to maintain their usual habits for 5 days.
61911133|NCT04963842|EXPERIMENTAL|Intervention phase (use of bio-plastic and no plastic food packaging material)|During the 5-day long intervention period, all participants will be asked to: i) refrain from packaged (cans, plastic, paper) ready to consume foods, and foods from take away/delivery/fast food and ii) use the bio-based food packaging material to package their food.
61911134|NCT00832039|ACTIVE_COMPARATOR|SelPCT|Patient receives sodium-selenite; causal therapy is guided by a PCT based algorithm.
61911135|NCT00832039|ACTIVE_COMPARATOR|SelKon|Patient receives sodium-selenite; causal therapy is not guided by a PCT based algorithm.
61911136|NCT00832039|PLACEBO_COMPARATOR|PlacPCT|Patient receives placebo; causal therapy is guided by a PCT based algorithm.
61911137|NCT00832039|PLACEBO_COMPARATOR|PlacKon|Patient receives placebo; causal therapy is not guided by a PCT based algorithm.
62101182|NCT04222244||Headache-Free Control Group (Control)|No interventions will be provided.
62101183|NCT06209060|EXPERIMENTAL|Hammock Position Group|Babies in the hammock position group will be placed in a hammock created by the researchers inside the incubator.
62101184|NCT06209060|EXPERIMENTAL|Nesting Group|Babies in the nesting group will be placed in a nest created by the researchers within the incubator.
62101185|NCT03881631|EXPERIMENTAL|Mindfulness Based Stress Reduction (MBSR) Program|The MBSR program is an eight-week-long course designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
62294831|NCT02987855|EXPERIMENTAL|AD-cSVF Arm 2|ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
62294832|NCT02987855|EXPERIMENTAL|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
62101186|NCT03881631|ACTIVE_COMPARATOR|Living Well (LW) Program|LW is an eight-week course of group presentations and discussions on topics related to the promotion of health and well-being in the context of dementia caregiving. LW is designed to teach participants how to improve their physical and emotional health as a complement to traditional medical treatments.
62101187|NCT03881631|NO_INTERVENTION|Usual Care|The usual care arm is a no intervention group wherein participants experience their usual circumstances.
62101188|NCT03995810|EXPERIMENTAL|Carnosine|Carnosine, capsulle, 2 g/day, 8 weeks
62294833|NCT03065829|EXPERIMENTAL|ASSIST|The ASSIST intervention will deliver daily doses of MMT and vary dose intensity of all components each day based on the subject's biophysical data. Across a 30-day period, the ASSIST intervention will capture and analyze data to deliver on-demand MMT, guided practices to promote sleep hygiene and physical activity. Each day, subjects will receive at least one prompt to practice MMT (about 5 minutes at a time). However, based on the subject's biophysical sensor data, subjects could receive a maximum of 5 alerts or prompts per day from the device to enhance stress reduction, sleep hygiene, or physical activity.
62101189|NCT02454543|OTHER|Radical prostatectomy and BST|BST plus radical prostatectomy with ext. lymphadenectomy
62101190|NCT02454543|OTHER|Best Systemic Therapy (BST)|e.g. Androgen deprivation therapy, chemotherapy, others
62101191|NCT05161403|ACTIVE_COMPARATOR|Hyaluronic acid.|1mm layer of hyaluronic acid on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third \& seventh day after extraction of teeth.
62101192|NCT05161403|ACTIVE_COMPARATOR|Honey|1mm layer of Honey on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third \& seventh day after extraction of teeth.
62294834|NCT03065829|EXPERIMENTAL|Attention-Control|This intervention exposes subjects to the wearable technology without the self-management components to minimize novelty effects. Subjects assigned to this condition will wear the device for 30 days, which offers them an opportunity to experientially learn to self-monitor and employ self-regulatory skills by viewing the display biophysical data. Subjects in this condition will not receive any prompts from the device.
62294835|NCT03593915|EXPERIMENTAL|Ph 1b and 2: MDS|"* Patients with previously untreated MDS~* Patients with MDS who have received \<6 cycles of HMAs (during dose escalation only)~* Patients with de novo (cause unknown) or secondary MDS (treatment-related) who are not eligible for intensive induction chemotherapy or stem cell transplant~  * All French-American-British (FAB) subtypes~ * Intermediate and above per IPSS-R groups"
62294836|NCT01816503||Fentanyl matrix|
62294837|NCT00926926|EXPERIMENTAL|Active OTG|
62101193|NCT05161403|PLACEBO_COMPARATOR|Saline|a piece of gauze moistened with normal saline will be applied directly to the sockets wound for 45 minutes at baseline and on the third \& seventh day after extraction of teeth.
62101194|NCT05998005|EXPERIMENTAL|Initial training group|Participants who are initially trained in the First Face training program
62101195|NCT05998005|OTHER|Waitlist-control group|Participants who are trained in the First Face training program 6 months after the initial training group
62101196|NCT03882489||Cohort 1 : Height 150-165 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 1 includes patients whose the height is between 150 and 165 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 40 mg in the cohort 1 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 25 to 50 mg for cohort 1.
62101197|NCT03882489||Cohort 2 : Height 166-180 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 2 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 45 mg in the cohort 2 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 30 to 55 mg for cohort 2.
62101198|NCT03882489||Cohort 3 : Height 181-195 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 3 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 50 mg in the cohort 3 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 35 to 60 mg for cohort 3.
62662703|NCT04058301|NO_INTERVENTION|Handout|Participants receive a generic handout about resources in Boston
62662704|NCT04058301|EXPERIMENTAL|Text message|Participants receive a generic handout about resources in Boston and a text message with a geographically proximate resource
62662705|NCT05584436||oocytes obtained without flushing|First accessible follicle larger than 12 mm
62662706|NCT05584436||oocytes obtained after flushing|Oocytes obtained after a total of 6 cc flushing of follicles that oocyte cumulus complex could not be obtained after the first aspiration
62662707|NCT04664387||patients with myocardial bridge|patients who underwent coronary angiography and was diagnosed as myocardial bridge
62662708|NCT04664387||patients without myocardial bridge|patients who underwent coronary angiography and was diagnosed as without myocardial bridge
62662709|NCT05054881|OTHER|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
62662710|NCT05054881|OTHER|Sciatic nerve block under ultrasound control without a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
62101199|NCT02109393|EXPERIMENTAL|MIRT group|"This group underwent a 4-weeks MIRT exploiting the use of a treadmill-plus (treadmill associated with visual cues and auditory feedbacks).~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
62101200|NCT02109393|EXPERIMENTAL|MIRT+Lokomat group|"This group underwent a 4-weeks MIRT involving the use of Lokomat® for 5 days per week in spite of treadmill-plus.~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
62101201|NCT02205931|EXPERIMENTAL|Ketogenic diet|8 week trial of the ketogenic diet (KD) therapy. Children allocated to KD therapy will have their diets individually calculated by a paediatric dietitian with consideration of daily calorie requirements, adequate protein intake for growth and vitamin and mineral supplementation. All diets will be implemented according to a classical KD protocol, i.e. based on a ratio of fat to carbohydrate and protein that will usually be between 2:1 and 4:1.
62294838|NCT00926926|PLACEBO_COMPARATOR|Placebo|
62662711|NCT06370585|EXPERIMENTAL|PRO-229|"* Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.~* Dosage:1 drop QID \[4\] (four times per day) for 7 days on right both eyes.~* Route of administration: Ophthalmic.~* Presentation: Multidose dropper bottle."
62662712|NCT06370585|ACTIVE_COMPARATOR|Lagricel® Ofteno PF|"* Sodium hyaluronate 0.4%. Ophthalmic solution.~* Dosage: 1 drop QID \[4\] (four times per day) for 7 days on right both eyes.~* Route of administration: Ophthalmic.~* Presentation: Multidose dropper bottle."
62662713|NCT00990288|EXPERIMENTAL|Hemostatic Matrix|2 vials of Floseal applied once at the end of surgery
62662714|NCT00990288|NO_INTERVENTION|Control|No intervention.
62294839|NCT05033002|NO_INTERVENTION|Treatment as Usual Group|This group will receive treatment as usual which means that no formal stigma reduction intervention will be provided. At the end of the follow-up period, this group will be invited to view the Labda Siku Moja stigma reduction intervention without follow-up.
62294840|NCT05033002|EXPERIMENTAL|Stigma Intervention Group|This group will participate in a 5 week intervention. Each week, intervention group participants will watch one ethnodrama segment of the Labda Siku Moja stigma reduction intervention followed by a guided debrief using motivational interviewing.
62294841|NCT02236689|ACTIVE_COMPARATOR|Arthroscopic tennis elbow release|This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
62662715|NCT05804968|EXPERIMENTAL|Digital HIV self disclosure intervention|"This study will develop a digital HIV onward disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. Participants will be asked to be involved in this study for 11 weeks, consisting of three weeks baseline, four weeks intervention and four weeks follow up.~A single case experimental design will be used to explore HIV disclosure intention, HIV disclosure behaviour, HIV disclosure motivation, general wellbeing and mood via daily and weekly measures throughout baseline, intervention and follow up phases. All these measures will be completed online via a secure qualtrics network.~Participants will further be asked to complete a participant experiences questionnaire to explore how they found this digital intervention. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K."
62662716|NCT02661477|OTHER|pegylated interferon + placebo|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ). Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will receive subcutaneous placebo (0,9% NaCl) injection once a week, two times.
62662717|NCT02661477|OTHER|placebo + pegylated interferon|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive will receivesubcutaneous placebo(0,9% NaCl) injection once a week, two times. Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).
62662718|NCT01078597||Patients with early Rheumatoid Arthritis|Patients , aged 18 years or over, diagnosed with Rheumatoid Arthritis, with evidence of disease activity within the last year.
62662719|NCT01860092||Argus II Retinal Prosthesis|Patients implanted with the Argus II Retinal Prosthesis
62294842|NCT02236689|PLACEBO_COMPARATOR|Non Operative|control group will not undergo a second portal or muscle release.
62294843|NCT02811835||Renal Transplant Recipients|Renal Transplant Recipients that were more than 1 year post-transplantation
62294844|NCT02811835||Healthy Controls|Healthy subjects being evaluated as potential living kidney donors
62662720|NCT04705753|EXPERIMENTAL|Cretan IAMA (CAPeo)|All patients are to receive Cretan IAMA (CAPeo) from Day 1.
62662721|NCT00219271|EXPERIMENTAL|Zoledronic acid|4 mg IV infused over 15 minutes every 3 months
62662722|NCT00410488|ACTIVE_COMPARATOR|Palonosetron - 1 Dose|"Arm 1: Palonosetron 0.25 mg intravenous (IV) for 1 dose (day 0).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
61911138|NCT04665869|EXPERIMENTAL|Combined balance and brisk walking training|Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session 2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session 3. Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)
61911139|NCT04665869|ACTIVE_COMPARATOR|Flexibility and strengthening exercise|"1. Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~3. Participants practice own flexibility and strengthening exercise 2-3 times/week (to aim at 150 min of exercise per week)"
61911140|NCT00475423|EXPERIMENTAL|1|
61911141|NCT02793648|EXPERIMENTAL|Treatment|Ascorbic acid 200mg twice a day for twelve weeks Alpha tocopherol 200mg twice a day for twelve weeks
62101202|NCT02205931|ACTIVE_COMPARATOR|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug (AED) for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy according to a standardised manual (consensus document) written following the initial workshop of the paediatric neurologists from all the trial centres.
62101203|NCT06713876||VA-ECMO-assisted PCI|
62101204|NCT04357418||hospital staff|
62101205|NCT04357418||close relatives.|
62101206|NCT06694389|EXPERIMENTAL|mRNA-1083 and Placebo|Participants 50 years of age and older will receive mRNA-1083 by intramuscular (IM) injection and placebo by subcutaneous (SC) or IM injection administered on Day 1.
62101207|NCT06694389|ACTIVE_COMPARATOR|Licensed influenza vaccine + SARS-CoV-2 vaccine|Participants of age 50 years and older will receive licensed influenza vaccine by SC or IM injection and SARS-CoV-2 vaccine by IM injection administered on Day 1.
62101208|NCT05788926|EXPERIMENTAL|Dose escalation of TG6050|Dose escalation with single or repeated administrations of TG6050 by intravenous route in patients with advanced NSCLC.
62101209|NCT01894347||Colistin inhalative|"Adult ICU patients with~* invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection~* indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital~Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology"
62101210|NCT05165069|EXPERIMENTAL|Mecobalamin group|Mecobalamin (0.5mg / time, 3 times / day) for 6 months
62101211|NCT05165069|PLACEBO_COMPARATOR|Placebo group|placebo (0.5mg / time, 3 times / day) for 6 months
62101212|NCT03869034|EXPERIMENTAL|A, Combination group (HAIC+PD-1)|HAIC+PD-1
62101213|NCT03869034|EXPERIMENTAL|B, HAIC group (HAIC only)|HAIC
62101214|NCT05913973|EXPERIMENTAL|Group 1|5 (micro)g Pvs230D1-EPA/50 (micro)g MM
62101215|NCT05913973|EXPERIMENTAL|Group 2|25 (micro)g Pvs230D1-EPA/50 (micro)g MM
62101216|NCT05913973|EXPERIMENTAL|Group 3|50 (micro)g Pvs230D1-EPA/50 (micro)g MM
62101217|NCT04654936|EXPERIMENTAL|MIND diet with support|This intervention group are to follow the MIND diet guidelines for 12 weeks with the support of a 12 week online theory driven website and resources
62101218|NCT04654936|EXPERIMENTAL|MIND diet no support|This group are to follow the MIND diet guidelines with no website support
62101219|NCT04654936|NO_INTERVENTION|Control|The group follow usual diet
62101220|NCT04165798||Prospective NSCLC Participants|Male and female participants with histologically-confirmed diagnosis of squamous or nonsquamous NSCLC will be screened for participation in 1 of 7 pembrolizumab substudies.
62101221|NCT00303303|EXPERIMENTAL|Fab initial and maintenance therapy|Active Fab Antivenom initial therapy followed by active Fab antivenom maintenance therapy
61911142|NCT02793648|PLACEBO_COMPARATOR|Placebo|colloidal Silica 200mg twice a day for twelve weeks
61911143|NCT05699473|EXPERIMENTAL|5-MTHF glucosamine|1 single dose (400µg)
61911144|NCT05699473|EXPERIMENTAL|5-MTHF calcium salt 1|1 single dose (400µg)
61911145|NCT05699473|EXPERIMENTAL|5-MTHF calcium salt 2|1 single dose (400µg)
62101222|NCT00303303|EXPERIMENTAL|Fab initial therapy; placebo maintenance|Active initial Fab antivenom therapy followed by placebo maintenance therapy.
62101223|NCT00303303|PLACEBO_COMPARATOR|Placebo initial and maintenance therapy|Placebo initial and maintenance therapy.
62101224|NCT02858934|EXPERIMENTAL|preoperative tomotherapy|This study is an open study investigating the effect on quality of life of a very short preoperative radiotherapy for early breast cancer, including approximately 24 women. Radiotherapy will be performed in 1 week and before the surgery in stead of following surgery.Preoperative radiotherapy has the advantage that the tumor is visible on imaging. This can result in smaller boost volumes. The surgery will follow shortly after termination of the radiotherapy, resulting in a very short treatment period.
62101225|NCT06562218|EXPERIMENTAL|cross training group|Group whose healthy arm (unbroken side) is strengthened
62101226|NCT06562218|EXPERIMENTAL|control group|group given conventional exercise to the fractured arm
62294845|NCT00825370|EXPERIMENTAL|Protocolized|"1 mg IV hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
62294846|NCT00825370|ACTIVE_COMPARATOR|Discretionary Care|Patients receive an IV opioid the type and dose of which is determined by the treating physician
62101227|NCT06277817|EXPERIMENTAL|expiratory rib cage compression group|Expiratory rib cage compression procedure phase; Three hours after the first aspiration data were obtained, before the second aspiration, expiratory rib cage compression was applied for 5 minutes in the right lateral and left lateral positions, applying to both lungs, with the most affected lung area first. Before and after the procedure, vital signs, blood gas parameters were measured and the amount of secretion collected during the aspiration process was weighed.
62101228|NCT06277817|EXPERIMENTAL|percussion vibration group|Percussion, vibration process stage; Three hours after the first aspiration data were obtained, before the second aspiration, percussion and vibration were applied 3-5 times to each area, starting from the right and left lower lobes, in the right lateral and left lateral positions, with the most affected lung area being applied to both lungs first. Vital signs, blood gas parameters were measured before and after the procedure, and the amount of secretion collected during the aspiration process was weighed.
61911146|NCT06074042||tuberculosis-associated COPD|"COPD patient who meets any of the following criteria is diagnosed as tuberculosis-associated COPD:~1. previously definite pulmonary tuberculosis and ever receiving standard antituberculosis therapy;~2. previously suspected pulmonary tuberculosis and having typical radiological findings consistent with tuberculosis sequelae;~3. no definite history of pulmonary tuberculosis but having positive T-SPOT.TB test accompanied with typical radiological findings consistent with tuberculosis sequelae."
62101229|NCT06277817|NO_INTERVENTION|control group|Control group phase; In this group, vital signs, blood gases, and secretion amount were recorded at the same time as the experimental groups, without any intervention.
62101230|NCT06703424|EXPERIMENTAL|Sit-cycling|Sit-cycling on a seat-cycle for 5 mins
62101231|NCT06703424|EXPERIMENTAL|Stand-twisting|Stand-twisting on a stand-twister for 5 mins
62101232|NCT06703424|NO_INTERVENTION|Sitting only|Sitting only for 5 mins
62101233|NCT06344455|EXPERIMENTAL|Convergent Group|
62294847|NCT06059586|EXPERIMENTAL|Pelvic health Assessment and Intervention|
62101234|NCT06344455|EXPERIMENTAL|Divergent Group|
62101235|NCT06344455|PLACEBO_COMPARATOR|Control Group|
62101236|NCT03711617||CKD-ND|patients with non-dialysis CKD
62101237|NCT03711617||CKD-MHD|patients with maintenance hemodialysis
62294848|NCT05086679|ACTIVE_COMPARATOR|Compression stockings with 25-30 mm Hg pressure|Compression stockings with 25-30 mm Hg pressure, as long as they could (ideal would be the majority of the time they are upright)
61911147|NCT06074042||non-tuberculosis associated COPD|COPD patient in whom neither medical history nor chest CT indicates evidence of pulmonary tuberculosis is diagnosed as non-tuberculosis associated COPD.
61911148|NCT02299973|PLACEBO_COMPARATOR|Placebo group (FMT with own stool)|Fecal microbiota transplantation with patient's own stool
61911149|NCT02299973|EXPERIMENTAL|Treatment group (FMT with donor stool)|Fecal microbiota transplantation with healthy donor stool
62101238|NCT06032923|NO_INTERVENTION|Healthy controls|This group will not receive the dietary supplement or placebo.
62101239|NCT06032923|ACTIVE_COMPARATOR|Subjects with SLE - Active|This study group will take the dietary supplement Nicotinamide Riboside capsules.
62294849|NCT05086679|SHAM_COMPARATOR|Compression stockings with up to 10 mm Hg pressure|Compression stockings with up to \<=10 mm Hg pressure, as long as they could (ideal would be the majority of the time they are upright)
62662723|NCT00410488|ACTIVE_COMPARATOR|Palonosetron - 3 Doses|"Arm 2: Palonosetron 0.25 mg IV for 3 doses (days 0, 2, 4).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
62662724|NCT02779296|EXPERIMENTAL|2-Octyl Cyanoacrylate Glue|At the surgical site, a thin layer of cyanoacrylate glue will be applied over the sutures at the time of closure.
62662725|NCT02779296|NO_INTERVENTION|No Glue|No cyanoacrylate glue will be applied.
62662726|NCT02399020|EXPERIMENTAL|SCIT group|Social Cognition and Interaction Training intervention group
62662727|NCT04896294|ACTIVE_COMPARATOR|Group 1 - HAP-containing toothpaste|"The use of HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
62662728|NCT04896294|EXPERIMENTAL|Group 2 - Zn Mg HAP-containing toothpaste|"The use of Zn Mg HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Zn-Mg-hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
62662729|NCT04896294|EXPERIMENTAL|Group 3 - FAP-containing toothpaste|"The use of FAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Fluorapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene."
62662730|NCT02789748|EXPERIMENTAL|Treatment ON|Kinesthetic stimulation administered during one night
62662731|NCT02789748|NO_INTERVENTION|Treatment OFF|NO kinesthetic stimulation administered during one night
62662732|NCT04327271|EXPERIMENTAL|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
62662733|NCT04327271|NO_INTERVENTION|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
62662734|NCT06315166|OTHER|Single Arm|Open(self-controlled) split-face design study. Thirty participants will undergo the treatments on one side of the face (buccal area). Treatments will be randomized with combination antibiotic/ FRF therapy.
62662735|NCT01744821|ACTIVE_COMPARATOR|Arm A: Vitamin D3 Group|Patients will take Vitamin D3 by mouth in the weeks prior to and including the morning of surgery. If blood test done at the start of the study shows that patients have a low (\< or = 30 ng/ml) Vitamin D level, patients will be given two 25,000 IU Vitamin D3 Tablets (for a total of 50,000 IU) to take once a week until surgery. If baseline Vitamin D level is \>30ng/ml, patients will be given on 2,000 IU Vitamin D3 tablet to take once a day until day of surgery.
62662736|NCT01744821|PLACEBO_COMPARATOR|Arm B: Placebo Group|Patients will take a placebo by mouth prior to and including the morning of surgery. If bloods tests done at the start of study show that the patients have a low (\< or = 30 ng/ml) Vitamin D level, patients will be given 2 placebo tablets to take once a week until surgery. If baseline Vitamin D level is \> 30 ng/ml, patients will be given on placebo tablet to take once a day until surgery.
62662737|NCT00541229|EXPERIMENTAL|1|sitagliptin 100 mg
62662738|NCT00541229|EXPERIMENTAL|2|sitagliptin 200 mg
62662739|NCT00541229|PLACEBO_COMPARATOR|3|Placebo
62101240|NCT06032923|PLACEBO_COMPARATOR|Subjects with SLE - Placebo|This study group will take the Placebo.
62101241|NCT04432974|EXPERIMENTAL|ACTIVA|ACTIVA closed-loop anesthesia control system
62101242|NCT05153174|EXPERIMENTAL|2 tablets of Sulforaphane|Participants will be given 2 extra strength tablets per day
62101243|NCT05153174|EXPERIMENTAL|4 tablets of Sulforaphane|Participants will be given 4 extra strength tablets per day
62101244|NCT06570551||2-5 year old participants|Wear the investigational device continuously for 15 days.
62101245|NCT06570551||6-17 year old participants|Wear the investigational device continuously for 15 days.
62101246|NCT05254197||Retrospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 1998, and who have had MR re-examination after first MR exam because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. It is practically impossible to obtain informed consent from patients of this retrospective cohort, and consent was waived by the Institutional Review Board. Target population of this retrospective cohort is 1,500 tumors.
62101247|NCT05254197||Prospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since February 2022, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. The cohort will consists of patients who agree to participate with written consent. Target population of this prospective cohort is 1,500 tumors.
62101248|NCT04815824|EXPERIMENTAL|Stationary Cycling|All participants will complete one, 60-minute bout of stationary cycling
62101249|NCT04815824|EXPERIMENTAL|Treadmill Walking|All participants will complete one, 60-minute bout of treadmill walking
62101250|NCT02303769|ACTIVE_COMPARATOR|Tamsulosin HCL 0.2mg|Harnal-D tablet (Tamsulosin HCL 0.2mg)
62101251|NCT02303769|EXPERIMENTAL|Tamsulosin HCL 0.4mg|GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)
62101252|NCT06637904|NO_INTERVENTION|Pre-phase standard of care|Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching.
62101253|NCT06637904|EXPERIMENTAL|Post-phase TriVerity Test|Participants in the post-phase will be managed incorporating the TriVerity Test results with standardized guidance for interpretation and resulting management actions.
62101254|NCT00803426|ACTIVE_COMPARATOR|1|Local anesthetic will be injected above the division of the sciatic nerve.
62101255|NCT00803426|EXPERIMENTAL|2|Local anesthetic will be injected below the division of the sciatic nerve, around the common peroneal and tibial nerves.
62101256|NCT04215341|EXPERIMENTAL|1|The study contains a single arm. All children participating in the study will receive the primary intervention which is physiotherapy.
62294850|NCT01411787|NO_INTERVENTION|Control Group|Patient will continue normal activities. Ki-67 will be measured in the initial core biopsy and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to initiation of neoadjuvant chemotherapy, and then again after the last chemotherapy dose. Body mass index, percent body fat, and improving fitness levels will also be measured.
62101257|NCT02036931||Metal on Polyethylene articulation|G7 cup with Metal on Polyethylene articulation (MOP)
62101258|NCT02036931||Ceramic on Polyethylene articulation|G7 cup with Ceramic on Polyethylene articulation (COP)
62101259|NCT02036931||Ceramic on Ceramic articulation|G7 cup with Ceramic on Ceramic articulation (COC)
62308220|NCT03180762|EXPERIMENTAL|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
62308221|NCT03180762|EXPERIMENTAL|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
62308222|NCT03180762|EXPERIMENTAL|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
62101260|NCT06712953|EXPERIMENTAL|the peer assessment group|Students in the peer assessment group were paired (by randomization, on their request) to have a teammate of the same sex before the extremity examination experience. In the following process, the students were asked to perform extremity examinations in line with the specified objectives.
62101261|NCT06712953|EXPERIMENTAL|the standardized patient group|Students in the standardized patient group were asked to perform extremity examinations per the specified objectives in standardized patient.
62101262|NCT01102361|EXPERIMENTAL|Transperineal Biopsy|Biopsy of the prostate using transperineal approach
62101263|NCT03083522|EXPERIMENTAL|OJS group|admission to Ojeok-san granule
62101264|NCT03083522|PLACEBO_COMPARATOR|Placebo Group|admission to placebo
62101265|NCT00961805|EXPERIMENTAL|Dance Group|Belly dance
62101266|NCT00961805|NO_INTERVENTION|Control Group|Waiting list
62101267|NCT03995043|EXPERIMENTAL|Control Intervention|"1. Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~2. Personal Support from community peer mentor to access counselling services through SRH"
62101268|NCT03995043|EXPERIMENTAL|Case Intervention|"1. Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~2. Personal Support from community peer mentor to access counselling services through SRH~3. Access to Contraception and counselling and service provision will be provided by the mobile reproductive health team at contraceptive access points."
62662740|NCT06201091|EXPERIMENTAL|the observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
62662741|NCT02101177||Patients under Dual therapy|- 1500 patients who started treatment between April 1st 2013 and March 31st 2014 and will be seen for their week 60 visit between July 1st 2014 and June 30th 2015 (Cohort A).
62662742|NCT02101177||Early Defaulters|- 1000 patients recruited between July 1st 2014 and estimated March 31st 2015, of which 200 are expected to be early defaulters and will be contacted by the study team (Cohort B).
62101269|NCT00883350|EXPERIMENTAL|RIDE|Participants randomized to utilize the RIDE e-health application for the duration of the 12 week intervention.
62101270|NCT00883350|NO_INTERVENTION|Control|Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. \[6-9\]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., \[6\].
62101271|NCT04768062|EXPERIMENTAL|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 96 weeks.
62101272|NCT03337503|EXPERIMENTAL|THC and CDB in a 1 to 1 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 2.5 mg CBD capsule"
62101273|NCT03337503|EXPERIMENTAL|THC and CBD in a 1 to 2 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 5 mg CBD capsule"
62101274|NCT03337503|EXPERIMENTAL|high CBD with trace THC|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~20 mg CBD with traces of THC"
62101275|NCT03337503|PLACEBO_COMPARATOR|placebo|"Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals.~carrier oil capsule"
62101276|NCT06710574|EXPERIMENTAL|idiopathic Rapid Eye Movement sleep behavior disorder (iRBD)|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time
62101277|NCT06710574|NO_INTERVENTION|Parkinson's disease without Rapid Eye Movement sleep behavior disorder|PD subjects without RBD matched for age and sex to PD with RBD, iRBD and healthy control subjects
62101278|NCT06710574|NO_INTERVENTION|Healthy control|Healthy subjects without RBD matched for age and sex to PD and iRBD subjects
62101279|NCT06710574|EXPERIMENTAL|Parkinson's disease with Rapid Eye Movement sleep behavior disorder group|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time, keep the original anti Parkinson's drugs
62101280|NCT06011200|EXPERIMENTAL|ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)|Intramuscular injection, 0.5ml
62101281|NCT06011200|ACTIVE_COMPARATOR|ACYW135 Group Meningococcal Polysaccharide Vaccine (MSPV4)|Subcutaneous injection, 0.5ml
62662743|NCT05915377||Readi Set Go Patient Oriented Sample|Hospitalized older adults at risk of developing delirium providing informed consent
62662744|NCT05915377||Readi Set Go Administrative Sample|All patient admitted to the study wards for the duration of the study
62737192|NCT01947283|EXPERIMENTAL|Intervention Patients & Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers.~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
62662745|NCT04203056|EXPERIMENTAL|AL-LAI: Long-Acting Injectable Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: For patients assigned to the AL-LAI (aripiprazole lauroxil- long-acting injections), initiation of AL-LAI will begin with a one-day initiation regimen (using AL-NCD IM (aripiprazole lauroxil NanoCrystal Dispersion)). Subsequent dosing of AL-LAI will be flexible based on clinician judgment. Treatment with AL-LAI can be initiated at a dose of 441mg or 661mg (administered monthly), 882mg (administered monthly or every 6 weeks), or 1064mg (administered every 2 months). Note: These dosages are not assigned levels of the intervention and dosage levels may be changed at any time throughout the 12-month intervention based on clinical need and clinician judgement. Starting dosages do not indicate separate treatment conditions.
62662746|NCT04203056|ACTIVE_COMPARATOR|ARI-ORAL: Aripiprazole Oral Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: Patients assigned to the oral medication condition will continue with ARI-ORAL. ARI-ORAL dosage will be flexible and dosage will be at the discretion of the treating psychiatrist. Patients discontinuing ARI-ORAL study drug after Randomization to oral antipsychotic medication, can remain in active treatment and follow-up within the study, and may be prescribed any of a number of first-line oral antipsychotics.
62101282|NCT06711094|EXPERIMENTAL|experimental|albumin-bound paclitaxel、Dalpiciclib and AI
62662747|NCT04909788||Healthy adults with regular exercise|Subjects will be asked to wear a small monitoring equipment before,during and after a long distance running (over 3 km).
62662748|NCT00092729|EXPERIMENTAL|1|etoricoxib
62662749|NCT00092729|PLACEBO_COMPARATOR|2|Placebo to match etoricoxib
62662750|NCT00092729|ACTIVE_COMPARATOR|3|naproxen sodium
62101283|NCT05646836|EXPERIMENTAL|Arm A: Dose-Escalation and Expansion: XmAb24306+Cevostamab|Participants will receive escalating doses of XmAb24306 with a fixed dose regimen for cevostamab up to the maximum tolerated dose (MTD). After dose escalation has been completed, up to two expansion cohorts each investigating different XmAb24306 doses in combination with cevostamab may be enrolled.
62101284|NCT05646836|EXPERIMENTAL|Arm B: Single-Agent Cevostamab Expansion|Participants will receive cevostamab alone.
62101285|NCT06607003|EXPERIMENTAL|P. vivax challenge agent derived from PvHMB-CCE001 Main Arm|Up to 16 subjects will undergo IBSM to further develop the P. vivax challenge agent derived PvHMB-CCE001 model including to evaluate transmission to mosquitoes using feeding assays and assess the host response to P. vivax infection.
62101286|NCT06607003|EXPERIMENTAL|P. vivax challenge agent derived from PvHMB-CCE001 Pilot Arm|1-2 subjects will undergo IBSM to establish the safety and infectivity of the P. vivax challenge agent derived from PvHMB-CCE001.
62101287|NCT06607003|EXPERIMENTAL|P. vivax challenge agent derived from PvHMB-CCE002 Main Arm|Up to 16 subjects will undergo IBSM to further develop the P. vivax challenge agent derived from PvHMB-CCE002 model including to evaluate transmission to mosquitoes using feeding assays and assess the host response to P. vivax infection.
62101288|NCT06607003|EXPERIMENTAL|P. vivax challenge agent derived from PvHMB-CCE002 Pilot Arm|1-2 subjects will undergo IBSM to establish the safety and infectivity of the P. vivax challenge agent derived PvHMB-CCE002 challenge agent.
62101289|NCT00927342|ACTIVE_COMPARATOR|Vivostat|
62101290|NCT00927342|ACTIVE_COMPARATOR|BioGlue|
62101291|NCT03915262||Crohn's Disease|
62101292|NCT06278857|EXPERIMENTAL|Single Arm|Participation involves seven dostarlimab sessions over 12 months, with a treatment protocol of four cycles every three weeks, followed by a three-week break, and then three cycles every six weeks.
62101293|NCT05798208||hypertensive|Covid patients with exacerbated hypertension or new hypertension post covid
62101294|NCT05798208||non hypertensive|Covid patients with no change in blood pressure pre and post covid
62101295|NCT05493787|NO_INTERVENTION|Passive control|No message
62101296|NCT05493787|ACTIVE_COMPARATOR|Active control message|A message that simply states that patients can get a flu shot at Geisinger
62101297|NCT05493787|EXPERIMENTAL|Ease message|A message emphasizing the ease of scheduling a flu shot at Geisinger
62101298|NCT05493787|EXPERIMENTAL|Waiting for you message|"A message that states the patient's flu shot is waiting for them at Geisinger"
62101299|NCT05493787|EXPERIMENTAL|Protect yourself - rare message|A message that emphasizes the rare, dangerous outcomes of getting the flu (e.g., hospitalization, pneumonia), and states that a flu shot can offer protection from those outcomes
62294851|NCT01411787|EXPERIMENTAL|Exercise|"Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.~Ki-67 will be measured in the initial core biopsy specimen and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to inititation of neoadjuvant chemotherapy and then again after the last chemotherapy dose in both arms. Body mass index, percent body fat, and improving fitness levels will also be measured."
62294852|NCT03392766|EXPERIMENTAL|Single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and brochial blocker
62294853|NCT03392766|EXPERIMENTAL|Double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube
62294854|NCT02060734|EXPERIMENTAL|lidocaine|The treatment group will receive a 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point. Three to five points injection.
62662751|NCT04028505|EXPERIMENTAL|Terlipressin Continuous Infusion|Standard of care being given at AKUH + Continuous infusion of Terlipressin (Terlipressin Injectable Product) at a rate of 0.5mg/hour for the first 24 hours
62662752|NCT04028505|ACTIVE_COMPARATOR|Terlipressin Bolus Infusion|Standard of care being given at AKUH + Bolus infusion of Terlipressin (Terlipressin Injectable Product) at a frequency of 2mg every six hourly for first 24 hours
62662753|NCT04906798|EXPERIMENTAL|Sequence1|"1. Period 1: Reference drug(D744)~2. Period 2: Test drug(CKD-385)"
62294855|NCT02060734|ACTIVE_COMPARATOR|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
62294856|NCT00510705|OTHER|1|Regular physical exercise training alone
62294857|NCT00510705|OTHER|2|Regular physical exercise training + metformin
62662754|NCT04906798|EXPERIMENTAL|Sequence2|"1. Period 1: Test drug(CKD-385)~2. Period 2: Reference drug(D744)"
61911150|NCT04517279|EXPERIMENTAL|Peer Approaches to Substances in Early Psychosis Programs|The Peer Approaches to Substances in Early Psychosis Programs arm is an intervention focused on enhancing the recovery capital of individuals in early psychosis care. The intervention is provided by a peer provider, operating on the coordinated specialty care team
61911151|NCT04517279|ACTIVE_COMPARATOR|Usual Care|The peer providers operating under the Usual Care condition will continue to provide peer support services to individuals within the coordinated specialty care team.
62101300|NCT05493787|EXPERIMENTAL|Protect yourself - frequent message|A message that emphasizes the outcomes that frequently occur in people with the flu (e.g., fever, chills, missing important events), and states that a flu shot can offer protection from those outcomes
62101301|NCT02844764|EXPERIMENTAL|StroMed + Platelet Rich plasma [PRP]|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product by direct injection to affected joints.
62101302|NCT06705413|ACTIVE_COMPARATOR|Aerobic exercise group|The participants will receive a program of aerobic exercise for 3 consecutive menstrual cycles.
61919835|NCT00214500|EXPERIMENTAL|Migalastat|"Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods.~Treatment Period:~* Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14).~* Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28).~* Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42).~* Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84).~Extension Period:~* Migalastat 25 mg BID for Weeks 12 through 48.~* Migalastat 50 mg QD for Weeks 48 through 96."
61919836|NCT01527357|EXPERIMENTAL|Fibrocaps + Gelatin Sponge|Single application of Fibrocaps plus gelatin sponge.
61919837|NCT01527357|ACTIVE_COMPARATOR|Gelatin Sponge|Single application of gelatin sponge alone.
62101303|NCT06705413|EXPERIMENTAL|Aerobic exercise and microbiome diet group|The participants will receive aerobic exercise in addition to microbiome diet for 3 consecutive menstrual cycles.
62101304|NCT06628479||Deep infiltrative endometriosis group|People over the age of 35 who have completed their fertility, do not want children and have chronic pelvic endometriosis with pain or patients diagnosed with adenomyosis due to abnormal uterine bleeding
62101305|NCT06628479||control group|Patients operated for tubal ligation without pelvic pain
62101306|NCT04582877|OTHER|FFR Measurement in Intermediate-Grade Coronary Stenosis|Participants with intermediate-grade coronary stenosis undergo measurement of fractional flow reserve using the test article (Zurich Pressure Guidewire System) and predicate article (Abbott PressureWire System).
62101307|NCT05823987|EXPERIMENTAL|H101 + Tislelizumab+ Lenvatinib|H101 intratumorally injection starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62101308|NCT01497444|EXPERIMENTAL|sorafenib and TH-302|Patients will be administered sorafenib tablets to take twice daily by mouth, every day of each cycle. Patients will also be given TH-302 intravenously (IV) on days 8, 15 and 22 of each cycle. A cycle is 28 days.
62101309|NCT01112072|ACTIVE_COMPARATOR|Intacs combined with CXL|Intacs placement followed by collagen crosslinking with UV light and riboflavin
62294858|NCT00510705|OTHER|3|Regular physical exercise training + glitazone
62294859|NCT00510705|NO_INTERVENTION|4|Control
62294860|NCT05792202|EXPERIMENTAL|Study group|double raw repair for full tear rotator cuff combined microfracture procedure
62662755|NCT02332707|EXPERIMENTAL|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
62662756|NCT02332707|EXPERIMENTAL|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
62101310|NCT01112072|ACTIVE_COMPARATOR|Intacs followed by CXL|Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later
62662757|NCT02332707|EXPERIMENTAL|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
62662758|NCT02332707|EXPERIMENTAL|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
62662759|NCT02332707|EXPERIMENTAL|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
62101311|NCT05772962||Children enrolled at CAC|Information regarding oral health will be gathered from the public dental health records of children enrolled at CAC.
62101312|NCT05772962||Children not enrolled at CAC|Information regarding oral health will be gathered from the public dental health records of children that have not been enrolled at CAC. This is a control group, matched by age and gender.
62101313|NCT05618301|EXPERIMENTAL|Motixafortide followed by Motixafortide + Natalizumab|"* Consenting and eligible patients will receive a single subcutaneous injection of motixafortide, followed by leukapheresis. Patient will then be followed for 8 weeks for adverse event monitoring.~* Following the 8-week monitoring period, patients will receive a single IV infusion natalizumab, then approximately 32 hours later, a single subcutaneous injection of motixafortide, followed by leukapheresis. Patients will then be followed for 8 weeks for adverse event monitoring."
62101314|NCT04298840|EXPERIMENTAL|Creatine Monohydrate|
62101315|NCT04298840|PLACEBO_COMPARATOR|Placebo|
62101316|NCT05120596|EXPERIMENTAL|T3P-Y058-739 Intravenous (IV)|Intravenous infusion
62101317|NCT05120596|EXPERIMENTAL|T3P-Y058-739 Intratumoural (IT)|Intratumoural injection
62101318|NCT05120596|EXPERIMENTAL|T3P-Y058-739 plus pembrolizumab|Intravenous infusion
62101319|NCT04659031|EXPERIMENTAL|Cohort D1|Single Dose 0.1 mg / kg ABC008
62101320|NCT04659031|EXPERIMENTAL|Cohort D2|Single Dose 0.5 mg / kg ABC008
62294861|NCT05792202|PLACEBO_COMPARATOR|Control group|double raw repair for full tear rotator cuff
62662760|NCT02332707|EXPERIMENTAL|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
62101321|NCT04659031|EXPERIMENTAL|Cohort D3|Single Dose 2.0 mg / kg ABC008
62101322|NCT04659031|EXPERIMENTAL|Cohort D4|Single Dose 5.0 mg / kg ABC008
62101323|NCT04659031|EXPERIMENTAL|Cohort D5|X.X mg / kg ABC008
62101324|NCT04659031|EXPERIMENTAL|Cohort 6|Single 2.0 mg / kg ABC008
62101325|NCT04659031|EXPERIMENTAL|MAD Phase Cohort 1|Multiple Dose 0.1 mg / kg ABC008 every 8 weeks
62101326|NCT04659031|EXPERIMENTAL|MAD Phase Cohort 2|Multiple Dose 0.5 mg / kg ABC008 every 8 weeks
62101327|NCT04659031|EXPERIMENTAL|MAD Phase Cohort 3|Multiple Dose 2.0 mg / kg ABC008 every 8 weeks
62101328|NCT04656470|EXPERIMENTAL|Dexmedetomidine|During the study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.5mcg/kg/hr will be maintained for an additional 20-30 minutes.
62101329|NCT01772719|EXPERIMENTAL|Study Arm|Study Arm
62101330|NCT02256787|EXPERIMENTAL|BILB 1941 ZW - single rising dose|Single rising dose part
62101331|NCT02256787|PLACEBO_COMPARATOR|Placebo|Single rising dose part
62101332|NCT02256787|EXPERIMENTAL|BILB 1941 ZW - tablet - fasted|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
62101333|NCT02256787|EXPERIMENTAL|BILB 1941 ZW - solution|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
62101334|NCT02256787|EXPERIMENTAL|BILB 1941 ZW - tablet - fed|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
62101335|NCT04415112|ACTIVE_COMPARATOR|Mediterranean Diet|The MD diet is rich in plant based foods including vegetables, whole cereal and fruit with the main added fat being extra virgin olive oil. In addition, the diet emphasises, while consumption of legumes, nuts and fish is high, consumption of red meat and home-made desserts is low, and consumption of fermented milk and poultry is moderate. The MD diet had a target macronutrient composition of 35-40% fat (with \<10% of energy as saturated fat), 40-44% carbohydrate and 20% protein.
61911152|NCT06090292|EXPERIMENTAL|Real TUS + Real FES|"Participants will receive Real TUS using a 2 channel transducer with parameters' of sonication being 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz). The Power of Real tbFUS will be set at 20W. This will be followed by motor point stimulation (MPS) of the right and left hand and forearm muscles i.e. Opponens Pollicis Brevis (OPB), 1st Lumbrical and First Dorsal Interosseous (FDI) muscles triggered in congruence with the voluntary effort of the participant during execution of bilateral functional tasks involving the use of two and three finger pinch grip (e.g.: picking up and moving marbles, ball bearings etc.). Parameters of stimulation will be 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
62101336|NCT04415112|ACTIVE_COMPARATOR|Low Fat Diet|The Low Fat diet had a target macronutrient composition of 55% of energy from carbohydrate, 20-25% from fat (with \<10% of energy as saturated fat) and 20-25% from protein. Nutrition education focused on choosing foods containing ≤3 grams of fat/serving, limiting added fats, and using low-fat meal preparation strategies. Parents were instructed to offer their children ample amounts of grains, vegetables, fruits, lean meats, low-fat dairy products and limit high-fat foods
62101337|NCT05657912||ECG Monitoring -TAVR patients|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
62101338|NCT04821544|NO_INTERVENTION|Control|Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period. This group will also receive placebo gummies that appear the same as the vitamin D gummies.
62101339|NCT04821544|EXPERIMENTAL|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
62101340|NCT04821544|EXPERIMENTAL|Vitamin D|Vitamin D gummies of 2,000 IU/day for 8 weeks.
62101341|NCT06370325|EXPERIMENTAL|Intervention Group|Participants randomized to the intervention group will undergo neuromuscular electrical stimulation (NMES) five days a week beginning three weeks postoperative and lasting for ten weeks. The intervention group will begin standard physical therapy at six weeks postoperative.
62101342|NCT06370325|ACTIVE_COMPARATOR|Control Group|Participants randomized to the control group will begin standard physical therapy at six weeks postoperative.
62101343|NCT06037382|EXPERIMENTAL|MoodTriggers App|"Mood Triggers provides personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction. Mood Triggers delivers ultra-brief interventions (less than 2 minutes long) where participants view videos which introduce an important skill to treat their anxiety and depressive."
62101344|NCT04004702|EXPERIMENTAL|Levetiracetam|All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year
62101345|NCT03720015|EXPERIMENTAL|Concurrent training|Three sessions per week of concurrent training during radiotherapy period. Each session will begin with warm-up (5-min cardiovascular activity at low-moderate intensity, joint mobility and one set of resistance exercises circuit at 30-40% 1RM). Resistance training will follow the warm-up, including 9 standard exercises involving major muscle groups of the lower and upper body: vertical bench press, parallel bar dip for triceps, seated rowing, standing dumbbell curl for biceps, leg press, deadlift and shoulder press. All these exercises will be realized following circuit training with 4 sets of 8-12 repetitions, using a training load of 70-80% RM. When patient will able to complete more than 12 repetitions, load will be increased progressively 10%. Cardiovascular training will be completed 20-30 min after resistance training, and it will include High-Intensity Interval Training (HIIT) of 3 min near to the second ventilatory threshold and 2 min near to the first ventilatory threshold.
62294862|NCT00238264|EXPERIMENTAL|Treatment (radiotherapy)|Patients undergo reduced-field conformal radiation therapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
62662761|NCT02332707|EXPERIMENTAL|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
62101346|NCT03720015|EXPERIMENTAL|Nutritional management|Prescribed diet controlling macronutrients according to patient body weight (\~4g/kg/day for carbohidrates, \~2g/kg/day for proteins, and \~1g/kg/day for fats). Patient will take one single dosage per day of probiotics (Arkoprobiotics® Defenses), 1 or 2 capsules of omega-3 fish oil concentrate (Solgar®, 600-1200mg depending on fat sources intake during the day), and a combine ingestion of 3g beta-hydroxybeta-methylbutyrate (HMB), 14g arginine, and 14g glutamine (HSN Raw Series®, all pure ingredients and making the ingestion adding each of them individually in a solution with 300-400 ml of water). During concurrent training sessions, between resistance exercise and HIIT, patient will also take 6g of BCAA's (HSN Raw Series®, 2:1:1) along with a banana. Additionally, patient could take whey isolated protein (Amix® IsoPrime CFM) to meet with some of the prescribed proteins intakes.
62101347|NCT04376164|NO_INTERVENTION|control group|was treated without laser intervention
62101348|NCT04376164|EXPERIMENTAL|laser group|received low level laser therapy
62101349|NCT04589611|EXPERIMENTAL|Phase I single amobarbital/Gel-One dose|Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
62101350|NCT04589611|ACTIVE_COMPARATOR|Phase IIa Part 1 amobarbital/Gel-One dose|20 subjects will be randomized to amobarbital/Gel-One single dose.
62101351|NCT04589611|PLACEBO_COMPARATOR|Phase IIa Part 1 Placebo|10 subjects will be randomized to amobarbital/Gel-One single dose.
62101352|NCT04589611|ACTIVE_COMPARATOR|Phase IIa Part 2 amobarbital/Gel-One dose|20 subjects will be randomized to one dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
62101353|NCT04589611|PLACEBO_COMPARATOR|Phase IIa Part 2 placebo|20 subjects will be randomized to one dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
62101354|NCT06505031|EXPERIMENTAL|TAK-861|Participants will receive TAK-861 tablets, orally, for 12 weeks.
62101355|NCT06505031|PLACEBO_COMPARATOR|Placebo|Participants will receive TAK-861-matching placebo tablets, orally, for 12 weeks.
62101356|NCT00826280|PLACEBO_COMPARATOR|Placebo plus Regadenoson|Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
62101357|NCT00826280|EXPERIMENTAL|Caffeine 200 mg plus Regadenoson|One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
62101358|NCT00826280|EXPERIMENTAL|Caffeine 400 mg plus Regadenoson|Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
62101359|NCT05692401|NO_INTERVENTION|Standard of Care|CAM boot prescribed as standard of care. No nutritional guidelines or upper body exercises instructions provided. Height and weight recorded at enrollment and final visit.
62101360|NCT05692401|ACTIVE_COMPARATOR|Nutrition and Exercise Instruction|CAM prescribed as standard of care. Nutritional guidelines provided and upper body exercise instructions provided. Height and weight recorded at enrollment and final visit. Subjects in this group will undergo a follow up interview that will ultimately be used to examine and assess the helpfulness of the intervention in preventing weight for CAM boot wearing patients.
62101361|NCT06714669|EXPERIMENTAL|Experimental Arm: Remimazolam Group|Experimental Group (Remimazolam Anesthesia Arm): Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy.
62101362|NCT06714669|ACTIVE_COMPARATOR|Control Arm: Propofol Group|"Control Group (Propofol Anesthesia Arm):~Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam."
62101363|NCT03805165||neonate|transcutaneous bilirubin(TCB) measurements were performed with 2977 neonates at designated time points. The mean NTL exposure during pregnancy was respectively calculated based on each participant's residential address over the study course.
62101364|NCT06310993|EXPERIMENTAL|Intervention|The exercise programme will include one weekly supervised exercise sessions and one weekly unsupervised exercise session. The frequency will be twice weekly, one supervised and one unsupervised session a week for 12 weeks. The exercises will be of moderate intensity aerobic interval exercise (performing at 60% maximum heart rate) combined with 1-3 sets of 6-12 Repetition Maximum (RM) resistance training. The type of exercise will be aerobic interval exercise (cycling) and Resistance training (3 exercises: chest press, biceps, and leg curl) The timing will be 4 x 4-minute cycling at 60%, max HR with 3 minutes active recovery. 3 sets with 2 minutes per set - around 20 minutes resistance training
62101365|NCT02637271|EXPERIMENTAL|Total Meal Replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
62294863|NCT03903757||Obese subjects with and without T2D|
62294864|NCT03903757||control subjects|
62294865|NCT05208229||Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol|Patients with mCRPC enrolled in the IRST 185.03 Lu-PSMA study, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.
62467138|NCT00075478|EXPERIMENTAL|Arm I (chemotherapy, TBI, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
62101366|NCT02637271|ACTIVE_COMPARATOR|Typical Diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
62101367|NCT06118255|EXPERIMENTAL|Fenfluramine Open-label|All study participants will initiate fenfluramine hydrochloride (HCl) treatment at 0.2 mg/kg/day in the Dose-Finding Period and may be up-titrated to a maximum of 0.8 mg/kg/day based on the Investigators discretion. The dose of fenfluramine HCl can be flexibly titrated during the Maintenance Period. Study participants, who discontinue early will participate in the Taper Period. All participants will complete an End of Treatment (EOT) Visit.
62101368|NCT06061484|ACTIVE_COMPARATOR|Control Group|Standard weight-based dosing of Ready-to-Use Therapeutic Food (RUTF) at a dose of 150-200 kcal/kg/day
62101369|NCT06061484|EXPERIMENTAL|SAM Experimental A|2 sachets (1000 kcal) of RUTF per day
62101370|NCT06061484|EXPERIMENTAL|SAM Experimental B|2 sachets (1000 kcal) per day while MUAC \< 115mm and/or edema and/or WHZ \< -3; then decreasing to 1 sachet (500 kcal) per day while MUAC 115-124 and WHZ -2 to -3 and no edema
62101371|NCT00840047|EXPERIMENTAL|Participants|Participants who meet the eligibility criteria in the study will receive methionine.
62101372|NCT02770664|EXPERIMENTAL|LC28-0126 Dose A|
62101373|NCT02770664|EXPERIMENTAL|LC28-0126 Dose B|
62101374|NCT02770664|EXPERIMENTAL|LC28-0126 Dose C|
62101375|NCT02770664|PLACEBO_COMPARATOR|Placebo|
62101376|NCT06502977|EXPERIMENTAL|Tarlatamab|Participants will receive tarlatamab as an intravenous (IV) infusions in 28-day cycles.
62101377|NCT04676802|EXPERIMENTAL|NSAIDS|Following surgery will receive NSAID capsules following surgery. Will take online and phone surveys.
62467139|NCT00075478|ACTIVE_COMPARATOR|Arm II (TBI, transplant, GVHD prophylaxis)|Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
62467140|NCT03170622||IBD|Children (age \<18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
62467141|NCT05992805||Volunteer Participants|Volunteer participants being scanned by a qualified clinician using various ultrasound machines.
62101378|NCT04676802|EXPERIMENTAL|Opioids|Following surgery will receive opioid capsules following surgery. Will take online and phone surveys.
62101379|NCT00287573|EXPERIMENTAL|Arm 1|
62101380|NCT00287573|ACTIVE_COMPARATOR|Arm 2|
62101381|NCT05412030|EXPERIMENTAL|Group 1|1 mcg AFX3772 administered intramuscularly 4 times within 12 months in Part 1 of the study.
62101382|NCT05412030|EXPERIMENTAL|Group 2|2 mcg AFX3772 administered intramuscularly 4 times within 12 months in Part 1 \& Part 2 of the study.
62101383|NCT05412030|EXPERIMENTAL|Group 3|5 mcg AFX3772 administered intramuscularly 4 times within 12 months in Part 1 \& Part 2 of the study.
62101384|NCT05412030|ACTIVE_COMPARATOR|Group 4|PCV13 administered intramuscularly 4 times within 12 months in Part 1 of the study.
62101385|NCT05412030|ACTIVE_COMPARATOR|Group 5|PCV20 administered intramuscularly 4 times within 12 months in Part 2 of the study.
62101386|NCT01051882|EXPERIMENTAL|MSC-NTF cells IM|Intramuscular administration in early stage patients
62467142|NCT01789177|EXPERIMENTAL|Modified incentive spirometry|Patients will be given a disposable incentive spirometer postoperatively and instructed to use the spirometer every hour while awake.
62101387|NCT01051882|EXPERIMENTAL|MSC-NTF cells IT|Intrathecal administration in progressive stage patients
62101388|NCT02157714|EXPERIMENTAL|PRX002|PRX002
62101389|NCT02157714|PLACEBO_COMPARATOR|Placebo|Placebo
62101390|NCT05072314|ACTIVE_COMPARATOR|Lidocaine|2% Lidocaine infusion intra-operative and 10% Lidocaine infusion post-operative.
62101391|NCT05072314|PLACEBO_COMPARATOR|Placebo|0.9% Saline infusion intra-operative and 0.9% Saline infusion post-operative.
62101392|NCT06146101|EXPERIMENTAL|Phase 2 Investigational Product - IHL-42X Low dose|IHL-42X (2.5 mg dronabinol + 125 mg acetazolamide), one capsule self-administered once daily every night approximately 1 hour prior to bed for 4 weeks.
62101393|NCT06146101|EXPERIMENTAL|Phase 2 Investigational Product - IHL-42X High dose|IHL-42X (5 mg dronabinol + 250 mg acetazolamide), one capsule self-administered once daily every night approximately 1 hour prior to bed for 4 weeks.
62101394|NCT06146101|PLACEBO_COMPARATOR|Phase 2 Placebo|One capsule self-administered once daily every night approximately 1 hour prior to bed for 4 weeks.
62101395|NCT06146101|EXPERIMENTAL|Phase 3 Investigational Product - IHL-42X|IHL-42X (dose will be identified based on the safety and efficacy results in Phase II), one capsule self-administered once daily every night approximately 1 hour prior to bed for 52 weeks.
62101396|NCT06146101|ACTIVE_COMPARATOR|Phase 3 Comparator - Reference Listed Drug/Dronabinol|One capsule of dronabinol (equivalent dose strength to that in the IHL-42X optimal dose strength) self-administered once daily every night approximately 1 hour prior to bed for 3 months then IHL-42X (optimal dose) one capsule self-administered once daily every night approximately 1 hour prior to bed for the remaining 9 months.
62101397|NCT06146101|ACTIVE_COMPARATOR|Phase 3 Comparator - Reference Listed Drug/Acetazolamide|One capsule of acetazolamide (equivalent dose strength to that in the IHL-42X optimal dose strength) self-administered once daily every night approximately 1 hour prior to bed for 3 months then IHL-42X (optimal dose) one capsule self-administered once daily every night approximately 1 hour prior to bed for the remaining 9 months.
62101398|NCT06146101|PLACEBO_COMPARATOR|Phase 3 Placebo|One capsule self-administered once daily every night approximately 1 hour prior to bed for 52 weeks.
62308223|NCT03180762|EXPERIMENTAL|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
62101399|NCT05967403|ACTIVE_COMPARATOR|Conventional CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional (prototype) closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia
62101400|NCT05967403|ACTIVE_COMPARATOR|Hermetic CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed-loop anaesthesia delivery system (CLADS).\[(Clarity Medical Private Ltd., Mohali, Punjab India\]. A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia
62101401|NCT04698291||Controls|This research aims to recruit only adult volunteers that have taken part of the Gene \& Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
62101402|NCT04698291||Cases|This research aims to recruit only adult volunteers that have taken part of the Gene \& Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
62101403|NCT01759979|EXPERIMENTAL|Laser and mechanical lithotripsy|Bile duct stones with be treated with cholangioscopy guided laser therapy in addition to mechanical basket and balloon techniques.
62101404|NCT01759979|ACTIVE_COMPARATOR|Mechanical lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloon for removal of large stones.
62101405|NCT00869570|EXPERIMENTAL|Arm A: Sorafenib & Capecitabine & RT|"Sorafenib: day 1 to 33 (5 weeks, including Saturday and Sunday) every 24 hours, immediately or within two hours after RT according to the dose escalation table during phase I, and the recommended dose during phase IIa. The intake stops at the last day of RT. On nonradiotherapy days (e.g. Saturday, Sunday), the tablets have to be taken at the same time as during the week.~* Capecitabine: day 1 to 33 (5 weeks, including Saturday and Sunday) according to dose escalation table during phase I, and at the recommended dose during phase IIa. The intake stops in the evening of the last day of RT.~* External beam RT: Monday through Friday for 5 weeks starting on day 1 (daily fraction 1.8 Gy, final dose 45 Gy) each day at the same time (e.g. 11:00 a.m. daily).~* Surgery: 6 weeks (± 1 week) after radiochemotherapy (RCT) has been completed"
62101406|NCT06714591|EXPERIMENTAL|Experimental: BL-M11D1 administered Day 1 per cycle|BL-M11D1 will be administered on Day 1 by intravenous infusion every 28 days.
62101407|NCT05553041|EXPERIMENTAL|18F-Fluciclovine PET-MRI in pediatric HGG or DMG participants|Single intravenous administration of 18F fluciclovine for PET-MRI Scan
62294866|NCT02291211|EXPERIMENTAL|S-1 plus cisplatin HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after palliative operation gastric cancer of stage IV limited peritoneal metastasis. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m\^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m\^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
62294867|NCT03120143|EXPERIMENTAL|Team sport and high protein group|This group participated in team sport based small-sided ball games with supplementation of a drink with a high content of protein after the training sessions
62294868|NCT03120143|EXPERIMENTAL|Team sport and low protein group|This group participated in team sport based small-sided ball games with supplementation of a drink low in protein content after the training sessions
62294869|NCT03120143|NO_INTERVENTION|Control group|This group continued their usual life style without intervention
62467143|NCT01789177|ACTIVE_COMPARATOR|Postoperative chest physiotherapy|Patients will be given standard postoperative chest physiotherapy, according to hospital protocol, but will not receive incentive spirometers.
62467144|NCT01305122|OTHER|OMS grade II glioma|neurocognitive tests
62467145|NCT02190877||Cohort 1: Subjects taking diuretic medication|All subjects will be in the same group, Cohort 1
61911153|NCT06090292|EXPERIMENTAL|Real TUS +Sham FES|"Participants will receive Real TUS using a 2 channel transducer with parameters' of sonication being 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz). The Power of Real tbFUS will be set at 20W. This will be followed by motor point stimulation (MPS) of the right and left biceps and long finger flexors triggered in congruence with the voluntary effort of the participant during execution of bilateral functional tasks involving the use of two and three finger pinch grip (e.g.: picking up and moving marbles, ball bearings etc.). Parameters of stimulation will be 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
62294870|NCT05264350|EXPERIMENTAL|Viiral® Nasal Spray group|The nasal spray to be administrated twice daily for 8 weeks.
62294871|NCT05264350|ACTIVE_COMPARATOR|Isotonic Saline Nasal Spray|The nasal spray to be administrated twice daily for 8 weeks.
62662762|NCT02332707|EXPERIMENTAL|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
62662763|NCT02332707|EXPERIMENTAL|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
62662764|NCT02332707|EXPERIMENTAL|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
62294872|NCT04919915|OTHER|Intervention group|Households are randomly assigned to the intervention group with asthma education and received two HEPA air cleaners designed to reduce PM and NH3.
62467146|NCT02642068||ADHD group|Drug-naïve adult ADHD Probands
62467147|NCT02642068||Sibling group|Unaffected Siblings of Drug-naïve Adult ADHD
62467148|NCT02642068||Control group|Age-, sex-, handedness-, and IQ-matched controls without lifetime ADHD or a family history of ADHD
62467149|NCT04666311||Adult presumptive TB cases|Adult presumptive TB cases (age ≥18years) with one or more TB symptoms (WHO recommended four-symptom screening; cough, weight loss, night sweats, fever) of any duration.
62467150|NCT03148808|EXPERIMENTAL|NVS Therapy|NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
62467151|NCT01211652||1|
62467152|NCT00635492||1|exenatide
62467153|NCT00635492||2|insulin
62467154|NCT01741844||Etravirine|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.
62101408|NCT06711406||ASRS-5 score above 14|This group consists of participants who have a score of 14 and above on the Adult ADHD Self-Report Scale (ASRS-5). Participants with these scores are more susceptible to ADHD. The group does two cognitive tests, the Sustained Attention to Response Test (SART) TEST. Furthermore, the assessment of their Postural Control is conducted using a force plate.
62101409|NCT06711406||ASRS-5 score Below 14|This group consists of participants who have a score below 14 on the Adult ADHD Self-Report Scale (ASRS-5). Participants with these scores are less susceptible to ADHD. Participants with these scores are more vulnerable to ADHD. The group does two cognitive tests, the Sustained Attention to Response Test (SART) TEST. Furthermore, the assessment of their Postural Control is conducted using a force plate.
61911154|NCT06090292|EXPERIMENTAL|Sham TUS +Real FES|"The Sham tbFUS paradigm will consist of 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz), however the ultrasound head will be flipped so that the active side faces away from the head. This will be followed by motor point stimulation (MPS) of the right and left hand and forearm muscles i.e. Opponens Pollicis Brevis (OPB), 1st Lumbrical and First Dorsal Interosseous (FDI) muscles triggered in congruence with the voluntary effort of the participant during execution of bilateral functional tasks involving the use of two and three finger pinch grip (e.g.: picking up and moving marbles, ball bearings etc.). Parameters of stimulation will be 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
62101410|NCT05974826|EXPERIMENTAL|Community Intervention (town: Cardona)|"The interventions aim to encourage a healthy lifestyle, including diet education, physical activity, and wellbeing.~The SI! Program for Secondary Schools: a four-year specially designed educational program for adolescents is applied.~The Fifty-Fifty Program implies two stages: 1) Training period; 2) a Peer-group intervention, designed to make the subjects participate actively in their healthcare"
62101411|NCT05974826|NO_INTERVENTION|Community Control (town: Sallent)|The participants on the control group only receive general health recommendation at the end of each assessment.
62101412|NCT05743881|EXPERIMENTAL|Part A: mRNA-1345, Dose 1 (Age Group: 8 to <24 months)|Participants will receive mRNA-1345 vaccine by intramuscular (IM) injection on Days 1, 57 and 113.
62101413|NCT05743881|EXPERIMENTAL|Part A: mRNA-1365, Dose 1 (Age Group: 8 to <24 months)|Participants will receive mRNA-1365 vaccine by IM injection on Days 1, 57 and 113.
62101414|NCT05743881|PLACEBO_COMPARATOR|Part A: Placebo (Age Group: 8 to <24 months)|Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
62101415|NCT05743881|EXPERIMENTAL|Part B: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)|Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
62101416|NCT05743881|EXPERIMENTAL|Part B: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)|Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
62101417|NCT05743881|EXPERIMENTAL|Part B: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)|Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
62662765|NCT02332707|EXPERIMENTAL|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
61911155|NCT02812888||Hyperthyroid Patients|Patients with hyperthyroidism
61911156|NCT02812888||NC group|Normal control subjects
62101418|NCT05743881|EXPERIMENTAL|Part B: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)|Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
62101419|NCT05743881|PLACEBO_COMPARATOR|Part B: Placebo (Age Group: 5 to <8 months)|Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
62467155|NCT01530620|EXPERIMENTAL|Propiverine hydrochloride ER|45 mg
62467156|NCT01530620|ACTIVE_COMPARATOR|Propiverine hydrochloride IR|15 mg
62467157|NCT03571893|EXPERIMENTAL|Weight Watchers Freestyle (Flex)|Participate in Commercially Available behavioral weight loss program delivered by Weight Watchers International in the community
62467158|NCT03571893|ACTIVE_COMPARATOR|DIY Personal Plan|Receive informational resources for healthy lifestyle change to promote weight loss
62101420|NCT05743881|EXPERIMENTAL|Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months exposed to nirsevimab)|Participants who have been previously exposed to nirsevimab will receive mRNA 1345 by IM on Days 1, 57, and 113.
62101421|NCT05743881|EXPERIMENTAL|Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months not exposed to nirsevimab)|Participants who have not been previously exposed to nirsevimab will receive mRNA 1345 by IM on Days 1, 57, and 113.
62101422|NCT06120582|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will receive ANB-002 at a dose 1. Follow-up for the assessment of dose-limiting toxicity (DLT) will be carried out for 28 days. If no DLT events are observed in the subject of Cohort 1, the following subjects will be included in Cohort 1.
62101423|NCT06120582|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will receive ANB-002 at a dose 2. The decision to continue enrolling in Cohort 1 or dosing in Cohort 2 will be made at the IDMC meeting. After the IDMC makes a decision regarding the dosing in Cohort 2 subjects, the next subject will be included in Cohort 2. If no DLT events are observed in the subject of Cohort 2, the following subjects will be included in Cohort 2.
62101424|NCT06120582|EXPERIMENTAL|Cohort 3|Subjects in Cohort 3 will receive ANB-002 at a dose 3. The decision to continue enrolling in Cohort 2 or dosing in Cohort 3 will be made at the IDMC meeting.
62101425|NCT06120582|EXPERIMENTAL|Cohort 4|Exploratory cohort. Subjects in Cohort 4 (with anti-AAV5 antibodies and/or hepatitis B in anamnesis) will receive ANB-002 at the dose 3.
62101426|NCT05905289||group A|young female patients diagnosed with malignant ovarian germ cell tumors underwent fertility-sparing surgery and adjuvant chemotherapy will be retrospectively investigated
62101427|NCT05144789|ACTIVE_COMPARATOR|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
62101428|NCT05144789|ACTIVE_COMPARATOR|Active TBS-DMPFC|The active group will receive theta-burst TMS stimulation.
62101429|NCT05144789|SHAM_COMPARATOR|Sham Comparator: Sham TBS-DLPFC or DMPFC|The sham group will receive sham theta-burst TMS stimulation.
62101430|NCT05618652|ACTIVE_COMPARATOR|Clinician Coaching Immediate Intervention Arm-- Caregivers|"Clinicians who receive the intervention will participate for up to 12 months, which includes completion of didactics, 8 audio-recorded clinical encounters, 4 feedback sessions, and completion of a post-intervention brief interview and survey. After completing didactic training elements, clinicians will receive coaching and professional feedback on their communication with caregivers of children in the hospital. The investigators will provide clinicians with illustrative examples from their encounters to prompt discussion and self-reflection.~Caregivers of hospitalized children will not know if their clinician has received the communication intervention. The investigators will recruit 40 caregivers in this arm."
62101431|NCT05618652|OTHER|Clinician Coaching Wait-List Control Arm-- Caregivers|"Clinicians in the wait-list control arm will initially serve as the control arm then receive the intervention to provide feasibility and acceptability data. The clinicians randomized the control arm will undergo didactics and feedback once their pre-intervention audio-recordings are complete.~Caregivers of hospitalized children will not know if their clinician has yet received the communication intervention. The investigators will recruit 40 caregivers in this arm prior to clinicians receiving the intervention."
62101432|NCT05320796|EXPERIMENTAL|Solution|Esomeprazol MUT Sandoz® 40mg as a single dose will be dissolved in 10ml tap water to create a solution and then applied per oral
62294873|NCT04919915|NO_INTERVENTION|Control group|Households are randomly assigned to the control group. They only received the asthma education during the study period. These households receive a HEPA air cleaner at the end of the study.
62101433|NCT05320796|ACTIVE_COMPARATOR|Tablet|Esomeprazo MUT Sandozl® 40mg tablet as a single dose will be given orally
62467159|NCT04943029|EXPERIMENTAL|PD-1+Chemo+surgery+PD-1|Participants will receive neoadjuvant Carrelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection and adjuvant Carrelizumab for 16 cycles.
62101434|NCT00138632|EXPERIMENTAL|1|
62101435|NCT00138632|EXPERIMENTAL|2|
62101436|NCT00138632|PLACEBO_COMPARATOR|3|
62101437|NCT04878380|ACTIVE_COMPARATOR|Tracking|Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.
62101438|NCT04878380|EXPERIMENTAL|Goal-Setting|"Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.~During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight."
62101439|NCT03061344|EXPERIMENTAL|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
62101440|NCT06413303|EXPERIMENTAL|Experiential Classroom Group|Participants accept experiential class to establish healthy behaviors. They are also managed continuously through WeChat group chat during prenatal clinical interval.
62101441|NCT06413303|NO_INTERVENTION|Standard Clinic Prenatal Care Group|Participants accept regular routine prenatal care following Chinese standard.
62101442|NCT04762342|EXPERIMENTAL|Training Group Multiple Sclerosis|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.~Balance- and functional exercises are included after week 8."
62101443|NCT04762342|NO_INTERVENTION|Control Group Multiple Sclerosis|Habitual lifestyle including standard care.
62294874|NCT03035760|EXPERIMENTAL|1|3 mg/kg orally once daily for 5 days (n = 8)
62294875|NCT03035760|EXPERIMENTAL|2|7.5 mg/kg orally once daily for 5 days (n = 8)
62294876|NCT03035760|EXPERIMENTAL|3|15 mg/kg orally once daily for 5 days (n = 8)
62294877|NCT03035760|EXPERIMENTAL|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
62294878|NCT05825248|EXPERIMENTAL|Reflex integration + fine and gross motor treatment|For 20 minutes per week for 8 weeks, this group will recieve 10 minutes of fine and gross motor treatment and 10 minutes of reflex integration exercises from the Move Play Thrive program.
62467160|NCT05309941|EXPERIMENTAL|Internal Cues Messaging|Participants will view a five-minute video focusing on intuitive eating principles.
62101444|NCT02938650|OTHER|Nitrosomonas eutropha spray|Subjects will receive nitrosmonas eutropha spray that they will apply twice a day.
62294879|NCT05825248|ACTIVE_COMPARATOR|Fine and gross motor treatment only|For 20 minutes per week for 8 weeks, this group will recieve 20 minutes of standard occupational therapy treatment consisting of fine and gross motor intervention.
62101445|NCT04449406||Individuals at risk of developing PDAC|"* Symptomatic participants (via direct recruitment to UroPanc and via study/tissue bank(s) i.e. UCL ADEPTs study)~* Asymptomatic participants (via study/tissue bank(s) i.e. University of Liverpool EUROPAC registry)~Medical history, demographic information and concomitant medications information will be collected at baseline, together with blood and urine samples. Urinary biomarkers and plasma CA19-9 will be measured and the results compared with imaging data (and pathology, if it becomes available)."
62294880|NCT04012749|ACTIVE_COMPARATOR|Advance directive|Messaging and advance directive distribution. All arms receive physician advance care planning education at the clinic level.
62294881|NCT04012749|ACTIVE_COMPARATOR|Advance directive and Prepare|Messaging and advance directive distribution plus introduction to the Prepare For Your Care website. All arms receive physician advance care planning education at the clinic level.
62101446|NCT01743729|EXPERIMENTAL|Lifitegrast|Lifitegrast Ophthalmic Solution (5.0%)
62101447|NCT01743729|PLACEBO_COMPARATOR|Placebo|
62101448|NCT03392337|EXPERIMENTAL|Open Label Narrowband UVB phototherapy|Open Label Narrowband UVB phototherapy for 12 weeks.
62101449|NCT02055482|EXPERIMENTAL|BAY85-3934|
62101450|NCT02055482|ACTIVE_COMPARATOR|Darbepoetin|
62101451|NCT06361940|EXPERIMENTAL|Standard-of-care Endocrine therapy|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy.
62294882|NCT04012749|ACTIVE_COMPARATOR|Advance directive, Prepare and Facilitator|Messaging and advance directive distribution, introduction to the Prepare For Your Care website, plus patient engagement from a trained facilitator who also can interact with the primary care physician. All arms receive physician advance care planning education at the clinic level.
62294883|NCT02461017||Endotracheal Leak|Assess for Audible Endotracheal Leak; Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
62294884|NCT05934214||immune-related adverse event reaction|Reports of identified immune-related adverse event reaction
62294885|NCT05448079|EXPERIMENTAL|Sexual counseling intervention group according to the PLISSIT model|Sexual counseling according to the PLISSIT model, randomized pretest-posttest
62294886|NCT05448079|EXPERIMENTAL|control|Non-counseling group
62467161|NCT05309941|ACTIVE_COMPARATOR|External Cues Messaging|Participants will view a five-minute video focusing on traditional nutrition education principles.
62101452|NCT01794377|ACTIVE_COMPARATOR|40 of an endurance training|Endurance training at 50% of VO2 peak measured by indirect calorimetry. Dietary Supplement: supplementation in fruits and vegetables.
62294887|NCT02856334||Chronic pelvic pain|Women with chronic pelvic pain
62294888|NCT02856334||Control group|Healthy women
62294889|NCT00158184|ACTIVE_COMPARATOR|Rx Opioid Abusers|Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
62294890|NCT00158184|ACTIVE_COMPARATOR|Rx Opioid Non-Abusers|Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.
62467162|NCT02418637|EXPERIMENTAL|Farm workers|This is a one arm intervention including farm workers and owners
62101453|NCT01794377|EXPERIMENTAL|30 minutes of a high intensity training|"This arm consist of an interval strength training for 30 min on bicycle ergometer (which include strengthening exercises in an high intensity interval training).~Dietary Supplement: supplementation in fruits and vegetables."
62101454|NCT03201809|EXPERIMENTAL|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
62101455|NCT03201809|ACTIVE_COMPARATOR|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
62467163|NCT04551261|EXPERIMENTAL|Part A|Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.
62101456|NCT02983214|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75 mg/day
62101457|NCT02983214|ACTIVE_COMPARATOR|Clopidogrel plus cilostazol|Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day
62101458|NCT06025734|EXPERIMENTAL|TTNS Treatment Arm|"Treatments Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session) During treatments, patient may experience a tingling sensation in the foot/ankle. Patient may have discomfort in the area when first adjusting to the correct amount of stimulation for patient.~Patient will have a visit with your doctor after 6 weeks of treatment at Scottish Rite. If patient have a good response to the treatments, they may be extended for another 6 weeks.~After treatments Bladder diary (completed at home, on paper over a 3-day period, recording catheterization volumes and amount of leakage by weighing pads/diapers) Complete questionnaires on paper (about 10 minutes) Complete urodynamic testing at Children's Medical Center (approximately 45-60 minutes)."
62101459|NCT06631274|OTHER|8 weeks of group counseling delivered in virtual environment|The treatment to be piloted is a 8 week virtual group counseling intervention with a focus on teaching participants skills to overcome emotional difficulties (Visit 1-4) and avoiding re-victimization (Visit 5-Visit 8).
62101460|NCT06631274|NO_INTERVENTION|control group|Participants in this arm do not receive the intervention at the same time as the treatment group.
62101461|NCT06487325||Group S1|Liver biopsy showed mild fatty liver
62294891|NCT02243384|EXPERIMENTAL|Laparoscopic Hepatectomy|Laparoscopic Hepatectomy
62294892|NCT02243384|ACTIVE_COMPARATOR|Radiofrequency Ablation|Radiofrequency Ablation
62294893|NCT01159262|EXPERIMENTAL|Dexmedetomidine 0.05 mcg/kg|Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
62294894|NCT01159262|EXPERIMENTAL|Dexmedetomidine 0.1 mcg/kg|Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
62467164|NCT04551261|EXPERIMENTAL|Part B|Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.
62467165|NCT05207956|EXPERIMENTAL|Enhanced Electronic Platform|A basic electronic platform for data collection that contains additional features designed to increase motivation to collect data and ease of data collection.
62294895|NCT01159262|EXPERIMENTAL|Dexmedetomidine 0.2 mcg/kg|Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
62467166|NCT05207956|ACTIVE_COMPARATOR|Electronic Platform Not Enhanced|A basic electronic platform for data collection.
62662766|NCT02332707|EXPERIMENTAL|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
62101462|NCT06487325||Group S2|Liver biopsy showed moderate fatty liver
62101463|NCT06487325||Group S3|Liver biopsy showed severe fatty liver
62101464|NCT00506519|EXPERIMENTAL|AT-150|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 125-175%
62101465|NCT00506519|EXPERIMENTAL|AT-250|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 225-275%
62101466|NCT00506519|ACTIVE_COMPARATOR|Control|The best standard treatment for the underlying condition only
62101467|NCT03596424|ACTIVE_COMPARATOR|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
62101468|NCT03596424|ACTIVE_COMPARATOR|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
62467167|NCT04141202||Exercise group|
62467168|NCT05417230|EXPERIMENTAL|RC48-ADC plus envafolimab|
62467169|NCT03661593|EXPERIMENTAL|Cataract guideline|In this patients we follow cataract guideline and correct the patients ametropia during the cataract surgery
62467170|NCT03661593|NO_INTERVENTION|Standard refraction|The patients gets an IOL ensuring his preoperatively refraction
62467171|NCT03666585|ACTIVE_COMPARATOR|mobile application actuated rehabilitation exercise guidance|
62467172|NCT03666585|ACTIVE_COMPARATOR|routine rehabilitation exercise guidance|
62467173|NCT02629094|EXPERIMENTAL|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
62467174|NCT05317052|EXPERIMENTAL|Massage|Massage therapy
62467175|NCT05317052|EXPERIMENTAL|Music|Music therapy
62467176|NCT05317052|NO_INTERVENTION|Control|Control
62467177|NCT01804777|EXPERIMENTAL|Amiloride 10 mg, 20 mg, and diet|Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
62467178|NCT01804777|ACTIVE_COMPARATOR|HCTZ 12.5 mg, 25 mg and diet|HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet
62101469|NCT03596424|ACTIVE_COMPARATOR|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
62101470|NCT02223793|EXPERIMENTAL|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
62101471|NCT02223793|EXPERIMENTAL|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
62662767|NCT02332707|EXPERIMENTAL|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
62662768|NCT02332707|EXPERIMENTAL|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
62101472|NCT02223793|EXPERIMENTAL|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
62101473|NCT06508723|OTHER|Test Group|The group in which implants with a Ti-Ultra surface are placed.
62101474|NCT06508723|OTHER|Control Group|The group in which implants with a Ti-Unite surface are placed.
62294896|NCT04833439|EXPERIMENTAL|Fasting Mimicking Diet|2 cycles of 3-day fasting mimicking spaced by a 2 week interval
62294897|NCT06112587|EXPERIMENTAL|Migraine and tension-type headache patients|Patients diagnosed by a neurologist following the 3rd edition of the International Classification of Headaches Disorders (ICHD-III)
62467179|NCT00913406|EXPERIMENTAL|1|Experimental=Standard formula with lutein added to the formula
62467180|NCT00913406|ACTIVE_COMPARATOR|2|Active Comparator=Standard formula
62467181|NCT02478957|EXPERIMENTAL|PA101|PA101, 40 mg administered via inhalation three times daily for 6 weeks
62467182|NCT02478957|PLACEBO_COMPARATOR|Placebo|Placebo, administered via inhalation three times daily for 6 weeks
62294898|NCT01482494||Pompe suspected patients|"Patients who go to an Internal Medicine clinic for examination of a limb-girdle myopathy.~Patients with asymptomatic hyper-CK-emia. Patients with a prior diagnosis of polymyositis. Patients with a myopathy of uncertain origin and respiratory insufficiency. Patients with polymyositis unresponsive to steroid therapy"
62467183|NCT02121886|EXPERIMENTAL|Parietal peritoneum|
62467184|NCT01486121|OTHER|S.O.S.-V|
62467185|NCT01486121|NO_INTERVENTION|Standard|
62467186|NCT02644434|ACTIVE_COMPARATOR|Conventional Strategy|Patients randomized to the conventional strategy group would undergo either jailed wire technique (diameter of side branch\<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of side branch≥2.5mm).
62467187|NCT02644434|EXPERIMENTAL|Intentional Strategy|Patients randomized to the intentional strategy group would undergo either jailed balloon technique (diameter of side branch\<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of side branch≥2.5mm).
62467188|NCT01458808|EXPERIMENTAL|Group A|Composed by 21 patients treated with reduction of 2 grams of sodium reduction in their habitual diet.
62467189|NCT01458808|EXPERIMENTAL|Group B|Composed by 20 patients treated by reduction of dialysate concentration from 138 to 135 mEq/L
62467190|NCT01458808|NO_INTERVENTION|Group C|Composed by 18 patients followed without changes in dialysate sodium concentration or diet sodium amount.
62467191|NCT04572659|EXPERIMENTAL|Group intervention|
61911157|NCT04152993|EXPERIMENTAL|RNS group|This study consists in only one arm. In this arm, the patients will undergo the placement of the RNS implant and the subsequent RNS programming to optimize the PTSD symptoms.
61911158|NCT01589770|OTHER|rheumatoid arthritis patients|People who have rheumatoid arthritis underwent cMRI
61911159|NCT01589770|OTHER|controls|people who do not have RA or other inflammatory disease underwent cMRI
62101475|NCT00928200|EXPERIMENTAL|Single Arm|All patients receive Vincristine, Dexamethasone, Doxorubicin, and Cytarabine. Dexrazoxane optional on Day 1. Erwinase is started between Days 3-5 and is given every M-W-F for a total of 10 doses. Patients with CNS 1 or 2 receive Methotrexate intrathecally on Day 15. Patients with CNS 3 receive Triple Intrathecal Therapy (Methotrexate, Cytarabine and Hydrocortisone) on Days 8, 15, and 22.
62101476|NCT06063850|EXPERIMENTAL|AMT-260|Cohort 1: AMT-260 starting dose (1.0x 10E12 gc/mL). Cohort 2: AMT-260 adapted dose (6.0x 10E11 gc/mL or 3.0x 10E12 gc/mL).
62101477|NCT02502162|EXPERIMENTAL|LDN|Naltrexone HCL, 4.5 mg, Once a day.
62101478|NCT02502162|PLACEBO_COMPARATOR|Placebo|Sugar pill
62101479|NCT04879134|EXPERIMENTAL|Apomorphine Injections|
62101480|NCT04879134|PLACEBO_COMPARATOR|Placebo Injections|
62101481|NCT02454907|ACTIVE_COMPARATOR|Control|One kind of communication with the clinic will be used.
62294899|NCT05838326|ACTIVE_COMPARATOR|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a arterial oxygen pressure (PaO2) and inspiratory oxygen fraction (FiO2) ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain a peripheral saturation (SpO2) between 92 and 98%."
62467192|NCT04572659|EXPERIMENTAL|Couple intervention|
62101482|NCT02454907|EXPERIMENTAL|Experimental|A different kind of communication with the clinic will be used.
62101483|NCT06712498|ACTIVE_COMPARATOR|External oblique intercostal plan block group|After endotracheal intubation, a 22-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
62101484|NCT06712498|OTHER|control group|No Intervention
62101485|NCT05766098||Patients with papillary thyroid cancer|
62101486|NCT03001362|EXPERIMENTAL|Radical External Beam RT for Colorectal Ca|A single arm consisting of: Radical external beam RT dose of 54 Gy in 30fx with radiosensitizing chemotherapy as per institutional standard
62101487|NCT06410508|EXPERIMENTAL|Engagement Intervention Group (experimental)|As described in further detail in the study description: In addition to regular early intervention treatment for psychosis, participants in this group will receive a brief 2-module engagement focused psychotherapeutic orientation co-delivered by a mental health clinician and a peer support worker. This intervention will involve integration of principles of CBT and motivational interviewing in order to target previously identified affective and cognitive barriers to young adults' engagement in treatment. Treatment targets include: self-stigma, negative perceptions/beliefs towards healthcare, negative past experiences with psychiatric services, recover, and external vs internal locus of control. Participants will be guided through a standard therapeutic protocol adapted from the original Munson et al. (2022), trial targeting these barriers over 2 90-120 minute sessions delivered 1 month apart.
62101488|NCT06410508|NO_INTERVENTION|Treatment as Usual Group (control)|As described in further detail in the study description, control participants will receive the usual treatment provided at our early intervention for psychosis clinic. Treatment as usual includes psychiatric monitoring of lowest effective dose pharmaceutical treatment (e.g., antipsychotics), and various psychosocial interventions including CBT for psychosis when indicated, occupational therapy, family education and support sessions, and support for client's educational or vocational goals. Those in the engagement intervention group (experimental) will also receive this treatment in addition to the experimental engagement intervention.
62101489|NCT04171661|EXPERIMENTAL|SASS|SASS applied on chronic skin wounds as skin graft
62467193|NCT04572659|NO_INTERVENTION|No intervention|
61911160|NCT01615497|ACTIVE_COMPARATOR|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on alcohol and substance abuse.
61911161|NCT01615497|EXPERIMENTAL|Web-based CBT4CBT for alcohol plus TAU|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
61911162|NCT01615497|ACTIVE_COMPARATOR|Web-based CBT with minimal clinical contact|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
61911163|NCT00866008|EXPERIMENTAL|1|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
61911164|NCT00866008|EXPERIMENTAL|2|Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
61911165|NCT03033147|EXPERIMENTAL|Amoxicillin/Clavulanate Potassium|Amoxicillin/Clavulanate Potassium 875 mg-125 mg orally 30 minutes before root canal treatment
62101490|NCT03307746|ACTIVE_COMPARATOR|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
62467194|NCT05259241|OTHER|Single arm study|"Cohort A: patients undergoing TAVR to evaluate which point-of-care test (ACT or aPTT) gives the best correlation with the coagulation status~Cohort B: patients undergoing PCI to evaluate which point-of-care test (ACT or aPTT) gives the best correlation with the coagulation status"
62467195|NCT02992938|EXPERIMENTAL|Acetazolamide|250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction
61911166|NCT03033147|PLACEBO_COMPARATOR|Placebo|placebo 30 minutes before root canal treatment
61911167|NCT02656680|EXPERIMENTAL|Continuous Enrollment (Randomized)|The Continuous Enrollment is a Facebook-delivered weight loss intervention. Participants in this arm were randomized to this Facebook group and started the intervention together. For this group, the study team continued to enroll participants through week 8.
61911168|NCT02656680|ACTIVE_COMPARATOR|Closed Enrollment (Randomized)|Closed Enrollment is a Facebook-delivered weight loss intervention. Participants in this arm were randomized to this Facebook group and started the intervention together. No additional participants were added to this group during the study.
61911169|NCT02656680|OTHER|Continuous Enrollment (Non-Randomized)|The Continuous Enrollment is a Facebook-delivered weight loss intervention. For this group, the study team continued to enroll participants through week 8. This arm captures only those participants that were added to the group during these 8 weeks. They were enrolled in the study after the original 80 participants were randomized.
61911170|NCT02917057||Exenatide once weekly initiators|Type 2 diabetes patients who initiated exenatide once weekly treatment during the index period
61911171|NCT02917057||Basal Insulin initiator cohort|Type 2 diabetes patients who initiated basal insulin treatment in the index period
61911172|NCT03520127||Females, 18 years of age or older|Females, 18 years of age or older, who will undergo the Intact procedure
61911173|NCT03400956|EXPERIMENTAL|Vilaprisan (A1)|Vilaprisan in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
61911174|NCT03400956|EXPERIMENTAL|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
61911175|NCT03400956|EXPERIMENTAL|Vilaprisan+Placebo (B2)|Vilaprisan in treatment period 1 for 12 weeks, and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
61911176|NCT05631678|EXPERIMENTAL|the effect of oral rifampicin on the pharmacokinetics of ASK120067 tablets|Take ASK120067 tablets orally once on the first day at 160mg in fast condition；Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASK120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
61911177|NCT05631678|EXPERIMENTAL|effect of oral itraconazole on the pharmacokinetics of ASK120067 tablets|Take ASK120067 tablets orally once on the first day at 80mg in fast condition；Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
61911178|NCT05535205|ACTIVE_COMPARATOR|Face-to-face preoperative assessment group|The face-to-face screening consist of two 20-minute consecutive consultations with a nurse and subsequently an anesthesiologist or PA. The nurse obtains basic patient health information, provides information on the upcoming hospital admission, and gives advice in lifestyle procedures around the surgery. The physician assesses the patient's health status based on co-morbidities, medication use, previous surgery, and lifestyle habits to predict preoperative risks and determine the optimal anesthetic technique. Additional diagnostics, such as blood tests or electrocardiogram, can be ordered and optional anesthetic techniques will subsequently be presented and discussed with the patient, after which informed consent will be obtained.
61919838|NCT02017171|EXPERIMENTAL|Allopurinol|Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function
61919839|NCT02017171|PLACEBO_COMPARATOR|Placebo|Oral placebo tablets
61919840|NCT01860573|ACTIVE_COMPARATOR|Standard amino acids|Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day
62101491|NCT03307746|ACTIVE_COMPARATOR|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
62467196|NCT02992938|PLACEBO_COMPARATOR|Placebo|An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction
62467197|NCT05049226|EXPERIMENTAL|Two doses of SV at interval 60 to less than 90 days|Participants who have received two doses of SV at interval 60 to less than 90 days
61919841|NCT01860573|EXPERIMENTAL|High amino acids|Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth
61919842|NCT03463876|EXPERIMENTAL|SHR-1210+Apatinib|Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
62101492|NCT06048341|EXPERIMENTAL|FNB|sono-guided femoral nerve injection with 20ml ropivacaine
62101493|NCT06048341|PLACEBO_COMPARATOR|No FNB|sono-guided femoral nerve injection with 20ml 0.9% saline
62101494|NCT06345105||AI group|AI monitoring of effective withdrawal time
62467198|NCT05049226|EXPERIMENTAL|Two doses of SV at interval 90 to less than 120 days|Participants who have received two doses of SV at interval 90 to less than 120 days
62467199|NCT05049226|EXPERIMENTAL|Two doses of SV at interval 120 to 180 days|Participants who have received two doses of SV at interval 120 to 180 days
62467200|NCT05400785|ACTIVE_COMPARATOR|Active CRM|
62467201|NCT05400785|SHAM_COMPARATOR|Sham CRM|
62662769|NCT02332707|EXPERIMENTAL|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
61911179|NCT05535205|ACTIVE_COMPARATOR|Digital preoperative assessment group|Patients in the digital preoperative assessment group are asked to complete an electronic screening questionnaire through the digital patient portal of the hospital. The questionnaire was designed by the anesthetic department physicians and consisted of 50 health related questions. Through the same digital patient portal, patients have access to animated instructional videos that provides information on anesthetic techniques, preoperative lifestyle advises and procedures around the upcoming surgery. The videos can be reviewed at any desired moment in time. A telephone appointment is scheduled solemnly to decide on the anesthesia technique and obtain informed consent since this process was technically not available in the electronic portal. Physicians were thoroughly instructed not to provide more information or answer questions. Patients are instructed to complete the electronic screening questionnaire and assess the animated videos before the scheduled appointment with the physician.
61911180|NCT01574001|EXPERIMENTAL|Antismoking intervention with minimal early follow-up|"an intervention according to the 5A's model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke"
61911181|NCT01574001|ACTIVE_COMPARATOR|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
62101495|NCT01189955|ACTIVE_COMPARATOR|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
62101496|NCT01189955|ACTIVE_COMPARATOR|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
62308224|NCT03180762|EXPERIMENTAL|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics \[PK\] of preceding dose levels; no more than 50 percent (%) of the highest dose tested \[though as high as possible within this restriction\] and considered well tolerated in Part 1) under fed conditions on Day 1.
62662770|NCT02332707|EXPERIMENTAL|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
62662771|NCT02332707|EXPERIMENTAL|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
62662772|NCT02332707|EXPERIMENTAL|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
62662773|NCT00314106|EXPERIMENTAL|TBI 1200 cGy + TIL +HD IL-2, prior IL-2|Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m\^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).
62662774|NCT00314106|EXPERIMENTAL|TBI 1200 cGy + TIL +HD IL-2, no prior IL-2|Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m\^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)
62662775|NCT00143572|OTHER|1|
62662776|NCT01023997||primary open-angle glaucoma|
62662777|NCT01023997||ocular hypertension patients|
62662778|NCT01023997||normal controls|
62662779|NCT01023997||Exfoliation patients|patients with exfoliation syndrome or exfoliative glaucoma
62662780|NCT06343701||Unilateral cerebral palsy|Cerebral Palsy (CP) is a group of permanent disorders in activity limitation, motor and posture development due to non-progressive damage to the developing fetus or infant brain. In spastic unilateral CP, involvement occurs unilaterally in one half of the body.
62662781|NCT06343701||Bilateral cerebral palsy|Cerebral Palsy (CP) is a group of permanent disorders in activity limitation, motor and posture development due to non-progressive damage to the developing fetus or infant brain. In spastic bilateral CP, involvement is seen bilaterally in all 4 extremities.
62662782|NCT06343701||Typically developing children|Children with typical development are children who behave in accordance with the developmental level expected for their age.
62662783|NCT05256368||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-80
62662784|NCT02099552||XLHED|Those with the condition of XLHED
62662785|NCT03934801||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
62662786|NCT00590876||1|T1DM patients with a history of severe hypoglycemia and/or hypoglycemia unawareness who have been selected based upon this history to undergo islet cell transplantation at the University of Minnesota.
62294900|NCT05838326|ACTIVE_COMPARATOR|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300 (as described above), patients will be randomly assigned to a second 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
62294901|NCT02604004|ACTIVE_COMPARATOR|Period 1|Epivir ® tablet 150-mg single dose (drug reference)
62294902|NCT02604004|EXPERIMENTAL|Period 2|Lamivudine 150-mg tablet single dose (drug test)
61911182|NCT01574001|EXPERIMENTAL|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
61911183|NCT06087419|EXPERIMENTAL|combination drug group|
62294903|NCT01311778|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo
62294904|NCT01311778|EXPERIMENTAL|CBD 400 mg|Subjects will receive 400 mg CBD
62294905|NCT01311778|EXPERIMENTAL|CBD 800mg|Subjects will receive 800 mg CBD
61911184|NCT05196711|EXPERIMENTAL|MAX-40070|MAX-40070 is a liniment with two dose specification: 0.5%, 2% (Weight/Volume). In SAD phase, MAX-40070 will be applied once in each cohort, and there will be 6 cohorts. For the first 2 cohorts, 0.5% MAX-40070 will be used. For the rest 4 cohorts, 2% MAX-40070 will be used. In MAD phase, MAX-40070 2% will be applied once daily for consecutive 14 days in each cohort.
61911185|NCT05196711|PLACEBO_COMPARATOR|Placebo|Placebo is a liniment with two dose specification: 0.5%, 2% (Weight/Volume) to match with active drug in 2:1 manner ( 6 active: 2 placebo in each cohort).
61911186|NCT00471614|EXPERIMENTAL|1|NucleomaxX
61911187|NCT00471614|PLACEBO_COMPARATOR|2|Placebo
62294906|NCT03304522|EXPERIMENTAL|VX-150|
62294907|NCT03304522|PLACEBO_COMPARATOR|Placebo|
62294908|NCT00110305|EXPERIMENTAL|TMC278 25 mg|Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
62294909|NCT00110305|EXPERIMENTAL|TMC278 75 mg|Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
62294910|NCT00110305|EXPERIMENTAL|TMC278 150 mg|Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
62294911|NCT00110305|ACTIVE_COMPARATOR|Efavirenz|Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
62294912|NCT00002586|EXPERIMENTAL|13-cis retinoic acid|13-cis retinoic acid 50 mg/d
61911188|NCT03670420|EXPERIMENTAL|Medical honey in addition to standard care|In addition to the usual care provided by the maternity unit, women allocated to this group apply honey on first and second degree perineal tears, episiotomies and anterior vulvar tears twice a day for four days from randomization.
61911189|NCT03670420|NO_INTERVENTION|Standard care|This group benefits from the standard care offered by the maternity: hygiene advice, analgesics, ice packs, buoys and positioning.
61911190|NCT04705844|EXPERIMENTAL|Adalimumab|single dose of adalimumab(160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen
61911191|NCT04705844|PLACEBO_COMPARATOR|Placebo|single dose of placebo (administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen
62294913|NCT00002586|EXPERIMENTAL|13-Cis Retinoic Acid and Tocopherol|13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
62467202|NCT00006365|EXPERIMENTAL|EBRT to the prostate followed by brachytherapy|Patients received 45 Gy of external beam radiation therapy (EBRT)to the prostate followed (within 2 to 6 weeks) by permanent iodine (I-125) brachytherapy 108 Gy.
62662787|NCT00590876||2|T1DM patients (C-peptide negative) who are matched for age, gender, and duration of diabetes, who also have a history of severe hypoglycemia and/or hypoglycemia unawareness meeting the criteria for islet cell transplantation. The hemoglobin A1c for each of these subjects will fall within 1% of the islet transplant recipient to whom they are matched.
62662788|NCT00590876||3|Nondiabetic subjects (fasting plasma glucose \< 110 mg/dl) who are matched for age and gender to the islet transplant recipient to whom they are matched.
62662789|NCT01235819|ACTIVE_COMPARATOR|Insulin alone|Type 1 DM only on Insulin
62662790|NCT01235819|ACTIVE_COMPARATOR|Insulin and Exenatide|Newly detected Type 1 DM on Insulin and exenatide
62662791|NCT01235819|ACTIVE_COMPARATOR|Insulin and Sitagliptin|Newly detected Type 1 DM using Insulin and Sitagliptin
62662792|NCT03969420|EXPERIMENTAL|Lead-In Cohort: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration \<90 days)
62662793|NCT03969420|EXPERIMENTAL|Lead-In Cohort: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
62662794|NCT03969420|EXPERIMENTAL|Stage 1: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration \<90 days)
62662795|NCT03969420|EXPERIMENTAL|Stage 1: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
62662796|NCT04718753|EXPERIMENTAL|Mindful Breathing Group|Mindful breathing intervention which has been used in mindfulness-based interventions
61911192|NCT03363022|EXPERIMENTAL|Standard Medical Treatment+Fecal Microbiota Transplant|
61911193|NCT03363022|ACTIVE_COMPARATOR|Standard Medical Treatment+Placebo|
61911194|NCT02102503|EXPERIMENTAL|MI and Medication review|The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.
61911195|NCT02102503|ACTIVE_COMPARATOR|Standard treatment|Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months.
61911196|NCT03093584|ACTIVE_COMPARATOR|Auricular stimulation|Auricular acupuncture with indwelling fixed auricular acupuncture needles
61911197|NCT03093584|EXPERIMENTAL|Expressive writing|Expressive writing - sharing the emotional expectations in front of forthcoming exam
61911198|NCT03093584|NO_INTERVENTION|No intervention|No intervention, just observation and monitoring of outcome measures
61911199|NCT01115192|EXPERIMENTAL|Group A|Patients with chronic blepharitis, that will be treated with blephacura
61911200|NCT01115192|EXPERIMENTAL|Group B|Patients with chronic blepharitis that will be treated with diluted baby shampoo
62294914|NCT00002586|NO_INTERVENTION|Observation|Observation
62294915|NCT03652922|EXPERIMENTAL|Propranolol|
62294916|NCT03652922|PLACEBO_COMPARATOR|Placebo|
62467203|NCT03858777|ACTIVE_COMPARATOR|Sarcoidosis patients without evidence of active myocarditis|A single blood draw.
62662797|NCT04718753|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
62662798|NCT03233750|EXPERIMENTAL|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
62662799|NCT03233750|ACTIVE_COMPARATOR|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
62662800|NCT02858258|ACTIVE_COMPARATOR|Standard Arm A|"R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM"
62662801|NCT02858258|EXPERIMENTAL|Experimental Arm A+I|"R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)"
62662802|NCT02858258|EXPERIMENTAL|Experimental Arm I|"R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)"
62101497|NCT06487364||Physiotherapy Group|There will be only one group in the study. Patients will only be applied to the physiotherapy program recommended by the specialist physician and physiotherapist. It is not possible to apply any additional treatment within the scope of the study.
61911201|NCT03452449||Lumbar spine surgery|Patients undergoing planned lumbar spine surgery
61911202|NCT01230203|OTHER|Computed tomography scan versus color duplex ultrasound|
61911203|NCT02867553|EXPERIMENTAL|Rituximab by intravenous|attack treatment (4 slow intravenous perfusions of rituximab at a dose of 375 mg / m2 on day 1, day 8, day 15 and day 22) and maintenance treatment (intravenous perfusions of rituximab at a dose of 375 mg / m2 every 2 months for 2 years).
62101498|NCT06313528|EXPERIMENTAL|LY3437943|LY3437943 administered subcutaneously (SC)
62662803|NCT01428245|EXPERIMENTAL|Progesterone, estrace|"oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days~oral estrace, 0.5-1 mg once a day for seven days"
62662804|NCT03325439|EXPERIMENTAL|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
61911204|NCT02867553|ACTIVE_COMPARATOR|multi-field radiotherapy|multi-fields radiotherapy with a dose between 20 and 30 gray and a fractionated dose over 2 at 3 weeks.
61911205|NCT01453582|EXPERIMENTAL|Propolis|Total Flavonoids of Propolis dropping pill
61911206|NCT01453582|PLACEBO_COMPARATOR|Placebo|Simulant of total Flavonoids of Propolis dropping pill
61911207|NCT03609593|EXPERIMENTAL|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
61911208|NCT00170690|EXPERIMENTAL|1|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
61911209|NCT00170690|EXPERIMENTAL|2|Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
62101499|NCT06313528|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62101500|NCT05862285|EXPERIMENTAL|Roche IMP(s) Monotherapy|Participants will continue to receive Roche IMP(s) monotherapy as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participants non-compliance, if local access becomes available or study termination by the Sponsor, whichever occurs first.
62101501|NCT05862285|EXPERIMENTAL|Roche Combined Agents|Participants will continue to receive Roche IMP(s) in combination with other agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participants non-compliance, if local access becomes available or study termination by the Sponsor, whichever occurs first.
62101502|NCT06614374|PLACEBO_COMPARATOR|Control group|Subjects will receive equivalent amounts of refined olive oil daily.
62101503|NCT06614374|EXPERIMENTAL|Low-dose fish oil group|Subjects will receive four fish oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day
62101504|NCT06614374|EXPERIMENTAL|High-dose fish oil group|Subjects will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day
62662805|NCT03807843|EXPERIMENTAL|V184|Participants will receive 2 vaccinations with V184 administered via intramuscular (IM) injection at 5 × 10\^5 Tissue Culture Infectious Dose (TCID50) per dose on Days 0 and 28.
62101505|NCT05099965|ACTIVE_COMPARATOR|Vaccine Group|60 participants will receive CMV-MVA Triplex® containing 5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine Encoding CMV Antigens by intramuscular (IM) deltoid injections.
61911210|NCT01263912|ACTIVE_COMPARATOR|LCPUFA Supplement|DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
61911211|NCT01263912|PLACEBO_COMPARATOR|A Placebo|400 mg/day corn oil
61911212|NCT01607827|ACTIVE_COMPARATOR|Polyp removal upon insertion and withdrawal|
62662806|NCT03807843|PLACEBO_COMPARATOR|Placebo|Participants will receive 2 injections of sterile physiological saline administered via IM injection on Days 0 and 28.
62662807|NCT02516436|EXPERIMENTAL|BEMA Buprenorphine NX|Buprenorphine with naloxone in a buccal film
62662808|NCT02516436|ACTIVE_COMPARATOR|Buprenorphine|Buprenorphine in a buccal film
61911213|NCT01607827|NO_INTERVENTION|Polyp removal upon withdrawal only|
61911214|NCT02427178|EXPERIMENTAL|Open label|"Hematopoietic allogeneic stem cells will be transplanted:~HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight."
61911215|NCT04469829|EXPERIMENTAL|secukinumab|patients with psoriasis and metabolic syndrome candidate for treatment with secukinumab standard doses
61911216|NCT04469829|ACTIVE_COMPARATOR|methotrexate|patients with psoriasis and metabolic syndrome candidate for treatment with methotrexate dosed 15 mg/week
62101506|NCT05099965|PLACEBO_COMPARATOR|Placebo Group|30 participants will receive a volume of placebo (7.5% Lactose in phosphate-buffered saline \[PBS\]) that matches the volume of the active vaccine injection by IM deltoid injections.
62101507|NCT05464108||Gastric intestinal metaplasia observed by IEE|Get pictures from gastric antrum body and angle by image-enhanced endoscopy in order to calculate the EGGIM score.
62101508|NCT05247840||diabetic children|Children aged 5-18 years (boys, girls) with type 1, type 2 and monogenic diabetes mellitus who are treated at the Endocrinology Department and Outpatient Clinic of Heim Pál National Pediatric Institute (HOGYI, Budapest, Hungary) will be enrolled. Definition of diabetes is based on the American Diabetes Association (ADA) criteria. All patients who meet the inclusion criteria will be informed of the possibility of taking part in the INTACT Trial.
62101509|NCT05247840||healthy children|Healthy children aged 5-18 years (boys, girls) without any acute or chronical disease will be will enrolled and the same tests will be performed on them as in diabetic children. Children with voided volume \<20 mL, postvoid residual volume \>15%, and signs of an overstretched bladder \[voided volume more than: 30 x age (years) + 30 mL\] will be excluded.
62662809|NCT02512419|EXPERIMENTAL|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on Social Cognitive Theory (SCT) and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals).
61911217|NCT03471572||1|Ovarian Cancer
61911218|NCT01761032||Infrequent tanners|Individuals who tan less than twice a week and do not meet modified DSM-IV criteria for tanning addiction.
62101510|NCT03528629|EXPERIMENTAL|Safety Part Arm A (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
62101511|NCT03528629|EXPERIMENTAL|Safety Part Arm B (IMAB362 dose-3)|Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).
62101512|NCT03528629|EXPERIMENTAL|Expansion Part (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
62662810|NCT02512419|ACTIVE_COMPARATOR|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
61911219|NCT01761032||Compulsive Tanners|Individuals who tan more than 3 times per week in a tanning bed. Tanning must cause disruption in daily functioning. Must meet modified DSM-IV criteria for tanning addiction
61911220|NCT01967381|PLACEBO_COMPARATOR|Arm 1|Subjects will be maintained on oral placebo.
61911221|NCT01967381|EXPERIMENTAL|Arm 2|Subjects will be maintained on oral oxazepam (Serax®).
61911222|NCT01967381|EXPERIMENTAL|Arm 3|Subjects will be maintained on oral naltrexone (Revia®).
62101513|NCT00182520|EXPERIMENTAL|1|Topiramate
62662811|NCT01660542|EXPERIMENTAL|doxorubicin/cyclophosphamide|Neoadjuvant Chemotherapy with Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide
62662812|NCT03228914|ACTIVE_COMPARATOR|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
61911223|NCT01967381|EXPERIMENTAL|Arm 4|Subjects will be maintained on oral naltrexone (Revia®) and oral oxazepam (Serax®).
62662813|NCT03228914|ACTIVE_COMPARATOR|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
62662814|NCT05405842|EXPERIMENTAL|Gastroparesis|Patients diagnosed with Gastroparesis.
62662815|NCT05405842|EXPERIMENTAL|Functional Dsypepsia|Patients diagnosed with Functional Dsypepsia.
62662816|NCT05405842|EXPERIMENTAL|Healthy Controls|Healthy volunteers (without Functional Dsypepsia or Gastroparesis)
62662817|NCT03227237||Case group|Introduction was given about research and researcher to participants. Got the assent from participants, consent from parents and collected baseline data (demographic variable, specific IPR variable) from the participants. Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants.Participants were asked to fill out IPR related information of pre delinquent period with paper \& pencil mode of technique. It took for each group of participants about 40 minutes. Collected data regarding conduct variables from parents with interview technique. On each day 8-16 participants were covered.
62662818|NCT03227237||Control group|Introduction was given about research and researcher to participants. Confirmed telephonic consent from Parents.Collected baseline data (demographic variable, specific IPR variable) from the participants.Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants. Participants were asked to fill out IPR related information of their past life from before 2 years with paper \& pencil mode of technique. It took for each group of participants about 40 minutes. On each day 8-20 participants were covered Got the written consent form parents and collected data regarding conduct variables from parents with interview technique.
61911224|NCT00510965|EXPERIMENTAL|A|
61911225|NCT02684890||Tinnitus patients|Patients with tinnitus lasting over 3 months
61911226|NCT02684890||Non-tinnitus patients|Patients without tinnitus
61911227|NCT03911843|EXPERIMENTAL|CASES|Of eligible subjects, 26/64 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months
62101514|NCT00182520|PLACEBO_COMPARATOR|2|placebo
62101515|NCT06634537|EXPERIMENTAL|Active Comparator: Insoles soft and hard and barefoot|Experimental: Active Comparator: Insoles soft The pattern will be performed 3 times per day (10 repetitions, 30 seconds each repetition). A daily Active Comparator: Insoles hard and barefoot en 3 month and 6 month.
62101516|NCT06634537|EXPERIMENTAL|Active Comparator: Insoles hard and soft and barefoot|Experimental: Active Comparator: Insoles hard The pattern will be performed 3 times per day (10 repetitions, 30 seconds each repetition). A daily Active Comparator: Insoles hard and barefoot en 3 month and 6 month.
62101517|NCT06634537|EXPERIMENTAL|Active Comparator: barefoot and insoles hard and soft|Experimental: Active Comparator: barefoot The pattern will be performed 3 times per day (10 repetitions, 30 seconds each repetition). A daily Active Comparator: Insoles hard and barefoot en 3 month and 6 month.
62294917|NCT01797718|ACTIVE_COMPARATOR|Testosterone|\~1mg/kg every 4 weeks for 6 months
62662819|NCT04665232||Patients affected by autoimmune diseases|Infertile patients suffering from autoimmune diseases to be subjected to IVF in which the luteal phase has been supplemented with 25 mg /die of aqueous subcutaneous progesterone
61911228|NCT03911843|ACTIVE_COMPARATOR|CONTROLS|Others 38/64 subjects joined to the study as data contributors, and were entered as controls (CONTR).
61911229|NCT02990247|EXPERIMENTAL|AMARS|Evaluation the resting ventilatory flow by applying a new technique called anharmonic morphological analysis of the respiratory signals (AMARS).
62101518|NCT05446389|EXPERIMENTAL|Intervention Group|Infants randomized in to the experimental group will receive the PAL intervention 2 times a week until the infant transitions to room air or \< 2L high flow nasal cannula and is able to begin attempting feeds by mouth. The PAL is an FDA cleared medical device that has a sensor that will connect to the infant's pacifier and can read the infant's suck. Then, the device plays music as positive reinforcement to help improve sucking skills. This intervention typically lasts about 15 minutes and is implemented while the infant is receiving gavage feeds.
62101519|NCT05446389|NO_INTERVENTION|Control Group|Infants randomized in to the control group will not receive music therapy intervention throughout NICU admission.
62101520|NCT06629558|ACTIVE_COMPARATOR|0.5%w/v Nano- silver nitrate solution|0.5% weight by volume(w/v) Nano- silver nitrate solution for bronchoscopic lung volume reduction in management of localized emphysema
62662820|NCT04792268|EXPERIMENTAL|Electronic clinical decision support|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm. An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~Automated electronic decision support will be provided as a combination of visual prompts on the individual patient's dashboard, accessed by clinicians when they view a patient record on the electronic health record supplemented by an email sent to the NHS Trust email account addresses of the participating ward clinician(s).~Alerts will include locally approved guideline-based recommendations for clinician-led monitoring and management of dysglycaemia and known diabetes, tailored to the individual patient based upon reported HbA1c values."
62662821|NCT04792268|NO_INTERVENTION|Treatment as usual|Clinicians will not have access to eCDSS on wards recruited to this arm and will deliver care as usual.
62662822|NCT02200081|EXPERIMENTAL|MGN1703|MGN1703, solution in Dulbecco's Phosphate-Buffered Saline (DPBS), 2 mL of 60 mg/4 mL (15 mg/mL), administered SC at 2 application sites twice weekly
62662823|NCT02200081|OTHER|Standard of care|Continous first line therapy
61911230|NCT05249335|EXPERIMENTAL|OST|2 days split dosing regimen
61911231|NCT05249335|ACTIVE_COMPARATOR|2L-PEG/Asc|2 days split dosing regimen
62101521|NCT06629558|ACTIVE_COMPARATOR|0.5%w/v silver nitrate solution|0.5%w/v silver nitrate solution for bronchoscopic lung volume reduction in management of localized emphysema
62101522|NCT06043271|EXPERIMENTAL|The EMPOWER Program|The EMPOWER Program (Sung et al., 2021) is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The SSI includes 5 elements based on the components of CBT.
62294918|NCT01797718|ACTIVE_COMPARATOR|Letrozole|2.5mg daily for 6 months
62467204|NCT03858777|EXPERIMENTAL|Sarcoidosis patients with evidence of active myocarditis|Two blood draws 2 months apart.
62662824|NCT03860753|EXPERIMENTAL|Pioglitazone|
62662825|NCT03860753|PLACEBO_COMPARATOR|Placebo|
62662826|NCT03062839|EXPERIMENTAL|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
62662827|NCT03062839|PLACEBO_COMPARATOR|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
61911232|NCT02706223|EXPERIMENTAL|Pharmacist Led|This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
61911233|NCT02706223|EXPERIMENTAL|Nurse Led|This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
61911234|NCT03240744|EXPERIMENTAL|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
61911235|NCT01622634|ACTIVE_COMPARATOR|Higher Protein Diet (PRO)|
61911236|NCT01622634|ACTIVE_COMPARATOR|Higher Carbohydrate Diet (CARB)|
61911237|NCT01622634|ACTIVE_COMPARATOR|PRO & Interval Exercise (PRO+EX)|
61911238|NCT01622634|ACTIVE_COMPARATOR|CARB & Interval Exercise (CARB+EX)|
61911239|NCT02730143|EXPERIMENTAL|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure after 6 days at low altitude
61911240|NCT00555308|EXPERIMENTAL|one|undergo EDTU
61911241|NCT03294577|ACTIVE_COMPARATOR|TAC + Pegfilgrastim|"Phase 3:TAC + Pegfilgrastim (6 mg)+ D5W placebo~D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W"
61911242|NCT03294577|EXPERIMENTAL|TAC + Pegfilgrastim + Plinabulin|Phase 3: TAC+ Plinabulin (40 mg) + Pegfilgrastim (6 mg)
61911243|NCT03866395|NO_INTERVENTION|Control Group|drug therapy according to the guidelines
61911244|NCT03866395|EXPERIMENTAL|Ivabradine Group|drug therapy according to the guidelines + Ivabradine 5 mg twice a day
61911245|NCT02306031|PLACEBO_COMPARATOR|placebo (ARTIFICIAL TEAR)|control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations.
61911246|NCT02306031|ACTIVE_COMPARATOR|diclofenac sodium drop|case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.. Theses drops continued up to 6 weeks with the same dose after operations.
61911247|NCT05550207|EXPERIMENTAL|AXS-07 (meloxicam-rizatriptan)|Up to 8 weeks
61911248|NCT02842905|ACTIVE_COMPARATOR|Control Group|Fitting Audiologist completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
61911249|NCT02842905|EXPERIMENTAL|Test Group|Participant's physician completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
62662828|NCT05813496|EXPERIMENTAL|IND Arm|200 patients will receive one tablet of 600 mg of alpha-lipoic acid twice a day orally for 24 weeks.
61911250|NCT02437227|EXPERIMENTAL|Experimental: CCT3833|The starting dose of CCT3833 is 20 mg, taken as two 10 mg capsules. The starting schedule is a once daily continuous dosing schedule, but other dosing regimens may be considered depending on tolerability and exposures.The first dose of continuous dosing defines Cycle 1 Day 1. All treatment cycles have a duration of 28 days.
61911251|NCT05480345|EXPERIMENTAL|Impedance cardiography|Impedance cardiography parameters recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany)
61911252|NCT02266953|EXPERIMENTAL|Use of communication tool about diet|The children and parents in the intervention group are visiting consultations at the child health centre where the public health nurses use a communication tool about diet in order to promote dialogue about themes concerning food and feeding practices. This intervention is carried out at consultations when the child is 10-, 12- and 15-18 months old.
61911253|NCT02266953|ACTIVE_COMPARATOR|Treatment as usual|The children and parents in the control group are visiting consultations at the child health centre where the public health nurses will conduct the consultations as usual and without use of the actual communication tool about diet. The consultations are carried out when the child is 10-, 12- and 15-18 months old.
61911254|NCT02241889|ACTIVE_COMPARATOR|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
61911255|NCT02241889|EXPERIMENTAL|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
61911256|NCT02241889|EXPERIMENTAL|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
61911257|NCT04286217||No prior hypertension (HTN); no HDP in pregnancy|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
62662829|NCT05813496|PLACEBO_COMPARATOR|Placebo Arm|200 patients will receive one tablet of placebo twice a day orally for 24 weeks.
61911258|NCT04286217||No prior HTN; de novo HDP, GH type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
61911259|NCT04286217||No prior HTN; de novo HDP, GH type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
61911260|NCT04286217||No prior HTN; de novo HDP, PE type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
61911261|NCT04286217||No prior HTN; de novo HDP, PE type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
61911262|NCT04286217||No prior HTN; no HDP in pregnancy; postpartum HDP|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
61911263|NCT04286217||Pre-existing HTN; no HDP in pregnancy|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
62662830|NCT04521452|EXPERIMENTAL|Evogliptin Group|evogliptin 5mg daily
62294919|NCT01629849|EXPERIMENTAL|BI 1021958 qd|Multiple rising dose
61911264|NCT04286217||Pre-existing HTN; de novo HDP, GH type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
61911265|NCT04286217||Pre-existing HTN; de novo HDP, GH type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
61911266|NCT04286217||Pre-existing HTN; de novo HDP, PE type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
61911267|NCT04286217||Pre-existing HTN; de novo HDP, PE type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
61911268|NCT04286217||Pre-existing HTN; no HDP in pregnancy; postpartum HDP|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia,with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
61911269|NCT04286217||Other causes of macular injury leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury leading to HDP, either gestational hypertension or preeclampsia
61911270|NCT04286217||Other causes of macular injury not leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury not leading to HDP
62101523|NCT06043271|NO_INTERVENTION|Waitlist as Usual|Participants in the control group will have their children remain on the waitlist until they are assigned to a therapist in the clinic.
62101524|NCT06530667|EXPERIMENTAL|treatment group|Patients treated by broadband collaborative pulse ablation
62101525|NCT05515094|EXPERIMENTAL|Intervention Arm (Empowerment Counseling Intervention)|The Empowerment Counseling Intervention (ECI) entails directly linking women to on-site case managers who will provide first-line support (i.e., a brief psychosocial support session) and a safety and health assessment to women who are attending to receive ANC and disclose violence. The intervention (e.g., the initial counselling session), adapted from current case management guidelines and the Safe and Sound intervention at health facilities, will be administered directly at the health facility after a woman screens positive for IPV. In line with a survivor centered approach, as part of the initial session, the survivor participant will be invited back for further counselling sessions as part of the intervention curriculum, in addition to being supported to access other services based on her preferences, such as group psychosocial support. The intervention manual acts as a guide and support for trained social workers to support the unique needs of each survivor.
62467205|NCT03858777|ACTIVE_COMPARATOR|Acute ST elevation myocardial infarction (STEMI)|Three blood draws, baseline, 6 hours and 24 hours.
62467206|NCT03858777|PLACEBO_COMPARATOR|Healthy controls|A single blood draw
62467207|NCT03020615|ACTIVE_COMPARATOR|Stable Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment \[a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea\]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
62662831|NCT04521452|NO_INTERVENTION|Non-evogliptin Group|DM medications except evogliptin and other DPP-4 inhibitors
61911271|NCT04133922|ACTIVE_COMPARATOR|GLP-1|GLP-1 infusion 1.2 pmol/kg/min for 150 min
62662832|NCT03060681|EXPERIMENTAL|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
62662833|NCT03060681|NO_INTERVENTION|C group|
62662834|NCT00857389|EXPERIMENTAL|Thio-Clo-Bu with Allo SCT|"Pre-transplant conditioning regimen:~Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF~Post haploidentical stem cell transplant participants:~Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses."
62662835|NCT05726136|EXPERIMENTAL|acetated Ringers|The circulatory effect of a bolus infusion with 4 ml/kg body weight of acetated Ringers will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
61911272|NCT04133922|ACTIVE_COMPARATOR|GLP-1 + Insulin clamp|GLP-1 infusion 1.2 pmol/kg/min for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min
61911273|NCT04133922|ACTIVE_COMPARATOR|Saline + Insulin clamp|Saline infusion at 30 ml/hr for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min.
61911274|NCT03896893|NO_INTERVENTION|Standard of Care|Routine bathing and skin care as per hospital practice
62101526|NCT05515094|NO_INTERVENTION|Standard of Care|Women in the comparison arm will receive the standard of care and be referred to support services at the nearby IRC Women's Protection and Empowerment (WPE) office.
62101527|NCT06712082|EXPERIMENTAL|PF-07264660|Participants will receive a single dose of PF-07264660 via IV infusion
62101528|NCT06712082|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo via IV infusion
62101529|NCT02837380|EXPERIMENTAL|FF/UMEC/VI|Subjects will receive single combination dose of FF/UMEC/VI 100/62.5/25 mcg via a DPI in the morning for 7 days.
62101530|NCT05407519|EXPERIMENTAL|Tislelizumab 200mg IV q3w + Sitravatinib 100mg PO qd|Tislelizumab 200mg IV q3w + Sitravatinib 100mg PO qd Tislelizumab and Sitravatinib will be administered until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 17 cycles of Tislelizumab.
62101531|NCT03191955||Cancer|Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery
62101532|NCT03191955||Non-cancer|Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions
62662836|NCT05726136|EXPERIMENTAL|albumin 5%|The circulatory effect of a bolus infusion with 4 ml/kg body weight of Albumin 5% will be studied. If cardiac output increases with 10% a second bolus will be infused and further studied.
62662837|NCT05726136|EXPERIMENTAL|albumin 20%|The circulatory effect of a bolus infusion with 1 ml/kg body weight of Albumin 20% will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
62467208|NCT03020615|EXPERIMENTAL|Intensive Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment \[a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea\]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
62101533|NCT05569486|EXPERIMENTAL|Green light-emitting diode (GLED)|Subjects randomized to this arm will be exposed to GLED 2 hours a day for 10 weeks
62101534|NCT05569486|PLACEBO_COMPARATOR|White light-emitting diode (WLED)|Subjects randomized to this arm will be exposed to WLED 2 hours a day for 10 weeks
62467209|NCT03503578|EXPERIMENTAL|EEG Dynamics|EEG data will be collected on patients receiving sevoflurane, and sevoflurane and ketamine together.
62467210|NCT05279482||group treated with standard dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
62467211|NCT05279482||group treated with mega dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
62467212|NCT04272060|EXPERIMENTAL|CT Angiography|Research CT angiography.
62662838|NCT02529332|EXPERIMENTAL|Omega-3 Supplementation Group|Omega-3 supplementation
62662839|NCT02529332|NO_INTERVENTION|Control Group|
62101535|NCT05705167|EXPERIMENTAL|Plitidepsin 2.5 mg|"Best standard care (as per applicable local, institutional, national, supranational COVID-19 treatment guidelines) and plitidepsin (administered as a 60-minute intravenous (IV) infusion, every 24 hours for 3 consecutive days, at a dose of 2.5 mg) will be administered to participants of the following groups:~* Group 1 - Participants receiving immune-suppression due to haematopoietic or organ transplantation.~* Group 2 - Participants receiving B-cell depleting therapies.~* Group 3 - Participants receiving other immune-suppressive therapies.~* Group 4 - Other situations with immune deficiencies."
62101536|NCT05705167|NO_INTERVENTION|Control|"Best standard care (as per applicable local, institutional, national, supranational COVID-19 treatment guidelines) ± other regulatory-approved antiviral (if clinically indicated) will be administered to participants of the following groups:~* Group 1 - Participants receiving immune-suppression due to haematopoietic or organ transplantation.~* Group 2 - Participants receiving B-cell depleting therapies.~* Group 3 - Participants receiving other immune-suppressive therapies."
62467213|NCT04272060|ACTIVE_COMPARATOR|Conventional Angiography|Standard medical care which includes cardiac catheterization and invasive coronary angiography.
62101537|NCT03519373||PER001|HIV 1-infected pregnant women
62467214|NCT00517530|EXPERIMENTAL|Phase I, NHL|Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
62467215|NCT00517530|EXPERIMENTAL|Phase I, CLL|Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
62467216|NCT00517530|EXPERIMENTAL|400/400 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
62467217|NCT00517530|EXPERIMENTAL|1600/800 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
62662840|NCT01860508|EXPERIMENTAL|pemetrexed|
62662841|NCT05835700|OTHER|Gasdermin-D levels in preterm labor (study group)|Maternal serum Gasdermin-D levels of pregnant women who were diagnosed with idiopathic preterm labor
62662842|NCT05835700|OTHER|Gasdermin-D levels in healthy pregnant women (control group)|Maternal serum Gasdermin-D levels of healthy pregnant women
62662843|NCT01704079|ACTIVE_COMPARATOR|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
62662844|NCT01704079|PLACEBO_COMPARATOR|Sugar pill to CTAP101 30 μg|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
62467218|NCT00517530|EXPERIMENTAL|400/400 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
62467219|NCT00517530|EXPERIMENTAL|1600/800 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
62467220|NCT00517530|EXPERIMENTAL|1000/1000 mg - Phase II, CLL|Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
62101538|NCT03519373||PER002|HIV 1-uninfected pregnant women
61911275|NCT03896893|EXPERIMENTAL|1% chlorhexidine gluconate (CHG)|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays (total of 8 days CHG application)
62294920|NCT01629849|PLACEBO_COMPARATOR|Placebo to BI 1021958 qd|Matching placebo as tablets
62101539|NCT03519373||PER003|HIV 1-uninfected non-pregnant women
62467221|NCT00517530|EXPERIMENTAL|Retreated Participants|Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
62467222|NCT02074605||Observation|Patients with melanoma who qualify for interferon treatment, but choose not to receive it.
62467223|NCT02074605||Interferon alpha|Patients who receive high dose interferon alpha for 4 weeks
62467224|NCT01361048|ACTIVE_COMPARATOR|oral metronidazole|control arm
62467225|NCT01361048|EXPERIMENTAL|neo penotran forte|neo penotran forte vaginal suppository twice a day for 7 days
62467226|NCT01361048|EXPERIMENTAL|neo penotran forte once a day|neo penotran forte vaginal suppository once a day for 7 days
62467227|NCT00846274|ACTIVE_COMPARATOR|Antithrombin III|
62467228|NCT00846274|EXPERIMENTAL|SK Antithrombin III|
62467229|NCT04328597||Chronic postoperative pain|Patients scoring 3 or more on the EuraHS Quality of Life assessment after elective inguinal hernia repair
62467230|NCT04328597||Non chronic postoperative pain|Patients scoring less than 3 on the EuraHS Quality of Life assessment after elective inguinal hernia repair
62467231|NCT05649228|EXPERIMENTAL|Capsaicin Palmitate|Cream containing 0.25% capsaicin palmitate will be applied to an 8 cm2 area of skin on the subject's forearm
62467232|NCT05649228|ACTIVE_COMPARATOR|Capsaicin|Cream containing 0.1% capsaicin will be applied to an 8 cm2 area of skin on the subject's forearm
62101540|NCT06625151|NO_INTERVENTION|Wait-list Control|After all the final outcome measures have been completed at T3 (two weeks after Time 2), participants will be offered the PCPM-EFI and PERPM-EFI.
62467233|NCT05649228|PLACEBO_COMPARATOR|Placebo Cream|Placebo cream will be applied to an 8 cm2 area of skin on the subject's forearm
62662845|NCT02041572|OTHER|Attentional Bias Retraining|Each participant receives 12 sessions. The first three sessions are baseline (assessment only) sessions. The last four sessions must be treatment sessions. The attentional bias intervention starts randomly on sessions 4 - 8, and continues until the end of the 12 sessions.
62662846|NCT06106997|OTHER|sCT workflow|sCT workflow
62662847|NCT04023253|EXPERIMENTAL|mirabegron|Receive mirabegron 2 mg treatment per day
61911276|NCT03896893|EXPERIMENTAL|Emollient therapy|Aquaphor skin cream applied from the neck down daily on weekdays (total of 8 days emollient application)
62101541|NCT06625151|EXPERIMENTAL|PCPM-EFI|At Time 2 (two weeks after baseline), participants will receive the PCPM-EFI. Participants in the PCPM-EFI condition will be offered the PERPM-EFI after all assessments have been completed at Time 3.
61911277|NCT03896893|EXPERIMENTAL|1% CHG plus emollient therapy|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays followed immediately by Aquaphor skin cream (total of 8 days CHG application plus emollient application)
61911278|NCT02349308||CentrosFLO Long Term Hemodialysis Catheter|Schedule placement of catheter. Arterial tip of the catheter should be placed at or just above the junction of the right atrium and superior vena cava, with the arterial lumen on the left side of the catheter. The venous limb will extend into the right atrium. Catheter will be locked with the usual heparin lock solution for a newly placed catheter (at least 500 units per lumen). Fluoroscopic images will document tip position.
62294921|NCT01629849|EXPERIMENTAL|BI 1021958 bid|Multiple rising dose
62294922|NCT01629849|PLACEBO_COMPARATOR|Placebo to BI 1021958 bid|Matching palcebo as tablet
62294923|NCT04003610|EXPERIMENTAL|Pemigatinib + Pembrolizumab|Combination of pemigatinib (13.5 milligrams \[mg\] once a day orally) plus pembrolizumab (200 mg every 3 weeks \[Q3W\] intravenously \[IV\])
62294924|NCT04003610|EXPERIMENTAL|Pemigatinib|Pemigatinib (13.5 mg once a day orally) alone
62294925|NCT04003610|ACTIVE_COMPARATOR|Standard of Care|Either gemcitabine plus carboplatin or pembrolizumab as standard of care. Gemcitabine 1000 mg/meters squared (m\^2) IV over 30 minutes on Days 1 and 8, followed by carboplatin (dosed to target area under the concentration-time curve \[AUC\] of 5 mg/milliliters \[mL\]/minute \[min\] or 4.5 mg/mL/min if required per local guidelines) on Day 1 or 2 of each 3-week cycle. Pembrolizumab 200 mg IV on Day 1 of each 21-day treatment cycle for up to 35 cycles or disease progression.
62467234|NCT04953234|EXPERIMENTAL|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with COVID-19 best standard of care
62467235|NCT01050088|EXPERIMENTAL|Sucrose|5cc sucrose solution
62467236|NCT01050088|PLACEBO_COMPARATOR|Saline|5cc saline p/o
62467237|NCT02591927|ACTIVE_COMPARATOR|Glucose-Insulin-Potassium|Rackley's Glucose-Insulin-Potassium formula consisting of 30% glucose (300 mg/L), 50 units of regular insulin per liter and 80 mEqu of KCL per liter.
62467238|NCT02591927|PLACEBO_COMPARATOR|Glucose 5%|Glucose 5%
62467239|NCT02004509|ACTIVE_COMPARATOR|anticoagulant|Prescription of oral anticoagulation for patients with silent AF (detected by the pacemaker).
62467240|NCT02004509|NO_INTERVENTION|Control|Patients with silent FA detected only by the pacemaker will no receive oral anticoagulation.
62467241|NCT00406068|EXPERIMENTAL|Mycobacterial cell wall-DNA complex|Mycobacterial cell wall-DNA complex
62467242|NCT00798447|EXPERIMENTAL|lipid emulsion with n-3 FA|
62467243|NCT00798447|ACTIVE_COMPARATOR|lipid emulsion without n-3 FA|
62467244|NCT00907413|EXPERIMENTAL|ERCP and PDT|Endoscopic Retrograde Cholangio Pancreatography (ERCP) and stenting combined with Photodynamic Dynamic Therapy ERCP and PDT
62467245|NCT00907413|ACTIVE_COMPARATOR|ERCP alone|Endoscopic Retrograde Cholangio Pancreatography (ERCP) with stenting alone
62467246|NCT01278550||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
62467247|NCT01278550||High risk cohort|Patients have history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have successful eradication of H. pylori based on histology
62467248|NCT03871920||intervention|any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist
62467249|NCT05013112|PLACEBO_COMPARATOR|Placebo group|Patients receive no additional therapy.
62467250|NCT05013112|EXPERIMENTAL|Metformin group|Patients receive metformin 500mg twice daily from discharge.
62467251|NCT05013112|EXPERIMENTAL|Empagliflozin|Patients receive Empagliflozin once daily from discharge.
62294926|NCT00851903|EXPERIMENTAL|Combination insulin glargine and sitagliptin|"Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 \< Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 \<FPG ≤ 5.5 mmol/L).~Sitagliptin: stable dose of 100 mg once a day administered with or without food."
62294927|NCT03083717||Patients with compensated heart failure|
62467252|NCT01936194|EXPERIMENTAL|Docosahexaenoic Acid (DHA)|infants receiving capsule containing DHA.
62467253|NCT01936194|OTHER|High Olive Oil|infants receiving capsule without DHA and EPA.
62467254|NCT01936194|EXPERIMENTAL|DHA+EPA|infants receiving capsule containing DHA and EPA.
62467255|NCT03728296|EXPERIMENTAL|islet body treatment group|
62467256|NCT05841316||Sugammadex ED95%|"Sugammadex 0.6 mg/kg will be given in the first patient. The primary outcome is the success of recovery from deep (PTC:1-3) to superficial neuromuscular block (TOFR: 0.4) in 5 minutes after the administration of sugammadex.~In case of success, the next patient will be given the same or reduced dose of 0.2 mg/kg sugammadex according to the randomisation scheme.~In case of failure, the next patient will be given an increased dose of 0.2 mg/kg sugammadex."
62467257|NCT03942120||Participants with Crohn's Disease|Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.
62467258|NCT03609983|EXPERIMENTAL|Daily Weighing|Participants will weigh themselves daily and receive feedback daily.
62467259|NCT03609983|EXPERIMENTAL|Weekly Weighing|Participants will weigh themselves weekly and receive feedback weekly.
62467260|NCT03609983|NO_INTERVENTION|No Weighing|Participants will refrain from weighing themselves.
62467261|NCT05297630||Jet Echo group|Biological markers from heart failure patients who underwent therapeutic adjustment according to a daily ultrasound scan
62467262|NCT05297630||Conventional management group|Biological markers from heart failure patients who had conventional management.
62294928|NCT03083717||Patients with decompensated heart failure|
62294929|NCT03083717||Healthy subjects|
62467263|NCT04756752||Fit and Vitaal program|People with a lower-limb amputation participating in the Fit and Vitaal rehabilitation program
62467264|NCT01331187|ACTIVE_COMPARATOR|Usual care|Usual care diagnostics. No routinely ultrasound examination
62467265|NCT01331187|EXPERIMENTAL|Routinely ulasonography|Patients will routinely be examined with ultrasound at admittance in addition to usual care diagnostics
62467266|NCT01683721||Winx|
62467267|NCT04455230|EXPERIMENTAL|Participants who have received gene therapy vector (FLT190)|
62294930|NCT03282032|EXPERIMENTAL|One-lung ventilation|Before surgical incision, 2-min of OLV followed by 2-min of TLV (1 cycle) is performed for 5 cycles.
62294931|NCT03282032|NO_INTERVENTION|Two-lung ventilation|Maintain two-lung ventilation until surgical incision
62294932|NCT00037648|PLACEBO_COMPARATOR|placebo|
62467268|NCT03904966|EXPERIMENTAL|ESWT+ Kinesiotaping|Low-dye Kinesio taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
62467269|NCT03904966|SHAM_COMPARATOR|ESWT+Shamtaping|Sham taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
62294933|NCT00037648|EXPERIMENTAL|anakinra|
62308225|NCT03180762|EXPERIMENTAL|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
62308226|NCT03790735||Diagnostic test|Targeted chromosomal aberrations detection by FISH (MDA TEST).
62467270|NCT03904966|OTHER|ESWT|Extracorporeal shock wave therapy for 5 sessions (5-week)
62467271|NCT04813718|ACTIVE_COMPARATOR|Synbiotic|Omni-Biotic Pro Vi 5
62467272|NCT04813718|PLACEBO_COMPARATOR|Placebo|similar looking and tasting
62467273|NCT04925817|EXPERIMENTAL|Diagnostic (ultrasound microvessel imaging)|Patients undergo 3 D ultrasound microvessel imaging over 45 minutes. Patients' medical records are reviewed.
62467274|NCT05994859|EXPERIMENTAL|SIRT|Treatment with SIRT.
62467275|NCT02406625|EXPERIMENTAL|Diaclectical Behavioral Therapy|15 adolescents with history of suicidal behaviors receiving Dialectical Behavioral Therapy.
62467276|NCT02406625|EXPERIMENTAL|Support Therapy|15 adolescents with history of suicidal behaviors receiving Support Therapy.
62467277|NCT02406625|NO_INTERVENTION|Controls|A group of 15 healthy controls that are not receiving any kind of therapy.
62467278|NCT02160210|EXPERIMENTAL|Ultrafine Endoscope|The ultrafine endoscope for colonoscopy with water method is performed in screening the colorectal diseases.
62467279|NCT03968796|ACTIVE_COMPARATOR|Group 1|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
62467280|NCT03968796|ACTIVE_COMPARATOR|Group 2|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
61911279|NCT00008450|EXPERIMENTAL|Treatment (cyclosporine, mycophenolate mofetil, transplant)|Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.
61911280|NCT06200142|EXPERIMENTAL|The unsolved|(In)capacitated patients (all ages/both genders) with a clinical (and/or family) history and abnormal additional examination (physical (neurological)/ biochemical/ radiological/ genetic) suspicious for an IEM, without diagnosis.
61911281|NCT05753579|ACTIVE_COMPARATOR|Control Group|In our study, stabilization exercises were applied to the patients in the control group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Stabilization exercises: It is an approach that is combined with diaphragmatic breathing and activates the passive. The stabilization exercise program was applied in three phases and was progressed in line with the developments in the patients.
62101542|NCT06625151|EXPERIMENTAL|PERPM-EFI|At Time 2 (two weeks after baseline), participants will receive the PERPM-EFI. Participants in the PERPM-EFI condition will be offered the PCPM-EFI after all assessments have been completed at Time 3.
62101543|NCT06625151|EXPERIMENTAL|PCPM-EFI plus PERPM-EFI|At Time 2 (two weeks after baseline), participants will receive the PCPM-EFI plus the PERPM-EFI.
62101544|NCT06628739||IM Cmin below deciles boundary|Patients with imatinib Cmin less than the decile boundary based on each imatinib Cmin distribution decile.
62101545|NCT06628739||IM Cmin above deciles boundary|Patients with imatinib Cmin greater than or equal to the decile boundary based on each imatinib Cmin distribution decile.
62101546|NCT04994262|EXPERIMENTAL|Intervention Group|"Patients in the intervention group will be given a lozenge with menthol at the 30th, 60th and 90th minutes after extubation and it will be explained that they should be dissolved in the mouth without swallowing, and the patients will be kept under observation during this time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. These parameters will be evaluated just before the menthol lozenge application at the 30th, 60th and 90th minutes.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded.~Second postoperative day: The comfort level of the patients will be evaluated using the General Comfort Scale Short Form."
62101547|NCT04994262|NO_INTERVENTION|Control Group|"Patients in the control group will be followed up according to their routine clinical procedures. Since there is no procedure or intervention in the clinical procedures, only the patients will be followed up. Patients in the control group will be followed up with the same forms at the same time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded hourly.~Second day after surgery: The comfort level of the patients will be evaluated and recorded using the General Comfort Inventory Short Form."
62101548|NCT04466566|PLACEBO_COMPARATOR|Saline|Saline will be infused during the study
62467281|NCT03968796|ACTIVE_COMPARATOR|Group 3|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
62467282|NCT03968796|PLACEBO_COMPARATOR|Group 4|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
62467283|NCT03901768|EXPERIMENTAL|Group dexamethasone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection
62467284|NCT03901768|EXPERIMENTAL|Group triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
62467285|NCT03901768|EXPERIMENTAL|Group dexamethasone with triamcinolone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection. 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
62467286|NCT03901768|PLACEBO_COMPARATOR|Placebo group|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
62662848|NCT04023253|EXPERIMENTAL|solifenacin|Receive solifenacin 5 mg treatment per day
62662849|NCT02842099|EXPERIMENTAL|TA or TAC plus X|Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
62662850|NCT02842099|ACTIVE_COMPARATOR|TA or TAC|Standard chemotherapy (TA or TAC) followed by no more chemotherapy
62662851|NCT03587597|EXPERIMENTAL|socket shield technique|socket shield technique with immediate temporization
62662852|NCT03587597|ACTIVE_COMPARATOR|conventional immediate implant|conventional implant placement with immediate temporization
62662853|NCT03423472|EXPERIMENTAL|Full intervention|Healthy Baby Toolkit (HBT) in addition to Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children \< 2y; especially diet diversity and vitamin A intake
62101549|NCT04466566|ACTIVE_COMPARATOR|Exendin-9,39|Exendin-9,39 will be infused during the study
62662854|NCT03423472|ACTIVE_COMPARATOR|Partial intervention|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children \< 2y; especially diet diversity and vitamin A intake
62662855|NCT03423472|OTHER|Control|Government standard of care for nutrition education through the Health Development Army
62662856|NCT06036238|ACTIVE_COMPARATOR|Standard of Care (Control)|Standard of care; alcohol counseling per Ministry of Health (MoH) guidelines
62308227|NCT02612597|EXPERIMENTAL|Bedrest|4 days of bedrest
62467287|NCT01406418|EXPERIMENTAL|Cohort 1: CR6261|2 mg/kg CR6261
62294934|NCT04134650|EXPERIMENTAL|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5mg + metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
62294935|NCT04134650|ACTIVE_COMPARATOR|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
62467288|NCT01406418|PLACEBO_COMPARATOR|Cohort 1: Placebo|5% dextrose in water
62101550|NCT06162351|EXPERIMENTAL|Single arm: treatment with PLX038|Patients will be treated at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).
62101551|NCT01273701|EXPERIMENTAL|TSTSU-N|TSTSU-N stands for Treatment for Schedule Two Substance Use, No Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-N will not receive telephone reminding before each visit.
62101552|NCT01273701|EXPERIMENTAL|TSTSU-T|TSTSU-T stands for Treatment for Schedule Two Substance Use, Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-T will receive telephone reminding before each visit.
62294936|NCT01891643|EXPERIMENTAL|Arm 1: Lenalidomide + Dexamethasone|"Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug"
62467289|NCT01406418|EXPERIMENTAL|Cohort 2: CR6261|5 mg/kg CR6261
62294937|NCT01891643|EXPERIMENTAL|Arm 2: Lenalidomide + Dexamethasone + Elotuzumab|"Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)~Dexamethasone 28 mg tablets by mouth once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15(cycles 3-18); Day 1 (cycle 19 \& beyond)\]~Dexamethasone 40 mg tablets by mouth once daily \[Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 \& beyond)\]~Dexamethasone 8 mg IV (intravenous) solution once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18); Day 1 (cycle 19 \& beyond)\]~Elotuzumab 10 mg/kg IV solution weekly \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18)\]~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 \& beyond)~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug"
62294938|NCT04610255|ACTIVE_COMPARATOR|Traditional physical therapy|Cervical isometrics and Muscle Stretching
62467290|NCT01406418|PLACEBO_COMPARATOR|Cohort 2: Placebo|5% dextrose in water
62467291|NCT01406418|EXPERIMENTAL|Cohort 3: CR6261|15 mg/kg CR6261
62467292|NCT01406418|PLACEBO_COMPARATOR|Cohort 3: Placebo|5% dextrose in water
62467293|NCT01406418|EXPERIMENTAL|Cohort 4: CR6261|30 mg/kg CR6261
62467294|NCT01406418|PLACEBO_COMPARATOR|Cohort 4: Placebo|5% dextrose in water
62467295|NCT01406418|EXPERIMENTAL|Cohort 5: CR6261|50 mg/kg CR6261
62662857|NCT06036238|EXPERIMENTAL|Healthy Living Intervention|Healthy Living Intervention in-person alcohol counseling with booster phone calls
62662858|NCT06285903|EXPERIMENTAL|Group Densah Bur|patients received dental implant using osseodensification via Densah bur
62662859|NCT06285903|EXPERIMENTAL|Group piezoelectric|patients received dental implant using hydrodynamic piezoelectric sinus lifting
62662860|NCT03419650|OTHER|Treatment arm|treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.
62294939|NCT04610255|EXPERIMENTAL|Dynamic myofascial release|Experimental group was given Dynamic myofascial release along with the cervical isometrics and muscle stretching
62294940|NCT01883141|EXPERIMENTAL|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure
62467296|NCT01406418|PLACEBO_COMPARATOR|Cohort 5: Placebo|5% dextrose in water
62467297|NCT01406418|EXPERIMENTAL|Cohort 6: CR6261|30 mg/kg CR6261
62467298|NCT01406418|PLACEBO_COMPARATOR|Cohort 6 Placebo|5% dextrose in water
62467299|NCT04869722|EXPERIMENTAL|Liquid Model|Whey protein beverages varying in protein levels
62467300|NCT04869722|EXPERIMENTAL|Solid Model|Protein fortified scones varying in fat levels
62467301|NCT03827291|EXPERIMENTAL|Quadratus lumborum block|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
62467302|NCT03827291|OTHER|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia.
62467303|NCT04400617||Assisted-living residents|The target population will be inactive men and women residents of the Brenda Strafford Foundation (\> 50 yrs. old). We expect the participants to be classified as inactivity, which will be defined as an engagement in \< 3 sessions/week of 20 min or more of vigorous exercise. Participants should be able to move independently without the assistance of a wheelchair.
62662861|NCT03819127|ACTIVE_COMPARATOR|Metformin|metformin 1 g twice a day for 24 weeks
62662862|NCT03819127|EXPERIMENTAL|Metformin plus vildagliptin|metformin 1 g plus vildagliptin 50 mg twice a day for 24 weeks
62662863|NCT03319888|EXPERIMENTAL|cpap group|CPAP treatment plus conservative treatment with lifestyle modifications.
62662864|NCT03319888|ACTIVE_COMPARATOR|control group|Conservative treatment with lifestyle modifications.
62662865|NCT00435643|ACTIVE_COMPARATOR|A|10 patients with severe OSAS (Apnea Hypopnea Index of more than 30 events per hour of sleep) were treated with nCPAP for three months and all mentioned measurements above were repeated.
62662866|NCT06379126||SIC group|SIC score≥4
62662867|NCT06379126||non-SIC group|SIC score\<4
62662868|NCT03415256|EXPERIMENTAL|passive vibration group|The passive vibration group patients will receive passive vibration (50 Hz, one cycle= 60 seconds working time with 2 seconds rest time) on their calf in supine position for ten minutes. The total number of sessions will be nine. Passive vibration will be given to the treatment group twice a week for four weeks (eight sessions) and the ninth session will be the follow up. At every session, the skin blood flow will be measured before, immediately, and 15 minutes after passive vibration.
62662869|NCT03415256|ACTIVE_COMPARATOR|no passive vibration group|The control group will not receive any treatment and continue their usual lifestyle. Balance, sensory measurement and skin blood flow will be taken at the beginning of the study, prior to the 5th treatment, and 1 week after the last intervention .
61911282|NCT05753579|EXPERIMENTAL|Intervention Group|In our study, stabilization exercises and spinal mobilization practices were performed to the patients in the intervention group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Mobilization applications were applied at Maitland IV degree as standard.Three mobilization methods were applied Anterior-Posterior Lumbal Spinal Mobilization Lumbal Spinal Rotational Mobilization Joint Mobilization in Lumbal Flexion Position
61911283|NCT00021073|EXPERIMENTAL|Treatment (alvocidib, combination chemotherapy)|"Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.~Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I."
61911284|NCT00754221|EXPERIMENTAL|1|
61911285|NCT00709579|PLACEBO_COMPARATOR|placebo|
61911286|NCT00709579|ACTIVE_COMPARATOR|RV3391A|
61911287|NCT00948467|EXPERIMENTAL|TAK-733|
61911288|NCT01439698||RFA for Pancreatico-biliary disorders|Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.
61911289|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
61911290|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
61911291|NCT03709576|EXPERIMENTAL|Pevonedistat and Azacitidine|The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.
61911292|NCT03279393|ACTIVE_COMPARATOR|PTSD Subjects|
61911293|NCT03279393|ACTIVE_COMPARATOR|Trauma Control Subjects|
61911294|NCT03279393|PLACEBO_COMPARATOR|Healthy Control Subjects|
62101553|NCT01273701|ACTIVE_COMPARATOR|OPD|OPD stands for Outpatient Department. Subjects in this arm will be methamphetamine users who voluntarily visit psychiatric clinics for treatment of mental disorders in National Taiwan University Hospital, Yunlin Branch. They will be referred to this study by their treating psychiatrists.
62662870|NCT01476072|NO_INTERVENTION|no treatment|MRI scans only
62737193|NCT01947283|EXPERIMENTAL|Intervention Patients, Control Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
62101554|NCT06510686|OTHER|İnspiratory muscle training|Inspiratory muscle training during 8 weeks
62294941|NCT02034123|EXPERIMENTAL|Dose Escalation Cohort|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
62101555|NCT06510686|OTHER|Core Stabilization|Inspiratory muscle training and core training during 8 weeks
62101556|NCT02091245|EXPERIMENTAL|KPT-330|KPT-330 will be administered twice a week on Days 1 and 3 for four weeks. Starting dose 30 mg/m2.In the dose-escalation cohort, three patients will initially be enrolled at each dose level and will be monitored for a DLT during the 28-day treatment cycle before dose escalation may occur.
61911295|NCT01964040|PLACEBO_COMPARATOR|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.
61911296|NCT01964040|EXPERIMENTAL|Group B-peri-DEX: Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline
61911297|NCT01964040|ACTIVE_COMPARATOR|Group B-sys-DEX:Systemic Dexmedetomidine|Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.
61911298|NCT02478567|EXPERIMENTAL|Scapular Training|Initiated scapular training exercise for the first 4 weeks followed by addition of rotator cuff exercises the next four weeks
61911299|NCT02478567|EXPERIMENTAL|Rotator Cuff Training|initiated rotator cuff training exercise for the first 4 weeks followed by addition of scapular training exercises the next four weeks.
62294942|NCT02034123|EXPERIMENTAL|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 30 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D
61911300|NCT02545543|EXPERIMENTAL|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
62101557|NCT03404609|EXPERIMENTAL|Accelerated course of modified continuous theta-burst stimulation (cTBSmod)|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
62101558|NCT06429618||Phenotype A|PHENOTYPE A: Hyperandrogenism + Ovulatory Dysfunction + PCOM
61911301|NCT02545543|ACTIVE_COMPARATOR|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
62101559|NCT06429618||Phenotype B|PHENOTYPE B: HA+OD
62101560|NCT06429618||Phenotype C|PHENOTYPE C: HA+PCOM
62101561|NCT06429618||Phenotype D|PHENOTYPE D: OD+PCOM
62662871|NCT04302324|EXPERIMENTAL|daratumumab/clarithromycin/pomalidomide/dexamethasone|"Induction Phase: 8 cycles (cycle length of 28 days)~* Daratumumab SC:~  1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8~* Clarithromycin~  500mg PO BID until VGPR or 8 cycles, whichever occurs first~* Pomalidomide 4mg PO on Days 1-21~* Dexamethasone 20mg IV as pre-medication on Day 1, 8 40mg PO on the day after daratumumab for Cycle 1 Days 15 and 22 40mg PO pre-daratumumab weekly for Cycle 2-6 20mg PO pre-daratumumab weekly for Cycle 7-8~Maintenance Phase (Cycle 9+): Up to 24 cycles (cycle length of 28 days)~* Daratumumab 1800 mg SC on Day 1~* Pomalidomide 4mg PO on Day 1-21~* Dexamethasone 20mg PO pre-daratumumab weekly for Cycles 9 and beyond"
62662872|NCT04087590|EXPERIMENTAL|PT003 treatment|
62101562|NCT04678128|ACTIVE_COMPARATOR|Dance4Healing control group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will not have a dance buddy.
62662873|NCT05771870|EXPERIMENTAL|Peer mentoring|The clinical practice day of the Child Health and Diseases Nursing course included mentoring practice. This is a 3rd-grade (5th semester) course that includes 6 hours of theory and 8 hours of practice in the applicable curriculum. The clinical practice of the Child Health and Diseases Nursing course is carried out for 14 weeks (one semester) 1 day a week at the Children's Units of the Karabük Training and Research Hospital in the program in which the study was done. Throughout all clinical practice days, mentors chosen from graduate students followed the students in the peer mentorship group during the medication preparation and administration processes, providing feedback on their positive, negative, or inadequacies.
61911302|NCT02719561|EXPERIMENTAL|Fatigue intervention|Fatigue Intervention is to be co-designed by participants, and likely to include education, energy conservation and activity promotion. Participants will also decide the name of the Fatigue Intervention
61911303|NCT01715129|EXPERIMENTAL|11.25mg|11.25mg, SC on Day 1 and Day 92
62294943|NCT06179901|ACTIVE_COMPARATOR|Integrative Korean Medicine Treatment group(IKMT group)|
62294944|NCT06179901|EXPERIMENTAL|MSAT group|
62294945|NCT05338229|EXPERIMENTAL|video game in CP children (pilot study)|The cerebral palsy children will play the engineer-built system, video-game based Kinect sensor 3 times/week for 5 weeks. Each session will last for 40 minutes. The video-game Kinect sensor was developed by the researcher team.
62101563|NCT04678128|EXPERIMENTAL|Dance4Healing Buddy Group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will have a dance buddy.
62101564|NCT05203172|EXPERIMENTAL|Binimetinib only treatment|For those participants receiving binimetinib treatment in parent studies
62101565|NCT05203172|EXPERIMENTAL|Encorafenib only Treatment|For those participants receiving encorafenib only treatment in parent studies
62101566|NCT05203172|EXPERIMENTAL|Encorafenib & Binimetinib Treatment|For those participants receiving encorafenib \& binimetinib treatment in parent studies.
62294946|NCT04222517|EXPERIMENTAL|Standart sublay retromuscular technique|Apply standard intervention (sublay retromuscular)
62294947|NCT04222517|EXPERIMENTAL|Standart sublay retromuscular technique with Hemoblock|Local hemostatic Hemoblock is used in retro-muscular and subcutaneous spaces
61911304|NCT05443139|EXPERIMENTAL|Interactive intervention|The participants will receive a self-applied intervention composed by 10 sessions following a multi component structure. The participants assigned to this condition will count with interactive resources such as Videos, Online Forum and Exercises embedded on the platform.
61911305|NCT05443139|EXPERIMENTAL|non-interactive intervention|Self-administered treatment with 10 sessions will be provided through care manuals in PDF format within the same web platform. Participants in this group will receive a manual within the platform with the same content of the sessions as the experimental group but in PDF format.
62294948|NCT05024006|NO_INTERVENTION|LSoC|Local Standard of Care
62662874|NCT05771870|EXPERIMENTAL|Nurse mentoring|The clinical practice day of the Child Health and Diseases Nursing course included mentoring practice. This is a 3rd-grade (5th semester) course that includes 6 hours of theory and 8 hours of practice in the applicable curriculum. The clinical practice of the Child Health and Diseases Nursing course is carried out for 14 weeks (one semester) 1 day a week at the Children's Units of the Karabük Training and Research Hospital in the program in which the study was done. Mentors from the clinical nursing community attended the students in the nurse mentoring group during the drug preparation and administration processes and provided feedback on their positive, negative, or inadequacies.
62662875|NCT04085640|EXPERIMENTAL|Obturator nerve block with Ropivacaine|Obturator nerve block will be performed before general anesthesia as descripted by Nielsen (RAPM, 2019). A linear transducer will be oriented in the transverse plane and placed in the inguinal crease. The tail of the transducer will be tilted distal in order to visualize the pectineus muscle (medial to the femoral vessels) at its insertion at the superior pubic ramus superficial to the external obturator muscle. An 80 mm nerve block needlewill be inserted in-plane from the lateral end of the transducer and advanced until the tip of the needle will be inside the interfascial plane between the pectineus and the obturator externus muscles. 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
62662876|NCT04085640|SHAM_COMPARATOR|Obturator nerve block with isotonic salin|The same procedure will be performed and 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles
62662877|NCT03877822|EXPERIMENTAL|Habitual activity and 2 days bed rest|Participants will undergo 2 days of habitual activity and 2 days bed rest
62101567|NCT05203172|EXPERIMENTAL|Treatment of Encorafenib & Binimetinib & Ribociclib|For those participants receiving treatment of encorafenib \& binimetinib \& ribociclib in parent studies
62662878|NCT04790383|EXPERIMENTAL|Advanced Self-Adhesive resin composite hybrid restorations|(Surefil one (Dentsply Sirona)).
62662879|NCT04790383|ACTIVE_COMPARATOR|Conventional resin composite restoration.|Sphere Tec, (Dentsply Sirona)
61911306|NCT05443139|NO_INTERVENTION|Waiting List group|The control condition consists of a 30-day waiting list, in which participants will not be able to access the interventions. After the waiting process, they will be given access to either the interactive intervention or the non-interactive intervention.
61911307|NCT00567255|EXPERIMENTAL|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
61911308|NCT00567255|PLACEBO_COMPARATOR|Placebo|Placebo with ancillary therapy
62662880|NCT05920239||Control Group|Individuals who were not suspected of having adhesive capsulitis based on clinical examination and MRI.
62662881|NCT05920239||Intervention Group|Patients diagnosed with adhesive capsulitis based on evaluations conducted by clinical specialists, primarily in the fields of physical medicine and rehabilitation, orthopedics and traumatology, and confirmed by two experienced radiologists specializing in musculoskeletal imaging through the evaluation of MRI.
62662882|NCT06104293|OTHER|Group 1|Concentration A - Concentration B - Concentration C - Concentration D
62662883|NCT06104293|OTHER|Group 2|Concentration B - Concentration C - Concentration D - Concentration A
62662884|NCT06104293|OTHER|Group 3|Concentration C - Concentration D - Concentration A - Concentration B
61911309|NCT03999775|ACTIVE_COMPARATOR|Calcium, vitamin D and bioactive collagen peptides supplement|In this arm, all patients received a sachet containing 5mg bioactive collagen peptides, 500 mg calcium lactate and 400 IU vitamin D3 per day.
61911310|NCT03999775|ACTIVE_COMPARATOR|Calcium and vitamin D supplement|In this arm, all patients received a chewable tablet containing 500 mg calcium carbonate and 400 IU vitamin D3 per day.
61911311|NCT04169971|EXPERIMENTAL|Music group|Will receive music during the operation conducted under spinal anaesthesia
61911312|NCT04169971|NO_INTERVENTION|Control group|Will not receive music during the operation conducted under spinal anaesthesia
61911313|NCT05228847|ACTIVE_COMPARATOR|Human milk-derived HMF|Fortification with human milk-derived product
61911314|NCT05228847|OTHER|Bovine milk-derived HMF|Current standard practice: Fortification with bovine milk-derived product
62101568|NCT05203172|EXPERIMENTAL|Treatment of Encorafenib & Binimetinib & Cetuximab|For those participants receiving treatment of encorafenib \& binimetinib \& cetuximab in parent studies
62101569|NCT06137469|EXPERIMENTAL|Acetaminophen+SHR20004|
62101570|NCT06137469|EXPERIMENTAL|Acetaminophen+Placebo|
62101571|NCT00389519|PLACEBO_COMPARATOR|Placebo|once per day
62101572|NCT00389519|EXPERIMENTAL|ramipril low dose|0.3125, 0.625, or 1.25 mg once a day, based on subject weight
62101573|NCT00389519|EXPERIMENTAL|ramipril mid dose|1.25, 2.5, or 5 mg once a day, based on subject weight
62101574|NCT00389519|EXPERIMENTAL|ramipril high dose|5, 10, or 20 mg once a day, based on subject weight
62294949|NCT05024006|EXPERIMENTAL|Rem+LSoC|Remdesivir with Local Standard of Care
62101575|NCT03356132||Textured Group|Women undergoing primary and secondary breast augmentation with Silimed® Textured Silicone Gel-Filled Breast Implant.
62662885|NCT02992379|ACTIVE_COMPARATOR|stabilizing splint|Active Comparator: stabilizing splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
62662886|NCT02992379|EXPERIMENTAL|pivot splint|"Experimental: pivot splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks.~Other Names: PS"
62662887|NCT00691964|EXPERIMENTAL|A|
62662888|NCT00691964|ACTIVE_COMPARATOR|B|
62662889|NCT00691964|PLACEBO_COMPARATOR|C|
62662890|NCT04853875|EXPERIMENTAL|Group A (Tetracycline, Metronidazole, and Bismuth)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Tetracycline 2g, Metronidazole 2g, and Bismuth subcitrate 480 mg
61911315|NCT04309799|OTHER|Single 10 minute session|Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
62101576|NCT03356132||Polyurethane Group|Women undergoing primary and secondary breast augmentation with Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
62101577|NCT02998827|EXPERIMENTAL|thalidomide|use thalidomide tablet by mouth, every night for at least 6 months
62101578|NCT02998827|ACTIVE_COMPARATOR|other treatment|the treatment include infliximab, azathioprine or enteral nutrition at least 6 months
62101579|NCT06650787|EXPERIMENTAL|According to the ultrasonic images give into stomach tube group|According to the ultrasonic images give into stomach tube group
61911316|NCT04309799|OTHER|Optional Extension|Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
61911317|NCT00574964|EXPERIMENTAL|1|
61911318|NCT03355690||Stroke patients|Stroke patients are treated according to the clinical practice which can be divided into: anti-aggregation, thrombectomy and/or thrombolysis
61911319|NCT06433596|EXPERIMENTAL|Autologous PRP|3 injections of 10 cc of autologous Platelet Rich Plasma (PRP) + 6 sessions of placebo shock waves
61911320|NCT06433596|EXPERIMENTAL|Combined therapy|3 injections of 10 cc of autologous PRP + 6 sessions of focal shock waves.
62101580|NCT06650787|ACTIVE_COMPARATOR|Conventional placing nasogastric tube group|Conventional placing nasogastric tube group
62101581|NCT00241644|EXPERIMENTAL|Rotarix 3-Dose Group|Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
62101582|NCT00241644|EXPERIMENTAL|Rotarix 2-Dose Group|Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
62101583|NCT00241644|PLACEBO_COMPARATOR|Placebo Group|Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.
62101584|NCT00521716|EXPERIMENTAL|A|
62101585|NCT06295796|EXPERIMENTAL|Moderate Renal Impairment|Participants with moderate renal impairment receive a single dose of MK-8527 on Day 1.
62101586|NCT06295796|EXPERIMENTAL|Severe Renal Impairment|Participants with severe renal impairment receive a single dose of MK-8527 on Day 1.
62101587|NCT06295796|EXPERIMENTAL|Healthy|Healthy participants receive a single dose of MK-8527 on Day 1.
62101588|NCT05553119||Home-based Pulmonary Rehabilitation and Health Coaching|Subjects with symptomatic bronchiectasis (CAT score ≥10) will receive a 12-week intervention with home-based pulmonary rehab (PR).
62101589|NCT05512390|EXPERIMENTAL|Dose Escalation ABBV-319|Participants with relapsed or refractory (R/R) B cell lymphomas including diffuse large b-cell lymphoma (DLBCL) or follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) will receive escalating doses of ABBV-319 in 21-day cycles, until the recommended Phase 2 dose (RP2D) is determined.
62294950|NCT05024006|EXPERIMENTAL|HCQ+LSoC|Hydroxychloroquine with Local Standard of Care
61911321|NCT06433596|PLACEBO_COMPARATOR|Placebo control|3 injections of 10 cc of saline solution + 6 sessions of placebo shock waves
62101590|NCT05512390|EXPERIMENTAL|(ABBV-319) Diffuse Large B-cell Lymphoma (DLBCL) Participants|Participants with R/R DLBCL will receive ABBV-319 in 21-day cycles.
62101591|NCT05512390|EXPERIMENTAL|(ABBV-319) Follicular Lymphoma (FL) Participants|Participants with R/R FL will receive ABBV-319 in 21-day cycles.
62101592|NCT05512390|EXPERIMENTAL|(ABBV-319) Chronic Lymphocytic Leukemia (CLL) Participants|Participants with R/R CLL will receive ABBV-319 in 21-day cycles.
62101593|NCT00108524|EXPERIMENTAL|Low Carbohydrate Ketogenic Diet|Participants receive dietary counseling over 48 weeks aimed at helping them to lower starch and sugar intake.
62467304|NCT04400617||Control group|Volunteers from the Brain in Motion II (BIM II) study (NCT03035851). The BIM II study aims to examine the mechanisms whereby exercise may improve sleep and cognition in men and women aged 50 to 80 years old. As the baseline measurements of the BIM II study are similar to the assessments proposed in this study, the assisted living residents will be matched with older individuals of the same age and cognitive performance who live independently to answer the last research question.
62467305|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
62467306|NCT05811689||sm tbs group|All patients will undergo densitometric examination with dual-energy x-ray absorptiometry (DXA) technique at our Facility.
62662891|NCT04853875|ACTIVE_COMPARATOR|Group B (Amoxicillin, Metronidazole, and Clarithromycin)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Amoxicillin 3g, Metronidazole 2g, and Clarithromycin 1g
62467307|NCT03344055|ACTIVE_COMPARATOR|Colonoscopy with Endocuff Vision (ECV)|ECV-assisted colonoscopy ( with the use of Endocuff Vision (ECV) Second generation)
62467308|NCT03344055|NO_INTERVENTION|Standard colonoscopy|Standard colonoscopy (without the use of Endocuff Vision (ECV) Second generation)
62467309|NCT03379103|ACTIVE_COMPARATOR|GP - sevoflurane|GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete
62662892|NCT04898556|ACTIVE_COMPARATOR|Active Treatment|Patients who will undergo treatment with Intrarosa (Prasterone 6.5mg) in ovules, will apply one ovule a day before going to bed for 12 weeks.
62662893|NCT04898556|PLACEBO_COMPARATOR|Control Group|Patients who will not undergo any treatment for vulvovaginal atrophy for 12 weeks.
62662894|NCT03125733|EXPERIMENTAL|STESD|Submucosal tunneling endoscopic septum division
62662895|NCT03240380|EXPERIMENTAL|joint crisis plan|Subjects benefit from a joint crisis plan and the process of its negotiation in addition to the usual in-patient or out-patient care.
62662896|NCT03240380|ACTIVE_COMPARATOR|crisis card|Subjects benefit from a crisis card in addition to the usual in-patient or out-patient care.
62662897|NCT05850507|EXPERIMENTAL|Study Group|Intramuscular injection of 25μg/0.5ml Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) in the deltoid muscle of the upper arm.
62662898|NCT05850507|ACTIVE_COMPARATOR|Control group|Intramuscular injection of 25 μg/0.5 ml recombinant novel coronavirus protein vaccine (CHO cells) into the deltoid muscle of the upper arm.
62662899|NCT05758454|OTHER|Oral health information|Intervention in form of a health/dental health information translated into different native language will be provided for the intervention group
62662900|NCT02711787|EXPERIMENTAL|Experimental group|Robotic device Gloreha (Gloreha, Idrogenet, Italy) and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
61911322|NCT06433596|ACTIVE_COMPARATOR|Shock waves|3 injections of 10 cc of saline solution + 6 sessions of waves of focal shock.
61911323|NCT05049083|EXPERIMENTAL|Treatment group A|
62101594|NCT00108524|ACTIVE_COMPARATOR|Low-Fat Diet plus Orlistat|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake, and additionally receive Orlistat taken 3 times daily.
62101595|NCT05052983|EXPERIMENTAL|Nemolizumab|
62101596|NCT05052983|PLACEBO_COMPARATOR|Placebo|
62294951|NCT05024006|EXPERIMENTAL|Lopi/Rito+LSoC|Lopinavir/Ritonavir with Local Standard of Care
61911324|NCT05049083|EXPERIMENTAL|Treatment group B|
61911325|NCT00680719|ACTIVE_COMPARATOR|1|Family Therapy plus HIV prevention
62101597|NCT04962334|EXPERIMENTAL|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
62294952|NCT05024006|EXPERIMENTAL|Lopi/Rito+IFN+LSoC|Lopinavir/Ritonavir and Interferon Beta 1a with Local Standard of Care
62101598|NCT04962334|PLACEBO_COMPARATOR|Placebo|Low caloric formula (Powder added to waster) without added vitamins and minerals
62101599|NCT01154556||HIV1 positive, NNRTI exposure and failure|
62101600|NCT06364137|EXPERIMENTAL|Teleo|Participants in this group will under therapy for 4 sessions using the Teleo virtual therapy video platform, sessions will be recorded and questionnaires and clinical data will be measured.
62101601|NCT06364137|ACTIVE_COMPARATOR|Standard videoconferencing|Participants in this group will under therapy for 4 sessions using standard video platforms (e.g. zoom or other publicly available product), sessions will be recorded and questionnaires and clinical data will be measured.
62101602|NCT06411145|EXPERIMENTAL|Cenegermin-bkbj|cenegermin-bkbj (20 mcg/mL) ophthalmic solution on corneal thickness administered as topical drops via anterior segment optical coherence tomography (AS-OCT), where cenergermin-bkbj stands for Topical Recombinant Human Nerve Growth Factor (rhNGF). Cenegermin-bkbj, the active ingredient of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution, is structurally identical to the human nerve growth factor (NGF) protein made in ocular tissues.
62101603|NCT04689698|EXPERIMENTAL|experimental group|
62101604|NCT05599360|EXPERIMENTAL|Vyxeos|
62101605|NCT06485596|EXPERIMENTAL|DCD Direct procurement|Direct procurement of DCD donor hearts
62294953|NCT05024006|EXPERIMENTAL|IFN+LSoC|Interferon Beta 1a with Local Standard of Care
62294954|NCT05024006|EXPERIMENTAL|ACB+LSoC|Acalabrutinib with Local Standard of Care
62294955|NCT06196411|EXPERIMENTAL|Study Group|Task-oriented Training Bobath Training
62294956|NCT06196411|ACTIVE_COMPARATOR|Control Group|Bobath Training
62294957|NCT04474730|ACTIVE_COMPARATOR|Watch Only|
62294958|NCT04474730|EXPERIMENTAL|Watch+App|
62294959|NCT00567723||1|Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol
62294960|NCT00567723||2|Historical control group: Patients with no lanthanum exposure
62294961|NCT00567723||3|Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product
62294962|NCT04396587|EXPERIMENTAL|Sufentanil|Sufentanil(0.1μg/kg)
62294963|NCT04396587|EXPERIMENTAL|Hydromorphone|Hydromorphone(20μg/kg）
62294964|NCT04396587|EXPERIMENTAL|Oxycodone|Oxycodone(60μg/kg)
61911326|NCT00680719|ACTIVE_COMPARATOR|2|Family Therapy only.
61911327|NCT01233518|OTHER|Single arm study|Patients will receive cCTA, ICA, FFR, and cFFR per protocol.
61911328|NCT05428878||Pregnant|pregnant women
61911329|NCT05428878||Non-pregnant|non-pregnant women
61911330|NCT00466492|OTHER|No sedatation intervention|The intervention group is the normal care in our institution, the control group is the golden standard
61911331|NCT05146453|EXPERIMENTAL|Intervention|This group of patients will undergo placement of US guided pectointercostal fascia blocks.
61911332|NCT05146453|PLACEBO_COMPARATOR|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
61911333|NCT05347147|EXPERIMENTAL|Presendin|2.0 mg
61911334|NCT05347147|PLACEBO_COMPARATOR|Placebo|
61911335|NCT00545285|ACTIVE_COMPARATOR|1|Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
61911336|NCT00545285|ACTIVE_COMPARATOR|2|Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
62101606|NCT02746900|EXPERIMENTAL|Cervical cerclage|After the woman is placed in the dorsal lithotomy position and the bladder is emptied with a urinary catheter to reduce the chance of bladder injury, surgical preparation with Betadine will be performed. Breisky retractors and Sims retractors will be used to exposure the entire cervix. Sponge ring forceps will be used to optimized visualization of the cervix and provide the necessary countertraction at the suture entry and exit sites. McDonald technique will be performed placing 4-6 bites circumferentially around the cervix. Only one stitch will be used. The suture will be places as high as feasible
61911337|NCT00545285|ACTIVE_COMPARATOR|3|Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
61911338|NCT00545285|ACTIVE_COMPARATOR|4|Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
61911339|NCT01658813|EXPERIMENTAL|5-Fluorouracil and Interferon|"5-Fluorouracil~Interferon-alfa-2b"
61911340|NCT06518850|SHAM_COMPARATOR|Sham Comparator（Normal oral cecum transit time）|Normal oral cecum transit time +functional abdominal distention +small intestinal bacterial overgrowth.Rifaximin (0.2g/ time, 4 times/day) was discontinued after 14 days of treatment.
61911341|NCT06518850|EXPERIMENTAL|Experimental（Abnormal oral cecum transit time）|Abnormal oral cecum transit time +functional abdominal distention +small intestinal bacterial overgrowth.Rifaximin (0.2g/ time, 4 times/day) was discontinued after 14 days of treatment.
62294965|NCT04396587|PLACEBO_COMPARATOR|normal saline|10ml
61911342|NCT04191083|EXPERIMENTAL|Motor Imagery|
61911343|NCT04191083|EXPERIMENTAL|Double Time Motor Imagery|
61911344|NCT04191083|EXPERIMENTAL|Action observation|
61911345|NCT04191083|PLACEBO_COMPARATOR|Placebo group|
61911346|NCT05639244|OTHER|First TRE, then regular diet|This group will start with 2 weeks TRE and will switch to the 2 week period of consuming their regular diet after a wash-out period.
61911347|NCT05639244|OTHER|First regular diet, then TRE|This group will start with the 2 week period of consuming their regular diet and will switch to 2 weeks TRE after a wash-out period.
61911348|NCT05852041|EXPERIMENTAL|Treatment (rhPSMA, PET-MRI, mpMRI)|Patients receive rhPSMA-7.3 IV then undergo PET-MRI and mpMRI of the prostate on study. Patients also undergo Decipher test at screening and MRI-PET prostate biopsy or radical prostatectomy within 90 days per standard of care.
61911349|NCT03769376|ACTIVE_COMPARATOR|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
61911350|NCT03769376|ACTIVE_COMPARATOR|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
61911351|NCT03138993|ACTIVE_COMPARATOR|Patient decision aid|
61911352|NCT03138993|SHAM_COMPARATOR|General sleep education|
61911353|NCT06013215|EXPERIMENTAL|Cochlear implant users with Neuro Zti array|Post-lingually cochlear implant users with 12 months of auditory experience Modifications of pulse parameters to determine the charge integration efficiency which is related with neuron survival population
61911354|NCT03681223|ACTIVE_COMPARATOR|Restorelle® Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Restorelle® sacrocolpopexy
61911355|NCT03681223|EXPERIMENTAL|Vertessa® Lite Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Vertessa® Y sacrocolpopexy
62308228|NCT02612597|EXPERIMENTAL|Exercise Training|6 weeks of aerobic endurance exercise training with 4 supervised sessions per week at an average intensity of 65 % of maximal heart rate
61911356|NCT02779361|EXPERIMENTAL|Green tea|Green tea consumption along 7 days.
61911357|NCT05245448|EXPERIMENTAL|tetrandrine|tetrandrine administered 40milligram (mg) orally thrice daily through Week 24.
61911358|NCT05245448|PLACEBO_COMPARATOR|placebo|Placebo administered orally thrice daily through Week 12. Starting at Week 12, participants were given tetrandrine 40 milligram (mg) orally thrice daily through Week 24.
61911359|NCT06032845|EXPERIMENTAL|Cryoablation combined with Tislelizumab and lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab and Lenvatinib will be initiated on day 1 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
61911360|NCT02958683||Pectus excavatum|Patients with pectus excavatum (funnel chest) condition undergo chest wall motion analysis
61911361|NCT02958683||Pectus carinatum|Patients with pectus carinatum (pigeon chest) condition undergo chest wall motion analysis
61911362|NCT02958683||Chronic obstructive pulmonary disease|Patients affected by COPD undergo chest wall motion analysis
61911363|NCT02958683||Diaphragm abnormality|Patients with abnormal function or structure of the diaphragm. Including diaphragmatic hernia/rupture and diaphragmatic paralysis undergo chest wall motion analysis
61911364|NCT02958683||Healthy control|People who do not have any diagnosed thoracic condition and who do not have symptoms/signs suggestive of undiagnosed thoracic disease undergo chest wall motion analysis
61911365|NCT02958683||Lung cancer|Patients with suspected or confirmed lung malignancy of all histological subtypes undergo chest wall motion analysis
61911366|NCT02958683||Pleural disease|Patients with pleural thickening and/or pleural effusion, pneumothorax, empyema undergo chest wall motion analysis
61911367|NCT02958683||Asthma|Patients diagnosed with asthma clinically or upon spirometry undergo chest wall motion analysis
61911368|NCT02958683||Cystic fibrosis|Patients diagnosed with cystic fibrosis clinically or biochemically undergo chest wall motion analysis
61911369|NCT02958683||Rib or sternal disease|Patients with an abnormality in the chest wall including fractures, osteomyelitis, malignancy of all histological subtypes, chest wall resection/reconstruction undergo chest wall motion analysis
61911370|NCT02257762|EXPERIMENTAL|Lipid-based nutrient supplement (LNS)|LNS added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
61911371|NCT02257762|ACTIVE_COMPARATOR|Corn-soy blend ++ (CSB++)|CSB++ porridge, eaten over 6 months, age 6-12 months to age 11-17 months
61911372|NCT02257762|ACTIVE_COMPARATOR|Sprinkles|Sprinkles added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
62101607|NCT02746900|NO_INTERVENTION|No intervention|Bed rest will be not recommended.
62101608|NCT04857944|EXPERIMENTAL|Personalised exercise group program + fitness tracker + app with motivational messages (A)|After study entry and baseline assessments, subjects will attend the one-month IDEA group sessions aimed at promoting physical activity and exercise. Participants randomly assigned to this study arm will use the smart band and the app with the motivation set enabled, allowing participants to receive the messages according to their compliance and adherence to the personalised prescriptions. After group sessions (week 4), study subjects will start receiving motivational messages up until the end of the trial (8 consecutive months).
62101609|NCT04857944|EXPERIMENTAL|Personalised exercise group program + fitness tracker + app without motivational messages (B)|Subjects will follow the same procedure as intervention A, with the difference that the app will have the motivation set disabled, therefore participants will not receive any messages regarding their compliance. After group sessions, study subjects will be expected to continue using the smart band and app up until the end of the trial (8 consecutive months).
62101610|NCT04857944|SHAM_COMPARATOR|Fitness tracker + app without motivational messages (CG)|After study entry and baseline assessments, all patients assigned to the control group will receive both the app and the smart band, but the motivation set will be disabled. Study subjects will be expected to use the smart band and app up until the end of the trial.
62101611|NCT00361309|EXPERIMENTAL|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
61911373|NCT02257762|NO_INTERVENTION|Control|Plain borbor and thereafter family foods, eaten over 6 months, age 6-12 months to age 11-17 months
62294966|NCT06503198|EXPERIMENTAL|Virtual Care|"Intervention group participants will be enrolled in a PVC program prior to admission, including receipt of a cellular-enabled tablet and Cloud DX remote monitoring equipment.~Through Cloud DX remote monitoring technology, intervention group participants will receive the following intervention: remote automated monitoring, frailty-tailored daily symptom survey, Katz Index of Independence in Activities of Daily Living survey, FAM-CAM survey, Virtual RN assessment, medications."
62294967|NCT06503198|NO_INTERVENTION|Standard Care|The standard care group will receive their post-hospital discharge management in alignment with standard of care at the hospital where they had surgery.
61911374|NCT00303589|EXPERIMENTAL|1|
61911375|NCT00303589|EXPERIMENTAL|2|
61911376|NCT00303589|ACTIVE_COMPARATOR|3|
61911377|NCT02122601|OTHER|LBSA0103|single arm , LBSA0103 only
61911378|NCT04622800|OTHER|Individuals applied with proprioceptive neuromuscular fasilition techniques|No exercise intervention was made.
61911379|NCT04563832|OTHER|Control group|standardized respiratory management.
61911380|NCT04563832|EXPERIMENTAL|Experimental group|same program as control group associated with the daily use of a hyperinsufflation technique (2 times per day during15 minutes, 5 days a week, for 2 years)
61911381|NCT01943474|EXPERIMENTAL|AccuCath IV Catheter Device|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
61911382|NCT01943474|ACTIVE_COMPARATOR|Conventional IV Catheter Device|Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
61911383|NCT00655915||Injection Patients|Those patients who receive corticosteroid injections for carpal tunnel syndrome
61911384|NCT00940667|EXPERIMENTAL|amlodipine/losartan 5/50mg|
61911385|NCT00940667|ACTIVE_COMPARATOR|amlodipine 5mg|
61911386|NCT02879045|EXPERIMENTAL|elasticity Belly® oil|Volunteer's abdomen skin are divided two parts through medioventral line, half of the abdomen skin will apply the elasticity Belly® oil
61911387|NCT05247528|PLACEBO_COMPARATOR|Placebo Comparator|"* Subjects randomized to the placebo arm, will receive a single subcutaneous injection each morning daily.~* Intervention: Placebo"
61911388|NCT05247528|EXPERIMENTAL|MANP|"* Subjects randomized to the experimental arm, will receive a single subcutaneous injection each morning daily. (multiple ascending dose cohorts)~* Intervention: Drug: MANP"
61911389|NCT04689412||Cases|Children spontaneously treated with nasal resveratrol at the beginning of each upper airways infection
61911390|NCT04689412||Controls|Children spontaneously treated with nasal lavage at the beginning of each upper airways infection
61911391|NCT00002805|EXPERIMENTAL|Treatment|Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.
61911392|NCT01997112|ACTIVE_COMPARATOR|Paracetamol|paracetamol 1g (500mg x2) four times daily for 14 day period
62467310|NCT03379103|PLACEBO_COMPARATOR|GC - control|GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with intravenous propofol for 15 minutes before the installation of ischemia by tourniquete.
61911393|NCT01997112|PLACEBO_COMPARATOR|Placebo|Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
61911394|NCT05218954||patients with heterotopic ossification|patients with heterotopic ossification following THR
61911395|NCT05218954||patients without heterotopic ossification|patients without heterotopic ossification following THR
61911396|NCT03337672|EXPERIMENTAL|Dexmedetomidine group|Subjects who receive dexmedetomidine for prevention of emergence delirium
62101612|NCT05634213|EXPERIMENTAL|saline injection|After the patient is placed on cardiopulmonary bypass, the surgeon will inject a saline into the atria.
62101613|NCT05634213|NO_INTERVENTION|standard of care|The patient will be placed on cardiopulmonary bypass as usual and the surgery will proceed without an attempt to inject saline into the atrial tissue.
61911397|NCT03337672|ACTIVE_COMPARATOR|Midazolam group|Subjects who receive midazolam for prevention of emergence delirium
61911398|NCT06163677||COVID-19 Positive|Laboratory-confirmed COVID-19 illness and at least one patient-reported symptom
61911399|NCT06163677||Influenza Positive|Laboratory-confirmed influenza illness and at least one patient-reported symptom
62294968|NCT04857021|ACTIVE_COMPARATOR|GABA|Take GABA capsule once daily before sleep for 14 days.
62467311|NCT03617523|EXPERIMENTAL|Fluzone Quadrivalent vaccine Group 1: 6 to <36 months|Participants (aged 6 to \<36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62467312|NCT03617523|EXPERIMENTAL|Fluzone Quadrivalent vaccine Group 2: 3 to <9 years|Participants (aged 3 to \<9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
61911400|NCT00813969|EXPERIMENTAL|Autologous MSC transplantation|
61911401|NCT06434402|EXPERIMENTAL|Emerging adults (ages18-25 years)|"Participants complete questionnaires over 20 minutes about their mood, health, and demographic information at baseline, and 1, and 3 months.~Participants are asked to write about their cancer experiences over 20 minutes (non-stop) for 4 weeks."
61911402|NCT06434402|EXPERIMENTAL|Young adults (ages 26-39 years)|"Participants complete questionnaires over 20 minutes about their mood, health, and demographic information at baseline, and 1, and 3 months.~Participants are asked to write about their cancer experiences over 20 minutes (non-stop) for 4 weeks."
61911403|NCT06434402|EXPERIMENTAL|General group (ages 18-39 years)|"Participants complete questionnaires over 20 minutes about their mood, health, and demographic information at baseline, and 1, and 3 months.~Participants are asked to write about their cancer experiences over 20 minutes (non-stop) for 4 weeks."
61911404|NCT02480036|EXPERIMENTAL|Combined IORT and Kyphoplasty|IORT with Kyphoplasty IORT Device: Intrabeam®
62101614|NCT00903721||1|Patients with perennial allergic rhinitis
62467313|NCT03617523|EXPERIMENTAL|Fluzone Quadrivalent vaccine Group 3: 18 to <65 years|Participants (aged 18 to \<65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
62101615|NCT00903721||2|Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)
62101616|NCT05964257|EXPERIMENTAL|HU-014|
62101617|NCT05964257|PLACEBO_COMPARATOR|Placebo|
62294969|NCT04857021|PLACEBO_COMPARATOR|Placebo|Take placebo capsule once daily before sleep for 14 days.
62294970|NCT02498210|EXPERIMENTAL|IVF after IVM|"If the patients will not concive during the IVM cycle . results of this following IVF cycle will be compared to the initial IVF preformance~Intervention : In Vitro Maturation Procedure"
62467314|NCT03617523|EXPERIMENTAL|Flublok Quadrivalent vaccine Group 4: 18 to <65 years|Participants (aged 18 to \<65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.
61911405|NCT05520710|EXPERIMENTAL|Therapy Group|The Therapy Group will receive 6-10 individual sessions of 30-60 minutes each, delivered by a trained Occupational Therapist or Speech-Language Pathologist. The therapy will be delivered over a 4-week timeframe, with the total number of sessions per participant depending on the number of sessions needed to achieve their treatment targets. Each participant in the Therapy Group will identify three cognitive targets for treatment. Progress in reaching those targets will be documented using Goal Attainment Scaling (GAS)
61911406|NCT05520710|ACTIVE_COMPARATOR|Educational Group|The education group will receive information about self-management of cognitive symptoms at the time of randomization, a common intervention for adults with mild Traumatic Brain Injury.
61911407|NCT01150669||Observational|Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.
61911408|NCT03573011|EXPERIMENTAL|2.0 ± 0.2 MBq/kg [18F]PSMA-11 dosing group|"To define the optimal \[18F\]PSMA-11 scan protocol, the quality of the PET images from patients that received 2.0 ± 0.2 MBq/kg will be compared to the images from patients that received 4.0 ± 0.4 MBq/kg.~Patients in this study arm will receive 2.0 ± 0.2 MBq/kg for acquiring the \[18F\]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm.~As for the use of radiopharmaceuticals, the ALARA ('as low as reasonably achievable') principle must be applied, this study arm is considered to be the reference."
62101618|NCT05304520||On Natalizumab: Switcher IV to SC Cohort|Participants who are already on natalizumab treatment, 300 milligrams (mg) IV infusion and who decide to switch to 2x150 mg SC injection administered as standard of care/routine clinical practice will be observed for up to 12 months.
62101619|NCT05304520||Natalizumab-Naive IV Cohort|Participants who initiate natalizumab, 300 mg, IV infusion injection administered as standard of care/routine clinical practice will be observed for up to 12 months
62101620|NCT05304520||Natalizumab-Naive SC Cohort|Participants who initiate natalizumab, 2x150 mg, SC injection administered as standard of care/routine clinical practice will be observed for up to 12 months.
62101621|NCT02292043||idiopathic dilated cardiomyopathy group|idiopathic dilated cardiomyopathy group treated with HTEA
62467315|NCT03617523|EXPERIMENTAL|Fluzone High-Dose vaccine Group 5: >=65 years|Participants (aged \>=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
61911409|NCT03573011|EXPERIMENTAL|4.0 ± 0.4 MBq/kg [18F]PSMA-11 dosing group|Concerning the dose of \[18F\]PSMA-11, the patients in this study arm will receive 4.0 ± 0.4 MBq/kg for the \[18F\]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm
61911410|NCT00128505|EXPERIMENTAL|mifepristone|
61911411|NCT02723487|NO_INTERVENTION|Group A|Control
61911412|NCT02723487|ACTIVE_COMPARATOR|Group B|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.125%), 0.5 ml/kg on each side.
61911413|NCT02723487|ACTIVE_COMPARATOR|Group C|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.25%), 0.5 ml/kg on each side.
61911414|NCT02823444||Peripheral Vascular Disease|Gender distribution will be approximately equal. The age range is 18-95, with increased prevalence in the elderly population.
61911415|NCT02823444||Control|In the initial sequence optimization stage, healthy volunteers will also be recruited.
61911416|NCT02524834|EXPERIMENTAL|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
61911417|NCT03933995||Mesenchymal stem cell|Long-term follow up of Mesenchymal stem cell group
61911418|NCT02556164|EXPERIMENTAL|Real EA|"Real EA as intervention is performed at the selected standard acupuncture points and De-qi is achieved with needle manipulation before electric stimulation is delivered."
62101622|NCT02292043||post-myocardial infarction group|post-myocardial infarction group treated with TEA
62101623|NCT03999944|OTHER|Sequence 1|"FRESCA Airbox Flow Generator set to fixed pressure first, then FRESCA Airbox Generator set to auto-adjusting pressure.~Second intervention within 1 - 10 days of first intervention."
62101624|NCT03999944|OTHER|Sequence 2|"FRESCA Airbox Flow Generator set to auto-adjusting pressure first, then FRESCA Airbox Generator set to fixed pressure.~Second intervention within 1 - 10 days of first intervention."
62101625|NCT04863885|EXPERIMENTAL|Phase 1 Dose Level 1|Participants will be treated at dose level 1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 8 mg/kg IV will be administered days 1 and 8 every 3 weeks.
62101626|NCT04863885|EXPERIMENTAL|Phase 1 Dose Level 2|Participants will be treated at dose level 2: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 10 mg/kg IV will be administered days 1 and 8 every 3 weeks.
62101627|NCT04863885|EXPERIMENTAL|Phase 1 Dose Level -1|If dose reduction is indicated, participants will be treated at dose level -1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 6 mg/kg IV will be administered days 1 and 8 every 3 weeks
62308229|NCT01663129||Leukemia Patient Group|Acute Lymphoblastic Leukemia (ALL)
62467316|NCT05122208||Famotidine Group|Patients who were administered Famotidine 160 mg/day PO or nasogastric.
62467317|NCT05122208||Control Group|Patients who were not administered Famotidine
61911419|NCT02556164|SHAM_COMPARATOR|Sham EA|Sham EA as intervention is performed for the control group at non-acupuncture points without needle manipulation. The electric stimulation in sham acupuncture was performed in a similar fashion to the real EA.
61911420|NCT04572360|EXPERIMENTAL|Cardiorespiratory Exercise plus Chinese Herbal Medicines Group|"Includes:~1.12-week progressive \& individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management \& habit formation; access to a call center; \& counselling sessions to enhance motivation to regularly engage in daily physical activities.~2.Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast \& dinner, 7days/week for 12 weeks."
61911421|NCT04572360|EXPERIMENTAL|Cardiorespiratory Exercise Group|"Includes:~A 12-week progressive \& individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management \& habit formation; access to a call center; \& counselling sessions to enhance motivation to regularly engage in daily physical activities."
61911422|NCT04572360|EXPERIMENTAL|Chinese Herbal Medicines Group|"Includes:~Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast \& dinner, 7days/week for 12 weeks."
61911423|NCT04572360|NO_INTERVENTION|Waiting List Group|The waiting list control sign will be adopted to conceal allocation results from the patients and further to reduce selection and confounding bias and increase their adherence to the study. Patients in the waiting list control group will receive no treatment in the study period (including a 12-week intervention period and a 12-week follow-up period). However, they will receive Chinese herbal medicines after the completion of the study (i.e., after the 3rd wave of measurements in the 25th weeks).
61911424|NCT00134420|ACTIVE_COMPARATOR|Growth Hormone Treatment|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
61911425|NCT00134420|OTHER|GH treatment delayed by one year|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
61919843|NCT02934529|ACTIVE_COMPARATOR|A1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every two weeks until progression in first-line or emergence of unacceptable toxicity.~De-escalation (e.g. to irinotecan plus cetuximab or FUFA plus cetuximab) is allowed, but cetuximab should be administered until progression if safety is adequate."
62101628|NCT04863885|EXPERIMENTAL|Phase 2: Treatment at Maximum Tolerated Dose (MTD)|Participants will be treated at with Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks plus the maximum tolerated dose of Sacituzumab Govitecan days 1 and 8 every 3 weeks.
62101629|NCT04713514|NO_INTERVENTION|Arm A : Best Supportive Care|Observational arm (Standard of care)
62467318|NCT01789294|EXPERIMENTAL|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects
62662901|NCT02711787|ACTIVE_COMPARATOR|Control group|Physiotherapy, occupational therapy and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
62101630|NCT04713514|EXPERIMENTAL|Arm B : OSE2101|"OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.~OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion."
62101631|NCT04713514|EXPERIMENTAL|Arm C : OSE2101 + Pembrolizumab|OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
62467319|NCT01789294|NO_INTERVENTION|Observation|A close clinical observation without therapy was taken in control patients, whom parents were alerted to refer immediately if symptoms persisted or get worse.
62662902|NCT01345799|EXPERIMENTAL|TRK-170 Low Dose|
62662903|NCT01345799|EXPERIMENTAL|TRK-170 Middle Dose|
62662904|NCT01345799|EXPERIMENTAL|TRK-170 High Dose|
62662905|NCT01345799|PLACEBO_COMPARATOR|Placebo|
62662906|NCT05484947||HIV-positive|Those that were actually tested and had HIV-positive results
62662907|NCT05484947||HIV-Negative|Those tested and had HIV-negative results
62662908|NCT05484947||HIV-Unknown|those who had not volunteered for HIV testing
62467320|NCT01789294|EXPERIMENTAL|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists
62294971|NCT04048512||Resection with intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection with intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio Pulmonary By pass (CPB)
62467321|NCT05541432|ACTIVE_COMPARATOR|Home exercise|Home exercise program, with biweekly group virtual education and exercise classes.
62662909|NCT05494138||The obese group|Obese patients (BMI ≥25 kg/m2) with chronic diseases such as cardiovascular disease, hypertension, diabetes, and metabolic syndrome. More than 10% of the patients in the obese group will be patients with a BMI ≥30.
62294972|NCT04048512||Resection without intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection without intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio pulmonary By Pass (CPB)
62662910|NCT05494138||The control group|Adults with BMI 18.5\~24.9 kg/m2.
62294973|NCT05814445|EXPERIMENTAL|Neuromuscular exercise program|Participants on a neuromuscular exercise program
62467322|NCT05541432|EXPERIMENTAL|Supervised strength training (group 1)|In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
62467323|NCT05541432|EXPERIMENTAL|Supervised strength training (group 2)|In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
62467324|NCT05621941|EXPERIMENTAL|Game-Supported Goal Management Training|Seven treatment sessions given once a week (60 minutes) under guidance of a clinical neuropsychologist and cognitive trainer or occupational therapist.
62467325|NCT05621941|ACTIVE_COMPARATOR|Information Group|Seven information sessions given once a week (60 minutes) under guidance of a clinical neuropsychologist.
62467326|NCT05345236|EXPERIMENTAL|QL1207|Subjects randomized into QL1207 group will receive QL1207 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
62662911|NCT01736059|EXPERIMENTAL|Stem cell treated|
62662912|NCT04120324||Eligible & Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty and is discharged home on the day of surgery.
61911426|NCT06224920||Alzheimer´s disease spectrum|"MCI-AD patients Evidence of minor cognitive impairment with essentially preserved everyday competence and evidence of reduced Aβ42 concentration in the cerebrospinal fluid. Score in the CERAD word list 1.5 SD below the normal range.~Patients with AD-dementia Evidence of pronounced cognitive impairment and relevant impairment of everyday life and evidence of reduced Aβ42 concentration in the cerebrospinal fluid (diagnostic criteria (NIA-AA fulfilled))."
62467327|NCT05345236|ACTIVE_COMPARATOR|Eylea®|Subjects randomized into Eylea® group will receive Eylea® 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
62467328|NCT06562413||Responders|Patients with high frequency episodic or chronic migraine undergoing treatment with monoclonal antibodies directed against calcitonin gene related peptide pathway (mAbs) who obtained a reduction in monthly migraine days equal or higher than 50% compared to pre-treatment values.
62467329|NCT06562413||NON-Responders|Patients with high frequency episodic or chronic migraine undergoing mAbs treatment who obtained a reduction in monthly migraine days \< 50% compared to pre-treatment values.
62467330|NCT03584139|EXPERIMENTAL|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
62467331|NCT03584139|ACTIVE_COMPARATOR|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
62467332|NCT02605928|EXPERIMENTAL|BIP Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It measures bioimpedance and detects synovial fluid during inta-articular injection.
62467333|NCT04189250|PLACEBO_COMPARATOR|Optimized carbonmonoxid rebreathing protocol (oCO)|2 min rebreathing period seated position capillary blood sampling
62467334|NCT04189250|ACTIVE_COMPARATOR|Automatized carbonmonoxide rebreathing protocol (aCO)|10 minutes rebreathing period supine position venous blood sampling
62467335|NCT00135941|EXPERIMENTAL|1|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
62294974|NCT05814445|ACTIVE_COMPARATOR|Institutional exercise program|Participants on an institutional exercise program
62294975|NCT05904587|NO_INTERVENTION|open mouth debonding|debonding of the bracket is done while the mouth of the patient is open and without any support to the teeth during the debonding procedure
62467336|NCT00135941|EXPERIMENTAL|2|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
62467337|NCT01394562|EXPERIMENTAL|Ferinject (ferric carboxymaltose)|
62101632|NCT01683695|ACTIVE_COMPARATOR|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
61911427|NCT06224920||corticobasal syndrome due to probable 4 repeat taupathy|Evidence of the typical clinical picture of an atypical Parkinson's syndrome with onset of symptoms \> 1 year. No evidence of reduced Aβ42 concentration in the cerebrospinal fluid. Fulfillment of the revised Armstrong criteria for probable CBS or the Movement Disorder's Society criteria for suggestive/possible PSP-CBS.
61911428|NCT06224920||subjective congnitive decline|Subjective memory impairment, with age-appropriate unremarkable neurocognitive test battery (CERAD) and no evidence of reduced Aβ42 concentration or increased total tau or phospho-tau concentration in the cerebrospinal fluid. Subjective cognitive deterioration over a period of 6 months to 5 years.
61911429|NCT05055245||Patients undergoing assisted reproductive technology|Patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
61911430|NCT01598142|OTHER|experienced assistant group|experienced endoscopist with an experienced assistant.
61911431|NCT01598142|OTHER|new trained assistant group|same experienced endoscopist with a new trained assistant
61911432|NCT00654147|ACTIVE_COMPARATOR|Raltegravir & Lopinavir/ritonavir|Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks
62294976|NCT05904587|EXPERIMENTAL|biting on soft elastomeric wafer|debonding of the bracket is done while the patient is biting on the preshaped soft elastomeric wafer (cut into a horseshoe shape) during the debonding procedure
62294977|NCT05904587|EXPERIMENTAL|biting on cotton roll|debonding of the bracket is done while the patient is biting on a cotton roll during the debonding procedure
62294978|NCT05904587|EXPERIMENTAL|biting on the mouthpiece of vibrational device|debonding of the bracket is done while the patient is biting on the mouthpiece of the vibrational device (SureSmile® VPro™) delivering vibrations to the dentition during the debonding procedure
62294979|NCT03860506|EXPERIMENTAL|PSI-697|
62294980|NCT03860506|PLACEBO_COMPARATOR|Placebo|
62294981|NCT02094599|EXPERIMENTAL|All Enrolled Participants|Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.
62294982|NCT05802030|EXPERIMENTAL|Plyometric training|The 8 weeks of plyometric training included push-ups and medicine ball exercises for the upper limbs and jumping, hopping exercises for the lower limbs. Exercises for the upper limbs were immediately followed by lower-limb exercises, with no intervening rest periods.
62294983|NCT05802030|ACTIVE_COMPARATOR|Routine training|During the intervention, the control group just continued with their routine training regime (e.g., normal fitness training, and injury prevention drills), twice a week, for the duration of the experiment.
62294984|NCT06655987|EXPERIMENTAL|Experimental Group|Participants receiving the Unrestrained Femoral Internal Rotation (UFIR) manipulation.
62294985|NCT06655987|PLACEBO_COMPARATOR|Control Group|Participants receiving a sham manipulation (gentle hand placement)
62294986|NCT05940675|EXPERIMENTAL|Generation Healthy Kids intervention|The intervention focuses on food and nutrition, physical activity, sleep and screen media habits, and engagement of the local stakeholders.
62294987|NCT05940675|NO_INTERVENTION|Control|The schools will continue with their regular school schedules.
62294988|NCT00927485|EXPERIMENTAL|Curcumin|Curcumin
62294989|NCT00927485|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pills)
62294990|NCT05402384|EXPERIMENTAL|AVTX-801, then Placebo|Each treatment period is 24 weeks, with 6-week washout period in between.
62294991|NCT05402384|PLACEBO_COMPARATOR|Placebo, then AVTX-801|Each treatment period is 24 weeks, with 6-week washout period in between.
62294992|NCT01597947|EXPERIMENTAL|Arm A|
62294993|NCT01597947|PLACEBO_COMPARATOR|Arm B|
62294994|NCT01627418|EXPERIMENTAL|Voucher|"Receive the intervention (Energy Voucher) the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
62294995|NCT01627418|OTHER|Control|"Receive the intervention the second winter enrolled in the study (thus No intervention : control arm). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
62294996|NCT04239209|PLACEBO_COMPARATOR|Direct Communication (control)|A direct response where the intensivist acknowledges that he is not certain but believes the patient will not survive hospitalization.
61911433|NCT00654147|ACTIVE_COMPARATOR|Raltegravir & emtricitabine/tenofovir|Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks
61911434|NCT05772988|EXPERIMENTAL|Beta-alanine|Beta-alanine to be given for three weeks
61911435|NCT05772988|PLACEBO_COMPARATOR|Maltodextrin|Placebo to be given for three weeks
61911436|NCT00228982|EXPERIMENTAL|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
61911437|NCT00228982|ACTIVE_COMPARATOR|Vancomycin|Vancomycin 1g q12h as 1h infusion, 7-14d
62294997|NCT04239209|ACTIVE_COMPARATOR|Indirect - other patients|An indirect response describing the prognosis of other people similar to the patient in question.
62294998|NCT04239209|ACTIVE_COMPARATOR|Indirect - physiology|An indirect response describing the severe physiologic abnormalities present in the patient and potential future problems.
62467338|NCT01394562|OTHER|Standard of Care|Standard of care. IV iron is not permitted
61911438|NCT05053373|EXPERIMENTAL|Electroacupuncture Added to Pelvic Floor Muscle Training|Patients will be in a prone position. Bilateral Zhongliao (BL33) and Huiyangacupoint (BL35) will be identified and punctured by an acupuncturist. The electrodes will be placed on the needle handles, and stimulate for 30 minutes at 50 Hz with a current intensity between 1 to 5 mA. PFMT will be performed 3 sets a day (morning, around noon, and night).
62467339|NCT01889719|EXPERIMENTAL|Vaccination with MVA-CMDR Group 1|Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
62467340|NCT01889719|ACTIVE_COMPARATOR|Vaccination with MVA-CMDR Group 2|Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
62101633|NCT01683695|PLACEBO_COMPARATOR|AMG 557 Matching Placebo|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
62101634|NCT03879447||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
62101635|NCT03879447||Lumbar spondylolisthesis group|Lumbar spondylolisthesis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
62101636|NCT06712940|EXPERIMENTAL|Intervention Condition|"Motivational Interviewing (MI) is a participant-centered yet directive method for enhancing readiness to change. The purpose of MI is to help an individual articulate their own reasons and develop their own plans for making behavioral change. The basic principles of MI as applied to violence risk reduction in victims of gun violence are as follows: Express Empathy, Develop Discrepancy, Roll with Resistance, and Support Self-Determination/Self- Efficacy. MI respects these values of self-determination and self-efficacy, and emphasizes the participant's right to make decisions about change. MI practitioners offer themselves as a consultant while respecting the participant as the real expert in their own life. MI also affirms the patient's ability to make changes and communicates trust in the patient's judgments about readiness and plans for change."
62101637|NCT06712940|NO_INTERVENTION|Treatment as Usual|"Patients assigned to the TAU condition will receive standard care for victims of violence at the Trauma Center. All TAU-assigned patients will be screened by psychiatry consult/liaison staff for posttraumatic symptoms, depression, and substance use. Patients with significant symptoms will be offered pharmacotherapy and/or supportive psychotherapy. Patients will also be provided with a list of community resources available for victims of violence, including mental health and social services.~Patients in TAU will receive the same information sheet (e.g., job training) provided to patients in the MI condition."
62101638|NCT05885126|EXPERIMENTAL|Intervention Group|Patients in the intervention group were allowed to paint mandala templates for 30 minutes during chemotherapy treatment after premedication. Before the application, the patients were informed by the practitioner and given a laptop table, mandala coloring books and crayons, they were asked to paint a mandala template of their choice. The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application. The patients in the intervention group were given the materials necessary for painting medallions after the treatment, and they were asked to apply at home for at least 30 minutes the day after the treatment. The patients were supported by telephone to paint while they were at home.
61911439|NCT05053373|EXPERIMENTAL|Sham Electroacupuncture Added to Pelvic Floor Muscle Training|The preparation for the patients will be the same as that for the patients who will receive EA. Whereas, instead of using real acupuncture needles, special designed placebo needles (size 0.30 × 25 mm) with the blunt-head will be used in the PFMT+sham EA group to penetrate the fixed pad to the skin surface but without skin penetration. The same procedure for deqi will be performed as in the PFMT+EA group. A special-designed cable (the intermediate wire of the cable is cut off but the appearance is normal) will be used to connect the electrodes to the electroacupuncture machine. Therefore, the electroacupuncture machine appears to work, but does not actually stimulated acupoints. The sham EA treatment will also be maintained for 30 minutes. PFMT will be performed 3 sets a day (morning, around noon, and night),
61911440|NCT03787043|EXPERIMENTAL|Sequence Group A|"1. 1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted~2. 2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fed"
61911441|NCT03787043|EXPERIMENTAL|Sequence Group B|"1. 1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fed~2. 2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted"
61911442|NCT05596097|EXPERIMENTAL|experimental group|According to the initial treatment plan of the patients, the patients were divided into R-CHOP and R-chemo groups. Both groups received zanubrutinib 160 mg bid p.o. d1-28 maintenance treatment for 12 months after induction and consolidation therapy reached the maximum efficacy.
61911443|NCT05904301||Systemic autoimmune and autoinflammatory diseases|
61911444|NCT06164821|EXPERIMENTAL|luspatercept arm|Luspatercept was given once subcutaneously every 3 weeks for 24 weeks in the treatment period, . Luspatercept was started at 1·0 mg/kg with titration up to 1·25 mg/kg, or reduction in the event of toxicity or excessive haemoglobin concentration increase.. During the treatment, the hemoglobin of patients before each injection of luspatercept should be monitored, and the common adverse reactions (AE) should be monitored. According to the judgment and practice of clinicians, the best supportive treatment, including blood transfusion, iron chelation therapy, and anti-infection treatment, should be provided for patients receiving luspatercept treatment. If the patient has blood transfusion, it is necessary to obtain the blood transfusion record from the hospital system.Concomitant use of iron chelating agents was also recorded.
61911445|NCT02489916|EXPERIMENTAL|CM4307|CM4307 300mg bid，until disease progression,death, unacceptable toxic eff ects, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest
61911446|NCT05503745|ACTIVE_COMPARATOR|CBT-E|Participants in the CBT-E condition will receive a total of 20 CBT-E sessions over 20 weeks. CBT-E treatment will consist of four stages. In particular, CBT aims to inform patients about the importance of self-control, the dangers of some restrictive behaviors such as self-induced vomiting. Moreover, CBT provides strategies to patients in order to monitor their usually dysfunctional behaviors and so increasing their awareness (i.e. food diary method) while reducing the availability of food and encourages activities that are incompatible with overeating. Patients will be trained in problem solving in order to change these feelings, as well as in increasing their self-awareness in order to recognize irrational thoughts about their body weight and shape. Additionally, they will be gradually exposed to foods that they had been avoiding.
61911447|NCT05503745|EXPERIMENTAL|CBT-F+MIT|"Participants in the CBT-F+MIT condition will receive a total of 20 sessions over 20 weeks. Specifically, 2 sessions will be based on CBT-F as usual only. During these sessions participants will receive psychoeducational training on eating behaviors and an introduction to the protocol tools, namely the monitoring form, weight chart, transdiagnostic formulation and Eating Problem Check List (EPCL).~These elements will be used at the beginning of the remaining 18 sessions, in order to monitor the regulations of eating behaviors as well eliciting narrative episodes. These materials will form the basis for the MIT-part of the session, in which therapists will seek to form with the patient a shared understanding of the psychological reasons underlying their ED symptoms and their maladaptive interpersonal functioning. MIT sessions will be integrated within the CBT-F protocol which will provide psycho-educational, nutritional re-education and management for ED."
61911448|NCT01633593|EXPERIMENTAL|donepezil|Donepezil 5mg/day during 2 weeks
62101639|NCT05885126|NO_INTERVENTION|Control Group|Participants in the control group did not receive any intervention during or after treatment.
62101640|NCT05395481|EXPERIMENTAL|LY3849891 (Part A)|Single ascending doses of LY3849891 administered subcutaneously (SC).
62101641|NCT05395481|EXPERIMENTAL|LY3849891 (Part B)|Repeated doses of LY3849891 administered SC.
62467341|NCT03079765|EXPERIMENTAL|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
61911449|NCT01633593|PLACEBO_COMPARATOR|placebo|placebo comparator to donepezil (double blind)
61911450|NCT02444000|EXPERIMENTAL|experimental|Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
62101642|NCT05395481|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC.
62101643|NCT05395481|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC.
62101644|NCT02851147||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
62101645|NCT01693094|NO_INTERVENTION|No decision aid|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
62101646|NCT01693094|ACTIVE_COMPARATOR|Decision Aid|One cohort will receive a decision aid.
62101647|NCT01359137|EXPERIMENTAL|Probation as usual|Routine supervision with no deferred jail condition.
62101648|NCT01359137|EXPERIMENTAL|Deferred jail|Discretionary deferred jail in response to violations of probation conditions.
62101649|NCT01359137|EXPERIMENTAL|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) which uses non-discretionary brief jail sanctions for probation violations.
62101650|NCT06629402|EXPERIMENTAL|PF614 50 mg|Oral 50 mg
62101651|NCT06629402|EXPERIMENTAL|PF614 100 mg|Oral 100 mg
62101652|NCT06629402|PLACEBO_COMPARATOR|Placebo|Inactive medication
62101653|NCT06711445||Tele- assessment Group|The participants were evaluated in two settings on different days (24-48 h apart): (i) in clinical settings (face-to-face) and (ii) at home via 'WhatsApp' phone application (both asynchronized and synchronized tele-assessment).
61911451|NCT02444000|ACTIVE_COMPARATOR|control|radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
61911452|NCT03487601|ACTIVE_COMPARATOR|Active tDCS|Active transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of active stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
62101654|NCT06707818||Patients scheduled for aesthetic breast surgery|This group includes patients undergoing aesthetic breast surgery between January 2024 and January 2025 who are assessed preoperatively, intraoperatively, and postoperatively.
62101655|NCT01551615|EXPERIMENTAL|Metformin then metformin + vandetanib|Metformin alone followed by metformin in combination with vandetanib
62101656|NCT06711588|EXPERIMENTAL|Walking on 0% slope at self-selected speed|All participants will walk on a treadmill, in a straight line, on a 0% slope, at their self-selected walking speed determined while walking overground.
62101657|NCT06711588|EXPERIMENTAL|Walking on 0% slope at 15% slower than self-selected speed|All participants will walk on a treadmill, in a straight line, on a 0% slope, at a speed that is 15% slower than their self-selected walking speed determined while walking overground.
62101658|NCT06711588|EXPERIMENTAL|Walking on 0% slope at 15% faster than self-selected speed|All participants will walk on a treadmill, in a straight line, on a 0% slope, at a speed that is 15% faster than their self-selected walking speed determined while walking overground.
61911453|NCT03487601|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of sham stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
62101659|NCT06711588|EXPERIMENTAL|Walking up an 8% slope at self-selected speed|All participants will walk on a treadmill, in a straight line, up an 8% slope, at their self-selected walking speed determined while walking overground up an 8% slope.
62101660|NCT06711588|EXPERIMENTAL|Walking down an 8% slope at self-selected speed|All participants will walk on a treadmill, in a straight line, down an 8% slope, at their self-selected walking speed determined while walking overground up an 8% slope.
62101661|NCT06711588|EXPERIMENTAL|Walking on 0% slope at self-selected speed while hand carrying a 5 kg load on their prosthetic side|All participants will walk on a treadmill, in a straight line, on a 0% slope, at their self-selected walking speed determined while walking overground, while carrying a 5 kg load in one hand on their prosthetic side.
62101662|NCT06711588|EXPERIMENTAL|Walking on uneven terrain at self-selected speed|All participants will walk on an uneven terrain treadmill, in a straight line, on a 0% slope, at their self-selected walking speed determined while walking on the uneven terrain treadmill.
62101663|NCT06711588|EXPERIMENTAL|Walking around a 2-meter diameter circle with the prosthesis on the inside of the circle|All participants will walk overground while following the outline of a 2-meter diameter circle, at their self-selected walking speed determined while walking around the circle, with their prosthetic limb on the inside of the circle.
62101664|NCT06711588|EXPERIMENTAL|Walking around a 2-meter diameter circle with the prosthesis on the outside of the circle|All participants will walk overground while following the outline of a 2-meter diameter circle, at their self-selected walking speed determined while walking around the circle, with their prosthetic limb on the outside of the circle.
62101665|NCT06253663|EXPERIMENTAL|MCL Cohort- KTE-X19|"Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV lymphodepletion chemotherapy for 3 days followed by KTE-X19 administered intravenously at a target dose of 2 x 10\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T cells/kg on Day 0.~For participants weighing ≥ 100 kg, a maximum flat dose of 2 x 10\^8 anti-CD19 CAR T cells will be administered."
62101666|NCT06253663|EXPERIMENTAL|ALL Cohort- KTE-X19|"Participants will receive cyclophosphamide 900 mg/m\^2/day intravenously (IV) for 1 day and fludarabine 25 mg/m\^2/day IV lymphodepletion chemotherapy for 3 days followed by KTE-X19 administered intravenously at a target dose of 1 x 10\^6 19 CAR T cells/kg on Day 0.~For participants weighing ≥ 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells will be administered."
62101667|NCT04986917|EXPERIMENTAL|Su2ura® approximation device - study device group|Patients with a primary umbilical hernia will be recruited to the study and the hernia will be repaired using the Su2ura® approximation device
62101668|NCT03106025|ACTIVE_COMPARATOR|Patients Receiving Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
62101669|NCT03106025|EXPERIMENTAL|Ocular Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis
62294999|NCT04239209|ACTIVE_COMPARATOR|Redirection|Redirection to a conversation about the values of the patient and possible future decisions.
62295000|NCT03394638|ACTIVE_COMPARATOR|Conventional group|"Treatment includes:~1. 10 individual and 3 group consultations at the outpatient department by several disciplines in the first postoperative year.~2. Additional visits if necessary~3. No further access to the BePATIENT website"
62295001|NCT03394638|EXPERIMENTAL|Online group|"Treatment includes:~Added to conventional group: Continuation of access to the BePATIENT website with:~1. eLearning programs~2. Informative videos~3. Patient network~4. Video consulting"
62295002|NCT03394638|EXPERIMENTAL|Device group|"Added to Online group:Four wireless devices, which are~1. Weight Scale~2. Blood Pressure~3. Oximeter~4. Activity Tracker"
62101670|NCT03199885|EXPERIMENTAL|Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)|Patients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
62467342|NCT03079765|ACTIVE_COMPARATOR|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
62467343|NCT03233724|EXPERIMENTAL|1/Dose Escalation|Decitabine (DAC)-Tetrahydrouridine (THU) + pembrolizumab at escalating doses
62467344|NCT03233724|EXPERIMENTAL|2/Dose Expansion|Decitabine (DAC)-Tetrahydrouridine (THU) + pembrolizumab at the dose established in Arm 1
62467345|NCT05387447|EXPERIMENTAL|Conversational Voice Assistant-Standard|Participants will complete a standard interactive routine with the voice assistant.
62662913|NCT04120324||Eligible but NOT Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty but is NOT discharged home on the same day as the surgery, and remains in hospital for a minimum of one night following surgery. Reasons for not being discharged same day include potential problems related to Surgery (eg. complication), Anesthesia (eg. prolonged effect), or patient factors (egs. pain, nausea, mobility difficulties, etc.).
62662914|NCT04120324||Not Eligible for Discharge Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and/or Anesthesia deems the patient to NOT be eligible for Same Day Discharge. The patient undergoes Primary Single Joint Total Hip Arthroplasty and remains for a minimum of one overnight in hospital following hip replacement surgery.
62662915|NCT02547935|EXPERIMENTAL|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
62662916|NCT02547935|EXPERIMENTAL|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
62662917|NCT02547935|PLACEBO_COMPARATOR|Placebo|Tablets administered orally once daily for 24 weeks
62662918|NCT02266017|EXPERIMENTAL|Mobile Pain Coping Skills Training|Coping Skills Training for pain will be delivered to participants using video-conferencing via a tablet computer.
62467346|NCT05387447|EXPERIMENTAL|Conversational Voice Assistant-Enhanced|Participants will complete a personalized and tailored interactive routine with the voice assistant.
62101671|NCT03199885|ACTIVE_COMPARATOR|Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)|Patients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
62101672|NCT06292182|EXPERIMENTAL|Treatment start at baseline|
62101673|NCT06292182|EXPERIMENTAL|Delayed treatment start at 3 months from baseline|
62101674|NCT06711835|EXPERIMENTAL|Group 1 (Normally Active Individuals)|Individuals with Normal Daily Activities
62101675|NCT06711835|EXPERIMENTAL|Group 2 (Athletic)|Participants who regularly engage in sports activities such as marathon running, basketball, or volleyball
62467347|NCT04715152|ACTIVE_COMPARATOR|ACB group|Patients will receive ultrasound-guided (USG) ACB with bupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline.
62467348|NCT04715152|PLACEBO_COMPARATOR|IA group|Patients will receive intra-articular bupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline.
62467349|NCT02345941|EXPERIMENTAL|Invervention|The intervention group will get tailored information on the Parent Action Report and the Parent Portal about child safety seats and booster seats.
62662919|NCT02266017|ACTIVE_COMPARATOR|In person Pain Coping Skills Training|Participants will be provided with an in-person pain coping skills training intervention
62662920|NCT04325347|EXPERIMENTAL|Virtual reality|Virtual Reality will be provided to all participants, just before sleeping.
62662921|NCT04325347|NO_INTERVENTION|Control|No specific intervention will be provided.
62662922|NCT02095860|EXPERIMENTAL|Treatment A: DCV 3DAA FDC fasted state|DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state
62662923|NCT02095860|EXPERIMENTAL|Treatment B: DCV 3DAA FDC with high-fat meal|DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal
62467350|NCT02345941|ACTIVE_COMPARATOR|Control|The control group will get tailored information in the Parent Action Report and the Parent Portal about smoke alarms.
62662924|NCT02095860|EXPERIMENTAL|Treatment C: DCV 3DAA FDC with light meal|DCV 3DAA FDC tablet by mouth once on specified days with light meal
62101676|NCT02661997|EXPERIMENTAL|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
62101677|NCT02661997|ACTIVE_COMPARATOR|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
62101678|NCT03545490|EXPERIMENTAL|Cohort 1-intervention|Oral supplements are given through oral route 2 weeks before radiotherapy.
62467351|NCT04817774|EXPERIMENTAL|Treatment group|Subjects undergo kidney transplant as per planned standard of care and are administered study drug post transplantation, up to 24 subjects.
62467352|NCT04817774|NO_INTERVENTION|Control group and Transplant donors|"Control group: Subjects undergo kidney transplant as per planned standard of care with no study drug administered, up to 6 subjects.~Transplant donors: Transplant donors for each subject in the treatment and control groups, up to 30 subjects."
62662925|NCT01859091|EXPERIMENTAL|Fat Reduction|
62101679|NCT03545490|ACTIVE_COMPARATOR|Cohort 1-Control|Oral supplements are given through oral route on demand during radiotherapy.
62101680|NCT03545490|EXPERIMENTAL|Cohort 2- Intervention|Oral supplements are given by tube feeding 2 weeks before radiotherapy.
62662926|NCT06508814|EXPERIMENTAL|12 mmHg Insufflation Pressure|Participants received 12 mmHg of insufflation pressure during their laparoscopic hysterectomy.
62662927|NCT06508814|ACTIVE_COMPARATOR|15 mmHg Insufflation Pressure|Participants received 15 mmHg of insufflation pressure during their laparoscopic hysterectomy.
62662928|NCT02578797|EXPERIMENTAL|Apalutamide|Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.
62101681|NCT03545490|ACTIVE_COMPARATOR|Cohort 2- Control|Oral supplements are given by tube feeding on demand during radiotherapy.
62467353|NCT05528744||Proband|Study participants who have suspected or confirmed CAGS based on having a variant of uncertain significance, likely pathogenic variant, or pathogenic variant in ANKRD17 and clinical features of the condition.
62101682|NCT06183502||MSM using or not using Pre-exposure prophylaxis|"60% of MSM using PrEP at baseline in Atlanta, Chicago, and San Diego to develop knowledge around PrEP use and adherence, condom use, sexual risk-taking behavior, and substance-using behaviors.~40% of MSM not using PrEP at baseline in Atlanta, Chicago, and San Diego to develop knowledge around PrEP use and adherence, condom use, sexual risk-taking behavior, and substance-using behaviors."
62662929|NCT02115477||Group with lymphadenectomy|The group of women with high risk endometrial cancer who undergoes pelvic and/or paraaortic lymphadenectomy at primary surgery
62662930|NCT02115477||Group without lymphadenectomy|The group of women with low risk endometrial cancer who do not have lymphadenectomy at primary surgery
62662931|NCT05177094|EXPERIMENTAL|LY3526318|Participants received 250 milligram (mg) of LY3526318 orally, once daily for the first 4 weeks and were switched to placebo once daily for the next 4 weeks of the treatment period.
62101683|NCT06664112||Labor|The women will be followed until and after the birth, under intrapartum ultrasound monitoring, with all clinical, ultrasonographic and obstetric parameters, analyzed by AIDA method.
62101684|NCT04513028|EXPERIMENTAL|Treatment|"All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan.~Pembrolizumab: 200 mg/100mL IV in three week intervals~Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days"
62101685|NCT05032755|EXPERIMENTAL|VLNC Group|Participants in this condition will be provided with Spectrum NRC102/103 (nonmenthol/menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco with reported nicotine yield (ISO) of 0.03 +/- 0.01 mg and a tar yield of 9 +/- 1.5. Participants will be asked to smoke only study cigarettes for 4 weeks.
62101686|NCT05032755|ACTIVE_COMPARATOR|NNC Group|Participants in this condition will be provided with Spectrum NRC600/601 (non-menthol/menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco with reported nicotine yield (ISO) of 0.8 +/- 0.15 mg and a tar yield of 10.5 +/- 1.5.
62101687|NCT01393470||Cohort A (Trial Cohort, Vaccinated during HPV-008)|"Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.~Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
62662932|NCT05177094|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally, once daily, for 8-weeks treatment period.
62662933|NCT03848078|OTHER|Optical Coherence Tomography arm|In the intervention arm, OCT imaging is performed which will take about 3 minutes. The decision on the most adequate treatment strategy will be based directly on the OCT diagnosis, but only when there is certainty about the presence of BCC and BCC subtype according to the OCT diagnosis. A 'safety' biopsy will be performed after the OCT scan. In patients where the OCT diagnosis leaves doubt or it is certain that there is no BCC, a biopsy will be taken anyway and the treatment decision will be based on the result of this punch biopsy.
62101688|NCT01393470||Cohort B1 + B2|"Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.~Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.~Cohort B2 (Trial Cohort, Non-Vaccinated)"
62467354|NCT05528744||Unaffected family members|Family members of the proband who do not have an ANKRD17 variant.
62467355|NCT01448902|EXPERIMENTAL|OC000459|
62662934|NCT03848078|NO_INTERVENTION|Regular care arm|In patients assigned to regular care, the result of punch biopsy will always be used to decide which treatment is most adequate. Therefore, a next consultation will be planned to discuss the outcome of the biopsy and the intended treatment strategy.
62467356|NCT01448902|PLACEBO_COMPARATOR|Placebo|
62467357|NCT01435265|ACTIVE_COMPARATOR|Normal Nurse Education|Subjects receive normal nurse education materials provided by their physician.
62467358|NCT01435265|EXPERIMENTAL|Additional Nurse Education-|Subjects will receive additional nurse education beyond the normal education materials provided by their physician
62467359|NCT05278481|ACTIVE_COMPARATOR|Reward Message with standard introduction|
62467360|NCT05278481|ACTIVE_COMPARATOR|Reward Message with culturally tailored introduction|
62467361|NCT05278481|ACTIVE_COMPARATOR|Threat/Self-efficacy with standard introduction|
62467362|NCT05278481|ACTIVE_COMPARATOR|Threat/Self-efficacy with culturally tailored introduction|
62662935|NCT03645447|EXPERIMENTAL|Taste test|Participants newly diagnosed with depression will be presented with a series of sugar solutions of 9 different concentrations in pseudo-random order. The threshold at which each participant reliably detects the sugar taste is determined before and after a first antidepressant. Mood Questionnaires will be used to determine whether a participant is clinically depressed at the time of the taste test and 6 to 8 weeks later.
62662936|NCT01245348||Schizophrenia|Patient with schizophrenia
62662937|NCT01245348||Bipolar|Patient with bipolar disorder
62101689|NCT01393470||Cohort C (Referent Cohort, Non-Vaccinated)|"Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.~Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).~Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
62101690|NCT06463665|EXPERIMENTAL|Single-arm run-in Olvi-Vec dose escalation Cohorts|"Cohort 1: Olvi-Vec administered over 3 consecutive days at 1,2,3 x 10e9 pfu followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI.~Cohort 2: Olvi-Vec administered over 3 consecutive days at 2,3,5 x 10e9 pfu followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI.~Cohort 3: Olvi-Vec administered over 4 consecutive days at 2,3,5,5 x 10e9 pfu followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI."
62101691|NCT06463665|EXPERIMENTAL|Experimental Arm|Olvi-Vec will be administered at the dose and schedule selected from the single-arm run-in Olvi-Vec dose escalation cohorts followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI.
62467363|NCT05278481|ACTIVE_COMPARATOR|Social norms message with standard introduction|
61911454|NCT04825197|EXPERIMENTAL|LRS Group|This arm will receive up to 4 doses (100 mg Kg) of Poractant alfa (Curosurf, Chiesi) every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV. Optimal recruitment is defined as adequate oxygenation using a fraction of inspired oxygen (FiO2) of 0.30 or less. The continuous distending pressure (CDP) will be increased stepwise (1 cmH2O every 2-3 min) as long as pulse oximetry (SpO2) improves. The FiO2 will be reduced stepwise, keeping SpO2 within the target range (87-94 %). The recruitment procedure will be stopped if oxygenation no longer improves or if the FiO2 is equal to or less than 0.30. The corresponding CDP will be called the opening pressure (CDPO). Next, the CDP will be reduced stepwise (1-2 cmH2O every 2-3 min) until the SpO2 deteriorates (by at least 2-3 points). The corresponding CDP will be called the closing pressure (CDPC). After a second recruitment maneuver at CDPO for 5 min, the optimal CDP (CDPOPT) will be set 2 cmH2O above the CDPC for at least 3 min.
61911455|NCT04825197|NO_INTERVENTION|Standard Group|This arm will be managed following the ward standard ventilatory protocol which does not contemplate neither surfactant administration nor recruitment manoeuvre.
61911456|NCT04725357|EXPERIMENTAL|Arthroscopic Labral Repair + postoperative Meloxicam|After surgery participants will receive a prescription of 20 pills of 15 mg Meloxicam
61911457|NCT04725357|ACTIVE_COMPARATOR|Arthroscopic Labral Repair without Meloxicam|After surgery participants will receive a prescription of 20 pills of 5/300 mg vicodin (hydrocodone/acetaminophen)
61911458|NCT03395119|SHAM_COMPARATOR|No Supplements|The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
61911459|NCT03395119|EXPERIMENTAL|Fish oil|Twenty healthy young adults will receive fish oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
61911460|NCT03395119|EXPERIMENTAL|Olive oil|Twenty healthy young adults will receive olive oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
61911461|NCT04585503|EXPERIMENTAL|Central nervous system monitoring|Each 20 patients will be implanted with subdural or intra cortical electrodes
62101692|NCT06463665|ACTIVE_COMPARATOR|Active Comparator Arm|Docetaxel starts in Week 0 and continues until disease progression is assessed by the BICR.
62101693|NCT06463665|OTHER|Active Comparator Arm Cross-over|Patients randomized into the Active Comparator can cross-over to receive the same treatment as given in the Experimental Arm following determination of (1) disease progression by BICR after receiving docetaxel treatment and (2) confirming eligibility.
62101694|NCT06421597|EXPERIMENTAL|Prednisolone group|
62467364|NCT05278481|ACTIVE_COMPARATOR|Social norms message with culturally tailored introduction|
62467365|NCT02351466||Children with Type 1 Diabetes|Subjects with T1 diabetes will undergo a physical exam and blood test as well as structural and functional brain MRI, neurocognitive testing and wear a continuous glucose monitor every 3 months for 24 months.
62101695|NCT06421597|PLACEBO_COMPARATOR|Placebo group|
62101696|NCT05808764|EXPERIMENTAL|Risdiplam|Participants will receive risdiplam once daily for 28 days.
62101697|NCT03178201|EXPERIMENTAL|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
62101698|NCT06472453|EXPERIMENTAL|Alveolar ridge preservation with Allograft/Xenograft group|The patients in both groups will go through the same treatment but with two different bone grafting materials depending on the assigned group. The patients in this group will have alveolar ridge preservation with the mixture of demineralized cortical allograft vallos®f and xenograft bone substitute called Bio-Oss®.
62101699|NCT06472453|ACTIVE_COMPARATOR|Alveolar ridge preservation with Allograft group|The patients in both groups will go through the same treatment but with two different bone grafting materials depending on the assigned group. The patients in this group will have alveolar ridge preservation with mineralized cortico-cancellous bone substitute called vallos®.
62101700|NCT05181306||Robotic surgery|
62101701|NCT05181306||Laparoscopic surgery|
62467366|NCT02351466||Healthy Controls|Subjects will undergo a physical exam and blood test as well as structural and functional brain MRI at baseline and after 24 months.
62101702|NCT06712758||Glaucoma patients in need of cataract surgery|Cataract surgery
62101703|NCT05483907|EXPERIMENTAL|BBT-877|200 mg twice daily (BID)of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
62101704|NCT05483907|PLACEBO_COMPARATOR|Placebo|200 mg twice daily (BID)of Placebo in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
62467367|NCT03878654|EXPERIMENTAL|Tauroursodeoxycholic Acid|TUDCA 1750 mg daily for 12 weeks
62467368|NCT01536574|EXPERIMENTAL|Requip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
62467369|NCT05388318|EXPERIMENTAL|Prolonged nightly fasting (PNF)|
62467370|NCT05388318|ACTIVE_COMPARATOR|Health Education Control (HEC)|
62467371|NCT00530725|ACTIVE_COMPARATOR|chest drainage|This represents the best current standard of care although this is quite controversial
62467372|NCT00530725|EXPERIMENTAL|close observation|This is the novel approach that has some justification in the literature
62467373|NCT03890471|EXPERIMENTAL|Preoperative telephone call|Patients will receive routine preoperative counseling in the clinic plus a provider initiated telephone call 3 days before surgery.
62662938|NCT02018107|EXPERIMENTAL|N-13 ammonia to image liver PET perfusion|This single-arm study involves the non-therapeutic administration of a radiopharmaceutical, N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation procedure. The N-13 ammonia perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure is performed according to our standard clinical practice and is not itself a research activity. The use of N-13 ammonia to image liver perfusion with a PET scanner is the research portion of the procedure. The participant will receive one or two IV doses of N-13 ammonia (10 mCi/dose) for intraprocedural assessment of ablation results. Not more than two doses will be administered and one or both doses will be administered on the day of the tumor ablation procedure only
61911462|NCT02376959|PLACEBO_COMPARATOR|Control Group|"Application of 8 spiritist passe simulation sessions by people without spiritist training at the same time and in the same environment as the treatment group."
62101705|NCT06444009|EXPERIMENTAL|Ivonescimab in combination with Nab-paclitaxel + Cisplatin|"Neoadjuvant:~Patients receive ivonescimab in combination with nab-paclitaxel + cisplatin for 3 cycles before surgery.~Surgery:~Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Adjuvant:~pCR: Patients receive adjuvant ivonescimab for 16 cycles.~no pCR:~Low/ Medium Risk:~Patients will be treated with intensity modulation radiation therapy (IMRT) alone. Once radiotherapy is complete these patients will receive adjuvant ivonescimab for 16 cycles~High Risk:~All patients will be treated with IMRT concurrent with cisplatin or other standard of care chemoradiotherapy regimen. Once chemoradiotherapy is complete these patients will receive adjuvant ivonescimab for 16 cycles."
62662939|NCT05742295|EXPERIMENTAL|Intervention group|vitamin K is used as a prophylactic dose to prevent cefoperazone/sulbactam coagulopathy.
62662940|NCT05742295|NO_INTERVENTION|Control group|
62467374|NCT03890471|NO_INTERVENTION|No preoperative telephone call|Patients will receive routine preoperative counseling in the clinic.
62467375|NCT05940909|OTHER|Sequence TR|25 subjects assigned to the sequence TR will receive a single oral dose of the test product Perindopril Erbumine/Indapamide/Amlodipine (1 x 8 mg/2.5 mg/10 mg tablet), marked as T in the sequence, in Period 1 and a single oral dose of the reference product Triplixam® (1 x 10 mg/2.5 mg/10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62662941|NCT05540327|EXPERIMENTAL|M5049 low dose + Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received low dose of M5049 in WILLOW study will continue to receive M5049 low dose and matching placebo.
62662942|NCT05540327|EXPERIMENTAL|M5049 medium dose+ Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received medium dose of M5049 in WILLOW study will continue to receive M5049 medium dose and matching placebo.
62662943|NCT05540327|EXPERIMENTAL|M5049 high dose + Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received M5049 matched placebo or high dose of M5049 in WILLOW study will receive M5049 high dose .
62662944|NCT05540327|EXPERIMENTAL|M5049 very high dose + Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received M5049 matched placebo or very high dose of M5049 in WILLOW study will receive M5049 very high dose.
62662945|NCT01674855|EXPERIMENTAL|DA-3031|PEG-G-CSF
62662946|NCT01674855|ACTIVE_COMPARATOR|Leucostim®|G-CSF
62662947|NCT05661968|EXPERIMENTAL|Online educational program|A 6-week educational program delivered online based on information and recommendations from international clinical practice guidelines for the management of back pain.
62662948|NCT05661968|NO_INTERVENTION|Control group|The control group will receive no intervention and will be instructed to follow their clinical practice normally.
62662949|NCT01847209|EXPERIMENTAL|CT Marking and VATS lung wedge resection|Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy.
62662950|NCT01069640|EXPERIMENTAL|URLC10-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*0201 or HLA-A\*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62662951|NCT01069640|EXPERIMENTAL|URLC10-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*0201 or HLA-A\*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62662952|NCT01069640|EXPERIMENTAL|URLC10-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*0201 or HLA-A\*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
62662953|NCT04029844|EXPERIMENTAL|Colibri Device|Treatment
61911463|NCT02376959|ACTIVE_COMPARATOR|"Treatment Group (Spiritist passe)"|"Application of 8 sessions of spiritist passe by spiritists with more than 2 years of experience in controlled environments for the same period as the control group."
61911464|NCT03556488||Pediatric CAP|Patients with a clinical diagnosis of CAP and radiographic evidence of lung consolidation, hospitalized in the Pediatric Unit.
61911465|NCT00232869|EXPERIMENTAL|1|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
61911466|NCT00232869|ACTIVE_COMPARATOR|2|SMART™ bare-metal stent
61911467|NCT00977301|EXPERIMENTAL|fosamprenavir/ritonavir/olanzapine|single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID
61911468|NCT00977301|ACTIVE_COMPARATOR|single dose olanzapine|Single dose of 10 mg olanzapine
61911469|NCT05824143|EXPERIMENTAL|Darigabat Followed by Darigabat + Carbamazepine|"Participants will receive darigabat tablet orally once on Day 1 of Treatment Period 1.~Participants will receive carbamazepine tablets, titrated up to a steady-state dose, orally, twice daily (BID) from Day 1 to 17 along with the darigabat tablet orally once on Day 16 of Treatment Period 2."
61911470|NCT05895916|EXPERIMENTAL|Extreme exercise group|1,144 km of road cycling on seven consecutive days
61911471|NCT01073462||Paricalcitol IV|Participants with chronic kidney disease stage 5 with secondary hyperparathyroidism and cardiac morbidity received intravenous (IV) paricalcitol (Zemplar) prescribed according to current practice with regards to dose, population and indication for up to 2 years.
61911472|NCT00689442|EXPERIMENTAL|1|JTT-705 600 mg and atorvastatin 20 mg
62101706|NCT06444009|EXPERIMENTAL|Cadonilimab in combination with Nab-paclitaxel + Cisplatin|"Neoadjuvant:~Patients receive cadonilimab in combination with nab-paclitaxel + cisplatin for 3 cycles before surgery.~Surgery:~Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Adjuvant:~pCR: Patients receive adjuvant cadonilimab for 16 cycles.~no pCR:~Low/ Medium Risk:~Patients will be treated with intensity modulation radiation therapy (IMRT) alone. Once radiotherapy is complete these patients will receive adjuvant cadonilimab for 16 cycles~High Risk:~All patients will be treated with IMRT concurrent with cisplatin or other standard of care chemoradiotherapy regimen. Once chemoradiotherapy is complete these patients will receive adjuvant cadonilimab for 16 cycles."
62101707|NCT06444009|EXPERIMENTAL|Penpulimab in combination with Nab-paclitaxel + Cisplatin|"Neoadjuvant:~Patients receive penpulimab in combination with nab-paclitaxel + cisplatin for 3 cycles before surgery.~Surgery:~Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Adjuvant:~pCR: Patients receive adjuvant penpulimab for 16 cycles.~no pCR:~Low/ Medium Risk:~Patients will be treated with intensity modulation radiation therapy (IMRT) alone. Once radiotherapy is complete these patients will receive adjuvant penpulimab for 16 cycles~High Risk:~All patients will be treated with IMRT concurrent with cisplatin or other standard of care chemoradiotherapy regimen. Once chemoradiotherapy is complete these patients will receive adjuvant penpulimab for 16 cycles."
62101708|NCT05284058|EXPERIMENTAL|Cardiac Magnetic Resonance Imaging|All patients who are candidates for surgical mitral valve repair through minimally-invasive access according to the standard of care will be considered for inclusion in this clinical study. All patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
62101709|NCT01064843||4 Imtec mini-dental implants (MDI)|4 Imtec MDI
62101710|NCT04969822|NO_INTERVENTION|Embryo selection by standard morphologic criteria|The embryo for transfer will be selected by the embryologist on the basis of the morphologic appearances on day 5, according to the Gardner criteria using the ranking guideline.
62662954|NCT05587153||Observational study in parturient who will be recruited for the study|this study will include the eligible parturient who will be assessed by perfusion index and by positional hemodynamic changes.
62662955|NCT02806999|EXPERIMENTAL|Berberine; Insulin|"Follow the previous administration program，participants will continue to receive intensive insulin therapy; Besides injecting insulin, participants will receive 500mg berberine twice a day for 8 days.~Drug: Berberine; Insulin"
62662956|NCT02806999|ACTIVE_COMPARATOR|Insulin|"Besides receiving intensive insulin therapy, participants will take a placebo twice a day for 8 days.~Drug: Insulin"
62662957|NCT03915457|EXPERIMENTAL|Dry immersion Control Group|5 days of dry-immersion
62662958|NCT03915457|EXPERIMENTAL|Thigh Cuffs intervention|5 days of dry-immersion with thigh cuffs
62737194|NCT01947283|NO_INTERVENTION|Control Patients, Intervention Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care. For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
61911473|NCT00689442|PLACEBO_COMPARATOR|2|Placebo and atorvastatin 20 mg
61911474|NCT03314246|OTHER|Intervention|FAST user
61911475|NCT03314246|OTHER|Control|Standard of care
61911476|NCT03597646|EXPERIMENTAL|Kinesio Taping|Kinesio Taping group consisted of 19 patients. Kinesio Tape was applied 2 times a week for a period of 4 weeks. Kinesio Taping was applied for musculus diaphragmaticus, musculus externus obliquus abdominis and internus obliquus abdominis.
61911477|NCT03597646|ACTIVE_COMPARATOR|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
61911478|NCT03597646|NO_INTERVENTION|Control|Control group also consisted of 19 CHF patients. No interventions were applied for them. Pharmacological treatment of control group continued and they were advised for using their medication properly.
62101711|NCT04969822|EXPERIMENTAL|Embryo selection by iDA|Time-lapse videos will be analyzed by iDA and the embryo for fresh transfer on day 5 will be prioritized on the strict basis of the embryo with the highest iDA score. For a frozen cycle; the first embryo to be warmed will be the one with the highest iDA score.
62101712|NCT06544928||All Subjects|"Device: RESP Biosensor The RESP Biosensor will be placed on the patient for recording of auscultory sound.~Other Names:~RESP"
62101713|NCT06709911|EXPERIMENTAL|Basic Manipulation Stretching Group|Focuses on relieving muscle tension and tendon adhesions in the flexor and extensor muscles of the wrist and hand. The intervention aims to improve soft tissue elasticity, enhance joint mobility, and restore functional wrist and hand movement through systematic stretching techniques.
62101714|NCT06709911|EXPERIMENTAL|Massage and Tui Na Manipulation|Uses a combination of massage and Tui Na techniques to target tendon sheaths and surrounding tissues in the wrist and hand. Specific acupoints, such as Hegu, Yangchi, and Waiguan, are stimulated to alleviate inflammation, improve blood circulation, and restore joint functionality. The intervention aims to enhance soft tissue elasticity and range of motion while reducing pain and stiffness.
62467376|NCT05940909|OTHER|Sequence RT|25 subjects assigned to the sequence RT will receive a single oral dose of the reference product Triplixam® (1 x 10 mg/2.5 mg/10 mg tablet), marked as R in the sequence, in Period 1 and a single oral dose of the test product Perindopril Erbumine/Amlodipine/Indapamide (1 x 8 mg/2.5 mg/10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62467377|NCT06272331|OTHER|Low-protein plant-based drink|Ingestion of a low-protein plant-based drink.
61911479|NCT06363305|EXPERIMENTAL|Dietary Capsaicin|Over-the-counter dose of 2 x 440 mg capsules (880 mg, Capsicum Pepper Blend, Daily Manufacturing, Rockwell, North Carolina, USA)
61911480|NCT06363305|PLACEBO_COMPARATOR|Placebo|The placebo will be 2 x 400-500 mg fiber (800 mg psyllium husk) capsules which were chosen to be of similar appearance (size, coloration, and texture).
62467378|NCT06272331|OTHER|High-protein plant-based drink|Ingestion of a high-protein plant-based drink
62467379|NCT06272331|OTHER|Cow's milk|Ingestion of cow's milk.
62662959|NCT03682640|EXPERIMENTAL|AIDIT protocol|"Treatment as usual with the addition of:~i) Azithromycin Monohydrate, three times a week (≥ 48 h between doses) during 52 weeks. 500 mg if body weight ≥ 30 kg, 250 mg if body weight \< 30 kg.~ii) Extra intensive insulin treatment periods for maximum beta-cell rest with Insulin lispro (Sanofi). This treatment will be given i.v. for one episode of 72 hours in the first week after inclusion and s.c. on seven 6-8 h occasions during the study year. The dose will be individually titrated to reach target blood glucose 4.0±0.5 mmol/L.~ii) Dietician support; Extra advice and support from the study dietician within the first week after randomization and after 1.5 and 4 months."
61911481|NCT05987176|NO_INTERVENTION|Standard of Care - Arm A|"Control arm as per standard of care patients go on routine follow up post surgery.~The control arm will consist of best supportive care. The study will be embedded within the regular clinical pathway for treatment and follow-up of patients with resectable NE LM. The follow-up will be according to current guidelines (e.g., Guidelines of the European Neuroendocrine Tumor Society for the management of advanced intestinal NET and pancreatic NET with locoregional and/or distant metastases).~Patients will be followed up in the study for 3 years according to standard post-surgical follow-up protocol and thereafter in their local institution life-long according to follow-up after liver resection for NE LM"
62101715|NCT06709911|EXPERIMENTAL|Blood flow restriction training group|Applies localized blood flow restriction using pressurized equipment on the proximal forearm, combined with low-load exercises such as wrist flexion, extension, clenching, and rotation. The goal is to stimulate muscle adaptation and strength development while minimizing mechanical stress on the joints, ultimately improving hand and wrist functionality.
62101716|NCT06709911|EXPERIMENTAL|Magnetic Bead Pressure Stimulation and Tui Na Manipulation Combined Intervention Group|Combines magnetic bead pressure stimulation and Tui Na manipulation to enhance therapeutic outcomes. Magnetic beads are applied to specific acupoints on the hand and wrist (e.g., Hegu, Ashi, Waiguan) to stimulate circulation and reduce tension. Tui Na techniques, including pressing, kneading, and massaging, further enhance the stimulation, alleviate inflammation, reduce tendon adhesions, and promote mobility recovery.
62662960|NCT03682640|NO_INTERVENTION|Control|Patients will receive treatment as usual (TAU). All patients will receive standard therapeutic treatment consisting of insulin replacement with insulin analogues aiming for normoglycemia from diagnosis. Rapid acting insulin analogue will be administered via insulin pump (continuous subcutaneous infusion) with access to insulin injections in case of malfunction in the pump system.
62737195|NCT01947283|NO_INTERVENTION|Control Patients & Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care."
61911482|NCT05987176|EXPERIMENTAL|Treatment - Arm B|"Treatment with Lutathera post surgery.~In the treatment arm 177Lu-DOTATATE will be applied. The frequency of administration will be 2 cycles (8±1weeks between each cycle). The rationale for 2 cycles instead of 4 (as per standard protocol in palliative setting), assumes that there will be no macroscopic residual tumour after liver resection. Thus, the treatment dose should be sufficient to target microscopic disease, and at the same time have smallest possible effect on healthy tissue."
61911483|NCT05999604|EXPERIMENTAL|annual ocrelizumab infusions|
62101717|NCT03578731||Consilium-APP|Patients with oncological, medical treatment for breast cancer, colon cancer, prostate cancer, lung cancer or hematological malignancies.
62101718|NCT02692846||Control participants with connective tissue disease|Not have a diagnosis of WS. Have a clinical or molecular diagnosis of connective tissue disease, between the ages of 1 and 70 years old
62101719|NCT02692846||Unaffected Control participants|Not have a diagnosis of WS or other connective tissue disease, between the ages of 1 and 70 years old
62101720|NCT02692846||WS participants|Have diagnosis of WS, between the ages of 5 and 70 years old. Be able to tolerate blood pressure measurements.
62101721|NCT06629077|EXPERIMENTAL|Middle-Aged Adults|Middle-Aged Adults between 55-69 years of age.
62101722|NCT06711952|OTHER|Subjective Cognitive Decline Questionnaire (SCD-Q)|Participants receive treatment as usual (appointment in the memory clinic, LMU) and will additionally fill out the questionnaires. A digital cognitive test will be performed.
62467380|NCT05697419|OTHER|DPT students at YSU|
62467381|NCT06217614|ACTIVE_COMPARATOR|(Manuka honey-green tea) interventional arm|• (Manuka honey-green tea) will topically be applied to the oral mucosa as oral rinse 3 times per day to treat xerostomia.
62467382|NCT06217614|PLACEBO_COMPARATOR|Saline mouthwash control group|Patients in the control arm followed the same protocol with normal saline rinses in the same bottles 3 times per day for xerostomia
61911484|NCT05999604|OTHER|semestrial ocrelizumab infusions|
61911485|NCT02853799|OTHER|Continuous Enteral Feeding|"Crossover Study:~Randomized to continuous enteral feeding first then crossed over to receive versus intermittent enteral feeding next."
62467383|NCT03387176||zonulin ≤17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
61911486|NCT02853799|OTHER|intermittent enteral feeding|"Crossover Study:~Randomized to intermittent enteral feeding first then crossed over to receive versus continuous enteral feeding next."
61911487|NCT00663949|ACTIVE_COMPARATOR|A,1,II|patients in this arm takes 25 mg captopril q8h
61911488|NCT00663949|ACTIVE_COMPARATOR|A,2,II|
61911489|NCT03513445|EXPERIMENTAL|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
61911490|NCT03513445|NO_INTERVENTION|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
61911491|NCT06419530|PLACEBO_COMPARATOR|Placebo group|In this arm, 4 placebo capsules would be oral administered by participants everyday for 84 days.
61911492|NCT06419530|ACTIVE_COMPARATOR|Fecal microbiota transplantation (FMT) group|In this arm, 4 FMT capsules would be oral administered by participants everyday for 84 days.
62101723|NCT06712992|EXPERIMENTAL|Trans-spinal direct current stimulation group|Patients in this group will receive Conventional Exercises in addition to tsDCS. We will apply a current density of 0.035 mA/cm2 and will deliver a total charge density of 42.8 mC/cm2, below the threshold values reported for tissue damage. For tsDcs, At the onset of tsDCS, the current will be increased for 30 s, and at the offset, it will be decreased for 30 s in a ramp-like manner. Participants will receive three sessions of treatment per week for four weeks, with a total of twelve sessions.
62662961|NCT02522182|EXPERIMENTAL|Intensive Secondary Prevention Programme|The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
62101724|NCT06712992|SHAM_COMPARATOR|Sham Trans-spinal direct current stimulation group|Patients in this group will receive Conventional Exercises in addition to SHAM tsDCS. For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions. Participants will receive three sessions of treatment per week for four weeks, with a total of twelve sessions.
62101725|NCT05258006|PLACEBO_COMPARATOR|Open flap debridement + allograft bone (Maxgraft)|
62101726|NCT05258006|ACTIVE_COMPARATOR|Open flap debridement + Autogenous demineralized nanoparticles|
62101727|NCT01200953||Confirmed or suspected exposure|Confirmed or suspected exposure to biodefense select agent, to agent of bioterrorism concern, to naturally-occurring pathogen in the environment, to EID agent, or to an individual
62101728|NCT01200953||Confirmed or suspected infection|Confirmed or suspected infection by biodefense select agent, by agent of bioterrorism concern, by naturally-occurring pathogen in the environment, or by emerging infectious disease agent
62101729|NCT01200953||Healthcare worker or healthy volunteer|Healthcare worker or healthy volunteer involved in simulation drills or exercises evaluating the Clinical Center admission, care, and infection control processes
62662962|NCT02522182|ACTIVE_COMPARATOR|Usual Treatment|The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
62662963|NCT01324752|EXPERIMENTAL|PA21 and Losartan with food|
62101730|NCT01200953||Healthcare worker surveillance|Healthcare worker surveillance of medical staff involved in the medical care of patients in the above 2 categories
62295003|NCT05971797|EXPERIMENTAL|Comorbidities|Upon admission to the hospital for surgery to replace large joints (knee or hip joints) and diagnosis with osteoarthritis of the knee or hip joint (M15.0, M16, M17), patients with comorbidities underwent 20-minute psychological counseling (PC) session. During PC the levels of depression (F32.0, F32.1 or F32.9) and anxiety (F41.0, F41.1, F41.3, F41.8 or F41.9) were assessed using the STAI and HADS questionnaires. In the experimental group, patients with identified increased levels of depression or anxiety underwent a session of rational-emotional-behavioral therapy, which aimed to modify incorrect thinking patterns. The level of anxiety and depression was reassessed after the surgery.
62467384|NCT03387176||zonulin >17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
62467385|NCT03047317|EXPERIMENTAL|MABp1|
62467386|NCT05075447|EXPERIMENTAL|ADHD group|Child diagnosed with ADHD
62662964|NCT01324752|EXPERIMENTAL|No PA21; Losartan with food|
62662965|NCT01324752|EXPERIMENTAL|PA21 with food and Losartan 2 hrs later|
61911493|NCT06419530|EXPERIMENTAL|Probiotic formula group|In this arm, 4 Probiotic formula capsules would be oral administered by participants everyday for 84 days.
62101731|NCT06700928|EXPERIMENTAL|Internal focus group|"After obtaining informed consent to participate in the study, all participants, regardless of group, will undergo an assessment by an experienced physiotherapist prior to group allocation. They will participate in exercise sessions lasting approximately 40 minutes, twice a week for 12 weeks in the internal focus group. A total of 24 sessions will be completed by each participant. Exercise sessions will be carried out by an experienced physiotherapist. Each training session will consist of warm-up (5 minutes), balance, transfer and reaching activities (10 minutes), internal focused walking (20 minutes) and cool-down (5 minutes) exercises.~The first assessment will be made before the sessions start and the final assessment will be made after the 12-week exercise program."
62295004|NCT05971797|NO_INTERVENTION|Comorbidities control|Upon admission to the hospital for surgery to replace large joints (knee or hip joints) and diagnosis with osteoarthritis of the knee or hip joint (M15.0, M16, M17), patients with comorbidities underwent 20-minute PC. During PC, their levels of depression (F32.0, F32.1 or F32.9) and anxiety (F41.0, F41.1, F41.3, F41.8 or F41.9) were assessed using the STAI and HADS questionnaires. In the first control group, patients with identified increased levels of depression or anxiety did not receive REBT therapy. The level of anxiety and depression was reassessed after the surgery.
62662966|NCT05861271|EXPERIMENTAL|Arm-1|"Pyrotinib: 400mg QD Po for half a year, and Capecitabine: 500mg Tid Po for half a year Use of endocrine drugs in endocrine receptor (HR)-positive patients after chemotherapy. For premenopausal patients: tamoxifen (10 mg po, bid, for 5 years) or toremifene (60 mg po, qd, for 5 years); for postmenopausal patients: letrozole (2.5 mg, po, qd for 5 years) or anastrozole (1 mg, po, qd for 5 years) or exemestane (25 mg, po, qd for 5 years).~After chemotherapy, radiation therapy will be started if necessary."
62662967|NCT05861271|NO_INTERVENTION|Arm-2|"No adjuvant chemotherapy or targeted therapy. Use of endocrine drugs in endocrine receptor (HR)-positive patients after chemotherapy. For premenopausal patients: tamoxifen (10 mg po, bid, for 5 years) or toremifene (60 mg po, qd, for 5 years); for postmenopausal patients: letrozole (2.5 mg, po, qd for 5 years) or anastrozole (1 mg, po, qd for 5 years) or exemestane (25 mg, po, qd for 5 years).~After chemotherapy, radiation therapy will be started if necessary."
61911494|NCT05191056|PLACEBO_COMPARATOR|Placebo drink|
61911495|NCT05191056|EXPERIMENTAL|MelaGene drink|
61911496|NCT00613067|EXPERIMENTAL|GAD|35 patients with Generalized Anxiety disorder
61911497|NCT06455267|EXPERIMENTAL|L-ornithine supplementation group|Patients in the L-ornithine supplementation group take oral ornithine capsules twice a day, three capsules per time, for 8 weeks, each containing 500mg of L-ornithine.
61911498|NCT06455267|NO_INTERVENTION|control group|The control group did not receive additional intervention.
61911499|NCT02398279|EXPERIMENTAL|L-Arginine-First|For the first three weeks, L-Arginine 3 g bid (500mg capsules 6 x 2), one week wash-out, then for the next three weeks placebo capsules (6 x 2)
61911500|NCT02398279|EXPERIMENTAL|Placebo-First|For the first three weeks, placebo capsules (6 x 2), one week wash-out, then for the next three weeks L-Arginine 3 g bid (500 mg capsules 6 x 2)
61911501|NCT02882152|EXPERIMENTAL|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
61911502|NCT02882152|ACTIVE_COMPARATOR|Morphine|intrathecal morphine
62101732|NCT06700928|EXPERIMENTAL|External focus group|"After obtaining informed consent to participate in the study, all participants, regardless of group, will undergo an assessment by an experienced physiotherapist prior to group allocation. They will participate in exercise sessions lasting approximately 40 minutes, twice a week for 12 weeks in the external focus group. A total of 24 sessions will be completed by each participant. Exercise sessions will be carried out by an experienced physiotherapist. Each training session will consist of warm-up (5 minutes), balance, transfer and reaching activities (10 minutes), external focused walking (20 minutes) and cool-down (5 minutes) exercises.~The first assessment will be made before the sessions start and the final assessment will be made after the 12-week exercise program."
62467387|NCT05075447|NO_INTERVENTION|control group|Children without any diagnosis
62467388|NCT05075447|EXPERIMENTAL|ADHD+ODD/CD group|Child diagnosed with ADHD+ODD/CD
62467389|NCT01560169||Gluten challenge|Gluten containing or gluten-free study food in established celiac disease patients
62467390|NCT01560169||Observation|Observation in newly diagnosed celiac disease patients
62467391|NCT00833339|EXPERIMENTAL|1|mifepristone
62662968|NCT01634594|EXPERIMENTAL|sevoflurane-remifentanil (group R)|Continuous infusion of remifentanil at 0.05 \~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC
62662969|NCT01634594|ACTIVE_COMPARATOR|sevoflurane-nicardipine (group N)|Continuous infusion of nicardipine at 1 \~ 7 mcg/kg/min with sevoflurane concentration of 1 MAC
62662970|NCT01634594|ACTIVE_COMPARATOR|sevoflurane-dexmedetomidine (group D)|Continuous infusion of dexmedetomidine at 0.2 \~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC
62662971|NCT03546959|EXPERIMENTAL|Lycra sleeve after botulinum toxin|8 hours a day lycra sleeve wear plus rehabilitation (for five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
62662972|NCT03546959|ACTIVE_COMPARATOR|Rehabilitation after botulinum toxin|Rehabilitation (five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
61911503|NCT02384642|ACTIVE_COMPARATOR|COMPASS|The COMPASS program will involve a structured intervention for girls between the ages of 10-14 that is intended to engage adolescent girls, those who are influential in their lives, service providers and other stakeholders, with the ultimate goal of co-creating environments in which girls are valued and safe. The program is centered on establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
61911504|NCT02384642|EXPERIMENTAL|COMPASS plus parenting|In the COMPASS plus parenting intervention arm, girls will receive the COMPASS intervention, and In addition to the safe spaces for girls, the COMPASS project will also implement structured activities for the parents and caregivers of participants. The study will examine the relative impact of the parenting initiative in addition to the program for adolescent girls. The study will seek to determine whether the structured intervention with girls' parents has an added impact on outcomes improve girls' safety and well-being.
61911505|NCT06448416||Unilateral Biportal Endoscopy (UBE) Technique|Patient with LDH treated by UBE
61911506|NCT01592656|ACTIVE_COMPARATOR|Non-invasive ventilation (NIV)|30 patients will receive NIV during 6 months = group 1
61911507|NCT01592656|PLACEBO_COMPARATOR|Control group|10 patients will act as control group, they will not be treated with NIV = group 2
61911508|NCT00729846|EXPERIMENTAL|A|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence \[300mw/cm2\] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
61911509|NCT00729846|EXPERIMENTAL|B|Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
61911510|NCT00178503|PLACEBO_COMPARATOR|MPH Trial-Placebo|24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase
61911511|NCT00178503|ACTIVE_COMPARATOR|MPH Trial: Low Dose|24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
61911512|NCT00178503|ACTIVE_COMPARATOR|MPH Trial: Med Dose|24 Participants with ASD-ADHD underwent 1 week at a medium dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
61911513|NCT00178503|ACTIVE_COMPARATOR|MPH Trial: High Dose|24 Participants with ASD-ADHD underwent 1 week at a high dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
61911514|NCT02373371|EXPERIMENTAL|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
61911515|NCT02373371|ACTIVE_COMPARATOR|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
61911516|NCT00737399|EXPERIMENTAL|1|Lifestyle Counseling with Emotional Freedom Techniques (EFT)
61911517|NCT04834960|OTHER|MOV Intervention|Pre-intervention and post-intervention design
61911518|NCT02153879|EXPERIMENTAL|Fenofibrate|Fenofibrate 145 mg/day for 12 weeks
61911519|NCT02153879|EXPERIMENTAL|Niacin plus Laropiprant|Niacin 2g/day plus Laropiprant for 12 weeks
61911520|NCT02470715||Molecular profile|Molecular profiled group receiving treatment based on genetics
61911521|NCT04134403|EXPERIMENTAL|Arm 1: Intervention|Arm will be those that are randomized to receive usual care plus hydrocortisone, thiamine and ascorbic acid.
61911522|NCT04134403|NO_INTERVENTION|Arm 2: Usual care|Arm will be those that are randomized to receive usual care alone.
61911523|NCT01397097|EXPERIMENTAL|Arm 1|
61911524|NCT01397097|ACTIVE_COMPARATOR|Arm 2|
62101733|NCT06700928|EXPERIMENTAL|No attention focus group|"After obtaining informed consent to participate in the study, all participants, regardless of group, will undergo an assessment by an experienced physiotherapist prior to group allocation. They will participate in exercise sessions lasting approximately 40 minutes, twice a week for 12 weeks in the no attention focus group. A total of 24 sessions will be completed by each participant. Exercise sessions will be carried out by an experienced physiotherapist. Each training session will consist of warm-up (5 minutes), balance, transfer and reaching activities (10 minutes), no attentional focus walking (20 minutes) and cool-down (5 minutes) exercises.~The first assessment will be made before the sessions start and the final assessment will be made after the 12-week exercise program."
62662973|NCT04524923||cohort group|Ninety-seven typically developing preschool children of both genders with age ranges from three to five years will be included in this study. Visual motor integration, quality of life and cognitive function were assessed by the Peabody Developmental Motor Scale, the Pediatric Quality of Life Inventory™ and the Pediatric Quality of Life Inventory™ cognitive functioning scale respectively
62101734|NCT06700928|NO_INTERVENTION|Control group|no-intervention
62101735|NCT06711237|EXPERIMENTAL|Self-Adhesive Resin Cement (RC)|Single-unit implant-supported single crowns were cemented to the abutments using a self-adhesive resin cement (RC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
62101736|NCT06711237|EXPERIMENTAL|Resin-modified Glass-Ionomer Cement (RMGIC)|Single-unit implant-supported single crowns were cemented to the abutments using a resin-modified glass-ionomer cement (RMGIC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
62101737|NCT02718443|EXPERIMENTAL|VXM01|VXM01 10E6 or 10E7 CFU
62101738|NCT06713486|EXPERIMENTAL|FIXED PRESSURE|Home nocturnal therapy either at the fixed pressure obtained in the polysomnography for 28 days
62101739|NCT06713486|ACTIVE_COMPARATOR|B|Dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode for 28 days.
62101740|NCT00512824|PLACEBO_COMPARATOR|1|
62101741|NCT00512824|ACTIVE_COMPARATOR|2|
62101742|NCT00512824|ACTIVE_COMPARATOR|3|
62101743|NCT00512824|ACTIVE_COMPARATOR|4|
62101744|NCT03829332|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
62101745|NCT03829332|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
62101746|NCT03924856|EXPERIMENTAL|Pembrolizumab + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.
62101747|NCT03924856|PLACEBO_COMPARATOR|Placebo + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.
62101748|NCT05671705||Stroke patients with sarcopenia|Group will be stratified according to gender
62101749|NCT05671705||Stroke patients without sarcopenia|Group will be stratified according to gender
62101750|NCT00508690|ACTIVE_COMPARATOR|IV|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
62101751|NCT00508690|ACTIVE_COMPARATOR|Oral/IV|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
62101752|NCT06650852|EXPERIMENTAL|BRII-179 + BRII-835 + PEG-IFNα|Participants will receive BRII-179, BRII-835 and PEG-IFNα as a combination therapy.
62101753|NCT06650852|ACTIVE_COMPARATOR|Placebo of BRII-179 + Placebo of BRII-835 + PEG-IFNα|Participants will receive placebo of BRII-179, placebo of BRII-835 and PEG-IFNα.
62101754|NCT04616482||Digital therapeutic carbohydrate restriction (TCR) program|The intervention involves 12 weeks of online/app-based behaviour change coaching. Each week the participant focuses on a different aspect of healthy eating habits designed to cut sugar and refined carbohydrates while encouraging and providing resources for lower-carbohydrate food options. Education is done through short videos and information sheets. Participants set goals and complete worksheets/tasks based on their individual goals.
62101755|NCT05544136|EXPERIMENTAL|Participants with Squamous Cell Carcinoma Head and Neck Cancer|Participants will be hypoxia-negative T0-3N1-2B small cell carcinoma head and neck cancer/SCC HNC patients (HPV-OPC, HPV- UPC with nodal metastasis(es), HPC, or LXC) who are eligible for definitive CRT with de-escalated radiation concurrent with 2 cycles of SOC chemotherapy. Hypoxia status will be determined by the absence of hypoxia radiotracer uptake on 18F-FMISO PET/CT imaging
62101756|NCT06388421||Cohort 1|Cohort 1 will include approximately 500 patients who are not receiving inhaled treprostinil at time of study enrollment.
62101757|NCT06388421||Cohort 2|Cohort 2 will include approximately 150 patients who are newly initiated on Tyvaso/Tyvaso DPI. For patients to be eligible for Cohort 2, they must have initiated Tyvaso/Tyvaso DPI at Baseline or ≤ 60 days prior to Baseline.
62467392|NCT00833339|PLACEBO_COMPARATOR|2|
62662974|NCT02092935|EXPERIMENTAL|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
62662975|NCT02092935|ACTIVE_COMPARATOR|Vancomycin|125 mg capsule four times a day for 10 days
62662976|NCT02166879||Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Chart review from patients undergoing elective surgery.
62662977|NCT02722291|EXPERIMENTAL|presbyopia|All participants perform all exams under 3 conditions, that is baseline, with out pinhole glasses, and with multiple pinhole glasses
62467393|NCT01459185|EXPERIMENTAL|S-1|Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
61911525|NCT03739242|EXPERIMENTAL|Nutraceutical combination|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
62662978|NCT01855906|ACTIVE_COMPARATOR|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
62467394|NCT01591603|EXPERIMENTAL|Group 1|
62101758|NCT06388421||Cohort 3|Cohort 3 will include approximately 350 patients who have been receiving Tyvaso/Tyvaso DPI for \> 60 days prior to Baseline.
62101759|NCT06377982|EXPERIMENTAL|hUCB treatment|Human cord blood infusion
61911526|NCT03739242|PLACEBO_COMPARATOR|Placebo|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
62101760|NCT06377982|NO_INTERVENTION|Placebo treatment|Placebo infusion
62101761|NCT05133037||Adolescent girls between 12-16 years old|Parental history of eating pathology or no parental history of eating pathology
62467395|NCT01591603|EXPERIMENTAL|Group 2|
62467396|NCT04546334|EXPERIMENTAL|Group A|Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block
62467397|NCT04546334|EXPERIMENTAL|Group B|Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment.
62467398|NCT04546334|EXPERIMENTAL|Group C|Patients that will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment.
62467399|NCT01133470|EXPERIMENTAL|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
62467400|NCT01133470|ACTIVE_COMPARATOR|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
62467401|NCT05207709|EXPERIMENTAL|Ribociclib + Endocrine Therapy|Ribociclib + Fulvestrant or Letrozole
62467402|NCT05207709|EXPERIMENTAL|Palbociclib + Endocrine Therapy|Palbociclib + Fulvestrant or Letrozole
62467403|NCT05207709|EXPERIMENTAL|Paclitaxel +/- Tislelizumab - Exploratory cohort|Additional experimental Cohort that includes patients with Basal-Like intrinsic subtype.
62467404|NCT05277025||Fibromyalgia|Participants who fulfill the 1990 and 2011 American College of Rheumatology Criteria for FM.
62467405|NCT05277025||Rheumatoid Arthritis|Participants who fulfill the 2010 American College of Rheumatology (ACR)-European League against rheumatism (EULAR) classification criteria for RA.
62467406|NCT05277025||Healthy Volunteers|Participants who do not have significant pain/fatigue/anxiety/depression.
62467407|NCT02833389|EXPERIMENTAL|Cohort A - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 1|Participants with 0.8-6.0 centimeters square (cm\^2) index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 1 for 12 weeks (a total of 4 doses).
62467408|NCT02833389|EXPERIMENTAL|Cohort B - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 2|Participants with 0.8-6.0 cm\^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
62467409|NCT02833389|EXPERIMENTAL|Cohort C - UTTR1147A, 0.8-6.0 cm^2, Mild Infection - Dose 2|Participants with 0.8-6.0 cm\^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
62467410|NCT02833389|EXPERIMENTAL|Cohort D - UTTR1147A, 1.5-6.0 cm^2, Mild Infection - Dose 2|Participants with 1.5-6.0 cm\^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
62467411|NCT02833389|EXPERIMENTAL|Cohort E - UTTR1147A, 0.8-6.0 cm^2, No infection - Dose 3|Participants with 0.8-6.0 cm\^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 3 for 12 weeks (a total of 4 doses).
62662979|NCT01855906|ACTIVE_COMPARATOR|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
62662980|NCT03677401|EXPERIMENTAL|5 mg Serlopitant Tablets|
62662981|NCT03677401|PLACEBO_COMPARATOR|Matching Placebo Tablets|
62662982|NCT01016587||COPD patients|Not hospitalized COPD patients, degree 2-4.
62101762|NCT05534633|OTHER|Participants requesting test(s) for HIV, HCV, and/or syphilis|
62101763|NCT05139732||control|Healthy participants
62101764|NCT05139732||Functional Neurological Disorder (FND)|People with the subtype functional paralysis
62101765|NCT05139732||Spinal Cord Injury (SCI)|Incomplete and complete paralysis with the ability to hold a pen
62101766|NCT01368861||control|water and normal physical comfort provided by mom
62101767|NCT01368861||sucrose|sugar and normal physical comfort provided by mom
62101768|NCT01368861||physical intervention|physical intervention using the 5 S's and water
62101769|NCT01368861||physical intervention and sucrose|Physical intervention using the 5 S's and sugar water
62101770|NCT06609863|EXPERIMENTAL|dTACE-HAIC plus Bevacizumab and Atezolizumab|dTACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then drug-eluting microspheres was used (100-300um, 300-500um). Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin every 4 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 200 mg intravenously every 2 weeks.
62101771|NCT05653674|EXPERIMENTAL|Experiment|The experimental group will consist of 40 students in total, 4 groups of 10 students each, and the students will receive face-to-face psychoeducation for 6 weeks, each session for 60 minutes.
62101772|NCT05653674|NO_INTERVENTION|Control|The control group will not receive any intervention during the application period and will be put on waitlist.
62662983|NCT04622956|EXPERIMENTAL|Experimental|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present. Filgrastim will be administered from day +5 until neutrophil recovery to ≥ 1,000/mcL for 3 days.
62662984|NCT04622956|NO_INTERVENTION|Control Group|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and mycophenolate mofetil (15 mg/kg/dose p.o. t.i.d. initiated on day +5). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present.
61911527|NCT00130247|EXPERIMENTAL|2EHRZ/2HR arm|Daily treatment with isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.
62101773|NCT06041087|EXPERIMENTAL|Exercise and Greek Yogurt (GY)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume \~200g Greek yogurt (0% milk fat). An additional blood sample will be taken at 1h post-exercise, followed by an additional \~200g of Greek yogurt. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
62662985|NCT01587404|EXPERIMENTAL|Constant Catheter Contact Force|No alteration of catheter contact force during recording period
62662986|NCT01587404|EXPERIMENTAL|Variable catheter contact force|change in contact force from low to high after 30seconds of recording.
61911528|NCT00130247|ACTIVE_COMPARATOR|2EHRZ/4HR arm|Daily treatment with Isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.
61911529|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
62101774|NCT06041087|EXPERIMENTAL|Exercise and Milk (Milk)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume \~500ml plain skim milk (0% milk fat). An additional blood sample will be taken at 1h post-exercise, followed by an additional \~500ml of skim milk. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
62662987|NCT00940173|OTHER|Group 1|Dose Group 1 (Receiving a dose of 10,000 IEQ/kg of DIABECELL(R))
62662988|NCT00940173|OTHER|Group 2|Dose Group 2 (Receiving a dose of 15,000 IEQ/kg of DIABECELL(R))
62662989|NCT00940173|OTHER|Group 3|Dose Group 3 (Receiving a dose of 20,000 IEQ/kg of DIABECELL(R))
62662990|NCT00940173|OTHER|Group 4|Dose Group 4 (Receiving a dose of 5,000 IEQ/kg of DIABECELL(R))
62662991|NCT03731013|EXPERIMENTAL|Mediterranean diet (MedDiet)|
62662992|NCT03731013|EXPERIMENTAL|Physical activity (PA)|
61911530|NCT03029884|EXPERIMENTAL|Sham DBS|"Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in sham, open-loop and closed-loop DBS, blinded to the participant.~Open Loop involves tonic stimulation of ACC of OFC brain region. During closed-loop DBS sessions, stimulation will be delivered in response to identified personalized, brain biomarkers of chronic pain.Sham involves no active stimulation - brain recordings will remain active with no active stimulation. Because more than 6 sequences were used, only 1 Arm/Group is defined."
62467412|NCT02833389|PLACEBO_COMPARATOR|Placebo|Participants will receive UTTR1147A matching placebo SC in each cohort for 12 weeks (a total of 4 doses).
62467413|NCT01305018|EXPERIMENTAL|Exercise and BCAA|
62467414|NCT01305018|EXPERIMENTAL|Exercise and Leucine|
62662993|NCT03731013|EXPERIMENTAL|Mediterranean diet and physical activity|
62662994|NCT03731013|NO_INTERVENTION|Control|
62662995|NCT01600859|EXPERIMENTAL|E2609|
62467415|NCT01305018|PLACEBO_COMPARATOR|Exercise and Placebo|
61911531|NCT03029884|EXPERIMENTAL|Open-Loop DBS and Closed-Loop DBS|"Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in sham, open-loop and closed-loop DBS, blinded to the participant.~Open Loop involves tonic stimulation of ACC of OFC brain region. During closed-loop DBS sessions, stimulation will be delivered in response to identified personalized, brain biomarkers of chronic pain.Sham involves no active stimulation - brain recordings will remain active with no active stimulation. Because more than 6 sequences were used, only 1 Arm/Group is defined."
62101775|NCT06041087|ACTIVE_COMPARATOR|Exercise and Carbohydrate (CHO)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume \~50g of maltodextrin mixed with water (\~500ml). An additional blood sample will be taken at 1h post-exercise, followed by an additional \~500ml of the maltodextrin drink. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
62101776|NCT06041087|PLACEBO_COMPARATOR|Exercise and Water (W)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume \~500ml water. An additional blood sample will be taken at 1h post-exercise, followed by an additional \~500ml water. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
62101777|NCT06056674|EXPERIMENTAL|U-PEACE Group|Participants in this group will receive the U-PEACE intervention (study participation to last approximately 13 weeks).
62101778|NCT06056674|ACTIVE_COMPARATOR|Services As Usual (SAU) Group|Participants in this group will receive service as usual (study participation to last approximately 13 weeks).
62467416|NCT04793347|EXPERIMENTAL|shock waves|group of patients with anal fissure will be treated with shock waves
62467417|NCT06459271|EXPERIMENTAL|Newly Diagnosed + Recently Recurred|n = 50 patients with ovarian cancer (stage III or IV) will be enrolled in the study (25 newly diagnosed and 25 recently recurred).
61911532|NCT02891785|EXPERIMENTAL|ANtiPain intervention|ANtiPain is a cancer pain self-management support intervention administered by nurses in an intervention session while the patient is still hospitalized and via phone calls after discharge. ANtiPain is based on three key strategies: information, skill building and nurse coaching.
62101779|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
62101780|NCT06491615||Participants|Participants with inherited eye diseases or relative of affected participant
62662996|NCT01600859|PLACEBO_COMPARATOR|Placebo for E2609|
62662997|NCT05405712|EXPERIMENTAL|Marigold APP|Participants randomized to receive the APP will be enrolled in an app based peer support program
61911533|NCT02891785|NO_INTERVENTION|standard care|Standard care will be described as part of the study.
62101781|NCT00586274|EXPERIMENTAL|CD34 selected haploidentical PBSCT|CD34 selected haploidentical PBSCT
62101782|NCT05202379|EXPERIMENTAL|SAD cohort 1A|first dose level with 6 active and 2 placebo healthy participants
62101783|NCT05202379|EXPERIMENTAL|SAD cohort 1B|second dose level with 6 active and 2 placebo healthy participants
62101784|NCT05202379|EXPERIMENTAL|SAD cohort 1C|third dose level with 12 active and 2 placebo healthy participants; food-effect cohort
62101785|NCT05202379|EXPERIMENTAL|SAD cohort 1D|fourth dose level with 6 active and 2 placebo healthy participants
61911534|NCT03691740|EXPERIMENTAL|Experimental|Ocular light will be applied via a mask. The participants allocated to the experimental group will receive blue light
61911535|NCT03691740|PLACEBO_COMPARATOR|Control|Ocular light will be applied via a mask. The participants allocated to the control group will receive red light
62101786|NCT05202379|EXPERIMENTAL|MAD cohort 2A|first dose level with 6 active and 2 placebo healthy participants dose x 14 days
62101787|NCT05202379|EXPERIMENTAL|MAD cohort 2B|second dose level with 6 active and 2 placebo healthy participants dose x 14 days
62101788|NCT05202379|EXPERIMENTAL|MAD cohort 2C|third dose level with 6 active and 2 placebo healthy participants dose x 14 days
62101789|NCT05202379|EXPERIMENTAL|MAD cohort 2D|forth dose level with 6 active and 2 placebo healthy participants dose x 5 days
62101790|NCT05202379|EXPERIMENTAL|MAD cohort 2E|forth dose level with 6 active and 2 placebo healthy participants dose x 5 days
62101791|NCT03658941|EXPERIMENTAL|No dural tenting sutures|No dural tenting techniques
62467418|NCT00957450||1|"Impact of organ motion~Characterize the impact of normal organ motion in the pelvic on tumour movement, during treatment. This will be assessed in patients with pelvic cancer."
62467419|NCT01661686|ACTIVE_COMPARATOR|Insertion of a partially covered SEMS|
62467420|NCT01661686|ACTIVE_COMPARATOR|Insertion of a Fully covered SEMS|
62467421|NCT01802086|ACTIVE_COMPARATOR|Emla-cream|Dose: 1 g Emla-cream, 1 hour.
62467422|NCT01802086|PLACEBO_COMPARATOR|Miniderm cream|Dose: 1 g Miniderm-cream, 1 hour.
62467423|NCT00746798|EXPERIMENTAL|ChimeriVax WN02 vaccine, low dose|Participants randomized to receive ChimeriVax WN02 vaccine, low dose
62467424|NCT00746798|EXPERIMENTAL|ChimeriVax-WN02 vaccine, medium dose|Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
62467425|NCT00746798|EXPERIMENTAL|ChimeriVax-WN02 vaccine, high dose|Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
62467426|NCT00746798|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive Placebo (Saline)
62467427|NCT01566396|EXPERIMENTAL|A3F|A3F, Fractional RF treatment
62662998|NCT05405712|NO_INTERVENTION|CONTROL|In the control arm participants will receive existing standardized peer recovery support resources from SAMHSA
62101792|NCT03658941|ACTIVE_COMPARATOR|Dural tenting sutures|Dural tenting techniques
62101793|NCT01930279||surface markers on T cells as assessed by FACS|
62662999|NCT06008002|ACTIVE_COMPARATOR|Group M|ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block
62663000|NCT06008002|ACTIVE_COMPARATOR|Group E|Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block
62663001|NCT06008002|ACTIVE_COMPARATOR|Group P|Patient-controlled analgesia with tramadol
62663002|NCT00774748|EXPERIMENTAL|I|All participants in the study will use the subcutaneous catheter twice for a period of one week each to inject the enoxaparin. For the remainder of the study the participants will inject subcutaneously.
62663003|NCT02782104|EXPERIMENTAL|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
62663004|NCT01051804|EXPERIMENTAL|Systane Ultra|Systane Ultra Lubricant Eye Drops
62101794|NCT06307795|EXPERIMENTAL|ANS014004 Monotherapy|"Part 1 aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of ANS014004.~Part 2 aims to determine the safety, tolerability and evaluate anti-tumor activity of ANS014004 as monotherapy in select solid tumors."
62101795|NCT02924454|EXPERIMENTAL|Metoprolol-Lipid emulsion|intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
62101796|NCT02924454|EXPERIMENTAL|Metoprolol - normal saline|intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
62101797|NCT02924454|EXPERIMENTAL|Normal saline-Lipid emulsion|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
62101798|NCT02924454|EXPERIMENTAL|Normal saline-normal saline|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
62101799|NCT06325553||1|"Case group (PFB transfusion) Inclusion criteria~1. Newly diagnosed acute leukemia (either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) patients underwent intensive chemotherapy~2. Age greater than 18 years~3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy~Exclusion criteria~1. Participants with positive platelet antibody detected by SPRCA method at presentation~Withdrawal or termination criteria~1. Loss to follow up or death before completion of first consolidation chemotherapy~2. Participants receiving granulocyte infusion during time of study~3. Participants receiving SDP transfusion during time of study"
62101800|NCT06325553||2|"Historical control group 1 (non-leukocyte depleted blood product) Inclusion criteria~1. Newly diagnosed acute leukemia (either AML or ALL) patients underwent intensive chemotherapy during 2018-2022~2. Age greater than 18 years~3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy~4. Participants receiving only non-leukocyte depleted blood products (LPB and LPPC)~Exclusion criteria~1. Loss to follow up or death before completion of first consolidation chemotherapy~2. Participants receiving granulocyte infusion during time of study"
62101801|NCT06325553||3|"Historical control group 2 (leukocyte depleted blood product) Inclusion criteria~1. Newly diagnosed acute leukemia (either AML or ALL) patients underwent intensive chemotherapy during 2018-2022~2. Age greater than 18 years~3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy~4. Participants receiving leukocyte depleted blood products (PFB and SDP)~Exclusion criteria~1. Loss to follow up or death before completion of first consolidation chemotherapy during 2018-2022~2. Participants receiving granulocyte infusion during time of study~3. Participants receiving non-leukocyte depleted blood products greater than 20% of all transfused blood products during induction and first consolidation chemotherapy"
62101802|NCT06547645|NO_INTERVENTION|Facility-based|Facility based post acute care at a skilled nursing facility, as is the standard care model.
62101803|NCT06547645|ACTIVE_COMPARATOR|Home-based|Home-based Post-Acute Care
62101804|NCT06033300|EXPERIMENTAL|suspected heparin-induced thrombocytopenia:|
62663005|NCT01051804|ACTIVE_COMPARATOR|Optive|Optive Lubricant Eye Drops
62663006|NCT01279200|ACTIVE_COMPARATOR|Urinary LH Kits|Patients randomized to this arm will monitor ovulation with home-based urinary LH kits (Ovulation Predictor Kits, OPK's).
62101805|NCT05538754|OTHER|EVO ICL|STAAR EVO implantable collamer lens (ICL) for the correction or reduction of myopia or myopia with astigmatism.
62101806|NCT06712823|EXPERIMENTAL|Treatment|Open-label treatment period (up to 2 years). The maximum atumelnant dose permitted is not to exceed the highest atumelnant dose explored in a parent study for the indication.
62663007|NCT01279200|ACTIVE_COMPARATOR|Midcycle ultrasound + hCG injection|Patients randomized to this arm will undergo ovulation monitoring with midcycle ultrasound and receive hCG injection if evidence of a mature size follicle.
62663008|NCT04591015|EXPERIMENTAL|DD-CA|In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
62101807|NCT06713174|OTHER|assessment of interleukin 8,10 pre and post|"Gingival crevicular fluid sampling Gingival crevicular fluid (GCF) will be collected at two different time points. The collection periods will be defined as follows: before initiating access into the root canal (period 1), and before canal filling (period 2).~Periapical Fluid sample:~Periapical fluid samples will be collected at two different time points. The collection periods will be defined as follows: just after crown access and before root canal filling , by introducing 3 sequential sterile absorbent paper points of a size compatible with the root canal. These paper points will be introduced into the canal until they extend 2 mm beyond the radiographically determined apex."
62101808|NCT06712108||Adult patients with hematologic disease who will receive double unit cord blood tranplant|
62101809|NCT04321642|EXPERIMENTAL|Entonox|Inhalation Entonox in active phase of labor ( cervical dilatation more than 5 cm ) Inhaled Entonox before true uterine contraction in 30 sec , inhaled in 4-5 times for 1 contraction
62101810|NCT04321642|ACTIVE_COMPARATOR|Not receive Entonox|Not receive any gas when archive in active phase of labor( cervical dilatation more than 5 cm )
62101811|NCT06366282|EXPERIMENTAL|Peritraumatic Distress Inventory (PDI) Tool - Trauma Counseling|Screening using Peritraumatic Distress Inventory (PDI) tool and one or more caregiver intervention during a single hospitalization
61911536|NCT03454009|EXPERIMENTAL|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
62101812|NCT06366282|ACTIVE_COMPARATOR|Peritraumatic Distress Inventory (PDI) Tool - Standard of Care|Screening using the Peritraumatic Distress Inventory (PDI) tool and standard of care related to acute stress and post-traumatic stress
62663009|NCT04591015|ACTIVE_COMPARATOR|Usual Care (UC)|UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
62295005|NCT05971797|ACTIVE_COMPARATOR|No comorbidities|Upon admission to the hospital for surgery to replace large joints (knee or hip joints) and diagnosis with osteoarthritis of the knee or hip joint (M15.0, M16, M17), patients without comorbidities underwent 20-minute PC session. During PC the levels of depression (F32.0, F32.1 or F32.9) and anxiety (F41.0, F41.1, F41.3, F41.8 or F41.9) were assessed using the the STAI and HADS questionnaires. In the second control group, patients with identified increased levels of depression or anxiety underwent a session of rational-emotional-behavioral therapy, which aimed to modify incorrect thinking patterns. The level of anxiety and depression was reassessed after the surgery.
62101813|NCT01763047|ACTIVE_COMPARATOR|etafilcon A/lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.
62101814|NCT01763047|ACTIVE_COMPARATOR|lotrafilcon B/etafilcon A|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.
62101815|NCT06545786||Non-cardiac surgery|Patients scheduled for non-cardiac surgery of intermediate to high risk
62101816|NCT04436120|OTHER|Tumor biopsy and blood draw|Tumor biopsy and blood draw
62663010|NCT01725399|PLACEBO_COMPARATOR|Water|Water will be given as the study subject's first oral intake after emergence from general anesthesia.
62663011|NCT01725399|EXPERIMENTAL|Apple Juice|Apple juice will be given as the study subject's first oral intake after emergence from general anesthesia.
61911537|NCT03454009|NO_INTERVENTION|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
62101817|NCT05328973|OTHER|ELEQUIL|Aromatherapy will be provided using a lavender-peppermint patch called an Aromatab.
62101818|NCT04679363|EXPERIMENTAL|Active release technique group|Active release technique group (ART group) will receive Oscillatory mobilization with active release technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
62101819|NCT04679363|EXPERIMENTAL|Post isometric relaxation group|Post isometric relaxation group (PIR group) will receive Oscillatory mobilization with post isometric relaxation technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
62101820|NCT06628999|EXPERIMENTAL|Visual Training Group|Visual Training Group: physical training exercises aiming to combine visual skills with basic motor actions for 16 consecutive weeks
62101821|NCT06628999|ACTIVE_COMPARATOR|Control Group|Control Group: active lifestyle based on healthy habits for 16 consecutive weeks
62663012|NCT03672162|ACTIVE_COMPARATOR|Gabapentin Group|Subjects will receive Gabapentin 600 mg (two capsules of Gabapentin 300 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
62663013|NCT03672162|ACTIVE_COMPARATOR|Celecoxib Group|Subjects will receive Celecoxib 400 mg (two capsules of Celecoxib 200 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
62101822|NCT06628999|EXPERIMENTAL|Visual Training-detraining Group|Visual Training-detraining Group: physical exercises physical training exercises aiming to combine visual skills with basic motor actions for 8 consecutive weeks. The last remaining 8 weeks (up to 16 week) the group will conduct a period of detraining in which no physical exercises will be administered
62101823|NCT06111235|EXPERIMENTAL|Cretostimogene after TURBT|Following screening confirmation of IR-NMIBC and complete resection of the tumor, participants will be treated with adjuvant cretostimogene.
62101824|NCT06111235|NO_INTERVENTION|Observation after TURBT|"Following screening confirmation of IR-NMIBC and complete resection of tumor, participants will enter observation.~Participants who recur with IR-NMIBC after TURBT and observation will be offered treatment with cretostimogene as per the treatment schedule in Arm A. This arm will be called the Extension Arm."
62101825|NCT02922972|EXPERIMENTAL|Platelet Rich Plasma|Interventions: Four injections of PRP: The first injection of A-PRP after complete resection of the keloid scar,Three additional injections were administered with a one-month interval.
62663014|NCT03672162|PLACEBO_COMPARATOR|Placebo group|Subjects will receive Placebo (two capsules of placebo) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
62663015|NCT01910441|EXPERIMENTAL|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
61911538|NCT06080139|EXPERIMENTAL|parenting sessions group|This arm will receive a culturally adapted parenting curriculum twice a week for 4 weeks during month 3 of the study
61911539|NCT06080139|ACTIVE_COMPARATOR|waitlist control group|This arm will receive a handout about parenting techniques in Spanish during month 3. They then receive the same parenting curriculum during month 4.
62101826|NCT04413565|EXPERIMENTAL|Two surgeon bilateral TKA group|2 surgeons will perform simultaneous total knee arthroplasty in this group.
62101827|NCT04413565|ACTIVE_COMPARATOR|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
62663016|NCT01910441|ACTIVE_COMPARATOR|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
62663017|NCT03909503|EXPERIMENTAL|Porcine-derived collagen wound dressing|The dressing is a sheet of collagen composed of type I collagen derived from porcine peritoneal membrane. The dressing also contains additional components from the procine extracellular matrix. The dressing is a currently marketed, cleared device in the United States indicated for the management of full- and partial-thickness wounds, including: pressure ulcers, diabetic ulcers, venous ulcers, and several other wound types.
62663018|NCT05527080||typically developing infants|recruitment at 5-8mos of age; infants are considered typically developing if they are born at term age with no neurologically significant medical history, and they are not medically followed up for a suspicion of such. The benchmark for this is taken from the nationally harmonized pre/postnatal screening practise.
61911540|NCT04744376||Major GIS Surgery|"The cohort includes all the patients who undergone major gastrointestinal (GIS) surgery.~Major GIS surgery includes:~1. Gastric surgery~2. Duodenal surgery~3. Pancreatic surgery~4. Hepatobiliary surgery~5. Colonic surgery~6. Rectal surgery"
61911541|NCT04595994|EXPERIMENTAL|Selinexor + Gemcitabine|"Dose escalation levels (Phase I):~All included patients will take both drugs:~Selinexor weekly (given on days 1,8 and 15 of each cycle) will be dispensed at different dose levels: dose level 1:60 mg, dose level 2: 60 mg, dose level 3: 60 mg, and dose level 4: 80 mg).~Gemcitabine weekly (given on days 1, 8 of each cycle) will be administered at different dose levels: (dose level 1:1000 mg/m2 (30 min), dose level 2:1000 mg/m2 (10 mg/m2/min), dose level 3:1200 mg/m2 (10 mg/m2/min) and dose level 4: 1200 mg/m2 (10 mg/m2/min)).~Selinexor: tablet (20 mg tablets) Oral use.~Gemcitabine: Concentrate for solution for infusion. Intravenous use."
61911542|NCT03320525|EXPERIMENTAL|Experimental|The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
61911543|NCT05557825||Radiodermatitis Case Group|03 patients with grade 2 to 4 radiodermatitis after radiotherapy for the treatment of head and neck cancer submitted to a PBM/PDT therapy protocol
61911544|NCT02400411|EXPERIMENTAL|Wheat bread|Bread-based meal
61911545|NCT02400411|EXPERIMENTAL|Wheat bread with margarine and ham|Bread-based meal
61911546|NCT02400411|EXPERIMENTAL|Wheat bread with margarine, ham and soup|Bread-based meal
61911547|NCT02400411|EXPERIMENTAL|Rye bread|Bread-based meal
61911548|NCT02400411|EXPERIMENTAL|Rye bread with margarine and ham|Bread-based meal
61911549|NCT02400411|EXPERIMENTAL|Rye bread with margarine, ham and soup|Bread-based meal
61911550|NCT02085642|EXPERIMENTAL|Acupuncture|True acupuncture
61911551|NCT02085642|SHAM_COMPARATOR|Sham needle|Retractable acupuncture needles will be used. No true transcutaneous needling through the skin
62295006|NCT02505984|ACTIVE_COMPARATOR|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
62295007|NCT02505984|PLACEBO_COMPARATOR|Placebo|Sub-group of participants receiving placebo nasal spray
62295008|NCT02113293|EXPERIMENTAL|CyclASol®|CyclASol®
62295009|NCT02113293|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle)
61911552|NCT01246154||EXERCISE TOLERANCE|
61911553|NCT00439049||A|Cocaine Dependent Subjects
61911554|NCT06131528|EXPERIMENTAL|Relaxation Breathing Exercises Group|This group preformed Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing on alternative pattern for 10 minutes to 30 minutes. These exercises are performed daily with 6 breaths per min. The minimum duration was 3 min for one session.
61911555|NCT06131528|ACTIVE_COMPARATOR|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management and include weight reduction, following the DASH eating plan with sodium restrictions, daily physical activity, and moderate alcohol consumption. In addition, all patients should be advised to stop smoking to reduce the risk of cardiovascular diseases.
61911556|NCT02700334|EXPERIMENTAL|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
61911557|NCT02700334|PLACEBO_COMPARATOR|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
61911558|NCT02635646|EXPERIMENTAL|Family and interdisciplinary approach|Family and interdisciplinary approach: Patients in this group will receive a Family and interdisciplinary approach that includes nutritional, physical activity and psychological counseling + metformin 850mg twice at day for 12 months
61911559|NCT02635646|ACTIVE_COMPARATOR|individual approach|individual approach: Patients in this group will receive individual approach that includes nutritional and physical activity counseling + metformin 850mg twice at day for 12 months
61911560|NCT04473235|EXPERIMENTAL|Literacy training|The basic-literacy training will be given for two hours/day for four days/week for 6 months. At baseline, participants will be randomized into four classes of 30. An expert in adult education will oversee the classes and meet the teachers periodically, and each class will count with a certified and experienced lead teacher and teacher aid. The intervention group will receive literacy training based on analytical and phonemic methods for enabling reading and writing
61911561|NCT04473235|ACTIVE_COMPARATOR|Non-literacy training|The comparator group will have access to non-literacy classes offered at the adult school, including geography, history, informatics, and sciences, but no literacy-training, for two hours/day for four days/week for 6 months.
62295010|NCT01482702|EXPERIMENTAL|weight loss intervention|Behavioral weight loss intervention
62295011|NCT01482702|EXPERIMENTAL|Weight Loss plus Resistance Training|Behavioral weight loss intervention with the addition of resistance training
62295012|NCT01482702|ACTIVE_COMPARATOR|Comparator|Group of women who did not receive chemotherapy
62295013|NCT05034640||Conventional Multiport Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had multiport video assisted thoracoscopic surgery for pediatric pneumothorax.
62295014|NCT05034640||Single Port Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had single port video assisted thoracoscopic surgery for pediatric pneumothorax.
62295015|NCT00870688||1|epilepsy patients
62295016|NCT01276288|ACTIVE_COMPARATOR|Reference 1|administration of BI 10773 once daily for 5 days (20 patients)
62295017|NCT01276288|ACTIVE_COMPARATOR|Reference 2|administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)
62295018|NCT01276288|ACTIVE_COMPARATOR|Reference 3|administration of torasemide (TOR) once daily for 4 days (10 patients)
62295019|NCT01276288|EXPERIMENTAL|Test 1|administration of BI 10773 + HTC once daily for 5 days (10 patients)
62295020|NCT01276288|EXPERIMENTAL|Test 2|administration of BI 10773 + TOR once daily for 5 days (10 patients)
62295021|NCT03541473|ACTIVE_COMPARATOR|Peptamen® 1.5 Vanilla|
62295022|NCT03541473|PLACEBO_COMPARATOR|Boost Plus® Vanilla|
62467428|NCT02512952|ACTIVE_COMPARATOR|Group 1|SRP with Open flap debridement (OFD) alone for treating periodontal pocket
62467429|NCT02512952|ACTIVE_COMPARATOR|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into bone defect
62663019|NCT05527080||neurodevelopmental concern|recruitment at 5-8mos of age; infants are recruited from the outpatient clinic in the New Children's hospital (NCH). They have either a known perinatal risk factor (e.g.stroke, HIE, meningitis), or they are referred to pediatric neurologists at NCH due to a suspected delay or deviance in neurodevelopment.
62663020|NCT05527080||hip dysplasia concern|recruitment at 2-6 weeks of age after perinatal clinical suspicion of hip dysplacia. These infants may be left out of follow-up (mild), or treated by orthopedic clinic with a soft brace (moderate) or a stronger cast (sever)
62663021|NCT05219786|EXPERIMENTAL|Decision Support Tool|In this arm study participants saw a decision support tool consisting of a video and a interactive decision aid (www.appyornot.org).
62101828|NCT02219490|EXPERIMENTAL|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.
62101829|NCT02356159|EXPERIMENTAL|1/Phase 1: Dose escalation arm|Induction chemotherapy, then palifermin at escalating doses, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
62101830|NCT02356159|EXPERIMENTAL|2/ Phase II arm|Induction chemotherapy, then palifermin at the MTDdetermined in Phase 1, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
62101831|NCT06711458|EXPERIMENTAL|Generative AI Discharge Instructions|At the time of discharge, patients will receive patient-friendly discharge instructions generated by GPT-4, an advanced natural language processing model, with the aim of enhancing patient readability and understandability in the discharge information.
62101832|NCT06711458|ACTIVE_COMPARATOR|Standard of Care Discharge Instructions|At the time of discharge, patients will receive standard discharge instructions (i.e., not generated by GPT-4).
62101833|NCT00967369|EXPERIMENTAL|Arm A (bortezomib, ifosfamide, carboplatin, etoposide)|ARM A: Patients receive bortezomib IV over 5 seconds on days 1 and 4, ifosfamide IV continuously over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on days 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62101834|NCT00967369|ACTIVE_COMPARATOR|Arm B (ifosfamide, carboplatin, etoposide)|Patients receive ifosfamide, carboplatin and etoposide as in Arm A. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62101835|NCT06711640|EXPERIMENTAL|LUCEMYRA: 0.54 mg|The initial LUCEMYRA dose for this study will be based on weight. Participants who weigh ≥45 kg will receive three 0.18 mg tablets (0.54 mg) QID.
62101836|NCT06711640|EXPERIMENTAL|LUCEMYRA: 0.36 mg|The initial LUCEMYRA dose for this study will be based on weight. Participants who weigh ≥30 to \<45 kg will receive two 0.18 mg tablets (0.36 mg) QID.
62101837|NCT03996239|EXPERIMENTAL|patients with clonal hematopoiesis|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
62101838|NCT03996239|EXPERIMENTAL|post treatment patients with breast or colorectal cancer|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
62101839|NCT03996239|EXPERIMENTAL|men with localized prostate cancer undergoing active surveillance|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
62101840|NCT03996239|EXPERIMENTAL|Individuals with Lynch Syndrome|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
62101841|NCT03996239|EXPERIMENTAL|Individuals enrolled on Early Drug Development (EDD) trials|Participants will receive structured exercise therapy for 24 weeks. Participants will be followed by standard of care clinical follow-up
62101842|NCT01313182|ACTIVE_COMPARATOR|3M Skin and Nasal Antiseptic|Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
62101843|NCT01313182|ACTIVE_COMPARATOR|Bactroban Nasal|Mupirocin calcium ointment, 2%
62663022|NCT05219786|ACTIVE_COMPARATOR|Infographic|Participant saw a static infographic providing information about the two treatments for appendicitis.
62101844|NCT06357364|EXPERIMENTAL|Cognitive Behavioral Therapy with Techniques of Starting on Time and Planning Realistically|5 session (one session a week) online group therapy including psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, identification of dysfunctional automatic thoughts, cognitive restructuring, relapse prevention) and a behavioral module: realistic planning, timely beginning.
62101845|NCT06357364|EXPERIMENTAL|Cognitive Behavioral Therapy with Technique of Working Time Restriction|5 session (one session a week) online group therapy including psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, identification of dysfunctional automatic thoughts, cognitive restructuring, relapse prevention) and a behavioral module: working time restriction.
62101846|NCT06357364|NO_INTERVENTION|Wait-list control group|no intervention
62663023|NCT04940806||120 patients with narcolepsy|
62467430|NCT02512952|ACTIVE_COMPARATOR|Group 3|SRP with Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into bone defect
62467431|NCT04055805||Fondazione Policlinico Universitario A. Gemelli, Roma|Polo Scienze della Salute della Donna e del Bambino
62467432|NCT04055805||Università degli Studi di Pavia|
62467433|NCT04055805||"Università di Napoli Federico II"|
62467434|NCT04055805||Università degli Studi di Siena|
62467435|NCT04055805||Azienda Ospedaliero-Universitaria Careggi Firenze|
62467436|NCT04055805||Fondazione Policlinico Universitario A. Gemelli Roma|U.O.C Chirurgia Senologica
62467437|NCT04055805||Istituto Nazionale dei Tumori di Napoli Fondazione G.Pascale|
62467438|NCT02107092|EXPERIMENTAL|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
62467439|NCT02549092|ACTIVE_COMPARATOR|Optimized Medical Treatment (OMT)|"Participants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG."
62467440|NCT02549092|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel (LCIG)|"Participants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.~The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day.~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG."
62663024|NCT02630654||GEP NETs|Patients with a suspected diagnosis of metastatic GEP NETs
62663025|NCT02630654||Healthy controls|Healthy controls matched by age and gender.
61911562|NCT04661761|EXPERIMENTAL|stimulated salivary flow rate|stimulated salivary flow rate determined in a crossover design: first using Paraffin Pellets from Aurosan GmbH; thereafter using Chewing wax from the Saliva-Check Buffer from GC Europe
61911563|NCT00591110|ACTIVE_COMPARATOR|1|Educational intervention communicating practical information about vision, eye conditions and eye care.
62467441|NCT02105103|OTHER|Accu-Chek® Insight Insulin Pump|
62467442|NCT02898168|EXPERIMENTAL|WA|
62467443|NCT02898168|ACTIVE_COMPARATOR|Control|
62467444|NCT05242432|EXPERIMENTAL|Cohort (C)1 Group (G)1: Adults, 60 years and older (Ad26/protein preF RSV Vaccine)|Participants will receive a single intramuscular (IM) injection of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26/protein preF RSV) vaccine on Day 1.
62467445|NCT05242432|PLACEBO_COMPARATOR|C1 G2: Adults, 60 years and older (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
62467446|NCT05242432|EXPERIMENTAL|C2 G3: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Ad26/protein preF RSV Vaccine)|Participants will receive a single IM injection of Ad26/protein preF RSV vaccine on Day 1.
62467447|NCT05242432|PLACEBO_COMPARATOR|C2 G4: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
62467448|NCT05598658|ACTIVE_COMPARATOR|RIC group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted at 6 and 18-24 hours after intravenous thrombolysis.
62467449|NCT05598658|PLACEBO_COMPARATOR|Sham-RIC group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted at 6 and 18-24 hours after intravenous thrombolysis.
62467450|NCT02024932|EXPERIMENTAL|BVS857 Part A Open label (Cohort 1)|Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
62295023|NCT02566720|OTHER|Treatment and MRI scanning|After informed consent has been obtained, the subjects will be examined by a physician and assigned a Disability Ratings Scale (DRS) score. Subjects will undergo MRI tractography study, which does not require the administration of contrast. All participants will receive oral amantadine at escalating doses to ensure tolerance (50mg twice daily for 7 days, then 100mg twice daily for 1 week, then 150mg twice daily, then 200mg twice daily). The usual length of stay on the inpatient brain injury program is ninety days. The MRI tractography study and DRS score will be repeated near the time of discharge or ninety days from enrollment.
62295024|NCT03900780|EXPERIMENTAL|PGT-A group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
62295025|NCT03900780|ACTIVE_COMPARATOR|Control group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
62295026|NCT01961531|EXPERIMENTAL|Accuboost APBI|28Gy delivered in 5 daily fractions
62101847|NCT02396940|PLACEBO_COMPARATOR|2D HD laparoscopy|Elective laparoscopic inguinal hernia repair performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
62101848|NCT02396940|ACTIVE_COMPARATOR|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
62101849|NCT03404960|EXPERIMENTAL|Arm A|Niraparib + Nivolumab
62295027|NCT04239846|EXPERIMENTAL|AC-701|AC-701 Topical Gel 0.3%
62295028|NCT04239846|PLACEBO_COMPARATOR|Placebo|Placebo Gel
62295029|NCT00956826|EXPERIMENTAL|Electrode added to device|With an electrode and a regular vacuum device
61911564|NCT00591110|SHAM_COMPARATOR|2|
61911565|NCT05517278|EXPERIMENTAL|Treatment Group|The treatment group will receive SurgX™ Antimicrobial Wound Gel™ applied over incision after closure and then re-applied at first dressing change on day of discharge in addition to standard of care.
61911566|NCT05517278|OTHER|Control Group|The control group will receive standard of care.
61911567|NCT02878356|ACTIVE_COMPARATOR|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
62467451|NCT02024932|EXPERIMENTAL|BVS857 Part A double blind (Cohort 2)|Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
62663026|NCT01550185|EXPERIMENTAL|Treatment (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
62663027|NCT01866670|EXPERIMENTAL|spiritual support|"-Spiritual Support: deep breathing + guided image + meditation~Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the experimental group, it will be developed the support spiritual intervention in all three meetings.~In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
62663028|NCT01866670|ACTIVE_COMPARATOR|relaxation therapy|"Relaxation Therapy Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the control group, it will be performed just relaxing in all three meetings. In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
62663029|NCT06461884|EXPERIMENTAL|Percussions|Group A: Percussions and diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
62663030|NCT06461884|EXPERIMENTAL|Diaphragmatic breathing exercise|Group B: Diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
62663031|NCT04289948|EXPERIMENTAL|Phage|
62663032|NCT04289948|PLACEBO_COMPARATOR|Placebo|
62663033|NCT04241731|EXPERIMENTAL|Raltitrexed Plus Cetuximab|Raltitrexed Plus Cetuximab
62101850|NCT03404960|EXPERIMENTAL|Arm B|Niraparib + Ipilimumab
62295030|NCT02752828|EXPERIMENTAL|LixiLan|"LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
62295031|NCT02752828|ACTIVE_COMPARATOR|insulin glargine|"Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
62295032|NCT05617170||Group 1 experimental group will subject to implanted rehabilitation programme|50 case of acute cerebrovascular stroke patients will subject to implanted rehabilitation programme based on telemedicine if avilable .
62295033|NCT05617170||Group 2 control group will subject to ordinary rehabilitation techniques|50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques .
62295034|NCT03476044|ACTIVE_COMPARATOR|Group Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
61911568|NCT02878356|ACTIVE_COMPARATOR|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
61911569|NCT02878356|ACTIVE_COMPARATOR|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
61911570|NCT00802815|EXPERIMENTAL|Etanercept|
61919844|NCT02934529|EXPERIMENTAL|B1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every 2 weeks for a maximum of 12 cycles~* Treatment may be de-escalated to irinotecan plus cetuximab or FUFA plus cetuximab, prior to 12 cycles, for toxicity if necessary, if the best response has been SD,~* Treatment may undergo 'switchover' to a fluoropyrimidine and bevacizumab, between 8 and 12 cycles, for toxicity if necessary, if the best response has been CR or PR,"
62295035|NCT03476044|ACTIVE_COMPARATOR|Group Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
62295036|NCT03399461||Group 1|Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.
62663034|NCT01514175|EXPERIMENTAL|ibuprofen versus ketoralac|IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
62663035|NCT01350973|EXPERIMENTAL|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 12 weeks.
62663036|NCT01350973|EXPERIMENTAL|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 12 weeks.
62663037|NCT01350973|EXPERIMENTAL|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.
62663038|NCT04253730|NO_INTERVENTION|Control Condition|Subjects will sit at rest wearing a liquid perfused suit containing thermoneutral water for 60 min. The suit will not be turned on during this period.
62663039|NCT04253730|EXPERIMENTAL|Cold Condition|Subjects will be cooled for 60-90 min at \~ 4-10°C using a liquid perfused suit. Subjects will then be rewarmed for 30 min at \~ 41°C using the liquid perfused suit.
62663040|NCT03318458|EXPERIMENTAL|Pilates group|
62663041|NCT03318458|NO_INTERVENTION|No intervention group|
62295037|NCT03399461||Group 2|Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.
62295038|NCT03399461||Group 3|Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.
62295039|NCT01717638|EXPERIMENTAL|B+R246_12_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295040|NCT01717638|EXPERIMENTAL|B+R246_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295041|NCT01717638|EXPERIMENTAL|B+R246_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295042|NCT01717638|EXPERIMENTAL|B246_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62663042|NCT03972917||ulipristal acetate based therapy|Fertile women under ulipristal acetate treatment
62663043|NCT02841735||Smartphone breathalyzer device & app|This is a small device that attaches to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in a simulated laboratory.
62663044|NCT02841735||BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in a simulated laboratory.
62663045|NCT02841735||Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in a simulated laboratory.
62663046|NCT03607084|EXPERIMENTAL|Intervention|The intervention group receives a school health program that has two components: the training of selected teachers to become school Health Workers and bi-annual health screenings of all students.
62101851|NCT02712619|EXPERIMENTAL|metformin 250mg|metformin 375/250 mg
62101852|NCT02712619|EXPERIMENTAL|metformin 1000mg|metformin 1000/1000 mg
62663047|NCT03607084|NO_INTERVENTION|Control|The control group receives regular school programming.
62663048|NCT02132468|EXPERIMENTAL|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
62663049|NCT04235075|EXPERIMENTAL|Pregnancy volunteer subjects|Subjects who will agree to participate in the study will be pregnant women referred to the Grenoble Alpes University Hospital for expert fetal cardiac ultrasound examination who have not revealed any abnormalities.
62663050|NCT02069184|EXPERIMENTAL|IV Acetaminophen|IV form, total of 4 doses (each 1000 mg), each every 6th hourly to a maximum dose of 4000 mg in 24 hours.
62663051|NCT02069184|EXPERIMENTAL|Saline as placebo|IV form, total 4 units, each given every 6th hourly in 24 hours.
62663052|NCT03588468|SHAM_COMPARATOR|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
62663053|NCT03588468|ACTIVE_COMPARATOR|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
62663054|NCT03588468|EXPERIMENTAL|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
62295043|NCT01717638|EXPERIMENTAL|B246_18_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295044|NCT01717638|EXPERIMENTAL|B246_24_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62101853|NCT01460381|EXPERIMENTAL|LY2216684 + Quinidine (CYP2C19 poor metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 poor metabolizer (PM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 was administered on Day 1.~Period 2 (Days 8-15): 300 mg quinidine sulfate controlled release was administered orally, once daily on Days 8-15. Additionally, a single, oral dose of 18 mg LY2216684 was administered on Day 11."
62295045|NCT01717638|EXPERIMENTAL|B+R234_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295046|NCT01717638|EXPERIMENTAL|B+R234_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295047|NCT01717638|EXPERIMENTAL|B+R234_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62467452|NCT02024932|PLACEBO_COMPARATOR|Placebo Part A double blind (Cohort 2)|Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
62467453|NCT02024932|EXPERIMENTAL|BVS857 Part B open-label (Cohort 4)|Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
62467454|NCT02024932|EXPERIMENTAL|BVS857 Part B double blind (Cohort 5)|Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
62295048|NCT01717638|EXPERIMENTAL|B12 14_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 12 and14 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295049|NCT01717638|EXPERIMENTAL|B18 20_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 18 \& 20 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295050|NCT01717638|EXPERIMENTAL|B24 26_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 24 \& 26 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
62295051|NCT01717638|EXPERIMENTAL|B48_50|Newly recruited 4 year old naive subjects who received 2 catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, two months apart, in the present study.
62295052|NCT00507247|EXPERIMENTAL|Daptomycin|6mg/kg/day intravenous (IV) for 10 days
62295053|NCT01724281||pregnant women between 19-30 weeks gestational age|No intervention, only follow up
62467455|NCT02024932|PLACEBO_COMPARATOR|Placebo Part B double blind (Cohort 5)|Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.
62467456|NCT05959681|EXPERIMENTAL|Study Cohort|A cohort of 60 biological females who volunteered to be part of the 6 months study.
62467457|NCT05098886|EXPERIMENTAL|Sequence A|
62467458|NCT05098886|EXPERIMENTAL|Sequence B|
62467459|NCT02533479|EXPERIMENTAL|Caloric restriction|three alternate days weekly along 4 weeks.
62663055|NCT00087412|EXPERIMENTAL|Treatment|Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62663056|NCT05349123|EXPERIMENTAL|Intervention|Home-based pulmonary rehabilitation that includes health coaching with mindful breathing module
62663057|NCT05349123|ACTIVE_COMPARATOR|Control|Home-based pulmonary rehabilitation that includes health coaching
62663058|NCT04882800|EXPERIMENTAL|First Intervention|Participants will be fit with currently available Lyric extended wear hearing aid device A in right ear and Lyric extended wear hearing aid with fitting modification device B in left ear for 14 days (Day 1 - Day 14 of study). They will then switch and be fit with Lyric extended wear hearing aid with fitting modification device B in the right ear and the commercially available Lyric device A in the left ear for 14 days (Day 15-Day 28 of study)
62663059|NCT02178956|EXPERIMENTAL|BBI608 plus Paclitaxel|
62663060|NCT02178956|PLACEBO_COMPARATOR|Placebo plus Paclitaxel|
62663061|NCT04870203|EXPERIMENTAL|baricitinib + anti-TNF|
62295054|NCT04522492|EXPERIMENTAL|internet CBT|Internet delivered cognitive behavioral therapy, thru 2 booster sessions. Each session will last 50 minutes. Fist session will involve: psychoeducation about the symptoms, evaluation of the skin picking habit, reinforcement of the habit reversal strategies. After 1 week, the second session will be applied, consisting of: strategies to cope with anxiety (breathing and muscle relaxation techniques) and to cope with depressive status (cognitive restructuring techniques).
62295055|NCT04522492|ACTIVE_COMPARATOR|Quality of life promotion|The therapist will send to the patient 2 videos with strategies to improve quality of life during the pandemia (1 video about social support and one video about sleep hygiene). After 1 week, the therapist will send to the patient another 2 videos with strategies do improve quality of life (dietary guidance and guidance on physical activity)
61911571|NCT06174168||Group 1|Patients who did not develop any complication in the EBUS-TBNA. Patients may experience intraoperative complications (bleeding, hypoxemia, hypotension, arrhythmia, bronchospasm, pneumothorax, subcutaneous emphysema/mediastinal emphysema, respiratory depression), and postoperative complications (bleeding, pneumonia, respiratory failure, atelectasis, pleural effusion/empyema, pulmonary embolism, pulmonary edema). Complications that develop (such as acute respiratory distress syndrome, delirium, and mortality) will be recorded. After the procedure, any complications that may develop in the patients within 30 days will be questioned and recorded.
61919845|NCT02934529|EXPERIMENTAL|B1 Switchover regimens|"Switchover to FUFA plus bevacizumab every three weeks (cycle duration 21 days) until progression in first-line or emergence of unacceptable toxicity.~Folinic acid, 5-FU, Bevacizumab~1st administration 90 min. in case of good safety, the second 60 min. further administration 30 min.~Or alternatively Switchover to capecitabine plus bevacizumab every three weeks (cycle duration 21 days) until progression in the first-line or emergence of unacceptable toxicity."
62101854|NCT01460381|EXPERIMENTAL|LY2216684 (CYP2C19 extensive metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 extensive metabolizer (EM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 administered on Day 1.~Period 2 (Days 8-15): EM participants did not participate in this period."
62295056|NCT01888094|EXPERIMENTAL|ultrasound guided for cannulation and examination|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
62295057|NCT01888094|OTHER|landmark method and examination with chest radiography|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
62467460|NCT03922906|EXPERIMENTAL|Motus Pure-Vu System|The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
62467461|NCT05527548|EXPERIMENTAL|ALN group|Patients receive weekly dose of 70mg of ALN and a standard rehabilitation program
62467462|NCT05527548|NO_INTERVENTION|Untreated group|Patients receive a standard rehabilitation program
62467463|NCT00675935|EXPERIMENTAL|1|One high-risk medical unit at each hospital will be randomly assigned to receive the fall prevention toolkit
62467464|NCT00675935|NO_INTERVENTION|2|One high-risk medical unit at each hospital will be randomly assigned to receive usual care as it relates to fall prevention; i.e., receives no intervention.
62467465|NCT02639741|ACTIVE_COMPARATOR|Oral Melatonin Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of melatonin (6 mg) or placebo tablet will be given one hour before the start of anesthesia.
62467466|NCT02639741|ACTIVE_COMPARATOR|Oral Vitamin C Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of vitamin C (2 gr) or placebo tablet will be given one hour before the start of anesthesia.
62467467|NCT02639741|PLACEBO_COMPARATOR|Oral Placebo Tablet|Preoperative single oral dose of placebo tablet will be given one hour before the start of anesthesia.
62467468|NCT01271530|EXPERIMENTAL|Exercise|
62467469|NCT01271530|NO_INTERVENTION|Control|
62101855|NCT02064751|EXPERIMENTAL|MultiPoint Pacing|CRT with MultiPoint Pacing
62295058|NCT03424226|EXPERIMENTAL|day of acetazolamide|acetazolamide 125mg twice a day, started morning of ascent
62663062|NCT04870203|PLACEBO_COMPARATOR|baricitinib + placebo|
62295059|NCT03424226|ACTIVE_COMPARATOR|night before acetazolamide|acetazolamide 125mg twice a day, started evening before ascent
62295060|NCT03688386|EXPERIMENTAL|Language Intervention|"1. Review language and infant bonding curriculum 2. 1st LENA recording and heart rate variability of mother reading to infant 3. Provide LENA linguistic feedback and review curriculum 4. 2nd LENA recording and heart rate variability of mother reading to infant 5. Provide LENA linguistic feedback and review curriculum 6. 3rd LENA recording and heart rate variability of mother reading to infant 7. Provide LENA linguistic feedback~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
62467470|NCT03193177||the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
62467471|NCT03786822|EXPERIMENTAL|Non-fluoroscopic Cryoballoon PVI|"1. Observation of pressure waveform change at the tip of the cryoballoon catheter from left atrial pressure to pulmonary vein pressure waveform.~2. Intracardiac echocardiography (ICE) imaging with no Doppler color evidence of peri-balloon high velocity leaks.~3. Intracardiac echo imaging showing no evidence of leak during agitated saline contrast injection into cryoballoon catheter positioned at pulmonary vein ostium."
62467472|NCT03786822|ACTIVE_COMPARATOR|Fluoroscopic Cryoballoon PVI|Standard cryoballoon PVI using radio opaque contrast pulmonary vein angiography
62663063|NCT05319704|ACTIVE_COMPARATOR|Test of effort, sub-maximal, progressive, carried out in eccentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
62663064|NCT05319704|PLACEBO_COMPARATOR|Test of effort, sub-maximal, progressive, carried out in concentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
62295061|NCT03688386|ACTIVE_COMPARATOR|Infant bonding|"1. Review infant bonding curriculum with mother 2. 1st LENA recording and heart rate variability of mother holding infant 3. Review infant bonding curriculum 4. 2nd LENA recording and heart rate variability of mother holding infant 5. Review infant bonding curriculum 6. 3rd LENA recording and heart rate variability of mother holding infant 7. Provide linguistic feedback of all 3 LENA recordings~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
61911572|NCT06174168||Group 2|Patients who developed complications during EBUS-TBNA. Patients may experience intraoperative complications (bleeding, hypoxemia, hypotension, arrhythmia, bronchospasm, pneumothorax, subcutaneous emphysema/mediastinal emphysema, respiratory depression), and postoperative complications (bleeding, pneumonia, respiratory failure, atelectasis, pleural effusion/empyema, pulmonary embolism, pulmonary edema). Complications that develop (such as acute respiratory distress syndrome, delirium, and mortality) will be recorded. After the procedure, any complications that may develop in the patients within 30 days will be questioned and recorded.
61911573|NCT02279407|PLACEBO_COMPARATOR|placebo|
61911574|NCT02279407|EXPERIMENTAL|Omega-3 carboxylic acids 4g / day|
62295062|NCT03041727|ACTIVE_COMPARATOR|Standard Group|"The subjects will be treated with a standard protocol of stretching and strengthening exercises , we require them to do the exercises by themselves during five weeks, one a day.~To make sure that they will do the protocol, we'll give them a diary to sign the daily section."
62101856|NCT06507735|EXPERIMENTAL|Mannose supplementation|Mannose supplementation will be given and subjects will be studied at baseline and after treatment.
62101857|NCT03401788|EXPERIMENTAL|Open Label Belzutifan|Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
62101858|NCT05826431|EXPERIMENTAL|Participants using Cubii|Participants will use the Cubii exercise unit at their homes for two months as they choose. They will maintain a log regarding their use of the device. They will complete validated self-report questionnaires (demographics, MS disease-related variables (e.g., pain, fatigue, falls), activity, exercise, quality of life, and biopsychosocial symptom variables) before and after the use of the exercise unit.
62101859|NCT05943938||ED Patients|All adult patients presenting to Emergency Departments (ED) in the Emory Healthcare system
62101860|NCT06378372|EXPERIMENTAL|Grupo 0|Group on which the pianistic intervention will be carried out
62295063|NCT03041727|EXPERIMENTAL|Intervention group|The subjects will be treated with the same protocol of the Standard Group, but in two section, they will receive a Fascial Manipulation approach.
62467473|NCT02841800|EXPERIMENTAL|Intra-luminal radiofrequency ablation|Intra-luminal radiofrequency ablation Admission for endoscopic retrograde cholangiopancreatography (ERCP) and stent placement after radiofrequency ablation. ERCP should be performed for 2 times with an interval of two months.
62467474|NCT03867994|EXPERIMENTAL|Group (A)|included 49 patients who received high dose statin (80 mg atorvastatin) 12 hours before CC and 40 mg just before CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
61911575|NCT02279407|EXPERIMENTAL|Dapagliflozin, 10mg / day|
61911576|NCT02279407|EXPERIMENTAL|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
61911577|NCT05967039||Control|This is a control group of individuals who were diagnosed with post-COVID-19 syndrome but did not underwent Physiotherapy.
61911578|NCT05967039||Intervention|This is an intervention group of individuals who were diagnosed with post-COVID-19 syndrome and underwent Physiotherapy
61911579|NCT00594945|EXPERIMENTAL|Intranasal Clonazepam 2 mg|
62467475|NCT03867994|EXPERIMENTAL|Group (B)|included 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continued for 24 hours after the CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
61911580|NCT00594945|EXPERIMENTAL|Intranasal Clonazepam 3 mg|
61911581|NCT00594945|EXPERIMENTAL|Intranasal Clonazepam both Dose Groups 2 mg & 3 mg|
61911582|NCT04805879|ACTIVE_COMPARATOR|FMT capsules|"Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool and each containing 0.67 ml of pelleted intestinal microbes.~PArticipants will recieve a loading dose of 60 capsules over 3 consecutive days followed by a booster dose of 20 caspules 1 month after and a second similar booster dose a month after that"
62101861|NCT05579080||NIV group|group that performed only non-invasive ventilation
62101862|NCT05579080||HFNC group|group that performed only oxygen therapy by high flow nasal cannula
62101863|NCT05579080||NIV and HFNC group|group that used non-invasive ventilation and oxygen therapy by high flow nasal cannula
62101864|NCT05579080||conventional oxygen therapy group|group that used only conventional oxygen therapy low-flow oxygen therapy.
62101865|NCT06712654|EXPERIMENTAL|AP306|A blood phosphate-lowering medication with a novel mechanism
62101866|NCT06712654|PLACEBO_COMPARATOR|Placebo of AP306|
62101867|NCT04349384||Colon adenocarcinoma|Patient who underwent surgical resection for colon adenocarcinoma
62101868|NCT04349384||Rectal adenocarcinoma|Patient who underwent surgical resection for rectal adenocarcinoma
62101869|NCT02537899|OTHER|Treatment|NeuroAiD
62295064|NCT06551623|EXPERIMENTAL|Midazolam cohort|"Midazolam Oral Solution will be given orally once daily within 0.5 hours after breakfast on Day 1 and Day 10.~TNP-2198 Capsules will be given orally twice daily within 0.5 hours after breakfast and dinner from Day 3 to Day 11."
62467476|NCT03867994|EXPERIMENTAL|Group (C)|included 47 patients who did not receive any medications but only hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization
62101870|NCT05982600||Cancer Pathway referred patient|Patient referred for assessment and excision of their skin lesion, because of a suspicion of melanoma by the referring doctor.
62101871|NCT01120275|EXPERIMENTAL|Treatment (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62101872|NCT05978583||physical and occupational therapy|Physical and occupational therapy consultation might be used to provide targeted prehabilitation interventions.
62101873|NCT06196528|EXPERIMENTAL|WristArt implantation|
62101874|NCT00530374|ACTIVE_COMPARATOR|1|Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
62101875|NCT00530374|PLACEBO_COMPARATOR|2|Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days
62101876|NCT04054661|OTHER|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor STANDARD point-of-care G6PD test and the point-of-care HemoCue hemoglobin test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
62101877|NCT01711918|EXPERIMENTAL|Domperidone|Participants will received domperidone at a dose of 10mg given up to three times per day
62101878|NCT06079593|EXPERIMENTAL|Gasless Surgery|
62101879|NCT06079593|ACTIVE_COMPARATOR|Standard surgery with gas tamponade|
62101880|NCT02365298|EXPERIMENTAL|etafilcon A|Worn in a daily disposable modality
62101881|NCT02365298|ACTIVE_COMPARATOR|nelfilcon A|Worn in a daily disposable modality
62101882|NCT05342636|EXPERIMENTAL|Pembrolizumab plus chemotherapy|Participants will receive pembrolizumab intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62295065|NCT06551623|EXPERIMENTAL|Clarithromycin cohort|"Clarithromycin tablets will be given orally within 0.5 hours after breakfast and dinner from Day 16 to Day 25.~TNP-2198 Capsules will be given orally twice daily within 0.5 hours after breakfast and dinner from Day 1 to Day 7 and from Day16 to Day 22, and once daily within 0.5 hours after breakfast on Day 8 and Day 23."
62295066|NCT00634231|EXPERIMENTAL|AdV-tk|AdV-tk + valacyclovir in combination with standard of care radiation
62467477|NCT05818839||UCP|Children diagnosed with unilateral spastic cerebral palsy
62467478|NCT05818839||TyD|Typically developing children
62295067|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
62295068|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
62467479|NCT04092023|OTHER|Control group|Participants in control group will be received usual care. They will be gone through yearly DM complication screening. A screening report and information sheet on general DM management will be issued to participants. Therapeutic goals will be set and further conventional health care education intervention will be referred.
62295069|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
62295070|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
62663065|NCT05319704|ACTIVE_COMPARATOR|Kinetic in eccentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
62101883|NCT05342636|EXPERIMENTAL|Coformulation Favezelimab/Pembrolizumab plus Chemotherapy|Participants will receive coformulation of favezelimab/pembrolizumab administered intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62295071|NCT04561505|ACTIVE_COMPARATOR|Holmium laser enucleation of prostate|patients that undergo Holmium laser enucleation of prostate (HoLEP) procedure
62101884|NCT05342636|EXPERIMENTAL|Pembrolizumab plus MK-4830 plus Chemotherapy|Participants will receive pembrolizumab intravenously plus MK-4830 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62101885|NCT05342636|EXPERIMENTAL|Pembrolizumab plus MK-4830 plus lenvatinib|Participants will receive pembrolizumab intravenously plus MK-4830 plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62295072|NCT04561505|ACTIVE_COMPARATOR|monopolar transurethral resection of prostate|patients that undergo monopolar transurethral resection of prostate
62295073|NCT03596346|ACTIVE_COMPARATOR|Test group|20 g of rapeseed ingredient (RI) daily
62295074|NCT03596346|PLACEBO_COMPARATOR|Control group|0 g of rapeseed ingredient (RI) daily
62295075|NCT03184948|ACTIVE_COMPARATOR|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.~\*No individual participants are recruited for this study."
62295076|NCT03184948|ACTIVE_COMPARATOR|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.~\*No individual participants are recruited for this study."
62295077|NCT03184948|NO_INTERVENTION|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.~\*No individual participants are recruited for this study."
62295078|NCT03677674|EXPERIMENTAL|dehydrated|The participants will be dehydrated (at least 2% of their body weight) before performing the Sterkowicz test.
62663066|NCT05319704|PLACEBO_COMPARATOR|Kinetic in concentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
62663067|NCT01970371|EXPERIMENTAL|Plazomicin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received 15 milligram per killogram (mg/kg) plazomicin therapy (plus meropenem or tigecycline) as a 30-minute intravenous (IV) infusion once daily for 7 to 14 days.
62663068|NCT01970371|ACTIVE_COMPARATOR|Colistin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received a 5 mg/kg IV loading dose (300 mg maximum) colistin (plus meropenem or tigecycline) followed by a 5 mg/kg/d maintenance dose divided into every 8 hours (q8h) or every 12 hours (q12h) for 7 to 14 days.
62101886|NCT04138628|EXPERIMENTAL|ctDNA screening arm|Flat dose 1200 mg Atezolizumab every three weeks for up to 13 months
62295079|NCT03677674|NO_INTERVENTION|euhydrated|The participants will be normally hydrated (= euhydration) before performing the Sterkowicz test (i.e. no specific intervention will be implemented).
62295080|NCT05078489|EXPERIMENTAL|Action-observation arm|Participants will be asked to watch videos of neck exercises without performing any exercise. The intervention will take approximately 15 minutes.
62295081|NCT05078489|PLACEBO_COMPARATOR|Placebo intervention|Participants will be asked to watch videos of landscapes. The intervention will take approximately 15 minutes.
62295082|NCT01936740|OTHER|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
62295083|NCT01936740|OTHER|HF easyTip 2.8mm|The phacoemulsifications tip used was the easyTip 2.8mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
62295084|NCT04701125|EXPERIMENTAL|Study group|Players receive selective head-neck cooling after concussion
62295085|NCT04701125|NO_INTERVENTION|control group|Players receive the standard sport-related concussion management
62295086|NCT00474916|EXPERIMENTAL|KRN5500|KRN5500 escalating dose of .6, 1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
62295087|NCT00474916|PLACEBO_COMPARATOR|Normal Saline|Placebo consists of IV infusion of normal saline
62295088|NCT04792229|EXPERIMENTAL|Experimental Group|"Standing on WBV device (frequency of 40 Hz); 3 Minute vibration with 3 minute rest.~Three times repetition . Total 18-minute vibrational therapy protocol. 3 days session per week"
62295089|NCT04792229|ACTIVE_COMPARATOR|Control Group|"Stretching exercise (hip adductors ,plantar flexors, external rotators of hip \& knee flexors).~Active and passive ROMS to lower extremities. Strengthening exercises (hip and knee extensors, ankle dorsiflexes) 3 Repetitions into 3 day session per week"
62295090|NCT03216993|OTHER|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
62295091|NCT03216993|EXPERIMENTAL|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
62663069|NCT01970371|EXPERIMENTAL|Plazomicin in Combination with Adjunctive Antibiotic|Cohort 2: Patients received 15 mg/kg as a 30 minute IV infusion once daily. BSI, HABP or VABP patients received plazomicin and any supplemental antibiotic therapy, according to Investigator's choice, for 7 to 14 days. cUTI or AP patients received plazomicin monotherapy only for 4 to 7 days with an option to switch to oral therapy on or after Day 5.
62663070|NCT06169670|EXPERIMENTAL|Patients Receiving Lipoaspirate with Viality|Patient will be undergoing fat transfers to the face with lipoaspirate processed using the Viality wash system.
62663071|NCT04361175|EXPERIMENTAL|letrozole group|letrozole group, Patients will receive 5 mg of letrozole oral tablets daily from day 2 of the cycle for 5 days for three successive cycles
62295092|NCT00907075|ACTIVE_COMPARATOR|NES With Energy Restriction|
62295093|NCT00907075|ACTIVE_COMPARATOR|NES Without Energy Restriction|
62295094|NCT00430118|EXPERIMENTAL|Induction Prot I/Dexa - reinduction Prot III|
62295095|NCT00430118|EXPERIMENTAL|Induction Prot I/Pred - reinduction Prot III|
62295096|NCT00430118|EXPERIMENTAL|Induction Prot I/Dexa - reinduction Prot II|
62295097|NCT00430118|ACTIVE_COMPARATOR|Induction Prot I/Pred - reinduction Prot II|
62295098|NCT00430118|EXPERIMENTAL|Induction Prot I/Dexa - reinduction 2x Prot III|
62295099|NCT00430118|EXPERIMENTAL|Induction Prot I/Pred - reinduction 2x Prot III|
62295100|NCT00430118|EXPERIMENTAL|Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III|
62295101|NCT00430118|EXPERIMENTAL|Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III|
62295102|NCT00430118|EXPERIMENTAL|Induction Prot I/Dexa - reinduction 6 HR courses + Prot II|
62295103|NCT00430118|ACTIVE_COMPARATOR|Induction Prot I/Pred - reinduction 6 HR courses + Prot II|
62295104|NCT00889096|ACTIVE_COMPARATOR|study day 1 propanolol|Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
62295105|NCT00889096|PLACEBO_COMPARATOR|study day 1 placebo|Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
62295106|NCT02016248|EXPERIMENTAL|Low Risk Cohort|"The low risk cohort will receive:~Stereotactic Ablative Body Radiotherapy as Monotherapy on the CyberKnife System"
62295107|NCT02016248|EXPERIMENTAL|High Risk Cohort|"The high risk cohort will receive:~28 treatments of external beam radiation therapy followed by Stereotactic Ablative Body Radiotherapy as a Boost on the CyberKnife System and hormonal therapy as indicated."
62295108|NCT03812809|EXPERIMENTAL|BPI-7711|BPI-7711: 180mg, QD, oral
62295109|NCT05147675|EXPERIMENTAL|Treatment Group (AlloRx)|Intravenous infusion and intraarticular injection (total dose of 100 million cells)
62295110|NCT02476487|EXPERIMENTAL|FDG PET CT|FDG PET CT
62295111|NCT02722044|EXPERIMENTAL|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
62295112|NCT06354933||Neurodegenerative dementias|Subjects with either Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies or corticobasal syndrome
62295113|NCT06354933||Control|Subjects without dementia
62295114|NCT05091138|ACTIVE_COMPARATOR|Mg and Bupivacaine|Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 150mg of Mg.
62295115|NCT05091138|ACTIVE_COMPARATOR|Buprenorphine and Bupivacaine|Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 300 mcg of buprenorphine.
62295116|NCT00195650|EXPERIMENTAL|Adalimumab|Open-label adalimumab 40 mg
62295117|NCT04285060|EXPERIMENTAL|Training Group|All participants are assigned to the training group with the Samsung GEMS-H.
62295118|NCT00486902|EXPERIMENTAL|Ketamine|Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.
62295119|NCT00486902|PLACEBO_COMPARATOR|Placebo|Subjects receive IV Saline 20 mL 5 minutes after infant delivery
62295120|NCT03759158|EXPERIMENTAL|NAC Arm|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
62295121|NCT03759158|PLACEBO_COMPARATOR|Placebo|
62295122|NCT01587950|PLACEBO_COMPARATOR|Sterile water|Participants to receive 250 microlitres (μL) of sterile water.
62295123|NCT01587950|EXPERIMENTAL|Potassium nitrate 5% solution|Participants to receive 250 μL of potassium nitrate 5% solution.
62295124|NCT01587950|EXPERIMENTAL|Potassium nitrate 2.5% solution|Participants to receive 250 μL of potassium nitrate 2.5% solution.
62295125|NCT00787293|EXPERIMENTAL|1|Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
62295126|NCT01006343|EXPERIMENTAL|Higher Protein (HP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The HP menus will contain 30% protein, 45% carbohydrate, and 25% fat. Subjects in the HP group will be provided with portioned, cooked and frozen pork products as part of their HP menu plan.
62295127|NCT01006343|EXPERIMENTAL|Lower Protein (LP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The LP group menus will contain 18% protein, 57% carbohydrate, 25% fat. The LP group will follow a lacto-ovo vegetarian menu with no striated tissue foods. Subjects in the LP group will be provided with selected, portioned dairy products.
62295128|NCT02514044|EXPERIMENTAL|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
62663072|NCT04361175|EXPERIMENTAL|Clomiphene Citrate group|Clomiphene Citrate group, Patients will receive 100 mg : Clomiphene Citrate daily starting on cycle day 2 for 5 days for three successive cycles
62295129|NCT02514044|EXPERIMENTAL|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
62295130|NCT02514044|EXPERIMENTAL|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
62663073|NCT04264585|EXPERIMENTAL|Standard ICBT|Clients assigned to the Standard ICBT condition will receive the standard version of the ICBT course, which consists of four lessons spread across the span of five weeks. Clients will receive five weeks of therapist support.
62663074|NCT04264585|EXPERIMENTAL|ICBT with Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive the Planning for Change lesson before Lesson 1 of the UniWellbeing Course.
62663075|NCT04264585|EXPERIMENTAL|ICBT with Booster|Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course.
62663076|NCT04264585|EXPERIMENTAL|ICBT with Motivational Interviewing and Booster|Clients assigned to the ICBT with Motivational Interviewing and Booster condition will receive access to both the Motivational Interviewing content (before Lesson 1 of the UniWellbeing Course) and the booster session (one month after ICBT course).
62663077|NCT01325441|EXPERIMENTAL|BBI608 and Paclitaxel 200mg BID|Patients will receive BBI608 orally continuously at 200mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
62663078|NCT01325441|EXPERIMENTAL|BBI608 and Paclitaxel 240mg BID|Patients will receive BBI608 orally continuously at 240mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
62295131|NCT02514044|EXPERIMENTAL|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
62295132|NCT02514044|EXPERIMENTAL|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
62295133|NCT02514044|EXPERIMENTAL|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
62295134|NCT00591734|EXPERIMENTAL|Intervention|All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
62295135|NCT04097548|EXPERIMENTAL|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care.
62295136|NCT04097548|NO_INTERVENTION|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care.
62295137|NCT01106755|EXPERIMENTAL|hemiparetic gait|gait training on ground level
62295138|NCT04444245|EXPERIMENTAL|ARM 1 Platelet Rich Plasma|Blood draw, processing of PRP, white blood cell poor, high platelet multiple \>/= 4, e.g. (Emcyte II Pure PRP) Endovaginal ultrasound guided intra-ovarian placement into ovarian parenchyma, preferably both if accessible.
62295139|NCT04444245|EXPERIMENTAL|ARM 2 emulsified tSVF and PRP|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple \>/= 4, e.g. Emcyte PRP Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue into tSVF (Tulip Nanofat device). Blending of Nanofat with PRP at a 3:1 ratio.~Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible."
62101887|NCT04370522||Cohort A: hormone-sensitive disease|"Patients who initiate ET in first line of advanced disease, they could be patients de novo with no previous ET or patients who received adjuvant ET and experience disease recurrence more than one year after its completion.~Patients will be divided in two subgroups according to having or not received previous ET."
62101888|NCT04370522||Cohort B: hormone-resistant disease|"Patients in progression who are starting a first or second line of ET for advanced Breast Cancer (BC) and showing one of following the hormone-resistance criteria to any ET:~For first line:~* Primary hormone-resistance: disease recurrence occurs within the first two years of adjuvant ET.~* Secondary hormone-resistance: disease recurrence occurs after the first two years of adjuvant ET or during the first year after its completion.~For second line:~* Primary hormone-resistance: disease progression occurs within the first 6 months of ET for advanced disease.~* Secondary hormone-resistance: disease progression occurs after the first 6 months of ET for advanced disease.~Patients will be divided in two subgroups according to having primary or secondary hormone-resistance."
62101889|NCT06711926|EXPERIMENTAL|Experimental: Beverage 1|Distilled water
62295140|NCT04444245|EXPERIMENTAL|ARM 3 emulsified tSVF and PRP, enriched with cSVF|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple \>/= 4, e.g. Emcyte PRP tSVF preparation: Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue (Tulip Nanofat device).~cSVF preparation: lipoaspiration as above. Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocol. Quantification of viable nucleated cell count with flow cytometry. Addition of pellet of viable nucleated cells to tSVF.~Blending of tSVF/cSVF emulsion with PRP at a 3:1 ratio. Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible.~Intervention:"
62295141|NCT04444245|EXPERIMENTAL|ARM 4 Intra-ovarian guided placement|Specifically designed 23 gauge modified oocyte harvester needle for ultrasound guided placement
62101890|NCT06711926|EXPERIMENTAL|Experimental: Beverage 2|Semi skimmed milk
62101891|NCT06711926|EXPERIMENTAL|Experimental: Beverage 3|Whey permeate
61911583|NCT04805879|PLACEBO_COMPARATOR|Placebo oral Capsules|Placebo casules are inactive capsules that look and weigh the same as the Active FMT caspules. Participants will follow the same schedule as the Active arm.
61911584|NCT02744950|ACTIVE_COMPARATOR|Intermediate/complex repair|This arm will have closures of scalp defects with deep and superficial suture placement.
61911585|NCT02744950|EXPERIMENTAL|Pulley stitches|This arm of the study will have only pulley stitches to close the entire defect.
61911586|NCT06034990||Survey participants|Participants in this cross-sectional survey will be physicians with specialty in Anesthesiology, Surgery, Critical care medicine, Pulmonology, Nephrology, General Medicine currently working in Surgical or Medical ICU in Southeast Asia in year 2023-2024
62101892|NCT05030311|EXPERIMENTAL|LOU064 25mg b.i.d.|Patients initially randomized to Remibrutinib during the Double-blind treatment period and continued Remibrutinib during the Open-label treatment period (Up to Week 52)
62101893|NCT05030311|PLACEBO_COMPARATOR|Placebo|Patients initially randomized to Placebo (Up to Week 24)
62101894|NCT03458780||Yellow Fever Vaccine Participant|Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
62101895|NCT02023944|OTHER|Intervention|12-week course on memory and aging, consists of psychoeducation and skills training
62101896|NCT02023944|NO_INTERVENTION|Control, No Intervention|"No Intervention, considered treatment as usual"
62101897|NCT05918133|OTHER|PM8002+nab-paclitaxel|PM8002 at 20 mg/kg (Q2W) and nab-paclitaxel at 100 mg/m2 on the 1st, 8th, and 15th days of each cycle until unacceptable toxicity or disease progression were observed. Each cycle contains 28 days.
62295142|NCT05134909|EXPERIMENTAL|Study: Keratoconus|Customized contact lenses will be fitted to each study subject based on their own optical defects.
62295143|NCT03751293|EXPERIMENTAL|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
62663079|NCT01325441|EXPERIMENTAL|BBI608 and Paclitaxel 400mg BID|Patients will receive BBI608 orally continuously at 400mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
62101898|NCT06714266|EXPERIMENTAL|Patients were treated with Trilaciclib + chemotherapy ± immune/targeted therapy|"Trilaciclib 240mg/m2, intravenous infusion for 30 minutes, completed within 4 hours before daily chemotherapy; Chemotherapy regimen: FP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; 5-FU 1000 mg/m2, intravenous infusion, D1-4; Q3W); TP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; Docetaxel 75mg/m2 or albumin paclitaxel 200mg, IV infusion, D1, 8; Q3W). The specific dose can be adjusted according to the situation.~Immunotherapy: pembrolizumab 200mg q2w Targeted therapy: cetuximab (400mg/m2 qw 250mg/m2 qw) Some patients could be treated with maintenance therapy, and the treatment regimen was immunotherapy or targeted therapy combined with treaclib."
62101899|NCT03751878|EXPERIMENTAL|Intervention arm|Evaluation of reporting inconsistencies between the CONSORT checklist and the information reported in the manuscript. Feedback is provided to authors.
62101900|NCT03751878|OTHER|Control arm|Standard peer review process.
62101901|NCT02076581||Stroke|Ten individuals with chronic stroke and limb spasticity will be recruited.
62101902|NCT02076581||Dystonia|Ten individuals with dystonic limbs and no spasticity will be recruited.
62101903|NCT02076581||Cerebral Palsy|Ten individuals with Cerebral palsy with the potential for a mix of dystonic and spastic abnormal tone in their affected limbs will be recruited.
62101904|NCT02076581||Neurologically normal|Thirty individuals without neurological injury that are age matched to the rest of the study population will be recruited.
62101905|NCT02117869|EXPERIMENTAL|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin hybrid grapefruit juice plus midazolam 5mg orally on the third day.
62101906|NCT02117869|ACTIVE_COMPARATOR|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
62101907|NCT02117869|OTHER|water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
62101908|NCT00175435|EXPERIMENTAL|1|2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
62101909|NCT00175435|ACTIVE_COMPARATOR|2|3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
62101910|NCT00175435|ACTIVE_COMPARATOR|3|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
62101911|NCT06703489|EXPERIMENTAL|Ventricular tachycardia catheter ablation|Ablation using the Sphere-9 Catheter with the Affera Mapping and Ablation System
62101912|NCT05698940|ACTIVE_COMPARATOR|Infundibulotomy|Infundibulotomy on one side of sinuses
62467480|NCT04092023|OTHER|Intervention group|The interventions are designed to address the seven key self-management behaviours identified by the Association of American Diabetes Educations: (1) healthy eating, (2) being active, (3) monitoring, (4) taking medication, (5) problem solving, (6) reducing risk, and (7) healthy coping. In addition, the Chronic Care Model elements of self-management support and patient centered-care approach is embraced during the intervention process. The nursing care components provided to participants will be included (a) self-care management knowledge, (b) skill-based learning and problem solving, (c) participants' participation and engagement, (d) participants' in goal setting, and (e) coordinate care, involve participants to make decision.
62663080|NCT01325441|EXPERIMENTAL|BBI608 and Paclitaxel 480mg BID|Patients will receive BBI608 orally continuously at 480mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
62101913|NCT05698940|SHAM_COMPARATOR|No Infundibultomty|No Intervention on other side of sinuses
62101914|NCT04202575|NO_INTERVENTION|conventional setup|Blood and gas from the coronary and cardiotomy suction devices is continuously evacuated via the additional reservoir to the standard reservoir.
62101915|NCT04202575|EXPERIMENTAL|Intervention setup|The connecting tube between the additional and standard venous reservoir is clamped. Thus, blood and gas from the coronary and cardiotomy suction devices are collected in the additional venous reservoir. During the intervention setup, the blood in the additional venous reservoir is only evacuated to the standard reservoir if the volume exceeded 800ml, and always with a remaining volume of 100 mL blood to keep the CO2-gas trapped in the additional venous reservoir.
62295144|NCT05152186|ACTIVE_COMPARATOR|tranexamic acid|Topical hemostatics as tranexamic acid or hydrogen peroxide in wound before skin closure to decrease perioperative blood loss
62663081|NCT01325441|EXPERIMENTAL|BBI608 and Paclitaxel 500mg BID|Patients will receive BBI608 orally continuously at 500mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
62663082|NCT02967029|ACTIVE_COMPARATOR|b group|b group controlled hypotension with esmolol hydrochloride
62663083|NCT02967029|ACTIVE_COMPARATOR|r group|r group controlled hypotension with remifentanil hydrochloride
62663084|NCT01901562|EXPERIMENTAL|Ductoscopic papillectomy|Ductoscopic papillectomy to treat pathological nipple discharge
62663085|NCT00876343|EXPERIMENTAL|1|Fixed dose
62663086|NCT00876343|EXPERIMENTAL|2|Titration dose
62663087|NCT00876343|PLACEBO_COMPARATOR|3|Placebo
62663088|NCT01815619|EXPERIMENTAL|on-site evaluation of specimens by cytopathologist|The specimen will be evaluated onsite by a cytopathologist during the procedure to render a diagnosis
62101916|NCT01400100|EXPERIMENTAL|Octreotide|Study patients receive after randomization a single shot of 5 mL 500 µg Octreotide in the gastroduodenal artery at the time of its transection.
62295145|NCT05152186|ACTIVE_COMPARATOR|Hydrogen peroxide|Topical hemostatics as hydrogen peroxide in wound before skin closure to decrease perioperative blood loss
62101917|NCT01400100|PLACEBO_COMPARATOR|Control|Control patients receive after randomization a single shot of 5 mL 0,9% NaCL solution in the gastroduodenal artery at the time of its transection.
62101918|NCT02527889|EXPERIMENTAL|Exercise Group|The exercise group will receive a supervised resistive exercise training. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists.
62101919|NCT02527889|NO_INTERVENTION|Control Group|The control group will receive no exercise training and continue to receive standard medical care.
62101920|NCT06703359||COPD referred for pulmonary rehabilitation.|Included participant were referred for pulmonary. During their baseline assessment, they performed the 6-Minute Stepper Test and were then followed for 5 years.
62101921|NCT03401385|EXPERIMENTAL|Dose Escalation - All Participants|All participants enrolled in the dose escalation part
62101922|NCT03401385|EXPERIMENTAL|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
62101923|NCT06711549|EXPERIMENTAL|Patients receiving Serratus Posterior Superior Plane Intercostal Plane block|The patients will undergosurgery after receiving an ultrasound guided serratus posterior superior intercostal plane block
62101924|NCT06711549|ACTIVE_COMPARATOR|Serratus Anterior Plane Block|The patients will undergosurgery after receiving an ultrasound guided serratus anterior plane block
62101925|NCT03962192|EXPERIMENTAL|Survey tools|Survey instruments are shared with reviewers.
62101926|NCT04701060|EXPERIMENTAL|Camrelizumab combined with apatinib|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
62101927|NCT06246422|EXPERIMENTAL|group A|after careful hemostasis for the bleeding points in the liver bed received 500 mg of Tranexamic acid dissolved in 20 ml normal saline locally in the liver bed through the right port, then introduction of a piece of gauze to keep the drug in place for about 3 minutes and then remove it and inserting a drain and close it for one hour after finishing the operation.
62101928|NCT06246422|EXPERIMENTAL|group B|they also underwent the same procedure with routine care for hemostasis until there was no significant bleeding and then instillation of 20 ml normal saline in the gallbladder bed , then drain was inserted and closed for 1 hour the sameway as group A.
62101929|NCT00557843|ACTIVE_COMPARATOR|bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
62101930|NCT00557843|PLACEBO_COMPARATOR|Placebo|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
62101931|NCT05348330|EXPERIMENTAL|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
62101932|NCT05348330|ACTIVE_COMPARATOR|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
62101933|NCT01269606|EXPERIMENTAL|Treatment sequence 1 - IM treatment group|
62101934|NCT01269606|EXPERIMENTAL|Treatment sequence 2 - IM treatment group|
62101935|NCT01269606|EXPERIMENTAL|Treatment sequence 1 - IV treatment group|
62101936|NCT01269606|EXPERIMENTAL|Treatment sequence 2 - IV treatment group|
62101937|NCT05824338|ACTIVE_COMPARATOR|General anesthesia with endotracheal tube|Currently the standard at our centre. Participants in this group will undergo lower lumbar surgery with general anesthesia with endotracheal intubation.
62101938|NCT05824338|ACTIVE_COMPARATOR|Spinal anesthesia with bupivacaine|Participants in this group will undergo lower lumbar surgery under spinal anesthesia with bupivacaine 0.5% 10-15 mg with fentanyl 10-15 mcg.
62101939|NCT05824338|EXPERIMENTAL|Spinal anesthesia with ropivacaine|Participants in this group will undergo lower lumbar surgery under spinal anesthesia with ropivacaine 0.5% 10-20 mg with fentanyl 10-15 mcg.
62101940|NCT06713070||Cohort 1 (Dementia)|The group that will contain the diseased participants (Dementic patients able to walk and perform gait analysis)
62101941|NCT01720043|EXPERIMENTAL|All participants|All participants enrolled
62101942|NCT05556356|PLACEBO_COMPARATOR|Control Group|Preoperative multivitamin and postoperative standardized pain management regimen
62101943|NCT05556356|EXPERIMENTAL|Test Group|: Preoperative acetaminophen and postoperative standardized pain management regimen
62101944|NCT06711848|NO_INTERVENTION|Control Group|This is the control group (arm). No educational intervention on oral cancer will be administered to this group.
62295146|NCT05152186|PLACEBO_COMPARATOR|Normal saline|Hemostasis in spine surgery
62295147|NCT04770766||Staff observation|Doctor-in-training and non-medical practitioner volunteers
62467481|NCT04239833|EXPERIMENTAL|SH-1028 tablets+Placebo Gefitinib|"SH-1028 tablets (200 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.~Interventions:~Drug: SH-1028 tablets 200 mg Drug: Placebo Gefitinib 250 mg"
62101945|NCT06711848|EXPERIMENTAL|Web-based Intervention Group|A web-based educational intervention on oral cancer will be administered to this group.
62101946|NCT06711848|EXPERIMENTAL|mHealth-based Intervention Group|An app-based educational intervention on oral cancer will be administered to this group.
62101947|NCT05552547|ACTIVE_COMPARATOR|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row.
62101948|NCT05552547|EXPERIMENTAL|24-Hour Blood Pressure Machine|Participants will be asked to wear this machine for 24 hours.
62101949|NCT05274789|PLACEBO_COMPARATOR|Placebo group|Use 250 ml of saline as placebo group.
62101950|NCT05274789|EXPERIMENTAL|Experimental group|Use dexmedetomidine as experimental group
62101951|NCT06041893||ATG/LD-PTCy group|Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center
62101952|NCT00310362|EXPERIMENTAL|Usual Care with nurse phone call|Usual Care--Nurses telephoned patients 7 days prior to appointment to remind patients about scheduled GI appointment and to answer any questions.
62101953|NCT00310362|EXPERIMENTAL|interactive voice response 3 days prior|Interactive voice response system was used to remind patients 3 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR3)
62101954|NCT00310362|EXPERIMENTAL|interactive voice response 7 days prior|Interactive voice response system was used to remind patients 7 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR7)
62101955|NCT02014558|EXPERIMENTAL|Gilteritinib 20 mg in Escalation Phase|Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
62101956|NCT02014558|EXPERIMENTAL|Gilteritinib 40 mg in Escalation Phase|Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
62101957|NCT02014558|EXPERIMENTAL|Gilteritinib 80 mg in Escalation Phase|Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
62467482|NCT04239833|ACTIVE_COMPARATOR|Gefitinib+Placebo SH-1028 tablets|"Gefitinib (250 mg orally, once daily) plus placebo SH-1028 tablets (200mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).~Interventions:~Drug: Gefitinib 250 mg Drug: Placebo SH-1028 tablets 200mg"
62101958|NCT02014558|EXPERIMENTAL|Gilteritinib 120 mg in Escalation Phase|Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
62101959|NCT02014558|EXPERIMENTAL|Gilteritinib 200 mg in Escalation Phase|Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
62101960|NCT02014558|EXPERIMENTAL|Gilteritinib 300 mg in Escalation Phase|Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
62101961|NCT02014558|EXPERIMENTAL|Gilteritinib 450 mg in Escalation Phase|Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
62101962|NCT02014558|EXPERIMENTAL|Gilteritinib 20 mg in Expansion Phase|Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.
62101963|NCT02014558|EXPERIMENTAL|Gilteritinib 40 mg in Expansion Phase|Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
62295148|NCT04770766||Patient questionnaires|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study
62467483|NCT00392847|ACTIVE_COMPARATOR|2|The first group will receive routine follow-up as currently provided by national community health and social services.
62467484|NCT00392847|EXPERIMENTAL|1|will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.
62467485|NCT01981720|EXPERIMENTAL|PRX-102 (pegunigalsidase alfa)|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
62295149|NCT04770766||Case study NHS Trusts|NHS organisations with an Emergency Department participating as a case study site
62295150|NCT04770766||All England NHS Trusts|NHS Trusts whose Emergency Department (n=183) records data is held by NHS Digital and will be provided anonymously/without individual patient consent (these anticipated hundreds of thousands of records are not included in the enrolled patient numbers)
62467486|NCT04495647|EXPERIMENTAL|WB-EMS_frail|
62467487|NCT04495647|ACTIVE_COMPARATOR|WB-EMS_robust|
61919846|NCT02934529|ACTIVE_COMPARATOR|A2 (third line)|"Treatment at the treating physician's discretion depending on the patient's general condition, with the exclusion of any anti-EGFR treatment whatsoever (such as for example cetuximab, panitumumab). Recommendations include Regorafenib in line with Grothey A et al, Lancet. 2013~or alternatively another anti-EGFR-free treatment according to the investigating physician's choice~Administration until progression occurs in the third line or unacceptable toxicity"
62101964|NCT02014558|EXPERIMENTAL|Gilteritinib 80 mg in Expansion Phase|Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
62295151|NCT04770766||Patient interviews|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview following completion of the patient questionnaire
62467488|NCT04495647|ACTIVE_COMPARATOR|WB-EMS_young|
62101965|NCT02014558|EXPERIMENTAL|Gilteritinib 120 mg in Expansion Phase|Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
62101966|NCT02014558|EXPERIMENTAL|Gilteritinib 200 mg in Expansion Phase|Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.
62101967|NCT02014558|EXPERIMENTAL|Gilteritinib 300 mg in Expansion Phase|Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.
62101968|NCT05378581|ACTIVE_COMPARATOR|standard|Use local anesthesic cream + nurse or parents distraction +/- anesthesic or anxiolytic gas
62101969|NCT05378581|EXPERIMENTAL|virtual reality|Use local anesthesic cream and virtual reality mask
62101970|NCT04341064|EXPERIMENTAL|SHINE|Participants will be randomized to receive an intervention that provides information on skin cancer and preventive strategies, features a personalized skin cancer prevention packet that focuses on students' UVR exposure and skin cancer risk, and includes the creation of a individualized sun protection action plan.
62101971|NCT04341064|NO_INTERVENTION|Standard Education|Participants will be randomized to receive information that covers general skin cancer education for pediatric populations.
62101972|NCT00512408||A|
62467489|NCT03143920|EXPERIMENTAL|Hyperbaric Oxygen|Hyperbaric oxygen therapy-2.4 atmosphere absolute for 90 minutes with 2-five minute air breaks administered daily, 5 days per week for 8 weeks total treatment.
62101973|NCT00512408||B|
62101974|NCT04166487|EXPERIMENTAL|Pembrolizumab Cycles 1-2|"* For the first two cycles, Pembrolizumab will be administered at a predetermined dose every 3 weeks.~* InVision plasma draw will take place at Cycle 1 Day 1 and Cycle 2 Day 1, with return of results to the treating oncologist prior to Cycle 3 Day 1.~* At Cycle 3, patients will be re-registered per the inclusion criteria into 3 arms;~  * PEMBROLIZUMAB Alone~ * PEMBROLIZUMAB + Doublet Chemotherapy"
62101975|NCT04166487|EXPERIMENTAL|Pembrolizumab Alone, Cycle 3+|"- Following imaging assessment at Cycle 3, participants will continue pembrolizumab alone if the following responses are observed:~* Response of Partial Response/Complete Response~* Response of Stable Disease with plasma response~* Response of Progressive Disease without worsening cancer symptoms AND plasma response"
62295152|NCT04770766||Staff interviews|Staff working in the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview
62295153|NCT04770766||Stakeholder interviews|Senior NHS clinicians, managers, commissioners and lay representatives with roles and interests in the non-medical practitioner workforce
62295154|NCT04392193|EXPERIMENTAL|Proton Particle Therapy for Cardiac Arrhythmia|Subjects who have an ICD with recurrent VT, VF, or VT storm who have failed one prior standard catheter-based ablation after device implantation, will subsequently undergo particle-based extracorporeal ablation.
62295155|NCT01914679|EXPERIMENTAL|Sham followed by device|4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments
62467490|NCT01086241|ACTIVE_COMPARATOR|A: routine 2D mammogram|Subject receives regular 2D mammogram.
62467491|NCT01086241|ACTIVE_COMPARATOR|B: Routine Mammogram + tomosynthesis|Routine Mammogram and tomosynthesis
62467492|NCT03974438|EXPERIMENTAL|Intervention - Acupunture (SDN)|Patients allocated to the intervention arm will receive SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain.
62467493|NCT03974438|SHAM_COMPARATOR|Control - Sham acupunture|Patients allocated to the control arm will receive sham-SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain. The sham procedure consists of a blunted needle, that does not penetrate the skin.
62467494|NCT01848938|ACTIVE_COMPARATOR|Smartphone treatment|Smartphone treatment with PFMT.
62467495|NCT01848938|NO_INTERVENTION|Waiting list|Waiting list for three months. They receive the smartphone application after follow-up.
62467496|NCT03752528||Part A Cohort|Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
62467497|NCT03752528||Part B Cohort|Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.
62467498|NCT00783861|EXPERIMENTAL|1|Lactic Acid (Dermacyd Femina)
62101976|NCT04166487|EXPERIMENTAL|Pembrolizumab + Doublet Chemotherapy, Cycles 3+|"* Following imaging assessment at Cycle 3, participants will receive pembrolizumab in combination with platinum doublet chemotherapy if they have a response of stable disease without plasma response, OR no plasma response and response of progressive disease without worsening cancer systems. Platinum doublet should be histology-appropriate and will be given on-label, per treating oncologist.~* PEMBROLIZUMAB~* Chemotherapy multiple agents systemic~  * PEMETREXED~ * CARBOPLATIN~ * PACLITAXEL"
62101977|NCT06631131|ACTIVE_COMPARATOR|Distalization with clear aligners supported by Class II elastics|Group 1: these patients were treated with sequential distalization with aligners supported by Class II elastics.
62101978|NCT06631131|ACTIVE_COMPARATOR|Distalization with clear aligners supported by miniscrew|Group 2: these patients were treated with sequential distalization with aligners supported by IZC miniscrews.
62101979|NCT01090609|EXPERIMENTAL|Stent implantation|Cronus Stent implantation
62101980|NCT01912326|ACTIVE_COMPARATOR|AF Suppression On|AF Suppression Algorithm On, optimized AF Pacemaker Programming
62101981|NCT01912326|ACTIVE_COMPARATOR|AF Suppression Off|AF Suppression programmed Off, Optimized Pacemaker Programming
62101982|NCT03246581|EXPERIMENTAL|Test Product|tiotropium pMDI 2 inhalations
62101983|NCT03246581|ACTIVE_COMPARATOR|Commercial Product|tiotropium pMDI 2 inhalations
62101984|NCT06711822|EXPERIMENTAL|Device|Shockplus-10
62101985|NCT03988387|EXPERIMENTAL|Peer Support PS)|Participants randomized to the PS arm will be assigned a trained peer supporter (PSr) to enhance adherence to PrEP.
62467499|NCT04300673|EXPERIMENTAL|All patients|Intervention: radio guided surgery
62467500|NCT05161611|EXPERIMENTAL|Zinc sulfate|Patients will receive 10mg/day zinc sulfate along with phototherapy after being diagnosed to have hyperbilirubinemia
62467501|NCT05161611|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo in addition to phototherapy
62101986|NCT03988387|EXPERIMENTAL|Reminders and Resource Transfer (RRT)|Participants randomized to the RRT arm will receive weekly SMS text messages and resource transfers to enhance adherence to PrEP.
62295156|NCT01549301|EXPERIMENTAL|Group D 10 i.v.|Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
62295157|NCT01549301|EXPERIMENTAL|Group C 5 i.v.|Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
62101987|NCT05797545|EXPERIMENTAL|Abbreviated Breast MRI for Breast Cancer Detection|Women are classified and randomly assigned into MRI sequence groups(1st round screening/2nd round screening : AB (abbreviated)-MRI / FP (full protocol)-MRI application group and FP (full protocol)-MRI / AB (abbreviated)). MRI (either AB-MRI or FP-MRI) assigned as the 1st round screening (baseline), mammography, and ultrasound are performed on the same day. For the 2nd round screening one year after the 1st round screening, a different MRI (i.e., FP-MRI if AB-MRI was performed in the previous year, AB-MRI if FP-MRI was performed in the previous year), mammography, and ultrasound were performed on the same day as the 1st round screening.
62101988|NCT05797545|EXPERIMENTAL|Full Protocol MRI for Breast Cancer Detection|Women are classified and randomly assigned into MRI sequence groups(1st round screening/2nd round screening : AB (abbreviated)-MRI / FP (full protocol)-MRI application group and FP (full protocol)-MRI / AB (abbreviated)). MRI (either AB-MRI or FP-MRI) assigned as the 1st round screening (baseline), mammography, and ultrasound are performed on the same day. For the 2nd round screening one year after the 1st round screening, a different MRI (i.e., FP-MRI if AB-MRI was performed in the previous year, AB-MRI if FP-MRI was performed in the previous year), mammography, and ultrasound were performed on the same day as the 1st round screening.
62101989|NCT03416218|EXPERIMENTAL|Intervention|All participants enrolled in the study will play Prognosis, the intervention being assessed in this study.
62101990|NCT00256308|EXPERIMENTAL|Oxaliplatin|Oxaliplatin-70mg/m2 IV over 120 min once a week during radiation. Radiation-200 centigray (cGy) per day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday.
62101991|NCT03193346|EXPERIMENTAL|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.
62101992|NCT03193346|PLACEBO_COMPARATOR|Placebo|Placebo matching BOTOX® \[Sodium chloride 0.9 milligrams (mg)\] IM injections in head/neck areas at Day 0 and Week 12.
62101993|NCT04667988|EXPERIMENTAL|RA patients|newly diagnosed RA will started therapy with conventional synthetic DMARDs (including methotrexate)
62295158|NCT01549301|EXPERIMENTAL|Group B 10 s.c.|Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
62295159|NCT01549301|EXPERIMENTAL|Group A 5 s.c.|Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
62467502|NCT02993380|EXPERIMENTAL|Stir-fried olive oil group|olive oil in heated under 150 degrees
62467503|NCT02993380|EXPERIMENTAL|Natural olive oil group|olive oil in without heated
62467504|NCT00286754|EXPERIMENTAL|Stage-matched intervention (SMI)|Stage-matched intervention (SMI)
62467505|NCT00286754|ACTIVE_COMPARATOR|Health Education Intervention (HEI)|Health Education Intervention (HEI)
62467506|NCT00286754|NO_INTERVENTION|Usual Care (UC)|Usual Care (UC)
62663089|NCT01815619|ACTIVE_COMPARATOR|off-site specimen evaluation|The specimen will be evaluated offsite by a cytopathologist during the procedure and render a diagnosis
62101994|NCT04667988|EXPERIMENTAL|control|JAK2 mutation assesment by PCR
62101995|NCT06085131||Argos Biometer|Preoperative biometry with the Argos device
62101996|NCT06714084|EXPERIMENTAL|Experimental Group|Cadonilimab in neoadjuvant chemotherapy and maintenance therapy for newly diagnosed advanced cervical cancer
62101997|NCT03956199|EXPERIMENTAL|experimental pulpotomy|
62101998|NCT03956199|ACTIVE_COMPARATOR|Root canal treatment|
62101999|NCT05335681|EXPERIMENTAL|Experimental group;|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen, and groin areas will be applied
62102000|NCT05335681|NO_INTERVENTION|Control group|No intervention will be made in the control group. In stages where the dilatation gap is 4 and 7 cm, the pain will be evaluated with the VAS scale at 0, 10, and 20 minutes.
62102001|NCT04956354||Phase 1a|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired for 8h during daytime, for 4 consecutive days. In addition, photographs of the skin at the site of placement of the sensors will be taken before sensors placement and after removal.~Hourly axillary temperature measured by the bedside nurse (as part of routine care) will be manually recorded for each patient by the research team. A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
62102002|NCT04956354||Phase 1b|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired between 2h to 8h during daytime, for 2 to 4 consecutive days. In addition, photographs of the skin at the site of placement of the sensors will be taken before sensors placement and after removal.~A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
62102003|NCT04956354||Phase 2|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired for a longer monitoring period - i.e., 96 consecutive hours. In consideration with device battery life, the devices will be replaced daily. In addition, photographs of the skin at the site of placement of the sensors will be taken at baseline, device replacement, and at 96h. The research team will also measure respirations using uncalibrated RIP belts at the level of the chest and abdomen (2 to 3 continuous hours each day). Two respiratory bands will be placed circumferentially around the infant's chest and around the abdomen to measure chest and abdominal wall movements, respectively.~A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
62102004|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence ABC|The subjects in Part 1 of the study, will receive a single dose of treatment A= adult TRIUMEQ (DTG 50 mg/ABC 600 mg/3TC 300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment B=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment C=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102005|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence BCA|The subjects in Part 1 of the study, will receive treatment B in TP1, treatment C in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102006|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence CAB|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment A in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102007|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence ACB|The subjects in Part 1 of the study will receive, treatment A in TP1, treatment C in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62295160|NCT03973814|ACTIVE_COMPARATOR|Prior to Thermax Warming|Baseline temperature
62295161|NCT03973814|ACTIVE_COMPARATOR|During warming|Temperature during Thermax warming
62295162|NCT03973814|ACTIVE_COMPARATOR|Post warming|Temperature after cessation of Thermax warming
62663090|NCT02054949|EXPERIMENTAL|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
62663091|NCT05186155||premature baby without ROP (Group 0)|ROP: retinopathy of prematurity
62663092|NCT05186155||ROP without treatment (Group 1)|ROP: retinopathy of prematurity
62663093|NCT05186155||ROP with laser photocoagulation treatment (Group 2)|ROP: retinopathy of prematurity
62663094|NCT05186155||ROP with anti-VEGF treatment (Group 3)|ROP: retinopathy of prematurity anti-VEGF: anti-Vascular Endothelial Growth Factor
62663095|NCT05186155||ROP with laser photocoagulation + anti-VEGF treatment (Group 4)|ROP: retinopathy of prematurity anti-VEGF: anti-Vascular Endothelial Growth Factor
62295163|NCT03512535||Stage 1|Samples from up to 20 participants will be used to finalise the analytical methods
62295164|NCT03512535||Stage 2|Samples from up to 200 participants will be used to then validate the normal ranges of these markers across different age ranges in both genders
62663096|NCT05186155||Fullterm baby (Group 5)|Fullterm baby
62663097|NCT05926531|EXPERIMENTAL|acute insomnia treatment group|CBTI and VR intervention for one week
62663098|NCT05926531|NO_INTERVENTION|acute insomnia control group|no intervention
62663099|NCT05926531|EXPERIMENTAL|chronic insomnia treatment group|CBTI and VR intervention for one week
62663100|NCT05926531|NO_INTERVENTION|chronic insomnia control group|no intervention
62663101|NCT02512562|ACTIVE_COMPARATOR|Group 1: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
62663102|NCT02512562|ACTIVE_COMPARATOR|Group 2: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
62663103|NCT04954872|ACTIVE_COMPARATOR|Training as usual|Standard Problem Management Plus training.
62663104|NCT04954872|EXPERIMENTAL|Equip-based training|Training that uses the Equip platform to assess competencies and incorporate this information into trainers and supervisors activities.
62102008|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence BAC|The subjects in Part 1 of the study will receive a single dose each of, treatment B in TP1, treatment A in TP2 and treatment C in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102009|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence CBA|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment B in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102010|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence DEF|The subjects in Part 2 of the study, will receive a single dose of treatment D= Adult DTG (50 mg, 1 conventional tablet) and adult 3TC (300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment E= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment F= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102011|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence EFD|The subjects in Part 2 of the study, will receive a single dose respectively of treatment E in TP1, treatment F in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102012|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence FDE|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment D in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102013|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence DFE|The subjects in Part 2 of the study, will receive a single dose of treatment D in TP1, treatment F in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102014|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence EDF|The subjects in Part 2 of the study, will receive a single dose of treatment E in TP1, treatment D in TP2 and treatment F in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102015|NCT03441984|EXPERIMENTAL|Subjects with treatment sequence FED|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment E in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
62102016|NCT02433509|EXPERIMENTAL|hUCB w/ Mannitol in acute ischemic stroke|"1. The cord blood need to be infusion within less than 10 days after the onset of stroke, with the cord blood mononuclear cells 200 million \~ 500 million will used.~2. 20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
62102017|NCT02892799|ACTIVE_COMPARATOR|Standard of Care|Patients randomized to the usual care arm will be treated almost the same as if they do not enroll in the study. They will be managed in accordance with best ICU (intensive care unit) practices, with treatment decisions made by the treating team. Often this will include blood draws (often 2 teaspoons once or twice per day, but sometimes exceeding this), assessments of cardiac function, assessments of fluid status, and other measures as dictated by the presenting illness (this is broad and will include antibiotics, diuretics, cardiac medications, ventilator and oxygen management, etc.). Patients in the usual care arm will not have diuresis managed by NICOM.
62102018|NCT02892799|EXPERIMENTAL|NICOM-Guided Diuresis|"Within 4 hours, patients will have their blood pressure obtained, a NICOM-based assessment of PLR (passive leg raise)-induced change in cardiac index, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7 am). This will allow determination of the fluid goal over the next 4 hours. Patients will receive furosemide to achieve the goal fluid balance, if needed as described in the accompanying protocol. Monitoring of electrolytes and renal function will be at the discretion of the treating physician.~Following the initial evaluation, at set times spaced every 4 hours apart, patients will have an ongoing evaluation of the day's fluid balance, hourly urinary output, and PLR/NICOM values. This diuresis protocol will continue for a total of seven 24-hour periods or until the primary means of oxygenation/ventilation has been withdrawn, whichever occurs first. Patients will be followed for a total of 60 days to evaluate outcome data."
62295165|NCT00820430||Control--Non-Osteoporotic Knee|Kellgren-Lawrence (KL) scale score of 0, Age: 18-35 years
62295166|NCT00820430||Minimal Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 1 or 2, Age: Older than 18; no upper limit
62295167|NCT00820430||Moderate Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 3, Age: Older than 18; no upper limit
62295168|NCT05415410|EXPERIMENTAL|Apraglutide Low Dose|Apraglutide SC injections, once weekly, for subjects with body weight of more than 50.0 kg.
62295169|NCT05415410|EXPERIMENTAL|Apraglutide High Dose|Apraglutide SC injections, once weekly, for subjects with body weight of more than 50.0 kg.
62295170|NCT05415410|EXPERIMENTAL|Apraglutide Standard Dose|Apraglutide SC injections, once weekly, for subjects with body weight between 40.0 kg to 49.9 kg.
62295171|NCT02851264||Optical enhancement technology examination|After routine examination by white-light endoscopy,the imaging mode will be switched to optical enhancement.Suspicious area will be recorded in detail. Then all enrolled patients will have their esophagus sprayed with iodine solution. Suspicious area will be also recorded in detail.After that biopsy specimens will be obtained respectively by forceps from each suspicious lesion recorded for histologic diagnosis.
62295172|NCT02619422|OTHER|Intensivo|intensive cardiac rehabilitation program in less time
62295173|NCT02619422|NO_INTERVENTION|Convencional|standard cardiac rehabilitation program
62295174|NCT06117189||Adult endodontic patients|Turkish version of Oral Health Impact on Daily Life questionnaire was applied to adult endodontic patients
62295175|NCT00216034|ACTIVE_COMPARATOR|1|TS-1 Group: The group treated with TS-1 mono-therapy
62295176|NCT00216034|EXPERIMENTAL|2|TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
62295177|NCT03252782|ACTIVE_COMPARATOR|Functional Treatment|Acrylic Splint Herbst Appliance
62295178|NCT03252782|ACTIVE_COMPARATOR|Distalization Treatment|Mini-implant-borne Distal Jet Appliance
62295179|NCT03812510|EXPERIMENTAL|A-101|Topical Solution
62663105|NCT03568617|EXPERIMENTAL|rTMS group|
62295180|NCT03819075|EXPERIMENTAL|Laser|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units.
62295181|NCT03819075|ACTIVE_COMPARATOR|Control|Standard periimplantitis treatment will be conducted in the control group.
62663106|NCT00107588|EXPERIMENTAL|Reinforcement for homework completion|
62663107|NCT00107588|ACTIVE_COMPARATOR|Reinforcement for Abstinence|
62663108|NCT00107588|ACTIVE_COMPARATOR|Case Management|
62663109|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts \>8,000 per day from activity monitoring.
62663110|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts \<5,000 per day from activity monitoring.
62663111|NCT03513731|EXPERIMENTAL|Adipose-derived stem cell injection|ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
62663112|NCT03513731|ACTIVE_COMPARATOR|Corticosteroid injection|The control group will undergo standard fluoroscopy guided injection of glucocorticoids and local anesthetics.
62663113|NCT01101048|PLACEBO_COMPARATOR|A|Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
61919847|NCT02934529|EXPERIMENTAL|B2 (third line)|"one cycle (cycle duration 14 days) consists of Irinotecan 125mg, Folinic acid, 5-FU, cetuximab wkly~Administration every 2 weeks until progression occurs in the third line or unacceptable toxicity~or depending on the patient's general condition and the study physician's decision~Irinotecan plus cetuximab in line with Cunningham D et al, N Engl J Med. 2004"
62102019|NCT06171789|EXPERIMENTAL|PRO1107|PRO1107 monotherapy in escalating doses in Part A and at the two recommended phase 2 doses in Part B
62102020|NCT06707324|ACTIVE_COMPARATOR|TAB group|20 ml of 0.25% bupivacaine + 8 mg dexamethasone between the rectus abdominis muscle and the transversus abdominis muscle on both sides
62102021|NCT06707324|ACTIVE_COMPARATOR|EOB group|20 ml of 0.25% bupivacaine+ 8 mg dexamethasone into the external oblique intercostal plane on both sides
62102022|NCT05231122|ACTIVE_COMPARATOR|Arm I (pembrolizumab, bevacizumab)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
62102023|NCT05231122|EXPERIMENTAL|Arm II (pembrolizumab, bevacizumab, CDX-1140)|Patients receive pembrolizumab IV over 30 minutes, bevacizumab IV over 30-90 minutes, and CDX-1140 IV over 90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
62102024|NCT06713707||Test Group|Patients with Parkinson's disease
62102025|NCT06713707||Control Group|Healthy group
62102026|NCT01511588||HH patients|Clinical patients with hypogonadotropic hypogonadism (HH)
62102027|NCT06313684|EXPERIMENTAL|Comprehensive Hybrid Cardiac Rehabilitation|The 24-week Cardiac Rehabilitation intervention will include evaluation, medical and nurse management, aerobic interval training, resistance exercise, psychosocial support, and education. These will initially be delivered in a health center, transitioning to home in 4 stages.
62295182|NCT02595034|EXPERIMENTAL|Clindamycin/BP Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%/5% applied twice daily (morning and evening) for 70 days (10 weeks).
62102028|NCT06313684|ACTIVE_COMPARATOR|Exercise and center-based Cardiac Rehabilitation|Cardiac rehabilitation with face-to-face continuous aerobic exercise sessions and resistance exercises.
62295183|NCT02595034|ACTIVE_COMPARATOR|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel applied twice daily (morning and evening) for 70 days (10 weeks).
62295184|NCT02595034|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle of the test product) applied twice daily (morning and evening) for 70 days (10 weeks).
62295185|NCT05657769|EXPERIMENTAL|Group I (Treatment)|Regular diabetes treatment with additional Medwell application and wearable device.
62295186|NCT05657769|ACTIVE_COMPARATOR|Group II (Control)|Regular diabetes treatment only with a diary card to record daily activities manually.
62663114|NCT01101048|ACTIVE_COMPARATOR|B|Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
62663115|NCT06369272||SPIKEVAX Exposed Pregnancy|Cohort includes pregnant women who were vaccinated with SPIKEVAX from last menstrual period (LMP) through the exposure ascertainment period for the outcome of interest.
62102029|NCT00878384|ACTIVE_COMPARATOR|Rate control|Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
62102030|NCT00878384|ACTIVE_COMPARATOR|Catheter Ablation|Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.
62102031|NCT06094140|EXPERIMENTAL|Single arm study, mFOLFIRINOX and durvalumab, neoadjuvant resectable pancreatic cancer.|"All patients enrolled to this study will receive mFOLFIRINOX, delivered Q2W for 6 cycles and durvalumab delivered Q4W for 3 cycles in the neoadjuvant setting for resectable or borderline resectable pancreatic cancer patients. Patients will then undergo restaging, discussion at MDM and surgical resection where appropriate. Following resection, patients will commence 6 cycles of adjuvant mFOLFIRINOX alone (or gemcitabine-based chemotherapy if deemed by investigator as more appropriate).~Patients will be followed up on study for 12 months from surgery, or from completion of neoadjuvant"
62102032|NCT06629376|EXPERIMENTAL|Experimental： group1|injection；strength；4mg
62102033|NCT06629376|EXPERIMENTAL|Experimental： group2|injection；strength；8mg
62295187|NCT00125047|EXPERIMENTAL|1|Typhoid Vi polysaccharide vaccine
62295188|NCT00125047|ACTIVE_COMPARATOR|2|Inactivated Hepatitis A vaccine
62467507|NCT04234685|EXPERIMENTAL|HIPL Therapy™ group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).~The HIPL Therapy™ group will receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks. Participants will lay in a relaxed position on a therapy plinth with the light applied using the Invitalizer 2.0. The phototherapy will illuminate the affected knee for 20 minutes. In the case of bilateral knee OA, the treatment time will be doubled and applied to both knees. The knee will be positioned at a determined distance from the lamp with an intensity setting of 150 mW/cm2."
62467508|NCT04234685|PLACEBO_COMPARATOR|Placebo Control group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).~The placebo control group will also receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks, in the same setting as the HIPL Therapy™ group and for the same duration. However, the intensity setting will be set at 5 mW/cm2, a dosage, at which there is no therapeutic benefit expected, but the light will still be visible to the participant."
62467509|NCT02972047|EXPERIMENTAL|Diaphragmatic Breathing|"Subjects randomized to the experimental intervention arm will receive instructions and rationale for Diaphragmatic Breathing in the postprandial state and receive detailed instruction in diaphragmatic breathing.~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will practice diaphragmatic breathing for 30 minutes after each meal.~1. During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~2. After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
62467510|NCT02972047|SHAM_COMPARATOR|Life style counseling|"Subjects randomized to the Sham Comparator intervention arm will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~1. During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~2. After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
62467511|NCT02341261|EXPERIMENTAL|Standard Care Counseling|Participants randomized to the control group will receive diet and exercise counseling at baseline and 9 months. Participants will wear an ActivePAL for 7 days at baseline, 9 months, and 18 months without stimulation.
62102034|NCT06629376|EXPERIMENTAL|Experimental： group3|injection；strength；12mg
62102035|NCT06629376|EXPERIMENTAL|Experimental： group4|injection；strength；16mg
62467512|NCT02341261|EXPERIMENTAL|Supervised Exercise and Counseling|"Participants randomized to the intervention will perform supervised aerobic, resistance and balance training twice weekly for 12 weeks, and weekly thereafter. Actigraphy-based counseling to reduce sedentary behavior will follow a similar taper. Daily text messages, tweets, emails, and social media posts at random times during waking hours will be used to provide reminders and motivational messages. Participants will have 11 separate 7-day continuous ActivePAL training session incorporating vibrostimulatory feedback spread across the treatment period."
62467513|NCT00669942|EXPERIMENTAL|Part 1 - AIN457A 0.3 mg/kg|AIN457A 0.3 mg/kg was administered intravenously as a single dose.
62102036|NCT06629376|EXPERIMENTAL|Experimental： group5|injection；strength；20mg
61919848|NCT05110001|PLACEBO_COMPARATOR|Standard Therapy|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
62102037|NCT06629376|PLACEBO_COMPARATOR|Placebo control group|The same volume of placebo as SSS11
62102038|NCT05448755|EXPERIMENTAL|Open label study drug treatment|
61919849|NCT05110001|EXPERIMENTAL|Cross-Linking with rose Bengal (RB-PDT)|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT
62102039|NCT02161510|EXPERIMENTAL|Part I: MK-2248 200 mg (Panel A)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
62295189|NCT02600299|EXPERIMENTAL|Intervention Arm|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship. This program is designed to take place on three individual days on a weekend. For each session, three major topics will be covered, with lectures and interactive workshop integrated. Sessions will be conducted by healthcare professionals who are experts/well-versed in their respective domains.
62295190|NCT02600299|PLACEBO_COMPARATOR|Usual Care|No active intervention provided.
62295191|NCT01992029||ALS Patients|
62295192|NCT01992029||Control patients suffering from neuropathy|
62295193|NCT01992029||Control patients suffering from myopathy|
62102040|NCT02161510|EXPERIMENTAL|Part I: MK-2248 ≤800 mg (Panel B)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
62102041|NCT02161510|EXPERIMENTAL|Part I: MK-2248 ≤800 mg (Panel C)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days.
62295194|NCT01992029||Control subjects|control patients without any neurological disease having an orthopedic surgery for shoulder disease
62295195|NCT01875497|EXPERIMENTAL|Dietary Supplement|Before the exercise, the individuals intake only one capsule with 205 mg of the grape fruit extract in capsule with 205 mg.
62295196|NCT03415165|ACTIVE_COMPARATOR|green tea buccal tablet|buccal tablet 3 times aday
62295197|NCT03415165|SHAM_COMPARATOR|corticosteroids topical|topical steroids 3 times aday
62295198|NCT00904787|EXPERIMENTAL|1|
62295199|NCT01368796|ACTIVE_COMPARATOR|Trivalent Influenza vaccine subunit|The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
62295200|NCT01368796|ACTIVE_COMPARATOR|Adjuvanted Tri-valent Influenza Vaccine|The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
62295201|NCT01368796|ACTIVE_COMPARATOR|Intradermal Tri-valent Influenza vaccine|(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
62295202|NCT01368796|ACTIVE_COMPARATOR|Trivalent Split-virion Influenza vaccine|Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
62295203|NCT02479243||Collateral Circulation|Symptomatic patients with unilateral MCA severe stenosis confirmed ≥ 90% by magnetic resonance angiography or 70-99% by conventional angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI.
62663116|NCT06369272||SPIKEVAX Distantly Exposed Pregnancy|Cohort includes pregnant women who were exposed to SPIKEVAX at least 60 days prior to LMP and not exposed to SPIKEVAX or any other COVID-19 vaccine from LMP through the exposure ascertainment period for the outcome of interest.
62663117|NCT06369272||Unvaccinated During Pregnancy|Cohort includes pregnant women not exposed to SPIKEVAX or any other COVID-19 vaccine within 60 days prior to LMP through the exposure ascertainment period for the outcome of interest.
62663118|NCT06369272||COVID-19 Infected During Pregnancy|Cohort includes pregnant women not exposed to SPIKEVAX or any other COVID-19 vaccine within 60 days prior to LMP through the exposure ascertainment period for the outcome of interest. These women also had at least one medically attended COVID-19 episode during the exposure ascertainment period outcome of interest.
62295204|NCT05374486|EXPERIMENTAL|NeuroExo|NeuroExo is a device which includes a robotic exoskeleton that you were in your affected arm to assist you with arm movements, a headset that you wear on your head to measure your brain activity and detect your intention to move, and a graphical user interface that allows you to initiate and stop neurotherapy, and track your motor performance.
62295205|NCT06124703|ACTIVE_COMPARATOR|dose-tapering regimen|The dose selection of oral prednisone is the maximum daily dose for 4 days, followed by a taper every 2 days
62295206|NCT06124703|EXPERIMENTAL|no taper regimen|The dose selection of oral prednisone is the maximum daily dose, applied for 5 consecutive days
62663119|NCT06324591|OTHER|patient with Chron's Disease|Only patient with Crohn's Disease
62663120|NCT01104051||Radiofrequency Ablation|The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
62663121|NCT01104051||Sham|subjects to be blinded,to receive sham procedure; The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
62663122|NCT05175365|EXPERIMENTAL|Dance|Patients allocated to this group will attend dance classes for patients with Parkinson's disease given once a week over a 4-month period for a total of 16 dance sessions.
62663123|NCT05175365|NO_INTERVENTION|Control|The control group will receive its rehabilitation care.
62295207|NCT04223466|EXPERIMENTAL|Subxiphoid group|Subxiphoid procedure for thymectomy.
62295208|NCT04223466|ACTIVE_COMPARATOR|VATS group|Video-assisted thoracoscopic thymectomy through chest wall.
62295209|NCT01811914|EXPERIMENTAL|intraoperative TTE|TTE if a hemodynamic instability occurs
62295210|NCT05021809|NO_INTERVENTION|Group A|control group will not receive any intracanal medication
62295211|NCT05021809|ACTIVE_COMPARATOR|Group B|Calcium hydroxide intracanal medication without iodoform (Metapaste )
62295212|NCT05021809|ACTIVE_COMPARATOR|Group C|Calcium hydroxide intracanal medication with iodoform (Metapex)
62663124|NCT01765491|EXPERIMENTAL|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy.
62663125|NCT01765491|ACTIVE_COMPARATOR|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy.
62102042|NCT02161510|EXPERIMENTAL|Part I: MK-2248 ≤800 mg (Panel D)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
62102043|NCT02161510|EXPERIMENTAL|Part II: MK-2248 200 mg (Panel E)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
62102044|NCT02161510|EXPERIMENTAL|Part II: MK-2248 ≤800 mg (Panel F)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
62102045|NCT02161510|EXPERIMENTAL|Part II: MK-2248 ≤800 mg (Panel G)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
62102046|NCT02161510|EXPERIMENTAL|Part II: MK-2248 ≤800 mg (Panel H)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
62102047|NCT02161510|EXPERIMENTAL|Part III: MK-2248 ≤800 mg (Panel I)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
62102048|NCT02161510|EXPERIMENTAL|Part III: MK-2248 ≤800 mg (Panel J)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
62102049|NCT06711172|EXPERIMENTAL|Health Coaching|
62102050|NCT06700993|EXPERIMENTAL|Experimental Condition|
62102051|NCT06700993|ACTIVE_COMPARATOR|Treatment as Usual|
62102052|NCT06627907||Group 1|Patients receiving a fluid challenge
62102053|NCT01605968|EXPERIMENTAL|BCT Silver Bandage|
62102054|NCT01605968|ACTIVE_COMPARATOR|Aquacel® Ag. Dressing|
62102055|NCT00692562|EXPERIMENTAL|A|
62102056|NCT04159948|PLACEBO_COMPARATOR|Water|Patients will be allowed to drink water up to 2 hours before their caesarean section.
62102057|NCT04159948|ACTIVE_COMPARATOR|Carbohydrate drink|Patients will be allowed to drink a designated carbohydrate drink up to 2 hours before their caesarean section.
62102058|NCT04159948|ACTIVE_COMPARATOR|Apple juice|Patients will be allowed to drink apple juice up to 2 hours before their caesarean section.
62102059|NCT05309486|EXPERIMENTAL|Online pilates group|Online pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates trainings.
62663126|NCT06522802|EXPERIMENTAL|Evaluation Arm|Only one group evaluated
62663127|NCT03893708|EXPERIMENTAL|Prenatal yoga|Each class will be outlined as follows: 1) opening greeting/intention setting, 2) pranayama (i.e., breathing exercises), 3) warm-up/sun salutations (i.e., flowing sequence), 4) yoga sequence (e.g., combination of sun salutations, vinyasa, and standing, seated, and/or balancing poses), 5) cool-down 6) Savasana (i.e., final resting pose), and 7) class closing. Meditation and breath awareness (e.g., linking each movement with breath) will be emphasized throughout each class. All classes will focus on safety and alignment and be appropriate for women during pregnancy by incorporating modifications to poses/exercises as necessary (e.g., yoga block, strap). Certified yoga instructors with a bachelors degree in a health related field and experience teaching pregnant women will instruct all yoga classes. Participants will be provided with a 'yoga during pregnancy' safety packet that includes a list of prenatal yoga poses that women may do at their own leisure at home.
62102060|NCT05309486|ACTIVE_COMPARATOR|Face-to-face pilates group|Face-to-face pilates training, which lasts for a total of 8 weeks, 3 days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Face-to-face pilates training will be held at Ankara Medipol University. To make the exercises more effective, the individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates exercises, 15 minutes of cool-down and stretching exercises, and the exercises will be performed as 10 repetitions. The same exercises will be applied in online pilates and face-to-face pilates trainings.
62102061|NCT03141788|OTHER|3M Clear Aligner|Clear Aligner for Orthodontic Treatment
62102062|NCT04980222|EXPERIMENTAL|Glofitamab + R-CHOP Immunochemotherapy|"Participants will receive step-up doses of glofitamab, starting on Day 8 of Cycle 3 (2.5 mg), Day 15 of Cycle 3 (10 mg), then 30 mg glofitamab will be given every three weeks (Q3W) onwards, on Day 8 of Cycles 4-6 and on Day 1 of Cycles 7-10. (cycle length = 21 days)~Participants will receive rituximab, cyclophosphamide, doxorubicin, and vincristine Q3W on Day 1 of Cycles 1-6. Prednisone or prednisolone will be administered daily (QD) on Days 1-5 of Cycles 1-6. (cycle length = 21 days)"
62102063|NCT00725413|EXPERIMENTAL|Arm 1|Healthy premenopausal women requiring a long-term method of contraception
62102064|NCT02029053|OTHER|Single Arm Study|Vaginal Lubrication Ring for Vaginal Dryness
62467514|NCT00669942|EXPERIMENTAL|Part 1 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as a single dose.
62102065|NCT06287450|EXPERIMENTAL|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of IN006 or matching-placebo on Day 0.
62102066|NCT06287450|EXPERIMENTAL|Cohort 2: Dose B in Younger Adults|Single injection of Dose B of IN006 or matching-placebo on Day 0.
62102067|NCT06287450|EXPERIMENTAL|Cohort 3: Dose C in Younger Adults|Single injection of Dose C of IN006 or matching-placebo on Day 0.
62102068|NCT06287450|EXPERIMENTAL|Cohort 4: Dose D in Younger Adults|Single injection of Dose D of IN006 or matching-placebo on Day 0.
62295213|NCT04250584|EXPERIMENTAL|Test Device|Novel Mandibular Advancement Device
62467515|NCT00669942|EXPERIMENTAL|Part 1 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
62467516|NCT00669942|EXPERIMENTAL|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
62102069|NCT06287450|EXPERIMENTAL|Cohort 5: Dose B in Older Adults|One injection of either Dose B of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
62102070|NCT06287450|EXPERIMENTAL|Cohort 6: Dose C in Older Adults|One injection of either Dose C of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
62102071|NCT06287450|EXPERIMENTAL|Cohort 7: Dose D in Older Adults|One injection of either Dose D of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
62102072|NCT06712693|EXPERIMENTAL|Experimental|All participants will be tested using all three types of domes: Power, Vented, Open.
62102073|NCT04669405|ACTIVE_COMPARATOR|HILT group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving high intensity laser therapy.
62102074|NCT04669405|OTHER|Control group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving exercise.
62102075|NCT06107920|NO_INTERVENTION|Arm I (Adjuvant chemotherapy) / Control arm|"Diverting stoma - colectomy - +/- adjuvant chemotherapy~The colectomy (open or laparoscopic) should be performed within 1 to 20 days after the randomization and with respect of the oncological quality criteria of resection. After completion of surgery, adjuvant chemotherapy will be discussed as follow:~* Low-risk stage II: No adjuvant treatment~* High-risk MSS stage II (vascular emboli, lymphatic or perinervous invasion, poor differentiation, \<12 harvested lymph nodes, perforation): Investigator's discretion~* pT1-T3N1: CAPOX (3 months) or FOLFOX (6 months)~* pT4 and/or N2: FOLFOX (6 months)"
62295214|NCT04250584|ACTIVE_COMPARATOR|Predicate Device|Predicate Mandibular Advancement Device
62467517|NCT00669942|PLACEBO_COMPARATOR|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
62467518|NCT00669942|EXPERIMENTAL|Parts 2 and 3 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
62663128|NCT03893708|ACTIVE_COMPARATOR|Pregnancy education|Participants will be asked to attend a group-based pregnancy education group (similar to a birth education class). The class format will include a didactic portion followed by group discussion (N=12). The following evidence-based topics (based on the American College of Obstetrics and Gynecologists) to be discussed may include (but not limited to): financial management in preparation for baby, preparing for labor and delivery, transitioning into motherhood, sleep hygiene, and baby bonding. A labor and delivery nurse and certified Dula will instruct all classes.
62102076|NCT06107920|EXPERIMENTAL|Arm II (Neoadjuvant Chemotherapy) / Experimental arm|"Patients receive systemic CAPOX or FOLFOX chemotherapy (3 months) within 21 days after the randomization. After completion of neoadjuvant chemotherapy and within 3 to 5 weeks, the colectomy (open or laparoscopic) will be performed with respect of the oncological quality criteria. Adjuvant chemotherapy will be discussed as follow:~* Low-risk stage II: No adjuvant treatment~* High-risk MSS stage II (vascular emboli, perinervous or lymphatic invasion, poor differentiation, \<12 harvested lymph nodes, perforation): Investigator's discretion~* Stage III: CAPOX or FOLFOX (3 months)"
62467519|NCT00669942|EXPERIMENTAL|Parts 2 and 3 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
62663129|NCT00536835|EXPERIMENTAL|Stage A|Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.
62467520|NCT00669942|EXPERIMENTAL|Parts 2 and 3 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
62467521|NCT00669942|PLACEBO_COMPARATOR|Parts 2 and 3 - Placebo|Placebo to AIN457A was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
62467522|NCT00669942|EXPERIMENTAL|Part 1 - Healthy Volunteers - AIN457A 3 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
62467523|NCT00669942|EXPERIMENTAL|Part 1 - Healthy Volunteers - AIN457A 10 mg/kg|AIN457A 10 mg/kg was administered intravenously as a single dose.
62467524|NCT00669942|PLACEBO_COMPARATOR|Part 1 - Healthy Volunteers - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
62467525|NCT02173418|EXPERIMENTAL|Ropivacaine|Phrenic nerve block with Ropivacaine
62467526|NCT02173418|PLACEBO_COMPARATOR|Placebo|Phrenic nerve block with Sodium chloride
62295215|NCT02354833|EXPERIMENTAL|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
62467527|NCT01054586||HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI|Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.
62467528|NCT01710657|PLACEBO_COMPARATOR|Placebo|Matching placebo for 16 weeks.
62467529|NCT01710657|EXPERIMENTAL|Lacosamide 200 mg/day|Lacosamide treatment of 200 mg/day (100 mg bid (twice daily)) for 16 weeks.
62295216|NCT02354833|EXPERIMENTAL|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
62295217|NCT02890719|EXPERIMENTAL|Genotype 1B|treatment 12 weeks
62295218|NCT02890719|EXPERIMENTAL|Genotype 1A and 4|treatment 16 weeks
62295219|NCT00371267|EXPERIMENTAL|Arm 1: Telephone-delivered CBT|Telephone-delivered cognitive behavior therapy for pain management
62295220|NCT00371267|ACTIVE_COMPARATOR|Arm 2: Telephone patient education|Telephone-delivered patient education regarding management of chronic pain
62295221|NCT06644989|SHAM_COMPARATOR|Sham Comparator|Half of Participants receive Spencer technique and half of participants received a sham treatment.
62295222|NCT06644989|EXPERIMENTAL|Experimental|Half of Participants receive Spencer technique and half of participants received a sham treatment.
62295223|NCT02229201|EXPERIMENTAL|Propofol|intravenous anaesthetic
62295224|NCT02229201|ACTIVE_COMPARATOR|Sevoflurane|volatile anaesthetic
62295225|NCT01865292|EXPERIMENTAL|Insulin degludec|
62295226|NCT01865292|ACTIVE_COMPARATOR|Insulin glargine|
62295227|NCT05529654|EXPERIMENTAL|Impella Arm|Impella 5.5 with SmartAssist
62295228|NCT05328947|EXPERIMENTAL|Normal Controls|
62295229|NCT04387292|EXPERIMENTAL|Ophthalmologic exam|
62295230|NCT01446211|EXPERIMENTAL|Test group - gusperimus|Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
62663130|NCT00536835|EXPERIMENTAL|Stage B|Evaluate safety, PK, pharmacodynamic (PD) \& tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.
62102077|NCT03303105|EXPERIMENTAL|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly \[except for a loading dose of 675 mg in subjects with CM\]).
62102078|NCT03303105|EXPERIMENTAL|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
62102079|NCT04680897|OTHER|Standard Group|Participants may resume vaginal penetration at 6 weeks.
62663131|NCT00525304|EXPERIMENTAL|1|Participants will receive a self-management program for chronic illness
62663132|NCT00525304|NO_INTERVENTION|Usaual Care|Usual Care; no additional intervention
62663133|NCT01830686|EXPERIMENTAL|Sugarcane bagasse|10 subjects will consume food (brownies and cookies) made with 13 g of sugarcane bagasse everyday for 4 weeks
62663134|NCT01830686|ACTIVE_COMPARATOR|Non-caloric, non-fermentable fiber|10 subjects will consume food (brownies and cookies) made with 13 g of non caloric, non-fermentable fiber everyday for 4 weeks
62663135|NCT01830686|PLACEBO_COMPARATOR|Minimal fiber|10 subjects will consume food (brownies and cookies) made with 4 g of dietary fiber everyday for 4 weeks
62663136|NCT04121013|ACTIVE_COMPARATOR|Mothership|Acute stroke patients with suspected large vessel occlusion will be directly transferred to the nearest transportation to the endovascular center
62663137|NCT04121013|NO_INTERVENTION|drip'n'ship|Acute stroke patients with suspected large vessel occlusion will be transferred to the closest local stroke centre or telemedicine hub as done with the current stroke protocol
62663138|NCT01878266|EXPERIMENTAL|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
62102080|NCT04680897|OTHER|Early Group|Participants may resume intercourse at 2 weeks
62102081|NCT01278862|EXPERIMENTAL|DVS veneer|veneer made by CAD/CAM method
62102082|NCT01278862|ACTIVE_COMPARATOR|Conventional veneer|Veneer made by laboratory technician
62102083|NCT02744079|ACTIVE_COMPARATOR|Low carbohydrate diet|45 subjects will receive a very low carbohydrate diet between a positive breast biopsy and surgical tumor removal
62663139|NCT01878266|EXPERIMENTAL|Hypofractionated Arm (2)|The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.
62663140|NCT01878266|OTHER|Conventional Arm (3)|The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.
62663141|NCT02195323|EXPERIMENTAL|MSC recipient|The patients with CKD who underwent intravenous injection of MSC.
62663142|NCT01222351|EXPERIMENTAL|BAY 94-9172|BAY 94-9172 PET/CT
62663143|NCT05125432|EXPERIMENTAL|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
62663144|NCT03344393|ACTIVE_COMPARATOR|ketamine hydrochloride|intravenous ketamine infusion in the intraoperative period
62295231|NCT01446211|ACTIVE_COMPARATOR|Control group|"The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.~The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
62467530|NCT01710657|EXPERIMENTAL|Lacosamide 400 mg/day|Lacosamide treatment of 400 mg/day (200 mg bid (twice daily)) for 16 weeks.
62663145|NCT03344393|ACTIVE_COMPARATOR|normal saline|intravenous normal saline infusion in the intraoperative period
62663146|NCT03737019|EXPERIMENTAL|ACT in County Council of Kalmar|Group education with ACT in six primary health care centers in County Council of Kalmar
62102084|NCT02744079|ACTIVE_COMPARATOR|Low fat diet|20 subjects will receive a lo fat diet between a positive breast biopsy and surgical tumor removal
62102085|NCT05869643|EXPERIMENTAL|Cohort 1 STP0404|
62102086|NCT05869643|PLACEBO_COMPARATOR|Cohort 1|
62102087|NCT05869643|EXPERIMENTAL|Cohort 2 STP0404|
62102088|NCT05869643|PLACEBO_COMPARATOR|Cohort 2|
62102089|NCT05869643|EXPERIMENTAL|Cohort 3 STP0404|
62102090|NCT05869643|PLACEBO_COMPARATOR|Cohort 3|
62102091|NCT02403323|EXPERIMENTAL|Part 1: Etrolizumab Open-Label Extension|Participants will receive open-label treatment with etrolizumab once every 4 weeks until commercial availability in their country or sponsor's decision to terminate the study, whichever is earlier (up to approximately 10 years after the first patient is enrolled).
62663147|NCT03737019|PLACEBO_COMPARATOR|Control health care centers of County Council of Jönköping|Five primary health care centers of County Council of Jönköping that do not get education.
62663148|NCT02981641|EXPERIMENTAL|Intraoperative radiotherapy (IORT) Group|Radiotherapy (Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1) + Sequential chemotherapy
61911587|NCT04185597|EXPERIMENTAL|HFP Intervention: Delivery by Community Farmers|"HFP- Delivered by community farmers, supported by the study and linked to eligible households to educate on growing nutritious food and poultry rearing or fish culture~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female community nutrition promoters (CNPs) will refer PLW to service delivery points; gradually this will be completed by peer leaders~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will later be replaced by peer leaders"
61911588|NCT04185597|EXPERIMENTAL|HFP Intervention: Delivery by agricultural Retailers|"HFP- Delivered by agricultural Retailers, supported by the study and linked to eligible households to educate on growing nutritious food and either poultry raring or fish culture~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female CNPs will refer PLW to service delivery points; gradually this will be completed by peer leaders~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will be replaced by peer leaders"
61911589|NCT04185597|ACTIVE_COMPARATOR|Standard of Practice|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
61911590|NCT02991989|EXPERIMENTAL|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening. They will also be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers.
61911591|NCT02991989|OTHER|Yogurt Only Group|For 28 days, this group will be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers. Apart from consuming the yogurt, this group will be asked to continue their normal lifestyle.
61919850|NCT01611454|EXPERIMENTAL|XPF thyroid collar|Administration of the XPF Thyroid Collar during the same type of interventional radiology procedures as Comparator arm above
62663149|NCT02981641|EXPERIMENTAL|Concurrent Chemoradiotherapy (CCRT) Group|Three dimensional conformal radiation therapy (3D-CRT) (Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30) + Concurrent chemotherapy (Gemcitabine(GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d) + Sequential chemotherapy
61919851|NCT01611454|ACTIVE_COMPARATOR|Equivalent collar|Administration of the Standard 0.5mm lead-equivalent thyroid collar during the same type of interventional radiology procedures as Comparator arm above.
62295232|NCT04739839||Inception cohort, former pupils in different schools in Western Zealand|1327 former Western Zealand pupils (originally 1389). Aged 14-15 in 1997. This is the first follow up on this cohort.
62295233|NCT03422822|EXPERIMENTAL|Abrocitinib 100 mg|Abrocitinib 100 mg QD PO
62295234|NCT03422822|EXPERIMENTAL|Abrocitinib 200 mg|Abrocitinib 200 mg QD PO
62467531|NCT03749512||Observational Group|Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
62467532|NCT03735251||Left Ventricular Diastoic Dysfunction Classification|normal diastole pattern：E/A\>1，DT 160\~220 ms，S/D \>1，AR 0.22-0.32m/sec，E/e'\< 8 diastolic dysfunction pattern Impaired relaxation pattern：E/A\< 1，DT \> 220 ms，S/D \> 1，AR 0.21-0.28 m/sec，E/e'\<10 Pseudo-normalization pattern：E/A\> 1，DT 150\~210 ms，S/D \< 1，AR ≥0.35m/sec，E/e'≥ 10 Restrictive pattern：E/A ≥ 2，DT \< 150 ms，S/D \<1，AR ≥0.25m/sec，E/e'≥10
62663150|NCT00031993|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62295235|NCT05652426||Group 1|Basal cerebral oximetry levels between 41-60%
62295236|NCT05652426||Group 2|Basal cerebral oximetry levels \> 61%
62295237|NCT05213871|EXPERIMENTAL|IASTM group|Group (A) will receive IASTM on the right upper trapezius and levator scapulae twice a week for four weeks in addition to a postural correction program.
62663151|NCT02737618|EXPERIMENTAL|Healthy subject|"Healthy subjects exposed to Trojan Chameleon Personal Lubricant applied by occlusive patch"
62102092|NCT02403323|NO_INTERVENTION|Part 2: Safety Monitoring|Participants who have stopped etrolizumab treatment (either by exiting Part 1 of this study or by entering directly from Study GA29144 \[NCT02394028\]) will be monitored for 92 weeks for progressive multifocal leukoencephalopathy (PML) and other safety events.
62102093|NCT04204564||paclitaxel coated balloon angioplasty|Procedures with paclitaxel coated balloon angioplasty of the superficial femoral-popliteal artery
62102094|NCT04204564||plain balloon angioplasty|Procedures with plain balloon angioplasty of the superficial femoral-popliteal artery
62102095|NCT04204564||paclitaxel eluting stent|Procedures with paclitaxel eluting stenting of the superficial femoral-popliteal artery
62102096|NCT04204564||bare metal stenting|Procedures with bare metal self expanding stenting of the superficial femoral-popliteal artery
62102097|NCT06713395|OTHER|control group|The control group was provided with standard postoperative care
62102098|NCT06713395|OTHER|observation group|The observation group received an additional PERMA-based integrated psychological intervention
62102099|NCT03120676|EXPERIMENTAL|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
62102100|NCT04406779||Patients with breast cancer|Patients with breast cancer
62102101|NCT04406779||Control|Healthy patients without breast cancer
62102102|NCT03468920|EXPERIMENTAL|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
62467533|NCT03981341|EXPERIMENTAL|Post menopausal sleep apnea|Post menopausal women with severe sleep apnea
62467534|NCT03981341|EXPERIMENTAL|Post menopausal non sleep apnea|Post menopausal women without sleep apnea
62467535|NCT05662111|ACTIVE_COMPARATOR|Etidronate|Etidronate 20 mg/kg for two weeks on and ten weeks off during 12 months
62467536|NCT05662111|PLACEBO_COMPARATOR|Placebo|Placebo for two weeks on and ten weeks off during 12 months
62102103|NCT03468920|ACTIVE_COMPARATOR|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
62102104|NCT06116266|EXPERIMENTAL|Co-Care|Patient participants with providers will receive primary care treatment plus the full Co-Care intervention which includes: Nurse Care Manager (NCM) visits, Addiction specialist consultations through NCM if indicated, and Health coaching sessions.
62102105|NCT06116266|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Patient participants with providers will receive primary care treatment as usual plus educational materials.
62467537|NCT03674489|ACTIVE_COMPARATOR|Neurodynamic Slider Mobilization|
62467538|NCT03674489|ACTIVE_COMPARATOR|Neurodynamic Tensioner Mobilization|
62467539|NCT03674489|SHAM_COMPARATOR|Sham Neurodynamic Mobilization|
62467540|NCT01723748|ACTIVE_COMPARATOR|surgery treated|"10 patients with well-controlled acromegaly for at least 6 months after surgery alone.~Stimulated with genotropin"
61919852|NCT02117414|EXPERIMENTAL|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
61919853|NCT02117414|SHAM_COMPARATOR|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
62102106|NCT05732818|EXPERIMENTAL|Lumbar Disc Nucleus Replacement following discectomy|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
62467541|NCT01723748|ACTIVE_COMPARATOR|SA treated|10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin
62663152|NCT00848432|EXPERIMENTAL|1|Optimal therapeutic doses of risperidone continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months in clinically stable schizophrenia patients
62663153|NCT00848432|EXPERIMENTAL|2|Optimal therapeutic doses of risperidone continued for 26 weeks followed by a 50% dose reduction for at least another 6 months in clinically stable schizophrenia patients
61919854|NCT01396330|OTHER|Stress|
61919855|NCT01712321|EXPERIMENTAL|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
61919856|NCT01712321|PLACEBO_COMPARATOR|Placebo|Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
61919857|NCT02352584|EXPERIMENTAL|GC3110A(Quadrivalent)|0.5ml, intramuscular, a single dosing
61919858|NCT02352584|ACTIVE_COMPARATOR|GC Flu (Trivalent)|0.5ml,intramuscular,a single dosing
61919859|NCT02352584|ACTIVE_COMPARATOR|GC3110A(Trivalent)|0.5ml,intramuscular,a single dosing
61919860|NCT00810927|ACTIVE_COMPARATOR|1|Phenylephrine (Neosynephrine®, Abbott Laboratories, North Chicago, IL, USA) dose: 1µg/(kg.min), infusion period 20 minutes
62102107|NCT06711354||Mother exposed to anti-CD20 ab|Mothers with MS exposed to monoclonal anti-CD20 antibody (Rituximab 500 mg iv alternatively Ofatumumab 20 mg sc or Ocrelizumab 300-600 mg iv) within 12 months before pregnancy or during pregnancy.
62102108|NCT06711354||Mother exposed to other DMT|Mothers with MS exposed to disease modifying therapy other than Rituximab, Ofatumumab or Ocrelizumab within 6 months before pregnancy
62102109|NCT06711354||Mother without DMT exposure|Mothers with MS without exposure to disease modifying therapy within 6 months before pregnancy
62102110|NCT04470817||Participants With Essential Hypertension|Participants diagnosed with essential hypertension and whom have been prescribed azilsartan medoxomil as a monotherapy or taken concomitantly with other anti-hypertension therapies in a routine clinical practical setting, will be observed prospectively over a period of 6 years.
62102111|NCT05928182|EXPERIMENTAL|Treatment Participants|Active treatment group participants
62102112|NCT04660370|EXPERIMENTAL|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
62102113|NCT04660370|EXPERIMENTAL|Sequence 2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
62102114|NCT06402435|EXPERIMENTAL|luminal-type breast cancer patients|The study included patients with a histologically confirmed of HR+/HER2-negative (Her2 immunohistochemistry of 0, 1+, or 2+/FISH-) breast cancer who met one of the following criteria: (1) primary tumor mass larger than 2 cm, (2) axillary lymph node metastasis, (3) a willingness to conserve the breasts, but where the ratio of the tumor size to the volume of the breast was large enough to make it difficult to conserve the breasts.
62102115|NCT00672256|EXPERIMENTAL|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
62102116|NCT04769024|ACTIVE_COMPARATOR|LUMEEN intervention|Participants in the LUMEEN intervention group will participate in the 12 LUMEEN Virtual Reality sessions of 45 minutes taking place twice a week for 6 weeks, in groups of 6 participants. The content of these sessions is described in the Intervention Description part of this document.
62102117|NCT04769024|SHAM_COMPARATOR|USUAL activities|Participants in the control group will participate in the 12 Control/non-digital stimulation sessions of 45 minutes taking place twice a week for 6 weeks, in groups of 6 participants instead of the LUMEEN Virtual Reality sessions. The content of these sessions is described in the Intervention Description part of this document.
62102118|NCT06713447|EXPERIMENTAL|NTI164 active|All participants will be in this arm (single intervention) and will receive NTI164.
62102119|NCT04191161|EXPERIMENTAL|Brace group|patients will receive their brace 2 weeks after the first consultation (usual delay to conceive and deliver the brace), they will be asked to wear the brace all day and will be allowed to redraw it at night. Brace must be worn for 3 months. A specific eduction on how to wear the brace will also be delivered. A thermal sensor chip will be placed in the brace to assess the observance. No physiotherapy will be prescribed during this period. Patient will attend to 3 consultations, day 0, 3 months and finally at 6 months later. These three consultations are part of usual care.
62102120|NCT04191161|PLACEBO_COMPARATOR|Control group|patients will continue physiotherapy sessions if already prescribed but no extra sessions will be prescribed. Pain killers will be adjusted. Patients will also attend to three consultations such as described above. Main outcome will be assessed at M3. After M3, patients who did not receive the brace will have the choice to receive it for the next 3 months and secondary outcome will be assessed at 6 months.
62102121|NCT05710744|NO_INTERVENTION|Family Members of patients in the ICU|Family members will join routine meetings with the physicians treating with their critically ill loved ones.
62102122|NCT05710744|OTHER|ICU Physicians|Physicians will view a tip sheet containing information about best practices of shared decision making with diverse individuals. Physicians will then conduct routine meetings with families of patients with acute respiratory failure.
62102123|NCT05939726|EXPERIMENTAL|Moisturising Cream with Vitamin E and Urea Cream|Participants who are randomised in this arm will receive a moisturising cream containing palm-oil-derived vitamin E concentrate for external application on both palms and soles, in addition to urea-based cream as the standard of care for PPE management. They will be required to apply the investigational cream first, followed by the urea-based cream, at least two times a day.
62102124|NCT05939726|EXPERIMENTAL|Moisturising Cream without Vitamin E and Urea Cream|Participants who are randomised to this arm will receive a basic or plain moisturising cream without Vitamin E for external application on both palms and soles, in addition to urea-based cream as the standard of care for PPE management. They will be required to apply the investigational cream first, followed by the urea-based cream, at least two times a day.
62102125|NCT05939726|ACTIVE_COMPARATOR|Urea Cream Only|Participants who are randomised to this arm will receive urea-based cream only as the standard of care for PPE management. They will be required to use the urea cream at least twice a day.
62102126|NCT05248035||Patient|Adult patient hospitalized in ICU for a duration of mechanical ventilation longer than 48 hours
62102127|NCT05549297|EXPERIMENTAL|Arm A: Tebentafusp Monotherapy|Participants receive tebentafusp as single agent.
62102128|NCT05549297|EXPERIMENTAL|Arm B: Tebentafusp + Pembrolizumab|Participants receive tebentafusp in combination with pembrolizumab.
62102129|NCT05549297|EXPERIMENTAL|Arm C: Investigator's Choice|Participants receive investigator's choice of therapy.
62467542|NCT04314362|EXPERIMENTAL|AZR-MD-001 Active|AZR-MD-001 ointment/semi-solid drug (1.0%)
62467543|NCT04314362|EXPERIMENTAL|AZR-MD-001 Active + Conventional Treatment|AZR-MD-001 ointment/semi-solid drug (1.0%) plus Hylo-Forte®
62467544|NCT04314362|EXPERIMENTAL|AZR-MD-001 vehicle|AZR-MD-001 vehicle control
62467545|NCT04511507||liver failure|patients diagnosed with acute liver failure or acute on chronic liver failure in accordance with national guidelines who require 3 consecutive sessions of hemoadsorption
62467546|NCT03214822|NO_INTERVENTION|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
62467547|NCT03214822|EXPERIMENTAL|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
62663154|NCT00848432|EXPERIMENTAL|3|Optimal therapeutic doses of risperidone continued for at least 1 year in clinically stable schizophrenia patients
61911592|NCT06504745|EXPERIMENTAL|Intervention Group|Peer educator students group (a group of six senior nursing students), provided Newborn Physical Assessment training to 4th-year students in the nursing laboratory every week. Each training was conducted with a group of 5 students. This each training consisted of 30 minutes of theoretical presentation using a PowerPoint presentation material and 20 minutes of skills application on a newborn model, totaling 50 minutes. Before the training, the NPA-KT was administered, and the students' skills were evaluated using the NPA-SCL. At the end of the training, the NPA-KT and the Peer Support Scale were administered to the students. Three weeks after the training, the students' knowledge levels were re-evaluated using the NPA-KT.
61911593|NCT06504745|ACTIVE_COMPARATOR|Control Group|The researchers provided Newborn Physical Assessment training to 4th-year students in the nursing laboratory every week. Each training was conducted with a group of 5 students. This training consisted of 30 minutes of theoretical presentation using a PowerPoint presentation material and 20 minutes of skills application on a newborn model, totaling 50 minutes. Before the training, the NPA-KT was administered, and the students' skills were evaluated using the NPA-SCL. At the end of the training, the NPA-KT and the Peer Support Scale were administered to the students. Three weeks after the training, the students' knowledge levels were re-evaluated using the NPA-KT.
62102130|NCT03985709|EXPERIMENTAL|Probiotcal group|Probiotic (Lactobacillus casei) once daily taken by 3 months
62102131|NCT06633796|EXPERIMENTAL|AMADEO|Rehabilitation treatment with occupational therapy, paraffin therapy and mobilization with robotic arm (AMADEO) of the fingers.
62102132|NCT06633796|OTHER|Standard care|Rehabilitation treatment with occupational therapy and paraffin therapy.
62102133|NCT02731521||3 Tesla Scanning and 7 Tesla Scanning|Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.
62102134|NCT05765734|EXPERIMENTAL|TAS3351 Part A (Dose Escalation)|Dose escalation will assess the safety and determine the recommended phase 2 dose and regimen of TAS3351 administered orally.
62102135|NCT05765734|EXPERIMENTAL|TAS3351 Part B (Dose Expansion)|TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose determined in Part A.
62102136|NCT05765734|EXPERIMENTAL|TAS3351 Part C (Phase 2)|To assess efficacy of TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose.
62102137|NCT02470104|EXPERIMENTAL|Enteral Donor Breastmilk|"* Donor milk will be pasteurized prior to use.~* Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~* Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~* It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
62102138|NCT02470104|NO_INTERVENTION|Control|• Children randomized to the control arm will receive standard enteral or parenteral nutrition per standard clinical practice, supervised by a registered dietician.
62102139|NCT06548477|EXPERIMENTAL|Intervention group (Albumin group)|Intervention group will receive of intermittent boluses of human albumin plus standard fluid therapy (with crystalloids only) to maintain a euvolemic fluid balance.
61911594|NCT05744440|EXPERIMENTAL|allogenic NK cells|Enrolled patients will receive prespecified dose of allogenic NK cells
61911595|NCT05986084|EXPERIMENTAL|CAB-LA PrEP|Following a negative HIV test, long-acting Cabotegravir Injection (CAB-LA) 600mg will be administered as a 3mL intramuscular (IM) injection in the gluteal muscle at enrollment, 1 month, and then every 2 months, for a maximum of 13 injections over 24 months of follow up.
61911596|NCT05905614|EXPERIMENTAL|SPH4336 Tablets|SPH4336 Tablets
61911597|NCT06255678||Patients undergoing PCI|Assessment of ΔvFFR and vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L) in patients with CCS or ACS.
61911598|NCT05116527|EXPERIMENTAL|High Dose THC|Participants will receive high dose THC.
61911599|NCT05116527|EXPERIMENTAL|Placebo THC|Participants will receive placebo THC.
61911600|NCT00156156|EXPERIMENTAL|1|
61911601|NCT00156156|EXPERIMENTAL|2|
62102140|NCT06548477|NO_INTERVENTION|Control (crystalloid group)|Control group will receive only standard fluid therapy with crystalloid solutions with intermittent boluses crystalloid solution to maintain euvolemic balance
61911602|NCT01555385|ACTIVE_COMPARATOR|Dietary supplement: high-protein breakfast|high-protein juice
62102141|NCT01833065|EXPERIMENTAL|EBX 10|Elobixibat 10 mg/day
62102142|NCT01833065|EXPERIMENTAL|EBX 5|Elobixibat 5 mg/day
62102143|NCT01833065|PLACEBO_COMPARATOR|PLCBO|Placebo
62102144|NCT06078384|EXPERIMENTAL|Cohort 1-Pembrolizumab plus Paclitaxel|Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles
61911603|NCT01555385|ACTIVE_COMPARATOR|Dietary supplement: high-carbohydrate breakfast|high-carbohydrate juice
61911604|NCT01555385|PLACEBO_COMPARATOR|Dietary supplement: low energy breakfast|low-calorie juice
61911605|NCT03712007|EXPERIMENTAL|MAMP therapy with MARPE expander|The experimental group will comprise 20 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-bone-borne expander as anchorage in the maxillary arch. The miniscrew assisted rapid palatal expander (MARPE) will be used.
61911606|NCT03712007|ACTIVE_COMPARATOR|MAMP therapy with Hyrax expander|The active comparator group will comprise 15 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-borne expander as anchorage in the maxillary arch. The conventional hyrax expander will be used.
61911607|NCT01126047|OTHER|PFT's, eCO, and pulse oximetry|All subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.
61911608|NCT01634425|NO_INTERVENTION|Group 1 - no pre-hospital biomarkers|Standard of Care
61911609|NCT01634425|EXPERIMENTAL|Group 2 - pre-hospital biomarkers|Troponin and BNP measured on a POC meter in the ambulance on the way to the hospital.
61911610|NCT01669057||Congenital heart defect（CHD） group|
61911611|NCT01669057||Normal control group|
62102145|NCT06078384|NO_INTERVENTION|Cohort 2-Observation|No treatment will be administered, patients will undergo standard surveillance every 6 months according to local practice.
62102146|NCT06713096|NO_INTERVENTION|Usual care|
62102147|NCT06713096|ACTIVE_COMPARATOR|Interventional care|
62295238|NCT05213871|EXPERIMENTAL|myofascial release group|Group (B) will receive a myofascial release on the right upper trapezius and levator scapulae twice a week for four weeks in addition to the postural correction program.
62295239|NCT01859403|PLACEBO_COMPARATOR|Usual Care|Usual care for veterans as part of the MOVE! program
62295240|NCT01859403|ACTIVE_COMPARATOR|Personalized Genomics|Personalized genomics information from the FIT Test, Pathway Genomics
62467548|NCT05964777|ACTIVE_COMPARATOR|Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|"rTMS and tACS have a profound impact on cognitive impairment.,The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000.~tACS has 5 high-precision targets, the total current is 2mA, and the stimulation frequency is 40hz. Under true stimulation, the current fade in and out time is 10 seconds, and the stimulation time is 30 minutes."
62295241|NCT00422279|EXPERIMENTAL|supraalevolar|Bone inductive implant (Nobel Replace Tapered Groovy) placed in the supralveolar position
62467549|NCT05964777|PLACEBO_COMPARATOR|Repetitive Transcranial magnetic stimulation and sham transcranial alternating current stimulation|"the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000.~tACS has 5 high-precision targets, the total current is 2mA, and the stimulation frequency is 40hz. Under sham stimulation, the current fade in and out time is 10 seconds, the other 29 minutes and 40 seconds, no real current passes through."
62467550|NCT05964777|PLACEBO_COMPARATOR|Sham repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|"The stimulus intensity was 20% of MT in the ShamComparator arm, and the remaining parameters were the same as the Active Comparator arm.~tACS has 5 high-precision targets, the total current is 2mA, and the stimulation frequency is 40hz. Under true stimulation, the current fade in and out time is 10 seconds, and the stimulation time is 30 minutes."
62467551|NCT03672604|PLACEBO_COMPARATOR|Part A: Single Dose|"Cohort 1 = 0.25 mg NLY01 Cohort 2 = 0.8 mg NLY01 Cohort 3 = 2.5 mg NLY01 Cohort 4 = 5 mg NLY01 Cohort 5 = 10 mg NLY01~All cohorts include 8 subjects randomized to receive a single dose of NLY01 or placebo (6 active, 2 placebo)."
62467552|NCT03672604|PLACEBO_COMPARATOR|Part B: Multiple Dose|"In Part B, NLY01 or placebo will be administered once-weekly for 4 doses. There will be 3 sequentially-enrolled, ascending-dose cohorts of 8 subjects (6 active, 2 placebo). Doses in Part B will be a fraction of the maximum tolerated dose (MTD) established in Part A.~Cohort 6 = 15% of the single-dose MTD Cohort 7 = 35% of the single-dose MTD Cohort 8 = 70% of the single-dose MTD"
62467553|NCT03672604|PLACEBO_COMPARATOR|Part C:Multiple Dose|"In Part C, NLY01 or placebo will be administered once-weekly for 6 doses.~Cohort 10 = 2.5 mg NLY01 Cohort 11 = 5 mg NLY01"
62467554|NCT05254301|EXPERIMENTAL|Personalized multimodal treatment|A combination of biometric parameter oriented nutritional counseling and a tailored physical training program.
62295242|NCT00422279|EXPERIMENTAL|Other|Bone inductive implant (Nobel Replace Tapered Groovy) placed in extraction socket
62295243|NCT03036878|EXPERIMENTAL|ReNu Injection|Injection of ReNu allograft into the joint capsule.
62467555|NCT05254301|ACTIVE_COMPARATOR|Standard care|Physiotherapy with standard care advice for gradual cardiorespiratory and resistance training. (In this standard care setting, nutritional screening nor counseling is included.)
62467556|NCT03586700|EXPERIMENTAL|Xiao zhong fang granules|Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
62467557|NCT03586700|PLACEBO_COMPARATOR|Placebo Xiao zhong fang granules|Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
62467558|NCT03677622|EXPERIMENTAL|Stroke volume (SV) group|"As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:~A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is \<10%.~The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery."
62663155|NCT01407367||Phase I and Phase II|"Phase I (First 100 participants):~Medical alert bracelet/necklace, Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs~Phase II (Next 250 participants):~Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs"
62663156|NCT02648906|EXPERIMENTAL|Choline alfoscerate|"Drug: Choline alfoscerate and Donepezil~concomitant administration"
62295244|NCT06386328|EXPERIMENTAL|Sequence 1|"* Period 1: A single oral dose of 2 tablets(CKD-378) under fasting condition~* Period 2: A single oral dose of 2 tablets(CKD-378) under fed condition"
62295245|NCT06386328|EXPERIMENTAL|Sequence 2|"* Period 1: A single oral dose of 2 tablets(CKD-378) under fed condition~* Period 2: A single oral dose of 2 tablets(CKD-378) under fasting condition"
62295246|NCT05124626|ACTIVE_COMPARATOR|One bar|MIRPE utilizing just one metallic bar
62295247|NCT05124626|ACTIVE_COMPARATOR|Two bars|MIRPE utilizing two metallic bars fixed with the bridge device
62295248|NCT04076826|EXPERIMENTAL|Protocol A (Dexmedetomidine)|Dexmedetomidine will be administered in accordance with hospital standard operating procedures (SOP).
62295249|NCT04076826|ACTIVE_COMPARATOR|Protocol B (Propofol / Midazolam)|Propofol and/or Midazolam will be administered in accordance with hospital standard operating procedures (SOP).
62295250|NCT01725880||No treatment|Observation
62102148|NCT06172595|EXPERIMENTAL|FET PET|"Upon recruitment, a single study visit will be scheduled where subjects undergo a limited 18F-FET PET/CT of the brain in SGH.~After the study visit, from time of recruitment, they will continue their regular clinic visits as clinically indicated, where they will be monitored for at least a year for stability or deterioration. If clinically indicated, they may undergo conventional MRI, alternative MRI imaging and/or histopathological correlation in their respective primary institutions.~During these follow-up visits, any adverse effects possibly attributed to the 18F-FET PET/CT can also be flagged up.~Any alternative MRI imaging performed (as part of clinical practice in the respective primary institutions) within 4 weeks of the 18F-FET PET/CT study will also be included in the comparative analysis."
62102149|NCT06631196|NO_INTERVENTION|control group|children will be subjected to standardized nursing care.
62102150|NCT06631196|EXPERIMENTAL|Interventional group (Jacobson's PMRT)|children will be subjected to the implementation of Jacobson's progressive muscle relaxation technique for children with leukemia undergoing chemotherapy.
62102151|NCT06714032|EXPERIMENTAL|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug
62102152|NCT06714032|PLACEBO_COMPARATOR|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug
62102153|NCT02901821||Control|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).
62102154|NCT02901821||Concussion|Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of PCSI concussion assessment interview tool and balance/cognition testing at time of injury, 1-2wks post injury, and 4wks post injury.
62102155|NCT06445660||Controls|Patients included in the AMESI study as suspected AMI
62102156|NCT06445660||AMI patients with salvageable bowel|"Patients included in the AMESI study with confirmed AMI, who did not undergo bowel resection~Patients with one of the following:~1. treated endovascularly and did not undergo bowel resection secondarily~2. received surgical revascularization without bowel resection (initial or secondary)~3. received explorative laparoscopy or laparotomy without the need for bowel resection (initially or secondarily)~4. received conservative treatment without the need for secondary bowel resection"
62102157|NCT06445660||AMI patients with non-salvageable bowel|"Patients included in the AMESI study with confirmed AMI who (one of the following):~1. underwent bowel resection initially~2. underwent bowel resection secondarily~3. did not undergo bowel resection because non-salvageable bowel~4. were changed to palliation due to the progression of ischaemia after any initial treatment with curative intention (including endovascular and conservative)"
62102158|NCT06232226|OTHER|Neuropsychological assessment|Determination of the neuropsychological profile
62295251|NCT04899908|EXPERIMENTAL|Stereotactic Radiation plus AGuIX gadolinium-based nanoparticles|"Randomly assigned participants will receive:~* AGuIX gadolinium-based nanoparticles 3-5 days before radiation is initiated~* AGuIX gadolinium-based up to 2x during radiation, depending on standard of care radiation treatment.~  * If standard of care radiation treatment involves only one day of radiation, participant will receive AGuIX gadolinium-based nanoparticles on the day of radiation.~ * If standard of care radiation treatment involves 5 or 6 days of radiation, participant will receive AGuIX gadolinium-based nanoparticles two-times (2x) in total, on the first and third day of radiation."
62467559|NCT03677622|ACTIVE_COMPARATOR|Restricted group|"Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake \<500 ml, NaCl 0.9% is given until 500 ml.~Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.~Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.~In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.~Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis."
62663157|NCT02648906|PLACEBO_COMPARATOR|Placebo|Drug: Donepezil only
62663158|NCT02657941|EXPERIMENTAL|Motivational group|psycho-education program inspired by motivational interviewing and behavioral psychotherapy
62663159|NCT02657941|ACTIVE_COMPARATOR|educational group|exclusively informative psycho-education program
62663160|NCT02774278|EXPERIMENTAL|Erlotinib|Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
62663161|NCT02151942||Control group|Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal
62663162|NCT02151942||Rehearsal group|Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal
62663163|NCT04028960|PLACEBO_COMPARATOR|Placebo|No active drug
62663164|NCT04028960|EXPERIMENTAL|Humulin-R|Insulin
62663165|NCT04529408||COVID-19 Follow up clinic|Patients attending routine post-COVID-19 follow up clinic
62663166|NCT04529408||Pulmonary Disease clinic|Patients attending routine outpatient appointment for pulmonary disease
62663167|NCT03770455|EXPERIMENTAL|Avelumab + 2nd generation ADT|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
62663168|NCT02518269|ACTIVE_COMPARATOR|G7 MoP (Arcom XL) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
62663169|NCT02518269|ACTIVE_COMPARATOR|G7 MoP (E1) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
62663170|NCT02518269|ACTIVE_COMPARATOR|G7 CoC + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
62663171|NCT03558724|EXPERIMENTAL|NIR endoscopy with 4.5 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
62102159|NCT04751747|EXPERIMENTAL|Supportive care (CT simulation, contrast agent)|Patients undergo CT stimulation with or without IV contrast over 1.5 hours on days -15 to -1, then undergo SOC chemoradiation on days 1-40. Patients also undergo additional CT scan simulations without IV contrast over 20 minutes each on days 15 and 29.
62102160|NCT02506426|ACTIVE_COMPARATOR|Endoscopic Sinus Surgery + Septoplasty|A surgery that uses special telescopes through the nostrils to make the nasal septum straight and open the facial sinuses without any incisions. The sinuses are opened using special microscopic instruments and the procedure takes approximately 90 - 120 minutes.
62102161|NCT02506426|EXPERIMENTAL|Septoplasty alone|A surgery that is performed to straighten a bent nasal septum. It is shorter (take approximately 25 - 30 minutes) and less invasive (do not open the facial sinuses) that might provide the same benefits compared to the larger and longer endoscopic sinus surgery.
62102162|NCT06322342|EXPERIMENTAL|2 mg/Mn/kg|6 subjects each will receive RVP-001 at a dose of 2 mg Mn/kg
62102163|NCT06322342|EXPERIMENTAL|7 mg/Mn/kg|6 subjects each will receive RVP-001 at a dose of 7 mg Mn/kg
62295252|NCT04899908|EXPERIMENTAL|Stereotactic Radiation plus placebo|"Randomly assigned participants will receive:~* Placebo 3-5 days before radiation is initiated~* Placebo up to 2x during radiation, depending on standard of care radiation treatment.~  * If standard of care radiation treatment involves only one day of radiation participant will receive Placebo on the day of radiation.~ * If standard of care radiation treatment involves 5 or 6 days of radiation participant will receive Placebo two-times (2x) in total, on the first and third day of radiation."
62295253|NCT05669690||Fresh breast milk|Fresh breast milk obtained from volunteer mothers will be divided into four parts. Fresh breast milk will be studied for microbiota composition immediately within 3 hours.
62295254|NCT05669690||Breast milk stored at +4'C for 3 days|One part of previously obtained fresh breast milk will be stored at +4'C at refrigerator for 3 days long, then microbiota composition will be studied.
62295255|NCT05669690||Breast milk stored at -20'C for 3 months|Last part of the same breast milk specimen will be freezed at -20'C for 3 months and microbiota composition of the 3 months frozen milk will be studied.
62295256|NCT04836949|EXPERIMENTAL|Shear Wave Elastography Group|
62295257|NCT04836949|ACTIVE_COMPARATOR|Conventional ultrasonography Group|
62295258|NCT02312024||Patients with severe sepsis/septic shock|Use of CytoSorb adsorber in patients with severe sepsis/septic shock
62295259|NCT02312024||Cardiac surgery with CPB: preemptive use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: preemptive use
62295260|NCT02312024||Cardiac surgery with CPB: postop. use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: postoperative use
62295261|NCT02312024||Patients with other indications|Use of CytoSorb adsorber in patients with other indications
62102164|NCT06322342|EXPERIMENTAL|12 mg/Mn/kg|6 subjects each will receive RVP-001 at a dose of 12 mg Mn/kg
62102165|NCT02306161|EXPERIMENTAL|Regimen A (VDC/IE)|See Design Details.
62102166|NCT02306161|EXPERIMENTAL|Regimen B (VDC/IE + ganitumab)|"INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.~LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.~CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15.~METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or EBRT.~MAINTENANCE: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes every 3 weeks for 8 cycles."
62102167|NCT06321172|EXPERIMENTAL|FES cycling group|Six months of FES-cycling trainings twice a week were performed for each pilot. Each session includes at most 30 minutes of stimulation.
62295262|NCT03663452|ACTIVE_COMPARATOR|Prolonged exposure training|
62295263|NCT03663452|EXPERIMENTAL|TACTICS|
62295264|NCT00260130|ACTIVE_COMPARATOR|1|Consuming fruit and vegetable juice
62295265|NCT00260130|ACTIVE_COMPARATOR|2|Consuming whole fruits and vegetables
62295266|NCT06195228|EXPERIMENTAL|Radioiodine-refractory differentiated thyroid cancer|advanced or metastatic thyroid cancer patients who are refractory to radioiodine treatment
62295267|NCT06195228|EXPERIMENTAL|Differentiated thyroid carcinoma not suitable for radioiodine therapy|advanced or metastatic differentiated thyroid cancer patients who are not suitable for radio iodine therapy, for example, DTC patients with huge neck tumor but cannot receive the thyroid ectomy
62295268|NCT06195228|EXPERIMENTAL|Medullary thyroid cancer|patients with advanced or metastatic medullary thyroid cancer
62295269|NCT06195228|EXPERIMENTAL|High-grade or poorly differentiated thyroid cancer|patients with advanced or metastatic High-grade or poorly differentiated thyroid cancer
62295270|NCT06195228|EXPERIMENTAL|Anaplastic thyroid cancer|patients with anaplastic thyroid cancer
62295271|NCT05258227|EXPERIMENTAL|Proprioceptive Strength Training|"* Conservation physical therapy includes TENS 15 min + Infrared 15 min simultaneously.~* Proprioceptive strength training for 30 min includes following exercises:~Strengthening of Quadriceps Ankle extensors and Hip abductors strengthening Zigzag walking Heel to toe walk forward and backwards toe to heel Standing on one leg while holding wall, eyes open and eyes closed"
62295272|NCT05258227|EXPERIMENTAL|Core Instability Strength Training|"* Conservational therapy includes TENS for 15 min+ Infrared for 15 min simultaneously.~* Core instability strength training for 30 minutes includes following exercises:~Quadriceps stretch, crook lying, abdominal hallowing Dynamic Hamstrings stretch Bridging arms at side Crook lying+lifting both legs at right angle with hands resting on thighs"
62102168|NCT06418906||Community adults aged 18 or above|This is a single-arm study with no intervention involved. Adults aged 18 or above from the community will be invited to fill out the same set of questionnaires on a total of two time points: baseline and two-week post-baseline.
62102169|NCT06315751|EXPERIMENTAL|Gemlapodect|Escalating doses of NOE-105 capsules
62102170|NCT06315751|PLACEBO_COMPARATOR|Placebo|Escalating doses of matching placebo
62102171|NCT05962385|EXPERIMENTAL|Healthy control|All participants receive the same procedures
62102172|NCT02280161||Ancillary-Correlative (germ-line mutation analysis)|Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis.
62102173|NCT06358638|EXPERIMENTAL|Recipients with a major ABO incompatible donor|Patients in this cohort are treated pre-HCT with Daratumumab, intravenously, on days -49, -42, -35 and -28. The conditioning regimen will consist of alemtuzumab, given subcutaneously, daily for 5 days (days -7 to -3) and low dose total body irradiation (TBI) 300 cGY on day -2 with gonadal shielding. Sirolimus will be given as GVHD prophylaxis for the first year with weaning thereafter based on donor T-cell chimerism. G-CSF, at 5 mcg/kg/day, will be given post stem cell infusion until neutrophil engraftment is achieved.
62102174|NCT06358638|EXPERIMENTAL|Recipients with red cell alloantibodies (non-ABO) against donor antigens|Patients in this cohort are treated pre-HCT with Daratumumab, intravenously, on days -49, -42, -35 and -28. The conditioning regimen will consist of alemtuzumab, given subcutaneously, daily for 5 days (days -7 to -3) and low dose total body irradiation (TBI) 300 cGY on day -2 with gonadal shielding. Sirolimus will be given as GVHD prophylaxis for the first year with weaning thereafter based on donor T-cell chimerism. G-CSF, at 5 mcg/kg/day, will be given post stem cell infusion until neutrophil engraftment is achieved.
62102175|NCT06253052|NO_INTERVENTION|Usual care|Fasting instructions as given by anaesthesiologist according to national guidelines (6 h solid meal and thick liquids, 2 h clear fluids).
62102176|NCT06253052|ACTIVE_COMPARATOR|Instructed guideline adherence|Patients should not involuntarily fast fluids for longer than 2 h.
62102177|NCT06253052|EXPERIMENTAL|Experimental intervention|Patients should not involuntarily fast fluids for longer than 30 min.
62295273|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
62102178|NCT06713317|EXPERIMENTAL|Part I 'HLB3-002'|Recombinant Hyaluronidase
62102179|NCT06713317|EXPERIMENTAL|Part I '0.9%NaCl'|0.9% Normal Saline
62102180|NCT06713317|EXPERIMENTAL|Part II 'HLB3-002'|Recombinant Hyaluronidase
62102181|NCT06713317|EXPERIMENTAL|Part II '0.9%NaCl'|0.9% Normal Saline
62102182|NCT05397470|EXPERIMENTAL|Part A: Placebo-controlled treatment period: Losmapimod|Participants will be randomized to receive losmapimod.
62295274|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
62102183|NCT05397470|PLACEBO_COMPARATOR|Part A: Placebo-controlled treatment period: Placebo|Participants will be randomized to receive placebo
62295275|NCT00976755|EXPERIMENTAL|Arm A: Everolimus|"Everolimus:~10mg daily"
62295276|NCT04725682|ACTIVE_COMPARATOR|Sequence 1 (TRTR)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of TRTR.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules (Applicant holder: Accord Healthcare, Inc.); Treatment R (Reference): 1 × 1mg RLD tacrolimus capsules"
62102184|NCT05397470|EXPERIMENTAL|Part B: Open-label extension|Participants will receive losmapimod, upon completion of all assessments for Part A.
62295277|NCT04725682|ACTIVE_COMPARATOR|Sequence 2 (RTRT)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of RTRT.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules (Applicant holder: Accord Healthcare, Inc.); Treatment R (Reference): 1 × 1mg RLD capsules"
62663172|NCT03558724|EXPERIMENTAL|NIR endoscopy with 10 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
62663173|NCT03558724|EXPERIMENTAL|NIR endoscopy with 25 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
62663174|NCT00296595|PLACEBO_COMPARATOR|Placebo|Placebo capsules + 500 mL/day of placebo juice
62102185|NCT04810455|EXPERIMENTAL|Purrble -- Intervention design and logic model|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing; see (Theofanopoulou et al 2019, Slovak et al 2018) for the design and data from previous deployments.~The toy is introduced to the child as an anxious creature that needs kind attention from humans. When picked up, the toy emits a frantic heartbeat that slows down if the child uses calm stroking movements. If the toy is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~* Level 1: in-the-moment soothing support to children in emotional moments when they would attempt to calm down.~* Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~* Level 3: shift in children's ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
62663175|NCT00296595|EXPERIMENTAL|Cranberry Juice|Placebo capsules + 500 mL/day of cranberry juice
62295278|NCT00646295|EXPERIMENTAL|A|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
62295279|NCT02628925||Recovery room|10 medical staff working in the recovery room
62295280|NCT02628925||Orthopedic ward|10 medical staff working on the orthopedic ward
62295281|NCT01246492|PLACEBO_COMPARATOR|45g glucose|glucose water
62467560|NCT05675215||Normal subjects with suspicion of psychopathological disorder|Adults over 18 years old who are fluent in French (oral and written). Participant with neurological or organic mental disorder (not induced by substances) including dementia, organic amnesic syndrome, delirium, other mental, personality or behavioural disorders due to brain damage, dysfunction or to physical disease.
62295282|NCT01246492|ACTIVE_COMPARATOR|45g glucose + 150mg aspartame|glucose water aspartame
62467561|NCT02373098|EXPERIMENTAL|FTY720|
62467562|NCT02373098|NO_INTERVENTION|Healthy volunteers|Healthy volunteers with no intervention or drug administered.
62467563|NCT02149745|EXPERIMENTAL|Calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by calling the patient's name
62663176|NCT00296595|EXPERIMENTAL|Fish Oil|2 g/day of fish oil + 500 mL/day of placebo juice
62663177|NCT00296595|EXPERIMENTAL|Cranberry Juice + Fish Oil|2 g/day of fish oil + 500 mL/day of cranberry juice
62663178|NCT02825810|EXPERIMENTAL|Cervical motor control group|
62663179|NCT02825810|NO_INTERVENTION|Control group|
62663180|NCT00433290|EXPERIMENTAL|A|
62663181|NCT00433290|PLACEBO_COMPARATOR|B|
62663182|NCT02594111|ACTIVE_COMPARATOR|Colchicine|Colchicine 1.8 mg PO over 1 hour
62663183|NCT02594111|PLACEBO_COMPARATOR|Placebo|Matching placebo
62663184|NCT05845073|EXPERIMENTAL|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
62663185|NCT05845073|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive an equivalent placebo for the duration of antibiotic therapy, and 14 day thereafter.
62663186|NCT03119311|EXPERIMENTAL|VOG group|Video-oculography
62663187|NCT03119311|ACTIVE_COMPARATOR|APCT group|alternative prism cover test
62663188|NCT00922389|EXPERIMENTAL|G-CSF + Stem cells|
62663189|NCT00922389|OTHER|No stem cell group|
62102186|NCT04810455|ACTIVE_COMPARATOR|Non-interactive plush toy -- active control group|"The investigators argue that a comparison with a non-active control-such as waiting list / treatment-as-usual (i.e., nothing)-would not allow us to distinguish the hypothesised impact on in-the-moment soothing of interactivity vs. the emergence of new family routines; and would be also open to unequal social desirability bias.~However, from the perspective of the hypothesised logic model (Levels 1-3), it is not necessary for the active control to have exactly the same form factor as the active toy, as long as it is comparable in size, shape, and appeal. In fact, the investigators have explicitly decided not to use deactivated Purrble units as active controls due to the increased risk of unblinding, whereby the participants search for or come across Purrble online (or notice the plastic enclosure with electronics inside the toy), and assume their unit is malfunctioning."
62663190|NCT00922389|ACTIVE_COMPARATOR|Standerd theraphy|Any therapy for diabetic foot CLI which is routinely practiced and accepted in India
62663191|NCT03853928|EXPERIMENTAL|Probiotics|50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .
62102187|NCT01739556|EXPERIMENTAL|Intervention Arm|Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
62295283|NCT01246492|ACTIVE_COMPARATOR|45g glucose + 20 mg saccharin|glucose water saccharin
62295284|NCT01246492|ACTIVE_COMPARATOR|45g glucose + 85mg asculfame - K|glucose water aseulfame- k
62295285|NCT02292849|EXPERIMENTAL|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
62295286|NCT02292849|ACTIVE_COMPARATOR|Referral|These individuals will receive a standard mental health referral to a community agency.
62295287|NCT06559436|EXPERIMENTAL|Intravenous thrombolysis|Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg.
62295288|NCT06559436|ACTIVE_COMPARATOR|Standard medical management|Standard medical management
62663192|NCT03853928|PLACEBO_COMPARATOR|Placebo|5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly). Duration of treatment Continuous, 1 cycle per month. Continuous treatment will be carried out from randomization to the development of the primary event or until the end of the study.
62663193|NCT01603147|PLACEBO_COMPARATOR|Saline|A total of 10 subjects will receive placebo
62295289|NCT03766425|EXPERIMENTAL|Aflibercept|Aflibercept applied intraoperatively as a subconjunctival injection at a dose of 0.05 ml (40 mg / ml) and one week after the operation at the same dose, also subconjunctival.
62295290|NCT03766425|ACTIVE_COMPARATOR|Mitomycin|Mitomycin applied during a surgery at a concentration of 0.3mg / ml for 3 min. on a soaked sponge.
62467564|NCT02149745|EXPERIMENTAL|Not calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by giving verbal stimulus other than the patient's name
62663194|NCT01603147|EXPERIMENTAL|ch-mAb7F9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively.
61911612|NCT04503733|EXPERIMENTAL|Q4W GMA301 IV injections (300 mg)|"Drug: Q4W GMA301 IV injections (300 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
62295291|NCT02086019|OTHER|Conservative Arm- Medical therapy|Medical therapy
62295292|NCT02086019|OTHER|Invasive Arm-angiogram with PCI or CABG|same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate
62295293|NCT06318884|EXPERIMENTAL|SCTB35|SCTB35 injection is subcutaneously given every week for the first 4 cycles, and thereafter every 3 weeks. Cycles will be repeated every 3 weeks until disease progression, study discontinuation, or death, whichever occurs first.
62295294|NCT01323296|ACTIVE_COMPARATOR|Ferumoxytol|Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.
62295295|NCT01323296|NO_INTERVENTION|Control|Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.
62295296|NCT02318056|EXPERIMENTAL|Aquacel® Ag Burn Glove|Application of Aquacel® Ag Burn Glove burn dressing
62295297|NCT02318056|ACTIVE_COMPARATOR|Mepilex® Transfer Ag|Application of Mepilex® Transfer Ag burn dressing
62663195|NCT05220930|EXPERIMENTAL|Foot bath for heel warming group|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap. Before piercing the heel, the heel will be wiped with a blanket and dried. After the intervention, blood collection from the heel will be performed by following the standard procedure steps that are routinely applied in the service.
62467565|NCT01993030|EXPERIMENTAL|HQ® Matrix Medical Wound Dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
62467566|NCT01993030|ACTIVE_COMPARATOR|Sidaiyi® wound dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.
62467567|NCT03548675|EXPERIMENTAL|Genotype-guided TCA treatment|Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
62467568|NCT03548675|ACTIVE_COMPARATOR|Standard TCA treatment|Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test
61911613|NCT04503733|EXPERIMENTAL|Q4W GMA301 IV injections (600 mg)|"Drug: Q4W GMA301 IV injections (600 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
61911614|NCT04503733|EXPERIMENTAL|Q4W GMA301 IV injections (1000 mg)|"Drug: Q4W GMA301 IV injections (1000 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
61911615|NCT04503733|EXPERIMENTAL|Q4W GMA301 IV injections (1800 mg)|"Drug: Q4W GMA301 IV injections (1800 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
61911616|NCT01917877|EXPERIMENTAL|study group|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
62467569|NCT03286465|EXPERIMENTAL|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
61911617|NCT01917877|ACTIVE_COMPARATOR|control|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
61911618|NCT02047344|EXPERIMENTAL|Antroquinonol (Hocena)|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
61911619|NCT01449643|ACTIVE_COMPARATOR|IMT Group|Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
61911620|NCT01449643|SHAM_COMPARATOR|Sham Group|Non-training protocol
61911621|NCT06154278|EXPERIMENTAL|Imdusiran (AB-729)|Participants receive subcutaneous injections of 60mg, one injection every 8 weeks for 4 doses.
62467570|NCT03286465|ACTIVE_COMPARATOR|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
62467571|NCT02703948|OTHER|Restylane Silk with Lidocaine|
62467572|NCT03493347|EXPERIMENTAL|Equine-assisted Occupational Therapy|All children will receive the Equine-assisted Occupational Therapy (EAOT) intervention, which includes occupational therapy administered in an equine environment. Common intervention activities include grooming, tacking, mounting, and riding the horse.
62467573|NCT01895205|EXPERIMENTAL|Iron isomaltoside 1000|A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
62467574|NCT01895205|ACTIVE_COMPARATOR|Red blood cell transfusion|"Allogenic RBC transfusion is dosed to trigger Hb:~* Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC~* Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
62467575|NCT02098876|ACTIVE_COMPARATOR|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
62467576|NCT02098876|ACTIVE_COMPARATOR|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
62467577|NCT05404386|EXPERIMENTAL|Study group|"Study group intervention consists of a mobile application called My Fight with Incontinence structured according to the health belief model, and a 3-month follow-up."
62467578|NCT05404386|OTHER|Control group|"In addition to routine care, control group intervention consists of the training booklet My Fight with Incontinence which includes healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence, and a 3-month follow-up."
62467579|NCT04844489|OTHER|Blood samples|
62467580|NCT04490941|EXPERIMENTAL|Intervention group|
62663196|NCT05220930|OTHER|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
61911622|NCT05260541|EXPERIMENTAL|Double-blind PRAX-114|Double-blind period - 40 or 60 mg PRAX-114 once daily in the evening
61911623|NCT05260541|PLACEBO_COMPARATOR|Double-blind Placebo|Double-blind period - placebo once daily in the evening
62102188|NCT01739556|NO_INTERVENTION|Standard Treatment|Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
61911624|NCT05260541|EXPERIMENTAL|Open-label Extension PRAX-114|Open-label extension period - 40 mg PRAX-114 once daily in the evening
61911625|NCT01528865|EXPERIMENTAL|Study Drugs|The medications to be used in this study are Lamivudine (EPIVIR®) and Tenofovir disoproxil fumarate (VIREAD®), medications already used in people with certain other types of viruses \[but not HERV-K(HML2)\] in their body. Treatment will last 16 weeks. This is an experiment combining these two drugs and has been issue an Investigational New Drug (IND) Exemption by the FDA.
62102189|NCT04499131|EXPERIMENTAL|I: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and vaginal natural micronized progesterone 400mg/12h
62102190|NCT04499131|EXPERIMENTAL|II: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/24h
62102191|NCT04499131|EXPERIMENTAL|III: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/12h
62295298|NCT02318056|ACTIVE_COMPARATOR|Xeroform®/Bacitracin®|Application of Xeroform® burn dressing and Bacitracin® topical antibiotic
62295299|NCT05742867||Cohort 1|High-risk Muscle-Invasive Bladder Cancer (MIBC) participants following radical cystectomy
62295300|NCT05411302|EXPERIMENTAL|Text4Support Arm|Patients in the intervention (Text4Support) arm of the study will receive the usual care (i.e. community care, follow-up appointments), plus daily automated supportive text messages from an online application.
62295301|NCT05411302|NO_INTERVENTION|Care as usual arm|Patients in the control arm of the study will receive the usual care, which includes the freely accessible Health Authority approved low-intensity e-mental health services. They will receive a single text message informing and encouraging them to utilize current MHAP resources on the NS Health website. They will not receive automated daily supportive text messages.
62295302|NCT03542838|EXPERIMENTAL|Resiniferatoxin|Resiniferatoxin is administered as a one-time dose, intra-articularly at a dose level of 5ug, 12.5ug, 20ug, 25ug, or 30ug.
62295303|NCT03542838|PLACEBO_COMPARATOR|Saline|Saline is administered as a one-time dose, intra-articularly.
62295304|NCT02909153|EXPERIMENTAL|single dose of Triferic in the peritoneal dialysis solution|The patient will receive a single dose of Triferic in the peritoneal dialysis solution (IP) during a long (12 hour) peritoneal dialysis dwell. Each Cohort will receive a different ascending IP dose ( 5 mg/L, 12.5 mg/L, 20 mg/L). Blood samples will be drawn periodically over a 12 hour period for analysis.
62295305|NCT02909153|EXPERIMENTAL|single IV dose of Triferic 6.6 mg over a 4 hour period|The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
62295306|NCT04275427|EXPERIMENTAL|study laser group|laser therapy on knee for 2 weeks
62102192|NCT04499131|EXPERIMENTAL|IV: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and a combination of subcutaneous natural progesterone 25mg/24h + vaginal natural micronized progesterone 400mg/24h
62295307|NCT04275427|NO_INTERVENTION|control group|no intervention
62295308|NCT01676038|ACTIVE_COMPARATOR|Pinless-Navigated Total Knee Arthroplasty|The patients underwent total knee arthroplasty using a Pinless-Navigated system that is designed to restore the mechanical alignment of the lower limb.
62295309|NCT01676038|ACTIVE_COMPARATOR|Conventional Total Knee Arthroplasty|The patients underwent total knee arthroplasty using conventional technique.
62295310|NCT01978704|EXPERIMENTAL|Glycaemic load|
62295311|NCT01978704|ACTIVE_COMPARATOR|Carbohydrates content|
62295312|NCT05807308|EXPERIMENTAL|technology-based cognitive and artistic therapeutic activities|The group receiving technology-based cognitive and artistic therapeutic activities
62663197|NCT06322498|EXPERIMENTAL|Intact uterus|Patients with intact uterus
62663198|NCT06322498|EXPERIMENTAL|Scarred uterus|Patients with scarred uterus
61911626|NCT02622906|PLACEBO_COMPARATOR|Placebo|1 injection per month during 6 months of the placebo product
61911627|NCT02622906|ACTIVE_COMPARATOR|Pasireotide|1 injection per month during 6 months of the Pasireotide LP (60mg/injection)
61911628|NCT02437123|EXPERIMENTAL|The Cedar Project mHealth Intervention|The Cedar Project mHealth intervention consists of a package of culturally-safe supports, including a mobile phone and long-distance cellular plan, weekly two-way text messaging, and support from community-based Cedar Advocates.
61911629|NCT02437123|NO_INTERVENTION|Comparison group|The comparison group will be sampled from The Cedar Project, an ongoing cohort study of young Indigenous people who use drugs under its existing informed consent with no change whatsoever to their participation in the overall study.
62295313|NCT05807308|NO_INTERVENTION|Control group|the group that did not receive any training
62295314|NCT01956006|EXPERIMENTAL|MIlrinone|ER milrinone
62467581|NCT04490941|OTHER|Control group|
61911630|NCT04348227||Before pandemic is declared|Positive endotracheal aspirates addressed from January 1st 2019 to January 1st 2020
61911631|NCT04348227||After pandemic is declared|Positive endotracheal aspirates addressed from February1st 2020 to February 1st 2021
62295315|NCT06366776||Treatment Group|Any patient with a 25-OH vitamin D level(s) always lower than 40 ng/ml (low level) with subsequent level(s) in the 40 ng/ml to 100 ng/ml range. The 40 ng/ml to 100 ng/ml range is maintained for three years.
62295316|NCT06366776||Control Group A|Any patient with a 25-OH vitamin D level always lower than 40 ng/ml with maintenance of that lower than 40 ng/ml level for 3 years.
62102193|NCT04499131|EXPERIMENTAL|V: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and intramuscular natural progesterone 50mg/24h
62102194|NCT04499131|ACTIVE_COMPARATOR|Natural menstrual cycle|Natural menstrual cycle (without any exogenous steroid hormone Treatment)
62295317|NCT06366776||Control Group B|Any patient who has an uninterrupted 25-OH vitamin D level greater than or equal 40 ng/ml and less than or equal to 100 ng/ml (sufficient level) for a continuous 3-year period. Prior to the 3-year period there were no levels lower than 40ng/ml or higher than 100 ng/ml.
62467582|NCT05033834||Group A|People received any registered COVID-19 vaccination
61911632|NCT02058745|ACTIVE_COMPARATOR|CAU+ (Enhanced Care as Usual)|CAU+ (Enhanced Care as Usual) is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page for the 10 month duration of the study.
61911633|NCT02058745|EXPERIMENTAL|CAU+ and SmartCare|CAU+ (Enhanced Care as Usual) for eight weeks, followed by eight weeks of SmartCare. SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management.
61911634|NCT02058745|EXPERIMENTAL|CAU+ and Beating the Blues and SmartCare|CAU+ (Enhanced Care as Usual) and Beating the Blues concurrently for eight weeks, followed by SmartCare for eight weeks. Beating the Blues is an established, web-based, self-directed, cognitive behavioral therapy for managing depressive symptoms.
62102195|NCT06711263|EXPERIMENTAL|chlorhexidine|Mouthwash will be used for these participants
62102196|NCT06711263|ACTIVE_COMPARATOR|Tea tree oil|Participants will use the mouthwash and plaque and gingival bleeding indice will be recorded at baseline, after 2 weeks and after 4 weeks
62102197|NCT06711263|ACTIVE_COMPARATOR|Reseverotriol|Participants will use the mouthwash and plaque and gingival bleeding indice will be recorded at baseline, after 2 weeks and after 4 weeks
62102198|NCT06711263|ACTIVE_COMPARATOR|Miswak|Participants will use the mouthwash and plaque and gingival bleeding indice will be recorded at baseline, after 2 weeks and after 4 weeks
62102199|NCT06369220|OTHER|Standard of Care (SOC) Arm: Standard Practice|In the SOC arm, the clinician will evaluate the participant based on standard practice.
62102200|NCT06369220|EXPERIMENTAL|Point of Care (POC) Arm: cobas® liat CT/NG/MG|In the POC arm, the clinician will evaluate the participant and will be provided POC test results upon which they may choose to base their clinical decisions.
62102201|NCT01531231||YOUNG HEALTHY NO CORONARY ARTERY DISEASE|- Whether an association between typical daily experiences and recovery time varies with age; this group will be compared to the older comparison group and to previous data collected from those subjects who participated in the Long QT Syndrome study (LQTS).
62102202|NCT01531231||OLDER HEALTHY NO CORONARY ARTERY DISEASE|- Determine whether daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD when comparing CAD patients with healthy patients
62102203|NCT01531231||HIGH RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether emotion assessed randomly throughout the day is associated with myocardial ischemia
62102204|NCT01531231||LOW RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether typical daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD
62102205|NCT00868231|EXPERIMENTAL|Aclidinium 400 μg bid|Aclidinium bromide 400 μg twice-daily by inhalation
62102206|NCT00868231|ACTIVE_COMPARATOR|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily by inhalation
62295318|NCT05122325|EXPERIMENTAL|Intervention group 1: Transcutaneous tibial nerve stimulation (TTNS)|"Transcutaneous application of low frequency electrical current over the tibial nerve TENS® EMS NMS60 for a 30 minutes session, twice a week.~Placing a small electrode 3 fingers up to the internal malleolus and 1 cm posterior (adjusting its placement with a point finder or testing with low frequencies of 2-3 Hz). A large electrode placed in the calcaneus."
62467583|NCT05033834||Group B|People developed COVID-19 infection after partial or full vaccination with any registered COVID-19 vaccine
62467584|NCT00352820||Interview + Questionnaire|
62467585|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
62467586|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
62467587|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
62467588|NCT03045250|ACTIVE_COMPARATOR|Type 1 Diabetes|Subjects with known Type 1 diabetes
61911635|NCT06221527|ACTIVE_COMPARATOR|conventional group|fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border.
61911636|NCT06221527|ACTIVE_COMPARATOR|study group|"placement of hyaluronic acid will be carried over gel foam and placed between fractured segments before plate fixation.~fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border."
62102207|NCT00868231|PLACEBO_COMPARATOR|Placebo|Placebo
62467589|NCT03045250|PLACEBO_COMPARATOR|Healthy Controls|Healthy controls
62102208|NCT05123638|EXPERIMENTAL|Virtual reality cycling exercise|These patient participants will receive 1 session of unsupervised stationary cycling exercise with the SYNCSENSE VR-technology every weekday of participation and be allowed up to 30min of voluntary exercise pr. session.
62102209|NCT05123638|ACTIVE_COMPARATOR|Conventional cycling exercise|These patient participants will receive 1 session of unsupervised stationary cycling exercise on every weekday of participation and be allowed up to 30min of voluntary exercise pr. session.
62295319|NCT05122325|EXPERIMENTAL|Intervention group 2: Genital vibration|Women will be instructed in the use of the Ferticare 2.0® vibrator with a frequency of 70 Hz, amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
62295320|NCT05122325|SHAM_COMPARATOR|Control group|A sham of TTNS intervention with the device turned off, twice a week.
62467590|NCT04786106|ACTIVE_COMPARATOR|CCH+PTT|Men will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit.
62467591|NCT04786106|ACTIVE_COMPARATOR|Surgery+PTT|Men will undergo either penile plication or I\&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.
62467592|NCT04525365|EXPERIMENTAL|Pleural aspiration|Pleural aspiration under sedation
62467593|NCT04525365|ACTIVE_COMPARATOR|Closed Thoracostomy|Actual management
62467594|NCT02059525||syphilis infected|all patients with a new diagnosis of syphilis, receiving treatment at the Institute of Tropical Medicine
62663199|NCT02918799|OTHER|Community cohort|Beirut community will receive the multi-component intervention Mpowerment; the community cohort of YMSM will be used to evaluate the effects of the intervention on the community, as the cohort participants may or may not have participated in the intervention.
61911637|NCT01413347|ACTIVE_COMPARATOR|pillow|confirmation of double-lumen tube position with a head on a pillow
61911638|NCT01413347|EXPERIMENTAL|neutral|confirmation of double-lumen tube position in neutral position of a head
62102210|NCT02931149|EXPERIMENTAL|Submucosal injection with PRP|All participants in the study received submucosal injection of PRP prior to endoscopic resection
62467595|NCT01641068|EXPERIMENTAL|Arm I (memory and thinking skills workshop)|Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).
62467596|NCT01641068|ACTIVE_COMPARATOR|Arm II (Education Workshop)|Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
62467597|NCT00941174|ACTIVE_COMPARATOR|Capsule: 400 microg 13C5-Calcium-L-Leucovorin|
62663200|NCT05592197|EXPERIMENTAL|RT+TACE+Lenvatinib|Patients in RT+TACE+Lenvatinib group will take oral lenvatinib first and receive TACE one day after oral administration of lenvatinib. RT will begin within 4 weeks after the first TACE.
61911639|NCT04631991||Non-pathological high myopia|Comprehensive ophthalmologic examination
61911640|NCT04631991||Control|Comprehensive ophthalmologic examination
61911641|NCT01343901||Bevacizumab|Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.
62467598|NCT00941174|ACTIVE_COMPARATOR|IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin|
62467599|NCT04821401|EXPERIMENTAL|Males study product|25 men will be randomized to Rejuvant
62663201|NCT05592197|ACTIVE_COMPARATOR|TACE+Lenvatinib|Patients in TACE+Lenvatinib group will take oral lenvatinib first and receive TACE one day after oral administration of lenvatinib.
62102211|NCT04127539|EXPERIMENTAL|Intervention|Will start a Strong \& Steady group exercise programme immediately after baseline testing.
62295321|NCT06301360|EXPERIMENTAL|I-EAET with therapist support|I-EAET is a 10 week treatment intervention combining principles from emotion focused therapies and neuroscience. Main components include psychoeducation on the body-mind connection, anxiety regulation with self-compassion exercises and different techniques for emotional exposure and processing. Participants have help from a therapist giving feedback.
62295322|NCT06301360|ACTIVE_COMPARATOR|I-EAET without therapist support|I-EAET is a 10 week treatment intervention combining principles from emotion focused therapies and neuroscience. Main components include psychoeducation on the body-mind connection, anxiety regulation with self-compassion exercises and different techniques for emotional exposure and processing. Participants works on their own and have only technical support.
62295323|NCT03669523|EXPERIMENTAL|Denosumab-nivolumab combination|Both drugs to be continued until progression or unacceptable toxicity and for a maximum of two years
62295324|NCT04604925||Remote patient monitoring for hypertension|RPM Integration: All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
62663202|NCT00954083|EXPERIMENTAL|DIR/Floortime intervention|1=DIR/Floortime intervention
62663203|NCT00954083|ACTIVE_COMPARATOR|routine care|2=routine care
62663204|NCT02008370|EXPERIMENTAL|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
61911642|NCT04838808|ACTIVE_COMPARATOR|Rivaroxaban|Rivaroxaban 2.5mg oral twice daily for 90-days
62663205|NCT00743093|EXPERIMENTAL|acetaminophen|acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
62663206|NCT00743093|PLACEBO_COMPARATOR|placebo|placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)
62102212|NCT05788094|EXPERIMENTAL|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"* Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
62295325|NCT04604925||Usual care|Matching patients from control practices will be selected from remaining Northwestern Medical Group primary care sites and be chosen to provide as sufficiently large number of eligible patients for comparison. These groups will contribute EHR data through the NM EDW but will not have any new procedures put in place
62295326|NCT02293109|EXPERIMENTAL|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62295327|NCT01800721|EXPERIMENTAL|Experimental Condition SNAP|"Behavioral Intervention SNAP HIV training and peer outreach~Participants learn skills for sexual health and peer outreach which includes talking with network members about HIV testing and prevention."
62467600|NCT04821401|PLACEBO_COMPARATOR|Males placebo|25 man will be randomized to placebo
62467601|NCT04821401|EXPERIMENTAL|Females study product|25 women will be randomized to Rejuvant
62467602|NCT04821401|PLACEBO_COMPARATOR|Females placebo|25 women will be randomized to placebo
62467603|NCT01379222|EXPERIMENTAL|ENGAGE PAS De Novo Subjects|The Endurant Stent Graft System Bifurcated device is administered to patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair, per the FDA approved Instructions For Use (IFU).
62467604|NCT03735030|EXPERIMENTAL|human hCG|
62467605|NCT03735030|ACTIVE_COMPARATOR|recombinant hCG|
62467606|NCT04544787|EXPERIMENTAL|Group 1: One Dose of Novel OPV2 Candidate 1|Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units \[CCID50\]).
62467607|NCT04544787|EXPERIMENTAL|Group 2: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
62467608|NCT04544787|EXPERIMENTAL|Group 3: One Dose of Novel OPV2 Candidate 2|Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
62467609|NCT04544787|EXPERIMENTAL|Group 4: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
62467610|NCT04544787|EXPERIMENTAL|Group 5: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
62467611|NCT04544787|EXPERIMENTAL|Group 6: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
62467612|NCT04544787|PLACEBO_COMPARATOR|Group 7: Two Doses of Placebo|Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).
62295328|NCT01800721|ACTIVE_COMPARATOR|SNAP Control Condition|"SNAP Control~Participants receive information on HIV/STDs as well as healthy eating and nutrition instruction."
62663207|NCT01967953|NO_INTERVENTION|Standard Group|"Recipients of lungs procured from brain death donors deemed suitable for transplantation according to standard criteria.~Events: lung procurement, cold storage on ice, transplantation."
62663208|NCT01967953|EXPERIMENTAL|EVLP Group|"Recipients of marginal lungs procured from brain death donors and reconditioned with ex-vivo lung perfusion (EVLP).~Events: lung procurement, cold storage on ice, reconditioning by EVLP, cold storage on ice, transplantation."
62663209|NCT04406831||New Unresectable Pancreatic Cancer|Individuals with biopsy-proven adenocarcinoma of the pancreas, classified as locally advanced or metastatic disease
62663210|NCT04406831||Control|Healthy individuals without cancer diagnoses to provide reference microRNA
62295329|NCT05589142|EXPERIMENTAL|eTRE with BCAA|participants allocated to this group will only consume calories during 0800h and 1600h daily. Prior to sleep, participants will consume a single bolus of 5.6g of BCAA.
62295330|NCT05589142|ACTIVE_COMPARATOR|eTRE|participants allocated to this group will only consume calories during 0800h and 1600h daily.
62295331|NCT03542994|OTHER|Cohort 1|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days
62295332|NCT03542994|OTHER|Cohort 2|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days
62295333|NCT03542994|OTHER|Cohort 3|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days
62295334|NCT03542994|OTHER|Cohort 4|12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days
62295335|NCT03542994|OTHER|Cohort 5|24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days
62295336|NCT03542994|OTHER|Cohort 6|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 660 mg, capsule, once daily, 29 days"
62295337|NCT03542994|OTHER|Cohort 7|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
62295338|NCT03542994|OTHER|Cohort 8|up to 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3g, capsule, once daily, 29 days
62295339|NCT03542994|OTHER|Cohort 9|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
62663211|NCT05249751||mild-moderate|Cases classified as mild-moderate fulfilled the following criteria: fever and respiratory symptoms, CORAD 1-5, and oxygen saturation (SpO2 92 percent),
62663212|NCT05249751||Severe|severe cases met the following criteria: fever and respiratory symptoms, CORAD 4-5, and oxygen saturation (SpO2 92 percent).
62663213|NCT02883556|EXPERIMENTAL|Pembrolizumab 200 mg|Pembrolizumab 200 mg administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
62663214|NCT04854746|ACTIVE_COMPARATOR|Cohort 1 Low Dose Active|VXA-GI.1-NN tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log10
62663215|NCT04854746|ACTIVE_COMPARATOR|Cohort 3 High Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log11
62663216|NCT04854746|PLACEBO_COMPARATOR|Cohort 1 Low Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
62663217|NCT04854746|PLACEBO_COMPARATOR|Cohort 3 High Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
62102213|NCT05788094|EXPERIMENTAL|Chloroquine plus Tafenoquine (450 mg adult dose)|"* Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
62295340|NCT05224778||Congenital Myotonic Dystrophy (CDM)|CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (\<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\>1,500).
62295341|NCT05224778||Childhood Myotonic Dystrophy (ChDM)|ChDM group includes those aged 1 to 4 years, 11 months at enrollment. Individuals must have a diagnosis of ChDM, which is defined as symptoms associated with DM1, absence of symptoms at birth, and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\>1,500).
62295342|NCT01264939|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
62467613|NCT02212847|EXPERIMENTAL|vestibular stimulation|
62663218|NCT04854746|ACTIVE_COMPARATOR|Cohort 2 Medium Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 3x10Log10
62663219|NCT04854746|PLACEBO_COMPARATOR|Cohort 2 Medium Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
62663220|NCT03117127|ACTIVE_COMPARATOR|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
62663221|NCT03117127|EXPERIMENTAL|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
62663222|NCT05693220|ACTIVE_COMPARATOR|Density gradient centrifugation|Patients will undergo sperm preparation by density gradient centrifugation
62663223|NCT05693220|ACTIVE_COMPARATOR|Zymot sperm separation device|Patients will undergo sperm preparation by the Zymot sperm separation device
62663224|NCT00754923|EXPERIMENTAL|Treatment: Sorafenib|Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
62663225|NCT03942588|EXPERIMENTAL|High-intensity interval training|Twice-weekly supervised high-intensity interval treadmill training in a laboratory setting for 10 weeks.
61911643|NCT04838808|PLACEBO_COMPARATOR|Placebo|Oral placebo tablet twice daily for 90-days
61911644|NCT06103331||child|identification and management of invasive fungal pathogen
61911645|NCT06103331||adult|identification and management of invasive fungal pathogen
61911646|NCT05457582|PLACEBO_COMPARATOR|Placebo plus high-intensity statin|Participants received placebo subcutaneous injections once every 2 weeks (Q2W) plus high-intensity statin treatment (Rosuvastatin, 20 mg, once daily)
61911647|NCT05457582|ACTIVE_COMPARATOR|PCSK 9 Inhibitor plus high-intensity statin|Participants received PCSK 9 Inhibitor Q2W subcutaneous injections
62295343|NCT01264939|EXPERIMENTAL|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
62295344|NCT06261814|EXPERIMENTAL|Diagnostic (CEUS)|"Patients receive lumason IV and undergo CEUS 2 weeks prior to TACE, during TACE, 1-2 weeks after TACE, and then 1-2 months after TACE.~Intervention(s)"
62467614|NCT03639662|EXPERIMENTAL|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
62663226|NCT03942588|NO_INTERVENTION|Control|Usual activities for 10 weeks
62663227|NCT01044199|EXPERIMENTAL|1: Pre-EP ID|Group of participants receiving PCEC rabies vaccine intradermally with the Pre-Exposure schedule.
62663228|NCT01044199|ACTIVE_COMPARATOR|2: Pre-EP IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Pre-Exposure schedule.
62663229|NCT01044199|EXPERIMENTAL|3: Booster ID|Group of participants receiving PCEC rabies vaccine intradermally with the Booster schedule.
62663230|NCT01044199|ACTIVE_COMPARATOR|4: Booster IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Booster schedule.
62663231|NCT00084253|ACTIVE_COMPARATOR|1|
62663232|NCT00084253|ACTIVE_COMPARATOR|2|
62663233|NCT01620346|ACTIVE_COMPARATOR|ICSI group|This group was provided with conventional intracytoplasmic sperm injection (ICSI). This treatment is routinely used to treat infertility. Sperm selection in the ICSI group is analysed under a magnification of 400x using an inverted microscope.
62663234|NCT01620346|EXPERIMENTAL|Intracytoplasmic morphologically selected sperm injection|Intracytoplasmic morphologically selected sperm injection (IMSI) is an established modified ICSI procedure. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
62663235|NCT00610519|ACTIVE_COMPARATOR|1|treatment with spray containing aromatic essential oils of some herbal plants.
62663236|NCT00610519|PLACEBO_COMPARATOR|2|spray containing placebo.
62663237|NCT04581746|OTHER|experimental arm|questionnaire and follow-up visit
62663238|NCT03517215|EXPERIMENTAL|Enhanced CB-ASP|If a site is randomized to the enhanced CB-ASP, prescribers at that site will be required to attend an education session. In the four months following the initial session, prescribers will be asked to complete one on-line eModule for each target condition (acute sinusitis, sore throat, acute bronchitis and acute uncomplicated cystitis) each month. Each module will take approximately 15 minutes to complete. Two audit and feedback reports (every 3 months) of their clinic's prescriptions for these conditions will be provided where they will be asked to review and discuss with their colleagues and study staff.
61911648|NCT03449784||patients with dyslipidemia non achieving LDL-C target|patients with dyslipidemia non achieving LDL-C target
61911649|NCT03449784||patients with dyslipidemia achieving LDL-C target|patients with dyslipidemia achieving LDL-C target
61911650|NCT05594615|EXPERIMENTAL|EDP-235, midazolam, rosuvastatin and caffeine|Subjects will receive EDP-235, midazolam, rosuvastatin and caffeine throughout the treatment period on respective dosing days
61911651|NCT05884801|EXPERIMENTAL|QLS1103 Dose Escalation and Expansion|
61911652|NCT04985396|EXPERIMENTAL|Platelet Rich Plasma (PRP) group|The PRP will be prepared based on the Sengodan et al, 2020 study.
61911653|NCT04985396|ACTIVE_COMPARATOR|Steroid group|"Steroid group will be treated with steroid injection. In this group, 2ml of Inj. Depo-Medrol 80 mg (Methylprednisolone) along with 1 ml lignocaine (0.25%) will be loaded in 5cc syringe and then the cocktail will be injected into medial calcaneal tuberosity at the most tender point using an aseptic technique as mentioned by Nishanth et.at,2018.~After the procedure, participants will be advised not to involve in any kind of rigorous activity with the affected foot for at least two days and then gradually return to their regular activities. All patients will be counseled to follow up in the next visit at 3 months and 6 months. The end-line information will be again recorded at 3 months and 6 months."
61911654|NCT04385329|EXPERIMENTAL|Experimental group:shock waves extended to gastrocnemius TrP|Focused shock wave therapy was extended from the plantar fascia to the gastrocnemius-soleus trigger points.
61911655|NCT04385329|ACTIVE_COMPARATOR|Control group: shock waves not extended to gastrocnemius TrP|A standard focused shock wave therapy exclusively targeted at the plantar fascia
62295345|NCT04179903|ACTIVE_COMPARATOR|Gym Trainer|Physical Activity program is performed in a group in a gym (Gym Group Training-GGT), with activity sessions conducted by a trainer graduated in Science and Techniques of Preventive and Adapted Physical Activity
62295346|NCT04179903|ACTIVE_COMPARATOR|Individual Home|Physical Activity program is performed at home individually (Individual Home Training-IHT), without the supervision of a trainer during the exercise session.
62295347|NCT01151137|EXPERIMENTAL|Dronedarone|Dronedarone 400 mg twice a day until the CSED
62295348|NCT01151137|PLACEBO_COMPARATOR|placebo|Placebo (for Dronedarone) twice a day until the CSED
62295349|NCT01147809|ACTIVE_COMPARATOR|Eltrombopag|Drug: eltrombopag olamine thrombopoietin receptor agonist
62295350|NCT01147809|PLACEBO_COMPARATOR|Placebo|Other: Placebo Placebo tablets with no active pharmaceutical ingredient
62295351|NCT00953394|EXPERIMENTAL|treatment arm|continuous 5 fluouracil infusion plus long-acting octreotide
62102214|NCT05788094|EXPERIMENTAL|Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)|"* Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
62102215|NCT05186818|EXPERIMENTAL|CK-3773274 up to 20 mg|Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 24 weeks
62102216|NCT05186818|PLACEBO_COMPARATOR|Placebo to match CK-3773274|Patients will receive placebo for up to 24 weeks
62295352|NCT01271686|EXPERIMENTAL|0.01% bimatoprost|bimatoprost 0.01% one time per day at bedtime for 4 weeks.
62295353|NCT03866200|EXPERIMENTAL|Resveratrol, Then Placebo|Participants first received Resveratrol 125 mg/day or 5 ml daily for 90 days. After a washout period of 30 days, they then received Placebo 5ml daily for 90 days.
62102217|NCT04587791|ACTIVE_COMPARATOR|CBD 400mg|CBD 400 mg
62102218|NCT04587791|ACTIVE_COMPARATOR|CBD 800mg|CBD 800mg
62102219|NCT04587791|ACTIVE_COMPARATOR|CBD 1200mg|CBD 1200mg
62102220|NCT04587791|PLACEBO_COMPARATOR|Saline|saline
62295354|NCT03866200|PLACEBO_COMPARATOR|Placebo, Then Resveratrol|Participants first received Placebo 5ml daily for 90 days. After a washout period of 30 days, they then received Resveratrol 125 mg/day or 5 ml daily for 90 days.
62295355|NCT00753389||1|
62295356|NCT05241158|ACTIVE_COMPARATOR|Group A|Group A: Counselling group Patients were given a briefing about the procedure; the use of local anesthetic along with potential benefits and side effects of the drug. The steps of the endoscopy procedure (gastroscopy or colonoscopy) were explained in detail including the position, intubation, biopsy or intervention wherever applicable, extubation and post-procedure observation period in the recovery room. Detailed instructions were provided regarding post-procedural care, introduction of diet \& follow-up.
62295357|NCT05241158|ACTIVE_COMPARATOR|Group B|Group B: Video group Patients in the visual aid group (video group) were provided with the same information mentioned in intervention group A. In addition to that, patients watched a 5 minutes video of the respective procedure. Video showed the animation of a gastroscopy or colonoscopy procedure with a voice over explaining all the steps of the procedure in addition to the pre and post-procedure precautions to be observed.
62295358|NCT03325764|OTHER|sleeve gastrectomy|Assessment before and after sleeve gastrectomy
62295359|NCT01217502|EXPERIMENTAL|Self management|
62295360|NCT01413893|EXPERIMENTAL|linifanib|
62295361|NCT04429022|EXPERIMENTAL|Prospective cohort|"Pre-Op:~* Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op)~* Acetaminophen 1000mg PO x1 prior to surgery (in pre-op)~Intra-Op:~* Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point) for total of 20mL~* Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL~* Will operate at \<15mmHg intra-abdominal pressure, with goal of \<12mmHg~* At end of procedure during closure of fascia, give 30mg ketorolac IV x 1~Post-Op:~* Gabapentin 300mg PO BID for 7 days~* Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN~* Celecoxib 200mg PO q 12h x 7d~* Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 x 5mg upon discharge (90MME) if patient did not use any opioids postoperatively while inpatient, will not prescribe opioid medication upon discharge"
62102221|NCT00504920||Symptom Assessment|Drawing blood samples and matching the test results with questionnaire responses for symptoms patients experience from transplant treatment.
62102222|NCT06023030||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
62295362|NCT04429022|ACTIVE_COMPARATOR|Historical Control|Traditional post-operative opioid medication regimen: Dilaudid 1mg IV PRN q3h while inpatient; Percocets 12 x 5mg/325 (90MME) upon discharge
62295363|NCT00925847|EXPERIMENTAL|1|
62467615|NCT03639662|NO_INTERVENTION|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
62663239|NCT03517215|ACTIVE_COMPARATOR|Standard CB-ASP|If a site is randomized to the standard CB-ASP strategy arm, prescribers will be offered the opportunity to attend the 1 hour introductory seminar by a web-link, provided with access to the short e-learning modules each month by email, and sent their clinic's audit and feedback reports by email for review two times during the study.
62663240|NCT03517215|NO_INTERVENTION|Control|If a site is randomized to the control arm, the site will not receive any active interventions. Prescribers at the site will be offered access to the eModules at the completion of the study and provided with one audit and feedback report of their clinic's antibiotic prescribing patterns for local quality improvement needs as desired.
62663241|NCT02080078|EXPERIMENTAL|Increasing dose of Theophylline|Patients will be put on the standard dose of 150 mg/day of erlotinib. Patients will be entered into the study on different dose levels of theophylline (100 mg/bid, 150 mg/bid, 200 mg/bid, or 200 mg/tid) for 28 days to find what is the lowest dose that effectively controls the diarrhea caused by erlotinib.
61911656|NCT01097200|OTHER|Elevate meshes|The use of Elevate (American Systems trade mark) meshes for the treatment of pelvic prolapse.
61911657|NCT01097200|OTHER|Sacrocolpopexy|Sacrocolpopexy for the correction of the prolapse
62102223|NCT06300840|NO_INTERVENTION|Baseline|Wearing no Balancebelt.
62102224|NCT06300840|SHAM_COMPARATOR|Sham condition|Wearing the BalanceBelt while it is switched off
62102225|NCT06300840|EXPERIMENTAL|Intervention|Wearing the BalanceBelt while it is switched on
62102226|NCT04502719||Screened|Patients with liver cirrhosis screened for malnutrition.
62102227|NCT05131919|EXPERIMENTAL|pembrolizumab|Treatment with pembrolizumab 200 mg.
62102228|NCT06711250|ACTIVE_COMPARATOR|control|bone grafting
62102229|NCT06711250|ACTIVE_COMPARATOR|study|bone grafting \& i PRF
62102230|NCT02634008|EXPERIMENTAL|Cohort 1|Paritaprevir/ritonavir/ombitasvir (75mg/50mg/12.5mg) and dasabuvir (250mg) with or without ribavirin (1000-1200mg) daily taken orally for 8 weeks.
62102231|NCT02634008|EXPERIMENTAL|Cohort 2|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 6 weeks
62467616|NCT03748953|EXPERIMENTAL|Ixazomib|"Ixazomib 3 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 1 through Cycle 4, during which if the participants have tolerated the initial dose, the dose may be escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 5 through Cycle 26, or until documented PD or intolerable toxicity, whichever occurs first.~Participants who received placebo-matching capsules before unblinding and have not yet experienced disease progression will have the opportunity to cross over to ixazomib maintenance."
62467617|NCT02597660|ACTIVE_COMPARATOR|Drug: Somatropin|Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
62467618|NCT02597660|PLACEBO_COMPARATOR|Drug: Placebo|Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
62295364|NCT04947293|EXPERIMENTAL|Yoga Exercise|Subjects in the experimental group will be invited to participate in 60-minute yoga sessions twice a week for 12 weeks. Each session will include postural (asanas), breathing (pranayama), and meditative exercises. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, blankets, blocks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support.
62102232|NCT02634008|EXPERIMENTAL|Cohort 3|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 4 weeks
62102233|NCT00666120|ACTIVE_COMPARATOR|1|Cow's milk based infant formula
62467619|NCT01565902|EXPERIMENTAL|Mild hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
62102234|NCT00666120|ACTIVE_COMPARATOR|2|Partially hydrolyzed cow's milk based infant formula
62102235|NCT06398899|EXPERIMENTAL|Group S|Sugammadex as reversal agent
62467620|NCT01565902|EXPERIMENTAL|Moderate hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
62102236|NCT06398899|ACTIVE_COMPARATOR|Group N|neostigmine and glycopyrrolate as reversal agent
62102237|NCT06714643|EXPERIMENTAL|active|
62102238|NCT06714643|SHAM_COMPARATOR|sham|
62102239|NCT05222269|EXPERIMENTAL|68Ga-PTF|150 (+/-50) Megabecquerel (MBq) 68Ga-PTF will be injected intravenously at three timepoints during the course of the standard of care treatment.
62102240|NCT03643965|EXPERIMENTAL|Nefecon|Nefecon 16 mg once daily by mouth for 9 months.
62102241|NCT03643965|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo oral capsule once daily by mouth for 9 months.
62102242|NCT04496674|EXPERIMENTAL|Treatment with bispecific Ab CC-1|administration of bispecific PSAMxCD3 Ab CC-1.
62467621|NCT01565902|EXPERIMENTAL|Severe hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
62102243|NCT03742219|EXPERIMENTAL|Lifestyle Intervention|Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
62102244|NCT02851030|EXPERIMENTAL|Move, Play, Learn! Intervention|This arm will receive the 10-week Move, Play, Learn! intervention immediately.
62102245|NCT02851030|NO_INTERVENTION|Waitlist Control|This arm will receive the 10-week intervention once follow-up measures on the primary outcome have been collected for both groups.
62102246|NCT05764824|ACTIVE_COMPARATOR|Blueberry group|Blueberry arm
62102247|NCT05764824|PLACEBO_COMPARATOR|Control group|Control arm
62102248|NCT00341497||Cohort|Persons seen at dental clinics at 6 Veterans Affairs Medical Centers who had clinically visibleoral lesions
62295365|NCT04947293|ACTIVE_COMPARATOR|Fitness and mobility exercise|Subjects in the control group will be invited to participate in more conventional exercise sessions, based on a fitness and mobility exercise (FAME) program, 60-minute per sessions twice a week for 12 weeks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support. The effectiveness of this program has already been demonstrated in previous studies.
62467622|NCT01565902|EXPERIMENTAL|Matched healthy subjects|Treatment with a single oral dose of 0.25 mg BAF312
62467623|NCT04438707|EXPERIMENTAL|Experimental group|
62102249|NCT02483299|ACTIVE_COMPARATOR|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
62102250|NCT02483299|ACTIVE_COMPARATOR|combined|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
62102251|NCT06098027|EXPERIMENTAL|[14C]CS0159|Single oral dose of 4mg \[14C\]CS0159
62102252|NCT01989442|EXPERIMENTAL|Nasal Mask|patients who receive NIV by nasal mask interface after randomization
62102253|NCT01989442|ACTIVE_COMPARATOR|nasal prong|patients who receive NIV by nasal prongs as interface after randomization
62102254|NCT04811287|ACTIVE_COMPARATOR|CTR with PRP|Carpal tunnel release with adjuvant platelet-rich plasma.
62102255|NCT04811287|PLACEBO_COMPARATOR|CTR without PRP|Carpal tunnel release without adjuvant platelet-rich plasma.
62102256|NCT02939690|EXPERIMENTAL|UVC and surface measurement formula|UVC insertion depth = Umbilicus to nipple distance minus 1cm
62102257|NCT02939690|ACTIVE_COMPARATOR|UVC and Birth weight based formula|UVC insertion depth=\[(3× birth weight (Kg) + 9)/2+1)\] cm
62102258|NCT05616221|EXPERIMENTAL|AP-PA02|Anti-pseudomonal bacteriophage
62102259|NCT05616221|PLACEBO_COMPARATOR|Placebo|Inactive isotonic solution
62102260|NCT02596906|EXPERIMENTAL|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
62102261|NCT02596906|SHAM_COMPARATOR|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
62467624|NCT04438707|ACTIVE_COMPARATOR|Control group|
61911658|NCT02183753|ACTIVE_COMPARATOR|Wood smoke|The dose of WSP to be used (500 µg/m3 for 2 hours) is based on prior studies which indicate the exposure is well tolerated, and is similar to that found in some indoor exposures in homes heated by wood burning (24-26). The route of administration (breathing air containing WSP at rest, nasally) is intended to mimic natural exposures.
61911659|NCT02183753|PLACEBO_COMPARATOR|clean air|Chapel Hill air which has been filtered to remove ambient air pollutants.
61911660|NCT05459090||Patients with drug resistant epilepsy|All patients with drug-resistant epilepsy who undergo neurosurgical resection of the epileptic focus.
61911661|NCT02434601|OTHER|Treatment of Dentin Surface|Treatment of Dentin Surface: Restoration made following the protocol recommended by the manufacturer of the materials.
62663242|NCT02080078|EXPERIMENTAL|Increasing dose of erlotinib|Patients will be kept on a specified dose of theophylline while the dose of erlotinib increases in each group of patients enrolled (200 mg/qd, 225 mg/qd, or 250 mg/qd) for 28 days to determine what the maximum dose of erlotinib that can be given with theophylline and maintain a safety profile.
62663243|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
62663244|NCT06321848||The ventilator weaning patients|Patients who have been on mechanical breathing for longer than 48 hours using an endotracheal tube and who fit the requirements to be weaned off of it
62663245|NCT05031130|NO_INTERVENTION|Control Group|For the control group, the researcher will provide routine care to pregnant adolescents.
62663246|NCT05031130|EXPERIMENTAL|Experimental group|For the experimental group, the researcher will provide the empowered program integrated with family support plus routine care.
62663247|NCT05870436||Positive group|The group that conducted the Methacholine Choline Provocation Test with Positive result
62663248|NCT05870436||Negative group|The group that conducted the Methacholine Choline Provocation Test with negative result
62663249|NCT00357162|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62663250|NCT02690376|OTHER|Magnetic Assisted Capsule Endoscopy|There is only one arm and its does not reach criteria for other options
62663251|NCT02467244||Euthyroid group|Fifty (50) age and sex matched euthyroid subjects will serve as the control group. Control euthyroid subjects will be evaluated once at baseline and after 12 weeks.
62295366|NCT00457405|ACTIVE_COMPARATOR|1|first 7 day treatment with dipyridamol and at least two weeks later 7 day treatment with placebo
62295367|NCT00457405|ACTIVE_COMPARATOR|2|first 7 day treatment with placebo and at least two weeks later 7 day treatment with atorvastatin
62663252|NCT02467244||Hypothyroid group|Fifty (50) hypothyroid patients attending the outpatient department of General Medicine, AIIMS, Bhubaneswar, will be recruited for the present study following inclusion and exclusion criteria.
61911662|NCT02434601|EXPERIMENTAL|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
61911663|NCT02434601|EXPERIMENTAL|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
61911664|NCT02186301|ACTIVE_COMPARATOR|Erlotinib Mono-Therapy|
62295368|NCT06657495|PLACEBO_COMPARATOR|Placebo|Placebo pilulae weighing 5g/pack, after a meal, 1pack/time x 2 times/day
62295369|NCT06657495|EXPERIMENTAL|Investigational product 1|estimated dose:TD0015 pilulae weighing 5g/pack , after a meal, 1pack/time x 2 times/day
62663253|NCT04640402|EXPERIMENTAL|Low-dose vaccine (18-59 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
62295370|NCT06657495|EXPERIMENTAL|Investigational product 2|1.5 times of estimated dose: TD0015 pilulae weighing 7.5g/pack , after a meal, 1pack/time x 2 times/day
62663254|NCT04640402|EXPERIMENTAL|Low-dose vaccine (18-59 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
62663255|NCT04640402|EXPERIMENTAL|High-dose vaccine (18-59 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
62663256|NCT04640402|EXPERIMENTAL|High-dose vaccine (18-59 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
62663257|NCT04640402|EXPERIMENTAL|Low-dose vaccine (60-85 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
62663258|NCT04640402|EXPERIMENTAL|Low-dose vaccine (60-85 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
62663259|NCT04640402|EXPERIMENTAL|High-dose vaccine (60-85 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
62663260|NCT04640402|EXPERIMENTAL|High-dose vaccine (60-85 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
61911665|NCT02186301|EXPERIMENTAL|Rociletinib Mono-Therapy|
61911666|NCT04389437|EXPERIMENTAL|NCD patients (case)|Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.
61911667|NCT04389437|OTHER|Control patients with memory complaint|Normal neuropsychological evaluation during assessment
61911668|NCT04389437|OTHER|Control patients without memory complaint|MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint
61911669|NCT04156542|NO_INTERVENTION|Control|In this school, we collected data throughout the entire study without implementing any intervention.
62295371|NCT02867306|EXPERIMENTAL|ASP1707 and methotrexate (MTX)|On day 1 patients will receive prescribed dose of MTX. On Days 3 through 8, patients will receive ASP1707 (twice daily). On Day 9, patients will receive a single dose in the morning. A single dose of MTX will be coadministered on Day 8.
62295372|NCT01761734|EXPERIMENTAL|text message|receipt of text message
62295373|NCT01761734|NO_INTERVENTION|usual care|usual care
62467625|NCT04529863||Tocilizumab|Reference group
62467626|NCT04529863||Abatacept|Exposure group
62663261|NCT04640402|PLACEBO_COMPARATOR|Low-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
62663262|NCT04640402|PLACEBO_COMPARATOR|Low-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
62663263|NCT04640402|PLACEBO_COMPARATOR|High-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
62663264|NCT04640402|PLACEBO_COMPARATOR|High-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
62663265|NCT04640402|PLACEBO_COMPARATOR|Low-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
62295374|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
62663266|NCT04640402|PLACEBO_COMPARATOR|Low-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
62663267|NCT04640402|PLACEBO_COMPARATOR|High-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
62663268|NCT04640402|PLACEBO_COMPARATOR|High-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
62102262|NCT02807753||Severe Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every 6 months.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
62102263|NCT02807753||Mild/Moderate Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every year.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
62102264|NCT06712290|PLACEBO_COMPARATOR|Corticosteroid|"Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or intra-articular (into the joints) use. It may be used to treat many different types of inflammatory conditions.~In this study, a 2.0cc dose injection of Kenalog-40 will be administered directly into the subacromial space using a 20G needle. 3mL of ropivacaine will be injected along with the steroid (as part of the same injection). Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used."
62295375|NCT00268814|EXPERIMENTAL|MTF, Psycho-education, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
62295376|NCT00268814|EXPERIMENTAL|MTF, Case management, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
62295377|NCT00268814|ACTIVE_COMPARATOR|MTF, Psycho-education, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
62295378|NCT00268814|ACTIVE_COMPARATOR|MTF, Case management, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
62295379|NCT00268814|EXPERIMENTAL|NIT, Psycho-education, Heroin|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
62663269|NCT03624036|EXPERIMENTAL|First Stage Cohort 1: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) will receive conditioning chemotherapy (fludarabine 30 mg/m\^2/day over 30 minutes and cyclophosphamide 500 mg/m\^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 1 x 10\^6 anti-cluster of differentiate 19 (CD19) chimeric antigen receptor (CAR) T cells/kg on Day 0.
62295380|NCT00268814|EXPERIMENTAL|NIT, Case management, Heroin|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
62295381|NCT00268814|ACTIVE_COMPARATOR|NIT, Psycho-education, Methadone|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
62295382|NCT00268814|ACTIVE_COMPARATOR|NIT, Case management, Methadone|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
62295383|NCT01843010|ACTIVE_COMPARATOR|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
62295384|NCT01843010|PLACEBO_COMPARATOR|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
62295385|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
62663270|NCT03624036|EXPERIMENTAL|First Stage Cohort 2: 2 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r CLL will receive conditioning chemotherapy (fludarabine 30 mg/m\^2/day over 30 minutes and cyclophosphamide 500 mg/m\^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 2 x 10\^6 anti-CD19 CAR T cells/kg on Day 0.
62663271|NCT03624036|EXPERIMENTAL|Second Stage Cohort 3: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r CLL and small lymphocytic lymphoma (SLL) with ≤1% malignant cells in peripheral blood or absolute lymphocyte count (ALC) \< 5,000 cells/μL will receive conditioning chemotherapy (fludarabine 30 mg/m\^2/day over 30 minutes and cyclophosphamide 500 mg/m\^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 1 x 10\^6 anti-CD19 CAR T cells/kg on Day 0.
62663272|NCT03624036|EXPERIMENTAL|Second Stage Cohort 4A: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r CLL who previously received two lines of therapy along with ibrutinib with or without anti CD20 antibodies, B-cell lymphoma 2 (BCL-2) and Phosphoinositide 3-kinase (PI3k) inhibitors will receive ibrutinib up to 30 hours prior to leukapheresis along with conditioning chemotherapy (fludarabine 30 mg/m\^2/day over 30 minutes and cyclophosphamide 500 mg/m\^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 1 x 10\^6 anti-CD19 CAR T cells/kg on Day 0.
62663273|NCT03624036|EXPERIMENTAL|Second Stage Cohort 4B: 2 x 10^6 Anti-CD19 CAR T Cells/kg|"Participants with r/r CLL who previously received two lines of therapy along with ibrutinib with or without anti CD20 antibodies, BCL-2 and PI3k inhibitors will receive ibrutinib up to 30 hours prior to leukapheresis along with conditioning chemotherapy (fludarabine 30 mg/m\^2/day over 30 minutes and cyclophosphamide 500 mg/m\^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 2 x 10\^6 anti-CD19 CAR T cells/kg on Day 0.~Upon completion of Cohort 4A, it was determined not to enroll participants in Cohort 4B."
62663274|NCT01492036||Gene Transfer Therapy|Study participants receiving gene therapy product at MD Anderson Cancer Center
62102265|NCT06712290|EXPERIMENTAL|CTM Boost|TM Boost (CTM Biomedical, Miami, FL) is a decellularized Human Cellular and Tissue Based Allograft (HCT/P) derived from placental connective tissue. It is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is regulated as a minimally-manipulated biologic by the FDA and is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is administered applied into the tissue via injection. Participant will undergo a single injection of 2.0cc of the injectable CTM allograft, administered using a 20G needle in the subacromial space. 3mL of ropivacaine will be mixed into the syringe prior to administration of the injection. Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used.
62663275|NCT04925934|EXPERIMENTAL|VIB7734 SC (dosing interval 1)|
62663276|NCT04925934|EXPERIMENTAL|VIB7734 SC (dosing interval 2)|
62102266|NCT05227313|EXPERIMENTAL|Eefooton oral solution|20ml, 3 times per day (daily dose: 60 ml)
62663277|NCT04925934|PLACEBO_COMPARATOR|Placebo SC (dosing interval 3)|
62663278|NCT02331407|EXPERIMENTAL|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
62102267|NCT05227313|PLACEBO_COMPARATOR|Placebo oral solution|oral solution matched placebo
62102268|NCT02008864|PLACEBO_COMPARATOR|Placebo|Wheat
62663279|NCT04924790||COVID-19 Urinary Stone|Patients diagnosed with obstructive urinary stones in the COVID-19 period
62102269|NCT02008864|ACTIVE_COMPARATOR|Senna|Senna
62663280|NCT04924790||PreCOVID-19 Urinary Stone|Patients diagnosed with obstructive urinary stones in the preCOVID-19 period
62663281|NCT00102635|EXPERIMENTAL|4-HPR + FTI|SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.
62663282|NCT05419440|ACTIVE_COMPARATOR|laparoscopic drainage of appendicular abscess|laparoscopic drainage of appendicular abscess laparoscopy drainage of pus ,excision of appendix and putting a drain
62663283|NCT05419440|NO_INTERVENTION|interventional radiology for management of appendicular abscess|insertion of a drain or pig tail under sonar or ct guided
62102270|NCT06288919|EXPERIMENTAL|Erythritol group|
62663284|NCT01537796|EXPERIMENTAL|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
62102271|NCT06288919|ACTIVE_COMPARATOR|Ultrasonic scaler|
62737196|NCT01947283|NO_INTERVENTION|Non-Randomized Controlled Trial Patients|Participants in this arm are patients who did not participate in the Randomized Controlled Trial. One to two patients will be recruited for each enrolled provider (Control and Intervention). One clinical session per patient will be audio recorded. These clinical recordings will be used to provide feedback only for Intervention providers during part 1 of the DECIDE-PC intervention.
62737197|NCT01947283|NO_INTERVENTION|Control Providers|Participants in this arm are providers who were randomized to the Control group. Control providers will not receive the DECIDE-PC intervention.
61911670|NCT04156542|EXPERIMENTAL|5-week Intervention with Post-intervention Data Collection|In this school, we collected baseline data for 5 weeks, implemented the intervention for five weeks, then removed the intervention and collected post-intervention data for five weeks.
61911671|NCT04156542|EXPERIMENTAL|Implement intervention for 15 weeks|In this school, we implemented the intervention on January 11, 2016, the day the study began.
62102272|NCT05611580|NO_INTERVENTION|Control|The participant in the control group receive usual care.
62102273|NCT05611580|EXPERIMENTAL|Intervention|The participants in the intervention group received the chronic disease risk reduction intervention.
62102274|NCT01684046|OTHER|PureMoist - RevitaLens|Opti-Free® PureMoist® MPDS used first, followed by RevitaLens MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
62102275|NCT01684046|OTHER|RevitaLens - PureMoist|RevitaLens MPDS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
61911672|NCT04156542|EXPERIMENTAL|Implement intervention for 12 weeks|In this school, we collected baseline data for three weeks and then implemented the intervention for the remaining twelve weeks.
61911673|NCT04156542|EXPERIMENTAL|Implement intervention for 9 weeks|In this school, we collected baseline data for six weeks and then implemented the intervention for the remaining nine weeks.
62295386|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
62295387|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
62663285|NCT01537796|EXPERIMENTAL|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
62663286|NCT01537796|EXPERIMENTAL|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
62102276|NCT05015972|EXPERIMENTAL|CTA30X UCAR-T treatment|CD19+ R/R B Hematologic Malignancies patients be treated with a single dose of CTA30X UCAR-T cells. Total dose of(5-30)\*10E6/kg cells will be administered at Day 0
62102277|NCT03166319|EXPERIMENTAL|Suspected CNS Vasculitis|Patients with suspected CNS vasculitis will undergo an MRI, including intracranial vessel wall imaging.
62295388|NCT04598542|EXPERIMENTAL|TA injection followed by LOR injection|IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.
62295389|NCT04598542|EXPERIMENTAL|LOR injection followed by TA injection|IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.
62295390|NCT01463254||Surveillance|- a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant
62102278|NCT05516342|EXPERIMENTAL|Experimental: Experimental, LEAD IT! Programming|Participants in the Experimental / LEAD IT! arm will take part in LEAD IT! programming for 18 weeks. The programming will occur twice per week, for a total of 36 sessions.
62102279|NCT05516342|NO_INTERVENTION|No Intervention: Control, Standard Care / Programming|Participants in the Control arm will receive standard care / programming.
62102280|NCT06299605|ACTIVE_COMPARATOR|14-day quadruple regimen|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
62102281|NCT06299605|EXPERIMENTAL|14-day triple regimen|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
62102282|NCT06299605|EXPERIMENTAL|7-day triple regimen|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
62102283|NCT05138172|PLACEBO_COMPARATOR|Sedation without forced air heating temperature management|Sedation without forced air heating temperature management = present standard in sedation during endoscopic retrograde cholangiography (ERC)
62102284|NCT05138172|EXPERIMENTAL|Sedation with forced air heating temperature management|Sedation without forced air heating temperature management = proposed new standard in sedation during endoscopic retrograde cholangiography (ERC)
62102285|NCT01106703|EXPERIMENTAL|PG102 group|
62102286|NCT01106703|PLACEBO_COMPARATOR|placebo group|
62102287|NCT06712784|EXPERIMENTAL|Treatment Packet|3-5 autistic BMC patients who have a history of engaging in challenging behaviors during needle-related procedures who are able to attend simulation sessions at BMC at least 2 times per month. A caregiver and clinician will also be recruited for each child participant.
62102288|NCT06055712|ACTIVE_COMPARATOR|One dose of IV cefazolin|Patients in group A will receive one dose of IV cefazolin and will have no further antibiotic administration.
62102289|NCT06055712|ACTIVE_COMPARATOR|24 hours IV cefazolin|Patients in group B will receive a dose of IV cefazolin every 8 hours for 24 hours (a total of 3 doses).
62102290|NCT06055712|ACTIVE_COMPARATOR|24 hours IV cefazolin plus 5 days oral cephalexin|Patients in group C will receive a dose of IV cefazolin every 8 hours for 24 hours (a total of 3 doses). Additionally, they will be instructed to take 5 days of oral cephalexin.
62102291|NCT04866043||NostraData Database|All prescriptions for lisdexamfetamine dimesylate available in the NostraData database at any time in the last 12 months will be collected in Australia.
62102292|NCT04866043||Physician Survey|Physician will provide de-identified data of participants who have been prescribed lisdexamfetamine dimesylate at least once during the study period for indications other than attention deficit hyperactivity disorder (ADHD) in Australia.
62102293|NCT05293470||Piqray|Patients prescribed with Piqray
62295391|NCT01463254||Prospective|a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment
62295392|NCT03069911|EXPERIMENTAL|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
62295393|NCT03069911|PLACEBO_COMPARATOR|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
62295394|NCT04975958|EXPERIMENTAL|DLT Observation Period I - AN2025 and Atezolizumab|During the DLT Observation I, patients will be treated with AN2025 and Atezolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The starting dose of AN2025 is 50 mg. If tolerated, then a subsequent cohort will escalate to 100 mg. A dose de-escalation cohort to 80 mg may occur if the 100 mg is not well tolerated. The dose of Atezolizumab will remain constant at 1200 mg every 3 weeks (Q3W) for each dose level of AN2025 and in each cohort. Atezolizumab is administered intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
62295395|NCT04975958|EXPERIMENTAL|DLT Observation Period II - AN0025 and Atezolizumab|During the DLT Observation II, patients will be treated with AN0025 and Atezolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The starting dose of AN0025 is 250 mg. If tolerated, then a subsequent cohort will escalate to 500 mg. If 250 mg AN0025 is not tolerated, de-escalate to 125 mg. The dose of Atezolizumab will remain constant at 1200 mg Q3W for each dose level of AN0025 and in each cohort. Atezolizumab is administered intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
62295396|NCT04975958|EXPERIMENTAL|DLT Observation Period III - AN2025, AN0025 and Atezolizumab|The DLT Observation III will be started after safety data review by the investigators and the sponsor of the double combination treatments in Observations I and II. Patients enrolled in Observation III will start with the recommended dose of AN0025 from Observation II, 1200 mg Atezolizumab, and AN2025 will start from 50 mg QD. Patients will be treated with all three study drugs until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The dose of Atezolizumab will be the same (i.e., 1200 mg Q3W) regardless of dose levels of AN2025 and cohorts. Atezolizumab is administered intravenously over 60 minutes every three weeks. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. The dose of AN0025 as determined in Observation II will remain constant for each dose level of AN2025 and each cohort, unless the investigators and the sponsor determine that the toxicity comes from the AN0025 + Atezolizumab combination.
62295397|NCT02443402|EXPERIMENTAL|Sitagliptin|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take sitagliptin. Subjects with stress hyperglycemia (defined as a BG \>180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
62295398|NCT02443402|PLACEBO_COMPARATOR|Placebo|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take a placebo. Subjects with stress hyperglycemia (defined as a BG \>180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
62663287|NCT02582632|EXPERIMENTAL|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks
62663288|NCT04038125|OTHER|Ozurdex Implant|Intravitreal injection of Ozurdex implant
62663289|NCT05913947|EXPERIMENTAL|Lithium|Lithium citrate from 12 mmol increased to result in af 12-hour se-lithium between 0.6 and 0.8 mmol/l
62102294|NCT05947500|ACTIVE_COMPARATOR|Arm 1 (tuvusertib)|Patients receive tuvusertib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI, biopsy, and collection of blood and stool at screening and on study. Patients with documented progression may cross over to Arm 2.
62102295|NCT05947500|EXPERIMENTAL|Arm 2 (tuvusertib, avelumab)|Patients receive tuvusertib PO QD on days 1-14 of each cycle and avelumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI, biopsy, and collection of blood and stool at screening and on study.
62295399|NCT03827161|EXPERIMENTAL|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
62663290|NCT05913947|EXPERIMENTAL|Cariprazine|Cariprazine from 1.5 mg to 3 mg daily in a single dose.
62663291|NCT04144764|EXPERIMENTAL|Workplace-based exercise group|
62295400|NCT03827161|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
62295401|NCT06321575|EXPERIMENTAL|Golazo® Peripheral Atherectomy System|Treatment atherectomy of the peripheral vasculature with the Golazo® Peripheral Atherectomy System.
62663292|NCT04144764|SHAM_COMPARATOR|Control group|
62663293|NCT06142552|EXPERIMENTAL|Prevention and Treatment Group (PPX group)|"Subjects received single and multiple doses of 50 IU/kg FRSW117 at first administration of V1 (D1), V4 (18w), and V7 (50w), and PK samples were collected until 168 h post-administration, respectively.~During prophylaxis, FRSW117 is used for breakthrough therapy if the subject has a breakthrough bleeding event (i.e., a bleeding event during prophylaxis) that requires treatment."
62663294|NCT06142552|EXPERIMENTAL|On Demand/Preventive Treatment Group (On Demand /PPX Group)|The appropriate dose and frequency of administration of FRSW117 is recommended until bleeding events are controlled or returned to pre-bleeding activity.
62663295|NCT06142552|EXPERIMENTAL|Perioperative management|Patients in the PPX and on demand /PPX groups will be allowed to undergo surgery (both major and minor) during the main trial period (prior to 50w), while FRSW117 will be administered perioperatively
62102296|NCT05843656|EXPERIMENTAL|Slow-wave-like transcranial direct current stimulation (tDCS)|tDCS during sleep
62102297|NCT05843656|EXPERIMENTAL|Spindle-like transcranial alternating current stimulation (tACS)|tACS during sleep
62102298|NCT05843656|SHAM_COMPARATOR|Sham stimulation during sleep|Sham
62102299|NCT05843656|ACTIVE_COMPARATOR|Wake in case participants could not take a nap|Active Comparator (with stimulation), in case participants could not take a nap
62102300|NCT04638777|ACTIVE_COMPARATOR|Real rTMS stimulation over M1 and PFC|
62102301|NCT04638777|ACTIVE_COMPARATOR|Real rTMS stimulation over M1 and sham rTMS over PFC|
62102302|NCT04638777|SHAM_COMPARATOR|Sham rTMS over M1 and PFC|
62102303|NCT05926505|PLACEBO_COMPARATOR|Placebo|Placebo is injected subcutaneously once daily for 4 weeks.
62102304|NCT05926505|EXPERIMENTAL|Anakinra|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks.
62102305|NCT04312126||Arm 1|46 healthy young (18-35) volunteers
62102306|NCT04312126||Arm 2|46 healthy older (50-80) volunteers
62102307|NCT04312126||Arm 3|46 chronic (\>6 months post-stroke) stroke patients
62663296|NCT00959452|EXPERIMENTAL|Psychotherapy|
62663297|NCT03974906|EXPERIMENTAL|GDT group|The fluid in GDT group (Goal-directed fluid therapy) will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the LiDCO monitoring system.
62663298|NCT03974906|NO_INTERVENTION|Control group|Patients in the control group received conventional fluid therapy, decided by the attending anesthesiologists based on the patient's hemodynamic condition and responses, to maintain MAP \>65 mm Hg, heart rate 50-100 bpm, and urine output \>0.5 ml/kg/h.
62663299|NCT02233088|EXPERIMENTAL|ELM Group|A 6-month group lifestyle intervention, consisting of 12 weekly and 6 bi-weekly 2-hour sessions. The sessions consist of 30-min physical activity, 30-min meal demonstration, and 60-min group behavioral intervention, with a focus on experiential learning in naturalistic setting. Sessions are facilitated by dietitian/personal trainer and behavioral specialist.
62663300|NCT02233088|OTHER|ELM Classes|A 6-month health education, consisting of 12 weekly and 6 bi-weekly 30-45 min sessions. The sessions consist of didactic classes, with a focus on health education curriculum. Sessions are facilitated by a health educator and medical providers.
62663301|NCT02233088|ACTIVE_COMPARATOR|ELM Individual|A 6-month intervention, that consists of educational manuals on physical activity, diet and stress reduction and recommended 3 medical visits every 3 months for medical counseling and feedback using 5A (Ask, Advise, Assess, Assist, and Arrange) framework . These Metabolic syndrome care materials and provider documentation will be embedded in electronic medical record system, and will be accessible to medical providers by usual means. This enhanced usual care by participant's usual health care provider focuses on metabolic syndrome and lifestyle modifications to reduce the risk of chronic disease.
61911674|NCT04156542|EXPERIMENTAL|Implement intervention for 6 weeks|In this school, we collected baseline data for nine weeks and then implemented the intervention for the remaining six weeks.
61911675|NCT02562118|EXPERIMENTAL|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by Letrozole 2.5mg daily + lenvatinib x 12 weeks (for Part A) or continuous till progression or intolerability (Part B)
62663302|NCT05252975|ACTIVE_COMPARATOR|Supine|Patients undergo supine setup and imaging for radiation planning
61911676|NCT03038477|EXPERIMENTAL|Durvalumab|Patients in Arm A will be given anti-PD-L1 antibody, durvalumab, every 2 weeks for a maximum of 26 doses if there is no radiographic evidence of disease recurrence. For Arm A, one cycle constitutes two durvalumab treatments on Day 1 and Day 15, respectively, repeated every 28 days.
61911677|NCT03038477|NO_INTERVENTION|No Durvalumab|Patients in Arm B will be observed.
61911678|NCT02446171|EXPERIMENTAL|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
62102308|NCT03861728|EXPERIMENTAL|Viral Conjunctivitis Treatment|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with 0.01% Hypochlorous acid
62102309|NCT03861728|PLACEBO_COMPARATOR|Viral Conjunctivitis Placebo|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with Basic Sterile Saline
62102310|NCT04635436|OTHER|Pathologic group|At least 20 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled.
62102311|NCT06712862||Research group|All patients will receive an integrated 18F-FDG PET/MR scan within 2 weeks before surgery.
62102312|NCT06712862||Control Group|All patients will receive integrated 18F-FDG PET/MR plus 99mTc MIBI G-MPI (gated myocardial perfusion imaging) within 2 weeks before surgery.
62102313|NCT01972139|EXPERIMENTAL|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
62102314|NCT01972139|OTHER|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
62102315|NCT04609553|ACTIVE_COMPARATOR|Usual care including ROR|Literacy promotion is a pediatric standard of care. Participants in this group will receive usual care that includes ROR, a primary care literacy promotion intervention.
62102316|NCT04609553|EXPERIMENTAL|ROR plus text messages|In addition to ROR, participants will receive three text messages per week, plus one interactive follow-up message per month, for the study period with scheduled breaks.
62102317|NCT04609553|EXPERIMENTAL|ROR plus text messages plus connection to community resources|In addition to ROR and text messages, participants will be referred to a county-based single point of entry system for referrals to community resources. This system simplifies access to poverty-reducing resources by creating a centralized access point, maintaining an updated data base of resources with existing capacity to support families, and providing case management.
62102318|NCT06000969|EXPERIMENTAL|Conventional group (group C)|Patients will be shifted to 100% Oxygen then; the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
62102319|NCT06000969|EXPERIMENTAL|Ultrasound-guided group (group US)|Patients will be shifted to 100% Oxygen then; the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
62102320|NCT02040844|OTHER|Cat-PAD Treatment 1|Received Cat-PAD Treatment 1 in Study CP007 \[NCT01620762\].No further treatment received in CP007A
62102321|NCT02040844|OTHER|Cat-PAD Treatment 2|Received Cat-PAD Treatment 2 in Study CP007 \[NCT01620762\].No further treatment received in CP007A.
62102322|NCT02040844|OTHER|Cat-PAD Treatment 3|Received Cat-PAD Treatment 3 in Study CP007 \[NCT01620762\]. No further treatment received in CP007A.
62102323|NCT02463162|NO_INTERVENTION|Control|"This group will receive usual care which is to receive no intervention."
62102324|NCT02463162|EXPERIMENTAL|Intervention|This group will receive the intervention which is two Conversations Matter videos about Advance Care Planning and Goals of Care Designations respectively
62102325|NCT05550480|EXPERIMENTAL|Continuous glucose monitoring|"Participants will monitor their glucose levels using CGM with access to interstitial glucose levels continuously throughout the day.~Each study period is preceded by 20 days of masked CGM assessment."
62102326|NCT05550480|NO_INTERVENTION|Self-monitoring of blood glucose|"Participants will monitor their blood glucose levels using a glucometer and a capillary blood sample from finger-pricking. Participants will in addition use masked CGM for the last 20 days of the study period to monitor glucose levels for comparison.~Each study period is preceded by 20 days of masked CGM assessment."
62102327|NCT06629246|ACTIVE_COMPARATOR|control group|The control group will receive conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition, for a treatment period of 7 days.
62102328|NCT06629246|ACTIVE_COMPARATOR|intervention group|The intervention group will receive Pogejiuxin Decoction orally, in addition to the treatment protocol given to the control group.The specific medicinal formula is as follows: Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
62102329|NCT06425055|EXPERIMENTAL|Single arm fixed dose escalation|This is a single arm fixed dose escalation with three dose levels of vonafexor, all QD.
62102330|NCT04968132|ACTIVE_COMPARATOR|Standard care group|This group will receive standard perioperative care, surgical treatment, and pain medications.
62102331|NCT04968132|EXPERIMENTAL|Opioid reduction group|Patients will participate in a multicomponent pathway coordinated by a trained coordinator who will facilitate patient participation and engagement with each interventional component.
62102332|NCT02374957|ACTIVE_COMPARATOR|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
62663303|NCT05252975|EXPERIMENTAL|Prone|Patients undergo prone setup and imaging for radiation planning
62102333|NCT02374957|NO_INTERVENTION|Control|No Cilostazol
62102334|NCT06712407|EXPERIMENTAL|16 mg QD then 8 mg QD|6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
62295402|NCT01453504|ACTIVE_COMPARATOR|Ever-DHAP|Combination of Everolimus and DHAP
62663304|NCT02941497|EXPERIMENTAL|Intensive intervention group|The intensive intervention group participates in development and implementation of the social marketing and health promotion campaign and peer-led campus activities and is assessed for their health-related behaviors. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
62663305|NCT02941497|EXPERIMENTAL|Diffuse intervention group|The diffuse intervention group receives the social marketing and health promotion campaign and participates in the peer-led campus activities and is assessed for their health related behaviors, but is not involved in the design and delivery of the intervention materials and activities. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
62663306|NCT03108001||Lean mothers|Participants that were in Glowing born from Lean mothers.
62663307|NCT03108001||Overweight mothers|Participants that were in Glowing born from Overweight mothers.
62663308|NCT03108001||Obese mothers|Participants that were in Glowing born from Obese mothers.
62295403|NCT01453504|PLACEBO_COMPARATOR|Placebo-DHAP|
62295404|NCT04766853|ACTIVE_COMPARATOR|Dexamethasone+Saline|
62295405|NCT04766853|EXPERIMENTAL|Dexamethasone+Hyaluronic Acid|
62295406|NCT03330327|EXPERIMENTAL|Part 1|Intravenous (IV) infusion of HM12470
62295407|NCT03330327|EXPERIMENTAL|Part 2: Sequence 1|Intravenous (IV) infusion of HM12470
62663309|NCT03108001||Exercise group mothers|Participants that were in Expecting born from mothers that were in the exercise group.
62295408|NCT03330327|EXPERIMENTAL|Part 2: Sequence 2|Intravenous (IV) infusion of HM12470
62295409|NCT04970329|EXPERIMENTAL|Systane|Instill one drop three times a day for one month.
62295410|NCT04970329|EXPERIMENTAL|Tears Naturale 2|Instill one drop three times a day for one month.
62295411|NCT04970329|PLACEBO_COMPARATOR|Placebo|Instill one drop three times a day for one month.
62295412|NCT01221857|EXPERIMENTAL|NiCord|
62295413|NCT02882607|EXPERIMENTAL|Intervention group|Reproductive Health Peer Groups
62295414|NCT02882607|NO_INTERVENTION|Control group|no intervention
62295415|NCT05328050||Achondroplasia|
62295416|NCT05328050||Hypochondroplasia|
62663310|NCT03108001||Non Exercise group mothers|Participants that were in Expecting born from mothers that were in the non- exercise group.
62295417|NCT04684199|ACTIVE_COMPARATOR|Melatonin|"Melatonin~All participants will receive a 5 mg. dose of melatonin before bed for a period of two weeks during study period."
62467627|NCT01903161|EXPERIMENTAL|delayed remote ischemic preconditioning|applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times)
62467628|NCT01903161|PLACEBO_COMPARATOR|control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
62467629|NCT00453362|EXPERIMENTAL|Erlotinib|"Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.~After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans."
62102335|NCT04269889|EXPERIMENTAL|Refractory Diamond-Blackfan Anemia in Eltrombopag|"Participants with Refractory Diamond-Blackfan Anemia will be administered Eltrombopag. Participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth."
62467630|NCT05351918||migrain days|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
62102336|NCT06713668|OTHER|Standard Pacing (75 bpm) then Augmented Pacing (100 bpm)|Backup pacing rate will be set to 75 bpm first then 100 bpm second
62102337|NCT06713668|OTHER|Augmented Pacing Rate (100 bpm) then Standard Pacing (75 bpm)|Backup pacing rate will be set to 100 bpm first then 75 bpm second
62102338|NCT04093570|EXPERIMENTAL|Main Extension Study: ASTX727|The recommended starting dose is the fixed-dose combination (FDC) standard dose (SD) tablet, containing 100 mg cedazuridine and 35 mg decitabine, once daily, Days 1 through 5 in 28-day cycles. Participants should receive ASTX727 at the same dose they received in the last cycle of their parent study; if an adjustment from that dose is required, a different total cycle dose may be employed, as guided by the dose adjustment guidelines in the parent study protocol.
62102339|NCT04093570|EXPERIMENTAL|Substudy Arm A: ASTX727 With High-Calorie/High-Fat Breakfast Meal on Day 4|"Participants received ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants fasted for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants received a high-calorie/high-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and continued to fast for at least 4 hours post-dose.~Participants continued treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they continued to receive ASTX727 unless there was occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study."
62102340|NCT04093570|EXPERIMENTAL|Substudy Arm B: ASTX727 With Low-Calorie/Low-Fat Breakfast Meal on Day 4|"Participants received ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants fasted for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants received low-calorie/low-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and will continue to fast for at least 4 hours post-dose.~Participants continued treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they continued to receive ASTX727 unless there was occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study."
62102341|NCT04355637|NO_INTERVENTION|Control|patients receiving standard of care to treat their pneumonia
62102342|NCT04355637|EXPERIMENTAL|Intervention|patients receiving standard of care to treat their pneumonia + inhaled budesonide
62102343|NCT04358861|EXPERIMENTAL|Experimental group|Nonsurgical Root canal therapy was performed using dental operating microscope in the experimental group.
62295418|NCT04684199|PLACEBO_COMPARATOR|Placebo|"Placebo~All participants will receive a placebo comparative in substance, color, and flavor, before bed for two weeks during the study."
62295419|NCT01564784|EXPERIMENTAL|Arm A|
62295420|NCT01564784|ACTIVE_COMPARATOR|Arm B|
62663311|NCT00799669||MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
62467631|NCT05351918||consumption of analgesics|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
62467632|NCT02378571|NO_INTERVENTION|Usual care|Participants assigned to usual care will also be provided with a GlowCap prior to discharge and will be instructed to take their loop diuretic from this bottle and to notify the study team about prescribed dose changes. This information, however, will solely be used to measure medication adherence and will not be provided to a member of the study team nor to any of the participants' health care providers until the completion of the study period, at least 1 month later. Participants will not be provided with any advice on heart failure adherence.
62663312|NCT00799669||MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
62102344|NCT04358861|ACTIVE_COMPARATOR|Control group|Nonsurgical Root canal therapy was performed without any magnification aid in control group.
62102345|NCT00498186|EXPERIMENTAL|Rotigotine|Rotigotine trans-dermal patch
62102346|NCT06567015|EXPERIMENTAL|STX-241|"Part 1: Dose Escalation and Backfilling components (Phase Ia) Participants will receive oral (PO) STX-241 twice daily (BID) at fixed doses: 10 mg, 20 mg, 40 mg, 80 mg, 120 mg, 180 mg on a continuous dosing schedule~Part 2: Dose Range Optimization (Phase Ib) Participants will receive oral (PO) STX-241 twice daily (BID) at fixed doses selected from Part 1 within the OBD-MTD range for Part 2 on a continuous dosing schedule.~Part 3: Expansion at RP2D (Phase II) Participants will receive oral (PO) STX-241 twice daily (BID) at RP2D dose on a continuous dosing schedule."
62102347|NCT01801319|ACTIVE_COMPARATOR|Stimulation|Libra Deep Brain Stimulation System is implanted and activated post implantation
62102348|NCT01801319|SHAM_COMPARATOR|No Stimulation|The Libra DBS System is implanted and not activated
62102349|NCT06228807||HFpEF patients with metabolic abnormalities|
62102350|NCT06228807||HFpEF patients without metabolic abnormalities|
62295421|NCT01725139|EXPERIMENTAL|Cohort 1-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 (0.25 mg twice daily \[bid\]) or placebo for approximately 8 days (7 to 10 days dosing)
62295422|NCT01725139|PLACEBO_COMPARATOR|Cohort 1-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing)
62295423|NCT01725139|EXPERIMENTAL|Cohort 2-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 1 and which could be escalated or deescalated or repeated from Cohort 1 dosing.
62663313|NCT05396391|EXPERIMENTAL|Phase Ia - Dose escalation|The goal of the Dose Escalation Phase (Part A) is to initially characterize the safety and tolerability of IAP0971, and more specifically to describe the DLTs for each dose level studied and to define the MTD based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.
62663314|NCT05396391|EXPERIMENTAL|Phase Ib - Dose extension|During the Dose Expansion Phase , patients will be enrolled to receive IAP0971 at the MTD established from the Dose Escalation Phase of the study.
61911679|NCT02446171|EXPERIMENTAL|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
62295424|NCT01725139|PLACEBO_COMPARATOR|Cohort 2-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
62295425|NCT01725139|EXPERIMENTAL|Cohort 3- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 2 and which could be escalated or deescalated or repeated from Cohort 2 dosing.
62295426|NCT01725139|PLACEBO_COMPARATOR|Cohort 3-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
61911680|NCT02446171|EXPERIMENTAL|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
62295427|NCT01725139|EXPERIMENTAL|Cohort 4- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 3 and which could be escalated or deescalated or repeated from Cohort 3 dosing.
62295428|NCT01725139|PLACEBO_COMPARATOR|Cohort 4- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
62663315|NCT05396391|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage|After finishing Phase 1, invesigators will discuss with the sponsor about how to carry out the Phase IIa due to the results acheived from Phase I.
61911681|NCT02446171|EXPERIMENTAL|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
61911682|NCT06422234|EXPERIMENTAL|Exergame Group|Participants will exercise 3 days a week for 6 weeks with the Ring Fit Adventure game on Nintendo Switch. The exergames to be played are selected by the physiotherapist and become more difficult as the weeks progress.
61911683|NCT06422234|ACTIVE_COMPARATOR|Game-free Exercise Group|The games selected for the exergame group will be held in a real environment, without games, 3 days a week for 6 weeks.
61911684|NCT06422234|NO_INTERVENTION|Control Group|Participants in this group will continue their normal life routines and the evaluations will be repeated 6 weeks after the first evaluation.
61911685|NCT00331552|EXPERIMENTAL|Arm I|Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
61911686|NCT00663247|PLACEBO_COMPARATOR|B|placebo used as control for comparison with active drug
61911687|NCT00663247|ACTIVE_COMPARATOR|A|
61911688|NCT01459289|ACTIVE_COMPARATOR|leaflet|
61911689|NCT01459289|ACTIVE_COMPARATOR|counseling|
61911690|NCT05934669|EXPERIMENTAL|Intranasal Midazolam|Dose/Concentration: 5mg/ml of 0.4mg/kg Midazolam (max dose 10mg). Adverse side effects include respiratory depression and hypotension. Intranasal Midazolam is standard of care for minimal procedures in pediatric ED.
62467633|NCT02378571|EXPERIMENTAL|Medication adherence telemonitoring|At discharge, participants in the intervention group will be instructed to take their loop diuretic exclusively from the GlowCap in the manner prescribed by their physician. A study team member will review the adherence data on a daily basis (except holidays and weekends) during the first 7 days after discharge, and then on, at minimum, a weekly basis. The study team member will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
61919861|NCT00810927|ACTIVE_COMPARATOR|2|NG-monomethyl-L-arginine (L-NMMA, Clinalfa, Läufelfingen, Switzerland) dose: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/(kg.min) over 15 minutes
62102351|NCT06461156|EXPERIMENTAL|HS-10504|"Subjects with advanced or metastatic NSCLC will be enrolled in dose-escalation stage. Dose escalation of HS-10504 will be done to determine maximum tolerated dose(Dose Escalation Stage).~Depending on data obtained from the dose-escalation stage, dose expansion may proceed with in subjects with advanced or metastatic NSCLC having an EGFR C797S mutation. It can be conducted at the potentially safe and effective doses(Dose Expansion Stage)."
62102352|NCT00817050|ACTIVE_COMPARATOR|Nasonex Followed by Flonase|
62102353|NCT00817050|ACTIVE_COMPARATOR|Flonase Followed by Nasonex|
62102354|NCT00691158|PLACEBO_COMPARATOR|1- Normal Saline|4.7 mls normal saline IV bolus
62102355|NCT00691158|ACTIVE_COMPARATOR|2 Metreleptin|IV Leptin bolus
62102356|NCT00691158|ACTIVE_COMPARATOR|3 Pramlintide|IV Pramlintide bolus at Timpoint +0 and +30 minutes
62102357|NCT00691158|ACTIVE_COMPARATOR|4 Leptin plus Pramlintide|leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes
62102358|NCT04676399|EXPERIMENTAL|Hydrochlorothiazide Pill (12.5 mg twice a day)|"Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Chronic pain~3. Dose(s): 12.5 mg twice per day for 14 days.~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"
62295429|NCT01725139|EXPERIMENTAL|Cohort 5- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 4 dosing.
62467634|NCT03243487|EXPERIMENTAL|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
62467635|NCT03243487|ACTIVE_COMPARATOR|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
62467636|NCT03002077|EXPERIMENTAL|Rapastinel|Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks.
62467637|NCT04475861|EXPERIMENTAL|L-arginine supplements|The enrolled subjects will then be randomized into two groups. Study Group: will take a supplementation pill containing 5 g L-arginine (0.5g/ pill, GNC, USA) All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
61919862|NCT00810927|PLACEBO_COMPARATOR|3|Physiologic saline solution
62102359|NCT04676399|PLACEBO_COMPARATOR|Placebo|"Has no active ingredients but is made to look like the study drug.~2 pills/day for 14 days."
62102360|NCT05581160|EXPERIMENTAL|12-months prospective multicenter longitudinal cohort with the biological samples collection.|This is a single-arm interventional study. After acceptance of the study (signature of the informed consent form), patients are included in the single-arm interventional study for a period of 12 months with follow-up visits every 3 months and intermediate visits in the case of the symptoms presence or sexual contacts with partners having STIs (corresponding to standard care for the PrEP users).
62102361|NCT03425643|EXPERIMENTAL|NAC + Neoadjuvant/Adjuvant Pembrolizumab|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \[75 mg/m\^2, IV; given on cycle day 1\] and either Gemcitabine \[1000 mg/m\^2, IV; given on cycle days 1 and 8\] or Pemetrexed \[500 mg/m\^2, IV; given on cycle day 1\].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \[200 mg, IV; given on cycle day 1\]."
62102362|NCT03425643|PLACEBO_COMPARATOR|NAC + Neoadjuvant/Adjuvant Placebo|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \[normal saline, IV; given on cycle day 1\] in combination with platinum doublet NAC, consisting of cisplatin \[75 mg/m\^2, IV; given on cycle day 1\] and either Gemcitabine \[1000 mg/m\^2, IV; given on cycle days 1 and 8\] or Pemetrexed \[500 mg/m\^2, IV; given on cycle day 1\].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \[normal saline, IV; given on cycle day 1\]."
62102363|NCT06381674|EXPERIMENTAL|Vestibular Therapy Augmented with Audio and Visual Real-Time Biofeedback|This arm will receive 12 sessions over 6-weeks of vestibular therapy for mTBI (concussion) based on clinical practice guidelines augmented with visual and audio real-time biofeedback.
62102364|NCT06381674|ACTIVE_COMPARATOR|Vestibular Therapy-Standard of Care|This arm will receive 12 sessions of vestibular physical therapy over 6-weeks based on clinical practice guidelines for mTBI (concussion).
62102365|NCT06598852|EXPERIMENTAL|TPVB group|Ultrasound-guided thoracic paravertebral nerve block was used for postoperative analgesia after thoracic surgery
62295430|NCT01725139|PLACEBO_COMPARATOR|Cohort 5- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
62467638|NCT04475861|NO_INTERVENTION|nutritional supports|"The enrolled subjects will then be randomized into two groups. Control group: will take a supplementation pill containing 5 g whey protein (5g/ pack, Santosa,Taiwan).~All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians."
62663316|NCT05011435||Users|users of the web-application
62663317|NCT02749890|EXPERIMENTAL|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
62663318|NCT02749890|ACTIVE_COMPARATOR|lixisenatide|"Lixisenatide (AVE0010) is injected subcutaneously (under the skin) once daily. It will be initiated with Dose 1 for 1 week and then continue with Dose 2 for 1 week followed by the maintenance dose of Dose 3 up to the end of treatment period.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
62663319|NCT01102283||Stent Group|
62663320|NCT04027309|ACTIVE_COMPARATOR|Arm A (Midostaurin)|Midostaurin (50 mg BID PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
62663321|NCT04027309|EXPERIMENTAL|Arm B (Gilteritinib)|Gilteritinib (120 mg QD PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
62663322|NCT02667834|EXPERIMENTAL|Social Cognition and Interaction Training (SCIT)|SCIT Social cognition and interaction training program.
62663323|NCT02667834|ACTIVE_COMPARATOR|Therapeutic education program (ETP)|Therapeutic education program
61911691|NCT05934669|EXPERIMENTAL|Intranasal Dexmedetomidine|Dose/Concentration: 100mcg/ml of 2mcg/kg Dexmedetomidine (max dose 100mcg). Adverse side effects include Hypotension and Bradycardia at high dosages. IV Dexmedetomidine is FDA approved and widely used in sedation. IN form isn't FDA approved; however, it has been approved to conduct research studies that have showed its efficacy in pre-operative settings, imaging-CT or MRI, dental procedures, and much more. Specifically, in a pediatric ED setting, Neville et al conducted a study comparing intranasal Dexmedetomidine and intranasal Midazolam prior to laceration repair in a pediatric emergency department and showed safe administration of Dexmedetomidine.
62295431|NCT01725139|EXPERIMENTAL|Cohort 6- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 5 dosing.
62467639|NCT02841033|EXPERIMENTAL|Daratumumab|Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month.
62467640|NCT02562378|EXPERIMENTAL|Experimental arm|Trastuzumab emtansine (T-DM1) will be administered at a fixed dose of 3.6 mg/kg IV on Day 1 every 3 weeks and three cohorts of patients with three different dose levels of conventional non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
62467641|NCT03671447|ACTIVE_COMPARATOR|ICU usual care|control condition
62663324|NCT00731003|EXPERIMENTAL|I|ATD procedure
62663325|NCT00731003|EXPERIMENTAL|II|Oxitriptan
62663326|NCT00731003|PLACEBO_COMPARATOR|III|Amino acid mixture with tryptophan
62663327|NCT00731003|PLACEBO_COMPARATOR|IV|Placebo capsule
62663328|NCT02148627|EXPERIMENTAL|LY3041658 (IV)|Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts.
61911692|NCT05934669|EXPERIMENTAL|Intranasal Ketamine|Dose/Concentration: 100mg/ml of 3mg/kg Ketamine (max dose 100mg). Adverse side effect include Laryngospasm. IV Ketamine is FDA approved and widely used in procedural sedation in pediatric EDs. IN form isn't FDA approved in pediatric population; however, it has also been approved to conduct research studies especially in combination with other medications. Gutherie et al conducted a study demonstrating intranasal Ketamine providing safe and successful anxiolysis in pediatric patients in an ED setting.
62102366|NCT06598852|EXPERIMENTAL|ESPB group|Ultrasound-guided erector spinae muscle block was used for postoperative analgesia after thoracic surgery
62295432|NCT01725139|PLACEBO_COMPARATOR|Cohort 6- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
62295433|NCT04996056|EXPERIMENTAL|TNX-1300|TNX-1300 Intravenous injection 200 mg once over 2 mins
62663329|NCT02148627|EXPERIMENTAL|LY3041658 (SC)|Single dose of LY3041658 administered subcutaneously (SC).
62663330|NCT02148627|PLACEBO_COMPARATOR|Placebo|Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion.
62663331|NCT01718496|ACTIVE_COMPARATOR|Morphine|Patient with advance COPD who will randomly receive single dose oral Morphine
62663332|NCT01718496|PLACEBO_COMPARATOR|Placebo|patient with advanced COPD who will receive Placebo
62663333|NCT00554697||1|
62663334|NCT00554697||2|
62663335|NCT01746875|EXPERIMENTAL|Treatment|aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
62663336|NCT01746875|NO_INTERVENTION|Observation|
62663337|NCT01848808|EXPERIMENTAL|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
62663338|NCT01848808|PLACEBO_COMPARATOR|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
62663339|NCT05688657|EXPERIMENTAL|Lens A|All participants wore Lens A for 15 minutes (Period 1)
62663340|NCT05688657|EXPERIMENTAL|Lens B|All participants wore Lens B for 15 minutes (Period 2)
62663341|NCT01989273||IVC Collapsibility >50% or IVC < 12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility \>50% or IVC diameter less than or equal to 12mm
62663342|NCT01989273||IVC Collapsibility <50% or IVC >12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility \<50% or IVC diameter \>12mm
62663343|NCT02013362|EXPERIMENTAL|Pralatrexate injection|Dietary Supplement: Vitamin B12, Folic Acid
62295434|NCT04996056|OTHER|Usual Care|Usual Care per the Emergency Department protocol for treating Cocaine Intoxication
62295435|NCT06153147||Late effects after nephrotoxic chemotherapies.|3 and 5 year kidney and blood pressure effects after cancer therapy.
62663344|NCT00634556|EXPERIMENTAL|levodopa solution 2mg/ml for i.v. use|"levodopa solution in saline, given intravenously, dosed as per final protocol in Black et al 2003."
62663345|NCT00634556|PLACEBO_COMPARATOR|Placebo|normal saline i.v.
62663346|NCT03918200||Study|Women with unexplained infertility
62663347|NCT03918200||Control|Fertile women who had normal physical and pelvic examination, regular menstrual cycles, don't use hormonal contraceptive, had one child at least.
62663348|NCT06118320||Drug treatment group of uric acid stones（DT group）|Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/packet) were administered to patients with residual stones (\>5 mm in diameter) after surgery or difficult-to-remove stones in the infrarenal calyces for a three-month intervention period. The medication was taken as follows: one packet after breakfast, one packet after lunch, and two packets after dinner. Participants were instructed to abstain from alcohol consumption, smoking, and the use of any probiotics or medications that lower uric acid levels during the therapeutic period.They were also instructed to monitor preprandial urine pH levels to maintain an effective range of 6.2-6.8.
62663349|NCT00303797|EXPERIMENTAL|Treatment (bortezomib, sorafenib tosylate)|"GROUP I (solid tumors-dose-escalation group): Patients receive oral sorafenib twice daily on days 1-21 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~GROUP II (multiple myeloma or chronic lymphocytic leukemia-maximum tolerated dose \[MTD\] group): Patients receive oral sorafenib at the MTD twice daily on days 3-21 of course 1 and on days 1-21 of each subsequent course. Patients also receive bortezomib IV over 3-5 seconds at the MTD on days 1, 4, 8, and 11.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62663350|NCT05331898|EXPERIMENTAL|Education Group|increase the rational drug use of the parents.
62663351|NCT05331898|NO_INTERVENTION|control|PARENTS CANNOT USE RATIONAL MEDICATION ON THEIR CHILDREN
62663352|NCT04611412||1 group|Group I consisted of 17 people (16.83%) with a uniform type of obesity
62663353|NCT04611412||2 group|Group II included 38 children with AO, and 20 of them had normal BLOOD pressure
62663354|NCT03291691||Standard of care: SCI|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided sciatic nerve block. N=15.
62663355|NCT03291691||Standard of care: FEM|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
62663356|NCT03291691||Standard of care: ISB|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided interscalene plexus block. N=15.
62663357|NCT03291691||Standard of care: AXP|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided axillary plexus block. N=15.
62663358|NCT03583346|EXPERIMENTAL|M6495|
62663359|NCT03583346|PLACEBO_COMPARATOR|Placebo|
62663360|NCT04181645|EXPERIMENTAL|SHR-120, Paclitaxel-albumin and Gemcitabine|"Subjects receive SHR-1210 200mg (Day 1) and Paclitaxel-albumin 125mg/m2 (Day1 and Day8) and gemcitabine 1000mg/m2 (Day 1 and Day 8) of each 21-day cycle for at most 6 cycles until documented PD or intolerable adverse event or new anti-cancer treatment or loss to follow-up or death.~Subjects receive SHR-1210 200mg (Day1) to maintain after 6 cycles treatment without PD or listed situation to terminate."
62663361|NCT05392660|EXPERIMENTAL|study arm|assumed upright position during first stage of labor
62663362|NCT05392660|NO_INTERVENTION|control arm|hospital routine care
62663363|NCT01810952|EXPERIMENTAL|Glargine/Lispro Insulin Arm|"Drug: Glargine insulin was administered per above.~Drug: Lispro insulin 0.2 unit/kg/day was administered per above. A coverage dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent was divided between 3 meals. The maximum starting coverage dose was 0.4 units/kg per day.~The prandial dose of lispro was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG is \>200 mg/dL. The prandial dose of lispro was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: prednisone or equivalent dose was determined by severity of exacerbation and clinician's judgement."
61911693|NCT02243423|EXPERIMENTAL|SUPINE group|The surgical table will remain horizontal after intrathecal (spinal) anesthesia injection for cesarean section. Choosing to position the patient supine is the intervention.
61911694|NCT02243423|ACTIVE_COMPARATOR|TILT group|The surgical table will be turned to 15° of left lateral tilt after patients are laid supine after spinal anesthesia injection. The tilted group is the control group.
61911695|NCT03452527|EXPERIMENTAL|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
62663364|NCT01810952|EXPERIMENTAL|Glargine/Lispro/NPH Insulin Arm|"Drugs Glargine and Lispro insulin included similar starting doses of glargine and lispro.~Drug: A coverage dose of NPH insulin 0.1 unit/kg/day for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the glucocorticoid. Maximum starting coverage dose was 0.4 units/kg per day. NPH dose was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was greater than 200 mg/dL. It was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: the dose of prednisone or equivalent glucocorticoid was determined by severity of exacerbation and clinician's judgement."
61911696|NCT03452527|EXPERIMENTAL|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
62295436|NCT00628355|EXPERIMENTAL|lidocaine injection|"Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks"
62467642|NCT03671447|EXPERIMENTAL|"Intervention ERIC"|intervention condition
62663365|NCT05378152|ACTIVE_COMPARATOR|Pipelle biopsy|This group will undergo an endometrial biopsy performed using a Pipelle catheter in the usual manner performed according to the physician either with or without a speculum and with or without a tenaculum. Local anaesthetic block may or may not be used as per clinical judgement.
62663366|NCT05378152|SHAM_COMPARATOR|No Pipelle biopsy|This group will undergo a sham procedure where a speculum is inserted into the vagina and then removed.
62663367|NCT00850642|PLACEBO_COMPARATOR|Placebo|12 day repeat dosing with placebo
62663368|NCT00850642|EXPERIMENTAL|GSK2190915 100mg|12 day repeat dosing treatment phase with 100mg GSK2190915.
62663369|NCT03941821||G/P treatment|Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment
62663370|NCT04991805||Benralizumab|Patients who have received Benralizumab.
62663371|NCT04991805||Other biologics|Patients who have received non benralizumab biologics.
62102367|NCT06598852|EXPERIMENTAL|TPVB combined ESPB group|Ultrasound-guided thoracic paravertebral nerve block combined with erector spinae muscle block was used for postoperative analgesia after thoracic surgery
62102368|NCT06598852|EXPERIMENTAL|ICNB group|Intercostal nerve block was used for postoperative analgesia after thoracic surgery
62102369|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
62102370|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
62102371|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
62102372|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
62102373|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
62663372|NCT04991805||Non-biologic|Patients who have received non biologic drug.
62663373|NCT02904343|EXPERIMENTAL|Group of domestic hemodialysis machine|
62663374|NCT02904343|ACTIVE_COMPARATOR|Group of imported hemodialysis machine|
62102374|NCT05760690|EXPERIMENTAL|Retro-Auricular Single-Site Endoscopic Thyroidectomy group|Patients in the retro-auricular single-site endoscopic thyroidectomy (RASSET) group will receive endoscopic thyroid lobectomy and central lymph node dissection.
62102375|NCT05760690|ACTIVE_COMPARATOR|Transoral Endoscopic Thyroidectomy Vestibular Approach group|Patients in the Transoral Endoscopic Thyroidectomy Vestibular Approach group will receive endoscopic thyroid lobectomy and central lymph node dissection.
62467643|NCT01820208|PLACEBO_COMPARATOR|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
62467644|NCT01820208|EXPERIMENTAL|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
62467645|NCT01526330|EXPERIMENTAL|Group A|
62663375|NCT05502887||Researched Group|All patients with newly diagnosed or preexistent hematological neoplasms at participating centers are intended to be registered within EndoCDO-H. Prior to inclusion, patients have to give their written informed consent.
62663376|NCT05690243|EXPERIMENTAL|Group therapy delivered via video telehealth|Nine sessions of 60 min each group therapy delivered via telehealth
62663377|NCT05690243|OTHER|Group therapy delivered via video telehealth - wait list control|Nine sessions of 60 min each group therapy delivered via telehealth after a waiting period.
62663378|NCT05594199|EXPERIMENTAL|Intervention Arm: Virtual Group|The intervention will involve participating in the study's virtual smoking cessation program. This program consists of 2 components: an e-learning module and a tailored email messaging program based on the participant's motivation to quit smoking and their Fagerstrom test for nicotine dependence score.
62663379|NCT05594199|NO_INTERVENTION|Control Arm: Standard Care|"This arm will receive standard care which may or may not include brief advice to quit smoking from any of the healthcare providers.~Providing smoking cessation intervention is not mandatory in standard care and may not be provided."
62102376|NCT05760690|ACTIVE_COMPARATOR|Transareola Endoscopic Thyroidectomy group|Patients in the Transareola Endoscopic Thyroidectomy group will receive endoscopic thyroid lobectomy and central lymph node dissection.
62102377|NCT00507208|EXPERIMENTAL|Dynasplint|Participants randomized to this arm will be treated with the Dynasplint Trismus System
62663380|NCT03626675|OTHER|study group|"They will be subjected to:~Preoperative A-complete ophthalmic examination will be done for every patient; B- Biometric parameters measured with the AS-OCT C- Medical fitness for all patients D- Informed consent will be obtained from all patients after through explanation of operation and its potential benefits and risks.~Surgery combined Phaco trabeculectomy~Post operative:~-Follow-up examinations will be performed for every patient at 1day, 1 week, 1 and 3 months postoperatively.~and biometric parameters measured with the AS-OCT before and after the surgery will be used to collect the data.~-The data will be managed and analysed with confidentiality by scientifically qualified persons"
62295437|NCT00628355|EXPERIMENTAL|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
62295438|NCT01943656|EXPERIMENTAL|Tobii™ Eyegaze System|Single arm, open label study.
62663381|NCT01405911|PLACEBO_COMPARATOR|Placebo|Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
62663382|NCT01405911|EXPERIMENTAL|Sitagliptin 25 mg|Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
62295439|NCT01212445|EXPERIMENTAL|PEG + E, 13.125 g|Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time
62102378|NCT00507208|ACTIVE_COMPARATOR|Control|Participants randomized to this arm will use tongue depressors for 3 months and if there is no improvement in their mouth opening at this timepoint, they will crossover to the Dynasplint Trismus System
62102379|NCT02862327|ACTIVE_COMPARATOR|intravenous dexamethasone|intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia
62467646|NCT01526330|EXPERIMENTAL|Group B|
62102380|NCT02862327|PLACEBO_COMPARATOR|intravenous placebo|intravenous injection of 2ml of NaCl 0.9% during regional anesthesia
62467647|NCT01526330|EXPERIMENTAL|Group C|
62467648|NCT01526330|PLACEBO_COMPARATOR|Group D|
62467649|NCT05662865|EXPERIMENTAL|Single, Experimental Group|SGLT2i + adaptive study diet of progressive dietary carbohydrate reduction
62467650|NCT00175058|NO_INTERVENTION|1|Control - Patients with acute anterior myocardial infarction revascularized by means of PCI with stenting within 6 hours of onset of symptoms, no experimental intervention
62467651|NCT00175058|EXPERIMENTAL|2|AO Therapy group - anterior acute myocardial infarction patients revascularized by means of PCI with stenting within 6 hours of symptom onset, receiving adjunctive infusion of hyperoxemic blood into target coronary artery for 90 minutes post-PCI.
62295440|NCT01212445|EXPERIMENTAL|PEG + E, 26.25 g|Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time
62663383|NCT01405911|EXPERIMENTAL|Sitagliptin 50 mg|Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.
61911697|NCT01579812|EXPERIMENTAL|Metformin|
62295441|NCT01212445|EXPERIMENTAL|PEG + E, 39.375 g|Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time
62102381|NCT04015986|EXPERIMENTAL|Intervention arm|MDCF-2 prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth).
62102382|NCT04015986|ACTIVE_COMPARATOR|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
62295442|NCT00680030||1|
62467652|NCT03352271|EXPERIMENTAL|Individualized Incremental hemodialysis|ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.
62295443|NCT03590860|EXPERIMENTAL|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
62295444|NCT03590860|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo matching LY3322207 administered SC
62295445|NCT03590860|EXPERIMENTAL|LY3322207 (Part B)|LY3322207 administered SC once weekly
62295446|NCT03590860|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
62295447|NCT03590860|EXPERIMENTAL|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
62467653|NCT03352271|ACTIVE_COMPARATOR|Thrice weekly dialysis|ESRD patients initiating a conventional thrice weekly hemodialysis program
62467654|NCT04704505|EXPERIMENTAL|Bipolar Androgen Therapy in addition to RADium-223 (RAD)|Participants will receive Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD).
62467655|NCT03949179||Pain and Disability Drivers Management model|Participating clinicians will use the PDDM model to guide assessment and treatment of their patients for a 6-weeks period.
62467656|NCT03437694|EXPERIMENTAL|Medication Optimization Intervention|This group will represent those participants whose medical records have been provided to the pharmacist.
62467657|NCT03437694|ACTIVE_COMPARATOR|Medication Optimization Control|This group will represent those participants whose medical records have not been provided to the pharmacist.
62663384|NCT03274297|EXPERIMENTAL|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
62663385|NCT03274297|EXPERIMENTAL|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
61911698|NCT05424783||Genomic Prostate Score assay and multi-parametric MRI of the prostate|Men with newly diagnosed NCCN very low to favorable intermediate risk prostate cancer will be enrolled at their post biopsy urologist visit. Once enrolled, participants will have their prostate tissue sent off for their Genomic Prostate Score assay and men will undergo a prostate MRI to evaluate for potentially missed clinically significant prostate cancer. In a subsequent urologist visit, participants will choose their treatment choice. Men who choose active surveillance for their primary treatment choice will be monitored per clinical routine by PSA, digital rectal exam, and active surveillance prostate biopsy in 12-18 months. After month 6, men will be followed through their electronic medical records system to track adherence to their 12-18 month active surveillance prostate biopsy.
61911699|NCT01924429|EXPERIMENTAL|On Drug then off Drug|Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
62102383|NCT06632132|EXPERIMENTAL|Hemodialysis nurses receiving antimicrobial resistance training|Hemodialysis nurses received educational program about antimicrobial resistance and uses in hemodialysis units. The program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities.
62102384|NCT06632132|NO_INTERVENTION|Control group|they were no given any educational content about the study intervention during the study. However, they were provided with the educational material received by experimental group via Chatbot software after evaluation completed
62467658|NCT03649841|ACTIVE_COMPARATOR|Arm I (ADT, abiraterone, prednisone)|Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
62467659|NCT03649841|EXPERIMENTAL|Arm II (ADT, abiraterone, prednisone, radiation therapy)|Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
62467660|NCT03265977|EXPERIMENTAL|H56:IC31|5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56
62663386|NCT03274297|EXPERIMENTAL|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
62663387|NCT03274297|EXPERIMENTAL|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
62102385|NCT05660967|EXPERIMENTAL|Epcoritamab monotherapy|
62102386|NCT05660967|EXPERIMENTAL|Epcoritamab in combination with lenalidomide|
62102387|NCT04098250|EXPERIMENTAL|Erenumab|140 mg erenumab
62102388|NCT04098250|PLACEBO_COMPARATOR|Placebo|placebo comparator
62102389|NCT06429527|EXPERIMENTAL|Remote follow-up|"One week postoperatively, the participants use the WHOeyes app to test their uncorrected visual acuity and fill in a self-made discomfort identification questionnaire.~Visit the clinics for review 1 day and 1 month post-cataract surgery."
62102390|NCT06429527|NO_INTERVENTION|Usual care|Participants routinely returned to the hospital for review 1 day, 1 week and 1 month post-cataract surgery
62295448|NCT05574140||Patient Population|Participants diagnosed with Generalized Anxiety Disorder
62295449|NCT05574140||Healthy Volunteers|Participants with no pre-existing conditions and who are on no medications.
62467661|NCT03265977|PLACEBO_COMPARATOR|Placebo|Normal saline, 0.5 mL IM, Days 0 and 56
62663388|NCT04505917|EXPERIMENTAL|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
62663389|NCT04505917|ACTIVE_COMPARATOR|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
61911700|NCT01924429|EXPERIMENTAL|Off drug then on drug|Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
62663390|NCT04505917|PLACEBO_COMPARATOR|placebo|Placebo Comparator: placebo 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
61911701|NCT04743570|PLACEBO_COMPARATOR|Placebo treatment|Placebo consisting of Ringer's lactate in matched volume to active drug is added to 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
62102391|NCT06294951||BPS group|Patients with BPS (subject to current diagnostic criteria and clinical guidelines).
62102392|NCT06294951||Control group|Patients with symptoms of bladder pain and evidence of current urinary tract infection.
62102393|NCT02492594||Pediatric patients with febrile neutropenia|Peripheral blood sampling - samples from 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed
62102394|NCT02492594||Adult patients with febrile neutropenia|Peripheral blood sampling - samples from 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed
62295450|NCT06590116|OTHER|Patients|Patients seeking physical therapy for low back pain
62295451|NCT06590116|OTHER|Physical therapists|Physical therapists treating enrolled patients
62295452|NCT05900115|EXPERIMENTAL|Web-based intervention|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
62295453|NCT05900115|ACTIVE_COMPARATOR|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
62663391|NCT04926233||COPD patients from US IBM Marketscan database|
62663392|NCT04926233||COPD patients from UK CPRD GOLD database|
62663393|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
62663394|NCT00740740||1|Patients scheduled for elective conventional aneurysm repair
62663395|NCT00740740||2|Patients scheduled for emergent conventional aneurysm repair
62295454|NCT04492904||COVID-19 Positive (Case)|Participants who were present for COVID-19 screening and their test results will later indicate positive of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
62467662|NCT03991260||The tested injected doses of 99mTc- ADAPT6 500 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 500 µg. Subjects withdrawn from the study for any reason will be replaced.
62467663|NCT03991260||The tested injected doses of 99mTc- ADAPT6 1000 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 1000 µg. Subjects withdrawn from the study for any reason will be replaced.
62467664|NCT02087514|ACTIVE_COMPARATOR|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
62467665|NCT02087514|EXPERIMENTAL|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
62467666|NCT02087514|EXPERIMENTAL|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
62467667|NCT02087514|EXPERIMENTAL|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
62467668|NCT02087514|EXPERIMENTAL|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
62663396|NCT00740740||3|Patients scheduled for aortic bypass surgery
61911702|NCT04743570|ACTIVE_COMPARATOR|Methylnaltrexone treatment|0.15 mg/kg methylnaltrexone will be dissolved in 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
61911703|NCT02984072|ACTIVE_COMPARATOR|Menthol|5% menthol in aqueous cream (Dermacool Forte)
61911704|NCT02984072|PLACEBO_COMPARATOR|Placebo|Aqueous cream
62102395|NCT06627738|EXPERIMENTAL|Experimental Arms|After their radiochemotherpy (Taxcis protocol), the eligible patients will be included in the study and will have a Cyberknife boost (5 sessions of 8 Gray, over 2 weeks maximum). They will have follow-up visits for 2 years post-treatment. Then, their disease and survival status will be recorded until 5 years post-treatment.
62102396|NCT01366196|PLACEBO_COMPARATOR|Control Group (C)|Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.
61911705|NCT02133170|ACTIVE_COMPARATOR|Psychopharmacological + MBCT|psychopharmacological treatment plus Mindfulness Based Cognitive Therapy (MBCT)
61911706|NCT02133170|ACTIVE_COMPARATOR|psychopharmacological + psychoeducation|psychopharmacological treatment plus structured group psychoeducation;
61911707|NCT02133170|OTHER|Psychopharmacological treatment.|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
62102397|NCT01366196|EXPERIMENTAL|Pregabalin Group (P)|Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.
62102398|NCT05584124|EXPERIMENTAL|Real M1 High Frequency rTMS|Participants will be randomly assigned to receive high-frequency repetitive transcranial magnetic stimulation (rTMS) to the top of their head for approximately 40 minutes.
62102399|NCT05584124|EXPERIMENTAL|Real LDLPFC High Frequency rTMS|Participants will be randomly assigned to receive high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left frontal part of their head for approximately 40 minutes.
62295455|NCT04492904||COVID-19 Negative/Other respiratory diseases (Control)|Participants who were present for COVID-19 screening and their test results will later indicate negative of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days
62295456|NCT03806244|NO_INTERVENTION|PREOP|Navigation without intraoperative acquisition of images: Use of conventional preoperative images (CT-MRI) to establish intraoperative navigation.
62467669|NCT02087514|EXPERIMENTAL|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
62467670|NCT02235662|EXPERIMENTAL|TFV IVR|TFV IVR is an intravaginal ring 55.0 mm in diameter, consisting of single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. Used for one month, the IVR delivers 8-10 mg/day TFV.
62663397|NCT05731596|ACTIVE_COMPARATOR|Group 1 (Rosuvastatin group)|Patients will receive Rosuvastatin 20mg/day orally for 3 months
62663398|NCT05731596|EXPERIMENTAL|Group 2 (CoQ10 group)|Patients will receive Coenzyme Q10 100 mg/day orally for 3 months
62663399|NCT01388426|EXPERIMENTAL|7eye( Panoptx)™ Moisture chamber glasses|7eye( Panoptx)™
62663400|NCT01995201|EXPERIMENTAL|Part 1: All patients|
62663401|NCT01995201|EXPERIMENTAL|Part 2 A: Sustained clinical remission|
62663402|NCT01995201|EXPERIMENTAL|Part 2 B: Low disease activity|
62663403|NCT00592111|EXPERIMENTAL|1|
62663404|NCT00592111|EXPERIMENTAL|2|
62663405|NCT00592111|EXPERIMENTAL|3|
62663406|NCT03763981|ACTIVE_COMPARATOR|prolene seton|Prolene thread will be used as seton treatment for perianal fistulas
62663407|NCT03763981|ACTIVE_COMPARATOR|silk seton|Silk thread will be used as seton treatment for perianal fistulas
62663408|NCT01870037|PLACEBO_COMPARATOR|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms \[µg\] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.
62663409|NCT01870037|EXPERIMENTAL|hMaxi-K 16000 µg|Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
62663410|NCT01870037|EXPERIMENTAL|hMaxi-K 24000 µg|Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
62663411|NCT00601627|EXPERIMENTAL|Panitumumab|"Chemotherapy concurrent with radiation: Radiation 5 days per week for 5½ weeks; Panitumumab on days 1, 15, and 29 of radiation therapy 5-fluorouracil (5FU) continuous infusion, starting on day 1 and through last day of radiation.~4-6 weeks after completion of radiation therapy: Gemcitabine on days 1, 8, and 15 of each cycle, for 3 cycles; Panitumumab on days 1 and 15 of each cycle, for 3 cycles. Maintenance therapy: Panitumumab on days 1 and 15 of each cycle, for 6 cycles."
62663412|NCT01767285|EXPERIMENTAL|Immediate Postpartum Etonogestrel Implant|Etonogestrel implant placed in the hospital after delivery, before discharge home.
62102400|NCT05584124|SHAM_COMPARATOR|Sham rTMS|Participants will be randomly assigned to receive sham/placebo repetitive transcranial magnetic stimulation (rTMS) to the their head for approximately 40 minutes. This is a control condition.
62102401|NCT02148809|EXPERIMENTAL|Blood Volume Analysis, Fluid|Preop I-131 is given and the BVA is performed, 6 hours after surgery the same procedure will be done to compare the TBV at both points
62102402|NCT00828919|EXPERIMENTAL|Treatment|Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study
62663413|NCT01767285|ACTIVE_COMPARATOR|Delayed postpartum etonogestrel implant|These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
62102403|NCT02074566|OTHER|2 times 1|PVI will be performed using a cryoballoon ablation application time of 2 times 1 minute
62102404|NCT02074566|OTHER|2 times 2|PVI will be performed using a cryoballoon ablation application time of 2 times 2 minutes
62102405|NCT02074566|OTHER|2 times 3|PVI will be performed using a cryoballoon ablation application time of 2 times 3 minutes
62102406|NCT02197689|EXPERIMENTAL|SMS Medication Reminder|763 patients were assigned to experimental group
62102407|NCT02197689|NO_INTERVENTION|No SMS Reminder|435 patients were assigned to control group as no SMS reminder
62467671|NCT02235662|EXPERIMENTAL|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm: a longer segment containing white TFV paste and a shorter one (20 mm) with a white LNG core. Used for one month, the IVR delivers 8-10 mg/day TFV and 20 μg/day LNG.
62467672|NCT02235662|PLACEBO_COMPARATOR|Placebo Intravaginal Ring|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month.
62467673|NCT01684657|PLACEBO_COMPARATOR|Placebo|This is the comparator. Placebo will be matched to color, taste, size, and smell.
62467674|NCT01684657|EXPERIMENTAL|Asenapine|This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
62467675|NCT02744820|PLACEBO_COMPARATOR|Cohort 1 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
62467676|NCT02744820|PLACEBO_COMPARATOR|Cohort 2 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
62467677|NCT02744820|PLACEBO_COMPARATOR|Cohort 3 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
62467678|NCT02744820|PLACEBO_COMPARATOR|Cohort 4 (Part 2)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
62467679|NCT00433147|EXPERIMENTAL|Afegostat tartrate 25 milligrams (mg) once per day|Afegostat tartrate was administered orally during the 4-week treatment period.
62663414|NCT02361931|EXPERIMENTAL|Treatment group (erythropoietin)|10 patients receive RMD-G1 (gel with 2000 IU/ml of erythropoietin) as an adjunct therapy to standard of care (SOC). Topical application on wound bed, daily for 12 weeks.
62102408|NCT04774224|ACTIVE_COMPARATOR|Baricitinib|Baricitinib is an oral JAK1/JAK2-selective inhibitor. Dosage: The dose of baricitinib is 1 x 4mg tablet once daily Duration of administration: 48 weeks Mode of administration: Orally, with or without food
62102409|NCT04774224|PLACEBO_COMPARATOR|Placebo|One placebo tablet once daily for a duration of 48 weeks. Placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
62102410|NCT01605331|EXPERIMENTAL|sustained-release recombinant human GH (SR-rhGH)|12-week subcutaneous administration, 2mg/week
62102411|NCT02121574||Zero-flux and ingestible thermometer|Ingestion of a capsule thermometer pre-operatively Attachment of a zero flux temperature electrode intraoperatively Standard oesophageal thermometer
62102412|NCT03354390|EXPERIMENTAL|Level 1 is 1 x 10^6 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight|Participants with Metastatic Clear Cell Renal Cell Carcinoma will receive a lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by an infusion of 1 x 10\^6 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight. Following infusion of HERV-E T-cells, participants will receive IL-2 (aldesleukin) which will be administered intravenously twice a day for 14 doses.
62467680|NCT00433147|EXPERIMENTAL|Afegostat tartrate 150 mg once per day|Afegostat tartrate was administered orally once per day during the 4-week treatment period.
62663415|NCT02361931|PLACEBO_COMPARATOR|Control group (standard of care)|10 patients receive SOC alone daily for 12 weeks. A moisturizing gel is applied on wound bed as a part of SOC.
62467681|NCT00433147|EXPERIMENTAL|Afegostat tartrate 150 mg once every four days|Afegostat tartrate was administered orally once every 4 days during the 4-week treatment period.
62467682|NCT00433147|EXPERIMENTAL|Afegostat tartrate 150 mg once every seven days|Afegostat tartrate was administered orally once every 7 days during the 4-week treatment period.
62467683|NCT02669745||Women of Chinese Descent|Females of Chinese descent, aged 18 year to 70 year, diagnosed with Stage 1 or Stage 2 (excluding those involving more than 3 lymph nodes) breast cancer.
62467684|NCT05998265|EXPERIMENTAL|FeetMe Rehabilitation arm|
62467685|NCT05998265|ACTIVE_COMPARATOR|Conventional physiotherapy arm|
62663416|NCT01015196|ACTIVE_COMPARATOR|Idarubicine|
62663417|NCT01015196|EXPERIMENTAL|Daunorubicine|
62102413|NCT03354390|EXPERIMENTAL|Level 2 is 5 x 10^6 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight|Participants with Metastatic Clear Cell Renal Cell Carcinoma will receive a lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by an infusion of 5 x 10\^6 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight. Following infusion of HERV-E T-cells, participants will receive IL-2 (aldesleukin) which will be administered intravenously twice a day for 14 doses.
62102414|NCT03354390|EXPERIMENTAL|Level 3 is 1 x 10^7 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight|Participants with Metastatic Clear Cell Renal Cell Carcinoma will receive a lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by an infusion of 1 x 10\^7 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight. Following infusion of HERV-E T-cells, participants will receive IL-2 (aldesleukin) which will be administered intravenously twice a day for 14 doses.
62102415|NCT03354390|EXPERIMENTAL|Level 4 is 5 x 10^7 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight|Participants with Metastatic Clear Cell Renal Cell Carcinoma will receive a lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by an infusion of 5 x 10\^7 HERV-E TCR transduced CD8+/CD34+ enriched T-cells per kg body weight. Following infusion of HERV-E T-cells, participants will receive IL-2 (aldesleukin) which will be administered intravenously twice a day for 14 doses.
62102416|NCT05877638|EXPERIMENTAL|SynePure with Catasyn|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel
62102417|NCT05877638|ACTIVE_COMPARATOR|Silvadene|Routine care wound rinse and Silvadene cream
62102418|NCT05507203|EXPERIMENTAL|ABX464 50mg|Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
62663418|NCT02515253|EXPERIMENTAL|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
62663419|NCT02515253|OTHER|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
62663420|NCT06178224||Participants (qualified)|This arm consists of participants who are able to collect all sample types No intervention is administered
62663421|NCT01132755|EXPERIMENTAL|Patients who require diagnostic laparoscopy|Diagnostic peritoneal lavage will be performed at the time of laparoscopy utilizing a Veress needle/Seldinger technique to insert a peritoneal dialysis catheter. This is not a new technique. The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon.
62102419|NCT05507203|EXPERIMENTAL|ABX464 25mg|Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
62102420|NCT05507203|PLACEBO_COMPARATOR|Placebo|Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
62295457|NCT03806244|EXPERIMENTAL|PEROP|Navigation with intraoperative acquisition of images: Intraoperative acquisition (robotic c-Arm) of images to establish intraoperative navigation.
62295458|NCT06601712|EXPERIMENTAL|Arm A|All PDMC drugs will be given to the caregivers at discharge with reminder support
62295459|NCT06601712|EXPERIMENTAL|Arm B|All PDMC drugs will be given by the community health workers (CHWs) to the caregivers at home, with reminder support
62295460|NCT06601712|ACTIVE_COMPARATOR|Arm C|All PDMC drugs will be given to the caregivers at discharge with no other adherence support approaches (no reminder)
62295461|NCT06484166|ACTIVE_COMPARATOR|Trolamine (Biafine)|Trolamine (Biafine; Genmedix Ltd, France) is cream packed in an opaque white bottle of 50g each, which is the same as the experimental group in appearance.
62663422|NCT02752477|EXPERIMENTAL|Opioid-free anesthetic (OFA) group|
62295462|NCT06484166|EXPERIMENTAL|Fullerene cream|Fullerene cream is cream packed in an opaque white bottle of 50g each, which is the same as the control group in appearance.
62295463|NCT05676710|EXPERIMENTAL|Experimental|PI3K inhibitors
62663423|NCT02752477|ACTIVE_COMPARATOR|Traditional Anesthesia (TA) group|
62663424|NCT02331498|OTHER|A Pazopanib|Open label study with one group
62663425|NCT02871362|EXPERIMENTAL|IQP-AS-118|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
62663426|NCT02871362|PLACEBO_COMPARATOR|Placebo|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
62663427|NCT01449032|ACTIVE_COMPARATOR|MSC|Adipose derived stem cells
62663428|NCT01449032|PLACEBO_COMPARATOR|Saline|
62295464|NCT03856957|EXPERIMENTAL|Endocuff colonoscopy|Colonoscopy performed with Endocuff
62102421|NCT05483842|EXPERIMENTAL|Reiki Group|Personal Information Form (PIF) and Beck Anxiety Scale (BAS) were administered to the Reiki group through face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After the pre-tests of the patients were completed, the application was made under the guidance of a researcher with a Usui Reiki Master \& Teacher degree and by a researcher with Reiki II training. In accordance with the Reiki Practice Protocol, an empty and silent room was selected in the hospital. Reiki was applied one-on-one to energy centers (crown chakra, forehead chakra, throat chakra, heart chakra, solar plexus, sacral region, root chakra, knees, ankle and feet) for 30 minutes. On the second day, 30 minutes of distant Reiki was applied. BAS was administered 1 week later; ECG was taken and biochemistry blood was taken.
62663429|NCT05491889||HCC patients with PPVT after TACE|determine frequency of short-term mortality (\< 3month) among HCC patients with PPVT after TACE, and to explore its predictors.
62663430|NCT00258661|EXPERIMENTAL|Osteopathic Manipulative Treatment|10-minute standardized OMT protocol + 5-minute nonstandardized component, twice daily for duration of hospitalization
62663431|NCT00258661|SHAM_COMPARATOR|Light-touch Treatment|10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs, twice daily for duration of hospitalization
62102422|NCT05483842|PLACEBO_COMPARATOR|Sham Reiki Group|Personal Information Form (PIF) and Beck Anxiety Scale (Scale) were administered to this group by face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After the pre-tests of the patients were completed. The Sham Reiki group was practiced by a student nurse who did not receive Reiki training by imitating the hand positions used in Reiki practice. Before the applications, the researcher, the student was told about aura equalization and chakras, the student only imitated gestures and facial expressions, but did not give Reiki energy to the patients. BAS was administered 1 week later; ECG was taken and biochemistry blood was taken.
62102423|NCT05483842|NO_INTERVENTION|Control Group|Personal Information Form (PIF) and Beck Anxiety Scale (BAS) were administered to this group by face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After 1 week, BAS, blood tests and ECG have applied again.
62102424|NCT00001247||1|Individuals with schizophrenia-spectrum illness from the community.
62663432|NCT00258661|NO_INTERVENTION|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
62663433|NCT02011334|EXPERIMENTAL|RoActemra/Actemra|
62663434|NCT01182961|EXPERIMENTAL|Treadmill +virtual reality training|
62295465|NCT03856957|PLACEBO_COMPARATOR|Conventional colonoscopy|Colonoscopy performed without any device
62295466|NCT04080206|EXPERIMENTAL|188-0551 Spray|Investigational Topical Spray Product
62295467|NCT04080206|ACTIVE_COMPARATOR|Reference Listed Drug (RLD)|FDA Approved Topical Cream
62295468|NCT02570451||undergoing any elective SDA surgical procedure|500 patients Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
62467686|NCT01442857|EXPERIMENTAL|Block technique|"Active Comparator: Arm 1: catheter injection 40 ml of LA through the catheter~Active Comparator: Arm 2: catheter and transarterial injection 20 + 10 ml transarterial block and 10 ml through the catheter"
62102425|NCT06255444||Overweight/Obese BMI|This group consists of overweight and obese patients diagnosed with cervical radiculopathy by a neurosurgeon.
62102426|NCT06255444||Normal BMI|This group consists of patients with normal BMI who were diagnosed with cervical radiculopathy by a neurosurgeon.
62102427|NCT06713434|EXPERIMENTAL|Experimental (Only Arm)|In this study, there are two main phases rather than separate arms. During the Observational Phase, no intervention is administered and subjects' natural history of ocular manifestations is documented. In the Treatment Phase, all subjects receive ELK-003 eye drops to assess their effect on ocular sign and symptons. Each subject serves as their own control by comparing outcomes between the Observational and Treatment Phases.
62102428|NCT05893303|EXPERIMENTAL|PNF Technique Group|Participants in this group will receive PNF techniques and gait training 3 times per week for 8 weeks
62102429|NCT05893303|ACTIVE_COMPARATOR|Gait Training Group|Participants in this group will receive only gait training 3 times per week for 8 weeks
62102430|NCT00331214|SHAM_COMPARATOR|Placebo|placebo patch for 6 months
62102431|NCT00331214|EXPERIMENTAL|Testosterone|Testosterone patch
62102432|NCT05989048|EXPERIMENTAL|Zavegepant|Zavegepant intranasal 10 mg
62102433|NCT05989048|PLACEBO_COMPARATOR|Placebo|Placebo
62102434|NCT06147830||Cohort A - Historical Cohort|Cohort A will comprise of approximately 2000 patients admitted for major bleedings in the presence of Factor Xa inhibitor treatment during a defined period (up to 2 years prior to commencing enrolment of patients in Cohort B). Patients who developed major bleeding in the presence of Factor Xa inhibitor treatment while already admitted in hospitals will also be included. Patients may or may not have received a reversal/replacement therapy. Patients are followed in medical charts from admission to discharge.
62663435|NCT01182961|ACTIVE_COMPARATOR|Treadmill alone|
62663436|NCT01182961|ACTIVE_COMPARATOR|standard of care exercise group|
62663437|NCT05855720||Intervention Group (IG)|Patients being treated in FIT model project
62663438|NCT05855720||Control Group (CG)|Patients being treated in standard care (control hospitals)
62663439|NCT05570422|EXPERIMENTAL|dose-escalation single arm|"Dose-escalation single arm, open label study. All eligible subjects will receive external beam radiotherapy (EBRT) with cisplatin (40 mg/m2) intravenously (IV) once weekly for 5 weeks (sixth dose optional) followed by image-guided brachytherapy (BT).~KRC-01 will be dosed intratumorally within 2 hours prior to EBRT starting from second week of EBRT.~There are two cohorts (n=5 per cohort) Cohort 1: Once-a-week between Monday to Thursday (not necessarily the same day every week) Cohort 2: Twice-a-week with a 1- or 2- day interval (either Mon+Wed, Mon+Thu, or Tue+Thu)"
62663440|NCT03530228|EXPERIMENTAL|Treatment A: Tegoprazan (C1)|Tegoprazan QD, oral administration
62102435|NCT06147830||Cohort B - Prospective Cohort|Cohort B will enrol approximately 2000 patients who were administered any reversal or replacement agent during the acute care phase for a major bleeding in the presence of Factor Xa inhibitor treatment at the participating sites. Patients will be followed up to three months after administration of reversal or replacement therapy.
62663441|NCT03530228|EXPERIMENTAL|Treatment B: Tegoprazan (C1)|Tegoprazan QD, oral administration
62102436|NCT06148272|EXPERIMENTAL|LY3971297 (Part A)|Single ascending doses of LY3971297 administered subcutaneously (SC) in healthy participants
62102437|NCT06148272|EXPERIMENTAL|LY3971297 (Part B)|Multiple ascending doses of LY3971297 administered SC in healthy participants
62102438|NCT06148272|EXPERIMENTAL|LY3971297 (Part C)|Multiple ascending doses of LY3971297 administered SC in healthy Chinese participants
62102439|NCT06148272|EXPERIMENTAL|LY3971297 (Part D)|Multiple ascending doses of LY3971297 administered SC in participants with obesity and hypertension
62467687|NCT06163079||Single women applying for sperm donation|"Inclusion of all single women consulting the Reproductive Medicine Service for a parenthood project by sperm donation between January 2021 and June 2023.~Exclusion :~* Minors~* Person under guardianship"
62467688|NCT06163079||women in relationship with a women applying for sperm donation|"Inclusion of all women in relationship with a women consulting the Reproductive Medicine Service for a parenthood project by sperm donation between January 2021 and June 2023.~Exclusion :~* Minors~* Person under guardianship"
62467689|NCT06163079||Heterosexuel couples applying for sperm donation|"Inclusion of all heterosexual couples consulting the Reproductive Medicine Service for a parenthood project by sperm donation between January 2021 and June 2023.~Exclusion :~* Minors~* Person under guardianship"
62663442|NCT03530228|EXPERIMENTAL|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
62663443|NCT03530228|EXPERIMENTAL|Group 1: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
62102440|NCT06148272|EXPERIMENTAL|LY3971297 (Part E)|Multiple doses of LY3971297 administered SC in healthy Japanese participants
62663444|NCT03530228|EXPERIMENTAL|Group 2: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
62663445|NCT03530228|ACTIVE_COMPARATOR|Group 3: Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days
62663446|NCT03530228|EXPERIMENTAL|Tegoprazan (C3)|Tegoprazan QD, oral administration
62663447|NCT04890990|ACTIVE_COMPARATOR|Black girl, control (BC)|\~120-second video of a Black adolescent girl, without depression
62102441|NCT06148272|PLACEBO_COMPARATOR|Placebo (Part A, B, C, D, E, & G)|Placebo administered SC
62102442|NCT06148272|EXPERIMENTAL|LY3971297 (Part F)|Single doses of LY3971297 administered intravenously (IV) in healthy participants
62467690|NCT03350347|EXPERIMENTAL|Molidustat (BAY85-3934)|Molidustat group
62467691|NCT03350347|ACTIVE_COMPARATOR|Darbepoetin alfa|Darbepoetin alfa group
62663448|NCT04890990|ACTIVE_COMPARATOR|Black girl, depressed (BD)|\~120-second video of a Black adolescent girl, depressed
62663449|NCT04890990|ACTIVE_COMPARATOR|Black girl, depressed, adjusted (BDa)|\~120-second video of a Black adolescent girl, depressed - adjusted for the specifics of being a Black girl (as informed by a focus group of Black girls and women)
62663450|NCT05205395||Women with stress incontinence|Women with urodynamic stress incontinence (USI) scheduled for mid-urethral sling surgery in the urogynecological department of a tertiary referral center were recruited.
62663451|NCT06038552||IM group|Imatinib(IM)
62663452|NCT06038552||IM combined with HR group|Imatinib(IM) combined with hepatic resection(HR)
62663453|NCT06038552||IM combined with RFA or TACE group|Imatinib(IM) combined with radiofrequency ablation (RFA) or transarterial chemoembolization (TACE)
62663454|NCT01597232|EXPERIMENTAL|Transfusion trigger based on WCPTS|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCPTS.
62663455|NCT01597232|ACTIVE_COMPARATOR|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively.
62663456|NCT01597232|ACTIVE_COMPARATOR|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience.
62102443|NCT06148272|EXPERIMENTAL|LY3971297 (Part G)|Multiple doses of LY3971297 administered SC in participants with decreased estimated glomerular filtration rate (eGFR)
62102444|NCT06357143|ACTIVE_COMPARATOR|CONTROL GROUP - STANDARD PHYSIOTHERAPY|Patients will undergo standard care which consists of an initial consultation with the physiotherapist to receive some recommendations about exercises, progression and health education
62467692|NCT06236893|EXPERIMENTAL|VH-01 vaginal suppository tablet|Participants will be instructed to take VH-01 vaginal suppository tablet (active product) as directed.
62467693|NCT06236893|PLACEBO_COMPARATOR|Placebo vaginal suppository tablet|Participants will be instructed to take the placebo vaginal suppository tablet as directed. The placebo vaginal suppositories do not contain active ingredients and are identical in appearance to the active product.
62467694|NCT00362765|EXPERIMENTAL|1|
62663457|NCT06145074|EXPERIMENTAL|Propranolol|Propranolol will be administered 40 mg twice daily (morning and evening) in 10 days prior to surgery for pancreatic cancer
62663458|NCT06145074|PLACEBO_COMPARATOR|Placebo|Placebo will be administered twice daily (morning and evening) in 10 days prior to surgery for pancreatic cancer.
62663459|NCT00675480|EXPERIMENTAL|T|Patients treated with thrombectomy: T
62295469|NCT02570451||scheduled for elective joint replacement surgery|Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form 211 patients Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
62663460|NCT00675480|ACTIVE_COMPARATOR|P|Patients treated with standard PCI with stent implantation
62663461|NCT01141309|EXPERIMENTAL|sorafenib with everolimus|This is a two-stage phase II study combining sorafenib with everolimus in patients with thyroid cancer.
62663462|NCT01594541||Patients Treated with CerefolinNAC®|
62295470|NCT04654312|EXPERIMENTAL|Intervention|Intake of HCT 25 mg, 1 tablet/d for 15 days
62663463|NCT01594541||Patients Not Treated with CerefolinNAC®|
62663464|NCT02751905|EXPERIMENTAL|BIIB074|Single oral dose on Day 1
62663465|NCT01107457|EXPERIMENTAL|10 mg Ixekizumab|"Part A:~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
62663466|NCT01107457|EXPERIMENTAL|25 mg Ixekizumab|"Part A:~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
62663467|NCT01107457|EXPERIMENTAL|75 mg Ixekizumab|"Part A:~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
62663468|NCT01107457|EXPERIMENTAL|150 mg Ixekizumab|"Part A:~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344."
62663469|NCT01107457|PLACEBO_COMPARATOR|Placebo|"Part A:~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
62663470|NCT01107457|EXPERIMENTAL|120 mg Ixekizumab|"Part B: (optional)~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
62663471|NCT01107457|EXPERIMENTAL|80 mg Ixekizumab|"Part B: (optional)~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
62663472|NCT04678674|EXPERIMENTAL|bone defect surgery|augmentation on insufficient alveolar ridges with autologous teeth will be performed (wisdom tooth or periodontally compromised tooth)
62663473|NCT04292951|EXPERIMENTAL|GDT group|Intraoperative fluid and inotropic/vasoactive drugs management based on information from FloTrac/EV1000
62663474|NCT04292951|ACTIVE_COMPARATOR|Control group|Intraoperative fluid and inotropic/vasoactive drugs management based on CVP, blood pressure, heart rate, and clinical signs at the discretion of attending anesthesiologists
62663475|NCT05897151|EXPERIMENTAL|Continuous spinal anesthesia|Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics. Norepinephrine starting dose 0.01 micg/kg/min will be ready for both groups if needed (main arterial pressure \< 70 or main arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics.
62663476|NCT05897151|ACTIVE_COMPARATOR|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18Gague) will be inserted. Induction will be done by fentanyl (2 mcg/kg), titrating dose. of propofol according to patient hemodynamic response and atracurium (0.5 mg/kg) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
62295471|NCT04654312|PLACEBO_COMPARATOR|Placebo|Intake of Placebo, 1 tablet/d for 15 days
62295472|NCT04407377|EXPERIMENTAL|Tolperisone 200 mg|Study Drug, Tolperisone 200mg TID
62295473|NCT04407377|EXPERIMENTAL|Tolperisone 400 mg|Study Drug, Tolperisone 400mg TID
62295474|NCT04407377|ACTIVE_COMPARATOR|Cyclobenzaprine|Active Comparator, Cyclobenzaprine 10mg TID
62295475|NCT04407377|PLACEBO_COMPARATOR|Placebo|Placebo, TID
62295476|NCT02331576|PLACEBO_COMPARATOR|rocaine|continuous femoral nerve block with ropivacaine alone.
62663477|NCT01859741|EXPERIMENTAL|OMP-59R5 Combination with Etoposide and Cisplatin|
62663478|NCT01859741|EXPERIMENTAL|Etoposide and Cisplatin plus Placebo|
62663479|NCT02741817|EXPERIMENTAL|Aspirin 20mg|Supplied with sachets of 100mg soluble aspirin and training, instructions and equipment will be provided to prepare 20 mg dose twice daily x14 then aspirin 75mg once daily x14
62663480|NCT02741817|EXPERIMENTAL|Aspirin 75mg|This is the standard dose of aspirin the participant will already be taking. The study will require the participants to switch to soluble aspirin for two weeks to enable accurate comparison with the other dose and to take their aspirin dose in the morning. Participants will be provided with a supply of soluble aspirin, along with training, instructions and equipment to help prepare it. They should not take their usual aspirin tablets whilst receiving the study medication, but should continue all other usual medications.
62663481|NCT04187521|OTHER|Sensitivity defect|Participants defined as having abnormal insulin sensitivity without an absolute defect in insulin secretion.
62663482|NCT04187521|OTHER|Secretory defect|Participants defined as having abnormal insulin secretion without a defect in insulin sensitivity.
62663483|NCT04187521|OTHER|Unclassified|Participants who cannot be classified as having abnormal insulin secretion or abnormal insulin sensitivity or who have both abnormal insulin sensitivity and abnormal insulin secretion.
62663484|NCT01257438|EXPERIMENTAL|Fluency Plus Endovascular Stent Graft|Fluency Plus Endovascular Stent Graft
62663485|NCT01257438|ACTIVE_COMPARATOR|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty only
61911708|NCT03102190|EXPERIMENTAL|Phase Ib|The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
61911709|NCT04095676|EXPERIMENTAL|VATS / surgical group|The VATS procedure must be completed as soon as possible and no later than 48 hours after randomisation. The surgery is performed with the patient in a 90 degree sideways position, using general anesthesia. Access is obtained through one to three ports, followed by purification and possibly decortication, and insertion of one pleural drain (sizes 24 - 32F) at the end of surgery. 20 ml Marcain is used as local analgetic and applied at the incision sites or as a nerve block. In the VATS group, suction on drain (- 15 cm H20) is applied in the first day after the procedure. Operator must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be registered and approved by the steering committee.
61911710|NCT04095676|ACTIVE_COMPARATOR|Drain and intrapleural therapy group|"Pigtail is applied as soon as possible and within 48 hours after randomisation. Drain placement is carried out using ULS. Operators (conductors of the procedure) must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be approved by the steering committee to conduct the procedure. A pigtail catheter (minimum 10F) is inserted. Operator determines the size of drain and whether drain placement is done with one-step or Seldinger technic.~The intrapleural therapy consists of treatment with the following two drugs:~* intrapleural Actilyse® (alteplase) 10 mg twice daily for three days~* intrapleural Pulmozyme® (DNase) 5 mg twice daily for three days"
61911711|NCT05277948|ACTIVE_COMPARATOR|treatment group|Active thumbtack needle will be used for the treatment group
61911712|NCT05277948|SHAM_COMPARATOR|control group|Sham thumbtack needle will be used for the control group
62663486|NCT00421993|EXPERIMENTAL|1|Adapalene/Benzoyl Peroxide Topical Gel
62663487|NCT00421993|ACTIVE_COMPARATOR|2|Adapalene Topical Gel
62663488|NCT00421993|ACTIVE_COMPARATOR|3|Benzoyl Peroxide Topical Gel
62663489|NCT00421993|PLACEBO_COMPARATOR|4|Topical Gel Vehicle
61911713|NCT05690256|EXPERIMENTAL|Intervention|Resilience Clinic
62663490|NCT02612675|ACTIVE_COMPARATOR|Standard ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
62663491|NCT02612675|EXPERIMENTAL|Low Carbohydrate ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
62663492|NCT06444373||subjects enrolled in lung cancer screening|Actual Smokers or formers smoker; Age \> 50 years.
62663493|NCT01543841||Advanced Cancer|Patients with histologically confirmed metastatic or unresectable solid tumors will have one tube of whole blood (\~6mL) collected at the time of venipuncture for routine sample collection. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
62663494|NCT01543841||Healthy Volunteers|Eligible volunteers will have one tube of whole blood (\~6mL) collected. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
62663495|NCT04022694|ACTIVE_COMPARATOR|Calorie/Control Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. It will simply state that those beverages are sold in the school store.
62295477|NCT02331576|ACTIVE_COMPARATOR|rocaine with fentanyl|continuous femoral nerve block with combination of ropivacaine and fentanyl.
62467695|NCT00362765|ACTIVE_COMPARATOR|2|
62467696|NCT00362765|ACTIVE_COMPARATOR|3|
62467697|NCT00362765|PLACEBO_COMPARATOR|4|
62467698|NCT02231749|EXPERIMENTAL|Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg|Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62467699|NCT02231749|ACTIVE_COMPARATOR|Arm B: Sunitinib 50 mg|"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks"
62663496|NCT04022694|EXPERIMENTAL|SSB Warning and Non-SSB Promotion Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. In addition, the message will state that SSBs are high in sugar and should be avoided, while low or no sugar beverages are healthier options and should be chosen.
62663497|NCT04022694|NO_INTERVENTION|Baseline for Calorie/Control Poster|We will collect baseline data from a group of students before posting the Calorie/Control Poster in the control school.
62663498|NCT04022694|NO_INTERVENTION|Baseline for SSB Warning and Non-SSB Promotion Poster|We will collect baseline data from a group of students before posting the SSB Warning and Non-SSB Promotion Poster in the intervention school.
62663499|NCT04877054|EXPERIMENTAL|Intervention Arm|Intervention sessions will occur \~once per week, with all 4 sessions being completed within 4-8 weeks. Each session will include an education and motivational interviewing (MI) component.
62663500|NCT04877054|ACTIVE_COMPARATOR|Education only Arm|Participants in the education-only control arm will receive one education session. The education session will occur via telephone or telehealth. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
62295478|NCT06568094|EXPERIMENTAL|HRS-5041 tablets combined with Abiraterone Acetate tablets（II）and Prednisone Acetate tablets|
62467700|NCT04146766|EXPERIMENTAL|eHealth|Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
62467701|NCT04146766|EXPERIMENTAL|wait list control|wait list control for 3 months and then Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
62467702|NCT03703791|ACTIVE_COMPARATOR|Group 1 (AR101 Treatment + standard of care)|Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.
62467703|NCT03703791|NO_INTERVENTION|Group 2 (Standard of Care Treatment)|Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.
62467704|NCT00089661|EXPERIMENTAL|AMG 162 / Denosumab|
62663501|NCT04298203|EXPERIMENTAL|Meal Replacement Therapy|Participants who are enrolled in the study will be administered a short-term (six weeks) meal replacement induction period. Because the trial is deigned to evaluate weight loss maintenance, participants must achieve at least 5% BMI reduction at week six of the meal replacement period in order to be randomized. Subjects will be asked to strictly follow the eating regimen, which will include a total of approximately 1,000 kcals per day of commercially-available liquid shakes (breakfast and lunch), pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables. Shakes/meals will be provided free of charge - fruits/vegetables will be purchased by the participants. Guidance will be provided regarding the use of the meal replacement shakes at school, and participants will be encouraged to engage in family meal sessions despite eating different foods.
62663502|NCT04298203|ACTIVE_COMPARATOR|Phentermine/Topiramate|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to phentermine/topiramate will start treatment at 3.75 mg/23 mg orally once daily in the morning for 14 days, then increased to 7.5 mg/46 mg orally once daily in the morning for 14 days, then be increased to 11.25 mg/69 mg orally once daily in the morning for 14 days, then increased to 15 mg/92 mg orally once daily in the morning for the remainder of the trial. Following the final study visit, participants will be down-titrated gradually by taking medication every other day for seven days before stopping treatment altogether.
62467705|NCT00089661|PLACEBO_COMPARATOR|Placebo|
62295479|NCT06568094|EXPERIMENTAL|HRS-5041 tablets combined with Docetaxel injection and Prednisone Acetate tablets|
62295480|NCT06568094|EXPERIMENTAL|HRS-5041 tablets combined with HRS-1167 tablets|
62295481|NCT06568094|EXPERIMENTAL|HRS-5041 tablets combined with SHR2554 tablets|
62295482|NCT01412879|EXPERIMENTAL|Arm I|Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.
62663503|NCT04298203|PLACEBO_COMPARATOR|Placebo|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to the placebo will receive inert tablets that look like the active comparator. In order to mimic the active comparator arm, subjects randomized to the placebo arm will up titrate their placebo at the beginning of the study treatment and will down titrate as in the active comparator arm. Participants will be instructed to take the medication under the supervision of a parent/guardian and pill counts of returned product will serve as a proxy of treatment compliance.
62663504|NCT02905864|EXPERIMENTAL|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
62663505|NCT02905864|PLACEBO_COMPARATOR|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
62663506|NCT04046653|EXPERIMENTAL|Study arm 1|Allin capsules (x2) and Sulforaphane capsules (x2) once daily for 4 weeks
62295483|NCT01412879|EXPERIMENTAL|Arm II|Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.
62663507|NCT04046653|EXPERIMENTAL|Study arm 2|Allin capsules (x2) and placebo capsules (x2) once daily for 4 weeks
62295484|NCT04567563|ACTIVE_COMPARATOR|Remote Ischemic Condition|
62295485|NCT04567563|NO_INTERVENTION|Standard of Care|
62295486|NCT02610985|ACTIVE_COMPARATOR|2-Dimensional laparoscopic hysterectomy|traditional 2-D laparoscopy
62295487|NCT02610985|EXPERIMENTAL|3-Dimensional laparoscopic hysterectomy|experimental 3-D laparoscopy
62663508|NCT04046653|EXPERIMENTAL|Study arm 3|Sulforaphane capsules (x2) and placebo capsules (x2) once daily for 4 weeks
62663509|NCT04046653|PLACEBO_COMPARATOR|Study arm 4|Placebo capsules (x4) once daily for 4 weeks
62663510|NCT00473499|EXPERIMENTAL|DEBlue stent|Paclitaxel coated balloon with CoCr stent mounted on it
62663511|NCT00473499|ACTIVE_COMPARATOR|Cypher stent|
62663512|NCT00473499|PLACEBO_COMPARATOR|Coroflex Blue stent|
62663513|NCT03186365|EXPERIMENTAL|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
62663514|NCT03186365|ACTIVE_COMPARATOR|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
62663515|NCT06031129|EXPERIMENTAL|Butorphanol|
62295488|NCT02811744|EXPERIMENTAL|Amnestic MCI cohort|Patients with Mild Cognitive Impairment (MCI) (up to 14) will be recruited primarily from the Penn Memory Center (PMC). Clinical diagnostic criteria (described in further detail in Study Procedures section) will be used to identify subjects who are meet criteria for amnestic MCI. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
62295489|NCT02811744|OTHER|Control cohort|Normal control subjects in the same age range (up to 6) will be recruited from a current ongoing study investigating neuroinflammation in late life depression and healthy controls, from the control group in which all subjects receive MRI and lumbar puncture (LP) and from the PMC research cohort. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
62663516|NCT06031129|PLACEBO_COMPARATOR|normal saline|
62663517|NCT04027621|ACTIVE_COMPARATOR|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
62102445|NCT06357143|EXPERIMENTAL|EXPERIMENTAL GROUP - REMOVE PROGRAM|"INITIAL STAGE:~* Aim: Recover mobility~* Exercises: Passive therapy, isometric exercises focused on middle deltoid.~* Goal: 80º passive flexion, 45º abduction, 5 N of abduction force STRENGTHENING STAGE~* Aim: Enhance scapulohumeral rhythm and strength rotator cura~* Exercises: Active-assisted therapy, isotonic exercises between 45-90º of forward flexión and abduction with dumbbells and isometric exercises focused on internal and external rotation.~* Goal: 100º passive flexion, 90º lateral abduction, 10 N of abduction force INTENSIVE STAGE~* Aim: Improve motor control and increase cross-sectional muscular área~* Exercises: Rowe with resistance band, wall push ups, lateral elevation with dumbbles, active external and internal rotation.~* Goal: 15 N of abduction force FUNCTIONAL STAGE~* Aim: Develope daily life activities~* Exercises: Overhead tasks, rowe with Kettlebell, internal and external rotations with resistance bands~* Goal: 20 N of abduction force"
62295490|NCT04177303|ACTIVE_COMPARATOR|Metformin|Patients will continue with their standard insulin therapy and will additionally receive orally metformin 2gr/day.
62295491|NCT04177303|PLACEBO_COMPARATOR|Placebo|Patients will continue with their standard insulin therapy and will additionally receive placebo
62295492|NCT03664726|EXPERIMENTAL|Episodic Future Thinking (EFT) & Neutral Narrative|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months). Participants will also be asked to think about a neutral narrative that describes a situation in which changes to their income are neutral or minimal
62467706|NCT01246076|EXPERIMENTAL|Lenalidomide|"Lenalidomide 50 mg/day for two 28 day cycles.~Patients who have bone marrow aplasia as defined by a cellularity of \<10% will be observed till counts recover. If patients do not progress following 2 cycles of HD lenalidomide, they will receive low dose lenalidomide 10 mg daily for 12 cycles."
62467707|NCT00035581|EXPERIMENTAL|Ampligen|Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks
62467708|NCT00035581|NO_INTERVENTION|No Ampligen|No Ampligen administered for first 24 weeks
62467709|NCT01885052|PLACEBO_COMPARATOR|1|Receives weekly assessment messages ONLY
62467710|NCT01885052|ACTIVE_COMPARATOR|2|Receives two week countdown messaging to quit date, and weekly assessment messages post quit date
62663518|NCT04027621|PLACEBO_COMPARATOR|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
62663519|NCT04250480|EXPERIMENTAL|Beta-alanine|4 g by mouth, 3 times per day with regular meals for 14 days.
62663520|NCT04250480|PLACEBO_COMPARATOR|Placebo|4 g by mouth, 3 times per day with regular meals for 14 days.
62663521|NCT05227235|EXPERIMENTAL|3D Telemedicine|3D Telemedicine system allowing patient to be seen in 3 dimensions
62663522|NCT05227235|ACTIVE_COMPARATOR|2D Telemedicine|2D Telemedicine system allowing patient to be seen in standard video call
62102446|NCT02689375|EXPERIMENTAL|Patients to receive spinal cord stimulator|
62102447|NCT05919849|EXPERIMENTAL|Expressive Writing|Participants in the expressive writing (EW) condition will be instructed to write in a free-form manner about the most stressful aspects of being a parent of an SGMY, following standard EW procedures.
62102448|NCT05919849|EXPERIMENTAL|Attachment-Based Writing|Participants in the attachment-based writing (ABW) condition will respond to distinct prompts created for the condition based on components of attachment-based family therapy (ABFT).
62295493|NCT03664726|ACTIVE_COMPARATOR|Episodic Recent Thinking (ERT) & Neutral Narrative|Participants will complete an episodic recent thinking task to generate episodic cues where they will list and describe events for different time periods. The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event. ERT participants will list positive recent events they enjoyed and list events that happened recently (e.g. 1 - 7 days ago). Participants will also be asked to think about a neutral narrative that describes a situation in which changes to their income are neutral or minimal (e.g. department job transfer).
62663523|NCT03199066||All NHL subtypes|no interventions
62663524|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
62663525|NCT03199066||FL|only patients with follicular lymphoma
62663526|NCT03199066||MCL|only patients with mantle cell lymphoma
62663527|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
62102449|NCT05919849|OTHER|Neutral Writing|Participants in the control condition will be asked to write about what they have done since waking up that morning.
62102450|NCT02397889|EXPERIMENTAL|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
62102451|NCT02397889|ACTIVE_COMPARATOR|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
62467711|NCT01885052|ACTIVE_COMPARATOR|3|Receives two week countdown messages to quit date, receives mulitiple messages per day post quit date with tips, encouragement and supportive messaging
62467712|NCT03648658|EXPERIMENTAL|Paracetamol 15mg/kg|
62467713|NCT05156619||Cohort#1|new annual breast cancer cases and cases of recurrence at Hadassah University hospital between 2018-2021 (700)
62663528|NCT03199066||MZL|only patients with marginal zone lymphoma
62663529|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
62663530|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
62663531|NCT03838705|OTHER|bariatric surgery patients|patients aged 18-65 years with ASA status II-III, BMI\>40 who were undergoing bariatric surgery operation
62663532|NCT04817982|EXPERIMENTAL|Perineural dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Dexamethasone will be added perineurally in this arm on the same day as the 'systemic dexamethasone' group.
62102452|NCT04807517|EXPERIMENTAL|Buspirone|Subjects will receive buspirone 2.5 mg each morning at the start of the trial. The dose will be increased by 2.5 mg per week in two divided doses daily depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 2.5 mg and the maximum total daily dose will be 30 mg. Medication will be dosed twice daily due to the short half-life (2-3 hours) of this medication.
62102453|NCT05043961||study group|"Patients who report \>50% pain relief after an intra articular sacroiliac joint injection but lasting less than 3 months who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study.~Intervention:~Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles"
62295494|NCT03664726|EXPERIMENTAL|Episodic Future Thinking (EFT) & Scarcity Narrative|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months). Participants will also be asked to think about a narrative to induce a scarcity mindset by describing a situation in which changes to their income are negative (e.g. loss of job).
62295495|NCT03664726|EXPERIMENTAL|Episodic Recent Thinking (ERT) & Scarcity Narrative|Participants will complete an episodic recent thinking task to generate episodic cues where they will list and describe events for different time periods. The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event. ERT participants will list positive recent events they enjoyed and list events that happened recently (e.g. 1 - 7 days ago). Participants will also be asked to think about a narrative to induce a scarcity mindset by describing a situation in which changes to their income are negative (e.g. loss of job).
62295496|NCT01390389|EXPERIMENTAL|CoQ10|"Subjects who meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed are assigned to this arm and administered the Coenzyme Q10 intervention. CoQ10 dosing guidelines:~* Visit 1 (Baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of Baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
62295497|NCT01390389|NO_INTERVENTION|Control|Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
62295498|NCT00384579|EXPERIMENTAL|1|Botulinum Toxin B
62295499|NCT00384579|PLACEBO_COMPARATOR|2|Placebo
62295500|NCT00448461|ACTIVE_COMPARATOR|1|heparin
62295501|NCT00448461|ACTIVE_COMPARATOR|2|bivalirudin
62295502|NCT03094130|ACTIVE_COMPARATOR|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
62295503|NCT03094130|EXPERIMENTAL|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
62295504|NCT01966731|EXPERIMENTAL|Hydroxyurea|After patient enrollment, a two-month pre-hydroxyurea evaluation phase will be used to perform baseline evaluations including nutritional and infectious assessments, and to provide supplements or treatments as deemed necessary. After the pre-hydroxyurea evaluation and supplementation phase, hydroxyurea dosing will be administered as a single daily dose, using capsules provided as a monthly supply in 200mg, 300mg, 400mg, or 500mg sizes.
62295505|NCT02421393|EXPERIMENTAL|Exercise|Supervised exercise training on top of standard care (exercise, EXE, group; n=100)
62295506|NCT02421393|NO_INTERVENTION|Control|Standard care including advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and and leisure-time physical activity (PA) (control, CON, group; n=100).
62295507|NCT03777514|ACTIVE_COMPARATOR|IV iron|"Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.~Participants in this group will also receive oral vitamin C as a placebo."
62295508|NCT03777514|ACTIVE_COMPARATOR|oral iron|Ferrous sulfate 325 mg (oral) tabs morning and evening. Participants in this group will also receive intravenous normal saline as a placebo.
62467714|NCT05156619||Cohort#2|Retrospective study - all clinical trial patients in the Sharett institute of oncology between 1.1.12-30.6.21 (300)
62295509|NCT04144972|ACTIVE_COMPARATOR|Active DBS|Chronic brain recordings and stimulation with bilateral implantations in pain-related brain regions. All participants will participate in active DBS, blinded to the participant.
62295510|NCT04144972|SHAM_COMPARATOR|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. brain recordings will remain active during this period. All participants will participate in inactive DBS, blinded to the participant.
62467715|NCT05156619||Cohort#3|all newly diagnosed recurrent/metastatic disease during the study period (200)
62467716|NCT02791880||TAVR patients|The group of interest is the patient population with aortic stenosis who are undergoing transcatheter aortic valve replacement (TAVR)
62467717|NCT03787030|EXPERIMENTAL|Vitamin E acetate|Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
62467718|NCT03787030|ACTIVE_COMPARATOR|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
62295511|NCT01225341|EXPERIMENTAL|onabotulinumtoxinA/placebo|Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.
62295512|NCT01225341|PLACEBO_COMPARATOR|Bacteriostatic normal saline/ onabotulnimtoxinA|Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.
62663533|NCT04817982|ACTIVE_COMPARATOR|Systemic dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as the 'perineural dexamethasone' group. Thereby, this ulnar nerve block will only be affected by the perineurally added dexamethasone that is absorbed and redistributed systemically.
62663534|NCT04817982|PLACEBO_COMPARATOR|Placebo|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as lidocaine group. This will be the actual placebo group.
62102454|NCT02735265|EXPERIMENTAL|Virtual reality group|45 min standard treatment plus 45 min virtual reality balance training used by Kinect for Xbox game. Game choosed based on motor learning principle. Training task such as reach or stepping in various direction, squat, stand up, upper trunk forward or lateral bench.
62102455|NCT02735265|ACTIVE_COMPARATOR|Standard treatment only group|90 min standard treatment. Depended on patient's ability, principle used by motor learning, sensory process, motor control, task oriented training, symmetry w't bearing.
62102456|NCT05541497|EXPERIMENTAL|Varenicline + Self-Change Pamphlet|"* Days 1-3: 0.5mg study pill once per day~* Days 4-7: 0.5mg study pill twice per day~* Weeks 2-8: 1mg study pill twice per day in combination with a minimal, self-guided behavior change booklet. This booklet includes general tips for e-cigarettes cessation and information about the free web-based e-cigarette cessation program sponsored by The Truth Initiative and Mayo called This is Quitting. This study will have an 8-week treatment period and a 4-week follow-up."
62467719|NCT02631772|EXPERIMENTAL|Late Cohort, Arm 1|Ledispasvir (LDV) and Sofosbuvir (SOF) monotherapy x 12 weeks
62467720|NCT02631772|ACTIVE_COMPARATOR|Late Cohort, Arm 2|Ledispasvir (LDV) and Sofosbuvir (SOF) +ribavirin x 12 weeks
62467721|NCT02694731|EXPERIMENTAL|Mobile application intervention|Participants receive a mobile app with a 5-week mindful eating program and ongoing tools for coping with cravings
62467722|NCT06195670|EXPERIMENTAL|SCRT + fruquintinib + sintilimab|
62663535|NCT04817982|ACTIVE_COMPARATOR|Perineural lidocaine|Bilateral ulnar nerve blocks with bupivacaine. Lidocaine will be added perineurally in this arm on the same day as the actual placebo group.
62663536|NCT05370326|EXPERIMENTAL|Enhanced Opioid Stewardship Program|Enhanced opioid stewardship program, tailored to the needs of hospitalized patients with chronic pain with opioid dependence, incorporating real-time guidance from an addiction medicine and pain-trained physician/pharmacist team
62663537|NCT05370326|NO_INTERVENTION|Standard of care|
62737198|NCT01947283|EXPERIMENTAL|Intervention Providers|Participants in this arm are providers who were randomized to the Intervention group. Intervention providers will receive the DECIDE-PC intervention. The DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.
62102457|NCT05541497|PLACEBO_COMPARATOR|Placebo + Self-Change Pamphlet|"* Days 1-3: 0.5mg placebo pill once per day~* Days 4-7: 0.5mg placebo pill twice per day~* Weeks 2-8: 1mg placebo pill twice per day in combination with a minimal, self-guided behavior change booklet. This booklet includes general tips for e-cigarettes cessation and information about the free web-based e-cigarette cessation program sponsored by The Truth Initiative and Mayo called This is Quitting. This study will have an 8-week treatment period and a 4-week follow-up."
62295513|NCT01972321|EXPERIMENTAL|Technology supported supervision|The technology supported supervision intervention will support the CHWs in providing quality case management for the under-fives who suffer from diarrhea, pneumonia and malaria through unlimited communication with their health facility supervisors and colleagues through closed-user-groups. It will enhance timely reporting of patient data and targeted support supervision on the CHWs who need support from their supervisors. With the CHWs receiving the above support and feedback messages, this will potentially increase CHW motivation, performance and retention. Data reported by CHWs can be used by the district planners to forecasting of medicine procurements and react to drug stock-outs or unusual data trends (e.g. disease outbreaks).
62295514|NCT01972321|EXPERIMENTAL|Community supported supervision|The community supported supervision intervention will set up village health clubs with the aim to improve child health through a community led forum with the CHW as the main focus point. Village health club meetings will provide a forum where CHWs and community members who are part of the club can work together to identify child health and CHW challenges. They will use village networks, knowledge, creativity and other assets.
62467723|NCT06195670|ACTIVE_COMPARATOR|Bevacizumab + Capecitabine|
62467724|NCT01037023||Patients administrated Topotecan|There is only one group. This group includes patients administrated Topotecan
62467725|NCT04128826|EXPERIMENTAL|Partial Range of Motion (PROM)|
62467726|NCT04128826|EXPERIMENTAL|Full Range of Motion (FROM)|
62467727|NCT04128826|NO_INTERVENTION|Control (CON)|
62467728|NCT04656223||MF/IND/GLY Breezhaler® plus Propeller Health|patients receiving MF/IND/GLY Breezhaler® plus electronic inhalation tracking sensor (Propeller Health) according to label
62467729|NCT04656223||Other FDC therapy|patients receiving ICS+LABA+LAMA FDC therapy according to label
62663538|NCT02626611|PLACEBO_COMPARATOR|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
62663539|NCT02626611|ACTIVE_COMPARATOR|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
62663540|NCT02626611|ACTIVE_COMPARATOR|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
62663541|NCT05573282||Sequential therapy of Regorafenib combined with ICIs|"Sequential therapy of Regorafenib combined with one kind of ICIs after standard HAIC treatment in advanced hepatocellular carcinoma (HCC).~ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs."
62102458|NCT04841486||"with history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy with history of spontaneous termination of pregnancy
62102459|NCT04841486||"without history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy without history of spontaneous termination of pregnancy
62102460|NCT06712446|EXPERIMENTAL|highfrequency rTMS+EFT|
62102461|NCT06712446|SHAM_COMPARATOR|sham rTMS+EFT|
62102462|NCT01487564|EXPERIMENTAL|Hydromorphone 16 mg|
62102463|NCT06021574|EXPERIMENTAL|A single intravenous administration of 1mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
62295515|NCT01972321|ACTIVE_COMPARATOR|Control arm|The CHWs in the control arm will be receiving the standard Ministry of Health designed package to integrated community case management support and supervision.
62295516|NCT06372717|EXPERIMENTAL|Dose Escalation Phase: APL-4098 monotherapy|Dose escalation with different dosing levels of APL-4098.
62295517|NCT06372717|EXPERIMENTAL|Dose Escalation Phase: APL-4098 and azacitidine|Dose escalation with different dosing levels of APL-4098 in combination with azacitidine (75 mg/m2).
62295518|NCT06372717|EXPERIMENTAL|Phase 2 Dose Expansion: APL-4098 monotherapy|
62295519|NCT06372717|EXPERIMENTAL|Phase 2 Dose Expansion: APL-4098 and azacitidine|
62295520|NCT04871815|EXPERIMENTAL|Treatment of COVID19 Long Haulers with sodium pyruvate nasal spray|This is a single arm, open label study. All subjects will be provided a log for monitoring symptoms associated with Long COVID and asked to record symptom severity using a likert scale for one week. All subjects will then use N115 sodium pyruvate nasal spray 3x daily for an additional week and continue to log their symptoms.
62295521|NCT01442025|PLACEBO_COMPARATOR|Cohort 1 =Control Group|the dose of IFX will be increased by 5 mg/kg (maximally 1 time) based on symptom relapse (usual clinical practice) Dose will be kept stable ofr the rest of the trial Dose decreases will not be allowed.
62295522|NCT01442025|ACTIVE_COMPARATOR|Cohort 2|Dose of IFX will be increased by 2.5 mg/kg (maximally 2 times) if the following criteria are met A dose increase is maintained for the following infusions
62295523|NCT01442025|ACTIVE_COMPARATOR|Cohort 3|Dose of IFX will be increased by 5 mg/kg (maximally 1 time) if the following criteria are met A dose increase is maintained for the following infusions
62295524|NCT06231017|EXPERIMENTAL|Adebrelimab + Cetuximab+ Chemotherapy|Adebrelimab + Cetuximab+ Chemotherapy
62663542|NCT06021379||AryoGen Pharmed Trastuzumab|AryoTrust is given at dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
62663543|NCT02871427|EXPERIMENTAL|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
62663544|NCT01709344|EXPERIMENTAL|PS-OT|Problem-solving Occupational Therapy
62663545|NCT01709344|OTHER|Usual care|Access to all supportive and rehabilitative services available at DHMC
62663546|NCT03575156|EXPERIMENTAL|Systemic lupus erythematosus (SLE)|
62663547|NCT03575156|EXPERIMENTAL|systemic scleroderma (SSc)|
61911714|NCT05690256|ACTIVE_COMPARATOR|Control|Enhanced pediatric primary care
62102464|NCT06021574|EXPERIMENTAL|A single intravenous administration of 2mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
62295525|NCT00610636|EXPERIMENTAL|1|The patients with secondary resectable colorectal hepatic metastasis undergoing surgery
62295526|NCT00610636|ACTIVE_COMPARATOR|2|The patients with secondary resectable colorectal hepatic metastasis who underwent continuous chemotherapy
62663548|NCT06286943|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose placebo capsules.
62663549|NCT06286943|EXPERIMENTAL|SCFAs|Colon-delivery Capsules of Short Chain Fatty Acids.
62102465|NCT06021574|EXPERIMENTAL|A single intravenous administration of 4mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
61911715|NCT03849573|EXPERIMENTAL|Mindfulness-based stress reduction + Hormone Therapy Education|
62102466|NCT06021574|EXPERIMENTAL|A single intravenous administration of 8mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
62295527|NCT01766648|EXPERIMENTAL|Far Cortical Locking screw fixation|Far Cortical Locking screw fixation
62295528|NCT01766648|ACTIVE_COMPARATOR|Standard screw fixation|Standard screw fixation
62467730|NCT05445310|EXPERIMENTAL|Furmonertinib|Patients will receive furmonertinib 80mg/d for 3 years or until disease recurrence or treatment cessation for other reasons.
62467731|NCT00520130|EXPERIMENTAL|A - Tacrolimus, methotrexate, sirolimus (TMS) Arm|TMS Arm
62102467|NCT02778308|ACTIVE_COMPARATOR|chemotherapy group|6 cycles of Gemcitabine + Cisplatin as per the following schedule Injection Gemcitabine 1 gm/kgm2 intravenous over 30 min Day1 and Day8 Injection Cisplatin 70 mg/m2 intravenous on Day1
62295529|NCT05532397|EXPERIMENTAL|QPOP-guided chemotherapy|Subjects enrolled in the study will be administered combination of chemotherapy derived from QPOP analysis based on in vitro drug screening panels which comprises anti-cancer agents which have previously been evaluated in recurrent high grade astrocytic glioma.
62295530|NCT01364987|EXPERIMENTAL|ASP015K and Mycophenolate Mofetil|
62102468|NCT02778308|NO_INTERVENTION|control group|follow up
62102469|NCT06614348|EXPERIMENTAL|Prednisolone acetate eye drop group|
62102470|NCT06614348|PLACEBO_COMPARATOR|hyaluronic acid eye drop group|
62102471|NCT00285558|EXPERIMENTAL|CBT with peer-enhanced activities|Cognitive behavioral treatment (CBT) with peer-enhanced adventure therapy. The peer intervention, ''adventure therapy,'' is based on the principles of Outward Bound and was expected to affect weight status through a positive effect on self-concept.
62102472|NCT00285558|ACTIVE_COMPARATOR|CBT with supervised aerobic exercise|Cognitive behavioral treatment (CBT) with supervised aerobic exercise. Activities for the supervised exercise intervention included use of treadmills, stationary bicycles, and other aerobic activities selected by participants, including dance videos and brisk walking within the clinic setting.
62102473|NCT05824351|EXPERIMENTAL|Tanzanian beeswax-pine adhesive|Each study subject will be tested with a thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
62102474|NCT05824351|ACTIVE_COMPARATOR|Domestic beeswax-pine adhesive|Each study subject will be tested with a thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
62102475|NCT05824351|ACTIVE_COMPARATOR|Control|Each study subject will be tested with a thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
62102476|NCT01045317|EXPERIMENTAL|intravenous or oral administration|
62102477|NCT02594176|EXPERIMENTAL|Test Product|2.2 g FLEXISEQ® twice daily
62102478|NCT02594176|PLACEBO_COMPARATOR|Placebo|2.2 g placebo twice daily
62102479|NCT06081361|EXPERIMENTAL|Short-Term Regimen|"Intervention will be determined based on Fluoroquinolones(FQs) resistance.~* For those sensitive to FQs: BDQ DLM CZD LFX(MFX) for 6 months~* For those resistant to FQs: BDQ DLM CZD CFZ for 6 months"
62102480|NCT06081361|ACTIVE_COMPARATOR|Standard Regimen|"Intervention will be determined based on Fluoroquinolones(FQs) resistance.~* For those sensitive to FQs: BDQ LZD LFX(MFX) CS CFZ regimen for 6 months, then LFX(MFX) CS CFZ for 12 months~* For those resistant to FQs: LFX(MFX) will be replaced by Pto, PZA, PAS or EMB"
62102481|NCT02959151|EXPERIMENTAL|CAR-T for liver cancer|A single dose of CART cells will be administered by vascular interventional therapy or by intra-tumor injection with a dose of （1.25\~4）×107 CAR positive T cells/cm3 tumor bulk. The volume of cell products and the time of cell perfusion process lasted would depend on the ways of cell perfused. And an interventional radiologist would operate the cell infusion.
62102482|NCT00364442|EXPERIMENTAL|Arm 1|investigational drug
62102483|NCT05096884|EXPERIMENTAL|Study arm - Metoprolol Succinate.|The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
62102484|NCT06529120|EXPERIMENTAL|Nite2Day|"Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills (Nite2Day)~The Nite2Day intervention will train participants in mindfulness-based sleep strategies and behavioral symptom management techniques. The Nite2Day intervention will consist of 6 weekly sessions that will between 45 and 60 minutes."
62102485|NCT05286541|EXPERIMENTAL|Lateralized buccal cortex group with xenograft|the buccal cortical bone was osteotomized and separated to be fixed in a lateralized position at the desired distance and the gap filled with Xenograft
62295531|NCT00379327|EXPERIMENTAL|Real Accupuncture|Acupuncture with a real needle that punctures the skin versus acupuncture needle that does not puncture the skin.
62295532|NCT00379327|PLACEBO_COMPARATOR|Non-puncturing Acupuncture|Acupuncture needle that touches but does not puncture the skin
62102486|NCT05286541|ACTIVE_COMPARATOR|lateralized buccal cortex with autogenous particulate|the buccal cortex was lateralized same as in the interventional group but the gap filled with autogenous particulate
62102487|NCT06526585|EXPERIMENTAL|Cyclic Sighing Breathing|"Ten minutes a day of active breathwork practice for 28 days delivered remotely through a video link.~Participants will also practice 10 minutes of active breathwork during the 2 MRI assessments, one before the start of the 28 days, and one after the completion of the 28 days."
62295533|NCT00123084|EXPERIMENTAL|Voice/Respiratory Treatment|4 Days a week for 4 weeks with focus on high intensity voice exercises
62295534|NCT00123084|EXPERIMENTAL|Articulation Treatment|4 days a week for 4 weeks with focus on high intensity articulation tasks
62295535|NCT00123084|NO_INTERVENTION|Subjects with PD in a no treatment group|Subjects do not receive therapy during experimental phases, and will be offered therapy at the end of the study enrollment period.
61911716|NCT03849573|ACTIVE_COMPARATOR|Hormone Therapy Education + Overall Health Education|
61911717|NCT03269162|EXPERIMENTAL|Jinfukang + Chemotherapy Group|
61911718|NCT03269162|PLACEBO_COMPARATOR|Chemotherapy Group|
61911719|NCT02661178|EXPERIMENTAL|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
62663550|NCT04267042|ACTIVE_COMPARATOR|Budesonide via Mucosal Atomization Device (MAD)|"Patients in this arm will administer budesonide using a mucosal atomization device (MAD, Wolfe-Tory Medical, Salt Lake City, UT) once a day at least 5 times a week for 6 months postoperatively. The MAD atomizes the medication into particles from 30-100 um in size thus increasing the surface area for drug absorption.~Budesonide is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the MAD syringe."
62663551|NCT04267042|ACTIVE_COMPARATOR|Budesonide via nasal saline irrigation (INSI)|"Patients in this arm will administer impregnated budesonide in nasal saline irrigation (INSI) using a NeilMed squeeze bottle (NeilMed Pharmaceuticals, Santa Rosa, California) once a day at least 5 times a week for 6 months postoperatively.~Budesonide is provided in nebules (1mg/2cc).Patients will place two nebules of budesonide into the 240mls of saline."
62663552|NCT00562328|EXPERIMENTAL|Alemtuzumab + Rituximab + GM-CSF|Alemtuzumab + Rituximab + GM-CSF
62663553|NCT04166331|PLACEBO_COMPARATOR|Control|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
61911720|NCT02661178|PLACEBO_COMPARATOR|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
61911721|NCT04179409|EXPERIMENTAL|AMONDYS 45|This arm will involve the treatment of boys with DMD who have a duplication of exon 45, for which AMONDYS 45 will target skipping of this exon.
62295536|NCT00123084|NO_INTERVENTION|Healthy Control Subjects|Subjects are without Parkinson disease and will not receive therapy.
62663554|NCT04166331|EXPERIMENTAL|Experimental|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
62663555|NCT06019988|OTHER|The Accountable Health Communities Health-Related Social Needs Screening Tool (AHC-HRSN)|Patients will be randomized to receive one of three social needs screening instruments. The AHC-HRSN is a 10-item tool developed by the Centers for Medicare and Medicaid Services to assess patient needs in 5 core domains, including housing instability, food insecurity, transportation problems, utility help needs, and interpersonal safety, with eight supplemental domains to collect information about financial strain, employment, family and community support, education, physical activity, substance abuse, mental health, and disabilities. The AHC-HRSN tool is designed to help physicians identify unmet needs and refer affected patients to appropriate community services.
62663556|NCT06019988|OTHER|Health Leads Social Screening Tool|Patients will be randomized to receive one of three social needs screening instruments. Health Leads is an 8-item survey with yes/no responses, which screens for food insecurity, utility needs, housing instability, childcare, financial resource strain, transportation challenges, education, and social isolation.
62295537|NCT05090956|EXPERIMENTAL|control|MRI exam; The sequences to be performed will be presented to the subject according to the focus to be performed. maximal duration of the exam: 2 hours (including subject set up)
61911722|NCT04179409|EXPERIMENTAL|EXONDYS 51|This arm will involve the treatment of boys with DMD who have a duplication of exon 51, for which EXONDYS 51 will target skipping of this exon.
61911723|NCT04179409|EXPERIMENTAL|VYONDYS 53|This arm will involve the treatment of boys with DMD who have a duplication of exon 53, for which VYONDYS 53 will target skipping of this exon.
61911724|NCT02830438|EXPERIMENTAL|Shear wave elastography group|Patients referred for kidney biopsy will then undergo shear wave elastography measurements.
61911725|NCT00722371|EXPERIMENTAL|Sitagliptin 100 mg|
61911726|NCT00722371|EXPERIMENTAL|Pioglitazone 15 mg|
61911727|NCT00722371|EXPERIMENTAL|Pioglitazone 30 mg|
61911728|NCT00722371|EXPERIMENTAL|Pioglitazone 45 mg|
61911729|NCT00722371|EXPERIMENTAL|Sitagliptin 100 mg/ Pioglitazone 15 mg|
61911730|NCT00722371|EXPERIMENTAL|Sitagliptin 100 mg/ Pioglitazone 30 mg|
62295538|NCT01740336|EXPERIMENTAL|A: Paclitaxel, GDC-0941|Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m\^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
62295539|NCT01740336|PLACEBO_COMPARATOR|B: Paclitaxel, Placebo|Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m\^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
62295540|NCT02522637|ACTIVE_COMPARATOR|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
62295541|NCT02522637|EXPERIMENTAL|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
62295542|NCT01293617|PLACEBO_COMPARATOR|Gelatin|
61911731|NCT00722371|EXPERIMENTAL|Sitagliptin 100 mg/ Pioglitazone 45 mg|
61911732|NCT01926327|ACTIVE_COMPARATOR|platelet reach plasma|The patients with osteoarthritis who underwent PRP injection.
62295543|NCT01293617|EXPERIMENTAL|Blackberries|
62737199|NCT02314156|EXPERIMENTAL|Arm I (transdermal telapristone acetate)|Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.
61911733|NCT01926327|PLACEBO_COMPARATOR|placebo|The patients with osteoarthritis who underwent Normal Saline injection.
61911734|NCT01642732|EXPERIMENTAL|Everolimus with combined hormonal and radiation therapy|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 10 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
61911735|NCT01958827|EXPERIMENTAL|Adalimumab 80 mg|All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
62737200|NCT02314156|ACTIVE_COMPARATOR|Arm II (oral telapristone acetate)|Patients receive placebo transdermally and telapristone acetate PO QD for 4 weeks.
61911736|NCT04796987||cervical myelopathy|MR images of patients with cervical myelopathy
61911737|NCT04796987||normal|normal section of the MRI of patients with cervical myelopathy
62295544|NCT06227832|EXPERIMENTAL|KP-001/Metformin|
62295545|NCT06227832|EXPERIMENTAL|KP-001/Midazolam|
62295546|NCT06227832|EXPERIMENTAL|KP-001/Clarithromycin|
62295547|NCT05300048|EXPERIMENTAL|Cohort 1a - Dose Modification without nab-paclitaxel|Subjects with any solid tumor will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months
62295548|NCT05300048|EXPERIMENTAL|Cohort 1b - Dose Modification with Nab-Paclitaxel|Subjects with endometrial cancer, ovarian clear cell or ovarian endometriod carcinoma will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months. In addition, these subjects will receive nab-paclitaxel intravenously weekly.
62295549|NCT05300048|EXPERIMENTAL|Cohort 2 - Expansion Colorectal Cancer|Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months
62467732|NCT00520130|EXPERIMENTAL|B - Cyclosporine (AC) Arm|AC Arm
62295550|NCT05300048|EXPERIMENTAL|Cohort 3 - Expansion Endometrial Cancer|Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
62295551|NCT05300048|EXPERIMENTAL|Cohort 4 - Expansion Ovarian Clear Cell or Ovarian Endometrioid Carcinoma|Subjects will receive dose of serabelisib as determined from Cohorts 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
62295552|NCT01276886||Acute Diverticulitis|
62295553|NCT03270748|EXPERIMENTAL|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day -6 through day -3) Fludarabine 40 mg/m2 per day for 4 days (from day -6 through day -3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
62295554|NCT03471455|ACTIVE_COMPARATOR|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
62467733|NCT04971772||"DCB (Legflow .035) group"|"treatment with Drug Coated Balloon angioplasty with the Legflow .035 Paclitaxel Balloon Dilatation catheter."
62467734|NCT04971772||POBA group|treatment with standard POBA (uncoated) angioplasty (type and brand at the physician's discretion)
62663557|NCT06019988|OTHER|National Comprehensive Care Network (NCCN) Distress Thermometer and Problem List (DT + PL)|Patients will be randomized to receive one of three social needs screening instruments. The NCCN Distress thermometer is a single-item tool designed to measure patients' current level of distress. Patients are asked to rate their distress using a 10-point Likert scale, where 0=no distress and 10=extreme distress. The Problem List (PL) helps physicians identify the sources of patients' distress and direct patients to appropriate support services. The NCCN DT+PL is a widely used, validated tool for evaluating distress in patients diagnosed with or receiving treatment for cancer.
62663558|NCT06019988|OTHER|Chatbot|Patients who do not respond to the survey within 48 hours of being first administered via MyPennMedicine will be sent the same survey via one of two modality arms. The chatbot is a bidirectional text-based conversational agent administered via WaytoHealth. Patients will again have 48 hours to respond via chatbot.
62663559|NCT06019988|OTHER|Interactive Voice Response (IVR) System|Patients who do not respond to the survey within 48 hours of being first administered via MyPennMedicine will be sent the same survey via one of two modality arms. The interactive voice response (IVR) system is administered via phone through WaytoHealth. Patients will be called over the phone and will receive the screening tool through IVR. Patients will again have 48 hours to respond via IVR.
62295555|NCT03471455|ACTIVE_COMPARATOR|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
62663560|NCT01584583||blood pressure monitor|Cuff circumference:22cm-36cm
62467735|NCT04089592|EXPERIMENTAL|Dex Group|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
62663561|NCT01584583||stethoscopy|Cuff circumference: 22cm-36cm
62663562|NCT03415009||HCV genotype 1 and genotype 2/3|DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917).
62663563|NCT01495247|EXPERIMENTAL|BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.
62663564|NCT01495247|EXPERIMENTAL|BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days
62295556|NCT03471455|ACTIVE_COMPARATOR|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
62295557|NCT03471455|ACTIVE_COMPARATOR|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
62295558|NCT01920906|EXPERIMENTAL|Biopsy and blood tests|All subjects will undergo a skin biopsy and blood tests
62295559|NCT05021926|EXPERIMENTAL|Investigational device|DKL crosslinked sodium hyaluronate 26
62663565|NCT00785629|ACTIVE_COMPARATOR|Calcium Acetate|667 mg with meals
62663566|NCT00785629|ACTIVE_COMPARATOR|Lanthanum Carbonate|500 mg with meals
62295560|NCT05021926|EXPERIMENTAL|Comparator product|Juvéderm Voluma™ with lidocaine (Allergan, Inc)
62295561|NCT03584009|EXPERIMENTAL|Venetoclax + Fulvestrant|Participants were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
62663567|NCT00785629|ACTIVE_COMPARATOR|Sevelamer Carbonate|800 mg with meals
62663568|NCT00785629|PLACEBO_COMPARATOR|Placebo|with meals
62663569|NCT04498104||Borderline Personality Disorder|Borderline personality disorder diagnosed participants
62467736|NCT04089592|EXPERIMENTAL|Fent Group|intravenous fentanyl at 2mcg/kg in 100ml saline
62467737|NCT06067243||HIP MRI-3 T|Young patients with coxalgia and clinical and imaging suspect for cartilage and/or labral lesion of the hip
62467738|NCT01901705|ACTIVE_COMPARATOR|Indigo|The Indigo naturalis ointment will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
62467739|NCT01901705|PLACEBO_COMPARATOR|Placebo|The Placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
62467740|NCT01503736|PLACEBO_COMPARATOR|Placebo|
62663570|NCT04498104||Control|Healthy participants
62467741|NCT01503736|EXPERIMENTAL|4g/day|Ferric Citrate for a total daily dose of 4g
62467742|NCT01503736|EXPERIMENTAL|6g/day|Ferric Citrate for a total daily dose of 6g
62467743|NCT02727010||mothers with motor impairment due to a rare disease|20 Women with motor impairment due to a rare disease
62467744|NCT02727010||mothers with motor impairment not related to a rare disease|controls, 20 women with motor impairment not related to a rare disease
62663571|NCT03320369|OTHER|Treatment|Elemental formula Intervention: Elemental Diet Therapy
62663572|NCT04510415|EXPERIMENTAL|Olmutinib 600mg|HM61713 600 mg (1 x 400 mg + 1 x 200 mg tablets) once daily (QD)
62663573|NCT01889030||Target population|This observational, cross-sectional, national multicenter designed study will describe the frequency of use of different evaluation methods (risk scores or subjective assessment) employed to determine the cardiovascular risk of patients in a primary care setting, at both General Practitioners (GPs) or Cardiologists offices.
62663574|NCT04796896|EXPERIMENTAL|mRNA-1273|"Part 1: Participants will receive 2 IM injections of mRNA-1273 at doses pre-specified for this study, on Days 1 and 29. Participants will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After protocol amendment (PA) 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.~Part 2: Participants will receive 2 IM injections of mRNA-1273 at dose selected from Part 1 on Days 1 and 29. Participants (6 to \<12 year) will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.~Part 3: Participants will receive 2 IM injections of mRNA-1273 on Days 1 and 29 as primary series then 1 IM injection as Dose 3, on Day 149 ≥3 months and ≤5 months after receipt of Dose 2 of primary series. All 3 injections will be administered at lower dose than that of Part 1."
62663575|NCT04796896|PLACEBO_COMPARATOR|Placebo|Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo on Day 1 and Day 29. Participants (6 to \<12 year old) will be offered an optional BD of mRNA-1273 at a dose lower than the dose that was chosen for the primary series for this age group, at least 6 months post-cross-over Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.
62663576|NCT04167670|EXPERIMENTAL|Vonoprazan dual therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.
62467745|NCT04078932|EXPERIMENTAL|Intervention|Cohort of residents trained in the conversation script who will utilize the script at pediatric clinic visits. Will evaluate baseline feelings of comfort and self-efficacy prior to being trained in the script (pre-intervention measures). After being trained in the conversation script (the intervention), the following will be measured (post-intervention measures): frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
62467746|NCT04078932|NO_INTERVENTION|Control|Cohort of residents at another clinical site with a similar community demographic make-up who do not receive the intervention. In the control group, we will measure frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
62663577|NCT04167670|EXPERIMENTAL|Vonoprazan triple therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.
62295562|NCT03584009|ACTIVE_COMPARATOR|Fulvestrant|Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
62467747|NCT02973763|EXPERIMENTAL|Alflutinib|patients take Alflutinib orally once per day at different dose
62467748|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
62467749|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
62467750|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
62467751|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
62467752|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
62467753|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
62467754|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
62467755|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
62663578|NCT04167670|ACTIVE_COMPARATOR|Lansoprazole triple therapy|Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.
62663579|NCT06189963|EXPERIMENTAL|SNK01|SNK01 will be administered as an IV infusion Q3W for up to 1 year.
62295563|NCT00849589|NO_INTERVENTION|1|Treatment as Usual (TAU)
62295564|NCT00849589|EXPERIMENTAL|2|Computerized Screening and Brief Physician Advice (SBA)
62295565|NCT00849589|EXPERIMENTAL|3|Computerized screening and brief physician advice with technological extenders (SBA/TE)
62295566|NCT01207466|OTHER|Nelfilcon A invest'l / nelfilconA comm'l|Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
62663580|NCT06189963|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as an IV infusion Q3W for up to 1 year.
62663581|NCT04733885|EXPERIMENTAL|Electrical Stimulation group|ES and lifestyle advice have been applied ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
62663582|NCT04733885|SHAM_COMPARATOR|Sham Electric Stimulation group|Sham ES and lifestyle advice have been applied Sham ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
62663583|NCT02769520|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
62663584|NCT01618591|EXPERIMENTAL|Acute Watery Diarrhea|
62663585|NCT01618591|EXPERIMENTAL|Acute Dysentery/Febrile|
62663586|NCT02680275|EXPERIMENTAL|Doxycycline,Dead Sea Peloid Gel,placebo|"1. Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally~2. Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally"
62295567|NCT01207466|OTHER|Nelfilcon A comm'l / nelfilconA invest'l|Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
61911738|NCT06329128|EXPERIMENTAL|Study Group|This group will get manuel therapy that combinated electroterapy and hm programme (exercise).
61911739|NCT06329128|ACTIVE_COMPARATOR|Control Group|This group will get traditional therapy (electrotherapy and exercise)
62295568|NCT06246383|ACTIVE_COMPARATOR|QActin|Cucumber extract
62295569|NCT06246383|PLACEBO_COMPARATOR|placebo|Placebo capsule
62295570|NCT06585306|EXPERIMENTAL|HFNC30L/min|patients pre-oxygenation with pure oxygen at 30L/min for 1 minute, followed by sedation with slightly slow but steady breathing, disappearance of eyelash reflex, and continued oxygen flow at 30 L/min
62295571|NCT06585306|EXPERIMENTAL|HFNC50L/min|patients pre-oxygenation with pure oxygen at 30L/min for 1 minute, followed by sedation with slightly slow but steady breathing, adjustment of oxygen flow to 50L/min after disappearance of eyelash reflex.
62295572|NCT06585306|EXPERIMENTAL|HFNC70L/min|patients pre-oxygenation with pure oxygen at 30L/min for 1 minute, followed by sedation with slightly slow but steady breathing, adjustment of oxygen flow to 70L/min after disappearance of eyelash reflex.
62295573|NCT01381081|EXPERIMENTAL|platelet-rich plasma intra-articular knee injections|a single intra-articular injection of PRP in knee osteoarthritis
62295574|NCT01381081|ACTIVE_COMPARATOR|Corticosteroid intra-articular knee injections|a betamethasone and bupivacaine intra-articular injection
62295575|NCT05247411|EXPERIMENTAL|Educational intervention|a Skype-videoconference, which included a 30 min educational intervention, was held with each subject.
62295576|NCT00432237|EXPERIMENTAL|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
62663587|NCT05817604||Localized Renal Cancer-One arm|Patients diagnosed with medically inoperable localized renal cancer \[Size \<7cm (cT1b)\] based on TC, MRI or PET Image Study.
62663588|NCT01101100|EXPERIMENTAL|AMG 827|AMG 827
62663589|NCT02233413|SHAM_COMPARATOR|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
62663590|NCT02233413|ACTIVE_COMPARATOR|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
62663591|NCT00154466|EXPERIMENTAL|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2.
62663592|NCT00154466|NO_INTERVENTION|postinfarction patients|those in the nontraining group continued their usual lifestyle
61911740|NCT02148900||Marfan|Diagnosis of Marfan syndrome, according to Ghent criteria.
61911741|NCT02148900||Marfan Related Disorders|Diagnosis of Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Familial Thoracic Aortic Aneurysm and Dissection.
61911742|NCT02148900||Control Subjects|Unaffected by Marfan or Marfan related disorders.
61911743|NCT01429337|EXPERIMENTAL|Normal hepatic function - group 1|Matched control for group 2 and 3 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in mild and moderate hepatic function groups. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
62295577|NCT00432237|EXPERIMENTAL|MK0974 150 mg|MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
62663593|NCT00154466|PLACEBO_COMPARATOR|healthy controls|Age-, weight-, and height-matched subjects without cardiovascular risk factors were selected as healthy controls.
62663594|NCT00447278|EXPERIMENTAL|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
61911744|NCT01429337|EXPERIMENTAL|Mild hepatic impairment - group 2|Subjects with mild impaired hepatic function - Child Pugh A classification score 5-6. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
61911745|NCT01429337|EXPERIMENTAL|Moderate hepatic impairment - group 3|Subjects with moderate hepatic function - Child Pugh B classification score 7-9. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
61911746|NCT01429337|EXPERIMENTAL|Severe hepatic impairment - group 4|Subjects with severe hepatic impairment function - Child Pugh C classification score 10-15. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
62663595|NCT00447278|ACTIVE_COMPARATOR|OEST|Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
62663596|NCT05207358|EXPERIMENTAL|RITUXILUP regimen|- 2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15. Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
62663597|NCT05207358|OTHER|EUROLUPUS regimen (Standard therapy)|3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment. All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
62663598|NCT03947034||Metabolic toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of metabolic toxicities(such as hyperammonemia) of patient treated by a drug, with a chronology compatible with the drug toxicity
62663599|NCT05356663|EXPERIMENTAL|Mulligan Mobilization with movement|Mulligan Mobilization with movement + Baseline treatment (Moist Heat Pack) Group will receive mulligan mobilization with movement with the frequency of 3 sets and 10 repetitions 3 times a week for 6 weeks.
62663600|NCT05356663|EXPERIMENTAL|Hold relax technique|Hold relax technique + Baseline treatment (Moist Heat Pack) Group will receive Hold Relax Technique of PNF included, 5 repetitions will be given 3 times/week for 6 weeks.
62102488|NCT06526585|EXPERIMENTAL|Box Breathing|"Ten minutes a day of active breathwork practice for 28 days delivered remotely through a video link.~Participants will also practice 10 minutes of active breathwork during the 2 MRI assessments, one before the start of the 28 days, and one after the completion of the 28 days."
62102489|NCT06526585|EXPERIMENTAL|Hypnosis|"Ten minutes a day of hypnosis practice for 28 days delivered remotely through an audio link.~Participants will also practice 10 minutes of hypnosis during the 2 MRI assessments, one before the start of the 28 days, and one after the completion of the 28 days"
62102490|NCT06526585|ACTIVE_COMPARATOR|Audiobook on Stress|"Ten minutes a day of listening to sections of an audiobook about stress for 28 days (passive listening) delivered remotely through an audio link.~Participants will also listen to the 10 minute segments during the 2 MRI assessments, one before the start of the 28 days, and one after the completion of the 28 days."
62663601|NCT06549972||ischemic stroke group|The ischemic stroke group will be recruited from inpatients in the Department of Neurology at the Northern Campus of Ruijin hospital.
62102491|NCT06711692||DMD children and adult|Paediatric and adults with DMD
62663602|NCT06549972||control group (healthy individuals)|The control group will be recruited from outpatient health check-up populations undergoing routine blood tests, biochemical tests, cranial CT, or MRI.
61911747|NCT01429337|EXPERIMENTAL|Normal hepatic function - group 5|Matched control for group 4 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in severe hepatic function group. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
61911748|NCT01411553|NO_INTERVENTION|Reusable ECG leadwires-ICU|Current ECG leadwires will be used
61911749|NCT01411553|ACTIVE_COMPARATOR|Disposable ECG leadwires-ICU|Disposable ECG-LW
61911750|NCT03899636|EXPERIMENTAL|IRE|
61911751|NCT03899636|ACTIVE_COMPARATOR|Control|
62102492|NCT03397160|NO_INTERVENTION|Usual care|Participants assigned to the control arm will receive usual care, including whatever information materials are provided to them by their urologist.
62295578|NCT00432237|EXPERIMENTAL|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
62295579|NCT00432237|PLACEBO_COMPARATOR|Placebo|Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
62295580|NCT02041559||robot assisted prostatectomy|robot assisted prostatectomy
61911752|NCT02395302|EXPERIMENTAL|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
62295581|NCT01552876|OTHER|etafilcon A / nelfilcon A / Filcon II 3|etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.
62295582|NCT01552876|OTHER|nelfilcon A / etafilcon A / Filcon II 3|nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.
62663603|NCT04039269|ACTIVE_COMPARATOR|Multiple (watch > 3 times)|Preoperative video information
62663604|NCT04039269|ACTIVE_COMPARATOR|single (watch 1 time)|Preoperative video information
62663605|NCT04039269|NO_INTERVENTION|conventional (do not watch)|Do not watch video
62663606|NCT05504278|EXPERIMENTAL|IBI351 in combination with Sintilimab and pemetrexed|
62663607|NCT05504278|EXPERIMENTAL|IBI351 in combination with Sintilimab pemetrexed and cis-platinum/carboplatin|
62663608|NCT05504278|EXPERIMENTAL|IBI351 monotherapy|
62663609|NCT05504278|EXPERIMENTAL|IBI351 in combination with Sintilimab|
62663610|NCT02756468||pts operated for pancreatic cancer|all pts operated of pancreatic resection for cancer in the involved units
61911753|NCT02906384|NO_INTERVENTION|routine PCI|PTV:25Gy/10F. Radiation technique: VMAT.
62663611|NCT05076123|EXPERIMENTAL|Experimental group-1 (M-CIMT group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) in addition to conventional therapy. M-CIMT is shorter versions of CIMT. The original CIMT devotes six or more hours for therapy and constraining of the intact arm for 90% of waking hours per day and over a period of two weeks. Researchers have observed that such a schedule of CIMT is exhaustive and possibly resulting in non-compliance. Because of this reason,s Modified shorter versions of CIMT (mCIMT) have been designed by researchers. Duration of M-CIMT interventions varies from 2 to 10 weeks and the treatment time also varies from as short as 30 minutes to three hours per day in various studies. Nevertheless both CIMT and mCIMT have shown promising success. M-CIMT emphasizes massed practice with the affected upper limb.
62663612|NCT05076123|EXPERIMENTAL|Experimental group-2 (M-CIMT+TES group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) and threshold electrical stimulation (TES) in addition to conventional therapy. TES is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes. TES provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction. TES can improve motor learning and motor performance by improving connections between sensory-motor cortical association regions in the brain.
62663613|NCT05076123|NO_INTERVENTION|Control group|participants in this group will be trained with conventional therapy. Conventional therapy consists of strength training, stretching exercises and functional activity training.
62663614|NCT05150288|EXPERIMENTAL|Formula-fed infants|Infants fed exclusively with experimental formula
62663615|NCT05150288|EXPERIMENTAL|Mixed-fed infants|Infants receiving breastmilk and experimental formula
62663616|NCT05150288|NO_INTERVENTION|Breast-fed infants|Reference group of exclusively breastfed
62295583|NCT03360812|EXPERIMENTAL|Intervention group|The intervention is an online training resource to improve the recognition of imminent death in palliative care patients. The intervention should take approximately 15 minutes to complete. During this time, the participants who are in the intervention arm will be shown the results of a previous study which identified how expert palliative care doctors recognise imminently dying palliative care patients. The intervention will be implemented via the website, immediately after participants have completed the first set of vignettes.
62295584|NCT03360812|NO_INTERVENTION|Control group|The participants assigned to the control group will not receive this additional information and will simply be informed that they are approximately half way through the task and will be asked to continue on to the next set of vignettes.
62467756|NCT00954395||1. anticoagulation suspension|eligible patients undergo measurement of residual venous obstruction (RVO) with compression ultrasound (CUS) in case of a previous deep vein thrombosis (DVT) and/or of pulmonary artery pressure (PAP) with echocardiography in case of previous pulmonary embolism (PE). In patients with RVO is less \< 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is below age and gender cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If all the D-dimer measurements are below the cut-offs, anticoagulation is definitely interrupted and patients are followed-up for two years.
61911754|NCT02906384|EXPERIMENTAL|HA-PCI|"PTV 25Gy/10F. Hippocampus avoidance: decrease the dose to HAZ as the following criteria: Dmin\<9Gy Dmax\<16Gy.~Radiation technique: VMAT."
62467757|NCT00954395||2. anticoagulation prolongation|If RVO is greater than 4 mm at CUS of the lower limbs and/or PAP is increased (\> 35 mmHg, \> 40 mmHg in the elderly or obese), anticoagulation is prolonged for additional 6 months and the measures of RVO and/oR PAP are repeated. In those in whom PAP is altered also after 6 months of additional therapy, anticoagulation is prolonged. In patients with RVO is less \< 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is above age and gender cut-offs , anticoagulation is prolonged. If D-dimer is below the cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If one of these D-dimer measurement is above the cut-off , anticoagulation is resumed for at least 6 months and patients are re-evaluated.
62467758|NCT01375660|PLACEBO_COMPARATOR|Arm 1|Placebo: One capsule weekly
62663617|NCT03975634|EXPERIMENTAL|Transcutaneous spinal stimulation|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while trunk control is assessed at 3 time points (acute) and/or while transcutaneous stimulation is applied in combination with activity-based locomotor training (40 sessions, 1.5 hours/day, 5 days/week; stimulation will be applied intermittently for no more than 10 minutes at a time during training)
62663618|NCT01584388|EXPERIMENTAL|Rituximab|
62663619|NCT00827242|EXPERIMENTAL|Tadalafil|
62663620|NCT00827242|PLACEBO_COMPARATOR|Placebo|
62102493|NCT03397160|ACTIVE_COMPARATOR|Decision Support Intervention (DSI)|"Participants assigned to the intervention will receive Decision Support Intervention in the form of a decision aid plus health coaching. The decision aid (delivered by internet and as a Portable Document Format (PDF) document) provides participants with a report on options and outcomes as described in the literature; along with more tailored risk information. The tailored risk information will include their estimated risk of harboring more aggressive prostate cancer based on their clinical/pathologic features (i.e., My Clinical Risk). The DSI was developed and piloted at UCSF according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332), and incorporates tailored risk models developed and validated."
62663621|NCT03796663|ACTIVE_COMPARATOR|Mindful Parenting Only|"Participants in this arm will receive only the Mindful Parenting Program at the start of the study. Bögels and Restifo's (2014) Mindful Parenting Program is an adaptation for parents of MBCT, and MBSR; the program will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will be asked continue to participate in data collection for the post-intervention assessment time point (i.e. 8 weeks after the completion of the Mindful Parenting group sessions) and for the 2-month follow up assessment time point (i.e. 16 weeks after the completion of the Mindful Parenting group sessions). After they have completed both assessments, they will be offered the opportunity to participate in the MATCH BPT program if they so choose (no data will be collected)."
62102494|NCT01744691|EXPERIMENTAL|ibrutinib|All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.
61911755|NCT02052414|EXPERIMENTAL|Gralise (Gabapentin ER)|"All patients will be treated with Gralise. Patients who are on pregabalin or gabapentin (lyrica or neurontin) will need to wash off the medication before starting Gralise.~Patients who are ready to take Gralise will start with starter pack, and will gradually titrate the dose up to 1800mg per day. After that, patient will take 1800mg per day out of the bottle.~Patient will be seen in clinic at 4weeks intervals for first 4 visits, and then there will be end of the study visit on week 15. On visit 4, week 12 of treatment, patients will be taught to taper off the study medication."
62102495|NCT06683534|EXPERIMENTAL|Use of oral quercetin to improve human microvascular function|Quercetin is a non-FDA approved, over-the-counter supplement that has been shown to improve oxidative capacity in blood vessels.
62295585|NCT06090071|ACTIVE_COMPARATOR|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts. Product will be topically applied to the assigned side of the face, either left or right side, at Day 0, Day 14, Day 28, Day 42, Day 70, and Day 98.
62295586|NCT06090071|PLACEBO_COMPARATOR|Placebo Moisturizer|Placebo Moisturizer will be topically applied to the assigned side of the face, either left or right side, at Day 0, Day 14, Day 28, Day 42, Day 70, and Day 98.
62467759|NCT01375660|EXPERIMENTAL|Arm 2|50K vitamin D2: One capsule weekly
62102496|NCT06683534|PLACEBO_COMPARATOR|Placebo|A placebo will be administered for 30 days followed by assessment of the subject's microvascular function.
62295587|NCT04247048|EXPERIMENTAL|Control group|Patients with no major LDL cholesterol abnormalities (patients eligible for LDL-apheresis, eg LDL-C\> 200 mg / dL for secondary prevention and 300 mg / LDL-C) dl in primary prevention)) and a level of Lp (a) \<50 mg / dl
62295588|NCT04247048|EXPERIMENTAL|High-dose group|Patients with no major LDL-cholesterol abnormalities (LDL-apheresis eligible patients, eg LDL-C\> 200 mg / dL for secondary prevention and 300 mg / dl in primary prevention)) and a level of Lp (a)\> 80 mg / dl
62663622|NCT03796663|EXPERIMENTAL|Mindful Parenting and BPT Combined|"Participants in this arm will receive the Mindful Parenting Program at the start of the study, which will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will receive receive individually-implemented MATCH BPT sessions, which will consist of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 1 hour sessions. The MATCH manual is comprised of 33 modules (i.e. coping, giving effective instructions, learning to relax, etc.). For the purpose of this study we will be utilizing the section on BPT, which consists of 12 modules with corresponding handouts and worksheets."
62663623|NCT01485835|EXPERIMENTAL|Ganetespib + Bortezomib + Dexamethasone|"Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks~* Cohort 1: 100 mg/m²~* Cohort 2: 100 mg/m²~* Cohort 3: 120 mg/m²~* Cohort 4: 144 mg/m²~* Cohort 5: 173 mg/m²~Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks~* Cohort 1: 1.0 mg/m²~* Cohort 2, 3, 4, 5: 1.3 mg/m²~Dexamethasone: Oral prior to bortezomib~* Cohort 1, 2, 3, 4, 5: 20 + 20 mg~* Day of and following bortezomib"
61911756|NCT02104388|EXPERIMENTAL|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
61911757|NCT02104388|PLACEBO_COMPARATOR|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
62663624|NCT02852083|EXPERIMENTAL|A: Biomodulatory treatment|treosulfan 250 mg p.o. twice daily, pioglitazone 45 mg p.o. once daily, clarithromycin 250 mg p.o. twice daily until progression or no clinical benefit observed, whichever comes first.
61911758|NCT04474548|EXPERIMENTAL|Ultrasound|"For participants randomly assigned to ultrasound use, a bedside ultrasound will be performed using the trans-abdominal probe during and/or immediately after placement of the IUD. The distance from the IUD arms to the fundus will be measured with the ultrasound, and the IUD will be defined as being in place when the distance from the top of the IUD to the fundus is measured to be 3mm or less. If the distance is greater than 4mm, the provider may reposition the IUD manually or with a ring forceps."
62295589|NCT03228368||Atezolizumab (MPDL3280)|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
62295590|NCT02661984||Healthy (no pulmonary disease)|Healthy children 4 - 6 years old with no pulmonary disease and not exhibiting respiratory illness or sinusitis.
62295591|NCT02661984||Asthmatic (physician diagnosed)|Asthmatic children 4 - 6 years old not exhibiting acute asthma symptoms, respiratory illness or sinusitis.
62295592|NCT00662961|EXPERIMENTAL|1|Periosteum
62295593|NCT00662961|EXPERIMENTAL|2|Bone
62295594|NCT02296411|EXPERIMENTAL|CHF 5259 12.5 µg|CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)
62467760|NCT01590485|PLACEBO_COMPARATOR|Starch capsule|starch with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
62467761|NCT01590485|ACTIVE_COMPARATOR|Saffron capsule|saffron with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
62102497|NCT06609213|EXPERIMENTAL|Intervention|This is a single arm study in which all participants receive the intervention.
62295595|NCT02296411|PLACEBO_COMPARATOR|CHF 5259 placebo|CHF 5259 placebo: 2 inhalations bid
62295596|NCT00519870|ACTIVE_COMPARATOR|I, II|I: nifedipine II: losartan
62295597|NCT06487156||Participants receiving first-line nivolumab plus ipilimumab|
62295598|NCT03784196||Acute Whiplash Associated Disorders|People suffering from acute WAD at the time of recruitment.
62663625|NCT02852083|ACTIVE_COMPARATOR|B: Standard Treatment|Nivolumab, 3 mg per kilogram of body weight every 2 weeks until disease progression according to RECIST 1.1 or unacceptable toxicity
62295599|NCT03784196||Healthy controls|Participants with no neck pain during the past 6 months, chronic pain or other medical disorders relevant to this study.
62663626|NCT00095966|EXPERIMENTAL|Treatment (sorafenib tosylate and gemcitabine hydrochloride)|Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62663627|NCT02183974|EXPERIMENTAL|Peptest|44 children at the age between 1 to 7 years diagnosed with bilateral or unilateral OME who underwent adenoidectomy and myringotomy with insertion of ventilation tube. Effusion was collected and analysed using Peptest, which contains monoclonal antibodies targeted against pepsin. Result of the Peptest was stated as positive (2 lines), negative (1 line) and invalid (no line).
62663628|NCT04605913|EXPERIMENTAL|Modified GCN+TTF treatment|The trial will compose of 2 parts with a total of 40 subjects. The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1. If 6 patients tolerate the dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
61911759|NCT04474548|NO_INTERVENTION|No ultrasound|For participants randomly assigned to no ultrasound use, provider will insert the IUD with a ring forceps and will use palpation of the fundus to determine whether or not the IUD is likely in place.
62295600|NCT00401440|ACTIVE_COMPARATOR|A|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
62295601|NCT00401440|ACTIVE_COMPARATOR|B|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
62295602|NCT01608425|NO_INTERVENTION|Control|Control group. Regular treatment.
62295603|NCT01608425|EXPERIMENTAL|Diabetes ulcer monitoring|Receives a telemedicine intervention: Diabetes ulcer monitoring.
62295604|NCT05439031|EXPERIMENTAL|Stereotactic Arrhythmia Radiotherapy|Patients will undergo stereotactic arrhythmia radiotherapy and subsequent follow-up.
62295605|NCT02340650||Bladder Cancer Patients|High resolution images of normal bladder tissue and suspicious bladder lesions will be collected from patients who present to the study site for clinical evaluation.
62663629|NCT04676776|EXPERIMENTAL|Missed period pill regimen|1.5 mg levonorgestrel given on day 1 200 mg mifepristone given on day 3
62663630|NCT02022930|EXPERIMENTAL|Hydros|Hydros Joint Therapy
62295606|NCT04453111|EXPERIMENTAL|Hyaluronic Acid (HA) + P-MMSCs|Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
62663631|NCT02022930|EXPERIMENTAL|Hydros-TA|Hydros-TA Joint Therapy
62663632|NCT02022930|ACTIVE_COMPARATOR|Triamcinolone acetonide|Triamcinolone acetonide
62663633|NCT01250665||clinically isolated syndrome|In this study the term clinically isolated syndrome (CIS) is defined according to the Task Force on Differential Diagnosis in MS, as a monophasic presentation of neurological symptoms with suspected underlying inflammatory demyelinating disease (Miller 2008).
62663634|NCT01250665||remitting, relapsing MS|remitting relapsing MS according to the criteria by Poser (Poser 1983) or McDonald (McDonald 2001)
62663635|NCT02465970|EXPERIMENTAL|TDCS session|Intervention : Stimulation is applied during a 60 min session with STARSTIM
62663636|NCT02465970|PLACEBO_COMPARATOR|TDCS Placebo|Intervention : Stimulation is not applied during a 60 min session with STARSTIM
62663637|NCT04109963|ACTIVE_COMPARATOR|RIC once per day|RIC performed once a day on one arm. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
61911760|NCT01319331|EXPERIMENTAL|Alpha-1 Antitrypsin (AAT, Aralast NP)|Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
62295607|NCT04453111|EXPERIMENTAL|Hyaluronic Acid (HA) + BM-MMSCs|Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
62295608|NCT04453111|ACTIVE_COMPARATOR|Hyaluronic Acid (HA)|Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients
61911761|NCT05513118||Post-menopausal women|
61911762|NCT05513118||Regularly mensturating women|
61911763|NCT01782001|EXPERIMENTAL|Vitamin A and zinc|combination of vitamin A and zinc supplements
62663638|NCT04109963|ACTIVE_COMPARATOR|RIC twice per day|RIC performed twice a day on one arm, approximately 12 hours apart. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
62663639|NCT03608332|NO_INTERVENTION|Group S|"weaning readiness will be evaluated with the standard criteria :- A) Clinical assessment:-~* Resolution of acute phase of disease for which patient was intubated~* Adequate cough~* Absence of excessive tracheobronchial secretions~B) Objective criteria:-~* Adequate oxygenation:PaO2\>60mmHg with PEEP\<8,SaO2\>90%,FIO2 \<0.5,PaO2/FIO2\>200~* Respiratory rate \<30~* PH and PaCO2 appropriate for patients' baseline respiratory status~* Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~* HR\<140 beats/minute~* Patient is arousable or Glasgow coma scale (GCS)\>13"
62663640|NCT03608332|EXPERIMENTAL|Group SD|"weaning readiness will be evaluated with the following criteria:- A) Clinical assessment:-~* Resolution of acute phase of disease for which patient was intubated~* Adequate cough~* Absence of excessive tracheobronchial secretions~B) Objective criteria:-~* Adequate oxygenation:PaO2\>60mmHg with PEEP\<8,SaO2\>90%,FIO2 \<0.5,PaO2/FIO2\>200~* Respiratory rate \<30~* PH and PaCO2 appropriate for patients' baseline respiratory status~* Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~* HR\<140 beats/minute~* Patient is arousable or Glasgow coma scale (GCS)\>13~C) Ultrasound criteria:-~• Diaphragmatic excursion \>11 mm"
62663641|NCT01567800|EXPERIMENTAL|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with prostate cancer
62663642|NCT03543267|EXPERIMENTAL|epileptic Patients|
62663643|NCT00728923|EXPERIMENTAL|1|Minocycline (NPL-2003)
61911764|NCT01782001|ACTIVE_COMPARATOR|Vitamin A and placebo|vitamin A with placebo
61911765|NCT00562666|EXPERIMENTAL|1|Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes
62663644|NCT06529887||Patients|Dialysis patients (hemodialysis and peritoneal dialysis)
62663645|NCT06529887||Professionnels|Nurses and nephrologists caring for the patient
62663646|NCT05118269|EXPERIMENTAL|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
62663647|NCT05118269|ACTIVE_COMPARATOR|Optimal Medical Therapy (Control)|Patients will be treated according to Optimal Medical Therapy
61911766|NCT00562666|EXPERIMENTAL|2|Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes
61911767|NCT00562666|EXPERIMENTAL|3|Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes
61911768|NCT00562666|EXPERIMENTAL|4|Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes
61911769|NCT02163343||No treatment|
62295609|NCT00550498|EXPERIMENTAL|A|Behcet's Disease with ocular lesions
62663648|NCT03729440||corrosive patients|
62663649|NCT05309850|EXPERIMENTAL|Usage of tool|Participants get access to the tool and use it regularly
61911770|NCT03873675||Study group|Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.
61911771|NCT01578512|EXPERIMENTAL|Face-to-Face|8 sessions of weekly group behavioral weight loss treatment
61911772|NCT01578512|EXPERIMENTAL|Web-based|Participants receive one group face-to-face session followed by 7 web-based lessons, reporting of key behaviors, and feedback on progress.
61911773|NCT01578512|ACTIVE_COMPARATOR|Single Session|Single session behavioral weight loss
61911774|NCT05628688||Test group|Up to 50 subjects will be enrolled with unilateral or bilateral edema in the upper or lower extremity.
61911775|NCT05628688||Control group|Up to 50 patients will be enrolled from a healthy volunteer group as a control, with no edema.
61911776|NCT01629199|EXPERIMENTAL|rhEGF(recombinant human Epidermal Growth Factor)|BID
61911777|NCT01629199|PLACEBO_COMPARATOR|placebo|BID
62102498|NCT05854628|EXPERIMENTAL|0.1% red flavonoids facial cream|0.1% red flavonoids facial cream
62102499|NCT05854628|PLACEBO_COMPARATOR|Placebo facial cream|Placebo moisturizing facial cream
62295610|NCT02183714|EXPERIMENTAL|Songha Night ®|
62102500|NCT04792099|EXPERIMENTAL|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) with blended oxygen delivered by binasal prongs or nasal mask.
62102501|NCT04792099|ACTIVE_COMPARATOR|Nasal Cannula|Blended oxygen delivered by nasal cannula (NC).
62663650|NCT05309850|NO_INTERVENTION|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease or type 2 diabetes is followed via clinical registries.
62663651|NCT02323815|ACTIVE_COMPARATOR|Control|Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
62663652|NCT02323815|EXPERIMENTAL|PROMIS intervention|"* Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age~* Caregivers with children 6-23 months of age that attend Counselling meetings will be provided with a monthly dose of SQ-LNS (20g/day)"
62663653|NCT00992836|EXPERIMENTAL|Influenza A (H1N1) 2009 monovalent vaccine|All participants received two doses of the H1N1 influenza virus vaccine, administered 21 days apart.
62663654|NCT02562885|EXPERIMENTAL|Acoustic pulses|"During NREM sleep:~1. 15 minutes without acoustic pulses~2. 15 minutes with acoustic pulses~3. 15 minutes without acoustic pulses~Two different protocols are applied:~(A) tone application at the Down-phase of sleep slow wave (SSW) (B) tone application at the Up-phase of SSW.~Participants with Rolandic epilepsy/BECTS or generalized spike waves: Protocol A and B alternatingly.~Participants with ESES/CSWS: only Protocol A."
62663655|NCT01327703|EXPERIMENTAL|Panzytrat® 25,000|
62663656|NCT01327703|ACTIVE_COMPARATOR|Kreon® 25,000|
62663657|NCT04215770|ACTIVE_COMPARATOR|Inj Co-amoxiclav|Group A children were advised Inj Co-amoxiclav 50 units/kg/day in 3 divided doses daily
62663658|NCT04215770|ACTIVE_COMPARATOR|Inj Benzyl Penicillin|Group B patients were advised inj Benzyl Penicillin 25000 units/kg/day in 3 divided doses
62663659|NCT02260622|ACTIVE_COMPARATOR|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
62663660|NCT02260622|EXPERIMENTAL|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
62663661|NCT05714332||Advanced practice physiotherapy and orthopedic surgeon group|Patients cared by both an advanced practice physiotherapist and an orthopedic surgeon.
62663662|NCT05714332||Orthopedic surgeon only group|Patients cared only by an orthopedic surgeon.
62663663|NCT05621473|EXPERIMENTAL|trial group|This arm of patients received tunnel PICC interventions
62663664|NCT05621473|EXPERIMENTAL|control group|This arm of patients received normal PICC interventions
62663665|NCT01671059||Tocilizumab|Participants with rheumatoid arthritis (RA) receiving tocilizumab either as combination therapy or monotherapy through routine clinical practice.
62663666|NCT06551493||Postnatal women|
62663667|NCT06551493||Registered midwives|
62102502|NCT01720719|ACTIVE_COMPARATOR|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
62102503|NCT01720719|EXPERIMENTAL|Atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
62102504|NCT06600685|OTHER|FMT arm|
62102505|NCT05608967||G_PREHapp|Experimental group will follow a prehabilitation programme through the PREHapp platform
62663668|NCT04227717|EXPERIMENTAL|Thoracic, lumbar and sacral spine lesions|Participants will have thoracic, lumbar and sacral spine lesions
62663669|NCT01275027|EXPERIMENTAL|Nutralin|Individuals with Type 2 Diabetes
62663670|NCT01275027|PLACEBO_COMPARATOR|Placebo|Individuals with Type 2 Diabetes
62663671|NCT03476642|ACTIVE_COMPARATOR|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
62663672|NCT03476642|ACTIVE_COMPARATOR|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
62102506|NCT05608967||G_Control|Control group will follow a prehabilitation programme according to usual practice
62102507|NCT03880422|EXPERIMENTAL|Supportive care (diet, exercise, education)|Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
62102508|NCT01019577|EXPERIMENTAL|Ixabepilone|
62102509|NCT05288101|ACTIVE_COMPARATOR|Control|Patients in CON group received a personalized diet and dry weight adjustment by BIVA. Anthropometrical, biochemical, dietary, QoL, handgrip strength (HGS) and bioimpedance measurements were performed. Malnutrition Inflammation Score (MIS) was applied
62663673|NCT06471803||acute myocardial infarction (AMI)|acute myocardial infarction
62663674|NCT06471803||Unstable angina (UA)|Unstable angina
62663675|NCT06471803||chronic coronary syndrome (CCS)|chronic coronary syndrome
62663676|NCT06471803||normal coronary artery (NCA)|normal coronary artery
62663677|NCT02406612|EXPERIMENTAL|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
62663678|NCT04876183|ACTIVE_COMPARATOR|Intervention Group|Web-based intervention (Selfapy for Binge Eating Disorder)
62663679|NCT04876183|NO_INTERVENTION|Waitlist Control Group|12-week waiting period
62663680|NCT05051839|EXPERIMENTAL|Radiographic bone level|
62663681|NCT05051839|EXPERIMENTAL|Peri implant soft tissue volume|
62663682|NCT04951960|OTHER|A group from higher PEEP to lower PEEP|Patient allocated for this arm are received from higher to lower PEEP setting.
62663683|NCT04951960|OTHER|A group from lower PEEP to higher PEEP|Patient allocated for this arm are received from lower to higher PEEP setting.
62663684|NCT02788045|EXPERIMENTAL|Group 1A: Ad26.Mos.HIV|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
62467762|NCT01822483|EXPERIMENTAL|Mycophenolate sodium|Arm1(Conversion):MPA AUC below 30mcg\*h ml-1 - MPS+Calcineurin inhibitor+prednisone
62295611|NCT02183714|PLACEBO_COMPARATOR|Placebo|
62295612|NCT05973370|PLACEBO_COMPARATOR|Control|Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 24 weeks.
62467763|NCT01822483|ACTIVE_COMPARATOR|Mycophenolate mofetil|Arm2(Maintained):MPA AUC between 30 to 60 mg\*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
62467764|NCT03158675|EXPERIMENTAL|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.~Intervention:~-Procedure: Fractional carbon dioxide laser.~-Drug: Topical corticosteroid.~-Radiation: Ultraviolet B narrow band."
62467765|NCT01232647|ACTIVE_COMPARATOR|Vitamin k1|1.0 mg of vitamin K1 (phylloquinone) and placebo MK4 will be given to one of the treatment arm for 18 months
62467766|NCT01232647|PLACEBO_COMPARATOR|placebo vitamin K1 and MK4|placebo pill of both vitamin K1 and MK4 given for 18 months to the control arm
62467767|NCT01232647|ACTIVE_COMPARATOR|Menatetrenone MK4|45 mg MK4 given daily and placebo vitamin K1 will be given to one of treatment arm for 18 months
62663685|NCT02788045|PLACEBO_COMPARATOR|Group 1B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
62663686|NCT02788045|EXPERIMENTAL|Group 2A: Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants will be included in an optional Long-term Extension (LTE) phase (3 years or 4 years Follow-up after Week 72, every 6 months visit) to assess immunogenicity and safety (serious adverse events \[SAEs\]).
62663687|NCT02788045|PLACEBO_COMPARATOR|Group 2B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
62295613|NCT05973370|ACTIVE_COMPARATOR|Ursodeoxycholic acid (UDCA)|Participants in this arm will receive ursodeoxycholic acid (UDCA) 500 mg/day + DMARDs for 24 weeks.
62663688|NCT01214720|EXPERIMENTAL|1|
62663689|NCT02558751|ACTIVE_COMPARATOR|HIV positive PPV23|HIV-positive individuals 50-65 years of age immunized with one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23
62295614|NCT02436109||study group|elective cesarean delivery patients
62295615|NCT06656104||Reference period|The center used the routine strategy based on the usual catheters and infusion systems (reference strategy). The duration of this period depending to the randomization of the center (i.e. 4 months, 8 months or 12 months)
62295616|NCT06656104||Experimental period|At the end of the reference period, center will progressively switch to the new multi-infusion strategy (experimental strategy). The center used the Multiline Neo system to the routine strategy. The duration of this period depending to the randomization of the center (i.e. 12 months, 8 months or 4 months)
62295617|NCT06335121|EXPERIMENTAL|Intervention - Aim 2|During the intervention period, PPIL staff will capture PrEP eligible women through an updated electronic flag alert in the patient's electronic medical record. The flag will alert to offer the patient PrEP navigation services and implement adapted POWER Up intervention strategies according to training.
62295618|NCT06335121|NO_INTERVENTION|Control - Aim 2|PPIL health centers will follow current PrEP navigation procedures using current monitoring system.
62295619|NCT04873687|EXPERIMENTAL|Intervention|The intervention arm will comprise study participants who receive intervention therapy (i.e eligible stable angina pectoris patients in intervention arm who agree to participate)
62295620|NCT04873687|NO_INTERVENTION|Control|Eligible stable angina pectoris patients in the control arm will receive no intervention therapy
62295621|NCT06657586|EXPERIMENTAL|neuromuscular exercises|Patients in group 1 received conservative treatment and neuromuscular exercises performed by a physiotherapist.
62295622|NCT06657586|ACTIVE_COMPARATOR|conservative treatment|Patients in group 2 received conservative treatment
62467768|NCT01884766||Epilepsy|All kind of epilepsy, including febrile seizures
62467769|NCT01884766||Control|children without seizures at presentation in the emergency but fever due to banal infections
62467770|NCT00369447|EXPERIMENTAL|1|200 mg dose
62467771|NCT00369447|PLACEBO_COMPARATOR|2|
62467772|NCT05566860|EXPERIMENTAL|BMI <27|
62467773|NCT05566860|EXPERIMENTAL|BMI 27-32|
62467774|NCT05566860|EXPERIMENTAL|BMI >32|
62467775|NCT04937348||GDM G1|Mothers diagnosed with gestational diabetes mellitus, treated with diet; and their newborns
62467776|NCT04937348||GDM G2|Mothers diagnosed with gestational diabetes mellitus, treated with insulin; and their newborns
62467777|NCT04937348||non-GDM / control group|"Healthy, non-diabetic mothers, without disturbances in glucose metabolism; and their newborns.~Control group."
62467778|NCT04627038|EXPERIMENTAL|LY3556050 600 mg|Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
62467779|NCT04627038|PLACEBO_COMPARATOR|Placebo|Participants received placebo BID every 12 hours for up to 8 weeks.
62467780|NCT00274937|EXPERIMENTAL|Stratum I (radiotherapy, chemoprotective agent)|Patients undergo radiotherapy 5 days a week for 8 weeks. Patients also receive amifostine subcutaneously on the same days they undergo radiotherapy.
62295623|NCT05805514|EXPERIMENTAL|Food and psychosocial intervention|In Food and psychosocial intervention, the nutrition workers will be responsible for providing egg through food voucher, psychosocial stimulation, nutrition education counselling, child water, sanitation and hygiene message, and multiple micronutrient powder among the selected mothers/infant pairs.
62467781|NCT00274937|EXPERIMENTAL|Stratum II (chemotherapy, chemoprotective agent, radiotherapy)|Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiotherapy and receive amifostine as in stratum I. Patients also receive 3 courses of cisplatin as before.
62467782|NCT05863962|EXPERIMENTAL|Stretching Exercises|walking with stretching exercises
62467783|NCT05863962|ACTIVE_COMPARATOR|Jacobson's Technique|walking with Jacobson's Relaxation Technique.
62467784|NCT06203717|EXPERIMENTAL|Alpha-Stim AID cranial electrotherapy stimulation|Four-week course of noninvasive cranial electrotherapy stimulation.
62467785|NCT02627066|ACTIVE_COMPARATOR|Volume Control|This group of patients will receive a volume reduction protocol that includes two primary components: 1) persistent ultrafiltration to slowly reduce patient's post-dialysis weight; and 2) persistent dietary education focused on reducing intake of dietary sodium and phosphorus additives
62467786|NCT02627066|ACTIVE_COMPARATOR|Volume Control + Exercise|This group of patients will receive the volume control intervention in addition to intensive counseling to increase their physical activity levels.
62467787|NCT06377657|EXPERIMENTAL|High-Intensity Interval Training|Participants in HIIT group underwent 3 sessions per week for 12 weeks. The HIIT protocol (maximum 60 cycles per 20-minute session) includes 8-second fast pedaling (approximately 80% of maximum heart rate (HR max)) followed by slow pedaling (20-30 rpm) for 12 seconds. To facilitate acceleration and limit the stagnation of the bicycle wheel, the selected resistance was very low (almost zero).
62467788|NCT06377657|EXPERIMENTAL|Aloe Vera supplementation|Participants in Aloe Vera group underwent supplementation with Aloe vera capsule containing 100 mg of Aloe vera gel powder in the morning immediately after waking up and one capsule after dinner.
62467789|NCT06377657|EXPERIMENTAL|HIIT + Aloe Vera|Participants in HIIT group underwent 3 sessions per week for 12 weeks. The HIIT protocol (maximum 60 cycles per 20-minute session) includes 8-second fast pedaling (approximately 80% of maximum heart rate (HR max)) followed by slow pedaling (20-30 rpm) for 12 seconds. To facilitate acceleration and limit the stagnation of the bicycle wheel, the selected resistance was very low (almost zero). Additionally, patients underwent supplementation with Aloe Vera capsules in the morning and after the dinner.
62467790|NCT06377657|NO_INTERVENTION|Control group|The control group continued their daily life activities for 12 weeks
62467791|NCT01882257|NO_INTERVENTION|Normal sleep breathing|Home-based sleep studies indicate no obstructive sleep apnea or nocturnal hypoventilation. No intervention.
62467792|NCT01882257|EXPERIMENTAL|BiPAP -Auto for sleep apnea|Patients whose home-based sleep study detects obstructive sleep apnea, but no nocturnal hypoventilation. Noninvasive ventilatory support will be prescribed according to standard clinical criteria.
61911778|NCT01844167|ACTIVE_COMPARATOR|Physical therapy arm (PT)|"* The TENS device used: FDA K071951~* Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
62467793|NCT01882257|EXPERIMENTAL|BiPAP (AVAPS) for nocturnal hypoventilation|Patients whose home-based sleep study detects nocturnal hypoventilation in the presence or absence of obstructive sleep apnea. Noninvasive ventilatory support will be prescribed according to standard clinical criteria. BiPAP/AVAPS (Phillips Respironics) is worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation.
62102510|NCT05288101|EXPERIMENTAL|Supplemented|Patients in SUPL group received a simultaneous intervention consisting of a personalized diet, 245 mL/d ONS and dry weight adjustment through BIVA, Anthropometrical, biochemical, dietary, QoL, handgrip strength (HGS) and bioimpedance measurements were performed. Malnutrition Inflammation Score (MIS) was applied
62102511|NCT02216786|EXPERIMENTAL|Fulvestrant and AZD2014 (continuous)|Experimental arm
62295624|NCT05805514|EXPERIMENTAL|Food intervention|In Food intervention, nutrition workers will give food egg, nutrition education counselling, water, sanitation and hygiene message, and multiple micronutrient powder among the selected mothers/infant pairs.
62295625|NCT05805514|PLACEBO_COMPARATOR|Control|In terms of control group, the nutrition workers will provide only nutrition education counselling among the selected mother-child pairs.
62467794|NCT03613337||current smokers|Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
62467795|NCT03613337||nonsmokers|Nonsmokers are those who never smoked in their lifetime.
62467796|NCT03613337||former smokers|Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
62295626|NCT04626063|ACTIVE_COMPARATOR|Isolated non-steroid anti-inflammatory drug group|A isolated NSAIDs group received 400 mg etodolac twice a day for 10 days in treatment of acute low back pain.
62467797|NCT02030353|EXPERIMENTAL|Self-regulation plus activity monitoring|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, tailored feedback, and activity monitoring.
61911779|NCT01844167|EXPERIMENTAL|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:~* The TENS device used: FDA K071951~* TENS is calibrated to allow for maximum range in the specifications.~* A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.~* The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.~* If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
62467798|NCT02030353|EXPERIMENTAL|Self-regulation|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, and tailored feedback.
61911780|NCT00246571|EXPERIMENTAL|A|
61911781|NCT00246571|ACTIVE_COMPARATOR|B|
62467799|NCT02030353|NO_INTERVENTION|Delayed intervention control|Participants will receive an individual in-person session and a digital smart scale, and a modified version of the self-regulation intervention after the 6-month assessment.
62467800|NCT06426004|EXPERIMENTAL|Patients and the patient's family|All patients and the patient's family will receive NPH-related education.
62467801|NCT06426004|EXPERIMENTAL|PCPs Training|Primary Care Provider (PCP) will receive NPH education.
62663690|NCT02558751|ACTIVE_COMPARATOR|HIV positive PCV13/PPV23|HIV-positive individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
62663691|NCT02558751|ACTIVE_COMPARATOR|HIV negative PCV13/PPV23|HIV-negative individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
61911782|NCT05018351|ACTIVE_COMPARATOR|Treatment as Usual-Integrated Care (TAU-IC)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-half of research participants will be randomized to integrated care alone.
61911783|NCT05018351|EXPERIMENTAL|Peer Navigator Program (PNP)|"Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~* scheduling and attending healthcare appointments;~* partnering with participant on tasks that arise from appointments;~* health-related goal setting; and~* taking action-steps toward health-related goals."
61911784|NCT04176601|EXPERIMENTAL|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
61911785|NCT01890720|EXPERIMENTAL|iNPWT|Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment using controlled sub-atmospheric pressure to assist and accelerate wound healing. Incisional Negative Pressure Wound Therapy (iNPWT) is a new NPWT devices, which can be used over clean closed surgical incisions. The device behaves in a similar fashion to existing conventional NPWT devices, i.e. transmission of negative pressure levels at the wound bed, tissue contraction and establishing a characteristic pattern of peri-wound blood flow and that it reduces and normalises tissue stresses at the incision
61911786|NCT01890720|ACTIVE_COMPARATOR|Standard wound dressing|The standard postoperative wound dressing is a normal wound dressing, used over clean closed incisions.
61911787|NCT04857229||All patient|All recruited patient will have their margins assessed with the confocal microscope with comparison of accuracy against gold standard histology.
61911788|NCT06432296|EXPERIMENTAL|M701 group|"M701 will be administered via intra-peritoneal infusion following sufficient drainage of malignant ascites.~The treatment regimen consists of a leading dose of 50μg on Day 1, followed by three infusions of the full dose of 400 μg M701 on Days 4, 11, and 18. If well tolerated, patients will continue to receive M701 infusions every 2 weeks as maintenance treatment.Additionally, these patients will receive systemic therapy as determined by the investigator."
61911789|NCT06432296|ACTIVE_COMPARATOR|Control group|Patients in the control group will undergo paracentesis on Day 1 and Day 18. If necessary, they may receive additional paracentesis during this period. Additionally, these patients will receive systemic therapy as determined by the investigator.
61911790|NCT00954252|EXPERIMENTAL|Test Article|
61911791|NCT00954252|PLACEBO_COMPARATOR|Placebo|
61911792|NCT02933671|EXPERIMENTAL|Suprainguinal Fascia Iliaca (SIFI) block|A nerve block technique using a numbing medication called ropivacaine.
62102512|NCT02216786|ACTIVE_COMPARATOR|Everolimus and Fulvestrant|Comparator arm
62295627|NCT04626063|EXPERIMENTAL|Non-steroid anti-inflammatory drug plus magnesium group|This group received 400 mg etodolac twice a day and 365 mg magnesium oral supplementation once a day for 10 days in treatment of acute low back pain.
62467802|NCT06426004|EXPERIMENTAL|CHWs assist PCPs|A community health worker (CHW) will assist PCP.
62663692|NCT05838599|EXPERIMENTAL|Topical IMQ and localized RT|After the initial study visit, patients will immediately begin use of imiquimod cream at designated lesions (those with combined size \>50cm2) nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with MF in 2 fractions of 4 Gy (total 8 Gy) over 2 days to the same designated lesions.
62102513|NCT02216786|ACTIVE_COMPARATOR|Fulvestrant|Control 1
62102514|NCT02216786|EXPERIMENTAL|Fulvestrant +AZD2014 (intermittent)|Experimental arm
62467803|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
62663693|NCT00635284|EXPERIMENTAL|ABI-009|
62663694|NCT01019551|EXPERIMENTAL|ARM A : ART intensification alone|Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
62663695|NCT01019551|EXPERIMENTAL|ARM B : ART intensification + Immunomodulation|Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
62102515|NCT06712875|EXPERIMENTAL|Cohort A|"Patients with histologically confirmed diagnosis of pediatric high- or low-grade glioma harboring a KIAA1549-BRAF fusion. Patients with NF1-associated gliomas or NF1-altered glioma.~Patients in Cohort A will receive trametinib and nivolumab combination therapy. Trametinib will be administered at 0.025 mg/kg/dose orally once daily.~Nivolumab will be administered at 6 mg/kg/dose intravenously every 4 weeks.~Cycle length will be every 28 days. Treatment will include 1 year or 13 cycles of combination therapy, whichever comes first. For patients with high grade glioma, therapy can be continued beyond the 13 cycles if they are deemed to have clinical benefit from the therapy. Patients will be followed for up to 5 years to evaluate clinical endpoints."
62295628|NCT04626063|ACTIVE_COMPARATOR|Non-steroid anti-inflammatory drug plus paracetamol group.|This group 400 mg etodolac twice a day and 500 mg paracetamol twice a day for 10 days in treatment of acute low back pain.
62663696|NCT02451878|EXPERIMENTAL|Intervention|The E-Couch self-help social anxiety module which is based on cognitive behavioural therapy principles. This module contains a literacy section and 5 toolkits comprising exposure practice, cognitive restructuring (modifying your thinking), attention practice, social skills training and relaxation. E-Couch is designed to be completed at the participant's own pace. It is free to use, browser-based and widely accessible on a range of connected devices.
62663697|NCT02451878|NO_INTERVENTION|Control|Wait list control (WLC)
62663698|NCT05943704|EXPERIMENTAL|Children with cow milk allergy.|Beef introduction for children proven to have cow milk protein allergy
62663699|NCT03415880|OTHER|Control group|Participants attend 4 workshops and undergo all measurements at t=0, t=3, t=6, and t=12 months.
62295629|NCT03114449|EXPERIMENTAL|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
62295630|NCT03114449|SHAM_COMPARATOR|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
62663700|NCT03415880|EXPERIMENTAL|Intervention group|Participants attend 4 workshops, receive a wrist-worn feedback physical activity monitor, a smartphone app, and telephone coaching. All participants undergo all measurements at t=0, t=3, t=6, and t=12 months.
62663701|NCT01603914|EXPERIMENTAL|scheduled wire-guided every six days|scheduled wire-guided every six days and a replacement of the catheter in a different place after 12 days from randomization.
62663702|NCT01603914|EXPERIMENTAL|Scheduled replacement every six days|Scheduled replacement every six days in a different location
62663703|NCT01603914|EXPERIMENTAL|replacement guided by clinical criteria|re change of catheter strategy guided by clinical suspicious of catheter-related bacteremia and replacement of the catheter in a different location.
62295631|NCT06657053||Patient with nose bleeding|Evaluation of recurrence epistaxis during the year after a first episode
62467804|NCT01378039|OTHER|Budesonide|patients who gave their agreement were randomised to 3 months treatment with either inhaled budesonide (400 µg BD) or placebo
62295632|NCT04657848|EXPERIMENTAL|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
62663704|NCT02314429|EXPERIMENTAL|Vaginal Ring|A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.
62663705|NCT01290250|EXPERIMENTAL|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
62663706|NCT01290250|PLACEBO_COMPARATOR|Orange juice with low levels of polyphenols|2 daily doses (250 ml each) during 3 months
62663707|NCT03927391|ACTIVE_COMPARATOR|reference (normal) dose|Normal dose of enzalutamide (160mg once daily)
62663708|NCT03927391|EXPERIMENTAL|test (reduced) dose|Reduced dose of enzalutamide (120mg once daily)
62467805|NCT05066438||Antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed AND must have received standardized counselling on and practiced antenatal hand expression for a minimum of 10 days beginning no earlier than 36 weeks gestational age.
62467806|NCT05066438||No antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed but have NOT received any standardized counselling on antenatal hand expression and have not practiced antenatal hand expression OR have practiced antenatal hand expression but for less than 10 days.
62663709|NCT05074147|EXPERIMENTAL|3 weeks antibiotherapy|Patients are treated 3 weeks with appropriate antibiotics after antibiogram evaluation.
62663710|NCT05074147|EXPERIMENTAL|6 weeks antibiotherapy|Patients are treated 6 weeks with appropriate antibiotics after antibiogram evaluation.
62663711|NCT02709369|EXPERIMENTAL|Active HIRREM|This is a single site, single-arm, open-label, developmental study. Participants are recruited to receive eight to twenty sessions of High-resolution, relational, resonance-based electroencephalic mirroring (HIRREM), in addition to their usual care.
62663712|NCT05367830|EXPERIMENTAL|the bone@bc app|Intervention group patients with breast cancer using the app Bone@BC
62663713|NCT05891444|ACTIVE_COMPARATOR|Transcranial random noise-Real|Participants will receive real tRNS once daily for two weeks
62663714|NCT05891444|SHAM_COMPARATOR|Transcranial random noise-Sham|Participants will receive sham tRNS once daily for two weeks
62663715|NCT04268511||Caudal epidural block group|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
62663716|NCT04268511||Pudendal nerve block group|The long axis of the ultrasound probe was positioned on a horizontal line connecting the ischial tuberosity that had been previously located by palpation to the anus. The ischial tuberosity could be easily identified as a hypoechoic area that is bounded superiorly by a hyperechoic line. The probe was then moved medially on the same axis until the rectum appeared as another hypoechoic area.
62663717|NCT01751685|EXPERIMENTAL|Kyphosis-specific spinal exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
62663718|NCT01751685|PLACEBO_COMPARATOR|Control|Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
62663719|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 1: 1A|"ccRCC molecular subgroup 1 -\> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
62663720|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 1: 1B|"ccRCC molecular subgroup 1 -\> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
62663721|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 4: 4A|"ccRCC molecular subgroup 4 -\> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
62295633|NCT04673058|EXPERIMENTAL|Spinal Manipulation Group|After the patients were evaluated in terms of somatic dysfunction, the appropriate techniques of Cervical Upglide Thrust, Cervical Downglide Thrust, Cervical Traction Thrust, Cervical Rotation Thrust, Cervico-Thoracic Distraction Manipulation, Cervico-Thoracic Lateral Glide (Spinous Push) Manipulation, Supine Screw Thoracic Thrust, Prone Thoracic Thrust, and Lumbar Spine Rotation Manipulation will be applied to patients.
62295634|NCT04673058|SHAM_COMPARATOR|Sham Manipulation Group|A treatment will be applied which is very similar to active treatment but aimed to have minimal therapeutic effect. For this, the practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position. In this way, the movement will be imitated without reaching the elastic zone and a stronger similarity will be provided compared to sham treatments such as light touch or massage.
62295635|NCT04673058|NO_INTERVENTION|No Intervention Group|These patients will receive only their pharmacological treatments.
62295636|NCT01649700|EXPERIMENTAL|Mesenchymal stem cells treatment|All subjects will receive autologous adipose-derived mesenchymal stem cells
62467807|NCT01183585|EXPERIMENTAL|1|
62663722|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 4: 4B|"ccRCC molecular subgroup 4 -\> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
62102516|NCT06712875|EXPERIMENTAL|Cohort B|"Patients with histologically confirmed diagnosis of pediatric low-grade glioma harboring a BRAFV600 mutation that is recurrent or progressive or non-brainstem pediatric high-grade glioma harbor ng BRAFV600 mutation that is newly diagnosed, recurrent, or progressive.~Cohort B will receive trametinib, nivolumab dabrafenib combination therapy. Trametinib will be administered at 0.025 mg/kg/dose orally once daily.~Nivolumab will be administered at 6 mg/kg/dose intravenously every 4 weeks. Dabrafenib will be administered at a dose of 5.25 mg/kg/day orally divided into two doses, which shall be taken 12 hours apart.~Cycle length will be every 28 days. Treatment will include 1 year or 13 cycles of combination therapy, whichever comes first. For patients with high grade glioma, therapy can be continued beyond the 13 cycles if they are deemed to have clinical benefit from the therapy. Patients will be followed for up to 5 years to evaluate clinical endpoints."
62102517|NCT04936217||Patients operated for Continent Cutaneous Urinary Diversion, April 2004 - October 2017|The study focuses of a population of 70 patients operated between April 2004 and October 2017 au Nîmes University Hospital for Cutaneous Urinary Diversion.
62102518|NCT06713915||prospective cohort|Women with suspected breast abnormalities in prospective cohort will be prospectively evaluated with CEM, including acquisition of low-energy (LE) images and reconstructed images (RI) showing enhancement, concurrently with breast ultrasound (US) evaluation.
62102519|NCT06713915||retrospective cohort|The retrospective cohort will select the mammography and breast US data (BI-RADS score) of female patients with suspected breast abnormalities who had previous baseline matching.
62102520|NCT05951595|EXPERIMENTAL|Artemether-Lumefantrine-Amodiaquine (ALAQ)|TACT group
62102521|NCT05951595|ACTIVE_COMPARATOR|Artemether-Lumefantrine (AL)|ACT 1 group
62102522|NCT05951595|ACTIVE_COMPARATOR|Artesunate-Amodiaquine (ASAQ)|ACT 2 group
62295637|NCT04404335||Healthy (control group)|"This group will include a total of 30 patients free of periodontitis Samples of crevicular fluid to quantity levels of antimicrobial peptide LL-37 will be taken at baseline~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 and also IL-4, IL-6 and IL-10"
62295638|NCT04404335||Periodontitis (test group)|"30 Periodontal patients (subdivided in 2 groups of 15, depending of the severity of their disease):~* 15 patients with Stage I-II periodontitis (mild/moderate)~* 15 patients with Stage III-IV periodontitis (severe).~Two sets of samples of crevicular fluid will be obtained before and after receiving a course of routine basic periodontal treatment (root scaling and planing).~A reevaluation visit to re-assess clinical periodontal parameters will take place at 4-6 weeks after treatment. New samples of crevicular fluid will then be taken at this stage to compare the level of LL-37 before and after the treatment.~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
62295639|NCT00289705|EXPERIMENTAL|Surgery|Laparoscopic gastric bypass
62295640|NCT00289705|NO_INTERVENTION|2|Traditional treatment for obesity
62295641|NCT04271462||Study group|Patients undergoing surgery (\>120 min) with the use of sevoflurane based general anaesthesia (in 1.0 MAC concentration).
62295642|NCT01986530||Healthy individuals|Participants will be healthy volunteers of both sexes recruited from the Greek Military Medical School personnel, Thessaloniki, Greece.
62663723|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 2: 2C|ccRCC molecular subgroup 2 -\> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
62295643|NCT01986530||Boost Subgroup|After an overnight fast, 40 participants will be provided a standardized mixed meal in two different quantities (125 ml, n=20 and 250 ml, n=20) and blood samples will be obtained before as well as 30 min after mixed meal ingestion
62663724|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 2: 2B|"ccRCC molecular subgroup 2 -\> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
62663725|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 3: 3B|"ccRCC molecular subgroup 3 -\> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
62295644|NCT01986530||Aerobic exercise|After an overnight fast, 20 participants will be subjected to aerobic exercise for 30 min and blood samples will be obtained at baseline and at 30 min
62295645|NCT01986530||Circadian variation Subgroup|20 of the participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period.
62295646|NCT01986530||Seasonal variation Subgroup|20 of the participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). Subjects will be instructed to maintain their normal exercise routine and dietary habits.
62295647|NCT03295825|OTHER|Biomarker|Blood sampling
62295648|NCT00785577|PLACEBO_COMPARATOR|Placebo|LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks
62295649|NCT00785577|ACTIVE_COMPARATOR|Pregabalin|"Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
62295650|NCT00785577|EXPERIMENTAL|LY545694 21 mg|"LY545694 21 milligrams (mg) BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
62663726|NCT02960906|EXPERIMENTAL|ccRCC molecular subgroup 3: 3C|ccRCC molecular subgroup 3 -\> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
62663727|NCT05855187|EXPERIMENTAL|T test|1 tablet contains 200 mg Modafinil administrated according to a randomization scheme with 240 ml of water.
62663728|NCT05855187|ACTIVE_COMPARATOR|R Reference|1 tablet contains 200 mg Modafinil administrated according to a randomization scheme with 240 ml of water.
62663729|NCT01525771|NO_INTERVENTION|No intervention|Single-center, open-label, prospective, single-arm, phase I-II study
62663730|NCT02622685|EXPERIMENTAL|DWP10292|"Drug: DWP10292 DWP10292 tablets, oral administration, multiple administration~Arms: DWP10292"
62663731|NCT02622685|PLACEBO_COMPARATOR|DWP10292 Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
62663732|NCT02622685|EXPERIMENTAL|Ursodeoxycholic acid (UDCA)|"Drug: Ursodeoxycholic acid (UDCA) UDCA tablets, oral administration, multiple administrations~Arms: Ursodeoxycholic acid (UDCA)"
62663733|NCT02622685|PLACEBO_COMPARATOR|Ursodeoxycholic acid (UDCA) Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
62102523|NCT05920122|EXPERIMENTAL|2% Chlorhexidine gluconate with 70% alcohol (ChloraPrep)|Including cases undergoing elective \&non elective caesarean section. Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
62663734|NCT02441283|NO_INTERVENTION|HCV-infected Participants|Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.
62663735|NCT01225744|EXPERIMENTAL|Cetuximab plus Irinotecan, Oxaliplatin and UFT|Cetuximab plus Irinotecan, Oxaliplatin, UFToral
62102524|NCT05920122|EXPERIMENTAL|4% chlorhexidine gluconate (Hibiclens)|Including cases undergoing elective \& nonelective caesarean section. Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
62295651|NCT00785577|EXPERIMENTAL|LY545694 49 mg|"LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
62295652|NCT00785577|EXPERIMENTAL|LY545694 105 mg|"LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
62663736|NCT01710085|EXPERIMENTAL|Diffusion weighted imaging, Recurrence|
62663737|NCT03822416|EXPERIMENTAL|Intervention|Intervention group will receive counseling and nicotine replacement therapy including the nicotine patch and/or nicotine lozenges.
62663738|NCT03822416|OTHER|Control|Control group will receive information about mental illness and smoking cessation and a listing of community resources available for assistance with smoking cessation.
62663739|NCT02071160|NO_INTERVENTION|Healthy Control|A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements
62663740|NCT02071160|NO_INTERVENTION|Hypothermia Group|HIE infants who will not receive melatonin and only receive routine cooling protocol.
62663741|NCT02071160|EXPERIMENTAL|Melatonin/ hypothermia group|HIE infants who will receive melatonin in addition to the routine cooling protocol
62295653|NCT02815215|EXPERIMENTAL|Intervention group|Minimally Invasive Carroll's Technique
62295654|NCT02815215|ACTIVE_COMPARATOR|Control group|Ponseti method
62295655|NCT04774003|EXPERIMENTAL|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1
62295656|NCT04774003|EXPERIMENTAL|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1
62295657|NCT04774003|PLACEBO_COMPARATOR|Placebo|Placebo x 1 dose (n=10) at Day 1
62663742|NCT02869035|EXPERIMENTAL|Treatment of MDD patients|Treatment of MDD patients with escitalopram
62663743|NCT02869035|NO_INTERVENTION|Healthy controls|No treatment.
62663744|NCT02869035|EXPERIMENTAL|Shift of treatment for MDD patients|Treatment of MDD patients with duloxetine
62663745|NCT05230927||Chronic Heart Failure|
62663746|NCT05230927||Chronic Obstructive Pulmonary Disease|
62295658|NCT04203914|EXPERIMENTAL|Intervention|Empagliflozin 25mg daily add-on therapy
62663747|NCT03823131|EXPERIMENTAL|Arm A: Tavo-EP, pembrolizumab, epacadostat|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks. Epacadostat will be administered at the dose level determined in the dose escalation safety lead-in.
62663748|NCT03823131|EXPERIMENTAL|Arm B: Tavo-EP, pembrolizumab|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks.
62737201|NCT03493061|EXPERIMENTAL|Systemic CPT-11 + HAI (FUDR+L-OHP)|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
62737202|NCT01221623|EXPERIMENTAL|AA4500|collagenase clostridium histolyticum
62737203|NCT01221623|PLACEBO_COMPARATOR|Placebo|Placebo
62295659|NCT01934504||Tolerant AAV|Tolerant participants with AAV
62102525|NCT06277999||Monitoring Cohort|Monitoring cohort will enroll a targeted minimum of 20 and a maximum of 100 participants ≥ 18 years of age who have been recently diagnosed with CDI by a licensed HCP and are receiving SOC antibiotic treatment, with treatment starting ≤ 5 days before study enrollment. Participants will be recruited from hospitals which perform C difficile laboratory diagnostic testing. Recruitment will occur over a 6-month period. Participants will be followed through Day 42, with a screening period from Day -5 to Day 1
62102526|NCT06277999||Discard Stool Cohort|The Discard Stool cohort will include stool specimens from up to 200 participants, ≥ 18 years of age, who have been recently diagnosed with CDI by a licensed HCP within the past 7 days. Participants in this cohort will be screened at the study site to confirm eligibility. Following the screening period, there will be no additional study activities for the participant to complete.
62102527|NCT05718297|EXPERIMENTAL|Experimental arm|Brigatinib 180 mg once daily p.o., with seven day lead-in at 90 mg once daily, for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent
62102528|NCT05718297|ACTIVE_COMPARATOR|Control arm|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
62295660|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
62102529|NCT02646592|EXPERIMENTAL|alfentanil|"Children under general anesthesia for elective surgery. Induction with sevoflurane or propofol according to the preference of the patient.~Maintenance with sevoflurane. 5 minutes before skin incision, first assessment of the pupillary pain index. Then injection of 10 µg/kg of alfentanil. After 5 minutes second assessment of pupillary pain index. End of study period, beginning of surgery."
62295661|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
62295662|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
62295663|NCT00943683|EXPERIMENTAL|1|Montelukast
62295664|NCT00943683|PLACEBO_COMPARATOR|2|Placebo
62295665|NCT02415309|ACTIVE_COMPARATOR|2 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 2mg melatonin.
62295666|NCT02415309|ACTIVE_COMPARATOR|10 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 10mg melatonin.
62295667|NCT02415309|PLACEBO_COMPARATOR|Sugar Pill|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of two different levels of melatonin versus placebo as premedication in patients undergoing a lumbar medial branch block (LMBB) procedure.
62295668|NCT04081805|ACTIVE_COMPARATOR|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
62102530|NCT06714656|EXPERIMENTAL|N of 1 intervention|Personalised food swaps and dietary advice on how to incorporate these swaps into the diet
62102531|NCT04077047|EXPERIMENTAL|iEngage|The intervention is a network-based, social support intervention to improve ALWH retention in HIV care and ART adherence. The specific intervention will be developed during Aim 2 of the study and uses qualitative findings, along with data from Aim 1, to develop an interventions that integrates participant feedback and borrows components from two existing interventions
62102532|NCT02112734|ACTIVE_COMPARATOR|vitamin D|400 IU /daily cholecalciferol/vitamin D
62102533|NCT02112734|PLACEBO_COMPARATOR|placebo|carrier formulation minus vitamin D
62102534|NCT05980468|EXPERIMENTAL|Intervention group|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session. Forms will be applied at the first meeting and for five weeks.
62102535|NCT05980468|NO_INTERVENTION|Control group|No application has been made. Forms will be applied at the first meeting and for five weeks.
62102536|NCT04411940|ACTIVE_COMPARATOR|Reference Product (Treatment A)|Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
62102537|NCT04411940|EXPERIMENTAL|Test Product (Treatment B)|Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
62295669|NCT04081805|ACTIVE_COMPARATOR|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcroablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
62295670|NCT04081805|ACTIVE_COMPARATOR|Promestriene|The patient will use intravaginal promestriene, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube to verify the correct use.
62295671|NCT03104582|EXPERIMENTAL|Biliary drainage 1|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage
62295672|NCT03104582|ACTIVE_COMPARATOR|Biliary drainage 2|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage
62295673|NCT03756792|ACTIVE_COMPARATOR|First Time Control|Patients with no prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
62295674|NCT03756792|EXPERIMENTAL|First Time Intervention|Patients with no prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
62467808|NCT02234661|EXPERIMENTAL|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
62663749|NCT03823131|EXPERIMENTAL|Arm C: Tavo-EP, pembrolizumab, CORVax|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30-minute IV infusion at a dose of 200 mg every 3 weeks. CORVax will be administered at a total dose of 0.2 mg of (S) protein plasmid in 120 microliter (uL) per lesion intratumorally into a maximum of 4 lesions of at least 0.3 mm in diameter for a total plasmid dose of 0.8 mg on treatment days 1 and 29 of cycle 1 followed by electroporation of the plasmid solution in infiltrated regions. On days when both tavo and CORVax is administered to the same lesions, tavo and CORVax will each be injected into the lesion followed by electroporation.
62102538|NCT06711302|SHAM_COMPARATOR|Sham group|Guideline-based therapy+Sham RIC is given twice a day with 60mmHg pressure.
62295675|NCT03756792|ACTIVE_COMPARATOR|Previous Experience Control|Patients with prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
62295676|NCT03756792|EXPERIMENTAL|Previous Experience Intervention|Patients with prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
62295677|NCT00873002|ACTIVE_COMPARATOR|LBH589|This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.
62295678|NCT04626622||ARVI and influenza prophylaxis with Kagocel (n=50)|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
62663750|NCT05202405|EXPERIMENTAL|Sequence A|Period 1 : Reference Drug(AD-221A and AD-221B) Period 2 : Test Drug(AD-221)
62663751|NCT05202405|EXPERIMENTAL|Sequence B|Period 1 : Test Drug(AD-221) Period 2 : Reference Drug(AD-221A and AD-221B)
62295679|NCT04626622||ARVI and influenza prophylaxis without any antiviral medicines (n=25)|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
62295680|NCT05409105|EXPERIMENTAL|Mangoes|Frozen mangoes, 2 cups per day (with 2 cups water), 2 weeks.
62295681|NCT05409105|ACTIVE_COMPARATOR|Water|Bottled water, 2 cups per day
62295682|NCT01922921|ACTIVE_COMPARATOR|Arm I (placebo)|Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.
62295683|NCT01922921|EXPERIMENTAL|Arm II (polysaccharide-K)|Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.
62467809|NCT02234661|NO_INTERVENTION|Control Standard of CAP|Control participants access to CAP array of service
62663752|NCT02979288|EXPERIMENTAL|A Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
62102539|NCT06711302|EXPERIMENTAL|RIC Group|Guideline-based therapy+RIC RIC is given twice a day with 200mmHg pressure.
62102540|NCT06448572|EXPERIMENTAL|EXL01 + Nivolumab|
62295684|NCT02893267|EXPERIMENTAL|PNS + PT|The PNS+PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
62467810|NCT00582673|EXPERIMENTAL|1|
62663753|NCT02979288|ACTIVE_COMPARATOR|B Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
62663754|NCT02979288|EXPERIMENTAL|C Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
62467811|NCT00582673|PLACEBO_COMPARATOR|2|
62467812|NCT01778205||Pregnant women|Pregnant women with confirmed viable fetus at first prenatal check-up at \<12 gestational weeks
62663755|NCT02979288|ACTIVE_COMPARATOR|D Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
62663756|NCT00555191|ACTIVE_COMPARATOR|1|PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSE REDUCED DIET FOR A PERIOD OF 3 MONTHS
62663757|NCT00555191|NO_INTERVENTION|2|these patients use their usual diet
62102541|NCT04005521|EXPERIMENTAL|Preventive intervention|Patient will perform daily exercise: jaw and swallwing exercises, as well as are encouraged to eat and drink for as long as possible during treatment
62102542|NCT04005521|NO_INTERVENTION|Control group|No intervention, only encouragement to eat and drink for as long as possible during treatment
62102543|NCT05889390|ACTIVE_COMPARATOR|wTAX (+ carboplatin) +AC|"1. wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks~2. AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x~3. Breast cancer tumor removal surgery (if feasible)"
62467813|NCT02264054|EXPERIMENTAL|[14C]talsaclidine, oral|single dose of 20 mg oral solution
62467814|NCT02264054|ACTIVE_COMPARATOR|[14C]talsaclidine, iv|single dose of 20 mg intravenous (iv) infusion
62467815|NCT03872674|NO_INTERVENTION|standard oxygenation(nasal cannula)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
62467816|NCT03872674|EXPERIMENTAL|high-flow humidified oxygen-delivery system(OptiFlow THRIVE)|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
62467817|NCT03824119|ACTIVE_COMPARATOR|Standard Postpartum Care|Subjects will receive NSAIDs (e.g. ibuprofen, ketorolac) for routine postpartum pain management.
62467818|NCT03824119|ACTIVE_COMPARATOR|Standard Postpartum Care without NSAIDs|Subjects will receive standard postpartum care without NSAID administration for pain management. Acetaminophen or narcotics will be substituted for ibuprofen as indicated by provider.
62467819|NCT00807196|EXPERIMENTAL|T|
62467820|NCT03352089||Aortic stenosis group|Patients with severe aortic stenosis \>70 years of age referred for aortic valve intervention
62102544|NCT05889390|EXPERIMENTAL|wTAX (+ carboplatin) +AC + mEHT|"1. wTAX + mWEHT~   1. wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks~  2. mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks~2. AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x~3. Breast cancer tumor removal surgery (if feasible)"
62102545|NCT04463264|EXPERIMENTAL|NTX active treatment|Intervention: NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
62467821|NCT03352089||Healthy volunteer group|Patients with no history of symptoms to suggest current cardiovascular disease \>70 years of age
62102546|NCT04463264|PLACEBO_COMPARATOR|Intervention: placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
62102547|NCT02501629|EXPERIMENTAL|Reslizumab 110 mg|Reslizumab was administered by subcutaneous injection (sc) in a dosage of 110 mg (1.0 mL) every 4 weeks for a total of six doses.
62102548|NCT02501629|PLACEBO_COMPARATOR|Placebo|Matching placebo was administered by subcutaneous injection (sc) 1.0 mL every 4 weeks for a total of six doses.
62102549|NCT04740255|OTHER|Straberi Epistamp Needling Treatment|Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Straberi Epistamp needling.
62102550|NCT04740255|OTHER|No Treatment|Non-Randomized patients with Postinflammatory Hyperpigmentation (PIH)
62102551|NCT05687266|EXPERIMENTAL|Dato-DXd + Durvalumab + Carboplatin|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 1120 mg durvalumab plus carboplatin area under the curve \[AUC\] 5 mg/mL/minute.
62295685|NCT02893267|ACTIVE_COMPARATOR|PNS + sham-PT|The PNS + sham-PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of sham outpatient physical therapy not focused on shoulder pain over the same four week period.
62102552|NCT05687266|ACTIVE_COMPARATOR|Histologic-specific therapy|"Non-squamous NSCLC participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m2 pemetrexed plus either AUC 5 mg/mL/minute carboplatin or 75 mg/m2 cisplatin.~Squamous NSCLC participants will be randomized to receive 200 mg of pembrolizumab plus 200 mg/m2 paclitaxel plus AUC 5 or 6 mg/mL/minute carboplatin."
62102553|NCT01474538|ACTIVE_COMPARATOR|Insulin Lispro, then Insulin Aspart|Insulin lispro \[100 units/milliliter (U/mL)\] administered by continuous subcutaneous insulin infusion (CSII) pump for 16 weeks in Treatment Period 1, followed by insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
62295686|NCT02893267|ACTIVE_COMPARATOR|sham-PNS + PT|The sham-PNS + PT Group will receive sham peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
62467822|NCT06043843|ACTIVE_COMPARATOR|Focused structured tele-education, medication adjustment and remote monitoring|
62467823|NCT06043843|NO_INTERVENTION|Control|Standard Care
62295687|NCT01722383||Chronic kidney disease|Stages 3-5 chronic kidney disease (pre-dialysis)
62102554|NCT01474538|ACTIVE_COMPARATOR|Insulin Aspart, then Insulin Lispro|Insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 1, followed by insulin lispro (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
62102555|NCT05629208|EXPERIMENTAL|Edecesertib|Participants will receive edecesertib 30 mg, once daily starting on Day 1 for up to 12 weeks.
62467824|NCT03879915||Prospective Dental Implant placement|Patients prospectively included and treated following current recommendations
62102556|NCT05629208|PLACEBO_COMPARATOR|Edecesertib Placebo|Participants will receive edecesertib placebo, once daily starting on Day 1 for up to 12 weeks.
62295688|NCT03632642|ACTIVE_COMPARATOR|Benzylpenicillin arm|Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
62467825|NCT03879915||Retrospective Dental Implant placement|Patients retrospectively included, that did not benefit from current recommendations
62467826|NCT02120937|EXPERIMENTAL|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
62295689|NCT03632642|ACTIVE_COMPARATOR|Flucloxacillin arm|Patients randomised to flucloxacillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 2g Q6H IVI or 2g Q4H for deep-seated or criticial illness infections.
62467827|NCT03550781|EXPERIMENTAL|Anti-inflammatory treatment group|Prednisone and/or cyclophosphamide
62467828|NCT03550781|NO_INTERVENTION|Control group|No intervention
62467829|NCT02140398|EXPERIMENTAL|Currettage|Endometrial Currettage (endometrial scrapping) will be performed at the time of laparoscopic ovarian drilling
62467830|NCT02140398|NO_INTERVENTION|Nothing|No endometrial curettage at time of Laparoscopic ovarian drilling
62467831|NCT01259583|EXPERIMENTAL|CO2|CO2 insufflation instead air insufflation in unsedated colonoscopy
62467832|NCT01259583|EXPERIMENTAL|Warm Water irrigation|warm water irrigation during the insertion phase of colonoscopy
62467833|NCT01304641||Atorvastatin Initiators|
62467834|NCT01304641||Simvastatin Initiators|
62467835|NCT02821897|EXPERIMENTAL|Target-controlled Intravenous Anaesthesia|Patients have a target controlled intravenous anaesthesia to implant the spinal cord stimulation lead with active cooperation during the surgery.
62467836|NCT02821897|ACTIVE_COMPARATOR|Total anesthesia|Patients have a total anaesthesia to implant the spinal cord stimulation lead without active cooperation during the surgery.
62467837|NCT03013634|EXPERIMENTAL|Dexmedetomidine Group|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
62467838|NCT03013634|PLACEBO_COMPARATOR|Normal saline Group|Equal volume normal saline substitute for dexmedetomidine
62467839|NCT00851526||Coronary bifurcation lesion|
62663758|NCT02181738|EXPERIMENTAL|Nivolumab (Cohort A, B, C and D)|"Cohort (A, B, C): Nivolumab: Specified dose on specified days~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days"
61911793|NCT02933671|PLACEBO_COMPARATOR|Sham group|The same nerve block technique as above, however using an inactive solution of salt water.
61911794|NCT01456767|ACTIVE_COMPARATOR|Lactobacillus plantarum WCFS1|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum WCFS1).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
62102557|NCT03226730|EXPERIMENTAL|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
62295690|NCT04640727||open reduction and internal fixation|open reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
61911795|NCT01456767|ACTIVE_COMPARATOR|Lactobacillus plantarum CIP104448|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104448).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
62102558|NCT03226730|EXPERIMENTAL|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
62102559|NCT03226730|EXPERIMENTAL|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
62102560|NCT03226730|NO_INTERVENTION|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
62102561|NCT06445374|EXPERIMENTAL|Inhaled Epinephrine|"The first inhalation will be administered as soon as possible (i.e., within approximately 30 seconds) following identification of a Grade 2 or greater SAR and confirmation of enrollment by the Principal Investigator. The second inhalation will be administered approximately 10 seconds later, and the subject will be observed for approximately 2 minutes for signs of symptom resolution.~Inhalations will continue in this manner until either:~1. resolution of systemic symptoms (defined as a reduction in SAR Grade to ≤1), or~2. maximum number of inhalations (8 inhalations) is reached, or~3. administration of intra-muscular epinephrine, whichever occurs earlier"
62102562|NCT03299491|EXPERIMENTAL|MWA+IEC intervention|
62102563|NCT03299491|EXPERIMENTAL|IEC intervention|
62102564|NCT03299491|NO_INTERVENTION|Control|
62102565|NCT05822271|EXPERIMENTAL|Orthodontic Aligner treatment|
62102566|NCT05822271|ACTIVE_COMPARATOR|Orthodontic fixed appliance treatment|
62295691|NCT04640727||closed reduction and internal fixation|closed reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
62295692|NCT04267640|EXPERIMENTAL|AMG0001 4mg|AMG0001 4mg + standard wound care
62295693|NCT04267640|EXPERIMENTAL|AMG0001 8mg|AMG0001 8mg + standard wound care
62295694|NCT04267640|PLACEBO_COMPARATOR|Placebo|Placebo + standard wound care
62295695|NCT02673281|EXPERIMENTAL|Walnut shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
62295696|NCT02673281|PLACEBO_COMPARATOR|Placebo shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
62295697|NCT04591093|ACTIVE_COMPARATOR|CI with FineHearing with 10 more apical electrodes activated then 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated first during 1 month then FineHearing Strategy with 10 more basal electrodes activated during 1 month
62663759|NCT03259308|EXPERIMENTAL|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
62663760|NCT03259308|EXPERIMENTAL|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using PFS on Week 0, Week 4 and Week 8.
62295698|NCT04591093|ACTIVE_COMPARATOR|CI with FineHearing with 10 more basal electrodes activated then 10 more apical electrodes activated|Cochlear implant with FineHearing Strategy with 10 more basal electrodes activated first during 1 month then FineHearing Strategy with 10 more apical electrodes activated during 1 month
62295699|NCT04519944||NVAF patients undergoing PCI|Patients with non-valvular atrial fibrillation (NVAF) who had successful percutaneous coronary intervention (PCI).
62663761|NCT03259308|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to ontamalimab SC injection using PFS on Week 0, Week 4, and Week 8.
62663762|NCT02013427|NO_INTERVENTION|Observational|Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
62663763|NCT02013427|ACTIVE_COMPARATOR|Naproxen & Omeprazole|Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
62663764|NCT02013427|PLACEBO_COMPARATOR|Placebo Only|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
62663765|NCT02174172|EXPERIMENTAL|Arm A: Atezolizumab with Ipilimumab|Participants will receive atezolizumab along with ipilimumab.
62663766|NCT02174172|EXPERIMENTAL|Arm B: Atezolizumab with Interferon alfa-2b|Participants will receive atezolizumab along with Interferon alfa-2b.
62663767|NCT02174172|EXPERIMENTAL|Arm C: Atezolizumab with PEG- interferon alfa-2a|Participants will receive atezolizumab along with PEG- interferon alfa-2a.
62295700|NCT04490889||Patients with PGT indication|Patients undergo in vitro fertilization with PGT-A or for PGT-SR indication
62295701|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
62295702|NCT04487665||positive COVID-19|patient diagnosed by nasopharyngeal positive COVID-19
62295703|NCT06181955|EXPERIMENTAL|Experimental|The participants in this group received Extracorporeal Shock Wave Therapy (ESWT) in addition to conventional physical therapy.
62663768|NCT02174172|EXPERIMENTAL|Arm D:Atezolizumab with PEG-interferon alfa-2a and Bevacizumab|Participants will receive atezolizumab along with PEG- interferon alfa-2a and bevacizumab.
62295704|NCT06181955|ACTIVE_COMPARATOR|Control group|The participants in this group received conventional physical therapy only.
62295705|NCT02562625|EXPERIMENTAL|Pembrolizumab Alone|If the patient is randomised to the Pembrolizumab Arm Only then they will receive 200mg of pembrolizumab every 3 weeks.
62663769|NCT02174172|EXPERIMENTAL|Arm E: Atezolizumab with Obinutuzumab|Participants will receive atezolizumab along with obinutuzumab or atezolizumab alone.
62663770|NCT00588224||1|adults
62663771|NCT00588224||2|adolescents
62663772|NCT01771913|SHAM_COMPARATOR|centrifuged fat graft|female patients who underwent breast reconstruction and present with volume insufficiency will undergo centrifuged fat graft for contour and volume refinements.
62663773|NCT01771913|ACTIVE_COMPARATOR|ADSCs enriched centrifuged fat graft|female patients who underwent breast reconstruction and present volume insufficiency will undergo ADSCs enriched fat grafting for volume and irregularity contour improvement
62663774|NCT01614119|EXPERIMENTAL|Sportsmen|One single group of active healthy subjects was investigated
62102567|NCT01642940|ACTIVE_COMPARATOR|Prasugrel|
62295706|NCT02562625|EXPERIMENTAL|Pembrolizumab plus Radiotherapy|If The patient is randomised to this arm they will receive 200mg of pembrolizumab every 3 weeks in combination with a radiotherapy dosage of 24Gy in 3 fractions to be given over 3 consecutive days (only).
62295707|NCT03448744|EXPERIMENTAL|combiantion therapy group|thymosin alpha 1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
62295708|NCT03448744|PLACEBO_COMPARATOR|entecavir group|ETV (0.5 mg orally, daily) at least for 72 weeks
62663775|NCT04339387||Coronavirus Disease 2019 positive, suitable for discharge|Patients with Coronavirus Disease 2019 who do not require supplemental oxygen, do not require intensive care unit-level care, and do not die.
62663776|NCT04339387||Coronavirus Disease 2019 positive, not suitable for discharge|Patients with Coronavirus Disease 2019 who do require supplemental oxygen, do require intensive care unit-level care, or do die.
62663777|NCT02927483|EXPERIMENTAL|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
62663778|NCT02927483|ACTIVE_COMPARATOR|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
62663779|NCT06349954|EXPERIMENTAL|single-session treatment group|single-session ERCP
62102568|NCT01642940|EXPERIMENTAL|Ticagrelor|
62102569|NCT03349684|EXPERIMENTAL|Acarbose plus metformin arm|Participants received loose combination of acarbose and metformin 3 times daily.
62102570|NCT03349684|ACTIVE_COMPARATOR|Metformin plus placebo arm|Participants received loose combination of placebo and metformin 3 times daily.
62102571|NCT01773122|EXPERIMENTAL|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
62102572|NCT01773122|EXPERIMENTAL|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
62102573|NCT01773122|EXPERIMENTAL|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
62663780|NCT06349954|EXPERIMENTAL|two-session treatment group|two-session ERCP
62663781|NCT01590875|EXPERIMENTAL|Adenosine arm|25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
62663782|NCT01590875|NO_INTERVENTION|Observation arm|25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.
62102574|NCT01773122|ACTIVE_COMPARATOR|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
62102575|NCT05875207|EXPERIMENTAL|Evidence based physical therapy combined with mindfulness (Low-Intensity)|"Physical therapists randomized to this arm will receive a manual on how to integrate MORE; mindfulness, mindful reappraisal, and mindful savoring savoring into routine outpatient physical therapy for patients with chronic musculoskeletal pain and long-term opioid treatment.~After 4 weeks to review the manual, the physical therapist's competency will be assessed during mock patient encounters using trained actors as standardized patients.~Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about pain and opioid use before, and after treatment. We plan on enrolling 2 patients for each physical therapist."
62102576|NCT05875207|OTHER|Standard physical therapy|"Physical therapists randomized to this arm will deliver routine treatment for someone with chronic musculoskeletal pain and long-term opioid treatment.~Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about pain and opioid use before, during and after treatment. We plan on enrolling 2 patients for each physical therapist."
62102577|NCT05875207|EXPERIMENTAL|Evidence based physical therapy combined with mindfulness (High-Intensity)|"Physical therapists randomized to this arm will receive 13 hours of training. The first 6 hours consists of prerecorded didactic lectures that the physical therapist can view on their own time. After viewing the lectures, participants will attend 6.25 hours of live experiential instruction to promote trainee competence in providing mindfulness, mindful reappraisal, and mindful savoring after which the participating physical therapist's competency will be assessed during mock patient encounters using trained actors as standardized patients. .~Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about pain and opioid use before, and after treatment. We plan on enrolling 2 patients for each physical therapist."
62102578|NCT06641037|EXPERIMENTAL|LY3866288 Cohort 1 (High-Fat Meal)|LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort
62102579|NCT06641037|EXPERIMENTAL|LY3866288 Cohort 2 (Low-Fat Meal)|LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort
62102580|NCT04945694|EXPERIMENTAL|Ultrasound-guided bilateral pecto-intercostal fascial block|Patients will receive bilateral ultrasound-guided pecto-intercostal fascial block
62102581|NCT04945694|PLACEBO_COMPARATOR|Intravenous fentanyl|Patients will receive only incremental doses of intravenous fentanyl
62102582|NCT06696287||Patients with fibromyalgia|
62102583|NCT01018511|PLACEBO_COMPARATOR|Placebo|Participants received 3 tablets once a day for 12 weeks. Placebo tamsulosin hydrochloride oral controlled absorption system (OCAS) 0.4 mg tablet; Placebo fixed dose combination (FDC) tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
62102584|NCT01018511|ACTIVE_COMPARATOR|TOCAS 0.4 mg|Participants received 3 tablets once a day for 12 weeks. Tamsulosin hydrochloride OCAS (TOCAS) 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
62102585|NCT01018511|EXPERIMENTAL|FDC 0.4 mg/6 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
62102586|NCT01018511|EXPERIMENTAL|FDC 0.4 mg/9 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
62102587|NCT02142439|EXPERIMENTAL|Intervention group 1|Exercise counseling 1 time/week, Strength training 3 times/week, dose: 5 RM x 3 sets.
62295709|NCT00635622|EXPERIMENTAL|1|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
62295710|NCT00635622|PLACEBO_COMPARATOR|2|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
62467840|NCT01804803|EXPERIMENTAL|T-SMBG|This group will perform SMBG using a smartphone-connected glucometer implemented with a software for real-time collection and transmission of measured glucose values to the remote server. SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS). A specific algorithm incorporated into the DSS will allow the patients to self-calculate the dose of basal insulin to be administered according to the measured fasting blood glucose levels for consecutive periods of three days. Glucose data and analyses will be made accessible to the patients and medical staff anytime and anywhere via the web. Patients will be also assisted by the diabetes medical team located at or connected with a call center 24-hours/day, 7 days/week.
62663783|NCT02890186|EXPERIMENTAL|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
62663784|NCT02890186|PLACEBO_COMPARATOR|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
62663785|NCT05702268|EXPERIMENTAL|High-dose|40 mg ICP-332 tablet 3 tablets, once a day
62663786|NCT05702268|EXPERIMENTAL|Low-dose|40 mg ICP-332 2 tablets + 1 placebo tablet once daily
62102588|NCT02142439|EXPERIMENTAL|Intervention group 2|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 10 RM x 3 sets.
62295711|NCT06656611|OTHER|prospective cervical cancer screening intervention|Evaluation of a cervical cancer screening outreach intervention using point-of-care High-Risk HPV (HPV-HR) tests on self-collected vaginal swabs
61911796|NCT01456767|ACTIVE_COMPARATOR|Lactobacillus plantarum CIP104450|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104450).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
61911797|NCT01456767|PLACEBO_COMPARATOR|Placebo|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of a placebo).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
62663787|NCT05702268|PLACEBO_COMPARATOR|Blank control|Placebo 3 tablets once daily
62663788|NCT00444249|ACTIVE_COMPARATOR|1|White Alcon IOL
62295712|NCT04987281|EXPERIMENTAL|Device feasibility (bronchoscopy, CT, indocyanine green)|During standard of care surgical resection, patients undergo robotic bronchoscopy and CT. Patients also receive indocyanine green via injection.
62663789|NCT00444249|ACTIVE_COMPARATOR|2|Yellow Alcon IOL
61911798|NCT05164107|EXPERIMENTAL|Globe Mapping and Pulsed Field Ablation System|
61911799|NCT04268602|EXPERIMENTAL|Intervention Group|intradermal 1% lidocain injection 4 cc+ exercise and transcutaneous electrical nerve stimulation
61911800|NCT04268602|NO_INTERVENTION|Control Group|exercise and transcutaneous electrical nerve stimulation
61911801|NCT02775240|ACTIVE_COMPARATOR|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
61911802|NCT02775240|EXPERIMENTAL|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
61911803|NCT02775240|ACTIVE_COMPARATOR|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
62295713|NCT03656913|EXPERIMENTAL|Study Group|Patients will receive both the clinically indicated and extremely low dose CT exams
62467841|NCT01804803|ACTIVE_COMPARATOR|SMBG|This group will perform SMBG using a regular glucometer and will report glucose data on paper charts (or download data from the glucometer onto the PC) at the planned study visits. Patients will not receive feed-back on their glucose levels nor instructions on how to potentially modify their drug therapy except when undergoing medical visits at the planned intervals. Patients, finally, will not be assisted by the diabetes team/call center.
62467842|NCT04794140|EXPERIMENTAL|one pass group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from a single pass for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
62102589|NCT02142439|EXPERIMENTAL|Intervention group 3|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 30 RM x 3 sets
62102590|NCT02142439|NO_INTERVENTION|Control group|Exercise counseling 1 time/week
62102591|NCT01645852|NO_INTERVENTION|Control|No specified diet for one week prior to hepatic resection.
62295714|NCT01542307|EXPERIMENTAL|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
62295715|NCT01542307|PLACEBO_COMPARATOR|Room Air|Medical air inhaled for 30 minutes during migraine attack
62295716|NCT04708912||1|Mild-Moderate COVID-19
62295717|NCT04708912||2|Severe COVID-19
62295718|NCT04708912||3|Convalsent (COVID-19)
62663790|NCT00444249|ACTIVE_COMPARATOR|3|White Hoya IOL
62663791|NCT00444249|ACTIVE_COMPARATOR|4|Yellow Hoya IOL
62663792|NCT02818257|EXPERIMENTAL|Strip A (wet)|Six strips of Strip A are applied on skin wetted with two different buffers (3 strips each)
62295719|NCT04708912||4|Healthy persons
62295720|NCT02599402|EXPERIMENTAL|Combination therapy: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab specified dose on specified days
62295721|NCT02599402|EXPERIMENTAL|Monotherapy: Nivolumab|Nivolumab specified dose on specified days
62295722|NCT06327230|NO_INTERVENTION|"Non-TEA group"|After enrollment, the subjects are given standard treatment, including continuous monitoring of vital signs, pain control with intravenous non-steroidal anti-inflammatory drugs (such as ibuprofen) and intravenous opioids (such as tramadol), goal-directed intravenous fluid resuscitation, correction of electrolyte and metabolic disturbances, nutritional support, use of antibiotics and sedatives as needed, necessary mechanical ventilation, continuous renal replacement therapy (CRRT) and other organ support therapies as needed.
62663793|NCT02818257|EXPERIMENTAL|Strip A (dry)|Six strips of Strip A are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
62663794|NCT02818257|EXPERIMENTAL|Strip B (wet)|Six strips of Strip B are applied on skin wetted with two different buffers (3 strips each)
62663795|NCT02818257|EXPERIMENTAL|Strip B (dry)|Six strips of Strip B are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
62663796|NCT02818257|EXPERIMENTAL|Strip C (wet)|Six strips of Strip C are applied on skin wetted with two different buffers (3 strips each)
62467843|NCT04794140|EXPERIMENTAL|two passes group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from two passes for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
61911804|NCT04278274||patients will be evaluated by artificial intelligence system and expert radiologist|the patients with locally advanced rectal cancer (LARC) finished the neoadjuvant treatment, and not yet receive total mesorectum excision (TME) surgery will be enrolled. The post-neoadjuvant treatment MRI images features of each enrolled patients will be captured by the artificial intelligence system, and evaluated by experienced radiologists as well. Blind to the pathologic report of TME specimen, both approaches further respectively yield a predicted pathologic response to neoadjuvant treatment for each enrolled patient, shown as pCR or non-pCR.
61911805|NCT05938049||Group A|patients whom fluid management will be guided by their IVC \& carotid Doppler measurements
62102592|NCT01645852|ACTIVE_COMPARATOR|Low calorie diet|Low calorie diet (five units of Optifast 800 {Nestle Nutrition, Vevey, Switzerland} plus an unlimited volume of calorie free fluids per day) for one week prior to hepatic resection.
62467844|NCT05123222|EXPERIMENTAL|ZIKV-SJRP/2016-184 Strain|Dose of 10ˆ2 PFU
62467845|NCT05123222|EXPERIMENTAL|ZIKV-Nicaragua/2016 Strain|Dose of 10ˆ2 PFU
61911806|NCT05938049||Group B|patients in whom the fluid management will not guided by IVC \& carotid Doppler measurements.
62102593|NCT02212886|EXPERIMENTAL|GA Depot 80mg|Monthly IM injection
62663797|NCT02818257|EXPERIMENTAL|Strip C (dry)|Six strips of Strip C are applied on skin that is either dry (3 strips) or wetted with buffer (3 strips)
62663798|NCT03470766|ACTIVE_COMPARATOR|Active Lead (AL)|One octad lead placed where contacts 4 and 5 span the T9-T10 disc space.
61911807|NCT02173262|OTHER|G-CSF|Participants will receive a daily injection of G-CSF while on chemotherapy for prevention of febrile neutropenia.
62102594|NCT02212886|EXPERIMENTAL|GA Depot 40mg|Monthly IM injection
62467846|NCT05123222|PLACEBO_COMPARATOR|Placebo|PlasmaLyte
62467847|NCT04667091|EXPERIMENTAL|Experimental|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Positional Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
62663799|NCT03470766|SHAM_COMPARATOR|Sham Lead (SL)|One octad lead implanted subcutaneously behind the IPG and will serve to dissipate the current from the battery
62663800|NCT03401333|EXPERIMENTAL|Text messaging and brief intervention|Brief motivational interview and 4-weeks of text messaging.
62295723|NCT06327230|EXPERIMENTAL|TEA group|Patient in lateral position, standard disinfection, puncture point selected at T7-T9 level, local anesthesia to pierce skin. Direct/lateral needle approach cautiously, confirm entry into epidural space with disappearance of resistance and negative pressure. Insert epidural catheter 3-5cm towards head, secure firmly. Test dose with 3mL 1% lidocaine injection to confirm epidural anesthesia efficacy and safety. Epidural infusion of 0.15% ropivacaine (250mL) + fentanyl (2.5mg) via patient-controlled pump at 5mL/h with bolus option. Adjust infusion rate 1-3mL/h based on pain needs.
62295724|NCT02304003|EXPERIMENTAL|Structured Physiotherapy regimen|Heavy-slow resistance training of rotator cuff . Scapular exercises. Manual mobilisation of glenohumeral joint . Stretching. Low Level Laser therapy
62663801|NCT02188732|EXPERIMENTAL|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
62663802|NCT02188732|ACTIVE_COMPARATOR|CBHH+SMT|"CBHH+SMT Community-Based Health Home (CBHH) PLUS Self-Management Training (SMT) of I-IMR~I-IMR integrates psychiatric illness self-management with strategies for medical illness self-management . The psychiatric component includes psychoeducation about illness and treatment, cognitive behavioral approaches to increase medication adherence, training and relapse prevention, teaching coping skills to manage persistent symptoms, and social skills training. The medical illness component consists of an individually tailored curriculum focused on managing physical illnesses using parallel skills and strategies taught for psychiatric illness self-management, as well as a nurse health care manager to facilitate coordination of necessary preventive and ongoing health care. The I-IMR curriculum consists of 10 modules delivered by an I-IMR specialist through eight months of weekly sessions customized to the specific needs and disorders of each client."
62663803|NCT02188732|ACTIVE_COMPARATOR|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW)
61911808|NCT02173262|OTHER|Ciprofloxacin|Participants will receive Ciprofloxacin 500 mg twice a day by mouth for 10 days of each cycle during chemotherapy for prevention of febrile neutropenia.
62295725|NCT02304003|OTHER|Standard care|Standard care offered in primary care while waiting for surgery , this may be but are not limited to : Wait and see, Drugs ( NSAIDS ), Corticosteroid injections, physiotherapy or other conservative treatment options.
62295726|NCT05225155||Control|Women without thrombophilia, submitted to in vitro fertilization techniques
62295727|NCT05225155||Untreated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, without treatment with enoxaparin
61911809|NCT03441672|EXPERIMENTAL|Intervention|Participants in the intervention group interact with the game technology to learn about prenatal screening, in addition to usual care provided in the clinic.
62102595|NCT04903028|SHAM_COMPARATOR|Sham rTMS|Investigators will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.
62102596|NCT04903028|ACTIVE_COMPARATOR|Active rTMS 10 Hz DLPFC|A stimulation frequency of 10 Hz, pulse train duration (on time) of 5 seconds, inter-train interval (off time) of 10 seconds (15 second cycle time), E-field-modeling to determine TMS intensity and coil orientation, total of 60 trains, session time of 15 minutes, and 3000-total pulses per day, will be delivered over the left DLPFC.
62102597|NCT02795806||1|Everybody for whom a clinical narrative report is created.
62102598|NCT05117515||Uni-Graft KDV Patch|
62102599|NCT06364150|EXPERIMENTAL|Cell treatment arm|Patients who receive Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction
61911810|NCT03441672|NO_INTERVENTION|Control|Participants in the control group learn about prenatal screening through usual care in the clinic.
61911811|NCT03708562|OTHER|endoAVF|
61911812|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
61911813|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
61911814|NCT02461472||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
61911815|NCT05473585|ACTIVE_COMPARATOR|Study EC + UB CC|Participants will make choices between the study e-cigarette (EC) device with tobacco flavor and their usual brand (UB) combusted cigarette (CC)
62295728|NCT05225155||Treated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, and treated with enoxaparin
62295729|NCT00817271|EXPERIMENTAL|1|
62295730|NCT00817271|EXPERIMENTAL|2|
62295731|NCT01621932|ACTIVE_COMPARATOR|Surgical approach 1|Direct anterior surgical approach with capsulectomy
62295732|NCT01621932|ACTIVE_COMPARATOR|Surgical approach 2|Direct anterior approach without capsulectomy
62295733|NCT04769557|EXPERIMENTAL|Paracetamol|Paracetamol
62295734|NCT04769557|PLACEBO_COMPARATOR|Placebo|placebo
62295735|NCT00267241|EXPERIMENTAL|1|ALI/ARDS patients
62295736|NCT01974817|EXPERIMENTAL|Vaccine|Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.
62295737|NCT04278443||Low dose rate brachytherapy|20 patients receiving low dose rate brachytherapy
62295738|NCT04278443||High dose rate brachytherapy|20 patients receiving high dose rate brachytherapy.
62467848|NCT04667091|ACTIVE_COMPARATOR|Comparator|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Myofascial Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
62663804|NCT02962466|EXPERIMENTAL|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo).
62663805|NCT02962466|NO_INTERVENTION|D3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo).
62663806|NCT02962466|NO_INTERVENTION|D5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo).
62663807|NCT00103506|ACTIVE_COMPARATOR|VELCADE (bortezomib) monotherapy|Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m\^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
62663808|NCT00103506|EXPERIMENTAL|DOXIL/CAELYX in combination with VELCADE (bortezomib)|Bortezomib (VELCADE) 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
62102600|NCT06456931|EXPERIMENTAL|Traditional Buddhist mindfulness training|This involves an 8-week program with weekly 2-hour sessions, and daily home practice of comparable duration to MBCT, conducted in groups of 15 participants. Sessions will be conducted by a lay mindfulness trainer inside a conference hall. Meditation practice will include sitting meditation, walking meditation, and loving-kindness meditation. In addition to meditation practice, sessions will involve teaching and discussing concepts related to mindfulness from the Pali Canon, placed within the context of fundamental principles of Buddhism. Anecdotes from Buddhist literature will also be used. Additionally, the participants will be given the opportunity to engage in religious rituals of their preference during the sessions. Participants will be encouraged to engage in meditation, along with preferred religious activities for at least 40 minutes a day.
62102601|NCT06456931|ACTIVE_COMPARATOR|Secular mindfulness based cognitive therapy|Secular MBCT groups (each consisting of 15 participants) will undergo the manualized 8-week MBCT program (Segal et al., 2002). Weekly 2-hour sessions will be conducted inside a conference hall at the Faculty of Medicine, University of Kelaniya by the principal investigator who is a senior registrar in psychiatry with over 6 years of personal experience in mindfulness practice. Daily home practice of 40 minutes will be recommended. Guided meditation recordings made in Sinhalese will be provided for home practice. Some cognitive behavioural exercises will be prescribed as part of homework (e.g., Pleasant and Unpleasant Events Calendars).
62102602|NCT05953350|EXPERIMENTAL|Phase Ib clinical trial|600mg bid dose of hydroxychloroquine group combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
62102603|NCT05953350|EXPERIMENTAL|Phase II clinical trial|After MTD was determined, RP2D dose was selected for phase II clinical trial.
62467849|NCT02495467|EXPERIMENTAL|MED Placebo then MED2005|Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
62467850|NCT02495467|EXPERIMENTAL|MED2005 then MED Placebo|Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
62467851|NCT02420834|EXPERIMENTAL|Tear Supplement Hypromellose 0.15%|Preservative free Hypromellose Eye Drops BP 0.15% applied as required for 1 month
62467852|NCT02420834|EXPERIMENTAL|Tear Supplement Hypromellose 0.4%|Preservative free Hypromellose Eye Drops BP 0.4% applied as required for 1 month
62663809|NCT01344200|ACTIVE_COMPARATOR|Phase I: Study drug Group 1 (Celecoxib 7 mg/kg)|Study participants randomized to this group will receive a single 7 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
62663810|NCT01344200|ACTIVE_COMPARATOR|Phase I: Study drug Group 2 (Celecoxib 14 mg/kg)|Study participants randomized to this group will receive a single 14 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
62295739|NCT06649994|EXPERIMENTAL|Active iTBS of the DLPFC|The experimental group will: i) receive an informative session; ii) 2 sessions of pre-treatment assessment (one with fMRI and one with questionnaires); iii) participate in 10 daily individual intervention sessions that consist of iTBS of the left dlPFC followed immediately inhibitory control training, that will last about 10-20 minutes each; iv) 2 sessions of post-treatment assessment (one with fMRI and one with questionnaires); v) one follow-up assessment session three months after completing the intervention
62295740|NCT06649994|EXPERIMENTAL|Active iTBS of the vmPFC|The experimental group will: i) receive an informative session; ii) 2 sessions of pre-treatment assessment (one with fMRI and one with questionnaires); iii) participate in 10 daily individual intervention sessions that consist of iTBS of the vmPFC followed immediately by inhibitory control training, that will last about 10-20 minutes each; iv) 2 sessions of post-treatment assessment (one with fMRI and one with questionnaires); v) one follow-up assessment session three months after completing the intervention
62295741|NCT06649994|PLACEBO_COMPARATOR|Active Control|The active control group will: i) receive an informative session; ii) 2 sessions of pre-treatment assessment (one with fMRI and one with questionnaires); iii) participate in 10 daily individual intervention sessions that consist of iTBS of the vertex (sham) followed immediately by inhibitory control training, that will last about 10-20 minutes each; iv) 2 sessions of post-treatment assessment (one with fMRI and one with questionnaires); v) one follow-up assessment session three months after completing the intervention
62295742|NCT03698201||Cohort 1 / High grade Glioma|"Cohort 1:~1. Histologically confirmed high grade glioma (grade III) or glioblastoma (GBM, astrocytoma grade IV)~2. Planned treatment (RT alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
62295743|NCT03698201||Cohort 2 / Low grade Glioma|"Cohort 2:~1. Histologically confirmed low grade (grade II) glioma~2. Planned treatment either~   * expectant monitoring or~  * RT alone or~  * Chemotherapy alone or~  * a combination of RT/Chemotherapy"
62663811|NCT01344200|PLACEBO_COMPARATOR|Phase II: Group A: Placebo|"Study participants will receive a single dose of placebo. Placebo will be liquid. The study participant will drink it.~The timing of when the study participants in this group will take placebo will be determined in a second randomization:~Group A.1: will take placebo 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.2: will take placebo 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.3: will take the placebo 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group A.5: will take the study medication 0 to 60 minutes prior to having their LP±BMA. The study medication will be taken at the hospital."
62295744|NCT02682836|EXPERIMENTAL|single arm|Walk with Ease physical activity intervention
62295745|NCT04449692|EXPERIMENTAL|80 µg s.c. dasiglucagon|80 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
62295746|NCT04449692|EXPERIMENTAL|120 µg s.c. dasiglucagon|120 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
62295747|NCT04449692|ACTIVE_COMPARATOR|15 g oral carbohydrate (dextrose tablets)|15 g of oral carbohydrate (dextrose tablets) will be administered when plasma glucose levels reach 4.5 mmol/l
62295748|NCT05516329|EXPERIMENTAL|18F-Thretide Injection|7±1 mCi (259±37 MBq) IV injection of 18F-Thretide
62295749|NCT03213665|EXPERIMENTAL|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62295750|NCT03176849|EXPERIMENTAL|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient will be classified as sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation according to current Endocrine Society Guidelines.
62467853|NCT02420834|EXPERIMENTAL|Tear Supplement Carboxymethylcellulose|Tear Supplement 3: Preservative free 0.25% Carboxymethylcellulose, electrolyte balanced (Theratears) applied as required for 1 month
62295751|NCT03176849|ACTIVE_COMPARATOR|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with standard of care per Endocrine Society Guidelines. This supplementation is based on a patient's initial vitamin D level.
62295752|NCT04924127||Discovery cohort|Retrospective frozen tissue and paired peripheral blood samples were obtained from the Huashan Glioma Biobank between October 2010 and August 2018. A total of 753 patients diagnosed with supratentorial diffuse glioma (WHO grade 2-4) aged 18-80 years were selected for the study.
62295753|NCT04924127||Validation cohort|From January to July 2021, 223 frozen tissue samples were retrieved from the Huashan Glioma Biobank. In addition, 107 frozen tumor samples were used to assess the detection accuracy of the IDH and TERTp mutation rapid test. The accuracy of this qPCR-based rapid test was further confirmed by Sanger and targeted sequencing.
62295754|NCT01175369|NO_INTERVENTION|Usual Care|Usual asthma care
62295755|NCT01175369|EXPERIMENTAL|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
62295756|NCT05192603|EXPERIMENTAL|Dietary intervention with Low FODMAP|The participants are given oral and written instructions on which diet that contains low contents of FODMAP.
62295757|NCT05192603|EXPERIMENTAL|Dietary intervention with SSRD|The participants are given oral and written instructions on which diet that contains SSRD.
62663812|NCT01344200|ACTIVE_COMPARATOR|Phase II: Group B: Study drug (Celecoxib 7 mg/kg)|"Study participants randomized to this group you will receive a single 7 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group B.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group B.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
62663813|NCT01344200|ACTIVE_COMPARATOR|Phase II: Group C: Study drug (Celecoxib 14 mg/kg)|"Study participants randomized to this group you will receive a single 14 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group C.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.4: will take the study medication 1 to 2 hours prior to having your LP±BMA. The study medication will be taken at the hospital.~Group C.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
62295758|NCT00496366|EXPERIMENTAL|Capecitabine (Xeloda) + Lapatinib (Tykerb)|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Lapatinib will be taken daily continuously for 21 days (Days 1- 21)."
62295759|NCT05791058|ACTIVE_COMPARATOR|Group A (ultrasound guided pericapsular nerve group shoulder block)|
62295760|NCT05791058|ACTIVE_COMPARATOR|Group B( ultrasound guided suprascapular and axillary nerve block)|
62295761|NCT05791058|ACTIVE_COMPARATOR|control group|
62295762|NCT06621407|EXPERIMENTAL|24 hours active subperiostal drainage|24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
62295763|NCT06621407|EXPERIMENTAL|24 hours passive subdural drainage|24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
62467854|NCT02420834|EXPERIMENTAL|Tear Supplement Liposomal spray|Preservative free Phospholipid liposomal spray (Tears Again) applied as required for 1 month
62295764|NCT01266564||Cohort|
62295765|NCT02368470|ACTIVE_COMPARATOR|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
62295766|NCT02368470|EXPERIMENTAL|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
62295767|NCT01274221|PLACEBO_COMPARATOR|Placebo|
62295768|NCT01274221|ACTIVE_COMPARATOR|SPD489|
62295769|NCT02318095|OTHER|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
62467855|NCT02187562|EXPERIMENTAL|Meloxicam/Aspirin|Meloxicam days 1-10 / Aspirin days 5-10
62467856|NCT02187562|ACTIVE_COMPARATOR|Aspirin|Aspirin 2 days
62467857|NCT00783367|EXPERIMENTAL|Lenalidomide plus rituximab with dexamethasone|Lenalidomide-low dose dexamethasone plus rituximab
62467858|NCT02884141||Patients|"Patients with documented fibromuscular dysplasia (see inclusion criteria).~Non-usual care added acts:~* blood sampling~* urine sampling~* renal echography"
62467859|NCT00518518|ACTIVE_COMPARATOR|1|
62102604|NCT04248764|EXPERIMENTAL|Foam roller group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, foam roler will be applied to the participants' quadriceps femoris muscles in a prone position for five minutes.
62467860|NCT00518518|PLACEBO_COMPARATOR|2|
62467861|NCT03292354|ACTIVE_COMPARATOR|Body Weight (BW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on body weight.
62467862|NCT03292354|ACTIVE_COMPARATOR|Cardiac output (CO)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on cardiac output.
62663814|NCT05387525|EXPERIMENTAL|Tirbanibulin 10 milligram per gram (mg/g) ointment|Participants will apply tirbanibulin ointment 10 mg/g once daily to the treatment field (TF) for 5 consecutive days beginning Day 1. At subsequent visits, participants will have the option of an additional 5-day course(s) (with at least 16 weeks between starting date of treatment courses) at the discretion of the investigator if actinic keratosis (AK) lesions are present in the TF and physical treatment is not appropriate.
62663815|NCT05387525|ACTIVE_COMPARATOR|Diclofenac Sodium 3% Gel|Participants will apply diclofenac sodium 3% gel twice daily to the TF for 60 to 90 days beginning Day 1, with the option of further courses every 6 months (with at least 6 months between starting date of treatment courses) if lesions are found to be present in the TF at follow up visits and physical treatment is not appropriate.
62663816|NCT02314884|EXPERIMENTAL|Cafusertib Hydrochloride|Cafusertib Hydrochloride d1q3w
62663817|NCT04991584|EXPERIMENTAL|14d concomitant therapy|Patients will receive a 14-day concomitant therapy Option 1:Amoxicillin+Tetracycline+Furazolidone+Vonoprazan fumarate or Esomeprazole Option 2: Amoxicillin+Furazolidone+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 3: Amoxicillin+Tetracycline+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 4: Amoxicillin+Clarithromycin+Levofloxacin+Vonoprazan fumarate or Esomeprazole Three options are selected according to the actual situation.
62102605|NCT04248764|EXPERIMENTAL|Massage group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, sports massage will be applied on the quadriceps femoris muscles for five minutes.
62102606|NCT04248764|NO_INTERVENTION|Control group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, the participants will rest in the long sitting position for 5 minutes.
62102607|NCT04606264|ACTIVE_COMPARATOR|Major Abdominal: Neuraxial Analgesia|Intrathecal morphine
62102608|NCT04606264|ACTIVE_COMPARATOR|Major Abdominal: Regional Analgesia Block 1|Paravertebral block
62102609|NCT04606264|ACTIVE_COMPARATOR|Major Abdominal: PONV Optimal Prophylaxis|"Pre-op~-perphenazine~Induction -dexamethasone~Emergence~-ondansetron"
62102610|NCT04606264|ACTIVE_COMPARATOR|Major Abdominal: PONV Supraoptimal Prophylaxis|"Pre-op~* aprepitant~* dimenhydrinate~* perphenazine~* ondansetron~Induction -dexamethasone~Emergence~-ondansetron"
62102611|NCT04606264|ACTIVE_COMPARATOR|Major Abdominal: Regional Analgesia Block 2|QL1
62102612|NCT04606264|ACTIVE_COMPARATOR|Major Abdominal: Neuraxial and Regional Analgesia Block 2|IT morphine and QL1
62102613|NCT04606264|ACTIVE_COMPARATOR|Major Abdominal: Neuraxial and Regional Analgesia Block 1|IT morphine and paravertebral
62102614|NCT03559361|PLACEBO_COMPARATOR|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
62467863|NCT03292354|ACTIVE_COMPARATOR|Lean Body weight (LBW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on Lean Body Weight.
62467864|NCT03292354|NO_INTERVENTION|Control group|Patients in this group will be included retrospectively and have received the standard CM injection protocol previously used in our department.
62467865|NCT06421870|ACTIVE_COMPARATOR|Dapagliflozin arm|70 patients will take dapagliflozin 10 mg per day for 1 year in addition to standard management for chronic kidney disease
62467866|NCT06421870|ACTIVE_COMPARATOR|Pentoxiphylline arm|70 patients will take pentoxifylline 400 mg twice daily for 1 year in addition to standard management for chronic kidney disease
62467867|NCT06421870|NO_INTERVENTION|Control|70 patients won't take either dapagliflozin or pentoxiphylline but they will continue their standard management for chronic kidney disease
62467868|NCT02458469|ACTIVE_COMPARATOR|Buspirone|This drug will be taken for two week period
62467869|NCT02458469|ACTIVE_COMPARATOR|Trazodone|This drug will be taken for two week period
62467870|NCT02458469|PLACEBO_COMPARATOR|Placebo|A placebo pill will be taken at bed time for two week period
62467871|NCT01602653|ACTIVE_COMPARATOR|1|the first group of patients received an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
62467872|NCT01602653|ACTIVE_COMPARATOR|2|The second grouop of patients received 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
62467873|NCT04891744|EXPERIMENTAL|Selinexor in combination with thalidomide and Dexamethasone|Selinexor in combination with thalidomide and Dexamethasone. Thalidomide will be given at 100mg/d d1-28,and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23. Treatment will be administered in 28-day cycles,include a total of 12 cycles. Selinexor dose escalation: 60, 80, 100mg respectively on day 1,8,15,22 for 4-week cycles. Then Selinexor will be given at the recommended dose level on phase II.
62102615|NCT03559361|ACTIVE_COMPARATOR|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
62102616|NCT03559361|ACTIVE_COMPARATOR|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
62102617|NCT05701462|EXPERIMENTAL|pleural disease|
62102618|NCT06712641|ACTIVE_COMPARATOR|Gentamicin + narrow spectrum betalactam|Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
62102619|NCT06712641|ACTIVE_COMPARATOR|Cefotaxime or piperacillin-tazobactam|Empirical therapy for suspected community-acquired sepsis with broad spectrum betalactam (either one of cefotaxime or piperacillin-tazobactam)
62102620|NCT01835340|EXPERIMENTAL|propofol|Propofol Patients will receive propofol anesthesia on the study day
62295770|NCT06651957||Observational|Participants undergo collection of 3 anal swab samples, complete questionnaires, and have their medical records reviewed on study. Participants with visible lesions undergo non-investigational high resolution anoscope with a non-investigational anal biopsy per usual care on study.
62295771|NCT03055026|EXPERIMENTAL|Rivaroxaban|Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
62295772|NCT03055026|PLACEBO_COMPARATOR|Placebo|Orally administered, OD for 3 weeks (extended prophylaxis)
62295773|NCT02832050|EXPERIMENTAL|Intervention|"The play therapy intervention consists of a standard of care delivered by a play specialist. The play specialist delivers interventions aimed in assisting the child through the process of undergoing procedures. The intervention is semi-structured in order to facilitate a systematic approach which remains individualised and child-centred.~The intervention requires patients to be classified as 'high risk' or 'low risk' for procedure-related anxiety. This is assessed for all patients at baseline based on parent and clinician opinion. The play specialist may re-classify patients at the initial assessment or at any point whilst working with the child. If this occurs, clear documentation of the rationale for this will be recorded. Patients classified as high risk receive additional preparation sessions as detailed in the standard of care."
62295774|NCT02832050|PLACEBO_COMPARATOR|Comparator|The comparator group will receive standard care of patients having blood tests within the Trust, which does not include the specific intervention of a play therapist routinely. As part of standard care if a child becomes particularly distressed a clinician may make a decision to refer the child for play therapy. If this occurs during the study period the child will be referred to the play specialist delivering the intervention for the study. The child will then receive play therapy as in the described intervention. They will be excluded from the main analysis but data will still be collected and analysed descriptively.
62295775|NCT01812642|EXPERIMENTAL|JNJ-37822681 10 milligram|JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.
62467874|NCT04254718|EXPERIMENTAL|Digital Storytelling|Legacy intervention via digital story for NICU parents
62102621|NCT02094794|EXPERIMENTAL|Treatment (TMLI, chemotherapy)|Patients undergo image guided TMLI on days -9 to -5, receive etoposide IV on day -4 and cyclophosphamide IV on day -2, and undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.
62467875|NCT05611593|EXPERIMENTAL|FOL100|Subjects will apply FOL100 lotion topically in the defined treatment area.
62663818|NCT00884949|EXPERIMENTAL|BMN 110|Within-patient Dose-Escalation
62102622|NCT04947501|EXPERIMENTAL|Participants with newly-diagnosed HR-Neuroblastoma|This pilot study of N9 as induction chemotherapy will enroll 30 patients with newly-diagnosed HR-NB. A first cohort of \>1 to 12-year old, and a second cohort of extended age \<19 years old. Both cohorts will be analyzed together.
62102623|NCT06486974|EXPERIMENTAL|Group 1|"Colgate MaxFresh Toothpaste - 0.243% NaF (1100 ppm F)~Total Polish 23 CHS TB Colgate Active Prevention Manual Toothbrush"
62102624|NCT06486974|ACTIVE_COMPARATOR|Group 2|"Colgate Great Regular Flavor Toothpaste - 0.76% Na MFP (1000 ppm F)~Colgate Adult Extra Clean soft-bristle toothbrush"
62102625|NCT06713733|ACTIVE_COMPARATOR|Dexamethasone|"submucosal dexamethasone is quite simple, less invasive, painless, convenient for the surgeon and offers a low cost solution. Submucosal injection offers advantage of concentrating the drug near the surgical area with less systemic absorption and no further manipulation of the tissues.~preoperative submucosal dexamethasone 8mg prior to incision locally."
62102626|NCT06713733|ACTIVE_COMPARATOR|Chymotrypsin|"oral trypsin chymotrypsin is proteolytic enzymes.~1 tab given 30 minutes prior to incision and 1 tab for three times a day for 5 days after extraction."
62102627|NCT02999282|EXPERIMENTAL|Presymptomatic real tDCS|Asymptomatic subjects - 10 days anodal transcranial direct current stimulation
62102628|NCT02999282|SHAM_COMPARATOR|Presymptomatic sham tDCS|Asymptomatic subjects - 10 days sham transcranial direct current stimulation
62102629|NCT02999282|EXPERIMENTAL|Symptomatic real tDCS|Symptomatic patients - 10 days anodal transcranial direct current stimulation
62102630|NCT02999282|SHAM_COMPARATOR|Symptomatic sham tDCS|Symptomatic patients - 10 days sham transcranial direct current stimulation
62102631|NCT03251651|EXPERIMENTAL|PPF|Patient who received propofol during the operation
62102632|NCT03251651|EXPERIMENTAL|DEX|Patient who received dexmedetomidine during the operation
62102633|NCT05677659|EXPERIMENTAL|VGL101|Solution administered via Intravenous Infusion (IV)
62295776|NCT01812642|EXPERIMENTAL|JNJ-37822681 20 milligram and placebo|JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
62102634|NCT04294082||Mindfulness based intervention|A shortened version of a mindfulness-based intervention originally developed by Jon Kabat-Zinn for management of chronic pain.
62102635|NCT06138587|EXPERIMENTAL|Phase 1/1b: CIML NK Cells + Interleukin-2|"5 eligible participants will be enrolled to determine the maximum tolerated dose (MTD) of CIML NK at starting dose level 0.~* Screening and baseline visit with assessments and bone marrow aspirate and biopsy.~* Day 0: Standard-of-care conditioning chemotherapy and stem cell infusion.~* Day 7: Predetermined dose of CIML NK cells 1x daily.~* Days 7, 9, 11, 13, 15: Predetermined dose of Interleukin-2 1x daily every other day (5 doses total).~* Dose limiting toxicity period for 6 weeks after infusion of CIML NK cells~If 0 or 1 dose limiting toxicity is observed at the dose level, then this dose will be the MTD and study will proceed to Phase 1b.~De-escalation to dose level -1 per protocol if ≥2 DLTs occur with dose Level 0.~In phase Ib, 10 additional participants will be enrolled at the maximum tolerated dose."
62102636|NCT04866563|EXPERIMENTAL|AX-8 to Placebo, Part 1 of the study|AX-8 BID, taken for 2 weeks, followed by a 1-week washout period and then Placebo BID, taken for 2 weeks.
62102637|NCT04866563|EXPERIMENTAL|Placebo to AX-8, Part 1 of the study|Placebo BID, taken for 2 weeks, followed by a 1-week washout period and then AX-8 BID, taken for 2 weeks.
62295777|NCT03917121|EXPERIMENTAL|Jet anesthesia|Local infiltration anesthesia delivered using Madajet XL® (MADA Medical Products, Inc., Carlstadt, NJ, USA) needle-free jet injector
62295778|NCT03917121|ACTIVE_COMPARATOR|Conventional infiltration anesthesia|Local infiltration anesthesia delivered using 25 gauged short needle attached, 1.8 ml carpule loaded standard metal dental syringe
62295779|NCT04255511|EXPERIMENTAL|Twin block|Removable Functional appliance
62295780|NCT04255511|ACTIVE_COMPARATOR|Fixed appliance|Preadjusted fixed appliance
62295781|NCT04240652||Subjects with fundus photography|Subjects diagnosed with diabetes or not who have fundus images from MMCs and other medical institutes.
62295782|NCT01122927|EXPERIMENTAL|Phase 1 and Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
62295783|NCT05704985|EXPERIMENTAL|DK210 (EGFR) Monotherapy (Dose escalation and expansion)|DK210 (EGFR) will be administered as monotherapy three times per week via subcutaneous (SC) administration. Dose will be escalated from 0.025 mg/kg to 0.3 mg/kg or until unacceptable toxicity, disease progression, or withdrawal of consent. An expansion cohort at the optimal dose will be enrolled in parallel with the combination arms.
62295784|NCT05704985|EXPERIMENTAL|DK210 (EGFR) + chemotherapy|In patients with good tolerance of first line systemic therapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with second-line intravenous (IV) chemotherapy until unacceptable toxicity, disease progression, or withdrawal of consent
62295785|NCT05704985|EXPERIMENTAL|DK210 (EGFR) + radiation|In patients with need of palliative radiation, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with short course radiation therapy (10 fractions or less) until unacceptable toxicity, disease progression, or withdrawal of consent
62295786|NCT05704985|EXPERIMENTAL|DK210 (EGFR) + immunotherapy|In patients with good tolerance of first line immunotherapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with intravenous (IV) immune checkpoint blockers until unacceptable toxicity, disease progression, or withdrawal of consent
62295787|NCT04727671|ACTIVE_COMPARATOR|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
62308230|NCT01663129||Rheumatic Disease Patient Group|"* Juvenile Idiopathic Arthritis (JIA)~* Systemic Lupus Erythematosis~* Juvenile Dermatomyositis~* Scleroderma~* Overlap Syndromes~* Sjogren's syndrome~* Sarcoidosis~* Systemic Vasculitis (excluding Kawasaki's disease and Henoch-Schonlein Purpura)~* Systemic vasculitis as defined by the Chapel Hill Concensus Conference on Nomenclature. Other forms of systemic vasculitis, including Giant cell (temporal) arteritis, Takayasu's arteritis, Polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome, Microscopic polyangiitis, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Behcet's disease, Other vasculitis~* Other rheumatic disease"
62663819|NCT01294540|EXPERIMENTAL|Experimental: 1|
62102638|NCT04866563|EXPERIMENTAL|AX-8 to Placebo, Part 2 of the study|AX-8 TID, taken for 2 weeks, followed by a 1-week washout period and then Placebo BID, taken for 2 weeks.
62102639|NCT04866563|EXPERIMENTAL|Placebo to AX-8, Part 2 of the study|Placebo TID, taken for 2 weeks, followed by a 1-week washout period and then AX-8 BID, taken for 2 weeks.
62102640|NCT03818659|ACTIVE_COMPARATOR|Self-Guided|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
62102641|NCT03818659|EXPERIMENTAL|Full Support|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
62102642|NCT03818659|NO_INTERVENTION|Usual Care|"The investigators will also conduct non-randomized comparisons of BP control in the Full Support and Self-Guided intervention arms to BP control in non-participating Usual Care institutions in PCORnet."
62102643|NCT05756426||Healthy Volunteers|Healthy Volunteers \>/= 18yrs of age without acute or chronic illness.
62102644|NCT02688972|EXPERIMENTAL|cold water immersion|
62295788|NCT04727671|EXPERIMENTAL|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
62295789|NCT00138216|EXPERIMENTAL|Oral Irinotecan, temozolomide and vincristine sulfate|see detailed description
62102645|NCT02688972|OTHER|control|13 volunteers
62102646|NCT06714162|EXPERIMENTAL|Experimental|dietary supplement
62102647|NCT02018666|EXPERIMENTAL|spontaneous NAVA mode|
62102648|NCT02018666|ACTIVE_COMPARATOR|Inspiratory pressure support (IPS)|
62295790|NCT04965519|EXPERIMENTAL|RC48-ADC|Eligible subjects received RC48-ADC treatment after enrollment, at a dose of 2.0 mg/kg, once every 2 weeks (the dosing time window in all cycles is -1 to 2 days), and the administration method is intravenous Drip.
62295791|NCT02013219|EXPERIMENTAL|Stage 1: Alectinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
62295792|NCT02013219|EXPERIMENTAL|Stage 1: Erlotinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycles) of each cycle thereafter along with erlotinib at a starting dose of 150 mg PO QD, for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless MTD is exceeded. The combination will be given to participants with EGFR TKI treatment-naive, locally advanced or metastatic NSCLC.
62295793|NCT02013219|EXPERIMENTAL|Stage 2: Alectinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
62295794|NCT02013219|EXPERIMENTAL|Stage 2: Erlotinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or MAD of the combination treatment established in Stage 1. Previously untreated (or with one prior treatment that was not an EGFR TKI), EGFR mutation positive, locally advanced or metastatic NSCLC participants will be included.
62295795|NCT00833092|PLACEBO_COMPARATOR|Sugar pill|Sugar Pill
62295796|NCT00833092|ACTIVE_COMPARATOR|magnesium|300 milligrams of magnesium daily
62295797|NCT04586491|EXPERIMENTAL|Study group/ Oral care protocol with saline solution|All patients took oral care protocol in the unit with saline solution
62295798|NCT04586491|EXPERIMENTAL|Control group/ Oral care protocol with sodium bicarbonate solution|All patients took oral care protocol in the unit with sodium bicarbonate solution
62295799|NCT00809133|EXPERIMENTAL|Part A|BIBW2992 + Paclitaxel
62295800|NCT00809133|EXPERIMENTAL|Part B|BIBW2992 + Paclitaxel + Bevacizumab
62295801|NCT00809133|EXPERIMENTAL|Part C|BIBW2992 + Carboplatin
62295802|NCT00809133|EXPERIMENTAL|Part D|BIBW2992 +Paclitaxel + Carboplatin
62102649|NCT01809379|EXPERIMENTAL|intraperitoneal chemotherapy|Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
62295803|NCT04626830|EXPERIMENTAL|Mobile Application Intervention|Participants in the intervention group will receive 6 months the mobile application (OKTED) for improving symptoms and adherence to oral anticancer agents. The mobile application will consist of three modules. The first module will include OAA-specific information, a calendar in which start/end dates can be record, and a medication reminder. The second module will include information about common and urgent symptoms and recommendations for the management of these symptoms. The last module will comprise a question and answer section.
62295804|NCT04626830|NO_INTERVENTION|Standard Care|Participants in the control group will receive standard oncology care only.
62295805|NCT04743050|ACTIVE_COMPARATOR|Control Group|The control group will be a group without EFA supplementation.
62467876|NCT05611593|ACTIVE_COMPARATOR|Propecia 1mg (oral Finasteride)|Participants will receive1 tablet of Propecia 1mg (oral Finasteride) once daily (q.d)
62102650|NCT04643743||Subjects who did receive POLYPATCH® for vascular angioplasty|Subjects who did receive POLYPATCH® at least one year ago for vascular angioplasty. 2 main sub-populations will be studied depending on location of surgery (carotid and femoral) but data will be collected for all subjects who did receive POLYPATCH.
62102651|NCT02465359|EXPERIMENTAL|Immune globulin subcutaneous (Human)|lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
62102652|NCT05128942|EXPERIMENTAL|Cohort 1: Age 11-17 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
62102653|NCT05128942|EXPERIMENTAL|Cohort 2: Age 11-17 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
62102654|NCT05128942|EXPERIMENTAL|Cohort 3: Age 2-10 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
62102655|NCT05128942|EXPERIMENTAL|Cohort 4: Treatment with Tildacerfont|Oral Tildacerfont administered daily for 4 consecutive weeks.
62102656|NCT05128942|EXPERIMENTAL|Cohort 5: Treatment with Tildacerfont|Oral Tildacerfont administered daily for 4 consecutive weeks.
62102657|NCT05128942|EXPERIMENTAL|Cohort 6: Treatment with Tildacerfont|Oral Tildacerfont administered twice daily for 4 consecutive weeks.
62102658|NCT05128942|EXPERIMENTAL|Cohort 7: Treatment with Tildacerfont|Oral Tildacerfont administered daily for 4 consecutive weeks.
62295806|NCT04743050|EXPERIMENTAL|1st Experimental Group|The first experimental group will receive supplementation with pure ALA fraction of EFA esters. 5 ml a day of OmegaRegen Original containing 2.9 g of ALA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
62102659|NCT05128942|EXPERIMENTAL|Cohort 8: Treatment with Tildacerfont|Oral Tildacerfont administered daily for 4 consecutive weeks.
62295807|NCT04743050|EXPERIMENTAL|2nd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen EPA+DHA containing 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
62295808|NCT04743050|EXPERIMENTAL|3rd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen MAMA containing 2.9 g of ALA, 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
62295809|NCT02036320|EXPERIMENTAL|etafilcon A with additive printed limbal ring|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
62467877|NCT02057458|EXPERIMENTAL|Acute Study: Sildenafil first, then Placebo|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
62295810|NCT02036320|ACTIVE_COMPARATOR|etafilcon A|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
62102660|NCT05128942|EXPERIMENTAL|Cohort 9: Treatment with Tildacerfont|Oral Tildacerfont administered daily for 4 consecutive weeks.
62102661|NCT05423587|EXPERIMENTAL|GAE Treatment|The genicular artery embolisation procedure identifies abnormal blood vessels in the knee via angiogram imaging. Through groin access and puncture of the femoral artery through a small sheath tiny microspheres (Embozene(TM)) will be injected into this area and reduce blood flow in order to reduce pain.
62102662|NCT05423587|SHAM_COMPARATOR|Sham Procedure|In the control (sham) arm patients will not undergo the embolisation procedure with microspheres, instead they will have 2ml of saline injected into their knee artery supplying the abnormal area of the knee. The remainder of the procedure is otherwise identical between the two groups.
62102663|NCT00072475|EXPERIMENTAL|Vatalanib|Adult patients with MDS receive treatment with vatalanib.
62102664|NCT01893320|EXPERIMENTAL|Vosaroxin + Decitabine|"The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).~Following the phase I portion, patients in phase II receive the following induction:~1. Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I.~2. Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I."
62467878|NCT02057458|EXPERIMENTAL|Acute Study: Placebo first, then Sildenafil|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
62467879|NCT02057458|EXPERIMENTAL|Sub-Chronic Study Sildenafil|Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Endothelial function will be determined within 48 hours following the last dose.
62102665|NCT05509439|EXPERIMENTAL|Home Transfusion|"This research study involves completing questionnaires, a brief interview, blood draws, and blood transfusions when needed.~* Home Transfusion Program Components~* Participants will be in the research study for up to six months"
62102666|NCT01674569|EXPERIMENTAL|50 mg X-82 oral alternate days|50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops
62102667|NCT01674569|EXPERIMENTAL|50 mg X-82 oral QD|50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops
62102668|NCT01674569|EXPERIMENTAL|100 mg X-82 oral alternate days|100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops
62102669|NCT01674569|EXPERIMENTAL|100 mg X-82 oral QD|100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
62102670|NCT01674569|EXPERIMENTAL|200 mg X-82 oral QD|200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
62102671|NCT01674569|EXPERIMENTAL|300 mg X-82 oral QD|300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.
62102672|NCT06067490|EXPERIMENTAL|RC1416|RC1416(SAD),single ascending (25mg-600mg) of RC1416 by subcutaneous injection
62295811|NCT00828451|EXPERIMENTAL|Preterm Infants for EGF Profiles|Premature infants born at \< 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of \[5,5,5-2H3\]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
62295812|NCT00371319|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus treatment
62295813|NCT00371319|ACTIVE_COMPARATOR|mycophenolate mofetil|mycophenolate mofetil
62295814|NCT01850615|EXPERIMENTAL|FIAsp and basal insulin + metformin|Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
62295815|NCT01850615|ACTIVE_COMPARATOR|Basal insulin + metformin|Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
62295816|NCT03376633|NO_INTERVENTION|Control group|These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 \[Cohort 1\] or 2018-19 and 2019-20 \[Cohort 2\] or after, and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
62295817|NCT03376633|EXPERIMENTAL|WOW Group and Individual Counseling|These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 \[Cohort 1\] or 2018-19 and 2019-20 \[Cohort 2\]. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
62102673|NCT06067490|PLACEBO_COMPARATOR|Placebo|Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
62102674|NCT05998590|EXPERIMENTAL|High protein intake supplementation|A daily 60g dose of whey protein supplementation received between 8-9pm during BT.
62102675|NCT05998590|EXPERIMENTAL|Moderate protein intake supplementation|A daily 20g dose of whey protein supplementation received between 8-9pm during BT.
62102676|NCT05998590|PLACEBO_COMPARATOR|Carbohydrate placebo supplementation|A daily isocaloric carbohydrate (maltodextrin) placebo received between 8-9pm during BT.
62295818|NCT01262898|EXPERIMENTAL|GSK962040 (10 mg)|GSK962040 10 mg
62295819|NCT01262898|EXPERIMENTAL|GSK962040 (50 mg)|GSK962040 50 mg
62295820|NCT01262898|EXPERIMENTAL|GSK962040 (125 mg)|GSK962040 125 mg
62467880|NCT02951962|EXPERIMENTAL|Twynsta 80/5mg|Day 1 \~ Day 9 : Twynsta 80/5mg / Day 10 \~ Day 14 : Twynsta 80/5mg + Crestor 20mg
62467881|NCT02951962|EXPERIMENTAL|Crestor 20mg|Day 1 \~ Day 5 : Crestor 20mg / Day 6 \~ Day 14 : Twynsta 80/5mg + Crestor 20mg
62102677|NCT05998590|OTHER|Control group|Control group, no daily supplement received, only participating in BT.
62295821|NCT01262898|EXPERIMENTAL|Placebo|Placebo
62295822|NCT04610814||Blood products during transport|Administration of appropriate blood products during transport
62295823|NCT04610814||Standard of Care|Receiving standard prehospital air medical care
62295824|NCT02498821|OTHER|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
62295825|NCT02498821|OTHER|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
62295826|NCT06583083|EXPERIMENTAL|experimental group|Sintilimab with P-GEMOX Regimen
62295827|NCT06583083|ACTIVE_COMPARATOR|control group|P-GEMOX Regimen
62467882|NCT05651126|EXPERIMENTAL|Placebo, Psilocybin_2, Psilocybin_5|Dose order: Placebo, Psilocybin 2mg, Psilocybin 5mg
62467883|NCT05651126|EXPERIMENTAL|Psilocybin_2, Placebo, Psilocybin_5|Dose order: Psilocybin 2mg, Placebo, Psilocybin 5mg
62467884|NCT05651126|EXPERIMENTAL|Psilocybin_2, Psilocybin_5, Placebo|Dose order: Psilocybin 2mg, Psilocybin 5mg, Placebo
62467885|NCT00794963|EXPERIMENTAL|Integrated care|Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
62663820|NCT01294540|PLACEBO_COMPARATOR|Placebo Comparator: 2|
61911816|NCT05473585|ACTIVE_COMPARATOR|Study EC + NNC CC|Participants will make choices between the study EC device with tobacco flavor and the normal nicotine content (NNC) investigational CC
61911817|NCT05473585|EXPERIMENTAL|Study EC + VLNC CC|Participants will make choices between the study EC device with tobacco flavor and the very low nicotine content (VLNC) investigational CC
61911818|NCT05473585|NO_INTERVENTION|Own EC + UB CC|Participants will make choices between their own EC device with their own tobacco flavor and their UB CC
62102678|NCT04619459|EXPERIMENTAL|Newborns receiving Kangaroo Mother Care (KMC)|The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. At Minute 5, the newborns' Apgar scores were assessed and recorded during KMC. The newborn's examination and injections (Hepatitis-B and K vit) were postponed until the first breastfeeding took place. A pediatrician performed a detailed examination of the newborns under the radiant infant warmer after the first breastfeeding. Following the examination, the newborn was positioned on the mother's breast for KMC. During this KMC, the newborn was administered 1 mg K vitamin in the right leg and 0.5 ml Hepatitis-B vaccine in the left leg via intramuscular injections. The KMC session was continued for 3 hours. Care attempt of mothers such as episiotomy repair was taken that the position of KMC.
62295828|NCT05372809|EXPERIMENTAL|SkinTE|SkinTE plus standard care
62295829|NCT05372809|OTHER|Control|Standard care alone
62295830|NCT05426356|ACTIVE_COMPARATOR|Non-Surgical Treatment|Non-surgical management (NSM) of sacral insufficiency or fragility fractures (SFIF)
61911819|NCT05206656|PLACEBO_COMPARATOR|Eribulin mesylate|"Metastatic breast cancer patients receive eribulin mesylate injection alone. The dosage is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle. Patients receive Eribulin untill progression.~Patients were observed for at least 6 months but no longer than 18 months."
61911820|NCT05206656|EXPERIMENTAL|Eribulin mesylate combined with Anlotinib|"Metastatic breast cancer patients receive Eribulin mesylate combined with Anlotinib. The dosage of Eribulin mesylate is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle.~Anlotinib dosage is 12mg per day for consecutive 14 days (21 days per cycle). Patients receive Anlotinib untill progression.~Patients were observed for at least 6 months but no longer than 18 months."
61911821|NCT01260675||NanoBUP Capsules|Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
61911822|NCT01260675||Suboxone Sublingual Tablets|Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
61911823|NCT04399746|EXPERIMENTAL|Combination|Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days).
62102679|NCT04619459|NO_INTERVENTION|Newborns receiving standard postpartum care (SPC):|He received the standard care of the hospital. KMC not applied.
62102680|NCT03067051|EXPERIMENTAL|PDT and verteporfin dose finding|"Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.~The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.~The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).~The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer ."
62102681|NCT06041802|EXPERIMENTAL|MK-3475A|Participants will receive MK-3475A subcutaneously for up to 18 administrations.
62102682|NCT03942822|EXPERIMENTAL|Chia supplemented group|8 weeks of 25 g/day of milled chia supplemented-isocaloric diet
62102683|NCT06710561|EXPERIMENTAL|Phase 1|Healthy subjects will receive intravenous injection of different doses of injectable SPN01 and placebo in a single dose.
62467886|NCT00794963|OTHER|Usual Care|Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community
62663821|NCT05710172|EXPERIMENTAL|Auditory Mirror Therapy Device|Modified 3M Peltor Tactical 300 Electronic Hearing Protector. The modification consists of connecting the left microphone to the right microphone tab on the circuit board, and vice versa.
61911824|NCT04399746|NO_INTERVENTION|Control|No intervention
62102684|NCT06710561|EXPERIMENTAL|Phase 2|Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
62102685|NCT06615310||dysphagia|3 Points and above according to the EAT-10 scale
62102686|NCT06615310||non-dysphagia|Under 3 points on the EAT-10 scale
62295831|NCT05426356|EXPERIMENTAL|Surgical Treatment|Surgical fixation of sacral insufficiency or fragility fractures (SFIF) with concomitant fusion of the sacroiliac (SI) joint
62467887|NCT01499147|ACTIVE_COMPARATOR|Arm 1|All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
61911825|NCT03044600||Young MEN1 Negative Group|Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
61911826|NCT05491460|ACTIVE_COMPARATOR|Apixaban|"Volunteers receive one oral dose of 5mg Apxiaban followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
62295832|NCT02016287|EXPERIMENTAL|sequential treatment|paclitaxel treatment and radiotherapy
62295833|NCT04378777||Surveillance cohort|Cohort descriptive data will include demographic variables (e.g. age, sex, race, ethnicity), clinical information on enrollment and key aspects of medical history (e.g. concomitant medications, for example). Patients will be longitudinally followed, up to 12 months.
62295834|NCT03705390|EXPERIMENTAL|ILB|ILB subcutaneous injection
62467888|NCT01499147|ACTIVE_COMPARATOR|Arm 2|All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
62467889|NCT02093494|EXPERIMENTAL|Initial Specimen Diversion Device (ISDD)|The ISDD will be used to collect the blood culture.
62467890|NCT02093494|ACTIVE_COMPARATOR|Lab standard practice (LSP)|The ISDD will not be used to collect the blood culture. Standard blood culture specimen collection kits will be utilized.
62663822|NCT05710172|SHAM_COMPARATOR|Sham Headphone Device|Non-Modified 3M Peltor Tactical 300 Electronic Hearing Protector
62663823|NCT01107990||Single right ventricles|
62663824|NCT01107990||Single left ventricles|
62663825|NCT05625464|EXPERIMENTAL|Intervention|Received SCTP monitoring and standard of care
62102687|NCT02274402||adults with glucocorticoids|Adults receiving Prednisone
62295835|NCT03601871|ACTIVE_COMPARATOR|Control group|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
62295836|NCT03601871|EXPERIMENTAL|Thalidomide group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
62295837|NCT03551548|PLACEBO_COMPARATOR|Reference treatment|
62295838|NCT03551548|EXPERIMENTAL|experimental treatment|Spironolactone 25 mg
62663826|NCT05625464|NO_INTERVENTION|Control|Received standard of care only
62663827|NCT05486286|EXPERIMENTAL|video assisted NG placement|This is a single-arm study. A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes.
62102688|NCT05985291||PDN treated with SCS and CMM|Painful diabetic neuropathy patients treated with burst stimulation along with conservative medical management as part of regular medical care.
62102689|NCT04550156|NO_INTERVENTION|Control Arm|Patients are treated according to current local standards
62102690|NCT04550156|EXPERIMENTAL|Colorectal Bundle Arm|Patients are treated according to the colorectal bundle
62102691|NCT04722276|ACTIVE_COMPARATOR|fraction of inspired oxygen 80%|
62102692|NCT04722276|EXPERIMENTAL|Fraction of inspired oxygen 80% with positive end expiratory pressure|
62102693|NCT03298113|EXPERIMENTAL|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
62102694|NCT03298113|OTHER|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
62295839|NCT03528525||Monogenic diseases cases|
62295840|NCT03258814||Active Supervised Training (AST)|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
62295841|NCT03258814||Standard of Care (SOC) Physiotherapy|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
62295842|NCT01129752||children at risk for depression|children at familial risk for depression
62295843|NCT00112476|EXPERIMENTAL|Treatment (bryostatin, temsirolimus)|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62295844|NCT01445171|OTHER|Study Valve|Subjects act as own control
62295845|NCT04910984|EXPERIMENTAL|Chatbot group|
62295846|NCT04910984|PLACEBO_COMPARATOR|TAU group|
62663828|NCT02347787|PLACEBO_COMPARATOR|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
62663829|NCT02347787|EXPERIMENTAL|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
62295847|NCT03234335||Myeloma patients with severe renal impairment|Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.
62295848|NCT02543242|EXPERIMENTAL|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
62663830|NCT06333964|EXPERIMENTAL|AST-001|
62663831|NCT06333964|PLACEBO_COMPARATOR|Placebo of AST-001|
62295849|NCT05092607|EXPERIMENTAL|Venous and Capillary blood sampling|Venous and Capillary blood sampling
62295850|NCT04317690||High Cholesterol|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high cholesterol, who are either taking medication for high cholesterol for 2 years or less; or have discussed managing high cholesterol in the past 2 years. These people will see items only pertaining to high cholesterol.
62295851|NCT04317690||High Blood Pressure|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high blood pressure, who are either taking medication for high blood pressure for 2 years or less; or have discussed managing high blood pressure in the past 2 years. These people will see items only pertaining to high blood pressure.
62663832|NCT01181128|EXPERIMENTAL|Individualized (Tailored) Prophylaxis|"On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A \>= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity."
62663833|NCT01181128|EXPERIMENTAL|Weekly Prophylaxis|65 IU/kg of rFVIIIFc via IV injection every 7 days
62663834|NCT01181128|EXPERIMENTAL|Episodic (On-Demand) Dosing|10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode
62102695|NCT03675737|EXPERIMENTAL|Pembrolizumab + Chemotherapy (FP or CAPOX regimen)|"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally twice a day (BID) on Days 1 to 14 Q3W (CAPOX regimen).~Participants who complete up to 35 administrations of pembrolizumab (approximately 2 years) or achieve a complete response (CR) but experience progression of disease (PD), can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year)."
62102696|NCT03675737|ACTIVE_COMPARATOR|Placebo + Chemotherapy (FP or CAPOX regimen)|Participants receive placebo on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5FU 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally BID on Days 1 to 14 Q3W (CAPOX regimen).
62102697|NCT02408562|EXPERIMENTAL|sNN0031|sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
62102698|NCT02408562|PLACEBO_COMPARATOR|Placebo|Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
62102699|NCT04291521||Adult trauma patients requiring RSI|Patients who received an induction medication for intubation.
62102700|NCT05927571|EXPERIMENTAL|Safety Lead-In Cohort|Participants will receive cevostamab, intravenously (IV), in combination with elranatamab, subcutaneously (SC), with step-up dosing of each drug in pre-phase following which they will receive elranatamab, at the assigned dose as a SC injection until disease progression or unacceptable toxicity. Participants will also receive cevostamab at the assigned dose as IV infusion until disease progression or unacceptable toxicity or up to 1 year on treatment, whichever occurs first.
62663835|NCT03950804||CHAPLE patients, without eculizumab treatment|Patients with suspected CHAPLE syndrome undergo flow-cytometry based CD55 surface staining of peripheral blood samples. Those patients with loss of CD55 protein expression are diagnosed with CHAPLE syndrome. A subgroup of the CHAPLE patients describe only mild symptoms and are not treated with eculizumab, but monitored closely for any disease progression.
62663836|NCT03950804||Control subjects- no intervention|Healthy subjects with no history of any chronic disease. All investigational analyses are performed on both the case and the control subjects. Therefore, the same type of biological specimens collected from the case group are collected from the control group simultaneously.
62663837|NCT03950804||Non-CHAPLE PILs|PIL patients with intact CD55 on flow-cytometry assesment undergo genetic testing to exclude a potential missense mutation in the CD55 gene that impairs its function while retaining protein expression. Overall, patients and their parents undergo exome sequencing as trios, and examined for potential gene mutations underlying their disease. Non-CHAPLE PILs are also examined by high-throughput investigation similarly to CHAPLE patients.
62663838|NCT03950804||CHAPLE patients on eculizumab|Among CHAPLE patients, there is a subgroup who receive eculizumab treatment. These patients are prospectively followed and biological samples collected at baseline as well as periodically under therapy. Eculizumab (Soliris) is being provided for CHAPLE patients on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to manufacturer's recommendations based on the weight of the patients.
62663839|NCT05268770||Tinnitus patients with good hearing|
62663840|NCT05268770||Healthy controls with good hearing|
62663841|NCT05277259|ACTIVE_COMPARATOR|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
62663842|NCT05277259|ACTIVE_COMPARATOR|Kinesiotaping|The Kinesiotaping method is a therapeutic taping technique which alleviates pain.
62663843|NCT05277259|ACTIVE_COMPARATOR|Conventional Physical Therapy|Hotpack, therapeutic ultrasound and tens applications.
62663844|NCT00032487|ACTIVE_COMPARATOR|Standard glycemic control|Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs
62663845|NCT00032487|EXPERIMENTAL|Intensive glycemic control|Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1
62295852|NCT04317690||Colorectal Cancer Screening|People between the ages of 50-75 with no previous diagnosis of colon cancer, who have been screened for colon cancer (or discussed screening for colon cancer) in the past 2 years, or who had first colon cancer screening in past 2 years. These people will see items only pertaining to colon cancer screening.
62102701|NCT05927571|EXPERIMENTAL|Dose Expansion Cohort|Participants will receive cevostamab, IV, in combination with elranatamab, SC, with step-up dosing of each drug in pre-phase following which they will receive elranatamab, at the assigned dose as a SC injection until disease progression or unacceptable toxicity. Participants will also receive cevostamab at the assigned dose as IV infusion until disease progression or unacceptable toxicity or up to 1 year on treatment, whichever occurs first.
62102702|NCT01188486|EXPERIMENTAL|pulmonary interstitial lymphography|stereotactic body radiation therapy \& pulmonary interstitial lymphography
62295853|NCT04317690||Breast Cancer Screening|Females between the ages of 40-50 with no previous diagnosis of breast cancer who have had mammogram (or discussed having a mammogram) in the past 2 years, or had first mammogram in past 2 years. These people will see items only pertaining to breast cancer screening.
61911827|NCT05491460|ACTIVE_COMPARATOR|Dabigatran|"Volunteers receive one oral dose of 150mg Dabigatran followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
61911828|NCT05491460|ACTIVE_COMPARATOR|Edoxaban|"Volunteers receive one oral dose of 60mg Edoxaban followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
61911829|NCT05491460|ACTIVE_COMPARATOR|Rivaroxaban|"Volunteers receive one oral dose of 20mg Rivaroxaban followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
61911830|NCT06534892|EXPERIMENTAL|RSV_PreS4|Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 4.
61911831|NCT06534892|EXPERIMENTAL|RSV_PreS5|Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 5.
61911832|NCT06534892|NO_INTERVENTION|RSV_1Dose|Participants in this group will not receive any additional dose of RSV PreF3 OA vaccine.
61911833|NCT06534892|EXPERIMENTAL|Crossover|Participants in this group will receive a single dose of RSVPreF3 OA vaccine.
62102703|NCT04343807|ACTIVE_COMPARATOR|PECS block|For patients in PECS group (PG), after induction of general anesthesia, the nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
62102704|NCT04343807|ACTIVE_COMPARATOR|Control Group|For patients in control group, after induction of general anesthesia, no nerve block will be performed and only intravenous nalbuphine will be given.
62467891|NCT01900080|EXPERIMENTAL|Same-Day ART Group|"Same-Day HIV testing and ART initiation:~All participants in the same-day ART group will receive rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for OIs, WHO staging, counseling and social support, and ART initiation on the day of presentation for HIV testing."
62467892|NCT01900080|ACTIVE_COMPARATOR|Standard ART Group|"Standard ART Initiation:~The standard group will receive the same services as the same-day ART group (including same-day HIV and CD4 cell testing) except that instead of same-day ART, they will receive the standard GHESKIO protocol of 3 sequential visits for ART readiness counseling and testing for OIs prior to ART initiation."
62467893|NCT01900080|EXPERIMENTAL|Sub-Study - Same-Day ART, CD4>500|Sub-Study - Same-Day CD4 Count and ART Initiation for Patients with CD4 Count \>500 cells/mm3: Participants will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.
62663846|NCT04651712|NO_INTERVENTION|Standard care|A treating physician must perform a clinical assessment within half an hour of patient arrival. This assessment includes the decision whether the patient is suspected of having pneumonia and if this is the case, a sputum specimen and chest x-ray will be ordered. Patients with suspected pneumonia who can deliver a sputum specimen will be randomly allocated with a 1:1 computer-generated randomization schedule with permuting blocks in relation to optimal therapeutical intervention strategy. All standard care sputum samples will be cultured and analysed according to the sites' standard procedures. Under standard care, the treating physician alone decides on the optimal therapeutical intervention.
62663847|NCT04651712|ACTIVE_COMPARATOR|POC-PCR analysis supplied with a recommended action list developed by a microbiologist|Along with standard analyses, the specimens will be analysed with POC-PCR and the treating physician will receive an action-list with the results from POC-PCR.
61911834|NCT00223236|ACTIVE_COMPARATOR|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
61911835|NCT00223236|PLACEBO_COMPARATOR|Placebo|Inactive ingredient matching the active medication in appearance
61911836|NCT01659879|EXPERIMENTAL|multimedia information|Health information concerning the child's diagnosis, treatment and recovery time after evaluation by the pediatrician, using a 15 minutes long standardized health information package with multimedia elements from the Norwegian website www.syktbarn.no (English version: www.childhealthguide.com)
62102705|NCT06492031||Icodextrin (ICO) Group|Icodextrin is only intended for intraperitoneal administration and is recommended for long dwell during CAPD (i.e., recommended dwell time from 8-16 hours). Administration will be done at a rate that is comfortable for the patient, typically within 10-20 minutes.
62102706|NCT06492031||Glucose Group|During CAPD, 2L of dialysis fluid is instilled into the peritoneal cavity and allowed to dwell for a certain period. The dwell time typically ranges from 4 to 8 hours during the day and 8 to 12 hours at night. This process is repeated 3 to 4 times a day, for 6 to 7 days a week. The frequency of solution exchanges may vary for each individual to achieve desired biochemical and solution control. Most solution exchanges utilize a 1.5% or 2.5% glucose dialysis solution. If more solution removal is required, a 4.25% glucose peritoneal dialysis solution can be used. Regular measurement of the patient's weight can be used to guide the setting of ultrafiltration volume.
62102707|NCT02970461|PLACEBO_COMPARATOR|Control Group|"Subjects will see in their Personal Health Record home page a simple text link pointing to their Bio page. Once in their Bio page, the site will display their personal information as usual with the only addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
62102708|NCT02970461|EXPERIMENTAL|Gamified Group|"Subjects will see in their Personal Health Record home page a graphical representation of the percentage of completeness their Bio page has that when clicked acts as a link to their Bio page. Once in their Bio page, the site will display graphical elements such grayed out fields, graphical representations of the percentage of completeness for each data group and on mouse hover over any field a tooltip will inform of what percentage of completeness will be awarded if the data is validated. Also, an addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
62663848|NCT04899206||ARBs only|Hypertensive patients under pharmacological treatment with ARBs
62663849|NCT04899206||ACEIs only|Hypertensive patients under pharmacological treatment with ACEIs
62295854|NCT04317690||Prostate Cancer Screening|Men between the ages of 45-69 with no previous diagnosis of prostate cancer who have been screened for prostate cancer (or discussed screening for prostate cancer) in the past 2 years or had first prostate cancer screening in the past 2 years. These people will see items only pertaining to prostate cancer screening.
62467894|NCT01900080|ACTIVE_COMPARATOR|Sub-Study - Pre-ART Care, CD4>500|Participants will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits.
62663850|NCT04899206||ARBs + ACEIs|Hypertensive patients under pharmacological treatment with ARBs and ACEIs
62663851|NCT04899206||Other Antihypertensive Drugs|Hypertensive patients under pharmacological treatment with non-angiotensin agents (diuretics, calcium channel blockers and/or β-blockers alone or combined among them)
61911837|NCT01659879|ACTIVE_COMPARATOR|verbal information|Verbal health information by a nurse in the acute ward concerning the child's diagnosis, treatment and recovery time, after the evaluation by the pediatrician
61911838|NCT00282464|ACTIVE_COMPARATOR|Ziprasidone 20 and 60mg|For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
61911839|NCT00282464|PLACEBO_COMPARATOR|Placebo|
61911840|NCT00318942|ACTIVE_COMPARATOR|1|Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
61911841|NCT00318942|EXPERIMENTAL|2|Colloids, including albumin, gelatines, starch any other synthetic colloids
61911842|NCT06102018||Breast cancer patients|No intervention. The patients who are diagnosed as breast cancer by postoperative pathological.
61911843|NCT06102018||Patients with benign breast lesions|No intervention. The patients who are diagnosed asbenign breast lesions by postoperative pathological.
61911844|NCT06102018||Healthy population|No intervention. The volunteers.
61911845|NCT04607798|EXPERIMENTAL|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments.
62295855|NCT03294993|EXPERIMENTAL|Ultrasound assess group|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
62295856|NCT01918254|EXPERIMENTAL|Lumretuzumab Dose Escalation|Participants will receive escalating doses of lumretuzumab starting at 1000 mg IV (on Day 1, except Cycle 1 where lumretuzumab will be administered on Day 2) along with paclitaxel 80 mg/m\^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
62295857|NCT01918254|EXPERIMENTAL|EPC1: Lumretuzumab (Prior Chemotherapy)|Extension phase Cohort 1 (EPC1): Participants will receive lumretuzumab 1000 mg IV (on Day 1) along with paclitaxel 80 mg/m\^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
62295858|NCT01918254|EXPERIMENTAL|EPC2: Lumretuzumab (Without Prior Chemotherapy)|Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m\^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
62663852|NCT04899206||Angiotensin Agents and Other Antihypertensive Drugs|Hypertensive patients under combined pharmacological treatment with Angiotensin Agents (ACEIs and/or ARBs) and Other Antihypertensives (non-angiotensin agents)
62102709|NCT06219785|ACTIVE_COMPARATOR|Active|"1. Patient lies down with legs extended.~2. In order to get a proper transmission, a drop of silicone oil is applied on the anatomical stand-off before putting the ring.~3. Connect the headpiece to the ring.~4. Apply ultrasound gel for proper energy transmission on the shaft of the penis~5. 1500 shocks to the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis~6. Duration of the procedure: approximately 30 minutes"
62295859|NCT02315521||Group 1|Fetuses with LUTO before 18 weeks
62295860|NCT02315521||Group 2|Fetuses with LUTO between 18 and 30 weeks
62295861|NCT02315521||Group 3|Fetuses with LUTO between 30 and 34 weeks
62295862|NCT02315521||Group 4|Fetuses with LUTO after 34 weeks
62295863|NCT03955367|ACTIVE_COMPARATOR|Pelvic Irradiation|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, and pelvic lymph nodes regions. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with IMRT.
62295864|NCT03955367|EXPERIMENTAL|Prophylactic EFI|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.
62295865|NCT03537664|EXPERIMENTAL|Total bacteria analysis after 1rst- and 2nd-visit procedures|DNA levels and activity (RNA/DNA ratio) of total bacteria after the first-visit procedures (root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation) and the second-visit protocol (intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation). Additionally, the composition of the active microbiome will be assessed by Next Generation Sequencing (NGS) analysis of the root canal samples, and the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
62295866|NCT03537664|OTHER|Bacterial species analysis after root canal preparation|DNA levels and activity (RNA/DNA ratio) of Bacteroidaceae sp. 272 , Cutibacterium acnes, Selenomonas spp., and Enterococcus faecalis after root canal preparation.Additionally, the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
62295867|NCT01061008|EXPERIMENTAL|Handgrip exercise|Handgrip exercise - patients allocated to this intervention will carry out an eight week post operative progressive handgrip exercise training program
61911846|NCT05647278|EXPERIMENTAL|Tegoprazan 50mg QD|Tegoprazan 50mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks
62295868|NCT01061008|ACTIVE_COMPARATOR|Treatment as usual|
62295869|NCT03276741|NO_INTERVENTION|Control Group|Routine care during labor (authorized clear liquid diet).
62295870|NCT03276741|ACTIVE_COMPARATOR|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
62295871|NCT00719199|EXPERIMENTAL|1|IMO 2055 is a novel phosphorothioate oligodeoxynucleotide that is an agonist of Toll-like Receptor 9 (TLR9).
62295872|NCT00477087|EXPERIMENTAL|GM-CSF Plus Mitoxantrone|GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.
62295873|NCT02154594|EXPERIMENTAL|Acacia|Rinse with 20 ml of Acacia catechu mouthwash twice daily for 15 days
62102710|NCT06219785|SHAM_COMPARATOR|Control|"1. Patient lies down with legs extended.~2. In order to get a proper transmission, a drop of silicone oil is applied on the anatomical stand-off before putting the ring.~3. Connect the headpiece to the ring.~4. Apply ultrasound gel for proper energy transmission on the shaft of the penis~5. 1500 shocks to the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis~6. Duration of the procedure: approximately 30 minutes"
62102711|NCT04796285|EXPERIMENTAL|Lab Clasp|A finger based device to assay interstitial fluid lactate
61911847|NCT05647278|ACTIVE_COMPARATOR|Esomeprazole 20 mg BID|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
61911848|NCT05579743|NO_INTERVENTION|Standard care|Patients randomized to receive standard of care will be provided with a wound care plan at the time of enrollment, and then follow-up in clinic on a biweekly basis (week 2, 4, 6, 8, 10, 12) for a wound check and care plan update as needed.
62295874|NCT02154594|ACTIVE_COMPARATOR|Chlorhexidine gluconate|Rinse with 10 ml of chlorhexidine mouthwash twice daily for 15 days
62295875|NCT02154594|PLACEBO_COMPARATOR|Distilled water|Rinse with 10 ml distilled water twice daily for 15 days.
62295876|NCT00751452||1|
62663853|NCT03474744|EXPERIMENTAL|Experimental Arm|"Induction Phase:~Cycle 1-6 (28 days cycle):~Copanlisib: 60 mg i.v. fixed dose days 1, 8, 15. Rituximab: 375 mg/m2 day 1 i.v.~Maintenance:~Start 2 months after start of the last induction cycle for patients at least achieving a stable response after induction.~Copanlisib: 60 mg i.v. fixed dose day 1 and day 15 every 4 weeks for a maximum of 12 cycles or until progression or study drug-related intolerable toxicity (month 2 to month 13 after end of induction).~Rituximab: 375 mg/m2 i.v. day 1 every 8 weeks for a maximum of 12 infusions or until progression or study drug-related intolerable toxicity (month 2 to month 24 after end of induction)"
61911849|NCT05579743|EXPERIMENTAL|Remote wound monitoring technology|Enrolled patients (and their caregivers, if applicable) are given an in-person training on how to use the smartphone app to self-assess their wound during regular dressing changes. Wound assessments are electronically transmitted to a secure, dedicated portal up to once a week for remote review by the study doctors. In-person follow-up is monthly (at the time of enrollment, week 4, week 8, and week 12).
62102712|NCT06630624|EXPERIMENTAL|Phase 1 Dose esclatation of IP-001|Intra-tumoral injection of IP-001 following MWA of two pre-defined colorectal liver metastases (CRLM). Patients will receive sequentially higher doses of the IP-001, always divided equally over the two CRLM, regardless of size. Starting dose will be 8 mL and the dose-escalating steps will be 4 mL up to a total of 16 mL per patient.
62102713|NCT06630624|EXPERIMENTAL|Phase 2 Part 1 MWA + IP-001|One to three colorectal liver metastases (CRLM) will be treated with MWA followed by intra-tumoral injection of IP-001.
62102714|NCT06630624|EXPERIMENTAL|Phase 2 part 2 RFA + IP-001|One to four colorectal liver metastases (CRLM) will be treated with RFA followed by intra-tumoral injection of IP-001.
62102715|NCT06630624|EXPERIMENTAL|Phase 2 part 2 MWA + IP-001|One to four colorectal liver metastases (CRLM) will be treated with MWA followed by intra-tumoral injection of IP-001.
62102716|NCT06630624|EXPERIMENTAL|Phase 2 part 2 IRE + IP-001|One to four colorectal liver metastases (CRLM) will be treated with IRE followed by intra-tumoral injection of IP-001.
61911850|NCT02051075|ACTIVE_COMPARATOR|PXN only|Sperm activation with PXN before ICSI
62663854|NCT04767750||HCC patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
62102717|NCT01760044|EXPERIMENTAL|Tissue oxygenation monitoring|Tissue oxygenation monitoring
62663855|NCT04767750||T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
61911851|NCT02051075|EXPERIMENTAL|PXN activation and oocyte activation|Sperm activation with PXN and oocyte activation
61911852|NCT00395057|EXPERIMENTAL|AGN 211745 Solution 1000 ug|AGN 211745 Solution 1000 ug
61911853|NCT00395057|EXPERIMENTAL|AGN 211745 Solution 300 ug|AGN 211745 Solution 300 ug
61911854|NCT00395057|EXPERIMENTAL|AGN 211745 Solution 100 ug|AGN 211745 Solution 100 ug
62102718|NCT02043717||CF patients|Both children and adults, with or without vitamin D deficiency.
62102719|NCT02419521|OTHER|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
62102720|NCT03474562|EXPERIMENTAL|Duowell Tab|Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks
62102721|NCT03474562|ACTIVE_COMPARATOR|Monorova Tab + Amlopin Tab|Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks
62295877|NCT00751452||2|
62295878|NCT03773952|EXPERIMENTAL|Oral 5-ASA + PBF-677 200 mg|Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
62295879|NCT03773952|PLACEBO_COMPARATOR|Oral 5-ASA + Placebo oral Capsules|Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
62295880|NCT02319369|EXPERIMENTAL|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
62102722|NCT01007708|EXPERIMENTAL|IDP-108|
62102723|NCT01007708|PLACEBO_COMPARATOR|Vehicle|
62102724|NCT02405390|EXPERIMENTAL|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
62102725|NCT02405390|ACTIVE_COMPARATOR|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
62102726|NCT04827459|EXPERIMENTAL|MI Sleep Coach Mobile Application|The Sleep Coach app includes evidence-based CBT-I strategies, interactive activities and a computerized dialogue agent to engage users in the adoption of and adherence to CBT-I strategies.
62102727|NCT01300832|EXPERIMENTAL|Duplex scan|Subjects undergo preoperative and post-operative duplex scanning of the lower extremities
62102728|NCT03613103|ACTIVE_COMPARATOR|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
62102729|NCT03613103|EXPERIMENTAL|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
62102730|NCT02511704|EXPERIMENTAL|Electronic cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) + Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) separated by 60 minutes"
62102731|NCT02511704|ACTIVE_COMPARATOR|Cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by cigarette (10 puffs) + Nicotine 0.8 mg, administrated by cigarette (10 puffs) separated by 60 minutes"
62102732|NCT06027151|NO_INTERVENTION|Scaling and root planning|Once the patients fulfill the inclusion criteria and are randomly assigned to this group, they undergo scaling and root planning by the consultant. Baseline values are recorded, and patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
62102733|NCT06027151|EXPERIMENTAL|Scaling and root planning plus metronidazole gel|After fulfilling the inclusion criteria and randomly assigning to this group, they undergo scaling and root planning by the consultant. Baseline values are recorded, and 1ml of 1% metronidazole gel is applied subgingivally. The patients are instructed not to spit or rinse for at least one hour. Then patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
62295881|NCT02319369|EXPERIMENTAL|Part 1A, Milademetan with 5-azacytidine (AZA)|Participants receive milademetan in combination with 5-azacytidine (AZA), with different dose schedules
62295882|NCT02319369|EXPERIMENTAL|Part 2, Cohort 1|Participants with refractory or relapsed acute myelogenous leukemia (AML) receive the recommended dose for Part 2 of milademetan or milademetan with5-azacytidine (AZA)
62663856|NCT04767750||HCC & T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
62663857|NCT04767750||Controls|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
62295883|NCT02319369|EXPERIMENTAL|Part 2, Cohort 2|Participants with newly diagnosed acute myelogenous leukemia (AML) unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
62663858|NCT03358953|OTHER|Electronic Cigarettes|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the electronic cigarette arm. They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
61911855|NCT00395057|ACTIVE_COMPARATOR|Ranibizumab 500 ug|Ranibizumab 500 ug
62102734|NCT06027151|EXPERIMENTAL|Scaling and root planning plus minocycline gel|After fulfilling the inclusion criteria and being randomly assigned to this group, the patients undergo scaling and root planning by the consultant. Baseline values are recorded, and 1ml of 2% minocycline gel is applied subgingivally. The patients are instructed not to spit or rinse for at least one hour. Then patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
62102735|NCT06027151|EXPERIMENTAL|Scaling and root planning plus combination of metronidazole and minocycline gels|After fulfilling the inclusion criteria and being randomly assigned to this group, the patients undergo scaling and root planning by the consultant. Baseline values are recorded, 1ml of the combination of 1% metronidazole gel and 2% minocycline gel is applied subgingivally. The patients are instructed not to spit or rinse for at least one hour. Then patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
62102736|NCT05753917|EXPERIMENTAL|Group A|"piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy). One or two implants were placed in each edentulous ridge along with an additional 3.3 x 8.5 mm implant, termed a study fixture, in an adjacent area"
62102737|NCT05753917|ACTIVE_COMPARATOR|Group B|"In Group B, all implant sites were prepared with conventional drills according to the manufacturer's protocol (Premium, Sweden \& Martina, Due Carrare, Padova, Italy); similarly to group A, one or two implants were placed in each edentulous ridge, and an additional 3.3 x 8.5 mm study-fixture was placed in the adjacent area."
62295884|NCT02319369|EXPERIMENTAL|Part 2, Cohort 3|Participants with high-risk myelodysplastic syndrome (MDS) receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
62295885|NCT00165009|NO_INTERVENTION|DUAL THERAPY|DUAL THERAPY
62295886|NCT00165009|EXPERIMENTAL|'Resolution clip|'Resolution clip
62663859|NCT03358953|OTHER|Nicotine replacement patches|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the nicotine replacement patch arm (standard care). They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
62663860|NCT02063776||Children on HDF|
62663861|NCT02063776||Children on conventional HD|
62663862|NCT03617432|EXPERIMENTAL|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
62295887|NCT05871203||Postoperative acute kidney injury|
62295888|NCT05871203||Postoperative non-acute kidney injury|
62295889|NCT00978302|PLACEBO_COMPARATOR|Placebo (vehicle)|
62295890|NCT00978302|EXPERIMENTAL|Avotermin|
62663863|NCT03617432|EXPERIMENTAL|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
62663864|NCT02939391|EXPERIMENTAL|KW-6356 Low Dose|Oral administration
62663865|NCT02939391|EXPERIMENTAL|KW-6356 High Dose|Oral administration
62663866|NCT02939391|PLACEBO_COMPARATOR|Placebo|Oral administration
62663867|NCT04540198|EXPERIMENTAL|GamePlan4Care (GP4C)|Participants in this arm will have access to full functionality and content of the online system GamePlan4Care (GP4C) including educational resources, skills training, and support tailored to their unique caregiving needs. Additional individualized feedback will be automatically generated based on responses to online questions and will include links to relevant site educational/skill-building content. Participants will be assigned a Dementia Care Specialist who will facilitate caregiver interactions with the online material and provide skills training via telephone or web-video conference. Study participants assigned to GP4C will receive 9 automated emails and 4 phone calls over a 6-month period.
62663868|NCT04540198|ACTIVE_COMPARATOR|Resources4Care (R4C)|"Participants in this arm will receive access to Resources4Care (R4C), a feature-limited version GamePlan4Care system. R4C will serve as an online hub for articles and videos about Alzheimer's disease and dementia. Educational topics will included information on: 1) Alzheimer's Disease \& Dementia, 2) Caregiving, 3) Caregiver Stress and 4) Home Safety. R4C will present a page on each topic with active links to two additional online sources on the same topic. Study participants assigned to R4C will receive two emails from their DCS encouraging the caregiver to review specific education materials. Each email will be followed by brief check-in calls (15-min each) at three months and five months after randomization."
62663869|NCT06052124|EXPERIMENTAL|Pilot Usability (Part 1)|Five patients will be enrolled to test whether the AR device functions appropriately, but no clinical decisions or changes to care will be determine by the AR device at this point.
62663870|NCT06052124|EXPERIMENTAL|AR Guided SEPS Placement (Part 2)|AR guidance is used to place SEPS drain
61911856|NCT05282914|EXPERIMENTAL|UI058|
61911857|NCT05282914|ACTIVE_COMPARATOR|UIC202004|
62295891|NCT01253733|EXPERIMENTAL|SMS and Internet|The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
62295892|NCT01253733|NO_INTERVENTION|Control|The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
62663871|NCT06052124|NO_INTERVENTION|Anatomical Guided SEPS Placement (Part 2)|Standard of care, non AR guided SEPS drain placement
62663872|NCT05004285|OTHER|MRI / [F-18]Florastamin|MRI and \[F-18\]Florastamin PET/CT are performed for each subject.
62663873|NCT00554723|EXPERIMENTAL|A|NeuroAid
62663874|NCT00554723|PLACEBO_COMPARATOR|B|NeuroAid matched Placebo
62295893|NCT02852525|OTHER|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction. Photographs will be taken and digitally stored. Biopsies (which are part of the routine diagnosis and surveillance of Barrett's) will be targeted based on the microscopic images. The histologic findings on the biopsy specimens will be compared to the microscopic images to determine the accuracy of the probe-based microscopy in predicting pathology.
62295894|NCT02066064|EXPERIMENTAL|Group A|Subjects will undergo complete standard colonoscopy, followed by G-EYE(TM) Colonoscopy
62663875|NCT02692079|EXPERIMENTAL|T-PRF+Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Test group sites were treated with T-PRF+allograft
62295895|NCT02066064|ACTIVE_COMPARATOR|Group B|Subject will undergo G-EYE(TM) colonoscopy followed by standard colonoscopy
62295896|NCT01128985|EXPERIMENTAL|001|Canagliflozin 50 mg 50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
62295897|NCT01128985|EXPERIMENTAL|002|Canagliflozin 100 mg 100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
62295898|NCT01128985|EXPERIMENTAL|003|Canagliflozin 300 mg 300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
62663876|NCT02692079|EXPERIMENTAL|Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Control group sites were treated with only allograft
62663877|NCT00614393|EXPERIMENTAL|Dalotuzumab 10 mg/kg Q1W (DB)|In double-blind (DB) Week 1, participants receive cetuximab 400 mg/m\^2 intravenously (IV) loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m\^2 IV one time each week (Q1W) maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
62663878|NCT00614393|EXPERIMENTAL|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)|In the open-label (OL) portion of the study, ≥6 participants receive cetuximab 400 mg/m\^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m\^2 IV + irinotecan IV. In DB Week 2, participants receive cetuximab 250 mg/m\^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m\^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m\^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
62663879|NCT00614393|EXPERIMENTAL|Dalotuzumab 10 mg/kg Q1W (OL)|In the OL portion of the study, ≥6 participants receive cetuximab 400 mg/m\^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m\^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m\^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
62295899|NCT01128985|PLACEBO_COMPARATOR|004|Placebo matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
62295900|NCT06657625||Pre-implementation cohort|Patients from January 1, 2017, to December 31, 2017, before the implementation of the performance improvement program.
62295901|NCT06657625||Post-implementation cohort|Patients from May 1, 2022, to April 30, 2024, after the implementation of the performance improvement program.
61911858|NCT04673110||Anastomotic leakage group|9 patients developed anastomotic leakage (8%) in a median of 8 days (range: 5-9) median CRP level postoperative day 4:164mg/dL
61911859|NCT04673110||no Anastomotic leakage group|117 patients (92%) median CRP level postoperative day 4: 64mg/dL
61911860|NCT03196700|EXPERIMENTAL|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered
61911861|NCT02793856|EXPERIMENTAL|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 1 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
61911862|NCT02793856|EXPERIMENTAL|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
61911863|NCT02793856|EXPERIMENTAL|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 4 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
61911864|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
62663880|NCT00614393|EXPERIMENTAL|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)|In DB Week 1, participants receive cetuximab 400 mg/m\^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants receive cetuximab 250 mg/m\^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m\^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m\^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
61911865|NCT04537780|PLACEBO_COMPARATOR|group 1|(Control group n= 22): Patients will receive Placebo once daily at bedtime for 12 weeks..
62102738|NCT03518983|SHAM_COMPARATOR|Sham Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) by the sham probe.
62295902|NCT06035822|EXPERIMENTAL|Debriefing with TeamGAINS|"The Intervention Group debriefings (n=15) were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool (Kolbe et al., 2013).~The intervention consisted of using the TeamGAINS tool as a debreifing script, during the debriefing, in accordance with the objectives of the clinical simulation scenario (CSC)."
62467895|NCT05912062||early-stage HER2-positive breast cancer neoadjuvant treatment|"For a total of 16 weeks, patients will be given dual antiHER2 blockade consisting of Cycle 1 Day 1 Pertuzumab 840mg + Trastuzumab 8mg/kg loading dose, followed by Paclitaxel starting at Cycle 1 day 8 and 15 at 80mg/m2. Followed by Pertuzumab 420mg + Trastuzumab 6mg/kg every three weeks and Paclitaxel days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks.~Adjuvant treatment (including the need of Anthracyclines) will be administered according clinical practice."
62102739|NCT03518983|ACTIVE_COMPARATOR|Active Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) at energy level 7.
62102740|NCT06200402|EXPERIMENTAL|Intervention|(Antibiotic-Loaded Cement Arm): This group will receive hip prosthesis surgery using antibiotic-loaded cement. The use of antibiotic-loaded cement is intended to investigate its effectiveness in reducing the rate of acute postoperative infections.
62102741|NCT06200402|PLACEBO_COMPARATOR|control|(Non-Antibiotic-Loaded Cement Arm): Participants in this group will undergo hip prosthesis surgery using non-antibiotic-loaded cement. This arm serves as the control to compare the outcomes with the antibiotic-loaded cement group.
62102742|NCT05365529|PLACEBO_COMPARATOR|Standard of Care|The participants in this arm will receive the standard health and nutritional wellness guidelines and will be required to log food entries through the use of a smartphone app.
62295903|NCT06035822|NO_INTERVENTION|Debriefing free|"The Control Group debriefings (n=15) were conducted by a teacher trained in clinical simulation methodology, with no experience in the use of any debriefing guide.~The intervention consisted of the debriefer applying his or her simulation experience and training to perform the debriefings freely, in accordance with the objectives of the clinical simulation scenario (CSC)."
62663881|NCT00614393|ACTIVE_COMPARATOR|Placebo + Cetuximab + Irinotecan (DB)|In DB Week 1, participants receive cetuximab 400 mg/m\^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m\^2 IV Q1W + irinotecan IV Q1W + DB normal saline (placebo) IV Q1W for up to 32 months of treatment.
62663882|NCT02319382|EXPERIMENTAL|2 markers: 18F-DPA-714 and 11C-PE2I|PET with the tracer \[18F\]DPA-714 and second PET with the tracer \[11C\]-PE2I. \[18F\]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. \[11C\]-PE2I allow measures dopaminergic neuronal loss.
62663883|NCT03988647|EXPERIMENTAL|Pembrolizumab + Palliative Radiation Therapy|Pembrolizumab will be administered at 200 mg IV every 3 weeks as standard of care. Palliative radiation therapy will be given between the first and second cycles of immunotherapy
62663884|NCT01452087|OTHER|Exercise Session|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
62295904|NCT06261879|EXPERIMENTAL|A sanitary pad as a menstrual blood collector|The sanitary pad is similar to the normal sanitary pad.
62467896|NCT04432233|EXPERIMENTAL|Intravenous therapy|Subjected enrolled will receive (a) a 10-day intravenous triple therapy containing esomeprazole 40 mg thrice a day, metronidazole 500 mg twice a day and levofloxacin 500 mg once a day and (b) esomeprazole 20 mg twice a day taken orally for 8 weeks.
61911866|NCT04537780|EXPERIMENTAL|Group 2|"Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.~The treatment duration will be 12 weeks."
61911867|NCT04911374|OTHER|Anti-Aging Face Moisturizer and Eye Cream|"Dual Regimen:~1. Multi-ingredient anti-aging face moisturizer~2. Multi-ingredient anti-aging eye cream"
61911868|NCT04234724|EXPERIMENTAL|Variant|Volunteers with known ANGPTL3 variants
61911869|NCT04234724|OTHER|Non-variant|Healthy volunteers with no ANGPTL3 variants
62102743|NCT05365529|EXPERIMENTAL|Time-Restricted Eating|The participants in this arm will limit the number of hours they eat in day to a 8-10-hour window and will also receive the standard health and nutritional wellness guidelines. They will also be required to log food entries through the use of a smartphone app.
62663885|NCT05015023|EXPERIMENTAL|Intervention|The behavioral intervention will be conducted on the experimental group for consecutive six months. The components of the intervention will be group health education, provision of IEC materials/Leaflets, and home visits.
61911870|NCT01523470|ACTIVE_COMPARATOR|stepwise withdrawal of NIV|On the day of decision of withdrawal (day0), the duration of non-invasive ventilator (NIV) will be decreased to 16 hours. On the following day (day1), the duration of NIV will be further decreased to 12 hours. The duration will be further decreased to 8 hours at night on the following day (day 2), and it will be stopped on the day after (day 3). Vital signs and blood gases will be monitored for a total of 5 days after withdrawal is planned (day 0 to day 5).
61911871|NCT01523470|EXPERIMENTAL|immediate withdrawal of NIV|The patient will have immediate withdrawal of non-invasive ventilator (NIV). Vital signs and blood gases will be monitored for 2 more days after NIV is stopped (day 0-2).
62102744|NCT06540196|EXPERIMENTAL|NodeAI|The ultrasound video and images of each LN will be analyzed by NodeAI, which will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
62102745|NCT06540196|ACTIVE_COMPARATOR|Surgeon|The ultrasound video and images of each LN will first be analyzed by the surgeon, who will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
62102746|NCT02127476|EXPERIMENTAL|KHK6640|KHK6640
62102747|NCT02127476|PLACEBO_COMPARATOR|Placebo|Placebo
62102748|NCT01535430||Eloquent area tumor|Standard of care with brain mapping, pre-, intra-, and post-operative.
62663886|NCT05015023|NO_INTERVENTION|Control|The routine care will be continued in the control group.
62663887|NCT04324489|EXPERIMENTAL|DAS181 Treatment|Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days
62295905|NCT05303740||Anlotinib|
62295906|NCT04290637|EXPERIMENTAL|No sea swimming|Stop sea swimming for 4-6 weeks
62295907|NCT04290637|ACTIVE_COMPARATOR|Sea swimming|Continue sea swimming for 4-6 weeks
62663888|NCT01184807|OTHER|OPB-51602|
61911872|NCT01009840|EXPERIMENTAL|IV busulfan|Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
62102749|NCT03631563|EXPERIMENTAL|Arm 1|ATG-F treated
62295908|NCT03182530|ACTIVE_COMPARATOR|ULTRA method group|
62295909|NCT03182530|ACTIVE_COMPARATOR|standard patent hemostasis group|
62295910|NCT03182530|EXPERIMENTAL|control group|
62295911|NCT01781455|EXPERIMENTAL|BBI503|
62295912|NCT00837187|ACTIVE_COMPARATOR|Intravenous dexmedetomidine|Dexmedetomidine is administered intravenously
62295913|NCT00837187|EXPERIMENTAL|Intranasal administration|Dexmedetomidine is administered intranasally
62295914|NCT00629083|EXPERIMENTAL|1|Bulkamid Hydrogel injection
62295915|NCT00629083|ACTIVE_COMPARATOR|2|Contigen injection
62663889|NCT05869409||People diagnosed with a psychotic disorder or an affective disorder|
62663890|NCT04002700||Target Cohort 1|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years without a recent dementia diagnosis.
62663891|NCT04002700||Target Cohort 2|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years without a recent dementia diagnosis.
62663892|NCT04002700||Target Cohort 3|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged greater than or equal to (\>=) 65 years.
62663893|NCT04002700||Target Cohort 4|Participants will be analyzed for stroke-risk who are new users of haloperidol aged \>= 65 year.
62663894|NCT04002700||Target Cohort 5|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years.
62663895|NCT04002700||Target Cohort 6|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years.
62663896|NCT04002700||Comparator Cohort 7|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years without a recent dementia diagnosis.
62663897|NCT04002700||Comparator Cohort 8|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged \>= 65 years.
62663898|NCT04002700||Comparator Cohort 9|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years.
62663899|NCT02214810|ACTIVE_COMPARATOR|Control- Marcain|Group 1 will receive non-liposomal bupivacaine introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
61911873|NCT02643056|EXPERIMENTAL|Panitumumab|6 mg/kg per administration
61911874|NCT02160002|ACTIVE_COMPARATOR|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
61911875|NCT02160002|ACTIVE_COMPARATOR|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
62102750|NCT03631563|ACTIVE_COMPARATOR|Arm 2|ATG treated
62295916|NCT03869814||Non-cancer|3,250 asymptomatic individuals without prior history of cancer
62295917|NCT03869814||Cancer|3,250 individuals with confirmed malignancy
62295918|NCT00703313|ACTIVE_COMPARATOR|2|described in intervention
62295919|NCT00703313|ACTIVE_COMPARATOR|3|described in intervention
62295920|NCT00703313|ACTIVE_COMPARATOR|1|described in intervention
62295921|NCT00316875|EXPERIMENTAL|Lapatinib Ditosylate and Doxil|
62295922|NCT04844138|EXPERIMENTAL|Online Self-Directed Program|Participants in this condition will complete our six-week online self-directed program as soon as it's available.
62295923|NCT04844138|OTHER|Waitlist|Participants in this condition will receive treatment as usual for six weeks, after which point they will be invited to complete our online program.
62663900|NCT02214810|EXPERIMENTAL|Experimental- Exparel|Group 2 will receive a mixture of non-liposomal bupivacaine and Exparel introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
62663901|NCT00330018|EXPERIMENTAL|1|PO Valganciclovir
62663902|NCT00330018|ACTIVE_COMPARATOR|2|PO Acyclovir
62663903|NCT04909255|ACTIVE_COMPARATOR|Antimuscarinic|oxybutynin, tolterodine, solifenacin
62663904|NCT04909255|EXPERIMENTAL|B3-agonist|mirabegron
62663905|NCT01533220|EXPERIMENTAL|Test group|"Naphazoline Hydrocloride (1.0mg) + Pheniramine Maleate (0.2mg) + Panthenol(5.0mg).~02 drops in each nostril every 12 hours for 3 days"
62663906|NCT01533220|ACTIVE_COMPARATOR|Comparator group|"Naphazoline Hydrocloride (0.5mg)~02 drops in each nostril every 12 hours for 3 days"
62663907|NCT05482243|NO_INTERVENTION|Habitual lifestyle period|"* All participants will be encouraged to keep their diet and physical activity similar to before the study period. Subjects will be asked to record their food intake and wear an Actical physical activity monitor for 3 days throughout the habitual lifestyle period (2 week days and 1 weekend day).~* All participants will be asked to ingest 20 mL deuterated water and take a saliva sample daily"
62295924|NCT02221089|EXPERIMENTAL|Retaron|
62663908|NCT05482243|EXPERIMENTAL|Exercise training period|"* All participants will be encouraged to keep their diet and physical activity similar to before the study period. Subjects will be asked to record their food intake and wear an Actical physical activity monitor for 3 days throughout the exercise training period (2 week days and 1 weekend day).~* Participants will be asked to ingest 20 mL deuterated water and take a saliva sample daily~* Participants will visit the University three times with 2-day intervals (e.g. Monday-Wednesday-Friday) for an exercise training session as described in 5.6.~* Following the training sessions, participants will be provided with a protein supplement as described in 5.7.~* Before and after ingestion of the protein supplement, participants will be asked to fill in a gastrointestinal tolerance and palatability survey."
62663909|NCT05557682||clinical performance|restoration of caries primary molars using two different restorative materials
62102751|NCT05921409|EXPERIMENTAL|MED DIET + AOVE|A six-months nutritional intervention with a Mediterranean diet, daily supplemented with 50 ml of extra virgin olive oil. The intake of the oil was divided in the main meals and needed to be consumed without cooking.
62295925|NCT02221089|PLACEBO_COMPARATOR|Placebo|
62295926|NCT05384301|EXPERIMENTAL|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
62102752|NCT05921409|PLACEBO_COMPARATOR|MED DIET + AO|A six-months nutritional intervention with a Mediterranean diet, daily supplemented with 50 ml of olive oil. The intake of the oil was divided in the main meals and needed to be consumed without cooking.
62295927|NCT00553995|EXPERIMENTAL|Salsalate|Salsalate
62295928|NCT00553995|PLACEBO_COMPARATOR|Placebo|Placebo
62663910|NCT05557682||psychological impact|evaluation of colour of restoration on the satisfaction of the children and impact on their hygiene
62295929|NCT04020744|ACTIVE_COMPARATOR|healthy elderly participants receiving feedback from the hippocampus|This group will consist of healthy elderly volunteers, who will receive feedback from their hippocampal activity.
62295930|NCT04020744|SHAM_COMPARATOR|healthy elderly participants receiving feedback from another area|This group will consist of healthy elderly volunteers, who will receive feedback from another brain area.
62295931|NCT04020744|EXPERIMENTAL|patients with MCI receiving feedback from the hippocampus|This group will consist of patients with mild cognitive impairment, who will receive feedback from their hippocampal activity.
62663911|NCT04410822||Patients enrolled|an age older than 18 years old and symptoms of FI according to Rome IV criteria.
62663912|NCT03776786|EXPERIMENTAL|Safety Arm - 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
62663913|NCT03776786|PLACEBO_COMPARATOR|Safety Arm - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62295932|NCT04020744|SHAM_COMPARATOR|patients with MCI receiving feedback from another brain area|This group will consist of patients with mild cognitive impairment, who will receive feedback from another brain area.
62295933|NCT00898547||Group 1|Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
62295934|NCT03939234|EXPERIMENTAL|Vaccination|Untreated CLL patients with unmutated IgHV gene with a cut of at maximum of 2 % mutations. According to guidelines from the European Research Initiative on CLL (ERIC).
62295935|NCT05760716||Experiment Group|"* The prone position was positioned within the application steps.~* The introductory characteristics form of the patients was filled in on the day the patient was included in the study.~* Blood gas results and mechanical ventilator respiration indicators were followed up in the PP for 5-10 days and the changes were recorded in the tolerance hours.~Arterial blood gas results, mechanical ventilator values, and ventilator-associated pneumonia status were monitored before the position was applied, during the position and after the patients were placed in the supine position by comparing the groups with and without the prone position.~• Nursing intervention application steps for VAP were followed during the PP and the changes were recorded."
62295936|NCT05760716||Control Group|Routine nursing care was applied without any intervention. 'Patient Information Form', 'Patient Follow-up Charts', 'Clinical Pulmonary Infection Score', 'Braden Pressure Wound Risk Assessment' and 'Ramsey Sedation Scale' were used.
62295937|NCT03757598|NO_INTERVENTION|Paper Partograph|The comparison group used the standard WHO Standard Paper Partograph approved in Kenya to monitor labor. Copies of the partograph were made available to the facilities.
62663914|NCT03776786|EXPERIMENTAL|Safety Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes.
62295938|NCT03757598|EXPERIMENTAL|ePartogram|ePartogram use by skilled birth attendant providers in health facilities. The intervention arm used the novel ePartogram or electronic partogram. The interface was of the same WHO approved partograph on an Android tablet. There were reminders to spur provider actions and alerts that were programmed in an algorithm.
62295939|NCT05422729|EXPERIMENTAL|Personalised mHeatlh-supported coaching programme|Three monthly individual consultation session, supported with a specific mobile application.
62295940|NCT05422729|ACTIVE_COMPARATOR|Traditional in-person health coaching programme|Three monthly individual consultation sessions.
62663915|NCT03776786|EXPERIMENTAL|Safety Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
62663916|NCT03776786|EXPERIMENTAL|Safety Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes.
62663917|NCT03776786|EXPERIMENTAL|Safety Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes.
61911876|NCT05910671|EXPERIMENTAL|Physical Activity Phone Calls and Notebook|The intervention will last 8 weeks. As part of the intervention the participants (parents) will receive a notebook with weekly newsletters that discuss behavioral strategies for physical activity changes, note pages, listing of local parks, and age-appropriate physical activities that parents and young children can do together. The intervention group will also have individual weekly telephone meetings with a physical activity coach. The weekly meeting is expected to last approximately 30 minutes. During this meeting, participants will discuss that week's behavioral strategy to promote physical activity, report on the past week's physical activity goals, failures and successes, and set goals for the next week. Each week parents will be asked to set a goal to be physically active with their child and a goal to be physically active alone.
61911877|NCT05910671|NO_INTERVENTION|Control|During the 8 weeks the participants in the control group will neither receive the intervention material nor have any contact with physical activity coaches. They will continue interacting with their young child as normal.
61911878|NCT03861494|OTHER|Enhanced Stroke Education|This group of participants will receive enhanced education provided by the Stroke Coordinator at the time of discharge. The enhanced education session will last 30 minutes with the participant.
61911879|NCT03861494|OTHER|Usual Stroke Education|This group of participants will receive the usual stroke education provided by the usual Neuroscience Registered Nurse throughout the hospitalization and at the time of discharge.
61911880|NCT06333197|EXPERIMENTAL|transparotid approch|Patients who diagnosed with extra capsular fracture of mandibular condyle will undergo Retromandibular transparotid approch
61911881|NCT06333197|EXPERIMENTAL|Retroparotid approch|Patients who diagnosed with extra capsular fracture of mandibular condyle will undergo Retromandibular retroparotid approch
61911882|NCT03655002|EXPERIMENTAL|Treatment (nivolumab, cyclophosphamide, IRX-2)|Patients receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
62663918|NCT03776786|EXPERIMENTAL|Efficacy Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62663919|NCT03776786|PLACEBO_COMPARATOR|Efficacy Arm - 2 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62663920|NCT03776786|EXPERIMENTAL|Efficacy Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62102753|NCT03764345|EXPERIMENTAL|Sofosbovir/Ledipasvir Daily|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
62102754|NCT04944693||Cohort 1|Anterior cruciate ligament-injured patients with excessive ATS
62663921|NCT03776786|PLACEBO_COMPARATOR|Efficacy Arm - 5 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62663922|NCT03776786|EXPERIMENTAL|Efficacy Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62102755|NCT04944693||Cohort 2|Anterior cruciate ligament-injured patients with minimal ATS
62295941|NCT02510807|EXPERIMENTAL|Pedometer group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided. The pedometer group will be instructed to carry the pedometer in their pocket during these exercise periods.
62663923|NCT03776786|PLACEBO_COMPARATOR|Efficacy Arm - 10 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62663924|NCT03776786|EXPERIMENTAL|Efficacy Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62663925|NCT03776786|PLACEBO_COMPARATOR|Efficacy Arm - 20 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
62663926|NCT05125497||In Vitro Fertilisation (IVF)-Patients|Patients aim to do In-Vitro-Fertilisation (IVF)
62663927|NCT04051580|EXPERIMENTAL|Lactated Ringer's solution|For patients randomized to lactated Ringer's solution (study group), lactated Ringer's solution is used as a base solution for del Nido cardioplegia.
62663928|NCT04051580|ACTIVE_COMPARATOR|PlasmaLyte-A|For patients randomized to PlasmaLyte-A (control group), PlasmaLyte-A (Baxter Healthcare Corporation, Deerfield, IL, USA) is used as a base solution for del Nido cardioplegia.
62102756|NCT01382810|ACTIVE_COMPARATOR|Altaire Gel forming solution|
62663929|NCT03869437|EXPERIMENTAL|Cefiderocol|Participants will receive Cefiderocol 2 grams administered intravenously over 3 hours, every 8 hours for a minium of 5 days and a maximun of 14 days.
62663930|NCT03869437|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|BAT will be chosen by the investigator and intravenously administered per country-specific guidelines.
62663931|NCT05730673|EXPERIMENTAL|Leronlimab in combinatiob with Regorafenib|Leronlimab (PRO 140) will be administered subcutaneously at a weekly dose of 700 mg in combination with staring dose of 80 mg Regorafenib at first week of the Cycle 1, followed by escalation of Regorafenib dose to 120 mg and 160 mg in second and third weeks of Cycle 1, respectively. No Regorafenib will be administered during the fourth week.
62663932|NCT05823454||Propofol|Intravenous infusion
62663933|NCT05823454||Dexmedetomidine|Intravenous infusion
62663934|NCT05823454||Esketamine|Intravenous infusion
62663935|NCT05823454||Sevoflurane|Inhalation anesthesia
62663936|NCT05823454||Remifentanil|Intravenous infusion
62102757|NCT01382810|PLACEBO_COMPARATOR|Refresh Tears|
62102758|NCT04586192|EXPERIMENTAL|COMET|Participants receive modules focused on cognitive restructuring, gratitude, behavioral activation and self-compassion. Participants were randomized to receive 3 of the 4 possible modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.Participants in the intervention condition were randomized to receive descriptions of the four modules at the beginning of the intervention that were phrased to focus on building and improving strengths (positive) or reducing negative emotions and behaviors (negative).
62102759|NCT04586192|SHAM_COMPARATOR|Self-Awareness Control|Participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
62102760|NCT04586192|NO_INTERVENTION|Waitlist|Participants filled out all pre-test and post-test measures without having access to COMET of the active control exercises. Participants in this condition will receive access to COMET at the end of the study.
62663937|NCT03248895|ACTIVE_COMPARATOR|Immediate (I-med)|Participants allocated to the I-med group will take part in the mobile DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up
62102761|NCT04883762|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|Study subjects will undergo standard bowel preparation and diagnostic colonoscopy with routine biopsies for pathologic assessment. FMT will be performed at the proximal extent of the colon reached, according to the same protocol used in prior randomized studies. FMT will use healthy donor stool provided by OpenBiome, a nonprofit 501(c)(3) organization that provides clinicians and hospitals with screened, filtered and frozen stool to be used for FMT. Routine clinical and research biopsies will be collected during the FMT colonoscopy procedure.
62663938|NCT03248895|ACTIVE_COMPARATOR|Delayed (D-med)|"Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up."
62663939|NCT02448043|OTHER|Right Hand Bimatoprost 0.01% drops, Left Hand Placebo|"* Bimatoprost 0.01% drops placed on the proximal nail folds of the right hand digits two times per day for 30 days.~* Saline solution drops placed on the proximal nail folds of the left hand digits two times per day for 30 days."
61911883|NCT04672954|PLACEBO_COMPARATOR|Placebo|Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
61911884|NCT04672954|EXPERIMENTAL|2.5 milligram (mg) BI 474121|2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
62102762|NCT00543725|ACTIVE_COMPARATOR|002|efavirenz 600 mg tablet once daily for 96 weeks
62102763|NCT00543725|EXPERIMENTAL|001|TMC278 25 mg tablet once daily for 96 weeks
62102764|NCT05275686|PLACEBO_COMPARATOR|Arm 1 (Placebo)|Arm 1 (placebo) will get placebo spray per day.
62102765|NCT05275686|ACTIVE_COMPARATOR|Arm 2 (EDS-FLU)|Arm 2 (EDS-FLU) will get 744 mcg of fluticasone propionate per day.
62102766|NCT05507281|SHAM_COMPARATOR|Control group|Patients received general anesthesia alone.
62102767|NCT05507281|EXPERIMENTAL|Ultrasound-guided Erector Spinae Plane Block|A 22-gauge needle is inserted at a puncture site lateral to the target spinous process using ultrasound imaging and advanced until contact is made with the transverse process. The local anesthetic agent will be injected between the transverse process and the erector spinae muscle using 20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg).
62102768|NCT05507281|EXPERIMENTAL|Retrolaminar Block|A 22-gauge needle is inserted at a puncture site lateral to the target spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina. The local anesthetic agent will be injected on the lamina using 20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg).
62102769|NCT05478122|EXPERIMENTAL|Interventional|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
62102770|NCT04730336|EXPERIMENTAL|Tixel Treatment|Tixel Treatment 3 Tixel treatment sessions, 2 weeks apart follow by 2 Follow up sessions
62102771|NCT02730767|EXPERIMENTAL|Intervention Group|Partially supervised exercise intervention: Survivors in the intervention group will be asked to add at least 2.5 hours of intense physical activities per week. These should include at least 30 min of strength building exercises and 2 hours of aerobic exercises per week. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
62102772|NCT02730767|NO_INTERVENTION|Control Group|The control group will keep their physical activity level constant over the 1 year of the study. Thereafter, they will have the opportunity to receive the same intervention than the intervention group had received (off-trial) to benefit in the same way from an active lifestyle.
62102773|NCT06474546|EXPERIMENTAL|Intervention|Diet (MedDiet)
62467897|NCT03041025|EXPERIMENTAL|Cohort 1: GSK2330811 100 mg|During Cohort 1, participants will receive a single dose of GSK2330811 100 mg by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
62102774|NCT05880238|EXPERIMENTAL|Sensory-motor training|The study group received group interventions that included self-regulation strategies and sensory-motor skill training in addition to preschool education. Group interventions were conducted with groups of up to 10 participants for a total of one hour, twice a week for 10 weeks.
62102775|NCT05880238|ACTIVE_COMPARATOR|Control|The control group continued with preschool education and did not receive any additional intervention.
62663940|NCT02448043|OTHER|Left Hand Bimatoprost 0.01% drops, Right Hand Placebo|"* Bimatoprost 0.01% drops placed on the proximal nail folds of the left hand digits two times per day for 30 days.~* Saline solution drops placed on the proximal nail folds of the right hand digits two times per day for 30 days."
62663941|NCT03615729||Rheumatoid arthritis patients|A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
62102776|NCT02466295|EXPERIMENTAL|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
62102777|NCT02466295|EXPERIMENTAL|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
62663942|NCT03615729||controls|A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers
62102778|NCT05006690|EXPERIMENTAL|Telerehabilitation Training Group|"In the telerehabilitation group, an individualized rehabilitation program according to the principles of clinical pilates exercises based on spinal stabilization will be applied via video conference, 3 days a week, 1 hour, online in real-time, accompanied by a physiotherapist, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of axial spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
62295942|NCT02510807|NO_INTERVENTION|Control group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided.
62295943|NCT03886168|EXPERIMENTAL|Immediate IGCIP|Immediate signal processing intervention of a biomedical device
62295944|NCT03886168|ACTIVE_COMPARATOR|Deferred IGCIP|Delayed signal processing intervention of a biomedical device
62295945|NCT01106001|ACTIVE_COMPARATOR|Levobupivacaine|Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children
62467898|NCT03041025|EXPERIMENTAL|Cohort 2: GSK2330811 300 mg|During Cohort 2, participants will receive a single dose of GSK2330811 300 mg by SC injection (3 vials of 1 mL each of GSK2330811 100 mg) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
62663943|NCT06368362|EXPERIMENTAL|Benign CBM-I - Chronic pain|Chronic pain participants randomised to receive benign CBM-I, which uses the Ambiguous Situations Task to train participants to neutral meanings of ambiguous scenarios.
62663944|NCT06368362|NO_INTERVENTION|No CBM-I - Chronic pain|Chronic pain participants randomised to the 'no CBM-I' condition complete the Ambiguous Situations Task without any form of bias modification.
62102779|NCT05006690|EXPERIMENTAL|Face-to-Face Training Group|"In the face-to-face training group, an individualized rehabilitation program according to the principles of clinical pilates exercises based on spinal stabilization will be applied in the clinic under the supervision of a physiotherapist for 1 hour, 3 days a week, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of axial spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
62663945|NCT06368362|EXPERIMENTAL|Benign CBM-I - Healthy|Healthy participants randomised to receive benign CBM-I, which uses the Ambiguous Situations Task to train participants to neutral meanings of ambiguous scenarios.
62663946|NCT06368362|OTHER|Pain-related CBM-I - Healthy|Healthy participants randomised to receive pain-related CBM-I, which uses the Ambiguous Situations Task to train participants to painful meanings of ambiguous scenarios.
62663947|NCT00693459|OTHER|Circular anal dilator|Circular anal dilator group-An anoscope has been developed that outlines the precise path for hemorrhoid excision. This instrument allows a modified Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation.
61911885|NCT04672954|EXPERIMENTAL|10 milligram (mg) BI 474121|10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
61911886|NCT04672954|EXPERIMENTAL|20 milligram (mg) BI 474121|20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
62102780|NCT03075696|EXPERIMENTAL|Part I: Dose Escalation|Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
62295946|NCT01106001|PLACEBO_COMPARATOR|Saline|Saline (also saline solution) is a general term referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water but is only sterile when it is placed intravenously, otherwise, a saline solution is a salt water solution.
62295947|NCT04401657|EXPERIMENTAL|FFR Measurement|Myocardia ischemia evaluation during adenosine stress testing
62295948|NCT01518530|EXPERIMENTAL|Passive Mobilization Cervical Spine|Patients with chronic neck pain according to the International Association of the Study of Pain criteria of the following types: facet joint disorder, post-whiplash injury, myofascial pain syndrome.
62467899|NCT03041025|PLACEBO_COMPARATOR|Cohort 1: Placebo|During Cohort 1, participants will receive a single dose of placebo by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
62467900|NCT03041025|PLACEBO_COMPARATOR|Cohort 2: Placebo|During Cohort 2, participants will receive a single dose of placebo by SC injection (3 vials of 1 mL each) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
62663948|NCT06101446|EXPERIMENTAL|Lavander Aromatherapy|Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system.
62663949|NCT02492386|EXPERIMENTAL|Treatment|Bioabsorbable everolimus-eluting stent deployment
62663950|NCT00899275||Ancillary-correlative|After the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. Patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). Autopsy tumor samples may also be submitted.
62663951|NCT04333498|EXPERIMENTAL|Receiving Feedback From DBS|This arm of participants will receive monthly feedback from medical providers on their adherence measured through DBS.
62663952|NCT04452006|EXPERIMENTAL|Part A (SAD) - A1, ACT-541478 10 mg fasted|SAD = single ascending dose
62663953|NCT04452006|EXPERIMENTAL|Part A (SAD) - A2, ACT-541478 30 mg fasted|SAD = single ascending dose
62663954|NCT04452006|EXPERIMENTAL|Part A (SAD) - A3 (Period 1), ACT-541478 100 mg fasted|SAD = single ascending dose
61911887|NCT04672954|EXPERIMENTAL|40 milligram (mg) BI 474121|40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
61911888|NCT05208918|ACTIVE_COMPARATOR|Epidural steroid group|Transforaminal steroid application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
62295949|NCT03741361||Anxiety and Depression|Female patients scheduled for hysteroscopic surgery under propofol-based intravenous anesthesia will be recruited in this prospective cohort study.
62295950|NCT03717740|EXPERIMENTAL|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
62295951|NCT03717740|PLACEBO_COMPARATOR|Placebo|Patients will take Placebo Oral Tablet once a daily oral tablet from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
62663955|NCT04452006|EXPERIMENTAL|Part A (SAD) - A3 (Period 2), ACT-541478 100 mg fed|SAD = single ascending dose
62663956|NCT04452006|EXPERIMENTAL|Part A (SAD) - A4, ACT-541478 300 mg fasted|SAD = single ascending dose
62663957|NCT04452006|EXPERIMENTAL|Part A (SAD) - A5, ACT-541478 1000 mg fasted|SAD = single ascending dose
62663958|NCT04452006|EXPERIMENTAL|Part B - B1-3, ACT-541478 low or high dose|
62663959|NCT04452006|EXPERIMENTAL|Part C (MAD) - C1, ACT-541478 30 mg, fasted|MAD = multiple ascending dose
62663960|NCT04452006|EXPERIMENTAL|Part C (MAD) - C2, ACT-541478 100 mg, fasted|MAD = multiple ascending dose
62663961|NCT04452006|EXPERIMENTAL|Part C (MAD) - C3, ACT-541478 300 mg, fasted|MAD = multiple ascending dose
62663962|NCT04452006|EXPERIMENTAL|Part C (Elderly) E1, ACT-541478, fasted|
62102781|NCT03075696|EXPERIMENTAL|Part II: Dose Escalation|"In each treatment regimen, participants will receive obinituzumab (Gpt) 1000 milligrams (mg) IV infusion on Day -7 (pre-treatment); or 2000 mg either administered on Day -7, or split into two 1000 mg doses on Days -1 and -7. The first glofitamab IV infusion will be given on Day 1 of Cycle 1 and a total of 12 cycles will be administered.~Monotherapy, glofitamab as a single agent: ascending doses of glofitamab administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with ascending doses of glofitamab on Day 1 of every 3 week cycle until either the MTD/OBD is defined.~Step-up dosing: Q3W, participants will receive an initial low dose of glofitamab on C1D1, followed by a higher dose on C1D8; the total dose in C1 will not exceed the previously determined MTD. Higher doses may be explored from C2 or later cycles."
62295952|NCT01479348|EXPERIMENTAL|1/Intravenous (IV) Tetrahydrouridine (THU)|\[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
62295953|NCT01479348|EXPERIMENTAL|2/Oral Tetrahydrouridine (THU)|\[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
62663963|NCT00248326||1|Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
62295954|NCT05555550|EXPERIMENTAL|18F-Fluciclovine|18F-Fluciclovine PET-MRI
62295955|NCT02279511|EXPERIMENTAL|24 hours infusion of ATP|
62295956|NCT02279511|EXPERIMENTAL|6 hours infusion of ATP|
62663964|NCT00248326||2|Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
62663965|NCT00571090||Thyroid nodule|Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled.
62663966|NCT03454958||Data collection|Data will be collected at four time points over the course of approximately one year and nine months. Participating couples (women and men) will be recruited during the first trimester of their first pregnancy. First measurement will take place in the week of the first routine ultrasound scan (week 12 of pregnancy) (=T0). First follow-up measures will take place six weeks postpartum (=T1). The second and third follow-up measurements will take place at six months postpartum (=T2) and twelve months postpartum (=T3).
61911889|NCT05208918|ACTIVE_COMPARATOR|PRF plus steroids group|Pulsed radiofrequency plus Depo-Medrol (steroid) application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
61911890|NCT01661582|PLACEBO_COMPARATOR|Filtered Air Exposure|Subjects will be exposed to filtered air for 1 hour during intermittent exercise in a purpose-built exposure facility
62295957|NCT02279511|PLACEBO_COMPARATOR|24 hours infusion of placebo|
62295958|NCT02279511|PLACEBO_COMPARATOR|6 hours infusion of placebo|
62295959|NCT00699790|EXPERIMENTAL|A1|
62295960|NCT00699790|PLACEBO_COMPARATOR|A2|
62663967|NCT02932943|EXPERIMENTAL|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
62663968|NCT02932943|PLACEBO_COMPARATOR|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
62663969|NCT01023321|EXPERIMENTAL|1|single ascending doses
62663970|NCT01023321|PLACEBO_COMPARATOR|2|single dose placebo
62102782|NCT03075696|EXPERIMENTAL|Part III: Dose Expansion|"Part III will start once MTD/OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment), followed by glofitamab at a fixed dose regimen or step-up dose regimen on a Q2W or Q3W dosing schedule as determined in Part II. A total of 12 cycles will be administered.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with glofitamab at the dosing regimen determined in Part II."
62663971|NCT01023321|EXPERIMENTAL|3|multiple dose, 7 or 14 days, oral solution
62102783|NCT03916380|NO_INTERVENTION|Group A|Tacrolimus Extended Release + Midazolam
62102784|NCT03916380|ACTIVE_COMPARATOR|Group B|Tacrolimus Extended Release + Midazolam + Grapefruit Juice
62102785|NCT00700414||Participants|Any participant who meets eligibility criteria and consents to participate in the trial.
62663972|NCT01023321|PLACEBO_COMPARATOR|4|multiple dose, 7 or 14 days, oral solution
62663973|NCT05145114|EXPERIMENTAL|Supine Group (SG)|
62102786|NCT04953897|EXPERIMENTAL|Group A: Severe Renal Impairment|Cancer participants with severe renal impairment not requiring dialysis (creatinine clearance \[CLcr\] \<30 mL/min/1.73m\^2)
62102787|NCT04953897|ACTIVE_COMPARATOR|Group B: Normal Renal Function|Cancer participants with normal renal function (CLcr ≥80 mL/min/1.73m\^2)
62102788|NCT06466473|ACTIVE_COMPARATOR|Phenytoin manufactured at Vega Baja site|
62102789|NCT06466473|EXPERIMENTAL|Phenytoin manufactored at Ascoli site|
62102790|NCT01899222||fundus imaging|retinal photograph obtained at visit
62102791|NCT04238624|EXPERIMENTAL|BRAF-mutant ATC|Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer
62102792|NCT05247216|EXPERIMENTAL|Hemay007 800 mg QD group|Drug: 800mg QD of Hemay007; daily oral administrtion for 12 weeks
62102793|NCT05247216|EXPERIMENTAL|Hemay007 1200 mg QD group|Drug: 1200mg QD of Hemay007; daily oral administrtion for 12 weeks
62663974|NCT05145114|EXPERIMENTAL|Prone Group (PG)|
62663975|NCT05145114|EXPERIMENTAL|Lateral Decubitus Group (LDG)|
62102794|NCT05247216|EXPERIMENTAL|Hemay007 600 mg QD group|Drug: 600mg QD of Hemay007; daily oral administrtion for 12 weeks
62663976|NCT02246894|EXPERIMENTAL|Optivate®|Optivate® (Human Coagulation Factor VIII)
62663977|NCT01328119|OTHER|hemodialysis patients|conventional hemodialysis patients
62663978|NCT00692796|EXPERIMENTAL|1|
62663979|NCT00792480|EXPERIMENTAL|Intensive Counseling Group|
62663980|NCT00792480|NO_INTERVENTION|Routine care group|"The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics \& Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle."
62663981|NCT03334266|EXPERIMENTAL|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
62663982|NCT03334266|OTHER|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
62102795|NCT05247216|PLACEBO_COMPARATOR|placebo group|Drug: placebo of Hemay007; daily oral administrtion for 12 weeks
62102796|NCT06622148|EXPERIMENTAL|Group I - Receive test product first and then reference product|
62102797|NCT06622148|EXPERIMENTAL|Group II - Receive reference product first and then test product|
62102798|NCT00030381|EXPERIMENTAL|Treatment (iododoxorubicin)|Patients receive iododoxorubicin IV over 15 minutes on days 1, 8, 15, and 22. Treatment repeats every 12 weeks for a total of 4 courses or a cumulative dose of 400 mg/m\^2 in the absence of disease progression or unacceptable toxicity.
62102799|NCT04281264|NO_INTERVENTION|NorCON|Normoxia Control Group
62102800|NCT04281264|ACTIVE_COMPARATOR|HypCON|Hypoxia Control Group
62102801|NCT04281264|PLACEBO_COMPARATOR|NorCIR|Normoxia Circuit Training with Elastic Bands Group
62102802|NCT04281264|EXPERIMENTAL|HypCIR|Hypoxia Circuit Training with Elastic Bands Group
62102803|NCT04281264|PLACEBO_COMPARATOR|NorVIB|Normoxia Whole-body Vibration Training Group
62102804|NCT04281264|EXPERIMENTAL|HypVIB|Hypoxia Whole-body Vibration Training Group
62102805|NCT01134575|EXPERIMENTAL|Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2|First patients \> 16 years and \< 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
62102806|NCT01134575|EXPERIMENTAL|Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin)|CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
62102807|NCT01134575|EXPERIMENTAL|Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2|First patients \> 16 years and \< 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
62102808|NCT04511650|EXPERIMENTAL|Razuprotafib 10 mg|Active Comparator
62102809|NCT04511650|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62102810|NCT04511650|EXPERIMENTAL|Razuprotafib 20 mg|Active Comparator
62102811|NCT04487587|ACTIVE_COMPARATOR|Active|Cediranib 20mg tablet OD (5 days out of 7) and Olaparib 300mg tablet BD (continuous) + standard of care
62663983|NCT05679505|EXPERIMENTAL|Left ear transcutaneous vagus nerve stimulation|"Left ear transcutaneous vagus nerve stimulation will be applied to the participants in this group.A continuous electrical stimulation with a current frequency of 10 Heartz (Hz) with a current transit time of 300 μs was applied to the participants in both groups. The participants included in both groups were treated with taVNS with the Vagustim device for 20 minutes once a day and for a total of 10 sessions application was made."
62102812|NCT04487587|PLACEBO_COMPARATOR|Placebo|Placebo Cediranib 20mg tablet OD (5 days out of 7) and Placebo Olaparib 300mg tablet BD (continuous) + standard of care
62102813|NCT06123117|EXPERIMENTAL|Daycare: STALL|Local ropivacaine infiltration + laparoscopically controlled TAP (transversus abdominis plane block). Daycare patients.
62102814|NCT06123117|ACTIVE_COMPARATOR|Daycare: local only|Local ropivacaine infiltration only. Daycare patients.
62102815|NCT06123117|EXPERIMENTAL|In-patient: STALL|Local ropivacaine infiltration + laparoscopically controlled TAP. In-patient surgery.
62102816|NCT06123117|ACTIVE_COMPARATOR|In-patient: local only|Local ropivacaine infiltration only. In-patient surgery.
62102817|NCT06123117|EXPERIMENTAL|Emergency: STALL|Local ropivacaine infiltration + laparoscopically controlled TAP. Emergency patients.
62102818|NCT06123117|ACTIVE_COMPARATOR|Emergency: local only|Local ropivacaine infiltration only. Emergency patients.
62102819|NCT05640596||exposed group (121 patients)|"Extrated from the population of full-term newborns (\> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who received at least one course of betamethasone before 34 weeks of amenorrhea for a threat of preterm delivery.~Exposure to an antenatal corticosteroid therapy was defined as the administration of at least one course of betamethasone (i.e. two doses of 12 mg, 24 hours apart). in intramuscular, before 34 weeks of amenorrhea, for a threat of premature delivery."
62102820|NCT05640596||nonexposed group (242 patients)|came from the population of full-term newborns (\> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who who had not been exposed to antenatal steroid therapy. Two controls were selected for a case, appaired on the month and year of birth and on the sex of the case patient.
62663984|NCT05679505|EXPERIMENTAL|Bilateral double ear transcutaneous vagus nerve stimulation|"Bilateral double ear transcutaneous vagus nerve stimulation will be applied to the participants in this group.A continuous electrical stimulation with a current frequency of 10 Heartz (Hz) with a current transit time of 300 μs was applied to the participants in both groups. The participants included in both groups were treated with taVNS with the Vagustim device for 20 minutes once a day and for a total of 10 sessions application was made."
62663985|NCT03778372||study|pediatric patients undergoing outpatient strabismus surgery, and receiving methadone
61911891|NCT01661582|EXPERIMENTAL|Dilute Diesel Exhaust Exposure|Subjects will be exposed to dilute diesel exhaust (\~300 mcg/m3) for 1 hour during intermittent exercise in a purpose-built exposure facility
61911892|NCT04630574||Patients with Huntington's disease|Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.
61911893|NCT01190423|EXPERIMENTAL|Family Based therapy for young adults|
61911894|NCT04791527|EXPERIMENTAL|Mind-body Intervention arm|Online yoga, meditation, behavior change tips, and nutrition tips
61911895|NCT04486898|EXPERIMENTAL|Music group|Music group will be receiving music intervention 3 times a day for 30 minutes per session for the duration of five (5) weeks period.
61911896|NCT04486898|NO_INTERVENTION|Usual care|Those who will be in this group will be ask to continue doing their actual activities and not to partake in any kind of music listening or therapy for the 5 week period.
62102821|NCT04157712|EXPERIMENTAL|Cohort A Capsule - Fasted|ALZ-801 171 mg or matching placebo once daily Day 1, ALZ-801 171 mg or matching placebo twice daily Days 2-7, ALZ-801 256.5 mg or matching placebo once daily Days 8-14
62102822|NCT04157712|EXPERIMENTAL|Cohort B Capsule - Fasted|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 or matching placebo mg twice daily Days 2-7, ALZ-801 340 mg or matching placebo once daily Days 8-14
62663986|NCT03778372||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving methadone
62663987|NCT00717080|EXPERIMENTAL|Arm 1|IOL surgery with Capsular Tension Ring
61911897|NCT05444998|EXPERIMENTAL|Intuzumab + pyrrolidone + nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~postoperative adjuvant therapy:4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy."
61911898|NCT02688322|EXPERIMENTAL|2 g q12 of sulbactam, 1 h infusion|2 g of sulbactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 1 h every 12 h.
61911899|NCT01488344|EXPERIMENTAL|BIBF 1120|
62102823|NCT04157712|EXPERIMENTAL|Cohort C Capsule - Fed|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 mg or matching placebo twice daily Days 2-7, ALZ-801 340 mg or matching placebo twice daily Days 8-13, ALZ-801 340 mg or matching placebo once daily Day 14
62102824|NCT04157712|EXPERIMENTAL|Cohort D Tablet - Fed|ALZ-801 265 mg or matching placebo once daily Day 1, ALZ-801 265 mg or matching placebo twice daily Days 2-6, ALZ-801 265 mg or matching placebo once daily Day 7
62295961|NCT05989503|ACTIVE_COMPARATOR|Simultaneous initiation|ARNi (initial dose 24/26mg b.i.d. or 49/51mg b.i.d. titrated to 97/103mg b.i.d. preferably in the first 3-6 weeks, up to 3 months of follow-up) and SGLT2i (10mg q.d.) on the same day or within ± 5 days.
61911900|NCT01247298|EXPERIMENTAL|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive stereotactic body radiation therapy (SBRT) which is 3 radiation treatments at 15 Gy, for a total of 45 Gy. Patients will be given Trans-Arterial Chemoembolization (TACE), prior to enrollment. (TACE is not performed as part of this clinical study, even though it is part of the inclusion criteria.)
61911901|NCT03737227|OTHER|Cinematographic recording|Cinematographic recordings of the asymptomatic participants during flexion and extension of the lumbar spine.Cinematographic recordings will be performed twice with an interval of two weeks.
61911902|NCT00338975|EXPERIMENTAL|1|Cognitive Behavioral Social Skills Training (CBSST)
61911903|NCT00338975|ACTIVE_COMPARATOR|2|Goal-Focused Supportive Contact (GFSC)
61911904|NCT01650012|EXPERIMENTAL|Eplerenone|Target of 50 mg/day
61911905|NCT01650012|PLACEBO_COMPARATOR|Placebo|Matching placebo
61911906|NCT05861622|EXPERIMENTAL|Novel moisturizer|Subjects will apply the test product twice daily, both in the morning and the evening.
62102825|NCT00387361|EXPERIMENTAL|1|
62295962|NCT05989503|ACTIVE_COMPARATOR|Sequential initiation|Initial (at randomization day) SGLT2i prescription (either empagliflozin or dapagliflozin, 10 mg q.d.) followed by an ARNi initiated between weeks 4 and 12 after randomization (sacubitril/valsartan at an initial dose of 24/26mg b.i.d. or 49/51mg b.i.d., and titrated to 97/103mg b.i.d. if tolerated, according to assistant physician decision)
62295963|NCT02049502|EXPERIMENTAL|fecal microbiota transplant|fecal microbiota transplant
61911907|NCT03313232|EXPERIMENTAL|Fragrance allergic patients|Patients with a previous positive patch test to oxidized R-Limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
61911908|NCT03313232|EXPERIMENTAL|Possible fragrance allergic patients|Patients with a previous doubtful patch test to oxidized R-limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
61911909|NCT03313232|EXPERIMENTAL|Healty controls|Healthy controls with no contact allergy to oxidized R-limonene. Healthy controls will have en initial diagnostic patch test with oxidized R-limonene performed followed by twice daily exposure to oxidized R-limonene at one concentration and a vehicle control on the forearms for up to three weeks.
61911910|NCT01479218|OTHER|PDA Occluder|single arm
62102826|NCT00387361|NO_INTERVENTION|2|
62102827|NCT02131740|EXPERIMENTAL|Eye rubbing intervention|eye rubbing performed for 1 minute in horizontal direction, clockwise rest for 5 seconds eye rubbing for a further 1 minute
62102828|NCT02131740|ACTIVE_COMPARATOR|No eye rubbing|no eye rubbing - comparator
62102829|NCT02327039|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg tablet once daily for 12 weeks
62102830|NCT02327039|PLACEBO_COMPARATOR|Placebo|Placebo 10 mg tablet once daily for 12 weeks
62663988|NCT00717080|PLACEBO_COMPARATOR|Arm 2|IOL surgery without Capsular Tension Ring
62663989|NCT02082288|EXPERIMENTAL|Edessy ICSI Outcome Embryo Score|ICSI
62663990|NCT02557789|EXPERIMENTAL|Treatment A|Lefamulin as a 600 mg IR tablet in the fasted state
62663991|NCT02557789|EXPERIMENTAL|Treatment B|Lefamulin as 600 mg API in capsule (three 200 mg capsules) in the fasted state
62663992|NCT02557789|EXPERIMENTAL|Treatment C|Lefamulin as 150 mg i.v. in 250 mL citrate buffered saline infused over 1 h
61911911|NCT01268280|EXPERIMENTAL|Treatment Sequence 1|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 CK-2017357 500 mg
61911912|NCT01268280|EXPERIMENTAL|Treatment Sequence 2|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 CK-2017357 250 mg
61911913|NCT01268280|EXPERIMENTAL|Treatment Sequence 3|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 500 mg
61911914|NCT01268280|EXPERIMENTAL|Treatment Sequence 4|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 Placebo
61911915|NCT01268280|EXPERIMENTAL|Treatment Sequence 5|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 250 mg
61911916|NCT01268280|EXPERIMENTAL|Treatment Sequence 6|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 Placebo
62102831|NCT01086124||Echocardiography 1 month|Patients will all have an echocardiography 1 month post myocardial infarction and 3 months post myocardial infarction
62295964|NCT06071611|EXPERIMENTAL|Oxygen-Ozone (O2-O3)|A small catheter is inserted into the rectum and a total amount of 150cc of O2-O3 mixture at the concentration of 30ug of O3 per cc of O2 over a 5-10 min period is administered.
62663993|NCT02557789|EXPERIMENTAL|Treatment D|Lefamulin as a 600 mg IR tablet one hour after breakfast
62663994|NCT04841174|EXPERIMENTAL|Abdominal Massage|"Participants in the experimental group will be given an abdominal massage twice a day for 15 minutes and three days in a row by the researcher. The massage will be done 2 hours after the child has been fed. Abdominal massage will be done using the I love u technique."
62102832|NCT06411418|EXPERIMENTAL|Single arm study|Occurrence of thromboembolic event(s)
62663995|NCT04841174|NO_INTERVENTION|Intraabdominal pressure|Intra-abdominal pressure measurements will be made twice a day before the abdominal massage is given to the participants. This measurement will be made in line with a protocol. The intraabdominal pressure will be measured using the bladder passage method. This measurement will be made in both control and experimental groups.
62663996|NCT04841174|NO_INTERVENTION|Gastric measurements|In the experimental and control groups, the abdominal circumference will be measured by the researcher twice a day for three days in a row. The gastric residual volume will be checked during the nurses' care time. The presence of vomiting and defecation will be checked during the care time of the nurses.
61911917|NCT00918060|EXPERIMENTAL|gel a|
61911918|NCT00918060|PLACEBO_COMPARATOR|gel b|
61911919|NCT05117918|PLACEBO_COMPARATOR|Traditional In-Person Clinic Visit Arm|Patients will receive overactive bladder (OAB) treatment as described in the Society for Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB clinical care pathway. These patients will have all visits in-person
61911920|NCT05117918|EXPERIMENTAL|Telemedicine Arm|Patients will receive OAB treatment as described in the SUFU OAB clinical care pathway but all visits will be performed via telemedicine
61911921|NCT00594425|EXPERIMENTAL|1|PDT using MAL concentration A
61911922|NCT00594425|EXPERIMENTAL|2|PDT using MAL concentration B
61911923|NCT00594425|PLACEBO_COMPARATOR|3|PDT using Placebo cream
62102833|NCT05602116|EXPERIMENTAL|1 x 1000000 C2C_ASCs/kg body weight|Trial participant 1 - 5 will be treated with 1 x 1000000 C2C_ASCs/kg body weight
62102834|NCT05602116|EXPERIMENTAL|2 x 1000000 C2C_ASCs/kg body weight|Trial participant 6 - 10 will be treated with 2 x 1000000 C2C_ASCs/kg body weight
62295965|NCT06071611|ACTIVE_COMPARATOR|Oxygen (O2)|A small catheter is inserted into the rectum and a total amount of 150cc of O2 over a 5-10 min period is administered.
61911924|NCT01698710|EXPERIMENTAL|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
61911925|NCT05378698|NO_INTERVENTION|Healthy arm|Healthy controls
62663997|NCT02590315|EXPERIMENTAL|Digital Breast Tomosynthesis - DBT|Invitation for breast screening and random allocation. Participants randomised to DBT will be screened with bilateral, two-view combo mode (DBT images are obtained with DM images). DBT participants will have an additional radiation exposure for the combined DM and DBT examinations.
61911926|NCT05378698|ACTIVE_COMPARATOR|Tralokinumab|Patients with AD
61911927|NCT04740905|EXPERIMENTAL|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
62102835|NCT06630754||adults aged 70yrs and older, eligible, and accepting of assessment in the SAOP.|
62102836|NCT05886751|EXPERIMENTAL|Video About Screening with Black Doctor|
62102837|NCT05886751|EXPERIMENTAL|Video About Screening with White Doctor|
62102838|NCT05886751|EXPERIMENTAL|Video About Screening with Black Patient|
62102839|NCT05886751|EXPERIMENTAL|Video About Screening with White Patient|
62663998|NCT02590315|ACTIVE_COMPARATOR|Conventional digital mammography - DM|Invitation for breast screening and random allocation. Participants randomised to DM will be screened with bilateral, two-view DM.
62663999|NCT04994184||Perforated duodenal ulcer|MORBIDITY AND MORTALITY
62664000|NCT01719276|ACTIVE_COMPARATOR|Graded Activity|Exercise treadmill, Strengthening of the lower limbs and trunk
62664001|NCT01719276|ACTIVE_COMPARATOR|Supervised exercises|Stretching, Strengthening, Motor Control
62664002|NCT01588509|EXPERIMENTAL|Romosozumab 140 mg|Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
62664003|NCT01588509|EXPERIMENTAL|Romosozumab 210 mg|Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
62664004|NCT00558883|ACTIVE_COMPARATOR|1|treatment with Acarbose: 2 weeks 1 x 50mg; 2 weeks 3 x 50mg; 16 weeks 3 x 100mg
62664005|NCT00558883|PLACEBO_COMPARATOR|2|treatment with placebo: 2 weeks 1 x 50mg 2 weeks 3 x 50mg 16 weeks 3 x 100mg
62664006|NCT01217450|EXPERIMENTAL|Treatment (selumetinib, cetuximab)|Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62664007|NCT01748682|EXPERIMENTAL|Liquid Diet Group|The group followed a very low calorie liquid diet for two weeks
62664008|NCT01748682|ACTIVE_COMPARATOR|Control Group|The group followed a very low calorie diet of normal consistency for two weeks.
62664009|NCT04890613|EXPERIMENTAL|Main Study Cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
62664010|NCT04890613|EXPERIMENTAL|Exploratory cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 250 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
62664011|NCT04890613|EXPERIMENTAL|Main Study Cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
62664012|NCT04890613|EXPERIMENTAL|Exploratory cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 325 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
62664013|NCT02128750|EXPERIMENTAL|revascularization group|Subjects in this arms have an contrast echographie with sonovue(r) then a revascularization and finnaly an other contrast echographie with sonovue.
62664014|NCT00766103|OTHER|crossover: hypo- and hypercarbia|
62664015|NCT04386148||laparoscopic colorectal surgery|Patients undergoing laparoscopic colorectal surgery with use of Obsidian ASG® during primary anastomosis.
62664016|NCT06420583|EXPERIMENTAL|Pulpotomy|MTA Pulpotomy
62664017|NCT06420583|ACTIVE_COMPARATOR|Extraction|Extraction
62664018|NCT00818844|EXPERIMENTAL|Nepafenac|Nepafenac 0.1% dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
62664019|NCT00818844|PLACEBO_COMPARATOR|BSS|BSS dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
62664020|NCT04337073|PLACEBO_COMPARATOR|normal saline (N) group|Before anesthesia induction, N group received corresponding intravenous normal saline of the same volume.
62664021|NCT04337073|ACTIVE_COMPARATOR|propofol (P) group|Before anesthesia induction, P group received intravenous injection of 0.3mg/kg propofol
62664022|NCT05993143|EXPERIMENTAL|Ivermectin (test product)|Ivermectin 9 mg and 18 mg immediate-released tablets to be taken orally once daily during 3 days at 600 µg/kg/day ± 120 µg/kg/day depending on their body weight.
62664023|NCT05993143|PLACEBO_COMPARATOR|Placebo (reference product)|Placebo tablets to be taken orally once daily during 3 days.
62664024|NCT00183898|EXPERIMENTAL|Oxaliplatin and Capecitabine|Oxaliplatin given every 21 days Capecitabine given daily x 14 days every 21 days
62664025|NCT03611660|ACTIVE_COMPARATOR|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
62664026|NCT03611660|EXPERIMENTAL|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
62664027|NCT06511128||group created with dexmedetomidine sedation|infusion will be started at a dose of 0.2-0.7 mcg/kg/h after a loading dose of 1 mg midazolam, 50 mcg fentanyl followed by 1 mcg/kg dexmetedomidine.
62664028|NCT06511128||group created with propofol sedation|After 1 mg midazolam and 50 mcg fentanyl are given, propofol infusion will be started at a dose of 50-100 mcg/kg/min, following an initial dose of 1 mg/kg
62664029|NCT01137760|PLACEBO_COMPARATOR|Sugar pill|
62664030|NCT01137760|EXPERIMENTAL|Galactooligosaccharide 2.5 g|
62102840|NCT05886751|EXPERIMENTAL|Video about Clinical Trials with Black Doctor|
62102841|NCT05886751|EXPERIMENTAL|Video about Clinical Trials with White Doctor|
62102842|NCT05886751|EXPERIMENTAL|Video about Clinical Trials with Black Patient|
62102843|NCT05886751|EXPERIMENTAL|Video about Clinical Trials with White Patient|
62102844|NCT02509390|EXPERIMENTAL|Severe trauma patients|All severe trauma patients (ISS\>15) admitted in our trauma center Blood samples (additional blood tubing)
62664031|NCT01137760|EXPERIMENTAL|Galactooligosaccharide 5.0 g|
62664032|NCT06121505|EXPERIMENTAL|Radiotherapy combined with sintilimab and chemotherapy|Subjects received radiotherapy (SBRT+LDRT). Sintilimab combined with standard platinum-containing double-drug chemotherapy was performed within 1 week after the end of radiotherapy.
62664033|NCT06121505|ACTIVE_COMPARATOR|Sintilimab+Chemotherapy|Subjects received sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles.
62664034|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
62664035|NCT03355456|ACTIVE_COMPARATOR|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
62664036|NCT03355456|ACTIVE_COMPARATOR|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
62467901|NCT00396279|EXPERIMENTAL|Denosumab|Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.
62102845|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
62102846|NCT06219603||excellent|participants who answered on \> 80 % of the questioned correctly
62467902|NCT01846585|OTHER|ABTI|Arousal Based Therapy for Insomnia
62467903|NCT01846585|OTHER|CBTI|Cognitive Behavioral Therapy for Insomnia
62664037|NCT01764581|EXPERIMENTAL|Tacrolimus dose regulation|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.
62664038|NCT01764581|NO_INTERVENTION|Control|immunosuppressive therapy is managed either by standard practice at our center (Control)
62664039|NCT00708669|ACTIVE_COMPARATOR|TAXUS group|
62664040|NCT00708669|ACTIVE_COMPARATOR|Cypher group|
62664041|NCT06116851||suspicion|"Inclusion criteria for the suspicion cohort include clinical suspicion for PCa and indication for PCA diagnostics based on any of the following: 1) elevated PSA (\>2.5 ng/ml), 2) palpable prostate tumor/nodule, 3) image finding suggestive of PCa.~The suspicion cohort will include a total of 300 subjects who will undergo PCa diagnostics including prostate MRI, and transrectal ultrasound (TRUS) guided prostate biopsies. After the diagnostic procedures all subjects are categorized to one of the following groups: 1) subject without PCa, 2) subject with clinically non-significant PCa (ISUP grade 1/Gleason 3+3), 3) clinically significant PCa (ISUP grade \>1/\>Gleason 3+3).~Based on the outcome of the PCa diagnostics and planned clinical treatment, subjects may be eligible to other cohorts as well."
62664042|NCT06116851||cancer (radical prostatectomy) cohort|Inclusion criteria for the cancer cohort include clinically significant prostate cancer planned to be treated with radical prostatectomy with or without pelvic lymph node dissection. The cancer cohort will include a total of 50 subjects.
62664043|NCT06116851||benign/TURP-cohort|Inclusion criteria for the benign (TURP) cohort includes benign prostate hyperplasia (BPH) planned to be treated with transurethral resection of the prostate (TURP). The benign/TURP-cohort will include a total of 50 subjects.
62102847|NCT06219603||good|participants who answered on 61 - 80 % of the questioned correctly
62467904|NCT06089018||Patients with Myotonic Dystrophy Type 1|This group will consist of participants with a confirmed genetic diagnosis of DM1 or DM2.
62664044|NCT06116851||benign/cystectomy|Inclusion criteria for the benign/cystectomy cohort includes bladder cancer planned to be treated with removal of the urinary bladder and prostate (cystoprostatectomy). The benign/cystectomy cohort will include a total of 25 subjects.
62664045|NCT02320396|EXPERIMENTAL|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
62664046|NCT02320396|PLACEBO_COMPARATOR|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
62664047|NCT04691232|EXPERIMENTAL|Regulatory T cells|Intravenous infusion of a single dose of 0.5x10e6, 1x10e6, 2x10e6, 5x10e6 or 10x10e6 Treg/kg body weight
62102848|NCT06219603||average|participants who answered on 41 - 60 % of the questioned correctly
62102849|NCT06219603||bad|participants who answered on 21 - 40 % of the questioned correctly
62664048|NCT04512872|EXPERIMENTAL|CT-P41|60 mg/mL single dose administration, Solution for injection in PFS
62664049|NCT04512872|ACTIVE_COMPARATOR|EU-approved Prolia|60 mg/mL single dose administration, Solution for injection in PFS
62664050|NCT02323438|ACTIVE_COMPARATOR|Usual Brand (UB) Cigarettes|Usual Brand Cigarette
62664051|NCT02323438|EXPERIMENTAL|Electronic Cigarette #1|VUSE® (original flavor, 29 mg nicotine)
62102850|NCT06219603||very bad|participants who answered on \<=20 % of the questioned correctly
62102851|NCT04619654|EXPERIMENTAL|Cataract Surgery with concurrent MIGS|
62295966|NCT06071611|PLACEBO_COMPARATOR|Placebo (Air)|A small catheter is inserted into the rectum and a total amount of 150cc of air over a 5-10 min period is administered.
62467905|NCT06089018||Healthy Controls|This group will consist of participants without a confirmed genetic diagnosis of DM1 or DM2.
62467906|NCT01300390||End-stage liver disease pre-transplant|Patients with end-stage liver disease (non-fulminant) awaiting liver transplant
62467907|NCT01313273|OTHER|Arm A|
62467908|NCT01313273|EXPERIMENTAL|Arm B|
62467909|NCT05174325|EXPERIMENTAL|Arm 1|Pre-operative Sintilimab + chemotherapy
62102852|NCT05042271||Meropenem: Patients who underwent TPE (Phase 1)|In phase 1, each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first therapeutic plasma exchange (TPE) and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
62102853|NCT05042271||Meropenem: after TPE (Phase 2)|was similar to phase 1 except that the meropenem administration and PK studies were conducted \>6 hours apart from the next TPE
62102854|NCT05397457|EXPERIMENTAL|Treatment group|
62102855|NCT05397457|NO_INTERVENTION|Control group|
62102856|NCT02473120|EXPERIMENTAL|Determination of ESR1 mutations|Blood sample will be collected every 3 months during two years to determine ESR1 mutations
62102857|NCT04782999|ACTIVE_COMPARATOR|Oral glucose tolerance test|"Oral glucose tolerance test with ingestion of 75 g glucose and blood sampling.~This test will be performed before and 3 months after RYGB."
62295967|NCT05888831|EXPERIMENTAL|Dose Escalation: BMS-986449 monotherapy|
62467910|NCT00260039|ACTIVE_COMPARATOR|1|Gardasil
62467911|NCT00260039|EXPERIMENTAL|2|HPV VLP vaccine -Dose regimen 1
62467912|NCT00260039|EXPERIMENTAL|3|HPV VLP vaccine -Dose regimen 2
62664052|NCT02323438|EXPERIMENTAL|Electronic Cigarette #2|VUSE® (menthol flavor, 26 mg nicotine)
62664053|NCT02323438|EXPERIMENTAL|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
62102858|NCT04782999|ACTIVE_COMPARATOR|Hyperglycemic clamp with saline infusion combined with arginine test|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 120 min with co-infusion of saline.~After 120 min an arginine test with infusion of 50 g Arginine is performed.~This test will be performed before, 1 week and 3 months after RYGB."
62295968|NCT05888831|EXPERIMENTAL|Dose Escalation: BMS-986449 + nivolumab|
62295969|NCT05888831|EXPERIMENTAL|Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts|
62295970|NCT06486831|NO_INTERVENTION|Control Group|Routine Plaster intervention will be applied to the control group. No action will be taken.
62295971|NCT06486831|EXPERIMENTAL|Experimental Group|During the plaster intervention process, the experimental group will squeeze the stress ball.
62664054|NCT02196103|EXPERIMENTAL|Expectant management|
62664055|NCT00462462|EXPERIMENTAL|1|Ethanol gel
62295972|NCT03240926|EXPERIMENTAL|Loop Band|Measure accuracy of vital sign measurements
62295973|NCT04511702|EXPERIMENTAL|Pegloticase 60 Minute Infusion with methotrexate (MTX)|Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
62295974|NCT04511702|EXPERIMENTAL|Pegloticase 45 Minute Infusion with methotrexate (MTX)|Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
62295975|NCT04511702|EXPERIMENTAL|Pegloticase 30 Minute Infusion with methotrexate (MTX)|Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
62295976|NCT00441688|EXPERIMENTAL|GI265235|
62664056|NCT00462462|ACTIVE_COMPARATOR|2|Ethanol solution
62664057|NCT01529996|EXPERIMENTAL|YAG laser|
62664058|NCT01529996|ACTIVE_COMPARATOR|Pulse Dye Laer|
62102859|NCT04782999|ACTIVE_COMPARATOR|Hyperglycemic clamp with GLP-1 infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusion of intraveneous glucose for 90 min with co-infusion of GLP-1.~This test will be performed before, 1 week and 3 months after RYGB."
62295977|NCT04964869|EXPERIMENTAL|Epinephrine solution injection group|In injected group, The saline epinephrine solution (1mg in 10ml N/S) is injected to 2 sites of cutted papilla (1 o'clock and 11 o'clock) by injected needle, at least 0.5ml per injected site, and must be protruded from submucosal layer.
62295978|NCT04964869|NO_INTERVENTION|non-injection group|In non injection group, the saline epinephrine solution is not given
62467913|NCT00260039|EXPERIMENTAL|4|HPV VLP vaccine -Dose regimen 3
62664059|NCT01594684|ACTIVE_COMPARATOR|drug eluting balloon|treatment with drug eltuing balloon
62664060|NCT01594684|PLACEBO_COMPARATOR|uncoated balloon|treatment with uncoated balloon
62664061|NCT01594684|ACTIVE_COMPARATOR|double drug eluting balloon|if treatment fails 30 days or later
62664062|NCT02117154||HbA1c, 6-day Professional CGM|6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart
62664063|NCT03295851|EXPERIMENTAL|IV Ferric Carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
62664064|NCT03295851|ACTIVE_COMPARATOR|Oral Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily
62664065|NCT02504203|ACTIVE_COMPARATOR|Intervention: BCG and OPV at home visits|Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
62102860|NCT04782999|ACTIVE_COMPARATOR|Hyperglycemic clamp with GIP infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 90 minutes with co-infusion of GIP.~This test will be performed before, 1 week and 3 months after RYGB."
62102861|NCT05060185|OTHER|single arm|the patients will be treated by the trial device
62102862|NCT04068103|ACTIVE_COMPARATOR|Arm I (blood stored and tested for ctDNA later)|Patients undergo active surveillance.
62295979|NCT03505437|EXPERIMENTAL|Stress + Exposure|Stress Condition: Cold water condition of the socially evaluated cold pressor test (SECPT; Schwabe et al, 2008).
62295980|NCT03505437|ACTIVE_COMPARATOR|Control + Exposure|Control condition: Warm water condition of the SECPT.
62295981|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
62295982|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
62295983|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
62467914|NCT03743961||Group A : control group|"Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients with 14 Questions) and QoL EORTC Q30 (Quality Qf Life with 30 Questions)~for patients with G8 score \> 14/17"
62467915|NCT03743961||Group B : geriatric intervention group|Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients) and QoL (Quality Qf Life) EORTC Q30 for patients with G8 score ≤14/17 ( in this arm there is two groups : patient who received geriatric intervention before treatment initiation (group A) and group of patient did not received geriatric intervention before treatment initiation( group B))
62664066|NCT02504203|NO_INTERVENTION|Control: No vaccines at home visits|For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.
62102863|NCT04068103|EXPERIMENTAL|Arm II (blood tested for ctDNA at baseline)|"Patients are assigned to 1 of 2 groups.~GROUP I (ctDNA DETECTED): At the discretion of the investigator, patients receive either oxaliplatin IV over 2 hours on day 1, leucovorin IV over 2 hours on day 1, and fluorouracil IV bolus over 2-4 minutes on day 1 and then by continuous IV over 46-48 hours repeated every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14 repeated every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity at the discretion of the investigator.~GROUP II (ctDNA NOT DETECTED): Patients undergo active surveillance."
62102864|NCT01174316|EXPERIMENTAL|autotitrating NIV|approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
62102865|NCT01174316|ACTIVE_COMPARATOR|Standard non-invasive ventilation|approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
62102866|NCT06226987||Fabry Disease with cardiac involvement|
62102867|NCT05045872|EXPERIMENTAL|ferumoxytol-enhanced renal magnetic resonance imaging|Patients will receive ferumoxytol-enhanced renal magnetic resonance imaging before renal angiography. Ferumoxytol (510 mg/17mL; Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing, China) will be diluted at 1:4 (v/v) and intravenously infused into the antecubital vein at a dose of 3 mg/kg with an infusion speed of 0.07 mL/s.
62102868|NCT06414980|EXPERIMENTAL|Experimental|On the day of the operation, patients will be given a menthol scent before the surgery. Data collection forms will be applied to the experimental group at specified intervals on the day of operation, at the clinic exit, before surgery, after surgery and in the recovery room (PACU). The day after the operation, a final interview will be held with the experimental group patients and questions will be asked about their experiences during the post-operative awakening process and these will be recorded.
62102869|NCT06414980|NO_INTERVENTION|Control|In the control group, which did not undergo any intervention, at the clinic exit on the day of the operation, vital values (pulse, blood pressure) were recorded at preoperative, postoperative and recovery room (PACU) intervals (Unit entrance, 5th minute, 10th minute, 15th minute and 20th minute). , body temperature, blood pressure and SpO2) will be taken. At the same time, the Modified Aldrete Score (MAS) and the Alertness and Sedation Observer Rating Scale (OSS/S) will be independently evaluated and recorded by the researcher.
62102870|NCT06628427||Elderly with Mild Cognitive Impairments|
62295984|NCT05150132|EXPERIMENTAL|Oral-B Genius® 8000 power toothbrush with Cross Action brush head with smartphone app for 8 weeks|Interactive PTB with Bluetooth® 4.0 connectivity smartphone app with Cross Action brush head using visually position detection feature. A triple pressure control system stops vibration, gives a visual warning, and reduces rotation speed in Daily Cleaning Mode-1.
62295985|NCT05150132|ACTIVE_COMPARATOR|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app for 8 weeks|PTB without Bluetooth® 4.0 connectivity without smartphone app with Cross Action brush head without using visually position detection feature triple pressure control system stops vibration, provides visual warning and reduces rotation speed. The group was asked to use PTB with daily cleaning mode 1 and brush head, but without using the Bluetooth app (without using the position detection system).
62664067|NCT04464447|OTHER|Group-based Acceptance and Commitment Therapy|Group-based Acceptance and Commitment Therapy (ACT) for adolescents presenting with multiple functional somatic syndromes.
62102871|NCT04090320|EXPERIMENTAL|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
62295986|NCT05150132|ACTIVE_COMPARATOR|Manual toothbrush: Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA) for 8 weeks|They were instructed to brush according to the Modified Bass technique.
62295987|NCT05230147|EXPERIMENTAL|Spinal cord stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define the stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. Stimulation is initiated within 2 min before tilting the table. Then verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
62467916|NCT02097550|EXPERIMENTAL|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
62467917|NCT02097550|NO_INTERVENTION|Standard of care|These patients will receive the standard of care from their physician.
62467918|NCT03509545|EXPERIMENTAL|CHF Patients: ER Torsemide 40 mg|CHF patients will be given 40 mg ER Torsemide
62467919|NCT03509545|ACTIVE_COMPARATOR|CHF Patients: Furosemide 40 mg|CHF patients are on 40 mg of Furosemide
62102872|NCT06526793|EXPERIMENTAL|Module 1: AZD0486 Monotherapy in Participants with Relapsed or Refractory Follicular Lymphoma|In Module 1, the efficacy and safety of AZD0486 at the RP2D will be evaluated in R/R FL. AZD0486 will be administered as intravenous infusion.
62102873|NCT06526793|EXPERIMENTAL|Module 2: AZD0486 Monotherapy in Participants with Relapsed or Refractory DLBCL|In Module 2, the efficacy and safety of AZD0486 at the RP2D will be evaluated in R/R DLBCL. AZD0486 will be administered as intravenous infusion.
62102874|NCT04045470|EXPERIMENTAL|Initial Cohort|"* Patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma~* Mandatory skin biopsy for corollary studies will be obtained~* Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)"
62102875|NCT04045470|EXPERIMENTAL|Expansion Cohort|"* Only patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma who plan to start systemic therapy as part of standard of care~* Mandatory skin biopsy for corollary studies will be obtained~* Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)~* Participants will receive standard of care therapy and clinical course followed~* Participants will undergo standard of care therapy as previously determined by treating oncologist and/or dermatologist prior to enrollment to study~* Participants will not be assigned any treatment intervention"
62102876|NCT05794022|OTHER|Cohort group|patient with ST-segment elevation myocardial infarction.
62467920|NCT00949481|EXPERIMENTAL|Supply|In each country, this arm will be comprised of women attending family planning clinics within the 5 facilities randomized to this group.
62467921|NCT00949481|EXPERIMENTAL|Demand|In each country, this arm will be comprised of women attending immunization clinics within the 5 facilities randomized to this group.
62467922|NCT00949481|NO_INTERVENTION|Control|In each country, this arm will be comprised of women attending family planning and immunization clinics in 5 facilities randomized to this group.
62467923|NCT01108094|EXPERIMENTAL|Cohort A - Itraconazole 400 mg|Oral itraconazole 400 mg as 200 mg twice daily, for 1 month, stratified by prior vismodegib history
62664068|NCT01631253|ACTIVE_COMPARATOR|single-port access laparoscopic ovarian cyst enucleation|Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)
62664069|NCT01631253|ACTIVE_COMPARATOR|two-port laparoscopic access ovarian cyst enucleation|Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.
62664070|NCT01631253|ACTIVE_COMPARATOR|four-port access laparoscopic ovarian cyst enucleation|Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.
62664071|NCT02605239|EXPERIMENTAL|bleaching teeth|Group of patients will be bleaching with 10% peroxide carbamide , and them will be assessed the impact on dental confidence , impact psychosocial and esthetic perception
62102877|NCT05729373|EXPERIMENTAL|SEP-363856|dosed once daily tablet
62102878|NCT05729373|PLACEBO_COMPARATOR|Placebo|dosed once daily tablet
62102879|NCT04440943|EXPERIMENTAL|CDX-527|"Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance.~Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase."
62102880|NCT05313672||IPF patients with UIP pattern requiring NIV|
62102881|NCT05313672||ARDS patients requiring NIV|
62467924|NCT01108094|EXPERIMENTAL|Cohort B - Itraconazole 200 mg|Oral itraconazole 200 mg as 100 mg twice daily, for up to 3 months
62467925|NCT01108094|NO_INTERVENTION|Untreated Control|Patients otherwise eligible but unwilling to take itraconazole were enrolled onto the control arm of the study and received no treatment
62467926|NCT00538421|ACTIVE_COMPARATOR|1|
62467927|NCT00538421|ACTIVE_COMPARATOR|2|
62467928|NCT04138147|ACTIVE_COMPARATOR|Superficial cervical plexus with auriculotemporal nerve blocks|
62467929|NCT04138147|EXPERIMENTAL|Cervical retrolaminar with auriculotemporal nerve blocks|
62664072|NCT01837303||Liquid based cytology|All participants will undergo both manual and conventional automated liquid based cytology (pap smear, cervical cytology).
62664073|NCT03436927|EXPERIMENTAL|Nintendo Wii Fit|Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
62664074|NCT03436927|EXPERIMENTAL|Balance Trainer|Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
62664075|NCT03436927|NO_INTERVENTION|Control|Patients in the 'Group III-control group' were included in the waiting list until the end of the study.
62664076|NCT03257397|EXPERIMENTAL|left iTBS and right cTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC
62664077|NCT03257397|ACTIVE_COMPARATOR|left and right iTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)
62102882|NCT02387346|EXPERIMENTAL|Real Stimulation|Participants in this group will receive Repetitive Transcranial Magnetic Stimulation, characterized by 900 pulses at 1Hz over the medial cerebellum at 120% resting motor threshold of the right first dorsal interosseous.
62102883|NCT02387346|SHAM_COMPARATOR|Sham Stimulation|Participants will receive Sham Repetitive Transcranial Magnetic Stimulation by having the coil angled at 90 degrees to the scalp; this will allow adequate noise output from the stimulator in the absence on real magnetic stimulation.
62102884|NCT06714500|EXPERIMENTAL|Intervention|
62664078|NCT02249780|EXPERIMENTAL|New treatment|In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
62664079|NCT02249780|ACTIVE_COMPARATOR|Standart treatment|In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.
62664080|NCT01761344|EXPERIMENTAL|Intraoperative measurement of cortisol|Intervention: During a routine procedure intraoperative cortisol is measured. Upon unsuccessful sampling, the sampling will be repeated.
62102885|NCT05653089|EXPERIMENTAL|All patients meeting the study eligibility criteria|
62102886|NCT02028884|EXPERIMENTAL|Satralizumab + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
62467930|NCT01587209||Divers with decompression sickness|The sole group under study is SCUBA divers who have sustained decompression sickness
62467931|NCT04898361|ACTIVE_COMPARATOR|PFO closure|Patients with embolic stroke of undetermined source (ESUS) with patent foramen ovale (PFO) eligible for interventional PFO occlusion receiving a structured electrophysiological study due to palpitations before the PFO closure. Extensive cardiac monitoring.
62467932|NCT04898361|NO_INTERVENTION|NO PFO|Patients with embolic stroke of undetermined source (ESUS) with NO patent foramen ovale (PFO) receiving a structured electrophysiological study due to palpitations. Extensive cardiac monitoring.
62467933|NCT06242119||J-PET group|The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the brain or the entire body.
62664081|NCT02487121|EXPERIMENTAL|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
62664082|NCT02487121|ACTIVE_COMPARATOR|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
62664083|NCT04136678|EXPERIMENTAL|treadmill back walking training|15 minutes conventional walking training, 15 minutes of treadmill back walking training, 15-minute treadmill forward walking training
62664084|NCT01228045|EXPERIMENTAL|Trastuzumab in Combination with TS-ONE and cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
62664085|NCT02315625|EXPERIMENTAL|1/ Arm 1 Sunitinib|Sunitinib
62664086|NCT02315625|EXPERIMENTAL|2/ Arm 2 Everolimus|Everolimus
62664087|NCT01484002||Crosslinked polyethylene liners|Polyethylene liners from joint replacements that were crosslinked and heat treated to eliminate free radicals.
62664088|NCT01484002||Conventional polyethylene liners|Polyethylene liners from joint replacements that manufactured from conventional UHMWPE and terminally sterilized by methods that did not involve gamma-irradiation.
62664089|NCT03994159|EXPERIMENTAL|PARO emotional robot|"Quasi-experimental before after study of the impact of the PARO robot on team dynamics among caregivers in geriatric wards caring for patients with dementia.~Pre intervention period: no PARO robot. Post-intervention period: with the PARO robot."
62664090|NCT02460003|EXPERIMENTAL|Physiotherapy program|Physiotherapy program and usual drugs
62664091|NCT02460003|ACTIVE_COMPARATOR|Home exercise program|Home exercise program and usual drugs
62664092|NCT04486144|EXPERIMENTAL|COVID19 Positive: Intervention Group (Receive extract)|These are patients that are COVID19 positive who elect to try the extract.
62664093|NCT04486144|NO_INTERVENTION|COVID19 Positive: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 positive who do NOT elect to try the extract
62664094|NCT04486144|EXPERIMENTAL|COVID19 Exposed: Intervention Group (Receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to try the extract.
62664095|NCT04486144|NO_INTERVENTION|COVID19 Exposed: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to NOT try the extract.
62664096|NCT00766818|EXPERIMENTAL|1|Kaletra
62467934|NCT05468021|NO_INTERVENTION|Comparison control|The control condition will consist of standard of care. The participants in the control arm will not receive the educational intervention after assessment.
62664097|NCT04926545|EXPERIMENTAL|Irinotecan naive cohort|"This cohort will enroll 6 postmenopausal female patients who have never received irinotecan treatment before. Patients in irinotecan naive cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 4 rounds of pharmacokinetic studies will be conducted.~Round 0 (before chemotherapy): pharmacokinetic testing (raloxifene 60mg as probe) before XCHT administration, then XCHT for 4 days with pharmacokinetic testing (raloxifene 60mg as probe) on the 4th day of XCHT administration.~Round 1(1st cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (without raloxifene) on day 4.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
62664098|NCT04926545|EXPERIMENTAL|Irinotecan used cohort|"This cohort will recruit 18 patients who were treated with irinotecan previously and have at least one diarrhea episode with a severity of more than grade 2. Patients in irinotecan used cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 3 rounds of pharmacokinetic studies will be conducted.~Round 1(1st cycle of chemotherapy): FOLFIRI, with pharmacokinetic testing (raloxifene 60mg as probe) on the first day of chemotherapy.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 4.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
62102887|NCT02028884|PLACEBO_COMPARATOR|Placebo + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
62664099|NCT03021915|OTHER|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
62664100|NCT00009893|EXPERIMENTAL|gemcitabine + leucovorin + fluorouracil|Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
62664101|NCT04227600|EXPERIMENTAL|Part1 JR-171|Drug: JR-171 IV infusion, dose escalation
62102888|NCT06629714||Cohort 1: Treatment-naïve, inoperable GC patients receiving first-line ICIs|For treatment-naïve, inoperable Esophageal Cancer or Gastric Cancer or Gastroesophageal junction (GEJ) Cancer patients who have received immune checkpoint inhibitors as first-line therapy.
62102889|NCT06629714||Cohort 2: Treatment-naïve, inoperable NSCLC patients receiving first-line ICIs.|For treatment-naïve, inoperable Non-Small-Cell Lung Cancer patients who have received immune checkpoint inhibitors as first-line therapy.
62102890|NCT02299921||Adult ICU patients with respiratory problem|Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs.
62102891|NCT02299921||Intubated Adult ICU patients with respiratory failure|A subset of subjects, adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation.
62664102|NCT04227600|EXPERIMENTAL|Part2 JR-171|Drug: JR-171 IV infusion, dose escalation, low dose, high dose
62664103|NCT02520466|ACTIVE_COMPARATOR|flavanol-containing drink|flavanol-containing drink
62664104|NCT02520466|PLACEBO_COMPARATOR|flavanol-free drink|flavanol-free drink matched for taste and calories
62664105|NCT01430884||Aspirate Blood|
62664106|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
62664107|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
62664108|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
62664109|NCT04779723|ACTIVE_COMPARATOR|LRYGB Procedure|LRYGB technique was performed by placing 4 to 6 trocars, a 150 cm ante-colic Roux-limb gastric pouch (30 to 50 ml) was created with linear stapled or circular stapled gastro-jejunostomy, a 50-cm long biliopancreatic limb was chosen. A passive drainage was kept near to the gastro-jejunostomy.
62664110|NCT04779723|ACTIVE_COMPARATOR|LSG Procedure|35 Fr bougie was used for the calibration of a gastric tube. 3 to 6 cm of longitudinal incision of the stomach was done at pylorus to the angle of His. Using of absorbable suture, the staple line was sewn.
62102892|NCT02537392|EXPERIMENTAL|Vitamin B Complex and Folic Acid|Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
62102893|NCT02537392|EXPERIMENTAL|Iron and Folic Acid|Daily supplements of iron (60 mg) and folic acid (0.4 mg).
62102894|NCT02537392|ACTIVE_COMPARATOR|Folic Acid|Daily supplement of 0.4 mg folic acid.
62664111|NCT01575990|EXPERIMENTAL|Making A Decision About CRC Screening|A decision support intervention that is a literacy sensitive paper based tool with educational information targeted to the patient's age and gender.
62664112|NCT01575990|PLACEBO_COMPARATOR|Drivers 65 Plus|The placebo comparator is an attention control with information about driving tips for drivers age 65 and older.
62664113|NCT03884426||Patients with MVP|The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.
62664114|NCT03884426||Normal relatives|Related healthy patients, for an average of 6 individuals per family
62102895|NCT02828605|NO_INTERVENTION|Control Group|Only receive surveys.
62664115|NCT02328729||Mandibular block with Epinephrine|Lidocaine 2% with 1:100,000 Epinephrine
62102896|NCT02828605|EXPERIMENTAL|Experimental Group|Receive VIP Transplant App and surveys.
62664116|NCT02328729||C-CLAD-IL with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
62664117|NCT02328729||Infiltration with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
62102897|NCT02697799|EXPERIMENTAL|High-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a high-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
62295988|NCT05230147|SHAM_COMPARATOR|Sham stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. No stimulation is initiated. Two minutes after, verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
62295989|NCT05669521|EXPERIMENTAL|TK112690|TK112690 treatment
62295990|NCT05669521|PLACEBO_COMPARATOR|Placebo|TK112690 formulation
62467935|NCT05468021|EXPERIMENTAL|Intervention condition|The participants in the intervention arm will receive the educational intervention after assessment.
62664118|NCT02328729||Mandibular block without Epinephrine|Mepivacain HCl 3% without Epinephrine
62664119|NCT02328729||Infiltration without Epinephrine|Mepivacain 3% without Epinephrine
62664120|NCT02328729||CCLAD-IL without Epinephrine|Mepivacain HCl 3% without Epinephrine
62664121|NCT04519398||COVID-19 patients with proved venous thrombosis|"1st group includes COVID-19 patients with proved~* venous thrombosis (deep vein thrombosis, pulmonary embolism or venous thrombosis occurring in more atypical places such as in the veins of the brain, liver, kidney, mesenteric vein and the veins of the arms)~* or arterial thrombosis (heart attacks, strokes)"
62664122|NCT04519398||Asymptomatic COVID-19 & those with mild or moderate disease|2nd group encompasses asymptomatic patients and those with mild or moderate disease, according to current guidelines, without thrombosis: no symptoms or evidence of lower respiratory disease by clinical assessment or imaging and a SpO2 \> 94%
62664123|NCT04519398||Severe disease, according to Guidelines, without thrombus|3rd group includes severe disease, according to current guidelines, without thrombosis: respiratory frequency \> 30 breaths per minute, SpO2 \< 94%, PaO2/FiO2 \< 300 mmHg, or lung infiltrates \>50%
62664124|NCT01377506|EXPERIMENTAL|Lifestyle counseling|Diabetes Prevention Program Lifestyle Balance Intervention delivered by lay health educator
62664125|NCT01377506|ACTIVE_COMPARATOR|Cognitive Training|Adaptation of SeniorWise Memory Training program for delivery by lay health educator, matched in duration and contact to the other study arm
62664126|NCT03491917||DBT plus S-View|Breast images utilizing DBT plus S-View
62664127|NCT03491917||FFDM alone|Breast images using FFDM alone only
62664128|NCT03171870|OTHER|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
62664129|NCT01060176|EXPERIMENTAL|High dosage|Tranexamic acid with a loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h
62664130|NCT01060176|EXPERIMENTAL|Medium dosage|Tranexamic acid with a loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h
62664131|NCT01060176|EXPERIMENTAL|Low dosage|Tranexamic acid with a loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h
61911928|NCT04740905|ACTIVE_COMPARATOR|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
61911929|NCT02836509|EXPERIMENTAL|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
62102898|NCT02697799|EXPERIMENTAL|Mid-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a mid-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
62664132|NCT01060176|PLACEBO_COMPARATOR|Control|Saline solution
62664133|NCT01402700|EXPERIMENTAL|Visi-Pro™ Balloon Expandable Stent System|The objective of the study is to confirm the safety and effectiveness of the Visi-Pro stent in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
62664134|NCT04558242|ACTIVE_COMPARATOR|Genix LLLT Therapeutic Cap|This is a low-level light device containing 150, 650 nanometer LEDs and 50, 940 nanometer LEDs of equal energy output, fixed at 10 milliwatts in a low profile helmet.
62664135|NCT04558242|SHAM_COMPARATOR|Sham Non-therapeutic Placebo Cap|Sham Placebo Cap low profile helmet containing no low-level light.
62664136|NCT03380572|EXPERIMENTAL|Senhance Cholecystectomy|Cholecystectomy operation performed using Senhance robotic system
62664137|NCT03380572|ACTIVE_COMPARATOR|Laparoscopic Cholecystectomy|Cholecystectomy operation performed using standard laparoscopic instruments
62664138|NCT05309005||ABI group|The patient group consists of 100 patients with acquired brain injury (e.g. cerebrovascular incidents, anoxia, encephalitis and non-progressive brain tumors)
62664139|NCT05309005||Healthy control group|100 healthy adults will be matched to the patients with respect to age, gender and education.
62664140|NCT03982953||PD patients with STN-DBS|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that are planned to undergo craniectomy with implantation of bilateral DBS electrodes in the subthalamic nucleus
62664141|NCT03982953||Controls - PD patients with medical treatment|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that do not undergo DBS for personal reasons or contraindications for this treatment. Age, sex and disease-severity matched with PD patients with STN-DBS.
62664142|NCT03353051||Group A: other - observational study|neonates ≥2000-\<2500g and born with a gestation age \<37 weeks.
62664143|NCT03353051||Group B: other- observational study|Group B will contain neonates \>2500g and born with a gestation age \<37 weeks.
62664144|NCT03353051||Group C: other - observational study|Group C will contain neonates ≥2000-\<2500g but with a gestation age \>37 weeks.
61911930|NCT02836509|EXPERIMENTAL|Ibuprofen group|Second Group: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
62664145|NCT03353051||Group D1:other - observational study|Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
62664146|NCT03353051||Group D2: other - observational study|Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs
62664147|NCT03353051||Group D3: other - observational study|Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
62664148|NCT02508064|EXPERIMENTAL|Part 1|BMS-663068 1 × 600 mg extended-release (ER) tablet formulation
62664149|NCT02508064|EXPERIMENTAL|Part 1: Prototype 1|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)
62664150|NCT02508064|EXPERIMENTAL|Part 1: Prototype 2|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)
62664151|NCT02508064|EXPERIMENTAL|Part 1: Prototype 3|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)
62664152|NCT02508064|EXPERIMENTAL|Part 1: Prototype 4|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)
62102899|NCT02697799|NO_INTERVENTION|No modified recruitment strategy|Subjects in this group will receive consent form without a modified recruitment strategy for research participation in the parent study.
62102900|NCT02148406|EXPERIMENTAL|Arm I (YST intervention)|Patients undergo YST intervention comprising four individualized, 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation during outpatient chemotherapy sessions in weeks 2, 4, 6, and 8. Patients practice awareness - noticing the current state and establishing relaxed breathing for 5 minutes; movement - 7 minutes of gentle movements coordinated with the breath (such as raising and lowering the arms); breathing practice - 3 minutes of inhaling cool air as if through a straw; and meditation - 5 minutes of focus on letting go of physical and mental tension. Patients review a handout describing the YST and to encourage patients to practice daily with strategies to increase adherence to home practice. Patients also receive an audio recording of the YST and devices to play the recording and are asked to keep a home practice log.
62102901|NCT02148406|ACTIVE_COMPARATOR|Arm II (attention control)|Patients attend four 30-minute sessions with an interventionist in weeks 2, 4, 6, and 8. During these sessions, patients are encouraged to discuss their experiences while receiving chemotherapy and do not receive instruction of movement, meditation or breathing practices. Patients will also be asked to write brief diary entries daily at home.
62102902|NCT05439655|EXPERIMENTAL|Epilepsy|patients with drug resistant epilepsy undergoing a surgical evaluation in the epilepsy monitoring unit
62102903|NCT01560143|OTHER|Tigecycline|All subjects receive a single dose of tigecycline
62102904|NCT00486733|NO_INTERVENTION|Standard of Care|Standard of Care Treatment; no study treatment
62102905|NCT00486733|EXPERIMENTAL|Standard of Care plus Study Treatment|Standard of Care Treatment plus study treatment
62102906|NCT00609648|EXPERIMENTAL|CARL|CARL computer program
62102907|NCT00609648|ACTIVE_COMPARATOR|Pamphlet|Reassuring pamphlet about dental injections
62102908|NCT06628466||Patients of either sex between the ages 18 and 70 years, suffering from Chronic neck pain|Each patient will begin with the start of physical therapy with Nuberol Forte for the symptomatic management of the chronic neck pain. Subjects will be observed for overall safety and effectiveness of study drug from visit 1 (baseline visit, screening and start of treatment), to visit 2 (Week 1-2, end of treatment) in the routine practice.
62102909|NCT02324114|EXPERIMENTAL|Rectal cancer|Detect plasma Hsp90α concentration of patients,
62102910|NCT01436409|OTHER|only vaginal touch|
62102911|NCT01436409|EXPERIMENTAL|vaginal touch +echography|
62102912|NCT00323089|EXPERIMENTAL|Surgical Arm|Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)
62102913|NCT00722748||Genebank|By creating a genebank from patient's blood donations we will ultimately be able to define genes for various cardiovascular conditions.
62102914|NCT05665855|EXPERIMENTAL|Ketone higher dose|An acute bout of exercise performed after the ingestion of a commercial supplement intended to provide \~0.6 g of ketone monoester per kg body mass of the participant.
62102915|NCT05665855|EXPERIMENTAL|Ketone lower dose|An acute bout of exercise performed after the ingestion of a commercial supplement intended to provide \~0.3 g of ketone monoester per kg body mass of the participant.
62102916|NCT05665855|PLACEBO_COMPARATOR|Control|An acute bout of exercise performed after the ingestion of a taste-matched placebo supplement.
62467936|NCT04986878|ACTIVE_COMPARATOR|Single shot adductor canal block|Following sterile preparation and draping, an ultrasound survey of the medial thigh was performed, halfway between the superior anterior iliac spine and the patella. The superficial femoral artery has been identified beneath the sartorius muscle in a short-axis view, with the vein just inferior and the saphenous nerve just lateral to the artery. A 20 Gauge, 120 mm, non-cuttings tip echogenic needle (SonoPlex STIM, Germany) needle was introduced in-plane, and 2 to 3 mL of LA bolus (0.25 % Bupivacaine) was used to confirm proper needle placement in the adductor canal near the saphenous nerve. Then, a bolus of 20 ml of Bupivacaine 0.25 % was injected through the needle
62467937|NCT04986878|ACTIVE_COMPARATOR|Continuous adductor canal block|a catheter was secured in place using Tegaderm. The catheters were connected to a pump that infused local anesthetic, 20 mL of 0.25 % bupivacaine, followed by 48 hours of continuous infusion of 0.125 % bupivacaine at 5 mL/h.
62467938|NCT00616408||A|Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR
62467939|NCT03919370||Cerebral ischemia|Patients undergoing planned surgery for carotid stenosis
62467940|NCT03919370||Reperfusion|Patients undergoing cerebral trombectomy.
61911931|NCT04062500||Patients with heart failure|patients treated in the hospital for acute heart failure in China
61911932|NCT00274924|EXPERIMENTAL|Group I (PET negative)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
62102917|NCT04465071|NO_INTERVENTION|Standard Treatment|Post-Cataract surgery standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
62467941|NCT03919370||Anaesthesia and surgery|Patients without preexisting cerebral injury undergoing abdominal surgery and anaesthesia
62467942|NCT05920343|EXPERIMENTAL|Rivaroxaban|Participants receiving study drug (Rivaroxaban)
62467943|NCT05920343|PLACEBO_COMPARATOR|Control|Participants receiving matched placebo
62664153|NCT02508064|EXPERIMENTAL|Part 1: Prototype 5|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)
62664154|NCT02508064|EXPERIMENTAL|Part 2|BMS-663068 1 × 600 mg ER tablet formulation
62664155|NCT02508064|EXPERIMENTAL|Part 2: Prototype 1|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)
62102918|NCT04465071|OTHER|Standard Treatment plus lubricating drops|Lubricant eye-drops (0.3% cross linked sodium hyaluronate, AEONTM Protect Plus and phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vita-mins A and E (AEONTM Repair) for 6 weeks post-Cataract surgery, in addition to the standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
62102919|NCT03032796|EXPERIMENTAL|BBT|Body-Brain Trainer
62102920|NCT03032796|ACTIVE_COMPARATOR|Body Trainer|Participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present, while completing all of the physical aspects of BBT. Thus this will be a physical training protocol.
62102921|NCT03032796|ACTIVE_COMPARATOR|Brain Trainer|"The Brain Trainer group will train using the same platform as the BBT group, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects)."
62102922|NCT03032796|PLACEBO_COMPARATOR|Expectancy Matched Control Group|The placebo-matched control group will engage in a battery of three apps in the laboratory that we believe will have no significant impact on cognition
62102923|NCT05541237|NO_INTERVENTION|Health|
62102924|NCT05541237|EXPERIMENTAL|Disease|
62102925|NCT06492577|ACTIVE_COMPARATOR|Pulmonary rehabilitation group|Participants in this arm will undergo a structured 21-day pulmonary rehabilitation (PR) program designed to improve lung function, exercise capacity, and overall physical health, conducted according to the American Thoracic Society (ATS) guidelines. The program includes aerobic exercises performed five days per week at moderate intensity (4-6 on the Borg RPE scale) for 30-45 minutes per session, including warm-up and cool-down periods. Strength training will be conducted three days per week on non-consecutive days, starting at 50% of the one-repetition maximum (1RM) and progressively increasing to 70% as tolerated, with each session lasting 20-30 minutes and including 2-3 sets of 8-12 repetitions for major muscle groups. Daily breathing exercises focusing on controlled techniques such as diaphragmatic and pursed-lip breathing will be performed for 10-15 minutes per session.
62102926|NCT06492577|EXPERIMENTAL|Progressive muscle relaxation group|Participants in this group will receive additional progressive muscle relaxation techniques designed to reduce anxiety and improve sleep quality in patients with long-term COVID-19 symptoms. Each PMR session will last for 20 minutes and will involve systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing.
62102927|NCT00540813|EXPERIMENTAL|Drug Eluting Balloon|
62102928|NCT02266810|EXPERIMENTAL|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
62102929|NCT02266810|ACTIVE_COMPARATOR|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
62295991|NCT03885297||Overweight/obese participants|Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan. Patients will additionally receive standard NHS Tier 3 lifestyle advice and support for the duration of the study. Lifestyle modification aimed at weight loss will be delivered by a dietician or other trained health care professional within individual sessions for a period of 6 months. Finally, all patients will be able to withdraw from treatment and/or the study at any point without giving any explanation. This will have no impact in their clinical management.
62467944|NCT02676024|NO_INTERVENTION|Control|Resuscitation teams will participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR without being provided cognitive aids. Participants in this group will be allowed to use any cognitive aid that they happen to keep with them and would normally use in their practice, for example, flash cards or smart phone apps.
62102930|NCT02266810|EXPERIMENTAL|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
62102931|NCT02266810|ACTIVE_COMPARATOR|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
62102932|NCT05068037|ACTIVE_COMPARATOR|STANDARD|"TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Patients will receive an antiemetic (ondansetron 4 mg). The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g.~PACU:~Analgesia in VAS\> 3: piritramide 3 mg p.p. Antiemetic for POSB: metoclopramide 10 mg"
62102933|NCT05068037|ACTIVE_COMPARATOR|CONTROL|"TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Group does not receive neither acupuncture nor antiemetics. The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g.~PACU:~Analgesia in VAS\> 3: piritramide 3 mg p.p. Antiemetic for POSB: ondansetron 4 mg."
62295992|NCT03284190||ASDH Copenhagen, Denmark|
62467945|NCT02676024|EXPERIMENTAL|Knowledge-based cognitive aid|"Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. However, they will be trained in using a knowledge-based cognitive aid, which will be used by a dedicated team member (the cognitive aid reader)."
62467946|NCT02676024|EXPERIMENTAL|Cognitive aids with roles defined (CARD)|Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. Participants will be trained to use the cognitive aids with roles defined (CARD) system. However, they will not be given knowledge-based cognitive aids and there will be no dedicated cognitive aid reader in the team.
62467947|NCT02676024|EXPERIMENTAL|Integrated cognitive aids|Participants will be trained to use the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid, which will be used by a dedicated cognitive aid reader.
62664156|NCT02508064|EXPERIMENTAL|Part 2: Prototype 2|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)
62295993|NCT03284190||ASDH Odense, Denmark|
62295994|NCT03284190||ASDH Århus, Denmark|
62295995|NCT03284190||ASDH Ålborg, Denmark|
62295996|NCT03284190||ASDH Lund, Sweden|
62295997|NCT03284190||ASDH Linköping, Sweden|
62664157|NCT02508064|EXPERIMENTAL|Part 2: Prototype 3|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)
62664158|NCT02508064|EXPERIMENTAL|Part 2: Prototype 4|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)
62102934|NCT05068037|ACTIVE_COMPARATOR|STUDY|"Before surgery, one of the team members will talk to the patient and perform brief medical hypnosis to gain the patient's confidence in the method and teach him the method of relaxing and building an imaginary safe place where he feels comfortable and safe. Therapeutic communication through hypnosis will be used as an additional method in order to improve the well-being and comfort of the patient, reduce stress and use sedatives.~TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Patients will receive acupuncture (PC6 and LI4 bilaterally) and no antiemetic The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g. Removal of acupuncture needles at the end of operation~PACU:~Analgesia in VAS\> 3: piritramide 3 mg p.p. Antiemetic for POSB: ondansetron 4 mg"
62467948|NCT00424047|EXPERIMENTAL|CC-5013 plus dexamethasone|Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
61911933|NCT00274924|EXPERIMENTAL|Group II (PET positive)|Patients receive R-ICE comprising rituximab IV on day 1, ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day 2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously once daily starting on day 4 and continuing until blood counts recover. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62102935|NCT06282835||Eravacyline combination|
62295998|NCT03284190||ASDH Gothenburg, Sweden|
62467949|NCT00424047|EXPERIMENTAL|Dexamethasone plus placebo|Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
62467950|NCT05769725|EXPERIMENTAL|Serplulimab in Combination With Docetaxel +S-1|
62467951|NCT05769725|PLACEBO_COMPARATOR|Docetaxel +S-1|
62467952|NCT01616225|ACTIVE_COMPARATOR|No Growth Hormone Supplementation|
62467953|NCT01616225|EXPERIMENTAL|Luteal Growth Hormone Start|Growth hormone starting in the luteal phase of the previous menstrual cycle.
62467954|NCT01616225|EXPERIMENTAL|Follicular Growth Hormone Start|Starting growth hormone during the follicular phase of the prior menstrual cycle.
62467955|NCT00717405|EXPERIMENTAL|1|
62467956|NCT06231784|OTHER|Lumina Implantation|Patients implanted with LUMINA IOL
62467957|NCT02815527||Fresubin Intensive|Adult critically ill non-septic ventilated patients admitted to the intensive care unit with an expected intensive care stay of four days or more.
62664159|NCT04811547||Ankle-Brachial Index value|Valid participants were separated into 0-0.60, 0.61-0.90, 0.91-0.99, and 1.00-1.40 four ABI subgroups.
62664160|NCT03697746|ACTIVE_COMPARATOR|Paracetamol|1000 mg Paracetamol vial intravenously
62664161|NCT03697746|ACTIVE_COMPARATOR|Dexketoprofen Trometamol|50 mg Dexketoprofen Trometamol vial intravenously
62664162|NCT03697746|ACTIVE_COMPARATOR|Ibuprofen|400 mg Ibuprofen vial intravenously
62664163|NCT01379209|EXPERIMENTAL|RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Dose escalation cohort 1 in part 1 of this study will include 2-6 patients"
62664164|NCT01379209|EXPERIMENTAL|RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 2 in part 1 of this study will include 2-6 patients"
61911934|NCT01268579|EXPERIMENTAL|ribavirin|This will be a single institution non-randomized study for patients with tonsil and/or base of tongue squamous cell cancer. This is a pilot study to obtain pharmacodynamic data regarding the effects of ribavirin on tonsil squamous cell cancer.
61911935|NCT05853731|EXPERIMENTAL|Green light therapy group|Subjects in the intensive care unit (ICU) setting after cardiac surgery will have green light therapy via green light emitting diode (GLED) for the duration of the ICU stay or up to 1 week.
61911936|NCT05853731|PLACEBO_COMPARATOR|Placebo Group|Subjects in the intensive care unit (ICU) setting after cardiac surgery will have filtered white light emitting diodes (WLED) as a placebo for the duration of the ICU stay or up to 1 week.
62102936|NCT05014204|EXPERIMENTAL|Interventional|All eligible patients will receive the endoscopic Endogenex procedure.
62102937|NCT05683301|EXPERIMENTAL|Arm 1|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Amlodipine 5 mg and Perindopril 4 mg once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Amlodipine 10 mg and Perindopril 8 mg once daily, orally
62295999|NCT03284190||ASDH Stockholm, Sweden|
62296000|NCT03284190||ASDH Uppsala, Sweden|
62296001|NCT03284190||ASDH Umeå, Sweden|
62296002|NCT06217250|ACTIVE_COMPARATOR|Conventional EMR|Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.
62296003|NCT06217250|EXPERIMENTAL|Underwater Cold EMR|Underwater Cold EMR (CS-EMR): after filling the lumen with water, initial submucosal injection of saline and methylene blue and subsequent piece-meal resection carried out with dedicated cold snare.
62308231|NCT01663129||Nephrotic Syndrome Patient Group|"Nephrotic syndrome will be classified according to the following categories:~Idiopathic nephrotic syndrome, without renal biopsy histology, presumed minimal change disease (MCD), Focal segmental glomerulosclerosis (FSGS), confirmed on biopsy, Minimal change disease, confirmed on biopsy Nephrotic syndrome with Henoch-Schonlein Purpura (HSP)."
62308232|NCT02533622||Standard of care|Patients admitted to the ICU will receive current standard of care related to mobility
62308233|NCT02533622||Progressive mobility|patients admitted to the ICU will receive mobility per Progressive Mobility protocol using TotalCare beds and lifts
62664165|NCT01379209|EXPERIMENTAL|RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 3 in part 1 of this study will include 2-6 patients"
62102938|NCT05683301|EXPERIMENTAL|Arm 2|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Perindopril 4 mg and Indapamide 1.25 mg once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Perindopril 8 mg and Indapamide 2.5 mg once daily, orally
62102939|NCT05683301|EXPERIMENTAL|Arm 3|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Amlodipine 5 mg and Indapamide 1.5 mg sustained release once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Amlodipine 10 mg and Indapamide 1.5 mg sustained release once daily, orally
62102940|NCT02000505|NO_INTERVENTION|Control|5 minutes chest-compression-only CPR, without any support
62308234|NCT02911987|EXPERIMENTAL|the 'cardio' HIT group|Group 1 receives HIT exercise, aimed only at improving cardiovascular endurance (the 'cardio' HIT group).
62308235|NCT02911987|EXPERIMENTAL|the 'general' HIT group|Group 2 receives HIT exercise aimed at improving both cardiovascular and general muscle condition (the 'general' HIT group ).
62664166|NCT01379209|EXPERIMENTAL|RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 4 in part 1 of this study will include 2-6 patients"
62664167|NCT01379209|EXPERIMENTAL|RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 5 in part 1 of this study will include 2-6 patients"
62664168|NCT01379209|EXPERIMENTAL|RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 6 in part 1 of this study will include 2-6 patients"
62664169|NCT01379209|EXPERIMENTAL|RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 7 in part 1 of this study will include 2-6 patients (optional)"
61911937|NCT03469869|EXPERIMENTAL|balanced and sustainable diet|The intervention group will receive menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the control group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
61911938|NCT03469869|ACTIVE_COMPARATOR|balanced diet|the intervention group receive get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
61911939|NCT05583513||Ambulatory Heart Failure|
61911940|NCT00743236|EXPERIMENTAL|Arm I|Patients undergo warm ischemia followed by partial nephrectomy.
61911941|NCT00743236|EXPERIMENTAL|Arm II|Patients undergo cold ischemia followed by partial nephrectomy.
61911942|NCT01710410|EXPERIMENTAL|DLPFC tDCS (left anode/right cathode)|Active transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
61911943|NCT01710410|EXPERIMENTAL|DLPFC tDCS (left cathode/right anode)|Active transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
61911944|NCT01710410|SHAM_COMPARATOR|DLPFC tDCS|Sham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
61911945|NCT01568528|EXPERIMENTAL|Oxytocin|The intranasal oxytocin intervention will be the administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. Each puff is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
61911946|NCT01568528|PLACEBO_COMPARATOR|Placebo|"Intranasal placebo The PBO/control will consist of the OT vehicle administered as three puffs in each nostril. Each puff is is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally.~Treatment assignment will be by random allocation in blocks of six. Both experimenters and subjects will be blind to the treatment they are receiving."
61911947|NCT01568528|OTHER|Healthy Controls|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will not receive oxytocin or placebo. They will only receive psychiatric screening interview, MATRICS Consensus Cognitive Battery (MCCB) assessment, urine drug screen, vision testing, and the three social cognition tasks.
62102941|NCT02000505|EXPERIMENTAL|PocketCPR|5 minutes chest-compression-only CPR, with support
62102942|NCT02000505|EXPERIMENTAL|Metronome|5 minutes chest-compression-only CPR, with support
62102943|NCT02000505|EXPERIMENTAL|110bpm Song|5 minutes chest-compression-only CPR, with support
62102944|NCT06192576||Olipudase alfa arm|
62102945|NCT04442672|EXPERIMENTAL|compartment syndrome model group(CSM group)|
62102946|NCT04442672|SHAM_COMPARATOR|sham group|
62308236|NCT02911987|EXPERIMENTAL|the 'lumbar' HIT group|Group 3 receives HIT exercise, aimed at improving both cardiovascular condition and specific trunk muscle condition (the 'lumbar' HIT group).
62664170|NCT01379209|EXPERIMENTAL|RGI-2001 + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons."
62102947|NCT05521867|ACTIVE_COMPARATOR|Endoscopic balloon dilation|Confirmed Crohn's disease with gastro-duodenal or ileo-colonic short (\<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy
62102948|NCT05521867|ACTIVE_COMPARATOR|Endoscopic stricturotomy with or without stricturoplasty|Confirmed Crohn's disease with gastro-duodenal or ileo-colonic short (\<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy
62102949|NCT03877796||Ovarian cancer patients|with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
62467958|NCT04854330|ACTIVE_COMPARATOR|Ketone ester|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml. Immediately following ingestion of the ketones, participants will be given 20 ml of calorie-free sparkling spring water (The Holywell Water Company Ltd, UK) in an attempt to remove any remaining flavour of the supplement.
62467959|NCT04854330|PLACEBO_COMPARATOR|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
62467960|NCT03957239|EXPERIMENTAL|Cranberry Beverage|Four prepackaged juice boxes (4.23 oz each) containing a whole milled cranberry beverage for 2 weeks
62467961|NCT03957239|PLACEBO_COMPARATOR|Placebo Group|Four prepackaged juice boxes (4.23 oz each) containing a cranberry-flavored beverage for 2 weeks
62467962|NCT06326762||Myocardial Dysfunction|
62467963|NCT06326762||No Myocardial Dysfunction|
62467964|NCT02301910|EXPERIMENTAL|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
62467965|NCT02301910|ACTIVE_COMPARATOR|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~* 55 to \<60 30 mg 6 ml~* 60 to \<70 35 mg 7 ml~* 70 to \<80 40 mg 8 ml~* 80 to \<90 45 mg 9 ml~* 90 50 mg 10 ml"
62467966|NCT02331394|EXPERIMENTAL|Chinese herbs formula: Shu Yu Wan|All participants will be offered the choice of taking the CH formula in capsules or sachets in addition to standard care. This study will use the Shu Yu Wan formula which comprises 23 different herbs and is based on the best evidence in the literature of use of CH in lung cancer.
62467967|NCT04060147|EXPERIMENTAL|Cilofexor|Participants will receive escalating doses of cilofexor 30 mg, 60 mg, and 100 mg.
62467968|NCT04709926||Paramedics that were eligible to take part in the PRESTO study|Paramedics that are employed by one of the four Ambulance Services involved in the PRESTO study and were eligible to complete the training provided by Manchester University NHS Foundation Trust to take part in the PRESTO study.
62467969|NCT04270448|ACTIVE_COMPARATOR|Control|Practice of a joystick based motor sequence task. Participants receive feedback that they have completed the practice trials in that block of practice.
62467970|NCT04270448|EXPERIMENTAL|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
62467971|NCT04270448|EXPERIMENTAL|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
62467972|NCT02630121|PLACEBO_COMPARATOR|Placebo/Fluticasone Propionate|Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
61911948|NCT03026101|EXPERIMENTAL|Migraine Intervention|Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain
62102950|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
62102951|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
62102952|NCT02434393||Late Life Depression|120 participants who meet the criteria for Major Depression or Late Life Depression (LLD)
62102953|NCT06631261||Bronchiectasis|Individuals with bronchiectasis
62467973|NCT02630121|ACTIVE_COMPARATOR|Oxymetazoline Hydrochloride /Fluticasone Propionate|Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
62467974|NCT04543760|OTHER|[PP sequence 1] - Wash-out - [SP sequence 2]|
62467975|NCT04543760|OTHER|[SP sequence 1] - Wash-out - [PP sequence 2]|
62664171|NCT02733328||AKI Patients|Patients with AKI
62467976|NCT05207280|EXPERIMENTAL|Noradrenaline plus Terlipressin|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours. Solution for infusion (Intravenous). And: Terlipressin with dose 1 mg every 6 hours diluted in a 50 mL serum to pass in 15-30 minutesin injectable solution. Intravenous (diluted in a 50 mL serum to pass in 15-30 minutes)
62467977|NCT05207280|PLACEBO_COMPARATOR|Noradrenaline plus placebo|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours in solution for infusion (Intravenous), and placebo with solution in vial with the same external appearance as terlipressin. 1 mg every 6 hours, diluted in a 50 mL serum to pass in 15-30 minutes in injectable solution Route of administration: Intravenous, diluted in a 50 mL serum to pass in 15-30 minutes
61911949|NCT01997242||stenting undergoing surgery|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic procedures
62296004|NCT05395221|EXPERIMENTAL|Virtual Reality Assisted Meditation+ no intervention Group|The first cohort will undergo weekly virtual reality guided meditations across a three-month rotation using the Guided Mediation Virtual Reality App available on the Oculus Quest 2 Virtual Reality system (Oculus, Menlo Park, CA). After completion of the three-month time span, residents will receive no intervention during the second three-month study period. . A post-study survey will be completed to assess for various parameters including residents desire for continuation of virtual reality guided meditation following completion of the survey, subjective value of virtual reality as a tool for burnout, and likeliness to recommend virtual reality guided meditation to a colleague.
62296005|NCT05395221|EXPERIMENTAL|No intervention + Virtual Reality Assisted Meditation group|The second cohort will receive no intervention during the three-month block. After completion of the three-month time span, residents will take a follow-up MBI and then will cross over to the opposite group. After completion of the second three-month study period, an additional MBI will be completed by the residents.. A post-study survey will be completed to assess for various parameters including residents desire for continuation of virtual reality guided meditation following completion of the survey, subjective value of virtual reality as a tool for burnout, and likeliness to recommend virtual reality guided meditation to a colleague.
62296006|NCT02757547|PLACEBO_COMPARATOR|Transcranial magnetic stimulation - Placebo Arm|A placebo TMS coil is used.
62296007|NCT02757547|ACTIVE_COMPARATOR|Transcranial magnetic stimulation - Active Arm|An active TMS coil is used.
62296008|NCT03011229|ACTIVE_COMPARATOR|Pro Core|Subject is randomized to ProCore standard needle.
62467978|NCT04826679|EXPERIMENTAL|Experimental|"Camrelizumab + Cisplatin + Nab-paclitaxel~Camrelizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Cisplatin (IV), dose=60mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
62467979|NCT01115465|OTHER|Macroplastique|Macroplastique will be used for the treatment in an open-label, five year, post-market study
62467980|NCT04877080|EXPERIMENTAL|Fast Dual CAR-T treatment|CD19+ R/R B-NHL patients be treated with a single dose of Fast Dual CAR-T cells. Total dose of (1-5)\*10E5/kg cells will be administered at Day 0.
62467981|NCT02816905|ACTIVE_COMPARATOR|Group A|20 eyes that received topical 0.1% Dexamethasone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
62467982|NCT02816905|ACTIVE_COMPARATOR|Group B|20 eyes that received topical 0.1 % Fluorometholone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
62467983|NCT02816905|ACTIVE_COMPARATOR|Group C|40 eyes that received topical 1% Rimexolone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
62467984|NCT03228719|ACTIVE_COMPARATOR|Control Group|Standardized Outpatient Physical Therapy after TKR
62467985|NCT03228719|EXPERIMENTAL|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
62467986|NCT05986357||Study group|120 healthy women presenting with threatened miscarriage.
62467987|NCT05986357||Control group|120 healthy women with an uncomplicated single pregnancy.
62467988|NCT06366906||Cohort A|Randomly (121 cases) divided as the training and test sets in a 7:3 ratio.
62664172|NCT02733328||Non-AKI Patients|Patients without AKI
61911950|NCT04644367|EXPERIMENTAL|Tai Chi group|The Tai Chi (TC) group will receive or be taught TC in a class size consisting of about 5-12 students. Classes will be taught by a TC master with more than 4 years of experience practicing either Yang or Wu style TC. The participants will be allowed to practice TC at home and during their leisure time so long as they keep an activity log of their daily TC practice. This monitoring form (i.e. activity log or journal) will be distributed to all members of this group and collected weekly.
62102954|NCT06631261||Healthy controls|
62102955|NCT03363256|EXPERIMENTAL|TAU+TES-NAV|Standard outpatient addiction treatment plus Therapeutic Education System adapted for AI/AN
62102956|NCT03363256|ACTIVE_COMPARATOR|TAU|Standard outpatient addiction treatment
62102957|NCT00536380|EXPERIMENTAL|5-mg Desloratadine|5-mg Desloratadine once daily
62102958|NCT00536380|EXPERIMENTAL|10-mg Desloratadine|10-mg Desloratadine once daily
62102959|NCT00536380|EXPERIMENTAL|20-mg Desloratadine|20-mg Desloratadine once daily
62296009|NCT03011229|EXPERIMENTAL|Medtronic Shark Core|Subject is randomized to Medtronic Sharkcore needle
62467989|NCT06366906||Cohort B|Segmented into two groups based on the batched collected, which were defined as external validation set1 (n = 68) and external validation set2 (n = 130)
62467990|NCT06378242|EXPERIMENTAL|Disitamab Vedotin Intravesical instiliations :Dose escalation cohort|Participants will receive Disitamab Vedotin for injection Intravesical instiliations into the bladder for 1 hour, D1, once a week.
62467991|NCT03962686||normoglycemics|In this cohort will be enrolled 30 normoglycemics patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis \> 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
62664173|NCT00002874|EXPERIMENTAL|Bicalutamide|Radiation therapy + bicalutamide
62664174|NCT00002874|PLACEBO_COMPARATOR|Placebo|Radiation therapy + placebo
62664175|NCT02090257|EXPERIMENTAL|TRANSIT, behavioral|The intervention group will receive more guidance during their transition from a pediatric center to the adult center
62102960|NCT01178515|SHAM_COMPARATOR|Full fat milk|Full fat milk contain 3% fat
62664176|NCT02090257|NO_INTERVENTION|Usual Care Group|The usual care group will receive a standard transfer of care from a pediatric center to an adult center.
62102961|NCT01178515|EXPERIMENTAL|Partially defatted milk|Partially defatted milk contains 2% of fat
62102962|NCT01178515|EXPERIMENTAL|Defatted milk|Defatted milk contains 1% fat
62664177|NCT03061643|EXPERIMENTAL|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
62296010|NCT02988856|EXPERIMENTAL|Magnetic lid system|All participants will trial a commercially available device and an experimental magnetic device.
62102963|NCT01231282|EXPERIMENTAL|diffusion-weighted MRI|MRI
62102964|NCT06630468|EXPERIMENTAL|Task-oriented occupational therapy (TOOT)|The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
62102965|NCT06630468|ACTIVE_COMPARATOR|Control group|Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
62296011|NCT03993717||Three to six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine three to six months after kidney transplant
62296012|NCT03993717||Twelve to thirty-six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine twelve to thirty-six months after kidney transplant
62664178|NCT02654509|EXPERIMENTAL|EEE vaccine|Eastern Equine Encephalitis Vaccine will be administered as primary doses of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area and booster doses of 0.1 mL given intradermally in the volar aspect of the forearm. The primary series will be administered on Days 0 and 26-35 with a booster at 6 months. Titers will be collected 28-35 days after the second primary vaccine is \< 1:40, the subject will receive a booster dose 28- 90 days of obtaining the titer result.
62664179|NCT06166173||Breast tumor|Female patients with breast tumors and/or axillary lymph node metastases who had markers placed before neoadjuvant chemotherapy (NACT), and patients undergoing preoperative marker localization after NACT
62664180|NCT01656499|ACTIVE_COMPARATOR|Arabinoxylanoligosaccharides (AXOS)|AXOS (2 x 5g WBE/day)
62664181|NCT01656499|PLACEBO_COMPARATOR|Maltodextrine (placebo)|Maltodextrine (2 x 5g/day)
62664182|NCT03298061|EXPERIMENTAL|Subjects from clinical study MEA115921|Subjects who participated in clinical study MEA115921 and who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.
62664183|NCT04021797|SHAM_COMPARATOR|Sham|For the sham condition, the electrodes will be attached to an ear location that has not been shown to engage the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the active tVNS condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
62664184|NCT04021797|EXPERIMENTAL|Active|For the active condition, the electrodes will be attached to the ear at a place previously demonstrated to stimulate the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the sham condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
62102966|NCT03273530|EXPERIMENTAL|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
62102967|NCT03273530|NO_INTERVENTION|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
62102968|NCT03273530|NO_INTERVENTION|Traditional Vocational Rehabilitation|general pre-vocational training and placement
62102969|NCT01656304|EXPERIMENTAL|Treatment (monoclonal antibody, antiangiogenesis)|Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
62102970|NCT01168401|EXPERIMENTAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus Bivalent GI.1 and GII.4 VLP Vaccine, adjuvanted with 50 microgram (mcg) MPL and 500 mcg Al(OH)3, IM, on Days 0 and 28.
62102971|NCT01168401|PLACEBO_COMPARATOR|Saline|
62102972|NCT06629194||Crohn's disease|"Patients who were diagnosed Crohn's disease~- Diagnosis of Crohn's disease is based on clinical, endoscopic, pathological, and/or radiological findings which is confirmed by clinical \& endoscopic response to Crohn's disease treatment"
62296013|NCT02456584|EXPERIMENTAL|DMPA 150|single subcutaneous injection of 150mg/mL of DMPA in the abdomen
62296014|NCT02456584|EXPERIMENTAL|DMPA 300|single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
62296015|NCT02456584|ACTIVE_COMPARATOR|DMPA 104|two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen
62296016|NCT03106233||LTP flap breast reconstruction|All consecutive patients who underwent LTP flap breast reconstructions (unilateral, bilateral or stacked unilateral) between September 2012 and November 2016 at three centers in Maastricht, the Netherlands, and New York and New Orleans, the United States, were included. Autologous breast reconstruction was performed by using the upper lateral thigh region as a donor site.
62296017|NCT06002152|EXPERIMENTAL|Bupivacaine|Participants randomized to this arm will receive 10ml of 0.25% bupivacaine on each side of the bilateral block. This will be done after induction of general anesthesia and prior to start of surgery.
62296018|NCT06002152|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive 10ml of saline on each side of the bilateral block. This will be done after induction of general anesthesia and prior to start of surgery.
62296019|NCT00886990||1|Receiving a single PI boosted by low dose ritonavir
62296020|NCT00886990||2|Receiving two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
62102973|NCT06629194||Intestinal tuberculosis|"Patients who were diagnosed intestinal tuberculosis.~* Criteria of intestinal tuberculosis diagnosis includes any of following:~  i. Presence of caseating granuloma on pathological examination of specimens ii. Presence of acid-fast bacilli on pathological examination of specimens iii. PCR positive for Mycobacterium tuberculosis iv. Tissue culture growing organisms consistent with Mycobacterium tuberculosis v. Negative results in i to iv but response to empirical treatment with antituberculous therapy~* All are required to have clinical and endoscopic response to antituberculous therapy (ATT) treatment"
62296021|NCT05759052||Cohort of adult survivors having been treated by vincristine|Cohort of adult survivors having been treated by vincristine for a childhood leukemia
62102974|NCT02144350|EXPERIMENTAL|Intervention|patients will undergo daily hyperbaric oxygen sessions in addition to IV steroids for 10 days.
62102975|NCT02144350|SHAM_COMPARATOR|Sham|Patients will undergo sham hyperbaric air sessions in addition to IV steroids for 10 days
62296022|NCT04025632|EXPERIMENTAL|0.3 mg/kg zilucoplan|Daily subcutaneous (SC) injection
62296023|NCT04025632|PLACEBO_COMPARATOR|Placebo|Daily subcutaneous (SC) injection
62296024|NCT01994187||CAS or CEA|CAS:the patient who accepted carotid angioplasty due to catotid artery stenosis CEA:the patient who accepted carotid endarterectomy due to catotid artery stenosis
62296025|NCT05806242||Validation|Elderly in-patients eligible for physiotherapy admitted to IRCCS-INRCA Hospital
62296026|NCT01491178||Patients with NVAF|
62296027|NCT05303454|EXPERIMENTAL|Cartoons|Reduce Pain and Fear Levels of Children
62467992|NCT03962686||patients with diabetes mellitus (DM) treated with statin|In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis \> 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
62467993|NCT03962686||patients with diabetes mellitus (DM) treated with statin plus PCSK9i|In this cohort will be enrolled 20 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis \> 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. These patients were treated before the surgical intervention by statin therapy daily (n 20) added to PCSK9i, 140 mg twice a month (n 30).
62467994|NCT01510730|NO_INTERVENTION|control group|no treatment for Helicobacter pylori infection
62467995|NCT01510730|ACTIVE_COMPARATOR|treatment group|treatment group receive eradication treatment for helicobacter pylori infection
62467996|NCT04615793|NO_INTERVENTION|CONTROL GROUP|The control group will receive flexibility exercises and strength training focusing on the trunk and lower limb muscles, postural control exercise in different positions and different surfaces and general endurance training . Control group will receive intervention in the form of five minutes warm up followed by 12 minutes of walking at their comfortable pace and concluded with a five minutes cool down
62467997|NCT04615793|EXPERIMENTAL|EXPERMINTAL GROUP|The experimental group will obtain Pilate exercises, consist of strengthening,stretching and coordinated exercises on lower and trunk muscle
62467998|NCT05139797||Artificial Intelligence Screening for Cardiac Amyloidosis|An artificial intelligence algorithm will produce a probability of cardiac amyloidosis that will trigger referral to specialty clinic for further evaluation.
62467999|NCT02874586|EXPERIMENTAL|Plasma exchange combination of immunosuppressive regimens|Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis
62468000|NCT01836341|EXPERIMENTAL|Afatinib w Cisplatin Pemetrexed Chemoradiation|"induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation\*~\*afatinib dose levels: 20mg daily, 30mg daily \& 40mg daily (3+3 design) Then adjuvant afatinib x 2 years"
62468001|NCT06013618|OTHER|naxitamab and GM-CSF only|Suitable for patients with high risk neuroblastoma who obtain CR after chemotherapy combined with surgery, radiotherapy and/or hematopoietic stem cell transplantation. The treatment cycle is repeated every 4 weeks for a total of 5 courses, and discontinuation of nasetuzumab and GM-CSF should be considered if disease progression or unacceptable toxicity occurs.
62468002|NCT06013618|OTHER|naxitamab and GM-CSF in combination with irinotecan and temozolomide|Suitable for high-risk group neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory); Patients who relapse after initial treatment. Repeat every 3 weeks until tumor progression, patient withdrawal, or toxicity becomes intolerable, up to 8 procedures.
62102976|NCT02302209|EXPERIMENTAL|Oxytocin|40 IU Oxytocin Intranasal
62102977|NCT02302209|PLACEBO_COMPARATOR|Placebo|Saline Nasal Spray
62296028|NCT05303454|EXPERIMENTAL|Musical-moving Toys|Reduce Pain and Fear Levels of Children
62296029|NCT05303454|NO_INTERVENTION|CONTROL|NOT Reduce Pain and Fear Levels of Children
62664185|NCT02819388|EXPERIMENTAL|Intervention|Contraceptive counseling
62102978|NCT04888585|EXPERIMENTAL|Dose A of ABBV-154|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 12 weeks in the placebo-controlled period, 66 weeks in the long term extension (LTE) period 1 and 104 weeks in LTE period 2.
62102979|NCT04888585|EXPERIMENTAL|Dose B of ABBV-154|Participants in this group will receive dose B of ABBV-154 SC eow for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
62102980|NCT04888585|EXPERIMENTAL|Dose C of ABBV-154 EOW|Participants in this group will receive dose C of ABBV-154 SC eow for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
62296030|NCT00087438|EXPERIMENTAL|Stereotactic body radiation therapy (SBRT)|20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
62296031|NCT03755622|ACTIVE_COMPARATOR|Group C (Conventional)|Group C consists of patients who receive Transplatal Arch (TPA) fabricated from conventionally made stone working model.
62296032|NCT03755622|EXPERIMENTAL|Group 3D ( Three Dimensional)|Group 3D consists of patients who receive Transpalatal Arch (TPA) made from 3D recontructed model.
62296033|NCT03547141|EXPERIMENTAL|botulinum toxin 1U|
62296034|NCT03547141|EXPERIMENTAL|botulinum toxin 5U|
62296035|NCT03547141|EXPERIMENTAL|botulinum toxin 15U|
62296036|NCT03547141|EXPERIMENTAL|botulinum toxin 30U|
62102981|NCT04888585|EXPERIMENTAL|Dose C of ABBV-154 E4W|Participants in this group will receive dose C of ABBV-154 SC every 4 weeks (e4w) for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
62102982|NCT04888585|EXPERIMENTAL|Placebo|Participants in this group will receive placebo SC eow for 12 weeks in the placebo-controlled period and will be re-randomized in 1:1 ratio to receive ABBV-154 dose B or C respectively SC eow for 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
62102983|NCT04759131|EXPERIMENTAL|BIVV001: Participants aged <6 Years|Participants aged less than (\<) 6 years received BIVV001 at a dose of 50 international units per kilogram (IU/kg) intravenous (IV) injection once-weekly (QW) prophylaxis for 52 weeks.
62102984|NCT04759131|EXPERIMENTAL|BIVV001: Participants aged 6 to <12 Years|Participants aged 6 to \<12 years received BIVV001 at a dose of 50 IU/kg IV injection QW prophylaxis for 52 weeks.
62102985|NCT01986374|EXPERIMENTAL|HCG is introduced with small catheter.|phase 1 non randomized pilot
62102986|NCT05735847||Total Knee Arhroplasty (TKA)|Study participants will be adults (i.e. at least 18 years old) who have diagnosis of KOA with an indication for primary Total Knee Arthroplasty (TKA).
62102987|NCT05735847||Unicompartmental Knee Arthroplasty (UKA)|Study participants will be adults (i.e. at least 18 years old) who have diagnosis of KOA with an indication for primary medial Unicompartmental Knee Arthroplasty (UKA).
62296037|NCT04241029|EXPERIMENTAL|Intervention with probiotics|Intervention with the probiotic compound IDOFORM®Travel. The patient will receive four capsules orally every 24 hour (12\*10\^9 cfu/day) for eight weeks as adjuvant therapy to his/her anti-TNF treatment. The intervention arm will at the end of intervention serve as their own controls compared to baseline data (before intervention).
62468003|NCT06013618|OTHER|naxitamab and GM-CSF in combination with irinotecan and temozolomide and PD-1 antibody|Suitable for high-risk group neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory); Patients who relapse after initial treatment. Repeat every 3 weeks until tumor progression, patient withdrawal, or toxicity becomes intolerable, up to 8 procedures.
62468004|NCT06024993|EXPERIMENTAL|FCV-VCV|After titration of ventilation in baseline VCV (all arms), participants will first receive 20 min of baseline-matched FCV and subsequently 20 min of baseline-matched VCV.
62468005|NCT06024993|EXPERIMENTAL|VCV-FCV|After titration of ventilation in baseline VCV (all arms), participants will first receive 20 min of baseline-matched VCV and subsequently 20 min of baseline-matched FCV.
62102988|NCT06631027||Elderly Participants (65 years and older)|This study focuses on a cohort of 1,027 elderly participants aged 65 years and older. The participants were assessed for their adherence to the Mediterranean, DASH, and MIND diets through a demographic questionnaire and dietary adherence scales. Cognitive function was evaluated using the Standardized Mini-Mental Test (SMMT). The study aims to explore the relationship between dietary patterns and cognitive health in this population.
62102989|NCT05973773|EXPERIMENTAL|Part A (Safety Lead in)|Part A: Safety Lead-In Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.
62102990|NCT05973773|EXPERIMENTAL|Part B|"Enrollment into the Phase 3 portion of the study will begin following completion of Part A.~Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle.~Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first."
62296038|NCT01602731|EXPERIMENTAL|Automated Medication Dispensing Device|Subjects with \<88% medication adherence, determined by 30-day pillcount, and with cognitive impairment (determined by Saint Louis University Mental Status score) proceeded to AMDD portion of study.
62296039|NCT00673595|ACTIVE_COMPARATOR|Varenicline|Participants on this arm will receive varenicline tablets for 15 days.
62468006|NCT02124434||Laparoscopic Sleeve Gastrectomy|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity
62296040|NCT00673595|PLACEBO_COMPARATOR|Placebo|Participants on this arm will receive placebo tablets for 15 days.
62468007|NCT02494544|ACTIVE_COMPARATOR|ConforMIS iTotal Knee replacement|iTotal patient-specific knee replacement system
62468008|NCT02494544|ACTIVE_COMPARATOR|DePuy total knee replacement|Off the shelf knee replacement system
62664186|NCT02819388|NO_INTERVENTION|Control|Control group without counseling
62102991|NCT06488170||Tildrakizumab|Participants who received Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the SmPC will be observed for Week 28.
62102992|NCT05114109|EXPERIMENTAL|Isatuximab|Isatuximab will be given intravenously.
62664187|NCT04555148|PLACEBO_COMPARATOR|Placebo|Saline
62102993|NCT01710150|PLACEBO_COMPARATOR|CTI ablation only|subjects undergoing cavo-tricuspid isthmus (CTI) ablation alone for Atrial flutter
62102994|NCT01710150|ACTIVE_COMPARATOR|CTI ablation and PVI.|subjects undergoing cavo-tricuspid isthmus (CTI) ablation for Atrial flutter and pulmonary vein isolation (PVI) for Atrial Fibrillation.
62102995|NCT06550115|EXPERIMENTAL|Control eating during overnight work shift|For 4 weeks, participants will eat during the biological night as is typically done in night shift workers.
62102996|NCT06550115|EXPERIMENTAL|Time-restricted eating during overnight work shift|For 4 weeks, participants will refrain from eating during the biological night while maintaining the same sleep opportunity and daily energy intake and macronutrient distribution without changing 24h energy intake.
62102997|NCT00880490|EXPERIMENTAL|1|Inhaled PT005 2.4 mcg
62102998|NCT00880490|EXPERIMENTAL|2|Inhaled PT005 4.8 mcg
62102999|NCT00880490|EXPERIMENTAL|3|Inhaled PT005 9.6 mcg
62103000|NCT00880490|PLACEBO_COMPARATOR|4|Inhaled Placebo
62103001|NCT00880490|ACTIVE_COMPARATOR|5|Formoterol Fumarate 12 mcg (Foradil Aerolizer)
62103002|NCT01599325|EXPERIMENTAL|Azacitidine|Azacitidine 75 mg/m\^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
62103003|NCT05722951|ACTIVE_COMPARATOR|Control group (+ve control)|levetiracetam \&/or sodium valproate
62103004|NCT05722951|EXPERIMENTAL|Treatment group|metformin + (levetiracetam \&/or sodium valproate)
62103005|NCT03625037|EXPERIMENTAL|Epcoritamab|Epcoritamab will be administered by subcutaneous injections in cycles of 28 days.
62103006|NCT04661670|ACTIVE_COMPARATOR|occlusal stabilization splints equilibrated by articulating paper|In this group the final occlusal correction will be performed with the patient in supine position using 20 um thick articulating paper and articulating foil 8 um thick. The patient will be asked to tap 3 times on the articulating paper and occlusal correction will be done using carbide laboratory bur and rubber cone till uniform contact on all teeth is achieved in centric relation which is illustrated on the splint by a series of uniformly appearing articulating paper dots. Then the patient will be asked to make protrusive and right and left excursions to ensure smooth anterior guidance and posterior disocclusion.
62103007|NCT04661670|ACTIVE_COMPARATOR|occlusal stabilization splints equilibrated by T-scan|"In this group the same adjustment sequence will be done using T Scan III (software version 8.0) computerized occlusal analysis, a new patient file will be opened, the patient's biological data will be entered, and the T Scan dental arch size is customized to fit the patients arch anatomy. The patient will be asked to clench to record occlusal force and areas that needs adjustment will be grinded using the paper marks as the guideline and carbide laboratory bur till bilateral force balance achieved and the center of force (COF) icon sits close to the midline.~Mandibular excursions are then adjusted in a similar fashion. Contacts rather than anterior and canine guidance will be eliminated till achieving anterior guidance and posterior disocclusion in time less than 0.5 seconds."
62103008|NCT02824003|EXPERIMENTAL|ISIS-GCGRRx|ISIS-GCGRRx once weekly dosing for 13 weeks
62103009|NCT02824003|PLACEBO_COMPARATOR|Placebo|once weekly dosing for 13 weeks
62103010|NCT05541757||control group|five healthy adults
62103011|NCT05541757||Study group|Twenty-five patients using the direct oral factor Xa inhibitor rivaroxaban
62103012|NCT04966208|ACTIVE_COMPARATOR|root coverage surgeries using autologous connective tissue for treatment of gingival recession|root coverage surgeries using tunneling technique of autologous connective tissue as a treatment of Miller class two gingival recession
62468009|NCT02494544|ACTIVE_COMPARATOR|Zimmer total knee replacement|Off the shelf knee replacement system
62103013|NCT04966208|EXPERIMENTAL|root coverage surgeries using xenogenic collagen matrix for treatment of gingival recession|root coverage surgeries using tunneling technique of mucodrm membrane ; xenogeneic collagen matrix as a treatment of Miller class two gingival recession
62468010|NCT02494544|ACTIVE_COMPARATOR|Biomet total knee replacement|Off the shelf knee replacement system
62468011|NCT02494544|ACTIVE_COMPARATOR|Smith & Nephew total knee replacement|Off the shelf knee replacement system
62664188|NCT04555148|EXPERIMENTAL|Low dose Treatment|Low dose treatment
62664189|NCT04555148|EXPERIMENTAL|Medium dose Treatment|Medium dose Treatment
62664190|NCT04555148|EXPERIMENTAL|High dose Treatment|High dose Treatment
62664191|NCT03361345|EXPERIMENTAL|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
62664192|NCT03361345|SHAM_COMPARATOR|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
62664193|NCT00469729|EXPERIMENTAL|StemEx|
62468012|NCT02494544|ACTIVE_COMPARATOR|Stryker total knee replacement|Off the shelf knee replacement system
61911951|NCT04644367|ACTIVE_COMPARATOR|Regular Physical Activity (control) group|The regular physical activity (control) group will be asked to maintain or engage in at least 60 minutes of regular physical activity on their own for three times per week. The participants will be instructed as to the type of regular PA that they may engage in. These types of PA include: walking, cleaning or performing chores inside the home, and/or climbing the stairs. No restriction will be made to limit others forms of physical activity; individuals in the control group will be permitted to engage in organized sports, instructor-led class such as boxing, dance, etc. to ensure the participant recruitment process is feasible. Similar to the TC group, participants in this group will be asked to complete an activity log (or journal) that will be collected weekly to monitor their regular PA levels.
62664194|NCT06392126|EXPERIMENTAL|Open Label|
62296041|NCT02115308|OTHER|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
62296042|NCT03839602|EXPERIMENTAL|reducing CTV|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC. The prescribe doses of GTVnx, GTVnd, CTV1 and CTV2 were 68Gy, 60-66Gy, 60Gy and 50-54Gy in 30 fractions, respectively.
62296043|NCT01021943|PLACEBO_COMPARATOR|Placebo|Half of the subjects will be assigned to receive either spironolactone or placebo for 6 months
62296044|NCT01021943|ACTIVE_COMPARATOR|spironolactone|Half of the subjects will be randomized to receive spironolactone for 6 months
62296045|NCT06656325|ACTIVE_COMPARATOR|Erchonia® FX405|The Erchonia® FX405 is made up of (3) 6405 nanometers red laser diodes and (1) 405 nanometers violet laser diode mounted in a robotic scanner device.
62296046|NCT06656325|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX405 but does not emit any therapeutic light.
62296047|NCT04733820|EXPERIMENTAL|Adjuvant chemotherapy group|"Participant will receive at least 2 cycles of adjuvant chemotherapy. If having any of the following factors, participant will receive additional 2 cycles of adjuvant chemotherapy per risk factor. All patients received maximum 6 cycles of postoperative chemotherapy.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 4cm before surgery."
62468013|NCT01650974|NO_INTERVENTION|conventional oxygen therapy|conventional nasal prong with FiO2 \~0.4
62664195|NCT04530851|NO_INTERVENTION|Conventional care|This group is conventional care of pregnant women after Cesarean section
62664196|NCT04530851|EXPERIMENTAL|ERAS protocol|This protocol for improve outcome of pregnant women after Cesarean section
61911952|NCT01848782|EXPERIMENTAL|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
61911953|NCT01848782|ACTIVE_COMPARATOR|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
62664197|NCT01191749|EXPERIMENTAL|Alemtuzumab|Alemtuzumab 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
62664198|NCT04529460||Previously COVID-19 positive|Previously confirmed PCR positive for COVID-19 And/or positive COVID-19 antibody test in the past six months
61911954|NCT01514162|EXPERIMENTAL|Trifecta Valve Group|Subjects implanted with a Trifecta valve.
62103014|NCT05622032||haploidentical HSCT patients|Patients receiving HSCT from a haploidentical donor. They also receive a treatment called cyclophosphamide as part of the protocol to prevent graft versus host disease at day 3 and 4 after transplantation.
62468014|NCT01650974|EXPERIMENTAL|HFNOT|high flow nasal oxygen therapy with starting FiO2 0.4 and Flow 40 L/min
62468015|NCT01650974|SHAM_COMPARATOR|sham-HFNOT|same device with FiO2 \~0.4, NO high flow
62664199|NCT04529460||Previously COVID19 negative|No previous symptoms of COVID-19
62664200|NCT00005850|EXPERIMENTAL|gemcitabine + cisplatin + fluoxetine|Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.
62468016|NCT00991965||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
62468017|NCT00322166|ACTIVE_COMPARATOR|Group A, Sunlight|Participants in this arm are required to sit in the sun most days of the week for 15 minutes
62468018|NCT00322166|ACTIVE_COMPARATOR|Group B, sunlight and calcium|Participants in this group receive sunlight and a calcium supplement
62468019|NCT00322166|NO_INTERVENTION|Group C|Control group
62664201|NCT00005774|EXPERIMENTAL|Early surfactant group|
62664202|NCT00005774|ACTIVE_COMPARATOR|Standard Practice group|
62664203|NCT04987905|EXPERIMENTAL|Experimental Group|"In the study, for 60 minutes once a week for 8 weeks the MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice). In addition to these, nurses will be required to keep a diary of the program. This app contains basic mindfulness exercises and does not pose any health risks to practitioners. While the MIND-BE program is carried out in the online environment, the cameras of the nurses in the experimental group will be turned on and the researcher who made the application will be able to see each nurse."
62296048|NCT04733820|NO_INTERVENTION|Control group|The participants receive no intervention.
61911955|NCT01054183|EXPERIMENTAL|Intubation using GlideScope Ranger|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team A to use the GlideScope Ranger for all intubations on that day.
61911956|NCT01054183|ACTIVE_COMPARATOR|intubation using direct laryngoscopy|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team B. Team B will do intubations using direct laryngoscopy only that day.
62296049|NCT02412865|EXPERIMENTAL|Intervention|quit4baby + text4baby
62296050|NCT02412865|OTHER|Control|text4baby
62296051|NCT05816603|EXPERIMENTAL|Real tDCS stimulation|Subjects randomized to receive real/active electrical stimulation.
62296052|NCT05816603|SHAM_COMPARATOR|Sham tDCS stimulation|Subjects randomized to receive sham/non-activating electrical stimulation.
62296053|NCT05896345|ACTIVE_COMPARATOR|SWL|Shockwave Lithotripsy (SWL)
62296054|NCT05896345|ACTIVE_COMPARATOR|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT)
62296055|NCT02739087|EXPERIMENTAL|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
62296056|NCT03192579|EXPERIMENTAL|Standard lipid lowering therapy|Start with only rosuvastatin 2.5mg and up to 20mg/day
62296057|NCT03192579|ACTIVE_COMPARATOR|Intensive lipid lowering therapy|Start EPA and rosuvastatin 10mg/day and up to 20mg/day
62296058|NCT06151925|ACTIVE_COMPARATOR|Laminaria tents group|Laminaria tent used to be inserted in cervix and left for 6-12 hours
62296059|NCT06151925|PLACEBO_COMPARATOR|vaginal prostaglandin group|Misoprostol 25 mcg inserted for one or multiple doses
62296060|NCT05102565|EXPERIMENTAL|Treatment group|6 weekly sleep education program
62296061|NCT00336102||Group 1 Breast Cancer Patient Cases|"Patients between the ages of 25 and 75, diagnosed with primary, operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin / Cytoxan (AC) plus a taxane are trial candidates.~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
62296062|NCT00336102||Group 2 Healthy Controls|"Controls will be women from the same general demographic area as Group 1 Cases, have no prior history of cancer and be within 5 years of the Group 1 case's age (+/- 5 years).~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
62468020|NCT02277847|EXPERIMENTAL|IDA 8mg/M2|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
62468021|NCT02277847|ACTIVE_COMPARATOR|IDA 10mg/M2|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
62296063|NCT04469569|OTHER|Delayed Intervention|Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPV-PROTECT intervention in Year 3, and to the sustainability condition in Year 4
62468022|NCT04582318|EXPERIMENTAL|Part 1 Dose Level 1 - Active|
62468023|NCT04582318|PLACEBO_COMPARATOR|Part 1 Dose Level 1 - Placebo|
62468024|NCT04582318|EXPERIMENTAL|Part 1 Dose Level 2 - Active|
62468025|NCT04582318|PLACEBO_COMPARATOR|Part 1 Dose Level 2 - Placebo|
62468026|NCT04582318|ACTIVE_COMPARATOR|Part 2 Multi-Dose Level 1 - Active|
62468027|NCT04582318|PLACEBO_COMPARATOR|Part 2 Multi-Dose Level 1 - Placebo|
62468028|NCT04582318|ACTIVE_COMPARATOR|Part 2 Multi-Dose Level 2 - Active|
62468029|NCT04582318|PLACEBO_COMPARATOR|Part 2 Multi-Dose Level 2 - Placebo|
62468030|NCT04503174||Pump Naive|New to insulin pump use
62468031|NCT04503174||6-13 YO|Subjects between the age of 6-13 years old.
62468032|NCT04503174||14-17 YO|Subjects between the age of 14-17 years old.
62468033|NCT04503174||Adults (18+)|Subjects are 18 years old and older.
61911957|NCT00936689|SHAM_COMPARATOR|Traditional TACE|Chemoembolization by standard technique: epirubicin (maximum dose of 75 mg) conjugated with an oil-based contrast medium (Lipiodol) at the maximum dose of 15 ml + gelatin sponge particles(particles of transient embolization material, required to obstruct the treated vessel).
61911958|NCT00936689|ACTIVE_COMPARATOR|TACE with microsphere|
62296064|NCT04469569|OTHER|Early Intervention|Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4
62296065|NCT06399315|EXPERIMENTAL|Level 1 Single dose|Dose level 1. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo
62296066|NCT06399315|EXPERIMENTAL|Level 2 Single dose|Dose level 2. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo
62296067|NCT06399315|EXPERIMENTAL|Level 3 Single dose|Dose level 3. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo
62296068|NCT06399315|EXPERIMENTAL|Level 3 Single dose after food|Dose level 3 with a fat meal. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo
62296069|NCT06399315|EXPERIMENTAL|Level 4 Single dose|Dose level 4. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo
62296070|NCT06399315|EXPERIMENTAL|Level 1 Multiple doses|Dose level 1. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo
62296071|NCT06399315|EXPERIMENTAL|Level 1 Multiple doses + rabeprazole|Dose level 2. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo. The drug is co-administered with rabeprazole
62296072|NCT06399315|EXPERIMENTAL|Level 2 Multiple doses|Dose level 2. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo
62296073|NCT06214312||Spontaneous ventilation|Anesthetized Children ventilated with a laryngeal mask airway in spontaneous ventilation with a positive end expiratory pressure of 5cmH2O.
62103015|NCT05622032||HLA-matched HSCT patients|Patients who receive HSCT from a HLA-matched donor.
62103016|NCT00906698|EXPERIMENTAL|BIBW 2992 and vinorelbine i.v|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine i.v.
62296074|NCT06214312||Pressure support ventilation|Anesthetized Children ventilated with a laryngeal mask airway in pressure support ventilation with a positive end expiratory pressure of 5cmH2O, maximum pressure not exceeding 15cmH2O.
62296075|NCT01536444|EXPERIMENTAL|Micrografting|
62296076|NCT05600127|EXPERIMENTAL|Avelumab|3 cycles of avelumab (Bavencio), 800mg intravenous instillation in 60 min, every 2 weeks.
62468034|NCT04503174||CGM Naive|Subjects have not used CGM in the 30 days prior to enrollment.
62468035|NCT04503174||HbA1c more than or equal to 8.5%|Subjects have an HbA1c of more than or equal to 8.5% in the 3 months prior to enrollment.
62468036|NCT04503174||HbA1c less than or equal to 8.5%|Subjects have an HbA1c of less than or equal to 8.5% in the 3 months prior to enrollment.
62664204|NCT04987905|NO_INTERVENTION|Control Group|No intervention will be made to the control group, only the data will be collected at the same time as the study group. After all data are collected (after the 12th week), the training content will be explained to the nurses in the control group and the MIND-BE program will be started for them as well. In this way, both groups will benefit from this program.
62664205|NCT01365572|ACTIVE_COMPARATOR|Xience V, drug-eluting stent|randomized implantation for DES restenotic lesion
62664206|NCT01365572|ACTIVE_COMPARATOR|Endeavor Resolute, drug-eluting stent|randomized implantation for DES restenotic lesion
62664207|NCT02944266||Hypovolemia group|Those patients who are said to be positive for one or more of the following TTE criteria are grouped under this , them being i.IVC diameter of less than 1 cm , ii.Caval index of \> 50%, iii.Left ventricular end diastolic area of \< 10 cm2 iv. VTI variation with respiration of \< 12.5%, are grouped under the hypovolaemia group .
62664208|NCT02944266||Normovolaemia group|Those patients without the above said TTE findings are hypothesised to be normovolaemic and grouped in here.
62664209|NCT02517229|OTHER|in balance control in response to microgravity|to evaluate changes in balance control in response to microgravity during reactive balance tasks compared to normal gravity.
62664210|NCT05613868|EXPERIMENTAL|Active, TPN-101|100 mg/day to 400mg/ study investigational drug TPN-101 once daily for 48 weeks followed by 12 weeks of follow-up period.
62664211|NCT01346683|EXPERIMENTAL|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
62664212|NCT02145676|EXPERIMENTAL|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
62664213|NCT02145676|EXPERIMENTAL|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
62664214|NCT02145676|PLACEBO_COMPARATOR|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
62664215|NCT00164723|OTHER|NSAID|patients taking NSAID will undergo capsule endoscopy
62664216|NCT00164723|OTHER|Aspirin|patients taking Aspirin will undergo capsule endoscopy
62664217|NCT00164723|OTHER|Non-user|patients didn't take NSAID or ASA will undergo capsule endoscopy
62664218|NCT00363168|EXPERIMENTAL|A|0.3 mg/0.05 ml dose of ranibizumab
62664219|NCT00363168|EXPERIMENTAL|B|0.5 mg/0.05 ml dose of ranibizumab
62664220|NCT04521140|EXPERIMENTAL|PKP with Dextenza (study)|"Patients undergoing PKP will receive Dextenza insert with:~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
62103017|NCT00906698|EXPERIMENTAL|BIBW 2992 and vinorelbine per os|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine per os.
62103018|NCT04963621|EXPERIMENTAL|Intervention|Child-Adolescent Emotion and Stress Intervention Program
62103019|NCT04963621|ACTIVE_COMPARATOR|waiting|treat as usual
62103020|NCT03795740|EXPERIMENTAL|Precise|precise PEA therapy with the guide of 3-D imaging techniques
62103021|NCT03795740|PLACEBO_COMPARATOR|Placebo|traditional PEA therapy solely by surgical probe and traditional CT scanning/pulmonary angiography method
62103022|NCT03074851|EXPERIMENTAL|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
62468037|NCT03481647|ACTIVE_COMPARATOR|Intervention|The intervention consists of professional oral care and swabbing of the mucosal membranes with a saline and bicarbonate solution, five daily rinses with a saline and bicarbonate solution, a diary to register oral care measures and rinses
62468038|NCT03481647|NO_INTERVENTION|Control|Professional oral care once a week according to existing routine
62468039|NCT03301948|EXPERIMENTAL|Overfeed|Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
62468040|NCT03301948|EXPERIMENTAL|Energy Balance|Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
62468041|NCT00076622||Randomized to drug continuation|Participants assigned to continue current antidepressant medication
62664221|NCT04521140|OTHER|PKP without Dextenza (Controlled)|"Patients undergoing PKP will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
62664222|NCT04521140|EXPERIMENTAL|DSEK with Dextenza (study)|"Patients undergoing DSEK will receive Dextenza insert with:~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
62664223|NCT04521140|OTHER|DSEK without Dextenza (Controlled)|"Patients undergoing DSEK will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
62103023|NCT03074851|OTHER|informational intervention|to give 1 month informational intervention
62103024|NCT03327155|EXPERIMENTAL|TDF/FTC (300mg/200mg) once daily|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.
62103025|NCT06135831|EXPERIMENTAL|Calciovitmag (CDCaMg)|Daily supplementation of diet with vitamin C (1000 mg), vitamin D3 (500 mg), calcium (Ca) (500 mg ) and magnesium (Mg) (300 mg)
62103026|NCT06135831|PLACEBO_COMPARATOR|Control|Daily supplementation of diet with vitamin D3 (500 mg), Ca (500 mg) and Mg (300 mg)
62103027|NCT06135831|EXPERIMENTAL|Phosphorovitmag (PDCaMg)|Daily supplementation of diet with bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)
62103028|NCT06135831|EXPERIMENTAL|Functional Olive paste|Daily supplementation of diet with 364 mg polyphenols via 50 g of an innovative functional food (Kalamata olive paste with mountain tea rich in polyphenols, (total phenolics 7,28±3.11 gallic acid/g) along with vitamin D3 (500 mg), Ca (500 mg) and Mg (300 mg)
62103029|NCT04647162|ACTIVE_COMPARATOR|medical group|Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.
62103030|NCT04647162|EXPERIMENTAL|surgical group|Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.
62103031|NCT01087177|EXPERIMENTAL|Exposure to Pedialink CEASE Trained Site|Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
62103032|NCT04003428|EXPERIMENTAL|Per-caesarean HIFU shots|Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
62103033|NCT04585347|EXPERIMENTAL|Regimen A|ALZ-801 171 mg tablet, fasting, once
62103034|NCT04585347|EXPERIMENTAL|Regimen B|ALZ-801 205 mg tablet, fasting, once
62103035|NCT04585347|EXPERIMENTAL|Regimen C|ALZ-801 205 mg tablet, after food once
62296077|NCT04814264|EXPERIMENTAL|Sex-matched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is matched to their sex (donor and recipient sex are the same). Patients in this arm will receive RBCs matched to their sex until discharge from hospital or death.
62296078|NCT04814264|EXPERIMENTAL|Sex-mismatched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is not matched to their sex (donor and recipient sex are not the same). Patients in this arm will receive RBCs mismatched to their sex until discharge from hospital or death.
62296079|NCT05242887||Older adults hospitalized in acute geriatric units|Response to a questionnaire
62468042|NCT00076622||Randomized to drug discontinuation|Participants assigned to discontinue current antidepressant medication (no antidepressant medication)
62664224|NCT04521140|EXPERIMENTAL|DMEK with Dextenza (study)|"will receive Dextenza insert with: topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
62103036|NCT04585347|EXPERIMENTAL|Regimen D|ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once
62664225|NCT04521140|OTHER|DMEK without Dextenza (Controlled)|"Patients undergoing DMEK will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
62103037|NCT03653975||Nodding syndrome|"I) probable Case of Nodding Syndrom (according to the WHO epidemiologic surveillance case definition) \*reported head nodding \*\* in a previously healthy person with at least 2 major and 1 minor criteria~Major criteria~* Age 3 to 18 y at onset of head nodding~* Nodding frequency 5 to 20 times per min~Minor criteria~* Other neurologic abnormalities~* Clustering in space or time with similar cases~* Triggering by eating or cold weather~* Delayed sexual or physical development~* Psychiatric manifestations~  * As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). \*\* Repetitive involuntary drops of the head toward the chest on \>2 occasions."
62103038|NCT03653975||epilepsy and onchocerciasis|"II) People with epilepsy (PWE) and onchocerciasis (n= 50)~* confirmed or suspected generalized and idiopathic epilepsy~* confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
62103039|NCT03653975||epilepsy, no onchocerciasis|"III) People with epilepsy (PWE) without onchocerciasis (n= 50)~* confirmed or suspected generalized and idiopathic epilepsy~* excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
62308237|NCT02911987|EXPERIMENTAL|the 'combined' HIT group|Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
62468043|NCT00076622||Participant preference to continue drug|Chose to continue antidepressant medication
62468044|NCT00076622||Participant preference to discontinue drug|Chose to discontinue antidepressant medication (no antidepressant medication)
62468045|NCT00496964|EXPERIMENTAL|1|Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
62468046|NCT00496964|PLACEBO_COMPARATOR|2|Placebo injection + exercise
62103040|NCT03653975||no epilepsy but onchocerciasis|"IV) Controls with onchocerciasis, otherwise healthy (n= 50)~* no evidence for epilepsy or other neurological diseases~* confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
62308238|NCT02911987|ACTIVE_COMPARATOR|control group|Group 5 receives MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group)
62468047|NCT00660647|EXPERIMENTAL|methotrexate + adalimumab|Methotrexate and intraarticular triamcinolone hexacetonide plus adalimumab.
62468048|NCT00660647|PLACEBO_COMPARATOR|methotrexate + placebo|Methotrexate and intraarticular triamcinolone hexacetonide and placebo
62468049|NCT00726739|EXPERIMENTAL|Arm I - LMI + aldesleukin|Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62468050|NCT00726739|ACTIVE_COMPARATOR|Arm II (control) - aldesleukin|Patients receive aldesleukin SC on days 1 and 2. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over and receive treatment on arm I.
61911959|NCT02810444|EXPERIMENTAL|BT595|Subjects received BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.
61911960|NCT05790161|EXPERIMENTAL|Sleep Restriction|3 nights with 6h sleep opportunity each.
61911961|NCT05790161|EXPERIMENTAL|Sleep Extension|3 nights with 9,5h sleep opportunity each.
61911962|NCT02156245|EXPERIMENTAL|"Conventional group"|
61911963|NCT02156245|EXPERIMENTAL|"Combined group"|
62103041|NCT03653975||no epilepsy, no onchocerciasis|"V) Healthy Controls without onchocerciasis (n= 50)~* no evidence for epilepsy or other neurological diseases~* excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
62468051|NCT00726739|EXPERIMENTAL|Arm III - Crossover Patients|"Patients who have progressive disease on Arm II were be offered crossover to Arm I provided they continued to meet all study criteria.~Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity"
62664226|NCT04557774||Liver cirrhosis group|All included patients were asymptomatic at the baseline with no evidence of neurological impairment. Patients with a history of moderate alcohol drinking plus hepatitis B/C virus infection, medication for sedation, MELD (Model for End-stage Liver Disease) score of more than 20, OHE, seizure, head trauma, stroke, dementia, Parkinson's disease, or any kind of focal neurologic deficits were excluded. Any patients who were suspected of alcohol induced direct neurologic damages such as Wernicke's encephalopathy, alcohol induced spinal cord disease, or alcohol induced peripheral nerve disease were excluded. After evaluating the data including the laboratory findings, image findings, endoscopic findings, and medical records of all these patients, as well as liver biopsy findings for some patients, we sub-classified these 88 patients into two groups: alcoholic LC and viral LC. Finally, 80 patients (viral: 37; alcohol: 43) with compensated LC were prospectively considered in this study.
62664227|NCT02397837|EXPERIMENTAL|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
62664228|NCT02397837|PLACEBO_COMPARATOR|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
61911964|NCT03896347||ViBone®|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
61911965|NCT03896347||Demineralized Bone Matrix|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
61911966|NCT03896347||Bone Morphogenetic Protein|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
61911967|NCT01107379||Balloon catheter device|Dilation of sinuses using Relieva Balloon Sinuplasty System
61911968|NCT04360278||Plasma Donors|Persons who have recovered from COVID-19 or have been immunized against SARS-CoV-2 who meet criteria to donate plasma.
62308239|NCT02012816|OTHER|Uncircumcised men|The program allows each man coming for circumcision to refer up to 5 uncircumcised men in their social network for VMMC services and receive a monetary reward for each successful referral.
62103042|NCT03653975||controls for Wechsler Nonverbal (WNV)|"Healthy Controls for cognitive assessment only, (n= 750)~no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
62103043|NCT06224270|EXPERIMENTAL|Adults with IBD|
62103044|NCT01124162|EXPERIMENTAL|Generic Test Product|Losartan 100mg Tablets
62103045|NCT01124162|ACTIVE_COMPARATOR|Reference Listed Drug|Cozaar® 100 mg Tablets
62103046|NCT03184545|EXPERIMENTAL|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
62103047|NCT03184545|ACTIVE_COMPARATOR|Only PT|Group 2: Only Physical therapy (PT).
62103048|NCT05584020|EXPERIMENTAL|ACL Repair|Patients under surgical anterior cruciate ligament repair
62103049|NCT05584020|OTHER|ACL Reconstruction|Patients under surgical anterior cruciate ligament reconstruction
62296080|NCT04894799|EXPERIMENTAL|Vestibular stimulation|all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
62308240|NCT05858411|EXPERIMENTAL|SRP+rhPDGF|After SRP the infrabony defect will be filled with a collagen sponge soaked in rhPDGF.
62468052|NCT02746484|EXPERIMENTAL|Ability platform program|Multi-domain at home rehabilitation program delivered through the Ability platform.
62468053|NCT02746484|ACTIVE_COMPARATOR|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
62468054|NCT01714180||Obese Patients|
62468055|NCT01714180||Non-obese Patients|
62468056|NCT03605030|ACTIVE_COMPARATOR|Novel Lead Based Armboard|
62468057|NCT03605030|PLACEBO_COMPARATOR|Standard Armboard|
62468058|NCT00492960|EXPERIMENTAL|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
62468059|NCT00492960|EXPERIMENTAL|Larazotide acetate 4 mg|larazotide acetate 4 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
62468060|NCT00492960|EXPERIMENTAL|Larazotide acetate 8 mg|larazotide acetate 8 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
62468061|NCT00492960|PLACEBO_COMPARATOR|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
62468062|NCT03922230||Early esophageal cancer group|Pathological examination diagnosed as Early esophageal cancer.The ratio of male to female is 3:1, and the age is between 50 and 70 years old.
62468063|NCT03922230||Middle and advanced ES group|Pathological examination diagnosed as Middle and advanced esophageal cancer.
62468064|NCT03922230||Normal group|Confirmed as the normal by health checkups.
62103050|NCT04088513|EXPERIMENTAL|Aspirin|Drugs:Aspirin
62103051|NCT04088513|ACTIVE_COMPARATOR|Clopidogrel|Drugs:Clopidogrel
62468065|NCT00831428||Scottish swimming team|
62468066|NCT03241784|EXPERIMENTAL|Treatment arm|All subjects are enrolled in the one arm consisting of infusions of autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth/kg and subcutaneous injections of Interleukin-2 at a dose of 2x10 to the fifth IU/m2 three times a week.
62468067|NCT04290845|EXPERIMENTAL|Relief-Hybrid|Relief-Hybrid relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
62468068|NCT04290845|NO_INTERVENTION|Referral to Mental Health/Usual Care|Continuation of medical attention and treatment provided by physicians and other medical professionals at the primary care practice. Referral for mental health based on clinical indication. Participants receive an educational booklet on pain.
62468069|NCT04758260|EXPERIMENTAL|Antioxidant Treatment|Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men
62468070|NCT00772941||Varenicline|Patients taking Varenicline.
62468071|NCT01372345|EXPERIMENTAL|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
62468072|NCT01372345|ACTIVE_COMPARATOR|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
62468073|NCT00989274|ACTIVE_COMPARATOR|Vaccine Sanofi A(H1N1) 15 ug & trivalent|120 participants selected by random
62103052|NCT06628674|EXPERIMENTAL|Core muscle exercise|
62103053|NCT06628674|OTHER|pelvic muscle exercise|
62103054|NCT05451082||Single Group Assignment|
62103055|NCT05846711|ACTIVE_COMPARATOR|Bedside BPPV diagnostics|Diagnostics of BPPV with manual tests using VNG goggles. The goggles will be added an IMU sensor detecting angulation and velocity (the physician will not get feedback from the sensor during the examination. This will only be used in later analysis).
62103056|NCT05846711|ACTIVE_COMPARATOR|TRV BPPV diagnostics|Diagnostics of BPPV using the TRV chair.
62103057|NCT02521844|EXPERIMENTAL|Dose Escalation|ETC-1922159 + pembrolizumab
62103058|NCT02521844|EXPERIMENTAL|Dose Expansion|ETC-1922159 as single agent until disease progression, then in combination with pembrolizumab at the recommended dose (RD) identified in the dose escalation segment
62308241|NCT05858411|ACTIVE_COMPARATOR|SRP+ collagen sponge|After SRP the infrabony defect will be filled with a collagen sponge soaked in saline solution.
62468074|NCT00989274|ACTIVE_COMPARATOR|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|120 participants selected in random form
62468075|NCT00989274|ACTIVE_COMPARATOR|Vaccine Sanofi A(H1N1) 7.5 ug|120 participants selected in random form
62468076|NCT00257673|EXPERIMENTAL|A|Active 30 mg MEM 1003
62468077|NCT00257673|EXPERIMENTAL|B|90 mg MEM 1003
62468078|NCT00257673|PLACEBO_COMPARATOR|C|Placebo for MEM 1003
62468079|NCT01967485|EXPERIMENTAL|Text Messaging|Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
62664229|NCT06543732|EXPERIMENTAL|eHealth with Participatory Approach if needed|Participants receive a personalized eHealth program and if needed, after 6 weeks the Participatory Approach (intervention) next to care as usual from occupational health care.
62664230|NCT06543732|NO_INTERVENTION|Control condition|Participants receive links to existing websites on return to work next to care as usual from occupational health care.
62664231|NCT02756442|EXPERIMENTAL|pregnant women with gestational diabetes|
62664232|NCT02756442|ACTIVE_COMPARATOR|pregnant women without gestational diabetes|
62664233|NCT04606719|OTHER|Blood Clot|It is induced through apical foramen by penetrating the periapical area by stainless steel file size 30 to fill the root canal system by growth factors also to be considered as scaffold
62664234|NCT04606719|ACTIVE_COMPARATOR|Standard PRF|Standard Platelet-rich fibrin will be prepared by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 3000 rpm for 10 min. After centrifugation, three layers will formed in the test tube-base layer of RBCs, top layer of a-cellular plasma, and a PRF clot in the middle. This clot will then pressed between two gauze pieces to form a membrane.
62664235|NCT04606719|EXPERIMENTAL|Advanced PRF|A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
62664236|NCT04247971||Obese, early-onset asthmatics|Obese adults (BMI\>or= 30) between the ages of 21-60 with an initial asthma diagnosis at \<12 years of age
62664237|NCT04247971||Obese, late-onset asthmatics|Obese adults (BMI \> or = 30) between the ages of 21-60 with an initial asthma diagnosis at \>12 years of age
62664238|NCT04247971||Obese non-asthmatics|Obese adults (BMI \> or = 30) between the ages of 21-60 with no asthma diagnosis
62664239|NCT00408226|EXPERIMENTAL|1|
62664240|NCT06109688|EXPERIMENTAL|Bovine lactoferrin|Sachets with bovine lactoferrin at a dosage of 100 mg/day for a period of 4 weeks.
62664241|NCT06109688|PLACEBO_COMPARATOR|Placebo|Matched sachets with maltodextrin for a period of 4 weeks.
62664242|NCT01595828|EXPERIMENTAL|Pitavastatin 4mg daily|4 mg tablets of pitavastatin by oral route for a period of 6 months
62664243|NCT05455398|EXPERIMENTAL|Round window niche enlargement group|The round window niche was surgically removed by general anesthesia, the round window membrane was opened as entirely as possible, and the blockage of the round window membrane was carefully identified.
62664244|NCT05455398|ACTIVE_COMPARATOR|Drum chamber injection group|Methylprednisolone (40 mg) was injected via puncture in the posterior quadrant of the tympanic membrane once daily for 7 d. Patients were instructed to remain supine for 30 min to keep the drug in the tympanic chamber and to avoid swallowing to prevent drug flow from the eustachian tube.
62664245|NCT05625750||Patients diagnosed with NAFLD|All subjects will receive the currently recognized routine test of NAFLD according to their disease and no additional intervention and treatment will be added for subjects
62664246|NCT00954538|EXPERIMENTAL|Part I, Healthy Participants|Healthy participants will receive a single intravenous (IV) dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part I of the study
62664247|NCT00954538|EXPERIMENTAL|Part II, HE and AD Participants|HE and AD participants will receive a single IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part II of the study
62664248|NCT00954538|EXPERIMENTAL|Part III, HE and AD Participants|HE and AD participants will receive two separate IV doses of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part III of the study
62664249|NCT03173963|ACTIVE_COMPARATOR|Drug|Empagliflozin 10mg once a day
62664250|NCT03173963|PLACEBO_COMPARATOR|Placebo|1 placebo tablet a day
62103059|NCT04599114|EXPERIMENTAL|VIRTUES Arm|Patients in the VIRTUES arm will be offered enrollment into the virtual atrial fibrillation care platform.
62103060|NCT00024466|EXPERIMENTAL|Vaccine|Participants are vaccinated with GVAX one month or more after finishing induction therapy (which is given as per standard of care). Two weeks later, participants go through leukapheresis on protocol, then receive autologous transplant as per standard of care. GVAX is administered eight subsequent times after the autologous transplant.
62103061|NCT03329365||ESUS/ETUS|Patients with embolic ischemic stroke or transient ischemic attack of undetermined source
62103062|NCT03329365||SSS-CVTUS|Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source
62103063|NCT06102174|PLACEBO_COMPARATOR|Placebo|Oral or Nasogastric tube (NG)
62664251|NCT02038842|EXPERIMENTAL|MVA HIV-B and LIPO-5 vaccines|MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28
62664252|NCT02038842|EXPERIMENTAL|LIPO-5 and MVA HIV-B vaccines|LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
62664253|NCT02038842|EXPERIMENTAL|GTU-MultiHIV B and LIPO-5 vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28
62664254|NCT02038842|EXPERIMENTAL|GTU-MultiHIV B and MVA HIV-B vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
62664255|NCT03735342|EXPERIMENTAL|Audio Recording|Participants receive a verbal discharge discussion with a provider, written discharge instructions and a re-playable audio recording of the discharge discussion with the discharging provider.
62664256|NCT03735342|NO_INTERVENTION|Usual care|Participants receive a verbal discharge discussion with a provider and written discharge instructions.
62664257|NCT02451735|NO_INTERVENTION|Intervention Development|Psychoeducational Intervention (PEI) development. PEIs include printed and DVD materials, and represent a commonly used and effective approach to implement theoretically based individual-level interventions. These materials serve as important sources of information for the general public, cancer patients, and survivors from a variety of backgrounds, including populations with limited health literacy. An interview and feedback collection process will take place to provide data to improve current PEI materials.
62664258|NCT02451735|EXPERIMENTAL|Intervention Pilot - Intervention Group|The intervention group will receive the PEI materials: video and booklet. Self-reported feedback will be collected and reviewed to compare response with the control group.
62664259|NCT02451735|ACTIVE_COMPARATOR|Intervention Pilot - Control Group|The control group will receive a patient factsheet about Genetic Counseling (GC). Self-reported feedback will be collected and reviewed to compare response with the intervention group.
62103064|NCT06102174|ACTIVE_COMPARATOR|Sisunatovir|Oral or NG tube
62296081|NCT04894799|ACTIVE_COMPARATOR|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
62103065|NCT04160689|ACTIVE_COMPARATOR|Group 1|Anyridge (Mega'Gen, Korea) 5° conical internal hexed connection
62103066|NCT04160689|ACTIVE_COMPARATOR|Group 2|Core (Bioimplant, Italy) 35° conical internal hexed connection (screw-vent style)
62103067|NCT06218186|EXPERIMENTAL|Medical Device: Wesper Lab (Single Arm)|Participants already undergoing a prescribed polysomnography (PSG) sleep study for the diagnosis of sleep apnea will be asked to simultaneously wear Wesper Lab, a home sleep test device.
62296082|NCT04132050|EXPERIMENTAL|R788|Patients are administered R788 for 24 weeks (double-blind period), followed by R788 for up to 52 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
62296083|NCT04132050|PLACEBO_COMPARATOR|Placebo|Patients are administered Placebo for 24 weeks (double-blind period), followed by R788 for up to 28 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
62296084|NCT06003062||Standard Topical NIghtly Dose|Treatment group
62296085|NCT02505048|EXPERIMENTAL|rucaparib|"Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.~Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously"
61911969|NCT02555280|OTHER|The coflex® Interlaminar Technology|The coflex device was designed to address the clinical needs of spinal stenosis patients by providing stabilization of the affected level without fusion. The coflex is an interspinous process functional dynamic implant designed to impart a stabilizing effect at the treated level(s). The coflex device was approved by FDA in 2012.
62468080|NCT01967485|ACTIVE_COMPARATOR|No Text Messaging|Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
62468081|NCT01286090|EXPERIMENTAL|001|Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
62468082|NCT01286090|EXPERIMENTAL|002|Placebo One tablet taken orally 4 times a day for up to 8 weeks.
62468083|NCT00770445|EXPERIMENTAL|Pioglitazone 15mg BID|Insulin therapy added
62468084|NCT00770445|EXPERIMENTAL|Pioglitazone 15mg + Metformin 850mg BID|Insulin Therapy Added
62468085|NCT00770445|ACTIVE_COMPARATOR|Metformin 850mg BID|Insulin therapy added
62468086|NCT05757245|EXPERIMENTAL|GMCN-508A|GMCN-508A infusion
62664260|NCT06225453|EXPERIMENTAL|Individualized strategy|"Targeting mean arterial pressure and systolic blood pressure of ≥ -20% of their baseline values in each patient during surgery. The baseline values are defined as the average of all measurements between one day before surgery and the morning of the surgery. The target is applied until discharge from the post-anesthesia care unit. If the patient is transported to the intensive care unit after surgery, not the post-anesthesia care unit, then the strategy is applied until the end of surgery.~The target is applied until discharge from the post-anesthesia care unit. It the patient is transported to the intensive care unit after surgery, not the post-anesthesia care unit, then the strategy is applied until the end of surgery."
62664261|NCT06225453|ACTIVE_COMPARATOR|Conventional strategy|Targeting a mean arterial pressure of 65 mmHg or higher and a systolic blood pressure of 90 mmHg or higher during surgery. The target is applied until discharge from the post-anesthesia care unit. If the patient is transported to the intensive care unit after surgery, not the post-anesthesia care unit, then the strategy is applied until the end of surgery.
62664262|NCT01889459||PCI for CTO|
62103068|NCT04448743||Covid-19 patients|
62103069|NCT04448743||patients with coronary artery disease|
62296086|NCT02912663|EXPERIMENTAL|Verapamil and Magnesium Sulfate|10mg of verapamil in 10 cc of normal saline and 1000mg of magnesium sulfate in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
62103070|NCT04448743||healthy volunteers|
62103071|NCT05520827|EXPERIMENTAL|Single Rising Dose part: BI 1584862|
62103072|NCT05520827|PLACEBO_COMPARATOR|Single Rising Dose part: Placebo|
62296087|NCT02912663|PLACEBO_COMPARATOR|Placebo|Control group will receive saline only
62468087|NCT00509561|ACTIVE_COMPARATOR|Chemo-radiotherapy|
62468088|NCT00509561|EXPERIMENTAL|Chemo-radiotherapy plus cetuximab|
62468089|NCT01061021|EXPERIMENTAL|Integrated Intervention|Five small group + 2 individual counseling behavioral intervention to simultaneously address HIV transmission risk reduction and HIV treatment adherence in men and women living with HIV/AIDS.
62468090|NCT01061021|ACTIVE_COMPARATOR|Comparison Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
62103073|NCT05520827|EXPERIMENTAL|Food effect part: BI 1584862 fed (treatment test, T)/ BI 1584862 fasted (treatment reference, R)|
62103074|NCT05520827|EXPERIMENTAL|Food effect part: BI 1584862 fasted (treatment reference, R)/ BI 1584862 fed (treatment test, T)|
62296088|NCT02150811||Hunner's ulcer|
62296089|NCT02792868||patient|patient with cardiovascular risk (moderate)
62296090|NCT00749203|EXPERIMENTAL|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
62468091|NCT02664805|ACTIVE_COMPARATOR|LEO 124249 ointment|Twice daily cutaneous application for 8 weeks
62468092|NCT02664805|PLACEBO_COMPARATOR|LEO 124249 ointment vehicle|Twice daily cutaneous application for 8 weeks
62664263|NCT02941003|EXPERIMENTAL|OCT treatment|Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
62664264|NCT02941003|EXPERIMENTAL|OCT free|Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
62664265|NCT04095013|EXPERIMENTAL|Group BF|hyperbaric Bupivacaine 10mg with fentanyl 10micrograms
62664266|NCT04095013|EXPERIMENTAL|Group BD|hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
62664267|NCT00395382|ACTIVE_COMPARATOR|1|Alendronate
62664268|NCT00395382|PLACEBO_COMPARATOR|2|Placebo
62664269|NCT03494179|EXPERIMENTAL|High Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
62664270|NCT03494179|EXPERIMENTAL|Low Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
62664271|NCT02965833|OTHER|CCP, then HMPS|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
62664272|NCT02965833|OTHER|HMPS, then CCP|Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
62664273|NCT05145036|ACTIVE_COMPARATOR|Tai Chi exercise|In addition to standard of care participants will be asked to apply Tai Chi. There are 8 movements. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: Ward-off, Rollback, Push, Press, Grab, Split, Elbow strike, and shoulder strike.
62664274|NCT05145036|ACTIVE_COMPARATOR|Comprehensive training|In addition to standard of care participants will be asked to apply Comprehensive training. There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: stretch exercise, strengthening exercise, and balance exercise.
62664275|NCT04502524|EXPERIMENTAL|Arm I (New website program, handout, text message)|Participants complete the new website smoking cessation program which provides values driven, mindfulness based coping skills and utilizes non-judgmental acceptance of uncomfortable internal states like cravings. Participants will also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with all session handouts and available resources provided by the VA for continued support for smoking cessation.
62664276|NCT04502524|ACTIVE_COMPARATOR|Arm II (Standard care VA website, handout, text message)|Participants use the standard of care website, which provides educational materials about cessation treatments, tools to cope with urges and relapse, how to stay motivated, and brief tips on coping with physical and mental health problems. Participants also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with a handout of available resources provided by the VA for continued support for smoking cessation.
62664277|NCT03033628|EXPERIMENTAL|DV group|"Device: injection using DentalVibe comfort system. giving maxillary infiltration dental local anesthesia with the aid of DentalVibe comfort system on one side of the maxillary arch prior extraction of primary molar tooth"
62664278|NCT03033628|ACTIVE_COMPARATOR|C group|"Device: traditional dental injection giving maxillary infiltration dental local anesthesia without the aid of DentalVibe comfort system on the other side of the maxillary arch prior extraction of primary molar tooth"
62664279|NCT06197282||COVID-19 Positive, Symptomatic|Patients undergoing major surgery with a documented positive COVID19 test with in 1 year of surgery and were symptomatic for COVID19 at the time of testing.
62664280|NCT06197282||COVID-19 Positive, Asymptomatic|Patients undergoing major surgery with a documented positive COVID19 test with in 1 year of surgery and were asymptomatic for COVID19 at the time of testing as well as at the time of surgery.
62664281|NCT06197282||Control: COVID-19 Negative|Patients undergoing major surgery with documented COVID19 negative testing prior to procedure.
62664282|NCT03297697||Arm 1: Lymphotrack|-Patients will be treated with frontline chemotherapy per the treating physician's discretion. Collection of the pre-treatment tumor biopsy to identify the tumor-specific clonotype and peripheral blood samples at various time points for assessment of minimal residual disease using the LymphoTrack MRD assay. The results of these studies will be performed in batches and therefore will not be available to patients and clinicians to make clinical decisions.
62664283|NCT00849472|EXPERIMENTAL|Treatment Arm|"Preoperative~Cycles 1-4 Doxorubicin 60 mg/m2 IV over 15 minutes + Cyclophosphamide 600 mg/m2 IV over 30 minutes of Day 1 every 21 days~followed by:~Cycles 5-8 Paclitaxel 80 mg/m2 IV over 60 minutes (Days 1, 8, and 15) every 28 days in combination with pazopanib (800 mg) PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning on Day 1 of the first paclitaxel cycle Until 7 days before surgery~Followed by Surgery~Postoperative Pazopanib 800 mg PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning 4-6 weeks after surgery 6 months from first postoperative dose"
62664284|NCT04217356||Hematopoietic stem cell transplant (HCT)|Standard of care hematopoietic stem cell transplant with a matched donor.
62664285|NCT04217356||Best available non-transplant therapies (BAT)|Standard of care treatment with a janus kinase (JAK) inhibitor drug called ruxolitinib or treatment with an antimetabolite drug called hydroxyurea.
62664286|NCT01431742|EXPERIMENTAL|BEMA Buprenorphine|buprenorphine buccal soluble film
62296091|NCT00749203|ACTIVE_COMPARATOR|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
62296092|NCT02113202|EXPERIMENTAL|Tracer dose: 4.5 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 4.5 mg of the fluorescent tracer bevacizumab-IRDye800CW.
62664287|NCT01618877|EXPERIMENTAL|Levetiracetam iv infusion|Levetiracetam intravenous (iv) infusion.
61911970|NCT02555280|ACTIVE_COMPARATOR|Decompression|Lumbar decompression back surgery is when a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment.
62664288|NCT01618877|PLACEBO_COMPARATOR|Placebo infusion|
62664289|NCT01849809|EXPERIMENTAL|Gamma Ventral Capsulotomy|
62103075|NCT03607799|EXPERIMENTAL|Dietary Intervention|"A personalized nutrition plan will be developed for each woman and will respect faith-based food choices and regional preferences. The plan will be delivered by a culturally congruent health coach, and consider baseline dietary intake, energy balance for recommended gestational weight gain, personal values and preferences, through setting 2-4 SMART goals. Participants assigned to the intervention group will receive text messages. Participants assigned to the intervention group will be given a Fitbit to track their steps and will receive simple text messages weekly, aimed at increasing walking. They will be given PDF resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the South Asian community."
62103076|NCT03607799|ACTIVE_COMPARATOR|Control|Participants in the control group will receive simple text messages weekly, aimed at increasing walking. They will be given PDF resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the South Asian community.
62103077|NCT01670019|EXPERIMENTAL|Asenapine 5-20 mg daily|Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability
62103078|NCT01670019|PLACEBO_COMPARATOR|Placebo 1-4 tablets daily|Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability
62296093|NCT02113202|EXPERIMENTAL|Tracer dose: 10 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 10 mg of the fluorescent tracer bevacizumab-IRDye800CW.
62664290|NCT01291342||Preeclampsia|30 preeclamptic pregnant women with gestational age \>24 weeks and no chronic medical disorders who are not in labor and their fetus is alive.
62664291|NCT01291342||Normal pregnancy|30 normotensive pregnant women with gestational age \>24 weeks and no chronic medical disorders who has no obstetrical problems, not in labor and their fetus is alive.
62664292|NCT01291342||Healthy non-pregnant|30 healthy non-pregnant control women not on medications and has not delivered a baby or conceived during the year before the breath collection
62664293|NCT03524378|OTHER|Ergonomic and movement modifications|No group assignment - all participants will self select suitable ergonomic or movement modifications
62664294|NCT02665117|ACTIVE_COMPARATOR|KMgCit + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.
62664295|NCT02665117|ACTIVE_COMPARATOR|KCl + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.
62664296|NCT01015079||Entire Taiwan women|
62664297|NCT03466372|EXPERIMENTAL|biofeedback 1|biofeedback training with progression of targets
62664298|NCT03466372|ACTIVE_COMPARATOR|biofeedback 2|biofeedback training with progression of targets and speeds
61911971|NCT03149848|EXPERIMENTAL|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
61911972|NCT03149848|EXPERIMENTAL|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
62103079|NCT01994161||Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
62103080|NCT03374046|NO_INTERVENTION|Control Group|Standard care
62296094|NCT02113202|EXPERIMENTAL|Tracer dose: 25 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 25 mg of the fluorescent tracer bevacizumab-IRDye800CW.
62664299|NCT04229576|ACTIVE_COMPARATOR|Using TENS to relief pain during hystroscopy|device intensity (amplitude) will be individually adjusted to each participant's maximum sensory level (strongest reported tingling feeling without pain and with no muscle contractions, the TENS output intensity will be increased during the treatment every time the patient accommodated to the TENS stimulus.
62664300|NCT04229576|PLACEBO_COMPARATOR|Using placebo TENS (not active) during hystroscopy|participants will be connected to the TENS unit in exactly the same way as participants in the active TENS group with the unit emitting the active indicator light and sound but delivering no electrical stimulation.
62664301|NCT02340325|OTHER|Acute Sensitivity Test to FS2 cream|Twenty (20) healthy volunteers will be assigned volunteer numbers and will have a testing areas identified by permanent marker on their backs. Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area once for 24 hours. The pouch order will be random, generated by the www.random.org list generator each application. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
61911973|NCT04365101|EXPERIMENTAL|Phase I|CYNK-001 infusions on Days 1, 4, and 7
62103081|NCT03374046|EXPERIMENTAL|Apneic Oxygenation Group|"During apneic period of intubation attempt, patient will be placed on nasal cannula~* If 0-2 years: 3L/min NC of 100% FiO2~* If \> or = to 2 through17 years: 5L/min NC of 100% FiO2"
62664302|NCT02340325|OTHER|Chronic Sensitivity Test to FS2 cream|Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
62664303|NCT04831112|EXPERIMENTAL|Honey|Topical honey to be used for dressing 4ml per square inch.
62664304|NCT04831112|ACTIVE_COMPARATOR|EUSOL|EUSOL soaked gauze to be placed over the wound as dressing.
62664305|NCT05055219||Group 1: Overweight or Obese Group (visits #1-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight. Overweight or obese, as defined by a BMI ≥ 85th percentile \& \<95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
61911974|NCT04365101|ACTIVE_COMPARATOR|Phase II|Randomized, open label; CYNK-001 infusions on Days 1, 4, and 7 compared to Control Group: Best Supportive Care
61911975|NCT00409331|EXPERIMENTAL|IMRT + Amifostine|Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.
61911976|NCT03529071|EXPERIMENTAL|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
62103082|NCT06500286|EXPERIMENTAL|Group A|• Group A receive caudal block placing the patient into the left lateral decubitus position. . The sacral hiatus was found by palpating the sacral cornu and a 22-G needle was placed through it. After passing through the sacrococcygeal 0.25% bupivacaine was administered at a dose of 0.2 ml/kg.the procedure was completed, the patient was placed into the supine Position.
61911977|NCT03529071|NO_INTERVENTION|Control|Individuals will not receive any intervention or surveys.
62103083|NCT06500286|EXPERIMENTAL|Group B|Group B US guided Dorsal penil block. The 5-10 MHz linear probe was placed at the penis root, making it possible to observe the corpus cavernosum, corpus spongiosum, dorsal artery and vein, and the deep penile fascia (Buck's fascia) on the transverse plane with gentle penile traction. The in-plane technique was then used to insert a 50-mm block needle toward the dorsal penile section from the lateral part of the penis root. The needle was then advanced from the hyperechoic superficial penis fascia (Dartos fascia) and the superficial sheath was passed. After advancing the needle into Buck's fascia, the needle was placed lateral to the dorsal artery, at a position between Buck's fascia and tunica albuginea. Negative aspiration was performed. US was then used to observe the distribution of the anesthetic while half of the total 0.25% bupivacaine dose (0.2 mL/kg) was administered (Fig. 1). Afterward, the same procedure was also performed on the other side of the penis.
62103084|NCT06629480|ACTIVE_COMPARATOR|BIC/TAF/FTC|
62103085|NCT06629480|ACTIVE_COMPARATOR|DTG/ABC/3TC|
62103086|NCT06630494|EXPERIMENTAL|Healthy Caucasian volunteers|Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
62103087|NCT01414166|EXPERIMENTAL|ERN/LRPT group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive ERN/LRPT for 16 weeks.
62103088|NCT01414166|PLACEBO_COMPARATOR|Placebo group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive placebo for 16 weeks.
62103089|NCT06230562|EXPERIMENTAL|Case group|
62103090|NCT06230562|ACTIVE_COMPARATOR|Control group|
62103091|NCT02525705|EXPERIMENTAL|Every EA patients|This is a one group interventional study. Every patient is included in the same arm.
62664306|NCT05055219||Group 2: Overweight or Obese Group (visits #3-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight, or children and young adults who previously participated in the study (completed visits #1-2 in previous study phase). Overweight or obese, as defined by a BMI ≥ 85th percentile \& \<95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
62296095|NCT02185521|EXPERIMENTAL|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
62664307|NCT05055219||Group 3: Normal Weight Control Group|Children and adolescents who are 8 to 17 years of age, who have do not have risk factors for diabetes such as being overweight or a history of type 2 diabetes in the family. Healthy weight, as defined by a BMI ≥ 5th percentile \& \< 85th percentile. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
62664308|NCT03419468|EXPERIMENTAL|1|iPad administration of Self Geriatric Assessment Measure (SGAM)
62103092|NCT00603447|EXPERIMENTAL|Carfilzomib + Lenalidomide + Dexamethasone|Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
62103093|NCT05967442|EXPERIMENTAL|Magnesium|Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
62103094|NCT05967442|ACTIVE_COMPARATOR|Metoclopramide|Metoclopramide 10mg in 50ml D5W over 20 minutes
62103095|NCT05967442|ACTIVE_COMPARATOR|Prochlorperazine|Prochlorperazine in 50ml D5W over 20 minutes
62103096|NCT03433261|NO_INTERVENTION|Normal Diet|The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.
62664309|NCT03419468|ACTIVE_COMPARATOR|2|Paper survey administration of Self Geriatric Assessment Measure (SGAM)
62664310|NCT05707325|EXPERIMENTAL|Dose Escalation in Solid tumors and Hematologic malignancies|In Dose Escalation part， all patients will be enrolled in different doses according to the Study Protocol for evaluate the recommend dose
62664311|NCT05707325|EXPERIMENTAL|Dose Expansion in Solid tumors and Hematologic malignancies|In Expansion part， all patients will be enrolled in recommended dose
62664312|NCT00580398|NO_INTERVENTION|Control|Usual care included physician advice to quit smoking.
62664313|NCT00580398|EXPERIMENTAL|Intervention|Intervention participants were provided with a cognitive-behavioral 12-week program consisting of varenicline (1mg bid, with initial titration up over week 1) and smoking cessation counseling targeted to the issues of thoracic cancer patients. We offered 7 counseling sessions but were flexible in offering additional counseling when needed. Counseling was delivered by a certified Tobacco Treatment Counselor using Motivational Interviewing (MI) techniques.
62103097|NCT03433261|EXPERIMENTAL|Ketogenic Diet|The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.
62103098|NCT04239339|PLACEBO_COMPARATOR|Control Group|The placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo pill.
62103099|NCT04239339|EXPERIMENTAL|Intervention Group|The intervention group will be administered 20mg of Escitalopram daily for approximately 3 weeks.
62103100|NCT00793806||Medical Tool|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
62103101|NCT04313452|PLACEBO_COMPARATOR|regular diet|50% of energy from carbohydrates, 30% fat and 20% from protein
62103102|NCT04313452|ACTIVE_COMPARATOR|Mediterranean diet|60% of energy from carbohydrates, 25% fat and 15% from protein
62103103|NCT01066065||Raltegravir Cohort|Patients taking RAL 400 mg BID with Truvada
62103104|NCT01066065||Darunavir Cohort|Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada
62296096|NCT01322815|EXPERIMENTAL|Chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
62296097|NCT01322815|EXPERIMENTAL|GI-4000 and bevacizumab|maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
62296098|NCT00757315|EXPERIMENTAL|1|
62296099|NCT00757315|ACTIVE_COMPARATOR|2|
62296100|NCT05533801|EXPERIMENTAL|Treatment A: Lecanemab 720 mg|Participants will receive a single SC dose of lecanemab 720 milligram (mg) in the lower abdomen using a vial and syringe on Day 1.
62296101|NCT05533801|EXPERIMENTAL|Treatment B: Lecanemab 720 mg|Participants will receive a single SC dose of lecanemab 720 mg in the lower abdomen using AI on Day 1.
62296102|NCT00104871|EXPERIMENTAL|Bortezomib|Bortezomib 1.3 mg/m\^2 intravenous (IV) at over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses.
62664314|NCT04472741|OTHER|FUSE|wide angle colonoscope
62664315|NCT04472741|OTHER|HD Pentax i10 colonoscopes|SFV instrument
62664316|NCT04472741|OTHER|Endocuff|Cuff on SFV
62664317|NCT04520100|NO_INTERVENTION|MRI without intervention|No hypnosis during MRI and care by regular MR technologist
62664318|NCT04520100|ACTIVE_COMPARATOR|MRI with clinical hypnosis and regular MR tech|Hypnosis during MRI and care by regular MR technologist
62296103|NCT05916352|ACTIVE_COMPARATOR|Caffeine Group|5 mg/kg caffein supplement will be given
62664319|NCT04520100|ACTIVE_COMPARATOR|MRI with care by MR Tech trained in empathic communication|No hypnosis during MRI and care by MR technologist who have been trained in emphatic communication
62664320|NCT04619537|EXPERIMENTAL|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
62664321|NCT02763358|OTHER|Bites and Steps displayed|All subjects will be assigned to one arm-daily bites and steps displayed on Bite Counter device
62664322|NCT02302456|EXPERIMENTAL|TXA|Intravenous administration of 1g of tranexamic acid within 2 minutes after birth and prophylactic oxytocin administration
61911978|NCT02825290|EXPERIMENTAL|Study group|hCG (Choriogonadotropin alfa; Ovitrelle 250 mcg) on day of embryo transfer \& GnRH-agonist (Triptorelin acetate; Decapeptyl 0.1 mg) after 4 days In addition to the usual progesterone luteal support.
61911979|NCT02825290|NO_INTERVENTION|Control group|The usual progesterone only luteal phase support.
61911980|NCT01282970|EXPERIMENTAL|BI 135585|once daily doses as oral solution or tablet formulation over 14 days
62296104|NCT05916352|PLACEBO_COMPARATOR|Placebo Group|Placebo will be given
62296105|NCT05916872|EXPERIMENTAL|experimental group|patients in this group will receive contract relax exercises along with EMS
62296106|NCT05916872|ACTIVE_COMPARATOR|control group|patients in groups B will receive conventional therapy.
62664323|NCT02302456|PLACEBO_COMPARATOR|Placebo|Intravenous administration of placebo within 2 minutes after birth and prophylactic oxytocin administration
62664324|NCT03910946||diabetic and renal|all cases included in the study will be subjected to : Full clinical history to rule out active TB ( history of current prolonged cough, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue.) Chest x ray TST (tuberculin sensitivity test) : injecting a 0.1 mL of liquid containing 5 TU (tuberculin units) PPD (purified protein derivative) into the top layers of skin of the forearm and read skin tests 48-72 hours after the injection
62664325|NCT03113955|EXPERIMENTAL|single -arm|A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
62664326|NCT00778180|EXPERIMENTAL|1|furosemide 80 mg tablets of Ranbaxy
62664327|NCT00778180|ACTIVE_COMPARATOR|2|Lasix® (furosemide) 80 mg tablets
62664328|NCT00321412|PLACEBO_COMPARATOR|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
62664329|NCT00321412|EXPERIMENTAL|1|AST-120, 2 gram sachets
62664330|NCT01253486|EXPERIMENTAL|Disease-related expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period
61911981|NCT01282970|PLACEBO_COMPARATOR|Placebo to BI 135585|once daily doses as oral solution or tablet formulation over 14 days
62664331|NCT01253486|ACTIVE_COMPARATOR|Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
62664332|NCT01253486|SHAM_COMPARATOR|Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
62103105|NCT06690151||Study population (Newborns with congenital heart defects and their two parents)|The study population will consist of 150 fetuses with a prenatally diagnosed critical congenital heart defect (CHD), at high risk of developing developmental delays, and their two parents.
62103106|NCT02627625|EXPERIMENTAL|test product A|tiotropium
62103107|NCT02627625|EXPERIMENTAL|test product B|tiotropium
62103108|NCT02627625|EXPERIMENTAL|test product C|tiotropium
62296107|NCT02625402|EXPERIMENTAL|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
62296108|NCT02625402|EXPERIMENTAL|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
62308242|NCT05858411|ACTIVE_COMPARATOR|SRP alone|SRP alone will be performed.
61911982|NCT04577157|EXPERIMENTAL|Intervention Arm|"The participants in the intervention group will receive Health@click (seven-item multifaceted educational and reminder module) through WhatsApp. This will be included daily notes for medication reminders, voice messages, Graphics-based Reminders (GBR), Twice-weekly Graphics-based Messages (GBM), and once-weekly lifestyle advice through video in addition to standard care (as being practiced routinely in the hospitals). Besides this, a 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects and interaction with different foods, and psychological support to the participants who feel the need."
62103109|NCT02627625|ACTIVE_COMPARATOR|Commercial product D|tiotropium
62103110|NCT02627625|ACTIVE_COMPARATOR|commercial product E|tiotropium
62103111|NCT02747992||PECS 0|receiving paravertebral block
62103112|NCT02747992||PECS 1|receiving paravertebral block and blocks targeting pectoral musculature
62468093|NCT05003635|ACTIVE_COMPARATOR|AFT+ EVEBRA device (intervention arm)|"Before and after the AFT surgery, patients are required to wear the EVEBRA expansion device for a total duration of 4 weeks. Thereafter patients will receive a PexyBra over the reconstructed breast.~Pre-operatively patients are required to wear the device for a total of 200 hours."
62468094|NCT05003635|NO_INTERVENTION|AFT without EVEBRA device (control arm)|Patients will receive the AFT treatment for total reconstruction without the requirement of wearing the EVEBRA device.
62468095|NCT02219620|EXPERIMENTAL|Music, Imagery, Movement intervention|Music, Imagery, Movement intervention: psychosocial intervention incorporating Music, Imagery and Movement
61911983|NCT04577157|NO_INTERVENTION|Control Arm|Participants in the control group will receive no intervention except in standard care (as per being practiced routinely in the hospitals).
61911984|NCT00918125||White educational video|Patients will view an educational video that contains White physicians and patients.
62103113|NCT02893228|EXPERIMENTAL|Group S (saline group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
62103114|NCT02893228|ACTIVE_COMPARATOR|Group C (control group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
62103115|NCT06714253|EXPERIMENTAL|RXRG001 Part 1|Open-label, single arm with 6 subsequent dose cohorts (3 single dose and 3 multiple dose cohorts) of RXRG001 administered intraductally in the salivary gland (unilateral)
62103116|NCT06714253|EXPERIMENTAL|RXRG001 Part 2|Randomized double-blind with 3 subsequent multiple dose cohorts. RXRG001 is administered intraductally in the salivary gland (bilateral)
62103117|NCT06714253|PLACEBO_COMPARATOR|Placebo Part 2|Randomized double-blind with 3 subsequent multiple dose cohorts. Placebo is administered intraductally in the salivary gland (bilateral)
62468096|NCT02219620|ACTIVE_COMPARATOR|Social Control|social control/interaction group
62468097|NCT05258474|EXPERIMENTAL|healthy subjects|healthy subjects (single-ascending and multiple-ascending doses)
62103118|NCT01877616|OTHER|diagnostic test|all persons with a definitive diagnosis of a major sleep disorder (insomnia, hypersomnia, sleep-disordered breathing) will be followed annually for at least five years
62103119|NCT01912001|OTHER|Telephone follow-up.|A member of the Home Dialysis team will telephone patients to follow-up on their symptoms, dialysis and care.
62103120|NCT04188288|EXPERIMENTAL|Neurofeedback|Three imaging (fMRI) sessions of experimental feedback.
62468098|NCT05258474|EXPERIMENTAL|IBD-patients|inflammatory bowel disease patients (multiple dose)
62468099|NCT04005677||lung cancer|
62468100|NCT04005677||benign lung nodule|
62468101|NCT04005677||lung nodule|
62468102|NCT02086747|ACTIVE_COMPARATOR|Acetaminophen|Postoperative 72 hours acetaminophen 1 g iv 4 times a day for 72 hours iv
62468103|NCT02086747|PLACEBO_COMPARATOR|isotonic|1 g intravenous %0.9 NaCl four times Daily for 72 hours
62468104|NCT03073330|EXPERIMENTAL|One Step|The intervention is gestational diabetes screening with 2 hour GTT 75 g load.
62103121|NCT04188288|OTHER|Control feedback|Three imaging (fMRI) sessions of control feedback.
62468105|NCT03073330|ACTIVE_COMPARATOR|Two Step|There is no intervention is this arm as patients will subjected to routine gestational diabetes screening with one hour glucola, 50 g load.
62664333|NCT01253486|NO_INTERVENTION|Control condition|Participants in the control condition do not receive any intervention and complete only the assessments
62664334|NCT04399005|EXPERIMENTAL|daily room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
61911985|NCT00918125||African-American educational video|Patients will view an educational video that contains African-American physicians and patients.
61911986|NCT00918125||Usual care|Patients will receive counseling about their condition and treatment options.
61911987|NCT02864901|EXPERIMENTAL|KSL-W 30 mg|3 times per day over 4 treatment days
61911988|NCT02864901|PLACEBO_COMPARATOR|Chewing Gum Placebo|3 times per day over 4 treatment days
62103122|NCT02121418|EXPERIMENTAL|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
62468106|NCT05294094|EXPERIMENTAL|intervention group|blended learning
62664335|NCT04399005|EXPERIMENTAL|after-each-case room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. After-each-case room disinfection was defined as after completing each case.
62468107|NCT05294094|ACTIVE_COMPARATOR|control group|Teaching format as usual
61911989|NCT00599131|EXPERIMENTAL|Chemotherapy/Radiation/Surgery|"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.~On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.~Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
61911990|NCT00949767|EXPERIMENTAL|BMS-866949 (Panel 1)|
61911991|NCT00949767|EXPERIMENTAL|BMS-866949 (Panel 2)|
61911992|NCT00949767|EXPERIMENTAL|BMS-866949 (Panel 3)|
61911993|NCT00949767|EXPERIMENTAL|BMS-866949 (Panel 4)|
62103123|NCT06632067||sugammadex|those who use sugammadex for reversal of neuromuscular blockade
62103124|NCT06632067||neostigmine|those who use neostigmine/atroping for reversal of neuromuscular blockade
62103125|NCT04878042|EXPERIMENTAL|Active|Mouth wash and nasal spray containing a diluted solution of hydrogen peroxide
62103126|NCT04878042|PLACEBO_COMPARATOR|Placebo|Mouth wash and nasal spray not containing a diluted solution of hydrogen peroxide
62664336|NCT00673829|EXPERIMENTAL|Phase Ia|
62664337|NCT00673829|EXPERIMENTAL|Phase Ib: Control|
62664338|NCT01935804|EXPERIMENTAL|Experimental: 1|Pioglitazone given 30mg/once daily for 12 months.
62664339|NCT01935804|ACTIVE_COMPARATOR|Active comparator: 2|Metformin given 850 mg/twice daily for 12 months.
61911994|NCT00949767|EXPERIMENTAL|BMS-866949 (Panel 5)|
61911995|NCT00949767|EXPERIMENTAL|BMS-866949 (Panel 6)|
61911996|NCT00949767|EXPERIMENTAL|BMS-866949 (Panel 7)|
61911997|NCT02335671|EXPERIMENTAL|Intra-operative Magnetic Resonance Imaging (MRI)|"* Preoperative diagnostic MRI~* Intra-operative MRI~* Standard lumpectomy and sentinel node biopsy if indicated, or standard axillary dissection if clinically indicated~* Specimen to Pathology and Mass Spectrometer (Analysis of Tissue Sample)"
61911998|NCT03653871|EXPERIMENTAL|Intervention|Performing arts instruction delivered 1 hour/week for 8 weeks.
61911999|NCT03653871|NO_INTERVENTION|Wait List Control|Control group. Performing arts instruction delivered upon completion of control period.
61912000|NCT04994470|EXPERIMENTAL|Web-based intervention group|Two-week web-based intervention
61912001|NCT04994470|SHAM_COMPARATOR|Web-based control group|Two-week web-based sham comparator
61912002|NCT03444532|EXPERIMENTAL|12-week aerobic exercise and cognitive-behavioral therapy|12-week aerobic exercise, two times per week, and cognitive-behavioral therapy for insomnia in total four sessions
61912003|NCT03444532|NO_INTERVENTION|Control group|Patients assigned to the control group will receive usual care
61912004|NCT05349253|EXPERIMENTAL|Garlic extracts|Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)
61912005|NCT05349253|PLACEBO_COMPARATOR|placebo|As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.
62664340|NCT01407419|EXPERIMENTAL|Treat to Target Intervention Strategy|Subjects at sites randomized to this arm will be expected to return to the clinic for Monthly Assessments until low disease activity (LDA) defined as CDAI of 10 or less has been achieved. Providers are prompted to accelerate therapy (Treatment Acceleration) at each visit that CDAI is \>10 (unless not felt to be medically appropriate or refused by the subject.) Accelerations are expected at least every 3 months, until/unless LDA has been achieved.
62664341|NCT01407419|NO_INTERVENTION|Control Group Treated with Usual Care|Subjects in this arm will be expected to complete study visits with their rheumatologist/study doctor at Baseline, Month 3, Month 6, Month 9 and Month 12. Data collection will occur at each of those visits. Subjects and Providers will continue managing disease per usual practices and do not receive protocol prompts relative to visit frequency or acceleration of therapy, regardless of disease activity level (by CDAI)
61912006|NCT02338336|PLACEBO_COMPARATOR|Placebo|Placebo
61912007|NCT02338336|EXPERIMENTAL|Nowarta110 3 drops|Nowarta110 3 drops administration
61912008|NCT02338336|EXPERIMENTAL|Nowarta110 6 drops|Nowarta110 6 drops administration
61912009|NCT02338336|EXPERIMENTAL|Nowarta110 10 drops|Nowarta110 10 drops administration
62664342|NCT02805998|EXPERIMENTAL|Web-based CBT-I|Sleepio delivers CBT-I through 6 weekly web-sessions. Treatment content is based on CBT for insomnia manuals and includes a behavioral component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, putting the day to rest) and an educational component (psycho-education, sleep hygiene).
62664343|NCT02805998|OTHER|Treatment as Usual|Our control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy. Use of non-study treatment will be tracked.
61912010|NCT05579067|EXPERIMENTAL|Evaluation of functional results and survival rate of peroneus longus tendon used for ACLR.|
61912011|NCT05579067|ACTIVE_COMPARATOR|Evaluation of functional results and survival rate of hamstring tendon used for ACL reconstruction.|
61912012|NCT00522132|ACTIVE_COMPARATOR|cohort 1|2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
61912013|NCT00522132|EXPERIMENTAL|cohort 2|4.0 mg/kg iv Artesunate at 0, 24 and 48 h
62103127|NCT05293301|EXPERIMENTAL|Periodontal Endosccope|One randomly assigned side of the mouth received deep cleaning treatment with the operator using a periodontal endoscope or Perioscopy® for magnification
62103128|NCT05293301|ACTIVE_COMPARATOR|Traditional Loupes|One randomly assigned side of the mouth received deep cleaning treatment with the operator using traditional loupe magnification
62103129|NCT06409195|EXPERIMENTAL|Cohort 1|Cohort 1: SM-020 gel 1.0% BID for 28 days to superficial BCCs
62103130|NCT06409195|EXPERIMENTAL|Cohort 2|Cohort 2: SM-020 gel 1.0% BID for 28 days to nodular BCCs
62468108|NCT02287675|ACTIVE_COMPARATOR|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
62664344|NCT06494163|EXPERIMENTAL|standard care + moderate-intensity continuous exercise training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min
61912014|NCT01603524|ACTIVE_COMPARATOR|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
61912015|NCT01603524|EXPERIMENTAL|OMSC + Performance Feedback Group|The OMSC + Provider Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic.
61912016|NCT02139059|ACTIVE_COMPARATOR|initial urinary drainage|initial urinary drainage to stabilize renal functions before ureteroscopy
61912017|NCT02139059|ACTIVE_COMPARATOR|direct ureteroscopy|direct ureteroscopy without initial urinary drainage
61912018|NCT04411381|ACTIVE_COMPARATOR|Telemedicine-based model of care|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
62103131|NCT06409195|EXPERIMENTAL|Cohort 3|Cohort 3: SM-020 gel 1.0% BID for 28 days to infiltrating BCCs
62468109|NCT02287675|ACTIVE_COMPARATOR|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:~In adults, to assist in the:~* localization of lymph nodes draining a primary tumor in patients with~* breast cancer or malignant melanoma when used with a hand-held gamma counter.~* evaluation of peritoneovenous (LeVeen) shunt patency in adults."
62664345|NCT06494163|EXPERIMENTAL|standard care + high-intensity interval training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min
62664346|NCT02104102|EXPERIMENTAL|Mirror group|Composed of 30 volunteers who carry out the mirror therapy, whose name shall Mirror Group (MG).
62103132|NCT06409195|EXPERIMENTAL|Cohort 4|Cohort 4: SM-020 gel 1.0% BID for 28 days to SCCISs
62468110|NCT06470880|ACTIVE_COMPARATOR|ARM A: Standard of care|Continuous dosing of encorafenib 450mg once daily plus binimetinib 45mg twice daily.
62468111|NCT06470880|EXPERIMENTAL|ARM B: Adaptive therapy|4 weeks of encorafenib 450mg once daily plus binimetinib 45mg twice daily, followed by adaptive cycles based on ctDNA TAB level
62468112|NCT05668520||weight stable|stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,
62468113|NCT05668520||weight loss|stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,
62468114|NCT02769715|ACTIVE_COMPARATOR|cast removable partial denture|patients received cast removable partial dentures fabricated using traditional lost-wax casting technique.
62468115|NCT02769715|EXPERIMENTAL|laser-sintered removable partial denture|patients received removable partial dentures fabricated using laser-sintering.
62468116|NCT05372926|EXPERIMENTAL|Venturi mask|Patients will be placed under oxygen therapy with Venturi mask at a constant flow of 15L/min and a set FiO2 of 50%. The real FiO2 will be mesured in the mask at rest.
62664347|NCT02104102|EXPERIMENTAL|Control Group - kinesiotherapy|Called by Control Group (CG), composed of 30 volunteers who will carry out the kinesiotherapy with the same sequence of movements for the Mirror Therapy that the MG, but without the view in the mirror, since it will be blocked.
62103133|NCT06409195|EXPERIMENTAL|Cohort 5|Cohort 5: SM-020 gel 1.0% BID for 28 days to SKs
62308243|NCT02846675|EXPERIMENTAL|SVF treatment (random knee)|A random knee (left or right) of subjects will be treated with autologous SVF.
62468117|NCT05372926|EXPERIMENTAL|High flow nasal canulae|Patients will be placed under high flow nasal canulae oxygen therapy with a constant flow of 50L/min and the real FiO2 provided by Venturi mask.
62468118|NCT01789905||Tigecycline (Tygacil)|Subjects who are treated with tigecycline
62468119|NCT03637153|EXPERIMENTAL|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
62468120|NCT03637153|EXPERIMENTAL|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
62468121|NCT03970421||patients without anticoagulant and / or antiplatelet treatment|Patients older than 16yo with no anticoagulant or antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
62468122|NCT03970421||patients on antiplatelet therapy (ASA and / or clopidogrel|Patients older than 16yo on antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
62664348|NCT00471120|EXPERIMENTAL|P2x7 Assay|Compare assay results with biopsy
62664349|NCT04488185|EXPERIMENTAL|Secukinumab 300mg|Randomized in a 2:1 ratio to secukinumab or placebo
62664350|NCT04488185|PLACEBO_COMPARATOR|Placebo|Randomized in a 2:1 ratio to secukinumab or placebo
62664351|NCT00361153|ACTIVE_COMPARATOR|1|Colesevelam hydrochloride
62664352|NCT00361153|PLACEBO_COMPARATOR|2|placebo
62103134|NCT02258295|EXPERIMENTAL|Intragel|Intragel (IBSA) has an average size of 800-1200 kDaltons. Intragel will give given with a concentration of 16mg/2cc. Each injection (2cc) injection will be given at baseline, then 2 weeks and 4 weeks from the baseline.
62664353|NCT02747160|EXPERIMENTAL|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a six-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
62664354|NCT05444127||Cases|patients with hepatic form of Wilson disease and those with neurological form
62664355|NCT05444127||controls|control population consulting in routine dental with panoramic dental imaging, outside of an emergency context
62664356|NCT03672825|EXPERIMENTAL|RECLAIM|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
62664357|NCT00504309|EXPERIMENTAL|4g P-OM3, then 1g P-OM3, then Placebo|4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
62664358|NCT00504309|EXPERIMENTAL|1g P-OM3, then 4g P-OM3, then Placebo|1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
62664359|NCT00504309|EXPERIMENTAL|Placebo, then 4g P-OM3, then 1g P-OM3|Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
62664360|NCT00504309|EXPERIMENTAL|4g P-OM3, then Placebo, then 1g P-OM3|4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
62664361|NCT00504309|EXPERIMENTAL|1g P-OM3, then Placebo, then 4g P-OM3|1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
62664362|NCT00504309|EXPERIMENTAL|Placebo, then 1g P-OM3, then 4g P-OM3|Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
62664363|NCT05302050|ACTIVE_COMPARATOR|Intervention BT-001 + Standard of Care|Patients in this arm will receive the BT-001 treatment for up to 18 months.
62664364|NCT05302050|OTHER|Standard of Care|Patients will have access to a control mobile application for 6 months and then will have the option to use the treatment for the remainder of the 18 month study
62664365|NCT02315820|EXPERIMENTAL|Induction of Labor (IOL)|Group I, Induction of Labor group (IOL). Women will be admitted for induction at 38-40+3 weeks when estimated fetal weight 3800-4500 gram.
62664366|NCT02315820|NO_INTERVENTION|Expectant|Group II. Will be expectantly managed until 40+6 weeks, or an induction indication will appear.
62664367|NCT04384874|ACTIVE_COMPARATOR|Silbernagel combined concentric-eccentric program|A graduated rehabilitation program using exercises with concentric and eccentric contractions and progressing to plyometric training. The exercises are performed daily with progression guided by pain symptoms. There is no specificity in prescribed exercise loading.
61912019|NCT04411381|NO_INTERVENTION|Traditional model of care|Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation
61912020|NCT05026190|OTHER|azoospermic patients|
62103135|NCT02258295|ACTIVE_COMPARATOR|Saline|Saline injections will be given similar to the active hyaluronic injections. Each injection (2cc) will be given at baseline, then 2 weeks and 4 weeks from the baseline.
62296109|NCT03124043|EXPERIMENTAL|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
62296110|NCT03124043|EXPERIMENTAL|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
62296111|NCT03467620|EXPERIMENTAL|Cannabidiol oral capsule|25-mg capsule of Cannabidiol (CBD) per day taken daily for a duration of 12 weeks.
62296112|NCT03467620|PLACEBO_COMPARATOR|Placebo oral capsule|One placebo capsule per day for a duration of 12 weeks
62296113|NCT00728429|NO_INTERVENTION|standard of care|normal anthracycline therapy
62296114|NCT00728429|EXPERIMENTAL|exercise program|
62296115|NCT03040154|EXPERIMENTAL|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
62296116|NCT03040154|OTHER|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
62296117|NCT00682630|EXPERIMENTAL|Clinical Trial Reference Tablets first, then To-Be-Marketed Tablets|Participants first received clinical trial reference 720:240 mg tablets on Day 0. After a washout period of 43 days, they then received to-be-marketed 720:240 mg tablets on Day 43, with a follow-up period of 42 days.
61912021|NCT00492063|EXPERIMENTAL|Cell culture-derived influenza vaccine (cTIV)|
61912022|NCT00492063|ACTIVE_COMPARATOR|Egg-derived influenza virus vaccine (TIV)|
61912023|NCT04802629||Term neonates|≥ 37+0 weeks of gestation
61912024|NCT04802629||Preterm neonates|≤ 36+6 weeks of gestation
62103136|NCT00409864|ACTIVE_COMPARATOR|PTBD|percutaneous biliary drainage
62296118|NCT00682630|EXPERIMENTAL|To-Be-Marketed Tablets first, then Clinical Trial Reference Tablets|Participants first received to-be-marketed 720:240 mg tablets on Day 0. After a washout period of 43 days, they then received clinical trial reference 720:240 mg tablets on Day 43, with a follow-up period of 42 days.
62296119|NCT05040529||PLDRH|patients who underwent pure laparoscopic donor right hepatectomy
62103137|NCT00409864|ACTIVE_COMPARATOR|Endoscopic stenting|ERCP and stenting
62103138|NCT00762658|EXPERIMENTAL|1|AN2728 Ointment, 5%
62103139|NCT00762658|EXPERIMENTAL|2|AN2728 Ointment, 2%
62103140|NCT00762658|EXPERIMENTAL|3|AN2728 Ointment, 0.5%
62103141|NCT00762658|PLACEBO_COMPARATOR|4|AN2728 Ointment Vehicle
62296120|NCT05040529||ODRH|patients who underwent conventaional open donor right hepatectomy
62296121|NCT02781974|EXPERIMENTAL|Intervention|Intervention consists of strength and balance exercise in group sessions, twice a week for 12 weeks
61912025|NCT00146159|EXPERIMENTAL|1|1st group: 12 mg Mitoxantrone/m²
61912026|NCT00146159|EXPERIMENTAL|2|2nd group: 9mg Mitoxantrone/m²
61912027|NCT00146159|EXPERIMENTAL|3|3rd group: 5mg Mitoxantrone/m²
61912028|NCT03829878|EXPERIMENTAL|CP101|CP101 (Full Spectrum Microbiota) Capsule
62103142|NCT00762658|ACTIVE_COMPARATOR|5|Betnesol®-V Creme (betamethasone 0.1 %)
62103143|NCT00762658|ACTIVE_COMPARATOR|6|Protopic® Ointment (tacrolimus 0.1 %)
62103144|NCT02224833|EXPERIMENTAL|Intervention|
62103145|NCT02224833|NO_INTERVENTION|Control|
62103146|NCT02359435|EXPERIMENTAL|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
62103147|NCT02359435|ACTIVE_COMPARATOR|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
62103148|NCT03044769||Patient with CLA with surgery|
62103149|NCT03044769||Patient with CLA without surgery|
62103150|NCT03350737|EXPERIMENTAL|Heparin-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
62468123|NCT03970421||patients on treatment with acenocoumarol and INR <2|Patients older than 16yo on acenocumarol and with INR \<2 attended at ED because of Head Injury and with a Head CT performed.
62468124|NCT03970421||Others|patients on anticoagulant therapy with acenocoumarol and INR\> = 2 or patients on treatment with direct thrombin inhibitors (dabigatran), or inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban) or patients on treatment with low molecular weight heparins (LMWH) attended at ED because of Head Injury and with a Head CT performed.
62468125|NCT00905931|EXPERIMENTAL|Active|
62468126|NCT00905931|PLACEBO_COMPARATOR|Placebo|
62468127|NCT00760630|EXPERIMENTAL|CDP LFC|all patients will have this calculation based upon diagnostic parameters with IVUS and FFR and/or CFR
62468128|NCT01513174|ACTIVE_COMPARATOR|Control Gefitinib|Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.
62468129|NCT01513174|EXPERIMENTAL|Experimental: Gefitinib in combination with olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.
62103151|NCT03350737|PLACEBO_COMPARATOR|Placebo-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
62103152|NCT04600180||Palliative treatment with immunotherapy|
62103153|NCT06193785|EXPERIMENTAL|Hypnosis|hypnosis realised by expert practitioner during electromyogram realisation
62103154|NCT06193785|NO_INTERVENTION|control|standard electromyogram realisation
62468130|NCT02247752|OTHER|Inactive carriers|
62468131|NCT03375463|EXPERIMENTAL|5 mg Tirzepatide SC (Solution)-Part A|Participants received 5 milligrams (mg) of tirzepatide subcutaneous (SC) solution formulation.
62468132|NCT03375463|EXPERIMENTAL|5 mg Tirzepatide SC (Lyophilized)-Part A|Participants received 5 mg of tirzepatide SC lyophilized formulation.
62468133|NCT03375463|EXPERIMENTAL|0.5 mg LY3298176 IV-Part B|Participants received Intravenous (IV) infusion of a single 0.5 mg dose of tirzepatide formulation.
62468134|NCT03375463|EXPERIMENTAL|5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C|Participants received tirzepatide subcutaneous solution at 5 mg on Days 1 (week 1) and 8 (Week 2), 7.5 mg on Day 15 (Week 3) and 10 mg on Day 22 (Week 4).
62468135|NCT03375463|PLACEBO_COMPARATOR|Placebo SC-Part C|Participants received SC injection of placebo.
62468136|NCT03375463|EXPERIMENTAL|0.5 mg LY3298176 Bolus IV-Part D|Participants received IV bolus of 0.5 mg tirzepatide lyophilized formulation.
62664368|NCT04384874|EXPERIMENTAL|SSC6|A multi-stage rehabilitation program with focus on strength and reactive strength targets, as well as running gait re-training. These exercises will be initially carried out 3 days per week for the first 6 weeks with specific load targets prescribed.
62664369|NCT02193893|ACTIVE_COMPARATOR|Stem/progenitor cells transplantation.|Intervention: Biological: Cell-based therapeutics Autologous bone marrow-derived stem/progenitor cells will be transplanted intrathecally (via a standard lumbar puncture) into early vs. progressive ALS subjects.
61912029|NCT03829878|PLACEBO_COMPARATOR|Placebo|Placebo for CP101
62103155|NCT05042791|EXPERIMENTAL|SRT combined with pyrotinib and capecitabine|"SRT: SRT needs to be comprehensively considered based on the size, number, and location of the lesion, and SRS and FSRT are performed according to clinical needs.~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
62103156|NCT05042791|ACTIVE_COMPARATOR|WBRT combined with pyrotinib and capecitabine|"WBRT: WBRT need to be considered based on the size, number, and location of the lesion.~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
62103157|NCT05526911|EXPERIMENTAL|Group 1|The pharmacokinetics of midazolam, a CYP3A4 substrate, and digoxin, a P-gp substrate, will be studied before and after dosing with TBAJ-876.
62103158|NCT03568162|EXPERIMENTAL|ISB 830 - Part 1 Group 1|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
62103159|NCT03568162|EXPERIMENTAL|ISB 830 - Part 1 Group 2|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
62103160|NCT03568162|EXPERIMENTAL|ISB 830 - Part 1 Group 3|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
62296122|NCT02781974|NO_INTERVENTION|Control|"Participants allocated in the control group are instructed to live as usual"
62296123|NCT00807664|EXPERIMENTAL|1|Biatain Ag dressing
62296124|NCT00807664|ACTIVE_COMPARATOR|2|Biatain dressing
62296125|NCT01149200|EXPERIMENTAL|TC-6499|
62296126|NCT01149200|PLACEBO_COMPARATOR|Placebo|
62296127|NCT04658069||One Cohort receiving routine hemodialysis therapy without any specific interventions|all HD patients enrolled in this study
62296128|NCT05207761|EXPERIMENTAL|Sequence 1|"1. Period 1: D565 7days~2. Period 2: D565+D930 91days"
62664370|NCT02193893|SHAM_COMPARATOR|Standard treatment of ALS|Symptomatic treatment of ALS without biologic cell-based treatment
62664371|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
62296129|NCT05207761|EXPERIMENTAL|Sequence 2|"1. Period 1: D930 91days~2. Period 2: D565+D930 7days"
62296130|NCT02569034|ACTIVE_COMPARATOR|Young Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
62296131|NCT02569034|EXPERIMENTAL|Older Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
62296132|NCT02133417||Women|Women with mammographically-detected breast lesions
62296133|NCT02917590|EXPERIMENTAL|Dual-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are instructed to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device. During walk over obstacles, subjects asked to perform simultaneously with a color word stroop task which requires subjects to see and answer the color of the name of a color words in the monitor (ignore the meaning) as quickly as possible, and loudly.
62296134|NCT02917590|SHAM_COMPARATOR|Single-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are asked to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device.
62296135|NCT05669742|ACTIVE_COMPARATOR|Group 1 as control group|
62296136|NCT05669742|ACTIVE_COMPARATOR|Group two as Empagliflozin|
62296137|NCT04089956||Extubation Success|extubation Success which defined as no need of reintubation or tracheostomy after extubation.
62296138|NCT04089956||Extubation Failure|Extubation Failure was defined as need for any invasive ventilatory support after fist extubation during ICU stay or tracheostomy befor any extubation attempt.
62664372|NCT04289038|EXPERIMENTAL|Autogenic Relaxation|Autogenic Relaxation: It is an exercise program consisting of standard sentences that describe the body's absolute comfort and calm features.
61912030|NCT03996369|EXPERIMENTAL|Etrasimod 2 mg|
61912031|NCT03996369|PLACEBO_COMPARATOR|Placebo|
61912032|NCT04062136|EXPERIMENTAL|Stem cell transplantation|1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation
61912033|NCT00497809|EXPERIMENTAL|1|AVI-014 2.5mcg/kg
61912034|NCT00497809|EXPERIMENTAL|2|AVI-014 5.0 mcg/kg
61912035|NCT00497809|EXPERIMENTAL|3|AVI014 10.0 mcg/kg
61912036|NCT00497809|ACTIVE_COMPARATOR|4|Filgrastim 5.0 mcg/kg
61912037|NCT05541887|ACTIVE_COMPARATOR|Intervention-Placebo|Participants in this arm will consume muscadine wine polyphenol for six weeks and then placebo for another six weeks. The two phases are separated by a 21-day washout period
62296139|NCT00609921|ACTIVE_COMPARATOR|1|ARQ197
62296140|NCT05786482|NO_INTERVENTION|Waitlist Control|
62296141|NCT05786482|EXPERIMENTAL|Online Program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
62296142|NCT05786482|EXPERIMENTAL|Online Program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief 1-to-1 weekly check-ins with a study team member
62103161|NCT03568162|PLACEBO_COMPARATOR|Placebo - Part 1 Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
62468137|NCT02496416|EXPERIMENTAL|Treatment|The treatment group will participate in an eight week aquatic exercise program during weeks 2-9 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Randolph, NJ.. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
62664373|NCT04289038|EXPERIMENTAL|Virtual Reality|Virtual reality: Playing games via smart phone with virtual reality glasses and headset.
62664374|NCT04289038|OTHER|Control Group|Routine nursing care and kidney function narration
62664375|NCT00920816|EXPERIMENTAL|A|
62664376|NCT00920816|ACTIVE_COMPARATOR|B|
62664377|NCT02445560|EXPERIMENTAL|Probiotic capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
62664378|NCT02445560|EXPERIMENTAL|Probiotic capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
62664379|NCT02445560|EXPERIMENTAL|Placebo capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
62664380|NCT02445560|PLACEBO_COMPARATOR|Placebo capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
61912038|NCT05541887|ACTIVE_COMPARATOR|Placebo-Intervention|Participants in this arm will first consume placebo for six weeks and then muscadine wine polyphenol for another six weeks. The two phases are separated by a 21-day washout period
62103162|NCT03568162|EXPERIMENTAL|ISB 830 - Part 2 Group 5|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
62308244|NCT02846675|PLACEBO_COMPARATOR|placebo treatment (the other knee)|The other knee of subjects will be treated with placebo.
62664381|NCT01158586|EXPERIMENTAL|Levobupivacaine|patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl
62664382|NCT01158586|ACTIVE_COMPARATOR|Ropivacaine|patient controlled epidural analgesia using 0.2% ropivacaine with 2ug/ml fentanyl
62664383|NCT02100631|EXPERIMENTAL|PXVX0200 in Older Adults|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
62664384|NCT02100631|PLACEBO_COMPARATOR|Placebo in Older Adults|Placebo physiological saline
62664385|NCT02100631|OTHER|Historical Control: Adults Aged 18-45|This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
62664386|NCT02659904|ACTIVE_COMPARATOR|Less than 2 mm|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: Less than 2 mm remaining palatal tissue thickness
62664387|NCT02659904|ACTIVE_COMPARATOR|2 mm or more|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: 2 mm or more remaining palatal tissue thickness
62664388|NCT01227811|ACTIVE_COMPARATOR|Enablex(R) 15 mg , single dose|
62664389|NCT01227811|EXPERIMENTAL|Darifenacin 15 mg tablets, single dose|
62664390|NCT02057991|NO_INTERVENTION|Group I (standard of care)|Patients and caregivers receive standard of care.
61912039|NCT06161896||DLBCL cohort|"Interventions for the DLBCL cohort are:~* Fecal samples~* Blood samples~* Bioelectrical impedance analyses~* Filling in questionnaires~All other procedures will be in accordance with local and national guidelines corresponding to clinical standard care."
62103163|NCT03568162|PLACEBO_COMPARATOR|Placebo - Part 2 Group 6|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
62103164|NCT00751036|EXPERIMENTAL|Nilotinib|Patients who were assigned to this treatment group received 400 mg. nilotinib bid.
62103165|NCT00751036|ACTIVE_COMPARATOR|Imatinib|Patients who were assigned to this treatment group received 400 mg. imatinib bid.
62103166|NCT00415675||Respiratory Tumor + Normal Tissue Motion|
62103167|NCT04639154|PLACEBO_COMPARATOR|control group|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of NaCl 0.9% will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB
62103168|NCT04639154|ACTIVE_COMPARATOR|tramadol 50|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 50 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
62103169|NCT04639154|ACTIVE_COMPARATOR|tramadol 100|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 100 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
62664391|NCT02057991|EXPERIMENTAL|Group II (educational video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure.
62664392|NCT02057991|EXPERIMENTAL|Group III (educational video, mindfulness exercise video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure and watch a 20-minute interactive mindfulness exercise video.
62664393|NCT05100667|EXPERIMENTAL|Mental fatigue|Stroop task
62664394|NCT05100667|PLACEBO_COMPARATOR|Control MF|Emotionally neutral documentary
62664395|NCT05510817|OTHER|RRMS patients|RRMS patients initiating a new DMT
61912040|NCT06161896||Healthy control cohort|"The control group applied in the current study is based on the Danish General Suburban Population Study (GESUS). The control subjects are selected from the GESUS cohort and matched according to age and gender.~Serial stool samples are planned in a subset of the control cohort with sampling time points corresponding to the DLBCL cohort. The sample material is handled and stored the same way as for the DLBCL cohort."
61912041|NCT03099343|EXPERIMENTAL|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
62103170|NCT01282775|NO_INTERVENTION|Environment / Usual Care|
62103171|NCT01282775|OTHER|WEB+ Environment|Web-based weight loss program (WEB) + Environment - Participants have access to a proven Web-based weight loss program with weekly lessons focused on lifestyle behavior changes
62103172|NCT01282775|OTHER|WEB + Cash Incentive for Weight Loss|Web-based Weight Loss Program + Cash Incentive for Weight Loss - participants have access to a proven web-based weight loss program plus they are paid cash based on the percent weight lost at 12 months compared to baseline.
62664396|NCT04278092|EXPERIMENTAL|Paclitaxel plus Cetuximab|Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
62664397|NCT04170933|EXPERIMENTAL|Magnetic recanalization|The subjects in this group will be treated by magnetic recanalization
62664398|NCT01001104|EXPERIMENTAL|0.75 mg LY2189265|
62664399|NCT01001104|EXPERIMENTAL|0.5 mg LY2189265|
62664400|NCT01001104|EXPERIMENTAL|0.25 mg LY2189265|
62664401|NCT01001104|PLACEBO_COMPARATOR|Placebo|
62664402|NCT05665842|EXPERIMENTAL|Music Application Group|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, PedsQL and AIQ will be applied.~After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, PedsQL and AIQ will be reapplied."
62664403|NCT05665842|EXPERIMENTAL|Sleep Hygiene Training Group|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
62664404|NCT05665842|NO_INTERVENTION|Control Group|No attempt will be made to the adolescents who will be in the control group, and the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied on the same dates in parallel with the education and music application groups.
62664405|NCT05144906||Blind women|The blind women group will include women who are congenitally blind or that were blinded early in life (up to the age of 7).
62664406|NCT05144906||Sighted women|Women with normal or corrected-to-normal eye sight.
61912042|NCT03099343|NO_INTERVENTION|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
61912043|NCT01391884||Dialysis, Non-diabetic|Hemodialysis
61912044|NCT01391884||Healthy control|
62103173|NCT01076218||Diabetes|Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps
62296143|NCT02692625|EXPERIMENTAL|Group A|"Group A (test group): This group consist of 80 children receiving the probiotic lozenges.~The Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). The probiotic lozenge is used twice daily for two months."
62308245|NCT02708511|EXPERIMENTAL|Diagnostic (Cu 64 DOTA-B-Fab)|Patients receive copper Cu 64-DOTA-B-Fab IV followed by PET/CT 60 minutes post-injection and 24 hours post-injection
62664407|NCT06413329||exposure|Patients' preoperative exercise level met the standard of American Exercise guidelines.
62103174|NCT05998668|EXPERIMENTAL|genital hygiene training|"Following the pretest, genital hygiene behaviors training was provided to the women in the intervention group by E.S.B., one the researchers. In addition, a genital hygiene brochure prepared by the researchers which included the same content as the training was given to each participant. The training program was carried out as oral instruction as well as using the demonstration method which is called as tell-show-do. Individual questions of the women were answered at the end of the training. In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Four weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method. Four weeks after the data collection tools used in the research were filled in as a pre-test, post-test data were obtained with the same measurement tools."
62664408|NCT06413329||control|Patients' preoperative exercise level did not meet the standard of American Exercise guidelines
62664409|NCT06181851||Infertile men|Patients diagnosed with idiopathic non-obstructive azoospermia
62664410|NCT06181851||Fertile men|fertile subjects (pregnancy within 12 months of the start of the research by the couple, according to WHO 2010 criteria)
62468138|NCT02496416|ACTIVE_COMPARATOR|Control|The control group will participate in an eight week stretching program during weeks 2-9 of the study. The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
62664411|NCT06181851||Old fertile men|Subjects known to have been fertile subjects (pregnancy within 12 months of the start of the research by the couple, according to WHO 2010 criteria)
62664412|NCT03110276|EXPERIMENTAL|EYP001a|
62296144|NCT02692625|PLACEBO_COMPARATOR|Group B|"Group B (control group): This group consist of 80 children receiving the placebo lozenges.~The placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.The placebo lozenges is used twice daily for two months."
62468139|NCT03211403|EXPERIMENTAL|SHR4640 2.5mg|6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo
62664413|NCT03110276|PLACEBO_COMPARATOR|Placebo|
62664414|NCT03594552|EXPERIMENTAL|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
62664415|NCT03594552|EXPERIMENTAL|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
62664416|NCT03594552|EXPERIMENTAL|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
62664417|NCT03594552|EXPERIMENTAL|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
62664418|NCT03594552|EXPERIMENTAL|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
62664419|NCT03594552|EXPERIMENTAL|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
62664420|NCT01666977|EXPERIMENTAL|Arm A|Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
62664421|NCT01666977|EXPERIMENTAL|Arm B|Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
62664422|NCT01666977|EXPERIMENTAL|Arm C|Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
62664423|NCT02412657|EXPERIMENTAL|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
62664424|NCT02412657|EXPERIMENTAL|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
62664425|NCT02412657|PLACEBO_COMPARATOR|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
62664426|NCT01922297|EXPERIMENTAL|Day Treatment MDFT-HIV|Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
62664427|NCT01922297|OTHER|Day Treatment SAU|The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper \& Bartlett 1998; National Institute of Justice, 2001).
62664428|NCT05043870|EXPERIMENTAL|infliximab and immunosuppressives therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
61912045|NCT00373438|NO_INTERVENTION|A|
61912046|NCT00373438|EXPERIMENTAL|B|Fetoscopic tracheal occlusion
61912047|NCT01909791|EXPERIMENTAL|Prompt Laser + Deferred Aflibercept|Focal/grid laser followed by intravitreal aflibercept if vision worsens
61912048|NCT01909791|ACTIVE_COMPARATOR|Observation + Deferred Aflibercept|No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
61912049|NCT01909791|EXPERIMENTAL|Prompt Aflibercept|Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
61912050|NCT01479426|EXPERIMENTAL|EFLA400(960mg)|
62103175|NCT05998668|NO_INTERVENTION|Routine checks|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms (A sociodemographic questionnaire, Genital Hygiene Behavior Inventory (GHBI), and Self-Care Agency Scale (SCAS). The post-test forms (GHBI, SCAS) were re-administered 4 weeks later to women who did not receive any intervention.
62103176|NCT03532178|EXPERIMENTAL|Group A|rocuronium + sugammadex / succinylcholine + normal saline
62296145|NCT05532956||Individual semi-structured interview|A semi-structured individual interview lasting a maximum of 1.5 hour ,conducted by a psychologist, remotely (telephone, videoconference) or at home
62664429|NCT05043870|ACTIVE_COMPARATOR|infliximab therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
62296146|NCT05532956||Collective interview|Group interviews lasting a maximum of 2 hours will consolidate the information obtained during individual interviews
61912051|NCT01479426|PLACEBO_COMPARATOR|Placebo(960mg)|
61912052|NCT02969408|EXPERIMENTAL|ABS eMDPI|Participants will receive 90 mcg of ABS via an eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks.
61912053|NCT00412373|EXPERIMENTAL|001|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
61912054|NCT00412373|EXPERIMENTAL|003|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
62103177|NCT03532178|EXPERIMENTAL|Group B|succinylcholine + normal saline / rocuronium + sugammadex
62296147|NCT01360255||Patients treated with TACE|Patients treated with transarterial chemoembolisation (TACE) are included in this clinical trial
62103178|NCT03780309|ACTIVE_COMPARATOR|EXERCISE|Participants participated in a the exercise training program and engaged in exercise self-monitoring.
61912055|NCT00412373|PLACEBO_COMPARATOR|002|Placebo for 6 weeks
61912056|NCT03473080|OTHER|Internet CBT|Participants and their parents receive 16 weeks of internet-delivered cognitive behavior therapy (CBT) with psychologist support.
61912057|NCT00600834||1|patients with moderate CKD (stage 3, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
61912058|NCT00600834||2|patients with severe CKD or kidney failure (stages 4 and 5, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2).
61912059|NCT01947907|EXPERIMENTAL|ACP-001, dose-level 1|Once weekly subcutaneous injection of ACP-001
61912060|NCT01947907|EXPERIMENTAL|ACP-001, dose-level 2|Once weekly subcutaneous injection of ACP-001
61912061|NCT01947907|EXPERIMENTAL|ACP-001, dose-level 3|Once weekly subcutaneous injection of ACP-001
61912062|NCT01947907|ACTIVE_COMPARATOR|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone (rhGH)
62103179|NCT03780309|EXPERIMENTAL|EXERCISE+PEH|Participants participated in the exercise training program and engaged in exercise self-monitoring and blood pressure self-monitoring (daily and before and after exercise).
62296148|NCT04077333|EXPERIMENTAL|MISA group|minimal invasive surfactant administration group
62296149|NCT04077333|NO_INTERVENTION|EISA group|conventional treatment: endotracheal intubation surfactant administration group
62296150|NCT04125680|OTHER|ESL Health Literacy Classes|The program will last 8 weeks with classes held online during evening hours. The curriculum will focus on using pedagogies for health literacy as a practice. Assessments will be administered pre-post intervention.
62296151|NCT02828267|NO_INTERVENTION|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
62103180|NCT02377531|OTHER|Early glucose screen group|Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load. If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
62103181|NCT02377531|OTHER|Standard glucose screen group|The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
62664430|NCT04529980|EXPERIMENTAL|Lactobacillus rhanmosus GG(LGG®) Group|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge.
62664431|NCT04529980|PLACEBO_COMPARATOR|Placebo Control Group|Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge.
62664432|NCT04649983|EXPERIMENTAL|Arm 1|Patients will be be treated with CD19 and CD22 CAR-T cells
62664433|NCT05363904||Atopic Dermatitis (Europe)|
62664434|NCT05363904||Healthy Controls (Europe)|
62664435|NCT05363904||Atopic Dermatitis (Tanzania)|
62664436|NCT05363904||Healthy Controls (Tanzania)|
62664437|NCT05363904||Atopic Dermatitis (Madagascar)|
62664438|NCT05363904||Healthy Controls (Madagascar)|
62664439|NCT06283108|EXPERIMENTAL|Virtual Reality Experimental|Standard CCLS care and distraction with Virtual Reality
62664440|NCT06283108|ACTIVE_COMPARATOR|Standard CCLS care|Standard CCLS care
62664441|NCT02538198|EXPERIMENTAL|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
62664442|NCT04407520||Adult patients with intellectual and/or physical disabilities|Adult patients with intellectual and/or physical disabilities requiring dental treatment under general anesthesia
62664443|NCT04948125|EXPERIMENTAL|treatment group|camrelizumab combined with apatinib
62664444|NCT04136301|EXPERIMENTAL|Informative video arm|"Nuliparus women admitted to an induction will be exposed to informative video with data regarding labor and possible obstetric emergencies such as cesarean delivery.~All patients will answer the State-Trait Anxiety Inventory (STAI) before and after intervention"
62664445|NCT04136301|NO_INTERVENTION|control arm|no intervention. All patients will answer the State-Trait Anxiety Inventory (STAI) before and after delivery.
62664446|NCT01543191|EXPERIMENTAL|PUR118|
62664447|NCT01543191|PLACEBO_COMPARATOR|Placebo|
62664448|NCT03996213|NO_INTERVENTION|supine group|induction of anesthesia will be initiated while patient in supine position
62664449|NCT03996213|ACTIVE_COMPARATOR|head down|induction of anesthesia will be initiated while patient in head down position
62664450|NCT03996213|ACTIVE_COMPARATOR|leg elevation|induction of anesthesia will be initiated while patient in leg elevation position
62664451|NCT04061629||Group C|Size of the cuffed ETT based on the Cole formula = (Age/4) + 4.
62664452|NCT04061629||Group D|size of the cuffed ETT based on the Duracher formula = (Age/4) + 3 + 0.5 mm.
62664453|NCT04061629||Group K|size of the cuffed ETT based on the Khine formula = (Age/4) + 3.
62664454|NCT06323993||Piezoelectric osteotomy|This group used piezoelectric osteotomy (exposure) to prepare the lateral window acceding maxillary sinus
62664455|NCT06323993||Round Bur|This group used round bur (control) to prepare the lateral window acceding maxillary sinus
62664456|NCT00742456|EXPERIMENTAL|I|Glucose
62664457|NCT00742456|PLACEBO_COMPARATOR|II|Placebo
62664458|NCT03650270|EXPERIMENTAL|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
62664459|NCT03650270|ACTIVE_COMPARATOR|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
62664460|NCT02931097|ACTIVE_COMPARATOR|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
62664461|NCT02931097|ACTIVE_COMPARATOR|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
62664462|NCT02931097|SHAM_COMPARATOR|Sham stimulation|No deep brain stimulation
62664463|NCT00902967|ACTIVE_COMPARATOR|1|Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
62664464|NCT00902967|PLACEBO_COMPARATOR|2|Placebo tablets of similar shape and color given at night time dosing
62664465|NCT06370975|EXPERIMENTAL|3% hypertonic Saline|
62664466|NCT06370975|EXPERIMENTAL|Ringer's lactated solution|
62664467|NCT06370975|EXPERIMENTAL|0.9% Normal saline|
62664468|NCT05047380||coccycodinia group|A total of 54 patients diagnosed with coccycodinia
62664469|NCT01433913|EXPERIMENTAL|Arm I (metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 4-12 weeks.
62664470|NCT01433913|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 4-12 weeks.
62664471|NCT01718067|EXPERIMENTAL|Vakum|VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique
62664472|NCT01718067|ACTIVE_COMPARATOR|Control|conventional manual ELTGOL technique
62664473|NCT04569370||Scoring Factor|Intervention: Procedure: Laparoscopic cholecystectomy
62103182|NCT05926765|EXPERIMENTAL|AAV2-hAQP1 Group 1|Eligible participants will receive up to 3 mL of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
62103183|NCT05926765|EXPERIMENTAL|AAV2-hAQP1 Group 2|Eligible participants will receive up to 3 mL of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
62664474|NCT04569370||Difficult criteria|Intervention: Procedure: Laparoscopic cholecystectomy
62664475|NCT01757847|ACTIVE_COMPARATOR|Brief MOVE-II active control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions to patient with overweight or obesity who have completed the VA San Diego MOVE program.
62664476|NCT01757847|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), has been effective in reducing distress, increasing quality of life, and improving other indices of health in a wide range of conditions from depression to diabetes. The ACT protocol for this study focuses on reducing binge eating and distress and improving functioning in individual who are overweight or obese. The protocol focuses on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life. The protocol will be delivered in four 2-hour weekly group sessions to patients with overweight or obesity who have completed the VA San Diego MOVE program.
62664477|NCT01142921|ACTIVE_COMPARATOR|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
62664478|NCT01142921|EXPERIMENTAL|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
62664479|NCT05492435|EXPERIMENTAL|m1 stimulation + dual task training|participants will receive real current over the primary motor area (M1)
62664480|NCT05492435|EXPERIMENTAL|stimulation in M1 and DLPF + dual task training|participants will receive real current over the M1 and over the dorsolateral prefrontal area (DLPFC)
62103184|NCT05926765|PLACEBO_COMPARATOR|Placebo group|Eligible participants will receive up to 3 mL of diluent via Stensen's duct to each parotid gland
62664481|NCT05492435|SHAM_COMPARATOR|sham stimulation + dual task training|Participants will receive simulated stimulation
62664482|NCT05791331|ACTIVE_COMPARATOR|A/Control|Surfactant administration following clinical assessment
62664483|NCT05791331|EXPERIMENTAL|B/Intervention|Surfactant administration following both lung mechanics assessment and clinical assessment
62664484|NCT05574049|ACTIVE_COMPARATOR|Single Dose|Once daily mouth strip containing 8mg of THCV and 10mg of CBD
62664485|NCT05574049|ACTIVE_COMPARATOR|Double Dose|Once daily mouth strip containing 16mg of THCV and 20mg of CBD
62664486|NCT05574049|PLACEBO_COMPARATOR|Placebo|Once daily mouth strip containing nothing
62664487|NCT03026725|EXPERIMENTAL|Tri-calcium Phosphate|clinpro tooth creme, i.e. Tri-calcium Phosphate, for 30 min/day after bleaching 4h with carbamide peroxide 20%
62664488|NCT03026725|PLACEBO_COMPARATOR|Placebo|a placebo creme will be applied for 30 min/day after bleaching 4h with carbamide peroxide 20%
62664489|NCT04251494||Phenylketonuria (PKU) participants|"During their outpatient clinic appointment, participants will:~* Undergo routine height and weight measurements and blood tests. A full patient history will be taken, including a record of cardiovascular disease within the family. Blood samples will be collected, including phenylalanine, lipids, vitamin B12 and related biomarkers.~* Complete a 14-item diet history questionnaire, and fill in a 3 day diet diary before they arrive at their outpatient clinic appointment, which will be collected after the participant signs the informed written consent form.~* Undergo assessment of carotid Intima-media thickness (CIMT), pulse wave velocity (PWV), ankle brachial pressure index (ABPI) and systolic and diastolic blood pressure."
62664490|NCT04251494||Age and gender matched reference controls|Only Phenylketonuria (PKU) patients will be studied. Controls are generated from the literature. Reference CIMT values exist for a healthy population based on age and gender (Engelen et al., 2013), eliminating the need to assess age- and gender-matched controls. The study would otherwise require performing blood tests and vascular assessments on healthy individuals, generating a risk of harm and a possible incidental finding. It would be inconvenient for controls because they would need to travel to hospital and undergo invasive venepuncture.
62664491|NCT03033836|EXPERIMENTAL|single arm|ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
62664492|NCT02205021||All subjects|
62664493|NCT02119000|EXPERIMENTAL|PEG electrolytes 2L/2L split dose|
62664494|NCT02119000|ACTIVE_COMPARATOR|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|
62103185|NCT00151996|EXPERIMENTAL|Methylphenidate + SPD503|
62103186|NCT00151996|EXPERIMENTAL|Amphetamine + SPD503|
62103187|NCT00941031|EXPERIMENTAL|Induction Single Dose|"Induction with single injection - Single: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12"
62664495|NCT02177357|EXPERIMENTAL|Pramipexole - escalation dose|
62664496|NCT02177357|PLACEBO_COMPARATOR|Placebo|
62103188|NCT00941031|EXPERIMENTAL|Induction Monthly Dose|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12"
62103189|NCT00941031|EXPERIMENTAL|Induction Early Loading Dose|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12"
62296152|NCT02828267|EXPERIMENTAL|BNI|In the BNI arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
62296153|NCT02828267|ACTIVE_COMPARATOR|BNI plus standard booster|In the BNI plus standard booster arm, patients will receive the 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. The messages will be standard messages for all those in this arm.
62103190|NCT00941031|PLACEBO_COMPARATOR|Placebo Dose|Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12
62103191|NCT06551922|EXPERIMENTAL|Instrumental Soft Tissue Mobilization Technique with Conservative Treatment|"Apply TENS for 10 minutes to administer a micro current therapy to participants. The IASTM will be applied for 90 seconds- 2 minutes on each muscle along with the stretching exercises. The intervention will be applied 3 times per week.~Muscle involved:~* Hip Adductors~* Hamstrings~* Quadriceps~* Patellar tendon~* Iliotibial band~* Calf muscles."
62103192|NCT06551922|EXPERIMENTAL|Conservative Treatment|For conservative treatment apply TENS for 10 minutes to administer a micro current therapy to participants. Than Stretching exercises ( Hamstrings and Quadriceps), Strengthening exercises (Quadriceps, Hamstring, Calf ), Balance exercises and Ice Therapy.
62103193|NCT06310564|EXPERIMENTAL|stereotactic ablative radiotherapy (SABR)|SABR to all the active sites of disease (1-3 oligometastases). 3D-CRT, IMRT and VMAT techniques are allowed, but IMRT and VMAT are strongly suggested.
62103194|NCT06310564|NO_INTERVENTION|no SABR|no SABR
62103195|NCT03429387|EXPERIMENTAL|FDG-PET/CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have an FDG-PET/CT performed to look for source of fever.
62308246|NCT06223425|EXPERIMENTAL|virtual reality Situation-Based Flipped Learning|students exposed to virtual reality Situation-Based Flipped Learning
62664497|NCT03247114|EXPERIMENTAL|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
61912063|NCT05642650|EXPERIMENTAL|Novel wearable device strategy group|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps.
61912064|NCT05642650|NO_INTERVENTION|Control group|Patients receive a standard of care for heart failure without a wearable device.
62103196|NCT03429387|ACTIVE_COMPARATOR|Conventional CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have a conventional CT (HRCT chest and sinuses +/- other regions as per clinician's discretion) performed to look for source of fever.
62103197|NCT06417489|EXPERIMENTAL|Combination therapy|Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient's tolerance situation. The minimum dose is 1000mg/day.
62103198|NCT06417489|ACTIVE_COMPARATOR|Sequential treatment group|Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient's tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\>7mmol/L, postprandial blood glucose (PPG)\>10mmol/L), 10 mg qd of Henagliflozin Proline was sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\>7mmol/L, PPG\>10mmol/L), 100 mg qd of Ruigeliflozin was added
62103199|NCT02793609|OTHER|Outpatient group|After insertion of double balloon induction catheter of labor, women are discharged overnight to home. Intervention is to let patient to go home.
62103200|NCT02793609|OTHER|Inpatient group|After insertion of double balloon induction catheter of labor, women are observed in the prenatal ward. Intervention is to observe women in the ward.
62103201|NCT01696721||Pediatric Patients Treated with Protons|Proton Radiation Therapy
62103202|NCT03586167|EXPERIMENTAL|LID014341|LID014341 contact lenses worn bilaterally (in both eyes) for 30 days on a daily wear basis
62103203|NCT03586167|ACTIVE_COMPARATOR|Biofinity|Comfilcon A contact lenses worn bilaterally for 30 days on a daily wear basis
62103204|NCT04965883|EXPERIMENTAL|Early Excision and Grafting|"* The early excision will be done surgically within 4-10 days post burn by whatson knife by tangential excision of burned tissue until capillary bleeding appears to make a good bed to be covered with grafts split thickness grafts STG at the same time.~* The first dressing will be in the fifth day post operative."
62103205|NCT04965883|EXPERIMENTAL|Dressing and Delayed Grafting|• Dressing will be done for the second group every other day until spontanous eschar seperation or after surgiacl debridrment of adherent eschar then for delayed grafting more than 10 days post burn.
62308247|NCT06223425|NO_INTERVENTION|traditional teaching strategies|Students exposed to traditional Learning
62664498|NCT03247114|EXPERIMENTAL|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
62664499|NCT03247114|EXPERIMENTAL|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
62664500|NCT03247114|EXPERIMENTAL|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
62664501|NCT03247114|EXPERIMENTAL|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
62664502|NCT03247114|EXPERIMENTAL|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
62664503|NCT03247114|EXPERIMENTAL|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
62103206|NCT06480409|EXPERIMENTAL|VR-based intervention|"The intervention group will participate in a structured VR-based relaxation program designed to improve mental health and reduce stress levels. The sessions will take place in a dedicated relaxation room equipped with immersive VR headsets and physiological sensors.~Intervention Procedure:~Duration and Frequency: Participants will engage in 15-minute VR relaxation sessions, held five times a week over a period of one month.~VR Content: The VR sessions will feature high-quality 360° videos with therapeutic audio, including guided relaxation, calming music, and nature sounds."
62308248|NCT05347654|ACTIVE_COMPARATOR|Standard strategy|Local treatment with silver sulphadiazine and tulle from day 0 to day 8. From the 9t h day and until healing, the dressings are made with tulle, every 48 hours.
62468140|NCT03211403|EXPERIMENTAL|SHR4640 10mg|6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo
62664504|NCT03247114|EXPERIMENTAL|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
62664505|NCT03247114|EXPERIMENTAL|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
62664506|NCT03247114|EXPERIMENTAL|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
62664507|NCT03339453|EXPERIMENTAL|Nasal Glucagon|Single dose of Nasal Glucagon.
62664508|NCT03339453|ACTIVE_COMPARATOR|Intramuscular Glucagon|Single intramuscular (IM) dose of Glucagon.
62664509|NCT03341429|EXPERIMENTAL|Treatment|"Daily subcutaneous injection of liraglutide 3.0 mg~Study dosing of liraglutide:~Week 1: 0.6 mg once daily Week 2: 1.2 mg once daily Week 3: 1.8 mg once daily Week 4: 2.4 mg once daily Week 5-24: 3.0 mg once daily~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
62664510|NCT03341429|PLACEBO_COMPARATOR|Control|"Daily subcutaneous injection of placebo; the same dosage regimen as treatment to be followed.~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
62664511|NCT04803500|ACTIVE_COMPARATOR|Simvastatin group|simvastatin gel (1.2 mg/0.1 ml of solid lipid nanoparticles) was locally applied to fill the jumping distance.
62664512|NCT04803500|PLACEBO_COMPARATOR|Control group|the solid lipid nanoparticles carrier was injected into the jumping distance.
62664513|NCT02034591|EXPERIMENTAL|Arm A-Apixaban|Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
62664514|NCT02034591|EXPERIMENTAL|Arm B-Apixaban|Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
62664515|NCT02034591|EXPERIMENTAL|Arm C-Apixaban|Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
62664516|NCT01248975|EXPERIMENTAL|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
62664517|NCT01248975|ACTIVE_COMPARATOR|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
62664518|NCT01248975|PLACEBO_COMPARATOR|FP/SAL 250/50mcg BID plus placebo BID|P/SAL 250/50mcg BID plus placebo BID
62664519|NCT02615353|EXPERIMENTAL|Lifestyle Intervention|6 months of a bi-weekly Nutrition Education, Physical Activity, and Behavioral Modification program
62664520|NCT02615353|PLACEBO_COMPARATOR|Usual Care Control|Medical screening and dietary counseling with a Endocrinologist and Registered Dietitian
62664521|NCT01723943|ACTIVE_COMPARATOR|Arm I (educational booklet)|"Participants receive the What's Happening to the Woman I Love? booklet, which focuses on ways to understand and deal with marital communication and relationship issues arising from breast cancer diagnosis."
62664522|NCT01723943|EXPERIMENTAL|Arm II (Helping Her Heal program)|"Participants undergo the Helping Her Heal educational counseling program comprising 5 1-hour sessions 2 weeks apart.~SESSION I: Participants learn stress management skills and discover ways stress affects themselves and their partner.~SESSION II: Participants practice attentive listening and reduce the tendency to try to distract patients from talking about sad or difficult aspects of the cancer experience.~SESSION III: Patients learn to help their spouse talk when she is quiet or withdrawn, to add to their understanding of what she is thinking and feeling, and to add to their ways of supporting her during especially difficult times with the cancer.~SESSION IV: Participants learn strategies for physically reconnecting with spouses.~SESSION V: Participants review skills from prior sessions, identify strategies he or she will continue to use to manage their personal stress, and identify ways to maintain connection and support."
62296154|NCT02828267|ACTIVE_COMPARATOR|BNI plus personalized booster|In the BNI plus personalized booster arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a text focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
62103207|NCT04798521|EXPERIMENTAL|Tele-HCV Treatment|Participants allocated to telemedicine intervention arm are scheduled for treatment assessment by a study clinician. For a majority of participants, this will also be the treatment initiation visit. If additional studies are necessary for routine treatment decision making, peers will assist participants in navigating health system barriers and arrangement of second telemedicine visit.
62103208|NCT04798521|ACTIVE_COMPARATOR|Community Linkage to Care|Participants allocated to the community linkage-to-care arm will complete screening, be offered enrollment, and undergo informed consent as in the telemedicine arm. Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment.
62103209|NCT04100044|EXPERIMENTAL|Health Services Research (physical therapist, exercise)|Patients meet with a physical therapist on day 0 and at 3 and 6 months and receive a personalized home exercise intervention consisting of aerobic and resistance training for 6 months. Patients also receive face-to-face sessions, video chats, or text message check-ins with physical therapist weekly for 6 weeks and then every other week for up to 24 weeks.
62664523|NCT03086343|ACTIVE_COMPARATOR|Primary Cohort: Abatacept/Upadacitinib 15 mg QD|Period 1: 500 mg (for body weight \<60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight \>100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 15 mg QD for 192 weeks.
62103210|NCT03365856||RA patients|As routinary clinical practice and observational study
62103211|NCT02162238|PLACEBO_COMPARATOR|purified water|Filtered water Pump water purified by the LSF-filtering device Intervention: Device: LSF-filtering device
62103212|NCT02162238|EXPERIMENTAL|zinc enriched purified water|Zinc water water purified and zinc-enriched by the LSF-filtering device Intervention: Device: LSF-filtering device
62103213|NCT03588065|EXPERIMENTAL|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
62103214|NCT03588065|ACTIVE_COMPARATOR|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
62103215|NCT03588065|SHAM_COMPARATOR|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
62103216|NCT05264337||Radical Cystectomy|Patients undergoing radical cystectomy with pelvic lymph node dissection for urinary bladder cancer
62103217|NCT05264337||Radical Prostatectomy|Patients undergoing radical prostatectomy with pelvic lymph node dissection for prostate cancer
62103218|NCT05264337||Retroperitoneal|Patients undergoing retroperitoneal lymph node dissection for testicular cancer
62103219|NCT05264337||Other|Patients undergoing other urologic surgery with lymph node dissection of inguinal, iliacal or retroperitoneal lymph nodes
62103220|NCT04569578|EXPERIMENTAL|Policy|The policy will be implemented on preschool level.
62103221|NCT04569578|NO_INTERVENTION|Regular practice|The control preschool will continue their regular practice.
62103222|NCT05358730|EXPERIMENTAL|IASTM + Standard Exercise Group|Patients were applied IASTM in combination with standard exercise program two days a week for six weeks. The IASTM technique was performed using six titanium-plated instruments in different sizes, shapes and treatment styles. ROM, crutch, roller, scapulothoracic and stretching exercises were given as home exercises during the treatment.
62103223|NCT05358730|ACTIVE_COMPARATOR|Standard Exercise Group|Patients were given a standard exercise program two days a week for six weeks. ROM, crutch, roller, scapulothoracic and stretching exercises were given as home exercises during the treatment.
62103224|NCT00640874||PIPET C|Contact group members of people with diagnosed influenza who are recommended to receive NA inhibitor prophylaxis for short periods of time will be enrolled following provision of informed consent.
62664524|NCT03086343|EXPERIMENTAL|Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD|Period 1: One 15 mg upadacitinib oral tablet QD for 24 weeks. Period 2: open label upadacitinib 15 mg QD for 192 weeks.
61912065|NCT00542438|ACTIVE_COMPARATOR|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
61912066|NCT00542438|ACTIVE_COMPARATOR|Environmental Assessment|Environmental assessments on a palm pilot either 3 times a day or once a day. Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
61912067|NCT00669409|EXPERIMENTAL|10 mcg/kg|
62664525|NCT03086343|EXPERIMENTAL|30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD|Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.
62664526|NCT03086343|ACTIVE_COMPARATOR|30 mg Cohort: Abatacept/Upadacitinib 30 mg QD|Period 1: 500 mg (for body weight \<60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight \>100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.
62664527|NCT04737694|EXPERIMENTAL|Ketone + Carbohydrate|573 mg/ kg body weight ketone ester + 110 g glucose
62664528|NCT04737694|ACTIVE_COMPARATOR|Carbohydrate|Isocaloric amount of glucose to match ketone + carbohydrate
62664529|NCT02417181|NO_INTERVENTION|General Practitioners Care|Usual medical care provided by a general practitioner at the out-of-hours primary care service
62664530|NCT02417181|EXPERIMENTAL|Physician Assistants Care|Medical care provided by the Physician Assistant at the out-of-hours primary care service
62664531|NCT00287820|ACTIVE_COMPARATOR|1|olanzapine
62664532|NCT00287820|ACTIVE_COMPARATOR|2|risperidone
62664533|NCT03641729|OTHER|Intervention|Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
62664534|NCT01104766|EXPERIMENTAL|Cariprazine 3mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
62664535|NCT01104766|EXPERIMENTAL|Cariprazine 6mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
62664536|NCT01104766|ACTIVE_COMPARATOR|Aripiprazole 10mg|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
62664537|NCT01104766|PLACEBO_COMPARATOR|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
62664538|NCT01021319||Acute ischemic stroke|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset.
62664539|NCT04408079|EXPERIMENTAL|TQB3558 Tablets|TQB3558 tablets administered orally once. Then TQB3558 tablet administered orally, once daily in 28-day cycle after 4 days of first administration.
62664540|NCT04864769|EXPERIMENTAL|Krill Protein Hydrolysate|Krill Protein Hydrolysate
62664541|NCT04864769|ACTIVE_COMPARATOR|Soy protein isolate|Soy Protein isolate
62664542|NCT04864769|ACTIVE_COMPARATOR|Whey protein isolate|Whey protein isolate
62664543|NCT04864769|SHAM_COMPARATOR|Control|Water
62664544|NCT00820092|ACTIVE_COMPARATOR|Xerecept 1.0|1.0 ug/kg/hr hCRF -24 hour IV infusion
62664545|NCT00820092|ACTIVE_COMPARATOR|Xerecept 2.0|2.0 ug/kg/hr-24 hour IV infusion
62664546|NCT00820092|ACTIVE_COMPARATOR|Xerecept 3.0|3.0 ug/kg/hr-24 hour infusion
62664547|NCT05053828||Non-diabetic controls on clopidogrel|Non-diabetic patients prescribed clopidogrel
62664548|NCT05053828||Diabetic patients on clopidogrel|Diabetic patients on clopidogrel
62664549|NCT05053828||Diabetic patients on antiplatelet drugs other than clopidogrel|Diabetic patients on antiplatelet drugs other than clopidogrel
62664550|NCT02193152|EXPERIMENTAL|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.~One cycle of pazopanib is 28 days."
62664551|NCT01808742||Treatment|Treatment with CryoTouch III device
62664552|NCT03791372|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
62664553|NCT03791372|EXPERIMENTAL|Cord Blood Mononuclear Cells(CBMNC)|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells\>1\*10\^7/kg). The infusion speed is 1ml/min.
62664554|NCT04569344||Patients with Covid-19|Patients with laboratory test positive for SARS-CoV-2 virus
62664555|NCT05569941|EXPERIMENTAL|Part A: SAD Cohorts 1-5 ABI-4334 Tablet|A single dose of ABI-4334 will be administered on Day 1 in dose-escalation cohorts with a starting dose of 30 mg. The doses for subsequent cohorts will be determined by evaluation of safety and PK data from previous cohorts.
62664556|NCT05569941|PLACEBO_COMPARATOR|Part A: SAD Cohorts 1-5 ABI-4334 Placebo Tablet|A single dose of placebo matching ABI-4334 will be administered on Day 1.
62664557|NCT05569941|EXPERIMENTAL|Part A: SAD Fed Cohorts 6-7 ABI-4334 Tablet|A single dose of ABI-4334 will be administered after a high-fat meal on Day 1 in cohort 6. A single dose of ABI-4334 will be administered on two separate occasions, once fasted and once after a high-fat meal in cohort 7. The dose administered will be determined after evaluation of cumulative safety and PK data from cohorts 1-5.
62664558|NCT05569941|PLACEBO_COMPARATOR|Part A: SAD Fed Cohorts 6 ABI-4334 Placebo Tablet|A single dose of placebo matching ABI-4334 will be administered on Day 1 after a high-fat meal on Day 1 in cohort 6.
62664559|NCT05569941|EXPERIMENTAL|Part B: MAD Cohorts 1-2 ABI-4334 Tablet|Once-daily doses of ABI-4334 will be administered from Day 1 to Day 8. Cohort B1 will receive a dose determined from evaluation of the data from the SAD cohorts. The doses for the subsequent cohort will be determined by evaluation of safety and PK data from previous cohorts.
61912068|NCT00669409|EXPERIMENTAL|100 mcg/kg|
62664560|NCT05569941|PLACEBO_COMPARATOR|Part B: MAD Cohorts 1-2 ABI-4334 Placebo Tablet|Once-daily doses of placebo matching ABI-4334 will be administered from Day 1 to Day 8.
62664561|NCT04115228|EXPERIMENTAL|Study device|Subjects who provide informed consent, meet all inclusion criteria, and no exclusion criterion, will have a study device implanted and followed closely for 26 weeks.
62664562|NCT02298491|EXPERIMENTAL|H.P. Acthar Gel|
62664563|NCT00430365|PLACEBO_COMPARATOR|placebo group|Administration of oral placebo
62664564|NCT00430365|EXPERIMENTAL|lenalidomide group|Administration of lenalidomide
62664565|NCT03876353|OTHER|Left Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
62664566|NCT03876353|OTHER|Right Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
62103225|NCT02494830|EXPERIMENTAL|ketamine 5 mg intravenous|
62296155|NCT01287104|EXPERIMENTAL|Pre-Bone Marrow Transplant (BMT) Prep Regimen|Pre-bone marrow transplant (BMT) Prep Regimen with Stem Cell and natural killer (NK) Cell Infusions coupled with Induction therapy
62296156|NCT05777928|EXPERIMENTAL|Sleeve gastrectomy group|Subjects with obesity candidates for sleeve gastrectomy
62296157|NCT05777928|EXPERIMENTAL|OverStitch™ Endoscopic Suturing System group|Subjects candidates for a revision bariatric surgery with Overstitch endoscopic
62664567|NCT02272101|EXPERIMENTAL|Vitamin D|Vitamin D 4,000 I.U. orally
62664568|NCT02272101|PLACEBO_COMPARATOR|Placebo|Placebo orally
62664569|NCT00088153|EXPERIMENTAL|Physiologic estrogen replacement|"Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month).~Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study"
62664570|NCT00088153|PLACEBO_COMPARATOR|Placebo|Placebo patches or pills
62664571|NCT03974009|EXPERIMENTAL|Calcaneal taping and Conventional therapy|Calcaneal Taping Technique along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
62664572|NCT03974009|ACTIVE_COMPARATOR|Sham taping and Conventional therapy|Sham taping along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
62664573|NCT05648851||Group 1 In person combination retrospective and prospective Natural History Study|Combination retrospective and prospective Natural History Study of patients living with Sanfilippo syndrome type D. The study will include home video of daily living activities via the RARE app, a mobile app designed for this study. In clinic visits will include neurocognitive, developmental, behavioral, biochemical, imaging measures as well as retrospective medical record analysis.
62664574|NCT05648851||Group 2 Retrospective medical record analysis|Retrospective collection and analysis of medical records of deceased or living patients.
62664575|NCT04742179|EXPERIMENTAL|Experimental group|The children belonging to the classes of the school complex undergoing the maintenance intervention.
62664576|NCT04742179|NO_INTERVENTION|Control group|The children belonging to the classes of the school complex that will not undergo the maintenance intervention.
62664577|NCT05462678|EXPERIMENTAL|Cognitive Rehabilitation|the first group carried out a training of CR by three memory modules of the Rehacom program (http://www.emsmedical.net).
62664578|NCT05462678|EXPERIMENTAL|Combined Training|the second group followed a mixed training program with the use of the version of the verbal memory module of the Rehacom program combined with the MR training.
62664579|NCT05462678|EXPERIMENTAL|Motor Rehabilitation|the third group carried out a traditional MR training.
62664580|NCT06018168|ACTIVE_COMPARATOR|Group One: Skincare Routine Only|Participants will follow instructions for the skincare routine only. Participants will complete the routine twice daily.
62664581|NCT06018168|ACTIVE_COMPARATOR|Group Two: Skincare Routine + Supplement|Participants will follow instructions for the skincare routine AND will take a daily supplement.
62664582|NCT03038139|EXPERIMENTAL|Cervical exercises|"Group A= Cervical correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~Applying exercises 3 times per week."
61912069|NCT00669409|EXPERIMENTAL|200 mcg/kg|
61912070|NCT00669409|EXPERIMENTAL|25 mcg/kg|
61912071|NCT00669409|EXPERIMENTAL|50 mcg/kg|
61912072|NCT00669409|PLACEBO_COMPARATOR|Placebo|
61912073|NCT03689907||Allogeneic Stem-Cell Transplant Recipients|"1. At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.~2. At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients."
61912074|NCT04306991|EXPERIMENTAL|Fever|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
61912075|NCT04306991|EXPERIMENTAL|Apyrexia|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
61912076|NCT03093688|EXPERIMENTAL|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
61912077|NCT04642001|OTHER|Group G1|Photon Laser III-DMC (without radiation emission) + My First- Colgate
61912078|NCT04642001|EXPERIMENTAL|Group G2|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rápido Alívio/GSK
61912079|NCT04642001|EXPERIMENTAL|Group G3|Photon Laser III-DMC (with irradiation emission) + My First- Colgate
61912080|NCT04642001|EXPERIMENTAL|Group G4|Photon Laser III-DMC (with irradiation emission) + Sensodyne® Rápido Alívio/GSK
61912081|NCT02642549|EXPERIMENTAL|Girls for Health Intervention (G4H)|G4H will integrate proven girls' education strategies with innovative vocational interventions to build 1350 girls' career aspirations and academic achievement
61912082|NCT02642549|NO_INTERVENTION|Control Condition|standard of care to support school attendance among girls (i.e., school tracking of attendance and reaching out to truant girls).
61912083|NCT04972643|EXPERIMENTAL|EPA and DHA intervention|EPA 1000mg and DHA 1000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
61912084|NCT04972643|EXPERIMENTAL|EPA intervention|EPA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
61912085|NCT04972643|EXPERIMENTAL|DHA intervention|DHA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
61912086|NCT04972643|PLACEBO_COMPARATOR|Placebo|Placebo 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
62664583|NCT03038139|EXPERIMENTAL|Lumbosacral exercises|"Group B= Cervical + Lumbosacral correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~The lumbosacral exercise program consist of 2 strengthening exercises and 4 stretching exercises.~Applying exercises 3 times per week."
61912087|NCT04379492|EXPERIMENTAL|Arm A - hydroxycholoroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
61912088|NCT04379492|PLACEBO_COMPARATOR|Arm B - placebo|Participants will receive placebo
61912089|NCT03923803||Chronic obstructive pulmonary disease|patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up
61912090|NCT00917215|EXPERIMENTAL|Active acupuncture|
61912091|NCT00917215|SHAM_COMPARATOR|Sham acupuncture|
61912092|NCT00917215|NO_INTERVENTION|Waiting list control|
61912093|NCT03635580|EXPERIMENTAL|rhGH/Jintropin AQ|Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.
61912094|NCT06059131|EXPERIMENTAL|KeenMind|
62103226|NCT02494830|EXPERIMENTAL|ketamine 10 mg oral|
62664584|NCT05503069|NO_INTERVENTION|Group A - Control|The control group will receive standard of care, which include basic training by lactation educators.
62103227|NCT02494830|EXPERIMENTAL|ketamine 20 mg oral|
62103228|NCT02494830|EXPERIMENTAL|ketamine 40 mg oral|
62103229|NCT02494830|EXPERIMENTAL|ketamine 80 mg oral|
62103230|NCT06393400|EXPERIMENTAL|Fecal Microbiota Transplantation|A single Fecal Microbiota Transplantation (FMT) with 100 g of healthy stool in 36-40 oral capsules once 24 hours after Polyethylene Glycol laxative preparation, followed by gemcitabine 1000 mg/m2 intravenously (IV) and nab-paclitaxel 125 mg/m2 IV on Day 1, Day 8, and Day 15 of each 28-day cycle at least 7 days after FMT.
62296158|NCT06320444||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
62664585|NCT05503069|EXPERIMENTAL|Group B - Intervention|"Women in the intervention arm will receive standard of care, which includes basic training in breastfeeding by lactation educators, and the action items related to the intervention.~The intervention will include the following~1. Providing a breast milk pumping machine to the mother,~2. Facilitating training session to improve dietary literacy for lactating mothers,~3. Distribution of educational material describing the benefits of continuing breastfeeding infants up to 12 months of age to family members, employers, day care managers/caregivers."
62664586|NCT01955018|EXPERIMENTAL|VeoTM|A new algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA) decreases the image noise up to 70% compared with the gold standard FBP model. Moreover, Veo improves spatial resolution with excellent detection of low and high contrast objects from a CT Dose Index (CTDIvol) equal to 0.3 mGy
62664587|NCT01955018|OTHER|gold standard FBP model|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality
62664588|NCT01129128|ACTIVE_COMPARATOR|Echinacea preparation 1|Commercially available Echinacea purpurea product
62664589|NCT01129128|ACTIVE_COMPARATOR|Echinacea preparation 2|Commercially available Echinacea purpurea product
61912095|NCT06059131|PLACEBO_COMPARATOR|Placebo|
61912096|NCT03189290|ACTIVE_COMPARATOR|ropivacaine|"Active Comparator: ropivacaine group~- Before general anaesthesia, ultrasound guided Quadratus Lumborum Block (QLB) will be performed with 30 mL 0.33% Ropivacaine"
61912097|NCT03189290|PLACEBO_COMPARATOR|placebo|"Sham Comparator: saline group~- Before general anaesthesia, ultrasound guided Sham Quadratus Lumborum Block (QLB) will be performed with 30 mL saline."
62103231|NCT01571921|EXPERIMENTAL|Gamma-Delta Tocotrienol|
62103232|NCT01571921|ACTIVE_COMPARATOR|TRF|
62296159|NCT06320444||Amyotrophic lateral sclerosis Patients|
62296160|NCT06320444||Multiple Sclerosis patients|
62296161|NCT06320444||Postpoliomyelitis syndrome patients|
62296162|NCT06320444||Muscular Atrophy patients|
62296163|NCT04506112|EXPERIMENTAL|TranS-C + Usual Care|Participants in this group will receive TranS-C and will continue with care in cardiac rehabilitation as usual.
62296164|NCT04506112|NO_INTERVENTION|Usual Care|Participants in this group will receive only usual care and thus will continue with care in cardiac rehabilitation as usual.
62664590|NCT01129128|PLACEBO_COMPARATOR|Placebo|Inert liquid that is similar in appearance and taste to the active Echinacea products
61912098|NCT00403169|EXPERIMENTAL|Lenalidomide for Advanced RCC|25 mg/day Lenalidomide for 21 days per cycle.
61912099|NCT01605149||Case|Patients with Type 1 Diabetes Mellitus
61912100|NCT02362568|NO_INTERVENTION|Cervical ultrasound exploration|A cervical ultrasound exploration will be performed in all patients admitted for a planned surgery performed under general anesthesia during the stay in the postoperative room.
61912101|NCT01238588|OTHER|Sevelamer Carbonate (Renvela)|Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
61912102|NCT00849836||Acute exacerbation|
61912103|NCT00849836||Stable disease|
61912104|NCT00849836||Healthy control|
61912105|NCT00815178|EXPERIMENTAL|Inspiratory muscle training|
61912106|NCT00815178|PLACEBO_COMPARATOR|Placebo|
62103233|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
62103234|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
62103235|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
62103236|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
62103237|NCT04764019|EXPERIMENTAL|Patients|Patients with chronic digestive symptoms in whom intestinal dysmotility is suspected
62103238|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
61912107|NCT02973880|EXPERIMENTAL|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
62103239|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
62103240|NCT02473562|EXPERIMENTAL|Varenicline|Varenicline capsule 1 mg BID
62468141|NCT03211403|EXPERIMENTAL|SHR4640 20mg|6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo
62103241|NCT02473562|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62103242|NCT06518499||Bascom's Pit-Pick procedure|The Bascom pit-pick procedure is performed under local anesthesia with the patient in a prone position, taking approximately 15-20 minutes. Pre-operative preparation includes shaving and cleaning the surgical area. Local anesthesia (lidocaine with adrenaline) is typically used, with general anesthesia as an alternative if needed. The surgical technique involves excising midline pits with a scalpel, removing infected granulation tissue and hairs through curettage or a lateral incision. Midline wounds and nearby secondary pits are sutured with polypropylene, while the lateral incision is left open and covered with a hydrofibre bandage to heal by secondary intention.
62296165|NCT05646056||Healthy subjects|
62296166|NCT05646056||Asymptomatic subjects with a history of left ventricular hypertrophy (LVH) and NYHA Class I|
62296167|NCT05646056||Asymptomatic subjects with a history of heart failure (HF) and NYHA Class I|
62468142|NCT03839303|EXPERIMENTAL|Mini Implant Supported Appliance|this group will receive an Infra-zygomatic Mini Implant Supported Appliance after leveling and alignment of the four upper incisors for 8 months or till class I canine or incisors realation is reached with follow up every month
62664591|NCT02408822|ACTIVE_COMPARATOR|PBA (Plain Balloon Angioplasty)|"Patient receiving endovascular treatment of a vascular access stenosis by plain balloon angioplasty (mechanical action, without drug)~2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure"
62296168|NCT05646056||Subjects with a history of hypertrophic cardiomyopathy (HCM) and NYHA Class I, II|
62296169|NCT04899648|EXPERIMENTAL|Behavioral Intervention|Receives nutrition and exercise intervention classes
62468143|NCT03839303|ACTIVE_COMPARATOR|Headgear|this group will receive a high pull headgear appliance attached to a removable acrylic maxillary splint for 8 months or till class I canine or incisors realation is reached with follow up every month
62468144|NCT05607264|EXPERIMENTAL|Kinsiotaping|patients who received kinesiotaping plus conventional treatment for chronic shoulder impingement syndrome.
62468145|NCT05607264|EXPERIMENTAL|Virtual Reality training|patients who received VR training plus conventional treatment for chronic shoulder impingement syndrome.
62468146|NCT05607264|ACTIVE_COMPARATOR|conventional treatment|patients who received conventional treatment for chronic shoulder impingement syndrome only.
62468147|NCT02667405|EXPERIMENTAL|Whirlpool|Immersion in Whirlpool during therapy
62103243|NCT06518499||Primary Closure|The primary closure technique for pilonidal sinus involves placing the patient in a prone position under spinal or general anesthesia, shaving and cleaning the surgical area, and making an elliptical incision to remove the affected tissue. A skin flap is then mobilized from the surrounding area to cover the excision site, and the wound is closed with sutures.
62103244|NCT06518499||Karydakis|The Karydakis primary closure procedure involves placing the patient in a prone position under spinal or general anesthesia. The surgical area around the natal cleft is shaved and cleaned thoroughly. A symmetric elliptical excision is performed 2 cm lateral to the midline, removing all affected pilonidal sinus tissue and some surrounding normal tissue. A skin flap, 2 cm wide and 1 cm thick, is mobilized from the contralateral side to cover the resultant defect. The flap is secured using a continuous suture technique, with the skin closed using polypropylene mattress sutures. A low-suction drain is used to standardize the procedure, removed when drainage decreases to less than 20 ml/day.
62103245|NCT02283255|ACTIVE_COMPARATOR|Aerobic Exercise Training Group|Aerobic Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months.
62103246|NCT02283255|ACTIVE_COMPARATOR|Inspiratory Muscle Training Group|Respiratory Training: muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
62664592|NCT02408822|EXPERIMENTAL|PTX|(PacliTaXel-coated balloon angioplasty) Patient receiving endovascular treatment of a vascular access stenosis by drug-eluting balloon angioplasty (mechanical action + antiproliferative drug - Paclitaxel) 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
62664593|NCT02800252|PLACEBO_COMPARATOR|Control Group|Full-mouth periodontal debridement and placebo
62103247|NCT02283255|ACTIVE_COMPARATOR|No Exercise Trainint Group|No Physical Activity: Control group (usual care)
62664594|NCT02800252|ACTIVE_COMPARATOR|Test 1|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
62664595|NCT02800252|ACTIVE_COMPARATOR|Test 2|omega-3 plus aspirin before periodontal therapy
62103248|NCT06306846|EXPERIMENTAL|experimental|"Step 1：neoadjuvant anti-PD-1 antibody and TP chemotherapy every 3 weeks 2 cycles~Step 2： SBRT with GTV expanded 3mm , 24Gy/3F, every other day within one week after the immunochemotherapy~Step 3：Subsequent surgery and adjuvant treatments.~Radical surgery will be performed within 4-6 weeks after the second cycle of immunochemotherapy，no matter the situation of the tumor regresses.~Patients with pathological MPR/CR were treated with PD-1 antibody every two weeks up to 6 cycles after surgery with no adjuvant chemoradiotherapy. Those not achieved MPR/CR will receive adjuvant radiotherapy or chemoradiotherapy according to NCCN guidelines."
62103249|NCT06306846|ACTIVE_COMPARATOR|control|"Step 1：neoadjuvant anti-PD-1 antibody and TP chemotherapy every 3 weeks 2 cycles~Step 2：Subsequent surgery and adjuvant treatments.~Radical surgery will be performed within 4-6 weeks after the second cycle of immunochemotherapy，no matter the situation of the tumor regresses.~Patients with pathological MPR/CR were treated with PD-1 antibody every two weeks up to 6 cycles after surgery without adjuvant chemoradiotherapy. Those not achieved MPR/CR will receive adjuvant radiotherapy or chemoradiotherapy according to NCCN guidelines."
62296170|NCT04899648|NO_INTERVENTION|Control Group|Does not receive any intervention classes
62296171|NCT02339467|EXPERIMENTAL|GO-OUT program|An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 3 months.
62296172|NCT02339467|ACTIVE_COMPARATOR|Task-oriented outdoor walking workshop|An outdoor walking workshop with stations to learn various outdoor walking skills and information.
62664596|NCT02930941|EXPERIMENTAL|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
62664597|NCT02930941|PLACEBO_COMPARATOR|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
62664598|NCT05448937|EXPERIMENTAL|3 MIX|Lesion sterilization and tissue repair; preparation of modified triple antibiotic paste tap: the chemotherapeutic agents used are metronidazole tablets 500 mg (flagyl®, sanofi, egypt), ciprofloxacin tablets 500 mg (ciproxcin®,. Epico, egypt,), and doxycycline capsules 100 mg (doxymycin™ dt, el-nile pharmaceuticals, egypt).
62664599|NCT05448937|ACTIVE_COMPARATOR|Zinc oxide and Eugenol Pulpectomy|zinc oxide and eugenol (prevestdent pro™, egypt).
62664600|NCT03155477|EXPERIMENTAL|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
62664601|NCT03155477|PLACEBO_COMPARATOR|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
62664602|NCT02710747|EXPERIMENTAL|Genetic Group|Dose (mg/week) = \[5.6044 - 0.02614 × Age \[in years\] + 0.0087 × Height \[cm\] + 0.0128 × Weight \[kg\] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 \*1/\*2 - 0.9357 × CYP2C9 \*1/\*3 - 1.0616 × CYP2C9 \*2/\*2 - 1.9206 × CYP2C9\*2/\*3 - 2.3312 × CYP2C9 \*3/\*3 - 0.1092 × Asian race - 0.5503 × amiodarone \]2
62664603|NCT02710747|NO_INTERVENTION|Control Group|Dose for the first three days after operation will be 4.5mg/d.
62664604|NCT04373941|EXPERIMENTAL|Kasai GCSF|The Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously by day 3 post Kasai surgery
62664605|NCT04373941|NO_INTERVENTION|Kasai no GCSF|The no GCSF group will not receive GCSF and receives the standard of care
62296173|NCT00666744|EXPERIMENTAL|1|Exercise Intervention - additional lower limb exercises will be completed by the person with stroke with the assistance of his/her family for 35 minutes daily for a period of 8 weeks.
62468148|NCT02667405|ACTIVE_COMPARATOR|Hot Pack|Hot Pack Application during therapy.
62468149|NCT00493831|EXPERIMENTAL|Nicotine replacement therapy (NRT)|any form of nicotine replacement would be allowed at subject discretion
62103250|NCT06306846|ACTIVE_COMPARATOR|Cetuximab+immunochemo|"Step 1：neoadjuvant anti-PD-1 antibody and TP chemotherapy combined with cetuximab every 3 weeks for 2 cycles~step2: Subsequent surgery and adjuvant treatments.~Radical surgery will be performed within 4-6 weeks after the second cycle of immunochemotherapy，no matter the situation of the tumor regresses.~Patients with pathological MPR/CR were treated with PD-1 antibody and cetuximab every two weeks up to 6 cycles after surgery without adjuvant chemoradiotherapy. Those not achieved MPR/CR will receive adjuvant radiotherapy or chemoradiotherapy according to NCCN guidelines."
62664606|NCT04373941|EXPERIMENTAL|No Kasai GCSF|The No Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously once the diagnosis of BA is established
62664607|NCT04373941|NO_INTERVENTION|No Kasai No GCSF|The No Kasai No GCSF group will receive the standard of care and will not receive GCSF
61912108|NCT02973880|ACTIVE_COMPARATOR|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
62103251|NCT06712745|EXPERIMENTAL|Feasibility|Patients treated with PULSAR will undergo treatment over a total duration of 2-5 months with 3-4 weeks between each fraction. PULSAR treatments completed within 6 months will be acceptable if treatment breaks are required. In the event of a complete response between fractions, remaining fractions will be withheld at the discretion of the treating physician. Treatment may also be terminated for selected grade 3 or higher AEs. Treatment may also be terminated for regional or systemic progression detected during the PULSAR treatment interval.
62103252|NCT02253186|EXPERIMENTAL|Group I|Patients wear, for 90 days, the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
62296174|NCT00666744|NO_INTERVENTION|2|Participants in this group will receive routine exercise therapy following stroke
62296175|NCT06337396|EXPERIMENTAL|Whole Genome Sequencing (WGS) and transcriptome analysis|"to investigate by WGS analysis the genome of selected patients with a detailed clinical characterization. WGS will be also performed on the DNA of the parent from which originated the CNV to look for any potential genomic signatures predisposing to the rearrangement detected in his/her son/daughter.~to investigate the expression profiles of structural variants by transcriptome analysis"
62296176|NCT01203488|EXPERIMENTAL|Experimental|Vitamin A group.
62296177|NCT01203488|SHAM_COMPARATOR|Control|Sham procedure Control group.
62296178|NCT00960271||NON SMALL CELL LUNG CANCER|Non small cell lung cancer, with clinical N2 disease, otherwise operable.
62296179|NCT05232734|EXPERIMENTAL|Oral caffeine group|Patients in this arm will receive treatment with oral caffeine
62296180|NCT05168930|EXPERIMENTAL|Cohort A: BTKi and BCL2i naive|Participants who have never received a BTK inhibitor or a BCL-2 inhibitor
62296181|NCT05168930|EXPERIMENTAL|Cohort B: BTKi or BCL2i exposed without disease progression|Participants who have received prior treatment with a BTK or BCL-2 inhibitor and discontinued treatment for any reason other than disease progression
62296182|NCT05168930|EXPERIMENTAL|Cohort C: BTKi exposed and with disease progression|Participants who experienced disease progression on a prior BTK inhibitor. Participants with BTK C481X mutation at enrollment will be excluded.
61912109|NCT00509262|EXPERIMENTAL|Sitagliptin|Sitagliptin + Placebo for Glipizide
61912110|NCT00509262|ACTIVE_COMPARATOR|Glipizide|Glipizide + Placebo for Sitagliptin
61912111|NCT01463137|SHAM_COMPARATOR|Control training with words|Computerized, internet-based control training program. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency.
62296183|NCT00471770||1|1.Core group: enrolled subjects who have isolated pneumococcal
62296184|NCT00471770||2|2.SPN group:enrolled subjects who have no isolated pneumococcal
62296185|NCT00471770||3|3.DCF group: Subjects screened but not enrolled
62296186|NCT05675709|NO_INTERVENTION|Comparison group|PCPs at the two clinics who do not receive the group training will serve as study comparators.
62296187|NCT05675709|EXPERIMENTAL|Other, Pragmatic|PCP participants complete group training. All training participants will also be offered series of short booster teaching points delivered virtually. Participants who complete the training also take part in pre-post knowledge assessments. PCP participants may also participate in a qualitative interview.
62296188|NCT05057390|EXPERIMENTAL|New Human Milk Fortifier|From the Baseline (start of intervention) each patient will receive the case study product for at least 4 weeks (28 days), with at least 1-week administration in the community.
62296189|NCT05803941|OTHER|Single arm|"Participants will be followed until death, lost to follow-up, or up to 10 years from first dose of AAA617, whichever occurs first.~There will be no study treatment administered to participants while participating in this study."
62296190|NCT00777543|OTHER|Control|The control is the wholegrain bread enriched with bran that has not been pretreated.
62296191|NCT00777543|EXPERIMENTAL|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
62664608|NCT02846402|EXPERIMENTAL|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
62103253|NCT02253186|NO_INTERVENTION|Group II|Patients wear, for 30 days, only a usual custom-made compressive armsleeve during Day-time and no garment during night-time. Then, for the next 60 days, patients wear the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
62103254|NCT06366074|EXPERIMENTAL|Watch-TEA|
62103255|NCT06366074|EXPERIMENTAL|Tethered TEA device|
62103256|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
62103257|NCT01854437||placebo|placebo 1 tab TDS
62103258|NCT04888455||Painful neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with probable or definite neuropathic pain according to the NeuPSIG algorithm.
62103259|NCT04888455||Painless neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with unlikely neuropathic pain according to the NeuPSIG algorithm.
62103260|NCT01501630||PET/CT and MRI|all patients will benefit from PET/CT and MRI
62103261|NCT02702674|ACTIVE_COMPARATOR|propranolol plus oxytocin|121 patients who will receive a capsule containing 20 mg propranolol (propranolol plus oxytocin) administrated orally before beginning induction and repeated after 8 hours if no sufficient uterine contractions reached.
62103262|NCT02702674|PLACEBO_COMPARATOR|placebo plus oxytocin|121 control patients who will receive a similar capsule as a placebo (oxytocin plus placebo) before beginning induction.
62103263|NCT05588154||Cohort 1|Healthy volunteers who will donate blood, and/or bone marrow and may donate other samples
62103264|NCT05588154||Cohort 2|Healthy volunteers who will donate stool samples only
62103265|NCT05481411|EXPERIMENTAL|Single Dose Olpasiran Hepatic Impairment|Participants will be enrolled in 1 of 3 hepatic impairment groups based on their hepatic impairment status, as determined by Child-Pugh classification. All participants will receive a single dose of olpasiran on Day 1.
62103266|NCT05481411|EXPERIMENTAL|Single Dose Olpasiran Normal Hepatic Function|Participants with normal hepatic function will be enrolled and will receive a single dose of olpasiran on Day 1.
62468150|NCT06486129|EXPERIMENTAL|Obesity hypoventilation syndrome patients treated with BPAP (NIV) therapy|Clinically stable patients with OHS and severe hypercapnia during the daytime, referred to the tertiary clinic for the initiation of long-term NIV to alleviate chronic respiratory failure were consecutively enrolled to the study
62103267|NCT04895579|EXPERIMENTAL|Copanlisib (30-60mg iv)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days or 1500mg day 1 q28d). They will also receive Copanlisib ranging from 30mg to 60mg (IV infusion on days 1 and 15, q 28 days).
62103268|NCT01394809|EXPERIMENTAL|Mental Practice|During motor imagery practice a person imagines performing a movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of movement performance. The guideline offers therapists structure and a strategy to deliver subject-specific imagery, and is based on principles of motor learning.
62468151|NCT00495222|EXPERIMENTAL|Tissue plication|The Endoscopic Suturing System (ESS) is used for tissue apposition and reduction of the size of a dilated GJ anastomosis in subjects who are regaining weight after successful weight loss following gastric bypass
62103269|NCT01394809|EXPERIMENTAL|Mirror Therapy|Mirror therapy is thought to work by using vision of the intact or good arm to replace or drive proprioception in the affected arm, and so normalise the afferent segment of the movement process.
62103270|NCT01394809|ACTIVE_COMPARATOR|Relaxation training|The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
62103271|NCT06630442|EXPERIMENTAL|Supportive care (food safety educational training)|Patients attend a food safety educational training program over 50 minutes on study.
62103272|NCT01182870|EXPERIMENTAL|cholecalciferol|cholecalciferol in doses 800-6000 IU per day
62103273|NCT01182870|PLACEBO_COMPARATOR|placebo|placebo identical looking as cholecalciferol capsules
62103274|NCT00984282|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle
62296192|NCT03648801||Hypertention, Dyslipidemia|NA (Observation study)
62468152|NCT02479503||French Adult Heart Transplantation Center|All center performing adult heart transplantation in France in 2015.
62296193|NCT03088501|EXPERIMENTAL|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
62468153|NCT05354479|ACTIVE_COMPARATOR|Expressed breast milk|Babies will get only expressed breast milk.
62468154|NCT05354479|EXPERIMENTAL|paracetamol plus expressed breast milk|Babies will get expressed breast milk plus paracetamol
62103275|NCT00984282|PLACEBO_COMPARATOR|Placebo|Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle
62103276|NCT03699735|ACTIVE_COMPARATOR|Hearing Aid with beam form principle_A|Device: Hearing Aid beam former principle_A (simulation of real ear condition). Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
62103277|NCT03699735|EXPERIMENTAL|Hearing Aid with beam form principle_B|Device: Hearing Aid beam former principle_B. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
62296194|NCT03088501|EXPERIMENTAL|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.~* Brief talk by health professionals.~* Role-plays"
62296195|NCT03088501|NO_INTERVENTION|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
62296196|NCT03411343|ACTIVE_COMPARATOR|Interscalene Block|Patients randomized to receive an intesrcalene block.
62296197|NCT03411343|EXPERIMENTAL|Costoclavicular Infraclavicular Block|Patients randomized to receive a costoclavicular infraclavicular block.
62296198|NCT03429218|EXPERIMENTAL|Single Arm TP-0184|Weekly dose of TP-0184 by oral administration
62296199|NCT04475328|EXPERIMENTAL|AngongNiuhuang|Drugs : AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
62296200|NCT04475328|PLACEBO_COMPARATOR|Placebo of AngongNiuhuang|Drugs : Placebo of AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
62296201|NCT05318521|ACTIVE_COMPARATOR|Ibuprofen Modified-Release Tablets 800 mg (IBUMR)|Ibuprofen Modified-Release Tablets 800 mg (IBUMR), twice daily with 12h interval, for 12-week treatment period.
62296202|NCT05318521|PLACEBO_COMPARATOR|placebo|placebo 800mg, twice daily with 12h interval, for 12-week treatment period.
62296203|NCT05929534|ACTIVE_COMPARATOR|active iTBS group|active iTBS combined with speech language therapy
62296204|NCT05929534|SHAM_COMPARATOR|sham iTBS group|sham iTBS combined with speech language therapy
62664609|NCT02846402|EXPERIMENTAL|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
61912112|NCT01463137|SHAM_COMPARATOR|Control training with words + pictures|Computerized, internet-based control training program. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
61912113|NCT01463137|ACTIVE_COMPARATOR|Positive bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
61912114|NCT01463137|ACTIVE_COMPARATOR|Positive bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
61912115|NCT01463137|ACTIVE_COMPARATOR|Negative bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
62296205|NCT05690321|ACTIVE_COMPARATOR|Active treatment|Administration of opium tincture (Dropizol)
62296206|NCT05690321|PLACEBO_COMPARATOR|Placebo treatment|Administration of placebo (identical to opium tincture in taste and appearance)
62664610|NCT02846402|NO_INTERVENTION|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
61912116|NCT01463137|ACTIVE_COMPARATOR|Negative bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
61912117|NCT02009384|EXPERIMENTAL|Ipilimumab|IV ipilimumab
61912118|NCT03048136|EXPERIMENTAL|Flat-Dose|Nivolumab flat dose + Ipilimumab
61912119|NCT03048136|EXPERIMENTAL|Weight-Based Dose|Nivolumab weight-based dose + Ipilimumab
61912120|NCT00806013||1|CYP2C9\*1/\*1 and CYP2C19\*1/\*1 alleles carrier
61912121|NCT00806013||2|CYP2C19 PMs (CYP2C19\*2/\*2, CYP2C19\*2/\*3 or CYP2C19\*3/\*3)
61912122|NCT00806013||3|CYP2C9\*1/\*3 and CYP2C19\*1/\*1 alleles carrier
61912123|NCT00196183|EXPERIMENTAL|1|trigger-guided ablation of paroxysmal atrial fibrillation
61912124|NCT00196183|EXPERIMENTAL|2|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
62103278|NCT03699735|EXPERIMENTAL|Hearing Aid with beam form principle_C|Device: Hearing Aid beam former principle_C. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
62103279|NCT02077738|EXPERIMENTAL|HFCWO|HFCWO for 15 min twice a day
62103280|NCT02077738|PLACEBO_COMPARATOR|placebo|not to receive high-frequency chest wall oscillation (HFCWO)
62664611|NCT06415331|ACTIVE_COMPARATOR|Conventional therapy|Subjects in this arm received interventions which were conventional, including opioid and non-opioid analgesics, adjuvant analgesics, muscle relaxants, and physiotherapy.
61912125|NCT01910077|EXPERIMENTAL|Tacrobell capsule 1mg|Tacrolimus 1mg / 1 capsule
61912126|NCT01910077|ACTIVE_COMPARATOR|Prograf capsule 1mg|Tacrolimus 1mg / 1 capsule
61912127|NCT00253708|EXPERIMENTAL|massage|"Patients received 3 massage therapy visits from massage therapists in initial week with a duration of 15-45 minutes.NOTE: Intervention 'management of therapy complications' has not been included in any Arm/Group Descriptions.~Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment"
61912128|NCT00253708|ACTIVE_COMPARATOR|no-touch control|Patients received 3 no-touch therapy visits from massage therapists who provided no-touch without healing intention.Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
61912129|NCT00253708|NO_INTERVENTION|Usual care|Patients did not receive visits from massage therapists. Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
61912130|NCT02856191|OTHER|Septic shock|
61912131|NCT02781740|ACTIVE_COMPARATOR|CPAP therapy|Continuation of the already established CPAP therapy.
61912132|NCT02781740|SHAM_COMPARATOR|Sham CPAP therapy|Sham-CPAP is achieved by setting the CPAP machine to the lowest pressure, insertion of a flow-restricting connector at the machine outlet, and insertion of six extra holes in the collar of the main tubing at the end of the mask to allow air escape and to prevent rebreathing of CO2.
61912133|NCT00704275|EXPERIMENTAL|A|0.05% cyclosporin
62296207|NCT05192187|EXPERIMENTAL|LBP|This group will be asked to complete self-reported questionnaires on a single occasion (cross-sectional)
62296208|NCT01573442|EXPERIMENTAL|Arm I|Patients receive testosterone (0.264mL) topical application daily for six months.
61912134|NCT00704275|ACTIVE_COMPARATOR|B|Refresh
61912135|NCT04065165|EXPERIMENTAL|Experimental arm|Lanreotide 120 mg q4w Telotristat Ethyl 250 mg TID
61912136|NCT04065165|PLACEBO_COMPARATOR|Control arm|Lanreotide 120 mg q4w Placebo TID
61912137|NCT03869801|ACTIVE_COMPARATOR|ESP Block|
61912138|NCT03869801|ACTIVE_COMPARATOR|QLB block|
61912139|NCT03470532|EXPERIMENTAL|Group A|buccal infiltration of 4% Articaine with epinephrine
61912140|NCT03470532|ACTIVE_COMPARATOR|Group B|buccal infiltration of 2% Mepivacaine with epinephrine
61912141|NCT03415776|EXPERIMENTAL|Twice weekly|Two sessions of hemodialysis per week
62296209|NCT01573442|PLACEBO_COMPARATOR|Arm II|Patients receive placebo (0.264mL) topical application daily for six months.
62664612|NCT06415331|EXPERIMENTAL|Conventional therapy + pulsed radiofrequency|Subjects in this arm received pulsed radiofrequency in addition to the same conventional therapy as the other arm.
62664613|NCT05389696|EXPERIMENTAL|Part1. Group1. MIT-001 SC 10mg|Single subcutaneous administration of 10mg MIT-001 or placebo
61912142|NCT03415776|EXPERIMENTAL|Thrice weekly|Three sessions of hemodialysis per week
61912143|NCT05982067|EXPERIMENTAL|mindfulness-based physical exercie|The participants will receive about 70-min MIPE program twice a week, which will be conducted in a hybrid way, a combination of face-to-face and at home by a qualified mindfulness therapist and a sport coach.
62103281|NCT00698659||patients on anti-VEGF therapy|"This study aims to assess the pharmacodynamic effects of anti-VEGF therapy. The following groups of patients will be approached:~Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab, sunitinib, and sorafenib) as part of routine clinical management or on clinical studies~All patients must be aged aged ≥ 21 years All patients must have a signed written informed consent prior to study enrollment. A separate consent will be obtained from patients already involved in a clinical study using anti-VEGF treatment.~Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments."
62103282|NCT02071511|ACTIVE_COMPARATOR|control group|Ablation of ventricular arrhythmias
62468155|NCT05378724|NO_INTERVENTION|Control group|All subjects eligible for inclusion in this study will receive usual care physiotherapy treatment. The number of treatment sessions and content of physiotherapy treatment sessions will depend on the diagnosis and needs of the individual patient. This study will not interfere with the content of the usual care physiotherapy treatment. Usual care physiotherapy sessions wil take approximately 20-30 minutes per session. They receive no additional intervention and will not use Hospital Fit as part of their physiotherapy treatment. The patients in the control group will receive an activity monitor to collect data about their physical activity levels. However, patients and their healthcare professionals will not receive feedback on patients' physical activity levels.
62468156|NCT05378724|EXPERIMENTAL|Intervention group|Patients in the intervention group will receive usual care physiotherapy and us Hospital Fit additionally. At the end of the last physiotherapy treatment session before discharge, or after a maximum of nine days of study inclusion (whichever comes first), the physiotherapist will remove the activity monitor and data collection will end.
62296210|NCT04653584||1|Parkinson Disease patients treated by domperidone according the recommendation
62296211|NCT04653584||2|Parkinson Disease patients treated by domperidone in misuse conditions regarding the recommendation
62296212|NCT04653584||3|Parkinson Disease patients without treathment by domperidone
62296213|NCT06491043|PLACEBO_COMPARATOR|placebo|normal saline, 4% human serum albumin
62468157|NCT04513730|EXPERIMENTAL|pelvic suspension device|A device will be built with the function of keeping the user in position of pelvic suspension promoting lumbar traction that will consist of a structure of pvc pipes and connections and padded material.
62468158|NCT03183037|EXPERIMENTAL|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
62468159|NCT03183037|PLACEBO_COMPARATOR|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
62468160|NCT03183037|ACTIVE_COMPARATOR|Usual Care Group|Twelve weeks of usual care.
62468161|NCT05906732|EXPERIMENTAL|Part 1: Arm A: 500 μg of Dofetilide BID in combination with dose-escalating LQT-1213 TID, orally|Dofetilide 500 μg BID (2 × 250 μg capsules), orally (Days 1-8) and LQT-1213 3 times a day (TID) low dose (Days 3 and 4), mid dose (Days 5 and 6), and high dose (not to exceed 0.747 mg/kg TID, daily dose 2.24 mg/kg/day) on Days 7 and 8. The specific doses will be determined before administration of the first dose of LQT-1213, but the high dose will not exceed 0.747 mg/kg TID or 2.24 mg/kg/day. Only 1 dose of dofetilide and LQT-1213 will be administered on Day 8.
62664614|NCT05389696|EXPERIMENTAL|Part1. Group2. MIT-001 SC 20mg|Single subcutaneous administration of 20mg MIT-001 or placebo
61912144|NCT05982067|PLACEBO_COMPARATOR|Health education|Health education consisting of discussion provided by a registered nurse will be conducted as a control of socialization and interaction.
61912145|NCT02831907||Cardiac surgery patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
61912146|NCT00791973|ACTIVE_COMPARATOR|Veramyst, then Placebo|fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
62296214|NCT06491043|EXPERIMENTAL|low-dose UMC119-06-05 treatment|normal saline, 4% human serum albumin, 1×10\^8 cells/subject
62664615|NCT05389696|EXPERIMENTAL|Part1. Group3. MIT-001 SC 40mg and IV 40mg|Single subcutaneous administration of 40mg MIT-001 or placebo and then signle intravenous administration of 40mg MIT-001 or placebo
62664616|NCT05389696|EXPERIMENTAL|Part2. Group1: MIT-001 SC 20mg|Multiple subcutaneous administration of 20mg MIT-001/day or placebo for 7days
62664617|NCT05389696|EXPERIMENTAL|Part2. Group2: MIT-001 SC 40mg|Multiple subcutaneous administration of 40mg MIT-001/day or placebo for 7days
62664618|NCT00620919|EXPERIMENTAL|1|Drug + MDCT
62664619|NCT04416542|NO_INTERVENTION|Control|Subjects in this group will be implanted with the Inspire UAS system and will undergo a standard in-lab PSG titration study at approximately 3 months post-activation and a 2-night HST at approximately 6 months post-activation
62664620|NCT04416542|ACTIVE_COMPARATOR|Home Monitoring|Subjects who have undergone implant of the Inspire UAS System and are randomized to this group will undergo a 2-night HST at 3 months post-activation. Depending on the results of the 2-night HST, the subject will either (a) undergo a PSG titration at 5 months post-activation and a 2-night HST at 6 months post-activation OR (b) undergo only a 2-night HST at approximately 6 months post-activation
62296215|NCT06491043|EXPERIMENTAL|high-dose UMC119-06-05 treatment|normal saline, 4% human serum albumin, 2×10\^8 cells/subject
62664621|NCT03933033|ACTIVE_COMPARATOR|Group A|treated with platelet rich plasma
62664622|NCT03933033|ACTIVE_COMPARATOR|Group B|treated with Erbium Yag Laser
62664623|NCT03933033|ACTIVE_COMPARATOR|Group C|treated with both line of treatments
62664624|NCT01056679|EXPERIMENTAL|AVD-Rev|Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
62664625|NCT01538303||measurement absolute flow and resistance|
62664626|NCT04182893||Pulmonary nodules population|We will enroll 300 pulmonary nodules penplein this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
62664627|NCT04182893||Healthy population|We will enroll 100 healthy penple in this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
62664628|NCT01801332|EXPERIMENTAL|intensive arm|Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days + intensive enteral nutrition by feeding tube for 14 days
62664629|NCT01801332|ACTIVE_COMPARATOR|control arm|"Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days +  classical  oral alimentation for 14 days"
62664630|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
62664631|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
62296216|NCT01882361|ACTIVE_COMPARATOR|injectable naltrexone|One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
62296217|NCT01882361|PLACEBO_COMPARATOR|placebo injection for naltrexone|placebo comparator injection starting at week 24 in a 48-week trial.
62468162|NCT05906732|PLACEBO_COMPARATOR|Part 1: Arm B: 500 μg of Dofetilide BID in combination with placebo|Dofetilide 500 μg BID (2 × 250 μg capsules), orally (Days 1-8) and placebo matched to LQT-1213 TID (Days 3-8). Only 1 dose of dofetilide and placebo matched to LQT-1213 will be administered on Day 8.
62664632|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
62664633|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
62664634|NCT06152315||mitral splay sign|Patients with at least mild mitral regurgitation and splay sign on color doppler echocardiography
62664635|NCT06152315||no mitral splay sign|Patients with at least mild mitral regurgitation and no splay sign on color doppler echocardiography
62664636|NCT02280954|EXPERIMENTAL|ICG injection group|This group will receive a single dose of ICG, infused over 40 minutes. During surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
62664637|NCT03976128|EXPERIMENTAL|Nordic Walking training|20 sessions of 45 minutes x 2 times/week x 10 weeks using NW
62664638|NCT03976128|ACTIVE_COMPARATOR|Conventional endurance training|20 sessions of 45 minutes x 2 times/week x 10 weeks using treadmill and cycloergometer training.
62664639|NCT00800514|EXPERIMENTAL|active|
62664640|NCT04758338|EXPERIMENTAL|CTS Program Arm|6-week intervention delivered via telehealth using the VUMC telehealth services.
62664641|NCT04758338|ACTIVE_COMPARATOR|Education Attention Control Arm|Receive educational materials either online, by email, or in print form.
62664642|NCT05516069|EXPERIMENTAL|Intervention|All participants
62664643|NCT04167462|EXPERIMENTAL|Arm A:BMS-986165 oral administration|
62664644|NCT04167462|PLACEBO_COMPARATOR|Arm B: Placebo oral administration|
62664645|NCT04229901|EXPERIMENTAL|HepaStem|Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 million of cells/kg of total body weight (7 day interval)
62664646|NCT04229901|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)
62664647|NCT04863521|EXPERIMENTAL|MHP Users|A subset of the population within the clinical setting will be requested to participate in this pilot while the rest of the population will receive standard of care.
62664648|NCT00191100|EXPERIMENTAL|1|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week~Two week rest period with no chemotherapy or radiation~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles"
62103283|NCT02071511|SHAM_COMPARATOR|intervention group|Ablation of ventricular arrhythmias + renal denervation
62296218|NCT02071940|EXPERIMENTAL|PLX3397|Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single cohort study and so there is no comparator arm - all patients receive the same treatment.
62664649|NCT00191100|ACTIVE_COMPARATOR|2|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week"
62664650|NCT05579340|NO_INTERVENTION|Usual care|
62664651|NCT05579340|EXPERIMENTAL|Ex1|Low exercise volume (150 min/week)
62664652|NCT05579340|EXPERIMENTAL|Ex2|High exercise volume (300 min/week)
62664653|NCT00667966|EXPERIMENTAL|Vardenafil + Placebo|Subjects received single dose of 10 mg vardenafil followed by 20 mg vardenafil and then crossed over to 10 mg placebo followed by 20 mg placebo.
62664654|NCT00667966|EXPERIMENTAL|Placebo + Vardenafil|Subjects received single dose of 10 mg placebo followed by 20 mg placebo and then crossed over to 10 mg vardenafil followed by 20 mg vardenafil.
62468163|NCT05906732|EXPERIMENTAL|Part 2: TID dosing of LQT-1213|LQT-1213 2.24 mg/kg/day TID (at time 0, 8 and 16 hours) on Days 2-4, with a final single morning dose on Day 4 at time 0, though these time points may be adjusted based upon emerging data.
62468164|NCT05906732|OTHER|Part 2: TID dosing of Placebo|Placebo matched to LQT-1213 (Day 1)TID
62468165|NCT01036360||physical activity|
62468166|NCT04373278||description of infection of free fibula flap reconstruction|
62468167|NCT04065035|ACTIVE_COMPARATOR|Topical Firming Body Moisturizer|Oil-in-water emulsion base containing emollients, botanical extracts, peptides, antioxidants, prebiotics, and modified theophylline ingredients.
62468168|NCT04065035|PLACEBO_COMPARATOR|Placebo Moisturizer|Oil-in-water emulsion base containing emollients.
62468169|NCT02023853|EXPERIMENTAL|ultrasonic, erythritol, metronidazole gel|
62468170|NCT04381962|EXPERIMENTAL|Azithromycin|Azithromycin 2x250mg capsules to be taken orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
62664655|NCT06505148|EXPERIMENTAL|Group A|Group A will prescribe study participants in group 1 acetaminophen and ibuprofen alternating treatment every three hours. The dosage will be weight-based.
62664656|NCT06505148|ACTIVE_COMPARATOR|Group B|Group B will be prescribed acetaminophen and ibuprofen combined treatment every 6 hours. The dosage will be weight-based.
62664657|NCT00226733|EXPERIMENTAL|A|Interval exercise training with high intensity
61912147|NCT00791973|ACTIVE_COMPARATOR|Placebo, then Veramyst|placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
62664658|NCT00226733|ACTIVE_COMPARATOR|B|Exercise training with moderate intensity
62468171|NCT04381962|NO_INTERVENTION|Usual standard care|Standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
62664659|NCT03670628|ACTIVE_COMPARATOR|720 shockwave therapy Group|Participants in this group will receive a total of 5 daily sessions of shockwave therapy within a week. Each therapy session will consist of 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
62664660|NCT03670628|SHAM_COMPARATOR|Sham shockwave therapy|Participants in this group will receive a total of 5 daily sessions of sham shockwave therapy within a week. Sham therapy will be applied to the penis and to the left and right crus (shaft near the base).
62296219|NCT06408844|EXPERIMENTAL|Experimental group|Training to improve physical activity behavior will be given to the experimental group for 8 weeks, based on the 5A model.
62296220|NCT06408844|NO_INTERVENTION|Control group|The control group will not receive any intervention and will be asked to continue their routine lives.
62296221|NCT00787111|EXPERIMENTAL|Fluoxetine ODT|Fluoxetine ODT ranging from 2mg to 54mg
62664661|NCT00972738|EXPERIMENTAL|1|montelukast
62664662|NCT00972738|ACTIVE_COMPARATOR|2|loratadine
62664663|NCT00972738|PLACEBO_COMPARATOR|3|placebo
62664664|NCT04137536|EXPERIMENTAL|Pancreatic Adenocarcinoma|Participants have metastatic pancreatic cancer who have received at least first line chemotherapy and have disease progression during or within 6 months of treatment.
62664665|NCT05876494||patients with ulcerative colitis|any patients with ulcerative colitis
62664666|NCT02511353|PLACEBO_COMPARATOR|placebo|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
62664667|NCT02511353|EXPERIMENTAL|ivermectin 300 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
62664668|NCT02511353|EXPERIMENTAL|ivermectin 600 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.
62664669|NCT05650892||Sample collection aortic tissue|Sample collection thoracic aorta tissue
62103284|NCT02757885|EXPERIMENTAL|Bone Marrow Recipient|Single arm open label study: Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) mismatched donor.
62296222|NCT04271267||Acute Rejection Cohort|The subset of samples corresponding to biopsy-proven acute rejection
62296223|NCT04271267||Rejection-free Cohort|The subset of samples corresponding to a transbronchial biopsy free of acute cellular rejection.
62103285|NCT04656236|EXPERIMENTAL|Intervention|3 hours of continuously intravenous infusion of 3-hydroxybutyrate.
62103286|NCT04656236|PLACEBO_COMPARATOR|Control|3 hours of continuously intravenous infusion of saline (NaCl).
62296224|NCT05595876|EXPERIMENTAL|Stent retriever|The patients will be treated to receive stent retriever (with or without contact aspiration) first line thrombectomy (experimental arm).
62296225|NCT05595876|SHAM_COMPARATOR|Contact aspiration|The patients will be treated to receive direct contact aspiration first line thrombectomy (control arm)
62296226|NCT00116454|EXPERIMENTAL|lipiocis group|intra-arterial hepatic administration, one 2200 MBQ dose, duration of treatment 1 week
62296227|NCT00116454|NO_INTERVENTION|control group|group untreated
62296228|NCT02272192|EXPERIMENTAL|ESDM15 hr/week|Children receive 15 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
62296229|NCT02272192|EXPERIMENTAL|ESDM 25 hr/week|Children receive 25 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
62296230|NCT02272192|EXPERIMENTAL|EIBI 15 hr/week|"Children receive 15 hours per week of 1:1 intervention at home plus parent training using Early Intensive Behavioral Intervention (EIBI) and following the Manual A Work in Progress"
61912148|NCT03126552|EXPERIMENTAL|Intervention|Four healthy hookworm-naive volunteers will be infected with 50 Necator americanus L3 larvae.
62296231|NCT02272192|EXPERIMENTAL|EIBI 25 hr/week|"Children receive 25 hours per week of 1:1 intervention at home plus parent training using EIBI and following the Manual A Work in Progress"
62296232|NCT01543321|EXPERIMENTAL|Tetrabenazine group|Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
62468172|NCT04258150|EXPERIMENTAL|Experimental|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 6 mg/kg (up to 480 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 (± 3 days) twice in total every 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Tocilizumab 8 mg/kg is given IV on day 1 (± 3 days) over 1-hour, repeated every 4 weeks. Tocilizumab infusion over 30 minutes is allowed after 5. infusion in the absence of infusion related events.
61912149|NCT02192840|ACTIVE_COMPARATOR|rDES Group|"Regular drug-eluting stent implantation, one of the following:~Device: LucChopin (Balton, Poland) Device: Prolim (Balton, Poland) Device: Xience Pro (Abott Vascular) Device: Biomatrix (Biosensors) Device: Promus (Boston Scientific) Device: Cypher (Cordis) Device: Taxus (Boston Scientific) Device: Coroflex Please (BBraun) Device: Resolute Integrity (Medtronic)"
62103287|NCT05448066|ACTIVE_COMPARATOR|Standard diagnosis|Patients followed in the allergy clinic with indication for allergen immunotherapy using only standard diagnosis.
62103288|NCT05448066|EXPERIMENTAL|CRD diagnosis|Patients followed in the allergy clinic with indication for allergen immunotherapy decided with standard diagnostic tools and molecular based diagnosis.
62296233|NCT01543321|PLACEBO_COMPARATOR|Plagebo group|Patients will receive a buccal tablet identical to the experimental product
62468173|NCT01638377|EXPERIMENTAL|Naltrexone|Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
62468174|NCT01638377|PLACEBO_COMPARATOR|Control|Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
62468175|NCT03852147|ACTIVE_COMPARATOR|Control group|hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.
61912150|NCT02192840|EXPERIMENTAL|BiOSS Group|New dedicated bifurcation stent BiOSS Expert (Balton, Warsaw, Poland) implantation
62296234|NCT03314285|OTHER|Neck Pain|Patients with chronic mechanical neck pain will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
62296235|NCT03314285|OTHER|Healthy volunteers|Healthy volunteers without any disease will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
62468176|NCT03852147|EXPERIMENTAL|Experimental group|perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.
61912151|NCT00991952|EXPERIMENTAL|Arm A (irinotecan hydrochloride, alvocidib)|Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62103289|NCT00926939|EXPERIMENTAL|Abstinence Contingent (AC)|This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
62103290|NCT00926939|EXPERIMENTAL|Submission Contingent (SC)|This group receives vouchers for submitting videos of their CO breath test.
62296236|NCT05617560|EXPERIMENTAL|Telemedical care|
62296237|NCT00831376|EXPERIMENTAL|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
62664670|NCT06532994||Survivors of ICU with Mechanical Ventilation|Survivors of ICU with Mechanical Ventilation are individuals who have been treated in an intensive care unit (ICU) and require the use of a mechanical ventilator to assist their breathing with no mortality events occurring.
62664671|NCT02305147||Patients with an idiopathic Parkinson Disease,|Patients with recent onset of Parkinson Disease: N=200
62664672|NCT02305147||Subjects at risk of PD|"Subjects at risk to develop Parkinson Disease:~* subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50~* subjects related to a patient with genetically confirmed Parkinson Disease: N=30"
62664673|NCT02305147||Controls|Healthy controls: N=50
62664674|NCT02305147||Patients with Parkinson Disease with genetic mutation|Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
62664675|NCT02997670|EXPERIMENTAL|Main patient cohort|Algorithmic Cardiac Resynchronisation Therapy Optimisation; Patients requiring CRT-D enrolled to receive algorithmic CRT optimisation at their device implantation. They will then be programmed to standard CRT settings for 12 weeks. Assessments will be performed and they will again undergo CRT optimisation using the specified algorithm. This time, they will be programmed to the settings giving maximal cardiac output on echocardiography, as assessed by LVOT VTI. After a further 12 weeks, they will again undergo assessment and the study will terminate.
62664676|NCT04903977|EXPERIMENTAL|Impedance spectroscopy|ONIRY examination
62103291|NCT03005249|EXPERIMENTAL|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
62103292|NCT03005249|EXPERIMENTAL|the control group|The patients will be assigned to the control group for cerebral palsy.
62103293|NCT04591184|EXPERIMENTAL|Active Covigenix VAX-001|Dose-ranging, 2 dose levels. 24 subjects receiving active i.m. vaccine
62103294|NCT04591184|PLACEBO_COMPARATOR|Placebo|Placebo injection. 12 subjects receiving placebo
62664677|NCT01026038|EXPERIMENTAL|1|1 dose (0.5 mL), IM of 13vPnC vaccine.
62103295|NCT02441075|EXPERIMENTAL|70% Ethanol|The study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
62103296|NCT03031756|EXPERIMENTAL|test|SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation, glycine powder air-polishing (GPAP) was performed for 10 seconds per surface after the instrumentation (Air-Flows Perio Powder, EMS, Nyon, Switzerland) was applied using a Perio-Flows hand-piece connected to an airflow unit (Air-Flow Masters, EMS).
62468177|NCT05713994||HAIC-A-T cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus bevacizumab (A) and atezolizumab (T) as conversion therapy for downstaging.
62664678|NCT05607043|OTHER|SARS-CoV-2 testing|There is only one arm in this study- the study is a non-randomized pilot. All the subjects will be tested for SARS CoV 2 viral infection as described.
62664679|NCT01402466|ACTIVE_COMPARATOR|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
62664680|NCT01402466|EXPERIMENTAL|Project Bridge|Participants randomized to this arm will be given the Project Bridge intervention
62664681|NCT00807872|OTHER|I-124 Mu 11-1F4 sterile injection|Single arm study
62664682|NCT02140827|EXPERIMENTAL|IMP education|patients in this group are educated about bowel preparation by instant messaging program and meanwhile a booklet was also sent to them.
62664683|NCT02140827|NO_INTERVENTION|normal education|patients in this group are educated about bowel preparation on the day of reservation by nurse for about 15 minutes and meanwhile a booklet was also sent to them.
62664684|NCT03852576|EXPERIMENTAL|Esophagus sprayed with KSP/QRH dimer|Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe
62103297|NCT03031756|ACTIVE_COMPARATOR|control|In the control group, SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation.
62296238|NCT00831376|ACTIVE_COMPARATOR|2: racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
62296239|NCT00831376|PLACEBO_COMPARATOR|3: Placebo|Patients will be asked to take two puffs four times a day for 2 weeks
62103298|NCT06163521|EXPERIMENTAL|Education|
62296240|NCT01449838|PLACEBO_COMPARATOR|Saline|Subjects were administered single dose or twice daily for 2.5 days repeat dose of placebo by the intravenous route.
62296241|NCT01449838|EXPERIMENTAL|Colistimethate sodium|2.5 milligrams (mg)/kilogram (kg) of CMS-NA (as colistin activity or 75,000 International Unit/kg) was administered as single dose or twice daily for 2.5 days repeat dose by the intravenous route.
62296242|NCT01935219|EXPERIMENTAL|Goal Management Training + Processing Speed Training|Group receives both Goal Management Training and as well as Processing Speed Training using DriveSharp software.
62296243|NCT01935219|ACTIVE_COMPARATOR|Processing Speed Training + Brain Health Workshop|Group receives both Processing Speed Training (using DriveSharp) and participates in a Brain Health Workshop that is matched to Goal Management Training for session length and contact with trainer.
62296244|NCT01935219|PLACEBO_COMPARATOR|Brain Health Workshop + computer assignments|Group participates in Brain Health Workshop and is provided with computer assignments to match for time spent on the computer in the other arms.
62296245|NCT04313946||Symptomatic Patients|Our goal is to identify an artificial intelligence algorithm that can be run on lung radiographs in patients with influenza / respiratory viral symptoms who come to the emergency department / triage. This algorithm aims to identify the radiographs of patients with COVID-19 and those with influenza pneumonitis, with accuracy verified by COVID-19 tests.
62296246|NCT02131844|EXPERIMENTAL|Facilitated early mobilization|Early mobilization facilitated by a dedicated health professional
62296247|NCT02131844|ACTIVE_COMPARATOR|Usual care|Instructions about early mobilization covered in a preoperative education session
62296248|NCT00702676|EXPERIMENTAL|1|Quetiapine Fumarate Immediate Release
62296249|NCT00702676|EXPERIMENTAL|2|Quetiapine Fumarate Extended Release
62103299|NCT03059082|OTHER|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
62103300|NCT03059082|OTHER|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
62103301|NCT03059082|OTHER|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
62103302|NCT00515086|EXPERIMENTAL|No Surgery (Everolimus 10 mg)|Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
62103303|NCT00515086|EXPERIMENTAL|Everolimus 10 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
62103304|NCT00515086|EXPERIMENTAL|Everolimus 5 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
62103305|NCT00515086|ACTIVE_COMPARATOR|Everolimus 0 mg + Surgery|Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
62103306|NCT02004613|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.
62103307|NCT02004613|PLACEBO_COMPARATOR|Placebo|normal saline administration matching dexmedetomidine rate of infusion.
62103308|NCT05626543|EXPERIMENTAL|Intervention|Participants in the Intervention arm will receive Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs based intervention.
62103309|NCT05626543|NO_INTERVENTION|Control|The control will work normally with intervention. The intervention material will be provided to the controls once the follow-up surveys are conducted after the intervention is given to the intervention arm.
62103310|NCT06326866||Individuals with A Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as A Rh (+) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62103311|NCT06326866||Individuals with A Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as A Rh (-) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62103312|NCT06326866||Individuals with B Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as B Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62664685|NCT04938947|EXPERIMENTAL|High-Intensity Resistance Training Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each resistance training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure (likely 8-12 repetitions) using 80% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2).
62103313|NCT06326866||Individuals with B Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as B Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62664686|NCT04938947|EXPERIMENTAL|Low-Intensity Resistance Training with Blood Flow Restriction Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure using 30% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2). Participants in this group will perform all leg extensions with blood flow restriction cuffs applied to the proximal thigh of both legs. The pressure that the cuffs are inflated to will be calculated based on estimates of each subject's arterial occlusion pressure from their thigh circumference. Once the target pressure is reached, the cuffs will not be deflated until after the final set of the training session.
62664687|NCT01051284|EXPERIMENTAL|Cyberknofe and Gemcitabine|Cyberknife radiation and 6 cycles Gemcitabine
62664688|NCT04212156||TMH test|Patient will be asked to lay supine while the head and neck maintained in a neutral position using a pillow under the head. By using digital depth gauge, the TMH will be measured from the anterior border of the thyroid cartilage directly on the thyroid notch till the anterior border of the mentum
62468178|NCT05713994||HAIC-Len-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and anti-PD-1 antibody as conversion therapy for downstaging.
62664689|NCT00816270|EXPERIMENTAL|1|Experimental operatory wound closure with liquid bandage (Johnson \& Johnson, Skillman, NJ, USA).
62664690|NCT04072471||Zurampic®|Patients exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) (lesinurad+XOI)
62664691|NCT04072471||Control group: xanthine oxidase inhibitor monotherapy|Patients exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat).
62103314|NCT06326866||Individuals with AB Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as AB Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62103315|NCT06326866||Individuals with AB Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as AB Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62468179|NCT05713994||HAIC-B-S cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus bevacizumab biosimilar (Byvasda, B) and Sintilimab (Tyvyt, S) antibody as conversion therapy for downstaging.
62468180|NCT05713994||HAIC-Apa-C cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus Apatinib (Apa) and Camrelizumab (C) antibody as conversion therapy for downstaging.
62468181|NCT05713994||HAIC-Sor-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus sorafenib (Sor) and anti-PD-1 antibody as conversion therapy for downstaging.
62468182|NCT05713994||HAIC-Don-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus donafenib (Don) and anti-PD-1 antibody as conversion therapy for downstaging.
62468183|NCT05713994||HAIC-Reg-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus regorafenib (Reg) and anti-PD-1 antibody as conversion therapy for downstaging.
62468184|NCT01356693|EXPERIMENTAL|Active drug|Bromelin. Extract from Ananas comosus, 3,3g on vehicle (methylparaben, propylparaben, honey from apis mellifera, sodium benzoate, ethylic alcohol, water) 5ml.
62468185|NCT01356693|PLACEBO_COMPARATOR|Placebo|Placebo comparator with the same characteristics of experimental drug, 5ml, single dose.
62468186|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
62468187|NCT04782232||Patients with failing/absence of the right heart|Patients with acute or chronic, conservatively uncontrollable heart failure of varying pathogenesis, graded as stage III or IV according to NYHA, with an anticipated need for short-term to long-term right ventricular or biventricular support.
62468188|NCT01982318|ACTIVE_COMPARATOR|VitroGro®ECM|A topical application of synthetic extracellular matrix (ECM) protein formulation to the wound bed) plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
62468189|NCT01982318|PLACEBO_COMPARATOR|Dulbecco's Phosphate Buffered Saline|Dulbecco's Phosphate Buffered Saline plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
62468190|NCT00965874|EXPERIMENTAL|Magnesium Sulfate high dose infusion|9 g Magnesium sulfate infusion over 30 minutes
62468191|NCT00965874|ACTIVE_COMPARATOR|Magnesium Sulfate low dose infusion|4.5 magnesium sulfate infusion over 30 minutes
62664692|NCT01239680|PLACEBO_COMPARATOR|Ringer's Lactate and Placebo for Glutamine|Ringer's Lactate 1 liter once over 6 hours
62664693|NCT01239680|EXPERIMENTAL|Ringer's Lactate with 25 grams Glutamine|Ringer's Lactate with 25 grams Glutamine (1 liter) once over 6 hours
62468192|NCT00965874|PLACEBO_COMPARATOR|placebo|serum salin
62468193|NCT03168633|EXPERIMENTAL|patients receiving emails|"Diagnosed DM2 patients who meet inclusion criteria. the patients will receive emails containing information about DM2 as a method of reminding patients of the importance of adjusting post diagnosis life-style changes.~web-based DM2 information pages"
62468194|NCT04088422||B-cell lymphoma|
62664694|NCT04649307|OTHER|MI-CBT|The treatment will be based on the AF treatment developed by the research group and further be developed and adapted during the course the study, based on the clinical presentation of the MI patients and their response to the CBT interventions detailed below. The MI-specific CBT will consist of 8 weekly face-to face digital video sessions with home assignments that can be reviewed and reported in the research groups secure platform. CBT for MI primarily targets two processes of disability; cardiac anxiety, and depressive inactivity
62664695|NCT01908244|NO_INTERVENTION|Control|No pentatonic music
62664696|NCT01908244|EXPERIMENTAL|Music|
62468195|NCT02685462|ACTIVE_COMPARATOR|Group 1 (Rosuvastatin)|Group 1 (12 subjects) will receive Rosuvastatin on Days 1 and 13.
62664697|NCT04924491|EXPERIMENTAL|10.000.000 thyTreg /kg|Autologous thyTreg 10.000.000
61912152|NCT00991952|ACTIVE_COMPARATOR|Arm B (irinotecan hydrochloride)|Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62103316|NCT06326866||Individuals with O Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as O Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62103317|NCT06326866||Individuals with O Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as O Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
62103318|NCT04582357|EXPERIMENTAL|Exercise arm|This arm is the only arm of the study, every patient is included in this arm, the patients will follow the physical activity program
62103319|NCT05451810|EXPERIMENTAL|Main Cohort: Epcoritamab Diffuse Large B-Cell Lymphoma (DLBCL)|Participants with relapsed or refractory (R/R) DLBCL will receive subcutaneous (SC) epcoritamab in 28 day cycles.
62664698|NCT04924491|EXPERIMENTAL|20.000.000 thyTreg /kg|Autologous thyTreg 20.000.000
62664699|NCT02786966|OTHER|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
62664700|NCT01756235||Participants with Rheumatoid Arthritis|Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.
62664701|NCT06165874|EXPERIMENTAL|non-small cell lung cancer|Patients were recruited in the Department of Thoracic Surgery
62664702|NCT04171076|EXPERIMENTAL|Intervention|Intervention: non-invasive spinal cord stimulation
62664703|NCT05564078||Subjects with Eosinophilic Asthma|
62664704|NCT05564078||Subjects without Asthma|
62664705|NCT01615718|EXPERIMENTAL|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
62664706|NCT01615718|SHAM_COMPARATOR|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
62664707|NCT01615718|ACTIVE_COMPARATOR|Active Electrical Stim/Sham Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.
62664708|NCT01615718|ACTIVE_COMPARATOR|Sham Electrical Stim/Active Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
62664709|NCT02197637|EXPERIMENTAL|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle
62664710|NCT04453683|ACTIVE_COMPARATOR|Group I ( Air Q)|nsertion of proper size Air-Q. ILA
62664711|NCT04453683|ACTIVE_COMPARATOR|Group II (ILMA)|nsertion of proper size ILMA
61912153|NCT05198375|ACTIVE_COMPARATOR|Control group (CG)|decision to administer exogenous surfactant when FiO2 \>0.30 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%.
61912154|NCT05198375|EXPERIMENTAL|LUS group (LUSG)|"decision to administer surfactant when LUS \> 8 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%.~The LUS group will receive surfactant administration as rescue therapy in case of LUS \< or = 8 but FiO2 \> 0.30 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%."
61912155|NCT03011892|PLACEBO_COMPARATOR|Double Blind (DB): Vehicle BID|Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
61912156|NCT03011892|ACTIVE_COMPARATOR|DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID|Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
61912157|NCT03011892|EXPERIMENTAL|DB: Ruxolitinib 0.15% Once Daily (QD)|Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
61912158|NCT03011892|EXPERIMENTAL|DB: Ruxolitinib 0.5% QD|Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
61912159|NCT03011892|EXPERIMENTAL|DB: Ruxolitinib 1.5% QD|Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
61912160|NCT03011892|EXPERIMENTAL|DB: Ruxolitinib 1.5% BID|Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
61912161|NCT03011892|PLACEBO_COMPARATOR|Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
61912162|NCT03011892|ACTIVE_COMPARATOR|OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
61912163|NCT03011892|EXPERIMENTAL|OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
62737555|NCT02120768|EXPERIMENTAL|Barrier resection|"Barrier resection was defined as en bloc removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs."
62103320|NCT05451810|EXPERIMENTAL|Main Cohort: Epcoritamab Classic Follicular Lymphoma (cFL)|Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.
62103321|NCT05451810|EXPERIMENTAL|Diversity Enriched Cohort: Epcoritamab DLBCL|Participants with R/R DLBCL will receive SC epcoritamab in 28 day cycles.
62103322|NCT05451810|EXPERIMENTAL|Diversity Enriched Cohort: Epcoritamab cFL|Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.
62296250|NCT04643184|EXPERIMENTAL|Management Program|Comanagement program (cardiological-geriatric) to carry out during hospitalization a comprehensive evaluation that allows to know the medical and socio-environmental needs of the patients to plan the required care at home and achieve an effective transition.
62296251|NCT04643184|NO_INTERVENTION|Usual Care|Usual care during hospitalizacion and discharge.
62296252|NCT04698876|EXPERIMENTAL|Outpatient measurement of intraocular pressure|The intervention group measures its intraocular pressure itself in their home environment for 7 days at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m. with a self-tonometer (iCareHOME).
62737556|NCT02120768|ACTIVE_COMPARATOR|1 cm resection|Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs.
62296253|NCT04698876|ACTIVE_COMPARATOR|Stationary measurements of intraocular pressure|The intraocular pressure of the control group is measured by means of rebound tonometry or Goldmann applanation tonometry in a clinic for minimum 24 hours at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m.
62296254|NCT03728088||Surgical Candidates|"Under- and postgraduate candidates applying for surgical training in general surgery, orthopedics, urology or plastic surgery at Ghent University Hospital.~All candidates will complete the rating scales concerning non-technical attributes in the period prior to the surgical selections."
62296255|NCT03728088||Surgical trainees|"Surgical trainees active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital or an affiliated non-academic training hospital.~All trainees will be invited to participate in the study. Trainees who agree to participate will complete the rating scales concerning non-technical attributes."
62296256|NCT03728088||Surgical staff|"Surgical staff members active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital.~All surgical staff members will be invited to participate in the study. Surgical staff members who agree to participate will complete the rating scales concerning non-technical attributes."
62296257|NCT04574999|EXPERIMENTAL|0.005% Estriol group|0.005% Estriol (50 μg/g) gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
62468196|NCT02685462|ACTIVE_COMPARATOR|Group 1 (Digoxin)|Group 1 (12 subjects) will receive Digoxin on Days 1 and 13.
62468197|NCT02685462|ACTIVE_COMPARATOR|Group 1 (Caffeine)|Group 1 (12 subjects) will receive Caffeine on Days 1 and 13.
62468198|NCT02685462|ACTIVE_COMPARATOR|Group 2 (Atorvastatin)|Group 2 (12 subjects) will receive Atorvastatin on Days 1 and 13.
62468199|NCT02685462|EXPERIMENTAL|Cenicriviroc|"Subjects in Group 1 and Group 2 will receive Cenicriviroc on Days 3-12.~Subjects in Group 3 will receive Cenicriviroc on Days 2-12."
62468200|NCT02685462|ACTIVE_COMPARATOR|Group 3 (Simvastatin)|Group 3 (12 subjects) will receive Simvastatin on Days 1 and 12.
62468201|NCT02760368|EXPERIMENTAL|Arm 1: Olokizumab q4w|Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
62468202|NCT02760368|EXPERIMENTAL|Arm 2: Olokizumab q2w|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
62468203|NCT02760368|PLACEBO_COMPARATOR|Arm 3: Placebo|Placebo Subcutaneous q2w + Methotrexate (oral)
62737557|NCT04217499||Patients with pelvic ring fractures|This retrospective study will be carried out on the data of patients who have received treatment or followed for a pelvic ring fracture, in the Orthopedic Surgery department of the Paris Saint-Joseph Hospital Group between January 2015 and September 2019.
62468204|NCT04011345|OTHER|Folic Acid Supplement [Phase 1]|Phase 1: Folic acid supplement (1 mg per day) for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Placebo for 12 weeks
62468205|NCT04011345|OTHER|Placebo [Phase 1]|Phase 1: Placebo for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Folic acid supplement (1 mg per day) for 12 weeks
62468206|NCT06324838|EXPERIMENTAL|Extended mesenteric resection|Arm receiving ileocecal resection with extended mesenteric resection.
61912164|NCT03011892|EXPERIMENTAL|OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
62103323|NCT00697892|EXPERIMENTAL|Group A4|healthy volunteers assigned to the efavirenz with artemether/lumefantrine intervention
62468207|NCT06324838|ACTIVE_COMPARATOR|Controls (Standard mesenteric resection)|Arm receiving standard ileocecal resection.
62103324|NCT00697892|EXPERIMENTAL|Group A3|healthy volunteers assigned to the lopinavir/ritonavir with artemether/lumefantrine intervention
62103325|NCT01922570|EXPERIMENTAL|Dietary supplements:parenteral nutrition|supplemental parenteral nutrition and enteral nutrition in case of failure (intake below 60% of energy needs) of enteral nutrition by day 3 after admission in the ICU or enteral nutrition only.
62103326|NCT06147245|EXPERIMENTAL|Person-centred culturally sensitive course of treatment|The intervention consists of a 12-month person-centred and culturally sensitive course of treatment.
62103327|NCT06147245|NO_INTERVENTION|Control|The control group will follow the standard care with regular visits at the T2D outpatient clinic at SDCC 3-4 times/year.
62103328|NCT04866056|EXPERIMENTAL|Treatment(Jaktinib+Azacitidine)|Patients receive azacitidine subcutaneously (SC) on days 1-7 and Jaktinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62103329|NCT02693626|EXPERIMENTAL|intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per day for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
62737558|NCT02405247||NSCLC without T790M mutation|NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
62103330|NCT02693626|NO_INTERVENTION|No cessation message intervention|Control group participants only will receive one text message every week, thanking them for being in the study, providing study center contact details, and reminding them of the time until their free month at the end of follow up. Another one to two messages will be sent per week until the end of the 24 week. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points.
62103331|NCT02693626|EXPERIMENTAL|Not intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per week for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
62296258|NCT04574999|PLACEBO_COMPARATOR|Placebo group|Placebo gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
62296259|NCT06109545||Women with suspicion of ovarian malignancy|Women with suspicion of ovarian malignancy depending on ultrasound, CT, MRI and CA 125
62468208|NCT05239754|EXPERIMENTAL|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
62468209|NCT04577846|ACTIVE_COMPARATOR|Intervention Arm|The intervention arm will be administered, either Cefazolin iv every 8 hours while NPO or cefalexin 500 mg q8 hours per oral if tolerating a diet.
62296260|NCT02249741|EXPERIMENTAL|Patients with osteoporosis|Treated with Ibandronic acid as per protocol
62468210|NCT04577846|PLACEBO_COMPARATOR|Control|Controls will be provided with initially IV placebo while NPO and then with a placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
62468211|NCT06189274|EXPERIMENTAL|Anatomy-Based Electrode Selection|For individuals in the anatomy-based electrode (ABE) group, magnetic resolution imaging (MRI) or computed tomography (CT) scans will be evaluated by MED-EL Canada employees. Based on these results, an appropriate electrode array will be selected.
62468212|NCT06189274|ACTIVE_COMPARATOR|Standard of Care Electrode Selection|The comparison in this study will be to current standard of care, which is to select a single electrode length for most patients, in this case the FLEX28 electrode, which is 28 mm long.
62468213|NCT02045160||Sulfamethoxazole-trimethoprim treatment|
62468214|NCT04202874|EXPERIMENTAL|Bupivacaine|Administration of 20ml of bupivacaine 0.25% on each side, for a total of 40ml.
62468215|NCT04202874|PLACEBO_COMPARATOR|Saline|Administration on 20ml of normal saline on each side, for a total of 40ml.
62468216|NCT05186662||WeChat group|
62468217|NCT05186662||Control group|
62737559|NCT01434628|EXPERIMENTAL|PrePex™ device|Adult male circumcision by the PrePex™ device
62296261|NCT05592340|ACTIVE_COMPARATOR|Control|Calorie labels shown on online restaurant menu
62296262|NCT05592340|EXPERIMENTAL|Carbon footprint labels|Carbon footprint labels shown on online restaurant menu next to every item in addition to calorie labels
62296263|NCT02603575|EXPERIMENTAL|Caspofungin and corticosteroids|patients treat with caspofungin and corticosteroids on the base of sulfanilamide
62468218|NCT04784520|EXPERIMENTAL|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
62468219|NCT05026567|ACTIVE_COMPARATOR|Reference Product A|
62468220|NCT05026567|EXPERIMENTAL|Experimental B|
62468221|NCT05026567|EXPERIMENTAL|Experimental C|
62468222|NCT05026567|EXPERIMENTAL|Experiment D|
62468223|NCT04905017|EXPERIMENTAL|Treatment with the Trisol System|
62468224|NCT02909478|EXPERIMENTAL|Aprepitant arm|Aprepitant + Tropisetron
62468225|NCT02909478|ACTIVE_COMPARATOR|Control arm|Dexamethasone+ Tropisetron
62664712|NCT05354934||People living with HIV|"The questionnaire includes the following modules~* Demography and socio-economic conditions~* Screening and modalities of discovery and announcement of HIV infection~* Time and modalities of introduction of antiretroviral drugs after diagnosis~* Knowledge of HIV infection~* The perception of follow-up in the health care service~* Experiences of stigma~* Barriers to accessing care~* Periods of loss of sight and reasons for this~* Perceived health status, mental health (PHQ4), chronic illness, functional limitations~* Addictions~* Social network and support~* Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
62296264|NCT02603575|ACTIVE_COMPARATOR|Caspofungin and no corticosteroids|patients treat with caspofungin on the base of sulfanilamide
62296265|NCT02603575|ACTIVE_COMPARATOR|corticosteroids and no caspofungin|patients treat with corticosteroids on the base of sulfanilamide
62468226|NCT02646865|EXPERIMENTAL|Self-Compassion Enhanced Cognitive-Behavioral Therapy|Group Cognitive-Behavioral Therapy for social anxiety enhanced with exercises targeting self-compassion
62468227|NCT02646865|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy|Standard Group Cognitive-Behavioral Therapy for social anxiety
62468228|NCT01542190|ACTIVE_COMPARATOR|ketorolac tromethamine|
62468229|NCT01542190|PLACEBO_COMPARATOR|Dextrano 70 / Hypromellose|
62664713|NCT00589368||1|stroke group
62664714|NCT00589368||2|control group
62664715|NCT00790036|EXPERIMENTAL|Everolimus|Participants who received Everolimus 10 mg (two 5 mg tablets), daily for 12 months
62664716|NCT00790036|PLACEBO_COMPARATOR|Placebo|Participants who received Everolimus placebo 10 mg (two 5 mg tablets), daily for 12 months
62664717|NCT01272895|EXPERIMENTAL|GENOUS stent|
62664718|NCT03847077|EXPERIMENTAL|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application
62664719|NCT03847077|ACTIVE_COMPARATOR|Standard counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
61912165|NCT03011892|EXPERIMENTAL|OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
61912166|NCT03011892|EXPERIMENTAL|OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
61912167|NCT03253471|EXPERIMENTAL|AL-611|
62103332|NCT03618095|EXPERIMENTAL|Main Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
62468230|NCT00911781||Infants with infantile hemangiomas|
62468231|NCT00704691|EXPERIMENTAL|Lenalidomide|
62468232|NCT04086030|SHAM_COMPARATOR|Sham Postoperative Rehabilitation|Patients in this group will complete the standardized postoperative rehabilitation program with sham BFR, which is pressure of 20 mmHG. Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set. The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
62664720|NCT06241443|EXPERIMENTAL|hybrid simulation|These students participated in a natural birth approach scenario with a hybrid simulation (n=28).
62664721|NCT06241443|ACTIVE_COMPARATOR|video-modeling group|The students in this group participated in a video modeling education (n=28).
61912168|NCT03253471|PLACEBO_COMPARATOR|Placebo to Match AL-611|
61912169|NCT02866851|EXPERIMENTAL|Monitoring by Web application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
62103333|NCT03618095|EXPERIMENTAL|Roll-In Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
62664722|NCT00065546|ACTIVE_COMPARATOR|1|Post-menopausal women randomized to receive estrogen replacement therapy.
62664723|NCT00065546|PLACEBO_COMPARATOR|2|Post-menopausal women randomized to receive a placebo.
62664724|NCT00065546|EXPERIMENTAL|3|Pre-menopausal women with specific genetic variants.
61912170|NCT04695613|ACTIVE_COMPARATOR|aminoacid group|patients received an IV amino acid infusion 150 ml/kg/hr starting just before and during anesthesia
62103334|NCT03618095|EXPERIMENTAL|Bicuspid Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
62296266|NCT02603575|ACTIVE_COMPARATOR|no corticosteroids and no caspofungin|patients treat with sulfanilamide only
62296267|NCT03639740|OTHER|Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor|Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor
62296268|NCT02779205|OTHER|0-1 year old child|Adipose tissue sample in 0-1 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
62296269|NCT02779205|OTHER|>1-10 year old child|Adipose tissue sample in \>1-10 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
62296270|NCT05503953|EXPERIMENTAL|AGSAVI|
62296271|NCT05503953|ACTIVE_COMPARATOR|AGLS|
62664725|NCT00692016|OTHER|Arm 1|
62664726|NCT00692016|OTHER|Arm 2|
62664727|NCT01331902|EXPERIMENTAL|Adenosine Followed by Nicorandil|
62664728|NCT01331902|EXPERIMENTAL|Nicorandil Followed by Adenosine|
62664729|NCT01718691|EXPERIMENTAL|SyB L-0501＋rituximab|
62664730|NCT04208932||MDD|major depressive disorder
62664731|NCT04208932||HC|healthy control
62296272|NCT03133767|EXPERIMENTAL|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
61912171|NCT04695613|ACTIVE_COMPARATOR|magnesium sulfate group|patients received an IV magnesium sulphate bolus and infusion 40 mg/kg starting just before and during anesthesia
61912172|NCT00965198||Clearlink Arm, EUH|Standard catheter access device at Emory University Hospital
62664732|NCT06403722||sFlt-1/PlGF: 110-205|Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF between 110-205.
62664733|NCT06403722||sFlt-1/PlGF: 206-654|Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF between 206-654.
62664734|NCT06403722||sFlt-1/PlGF: 655-999|Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF between 655-999.
62664735|NCT06403722||sFlt-1/PlGF > 1000|Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF above 1000.
62664736|NCT03343028||Psychotherapy|The investigators will assess and acquire data on these Veterans across the course of the project prior to and after receiving Prolonged Exposure (PE) or Cognitive Processing Theory (CPT) treatment at VA Palo Alto (VAPAHCS) and the Albuquerque VA. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva at baseline on these Veterans and again 3 months after treatment to assess prediction and durability of the clinical and brain/behavioral metrics. All study assessments will take place at Stanford University/VAPAHCS. Subjects will be recruited through VAPAHCS and Albuquerque VA. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
62664737|NCT03343028||Healthy Controls|The investigators will assess and acquire data on these Veterans who do not have history of PTSD and have no history of any Axis I psychiatric disorder, are taking psychotropic medication, or use illicit drugs. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva once. All study assessments will take place at Stanford University. Subjects will be recruited through public flying, online ads and VAPAHCS. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
62664738|NCT05521477|EXPERIMENTAL|participant procedure|"each participant will go through 3 phases of identical protocol. In each phases blood and stools will be collected at specific days, as well as cardiometabolic measures, transit time, cognitive tests and food consumption.~Each phase last 2 weeks with a washout period of 1 month in between. In the first phase, no treatment will be provided, in the second phase a low dose of probiotic (once a day for five days) will be given and in the third phase high dose of probiotic (twice a day for five days) will be administered."
62664739|NCT05375799||COVID-19 in use of ELMO|This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, who used the Assisted Breathing Helmet - ELMO.
62664740|NCT00915187|ACTIVE_COMPARATOR|Control|
61912173|NCT00965198||VLINK Arm, EUHM|Novel, silver-coated catheter access device at Emory University Hospital Midtown
61912174|NCT00965198||Clearlink, EUM|Standard catheter access device at at Emory University Hospital Midtown
62664741|NCT00915187|EXPERIMENTAL|CCS/C (Adjuvant Formulation)|
62664742|NCT05052645|NO_INTERVENTION|Standard of Care Group|Subjects will receive standard of care neuropathic pain treatment without acupuncture.
62664743|NCT05052645|EXPERIMENTAL|Acupuncture Treatment Group|Subjects will receive acupuncture treatment in addition to to the standard of care neuropathic pain treatment.
62664744|NCT06095193|EXPERIMENTAL|Experimental: menopause education|Women will be taught the physiology of female reproductive organs, physiology of menopause, vaginal symptoms in menopause, sexual myths in menopause and practices that will support sexuality in menopause, in 50 minutes for 4 weeks.
62664745|NCT06095193|NO_INTERVENTION|control group|No intervention will be made
61912175|NCT00965198||VLINK Arm, EUH|Novel, silver-coated catheter access device at Emory University Hospital
61912176|NCT05610189|EXPERIMENTAL|Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg|"Participants will receive tavapadon 1x15 mg tablet, orally, once daily (QD) from Day 15 to 21.~Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 22 to 28."
62737560|NCT00442533|EXPERIMENTAL|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
62103335|NCT05343884|OTHER|Dynamic myocardial perfusion imaging|Dynamic myocardial perfusion imaging is performed to obtain additional measurements of coronary blood flow, compared to conventional imaging.
62103336|NCT05343884|OTHER|Conventional myocardial perfusion imaging|Conventional myocardial perfusion imaging which is based on standard routine clinical myocardial perfusion imaging.
62737561|NCT01373255|EXPERIMENTAL|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
62737562|NCT01373255|NO_INTERVENTION|No intervention|no intervention prior to cesarean
62737563|NCT06659497|EXPERIMENTAL|intervention|Patients in this group participate in a web-based training application. Patients are asked pre-test questions before the training and pre-test questions after the training.
61912177|NCT05610189|EXPERIMENTAL|Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg|"Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 15 to 21.~Participants will receive tavapadon 1x15 mg tablet, orally, QD from Day 22 to 28."
61912178|NCT03657303||Healthy volunteers|
62737564|NCT06659497|NO_INTERVENTION|Control|No intervention is made for patients in this group. Patients are asked pre-test questions before treatment and pre-test questions after treatment.
61912179|NCT03657303||Osteoarthritis patients|
61912180|NCT02339220|EXPERIMENTAL|Standard CI Therapy Group|This group will receive Constraint-Induced Movement Therapy (CIMT) with the Standard Transfer Package (sTP).
61912181|NCT02339220|EXPERIMENTAL|Enhanced CI Therapy Group|This group will receive CIMT with the enhanced Transfer Package (eTP).
61912182|NCT02339220|ACTIVE_COMPARATOR|Standard Fitness Training Group|This group will receive Lakeshore Enriched Fitness Training (LEFT) with the standard Transfer Package (sTP).
61912183|NCT02339220|ACTIVE_COMPARATOR|Enhanced Fitness Training Group|This group will receive LEFT with the enhanced Transfer Package (eTP)
62664746|NCT06552195|EXPERIMENTAL|Shoulder anatomy with augmented reality (AR) , hips anatomy with traditional learning (TL)|Participants first learn the shoulder anatomy with AR. After a washout period of three weeks, they will learn the hips anatomy with traditional Learning (TL) methods
61912184|NCT06284629|EXPERIMENTAL|Intervention|The intervention consists of a wrist-worn wearable sensor that tracks motor symptoms and an app for patient-reported outcomes.
62103337|NCT04315454|PLACEBO_COMPARATOR|Group A|patients will receive 20 ml of normal saline into interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
62103338|NCT04315454|EXPERIMENTAL|Group B|Patients will receive 20 mg 0.25% Levobupivacaine into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
62664747|NCT06552195|ACTIVE_COMPARATOR|Traditional learning (TL) group.|Participants first learn the shoulder anatomy with Traditional learning methods. After a washout period of three weeks, they will learn the hips anatomy with augmented reality (AR)
62664748|NCT05701735|NO_INTERVENTION|Routine care|Routine in-house workflow for initial and follow-up consultation, disclosure of diagnosis, and apprisal and counseling regarding treatment options
62664749|NCT05701735|EXPERIMENTAL|Patient decision aid|Routine in-house workflow for initial and follow-up consultation, disclosure of diagnosis, and apprisal and counseling regarding treatment options plus provision of a decision aid after the initial consultation
62664750|NCT05463770|EXPERIMENTAL|SEP-363856|
61912185|NCT06284629|ACTIVE_COMPARATOR|Standard of Care|The control group will wear the wrist-worn wearable sensor, but not be able to view the tracked data. They will report symptoms in the app, but the patient-reported outcomes won't be included in the clinical visits during the trial
61912186|NCT00401388|EXPERIMENTAL|Group A: chondrosarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
61912187|NCT00401388|EXPERIMENTAL|Group B: alveolar soft part sarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of alveolar soft part sarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
62103339|NCT06398223||Carotid endarterectomy (CEA) (Group 1)|Subjects with unilateral carotid artery stenosis and planned CEA
62103340|NCT06398223||Carotid artery stenting (Group 2)|Subjects with unilateral carotid artery stenosis and planned carotid artery stenting
62103341|NCT06398223||Healthy Control Group (Group 3)|Healthy age- and sex-matched control subjects
62103342|NCT05974943|EXPERIMENTAL|the pre-post training and 3rd-month evaluations of problem-solving skills of the nurse managers in|The research was conducted with randomized control, pretest-posttest, experimental, and control group design. By using G\*Power analysis, it was determined that the experimental group of the nurse managers was 30 people and included randomly in the sample calculation of the study. The experimental group was given 2 days of problem-solving and decision-making training. Before the training, the nurse administrators in the experimental group were administered the Participant Information Form-Nurse Manager, PSI, DMSS and two Case Evaluation Forms and Problem Solving and Decision Making Information Form-Pre-Test-Post-Test.
62296273|NCT03133767|EXPERIMENTAL|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
62296274|NCT01594112||Patient with at least one ID|Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.
62296275|NCT05397314|EXPERIMENTAL|Punalpin|
62296276|NCT05397314|PLACEBO_COMPARATOR|Placebo|
62664751|NCT04096859||PremiCron®|Assessment of PremiCron suture for cardiac valve reconstruction and replacement
61912188|NCT00401388|EXPERIMENTAL|Group C: extra-skeletal myxoid|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of extra-skeletal myxoid chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
62296277|NCT06468358|EXPERIMENTAL|Phase Ib, Dose Escalation of LB1410 in combination with LB4330|Up to 4 dose cohorts will be enrolled in the dose-escalation part with the standard 3+3 dose escalation algorithm approach.
62664752|NCT01540734|ACTIVE_COMPARATOR|Marketed paracetamol|marketed formulation
62664753|NCT01540734|EXPERIMENTAL|Experimental paracetamol formulation|Experimental formulation
62664754|NCT04871438|EXPERIMENTAL|FGM|Flash glucose monitoring at weeks 0-2, weeks 6-8 post-discharge
62664755|NCT04871438|NO_INTERVENTION|SMBG|Self-monitoring of blood glucose at least 4 times a day, 3 days a week
61912189|NCT04869748|EXPERIMENTAL|experimental group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Perfetti method on affected elbow flexor.Immediate after session, last outcome assessment was collected.
61912190|NCT04869748|ACTIVE_COMPARATOR|control group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Passive stretching on affected elbow flexor.Immediate after session, last outcome assessment was collected.
61912191|NCT06246942|EXPERIMENTAL|Healthy Participants|"All participants will be scheduled for a minimum of four separate visits. The first visit will consist of MRI scanning sessions (including T1 and T2 structural MRI, diffusion MRI, and resting-state fMRI), followed by a single-pulse TMS session to determine the participant's resting motor threshold. The remaining three visits consist of a series of TMS-EEG runs using the paired associative stimulation (PAS) methodology. Each visit will be restricted to a single asynchrony condition with every participant receiving all three conditions over the course of the three visits. Participants will not be informed of which asynchrony condition they are receiving on any given visit.~Some subjects may be invited for additional sessions for the purposes of optimizing TMS, EEG, or MRI parameters, and to assess test-retest reliability."
61912192|NCT05408793|EXPERIMENTAL|Transcranial Pulse Stimulation (TPS group)|Subjects in the TPS group will be given 6 verum TPS sessions (Pulse: 800 / session) across two weeks time, with 3 sessions per week.
61912193|NCT05408793|SHAM_COMPARATOR|Sham TPS Group|Subjects in the Sham TPS group will be given 6 sham TPS sessions across two weeks time, with 3 sessions per week.
62664756|NCT02455414||Wolfram Syndrome Group|"* Participant has confirmation of a WFS1 mutation OR~* Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old"
62664757|NCT02455414||WFS Pre-symptomatic Sibling Group|"* Has had genotyping~* Willingness to share result of genotyping~* Participant has confirmation of WFS1 (+/+) mutation but is asymptomatic."
62664758|NCT02455414||WFS Control Sibling Group|"* Has had genotyping~* Willingness to share result of genotyping~* Patient has confirmation of NO WFS1 mutation (-/-) or confirmation as a carrier (+/- or -/+)."
62664759|NCT02455414||T1DM Group|"* Age within the 0-28 yrs age range of WS participant~* Dx of T1 diabetes mellitus"
62664760|NCT02455414||Healthy Control (HC) Group|• Age within the 0-28 yrs age range of WFS participants
62664761|NCT02455414||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
62664762|NCT01957800|EXPERIMENTAL|Website|Group will be asked to complete a daily plan online for specific situations that tempt people to overeat. The website can be accessed online using a computer or smart phone and will allow participants to view others' plans. Participants will also be asked to enter their weight online every week.
62664763|NCT01957800|ACTIVE_COMPARATOR|Usual Care|Group will be given access to the online intervention after the 3-month study ends.
62664764|NCT01056575|EXPERIMENTAL|OC000459|
62664765|NCT02004795|EXPERIMENTAL|BNCT+ IG-IMRT|single arm
62664766|NCT00142753|ACTIVE_COMPARATOR|A1: ATN 024 Energix-B Standard Adult Dose|
62664767|NCT00142753|EXPERIMENTAL|A2: ATN 024 Engerix-B Increased Adult Dose|
62664768|NCT00142753|ACTIVE_COMPARATOR|A3: ATN 024 Twinrix Standard Adult Dose|
62664769|NCT00142753|EXPERIMENTAL|B1: ATN 025 Recombivax|
62664770|NCT00142753|EXPERIMENTAL|B2: ATN 025 Twinrix|
62664771|NCT00879359|EXPERIMENTAL|I|
62664772|NCT04807530|ACTIVE_COMPARATOR|Medial/Superior Prefrontal TMS|10 Hz High frequency TMS applied to the mPFC
62664773|NCT04807530|PLACEBO_COMPARATOR|Posterior Parietal TMS|10 Hz high frequency TMS applied to the posterior parietal cortex
61912194|NCT03348592|EXPERIMENTAL|Oligofructose-enriched inulin (p-inulin)|Participants are on no treatment for 8 weeks, then the pre-biotic p-inulin for 12 weeks, then no treatment for 8 weeks. Inulin is derived from chicory root fiber. The dose is 16 grams of p-inulin powder per day.
62664774|NCT03010865|EXPERIMENTAL|Sodium Butyrate|Dietary Supplement: Sodium Butyrate 4.38 gms of sodium butyrate per day for 12 weeks
62664775|NCT03010865|PLACEBO_COMPARATOR|Placebo Oral Capsule|Placebo Oral Capsule placebo capsules containing approximately 9 mg of sodium butyrate per day
62664776|NCT02346422|EXPERIMENTAL|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 \[AAV1\]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10\^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
62664777|NCT02346422|PLACEBO_COMPARATOR|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
62664778|NCT05350423|EXPERIMENTAL|Thulium Fibre Laser (TFL)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Thulium fibre laser (TFL)
62664779|NCT05350423|EXPERIMENTAL|Holmium:Yttrium-Aluminum-Garnet (Ho:YAG)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Holmium:Yttrium-Aluminum-Garnet (Ho:YAG) laser
62664780|NCT05057208||Vaccinated|COVID Vaccinated
62664781|NCT05057208||Non-vaccinated|COVID Non-vaccinated
62664782|NCT06190119||POAG Group|POAG patients who underwent filtering surgery, cataract surgery or MIGS.
62664783|NCT06190119||Control Group|Healthy patients who underwent cataract surgery.
62664784|NCT04303637||High school student|13-18 year old students enrolled in schools within Singapore.
61912195|NCT06082401|EXPERIMENTAL|Treatment Group|EVLP + HDF
62664785|NCT03421561|EXPERIMENTAL|DCB Subjects|"The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.~Basic Catheter Specifications~* Guidewire: 0.035~* Balloon Length: 40/80/120 mm~* Sheath Compatibility: greater than or equal to 6 French~* Balloon Diameter: 4/5/6 mm~* Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
62664786|NCT03421561|PLACEBO_COMPARATOR|PTA Subjects|"The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).~Basic Catheter Specifications~* Guidewire: 0.035~* Balloon Length: 40/80/120 mm~* Sheath Compatibility: greater to or equal to 6 French~* Balloon Diameter: 4/5/6 mm~* Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use."
62664787|NCT03014362|ACTIVE_COMPARATOR|TMS active|"Neuronetics NeuroStar XPLOR magnetic stimulator - Active;~Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care)."
62664788|NCT03014362|SHAM_COMPARATOR|TMS sham|"Neuronetics NeuroStar XPLOR magnetic stimulator - Sham;~Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
62664789|NCT02600793|EXPERIMENTAL|Arm 1|Single dose IV ceftaroline will be administered
62664790|NCT02127541|EXPERIMENTAL|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|This is a cross-over study comparing three imaging methods (68Ga-DOTA-exendin-4 PET/CT, 111In-DOTA-exendin-4 SPECT/CT, MRI) in the same patient.
62664791|NCT04398966|EXPERIMENTAL|PAE Procedure|This will be a single arm, uncontrolled, non-blinded study of PAE using HydroPearl Beads in a small population of 30 subjects with benign prostate hyperplasia (BPH)
62664792|NCT02736214|EXPERIMENTAL|Lifestyle counseling|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
62664793|NCT02736214|NO_INTERVENTION|Control group|The control group answered a baseline questionnaire in the waiting room and received standard care.
62664794|NCT04601285|EXPERIMENTAL|Dose Escalation|
62664795|NCT04589767||children admitted in PICU|children enrolled will be evaluated by two nurses using CAPD Italian version. One nurse will repeat the evaluation two minutes later.
62664796|NCT00382070|EXPERIMENTAL|Group 2 Letrozole|Patients receive oral letrozole once daily for up to 5 years.
62664797|NCT00382070|PLACEBO_COMPARATOR|Group 1 Placebo|Patients receive oral placebo once daily for up to 5 years.
61912196|NCT06082401|ACTIVE_COMPARATOR|Control Group|EVLP
62308249|NCT05347654|EXPERIMENTAL|Strategy incorporating a poly-absorbent dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
62664798|NCT04149353|EXPERIMENTAL|PET/MR|Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.
62664799|NCT02707744||sinus rhythm|patients with heart failure and sinus rhythm
62664800|NCT02707744||atrial fibrillation|patients with heart failure and atrial fibrillation
61912197|NCT02648633|EXPERIMENTAL|Nivolumab & Valproate Following G.K.|Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
61912198|NCT01850927|ACTIVE_COMPARATOR|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
62308250|NCT02143271|EXPERIMENTAL|KHK7580|
61912199|NCT01850927|SHAM_COMPARATOR|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
61912200|NCT02663726|EXPERIMENTAL|Yoga intervention group|10 weekly 75-min sessions of specialised yoga plus written advice about physical activity for older adults
61912201|NCT02663726|ACTIVE_COMPARATOR|Waiting list control group|Usual care plus written advice about physical activity for older adults
61912202|NCT00345644|EXPERIMENTAL|1|
61912203|NCT00345644|PLACEBO_COMPARATOR|2|
62296278|NCT06468358|EXPERIMENTAL|Phase II, Expansion Cohorts of LB1410 in combination with LB4330|"This part includes IIa and IIb. Phase IIa will be enrolled subjects at the dose level with initial anti-tumor activity observed in Phase Ib, the numbers of patients enrolled in the phase IIa could be adjusted based on previously available safety and preliminary efficacy data; the dose level of the phase IIb is the RP2D dose level determined in the phase Ib. The planned expanded cohorts are as follows:~Cohort A: pancreatic ductal adenocarcinoma;~Cohort B: cholangiocarcinoma;~Cohort C: colorectal cancer;~Cohort D: recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer;~Cohort E: other solid tumors (non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, cervical squamous cell carcinoma, and endometrial carcinoma)."
62296279|NCT02747784|EXPERIMENTAL|Study group experimental|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Divided Attention 2 (GEA2)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
62468233|NCT04086030|EXPERIMENTAL|BFR Postoperative Rehabilitation|Assigned intervention of BFR where exercises are performed with BFR at 80% limb occlusion pressure (LOP). Patients in this group will undergo blood flow restriction (BFR) training during their postoperative rehabilitation program (use an inflatable cuff that prevents blood flow from flowing out of the leg while patients perform physical therapy exercises). Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set.16 The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
62468234|NCT03173391|EXPERIMENTAL|HMS5552|75mg BID
62468235|NCT03173391|PLACEBO_COMPARATOR|Placebo|BID
62468236|NCT00781586|EXPERIMENTAL|Arm 1|
62468237|NCT00781586|ACTIVE_COMPARATOR|Arm 2|
62468238|NCT00781586|PLACEBO_COMPARATOR|Arm 3|
61912204|NCT03878693|EXPERIMENTAL|A|Oral APAP and IV Fomepizole.
61912205|NCT03878693|ACTIVE_COMPARATOR|B|Oral APAP.
61912206|NCT04457388|EXPERIMENTAL|Tele-Yoga Therapy|Individualised Yoga therapy based on participant's clinical condition and personal needs. Twice a week sessions were carried out by trained and experienced Yoga therapist via video conference with each therapy for individualized based on each participant.
61912207|NCT06300593||PCOS phenotype A|clinical and/or biochemical hyperandrogenism (HA) + ovulatory dysfunction (OD) + polycystic ovarian morphology (PCOM)
61912208|NCT06300593||PCOS phenotype B|HA + OD
62468239|NCT01390233|ACTIVE_COMPARATOR|Urinary Balloon Catheter Only|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
62468240|NCT01390233|ACTIVE_COMPARATOR|Prepadil Only|Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
62468241|NCT01390233|EXPERIMENTAL|Combined Urinary Catheter & Prepidil Gel|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. Prepidil gel will be inserted through the catheter into the lower uterine segment, in a dose equivalent to manufacturer's recommendation. No oxytocin or other intervention will commence until 6 hours after insertion of the catheter and administration of prepidil gel (even if catheter is spontaneously expelled). After 6 hours, digital exam will be performed and Bishop score recorded. If no active labor, standardized protocol of oxytocin will commence.
62664801|NCT03888274|EXPERIMENTAL|Active|
62664802|NCT00494312|EXPERIMENTAL|Pioglitazone QD|
62664803|NCT00494312|ACTIVE_COMPARATOR|Glyburide QD|
62737565|NCT04646746|EXPERIMENTAL|100 g of 100% wheat bread|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
61912209|NCT06300593||PCOS phenotype C|HA + PCOM
61912210|NCT06300593||PCOS phenotype D|OD + PCOM
61912211|NCT01162798|ACTIVE_COMPARATOR|Control|commercially available formula
61912212|NCT01162798|EXPERIMENTAL|Test|test formula
62103343|NCT05974943|NO_INTERVENTION|the pre-post training and 3rd-month evaluations of the decision-making skills of the nurse managers|The research was carried out in randomized control, pretest-posttest, experimental and control group design. In the sample calculation of the study, 30 of the manager nurses were determined by using G\*Power analysis as the control group and were included randomly. No intervention was made in the control group. At the same time as the experimental group, the nurse administrators in the control group were also administered the Participant Information Form-Nurse Manager, PSI and DMSS.
62296280|NCT02747784|ACTIVE_COMPARATOR|Study group active comparator|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Working memory (WOME)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
62296281|NCT02747784|NO_INTERVENTION|Control group|48 female control subjects aged 18 years or older (24 without surgery, 24 with urogynecological or breast cancer surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
62103344|NCT05974943|NO_INTERVENTION|pre-training and 3rd-month evaluations of regarding the problem-solving and decision-making skills|Three months after the initial assessment, the nurse managers in the experimental and control groups were administered PCI and CVSQ.
62103345|NCT05165030|EXPERIMENTAL|Blood Sample|Blood Sample
62296282|NCT03617731|ACTIVE_COMPARATOR|IA|Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
62468242|NCT05001022|EXPERIMENTAL|ALG-020572|Subcutaneous injections of ALG-020572 in HV or CHB subjects, up to 7 injections over the course of up to 29 days
62468243|NCT05001022|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 7 injections over the course of up to 29 days
62468244|NCT02285894|EXPERIMENTAL|Inspiratory hold|Mechanical inspiratory pressure held for 10 seconds at a time.
62468245|NCT02517684|EXPERIMENTAL|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
62468246|NCT02517684|ACTIVE_COMPARATOR|Step-up|Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
62468247|NCT01249222|NO_INTERVENTION|conventional treatment|
62468248|NCT01249222|EXPERIMENTAL|Plasmapheresis|
62468249|NCT05701930|EXPERIMENTAL|Experimental:|pecha kucha will be practiced
62468250|NCT05701930|NO_INTERVENTION|control|Routine maintenance will be applied.
61912213|NCT03448874|EXPERIMENTAL|Seal-G MIST System|Seal-G MIST System is a surgical sealant that will be applied adjunctively to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
61912214|NCT03448874|NO_INTERVENTION|Standard of care|Patients in the control arm will receive the standard of care \[SOC\] for colorectal resection surgery with primary anastomosis (no additional intervention)
62468251|NCT03645785|ACTIVE_COMPARATOR|Normal Diet/Drinking|Baseline diet and drinking patterns for patients. This is the pre-intervention baseline for cross-over analysis
62468252|NCT03645785|EXPERIMENTAL|Increased fluid Intake and Citrate Supplementation|Patients will increase fluid (with goal to double their baseline) and further take a citrate supplement in the form of True Lemon (citric acid).
61912215|NCT05367375||removing patellofemoral joint osteophytes|remove osteophyte at patella, medial femoral condyle and lateral femoral condyle
62103346|NCT01394666||CP-CML patients who have failed Imatinib 400 mg daily|
62103347|NCT04164628|EXPERIMENTAL|Experimental Group: quality of life assessment|Women's quality of life will be evaluated.
62103348|NCT06708429||Lynch syndrome (MLH1), without colorectal cancer and without advanced adenomas|A cohort of individuals with a germline pathogenic variant in the MLH1 gene, that confers a diagnosis of Lynch syndrome, who are found to be cancer-free and adenoma-free at the time of colonoscopy evaluation
61912216|NCT05367375||non-removing patellofemoral joint osteophytes|no remove osteophyte at patella, medial femoral condyle and lateral femoral condyle
61912217|NCT04322370|ACTIVE_COMPARATOR|Group A|VersaWrap Treatment Arm- Zone 2 flexor tendon repair with the use of VersaWrap
62664804|NCT06173648|EXPERIMENTAL|All Study Participants.|Single study group that requires extraction of mandibular incisors for other reasons. Teeth are accessed, subject to filing, pulp extirpation, and treated with endodontic solutions. Some teeth of the participants are then subject to study intervention consisting of an ICG solution into the root followed by laser exposure of the solution in situ. After laser exposure, the pulp chamber and roots are rinsed then mechanically extracted. Other teeth of some participants will not be subject to the ICG and laser intervention, but will proceed to the final rinse and extraction. After extraction, specimens are fixed, stained, and mounted for visual examination under a microscope. Images of tissue are captured for documentation. Samples are examined for histological and morphological condition of the periodontal ligament, cementum, and collagen attached to the external surface of the extracted tooth root.
62664805|NCT03255954|EXPERIMENTAL|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
62664806|NCT04200924||Children with idiopathic toe walking|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
62664807|NCT04200924||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
62664808|NCT06480955||Full cohort|Cryoablation with curative-intent of bone metastases from oligometastatic or bone oligo-progressive disease.
62664809|NCT05432453||Women with constipation|"Bowel functional markers (defecation frequency, defecation time, and stool density) and constipation-related quality of life of women with constipation will be evaluated with the Constipation Severity Scale, Constipation Quality of Life Scale, 7-day bowel diary, and Bristol Stool Scale.~Sacroiliac joint dysfunctions of women with constipation will be evaluated by standing forward bending test, sitting forward bending test, compression test, posterior friction test and Patrick-Faber test."
62664810|NCT05432453||Women without constipation (Control)|"Bowel functional markers (defecation frequency, defecation time, and stool density) and constipation-related quality of life of women without constipation will be evaluated with the Constipation Severity Scale, Constipation Quality of Life Scale, 7-day bowel diary, and Bristol Stool Scale.~Sacroiliac joint dysfunctions of women without constipation will be evaluated by standing forward bending test, sitting forward bending test, compression test, posterior friction test and Patrick-Faber test."
62664811|NCT00377481|EXPERIMENTAL|1|
61912218|NCT04322370|ACTIVE_COMPARATOR|Group B|Standard of Care Treatment Arm- Zone 2 flexor tendon repair
62664812|NCT00377481|ACTIVE_COMPARATOR|2|
61912219|NCT04313647|EXPERIMENTAL|1X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
62296283|NCT03617731|EXPERIMENTAL|IB|Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
62296284|NCT03617731|ACTIVE_COMPARATOR|IIA|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
62308251|NCT06292312|EXPERIMENTAL|Treatment group|Patients in this grop are the group to which craniosacral therapy and convensional physiotherapy will be applied.
62468253|NCT06323876||University of Chicago|This cohort will have prior consent to the Natural History of Interstitial Lung Disease, which is an ongoing, longitudinal cohort of patients with clinically diagnosed ILD, including IPF. Patients are recruited from University of Chicago Interstitial Lung Disease Program during their clinic visit. Blood, plasma, and serum samples are collected upon enrollment and stored in a biorepository at University of Chicago. Subsets of patients have repeat blood draw at return clinic visits for specific research studies. The investigators propose collection of 1-year HRCTs, FVC, and DLCO.
61912220|NCT04313647|EXPERIMENTAL|2X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
61912221|NCT04313647|EXPERIMENTAL|4X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
62103349|NCT06708429||Lynch syndrome (MLH1), with colorectal cancer or advanced adenomas|A cohort of individuals with a germline pathogenic variant in the MLH1 gene, that confers a diagnosis of Lynch syndrome, who are found to have colorectal cancer or an adenoma at the time of colonoscopy evaluation
62103350|NCT06708429||Lynch syndrome (MSH2), without colorectal cancer and without advanced adenomas|A cohort of individuals with a germline pathogenic variant in the MSH2 gene, that confers a diagnosis of Lynch syndrome, who are found to be cancer-free and adenoma-free at the time of colonoscopy evaluation
62103351|NCT06708429||Lynch syndrome (MSH2), with colorectal cancer or advanced adenomas|A cohort of individuals with a germline pathogenic variant in the MSH2 gene, that confers a diagnosis of Lynch syndrome, who are found to have colorectal cancer or an adenoma at the time of colonoscopy evaluation
62103352|NCT06708429||Lynch syndrome (MSH6, without colorectal cancer and without advanced adenomas|A cohort of individuals with a germline pathogenic variant in the MSH6 gene, that confers a diagnosis of Lynch syndrome, who are found to be cancer-free and adenoma-free at the time of colonoscopy evaluation
62103353|NCT06708429||Lynch syndrome (MSH6), with colorectal cancer or advanced adenomas|A cohort of individuals with a germline pathogenic variant in the MSH6 gene, that confers a diagnosis of Lynch syndrome, who are found to have colorectal cancer or an adenoma at the time of colonoscopy evaluation
62103354|NCT06708429||Lynch syndrome (PMS2), without colorectal cancer and without advanced adenomas|A cohort of individuals with a germline pathogenic variant in the PMS2 gene, that confers a diagnosis of Lynch syndrome, who are found to be cancer-free and adenoma-free at the time of colonoscopy evaluation
62103355|NCT06708429||Lynch syndrome (PMS2), with colorectal cancer or advanced adenomas|A cohort of individuals with a germline pathogenic variant in the PMS2 gene, that confers a diagnosis of Lynch syndrome, who are found to have colorectal cancer or an adenoma at the time of colonoscopy evaluation
62103356|NCT06708429||Lynch syndrome (MSH2, exon 8 deletion), without colorectal cancer and without advanced adenomas|A cohort of individuals with a germline pathogenic exon 8 deletion in the MSH2 gene, that confers a diagnosis of Lynch syndrome, who are found to be cancer-free and adenoma-free at the time of colonoscopy evaluation
62103357|NCT06708429||Lynch syndrome (MSH2, exon 8 deletion), with colorectal cancer or advanced adenomas|A cohort of individuals with a germline pathogenic exon 8 deletion in the MSH2 gene, that confers a diagnosis of Lynch syndrome, who are found to have colorectal cancer or an adenoma at the time of colonoscopy evaluation
62103358|NCT06708429||Non-Lynch syndrome, with colorectal cancer|A cohort of individuals without a germline pathogenic variant in any of the mismatch repair genes (MLH1, MSH2, MSH6, PMS2), who are found to have colorectal cancer at the time of colonoscopy evaluation
62103359|NCT06708429||Non-Lynch syndrome, with high-risk adenomas|A cohort of individuals without a germline pathogenic variant in any of the mismatch repair genes (MLH1, MSH2, MSH6, PMS2), who are found to have high-risk adenomas at the time of colonoscopy evaluation
62103360|NCT06708429||Non-Lynch syndrome, with low-risk adenomas|A cohort of individuals without a germline pathogenic variant in any of the mismatch repair genes (MLH1, MSH2, MSH6, PMS2), who are found to have low-risk adenomas at the time of colonoscopy evaluation
62103361|NCT06708429||Non-Lynch syndrome, without colorectal cancer and without colorectal adenomas|A cohort of individuals without a germline pathogenic variant in any of the mismatch repair genes (MLH1, MSH2, MSH6, PMS2), who are found to be cancer-free and adenoma-free at the time of colonoscopy evaluation
62103362|NCT00841282|ACTIVE_COMPARATOR|1|Water Infusion in lieu of Air Insufflation Colonoscopy
62103363|NCT00841282|PLACEBO_COMPARATOR|2|Air Insufflation Colonoscopy
62103364|NCT03451643|EXPERIMENTAL|Endoscopic Expandable Stent|Procedure/Surgery. Endeosocpically a self-expandable metal stent will be placed in the colon rectum. Chemotherapy will be added
62468254|NCT06323876||University of Virginia|This cohort will have prior consent to the Natural History of Interstitial Lung Disease, which is an ongoing, longitudinal cohort of patients with clinically diagnosed ILD, including IPF. Patients are recruited from the UVA Interstitial Lung Disease Program during their clinic visit. Blood, plasma, and serum samples are collected upon enrollment and stored in a biorepository at UVA (Pinn Hall RM#2232B, IRB#20937). Subsets of patients have repeat blood draw at return clinic visits for specific research studies. The investigators propose collection of 1-year HRCTs, FVC, and DLCO.
62468255|NCT00857935|EXPERIMENTAL|1|NatrOVA Creme Rinse - 1%
62468256|NCT00857935|ACTIVE_COMPARATOR|2|NIX Creme Rinse
62664813|NCT00174668|EXPERIMENTAL|1|Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously
62664814|NCT00174668|ACTIVE_COMPARATOR|2|Two daily injection conventional insulin therapy
62664815|NCT06267404|EXPERIMENTAL|Iliopsoas positional release|Group A (Iliopsoas positional release group) Positional release therapy will be administered on both Iliopsoas muscles, three sets on each side with 30 seconds hold on tender point. A rest of 15 seconds will be given between all sets.
62664816|NCT06267404|ACTIVE_COMPARATOR|Conventional therapy|Group B (Conventional therapy) Conventional Physical therapy i.e. Ultrasonic therapy 3 min 1 MHz, TENS 10 min, hot pack for 10 min and back strengthening exercises.
62664817|NCT01276652|ACTIVE_COMPARATOR|Environmental modification|Subjects assigned to this group receive the environmental modification intervention for 48 hours beginning the morning after enrollment.
62664818|NCT01276652|NO_INTERVENTION|Usual care (randomized)|"Usual care is provided for the first 48 hours. Subsequently, in the initial protocol, subjects received 48 hours of the environmental modification intervention so long as they remained in the ICU during this time. The opportunity to receive the Delayed intervention was later removed from the protocol."
62664819|NCT01276652|NO_INTERVENTION|Usual care (observational)|Usual care was provided.
62664820|NCT05546528|EXPERIMENTAL|photobiomodulation|photobiomodulation application with the Laser Therapy XT device
61912222|NCT04313647|EXPERIMENTAL|6X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
62103365|NCT03451643|ACTIVE_COMPARATOR|Colorectal Resection|Procedure/Surgery. A standard open or laparoscopic surgery will be performed to remove the colorectal cancer. Chemotherapy will be added
62103366|NCT02714829|EXPERIMENTAL|Inject BMP|ExcelOS-inject containing rhBMP-2
61912223|NCT04313647|EXPERIMENTAL|8X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
62468257|NCT01305226|EXPERIMENTAL|Test - THR-100|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
62296285|NCT03617731|EXPERIMENTAL|IIB|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
62103367|NCT02714829|ACTIVE_COMPARATOR|ExcelOS-inject|ExcelOS-inject without rhBMP-2
62103368|NCT02755584||Healthy Volunteers|between the ages of 20-39 years and 70 years old and older
62103369|NCT05152524|EXPERIMENTAL|Treatment|Mechanical thrombectomy with Tigertriever 13 EVT + MM (without thrombolysis).
62103370|NCT05152524|NO_INTERVENTION|Control|Medical Management alone (without thrombolysis).
62103371|NCT01928511|ACTIVE_COMPARATOR|Continued oral nucleos(t)ide therapy|Patients assigned to this arm will continue their nucleos(t) analogue
62103372|NCT01928511|EXPERIMENTAL|Add on peg-interferon|Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
62468258|NCT01305226|ACTIVE_COMPARATOR|Streptokinase|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
62468259|NCT03537872|EXPERIMENTAL|Miner-Friendly (MF) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.~Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies."
61912224|NCT05973149|EXPERIMENTAL|QLH12016 dose escalation|Daily dosages are predetermined by Safety Monitoring Committee after the initial starting dose cohort at the end of Cycle 1 (each cycle is 28 days)
61912225|NCT05973149|EXPERIMENTAL|QLH12016 in mCRPC with specific biomarkers|Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A
62296286|NCT02134600|EXPERIMENTAL|Omega-3 enriched fruit juice|Single arm study: Omega-3 enriched fruit juice in increasing dosage
61912226|NCT05973149|EXPERIMENTAL|QLH12016 in mCRPC without specific biomarkers|Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A
61912227|NCT05973149|EXPERIMENTAL|QLH12016 in less pretreated mCRPC|Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A
61912228|NCT02398149||PwMS receiving care at the Mandell Center|
61912229|NCT04097782|NO_INTERVENTION|Control Group|"Prior to the study, primiparous pregnant women presented to the outpatient clinic for routine pregnancy control were introduced with free prenatal education classes and they were invited to participate in the study.~Primiparous women who volunteered to participate in the study and met the inclusion criteria were included in the study and they formed the experimental and control group. Control group did not receive antenatal education and they received prenatal care service routinely provided at the polyclinics of the same hospital."
61912230|NCT04097782|EXPERIMENTAL|Experimental Group|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
61912231|NCT04514354|EXPERIMENTAL|GEST Visit|As described in the detailed study description, the GEST Visit included measures of cardiovascular health at Hartford Hospital. These measures included BMI, waist circumference, exhaled carbon monoxide (CO), vascular health (i.e., carotid intimal medial thickness and arterial stiffness), HRV, resting BP, the GEST, and blood draws pre- and post-GEST to obtain SCD and CVD biomarkers.
61912232|NCT04514354|NO_INTERVENTION|CONTROL Visit|On either Visit 3 or 4, subjects performed the CONTROL Visit. Resting auscultatory blood pressure was measured according to AHA standards. At the conclusion of CONTROL, subjects were fitted for the ABP monitor. Subjects were instructed to proceed with normal activities, not to exercise, and to keep their arm still and extended at their side when each ABP measurement was being taken. Subjects carried a standard journal, recording activities performed during each measurement, any unusual physical or emotional events, and sleep and wake times. The following morning, subjects detached the monitor and returned it that day to the study investigators.
62103373|NCT01928511|EXPERIMENTAL|switch to peg-interferon|Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly
62103374|NCT03955419|NO_INTERVENTION|Control group|Participants in the control group will be fasted from midnight until surgery.
62103375|NCT03955419|EXPERIMENTAL|Study group|Participants will receive 800 mL of carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg). They will drink this beverage freely, starting from the evening before surgery until 2 hours before surgery.
62296287|NCT01696812|EXPERIMENTAL|electrode position, STN DBS, Parkinson' disease|To determine the electrode positions with the relationship of the STN from the fused images of the preoperative MRI and the postoperative CT via web-site.
62296288|NCT04917874|EXPERIMENTAL|B-VEC|Open label B-VEC topical treatment of DEB wounds.
62468260|NCT03537872|ACTIVE_COMPARATOR|Public Sector (PS) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.~Public Sector (PS) Health Facilities TB/HIV Integration Strategies"
62468261|NCT06455982|EXPERIMENTAL|Delta of before/after the intervention|2 months of reduced carbohydrate menu combined with a ketogenic MCT supplement
62468262|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
62468263|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
62468264|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
62664821|NCT05546528|SHAM_COMPARATOR|photbiomodulation-sham|photobiomodulation application with the Laser Therapy XT device off
62664822|NCT02673385||Brazelton scale|Procurement across Brazelton scale
62664823|NCT02673385||No test|usual care
62103376|NCT05966051||Children attending primary school|In this study will be included children 6-11 years and their families, whose parents will provide written consent to participate,
62296289|NCT06656845|EXPERIMENTAL|To determine the feasibility of a patient self-management app in patients with knee osteoarthritis|The intended purpose of the app (Genus) is to provide information on osteoarthritis and recommended treatment for people with knee OA.
62296290|NCT02149641||Nasopharyngeal cancers|Intensitiy modulated radiotherapy with chemotherapy
61912233|NCT01227629|EXPERIMENTAL|dabigatran 50 mg twice daily (bid)|Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).
62296291|NCT00345605|EXPERIMENTAL|HDA|"High Dose Arm~Wash-out then 7 days of:~Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA"
62296292|NCT00345605|EXPERIMENTAL|LDA|"Low Dose Arm~Wash-out followed by 7 days of:~Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA"
62296293|NCT05596214|EXPERIMENTAL|Curcumin-Berberine (coptis) therapy|Cur-Berberine (Coptis) treatment will consist: 2 capsules of 500 mg Berberine (Coptis) before breakfast (a total of 1.0gr Berberine) and 3 capsules of 500mg curcumin before dinner (a total of 1.5gr curcumin).
62296294|NCT05596214|PLACEBO_COMPARATOR|Placebo|2 capsules of 500 mg placebo before breakfast and 3 capsules of 500mg placebo before dinner.
62296295|NCT06638112|ACTIVE_COMPARATOR|General anesthesia|The patient undergoes shoulder arthroscopy under general anesthesia after receiving a preoperative brachial plexus block for intra- and postoperative analgesia.
61912234|NCT01227629|EXPERIMENTAL|dabigatran 50 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.
62296296|NCT06638112|EXPERIMENTAL|Brachial plexus block|The patient undergoes shoulder arthroscopy under brachial plexus block and intraoperative sedation with remimazolam.
62296297|NCT06016816|ACTIVE_COMPARATOR|Endoscopic bilateral sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
62468265|NCT05564897|EXPERIMENTAL|Combination of H101 with Camrelizumab treatment|Patients receive a combination therapy of PD-1 inhibitor Camrelizumab with oncolytic adenovirus H101 for up to 1 years. Camrelizumab are administered at dose of 200 mg i.v. every 3 weeks. H101 are instilled intravesically with a dose of 5×10\*11 Vp in a 50 mL normal saline solution via a catheter, and dwell time is 1 to 2 hours,. Intravesical H101 is instilled weekly for 6 weeks for both induction and maintenance treatments.
61912235|NCT01227629|EXPERIMENTAL|dabigatran 50 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
61912236|NCT01227629|EXPERIMENTAL|dabigatran 150 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
61912237|NCT01227629|EXPERIMENTAL|dabigatran 150 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
61912238|NCT01227629|EXPERIMENTAL|dabigatran 150 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
61912239|NCT01227629|EXPERIMENTAL|dabigatran 300 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
61912240|NCT01227629|EXPERIMENTAL|dabigatran 300 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
61912241|NCT01227629|EXPERIMENTAL|dabigatran 300 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
61912242|NCT01227629|ACTIVE_COMPARATOR|warfarin|once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0
61912243|NCT01445548|EXPERIMENTAL|Sirolimus|"Participants initially received a 20 μL (440 μg) intravitreal injection sirolimus in the study eye at baseline and every two months thereafter unless contraindicated.~As of September 2012, sirolimus intravitreal injections were no longer administered to participants."
61912244|NCT03613272|EXPERIMENTAL|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
61912245|NCT03613272|EXPERIMENTAL|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
62103377|NCT04886596|EXPERIMENTAL|RSVPreF3 Group|Participants in this group received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants were re-randomized into 2 groups: participants in one receiving an additional dose of RSVPreF3 OA vaccine before Season 2; participants in the other receiving a dose of placebo before Season 2.
62103378|NCT04886596|PLACEBO_COMPARATOR|Placebo Group|Participants in this group received 1 dose of placebo at Day 1 and received an additional dose of placebo before Season 2.
62468266|NCT01278732||untreated persons with suspected hypertension|
62468267|NCT02738723|EXPERIMENTAL|GROUP 1|SBRT plus EP
62468268|NCT02738723|ACTIVE_COMPARATOR|GROUP 2|IMRT plus EP
62468269|NCT03552393|EXPERIMENTAL|Mircera|Mircera will be administered subcutaneously once every 4 weeks
62103379|NCT01895140|EXPERIMENTAL|Early renal denervation|Renal denervation takes place immediately after patient is randomized.
62103380|NCT01895140|OTHER|Delayed renal denervation|Renal denervation takes place 6 months after the patient is randomized.
62664824|NCT01463345|EXPERIMENTAL|Conservative Transfusion Arm|Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
62664825|NCT01463345|ACTIVE_COMPARATOR|Liberal Transfusion Arm|Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
62103381|NCT00823979|EXPERIMENTAL|UK- 453,061 Dose One|
62103382|NCT00823979|EXPERIMENTAL|UK- 453,061 Dose Two|
62296298|NCT06016816|PLACEBO_COMPARATOR|Placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
62296299|NCT04319848|EXPERIMENTAL|TE-EK treatment group|The TE-EK surgery will be performed by the Principle Investigator with a standard DSAEK technique. The PI has performed over 300, EK surgeries and we have previously shown that the corneal endothelial loss rates from the PI are 16% at 1 year with a primary graft failure rates of \<1.5%. A patient's participation in the study or not will not change the treatment strategy in any manner.
62468270|NCT01674166|EXPERIMENTAL|prucalopride|single dose 0.03 mg/kg prucalopride open label
62468271|NCT01954394|EXPERIMENTAL|Alirocumab 75 or 150 mg Q2W|Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
62664826|NCT05095337|EXPERIMENTAL|[14C]SHR1459|
61912246|NCT01447212|EXPERIMENTAL|Hydromorphone|Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
61912247|NCT01447212|ACTIVE_COMPARATOR|Diacetylmorphine|Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.
62664827|NCT01311661|EXPERIMENTAL|Olodaterol medium daily dose|Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
62664828|NCT01311661|EXPERIMENTAL|Olodaterol high daily dose|Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases
61912248|NCT03971877||Patients admitted in ICU or oncohaematology ward|
61912249|NCT00997113|ACTIVE_COMPARATOR|Propofol|propofol only for deep procedural sedation
62103383|NCT00823979|ACTIVE_COMPARATOR|Comparator|
62103384|NCT04984876|EXPERIMENTAL|ligelizumab 240 mg|ligelizumab 240 mg subcutaneous injection for 52 weeks
62103385|NCT04984876|EXPERIMENTAL|ligelizumab 120 mg|ligelizumab 120 mg subcutaneous injection for 52 weeks
62296300|NCT02078479|ACTIVE_COMPARATOR|Real rTMS|The active group received Real rTMS over the hand area of motor cortex (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold) every day for ten consecutive days (5 days/week).
62468272|NCT00102440|EXPERIMENTAL|Febuxostat 80 mg QD|
62468273|NCT00102440|EXPERIMENTAL|Febuxostat 120 mg QD|
62468274|NCT00102440|ACTIVE_COMPARATOR|Allopurinol 300 mg QD|
62468275|NCT02407275|OTHER|biological sample|Genomic \& culturomic analyses
62468276|NCT05122650|EXPERIMENTAL|10 milligram (mg) JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.
62468277|NCT05122650|EXPERIMENTAL|20 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.
62468278|NCT05122650|EXPERIMENTAL|30 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.
62468279|NCT05122650|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo from Day 1.
62664829|NCT02724644|EXPERIMENTAL|EN3835 Active|EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
62664830|NCT02724644|PLACEBO_COMPARATOR|EN3835 Placebo|Placebo
62664831|NCT06470464|EXPERIMENTAL|thalidomide combined with chemotherapy in the treatment of relapsed or refractory yolk sac tumor|This study employed an open single-group clinical laboratory design method (Simon Phase II study) to investigate the efficacy and safety of combining thalidomide with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin) in the treatment of children with recurrent or refractory YST. AFP levels were assessed after each course of treatment, while imaging evaluations were conducted every two courses. The remission rate following chemotherapy in this single-group clinical trial was compared to that reported in the literature for treating recurrent or refractory yolk sac tumor, evaluating overall remission rate (ORR) and event-free survival rate (EFS), as well as monitoring and recording chemotherapy-related side effects.
62664832|NCT05903443||BD group|All cases met the (brain death) BD clinical evaluation criteria, which were as follows: the cause of coma was known; exclusion of reversible coma; deep coma, Glasgow coma scale (GCS) = 2T; absence of five brain stem reflexes (pupillary light reflex, corneal reflex, oculocephalogyric reflex, oculovestibular reflex, and cough reflex); and no spontaneous respiration. Furthermore, according to whether the apnea test (AT) data were missing (implemented or completed), the patients were divided into the BD1 group (no AT missing group) and BD2 group (AT missing group).
62664833|NCT05903443||non-BD group|All cases were from BDQCHs and fulfilled the criteria for coma (GCS of 3-5 points), but did not meet the clinical criteria for BD, such as retaining the brainstem reflex or having spontaneous respiration. For coma cases, all assessment items, specifications of technical operations, assessment steps, and evaluators were conducted in accordance with the requirements for BDD. Cases with coma were then submitted to the BQCC/NHC quality control system.
61912250|NCT00997113|ACTIVE_COMPARATOR|Propofol/alfentanil|Propofol with alfentanil for deep procedural sedation
62103386|NCT04984876|EXPERIMENTAL|Placebo 8 weeks and ligelizumab 120 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks
62103387|NCT04984876|EXPERIMENTAL|Placebo 16 weeks and ligelizumab 120 mg/240 mg|Placebo subcutaneous injection for first 16 weeks and ligelizumab 120 mg OR 240 mg subcutaneous injection for 36 weeks
62103388|NCT04984876|EXPERIMENTAL|Placebo 8 weeks and ligelizumab 240 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks
62103389|NCT02616367|EXPERIMENTAL|liposomal bupivacaine Periarticular injection|Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).
62103390|NCT02616367|ACTIVE_COMPARATOR|Ropivacaine Periarticular Injection|Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine
62103391|NCT04222660|EXPERIMENTAL|Type 2 diabetes without neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
62103392|NCT04222660|EXPERIMENTAL|Type 2 diabetes with neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
62103393|NCT04222660|EXPERIMENTAL|Normal subjects, aged match with no symptoms of diabetes|Healthy, aged matched control subjects will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
62103394|NCT06421831|EXPERIMENTAL|single dose cohort|1.2x10\^14 vg/person of GC101 delivered one-time intrathecally
62103395|NCT01885364|PLACEBO_COMPARATOR|Placebo & propofol|Pretreatment with normal saline before injection of propofol
62296301|NCT02078479|SHAM_COMPARATOR|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce the same of subjective sensation of rTMS
62296302|NCT05218811|EXPERIMENTAL|Treatment group|Patients underwent Cryotheapy assisted partial nephrectomy
62296303|NCT02154646|EXPERIMENTAL|LY2157299 + Gemcitabine|150 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days without study drug (28 day cycle.) Gemcitabine 1000 milligram per square meter will be administered intravenously (IV) on Days 8, 15, and 22 in each cycle (28 day cycle). Participants may continue to receive treatment until discontinuation criteria are met.
62296304|NCT05146908||Patients in intensive care|Ventilated intubated patients for whom enteral nutrition is planned
62296305|NCT06656156|EXPERIMENTAL|Proprioceptive neuromuscular facilitation technique|Proprioceptive neuromuscular facilitation technique along with conventional treatment
62296306|NCT06656156|ACTIVE_COMPARATOR|Conventional treatment|Tens and hotpack
62468280|NCT02865005|ACTIVE_COMPARATOR|Dapsone 5.0% Gel (Allergan)|Dapsone 5.0% Gel applied twice daily for 84 days
62468281|NCT02865005|EXPERIMENTAL|Dapsone 5.0% Gel (SEEGPharm)|Dapsone 5.0% Gel applied twice daily for 84 days
61912251|NCT04976270|EXPERIMENTAL|GLPG3667 SD|Participants will receive a single dose of GLPG3667
62468282|NCT02865005|PLACEBO_COMPARATOR|Placebo|Vehicle of Experimental Gel applied twice daily for 84 days
62468283|NCT03185039|EXPERIMENTAL|kidney cancer|Localized, oligometastatic or metastatic
62468284|NCT01757470||Caprelsa Patient|All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
61912252|NCT04976270|PLACEBO_COMPARATOR|Placebo SD|Participants will receive a single dose of matching placebo
61912253|NCT04976270|EXPERIMENTAL|GLPG3667 MD|Participants will receive repeated doses of GLPG3667 for 13 days.
61912254|NCT04976270|PLACEBO_COMPARATOR|Placebo MD|Participants will receive repeated doses of matching placebo for 13 days.
61912255|NCT00970775|EXPERIMENTAL|1. AZD2423|
61912256|NCT00970775|PLACEBO_COMPARATOR|2. Placebo|
61912257|NCT04280809|EXPERIMENTAL|Laser|Subsequently to the suture, laser was applied in the right or left side randomly on each patient, according to a sheet of randomization. GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2.
61912258|NCT04280809|NO_INTERVENTION|Non-laser|Every patient, on the control side, the same handpiece was applied intraorally, but laser was not activated
61912259|NCT03133962|OTHER|Patients applying for CAP or long-term central catheter|
62103396|NCT01885364|EXPERIMENTAL|esmolol 0.05 mg/kg & propofol|Pretreatment with esmolol 0.05 mg/kg before injection of propofol
62103397|NCT01885364|EXPERIMENTAL|esmolol 1 mg/kg & propofol|Pretreatment with esmolol 1 mg/kg before injection of propofol
62296307|NCT04613206|EXPERIMENTAL|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.7 mL HD-IIV (60µg of each influenza antigen) 28-42 days apart
62296308|NCT04613206|EXPERIMENTAL|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.5 mL SD-IIV (15µg of each influenza antigen) 28-42 days apart
62468285|NCT01757470||Caprelsa Prescriber|All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
62468286|NCT03717350|PLACEBO_COMPARATOR|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously
62468287|NCT03717350|ACTIVE_COMPARATOR|Antibiotic|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously
62468288|NCT05197322|OTHER|Tumour Mutation Burden high or medium (or MSI-High)|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test or FOUNDATIONONE® Liquid CDx should be available and patients will continue their treatment as follows:~TMB-high (defined as ≥20 mutations per Mb) or medium (defined as 6-19 mutations per Mb); FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx test (or MSI-H if FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx test is not evaluable):~* A further two cycles of pembrolizumab 200 mg IV every 21 days~* Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
62468289|NCT05197322|OTHER|Tumour Mutation Burden low or unevaluable|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx test should be available and patients will continue their treatment as follows:~TMB-low (defined as ≤5 mutations per Mb); FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx OR if FOUNDATIONONE test and MSI result by PCR are both not evaluable):~• Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
62468290|NCT00793663|EXPERIMENTAL|1|The effect of xenon as an anaesthetic on the depth of hypnosis.
62468291|NCT00793663|ACTIVE_COMPARATOR|2|The effect of sevoflurane as an anesthetic on the depth of hypnosis
62468292|NCT00793663|EXPERIMENTAL|3|Dexamethasone as prevention of postoperative nausea and vomiting after xenon or sevoflurane anesthesia
61912260|NCT03206996|EXPERIMENTAL|Child Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
62103398|NCT01885364|ACTIVE_COMPARATOR|remifentanil 0.35 ug/kg & propofol|Pretreatment with remifentanil 0.35 ug/kg before injection of propofol
62103399|NCT06083233|EXPERIMENTAL|"Study group Responders"|Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anesthesia. Before surgery patients undergo lumbar puncture or external lumbar drainage placement to confirmed the diagnosis and responsivity to VP shunt placement.
62103400|NCT06083233|EXPERIMENTAL|"Study group Non-responders"|Patients with diagnosed hydrocephalus. VP shunt non-responsivity confirmed.
62103401|NCT06629493|EXPERIMENTAL|Alcohol use disorder treatment plus Fitbit Versa 3|Participants will receive in-patient treatment for alcohol use disorder plus an activity tracker
62103402|NCT06629493|ACTIVE_COMPARATOR|Alcohol use disorder treatment|Participants will receive in-patient treatment for alcohol use disorder
62103403|NCT00583843||Ultrasound|The group of women who are being followed by Ultrasound.
62103404|NCT06244108|EXPERIMENTAL|OTHP Group (Intervention Group)|Children with Down syndrome will undergo an 8-week occupational therapy home program (OTHP). Evaluations will be conducted at the beginning and end of the intervention, and the results will be compared.
62296309|NCT04613206|EXPERIMENTAL|One Dose High Dose Quadrivalent Inactivated Influenza Vaccine|one dose of 0.7 mL HD-IIV (60µg of each influenza antigen) followed by placebo 28-42 days later
62664834|NCT02602197|ACTIVE_COMPARATOR|Paracetamol|1 gr paracetamol received intravenously bolus 15 minutes after anesthetic induction and at the postoperative 6 th,12 th, 18 th and 24 th hours
62296310|NCT05484193|EXPERIMENTAL|GnRH-agonist group|In the GnRH-a group, LPS was initiated on the evening after the OPU, using Nafareline (Synarel nasal spray 200mg used once), followed by twice daily (total 400mg/day) until the day of serum β-hCG pregnancy test, and then stopped, regardless of the test results
62664835|NCT02602197|ACTIVE_COMPARATOR|Dexketoprofen|50 mg dexketoprofen received intravenous bolus 15 minutes after anesthetic induction and at the postoperative 8 th,16 th and 24 th hours.
62664836|NCT00634387|ACTIVE_COMPARATOR|A|Anthocyans
62664837|NCT00634387|PLACEBO_COMPARATOR|B|no effective agent
62664838|NCT02007772|ACTIVE_COMPARATOR|BiPAP breathing support|BiPAP is used over a period of 6 weeks (outpatient)
62664839|NCT02007772|EXPERIMENTAL|nHF / TNI breathing support|nasal high-flow is used over a period of 6 weeks (outpatient)
62664840|NCT01091467||Patients with HF|Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%
62664841|NCT05496010|EXPERIMENTAL|Dry Needling|Dry needling will be performed on the patients of group A after the diagnosis of trigger points in particular muscles.The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved.
62664842|NCT05496010|ACTIVE_COMPARATOR|Ischemic Compression Technique|Ischemic Compression technique will be performed on the patients of group B after the diagnosis of trigger points in particular muscles by diagnostic ultrasound. The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved.
62664843|NCT02265744|EXPERIMENTAL|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
62664844|NCT02265744|EXPERIMENTAL|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
62664845|NCT02265744|EXPERIMENTAL|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
62664846|NCT02265744|EXPERIMENTAL|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
62664847|NCT02265744|PLACEBO_COMPARATOR|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
62664848|NCT04370600|ACTIVE_COMPARATOR|Group A|These patients will receive ketone supplementation between visits 1 and 2 and will receive placebo drink between visits 2 and 3 (after the washout period).
62664849|NCT04370600|ACTIVE_COMPARATOR|Group B|These patients will receive ketone supplementation between visits 2 and 3 (after the washout period) and will receive placebo drink between visits 1 and 2
62468293|NCT00793663|PLACEBO_COMPARATOR|4|
62468294|NCT00793663|EXPERIMENTAL|5|Ondansetron, to determine the onset-time of ondansetron when used as rescue medication for postoperative nausea and vomiting
62664850|NCT03546543|EXPERIMENTAL|Supine|
62664851|NCT03546543|EXPERIMENTAL|Prone|
62664852|NCT04071886|EXPERIMENTAL|Mindfulness-Based Training|Participants in the Mindfulness-Based Training arm will receive 2 weeks of Mindfulness-Based Training for at least 30 minutes every day.
62664853|NCT04071886|ACTIVE_COMPARATOR|Relaxation Training|Participants in the Relaxation Training arm will receive 2 weeks of Relaxation Training for at least 30 minutes every day.
62664854|NCT03022175|EXPERIMENTAL|SPR741|"SPR741 is a novel chemical entity known as a potentiator that specifically interacts with the outer membrane of Gram-negative bacteria to increase the membrane's permeability. This increase in permeability allows Gram-positive antibiotics to enter and kill the cell.~SAD cohorts: Subjects will receive single doses of SPR741 over 60 minute IV infusion. Planned doses to be studied are 5, 15, 50, 100, 200, 400, 600 and 800 mg.~MAD cohorts: Subjects will receive SPR741 over 60 minute IV infusion three times a day (TID). Four dose groups will be studied. Doses will be determined by assessing SAD cohort data."
62468295|NCT00793663|PLACEBO_COMPARATOR|6|
62468296|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
62664855|NCT03022175|PLACEBO_COMPARATOR|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over 60 minutes.~MAD: Subjects will receive TID infusions of placebo over 60 minutes for 14 days"
62664856|NCT03480074|ACTIVE_COMPARATOR|Staple Ligation|Arm 1: Staple Ligation
62664857|NCT03480074|ACTIVE_COMPARATOR|Selective Suture Ligation|Arm 2: Selective Suture Ligation
62664858|NCT03480074|ACTIVE_COMPARATOR|Single Suture Ligation|Arm 3: Single Suture Ligation
62103405|NCT06244108|NO_INTERVENTION|None OTHP Group (Control group)|The control group (non-OTHP) will not receive occupational therapy home program, even if they have Down syndrome. Evaluations will be conducted at 8-week intervals, with the first and last evaluations being compared.
62468297|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
62468298|NCT01623362|EXPERIMENTAL|Low-fluoride acidic dentifrice|
62468299|NCT01623362|NO_INTERVENTION|Conventional dentifrice|1100µgF/g-pH7.0
62103406|NCT00515840|SHAM_COMPARATOR|1|equal time with health care professional (asthma nurse)
62468300|NCT01623362|EXPERIMENTAL|neutral pH and low-fluoride dentifrice|550 ppm pH 7
62664859|NCT03940534|ACTIVE_COMPARATOR|Start with Mobile Device|
62664860|NCT03940534|ACTIVE_COMPARATOR|Start without Mobile Device|
62664861|NCT03893214|EXPERIMENTAL|intervention group|Virtual reality exposure for acrophobia - this arm receives the virtual reality exposure intervention in the initial phase and has a four-week follow-up assessment.
62103407|NCT03639441|EXPERIMENTAL|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62664862|NCT03893214|PLACEBO_COMPARATOR|waitlist control group|This arm watches a movie in the initial phase in order to control for effects of behavioral approach test that is done before and after the intervention and for time effects. In the second phase after four weeks, this arm receives the virtual reality exposure after collection of outcome measures.
62664863|NCT00696566|EXPERIMENTAL|A|All subjects will receive Clopidogrel and Rifampicin.
62103408|NCT03639441|ACTIVE_COMPARATOR|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62103409|NCT02836665|NO_INTERVENTION|A: Control group|Patients of group A wait routinely until the dermatological investigator in charge arrives at the emergency room. Once the dermatological investigator is on site, he gives a diagnosis and proposes a therapy.
62103410|NCT02836665|EXPERIMENTAL|B: Telemedicine for dermatological emergency patients|"For Patients of group B study-related photographs of the skin lesion and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal."
62103411|NCT06337110|EXPERIMENTAL|Lu AF28996|Participants will receive a single oral dose of Lu AF28996.
62103412|NCT01240356|EXPERIMENTAL|Phase I: Healthy Volunteers|Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
62103413|NCT01240356|EXPERIMENTAL|Phase II: 0-3 hour Patients|Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
62468301|NCT03003871|EXPERIMENTAL|advanced oral hygiene care programmes|participants were provided with a powered toothbrush (Oral-B® AdvancePowerTM 400 series), 0.2% chlorhexidine gluconate mouth rinse, 10 mls twice daily (CorsodylPTMP), standardized toothpaste (Colgate Maximum Cavity Protection) and oral hygiene instruction.
62468302|NCT03003871|ACTIVE_COMPARATOR|conventional oral hygiene care programme|participants were provided with a manual toothbrush (Oral-B® Pro-Health All-In-One), supply of a standardized toothpaste (Colgate Maximum Cavity Protection®) and oral hygiene instruction
62468303|NCT03855579|EXPERIMENTAL|Levosimendan|Intraoperative infusion of Levosimendan
62468304|NCT03855579|ACTIVE_COMPARATOR|Milrinone|Intraoperative infusion of Milrinone
62468305|NCT04527575|EXPERIMENTAL|"EpiVacCorona (An Open Study)"|Group 1: 14 volunteers who will be vaccinated with the EpiVacCorona vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
62664864|NCT05818033|EXPERIMENTAL|Intervention group|CARE1.02
62664865|NCT05818033|ACTIVE_COMPARATOR|Control group|Single-vision spectacle lens
62664866|NCT05179512||Tiotropium|Reference group
62664867|NCT05179512||Salmeterol/Fluticasone|Exposure group
62664868|NCT00669344|PLACEBO_COMPARATOR|II|Placebo
62664869|NCT00669344|EXPERIMENTAL|I|Rivastigmine
62103414|NCT01484106|EXPERIMENTAL|Treatment group|"Patients will be randomized (1:1, stratified by site, in permutation blocks of 4) to the Treatment or Standard Care arms."
62103415|NCT01484106|ACTIVE_COMPARATOR|Control|Standard of Care
62103416|NCT05009446|EXPERIMENTAL|Preoperative radiotherapy and chemotherapy|Preoperative radiotherapy and chemotherapy plus endoscopic surgery
62664870|NCT05965895|ACTIVE_COMPARATOR|US-guided SAP block group|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
62103417|NCT04264442|EXPERIMENTAL|Losmapimod|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor.
62103418|NCT02728271|EXPERIMENTAL|HPC cell infusion|Autologous HPC will be infused within 24 hours of completing the chemotherapy. A total of 5 x 106/kg CD34+ HPC will be infused. The remaining HPC will be stored as back-up, to be used in case of graft failure.
62103419|NCT00476203|EXPERIMENTAL|1|Immediate yoga classes offered
62103420|NCT00476203|OTHER|2|Delayed yoga classes (after 6 months) offered \[wait list control group\]
62103421|NCT06095310|EXPERIMENTAL|Homogeneous groups|
62103422|NCT05380531|EXPERIMENTAL|Mother undergoing planned Cesarean section|Mother subject will have genotyping blood draw performed at the time of controlled delivery (CD). Blood samples and breast milk samples will also be taken during the oxycodone dosing schedule.
62103423|NCT05380531|EXPERIMENTAL|Infant|Infant subject will have genotyping blood draw performed only at the time of controlled delivery (CD)
62664871|NCT05965895|ACTIVE_COMPARATOR|Dexmedetomidine group|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
62664872|NCT01331005|PLACEBO_COMPARATOR|Placebo|Placebo will be given three times per day for one year
62468306|NCT04527575|EXPERIMENTAL|"EpiVacCorona (A Simple, Blind, Randomized Study)"|Group 2: Administration of the EpiVacCorona vaccine, intramuscularly, twice, 21 days spaced apart, at a dose of 0.5 ml (43 volunteers)
62103424|NCT02242942|EXPERIMENTAL|Safety Run-in Obinutuzumab + Venetoclax|Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
62468307|NCT04527575|PLACEBO_COMPARATOR|"Placebo (A Simple, Blind, Randomized Study)"|Group 3: Тhe use of placebo (sodium chloride, solvent for the preparation of dosage forms for injection 0.9%) intramuscularly twice space 21 days apart at a dose of 0.5 ml (43 volunteers)
62468308|NCT05820958|EXPERIMENTAL|Experimental group|The experimental group received an intervention in the form of intensified tactile contact of a mother with the newborn.
62664873|NCT01331005|ACTIVE_COMPARATOR|nepafenac 0.1% drops|Nepafenac drops will be given three times per day for one year
62664874|NCT03247244|OTHER|1|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD \<0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC \<0.3%, CBD \<0.3%).
62664875|NCT03247244|OTHER|2|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC \<0.3%, CBD \<0.3%), A (THC 10%, CBD \<0.5%), C (THC 0.6%, CBD 14%).
62664876|NCT03247244|OTHER|3|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD \<0.5%), placebo D (THC \<0.3%, CBD \<0.3%), B (THC 8.6%, CBD 8.6%).
62664877|NCT03247244|OTHER|4|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC \<0.3%, CBD \<0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD \<0.5%).
62664878|NCT06280105|EXPERIMENTAL|cadonilimab+regorafenib|
62664879|NCT00731198|EXPERIMENTAL|1|Drotaverine hydrochloride
62664880|NCT00731198|ACTIVE_COMPARATOR|2|Hyoscine-N-butylbromide
62664881|NCT02908321|ACTIVE_COMPARATOR|CBT|
62664882|NCT02908321|NO_INTERVENTION|WL|
62664883|NCT00407667|EXPERIMENTAL|1|patients receive 20 min of anodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
62664884|NCT00407667|EXPERIMENTAL|2|patients receive 20 min of cathodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
62296311|NCT05484193|ACTIVE_COMPARATOR|Progesterone group|In the progesterone group, LPS was initiated on the morning after OPU, using micronized progesterone ( PV Utrogestan 300mg, 3 times daily), until serum β-hCG pregnancy tests results were available. If a β-hCG pregnancy was confirmed, LPS was continued until the end of the 8th gestational week
62468309|NCT05820958|NO_INTERVENTION|Control group|The control group received no intervention similar to experimental intervention.
62664885|NCT00407667|SHAM_COMPARATOR|3|patients receive 20 min of sham transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
62664886|NCT03447145|EXPERIMENTAL|TQ-B3203|
62664887|NCT02204462|EXPERIMENTAL|Newly diagnosed breast cancer|Patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e. index cancer). Patients will undergo FBnTP PET imaging for detection of malignant breast cancer.
62103425|NCT02242942|EXPERIMENTAL|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
62308252|NCT06292312|ACTIVE_COMPARATOR|Control group|Patients in this group are the group to which conventional physiotherapy will be applied.
62103426|NCT02242942|EXPERIMENTAL|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
62103427|NCT05615220|EXPERIMENTAL|1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl)|Ecopipam 11.2, 22.4, 33.6, 44.8, 67.2 and 89.6 mg tablets (containing 12.5, 25, 37.5, 50, 75 and 100 mg ecopipam HCl, respectively); 1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl) target dose; oral administration daily in evenings.
62308253|NCT06153381|EXPERIMENTAL|Chatbot care|
62308254|NCT06153381|ACTIVE_COMPARATOR|Standard care|
62468310|NCT05398718||Sotrovimab Arm|
62468311|NCT05398718||Control|
62468312|NCT04910178|EXPERIMENTAL|Empa group|patients will be given Empagliflozin 25 mg once daily
62468313|NCT04910178|EXPERIMENTAL|PTX group|patients will be given PTX 400 mg twice daily or 3 times daily
62468314|NCT04910178|EXPERIMENTAL|UDCA group|patients will be given UDCA 500 mg twice daily
62468315|NCT04910178|PLACEBO_COMPARATOR|Placebo|patients will be given a placebo
62664888|NCT02843607|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62664889|NCT02843607|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
62664890|NCT02551575|ACTIVE_COMPARATOR|Treatment of MTX and HCQ|Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.
62664891|NCT02551575|EXPERIMENTAL|Treatment of TCM|Patients were treated with oral Qingre Huoxue granule, Qingre Huoxue external preparation, methotrexate placebo and hydroxychloroquine placebo.
62664892|NCT02551575|EXPERIMENTAL|Integrative Medicine|The patients were treated with methotrexate, hydroxychloroquine, oral Qingre Huoxue granule and Qingre Huoxue external preparation.
62664893|NCT05129085|EXPERIMENTAL|Group ESI|Patients in group ESI will undergo epidural steroid injection.
62664894|NCT05129085|ACTIVE_COMPARATOR|Group EPRP|Patients in group EPRP will undergo epidural PRP injection.
62664895|NCT03976700|EXPERIMENTAL|Bufei Jianpi granule|Patients in this arm will receive Bufei Jianpi granule.
62664896|NCT03976700|PLACEBO_COMPARATOR|Placebo Bufei Jianpi granule|Patients in this arm will receive placebo Bufei Jianpi granule.
62664897|NCT05314725|EXPERIMENTAL|SGLT-2 inhibitor|
62664898|NCT05314725|PLACEBO_COMPARATOR|placebo|
62296312|NCT05987761|EXPERIMENTAL|PRT Treatment Group|After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-intervention MRI brain scan and behavioral assessments and will then be assigned randomly to one of two arms of intervention for 9 weeks. Participants in the PRT Treatment Group will complete an 9-week intervention, PRT for Adolescents, to improve the adolescent's social skills. Following the completion of the 9-week intervention, participants will be asked to complete a second MRI brain imaging session, followed by post-measure appointments in order to assess immediate effects of the intervention.
62664899|NCT06071988|EXPERIMENTAL|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
62664900|NCT06071988|EXPERIMENTAL|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
62296313|NCT05987761|EXPERIMENTAL|Delayed Treatment Group|After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-intervention MRI brain scan and behavioral assessments and will then be assigned randomly to one of two arms of intervention for 9 weeks. After 9-weeks without any intervention, participants in the Delayed Treatment Group will be asked to complete a second MRI brain imaging session, followed by post-measure appointments, and will then receive the PRT intervention at the end of the study.
62468316|NCT02155465|EXPERIMENTAL|Ruxolitinib and Erlotinib|"Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.~Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily."
62468317|NCT06118970||Patients with fibromyalgia syndrome|"Patients with fibromyalgia will be recruited at the UZ hospital in Brussels, at local patient organisations (e.g. VLFP), at the Vrije Universiteit Brussel and via social media alerts.~This syndrome must be confirmed by a medical diagnosis. Participants should be able to understand English, Dutch or French, they must have signed an in-formed consent and they must be at least 18 years old. Patients with other diagnoses will be excluded from this study (e.g., osteoarthritis, rheumatoid arthritis, post-cancer pain, as well as patients with primary psychiatric/neurological conditions or psychopathological disorders). Subjects with a history of substance abuse or pathological gambling and individuals with color blindness will also be excluded."
62468318|NCT06118970||Healthy controls|Healthy controls will be recruited through the University of Brussels or through social media alerts. Their exclusion criteria included, in addition to those specified for the fibromyalgia group, those who were suffering from fibromyalgia or had a severe rheumatic illness. Subjects should not have pain currently or have a recent history of pain (within the past 3 months).
62468319|NCT03113422|EXPERIMENTAL|Induction Venetoclax|Cycle 1-6: Obinutuzumab intravenously (IV) and bendamustine IV. Cycle 2-6: Venetoclax (oral)
62468320|NCT03113422|EXPERIMENTAL|Maintenance Venetoclax|Patients with stable or improved disease will receive venetoclax by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab IV every 2 months for 12 cycles.
62468321|NCT05210062||Exposure to suxamethonium during ECT|A single group is planned in this study, consisting of patients with a medical indication for ECT for psychiatric pathologies which are resistant to medical treatment (depression, mania, hallucinatory episode in particular).
62468322|NCT02400047|EXPERIMENTAL|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
62468323|NCT02400047|EXPERIMENTAL|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
62468324|NCT02400047|ACTIVE_COMPARATOR|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
62468325|NCT01557712|EXPERIMENTAL|Ketamine+venlafaxine|one injection of 0.5 mg/kg of kentamine the first day plus venlafaxine (150-375 mg day) during 6 weeks
62468326|NCT01557712|ACTIVE_COMPARATOR|venlafaxine|venlafaxine (150-375 mg day) during 6 weeks
62664901|NCT02550210|EXPERIMENTAL|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
62664902|NCT02867852|EXPERIMENTAL|Abiraterone acetate|Abiraterone acetate 1 g/day must be taken as four 250-mg tablets daily on an empty stomach. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Prednisone (prednisolone when prednisone is not available) 5 mg will be given orally twice a day.
62664903|NCT05619523|EXPERIMENTAL|Intervention: DIY Tool Classrooms|Developing Inclusive Youth (DIY) classrooms complete a pretest and posttest survey in addition to completing 8 scenarios using the DIY online tool and a class discussion for each scenario.
62296314|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
62296315|NCT03572088|ACTIVE_COMPARATOR|Terlipresssin|Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
62664904|NCT05619523|NO_INTERVENTION|Control: Business As Usual Classrooms|"The control group follows a Business-As-Usual plan (no alternative program is implemented for the control group.) They complete a pretest and posttest in the same weeks as the experimental group."
62664905|NCT05341245|EXPERIMENTAL|Graphene oxide group|The surgical defect will be managed by open flap debridement and application of Graphene oxide
62664906|NCT05341245|OTHER|Open flap group|The surgical defect will be managed by open flap debridement
62664907|NCT05562921||Case|
62664908|NCT05562921||Control|
62103428|NCT05615220|PLACEBO_COMPARATOR|Placebo during R/WD Phase|Matching Placebo tablets during R/WD period taken orally in the evening.
62664909|NCT02011763|EXPERIMENTAL|Study Group|Toddlers, children and adolescents aged 12 months to 15 years
61912261|NCT03206996|EXPERIMENTAL|Parental Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
62103429|NCT06712563||BGF Initiators|New initiators of BGF without prior BGF exposure
62296316|NCT03572088|PLACEBO_COMPARATOR|Control|patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)
62296317|NCT03415555|EXPERIMENTAL|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
62296318|NCT03415555|EXPERIMENTAL|PCA|Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.
62296319|NCT04460430|EXPERIMENTAL|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
62296320|NCT00778830|EXPERIMENTAL|Cetuximab plus FOLFIRI|
62296321|NCT00778830|EXPERIMENTAL|Cetuximab plus FOLFOX|
62296322|NCT06483919||SCLC patients with brain metastasis|
62296323|NCT06483919||SCLC patients without brain metastasis|
62103430|NCT06711315|EXPERIMENTAL|Intervention Group|Oral mucositis education was given, oral care was requested for 14 days and monitored on days 0, 3, 7 and 14.
62296324|NCT02210780|EXPERIMENTAL|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
62296325|NCT02210780|EXPERIMENTAL|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
62296326|NCT03189108||Cohort 1|Patients with a diagnosis of malignant solid tumor
62296327|NCT06338644||Primary resistant to endocrine therapy|Primary endocrine resistance is defined as a relapse within 2 years of adjuvant endocrine treatment or disease progression during the first 6 months of first-line endocrine therapy for advanced or MBC
61912262|NCT00933413|EXPERIMENTAL|Dermacyd Silver Frutal (Lactic Acid)|Application of Lactic acid during 21 consecutive days
61912263|NCT02975583|ACTIVE_COMPARATOR|Experimental: Vorapaxar|Drug: Vorapaxar 2.08 mg orally daily for a year Other name: Zontivity
61912264|NCT02975583|PLACEBO_COMPARATOR|Placebo Comparator: Placebos|Medication: Matching Placebo Daily tablet
62103431|NCT06711315|NO_INTERVENTION|Control Group|Children in the control group will receive standard care. Mouthwash with sodium bicarbonate (after each feeding), mycostatin (2x1) and tranflex (3x1). Toothbrush and dental floss are not used. At the end of the 14th day, the child and caregiver in the control group will receive Oral Care Protocol Training to Prevent Oral Mucositis.
62103432|NCT04675255|ACTIVE_COMPARATOR|Immediate switch|Immediate switch
62103433|NCT04675255|ACTIVE_COMPARATOR|Delayed switch|Delayed switch
61912265|NCT04011371|EXPERIMENTAL|Cyanoacrylate closure|Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.
62103434|NCT03392662||Hemopatch Sealant Use with Hepatobiliary Surgery|
62103435|NCT03392662||Hemopatch Sealant Use with General Surgery|
62103436|NCT03392662||Hemopatch Sealant Use with Lung Surgery|
62103437|NCT03392662||Hemopatch Sealant Use with Cardiovascular Surgery|
62103438|NCT03392662||Hemopatch Sealant Use with Neurological/Spinal Surgery|
62103439|NCT03392662||Hemopatch Sealant Use with Urologic Surgery|
62103440|NCT02054247|EXPERIMENTAL|ultrasound|ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2
62103441|NCT02054247|EXPERIMENTAL|pulsed ultrasound|pulsed ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4
62103442|NCT02054247|PLACEBO_COMPARATOR|placebo ultrasound|placebo ultrasound : same ultrasound device as described above seemed to be working but without delivering any output
62103443|NCT04109118|OTHER|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|"This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.~Of note, this is a pilot trial for feasibility and acceptability. There is no randomization and we are not comparing arms."
62103444|NCT06453356|EXPERIMENTAL|Zavegepant 10mg|Intranasal (IN) 10mg spray on Day 1
62296328|NCT06338644||Secondary resistant to endocrine therapy|Secondary resistance is defined in early BC as a relapse that occurs after at least 2 years of endocrine therapy and during or within the first year of completing adjuvant endocrine therapy. In advanced BC or MBC, secondary resistance is defined as disease progression after more than 6 months of endocrine therapy
62296329|NCT02333227|NO_INTERVENTION|Control|Cluster of sites not receiving xylitol gum. This is a cluster randomized trial, whereby 4 sites will not receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
62296330|NCT02333227|EXPERIMENTAL|Xylitol|Cluster of sites receiving xylitol gum.
62296331|NCT00979394||Patients with type 2 diabetes|
62296332|NCT01120639|EXPERIMENTAL|Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) \< 60 cm³ vs 60 to 150 cm³.
62296333|NCT01120639|EXPERIMENTAL|Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) \< 60 cm³ vs 60 to 150 cm³.
62296334|NCT01120639|EXPERIMENTAL|Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) \< 60 cm³ vs 60 to 150 cm³.
62664910|NCT03969537||Telemedicine|The patients selected to participate in the study are cervical dystonia (CD) patients who receive treatment at Vanderbilt University Medical Center, where the study takes place.
62103445|NCT05074498|EXPERIMENTAL|Part 1: TB006|Participants will be randomized to 1 of 3 ascending dose groups to receive a total of 5 once-weekly doses of TB006, infused over 1 hour.
62103446|NCT05074498|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will be randomized to receive 5 once-weekly doses of matching placebo.
62103447|NCT05074498|EXPERIMENTAL|Part 2: TB006|Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
62103448|NCT05074498|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will be randomized to receive matching placebo. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
62103449|NCT01113112||Biobehavioral factors|Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
62296335|NCT01120639|EXPERIMENTAL|Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) \< 60 cm³ vs 60 to 150 cm³.
62296336|NCT06222892|EXPERIMENTAL|Part 1: Participants with moderate hepatic impairment receiving Camlipixant|Participants with moderate hepatic impairment will receive Camlipixant
62103450|NCT02799212|EXPERIMENTAL|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
62296337|NCT06222892|EXPERIMENTAL|Part 1: Healthy participants (matched to moderate hepatic impairment) receiving Camlipixant|Healthy participants (matched to moderate hepatic impairment) will receive Camlipixant
62103451|NCT02799212|PLACEBO_COMPARATOR|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
62296338|NCT06222892|EXPERIMENTAL|Part 2: Participants with mild hepatic impairment receiving Camlipixant|Participants with mild hepatic impairment will receive Camlipixant
62296339|NCT06222892|EXPERIMENTAL|Part 2: Participants with severe hepatic impairment receiving Camlipixant|Participants with severe hepatic impairment will receive Camlipixant
62296340|NCT06222892|EXPERIMENTAL|Part 2:Healthy participants(matched to mild and/or severe hepatic impairment)receiving Camlipixant|Healthy participants(matched to mild and/or severe hepatic impairment)will receive Camlipixant
62296341|NCT03007264|EXPERIMENTAL|CAP treated|volar arm will be treated with cold atmospheric plasma.
62664911|NCT02624089|EXPERIMENTAL|Ropivacaine Group|This group will receive nebulized ropivacaine 0.5% based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered once at the onset of pneuomoperitoneum during appendectomy.
62103452|NCT06411379|EXPERIMENTAL|sonelokimab|Subjects randomized to this arm will receive sonelokimab 120 mg Q2W from Weeks 0 to 6 then 120 mg Q4W starting at Week 8 up to Week 48.
61912266|NCT01913587|EXPERIMENTAL|Acupuncture & Nerve block|Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
62103453|NCT06411379|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo Q2W from Weeks 0 to 6 then Q4W starting at Week 8 up to Week 16. They will receive sonelokimab 120 mg Q2W for 4 doses from Weeks 16 to 22 then Q4W from Week 24 up to Week 48
62103454|NCT06121999|ACTIVE_COMPARATOR|Acceptance-based behavioral weight loss program (ABWL)|Participants meet individually for 30 - 60 minutes with an occupational therapist for 13 consecutive weeks at a gastroenterology office. Outcome data is collected at baseline (visit 1) and at the end of the study (visit 13), Participants work on two modules per week in-between visits. During visits the participants' weight is recorded, module contents and worksheet information is reviewed and recorded, and suggestions are made as indicated in the clinician guide.
62103455|NCT06121999|EXPERIMENTAL|Occupational Therapy behavioral lifestyle intervention|Participants meet individually for 60-90 minutes with an occupational therapist for 13 consecutive weeks at a gastroenterology office. Outcome data is collected at baseline (visit 1) and at the end of the study (visit 13). The Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessment are also used for intervention in the areas of motivation for occupation, pattern of occupation, communication \& interaction skills, motor skills, process skills, and environment. Participants are also educated about practice guidelines for MASLD/MASH such as a Mediterranean (MED) diet and a personalized exercise plan. In-between visits, participants work on two modules of the control intervention and implement dietary and lifestyle modifications discussed during the visit.
62103456|NCT05895929|EXPERIMENTAL|Mepolizumab treatment arm|Nasal epithelial cells will be exposed in vitro to mepolizumab in culture.
62103457|NCT05895929|NO_INTERVENTION|Control arm|Nasal epithelial cells will be exposed in vitro to media without mepolizumab in culture
62103458|NCT04208737|NO_INTERVENTION|control group|"3 FRC measurements will be perforemed, whereby : First measurement; after aneshesia induction and intubation. Second measurement; after pneumoperitoneum Third measurement; end of the operation~After the operation,Postoperative Room Air Test (RAT) will be applied."
62296342|NCT03007264|EXPERIMENTAL|CAP on bacteria|volar arm with bacteria will be treated with cold atmospheric plasma.
62296343|NCT03007264|NO_INTERVENTION|no CAP on bacteria|volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.
62296344|NCT03932526|ACTIVE_COMPARATOR|Vinorelbine + placebo group|92 enrolled patients will be assigned to receive oral vinorelbine plus placebo until disease progression or other criteria for administration termination.
62664912|NCT02624089|PLACEBO_COMPARATOR|Placebo group|This group will receive placebo (normal saline) based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered at the onset of pneuomoperitoneum during appendectomy.
62103459|NCT04208737|EXPERIMENTAL|study group|"5 FRC measurements will be performed We will apply recruitment maneuver two times to patients with 30cmH2O pressure for 15 seconds .~First Recruitment maneuver will be applied after the fşrst measurement of FRC following intubation Second Recuitment maneuver will be applied at the end of operation~First FRC measurement after anesthesia induction and intubation. Second FRC measurement after first recruitment maneuver Third FRC measurement; after pneumoperitoneum Fourth FRC measurement before second recruitment maneuver Fifth FRC measurement after second recruitment maneuver and at the end of operation"
62664913|NCT02624089|NO_INTERVENTION|Non-enrolled group|This group will not receive either intervention (ropivicaine) or placebo (normal saline), but will have primary and secondary endpoints evaluated.
62103460|NCT03719677|EXPERIMENTAL|Habit development intervention|Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.
62296345|NCT03932526|EXPERIMENTAL|Vinorelbine + Apatinib group|92 enrolled patients will be assigned to receive oral patatinib mesylate in combination with vinorelbine until disease progression or other criteria for administration termination.
62296346|NCT02367950|EXPERIMENTAL|Single Arm Study|All participants receive active treatment (exercise) tailored to their level of health ad fitness
62296347|NCT01968941|EXPERIMENTAL|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT)
62296348|NCT01968941|ACTIVE_COMPARATOR|Conventional Radiotherapy|Conventional Radiotherapy (CRT)
62664914|NCT00914212|ACTIVE_COMPARATOR|1|Sibutramine
62664915|NCT00914212|PLACEBO_COMPARATOR|2|Placebo
62664916|NCT01779362|ACTIVE_COMPARATOR|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.
62664917|NCT01779362|ACTIVE_COMPARATOR|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.
62664918|NCT01779362|PLACEBO_COMPARATOR|Placebo|Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.
62664919|NCT01779362|ACTIVE_COMPARATOR|Liraglutide + Metformin|Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
62664920|NCT02840565|EXPERIMENTAL|BIA 5-453 25 mg or placebo|Multiple oral doses of BIA 5-453 25 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
62296349|NCT06325449|EXPERIMENTAL|STREAM Weight-loss Program|All patients who participate in the study will be recruited to the Intervention Arm and will undergo the STREAM program, a 24-week weight loss program which includes meal replacement, dietician teaching and regular appointments with their bariatric medicine specialist.
62664921|NCT02840565|EXPERIMENTAL|BIA 5-453 50 mg or placebo|Multiple oral doses of BIA 5-453 50 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
62296350|NCT02091440|OTHER|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
62296351|NCT02790229|EXPERIMENTAL|anti-gravity treadmill arm|Treatment with anti-gravity treadmill (alter G®)
62296352|NCT02790229|OTHER|control arm|Treatment with standardized physiotherapy
62296353|NCT06334939||EA group|The group that includes patients who develop Emergence agitation after anesthesia and during the recovery period.
62664922|NCT02840565|EXPERIMENTAL|BIA 5-453 100 mg or placebo|Multiple oral doses of BIA 5-453 100 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
62664923|NCT02840565|EXPERIMENTAL|BIA 5-453 200 mg or placebo|Multiple oral doses of BIA 5-453 200 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
62296354|NCT06334939||Non EA Group|The group will include calm patients who do not develop Emergence agitation after anesthesia and during the recovery period.
62296355|NCT02052102|ACTIVE_COMPARATOR|No prior therapy, DIBH irradiation|Cohort 1 - No prior anthracycline-based chemotherapy or herceptin, deep inspiration breath hold breast radiation therapy
61912267|NCT01913587|ACTIVE_COMPARATOR|Nerve block|Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
62296356|NCT02052102|ACTIVE_COMPARATOR|No prior therapy, FB technique|Cohort II - no prior Anthracycline based chemotherapy or Herceptin and (ii) to receive FB RT (not able to hold breath for at least 20 seconds or does not have a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
62664924|NCT02840565|EXPERIMENTAL|BIA 5-453 400 mg or placebo|Multiple oral doses of BIA 5-453 400 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
62664925|NCT02840565|EXPERIMENTAL|BIA 5-453 600 mg or placebo|Multiple oral doses of BIA 5-453 600 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
62664926|NCT04649554|EXPERIMENTAL|Experimental: ExAblate 4000 System|Exablate treatment on Neuropathic Pain
62664927|NCT05962372|EXPERIMENTAL|Intervention|Intervention group will receive culturally-tailored portion-control Mediterranean-like advice through monthly individual counseling for 6 months, reinforced with daily text messages for 12 months, and a monthly household supply of legumes (i.e., beans and peanuts), vegetable oils (i.e., olive oil + a blend of canola and soybean), and locally sourced assorted fruit and vegetables for 18 months. From months 18 to 24, we will monitor maintenance of behavior (no food or counseling) with support from the nutritionist available.
61912268|NCT03277820|EXPERIMENTAL|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
62664928|NCT05962372|ACTIVE_COMPARATOR|Control|Control group will receive portion-control standard non-tailored nutritional counseling in monthly individual sessions for 6 months, reinforced with daily text messages for 12 months, and monthly supermarket vouchers (no foods) for 18 months. From months 18 to 24, we will monitor maintenance of behavior (no voucher or counseling), with support from the nutritionist available.
62664929|NCT04664296||Children|Hospitalized children, 0 to 17 years of age, 25 subjects, consecutive sample survey
62103461|NCT05732428|EXPERIMENTAL|ARV-471|
62103462|NCT01370109||Penn Site|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks, with additional follow-up at 1 and 2 years.
62103463|NCT01370109||Vanderbilt University Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
62103464|NCT01370109||Case Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
62103465|NCT01370109||University of Wisconsin at Madison|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
62296357|NCT02052102|ACTIVE_COMPARATOR|Prior therapy, DIBH irradiation|Cohort III - Prior Anthracycline-based chemotherapy or Herceptin, and (ii) eligible to receive DIBH RT. (Patient has a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
62664930|NCT04664296||Adults|Hospitalized adults, 18 years and above, 50 matched subjects
62664931|NCT01843881|EXPERIMENTAL|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
62664932|NCT01843881|PLACEBO_COMPARATOR|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
62664933|NCT00552903|EXPERIMENTAL|1|Active intervention - personal health coaching provided
61912269|NCT03277820|NO_INTERVENTION|Control group|No intake of Probactiol Mini
61912270|NCT04269382|OTHER|Combined non-invasive and invasive BP measurements|Patients will all undergo measurement of BP through 3 different techniques over a 30-min period: continuous noninvasive BP measurement (with the finger cuff and Clearsight™ device), repeated intermittent oscillometric NIBP measurements with a cuff placed around a calf or an arm, and continuous invasive BP measurement (through an indwelling arterial catheter).
61912271|NCT01931215|ACTIVE_COMPARATOR|morphine group|spinal anesthesia with intrathecal morphine
61912272|NCT01931215|EXPERIMENTAL|TAP group|TAP-block with ropivacaine and clonidine
61912273|NCT02487342|EXPERIMENTAL|milk|semi-skimmed milk (\< 2% fat, Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
61912274|NCT02487342|ACTIVE_COMPARATOR|orange fruit-juice|orange fruit-juice (Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
61912275|NCT00869778|EXPERIMENTAL|εPA-44 900μg|Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
62103466|NCT05468606|EXPERIMENTAL|GA2 group (unadjuvanted group)|Immunization with 50 GA2-infected mosquito bites
62103467|NCT05468606|PLACEBO_COMPARATOR|Infectivity controls (placebo group)|Mock-immunization with 50 uninfected-mosquito bites
62103468|NCT05468606|EXPERIMENTAL|BCG group|Immunization with 50 GA2-infected mosquito bites and a standard intradermal BCG vaccination (0.1 mL)
62103469|NCT05468606|EXPERIMENTAL|YF-17D group|Immunization with 50 GA2-infected mosquito bites and a one fifth fractional (0.1 mL) intradermal YF-17D vaccination
62103470|NCT05468606|EXPERIMENTAL|Imiquimod group|Immunization with 50 GA2-infected mosquito bites and 250mg imiquimod cream 5%
62296358|NCT05422976|EXPERIMENTAL|EVI-01 treatment|EVI-01 should be injected within the synovial cavity using standard procedures for intra-articular (IA) injections by a physician skilled in performing IA injections.
62296359|NCT06381583||Patients with Esophageal Adenocarcinoma [Malignant Tissue]|"Individuals who underwent endoscopy and were found to only have one of the following:~* Esophageal adenocarcinoma of any stage~* Esophageal adenocarcinoma confined to the mucosa (stage Tis)"
62296360|NCT06381583||Patients with Esophageal Adenocarcinoma [Matching Normal Tissue]|"Individuals who underwent endoscopy and were found to only have one of the following:~* Esophageal adenocarcinoma of any stage~* Esophageal adenocarcinoma confined to the mucosa (stage Tis)"
62296361|NCT06381583||Patients with Esophageal Adenocarcinoma or High-Grade Dysplasia Barrett's Esophagus [Test Cohort]|"Individuals who underwent endoscopy and were found to only have one of the following:~* Barrett's Esophagus, with high-grade dysplasia, independently of Barrett's segment length~* Esophageal adenocarcinoma of any stage~* Esophageal adenocarcinoma confined to the mucosa (stage Tis)"
62664934|NCT00552903|NO_INTERVENTION|2|Control arm - no intervention, data on health outcomes collected at baseline (entry to the study) and during the 12 month follow-up
62664935|NCT00620542|EXPERIMENTAL|Rosuvastatin 20 mg|Rosuvastatin 20 mg distributed in 2-week run-in period
61912276|NCT00869778|EXPERIMENTAL|εPA-44 600μg+Placebo 300μg|Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
62664936|NCT00620542|ACTIVE_COMPARATOR|Atorvastatin 40 mg|Atorvastatin 40 mg distributed in 2-week run-in period
62664937|NCT00620542|EXPERIMENTAL|Rosuvastatin 40 mg|Rosuvastatin 40 mg distributed in core 2-year study
62664938|NCT00620542|ACTIVE_COMPARATOR|Atorvastatin 80 mg|Atorvastatin 80 mg distributed in core 2-year study
61912277|NCT00869778|PLACEBO_COMPARATOR|Placebo 900μg|Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
61912278|NCT05425316||Patients with Cirrhosis|This group will be composed of 200 patients with cirrhosis. Patients will be enrolled regardless of compensated vs. decompensated status, prior history of HE, Model for End Stage Liver Disease (MELD), and cirrhosis etiology.
61912279|NCT05425316||Patients without Cirrhosis|This group will be composed of 50 patients without cirrhosis to act as controls. They will have been found on Fibroscan to not have significant fibrosis.
62103471|NCT04087044|EXPERIMENTAL|Vestibular dysfunction|66 patients: 30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine
62103472|NCT04087044|OTHER|Control|120 aged matched controls
62664939|NCT04003571|EXPERIMENTAL|Augmented reality with functional electrical stimulation group|Ten participants in group A will undergo 30 minutes interactive augmented reality with functional electrical stimulation intervention and 30 minutes traditional physiotherapy per day, 3 days a week for 8 weeks.
62468327|NCT02543203|ACTIVE_COMPARATOR|A/C - Reconnect, Then Coconut Oil Comparator|"Participants randomized to treatment order A/C, received Reconnect for 3-months each day, morning and evening. After a washout period of one-month, they received the Coconut Oil Comparator morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
62664940|NCT04003571|ACTIVE_COMPARATOR|Traditional physiotherapy group|Ten participants in group B will undergo 30 minutes treadmill and balance training as well as 30 minutes traditional conventional physiotherapy a day, 3 days a week, for 8 weeks.
62664941|NCT03601052|EXPERIMENTAL|Remlarsen - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
62103473|NCT04423588|OTHER|Dexlansoprazole|The PPI Dexilant (active substance: dexlansoprazole) is administered to the study participants in a prophylactic Regimen for 6 months after the PRYGB-surgery. This drug is already approved by Swissmedic and on the markets in Switzerland. The dosage is 1 capsule 60 mg per os daily in the morning.
62103474|NCT05223413|ACTIVE_COMPARATOR|Remote Ischemic Conditioning|Remote Ischemic Conditioning (RIC): Patients will undergo weekly RIC during the entire span of the chemotherapy period. Each RIC session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation
62103475|NCT05223413|SHAM_COMPARATOR|simulated RIPC (Sham)|Control group (Sham): Patients will undergo weekly simulated RIC (sham) during the entire span of the chemotherapy period. Each sham session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation.
62468328|NCT02543203|SHAM_COMPARATOR|C/A - Coconut oil Blend, Then Reconnect|"Participants randomized to treatment order C/A received the Coconut Oil Comparator for 3-months each day, morning and evening. After a washout period of one-month, they received Reconnect morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
62468329|NCT04507711|EXPERIMENTAL|0 ng/ml|Blood specimen which was added of 0 ul of palonosetron
62468330|NCT04507711|EXPERIMENTAL|25 ng/ml|Blood specimen which was added of 1 ul of palonosetron
62664942|NCT03601052|PLACEBO_COMPARATOR|Placebo - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
62664943|NCT01013753|EXPERIMENTAL|Olodaterol (BI 1744) low|Low dose inhaled orally once daily from the Respimat inhaler
62664944|NCT01013753|EXPERIMENTAL|Olodaterol (BI 1744) very low|Very low dose inhaled orally once daily from the Respimat inhaler
62664945|NCT01013753|EXPERIMENTAL|Olodaterol (BI 1744) medium|Medium dose inhaled orally once daily from the Respimat inhaler
62664946|NCT01013753|EXPERIMENTAL|Olodaterol (BI 1744) high|High dose inhaled orally once daily from the Respimat inhaler
62664947|NCT01013753|ACTIVE_COMPARATOR|Formoterol 12 mcg|12mcg inhaled twice daily from the Aerolizer inhaler
62664948|NCT01013753|PLACEBO_COMPARATOR|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
62664949|NCT00576615||1: placebo|placebo solution
62664950|NCT00576615||2: propofol|propofol
62664951|NCT00834938||1|Patients with DM2 undergoing RYGB with remission of DM2
62664952|NCT00834938||2|Patients with DM2 undergoing RYGB without remission of DM2
62664953|NCT03204825|EXPERIMENTAL|Active TENS|Participants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
62664954|NCT03204825|PLACEBO_COMPARATOR|Placebo TENS|Placebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
62664955|NCT03204825|EXPERIMENTAL|Patient-Centred Education|Patient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
62664956|NCT03204825|EXPERIMENTAL|Patient-Centred Education + Active TENS|Combination of Patient-Centred Education arm and Active TENS arm.
62664957|NCT02649933||Watch PAt 200|obese pregnant women, pregnancy between 12 and 15 weeks
62103476|NCT04735354||sacubitril/valsartan|Patients administered sacubitril/valsartan by prescription
62103477|NCT03542708|EXPERIMENTAL|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma.
62103478|NCT03542708|NO_INTERVENTION|Control|The contralateral ovary will not be injected.
62103479|NCT03697213||General Practitioners|Registered General Practitioners in one of the six participating countries.
62664958|NCT01410604|EXPERIMENTAL|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
62664959|NCT01410604|PLACEBO_COMPARATOR|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
62664960|NCT01348698||Adrenal Gland Neoplasm|To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells. Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor.
62664961|NCT01078545||Adv. PCa patients with LUTS treated with GnRH analogue|Patients with advanced prostate cancer and lower urinary tract symptoms treated with GnRH analogue Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine)
62664962|NCT05371704|EXPERIMENTAL|Supplementation|In this arm of the study, participants will take 1 multivitamin pill each day for 10 days. If this is the participant's first trial, they will also record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate their diet recorded from their first trial.
62664963|NCT05371704|OTHER|Control|In this arm of the study, participants will not supplement with any multivitamin. If this is the participant's first trial, they will record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate the diet recorded from their first trial.
62664964|NCT04565938|EXPERIMENTAL|one-step self-etch adhesive with enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive with enamel etching
62103480|NCT05039918|EXPERIMENTAL|Intervention|"Following randomisation, infants will receive CT-optimal stimulation (gentle stroking) at a velocity of 3cm/s over the area which the infant will be stroked (10cm) for a duration of 10s applied proximally to the pain site prior to the heel prick. Location of the heel prick will be based on clinical judgement. There will be an inter-stimulus interval of approximately 1 second between the end of the touch and heel prick, and touch stimulation will be applied to the lower leg ipsilateral to the heel receiving the noxious stimuli. All infants will have cardio-respiratory monitoring during the intervention. All other environmental factors will be as standard care (e.g., temperature, lighting and sounds).~The heel prick will be performed by a member of the infants designated clinical team who have performed the procedures in a standardised manner according to the institutional and unit policy."
62103481|NCT05039918|NO_INTERVENTION|Control|Infants who are randomised to the control group will receive standard care consistent with neonatal policy. The infant will undergo a heel prick in the incubator or crib in an identical fashion to the infants in the intervention group.
62468331|NCT04507711|EXPERIMENTAL|250 ng/ml|Blood specimen which was added of 10 ul of palonosetron
62664965|NCT04565938|EXPERIMENTAL|one-step self-etch adhesive without enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive without enamel etching
62296362|NCT06381583||Patients with Low-Grade Dysplasia or Long Segment Barrett's Esophagus [Test Cohort]|"Individuals who underwent endoscopy and were found to only have Barrett's Esophagus, with one of the following:~* Craniocaudal maximal extension of 3 cm or more~* Low-grade dysplasia at most, independently of Barrett's segment length"
62468332|NCT04507711|EXPERIMENTAL|2500 ng/ml|Blood specimen which was added of 100 ul of palonosetron
62664966|NCT04565938|EXPERIMENTAL|two-step etch-and-rinse adhesive|Non carious cervical lesions which will receive composite-resin restorations, with a two step etch-and-rinse adhesive
62664967|NCT01851512|EXPERIMENTAL|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
62664968|NCT01851512|EXPERIMENTAL|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
62664969|NCT01888588||Cases|Patients with symptomatic peptic ulcer (UPU)
62664970|NCT01888588||Control group|Control group without symptomatic peptic ulcer (UPU).
62296363|NCT06381583||Individuals Without Esophageal Adenocarcinoma or Barrett's Esophagus [Test Cohort]|Individuals who underwent endoscopy and were found not to have any Barrett's Esophagus or adenocarcinoma.
62296364|NCT06381583||Patients with Esophageal Adenocarcinoma or High-Grade Dysplasia Barrett's Esophagus [Training]|"Individuals who underwent endoscopy and were found to only have one of the following:~* Barrett's Esophagus, with high-grade dysplasia, independently of Barrett's segment length~* Esophageal adenocarcinoma of any stage~* Esophageal adenocarcinoma confined to the mucosa (stage Tis)"
62296365|NCT06381583||Individuals Without Esophageal Adenocarcinoma or Barrett's Esophagus [Training Cohort]|Individuals who underwent endoscopy and were found not to have any Barrett's Esophagus or adenocarcinoma.
62296366|NCT06381583||Patients with Esophageal Adenocarcinoma or High-Grade Dysplasia Barrett's Esophagus [Validation]|"Individuals who underwent endoscopy and were found to only have one of the following:~* Barrett's Esophagus, with high-grade dysplasia, independently of Barrett's segment length~* Esophageal adenocarcinoma of any stage~* Esophageal adenocarcinoma confined to the mucosa (stage Tis)"
62468333|NCT00936169|EXPERIMENTAL|IVUS optimised stent implantation|
62664971|NCT03570424|PLACEBO_COMPARATOR|Placebo|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
62664972|NCT03570424|EXPERIMENTAL|Whey Protein|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
62664973|NCT03570424|EXPERIMENTAL|Whey Protein Hydrolysate|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
62664974|NCT05276453|EXPERIMENTAL|GMove Suit|Participants randomised to a group including normal therapy (physiotherapy) and the use of a lower-limb compression (GMove) Suit. All participants have previously completed normal NHS therapy.
62664975|NCT05276453|ACTIVE_COMPARATOR|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
62103482|NCT02388555||Pre-operative group|Respectively recruited patients with DLS. Patients in this group were not surgically treatment. Only pre-operative radiographic parameters were measured.
62103483|NCT02388555||Surgically treated group|All DLS patients received posterior osteotomy correction of spinal deformity. The immediate post-operative radiographic measurements were performed.
62468334|NCT00936169|ACTIVE_COMPARATOR|angiographically guided DES implantation|
62468335|NCT00532090|EXPERIMENTAL|1|
62468336|NCT00532090|EXPERIMENTAL|2|
62468337|NCT00532090|EXPERIMENTAL|3|
62468338|NCT05004194|EXPERIMENTAL|Cold water caloric stimulation|50 cc of ice-cold water irrigation into the right ear at 1-2 cc/second, once per participant.
62664976|NCT06520059|ACTIVE_COMPARATOR|Intraosseous and intra-articular PRP|Two intraosseous injections of PRP and another intra-articular injection of PRP on the same day.
62664977|NCT06520059|ACTIVE_COMPARATOR|Intra-articular PRP|Patients submited to two intra-articular injections of PRP, separated by one week.
62664978|NCT02214732|EXPERIMENTAL|MBCT + Treatment as Usual (TAU)|"Behavioural: Mindfulness Based Cognitive Therapy~Participants in the MBCT group attend an 8 week course of a modified MBCT program for pregnant women, delivered by a licensed clinical psychologist."
62103484|NCT02180113|OTHER|Fibroscan®|Fibroscan® is an active non implantable medical device using ultrasound. It has been designed to measure liver stiffness in a painless, rapid and non invasive manner. It is a diagnostic aid tool. In this study, Spleen Stiffness Measurement will be assessed using a dedicated FibroScan® device which has been developed specifically to assess spleen stiffness.
62103485|NCT02874261|EXPERIMENTAL|Whole Body Periodic Acceleration|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation is 120 cycles/minute; cpm) as well as a distance traveled 16 mm."
62103486|NCT05203913|EXPERIMENTAL|Experimental arm|This arm consists in treatment with cisplatin + nab-paclitaxel + nivolumab during radiotherapy on bladder followed by nivolumab alone after the end of radiotherapy
62103487|NCT06701331|PLACEBO_COMPARATOR|Placebo / Upadacitinib + Topical Corticosteroids (TCS)|Participants will receive placebo orally once a day (QD) in combination with TCS for 12 weeks in the double-blind treatment period. At Week 12 participants will then be switched to receive open-label upadacitinib daily adult equivalent dose in combination with TCS.
62103488|NCT06701331|EXPERIMENTAL|Upadacitinib + Topical Corticosteroids (TCS)|Participants will be randomized to receive the upadacitinib daily adult equivalent dose in combination with TCS once a day (QD) during the double-blind and open label treatment periods for a total of 52 weeks
62103489|NCT02622230|EXPERIMENTAL|Mianhuahua Flavonoids Tablets|Mianhuahua Flavonoids Tablets, oral administration
62103490|NCT02622230|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration
62103491|NCT06055907||NOR+ARG|Critically ill patients receiving norepinephrine and argipressin, with antithrombotic prophylaxis with 5000 IU of dalteparin.
62468339|NCT00929929|EXPERIMENTAL|L-Leucine|This arm receives a supplement of leucine along with a progressive resistance exercise program.
62468340|NCT00929929|PLACEBO_COMPARATOR|Maltodextrin|This arm receives a supplement of maltodextrin along with a progressive resistance exercise program.
62664979|NCT02214732|NO_INTERVENTION|Treatment as Usual (TAU)|Participants in the TAU group access community resources for pregnant women experiencing psychological distress.
62103492|NCT06055907||NOR|Critically ill patients receiving norepinephrine alone, with antithrombotic prophylaxis with 5000 IU of dalteparin.
62296367|NCT06381583||Patients with Low-Grade Dysplasia or Long Segment Barrett's Esophagus [ValidationCohort]|"Individuals who underwent endoscopy and were found to only have Barrett's Esophagus, with one of the following:~* Craniocaudal maximal extension of 3 cm or more~* Low-grade dysplasia at most, independently of Barrett's segment length"
61912280|NCT04572555|EXPERIMENTAL|Heat Treatment Group|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak. The subjects were instructed on the application of the thermophores. Thermoforming was applied wrapped in towels in order to shield the subjects from the effects of direct heat. In a study, heat packs that had a temperature of 38.9 °C were used for treatment of dysmenorrhea. In this study, the temperature of the water used in the thermoforming process was 45 °C. Considering the risk of the thermophores cooling down and the shielding provided by the towels, the water temperature was kept higher compared to those in other studies. The temperature of the water was measured using a liquid thermometer. Heat treatment was applied for 20 minutes without interruptions.
61912281|NCT04572555|NO_INTERVENTION|Control Group|No Intervention
61912282|NCT01129583|EXPERIMENTAL|Botulinum Toxin|100 U injected into biceps, 100 U into brachialis
61912283|NCT01129583|PLACEBO_COMPARATOR|Saline|100 U injected into biceps, 100 U into brachialis
62468341|NCT05391685|EXPERIMENTAL|therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only
62468342|NCT05391685|EXPERIMENTAL|therapeutic ultrasound+scar release techniques|Study group will be treated by various scar release techniques in addition to therapeutic ultrasound
62664980|NCT01053468|EXPERIMENTAL|PA Behavior Intervention|Physical Activity Resource Kit
62664981|NCT01053468|ACTIVE_COMPARATOR|Standard Materials|Receive physical activity handout from the Canadian Public Health Agency
62664982|NCT06053229|EXPERIMENTAL|Massage|Subjects will receive a daily 30 minute percussive massage treatment on the knee extensor muscles twice per day during the 10 day immobilization period
62664983|NCT06053229|SHAM_COMPARATOR|Control|This group will lie on the bed for a total of 30 minutes, but receive no massage
62664984|NCT02482844|OTHER|Pacemaker|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (\> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
62296368|NCT06381583||Individuals Without Esophageal Adenocarcinoma or Barrett's Esophagus [Validation Cohort]|Individuals who underwent endoscopy and were found not to have any Barrett's Esophagus or adenocarcinoma.
62296369|NCT03763786|EXPERIMENTAL|No GnRH antaogonist|Cetrorelix Acetate (NOT given) Daily 0.25mg Subcutaneous injection for 7 days
62664985|NCT02482844|OTHER|holter implantable|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (\> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
62103493|NCT05310929|EXPERIMENTAL|Group N ( nitroglycerine group )|Group N received nitroglycerin intravenous infusion in a concentration of 1 mg/ml, thus 1µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient. The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes.
62103494|NCT05310929|EXPERIMENTAL|Group L (labetalol group)|. Group L received labetalol intravenous infusion in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication was 5 ml/hr. The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes.
62296370|NCT03763786|ACTIVE_COMPARATOR|Standard GnRH antoagonist|Cetrorelix Acetate (control) Daily 0.25mg Subcutaneous injection for 7 days
62296371|NCT03747445||Roux-en-Y gastric bypass patients|severely obese non-diabetic adult female patients scheduled for RYGB
62296372|NCT03747445||Normal weight controls|normal weight healthy non-diabetic adult females
62296373|NCT03747445||Obese controls|Severely obese non-diabetic adult female patients not scheduled for RYGB
62664986|NCT05278091||Patients with CANVAS with genetic confirmation|Patients with CANVAS with genetic confirmation (RFC1 gene mutation)
62664987|NCT05278091||others patients|Patients with axonal neuropathy, autoimmune neuronopathy and anti-MAG neuropathy
62664988|NCT05278091||Healthy controls|Patients without CANVAS or other neuropathy
62103495|NCT02214667|EXPERIMENTAL|DDMI-IGT|Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing (\[DDMI\] one session before release from jail) and integrated group therapy (\[IGT\] 12 community-based sessions over a 2-month period).
62103496|NCT02214667|ACTIVE_COMPARATOR|Usual care|Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
62103497|NCT03795077|NO_INTERVENTION|Control group|Control group followed traditional lectures about professional ethics during 3 months as usual.
62103498|NCT03795077|EXPERIMENTAL|Experimental group|Experimental group followed the programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used. Techniques used: concept maps, glossaries, brainstorming, four corners activity, aquarium, philip 6-6, kahoot, Realm Individual-Process Situation, reduced groups, guided debates, and discussion groups.
62296374|NCT01121289|EXPERIMENTAL|NN1218, formulation A|
62296375|NCT01121289|EXPERIMENTAL|NN1218, formulation B|
62296376|NCT01121289|EXPERIMENTAL|NN1218, formulation B (high)|
62296377|NCT01121289|EXPERIMENTAL|NN1218, formulation C|
62296378|NCT01121289|EXPERIMENTAL|NN1218, formulation D|
62296379|NCT01121289|ACTIVE_COMPARATOR|insulin aspart|
61912284|NCT02298335|EXPERIMENTAL|prednisone|First,full-dose induction period, then protracted tapering period.
62296380|NCT02295202|EXPERIMENTAL|CPAP|CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.
62664989|NCT01609387|EXPERIMENTAL|Gastric Banding new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
62664990|NCT01609387|ACTIVE_COMPARATOR|Gastric Banding current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
62296381|NCT02295202|PLACEBO_COMPARATOR|Placebo|Nasal Strips
62296382|NCT04295590|EXPERIMENTAL|Frequency then Intensity|Training period 1: Frequency comparison Training period 2: Intensity comparison
62296383|NCT04295590|EXPERIMENTAL|Intensity then Frequency|Training period 1: Intensity comparison Training period 2: Frequency comparison
62296384|NCT02507830||Glubran 2 fixation|Mesh fixation with Glubran 2 glue in primary inguinal hernia repair
62296385|NCT02553837|EXPERIMENTAL|Treatment only|Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
62296386|NCT01624584|EXPERIMENTAL|Experimental treatment|6 sessions of anxiety treatment
62664991|NCT01609387|EXPERIMENTAL|RYGB new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients
61912285|NCT05387499|EXPERIMENTAL|Single Ascending Dose Phase|Drug: NP-011 Dosage: 250μg, 500μg, 1000μg, 2000μg, 4000μg Dosage Form: Liquid for IV injection Route of Administration: Intravenous
61912286|NCT05387499|EXPERIMENTAL|Multiple Ascending Dose Phase|Drug: NP-011 Dosage: 1000μg, 2000μg, 4000μg Dosage Form: Liquid for IV injection Route of Administration: Intravenous
61912287|NCT05387499|PLACEBO_COMPARATOR|Placebo|Dosage Form: Liquid for IV injection Route of Administration: Intravenous
61912288|NCT00646932|EXPERIMENTAL|1|
61912289|NCT00646932|EXPERIMENTAL|2|
61912290|NCT00646932|EXPERIMENTAL|3|
62664992|NCT01609387|ACTIVE_COMPARATOR|RYGB current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients)
62664993|NCT01609387|EXPERIMENTAL|Gastric sleeve new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
62103499|NCT04666454|ACTIVE_COMPARATOR|Randomisation 1: Adenosine and Dipyridamole|Adenosine infusion 70 µg/kg/min for 3 hours, followed (first dose 60 minutes apart from the end of the adenosine infusion) by daily oral treatment with the adenosine reuptake inhibitor dipyridamole (200 mg b.i.d.) until normalization of Left Ventricular (LV) function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or at any subsequent echocardiographic examination, or for 30+7 Days.
62103500|NCT04666454|OTHER|Randomisation 1: Control|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology.
62103501|NCT04666454|ACTIVE_COMPARATOR|Randomisation 2: Apixaban|Apixaban 5mg b.i.d. per oral until normalization of LV function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or any subsequent echocardiographic examination, or for 30+7 Days.
62664994|NCT01609387|ACTIVE_COMPARATOR|Gastric sleeve current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
62664995|NCT00119639|EXPERIMENTAL|Arm 1|
62664996|NCT00744198|ACTIVE_COMPARATOR|1|Autologous sling
62664997|NCT00744198|ACTIVE_COMPARATOR|2|Synthetic sling
62664998|NCT00744198|ACTIVE_COMPARATOR|3|Biological sling
62664999|NCT06302036|NO_INTERVENTION|control group|No application will be performed on the participants in the control group, and as in the intervention group, pre-tests (PSI and STAI) will be carried out immediately after the depression risk determination is made (after the BDI application), and post-tests will be carried out after the interviews are completed. All students in the control group will be reminded of their high scores on the depression scale and will be advised to seek medical help.
62665000|NCT06302036|EXPERIMENTAL|experimental group|For applications and information, a computer-assisted zoom program or other online programs that can provide meetings (Google meet, teams program or WhatsApp video call) will be used. The students in the intervention group will be informed about the function and application of EFT, it will be explained practically, and the application steps will be taken. This stage is planned to take approximately 15 minutes.
62665001|NCT05098990|EXPERIMENTAL|Jinfukang oral liquid+Platinum-based doublet chemotherapy|"The usage cycle of Jinfukang oral liquid will be consistent with platinum-based doublet chemotherapy. Jinfukang oral liquid will be taken at day 5 after chemotherapy, and will be taken continuously 3 times per day and 30 mL per time at least 4 cycles. The usage of platinum-based doublet chemotherapy will be performed following the details described at the Primary Lung Cancer Diagnosis and Treatment Guidelines and Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer."
61912291|NCT00646932|EXPERIMENTAL|4|
61912292|NCT03028337|EXPERIMENTAL|Spine Radiosurgery - 1 Dose|Participants receive spine radiosurgery in a single large dose.
61912293|NCT03028337|ACTIVE_COMPARATOR|Spine Radiosurgery - 3 Doses|Participants receive spine radiosurgery over 3 smaller doses.
61912294|NCT03796845|EXPERIMENTAL|No-limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
61912295|NCT03796845|ACTIVE_COMPARATOR|Limited movement after surgery|Participants should move their arms with restricted movements on the first postoperative day, with maximum amplitude of 90º for flexion and abduction of the shoulder, until withdrawal surgical points. Actual hospital's routine.
61912296|NCT02310087|ACTIVE_COMPARATOR|astaxanthin with vitamin E|The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.
62103502|NCT04666454|NO_INTERVENTION|Randomisation 2: No anticoagulant therapy|
62103503|NCT02963142||SCAP requiring ECMO|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require extra-corporeal membrane oxygenation and a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
62296387|NCT01624584|ACTIVE_COMPARATOR|Traditional Treatment|Six sessions of anxiety treatment
62296388|NCT02970773|OTHER|rivaroxaban|Rivaroxaban Oral Tablet
62296389|NCT00212407|EXPERIMENTAL|Umbilical cord blood unit(s) transplant|Transplantation of cryopreserved umbilical cord blood unit(s)
62665002|NCT05098990|ACTIVE_COMPARATOR|Platinum-based doublet chemotherapy|"The usage of platinum-based doublet chemotherapy will be performed following the details described at the Primary Lung Cancer Diagnosis and Treatment Guidelines and Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer."
61912297|NCT02310087|PLACEBO_COMPARATOR|placebo|The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.
61912298|NCT02645838|EXPERIMENTAL|Motivational interviewing group|"1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician~2. Follow-up telephone call，provided by family physician"
62296390|NCT05736263|EXPERIMENTAL|Moderate intensity exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform moderate-intensity aerobic exercise
62665003|NCT01980576||Pre-operative pain measurement|Patients with low back pain
62103504|NCT02963142||SCAP requiring ITU support|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require intensive care support and undergo a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
62665004|NCT05297838|ACTIVE_COMPARATOR|Ice Bath then VR and Bike During Ice Bath (Ice Bath vs VR Bike)|"Participants will immerse hand in ice bath and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~After a washout period of 5 minutes, patients will immerse hand in ice bath keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset.Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~This occurred for both dominant and non-dominant hand. Randomization of dominant and non-dominant hands to the study conditions occurred prior to initiating the intervention."
62665005|NCT05297838|ACTIVE_COMPARATOR|VR with Ice Bath then Bike with VR During Ice Bath (VR vs VR Bike)|"Patients will immerse hand in ice bath keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset.Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~After a washout period of 5 minutes, Participants will immerse hand in ice bath while utilizing stationary bike and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~This occurred for both dominant and non-dominant hand. Randomization of dominant and non-dominant hands to the study conditions occurred prior to initiating the intervention."
61912299|NCT02645838|NO_INTERVENTION|Brief advice group|Brief advice without motivational interviewing (about 5 mins), provided by family physician
61912300|NCT03907618||Group 1 diagnosed with Diabetes Mellitus|Patients with Type 1 Diabetes Mellitus aged 18-40 years who had ovarian reserve with gynecological examination
61912301|NCT03907618||group 2 control group|Healthy volunteer patients aged 18-40 years who have no diagnosis of Type 1 Diabetes Mellitus and whose ovarian reserve is evaluated by gynecological examination
61912302|NCT03991546|EXPERIMENTAL|Acceptance and Commitment Therapy|Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy.
61912303|NCT03991546|NO_INTERVENTION|Control group|Subjects randomizing into this arm did not receive the text message study intervention.
61912304|NCT06065111||study tendon damage in osteogenesis imperfecta patients|The study will be conducted in three centers: Brussels (30 patients, clinique Saint-Luc, Lille (30 patients) and Paris (50 patients). Patients will be recruited regardless of their form of osteogenesis imperfecta.
61912305|NCT03856268||ARM 1: 'Surgical Menopause' Group|Premenopausal women having an oophorectomy.
61912306|NCT03856268||"ARM 2: Drug-Induced Menopause'"|Premenopausal women with gonadal suppression
62665006|NCT02927145|ACTIVE_COMPARATOR|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
62665007|NCT02927145|ACTIVE_COMPARATOR|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
62665008|NCT02927145|ACTIVE_COMPARATOR|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
62665009|NCT02927145|ACTIVE_COMPARATOR|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
62665010|NCT02927145|ACTIVE_COMPARATOR|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
62665011|NCT02927145|NO_INTERVENTION|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
62665012|NCT02927145|ACTIVE_COMPARATOR|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
61912307|NCT03856268||'Comparative (Control)' Group|Premenopausal women with regular cycles.
61912308|NCT01981057||Numeta|parenteral receipt prescribed with Numeta
62665013|NCT02927145|NO_INTERVENTION|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
62665014|NCT02927145|NO_INTERVENTION|Group 9 -Phase IIa|Group 9 are new infectivity controls
61912309|NCT01981057||Individual|individually prescribed parenteral receipt
61912310|NCT02299778|EXPERIMENTAL|1mg of 13C6-p-aminobenzoic acid|
62103505|NCT02963142||Healthy controls|"Healthy volunteers who undergo bronchoscopy as part of a designated research bronchoscopy list.~Molecular laboratory techniques will be applied to bronchoalveolar lavage samples."
62296391|NCT05736263|EXPERIMENTAL|High intensity interval exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform High intensity interval exercise
62665015|NCT04077398|EXPERIMENTAL|low volume High concentration group|1.Low Volume: 30 subjects randomized to Low Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,75% ropivacaine x 15 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age \<70, max dose 20 mcg for age \>70) + dexamethasone 4 mg
61912311|NCT03176017|ACTIVE_COMPARATOR|Ejaculatory sparing TUIP|Ejaculatory sparing TUIP
61912312|NCT03176017|PLACEBO_COMPARATOR|Conventional TUIP|regular non ejaculatory sparing TUIP
61912313|NCT03928093|EXPERIMENTAL|Pregabalin followed by placebo|The study has a crossover design. Participants in this arm will receive pregabalin during the first study treatment period for ten weeks and placebo during their second ten-week treatment period . The dose will depend on the participant's weight and phase of treatment period. Each treatment period consists of 4 weeks of escalating dose until the desired maximum , 4 weeks of active treatment and 2 weeks of titrating down.
62103506|NCT02774252|EXPERIMENTAL|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62103507|NCT04457141|OTHER|first:shod ,second:minimalist shoes|"The first group will race with conventional shoes and then minimalist shoes. The group run 5 minutes for warming and then 30 seconds at 6km/h, 30 seconds at 9 km/h and 30 seconds at 11km/h.~They have a washout period of 10 minutes between both interventions."
62296392|NCT05736263|EXPERIMENTAL|Combined exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform combined exercise
62665016|NCT04077398|EXPERIMENTAL|high volume low concentration|2.High Volume: 30 subjects randomized to High Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,375% ropivacaine x 30 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age \<70, max dose 20 mcg for age \>70) + dexamethasone 4 mg
62665017|NCT04339972|EXPERIMENTAL|Active LIFUP then Sham LIFUP|Real LIFUP is delivered to the participant for visit 1, followed by sham lifup visit 2
62665018|NCT04339972|SHAM_COMPARATOR|Sham LIFUP then Active LIFUP|Sham LIFUP is delivered to the participant for visit 1, followed by real lifup visit 2
62665019|NCT02587286|EXPERIMENTAL|Gather app|Use of the Gather mHealth diabetes management system
62665020|NCT02587286|NO_INTERVENTION|Control|Control group participants will be recruited from the same clinics and will also fit all study inclusion and exclusion criteria. Participants will be recommended to test their BG as per usual care in India. Providers will not contact control group participants between regular visits, though they will respond to queries directed at them in typical fashion.
62665021|NCT04441398|EXPERIMENTAL|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
62665022|NCT04441398|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo TID.
62665023|NCT04413851||Dementia|Subjects with a diagnosis of dementia who are experiencing agitation severe enough that it interferes with activities of daily living or social interaction.
62665024|NCT00062504|EXPERIMENTAL|1|Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
62665025|NCT00062504|EXPERIMENTAL|2|Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
62665026|NCT00062504|EXPERIMENTAL|3|Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
62665027|NCT03387046|EXPERIMENTAL|D-aspartate + IFN beta-1a + Methylprednisolone|Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
62665028|NCT03387046|PLACEBO_COMPARATOR|Placebo + IFN beta-1a + Methylprednisolone|Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
61912314|NCT03928093|EXPERIMENTAL|Placebo followed by Pregabalin|Participants will receive placebo during the first treatment period of the study(10 weeks) followed by 10 weeks of pregabalin treatment . The dose will depend on the participant's weight and phase of the treatment period . Each treatment period consists of 3 phases: 4 weeks of escalating dose until the desired maximum, 4 weeks of active treatment and 2 weeks of titrating down.
62296393|NCT05736263|EXPERIMENTAL|Resistance exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform resistance exercise
62296394|NCT05626088||Retrospective Cohort|Participants diagnosed with UC or CD with prescription of vedolizumab, and were included in the PSP program (which has started in 2016) before the study starts will be observed retrospectively in this study.
62296395|NCT05626088||Prospective Cohort|Participants diagnosed with UC or CD with prescription of vedolizumab, and have participation in PSP after the study start will be observed prospectively in this study.
62296396|NCT02180009||normal control|healthy people
62665029|NCT04713995|OTHER|All Study Participants|"Enrolled with: AxSpA diagnosis, HLA-B27 positive, mASDAS \> or = 1.3 and HLA-B27 positive. Will complete surveys online or on an app, about mental and physical health and how they are doing, submits and collection of samples (blood, stool, saliva, urine, fasting blood test at local lab). Receives results of some of the analysis of samples. Participants that qualify and complete the first set of samples can be eligible for the 3 and 6 month longitudinal follow-up collection kits.~All participants receive dietary recommendations based on samples collected and the analysis of the microbiome."
62665030|NCT03543774|ACTIVE_COMPARATOR|simvastatin treatment|
62665031|NCT03543774|SHAM_COMPARATOR|EZE/simvastatin 10/20 mg treatment|
62665032|NCT03543774|SHAM_COMPARATOR|EZE/simvastatin 10/40 mg treatment|
62665033|NCT05875480|EXPERIMENTAL|synchronized telerehabilitation group|Patients in the synchronized telerehabilitation group had taken real time videoconferencing rehabilitation by physiotherapist 2 times a week, during 4 weeks.
62665034|NCT05875480|EXPERIMENTAL|asynchronized telerehabilitation group|Patients in the asynchronized telerehabilitation group had done the postoperative rehabilitation with exercise videos via application.
61912315|NCT02776319|EXPERIMENTAL|Active|Non-invasive brain stimulation (active)
61912316|NCT02776319|PLACEBO_COMPARATOR|Sham/Placebo|Non-invasive brain stimulation (sham)
61912317|NCT05394493||patients with advanced renal cell carcinoma|
62103508|NCT04457141|OTHER|first:minimalist shoes ,second:shod|"The second group will race with minimalist shoes and then conventional shoes. The group run 5 minutes for warming and then 30 seconds at 6km/h, 30 seconds at 9km/h and 30 seconds at 11km/h.~They have a washout period of 10 minutes between both interventions."
62103509|NCT00635817|EXPERIMENTAL|Leuprolide acetate 11.25 mg|There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
62103510|NCT00635817|EXPERIMENTAL|Leuprolide acetate 30 mg|There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
62103511|NCT05621798|ACTIVE_COMPARATOR|Hearing Aid Manufacturer's Software Group|Participants' hearing aids are fitted by using manufacturer's software.
62103512|NCT05621798|ACTIVE_COMPARATOR|REM Group|Participants' hearing aids are fitted by REM (Real Ear Measurements) method.
62103513|NCT01644162|OTHER|iVAPS ventilation|3 months of ventilator use in iVAPS mode with data monitoring
62103514|NCT04531514|EXPERIMENTAL|Sensitivity to phonological rules & referents OR: Toddlers|OR condition
62103515|NCT04531514|EXPERIMENTAL|Sensitivity to phonological rules & referents FR: Toddlers|Family Resemblance condition
62103516|NCT06631066|NO_INTERVENTION|neoadjuvant chemotherapy arm|"The patients in this arm will recieve neoadjuvant chemotherapy (with anti-her2 agents if indicated) according to the national guidelines.~post systemic treatment imaging will be done to assess the response, followed by surgery as indicated.~Adjuvant radiotherapy as well as hormonal or target therapy will be prescribed as indicated.~Radiation therapy will be delivered in hypofractionated course (40.05 Gray over 15 fractions with boost to tumor bed 10 Gray over four fractions) to the breast/ chestwall as well as regional lymphatics."
62103517|NCT06631066|EXPERIMENTAL|Neoadjuvant chemoradiation arm|The patients in this arm will recieve neoadjuvant chemotherapy with preoperative radiotherapy concurrently with taxanes. Surgery is done 6-8 weeks as indicated, followed by systemic treatment according to the guidelines.
62103518|NCT03873324|EXPERIMENTAL|CPL500036|"PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
62103519|NCT03873324|PLACEBO_COMPARATOR|Placebo|PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
62103520|NCT01385280|EXPERIMENTAL|Arm I|Patients receive oral therapeutic estradiol once daily on days 1-3, twice daily on days 4-7, and thrice daily on days 8-90. Beginning on day 98, patients receive oral exemestane once daily in the absence of disease progression or unacceptable toxicity. Also laboratory biomarker analysis and enzyme-linked immunosorbent assay will be taken for correlative studies.
62296397|NCT02180009||sepsis|mild response to infection
62296398|NCT02180009||severe sepsis|infection with at least one organ dysfunction
62296399|NCT02180009||septic shock|patients with septic shock
62296400|NCT02485717|EXPERIMENTAL|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
62665035|NCT05875480|ACTIVE_COMPARATOR|supervized conventional rehabilitation group|Patients in the supervised physiotherapy group had taken their rehabilitation sessions in the physiotherapy department of the hospital twice a week, during 4 weeks.
62665036|NCT00222274|EXPERIMENTAL|1|RSA Biofeedback: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J\&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
62665037|NCT00222274|ACTIVE_COMPARATOR|2|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J\&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
61912318|NCT01642628|EXPERIMENTAL|Body Image/Mirror Education|Participants in the mirror arm will receive a mirror and mirror viewing education from oncology nurse navigators.
62103521|NCT02573740|EXPERIMENTAL|ABT-957|ABT-957 given twice a day for 84 days
62103522|NCT02573740|PLACEBO_COMPARATOR|Placebo|Placebo given twice a day for 84 days
62103523|NCT04320264||Low oxidizers/high lactate|Individuals with low aerobic oxidation
62103524|NCT04320264||High oxidizers/low lactate|Individuals with high aerobic oxidation
62103525|NCT04320264||Obese|Severely obese scheduled for surgery
62103526|NCT06713343|ACTIVE_COMPARATOR|Group L|Patients in Group L will be ventilated with a classical laryngeal mask (cLMA) stored at 10 °C to 12 °C (low temperatures)
62103527|NCT06713343|ACTIVE_COMPARATOR|Group R|Patients in Group R will be ventilated with a classical laryngeal mask (cLMA) stored at 22 °C to 25 °C (room temperatures)
62103528|NCT05641896|EXPERIMENTAL|[18F]FAPI-74 PET/CT|Patients receive \[18F\]FAPI-74 intravenously followed by PET/CT 60 minutes (+/-10minutes) later
62103529|NCT03293264|EXPERIMENTAL|Exercise training group|The intervention group will be encouraged to perform 150 min of exercise training per week for 6 months. Subjects will be provided with individual feedback and exercise Training prescriptions. After month 6 subjects will be randomized to three different groups for follow-up observation.
62103530|NCT03293264|NO_INTERVENTION|Waiting-control group|The control group will be provided with general informations on a healthy lifestyle. After 6 months wait-list-control months subjects will receive the guided exercise training intervention for 6 months.
62103531|NCT02943655|ACTIVE_COMPARATOR|combined oral contraceptives|oral second generation pills one tablet daily
62296401|NCT02485717|PLACEBO_COMPARATOR|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
62468343|NCT03375853|ACTIVE_COMPARATOR|Control Condition|Participants will complete computer based response training tasks that will incorporate pictures of birds, flowers, and mammals. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the experimental condition, only the appearance and context of the stimuli will be different (i.e., non-food versus food items). The computer tasks described above comprise the Generic Response Training Control Intervention.
62665038|NCT06374290|EXPERIMENTAL|Treatment|
62665039|NCT05639595|EXPERIMENTAL|Intervention|The designated health center staff will receive a web interface that will allow them to offer job aid for supervision, including real-time information about VHSGs' performance in the form of process indicators and coverage of MCH services. The tool will also support health center staff in their daily tasks, such as high-risk patient tracking, low-supply-inventory alerts, supply chain management, electronic health records, vital events tracking, and automatic calculation of performance-based incentives and motivation for VHSGs. The mobile application will be offered to two female VHSGs from each of the 200 villages connected to their respective health centers in the intervention arm. The mobile application will provide job aid to VHSGs for scheduling home visit tasks, including ANC, home-based newborn care, reporting outcomes of pregnancies, and follow-up visits of complicated cases.
61912319|NCT01642628|NO_INTERVENTION|Standard Care|Patients allocated to the control group will receive the usual pre and post-op standard care that does not include the use or discussion of mirrors.
61912320|NCT03956043||Patients with suspected sepsis in Emergency Department|Patients with suspected sepsis treated by the sepsis emergency team or the medical emergency team in the Emergency Department of Oslo University Hospital Oslo are included prospectively.
62103532|NCT02943655|ACTIVE_COMPARATOR|medroxyprogesterone acetate|oral 5 mg daily
62103533|NCT02943655|ACTIVE_COMPARATOR|non-steroidal anti-inflammatory|oral 500 mg mefenamic acid three times per day
62103534|NCT05133362|ACTIVE_COMPARATOR|Standard Care with Ekso Group|Participants in the SCG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. For each participant, an individualized plan of care consistent with evidence-based practice standards will be provided based on rehabilitation goals. The interventions during each treatment session will include forward gait training with EksoNR, neuromuscular movement-related tasks, mobility tasks, and interventions using products and technology, and education for caregivers, family, and friends.
62296402|NCT01296906|EXPERIMENTAL|Population-based Reminder/Recall|Recall is performed centrally by public health departments for all children in need of immunizations in a geographic area.
62296403|NCT01296906|EXPERIMENTAL|Practice-based Reminder/Recall|Reminder/Recall is performed by individual private practices for their patients who appear in need of immunizations.
62296404|NCT05844917|EXPERIMENTAL|50 character|
62665040|NCT05639595|NO_INTERVENTION|Control|All villages under the health center's catchment areas in the control arm will continue to receive the MCH standard care provided by the government and other local and international non-governmental organizations (NGOs) and facilitated by VHSGs. VHSGs in both intervention and control arms will receive refresher training on maternal, neonatal, and childcare to avoid ethical issues that may arise and to ensure that change in outcomes in the intervention arm is due only to i-MoMCARE, but not the VHSGs MCH training.
61912321|NCT05306821|EXPERIMENTAL|Implementation of an electronic tool for risk stratification and thromboprophylaxis prescription|
61912322|NCT05306821|EXPERIMENTAL|Implementation of educative sessions and pocket cards for thromboprophylaxis|
62665041|NCT02927626|EXPERIMENTAL|Yang Yin Fu Zheng therapy|
62665042|NCT02927626|PLACEBO_COMPARATOR|Routine medical care|
62665043|NCT06523790|EXPERIMENTAL|Yoga Group|Participants in this group will undergo 90-minute yoga sessions, 3 times per week, for 8 months. The yoga intervention includes a combination of asanas (postures), pranayama (breathing exercises), and meditation designed to improve flexibility, strength, and mental well-being.
62665044|NCT06523790|EXPERIMENTAL|Walking Group|Participants in this group will engage in one-hour fast-paced walking sessions, 6 times per week, for 8 months. The walking intervention is designed to improve cardiovascular fitness, endurance, and support weight loss.
62665045|NCT06430060|EXPERIMENTAL|Colgate Dual Zinc Toothpaste|toothpaste
62665046|NCT06430060|ACTIVE_COMPARATOR|Colgate Cavity Protection Toothpaste|toothpaste
62665047|NCT01146353||CRRT Patients receiving Peramivir|"Eligible patients are male or female patients ≥18 years of age who are hospitalized, undergoing CVVH or CVVHD, and receiving peramivir.~Eligible patients will additionally have the following: blood flow rate will be required to be ≥100 mL/ min with an ultrafiltrate +/- dialysis flow rate greater than or equal to 3000mL/hr, and the continuous renal replacement therapy must be scheduled to run for the full duration of the dosing interval (full 24 hours).~Written informed consent in a form approved by the Northwestern University and the Midwestern University Institutional Review Boards will be granted by the patient."
62665048|NCT01639521|EXPERIMENTAL|Arm A (gemcitabine hydrochloride, cisplatin)|Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62103535|NCT05133362|EXPERIMENTAL|Standard Care with Ekso and Backward Walking Group|Participants in the SCBWG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. Once a week, each participant will receive standard care as described in the standard care with Ekso group.Once a week, each participant will receive backward walking training with EksoNR during their treatment session.
62665049|NCT01639521|EXPERIMENTAL|Arm B (MVAC)|Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62665050|NCT04002271|ACTIVE_COMPARATOR|Group SA|Patients in Group SA will undergo spinal anaesthesia.
62665051|NCT04002271|ACTIVE_COMPARATOR|Group GAS|Patients in Group GAS will undergo general inhalational anaesthesia using sevoflurane.
62665052|NCT04002271|EXPERIMENTAL|Group TIVA|Patients in Group TIVA will undergo general anaesthesia using propofol total intravenous anaesthesia.
62665053|NCT04822415|EXPERIMENTAL|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
62665054|NCT04822415|ACTIVE_COMPARATOR|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
62103536|NCT05048355|EXPERIMENTAL|Power Knee Mainstream Dynamic|Users are measured using their prescribed microprocessor knee and after wearing the Power Knee Mainstream dynamic for the adaptation period, they are measured again.
62665055|NCT04163380|EXPERIMENTAL|Early Follicular Phase (EFP)|
62665056|NCT04163380|EXPERIMENTAL|Late Follicular Phase (LFP)|
62665057|NCT04163380|EXPERIMENTAL|Early Luteal Phase (ELP)|
62665058|NCT04163380|EXPERIMENTAL|Late Luteal Phase (LLP)|
62665059|NCT03526146|EXPERIMENTAL|PLIE|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
62665060|NCT03526146|NO_INTERVENTION|Usua Care|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the senior center, which include a combination of daily physical, mental and social activities.
62665061|NCT00429299|ACTIVE_COMPARATOR|Arm A|Chemotherapy plus trastuzumab
61912323|NCT05849961||Prospective Subjects|Enrolled in the study pre-surgery. Subjects who agree to participate in the study that have not had surgery prior to being enrolled in the study.
61912324|NCT05849961||Retrospective to Prospective|Subjects enrolled in the study post- surgery then continue to participate in the study prospectively. Subjects who agree to participate in the study that have undergone surgery prior to enrollment in the study. Data for these subjects will collected from the subject's medical record for the time period prior to enrollment in the study containing data pertaining to the index surgery (retrospective data) and from the patient after they are enrolled in the study during the post-operative time period (prospectively).
62665062|NCT00429299|EXPERIMENTAL|Arm B|Chemotherapy plus lapatinib
62665063|NCT00429299|ACTIVE_COMPARATOR|Arm C|Chemotherapy plus trastuzumab plus lapatinib
62665064|NCT00848185||Antagonist-hCG for triggering|Protocol with antagonist and hCG to trigger oocyte maturation
62665065|NCT00848185||Antagonist-aGnRH for triggering|Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
62665066|NCT00848185||Long protocol-hCG for triggering|Long Protocol and hCG to trigger oocyte maturation
62665067|NCT02109224|EXPERIMENTAL|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62665068|NCT05909423|EXPERIMENTAL|Treatment arm|Intratumoral flu vaccine treatment Systemic single dose pembrolizumab treatment
62665069|NCT00552162|ACTIVE_COMPARATOR|1|NOTES Transvaginal cholecystectomy The gallbladder will be dissected free and will be removed through an incision in the vagina.
62665070|NCT00552162|ACTIVE_COMPARATOR|2|NOTES Transvaginal Appendectomy. The appendix will be dissected free and will be removed through an incision in the vagina.
62665071|NCT02428647|ACTIVE_COMPARATOR|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
62296405|NCT05119387||Individuals diagnosed with ALS|Individuals diagnosed with ALS that are being followed through the Norwegian health-care system. ALS patients ( probable or definite per El-Escorial criteria)
62665072|NCT02428647|PLACEBO_COMPARATOR|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
62665073|NCT02428647|ACTIVE_COMPARATOR|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
62665074|NCT02428647|ACTIVE_COMPARATOR|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
62665075|NCT05791084|NO_INTERVENTION|A=Control group who receives customary information prior to RT with DIBH.|Usual care and information before start of radiotherapy with DIBH.
61912325|NCT05849961||Retrospective Only Subjects|Subjects enrolled in the study post-study surgery with no intent to continue as prospective subjects. Patient's clinical record includes a signed HIPAA waiver allowing for the use of clinical record data for the purpose of clinical research outside of the operating institution.
61912326|NCT02723045|ACTIVE_COMPARATOR|Open modified Lichtenstein repair|Patients will undergo open repair of their inguinal hernias
61912327|NCT02723045|ACTIVE_COMPARATOR|Laparoscopic TEP inguinal hernia repair|Patients will undergo laparoscopic repair of their inguinal hernias
62665076|NCT05791084|EXPERIMENTAL|B=Intervention group usual care and the DIBH-App to practice at-home before RT with DIBH.|Usual care and information and a mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.
61912328|NCT03726996|EXPERIMENTAL|Children with INAD|Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
61912329|NCT05757232||Breast cancers cases diagnosed with tomosynthesis and ultrasound|
62665077|NCT01483651|EXPERIMENTAL|Low, Medium and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
61912330|NCT05757232||Brest cancers cases diagnosed with mammography and ultrasound|
62103537|NCT01102322||1|
62103538|NCT05471232||Enrollees|These participants will be subject to whole genome sequencing to identify genetic changes and a EHR-Based network model to predict psychiatric outcomes in youth with IDDs.
62103539|NCT05471232||Historical Control Group|A historical control group from public databases will be used to compare against enrollees.
62103540|NCT00598013|EXPERIMENTAL|1|
62665078|NCT01483651|EXPERIMENTAL|Low, High and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
61912331|NCT05062395||Observational (diet, FDG PET CT)|Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive FDG then undergo PET CT.
61912332|NCT02619773|EXPERIMENTAL|Mupirocin dressing|"Mupirocin + island dressing applied to surgical incision until postoperative day 5.~Intervention: mupirocin ointment applied to extrication incision."
61912333|NCT02619773|NO_INTERVENTION|Island dressing|Island dressing applied to surgical incision until postoperative day 2. This arm will not undergo any intervention.
61912334|NCT06129513|ACTIVE_COMPARATOR|Whey protein isolate|Following a bout of bilateral resistance exercise, participants will ingest 32 g protein from whey protein isolate
61912335|NCT06129513|EXPERIMENTAL|Plant-blend isolate|Following a bout of bilateral resistance exercise, participants will ingest 32 g protein from a novel plant-blend protein isolate
62103541|NCT00598013|NO_INTERVENTION|2|
62103542|NCT05822609|EXPERIMENTAL|Semaglutide|Semaglutide group from 0.25mg to 1.0mg
62103543|NCT05822609|PLACEBO_COMPARATOR|Placebo|Placebo group
62103544|NCT02647749|EXPERIMENTAL|Group 1 : Cardiac rythm radiofrequency ablation|Prospective recruitment
62103545|NCT02647749|EXPERIMENTAL|Group 1: Implantation or programming of a pacemaker|Prospective recruitment
62103546|NCT02647749|EXPERIMENTAL|Group 1: Risk of serious arrhythmias or sudden death|Prospective recruitment
62103547|NCT02647749|ACTIVE_COMPARATOR|Group 2: Cardiac rythm radiofrequency ablation|Retrospective recruitment
62103548|NCT02647749|ACTIVE_COMPARATOR|Group 2 : Implantation or programming of a pacemaker|Retrospective recruitment
62296406|NCT02065089|EXPERIMENTAL|playing the ipad quiz game|There will only be one arm--any patient who consents to participate in the intervention (playing the ipad quiz game)
62296407|NCT00878124|EXPERIMENTAL|CoQ10|Coenzyme Q10 co-treatment
62296408|NCT00878124|PLACEBO_COMPARATOR|Placebo control|Placebo Co-treatment
62296409|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.~Consultation of the patient's medical files at the hospital."
62665079|NCT01483651|EXPERIMENTAL|Medium, Low and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
62665080|NCT01483651|EXPERIMENTAL|Medium, High and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
62665081|NCT01483651|EXPERIMENTAL|High, Low and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
62103549|NCT02647749|ACTIVE_COMPARATOR|Group 2 : Risk of serious arrhythmias or sudden death|Retrospective recruitment
62103550|NCT05014555||Group A Non-biologic Group|Participants on treatment regimen of mesalamine monotherapy or thiopurine monotherapy, or corticosteroids.
62103551|NCT05014555||Group B Anti-TNF Group|Participants on treatment regimen of maintenance montherapy of infliximab (at least 8 every 8 weeks), golilumamb (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly), or combination therapy of anti-TNF therapy as described above along with either 15mg of methotrexate or azathiprine at least 1.0mg/kg or 6MP 0.5mg/kg.
62103552|NCT05014555||Group C Ustekinumab Group|Participants on treatment regimen of ustekinumab monotherapy or combination therapy with methotrexate or azathioprine.
62103553|NCT05014555||Group D Vedolizumab Group|Participants on vedolizumab monotherapy or combination therapy with methotrexate or azathioprine.
62103554|NCT02612584|EXPERIMENTAL|Pinhole soft contact lens|
62103555|NCT01450943|ACTIVE_COMPARATOR|Standard of care|debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape
62296410|NCT03277196|EXPERIMENTAL|Ivacaftor Arm|"Participants less than (\<) 24 months of age and weighing 5 to less than (\<) 7 kilogram (kg) received 25 mg IVA every 12 hours (q12h), 7 to \<14 kg received 50 mg IVA q12h, and those weighing 14 to \<25 kg received 75 mg IVA q12h.~Participants more than or equal (\>=) 24 months of age and weighing \<14 kg received 50 mg IVA q12h, and those weighing more than or equal to (\>=)14 kg received 75 mg IVA q12h in the treatment period for up to 96 weeks.~Doses were determined based on safety and pharmacokinetic (PK) data from parent study, age and weight."
62103556|NCT01450943|EXPERIMENTAL|Dermagraft|debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
62103557|NCT01450943|EXPERIMENTAL|Oasis|debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
62296411|NCT03277196|NO_INTERVENTION|Observational Arm|
62103558|NCT03372733|EXPERIMENTAL|Group 1|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2weeks and cross-over to the palmitoleate-rich oil
62296412|NCT02623179|ACTIVE_COMPARATOR|A-Culture and Sensitivity group|Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
62296413|NCT02623179|ACTIVE_COMPARATOR|B-Diagnosis by Molecular Testing|Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
62296414|NCT03232541|OTHER|Standard care (A)|Standard antiemetic treatment (A) with neutral communication (A1) or positive communication (A2)
62103559|NCT03372733|EXPERIMENTAL|Group 2|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the control olive oil
62103560|NCT03241888|ACTIVE_COMPARATOR|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62296415|NCT03232541|PLACEBO_COMPARATOR|Sham acupuncture (B)|Standard antiemetic treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
62296416|NCT03232541|EXPERIMENTAL|Genuine acupuncture (C)|Standard antiemetic treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
62296417|NCT03088514|EXPERIMENTAL|NITRATE-LVH intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months
62665082|NCT01483651|EXPERIMENTAL|High, Medium and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
62665083|NCT03685513|ACTIVE_COMPARATOR|Metal ceramic single posterior crowns|Metal copings veneered with feldspathic porcelain
62665084|NCT03685513|EXPERIMENTAL|BioHPP PEEK-based single posterior crowns|BioHPP PEEK copings veneered with composite resin
62665085|NCT01696253||Subjects at risk for Alport sydrome|
62103561|NCT03241888|ACTIVE_COMPARATOR|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62665086|NCT01696253||Newly identified subjects with Alport syndrome|
62665087|NCT04675476|EXPERIMENTAL|Multilevel Intervention|
62665088|NCT04675476|NO_INTERVENTION|Nonequivalent Control Group|
62103562|NCT03241888|EXPERIMENTAL|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62665089|NCT05737147||100 adult patients of both genders scheduled for cardiac surgery|100 adult patients of both genders scheduled for cardiac surgery with CPB for either coronary artery bypass grafting (CABG), aortic valve replacement (AVR), mitral valve replacement (MVR) or CABG + AVR.
62665090|NCT05383703|EXPERIMENTAL|Treatment of MNC-168 enteric-coated capsules as a single oral drug|Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. The dosage increased in different stages. Each phase was administered once a day for three weeks.
62296418|NCT03088514|PLACEBO_COMPARATOR|NITRATE-LVH placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
62665091|NCT04656119||patients without irAEs or patients with good efficacy|
62665092|NCT04656119||patients with irAEs or patients with poor efficacy|
62665093|NCT04894240|EXPERIMENTAL|Monepantel treatment arm|Monepantel tablets will be administered to participants in this arm daily for 28 days. Dose escalation will occur at the end of each 28 day period according to a modified Fibonacci sequence based upon recommendations from the safety management committee
62665094|NCT01665027|EXPERIMENTAL|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head. He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers).
62665095|NCT01665027|EXPERIMENTAL|routine manual maneuvers for fetal head extraction|"Procedure/Surgery:~fetal head techniques like fundal pushing, pulling technique or reverse breech extraction"
62665096|NCT03015701|EXPERIMENTAL|Arm 1|Mifepristone 200 mg orally daily for two years
62665097|NCT03015701|PLACEBO_COMPARATOR|Arm 2|Placebo orally daily for two years
62665098|NCT05548855||Heart Transplant or Cardiac Assist Device|Female and male patients with confirmed diagnosis of Danon disease based on a genetic test positive for a mutation in LAMP2 For living patients who underwent heart transplantation or placement of a cardiac assist device, and for deceased patients, at least 1 MRI or echo assessment prior to heart transplantation/cardiac assist device placement or death.
62665099|NCT05548855||No Intervention|Female and male patients with confirmed diagnosis of Danon disease based on a genetic test positive for a mutation in LAMP2 for living patients (who have not undergone heart transplantation or placement of a cardiac assist device), availability of at least 6-month cardiology follow-up data
62665100|NCT04689243|EXPERIMENTAL|ALA-PDT|
61912336|NCT04707859||Cohort|"Participants consenting to the study will undergo:~a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for \> 10 years~Patients with suspicion of coronary stenosis detected by CCTA will after undergo:~b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)"
61912337|NCT06437431|EXPERIMENTAL|glenzocimab|
61912338|NCT06437431|PLACEBO_COMPARATOR|placebo|
62103563|NCT02962336|EXPERIMENTAL|Test|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide (40+10+25) mg Tablets
62103564|NCT02962336|ACTIVE_COMPARATOR|Reference|Tribenzor (40+10+25) mg Tablets of Daichi Sankyo Inc, USA
62103565|NCT01208467||Basic science (DNA analysis)|DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
62103566|NCT03438487||Flucelvax Trivalent or Quadrivalent Influenza Vaccine|Flucelvax Trivalent or Quadrivalent exposure in pregnancy
62103567|NCT00938340|EXPERIMENTAL|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
62296419|NCT03088514|EXPERIMENTAL|NITRATE-CBP intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month
62296420|NCT03088514|PLACEBO_COMPARATOR|NITRATE-CBP placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
62296421|NCT03545464|EXPERIMENTAL|Antihistamines + placebo of cortancyl|"- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.~Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally"
62665101|NCT04689243|OTHER|red light|
62665102|NCT03426150|EXPERIMENTAL|CPP-ACP|Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
62665103|NCT03426150|PLACEBO_COMPARATOR|Deionized water|Deionized water application on the specimen surface for 3 min
62103568|NCT00938340|EXPERIMENTAL|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
62665104|NCT04772235|EXPERIMENTAL|Advanced and/or metastatic EGFR mutant NSCLC|Eligible advanced and/or metastatic EGFR mutant NSCLC patients will receive the combination of osimertinib and repotrectinib.
62665105|NCT04267315|ACTIVE_COMPARATOR|Active|3 weekly sessions of TPI. Participants will undergo 1mL injections of 1% lidocaine in the muscles identified with either active or latent trigger points at the initial assessment. The same muscles will be injected at all procedures.
62665106|NCT04267315|SHAM_COMPARATOR|Placebo|3 weekly sessions of subcutaneous saline injections. Participants will undergo 0.2mL subcutaneous saline injections superficial to the trigger points identified at initial assessment. The same superficial sites will be injected in all procedures.
61912339|NCT05735210|EXPERIMENTAL|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|Mean difference between the Polso™ Watch and reference measurement, and the associated standard deviation using data from the rest and induced change measurements following initialization
62665107|NCT00455455|ACTIVE_COMPARATOR|Optifree RepleniSH Multipurpose Disinfecting Solution|
62665108|NCT00455455|ACTIVE_COMPARATOR|ReNu Multiplus Multipurpose Solution|
62665109|NCT00602784|EXPERIMENTAL|IC41-B-01/02|peptide dose 0.00 mg, polyarginine dose 2.00 mg
62103569|NCT00938340|EXPERIMENTAL|Walnut oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
62665110|NCT00602784|EXPERIMENTAL|IC41-C-01/02|peptide dose: 5.00 mg, polyarginine dose: 0.00 mg
62103570|NCT00938340|EXPERIMENTAL|Walnut skins|Separated, ground walnut skins incorporated into inert food carrier
62665111|NCT00602784|EXPERIMENTAL|IC41-G-01/02|peptide dose: 2.50 mg, polyarginine dose: 1.25 mg
62665112|NCT00602784|EXPERIMENTAL|IC41-H-01/02|peptide dose: 2.50 mg, polyarginine dose: 2.00 mg
62665113|NCT00602784|EXPERIMENTAL|IC41-K-01/02|peptide dose: 5.00 mg, polyarginine dose: 2.00 mg
62665114|NCT02995889|EXPERIMENTAL|FLT-PET|
62665115|NCT03838913||IPNB|intraductal papillary neoplasm of the bile duct
62665116|NCT04558827|EXPERIMENTAL|Low Carb / Time Restricted Feeding|Participants will eat a low carbohydrate diet (30-60 grams) in a time restricted feeding window (2 meals within 8 hours) daily for the duration of the study (6 months).
61912340|NCT04399460|EXPERIMENTAL|Low Dairy Energy Restrictive Diet|Low-dairy (\<1 serving/day) and 500kcal/deficit per day energy restrictive diet
61912341|NCT04399460|EXPERIMENTAL|3 Servings of Full-Fat Dairy with Energy Restrictive diet|Energy-restrictive diet (500 kcal/deficit per day) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
61912342|NCT04399460|EXPERIMENTAL|3 Servings of Full-Fat Dairy but no energy restriction|Normal diet (no energy restriction) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
62103571|NCT04837495|ACTIVE_COMPARATOR|Stellate Ganglion block group|will include 20 patients: each one will receive 10 ml lidocaine 2% right stellate ganglion block (RSGB) under sonar guidance
62103572|NCT04837495|NO_INTERVENTION|Control group|will include 20 patients: a control group
62103573|NCT00918541||A|asymptomatic patients with mild to moderate carotid artery stenosis
62103574|NCT02662192|EXPERIMENTAL|Intervention|Exercise + health education + auditory rehabilitation 10 weeks of exercise, interactive health education, socialization and auditory rehabilitation program
62665117|NCT02153827|EXPERIMENTAL|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
62665118|NCT02153827|SHAM_COMPARATOR|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
62665119|NCT05415657|EXPERIMENTAL|Denosumab|Denosumab 60 mg were injected subcutaneously Q6M on the same day after lumbar fusion surgery, and all patients received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
62665120|NCT05415657|PLACEBO_COMPARATOR|Placebo|Equal volume of saline (0.9%) as placebo were injected subcutaneously Q6M on the same day after lumbar fusion surgery, and all patients received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
62665121|NCT05573009|EXPERIMENTAL|Training Group|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~At least 3-days of the cognitive behavioral approach-based stress reduction program will be given as face to face interviews to the intervention group during hospitalisation, and the remaining sessions will be given at the bedside as long as the hospitalization continues. If the patient is discharged, the remaining 2 sessions will be completed online."
62103575|NCT02662192|ACTIVE_COMPARATOR|Auditory rehabilitation alone|"auditory rehabilitation alone~1 hour of group auditory rehabilitation once a week for 10 weeks"
62103576|NCT02817633|EXPERIMENTAL|Part 1a: TSR-022 monotherapy|
62103577|NCT02817633|EXPERIMENTAL|Part 1b: TSR-022 in combination with nivolumab|
62665122|NCT05573009|NO_INTERVENTION|Control Group|Routine nursing care will be provided to the control group along with a stress management manual.
62665123|NCT04622995||Exposed|Patients prescribed opiate replacement therapy plus a benzodiazepine.
62103578|NCT02817633|EXPERIMENTAL|Part 1c: TSR-022 in combination with TSR-042|
62103579|NCT02817633|EXPERIMENTAL|Part 1d: TSR-022 in combination with TSR-042 and TSR-033|
62103580|NCT02817633|EXPERIMENTAL|Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)|
62665124|NCT04622995||Unexposed|Patients prescribed opiate replacement therapy with no benzodiazepine prescribing.
62665125|NCT03678662|EXPERIMENTAL|hyperalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-enhancing effects.
62103581|NCT02817633|EXPERIMENTAL|Part 1f: TSR-022 in combination with TSR-042 and Docetaxel|
62103582|NCT02817633|EXPERIMENTAL|Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin|
62665126|NCT03678662|EXPERIMENTAL|hypoalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-diminishing effects.
62665127|NCT03678662|ACTIVE_COMPARATOR|Neutral|In this group the subjects expectations are not manipulated
62665128|NCT01973400|EXPERIMENTAL|Tocotrienol|200 mg, twice a day, 12 months
62665129|NCT01973400|PLACEBO_COMPARATOR|Placebo|200 mg, twice a day, 12 months
62665130|NCT04073576|EXPERIMENTAL|AHCL|Advanced Hybrid Closed Loop
62665131|NCT04073576|ACTIVE_COMPARATOR|SAP+PLGM|Sensor Augmented Pump with Predictive Low Glucose Monitoring
62665132|NCT01003626|EXPERIMENTAL|IFP Measurement|Tumor interstitial fluid pressure (IFP) assessments
61912343|NCT04967040|ACTIVE_COMPARATOR|group 1 : medial plantar artery flap|
61912344|NCT04967040|ACTIVE_COMPARATOR|group 2 : distally based sural artery flap|
62665133|NCT06043570|EXPERIMENTAL|Remote Monitoring follow up|
62665134|NCT06043570|NO_INTERVENTION|Conventional Follow up|
62665135|NCT03850106|PLACEBO_COMPARATOR|Placebo|Placebo (microcrystalline cellulose)
62665136|NCT03850106|ACTIVE_COMPARATOR|Indus810|Indus810 ( 500mg/d)
62665137|NCT04118972|EXPERIMENTAL|Functionality Mirror Exposure & Journal|"A text-based functionality gratitude journaling prompt three times weekly paired with three weeks of weekly functionality-based guided mirror exposure sessions in the lab (the IM FAB program)"
62665138|NCT04118972|ACTIVE_COMPARATOR|Pure Mirror Exposure & Gratitude Journal|Thrice weekly generic (non body-focused) gratitude text prompts and pure mirror exposure in the lab. Participants are not given instructions on how to examine body parts, only instructed to examine the same specific body parts as the Functionality group to control specifically for impacts of the body functionality focus.
62665139|NCT04118972|NO_INTERVENTION|Assessment only control|Assessments at Week 1, Week 3, and 1- and 4-month follow-ups, identical to those received by participants in the active condition
62665140|NCT00853385|EXPERIMENTAL|5mg|
62665141|NCT00853385|EXPERIMENTAL|10 mg|
62665142|NCT00853385|PLACEBO_COMPARATOR|Placebo Sequence 1|
62665143|NCT00853385|PLACEBO_COMPARATOR|Placebo Sequence 2|
62103583|NCT02817633|EXPERIMENTAL|Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin|
62103584|NCT02817633|EXPERIMENTAL|Part 2: Cohort A Melanoma-TSR-022 as monotherapy|
62103585|NCT02817633|EXPERIMENTAL|Part 2: Cohort A Melanoma-TSR-022 with TSR-042|
62103586|NCT02817633|EXPERIMENTAL|Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy|
62103587|NCT02817633|EXPERIMENTAL|Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042|
61912345|NCT01512732||healthy control group|Young (20-49) and Older (50-70) healthy group (n=60)
61912346|NCT01512732||Parkinson's disease patients|(n=30).
61912347|NCT01512732||Major depressive disorder patients|(n=30).
62103588|NCT02817633|EXPERIMENTAL|Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy|
62103589|NCT02817633|EXPERIMENTAL|Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042|
62103590|NCT02817633|EXPERIMENTAL|Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042|
62103591|NCT02817633|EXPERIMENTAL|Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel|
62103592|NCT02817633|EXPERIMENTAL|Part 2: Cohort F- Hepatocellular carcinoma (HCC)-TSR-022 with TSR-042|
62103593|NCT04097886|EXPERIMENTAL|Morning Exercise Group|Participants perform moderate exercise in the morning.
62103594|NCT04097886|EXPERIMENTAL|Evening Exercise Group|Participants perform moderate exercise in the evening.
62103595|NCT05566847|NO_INTERVENTION|Arm 1: Usual Care|Participants will receive standard care for newly diagnosed Type 2 Diabetes.
62665144|NCT00853385|ACTIVE_COMPARATOR|adalimumab|
62665145|NCT00112853|EXPERIMENTAL|Treatment (tipifarnib, etoposide)|"Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD."
62665146|NCT01807520|EXPERIMENTAL|Secukinumab (AIN457) 150 mg|Participants assigned to secukinumab 150 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
62665147|NCT01807520|EXPERIMENTAL|Secukinumab (AIN457) 300 mg|Participants assigned to secukinumab 300 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
62665148|NCT01807520|PLACEBO_COMPARATOR|Placebo|Patients assigned to placebo were dosed weekly for five weeks, then at Week 8 and Week 12. At Week 16, placebo patients were randomized in a 1:1 ratio, to receive secukinumab either 150 mg or 300 mg and were dosed weekly for five weeks starting at Week 16, then once every four weeks up to and including Week 132. All doses of study treatment are administered by sub-cutaneous injections.
62665149|NCT01908842|ACTIVE_COMPARATOR|Buprenorphine; then OL BNX film, then BNX tablets|Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
62665150|NCT01908842|EXPERIMENTAL|BNX tablets, then OL BNX tablets, then BNX film|Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
62665151|NCT01381640|ACTIVE_COMPARATOR|Marketed paracetamol|Marketed formulation
62665152|NCT01381640|EXPERIMENTAL|Experimental paracetamol formulation|Experimental formulation
62665153|NCT01381510||Adherent BPH patients|Patients with benign prostatic hyperplasia (BPH) who are adherent to 5-alpha reductase inhibitor (5ARI) therapy based on a medication possession ratio (MPR). Analyses will be conducted with threshold adherence levels of 70%, 75% and 80%
62103596|NCT05566847|EXPERIMENTAL|Arm 2: Physician Education|Physicians in service areas randomized to this arm were invited to a physician education session on therapeutic inertia.
62103597|NCT05566847|EXPERIMENTAL|Arm 3: Physician Education + Accountable Population Manager Outreach|Physicians in service areas randomized to this arm were invited to a physician education session on therapeutic inertia. Patients enrolled in this arm may receive proactive outreach from an Accountable Population Manager (APM).
62103598|NCT00420589|PLACEBO_COMPARATOR|1|Arm 1: MK0364 Pbo capsules once daily
62103599|NCT00420589|EXPERIMENTAL|2|Arm 2: MK0364 0.5 mg capsule once daily
62103600|NCT00420589|EXPERIMENTAL|3|Arm 3: MK0364 1 mg capsule once daily
62103601|NCT00420589|EXPERIMENTAL|4|Arm 4: MK0364 2 mg capsule once daily
62665154|NCT01381510||Non-adherent BPH patients|Patients with BPH who are not adherent to 5ARI therapy based on an MPR and threshold levels of less than 70%, less than 75% and less than 80%
62665155|NCT03795909|EXPERIMENTAL|Ruxolitinib and Placebo|Ruxolitinib 2.5 mg twice daily by oral
62103602|NCT05478902|EXPERIMENTAL|Exercise Therapy|"This group will receive the Shape Up My Shoulders (SUMS) protocol and it will be led by a physiotherapist trained in therapeutic exercise. It will last 12 weeks and it will be divided in 3 stages.~Stage I- Early-stage rehabilitation exercises (i.e., breathing and relaxation exercises, ball rolling exercises, hand gripping exercises, mental imagery and contralateral side exercises) and Shoulder Symptom Modification Procedure (SSMP). This stage typically lasts 1 to 2 weeks.~Stage II - Isometric, eccentric and heavy slow resistance exercises. The final part of Stage II is a progression from eccentric only to eccentric and concentric contractions.~Stage III - Functional program. This stage starts in week 5 or 6 and progressed to week 12. Involves pushing, pulling, throwing, lifting, carrying, and precision (sensory-motor control) exercises."
62296422|NCT03545464|ACTIVE_COMPARATOR|Association of antihistamines and cortancyl|"- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.~Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally"
62296423|NCT03485989|EXPERIMENTAL|Hazelnuts|Participants given 2 ounces (\~57 grams) of dry roasted hazelnuts to consume each day.
62308255|NCT00058799|EXPERIMENTAL|Dose Level 1|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
62665156|NCT03795909|PLACEBO_COMPARATOR|Placebo and Ruxolitinib|Sugar pill 2.5 mg twice daily by oral
62665157|NCT00594555|EXPERIMENTAL|Single Arm - treatment period|"Drug Name/Days Administered~Neupogen/Days 1-6~CLAG/Days 2-6~Gleevec/Days 2-15"
62665158|NCT04548128||Treatment Arm|The treatment arm will have the HM3 LVAS implanted utilizing a technique other than full median sternotomy (e.g. thoracotomy).
62665159|NCT01625182|EXPERIMENTAL|Fingolimod (FTY720)|Participants received Fingolimod 0.5 mg orally once daily.
62296424|NCT00710645||Arm I|50 subjects with multiple sclerosis will be tested one time on the Lido Workset. The test will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
62665160|NCT01625182|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to Fingolimod orally once daily.
62665161|NCT04134871|EXPERIMENTAL|Intervention group|Participants randomised to the intervention group will be invited to attend a group education session where they will be given a step counter and activity diary, they will be invited to weekly group walks and fortnightly coaching 1-1 sessions aimed at setting and reviewing goals to increase physical activity and reduce sedentary behaviour
62103603|NCT05478902|ACTIVE_COMPARATOR|Extracorporeal Shockwave Therapy|This group will receive high energy Extracorporeal Shockwave Therapy (ESWT) applied by an experienced physiotherapist. ESWT will be applied on the most tender point of the shoulder, located by palpation. The dose will be 1500 impulses per session without anaesthesia and an intensity between 0.15 and 0.30 mJ/mm2 depending on patient tolerance. A total of 4 treatment sessions (1 session per week) with 1 week of rest between sessions will be implemented. Patient's position during the treatment will be seated in supine position with shoulder hyperextension and internal rotation with the hand placed below the contralateral glute with the palm touching the table.
62308256|NCT00058799|EXPERIMENTAL|Dose Level 2|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
62665162|NCT04134871|NO_INTERVENTION|Control group|Participants randomised to the control group will be given an information leaflet about being more active during a one-off 1-1 consultation.
62665163|NCT01461837|EXPERIMENTAL|Haplo Stem Cell Transplantation|CD34 selected T-cell depleted allogeneic SCT
62665164|NCT04242745|EXPERIMENTAL|Intervention group|Procedure/Surgery:The intervention group was given education and a wristwatch which gave an audible alarm to remind them to drink liquid.
62665165|NCT04242745|NO_INTERVENTION|Control group|The control group was given only education.
62308257|NCT00058799|EXPERIMENTAL|Dose Level 3|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
62665166|NCT03639389|ACTIVE_COMPARATOR|Analgesics, multimodal|Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics
62665167|NCT03639389|EXPERIMENTAL|Bupivacaine|Spinal anesthetic with bupivacain + fentanyl/sufentanil
62665168|NCT01932463|EXPERIMENTAL|ExAb;ate MRgFUS|
62665169|NCT02716285|EXPERIMENTAL|Ileocolonic release peppermint oil|Colon-targeted-delivery capsule containing 182mg of Peppermint Oil, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
62665170|NCT02716285|EXPERIMENTAL|Small intestinal release peppermint oil (Tempocol®)|Enteric-coated capsule containing 182mg of Peppermint Oil that release the oil in the small intestine, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
62296425|NCT00710645||Arm II|25 normal subjects will be tested on the Lido workset. The testing will be performed one time for each patient and will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected control subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
61912348|NCT06280014|EXPERIMENTAL|Mefenamic acid was used to see post operative effects after extraction of 3rd molar in study group|In this study of 30 patients, 22 females and 8 males, 60 fully impacted lower wisdom teeth were extracted bilaterally and in the same position. One of the bilaretal teeth of the patients was randomly selected and mefenamic acid was used as a drug to see post operative effects after extraction of impacted 3rd molars in the study group.
62665171|NCT02716285|PLACEBO_COMPARATOR|Placebo|Capsule containing microcrystalline cellulose, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
62103604|NCT05478902|ACTIVE_COMPARATOR|Ultrasound-Guided Percutaneous Irrigation|This intervention will be performed by an experienced interventionist radiologist in two sessions. The shoulder position will be with hyperextension and internal rotation with the hand behind the back. One 20 mL syringe with saline solution, one with an anaesthetic with 20 mg/mL of mepivacaine 2% and another syringe with a corticoid injection with 40 mg/mL of triamcinolone acetonide will be prepared before the intervention. Firstly, the anaesthetic will be injected directed to the calcification. Then, the procedure will consist of injecting saline solution and aspiring the calcific deposits until it is neither possible to aspire more inside the syringe nor to detect any calcifications with ultrasound imaging. After that, a corticoid will be injected to the bursa to prevent the appearance of subacromial bursitis. Finally, an anaesthetic will be injected during the extraction of the needle.
62665172|NCT02575625|EXPERIMENTAL|Fibroscan exam|"Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).~Experimental procedures consist in:~* Fibroscan measure, preceded by tracking sonography.~* liver MRI (for substudy about MRI comparison, in step 2)~* a blood test for biological assessment of liver functions"
62665173|NCT05460247|EXPERIMENTAL|Pea protein diet|
62468344|NCT03375853|EXPERIMENTAL|Experimental Condition|"Participants will complete computer-based response training tasks that will incorporate pictures of healthy food, unhealthy food, and glasses of water. As part of the computer-based training, participants will be instructed to respond or inhibit responses to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the control condition, only the appearance and context of the stimuli will be different (i.e., food versus non-food items). The computer tasks described above comprise the Computer Based Response Training Weight Loss Intervention. To optimize the intervention, we narrowed the low-calorie food stimulus set to make a better distinction between high-calorie and low-calorie foods and we changed the filler images (water and furry mammals) in the go/no-go task from 100% go to 50% go and 50% no-go to measure learning of stimulus-specific respond associations."
62296426|NCT04762030|EXPERIMENTAL|Experimental Group|
62296427|NCT03136939||type 1 diabetes|
62468345|NCT03122990|EXPERIMENTAL|Full mouth scaling and root planing|FM-SRP No surgical periodontal treatment will be performed in all dentition within 24 hours
62665174|NCT05460247|EXPERIMENTAL|Whey protein diet|
62665175|NCT05460247|EXPERIMENTAL|Soy protein|
62665176|NCT05460247|EXPERIMENTAL|Rice protein|
61912349|NCT06280014|PLACEBO_COMPARATOR|Dexketoprofen was used to see post operative effects after extraction of 3rd molar in control group|Bilateral impacted wisdom teeth of the patients were randomly selected. After the tooth in the experimental group was extracted, the other impacted wisdom tooth was selected as the control group and dexketoprofen was used as a drug to see post operative effects.
61912350|NCT01685645|EXPERIMENTAL|Study population|"The study population consists of male and female patients admitted for programmed major knee surgery (arthroplasty) with a truncal analgesic block (femoral nerve block with a sciatic block) and operated under general anesthesia.~See inclusion and exclusion criteria.~Intervention: AlgiScan"
61912351|NCT00590928|ACTIVE_COMPARATOR|1|patients with indication for stress ulcer prophylaxis and gastric pH \< 4
62296428|NCT03136939||type 2 diabetes|
62296429|NCT03136939||healthy people|
61912352|NCT00590928|ACTIVE_COMPARATOR|2|patients with indication for stress ulcer prophylaxis and gastric pH \< 4
61912353|NCT02622997|EXPERIMENTAL|Flocked swab 1|Cervico-vaginal self-sample taken with first flocked swab followed by cervico-vaginal self-sample taken with a second flocked swab and finally cervico-vaginal self-sample taken with a HerSwab device
61912354|NCT01516333|EXPERIMENTAL|Diet 1|High GI; High Carb; High GL
61912355|NCT01516333|EXPERIMENTAL|Diet 2|High GI, Low Carb, Med GL
62296430|NCT04528485|EXPERIMENTAL|Sea swimming|8 sessions over 4 weeks of swimming-based activities in the sea
62296431|NCT03732547|EXPERIMENTAL|'PolyIC plus PD-1 mAb' and 'PD-1 mAb'|"'PolyIC plus PD-1 mAb' group: PolyIC, 2mg, i.m., every other day, for three weeks. PD-1 mAb, 200mg, i.v., every three weeks.~'PD-1 mAb' group: PD-1 mAb, 200mg, i.v., every three weeks."
62665177|NCT01319968||Postpartum patients|100 postpartum women attending the clinic for their postpartum visit will be evaluated for vaginal atrophy, vaginal symptoms and dyspareunia.
62296432|NCT04713943|EXPERIMENTAL|>Your< Iron Syrup|
61912356|NCT01516333|EXPERIMENTAL|Diet 3|Low GI, High Carb, Med GL
61912357|NCT01516333|EXPERIMENTAL|Diet 4|Low GI, Low Carb, Low GL
61912358|NCT00740376|EXPERIMENTAL|Uniglide Mobile Bearing|Uniglide Mobile Bearing Unicondylar Knee System (MBK)
62665178|NCT03568903|EXPERIMENTAL|Intervention group|Comprehensive physical therapy intervention in small groups (3 members), altogether 16 sessions were performed during a period of 8 weeks (twice a week). Each session lasted 1 hour.
62665179|NCT03568903|NO_INTERVENTION|Control group|Control group members did not receive any specific intervention during study period, but if needed, medical treatment (medication, it's dosage etc) of Parkinson Disease was changed during study period. They were assigned to individual therapy after the study period.
62296433|NCT04713943|OTHER|Placebo|
62296434|NCT02018692|EXPERIMENTAL|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
62665180|NCT00081458|PLACEBO_COMPARATOR|placebo|Placebo injectable subcutaneously daily into the thigh or abdomen
62665181|NCT00081458|EXPERIMENTAL|2|teduglutide 0.05 mg/kg/d
62665182|NCT00081458|EXPERIMENTAL|3|teduglutide 0.1 mg/kg/d
62665183|NCT02993900|EXPERIMENTAL|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
62665184|NCT02035293|OTHER|PEP|No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
62296435|NCT02018692|PLACEBO_COMPARATOR|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
62296436|NCT03522129|ACTIVE_COMPARATOR|Active Treatment- CT1812 560 mg|
62296437|NCT03522129|ACTIVE_COMPARATOR|Active Treatment- CT1812 280 mg|
62296438|NCT03522129|ACTIVE_COMPARATOR|Active Treatment- CT1812 90 mg|
62468346|NCT03122990|ACTIVE_COMPARATOR|Quadrant Scaling and Root Planing|"Q-SRP No surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
62665185|NCT04952896||Group of patients with pigmented villonodular synovitis|Diagnosis confirmed by arthroscopic pathological biopsy.
62665186|NCT04952896||Group of patients with rheumatoid arthritis|Diagnosis determined by clinical history, laboratory tests and arthroscopic pathology biopsy.
62665187|NCT04952896||Group of patients with gout|Diagnosis was determined by laboratory tests, energy spectrum imaging and arthroscopic pathology biopsy.
62665188|NCT00500890|EXPERIMENTAL|Carboplatin + Etoposide + Vincristine|Carboplatin 350 mg/m\^2 by vein, Over 2 Hours x 2 Days. Etoposide 100 mg/m\^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
62665189|NCT00500890|EXPERIMENTAL|Cyclophosphamide + Etoposide + Vincristine|Cyclophosphamide 1 g/m\^2 by vein, Over 1 Hour x 2 Days. Etoposide 100 mg/m\^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
62665190|NCT06062069|EXPERIMENTAL|CT-868 Low Dose|Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 1.8 mg, and it will be administered once daily for a total duration of 16 weeks.
62665191|NCT06062069|EXPERIMENTAL|CT-868 Medium Dose|Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 4.1 mg, and it will be administered once daily for a total duration of 16 weeks.
61912359|NCT00740376|ACTIVE_COMPARATOR|Uniglide Fixed Bearing|Uniglide Fixed Bearing Unicondylar Knee System (FBK)
61912360|NCT05585944|ACTIVE_COMPARATOR|control|healthy participants
61912361|NCT05585944|ACTIVE_COMPARATOR|cases|cases of immune thrombocytopenic purpura
62296439|NCT03522129|PLACEBO_COMPARATOR|Placebo Comparator - Placebo|
62308258|NCT05815238||Young Adult|20-35
62308259|NCT05815238||Mild Adults|35-50
62308260|NCT05815238||Older Adults|50-65
62308261|NCT03863938|EXPERIMENTAL|Tegoprazan 50mg under fasting condition|Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day
62308262|NCT03863938|EXPERIMENTAL|Tegoprazan 50mg before the meal|Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day
62665192|NCT06062069|EXPERIMENTAL|CT-868 High Dose|Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 6.6 mg, and it will be administered once daily for a total duration of 16 weeks.
62103605|NCT05478902|NO_INTERVENTION|Wait and Watch group|The wait and see group will not receive any intervention and will serve as a control group to determine the natural history of RCCT. If one treatment proves to be more effective then participants in the other groups will be offered that treatment after 12 months, or before, if the investigation finishes early due to an obvious group difference and a need to break randomisation codes.
62665193|NCT06062069|PLACEBO_COMPARATOR|CT-868 Placebo|Participants in this arm will receive a placebo designed to match the appearance and formulation of the drug CT-868. The intervention consists of a subcutaneous injection of this placebo. The placebo will be administered once daily for a duration of 16 weeks.
62103606|NCT01385865|EXPERIMENTAL|Mulberry leaf extract|
62665194|NCT05297760|ACTIVE_COMPARATOR|Polvac|Polvac Grass+Rye
62665195|NCT05297760|PLACEBO_COMPARATOR|Placebo|Saline
62665196|NCT03142750|EXPERIMENTAL|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
62665197|NCT03308643|EXPERIMENTAL|Oxytocin infusion|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
62665198|NCT03308643|PLACEBO_COMPARATOR|Placebo|Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.
62103607|NCT01385865|PLACEBO_COMPARATOR|Placebo|
62103608|NCT02836678|ACTIVE_COMPARATOR|Control group|Ridge splitting, immediate implantand PRF.
62103609|NCT02836678|EXPERIMENTAL|Test group|Ridge splitting, immediate implant, Nanobone with PRF.
62103610|NCT04921761|PLACEBO_COMPARATOR|Group A|Women who received the conventional epidural technique (group A). Intervention: Procedure: Conventional epidural
62103611|NCT04921761|ACTIVE_COMPARATOR|Group B|Women who received the dural puncture epidural technique (group B). Intervention: Procedure: Dural puncture epidural
62103612|NCT00831597|EXPERIMENTAL|Bendamustine with rituximab|All patients received combination bendamustine with rituximab
62468347|NCT05880056|EXPERIMENTAL|(Nerkardou 5 mg) & (Nerkardou 10 mg)|"One ODF of bisoprolol 5 mg (Nerkardou 5 mg) Dosage form description: Bisoprolol oral dissolved film ODF: equivalent to 5 mg of bisoprolol fumarate.~One ODF of bisoprolol 10 mg (Nerkardou 10 mg) Dosage form description: Bisoprolol oral dissolved film ODF: equivalent to 10 mg of bisoprolol fumarate."
62468348|NCT02055963|EXPERIMENTAL|Minocycline|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
62468349|NCT02055963|PLACEBO_COMPARATOR|Placebo|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
62468350|NCT03186456|EXPERIMENTAL|Group 1|Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1\*10\^6/kg
62468351|NCT03186456|PLACEBO_COMPARATOR|Group 2|Aspirin Tablet, 100mg/d; Placebo
62468352|NCT02772289|EXPERIMENTAL|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
62468353|NCT02772289|EXPERIMENTAL|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
62468354|NCT02772289|PLACEBO_COMPARATOR|Placebo|Placebo without Mesenchyme Stem Cells
62665199|NCT00766220|ACTIVE_COMPARATOR|SIR-Spheres + Therapy|SIR-Spheres with Cetuximab + Irinotecan Therapy
62665200|NCT00766220|ACTIVE_COMPARATOR|Therapy Only|Cetuximab + Irinotecan Therapy
62665201|NCT03982654|EXPERIMENTAL|Bloomlife|
62665202|NCT00075374|EXPERIMENTAL|Docetaxel|
62665203|NCT01457027|EXPERIMENTAL|All subjects|
62665204|NCT04663217||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
62103613|NCT02090309|ACTIVE_COMPARATOR|Hydrocortisone injection|I.V Hydrocortisone 100 mg single bolus.
62103614|NCT02090309|PLACEBO_COMPARATOR|normal saline|I.V normal saline 0.9% a single bolus of 5 ml.
62296440|NCT06352177|NO_INTERVENTION|Standard of Care|Participants in this group will receive counseling about best MASLD clinical practices in accordance with AASLD and ACSM practice guidelines Because in-office hepatology counseling for lifestyle intervention occurs every 12-24 wks,standard counseling will occur at each in-person visit. Mediterranean-informed, hypocaloric dietary counseling will be provided by a study investigator, with specific instructions to limit carbohydrates and saturated fat and enrich dietary intake with high fiber and unsaturated fats. Physical activity goals of 150 min/wk. of moderate intensity of 75 min/wk. of vigorous intensity activity will be suggested. To reinforce this education and promote self-monitoring, participants in this group will also receive a digital scale and fitness activity tracker.
62103615|NCT06631820|NO_INTERVENTION|control phase|patients will undergo 8 weeks without the supplement after enrolment to allow for a control phase
62103616|NCT06631820|EXPERIMENTAL|experimental phase|after 8 weeks of control phase, patients will receive the supplement for 8 weeks
62665205|NCT04663217||Pulmonary hypertension due to left heart disease|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure above 15 mmHg with left heart disease, classified into group 2 of the clinical classification of pulmonary hypertension.
62665206|NCT04663217||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
62665207|NCT04663217||Control|Patients with mean pulmonary arterial pressure below 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with exclusion of pulmonary hypertension.
62468355|NCT00267592|EXPERIMENTAL|enzyme-inducing antiseizure drug|A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group.
62468356|NCT04349917|PLACEBO_COMPARATOR|Placebo, then Methylphenidate|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
62468357|NCT04349917|EXPERIMENTAL|Methylphenidate, then Placebo|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
62468358|NCT00864591||SPECT and stress CMR patients|"patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.~The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.~Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study."
62468359|NCT00537979|ACTIVE_COMPARATOR|Paricalcitol injection|ABT-358 Zemplar
62665208|NCT01794416|ACTIVE_COMPARATOR|Thoracoscopic epicardial ablation|"Patients were treated with video-assisted thoracoscopy under general anesthesia. PVI was performed from the epicardial side with a bipolar RF ablation clamp (AtriCure). At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. An additional application was made in the interatrial Waterston groove in the right side to isolate the ganglionic plexi from the atria. On the left side, the ligament of Marshal was cut, but no additional ablation of ganglionic plexi was pursued.~The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
62665209|NCT01794416|ACTIVE_COMPARATOR|Endocardial catheter ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster). The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
62468360|NCT00537979|ACTIVE_COMPARATOR|Paricalcitol capsules|ABT-358 Zemplar
62665210|NCT00243061|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62665211|NCT00286455|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62296441|NCT06352177|EXPERIMENTAL|Intervention|This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations including our pilot study in individuals with MASLD. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.
62296442|NCT02406846||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
62296443|NCT02406846||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
62468361|NCT04078022|EXPERIMENTAL|Cohort 1: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
62468362|NCT04078022|EXPERIMENTAL|Cohort 2: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
62468363|NCT04078022|EXPERIMENTAL|Cohort 3: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
62468364|NCT04078022|EXPERIMENTAL|Cohort 4: Shigella Vaccine Only, No Challenge|All volunteers receive the investigational Shigella vaccine (n=12). No Shigella challenge.
62468365|NCT01667185||Pediatric subjects with diabetes mellitus|
62468366|NCT01848340|EXPERIMENTAL|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
62468367|NCT01848340|EXPERIMENTAL|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
62468368|NCT01848340|PLACEBO_COMPARATOR|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
62296444|NCT02406846||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
62468369|NCT06321991|PLACEBO_COMPARATOR|Dupuytren Disease patients receiving Vasiline (Placebo)|40 patients with Dupuytren Disease (primary DD nodules: stage 0, no contracture in the involved hand) will be randomized into the group where they will receive Vasiline
62468370|NCT06321991|ACTIVE_COMPARATOR|Dupuytren Disease patients receiving Remederm® (Vitamine E creme)|40 patients with Dupuytren Disease (primary DD nodules: stage 0, no contracture in the involved hand) will be randomized into the group where they will receive Remederm® (Vitamine E creme)
62468371|NCT04464330||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, patients who has suffered the Anterior Cruciate Ligament injury.
62665212|NCT00286455|EXPERIMENTAL|Alogliptin 25 mg QD|
62103617|NCT05246553|EXPERIMENTAL|Modified cochlear implant recipients|"Patients suffering from severe to profound hearing loss and severe bilateral vestibulopathy implanted with a modified cochlear implant providing 1 to 3 extracochlear electrodes implanted in proximity to the ampullary branches of the vestibular nerve (vestibular electrodes).~All experiments will be carried out while the vestibular electrodes are inactive, and while electrical stimulation is delivered to one or several vestibular electrodes, with and without concurrent cochlear stimulation."
62103618|NCT05246553|ACTIVE_COMPARATOR|Cochlear Implant Patients (CI)|Unilateral or bilateral cochlear implant recipients with normal vestibular function documented within the clinical follow up of their cochlear implant, and without previous history of vestibular symptoms or complaints.
62103619|NCT05246553|ACTIVE_COMPARATOR|Bilateral vestibulopathy Patients (BV)|Patients with documented diagnosis of bilateral vestibulopathy, according to the guidelines of the Barany society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
62103620|NCT05246553|ACTIVE_COMPARATOR|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
62103621|NCT05246553|NO_INTERVENTION|Healthy Subjects (HS)|Normal auditory functiona and without previous auditory or vestibular symptoms or complaints. Normal vestibular function documented with the video-head impulse test.
62103622|NCT04056104|EXPERIMENTAL|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters
62103623|NCT01444287|PLACEBO_COMPARATOR|Spectacles No Lenses|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
62103624|NCT01444287|EXPERIMENTAL|narafilcon B|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
62103625|NCT01444287|ACTIVE_COMPARATOR|polymacon|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
62103626|NCT01444287|ACTIVE_COMPARATOR|lotrafilcon A|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
62103627|NCT05708833|EXPERIMENTAL|intraosseous venous access|intraosseous venous access
62468372|NCT04464330||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
62468373|NCT00904553||Novalis Shaped Beam Surgery|Patients with limited brain metastases (mostly solitary brain metastasis) treated with Novalis Shaped Beam Surgery followed by planned craniotomy and resection of the metastases.
62468374|NCT03197207|EXPERIMENTAL|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
62103628|NCT05708833|ACTIVE_COMPARATOR|peripheral venous access|Limiting use of intraosseous access (intraosseous access possible after 3 attempts of peripheral venous access)
62103629|NCT05365607|EXPERIMENTAL|NightWare|In individuals randomized to the active condition, when the stress index is reached during sleep, NightWare will intervene with varying degrees of vibratory stimulation to the watch over a variable length of time to arouse the person out of the nightmare without awaking.
62103630|NCT05365607|SHAM_COMPARATOR|Sham NightWare|In individuals randomized to the sham condition, the NightWare intervention will not be enabled.
62103631|NCT00779571|EXPERIMENTAL|Crispbread|Intervention: Crispbread LCD
62468375|NCT03197207|EXPERIMENTAL|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
62665213|NCT00286455|PLACEBO_COMPARATOR|Placebo QD|
62103632|NCT00779571|ACTIVE_COMPARATOR|Liquid meal replacement|Intervention: LMR LCD
62103633|NCT01757509|OTHER|Intervention group|Participants in this group will receive a set dancing intervention along with their usual care.
62103634|NCT01757509|NO_INTERVENTION|Control Group|The control group will continue with their usual medical regime, activities of daily living and exercise habits and at the end of the study participants in this group will be offered the set dancing intervention.
62665214|NCT05355207|EXPERIMENTAL|TRL1068|all subjects will receive a single intravenous dose of 15 mg/kg of TRL1068 on Day 1
62468376|NCT05619289|ACTIVE_COMPARATOR|Vitamin D2 (Ergocalciferol)|One time, oral dose of Vitamin D2 administered via 6 50,000 IU Ergocalciferol capsules. Capsules will be encapsulated and masked to be indistinguishable from placebo.
62103635|NCT03078920|OTHER|11 unilateral adult cochlear implant users|Speech Reception Threshold (SRT) measured with an adaptive test
62103636|NCT05479045|EXPERIMENTAL|NY-ESO-1 Peptide vaccine plus Toripalimab-tpzi|
62103637|NCT01805856|EXPERIMENTAL|Group A (intervention PIPC)|Patients in group A (intervention PIPC) were given AMP of 2g PIPC intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose PIPC was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
62103638|NCT01805856|EXPERIMENTAL|Group B (intervention CEZ)|Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
62103639|NCT01805856|NO_INTERVENTION|Group C (without AMP)|Patients in Group C underwent surgery without any AMP.
62103640|NCT06609850|ACTIVE_COMPARATOR|TACE plus Lenvatinib|"TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.~Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )"
62468377|NCT05619289|PLACEBO_COMPARATOR|Placebo|One time, oral dose of 6 placebo capsules filled with inert powder and encapsulated and masked to be indistinguishable from active comparator.
62468378|NCT03653260|EXPERIMENTAL|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
62468379|NCT03653260|PLACEBO_COMPARATOR|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
62665215|NCT02687737|EXPERIMENTAL|Exercise|The participants will have the following tests performed: Maximum Expiratory Pressure (MEP), insertion of a fine-wire electromyography (EMG) electrode into the mid-line base of the tongue, will complete swallowing tasks and breathing tasks under Videofluoroscopy (fluoroscopy on only during the actual task)
62296445|NCT02406846||cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
62296446|NCT05865483||Participant group: mild disease|Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 1-2 (n=30)
62296447|NCT05865483||Participant group: moderate disease|Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 3 (n=30)
62296448|NCT05865483||Participant group: severe disease|Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 4-5 (n=30)
62296449|NCT05865483||Control group|No disease (n=60) age and sex-matched
62665216|NCT01326221||1|Single dose of Truvada
62665217|NCT01196611|EXPERIMENTAL|Function Voice Exercises|Behavioral: Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
62665218|NCT01196611|EXPERIMENTAL|Voice amplification|Behavioral: Voice amplification Patients will use VA over a course of 6 weeks.
62665219|NCT00536614|NO_INTERVENTION|A|arm A) gemcitabine/cisplatin in combination with Cetuximab arm B) gemcitabine/cisplatin alone
62737566|NCT04646746|EXPERIMENTAL|Nude barley 50%|"Intake of 250 ml of tap water and 100 g of bread baked with 50% nude barley flour and 50% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
62737567|NCT04646746|EXPERIMENTAL|Nude barley 75%|"Intake of 250 ml of tapwater and 100 g of bread baked with 75% nude barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
62737568|NCT04646746|EXPERIMENTAL|Gen-modified high-amylose barley|"Intake of 250 ml of tap water and 100 g of bread baked with 50% gene-modified high-amylose barley and 50% wheat. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~The gene-modified barley is produced by researchers at Aarhus and Copenhagen Universities as published in 'Carciofi M, et al., Concerted suppression of all starch branching enzyme genes in barley produces amylose-only starch granules. BMC Plant Biol. 2012 Nov 21;12:223. doi: 10.1186/1471-2229-12-223' The wheat flour is standard commercial available flour."
62737569|NCT03532698||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
62737570|NCT03532698||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
62737571|NCT05538910|PLACEBO_COMPARATOR|Arm 1: Placebo|Placebo patch + Placebo Pill
62737572|NCT05538910|EXPERIMENTAL|Arm 2: Nicotine Patch|Nicotine Patch + Placebo Pill
62737573|NCT03818763|EXPERIMENTAL|Autologous CD34+PBSC transduced with a lentiviral vector|Patients will receive a patient specific (autologous) cytokine mobilized CD34+Peripheral Blood Stem Cells (PBSC) transduced ex vivo with a lentiviral vector containing cDNA encoding the human B-domain deleted FVIII protein.
62737574|NCT03404063|EXPERIMENTAL|Active Group|Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
62737575|NCT03404063|PLACEBO_COMPARATOR|Control Group|Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.
62737576|NCT01963182|EXPERIMENTAL|irinotecan dose based on genetic polymorphism of UGT1A1|
62665220|NCT04781465|EXPERIMENTAL|Immersive Virtual Reality|"The patients are divided into groups of 3. Each group of patients will attend 2 days of care per week (for 4 weeks) Group N ° 1: Monday and Thursday. Group N ° 2: Tuesday and Friday.~At each visit, the patient will participate in:~\[a Kinesitherapy treatment and a Virtual Immersion treatment\] + \[a Balneotherapy treatment or an Adapted Physical Activity treatment). Each treatment lasts 1 hour 10 minutes.~Each patient will therefore come to the center 8 times over 1 month, or 4 hours 40 minutes a week, not counting virtual reality.~If the groups are not full or according to the advice of the healthcare team, only one group will be selected (always 3 patients) and will attend 3 days per week."
62665221|NCT02826551|PLACEBO_COMPARATOR|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
62665222|NCT02826551|EXPERIMENTAL|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
62665223|NCT05664945|EXPERIMENTAL|pulmonary tele-rehabilitation (PTR)|"Recieve supervised PTR 2/weekly, session duration of 60 min; 35 min of exercise and 25min of patient education for 10-weeks (primary endpoint).~Delivered from Hvidovre/Bispebjerg Hospital to groups of 4-6 patients who exercise at home and communicate via tablet-camera.~After 10-weeks of PTR, participants are offered once weekly PTR for 60minuttes in groups of 4-8 patients throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
62103641|NCT06609850|EXPERIMENTAL|TACE plus Lenvatinib and ablation|"TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.~Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day ) Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size."
62103642|NCT01440244|OTHER|Single group assignment|Cervical mediastinoscopy
62103643|NCT03585361|EXPERIMENTAL|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
62103644|NCT03585361|ACTIVE_COMPARATOR|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
62103645|NCT06628492|EXPERIMENTAL|group A implant inserted by stainless steel surgical guide|
62103646|NCT06628492|ACTIVE_COMPARATOR|group B implant inserted by resin surgical guide|
62103647|NCT04990791|OTHER|Aspirin 20mg|Aspirin 75 mg OD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD
62103648|NCT04990791|OTHER|Asprin 75mg|Aspirin 75 mg OD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD
62103649|NCT02690103|ACTIVE_COMPARATOR|Group 1|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
62103650|NCT02690103|EXPERIMENTAL|Group 2|Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.
62468380|NCT01939717|OTHER|Dance group|Participants allocated to this group will continue with their usual care and participate in a set dancing class.
62468381|NCT01939717|NO_INTERVENTION|Control group|Participants allocated to this group will act as a control group and continue to receive their usual care only.
62103651|NCT04215978|EXPERIMENTAL|Phase 1a: BGB-A445 Monotherapy|Dose Escalation Part A: Participants will receive intravenous (IV) infusion of BGB-A445 in sequential cohorts of approximately 8 increasing dose levels on day 1 of each 21-day cycle
62103652|NCT04215978|EXPERIMENTAL|Phase 1a: BGB-A445 + Tislelizumab Combination Therapy|Dose Escalation Part B: Participants will receive IV infusion of BGB-A445 in sequential cohorts of approximately 6 increasing dose levels plus 200mg tislelizumab on day 1 of each 21-day cycle
62103653|NCT04215978|EXPERIMENTAL|Phase 1b:BGB-A445 Monotherapy|Dose Expansion Part A: Participants will receive recommended doses of IV BGB-A445 as determined from Phase 1a Dose Escalation; BGB-A445 will be evaluated in two tumor types
62468382|NCT04723810|EXPERIMENTAL|Cohort 1|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has not been fully studied will be enrolled: glioma, breast cancer, colon cancer, rectal cancer, head and neck cancer, pulmonary metastasectomy (colorectal mets), thymoma, ovarian cancer, prostate cancer, renal cell carcinoma, thyroid cancer, parathyroid adenoma, mesothelioma, esophageal cancer, pancreas cancer, stomach cancer.
62468383|NCT04723810|EXPERIMENTAL|Cohort 2|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has been fully studied will be enrolled: non-small cell lung cancer, metastatic sarcoma to the lung, brain meningioma.
62103654|NCT04215978|EXPERIMENTAL|Phase 1b: BGB-A445 + Tislelizumab and Chemotherapy Combination Therapy|Dose Expansion Part B: Participants will receive recommended dose IV infusion of BGB-A445 plus 200mg tislelizumab and chemotherapy
62665224|NCT05664945|EXPERIMENTAL|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR program. Patient goal is to achieve at least 20 min of self-initiated muscle-endurance based exercise 3days/weekly for 10-weeks (primary endpoint).~The first session is a home visit by an experienced respiratory physiotherapist and with focus on establishment of exercise goals, formal exercise prescription and education.~The home visit is followed by 1/weekly session for 10-weeks.The sessions is delivered from Hvidovre/Bispebjerg Hospital via tablet-camera or telephone call.~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 patients throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
62665225|NCT05664945|ACTIVE_COMPARATOR|Control|Control group will receive usual care; medication, scheduled follow-up visit and possible phone contact with GP or the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.
62665226|NCT04679246|EXPERIMENTAL|General Intervention|The strategies will be implemented in the three intervention elementary schools. The schools were conveniently chosen for the size of the student population. In addition to having a sufficient population, it was important that the authorities of each school site agreed to participate.
62665227|NCT04679246|EXPERIMENTAL|Subsample intervention|A group will be randomly selected from each school grade from the intervention schools, and within each chosen group 12 children will be randomly selected per group (48 children in total per school).
62665228|NCT04679246|NO_INTERVENTION|Control|Three primary schools were selected from a close locality (Villa Corona, Jalisco). This was chosen because it is similar in relation to the social, economic, and geographical context to the locality of intervention. The schools were selected for the similarity in the size of the student population of the intervention schools.
62665229|NCT04922528|EXPERIMENTAL|Near-Infrared Fluorescence Cholangiography|Standard laparoscopic cholecystectomy completed with a combination of white light imaging and near-Infrared fluorescence cholangiography after administering 5 mg of a 25 mg/10 mL solution of indocyanine green (ICG) intravenously prior to the operation
62665230|NCT04922528|ACTIVE_COMPARATOR|White Light Imaging|Standard laparoscopic cholecystectomy completed with only standard white light imaging only
62665231|NCT00331487|EXPERIMENTAL|Pioglitazone QD|
62468384|NCT02548897|EXPERIMENTAL|Freezing of gait in PD|All participants will undergo an deep brain stimulation (DBS) for the FOG, and an electroencephalography (EEG) to better understand the neurophysiological underpinnings of the symptom. In addition, review changes in scalp recorded EEG and gait parameters during natural FoG episodes while participants are ambulatory in an advanced gait laboratory setting using a wireless EEG amplifier with active electrodes.
62468385|NCT00496548|EXPERIMENTAL|1|Fecal calprotectin and urinary PGE-M levels will be tested on all participants.
62665232|NCT00331487|ACTIVE_COMPARATOR|Rosiglitazone QD|
62665233|NCT01572142||Parkinson disease group|Subjects with Parkinson disease
62665234|NCT03372421|EXPERIMENTAL|Social Story|Participants will read information about what to expect from the assessment in the format of a Social Story
62665235|NCT03372421|ACTIVE_COMPARATOR|Standard Information|Participants will read standard information about what to expect from the assessment.
62665236|NCT04922281|ACTIVE_COMPARATOR|ICM/CIED/non-invasive LT-ECG patch arrhythmia detection guided Management|"Implantable device (ICM/CIED) that provides accurate daily transmission of cardiac electrical data for arrhythmia detection. Patients without an existing CIED who prefer to use noninvasive LT-ECG monitoring will be offered to use the Carnation Ambulatory Monitor (CAM™; Bardy Diagnostics). The CAM™ is patch approved for LT-ECG monitoring applied to the skin over the chest for a time-period of 7-days every 2 months for cardiac electrical data for arrhythmia detection."
62665237|NCT04922281|PLACEBO_COMPARATOR|Conventional Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
62665238|NCT02251392|EXPERIMENTAL|Chamomila recutita Gel|Experimental Group 1 - patients will apply the gel since the begging of radiodermatitis, three times a day. The dose is being determined in a Phase II study that is being conducted. Topical application of gel is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
62665239|NCT02251392|EXPERIMENTAL|Chamomila recutita Infuse 2,5%|Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
62737577|NCT02450435||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
62103655|NCT04215978|EXPERIMENTAL|Phase 1b: BGB-A445 Monotherapy|Dose Expansion Part C: Participants will receive 1 dose level of BGB-A445
62103656|NCT05471167||Birth cohort 2010|Children born from 01/07/2010 followed up until 30/06/2016
62103657|NCT05471167||Birth cohort 2011|Children born from 01/07/2011 followed up until 30/06/2017
62103658|NCT05471167||Birth cohort 2012|Children born from 01/07/2012 followed up until 30/06/2018
62103659|NCT05471167||Birth cohort 2013|Children born from 01/07/2013 followed up until 30/06/2019
62103660|NCT05471167||Birth cohort 2014|Children born from 01/07/2014 followed up until 30/06/2020
62103661|NCT05471167||Birth cohort 2015|Children born from 01/07/2015 followed up until 30/06/2021
62103662|NCT05471167||Birth cohort 2016|Children born from 01/07/2016 followed up until 30/06/2022
62103663|NCT05471167||Birth cohort 2017|Children born from 01/07/2017 followed up until 30/06/2022
62103664|NCT05471167||Birth cohort 2018|Children born from 01/07/2018 followed up until 30/06/2022
62103665|NCT05471167||Birth cohort 2019|Children born from 01/07/2019 followed up until 30/06/2022
62103666|NCT05471167||Birth cohort 2020|Children born from 01/07/2020 followed up until 30/06/2022
62103667|NCT05252624|ACTIVE_COMPARATOR|Active Comparator: Henagliflozin|Single 5 mg tablet, administered orally once daily for 6 months
62103668|NCT05252624|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Single 5 mg tablet, administered orally once daily for 6 months
62103669|NCT02723851||Acute MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT).
62296450|NCT05865483||Caregiver group|Spends at least one mealtime daily assisting with a person with DM1 already enrolled in the study. Expect ratio of 1:2 caregiver:participant (approx n=45)
62103670|NCT02723851||Non-MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT).
62296451|NCT05551130|ACTIVE_COMPARATOR|Equia Group|Equia system bulk fill glass hybrid material
62296452|NCT05551130|ACTIVE_COMPARATOR|Charisma Group|Charisma Smart universal composite resin
62296453|NCT00576771|EXPERIMENTAL|1|"ALI/ARDS patients~evaluated the effect of PSV, NAVA and assisted controlled mechanical ventilation by patient through a button"
62296454|NCT00626873|EXPERIMENTAL|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
62468386|NCT05617222|ACTIVE_COMPARATOR|Bed rest- Control|One leg will be subjected to disuse by bed rest and will not receive further treatment during the bed rest period.
62468387|NCT05617222|EXPERIMENTAL|Bed rest + NMES|One leg will be subjected to disuse by bed rest and will in addition receive neuromuscular electrical stimulation of the quadriceps muscle 3 times/day.
62103671|NCT02027935|EXPERIMENTAL|Treatment (T cells, chemo, aldesleukin, ipilimumab)|Beginning 48 to 72 hours prior to T cell infusion, patients receive cyclophosphamide IV over 30-60 minutes. Patients then receive autologous CD8+ melanoma-specific T cells IV over 30-60 minutes on day 0, aldesleukin SC BID on days 0-13 and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
62296455|NCT06656624|ACTIVE_COMPARATOR|physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS|
62296456|NCT06656624|EXPERIMENTAL|Ribociclib combined with AI±OFS|
62296457|NCT02406755|NO_INTERVENTION|Control|This control group will not receive an intervention.
62296458|NCT02406755|ACTIVE_COMPARATOR|one-sensory self care|Daily moisturizing body care with an odorless moisturizer (Todo Dia® - Natura) for 30 days.
62296459|NCT02406755|ACTIVE_COMPARATOR|bi-sensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days.
62296460|NCT02406755|ACTIVE_COMPARATOR|multisensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days, and will watch a video with music and images of nature during self-care.
62296461|NCT01392833|ACTIVE_COMPARATOR|steroids|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day for six months followed by oral prednisone 0.2 mg/kg every other day for a further six months.
62296462|NCT01392833|EXPERIMENTAL|steroids plus azathioprine|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further six months.
62468388|NCT04506502|EXPERIMENTAL|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
62468389|NCT05172219|ACTIVE_COMPARATOR|Message Type PNSL: Physician sender, No Survey Link|In this arm, the Physician is message sender and the message does not include a link to a survey that initiates asynchronous care.
62296463|NCT01146470|EXPERIMENTAL|RGC 200 mg|
62296464|NCT01146470|EXPERIMENTAL|RGC 400 mg|
62296465|NCT01146470|PLACEBO_COMPARATOR|Placebo|
62296466|NCT01235676|EXPERIMENTAL|Diet|Calorie restriction to reduce weight gain
62296467|NCT01235676|EXPERIMENTAL|Exercise|Exercise to reduce weight gain
62296468|NCT05435521|EXPERIMENTAL|People living with HIV group 40 participants|40 participants with HIV
62296469|NCT05435521|ACTIVE_COMPARATOR|People without HIV|20 participants without HIV
62296470|NCT00619229|EXPERIMENTAL|Alprostadil|Alprostadil
62296471|NCT00619229|PLACEBO_COMPARATOR|Placebo|Placebo
62468390|NCT05172219|ACTIVE_COMPARATOR|Message Type PSL: Physician sender, Survey Link|In this arm, the Physician is message sender and the message does include a link to a survey that initiates asynchronous care.
62468391|NCT05172219|ACTIVE_COMPARATOR|Message Type SNSL: System sender, No Survey Link|In this arm, the Health System is message sender and the message does not include a link to a survey that initiates asynchronous care.
62468392|NCT05172219|ACTIVE_COMPARATOR|Message Type SSL: System sender, Survey Link|In this arm, the Health System is message sender and the message does include a link to a survey that initiates asynchronous care.
62468393|NCT03048526|EXPERIMENTAL|NovaTears®|
62468394|NCT03048526|ACTIVE_COMPARATOR|Hydrabak®|Unpreserved sodium chloride (0.9%) eye drops in ABAK® system
62468395|NCT01840735|ACTIVE_COMPARATOR|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
62468396|NCT01840735|PLACEBO_COMPARATOR|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
62665240|NCT02251392|ACTIVE_COMPARATOR|Urea cream based|Control Group - usual care to treat radiodermatitis, patients will apply the infuse since the begging of radiodermatitis, three times a day. Radiodermatitis grade and intensity is going to be evaluated. Topical application of urea is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
62665241|NCT02448082|PLACEBO_COMPARATOR|Shampoo (inactive)|Shampoo containing no active anti-dandruff ingredients will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the placebo group will wash their hair with 25ml of the placebo shampoo per hair washing session.
62296472|NCT05760495||Single arm|ART-experienced PLWH
62296473|NCT03845530|ACTIVE_COMPARATOR|Hemodialysis group|Blood sample taken and sent to laboratory for analysis
62296474|NCT03845530|ACTIVE_COMPARATOR|Peritoneal dialysis|Blood sample taken and sent to laboratory for analysis
62296475|NCT01126229|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: placebo
62468397|NCT00010205|EXPERIMENTAL|Treatment (benzoylphenylurea)|Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
62468398|NCT06263972|ACTIVE_COMPARATOR|Direct Stimulation of the Primary Motor Cortex (M1) Combined With Aerobic Activity.|low current electrical stimulation to Motor cortex for 3 weeks.
62665242|NCT02448082|EXPERIMENTAL|Sodium shale oil sulponate 1% shampoo|Shampoo containing sodium shale oil sulponate 1% will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the experimental group will wash their hair with 25ml of the sodium shale oil sulponate 1% shampoo per hair washing session.
62665243|NCT00565786||ArCom® Polyethylene|ArCom® Polyethylene
62665244|NCT00565786||ArComXL® Polyethylene|ArComXL® Polyethylene
62665245|NCT06216366|PLACEBO_COMPARATOR|Control|Sterile normal saline 0.9% IV immediately prior to hyperbaric chamber exposure, and immediately after exposure
62665246|NCT06216366|ACTIVE_COMPARATOR|rhu-pGSN pre-exposure|rhu-pGSN 24 mg/kg IV immediately prior to hyperbaric chamber exposure, and sterile normal saline 0.9% IV immediately after exposure
62665247|NCT06216366|ACTIVE_COMPARATOR|rhu-pGSN post-exposure|Sterile normal saline 0.9% IV immediately prior to hyperbaric chamber exposure, and rhu-pGSN 24 mg/kg IV immediately after exposure
62296476|NCT01126229|EXPERIMENTAL|300 mg/d Resveratrol|Dietary Supplement: 300 mg/d Resveratrol
62296477|NCT01126229|EXPERIMENTAL|1000 mg/d Resveratrol|Dietary Supplement: 1000 mg/d Resveratrol
62296478|NCT00190775|EXPERIMENTAL|Atomoxetine|Atomoxetine 40 milligrams (mg) once daily (QD) for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
62296479|NCT00190775|PLACEBO_COMPARATOR|Placebo|Placebo is administered once daily (QD), orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
62296480|NCT04774250|EXPERIMENTAL|Zonisamide|For subjects randomized to zonisamide, the package will contain one zonisamide capsule (100 mg PO).
62296481|NCT04774250|PLACEBO_COMPARATOR|Placebo|For the subjects randomized to placebo, the package will contain one placebo capsule that looks, smells, and taste the same as zonisamide capsule.
62296482|NCT05486078|EXPERIMENTAL|MD-Tissue Medical Device|
62296483|NCT02861170|EXPERIMENTAL|Brief Mindfulness-Based Intervention|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety as well as a 10-minute mindfulness-based intervention called a body scan at 3 different time-points (T1 - 1 week prior to surgery, T2 - within 4 hours before surgery, and T3 - approximately 24 hours after transfer from recovery to the orthopedic floor).
62296484|NCT02861170|NO_INTERVENTION|Education|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety.
62296485|NCT01497171|ACTIVE_COMPARATOR|Elevate Mesh|Elevate transvaginal mesh - surgical repair of prolapse
62296486|NCT01497171|ACTIVE_COMPARATOR|Anterior Colporrhaphy|Anterior colporrhaphy - surgical repair of prolapse
62468399|NCT06263972|ACTIVE_COMPARATOR|Direct Stimulation the Prefrontal Cortex Combined With Aerobic Activity|with low current electrical stimulation to Prefrontal cortex for 3 weeks.
62665248|NCT00033345|EXPERIMENTAL|High-Risk Breast Cancer|All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
62665249|NCT05878314||Group A: Tamoxifen|Patients with early HR+/HER2- Breast cancer receiving Tamoxifen
62665250|NCT05878314||Group B: Aromatase Inhibitor (+GnRH if premenopausal)|Patients with early HR+/HER2- Breast cancer receiving Aromatase Inhibitor (+GnRH if premenopausal)
62665251|NCT05878314||Group C: Control group|no preoperative endocrine treatment
62665252|NCT03959475||Saint-Etienne Hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
62665253|NCT03959475||Firminy hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
62665254|NCT03959475||South Lyon hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
62665255|NCT03959475||Bordeaux hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
62665256|NCT03959475||Saint-Chamond hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
62665257|NCT03959475||Angers hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
62665258|NCT03959475||Clermont Ferrand hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
62296487|NCT01258920|EXPERIMENTAL|Paliperidone palmitate|Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
62665259|NCT02617862|EXPERIMENTAL|PCI imaging system|
62665260|NCT06118073|ACTIVE_COMPARATOR|Total knee replacement with Headspace|Participants scheduled for primary total knee replacement will be randomized to receive the mindfulness intervention (a smartphone-based mindfulness application).
62665261|NCT06118073|ACTIVE_COMPARATOR|Total knee replacement without Headspace|Participants scheduled for primary total knee replacement will not receive the mindfulness intervention.
62665262|NCT00976898|EXPERIMENTAL|Proton Beam Irradiation|This is a single arm study. All study participants will receive proton radiation therapy.
62665263|NCT00652132|ACTIVE_COMPARATOR|Arm I (cisplatin)|Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
62665264|NCT00652132|EXPERIMENTAL|Arm II (cisplatin + STS)|Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
62665265|NCT03549195|ACTIVE_COMPARATOR|ICG|
62665266|NCT03549195|ACTIVE_COMPARATOR|ICG-CP|CP, control peptide
62665267|NCT03549195|EXPERIMENTAL|ICG-TMTP1|also named as TMTP1-ICG
62308263|NCT03863938|EXPERIMENTAL|Tegoprazan 50mg after the meal|Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day
62665268|NCT02801773|EXPERIMENTAL|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and adjunct probiotic one lozenge containig Lactobacillus reuteri per day during 3 month
62665269|NCT02801773|PLACEBO_COMPARATOR|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and one lozenge containig placebo (mint lozenge) per day during 3 month
62665270|NCT01454999|EXPERIMENTAL|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
62665271|NCT01454999|EXPERIMENTAL|CTI + text|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change. Tailored feedback messages based on stage of change will also be sent by cell phone.
62665272|NCT02463877|EXPERIMENTAL|Minimally-Invasive Procedure|single-arm study of laparoscopic cytoreduction and HIPEC
62665273|NCT03457584|ACTIVE_COMPARATOR|BSS arm|BSS is given at the end of surgery
62665274|NCT03457584|EXPERIMENTAL|air arm|air-tamponade is given at the end of surgery
62665275|NCT06329557|ACTIVE_COMPARATOR|Survey and Coaching|Individual coaching with a trained patient experience professional (XTEC coach) will occur individually with clinicians 3-4 times over several weeks. The coach will assist participants with improving communication with patients.
62665276|NCT06329557|ACTIVE_COMPARATOR|Survey and Communication Class|A one-hour communication class will take place during the workday. The class will be offered virtually or in person for a group of clinicians to attend.
62665277|NCT06329557|NO_INTERVENTION|No Intervention|Surveys only
62103672|NCT03888820|EXPERIMENTAL|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
62665278|NCT05711147|EXPERIMENTAL|Definitive abutment|Definitive prosthetic abutment placed at the moment of implant placement
62296488|NCT05992467|EXPERIMENTAL|WECARE|Participants will first complete a baseline survey online, then subscribe to the WECARE official account on their own WeChat accounts and begin receiving the 7-week interactive and personalized program. The program content includes short video clips, pictorial messages, and audio recordings. Each week, the WECARE program is focused on a theme aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Four weeks after the intervention or 11 weeks after the baseline, participants will complete a follow-up survey online.
62296489|NCT06500741||Participants|Participants will include urologists or oncologists for the physician interviews and prostate cancer patients for the patient interviews and surveys.
62296490|NCT05278390|EXPERIMENTAL|Thoracic CT Scan|
62296491|NCT00278876|EXPERIMENTAL|imatinib mesylate|patients receiving adjuvant imatinib mesylate
62665279|NCT05711147|ACTIVE_COMPARATOR|Healing abutment|Conventional healing abutment placed at the moment of implant placement and removed 4 times during prosthesis making
62665280|NCT01205308|ACTIVE_COMPARATOR|Stanol ester spread|Vegetable oil based margarine with stanol ester enrichment
62665281|NCT01205308|PLACEBO_COMPARATOR|control spread|Vegetable oil based margarine without stanol ester enrichment
62665282|NCT00546273|EXPERIMENTAL|RUTI 5 micrograms of FCMtb|RUTI dose: 5 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
62665283|NCT00546273|EXPERIMENTAL|RUTI 25 micrograms of FCMtb|RUTI dose: 25 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
62665284|NCT00546273|EXPERIMENTAL|RUTI 100 micrograms of FCMtb|RUTI dose: 100 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
62665285|NCT00546273|EXPERIMENTAL|RUTI 200 micrograms of FCMtb|RUTI 200 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
62665286|NCT00546273|PLACEBO_COMPARATOR|placebo|placebo of the vaccine RUTI (total n=8, n=2 for each period)
62665287|NCT03349515|ACTIVE_COMPARATOR|Group A - povidone-iodine ophthalmic solution.|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.
62103673|NCT03888820|SHAM_COMPARATOR|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
62103674|NCT06356207||Patients affected by neuronally mediated syncope|
62103675|NCT04795089||Patients|Patients with iNPH and shunt surgery.
62103676|NCT04795089||Healthy individuals|Healthy controls with similar gender and age distribution as the patients.
62665288|NCT03349515|ACTIVE_COMPARATOR|Group B - ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution, with the right eye to receive the drops first.
62665289|NCT02221414|EXPERIMENTAL|Treatment A (FDC)|
62665290|NCT02221414|ACTIVE_COMPARATOR|Treatment B (single agents)|
62665291|NCT05301634|ACTIVE_COMPARATOR|Group A|the patients will receive bilateral infraorbital block
62665292|NCT05301634|ACTIVE_COMPARATOR|Group B|the patients will receive topical intranasal application of bupivacaine
62103677|NCT02334306|EXPERIMENTAL|MEDI5872 210 mg|Participants will receive a fixed SC dose of 210 mg MEDI5872 every week (QW) from Days 1 to 15 and then every 2 weeks (Q2W) from Days 29 to 85 in double-blind period. In open-label period, participants will continue dosing of MEDI5872 210mg Q2W from Days 99 to 183 and will receive an additional dose of blinded placebo on Day 106.
62665293|NCT04613570|EXPERIMENTAL|Yearly endoscopy|Upper gastrointestinal endoscopy every year (12-16 months)
62665294|NCT04613570|OTHER|Endoscopy every 3 years|Upper gastrointestinal endoscopy every three years (32-40 months)
62665295|NCT03657953|ACTIVE_COMPARATOR|anterior (MI-A) surgical approach|The minimally invasive anterior surgical approach was carried out using a modified Smith-Petersen access as described by Bender et al. (Bender et al. 2009) with the patient in supine position.
62665296|NCT03657953|ACTIVE_COMPARATOR|anterolateral (MI-AL) surgical approach|For the minimally invasive anterolateral surgical approach, a modified Watson-Jones approach according to Röttinger (Rottinger et al. 2006) was applied with the patient in supine position.
62665297|NCT03657953|ACTIVE_COMPARATOR|direct lateral (DLA) surgical approach|The direct lateral surgical approach was performed according to the technique described by Hardinge et al. (Hardinge et al. 1982) with the patient positioned supine
62665298|NCT02846428|ACTIVE_COMPARATOR|5-Fluorouracil + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of 5-FU + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
62103678|NCT02334306|PLACEBO_COMPARATOR|Placebo/MEDI5872 210 mg|Participants will receive a SC dose of placebo matching with MEDI5872 QW on Days 1, 8, and 15 and then Q2W from Days 29 to 85 in double-blind period. In open-label period, participants will receive a fixed SC dose of 210 mg MEDI5872 QW (Days 99 to 113) and Q2W (Days 127 to 183) in open-label period.
62103679|NCT01126840||Questionnaire + Telephone Interview|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete. The phone interview should take 30-45 minutes to complete.
62103680|NCT02430532|EXPERIMENTAL|Dimethyl fumarate|BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
61912362|NCT04176042|EXPERIMENTAL|Track 1|"Subjects will be randomized to one of two 4-week tracks.~Track 1 (intervention + follow-up) will consist of the following:~Subjects will be randomized to one of two 4-week tracks. Track 1 (intervention + follow-up) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention participants will complete a baseline questionnaire battery consisting of measures including demographics, medical history and sleep. After completion, a 2-hour educational presentation will take place with a question-and-answer session. Participants will then complete post-intervention questionnaires to assess immediate impact of the session on knowledge, beliefs and practices. After 4 weeks, Track 1 participants will be contacted and will be asked to re-complete all baseline questionnaires (see above), in order to evaluate changes over 4 weeks."
61912363|NCT04176042|ACTIVE_COMPARATOR|Track 2|"Subjects will be randomized to one of two 4-week tracks. Track 2 (wait list + intervention) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention for Track 1 participants will complete the same baseline questionnaire battery.~An identical intervention session, scheduled 4 weeks into the future. At that time, an identical procedure to the other track will be followed, including the pretest questionnaires, 2-hour session, and post-session assessment. No additional 4-week follow-up will be performed."
61912364|NCT05292898|EXPERIMENTAL|LCAR-AIO Cells|Each subject will be treated with LCAR-AIO Cells
61912365|NCT00621621|EXPERIMENTAL|Freezor Catheter for AVNRT|Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
61912366|NCT00621621|OTHER|External Data Supporting the Study|This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.
61912367|NCT04130737|EXPERIMENTAL|TORUS Stent Graft System|The TORUS Stent Graft System (SGS) is comprised of a Stent Graft (SG) and a Stent Graft Delivery System (SGDS).
62665299|NCT02846428|EXPERIMENTAL|Capecitabine + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of capecitabine + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
62665300|NCT05520775|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide via subcutaneous injections at escalating doses (.25mg to 1.0mg) over 9 weeks.
62103681|NCT02430532|EXPERIMENTAL|Placebo|BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
62103682|NCT06540287||Group 1 cohort: Healthy Older Adults (HOA)|This cohort will include healthy older adults, aged 65y or over, who participate in less than 60 minutes of structured exercise each week.
62103683|NCT06540287||Group 2 cohort: Elite Older Athletes (EOA)|This cohort will include healthy older adults, aged 65y or over, who are elite athletes for their age (determined by interview and VO2max)
61912368|NCT05315869||Retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix located in the retrocaecal position.
61912369|NCT05315869||Non-retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix not located in the retrocaecal position.
61912370|NCT06339476|EXPERIMENTAL|Serum ADMA, MDA and M30 levels mesurment|With the permission of the participants, 7 ml of venous, fasting blood samples were collected during the early follicular phase. In the blood serum of the participants, M30, ADMA, and MDA levels were measured by using commercial ELISA test kits.
61912371|NCT06339476|NO_INTERVENTION|diagnosis of the study group|Determination of the patient and control group to be included in the study group by the relevant gynecologist.
62103684|NCT05021419|ACTIVE_COMPARATOR|Standard Arm|"Active Comparator: Standard Arm~Both the current the European society of cardiology guidelines and National Institute of Health and Care Excellence currently advise that chronic stable heart failure patients with severely impaired left ventricular systolic function should initially be optimized as follows:~Visit 1: ACEi/ARB and Low Betablocker commenced Visit 2: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 3: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 4: Switch ACEi/ARB to Entresto 100mg Visit 5: Modify Entresto dose to 200mg Visit 6: MRA Added Visit 7: MRA up-titrated Visit 8: SGLT2i started"
62296492|NCT03817671|OTHER|Control arm (5% O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 5% O2, and 89.3% N2 till embryo transfer
62468400|NCT06263972|SHAM_COMPARATOR|Shame Stimulation Combined With Aerobic Activity|Shame low current electrical stimulation to cortex for 3 weeks.
62665301|NCT05520775|SHAM_COMPARATOR|Sham/Placebo|Participants will receive sham subcutaneous injections over 9 weeks.
62665302|NCT01601795|ACTIVE_COMPARATOR|Sevoflurane|During cardiopulmonary bypass, sevoflurane will be administered through a vaporizer integrated into heart-lung-machine.
62296493|NCT03817671|EXPERIMENTAL|Experimental arm (2%O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 2% O2, and 92.3% N2 till embryo transfer
62468401|NCT05488808|ACTIVE_COMPARATOR|Active and then sham rTMS|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the arm.
62468402|NCT05488808|SHAM_COMPARATOR|Sham and the active rTMS|Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS.
62468403|NCT00546897|EXPERIMENTAL|Cohort 1|"Lenalidomide 50 mg/day oral for 14 days followed by 30 days of rest. Lenalidomide 50 mg/day oral for 21 days (this is Cycle 1 and Cycle 2).~If no progressive disease (PD) then lenalidomide 10 mg/day oral for 28 days for 12 cycles."
62468404|NCT00546897|EXPERIMENTAL|Cohort 2|"Cycle 1: Oral lenalidomide 50 mg/day x 28 days induction therapy. Treatment will then depend on the response to Cycle 1: if patients obtain a complete remission (CR) they will proceed to low dose lenalidomide therapy, if patients have a non-CR they will receive a second high dose cycle of lenalidomide 50 mg/day x 28 days (Cycle 2) Cycle 2 consists of lenalidomide 50mg/day x 28 days Further treatment will depend on the response to Cycle 2: if patients obtain a CR/partial remission (PR)/stable disease (SD) they will proceed to low dose lenalidomide therapy, if patients have PD they will be removed from the study.~Low Dose Cycles: low dose lenalidomide therapy consisting of 10 mg daily for a 28 day cycle.be 1) For patients that achieve a CR, 2 cycles of low dose lenalidomide will be administered, and then patients observed off therapy. For patients with PR/SD, low dose lenalidomide will continue for a total of 6 cycles and then patients will be observed off therapy."
62665303|NCT01601795|ACTIVE_COMPARATOR|Isoflurane|During cardiopulmonary bypass, isoflurane will be administered through a vaporizer integrated into heart-lung-machine.
62665304|NCT02658474|EXPERIMENTAL|ACT-group|Group based Acceptance and Commitment Therapy. The patients will attend to three sessions which last for three days. Between the sessions the patients will train at home on ACT related topics. The whole intervention will last for three months.
62665305|NCT02658474|NO_INTERVENTION|Primary care|Treatment in a primary care setting.
62103685|NCT05021419|EXPERIMENTAL|Streamlined protocol arm|"Patients are optimized according to the accelerated protocol adapted from and based on the principles proposed by Prof McMurray and Prof Packer (Circulation 2021;143:875-877)~Visit 1: Low Dose Beta Blocker started, SGLT2i started + Entresto 100 mg bd started~Visit 2: MRA Added if renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 3: MRA up-titrated if BP and renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 4+: Betablocker increased if BP and pulse rate permit. Further visits may be required to facilitate a gentle up-titration of betablockers."
62103686|NCT05493722|EXPERIMENTAL|Stimulation Group A|Participants with already implanted DBS will receive stimulation order 1. PS, OS, OS.
62103687|NCT05493722|EXPERIMENTAL|Stimulation Group B|Participants with already implanted DBS will receive stimulation order 1. OS, PS, OS.
62103688|NCT05493722|EXPERIMENTAL|Stimulation Group C|Participants with already implanted DBS will receive stimulation order 1. OS, OS, PS.
62103689|NCT01751997|ACTIVE_COMPARATOR|Transplants from 8/8-matched unrelated|Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
61912372|NCT01894568|EXPERIMENTAL|Insulin Peglispro|Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs).
62103690|NCT01751997|EXPERIMENTAL|Transplants from family-mismatched/haploidentical donors|Participants will receive FMT using a reduced intensity conditioning regimens.
62103691|NCT01579656|EXPERIMENTAL|Salba|25g of ground Salba baked into a bran muffin
62103692|NCT01579656|EXPERIMENTAL|Poppy|25g of ground poppy seeds baked into a bran muffin
62103693|NCT01579656|EXPERIMENTAL|Flaxseed|25g of ground flaxseed baked into a bran muffin
62103694|NCT01579656|EXPERIMENTAL|Sesame|25g of ground sesame seeds baked into a bran muffin
62103695|NCT01579656|PLACEBO_COMPARATOR|Wheat Bran|Bran muffin matched for total available carbohydrates, total dietary fibre and calories
62665306|NCT06478030||Screening cohort|Healthy participants aged 40-74 years from Fenghua District, Ningbo City.
62103696|NCT06713798|EXPERIMENTAL|A1 : the patients naïve from systemic treatment - atezolizumab + tiragolumab|
62103697|NCT06713798|EXPERIMENTAL|A2 : the patients naïve from systemic treatment - atezolizumab|
62103698|NCT06713798|EXPERIMENTAL|B: patients with previous exposure to ICI - atezolizumab + tiragolumab|
62103699|NCT06249789|ACTIVE_COMPARATOR|Spinal Anesthesia|This arm gets preoperative single-dose spinal anesthesia plus an ultrasound-guided Fascia Iliaca Compartment Block (FICB).
62468405|NCT01452022|EXPERIMENTAL|Inductigraft|open label non randomised to assess performance of synthetic bone graft using the product, Inductigraft, in posterolateral lumbar fusion
62737578|NCT02450435||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
62103700|NCT06249789|ACTIVE_COMPARATOR|General Anesthesia|This arm gets preoperative general anesthesia plus an ultrasound-guided Fascia Iliaca Compartment Block (FICB).
62665307|NCT00433537|EXPERIMENTAL|VcR-CVAD induction followed by maintenance rituximab|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Maintenance rituximab: Beginning 4-8 weeks after completion of induction therapy, patients receive rituximab IV over 3-4 hours once weekly for 4 weeks. Treatment repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62665308|NCT00433537|EXPERIMENTAL|VcR-CVAD induction followed by ASCT|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) SC or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~ASCT: After completion of induction therapy, patients who are eligible may have the option to receive consolidation therapy for autologous stem cell transplantation (off-study). These patients undergo stem cell harvest during courses 4, 5, or 6 of induction therapy."
62665309|NCT00221104|ACTIVE_COMPARATOR|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
62665310|NCT00221104|NO_INTERVENTION|No intervention|Patient has no intervention.
62103701|NCT03582956|OTHER|Adolescent Overweight|Adolescents with T1D and overweight/obesity
62103702|NCT03582956|OTHER|Adolescent Typical|Lean adolescents with T1D
62103703|NCT03582956|OTHER|Young Adult|Young adults with T1D with a euglycemic hyperinsulinemic clamp with tracer enhancement
62665311|NCT05312333||critically-ill childern|
62665312|NCT03608969||Study Group|Children with cerebral palsy aged 3-16 years will be evaluated in terms of the orofacial function using the Nordic Orofacial test- screening (NOT-S). Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) level and Communication Function Scale (CFS) of child will be recorded. Oral health related quality of life will be assessed using the Parental- Caregiver Perceptions Questionnaire. Caries experience will be measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft)
62665313|NCT03791021||third trimester pregnant women|the group of participants in this research would include approximately 100 subjects in the third trimester of their pregnancy. the participants would be collected in the central area of Israel from various socioeconomic groups. each participant would be asked to make draw a person (DAP) test, and answer a number of questionnaires including Edinburgh Postnatal Depression Scale (EPDS), Beck Depression Inventory II (BDI-II), and Traumatic Events Questionnaire (TEQ).
62665314|NCT01526382|ACTIVE_COMPARATOR|intervention arm|patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
62103704|NCT05809076|EXPERIMENTAL|real tACS|
62103705|NCT05809076|SHAM_COMPARATOR|sham tACS|
62103706|NCT06631963|OTHER|Group EAET delivered through telehealth|Group-based Emotional Awareness and Expression Therapy (EAET) delivered through telehealth is a form of psychotherapy that helps individuals recognize and express emotions that may be contributing to physical symptoms. It is conducted in a group setting, allowing participants to share their experiences and support each other. Through a virtual platform, patients engage in structured sessions led by a therapist, where they explore emotional connections to their symptoms, practice emotional expression, and develop healthier coping mechanisms. The telehealth format enables access to therapy from remote locations, enhancing convenience and flexibility while maintaining the benefits of group interaction.
62665315|NCT01526382|PLACEBO_COMPARATOR|control arm|Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
62103707|NCT06517472||Bascom's pit-picking|In the pit-picking technique, midline pits will be excised with minimal tissue removal (skin margin \<1 mm). Hairs in the sinuses will be removed along with the curetted tissues. The midline excision areas and secondary pits excised near the midline will be closed with 3-0 polypropylene.
62665316|NCT03116815|OTHER|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
61912373|NCT01894568|ACTIVE_COMPARATOR|Insulin Glargine|Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs.
62296494|NCT06234267|EXPERIMENTAL|Dietary Quality|Receive daily text messages for promoting dietary quality.
62296495|NCT06234267|EXPERIMENTAL|Physical Activity|Receive daily text messages for promoting physical activity.
61912374|NCT04108117||Robotic nipple sparing mastectomy group/RNSM|"Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.~The estimated sample size for this arm is 300 cases."
61912375|NCT04108117||Conventional nipple sparing mastectomy group/CNSM|"Cases or Patients who underwent conventional nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Conventional nipple-sparing mastectomy should not be performed using robotic or endoscopic surgical systems. Axillary or lateral incisions that are similar to incisions in robotic nipple-sparing mastectomy are not allowed. Other than axillary or lateral incisions can be performed for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with nipple-sparing mastectomy without immediate reconstruction are excluded.~The estimated sample size for this arm is 300 cases."
61912376|NCT02202330|PLACEBO_COMPARATOR|Standard Care, Organized Discharge|Stroke patients are given instructions before discharge regarding diet, need for rehabilitation, possible complications, medication use and information booklets are also handed out. This information is imparted by a multidisciplinary team consisting of a neuro physician, a stroke nurse, a dietitian and a physiotherapist. These are verbal instructions and handouts are written in English. On the day of discharge, or 24 hours prior to discharge, a discharge coordinator details the skills learnt . A detailed written discharge summary is given out detailing all aspects of care, follow-up, medications and test results.
61912377|NCT02202330|EXPERIMENTAL|Video Arm, Standard Discharge|"Intervention is as follows:~1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
62103708|NCT06517472||Crystallized phenol|In crystallized phenol treatment, the pit will be expanded with the help of a clamp, and after confirming it is uncomplicated, hair and infected tissue will be cleaned. Nitrofurazone will be applied to the pit edges. Crystallized phenol will be filled into the sinus with the help of a clamp.
62296496|NCT06234267|EXPERIMENTAL|Sleep Hygiene|Receive daily text messages for promoting sleep hygiene.
62296497|NCT04576442|EXPERIMENTAL|Asthma-PASS Intervention|Collaboration with PCPs to optimize management. Community Health Worker (CHW) to ensure PCP plan is followed. Two asthma education sessions with children/caregivers focusing on self-efficacy and physical activity promotion. Promotion of asthma awareness in school. School personnel training in asthma
62665317|NCT05776719|ACTIVE_COMPARATOR|Health & Wellness|8 weeks, once weekly 90 minute sessions, groups of 8-10 subjects, gender stratified
62296498|NCT04576442|ACTIVE_COMPARATOR|Asthma Management Comparison Group|Includes two sessions of basic asthma education and PCP notification of child's asthma severity level.
62665318|NCT05776719|EXPERIMENTAL|Warrior Renew|8 weeks, once weekly 90 minute sessions, groups of 8-10 subjects, gender stratified
62665319|NCT06091033|EXPERIMENTAL|Fermented rice group|This group takes black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks.
62296499|NCT06399757|EXPERIMENTAL|Phase 1: Dose Escalation|"Dose escalation with increasing dose levels of APL-5125 to identify Recommended Phase 2 Dose.~Possibility to expand into select populations"
62665320|NCT06091033|PLACEBO_COMPARATOR|Control group|This group takes a placebo for 8 weeks.
62665321|NCT05139147|EXPERIMENTAL|DAISe Thrombectomy System|Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.
62296500|NCT06399757|EXPERIMENTAL|Phase 2: Dose Expansion/Optimization|Up to 2 dose levels of APL-5125 in a selected population
62296501|NCT03618030|EXPERIMENTAL|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
62296502|NCT03618030|PLACEBO_COMPARATOR|Placebo Treatment|Matched placebo
62296503|NCT01739426|EXPERIMENTAL|Study population|"The population is composed of patients with a confirmed Zenker's diverticulum.~Intervention: Repair w/LigaSure"
62296504|NCT00782249|EXPERIMENTAL|1|Vagus nerve stimulation paradigm #1
62296505|NCT00782249|EXPERIMENTAL|2|Vagus nerve stimulation paradigm #2
62296506|NCT00782249|EXPERIMENTAL|3|Vagus nerve stimulation paradigm #3
62296507|NCT01083108|ACTIVE_COMPARATOR|Non-surgical Arm|Low-calorie Diet
62296508|NCT01083108|EXPERIMENTAL|Surgical Arm|Roux-en-Y Gastric Bypass
62665322|NCT01857518|OTHER|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
62665323|NCT01857518|OTHER|Healthy adolescent control Group|Healthy adolescents recruited from general population
62665324|NCT01755637|EXPERIMENTAL|Albendazole tablet (Aqua Based)|Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment.
62665325|NCT01755637|ACTIVE_COMPARATOR|Albendazole tablet (Alcohol Based)|Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment.
62665326|NCT01309711||HIE|Moderate of severe neonatal encephalopathy
62665327|NCT00267670|EXPERIMENTAL|Pentoxifylline|400mg PO TID
62665328|NCT00267670|PLACEBO_COMPARATOR|Placebo|1 pill PO TID
62665329|NCT02219542|PLACEBO_COMPARATOR|a standard general anesthesia|a standard general anesthesia and with transversus abdominis plane block 20 ml 0.9% sodium chloride
62665330|NCT02219542|EXPERIMENTAL|transversus abdominis plane block|a standard general anesthesia with transversus abdominis plane block 20 mL 0.25% ropivacaine
62665331|NCT00456118||repeated miscarriages|60 womens for repeated miscarriages will be included
62665332|NCT00456118||Preeclampsia|70 women for pre-eclampsia will be included
62665333|NCT00456118||intervillites|20 women for intervillites will be included
62665334|NCT05963230||Volunteer Participants|Healthy adult (18+ years old) volunteers
62103709|NCT06517472||Combined treatment|In the combined treatment, crystallized phenol will be applied after pit picking, and the pit area will be left to secondary healing.
62665335|NCT02939781||Febrile critically ill children|Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.
61912378|NCT04803682|EXPERIMENTAL|Prevention (ASPIRE, mentorship)|"Participants complete online ASPIRE course over 3.5-4 hours.~HIGH SCHOOL MENTORS: Eleventh grade high school students receive mentor training over 4-5 hours on how to mentor ninth grade students.~ALL STUDENTS: Mentors and mentees are paired up so that eleventh grade high school students mentor the ninth grade high school students over 30 minutes for 7 sessions about the different types of tobacco products (such as cigarettes, cigars, hookah, and so on) and the dangers of these products."
62103710|NCT06124118|EXPERIMENTAL|Device Duration Level 1|Participants in Device Duration Level 1 will receive Tumor Treatment Fields (TTF) therapy during standard of care consolidation durvalumab.
62103711|NCT06124118|EXPERIMENTAL|Device Duration Level 2|Participants in in Device Duration Level 2 will begin TTF therapy during SOC durvalumab and SOC Concurrent chemoradiation following Device Duration Level 1.
62665336|NCT03837834|EXPERIMENTAL|4 MIN X 4 MIN HIIT of FES-LCE|4 min of high-intensity phase intersperses with 4 min of low-intensity phase for a total of 5 bouts.
62103712|NCT03824652|EXPERIMENTAL|Usual Diet + Walnuts|Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
62296509|NCT04610099|ACTIVE_COMPARATOR|Standard SG|100 patients undergo a standard sleeve gastrectomy
62296510|NCT04610099|EXPERIMENTAL|Banded SG|100 patients undergo a banded sleeve gastrectomy
62296511|NCT04117750|ACTIVE_COMPARATOR|intervention group|55 female patients with PCO
62296512|NCT04117750|PLACEBO_COMPARATOR|non -intervention group|40 female patients with PCO and 50 healthy women matched to PCOS women as regard age and ethnic origin.
62296513|NCT01276821|PLACEBO_COMPARATOR|Standard Treatment|L-Epinephrine and Normal Saline (0.9%)
62296514|NCT01276821|ACTIVE_COMPARATOR|Study Treatment|L-Epinephrine and Hypertonic Saline (3%)
62296515|NCT04274322||Cohort 1|High NUTRIC score
62296516|NCT04274322||Cohort 2|low NUTRIC score
62665337|NCT03837834|EXPERIMENTAL|2 MIN X 2 MIN HIIT of FES-LCE|2 min of high-intensity phase intersperses with 2 min of low-intensity phase for a total of 10 bouts.
61912379|NCT05221502|EXPERIMENTAL|Arm 1|Delamanid + Bedaquiline + OPC-167832 10 mg
61912380|NCT05221502|EXPERIMENTAL|Arm 2|Delamanid + Bedaquiline + OPC-167832 30 mg
61912381|NCT05221502|EXPERIMENTAL|Arm 3|Delamanid + Bedaquiline + OPC-167832 90 mg
61912382|NCT05221502|ACTIVE_COMPARATOR|Arm 4|RHEZ
61912383|NCT02996032||Heart Failure|Patients admitted to the hospital with acute decompensated heart failure expected to be hospitalized for at least 72 hours
62103713|NCT03824652|ACTIVE_COMPARATOR|Usual Diet|Usual diet for 4-10 weeks
62103714|NCT01718132||postoperative patients|
62103715|NCT01014338|ACTIVE_COMPARATOR|ACE-inhibitor|
62103716|NCT01014338|PLACEBO_COMPARATOR|Sugar Pill|
62296517|NCT01416129|ACTIVE_COMPARATOR|Active Comparator: Prosthetic socket standard of care|
62296518|NCT01416129|ACTIVE_COMPARATOR|Active Comparator: Prosthetic brimless socket|
62296519|NCT01817140||Patient MRI|Adult patients with possible maxillofacial and/or mandibular bone invasion with oral cancer or osteoradionecrosis who are scheduled for surgery. All eligible and consented participants will have MRI scans obtained using 3T and 4T magnets prior to their surgery.
62296520|NCT01817140||Normal MRI|Healthy adult volunteers recruited to test the comfort of the coil apparatus and to determine configurations which lead to satisfactory image acquisition.
62296521|NCT02355301||patients with orthopedic disorders|Patients with muscular skeletal impairments receiving a treatment (A, B, C...). The investigators compare these treatments (A, B, C...) in function of ICF model in order to improve the quality of care in orthopedic department.
62296522|NCT05129150||assessment of cognitive functions|Assessment of cognitive disorders with an ultrasound examination performed in routine care during a day hospital.
62296523|NCT00743795|PLACEBO_COMPARATOR|1|Peginterferon and ribavirin + placebo BID for 48 weeks + 24 weeks treatment-free follow-up (n = 50)
62296524|NCT00743795|EXPERIMENTAL|2|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up (n = 100)
62296525|NCT00743795|EXPERIMENTAL|3|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up. However, subjects who achieve RVR (HCV RNA undetectable at Week 4) and maintain that response through Week 24 will stop all study drugs at Week 24 and be followed for an additional 48 weeks (n = 50).
62296526|NCT02249052|ACTIVE_COMPARATOR|AA4500|single injection of 0.58 mg study drug
62296527|NCT02249052|PLACEBO_COMPARATOR|Placebo|single injection of placebo
62665338|NCT02632214|EXPERIMENTAL|Deaf|Group of early profound deaf participants fMRI measure
61912384|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
61912385|NCT03650946||2|men with rising PSA after local definitive treatments
61912386|NCT03650946||3|m0CRPC with a PSA \>1.0 or 2.0
61912387|NCT03381729|EXPERIMENTAL|Dose A|Intrathecal administration 6.0 X 10\^13 vg of onasemnogene abeparvovec-xioi
61912388|NCT03381729|EXPERIMENTAL|Dose B|Intrathecal administration 1.2 X 10\^14 vg of onasemnogene abeparvovec-xioi
61912389|NCT03381729|EXPERIMENTAL|Dose C|Intrathecal administration 2.4 X 10\^14 vg of onasemnogene abeparvovec-xioi
61912390|NCT01585519|NO_INTERVENTION|(Group 1) Low Apple Diet|
61912391|NCT01585519|EXPERIMENTAL|(Group 2) 2 High Apples|
61912392|NCT01585519|EXPERIMENTAL|(Group 3) 2 Low Apples|
61912393|NCT01585519|EXPERIMENTAL|(Group 4) 2 x 4.4g apple granules|
61912394|NCT01585519|EXPERIMENTAL|(Group 5) 2 x Apple Extract Capsules|
62103717|NCT05244447|EXPERIMENTAL|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 6 weeks. Participants also receive life coaching and on-going job readiness support.
62296528|NCT06656754|EXPERIMENTAL|Isometric Reaching condition|"In this arm the participant participates in Isometric Reaching in which they are not allowed to freely reach to the target, instead the forces they apply on the robot handle drives a reaching arm simulation"
62296529|NCT06656754|NO_INTERVENTION|Control Reaching condition|In this condition the participant moves toward target freely and the visual feedback is based on hand position and not an arm simulation.
62296530|NCT05019456|EXPERIMENTAL|Vaccine|Participants who elect to receive the vaccine
62296531|NCT06131710|EXPERIMENTAL|Isolated Strengthening Exercises|Isolated strengthening exercises refers to set of exercises that are used to treat a specific part of body. In our study, isolated strengthening exercises including 10 repetition of 3 sets of legs extensions,10 repetition of 3 sets squats and 10 repetition of 3 sets lunges are used. These exercises aim to improve the pain and range of motion of knee by acting on quadriceps.
62296532|NCT06131710|EXPERIMENTAL|Combined Strengthening Exercises|The Combined strengthening group will perform the same isolated strengthening exercises, but with the addition of proximal strengthening exercises for the hip and core muscles. These exercises include 10 repetitions of bridging(3 sets), 10 repetitions of clamshells(2 sets), 10 repetition of 3 sets of legs extensions,10 repetition of 3 sets squats,10 repetition of 3 sets lunges and 10 repetitions of planks(2 sets).
62296533|NCT03671122||PREFERS main study|500 patients with new onset heart failure will be characterized into those with HFpEFand HFrEF at baseline and undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis
61912395|NCT06332742||Exposome group|"5g lotus seed heart, 3g coptis, 15g uncaria, 15g fried jujube kernel, 10g dried rehmannia glutinosa, 9g dogwood meat, 10g salvia miltiorrhiza, 30g floating wheat.~1 dose per day, decocted in water twice, 200ml each time, taken warmly after breakfast and dinner"
61912396|NCT06332742||Non-exposed group|All patients who met the inclusion criteria and did not use Qingxin Zishen Decoction.
61912397|NCT03830723|OTHER|Rekovelle (Follitropin delta)|All participants will receive a prescription for study medication Rekovelle (follitropin delta)
61912398|NCT03468569|EXPERIMENTAL|Functional Movement Screen|Movement Analysis for injury risk
61912399|NCT03468569|EXPERIMENTAL|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
62296534|NCT03671122||CABG PREFERS|500 Patients undergoing elective by pass surgery with or without diastolic or systolic dysfunction as Proxy for HFpEF and HFrEF will undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis and cardiac biopsies
62308264|NCT04236453|EXPERIMENTAL|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide \[D/C/F/TAF\] as one fixed dose combination \[FDC\] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
62665339|NCT02632214|EXPERIMENTAL|Hearing signers|Group of hearing signer controls fMRI measure
62665340|NCT02632214|SHAM_COMPARATOR|Hearing non signers|Group of hearing non signer controls fMRI measure
61912400|NCT03468569|EXPERIMENTAL|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
61912401|NCT03468569|EXPERIMENTAL|Illinois Agility Test|Agility measurement, Functional Movement Screen
61912402|NCT03468569|NO_INTERVENTION|Injury History|Athletes injury history for last year was recorded as injury count.
62103718|NCT06480656|EXPERIMENTAL|Eccentric cycling exercise|
61912403|NCT02665403|EXPERIMENTAL|play intervention|30 minutes of hospital play interventions
61912404|NCT02665403|PLACEBO_COMPARATOR|control|usual care
61912405|NCT05488821|EXPERIMENTAL|QLH11906|QLH11906 Tablets
61912406|NCT02038270||surgical patients|120 Adult patients, that are having a routine surgical procedure.
61912407|NCT01374035|EXPERIMENTAL|Participating GPs|GPs working at randomly selected GP centers/offices within the region that are invited to participate and signs a written informed consent to participate. (N=30-40)
61912408|NCT01374035|NO_INTERVENTION|Control group|GPs working at randomly selected GP centers/office within the region that are not invited to participate, will form the control group. (N=30-40)
61912409|NCT03158792|ACTIVE_COMPARATOR|Enoxaparin 20 mg|
61912410|NCT03158792|ACTIVE_COMPARATOR|Enoxaparin 30 mg|
61912411|NCT02642588|EXPERIMENTAL|energy gel|women will be given 22 g of carbohydrates every 45-60 minutes for up to 8 hours or until delivery during the active phase of labor
61912412|NCT02642588|NO_INTERVENTION|control|women will be given only clear liquids during labor
61912413|NCT00000460||Low intensity exercise|
61912414|NCT00000460||High intensity exercise|
61912415|NCT04315584|EXPERIMENTAL|Diagnostic|Study subjects will receive 18FDG via an IV before undergoing one PET/CT scan over 60 minutes. They will then receive an IV injection of Gadovist for contrast before undergoing a multiparametric MRI scan. Subjects will also receive (18)F-FDOPA via an IV before undergoing another PET/CT scan over 60 minutes.
61912416|NCT05015413|EXPERIMENTAL|shock wave group|Group A will receive shockwave therapy 2 session per week for 6 weeks
62103719|NCT06480656|ACTIVE_COMPARATOR|Concentric cycling exercise|
62665341|NCT03073447|OTHER|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (\< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
62665342|NCT04483037|ACTIVE_COMPARATOR|split dose, day before, colonoscopy in the morning (Observation Group)|routine bowel preparation before colonoscopy in the morning
62665343|NCT04483037|ACTIVE_COMPARATOR|split dose, day before, colonoscopy in the afternoon (Random)|routine bowel preparation before colonoscopy in the afternoon
62665344|NCT04483037|EXPERIMENTAL|two dose in the same day, colonoscopy in the afternoon (Random)|experimental group
62665345|NCT05142059|EXPERIMENTAL|Experimental cohort|Participants will be involved in an evaluation program combining physical tests and self-administered questionnaires. Participants will be followed for 1 year with evaluations taking place at 6 months (occurrence of a fall) and at 1 year (the same evaluation, as initial).
62665346|NCT06357702|EXPERIMENTAL|Physical Self Regulation|2 experimental telehealth sessions approximately 2 weeks apart
62665347|NCT06357702|ACTIVE_COMPARATOR|Psycho-education|2 control telehealth sessions approximately 2 weeks apart
62665348|NCT04895124||Healthy volunteers|
62665349|NCT04895124||Healthy smokers|
61912417|NCT05015413|EXPERIMENTAL|low level laser group|Group B will receive low level laser therapy 2 session per week for 6 weeks
61912418|NCT05850494|EXPERIMENTAL|Treatment A: HFO propellant only MDI|Test arm, 4 inhalations per dose
62103720|NCT01526603|OTHER|Patients Treated for Neuroblastoma|According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.
62103721|NCT04489784|EXPERIMENTAL|Treatment|Laser treatment on ballerina's feet.
62296535|NCT02208648||Deceased|"Peri-operative mortality (within 90 days). Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
62296536|NCT02208648||Matched control|"Patients who survived beyond 90 days peri-operatively. Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
62665350|NCT04895124||COPD GOLD I|
62296537|NCT02219230|EXPERIMENTAL|Prosthetic knee|Subjects crossed over between interventions (three different prosthetic knees). Knee conditions include 1) Active knee (Ossur Power Knee II); 2) Adaptive knee (Ossur Rheo); and 3) Passive knee (Various manufacturers)
62296538|NCT03550690||Large Volume Paracentesis|Patient has repeated large volume paracentesis for recurrent ascites secondary to cancer
62665351|NCT04895124||COPD GOLD II|
61912419|NCT05850494|ACTIVE_COMPARATOR|Treatment B: HFA propellant only MDI|Reference arm, 4 inhalations per dose
62665352|NCT04895124||COPD GOLD III/IV|
61912420|NCT05503901|EXPERIMENTAL|Group 1: STN1012600 0.002%|
61912421|NCT05503901|EXPERIMENTAL|Group 2: STN1012600 0.002%|
61912422|NCT05503901|EXPERIMENTAL|Group 3: STN1012600 0.002% + Timolol 0.5%|
62665353|NCT00954135|ACTIVE_COMPARATOR|letrozolo+cyclophosphamide|
62665354|NCT00954135|EXPERIMENTAL|letrozolo+sorafenib+cyclophosphamide|
61912423|NCT04918342|ACTIVE_COMPARATOR|Individual Exercise Instruction|The participant will receive individual exercise instruction.
62103722|NCT04363762|EXPERIMENTAL|Internet-based multimodal pain program|The iMPP is based on CBT and self-management principles that help patient cope with chronic TMD pain. The iMPP translates a face-to-face therapy to a software platform program.
62665355|NCT03478878|EXPERIMENTAL|Participants|Participants with reticular pseudodrusen
62665356|NCT02058277|OTHER|Healthy volunteers|Healthy volunteers taking a single dose of bosutinib and a single dose of bosutinib plus aprepitant in random order
62665357|NCT03388944|EXPERIMENTAL|PCT group|PCT group
62665358|NCT03388944|NO_INTERVENTION|Standard practice group|No intervention
62665359|NCT04628910|ACTIVE_COMPARATOR|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
62665360|NCT04628910|EXPERIMENTAL|Simulated Flotation Therapy|Participants will utilize the Zerobody dry flotation therapy.
62665361|NCT01640106|EXPERIMENTAL|Omega-3|Treatment arm, using the omega-3 product (fish oil/paste)
62665362|NCT01640106|PLACEBO_COMPARATOR|Control|Placebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste
62665363|NCT02390388|ACTIVE_COMPARATOR|pudendal block group|nerve stimulated pudendal nerve block performed under general anesthesia
62665364|NCT02390388|ACTIVE_COMPARATOR|Caudal block group|caudal block performed under general anesthesia
62665365|NCT06359522|OTHER|Trancatheter occlusion|Patients who are being treated with transcatheter occlusion for PDA closure are eligible to participate in this study for NIRS monitoring.
62103723|NCT04363762|ACTIVE_COMPARATOR|Occlusal splint|Participants randomized to active control received a hard Michigan-type stabilization splint placed in the upper jaw by one of two calibrated general dentists {Ramfjord, 1994 #276}. The occlusal splint was chosen as the control treatment because it is a conventional and reversible treatment of TMD pain, and it has a known moderate efficacy {Welfare, 2011 #266}.
62296539|NCT03550690||Semi-permanent drain|Patient has a semi-permanent drain (Rocket Indwelling Pleural Catheter) placed for recurrent ascites secondary to cancer
62468406|NCT04299594||sickle cell disease patients|150 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study
62468407|NCT03863418|EXPERIMENTAL|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG (10 billion Colony Forming Units/CAPSULE)
62665366|NCT06359522|OTHER|Medical closure|Patients who are being treated with tylenol or indomethacin for medical closure of their PDA are eligible to participate in this study for NIRS monitoring.
62103724|NCT01447914|EXPERIMENTAL|ARQ 197 Treatment (Tivantinib)|Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.
62103725|NCT05409404|EXPERIMENTAL|Aerobic exercise + hot water immersion|3 sessions per week, over an 8 week period, with each session consisting of 30 minutes of aerobic exercise (10 minutes cycling, jogging and rowing) at a power output equivalent to 65-75% of maximal heart rate followed by 30 minutes of whole body hot water immersion at 40°C.
62103726|NCT05409404|ACTIVE_COMPARATOR|Aerobic exercise + thermoneutral water immersion|3 sessions per week, over an 8 week period, with each session consisting of 30 minutes of aerobic exercise (10 minutes cycling, jogging and rowing) at a power output equivalent to 65-75% of maximal heart rate followed by 30 minutes of whole body water immersion at 34°C.
62103727|NCT05886335||Cystitis hemorrhagic|Cystitis hemorrhagic grade II-III
62665367|NCT01434797||Confirmed CVCP infection before removal|Patients with permanent central venous catheter infection confirmed by conventional method
62665368|NCT01434797||Presumed CPVP infection before removal|Patients with probable permanent central venous catheter infection (standard methods for infection detection not conclusive)
62665369|NCT01434797||Uninfected CVCP before removal|Patients with planned permanent central venous catheter removal (no infection)
62665370|NCT00450749|PLACEBO_COMPARATOR|Arm I (placebo)|Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.
62665371|NCT00450749|EXPERIMENTAL|Arm II (low-dose lycopene)|Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
62103728|NCT05886335||Non Cystitis hemorrhagic|Non cystitis hemorrhagic or grade I
62103729|NCT05943795|EXPERIMENTAL|Experimental group|Participants receive SI-B001 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62103730|NCT05943795|EXPERIMENTAL|Control group|Participants receive Docetaxel as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62103731|NCT05702203|NO_INTERVENTION|Standard Care|Infants allocated to the control group will receive standard care during admission. Standard care includes involvement of a multi-professional team consisting of medical and nursing team, psychologists/psychiatrists, social workers, breastfeeding counsellor, speech therapist, nutritional counsellor and physiotherapists
62296540|NCT01474577||pts who have had Rb-82 PET myocardial perfusion imaging|Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone.
62296541|NCT01409317|EXPERIMENTAL|Deep Transcranial Magnetic Stimulation|
62296542|NCT01409317|ACTIVE_COMPARATOR|Repetitive Transcranial Magnetic Stimulation|
62296543|NCT01870544|EXPERIMENTAL|LGG Administration|Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2\*10\^10 organisms. The LGG is contained in capsules (1\*10\^10 organisms per capsule), and two capsules will be taken per day.
62296544|NCT01870544|PLACEBO_COMPARATOR|Placebo|Placebo to be taken orally for 44 days.
62296545|NCT05177484|EXPERIMENTAL|Ferric maltol|
62296546|NCT05177484|NO_INTERVENTION|Standard Care|
62296547|NCT05296967|EXPERIMENTAL|Chewing gum|POI patients are asked to chew 20 minutes x2/ day
62468408|NCT03863418|PLACEBO_COMPARATOR|placebo|maltodextrin
62296548|NCT05296967|NO_INTERVENTION|No chewing|POI patients receive no intervention
62296549|NCT03373019|EXPERIMENTAL|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
62468409|NCT00722124|ACTIVE_COMPARATOR|SAMe 800|Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
62468410|NCT00722124|ACTIVE_COMPARATOR|SAMe 1600|Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
62468411|NCT00722124|PLACEBO_COMPARATOR|Placebo|Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
62468412|NCT03202277|EXPERIMENTAL|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
62665372|NCT00450749|EXPERIMENTAL|Arm III (high-dose lycopene)|Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
62665373|NCT04693728|ACTIVE_COMPARATOR|Behavioral Intervention|The study intervention arm was a behavioral treatment that consisted of training resilient intrinsic self-regulation strategies to help alleviate chronic pain.
62665374|NCT04693728|NO_INTERVENTION|Wait-list with no treatment|The control comparison arm consisted of a wait-list condition in which participants received no treatment during a time interval comparable to the intervention arm.
62665375|NCT02412319|EXPERIMENTAL|Experimental Group|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
62103732|NCT05702203|EXPERIMENTAL|Creative Music Therapy|A certified, well-trained and experienced music therapist will formulate an individualized, culturally adapted treatment plan based on an initial infant-parent assessment, which includes assessment of parental needs, musical heritage, culture, context, and parental integration in the therapeutic process. During hospitalization 3 times per week 20 minutes of creative music therapy sessions will be performed, a minimum of 10 therapy session. After discharge, every other two weeks a music therapy session will be performed at home until the age of six months.
62665376|NCT02412319|PLACEBO_COMPARATOR|Comparator Group|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
61912424|NCT04918342|EXPERIMENTAL|Group Exercise Instruction|The participant will receive the instruction in a group of up to 9 other participants.
62296550|NCT02948166|ACTIVE_COMPARATOR|Stenting of the femoral artery|A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.
62296551|NCT02948166|EXPERIMENTAL|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.
62308265|NCT04236453|ACTIVE_COMPARATOR|Treatment B|Participants will receive Treatment B (a single dose of Darunavir \[DRV\], Emtricitabine/Tenofovir Alafenamide \[F/TAF\] and Cobicistat \[COB\] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
62665377|NCT06285604||IRBC|Anemic neonates with irradiated red blood cells transfusions.
62665378|NCT06285604||WRBC|Anemic neonates with washed red blood cells transfusions.
62665379|NCT06285604||LPRBC|Anemic neonates with leukocyte privative red blood cells transfusions.
62468413|NCT03202277|ACTIVE_COMPARATOR|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
62468414|NCT02996682|EXPERIMENTAL|SOF/VEL|SOF/VEL for 12 weeks
62468415|NCT02996682|EXPERIMENTAL|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
62468416|NCT01287910|OTHER|All Patients|All patients undergo the same study procedures
62468417|NCT04702945||Registry participants|Patients presenting to participating emergency departments with suspected and or confirmed COVID-19.
62468418|NCT01707420|ACTIVE_COMPARATOR|Gabapentin|gabapentin, 20 mg/kg, single dose, 60 min prior to surgery
62665380|NCT05680701|ACTIVE_COMPARATOR|real tACS|The investigators will administer the transcranial alternating current stimulation (tACS) intervention at 10 Hz to the participants. This intervention will utilize 6 electrodes; electrode placement and current parameters for each electrode have been optimized using a standard brain to generate an average electric field of 0.25 V/m. To ensure adherence to current safety recommendations for tACS, optimizations will be constrained to a maximum of total injected current 4.0 mA and a max. current per electrode of 2.0 mA. Stimulation will start and end with a 60 s ramp up/down to maximize comfort. This standard approach is both well-tolerated and safe in older adults. In a separate visit, we will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session.
62468419|NCT01707420|PLACEBO_COMPARATOR|liquid placebo|subjects randomized to the liquid placebo arm will receive a single dose elixir of 0.4 mL/kg given 60 min prior to surgery
62468420|NCT02147925|ACTIVE_COMPARATOR|Liraglutide|Liraglutide combined with metformin
62468421|NCT02147925|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine combined with metformin
62468422|NCT02147925|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin combined with metformin
62665381|NCT05680701|SHAM_COMPARATOR|sham tACS|The investigators will administer the sham tACS intervention to the participants. They will use an active sham in which very low-level alternating currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session.
62665382|NCT05340595|OTHER|Control group|The primer (Transbond XT Primer; 3M Unitek, California) was applied in a thin and uniform coat. Then the adhesive resin (Transbond LR Light Cure Adhesive Paste; 3M Unitek, California) was administered to the lingual surface of the anterior teeth and the lingual retainer was placed in position. The adhesive resin was polymerized from two directions for a total of 20 s using a visible-light curing unit (Hilux 200, Benlioglu Dental Inc., Ankara, Turkey) with an output power of 600 mW/cm2.
61912425|NCT04549207|ACTIVE_COMPARATOR|Standard BMA frequency|Continue standard BMA frequency (every 4 or 12 weeks) as administered previously. If a change in BMA frequency (every 4 weeks to every 12 weeks OR every 12 weeks to every 4 weeks) was prescribed by the physician, this would still be considered on protocol treatment.
61912426|NCT04549207|ACTIVE_COMPARATOR|De-escalate BMA to once every 24 weeks|Bone modifying agent once every 24 weeks.
61912427|NCT02737033|EXPERIMENTAL|Rhodiola|Rhodiola rosea 800mg single dose
61912428|NCT02737033|PLACEBO_COMPARATOR|Placebo|placebo 800mg single dose
61912429|NCT05507788|EXPERIMENTAL|Cushion|Three seating conditons (Quadtro Select 10cm, Starlock 10cm, and Starlock 13cm)
61912430|NCT05313776||Post-stroke|"People with a first ever ischemic stroke of the middle cerebral artery presenting severe motor deficits of the upper-limb at onset.~The patients"
62103733|NCT06016686|EXPERIMENTAL|VNS|participants with surgically implanted VNS electrodes to treat drug-resistant epilepsy
62103734|NCT06016686|EXPERIMENTAL|non-VNS participants|participants without implanted VNS devices
62103735|NCT05564988|EXPERIMENTAL|Preconditionning|Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
62468423|NCT04667494|EXPERIMENTAL|Sonotherapy|All participants will undergo sonotherapy
62665383|NCT05340595|ACTIVE_COMPARATOR|Study group|In the study group, the SEP (3M Unitek, Monrovia, California) was used according to the manufacturer's instructions, namely it was administered to the lingual surfaces of the teeth and rubbed for 3 s. Then a gentle burst of dry air was delivered to thin the primer. In the control group, the lingual surfaces of the teeth were etched using 37% phosphoric etchant liquid gel (3M Espe, St Paul, Minnesota, USA) for 30 s, followed by rinsing and drying.
62103736|NCT05564988|NO_INTERVENTION|Control|For subjects assigned to the control group, the pneumatic cuff is placed around the upper arm, and inflation of a blood pressure to a lower pressure (50mmHg) which will result in no impairment of antegrade flow.
62103737|NCT06555029|EXPERIMENTAL|Arm A: EHR Changes, EHR Training, and CSM theory-based Oral Health Training|AAAC EHR Changes, Medical staff EHR Training, Clinician CSM theory based education and skills training
62103738|NCT06555029|ACTIVE_COMPARATOR|Arm B: Control Arm with Standard ADA Oral Health Training|ADA-based education for clinicians only
62103739|NCT06713616|EXPERIMENTAL|Racemic Ketamine|Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.
62103740|NCT06713616|EXPERIMENTAL|Spravato (Esketamine)|Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.
62665384|NCT04094389|EXPERIMENTAL|Orthotic continuous wear group|Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance.
62665385|NCT04094389|EXPERIMENTAL|Orthotic wear during waking hours only group|Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping.
62665386|NCT04094389|EXPERIMENTAL|Orthotic wear only while sleeping group|In the night-wear group, participants will be told to wear their orthosis only at night.
62103741|NCT04057456|PLACEBO_COMPARATOR|Placebo diet and placebo capsules|Participants taking the placebo diet and capsules
62103742|NCT04057456|ACTIVE_COMPARATOR|Placebo diet and Nabilone capsules|Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.
62468424|NCT05168670|EXPERIMENTAL|Study arm|Protection of eyes with tinted soft scleral eye shields followed by IPL administration directly on eyelids
62468425|NCT03928197|OTHER|Healthy Volunteers|
62468426|NCT03928197|OTHER|Volunteers with Venous Insuficiency|
62468427|NCT06362772||125I seed implantation treatment group|125I seed implantation treatment group
62468428|NCT02202486||Migraine with aura|Brain MRI
62468429|NCT02202486||Migraine without aura|Brain MRI
62468430|NCT02202486||Chronic migraine|Brain MRI
62468431|NCT00383656|EXPERIMENTAL|Pulsatile GnRH|All participants will be administered GnRH intravenously by means of a portable infusion pump that delivers boluses at specific intervals.
62468432|NCT03656783|OTHER|HIV patients on stable therapy|HIV patients on stable therapy switching from Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
62468433|NCT02600286|EXPERIMENTAL|1|"Arm (1) will be randomised to receive either :~* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
62468434|NCT02600286|EXPERIMENTAL|2|"Arm (2) will be randomised to receive either :~* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
62468435|NCT02600286|EXPERIMENTAL|3|"Arm (3) will be randomised to receive either :~* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
62468436|NCT06009146||Rutherford scale < 4|
62468437|NCT06009146||Rutherford scale 4-5|
62468438|NCT06009146||Rutherford scale 6|
62468439|NCT00581971|EXPERIMENTAL|Celecoxib+Carboplatin/Paclitaxel+Radiation Therapy|
62468440|NCT01956786|ACTIVE_COMPARATOR|Amlodipine|5mg amlodipine,once daily for 8 weeks
62468441|NCT01956786|EXPERIMENTAL|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
62468442|NCT01956786|EXPERIMENTAL|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
62468443|NCT01272453||Control Group|Data from patients in the control group will be obtained retrospectively from patient medical records and stored image data
62468444|NCT01272453||Prospective Patient Group|Data from patients in the Flash group will be obtained prospectively from scanner consoles and medical records.
62468445|NCT02433977|EXPERIMENTAL|Conjugated Linolenic Acid + NOx|"This is a single arm study~Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
62468446|NCT05875142|ACTIVE_COMPARATOR|T - Digital Tutorial overview|A digital tutorial consisting of a curriculum dashboard for review of 10(?) modules, including videos, PDFs, text and quizzes, which are to be self-administered over two weeks. Modules remain available during the 10-week post tutorial period. Participants receive weekly contact encouraging engagement in all of the materials available to them.
62468447|NCT05875142|EXPERIMENTAL|TM - Digital Tutorial plus training Materials|Participants receive the digital tutorial (T) as described above plus access to 10 modules of digital training materials released weekly over the 10-week post tutorial period.
62468448|NCT05875142|EXPERIMENTAL|TMC - Digital Tutorial plus training Materials plus feedback and Coaching|Participants receive the digital tutorial (T) plus the digital Training materials as described in the two arms above plus they submit audio recordings of sessions with clients and receive feedback on their application of CRAFT and coaching on how to improve.
62468449|NCT01629433||botulinum A toxin|18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics.
62468450|NCT03713333|EXPERIMENTAL|Technology-Enabled Visitations|Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.
62665387|NCT02885675||ARDS|
62468451|NCT03713333|NO_INTERVENTION|Standard-Care Visitations|Standard-care is defined as the range of services available during usual patient care. Handheld Imaging and digital health screening will be performed in the control group after the patient-physician encounter. As such, patients and physicians will be blinded to the diagnostic findings unless an abnormal finding is detected that requires physician review and triage for further care.
62468452|NCT04320147|EXPERIMENTAL|MRI tartget biopsy|"1. MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.~2. Next conventional ultrasound-guided 12-core systematic biopsy would be performed by urologist. This portion will be performed without information of the MRI report."
62665388|NCT02885675||Healthy control|
61912431|NCT05313776||Controls|Age and sexe matched healthy subjects without known neurological and or psychological deficits.
62468453|NCT04395417|EXPERIMENTAL|Hyaluronic acid injection group|This is the study group in whom Hyaluronic acid injection was injected at lateral epicondylitis site.
62468454|NCT04395417|ACTIVE_COMPARATOR|Prolotherapy injection group|This is the control group in whom prolotherapy injection was given at lateral epicondyle site.
62468455|NCT01039961|EXPERIMENTAL|1 mg IV|Unit Dose Strength: 0.4 mg/mL
62468456|NCT01039961|EXPERIMENTAL|?mg IV|dose to be determined based on PK of first IV dose
62468457|NCT01039961|EXPERIMENTAL|15 mg (oral)|two 7.5 mg tablets
62468458|NCT05431166|EXPERIMENTAL|Immediate Treatment Group|8 weeks of Yoga Classes during first 8 weeks of study
62468459|NCT05431166|ACTIVE_COMPARATOR|Waitlist Control|8 weeks of Yoga Classes during second 8 weeks of study
62665389|NCT02260986|EXPERIMENTAL|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
62665390|NCT02260986|EXPERIMENTAL|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
62103743|NCT04057456|ACTIVE_COMPARATOR|Anti-inflammatory diet and placebo capsules|This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc).
62296552|NCT03848819|OTHER|Control pursed lip breathing|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe adopting the pursed lip breathing technique. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
62296553|NCT03848819|EXPERIMENTAL|pNIV|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe via the VitaBreath device. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
62296554|NCT02087566|OTHER|Administration of linezolid to 6 healthy volunteers|Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr ˃80 ml/min)}
62296555|NCT02087566|OTHER|Administration of linezolid to 6 acute renal failure patients|Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)}
62296556|NCT02087566|OTHER|Administration of linezolid to 6 ESRD patients|Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of \>60 kg (calculated as {height (cm) -100}×0.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)}).
62296557|NCT06404190|EXPERIMENTAL|DIODE LASER PHOTOACTIVATION OF 3% HYDROGEN-PEROXIDE FOR POCKET DECONTAMINATION - A CLINICAL STUDY|1)To evaluate the effectiveness of 3% hydrogen peroxide as an adjunct to scaling and root planning with diode laser irriadation 2. To compare the clinical and microbiology outcome of SRP + 3% hydrogen peroxide + diode laser and SRP alone
62296558|NCT05662592|EXPERIMENTAL|Treatment Arm|Broadband light treatment will be provided on pigmented skin lesions
62468460|NCT01846923|EXPERIMENTAL|PCV13|
62665391|NCT02260986|EXPERIMENTAL|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
62665392|NCT01374464|ACTIVE_COMPARATOR|High Volume, High Concentration|
62103744|NCT04057456|ACTIVE_COMPARATOR|Anti-inflammatory diet and Nabilone capsules|"Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.~This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc)."
62665393|NCT01374464|ACTIVE_COMPARATOR|High Volume, Low Concentration|
62665394|NCT01374464|ACTIVE_COMPARATOR|Low Volume, High Concentration|
62665395|NCT01374464|ACTIVE_COMPARATOR|Low Volume, Low Concentration|
62665396|NCT01305629|EXPERIMENTAL|Intervention Condition|Twelve sessions of spiritual self schema counseling, adapted to target target medication adherence and substance use.
62665397|NCT01305629|ACTIVE_COMPARATOR|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition.
62665398|NCT02325895|NO_INTERVENTION|Control (0 g Dried plum/day)|Participants only received 400IU of vitamin D and 500mg of calcium daily for 6 months.
62665399|NCT02325895|EXPERIMENTAL|50 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 50g of dried plum daily for 6 months.
62665400|NCT02325895|EXPERIMENTAL|100 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 100g of dried plum daily for 6 months.
62103745|NCT04501224|EXPERIMENTAL|switch to tenofovir alafenamide fumarate|Patients will switch to tenofovir alafenamide fumarate treatment, 25mg，once a day
62468461|NCT00312663|EXPERIMENTAL|10ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
62468462|NCT00312663|EXPERIMENTAL|50ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
62665401|NCT03555344|EXPERIMENTAL|Mantra Chikitsa|Mantra chanting for 15 mins
62665402|NCT03555344|NO_INTERVENTION|Wait list control|Rest for 15 Mins
62665403|NCT06152354|ACTIVE_COMPARATOR|Control group|20 mandibular primary molars in which pulpectomy were performed by hand instrumentation system using K- File from size 15 to size 35.
62665404|NCT06152354|EXPERIMENTAL|Experimental group|20 mandibular primary molars in which pulpectomy were performed by rotary system using Kedo-SG rotary file system according to manufacturer's instructions .
62665405|NCT05011032|OTHER|Control Group|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
62665406|NCT05011032|EXPERIMENTAL|Non-diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
61912432|NCT00534313|ACTIVE_COMPARATOR|Abatacept (30/10)|Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing \<60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \>100 kg received 1000 mg) thereafter.
61912433|NCT00534313|ACTIVE_COMPARATOR|Abatacept (10/10)|Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing \<60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \>100 kg received 1000 mg).
61912434|NCT00534313|ACTIVE_COMPARATOR|Abatacept (3/3)|Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.
61912435|NCT00534313|PLACEBO_COMPARATOR|Placebo|Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.
61912436|NCT02758405|EXPERIMENTAL|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62103746|NCT04501224|ACTIVE_COMPARATOR|Continue with the original regimen|Patients will continue with the original regimen treatment, entecavir, 0.5mg once a day, or tenofovir disoproxil fumarate 300mg once a day
62103747|NCT03812159|EXPERIMENTAL|Presurgical planning|Undergo crania-vault reconstruction following the presurgical planning (iCSPlan)
62103748|NCT03353584|NO_INTERVENTION|Standard Care|Participants receive standard care treatment for their vaso-occlusive crisis. Participants will be randomized by age.
62103749|NCT03353584|ACTIVE_COMPARATOR|Virtual Reality|Participants receive standard care treatment for their vaso-occlusive crisis. In addition, they will have a 15-minute Virtual Reality Therapy session. Participants will be randomized by age.
62468463|NCT04470557||Patients with COVID-19|The patients will be subjected to to laboratory analyses, a number of hematological, immunological and biochemical parameters like total leucocytic count and differential count of CBC, ESR, D- dimer levels in plasma, CRP, serum urea and creatinine levels, serum levels of AST, ALT liver enzymes, serum ferritin levels Also, CT scan of chest, clinical assessment and the severity and course of the disease.
62468464|NCT04476329|ACTIVE_COMPARATOR|A|"Arm A: Regorafenib Cycle 1:~* 80 mg daily Week 1~* 120 mg daily Week 2~* 160 mg daily week 3 then 1 week off followed by Cycle 2+ (160 mg for 21 days/1 week off) Subsequent Treatment Cycles~* 160 mg daily for 21 days, then 1 week off."
62468465|NCT04476329|ACTIVE_COMPARATOR|B|"Arm B: Regorafenib Cycle 1:~* 160 mg daily for 21 days/then 1 week off Subsequent Treatment Cycles~* 160 mg daily for 21 days, then 1 week off"
62737579|NCT02450435||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
61912437|NCT02758405|EXPERIMENTAL|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
61912438|NCT02758405|EXPERIMENTAL|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
61912439|NCT02758405|EXPERIMENTAL|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
61912440|NCT01147133|EXPERIMENTAL|Original|Treatment phase with the original formulation of clopidogrel
62103750|NCT05095428|EXPERIMENTAL|PARTS|The Program for Alleviating and Resolving Trauma and Stress (PARTS) Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
62103751|NCT05095428|ACTIVE_COMPARATOR|NBSR-T|The Nature Based Stress Reduction for Trauma Survivors (NBSR-T) Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
62103752|NCT04994743|EXPERIMENTAL|Cohort 1: CORT113176 150 mg|Participants will receive CORT113176 150 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days.
62737580|NCT02450435||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
62103753|NCT04994743|PLACEBO_COMPARATOR|Cohort 1: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
62103754|NCT04994743|EXPERIMENTAL|Cohort 2: CORT113176 300 mg|Participants will receive CORT113176 300 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Progression from Cohort 1 to 2 will be done based on safety and tolerability outcome from Cohort 1 and only after Cohort 1 has received study drug for ≥7 days.
62103755|NCT04994743|PLACEBO_COMPARATOR|Cohort 2: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
62103756|NCT04994743|EXPERIMENTAL|Cohort 3: CORT113176 ≥300 mg|Participants will receive CORT113176 ≥300 mg not to exceed 450 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Cohort 3 is optional, and progression from Cohort 2 to 3 be done based on safety and tolerability outcome from Cohort 2 and only after Cohort 2 has received study drug for ≥7 days.
62103757|NCT04994743|PLACEBO_COMPARATOR|Cohort 3: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
62103758|NCT00575978|EXPERIMENTAL|Hydralazine|"The objective of this study is to determine the MTD for hydrazaline added to standard neoadjuvant chemotherapy for operable breast cancer. Four dose levels of hydrazalline are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
62665407|NCT05011032|EXPERIMENTAL|Diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
62103759|NCT06629870|PLACEBO_COMPARATOR|Control|
62103760|NCT06629870|ACTIVE_COMPARATOR|hypnotherapy|
62103761|NCT06629870|ACTIVE_COMPARATOR|virtual reality|
62103762|NCT06629870|ACTIVE_COMPARATOR|mindfulness-based meditation|
62103763|NCT05714033|EXPERIMENTAL|Group 1|Group 1, Participants will receive VESAP during the bronchoscopy. Ventilatory Strategy To Prevent Atelectasis versus a Lateral Decubitus Strategy During Robotic Bronchoscopy
62103764|NCT05714033|EXPERIMENTAL|Group 2|Group 2, Participants will receive LADS Lateral Decubitus Strategy During Robotic Bronchoscopy during the bronchoscopy.
62468466|NCT01873586|EXPERIMENTAL|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold (posterolateral gutter at the symptomatic side)
62468467|NCT01873586|ACTIVE_COMPARATOR|Local autograft|Local autograft (posterolateral gutter at the contralateral side)
62665408|NCT03253822|EXPERIMENTAL|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
62665409|NCT03253822|NO_INTERVENTION|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
62665410|NCT03253822|NO_INTERVENTION|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
62665411|NCT02537470|OTHER|Arm 1|Placebo
61912441|NCT01147133|ACTIVE_COMPARATOR|Generic|Treatment phase with the generic clopidogrel
62103765|NCT00713934|EXPERIMENTAL|1|
62103766|NCT00713934|EXPERIMENTAL|2|
62103767|NCT01506362|EXPERIMENTAL|A synthetic oligonucleotide for treatment of IBD.|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
62296559|NCT01360996|EXPERIMENTAL|3 mg DRSP/20 μg EE--normal weight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~Normal weight -BMI 18-24.9 kg/ m2"
62665412|NCT02537470|EXPERIMENTAL|Arm 2|Biphasic remogliflozin etabonate
62665413|NCT03940677|OTHER|Parkinson's disease patient|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination for motor and non motor symptoms
62665414|NCT03940677|OTHER|Healthy controls|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination
62665415|NCT04955925||Sevoflurane group|Anesthesia is maintained with sevoflurane during the surgery.
62665416|NCT04955925||Propofol group|Anesthesia is maintained with total venous anesthesia using propofol during the surgery.
62103768|NCT02157493|EXPERIMENTAL|Arrowhead Business Group Curriculum|The Arrowhead Business Group (ABG) Curriculum is a 22-session youth entrepreneurship/life-skills intervention delivered by trained American Indian paraprofessionals from the community to mixed-gender groups of approximately 25 youth. The intervention is delivered over a 3 night/4 day camp along with weekend workshops once a month for 6 months during the academic year. Depending on the time of enrollment, subjects will receive follow-up assessments at 6-month intervals for up to 36-months post-intervention. (Subjects in this cohort will also receive the activities associated with the control condition.)
62103769|NCT02157493|ACTIVE_COMPARATOR|Recreational League Control Condition|The Recreational League Control Condition will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Sports and recreational activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
62468468|NCT02779894|NO_INTERVENTION|Hospital group|Patients referred to the sleep unit and randomized to Hospital group. Participants will be diagnosed in the hospital either by Polysomnography , Respiratory Polygraphy or one night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the titration and adjustment of patient's will be accomplished at the hospital. This patient's will be monitored during 3 months of the study at the hospital.
62468469|NCT02779894|OTHER|ICT group|Patients referred to the sleep unit and randomized to intervention group. Participants will be diagnosed at home by 3 night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the adjustment will be performed at the CPAP supplier center, titration will be performed at home and patient's compliance and treatment will be controlled via remote. During the 3 months of the study patient's will be controlled via phono/video conferences and with a platform designed for the study.
62468470|NCT03207880|EXPERIMENTAL|MLPT|Multi-level pregnancy test
62103770|NCT02575391|EXPERIMENTAL|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
62103771|NCT05290740|ACTIVE_COMPARATOR|group A|
62103772|NCT05290740|ACTIVE_COMPARATOR|group B|
62103773|NCT00785772|EXPERIMENTAL|1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min|
62468471|NCT04056182|EXPERIMENTAL|Lofexidine|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
62468472|NCT03338075||CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
62468473|NCT03338075||RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
62468474|NCT01399034||MicroRNA study|Obese group (+ periodontitis group) Non-obese group (+ periodontitis group)
62468475|NCT01399034||DNA methylation study|Periodontitis group Healthy periodontium group
62468476|NCT05038657|EXPERIMENTAL|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
62468477|NCT00977522|EXPERIMENTAL|PF-03463275|
62468478|NCT00977522|PLACEBO_COMPARATOR|Placebo|
62468479|NCT04416230|EXPERIMENTAL|Massage|Infants randomized to the massage intervention received a 30 minute massage daily for the 7 day study.
62468480|NCT04416230|ACTIVE_COMPARATOR|Quiet Time|Infants randomized to the Quiet Time intervention experienced a 30 minute time during which non-essential clinical caregiving tasks were restricted.
62296560|NCT01360996|EXPERIMENTAL|3 mg DRSP/20 μg EE- Overweight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 25-29.9 kg/ m2"
62296561|NCT01360996|EXPERIMENTAL|3 mg DRSP/20 μg EE- Grade 1 obese|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 30-34.9 kg/ m2"
62296562|NCT04716322|OTHER|Adapted Physical Activity|A 16-week health-adapted physical activity program and 5-year follow-up
62296563|NCT03268629|EXPERIMENTAL|Mindfulness-Based Joyful Sleep|The proposed 'Joyful Sleep' program will be conducted weekly, 2 hours per session, 8 sessions, group-based in mindfulness. The content and skills are based upon MBSR, MAPs and Tai Chi. The proposed topics include: 1) mindfulness and insomnia, 2) mindful awareness of stress, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, 6) moving mindfulness meditation: the first taste of Tai Chi, 7) moving mindfulness meditation: the second taste of Tai Chi, 8) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, body scan meditation, sitting meditation, standing meditation, walking meditation, Taichi, and daily life meditation.
62296564|NCT03268629|ACTIVE_COMPARATOR|CBT-I|The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
62296565|NCT01205009|ACTIVE_COMPARATOR|Ovitrelle supplemantation|The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
62296566|NCT01205009|NO_INTERVENTION|no Ovitrelle supplementation|
62103774|NCT00785772|EXPERIMENTAL|2: Patients with CLcr 15-29 mL/min|
62103775|NCT00785772|EXPERIMENTAL|3: Patients with CLcr 30-59 mL/min|
62103776|NCT03772964|EXPERIMENTAL|500mg exposure|Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
62103777|NCT03772964|EXPERIMENTAL|1000mg exposure|Subjects will be exposed to 1000mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
62103778|NCT03772964|EXPERIMENTAL|1500mg exposure|Subjects will be exposed to 1500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
62103779|NCT03772964|PLACEBO_COMPARATOR|Placebo|Subjects will be exposed to placebo for up to 90 days.
62103780|NCT01333514|EXPERIMENTAL|Carbohydrate based prandial insulin dosing|Subjects will received prandial insulin based on the amount of carbohydrates consumed.
62103781|NCT01333514|ACTIVE_COMPARATOR|Usual Care Prandial insulin dosing|Subjects will received prandial insulin if they consume 50% or more of their meal-tray as is the usual care.
62103782|NCT04455048|EXPERIMENTAL|Intervention Group|A single-session manipulation with a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied each week for two weeks.
62103783|NCT04455048|SHAM_COMPARATOR|Control Group|A sham manipulation without a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied.
62103784|NCT05686356|EXPERIMENTAL|Arm 1 (S1200BP)|Sutezolid 1200mg QD plus bedaquiline and pretomanid for 4 months
62103785|NCT05686356|EXPERIMENTAL|Arm 2 (S1600BP)|Sutezolid 1600mg QD plus bedaquiline and pretomanid for 4 months
62103786|NCT05686356|EXPERIMENTAL|Arm 3 (S1600BPN)|Sutezolid 1600mg QD plus bedaquiline pretomanid and N-acetyl cysteine for 4 months
62296567|NCT03232307|EXPERIMENTAL|Treatment (ibrutinib, rituximab, lenalidomide, dexamethasone)|Participants receive ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also receive rituximab IV on days 1, 8, 15 and 22 in course 1 and 2, on day 1 of course 3-8, and then on day 1 of every other 28-day course, lenalidomide PO on days 1-21, and dexamethasone PO weekly. Treatment with rituximab repeats every 28 days for 2 years, with lenalidomide for 1 year, and with dexamethasone for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62296568|NCT05312502|EXPERIMENTAL|Experimental: Birth Ball|In the second stage, the birth ball application was made and followed. Pregnant women with a vaginal opening of 4 cm admitted to the delivery room were instructed to sit on the delivery ball for a total of 30 minutes. A stopwatch clock was used to determine these 30 minutes. The pregnant woman was not asked to sit on the ball all the time, and she could take a break for rest or other needs. The birth ball, which is suitable for women's use, was preferred in 45 cm dimensions, and the pilates circle was used as a stabilizer. Under the supervision of the researcher, the pregnant women sat upright on the ball and began to rock back and forth. Meanwhile, the researcher held the pregnant woman's hand. In order for the pregnant woman not to lose her balance, the birth ball was placed on a pilates circle and she was supported by the researcher in making the movements.
62296569|NCT05312502|NO_INTERVENTION|Control|A routine care was performed.
62296570|NCT06656013|EXPERIMENTAL|Motivational Interview|Preparation and motivational interviewing practice consisting of 4 sessions
62468481|NCT02576353|EXPERIMENTAL|Cohort 1|After a 10-hour fast, the 10 participants in this cohort are randomized to receive Fentanyl Sublingual (under the tongue) Spray (FSS) 100 mcg (n=8), or Fentanyl Citrate Intravenously (FCIV) 50 mcg (n=2).
62103787|NCT05686356|ACTIVE_COMPARATOR|Arm 4 (HRZE)|Rifafour (2HRZE/4HR)
62103788|NCT06281717|EXPERIMENTAL|Fetal Endotracheal Occlusion (FETO)|Participants with severe congenital diaphragmatic hernia will undergo the FETO therapy.
62103789|NCT04469218|NO_INTERVENTION|Control Group|Subjects in the control group will receive the standard of care intervention for peripheral IVs at the study hospital.
62103790|NCT04469218|EXPERIMENTAL|SafeBreak Vascular Group|Subjects in the SafeBreak Vascular group will have as near to identical treatment as possible to the control group with the exception that a SafeBreak Vascular device will be placed in the peripheral IV line.
62103791|NCT06442995|EXPERIMENTAL|Magnesium Sulfate|Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space
62103792|NCT06442995|PLACEBO_COMPARATOR|Isotonic saline|Injection of Isotonic saline + 2 mg morphine into the epidural space
62103793|NCT04648046|EXPERIMENTAL|Low Dose CAR-T Cells Only|Participants will NOT undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
62103794|NCT04648046|EXPERIMENTAL|Conditioning + Low Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
62103795|NCT04648046|EXPERIMENTAL|Conditioning + High Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused into the participant. ART will be interrupted immediately after infusion.
62103796|NCT04408183|EXPERIMENTAL|GLS-1200|1 mL of GLS-1200 per nostril, TID
62103797|NCT04408183|PLACEBO_COMPARATOR|0.9 %Saline|1 mL of 0.9% Saline per nostril, TID
62103798|NCT06332378|EXPERIMENTAL|ball training exercise|
62103799|NCT06332378|EXPERIMENTAL|Frenkel training exercise|
62103800|NCT06332378|OTHER|control group|
62103801|NCT03310983||ADORE- 200 mg/day|Participants enrolled in the ADORE study that were randomly assigned to the 200 mg/day group that consented to participate in ADORE-GAINS.
62103802|NCT03310983||ADORE - 1000 mg/day|Participants enrolled in the ADORE study that were randomly assigned to the 1000 mg/day group that consented to participate in ADORE-GAINS.
62468482|NCT02576353|EXPERIMENTAL|Cohort 2|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 200 mcg (n=8), or FCIV 50 mcg (n=2).
62665417|NCT02217033|PLACEBO_COMPARATOR|Purified Water|"In this arm, eligible subjects will begin to consume purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume the placebo through their chemotherapy and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: \<150 lb = 2 bottles/day; ≥150 lb and \<225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume placebo for a minimum of 168 days."
62665418|NCT02217033|EXPERIMENTAL|'R' (Electro-kinetically altered beverage)|"Patients randomized to this arm will begin to consume R (Electro-kinetically altered beverage) just prior to the 1st cycle of chemotherapy and continue it through their chemotherapy cycles and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: \<150 lb = 2 bottles/day; ≥150 lb and \<225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume R for a minimum of 168 days."
62665419|NCT00369759||1|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
61912442|NCT01215916|EXPERIMENTAL|Experimental: Pemetrexed followed by LY573636|Pemetrexed on Day 1 followed by LY573636 on Day 4
62103803|NCT03431779|EXPERIMENTAL|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
62103804|NCT03431779|ACTIVE_COMPARATOR|Surgical excision|Excision of painful areas
62103805|NCT01605136|EXPERIMENTAL|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
62103806|NCT01605136|PLACEBO_COMPARATOR|Placebo|One placebo subcutaneous implant every 2 months for 6 months.
62103807|NCT05731661|EXPERIMENTAL|Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care|
62103808|NCT05731661|ACTIVE_COMPARATOR|Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care|
62103809|NCT05731661|OTHER|Observational cohort|
62103810|NCT06107517|EXPERIMENTAL|DREAMS-OT Arm (Intervention Group)|Patients will receive an early and intensive occupational therapy protocol starting within the first 15 hours after extubation.
62103811|NCT06107517|NO_INTERVENTION|Standard Care Arm (Control Group)|Standard care OT as per current ICU setting
62103812|NCT05317962||COVID-19 positive patients admitted to hospital|
61912443|NCT01215916|EXPERIMENTAL|Experimental: LY573636 followed by Pemetrexed|LY573636 on Day 1, pemetrexed on Day 4
61912444|NCT01215916|EXPERIMENTAL|Experimental: LY573636 and Pemetrexed on Day 1|LY573636 and Pemetrexed on Day 1
61912445|NCT06276738||Patients at increased risk for developing pancreatic cancer|Patients who exhibit symptoms suggestive of PDAC (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) or have evidence of imaging studies suggestive of PDAC will undergo LINFU® testing.
61912446|NCT04397770|EXPERIMENTAL|Camre+Apa+TMZ|
61912447|NCT05214079|ACTIVE_COMPARATOR|1 , Left paratracheal pressure|50 male
61912448|NCT05214079|ACTIVE_COMPARATOR|2, Left paratracheal pressure|50 female
61912449|NCT04987944|EXPERIMENTAL|BHV3500|Zavegepant 150 mg BID
61912450|NCT04987944|PLACEBO_COMPARATOR|Placebo|Matching placebo 150 mg BID
62665420|NCT00369759||2|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
62665421|NCT00369759||3|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
62665422|NCT05509621|EXPERIMENTAL|Supine position|To determine the effect of supine position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
62665423|NCT05509621|EXPERIMENTAL|Prone position|To determine the effect of prone position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
62103813|NCT02949817|EXPERIMENTAL|IMU sensor training group(intervention group)|video-game based rehabilitation therapy system training group
62468483|NCT02576353|EXPERIMENTAL|Cohort 3|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 400 mcg (n=8), or FCIV 50 mcg (n=2).
62468484|NCT02576353|EXPERIMENTAL|Cohort 4|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 600 mcg (n=8), or FCIV 50 mcg (n=2).
62468485|NCT02576353|EXPERIMENTAL|Cohort 5|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 800 mcg (n=8), or FCIV 50 mcg (n=2).
62468486|NCT00925119|EXPERIMENTAL|Atenolol|Participants will receive atenolol for 8 weeks.
62468487|NCT03589170||People over 60 years of age|People over 60 years of age without previous known atrial fibrillation
62665424|NCT05509621|EXPERIMENTAL|Left lateral position|To determine the effect of left lateral position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
62665425|NCT05509621|EXPERIMENTAL|Right lateral position|To determine the effect of right lateral position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
62468488|NCT03348423|EXPERIMENTAL|DEX-IN 50 µg|Dexmedetomidine Intranasal Spray
62468489|NCT03348423|ACTIVE_COMPARATOR|Fentanyl 50 µg|Intravenous Fentanyl
62665426|NCT05509621|EXPERIMENTAL|Quarter prone position|To determine the effect of quarter prone position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
62665427|NCT06137053||Exposed group|Standard treatment for SLE + Telitacicept 160 mg qw
62665428|NCT06137053||Control group|Standard treatment for SLE
62665429|NCT04321499||lung cancer|stage IA-IIIA lung cancer
62665430|NCT04321499||benign nodules|ruled out lung cancer via Operation or CT-scan follow-up
62665431|NCT02604745||Degenerative Mitral Regurgitation|This cohort includes patients that have had mitral valve surgery for Degenerative Mitral Regurgitation (Type II)
62103814|NCT02949817|ACTIVE_COMPARATOR|Conventional OT group (control group)|conventional training group (control group)
62665432|NCT03693898|OTHER|Persons with collagen VI defect|Observational
62665433|NCT01642966|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 10mg/day for 15 days
62665434|NCT01642966|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
62103815|NCT04815057|EXPERIMENTAL|Education|wellness education
62296571|NCT06656013|NO_INTERVENTION|Control|There will be no intervention
62665435|NCT02029547|EXPERIMENTAL|Physician Readers|Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.
62665436|NCT01620099|EXPERIMENTAL|Asthmatic nonsmokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who never smoked. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
62665437|NCT01620099|ACTIVE_COMPARATOR|Asthmatic smokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who smoked with a smoking habit ranging from 10 to 20 pack/years. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
62296572|NCT00779129|EXPERIMENTAL|Single Arm|Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2
62296573|NCT06030011|EXPERIMENTAL|NYU Electronic Patient Visit Assessment (ePVA) plus Usual Care|
61912451|NCT02133443|ACTIVE_COMPARATOR|Pressure Support Ventilation|Device: PSV - pressure support ventilation
62296574|NCT06030011|ACTIVE_COMPARATOR|Usual Care|
62296575|NCT06654648|EXPERIMENTAL|Combined exercise nutrition intervention group|"Customized exercise and nutrition intervention(food for nutrition:whey protein isolate powder) by underlying disease and functional state for 12 weeks during intervention period.~\*Whey protein isolate powder is provided to compensate for the insufficient amount of protein calculated through a questionnaire."
62296576|NCT06654648|ACTIVE_COMPARATOR|Conventional medial care group|Conventional medical care service for 12weeks during intervention period.
62468490|NCT03348423|PLACEBO_COMPARATOR|Placebo|Placebo
62468491|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
62468492|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
62468493|NCT04504240|EXPERIMENTAL|Group A: FAMOTIDINE treatment group|FAMOTIDINE 40mg to 60mg 8hourly in an empty stomach along with other treatments.
62468494|NCT04504240|ACTIVE_COMPARATOR|Group B: Control group|Treatment as given with a PPI.
62468495|NCT05621226|EXPERIMENTAL|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
62665438|NCT03562507|EXPERIMENTAL|ESK981 Monotherapy|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
62665439|NCT03562507|EXPERIMENTAL|ESK981 and Nivolumab|"ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles~Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle"
62665440|NCT01149538|EXPERIMENTAL|Choline Bitartrate|Choline Bitartrate supplementation
62665441|NCT01149538|PLACEBO_COMPARATOR|Placebo|Placebo for choline bitartrate supplementation
62665442|NCT03131661||SpA with DMARDs|Participants with first diagnosis or confirmed diagnosis of Spondyloarthritis (SpA) and naïve to conventional, targeted or biological Disease modifying anti-rheumatic drugs (DMARDs) will be observed in order to describe SpA characteristics and pattern of clinical presentation.
62665443|NCT01452217|EXPERIMENTAL|Secretin|
62665444|NCT06462872||Critically ill cirrhotics|Critically ill cirrhosis patient admitted in liver ICU with new onset acute GI tract paralysis and develop feed intolerance.
62665445|NCT00032539||1|
62665446|NCT02233153||Pre-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
62665447|NCT02233153||Post-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
62665448|NCT02233153||Pre-Elder Friendly Surgical Control Group|Elder Acute Care and Emergency Surgery patients
62665449|NCT02233153||Post-Elder Friendly Surgical Control Group|
62665450|NCT01765998|EXPERIMENTAL|Probiotic|To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
62665451|NCT01765998|PLACEBO_COMPARATOR|placebo|This will be the comparison group to the experimantal group that recives Probiotic.
62665452|NCT02898506|ACTIVE_COMPARATOR|Liraglutide|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with Victoza®
62665453|NCT02898506|PLACEBO_COMPARATOR|Placebo|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with placebo
62468496|NCT05621226|EXPERIMENTAL|Message communicating latest data on COVID transmission in patient's area|This condition will use a text message informing the participant of the latest data on COVID transmission in participant's area and recommend a COVID vaccination.
62665454|NCT01692015|EXPERIMENTAL|Diet and nosebleed questionnaire|Participants will only be required to fill in two paper questionnaires, one on dietary history, and one on nosebleed severity.
62665455|NCT01692015|EXPERIMENTAL|Weighed food diary arm|Participants will be required to weigh their food for one week to generate a food dairy, and have a single blood test, in addition to filling in the two paper questionnaires, one on dietary history, and one on nosebleed severity.
62665456|NCT03240445|EXPERIMENTAL|Period 1|ODM-203 dosed after food
62665457|NCT03240445|EXPERIMENTAL|Period 2|ODM-203 dosed before food
62665458|NCT03240445|EXPERIMENTAL|Periods 3-6|ODM-203 dosed as a tablet or dispersion
62665459|NCT03908008|ACTIVE_COMPARATOR|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
62103816|NCT05754463|EXPERIMENTAL|athletes|Plyometric training was applied to the athletes (Group 1) (n=27) participating in our study, 2 days a week for 6 weeks, after 20 minutes of warming up and stretching movements before each training. Sociodemographic characteristics of the athletes were recorded. Dynamic balance test was applied with Y balance test and static balance was applied with strok balance test before and after plyometric training. Proprioception assessment was applied with kinematic angle reproduction test before and after plyometric training.
62665460|NCT03908008|EXPERIMENTAL|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
62665461|NCT06161090|EXPERIMENTAL|Group 75 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
62665462|NCT06161090|EXPERIMENTAL|Group 150 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
62665463|NCT06161090|EXPERIMENTAL|Group 300 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
62665464|NCT06161090|EXPERIMENTAL|Group 600 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
62665465|NCT06161090|PLACEBO_COMPARATOR|Placebo|Placebo, Subcutaneous
62665466|NCT05551897|EXPERIMENTAL|Treatment Arm|Subjects will receive a single oral dose of Camizestrant on Day 1 of treatment period 1. Following washout period of 7 to 10 days, subjects will receive Itraconazole on Days 1, 2, and 3 of treatment period 2, and single oral dose of Camizestrant plus a dose of Itraconazole on Day 1, followed by Itraconazole alone on Day 2 and Day 3 of treatment period 3.
62665467|NCT04491994|NO_INTERVENTION|Standard of Care (SOC)|Patients selected in supportive arm will be given daily standard doses of oral Vit C (2g), Vit D (alfacalcidiol 1µg), Zinc (50mg) and paracetamol (as required).
62665468|NCT04491994|EXPERIMENTAL|HCQ arm|Patients selected in experimental arm will be given Tab HCQ (400mg BD on D0 followed by 200mg BD D1-D5) in addition to supportive treatment
62665469|NCT03483220||cases|patients with cannabis use disorder
62665470|NCT00694343|EXPERIMENTAL|Group A|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
62665471|NCT00694343|ACTIVE_COMPARATOR|Group B|1000 mL Ringer's Lactate solution
62665472|NCT05919251|ACTIVE_COMPARATOR|Healthy Older Adults|This subset of subject's have a fair history with this methodology and are being used as the comparator. Age matched older adults
62665473|NCT05919251|EXPERIMENTAL|Subject's Post Stroke|Individuals post stroke have recently participated in this ongoing investigation in a live format but these subjects are now entered into a telehealth arm. In the future others will participate in the live format
62665474|NCT04377386|EXPERIMENTAL|Intervention group: 1000 IU DV|The 75 participants assigned to the intervention group will take 1 DV capsule of 1000 IU daily for 15 weeks.
62665475|NCT04377386|PLACEBO_COMPARATOR|Control group: 200 IU DV|The 75 participants of the control group will take 1 DV capsule of 200 IU daily for 15 weeks, this dose being the minimum recommended for children. The above, considering that it is ethical for the control group to receive a minimum dose of supplementation.
62665476|NCT00670384|ACTIVE_COMPARATOR|Dose Group A|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
62665477|NCT00670384|ACTIVE_COMPARATOR|Dose Group B|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
62665478|NCT00670384|PLACEBO_COMPARATOR|Placebo|
62665479|NCT02748031|EXPERIMENTAL|eligible patients group|
62665480|NCT02016508|EXPERIMENTAL|autologous bone marrow stem cells|use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients
62665481|NCT02416271|EXPERIMENTAL|Teriparatide|20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
62665482|NCT02416271|ACTIVE_COMPARATOR|Alendronate|10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
62665483|NCT06295952|EXPERIMENTAL|Pasireotide|All patients will initiate open-label treatment with pasireotide LAR on week 1 in the outpatient setting. Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days. Administration of pasireotide will align with package inset. Patients must return to the study center every 28 days (+/- 7 days) to receive study medication and for evaluation.
62665484|NCT02405962|PLACEBO_COMPARATOR|Control group|Parents of children with asthma will receive one session of asthma educational talk as the usual care, plus three weekly sessions of telephone calls to assess the child's asthma symptoms
62665485|NCT02405962|EXPERIMENTAL|ACT group|Parents of children with asthma will receive four sessions of group-based ACT intervention integrated with asthma education (its content will be the same as that of the Control Group).
62665486|NCT04426162|EXPERIMENTAL|Memory Boot Camp Participants|All subjects undergo a 12-week control period, followed by a multi-domain 12-week memory program.
62468497|NCT05770063|EXPERIMENTAL|intervention group|compound amino acid supplement
62665487|NCT02299167|EXPERIMENTAL|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
62665488|NCT03363035|EXPERIMENTAL|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily
62665489|NCT03363035|EXPERIMENTAL|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily
62665490|NCT03363035|ACTIVE_COMPARATOR|enoxaparin|Enoxaparin 1mg/kg twice daily SC twice daily
62665491|NCT05883878|NO_INTERVENTION|Standard of Care|Participants will receive traditional lifestyle advices in order to reduce the risk.
62665492|NCT05883878|EXPERIMENTAL|Genetic testing - PRS|Participants will receive the information of the genetic cardiovascular risk (PRS) and personalized advices.
62665493|NCT05883878|EXPERIMENTAL|Digital intervention - app and wearable device|Participants will receive an app and a wearable device for the evaluation of various parameters.
62665494|NCT05883878|EXPERIMENTAL|Digital intervention and genetic testing - PRS|Participants will receive both app and wearable device and PRS information
62665495|NCT06040619|EXPERIMENTAL|Therapy Together|Participants will complete the 8-week Therapy Together program.
62665496|NCT06040619|ACTIVE_COMPARATOR|Usual Care|Participants will complete 8 weeks of usual care in early intervention.
62665497|NCT05442632|EXPERIMENTAL|Experimental: 1|durg：Hetrombopag 5mg，once daily，oral
62665498|NCT05442632|EXPERIMENTAL|Experimental: 2|Ndurg： Placebo 5mg，once daily，oral
62665499|NCT02470572|ACTIVE_COMPARATOR|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
62665500|NCT02470572|PLACEBO_COMPARATOR|Conventional light microscope|conventional light microscope
62103817|NCT05754463|ACTIVE_COMPARATOR|karate|Plyometric training was applied to the karate practitioners (Group 2) (n=27) participating in our study, 2 days a week for 6 weeks, after 20 minutes of warming up and stretching movements before each training. Sociodemographic characteristics of the athletes were recorded. Dynamic balance test was applied with Y balance test and static balance was applied with strok balance test before and after plyometric training. Proprioception assessment was applied with kinematic angle reproduction test before and after plyometric training.
62665501|NCT03415269|EXPERIMENTAL|20 mg ambroxol|20 mg ambroxol lozenge delivered once on one day
62665502|NCT04241523|EXPERIMENTAL|Treatment|The patients will receive lenvatinib treatment and will be evaluated for the feasibility of liver resection every 8 weeks. For those who underwent liver resection, they will receive lenvatinib treatment for another 48 weeks. In case of tumor recurrence, intolerance, death, or need for other antitumor treatment, the treatment shall be stopped.
62665503|NCT00908778|EXPERIMENTAL|Vitreosolve I|Intravitreal injection
62296577|NCT06228755|EXPERIMENTAL|Training, Coaching, and Orientation|Clinic personnel will receive training for delivering integrative medicine group visits (IMGV) and ongoing coaching in delivering IMGV for patients with chronic pain. Clinic patients will participate in orientation and the 9-week IMGV.
62296578|NCT02765659|OTHER|Community 1|Receives Mzake ndi Mzake T1 immediately after baseline
62296579|NCT02765659|OTHER|Community 2|Receives Mzake ndi Mzake T2 immediately after Post-T1 evaluation
62665504|NCT00908778|EXPERIMENTAL|Vitreosolve|Intravitreal injection
62665505|NCT00471354|EXPERIMENTAL|Atomoxetine|0.5 mg/kg/day once a day (QD), by mouth (PO), starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
62665506|NCT01290731|EXPERIMENTAL|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24 (PR 24). Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than (\<) 1.2 log10 IU/mL detectable or undetectable of at Week 4, and undetectable HCV RNA levels at Week 12. All other participants will continue PR until Week 48 (PR 48).
62296580|NCT02765659|OTHER|Community 3|Receives Mzake ndi Mzake T3 immediately after Post-T2 Evaluation
62665507|NCT01800058||Circulating prostatic tumor cells in the peripheral blood|"Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):~1. prior to any treatment;~2. following AD and prior to RT; and~3. following the end of RT (1-3 months afterwards).~4. six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination~The quantification of CTC in blood samples will be done with the CellSearch® system."
62665508|NCT01566162|EXPERIMENTAL|Lurasidone|Lurasidone 40 - 80mg flexible dose
62665509|NCT04124796|EXPERIMENTAL|target subjects|"target subjects patients are expected, corresponding to the average population received each year for a CBCa in the unit."
62665510|NCT04124796|ACTIVE_COMPARATOR|health care team|the health care team managing these patients
62103818|NCT06518005|EXPERIMENTAL|Treatment with imlifidase|Each participant will be treated with imlifidase
62296581|NCT04836039||Physiotherapists|Individuals between the ages of 22-65 who continue to work as a self-employed or employee physiotherapist.
62468498|NCT05770063|PLACEBO_COMPARATOR|control group|placebo
62103819|NCT06518005|EXPERIMENTAL|Treatment with GNT0003|Each participant will be treated with GNT0003
62296582|NCT04704934|EXPERIMENTAL|Trastuzumab deruxtecan|Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle.
62296583|NCT04704934|ACTIVE_COMPARATOR|Ramucirumab + paclitaxel|Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
62296584|NCT05559814|EXPERIMENTAL|Peppermint oil|1.6% peppermint oil solution 50 ml(Peppermint oil plus simethicone and tween)
62296585|NCT05559814|PLACEBO_COMPARATOR|Placebo|Placebo solution 50ml(Simethicone plus tween)
62468499|NCT00518830|EXPERIMENTAL|PND-MCI|The multi-component intervention involved a psychoeducational group, treatment adherence support, and pharmacotherapy if needed
62468500|NCT00518830|ACTIVE_COMPARATOR|usual care|'Usual care' included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
61912452|NCT02133443|ACTIVE_COMPARATOR|Neurally Adjusted Ventilatory Assist|Device: Partial ventilator support with partial ventilation mode (NAVA)
62103820|NCT04488250|OTHER|Low-to-mid functioning HIV/AIDS patients|Low-to-mid functioning HIV/AIDS patients greater than 18 years of age with stroke co-morbidity.
62103821|NCT04488250|OTHER|Stroke survivors|Stroke survivors greater than 18 years of age with hemiplegia with and without HIV/AIDS.
62103822|NCT06629597|EXPERIMENTAL|YL201|Participants are randomized to receive YL201 monotherapy intravenously on Day 1 of each 3-week cycle at RP3D dose level, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent as specified in the protocol.
62103823|NCT06629597|ACTIVE_COMPARATOR|Investigator's choice of chemotherapy, including docetaxel, capecitabine, or gemcitabine|Participants are randomized to receive docetaxel/capecitabine/gemcitabine every 3 weeks per prescribing information, until PD, unacceptable toxicity, or withdrawal of consent as specified in the protocol.
62296586|NCT05962008|ACTIVE_COMPARATOR|Omega-3-phosphatidylserine derived from herring roe|Take 300 mg/day of omega-3-phosphatidylserine derived from herring roe.
62296587|NCT05962008|ACTIVE_COMPARATOR|Phosphatidylserine derived from soybean|Take 300 mg/day of phosphatidylserine derived from soybean.
62296588|NCT05962008|PLACEBO_COMPARATOR|Placebo|Take 0 mg/day of phosphatidylserine.
62296589|NCT04996693|OTHER|Scanner 1|Imaging performed on scanner 1: Photon-Counting Detector CT
62296590|NCT04996693|OTHER|Scanner 2|Imaging performed on scanner 2: Energy-Integrating Detector CT (128-slice)
62296591|NCT04996693|OTHER|Scanner 3|Imaging performed on scanner 3: Energy-Integrating Detector CT (20-slice)
62296592|NCT02317510|ACTIVE_COMPARATOR|group 1|Laparoscopic cholecystectomy in General Anesthesia
62296593|NCT02317510|ACTIVE_COMPARATOR|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
62296594|NCT03904680|ACTIVE_COMPARATOR|Methotrexate|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week for 3 months.
62296595|NCT03904680|ACTIVE_COMPARATOR|Methotrexate and Vitamin D|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week and Vitamin D intramuscular injections with the dose of 200,000 IU per month for 3 months.
62296596|NCT04746586||Cases|20 patients with adolescent idiopathic scoliosis in a ratio of 5:1 between females and males will be enrolled.
62296597|NCT04746586||Controls|10 healthy controls, of which 5 females and 5 males will be enrolled.
62296598|NCT05937477||Neoadjuvant, Adjuvant Chemotherapy Arm|Patients diagnosed with lung, head and neck, or esophageal cancer and undergoing Neoadjuvant, Adjuvant chemotherapy.
62296599|NCT05937477||Palliative Chemotherapy Arm|Patients diagnosed with lung, head and neck, or esophageal cancer and undergoing Palliative chemotherapy.
62296600|NCT01591005|EXPERIMENTAL|CEA with sonolysis|endarterectomy with sonolysis (continual transcranial Doppler monitoring)
62296601|NCT01591005|PLACEBO_COMPARATOR|CEA without sonolysis|endarterectomy without sonolysis
62296602|NCT01591005|EXPERIMENTAL|carotid stenting with sonolysis|carotid stenting with sonolysis (continual transcranial Doppler monitoring)
62296603|NCT01591005|PLACEBO_COMPARATOR|carotid stenting without sonolysis|carotid stenting without sonolysis
62296604|NCT02859038|EXPERIMENTAL|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy.
62468501|NCT02224742|EXPERIMENTAL|LeucoPatch|Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets
62468502|NCT02224742|ACTIVE_COMPARATOR|Usual care|Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines
61912453|NCT03940976|EXPERIMENTAL|Afatinib|
61912454|NCT03450330|EXPERIMENTAL|daily dose of AZD4205|daily dose of AZD4205
62468503|NCT05454111|ACTIVE_COMPARATOR|CARTO-Finder-guided ablation plus PVI|Pulmonary vein circumferential isolation + + ablation of sites recognized by CARTO-Finder module as the core of rotors.
62468504|NCT05454111|EXPERIMENTAL|Multiscale entropy-guided ablation plus PVI|Pulmonary vein circumferential isolation + ablation of sites recognized by multiscale entropy analysis as the core of rotors.
62468505|NCT01066143|EXPERIMENTAL|Seroquel XR|
62468506|NCT03283137|EXPERIMENTAL|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
62665511|NCT04404556|EXPERIMENTAL|Diabetes Journey|Diabetes Journey is a web-based intervention to address key adherence barriers. Participants randomized to this arm will first receive the mandatory Introduction and Problem-Solving Module. Based on their elevations on the Barriers to Diabetes Adherence measure, participants will receive up to 7 modules in total. Participants will navigate through the web-based theme park map and complete modules independently and then will have accompanying Zoom telehealth sessions with a therapist.
62468507|NCT06331247|PLACEBO_COMPARATOR|Control arm|Usual medical care (including general dietary advice).
62468508|NCT06331247|ACTIVE_COMPARATOR|MIND diet intervention arm|Usual medical care (including general dietary advice) plus the MIND diet intervention.
62665512|NCT04404556|ACTIVE_COMPARATOR|Enhanced Standard of Care|Participants randomized to Enhanced Standard of Care will receive general education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) from each site across 12-weeks. Content to address adherence barriers were modified and or newly developed for the Enhanced Standard of Care group via the T1DToolkit website.
62665513|NCT03126149|EXPERIMENTAL|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
61912455|NCT05537870|ACTIVE_COMPARATOR|cancer navigator care|experimental group: case manager care combined cancer nurse navigator care
62296605|NCT02859038|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy.
62296606|NCT06617481|OTHER|Open Label Main Arm|Single Arm receiving PET scan with 18F-rhPSMA-7.3 (Posluma)
62468509|NCT01404988|EXPERIMENTAL|Telephone-Delivered BI|Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
62468510|NCT01404988|EXPERIMENTAL|Telephone-Delivered BEI|Behavioral \& Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
62468511|NCT01404988|PLACEBO_COMPARATOR|Telephone-Delivered API|Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
62468512|NCT05410301|EXPERIMENTAL|Patients: sBE device applied during sleep, in combination with Lomustine and Bevacizumab|The sBE device is to be used 8 hours a day by the patients, during sleep, for 8 weeks, while also receiving standard chemotherapy Lomustine and Bevacizumab
62468513|NCT05410301|EXPERIMENTAL|Partners of Patients (who sleep in same bed): sBE|Up to 12 associated unaffected partners may agree to sleep within the investigational sBE device congruent with the period of exposure of their rGBM partner (8 weeks + possible extension)
62468514|NCT04023539|ACTIVE_COMPARATOR|Intervention group|Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
62468515|NCT04023539|PLACEBO_COMPARATOR|Control group|Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
62468516|NCT05963178|EXPERIMENTAL|Cohort|
62665514|NCT03126149|PLACEBO_COMPARATOR|Cohort 1_Period 1_Placebo|Single dose of placebo
62665515|NCT03126149|EXPERIMENTAL|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
61912456|NCT05537870|PLACEBO_COMPARATOR|case manager care|control group: only case manager care(usual care)
62103824|NCT00886613|EXPERIMENTAL|V212|Participants randomized to receive V212 (heat treated VZV Vaccine)
62296607|NCT00867750|EXPERIMENTAL|RE|Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
62665516|NCT03126149|PLACEBO_COMPARATOR|Cohort 1_Period 2_Placebo|Single dose of placebo
62665517|NCT03126149|EXPERIMENTAL|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
62468517|NCT01665209|EXPERIMENTAL|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
62468518|NCT01665209|ACTIVE_COMPARATOR|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
62468519|NCT01534520|EXPERIMENTAL|Group 1: Intravaginal 2% lidocaine gel|Intravaginal insertion of 4mL of 2% lidocaine gel
62468520|NCT01534520|PLACEBO_COMPARATOR|Group 2: Intravaginal placebo gel|Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
62468521|NCT06347562|EXPERIMENTAL|Optical Genome Mapping|explore the ability of Optical Genome Mapping (OGM) to detect known constitutional chromosomal aberrations.
62468522|NCT05076253|ACTIVE_COMPARATOR|Ivermectin|Ivermectin 12 mg per day for 5 plus standard care
62468523|NCT05076253|PLACEBO_COMPARATOR|Placebo|Placebo plus standard care
62468524|NCT03539003|EXPERIMENTAL|sevoflurane (Group S)|general anesthesia with sevoflurane
62468525|NCT03539003|ACTIVE_COMPARATOR|desflurane (Group D)|general anesthesia with desflurane
62665518|NCT03126149|PLACEBO_COMPARATOR|Cohort 1_Period 3_Placebo|Single dose of placebo
62665519|NCT03126149|EXPERIMENTAL|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
62665520|NCT03126149|PLACEBO_COMPARATOR|Cohort 1_Period 4_Placebo|Single dose of placebo
62665521|NCT03126149|EXPERIMENTAL|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
62103825|NCT00886613|ACTIVE_COMPARATOR|Zostavax™|Participants randomized to receive Zostavax™ (Zoster Vaccine, live)
62296608|NCT00867750|ACTIVE_COMPARATOR|TACE|Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
62296609|NCT03783195|EXPERIMENTAL|High GRS group|This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
62468526|NCT03539003|ACTIVE_COMPARATOR|total intravenous anesthesia (Group T)|general anesthesia with total intravenous anesthesia
62665522|NCT03126149|PLACEBO_COMPARATOR|Cohort 2_Period 1_Placebo|Single dose of placebo
62665523|NCT03126149|EXPERIMENTAL|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
62665524|NCT03126149|PLACEBO_COMPARATOR|Cohort 2_Period 2_Placebo|Single dose of placebo
62665525|NCT03126149|EXPERIMENTAL|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
62665526|NCT03126149|PLACEBO_COMPARATOR|Cohort 2_Period 3_Placebo|Single dose of placebo
62665527|NCT03126149|EXPERIMENTAL|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
62665528|NCT03126149|PLACEBO_COMPARATOR|Cohort 2_Period 4_Placebo|Single dose of placebo
62665529|NCT03122665|ACTIVE_COMPARATOR|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
62665530|NCT03122665|ACTIVE_COMPARATOR|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
62665531|NCT01386177|EXPERIMENTAL|doxazosin, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
62665532|NCT00308685|EXPERIMENTAL|Albuterol-HFA-BAI|ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
62665533|NCT00308685|PLACEBO_COMPARATOR|Placebo-HFA-BAI|Placebo
62665534|NCT04308694|EXPERIMENTAL|Pharmacy-based methadone treatment|Participants will have their usual methadone dose administered and dispensed at a participating pharmacy. All other methadone services including counseling, drug testing, and medical services will be delivered as usual at the Methadone Program.
62665535|NCT05150470|OTHER|open label|Single Group Assignment
62103826|NCT00886613|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive placebo
62296610|NCT03783195|EXPERIMENTAL|Low GRS group|This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
62296611|NCT03478826||ILD|250 patients (male and females \>18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
62665536|NCT01011725|EXPERIMENTAL|Postmenopausal Women- Active Agent Group|
62665537|NCT01011725|PLACEBO_COMPARATOR|Postmenopausal Women- Placebo|Placebo
62665538|NCT02539693|EXPERIMENTAL|Clonidine 75|Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).
62665539|NCT02539693|EXPERIMENTAL|Clonidine 150|Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).
62665540|NCT01227395||Azithromycin|Patients taking Azithromycin.
62665541|NCT01625767|EXPERIMENTAL|Approach Avoidance Task experiment|Approach Avoidance Task experiment
62103827|NCT06631885|ACTIVE_COMPARATOR|control group: using AAE protocol|revascularization using blood clot according to the standardized protocol of the American association of endodontics
62103828|NCT06631885|EXPERIMENTAL|test group|diode laser will be used to activate photosensitized nano chitosan 2% for canal disinfection instead of NaOCl in the first visit of revascularization protocol
62103829|NCT01201187|EXPERIMENTAL|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
62296612|NCT03478826||Healthy|100 healthy participants as a control group.
62468527|NCT04327453|EXPERIMENTAL|XP-endo Finisher file|removal of double antibiotic paste intracanal medication with XP-endo Finisher file
62665542|NCT02032784|EXPERIMENTAL|Octreotide|Octreotide 100mcg subcutaneous every 8 hours for 5 days
62665543|NCT02032784|OTHER|no octreotide|No Octreotide
62665544|NCT01138046|EXPERIMENTAL|Lap+weekly Pacli|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
62665545|NCT00308282|EXPERIMENTAL|A|
62665546|NCT00308282|PLACEBO_COMPARATOR|B|
62665547|NCT06381843|EXPERIMENTAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|Participants who received 3 doses of Inactivated COVID-19 vaccines with the third dose at least 6 months (≥180 days) prior to enrolment. N=60 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
62665548|NCT06381843|ACTIVE_COMPARATOR|Inactivated COVID-19 vaccines|Participants who received 3 doses of Inactivated COVID-19 vaccines with the third dose at least 6 months (≥180 days) prior to enrolment. N=60 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
62665549|NCT05362019|EXPERIMENTAL|intervention group|"A mobile phone based service system developed by the research group will be used to provide one-to-one service for the intervention group."
62665550|NCT05362019|ACTIVE_COMPARATOR|control group|Routine family planning services will be provided to the control group.
62665551|NCT00416949|EXPERIMENTAL|Patient-specific 3D-RD Dosimetry|Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
62665552|NCT03952741|EXPERIMENTAL|Cognitive Functional Therapy|The intervention is a targeted cognitive functional therapy and will be based on examination findings. It is behaviorally directed with a focus on normalizing mal-adaptive pain, cognitive and movement behaviors in a graduated manner. In the evaluation process it is considered whether the patient has adjusted to the back complaints in a positive way (confrontation, active coping, minimal avoidance behavior) or in a negative way (passive coping, fear and avoidance behavior). Work related issues will be a particular focus, with the aim of achieving close co-operation between the worker, the workplace and the worker's responsible health care provider.
62665553|NCT03952741|ACTIVE_COMPARATOR|Cognitive Patient Education and PT|The intervention in the second group will receive much training in cognitive coping techniques after the COPE LBP trial principles (Werner et al. 2010). The educational part of the COPE for new instructors with a PT background takes 2 days supervised by Werner and his group, with regular follow-up meeting with the project leaders, together with a psychologist trained in cognitive therapy
62665554|NCT02691663|ACTIVE_COMPARATOR|Oral bicarbonate supplementation group|0.3 meq/kg/day NaHCO3 capsules
62665555|NCT02691663|PLACEBO_COMPARATOR|Placebo group|Methylcellulose capsules
62665556|NCT05916248|EXPERIMENTAL|Personalized neoantigen vaccine or neoantigen tumor vaccine + Pembrolizumab|In dose escalation phase, subject will only receive personalized neoantigen tumor vaccine. In dose expansion phase, subject will receive personalized neoantigen tumor vaccine combination with Pembrolizumab
62665557|NCT00815737|EXPERIMENTAL|A|
62665558|NCT00815737|PLACEBO_COMPARATOR|B|
62665559|NCT02292225|EXPERIMENTAL|IPI-145 in Combination with Obinutuzumab|
62468528|NCT04327453|EXPERIMENTAL|Irrisafe Ultrasonic tip|removal of double antibiotic paste intracanal medication with passive ultrasonic irrigation
62468529|NCT04327453|ACTIVE_COMPARATOR|side vented needle|removal of double antibiotic paste intracanal medication with conventional syringe irrigation
62665560|NCT03707730|EXPERIMENTAL|AGY|capsule containing egg yolk with AGY
62665561|NCT03707730|PLACEBO_COMPARATOR|placebo|capsule containing plain egg yolk
62665562|NCT01456338|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based, manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
62665563|NCT01456338|ACTIVE_COMPARATOR|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
62665564|NCT03432962||Food code group|The participants freely selected foods from the online dietary assessment tool to record what they had eaten over the last 24h. They then provided information on brand details. The recalls were recoded to take into account all branded items and then recoded again to take represent all generic (ie. no brands) foods.
62665565|NCT01761227|EXPERIMENTAL|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
62665566|NCT01761227|PLACEBO_COMPARATOR|Placebo|3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
62665567|NCT05265754|EXPERIMENTAL|Experimental group|In the hand area, firstly, the points will be determined by means of the diagnostic stick and massage will be applied with buckwheat seeds. This massage will be 3 sessions a week, and a total of 6 sessions in 2 weeks.
62665568|NCT05265754|NO_INTERVENTION|control group|A questionnaire will be applied to the patients by the researcher. Questionnaires will be made as pre-test and post-test.
62665569|NCT02324595|EXPERIMENTAL|Laparoscopic Interval Debulking Surgery|Patients affected by advanced epithelial ovarian cancer already submitted to neoadjuvant chemotherapy with evidence of complete/partial response
62665570|NCT06120972|EXPERIMENTAL|Olaparib (maintenance)|300 mg Olaparib (tablets) will be taken orally, twice a day (approximately every twelve hours)
61912457|NCT02811627|EXPERIMENTAL|Memantine and Magnetic Resonance Imaging|"Subjects will be started on memantine post the imaging session.~Memantine is available commercially as Namenda, Namenda XR and in the liquid form (for subjects who do not wish to take pills). Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks."
62103830|NCT01201187|PLACEBO_COMPARATOR|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
62103831|NCT02375321|EXPERIMENTAL|Group A|Study Group: patients with OSA and depressive symptoms treated with CPAP and psychological support
62103832|NCT02375321|NO_INTERVENTION|Group B|Control Group: patients with OSA and depressive symptoms treated with CPAP
62103833|NCT06123988|EXPERIMENTAL|Prolonged Overnighting Fasting Alone (POF Alone) Group|"Participants in this group will undergo a 12-week program of prolonged overnight fasting (POF), and weekly session with a trained health coach. Sessions may be delivered in-person, by telephone or by video call. Participants will also complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints.~Total participant duration is about 12 months."
62296613|NCT03478826||Pneumonia|25 patients with pneumonia as a control group.
62665571|NCT00989027|NO_INTERVENTION|No treatment|A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
62665572|NCT00989027|ACTIVE_COMPARATOR|Treatment|Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.
62665573|NCT00221325|EXPERIMENTAL|Rituximab Plus MTX|
62103834|NCT06123988|ACTIVE_COMPARATOR|Exercise Alone (EXE Alone) Group|"Participants in this group will undergo a 12-week exercise program during three weekly sessions supervised by a trained health coach. Sessions may be delivered in-person, or virtually via telehealth. Participants will also complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints.~Total participant duration is about 12 months."
62665574|NCT06135259|EXPERIMENTAL|erythropoietin mucoadhesive thermosensitive hydrogel|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan (5%) and glycerophosphate (20%).
61912458|NCT03381833|ACTIVE_COMPARATOR|Group A - Delayed therapy|standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks
61912459|NCT03381833|ACTIVE_COMPARATOR|Group B - Immediate therapy|standard chelation therapy plus LJPC-401 for 52 weeks
62665575|NCT06135259|ACTIVE_COMPARATOR|Triamcinolone Mucoadhesive gel|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
62665576|NCT03390153|EXPERIMENTAL|semi flexible socket group|A new form of residuum containment is the semi-flexible carbon fiber prosthetic socket. A semi-flexible carbon fiber socket is constructed with the same security for the subject in mind, and is even more lightweight than a rigid socket. The carbon fiber and resin used in a semi-flexible socket may provide the same durability and stability as previous designs, but will deform, intentionally, without failing (breaking). This distinct feature of semi-flexible sockets makes them a potential option for people living with limb loss. By moving slightly with the residual limb, the socket-user-interface should experience fewer forces/stresses, and yield greater comfort for the prosthetic user.
62103835|NCT06123988|ACTIVE_COMPARATOR|Prolonged Overnight Fasting and Exercise (POF+EXE) Group|"Participants in this group will undergo a 12-week combined program of the prolonged overnight fasting and exercise interventions as described in the POF Alone and EXE Alone arm descriptions respectively. Participants will complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints.~Total participation is about 12 months."
62737581|NCT03470740|OTHER|intervention group|An individualized rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.
62737582|NCT03470740|NO_INTERVENTION|control group|The control group received general information on rheumatoid arthritis care and follow-up.
62737583|NCT02645045||Dry eye|Patients with dry eye syndrome
62737584|NCT02645045||normal|Patients without dry eye
62737585|NCT05908357|EXPERIMENTAL|Exergaming Group (EG)|"The EG will participate in the intervention protocol with exergaming and will also receive the guidance booklet at the end of the treatment. Protocol: twice a week, with a total duration of 40-45 minutes each, conducted by a single physiotherapist. The initial 10 minutes will be for reception, accommodation/heating and anticipation of the service. The Exergaming will last 25-30 minutes, observing the children's reactions to the dosage of the game and the manual and verbal interventions of the physiotherapist. The final 5 minutes will be for cooling down (relaxing music).~The video game will be the Xbox 360 with a Kinect TM sensor , which captures body movement during the game. The game will be Kinect Adventures!, and minigames: peak of reflections and 20,000 leaks. During the game, the physiotherapist will stimulate the child's proprioception in order to promote sensory and verbal feedback. The intervention will last 12 weeks, with 2 weekly sessions, totaling 24 sessions."
62737586|NCT05908357|ACTIVE_COMPARATOR|Control Group (CG)|The CG will be formed by participants admitted to the institution and who are on the waiting list for physiotherapy care and will follow the guidelines of the physiotherapy booklet with recommendations for physical activities that encourage the child's usual mobility, such as: moments of play with the family, walks outdoors and encourage varied ludic motor experiences. This booklet will be created by the researcher and will not change the routine of the service. The CG will be telemonitored biweekly via messaging application by the researcher, through a personal telephone, with a proposal to check the progress of the application of the booklet, clarify doubts with the family and monitor the child. This telemonitoring protocol was established exclusively for the research.
62737587|NCT04947345|EXPERIMENTAL|Experimental group: Remimazolam Besylate|Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of Remimazolam is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.2-1 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and Remimazolam, no analgesic or sedative could be used during the experimental time period.
62103836|NCT06123988|OTHER|Attention Control (AC) Group|"Participants in this group will receive other supportive care in the form of general health education sessions with a trained health coach. These bi-weekly sessions will be administered via telephone or video call in six (6) sessions over approximately 12 weeks. Participants will also complete health-related quality of life questionnaires at designated study timepoints.~Total participation is about 12 months."
62103837|NCT03545789|EXPERIMENTAL|[18F]MNI-958|To measure blood metabolites of \[18F\]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
62103838|NCT03275896|EXPERIMENTAL|Descemet Membrane Transplantation|Patients with severe, symptomatic Fuch's Endothelial Dystrophy (FED) will be offered Descemet Membrane Transplantation (DMT) for their condition.
62665577|NCT03390153|ACTIVE_COMPARATOR|rigid fiber socket group|A rigid carbon fiber socket is constructed for security and is mechanically lightweight to ensure stability and efficient build height. Carbon is used for its durability and stability. It proves to be a detriment in comfort and flexibility. The standard for carbon fiber weaves come in two forms: Unidirectional (UD) and Bidirectional (BD). UD carbon fiber has a zero-degree alignment, which is highly durable when compressed, but has low torsional durability. The BD carbon fibers are aligned in a 90 degree angle allowing for moderate compression and torsional strength. When oriented at 45 degrees to the line of progression, fibers become more flexible and exhibit greater torsional strength. Resins and glass composites are added to ensure security and sturdiness.
62103839|NCT02908620|EXPERIMENTAL|One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session.
62103840|NCT02908620|EXPERIMENTAL|2 sprays CTY-5339-A, then 1 spray CTY-5339-CB +1 spray placebo|Two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session.
62103841|NCT02908620|EXPERIMENTAL|One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
62296614|NCT03931174|ACTIVE_COMPARATOR|Addiction Technology Transfer Center (ATTC) Training|Half of the opioid treatment centers will receive the ATTC training strategy.
62296615|NCT03931174|EXPERIMENTAL|Enhanced ATTC (E-ATTC) Training Strategy|Half of the opioid treatment centers will receive the E-ATTC training strategy.
62665578|NCT01368770|EXPERIMENTAL|Coronary CTA|Coronary CTA using standard protocols
62665579|NCT01368770|ACTIVE_COMPARATOR|Stress MPI SPECT|Stress-rest MPI SPECT using standard protocols
61912460|NCT03673761||Cushing's syndrome|"a) Patients with Sd Cushing (SC): 40 women (25-60 years) with SC, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~* muscle MRI~* dual-energy x-ray absorptiometry~* muscle ultrasounds~* blood testing"
61912461|NCT03673761||acromegaly|"b) Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / Insulin-like-Growth Factor (IGF-I) controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~* muscle MRI~* dual-energy x-ray absorptiometry~* muscle ultrasounds~* blood testing"
62296616|NCT05452603||Study group|Thirty consecutive patients with GERD symptoms and an acid exposure time (AET) measured by impedance measurement/pH between 4 and 6% will be included.
61912462|NCT03673761||Healthy controls|"Controls: n = 40; normal healthy control paired by age, sex and BMI will be included.~This group will under go the following procedures:~* muscle MRI~* dual-energy x-ray absorptiometry~* muscle ultrasounds~* blood testing"
61912463|NCT05070546|EXPERIMENTAL|Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)|Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.
62665580|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
61912464|NCT05070546|PLACEBO_COMPARATOR|C1 G2: Healthy Adults, 18-59 Years (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
62296617|NCT05733455|EXPERIMENTAL|Alpelisib treatment|Participants will ingest a single dose of alpelisib 300 mg (two overencapsulated 150-mg tablets)
62296618|NCT05733455|PLACEBO_COMPARATOR|Placebo treatment|Participants will ingest a single dose of placebo (two capsules filled with microcrystalline cellulose)
61912465|NCT05070546|EXPERIMENTAL|C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)|Participants will receive a single IM injection of study vaccine on Day 1.
61912466|NCT05070546|PLACEBO_COMPARATOR|C2 G4: High Risk Adult, 18-59 Years (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
61912467|NCT05070546|EXPERIMENTAL|C3 G5: Adults, 65 Years and Older (RSV Vaccine)|Participants will receive a single IM injection of study vaccine on Day 1.
61912468|NCT05070546|PLACEBO_COMPARATOR|C3 G6: Adults, 65 Years and Older (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
61912469|NCT00573729|EXPERIMENTAL|Pulsed Dye Laser 577 nm|Pulsed Dye Laser Treatment 577 nm treatment of Port Wine Stain Birthmarks
62296619|NCT02155426||Treatment|Treatment: Chemotherapy or targeted therapy
61912470|NCT00573729|EXPERIMENTAL|Pulsed Dye Laser 595 nm|Pulsed Dye Laser Treatment 595 nm treatment of Port Wine Stain Birthmarks
62103842|NCT02908620|EXPERIMENTAL|1 spray CTY-5339-CB +1 spray placebo, then 2 sprays CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
62103843|NCT02870543|PLACEBO_COMPARATOR|Placebo|Placebo
62103844|NCT02870543|ACTIVE_COMPARATOR|Phytolacca decandra|The Phytolacca decandra with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
62103845|NCT02870543|ACTIVE_COMPARATOR|Melissa officinalis|The Melissa officinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
62103846|NCT02870543|EXPERIMENTAL|Phyt.decandra + Melissa offic.|The combination of Phytolacca decandra with Melissa offcicinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
62103847|NCT06179095|EXPERIMENTAL|Virtual reality group|Virtual reality to be applied to women undergoing intrauterine device insertion.
62103848|NCT06179095|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practive on their own to reduce anxiety during intrauterine device insertion.
62296620|NCT04810273|EXPERIMENTAL|early mobilization (ER) group|Participants in the EM group will undergo the progressive early mobilization protocol in the trauma ICU in a manner consistent with the our hospital practice guidelines indicated by the Modified ICU Mobility Scale for progressive mobilization during the ICU stay. EM will be started with in-bed exercises and, if no medical contraindications are present, progressed from sitting in bed with the head tilted \>60° to sitting on the edge of the bed to standing (including pre-gait exercises to improve postural stability, static and dynamic balance, and marching on the spot) and, finally, to walking.
62296621|NCT04810273|ACTIVE_COMPARATOR|standard early rehabilitation (SER) group|Patients in the SER group (Progressive upright positioning protocol) will receive standard physiotherapy including passive range of motion exercises, active exercises, bed mobility, and respiratory therapy during their ICU stays. In the SER group, out-of-bed mobilization (\>=Level III in the Modified Trauma ICU Mobility Scale) will be started as soon as possible after ICU discharge but at least Level III (sitting on the edge of bed) above 7 days of onset.
62296622|NCT06464107|EXPERIMENTAL|Biopsy proven hyperplasia/endometrial cancer with planned hysterectomy|Women with biopsy proven hyperplasia/endometrial cancer with planned hysterectomy
62296623|NCT06464107|EXPERIMENTAL|Benign clinical indications|Women with planned hysterectomy for benign clinical indications
62296624|NCT05507424|ACTIVE_COMPARATOR|Prone Positioning During Delayed Cord Clamping|Newborns delivered between 25w+0d and 29w+6d gestation who have been randomized in 1:1 fashion to prone positioning during routine delayed cord clamping.
61912471|NCT01962038|ACTIVE_COMPARATOR|Combined Aerobic and Resistance Exercise/Cognitive Training|
62103849|NCT02870270||Head and neck cancer patients|Patients with head and neck cancer who were ≥ 18 years old and had ≥ 16 teeth and no removable prosthesis or dental implants consisting of more than one teeth were included
62296625|NCT05507424|ACTIVE_COMPARATOR|Supine Positioning During Delayed Cord Clamping|Newborns delivered between 25w+0d and 29w+6d gestation who have been randomized in 1:1 fashion to supine positioning during routine delayed cord clamping.
62103850|NCT04485221||Children with a TECPR2 mutation|"Children with a TECPR2 mutation, age 18 months to 12 years old.~Assessments will include collection of genetic mutation reports, functional assessments, and questionnaires. There will be a singular blood draw and skin biopsy."
62103851|NCT03688828|EXPERIMENTAL|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate
62103852|NCT03688828|ACTIVE_COMPARATOR|Quadruple Therapy|Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate
62665581|NCT03346317|EXPERIMENTAL|dried biological amnion graft|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
61912472|NCT01962038|ACTIVE_COMPARATOR|Stretching Exercises/Cognitive Training|
61912473|NCT03874429|EXPERIMENTAL|T2259|1 drop in each eye 2 to 4 times daily
61912474|NCT03874429|ACTIVE_COMPARATOR|Vismed Multi|1 drop in each eye 2 to 4 times daily
62665582|NCT03346317|EXPERIMENTAL|estrogen|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
62665583|NCT05552131|EXPERIMENTAL|Coronary lithotripsy catheter system + drug-eluting stent|
62665584|NCT00910390|PLACEBO_COMPARATOR|Slow Freezing|Standard freezing protocol (slow freezing) of preimplantation embryos
61912475|NCT00684047|EXPERIMENTAL|FS Grifols Preliminary Part (I)|Open label administration of FS Grifols to all subjects
61912476|NCT00684047|EXPERIMENTAL|FS Grifols Primary Part (II)|Single-blind, randomized (2:1)
61912477|NCT00684047|ACTIVE_COMPARATOR|Manual Compression Primary Part (II)|Single-blind, randomized (2:1)
62103853|NCT03368001|EXPERIMENTAL|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
62103854|NCT03368001|ACTIVE_COMPARATOR|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
62103855|NCT04934228|PLACEBO_COMPARATOR|Placebo|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of placebo to the research coordinator to give to the research participant.~The placebo is an inert substance with no intended medical value and is used as a negative control for comparison with the study drug.~Participants will receive a Placebo Pill; has no active ingredients but is made to look like the study drug."
62665585|NCT00910390|EXPERIMENTAL|VIT-Irvine|Vitrification with Irvine solution (rapid freezing) of preimplantation embryos
62665586|NCT00910390|EXPERIMENTAL|VIT-Vitrolife|Vitrification (rapid freezing) with Vitrolife solution
62665587|NCT06277726|EXPERIMENTAL|Emotional freedom technique group|Pre-test data will be collected after women are informed about the emotional freedom technique. After the pre-test data is collected, the emotional liberation technique will be applied to the women. After the emotional liberation technique session is completed, the intrauterine device (IUD) will be applied. Post-test data will be collected within 10 minutes after IUD application is completed.
62665588|NCT06277726|EXPERIMENTAL|Music group|Women in the music group will be informed about the procedure steps before intrauterine device (IUD) application and pre-test data will be collected. After the pre-test data is collected, the music list prepared by the women and researchers will be shown and the women will be asked to choose a piece. Women who do not want to listen to any music on this list will be allowed to listen to the music they prefer. The music concert will be performed with headphones, and women will be asked to listen to the music until the IUD application process is completed. Post-test data will be collected within 10 minutes after IUD application.
62665589|NCT06277726|OTHER|Control group|No intervention will be applied to women in the control group.
62665590|NCT02650557||CSF group|consecutive patients with angiographically documented CSF
62665591|NCT02650557||control group|age- and gender-matched control subjects
62665592|NCT06449664|EXPERIMENTAL|Exercise|The participants will exercise twice weekly performing the newly developed training concept including flywheel resistance training followed by aerobic cycling intervals.
62665593|NCT06449664|NO_INTERVENTION|Control group|The participants will receive usual care only.
61912478|NCT04821362|NO_INTERVENTION|Standard technique group|In this group, peripheral intravenous catheter insertion will be performed routinely.
61912479|NCT04821362|ACTIVE_COMPARATOR|Ultrasound group|In this group, peripheral intravenous catheter insertion will be performed with ultrasound. A linear probe will be used for procedures.
61912480|NCT04821362|ACTIVE_COMPARATOR|Near Infrared Device Group|In this group, peripheral intravenous catheter insertion will be performed with AccuVein AV 400.
61912481|NCT05694377|EXPERIMENTAL|TR group|The training group (TR) will undergo 3 weeks of electroencephalography-based neurofeedback (EEG-NFB). EEG-NFB training.
61912482|NCT05694377|NO_INTERVENTION|CO group|Control group (CO) will not undergo 3 weeks of EEG-NFB training.
62665594|NCT01470807|EXPERIMENTAL|portable artificial pancreas system with CTR algorithms|This is the only arm of the study and concerns all patients.
62665595|NCT03395990|ACTIVE_COMPARATOR|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
62665596|NCT03395990|SHAM_COMPARATOR|saline|15 ml of 0.9% saline via a femoral nerve block technique
62665597|NCT05901961|ACTIVE_COMPARATOR|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
62665598|NCT05901961|ACTIVE_COMPARATOR|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
62665599|NCT05901961|ACTIVE_COMPARATOR|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
62103856|NCT04934228|EXPERIMENTAL|Clonidine|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of clonidine to the research coordinator to give to the research participant.~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth"
62296626|NCT06657456|EXPERIMENTAL|Experimental|Consumption of dietary supplement capsules for 56 days.
62296627|NCT06657456|PLACEBO_COMPARATOR|Control Group|Identically appearing placebo capsules consumed for 56 days.
62296628|NCT02810990|EXPERIMENTAL|Bosutinib treatment|
62296629|NCT04814979|EXPERIMENTAL|Experimental Group|Low-intensity pulsed ultrasound along with routine physical therapy
62296630|NCT04814979|ACTIVE_COMPARATOR|Control Group|Routine physical therapy alone
62665600|NCT00709800|EXPERIMENTAL|2|
61912483|NCT05857280|ACTIVE_COMPARATOR|EXOPULSE Mollii Suit Stimulation Active|This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes.
62665601|NCT00709800|EXPERIMENTAL|3|
62665602|NCT00709800|EXPERIMENTAL|4|
62665603|NCT00709800|PLACEBO_COMPARATOR|5|
61912484|NCT05857280|SHAM_COMPARATOR|EXOPULSE Mollii Suit Stimulation Sham|This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes.
61912485|NCT02840084|EXPERIMENTAL|Treatment Patients|In stage I, 10 women aged 22 years or older who have received silicone or saline breast implants for subglandular or submuscular breast augmentation, and who subsequently developed Baker Grade III capsular contracture, will be invited to participate. In Stage II, the study group will be expanded to include an additional 50 patients who have received saline or silicone gel implants, placed in either the subglandular or submuscular position, with Grade III capsular contracture of the breast. The intervention will be treatment with the Aspen(TM) Ultrasound System.
61912486|NCT03740815|EXPERIMENTAL|Serratus plane block plus sedation|Serratus plane block plus intravenous sedation as anesthetic technique during axillary dissection procedure.
62103857|NCT04934228|EXPERIMENTAL|Hydrochlorothiazide (HCTZ)|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of Hydrochlorothiazide to the research coordinator to give to the research participant.~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"
62296631|NCT04436302|EXPERIMENTAL|Intervention|Dividat senso exergame device
62296632|NCT04436302|ACTIVE_COMPARATOR|Control|Listening to music
62296633|NCT01099111||Irritable Bowel Syndrome|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
62296634|NCT01099111||Ulcerative Colitis|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
62296635|NCT01099111||Crohn's Disease|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
62296636|NCT01099111||Colo Rectal Cancer|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
62665604|NCT00709800|EXPERIMENTAL|1|
62665605|NCT00136474|ACTIVE_COMPARATOR|Group 1|Amifostine plus radiation therapy
62665606|NCT00136474|ACTIVE_COMPARATOR|Group 2|Radiation therapy alone
62665607|NCT04094480|ACTIVE_COMPARATOR|endoloop ligation|securing appendicular base with endoloops
62665608|NCT04094480|ACTIVE_COMPARATOR|non absorbable polymeric clips|securing appendicular base with non absorbable polymeric clips
62665609|NCT03172000|ACTIVE_COMPARATOR|Colonoscopy and biopsy|IBD patients
62665610|NCT03172000|NO_INTERVENTION|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
62665611|NCT06097572|EXPERIMENTAL|Peanut|Participants with possible allergy to peanut
62665612|NCT06097572|EXPERIMENTAL|Cow's Milk|Participants with possible allergy to cow's milk
62665613|NCT03435419||CL suspects|"Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria \& Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.~These will be tested by diagnostic tests under evaluation:~i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR."
62103858|NCT03557333|EXPERIMENTAL|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
62103859|NCT01725347||African American Girls|-25% of sample is African American Girls
62665614|NCT03166254|EXPERIMENTAL|Cohort A: Stage IV squamous NSCLC|"* 4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~* Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~* All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~* Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
62665615|NCT03166254|EXPERIMENTAL|Cohort B: Extensive stage SCLC|"* 4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~* Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~* All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~* Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
62103860|NCT01725347||African American Boys|-25% of sample is African American Boys
62103861|NCT01725347||Hispanic American Girls|-25% of sample is Hispanic American Girls
62665616|NCT02219204|ACTIVE_COMPARATOR|Acupuncture treatment|"This will be performed twice weekly for 30 days. There will be 8 sessions of acupuncture treatments in total.~The needles to be use around the eyes will have the dimensions of 0.25 (diameter) x 13mm (length), while 0.25 x 25mm needles will be used behind the ear (feng chi) and 0.30 X 25mm needles on the upper and lower limbs. These needles will remain in the points for 20 minutes. The depth of penetration will be about 1-2 mm."
62665617|NCT02219204|ACTIVE_COMPARATOR|Herbal treatment|"This formulation is called qi ju gan lu yin or Lycium berry, a chrysanthemum beverage. This is a modified version of qi ju di huang wan published previously. The senior TCM collaborator, Prof Wei QP has made this modification in order to treat the dry eye patients with lung-kidney yin deficiency."
62665618|NCT02219204|NO_INTERVENTION|Eye drops|
62103862|NCT01725347||Hispanic American Boys|-25% of sample is Hispanic American Boys
62296637|NCT01099111||Control: Normal Subjects|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
62296638|NCT03505268|EXPERIMENTAL|telemedicine intervention|The intervention group, in addition to usual care, will get 10 telemedicine interventions by a certified nurse and dietitian who both specialize in treatment of type 1 diabetes.
62296639|NCT03505268|NO_INTERVENTION|usual care|Usual care consisted of visits to the diabetes center every three months and communication with their doctor by phone when needed.
62296640|NCT03343964||Children with moderate to severe TBI|
62296641|NCT01400737|EXPERIMENTAL|ibuprofen|The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
62665619|NCT01033942|EXPERIMENTAL|FTC/TDF as PrEP|Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
62665620|NCT01033942|PLACEBO_COMPARATOR|Placebo Pill Control|Blinded administration of placebo pill; HIV behavioral intervention
62665621|NCT01033942|ACTIVE_COMPARATOR|No Pill Control|Subjects receive HIV behavioral intervention but no pill.
62103863|NCT06220045|EXPERIMENTAL|Polyvinylidene fluoride mesh|"In all patients, surgery will be performed according to their individual pathology. Once midline laparotomy closure is initiated, randomization will be conducted, and patients will be assigned to one of the two groups.~PVDF Group (Polyvinylidene Fluoride Mesh): Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh"
62103864|NCT06220045|EXPERIMENTAL|Prophylactic polypropylene mesh|"In all patients, surgery will be performed according to their individual pathology. Once midline laparotomy closure is initiated, randomization will be conducted, and patients will be assigned to one of the two groups.~PP Group (Polypropylene Mesh): Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
62103865|NCT04034121|OTHER|DESolve Cx|DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
62103866|NCT04465578|ACTIVE_COMPARATOR|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
62103867|NCT04465578|ACTIVE_COMPARATOR|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
62103868|NCT02797405|OTHER|Standard treatment|The patients will receive standard treatment according to international recommendations depending on their type of cancer.
62296642|NCT02783560|EXPERIMENTAL|Sleep First|Families in this condition will receive a behavioral sleep intervention program (The Sleep Train Program) first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive the mealtime intervention (The Family Mealtimes Program).
62468530|NCT02131805|EXPERIMENTAL|Electronic Skin Surface Brachytherapy|The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
61912487|NCT02673541|ACTIVE_COMPARATOR|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
62296643|NCT02783560|ACTIVE_COMPARATOR|Mealtimes First|Families in this active comparison condition will receive a behavioral treatment to promote positive family mealtimes first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive a behavioral sleep intervention (The Sleep Train Program).
62296644|NCT03023748|EXPERIMENTAL|intravenous paricalcitol solutions|"Intravenous paricalcitol will be administered twice or thrice weekly post-hemodialysis with a dose based on the baseline iPTH level divided by 120.~For instance, with a baseline iPTH 1200pg/mL, an induction dose of 10mcg twice or thrice weekly will be given. The maximum weekly dose allowed is 30mcg. Subsequent dose titration may be required depending on the serum PTH level. Intravenous paricalcitol will be continued up to 24 months."
62296645|NCT03617705|OTHER|All participants (HIV+ and HIV- drinkers)|All participants were planned to complete the BACtrack Skyn biosensor in two lab sessions, and wear the Skyn biosensor for two weeks in the field. However, due to COVID, not all participants were able to complete the lab sessions.
62296646|NCT05641350|EXPERIMENTAL|Emotional eating intervention|Emotional eating intervention
62296647|NCT05641350|NO_INTERVENTION|Waiting list|Waiting list
61912488|NCT02673541|ACTIVE_COMPARATOR|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
62296648|NCT04423848|EXPERIMENTAL|Home Hospital for Lymphoma|The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
62296649|NCT01128205||Diagnosed for 6 months or more|
62468531|NCT05970653|ACTIVE_COMPARATOR|RIC Group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days or from enrollment to discharge.
62468532|NCT05970653|PLACEBO_COMPARATOR|Sham-RIC Group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days or from enrollment to discharge.
62665622|NCT05467202|EXPERIMENTAL|Treatment group|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
62665623|NCT04490655|EXPERIMENTAL|Active somatosensory training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that focuses on the retraining of both motor and somatosensory functions, for a maximum of one hour per session.
62665624|NCT04490655|ACTIVE_COMPARATOR|Motor-based training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that is purely motor based, for a maximum of one hour per session.
61912489|NCT01770444|EXPERIMENTAL|Low-dose cardiac CT|Patients randomized to this group will be assessed by low-dose cardiac CT protocol.
61912490|NCT01770444|OTHER|Conventional cardiac CT|Patients randomized to this group will be assessed by conventional cardiac CT protocol.
62296650|NCT02513446|EXPERIMENTAL|BI 1026706|Single dose
61912491|NCT01782469||Rheumatoid Arthritis (RA) participants|Male or female participants at least 18 years of age with diagnosis of RA
61912492|NCT01565304|EXPERIMENTAL|POWER Through Choices|10-session group-based sexual education curriculum
62468533|NCT02281591|EXPERIMENTAL|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
62296651|NCT02513446|EXPERIMENTAL|BI 1026706 + Itraconazole|7 days of itraconazole treatment combined with a single dose of 1026706 on day 4
62296652|NCT02160067|EXPERIMENTAL|Treatment A|Second generation patch BTDS 12.6mg
62468534|NCT02281591|ACTIVE_COMPARATOR|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
62468535|NCT02281591|ACTIVE_COMPARATOR|S-licarbazepine|450 mg of S-licarbazepine
62665625|NCT03959319|EXPERIMENTAL|Movement Pattern Training|Focus will be on task-specific training to improve lower extremity movement patterns during basic daily tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Tasks will be prioritized based on patient-report of activity limitations during the baseline examination. For example, during the first visit, the treating physical therapist will begin with the daily and patient-specific tasks that the patient reported as being most bothersome. Exercises will include repeated practice of functional tasks using optimized movement patterns. Based on the participant's performance, the difficulty of the task-specific activities will be progressed by varying the repetitions performed, increasing the load or changing the support surface. The home program will consist of repeated practice of tasks performed during the supervised sessions.
62296653|NCT02160067|EXPERIMENTAL|Treatment B|Second generation patch BTDS 3.15mg
62296654|NCT02160067|ACTIVE_COMPARATOR|Treatment C|First generation patch BuTrans 20mg
62103869|NCT01855464|EXPERIMENTAL|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
62103870|NCT01855464|ACTIVE_COMPARATOR|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
62103871|NCT05358093||45|
62103872|NCT03491956|OTHER|DFPP group|self contrast (before and after DFPP)
62103873|NCT01139697||Patients with systolic heart failure|Patients with systolic heart failure defined as ejection fraction \<45%
62665626|NCT03959319|ACTIVE_COMPARATOR|Manual Therapy (Joint Mobilization)|Focus will be on reducing pain and improving pain-free range of motion using manual techniques provided by the physical therapist and exercise performed in the home program. Patient education will include instruction to the benefits of manual therapy and the proposed effects on pain and joint mobility. Joint mobilizations to be used with each patient will be prioritized based on the restrictions, defined as stiffness or pain that is limiting joint range of motion, noted on the patient's baseline examination. For example, during the first visit, the treating physical therapist will begin with the two most restricted motions noted in the baseline exam and perform a standard assessment to determine treatment parameters. The home program will include joint range of motion and stretching exercises to complement techniques performed during the supervised sessions.
61912493|NCT01565304|NO_INTERVENTION|Usual services|No intervention
62296655|NCT02160067|ACTIVE_COMPARATOR|Treatment D|First generation patch BuTrans 5mg
62296656|NCT06574035|EXPERIMENTAL|Intervention Group|"Participants randomized to the intervention group will receive 8 one hour virtual sessions of individual cognitive behavioral therapy (CBT) that will take place via U-M Zoom, which is a HIPAA compliant virtual conferencing platform.~Participants in this group will also receive 8 one hour virtual sessions of individual exercise.~Participants in this group will also receive 8 one hour virtual group discussion sessions that will serve as on-going support. This group (4-8 participants) discussion will be facilitated by one CBT Interventionist and one Exercise Interventionist. These sessions will take place following the individual sessions of CBT and Exercise."
62296657|NCT06574035|ACTIVE_COMPARATOR|Control Group|Participants randomized to the control group will receive enhanced usual care (EUC). The EUC group will receive 8 sessions of standard Cognitive Behavioral Therapy.
62296658|NCT04757129||thrombolysis success group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
62296659|NCT04757129||thrombolysis failure group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
62296660|NCT06657430||Patients and their caregivers|Patients (and their caregivers) with psychiatric disorders for which risperidone is indicated, including schizophrenia, bipolar disorder, autism spectrum disorder, conduct disorder, and mental retardation.
62468536|NCT02281591|ACTIVE_COMPARATOR|R-licarbazepine|450 mg of Rlicarbazepine
62468537|NCT04017156|EXPERIMENTAL|Test site (torque of <10 Ncm)|The test sites (\<10 Ncm) will be over-prepared with drills of larger diameter
62468538|NCT04017156|OTHER|Control site (torque of ~30 Ncm)|the standard sites (\~30 Ncm)will be prepared with the corresponding drills suggested by the manufacturer
62468539|NCT05516056|EXPERIMENTAL|ERAS group|First 50 patients included in the ERAS pathway for cholecystectomy in CHUK, Rwanda
62665627|NCT04073407|ACTIVE_COMPARATOR|AXA1957|AXA1957 20.4g
62103874|NCT03523910|EXPERIMENTAL|Patient|A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
62103875|NCT03612115|EXPERIMENTAL|Neuromuscular electrical stimulation intervention|Neuromuscular electrical stimulation treatment
62296661|NCT00797121|EXPERIMENTAL|Preoperative biliary drainage|
62468540|NCT02640521|NO_INTERVENTION|Control Parents|
62665628|NCT04073407|PLACEBO_COMPARATOR|Placebo|Placebo 24g
62665629|NCT02879162|EXPERIMENTAL|Durvalumab + Tremelimumab|Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4
61912494|NCT02203201||Study group|NCWS patients who had showed a negative celiac disease serology and a Marsh 0-1 duodenal histology, but who had displayed a positive EmA assay in the culture medium of the duodenal biopsies (EmA-biopsy).
61912495|NCT02203201||Control group|NCWS patients with negative EmA-biopsy.
61912496|NCT00977457|EXPERIMENTAL|Diagnostic (specimen collection)|Patients receive prostatic massage and undergo a digital rectal examination. Laboratory assessments are performed and blood samples are collected for molecular biology testing. On the day of the scheduled prostatectomy, a second blood collection is performed prior to surgery.
61912497|NCT06286176|EXPERIMENTAL|Behavioral: videos|4 videos are created and distributed to subjects in the intervention group. Video 1: 10 days before delivery Video 2: the day of the delivery Video 3: 1 week postpartum Video 4: 1 month postpartum Videos content: encouraging message, information related to breastfeeding management This is arm in applied in all subjects on the intervention group
62103876|NCT03612115|NO_INTERVENTION|Control|No additional intervention
62103877|NCT05765591|EXPERIMENTAL|Balneotherapy group|"The patients allocated to the Balneotherapy group were subject to 3 weekly sessions of Balneotherapy together with an structured program of aquatic exercises on alternate days in groups of 8 during 4 weeks. The weekly planning was structured as following:~1. st day: Pool, shower, inhalation and aquatic exercises~2. nd day: Pool, shower, inhalation.~3. rd day: Pool, shower, inhalation and aquatic exercises"
62103878|NCT05765591|NO_INTERVENTION|Control group|Patients from the control group were instructed to not participate in any BT-related activity during the duration of the study and to continue with usual care and activities
62665630|NCT01106950|EXPERIMENTAL|Treated Patients|Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
62103879|NCT06629285|ACTIVE_COMPARATOR|Conventional ice treatment|
62103880|NCT06629285|EXPERIMENTAL|Continuous compression cryotherapy|
62103881|NCT04026191|OTHER|Orthovisc-T|
62103882|NCT00795197||Screening Group|Screening Group
62103883|NCT05857293|EXPERIMENTAL|Cyanotic neonate|Cyanotic neonates with PDA dependent pulmonary circulation will be treated with catheter guided PDA stent implantation to keep duct patency and improve oxygen saturation
62103884|NCT04371718|EXPERIMENTAL|JKB-122 Low dose|JKB-122 5 mg daily for 104 weeks
61912498|NCT06286176|EXPERIMENTAL|Behavioral: Whatsapp group|"4 Whatsapp groups were created. Each Whatsapp group was moderated by 1 infant feeding helper. Each whatsapp group consisted of 10-15 subjects.~Mothers asked breastfeeding related questions to infant feeding helpers and also exchange experience with the other mothers on the group.~This is arm in applied in all subjects on the intervention group. Mothers of the intervention group joined their corresponding whatsapp group 10 days before expected delivery date and the duration of the intervention involving the whatsapp group was until 6 months postpartum."
61912499|NCT04757428|ACTIVE_COMPARATOR|Lithium disilicate|The intervention will be: Prosthetic endocrown
61912500|NCT04757428|ACTIVE_COMPARATOR|Hybrid nanoceramic|The intervention will be: Prosthetic endocrown
62296662|NCT00797121|NO_INTERVENTION|Controlled group|
62103885|NCT04371718|EXPERIMENTAL|JKB-122 Medium dose|JKB-122, 15 mg daily for 104 weeks
62103886|NCT04371718|EXPERIMENTAL|JKB-122 High dose|JKB-122 35 mg daily for 104 weeks
62103887|NCT04371718|PLACEBO_COMPARATOR|Placebo|Matched placebo, daily for 104 weeks
62103888|NCT00686946||NRAMP|Participants take their antipsychotic medication as prescribed by their clinical treating teams.
62103889|NCT05684003|EXPERIMENTAL|Intervention group|Neuromuscular exercise based injury-prevention program
62103890|NCT05684003|NO_INTERVENTION|Control group|Nonspecific warm-up including a combination of aerobic exercises and range of motion exercises.
62103891|NCT00882648||Drug dependent women|All drug dependent women enrolled in comprehensive substance abuse treatment at the Center for Addiction and Pregnancy of Johns Hopkins University between 2004 and 2009; retrospective chart review.
62665631|NCT01467804|EXPERIMENTAL|Chinese medicine|There are 90 patients with mild to moderate depress in JWXY group, who take the JWXY capsule, and placebo of Sertraline, for 2 months
62665632|NCT01467804|ACTIVE_COMPARATOR|westen medicine|There are 90 patients with mild to moderate depress in westen medicine group, who take Sertraline, and placebo of the JWXY capsule, for 2 months
62665633|NCT04320875|EXPERIMENTAL|Transcranial direct current stimulation (tDCS) group|Fourty patients with KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
62665634|NCT04320875|ACTIVE_COMPARATOR|Conventional Physiotherapy (CPT) group|Individual with KOA will be educated on how to do the set of exercises correctly at their home during the first session. Consisted of nine exercises including muscle strengthening and flexibility training.
61912501|NCT04674540||Sedation and Analgesia Implementation Status Group|To investigate the implementation status of sedation and analgesia in ICU critical patients.
62103892|NCT06629428|EXPERIMENTAL|Ublituximab|This arm will receive a 48-week ublituximab treatment.
61912502|NCT00873873||Persistent obstruction|(pattern of asthma progression)
61912503|NCT00873873||Late obstruction|(pattern of asthma progression)
62103893|NCT02566148||HIV group|group living with HIV
62103894|NCT02566148||Hepatitis B group|group living with chronic hepatitis B
62103895|NCT02566148||Reference group|group who has neither HIV nor hepatitis B
62103896|NCT05603442|EXPERIMENTAL|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed at second (T2), fifth (T5), ninth (T9), and twelfth (T12) thoracic vertebra. The ultrasonography is performed by using a high-frequency linear-array ultrasound transducer. A Tuohy needle is inserted in-plane to the ultrasound beam in a lateral-to-medial direction gently to contact the spinous process, into the skeletal muscle plane of the erector spinae muscle. Then, the needle tip is moved to reach the angle between the transverse process and spinous process. Subsequently, the needle tip is gently inserted and advanced for 2 mm along with the superior limit of the vertebral pedicle, until losing contact with the bone. Five ml methylene blue 1% dye (MB) are subsequently injected. The anesthetic procedure is bilaterally performed. Two continuous catheter sets were used and threaded 1 cm from the needle tip, for a bilateral continuous block. The catheters are inserted from the caudal to the cephalic direction.
62296663|NCT00764725|ACTIVE_COMPARATOR|A|MTX+SSZ+Plaquenil
62296664|NCT00764725|ACTIVE_COMPARATOR|B|MTX+Infliximab
61912504|NCT00873873||Late normal|(pattern of asthma progression)
62103897|NCT04478305|OTHER|Intervention group|Patient will be provided with study medication. To be taken once a day for 16 weeks (112 days). Active drug brand name - Duavive/Duavee. Dose consisting of 1 pill of 0.45mg conjugated estrogens and 20mg bazedoxifene as bazedoxifene acetate.
62103898|NCT06631625|EXPERIMENTAL|Group L receiving intravenous lidocaine infusion only|Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
62103899|NCT06631625|EXPERIMENTAL|Group LK receiving lidocaine and ketamine infusion|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
62296665|NCT04697914|PLACEBO_COMPARATOR|Control Sock|Control comercial Socks (Lurbel Tierra). These socks are designed to perform trekking.
62296666|NCT04697914|EXPERIMENTAL|Experimental Relief Pressure sock|Experimental Socks (Lurbel Tierra based), with a discharge element (in the own fabric and fibres of the sock).
62296667|NCT05369806|EXPERIMENTAL|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages. The NLP model will be applied to messages and will highlight those determined to be urgent.
62296668|NCT03095092|EXPERIMENTAL|BIA 6-512 fed|BIA 6-512 400 mg following a standard meal
61912505|NCT00873873||Persistent normal|(pattern of asthma progression)
62296669|NCT03095092|EXPERIMENTAL|BIA 6-512 fasting|BIA 6-512 400 mg following at least 8 h of fasting
62665635|NCT03165903|EXPERIMENTAL|Cue and Implementation-Intention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption.
61912506|NCT00950677|ACTIVE_COMPARATOR|exenatide|exenatide one dose
62296670|NCT06041243|EXPERIMENTAL|Treatment|Game-based balance exercises on BoBo Home Balance Board
62296671|NCT06041243|NO_INTERVENTION|Control|
61912507|NCT00950677|ACTIVE_COMPARATOR|pramlintide|pramlintide one dose
62103900|NCT06631625|EXPERIMENTAL|Group LD receiving lidocaine and dexmedetomidine infusion|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
62665636|NCT03165903|OTHER|Control Arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message.
62665637|NCT03390491|EXPERIMENTAL|OnTrack>TheGame (OTG)|Participants randomized to the OTG group (n=100) will have the option to play the online role-playing game for a period of 2 months. They will receive weekly email reminders that the game remains available to them.
62103901|NCT05591079|EXPERIMENTAL|1.4mg CS0159|One tablet daily for 12 weeks
62103902|NCT05591079|EXPERIMENTAL|2mg CS0159|One tablet daily for 12 weeks
62103903|NCT05591079|PLACEBO_COMPARATOR|PLACEBO|One tablet daily for 12 weeks
62103904|NCT05779722|EXPERIMENTAL|Intervention|wrapping the participants in a vapor barrier as the inner layer (intervention),
62103905|NCT05779722|NO_INTERVENTION|No intervention|without the vapor barrier to serve as a negative control
62103906|NCT06504875||CapeOX+PD-1+IL-2|Tislelizumab 200mg ivd D1 + Interleukin 2 100IU HD,QOD d1-d14 +CapeOX (Capecitabine: 1000mg/m2 bid po, d1-d14；Oxaliplatin 130mg/m2 ivd, d1) 6 cycles
62103907|NCT00956449|EXPERIMENTAL|1|
62665638|NCT03390491|OTHER|Recovery Videos (RV)|Participants randomized to the RV group (n=100) will have the option to visit a website that will contain the recovery videos and the static information that is contained in the game. The RV group will also have 2 months to view the materials on the website and will receive weekly email reminders that the website/videos remain available to them. At the end of the study (after the follow-up assessment), the RV participants will be provided access to the game.
62665639|NCT00875329||Group 1|A convenience sample of 97VHA patients who served during the OEF or OIF era, who are targeted in CPRS as requiring the TBI Clinical reminder will be included. This includes all ages, both sexes, and all races and ethnicities.
62665640|NCT01804335|EXPERIMENTAL|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
62665641|NCT01897389|EXPERIMENTAL|Sequence 1: abiraterone acetate|Treatment sequence 1 is defined as: AEBD
62665642|NCT01897389|EXPERIMENTAL|Sequence 2: abiraterone acetate|Treatment sequence 2 is defined as: BACE
62665643|NCT01897389|EXPERIMENTAL|Sequence 3: abiraterone acetate|Treatment sequence 3 is defined as: CBDA
62665644|NCT01897389|EXPERIMENTAL|Sequence 4: abiraterone acetate|Treatment sequence 4 is defined as: EDAC
62665645|NCT01897389|EXPERIMENTAL|Sequence 5: abiraterone acetate|Treatment sequence 5 is defined as: DECA
62665646|NCT01897389|EXPERIMENTAL|Sequence 6: abiraterone acetate|Treatment sequence 6 is defined as: EADB
62665647|NCT01897389|EXPERIMENTAL|Sequence 7: abiraterone acetate|Treatment sequence 7 is defined as: ABEC
61912508|NCT03869268|ACTIVE_COMPARATOR|No Drug|"Patients will be randomised to receive no drug for the first medication period (10 days).~Patient will then be allocated to receive ticagrelor 90mg twice daily for the second medication period (10 days)"
61912509|NCT03869268|ACTIVE_COMPARATOR|Ticagrelor 180 mg|"Participants will be randomised to receive loading dose of ticagrelor 180 mg on the last day of the first medication period (10-14 days).~Participants will then be allocated to receive no aspirin but a loading dose of ticagrelor 180 mg on the last day of treatment for the second medication period (10-14 days)."
62296672|NCT06487351|EXPERIMENTAL|The adapted PHBI|The intervention group will be given access to the adapted PHBI.
62296673|NCT06487351|ACTIVE_COMPARATOR|NIH Implicit Bias course|"The control group will be instructed to take the course, NIH Implicit Bias."
62665648|NCT01897389|EXPERIMENTAL|Sequence 8: abiraterone acetate|Treatment sequence 8 is defined as: BCAD
62665649|NCT00551356|ACTIVE_COMPARATOR|2|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
62665650|NCT00551356|ACTIVE_COMPARATOR|1|Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.
62103908|NCT02624778|PLACEBO_COMPARATOR|Part A: Placebo Single Dose (SD)|Participants received single intravenous (IV) dose of placebo.
62103909|NCT02624778|EXPERIMENTAL|Part A: 10 Milligram Per Kilogram (mg/kg) LY3002813 SD|Participants received single IV dose of 10 mg/kg LY3002813.
62103910|NCT02624778|EXPERIMENTAL|Part A: 20 mg/kg LY3002813 SD|Participants received single IV dose of 20 mg/kg LY3002813.
62103911|NCT02624778|EXPERIMENTAL|Part A: 40 mg/kg LY3002813 SD|Participants received single IV dose of 40 mg/kg LY3002813.
62103912|NCT02624778|PLACEBO_COMPARATOR|Part B: Placebo Q2W|Participants received multiple IV dose of placebo every 2 weeks (Q2W) for 24 weeks.
62103913|NCT02624778|EXPERIMENTAL|Part B: 10 mg/kg LY3002813 Q2W|Participants received multiple IV dose of 10 mg/kg LY3002813 Q2W for 24 weeks.
62103914|NCT02624778|PLACEBO_COMPARATOR|Part C: Placebo Q4W|Participants received multiple IV dose of placebo every 4 weeks (Q4W) for 72 weeks.
62103915|NCT02624778|EXPERIMENTAL|Part C:10 mg/kg LY3002813 Q4W|Participants received multiple IV dose of 10 mg/kg LY3002813 Q4W for 72 weeks.
62103916|NCT02624778|EXPERIMENTAL|Part C:20 mg/kg LY3002813 Q4W|Participants received multiple IV dose of 20 mg/kg LY3002813 Q4W for 72 weeks.
62103917|NCT00926393|ACTIVE_COMPARATOR|Quetiapine Immediate Release (IR)|Quetiapine 25, 100, 200 and 300 mg
62468541|NCT02640521|ACTIVE_COMPARATOR|Treatment Parents|Chart reminders (paper or electronic medical records, depending on clinic wishes) to prompt providers to ask about in home smoking at every medical visit; establishing a New York State Quit line referral system in the pediatric practice; and amending the training curriculum for providers and the patient education materials that are part of a provider toolkit, to focus on the negative impact of second hand smoke (SHS) on their children,and specifically, asthma outcomes.
62665651|NCT02011464|EXPERIMENTAL|Exparel infiltration|Exparel infiltrated into the posterior compartment of the knee
62665652|NCT02011464|PLACEBO_COMPARATOR|Control|Saline infiltrated into posterior compartment
62665653|NCT04847921|EXPERIMENTAL|people who use drugs with severe Gram-positive infections|As per inclusion and exclusion criteria
62665654|NCT06091384|EXPERIMENTAL|Inspiratory Muscle Strength Training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for 6 weeks.
62665655|NCT06091384|SHAM_COMPARATOR|Sham- Inspiratory Muscle Training|Using a handheld device, participants will perform 30 breaths a day at 15% of maximal inspiratory pressure, six days a week, for 6 weeks.
62665656|NCT00621530|EXPERIMENTAL|Ketorolac|ketorolac 2 mg ketorolac tromethamine opthalmic solution
62103918|NCT00926393|ACTIVE_COMPARATOR|Quetiapine Extended Release (XR)|Quetiapine 50, 200, 300
62665657|NCT00621530|PLACEBO_COMPARATOR|Placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
62103919|NCT02696629||Education and follow up|Participants who refuse or fail to have PAP treatment or Oral appliance or other treatments for sleep apnea. They also refuse or have counter-indication for surgical treatment. The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
62103920|NCT02696629||Upper airway surgery|Participants who undergo uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery.
62103921|NCT02696629||Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
62103922|NCT05113927|NO_INTERVENTION|Standard of Care|Lumpectomy with usual intraoperative margin assessment
62103923|NCT05113927|EXPERIMENTAL|Device|Imaging of all margins with investigational device
62103924|NCT02534896|EXPERIMENTAL|Treatment 1: Sunpharma1505 (Low dose) and Placebo|
62103925|NCT02534896|EXPERIMENTAL|Treatment II: Sunpharma1505 (High Dose) and Placebo|
62103926|NCT02534896|ACTIVE_COMPARATOR|Treatment III: Reference1505 and Placebo|
62103927|NCT04242758|EXPERIMENTAL|Dapaglifozin|People undergoing SGLT2i (Dapaglifozin) therapy
62103928|NCT04242758|EXPERIMENTAL|Hydrochlorothiazide|People undergoing thiazide (Hydrochlorothiazide) therapy
62103929|NCT03047590|EXPERIMENTAL|Choice-No Affect|These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
62103930|NCT03047590|EXPERIMENTAL|Choice-Affect|These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
62296674|NCT06656442|ACTIVE_COMPARATOR|Trimetazidine and Standard of care|AIS patients receiving standard of care and Trimetazidine 35mg/12hrs within 12 hours of admission
62296675|NCT06656442|NO_INTERVENTION|Standard of care only|AIS patients receiving standard of care only.
62468542|NCT00736970|EXPERIMENTAL|1|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus
62665658|NCT02286830|ACTIVE_COMPARATOR|zoledronic acid|treatment with zoledronic acid for 4 years
62665659|NCT02286830|PLACEBO_COMPARATOR|no treatment|treatment with zoledronic acid withheld after two years
62665660|NCT00440024|EXPERIMENTAL|Cell A|Study controlled daily skin care regimen during 'rest period' consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
62665661|NCT00440024|PLACEBO_COMPARATOR|Cell B|Subject controlled normal skin care regimen during 'rest period, followed by study controlled daily skin care regime consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
62665662|NCT04093284|EXPERIMENTAL|Group A|The needle-free jet injector Continuous insulin therapy for 9 days, then changed to conventional insulin pen therapy for 9 days
62665663|NCT04093284|EXPERIMENTAL|Group B|The conventional insulin pen therapy for 9 days, then changed to needle-free jet injector Continuous insulin therapy for 9 days
62665664|NCT00665639|EXPERIMENTAL|1|Daily dose
62665665|NCT00665639|ACTIVE_COMPARATOR|2|
62665666|NCT00665639|EXPERIMENTAL|3|Every other day dose, alternating with placebo
61912510|NCT03869268|ACTIVE_COMPARATOR|Aspirin 20mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
61912511|NCT03869268|ACTIVE_COMPARATOR|Aspirin 20 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
61912512|NCT03869268|ACTIVE_COMPARATOR|Aspirin 75 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
61912513|NCT03869268|ACTIVE_COMPARATOR|Aspirin 75 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days)."
61912514|NCT03869268|ACTIVE_COMPARATOR|Aspirin 300 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 300 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
61912515|NCT03869268|ACTIVE_COMPARATOR|Aspirin 300 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10-14 days) plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 300 mg once daily for the second medicaion period (10-14 days)."
61912516|NCT03802214||vedolizumab-UC-naïve to TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy
61912517|NCT03802214||vedolizumab-UC- previous TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure
61912518|NCT02937584|EXPERIMENTAL|GP MDI (PT001) 14.4 μg|Glycopyrronium
61912519|NCT02937584|EXPERIMENTAL|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
62103931|NCT03047590|EXPERIMENTAL|No Choice-Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). Meanwhile, these participants are instructed to focus on the good feelings that come with exercise. this is heart rate-based exercise intensity with a focus on positive affect."
62665667|NCT00769405|EXPERIMENTAL|Arm I|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery). Patients also undergo CHIP comprising oxaliplatin intraperitoneally during surgery and hyperthermia for 30 minutes.
61912520|NCT03289520|EXPERIMENTAL|Clopidogrel|
61912521|NCT03289520|PLACEBO_COMPARATOR|Placebo|
61912522|NCT05758701|EXPERIMENTAL|Cohort 1|A cohort will be given a 1/3rd reduced dose of iodinated contrast agent (33 ml).
62665668|NCT00769405|EXPERIMENTAL|Arm II|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery).
61912523|NCT05758701|EXPERIMENTAL|Cohort 2|If imaging with 1/3 dose is satisfactory, a second cohort with 1/4th the standard dosage (25 ml) will be assessed. If images are not satisfactory, contrast dose will be increased to 50 ml.
61912524|NCT02921061|EXPERIMENTAL|Treatment (decitabine, G-CLAM)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.~RE-INDUCTION: Patients who do not achieve MRDneg CR after first induction are eligible for re-induction. Patients receive the same treatment as during induction except that decitabine is omitted.~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction, patients are eligible to receive filgrastim, cladribine, and cytarabine as in Induction. Treatment may be repeated for up to 4 courses in the absence of disease progression or unacceptable toxicity. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks)."
61912525|NCT01229462|OTHER|Combigan®|One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
61912526|NCT01229462|ACTIVE_COMPARATOR|Alphagan® and Timolol Concurrent|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
61912527|NCT00592774|PLACEBO_COMPARATOR|Placebo Cohort 1|
61912528|NCT00592774|EXPERIMENTAL|Perampanel Cohort 1, 3-week Titration|
61912529|NCT00592774|EXPERIMENTAL|Placebo Cohort 2|
61912530|NCT00592774|EXPERIMENTAL|Perampanel Cohort 2, 1-week Titration|
61912531|NCT00592774|EXPERIMENTAL|Perampanel Cohort 2, 2- Week Titration|
61912532|NCT03302182|EXPERIMENTAL|fasting group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.~For group1:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group2:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
62103932|NCT03047590|ACTIVE_COMPARATOR|No Choice-No Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). This is heart rate-based exercise intensity with no focus on positive affect."
62103933|NCT06710405|EXPERIMENTAL|Lidocaine group|"Anesthesia induction is performed according to the standard protocol. Monitoring includes electrocardiography, pulse oximetry, arterial blood pressure, depth of anesthesia (Patient State Index, PSI), and pain score (Analgesia Nociception Index).~In the lidocaine group, a single bolus dose of lidocaine 1.5 mg/kg is administered concurrently with the induction of anesthesia, followed by a continuous infusion of lidocaine at a rate of 1.5 mg/kg/hr."
62103934|NCT06710405|PLACEBO_COMPARATOR|Control group|The control group receives a continuous infusion of normal saline in the same volume as that administered to the lidocaine group.
62103935|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram \[mcg/kg\]) every 2 weeks (q2w) up to 9 months
62103936|NCT04692948|EXPERIMENTAL|TAA6 cell injection|"Drug: TAA6 cell injection（Targeting CD276 autologous chimeric antigen receptor T cells）~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells.Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
62103937|NCT05583240|EXPERIMENTAL|Essential Oils|
62103938|NCT06688734|EXPERIMENTAL|Initial Water Seal|After chest tube placement, the chest tube will be placed to 20cm H2O of suction for 1 minute to evacuate all pneumothorax. After this, the chest tube will be placed to water seal, defined as the water seal chamber on the chest tube drainage system being filled up to the 2cm line and not on suction. All other management decisions related to the chest tube will be left to the providers.
62103939|NCT06688734|EXPERIMENTAL|Initial Suction|After chest tube placement, the suction group will have their chest tube placed to 20cm H2O of suction delivered by the chest tube drainage suction. All other management decisions related to the chest tube will be left to the providers.
62103940|NCT03201757|EXPERIMENTAL|ALKS 3831|Coated bilayer tablet
62103941|NCT04417712||Patients with ventricular septal defect|"All patients who signed informed consent and are implanted with a KONAR-MF™ VSD Occluder device will undergo follow-up (FU) evaluations as per local hospital standards and corresponding IFU which is expected to be at the following time points post-implant:~* Before discharge~* 1-3 months after the Procedure~* 6 months after the procedure~* 12 months after the procedure"
62103942|NCT02219906|PLACEBO_COMPARATOR|Placebo|Placebo capsule given three times daily X 3 weeks
62103943|NCT02219906|EXPERIMENTAL|Resveratrol|Resveratrol 1 gram three times daily X 3 weeks
62296676|NCT06286423|EXPERIMENTAL|Colchicine 0.6 mg treatment group|Treatment group will be given active drug (0.6mg Colchicine) 2x/day (once if subject has kidney disease) for 14 days. Subsequently treatment group subjects will be given active drug (0.6mg Colchicine) 1x/day for 76 +/- days (or once every other day if subject has kidney disease).
62296677|NCT06286423|PLACEBO_COMPARATOR|Control/Placebo group|Control/Placebo group will be given placebo that looks identical to study drug with no active ingredients and will take 2x/day (once if subject has kidney disease) for 14 days. Subsequently Control/Placebo group will be given placebo 1x/day for 76 +/- days (or once every other day if subject has kidney disease).
62296678|NCT02772783|EXPERIMENTAL|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
62296679|NCT02772783|EXPERIMENTAL|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
62296680|NCT02772783|ACTIVE_COMPARATOR|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
62296681|NCT00282243|EXPERIMENTAL|Tacrolimus MR|"After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study.~Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons."
62296682|NCT02471287||Affected Participants|Participants with eye disease
62296683|NCT02471287||Healthy volunteers|Unaffected first degree relatives of participants with a known or suspected inherited eye disease.
62296684|NCT06349629|EXPERIMENTAL|Clinical effect of 3D printed magnesium alloy prosthesis for repairing proximal humerus bone defect.|The 3D printed magnesium alloy prosthesis is used to repair the proximal humerus fracture with bone defect, and the dynamic process of prosthesis degradation, fracture healing and new bone growth will be observed.
62665669|NCT01198548|EXPERIMENTAL|Treatment (FOLXFOX, bevacizumab, cholecalciferol)|Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin\* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: \*Treatment with oxaliplatin is discontinued after course 8
62665670|NCT06334198|ACTIVE_COMPARATOR|Active treatment|Naldemedine + tramadol
62665671|NCT06334198|PLACEBO_COMPARATOR|Placebo treatment|Placebo + tramadol
62665672|NCT02186067|EXPERIMENTAL|Referral System|"Referral System:~Primary Level Secondary Level Tertiary Level"
62665673|NCT02186067|NO_INTERVENTION|Control|Usual/routine care will be provided to the patients
62665674|NCT04093076|EXPERIMENTAL|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device.
61912533|NCT03302182|EXPERIMENTAL|Fed group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.~For group3:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group4:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
62665675|NCT04093076|EXPERIMENTAL|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit.
62665676|NCT04093076|PLACEBO_COMPARATOR|Placebo Group C|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device.
61912534|NCT03048383|ACTIVE_COMPARATOR|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
62103944|NCT04454567|EXPERIMENTAL|ABI-H0731 + SOC NrtI|Participants with chronic hepatitis B virus (HBV) infection with partial virologic suppression on NrtI alone will receive ABI-H0731 300 mg once daily plus standard of care (SOC) NrtI for 96 weeks, followed by SOC NrtI alone for an additional 24 weeks (120 weeks total).
62103945|NCT04454567|PLACEBO_COMPARATOR|Placebo + SOC NrtI|Participants with chronic HBV infection with partial virologic suppression on NrtI alone will receive placebo to ABI-H0731 once daily plus SOC NrtI for 48 weeks, followed by ABI-H0731 300 mg once daily plus SOC NrtI for Weeks 48 to 96, followed by SOC NrtI alone for Weeks 96 to 120.
62103946|NCT01569906||UVB|Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy
62103947|NCT01569906||Controls|Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment
62103948|NCT06614972||balloon-expandable drug-eluting stent|Patients were treated with balloon-expandable drug-eluting stent.
62103949|NCT04859777|EXPERIMENTAL|Part A:|Dose-escalation oral MPT-0118 BID
62103950|NCT04859777|EXPERIMENTAL|Part B:|Dose-escalation oral MPT-0118 BID + pembrolizumab (IV)
62103951|NCT04859777|EXPERIMENTAL|Part C:|Dose-expansion oral MPT-0118 BID + pembrolizumab (IV)
62296685|NCT06349629|EXPERIMENTAL|Clinical effect of 3D printed magnesium alloy prosthesis for repairing distal radius bone defect.|The 3D printed magnesium alloy prosthesis is used to repair the distal radius fracture with bone defect, and the dynamic process of prosthesis degradation, fracture healing and new bone growth will be observed.
62665677|NCT04093076|PLACEBO_COMPARATOR|Placebo Group D|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit..
62103952|NCT00598897|EXPERIMENTAL|clarithromycin and rifabutin/rifampin|Clarithromycin and rifabutin/rifampin with ethambutol given three times weekly.
62103953|NCT02350595|EXPERIMENTAL|Lean fish|Participants eat 750g of lean fish per week for 8 weeks.
62103954|NCT02350595|EXPERIMENTAL|Fatty fish|Participants eat 750g of fatty fish per week for 8 weeks.
62103955|NCT02350595|NO_INTERVENTION|Control|Participants eat as normal, but avoid fish and seafood for 8 weeks.
62103956|NCT03742713|EXPERIMENTAL|CPC634 (CriPec® docetaxel)|CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2
62103957|NCT01356225|EXPERIMENTAL|Intranasal Ketorolac tromethamine|
62103958|NCT01356225|PLACEBO_COMPARATOR|Intranasal placebo|
62103959|NCT02195557||Synvisc®|
62665678|NCT01870570|OTHER|Reference Glucose|Glucose Standard (50g of Glucose)
62665679|NCT01870570|EXPERIMENTAL|Food Product A: Corn Flakes|Corn Flakes
62665680|NCT01870570|EXPERIMENTAL|Food Product B: Ginger Bread|Ginger Bread
62665681|NCT01870570|EXPERIMENTAL|Food Product C:Sandwiched Breakfast Biscuit|Sandwiched Breakfast Biscuit
62665682|NCT01870570|EXPERIMENTAL|Food Product D: Crackers Nature|Crackers Nature
62665683|NCT01870570|EXPERIMENTAL|Food Product E: Breakfast Biscuit|Breakfast Biscuit
62665684|NCT01870570|EXPERIMENTAL|Food Product F: White Bread|White Bread
62665685|NCT03147287|ACTIVE_COMPARATOR|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
62665686|NCT03147287|EXPERIMENTAL|Fulvestrant with Palbociclib|"* Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~* Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
62665687|NCT03147287|EXPERIMENTAL|Fulvestrant with Palbociclib and Avelumab|"* Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~* Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly~* Avelumab will be administered intravebously once every 2 weeks"
62665688|NCT02591303|EXPERIMENTAL|Insomnia group|Patients with insomnia: sleep complaints, of more than 3 nights a week, more than 3 months, affected daytime functioning, objectified low sleep quality (Sleep Efficiency \<85%) with 10 days actigraphy
62665689|NCT02591303|EXPERIMENTAL|Control group|No sleep problems either self reported or objectified through actigraphy (Sleep Efficiency \>85%)
62665690|NCT06418815|EXPERIMENTAL|Concept Map Group|The intervention group will create a concept map regarding neonatal toxic stress.
62665691|NCT06418815|NO_INTERVENTION|Control Group|During the application process of the research, knowledge tests will be applied as pre-test and post-test
62665692|NCT03343574|EXPERIMENTAL|Abdominal Strengthening Exercise|All participants in this arm shall perform exercises for the strengthening of abdominal muscles for a period of three months in addition to the routine care provided to them for the management of Parkinson's Disease. The exercises are structured and need to be performed on a routine basis.
62103960|NCT06713109|NO_INTERVENTION|arm1|Will receive standard breastfeeding training and after 3 weeks the final test will be administered
62103961|NCT06713109|EXPERIMENTAL|arm2|A motivational interview will be conducted to get information about the breastfeeding problem and the level of loss and to try to support it with interviews.
62103962|NCT06443021|OTHER|Peritoneal dialysis (PD)|"During the clinical phase, patients are treated continuously with the PD cycler sleep•safe harmony.~The total duration of the clinical for the individual patient comprises a maximum of 17 weeks starting from V0"
62296686|NCT06349629|EXPERIMENTAL|Clinical effect of 3D printed magnesium alloy prosthesis for repairing tibial plateau bone defect.|The 3D printed magnesium alloy prosthesis is used to repair the tibial plateau fracture with bone defect, and the dynamic process of prosthesis degradation, fracture healing and new bone growth will be observed.
62296687|NCT02706639||SVAS/SVAS-like group|Children or adults must: be between the ages of 0-85; have clinical features of SVAS; SVAS-like condition; have genetic testing results that imply affected status (SVAS has decreased penetrance)
62665693|NCT03343574|NO_INTERVENTION|Routine Care|All participants in this group shall continue to obtain routine care for the management of Parkinson's Disease.
62103963|NCT01823341|ACTIVE_COMPARATOR|Pump suspension algorithm|The pump suspension algorithm will be running actively on the study laptop during the night and suspend the pump if the algorithm predicts hypoglycemia.
62296688|NCT02706639||Unaffected related (family member) controls|Children or adults: family members be between the ages of one month old and 85 years old, not carry a diagnosis of WS, SVAS, an SVAS-like condition or a known (at the time of enrollment) WS gene region variant.
62296689|NCT02706639||Unaffected unrelated controls|Adults, 18-85: unrelated controls be between the ages 18 and 85 years old, not carry a diagnosis of WS, SVAS, an SVAS-like condition or a known (at the time of enrollment) WS gene region variant.
62665694|NCT02837653|EXPERIMENTAL|Experimental|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home, and a personalized Physical Activity Counseling based on the Cardiovascular Risk of Each Patient
62665695|NCT02837653|ACTIVE_COMPARATOR|Control|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home.
62103964|NCT01823341|NO_INTERVENTION|Standard of Care|The control algorithm will run passively and not suspend the patient's pump.
62103965|NCT00679276||1|Patients having surgical repair of a vaginal prolapse .
62103966|NCT01266044|EXPERIMENTAL|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
62296690|NCT02706639||WS group|Children or adults must: be between the ages of 0 and 85; have a presumed or confirmed diagnosis of WS; have a parent/guardian available to provide consent and assist in answering medical questions
62296691|NCT02706639||WS region gene changes|Children or adults must: be between the ages of 0-85; have clinical or research genetic testing that reports gene variation in one or more genes in the WS region (ELN variants alone will be considered in the SVAS category but other changes to the region that include ELN plus other genes may be grouped in this category).
62665696|NCT02450474|OTHER|A: baseline - IPC|"A: baseline - IPC - washout - NMES - washout - follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. IPC phase will consist of normal care plus IPC of the lower limbs for the duration of each dialysis session."
62665697|NCT02450474|OTHER|B: baseline - NMES|"B: baseline - NMES - washout - IPC - washout follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. NMES phase will consist of normal care plus stimulation of the foot and calf muscles for a period of one hour during dialysis."
62665698|NCT02949453|EXPERIMENTAL|patients after suicidal episode|Patients receiving a telephone-delivered intervention after deliberate self-harm (DSH)
62665699|NCT04740970|EXPERIMENTAL|JNJ-64304500|Participants will receive JNJ-64304500 dose 1 subcutaneous (SC) injection at Week 0 and then dose 2 SC injection every 2 weeks from Week 2 through Week 22.
62665700|NCT04740970|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo SC injection at Week 0 and then every 2 weeks from Week 2 through Week 22.
62665701|NCT03006120||Group 1|Conservative management
62665702|NCT03006120||Group 2|Angiografic stenting
62665703|NCT03006120||Group 3|Surgery
62665704|NCT00180453|EXPERIMENTAL|1|Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
62665705|NCT00180453|ACTIVE_COMPARATOR|2|Abbott Vascular MULTI-LINK VISION® BMS
62665706|NCT05188794|ACTIVE_COMPARATOR|group L|Lateral transversus abdominis plane(TAP) block
62665707|NCT05188794|ACTIVE_COMPARATOR|Group P|Posterior transversus abdominis plane block
62665708|NCT00294398|OTHER|Standard Asthma ED Discharge Therapy|Standard asthma therapy including oral corticosteroids, albuterol, education and discharge instructions.
62665709|NCT00294398|EXPERIMENTAL|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
62665710|NCT00968942|ACTIVE_COMPARATOR|Dose A|RT001
62665711|NCT00968942|PLACEBO_COMPARATOR|Dose B|Placebo
62665712|NCT05886023|ACTIVE_COMPARATOR|Active Intervention|The intervention comprises vegetable burger containing high nitrate vegetables (100g of spinach, \~1000mg/kg FW nitrate) on white bread sandwich, provided at breakfast and lunch.
62103967|NCT01266044|ACTIVE_COMPARATOR|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
62103968|NCT01266044|OTHER|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
62103969|NCT06626334|EXPERIMENTAL|Bright Blue Light|The light therapy lamp will be covered with a filter selecting for short wavelength blue light (peak 442 nm, intensity \~1400 lux).
62103970|NCT06626334|ACTIVE_COMPARATOR|Bright Full-Spectrum (White) Light|The light therapy lamp will be covered with a filter modifying only the light's intensity (\~1400 lux).
62103971|NCT06626334|OTHER|Usual Ambient Light|Participants assigned to the usual light arm will be exposed only to the usual lighting conditions of the hospital ward.
62103972|NCT03158948|EXPERIMENTAL|nangibotide 0.3 mg/kg/h|
62103973|NCT03158948|EXPERIMENTAL|nangibotide 1.0 mg/kg/h|
62103974|NCT03158948|EXPERIMENTAL|nangibotide 3.0 mg/kg/h|
62103975|NCT03158948|PLACEBO_COMPARATOR|Placebo to nangibotide|
62103976|NCT06627582|EXPERIMENTAL|Postmastectomy Reconstruction Participants|Participants will be postmastectomy reconstruction and \>/= 6 months postoperative
62296692|NCT03471403||FAP|FAP patients with duodenal adenomas
62665713|NCT05886023|PLACEBO_COMPARATOR|Control Intervention|The intervention comprises vegetable burger containing low nitrate vegetables (200g of peas, sweet corn, \< 30 mg/kg FW nitrate) on white bread sandwich, provided at breakfast and lunch.
62665714|NCT04979013|EXPERIMENTAL|Smoking Abstinence|14-day Smoking Abstinence
62665715|NCT02295449|EXPERIMENTAL|1|
62665716|NCT02097277|PLACEBO_COMPARATOR|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
62665717|NCT02097277|EXPERIMENTAL|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
62665718|NCT02097277|EXPERIMENTAL|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
62665719|NCT02097277|EXPERIMENTAL|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
62665720|NCT02097277|EXPERIMENTAL|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
62665721|NCT02792127|EXPERIMENTAL|Experimental|These participants will be given access to a six-month online program for social anxiety.
62665722|NCT02792127|NO_INTERVENTION|Wait List Control|These participants will not be given an intervention until after they have completed the study.
62665723|NCT05084404|EXPERIMENTAL|4 mg/day of WY-8678 (guanabenz acetate)|
62665724|NCT05084404|EXPERIMENTAL|8 mg/day of WY-8678 (guanabenz acetate)|
62665725|NCT00725660||1|Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination.
62665726|NCT05616897|OTHER|Medicine students|students with normal expected fitness
61912535|NCT03048383|ACTIVE_COMPARATOR|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
61912536|NCT03048383|ACTIVE_COMPARATOR|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
61912537|NCT04033588|OTHER|Freedom® Total Knee System|A prospective, multi-centre, non-comparative, post-market clinical follow-up study to evaluate the survivorship, safety and performance of the Freedom® Total Knee System in United Kingdom
61912538|NCT05977881|OTHER|SCOPE Cohort|A cohort of PWUD (N=500) living in Baltimore. We will follow-up with participants every 6 months (for 18 months) in five recruitment zones throughout Baltimore (n=125/zone). The four recruitment zones will overlap the intervention sites. There will be four study visits (baseline, 6 months, 12 months, 18 months) total for participants.
61912539|NCT06009185|EXPERIMENTAL|HTD < 200 mg zamicastat|Tablets for oral administration under fed conditions. Zamicastat has to be taken in the morning after breakfast. Each patient will continue treatment with the individual highest tolerated dose (HTD) he/she was taking at MPV3 of the study BIA-51058-201 and will take this dose until visit V5.
62296693|NCT02047006|EXPERIMENTAL|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Rivaroxaban is given as a single oral dose of 10 mg immediately after three subsequent dialysis sessions. Patients remain in the hospital from the intake of the first dose until 48 hours after the intake of the third dose.~Effect of dialysis on levels of rivaroxaban:~Rivaroxaban is given as a single oral dose of 10 mg in the morning when dialysis is scheduled in the afternoon, or the previous evening when dialysis is scheduled in the morning. The interval between the two doses was at least 48 hours. Dialysis is scheduled 6 to 8 hours after the intake of rivaroxaban."
62665727|NCT05616897|OTHER|Physical education students|students with better expected fitness
62665728|NCT06025370|EXPERIMENTAL|Swimmer Position|
62665729|NCT06025370|ACTIVE_COMPARATOR|Arms at side|
61912540|NCT06009185|EXPERIMENTAL|HTD 200 mg zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat (two tablets of 100 mg). Zamicastat has to be taken in the morning after breakfast. Each patient will continue treatment with the individual highest tolerated dose (HTD) he/she was taking at MPV3 of the study BIA-51058-201 and will take this dose until visit V5.
61912541|NCT05979545|ACTIVE_COMPARATOR|Intervention|Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected.
62103977|NCT01005992|EXPERIMENTAL|Laser treated scar|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
62296694|NCT01049776|EXPERIMENTAL|Pazapanib (GW786034)|
62296695|NCT01042262|EXPERIMENTAL|Oxygen Group|Subjects received 100% oxygen via nasal cannula (flow =2 L/min)
62665730|NCT00105508|EXPERIMENTAL|Sarizotan|
62665731|NCT00105508|PLACEBO_COMPARATOR|Placebo|
62665732|NCT01769872|EXPERIMENTAL|Autologous Adipose Tissue derived MSCs|
62665733|NCT04701320|EXPERIMENTAL|Glass carbomer|Nano hydroxyapatite Reinforced Glass Ionomer that results in chemical bond formation with tooth structure mimic that of enamel tissue
62665734|NCT04701320|ACTIVE_COMPARATOR|Fuji ix|Conventional Glass Ionomer cement fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics, a wear resistant, self-adhesive
62665735|NCT00004859|ACTIVE_COMPARATOR|Arm A (Paclitaxel + Carboplatin + RT)|"Induction chemotherapy dosing: Paclitaxel, 225 mg/m² (3 hour infusion) Day 1. Carboplatin, area under the plasma drug concentration versus time curve (AUC) =6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1~Concurrent chemotherapy / radiotherapy dosing: Paclitaxel, 45 mg/m2, administered weekly during radiotherapy over one hour. Carboplatin, AUC=2, 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy~Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV"
61912542|NCT05979545|NO_INTERVENTION|Control|Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.
61912543|NCT01322776|EXPERIMENTAL|Bortezomib,Fludarabine,Cyclophosphamide|
61912544|NCT05380362|EXPERIMENTAL|Venous Angioplasty|20 patients will have venous angio plasty
61912545|NCT05380362|SHAM_COMPARATOR|Angio with no plasty|Patients will be brought to the angio suite and given and angio but no plasty although patient will not be aware of which treatment they are having.
62296696|NCT01042262|PLACEBO_COMPARATOR|Control Group|Subjects were attached to a nasal cannula without any oxygen flow.
62296697|NCT06529796|EXPERIMENTAL|Cohort 1: Mild Hepatic Impairment|Participants will receive a single dose of IXP on Day 1.
62296698|NCT06529796|EXPERIMENTAL|Cohort 2: Matched Healthy Participants|Healthy participants matched to Cohort 1 will receive a single dose of IXP on Day 1.
62296699|NCT06529796|EXPERIMENTAL|Cohort 3: Moderate Hepatic Impairment|Participants will receive a single dose of IXP on Day 1.
61912546|NCT04810728|EXPERIMENTAL|Extract Psidii guava|2 Capsule of extract Psidii guava, three times daily
61912547|NCT04810728|ACTIVE_COMPARATOR|Standard therapy|Standard therapy for Covid-19 patient (vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
61912548|NCT04892056|EXPERIMENTAL|Anterior Segment Retraction using Friction mechanics by elastomeric power chains|"Elastomeric power chains extending from 8mm crimpable hooks, distal to the lateral incisors, on 0.017x0.025 Stainless Steel WIres, to the mini-screws. The power chains delivered 160g of force per side."
61912549|NCT04892056|EXPERIMENTAL|Anterior Segment Retraction using Frictionless mechanics by T-loops|"T shaped closing loops were fabricated on 0.017x0.025 Titanium- Molybdenum wires (TMA) were used to deliver 160g of force per side by 4mm distal activations."
61912550|NCT05273073|ACTIVE_COMPARATOR|Probiotics group|83 participants received probiotics for 12-week
61912551|NCT05273073|PLACEBO_COMPARATOR|Placebo group|83 participants received placebo for 12-week
61912552|NCT05830110|ACTIVE_COMPARATOR|Active vibrotactile coordinated reset|mechanical vibrotactile stimulation to the fingers in a defined pattern
62296700|NCT06529796|EXPERIMENTAL|Cohort 4: Matched Healthy Participants|Healthy participants matched to Cohort 3 will receive a single dose of IXP on Day 1.
62665736|NCT00004859|EXPERIMENTAL|Arm B (Paclitaxel + Carboplatin + RT+ Thalidomide)|"paclitaxel, carboplatin, and radiotherapy are same as those in Arm A.~thalidomide: Induction chemotherapy dosing, oral daily, starting Day 1 for 24 months or until disease progression. Concurrent chemotherapy / radiotherapy dosing, oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg."
62665737|NCT01105130|PLACEBO_COMPARATOR|Arm I - Placebo|Patients receive oral placebo twice daily (total of 6 capsules per day).
61912553|NCT05830110|SHAM_COMPARATOR|Sham vibrotactile coordinated reset|mechanical vibrotactile stimulation to the fingers in a defined pattern
61912554|NCT05946434|EXPERIMENTAL|Kinesio Tape Group|Kinesio tape applied along with conventional treatment
62665738|NCT01105130|EXPERIMENTAL|Arm II - low dose|Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
62665739|NCT01105130|EXPERIMENTAL|Arm III - high dose|Oral L-arginine twice daily = 6 capsules per day.
62665740|NCT01406912|ACTIVE_COMPARATOR|Recreational Activity Arm|recreational activity includes playing cards, ominoes, jenga or a ball game.
62665741|NCT01406912|EXPERIMENTAL|Wii Gaming System Arm|Use of Wii gaming technology (e.g. commercially available games)
62665742|NCT02839460||subjects with sarcopenia|"Screening Procedures (Physical Exam, Height \& Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
62665743|NCT02839460||healthy, physically-active controls|"Screening Procedures (Physical Exam, Height \& Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
62665744|NCT01088893|NO_INTERVENTION|observation|
62665745|NCT01088893|EXPERIMENTAL|Everolimus|
62665746|NCT03174522|EXPERIMENTAL|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
62665747|NCT03174522|PLACEBO_COMPARATOR|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
62665748|NCT02989389|EXPERIMENTAL|LY3323795 (Part A)|Participants received escalating doses of 0.3 mg (milligrams), 1 mg, 3 mg, 10 mg, 30 mg and 100 mg of LY3323795 orally.
62665749|NCT02989389|PLACEBO_COMPARATOR|Placebo (Part A)|Participants received placebo identical to LY3323795 orally.
62665750|NCT02989389|EXPERIMENTAL|LY3323795 (Part B)|Participants received 6 mg, 20 mg and 80 mg of LY3323795 orally.
62665751|NCT02989389|PLACEBO_COMPARATOR|Placebo (Part B)|Participants received placebo identical to LY3323795 orally.
62665752|NCT02989389|EXPERIMENTAL|LY3323795 (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
62665753|NCT02989389|EXPERIMENTAL|LY3323795 + Itraconazole (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
62665754|NCT01286649|OTHER|Injection of verum and control|Patients will receive randomized, blinded, injections of BOTH autologous hair follicle cells in medium (verum) and of medium alone (control) into two separate pre-defined treatment areas on their scalp.
62665755|NCT02509702|EXPERIMENTAL|Connected to Care|The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months. There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
62665756|NCT02509702|NO_INTERVENTION|Control|The control group will receive standard care, which is a follow-up appointment at 14 months written on an appointment card.
62665757|NCT00771602|EXPERIMENTAL|Rituximab|Group 1: 375 mg/m\^2 IV Rituximab Alone
62665758|NCT00771602|EXPERIMENTAL|Alemtuzumab|Group 2: 30 mg SQ Alemtuzumab Alone
62665759|NCT00771602|EXPERIMENTAL|Rituximab + Alemtuzumab|Group 3: 375 mg/m\^2 Rituximab + 30 mg SQ Alemtuzumab
62665760|NCT05786300|EXPERIMENTAL|Treatment Group|"The Treatment Group will follow the rehabilitation protocol with the addition of the Neuromuscular Electrical Stimulation Superimposed onto Movement (NMES+) as part of the rehabilitation protocol.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz"
62665761|NCT05786300|ACTIVE_COMPARATOR|Control Group|"The Control Group will follow the same rehabilitation protocol with no addition of the NMES+.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
61912555|NCT05946434|EXPERIMENTAL|Rigid tape Group|Rigid tape applied along with conventional treatment
61912556|NCT02530047|EXPERIMENTAL|Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ)|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10\^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
61912557|NCT02820532|OTHER|Tracking|The volunteers will be placed on the treatment couch. Their respiratory motion will be measured and the treatment couch will be moved accordingly. During the couch motion experiment the heartbeat, the skin humidity, the respiratory characteristics and the pupil motion will be additionally measured.
62296701|NCT05605756|EXPERIMENTAL|Botox therapy effects on seizure|
62665762|NCT02194491|EXPERIMENTAL|[11C]AS2471907 administration (Part 1)|Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.
62665763|NCT02194491|EXPERIMENTAL|ASP3662 administration (Part 2)|The dose levels used in part 2 will depend on the ongoing analysis of EO (enzyme occupancy) from previously dosed subjects.
62665764|NCT06111625|EXPERIMENTAL|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion. Patients underwent myeloablative conditioning therapy consisting of fludarabine-and-busulfan-based regimen. Peripheral stem cells from HLA-matched sibling donors (MSD), matched unrelated donors (MUD), or haploidentical donors (HID) were reinfused two days after conditioning. Follow-up examinations were scheduled at +1, +2, +3, +4, +6, +9, +12, +18, and +24 months post-transplant.
62665765|NCT04560218|EXPERIMENTAL|Uterotonic agents group A|Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab
62665766|NCT04560218|EXPERIMENTAL|Uterotonic agents group B|Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo sublingually 2 tab
62103978|NCT01005992|ACTIVE_COMPARATOR|Standard scar management|The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
62665767|NCT04560218|NO_INTERVENTION|Uterotonic agents group C|Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2 tab
62665768|NCT01016002|EXPERIMENTAL|Intervention|
62665769|NCT05795335||Patients have received or plan to receive CDK4/6 inhibitors for advanced disease.|
62665770|NCT02802475||acquired chronic, focal, epilepsy|patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
62665771|NCT02802475||new onset epilepsy|patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
62103979|NCT03539159|EXPERIMENTAL|Allogeneic conventional sized serum eye drops|
62665772|NCT02746939|NO_INTERVENTION|Pre-curriculum assessment|Assessments will be administered to 3rd and 4th grade students prior to receiving curriculum training in fitness and nutrition.
62103980|NCT03539159|EXPERIMENTAL|Allogeneic micro sized serum eye drops|
62296702|NCT03180736|EXPERIMENTAL|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
62665773|NCT02746939|EXPERIMENTAL|Post-curriculum assessment|Assessments will be administered to 3rd and 4th grade students (matched from pre-curriculum assessment) after receiving 4-6 week InSciEd Out Fitness and Nutrition Curriculum.
62665774|NCT01815463||colorectal neoplasia|No interventions Record colorectal neoplasia
62665775|NCT04245163|EXPERIMENTAL|Intervention Group|Participants in the intervention group will be invited for the training program.
62665776|NCT04245163|NO_INTERVENTION|Control Group|Participants who will be randomized in control group will receive normal care (the care that each clinic provides to the patients) and will be given an educational material (without telling them that they are in the control group). They will receive, however, the education class later (at the end of the study).
62665777|NCT02473744|EXPERIMENTAL|Oedematous lower limb subcutaneous drainage|In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
62665778|NCT02049879|EXPERIMENTAL|Injection|Corticosteroids injection
62665779|NCT02339207|PLACEBO_COMPARATOR|Placebo|Placebo dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
62665780|NCT02339207|EXPERIMENTAL|AL-335|AL-335 dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
62665781|NCT03790969|EXPERIMENTAL|26 gauge needle|intervention group
62665782|NCT03790969|ACTIVE_COMPARATOR|23 gauge needle|control group
62665783|NCT05872126|OTHER|VATS surgical pleurodesis|Patients in whom we use VATS-surgical pleurodesis for malignant pleural effusion.
62665784|NCT05872126|OTHER|Tube drainage|Patients in whom we use tube drainage for malignant pleural effusion.
62665785|NCT05667129|EXPERIMENTAL|XEN-101|Capsule formulation
61912558|NCT06210932|EXPERIMENTAL|Intervention group-seed video|The participants will engage in a total of four weeks of intervention. The intervention sessions are conducted three times per week, there will be a total of 12 intervention sessions. The intervention group will receive a social, emotional, and ethical development video intervention. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
62103981|NCT05038124|EXPERIMENTAL|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction. Active sparing of the intended surgical approach will be incorporated into the radiation plan by creating an avoidance structure. Surgical stabilization will proceed within 1 week of completion of radiotherapy. Pathologic specimens will be obtained intraoperatively via existing surgical access for histologic and molecular analysis. An optional research MRI with perfusion will be performed within 30 days prior to radiation simulation and within one-week after radiation therapy using 3T scanner. If patients receive radiation simulation at a non-MSK Manhattan site, MRI with Perfusion will not be performed.
62103982|NCT01762371|EXPERIMENTAL|K-Pat|Getting one time one hour of Khalifa's therapy for ACL injury treatment.
62296703|NCT03180736|ACTIVE_COMPARATOR|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
62665786|NCT05667129|PLACEBO_COMPARATOR|Placebo|Capsule formulation
62665787|NCT02981251|EXPERIMENTAL|Intervention|Health education with support by trained female health volunteer
62665788|NCT02981251|NO_INTERVENTION|Control|Extra intervention will not be provided except usual care by their physician of the participant.
62665789|NCT06125990|EXPERIMENTAL|Study Group (SGr)|In addition to institutional conventional rehabilitation, this group included breathing exercises to increase lung volumes and a 21-minute breathing exercise with video-based biofeedback.
62665790|NCT06125990|SHAM_COMPARATOR|Control Group (CGr)|This group was given only institutional conventional rehabilitation.
62665791|NCT00126217|EXPERIMENTAL|1|
62665792|NCT00126217|NO_INTERVENTION|2|
62665793|NCT03406975|ACTIVE_COMPARATOR|Control Group: Lifestyle Modification|Participants randomized to the control group (lifestyle modification only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation.
62665794|NCT03406975|EXPERIMENTAL|Treatment Group: Overstitch ESG Procedure|Participants randomized to the treatment group will proceed to have the Overstitch Endoscopic Sleeve Gastroplasty (ESG) at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. ESG patients who have not achieved \>25% EWL at the end of Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
62665795|NCT03406975|EXPERIMENTAL|Crossover Group: Lifestyle Intervention to ESG Procedure|Control group participants (lifestyle modification only) who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL or have a BMI \>30 measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program of 12 months.
62665796|NCT03509155|NO_INTERVENTION|Control group|The first arm as a control group obtaining only routine IYCF consultation by the posyandu (integrated health service post) cadres and without the provision of biscuits.
62665797|NCT03509155|ACTIVE_COMPARATOR|National portion & IYCF counseling|The second arm as the national portion \& IYCF counseling group to get biscuit with standardized portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist.In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
61912559|NCT06210932|NO_INTERVENTION|Control group-languag enhancement video|The participants will engage in a total of four weeks of intervention. The intervention sessions are conducted three times per week, there will be a total of 12 intervention sessions. The participants in control group will watch a language enhancement video.
61912560|NCT04678687|OTHER|COVID-19 group|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
61912561|NCT05207189|EXPERIMENTAL|UVT|Biological sling used as a replacement of the synthetic sling.
61912562|NCT02236182|EXPERIMENTAL|Ipratropium Bromide low|delivered via RESPIMAT®
61912563|NCT02236182|EXPERIMENTAL|Ipratropium Bromide high|delivered via RESPIMAT®
61912564|NCT02236182|PLACEBO_COMPARATOR|Placebo|delivered via RESPIMAT®
61912565|NCT05624710|EXPERIMENTAL|Group 1: Severe Hepatic Impairment|Participants with severe hepatic impairment (Class C Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
61912566|NCT05624710|EXPERIMENTAL|Group 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Class B Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
61912567|NCT05624710|EXPERIMENTAL|Group 3: Mild Hepatic Impairment|Participants with mild hepatic impairment (Class A Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
61912568|NCT05624710|EXPERIMENTAL|Group D: Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of INCB054707 on Day 1.
62103983|NCT00574886|EXPERIMENTAL|1 High dose BEAM chemotherapy, transplant & idiotype vaccine therapy|This is a compassionate use protocol for participants who failed induction chemotherapy + Vaccine on previous trials. These participants then went on to high dose BEAM chemotherapy and transplant, then received idiotype vaccine therapy at 3 months post transplant. Vaccine was given monthly x 4 series, with a fifth series given 12 weeks after the fourth. Participants were then followed annually until progression or death with standard staging.
62665798|NCT03509155|EXPERIMENTAL|Adjusted portion & local food counseling|the third arm as the adjusted portion \& local food counseling group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food. In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
62665799|NCT02581423|EXPERIMENTAL|Capecitabine|Participants will receive capecitabine for up to approximately 6 months.
62665800|NCT03070145|EXPERIMENTAL|Exercise Intervention|"* 12-weeks brisk walking and strength training~* 150 minute moderate aerobic activities, such as brisk walking~* Strength training 3 days /week~* One on one sessions with exercise physiologist~* Optional group sessions"
62665801|NCT03070145|NO_INTERVENTION|Usual Care|Usual Care provided
62665802|NCT01191385||Group 1|
62103984|NCT02933320|EXPERIMENTAL|Part A: Arm 1: BI-1206 single agent dose escalation phase|BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).
62103985|NCT02933320|EXPERIMENTAL|Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase|Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).
62296704|NCT03488199|ACTIVE_COMPARATOR|Stent Acculink™ (RX ACCULINK CAROTID STENT SYSTEM)|50 Carotid stenting (RX ACCULINK CAROTID STENT SYSTEM)
62468543|NCT06189833|EXPERIMENTAL|D-VRd + ASCT + DVRD|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRD) for 4 induction cycles prior to and 2 consolidation cycles following autologous stem cell transplantation.~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6 Bortezomib SC 1.3mg/m2 on days 1, 8, 15, 22 of cycle 1-6 Lenalidomide orally 25 mg once daily on days 1-21 of cycle 1-6 Dexamethasone 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22 and 23 of cycle 1-6"
62665803|NCT02819375|ACTIVE_COMPARATOR|Group Propofol|anesthesia will induced 1 mg/kg propofol
62665804|NCT02819375|ACTIVE_COMPARATOR|Group propofol/remifentanil|anesthesia will induced 0.5 mg/kg propofol and 1 µg/kg remifentanil
62665805|NCT02819375|ACTIVE_COMPARATOR|Group propofol/ketamine|anesthesia will induced propofol 0.5 mg/kg and ketamine 0.5 mg/kg
62665806|NCT03611127|EXPERIMENTAL|early pulmonary rehabilitation (EPR)|early pulmonary rehabilitation started shortly after hospital discharge for COPD exacerbation.
62665807|NCT03611127|NO_INTERVENTION|Usual care (UC)|No pulmonary rehabilitation for this group
62665808|NCT00266812|EXPERIMENTAL|Chemotherapy with temozolomide and radiotherapy|
62665809|NCT00266812|ACTIVE_COMPARATOR|Radiotherapy alone|
62665810|NCT04983732|EXPERIMENTAL|FL-101-IV|FL-101 single IV infusion over 60-minutes
62665811|NCT04983732|EXPERIMENTAL|FL-101-SC|FL-101 single SC injection
62665812|NCT06181500|EXPERIMENTAL|Home-based multicomponent exercise intervention program|
62665813|NCT02629458|EXPERIMENTAL|Patients requiring surgery|
62665814|NCT01597362|OTHER|Veress needle technique|
62665815|NCT01597362|OTHER|Direct trocar technique|
62665816|NCT01597362|OTHER|Open technique|
62296705|NCT03488199|EXPERIMENTAL|Stent CGuard™ (The CGuardTM Embolic Prevention System (EPS))|50 Carotid stenting (The CGuardTM Embolic Prevention System (EPS))
62468544|NCT05704881||Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease|Patient admitted for acute Exacerbation of COPD. The measurement of EtCO2 will be performed at the emergency department
62468545|NCT01159860|ACTIVE_COMPARATOR|Cryosurgery|One lesion on the patients' trunk or proximal extremities will be treated with cryosurgery.
62468546|NCT01159860|ACTIVE_COMPARATOR|Curettage|One lesion on one side of the patients' trunk or proximal extremities will be treated by curettage.
62665817|NCT01555931|EXPERIMENTAL|Immediate|Placement within 48 hours of delivery
62665818|NCT01555931|ACTIVE_COMPARATOR|Control|Placement 4-8 weeks after delivery
62665819|NCT05713448||Type 1 diabetes|Individuals with type 1 diabetes
62665820|NCT02318979|EXPERIMENTAL|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
62665821|NCT02318979|EXPERIMENTAL|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
62665822|NCT02273453|EXPERIMENTAL|Songha® Night|
62665823|NCT02273453|ACTIVE_COMPARATOR|Placebo + Oxazepam|
62665824|NCT02273453|PLACEBO_COMPARATOR|Placebo|
62665825|NCT05752864|EXPERIMENTAL|spine manual therapy of sacroiliac joint|The group which treats spine manual therapy of sacroiliac joint
62665826|NCT05752864|ACTIVE_COMPARATOR|Superficial heat therapy|Group treated with superficial heat therapy for 20 minutes
62665827|NCT03853200|EXPERIMENTAL|Group I|QMix the solution under investigation which includes CHX EDTA and detergent QMix Root Canal Irrigant
62665828|NCT03853200|ACTIVE_COMPARATOR|Group II|it involves use of two irrigant solutions, 17%EDTA+2%Chlorhexidine
62665829|NCT03853200|ACTIVE_COMPARATOR|Group III|17% EDTA with no antibacterial activity . the control group
62665830|NCT03870321|EXPERIMENTAL|Core training|The subjects who are in the experimental group will carry out the Core training routine
62665831|NCT03870321|NO_INTERVENTION|Control|The subjects who are in the control group will not receive intervention and will continue with their daily routine and training
62665832|NCT03523351|ACTIVE_COMPARATOR|Standard of care|Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT).
62665833|NCT03523351|EXPERIMENTAL|Selective radiation to ≤5 highest risk bone metastases|Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) \&/or disease with posterior element involvement.
62665834|NCT04916249|EXPERIMENTAL|Tibetree pain relieving plaster|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
62665835|NCT04916249|PLACEBO_COMPARATOR|Placebo plaster groups|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
62665836|NCT04359459||Mild COVID-19|Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.
62665837|NCT04359459||Severe COVID-19|Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.
62665838|NCT04359459||Very Severe COVID-19|Patients with very severe disease admitted to intensive care, who require mechanical ventilation.
62665839|NCT00668564|EXPERIMENTAL|Intent-to-Treat|All patients treated with study regimen.
62665840|NCT02115503||Cohort 1|Cohort 1 will consist of those having primarily Class I antibody development post-transplant
62665841|NCT02115503||Cohort 2|Cohort 2 will include those having primarily Class II antibody development post-transplant
62665842|NCT02115503||Cohort 3|Cohort 3 will consist of the remaining subjects that have a mix of Class I and II antibodies.
62665843|NCT05768464|EXPERIMENTAL|study group|"Drug: Toripalimab 240mg, intravenously every 3 weeks~Drug: Axitinib 5 mg orraly twice daily"
62665844|NCT00489268|ACTIVE_COMPARATOR|Phase I: 6 J/cm2|Subjects randomized to the energy density group of 6 J/cm2 through the HALO Ablation System.
62665845|NCT00489268|ACTIVE_COMPARATOR|Phase I: 8 J/cm2|Subjects randomized to the energy density group of 8 J/cm2 through the HALO Ablation System.
62665846|NCT00489268|ACTIVE_COMPARATOR|Phase I: 10 J/cm2|Subjects randomized to the energy density group of 10 J/cm2 through the HALO Ablation System.
62665847|NCT00489268|ACTIVE_COMPARATOR|Phase I: 12 J/cm2|Subjects randomized to the energy density group of 12 J/cm2 through the HALO Ablation System.
62665848|NCT00489268|ACTIVE_COMPARATOR|Phase II|All Halo 360 treatments performed at 10 J/cm2 through the HALO Ablation System. All Halo 90 treatments performed at 12 J/cm2 through the HALO Ablation System.
62665849|NCT03316560|EXPERIMENTAL|Group 1: Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 1 of rAAV2tYF-GRK1-RPGR study drug.
62665850|NCT03316560|EXPERIMENTAL|Group 2: Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug.
62665851|NCT03316560|EXPERIMENTAL|Group 3 Phase 1/2 Dose Escalation|Group 3 male subjects at least 18 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
62665852|NCT03316560|EXPERIMENTAL|Group 4 Phase 1/2 Dose Escalation|Group 4 male subjects at least 6 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
62665853|NCT03316560|EXPERIMENTAL|Group 5 Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug.
62665854|NCT03316560|EXPERIMENTAL|Group 6 Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 6 of rAAV2tYF-GRK1-RPGR study drug.
62665855|NCT00918450|EXPERIMENTAL|1|
62665856|NCT02736812|EXPERIMENTAL|French Lyophilized Plasma|receives French Lyophilized Plasma with the usual treatment for post traumatic hemorrhagic shock as given in the recommendations for best practice
62665857|NCT02736812|ACTIVE_COMPARATOR|Normal Saline Solution|receives Normale Saline Solution with the usual treatment of post traumatic hemorrhagic shock as given in the recommendations for best practice
62665858|NCT02990377|EXPERIMENTAL|RL-supported IVR intervention|Participants in the intervention group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED plus the RL-supported IVR intervention.
62665859|NCT02990377|NO_INTERVENTION|Enhanced Usual Care|Participants in the enhanced usual care group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED.
62665860|NCT01122953|EXPERIMENTAL|Phenytoin|
62665861|NCT01122953|ACTIVE_COMPARATOR|Epamin|
62665862|NCT02940379|EXPERIMENTAL|Cohort 1|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
62665863|NCT02940379|EXPERIMENTAL|Cohort 2|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
62665864|NCT00790933|EXPERIMENTAL|Vedolizumab 300 mg|Vedolizumab 300 mg, 30-minute intravenous (IV) infusion every 4 weeks, starting at Week 0 for approximately up to 510 weeks.
62665865|NCT00005145||Observational, no interventions|
62665866|NCT01505335||Implant osteotomy measurements|Drilled implant locations
62665867|NCT06011226||Phase 1: development of the questionnaire|"development of the patient reported outcome: The strategy consists of four phases:~1. structured litterature review~2. Group of experts: identification of the main areas to be covered by the questionnaire in order to draw up the focus group moderation guide~3. focus groups: A discussion session will explore patient symptomatology, the functional impact of the disease, quality of life and the problems faced by patients from their point of view."
62665868|NCT06011226||Phase 2: pilot phase|Once the initial version of the self-questionnaire has been developed, it will be tested on a group of 40 patients with either Chiari malformation with syringomyelia (n = 20), isolated Chiari malformation (n = 10) or isolated syringomyelia (n = 10), managed by the CRMR C-MAVEM at Bicêtre Hospital.
62103986|NCT02933320|EXPERIMENTAL|Part B: Arm1: BI-1206 single agent expansion phase|Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.
62103987|NCT02933320|EXPERIMENTAL|Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase|Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.
62103988|NCT06242964|EXPERIMENTAL|PRISM-SN Intervention|Skill-based psychosocial program
62103989|NCT06242964|NO_INTERVENTION|Usual Care|Standard psychosocial care
62103990|NCT05587140|EXPERIMENTAL|Acupuncture like TENS|The study would use acupuncture like TENS for 30 minutes
62103991|NCT05587140|EXPERIMENTAL|Conventional TENS|The study would use conventional TENS for 30 minutes
62103992|NCT05587140|EXPERIMENTAL|Sham TENS|The study would use sham TENS for 30 minutes
62665869|NCT06011226||Phase 3: national testing of the questionnaire|the 3rd phase will be submitted to the Human Subjects Protection Review Board according to the progression of the first two phases.
62103993|NCT03767764||HCC|Patients with diagnosis of Hepatocellular carcinoma
62103994|NCT03767764||Cirrhosis|Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC
62103995|NCT03767764||Chronic liver diseases|Patients with the diagnosis of Chronic liver diseases without cirrhosis
62665870|NCT04462172|EXPERIMENTAL|Synthes Femoral Neck System (FNS)|Synthes Femoral Neck System (FNS) was developed with the intention to combine advantages of DHS (dynamic hip screw) and MCS (multiple cancellous screw). The FNS implants consist of plates, bolts, locking screws and antirotating-screws. The plate consists of a small base plate with one or two locking holes and a barrel portion. The barrel allows for gliding of the head elements while restricting rotation around the head-neck axis, so FNS is a fixed-angle gliding fixation device that allows for controlled collapse of the femoral neck, like DHS. The FNS was also designed to minimize implant footprint on the bone with its compact design, like MCS. Furthermore, the FNS was designed to reduce the length of incision necessary for implant insertion when compared to DHS. This new concept of femoral neck fracture fixation still emphasizes the biology of fracture healing by initial fracture compression.
62665871|NCT04462172|ACTIVE_COMPARATOR|Multiple cancellous screws (MCS)|Multiple cancellous screws (MCS) fixation is the most common and classic method to deal with femoral neck fractures which is less invasive and retains more viable bone, compared with dynamic hip screw (DHS) fixation that appears biomechanically more stable. In this study, three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
62665872|NCT06493799|EXPERIMENTAL|LAENNEC 10 ml(Intravenous Injection)|Dosing twice a week for 6 weeks
62665873|NCT06493799|ACTIVE_COMPARATOR|LAENNEC 4 ml(Subcutaneous Injection)|Dosing twice a week for 6 weeks
62665874|NCT04386837||Aphasics|Patients with a left MCA infarct due to CVA will be included in the study. Each subject will be administered an aphasia screening test less than 3 minutes in length. The same test will be administered by another clinician to the same patient within a maximum of 12 hours to assess the inter-rater reliability of the test.
62665875|NCT04041128|EXPERIMENTAL|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
62665876|NCT05129709|EXPERIMENTAL|"My Health Priorities Identification Program"|"The intervention, the My Health Priorities Identification Program consists of four self-directed, web-based modules intended to guide patients with MCCs in identifying their own health priorities. These priorities can then be used to guide discussions with family caregivers and clinicians regarding specific goals and preferences that they wish to guide future treatment decisions. Most models of palliative care have been developed based on white middle-class populations and may not apply to African Americans (AA) who have a very different cultural value set."
62665877|NCT05049694|EXPERIMENTAL|zirconia crowns|esthetic crowns for capping permanent molars with caries
62665878|NCT05049694|EXPERIMENTAL|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
62665879|NCT01789775|PLACEBO_COMPARATOR|CD07805/47 gel Placebo|Placebo
62665880|NCT01789775|EXPERIMENTAL|CD07805/47 gel|Intervention: Drug: CD07805/47 gel
62665881|NCT03274089|EXPERIMENTAL|Kiosk intervention group|
62665882|NCT03274089|NO_INTERVENTION|Nurse clinician control group|
61912569|NCT03290482||EE Study Patients 2000-2008|"All patients with the diagnosis of EE from the study period 2000 to 2008. Sixty patients participated in the 10 year follow up phone interview and questionnaire. These are the subjects we will contact to see if they are interested in participating in this study.~If interested in participating, subjects will complete:~1. Evaluation by the PI physical examination~2. Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) questionnaires~3. Barium Esophagram with maximal and minimal esophageal diameter measurement~4. EsophaCap cytology"
61912570|NCT04155411|EXPERIMENTAL|Dasatinib 70 mg|
62103996|NCT03767764||Control|Normal human serum from donors without liver disease
62103997|NCT03842150||derivation cohort|
62665883|NCT05134844|EXPERIMENTAL|Halliwick Snoezelen Group|Hydrotherapy in a multi-sensory Snoezelen environment
62665884|NCT05134844|EXPERIMENTAL|Land Snoezelen Group|Land multi-sensory Snoezelen environment
62665885|NCT06025461||fibroadenoma group|
62665886|NCT06025461||breast hyperplasia group|
62665887|NCT06025461||other types of benign nodules group|
62665888|NCT06025461||non-specific invasive carcinoma group|
62665889|NCT06025461||other types of breast cancer group|
62665890|NCT01166334|ACTIVE_COMPARATOR|WebQuit study group|Intervention arm 1 (identity and description withheld to protect integrity of study)
62665891|NCT01166334|ACTIVE_COMPARATOR|WebQuit control group|Intervention arm 2 (identity and description withheld to protect integrity of study)
62665892|NCT03149419|ACTIVE_COMPARATOR|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
62665893|NCT03149419|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
62665894|NCT04894188|EXPERIMENTAL|Neoadjuvant RT and ADT|"Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).~Gosereline 3.6mg sc injection at week 1, week 5, and week 9"
62665895|NCT04894188|ACTIVE_COMPARATOR|Neoadjuvant ADT|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
62665896|NCT01509807|ACTIVE_COMPARATOR|Group 1|IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
62665897|NCT01509807|EXPERIMENTAL|Group 2|EXPAREL (bupivacaine liposome injectable suspension)
62665898|NCT06063343|EXPERIMENTAL|KAND145 for SAD (Part 1)|In Part 1, SAD of KAND145 will be administered to up to 6 cohorts. Six participants in each cohort will receive KAND145. The first cohort will receive a starting dose of 60 mg KAND145 which is expected to lead to an average drug plasma concentration (Cave) of 0.2 µM. The maximum dose will be chosen to achieve a Cave of 10 µM.
62665899|NCT06063343|PLACEBO_COMPARATOR|Placebo for SAD (Part 1)|In Part 1, 2 participants per cohort in up to 6 cohorts will receive placebo at the same dosing frequency as detailed for the experimental arm.
62103998|NCT03842150||validation cohort|
62296706|NCT06105138|EXPERIMENTAL|200mg Cannabidiol|- A single dose of 200mg commercially available (product code T-L-A-5) water-soluble solution supplied by Caliper Foods, to be consumed orally (mixed with water).
62296707|NCT06105138|EXPERIMENTAL|30mg Cannabidiol,|- A single dose of 30mg commercially available (product code T-L-A-5) water-soluble solution supplied by Caliper Foods, to be consumed orally (mixed with water).
62296708|NCT06105138|PLACEBO_COMPARATOR|Placebo|- A single dose of water-soluble Placebo solution supplied by Caliper Foods, to be consumed orally (mixed with water).
62296709|NCT01438645|EXPERIMENTAL|ScopeGuide-assisted colonoscopy|These patients will undergo colonoscopy with the assistance of the Olympus ScopeGuide system.
62296710|NCT01438645|NO_INTERVENTION|Conventional colonoscopy|These patients will undergo colonoscopy identical to that in the intervention arm, except with endoscopes lacking the ScopeGuide system.
62665900|NCT06063343|EXPERIMENTAL|KAND145 for MAD (Part 2)|In Part 2, MAD of KAND145 will be administered to up to 5 cohorts. Six participants in each cohort will receive doses of KAND145 BID for 8 days. The first cohort will receive a dose of KAND145 which is expected to lead to a Cave of 2 µM. The maximum daily dose will be 3000 mg KAND145.
62665901|NCT06063343|PLACEBO_COMPARATOR|Placebo for MAD (Part 2)|In Part 2, 2 participants per cohort in up to 5 cohorts will receive placebo at the same dosing frequency as detailed for the experimental arm.
62665902|NCT02019251|EXPERIMENTAL|Post single or double lung transplant|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using Disposable Face mask and a standard Douglas Bag system.
62665903|NCT01370538|EXPERIMENTAL|Esomeprazole 20 mg|
62665904|NCT01370538|PLACEBO_COMPARATOR|Placebo|
62665905|NCT02785042|EXPERIMENTAL|Normal healthy volunteers|imaging with Heidelberg Spectralis OCT
62665906|NCT05880043|EXPERIMENTAL|Dose escalation phase: GIC-102 monotherapy|"* Low Dose level 1: 1 x 10\^9 cells~* Mid Dose level 2: 3 x 10\^9 cells~* High Dose level 3: 1 x 10\^10 cells"
62103999|NCT05001828|EXPERIMENTAL|Previously Treated AML|Previously treated AML based on the revised revised 2022 WHO criteria with age at least 18 years.
62296711|NCT04673981|EXPERIMENTAL|patient treated for a oral cavity and oropharynx cancer|questionnaire and tests to evaluate neuropathic pain
62296712|NCT00780403|ACTIVE_COMPARATOR|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
62296713|NCT00780403|ACTIVE_COMPARATOR|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
62296714|NCT02909868|EXPERIMENTAL|RV location|All included subjects will undergo the PV loop test with 'BackBeat PHC' ON and OFF
62308266|NCT02097199||Sports group|The cohort will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (\>6 hours/day) doing no or less physical activity (\<30 minutes quick walking/day) who want to engage more in physical activity (at least 150 minutes of at least moderate intensity per week). The gain in workload will be objectified and quantified by performing a bicycle stress test at the beginning of the study and after 8 months of physical engagement.
62665907|NCT05880043|EXPERIMENTAL|Dose expansion phase: GIC-102 monotherapy|- Dose level: RP2D
62665908|NCT05644509|EXPERIMENTAL|Oncolytic Virus Injection（Revottack）+PD-1|"In the first three cycles, the subjects were administered on the first day and the sixth day of each cycle respectively; At the beginning of the fourth cycle, the subjects were administered on the sixth day of each cycle, 14 days a cycle.~PD-1 inhibitor(Toripalimab) Intravenous infusion, once every 2 weeks from the 6th day."
61912571|NCT01704612|ACTIVE_COMPARATOR|Diabete group|Patient with type 2 diabete received 20 mL ropivacaine
61912572|NCT01704612|SHAM_COMPARATOR|Control group|no diabete reveived 20 mL ropivacaine
61912573|NCT02965092|EXPERIMENTAL|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2 in the absence of disease progression or unacceptable toxicity.
61912574|NCT00852371|ACTIVE_COMPARATOR|Combination of Amodiaquine +sulfadoxine-pyrimethamine|Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
61912575|NCT00852371|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
61912576|NCT00852371|PLACEBO_COMPARATOR|Placebo|Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
61912577|NCT00852371|ACTIVE_COMPARATOR|Sulfadoxine-pyrimethamine alone|sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
61912578|NCT01685333|OTHER|Group A|First Period: Test Drug (Epoetin Alfa) Second Period: Comparator Drug
61912579|NCT01685333|OTHER|Group B|First period: Comparator drug Second Period: Test drug (Epoetin alfa)
61912580|NCT00942071|EXPERIMENTAL|1. MVA-NP+M1 ID|12 volunteers to receive MVA-NP+M1 via ID route
61912581|NCT00942071|EXPERIMENTAL|2. MVA-NP+M1 IM|16 volunteers to receive MVA-NP+M1 via IM route
61912582|NCT00942071|EXPERIMENTAL|3. MVA-NP+M1 IM upper age group|30 volunteers to receive MVA-NP+M1 via IM route
61912583|NCT03626298|PLACEBO_COMPARATOR|Adapalene and placebo (ADAP)|
61912584|NCT03626298|EXPERIMENTAL|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
62104000|NCT05001828|EXPERIMENTAL|Untreated AML With High Risk Features|Untreated AML per 2022 WHO criteria with high-risk features and not a candidate for intensive chemotherapy because of age 60 years or older, age-related comorbidities, cardiac disease, prior anthracycline use, high probability of treatment-related mortality, or otherwise would not benefit from intensive chemotherapy treatment.
62104001|NCT01554592|EXPERIMENTAL|Statin withdrawal|Participants will received a placebo for 12 weeks.
62104002|NCT01554592|ACTIVE_COMPARATOR|Stable statin therapy|Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
62104003|NCT03767114|EXPERIMENTAL|cases of psoriasis|group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR
62104004|NCT03767114|EXPERIMENTAL|normal controls|group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR
62104005|NCT06249841|EXPERIMENTAL|Forceps biopsy against Cryoprobe biopsy|A total of 6 forceps biopsies and 3 cryobiopsies will be taken for each patient, corresponding to a 2:1 ratio. The biopsies are divided into blocks of two (6 forceps, 3 cryo). The biopsy technique blocks are randomized, resulting in a sequence of 6 forceps biopsies followed by 3 cryobiopsies
62104006|NCT06249841|ACTIVE_COMPARATOR|Cryoprobe biopsy against Forceps biopsy|A total of 6 forceps biopsies and 3 cryobiopsies will be taken for each patient, corresponding to a 2:1 ratio. The biopsies are divided into blocks of two (6 forceps, 3 cryo). The biopsy technique blocks are randomized, resulting in a sequence of 3 cryobiopsies followed by 6 forceps biopsies.
62104007|NCT00462969|EXPERIMENTAL|1|pre-surgical SHG
62104008|NCT03877471|EXPERIMENTAL|Low dosage|The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.
62665909|NCT01111669|EXPERIMENTAL|Tranexamic Acid|Patients in the tranexamic acid (TA) group will receive a bolus of TA, prepared according to patient weight (15mg / kg loading dose). The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation for the duration of the operation.
62104009|NCT03877471|EXPERIMENTAL|Medium dosage|The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.
62104010|NCT03877471|EXPERIMENTAL|High dosage|The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary.
62104011|NCT00822913|EXPERIMENTAL|Botulinum A toxin|Botulinum A toxin intravesical injection
62104012|NCT00904527|EXPERIMENTAL|Relaxation|Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
62104013|NCT00904527|NO_INTERVENTION|without relaxation|Patients have no relaxation (only medical treatment+ education)
62665910|NCT01111669|PLACEBO_COMPARATOR|Normal Saline|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution as the intervention group. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of normal saline for the duration of the operation.
62296715|NCT02214849|EXPERIMENTAL|LATCH Intervention|Women enrolled in the WIC program and receiving breastfeeding peer counseling services will receive text messages to support them with their breastfeeding intentions. They will start receiving automated text messages starting in pregnancy and continuing throughout the first 6 months after giving birth. Messaging during pregnancy will emphasize what to expect in the hospital, the onset of lactation, skin-to-skin contact with baby, early and often breastfeeding in post-partum period, milk transfer (suck \& swallow), positioning (with links), common breastfeeding problems and how to seek help. Throughout the study, participants will be able to respond to automated text messages with specific questions that will be received and answered by their WIC program peer counselors. Texting will also have prompts to respond occasionally (at minimum once every two weeks) to ensure that phone is still in service and that the participant in the intervention arm are receiving intervention.
62104014|NCT00864682|PLACEBO_COMPARATOR|Placebo|Saline pretreatment, saline admixture
62104015|NCT00864682|ACTIVE_COMPARATOR|Lidocaine pretreatment|Lidocaine pretreatment / saline-propofol admixture
62104016|NCT00864682|ACTIVE_COMPARATOR|Lidocaine-Propofol admixture|saline pretreatment / Lidocaine-propofol admixture
62104017|NCT05235750|EXPERIMENTAL|Writing|This is a single-group study with one arm only.
62296716|NCT04073667|EXPERIMENTAL|Early Rehabilitation Group|The first six weeks (1st-6th) will be followed as an exercise group and the second six weeks (7th-12th) will be followed as a control group without any intervention.
62308267|NCT06320951|EXPERIMENTAL|Experimental: Vericiguat|The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
62665911|NCT05212142|SHAM_COMPARATOR|Traditional intervention: verbal education|
62104018|NCT06629610|EXPERIMENTAL|Immediate Intervention|"This arm is made up of two communities that will receive the intervention at the beginning of the trial. The intervention includes three components, all supported by social media.~Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in workshops. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals."
62104019|NCT06629610|EXPERIMENTAL|Delayed Intervention|"This arm is made up of two communities that will receive the intervention at the after the immediate arm. The intervention includes three components, all supported by social media.~Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in workshops. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals."
62104020|NCT03139175|EXPERIMENTAL|temporomandibular disorder group|subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system
62104021|NCT03139175|ACTIVE_COMPARATOR|chronic low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
62104022|NCT03139175|OTHER|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
62104023|NCT01391013|EXPERIMENTAL|Monotherapy|Monotherapy: darunavir/ritonavir (DRV/r) will be administered for 48 weeks.
62104024|NCT01391013|EXPERIMENTAL|Combination therapy|DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
62296717|NCT04073667|EXPERIMENTAL|Late Rehabilitation Group|The first six weeks (1st-6th) will be followed as a control group without any intervention and the second six weeks (7th-12th) will be followed by exercise.
62296718|NCT00412529|EXPERIMENTAL|Telbivudine|
62296719|NCT00412529|ACTIVE_COMPARATOR|Entecavir|
62296720|NCT02844855|ACTIVE_COMPARATOR|patients with Alzheimer disease|Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
62296721|NCT02844855|ACTIVE_COMPARATOR|patients with Parkinson disease|Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
62296722|NCT02844855|SHAM_COMPARATOR|healthy controls|Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
62665912|NCT05212142|EXPERIMENTAL|New intervention: verbal education, visual aids, and motivational interviewing|
62104025|NCT01525433|NO_INTERVENTION|Control|
62104026|NCT01525433|ACTIVE_COMPARATOR|Low Intensity Information (DVD)|A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
62104027|NCT01525433|ACTIVE_COMPARATOR|High Intensity Information (Promotora)|A higher intensity information program consisting of the video plus a 'promotora' or lay-community health educator led-intervention at the participant's home to encourage cervical cancer screening.
62104028|NCT06529809|EXPERIMENTAL|Accelerated Brachytherapy Forward Chemo Radiation Therapy|Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) combines hypofractionated external beam radiation therapy (EBRT) with concurrent chemotherapy and early upfront, image-guided brachytherapy. In this study, patients start with 2 fractions of brachytherapy prior to initiation of EBRT-based chemoradiotherapy. Total time from treatment planning is approximately 36-42 days.
62296723|NCT04433117|OTHER|Control Group|Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
62296724|NCT04433117|EXPERIMENTAL|Test Group|The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
62296725|NCT02303054|EXPERIMENTAL|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on an Prostatic multi-parametric MRI (mpMRI) of the prostate will be considered for enrollment. If followed by a positive MRI-US targeted biopsy of the prostate, men who be offered enrollment into the study. All men enrolled in the study will undergo bipolar radiofrequency ablation. Efficacy will be assessed through MRI-US biopsy after focal bipolar RFA.
62296726|NCT06217679|EXPERIMENTAL|Control Oral Glucose Tolerance Test|This visit will include a baseline OGTT to be used as a pre-exercise baseline measure for each of the arms. Participants will then consume a 75g glucose beverage (Trutol, Thermo Scientific) and blood samples will be drawn at 0, 10, 20, 30, 45, 60, 75, 90 and 120 minutes post consumption.
62296727|NCT06217679|EXPERIMENTAL|High intensity interval exercise (HIIE)|Participants performed a High intensity interval exercise (HIIE) bout which includes 10 x 1 min at 90% maximum heart rate (HRmax) with 5 min warm up and 5 min cool down at 50watts (low state steady cycling). 90mins following the exercise bout participants will undergo another oral glucose tolerance test.
62296728|NCT06217679|EXPERIMENTAL|Moderate intensity continuous exercise (MICE)|Participants performed a Moderate intensity continuous exercise (MICE) bout which includes 30 min at 65% maximal aerobic capacity (VO2max). 90mins following the exercise bout participants will undergo another oral glucose tolerance test.
62296729|NCT06217679|EXPERIMENTAL|Low-load, high-repetition resistance exercise (LL-HR)|Participants performed a Low-load, high-rep resistance exercise (LL-HR) bout which includes a whole body resistance exercise bout, 3 sets at 30% maximum strength (1RM) for leg press, knee extension, hamstring curl, lat pulldown, shoulder press, chest press, 20-25 reps, last set to failure. 90mins following the exercise bout participants will undergo another oral glucose tolerance test.
62665913|NCT03022214|EXPERIMENTAL|Placebo|5 capsules of placebo (microcrystalline cellulose) taken once in the morning with breakfast and once in the evening with dinner for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal
62665914|NCT03022214|EXPERIMENTAL|Intervention|"For presentation to volunteers, the daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule to be taken for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal"
62104029|NCT05647356|EXPERIMENTAL|Bicalutamide|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited.
62104030|NCT06709209||Ulcerative Colitis patients|UC patients who have been scheduled for colonoscopy for disease assessment or surveillance
62104031|NCT01017861||Pregnant, 12th week|Pregnant women in the 12th week of pregnancy.
62104032|NCT01017861||Pregnant, 28th week|Pregnant women in the 28th week of pregnancy.
62665915|NCT06278168|EXPERIMENTAL|Experimental awareness group|Twenty children in the experimental group will undergo individual training in which they will watch relaxation videos with the Oculus device. The group sessions will be the same for both groups.
62104033|NCT01017861||Pregnant, full term|Pregnant women at full term, in hospital for an elective cesarean section.
62104034|NCT01017861||Non pregnant women|Non pregnant women
62104035|NCT06631118|ACTIVE_COMPARATOR|Group A|Group (A ) : will receive ultrasound guided pericapsular nerve group block (PENG) followed by spinal anesthesia.
62104036|NCT06631118|ACTIVE_COMPARATOR|Group B|Group B will receive low dose intravenous Propofol \[0.7mg/kg\] over 30 seconds followed by spinal anesthesia and so far, this is the most common and standard technique to achieve sitting position during spinal anesthesia for patients with hip fractures.
62104037|NCT01311713|EXPERIMENTAL|CEP-9722 Dose 1 QD|Participants will receive Dose 1 of CEP-9722 tablet once daily (QD) orally with a standard meal for up to 6 cycles of 28 days each.
62104038|NCT01311713|EXPERIMENTAL|CEP-9722 Dose 1 BID|Participants will receive Dose 1 of CEP-9722 tablets twice daily (BID) orally with a standard meal for up to 6 cycles of 28 days each.
62104039|NCT01311713|EXPERIMENTAL|CEP-9722 Dose 2 BID|Participants will receive Dose 2 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
62104040|NCT01311713|EXPERIMENTAL|CEP-9722 Dose 3 BID|Participants will receive Dose 3 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
62104041|NCT01311713|EXPERIMENTAL|CEP-9722 Dose 4 BID|Participants will receive Dose 4 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
62104042|NCT01311713|EXPERIMENTAL|CEP-9722 Dose 5 BID|Participants will receive Dose 5 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
62296730|NCT03754985||Hyperbaric Oxygen Therapy|The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.
62296731|NCT00144170|OTHER|Tipranavir(TPV)/low dose ritonavir(r)|
62665916|NCT06278168|OTHER|Traditional awareness group|Twenty children in the control group will undergo individual training without using Oculus device. The group sessions will be the same for both groups.
62665917|NCT03479151|EXPERIMENTAL|MR-HIFU of painful bone metastases|Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
62665918|NCT05714436||Work Package 1a|Longitudinal interviews with patients and family carers to generate thematic framework for co-design workshops
62104043|NCT01311713|EXPERIMENTAL|CEP-9722 Dose 6 BID|Participants will receive Dose 6 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
62104044|NCT05604274||Healthy controls|
62104045|NCT05604274||Patients with cirrhosis on lactulose|
62104046|NCT05604274||Patients with cirrhosis on rifaximin|
62104047|NCT03789799|EXPERIMENTAL|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
62104048|NCT03789799|PLACEBO_COMPARATOR|Placebo|From the first postoperative day for ten days, single vaginal capsule per day of sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
62104049|NCT06433895|EXPERIMENTAL|Manual therapy + Exercise group|Both groups will be instructed in the performance of isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation as a home programme for a six-week period. Additionally, patients in the manual therapy group will receive manual therapy on a weekly basis for a total of six sessions.
62104050|NCT06433895|ACTIVE_COMPARATOR|Exercise group|Both groups will be instructed in the performance of isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation as a home programme for a six-week period.
62104051|NCT02518711|EXPERIMENTAL|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
62104052|NCT02518711|NO_INTERVENTION|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
62104053|NCT02157402|EXPERIMENTAL|Intervention Group|The intervention group will received activities and social events designed according 8 social marketing Benchmark criteria to promote healthy lifestyles.
62296732|NCT00144170|OTHER|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
62665919|NCT05714436||Work Package 1b|On-line focus groups with healthcare professionals to generate thematic framework for co-design workshops
62665920|NCT05714436||Work Package 2|Co-design workshops to generate decisions about priority areas for intervention development
62665921|NCT01669850|EXPERIMENTAL|Clipped anastomosis|A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
62104054|NCT02157402|NO_INTERVENTION|Control Group|The control group will not received any intervention activities and social events to promote healthy lifestyles.
62104055|NCT00282776|ACTIVE_COMPARATOR|TAU|Participants will receive treatment as usual
62104056|NCT00282776|EXPERIMENTAL|DCM|Participants will receive care management for postpartum depression
62104057|NCT03441048|EXPERIMENTAL|Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m\^2/day IV over two hours on days 2-6; cytarabine 2 gm/m\^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m\^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
62104058|NCT03441048|EXPERIMENTAL|Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m\^2/day IV over two hours on days 2-6; cytarabine 2 gm/m\^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m\^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
62104059|NCT03441048|EXPERIMENTAL|Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m\^2/day IV over two hours on days 2-6; cytarabine 2 gm/m\^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m\^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
62104060|NCT03441048|EXPERIMENTAL|Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m\^2/day IV over two hours on days 2-6; cytarabine 2 gm/m\^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m\^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
62104061|NCT03441048|EXPERIMENTAL|Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m\^2/day IV over two hours on days 2-6; cytarabine 2 gm/m\^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m\^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
62104062|NCT03441048|EXPERIMENTAL|Lintuzumab Ac225 Recommended Phase 2 Dose (RP2D)|The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m\^2/day IV over two hours on days 2-6; cytarabine 2 gm/m\^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m\^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
62104063|NCT04784741|OTHER|Control group|The control group was given the static hamstring muscle stretches, five sessions on alternative days according to the set protocols.
62104064|NCT04784741|EXPERIMENTAL|Experimental Group|Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.
62104065|NCT04441242|PLACEBO_COMPARATOR|Retrospective: Low lighting during screening colonoscopy|Screening colonoscopies performed with low lighting conditions.
62296733|NCT02338843|EXPERIMENTAL|LJPC-501 (angiotensin II)|Treatment arm
62296734|NCT02338843|PLACEBO_COMPARATOR|Placebo (0.9% sodium chloride solution)|Placebo arm
62296735|NCT02386774|OTHER|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
62296736|NCT02386774|OTHER|diabetic patients|
62665922|NCT01669850|ACTIVE_COMPARATOR|Handsewn anastomosis|A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.
62665923|NCT00991432||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
62665924|NCT03474835|OTHER|ISCHEMIC HEART DISEASE and PROSTATE ADENOCARCINOMA|
62665925|NCT03474835|NO_INTERVENTION|ISCHEMIC HEART DISEASE and PROSTATE hyperplasia|
62104066|NCT04441242|ACTIVE_COMPARATOR|Prospective: Ambient lighting during screening colonoscopy|Screening colonoscopies performed with ambient lighting conditions.
62104067|NCT03602755||Patients with newly diagnosed transplant-ineligible MM|Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.
62104068|NCT06026189|NO_INTERVENTION|Care-as-usual|In the ''care-as-usual'' arm, all patients undergo 'care-as-usual', i.e. a cystoscopy and upper tract imaging (ultrasound or CT-scan)
62104069|NCT06026189|EXPERIMENTAL|'Urine-first' strategy|In the intervention arm, the urine test is used to triage patients for a diagnostic workup ('urine-first' strategy). Only patients with an abnormal test result undergo cystoscopy and upper tract imaging.
62104070|NCT02062827|EXPERIMENTAL|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
62104071|NCT05457361|EXPERIMENTAL|VAH regimen|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
62104072|NCT05457361|ACTIVE_COMPARATOR|VA regimen|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
62104073|NCT04134325|EXPERIMENTAL|Arm 1: Relapse After Prior CD30 CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
62104074|NCT04134325|EXPERIMENTAL|Arm 2: Relapse with no Prior CD30 CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have not received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
62104075|NCT01700569|EXPERIMENTAL|Folinic Acid|"Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a 3x3 method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg."
62104076|NCT04541641|EXPERIMENTAL|osteotome group|
62104077|NCT04541641|EXPERIMENTAL|New Reverse Drilling technique|
62104078|NCT04181632|ACTIVE_COMPARATOR|Shot Blocker|The three interventional groups are currently marketed distraction devices. Arm 1 will be Shot Blocker® Number 1-25 (RED).
62104079|NCT04181632|NO_INTERVENTION|Control Group|The control group is the current clinical standard of care option for pre-allergy injection application. Ethyl Chloride/Pain Ease Spray Number 76-100 (YELLOW).
62104080|NCT04181632|ACTIVE_COMPARATOR|Buzzy I|The three interventional groups are currently marketed distraction devices. Arm 2 will be Buzzy® I (vibrating only) Number 26-50 (GREEN).
62665926|NCT01415570||Chronic Hemodialysis Patients|Adult hemodialysis patients
62665927|NCT01415570||Chronic hemodialysis patients|Adult hemodialysis patients
62104081|NCT04181632|ACTIVE_COMPARATOR|Buzzy II|The three interventional groups are currently marketed distraction devices. Arm 3 will be Buzzy® II (vibrating and ice wings) Number 51-75 (BLUE).
62104082|NCT05999461||cases|behcet patients
62104083|NCT05999461||control|age and sex matched healthy volunteers
62104084|NCT06711003|EXPERIMENTAL|EECP+PAC|Patients receive 35 times EECP treatments during standard PAC program.
62104085|NCT06711003|ACTIVE_COMPARATOR|PAC|Patients receive standard PAC program.
62104086|NCT05438732|EXPERIMENTAL|SING-IMT Implanted|the implanted eye will be the study eye which receives the SING-IMT. Implantation will occur during routine cataract surgery using a proprietary delivery system (loading cartridge and injector), via an approximately 6.5mm incision
62665928|NCT04607382||Low-dose estrogen progestin products (LEP)|The patients in the LEP cohort should not have taken LEP in the last 2 months before the enrollment in the study, and will take LEP during the study period.
62665929|NCT04607382||Non-LEP|Those patients in the Non-LEP cohort should not have taken LEP in the last 2 months before the enrollment and will take NSAIDs and/or Chinese medicine (CM) during the study period.
62665930|NCT06476249||cough|Patients who met the inclusion and exclusion criteria and underwent thoracoscopically assisted pneumonectomy with postoperative cough
62665931|NCT06476249||Uncough|Patients who met the inclusion and exclusion criteria and underwent thoracoscopically assisted pneumonectomy without postoperative cough
62665932|NCT05810662|ACTIVE_COMPARATOR|Ringer lactate|Ringer's lactate solution, or lactated Ringer's solution, is a type of isotonic, crystalloid fluid further classified as a balanced or buffered solution used for fluid replacement. The contents of Ringer's lactate include sodium, chloride, potassium, calcium, and lactate in the form of sodium lactate, mixed into a solution with an osmolarity of 273 mOsm/L and pH of about 6.5.
62104087|NCT03837925|EXPERIMENTAL|ATORVASTATIN|Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine
62104088|NCT03837925|PLACEBO_COMPARATOR|PLACEBO|Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm
62104089|NCT03997123|EXPERIMENTAL|Capivasertib + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Capivasertib: Oral tablets. 400 mg of Capivasertib (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
62296737|NCT03634982|EXPERIMENTAL|RMC-4630|RMC-4630 for oral administration
62308268|NCT06320951|PLACEBO_COMPARATOR|Placebo|The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
62308269|NCT00837681||lung disease|hematopoietic stem cell transplantation (HSCT)
62104090|NCT03997123|PLACEBO_COMPARATOR|Placebo + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
62665933|NCT05810662|ACTIVE_COMPARATOR|5%dextrose in 0.9%saline|"5% Dextrose and 0.45% Sodium Chloride Injection, USP solution is sterile and nonpyrogenic. It is a large volume parenteral solution containing dextrose and sodium chloride in water for injection intended for intravenous administration.~Each 100 mL of 5% Dextrose and 0.45% Sodium Chloride Injection, USP contains dextrose, hydrous 5 g and sodium chloride 0.45 g in water for injection. Electrolytes per 1000 mL: sodium (Na+), 77 mEq; chloride (Cl-) 77 mEq. The osmolarity is 406 mOsmol/L (calc.), which is hypertonic. The caloric value is 170 kcal/L.~The pH is 4.3 (3.5 to 6.5). 5% Dextrose and 0.45% Sodium Chloride Injection, USP contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection."
62296738|NCT05655585|EXPERIMENTAL|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
62665934|NCT06305065|EXPERIMENTAL|KUNWU Navigation TKA procedure|"Yuanhua Orthopaedic Robotic Systems, KUNWU, is an open-platform robotic system that does not restrict surgeons in choosing the type of prosthesis implant. It is the only Orthopaedic Robotic System in Hong Kong registered with the HK Department of Health Medical Devices Control Office (MDCO) as an open platform system. Unlike other manufacturer's implant-based robots (closed systems), Yuanhua's objective is to provide maximum flexibility in choosing the best implant for each patient. Closed system robots not only impact the surgeon's choice of implant for an individual patient but also affect the hospital's implant purchases over multiple years without any negotiation power on pricing. This business model is often referred to as a razor and razor blade model."
62665935|NCT06305065|EXPERIMENTAL|CORI Surgical System TKA procedure|"REAL INTELLIGENCE™ CORI™ (CORI Surgical System) is a computer-assisted orthopedic surgical system. CORI Surgical System is designed to aid surgeons in planning and executing a procedure involving bone preparation for total knee arthroplasty (TKA) procedures.~CORI Surgical System is comprised of a console control unit, optical tracking camera, primary and secondary input displays (tablet and optional display monitor), and foot pedal. The CORI Surgical System software consists of a patient and user management module, a surgical planner, and an intra-operative cutting module."
62665936|NCT06305065|ACTIVE_COMPARATOR|Conventional TKA procedure|This group will perform the standard TKA procedure.
62665937|NCT05461898|EXPERIMENTAL|Inpatient Rehabilitation + Inspiratory Muscle Training|"* The inpatient rehabilitation program included individualized, functional goal-oriented treatment, with approximately 5 hours of intervention a day, 5 days/week for a total of 6 weeks, with integrated rehabilitation care.~* The inspiratory muscle training included a 6 weeks intervention with electronic-controlled valve device"
62665938|NCT05461898|ACTIVE_COMPARATOR|Inpatient Rehabilitation|- The inpatient rehabilitation program included individualized, functional goal-oriented treatment, with approximately 5 hours of intervention a day, 5 days/week for a total of 6 weeks, with integrated rehabilitation care.
62665939|NCT01938937|EXPERIMENTAL|Transcranial bright light exposure|Transcranially administered bright light exposure for 12 minutes
62104091|NCT06507657|EXPERIMENTAL|Experimental group|
62104092|NCT06507657|PLACEBO_COMPARATOR|Placebo group|
62104093|NCT02838316|EXPERIMENTAL|150 x 106 dosage|10 subjects will be receiving a dosage of 150 x 106 AMDC-GIR
62665940|NCT01938937|SHAM_COMPARATOR|Transcranial sham exposure|Transcranially administered sham exposure for 12 minutes
62665941|NCT05413460|EXPERIMENTAL|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
62104094|NCT02838316|EXPERIMENTAL|300 x 106 dosage|10 subjects will be receiving a dosage of 300 x 106 AMDC-GIR
62104095|NCT04903483|OTHER|target-controlled infusion (propofol) with depth of anesthesia monitoring|In this group, propofol dosing is adjusted with bispectral index monitoring.
62296739|NCT05655585|EXPERIMENTAL|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
62296740|NCT01143480||ABCA1|SNP or allele of interest
62665942|NCT05413460|NO_INTERVENTION|Control|Electrodes are placed at acupoints and connected to the stimulator. But no stimulation is given during surgery.
62665943|NCT04358562|EXPERIMENTAL|Gefitinib with Anlotinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily and Anlotinib 10mg oral d1-14, every 3 weeks
62665944|NCT04358562|EXPERIMENTAL|Gefitinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily
62665945|NCT01174459||Patient with Restless Legs Syndrome|
62665946|NCT05527522|PLACEBO_COMPARATOR|Control|Control arm: Who received the usual practice.
62104096|NCT04903483|OTHER|target-controlled infusion (propofol) without depth of anesthesia monitoring|In this group, propofol dosing is adjusted without bispectral index monitoring.
62296741|NCT01143480||APOE|SNP or allele of interest
62296742|NCT01143480||APOL1|SNP or allele of interest
62296743|NCT01143480||CD14|SNP or allele of interest
62296744|NCT01143480||CD44|SNP or allele of interest
62296745|NCT01143480||IRGM|SNP or allele of interest
62104097|NCT05612243|EXPERIMENTAL|Yogurt enriched with probiotics and polyphenols|Participants will consume a meal including 200g of yogurt containing Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g)
62296746|NCT01143480||ITIH3|SNP or allele of interest
62296747|NCT01143480||ITIH4|SNP or allele of interest
61912585|NCT04585971||Subjects|Cerebral blood flow of a subject is measured using three methods in both common carotid and vertebral arteries. 1) Phase-contrast MR 2) Doppler sonography 3) Signal Intensity Gradient (SIG) To determine whether there is a correlation between the measured values, the correlation coefficient is calculated and analyzed.
61912586|NCT04903821|EXPERIMENTAL|Group A (Child- Pugh A)|Participants with mild impaired hepatic function (Child-Pugh A), including at least 2 female participants.
62665947|NCT05527522|EXPERIMENTAL|Intervention|Intervention arm: Who received an individualized diet, educational intervention with/without nutritional supplements depending on the degree of malnutrition plus usual practice
62665948|NCT02122952|EXPERIMENTAL|Cohort 1|6.7 X 10\^13 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=3)
62296748|NCT01143480||MyD88|SNP or allele of interest
62296749|NCT01143480||TIRAP|SNP or allele of interest
62296750|NCT01143480||TLR4|SNP or allele of interest
62665949|NCT02122952|EXPERIMENTAL|Cohort 2|2.0 X 10\^14 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=12)
62665950|NCT02866383|EXPERIMENTAL|Nivolumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT and then every 2 weeks (q2w), for a maximum of 52 weeks
62665951|NCT02866383|EXPERIMENTAL|Nivolumab & Ipilimumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT. Thirty minutes after the completion of nivolumab infusion patients will receive ipilimumab 1 mg/kg over 90 minutes IV as an IV infusion. Nivolumab will be given every 2 weeks (q2w) and ipilimumab every 6 weeks (q6w), respectively for a maximum of 52 weeks
62665952|NCT06114199|ACTIVE_COMPARATOR|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
62665953|NCT06114199|EXPERIMENTAL|Produce Prescription Program (PPRx) Standard plus Smartphone App|Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus the same standard nutrition education materials provided to the control group consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code. Additionally, participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
62665954|NCT03899090|EXPERIMENTAL|Float Pool|Floating supine in a pool for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
62665955|NCT03899090|ACTIVE_COMPARATOR|Float Chair|Floating supine in a zero-gravity chair for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
61912587|NCT04903821|EXPERIMENTAL|Group B (Child-Pugh B)|Participants with moderate impaired hepatic function (Child-Pugh B), including at least 2 female participants
61912588|NCT04903821|EXPERIMENTAL|Control A match controls for group A|Matched control participants for Group A with normal hepatic function.
62296751|NCT01143480||TLR5|SNP or allele of interest
62296752|NCT01143480||TNFa|SNP or allele of interest
62296753|NCT04379752|EXPERIMENTAL|Cold-atmospeheric pressure plasma activated solution|Treatment arm subjects receive the trial intervention
62296754|NCT05987644|EXPERIMENTAL|Phase 1b: Experimental|600mg alectinib taken orally twice daily
62296755|NCT05987644|EXPERIMENTAL|Phase 2: Arm A|600mg alectinib taken orally twice daily
62296756|NCT05987644|EXPERIMENTAL|Phase 2: Arm B|Subjects will receive SRS prior to taking alectinib. 24 hours after, but no more than 7 days after last radiation dose, alectinib should be taken at 600mg orally twice daily
62296757|NCT04807361||(1) Multifocal soft contact lenses (MFCLs)|Assess accommodative function of myopic children wearing MFCLs for myopia control treatment. Accommodative stimulus-response functions and accommodative lags will be determined during one, one hour measurement session for four stimulus distances using an IR video refractometer (PowerRefractor). MFCL subjects will also be tested while wearing SVCL distance corrections for comparison.
61912589|NCT04903821|EXPERIMENTAL|Control B match controls for group B|Matched control participants for Group B with normal hepatic function
61912590|NCT01390064|EXPERIMENTAL|Initial Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
61912591|NCT01390064|ACTIVE_COMPARATOR|Escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
61912592|NCT01390064|ACTIVE_COMPARATOR|De-escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms
62296758|NCT04807361||(2) orthokeratology|Assess accommodative function of myopic children wearing Orthokeratology for myopia control treatment.
62296759|NCT04807361||(3) low-dose atropine|Assess accommodative function of myopic children using low-dose atropine eye drops for myopia control treatment.
61912593|NCT03874260|EXPERIMENTAL|statin / fenofibrate|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O
62296760|NCT04807361||(4) single vision spectacle correction (control)|Assess accommodative function of myopic children wearing single vision spectacle lenses.
62296761|NCT01982825|EXPERIMENTAL|Online intervention arm|Bi-weekly (MTh) for 6 weeks, participants will receive an email asking them to report number of cigarettes smoked, alcoholic drinks, engagement in physical activity, and overall mood the two-three days before. Upon answering, they will be launched to the site which will contain health messaging focused on smoking and other health topics.
62665956|NCT03899090|EXPERIMENTAL|Float Pool Preferred|Floating supine in a pool for a preferred amount of time (6 total sessions, up to 2 hours/session, as frequently as they prefer within a 12-week period with a minimum of 24 hours between sessions)
62665957|NCT05832983|NO_INTERVENTION|Control|Participants in the control arm will receive the current standard of nursing care for treating anxiety prior to receiving the intra-articular injection (emotional support, distraction, and/or therapeutic touch as necessary).
62665958|NCT05832983|EXPERIMENTAL|Experimental Group A|Participants in Group A will receive a guided meditation prior to receiving the intra-articular injection.
62665959|NCT05832983|EXPERIMENTAL|Experimental Group B|Participants in Group B will receive an Elequil Aromatab and the same guided meditation delivered to Group A prior to receiving the intra-articular injection.
62665960|NCT02487199|EXPERIMENTAL|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) for 12 weeks.
62665961|NCT02487199|EXPERIMENTAL|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\]) for 12 weeks.
62665962|NCT04721262||Patients prescribed Ferumoxytol for iron deficiency anemia|Patients with iron deficiency anemia are commonly prescribed Ferumoxytol periodically as part of their standard clinical care. Multiple studies have characterized the efficacy and safety of Ferumoxytol in the treatment of iron deficiency anemia. Patients prescribed Ferumoxytol for iron-deficiency anemia typically include otherwise healthy women with heavy menstrual periods, patients with inflammatory bowel disease, and patients with chronic kidney disease. Such patients make ideal candidates for characterizing the effects of Ferumoxytol on novel imaging devices by obviating a medically unnecessary injection of the contrast agent.
62104098|NCT05612243|ACTIVE_COMPARATOR|Yogurt enriched with probiotics|Participants will consume a meal including 200g of yogurt containing Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g)
62665963|NCT01948778|EXPERIMENTAL|oXiris™ filter|oXiris™ filter
61912594|NCT03874260|PLACEBO_COMPARATOR|statin / fenofibrate placebo|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
62665964|NCT01948778|EXPERIMENTAL|Toraymyxin Filter|Toraymyxin Filter
62665965|NCT01948778|OTHER|Standard of Care|Standard of Care CRRT if necessary
62104099|NCT05612243|PLACEBO_COMPARATOR|Plain yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing oat flakes (1g), as well as two slices of white bread (80g) with butter (30g)
62104100|NCT03947164|OTHER|Case group|"Case :~- Patient operated at Rennes University Hospital of anterior POP and / or posterior POP via vaginal and / or abdominal way.~POPs will be classified in stages 2-4 using the ICS classification;~* Without urinary incontinence associated effort (eliminated by the interrogation);~* Registered to a health insurance system;~* Having received information on the protocol and giving informed written consent."
62104101|NCT03947164|OTHER|Control group|"Control:~Patient operated at the Rennes University Hospital for a vaginal or abdominal hysterectomy for a benign reason.~* No POPs and no urinary incontinence eliminated during the interrogation and clinical examination.~* Registered to a health insurance system;~* Having received information on the protocol and giving informed written consent."
62468547|NCT04249830|EXPERIMENTAL|Stem Cell Transplant -Malignant|The participant with a malignancy will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. Participants will be followed for outcomes for two years.
62665966|NCT02153853||Rectal cancer|Patients undergoing laparoscopic surgery for rectal cancer at the Department of Gastrointestinal Surgery, Hvidovre Hospital, Copenhagen, Denmark.
62665967|NCT00432120|ACTIVE_COMPARATOR|A|"nonselective - clopidogrel 600 mg \>6 hours before coronary angiography;"
61912595|NCT02150902|EXPERIMENTAL|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
61912596|NCT02150902|ACTIVE_COMPARATOR|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
61912597|NCT06220890|EXPERIMENTAL|Class IV lesion with 2 mm bevel (BV)|All the enamel margins will be beveled at a 45-degree angle of the width of approximately 2 mm, enamel selectively etched, bonding of tooth using universal adhesive will be done and restored with nano-filled composite.
62104102|NCT03732820|EXPERIMENTAL|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
62468548|NCT04249830|EXPERIMENTAL|Stem Cell Transplant - Non-Malignant|The participant with a non-malignant disease will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. Participants will be followed for outcomes for two years.
62468549|NCT00714090|ACTIVE_COMPARATOR|A|Double active comparator : venlafaxine (150 mg/day) and rTMS (5 times/week)
62468550|NCT00714090|EXPERIMENTAL|B|active rTMS (5 times/week) and sham venlafaxine (150 mg/day)
62468551|NCT00714090|SHAM_COMPARATOR|C|sham rTMS (5 times/week) and active venlafaxine (150 mg/day)
62468552|NCT05342740||Case group-CWD|diabetic patients with chronic wounds (CWD)
62468553|NCT05342740||Control group 1-ND|patients without diabetes (ND)
62665968|NCT00432120|ACTIVE_COMPARATOR|B|"selective - clopidogrel 600 mg in the cath-lab after coronary angiography, only in case of percutaneous coronary intervention"
62665969|NCT04588272||2 liters|40 patients will receive O2 supply at rate of 2 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
62665970|NCT04588272||4 liters|40 patients will receive receive O2 supply at rate 4 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
62665971|NCT04588272||6 liters|: 40 patients will receive O2 supply at rate 6 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
62665972|NCT03489525|EXPERIMENTAL|Dose Escalation, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
62665973|NCT03489525|EXPERIMENTAL|Dose Expansion, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with R/R MM in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
62665974|NCT04828525|EXPERIMENTAL|Experimental|participants will be given corticosteroids in addition to conventional treatment
62104103|NCT03732820|PLACEBO_COMPARATOR|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
62104104|NCT01988350||Non-smokers|
62104105|NCT01988350||Smokers|
62104106|NCT01553825||Pathologically diagnosed carcinoma|
62104107|NCT01701609|EXPERIMENTAL|Cognitive Remediation Therapy|CRT: Frontal/Executive Program. The program has a duration of 40 sessions, with two session for week. Is is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
62665975|NCT04828525|PLACEBO_COMPARATOR|Placebo|participants will be given normal saline in addition to conventional treatment
62665976|NCT03615534|PLACEBO_COMPARATOR|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
62665977|NCT03615534|ACTIVE_COMPARATOR|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
62665978|NCT03615534|ACTIVE_COMPARATOR|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
62665979|NCT03615534|ACTIVE_COMPARATOR|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
62665980|NCT04078308|EXPERIMENTAL|Mesenchymal Stem Cells Transplantation|The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells
62104108|NCT04312191|NO_INTERVENTION|Control Group|The Control Group participants (Group A) will be initiating radiation therapy and receiving only standard of care therapy per their Radiation Oncologist.
62665981|NCT04078308|PLACEBO_COMPARATOR|Placebo|The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)
62104109|NCT04312191|EXPERIMENTAL|Test Group|The Test Group participants (Group B) will be initiating radiation therapy and receiving standard of care therapy per their Radiation Oncologist. This group will also be taught mantra-based meditation to use during each radiation treatment session and encouraged to practice MM ad libitum outside of the treatment setting.
62104110|NCT04163484||Stable coronary artery disease|
62296762|NCT01982825|ACTIVE_COMPARATOR|Online control arm|Control participants will receive bi-weekly emails (MTh) over 6 weeks but in the context of a standard smoking cessation website. Because we are primarily testing the check-ins, tailored feedback, and market research-based mini-drama and other web content, we feel that this control group will isolate the hypothesized active elements of our program.
62104111|NCT04163484||ST-elevation myocardial infarction|
62296763|NCT06192121|NO_INTERVENTION|Control|Standart Health Care which is provided regular from ministry of health for 3 months
62296764|NCT06192121|EXPERIMENTAL|Experiment|Standart Health Care which is provided regular from ministry of health for 3 months Web Based Education for 3 months 3 reminder messages (SMS) per week
62296765|NCT00791726||1|Patients with noninfectious uveitis and macular edema
62296766|NCT03959189|EXPERIMENTAL|ERX-963 then placebo|Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.
62296767|NCT03959189|EXPERIMENTAL|Placebo then ERX-963|Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.
62296768|NCT03567655|EXPERIMENTAL|Single group|Farlutal tab. 500mg/ Pfizer to be administered
62296769|NCT04837417||Pathologic group|At least 10 male participants who underwent anterior cruciate ligament arthroscopic reconstruction using semitendinosus and gracilis tendons graft, between 6 and 18 months before the tests
62296770|NCT00807469||1|20 healthy individuals not susceptible for COPD (age 18-40 years, \>0\>10 packyears, FEV1/VC \>70%, FEV1 \>85% predicted)
62665982|NCT05842707|EXPERIMENTAL|Part 1 (dose escalation) and Part 2 (dose expansion)|"Part 1 (dose escalation)~the dose of dualCAR-NK19/70 participants receive will depend on when you join this study. Up to 3 dose levels of dualCAR-NK19/70 will be tested. About 3-6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level of dualCAR-NK19/70. Each new group will receive a higher dose of dualCAR-NK19/70 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of dualCAR-NK19/70 is found.~Part 2 (dose expansion)~Participants will receive dualCAR-NK19/70 at the recommended dose that was found in Part 1."
62665983|NCT01806792|EXPERIMENTAL|Risendronate and Cholecalciferol combination|risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.
62665984|NCT01806792|ACTIVE_COMPARATOR|Risedronate|risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.
62665985|NCT04607551|EXPERIMENTAL|Prone positionning|
62468554|NCT05342740||Control group 2-NWD|diabetic patients without newly identified wound (NWD)
62468555|NCT03059966|EXPERIMENTAL|Enamel Matrix Derivative|Microsurgery for root coverage associated with Enamel Matrix Derivative
62468556|NCT03059966|PLACEBO_COMPARATOR|Placebo|Microsurgery for root coverage associated with a Placebo comparator
62665986|NCT04607551|ACTIVE_COMPARATOR|Supine position|
62665987|NCT05697692|PLACEBO_COMPARATOR|Placebo|Saline 0.9%
62665988|NCT05697692|ACTIVE_COMPARATOR|Heparin sodium|70 international units (IU)/kg Heparin sodium
62104112|NCT04163484||Non-ST-elevation myocardial infarction|
62104113|NCT00121940|EXPERIMENTAL|Guided Care|
62665989|NCT03535688|EXPERIMENTAL|D-cycloserine|D-cycloserine 200 mg twice daily
62104114|NCT00121940|NO_INTERVENTION|Usual Care|
62104115|NCT05920577|EXPERIMENTAL|Exergames and resistance training group|Participants will receive exergaming and resistance training programme over a period of 12 weeks
62665990|NCT03535688|PLACEBO_COMPARATOR|Placebo|Placebo twice daily
62665991|NCT03594344|EXPERIMENTAL|Hyperbaric oxygen therapy|30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.
62665992|NCT03594344|NO_INTERVENTION|Control group|Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.
62104116|NCT05920577|ACTIVE_COMPARATOR|Resistance training group|Participants will receive resistance training programme over a period of 12 weeks
62104117|NCT05557721||MP-TLT in topical anesthesia|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage. Thereafter, MP-TLT will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations. In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning.
62104118|NCT03163862|PLACEBO_COMPARATOR|Placebo|Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
62296771|NCT00807469||2|20 healthy individuals susceptible for COPD (age 18-40 years \>20 packyears, FEV1/VC \>70%, FEV1 \>85% predicted) and high prevalence of COPD in smoking family members older than 45 years
62296772|NCT00807469||3|20 healthy individuals very susceptible for COPD (age 18-40 years, \> 0 \> 10 packyears, FEV1/VC \>70%, FEV1 \>85% predicted), and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
62665993|NCT02850562|ACTIVE_COMPARATOR|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
62296773|NCT00807469||4|30 healthy individuals not susceptible for COPD (age 40-75 years, \>20 packyears, FEV1/VC \>70%, FEV1 \>85% predicted)
62296774|NCT00807469||5|30 COPD patients with GOLD stage II (age 40-75 years, \>10 packyears, FEV1/VC \<_70%, FEV1 50-80% predicted)
62296775|NCT05742321||Patients with FECD|Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of data and a blood sample
62296776|NCT01477450|ACTIVE_COMPARATOR|1 L/min ; 16 mL|Cylinder oxygen delivery (1 L/min) followed by pulse-dose oxygen by concentrator (16 mL)
62296777|NCT01477450|ACTIVE_COMPARATOR|2 L/min ; 32 mL|Cylinder oxygen delivery (2 L/min) followed by pulse-dose oxygen by concentrator (32 mL)
62296778|NCT01477450|ACTIVE_COMPARATOR|3 L/min ; 48 mL|Cylinder oxygen delivery (3 L/min) followed by pulse-dose oxygen by concentrator (48 mL)
62296779|NCT01283256||Experimental|
62296780|NCT04647214||Bimatoprost intracameral implant (DURYSTA) 10μg|Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
62296781|NCT01254344|EXPERIMENTAL|Ertapenem sodium 1 g|Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
62296782|NCT01254344|ACTIVE_COMPARATOR|Ceftriaxone sodium 2 g|Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose
62296783|NCT02427165|PLACEBO_COMPARATOR|Placebo|Single dose of nebulised placebo solution
62296784|NCT02427165|EXPERIMENTAL|RPL554 Dose 1|0.4 mg single dose nebulised RPL554
62296785|NCT02427165|EXPERIMENTAL|RPL554 Dose 2|1.5 mg single dose nebulised RPL554
62665994|NCT02850562|EXPERIMENTAL|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
62665995|NCT00712049|ACTIVE_COMPARATOR|1|Nicotinic acid + Simvastatin
62665996|NCT00712049|ACTIVE_COMPARATOR|2|Simvastatin
62665997|NCT03237663|EXPERIMENTAL|One enteric capsule|
62665998|NCT03237663|EXPERIMENTAL|Two enteric capsule|
61912598|NCT06220890|EXPERIMENTAL|Class IV lesion with 2mm stair-step chamfer (SSC)|Enamel margins facially will be prepared 2mm deep in stair-step chamfer form, enamel selectively etched, and bonding of tooth using universal adhesive will be done and restored with nano-filled composite.
61912599|NCT04140032|EXPERIMENTAL|Intervention group|Centers in the group will participate in the A-B-C Healthy Me/Soy Saludable multi- component nutrition and physical activity preschool intervention.
61912600|NCT04140032|NO_INTERVENTION|Control group|"Preschools in the group will continue with usual care practices. Control group preschools will receive intervention materials and accompanying instructions after follow-up measures are collected for each cohort."
61912601|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
61912602|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
61912603|NCT03848156||CRSwNP AERD allergic|Patients suffering from chronic rhinosinusitis with nasal polyps, allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
62296786|NCT02427165|EXPERIMENTAL|RPL554 Dose 3|6 mg single dose nebulised RPL554
62296787|NCT02427165|EXPERIMENTAL|RPL554 Dose 4|24 mg single dose nebulised RPL554
62296788|NCT02427165|ACTIVE_COMPARATOR|Salbutamol Dose 1|2.5 mg single dose nebulised salbutamol
62296789|NCT02427165|ACTIVE_COMPARATOR|Salbutamol Dose 2|7.5 mg single dose nebulised salbutamol
61912604|NCT03848156||CRSwNP AERD non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
61912605|NCT03848156||CRSwNP non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy - biopsy for RNA sequencing
61912606|NCT03848156||CRSwNP allergic|Patients suffering from chronic rhinosinusitis with nasal polyps with allergy - biopsy for RNA sequencing
61912607|NCT03469778|EXPERIMENTAL|Robotic Therapy|After consent, 10 participants will be included in a training program, as described below: 1º session will be robotic calibration and assessment; the following 18 sessions will be conducted the robotic therapy for upper limbs, three times a week. Each session will have a total duration of 55 minutes, including initial patient positioning and adjusting and after a sequence of game tasks.
61912608|NCT02201342|EXPERIMENTAL|Udenafil Dose Level 1 qd|Udenafil tablet dose Level 1 daily for 5 days
61912609|NCT02201342|EXPERIMENTAL|Udenafil Dose Level 1 bid|Udenafil Dose Level 1 twice daily for 5 days.
61912610|NCT02201342|EXPERIMENTAL|Udenafil Dose Level 2 qd|Udenafil tablet dose level 2 once daily for 5 days.
61912611|NCT02201342|EXPERIMENTAL|Udenafil Dose Level 2 bid|Udenafil tablet dose level 2 twice daily for 5 days
62296790|NCT04938856|EXPERIMENTAL|Test Group|Oral administration of Lamnet (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
62296791|NCT04938856|ACTIVE_COMPARATOR|Reference Group|Oral administration of Lamictal (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
62296792|NCT00023322|EXPERIMENTAL|Peginterferon Alpha-2a|Patients with hepatitis D virus (HDV) infection are treated with pegylated alpha interferon therapy for 3 years. The dose of the drug is 180 mcg/week.
62296793|NCT04751721|EXPERIMENTAL|CoronoVac Vaccine Group|
62665999|NCT02928432|EXPERIMENTAL|Steroids switch|CRPC patients with biochemical and/or limited radiological progression after at least 12 weeks of AA + prednisone.
62666000|NCT05643508|EXPERIMENTAL|(D) DWC202206 + DWC202207|
62468557|NCT04535830|EXPERIMENTAL|Flash glucose monitor system(FSL)|Except at baseline and at the end of the experiment,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month.
62666001|NCT05643508|ACTIVE_COMPARATOR|(P+D) DWC202206 + DWC202207|
62666002|NCT05643508|ACTIVE_COMPARATOR|(D+P) DWC202206 + DWC202207|
62666003|NCT03977688||none Cyto|septic shock, refractory, without Cytokin-adsorption therapy
62104119|NCT03163862|EXPERIMENTAL|G-CSF group|"Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.~The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer"
62104120|NCT03163862|SHAM_COMPARATOR|Comparative group|patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
62104121|NCT01719536|EXPERIMENTAL|Icotinib|Icotinib 125mg is administered orally three times per day.
62296794|NCT00013078|OTHER|Arm 1|
62468558|NCT04535830|NO_INTERVENTION|Self-monitoring blood glucose(SMBG)|People at SMBG group will wear the sensor at baseline and at the end of the experiment for data analysis only,and will have a care visit every month.
62666004|NCT03977688||cyto|septic shock, refractory, treated with Cytokin-adsorption therapy
62666005|NCT03805139|EXPERIMENTAL|Ajwa Dates group|55-65gms Ajwa dates 7 days a week for 6 weeks
62666006|NCT03805139|NO_INTERVENTION|Control|No intervention
62666007|NCT04076215|EXPERIMENTAL|Pariticapnts with PTSD|
62666008|NCT04076215|EXPERIMENTAL|Pariticapnts without PTSD (controls)|
62666009|NCT00778414|EXPERIMENTAL|1|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension of ranbaxy
62666010|NCT00778414|ACTIVE_COMPARATOR|2|Augmentin ES - 600
62666011|NCT05676645||Participants|Breastfeeding women who have been prescribed (by a clinician independent from the study team) artemether-lumefantrine to treat uncomplicated malaria
62666012|NCT04731116|EXPERIMENTAL|CANNABIDIOL|CANNABIDIOL 5% 3 ml twice daily for 14 days.
61912612|NCT02201342|EXPERIMENTAL|Udenafil Dose Level 3 qd|Udenafil tablet dose level 3 daily for 5 days
61912613|NCT02201342|NO_INTERVENTION|No Drug|No drug
61912614|NCT05937464|EXPERIMENTAL|Exoskeleton ExoAthlet group|
61912615|NCT05937464|EXPERIMENTAL|Lokomat Free-D group|
61912616|NCT01006603|EXPERIMENTAL|1|Saxagliptin 5 mg
61912617|NCT01006603|ACTIVE_COMPARATOR|2|Glimepiride 1 - 6 mg
61912618|NCT01821573|EXPERIMENTAL|Botox Injection|Patients treated by botulinum toxin.
61912619|NCT01821573|PLACEBO_COMPARATOR|Saline Solution|Patients treated with saline solution.
61912620|NCT05607069||COVID-19 previous infection|
61912621|NCT00391183|ACTIVE_COMPARATOR|Endoscopic stenting|patients with biliary obstruction will undergo endoscopic stenting.
61912622|NCT00391183|NO_INTERVENTION|Best supportive care|
61912623|NCT02069340|EXPERIMENTAL|Arm I (zoledronic acid over 15 minutes)|Patients receive zoledronic acid IV over 15 minutes on day 1.
61912624|NCT02069340|EXPERIMENTAL|Arm II (zoledronic acid over 30 minutes)|Patients receive zoledronic acid IV over 30 minutes on day 1.
61912625|NCT04926402|NO_INTERVENTION|Standard of care|The control group received standard routine care
61912626|NCT04926402|EXPERIMENTAL|Kangaroo care education program|The experimental group received a maternal kangaroo care education program
61912627|NCT06433856|EXPERIMENTAL|CWI|The CWI protocol consists of participants standing, with only their underwear and a t-shirt, in a portable tub for cold water therapy (Qryo, Italy), with the water to their hips being constantly maintained at 10±0.5 °C by a cooling system that pumped and stirred the water inside the tub and around the participant's lower limbs. Water temperature and the duration of the immersion, which is 12 minutes for all the participants considering they were characterized by similar anthropometrics and body composition, were based on previous literature
61912628|NCT06433856|EXPERIMENTAL|PMT|"The PMT protocol is performed with the application of a percussive therapy gun (Theragun Elite, Therabody, USA). The participants rests with their underwear and a t-shirt on a treatment bed, and the percussive therapy gun with a standard ball, 16 mm amplitude of percussions, and a frequency of 30 Hz, is applied to the thigh muscles of both lower limbs, 3 min on the anterior and 3 min on the posterior area of each thigh. The protocol is based on previous literature and adapted to the specific aims of this study."
61912629|NCT06433856|NO_INTERVENTION|PAS|The control condition (PAS) consists of participants resting on a chair for 12 minutes in a quiet room at 25 °C.
61912630|NCT06092229|ACTIVE_COMPARATOR|Palpation|digital palpation used to identify the cricothyroid membrane
61912631|NCT06092229|EXPERIMENTAL|Ultrasonography|Ultrasonography (TACA approach) used to identify the cricothyroid membrane
61912632|NCT04738318|EXPERIMENTAL|Treatment Arm (Glucocorticoid)|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone. Following surgery, the participant will be provided with a 1) six-day oral methylprednisolone taper course.
61912633|NCT04738318|PLACEBO_COMPARATOR|Control Arm (Placebo)|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
61912634|NCT05506605|EXPERIMENTAL|Switch from Etravirine to Doravirine|Switch from etravirine to Doravirine (Pifeltro) 100 mg each day
61912635|NCT04052802|EXPERIMENTAL|Bioactive resin (Giomer)|"This group of patients will receive a bioactive resin Beautifil flow plus X (Shofu Dental) for treatment of their demineralized fissures"
62104122|NCT01719536|ACTIVE_COMPARATOR|Chemotherapy|Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.
62666013|NCT03972228|EXPERIMENTAL|Microdevice Intervention|The intervention to be administered is the placement of the microdevice containing 19 FDA-approved drugs into the lung lesion and the device's subsequent surgical resection. All study subjects will receive this same intervention; there is only one arm.
62104123|NCT01539603|EXPERIMENTAL|DEB-BMS|Drug eluting balloon + Bare metal stent
62104124|NCT01539603|ACTIVE_COMPARATOR|Drug eluting stent|conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
62104125|NCT01339702||"Pre-implementation cohort (before)"|This cohort is a combination of retrospective and some prospective severe TBI patients cared for in the EMS systems of Arizona BEFORE implementation of the national prehospital TBI management guidelines
62104126|NCT01339702||"Post-implementation cohort (after)"|"This cohort is a comprised of prospective severe TBI patients cared for in the EMS systems of Arizona AFTER training EMS providers in the implementation of the national prehospital TBI management guidelines. It is intended that these patients will receive the bundle of care specified in the TBI Guidelines."
62104127|NCT04252066||Cohort 1|Cohort 1 will be pregnant and/or breastfeeding patients who have Fabry Disease, and have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
62104128|NCT04252066||Cohort 2|Cohort 2 will be pregnant and/or breastfeeding patients who have Fabry Disease, who were not exposed to migalastat during pregnancy and/or breastfeeding.
62104129|NCT02243592||Ancillary-Correlative (molecular profiling)|Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
62104130|NCT00409058|EXPERIMENTAL|Teen Online Problem Solving|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
62296795|NCT06401980|EXPERIMENTAL|Arm A: Experimental|"Standard of Care~+ Darolutamide 2 x 600 mg BID until radiographic PD"
62296796|NCT06401980|OTHER|Arm B: Control|Standard of Care
62104131|NCT00409058|EXPERIMENTAL|Internet Resources Comparison|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
62296797|NCT02898012|EXPERIMENTAL|Temozolomide and Bevacizumab|Single experimental arm with two drugs : Temozolomide and Bevacizumab
62296798|NCT00712101|EXPERIMENTAL|1|Abciximab bolus administration intracoronary
62296799|NCT00712101|ACTIVE_COMPARATOR|2|Abciximab bolus intravenously
62296800|NCT01340183|EXPERIMENTAL|AZD5099|IV Dose
62296801|NCT01340183|PLACEBO_COMPARATOR|Placebo|IV Dose
62296802|NCT01086787||Non heart failure patients|Patients without heart failure undergoing open chest surgery
62296803|NCT01086787||Orthopedic patients|Patients without heart failure undergoing orthopedic surgery
62296804|NCT01086787||Heart failure patients|Patients with heart failure undergoing open chest surgery.
62296805|NCT01947023|EXPERIMENTAL|Treatment (lapatinib, dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 of each cycle. After two weeks of single agent dabrafenib, patients also start receiving lapatinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo tumor biopsy, blood sample collection, ECHO or MUGA, as well as PET, CT, and/or MRI during screening and on study.
62296806|NCT05864378||The POCUS group|Patients who were evaluated by ED physicians who perform POCUS intestinal loops examination as part of their clinical practice
62296807|NCT05864378||The non-POCUS group|Patients who were evaluated by ED physicians who do not perform POCUS intestinal loops examination for any reason
62666014|NCT01479530|PLACEBO_COMPARATOR|Placebo|
62666015|NCT01479530|EXPERIMENTAL|Azilect®|
61912636|NCT04052802|EXPERIMENTAL|Conventional resin|"This group of patients will receive a conventional resin Filtek Z350xt Flowable composite (3M ESPE) for treatment of their demineralized fissures"
61912637|NCT05896280|ACTIVE_COMPARATOR|EST in common bile duct stones|With routine EST surgery, the sphincter is cut open and stones are removed
61912638|NCT05896280|EXPERIMENTAL|ECPP in common bile duct stones|Common bile duct stones are removed after EST, and then ECPP is performed.
62468559|NCT00208403|ACTIVE_COMPARATOR|1|Acryloc™ GHV
62468560|NCT00208403|ACTIVE_COMPARATOR|2|Palacos R
62666016|NCT04225143|EXPERIMENTAL|bilateral|25 patients with an overactive bladder
62666017|NCT04225143|ACTIVE_COMPARATOR|unilateral|25 patients with an overactive bladder
62666018|NCT00685282|OTHER|COGNITIVE BEHAVIORAL INTERVENTIONS|PSYCHOLOGICAL INTERVENTIONS TO INCLUDE, RELAXATION, STRESS REDUCTION, GUIDED IMAGERY, BREATHING EXERCISES
62666019|NCT05058456|EXPERIMENTAL|Single-arm|
62666020|NCT00762788|ACTIVE_COMPARATOR|senofilcon A contact lens|ACUVUE OASYS
62666021|NCT00762788|ACTIVE_COMPARATOR|lotrafilcon A contact lens|NIGHT\&DAY
61912639|NCT04839562|EXPERIMENTAL|solriamfetol|Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
62104132|NCT01766856||children undergoing myringoplasty/tympanoplasty|child having repair of eardrum because of hole in eardrum after tube extruded or after tube removal
62104133|NCT06617689|EXPERIMENTAL|Arm 1: Group-based teaching|In this arm, all three educational activities are included: Teaching (in a group), distribution of free dental hygiene samples, and advice on reading the customised website. This arm is compared to Arm 2.
62104134|NCT06617689|ACTIVE_COMPARATOR|Arm 2: Comparator to Arm 1|In this arm, patients are distributed free dental hygiene samples, and given advice on reading the customised website. This arm is compared to Arm 1.
62296808|NCT03332069|EXPERIMENTAL|Study|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)
62296809|NCT03332069|ACTIVE_COMPARATOR|Control|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin
62296810|NCT02163070|EXPERIMENTAL|whey drink|consumption of 220 milliliters of whey drink three times a week,
62296811|NCT02163070|EXPERIMENTAL|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
62296812|NCT02163070|EXPERIMENTAL|vitaminE|consumption of 400 milligrams of vitamin E three times a week,
62666022|NCT00762788|ACTIVE_COMPARATOR|lotrafilcon B contact lens|O2Optix
62666023|NCT00762788|ACTIVE_COMPARATOR|balafilcon A contact lens|PureVision
62104135|NCT06617689|EXPERIMENTAL|Arm 3: Goodiebag|In this arm, patients are distributed free dental hygiene samples, and given advice on reading the customised website. This arm is compared to Arm 4.
62104136|NCT06617689|ACTIVE_COMPARATOR|Arm 4: Comparator to Arm 3|In this arm, patients are adviced on reading the customised website. This arm is compared to Arm 3.
62104137|NCT02074956|EXPERIMENTAL|Cohort 1 AERAS-404|"H4 Antigen at 5 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
62104138|NCT02074956|EXPERIMENTAL|Cohort 2 AERAS-404|"H4 Antigen at 15 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
62104139|NCT02074956|EXPERIMENTAL|Cohort 3 AERAS-404|"H4 Antigen at 50 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
62104140|NCT02074956|EXPERIMENTAL|Cohort 4 AERAS-404|"H4 Antigen at 150 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
62104141|NCT02074956|EXPERIMENTAL|Cohort 5 AERAS-404|"H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer~2 doses at Study days 0 and 56"
62104142|NCT06554483|EXPERIMENTAL|neuroscience based proprioceptive exercise training group|Neuroscience based proprioceptive training using laser pointer A pre-created wallpaper indicating various directions is fixed on the wall 90 cm away from the patient (at the level of the patient's knee when the patient is standing upright). Then, the laser pointer (producted by NMC training system) will fixed to the patient's knee with the help of a velcro so as not to interfere with the patient's knee movement. At the beginning of the exercise, the patient is asked to move the light on the laser pointer to the midpoint of the wallpaper. The patient is then asked to follow the instructions on the wallpaper by moving the knee in flexion-extension, medio-lateral directions. These instructions are continued throughout the exercise in different directions. Meanwhile, the patient is asked to perform mild cognitive tasks such as counting numbers, names of people starting with any letter, city names or animal names. The training continued for approximately 20 minutes.
62296813|NCT02163070|NO_INTERVENTION|D- control|control group: no intervention,
62296814|NCT03744650|EXPERIMENTAL|"Care4Heart programme"|The single group pretest and repeated posttest longitudinal study design is adopted in the main study. All the recruited participants received the study intervention
62296815|NCT04792294||Lung transplant recipients with chronic lung allograft dysfunction|Lung transplant recipients with chronic lung allograft dysfunction, who underwent extracorporeal photopheresis
62296816|NCT06179472|EXPERIMENTAL|Balloon Arm|Participants who consent to the insertion and the removal of the Balt GOLDBAL2 Balloon.
62296817|NCT06179472|NO_INTERVENTION|No Treatment|Patients who have been diagnosed with severe CDH at our site but choose not to participate in the study.
62296818|NCT06041555||ISRAR Cohort|All patient treated with the LINAC UNITY MRI radioguided radiotherapy for a prostate, kidney cancer, cervix, head and neck cancer or glioblastoma.
62296819|NCT03290014||Good sleepers|COPD patients with good sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
62666024|NCT00762788|ACTIVE_COMPARATOR|comfilcon A contact lens|Biofinity
62666025|NCT00762788|ACTIVE_COMPARATOR|etafilcon A contact lens|ACUVUE 2
62666026|NCT03560596|EXPERIMENTAL|High Risk Latino Patients Adherence Intervention|74 high risk Latinos with uncontrolled hypertension
62666027|NCT03560596|ACTIVE_COMPARATOR|High Risk Latinos Usual Care|74 high risk Latinos with uncontrolled hypertension
62296820|NCT03290014||Bad sleepers|COPD patients with poor sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
62296821|NCT04036825|EXPERIMENTAL|Liquid Nutritional Supplement from Hospital Product|This group received liquid nutritional supplement from hospital product. The product is in a form of low lactose milk ready to drink with volume 200 ml and will be given 2 times daily for 14 days. This product is consist of 1.017 kcal/ml, 10 vitamin and 9 mineral
62666028|NCT02439619|EXPERIMENTAL|Feasibility Trial|
62666029|NCT04747002|ACTIVE_COMPARATOR|Administration Group|Patients who are injected with DSP-7888.
62666030|NCT04747002|NO_INTERVENTION|Non-administration Group|Patients who are only under observation.
62666031|NCT04545372|EXPERIMENTAL|the study group|the study group (GA) was treated only by the disease modifying drug (interferon beta-1a) in addition to aerobic exercise.
62666032|NCT04545372|NO_INTERVENTION|the control group|control group (GB)was treated only by the disease modifying drug (interferon beta-1a)
62666033|NCT00694122|ACTIVE_COMPARATOR|Glargine (Lantus) insulin|"Long acting insulin, glargine, that subject currently used as an outpatient. SC injections. Dose given at 22:00 is based on past week blood glucose data during evening overnight hours and AM glucose. 20.2 +/- 11.7 units glargine (mean +/- SD).~Glargine (Lantus): Sanolfi Aventis~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the NPH insulin arm."
62104143|NCT06554483|ACTIVE_COMPARATOR|Proprioceptive exercise group|A proprioceptive training regimen will established with Swiss balls. The proprioceptive activities are advanced on a weekly basis in order to test the patient's balance in response. Patients have training in three stages: beginning, intermediate, and advanced. Each exercise is performed as 3x10 repetitions. Between sets, 2-3 minutes rest breaks is given. The beginning phase is applied in the 1st and 2nd weeks, the intemediate phase in the 3rd and 4th weeks, and the advanced phase in the 5th and 6th weeks.
62104144|NCT01253824|EXPERIMENTAL|NPC-01|1mg norethisterone and 0.02mg ethinyl estradiol
62104145|NCT01253824|ACTIVE_COMPARATOR|IKH-01|1mg norethisterone and 0.35mg ethinyl estradiol
62104146|NCT06053931|NO_INTERVENTION|Control group|"The women will fill out an descriptive characteristics questionnaire, which include questions such as age, education and employment status, number of pregnancies and children etc. Mothers will be asked to mark before breastfeeding on their comfort on the Visual Analog Scale. The number 0 on the scale indicates that it is not comfortable at all, and the number 10 indicates that the comfort is complete.The baby's stress level will measure with the Newborn Stress Scale before breastfeeding. While the mother is breastfeeding her baby, the breastfeeding process will be evaluated by the researcher with the LATCH Breastfeeding Assessment Tool. Baby's stress level will be evaluated at the 1st minute of breastfeeding with the Newborn Stress Scale. After the breastfeeding process is completed, the mother will be asked to fill out the Visual Analog Scale again to evaluate her comfort."
62104147|NCT06053931|EXPERIMENTAL|Lullaby group|"The women will fill out an descriptive characteristics questionnaire. Mothers will be asked to mark before breastfeeding on their comfort on the scale.~The baby's stress level will measure with the Newborn Stress Scale before breastfeeding.~Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes.~During the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~The baby will be observed by the researcher at the first minute of breastfeeding, and the Newborn Stress Scale will be filled in again.~The LATCH assessment will be done within the first 15 minutes of breastfeeding. After breastfeeding is over, they will be asked to fill in the Visual Analog Scale in order to evaluate the comfort of the mother."
62104148|NCT06053931|EXPERIMENTAL|White noise group|"The women will fill out an descriptive characteristics questionnaire. Mothers will be asked to mark before breastfeeding on their comfort on the scale.~The baby's stress level will measure with the Newborn Stress Scale before breastfeeding.~Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes During the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~The baby will be observed by the researcher at the first minute of breastfeeding, and the Newborn Stress Scale will be filled in again.~The LATCH assessment will be done within the first 15 minutes of breastfeeding. After breastfeeding is over, they will be asked to fill in the Visual Analog Scale in order to evaluate the comfort of the mother."
62104149|NCT05730205|ACTIVE_COMPARATOR|Nexplanon|
62104150|NCT05730205|NO_INTERVENTION|Baseline|
62104151|NCT00233792|OTHER|1|sirolimus coated Bx VELOCITY stent - fast release
62104152|NCT00233792|OTHER|2|sirolimus coated Bx VELOCITY stent - slow release
62104153|NCT00218556|EXPERIMENTAL|Depression prevention|Cognitive behavioral treatment for depression.
62104154|NCT00218556|NO_INTERVENTION|Control|Treatment as usual.
62666034|NCT00694122|ACTIVE_COMPARATOR|NPH insulin|"Long acting insulin, NPH, that participant was currently while an outpatient. SC injections. Dose (units) given at 22:00 is based on past week blood glucose during evening overnight period and AM glucose. 20.7 +/- 10.0 units NPH (mean +/- SD).~NPH: Eli Lilly~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the glargine (Lantus) insulin arm."
62666035|NCT00256607||coronary artery calcium (CAC)|Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
62666036|NCT02279251|ACTIVE_COMPARATOR|Brief CBT (VÅG)|This is a brief five session CBT group intervention developed at Uni Research. The intervention include self-help material (Psychological First Aid) for the adolescents to use at home between sessions.
62104155|NCT05448261|EXPERIMENTAL|Emotion-centered problem-solving intervention (EPi)|The EPi comprises four weekly 60 minutes individual face-to-face session (45 minutes of emotion-centered problem-solving intervention and 15 minutes of stroke education), followed by two bi-weekly telephone follow-ups (30 minutes) and one face-to-face round up session (60 minutes). The content of the stroke education will be based on a developed booklet for local family caregivers (please refer to control group).
62104156|NCT05448261|SHAM_COMPARATOR|Stroke education|The CG will receive basic education on stroke caregiving, as research indicates that basic education is not effective in improving problem-solving coping abilities and depressive symptoms. Four weekly individual stroke education (60 minutes/session) will be conducted by a trained research nurse. It will be based on a developed information booklet for local stroke caregivers. The participants will received three biweekly phone calls for general greetings. Questions relating to stroke caregiving raised by the caregivers will be answered according to the educative content. Any extra information provided will be documented.
62468561|NCT01066182|EXPERIMENTAL|DHA supplement|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
62666037|NCT02279251|ACTIVE_COMPARATOR|Established CBT program (Cool Kids)|An established, 10 session CBT group program (school version) developed by researchers at Macquarie University, Australia. The intervention has previously not been evaluated with Norwegian adolescents.
62104157|NCT06714617|EXPERIMENTAL|Dose Escalation|
62104158|NCT06714617|EXPERIMENTAL|Dose Finding|
62104159|NCT06714617|EXPERIMENTAL|Dose Expansion|
62666038|NCT02279251|NO_INTERVENTION|Waitlist|Waiting period is ten weeks, then participants are randomized to one of the two active interventions
62666039|NCT04273789|EXPERIMENTAL|far infrared reflecting sleepwear|Sleepwear (shorts + tshirt) with far infrared reflecting ceramic print produced by Dagsmejan AG (Zurich, Switzerland)
62666040|NCT04273789|PLACEBO_COMPARATOR|Placebo sleepwear|Sleepwear (shorts + tshirt)
62296822|NCT04036825|PLACEBO_COMPARATOR|Placebo|This group received standard liquid nutritional supplement as a placebo. Placebo will be given 2 times daily for 14 days
62296823|NCT01213056|ACTIVE_COMPARATOR|Mindfulness Based Cognitive Therapy * (MBCT)|Mindfulness based cognitive therapy aimed to improve coping with, and managing chronic headache pain.
62666041|NCT03565653|EXPERIMENTAL|High dietary salt|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing uniodized table salt. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
62666042|NCT03565653|EXPERIMENTAL|Placebo|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing a placebo (dextrose). Participants will complete both interventions in random order. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
62666043|NCT06139640|ACTIVE_COMPARATOR|The effects of rose oil on pain and anxiety level on pediatric dental patient|Rose oil aromatherapy
62666044|NCT06139640|NO_INTERVENTION|The effects of no treatment on pain and anxiety level on pediatric dental patient|
62666045|NCT06334900||Anti-GAD encephalitis|This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.
61912640|NCT04839562|PLACEBO_COMPARATOR|placebo|Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
62666046|NCT02691611||Alpha-1 Antitrypsin|All AATD patients who will start treatment with alpha-1 antitrypsin augmentation therapy
62666047|NCT02691611||Healthy Control|Healthy controls with no lung diseases
62666048|NCT04040855|EXPERIMENTAL|Intervention|Patients in the intervention groups received multi-professional medication reviews. A nurse performed a symptom evaluation, a pharmacist assessed the drug list and made adjustment suggestions and finally a physician took action and performed medication changes.
62666049|NCT04040855|NO_INTERVENTION|Control|Patients were treated according to the usual routine.
62666050|NCT01926600||PO|administrated by per oral
62666051|NCT01926600||IV|Administrated by intravenous
62666052|NCT01926600||SL|administrated by sublingual
61912641|NCT02983318||PET/MRI using 18[F]EPPA ligand|given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand
61912642|NCT02042820||Dry Eye Disease|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~* Tear Break Up Time (TBUT)~* Ocular Surface Disease Index (OSDI)~* Schirmer's II test~* Conjunctival staining with lissamine green~* Corneal staining with fluorescein~* Conjunctival redness assessment"
61912643|NCT02042820||Control|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~* TBUT~* OSDI~* Schirmer's II test~* Conjunctival staining with lissamine green~* Corneal staining with fluorescein~* Conjunctival redness assessment"
61912644|NCT05069701|EXPERIMENTAL|Healthy volunteers|SVV test will be done.
61912645|NCT01789931|EXPERIMENTAL|Research arm|"The participants will undergo an examination day in which they will complete VO2max test to evaluate their aerobic fitness. Afterwards they'll undergo 3 heat tolerance test (HTT) days: without CB protective clothing, with CB protective clothing, and with work clothes. During the tests, a Lifebeam sensor will be attached to their skin."
61912646|NCT02073383|EXPERIMENTAL|Around Artery|"Intervention Name: Axillary brachial plexus block~Group A: 30 ml of 0.375% bupivacaine will be injected around the artery . If this were a clock, would deposit 7,5 ml of anesthetic in positions 0, 3, 6 and 9 ."
61912647|NCT02073383|EXPERIMENTAL|Two injections|Group 2: 30 ml of bupivacaine 0.375 % below the artery will be injected in the 6 o'clock position .
61912648|NCT02073383|ACTIVE_COMPARATOR|Perineural|Group Perineural : 10 ml of bupivacaine 0.375 % will be injected around the median, ulnar and radial nerves .
61912649|NCT05171452||Group A: Adult IBD with active inflammation|
61912650|NCT05171452||Group B: Adult IBD in remission|
62104160|NCT05876910|EXPERIMENTAL|Voice and Electrocorticography (ECoG) recording during Speech Production Tasks|Participants produce speech following visual cues on a computer while ECoG signals for neural activity and voice was recorded during their inpatient hospitalization at the University of California, San Francisco (UCSF).
62104161|NCT06631651|EXPERIMENTAL|Brachioradialis Release Group|During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture
62104162|NCT06631651|SHAM_COMPARATOR|Classic (Non-brachioradialis Release) Group|During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed
62104163|NCT03450876||Healthy Control|Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
62666053|NCT02416141|ACTIVE_COMPARATOR|Fast release oro-dispersible tramadol|"This group receives a fast release oro-dispersible tramadol 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of fast release oro dispersible tramadol 50 mg"
62666054|NCT02416141|PLACEBO_COMPARATOR|Placebo-controlled arm|"This group receives a placebo 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of placebo"
62666055|NCT05979597|ACTIVE_COMPARATOR|Group SFIB (Suprainguinal fascia iliaca block)|In the patient lying in the supine position, a high-frequency linear probe is inserted under sterile conditions, using an in-plane technique, 1 cm cephalad of the inguinal ligament with a needle. Using hydro-dissection, the fascia iliaca is separated from the iliac muscle and a space is created where the needle can be advanced cranially, and the procedure will be completed by injecting local anesthetic into this space.
62666056|NCT05979597|ACTIVE_COMPARATOR|Group SFIB+dexa (Suprainguinal fascia iliaca block+dexamethasone)|In the patient lying in the supine position, a high-frequency linear probe is inserted under sterile conditions, using an in-plane technique, 1 cm cephalad of the inguinal ligament with a needle. Using hydro-dissection, the fascia iliaca is separated from the iliac muscle and a space is created where the needle can be advanced cranially, and the procedure will be completed by injecting local anesthetic+dexamethasone into this space.
62666057|NCT00422435|EXPERIMENTAL|Drug eluting stent|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
62104164|NCT03450876||24 to < 36 months post-ipilimumab treatment|24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands
62666058|NCT02471742||NAC-PC|patients treated with neoadjuvant chemotherapy and NAC-sparing mastectomy
62666059|NCT02471742||NAC|patients treated NAC-sparing mastectomy and adjuvant therapy
62104165|NCT03450876||≥ 36 to < 48 months post-ipilimumab treatment|36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands
62104166|NCT03450876||≥ 48 months post-ipilimumab treatment|Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands
62104167|NCT01737008|EXPERIMENTAL|Dacomitinib with Radiotherapy|Dacomitinib, 15mg to 45mg orally, once daily. Radiotherapy, once daily (Monday to Friday) over six weeks.One day on weeks 2 to 6 the participants will receive treatment twice daily (bid).
62104168|NCT01737008|EXPERIMENTAL|Dacomitinib and Chemoradiotherapy|Dacomitinib: 15mg to 45mg orally, once daily. Radiotherapy: Once daily (Monday to Friday) over seven weeks. Twice daily (bid) treatments may be introduced to compensate for treatment days missed due to statutory holidays, or machine maintenance. Cisplatin: 100mg/m2 intravenously; weeks 1, 4, and 7.
62104169|NCT01594502||Dutasteride Year 2 PCa|Subject assigned to dutasteride, prostate cancer found on Year 2 biopsy.
62104170|NCT01594502||Placebo Year 2 no PCa, Year 4 PCa|Subject assigned to placebo, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
62104171|NCT01594502||Dutasteride Year 2 no PCa, Year 4 PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
62104172|NCT01594502||Placebo, Year 2 and 4 no PCa|Subject assigned to placebo, no prostate cancer found on Year 2 or Year 4 biopsy.
62104173|NCT01594502||Dutasteride, Year 2 and 4 no PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 or Year 4 biopsy.
62468562|NCT01066182|PLACEBO_COMPARATOR|Sunflower oil capsule|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
62468563|NCT05817747|EXPERIMENTAL|Surgery|Participants will after the dialogue support tool has been undergo surgery.
62296824|NCT01213056|NO_INTERVENTION|Delayed Treatment Control * (DT)|
62296825|NCT02176486|EXPERIMENTAL|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
62104174|NCT01594502||Placebo, Year 2 PCa|Subject assigned to placebo, prostate cancer found on Year 2 biopsy.
62104175|NCT02978521|EXPERIMENTAL|Intervention Group|"Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:~12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill."
62104176|NCT02978521|NO_INTERVENTION|Control Group|CG will receive information and recommendations on physical activity
62104177|NCT05165290|ACTIVE_COMPARATOR|LAT, 0.005%|Commercially available FDA-approved generic latanoprost ophthalmic solution, 0.005%
62104178|NCT05165290|EXPERIMENTAL|TC-002|TC-002, TearClear latanoprost ophthalmic solution, 0.005%
62104179|NCT01320371||Barbed sutures|Barbed sutures are self-anchoring, requiring no knots for wound closure.
62104180|NCT01320371||Knotted sutures|Knotted sutures used for traditional surgical closures.
62104181|NCT02272517|ACTIVE_COMPARATOR|Escitalopram 10-20 mg|Encapsulated tablets once daily for 8 weeks
62104182|NCT02272517|EXPERIMENTAL|Vortioxetine 10-20 mg|Encapsulated tablets once daily for 8 weeks
62104183|NCT05926271|EXPERIMENTAL|Genotype guided arm|"In this study arm, patients with Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) who are extensive or ultra-rapid metabolizers as per their CYP2C19 genotype and have undergone successful percutaneous coronary intervention (PCI) will receive a genotype-guided monotherapy.~The intervention will be clopidogrel, a potent P2Y12 inhibitor, administered in accordance with the patient's specific genotype. Clopidogrel following PCI will be given with an initial loading dose (300-600mg orally), followed by a maintenance dose of 75mg daily for a defined period, at least 6 months."
62104184|NCT05776576||Special needs children and adolescents with physical disabilities and their parents|"Project consists of three main stages as evaluation, education and experimentation. For evaluation, firstly physical activity levels of individuals with special needs, barriers in physical activity, and motivators will be determined with an interactive roundtable meeting with children, adolescents and their parents. Afterwards, posture analyzes of individuals with special needs will be performed by physiotherapists. For education, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after that posture and ergonomics education will be given to the participants individually. For experimentation, group exercises, dance therapy and technology-supported exercise educations will be implemented by physiotherapists, taking into account the previous evaluations."
62104185|NCT04742855||Group A|It will consist of 10 adults and 5 children. They will get the yogurt strains
62104186|NCT04742855||Group B|It will consist of 10 adults and 5 children. They will get the Bifidobacterium strains.
62104187|NCT04742855||Group C|It will consist of 10 adults and 5 children. They will get the placebo.
62468564|NCT05817747|PLACEBO_COMPARATOR|Non-surgery|Participants will after the dialogue support tool has been used not undergo surgery.
62666060|NCT02471742||PC|patients treated with neoadjuvant chemotherapy and conventional mastectomy
62666061|NCT01149252|PLACEBO_COMPARATOR|Psoralait|
62666062|NCT03107000|ACTIVE_COMPARATOR|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
62666063|NCT03107000|ACTIVE_COMPARATOR|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
62104188|NCT03299387|ACTIVE_COMPARATOR|Oral Nitrofurantoin|Participants will randomized to oral nitrofurantoin
62104189|NCT03299387|ACTIVE_COMPARATOR|Intravesical Gentamicin|Participants will be randomized to intravesical gentamicin
62104190|NCT06141057|EXPERIMENTAL|Group 1: Delayed regimen|12 volunteers receiving three doses of 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62104191|NCT06141057|EXPERIMENTAL|Group 2: Delayed Fractional Regimen|12 volunteers receiving two doses of 50 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and one dose of 10 µg RH5.1 with 50 µg of Matrix-M on day 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
62104192|NCT04295538|EXPERIMENTAL|Elezanumab|Participants will receive elezanumab dose A
62104193|NCT04295538|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for elezanumab
62104194|NCT03095911|ACTIVE_COMPARATOR|News with Spin|News items reporting results of RCTs with spin
62666064|NCT05791591|EXPERIMENTAL|NUV001 - IR|Sickle cell disease patients receiving NUV001 Immediate release gel capsule formulation
62666065|NCT05791591|EXPERIMENTAL|NUV001 - GR|Sickle cell disease patients receiving NUV001 Gastro resistant gel capsule formulation
62104195|NCT03095911|EXPERIMENTAL|News without spin|News items reporting results of RCTs without spin
62104196|NCT00097253|EXPERIMENTAL|Lavender|
62666066|NCT05791591|PLACEBO_COMPARATOR|Placebo|Sickle cell disease patients receiving Placebo
62666067|NCT05967559|EXPERIMENTAL|Experiment group|The experimental group received online flipped learning training for six weeks.
62666068|NCT05967559|OTHER|Control groups|The control group received traditional learning training for 6 weeks.
62104197|NCT00097253|EXPERIMENTAL|Citrus|
62104198|NCT00097253|PLACEBO_COMPARATOR|Water|
62104199|NCT05925712|EXPERIMENTAL|Crossover ABA|Group 1 starts using the ventilating suspension system (condition A), group 2 starts using non-ventilating suspension system (condition B) and then they cross-over to the other system, two times.
62296826|NCT02176486|EXPERIMENTAL|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
62296827|NCT02176486|EXPERIMENTAL|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
62296828|NCT02176486|EXPERIMENTAL|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
62296829|NCT02176486|PLACEBO_COMPARATOR|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in 28-day cycle, Cycles 1 through 3.
62296830|NCT00963807|EXPERIMENTAL|Treatment|Patients receive docetaxel IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo FDG PET/CT, FLT PET/CT, and thoracic CT at baseline and the end of cycles 1 and 2 and then undergo surgery.
62104200|NCT05925712|EXPERIMENTAL|Crossover BAB|Group 1 starts using the ventilating suspension system (condition A), group 2 starts using non-ventilating suspension system (condition B) and then they cross-over to the other system, two times.
62296831|NCT02867696|ACTIVE_COMPARATOR|Standard Care|Standard Care serves as the no treatment control in this project. Participants in this group will receive the typical care from their surgeon following bariatric surgery. No additional interventions will be given to participants randomized to this group.
61912651|NCT04173598|EXPERIMENTAL|Intervention Group|An intervention group consisting of a dyad (patient + family carer) benefiting in addition to the usual treatment from the intervention for the family carer.
61912652|NCT04173598|ACTIVE_COMPARATOR|Control Group|A group consisting of a dyad (patient + caregiver) with usual care (control group)
62296832|NCT02867696|EXPERIMENTAL|Technology-based Intervention (TECH)|TECH is the experimental group in this project. A minimal-contact technology-based intervention for weight management will be given to this group in addition to the standard or typical care received from their surgeon following bariatric surgery.
62296833|NCT04746326|OTHER|Conservative treatment|Conservative treatment stopping oral intake, intravenous antibiotic therapy.
62296834|NCT04746326|OTHER|Operative treatment|Operative procedure Right hemicolectomy Wedge resection of cecum Diverticulectomy + appendectomy Diverticulectomy Appendectomy + drainage
62296835|NCT06256848|EXPERIMENTAL|rehabilitation treatment+ Myofascial Release group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
62296836|NCT06256848|ACTIVE_COMPARATOR|rehabilitation treatment group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
62296837|NCT05576220|EXPERIMENTAL|Intervention group|Subjects being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
61912653|NCT01646866||Siblings of Children with Autism Spectrum Disorders|This group is comprised of 6-12 month old siblings of a child with an expert clinical diagnosis of autism spectrum disorders.
61912654|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
61912655|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
61912656|NCT01845623|EXPERIMENTAL|Treatment A|
61912657|NCT01845623|EXPERIMENTAL|Treatment B|
61912658|NCT01845623|PLACEBO_COMPARATOR|Treatment C|
61912659|NCT04650061|EXPERIMENTAL|PIMA Group|"1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D21-D90-D120-D180 depending of the care plan, through the channel that belong for each care plan"
61912660|NCT04650061|ACTIVE_COMPARATOR|Control|"1. Training program~2. Schedule next visits~3. Follow-up D21-D90-D120-D180 using the same process: visit at home or phone."
61912661|NCT05053932||Patients included in Drepagreffe 1 study (NCT01340404)|biological collection
61912662|NCT02816567|EXPERIMENTAL|NMBA group|
61912663|NCT02816567|PLACEBO_COMPARATOR|placebo group|
61912664|NCT00115323|ACTIVE_COMPARATOR|1|Problem solving intervention
61912665|NCT00115323|ACTIVE_COMPARATOR|2|Attention control intervention
61912666|NCT01753050|NO_INTERVENTION|Standard care|No specific hemodynamic optimization measures
61912667|NCT01753050|EXPERIMENTAL|Hemodynamic optimization|Hemodynamic optimization by stroke volume monitoring
61912668|NCT01650129|EXPERIMENTAL|BIAsp|
61912669|NCT01650129|EXPERIMENTAL|BHI|
61912670|NCT00053898|ACTIVE_COMPARATOR|Group 1|tamoxifen 20 mg/day and an anastrozole look-alike placebo for 5 years
61912671|NCT00053898|EXPERIMENTAL|Group 2|anastrozole, 1 mg/day and an tamoxifen look-alike placebo for 5 years
61912672|NCT04942457|EXPERIMENTAL|Fasting|Participants will be councelled and accompanied to follow a prolonged fasting regime of 7-10 days in an outpatient setting under medical supervision. Additionally qualitative interviews will be conducted by few participants in the experimental arm, as well as their respective Healthcare Providers (Doctors/Medical Staff).
61912673|NCT04942457|NO_INTERVENTION|Control group|waiting list, usual diet should be maintained
61912674|NCT04564131|EXPERIMENTAL|reflexology practice|"Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism.~Experimental group participants will be given 10 sessions of reflexology massage twice a week for 5 weeks. A total of three follow-ups will be performed in the 1st session, the 5th session and the 10th session. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied."
61912675|NCT04564131|EXPERIMENTAL|Control|Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism. 1. 3. 5. A total of three follow-ups will be done once in the week. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied.
61912676|NCT00714571|ACTIVE_COMPARATOR|MST healthy older adults Stage 1|Mnemonic strategy training
61912677|NCT00714571|ACTIVE_COMPARATOR|MST MCI Stage 1|Exposure training
61912678|NCT00714571|ACTIVE_COMPARATOR|XP healthy older adults Stage 1|XP healthy older adults Stage 1
61912679|NCT00714571|ACTIVE_COMPARATOR|XP MCI Stage 1|XP MCI Stage 1
62104201|NCT04372992|EXPERIMENTAL|Early stoma closure|Ileostomy closure between 30 and 40 day after rectal resection
62104202|NCT04372992|ACTIVE_COMPARATOR|Delayed stoma closure|Ileostomy closure 15 days from the end of adjuvant therapy (up to 60 days)
62296838|NCT05576220|NO_INTERVENTION|Control Group|Retrospective data from the control group comprised of 105 patients directly preceding the intervention group who are underwent stem cell transplant or CAR-T therapy. Such control group information will be obtained via a research data request. Only de-identified data will be obtained for these subjects.
62296839|NCT00789347||1|Healthy volunteers
61912680|NCT00714571|ACTIVE_COMPARATOR|MST healthy older adults Stage 2|MST healthy older adults Stage 2
61912681|NCT00714571|ACTIVE_COMPARATOR|SCT healthy older adults Stage 2|SCT healthy older adults Stage 2
61912682|NCT05171725||Sleep and Circadian Disorders|Observational deep phenotyping of people presenting with Sleep and Circadian disorders. Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
61912683|NCT05171725||Neurocognitive Disorders|Observational deep phenotyping of people presenting with Dementia (including Alzheimer's disease, vascular disease, frontotemporal dementia). Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
61912684|NCT05171725||Epilepsy disorders|Observational deep phenotyping of people presenting with seizures and Epilepsy disorder. Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
61912685|NCT05171725||Healthy controls|Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
61912686|NCT01935310|EXPERIMENTAL|imiquimod use in photoaging|Evaluate the efficacy and safety of imiquimod as a treatment option for photoaging photoaging equal to or greater than 3.
61912687|NCT00432601|EXPERIMENTAL|Arm 1|Patients will receive Michigan Cancer Consortium decision aid.
61912688|NCT00432601|ACTIVE_COMPARATOR|Arm 2|Patients will receive National Comprehensive Cancer Network decision aid.
61912689|NCT03273569|EXPERIMENTAL|Women with placenta accreta|PDI-UC protocol
61912690|NCT03550859|EXPERIMENTAL|Duowell Tab. 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
61912691|NCT03550859|ACTIVE_COMPARATOR|Micardis Tab. 40mg|Telmisartan 40mg qd for 48 weeks
61912692|NCT04980326|EXPERIMENTAL|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2) in addition to Psychological First Aid (PFA) and care-as-usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.~Participants allocated to the experimental arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria."
61912693|NCT04980326|ACTIVE_COMPARATOR|Psychological First Aid (PFA)|Participants allocated to the control arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.
61912694|NCT03705936|SHAM_COMPARATOR|Sham 1Hz rTMS--5Hz rTMS|Participants will receive sham 1Hz rTMS, then immediately followed by 5Hz rTMS.
61912695|NCT03705936|EXPERIMENTAL|1Hz rTMS--5Hz rTMS|Participants will receive 1Hz rTMS, then immediately followed by 5Hz rTMS.
61912696|NCT03705936|EXPERIMENTAL|1Hz rTMS--30-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 30 minutes break, then followed by 5Hz rTMS.
61912697|NCT03705936|EXPERIMENTAL|1Hz rTMS--60-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 60 minutes break, then followed by 5Hz rTMS.
61912698|NCT03705936|SHAM_COMPARATOR|Sham 5Hz rTMS--1Hz rTMS|Participants will receive sham 5Hz rTMS, then immediately followed by 1Hz rTMS.
61912699|NCT03705936|EXPERIMENTAL|5Hz rTMS--1Hz rTMS|Participants will receive 5Hz rTMS, then immediately followed by 1Hz rTMS.
61912700|NCT03705936|EXPERIMENTAL|5Hz rTMS--45-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 45 minutes break, then followed by 1Hz rTMS.
61912701|NCT03705936|EXPERIMENTAL|5Hz rTMS--90-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 90 minutes break, then followed by 1Hz rTMS.
61912702|NCT00296608|ACTIVE_COMPARATOR|Radiotherapy|RT was delivered with photons from a linear accelerator with an energy level of 8MVor above.
62104203|NCT04157842|EXPERIMENTAL|total hip replacement with subtrochanteral osteotomy|subtrochanteral osteotomy is applied during total hip replacement
62104204|NCT04157842|SHAM_COMPARATOR|total hip replacement with no osteotomy|no osteotomy is applied during total hip replacement.
62104205|NCT01724255||staple removal day 4 dressing removal day 1|early staple removal and early dressing removal
62296840|NCT00789347||2|Patient with neuropathic pain
62296841|NCT00789347||3|patients without neuropathic pain
62296842|NCT03343821||Frail elderly patient|
62296843|NCT01999738|EXPERIMENTAL|Part A - MTD (Treatment 1)|"Treatment 1 is BIW on Days 1, 4, 8, and 11 of a 3-week schedule (BIW).~Intervention: EC1456 and EC20"
62296844|NCT01999738|EXPERIMENTAL|Part A - MTD (Treatment 2)|"Treatment 2 is EC1456 QW on Days 1 and 8 of a 3-week schedule (QW).~Intervention: EC1456 and EC20"
62666069|NCT04995159|EXPERIMENTAL|Poststent SAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with SAPT strategy
62666070|NCT04995159|ACTIVE_COMPARATOR|Poststent DAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with DAPT strategy
62104206|NCT01724255||staple removal day 4 dressing removal day 4|early staple removal and day 4 dressing removal
62104207|NCT01724255||staple removal day 7, dressing removal day 1|late staple removal and early dressing removal
62104208|NCT01724255||staple removal day 7, dressing removal day 7|late staple removal and late dressing removal
62104209|NCT01724255||staple removal day 7, dressing removal day 4|late staple removal and day 4 dressing removal
62104210|NCT02735187|ACTIVE_COMPARATOR|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
62104211|NCT02735187|ACTIVE_COMPARATOR|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
62104212|NCT05358717|EXPERIMENTAL|PTC518 5 mg|Participants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months.
62666071|NCT04561453||Resected Biliary Duct Cancer|
62666072|NCT00514527|EXPERIMENTAL|1|
62104213|NCT05358717|EXPERIMENTAL|PTC518 10 mg|Participants will receive PTC518 10 mg tablets once daily orally for 12 months.
62104214|NCT05358717|EXPERIMENTAL|PTC518 20 mg|Participants will receive PTC518 20 mg tablets once daily orally for 12 months.
62104215|NCT05358717|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to PTC518 tablets once daily orally for 12 months.
62104216|NCT02374333|EXPERIMENTAL|huCART19|CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection
62104217|NCT04517994|EXPERIMENTAL|Active Treatment|The intervention includes components from empirically validated interventions for intimate relationship difficulties and PTSD. This includes core themes of trust, self-esteem, power and control, conflict-management skills, and communication skills training.
62104218|NCT04517994|ACTIVE_COMPARATOR|Supportive Treatment|Broadly based on the principles and techniques of client centered (Rogerian) therapy, and the fundamental principles and practices for experiential group psychotherapy as specified by Yalom. The group also draws upon the work of Murphy's Supportive Therapy protocol specifically for group intervention with domestic abuse perpetrators.
62104219|NCT06629974|EXPERIMENTAL|Intervention group|Participants in this group were administered the pre-intervention introductory information form, The Parental Self-Efficacy Scale, the Zarit Care Burden Scale, the Perceived Stress Scale and the Family Empowerment Scale. Then, a group empowerment training program consisting of four sessions in total was applied to the participants. Two motivational interview sessions were conducted with each participant in the intervention group 10 days after the empowerment training program. One month after the motivational interview sessions were completed, post-test data were collected.
62296845|NCT01999738|EXPERIMENTAL|Part A - MTD (Treatment 3)|"Treatment 3 is EC1456 QW on Days 1, 8, and 15 of a 3-week schedule (CWD).~Intervention: EC1456 and EC20"
62296846|NCT01999738|EXPERIMENTAL|Part A - MTD (Treatment 4)|"Treatment 4 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule (QIW).~Intervention: EC1456 and EC20"
62296847|NCT01999738|EXPERIMENTAL|Part B - Efficacy (Treatment 5)|"Treatment 5 is EC1456 BIW. Once a dose is determined in Part A, Part B will begin with 3-6 subjects who will receive consecutive day dosing on Days 1, 2, 8, and 9 of a 3-week schedule. If this is not tolerated, the BIW cohort will continue with dosing on Days 1, 4, 8, and 11 of a 3-week schedule.~Intervention: EC1456 and EC20"
62296848|NCT01999738|EXPERIMENTAL|Part B - Efficacy (Treatment 6)|"Treatment 6 is EC1456 QW on Days 1 and 8 of a 3-week schedule or CWD on Days 1, 8 and 15 of a 3-week schedule.~Intervention: EC1456 and EC20"
62296849|NCT01999738|EXPERIMENTAL|Part B - Efficacy (Treatment 7)|"Treatment 7 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule for at least two cycles. If the patient is eligible to continue treatment (based upon treatment response and tolerability), he/she may opt to continue on the QIW schedule or change to the Treatment 6 regimen schedule (once its MTD and schedule have been determined).~Intervention: EC1456 and EC20"
62296850|NCT01902108|EXPERIMENTAL|Clonidine|Clonidine 150μg added to bupivacaine in a local infiltration before wound incision
62296851|NCT01902108|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine 0.25 % alone in the wound infiltration
62296852|NCT02806401|EXPERIMENTAL|landmark|landmark method_subclavian venous cannulation
62666073|NCT00514527|EXPERIMENTAL|2|
62666074|NCT00514527|EXPERIMENTAL|3|
62666075|NCT03718000|NO_INTERVENTION|Control|Participants in this group received no intervention during t he holiday season
62666076|NCT03718000|EXPERIMENTAL|Daily Self-Weighing (DSW)|Participants in this group performed daily self-weighing using digital WiFi scales during the holiday season
62104220|NCT06629974|NO_INTERVENTION|Control group|No intervention was applied to the control group. The data collection tools applied to the intervention group in the pre-test and post-test were also applied to the control group.
62666077|NCT00999076||Sputum with positive AFB smear|
62666078|NCT02730130|EXPERIMENTAL|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
62666079|NCT03606070|OTHER|Patients with NSCLC|"Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.~Patients will realize:~* a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~* a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
62666080|NCT00369018|ACTIVE_COMPARATOR|MAL 3|
62104221|NCT04700007|EXPERIMENTAL|Study group|
62296853|NCT02806401|ACTIVE_COMPARATOR|US_Ax|ultrasound guided axillary venous cannulation
62666081|NCT00369018|ACTIVE_COMPARATOR|MAL 12|
62666082|NCT00369018|ACTIVE_COMPARATOR|HAL 10, 3|
62666083|NCT00369018|ACTIVE_COMPARATOR|HAL 10, 12|
62104222|NCT06231628|EXPERIMENTAL|Patients|"A single arm with patients with advanced cancer who have all of the following:~1. refractory pain and/or gait disturbance caused by pelvic bone metastasis, did not respond to conservative treatment.~2. osteolytic lesion (in predominance) suitable for the pain.~3. limited life expectancy (less than 3 years) or stopping medical treatment.~Exclusion criteria:~There are no absolute contraindications for the procedure; however, the relative contraindications are:~1. patients in poor condition with an expected survival period of less than 3 months.~2. patients with stable course, with long life expectancy (more than 3 years) or those considered candidates for major pelvic surgery including tumor removal and hip arthroplasty.~3. presence of bone destruction with soft tissue mass contaminating important organs, nerves and blood vessels (improvement is not expected).~4. Patients refusing to give a written consent to the study protocol."
62104223|NCT04131829|NO_INTERVENTION|Healthy Controls|The healthy control group will be an age matched sample of unmedicated healthy adults who will be recruited and imaged once at baseline and the data compared with that of OCD subjects at baseline.
62104224|NCT04131829|EXPERIMENTAL|OCD Group|The OCD group will comprise of unmedicated individuals with clinically significant OCD symptoms. OCD Subjects will be randomized, double-blind, to receive immediate or delayed (by 6 weeks as a placebo lead-in) pharmacotherapy.
62104225|NCT02888613|OTHER|Mini laparotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with transperitoneal approach
62104226|NCT02888613|OTHER|Mini lumbotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with retroperitoneal approach
62104227|NCT03288220||Healthy volunteers|Healthy volunteers age 50 and older
62666084|NCT00369018|ACTIVE_COMPARATOR|HAL 40, 3|
62104228|NCT03288220||Stroke patients|Stroke patients aged 18 and older
62104229|NCT03645356|ACTIVE_COMPARATOR|fixed appliances|patients will be treated using fixed appliances in order to align their teeth after extraction of four premolars
62104230|NCT03645356|EXPERIMENTAL|clear aligners|patients will be treated using clear aligners in order to align their teeth after extraction of four premolars
62104231|NCT02549443|ACTIVE_COMPARATOR|Insulin|hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
62104232|NCT02549443|ACTIVE_COMPARATOR|Insulin and amino acids|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~Amino Acids (AA) in amounts to preserve normal AA"
62104233|NCT02549443|ACTIVE_COMPARATOR|Insulin and hyperaminoacidemia|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~AA in amounts to increase AA plasma concentrations to supra-normal levels (hyperaminoacidemia)"
62296854|NCT05405426|ACTIVE_COMPARATOR|Indication-based red blood cell transfusion strategy|Red blood cell transfusion will occur if the center-specific hemoglobin/hematocrit threshold for transfusion is met AND at least one of the following conditions is present: a) moderate or severe bleeding; b) reduced tissue oxygen delivery, defined as serum lactate \>5 mmol/L or 2 serum lactate levels \> 3 mmol/L measured 2 hours apart; or c) hemoglobin \< 8 g/dL or hematocrit \< 25%, except for neonates (age =\< 28 d) and children with single ventricle congenital heart disease (age \< 1 y) RBC transfusion for hemoglobin \< 10g/dL or hematocrit \<30% is allowed.
62296855|NCT05405426|OTHER|Center-specific hemoglobin/hematocrit threshold-based red blood cell transfusion strategy|Red blood cell transfusion will occur according to each study center's standard of care strategy, typically based on a particular hemoglobin threshold or hematocrit threshold. When hemoglobin or hematocrit decrease to the threshold, red blood cell transfusion is administered.
62296856|NCT04687124|ACTIVE_COMPARATOR|Fish oil|dietary counselling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
62296857|NCT04687124|PLACEBO_COMPARATOR|standard care|The departmental usual procedure with the possibility of requiring of a dietician when needed
62296858|NCT06657781||leptospirosis|patient suffering from leptospirosis
62296859|NCT06657781||bacterial|patient suffering from bacterial infections including in-hospital-acquired-infections
62666085|NCT00369018|ACTIVE_COMPARATOR|HAL 40, 12|
62104234|NCT04678934||Bicuspid aortic valve subgroup|For analysis in Bicuspid aortic valve population.
62104235|NCT06713135|EXPERIMENTAL|vamorolone|On Day 1, Subjects will roll over from a previous vamorolone program and continue treatment with vamorolone under this protocol. During the study, vamorolone will be administered at a dose range between 2 mg/kg/day and 6 mg/kg/day for boys weighing \<40 kg. For boys weighing 40 kg or above, the dose range will be 80 mg to 240 mg once daily.
62104236|NCT06575959|EXPERIMENTAL|Moderate Hepatic Impairment (HI)|Participants will receive a single oral dose of enlicitide on Day 1
62104237|NCT06575959|EXPERIMENTAL|Healthy Controls|Participants will receive a single oral dose of enlicitide on Day 1
62104238|NCT06575959|EXPERIMENTAL|Mild HI|Participants will receive a single oral dose of enlicitide on Day 1
62296860|NCT06657781||viral|patient suffering from viral infection except COVID-19
62296861|NCT06657781||Control|patients non infected
62666086|NCT01937442|EXPERIMENTAL|Thalidomide Celgene™ 200mg once daily|5-day period of thalidomide treatment
62666087|NCT01341041|EXPERIMENTAL|chlorine dioxide|2 arms
62666088|NCT01341041|ACTIVE_COMPARATOR|saline|one time wash with 50-100cc of normal saline
62666089|NCT02874898|ACTIVE_COMPARATOR|Heavy marijuana use|Heavy marijuana users with PTSD
62666090|NCT02874898|ACTIVE_COMPARATOR|No marijuana use|Non-marijuana users with PTSD
62104239|NCT06630741||patients in alternative midwifery units (AMU)|In alternative midwifery birth units: personalized follow-up with a midwife from the beginning of pregnancy, birth and parenthood preparation classes and delivery (birth room)
62104240|NCT06630741||patients in standard obstetric units (SOU)|In standard obstetric units, most full time midwives are rostered to work. They follow women during their pregnancy but not through labour. All low-risk pregnant women benefit from 5 prenatal consultations with a general practitioner, a midwife or an obstetrician, then 2 consultations with a midwife in maternity hospital of delivery. Couples have got the option to elaborate a birth project if desired.
62666091|NCT03974958|EXPERIMENTAL|AAA patients|Patients with abdominal aortic aneurysm (AAA)
62104241|NCT02755363|ACTIVE_COMPARATOR|osteopathic manual therapy (OMT group)|patients who will undergo manual osteopathic therapy.
62104242|NCT02755363|PLACEBO_COMPARATOR|control group (C group)|patients who will undergo manual therapy not aimed to decrease hyperinflation.
62104243|NCT05717985|ACTIVE_COMPARATOR|de-epithelized gingival graft|A type of mucogingival surgery where a gingival graft is harvested from the palate, prepared chairside and placed on a recipient site to augment it. Dressing material and sutures is placed at the donor site.
62104244|NCT05717985|EXPERIMENTAL|modified combined approach|A type of mucogingival surgery where a gingival graft is harvested from the palate, prepared chairside and placed on a recipient site to augment it. A part of the prepared tissues namely the epithelial layer is replaced at the donor site and sutured.
62104245|NCT05419557|ACTIVE_COMPARATOR|Intervention|12 week virtual family-based health eating program
62104246|NCT05419557|NO_INTERVENTION|Comparison|Standard in-office counseling about diet
62104247|NCT00782041|EXPERIMENTAL|1|Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
62104248|NCT04388488|EXPERIMENTAL|CONNECT TF|Trans-femoral amputees currently using a conventional handmade socket will be fitted with the CONNECT TF adaptable socket system for 6 weeks and their current existing conventional socket for 6 weeks, data collection on both sockets will be performed and outcomes compared.
62296862|NCT06657781||viral infection SARS-COv2 +|patient suffering from COVID-19 previously enrolled in PLAQCOVID trial.
62104249|NCT03712293|EXPERIMENTAL|BBB Disruption with Chemotherapy Arm|All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
62104250|NCT02751099||de novo renal transplanted patients|renal transplanted patients
62104251|NCT03489265|OTHER|Eluxadoline followed by Placebo|Following a 2-week run-in period, patients will receive Eluxadoline 100 mg twice daily for 4 weeks then placebo tablets taken twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
62104252|NCT03489265|OTHER|Placebo followed by Eluxadoline|Following a 2-week run-in period, patients will receive placebo twice daily for 4 weeks then Eluxadoline 100 mg twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
62296863|NCT00977652|ACTIVE_COMPARATOR|Active stimulation|Percutaneous posterior tibial nerve stimulation
62296864|NCT00977652|SHAM_COMPARATOR|sham stimulation|Inefficient percutaneous posterior tibial nerve stimulation
62296865|NCT03420560|EXPERIMENTAL|warmer temperature|To compare the incidence and intensity of pain on injection that is caused by propofol in warm temperature（27℃） versus normal temperature(23℃).
62296866|NCT03420560|PLACEBO_COMPARATOR|normal temperature|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol in different room temperature(27 VS 23).
62296867|NCT00716443|ACTIVE_COMPARATOR|Pliaglis® Cream|tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
62296868|NCT00716443|ACTIVE_COMPARATOR|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
62296869|NCT00503191|EXPERIMENTAL|Intention-based therapy treatment for autism|NeuroModulation Technique
62468565|NCT02478190|EXPERIMENTAL|Tight control|Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.
62104253|NCT05933720|ACTIVE_COMPARATOR|Patients who undergo routine conservative treatment|The patients who undergo routine conservative treatment for peripheral atherosclerotic occlusive disease as per clinical guidelines
62104254|NCT05933720|EXPERIMENTAL|Patients who undergo treatment with polypeptides|The patients who undergo treatment with a complex of polypeptides isolated from the vessels of cattle is administered in / m, adults 1 vial (5 mg) 1 time / day 2 times a week. The course of treatment is 10 injections.
62104255|NCT05933720|ACTIVE_COMPARATOR|Patients who undergo femoral-popliteal bypass with a synthetic graft above the knee|Patients who undergo the surgical method of treatment i.e. femoral-popliteal bypass grafting with a synthetic graft above the knee and routine conservative treatment as per clinical guidelines
62104256|NCT05933720|EXPERIMENTAL|Patients who undergo femoral-popliteal bypass grafting and treatment with polypeptides|Patients who undergo the surgical method of treatment i.e. femoral-popliteal bypass grafting with a synthetic graft above the knee with following treatment with a complex of polypeptides isolated from the vessels of cattle is administered in / m, adults 1 vial (5 mg) 1 time / day 2 times a week. The course of treatment is 10 injections.
62104257|NCT04301674||Occupational Asthma|Patients refered for assesment of occupational asthma
62104258|NCT04301674||Respiratory Healthy Control|Employees at Oslo University Hospital
62296870|NCT04918121|EXPERIMENTAL|Yutiq|A sustained-release steroid insert (Yutiq) will be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery.
62296871|NCT04918121|NO_INTERVENTION|Control|Non-study eye will not receive the Yutiq insert
62296872|NCT01128712|OTHER|Group 1|Pregabalin (150mg/day)
62296873|NCT01128712|OTHER|Group 2|Pregabalin (450mg/day)
62296874|NCT05250856|EXPERIMENTAL|CNP-201 1 mg|intravenous infusion on Day 1 and Day 8: 1 mg CNP-201
62296875|NCT05250856|EXPERIMENTAL|CNP-201 2 mg|intravenous infusion on Day 1 and Day 8: 2 mg CNP-201
62296876|NCT05250856|EXPERIMENTAL|CNP-201 4 mg|intravenous infusion on Day 1 and Day 8: 4 mg CNP-201
62666092|NCT03974958|EXPERIMENTAL|PAOD patients|patients with peripheral arterial obstructive disease (PAOD)
61912703|NCT00296608|EXPERIMENTAL|Chemotherapy and radiotherapy|The first CT cycle was administered from days 1 to 5 of the RT treatment. LV 20 mg/m2/d was delivered intravenously immediately before administration of FU. FU 350 mg/m2/d was delivered during 20 minutes in 100 mL of saline infusion, 1 hour before RT. The second cycle was administered from days 29 to 33 of the RT treatment using the same schedule.
61912704|NCT04156516|EXPERIMENTAL|HEART|sexual health intervention that focuses on communication skills
61912705|NCT04156516|ACTIVE_COMPARATOR|HealthyMinds|Attention-matched control: Growth mindset intervention
62296877|NCT05250856|EXPERIMENTAL|CNP-201 8 mg|intravenous infusion on Day 1 and Day 8: 8 mg CNP-201
62666093|NCT02641353|EXPERIMENTAL|Treatment A: Apremilast 30 mg Tablet - Fasted|A single oral dose of 30 mg apremilast tablet after an overnight fast.
62104259|NCT01119703||Arm 1: Healthy, elderly participants|Healthy participants 65 years old and older.
62296878|NCT05250856|PLACEBO_COMPARATOR|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
62296879|NCT04418817||Modulus XLIF Interbody System|
62296880|NCT05373238||Early Discharge|\< discharge before 24 hours
62666094|NCT02641353|EXPERIMENTAL|Treatment B: Apremilast 30 mg Oral Suspension - Fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.
62296881|NCT05373238||Late Discharge|discharge after 24 hours
62296882|NCT05013840||Physicians using neuromodulation|
62666095|NCT02641353|EXPERIMENTAL|Treatment C - Apremilast 30 mg Oral Suspension - Fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.
62666096|NCT03734094|EXPERIMENTAL|Ceramic Barrier|The use of a ceramic barrier to induce bone formation during GBR
62666097|NCT03734094|ACTIVE_COMPARATOR|Titanium mesh|The use of a titanium mesh to induce bone formation during GBR
62666098|NCT04415918|EXPERIMENTAL|Intervention group|Recruited patient according inclusion/exclusion criteria
62104260|NCT01119703||Arm 2: Healthy, young, participants|Healthy participants 25 to 40 years old.
62104261|NCT04675463|OTHER|Budesonide/Glycopyrronium/Formoterol arm|52 weeks treatment
61912706|NCT02982512|NO_INTERVENTION|Control recording|Recording of local field potentials without drugs from the deep brain stimulator
61912707|NCT02982512|EXPERIMENTAL|Dexmedetomodine recording|Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator
62104262|NCT04675463|OTHER|Glycopyrronium/Formoterol arm|52 weeks treatment
62296883|NCT00875758|ACTIVE_COMPARATOR|Standard threshold|
62296884|NCT00875758|EXPERIMENTAL|Low-threshold|
62296885|NCT04471896|EXPERIMENTAL|Treatment Arm|Participants will receive an infrared therapy device for use at home for 60 days. Participants will use the device every day for 10-20 minutes during the intervention period.
62296886|NCT01767584|EXPERIMENTAL|A (reference)/ B (test)|initial administration of reference and cross-over to test
62296887|NCT01767584|EXPERIMENTAL|B (test)/ A (reference)|initial administration of test and cross-over to reference
62296888|NCT00872313||1|Psychoses within the first 3 months postpartum
62296889|NCT00872313||2|Psychoses \> 3 months to 6 months postpartum
62296890|NCT02082197|EXPERIMENTAL|ABT-SLV176|ABT-SLV176 administered daily
62296891|NCT02137044|EXPERIMENTAL|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
62296892|NCT02137044|NO_INTERVENTION|Usual Care|Subjects assigned to usual care were informed by the CCM of their depressive and pain symptoms and that they should consult with their MS or primary care provider about possible care for these conditions. Study personnel did not make any further attempts to influence usual care participants' depression or pain management unless a psychiatric emergency arose (e.g., suicidal ideation was detected at baseline or any of the outcome assessments).
62296893|NCT02792140|NO_INTERVENTION|Baseline|reporting of dreams
62296894|NCT02792140|EXPERIMENTAL|Naltrexone|daily administration of 50mg Naltrexone, reporting of dreams
62296895|NCT02792140|PLACEBO_COMPARATOR|Placebo|daily administration of Placebo, reporting of dreams
62296896|NCT01283737|EXPERIMENTAL|DBX|DBX Putty in glass syringe
62296897|NCT01283737|ACTIVE_COMPARATOR|Mosaicplasty|
62296898|NCT06062719|ACTIVE_COMPARATOR|control|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
62296899|NCT06062719|EXPERIMENTAL|study|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
62666099|NCT04415918|NO_INTERVENTION|Historical control|Cohort of historical patients matched to study population to serve as control
62104263|NCT02492464|ACTIVE_COMPARATOR|Red yeast rice|Red yeast rice extract 200 mg, containing 10 mg monacolin K per daily dose, 1 capsule per day, per 6 months
62104264|NCT02492464|PLACEBO_COMPARATOR|Placebo|Placebo 200 mg (neutral fibre), 1 capsule per day, per 6 months
62104265|NCT01315535||Fast Titration|
62104266|NCT01315535||Regular Titration|
62666100|NCT01200355|EXPERIMENTAL|micafungin|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
62666101|NCT01200355|EXPERIMENTAL|posaconazole|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
62666102|NCT04080284|EXPERIMENTAL|Niraparib|"Oral niraparib~-Cohort - Uterine serous carcinoma"
62296900|NCT05723887|EXPERIMENTAL|Experimental (ABIP group)|The ABIP was created by the researchers in line with the literature and consisted of interventions that affect and increase prenatal attachment Gölbaşı et al., 2015; Güney \& including perceiving /counting fetal movements, music therapy, preparation for the baby, writing notes/letters to the baby, watching images of the fetus/pregnancy. The program was completed in a total of five days, with one intervention per day. An ABIP kit, which contained the materials to be used by pregnant women during ABIP interventions, was provided to them by the researchers at the first meeting. ABIP intervention materials were included in the ABIP kit, using five different colored envelopes (Appendix 1). Pregnant women were also informed about the interventions and materials of ABIP by the researchers at the first meeting.
62296901|NCT05723887|NO_INTERVENTION|control groups|No Intervention: Control group standard care group
62296902|NCT06368947|EXPERIMENTAL|intervention|Therapeutic play sessions will be organized twice a week for 4 weeks during chemotherapy treatment for children diagnosed with acute lymphoblastic leukemia in the intervention group.
62296903|NCT06368947|NO_INTERVENTION|control|Routine treatment will be applied to children in the control group receiving chemotherapy during their treatment.
62666103|NCT03915379|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive JNJ-67571244. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
62296904|NCT05321186|OTHER|minimally invasive spinopelvic fixation.|"the arm will include skeletally mature patients (between the age of 18-60) presenting with sacral fractures (provided that the fracture line passes below the level of S2) associated with lumbosacral instability) with the following inclusion and exclusion criteria.~1. Inclusion criteria:~   1. Unilateral or bilateral L5-S1 facet fractures (AO classification type C1 and C2)~  2. Spinopelvic dissociation (AO type C3)~  3. Traumatic lumbosacral dislocation~2. Exclusion criteria:~   1. unwillingness to participate in the study~  2. pathological fractures~  3. other medical comorbidities that preclude surgical intervention."
62296905|NCT00966927||subjects with spina bifid|subjects with spina bifid between 14 and 21 years old referred to Unit for Care of Spina Bifid Hospital of Parma
62296906|NCT00794586|EXPERIMENTAL|FTI 80mg/20mg BID|Fosfomycin/Tobramycin combination 80mg/20 mg inhaled twice daily
62666104|NCT03915379|EXPERIMENTAL|Part 2: Dose Expansion|Participants in 2 expansion cohorts of acute myeloid leukemia (AML) or either high-risk myelodysplastic syndromes (MDS) or very high-risk MDS will receive JNJ-67571244 at the RP2D determined in Part 1.
62666105|NCT05959291|EXPERIMENTAL|anti-HER-2 Group|Participants in this group will be monitored to see if patients discontinuing maintenance of anti-HER-2 treatments with ctDNA monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission. Participants will be in this group for up to 3 years.
62666106|NCT01972178|EXPERIMENTAL|PRC-4016|PRC-4016, oral administration once daily, capsule
62666107|NCT01972178|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration once daily, capsule
62666108|NCT03590002|EXPERIMENTAL|Electronic ICU Medical Transfer Tool|ICUs allocated to the experimental arm will have access to the electronic Medical Transfer of Care Documentation Tool within the clinical information system (CIS) in order to prepare ICU transfer of care documents for the receiving medical care team.
62666109|NCT03590002|NO_INTERVENTION|Dictated ICU Medical Transfer|Usual Care, ICUs in the control group will only have access to the dictation documentation system as the standard method to prepare ICU medical transfer documents. New ICU medical staff responsible for preparing transfer documents will receive the usual training on the dictation system.
62104267|NCT01315535||Fast Tritation Including Mandibular Exercises|
62104268|NCT01315535||Regular Tritation Including Mandibular Exercises|
62104269|NCT01501214|ACTIVE_COMPARATOR|Atosiban|
62104270|NCT01501214|PLACEBO_COMPARATOR|Placebo|Normal saline
62104271|NCT01300858|EXPERIMENTAL|EGEN-001|
62104272|NCT02050594||Melanoma patients on Ipilimumab|All unresectable, recurrent or metastatic melanoma patients
62104273|NCT06628973|EXPERIMENTAL|Social prescription|The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions.
62104274|NCT06628973|NO_INTERVENTION|Control|Usual Care
62104275|NCT05450029|EXPERIMENTAL|Chemoradiotherapy and PD1 inhibitor|Chemoradiotherapy and PD1 inhibitor
62104276|NCT04630652|EXPERIMENTAL|Psoriasis treatment with risankizumab|Moderate-to-severe psoriasis treatment with risankizumab for 16 weeks
62104277|NCT03855644||Pelvic fracture patients|(1) 1\<Age\<80, and Chinese residents living in China more than 3 years; (2) Hemoglobin value less than 100g/L during hospitalization; Not suffered from pelvic fracture within 3 months; Not suffer from pathological fractures of the pelvis caused by malignant tumors; without chronic anemia and coagulopathy; accept blood transfusion
62104278|NCT06343285|SHAM_COMPARATOR|Arm 1|Inactive stimulation - device is powered on, but motors are inactive and amplitude is set to 0%
62104279|NCT06343285|ACTIVE_COMPARATOR|Arm 2|Treatment with the wearable device set to a specific dermatome, duty cycle and amplitude
62104280|NCT06343285|ACTIVE_COMPARATOR|Arm 3|treatment with the wearable device set to frequency-match the subject's tremor, duty cycle of and amplitude are set
62104281|NCT02952261|OTHER|CT-guided localization|This group of participants received conventional CT-guided lung nodule localization.
62104282|NCT02952261|EXPERIMENTAL|template-guided localization|Three-dimensional printed template was customized based on participant's computed tomography information. Participants received template-guided lung nodule localization.
62104283|NCT04446689|ACTIVE_COMPARATOR|Biofeedback|The intervention group will develop an activity with self-monitoring called Cardiovascular Biofeedback or Cardiac Frequency Variability (CFV). This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph. This photoplethysmograph verifies blood flow alterations through an optical method. Cardiac frequency oscillations may be estimated both by the quantity of blood infrared lights absorbed or reflected, and by variations in blood volume and pressure. Captured physiological signs will be recorded during ten minutes by the Software Emwave Pro Plus®, which is adapted to biofeedback training.
62104284|NCT04446689|NO_INTERVENTION|activity without self monitoring|"The placebo group will develop an activity without self monitoring. In order to keep blindness between the groups the activities will be processed by an electronic device - the on line app Jigsaw Puzzles. This app consists of a puzzle with different levels of difficulties, and is played in a tablet.~Each participant will be performing in the study during four weeks, with two encounters each week (total: four weeks). While the participant will be performing its activity he/she will be monitored by the researchers through CFV (Cardiac Frequency Variability) - with no visualization of the computer monitor.~The control group will answer the research protocol in two moments (D1 and D8), to evaluate"
62104285|NCT04449744|ACTIVE_COMPARATOR|MySafeRx Group A-(coaching + medication dispenser)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
62104286|NCT04449744|EXPERIMENTAL|MySafeRx Group B-(coaching + dispenser based on clinical need)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a manual lockbox, and a standardized protocol for supervising self-administration of medication via videoconferencing. Participants will be assessed bi-weekly by their clinical team for substance abuse, coaching and medication adherence, compliance with urine drug screen policies, safety/ risk or mental health concerns, and diversion. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study.
62104287|NCT03514589|ACTIVE_COMPARATOR|Arm 1|250 mcg IV synacthen
62104288|NCT03514589|EXPERIMENTAL|Arm 2|Nasal Synacthen
62104289|NCT01843465||Cryoablation of atrial fibrillation|
62104290|NCT04846101|EXPERIMENTAL|Anterior restorations using single shade OMNICHROMA composite|Anterior class III and Class IV cavities will be restored using single shade composite material according to standard protocols of etching, bonding and composite placement.
62104291|NCT04846101|ACTIVE_COMPARATOR|Anterior restorations using multi-shade composite|Shade selection for the tooth will be performed prior to the placement of the restoration. Anterior class III and Class IV cavities will be restored using multi-shade composite material according to standard protocols of etching, bonding and composite placement.
62104292|NCT04222270|EXPERIMENTAL|Intervention|Caregiver peer support from Champion caregivers (Peer mentors) to caregivers of unsuppressed children living with HIV (CLHIV) on child care and medication adherence strategies to enhance achievement of viral suppression: Champion Caregivers (Peer Mentors) will be assigned to the intervention arm and will be trained to support 10-15 caregivers for 18 months post enrollment. Champion Caregivers (CCs) be trained using an adapted Mentor-Mother Peer Support curriculum and topics will include pediatric treatment gaps, ARV formulations/dosing, adherence counseling, and virological failure/suppression. Champion caregivers will conduct monthly-to-quarterly 30 min to 1 hr clinic-aligned caregiver group training sessions and home visits at least once quarterly, targeting Child living with HIV (CLHIV) adherence, age-appropriate disclosure, and keeping clinic appointments. The intervention arm will in addition to peer support intervention, receive routine standard of care at the health facility.
62296907|NCT00794586|EXPERIMENTAL|FTI 160mg/40mg BID|Fosfomycin/Tobramycin combination 160 mg/40 mg inhaled twice daily
62296908|NCT00794586|PLACEBO_COMPARATOR|Placebo A BID|Placebo A inhaled twice daily
62296909|NCT00794586|PLACEBO_COMPARATOR|Placebo B BID|Placebo B inhaled twice daily
62666110|NCT02803541|EXPERIMENTAL|12 day mainstream summer camp experience|The 12 day mainstream camp experience involves increased exercise from baseline at home. Can this exercise and peer contact improve physical endurance as measured by the 6 minute walk test and self concept as measured by a modified Harter scale
62666111|NCT04234230||VAD Patients|Patients with implanted ventricular assist device in the outpatient setting
62666112|NCT03537456|EXPERIMENTAL|mRDX-02-17|"mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:~* Hypotrophic tissues~* Tissue hypotonicity~* Crow's feet~* Glogau III - IV~* Fiztpatrick I - VI~* WSRS (Wrinkle Severity Ranking Scale): 2-5"
62296910|NCT00444015|EXPERIMENTAL|Dose Escalation|
62666113|NCT00520468|EXPERIMENTAL|Cytokine-Immunotherapy|Erythropoietin 40,000 units subcutaneously (SQ) weekly; G-CSF 300 mcg SQ twice a week; Prednisone 60 mg/Day for 7 days, taper over 1 month; Cyclosporin A 300 mg orally daily
62666114|NCT03188471|EXPERIMENTAL|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
62296911|NCT03551522|EXPERIMENTAL|Seladelpar 10 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
62296912|NCT03551522|EXPERIMENTAL|Seladelpar 20 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
62296913|NCT03551522|EXPERIMENTAL|Seladelpar 50 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
62296914|NCT03551522|PLACEBO_COMPARATOR|Placebo|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
62296915|NCT03339141|PLACEBO_COMPARATOR|supine position|Patients are placed in the supine position at 0° from arrival in the room until intubation
62104293|NCT04222270|NO_INTERVENTION|Control|Unsuppressed Children living with HIV and their caregivers recruited in the control arm will receive no champion caregiver peer support intervention but will continue to receive the standard of care at their health facilities which include routine care, including age-appropriate antiretroviral therapy and clinic appointments (typically every 2-3 months). Routine, albeit brief (5-10 min) adherence counselling is provided to CLHIV/caregivers by trained healthcare workers (HCWs) at every visit. In Nigeria, routine VL is done at 6 months post-ART initiation and repeated 12 months post- initiation 20. VL is done yearly thereafter for suppressed clients. Those unsuppressed receive 3-months' enhanced adherence counselling (EAC) (15-30 min) by Healthcare workers, with intensified appointment schedules and repeat VL upon EAC completion. This rigorous intervention continues until viral suppression is achieved or ART is switched; drug resistance testing (DRT) is not routine.
62666115|NCT03188471|ACTIVE_COMPARATOR|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
62666116|NCT04517539|EXPERIMENTAL|SBRT+GM-CSF+INF-αb|Metastasis lesion will be treated with a SBRT of 30Gy/5F from day 1 to day 5 . Injection of Immunological Agenthuman recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.Subcutaneous injection of Peginterferon alfa-b2(90ug) will be executed in day8. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Injection of Peginterferon alfa-b2(90ug) will be executed in day8 of this cycle.
62666117|NCT05665647|EXPERIMENTAL|Cohort 1: SIM0417/ritonavir and itraconazole|Interaction between SIM0417/ritonavir and itraconazole
62666118|NCT05665647|EXPERIMENTAL|Cohort 2: SIM0417/ritonavir and rifampicin|Interaction between SIM0417/ritonavir and rifampicin
62666119|NCT05665647|EXPERIMENTAL|Cohort 3: SIM0417/ritonavir and midazolam|Interaction between SIM0417/ritonavir and midazolam
62666120|NCT02958670|EXPERIMENTAL|18F-AV-1451-PET|All subjects receive a Scan for assessment of TAU with the radiotracer 18-F-AV-1451
62666121|NCT03802110|EXPERIMENTAL|Single Arm|Defibrillation threshold (DFT) testing Arm
62666122|NCT02275091||Diabetes|Children with diabetes type 1 , 12-21 years old
62666123|NCT02275091||Healthy|Healthy children 12-21 years old
62666124|NCT05431790|EXPERIMENTAL|Absorbable screw (Natong Biotechnology (Beijing) Co., Ltd.)|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.
62666125|NCT05431790|ACTIVE_COMPARATOR|Absorbable screw (Inion Oy, INION, Finland)|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by INION.
62666126|NCT05031221|EXPERIMENTAL|Yoga + behavioral weight loss|In person and virtual yoga + 150 minutes of moderate-to-vigorous physical activity/week + weekly instruction on dietary strategies for weight loss
62666127|NCT04631276|EXPERIMENTAL|Single evaluation of H3 receptor occupancy|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 2.5, 25 mg TS-091 prior to an evaluation of H3 recepto occupancy
62666128|NCT04631276|EXPERIMENTAL|Multiple evaluations of H3 receptor occupancy|Subjects received single-dose of 5, 12.5, 25 mg TS-091 prior to Multiple evaluations of H3 recepto occupancy
62104294|NCT03208270|EXPERIMENTAL|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
62296916|NCT03339141|ACTIVE_COMPARATOR|25° head-up position|Patients are placed in the 25° head-up position (half-seat or whole body proclive) from arrival in the room until intubation.
62666129|NCT06260293|EXPERIMENTAL|Exercise group|
62666130|NCT06260293|NO_INTERVENTION|Usual care group|
62666131|NCT06023537|EXPERIMENTAL|Behavioral Weight Loss Intervention|
62666132|NCT05609227|EXPERIMENTAL|mobile application|Participants will get a mobile application containing information about information about all stages of stem cell transplantation process (pre, during and post).
62666133|NCT05609227|NO_INTERVENTION|Control|Participants will receive routine care.
62666134|NCT02723422|EXPERIMENTAL|Prehabilitation Visit/Increased Physical Therapy post-TAVR|
62666135|NCT02723422|ACTIVE_COMPARATOR|Control|Standard of care physical therapy post-TAVR
62666136|NCT03357055|EXPERIMENTAL|Ketamine arm|Ketamine group will receive an IV infusion of 0.25mg/kg of ketamine in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure patients will receive 0.25mg/kg of ketamine infusion at 10ml/hour until the end of operation.
62666137|NCT03357055|PLACEBO_COMPARATOR|Control arm|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation.
62666138|NCT04616521|EXPERIMENTAL|Asymmetric DBS group|In this arm, a one-staged combined unilateral STN and contralateral GPi DBS will be implanted into PD patients. For postural instability and gait difficulty (PIGD)-dominant patients, the GPi in the side contralateral to the leg with longer step length will be targeted. For tremor-dominant (TD) patients, the STN in the side contralateral to the body side that mostly affected will be targeted. For PD patients of mixed type, the choice of target will depend on the judgement of a multidisciplinary team based on clinical features.
62666139|NCT06240182|ACTIVE_COMPARATOR|Conventional surgery|performing surgery by surgical carbide burs
62666140|NCT06240182|EXPERIMENTAL|Piezoelectric surgery|surgery performed using piezoelectric device
62666141|NCT04385992|EXPERIMENTAL|All enrolled patients|Enrolled patients following inclusion criteria
62666142|NCT02909595|EXPERIMENTAL|Balloon catheter group|Bile duct stones extraction was carried out with a balloon catheter.
62666143|NCT02909595|ACTIVE_COMPARATOR|Basket catheter group|Bile duct stones extraction was carried out with a basket catheter.
62666144|NCT06329310|EXPERIMENTAL|aXess-E conduit|
62468566|NCT02478190|EXPERIMENTAL|Loose control|Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.
62666145|NCT01091207|EXPERIMENTAL|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
62666146|NCT02580071|EXPERIMENTAL|Sheng-Yu-Tang|"Treatment group will receive standard of care, as well as:~2-3 months post-HSCT, patients will be administered the herbal formula Sheng-Yu-Tang (聖愈湯), which they will receive for 6 months. The herbal formula will be provided from a GMP herbal company and will be given in granulated form."
62468567|NCT02217293|ACTIVE_COMPARATOR|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury
62666147|NCT02580071|NO_INTERVENTION|Control|Control group will receive standard of care
62666148|NCT05779644|EXPERIMENTAL|Liraglutide group|Liraglutide is injected once a day.
62666149|NCT05779644|EXPERIMENTAL|Semaglutide group|Semaglutide is injected once a week.
62666150|NCT05779644|EXPERIMENTAL|Metformin group|Metformin is taken orally daily.
62666151|NCT06218550|PLACEBO_COMPARATOR|Oral Placebo|A brownie containing no experimental drugs will be eaten by study participants
62666152|NCT06218550|EXPERIMENTAL|Oral administration of 30mg ∆8-THC|A brownie infused with 30mg ∆8-THC will be eaten by study participants
62666153|NCT06218550|EXPERIMENTAL|Oral administration of 60mg ∆8-THC|A brownie infused with 60mg ∆8-THC will be eaten by study participants
62666154|NCT06218550|EXPERIMENTAL|Oral administration of 30mg ∆9-THC|A brownie infused with 30mg ∆9-THC will be eaten by study participants
62666155|NCT06218550|PLACEBO_COMPARATOR|Administration of vaporized Placebo|"Participants will inhale ambient air through a handheld vaporizer (minimum 15 puffs)"
62666156|NCT06218550|EXPERIMENTAL|Administration of vaporized 30mg ∆8-THC|"Participants will inhale 30mg ∆8-THC using a handheld vaporizer (minimum 15 puffs)"
62666157|NCT06218550|EXPERIMENTAL|Administration of vaporized 60mg ∆8-THC|"Participants will inhale 60mg ∆8-THC using a handheld vaporizer (minimum 15 puffs)"
62666158|NCT06218550|EXPERIMENTAL|Administration of vaporized 30mg ∆9-THC|"Participants will inhale 30mg ∆9-THC using a handheld vaporizer (minimum 15 puffs)"
62666159|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
62666160|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
62666161|NCT06016751||cranial damage|Our study was a prospective observational study which included only a group of patients who were diagnosed with acute craniocerebral injury.
62666162|NCT05165043||PC group|"The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included. The patients were characterized in terms of age, sex, causes of liver cirrhosis, adverse events (AEs) during position change, additional findings after body position change, treatment regimens and follow-up information.~During position changing procedure, endoscopist withdrew the gastroscope from the stomach and patients changed from the left lateral position to the right lateral position with the help of the nurses. Then endoscopist reinserted the gastroscope into the stomach and tried to detect the addition varices after position change.~Bleeding varices were treated by injection of N-butyl-Cyanoacrylate glue (glub B or Beltran, Compex) or/and Lauromacrogol (Shanxi, Tianyu)."
62104295|NCT03208270|ACTIVE_COMPARATOR|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
62104296|NCT05751200||CARS group|In the CARS group, 3-0 polypropylene was used to suture the proximal end of aortic with the vascular grafts continuously, followed by one interrupted suture loop of 3-0 polypropylene for reinforcement.
62104297|NCT05751200||XJ-procedure group|In the XJ-procedure group, a 1.5-2cm wide bovine pericardial patch and graft ring were placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft was intermittently sutured to full layers of aortic vascular with 2-0 pad polyester sutures. Finally, the eversion and aortic wall were continuously sutured together in one more turn.
62104298|NCT02781584|EXPERIMENTAL|Cohort 1: SEL 18 mg (Non-cirrhotic)|Non-cirrhotic participants will receive selonsertib (SEL) 18 mg tablet orally once daily for 12 weeks.
62104299|NCT02781584|EXPERIMENTAL|Cohort 2: FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive firsocostat (FIR) 20 mg tablet orally once daily for 12 weeks.
62104300|NCT02781584|EXPERIMENTAL|Cohort 3: CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive cilofexor (CILO) 30 mg tablet once daily for 12 weeks.
62104301|NCT02781584|EXPERIMENTAL|Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
62104302|NCT02781584|EXPERIMENTAL|Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
62104303|NCT02781584|EXPERIMENTAL|Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive CILO 30 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
62468568|NCT02217293|NO_INTERVENTION|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
62104304|NCT02781584|EXPERIMENTAL|Cohort 7: CILO 20 mg (Cirrhotic)|Participants with Child-Pugh-Turcotte Class A cirrhosis will receive FIR 20 mg tablet once daily for 12 weeks.
62468569|NCT01125059|ACTIVE_COMPARATOR|Methadone Group|0.2 mg/kg IV methadone
62468570|NCT01125059|PLACEBO_COMPARATOR|Placebo Group|5 mL saline bolus
62468571|NCT03776422|EXPERIMENTAL|Mobile self-help intervention|This study uses automated self-help interventions designed as a kit of smartphone tools.
62468572|NCT00892892|EXPERIMENTAL|Arm 1|Rilmenidine as a sympatholytic agent for three months
62468573|NCT00892892|ACTIVE_COMPARATOR|Arm 2|Nitrendipine as a non-sympatholytic agent for three months
62104305|NCT02781584|EXPERIMENTAL|Cohort 8: CILO 30 mg (Cirrhotic)|Participants with Child-Pugh-Turcotte Class A cirrhosis will receive CILO 30 mg tablet once daily for 12 weeks.
62104306|NCT02781584|EXPERIMENTAL|Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
62104307|NCT02781584|EXPERIMENTAL|Cohort 10: FIR 20 mg + FENO 48 mg|Participants will receive fenofibrate (FENO) 48 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 48 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
62104308|NCT02781584|EXPERIMENTAL|Cohort 11: FIR 20 mg + FENO 145 mg|Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 145 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
62104309|NCT02781584|EXPERIMENTAL|Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g|Participants will receive Vascepa® (VAS) 2 g capsule orally twice daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + VAS 2 g capsule twice daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
62104310|NCT02781584|EXPERIMENTAL|Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg|Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + FENO 145 mg tablet orally once daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
62104311|NCT01323660|EXPERIMENTAL|GSK573719/GW642444 125/25|125mcg/25mcg nDPI
62104312|NCT01323660|EXPERIMENTAL|GSK573719/GW642444 62.5/25|62.5mcg/25mcg nDPI
62104313|NCT01323660|EXPERIMENTAL|GSK573719/ 125|125mcg nDPI
62104314|NCT01323660|EXPERIMENTAL|GSK573719 62.5|62.5mcg nDPI
62104315|NCT01323660|EXPERIMENTAL|GW642444 25|25mcg nDPI
62104316|NCT01323660|PLACEBO_COMPARATOR|Placebo|Plb nDPI
62104317|NCT01723670|EXPERIMENTAL|CHF 5074 1x|oral tablet, multidose
62104318|NCT01723670|EXPERIMENTAL|CHF 5074 2x|oral tablet, multidose
62104319|NCT01723670|PLACEBO_COMPARATOR|Placebo|placebo, oral tablet, multidose
62104320|NCT01392755|EXPERIMENTAL|1|
62104321|NCT01392755|EXPERIMENTAL|2|
62104322|NCT06314256|ACTIVE_COMPARATOR|Injectable PRF|i-PRF is produced by cenrifugation of patients own blood. Injection of 0.1-0.2 ml per interdental papilla 2 times with 3-week interval.
62104323|NCT06314256|ACTIVE_COMPARATOR|Hyaluronic Acid|"Teosyal® Global Action PureSense. Composition: Cross-linked hyaluronic acid (HA): 25 mg/ml Lidocaine; 0,3%, (injection).~Injection of 0.1-0.2 ml per interdental papilla 2 times with 3-week interval."
62296917|NCT01407120|EXPERIMENTAL|Mother Program|11 session program focused on parenting skills
62296918|NCT01407120|EXPERIMENTAL|Mother Plus Child Program|11 session Mother Program focused on parenting skills plus 11 session Child program focused on child coping skills
62296919|NCT01407120|NO_INTERVENTION|Literature Control|Families received books on children's post-divorce adjustment
62296920|NCT01201499|ACTIVE_COMPARATOR|Intrathecal morphine|A single shot of intrathecal morphine given before the induction of general anesthesia. Followed by postoperative IV patient-controlled morphine analgesia.
62296921|NCT01201499|ACTIVE_COMPARATOR|Continuous IV remifentanil|Continuous administration of IV remifentanil during surgery, supported by a single bolus of IV morphine at the end of surgery. Followed by postoperative IV patient-controlled morphine analgesia.
62296922|NCT01065935|ACTIVE_COMPARATOR|ALN-RSV01|
62104324|NCT04756401|EXPERIMENTAL|Treatment (carfilzomib, daratumumab, dexamethasone, selinexor)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62104325|NCT05879666|EXPERIMENTAL|Reproductive Health Professionals - EHL|All participants will complete a pre-course survey, engage in the online educational intervention, then complete 2 post-course surveys. They have the option to provide urine samples before and after the intervention.
62104326|NCT00925730|EXPERIMENTAL|Pimecrolimus cream 1%|Pimecrolimus
62104327|NCT04133363|EXPERIMENTAL|Ridge preservation using L-PRF/ FDBA Layered|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
62104328|NCT04133363|EXPERIMENTAL|Ridge preservation using L-PRF/ FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
62104329|NCT04133363|EXPERIMENTAL|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF alone
62104330|NCT00207649|NO_INTERVENTION|Control group|standard informational brochures
62104331|NCT00207649|EXPERIMENTAL|Web curriculum for physicians only|Both intervention arms will use a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In one of the intervention arms, the physicians saw the web-based interactive curriculum and the patient received the brochure.
62104332|NCT00207649|EXPERIMENTAL|Web curriculum for physicians and patients|In the other intervention arm, the physicians saw the web-based curriculum and the patient received interactive curriculum covering content similar to that contained in the web-based interactive curriculum for physicians.
62104333|NCT03109015|ACTIVE_COMPARATOR|Schedule 4/2|
62296923|NCT01065935|PLACEBO_COMPARATOR|Normal saline|
62296924|NCT05793619|EXPERIMENTAL|Condition 1 : prototypes (816-v1 301) to (816-v1 355) every week|Application on the brown spots of the face for the prototypes (816-v1 301) to (816-v1 355) at D0, D7, D14, D21, D28 and D35
62296925|NCT05793619|EXPERIMENTAL|Condition 2 : prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on the brown spots of the face for the prototypes (816-v1 301) to (816-v1 355) at D0, D14, D28, D42, D56 and D70
62666163|NCT02120079|ACTIVE_COMPARATOR|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch \& Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
61912708|NCT05782816|ACTIVE_COMPARATOR|Low dose oxytocin|The low dose oxytocin group will receive a controlled infusion pump at a proximal port on the peripheral IV line. The infusion will start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Oxytocin infusion rate is adjusted to maintain adequate uterine contractions.
62104334|NCT03109015|EXPERIMENTAL|Schedule 2/1|
62104335|NCT04912362|EXPERIMENTAL|YAG iridotomy+CLASS|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
62104336|NCT04912362|NO_INTERVENTION|CLASS|CO2 Laser-Assisted Sclerectomy Surgery only
62296926|NCT01039207|EXPERIMENTAL|Treatment (rilotumumab)|Patients receive rilotumumab IV over 30-60 minutes on days 1 and 14. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
62666164|NCT02120079|ACTIVE_COMPARATOR|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch \& Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
62296927|NCT01477021|EXPERIMENTAL|Treatment (NY-ESO-1 specific CD8+ T cells)|Patients receive cyclophosphamide IV on days -3 and -2. Patients receive NY-ESO-1-specific T cells IV on day 0.
62296928|NCT03637049|EXPERIMENTAL|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
62296929|NCT01548261||Health people.|
62296930|NCT00389207|ACTIVE_COMPARATOR|NVP bid|nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
61912709|NCT05782816|ACTIVE_COMPARATOR|High dose oxytocin|The high dose oxytocin group will receive a controlled infusion pump at a proximal port on the peripheral IV line. The infusion will start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Oxytocin infusion rate is adjusted to maintain adequate uterine contractions.
61912710|NCT03466593|EXPERIMENTAL|Prospective cohort-prehabilitation|A prehabilitation program including advice about diet, increased physical activity and cessation of smoking and drinking alcohol.
62104337|NCT04278989|EXPERIMENTAL|Anti-tumor B|1,200 mg three times a day.
62104338|NCT04060355|EXPERIMENTAL|Savvy Participants|Using an on-line survey method, each caregiver will be asked to complete the post-program fidelity monitoring survey that seeks responses to the program (feel more knowledgeable, more competent, better equipped, etc.) and asks them to assess the interventionist's performance and verify that certain key elements of the program were covered.
62104339|NCT04060355|EXPERIMENTAL|Interventionists|Three recorded semi-structured video interviews will be conducted with each interventionist. One will occur immediately after training; this will focus on their sense of the completeness and adequacy of the training program, including the training methods, videos, and materials, and their perceived readiness to lead the program. Another interview will be done immediately after the conduct of each of the two Savvy programs they lead, asking them to report on their performance as interventionists, including any adaptation processes in which they might have engaged, and to reflect on ways the training might be improved to strengthen their skills, including for adaptation.
62104340|NCT04060355|EXPERIMENTAL|Organizational Leaders|Recorded semi-structured video interviews with sponsoring organizations' key contact persons will be conducted immediately after the interventionist training and then after each of the two Savvy offerings. The conversation will focus on identifying ways to strengthen and improve the training, certification, and fidelity monitoring system. Information about time and resource costs of the program, caregiver demand, and caregiver recruitment and feedback will be also collected.
62104341|NCT05730764|EXPERIMENTAL|Support systems assist doctors in decision-making|Doctors judge the risk of fertilization disorders and make clinical decisions with the support of a decision-making system.
62104342|NCT05730764|OTHER|Clinicians follow a routine protocol|Doctors judge the risk of fertilization disorders and make clinical decisions based on clinical experience
62104343|NCT06187701|EXPERIMENTAL|Co-Active Therapeutic Theatre (Co-ATT)|Drama therapy will be used to treat participants with co-occurring primary psychiatric and substance use disorders
62296931|NCT00389207|EXPERIMENTAL|NVP qd|nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
62296932|NCT00389207|ACTIVE_COMPARATOR|ATZ/r|ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
62296933|NCT01814657|PLACEBO_COMPARATOR|Normal Saline|Conscious sedation and sterile normal saline (placebo) paracervical block
62296934|NCT01814657|ACTIVE_COMPARATOR|Lidocaine|Conscious sedation and Lidocaine hydrochloride 1% solution paracervical block
62296935|NCT03931655||Spectroscopic photoacoustic imaging|Any suspicious lymph nodes identified through ultrasound will be imaged with spectroscopic photoacoustic imaging, which is a diagnostic test to measure saturated oxygen in the nodes.
61912711|NCT03466593|ACTIVE_COMPARATOR|Retrospective cohort|Routine care before the prehabilitation program was introduced
61912712|NCT03466593|EXPERIMENTAL|Extra early mobilization|Mobilization the day of surgery
61912713|NCT03466593|ACTIVE_COMPARATOR|Traditional mobilization|Routine care with mobilization the day after surgery
62104344|NCT04378582||COVID-19 confirmed|Patients with confirmed COVID-19 by RT-PCR or serological test
62104345|NCT04378582||COVID-19 suspected|Patients suspected COVID-19, as defined by clinical history and course, who have negative RT-PCR or serological test but where treated and cared for as COVID-19 patients
62296936|NCT03603743|EXPERIMENTAL|high intensity interval training|high intensity interval training: two sets of 8-min intervals at 100% of peak power output (PPO). Each interval set was composed of repeated bouts of 30 s at 100% of PPO interspersed by 30 s of passive recovery in the seated position. Four minutes of passive recovery were allowed between the two sets.
61912714|NCT03758885|EXPERIMENTAL|Nolasiban 900 mg|Nolasiban dispersible tablets for single oral administration
61912715|NCT03758885|PLACEBO_COMPARATOR|Placebo|Placebo dispersible tablets for single oral administration
61912716|NCT05694143|OTHER|Intervention group|Intervention group: Participants assigned to the intervention group will receive both will receive educational intervention including educational booklet will be distributed to the participants in the first session, and they will be asked to take it home and read it within one week. The booklet's content will include the risk factors of NCD and the benefits of adopting a healthy diet and physical activity in reducing overweight and obesity. Then, the educational classes will include six weekly teaching units. The general objective is to prevent obesity among students by delivering education and behavioural skills. The training units will be carried out in the schools. Each training unit will end with activities. The adolescents will learn more about their susceptibility to obesity and weight gain and how to make better decisions and feel better about themselves through these activities.
61912717|NCT05694143|OTHER|Control group: No Intervention|Participants randomized to the control group in this study will not receive any intervention (They will have their regular curriculums and normal physical activity routine).
61912718|NCT00052442|EXPERIMENTAL|135 mg/m^2 Pralatrexate 1/2 weeks|Pralatrexate (PDX) 135 mg/m\^2 administered as an intravenous (IV) infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.
61912719|NCT00052442|EXPERIMENTAL|30 mg/m^2 Pralatrexate 3/4 weeks|PDX 30 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.
61912720|NCT00052442|EXPERIMENTAL|30 mg/m^2 Pralatrexate 6/7 weeks|PDX 30 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
61912721|NCT00052442|EXPERIMENTAL|45 mg/m^2 Pralatrexate 6/7 weeks|PDX 45 mg/m\^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
61912722|NCT00052442|EXPERIMENTAL|270 mg/m^2 Pralatrexate 2/4 weeks|PDX (270 mg/m\^2) administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.
61912723|NCT01811667|EXPERIMENTAL|Sirolimus|Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.
61912724|NCT00890045|ACTIVE_COMPARATOR|Control graft|Conventional ePTFE hemodialysis graft
61912725|NCT00890045|EXPERIMENTAL|HeRO Vascular Access Device|HeRO Vascular Access Device
61912726|NCT02203175|PLACEBO_COMPARATOR|Group C (plasebo): no pretreatment|saline injection
61912727|NCT02203175|ACTIVE_COMPARATOR|propofol and fentanyl|propofol 50 mg with fentanyl 50 mcgr iv during anesthesia induction ones time
61912728|NCT01642810|ACTIVE_COMPARATOR|Treatment-as-usual|Participants continue their pre-study treatment plan, based on their physician/other professional recommendations
61912729|NCT01642810|EXPERIMENTAL|Online ABBT treatment + TAU|Participants to complete a 6-unit online Acceptance-based behavioural treatment including training in pacing, mindfulness, acceptance, cognitive defusion, willingness, and exercise while also maintaining their pre-study treatment.
61912730|NCT03844295|EXPERIMENTAL|Activated Inspire® Upper Airway Stimulation System|INSPIRE® device will be active a month
61912731|NCT03844295|PLACEBO_COMPARATOR|Inactivated Inspire® Upper Airway Stimulation System|"After a period 15 days of wash-out the INSPIRE® device will be inactivated for a second period of one month."
61912732|NCT02048241|OTHER|Placebo plus Parent Management Training|Pills matching Intuniv Tablets without active medication combined with weekly Parent Management Training
61912733|NCT02048241|EXPERIMENTAL|Intuniv plus Parent Management Training|Administration of Intuniv in increasing doses from 1 mg to 2 mgs to 3 mgs to 4 mgs as tolerated over a period of 4-6 weeks, combined with weekly Parent Management Training
61912734|NCT04594057|ACTIVE_COMPARATOR|Early Start|Begin 6 weeks of gaze and postural stability training 10-14 days following surgery.
61912735|NCT04594057|EXPERIMENTAL|Delayed Start|Begin 6 weeks of gaze and postural stability training 6 weeks following surgery.
61912736|NCT05165589|EXPERIMENTAL|Part 1: Initial data collection for device feasibility|3 subjects for 4 days included to collect initial data for algoritm development for device feasibility
61912737|NCT05165589|EXPERIMENTAL|Part 2: Device feasibility|10 subjects for 7 days included to evaluate device feasibility
61912738|NCT01120067|EXPERIMENTAL|Intensive Treatment|Intensive 3 week treatment for pain and PTSD. This includes elements of Cognitive Processing Therapy and CBT for Chronic Pain
61912739|NCT01120067|EXPERIMENTAL|Treatment as Usual|Treatment as Usual. Participants are eligible for all treatment services as needed except for treatment of pain or PTSD
62104346|NCT06314594|NO_INTERVENTION|control|Conventional treatment
61912740|NCT06324227|EXPERIMENTAL|multimodal music therapy group|using twice a week, 12 weeks music intervention with singing and physical movement with rhythm
61912741|NCT06324227|EXPERIMENTAL|no intervention group|no intervention
61912742|NCT01407003|EXPERIMENTAL|LIK066 in healthy subjects|
61912743|NCT01407003|PLACEBO_COMPARATOR|Matching placebo in healthy subjects|
61912744|NCT01407003|EXPERIMENTAL|LIK066 in patients with type 2 diabetes mellitus|
61912745|NCT01407003|PLACEBO_COMPARATOR|Matching placebo in patients with type 2 diabetes mellitus|
61912746|NCT06213675|EXPERIMENTAL|the experimental group|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
61912747|NCT06213675|ACTIVE_COMPARATOR|The control group|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
61912748|NCT04308733|ACTIVE_COMPARATOR|real tDCS|30 patients will be treated with real anodal tDCS over the contralateral pharyngeal motor cortex
61912749|NCT04308733|SHAM_COMPARATOR|sham tDCS|30 patients will be treated with sham tDCS over the contralateral pharyngeal motor cortex
62104347|NCT06314594|EXPERIMENTAL|intervention|Using paradigms based on transfer learning and semi-supervised learning, using multiple learning methods, transformer image classification algorithms and other mathematical methods, an early warning model and stepped treatment model for adolescent scoliosis were developed and verified, and a cost-effectiveness analysis was conducted at the same time.
62104348|NCT05338242|EXPERIMENTAL|Real-Time Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
62666165|NCT04055519|OTHER|LID017569, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
62666166|NCT04055519|OTHER|Biofinity, then LID017569|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
61912750|NCT03467009|EXPERIMENTAL|iPACT Intervention|"1. In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.~2. Eight-week longitudinal tailored CBT-based text-message program."
61912751|NCT03467009|ACTIVE_COMPARATOR|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
61912752|NCT03467009|EXPERIMENTAL|iPACT Intervention- App|"1. In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the message portion of the intervention delivered via app.~2. Eight-week longitudinal tailored CBT-based message program delivered via app."
61912753|NCT02436980|ACTIVE_COMPARATOR|tramadol|1mg/kg of tramadol drop (Contramal® drop, Abdi Ibrahim Ilaç San.,istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, Group T who were separated randomly to two premedication groups.
62104349|NCT05338242|NO_INTERVENTION|No Feedback|Participants will have exposure levels monitored by the same device, but it will only display the date/time and will not provide real-time feedback.
62296937|NCT03603743|ACTIVE_COMPARATOR|moderate intensity and continuous exercise|moderate intensity and continuous exercise: 30 minutes at 60% of PPO.
62296938|NCT05037929|EXPERIMENTAL|Astegolimab Q2W|Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).
62666167|NCT01501097|NO_INTERVENTION|Control group|
62666168|NCT01501097|EXPERIMENTAL|early HV-crrt|
62666169|NCT03464838|EXPERIMENTAL|Real Stimulation tDCS with CBT|16 participants will attend to one weekly tDCS stimulation session with intensity 1.8 milliamps for 8 consecutive weeks. Following the tDCS session, participants will attend to a cognitive behavioural therapy (CBT) session. One tDCS + CBT session per week (Total: 8 sessions).
62666170|NCT03464838|SHAM_COMPARATOR|Sham tDCS with CBT|16 participants will attend to one weekly Sham tDCS session with intensity 0 milliamps for 8 consecutive weeks. Following the Sham tDCS session, participants will attend to a CBT session. One Sham tDCS + CBT session per week (Total: 8 sessions).
62296939|NCT05037929|EXPERIMENTAL|Astegolimab Q4W|Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).
62296940|NCT05037929|PLACEBO_COMPARATOR|Placebo|Participants will receive SC placebo Q2W.
62296941|NCT03963973|EXPERIMENTAL|RDN-929|low, medium and high dose of RDN-929 capsules
62296942|NCT03963973|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules
61912754|NCT02436980|ACTIVE_COMPARATOR|midazolam|0.15 mg/kg of midazolam (Dormicum®, ampoule, Roche Products A.Ş., istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, to Group M who were separated randomly to two premedication groups.
61912755|NCT00727532|EXPERIMENTAL|Sorafenib|Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.
62104350|NCT06631404||group SLE|Patients with SLE
62296943|NCT05911022|ACTIVE_COMPARATOR|Group A (Colchicine group)|consisted of COVID-19 participants with mild to moderate disease who received the recommended course of care in accordance with the protocol established by the Egyptian Supreme Council of University Hospitals, as well as Colchicine tablets (0.5 mg) three times per day for three days and subsequently twice per day for four days
62666171|NCT04652310|ACTIVE_COMPARATOR|Extended-Short Nail|Implantation of TFNA extended-short nail (235 mm)
62666172|NCT04652310|ACTIVE_COMPARATOR|Long nail|Implantation of TFNA long nail (260-480 mm)
62666173|NCT05775705|EXPERIMENTAL|L-DEP and PD-1 antibody|PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
61912756|NCT02671916||all patients|questionnaire for patients with ICU stay at least 5 days or longer without interruption at the ICU
61912757|NCT01766700|EXPERIMENTAL|No calorie beverages|2 no calorie beverages per day.
61912758|NCT01766700|ACTIVE_COMPARATOR|Water|2 water beverages per day.
62666174|NCT06245707|EXPERIMENTAL|Ponticelli group|Patients with idiopathic membranous nephropathy were treated with Ponticelli protocol,that is alternating prednisone or methylprednisone -cyclophosphamide every other month
61912759|NCT05255185|EXPERIMENTAL|All the patients|domino therapy treat the infection around the prosthesis after the limb salvage surgery of bone tumor
61912760|NCT01001299|EXPERIMENTAL|Single arm|
61912761|NCT04191460|EXPERIMENTAL|WP-I dose A|n=7. Injection of 0.05 mg/kg cRGD-ZW800-1, within 16-20 hours before imaging/surgery
61912762|NCT04191460|EXPERIMENTAL|WP-I dose B|n=7. Injection of (to be determined) mg/kg RGD-ZW800-1, within (to be determined) hours before imaging/surgery.
61912763|NCT04191460|EXPERIMENTAL|WP-II selected dose|n=14: expansion cohort (n=14) will be added to the group of patients that had received the selected dose in WP-I. Injection of 0.05 ór (to be determined) mg/kg cRGD-ZW800-1, within 48 hours before imaging/surgery.
61912764|NCT05820997|ACTIVE_COMPARATOR|Paravertebral Block Pre Procedure|Subject will receive a preoperative paravertebral block only
61912765|NCT05820997|NO_INTERVENTION|No Paravertebral Block|Subject will receive no paravertebral block.
62104351|NCT06631404||group control|matched healthy subjects
62104352|NCT05224362|EXPERIMENTAL|Hip Region|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the hip region.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
62296944|NCT05911022|ACTIVE_COMPARATOR|Group B (Probiotic group)|consisted of COVID-19 participants with mild and moderate COVID-19 severity got probiotics in the form of oral sachets once daily for two weeks in addition to protocol prescribed by the Egyptian Supreme Council of University Hospitals.
62666175|NCT06245707|EXPERIMENTAL|Rituximab group|Patients with idiopathic membranous nephropathy were treated with Rituximab.The specific dosage of rituximab depends on the guidance of peripheral blood B cells.
62666176|NCT04518410|EXPERIMENTAL|Bamlanivimab 7000 mg (Phase 2)|Administered by IV infusion.
62666177|NCT04518410|PLACEBO_COMPARATOR|Bamlanivimab 7000mg Placebo (Phase 2)|Administered by IV infusion
62666178|NCT04518410|EXPERIMENTAL|Bamlanivimab 700mg (Phase 2)|Administered by IV infusion
62666179|NCT04518410|PLACEBO_COMPARATOR|Bamlanivimab 700mg Placebo (Phase 2)|Administered by IV infusion
62666180|NCT04518410|EXPERIMENTAL|Bamlanivimab 700mg (Phase 3)|Administered by IV infusion
62666181|NCT04518410|EXPERIMENTAL|BRII-196+BRII-198 (Pooled Phase 2/3)|Administered by IV infusion
62666182|NCT04518410|PLACEBO_COMPARATOR|BRII-196+BRII-198 Placebo (Pooled Phase 2/3)|Administered by IV infusion
62666183|NCT04518410|EXPERIMENTAL|AZD7442 (IV) (Phase 2)|Administered by IV infusion
62104353|NCT05224362|EXPERIMENTAL|Chest Region|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
62104354|NCT05224362|PLACEBO_COMPARATOR|No elastic band|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
62666184|NCT04518410|PLACEBO_COMPARATOR|AZD7442 (IV) Pooled Placebo (Phase 2)|Administered by IV infusion; shared placebo includes AZD7442 (IM) placebo and placebo from other comparator arms in the study.
62104355|NCT03697733|EXPERIMENTAL|Oral Etoricoxib group|Subjects will receive oral Etoricoxib120 mg 30 minutes before fractional curettage then added intravenous Propofol 2 mg/kg when start the procedure
62104356|NCT03697733|PLACEBO_COMPARATOR|Intravenous Fentanyl group|Subjects will receive oral placebo \[folic acid\] 1 tab 30 minutes before the procedure then added intravenous Propofol 2 mg/kg and Intravenous Fentanyl 1 microgram/kg when start the procedure
62296945|NCT05911022|PLACEBO_COMPARATOR|Group C (Control group)|consisted of COVID-19 participants with mild and moderate severity who received the recommended course of care in accordance with the protocol established by the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks, and necessary protocol of management based on case assessment and severity).
62296946|NCT06656533|EXPERIMENTAL|MORNING GROUP|Five participants (21 to 45 years old) experiencing clinically meaningful insomnia symptoms will be enrolled and will receive 10 sessions of right dorsolateral prefrontal cortex (DLPFC) rTMS therapy in the morning over two consecutive weeks.
62296947|NCT06656533|EXPERIMENTAL|EVENING GROUP|Five participants (21 to 45 years old) experiencing clinically meaningful insomnia symptoms will be enrolled and will receive 10 sessions of right dorsolateral prefrontal cortex (DLPFC) rTMS therapy in the evening over two consecutive weeks.
62296948|NCT03592459|EXPERIMENTAL|Device feasibility (Macy catheter, opioids)|Patients undergo placement of rectal catheter and receive opioids through the Macy catheter.
62666185|NCT04518410|EXPERIMENTAL|AZD7442 (IM) (Phase 2)|Administered by IM injection
62296949|NCT02226965|EXPERIMENTAL|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
62296950|NCT02882477|EXPERIMENTAL|Deferiprone and Acetylcystein|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200 mg divided in 2 doses 5 months duration
62296951|NCT02882477|EXPERIMENTAL|Deferiprone and Acetylcystein with Sitagliptin and Metformin|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200mg divided in 2 doses PO Januet 50/500 if BW \< 30kg and 50/850 if BW\> 30kg \*2/D 5 months duration
62296952|NCT03280212|EXPERIMENTAL|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants \<60kg will receive 500mg two times daily (BID), and participants \>100kg will receive 1000mg BID."
62666186|NCT04518410|PLACEBO_COMPARATOR|AZD7442 (IM) Pooled Placebo (Phase 2)|Administered by IM injection; shared placebo includes AZD7442 (IV) placebo and placebo from other comparator arms in the study.
62296953|NCT03280212|NO_INTERVENTION|Control Arm|"No intervention~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
62666187|NCT04518410|EXPERIMENTAL|SNG001 (Phase 2)|Administered by inhalation
62666188|NCT04518410|PLACEBO_COMPARATOR|SNG001 Pooled Placebo (Phase 2)|Administered by inhalation; shared placebo includes placebo from other comparator arms in the study.
62666189|NCT04518410|EXPERIMENTAL|Camostat (Phase 2)|Administered as oral tablets
62296954|NCT03981601|ACTIVE_COMPARATOR|lovastatin 40 mg with bone graft|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
62296955|NCT03981601|ACTIVE_COMPARATOR|without drug with bone graft|after tooth extraction, put the bone graft wifin tooth socket
62666190|NCT04518410|PLACEBO_COMPARATOR|Camostat Pooled Placebo (Phase 2)|Administered as oral tablets; shared placebo includes placebo from other comparator arms in the study.
62666191|NCT04518410|EXPERIMENTAL|SAB-185 (low dose) (Phase 2)|Administered by IV infusion
62666192|NCT04518410|PLACEBO_COMPARATOR|SAB-185 (low dose) Pooled Placebo (Phase 2)|Administered by IV infusion; includes SAB-185 (high dose) placebo and placebo from other comparator arms in the study.
62104357|NCT04977960|NO_INTERVENTION|Reference group|"Patients randomized to the Reference Group will receive the standard-of-care treatments, according to institutional procedures in force:~* Dexamethasone i.v. 6 mg die for consecutive 5 days~* Methylprednisolone i.v. 40 mg bid for consecutive 10 days~* Low-molecular-weight-heparin i.v. at standardized dose of 70 UI/kg twice~* Remdesivir i.v. 200 mg in bolus (1st day) then 100 mg die for 4 days; remdesivir will be used only in patients supported with low-flow nasal cannula oxygen or Venturi mask~* Antibiotic therapy:~  * azithromycin: 500 mg/die per os for 5 days~ * ceftriaxone: 2 g i.v. die for 8 days"
62104358|NCT04977960|EXPERIMENTAL|Experimental Group|Patients randomized in the Experimental Group will receive canrenone as add-on therapy to standard-of-care treatments. Different starting doses of i.v. canrenone will be administrated in a single or double infusion per day, for 7 days, according to the serum concentration of potassium at randomization
62104359|NCT05025449|EXPERIMENTAL|Non-enhanced FAST exam followed by BEFAST exam|Participants in the emergency department with hemodynamically stable blunt abdominal trauma will receive the standard of care Focused Assessment with Sonography for Trauma (FAST) exam followed by a Bubble-Enhanced FAST exam.
62104360|NCT06478680|ACTIVE_COMPARATOR|High intensity gait training|One session of conventional neurorehabilitation intervention per week One session of Forward Walking with EksoGT per week
62104361|NCT06478680|EXPERIMENTAL|Exoskeleton mediated gait training|Two sessions of High-Intensity Gait Training
62104362|NCT06226974|NO_INTERVENTION|Control Condition|5-minute rest.
62104363|NCT06226974|ACTIVE_COMPARATOR|Static Stretching of 30 seconds Condition|"Static stretching of 30 seconds of muscles around the shoulder of the dominant upper limb:~* Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
62104364|NCT06226974|ACTIVE_COMPARATOR|Static Stretching of 90 seconds Condition|"Static stretching of 90 seconds of muscles around the shoulder of the dominant upper limb:~* Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
62104365|NCT06630572|EXPERIMENTAL|TREATMENT|Rifaximin (1100 mg/die) - 550 b.i.d.
62104366|NCT06630572|PLACEBO_COMPARATOR|PLACEBO|Placebo - b.i.d.
62104367|NCT00178984||poor blood flow|Group with partial ischemia to the small intestine
61912766|NCT03157570|EXPERIMENTAL|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
62104368|NCT00178984||Good blood flow|Group with normal blood flow, given different conditions to effect electrical currents in normal smooth muscle
62104369|NCT00362843||healthy volunteers|healthy volunteers
62296956|NCT03377634|EXPERIMENTAL|Intervention|Participants receive the MORPH intervention.
61912767|NCT03157570|NO_INTERVENTION|Control group|The control group have no intervention and receives only standard care.
61912768|NCT01993836|ACTIVE_COMPARATOR|Total Intravenous Anesthesia with Propofol|Patients in this arm will receive general anesthesia with propofol as the primary amnestic agent.
61912769|NCT01993836|ACTIVE_COMPARATOR|General anesthesia with Isoflurane|Patients in this arm will undergo general anesthesia with isoflurane as the primary amnestic agent.
61912770|NCT03774823|EXPERIMENTAL|Freeze Plus|Subjects in this arm will receive treatment using RF and PEMF
61912771|NCT03774823|EXPERIMENTAL|Ultrasound|Subjects in this arm will receive treatment using ultrasound
62666193|NCT04518410|EXPERIMENTAL|SAB-185 (low dose) (Phase 3) Non-OMICRON population|"Administered by IV infusion.~The Non-Omicron subpopulation enrolled under Protocol Version 7 was defined as all participants enrolled under Protocol Version 7 excluding those in the Omicron subpopulation.~Omicron/Non-Omicron subpopulation definitions were updated in Version 10.0 of the Primary SAP to be based on the timing of emergence of the Omicron variant within the study population as follows:~* Variant information from any sample (i.e., not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~* For participants without variant information, those randomized under Protocol Version 7.0 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
62666194|NCT04518410|ACTIVE_COMPARATOR|Casirivimab and Imdevimab (Phase 3) Non-OMICRON population|"Administered by IV infusion.~The Non-Omicron subpopulation enrolled under Protocol Version 7 was defined as all participants enrolled under Protocol Version 7 excluding those in the Omicron subpopulation.~Omicron/Non-Omicron subpopulation definitions were updated in Version 10.0 of the Primary SAP to be based on the timing of emergence of the Omicron variant within the study population as follows:~* Variant information from any sample (i.e., not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~* For participants without variant information, those randomized under Protocol Version 7.0 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
61912772|NCT02608333|EXPERIMENTAL|ESDM-12|ESDM -12 : 60 children will receive 12 hours a week of ESDM ( Early Start Denver Model)intervention delivered by trained therapists during 2 years.ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
62104370|NCT00362843||patients|Patients with Fragile X Syndrome
62104371|NCT04679935|EXPERIMENTAL|Brolucizumab 6 mg non-loading|One initial injection followed by treatment every 12 weeks.
62104372|NCT04679935|EXPERIMENTAL|Brolucizumab 6 mg loading|3 x 4-weekly injections followed by treatment every 12 weeks.
62104373|NCT05457491|EXPERIMENTAL|Human platelet extract (HPE)|Subjects will follow a standardized twice daily skin care regimen of applying morning and night. Morning skin care routine includes Vanicream Gentle Facial Cleanser, human platelet extract, and EltaMD UV Daily Broad-Spectrum SPF 40, or Vanicream Lite Lotion. Evening skin care routine includes Vanicream Gentle Facial cleanser, human platelet extract, and EltaMD PM Therapy Facial Moisturizer or Vanicream Lite Lotion
62666195|NCT04518410|EXPERIMENTAL|SAB-185 (high dose) (Phase 2)|Administered by IV infusion
62666196|NCT04518410|PLACEBO_COMPARATOR|SAB-185 (high dose) Pooled Placebo (Phase 2)|Administered by IV infusion; includes SAB-185 (low dose) placebo and placebo from other comparator arms in the study.
62666197|NCT04518410|EXPERIMENTAL|BMS 986414+BMS 986413 (Phase 2)|Administered as subcutaneous (SC) injections
62104374|NCT06629012||Innervated group|Patients received breast neurotization
62104375|NCT06629012||Non-innervated group|Patients did not receive breast neurotization
62296957|NCT03377634|NO_INTERVENTION|Control|The wait list control participants receive usual care and are offered intervention materials on completion of the study.
62296958|NCT01523821|OTHER|Cohort 1 (30 mg/kg)|Alpha 1 anti-trypsin (AAT) will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 30mg/kg (maintenance dose) every other day (QOD) on days 3, 5, 7, 9, 11, 13 \& 15.
61912773|NCT02608333|ACTIVE_COMPARATOR|Control group|control group: 120 children will receive heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period
62666198|NCT04518410|PLACEBO_COMPARATOR|BMS 986414+BMS 986413 Pooled Placebo (Phase 2)|Administered as subcutaneous (SC) injections; shared placebo includes placebo from other comparator arms in the study.
62666199|NCT04518410|EXPERIMENTAL|SAB-185 (low dose) (Phase 3) OMICRON population|"Administered by IV infusion The Omicron subpopulation enrolled under Protocol v.7 was defined as (1) all participants randomized under Protocol v.7 infected with the Omicron variant as identified on sequencing of NP sample obtained on day 0, plus (2) all participants randomized under Protocol v.7 on/after December 26, 2021, who do not have variant information available from sample obtained on day 0.~Definitions were updated in Primary SAP v10.0 to be based on timing of emergence of Omicron variant within the study population as follows:~* Variant information from any sample (i.e. not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~* For participants without variant information, those randomized under Protocol v7 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
61912774|NCT01106417|EXPERIMENTAL|NeoFuse|"Anterior Cervical Discectomy and Fusion with NeoFuse.~NeoFuseTM is constituted of STRO-3 immunological selected allogeneic MPCs, which are derived from adult bone marrow mononucleated cells that are culture-expanded and subsequently cryopreserved.~The allogeneic MPCs are formulated in concentrations of nucleated cells in a 5 mL volume and are cryopreserved in 7.5% dimethyl sulfoxide (DMSO)/50% Alpha Modified Eagle's Medium (MEM) and 42.5% ProFreeze®. The final formulation consists of 0.15mL (approximately 10 million MPCs) of thawed NeoFuse™ thawed NeoFuseTM combined with the amount of MasterGraftTM Matrix to fill the PEEK cage per ACDF level."
62296959|NCT01523821|OTHER|Cohort 2 (60 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 60 mg/kg (maintenance dose) QOD on days 3, 5, 7, 9, 11, 13 \& 15.
62296960|NCT01523821|OTHER|Cohort 3 (90 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg on days 1, 3, 5, 7, 9, 11, 13 \& 15.
62104376|NCT05349864|EXPERIMENTAL|PF-07284890 Sequence 1|"PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
62296961|NCT04723095||Observational (medical chart review)|Patients' medical records are reviewed retrospectively and prospectively. Patients are followed up by email, telephone, or U.S. mail every 4 months for up to 10 years from date of initial study enrollment. Patients, who are beyond 5 years from their initial diagnosis, are followed up by email, telephone, or U.S. mail annually.
62468574|NCT02007031||Hypertensive subjects|Hypertensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
62666200|NCT04518410|ACTIVE_COMPARATOR|Casirivimab and Imdevimab (Phase 3) OMICRON population|"Administered by IV infusion The Omicron subpopulation enrolled under Protocol v.7 was defined as (1) all participants randomized under Protocol v.7 infected with the Omicron variant as identified on sequencing of NP sample obtained on day 0, plus (2) all participants randomized under Protocol v.7 on/after December 26, 2021, who do not have variant information available from sample obtained on day 0.~Definitions were updated in Primary SAP v10.0 to be based on timing of emergence of Omicron variant within the study population as follows:~* Variant information from any sample (i.e. not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~* For participants without variant information, those randomized under Protocol v7 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
62666201|NCT00890162|ACTIVE_COMPARATOR|Omalizumab|Subjects will receive two doses of Omalizumab while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
62666202|NCT00890162|PLACEBO_COMPARATOR|Placebo|Subjects will receive two doses of placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
62666203|NCT01251679|NO_INTERVENTION|Control|Control: nutrition, physical activity and smoking cessation education
62666204|NCT01251679|EXPERIMENTAL|Hand washing|Intervention 1: hand washing education and material
61912775|NCT01106417|ACTIVE_COMPARATOR|MasterGraft Granules|"Anterior Cervical Discectomy and Fusion with MasterGraft Granules~MASTERGRAFT® GRANULES are a medical-grade, polyporous resorbable ceramic hybrid composed of 15% hydroxyapatite (HA) and 85% beta-tricalcium phosphate (β-TCP). The combination of these natural bone materials provides surgeons with an osteoconductive, porous implant that improves osteointegration by allowing cells to colonize throughout the implant and optimize the bone healing process"
61912776|NCT00001131|EXPERIMENTAL|A|Patients will recieve a daily, self-administered subcutaneous injection of IL-2 while continuing treatment with their current oral anti-HIV medications
62296962|NCT00740805|EXPERIMENTAL|Treatment (veliparib, cyclophosphamide, doxorubicin)|"GROUP I: Patients receive veliparib PO every 12 hours on days 1-4 and cyclophosphamide IV over 60 minutes on day 3.~GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over 60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3.~GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1.~GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1.~In all groups, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62296963|NCT05237245||1|Adult T-cell leukemia / lymphoma (ATL) patients
62296964|NCT05237245||2|HTLV-1 chronically infected patients without ATL
62666205|NCT01251679|EXPERIMENTAL|Hand washing and surgical mask|Intervention 2: hand washing education and material AND paper surgical face masks
62666206|NCT05316870|EXPERIMENTAL|Intervention group|The standardized anticoagulation management program of atrial fibrillation in primary medical institutions was implemented for the patients with atrial fibrillation in the intervention group.
62666207|NCT05316870|OTHER|Control group|The current general practitioner management mode was continued for the patients with atrial fibrillation in the control group.
62666208|NCT03630601|EXPERIMENTAL|Diagnostic (photoacoustic imaging)|Participants undergo PAI on different parts of the body over 20 minutes for up to 5 imaging sessions for 6 months.
62666209|NCT01193985|EXPERIMENTAL|Intervention|
62666210|NCT05364255|EXPERIMENTAL|[14C]AZD9833 (D8532C00005)|Oral Solution, 75 mg (NMT 0.67 MBq)
62296965|NCT00722293|EXPERIMENTAL|Arm A|once daily oral administration of pazopanib for Days 1-21 days in combination with epirubicin given as a bolus intravenous administration on Day 3
62296966|NCT00722293|EXPERIMENTAL|Arm B|once daily oral administration of pazopanib for Days 1-8 of a 3-week cycle in combination with epirubicin (bolus intravenous administration) on Day 3
62296967|NCT00722293|EXPERIMENTAL|Arm C|epirubicin (bolus intravenous administration) on Day 1 with once-daily oral administration of pazopanib for Days 14-21 of a 3-week cycle
62296968|NCT00722293|EXPERIMENTAL|Arm D|once-daily oral administration of pazopanib (according to schedule selected from either Arm A, B, or C) (3 week cycle) in combination with doxorubicin (bolus intravenous administration) on Day 1 or 3, depending on the schedule selected from either Arm A, B, or C
62296969|NCT04114305||Intervention|HIV-infected pregnant women enrolled in ECD program implemented by m2m program; women followed during pregnancy and 18 months post-partum with their infants.
62666211|NCT00250718|EXPERIMENTAL|Arm 1 Combination Treatment|"Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient"
62296970|NCT04114305||Control|HIV-infected pregnant women receiving routine care in clinics without ECD program; women followed during pregnancy and 18 months post-partum with their infants.
62296971|NCT05932732|OTHER|HydraFacial Syndeo Treatment|Three HydraFacial Syndeo Treatment will be performed 28 days apart at the Pflugerville site.
62296972|NCT05932732|OTHER|Hydrafacial Elite MD Treatment|hree HydraFacial Elite MD Treatment will be performed 28 days apart at the Houston site.
62296973|NCT00294125|EXPERIMENTAL|1|Participants will receive daily flavocoxid for 12 weeks.
62296974|NCT00294125|PLACEBO_COMPARATOR|2|Participants will receive placebo for 12 weeks.
62296975|NCT01171612||Coronary Stent|Patients with coronary Bare Metal Stent (BMS) or Drug Eluting Stent (DES) undergoing noncardiac surgery
62296976|NCT04954482||The experimental group|The included specimens were used to establish a new posterior fork reconstruction procedure.
62296977|NCT04954482||The validation group|The included specimens were used to validate the new posterior fork reconstruction procedure.
62296978|NCT00885365|EXPERIMENTAL|Bramitob|tobramycin / Bramitob administered 300mg twice a day for 4 weeks
62666212|NCT02668419|ACTIVE_COMPARATOR|Usual Care|Patients in this group were subject to regular Physical Therapy Sessions in the hospital and each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise.
62666213|NCT02668419|EXPERIMENTAL|Neuromuscular Electrical Stimulator|Lower limb muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min. Heart rate, blood pressure, respiratory rate and pulse oximetry were monitored throughout the sessions, in all patients.
62666214|NCT04706221|EXPERIMENTAL|Blood Volume Monitoring|
62666215|NCT06475378|ACTIVE_COMPARATOR|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I) will be provided and seen as 'no intervention'
62666216|NCT06475378|EXPERIMENTAL|CBT-I + Moonbird (MB)|Cognitive Behavioral Therapy for Insomnia (CBT-I) will be combined with a technology supported breathing exercises with a tactile breath pacer device (Moonbird)
62666217|NCT06475378|SHAM_COMPARATOR|CBT-I + MBsham|Cognitive Behavioral Therapy for Insomnia (CBT-I) will be combined with a non-functioning technology supported breathing exercises with a tactile breath pacer device (Moonbird)
62296979|NCT00885365|ACTIVE_COMPARATOR|TOBI|tobramycin / TOBI administered 300mg twice a day for 4 weeks
62296980|NCT04732663||Persistently Symptomatic Covid-19 (PS-CoV)|PS-CoV will be defined as individuals with a history of molecular testing confirmed COVID-19 infection, recovered from acute infection but with ongoing symptoms (self-reported, pulmonary, cardiac, musculoskeletal or other symptoms) of at least 4 weeks' duration. Recovery from acute infection will be defined according to provincial health guidelines: at least 10 days' (14 in those hospitalized; 21 in those with immunocompromise) from onset of symptoms with at least 24 hours without a fever, without taking anti-pyretic medications and improvement of other symptoms.
62296981|NCT04732663||Recovered Covid-19|Recovered Covid-19 Survivors will be defined as individuals without complaint of a persisting covid-19 symptom. Recovered Covid-19 survivors will be matched to PS-CoV for age, sex, body mass index and time post corona virus infection.
62296982|NCT04732663||Control|Covid Naïve Controls will be defined as individuals who have no known history of covid-19. Control participants will be matched to PS-CoV for age, sex and body mass index.
62104377|NCT05349864|EXPERIMENTAL|PF-07284890 Sequence 2|"PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
62104378|NCT02606734|OTHER|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
62104379|NCT06206473|EXPERIMENTAL|ICU patients with ARDS and delirium|ICU patients with ARDS and delirium will be assessed twice: in the acute phase of ICU-related delirium (V1) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and 6 months ± 2 weeks later (V2) using a multi-domain clinical neurocognitive and psychological assessment battery.
62666218|NCT00809146|ACTIVE_COMPARATOR|Intramuscular (IM) anticonvulsant|This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
62104380|NCT05971225|ACTIVE_COMPARATOR|Follow up group|participants with experience of \>6 months in-office device interrogation, then started remote monitoring
62104381|NCT05971225|EXPERIMENTAL|Remote group|participants with newly implanted device with study agreement, and then started remote monitoring
62104382|NCT03681730|EXPERIMENTAL|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
62104383|NCT03681730|NO_INTERVENTION|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
62104384|NCT04780828||GROUP I|Group I will include cases classified as normal weight (healthy) with a body mass index of 18.5-24.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined for this group will be made. Since this group was not considered as obese, it was determined as the control group.
62104385|NCT04780828||GROUP II|Group II will include cases classified as overweight and having a body mass index of 25.0-29.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
62104386|NCT04780828||GROUP III|Group III will include cases classified as class I obese, with a body mass index of 30.0-34.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
62104387|NCT04780828||GROUP IV|Group IV will include cases classified as class II obese, with a body mass index of 35.0-39.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
62104388|NCT04780828||GROUP V|Group V will include cases classified as class III (morbid) obese, with a body mass index of 40 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
62666219|NCT00809146|ACTIVE_COMPARATOR|Intravenous (IV) anticonvulsant|This group gets active treatment with an anticonvulsant by the intravenous route of administration.
62666220|NCT01680172|EXPERIMENTAL|Ketamine|Single dose of ketamine (0.5 mg/kg)
62666221|NCT01680172|PLACEBO_COMPARATOR|Placebo|Single dose of placebo
62666222|NCT04964388|EXPERIMENTAL|GLP-1 cohort|Participants on GLP-1 receptor agonists
62666223|NCT04964388|NO_INTERVENTION|Non GLP-1 cohort|Participants not on GLP-1 receptor agonists
62666224|NCT04389138|NO_INTERVENTION|Comparison|In this arm participants will attend 3 study visits to complete study questionnaire and assessments. In between these visits, participants will be asked to wear an activity monitor and record an activity diary for one week. Other than this, participants will continue to receive only standard of care treatment.
62666225|NCT04389138|EXPERIMENTAL|Intervention arm|In this arm participants will attend the same 3 study visits to complete study questionnaires and assessments. Participants will be asked to wear an acitvity monitor and record an activity diary for one week after the study visits. In between baseline and 6 month follow up, intervention arm participants will receive study physiotherapy. This will consist of an individual assessment and 4 additional sessions of physiotherapy.
62104389|NCT06468657||reduced ejection fraction|EF below 50
62104390|NCT06468657||preserved ejection fraction|EF above 50
62666226|NCT02909647|ACTIVE_COMPARATOR|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
62296983|NCT05319860|ACTIVE_COMPARATOR|Standard of Care With No Study Intervention|Participants will receive standard medical care, consisting of antiemetic medicine at the first sign of Chemotherapy-Induced Nausea and Vomiting (CINV) on a schedule as prescribed by the healthcare provider.
62296984|NCT05319860|EXPERIMENTAL|Standard of Care With Study Intervention|Participants will receive an aromatherapy inhaler for complementary in addition to their standard of care antiemetic medication for Chemotherapy-Induced Nausea and Vomiting (CINV).
62296985|NCT02160457|EXPERIMENTAL|Intervention with IGA|Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis (IGA)
62666227|NCT02909647|ACTIVE_COMPARATOR|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
61912777|NCT00001131|ACTIVE_COMPARATOR|B|Patients will only follow their current oral anti-HIV medication regimen. No additional IL-2 injection will be given.
61912778|NCT03505931||Eluvia|Patients treated with Eluvia stent
62296986|NCT02160457|NO_INTERVENTION|Intervention without IGA|'Care as usual' - Individually tailored interdisciplinary interventions based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations BUT NOT (IGA).
62296987|NCT05865327|EXPERIMENTAL|Cryoneurolysis Group|In addition to all standard of care analgesia treatments, CN will be performed on the ICN of each broken rib using the Iovera CN device and Generation 2 Iovera tip under ultrasound guidance.
61912779|NCT03037723|OTHER|Prone/Supine Simulation|It is institutional policy to perform CT simulation in left-sided breast cancer patients with and without the respiratory gating (this is one CT scan), in the face-up position. It is also standard of care to perform the face-down CT simulation in large breasted women. Both of these simulations are meant to reduce the exposure of the heart and lungs to radiation. In this study, all left-sided breast cancer patients that consent will receive face-up CT simulation with and without gating AND face-down CT simulation, regardless of breast size; thus, each patient is their own control.
62296988|NCT05865327|SHAM_COMPARATOR|Standard Care Group|Participants in the control group will receive all standard of care analgesia treatments as well as sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding.
62296989|NCT04060615|OTHER|Patients with chronic total occlusion of the coronary artery|In each patient before the PCI procedure, the investigators will assess myocardial viability, functional parameters of collateral blood vessels, and quality of life. 24h and 6 months after the procedure these parameters will be reevaluated as well as functional parameters of the treated coronary artery.
62468575|NCT02007031||Normotensive subjects|Normotensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
62468576|NCT01327222|EXPERIMENTAL|bevacizumab|three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
62468577|NCT01327222|NO_INTERVENTION|control|monthly follow-up
61912780|NCT04038203||Neonates with UAC placement|Neonates with birth weight less than 1500 grams with UAC placed on admission. Raman measurements will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
62468578|NCT00567320|ACTIVE_COMPARATOR|Varenicline|
62666228|NCT02536794|EXPERIMENTAL|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
62666229|NCT03222128|EXPERIMENTAL|PIIS3i - SAPIEN 3|PIIS3i - SAPIEN 3 is Operable Group
62666230|NCT02357433|EXPERIMENTAL|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization
62666231|NCT02357433|NO_INTERVENTION|Control Group|Standard practice
62666232|NCT06021496|NO_INTERVENTION|control group|Participants in the control group continued to receive standard cervical cancer screening service of the Ministry of Health. No further intervention was made.
62666233|NCT06021496|EXPERIMENTAL|Face-to-face training group|"In addition to the standard cervical screening service of the Ministry of Health, face-to-face health education through home visits and a reminder by phone call were made once.~brochure given"
62666234|NCT06021496|EXPERIMENTAL|Online training group|In addition to the standard cervical screening service of the Ministry of Health, online health education via video call and a reminder with a phone call once. A digital brochure was given.
62666235|NCT02129556|EXPERIMENTAL|MK-3475 with trastuzumab (single arm)|"Phase Ib: MK-3475 at dose of 2 mg/kg or 10 mg/kg (i.v.), or a fall-back dose of 1 mg/kg, together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
62666236|NCT03837938|EXPERIMENTAL|Levopront® syrup 30 mg/5 ml|Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml (60 mg) t.i.d. for 7 days. The study drugs was taken 3 times a day, at intervals of at least 6 hours, between meals for 7 days.
62666237|NCT03837938|ACTIVE_COMPARATOR|Libexin® 100 mg tablets|Libexin® (prenoxdiazine) 100 mg tablets. Libexin® was administered orally, 1 tablet (100 mg) 3 times a day for 7 days.
62666238|NCT05327738|EXPERIMENTAL|Treatment (atezolizumab, Y-90, cabozantinib)|"CYCLE 1: Patients receive atezolizumab IV over 60 minutes on day 1. Within 14 days, patients receive Y-90 intra-arterially.~CYCLES 2+: Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib PO QD on days 1-21. Treatment repeats every 21 days for a total of 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit may continue receiving atezolizumab and cabozantinib beyond cycle 12 at the discretion of the PI."
62666239|NCT05702151|ACTIVE_COMPARATOR|Morphine infusion|IV morphine 50mcg/kg/h infusion with Patient Controlled Analgesia extra bolus on demand of 1mg (lockout interval 20 minutes), and paracetamol 1g every 8 hours.
62468579|NCT00567320|ACTIVE_COMPARATOR|Sugar Pill or Placebo|Placebo is compared to active drug varenicline
62104391|NCT04109690|EXPERIMENTAL|CPX-351|Phase I will evaluate the safety and tolerability of CPX-351 (44mg/m2 of daunorubicin and 100mg/m2 of cytarabine) administered on 2 days (day 1 and day 5) to determine the Phase II dose. Phase II will evaluate the efficacy of the RP2D.
62104392|NCT02414230||Experimental F 18 T807|
62666240|NCT05702151|EXPERIMENTAL|ESP Block analgesia|"After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed.~An infusion of ropivacaine 0.16% at 10ml/h is started in the operating room. Patient Controlled Analgesia pump will be connected with 1mg IV morphine bolus on demand, and paracetamol 1g every 8 hours, is also delivered."
61912781|NCT01492946||Elective surgical patients|Elective surgical patients in the Charité University Berlin Campus Charité Mitte
62296990|NCT01629303|EXPERIMENTAL|Arm on-off|"After the definitive implantation, stimulators are placed in position OFF during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks"
62296991|NCT01629303|EXPERIMENTAL|Arm off-on|"After the definitive implantation, stimulators are placed in position ON during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks"
62296992|NCT05535361|EXPERIMENTAL|Eclipse XL1 Coil Treatment Group|All subjects will be assigned to the XL1 Coil treatment group.
62296993|NCT02388295|EXPERIMENTAL|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
62296994|NCT02388295|PLACEBO_COMPARATOR|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
62296995|NCT01755988|NO_INTERVENTION|Usual care|
62296996|NCT01755988|EXPERIMENTAL|Educational website.|Educational website (in addition to usual care).
62296997|NCT01755988|EXPERIMENTAL|Website and interactive platform with telemonitoring.|Adjusted care pathway, including both the educational website and an interactive web-based platform with telemonitoring facilities. In this arm all routine consultations with heart failure nurses and general practitioner will be substituted by this combination of telemonitoring facilities connected to an interactive web-based platform plus the Dutch version of the European Society of Cardiology (ESC) website on heart failure.
61912782|NCT00159822|EXPERIMENTAL|1|
61912783|NCT05214053|EXPERIMENTAL|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
61912784|NCT00686634|EXPERIMENTAL|1|Sitagliptin 100 mg once daily
62104393|NCT06714396|EXPERIMENTAL|QRL-101|Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
62104394|NCT06714396|EXPERIMENTAL|Placebo|Single doses of comparator placebo will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
62104395|NCT03018145|EXPERIMENTAL|Standard stretcher group|Use a standard stretcher car as a transporting method in the operating room
62104396|NCT03018145|ACTIVE_COMPARATOR|Wagon group|Use a wagon as a transporting method in the operating room
62104397|NCT03664661|EXPERIMENTAL|experimental group|BCMA nanobody CAR-T cells
62104398|NCT04968574|EXPERIMENTAL|ENV-101|taladegib, 200 mg tablet, once daily for 12 weeks
62104399|NCT04968574|PLACEBO_COMPARATOR|placebo|placebo, tablet, once daily for 12 weeks
62296998|NCT00843180|EXPERIMENTAL|massage|
62296999|NCT00843180|NO_INTERVENTION|control|usual care only as control arm
62297000|NCT03977233|EXPERIMENTAL|SingleArm: FOLFIRINOX|Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.
62297001|NCT02585557|EXPERIMENTAL|Cluster A|50 practices randomly assigned to start intervention at month 9. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
62297002|NCT02585557|EXPERIMENTAL|Cluster B|50 practices randomly assigned to start intervention at month 11. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
62297003|NCT02585557|EXPERIMENTAL|Cluster C|50 practices randomly assigned to start intervention at month 12. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
62297004|NCT02585557|EXPERIMENTAL|Cluster D|50 practices randomly assigned to start intervention at month 14. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
62297005|NCT02585557|EXPERIMENTAL|Cluster E|50 practices randomly assigned to start intervention at month 16. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
62297006|NCT02102750|EXPERIMENTAL|tafluprost|
62666241|NCT03427281|EXPERIMENTAL|Cohort: Belgian orthopaedic surgeons & neurosurgeon|
62666242|NCT05017155|ACTIVE_COMPARATOR|Lamotrigine|When on the lamotrigine treatment arm, the participant will commence at lamotrigine 25mg (milligram) daily for two weeks; then increase to 25mg twice daily for two weeks; then increase to 50mg daily for one week; then increase to 100mg in the morning, 50mg at midday and 50mg at night for one week; then increase to 100mg in the morning, 50mg at midday and 100mg at night for two weeks.
62666243|NCT05017155|ACTIVE_COMPARATOR|Mexiletine|When on the mexiletine treatment arm, the participant will commence at mexiletine 100mg daily for two weeks; then increase to 200mg daily for two weeks; then increase to 200mg twice daily for one week; then increase to 200mg three times a day for one week; then remain on 200mg three times a day for two weeks.
62666244|NCT03195530||Elderly patients|Patients over 65 years, scheduled to general surgery, requiring general anesthesia
61912785|NCT05026814||Women with FGM/C|Women who requested clitoral reconstruction after FGM/C between 01/2013 until 04/2021 and underwent multidisciplinary care consisting of psychosexual care (PC) with or without CR. To be included the women had to attend at least one session with the psychologist as part of psychosexual care.
62666245|NCT04481282|EXPERIMENTAL|Terbutaline plus Danazol group|Terbutaline 2.5mg tid po plus danazol 200mg bid po for 12weeks
62666246|NCT00649948|EXPERIMENTAL|1|Metformin Hydrochloride ER Tablets 500 mg
62666247|NCT00649948|ACTIVE_COMPARATOR|2|Glucophage XR 500 mg
62666248|NCT05663788|EXPERIMENTAL|E-learning module gastroenterologists|Gastroenterologists participating in the e-learning module
62666249|NCT05663788|NO_INTERVENTION|Control group|Gastroenterologists not participating in the e-learning module
62666250|NCT04608864|EXPERIMENTAL|varicocelectomy arm|The varicocelectomy procedure will be performed three months before ICSI for men with with male-factor infertility and were diagnosed clinically with varicocele
62666251|NCT04608864|NO_INTERVENTION|Control (No varicocelectomy) arm|Couples with male-factor infertility and males were diagnosed clinically with varicocele will undergo ICSI
62666252|NCT04705584|ACTIVE_COMPARATOR|Topical steroids|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.
62666253|NCT04705584|EXPERIMENTAL|Topical Cyclosporine A|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Cyclosporine A 2% Topical eye drops 2 times per day for 6 weeks.
62666254|NCT04705584|EXPERIMENTAL|Topical Tacrolimus|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Tacrolimus A 0.3% Topical eye drops 2 times per day for 6 weeks.
62666255|NCT04056429|EXPERIMENTAL|BHA|Subjects treated with BHA + standard of care
62666256|NCT04056429|NO_INTERVENTION|Control|Subjects treated as per standard of care
62297007|NCT03617926|EXPERIMENTAL|Test product|Water-based lotion (internal code (X92001666)
62297008|NCT03617926|ACTIVE_COMPARATOR|Reference|Commercial, pyrethrin-based shampoo (RID shampoo)
62666257|NCT04776772|PLACEBO_COMPARATOR|Soccer player placebo|Soccer player consuming placebo sticks filled with 300 mg excipient of maltodextrin
62666258|NCT04776772|EXPERIMENTAL|Soccer player synbiotic|Soccer players consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
62666259|NCT04776772|PLACEBO_COMPARATOR|Sedentary individuals placebo|Sedentary individuals consuming placebo sticks filled with 300 mg excipient of maltodextrin
62666260|NCT04776772|EXPERIMENTAL|Sedentary individuals synbiotic|Sedentary individuals consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
62666261|NCT02158598|NO_INTERVENTION|wash-out|2 months
62666262|NCT02158598|EXPERIMENTAL|Vitamin D chewable tablet supplementation|A chewable vitamin D tablet containing 1000 IU to be taken once a day for 2 months.
62666263|NCT02158598|EXPERIMENTAL|Vitamin D pill supplementation|A vitamin D pill containing 1000 IU to be taken once a day for 2 months.
62666264|NCT04428944|ACTIVE_COMPARATOR|PV antral isolation alone (PVAI)|PV antral isolation alone (PVAI)
62666265|NCT04428944|ACTIVE_COMPARATOR|PV antral isolation plus ablation of drivers|PV antral isolation plus ablation of drivers (PVAI+drivers)
62666266|NCT04428944|ACTIVE_COMPARATOR|PV antral isolation plus isolation of posterior wall|PV antral isolation plus isolation of LA posterior wall (PVAI+Box)
62666267|NCT01834261|ACTIVE_COMPARATOR|Oxytocin|Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
62666268|NCT01834261|PLACEBO_COMPARATOR|Placebo|Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
62666269|NCT04650945|ACTIVE_COMPARATOR|isCGM-arm|isCGM (intermittently scanned continuous glucose monitor) data obtained from a FreeStyle Libre Flash continuous glucose monitoring system will be viewed real-time and used to adjust diabetes treatment
61912786|NCT01153776|EXPERIMENTAL|64-slice CT angiography|64-slice CT angiography
62104400|NCT04393896|EXPERIMENTAL|intervention group|Participants in the intervention group will receive the usual financial benefits of the Reward Policy as well as the WIFI program which will include three key components: psycho-education through WOA publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call.
62104401|NCT04393896|NO_INTERVENTION|control group|Participants in the control group will receive the usual financial benefits of the Reward Policy and receive payment from the Changsha psychiatric hospital. However, they will not have access to the WIFI program since they cannot scan the WeChat barcode for the research.
62104402|NCT04570761|EXPERIMENTAL|ON-Stim|acoustic stimulation
62104403|NCT04570761|SHAM_COMPARATOR|OFF-Stim|no acoustic stimulation
62104404|NCT02728245|PLACEBO_COMPARATOR|Control group|"Placebo drug 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
62104405|NCT02728245|EXPERIMENTAL|Case group|"Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
62104406|NCT01048151|EXPERIMENTAL|Single|TNFerade™ Biologic + Radiation
62104407|NCT06134505|EXPERIMENTAL|Experimental: Experimental Group1|Barrier cream group 1 consists of a mixture of propolis, beeswax, queen bee larva and plant oil
62104408|NCT06134505|EXPERIMENTAL|Experimental: Experimental Group2|Olive oil group
62104409|NCT06134505|ACTIVE_COMPARATOR|Control Group|Barrier cream group 2 consists of zinc oxide
62104410|NCT06075706|EXPERIMENTAL|MC0518|Participants will be treated with intravenous infusions of MC0518 at a dose of 1 to 2\*10\^6 cells per kilogram (cells/kg) (based on body weight at the Screening Visit). Infusions will be administered once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
62104411|NCT06075706|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|Participants will receive one of the following systemic BATs based on the Investigator's decision: extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX).
62104412|NCT02990858|EXPERIMENTAL|PRO 140|
62104413|NCT06152029||Patients treated with a temporary PNS system|These patients will receive a temporary PNS system for their knee pain secondary to osteoarthritis
62104414|NCT00587132|EXPERIMENTAL|New Onset Diabetes|"Adults diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
62104415|NCT00587132|EXPERIMENTAL|Familial Pancreatic Cancer|"Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
62104416|NCT00587132|EXPERIMENTAL|Peutz-Jeghers Syndrome|"Adults age 35-99 with Peutz-Jeghers syndrome.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
62104417|NCT00587132|EXPERIMENTAL|Clinical Symptoms of Pancreatic Cancer, Normal CT|"Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
62104418|NCT02377362|EXPERIMENTAL|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
62104419|NCT02377362|PLACEBO_COMPARATOR|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
62297009|NCT01307423|EXPERIMENTAL|Apremilast 20mg|Apremilast 20mg twice daily, orally
62297010|NCT01307423|EXPERIMENTAL|Apremilast 30mg|Apremilast 30mg twice daily, orally
61912787|NCT02108262|EXPERIMENTAL|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
62104420|NCT02377362|EXPERIMENTAL|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
62104421|NCT02377362|PLACEBO_COMPARATOR|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
62104422|NCT02377362|EXPERIMENTAL|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
62104423|NCT02377362|PLACEBO_COMPARATOR|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
62104424|NCT02805387|NO_INTERVENTION|no treatment|Dystocic women where no bicarbonate was given
62104425|NCT02805387|EXPERIMENTAL|Treatment|Dystocic women where bicarbonate was ingested
62104426|NCT06109779|EXPERIMENTAL|Arm A|Rilvegostomig IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)
62104427|NCT06109779|PLACEBO_COMPARATOR|Arm B|Placebo IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)
62104428|NCT05390476|EXPERIMENTAL|Tucidinostat and metronomic capecitabine group|
62104429|NCT05390476|ACTIVE_COMPARATOR|metronomic capecitabine group|
62104430|NCT03681691|EXPERIMENTAL|Post menopausal women with diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes
62104431|NCT03681691|EXPERIMENTAL|Post menopausal women without diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.
62297011|NCT01307423|PLACEBO_COMPARATOR|Placebo + 20mg Apremilast|Placebo + 20mg Apremilast tablets administered twice daily
62297012|NCT01307423|PLACEBO_COMPARATOR|Placebo + 30mg Apremilast|Placebo + 30mg Apremilast tablets administered twice daily
62297013|NCT06103110|EXPERIMENTAL|anterior repositioning appliance followed by Infra-red LED therapy|anterior repositioning appliance followed by Infra-red LED therapy
62297014|NCT06103110|EXPERIMENTAL|Infra-red LED therapy followed by anterior repositioning appliance|Infra-red LED therapy followed by anterior repositioning appliance
62297015|NCT06103110|EXPERIMENTAL|anterior repositioning appliance followed by Low level Laser therapy|anterior repositioning appliance followed by Low level Laser therapy
62468580|NCT04721795|EXPERIMENTAL|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
62468581|NCT04721795|ACTIVE_COMPARATOR|Anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs only consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
62468582|NCT02502474|EXPERIMENTAL|Patients undergoing a colonoscopy|Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
62468583|NCT03570905|EXPERIMENTAL|Sugartong Splint|
62666270|NCT04650945|NO_INTERVENTION|POC-arm|POC glucose readings are used to adjust diabetes treatment. CGM data from the Freestyle Libre monitor are blinded to all and only gathered for comparison purposes to intervention group.
62666271|NCT03390192|EXPERIMENTAL|Dual-mode stimulation|"Dual-mode stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and active tDCS. 1 Hz of rTMS is applied over the contralesional M1 for 20 minutes with simultaneous application of anodal tDCS on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
62666272|NCT03390192|ACTIVE_COMPARATOR|Single sham stimulation|"Single sham stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and sham tDCS. 1 Hz of rTMS over the contralesional M1 was applied for 20 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
61912788|NCT02108262|EXPERIMENTAL|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
62104432|NCT05020795|EXPERIMENTAL|Balloon inflation|Endovascular thrombectomy with simultaneous balloon inflation using a balloon guide catheter
62297016|NCT06103110|EXPERIMENTAL|Low level Laser therapy followed by anterior repositioning appliance|Low level Laser therapy followed by anterior repositioning appliance
62297017|NCT06208488|EXPERIMENTAL|Gefurulimab PFS-SD|Participants will be administered gefurulimab as a single dose of 600 mg by PFS-SD on the abdomen, thigh, or upper arm.
62468584|NCT03570905|EXPERIMENTAL|Clam Shell Splint|
62468585|NCT03953950|EXPERIMENTAL|Combination of spironolactone and losartan|
62468586|NCT03953950|ACTIVE_COMPARATOR|Losartan Alone|
62468587|NCT05805865|EXPERIMENTAL|Toothpaste Tablet|Subjects are instructed to use one toothpaste tablet for brushing. Brushing is recommended twice daily for two minutes.
62468588|NCT05805865|ACTIVE_COMPARATOR|Conventional Toothpaste|Subjects are instructed to use the toothpaste for brushing. Brushing is recommended twice daily for two minutes.
62468589|NCT05165823|EXPERIMENTAL|Sodium restriction|
62468590|NCT05165823|NO_INTERVENTION|Usual diet|
62468591|NCT01042522|EXPERIMENTAL|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62468592|NCT01042522|EXPERIMENTAL|Arm II (bleomycin sulfate, etoposide phosphate, cisplatin)|Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62468593|NCT05884762|EXPERIMENTAL|Interventional group|electroencephalographic neurofeedback + traditional reference rehabilitation programme
62468594|NCT05884762|SHAM_COMPARATOR|Control group|SHAM electroencephalographic neurofeedback + traditional reference rehabilitation programme
62468595|NCT01677962|EXPERIMENTAL|dendritic cell and Poly-ICLC vaccination|Dendritic cell and Poly-ICLC vaccination will be administered directly into the tumor on Day 0 and Day 14 of Treatment Phase. Subjects will then have standard of care procedures along with injections of Poly-ICLC and dendritic cells for the remainder of the study.
62104433|NCT05020795|ACTIVE_COMPARATOR|No balloon inflation|Endovascular thrombectomy without simultaneous balloon inflation using a balloon guide catheter
62297018|NCT06208488|EXPERIMENTAL|Gefurulimab AI|Participants will be administered gefurulimab as a single dose of 600 mg by AI on the abdomen, thigh, or upper arm.
61912789|NCT02108262|PLACEBO_COMPARATOR|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
62297019|NCT04376619|EXPERIMENTAL|KDIGO guidelines|Part 1 of study, those identified as high risk for AKI then will have Kidney Disease Global Improving outcomes guideline implemented to see if this reduces incidence of AKI
62297020|NCT04376619|EXPERIMENTAL|RIPC|part 2 of study, those identified as high risk of AKI will have Kidney Disease Improving Global Outcomes guidelines and RIPC implemented to see if this reduces incidence of AKI compared to part 2 of study
62468596|NCT01169883|ACTIVE_COMPARATOR|Attention Control Group|1) Doctor Asthma Messages delivered over a 10 week time period; 2) Asthma Supervision; and 3) Music Tracks.
62468597|NCT01169883|EXPERIMENTAL|Intervention Group|1) Coping Peer Support delivered over a 10 week time period; 2) Coping Peer Asthma Messages delivered over a 10 week time period; 3) Asthma Supervision; and 4) Music Tracks.
62468598|NCT04195022|EXPERIMENTAL|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
62468599|NCT04195022|ACTIVE_COMPARATOR|Bulk fill resin composite|Single placement of Bulk fill resin composite on atypical cavities.
62468600|NCT04587570|EXPERIMENTAL|Group 1: Infiltration of PRP|The proband gets Platelet Rich Plasma injected in the thumb saddle joint.
62468601|NCT04587570|EXPERIMENTAL|Group 2: Infiltration of Fat|The proband gets fat injected in the thumb saddle joint.
62468602|NCT04587570|EXPERIMENTAL|Group 3: Infiltration of PRP and Fat|The proband gets a mixture of Platelet Rich Plasma (PRP) and Fat injected in the thumb saddle joint.
61912790|NCT00575835|ACTIVE_COMPARATOR|1|
62104434|NCT04046523|EXPERIMENTAL|Healthy Controls|In the first phase of the experiment, 20 healthy controls will test the VO device to determine whether the camera with a CCD or CMOS lens is the most appropriate for use in ICP patients and to synchronize the VO, ECG, PPG, IOP and respiratory signals.
61912791|NCT00575835|EXPERIMENTAL|2|
61912792|NCT00851968|ACTIVE_COMPARATOR|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
62104435|NCT04046523|EXPERIMENTAL|Transfer Function Estimation|Subjects in the second phase of the experiment (70 subjects total) will be randomized to either Group A or Group B. We anticipate that 25 adult and 10 pediatric (ages 4-17) patients will participate in each group. Individuals in Group A will have two inter-leaved examinations (1-14 days apart). Data from the first examination will serve for SVP-ICP transfer function estimation and data from the second examination will serve for the intra-group verification for the estimated transfer function.
62104436|NCT04046523|EXPERIMENTAL|Intra-Group Verification|Individuals in Group B will undergo one examination. Data from Group B participants will serve as the inter-group re-test verification of the estimated transfer function.
62104437|NCT04084769|EXPERIMENTAL|Group 1: MenACYW Conjugate vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
62104438|NCT04084769|EXPERIMENTAL|Group 2: MenACYW Conjugate vaccine (Menveo Vaccine-primed)|Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
62104439|NCT04084769|EXPERIMENTAL|Group 3: MenACYW Conjugate vaccine + Trumenba vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).
62104440|NCT04084769|EXPERIMENTAL|Group 4: MenACYW Conjugate vaccine + Bexsero vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).
62104441|NCT02341989|EXPERIMENTAL|Bleomycin-Etoposide-Cisplatin|One course of adjuvant BEP.
62468603|NCT04587570|PLACEBO_COMPARATOR|Group 4: Infiltration of NaCl|The proband gets NaCl injected in the thumb saddle joint.
62468604|NCT02785003|EXPERIMENTAL|Ketamine Infusion|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the ketamine solution at a calculated dose of 0.25 mg/kg. A continuous infusion of ketamine will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
62468605|NCT02785003|PLACEBO_COMPARATOR|Saline Placebo|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the saline solution at a calculated dose of 0.25 mg/kg. A continuous infusion of saline will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
62468606|NCT06317103||Trial group|"The gastro-endoscopic images in this group are classified as Mucosa or Submucosa by WADYMED endo."
62468607|NCT06317103||Control group|"The gastro-endoscopic images in this group are interpreted as Mucosa or Submucosa by the endoscopists."
62468608|NCT04463602|EXPERIMENTAL|Desidustat + Standard of Care|"Test: Desidustat + Standard of care~Desidustat 100 mg for the duration of 14 days along with the recommended standard of care at the time of conduct of trial."
62468609|NCT04463602|ACTIVE_COMPARATOR|Standard of Care|"Control: Standard of care~Standard of care treatment for the duration of 14 days at the time of conduct of trial."
62468610|NCT06275061||Metabolic and Bariatric Surgery|Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
62468611|NCT03705065|EXPERIMENTAL|Treatment Group 1|Bupivacaine HCI by instillation into each pectoral pocket.
62468612|NCT03705065|EXPERIMENTAL|Treatment Group 2|Bupivacaine HCI by injection into each pectoral pocket.
62468613|NCT04827732|EXPERIMENTAL|Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"* Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 1.~* The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
62468614|NCT04827732|EXPERIMENTAL|Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"* Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 2.~* The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
61912793|NCT00851968|EXPERIMENTAL|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy
61912794|NCT00851968|EXPERIMENTAL|portal vein occlusion|Patients with HCC received portal vein occlusion in hepatectomy
61912795|NCT02009605|EXPERIMENTAL|one arm|Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.
61912796|NCT03841578|EXPERIMENTAL|Healthy|10 participants (matched per gender), aged 25-35 years old who accepts the consumption of dark chocolate plus a 'NutriDrink' previous to signing an informed consent and providing authorization to the handling of their personal data
62468615|NCT04827732|EXPERIMENTAL|Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"* Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 3.~* The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
62666273|NCT03071744|OTHER|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
62666274|NCT05396300|EXPERIMENTAL|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x106 cells/kg
62666275|NCT05396300|EXPERIMENTAL|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x106 cells/kg
61912797|NCT00005646|EXPERIMENTAL|Paclitaxel|Patients receive paclitaxel for up to 4 cycles. One cycle = weekly drug for 6 weeks and 2 weeks rest
61912798|NCT01027390|EXPERIMENTAL|1 hr training 50% supervision|1 hr training 50% supervision
61912799|NCT01027390|EXPERIMENTAL|3 x 20 min training 50% supervision|3 x 20 min training 50% supervision
62666276|NCT01049828||Slightly or Non-Bothered Tinnitus Group|"Identified by a Tinnitus Handicap Index \<36 and a subjective description of their tinnitus as no or slight bother.~A control group has been collected through a different study, i.e. no controls will be recruited in this study."
61912800|NCT01027390|EXPERIMENTAL|3 x 20 min training initial instructions|3 x 20 min training initial instructions
61912801|NCT01027390|EXPERIMENTAL|10 x 6 min training 50% supervision|10 x 6 min training 50% supervision
61912802|NCT01027390|NO_INTERVENTION|reference|no training
62104442|NCT02341989|ACTIVE_COMPARATOR|Carboplatin|One course of adjuvant carboplatin AUC7
62104443|NCT02435901|EXPERIMENTAL|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients \<10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients \> 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
62104444|NCT00699738|EXPERIMENTAL|1|Healthy women during pregnancy and in the postpartum period, breastfeeding
62104445|NCT00699738|ACTIVE_COMPARATOR|2|Healthy women during pregnancy and in the postpartum period,bottlefeeding
62104446|NCT00699738|NO_INTERVENTION|3|Healthy non-pregnant women
62104447|NCT06629090|EXPERIMENTAL|Young Adults|Young Adults between 20-40 years of age.
62104448|NCT00542386|EXPERIMENTAL|1|
62104449|NCT00542386|PLACEBO_COMPARATOR|2|
62297021|NCT06275126|NO_INTERVENTION|Usual care|"Prior to institutional crossover, participants receive care as per usual for 6 months (run-in period) and are not sent CONSYDER."
62297022|NCT06275126|OTHER|CONSYDER decision aid|Web-based breast cancer surgery decision aid
61912803|NCT03511898|EXPERIMENTAL|THR-149 dose level 1|
61912804|NCT03511898|EXPERIMENTAL|THR-149 dose level 2|
61912805|NCT03511898|EXPERIMENTAL|THR-149 dose level 3|
61912806|NCT03233880|ACTIVE_COMPARATOR|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
61912807|NCT03233880|PLACEBO_COMPARATOR|placebo group|- Matching placebo orally, single dose
62104450|NCT04379986|EXPERIMENTAL|Standardized measures in the cardiac catheterization laborator|Immediately after coronary angiography, intra-arterial BP waveforms will be recorded using a fluid-filled catheter via right femoral or radial access. The catheter will be flushed before any waveform recordings is made. At first, the catheter will be positioned in the aorta for 3 minutes of stable BP waveforms recording. Intracoronary nitroglycerin will be administered at a dose of 300 µg, newly preceding 3 minute of recording. At the end of the coronary angiography, additional 3 minutes of recording will be performed in the aorta.
62104451|NCT04379986|EXPERIMENTAL|Standardized measures in the intensive care unit|Invasive BP monitoring is a commonly used technique in the ICU and is used to guide many intensive care unit therapies. Enrolled patients must have had an arterial catheter in place at the time of inclusion to the study. Arterial catheterization will be performed by the intensive care team according to current medical guidelines. No arterial catheters were placed for the sole purpose of this study. The Senbiosys device will be placed on the opposite arm of the arterial catheter for simultaneous measurements.
62104452|NCT01501435|EXPERIMENTAL|CJ-30039|Incrementally Modified Drugs of fenofibric acid
62297023|NCT03714126||HF patients|HF patients will use the Cordio Medical app to record in their hospital visits and at home.
62297024|NCT04470895||Usual falling patients|"a group enrolling the patients who completed the inclusive criteria and have had at least one fall in the last 12 months in addition to the possible fall causing the index fracture.~These patients must answer positively the following question Have you fallen in the last 12 months, regardless of the current fracture?"
62104453|NCT01501435|ACTIVE_COMPARATOR|fenofibric acid|Greencross Lipidil Supra 160mg
62104454|NCT05837676|EXPERIMENTAL|PST-Concussion|Treatment arm. Six, approximately 30-minute telehealth treatment sessions comprised of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
62104455|NCT05837676|OTHER|Treatment as usual (TAU)|Control arm. Primary care treatment as usual. Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
62104456|NCT06406543|EXPERIMENTAL|Low dose, high frequency vitamin D repletion|receive 7,000 IU oral drops daily for 12 weeks, followed by 3,500 IU daily for 24 weeks
62104457|NCT06406543|EXPERIMENTAL|Medium dose, medial frequency vitamin D repletion|50,000 IU oral solution weekly for 12 weeks, followed by 25,000 weekly for 24 weeks
62104458|NCT06406543|EXPERIMENTAL|High dose, low frequency vitamin D repletion|100,000 IU every other week for 12 weeks, followed by 50,000 every other week for 24 weeks
62104459|NCT03826693|EXPERIMENTAL|Experimental: Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
62104460|NCT03826693|PLACEBO_COMPARATOR|Control: Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
62297025|NCT04470895||Unusual falling patients|"a group enrolling the patients who also completed the inclusive criteria, but are defined as unsual falling patients. These patients must answer negatively the following question: Have you fallen in the last 12 months, regardless of the current fracture?"
62297026|NCT05995704|EXPERIMENTAL|Apraglutide SC injections|
62297027|NCT05995704|PLACEBO_COMPARATOR|Placebo|
62297028|NCT01564706|EXPERIMENTAL|Healthy Volunteers|Healthy male or female subjects, between 18 and 85 years of age.
62297029|NCT04996719|EXPERIMENTAL|Rapamycin|find safe doses for patients who have heart failure with preserved ejection fraction
62297030|NCT04640714|EXPERIMENTAL|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|"Participants with advanced cancer will receive a video visit conducted by an oncology Nurse Practitioner (NP) within three (3) business days of hospital discharge.~The visit will involve: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.~Participant and clinician may also be interviewed for their feedback on the video visit.~The ultimate goal of the intervention is to improve patients' confidence in managing their health condition and reduce burdensome health care utilization after discharge, particularly reducing 30-day hospital readmissions."
62297031|NCT00251602|EXPERIMENTAL|1|II ACE genotype
62468616|NCT02943447|EXPERIMENTAL|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
62666277|NCT01573377|EXPERIMENTAL|metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
61912808|NCT04418401|EXPERIMENTAL|Experimental group|Treatment with Donafenib 100mg PO BID，and anti-PD-1 antibody 3mg/kg ivgtt Q2W. Treatment will last 6 months, unless the tumor recurrence.
62104461|NCT01037933|ACTIVE_COMPARATOR|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
62104462|NCT01037933|ACTIVE_COMPARATOR|Non-humor intervention|"A 45-minute non-humorous DVD The A to Z of Steam Railways using a portable DVD player."
62104463|NCT05649098|EXPERIMENTAL|Open-Label Dupilumab|
62104464|NCT01473719|ACTIVE_COMPARATOR|motivational intervention|7-session individual motivationally-based intervention
62104465|NCT01473719|PLACEBO_COMPARATOR|health education|7-session individual session focusing on health education
62104466|NCT03401398|ACTIVE_COMPARATOR|Treatment|Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.
62297032|NCT00251602|EXPERIMENTAL|2|ID ACE genotype
62666278|NCT01573377|EXPERIMENTAL|Ethinylestradiol and Cyproterone Acetate|From the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill.
62666279|NCT02053116|EXPERIMENTAL|PF-05175157|
62666280|NCT02053116|PLACEBO_COMPARATOR|Placebo|
61912809|NCT05709132|EXPERIMENTAL|iPeer2Peer Program|
61912810|NCT05709132|NO_INTERVENTION|Standard of Care Waitlist Control Group|
61912811|NCT00469170|EXPERIMENTAL|A|vaginal ring first 12 weeks \& observational safety last 12 weeks
61912812|NCT00469170|EXPERIMENTAL|B|observational safety first 12 weeks \& vaginal ring last 12 weeks
61912813|NCT03951168|OTHER|Routine Management|The patients were divided into routine diabetic health education management model group. Patients who meet the criteria for admission and discharge.
62104467|NCT03401398|PLACEBO_COMPARATOR|Placebo|Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.
62104468|NCT02787967|EXPERIMENTAL|NEXThaler® 35/4µg|CHF 1535 35/4µg NEXThaler® Dry Powder Inhaler, 4 inhalations. Total Dose: BDP 200µg FF 16µg
62104469|NCT02787967|ACTIVE_COMPARATOR|Reference treatment|Drug: free comb. beclomethasone DPI and formoterol DPI 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
62104470|NCT01428895|ACTIVE_COMPARATOR|Surgery Alone|
62104471|NCT01428895|ACTIVE_COMPARATOR|Surgery + Radiation Therapy|
62104472|NCT05700539|EXPERIMENTAL|Internet-based cognitive behavioral therapy|
62297033|NCT00251602|EXPERIMENTAL|3|DD ACE genotype
62297034|NCT00251602|PLACEBO_COMPARATOR|4|II ACE genotype
62297035|NCT00251602|PLACEBO_COMPARATOR|5|ID ACE genotype
62297036|NCT00251602|PLACEBO_COMPARATOR|6|DD ACE genotype
62297037|NCT00363961|EXPERIMENTAL|1|resistance exercise
62297038|NCT00363961|SHAM_COMPARATOR|2|flexibility exercises
62297039|NCT03127449|EXPERIMENTAL|Alflutinib|patients take Alflutinib orally once per day at different dose
62297040|NCT01713634|EXPERIMENTAL|Low Apro/K Diet|Subjects consume a prescribed diet for 4 days with a low ratio of animal protein to potassium (0.3-0.6 g/mEq).
62104473|NCT05700539|NO_INTERVENTION|Wait-list control|
62297041|NCT01713634|EXPERIMENTAL|High Apro/K Diet|Subjects consume a prescribed diet that has a high ratio of animal protein to potassium (1.0-1.3 g/mEq) for 4 days.
62468617|NCT02943447|EXPERIMENTAL|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.
62666281|NCT04627584|ACTIVE_COMPARATOR|MW33 injection-1200mg|
62666282|NCT04627584|ACTIVE_COMPARATOR|MW33 injection-2400mg|
62666283|NCT04627584|PLACEBO_COMPARATOR|Placebo|
62666284|NCT01124539|EXPERIMENTAL|AR-67|
62666285|NCT01010438||Adults|Adult patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
62666286|NCT01010438||Children (1-17)|Pediatric patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
62666287|NCT06465056|ACTIVE_COMPARATOR|Right side treatment|Patients receive botulinum toxin A in right side eyebrow scar and saline in left side scar.
62666288|NCT06465056|ACTIVE_COMPARATOR|Left side treatment|Patients receive botulinum toxin A in left side eyebrow scar and saline in right side scar.
62666289|NCT06231121||Patients|Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.
62468618|NCT02943447|PLACEBO_COMPARATOR|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
62468619|NCT02943447|EXPERIMENTAL|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.
62666290|NCT03418974|EXPERIMENTAL|Pitavastatin treatment|The drug pitavastatin is given to the patient according to the doctor's order and restricted to BangZhi produced by Jiangsu Wanbang Medicine Marketing Co., Ltd..
62666291|NCT03418974|EXPERIMENTAL|Atorvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
62666292|NCT03418974|EXPERIMENTAL|Rosuvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
62666293|NCT01527669|EXPERIMENTAL|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
62666294|NCT01527669|EXPERIMENTAL|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
62666295|NCT00997126|ACTIVE_COMPARATOR|Propofol|Propofol 1m g/kg IV followed by 0.5 mg/kg IV prn sedation
62666296|NCT00997126|ACTIVE_COMPARATOR|Alfentanil|Sedation using alfentanil 10 ug/kg followed by 5 ug/kg prn sedation
62666297|NCT04400747|EXPERIMENTAL|weekly treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 50,000 IU of vitamin D weekly for 8 weeks.
62666298|NCT04400747|EXPERIMENTAL|daily treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 6,000 IU of vitamin D daily for 8 weeks.
62666299|NCT04400747|NO_INTERVENTION|control group|20 patients with high calcium (Ca) values in blood tests, patients with kidney and urinary stones, as well as patients who refuse to use vitamin D supplements will be included in the control group
62666300|NCT00593073|EXPERIMENTAL|1|Tailored Reminder Message
62666301|NCT00593073|EXPERIMENTAL|2|General Reminder Message
62666302|NCT05721027|EXPERIMENTAL|Ibuprofen + dexamethasone + educational intervention|Ibuprofen 400 mg PO every 8 hours as needed for 7 days + dexamethasone 16 mg PO for day 1 and day 2. Research personnel will provide each participant with a 15-minute educational intervention.
62666303|NCT05721027|PLACEBO_COMPARATOR|Ibuprofen + placebo + educational intervention|Ibuprofen 400 mg PO every 8 hours as needed for 7 days + placebo PO for day 1 and day 2. Research personnel will provide each participant with a 15-minute educational intervention.
61912814|NCT03951168|EXPERIMENTAL|Standardized Management|The patients were divided into standardized diabetes health education management model group. Patients who meet the criteria for admission and discharge.
61912815|NCT02671162|PLACEBO_COMPARATOR|Wheat|Placebo capsule/ 2 capsule 3 times per day
62104474|NCT03321760|EXPERIMENTAL|Run-In Dose 1|10 Gy dose delivered to the primary tumor \& 10 Gy to the hilar (N1) node over 5 fractions
62104475|NCT03321760|EXPERIMENTAL|Run-In Dose -1|10 Gy dose delivered to the primary tumor \& 9 Gy to the hilar (N1) node over 5 fractions
62104476|NCT03321760|EXPERIMENTAL|Run-In Dose -2|10 Gy dose delivered to the primary tumor \& 8 Gy to the hilar (N1) node over 5 fractions
62104477|NCT03321760|EXPERIMENTAL|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
62297042|NCT05985681|EXPERIMENTAL|Arm I (RG1-VLP, Gardasil-9)|Patients receive RG1-VLP IM for 3 doses at months 0, 2, and 6 in the absence of unacceptable toxicity. Patients may also receive Gardasil-9 via injection for 3 doses at 6 months after the 3rd study vaccination (month 12), then at months 14 and 18 in the absence of unacceptable toxicity. Patients also undergo blood sample collection on study and may undergo vaginal swab collection on study.
62297043|NCT05985681|PLACEBO_COMPARATOR|Arm II (saline placebo, Gardasil-9)|Patients receive saline placebo IM for 3 doses at months 0, 2, and 6 in the absence of unacceptable toxicity. Patients may also receive Gardasil-9 via injection for 3 doses at 6 months after the 3rd saline injection (month 12), then at months 14 and 18 in the absence of unacceptable toxicity. Patients also undergo blood sample collection on study and may undergo vaginal swab collection on study.
62297044|NCT03372525|EXPERIMENTAL|HFOV|Ventilated infants were randomized to HFOV.
62297045|NCT03372525|ACTIVE_COMPARATOR|CMV|Ventilated infants were randomized to CMV.
62297046|NCT02484872||Lung neoplasms|Lung neoplasms irrespective of stage and histology
61912816|NCT02671162|ACTIVE_COMPARATOR|Fumaria|Fumaria capsule (0.5 mg Fumaria parviflora L.) / 2 capsule 3 times per day.
62468620|NCT04739566|EXPERIMENTAL|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib 150 mg orally (PO) twice daily, trametinib 2mg PO once daily for 3 months
62666304|NCT05480371|ACTIVE_COMPARATOR|Conventional endotracheal suctioning|Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations: closed suction system, suction catheter with maximal internal-to-external diameter ratio of 0.5, delivery of 100% oxygen 30 s immediately before and 1 min after the procedure, duration of 15 s, and vacuum pressure of ±150 mmHg
62666305|NCT05480371|EXPERIMENTAL|mechanical insufflation exsufflation|The mechanical insufflation-exsufflation will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause, and tracheal suctioning will be performed at the end of the procedure. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions. The secretion collected after each procedure will be stored in a disposable bronchial secretion collector for later weighing
62666306|NCT02820636|EXPERIMENTAL|InVita|Participants receive the Socio-Cognitive Behavior Therapy (S-CBT) treatment.
62666307|NCT02820636|ACTIVE_COMPARATOR|Treatment as Usual|Intensive outpatient therapy of standard care for adolescents and their parents
62666308|NCT04067245|OTHER|Tetrasodium EDTA cathether lock solution|There is only one arm in this study where home parenteral nutrition patients who meet the inclusion criteria will receive tetrasodium EDTA catheter lock solution.
62666309|NCT01987674|EXPERIMENTAL|Pre-meal protein drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
62666310|NCT01987674|PLACEBO_COMPARATOR|Water drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
61912817|NCT00749814|EXPERIMENTAL|A|Study group will receive melatonin.
61912818|NCT00749814|PLACEBO_COMPARATOR|B|Placebo
61912819|NCT00749814|NO_INTERVENTION|C|No intervention control group.
62666311|NCT05151614|EXPERIMENTAL|Colchicine group|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy
62666312|NCT05151614|NO_INTERVENTION|Control group|"The patients in this group will receive only standard care which will include all or some of the following, according to the clinical condition of each patient:~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* Dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed"
62468621|NCT03290781|EXPERIMENTAL|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 \[NCT03259334\] and SHP647-302 \[NCT03259308\]) will receive 25 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
62666313|NCT01481779|EXPERIMENTAL|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
62297047|NCT02367846|EXPERIMENTAL|Combined Oral Contraceptive (COC)|We are testing the effects of a COC (Apri (Reclipsen); 30 µg EE, 150 µg desogestrel). On the first day of the intervention, the participants randomized to COC will begin taking the pill. One pill will be ingested orally at the same time each day for days 1-49 of the intervention. Pills ingested during days 1-21 and during days 29-49 will be active tablets. Pills ingested on days 22-28 will be tablets without active ingredients. Each participant in the COC group will ingest a pill from the first pack each day for the first 28 days then begin the second pack. If a participant is unable to collect a 24-h urine sample on day 49, she will take active tablets from the third pill pack until she has collected the 24-h urine sample.
62297048|NCT02367846|EXPERIMENTAL|Contraceptive Vaginal Ring (CVR)|We are testing the effects of the vaginal ring (Nuva Ring; 15 µg/d EE, 120 µg/d etonogestrel). When randomized to CVR, participants will insert the contraceptive ring into their vagina . The ring will be worn during weeks 1-3, and again during weeks 5-7. During week 4, no ring will be worn to allow for withdrawal bleeding. If a participant is unable to collect a 24-h urine sample on day 49, they will insert a third ring which will remain in the vagina until she has collected a 24-h urine sample.
62666314|NCT01481779|ACTIVE_COMPARATOR|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
62666315|NCT01836822|EXPERIMENTAL|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
62666316|NCT01906164|EXPERIMENTAL|ALS-008176|
62666317|NCT01906164|PLACEBO_COMPARATOR|Placebo|
62666318|NCT01565551||Early-Presenting TBI: Acute Sites|This cohort of patients are studied after acute presentation within 24 hours of TBI to one of the three TRACK-TBI acute Level I Trauma Centers (SFGH, UPMC, UMCB).
62297049|NCT02582671||Participants with HCV genotype 1|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
62297050|NCT01559909|EXPERIMENTAL|Socket wall height|
62297051|NCT05773391|EXPERIMENTAL|Diarrhea group|Patients with diarrhea after taking pyrrolidine/naratinib，implement intervention (Yihuo 0.2g po bid+ Gold bifidum 2g po tid)
62297052|NCT05773391|NO_INTERVENTION|No diarrhea group|Patients without diarrhea after taking pyrrolidine/naratinib
62666319|NCT01565551||Late-Presenting TBI: Rehabilitation Center|This cohort of patients are studied after presentation to the TRACK-TBI rehabilitation site (MSMC).
62297053|NCT03389243|EXPERIMENTAL|metamizol|analgesic drug
62297054|NCT03389243|EXPERIMENTAL|paracetamol|analgesic drug
62468622|NCT03290781|EXPERIMENTAL|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 \[NCT03259334\] and SHP647-302 \[NCT03259308\]) will receive 75 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
62468623|NCT03290781|PLACEBO_COMPARATOR|Placebo|Participants will receive 25 mg or 75 mg ontamalimab or placebo matched to ontamalimab in the induction studies (SHP647-301 \[NCT03259334\] and SHP647-302 \[NCT03259308\]) will receive placebo matched to ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
62468624|NCT01878292|PLACEBO_COMPARATOR|Placebo|Dose-matched placebo tablets, once per day, oral administration
62468625|NCT01878292|EXPERIMENTAL|Vilazodone 15 mg|15 mg vilazodone tablets, once per day, oral administration
62468626|NCT01878292|EXPERIMENTAL|vilazodone 30 mg|30 mg vilazodone tablets, once per day, oral administration
62468627|NCT06231745|ACTIVE_COMPARATOR|control group|group one (control group): 50 patients will receive the conventional DMARDs therapy (methotrexate 7.5 mg IM once weekly) plus placebo tablets
62468628|NCT06231745|ACTIVE_COMPARATOR|Comparative group|50 patients will receive the conventional DMARDs therapy (methotrexate 7.5 mg IM once weekly) plus 20 mg paroxetine daily
62468629|NCT01942746|ACTIVE_COMPARATOR|Blueberry Juice|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
61912820|NCT04840030|NO_INTERVENTION|Standard health advice (SHA-control)|"The participant will receive verbal information of risk factors and information, reassessment, and written materials regarding approved recommendations on active and healthy aging on topics such as diet, physical activity, cognitive training as well as risk factor control following the state of the art and published guidelines by the Department of Health of the Basque Government/ Basque Country Public Health System (Osakidetza) and the WHO (Guidelines for risk reduction of cognitive decline and Dementia and the Guidance on person-centered assessment and pathways in primary care - ICOPE). Participants in this group will receive the best standard health care from their primary care and specialist health teams according to already established routines as well as usual social services assessments and care as needed."
62104478|NCT03804411|EXPERIMENTAL|Treatment chosen by automated decision-making system|Group A: type 2 diabetic patients randomized to receive antidiabetic drugs according to predictors chosen with developed automated decision-making system: subgroup 1A- addition of vildagliptin 100 mg/day, subgroup 2A - addition of sitagliptin 100 mg/day, subgroup 3A- addition of dapagliflozin 10 mg/day, subgroup 4A- addition of empagliflozin 10 mg/day, subgroup 5A- addition of liraglutide 1,2-1,8 mg/day, subgroup 6A- addition of exenatide 20 μg/day, subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide.
62104479|NCT03804411|EXPERIMENTAL|Treatment based on standard recommendations|Group B: type 2 diabetic patients randomized to receive antidiabetic drugs according to standard recommendations : subgroup 1B- addition of vildagliptin 100 mg/day, subgroup 2B - addition of sitagliptin 100 mg/day, subgroup 3B- addition of dapagliflozin 10 mg/day, subgroup 4B- addition of empagliflozin 10 mg/day, subgroup 5B- addition of liraglutide 1,2-1,8 mg/day, subgroup 6B- addition of exenatide 20 μg/day, subgroup 7B - addition of glimepiride, subgroup 8B - addition of gliclazide.
62104480|NCT06343558||Healthy controls|
62104481|NCT06343558||Parkinson's disease patients|
62104482|NCT06343558||Multiple sclerosis patients|
62104483|NCT06343558||Peripheral neuropathies of the lower limbs|
62104484|NCT06343558||Rare and ultrarare neurological diseases|
62297055|NCT03389243|EXPERIMENTAL|metamizole & paracetamol|analgesic drugs
62297056|NCT00686127|ACTIVE_COMPARATOR|Lidocaine Patch|Drug: lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1 patch was applied topically to the affected site(s) for 12 hours each day.
62104485|NCT04332653|EXPERIMENTAL|Phase 1b: NT-I7 Dose Escalation|"NT-I7 will be administered on Day 1 of alternate 21 day cycles (Cycle 1, 3, 5 etc.). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62104486|NCT04332653|EXPERIMENTAL|Phase 2a: CPI Treated Triple Negative Breast Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory triple negative breast cancer (TNBC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62297057|NCT00686127|PLACEBO_COMPARATOR|Placebo Patch|Drug: placebo patch, 1 patch was applied topically to the affected site(s) for 12 hours each day.
62297058|NCT02246361|NO_INTERVENTION|Phase 1 (without PIL)|No particular intervention during consultation for the patient
62297059|NCT02246361|EXPERIMENTAL|Phase 2|Patient Information Leaflet is given to the patient during the consultation
62297060|NCT01140087|EXPERIMENTAL|Interventional|Face Transplantation
62468630|NCT01942746|ACTIVE_COMPARATOR|Blueberry Capsules|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
62468631|NCT01942746|PLACEBO_COMPARATOR|Placebo|Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
62297061|NCT00680225|EXPERIMENTAL|Lucentis Injection|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
62297062|NCT04205435|EXPERIMENTAL|β-globin restored autologous HSC|each subject will accept one dose of β-globin restored autologous hematopoietic stem cells
62297063|NCT00270894|EXPERIMENTAL|Neoadjuvant therapy|Neoadjuvant therapy will consist of epirubicin (100 mg/m\^2) + cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments.
62297064|NCT03985176||Aneurysmal SAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
62297065|NCT05975229|EXPERIMENTAL|experimental|Educational pamphlet and knitting program
62297066|NCT05975229|OTHER|control|Educational pamphlet and assigned to a waiting list
62297067|NCT02298101|ACTIVE_COMPARATOR|Aeroneb Solo Adapter|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo Adapter
62297068|NCT02298101|ACTIVE_COMPARATOR|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via a standard jet nebulizer, the Opti-Mist Plus Nebulizer
62468632|NCT01942746|NO_INTERVENTION|Washout (S2 and L1)|Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
62468633|NCT04713137|ACTIVE_COMPARATOR|Erythritol|20 volunteers receive 50g erythritol dissolved in 300mL tap water as an oral pre-load.
62468634|NCT04713137|ACTIVE_COMPARATOR|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
62297069|NCT05200793|ACTIVE_COMPARATOR|Metformin arm (control group)|Patients will receive Metformin (1500 mg orally/day) for 12 weeks .
62468635|NCT04713137|ACTIVE_COMPARATOR|Sucralose|20 volunteers receive 0.0558g sucralose dissolved in 300mL tap water as an oral pre-load.
62468636|NCT04713137|PLACEBO_COMPARATOR|Water|20 volunteers receive 300mL tap water as an oral pre-load.
62468637|NCT05326841|EXPERIMENTAL|Cholecalciferol group|Participants in this arm take a vitamin D3 dose 5000 international units (IU) daily by mouth for a duration of 12 weeks
62297070|NCT05200793|ACTIVE_COMPARATOR|Empagliflozin arm|Patients will receive Empagliflozin (25 mg orally/day) for 12 weeks.
62468638|NCT05326841|PLACEBO_COMPARATOR|placebo group|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks
62297071|NCT05200793|ACTIVE_COMPARATOR|Linagliptin arm|Patients will receive Linagliptin (10 mg orally/day) for 12 weeks
62297072|NCT00096733||Donors|Living liver donors. This label may also refer to those evaluated for liver donation who did not go on to donate, i.e., potential living liver donors.
62297073|NCT00096733||Recipients|Liver transplant recipients (either living or deceased donor). This label may also refer to those who were evaluated for liver transplantation, but never received a transplant, i.e., potential recipients.
62104487|NCT04332653|EXPERIMENTAL|Phase 2a: CPI Treated Non-small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory non-small cell lung cancer (NSCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62104488|NCT04332653|EXPERIMENTAL|Phase 2a: CPI Treated Small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory small cell lung cancer (SCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62104489|NCT04332653|EXPERIMENTAL|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62468639|NCT01046474|EXPERIMENTAL|reducing beverages and sugar and increase physical activity|reduction of beverages and sugar and increasing physical activity
62666320|NCT03161054|EXPERIMENTAL|One arm for all patient|"Induction phase:~Eligible Pts will receive 6 cycles (every 28 days) of the DEVEC combination: DE: Prednisone, V: Vinorelbine, E: Etoposide, C: Cyclophosphamide and R:Rituximab ; R will be administered only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of R will not repeat it during the metronomic therapy.~Super-frail patients will not receive etoposide during cycles 1 and 2.~Maintenance Phase:~Pts in CR, CRu and PR at the end of the induction phase, will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles.~Post Maintenance Phase:~Pts in CR/CRu at the EOT may, at discretion of the local investigator, continue maintenance with only Vinorelbine and Prednisone for up to further 12 months, progression or inacceptable toxicity at the same doses of maintenance"
62666321|NCT02086045|OTHER|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|DESolve Scaffold
62666322|NCT01732783||Metastatic Colorectal Cancer|Participants with wild-type RAS metastatic colorectal cancer who were receiving panitumumab in combination with chemotherapy.
62104490|NCT04332653|EXPERIMENTAL|Phase 2a: CPI Naïve Pancreatic Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62666323|NCT03423693||Asthma with SAO+|Asthmatic patients with RV/TLC \> or = 40
62666324|NCT03423693||Asthma with SAO-|Asthmatic patients with RV/TLC \< 40
62104491|NCT04332653|EXPERIMENTAL|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer, Expansion Cohort|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive 1200 µg/kg of NT-I7 and and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62666325|NCT03423693||ACO|Asthmatic patients with smoking \> or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC \< 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 \> or = 200 ml and FEV1% \> or =12% after BD)
62666326|NCT03423693||COPD|Patients with history of smoking \> or = 10 pack year with post-BD FEV1/FVC \< 0.7 and negative BD reversibility (absolute increase in FEV1 \< 200 ml and FEV1% \<12% after BD)
62104492|NCT04332653|EXPERIMENTAL|Phase 2a: CPI Naïve Pancreatic Cancer, Expansion Cohort|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC).Participants will receive 1200 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62104493|NCT04332653|EXPERIMENTAL|Biomarker Cohort: CPI Naïve Ovarian Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory ovarian cancer (OC). Participants will receive a starting dose of 960 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
62104494|NCT03679546|EXPERIMENTAL|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
62104495|NCT03679546|EXPERIMENTAL|Vedolizumab|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
62104496|NCT02678052||Cohort 1: No Chronic Disease|Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
62468640|NCT01046474|NO_INTERVENTION|control -no intervention|
62468641|NCT03983057|NO_INTERVENTION|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
62468642|NCT03983057|EXPERIMENTAL|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2, Anti-PD-1 antibody 3mg/kg
62468643|NCT00965185|EXPERIMENTAL|Atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
62468644|NCT00965185|PLACEBO_COMPARATOR|placebo|
62468645|NCT03719898|EXPERIMENTAL|Brigatinib|90 mg daily orally for 7 days, then 180 mg daily orally during first cycle; 180 daily orally thereafter during every subsequent cycle. Each cycle has 28 days
62468646|NCT05632874|EXPERIMENTAL|Breathing Exercise|
62104497|NCT02678052||Cohort 2: UC/CD Prospective Cohort|Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
62104498|NCT06609356|EXPERIMENTAL|High insulin|"Participants will receive a high insulin infusion (Hi-Ins) prior to quantifying insulin resistance and endothelial function. This infusion will result in participants having insulin levels similar to patients with type 1 diabetes for five hours."
62104499|NCT06609356|ACTIVE_COMPARATOR|Normal insulin|"Participants will receive a normal insulin infusion (Eu-Ins) prior to quantifying insulin resistance and endothelial function. This infusion will result in participants having insulin levels similar to people without diabetes and people with GCK-MODY for five hours."
62104500|NCT01242085|ACTIVE_COMPARATOR|control group|control group will have standard instrumentation of their knee replacement
62104501|NCT01242085|EXPERIMENTAL|trumatch group|the trumatch patient will have custom instruments made from preop CT scans
62104502|NCT01171924|EXPERIMENTAL|Arm A: 5 days/week schedule|
62104503|NCT01171924|EXPERIMENTAL|Arm B: 3 days/week schedule|
62104504|NCT05629598|EXPERIMENTAL|A1|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.004 (conversion coefficient), Q2W for administration.
62104505|NCT05629598|EXPERIMENTAL|B1|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.008 (conversion coefficient), Q2W for administration.
62104506|NCT05629598|EXPERIMENTAL|A2|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.004 (conversion coefficient), Q4W for administration.
62104507|NCT05629598|EXPERIMENTAL|B2|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.008 (conversion coefficient), Q4W for administration.
62468647|NCT05984251|EXPERIMENTAL|Cohort 1|During Period 1, participants will receive a single dose of CCX168 1 mg or placebo. During the second study period, participants will receive the same dose as during the first period but once daily (QD) for a period of 7 days continuously.
62297074|NCT05219695|EXPERIMENTAL|HMIgFUS|Each study participants' tumors will be imaged using Harmonic Motion Imaging (HMI), an ultrasound elastography method. A central portion of the tumor will then be ablated and monitored using Harmonic Motion Imaging guided Focus Ultrasound (HMIgFUS). Only one portion of the tumor will be ablated; the other portions of the tumor, including tumor margins, will not be ablated. Following ablation, the tumor will be imaged again using HMI.
62297075|NCT04256928|EXPERIMENTAL|Intervention group|"This group of participants will have any body hair in the operative field clipped with an electrical clipper by hospital personnel, during preparation for planned surgery.~4 microbiological samples will be taken from all participants in this group."
62297076|NCT04256928|NO_INTERVENTION|Control group|"This group of participants serve as the control group. Any body hair in the operative field is left intact.~4 microbiological samples will be taken from all participants in this group."
62104508|NCT05629598|ACTIVE_COMPARATOR|C|Human erythropoietin injection；Refer to the product instructions.
62297077|NCT05191628|EXPERIMENTAL|Visio-AMTRIX|Disk of amniotic membrane apposed or buried on recurrent macular hole by the Investigator after vitrectomy and fluid-gas exchange.
62297078|NCT03427437|ACTIVE_COMPARATOR|Conventional Group|Caudal block was performed by conventional method with %0,25 bupivacaine plus 1/200.000 adrenalin
62297079|NCT03427437|ACTIVE_COMPARATOR|Ultrasound Group|Caudal block was performed by ultrasound method with %0,25 bupivacaine plus 1/200.000 adrenalin
62297080|NCT01097902|ACTIVE_COMPARATOR|Ibuprophen 800 mg|Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
62297081|NCT01097902|PLACEBO_COMPARATOR|Placebo|Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
62297082|NCT03642561|EXPERIMENTAL|RFA group|Patients in RFA group will accept RFA treatment
62297083|NCT03642561|ACTIVE_COMPARATOR|TACE group|Patients in TACE group will accept TACE treatment
62297084|NCT02834130|OTHER|children from 2 to 10 years with haemophilia or allied HBD, wh|
62297085|NCT05189899|ACTIVE_COMPARATOR|With virtual reality|One hemodialysis session with virtual reality
62297086|NCT05189899|NO_INTERVENTION|without virtual reality|One hemodialysis session without virtual reality
62468648|NCT05984251|EXPERIMENTAL|Cohort 2|During Period 1, participants will receive a single dose of CCX168 3 mg or placebo. During the second study period, participants will receive the same dose as during the first period but QD for a period of 7 days continuously.
62104509|NCT04871607|EXPERIMENTAL|Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)|Patients receive 'cold' basiliximab IV followed by yttrium Y 90 basiliximab IV on day -14. Patients also receive carmustine IV on over 4 hours day -6, etoposide IV over 1 hours QD and cytarabine IV over 2 hours BID or QD on days -5 to -2, and melphalan IV over 1 hours on day -1. Patients then receive HPC-A product via infusion on day 0. Beginning day 5, patients receive G-CSF (or biosimilar) SC or IV until ANC \> 500 for 3 consecutive days or according to the treating physician's best clinical judgement.
62104510|NCT03181724|ACTIVE_COMPARATOR|Decision Aid|Cohort that will receive a decision aid.
62104511|NCT03181724|NO_INTERVENTION|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
62104512|NCT05741944|EXPERIMENTAL|Care with the use of PERSARC (intervention)|Patients in the intervention condition receive usual care with PERSARC added at two points in the decision making process. First, PERSARC will be used in multidisciplinary tumour boards (MTB) by STS professionals to guide treatment advice. Second, PERSARC will be used in patient consultations where the oncological/orthopaedic surgeon informs the patient about his/her diagnosis and discusses the benefits and harms of all relevant treatment options.
62104513|NCT05741944|SHAM_COMPARATOR|standard care (control)|All patients in the control condition receive standard care
62104514|NCT06321419|EXPERIMENTAL|Advanced Trauma Life Support|The intervention will be ATLS® training, a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. Physicians will be trained in an accredited ATLS® training facility in India.
62104515|NCT06321419|NO_INTERVENTION|Standard care|Standard care varies across hospitals in India, but trauma patients are initially managed by casualty medical officers, surgical residents, or emergency medicine residents. They are mainly first- or second-year residents who resuscitate patients, perform interventions and refer patients for imaging or other investigations. Compared with other settings where a trauma team approach is adopted, nurses and other healthcare professionals are only involved to a limited extent during the initial management.
62104516|NCT04483843||CPE patients|All patients prehospitally treated for cardiogenic pulmonary edema in the pre-hospital emergency setting in the Central Bohemian region, Czech Republic.
62104517|NCT01802229|ACTIVE_COMPARATOR|Suture|Umbilical port-site closure with simple suture of the fascia.
62297087|NCT02299193|EXPERIMENTAL|Cognitive Behavioral Therapy|online sessions on how behaviors and thoughts that can affect sleep.
62297088|NCT02299193|SHAM_COMPARATOR|Healthy Sleep Habits|online sessions about healthy sleep practices
62297089|NCT02725502|ACTIVE_COMPARATOR|Linagliptin treatment group|Group will receive linagliptin ( 5 mg / day ) for 3 months in addition to their insulin
62468649|NCT05984251|EXPERIMENTAL|Cohort 3|During Period 1, participants will receive a single dose of CCX168 10 mg or placebo. During the second study period, participants will receive the same dose as during the first period but QD for a period of 7 days continuously.
62468650|NCT05984251|EXPERIMENTAL|Cohort 4|During Period 1, participants will receive a single dose of CCX168 30 mg or placebo. During the second study period, participants will receive the same dose as during the first period or placebo twice daily (BID) for a period of 7 days continuously.
62468651|NCT05984251|EXPERIMENTAL|Cohort 5|During Period 1, participants will receive a single dose of CCX168 100 mg or placebo. During the second study period, participants will receive the same dose as during the first period or placebo BID for a period of 7 days continuously.
62468652|NCT03808064|EXPERIMENTAL|Intervention arm|After randomization, the FCHVs in the intervention arm will receive training, health education materials and a recording register. After receiving training, they will educate women of their respective ward on cervical cancer screening and prevention through home visits and maintain records in their service register.
62468653|NCT03808064|NO_INTERVENTION|Control arm|There won't be any intervention in the control arm.
62468654|NCT01619930|EXPERIMENTAL|1a|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
62468655|NCT01619930|EXPERIMENTAL|1b|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
62104518|NCT01802229|EXPERIMENTAL|Prophylactic mesh|Umbilical port-site closure with mesh placement
62104519|NCT02992275|EXPERIMENTAL|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
62297090|NCT02725502|PLACEBO_COMPARATOR|Placebo group|Group will receive placebo for 3 months in addition to their insulin
62297091|NCT06327152|ACTIVE_COMPARATOR|Caffeine Group|Infants randomized to receive caffeine will continue to receive caffeine at standard of care maintenance dose of 10-15 mg/kg/day given every 24 hours. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.
62297092|NCT06327152|PLACEBO_COMPARATOR|Placebo Group|Infants randomized to the placebo group will be given sterile water at an equivalent volume to the volume if caffeine were to be given, using the previous weight-based caffeine dose. The placebo will be given every 24 hours. The dose/volume will be weight adjusted every 7 days, starting on the day of enrollment. The placebo will be given enterally, via nasogastric tube or by mouth.
62297093|NCT05782530||medical stuff in obstetrics|medical doctors, nurses, midwives
62297094|NCT00868049||1|Obese subjects
62297095|NCT00868049||2|Normal-weight subjects
62297096|NCT01475890|ACTIVE_COMPARATOR|7000IU/day|29 subjects will be randomized to receive 7000IU/day of vitamin D3.
62297097|NCT01475890|PLACEBO_COMPARATOR|Placebo|29 subjects will be randomized to receive placebo.
62297098|NCT02938182|EXPERIMENTAL|clopidogrel|clopidogrel tablet 75mg daily for three months
62297099|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
62666327|NCT02753673||Breast Cancer|The assessments are all qualitative. The assessments include an in-person, open-ended qualitative interview, during which the interviewer will use an interview guide to ensure that all relevant topics are discussed. Participants will also complete the Patient Expectations with Breast Reconstruction questionnaire using the think-aloud technique in order to identify which questions reflect the expectations of BCT patients, which questions need modification to reflect the expectations of BCT patients and which questions are not appropriate for BCT patients. The responses to the expectations questionnaire for this portion of the interview will not be recorded or analyzed; only the participants' thoughts and opinions about the questions will be recorded.
62666328|NCT04899037||Osseointegrated Device Uptake|The participants in this group will be in the 18-85 year age range who have a hearing loss configuration that would benefit from an OID and choose to uptake an OID.
62666329|NCT04899037||Osseointegrated Device Non Uptake|The participants in this group will be in the 18-85 year age range and who a hearing loss configuration that would benefit from an OID but choose to not uptake an OID.
62297100|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
62297101|NCT01974791|EXPERIMENTAL|GET Living Treatment|
62297102|NCT05243888|NO_INTERVENTION|control|The control arm corresponds to women receive a conventional invitation letter sent by post to the home address of eligible women recommending them to make an appointment to a doctor or a midwife for the collection of a cervical specimen.
62297103|NCT05243888|EXPERIMENTAL|vaginal self-sampling|eligible women receive at their home address a vaginal self-sampling kit in addition to the conventional invitation letter
62297104|NCT05243888|EXPERIMENTAL|urinary self-sampling|eligible women receive at their home address a urine collection kit in addition to the conventional invitation letter
62297105|NCT06387056|EXPERIMENTAL|Queue 1|Rezvilutamide plus ADT plus docetaxel.
62297106|NCT06387056|EXPERIMENTAL|Queue 2|Rezvilutamide plus ADT plus pamiparib.
62297107|NCT06387056|EXPERIMENTAL|Queue 3|Rezvilutamide plus ADT plus cisplatin.
62297108|NCT06387056|EXPERIMENTAL|Queue 4|Rezvilutamide plus ADT plus tislelizumab.
62297109|NCT06656962|EXPERIMENTAL|The Telitacicept treatment group|
62297110|NCT06412341|EXPERIMENTAL|ABC + Macmillan body image booklet|"Accepting your Body after Cancer (ABC) + Macmillan Cancer Support psycho-educational body image booklet~ABC comprises seven 2-hour group sessions (with approximately 8 women per group) delivered online via Microsoft Teams and across 7 consecutive weeks. The intervention aims to improve body image among women treated for BC. Rooted in CBT, ABC uses strategies to alter unhelpful thoughts, reduce anxiety, and promote non-avoidant behaviours. Other topics are also explored, including sociocultural pressures for women, intimacy, physical activity, self-care, mindfulness, and relaxation. The sessions will be guided using PowerPoint slides, which will include text, images, and videos. Each session will include individual and group-based activities, and participants will be asked to complete between-session readings and activities. (Macmillan Cancer Support psycho-educational body image booklet is described below)."
62297111|NCT06412341|OTHER|Macmillan body image booklet (usual care)|"Macmillan Cancer Support psycho-educational body image booklet (only)~Discussions with PPI advisors indicated that some form of body image-specific support should be provided for the control arm. Macmillan's freely available psychoeducational body image booklet was considered appropriate, given that the thorough 77-page booklet provides a substantial amount of support and guidance relating to managing body image concerns. It explains the effects of cancer on body image, and provides practical guidance (e.g., make-up) and psychoeducational guidance (e.g., managing others' reactions), in addition to some CBT strategies. Upon randomisation to the control arm, participants will be sent the Macmillan body image booklet and encouraged to work through it gradually. The booklet can be accessed via the following webpage: https://cdn.macmillan.org.uk/dfsmedia/1a6f23537f7f4519bb0cf14c45b2a629/791-source/body-image-mac14192"
62297112|NCT06356506||Modeling group|The data of modeling group is used to construct a predictive model of AIH end-point events.
62297113|NCT06356506||Validation group|Validation group is used to validate the predictive model externally.
62468656|NCT01619930|EXPERIMENTAL|2a|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
62666330|NCT04310228|EXPERIMENTAL|Favipiravir Combined With Tocilizumab group|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
62666331|NCT04310228|ACTIVE_COMPARATOR|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
62666332|NCT04310228|ACTIVE_COMPARATOR|Tocilizumab group|The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
62666333|NCT01684605|ACTIVE_COMPARATOR|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
62666334|NCT01684605|EXPERIMENTAL|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
62104520|NCT04511663|ACTIVE_COMPARATOR|intervention group|The intervention group received assertive community treatment, in which the team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers.
62666335|NCT02988388||Lung biopsy/lobectomy|Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases.
62104521|NCT04511663|OTHER|control group|The control group received basic public health services which is regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge.
62104522|NCT05996133|EXPERIMENTAL|MCP Block|Bilateral Multifidus Cervicis plane block using 30 mL of 0.25% bupivacaine + 0.5 mL (5 mg) preservative-free dexamethasone + 0.1 mL epinephrine 1:400,000.
62104523|NCT05996133|SHAM_COMPARATOR|Sham Block|Bilateral sham block using 3 mL of normal saline injections subcutaneously on the neck.
62468657|NCT01619930|EXPERIMENTAL|2b|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
62666336|NCT00727064|ACTIVE_COMPARATOR|DVS/VEN|
62666337|NCT00727064|ACTIVE_COMPARATOR|VEN/DVS|
62104524|NCT05755035|EXPERIMENTAL|Randomized Crossover Treatment Epoch: TAK-881 followed by HYQVIA (Sequence 1)|Participants aged \>=16 years will receive 6 or 8 infusions at full doses of TAK-881 followed by HYQVIA in sequence 1. The first full dose of TAK-881 will be administered either 2 weeks after the second ramp-up dose (applicable for participants pretreated with IGIV or cIGSC) or 3 or 4 weeks after the last infusion of their pre study immunoglobulin G (IgG) treatment (applicable for participants pre-treated with HYQVIA).
62104525|NCT05755035|EXPERIMENTAL|Randomized Crossover Treatment Epoch: HYQVIA followed by TAK-881 (Sequence 2)|Participants aged \>=16 years will receive 6 or 8 infusions at full doses of HYQVIA followed by TAK-881 in Sequence 2. The first full dose of HYQVIA will be administered either 2 weeks after the second ramp-up dose (applicable for participants pretreated with IGIV or cIGSC) or 3 or 4 weeks after the last infusion of their pre study IgG treatment (applicable for participants pre-treated with HYQVIA).
62297114|NCT05384730|EXPERIMENTAL|Intervention Arm|This group will receive the weekly group exercise and nutrition support which will be delivered online by trained volunteers. The duration of the intervention is 12 weeks.
62104526|NCT05755035|EXPERIMENTAL|Single Arm Treatment Epoch: TAK-881|Pediatric participants aged 2 to \<16 years will receive 6 or 8 infusions at full doses of TAK-881. The first full dose of TAK-881, will be administered either 2 weeks after the second ramp-up dose (applicable for participants pretreated with IGIV or cIGSC) or 3 or 4 weeks after the last infusion of their prestudy IgG treatment (applicable for participants pre-treated with HYQVIA).
62104527|NCT05312541|PLACEBO_COMPARATOR|Opioid Based Anesthesia|Pre induction of general anesthesia with placebo 1 h before surgery. induction of general anesthesia with fentanyl1ug/kg/ iv then infusion of 1 ug/kg/h
62104528|NCT05312541|ACTIVE_COMPARATOR|opioid free anesthesia|Pre induction of general anesthesia with gabapentin 300 mg tab 1 h before surgery. induction of general anesthesia with ketamine 0.5 mg/kg iv, Lidocaine 1 mg/kg iv then continuous infusion with 2 mg/kg/hr, dexamethasone 0.1 mg/kg.iv, magnesium sulfate 20 mg/kg.iv
62104529|NCT02885051|EXPERIMENTAL|preterm newborn|Newborns hospitalized in the neonatal or Neonatal Resuscitation unit of Brest University Hospital and born before 36 weeks of gestation who will have recording of skin conductance and heart rate variability.
62104530|NCT02228811|EXPERIMENTAL|DCC-2701 tablet|DCC-2701 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
62666338|NCT02959762|PLACEBO_COMPARATOR|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
62666339|NCT02959762|ACTIVE_COMPARATOR|Low-Dose Vitamin K2 (45-mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
62104531|NCT03452306|EXPERIMENTAL|Metformin|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
62104532|NCT03452306|ACTIVE_COMPARATOR|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fed condition"
62104533|NCT04732676|EXPERIMENTAL|Experimental group|participants will receive and use during 4 weeks the full interventional version of the smartphone application (combining EMA + EMI) targeting craving and personal situations at risk for use
62104534|NCT04732676|PLACEBO_COMPARATOR|control group|: participants will receive and use a restricted version of the smartphone application (only EMA: 4 electronic questionnaires per day to assess main problematic substance use / addictive behavior) during 4 weeks
62104535|NCT02721511|EXPERIMENTAL|Furosemide injection solution 8mg/mL|8mg/mL (total dose=80mg) of furosemide injection solution administered subcutaneously as 30mg over the first hour and then as 12.5 mg per hours over the subsequent 4 hours.
62666340|NCT02959762|ACTIVE_COMPARATOR|High-Dose Vitamin K2 (90-mcg/d)|The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
62104536|NCT00715390||1-Children receiving anesthesia|The sample of patients screened will be the entire electronic anesthesia record database from 1998 until 2004 looking for subjects that have dysrhythmias.
62104537|NCT04544995|EXPERIMENTAL|Part 1A: Dose Escalation|Participants with body weight of ≥ 20 kilogram (kg) and who can swallow niraparib tablets will receive niraparib tablets and dostarlimab.
62104538|NCT04544995|EXPERIMENTAL|Part 1B: Dose Escalation|Participants who are \<8 years of age will receive niraparib TfOS and dostarlimab.
62104539|NCT04544995|EXPERIMENTAL|Part 2 Safety Run-in|Participants with osteosarcoma or neuroblastoma who are ≥8 years of age will receive niraparib TfOS and dostarlimab.
62666341|NCT04913675|ACTIVE_COMPARATOR|Main Study - Sotrovimab 500 mg IV|
62666342|NCT04913675|EXPERIMENTAL|Main Study - Sotrovimab 500 mg IM|
62666343|NCT04913675|EXPERIMENTAL|Main Study - Sotrovimab 250 mg IM|
62666344|NCT04913675|EXPERIMENTAL|Substudy (Cohort A) - Sotrovimab 2000 mg IV|
62666345|NCT04913675|EXPERIMENTAL|Substudy (Optional Cohort B1) - Sotrovimab 2000 mg IV|
62104540|NCT04544995|EXPERIMENTAL|Part 2A: Cohort Expansion for Osteosarcoma|Participants with osteosarcoma will receive the RP2D of the combination of niraparib and dostarlimab.
62104541|NCT04544995|EXPERIMENTAL|Part 2B: Cohort Expansion for Neuroblastoma|Participants with neuroblastoma will receive the RP2D of the combination of niraparib and dostarlimab.
62104542|NCT06222619||Resection without PVE|Resection of bile duct and associated hemi-liver without portal vein embilzation
62104543|NCT06222619||Resection after PVE|Resection of bile duct and associated hemi-liver after portal vein embilzation
62104544|NCT06222619||No resection after PVE|No resection of bile duct and associated hemi-liver after portal vein embilzation
62666346|NCT04913675|EXPERIMENTAL|Substudy (Optional Cohort B2) - Sotrovimab 2000 mg IV|
62104545|NCT01268345|EXPERIMENTAL|Andon|Andon blood glucose test strips with test meter
62104546|NCT01268345|ACTIVE_COMPARATOR|Lifescan|
62666347|NCT04913675|EXPERIMENTAL|Substudy (Optional Cohort C) - Sotrovimab up to 3000 mg IV|
62666348|NCT05598983||COPD patients|Group will consist of individuals who have been diagnosed with COPD, living in their home and not recently discharged from the hospital for an exacerbation.
62666349|NCT05598983||Discharged COPD patients|Group will consist of individuals who have been diagnosed with COPD, living in their home, and are being discharged from the hospital for an exacerbation.
62666350|NCT05678114|EXPERIMENTAL|Hyperandrogenic PCOS|
62666351|NCT05678114|EXPERIMENTAL|Non-hyperandrogenic PCOS|
62666352|NCT01209468|ACTIVE_COMPARATOR|oral appliance 2|Patients in treatment arm/group B will have a customized twinblock OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized monobloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the monobloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
62666353|NCT01209468|EXPERIMENTAL|oral appliance 1|Patients in treatment arm/group A will have a customized monobloc OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized twin-bloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the twin-bloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
62468658|NCT01619930|EXPERIMENTAL|3a|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
62468659|NCT01619930|EXPERIMENTAL|3b|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
62104547|NCT00388011|EXPERIMENTAL|1|Intranasal morphine 3.75 mg
62104548|NCT00388011|EXPERIMENTAL|2|Intranasal morphine 7.5 mg
62104549|NCT00388011|EXPERIMENTAL|3|Intranasal morphine 15 mg
62104550|NCT00388011|EXPERIMENTAL|4|Intranasal morphine 30 mg
62104551|NCT00388011|ACTIVE_COMPARATOR|5|Intravenous morphine 7.5 mg
62104552|NCT00388011|PLACEBO_COMPARATOR|6|Intranasal placebo
62104553|NCT03244176|OTHER|Open-label|Avelumab - Single-arm open label study
62104554|NCT03022903|OTHER|Photodynamic Therapy (PDT)|PDT with ALA (photosensitizer) for 3 hours
62468660|NCT01619930|EXPERIMENTAL|4a|"In phase 1, group 4 undergoes behavioral activation without added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
62468661|NCT01619930|EXPERIMENTAL|4b|"In phase 1, group 4 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
62666354|NCT03312907|PLACEBO_COMPARATOR|Belimumab + Placebo|Eligible subjects will receive Belimumab 200 milligrams (mg) to be administered subcutaneously (SC) on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab-placebo to be administered by intravenous (IV) infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), and/or corticosteroids tapered down to prednisone equivalent of less than or equal to (\<=) 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
61912821|NCT04840030|EXPERIMENTAL|Multidomain intervention (MM-Int)|Participants in this group will receive the same verbal and written recommendations as to the ones in the SHA-Control group but then they will perform a 2 year structured program with periodic individual and group visits regarding 1) Risk factor control (vascular factors, polypharmacy); 2) Cognitive training, 3) Physical activity, 4) Dietary changing program and 5) emotional counseling and social engagement.
61912822|NCT04715334|EXPERIMENTAL|Single arm study|The intervention is the Mollii suit which is fitted and programmed by the Mollii suit distributor, Inerventions and will be administered by trained physiotherapists from KKH. Participants will be involved in the Intervention phase of the study for 4 weeks with treatment duration of 60 min/ session every day.
61912823|NCT03255070|EXPERIMENTAL|ARX788 Phase 1a (Dose Escalation)|ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.
62297115|NCT04095520|ACTIVE_COMPARATOR|Paste Type Traditional Composite-GC G Aenial Anterior|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with microhybrid composite
61912824|NCT03255070|EXPERIMENTAL|ARX788 Phase 1b (Dose Expansion)|ARX788 will be administered every 3 weeks (Q3W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
62104555|NCT00535067||Breast Cancer Survivors|
62104556|NCT04385342|ACTIVE_COMPARATOR|FSH then HP-hMG|Women will receive 225 IU FSH alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm, the 150 IU HP-hMG will substitute FSH and continued to the day of triggering
62468662|NCT01619930|NO_INTERVENTION|Phase 1 Waiting list control group|Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
62468663|NCT03625856|EXPERIMENTAL|Intervention|1500 mg Chlorella Vulgaris capsule
62468664|NCT03625856|PLACEBO_COMPARATOR|Control|1500 mg placebo (starch)
62468665|NCT01900340|PLACEBO_COMPARATOR|iv saline, intraduodenal saline|intravenous infusion of saline plus intraduodenal administration of saline
62468666|NCT01900340|ACTIVE_COMPARATOR|IV exendin(9-39) plus intraduodenal (ID) saline|intravenous infusion of exendin(9-39) plus intraduodenal administration of saline
62468667|NCT01900340|PLACEBO_COMPARATOR|IV saline, intraduodenal nutrient|intravenous infusion of saline plus intraduodenal administration of nutrient
62297116|NCT04095520|EXPERIMENTAL|Injectable Composite- GC G Aenial Universal Injectable|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with injectable form composite
62297117|NCT03529656|NO_INTERVENTION|Pre-ERP|A group of patients who underwent liver transplantation surgery before the early rehabilitation program
62297118|NCT03529656|EXPERIMENTAL|Post-ERP|A group of immediate liver transplant patients who had an early rehabilitation program in ICU care
62297119|NCT02760251|EXPERIMENTAL|Romiplostim|Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC). Followup examination at week 52.
62666355|NCT03312907|EXPERIMENTAL|Belimumab + Rituximab|Eligible subjects will receive Belimumab 200 mg to be administered SC on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab 1000 mg to be administered by IV infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of \<= 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
62666356|NCT03312907|OTHER|Belimumab + Standard therapy|Eligible subjects will receive open-label Belimumab 200 mg administered SC on Day 1 and then weekly (i.e., every 7 days) until Week 104. Subjects will also receive standard therapy including immunosuppressant, anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of \<= 5 mg/day until Week 104.
61912825|NCT06131762|EXPERIMENTAL|Active release technique|ART performed from long sitting position, the therapist started by shortening the muscle or fascia of affected limb then apply very specific pressure with hand as we stretch tissue is lengthened. Active movement is done whenever possible according to the instructions given by therapist. ART for 8-10 minutes will be given.
61912826|NCT06131762|EXPERIMENTAL|Positional release technique|Positional release technique where participant lie supine with the affected limb out of the plinth and then by application of brief mechanical pressure on tender point with one fingertip in order to determine tenderness. The foot should then be positioned, most probably into pure plantarflexion and gentle fine-tuned by rotation, until the score in the tender point has reduce by at least 70%. This position is held for 90 seconds with 3 repetitions i.e. total of 270 seconds was given.
61912827|NCT06131671|EXPERIMENTAL|Intervention|This group will receive whole-body electrical stimulation associated with exercises for upper, lower limbs and trunk for twice a week, for eight weeks, totaling 16 sessions.
62104557|NCT04385342|ACTIVE_COMPARATOR|FSH + HP-hMG|Women will receive 150 IU FSH plus 75IU HP-hMG from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm 150 IU HP-HMG till day of triggering
62468668|NCT01900340|ACTIVE_COMPARATOR|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
62468669|NCT03153930|PLACEBO_COMPARATOR|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
62468670|NCT03153930|EXPERIMENTAL|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
62666357|NCT04727749|EXPERIMENTAL|Therapy Dog Team Visit|Patient interacts with the therapy dog and handler.
61912828|NCT06131671|NO_INTERVENTION|Control|This group will not receive any type of electrical stimulation or exercise.
62308270|NCT06261528|EXPERIMENTAL|Circadian Focused Light Therapy for Fatigue Reduction in Progressive Multiple Sclerosis (NO-FATIGUE)|This will be an open label, single arm, single center phase 1 research study designed to generate safety data, biomarker data, and preliminary efficacy data to reduce fatigue in patients with progressive MS, to include PPMS and SPMS
62666358|NCT04727749|NO_INTERVENTION|No Therapy Dog Team Visit|No patient interaction with the therapy dog or handler.
62666359|NCT01221909|EXPERIMENTAL|Tranexamic acid single dose of 500mg|
62666360|NCT01221909|PLACEBO_COMPARATOR|Saline|
62666361|NCT04309630|ACTIVE_COMPARATOR|intercostal block|patients received intercostal block will be evaluated by visual analog score for pain assesment
62666362|NCT04309630|EXPERIMENTAL|erector spina plane block|patients received erector spina plane block will be evaluated by visual analog score for pain assesment
62666363|NCT03404167|EXPERIMENTAL|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
61912829|NCT02666157|ACTIVE_COMPARATOR|Dabigatran|oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period
62666364|NCT01244282|EXPERIMENTAL|All Participants|fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol
61912830|NCT02666157|ACTIVE_COMPARATOR|Rivaroxaban|oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period
62308271|NCT00944944||Gyn Pts with lymphedema|
62308272|NCT00944944||Gyn Pts without Lymphedema|
62468671|NCT01518972|EXPERIMENTAL|Prazosin|Prazosin medication
62666365|NCT03419871||monitoring sleep effects on toddlers|Monitoring the sleep characteristics of toddlers living in economically stressed communities.
62666366|NCT00580099|EXPERIMENTAL|1|4 weeks of assisted exercise using passive range of motion on all major joints
61912831|NCT02666157|ACTIVE_COMPARATOR|Apixaban|oral apixaban 5 mg (2.5 mg in specific population) bid for entire study period
61912832|NCT02977182|NO_INTERVENTION|Control Group|The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
61912833|NCT02977182|EXPERIMENTAL|Active Treatment Group|The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
62468672|NCT01518972|PLACEBO_COMPARATOR|Placebo|Placebo medication
62468673|NCT02426762|EXPERIMENTAL|Sealant skin closure|A quick skin sealant would be applied after laparoscopic surgery. All abdominal wounds are sealed by smearing the quick sealant (skin adhesive) twice. No additional gauges should be appended on wound areas. No further wound care should be applied unless any effusion or bleeding emerged around it.
62468674|NCT03430869|EXPERIMENTAL|F-18 AV-45|F-18 AV-45 imaging
62468675|NCT03430869|EXPERIMENTAL|F-18-THK-5351|F-18-THK-5351 imaging
62468676|NCT00569153|EXPERIMENTAL|Arm 1 (TAK-700)|
62468677|NCT00569153|EXPERIMENTAL|Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)|
62468678|NCT00569153|EXPERIMENTAL|Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)|
62468679|NCT00569153|EXPERIMENTAL|Arm 4 (TAK-700 at 600 mg)|
61912834|NCT01604278|ACTIVE_COMPARATOR|NVA237 + indacaterol|
61912835|NCT01604278|PLACEBO_COMPARATOR|Placebo to NVA237 + indacaterol|
61912836|NCT03458715|EXPERIMENTAL|SGLT2 inhibitor (Empagliflozin 25 MG)|We add SGLT2 inhibitor (Empagliflozin 25 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy for 6 months.
61912837|NCT03458715|ACTIVE_COMPARATOR|DPP4 inhibitor (Linagliptin 5 MG)|We add DPP4 inhibitor (Linagliptin 5 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy.for 6 months.
62468680|NCT04040426|EXPERIMENTAL|Human split thickness skin allograft (Theraskin™)|Theraskin™ is an all-human split thickness skin allograft with a native extracellular matrix that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing. Theraskin™ is an allograft tissue and will be used in compliance with homologous use by the FDA under section 361 of the PHS Act and 21 CFR Part 1271
62468681|NCT04040426|ACTIVE_COMPARATOR|Fibracol wound dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
62666367|NCT00580099|ACTIVE_COMPARATOR|2|cuddle for 20 minutes
62666368|NCT01271738|ACTIVE_COMPARATOR|Breast Conserving Surgery (BCS)|
62666369|NCT01271738|ACTIVE_COMPARATOR|Breast Conserving Surgery with Additional 5 Margins (BCS + M)|
62666370|NCT01370889|EXPERIMENTAL|Basic Science (resveratrol)|Patients receive resveratrol PO QD for 12 weeks.
62666371|NCT06552026|EXPERIMENTAL|iTBS stimulation|The iTBS stimulation lasted 3 min 9 s and delivered at triplet 50 Hz bursts, repeated at 5 Hz with 2s on, 8 s off, 600 pulses per session at 80% of the rest motor threshold(RMT) . Behavior and EEG dataset should be acquired before the first iTBS session and after the last iTBS session.
62666372|NCT06552026|ACTIVE_COMPARATOR|10 Hz-rTMS stimulation|The rTMS stimulation lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold(RMT) . Behavior and EEG dataset should be acquired before the first rTMS session and after the last rTMS session.
62666373|NCT03090269|EXPERIMENTAL|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
62666374|NCT05298839||COVID-19|
62666375|NCT05298839||Non COVID-19|
62666376|NCT06159036|EXPERIMENTAL|Group 1|Strength training in inertial machines for 2 days and around 12 weeks.
62666377|NCT06159036|ACTIVE_COMPARATOR|Group 2|Control group developed conventional strength training with squats, deadlifts, hip thrust jumps for 2 days and around 12 weeks.
62666378|NCT02478671|EXPERIMENTAL|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
62666379|NCT02855983|EXPERIMENTAL|A (Fat grafting initially)|"A PATHWAY -~Intervention: autologous fat grafting to the foot, occur first~Fat graft study intervention procedure to occur first, next post-operative follow up visits (V1-V4). The Subject will after Month 6 (V4) crossover to Pathway B to complete Observation visits V1 (Month 2) and V2 (Month 6). After completion of V2 (Month 6), the subject will have completed study participation."
62104558|NCT05427357|EXPERIMENTAL|Diseased side of the patellofemoral pain syndrome (PFPS) group (40 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in diseased side of the PFPS group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
62104559|NCT05427357|EXPERIMENTAL|Healthy side of the patellofemoral pain syndrome (PFPS) group (40 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in healthy side of the PFPS group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
62297120|NCT06618157|OTHER|No oral dopaminergic medication|"While off of oral dopaminergic medication, MDS-UPDRS III (clinical scale) will be collected in different scenarios (each setting will be recorded for 20 minutes): during no DBS stimulation, usual care stimulation, cerebellothalamic optimized, and pallidothalamic optimized.~Each participant will also wear a smartwatch (Apple watch) on each upper arm throughout the research encounter to collect total minutes with tremor, total minutes with dyskinesia, and severity of tremors and dyskinesia."
62468682|NCT04915053|EXPERIMENTAL|ABG Black Garlic Extract|Daily intake of a 550 mg tablet, containing 250 mg of Black Garlic Extract and 300 mg of excipients.
62666380|NCT02855983|OTHER|B (Standard of care initially)|"B PATHWAY -~Intervention: standard of care (observation) for the first year, followed by autologous fat grafting to the foot~Observation visit will occur first, next the subject will have two Observation visits V1 (Month 2) and V2 (Month 6). The subject will then crossover to Pathway A. The subject will be assessed by the PI his/her for continued study eligibility. Once the continued eligibility has been determined, the subject will have the interventional fat graft procedure and subsequent post-operative follow up visits (V1-V4). After completion of Post-op V4 (Month 6), the subject will have completed study participation."
62666381|NCT01359423|EXPERIMENTAL|long coverage|Primary long full coverage stenting
62666382|NCT01359423|ACTIVE_COMPARATOR|short spot|primary short spot stenting
62666383|NCT03510702||Periodontal patients.|Taking gingival Crevicular fluid.
62666384|NCT03510702||Periodontally healthy patients.|Taking gingival Crevicular fluid.
62104560|NCT05427357|OTHER|Both side of the healthy control group (80 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in side of the both side of the healthy control group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
62666385|NCT05529953|EXPERIMENTAL|Oleanolic acid-enriched functional olive oil|"functional olive oil elaborated enriching the control olive oil with Oleanolic acid up to 600 mg OA/kg oil.~Single oral intake of 55 mL of functional olive oil (dose equivalent to 30 mg OA)."
62104561|NCT05693155||Individuals with a gambling problem|Recruited from a gambling disorder treatment unit and/or from social media advertising addressing individuals with a gambling problem.
62297121|NCT06618157|OTHER|On oral dopaminergic medication|"While on oral dopaminergic medication, MDS-UPDRS III (clinical scale) will be collected in different scenarios (each setting will be recorded for 20 minutes): during no DBS stimulation, usual care stimulation, cerebellothalamic optimized, and pallidothalamic optimized.~Each participant will also wear a smartwatch (Apple watch) on each upper arm throughout the research encounter to collect total minutes with tremor, total minutes with dyskinesia, and severity of tremors and dyskinesia."
62666386|NCT05529953|ACTIVE_COMPARATOR|Control olive oil|"commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.~Single oral intake of 55 mL of commercial olive oil"
62666387|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
62666388|NCT01456923|ACTIVE_COMPARATOR|Control (chemotherapy and surgery)|Patients treated with chemotherapy + surgery
62104562|NCT05693155||Concerned significant others|Recruited as concerned signifiant others of patients at a gambling disorder treatment unit and/or in social media advertising addressing concerned significant others of individuals with a gambling problem.
62104563|NCT03093610|ACTIVE_COMPARATOR|Traditional|The chest tube in the traditional Group will be managed according to the current Guidelines of the investigators' department.
62104564|NCT03093610|ACTIVE_COMPARATOR|Test group|"The chest tube in the Test Group will constitute the experimental Group. The chest tube will be removed when the fluid production over 24h has reached a weight related threshold."
62104565|NCT00664846|EXPERIMENTAL|1|
62104566|NCT00664846|ACTIVE_COMPARATOR|2|
62104567|NCT04472767|EXPERIMENTAL|Cabozantinib with Ipilimumab/Nivolumab and TACE|"Subjects receive Cabozantinib 40 mg daily on days 1-28 of a 28 day cycle, this is to be started 7-14 days after the last TACE procedure.~Nivolumab 480 mg IV on day 1 of a 28 day cycle (cycle 2 and beyond), this is to be started 7-14 days after the last TACE procedure.~Nivolumab: 3mg/kg IV on day 1 of a 21 day cycle x 1 dose.~Ipilimumab: 1 mg/kg on day 1 of a 21 day cycle x 1 dose~TACE: Within 3-4 weeks of cycle 1 day 1; may be done up to 3 times (9-12 weeks total), the intervals between each TACE treatment can vary based on investigator's discretion"
62104568|NCT00631917|EXPERIMENTAL|Aliskiren|For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
62104569|NCT00631917|ACTIVE_COMPARATOR|Ramipril|For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
62104570|NCT01346605||CCTA patients|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac catheterization laboratory for an invasive coronary angiogram or patients presenting with chest pain and clinical indication of Coronary CT Angiography and an initial calcium score above 300
62104571|NCT06460519||Intensive care unit patient with shock, who don't be in perioperative of cardiac surgery|"Patients of age superior or equal of 18 years, with a vasopressor support superior 0.5 µg/kg/min of equivalent norepinephrine during more than 30 minutes.~The patients are not in perioperative of cardiac surgery (between the beginning of the intervention and 7 days after).~The patients have a monitoring of arterial pressure with a radial arterial catheter, and the physician decided to have a monitoring of arterial pressure with a femoral arterial catheter."
62104572|NCT04731610|OTHER|Post-operative radiotherapy|Tumour resection followed by radiotherapy.
62468683|NCT04915053|PLACEBO_COMPARATOR|Placebo|Daily intake of a 550 mg tablet, containing 250 mg of microcrystalline cellulose and 300 mg of excipients
62468684|NCT03401918|EXPERIMENTAL|Patients with recurrent pregnancy loss or unexplained infertility|"Patients with recurrent pregnancy loss or unexplained infertility will have an assessment of the uterine environment at the time of implantation, followed by testing of uterine endometrial gene expression using the ERA test and the uterine micro biome.~Those who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome."
62468685|NCT03401918|EXPERIMENTAL|Healthy Control Patients|Patients who have had a normal delivery and no history of infertility or recurrent pregnancy loss will have assessment of the uterine environment at the time of implantation.
62666389|NCT01456923|ACTIVE_COMPARATOR|Study|Patients treated only with chemotherapy
62104573|NCT04731610|OTHER|Surveillance after tumour resection|Tumour resection
62104574|NCT05623995|EXPERIMENTAL|Treatment arm|Participants will receive PCSK9 inhibitors added to guideline recommended statin therapy.
62104575|NCT05623995|ACTIVE_COMPARATOR|Control arm|Patients will continue to taking guideline recommended statin therapy.
62104576|NCT03459183|EXPERIMENTAL|Infrasound - verum|In this condition, participants are exposed with non-audible infrasound from the Infrasound (85dB; 6Hz) source, for 8 constant hours during their night sleep. The source is placed close to the participant's bed (approximately 1-2 meters).
62297122|NCT04946318|PLACEBO_COMPARATOR|24-week Placebo|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 24 weeks
62297123|NCT04946318|PLACEBO_COMPARATOR|12-week wash out + 12-week Placebo|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and Placebo inhaled once daily for 12 weeks"
62297124|NCT04946318|PLACEBO_COMPARATOR|12-week Placebo|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with Placebo inhaled once daily for 12 weeks
62297125|NCT04946318|EXPERIMENTAL|24-week CSJ117|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated once daily for 24 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
62297126|NCT04946318|EXPERIMENTAL|12-week wash out + 12-week CSJ117|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and then they will be treated once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 12 weeks."
61912838|NCT05724043|EXPERIMENTAL|SmartJournal|Nursing homes in the intervention group will receive the SmartJournal intervention. They will be provided with toolboxes including tablets with SmartJournal installed, antibacterial touchscreen wipes, flashlights for monthly oral inspections, instruction video, instruction book and SmartJournal information posters. They will also receive oral hygiene equipment packages including toothbrushes for permanent teeth and prosthetic devices, dental floss, interdental brushes, toothpaste and inspection mirrors. Training, follow-up and technical support for SmartJournal usage will be provided by project staff employed at the Oral Health Centre of Expertise Rogaland. The intervention will last for 12 weeks.
61912839|NCT05724043|NO_INTERVENTION|Control group|Nursing homes in the control group will also receive oral hygiene equipment packages but will, in contrast to the intervention group, continue with existing oral care routines.
61912840|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection \[Japanese Pharmacopoeia\]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
61912841|NCT00830791|EXPERIMENTAL|MK-0941 20 mg Mild Renal Insufficiency|MK-0941 20 mg administered to participants with mild renal insufficiency and type 2 diabetes.
62104577|NCT03459183|PLACEBO_COMPARATOR|Infrasound - placebo|In this condition, participants are not exposed to any sound. The infrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Infrasound dummy source looks exactly like the active infrasound source but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
62104578|NCT03459183|EXPERIMENTAL|Ultrasound - verum|In this condition, participants are exposed to non-audible ultrasound, emitted by the Ultrasound (10dB below hearing threshold; 22.4 kHz) source for 8 constant hours during their night sleep. The source is placed close to the participant's bed (1-2 meters), at the level of the participant's head (for instance on a nightstand).
62104579|NCT03459183|PLACEBO_COMPARATOR|Ultrasound - placebo|In this condition, participants are not exposed to any sound. The Ultrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Ultrasound dummy source looks exactly like the active ultrasound source, but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
62104580|NCT05709457|EXPERIMENTAL|RCT Participants|Women and children who participated in the earlier study.
62104581|NCT05709457|NO_INTERVENTION|Non-RCT participants|Women and children in the same communities included in the earlier study who did not participate in that study.
62104582|NCT03752515||case-ACS-MACE|ACS patients with poor prognosis
62104583|NCT03752515||control-ACS-MACE|ACS patients with good prognosis
62104584|NCT03752515||Health-control|general population without ACS
62104585|NCT04887688|EXPERIMENTAL|Group A: Wound treated using exciflex|Intervention treated wounds in Group A participants will be covered using the exciflex bandage which will be activated to deliver ES using a 10% duty cycle, i.e. ES will be active for 1 minute out of every 10 minutes. ES will be delivered for up to 10 weeks or until the wound is healed for 3 days. The exciflex bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. The exciflex power/control module will then be transferred to a new sterile flexible substrate and the exciflex bandage reapplied to the wound.
62297127|NCT04946318|EXPERIMENTAL|12-week CSJ117|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
62297128|NCT01350661||Asthma control level assessment|
62297129|NCT03987945||Left atrial appendage occlusion|Patients with non-valvular atrial fibrillation who have received left atrial appendage occlusion procedure.
61912842|NCT00830791|EXPERIMENTAL|MK-0941 20 mg Moderate Renal Insufficiency|MK-0941 20 mg administered to participants with moderate renal insufficiency and type 2 diabetes.
61912843|NCT00830791|EXPERIMENTAL|MK-0941 5 mg Severe Renal Insufficiency|MK-0941 5 mg administered to participants with severe renal insufficiency and type 2 diabetes.
61912844|NCT00830791|EXPERIMENTAL|MK-0941 20 mg Matched Controls|MK-0941 20 mg administered to age-, gender-, race-, body mass index (BMI)-, and hemoglobin A1C (HbAIc)-matched control subjects with normal renal function and type 2 diabetes.
62297130|NCT06046482|EXPERIMENTAL|Cohort A|Participants will receive magrolimab and cetuximab along with pembrolizumab.
62297131|NCT06046482|EXPERIMENTAL|Cohort B|Participants will receive magrolimab and cetuximab along with docetaxel.
62297132|NCT02048904|ACTIVE_COMPARATOR|Sitagliptin|100 mg/day for 3 months
62297133|NCT02048904|PLACEBO_COMPARATOR|Placebo|1 pill/day for 3 months
62468686|NCT01387633|EXPERIMENTAL|Educational intervention through telephone contact|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
62297134|NCT02369783|EXPERIMENTAL|Questionnaire and interview|The patient complete the questionnaire on the tablet to better know their social situation and any difficulties. Then, he will be interview during thirty minutes with a social worker and a nurse navigator. At the end of this intervention we will be offered to the patient monitoring and appropriate resources to its situation.
62468687|NCT01387633|ACTIVE_COMPARATOR|Educational intervention group|Educational intervention group for people with diabetes through Diabetes Conversation Maps.
62104586|NCT04887688|NO_INTERVENTION|Group B: Wound treated using standard of care|Control treated wounds in Group B participants will be covered with a standard of care hydrogel dressing such as Restore (Hollister Inc) together with Tegaderm . The SoC dressing will be used for up to 10 weeks or until the wound is healed for 3 days. The SoC bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. A fresh sterile SoC bandage will then be reapplied to the wound.
62297135|NCT01624142|EXPERIMENTAL|Evolocumab|Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
62297136|NCT06603883|NO_INTERVENTION|Control group|Receive ICU standard treatment.
62468688|NCT04990180|EXPERIMENTAL|Shared Decision Making Intervention|The intervention is a shared decision making consultation supported by a patient decision aid and decision coaching for healthcare professionals.
62666390|NCT01363440|ACTIVE_COMPARATOR|Macular Laser Photocoagulation Treatment (Control)|Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
62666391|NCT01363440|EXPERIMENTAL|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
62666392|NCT01363440|EXPERIMENTAL|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
62104587|NCT01802203||truFreeze spray cryotherapy|truFreeze Spray Cryotherapy administered as routine clinical care
62666393|NCT05143775|EXPERIMENTAL|new surgical plan group|The investigators use a monopolar stimulator to determine and retain the tumor margin within 5mm in the sensitive area which is posterior superior longitudinal fasciculus or posterior arcuate fasciculus.
62666394|NCT05143775|ACTIVE_COMPARATOR|traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified, those points would be retained to avoiding language function impairment after the tumor resection.
62666395|NCT03802357|EXPERIMENTAL|High training intensity|Exercise Training with high intensities consists of a cycling Interval Training at 100% of the individual Peak work rate, resistance Training for 3 sets à 8 repetitions and squats on a Vibration plate.
62666396|NCT03802357|ACTIVE_COMPARATOR|moderate training intensity|Exercise Training with moderate intensities consists of a cycling endurance Training at 60% of the individual Peak work rate, resistance Training for 3 sets à 20 repetitions and squats on the floor.
61912845|NCT00830791|EXPERIMENTAL|MK-0941 5 mg Matched Controls|MK-0941 5 mg administered to age-, gender-, race-, body mass index (BMI)-, and HbAIc-matched control subjects with normal renal function and type 2 diabetes.
61912846|NCT04108351|EXPERIMENTAL|Zopiclone|
61912847|NCT04108351|PLACEBO_COMPARATOR|Placebo|
62104588|NCT06368180|EXPERIMENTAL|Robotic assisted gait training group|This group had gait training using a robotic treadmill training system that uses body weight support belt, and driven gait orthoses (pediatric orthoses) for both legs.
62297137|NCT06603883|EXPERIMENTAL|FMT intervention Group|In addition to ICU standard treatment, 50ml commercial intestinal bacterial suspension was administered via a naso-jejunal tube to the jejunum from 11:00 to 13:00 every day for 3 consecutive days.
62297138|NCT05012748|EXPERIMENTAL|Ketogenic diet|The participants are instructed to follow a ketogenic diet consisting of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant.
62297139|NCT05012748|NO_INTERVENTION|Normal western diet|The participants are instructed to follow a normal western diet without emphasising any particular macronutrient.
62297140|NCT03538028|EXPERIMENTAL|INCAGN02385|Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
62666397|NCT00693264|EXPERIMENTAL|1|Participants will take 1- 750 mg capsule of Hoodia gordonii and have the primary and secondary outcomes measured over an 8 hour visit.
62666398|NCT00693264|PLACEBO_COMPARATOR|2|Participants will take a placebo capsule and have the primary and secondary outcome measures taken over an 8 hour study day.
62104589|NCT06368180|ACTIVE_COMPARATOR|Body weight support treadmill training group|This group had gait training using while the participant's body weight was supported over the treadmill by the Biodex Unweighting System.
62104590|NCT05650333|EXPERIMENTAL|Ritlecitinib 20 mg|Participants will receive Ritlecitinib 20 mg by mouth once daily (QD).
62104591|NCT02827162||Case D1|Subject having experienced a Virologically confirmed dengue infection, from the first injection until the end of the active phase, excluding Case D3 subjects
62297141|NCT02774590|EXPERIMENTAL|Timolol to split face for 8 weeks|All 24 subjects will receive study drug and everyone will be randomized to which side of the face is treated with study drug first (right half-face versus left half-face). After 8 weeks of split-face treatment every night before bed, the subjects will be instructed to start treating both sides for another 8 weeks. Up to 30 subjects may be enrolled to ensure a target sample size of 24 (12 acne cases, 12 rosacea cases). This is an exploratory study. No part of this protocol will be considered routine care.
62297142|NCT00239031|EXPERIMENTAL|1|
62297143|NCT03367156|EXPERIMENTAL|Group I (dexamethasone)|Patients receive dexamethasone PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
62297144|NCT03367156|ACTIVE_COMPARATOR|Group II (placebo, dexamethasone)|Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
62297145|NCT01288768|ACTIVE_COMPARATOR|Arthroscopy|Knee arthroscopy + Exercise therapy
62297146|NCT01288768|NO_INTERVENTION|Exercise therapy|Exercise therapy alone
62297147|NCT00638872|EXPERIMENTAL|1|PDRN
62297148|NCT00638872|PLACEBO_COMPARATOR|placebo|placebo
62297149|NCT04730895|EXPERIMENTAL|Oral 13 cis retinoic acid|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
62297150|NCT04730895|EXPERIMENTAL|Aerosolized 13 cis retinoic acid|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days. All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
62297151|NCT04730895|EXPERIMENTAL|13 cis retinoic acid doses orally in combination with spike protein based vaccine|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
62297152|NCT04730895|EXPERIMENTAL|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
61912848|NCT04054947|EXPERIMENTAL|Suicide Prevention Program|Behavioral: Suicide Prevention Program Structured care management to improve adherence to discharge planning.
62104592|NCT02827162||Case D3|Subject having experienced a Virologically confirmed dengue infection, from 28 days after the third injection until the end of the Active Phase of the proof of concept (PoC) efficacy study
62297153|NCT04730895|SHAM_COMPARATOR|spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|The participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
62297154|NCT01568723||Radiofrequency ablation|participants with barrett's esophagus with high grade dysplasia who undergo radiofrequency ablation (RFA)
62297155|NCT01331161|EXPERIMENTAL|Older group|Participants between the ages of 60-79
62297156|NCT01331161|EXPERIMENTAL|Younger group|Participants between the ages of 25-40
61912849|NCT04054947|NO_INTERVENTION|Usual Care|Standard care that occurs as part of mental health treatment
61912850|NCT02837081|ACTIVE_COMPARATOR|Preauthorization group|Strategy 1 of antimicrobial stewardship: Prescriptions of antimicrobial agents are done real-time by infectious diseases physician consultant. Use restricted without real-time authorization.
61912851|NCT02837081|EXPERIMENTAL|Prospective audit|Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.
61912852|NCT03954678|EXPERIMENTAL|Exercise Group|Participants randomized to the activity intervention will aim for taking 10,000 steps per day and completing strength training exercises three times per week.
62104593|NCT02827162||Control I|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and belonging to the PoC efficacy study immunogenicity subset
62297157|NCT01526148|ACTIVE_COMPARATOR|Lithium|
62297158|NCT01526148|ACTIVE_COMPARATOR|Quetiapine|
61912853|NCT03954678|ACTIVE_COMPARATOR|Nutrition Group|Participants randomized to the nutrition intervention will consume a liquid over-the-counter nutrition supplement two times per day.
61912854|NCT00862420|EXPERIMENTAL|Clopidogrel|75 mg clopidogrel once daily from Day 1 to Week 12
62297159|NCT05269576|EXPERIMENTAL|Single arm that receive two different interventions (clinical practice and clinical simulation).|"An analysis is carried out to the entire group prior to intervention. A second analysis is carried out to the entire group after one of the two interventions. Finally, a last analysis is carried out to the entire group after complete both types of interventions.~We apply the study in a group of medicine students of 3rth course of the degree. We examine their competencies at the beginning of the course. Re-examination is done after they do a period of clinical practice or a period of clinical simulation. At the end of the course, all the students done both interventions (clinical practice and clinical simulation), moment when we do the last examination of their competencies."
62297160|NCT01147679||bvFTD|This group will include 33 patients who have been diagnosed with behavioral variant frontotemporal dementia by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
62468689|NCT04165330|EXPERIMENTAL|AL3818 plus nivolumab|"Part 1: All participants will be assigned to receive AL3818 capsules orally, once daily at sequential deescalating doses (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (on Day 1 and Day 15) for a single 21-day cycle. Participants may continue study treatment at the AL3818 cohort dose at investigator discretion.~Part 2: All participants will receive AL3818 capsules orally, once daily at the RP2D determined from Part 1 (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (every 2 weeks starting on Cycle 1, Day 1) in 21-day cycles, for up to 24 cycles of total AL3818 therapy."
62468690|NCT03196570|EXPERIMENTAL|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
62468691|NCT03196570|ACTIVE_COMPARATOR|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
62468692|NCT02052947|OTHER|SPEC-DaTscan|SPEC-DaTscan
62468693|NCT06560580|OTHER|Older group|Patients were divided into two groups based on age: the younger group (\<40 years) and the older group (≥40 years). PSM (1:1) was used to ensure no significant differences in baseline characteristics between the two groups
61912855|NCT00862420|ACTIVE_COMPARATOR|Ticlopidine|200 mg ticlopidine once daily from Day 1 to Week 12
62297161|NCT01147679||Alzheimer's disease|This group will include 33 patients who have been diagnosed with clinically probable Alzheimer's disease by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
62468694|NCT06560580|OTHER|Younger group|Patients were divided into two groups based on age: the younger group (\<40 years) and the older group (≥40 years). PSM (1:1) was used to ensure no significant differences in baseline characteristics between the two groups
62468695|NCT06278545|EXPERIMENTAL|Modified FOLFIRINOX regimen D1=D15 (1 course every 14 days)|
62468696|NCT06278545|ACTIVE_COMPARATOR|Modified FOLFOX regimen D1=D15 (1 course every 14 days)|
62468697|NCT05985317|ACTIVE_COMPARATOR|Collagen membrane covering BMAC loaded on bovine graft|Collagen membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative
62468698|NCT05985317|ACTIVE_COMPARATOR|PRF membrane covering BMAC loaded on bovine graft|Platelet rich fibrin membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative
62297162|NCT01147679||Controls|33 health individuals without clinically significant cognitive impairments will be enrolled in this study.
62297163|NCT00525291|EXPERIMENTAL|EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
62297164|NCT00525291|ACTIVE_COMPARATOR|EMG-biofeedback alone|
62297165|NCT04407715|PLACEBO_COMPARATOR|High Flow Anesthesia, Low Flow Anesthesia|. The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow. Group 1 (n = 40) was operated under high flow anesthesia with 50% O2 - 50% air at 2 L/min and desflurane at 1.1 MAC for the duration of the surgery. For anesthesia maintenance, Group 2 (n=40) was administered 50% oxygen - 50% air at 2 L/min and desflurane for 10-15 minutes. After reaching 1.1 MAC, it was switched to minimal flow with 50-60% oxygen- 40-50% air at 0.5 L/min and desflurane. 10 minutes before the end of the surgery, it was switched to high flow with 50% oxygen -50% air at 2 L/min.
62468699|NCT01394497|EXPERIMENTAL|NAC procurement protocol|The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco-regional infusion into the portal vein before cross-clamping.
62468700|NCT01394497|NO_INTERVENTION|Standard procurement procedure|Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back-table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.
62468701|NCT00838149|ACTIVE_COMPARATOR|Glutamine|Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
62468702|NCT00838149|PLACEBO_COMPARATOR|Whey Protein|"Whey Protein:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
62468703|NCT03672266||Neurological Disorder|Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia
62666399|NCT03005756|EXPERIMENTAL|Robot-assisted Radiofrequency Ablation|CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
62666400|NCT02646059|EXPERIMENTAL|Text group|Text messages containing reminds of blood donation information would be sent to donors in this group.
62666401|NCT02646059|EXPERIMENTAL|Telephone group|Investigators would give telephone calls to the donors in this group, ask the reasons why they stopped donating blood.
62666402|NCT02646059|NO_INTERVENTION|Control group|No intervention will be giving to this group.
62297166|NCT04407715|ACTIVE_COMPARATOR|Peroperetive Optic Nerve Sheath Diameter|Optic nerve sheath diameter measurements were performed by an experienced and the same anesthetist. In the measurements, the GE Healthcare Logiq e series USG device and 12-MHz linear probe were used. Longitudinal and transverse axis images were obtained on both eyelids while the patient was in the supine position. Measurements were taken 3 mm behind the optic nerve head
62297167|NCT03731663|EXPERIMENTAL|Appetizing Food exposure group|Participants allocated to this group will watch a 3-minute video presenting a series of pictures of appetizing foods eaten in facilities in a tourist destination. An audio of a young adult describing herself eating these foods during a trip to London will be played.
62297168|NCT03731663|SHAM_COMPARATOR|Control content watching group|Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
62468704|NCT03672266||Neurotypical|Healthy individuals with no known neurological disorders
62468705|NCT05162664|OTHER|Healthy controls|Healthy controls
62468706|NCT05162664|OTHER|Patients with migraine|
62666403|NCT00585650|EXPERIMENTAL|Treatment Group|Etanercept (Enbrel) 50mg twice weekly injections for 12 weeks
62666404|NCT00585650|PLACEBO_COMPARATOR|Placebo Group|Placebo Injections twice weekly for 12 weeks
62666405|NCT02517489|EXPERIMENTAL|Hydrocortisone|Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
62104594|NCT02827162||Control E|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and not belonging to the PoC efficacy study immunogenicity subset
62104595|NCT02703129|EXPERIMENTAL|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
62104596|NCT00702429|EXPERIMENTAL|1|Patients achieve of parodontopathies
62297169|NCT06036875||Health Services Research|Patients complete a survey and may participate in an interview on study.
62297170|NCT05238051|NO_INTERVENTION|Gastric residual volume group|Patients undergoing enteral nutrition with continuous infusion and intermittent gastric residual volume measurement in the intensive care unit
61912856|NCT01791959|ACTIVE_COMPARATOR|Synbiotic|2 synbiotic capsules for 28 weeks
61912857|NCT01791959|PLACEBO_COMPARATOR|maltodexterin|two capsules per day for 28 weeks
62297171|NCT05238051|EXPERIMENTAL|Non- Gastric residual volume group|Patients undergoing enteral nutrition with continuous infusion and intermittent gastric residual volume measurement was not measured in the intensive care unit
62297172|NCT00128687|EXPERIMENTAL|Immediate Intervention|Participants in both arms continue to receive usual medical care throughout the study period. In addition, participants randomized to Immediate Intervention receive intensive case management for Coronary heart disease (CHD) risk reduction for 15 months and then a maintenance program for a minimum of 12 months to assess the durability of initial intervention changes.
62666406|NCT02517489|PLACEBO_COMPARATOR|Placebo|Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
62666407|NCT06099379|EXPERIMENTAL|CBD:THC Group 1|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62666408|NCT06099379|EXPERIMENTAL|CBD:THC Group 2|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62297173|NCT00128687|PLACEBO_COMPARATOR|Delayed Intervention|Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
62297174|NCT01472523||Controls|
62666409|NCT06099379|EXPERIMENTAL|CBD:THC Group 3|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62297175|NCT01472523||Aneuploidy|T13, 18, 21 and other chromosomal abnormalities yet to be determined
62297176|NCT05637268|EXPERIMENTAL|treatment group|"Treatment with camrelizumab combined with chemotherapy was planned for 4 to 6 cycles, after which carrilizumab monotherapy was maintained until disease progression, unacceptable toxicity, or patient withdrawal.~A total of 4 to 6 cycles, after carrilizumab maintenance treatment for one year."
62297177|NCT03182439|ACTIVE_COMPARATOR|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
61912858|NCT02972476|ACTIVE_COMPARATOR|1: Symbicort 400/12 & Eklira Genuair|Budesonide 400mcg \& formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
61912859|NCT02972476|ACTIVE_COMPARATOR|2: Seretide 500/50 & Eklira Genuair|Fluticasone propionate 500mcg \& salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
61912860|NCT02972476|ACTIVE_COMPARATOR|3: Seretide 250/50 & Eklira Genuair|Fluticasone propionate 250mcg \& salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
62104597|NCT00702429|PLACEBO_COMPARATOR|2|Patients without parodontales diseases
62104598|NCT02095158|EXPERIMENTAL|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
62104599|NCT04543513|EXPERIMENTAL|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
62104600|NCT02141347|OTHER|Part A|Dose escalation of tremelimumab mono therapy for advanced solid malignancies
62104601|NCT02141347|OTHER|Part B|Combination therapy of tremelimumab and MEDI4736 for advanced solid malignancies
62104602|NCT02141347|OTHER|Part C|Fixed dose of tremelimumab for malignant mesothelioma
62104603|NCT02920398|EXPERIMENTAL|N8-GP pivotal|
62104604|NCT02920398|ACTIVE_COMPARATOR|N8-GP commercial|
62104605|NCT06628440||Patients|intensive care patient with oro-tracheal intubation
62104606|NCT05100966|NO_INTERVENTION|Usual Care|Participants in the control arm will receive usual care which involves patient education that all participants who are scheduled for hip/knee replacement receive at the arthroplasty centre. This may include recommendations to attend fitness classes or discuss nutrition tips and smoking cessation initiatives with their family doctor or other healthcare provider before surgery.
62104607|NCT05100966|ACTIVE_COMPARATOR|FitJoints Multi-modal Intervention|
62104608|NCT01125228||AZT Alone|Zidovudine 200mg by mouth every 4hr
62666410|NCT06099379|EXPERIMENTAL|CBD:THC Group 4|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62666411|NCT06099379|EXPERIMENTAL|CBD:THC Group 5|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62666412|NCT01899885|NO_INTERVENTION|historic control group|Standard treatment in the historic control group
62666413|NCT01899885|ACTIVE_COMPARATOR|Intervention group|"AHA (Acute Highrisk Abdominalsurgery): Optimized Course:~Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~1. standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~2. GDT-LiDCO fluid management pre-, per- and postoperative~3. Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~4. Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
61912861|NCT02972476|ACTIVE_COMPARATOR|4: Duaklir Genuair|Aclidinium bromide 340mcg \& formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
62104609|NCT01125228||AZT plus IFN|-Zidovudine 200mg by mouth every 4hr -Alpha Interferon 1 million units once a day, escalating
62104610|NCT01125228||IFN Alone|-Alpha Interferon 1 million units once a day, escalating
62104611|NCT06306859|EXPERIMENTAL|SIKIDI group|The experimental arm will be given to access to m-health to monitor and education provision.
62104612|NCT06306859|ACTIVE_COMPARATOR|Comparator|The comparator group will be given standard care
61912862|NCT02083198||High Chloride|Patients receiving .9% sodium choride for resuscitation
61912863|NCT02083198||Low chloride|Patients receiving Plasmalyte for resuscitation
61912864|NCT02051699||One-leg standing view|
61912865|NCT02051699||both-leg standing view|
61912866|NCT01908946|EXPERIMENTAL|SMS Reminders|SMS reminders
61912867|NCT01908946|NO_INTERVENTION|Standard verbal counseling|One time standard verbal counseling at the time of initial visit and timing for EPI vaccines at 6, 10 and 14 weeks
62104613|NCT06367413|PLACEBO_COMPARATOR|Placebo|Participants in this arm will execute 150 eccentric muscle contractions an receive a placebo supplement consisted of carbohydrate (maltodextrin).
62104614|NCT06367413|EXPERIMENTAL|NAC|Participants in this arm will execute 150 eccentric muscle contractions an receive a N-acetylcysteine supplement.
62104615|NCT06367413|EXPERIMENTAL|PRoNAC|Participants in this arm will execute 150 eccentric muscle contractions an receive a supplement consisted of N-acetylcysteine and whey protein.
62104616|NCT05408455|EXPERIMENTAL|EMST (Expiratory Muscle Streght Training) group|EMST at a pressure value between 50-75% will be applied for 8 weeks, 3 days a week and 24 sessions in total.
62104617|NCT05408455|SHAM_COMPARATOR|Sham EMST Group|EMST without threshold loading will be applied for 8 weeks, 3 days a week and 24 sessions in total.
62104618|NCT06118736|EXPERIMENTAL|Adductor tenotomy + Temporary Medial Hemi-epiphysiodesis of the proximal femur|Standard care + intervention
62104619|NCT06118736|NO_INTERVENTION|Adductor tenotomy|Standard care
62104620|NCT06316674||Anorexia Nervosa (AN)|People affected by AN (DSM5); female, age 18-55, BMI ≤ 17.5 Kg/m2
62666414|NCT05550181||with hypocapnia|We will use the intraoperatively collected etCO2 levels to classify patients as either 'with hypocapnia' or 'without hypercapnia', using the cutoff of 35 mmHg. A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study
62468707|NCT04714294|EXPERIMENTAL|SAD: Each volunteer will receive 6 mg, 10mg, 20mg, 40mg(or TBD) of IP once daily for 1 day|Drug: HPP737 or placebo One 1 mg capsule and one 5mg capsule taken orally (by mouth) once daily for SAD arm 1/ Two 5mg capsule taken orally (by mouth) once daily for SAD arm 2/ Four 5mg capsule taken orally (by mouth) once daily for SAD arm 3/ Eight 5mg capsule taken orally (by mouth) once daily for SAD arm 4
62666415|NCT05550181||without hypocapnia|We will use the intraoperatively collected etCO2 levels to classify patients as either 'with hypocapnia' or 'without hypercapnia', using the cutoff of 35 mmHg. A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study, and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
62666416|NCT04657900||All eligible patients|Observational cohort using anonymized patient-level primary care data linked to secondary administrative data; CPRD-GOLD and CPRD-AURUM.
62666417|NCT04939584|EXPERIMENTAL|Intervention|"The study will be conducted using the venous cannulations that are standard of care for the indicated procedure. Additional access points may be necessary if access to coronary sinus is difficult from existing femoral venous cannulations. Sterile study leads or EP catheters will be temporarily placed into the RA, CS, and RV (for R-wave sensing using intracardiac electrograms - optional) which will be connected to the investigational device (CESS).~Up to two MPTs will be delivered and subject responses following each MPT regarding perception and acceptability of MPT to treat AF will be obtained. MPT voltages will not exceed 100V."
62666418|NCT05408221|EXPERIMENTAL|Rulonilimab|with PD-1 Inhibitors
62104621|NCT06316674||Healthy controls (HC)|female, age 18-55, BMI between 18.5 Kg/m2 and 25 Kg/m2
62104622|NCT05739123||Exposed Cohort|Pregnant women who are exposed to relugolix-containing therapy at any time during pregnancy
62104623|NCT05739123||Unexposed Cohort|Pregnant women with conditions for which relugolix-containing therapy may be prescribed for indications that are approved or under phase 3 development and who are not exposed to relugolix-containing therapy at any time during pregnancy
62297178|NCT03182439|ACTIVE_COMPARATOR|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
62297179|NCT03182439|ACTIVE_COMPARATOR|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
62666419|NCT05408221|PLACEBO_COMPARATOR|Rulonilimab placebo|without PD-1 Inhibitors
62666420|NCT04970108|EXPERIMENTAL|Egito|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Egito, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan placebo, oral."
62666421|NCT04970108|ACTIVE_COMPARATOR|Empagliflozin + telmisartan|"The patient must take 3 tablets once a day, as follows:~1 tablet Egito placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan, oral."
62666422|NCT00690898|EXPERIMENTAL|Lanreotide autogel 120 mg|
62666423|NCT03411538||Hospital-acquired bacterial infection|
62666424|NCT02845388|ACTIVE_COMPARATOR|estradiol valerate|estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
62666425|NCT02845388|ACTIVE_COMPARATOR|Sildenafil citrate and estradiol valerate|Sildenafil citrate 25 mg every 6 hours orally in combination with estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
62666426|NCT02156661|ACTIVE_COMPARATOR|Oxytocin|"Oxytocin: Syntocinon-Spray, Novartis~intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT"
62666427|NCT02156661|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
62297180|NCT03182439|ACTIVE_COMPARATOR|Apple Watch|Apple Watch Heart Rate Monitoring Device
62297181|NCT01836861|EXPERIMENTAL|IPI-145 and [14C] IPI-145|
62297182|NCT06249529|EXPERIMENTAL|Interventional|Patients in the interventional arm will receive implant of one or more airway bypass devices.
62297183|NCT01543750|EXPERIMENTAL|Study Medication|4-aminopyridine 10mg twice daily for 8 weeks
62297184|NCT01543750|EXPERIMENTAL|Placebo|placebo twice daily for 8 weeks
62297185|NCT02814721|NO_INTERVENTION|Standard cannulation|The standard cannulation protocol of the center was defined as using 17 gauge needles for the first 3 dialysis sessions, followed by 16 gauge for the next 3, and finally 15 gauge for subsequent sessions.
62468708|NCT04714294|EXPERIMENTAL|MAD: Each volunteer will receive 10mg, 20mg, 40mg(or TBD) of IP once daily for 7 days|Drug: HPP737 or placebo Two 5mg capsule taken orally (by mouth) once daily for MAD arm 1/ Four 5mg capsule taken orally (by mouth) once daily for MAD arm 2/ Eight 5mg capsule taken orally (by mouth) once daily for MAD arm 3
62468709|NCT02169115|EXPERIMENTAL|Omalizumab 150mg|
62468710|NCT02169115|EXPERIMENTAL|Omalizumab 300mg|
62468711|NCT02169115|PLACEBO_COMPARATOR|Placebo|
62468712|NCT01029522|EXPERIMENTAL|Lipilou 20mg|
62666428|NCT04620538||Controls|Healthy Controls with or without risk factors for Chronic Liver Disease (i.e. patients referred due to concerns re: liver disease but found to have no evidence of chronic liver disease following assessment)
62666429|NCT04620538||Fibrosis|Patients with evidence of Liver Fibrosis on the basis of current diagnostic techniques / expert opinion.
62666430|NCT04620538||Compensated Cirrhosis|Patients with evidence of Compensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
62468713|NCT01029522|ACTIVE_COMPARATOR|Lipitor 20mg|
62666431|NCT04620538||Decompensated Cirrhosis|Patients with evidence of Decompensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
62666432|NCT04620538||Hepatocellular Carcinoma|Patients with evidence of Hepatocellular Carcinoma on the basis of current diagnostic techniques / expert opinion.
62666433|NCT03573856|ACTIVE_COMPARATOR|Active Living|Three component behavioral intervention consisting of group-based classes, individual motivational interviewing-based sessions, and resource toolbox
62104624|NCT06085820|EXPERIMENTAL|Experimental (birth ball)|"Group B~* Meeting~* The researcher will introduce himself/herself, provide information about the research and obtain verbal and written consent.~* Privacy will be ensured~* After the routine maintenance of the hospital is carried out in the latent phase, the researcher will first introduce the birthing ball to the pregnant women and the movements to be performed will be demonstrated by the researcher.~Starting from the active phase, movements will be performed for 20 minutes every hour. During the contraction, there will be a break until the contraction ends, and the pregnant woman will be given the opportunity to rest in a comfortable position. The same movements will be applied again. The partograph will be recorded. VAS and VCS will be applied.~* When the perineum is crowned, the pregnant woman will be taken to the table.~* SEMSNB will be applied within 1-4 hours after birth."
62297186|NCT02814721|ACTIVE_COMPARATOR|Ultrasound guided cannulation|The study protocol involved similar up titration of needle size over a 3-week period, except that a pre-cannulation evaluation of the fistula was performed using the Sonic Window ultrasound device. The device was used to evaluate and identify the optimal site of cannulation (image 1). Depending upon the cannulator's preference, real-time guidance could be employed during cannulation (image 2, 3). The cannulations were performed by 4 selected personnel trained in device use and successfully completed a competency evaluation on simulator models and a mature dialysis fistula.
62297187|NCT04690699|EXPERIMENTAL|Cohort E: Lerapolturev|Subjects will be treated with lerapolturev by intravesical instillation
62468714|NCT02851992|OTHER|GTS cementless stem|Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
62468715|NCT01841554|EXPERIMENTAL|Single|
62468716|NCT03220802|EXPERIMENTAL|Test group|participants receive a daily dose of OMNI-BiOTiC PPI for three months
62468717|NCT02848742|EXPERIMENTAL|Treatment with cryotherapy device|To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.
62468718|NCT00637741|EXPERIMENTAL|Everflex 200|study group treated with at least one 200 mm Everflex stent
62468719|NCT01577303|EXPERIMENTAL|CBM training program variant 1|Attention training towards positive cues using words as stimuli
62468720|NCT01577303|EXPERIMENTAL|CBM training program variant 2|Attention training towards positive cues using words and faces as stimuli
62468721|NCT01577303|EXPERIMENTAL|CBM training program variant 3|Attention training towards negative using words as stimuli
62468722|NCT01577303|EXPERIMENTAL|CBM training program variant 4|Attention training towards negative using words and faces
62666434|NCT03573856|PLACEBO_COMPARATOR|Health and Safety|One component health and safety program consisting of group classes
62666435|NCT00330096|EXPERIMENTAL|Hesperidin-rich food|
62666436|NCT00330096|PLACEBO_COMPARATOR|No intervention: Placebo|
62666437|NCT02911467|EXPERIMENTAL|MR imaging with hyperpolarized 13C pyruvate of men with CRPC|75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.
62666438|NCT00299221|ACTIVE_COMPARATOR|Monotherapy|Tacrolimus alone
62666439|NCT00299221|ACTIVE_COMPARATOR|Combination therapy|tacrolimus with mycophenolate mofetil
62666440|NCT02293499|ACTIVE_COMPARATOR|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
61912868|NCT01135667|ACTIVE_COMPARATOR|clopidogrel|clopidogrel 150 mg once daily for 30 days (and then 75 mg for additional 11 months - not study related)
62468723|NCT01577303|EXPERIMENTAL|Control training variant 1|Control training condition using words as stimuli
62468724|NCT01577303|EXPERIMENTAL|Control training variant 2|Control training condition using words and faces as stimuli
62468725|NCT01857167|EXPERIMENTAL|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
62468726|NCT01857167|EXPERIMENTAL|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
62666441|NCT02293499|ACTIVE_COMPARATOR|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
62666442|NCT05257187|ACTIVE_COMPARATOR|6 hour foley catheter retention|Patients will have the foley catheter in place for up to 6 hours starting from insertion time to removal. If the catheter falls out earlier than the 6 hour mark, the patient will still be included for analysis.
62666443|NCT05257187|PLACEBO_COMPARATOR|12 hour foley balloon retention|Patients will have the foley catheter in place for up to 12 hours starting from insertion time to removal. If the catheter falls out earlier than the 12 hour mark, the patient will still be included for analysis.
62666444|NCT01692587|NO_INTERVENTION|Control|No changes in dietary group
62666445|NCT01692587|EXPERIMENTAL|Protein restrictive diet|reduced protein diet
62666446|NCT02399800|EXPERIMENTAL|EUS with Celiac Block|Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
62666447|NCT02399800|ACTIVE_COMPARATOR|EUS without Celiac Block|Patients will undergo EUS but no celiac block will be performed
62666448|NCT02625012||Vitiligo|A serial of vitiligo patients under treatment with UVB-NB
62666449|NCT04862208|EXPERIMENTAL|Carbohydrate-based breakfast + exercise|maltodextrin
62666450|NCT04862208|EXPERIMENTAL|Protein-based breakfast + exercise|whey
62666451|NCT04862208|EXPERIMENTAL|Fasted breakfast + exercise|water
62666452|NCT04862208|SHAM_COMPARATOR|Carbohydrate-based breakfast + no exercise|maltodextrin
62666453|NCT03653078|EXPERIMENTAL|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
62297188|NCT04690699|EXPERIMENTAL|Cohort F: Lerapolturev + 5% DDM|Subjects will be treated with lerapolturev by intravesical instillation after a sequence of 5% DDM and saline washes
62666454|NCT03653078|NO_INTERVENTION|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
62666455|NCT04740190|EXPERIMENTAL|interventional arm|Single fraction, low dose (2Gy) whole brain radiation therapy, followed by combination talazoparib and carboplatin
62666456|NCT01554813|EXPERIMENTAL|Influenza split vaccine of 15μg HA|15μg HA/strain/0.5ml/vial
62666457|NCT01554813|EXPERIMENTAL|Influenza split vaccine of 15 μg HA|15μg HA/strain/0.5ml/syringe
62666458|NCT01554813|ACTIVE_COMPARATOR|Influenza split vaccine|15μg HA/strain/0.5ml/syringe
62666459|NCT04825899||NGS Panel|patients who had NGS 481 gene mutation detected
62666460|NCT01503801|EXPERIMENTAL|inhaled nitric oxide|The preterm infants in the experimental group inhaled nitric oxide
62666461|NCT01503801|ACTIVE_COMPARATOR|oxygen|The preterm infants enrolled but subjected to routine respiratory support.
62666462|NCT04038398|OTHER|FiO2 : 100% - 50% - 21%|see above
62666463|NCT04038398|OTHER|FiO2: 21% - 50% - 100%|see above
62666464|NCT05285449|ACTIVE_COMPARATOR|Dietary Supplement: Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate
61912869|NCT01135667|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 10 mg once daily for 30 days (and then clopidogrel 75 mg once daily for additional 11 months - not study related)
62297189|NCT03431220|EXPERIMENTAL|RENASYS TOUCH NPWT System|Negative Pressure Wound Therapy (NPWT)
62666465|NCT05285449|PLACEBO_COMPARATOR|Dietary Supplement: CBD matching Placebo|Matching Placebo
62666466|NCT03923920||Spinal Stenosis Biopsy|Biopsy of ligamentum flavum tissue during spinal stenosis surgery sent to pathology for amyloid-specific analysis
62308273|NCT02146781|PLACEBO_COMPARATOR|0.80 mL Saline Placebo Cohort 1|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan and are skin test positive or negative at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens.~Cohort # 1: Subjects will receive four 0.200 mL volume intradermal injections of saline control as a placebo control using the Biojector device.~Intervention: Saline Control via Intradermal route."
62666467|NCT01910532|EXPERIMENTAL|Clevidipine|Using Clevidipine for the treatment of acute hypertension defined SBP \> 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
62666468|NCT05664594|EXPERIMENTAL|Perceptual Discrimination Training|Training will involve Gabor patch and other visual stimuli discrimination exercises that focus on improving signal-to-noise resolution and attentional control with minimal working memory/cognitive control effects. On each training trial, participants are required to distinguish a target stimulus among a set of distractor stimuli. The similarity between target and distractors increases in level of difficulty based on an adaptive perceptual processing staircase function. Consecutive correct responses lead to increased modulation of the distractors to be more similar to the target, while 1 incorrect response drops the user to an easier level. Difficulty is adapted to maintain an 80% correct response rate. Each session will consist of 4 exercises requiring \~45 minutes. with 40 trials for each exercise.
62666469|NCT05664594|EXPERIMENTAL|Visual Cognitive Control Training|"Training will involve maintaining accurate representations of cognitive context (the rule) in working memory during response selection. On each training trial, participants must observe stimuli, and hold the correct response context on-line in order to select the correct response from among the stimuli. Training is adaptive using a staircase function, such that two consecutive correct responses increases either the speed of stimuli presentation or the working memory load via an increased number of stimuli that are presented; one incorrect response reduces the cognitive load. Each session will consist of 45 exercises requiring \~45 minutes."
62666470|NCT02239055||Focus Group 1|Staff Perceptions
62666471|NCT02239055||Focus Group 2|Staff Perceptions
62666472|NCT03368677||Teriflunomide group|20 MS patients who are using teriflunomide medication under the supervision of their treating neurologist.
62666473|NCT03368677||No disease modifying treatment|10 MS-patients who do not use any regular disease modifying MS treatment of their own volition
62666474|NCT02703025|EXPERIMENTAL|GCB 70 administered group|Green coffee bean extract capsule 500mg, BD
62666475|NCT03967327|ACTIVE_COMPARATOR|MOR SR|"This arm includes MOR SR and placebo for BUP TDS, detailed information is as below:~Treatment dosage form dosage frequency duration MOR SR Tablet 10,30,60mg q12h 8 weeks~Placebo for Patch -- every 3-4 days 8 weeks BUP TDS"
62666476|NCT03967327|EXPERIMENTAL|BUP TDS|"This arm includes BUP TDS and placebo for MOR SR, detailed information is as below:~Treatment dosage form dosage frequency duration Placebo for Tablet -- q12h 8 weeks MOR SR~BUP TDS Patch 20/30/40mg every 3-4 days 8 weeks"
62666477|NCT04332120|ACTIVE_COMPARATOR|Mini Laparotomic|In patients undergoing spinal anesthesia, a suprapubic 3-5 centimeter incision was entered into the abdomen. After both tubes were isolated, bilateral tube ligation was performed by Pomeroy method. After bleeding control was achieved, it was repaired in accordance with the anatomy of the abdomen.
62468727|NCT01857167|PLACEBO_COMPARATOR|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
62666478|NCT04332120|ACTIVE_COMPARATOR|Laparoscopic|In patients undergoing general anesthesia, Verres was inserted into the abdomen through the umbilicus. Pneumo peritoneum was created with carbon dioxide (CO2). Optical imaging was placed into the abdomen from the umbilicus with 10-trochar. Auxiliary trochars from 3 centimeter supero-medial of both spina iliaca anterior superior were placed in the abdomen. bilateral tubas were isolated. Bilateral tubal ligation was performed with the help of bipolar cautery. bleeding control was achieved. trochars were taken out of the abdomen. the skin was closed.
62666479|NCT04332120|ACTIVE_COMPARATOR|posterior colpotomy|The patient underwent spinal anesthesia and was placed in a high lithotomy position. cervical uteri was observed with the help of speculum. A 3 centimeter vertical incision was opened 2 centimeter below the cervix uteri. Peritoneal cavity was entered from this area. bilateral tubas were isolated. Bilateral tubal ligation was performed using the pomeroy method. bleeding control was achieved. peritoneal and posterior cervical incision line was repaired.
62666480|NCT05788965|OTHER|Single Arm|This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with CFRD.
62666481|NCT05982119|OTHER|Patients with DMD/FSHD/CMT/DM1/CNM/FKRPmutation or control subjects|"Patients and control subjects will be included over a 3-years study period. Patients will be examined by a neuropaediatrician or neurologist and perform standardized assessments (timed tests, motor function tests, and strength tests) at baseline and then every 6 to 12 months (depending on age).~From February 2024, controls subjects can be remotely recruited and enrolled. They won't be evaluated on site, but data, such as age, sex, weight, and height, will be collected by phone or visio-conference at inclusion and every 6 months for 3 years.~Patients will be asked to wear the device during 1 to 3 months at baseline (depending on disease group) and then for 1 month every 3-12months (depending on age and disease group).~Control subjects will be examined by a physician and perform the same tests than those for ambulant patients at baseline and 12 months. Control subjects will be asked to wear the device for two months (one month at inclusion, one month 11 months after inclusion)."
62666482|NCT00133354|ACTIVE_COMPARATOR|Arimidex and Growth Hormone|
62468728|NCT01618097|EXPERIMENTAL|DVD Decision Aid|Patient assigned to watch DVD decision aid.
62666483|NCT00133354|PLACEBO_COMPARATOR|Placebo and Growth Hormone|
62666484|NCT00990769|EXPERIMENTAL|"High-normal BIS (Lighter anesthesia)"|Depth of anesthesia is titrated to a BIS of 55-60
62666485|NCT00990769|EXPERIMENTAL|"Low-normal BIS (Deeper anesthesia)"|Depth of anesthesia is maintained at a BIS level of 40-45
62666486|NCT00109369|EXPERIMENTAL|Active|Provider and patient receive Diabetes Information System services
62666487|NCT00109369|NO_INTERVENTION|Control|Usual Care
62666488|NCT04795323|EXPERIMENTAL|Cohort 1: TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
62468729|NCT01618097|EXPERIMENTAL|Internet Based Decision Aid|Patient assigned to watch OA specific internet based decision aid.
62468730|NCT03809130|EXPERIMENTAL|Arm I (Untire application)|Patients use Untire application intervention after baseline up to 6 months.
62468731|NCT03809130|ACTIVE_COMPARATOR|Arm II (Untire application)|Patients use Untire application intervention after 3 months up to 6 months.
62468732|NCT00804180|OTHER|Coping skills intervention|Self-Injection Anxiety Counseling: Evaluation of a group treatment for injection-related anxiety. The intention of the study is to obtain basic evaluation of a clinical treatment offered in a natural clinic setting, and does not include a control group, or procedure for random assignment of participants.
62666489|NCT04795323|EXPERIMENTAL|Cohort 2: TARA v3.2, both non-pharmacological and pharmacological self-management support|TARA is a digital behaviour change intervention (DBCI) intended to support patients with COPD in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA is used independently at home by patients via an internet-enabled device and is a fully online digital system that offers guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication) in TARA version 3.1 (v3.1). Additionally, in TARA v3.2, pharmacological self-management support module (including modules on inhaler techniques and correct use of inhalers, plus a module to close track inhaler use and symptoms over a 7-day period) was included. The study comprised a screening (pre-TARA) period (included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
62666490|NCT01384409|EXPERIMENTAL|KW-3357|
62666491|NCT00169260|EXPERIMENTAL|1|Intervention
62666492|NCT00169260|PLACEBO_COMPARATOR|2|Control
62666493|NCT04481659|EXPERIMENTAL|A group|Patients who are initially staged as T1-2, according to MRI and intraluminal ultrasound, are assigned to the direct surgery group (determined by the multidisciplnary team \[MDT\] group)
62666494|NCT04481659|EXPERIMENTAL|B group|Patients who are initially staged as T3M0, according to MRI and intraluminal ultrasound, should undertake preoperative chemoradiotherapy (determined by the MDT group). The operation was performed 8-12 weeks after the end of the chemoradiotherapy.
62666495|NCT05728229|EXPERIMENTAL|Experimental Group (GS)|GS patients, in addition to the pharmacological therapy foreseen by the clinical conditions, will take 1 sachet a day of SiderAl® Med, a food for special purposes, for 28 days. GS patients will take the food for special purposes during hospitalization (between T0 and T1) and during the 1 month of returning home (between T1 and T2). During the second month of returning home (between T2 and T3), GS patients will no longer take the food for special purposes.
62666496|NCT05728229|NO_INTERVENTION|Control Group (GC)|The patients of the GC, on the other hand, will continue to take the drug as required by their clinical conditions and will not take the SiderAL® Med food for special purposes, but will only be observed and evaluated at the various time-points foreseen by the study.
62666497|NCT03189953|EXPERIMENTAL|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
62308274|NCT02146781|EXPERIMENTAL|2.16 mg of CryJ2-DNA-LAMP plasmid vaccine Cohort 2|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 2: Subjects receive four (4) injections of 0.200 mL volumes (2.7 mg/mL) for a single dose of 2.16 mg of CryJ2-DNA-LAMP plasmid vaccine; intradermally (ID) administered using the Biojector device (each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
62468733|NCT00473330|EXPERIMENTAL|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
62666498|NCT03805048|OTHER|Native Vessel PCI|All patients with a significant stenosis (\>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
62666499|NCT03805048|OTHER|Graft PCI|All patients with a significant stenosis (\>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the bypass graft will be performed following current standards and at the discretion of the operating interventional cardiologist. Only commercially available second generation DES will be used in the treatment of bypass grafts. The second generation DES used in this study will be the XIENCE Sierra stent. The use of a filter-wire during the procedure will be left at the discretion of the operator.
62666500|NCT02050295|EXPERIMENTAL|Nerve block washout|Patients will receive a washout infusion of saline through their perineural catheter to reverse their motor block while maintaining the sensory block.
62666501|NCT02050295|SHAM_COMPARATOR|Sham washout|Patients will receive an infusion of saline run just enough to maintain catheter patency.
62666502|NCT01422447|EXPERIMENTAL|community intervention|Feedback on assessment results: distribute relevant brochures and hold regular lectures on depression, anxiety and alcohol-abuse.
61912870|NCT02935829|EXPERIMENTAL|Glucose as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61912871|NCT02935829|EXPERIMENTAL|Carob preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
62308275|NCT02146781|EXPERIMENTAL|1.08 mg CryJ2-DNA-LAMP plasmid vaccine Cohort 3|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 3: Subjects will receive two (2) injections of 0.200 mL (2.7 mg/mL) for a single dose intradermally (ID) for a single dose of 1.08 mg CryJ2-DNA-LAMP plasmid vaccine administered using the Biojector device, each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
62468734|NCT00473330|EXPERIMENTAL|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
62666503|NCT01422447|ACTIVE_COMPARATOR|regular intervention control|the subjects in the control group live in the used model
62666504|NCT01635647|ACTIVE_COMPARATOR|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
62666505|NCT01635647|PLACEBO_COMPARATOR|Rabies vaccine|2 x 2.5IU Verorab
62666506|NCT06516848|EXPERIMENTAL|High Intensity Inspiratory Muscle Training Group (H-IMT)|
62666507|NCT06516848|EXPERIMENTAL|Low Intensity Inspiratory Muscle Training Group (L-IMT)|
62666508|NCT02274428|OTHER|pneumostem group|single arm, pneumostem treated infants
62666509|NCT01911325|EXPERIMENTAL|Phase Ib: Buparlisib + docetaxel|Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.
62104625|NCT06085820|EXPERIMENTAL|Experimental (birth dance)|"Group C~* Meeting~* The researcher will introduce himself/herself, provide information about the research and obtain verbal and written consent.~* Privacy will be ensured~* The environment will be made suitable~* The pregnant woman will be asked to wear slippers that make her feel comfortable.~* Pregnant will be given training on how to perform the birth dance during the latent phase. VCS and VAS will be applied.~Birth dance practice will be started on the pregnant woman starting from the active phase.~* Starting from the active phase, the partograph will be recorded.~* Birth dance cervical dilation will be performed for 20 minutes every hour, in the range of 5-8 cm.~* At the end of the active phase, VCS and VAS will be applied again. The researcher will be with the pregnant woman throughout the application and labor.~* When perineum is crowned, the pregnant woman will be taken to the delivery table.~SEMSNB will be applied within 1-4 hours after birth."
62308276|NCT05057624|PLACEBO_COMPARATOR|non-GC-MRT|Placebo- music will play at all times during the trials.
62666510|NCT01911325|EXPERIMENTAL|Phase II: Buparlisib + docetaxel|Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
62666511|NCT01911325|PLACEBO_COMPARATOR|Phase II: Placebo + docetaxel|Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
62666512|NCT03144206|EXPERIMENTAL|Hyperbaric Oxygen Group|Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period
62666513|NCT03144206|NO_INTERVENTION|Standard of Care Group|Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period
62666514|NCT04565223|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|"5 sessions of Cognitive behavioral therapy for insmonia and an extra session for benzodiazepine withdrawal (if necessary).~The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal"
62666515|NCT04565223|NO_INTERVENTION|Usual care|Usual care from GPs or nurses
62666516|NCT00344825||Group 1|
62666517|NCT06217146|EXPERIMENTAL|MediCane's medical cannabis oil|
62666518|NCT06217146|PLACEBO_COMPARATOR|Placebo|
62666519|NCT02829814|EXPERIMENTAL|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
62666520|NCT02829814|PLACEBO_COMPARATOR|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
62666521|NCT01292538|EXPERIMENTAL|Erchonia GLS 532nm|532nm green laser light therapy.
62666522|NCT01292538|SHAM_COMPARATOR|Placebo laser|Sham light output with no therapeutic benefit
62666523|NCT05044988|EXPERIMENTAL|HS-10342|Each subject will receive repeat doses (C1, C2...) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62666524|NCT03509597|EXPERIMENTAL|Aerobic Exercise|This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
62666525|NCT03509597|EXPERIMENTAL|Cognitive Training|The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
62666526|NCT03509597|SHAM_COMPARATOR|Treatment as usual|The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.
62666527|NCT01171573||Myositis Patients|Cases with myositis PM DM IBM Venepuncture
62666528|NCT01171573||Healthy controls|Control
62666529|NCT05840406|ACTIVE_COMPARATOR|Group SA|No TAP block applied.
62308277|NCT05057624|ACTIVE_COMPARATOR|GC-MRT|Music will only play when participants view angry faces and will stop when they look at neutral faces.
62308278|NCT05057624|EXPERIMENTAL|GC-MRT-exp|Music will only play when participants look at neutral faces and will stop when they view angry faces.
62308279|NCT04150432|EXPERIMENTAL|propofol|propofol general anesthesia, exhaled measurement of propofol
62666530|NCT05840406|EXPERIMENTAL|Group L|Ultrasound-guided bilateral TAP block (in-plane technique) will be performed in this group. Levobupivacaine 0.25 % 20 ml will be administered in the block on each side.
62666531|NCT05840406|EXPERIMENTAL|Group D|Ultrasound-guided bilateral TAP block (in-plane technique) will be performed in this group. Levobupivacaine 0.25 % 20 ml + dexmedetomidine 0,5 μg/kg will be administered in the block on each side.
62666532|NCT04344093|EXPERIMENTAL|Connected patch validation|
62666533|NCT00688779|EXPERIMENTAL|1|
62666534|NCT00688779|PLACEBO_COMPARATOR|2|
62104626|NCT06085820|NO_INTERVENTION|control group|"Midwifery Interventions Made to the Control Group~* The pregnant woman will be greeted politely.~* The researcher will introduce himself/herself, provide information about the research and obtain verbal and written consent.~* Privacy will be ensured~* An introductory information form will be filled out.~* Routine monitoring and care will be provided by the medical staff working in the delivery room.~* At the end of each phase (latent, active), GKS and SCS will be applied once.~* EFM (Electronic Fetal Monitoring) will be applied in each phase.~* Child Heart Sound (CHS) will be listened to every half hour and recorded on the partograph.~* Cervical changes will be evaluated with bimanual examination and recorded on the partograph.~* When the perineum is crowned, the pregnant woman will be taken to the table.~* NDAMDÖ will be applied to women taken to the postpartum room within a period of 1-4 hours."
62297190|NCT05823142|EXPERIMENTAL|CB-sleep|Initial instruction for the CB-sleep intervention will occur 60-minute telehealth session. The initial action planning session with a sleep report and booster sessions will be interactive and stage matched. The intervention will include an interactive PowerPoint with the participant's clinician sleep report with personalized feedback. They will be encouraged to systematically extend their time in bed by 1 hour and maintain the extension on both weekends and weekdays. Weekly titration will occur according to the following parameters: if sleep efficiency is ≥ 85%, time in bed is increased by 15 minutes per week until a total of a 1 hour increase in time in bed is achieved, if sleep efficiency is \<85%, time in bed remains the same. There will be weekly follow-ups (email, phone, text, video chat) and telehealth 4-week booster sessions. Sleep reports generated by the baseline actigraphy report will be shared with participants with brief action planning and goal setting.
62666535|NCT01144806|ACTIVE_COMPARATOR|Group 1|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
62666536|NCT01144806|ACTIVE_COMPARATOR|Group 2|Ready to use therapeutic food (RUTF / PlumpyNut)will be provided to parent/care givers of children with severe malnutrition in enrolled in this group
62666537|NCT02022527|EXPERIMENTAL|Combination|Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement \& 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.
61912872|NCT02935829|EXPERIMENTAL|White bread as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61912873|NCT02935829|EXPERIMENTAL|Carob snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61912874|NCT02935829|EXPERIMENTAL|Chocolate cookie snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62308280|NCT05295277||Standard of care genetic testing group|Individuals with genomic test results from a standard of care (SOC) test (such as CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS, etc.) will be enrolled in the study to compare the SOC result to results from optical genome mapping.
62308281|NCT03089567|NO_INTERVENTION|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
62666538|NCT02022527|ACTIVE_COMPARATOR|Warfarin|Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement \& 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.
62666539|NCT01940146|PLACEBO_COMPARATOR|SPARC Placebo|
62666540|NCT01940146|EXPERIMENTAL|SPARC1310 I|
62666541|NCT01940146|EXPERIMENTAL|SPARC1310 II|
62666542|NCT01940146|EXPERIMENTAL|SPARC1310 III|
62666543|NCT02619513|NO_INTERVENTION|General anesthesia group(Group GA)|Group GA received general anesthesia only and intravenous analgesia pump.
62666544|NCT02619513|EXPERIMENTAL|TEB group(Group GE)|Group GE received continuous thoracic epidural block(TEB) combined with general anesthesia and postoperative continuous thoracic epidural analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
62666545|NCT02619513|EXPERIMENTAL|PVB without DEX group (Group GT)|Group GT received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block(PVB) combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
62666546|NCT02619513|EXPERIMENTAL|PVB with DEX group(Group GTD)|Group GTD received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia,but with dexmedetomidine 0.5μg/kg added to ropivacaine in PVB as an adjuvant.
62666547|NCT06264622|EXPERIMENTAL|Low Dose|250 mg/day of Garlic Extract
61912875|NCT02935829|EXPERIMENTAL|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
62666548|NCT06264622|EXPERIMENTAL|High Dose|600 mg/day of Garlic Extract
62666549|NCT06264622|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62666550|NCT02169999|EXPERIMENTAL|Personalized Diabetes Care Website|Subjects are exposed to Personalized Diabetes Care website.
62666551|NCT02169999|NO_INTERVENTION|No Exposure To Website|Subjects are not exposed to Personalized Diabetes Care website
62104627|NCT02611648|NO_INTERVENTION|standard HLD|Standard high-level disinfectant (metricide ortho-phthalaldehyde) currently performed at BIDMC (standard HLD)
62104628|NCT02611648|EXPERIMENTAL|double HLD|Double the exposure time of the standard high level disinfectant (metricide ortho-phthalaldehyde)
62666552|NCT02960789|EXPERIMENTAL|Dehydrated Children|"Children between the ages of 2 to 18 years of age presenting to the Emergency Department at Children's Hospital Boston with complaints such as Dehydration, Gastroenteritis, Vomiting, and or Intolerance of POs be approached by study personnel for possible participation in the study.~Interventions:~* Undertake and record a formalized clinical assessment of hydration status~* Take a measurement of body weight on calibrated scales~* RF wristband hydration status measurement~* Measure capillary refill time with manual stopwatch~* CRT device hydration status measurement"
62666553|NCT05442931|EXPERIMENTAL|Pregabaline|Preoperative oral dose of pregabalin for control blood pressure and decrease dose of nitroglycerine consumption
62666554|NCT05442931|EXPERIMENTAL|Magnesium sulfate|Preoperative intravenous dose for control blood pressure and heart rate
62666555|NCT05442931|EXPERIMENTAL|Nitroglycrine|Measuring the total dose of nitroglycerine used, using a syringe pump
62666556|NCT05331924|ACTIVE_COMPARATOR|IPL therapy|Fifteen patients with severe to moderate evaporative dry eye disease were treated with 3 sessions of IPL therapy.
62104629|NCT02611648|EXPERIMENTAL|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
62666557|NCT05331924|ACTIVE_COMPARATOR|Punctal plugs|Fifteen patients with severe to moderate evaporative dry eye disease were treated with silicone punctal plug insertion.
62666558|NCT04069520|EXPERIMENTAL|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
62666559|NCT04069520|SHAM_COMPARATOR|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
62666560|NCT00947466|EXPERIMENTAL|Patch|
62666561|NCT02447029|EXPERIMENTAL|Active Comparator|Drug: vaginal 2% Xylocaine
62666562|NCT02447029|OTHER|standard lidocaine paracervical block|standard lidocaine paracervical block
62666563|NCT03185507|EXPERIMENTAL|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
61912876|NCT04384367|EXPERIMENTAL|Rizatriptan 10mg+ Naproxen 550mg|Rizatriptan 10mg+ Naproxen 550mg
61912877|NCT04384367|ACTIVE_COMPARATOR|Maxalt 10mg|Rizatriptan10mg
62308282|NCT03089567|ACTIVE_COMPARATOR|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
62308283|NCT03089567|EXPERIMENTAL|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
62666564|NCT03185507|NO_INTERVENTION|Control|Participants sat quietly for 20 minutes
61912878|NCT04384367|ACTIVE_COMPARATOR|Flanax 550mg|Naproxen 550mg
61912879|NCT04384367|PLACEBO_COMPARATOR|Placebo|Placebo
62308284|NCT00000249|NO_INTERVENTION|Control|Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes
62308285|NCT00000249|ACTIVE_COMPARATOR|20% N2O|Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 \& 30 minutes
62308286|NCT00000249|ACTIVE_COMPARATOR|30% N2O|Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes
62666565|NCT05531097|EXPERIMENTAL|HSK31679|
62666566|NCT05531097|PLACEBO_COMPARATOR|Placebo|
62666567|NCT03459586|EXPERIMENTAL|9zest app facilitated exercise|App to facilitate exercises for 3 times a week for 12 weeks. The app includes physical therapist-designed exercises that are modified using an algorithm to the participants physical capabilities and PD status. Exercises include strengthening, balance, range of motion, and endurance type exercise.
61912880|NCT05886985|EXPERIMENTAL|MatriPlax|Each subject will receive 2x10\^7, 4x10\^7, or 8x10\^7 pcMSCs per administration
62666568|NCT03718260|EXPERIMENTAL|Cohort 1|Men who are node positive or who have persistently detectable PSA after initial radical prostatectomy will be restaged with \[18F\]-DCFPyL PET/ CT scan (PSMA PET)
62666569|NCT03718260|EXPERIMENTAL|Cohort 2|Men with biochemical failure after initial prostatectomy will be restaged with \[18F\]-DCFPyL PET/ CT scan (PSMA PET)
62104630|NCT01311648|EXPERIMENTAL|PTPs 0-12 years|Previously treated patients (PTPs) aged below 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (EDs) in main study - Part A. Participants having reached at least 50 EDs in main study - Part A were offered participation in an open label extension study (optional). Participants who transitioned from main study - Part A to the extension study received BAY81-8973, 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study).
62104631|NCT01311648|EXPERIMENTAL|PUPs/MTPs 0-<6 years|Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days (EDs) with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development in main study - Part B. Participants having reached at least 50 EDs in main study - Part B were offered participation in an open label extension study and received BAY81-8973 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study); participants who developed an inhibitor in main study - Part B were offered participation in open label extension study and received Immune Tolerance Induction (ITI) treatment with BAY81-8973 until successful eradication of the inhibitor, or until failure, for approximately 18 months.
62104632|NCT06122935|EXPERIMENTAL|Test Group|Plasma collection using a new plasma collection volume nomogram (software version 2.0) for the Aurora Xi Plasmapheresis System
62468735|NCT00473330|SHAM_COMPARATOR|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata \[PRN\]) for up to 24 additional months.
62666570|NCT03718260|EXPERIMENTAL|Cohort 3|Men with biochemical failure after initial radical prostatectomy and salvage radiotherapy will be restaged with \[18F\]-DCFPyL PET/ CT scan (PSMA PET)
62666571|NCT03718260|EXPERIMENTAL|Cohort 4|Men with biochemical failure after initial radical prostatectomy with or without adjuvant/ salvage radiotherapy who are currently on salvage hormone therapy will be restaged with \[18F\]-DCFPyL PET/ CT scan (PSMA PET)
62666572|NCT03718260|EXPERIMENTAL|Cohort 5|Men who have prior PSMA directed treatment for oligometastatic disease, such as lesion directed therapy (e.g. stereotactic radiosurgery) or systemic therapy (e.g. hormone therapy or chemotherapy) with subsequent biochemical failure will be restaged with \[18F\]-DCFPyL PET/ CT scan (PSMA PET)
62666573|NCT03718260|EXPERIMENTAL|Cohort 6|Men with biochemical failure after primary radiation therapy (external beam, brachytherapy or combinations together with or without hormone therapy) will be restaged with \[18F\]-DCFPyL PET/ CT scan (PSMA PET)
62666574|NCT03718260|EXPERIMENTAL|Cohort 7|\[18F\]-DCFPyL as a problem-solving tool in patients with prostate cancer when confirmation of the site of disease and/or disease extent may impact clinical management. Patients in this cohort require approval from an independent adjudication by Cancer Care Ontario.
62666575|NCT02480361|EXPERIMENTAL|Acupuncture|The patients who were received acupuncture after gastric cancer surgery
62666576|NCT02480361|NO_INTERVENTION|Non-acupuncture|The patients who were not received acupuncture after gastric cancer surgery
62666577|NCT04185727|NO_INTERVENTION|Standard of Care (SOC)|Therapy control group
62666578|NCT04185727|EXPERIMENTAL|Standard of Care (SOC) + strength training|Strength training intervention as add on to therapy
61912881|NCT01621815|ACTIVE_COMPARATOR|Anxiety and Depression|Adolescents diagnosed with anxiety and/or depression
61912882|NCT01621815|ACTIVE_COMPARATOR|ADD|Adolescents diagnosed with ADD (without hyperactive element)
61912883|NCT01621815|ACTIVE_COMPARATOR|ADHD, Behavioral|Adolescents diagnosed with ADHD (with hyperactivity), with or without behavioral problems
61912884|NCT01621815|ACTIVE_COMPARATOR|PDD|Adolescents diagnosed with PDD Spectrum Disorders
61912885|NCT01621815|ACTIVE_COMPARATOR|Control|Adolescents without a psychiatric diagnosis
61912886|NCT04628533|EXPERIMENTAL|Four Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 16 weeks in a well-established behavioral weight loss program.
61912887|NCT04628533|ACTIVE_COMPARATOR|Six Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 24 weeks in a well-established behavioral weight loss program.
61912888|NCT04647981||Xpert® Bladder Test|A urine sample is collected before cystoscopy.
61912889|NCT04140123|EXPERIMENTAL|ZSP1601-Dose 1|ZSP1601-50mg once daily
61912890|NCT04140123|EXPERIMENTAL|ZSP1601-Dose 2|ZSP1601-50mg twice daily
61912891|NCT04140123|EXPERIMENTAL|ZSP1601-Dose 3|ZSP1601-100mg once daily
61912892|NCT04140123|PLACEBO_COMPARATOR|Placebo|Placebo
61912893|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|FDG PET scan,T1-weight MRI and blood were obtained for each participant
61912894|NCT00493857|EXPERIMENTAL|2|Nimotuzumab 400mg every week or every two weeks
61912895|NCT05391191|EXPERIMENTAL|MitrAssist TRISKELE® transcatheter aortic valve system|Device: MitrAssist TRISKELE® transcatheter aortic valve system
62104633|NCT06122935|ACTIVE_COMPARATOR|Control Group|Plasma collection using the marketed (version 1.3) of AuroraXi Plasmapheresis System
62666579|NCT03595748|EXPERIMENTAL|Peer mentorship intervention|This arm of mentees will be assigned to weekly telephone calls with a matched mentor over a period of 3 months.
62666580|NCT03595748|NO_INTERVENTION|Usual Care|This arm of mentees will not get a telephone intervention by an assigned mentee
62104634|NCT06065800||STEELEX®|STEELEX® Sternum Set in Patients undergoing cardiac surgery
62104635|NCT06631508|EXPERIMENTAL|Preoperative Period, Education video|"Follow-up Group: Preoperative data of patients who will undergo pelvic organ prolapse surgery will be collected. Then, the preoperative patient education video will be watched. If patient has any questions will be answered.~Control Group: No intervention. Control Group's data will be collected.~Data collection forms to be used in the preoperative period:~* Introductory Characteristics Form~* Pelvic Organ Prolapse Quality of Life Scale~* Pelvic Organ Prolapse Symptom Score~* Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire~* State-Trait Anxiety Inventory Short Version~* Preoperative Functional Health Patterns Evaluation Form"
62104636|NCT06631508|EXPERIMENTAL|Postoperative Period, Education video|"Patient data will be collected within 24-48 hours in the postoperative period. The postoperative patient education video will be watched before the patient is discharged. If patient has any questions, they will be answered.~Control Group: No intervention. Control Group's data will be collected.~Data collection forms to be used in the postoperative period:~* Postoperative Data Collection Form~* State-Trait Anxiety Inventory Short Version~* Postoperative Functional Health Patterns Evaluation Form~* Nursing Diagnoses Checklist After POP Surgery"
62297191|NCT05823142|NO_INTERVENTION|Attention Control Enhanced Usual Care arm|After baseline, the RA assigned to this condition will schedule a 60-minute telehealth appointment to provide instruction for enhanced usual care at the initial consultation visit via contact at T1 (60-minute telehealth session in a private location). The time-balanced follow-up sessions will remain neutral and focused on health perceptions, current plan of care, and relationship building as opposed to the CB-sleep condition's focus on sleep promotion and extension. The RA assigned to the control condition will ask participants to (a) describe how they are doing and (b) ask how confident they are in achieving the goals they have set for themselves. These calls will help to build a relationship with participants to promote study retention. The investigators recognize that participants may obtain self-initiated diabetes self-management in this group, which will vary and will use a Diabetes Self-Management Tracking Form to monitor weekly information acquisition.
62297192|NCT01193764|EXPERIMENTAL|cocoa|unsweetened 100% cocoa (Ghirardelli)
62666581|NCT06304571|EXPERIMENTAL|HC006 Dose Escalation|
62297193|NCT01193764|PLACEBO_COMPARATOR|placebo|hydrolyzed gelatin powder (Gelita)
62297194|NCT04052139|ACTIVE_COMPARATOR|Low-dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
62666582|NCT06304571|EXPERIMENTAL|HC006 Dose Expansion|
62666583|NCT00021255|EXPERIMENTAL|Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)|Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
62666584|NCT00021255|EXPERIMENTAL|AC followed by Docetaxel + Herceptin (AC→TH)|Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
62666585|NCT00021255|EXPERIMENTAL|Docetaxel + Carboplatin + Herceptin (TCH)|Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
62666586|NCT05158803||covid 19 in acute phase|
62666587|NCT05158803||covid 19 follow up|
62666588|NCT05420454|ACTIVE_COMPARATOR|TCbHP|HER2-positive breast cancer
62666589|NCT05420454|EXPERIMENTAL|nPCbHP|HER2-positive breast cancer
62666590|NCT05420454|ACTIVE_COMPARATOR|EC-T|Luminal breast cancer (HER2-, LN+), and triple negative breast cancer
62666591|NCT05420454|EXPERIMENTAL|ddEC-wnP|Luminal breast cancer (HER2-, LN+), and triple negative breast cancer
62666592|NCT05831072|EXPERIMENTAL|Mindfulness-cognitive oriented group|Participants will receive a 4-week intervention of mindfulness-cognitive oriented group program.
62666593|NCT00114777|ACTIVE_COMPARATOR|Cyclosporin A|
62666594|NCT00114777|EXPERIMENTAL|Belatacept Less Intensive Regimen (LI)|
62666595|NCT00114777|EXPERIMENTAL|Belatacept More Intensive Regimen (MI)|
62666596|NCT03899493||Primiparous & Multiparous|Women having borne at least one child \> 20 weeks gestational age
62666597|NCT03899493||Nulliparous|Women in whom this is their first pregnancy \> 20 weeks who are anticipated to deliver
62666598|NCT02807090|EXPERIMENTAL|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
62666599|NCT02807090|EXPERIMENTAL|Circular Dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
62666600|NCT00906581|EXPERIMENTAL|Behavioral|Behavioral
62104637|NCT06631508|EXPERIMENTAL|2th week after discharge|"The patient's data will be collected by telephone follow-up two weeks after discharge.~Control Group: No intervention. Control Group's data will be collected.~Data collection forms to be used at the two weeks after discharge:~* Pelvic Organ Prolapse Quality of Life Scale~* Pelvic Organ Prolapse Symptom Score~* State-Trait Anxiety Inventory Short Version~* After Discharge Functional Health Patterns Evaluation Form~* Nursing Diagnoses Checklist After POP Surgery"
62468736|NCT05764330|ACTIVE_COMPARATOR|Arm I (CER)|Patients undergo CER intervention consisting of remote lesson containing information and behavioral strategies about weight loss, session with study interventionist to review lessons, and self-monitoring of body weight. Patients also undergo collection of blood samples throughout the trial.
62104638|NCT06631508|EXPERIMENTAL|6th week after discharge|"The patient's data will be collected by telephone follow-up six weeks after discharge.~Control Group: No intervention. Control Group's data will be collected.~Data collection forms to be used at the six weeks after discharge:~* Pelvic Organ Prolapse Quality of Life Scale~* Pelvic Organ Prolapse Symptom Score~* State-Trait Anxiety Inventory Short Version~* After Discharge Functional Health Patterns Evaluation Form~* Nursing Diagnoses Checklist After POP Surgery"
62666601|NCT00906581|NO_INTERVENTION|Waitlist control|Waitlist control
62297195|NCT04052139|ACTIVE_COMPARATOR|Gabapentin|Participants randomized to the gabapentin arm begin on a dose of 300 mg daily (300 mg qd). In week 2, participants will take 300 mg of gabapentin three times daily. In week 3 the dose will be titrated up to 1800 mg daily (300 mg+300 mg tid) will remain on the dose until week 8, when they will be tapered back down to 900 mg daily (300 mg tid). In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
62666602|NCT05563974|EXPERIMENTAL|Women who agree to receive family led postnatal care|This group will receive Family-led Postnatal Care-FPNC
62666603|NCT05563974|NO_INTERVENTION|Women who receive standard of care for postnatal care|Women will get the standard of care for postnatal care
62468737|NCT05764330|EXPERIMENTAL|Arm II (IF)|Patients undergo IF intervention consisting of remote lesson containing information and behavioral strategies about fasting, session with study interventionist to review lessons, and self-monitoring of body weight. Patients also undergo fasting 2 days per week and eat according to the NCI guidelines the remaining 5 days. Patients also undergo collection of blood samples throughout the trial.
61912896|NCT04457895|EXPERIMENTAL|Experimental arm|"For experimental arm patients, there will be a 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga (the first on site and by videoconference for the others).~Starting the first day of the yoga practice there will be one daily 15 min session at home with My Yoga Guide and the audio guide during 12 weeks."
62666604|NCT06271980||Survivors of early-onset colorectal cancer, with recurrent disease (Training Cohort)|Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the first cohort
62666605|NCT06271980||Survivors of early-onset colorectal cancer, with no recurrent disease (Training Cohort)|Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the first cohort
62666606|NCT06271980||Survivors of early-onset colorectal cancer, with recurrent disease (Validation Cohort)|Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
61912897|NCT04457895|PLACEBO_COMPARATOR|control arm|The control arm patients will have standard care. They will be proposed to participate in the physical therapy - yoga - educational program after the end of the study.
61912898|NCT05818605|EXPERIMENTAL|Moderate Intensity Exercise arm|All patients randomized to the exercise training group will undergo a single supervised in-hospital exercise session that includes an exercise consultation with a certified exercise physiologist. Following that they will exercise at-home with video supervision 3 times a week for a period of 24 weeks.
61912899|NCT05818605|NO_INTERVENTION|Usual physical activity arm|Patients randomized to the usual-activity group will be instructed to continue their current activity without initiating or intensifying any existing exercise regimens for the duration of the study
62468738|NCT06268197|EXPERIMENTAL|Yoga Intervention|Interoception-based yoga intervention, 2x/week for 6 weeks.
62666607|NCT06271980||Survivors of early-onset colorectal cancer, with no recurrent disease (Validation Cohort)|Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
62666608|NCT03938870||Experimental: Group 1|30 Young Normal Controls(YNC) ages 18 \& Older will enroll to evaluate leucine infusion methods of labeling, vs. the oral method. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
62104639|NCT06631508|EXPERIMENTAL|10th week after discharge|"The patient's data will be collected by telephone follow-up ten weeks after discharge.~Control Group: No intervention. Control Group's data will be collected.~Data collection forms to be used at the ten weeks after discharge:~* Pelvic Organ Prolapse Quality of Life Scale~* Pelvic Organ Prolapse Symptom Score~* State-Trait Anxiety Inventory Short Version~* After Discharge Functional Health Patterns Evaluation Form~* Nursing Diagnoses Checklist After POP Surgery"
62104640|NCT06631508|EXPERIMENTAL|14th week after discharge|"The patient's data will be collected by telephone follow-up fourteen weeks after discharge. Additionally, on the 14th week, a satisfaction form will be applied to the Follow-up Group to evaluate the education videos.~Control Group: No intervention. Control Group's data will be collected. After the data is collected, postoperative education video will be watched.~Data collection forms to be used at the fourteen weeks after discharge:~* Pelvic Organ Prolapse Quality of Life Scale~* Pelvic Organ Prolapse Symptom Score~* Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire~* State-Trait Anxiety Inventory Short Version~* After Discharge Functional Health Patterns Evaluation Form~* Nursing Diagnoses Checklist After POP Surgery~* Satisfaction Evaluation Form (Only Follow-up Group)"
62104641|NCT05403307||Two doses or more of BNT162b2|Defined as ≥ 2 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
62104642|NCT05403307||One dose of BNT162b2|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
62297196|NCT04052139|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo to be taken three times daily for 8 weeks.
62297197|NCT03515187|EXPERIMENTAL|A1 Medicine treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days
62297198|NCT03515187|EXPERIMENTAL|A2 Combined treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution，with meibomian gland massage , 28 days
62297199|NCT03515187|PLACEBO_COMPARATOR|B1 Control group|Placebo
62297200|NCT03515187|EXPERIMENTAL|B2 Experiment group|0.3%sodium hyaluronate ophthalmic solution, 12 months
62297201|NCT01636557|EXPERIMENTAL|Sirukumab and 5-probe cocktail|The 5-probe cocktail will consist of oral doses of midazolam, warfarin/vitamin K, omeprazole, and caffeine.
62297202|NCT04337437|EXPERIMENTAL|Genakumab injection：5 groups|150 mg/1ml/bottle, single subcutaneous injection. Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,
62297203|NCT04337437|PLACEBO_COMPARATOR|Placebo for this trial : 5 groups|"The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.~Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,"
62297204|NCT04240587|ACTIVE_COMPARATOR|TrueTear™ intranasal neurostimulator (ITN) Active Arm|TrueTear™ intranasal neurostimulator (ITN) with active tips - The tips carry the current from the base to the nasociliary nerve.
62297205|NCT04240587|PLACEBO_COMPARATOR|TrueTear™ intranasal neurostimulator (ITN) Placebo/Sham Arm|"TrueTear™ intranasal neurostimulator (ITN) with sham tips - The sham tips and do not properly carry the current."
62297206|NCT05694598|EXPERIMENTAL|VGR-R01|Single-dose Subretinal Administration of VGR-R01
62297207|NCT02714179|ACTIVE_COMPARATOR|Group Preemptive (Group PE),|Group I: i.V. paracetamol 1 g (100 ml) was given 30 min before induction of anesthesia.
61912900|NCT05863598|EXPERIMENTAL|Enhancing protective factors|Participants will learn to improve their body image through body appreciation tasks, body image flexibility and focus on body functionality appreciation. They also learn to focus on important life values, be more accepting of themselves, and learn to eat regularly and with attention to bodily needs and signals. This is don in interactive ways, and by using a cognitive dissonance frame.
61912901|NCT05863598|PLACEBO_COMPARATOR|Expressive writing|Participants will be instructed to write about any thoughts, feelings, images, memories, interceptions, ideas or emotions related to their body for the same during as the active intervention (i.e., 40 minutes/week across four consecutive weeks).
61912902|NCT00133978|EXPERIMENTAL|Glutamine|Glutamine supplementation
61912903|NCT00133978|EXPERIMENTAL|Antioxidants|Antioxidant supplementation
62104643|NCT05403307||One dose or more of BNT162b2|Defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
62104644|NCT05403307||Two doses of BNT162b2|Defined as 2 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset.
62104645|NCT05403307||Three doses of BNT162b2|Defined as 3 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 3rd dose and acute respiratory illness (ARI) symptom onset.
62104646|NCT05403307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines according to Brazil National Immunization Program recommendations.
62297208|NCT02714179|ACTIVE_COMPARATOR|Group Preventive (Group PV),|Group II: i.V. paracetamol 1 g (100 ml) was given before the end of surgery.
62297209|NCT04360304|EXPERIMENTAL|Study group|
62104647|NCT05403307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
62104648|NCT00261547|EXPERIMENTAL|Rituximab|this study has only one arm as the treatment group
62297210|NCT01798303|EXPERIMENTAL|LY2940094|40 mg LY2940094 oral tablet, QD for 8 weeks
62666609|NCT03938870||Experimental: Group 2|Group 30 CDR \> 0. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
62666610|NCT03938870||Experimental: Group 3|Group of 40 CDR = 0 Age Matched. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
61912904|NCT00133978|EXPERIMENTAL|Glutamine + Antioxidants|Glutamine and antioxidant supplementation
61912905|NCT00133978|PLACEBO_COMPARATOR|Placebo|Non-isonitrogenic, iso-caloric placebo solution
61912906|NCT01070147|EXPERIMENTAL|Control|The control group will receive a paper-based printed asthma guideline.
61912907|NCT02799420|EXPERIMENTAL|pCLE group|The intervention group
61912908|NCT02799420|ACTIVE_COMPARATOR|WLE group|The control group
61912909|NCT04898205|EXPERIMENTAL|Treadmill Exercise with Supplemental Oxygen|Participants will receive 24 sessions (2 x week for 12 weeks) of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
62104649|NCT01320709|EXPERIMENTAL|Arm 1|
62104650|NCT01320709|EXPERIMENTAL|Arm 2|
62104651|NCT01320709|PLACEBO_COMPARATOR|Arm 3|
62104652|NCT01320709|EXPERIMENTAL|Arm 4|
62297211|NCT01798303|PLACEBO_COMPARATOR|Placebo|Identically matched placebo oral tablet, QD for 8 weeks
62297212|NCT01901887|EXPERIMENTAL|Study Juice|"3,300 mg of Omega-3 HUFAs per day for 6 months~Other names: none"
62297213|NCT01901887|PLACEBO_COMPARATOR|Placebo Juice|"3,300 mg of macadamia nut oil per day for 6 months~Other names: none"
62297214|NCT00876642|EXPERIMENTAL|1|
62297215|NCT00876642|NO_INTERVENTION|2|
62308287|NCT00000249|ACTIVE_COMPARATOR|40% N2O|Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes
62308288|NCT02241018|EXPERIMENTAL|Mesenchymal stem cells|MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.
62666611|NCT01118091|ACTIVE_COMPARATOR|Arm 1-Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
62666612|NCT01118091|EXPERIMENTAL|Arm 2 - Adoptive cell therapy|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x10\^8) and the administration of high-dose aldesleukin.
62666613|NCT02305615||Participants with CRC|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, the treatment will be determined according to the treating physician decision. Eligible participants will be observed for safety and efficacy of continued bevacizumab plus fluoropyrimidine-based doublet chemotherapy treatment in routine clinical practice for 1 year.
62666614|NCT05412420|EXPERIMENTAL|Patient Self-Reporting of Symptoms|
62666615|NCT01113957|EXPERIMENTAL|Arm A|ABT-888 in combination with temozolomide
62666616|NCT01113957|ACTIVE_COMPARATOR|Arm B|pegylated liposomal doxorubicin alone
62666617|NCT02786667|EXPERIMENTAL|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
62297216|NCT02243501|EXPERIMENTAL|Intervention Group|The Intervention Group receives access to the BNBD intervention, and can access alternative resources while enrolled in the study. The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
62297217|NCT02243501|NO_INTERVENTION|Usual Care Group|The Usual Care Group will receive no treatment until after the 8 month follow-up assessment. The Usual Care Group can access alternative resources and additional programs and services while enrolled in the study.
62297218|NCT04533711|EXPERIMENTAL|OA-PCP|Participants assigned to the OA-PCP intervention will receive an initial physical activity (PA) coaching call then, 5 more calls over the course of 12 months. Participants, if they agree, will also receive monthly check-in emails between phone calls.
62297219|NCT04533711|PLACEBO_COMPARATOR|Attention Control|Participants assigned to the Attention Control group will receive the same number of phone calls over the course of 12 months, focused on understanding osteoarthritis (OA) and current information on treatment options. Participants, if they agree, will also receive monthly check-in emails between phone calls.
62297220|NCT03960528|ACTIVE_COMPARATOR|Under direct vision erector spinae plane block|"20 ml bupivacaine 0,25%+ lidocaine 1% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
62297221|NCT03960528|SHAM_COMPARATOR|Control group|"20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
62468739|NCT01543360|ACTIVE_COMPARATOR|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein).
62468740|NCT01543360|ACTIVE_COMPARATOR|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein).
62468741|NCT03266263|EXPERIMENTAL|automatic computer-led feedback|automated feedback for CPR quality provided by computers
62468742|NCT03266263|ACTIVE_COMPARATOR|instructor-led feedback|feedback for CPR quality provided by instructors
62468743|NCT02681263|EXPERIMENTAL|Temocillin|"Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.~Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients)."
62666618|NCT02786667|PLACEBO_COMPARATOR|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
62666619|NCT05638984|EXPERIMENTAL|low-dose decitabine combined with tirelizumab|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion.
62666620|NCT05638984|ACTIVE_COMPARATOR|tirelizumab|Tirelizumab injection, 10ml: 100mg/1 bottle, 200mg, Q3W, D1 IV infusion.
62666621|NCT01500096|ACTIVE_COMPARATOR|American ginseng 1000 mg/day|4-week of American ginseng 1000 mg/day every morning
62666622|NCT01500096|PLACEBO_COMPARATOR|Placebo for American ginseng 1000 mg/day|4-week of placebo for American ginseng 1000 mg/day every morning
62666623|NCT01500096|ACTIVE_COMPARATOR|American ginseng 3000 mg/day|4-week of American ginseng 3000 mg/day every morning
62666624|NCT01500096|PLACEBO_COMPARATOR|Placebo for American ginseng 3000 mg/day|4-week of placebo for American ginseng 3000 mg/day every morning
62666625|NCT05824585|EXPERIMENTAL|DZD8586|
62666626|NCT02027571|EXPERIMENTAL|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( \> 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
62666627|NCT05551988||diabetic foot ulcer patients|Diabetic foot ulcer patients with and without diabetic foot amputation
62666628|NCT00704834||1|Normal Controls
62666629|NCT00704834||2|Patients with a clinically isolated syndrome (CIS)
62666630|NCT00704834||3|Patients with relapsing, remitting Multiple Sclerosis (RRMS) who are not on treatment
62666631|NCT00704834||4|Patients with Chronic Progressive Multiple Sclerosis who are not on treatment
62104653|NCT05781269|EXPERIMENTAL|VLCKD-group|The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.
62104654|NCT05781269|EXPERIMENTAL|r-MedDiet|The dietary treatment of the r-MedDiet group will provide for an average caloric deficit equal to 1000 kcal of the estimated total daily energy expenditure starting from the basal metabolic rate measured with indirect calorimetry and multiplied by the level of physical activity (LAF) defined on the basis of the Godin questionnaire. The diet will be personalized in 3 or 5 meals/day. Upon reaching the target weight, a Mediterranean-type diet plan will be set with a caloric intake equal to the estimated energy requirement
62104655|NCT05993403|EXPERIMENTAL|Intercultural Sensitivity Education|Data collection tools were applied to this group before the research. A training program consisting of three sessions was applied to the intervention group. Each training session lasted an average of 90-100 minutes. Various methods and techniques were used in the trainings.
62104656|NCT05993403|NO_INTERVENTION|Control|Data collection tools were applied to this group before the research. No intervention was applied to this group.
62104657|NCT02126397|ACTIVE_COMPARATOR|polyps resection with Laser Diode|application of the laser diode by hysteroscopy to remove the endometrial polyp
62104658|NCT02126397|ACTIVE_COMPARATOR|polyps resection with bipolar electrode|application of the bipolar electrode Versapoint by hysteroscopy to remove the endometrial polyp
62104659|NCT00744250|OTHER|1|"Pre-treatment vs. post-treatment-~In the first phase, before administration of the capsules and liquid diet, baseline gastric and duodenal secretions will be aspirated via the oro-enteric tube. Subjects will get 5 placebo capsules at Time=0 given orally with the liquid Lundh diet. Pancreato-biliary and duodenal secretions in the duodenal region will be aspirated continuously over the first 20 min. Gastric and duodenal fluids will be aspirated from 20-180 min at specified time points. Following a rest of 1 hour, the same process will be repeated with the drug capsules. At the end of the study the catheter will be removed and patient will be offered a meal."
62104660|NCT04853576|EXPERIMENTAL|EDIT-301|EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
62104661|NCT00567879|EXPERIMENTAL|Panobinostat with trastuzumab|Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.
62104662|NCT04482348|ACTIVE_COMPARATOR|the mind is a great story teller-positively framed|explanations for more pain than expected
62104663|NCT04482348|ACTIVE_COMPARATOR|the mind is a great story teller-negatively framed|explanations for more pain than expected
62104664|NCT04482348|ACTIVE_COMPARATOR|emotionally-framed explanation-stressed or down-positive frame|explanations for more pain than expected
62104665|NCT04482348|ACTIVE_COMPARATOR|emotionally-framed explanation-stressed or down-negative frame|explanations for more pain than expected
62297222|NCT02954315|EXPERIMENTAL|Almond arm|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
62666632|NCT03310515||HIV-1 uninfected high risk subjects|The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.
62297223|NCT02954315|NO_INTERVENTION|Western diet Snack (Granola bar + Pretzels)|The control snack will be a typical western diet snack (see Table 1). The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
62297224|NCT00815646|EXPERIMENTAL|Sildenafil|Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.
62297225|NCT01715844|ACTIVE_COMPARATOR|L-citrulline|3-gr/day of L-citrulline effervescent powder mix
62666633|NCT02513199|EXPERIMENTAL|Participants with HCC|Participants with HCC with a lesion greater than 3 cm treated with TACE/SBRT combination
62737204|NCT01375816|ACTIVE_COMPARATOR|FOLFIRI 1 or m FOLFIRI3-Bevacizumab|"FOLFIRI 1-Bevacizumab:~Day 1 H0 : Bevacizumab 5 mg/kg, 30-90 min infusion H+1: Irinotecan 180 mg/m² in 250 ml NaCl 0.9%, 1h infusion Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) over 2h H + 3: 5-FU bolus 400 mg/m², 15 min infusion H + 3.5: 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14~modified FOLFIRI3-Bevacizumab H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H+1:Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion H+1: Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) 2-h infusion H + 3: 5-FU continuous infusion 2400 mg/m² 46-h infusion Day 3 (H+49) H0 Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion End of cycle: day 14"
62104666|NCT04482348|ACTIVE_COMPARATOR|"mixed emotion and cognition (mind and body work together)"|explanations for more pain than expected
62104667|NCT04482348|ACTIVE_COMPARATOR|"physically based explanations over-excited state"|explanations for more pain than expected
62104668|NCT04482348|ACTIVE_COMPARATOR|"physically based explanations overstimulated"|explanations for more pain than expected
62104669|NCT00295867|EXPERIMENTAL|Zoledronic Acid|Patients women with early stage breast cancer and evidence of occult malignant cells in bone marrow aspirates following adjuvant chemotherapy will receive zoledronic acid (Zometa) 4mg, given intravenously over 15 minutes, once a month for two years.
62104670|NCT05283369|EXPERIMENTAL|Videogame therapy|Participants will receive conventional physical therapy, plus 300 minutes of videogame in-home therapy a week, for 8 weeks.
62104671|NCT05283369|ACTIVE_COMPARATOR|Conventional therapy|Participants will receive conventional physical therapy, plus conventional occupational therapy, as prescribed by the doctor for 8 weeks.
62297226|NCT01715844|PLACEBO_COMPARATOR|Placebo|3 gr of Placebo/day matching L-citrulline effervescent powder
62666634|NCT05232526|EXPERIMENTAL|Mental imagery (MI) and exercise program|MI will start immediately when the sample is going to start the exercise program. The intervention group will undergo 24 sessions of imagery, starting from the 1st exercise program session. Participants of the intervention group will undergo a 45-minute imagery session sitting in a quiet place after the end of every exercise program session. The content of every imagery session is alike with the content of the exercise program session. That means that every session includes imagery of the same exercises of the exercise program performed earlier by the subject in the Day Center. Sessions are identical for all subjects of the intervention group. The total duration of the physiotherapy exercise program will be 24 sessions, 2 times/week, duration of 45 minutes each session, 3 months (12 weeks).
62104672|NCT02180087|PLACEBO_COMPARATOR|placebo group|Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours
62104673|NCT02180087|OTHER|ketopofen quarter dose|"Group 2 : Ketoprofen quarter dose (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours."
62104674|NCT02180087|OTHER|ketoprofen half-dose|"Group 3 : Ketoprofen half-dose (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours."
62104675|NCT02180087|OTHER|Ketoprofen full dose|"Group 4 : Ketoprofen full dose (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours"
62104676|NCT03007459||Female Fitness Athletes|Psychological health and physiological health of fitness athletes
62104677|NCT03007459||Female, physically active Controls|Psychological health and physiological health of female controls
62104678|NCT06118892|EXPERIMENTAL|MISHA Knee System|
62104679|NCT02949570|EXPERIMENTAL|Treatment|
62104680|NCT04286022|EXPERIMENTAL|Speed Loss 20% Group|The SL20% group will carry out a program based on the limitation of the speed loss, allowing to perform the exercise only until a speed loss of 20% is achieved, following a similar methodology previously published (Pareja-Blanco et al., 2017). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 6-series routine with an open number of repetitions will be carried out twice, allowing as many repetitions as possible to perform until a 20% loss of execution speed is reached. The intensity of work will be 70% 1RM, resting 4 minutes between sets. As an only exercise, an elbow flexion (bicep curl) with dumbbell will be performed.
62104681|NCT04286022|EXPERIMENTAL|Reduced Rest Time Group|The RRT group will carry out a program based on the reduction of rest time between series, following a previously published methodology (Stragier et al., 2019). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 5 series routine with progressive repetition volume (3 to 7) at 70% 1RM will be performed twice, resting 15 seconds between sets and 150 seconds between each of the 2 blocks. The exercise to be performed will be an elbow flexion (bicep curl) with dumbbell.
62666635|NCT05232526|PLACEBO_COMPARATOR|Exercise program|The total duration of the physiotherapy exercise program will be 24 sessions, 2 times/week, duration of 45 minutes each session, 3 months (12 weeks).
62666636|NCT03878459|EXPERIMENTAL|Intervention|pioglitazone treatment
62104682|NCT01265758|EXPERIMENTAL|Telemetric ECG monitoring|Telemetric 14-days Full Disclosure ECG recording.
62666637|NCT03878459|PLACEBO_COMPARATOR|control|subjects will receive placebo
62666638|NCT05804500|EXPERIMENTAL|Cardiac Telerehabilitation Arm|In this prospective, single-arm study, we will look at the initiation, participation, sustained engagement, and safety of 100 adult subjects (ages 45 years or older) with recent (within the past 60 days) clinician referral to CR who are offered CTR via the RecoveryPlus platform.
62666639|NCT01092156|ACTIVE_COMPARATOR|Education on Infant-led latching|
62297227|NCT04372238|EXPERIMENTAL|RAPIDS intervention|Participants randomized to receive the RAPIDS intervention will receive a fentanyl specific behavioral intervention and a brief behavioral intervention to increase willingness to use fentanyl test strips and engage in overdose risk reduction behaviors, in addition to standard OEND.
62666640|NCT01092156|NO_INTERVENTION|Standard education|
62104683|NCT01265758|ACTIVE_COMPARATOR|Standard 24-hours Holter ECG recording|Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
62104684|NCT06180148|ACTIVE_COMPARATOR|Mechanical insufflator-exsufflator|Standard postoperative care plus mechanical insufflator-exsufflator during the first postoperative day.
62104685|NCT06180148|NO_INTERVENTION|Standard care|Standard postoperative care without mechanical insufflator-exsufflator.
62104686|NCT03342651|OTHER|Observational research|Vitamin D levels and respiratory complications; observational research.
62104687|NCT04011033|EXPERIMENTAL|TAE/TACE+iNKT for unresectable HCC|TAE/TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TAE/TACE will be performed at 0th and 4th week. 5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
62104688|NCT04011033|OTHER|TAE/TACE for unresectable HCC|TAE/TACE will be conducted at 0th week and 4th week.
62104689|NCT00713739|EXPERIMENTAL|1|Alfuzosin 10mg daily
62666641|NCT05615441|ACTIVE_COMPARATOR|ANI-guided|Patients receiving remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
62104690|NCT00713739|ACTIVE_COMPARATOR|2|Nifedipine XL 30mg daily
62104691|NCT00713739|ACTIVE_COMPARATOR|3|Doxazosin 4 mg daily
62104692|NCT00713739|ACTIVE_COMPARATOR|4|Prazosin 1 mg BID
62104693|NCT03465488|EXPERIMENTAL|Subjects|All participants that meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study and receive a subject identifier (SubjectID). At baseline, all participants will receive a single treatment of albendazole 400mg and their stool will be examined for helminth eggs. Two to three weeks after treatment a follow-up examination of their stool is performed.
62104694|NCT01766167|EXPERIMENTAL|MP-424|
62666642|NCT05615441|EXPERIMENTAL|Standard|Patients receiving remimazolam-based total intravenous general anesthesia based on hemodynamic variables and without ANI nociception monitoring
62666643|NCT03462147|SHAM_COMPARATOR|SHAM|No stimulation will be given
62666644|NCT03462147|EXPERIMENTAL|High Density Stimulation|New way of spinal cord stimulation
62666645|NCT03462147|ACTIVE_COMPARATOR|Conventional stimulation|the most used stimulation of the spinal cord
62666646|NCT06294613|OTHER|vitreoretinal surgery supported by Luca System|
62666647|NCT06314971||T1 Colorectal Cancer, With Recurrence (Training)|Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort
62666648|NCT06314971||T1 Colorectal Cancer, Without Recurrence (Training)|Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort
62297228|NCT04372238|ACTIVE_COMPARATOR|Standard OEND|In the control arm participants will receive standard overdose education and naloxone distribution (OEND).
62297229|NCT05792384|EXPERIMENTAL|transbronchial cryobiopsy|transbronchial cryobiopsy with a 1.1 mm flexible cryoprobe
62297230|NCT05792384|ACTIVE_COMPARATOR|transbronchial lung biopsy|transbronchial lung biopsy with biopsy forceps
62666649|NCT06314971||T1 Colorectal Cancer, With Recurrence (Validation)|Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort
62666650|NCT06314971||T1 Colorectal Cancer, Without Recurrence (Validation)|Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort
62666651|NCT03851991|ACTIVE_COMPARATOR|arbidol|200mg, three times per day, for 2-5 Days.
62666652|NCT03851991|PLACEBO_COMPARATOR|control|two capsules, three times per day, for 2-5 Days.
62104695|NCT06617169|EXPERIMENTAL|Level 0 - MNPR-101-PCTA-177Lu 480 MBq|
62297231|NCT04958785|EXPERIMENTAL|Safety Run-in Cohort 1: Magrolimab + Nab-Paclitaxel or Paclitaxel|"Participants with untreated unresectable, locally advanced or metastatic TNBC whose tumors are not appropriate for immune checkpoint inhibitor therapy will receive the following:~* magrolimab in de-escalating doses to establish RP2D~* nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days."
62666653|NCT00538538|ACTIVE_COMPARATOR|A|Does not receive Gas bubble
62666654|NCT00538538|ACTIVE_COMPARATOR|B|Does receive gas bubble
62666655|NCT01076933|EXPERIMENTAL|rTMS|rTMS sessions
62666656|NCT01076933|SHAM_COMPARATOR|control|sham rTMS (control)
62666657|NCT05581264|EXPERIMENTAL|Self-Management Education Program|Participants received the diabetes self-management education program. The education and counseling were maintained through follow-up via phone for the intervention group
62666658|NCT05581264|NO_INTERVENTION|No Intervention/Control Group|Participants received the usual medical care prescribed by the patient's attending doctor.
62666659|NCT03157791|EXPERIMENTAL|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
62666660|NCT03157791|NO_INTERVENTION|Control|Group B will receive no simethicone tablets.
62666661|NCT06144307||External Oblique Fascial Plan Block|
62666662|NCT06144307||Subcostal Transversus Abdominis Plan Block|
62666663|NCT06144307||Control|
62666664|NCT01773902|EXPERIMENTAL|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if \>1500g b.w. until 1 week before discharge
62666665|NCT01773902|EXPERIMENTAL|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
62666666|NCT01773902|ACTIVE_COMPARATOR|Standard protein supplementation|Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge
62666667|NCT01732692|EXPERIMENTAL|MOVIPREP (Morning-only dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
62666668|NCT01732692|OTHER|MOVIPREP (Split-dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.
62666669|NCT02353741|EXPERIMENTAL|EGFR-TKIs combined with radiotherapy|EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.
62666670|NCT03453970|EXPERIMENTAL|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
62297232|NCT04958785|EXPERIMENTAL|Phase 2 Cohort 1 Arm A: Magrolimab + Nab-Paclitaxel or Paclitaxel|"Participants with mTNBC will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days.~Magrolimab will be continued until development of unacceptable toxicity that cannot be clinically managed by dose or schedule modifications. Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity."
62666671|NCT03453970|NO_INTERVENTION|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
62666672|NCT01892852|EXPERIMENTAL|Acupuncture|Acupuncture treatment
62666673|NCT01892852|NO_INTERVENTION|Control|No other active treatment or sham acupuncture for this symptoms
62666674|NCT00934882|EXPERIMENTAL|Arm 1|
61912910|NCT04898205|SHAM_COMPARATOR|Treadmill Exercise with Air|Participants will receive 8 sessions (2 x week for 4 weeks) of treadmill exercise combined with air delivered via nasal cannula during exercise and 5-minutes of recovery. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
61912911|NCT04898205|SHAM_COMPARATOR|Supplemental Oxygen Only|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of 6 liters per minute of continuous oxygen via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
61912912|NCT04898205|PLACEBO_COMPARATOR|No Intervention|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of air via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
61912913|NCT05212129|ACTIVE_COMPARATOR|Treatment Arm A (hEDS)|(n=60) patients who meet criteria for hEDS or Hypermobile Spectrum Disorder (HSD) will receive aVNS (acoustic vagal nerve stimulation) therapy via filtered vocal music sound therapy using the Safe and Sound protocol (randomized 1:1 to active vs sham music; double blind study design)
61912914|NCT05212129|EXPERIMENTAL|Treatment Arm B (ANS Dysfunction)|(n=30) patients with concerns for ANS dysfunction (with or without hEDS) will receive auricular percutaneous vagal nerve stimulation (pVNS) therapy. Additional sub-study option: 15-20 subjects will undergo gastric MRI and (those who consent to it) will also participate in a biobank blood sample collection study.
62666675|NCT00441896|EXPERIMENTAL|ganaxolone|ganaxolone
61912915|NCT04822584|EXPERIMENTAL|Phototherapy associated with active treatment|"Baricitinib 4 mg/day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of baricitinib)"
61912916|NCT04822584|PLACEBO_COMPARATOR|Phototherapy associated with placebo|"Placebo once a day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of placebo of baricitinib)."
61912917|NCT03492840|ACTIVE_COMPARATOR|Cohort 1 - Dercum's Disease|Nodular size - diameter (cm) 2-2.9, 3-3.9, 4-8 Total dose of RZL-012(mg) 10 15 20 Dose per NOAEL 1/25th , 1/18.75th, 1/12.5th Number of injections: 2,3,4
61912918|NCT03492840|ACTIVE_COMPARATOR|Cohort 2 - Lipedema|Total dose of RZL-012 (mg) 60 , 80 Dose per NOAEL: 1/4.6888, 1/3.125 Number of injections: 12, 16
61912919|NCT06059352||ASD+ CAPD|This group includes children and adolescence with ASD who also have CAPD. No intervention will be applied to this group.
61912920|NCT06059352||ASD- CAPD|This group includes children and adolescence with ASD who are not affected by CAPD. No intervention will be applied to this group.
61912921|NCT05334095|ACTIVE_COMPARATOR|Perclose ProGlide|Perclose ProGlide 6F Suture-Mediated Closure (SMC) System
61912922|NCT05334095|PLACEBO_COMPARATOR|Angio-seal VIP|Angio-seal VIP Vascular Closure Device
61912923|NCT05307367|EXPERIMENTAL|WP1-3|WP1+2: no intervention WP3: exercise training as intervention
61912924|NCT06055335|EXPERIMENTAL|Medium flow anesthesia|After reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane.
61912925|NCT06055335|EXPERIMENTAL|Minimal flow anesthesia|After reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane.
61912926|NCT00782431|EXPERIMENTAL|1|Vero cell-derived, trivalent, seasonal influenza vaccine
61912927|NCT00782431|ACTIVE_COMPARATOR|2|Licensed egg-derived, trivalent seasonal influenza vaccine
61912928|NCT04334018|PLACEBO_COMPARATOR|conventional CRT|
61912929|NCT04334018|EXPERIMENTAL|MPP CRT|
62666676|NCT00441896|PLACEBO_COMPARATOR|non-active drug|placebo
62666677|NCT01866592|OTHER|Single-Arm, open-label extension trial|Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks.
62666678|NCT04328285|EXPERIMENTAL|Hydroxychloroquine (HCQ) vs Placebo|"Group 1.1: HCQ 200 mg : 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards~Group 1.2: Placebo of HCQ, 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards."
62666679|NCT04328285|EXPERIMENTAL|Lopinavir/ritonavir (LPV/r) vs Placebo|"Group 2.1: LPV/r 200/50 mg, 2 tablets twice daily~Group 2.2: Placebo of LPV/r, 2 tablets twice daily"
62666680|NCT00396669|EXPERIMENTAL|Dopamine release|
62666681|NCT02390375|EXPERIMENTAL|A|DW-0929
61912930|NCT04409639|EXPERIMENTAL|Treatment: all patients|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
62104696|NCT06617169|EXPERIMENTAL|Level 1 - MNPR-101-PCTA-177Lu 960 MBq|
62104697|NCT06617169|EXPERIMENTAL|Level 2 - MNPR-101-PCTA-177Lu 1440 MBq|
62297233|NCT04958785|ACTIVE_COMPARATOR|Phase 2 Cohort 1 Arm B: Nab-Paclitaxel or Paclitaxel|"Participants with mTNBC will receive nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days.~Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity."
62104698|NCT06617169|EXPERIMENTAL|Level 3 - MNPR-101-PCTA-177Lu 1920 MBq|
62104699|NCT06617169|EXPERIMENTAL|Level 4 - MNPR-101-PCTA-177Lu 2240 MBq|
62104700|NCT03580967|OTHER|Drug: Vortioxetine|
62468744|NCT03680248|EXPERIMENTAL|Healthy subjects, Fat|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention
62468745|NCT03680248|EXPERIMENTAL|Steatosis, Fat|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention
62666682|NCT02390375|ACTIVE_COMPARATOR|B|Rosuvastatin
62666683|NCT01181843||Cesearean sections receiving duramorph|
62666684|NCT00986232|EXPERIMENTAL|1|ProQuad (low dose)
62666685|NCT00986232|EXPERIMENTAL|2|ProQuad (middle dose)
62666686|NCT00986232|EXPERIMENTAL|3|ProQuad (high dose)
62666687|NCT00986232|ACTIVE_COMPARATOR|4|M-M-R II + PUVV
62666688|NCT00231933|ACTIVE_COMPARATOR|1|Participants will receive standard care incorporating illness management recovery
62666689|NCT00231933|EXPERIMENTAL|2|Participants will receive illness management recovery plus person-centered planning
62666690|NCT00231933|EXPERIMENTAL|3|Participants will receive illness management recovery plus person-centered planning and community integration
62666691|NCT04035083|EXPERIMENTAL|Laser activated irrigation|Laser activated irrigation of sodium hypochlorite using a 980 nm diode laser device
62666692|NCT04035083|ACTIVE_COMPARATOR|Passive ultrasonic irrigation|passive ultrasonic irrigation of sodium hypochlorite using an ultrasonic laser device
62666693|NCT03459651|EXPERIMENTAL|ANS training|
62666694|NCT02530866|ACTIVE_COMPARATOR|Standard care|Women in this arm will target fasting blood glucose values \<95 mg/dL and 1 hour post-prandial values \<140 mg/dL
62666695|NCT02530866|EXPERIMENTAL|Intensive therapy|Women in the arm will target fasting blood glucose values \<90 mg/dL and 1 hour post-prandial values \<120 mg/dL.
62666696|NCT04698486|ACTIVE_COMPARATOR|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD~MR spectroscopy verified no steatosis"
62666697|NCT04698486|ACTIVE_COMPARATOR|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD~MR spectroscopy verified steatosis"
61912931|NCT00807573|EXPERIMENTAL|Paclitaxel, Bevacizumab & Pemetrexed|During each 28-day cycle, paclitaxel, pemetrexed and bevacizumab will be given intravenously on days 1 and 15. Paclitaxel will be administered at 90mg/m\^2 over 60 minutes on days 1 and 15. Pemetrexed 500mg/m\^2 will be administered over 10 minutes on days 1 and 15. Bevacizumab will be given at 10mg/kg over 20 minutes on days 1 and 15
61912932|NCT05999760|ACTIVE_COMPARATOR|Group I (patients received Versacryle removable partial denture)|patients having Kennedy class I received maxillary Versacryle removable partial denture
61912933|NCT05999760|ACTIVE_COMPARATOR|Group II (patients received CAD/CAM fabricated removable partial denture)|patients having Kennedy class I received maxillary CAD/CAM fabricated removable partial denture
61912934|NCT04200040|EXPERIMENTAL|treatment group|"OrienX010 will be administered once every two weeks by intratumoral injection. The treatment dose , depends on the patient's tumour size, The maximum dose of OrienX010 in at each treatment , the expected accumulated dose in 10 mL. The investigator should be confirmed the injectable tumor size and adequate dose within 24 hours prior to treatment.~OrienX010 treatment will be continuous and extend from first dose of study medication until to complete response, clinical related progression disease (PDr), untolerated toxicities, lost to follow up, death or meet end of treatment criteria."
61912935|NCT04200040|ACTIVE_COMPARATOR|Control group|Dacarbazine will be administered once every three weeks by intravenous 1000mg/square meter. Dacarbazine treatment will be continuous and extend from first dose of study medication until to progression disease (PD), untolerated toxicities, lost to follow up, death or meet end of treatment criteria.
61912936|NCT04738305|OTHER|Dignity Therapy Intervention|All the patients that accepted to participate in the study were provided with Dignity Therapy Intervention. A short-term intervention aimed at reducing existential distress of patients facing with advanced illness.
61912937|NCT05581901|EXPERIMENTAL|Methadone (Dose 1)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
62297234|NCT04958785|EXPERIMENTAL|Safety Run-in Cohort 2: Magrolimab + Sacituzumab govitecan|"Participants with unresectable, locally advanced or metastatic TNBC who have received at least 1 and no more than 2 prior lines of treatment in the unresectable, locally advanced or metastatic setting will receive the following:~* magrolimab in de-escalating doses to establish RP2D~* sacituzumab govitecan on Days 1 and 8~Each cycle is 21 days."
62297235|NCT04958785|EXPERIMENTAL|Phase 2 Cohort 2: Magrolimab + Sacituzumab govitecan|"Participants with mTNBC will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with sacituzumab govitecan on Days 1 and 8. Each cycle is 21 days.~Magrolimab will be continued until development of unacceptable toxicity that cannot be clinically managed by dose or schedule modifications.sacituzumab govitecan will be continued until development of unacceptable toxicity."
62666698|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI \<25.
61912938|NCT05581901|EXPERIMENTAL|Methadone (Dose 2)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
62666699|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI \> or = 25 and \<30.
62666700|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI \> or = 30.
62666701|NCT03035539|ACTIVE_COMPARATOR|Standard treatment|Standard treatment after randomization
62666702|NCT03035539|EXPERIMENTAL|Cardiac Rehabilitation|The rehabilitation programme includes education, physical exercise, optimisation of the medical treatment, and discussion of implications for the daily life of each participant.
62666703|NCT00929032||Liver transplant recipient|Liver transplant recipient
62104701|NCT06434857|EXPERIMENTAL|Strength Training Group|"The main part of the strength training program will have the following exercises: wall push-ups, arm raises, elbow push-ups and extensions, weighted pronosupination, hand press, knee and hip hinge squat, deadlifts, front and sagittal plan stride, and heel raises.~It will consist on different phases:~1. st phase: exercise adaptation: the correct execution of upper and lower limb exercises will be taught for one month.~2. nd phase: Resistance training: During the following seven months, strength exercises will be performed at slow and normal speed of the movement patterns learned in the training course, increasing load and volume according to each subject's individual progress."
62104702|NCT06434857|ACTIVE_COMPARATOR|Multimodal Exercise Group|"The main part of the multicomponent exercise program integrates different exercise modalities: Aerobic, mobility, strength, balance and coordination exercises. Playful activities or games are also included.~Exercises will be turned gradually more demanding along the duration of the program."
62297236|NCT02109237|EXPERIMENTAL|Bronchiolitis Obliterans 2 & 3|Assessment of sleep disorders and treatment if required
62666704|NCT02777788|ACTIVE_COMPARATOR|chemotherapy|"Eligible subjects will be treated with platinum-doublet 2 cycles chemotherapy:pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin. Each cycle was 21-days.~Dosage:pemetrexed i.v.500mg/m2 d1 ; docetaxel i.v.75mg/m2 d1 ; gemcitabine i.v.1250 mg/m2 d1,d8 ; paclitaxel i.v.175mg/m2 d1 ; vinorelbine i.v.25mg/m2 d1,d8; carboplatin i.v.area under curve (AUC) 5 d1 ；cis-platinum i.v.75mg/m2 d1（or divided into 3days）；nedaplatin i.v.80mg/m2 d1."
62297237|NCT02109237|ACTIVE_COMPARATOR|Bronchiolitis Obliterans 0|Assessment of sleep disorders and treatment if required
62297238|NCT01822561|EXPERIMENTAL|Eplerenone|All patients in this study will receive Eplerenone 50mg once daily for 4 weeks.
62297239|NCT02570373|EXPERIMENTAL|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
62297240|NCT05412706|EXPERIMENTAL|Treatment Arm|Treatment with Niraparib must be started after at least 2 weeks and no later than 6 weeks after the end of platinum-based induction therapy.
62297241|NCT06190483|EXPERIMENTAL|Diazepam/Placebo|Participant\&#39;s receive diazepam on 1st MRI scan, and placebo (ascorbic acid) on 2nd MRI scan
61912939|NCT05581901|EXPERIMENTAL|Methadone (Dose 3)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
62297242|NCT06190483|EXPERIMENTAL|Placebo/Diazepam|Participant\&#39;s receive placebo (ascorbic acid) on 1st MRI scan, and diazepam on 2nd MRI scan
62666705|NCT02777788|EXPERIMENTAL|TCM combined chemotherapy|TCM：JinFuKang plus XingZaoRuanJian, chemotherapy will be the same. JinFuKang po.tid.30ml d6-d21 XingZaoRuanJian po.tid.30ml d6-d21
62666706|NCT06188546|PLACEBO_COMPARATOR|Group 0|Will receive no drugs for pruritis prophylaxis
62666707|NCT06188546|ACTIVE_COMPARATOR|Group 1|Will receive 1ml of propofol 10 mg/ml
62666708|NCT06188546|ACTIVE_COMPARATOR|Group 2|Will receive 2 ml of propofol 10mg/ml
61912940|NCT05466487|EXPERIMENTAL|Active tACS|
61912941|NCT05466487|SHAM_COMPARATOR|Sham tACS|
61912942|NCT02556476||ICU patients|The actual cohort of 148 critically ill medical patients that received the treatment in the intensive care unit (ICU). The interventions include interventions that are usually performed within the ICU such as mechanical ventilation, non-invasive ventilation, neuromuscular blockade, renal replacement therapy.
61912943|NCT01857557|EXPERIMENTAL|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
61912944|NCT01857557|NO_INTERVENTION|Control Group|Patients receiving usual headache care but no exercise program
61912945|NCT02217527|EXPERIMENTAL|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
61912946|NCT02217527|EXPERIMENTAL|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
61912947|NCT06458218|EXPERIMENTAL|Intervention arm|We have constructed a pay-for-population mechanism to encourage medical workers caring for population health. We will ask study populations to finish online COPD-SQ questionnaire with notification of his or her COPD high risk status. For high-risk COPD population, we will provide a face-to-face survey and examination, and provide a multi-component intervention at baseline. We give community-based spirometry pulmonary function test and education; If individuals who are COPD patients, they will be encouraged to seek treatment to the superior hospitals. A CBT-based digital health program will be provided. Also health education will be given. Additionally, we provide (1) a digital health intervention programs to smokers; (2) CBT-based health education for the abnormal BMI; (3) active recruitment into National Essential Public Health Program for those with high blood pressure and blood glucose. Intensive follow-ups will be conducted at month 3, 6, 12.
62666709|NCT06188546|ACTIVE_COMPARATOR|Group 3|Will receive 3 ml of propofol 10mg/ml
62666710|NCT05455450|EXPERIMENTAL|EMDR + NPC|8-16 eye movement desensitisation and reprocessing therapy (EMDR) sessions, plus 1 month follow up session after the therapy has ended. Participants will also attend neuropsychiatric follow-up appointments as part of standard medical care.
62666711|NCT05455450|OTHER|Neuropsychiatric Care (NPC)|Standard medical care
62666712|NCT01851369|EXPERIMENTAL|Combination Treatment with Oral methoxyamine hydrochloride (TRC102) and oral Temozolomide (TMZ)|Combination treatment with oral methoxyamine hydrochloride (TRC102) and oral Temozolomide (TMZ) for days 1-5 of 28-day cycles.
62666713|NCT02606253|ACTIVE_COMPARATOR|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
62297243|NCT00380562|EXPERIMENTAL|Volunteer|High intensity volunteering (15 hours a week or greater) in Baltimore City Schools with children in grades K-3
62297244|NCT00380562|NO_INTERVENTION|Control|Usual activities
62666714|NCT02606253|EXPERIMENTAL|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
62666715|NCT02606253|EXPERIMENTAL|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
62666716|NCT05577104|EXPERIMENTAL|the NPWT group|For patients in the NPWT group, the wound bed preparation was facilitated by VAC device.
62666717|NCT05577104|ACTIVE_COMPARATOR|the control group|For patients in the control group, the wound bed preparation was facilitated by alginates dressing change method.
62666718|NCT02931110|EXPERIMENTAL|CBL0137 Dose Escalation|"* Dose Level 1: 150mg/m2, IV~* Dose Level 2: 180mg/m2, IV~* Dose Level 3: 240mg/m2, IV~* Dose Level 4: 320mg/m2, IV~* Dose Level 5: 400mg/m2, IV~* Dose Level 6: 540mg/m2, IV~* Dose Level 7: 650mg/m2, IV~* Dose Level 8: 780mg/m2, IV~* Dose Level 9: 950mg/m2, IV~* Dose Level 10: 1150mg/m2, IV~* Dose Level 11: 1400mg/m2, IV~* Dose Level 12: 1700mg/m2, IV~* Dose Level 13: 2000mg/m2, IV~* Dose Level 14: 2400mg/m2, IV~* Dose Level 15: 2900mg/m2, IV~* Dose Level 16: 3500mg/m2, IV"
62666719|NCT05226000|EXPERIMENTAL|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
62297245|NCT00775164|EXPERIMENTAL|pioglitazone|Pioglitazone: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
62297246|NCT00775164|ACTIVE_COMPARATOR|Metformin|Metformin XR; 1000 mg once daily for 16 weeks.
62297247|NCT02033226|EXPERIMENTAL|Amniotic Membrane|The test site was treated as follows; After placement and proper condensation of natural Hydroxyapatite graft in the defect, AM was cut based on defect anatomy of surgical site and then adapted over the bone graft and alveolar bone extending from base of the flap reflection to the tooth surface.
62297248|NCT02033226|PLACEBO_COMPARATOR|Control group (Hydroxyapatite only)|The control site was treated by graft placement (Hydroxyapatite) only
62468746|NCT03680248|OTHER|Healthy subjects, Fasting|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting
62468747|NCT03680248|OTHER|Steatosis, Fasting|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting
62666720|NCT01933425|ACTIVE_COMPARATOR|Deep neuromuscular block followed by no neuromuscular block|"Deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg followed by no neuromuscular blockade with sugammadex 8 mg/kg and placebo reversal.~Measurements of intraabdominal distance during deep neuromuscular blockade and without neuromuscular blockade"
62666721|NCT01933425|PLACEBO_COMPARATOR|No neuromuscular block followed by deep neuromuscular block|"No neuromuscular blockade with placebo followed by deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg and reversal with sugammadex 8 mg/kg.~Measurements of intraabdominal distance during no neuromuscular blockade and during deep neuromuscular blockade."
62666722|NCT01761188|EXPERIMENTAL|STABLE-SR|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm ( STABLE-SR)
62666723|NCT01761188|EXPERIMENTAL|Control Group|conventional stepwise ablation approach for persistent AF(CPVI + Lines +CFE) .
62666724|NCT01186081|EXPERIMENTAL|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
62666725|NCT01186081|ACTIVE_COMPARATOR|Postoperative chemoradiotherapy|Postoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
62666726|NCT04964232|EXPERIMENTAL|Temperature monitoring group|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
62666727|NCT01427946|EXPERIMENTAL|Retaspimycin HCl (IPI-504) and Everolimus|Retaspimycin HCl (IPI-504) and everolimus will be administered on a 21-day cycle. All patients will remain on study until progression of disease or intolerability to study treatments occurs.
62666728|NCT03306381|EXPERIMENTAL|Dietary intervention subject group|n=130. Participants on low FODMAP-similar diet during 4-week study period.
62666729|NCT03306381|NO_INTERVENTION|Control group|n=20. Participants on traditional IBS diet during 4-week study period.
62666730|NCT02548182|NO_INTERVENTION|control|A standardized education material on diet, exercise, and behavior modification were provided to all participants, and each participant received a one-to-one education on diet and exercise from a trained nurse for 5 minutes each session.
62666731|NCT02548182|ACTIVE_COMPARATOR|smartcare|Participants allocated to a smartcare arms received the Fit.life™ wireless physical activity tracker (Fit.life™, Suwon, Korea) that measures daily and weekly physical activity. It is convenient for data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer, and has been validated for measurement of free-living physical activity in adults \[REF\]. Participants allocated to a smartcare arms were also provided a standardized education material on diet, exercise, and behavior modification.
62666732|NCT02548182|ACTIVE_COMPARATOR|smartcare plus financial incentives|Participants in the 'smartcare plus financial incentive' arms were told that they are entitled to receive financial incentives depending on their achievement of the physical activity and weight target, and the amount they ca expect .The investigators provide financial incentives classified as process-based incentive and outcome-based incentive in addition to smartcare group intervention. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group.
62104703|NCT06434857|NO_INTERVENTION|Control Group|Participants in this group should continue with their usual dietary pattern and level of physical activity, without changing their lifestyle habits during the study period. They will not participate in the strength exercise program, nor will they perform systematic, programmed and supervised physical exercise in any other program.
62308289|NCT02241018|EXPERIMENTAL|CD25 Mc Ab & calcineurin inhibitors|CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given.
62308290|NCT02344940|EXPERIMENTAL|toremifene|patients who will be treated with toremifene.
62666733|NCT01792466|EXPERIMENTAL|Transpacnreatic sphincterotomy|In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
62666734|NCT01792466|NO_INTERVENTION|Double wire without sphincterotomy|In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation
62297249|NCT06390670|EXPERIMENTAL|COL supplementation|"The experimental procedure for each participant in this group includes a 12-week period of COL supplementation.~The entire study protocol included familiarization and 4 main visits to the laboratory (T1-T4; pre/post supplementation with COL and PLA). After the familiarization, enrolled volunteers were randomly assigned (stratified randomization) to the treatment order by an impartial biostatistician. A 4-week washout period was introduced between treatments. The main study protocol included body mass and composition evaluation, 3 saliva and blood samplings (resting \[REST\]; 3 min \[POST-EX\] and 60 min after completion of the second test exercise \[REC\]) and 2 exercise protocols during each of T1-T4 study visit (interspaced with 50 min of passive rest and 10 min of warm-up before the second exercise test). All testings were performed in the morning hours at the same time for the participant, to avoid physiological diurnal fluctuations in measured saliva and blood outcomes."
62308291|NCT02344940|ACTIVE_COMPARATOR|tamoxifen|patients who will be treated with tamoxifen.
62666735|NCT05700838|EXPERIMENTAL|Cough Skill Training|During cough skill training, participants will be seated in front of a computer with real-time visualization of their cough waveform. A target line will be provided, and participants will be instructed to perform a single voluntary cough so that their peak flow is within the target's range. Participants will be instructed to continue the cough training regardless of initial accuracy.
62666736|NCT03888079||Local anesthetic|Patients who chose local anesthesia for their surgery
62666737|NCT03888079||General anesthetic|Patients who chose general anesthesia for their surgery
62666738|NCT00005585|EXPERIMENTAL|Arm I: (combination chemotherapy)|CONSOLIDATION: Pts receive Methotrexate(MTX) IV over 24 hrs on day 1 and oral leucovorin calcium (CF) every 6 hrs for 3 doses at 42 hours after initiation of MTX infusion during weeks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine(6-MP) daily wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM twice a day on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
62666739|NCT00005585|EXPERIMENTAL|Arm II (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV over 4 hrs on day 1 and oral leucovorin calcium (CF) during wks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine (6-MP) daily on wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM 2x on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX weekly on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
62666740|NCT00005585|EXPERIMENTAL|Arm III (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV and leucovorin calcium (CF) as in arm I on wks 7, 10, 13, 24, 27, and 30. Pts also receive oral mercaptopurine (6-MP) daily on wks 5-13 and then on wk 24 and continuing until the end of consolidation; MTX IT on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone (DM) twice daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase intramuscularly on wk 16; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV on day 1 of wk 20; cytarabine IV or subcutaneously on days 2-5 of wks 20 and 21; and oral thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive oral 6-MP daily on wks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during wks 41, 57, 73, 89, and 105; oral MTX weekly on wks 33-130 (except during wks of IT MTX); and MTX IT on wks 37, 49, 61, 73, 85, 97, and 109.
62666741|NCT00005585|EXPERIMENTAL|.Arm IV (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) and leucovorin calcium (CF) on wks 7, 10, 13, 24, 27, and 30. Pts receive mercaptopurine(6-MP) daily weeks 5-13 then beginning wk 24 and continuing until end of consolidation; MTX on wks 7, 10, 13, 16, 20, 21, and 30; dexamethasone (DM) 2x daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase on wk 16; daunorubicin hydrochloride on day 1 of wks 16-18; cyclophosphamide on day 1 of wk 20; cytarabine on days 2-5 of wks 20 and 21; thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive mercaptopurine(6-MP) daily on weeks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during weeks 41, 57, 73, 89, and 105; oral MTX weekly on weeks 33-130 (except during weeks of IV MTX); and IV MTX on weeks 37, 49, 61, 73, 85, 97, and 109.
62666742|NCT03634150|EXPERIMENTAL|Single arm Nerofe followed by Doxorubicin|IV treatment of Nerofe 96 mg\\m2 followed by IV Doxorubicin 10mg\\m2 Once weekly
62104704|NCT04529993|EXPERIMENTAL|Interstitial pulmonary fibrosis|
62104705|NCT04529993|EXPERIMENTAL|Chronic obstructive pulmonary disease|
62104706|NCT04529993|EXPERIMENTAL|Healthy volunteers|
62666743|NCT01714440||Transplant Recipients Cohort|Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
62666744|NCT01714440||Transplant Donors Cohort|Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
62666745|NCT01714440||Activity&mRNA Expression Substudy Cohort|A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.
62666746|NCT03736369|EXPERIMENTAL|DWP14012 40mg|Orally, once daily
61912948|NCT06458218|NO_INTERVENTION|Control Arm|Those who are assigned in the control arm, we will ask them to finish the same COPD-SQ online questionnaire with notification of his or her COPD high risk status and a face-to-face survey. No physical examinations, community-based pulmonary function tests will be given.
61912949|NCT03189498|EXPERIMENTAL|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate \[eGFR\] greater than or equal to \[\>=\] 90 milliliter per minute \[mL/min\]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4\*250-mg tablets) on Day 1 of treatment period.
61912950|NCT03189498|EXPERIMENTAL|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR \>=60 to less than \[\<\] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250-mg tablets) on Day 1 of treatment period.
61912951|NCT03189498|EXPERIMENTAL|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR \>=30 to \<60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250-mg tablets) on Day 1 of treatment period.
61912952|NCT03189498|EXPERIMENTAL|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR \>= 15 to \<30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250-mg tablets) on Day 1 of treatment period.
62666747|NCT03736369|ACTIVE_COMPARATOR|Esomeprazole 40mg|Orally, once daily
62666748|NCT04000256||Spinal Cord Injury|The data during the first visit involves questionnaires, performance and observational measures for baseline evaluation. The 2nd to 8th visit involves feedback survey and interview data collection based on experiences of participants undergoing activity-based training using upper extremity rehabilitation equipment.
62666749|NCT05993169|NO_INTERVENTION|Control|Normal Care
62666750|NCT05993169|EXPERIMENTAL|Nutritional consultation|Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
62666751|NCT04578132||Genitourinary cancer patients that suffered COVID-19|Patients diagnosed with genitourinary cancer (urothelial, kidney, prostate and germ) that suffered from COVID-19 infection prior to cancer treatment, during treatment, or after treatment.
62666752|NCT03112551|ACTIVE_COMPARATOR|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
62666753|NCT03112551|EXPERIMENTAL|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
62666754|NCT03622840|OTHER|Parkinson's disease patients with cognitive impairment|Online cognitive remediation program.
62666755|NCT05016050|EXPERIMENTAL|Digital therapeutic|Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.
62666756|NCT06039475||Case|Patients with AMS/HACE/HAPE
62666757|NCT06039475||Control|Healthy Individuals
62666758|NCT03853837||Prospective Fontan patients|Fontan patients to be enrolled and complete study tests/procedures
62666759|NCT03853837||Retrospective Fontan patients|Fontan patients to be retrospectively reviewed and used as control subjects
62666760|NCT05842980||sepsis|sepsis patients
62666761|NCT03520387|EXPERIMENTAL|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves
62666762|NCT03520387|ACTIVE_COMPARATOR|Simulated lumbar radiofrequency ablation (simulated LRFA)|Simulated radiofrequency ablation of the dorsal rami of the lumbar spinal nerves(simulated LRFA), with targeted steroid injections
62666763|NCT03520387|EXPERIMENTAL|AcTIVE-CBT|Activity-Tracker Informed Video-enabled Cognitive Behavioral Therapy (AcTIVE-CBT)
62666764|NCT03520387|ACTIVE_COMPARATOR|TBSCE|Telephone-based self-directed CBT and education (TBSCE)
62737205|NCT01375816|EXPERIMENTAL|FUPEP-Bevacizumab|"Day 1 H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H +1 :PEP02 80 mg/m² , 1h30 infusion. The infusion time could be reduced to 1h from cycle 2 if no acute infusion reaction has occured in cycle 1.~H +1 : Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) , 2-h infusion H +3 : 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14"
62737206|NCT03569449|EXPERIMENTAL|Group 1- Goat|Clinic-based visit, usual care, standard pediatric surveillance, and structured visits
62737207|NCT03569449|EXPERIMENTAL|Group 2- Cow|Clinic-based visit, usual care, enhanced pediatric surveillance, and structured visits
62104707|NCT04172844|EXPERIMENTAL|Pevonedistat Dose Escalation|This study uses a varied 3 + 3 design. Three patients will be started at a dose of 10 mg/m\^2 days 1, 3 and 5. If no DLTs are observed in the first 3 participants, then a new cohort will be enrolled at the next planned dose level of 15 mg/m\^2 days 1, 3 and 5. If two out of three subjects experience a DLT, then they will de-escalate one dose level. If one subject in three experiences a DLT, then expand up to three subjects at 20 mg/m\^2 day 1, 3 and 5. If two out of six subjects experience a DLT, de-escalate one level. All subjects will receive Azacitidine and Venetoclax at the indicated dosages and timing.
62666765|NCT03360669|EXPERIMENTAL|Sequence: Clinical/Research|Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second. The sequence randomization corresponds to the intervention. Visits will be at least a day apart but within a two-week period. During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device. During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms. They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer. AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
62666766|NCT03360669|ACTIVE_COMPARATOR|Sequence: Research/Clinical|Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence. The intervention to which they are randomized corresponds to the sequence of the visits.
62666767|NCT04208711|OTHER|positive HIV patient not treated by ARV yet|"Before starting HIV treatment, 15 patients will be included in the study and 50mL of whole blood will be taken. After treatment initiation 8 of the 15 patients will entered in the follow-up phase for 1 year (5 followup visit, M1, M3, M6, M9, M12) and 30mL of whole blood will be taken at each visit.~The duration of the study for the 7 other patients will be 1 day."
62104708|NCT04172844|EXPERIMENTAL|Dose Expansion Phase|Patients will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase.
62666768|NCT03137368|EXPERIMENTAL|treatment group|Exemestane Tablets combined with ovarian function suppression/ablation
62666769|NCT03137368|ACTIVE_COMPARATOR|control group|Tamoxifen Tablets combined with ovarian function suppression/ablation
62104709|NCT06487975|EXPERIMENTAL|Bacillus Subtilis|Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)
62666770|NCT02259322|ACTIVE_COMPARATOR|Standard-of-Care|Standard-of-care is the continuation of any treatment or recommendations participants receive from his/her bariatric surgeon/team.
62666771|NCT02259322|EXPERIMENTAL|Behavioral Weight Loss Treatment|Guided self-help Behavioral Weight Loss Treatment
62104710|NCT06487975|PLACEBO_COMPARATOR|Placebo|1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)
62104711|NCT04599946|EXPERIMENTAL|Experimental formula|Infant and follow-on goat milk formula
62666772|NCT02259322|EXPERIMENTAL|Cognitive Behavioral Therapy|Guided self-help Cognitive Behavioral Therapy
62666773|NCT02802722|ACTIVE_COMPARATOR|Immediate supplementation|Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
62666774|NCT02802722|PLACEBO_COMPARATOR|Delayed supplementation|Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
62666775|NCT01060956|ACTIVE_COMPARATOR|Reporting on two bacteria in urine culture|The microbiology laboratory will report on the isolation and susceptibilities of two different bacteria in urine culture
62104712|NCT04599946|ACTIVE_COMPARATOR|Control formula|Infant and follow-on cow milk formula
62104713|NCT00058058|EXPERIMENTAL|MRI Evaluation of Contralateral Breast|The cohort is a distinct population of women at high risk for breast carcinoma: women with a recent (within 60 days) personal diagnosis of breast cancer who will have MRI to evaluate the contralateral breast.
62104714|NCT03419780|ACTIVE_COMPARATOR|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
62104715|NCT03419780|ACTIVE_COMPARATOR|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
62666776|NCT01060956|PLACEBO_COMPARATOR|"reporting mixed growth"|The microbiology laboratory will report on mixed growth in urine culture
62666777|NCT02919332||Diagnostic (18F-FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
62104716|NCT04204408|EXPERIMENTAL|Single dose (part 1) Mim8|Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.
62104717|NCT04204408|PLACEBO_COMPARATOR|Single dose (part 1) placebo|Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.
62104718|NCT04204408|EXPERIMENTAL|Multiple dose (part 2)|Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.
62104719|NCT03450109|EXPERIMENTAL|LY01005|One LY01005 3.6 mg gluteal IM injection.
62104720|NCT03450109|ACTIVE_COMPARATOR|Zoladex|One Zoladex 3.6 mg subcutaneous injection into the anterior abdominal wall
62104721|NCT05975554|EXPERIMENTAL|Low dose interleukin-2|Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC.
62104722|NCT05975554|ACTIVE_COMPARATOR|Control|Standard of care treatment
62666778|NCT01033071|EXPERIMENTAL|Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD|
62104723|NCT05825235|EXPERIMENTAL|Pramipexole|Pramipexole prolonged-release tablet with doses ranging from 0.26 mg base to 3.15 mg base / day, study duration 6 months
62297250|NCT06390670|PLACEBO_COMPARATOR|PLA treatment|"The experimental procedure for each participant in this group includes a 12-week period of PLA supplementation.~The entire study protocol included familiarization and 4 main visits to the laboratory (T1-T4; pre/post supplementation with COL and PLA). After the familiarization, enrolled volunteers were randomly assigned (stratified randomization) to the treatment order by an impartial biostatistician. A 4-week washout period was introduced between treatments. The main study protocol included body mass and composition evaluation, 3 saliva and blood samplings (resting \[REST\]; 3 min \[POST-EX\] and 60 min after completion of the second test exercise \[REC\]) and 2 exercise protocols during each of T1-T4 study visit (interspaced with 50 min of passive rest and 10 min of warm-up before the second exercise test). All testings were performed in the morning hours at the same time for the participant, to avoid physiological diurnal fluctuations in measured saliva and blood outcomes."
62297251|NCT00710190|EXPERIMENTAL|Rheos Implant|
62297252|NCT04033289|EXPERIMENTAL|experimental group|
62297253|NCT04033289|NO_INTERVENTION|control group|
62297254|NCT06179992|EXPERIMENTAL|Experimental group|The experimental group used the GGED module for 15 days after the first assessment.
62297255|NCT06179992|ACTIVE_COMPARATOR|Control group|The control group used the GGED module for 15 days after the second assessment.
62297256|NCT06657248||univation® XF Pro|Primary medial unicompartmental knee arthroplasty treated with implantation of unicompartmental knee prosthesis univation® XF Pro
62297257|NCT06063473|EXPERIMENTAL|Trifarotene Cream 0.005%|The study medication will be applied topically once daily at bedtime to the affected areas of the face as a thin layer, avoiding contact with the mouth, eyes, and other mucous membranes, for 84 consecutive days.
62666779|NCT01033071|EXPERIMENTAL|Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD|
62666780|NCT01033071|ACTIVE_COMPARATOR|Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD|
62104724|NCT01081379||pre-conception immunity|pre-conception immunity- pregnant women with CMV seropositive
62104725|NCT01081379||primary CMV infection|primary CMV infection- pregnant women with primary CMV infection (defined as CMV IgG sero-conversion, the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies).
62104726|NCT02949648||Electronic cigarette ever user|Youth Quitline callers who reported ever use of e-cigarette at baseline.
62104727|NCT02949648||Electronic cigarette never user|Youth Quitline callers who reported never use of e-cigarette at baseline.
62104728|NCT04322656|ACTIVE_COMPARATOR|Effect of Lipiflow treatment on biometrical outcomes|One eye of each patient will be treated with Lipiflow
62104729|NCT04322656|NO_INTERVENTION|Control eye|The contralateral eye will serve as control eye
62104730|NCT05461924||long-segment HSCR|Aganglionosis of non-rectosigmoid HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum
62104731|NCT05461924||rectosigmoid HSCR|Aganglionosis confined to the rectosigmoid
62297258|NCT06063473|ACTIVE_COMPARATOR|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be applied topically once daily at bedtime to the affected areas of the face as a thin layer, avoiding contact with the mouth, eyes, and other mucous membranes, for 84 consecutive days.
62297259|NCT06063473|PLACEBO_COMPARATOR|Placebo Control|The study medication will be applied topically once daily at bedtime to the affected areas of the face as a thin layer, avoiding contact with the mouth, eyes, and other mucous membranes, for 84 consecutive days.
62297260|NCT00586365|EXPERIMENTAL|1|Will receive 500 mg Naproxen twice a day for two weeks
62297261|NCT00586365|NO_INTERVENTION|2|Will not receive naproxen
62297262|NCT06067854||Neonates under general anaesthesia without regional anaesthesia|the standard procedure - without regional anaesthesia
62666781|NCT06208631|EXPERIMENTAL|Gait modification|Participants will learn to change muscle coordination while walking through real-time haptic biofeedback based on the activation of the gastrocnemius muscle
62666782|NCT01872936|OTHER|Miravirsen every other week dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
62666783|NCT01872936|OTHER|Miravirsen monthly dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.
62666784|NCT05644483|EXPERIMENTAL|remimazolam group|patients who receive remimazolam-remifentanil based total intravenous anesthesia
62666785|NCT05644483|ACTIVE_COMPARATOR|propofol group|patients who receive propofol-remifentanil based total intravenous anesthesia
62666786|NCT02288871|OTHER|"Sutureless valve"|"Patients who underwent aortic valve replacement with a sutureless aortic valve.~An echocardiogram and a cardiac CT-scan will be conducted."
62666787|NCT02288871|OTHER|"Sewed-in valve"|"Patients who underwent aortic valve replacement with a sewed-in aortic valve. An echocardiogram and a cardiac CT-scan will be conducted."
61912953|NCT03189498|EXPERIMENTAL|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR \<15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
62666788|NCT04462146|EXPERIMENTAL|Internet-based intervention|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
62666789|NCT04462146|ACTIVE_COMPARATOR|Face-to-face treatment by videoconference|Face-to-face Intervention by videoconference applied by a therapist: Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
62666790|NCT06033664|EXPERIMENTAL|Grocery Prescription Program|Participants will receive the Fresh Funds through Instacart
62666791|NCT02851524|EXPERIMENTAL|posturography|
61912954|NCT05060809|EXPERIMENTAL|Hemodialysis patient with high level of dp uc-MGP|one hundred and twenty hemodialysis patients with high level of dephosphorylated uc-MGP received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by Kauppila score.In addition, study patients were subjected to an echocardiography at baseline as well as 6 months post vitamin K1 supplementation. Echocardiography was performed by the same operator.
62104732|NCT00303849|EXPERIMENTAL|Treatment (etoposide, mannitol, melphalan, carboplatin, STS)|Patients receive etoposide phosphate IV over 10 minutes, mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes on days 1 and 2. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Courses repeat every 4 to 6 weeks for up to 12 months.
62104733|NCT03852758|EXPERIMENTAL|Outdoor Exercise|2 sessions of outdoor exercise per week
62666792|NCT02523638|OTHER|Pegylated- Proline-Interferon alpha-2b|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen single arm
62104734|NCT03852758|EXPERIMENTAL|Indoor Exercise|2 sessions of indoor exercise per week
62297263|NCT06067854||Neonates under general anaesthesia with regional anaesthesia|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
62666793|NCT04329741|EXPERIMENTAL|Intervention|6-week basic dog obedience training course
62666794|NCT04329741|NO_INTERVENTION|Control|Waitlist control
62666795|NCT03414632|OTHER|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
62666796|NCT02411136|EXPERIMENTAL|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
62666797|NCT02411136|PLACEBO_COMPARATOR|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
62666798|NCT02665936|ACTIVE_COMPARATOR|group L|Epidural levobupivacaine 0.125% (Chirocaine) in normal saline in a total volume of 10 ml will be administered epidurally in active stage of labor
62666799|NCT02665936|ACTIVE_COMPARATOR|group LD4|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 4 mg in a total volume 10 ml
62104735|NCT03103412|EXPERIMENTAL|TD-3504 Low-Dose|6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
62104736|NCT03103412|EXPERIMENTAL|TD-3504 Mid-Dose|6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
62104737|NCT03103412|EXPERIMENTAL|TD-3504 High-Dose|6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
62104738|NCT03103412|PLACEBO_COMPARATOR|Placebo|6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.
62666800|NCT02665936|ACTIVE_COMPARATOR|group LD8|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 8 mg in a total volume 10 ml
61912955|NCT03588962|EXPERIMENTAL|Metal allergy driven restenosis|Patients with angiographically proven in-stent restenosis developed after technically correct implantation. Patch tests for the metals used in stent production will be applicated. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
62666801|NCT02068599|EXPERIMENTAL|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
61912956|NCT03588962|PLACEBO_COMPARATOR|Looking for allergic restenosis|Patients with (technically correctly) implanted stent. Patch tests will be applicated to identify cases with contact allergy. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards.The patients will then be monitored for a 12 months follow-up period in purpose of evaluating the dependance between in-stent restenosis and contact allergy. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
62666802|NCT02068599|EXPERIMENTAL|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
62666803|NCT02068599|PLACEBO_COMPARATOR|Placebo|Placebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
62666804|NCT05740592|EXPERIMENTAL|tooth-tooth borne RPE with MOPs|many approaches have been established to speed up orthodontic tooth movement and to decrease adverse effects. These methods are classified as, microinvasive methods include cortectomies and distraction osteogenesis and microinvasive methods include micro-osteoperforations (MOPs) and piezocision Microtrauma to the bone showed increase the synthesis of cytokines and chemokines, which are routinely released when orthodontic forces are applied . As a result, the affected area is undergoing a faster bone regeneration process
61912957|NCT01695278|ACTIVE_COMPARATOR|Standard Care|Participants will receive standard care from physicians for monitoring and treating their diabetes. They are placed on a wait list to receive the intervention.
62737208|NCT03569449|EXPERIMENTAL|Group 3- Horse|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and structured visits
61912958|NCT01695278|EXPERIMENTAL|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
61912959|NCT04839575|ACTIVE_COMPARATOR|Latiglutenase|IMGX003
61912960|NCT04839575|PLACEBO_COMPARATOR|Placebo|Placebo
61912961|NCT03254615|EXPERIMENTAL|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
61912962|NCT03254615|EXPERIMENTAL|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
62104739|NCT03916614|EXPERIMENTAL|START treatment|Participants randomized into the treatment arm will receive the START intervention as described above alongside usual care from the VPOP staff
62104740|NCT03916614|ACTIVE_COMPARATOR|standard of care|Those randomized to the control arm will receive the usual screening for PTSD and referral for outpatient services if warranted as well as usual care from VPOP staff.
62104741|NCT02345200|ACTIVE_COMPARATOR|Ataxia telangiectasia|26 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
62104742|NCT02345200|ACTIVE_COMPARATOR|Healthy subjects|26 age and sex matched subjects without any chronic disease or hormone displacement will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
62297264|NCT02872103|EXPERIMENTAL|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
61912963|NCT03254615|EXPERIMENTAL|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
62297265|NCT02872103|PLACEBO_COMPARATOR|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
62104743|NCT04733300|EXPERIMENTAL|Mindfulness-Based College - Standard Dose|MBC standard dose is a 9-week, 9 session program providing systematic and intensive training in mindfulness meditation practices. The curriculum is grounded in the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum. MBSR was adapted to the young adult life stage by: (1) Training mindfulness skills such as attention control, self-awareness and emotion regulation, using the MBSR curriculum, and (2) applying these skills to the health behaviors and priorities most relevant to young adults. Specific behaviors and priorities targeted are social relationships, sleep, stress, diet, physical activity, obesity, alcohol consumption, substance use, digital media use, and performance (e.g. athletic, artistic and academic). The intervention is administered live, online via a video conferencing platform. The standard dose class meets once a week for 2.5 hours for 9 weeks. There is also an all-day retreat that takes place around week 6 of the program.
62104744|NCT04733300|EXPERIMENTAL|Mindfulness-Based College - Low Dose|The MBC low-dose program is mirrored after the standard MBC program (described previously); however, instead of meeting for 2.5 hours each week, the low-dose MBC program is abbreviated to meet for 1.5 hours each week for the 9 weeks. MBC low-dose will be administered live, online via the free video conferencing platform, Zoom.
62104745|NCT04733300|ACTIVE_COMPARATOR|Health education control group|Those randomized to the health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
62104746|NCT02212717|ACTIVE_COMPARATOR|EUS-guided gallbladder drainage|
62104747|NCT02212717|ACTIVE_COMPARATOR|Percutaneous cholecystomy|
62104748|NCT00326027|ACTIVE_COMPARATOR|1|Pantoprazole 20 mg
62104749|NCT00326027|ACTIVE_COMPARATOR|2|Pantoprazole 40 mg
62104750|NCT04012606|EXPERIMENTAL|TORIPALIMAB|
62104751|NCT04012606|ACTIVE_COMPARATOR|Chemotherapy|
62104752|NCT01054430|OTHER|Normal|Subjects with normal hepatic function
62104753|NCT01054430|OTHER|Mild Hepatic Dysfunction|Subjects with mild hepatic impairment
62104754|NCT01054430|OTHER|Moderate hepatic dysfunction|Subjects with moderal hepatice impairment
62666805|NCT05740592|EXPERIMENTAL|Tooth-Tooth borne RPE with Piezocision group|"Piezosurgery is an ultrasonic micro vibration-based bone cutting method. It used as a careful, promising, and soft tissue sparing method. In addition to its simplicity of use in the clinic, scientific evidence from animal models measuring wound healing and bone formation suggests that, piezosurgery has a better tissue response than traditional bone-cutting procedures~."
62104755|NCT04691778|ACTIVE_COMPARATOR|CTO PCI using antegrade wiring strategy starting with the Gladius guidewire|Study subjects will undergo CTO PCI with primary antegrade wiring strategy starting with the Gladius guidewire. In case of failed CTO crossing with the Gladius wire, the decision on continuing antegrade wire escalation with a different wire or switching to a different CTO PCI strategy will be left to the discretion of the operator.
62666806|NCT05740592|ACTIVE_COMPARATOR|Tooth-Bone borne RPE group (MARPE)|The MARPE is a RPE device with a rigid element that attached to palate by the aid of miniscrew, exerting the expansion force directly to the maxilla's basal bone
62666807|NCT02216409|EXPERIMENTAL|Treatment (Hu5F9-G4)|Hu5F9-G4 monotherapy
62104756|NCT04691778|OTHER|CTO PCI using standard antegrade wire escalation strategy|Control subjects will undergo CTO PCI using standard antegrade wiring strategy starting with the lower/intermediate penetration force guidewires and, if necessary, escalating up to high gram-force guidewires, but without the use of first-choice Gladius guidewire.
62104757|NCT06632093||HAIC plus Lenvatinib and PD-1 inhibitors|Each patient should receive at least 2 cycles of HAIC and 1cycles of PD-1 plus Lenvatinib. The interval between HAIC and Lenvatinib plus PD-1 inhibitors should be within 2 weeks.
62104758|NCT06409637|EXPERIMENTAL|FOLFOX plus Lenvatinib|"FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.~Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study."
62104759|NCT03377855|EXPERIMENTAL|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
62666808|NCT05122819|EXPERIMENTAL|Group A|Intraligamentary Injection by Jet Injector
62666809|NCT05122819|EXPERIMENTAL|Group B|Intraligamentary Injection by regular Dental Anesthesia Syringe
62666810|NCT05122819|ACTIVE_COMPARATOR|Group C|Inferior Alveolar Nerve Block
62104760|NCT05391048|EXPERIMENTAL|IMP4297 first 5*20mg then 10*10mg|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
62104761|NCT05391048|EXPERIMENTAL|IMP4297 first 10*10mg then 5*20mg|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
62666811|NCT04195412|EXPERIMENTAL|tDCS|Bihemispheric tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After stimulation, individual and intensive upper limb rehabilitation will be performed.
62666812|NCT04195412|SHAM_COMPARATOR|Control|Bihemispheric sham tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After sham stimulation, individual and intensive upper limb rehabilitation will be performed.
62666813|NCT05548504|ACTIVE_COMPARATOR|Photon therapy|50-66Gy/ 24 fractions, inhomogeneous dose distribution Photon therapy
62666814|NCT05548504|EXPERIMENTAL|Proton therapy|50-66Gy/ 24 fractions, inhomogeneous dose distribution Proton therapy
62666815|NCT06072313|EXPERIMENTAL|Monopolar electrical diathermy plus therapeutic yoga|The Experimental Group formed by 30 subjects will receive two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) by means of the Physicalm® device (device developed by Biotronic Advance Develops SL), and one session of therapeutic neck yoga per week. Diathermy is applied by means of rotational and translational movements, adapting to the muscular fibers of the cervical area, with a pulsed emission of 840 KHz AND 30v dynamically during a treatment time of 20 minutes.
62666816|NCT06072313|ACTIVE_COMPARATOR|Therapeutic Exercise|"The Control Group formed by 30 subjects will be administered a supervised therapeutic exercise with the same protocol of postures and sequences as in the Experimental Group, but for three days a week. The duration of the sessions will be 60 minutes.~The yoga program will be designed specifically for people who have chronic neck pain and no previous experience with therapeutic exercise. Classes will be led by a certified Iyengar yoga instructor and physical therapist. The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Props such as belts, blocks, and blankets will be used to enhance safety and alignment. Participants will be asked to focus on their posture, joint positions, and muscle tension in each exercise posture. No formal breathing techniques will be used, but participants will be instructed to align their breath with their movements."
62666817|NCT00926120|EXPERIMENTAL|Mogroside sweetener|All subjects will received Mogroside. Mogroside sweetener administered at a dosage level of 5 g every 6 hours for 14 days.
62666818|NCT00726557||PegIntron + Rebetol|There will be a distinction between the patients depending on the type of substitution drug used (secondary parameters).
62666819|NCT03723070|EXPERIMENTAL|PV Cryoablation|Ablation of the ostium of the pulmonary veins (PV) as a means to electrically isolate the veins in the treatment of atrial fibrillation. A cryoablation balloon will be inserted into the left atrium and cryo applications will be administered to create an endocardial thermal injury by using the Cryterion Cardiac Cryoablation System
62104762|NCT06146985|EXPERIMENTAL|Differentiated Thyroid Cancer refractory to standard treatment（DTC）|Participants will receive 1200mg Adebrelimab i.v. once every 3 weeks and 20 mg Famitinib orally before or after the meal every day for 3 weeks until PD and/or endurable toxicity appears.
62666820|NCT06147154||Pancreatic head cancer (PHC) tumor tissues|
62666821|NCT06147154||Pancreatic head cancer (PHC) matched non-tumor tissues|
62666822|NCT06147154||Pancreatic body/tail cancer (PBTC) tumor tissues|
62666823|NCT06147154||Pancreatic body/tail cancer (PBTC) matched non-tumor tissues|
62666824|NCT04921163|ACTIVE_COMPARATOR|aluminium|4-day test periode with intake of aluminium pancakes
62666825|NCT04921163|PLACEBO_COMPARATOR|placebo|4-day test periode with aluminium-free pancakes
62666826|NCT04921163|PLACEBO_COMPARATOR|second placebo|Again a 4-day test periode with aluminium-free pancakes
62666827|NCT02112591|ACTIVE_COMPARATOR|Transobturator suburethral tape (TOT)|transobturator approaches for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide
62666828|NCT02112591|EXPERIMENTAL|S-TOT|transobturator subtrigonal tape: S-TOT
62666829|NCT02677389|EXPERIMENTAL|Arm I (Enhanced SCP)|See Detailed Description
62666830|NCT02677389|ACTIVE_COMPARATOR|Arm II (SCP)|"Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on Healthy Habits at 1, 2, 4, and 8 weeks. Specific topics in emails include positive self-talk, daily relaxation breathing techniques, better sleep, and ways to find pleasure."
62666831|NCT01666405|EXPERIMENTAL|Urgent(R) PC Neuromodulation System|Urgent(R) PC Neuromodulation System
62666832|NCT00849329|EXPERIMENTAL|Period 1|1250mg lapatinib once daily in the morning
62666833|NCT00849329|EXPERIMENTAL|Period 2|1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.
62666834|NCT04368910|EXPERIMENTAL|Pyronaridine - artesunate|"Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
62737209|NCT03569449|EXPERIMENTAL|Group 4- Pig|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and structured visits
62737210|NCT03569449|EXPERIMENTAL|Group 5- Sheep|Clinic-based visit, usual care, standard pediatric surveillance, and individually-tailored visits
62737211|NCT03569449|EXPERIMENTAL|Group 6- Llama|Clinic-based visit, usual care, enhanced pediatric surveillance, and individually-tailored visits
62666835|NCT04368910|ACTIVE_COMPARATOR|Chloroquine|"Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
62666836|NCT04270773|OTHER|Only arm|Single arm, Receiving treatment
62666837|NCT05188612||Male|Non-interventional patient registry
62666838|NCT05188612||Female|Non-interventional patient registry
62666839|NCT05188612||Elderly|Non-interventional patient registry
62297266|NCT05714904|EXPERIMENTAL|Dose escalation|"2 cohorts of 3 patients each. All the patients enrolled in the study will receive a single subretinal injection in one eye.~Cohort 1: Subretinal administration of a single low dose ZVS101e at Day 0. Cohort 2: Subretinal administration of a single high dose ZVS101e at Day 0."
62666840|NCT05188612||Hypertension|Non-interventional patient registry
62666841|NCT05188612||Diabetes|Non-interventional patient registry
62666842|NCT05188612||Dyslipidemias|Non-interventional patient registry
62666843|NCT05188612||Smoking|Non-interventional patient registry
62104763|NCT06146985|EXPERIMENTAL|Medullary Thyroid Cancer(MTC)|Participants will receive 1200mg Adebrelimab i.v. once every 3 weeks and 20 mg Famitinib orally before or after the meal every day for 3 weeks until PD and/or endurable toxicity appears.
62104764|NCT06146985|EXPERIMENTAL|Anaplastic Thyroid Carcinoma（ATC）|Participants will receive 1200mg Adebrelimab i.v. once every 3 weeks and 20 mg Famitinib orally before or after the meal every day for 3 weeks until PD and/or endurable toxicity appears.
62104765|NCT02471391|EXPERIMENTAL|Ibrutinib + ABT-199|
62104766|NCT02704481|EXPERIMENTAL|Mifepristone-misoprostol|Women randomized to receive 200 mg mifepristone to take on Day 1, 800 mcg buccal misoprostol to take 24-48 hours after later, and four placebo misoprostol pills to take a further 3-12 hours later.
62297267|NCT03501056|EXPERIMENTAL|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
62666844|NCT05188612||Kidney Disease|Non-interventional patient registry
62297268|NCT03501056|ACTIVE_COMPARATOR|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length\<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
62666845|NCT05188612||Heart Diseases|Non-interventional patient registry
62666846|NCT05188612||Vascular diseases|Non-interventional patient registry
62666847|NCT06165965|EXPERIMENTAL|Treatment(Experimental): JLP-2008|- Group I(Peroid I-Comparator\[JT-001,JT-002\], Peroid II-JLP-2008), Group II(Period I-JLP-2008, Period II-Comparator\[JT-001,JT-002\])
62666848|NCT06165965|ACTIVE_COMPARATOR|Control(Active Comparator): JC-013|- Group I(Peroid I-Comparator\[JT-001,JT-002\], Peroid II-JLP-2008), Group II(Period I-JLP-2008, Period II-Comparator\[JT-001,JT-002\])
62104767|NCT02704481|EXPERIMENTAL|Misoprostol-misoprostol|Women randomized to receive a placebo mifepristone pill to take on Day 1 and two doses of 800 mcg buccal misoprostol, the first of which should be taken 24-48 hours after the placebo and the second of which should be taken 3-12 hours after the first misoprostol dose.
62666849|NCT03963830|EXPERIMENTAL|MOVE UP-Sustainability|12-week lifestyle intervention focusing on diet and activity
62666850|NCT03312166|EXPERIMENTAL|Compression device|
62666851|NCT05132946|ACTIVE_COMPARATOR|Group (B): will receive erector spinae plane block.|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
62666852|NCT05132946|NO_INTERVENTION|• Group (C): will not receive any block.|
62666853|NCT01536509|EXPERIMENTAL|Telehealth Behavioral Treatment|
62666854|NCT01536509|ACTIVE_COMPARATOR|Education Only|
62666855|NCT05735496|EXPERIMENTAL|TQB2102 injection|intravenous infuse TQB2102 injection every three weeks, 21 days as a treatment cycle. (1.5mg/kg, 3mg/kg, 4.5mg/kg, 6mg/kg, 7.5mg/kg, 9mg/kg)
62666856|NCT00714038||1|Patients with asthma in primary care
62666857|NCT04379115|ACTIVE_COMPARATOR|Active (tDCS) + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS)
62666858|NCT04379115|SHAM_COMPARATOR|Sham (tDCS) + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
62666859|NCT02478502|EXPERIMENTAL|Cabazitaxel (single arm study)|Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)
62666860|NCT01343914||Cohort|
62666861|NCT01351558|NO_INTERVENTION|Control|No intervention for 12 weeks
61912964|NCT02639858|EXPERIMENTAL|Docetaxel-PM|Docetaxel-PM 75mg/m2 IV infusion
62104768|NCT00777556|EXPERIMENTAL|DR-104|One tablet for emergency contraception
62104769|NCT02072005||Regular cigarette smokers|
62104770|NCT01909232|EXPERIMENTAL|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
62104771|NCT01909232|SHAM_COMPARATOR|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
62104772|NCT02900365|EXPERIMENTAL|Early cataract surgery group|"Eyes which presented with cataract and underwent surgery within 1 week were included in the early procedure group. They underwent early cataract surgery \& IOL implantation"
62104773|NCT02900365|EXPERIMENTAL|Late cataract surgery group|"Eyes which presented with cataract and underwent surgery at least 1 month after trauma were included in the secondary procedure group.They underwent Late cataract surgery \& IOL implantation."
62104774|NCT01693965|OTHER|sputum samples|
62666862|NCT01351558|ACTIVE_COMPARATOR|Knee muscle strengthening exercises|
62666863|NCT01351558|ACTIVE_COMPARATOR|Upper extremity strengthening exercises|
62666864|NCT01351558|ACTIVE_COMPARATOR|Cardiovascular fitness exercises|
62666865|NCT03106805|EXPERIMENTAL|insertion by the end of the 4th week postpartum|
62104775|NCT06693817|OTHER|Vaginal Birth|Wireless monitoring system placed first for vaginal birth. 15-20 minutes later, the wired monitoring system is placed. Both systems stay in place for 2 hours.
62297269|NCT03501056|NO_INTERVENTION|conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62297270|NCT01838057||painPREMIER cohort|
62666866|NCT03106805|ACTIVE_COMPARATOR|insertion by the end of the 6th week postpartum|
62666867|NCT06272656||HCC Patients treated with TACE|HCC patients who have received initial diagnosis and treatment in our hospital and are planning to receive TACE.
62666868|NCT02464358|EXPERIMENTAL|IMB Intervention Group|"The IMB group received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, they received the following:~1. Additional educational content related to HPV, Cervical Cancer, and HPV vaccination,~2. Motivational content to help identify and problem-solve benefits and barriers to vaccination,~3. Skills-building content, including brief communication skills training and ways to access the vaccine."
62666869|NCT02464358|ACTIVE_COMPARATOR|Attention Control Group|The attention control group also received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, to maintain consistency with the treatment's presentation format, participants watched a set of short video clips encompassing aspects of women's general and sexual health.
61912965|NCT00773227|EXPERIMENTAL|1|All patients included
61912966|NCT04939506|EXPERIMENTAL|Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing|Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
61912967|NCT00571402|EXPERIMENTAL|FFT|Family-focused therapy (FFT) and pharmacotherapy for adolescents, a 21 session family psychoeducational interventio0n administered with best practice medication treatment
61912968|NCT00571402|ACTIVE_COMPARATOR|Echanced Care|Enhanced care (EC) and pharmacotherapy for adolescents
62104776|NCT06693817|OTHER|C-Section Birth|System placement randomized for C-section. One system placed first and the alternate placed immediately after. Both systems stay in place for 2 hours.
62297271|NCT01838057||Control cohort|
62297272|NCT02883699|ACTIVE_COMPARATOR|Endurance Training Group 1|Standard endurance training
62297273|NCT02883699|EXPERIMENTAL|Endurance Training Group 2|Polarized endurance training
62297274|NCT02883699|ACTIVE_COMPARATOR|Resistance Training Group 1|Standard resistance training
62297275|NCT02883699|EXPERIMENTAL|Resistance Training Group 2|Daily undulating periodization resistance training
62297276|NCT03422484||People with at least one medication error|People with at least one medication error at hospital admission
62666870|NCT01993303||Single Cohort|Population: 19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male. Radionuclide Dosage: Rb-82 doses were rest 53+/-5 mCi and stress 53+/-6 mCi All were stress with Dipyridamole.
62104777|NCT04558996||OBS COVID 3|"Objective/s The purpose of this study was to test if pregnant patients with COVID-19 have more obstetrical morbidity than those non-infected.~* Determine the variables that are associated with more maternal and neonatal morbidity.~* Quantify the risk of adverse pregnancy outcomes (e.g., miscarriage, stillbirth, growth restriction) and neonatal outcomes (e.g., NICU, prematurity, death, birth defects).~Design Longitudinal cohort case study to quantify the obstetrical and perinatal morbi-mortality throughout all hospitals in Spain with a universal, consecutive PCR based screening program.~Recruitment: 1st March 2020 to 30 September 2020. Spanish sites collected in Appendix 1."
62104778|NCT04558996||OBS COVID 4|Substudy 4. Epidemiological prevalence study Objective/s Determine the prevalence of SARS_COV2 infection in Spanish pregnant women Design Cross-sectional study. The nQuery Advisor Release 7.0 software was used to calculate the sample size, based on the available data. As we do not have data on the prevalence of COVID-19, we set an expected percentage of 50% (a situation that maximizes the sample size) of asymptomatic women during delivery. We determined the sample size for a COVID-19 delivery prevalence study with an expected prevalence of 50%, a 95% confidence level and 5% accuracy, resulting in a sample size of 1056 pregnant women.
62104779|NCT06189742|NO_INTERVENTION|Non-allergic Participants|
62104780|NCT06189742|EXPERIMENTAL|Allergic Participants|
62104781|NCT04243343|EXPERIMENTAL|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program.
62104782|NCT04243343|ACTIVE_COMPARATOR|Standard of care|Standard of care prescribed home exercise program.
62104783|NCT02017106|EXPERIMENTAL|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
62104784|NCT02017106|ACTIVE_COMPARATOR|Sequential Phlebectomies|Endovenous laser ablation only
62104785|NCT02633189|EXPERIMENTAL|erlotinib and bevacizumab|
62104786|NCT02633189|ACTIVE_COMPARATOR|erlotinib|
62104787|NCT04088188|EXPERIMENTAL|Arm A (ivosidenib, cisplatin, gemcitabine)|Patients receive ivosidenib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62104788|NCT04088188|EXPERIMENTAL|Arm B (pemigatinib, cisplatin, gemcitabine)|Patients receive pemigatinib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62297277|NCT03422484||People without medication error at hospital admission|People without medication error at hospital admission
61912969|NCT03615508|OTHER|10% phenylephrine|All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
62666871|NCT04801693|EXPERIMENTAL|BI 1819479|single rising doses (SRD) part
62104789|NCT03412942|OTHER|Treatment with FISH device|Vascular closure to be performed with FISH device.
61912970|NCT03718975|EXPERIMENTAL|Successor of Phonak Audéo B90|The successor of the Phonak Audéo B90 is a Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
61912971|NCT03718975|ACTIVE_COMPARATOR|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
61912972|NCT00400296|EXPERIMENTAL|1|
62104790|NCT06068166|EXPERIMENTAL|GDMT plus TEA|"The patients received maximally tolerated guideline-directed medical therapy (GDMT) plus TEA.~Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures."
62104791|NCT06068166|ACTIVE_COMPARATOR|GDMT|The patients received maximally tolerated GDMT.
62104792|NCT02175537|EXPERIMENTAL|Microclinic social induction training|BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors.
62104793|NCT02175537|NO_INTERVENTION|Controls|Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm
62104794|NCT03761784|EXPERIMENTAL|S6G5T-3|Participants will topically apply S6G5T-3 cream, once daily to face for 12 weeks.
62104795|NCT03761784|PLACEBO_COMPARATOR|S6G5T-8 Vehicle Cream|Participants will topically apply S6G5T-8 vehicle cream, once daily to face for 12 weeks.
61912973|NCT02602678|EXPERIMENTAL|PRONE-Supine|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
61912974|NCT02602678|EXPERIMENTAL|SUPINE - Prone|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
61912975|NCT00203008||Observational procedure|Patients will be examined and any suspicious skin abnormalities will be biopsied
62297278|NCT06326944|ACTIVE_COMPARATOR|Group A|Patients will receive fascia transversalis block
62297279|NCT06326944|ACTIVE_COMPARATOR|Group B|Patients will receive Transversus abdominus plane block
62297280|NCT04093830|EXPERIMENTAL|pre-lingually deafened children with cochlear implant|pre-lingually deafened children with cochlear implant who continuously used bimodal hearing.
62297281|NCT03494283||CrossFit injuries|
62297282|NCT04776850|EXPERIMENTAL|Treatment (PTIS, HCT)|See Detailed Description.
61912976|NCT01086839|EXPERIMENTAL|sodium chloride 6%|"Cross-Over! experimental (days 1 - 28), then Wash-Out (28 days),then placebo comparator (days 57 - 85)."
62297283|NCT00592683|ACTIVE_COMPARATOR|Aripiprazole plus Fish Oil|Subjects administered aripiprazole and randomized to receive fish oil
62297284|NCT00592683|PLACEBO_COMPARATOR|Aripiprazole plus Placebo|Subjects administered aripiprazole and randomized to receive placebo
62297285|NCT00249379|EXPERIMENTAL|Acamprosate|Subjects randomized to receive acamprosate
62297286|NCT00249379|NO_INTERVENTION|No medication|No medication intervention (subjects do not receive acamprosate), but do receive Building Social Networks counseling
62297287|NCT01299025|NO_INTERVENTION|Control|Participants allocated as controls receive no treatment. They may be physically active as usual.
62666872|NCT04801693|PLACEBO_COMPARATOR|Placebo|Single rising doses (SRD) part
62297288|NCT01299025|EXPERIMENTAL|Training with Nintendo Wii Fit|Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week
62297289|NCT05991024||The primary group|"Patients diagnosed with incisional hernia in our hospital's electronic medical record system were divided into two groups: primary group and recurrent group based on whether the incisional hernia recurred after incisional hernia repair,who were screened out with abdominal wall incisional hernia."
62297290|NCT05991024||The recurrent group|"Patients diagnosed with incisional hernia in our hospital's electronic medical record system were divided into two groups: primary group and recurrent group based on whether the incisional hernia recurred after incisional hernia repair,who were screened out with abdominal wall incisional hernia."
62297291|NCT02210156|PLACEBO_COMPARATOR|Placebo|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
62666873|NCT04801693|EXPERIMENTAL|BI 1819479 fed - fasted arm|Food effect part
62666874|NCT04801693|EXPERIMENTAL|BI 1819479 fasted - fed arm|Food effect part
62666875|NCT02466542|PLACEBO_COMPARATOR|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
62666876|NCT02466542|ACTIVE_COMPARATOR|Esmolol group|Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
62297292|NCT02210156|EXPERIMENTAL|Omniplus Supreme|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
62666877|NCT02324322|EXPERIMENTAL|Exoskeleton training|"To examine the effectiveness of robotic exoskeleton-assisted over ground walking (5 hrs. p/wk, 100 sessions, 20 wks = 100 hrs) to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI. Combined with our current training protocol where people step 1500-2000/session we predict that the 2,000 lower extremity muscle contractions will be sufficient in our proposed exoskeletal study.~MRI's will be performed to accurately assess muscle CSA of each lower limb to determine individual's muscle thigh and shank volume.~Muscle Biopsies for the quadricep muscle will be performed to determine changes in BMD and bone structure due to intensive exoskeleton assisted walking."
62666878|NCT05957523|EXPERIMENTAL|Group A (high-frequency group )|Subjects aged 18 to 45 years and in good health agree to participate in the clinical trial and sign an informed consent form. The high-frequency remote ischemic preconditioning (RIPC) group will undergo RIPC training continuously for seven days, twice daily, with each session consisting of four cycles of 5 minutes of ischemia followed by 5 minutes of reperfusion.
62666879|NCT05957523|EXPERIMENTAL|Group B (low-frequency group )|Subjects aged 18 to 45 years and in good health agree to participate in the clinical trial and sign an informed consent form. The low-frequency RIPC group will follow the same cycle and compression pattern but will train only once a day.
62297293|NCT05327062|EXPERIMENTAL|CRT implantation guided by XSpline|The sample size estimation was based on two recent studies including CRT patients with similar clinical and demographic characteristics as in this study: the SMART-MSP and the SMART CRT. The SMART-MSP is a prospective, observational study that enrolled 584 CRT recipients at 52 US sites. In a typical modern CRT population, 75% of patients had a reduction of the end-systolic volume ≥ 15% at 6-month follow-up. The SMART-CRT study enrolled 699 CRT patients randomized to a treatment arm and a control group. At 6-months follow-up, a reduction of LVESV ≥15% was achieved for 67.7% of the patients in the control group and for 74.8% of those in the treatment arm. Therefore, it is assumed that in a modern CRT population at least 70% of the patients will have a reduction of the LVESV ≥15% of the baseline value at 6-months after CRT implantation. To demonstrate that this proportion of patients can be equally achieved with the approach tested in this study at least 150 patients need to be included.
62666880|NCT06529705|EXPERIMENTAL|Adults with diabetes treated by MDI|
62297294|NCT05116657||SARS-CoV2 OSA|Patients will be recruited from both Post-COVID19 and Sleep Clinics run through Beaumont Hospital, Beaumont, Dublin, Ireland. This will allow for the recruitment of patients with and without a history of SARS-CoV-2 infection.
62297295|NCT05116657||Non-SARS-CoV2 OSA|Patients will be recruited from both Post-COVID19 and Sleep Clinics run through Beaumont Hospital, Beaumont, Dublin, Ireland. This will allow for the recruitment of patients with and without a history of SARS-CoV-2 infection.
62297296|NCT05657262|EXPERIMENTAL|experimental group|The experiment group will be applied with the Z technique. While applying the medicine with the Z technique, the tissue will be lifted with the thumb and forefinger of the left hand and pulled to the right, and the medicine will be slowly applied after the injector needle enters the tissue. When the application is finished, first the injector will be withdrawn, then the tissue will be released and the tissues will be restored (Altun, 2018).
62666881|NCT05675085|OTHER|RIBBS arm|This clinical trial is a single-arm study in which asymptomatic 45-year-old women undergo a triple screening test: (1) two-view tomosynthesis of both breasts; (2) calculation of volumetric breast density (VBD); (3) assessment of breast cancer risk using the Tyrer-Cuzick model. Mean VBD and lifetime risk (LTR) are used to determine the type of imaging and frequency of subsequent screening cycles.
62666882|NCT03745781|EXPERIMENTAL|open-label placebo|open-label placebo
62666883|NCT03745781|NO_INTERVENTION|treatment as usual|
62737212|NCT03569449|EXPERIMENTAL|Group 7- Cat|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and individually-tailored visits
62297297|NCT05657262|OTHER|Control group|In the control group, the vaccine will be administered slowly with the standard technique.
62297298|NCT02786069|EXPERIMENTAL|Single arm|
62104796|NCT06630507||ECC staff receiving educational module|Active healthcare providers (including emergency medicine physicians, nurse practitioners, physician assistants, and residents, as well as nurses, multi-skilled technicians, and paramedics) in the SMH-Sarasota ECC will fill out the initial surveys, complete the implicit bias education, and do the posttest (re-administer the Measuring Change in Overcoming Implicit Biases in Behavior by Emergency Medicine Personnel questionnaire).
62104797|NCT06630507||ECC staff not receiving educational module|"Active healthcare providers (including emergency medicine physicians, nurse practitioners, physician assistants, and residents, as well as nurses, multi-skilled technicians, and paramedics) in the SMH-Venice ECC will fill out the initial surveys and do the posttest (re-administer the Measuring Change in Overcoming Implicit Biases in Behavior by Emergency Medicine Personnel questionnaire).~Once all data is collected from both groups, the Venice Campus ECC will be given the ECC implicit bias education."
62104798|NCT02888509||healthy control|Well mathed with patients in age, gender, education
62104799|NCT02888509||major depression disorder|patients with major depression disorder
62104800|NCT02888509||anxiety disorder|patients with anxiety disorder
62104801|NCT02888509||bipolar depression disorder|patients with bilopar depression disorder
62104802|NCT06628518|EXPERIMENTAL|FAmily oriented Mindfulness informed Legal Education (FAMiLE)|The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a four sessions intervention lasting approximately 90 minutes each. A session will be delivered weekly for 4 weeks.
62104803|NCT06628518|NO_INTERVENTION|Control - Waitlist Group|The control group will not receive an intervention until after the assessment periods at baseline, end of intervention and 3 months follow up before they will be administered the FAMiLE intervention.
62104804|NCT03620929|EXPERIMENTAL|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
62104805|NCT03620929|NO_INTERVENTION|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
61912977|NCT01086839|PLACEBO_COMPARATOR|sodium chloride 0,9%|"Cross-Over! placebo comparator (days 1 - 28), then Wash-Out (28 days),then experimental (days 57 - 85)."
62104806|NCT03352388|EXPERIMENTAL|Snack|Dairy- and berry-based snacks
62104807|NCT03352388|NO_INTERVENTION|Reference|No snacks
62104808|NCT04783181|EXPERIMENTAL|Dose Level 1|BBP-631 lowest dose, administered once, intravenously (IV)
62104809|NCT04783181|EXPERIMENTAL|Dose Level 2|BBP-631 middle dose, administered once, IV
62104810|NCT04783181|EXPERIMENTAL|Dose Level 3|BBP-631, high dose, administered once, IV
62666884|NCT03901209|EXPERIMENTAL|Laser osteotomy|The planned mid-face osteotomy (e.g. LeFort I) is performed using the CARLO osteotomy device, where a patient-specific intervention plan based on preoperative imaging is loaded on the system to allow the device to show and suggest a location for the osteotomy.
62104811|NCT04783181|EXPERIMENTAL|Dose Level 4|BBP-631, highest dose, administered once, IV
62104812|NCT05819190|EXPERIMENTAL|Healsea Rescue* group|Subjects will receive Healsea Rescue\* according to its intended use.
62104813|NCT05819190|PLACEBO_COMPARATOR|Placebo group|Subjects will receive Placebo according to identical posology, instructions for use, contraindication, precaution of use and labelling to those of Healsea Rescue.
62104814|NCT05080192||Fenofibrate recipients|Approximately 20 subjects who were randomized to the Fenofibrate arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
62104815|NCT05080192||Placebo recipients|Approximately 20 subjects who were randomized to the placebo arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
62104816|NCT02592837|EXPERIMENTAL|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
62104817|NCT02592837|ACTIVE_COMPARATOR|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
62104818|NCT06609928|EXPERIMENTAL|Treatment (FH-FOLR1 CAR T)|Patients undergo apheresis to obtain T cells for product manufacturing. Patients receive lymphodepleting chemotherapy with fludarabine IV on days -4 to -1 and cyclophosphamide IV on days -4 and -3. Patients receive FH-FOLR1 CAR T IV on day 0. Patients undergo ECHO at screening, undergo collection of CSF and blood samples and bone marrow aspiration/biopsy throughout the study, and may undergo PET scan on study and during follow up.
62297299|NCT06458764||Patients|
61912978|NCT05542745|ACTIVE_COMPARATOR|palatal retractor|palatal retraction
61912979|NCT05542745|ACTIVE_COMPARATOR|buccal retractor|buccal retraction
62104819|NCT01043549|ACTIVE_COMPARATOR|Stimulation|Repetitive transcranial stimulation of the posterior parietal cortex
62104820|NCT01043549|SHAM_COMPARATOR|Sham stimulation|
62104821|NCT01270789|EXPERIMENTAL|Liraglutide|
62104822|NCT01270789|PLACEBO_COMPARATOR|Placebo|
62297300|NCT06458764||Controls|
62666885|NCT02966925|EXPERIMENTAL|Treatment with Cellular Matrix|Patients will be treated with a combination of PRP/HA prepared with Cellular Matrix BCT-HA Kit
62666886|NCT05345587|EXPERIMENTAL|Prolife group|scheduled consultation with the hospital clinical pharmacist, therapeutic follow-up and collection of clinical information by the patient via the THESS monitoring system
62666887|NCT05345587|NO_INTERVENTION|Standard care|
62666888|NCT05388175|EXPERIMENTAL|Less invasive surfactant administration (LISA) with a rigid catheter|Participants will simulate the procedure of surfactant administration by using a rigid catheter
62104823|NCT03354533|OTHER|Treatment with ORL-1F - L-fucose|
62666889|NCT05388175|ACTIVE_COMPARATOR|Less invasive surfactant administration (LISA) with a soft catheter|Participants will simulate the procedure of surfactant administration by using a soft catheter
62104824|NCT04806919|NO_INTERVENTION|Control group: Amelgen ® 400 mg BID|Continue daily dose progesteron
62666890|NCT02702310||Quality of Life/ Grading Skin Findings|Patients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
62666891|NCT05390554|EXPERIMENTAL|Buteyko Breathing Technique|single group pre-post test
62104825|NCT04806919|EXPERIMENTAL|Intervention group: Amelgen ® 400 mg TID|Increase daily progesteron dose
62104826|NCT03901729|EXPERIMENTAL|Arm 1|BAY1753011 30mg in addition to standard of care (SoC) for part A and part B
62104827|NCT03901729|PLACEBO_COMPARATOR|Arm 2|Placebo of BAY1753011 in addition to SoC for part A and part B
62104828|NCT03901729|EXPERIMENTAL|Arm 1-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
62666892|NCT05549245|EXPERIMENTAL|High-flow Nasal Cannula Oxygen Therapy group|
62666893|NCT05549245|OTHER|Continues Positive Airway Pressure group|
62308292|NCT02572037||Group I|Penile sensory hyperexcitability: Latencies of GPSEP and/or DNSEP of them are abnormal. They will receive treatment of Compound Lidocaine Cream-a kind of local anaesthetics that is widely used to treat PE.
62666894|NCT02744768|EXPERIMENTAL|Treatment|"Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31.~HLA typing will be performed immediately after the diagnosis for eligible patients.~MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation."
62666895|NCT03939832|ACTIVE_COMPARATOR|FiO2 0.5|
62666896|NCT03939832|ACTIVE_COMPARATOR|FiO2 1.0|
62104829|NCT03901729|ACTIVE_COMPARATOR|Arm 1-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
62666897|NCT02004171|EXPERIMENTAL|electronic cigarette|electronic cigarette 24mg cartridges; 1-2 cartridges daily
62666898|NCT02004171|ACTIVE_COMPARATOR|nicotine inhaler|nicotine inhaler 10mg cartridge; max 16 cartridges daily
62666899|NCT00346528|EXPERIMENTAL|NGOIS|
62308293|NCT02572037||Group II|Sympathetic hyperexcitability: Latency of PSSR are abnormal.They will be treated with Dapoxetine(Priligy)-a kind of selective serotonin reuptake inhibitor(SSRI) which has been shown effective to PE.
62308294|NCT02572037||Group III|Mixed type: Both Latencies of GPSEP and/or DNSEP and Latency of PSSR are abnormal.They will receive both Compound Lidocaine Cream and Dapoxetine.
62666900|NCT00346528|ACTIVE_COMPARATOR|BSS Plus|
62666901|NCT05430295|ACTIVE_COMPARATOR|Eyhance intraocular lens|10 patients bilaterally implanted with Eyhance intraocular lens
62666902|NCT05430295|ACTIVE_COMPARATOR|Tecnis 1 piece intraocular lens|10 patients bilaterally implanted with Tecnis 1 piece intraocular lens
62104830|NCT03901729|EXPERIMENTAL|Arm 2-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
62104831|NCT03901729|ACTIVE_COMPARATOR|Arm 2-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
62666903|NCT03549260|EXPERIMENTAL|LIB003 150 mg or matching placebo|SC LIB003 150 mg or placebo every 4 weeks
62666904|NCT03549260|EXPERIMENTAL|LIB003 300 mg or matching placebo|SC LIB003 300 mg or placebo every 4 weeks
62666905|NCT03549260|EXPERIMENTAL|LIB003 350 mg or matching placebo|SC LIB003 350 mg or placebo every 4 weeks
62666906|NCT06268119|NO_INTERVENTION|Control group (standard clinical care)|Control group receiving standard care administered by doctors and nurses for delirium management in the intensive care unit
62666907|NCT06268119|EXPERIMENTAL|Intervention group (care with protocol)|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
62666908|NCT03274661|EXPERIMENTAL|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
62666909|NCT05206539|EXPERIMENTAL|SAP11-4 group (Gr CR)|The Gr CR will receive treatment with Curodont RepairTM (Credentis; Windisch, Switzerland), according to the manufacturer's instructions.
62666910|NCT05206539|ACTIVE_COMPARATOR|CPP-ACFP group (Gr V)|The Gr V will receive treatment with MI varnishTM (GC Corporation, Tokyo, Japan), according to the manufacturer's instructions.
62104832|NCT05837780|EXPERIMENTAL|conventionally constructed nasoalveolar molding devices (control group)|control group: patients receiving conventionally constructed nasoalveolar molding devices
62104833|NCT05837780|EXPERIMENTAL|Digitally constructed nasoalveolar molding devices (test group)|test group: patients receiving digitally constructed nasoalveolar molding devices
62104834|NCT03881657|EXPERIMENTAL|Intervention Group|The intervention group received a reverse colocated integrated behavioral health intervention or usual care
62104835|NCT03881657|ACTIVE_COMPARATOR|Control Group|The control group received behavioral health services only (usual care)
62104836|NCT05333887|EXPERIMENTAL|PFC+|In this condition, therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support.
62104837|NCT05333887|NO_INTERVENTION|Waitlist|In this condition, parents are placed on a waitlist where they continue life as usual. After the waitlist they participate in the PFC+ program.
62104838|NCT03722446|OTHER|Arrow Catheter Kit.|Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
62308295|NCT02572037||Group IV|Others: Both Latencies of GPSEP, DNSEP and Latency of PSSR are normal.They will receive further tests. (This group is not the main objects to be observed in this study.)
62666911|NCT05206539|ACTIVE_COMPARATOR|Resin infiltration group (Gr I)|The Gr I receive treatment with Icon Vestibular (DMG, Germany), according to the manufacturer's instructions.
62104839|NCT03722446|OTHER|B.Braun Catheter Kit|Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
62104840|NCT01025583|ACTIVE_COMPARATOR|group 1 (standard ORS)|Children with acute diarrhea receive standard hypotonic ORS.
62104841|NCT01025583|ACTIVE_COMPARATOR|Group 2 (hypotonic super-ORS)|Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
62104842|NCT03136263|EXPERIMENTAL|Drug order: Oxytocin - placebo|
62104843|NCT03136263|EXPERIMENTAL|Drug order: Placebo - oxytocin|
62104844|NCT05487703||Clinical characteristics|clinical characteristics of adult patients with Rheumatoid Arthritis (RA) initiating tofacitinib
62104845|NCT03105128|EXPERIMENTAL|Risankizumab Dose 1 (Period 1)|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
62104846|NCT03105128|EXPERIMENTAL|Risankizumab Dose 2 (Period 1)|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
62104847|NCT03105128|PLACEBO_COMPARATOR|Placebo (Period 1)|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
62104848|NCT03105128|EXPERIMENTAL|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
62104849|NCT03105128|EXPERIMENTAL|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
62104850|NCT03105128|EXPERIMENTAL|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
62104851|NCT03545217|EXPERIMENTAL|intervention group|
62666912|NCT05206539|PLACEBO_COMPARATOR|Control group (Gr NT)|The control group (Gr NT) receive no intervention except brushing twice daily with aminofluoride toothpaste and toothbrush provided by researcher.
62666913|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
62666914|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
62666915|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
62104852|NCT03545217|NO_INTERVENTION|control group|
62104853|NCT02956499|EXPERIMENTAL|Cohort 1|single intravenous dose
62104854|NCT02956499|EXPERIMENTAL|Cohort 2|single intravenous dose
62104855|NCT02956499|EXPERIMENTAL|Cohort 3|single intravenous dose
62104856|NCT02956499|EXPERIMENTAL|Cohort 4|single intravenous dose
62104857|NCT02956499|EXPERIMENTAL|Cohort 5|single intravenous dose
62104858|NCT02956499|EXPERIMENTAL|Cohort 6|single intravenous dose
62104859|NCT02956499|EXPERIMENTAL|Cohort 7|multiple intravenous doses
62104860|NCT02956499|EXPERIMENTAL|Cohort 8|multiple intravenous doses
62104861|NCT02956499|EXPERIMENTAL|Cohort 9|multiple intravenous doses
62104862|NCT02956499|EXPERIMENTAL|Cohort 10|multiple intravenous doses
62104863|NCT06165731|EXPERIMENTAL|Diaphragmatic Breathing Exercise (DB)|Participants will undergo a total of 10 minutes of at-home diaphragmatic breathing exercises (5 minutes in the morning and 5 minutes in the evening) with the practice of standard bladder hygiene recommendations. Participants will exercise daily for a total of 4 weeks and complete daily exercise logs.
62104864|NCT06165731|ACTIVE_COMPARATOR|Educational Handout (EH)|Participants assigned to this group will participate in the usual standard care of bladder hygiene, which will include common practices of timed voiding, reduction in constipation, avoidance of bladder irritants, daily recommended aerobic exercise, adequate hydration, and appropriate perineal hygiene. Participants will practice standard bladder hygiene recommendations daily for a total of 4 weeks.
62104865|NCT06356584|EXPERIMENTAL|Immunotherapy plus targert therapy|Sintilimab combined with fruquintinib/regorafenib ± radiotherapy (based on the presence of liver metastases).
62104866|NCT06356584|NO_INTERVENTION|Target therapy|fruquintinib/regorafenib
62104867|NCT04272073|ACTIVE_COMPARATOR|Standard Care|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
62468748|NCT03680248|EXPERIMENTAL|Healthy subjects, Fat+Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration
62666916|NCT00927082|EXPERIMENTAL|PEG-IFN 90mcg 24 Wks|Participants received Pegasys (Pegylated interferon alfa-2a \[PEG-IFN\]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.
62666917|NCT00927082|EXPERIMENTAL|PEG-IFN 180mcg 24 Wks|Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.
62666918|NCT00927082|EXPERIMENTAL|PEG-IFN 90mcg 48 Wks|Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
62104868|NCT04272073|EXPERIMENTAL|High-Protein mediterranean Diet and Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet~* eating more fruit and vegetables,~* reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),~* replacing butter and margarine by olive oil as the main culinary fat,~* reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 dairy-based protein shakes to consume each day)."
62104869|NCT02989012|EXPERIMENTAL|Drugs for experimental group|GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
62104870|NCT02989012|SHAM_COMPARATOR|Drugs for control group|Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
62104871|NCT06117254|ACTIVE_COMPARATOR|Communication Counseling|Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including tips on environmental modification and communication repair strategies.
62104872|NCT06117254|EXPERIMENTAL|Hearing Aids|Individuals randomized to this group will receive communication counseling as well as hearing aids set to provide a low level of amplification.
62104873|NCT06117254|EXPERIMENTAL|Hearing Aids with Remote Microphones|Individuals randomized to this group will receive communication counseling as well as hearing aids set to provide a low level of amplification and remote microphones that can be used in some situations to improve the signal-to-noise ratio.
62104874|NCT05831280|EXPERIMENTAL|Experimantal Group|In the study, 8 sessions of laughter yoga will be applied to the women in the experimental group twice a week for 4 weeks.
62104875|NCT05831280|NO_INTERVENTION|Control Group|no intervention will be applied to the control group
62104876|NCT01430702|EXPERIMENTAL|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
62308296|NCT01215539|EXPERIMENTAL|Panitumumab,capecitabine,oxaliplatin|"Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg.~Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 Capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14"
62468749|NCT03680248|EXPERIMENTAL|Steatosis, Fat+Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration
62468750|NCT03680248|EXPERIMENTAL|Healthy subjects, Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration
62468751|NCT03680248|EXPERIMENTAL|Steatosis, Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration
62468752|NCT03680248|EXPERIMENTAL|Healthy subjects, Fat+Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration
62468753|NCT03680248|EXPERIMENTAL|Steatosis, Fat+Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration
62468754|NCT03680248|EXPERIMENTAL|Healthy subjects, Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration
62468755|NCT03680248|EXPERIMENTAL|Steatosis, Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration
62468756|NCT03585790|OTHER|Multifocal Optics first, then Single Vision Optics|First Intervention (1 week) Second Intervention (1 week)
62468757|NCT03585790|OTHER|Single Vision Optics first, then Multifocal Optics|First Intervention (1 week) Second Intervention (1 week)
62468758|NCT02452164|ACTIVE_COMPARATOR|Teaching group|Parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals at the first study visit.
62468759|NCT02452164|OTHER|Control group|Families receive the cellphone otoscope as if they had bought it themselves from the internet. After the first study week, parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals.
62468760|NCT05013372|OTHER|Dose-escalation|Dose -1：0.1×10E+6/kg Dose 1：0.25×10E+6/kg Dose 2：0.5×10E+6/kg Dose 3：1.0×10E+6/kg Dose 4：2.0×10E+6/kg
62468761|NCT02495415|EXPERIMENTAL|Fenretinide emulsion|Patients enrolled will receive 600 mg fenretinide/m2/day on Day 1, followed by 1200 mg fenretinide/m2/day on Days 2 - 5 as a continuous intravenous infusion via central line over 5 days. Cycles are repeated every 3 weeks.
62468762|NCT03388671|ACTIVE_COMPARATOR|TAB Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Transversus abdominis plane block.
61912980|NCT02386670|EXPERIMENTAL|tDCS + CR|"Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions promotes transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
61912981|NCT02386670|SHAM_COMPARATOR|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
61912982|NCT02723071|EXPERIMENTAL|Cohort A: Ocrelizumab 200 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 200 milligram per square meter (mg/m\^2) given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
61912983|NCT02723071|EXPERIMENTAL|Cohort B: Ocrelizumab 375 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 375 mg/m\^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
61912984|NCT02723071|EXPERIMENTAL|Cohort C: Ocrelizumab 375/750 mg/m^2|Participants will receive first infusion of ocrelizumab 375 mg/m\^2 followed by 7 infusions of 750 mg/m\^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
61912985|NCT06036147|EXPERIMENTAL|Pathway 1|All interventions: cf-CBT, PST \& CM
61912986|NCT06036147|EXPERIMENTAL|Pathway 2|cf-CBT \& PST
61912987|NCT06036147|EXPERIMENTAL|Pathway 3|cf-CBT \& CM
61912988|NCT06036147|EXPERIMENTAL|Pathway 4|cf-CBT only
61912989|NCT06036147|EXPERIMENTAL|Pathway 5|PST \& CM
61912990|NCT06036147|EXPERIMENTAL|Pathway 6|PST only
61912991|NCT06036147|EXPERIMENTAL|Pathway 7|CM only
61912992|NCT06036147|NO_INTERVENTION|Pathway 8|No interventions
61912993|NCT00498667||PET/CT|all patients with aggressive lymphoma who had a baseline and interim pet/ct study
61912994|NCT00646243||1 Heart Failure|216 consecutive consenting patients with refractory heart failure candidate to cardiac resynchronization therapy by clinical and electrocardiographic criteria
61912995|NCT00646243||2 Healthy subjects|120 healthy subject includes defined as absence of history and symptoms of any cardiovascular disease, normal physical examination and ECG.
61912996|NCT04825353|EXPERIMENTAL|ECIRS-Group|
61912997|NCT04825353|ACTIVE_COMPARATOR|SPCNL-GRoup|
61912998|NCT04353804|EXPERIMENTAL|Computerized Cognitive Rehabilitation|Computerized Cognitive Rehabilitation
61912999|NCT04353804|ACTIVE_COMPARATOR|Active Control computer games|Active Control computer games
61913000|NCT05671809||NCRT with surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is NCRT with surgery.
61913001|NCT05671809||NCT with surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is NCT with surgery.
62468763|NCT03388671|ACTIVE_COMPARATOR|Psoas Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided psoas block.
61913002|NCT05671809||surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is surgery.
61913003|NCT01382147|EXPERIMENTAL|S-HAM|S-HAM (S-HAMescalated for younger patients and S-HAMbasis for elderly patients)
62468764|NCT03666728|EXPERIMENTAL|SHR-1210+BP102|Subjects receive SHR-1210 200 mg and BP102 15 mg/kg in day 1 intravenously every 3 weeks, until disease progression or unacceptable toxicity.
62468765|NCT03682341||Group A|Patients with ovarian endometriosis cyst
62468766|NCT03682341||Group B|Patients with ovarian teratoma cyst
62468767|NCT02994810|EXPERIMENTAL|Intervention group|Guidelines and review of the breastfeeding techniques.
62468768|NCT02994810|NO_INTERVENTION|Control group|The control group will receive home visits only when the baby is 6 months of life, they will be re-evaluated by the researchers as the practice of exclusive breastfeeding and the technical and nursing management, and will be asked about the main difficulties encountered in maintaining breastfeeding.
62468769|NCT02608788|ACTIVE_COMPARATOR|S.L.® & Difflam Forte ®|"1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg and 3.0 mg/ml Benzydamine ,Difflam Forte ® 5.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
61913004|NCT01382147|ACTIVE_COMPARATOR|TAD-HAM (younger) or HAM-HAM (elderly)|is TAD-9 - HAM for younger patients (with 2 mandatory induction cycles) and HAM (- HAM) for the elderly patients with the second HAM cycle only applied in the case of inadequate blast clearance (\> 5%) in the day 16 bone marrow aspirate
61913005|NCT01987921||Pediatric Intensive Care Unit Patients|All patients will be included in a single cohort initially (admission to the PICU) and then cohorted into groups based on development of severe AKI (Stage 2-3 KDIGO by either Cr or UOP criteria) within the first seven days, renal angina risk strata, medical admission diagnoses, and outcomes.
61913006|NCT04902300||Adolescent|adolescent attending high school
62468770|NCT02608788|PLACEBO_COMPARATOR|placebo ( for Acular® )|placebo(distilled water)spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
62468771|NCT02608788|ACTIVE_COMPARATOR|Acular® & S.L.®|"5％ Ketorolac Tromethamine , Acular® 8.0 mg and 1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
62666919|NCT00927082|EXPERIMENTAL|PEG-IFN 180mcg 48 Wks|Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
62104877|NCT05692258|EXPERIMENTAL|Acupuncture therapy + basic therapy|"Acupuncture treatment-Selected acupoints: Dazhui (GV14) , Feishu(BL13), Dingchuan(EX-B1), Tiantu(CV22), Danzhong(RN17), Quchi(LI11), Kongzui(LU6), Neiguan(PC6), Yinlingquan(SP9), Fenglong(ST40), Qihai(cv6). Once a day for 10 consecutive times.~Western medicine treatment (basic treatment) : According to the Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial 10th Edition) issued by the General Office of the National Health Commission and the General Department of the National Administration of Traditional Chinese Medicine, patients are arranged to be quarantined in hospitals for treatment. Conventional Western medicine treatment includes supportive treatment, antiviral therapy, immunotherapy, anticoagulant therapy, antibiotic therapy, etc."
62104878|NCT05692258|SHAM_COMPARATOR|sham acupuncture + basic therapy|sham acupuncture. Acupoint selection, body position, intervention time and course of treatment are the same as those in acupuncture treatment group. After acupoint disinfection, fixed pad is pasted on the acupoint, and 1.5 blunt needle will be used to Pierce directly through the sham instrument to fix pad to the skin surface without piercing the skin, and do not require Deqi. Western medicine treatment (basic treatment) is the same as the acupuncture group.
62297301|NCT04493164|EXPERIMENTAL|Treatment (CPX-351, ivosidenib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and ivosidenib PO QD on days 1-28. Patients who do not achieve complete remission may receive a second cycle of induction therapy in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission proceed to consolidation.~CONSOLIDATION: Patients receive CPX-351 IV over 90 minutes on days 1 and 3, and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ivosidenib PO QD for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who are experiencing clinical benefit and who have not experienced excessive toxicity after completion of 2 years of maintenance may be eligible to continue therapy after discussion with the principal investigator."
62297302|NCT02040142|EXPERIMENTAL|HIPEC + Mitomycin C|HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, will be administered into the inflow line of the perfusion circuit once target temperature is reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, will be administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period has elapsed, the perfusate will be drained into the waste reservoir. The peritoneal cavity will be rinsed/washed-out.
62297303|NCT04820270|EXPERIMENTAL|Autologous Tregs in allogenic islet transplantation|Autologous Tregs are given simultaneously to the patient with the islets
62468772|NCT02608788|EXPERIMENTAL|Difflam Forte ® & Acular®|"3.0 mg/ml Benzydamine , Difflam Forte ® 5.0 mg and 5％ Ketorolac Tromethamine Acular® 8.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
62666920|NCT04602000|EXPERIMENTAL|CT-P59 40 mg/kg group (Part 1)|CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
62666921|NCT04602000|EXPERIMENTAL|CT-P59 80 mg/kg group (Part 1)|CT-P59 (regdanvimab), 80 mg/kg by IV infusion once
62666922|NCT04602000|PLACEBO_COMPARATOR|Placebo group (Part 1)|Placebo, matching in volume of CT-P59 80 mg/kg by IV infusion once
62666923|NCT04602000|EXPERIMENTAL|CT-P59 40 mg/kg group (Part 2)|CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
62666924|NCT04602000|PLACEBO_COMPARATOR|Placebo group (Part 2)|Placebo, matching in volume of CT-P59 40 mg/kg by IV infusion once
62666925|NCT04845971|EXPERIMENTAL|Adult male and female patients who are hospitalized with COVID-19-induced pneumonia.|Eligible patients will be treated with Saisei MAF capsules stronger version, oral administration 2-3 capsules, 3 times per day, 30 minutes before food or in the morning, afternoon and before bed time. The treatment duration will be 21 days. Patients are also provided with nutritional supplementation of Vitamin D3, 10.000 IU per day, monitoring the blood levels of such a vitamin. Efficacy and safety assessments will be performed on Days 0, 7, 14, 21, and 28.
62666926|NCT01197235|EXPERIMENTAL|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
62666927|NCT01197235|PLACEBO_COMPARATOR|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
62666928|NCT02204735|EXPERIMENTAL|MORNING|Participants will be instructed to consume 50% of their energy intake in their first eating bout, 30% in their second eating bout, and 20% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 600 kcal in their first eating bout, 360 kcal in their second bout, and 240 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
62666929|NCT02204735|EXPERIMENTAL|EVENING|Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
62666930|NCT01540539|EXPERIMENTAL|Dosing cohort 1|
62666931|NCT01540539|EXPERIMENTAL|Dosing cohort 2|
62666932|NCT01540539|EXPERIMENTAL|Dosing cohort 3|
62666933|NCT01540539|EXPERIMENTAL|Dosing cohort 4|
62666934|NCT01540539|EXPERIMENTAL|Dosing cohort 5|
62666935|NCT01540539|EXPERIMENTAL|Dosing cohort 6|
62666936|NCT01540539|EXPERIMENTAL|Dosing cohort 7|
62666937|NCT01540539|EXPERIMENTAL|Dosing cohort 8|
62666938|NCT01124474|NO_INTERVENTION|Standard fluid management|Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
62666939|NCT01124474|OTHER|Vigileo model number MHM1|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.
62666940|NCT04094805|ACTIVE_COMPARATOR|Rocaltrol Combining HD-DXM|Rocaltrol 0.25 μg once per day, 1 month; HD-DXM (orally at 40 mg daily for 4d )
62666941|NCT04094805|ACTIVE_COMPARATOR|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
62666942|NCT04913636|EXPERIMENTAL|Test Group|
62666943|NCT04913636|SHAM_COMPARATOR|Control Group|
62666944|NCT00860925|EXPERIMENTAL|active clonidine and active ASA|
62666945|NCT00860925|EXPERIMENTAL|active clonidine and ASA placebo|
62666946|NCT00860925|EXPERIMENTAL|Clonidine placebo and active ASA|
62104879|NCT06631690|ACTIVE_COMPARATOR|Peroneus longus autograft group|"* Isokinetic dynamometer is a three multi-joint testing and rehabilitation device. It will be used to measure concentric peak torques of ankle planter flexor and eccentric peak torque of evertor~* The modified Star Excursion Balance Test will be used to evaluate the dynamic balance with a series of unilateral balance tests~* Single leg Stance (SLS) test to assess balance, especially when performed in a static position"
62104880|NCT06631690|ACTIVE_COMPARATOR|hamstring autograft group|"* Isokinetic dynamometer is a three multi-joint testing and rehabilitation device. It will be used to measure concentric peak torques of ankle planter flexor and eccentric peak torque of evertor~* The modified Star Excursion Balance Test will be used to evaluate the dynamic balance with a series of unilateral balance tests~* Single leg Stance (SLS) test to assess balance, especially when performed in a static position"
62104881|NCT06388109|EXPERIMENTAL|Immediate Start|Participants in the immediate start arm will download and begin use of the Positive Peers app at the enrollment visit.
62104882|NCT06388109|ACTIVE_COMPARATOR|Delayed Start|Participants in the delayed start arm will download and begin use of the Positive Peers app 6 months after enrollment
62104883|NCT06388109|NO_INTERVENTION|Observational Cohort|Participants in the observational cohort have declined participation in the clinical trial but agree to do the baseline survey and have medical outcomes data recorded.
62104884|NCT00145535|EXPERIMENTAL|1|Titanium sapphire laser treatment
62104885|NCT00145535|ACTIVE_COMPARATOR|2|Argon laser treatment
62104886|NCT02831114|EXPERIMENTAL|Intervention|The nine participants in the intervention arm will receive 18 acupuncture treatments over the course of 12 weeks (2 treatments per week for 6 weeks and 1 treatment per week for 6 weeks). They will undergo assessments at baseline, 6 weeks, and 12 weeks through the use of questionnaires and blood tests. The participants will also be allowed to continue their conventional therapy for TIPN.
62104887|NCT02831114|NO_INTERVENTION|Control|The nine participants in this arm will undergo the same assessments as the intervention arm at baseline, 6 weeks, and 12 weeks. They will not receive any acupuncture treatments during this time, but will be allowed to continue their conventional therapy. The control arm will be offered the same 18 acupuncture treatments after a wait of at least 12 weeks.
62104888|NCT00533039|PLACEBO_COMPARATOR|Control|Subjects take 2 tablets BID. Placebo tablets are identical to active medication.
62104889|NCT00533039|EXPERIMENTAL|Varespladib (A-002)|Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
62104890|NCT03771898|EXPERIMENTAL|SHP611|Participants will receive 150 milligrams (mg) of SHP611 intrathecally (IT) via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once weekly for 106 weeks in six groups (Group A, B, C, D, E, and F) based on participant's age and motor dysfunction.
62104891|NCT05181449|EXPERIMENTAL|Twin Precision Treatment (TPT)|Twin Precision Treatment (combination of AI and lifestyle coaching)
62104892|NCT05181449|NO_INTERVENTION|Usual Care (UC)|Usual care prescribed by Cleveland Clinic diabetes specialists and primary care physicians
62104893|NCT05115890|EXPERIMENTAL|Exercise training|Patients with HFpEF will participate in the 8 weeks of supervised, two-legged, knee extensor exercise training for 3 days per week. Each exercise session will involve a 5-min warm-up and a 5-min cool-down, and exercise intensity will range between 40%-90% of maximal work rate. Maximal work rate will be re-assessed every two weeks.
62297304|NCT04702737|EXPERIMENTAL|Part 1: Dose Exploration|The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.
62104894|NCT06630403||Children with Bronchiectasis Experiment Group|"Children with bronchiectasis Participants will be required to sign an informed consent form before the evaluation.~Assesment Methods:~1. Demographic data will be collected verbally.~2. The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.~3. Pulmonary Function Test will be applied.~4. Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.~5. Functional capacity of the patient will be evaluated with the 6 Minute Walk Test.~6. Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea.~7. Quality of life will be assessed with the Quality of Life Scale for Children.~8. Fear of movement will be assessed with the Tampa Kinesiophobia Scale.~9. Motor Imagery ability will be assessed with the Movement Imagery Questionnaire-3, Vividness of Movement Imagery.~10. Cognitive functions will be assessed with Trail Making Test and Stroop Test."
62104895|NCT06630403||Healthy Controls|"Healthy Peers~Participants will be required to sign an informed consent form before the evaluation.~Assessment Methods:~1. Demographic data (age, height, weight, BMI) will be collected verbally via the assessment form.~2. Pulmonary Function Test will be applied.~3. Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.~4. Functional capacity of the patient will be evaluated with the 6 Minute Walk Test.~5. Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea.~6. Quality of life will be assessed with the Quality of Life Scale for Children.~7. Fear of movement will be assessed with the Tampa Kinesiophobia Scale.~8. Motor Imagery ability will be assessed with the Movement Imagery Questionnaire-3, Vividness of Movement Imagery.~9. Cognitive functions will be assessed with Trail Making Test and Stroop Test."
62297305|NCT04702737|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive the RP2D/MTD identified in Part 1 (dose exploration) of the study.
62297306|NCT00321516|EXPERIMENTAL|1|
62297307|NCT04079023||Obese|30 obese patients (12 M/ 18 F) with a mean BMI of 46 candidate to SG Alcohol drink mean volume: 158 Ml administered in 10 minutes
62297308|NCT01172379|EXPERIMENTAL|Experimental 1|
61913007|NCT02674854|EXPERIMENTAL|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
62297309|NCT01172379|EXPERIMENTAL|Experimental 2|
62297310|NCT01172379|EXPERIMENTAL|Experimental 3|
62297311|NCT01172379|PLACEBO_COMPARATOR|Placebo Comparator|
62297312|NCT02497703|EXPERIMENTAL|Knee robot|This robotic system has been developed to facilitate functional motor recovery by practices walking with a one joint motor powered exoskeleton
62297313|NCT05693584|EXPERIMENTAL|Virtual reality glasses|Experimental group:Group applying virtual reality glasses
62297314|NCT05693584|NO_INTERVENTION|Routine practices|No procedure was performed on the patients other than the routine practices of the clinic.
62468773|NCT01683682|EXPERIMENTAL|BIBF 1120, Vinorelbine, Carboplatin|"To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
62666947|NCT00860925|PLACEBO_COMPARATOR|Clonidine placebo and ASA placebo|
62666948|NCT00368849|EXPERIMENTAL|40 milligram twice a day atomoxetine|Participants received 40 milligram twice a day atomoxetine for 4 weeks.
62666949|NCT00368849|PLACEBO_COMPARATOR|Twice a day matching placebo|Participants received twice a day matching placebo for 4 weeks.
62104896|NCT05097573|EXPERIMENTAL|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, stretch marks and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
62104897|NCT03738137|EXPERIMENTAL|Narcotrend|After 0.1µg/kg sufentanil is applied, miidazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the Narcotrend index stage C.
62297315|NCT01830530|EXPERIMENTAL|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
62297316|NCT01830530|PLACEBO_COMPARATOR|Placebo|Two tablets containing placebo daily in the morning
62297317|NCT02064764|ACTIVE_COMPARATOR|Cryoablation only|Pulmonary vein isolation
62468774|NCT05710562||Anticoagulated population|Adult patients under oral anticoagulation therapy
62666950|NCT00442689|EXPERIMENTAL|1|oral contraceptive (35 mg ethinyl estradiol)
62666951|NCT00442689|EXPERIMENTAL|2|Flutamide 250 mg twice daily
62666952|NCT00442689|PLACEBO_COMPARATOR|3|Placebo
62666953|NCT01074580||Deterioration, Crohn's disease|Patients \> 18 years old with a deterioration of Crohn's disease defined by CDAI \>150 and requiring treatment with systemic steroids or TNF alfa inhibitors
62297318|NCT02064764|EXPERIMENTAL|Cryoablation and renal nerve denervation|Pulmonary vein isolation plus renal nerve denervation
62297319|NCT04845217|EXPERIMENTAL|Peppermint Oil|Participants in the intervention (peppermint oil) arm will receive soft gels of enteric-coated peppermint oil (0.2mL=200mg). The enteric coated peppermint oil soft gel utilized in this study is Peptogest Peppermint Oil from Schwabe North America (Nature's Way Brand).
62297320|NCT04845217|PLACEBO_COMPARATOR|Coconut Oil|Participants in the placebo (coconut oil) arm will receive soft gels of enteric coated coconut oil. The enteric coated coconut oil soft gel utilized in this study is Coconut Oil from Schwabe North America (Nature's Way Brand).
62468775|NCT00648947|EXPERIMENTAL|1|Clopidogrel Bisulfate Tablets 75 mg
62468776|NCT00648947|ACTIVE_COMPARATOR|2|Plavix® Tablets 75 mg
62468777|NCT06370507||Pediatric patients undergoing sedation or general anesthesia|Pediatric patients undergoing sedation or general anesthesia subjected to ventilation distribution assessment via electrical impedance tomography
62468778|NCT06471985|ACTIVE_COMPARATOR|Enya + Pain test|In this arm, participants will listen to Enya in headphones while being exposed to the Cold Pressor Test.
61913008|NCT02674854|ACTIVE_COMPARATOR|Netarsudil (AR-13324) ophthalmic solution 0.02%|Netarsudil 0.02% ophthalmic solution
61913009|NCT02674854|ACTIVE_COMPARATOR|Latanoprost ophthalmic solution 0.005%|Latanoprost 0.005 % ophthalmic solution
61913010|NCT03787381|OTHER|Intervention|Uterine scar will be evaluated by vaginal ultrasound examination
62297321|NCT02160418|NO_INTERVENTION|Control|36 Participants will be sent a new toothbrush and will be asked to use it in place of their current brush. They also receive twice daily reminders via sms to brush their teeth.
62297322|NCT02160418|EXPERIMENTAL|Financial Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. They will also be offered financial incentives twice a day to brush their teeth.
62468779|NCT06471985|ACTIVE_COMPARATOR|Slayer + Pain test|In this arm, participants will listen to Slayer in headphones while being exposed to the Cold Pressor Test.
62666954|NCT02310347|EXPERIMENTAL|Marinol|"* generic name: dronabinol~* dosage: 0.1 mg/kg~* frequency: 2 times a single dose~* duration: acute adminstration"
62666955|NCT02310347|PLACEBO_COMPARATOR|Placebo|Empty hard gelatin capsules
62666956|NCT03509584|EXPERIMENTAL|part #1a|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
62666957|NCT03509584|EXPERIMENTAL|part #1b|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
62666958|NCT03509584|EXPERIMENTAL|part #2a|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
62666959|NCT03509584|EXPERIMENTAL|part #2b|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
62666960|NCT05161936|EXPERIMENTAL|Lumasiran Dose 1|Participants will be administered lumasiran by subcutaneous (SC) injection.
62104898|NCT03738137|EXPERIMENTAL|BIS|After 0.1µg/kg sufentanil is applied, midazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by bispectral index (BIS; between 70 and 85).
62104899|NCT03738137|EXPERIMENTAL|No monitoring|After 0.1µg/kg sufentanil is applied, midazolam iss given by non-anaesthetist physicians according to patient's tolerance .
62104900|NCT03738137|EXPERIMENTAL|Lidocaine|Only topical anesthesia was applied.
62104901|NCT03835546||Early treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy presenting recent HIV-1 infection. Recent HIV-1 infection was defined as having a positive plasma viral load and/or p24 antigen with a negative ELISA or having a positive ELISA and undetermined Western-Blot, or having a positive ELISA and absence of p31 antigen in a positive Western-Blot, or seroconversion ELISA in less than 3 months.
62104902|NCT03835546||Regularly treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy, did not fulfil the criteria for recent HIV-1 infection, and had an estimated time \>6 months reported by the patient and/or by the responsible physician since HIV transmission.
62666961|NCT05161936|EXPERIMENTAL|Lumasiran Dose 2|Participants will be administered lumasiran by SC injection.
62297323|NCT02160418|EXPERIMENTAL|Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
62297324|NCT02160418|EXPERIMENTAL|Financial and Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice daily they receive financial incentives to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
62297325|NCT04161040|EXPERIMENTAL|Relapse (experimental) Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. For the Relapse (experimental) Group, the second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Then, during the third phase, the incentives will be discontinued.
62468780|NCT03945422|EXPERIMENTAL|Treatment Arm|Subject will receive AccuTite/FaceTite and Morpheus8 treatment
62468781|NCT02548234|EXPERIMENTAL|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
62104903|NCT03835546||Seronegative volunteers|HIV-uninfected volunteers, matched to age, sex, and educational level with groups A and B.
62104904|NCT01536730|EXPERIMENTAL|Homework Intervention Strategy|
62104905|NCT01536730|NO_INTERVENTION|Control|
62104906|NCT06390592|OTHER|Peritoneal dialysis (PD)|"During the clinical phase, patients are treated continuously with the PD cycler sleep•safe harmony.~The total duration of the clinical phase is six weeks and is divided into 3 Phases à 2 weeks (Clinical phase I, II, and III) which only differ in the FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)"
62104907|NCT01338727|EXPERIMENTAL|Breastfeeding Peer Counseling|
62104908|NCT01338727|NO_INTERVENTION|Standard Care|
62104909|NCT01738555|EXPERIMENTAL|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
62104910|NCT01738555|EXPERIMENTAL|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
62297326|NCT04161040|EXPERIMENTAL|Fatigue Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. The second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Participants in this arm will continue to earn incentives during Phase 3 to control reductions in physical activity due to fatigue.
62468782|NCT02548234|EXPERIMENTAL|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
62468783|NCT01705301||Deep Brain Stimulation|Patient's undergoing the clinical procedure of Deep Brain Stimulation will have the experimental protocol that involves, after implantation of the DBS electrodes, a single electrochemical recording electrode, from the WINCS system, implanted along the same trajectory path as the electrophysiology and the DBS electrode
62468784|NCT02621996|EXPERIMENTAL|Hammock group|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
62666962|NCT05161936|PLACEBO_COMPARATOR|Placebo|Participants will be administered placebo by SC injection.
62666963|NCT00235313|EXPERIMENTAL|1|adaptation of the nicotine patch with salivary cotinine
62666964|NCT00235313|OTHER|2|normal following with a nicotine patch
62104911|NCT01207908|EXPERIMENTAL|IGF-1|IGF-1 plus standard steroid treatment
62666965|NCT05124782||Patients with rheumatoid arthritis|Patients seen in virtual consultation
62666966|NCT02497755|EXPERIMENTAL|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
62666967|NCT01436500|EXPERIMENTAL|5 mg ifetroban, Type 1|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
62104912|NCT01207908|NO_INTERVENTION|Standard steroid treatment alone|Standard daily steroid treatment for DMD
62104913|NCT03213470|OTHER|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed based on the clinical and radiological (including MRI) diagnoses at the symptom onset after Jan-01-2016
62104914|NCT00849147|EXPERIMENTAL|Haploidentical Bone Marrow Transplant|Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
62104915|NCT06288152|EXPERIMENTAL|Intervention Group|STS plus standard of care
62666968|NCT01436500|PLACEBO_COMPARATOR|Placebo, Type 1|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.
62104916|NCT06288152|NO_INTERVENTION|Control Group|Standard of care
62104917|NCT04927975|EXPERIMENTAL|Upa 22 mg Period 1, then Upa 22 mg Period 2|Participants received upadacitinib 22 mg administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 22 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
62104918|NCT04927975|EXPERIMENTAL|Upa 11 mg Period 1, then Upa 11 mg Period 2|Participants received upadacitinib 11 mg administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 11 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
62104919|NCT04927975|EXPERIMENTAL|Upa 6 mg Period 1, then Upa 6 mg Period 2|Participants received upadacitinib 6 mg administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 6 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
62104920|NCT04927975|EXPERIMENTAL|Placebo Period 1, then Upa 22 mg Period 2|Participants received Placebo for upadacitinib administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 22 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
62104921|NCT04927975|EXPERIMENTAL|Placebo Period 1, then Upa 11 mg Period 2|Participants received Placebo for upadacitinib administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 11 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
62104922|NCT06418529||rheumatoid arthritis|Patients diagnosed with rheumatoid arthritis
62104923|NCT05926050|EXPERIMENTAL|Dietary supplement intervention|Participants were treated with 2 tablets containing extracts of American ginseng, bacopa monnieri and coffee fruit
62104924|NCT05926050|PLACEBO_COMPARATOR|Placebo Treatment|Participants received 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
62104925|NCT02393898||Elderly Participants with Ovarian Cancer|Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.
62104926|NCT05348577|EXPERIMENTAL|capivasertib + docetaxel|Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.
62468785|NCT02621996|ACTIVE_COMPARATOR|control group|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
62468786|NCT03079466|ACTIVE_COMPARATOR|Treatment CPAP|A group treated with CPAP
62666969|NCT01436500|EXPERIMENTAL|5 mg ifetroban, Type 2|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
62666970|NCT01436500|EXPERIMENTAL|15 mg ifetroban, Type 1|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
62104927|NCT05348577|PLACEBO_COMPARATOR|placebo + docetaxel|Participants receive placebo in combination with docetaxel and steroids on a background of ADT.
62104928|NCT00569946|EXPERIMENTAL|AG-013736|
62104929|NCT06028932|EXPERIMENTAL|Sacituzumab govitecan, 10 mg/kg|Sacituzumab govitecan, 10 mg/kg for the first 2 weeks of 21-day cycle until progression or adverse effects prohibit further treatment
62104930|NCT06631378|EXPERIMENTAL|Transverse groin incision|
62104931|NCT06631378|ACTIVE_COMPARATOR|Longitudinal groin incision|
62104932|NCT04657991|EXPERIMENTAL|Triplet Arm|Encorafenib and Binimetinib in combination with Pembrolizumab
62104933|NCT04657991|ACTIVE_COMPARATOR|Control Arm|Pembrolizumab
62104934|NCT04034758|PLACEBO_COMPARATOR|Placebo capsule arm|Oral administration of 30 placebo capsule containing edible pigmented starch together with full dose of oral 5-Aminosalicylic acid(5-ASA).
62104935|NCT04034758|ACTIVE_COMPARATOR|SQIMC-md FMT arm|Oral administration of 30 SQIMC-md capsules containing 2\*10\^13 copies of prepared fecal microbiota lyophilized powder from multiple healthy donors' fresh feces together with full dose of oral 5-Aminosalicylic acid(5-ASA).
62297327|NCT04161040|NO_INTERVENTION|No-Incentive Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. Participants in this arm will not earn incentives during any of the three phases to control for the possibility that participants will engage in some physical activity in the absence of incentives.
62297328|NCT03046251|OTHER|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
62468787|NCT03079466|SHAM_COMPARATOR|group without treatment|
62666971|NCT01436500|EXPERIMENTAL|15 mg ifetroban, Type 2|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
62666972|NCT01436500|EXPERIMENTAL|50 mg ifetroban, Type 1|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
62666973|NCT01436500|EXPERIMENTAL|50 mg ifetroban, Type 2|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
62666974|NCT01436500|EXPERIMENTAL|150 mg ifetroban, Type 2|60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
62666975|NCT01436500|PLACEBO_COMPARATOR|Placebo, Type 2|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.
62104936|NCT02078934|EXPERIMENTAL|Weight Loss|Patients with complex incisional/ventral hernias who are too obese to undergo hernia repair.
62104937|NCT02132702|EXPERIMENTAL|Ekso treatment|
62104938|NCT03678116|PLACEBO_COMPARATOR|Sugar Pill (Placebo)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
62104939|NCT03678116|EXPERIMENTAL|Caffeine (plus Teacrine and Cayenne)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
62104940|NCT03678116|EXPERIMENTAL|Caffeine (plus Teacrine)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
62104941|NCT00946751|EXPERIMENTAL|1|Levetiracetam Tablets, 750 mg (Sandoz Inc.)
62104942|NCT00946751|ACTIVE_COMPARATOR|2|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
62104943|NCT02113163|ACTIVE_COMPARATOR|Cohort A - Low Dose|Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg
62104944|NCT02113163|ACTIVE_COMPARATOR|Cohort B - High Dose|Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg
62104945|NCT00502593|EXPERIMENTAL|GSK1562902A-A Lot 1 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104946|NCT00502593|ACTIVE_COMPARATOR|Fluarix-A 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104947|NCT00502593|EXPERIMENTAL|GSK1562902A-A Lot 1 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104948|NCT00502593|ACTIVE_COMPARATOR|Fluarix-A 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104949|NCT00502593|EXPERIMENTAL|GSK1562902A-B Lot 2 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104950|NCT00502593|ACTIVE_COMPARATOR|Fluarix-B 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62468788|NCT01413581|EXPERIMENTAL|rhBSSL|rhBSSL (recombinant human bile-salt-stimulated lipase)
62666976|NCT06283030|EXPERIMENTAL|Hypoglossal nerve stimulation|
62104951|NCT00502593|EXPERIMENTAL|GSK1562902A-B Lot 2 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104952|NCT00502593|ACTIVE_COMPARATOR|Fluarix-B 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104953|NCT00502593|EXPERIMENTAL|GSK1562902A-C Lot 3 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62468789|NCT01413581|PLACEBO_COMPARATOR|Placebo|Placebo
62468790|NCT03864575|EXPERIMENTAL|Combination Group|Celecoxib 400 mg/d Nivolumab 240 mg q2w
62468791|NCT00837486|ACTIVE_COMPARATOR|Active Group - Active Stimulation|Receive active stimulation with Reclaim™ DBS System
62297329|NCT03046251|NO_INTERVENTION|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
62468792|NCT00837486|SHAM_COMPARATOR|Control Group - Sham Stimulation|Receive sham stimulation with Reclaim™ DBS System
62468793|NCT04468503|ACTIVE_COMPARATOR|1 g per kg body weight per day|"Protein will be receive by patients that is 1g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.~Base line characters(BMI, nitrogen Balance, Protein biomarker, LFTs, RFTs, GCS)"
62468794|NCT04468503|ACTIVE_COMPARATOR|2 g per kg body weight per day|"Protein will be receive by patients that is 2g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.~Base line characters(BMI, nitrogen Balance, Protein bio marker, LFTs. , RFTs, GCS)"
62468795|NCT01773330|EXPERIMENTAL|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
62666977|NCT02387918|ACTIVE_COMPARATOR|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
62666978|NCT02387918|ACTIVE_COMPARATOR|Acupuncture|Acupuncture at point Neiguan (Pericardium-6) bilaterally and at point CV13 (Shang Wen) with acupuncture needles (0.25x25 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed after 20 minutes
62666979|NCT02612467|EXPERIMENTAL|Stratified care|Patients are stratified into low, medium, high risk of poor outcome. Stratified care are delivered by special trained physiotherapists according to risk group
62666980|NCT02612467|ACTIVE_COMPARATOR|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
62104954|NCT00502593|ACTIVE_COMPARATOR|Fluarix-C 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104955|NCT00502593|EXPERIMENTAL|GSK1562902A-C Lot 3 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104956|NCT00502593|ACTIVE_COMPARATOR|Fluarix-C 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
62104957|NCT03980964|EXPERIMENTAL|Active NMES|Treatment arm receives an active NMES therapy including a conductive garment with NMES therapy, electrodes, and mobile app.
62104958|NCT03980964|SHAM_COMPARATOR|Inactive NMES|Control arm receives inactive NMES therapy including a conductive garment (no NMES and no electrodes), and mobile app.
62104959|NCT01898676|ACTIVE_COMPARATOR|Divalproex Sodium Extended Release 250mg|Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
62104960|NCT01898676|ACTIVE_COMPARATOR|DEPAKOTE 250mg|Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
62297330|NCT02405533|EXPERIMENTAL|Group 1|AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.
62297331|NCT02405533|PLACEBO_COMPARATOR|Group 2|Placebo once a day on an empty stomach x 12 months
62297332|NCT00917384|EXPERIMENTAL|ramucirumab|Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
62297333|NCT00917384|PLACEBO_COMPARATOR|Placebo|Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
62297334|NCT05159180||patients with atrial arrhythmias undergoing catheter ablation of these|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
62468796|NCT01439880|ACTIVE_COMPARATOR|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product \[all-IP\] period.
62468797|NCT01439880|EXPERIMENTAL|Evolocumab + SOC|Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
62468798|NCT03790345|EXPERIMENTAL|Experimental group 1|15 subjects will be randomly assigned to adjuvant treatment with 200mg of vitamin B6 (pyridoxine).
62468799|NCT03790345|EXPERIMENTAL|Experimental group 2|15 subjects will be randomly assigned to adjuvant treatment with 2mg of vitamin B12 (cobalamin).
62468800|NCT03790345|SHAM_COMPARATOR|Placebo oral tablet|15 subjects will be randomly assigned to adjuvant treatment with placebo.
62468801|NCT04825808||Patients|Consecutive elderly (≥55 years) patients, recruited and registered in the stroke database of two centres (Nîmes University Hospital and Montpellier University Hospital, France), presenting with cSAH with suspected, possible, or probable CAA.
62104961|NCT03615001|EXPERIMENTAL|Urodynamics Arm|
62104962|NCT03172403|EXPERIMENTAL|Patients with digestive cancer requiring resection surgery|"Patients with cancer of digestive system requiring resection surgery will be included. They will have measure of height and weight, blood samples, skeletal muscle force, skeletal muscle index and muscle biopsy.~V1: Inclusion will be effectuated at the time of anaesthetic consultation V2: The day before and day of resection surgery about 1 month after V3: Follow-up at 1 month V4: Follow-up at 3 months V6: Follow-up at 6 months"
62297335|NCT06657716||Eyes with normal anterior segment|
62297336|NCT06657716||Eyes with abnormal anterior segment|
62297337|NCT02974244||exenatide once weekly|type 2 diabetes who initiated exenatide once weekly treatment in the index period
62297338|NCT02974244||basal insulin|type 2 diabetes patients who initiated basal insulin treatment in the index period
62297339|NCT01397851|EXPERIMENTAL|Treatment: Insecticide-treated net|Smallholder farmers in the treatment group are informed that they won a raffle, and receive a free insecticide-treated net
62297340|NCT01397851|NO_INTERVENTION|Control|Smallholder farmers in the control group are informed that they had a chance to win an insecticide-treated mosquito net in a raffle, but did not end up winning
62468802|NCT01209390||Osteochondral lesions|Patients with osteochondral lesions in the knee, the ankle, or other joint
62468803|NCT03281460|EXPERIMENTAL|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
62468804|NCT03281460|ACTIVE_COMPARATOR|without any morcellation bag|without any morcellation bag
62468805|NCT05562518|ACTIVE_COMPARATOR|Estrogen|locally administered estrogen (oestriol)
62468806|NCT05562518|ACTIVE_COMPARATOR|Dehydroepiandrosterone|locally administered dehydroepiandrosterone (DHEA)
62468807|NCT05562518|ACTIVE_COMPARATOR|Estrogen + probiotics|locally administered estrogen (oestriol) + probiotics
62468808|NCT05562518|ACTIVE_COMPARATOR|Moisturizer|locally administered hyaluronic acid
62468809|NCT00355797|ACTIVE_COMPARATOR|Closed Loop Stimulation (CLS)|Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
62666981|NCT00152854|ACTIVE_COMPARATOR|A, 1, acetaminophen|acetaminophen
62104963|NCT05088226|EXPERIMENTAL|Ruxolitinib combined with Chidamide|Experimental: Ruxolitinib combined with Chidamide. All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid \[p.o.\], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)
62104964|NCT05826834|EXPERIMENTAL|Ball rolling|The ball-rolling group will be asked to roll the ball on the trapezius muscle.
62104965|NCT05826834|NO_INTERVENTION|Control|The control group with no intervention
62104966|NCT01495195|EXPERIMENTAL|Donepezil, high-dose|Titration of donepezil to 22.5 mg daily
62104967|NCT01495195|EXPERIMENTAL|Selegiline & low-dose donepezil|Low-Dose Donepezil \[titrated to 10 mg daily\] and transdermal selegiline \[6 mg daily\]
62104968|NCT01495195|EXPERIMENTAL|Selegiline & high-dose donepezil|High-Dose Donepezil \[titrated to 22.5 mg daily\] and transdermal selegiline \[6 mg daily\]
62104969|NCT01495195|PLACEBO_COMPARATOR|Sugar pill|Inert pill for comparison
62104970|NCT03960983|EXPERIMENTAL|Elderly pacients with complete dentures and Tongue Scraper|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of repeated before these steps
62104971|NCT03960983|ACTIVE_COMPARATOR|Elderly pacients with complete dentures and PDT|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
62104972|NCT02963220|EXPERIMENTAL|CBT-AR|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-AR. There is no control group.
62297341|NCT02743858||Patients who consent for ALND|In patients treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed at baseline (prior to surgery), post-operatively (after surgery) \& at scheduled timepoints of 6 months, 12 months, 18 months, \& 24 months after surgery for a total of 2 years. For a patient who is diagnosed with lymphedema at ≥ 13 months after surgery, surveillance will continue for an additional 12 months after \[lymphedema\] diagnosis, \& total surveillance time may exceed 2 years. Height \& weight will be obtained for each patient at baseline \& at each scheduled visit for the purpose of calculating BMI. All patients will complete the ULL-27 (upper limb lymphedema) quality-of-life questionnaire at baseline \& at each scheduled visit.
62104973|NCT03043066|PLACEBO_COMPARATOR|Group A -control group|15 subjects underwent scaling and root planing
62297342|NCT02743858||Patients treated with SLNB alone|Study requirements which include arm measurements, height and weight and completion of a questionnaire at a single long-term follow-up timepoint, will be explained to the patient
62104974|NCT03043066|ACTIVE_COMPARATOR|Group B-Interventional group|15 subjects underwent scaling and root planing along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
62297343|NCT02743858||ALND Translational Study Patients|Patients will also be counseled about blood draws, which will include withdrawal of up to 20 mL of blood. Patients who are eligible and agree to participate will sign a consent form. Arm measurements, height and weight, blood draw (if applicable), and baseline questionnaire will be performed at first contact if possible, or at a follow-up scheduled visit prior to surgery.
62297344|NCT02639377|EXPERIMENTAL|Chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
62468810|NCT00355797|ACTIVE_COMPARATOR|Standard Rate Adaptive Technology (R)|Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
62468811|NCT00355797|ACTIVE_COMPARATOR|Non-rate adaptive pacing (DDD)|Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.
62468812|NCT05000658|EXPERIMENTAL|group A|HSC one injection of 4 mL soluble Dexamethasone phosphate (16 mg) (equivalent to 100 mg Prednisone), followed by up to 16 mL saline (depending on tolerance)
62468813|NCT05000658|PLACEBO_COMPARATOR|group B|HSC one injection of 4mL of saline and then up to 16 mL of saline (depending on tolerance)
62468814|NCT00609960|NO_INTERVENTION|1|no medication or clowns present during the preopertaive phase
62104975|NCT01935258|EXPERIMENTAL|Psychosomatic therapy|Psychosomatic therapy consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS. Psychosomatic therapy delivered by a psychosomatic therapist.
62104976|NCT01935258|OTHER|care as usual|Usual care of the general practitioner
62104977|NCT06411665|EXPERIMENTAL|Oliceridine group|Patient-controlled analgesia pump is provided immediately after surgery. The pump is established with oliceridine 15 mg, diluted with normal saline to 100 ml, and programmed to deliver 2-ml boluses with a 10-min lockout interval and a background infusion rate at 1 ml/h. The pump will be used during the first 3 days after surgery.
62104978|NCT06411665|ACTIVE_COMPARATOR|Morphine group|Patient-controlled analgesia pump is provided immediately after surgery. The pump is established with morphine 50 mg, diluted with normal saline to 100 ml, and programmed to deliver 2-ml boluses with a 10-min lockout interval and a background infusion rate at 1 ml/h. The pump will be used during the first 3 days after surgery.
62104979|NCT06118229||NSCLC patients wearing wearable smart devices|NSCLC patients wearing wearable smart devices while utilizing PROs for regular follow-up
62104980|NCT05085184|EXPERIMENTAL|UI018|
62104981|NCT05085184|ACTIVE_COMPARATOR|UIC201806 and UIC201602|
62104982|NCT02165059||GI Neuromuscal Disorder Cohort|Patients who are undergoing surgical full-thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of GI neuromuscular disorder
62104983|NCT02165059||GI Surgery Patients without neuromuscal disorders (control) cohort|Patients undergoing esophagectomy, sleeve gastrectomy for obesity, Roux-en-Y gastric bypass, whipple surgery, transplant surgery, or organ donors.
62104984|NCT06063330|EXPERIMENTAL|Low Dose of RQ-01|Subjects in this arm will receive 5 mg per day (for 3 days) of RQ-01
62666982|NCT00152854|PLACEBO_COMPARATOR|B placebo|placebo PO qid
62666983|NCT05643690||Clinical Validation Group|Patients with suspected bladder cancer (including hematuria, inflammatory bladder, suspicious ultrasound results)
62666984|NCT02804646|EXPERIMENTAL|endostar and chemotherapy group|recombinant human endostatin(endostar) injection was continuous intravenous transfusion for 7 days,with the dose of 15mg/m2 per one day,every 21 days of a cycle,combined with pemetrexed plus cisplatin or carboplatin.
62666985|NCT02804646|ACTIVE_COMPARATOR|chemotherapy group|pemetrexed injection was intravenous with the dose of 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin,without recombinant human endostatin.
62666986|NCT05556018|EXPERIMENTAL|Tailor-made CRT delivery|Cardiac resynchronization therapy given according to Electrical Activation Mapping result
62666987|NCT04221152|EXPERIMENTAL|Treatment of empagliflozin|"The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study.~The administration is oral administration with water once daily before or after breakfast."
62666988|NCT01063582||fighter pilots f-16|This group is made up of pilots from the F-16 Venezuelan military air force stationed in the Base Vicente Landaeta Gil de Barquisimeto, Lara State.
62666989|NCT01063582||aircraft maintenance personnel f-16|Staff responsible for the preparation of aircraft for the flight and maintenance in the hangar at the airbase Vicente Landaeta Gil de Barquisimeto, Lara. Venezuela
62666990|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
62666991|NCT02212977|ACTIVE_COMPARATOR|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
62666992|NCT02212977|EXPERIMENTAL|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
62666993|NCT00490997|ACTIVE_COMPARATOR|1|Ketamine only arm
62468815|NCT00609960|ACTIVE_COMPARATOR|2|midazolam a anxiolytic drug was given in the preoperative phase
62468816|NCT00609960|ACTIVE_COMPARATOR|3|clowns where present during the preoperative phase
62666994|NCT00490997|ACTIVE_COMPARATOR|2|Ketamine-Propofol arm
62666995|NCT00663143||Stromal Cell Sample|
62666996|NCT00853047|EXPERIMENTAL|Telotristat Etiprate 150 mg Core Phase|Telotristat etiprate capsules,150 mg orally 3 times daily for 28 days in the double-blind treatment period (core phase) in combination with stable-dose octreotide long-acting release (LAR) depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
62666997|NCT00853047|EXPERIMENTAL|Telotristat Etiprate 250 mg Core Phase|Telotristat etiprate capsules, 250 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
62666998|NCT00853047|EXPERIMENTAL|Telotristat Etiprate 350 mg Core Phase|Telotristat etiprate capsules, 350 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
62666999|NCT00853047|EXPERIMENTAL|Telotristat Etiprate 500 mg Core Phase|Telotristat etiprate capsules, 500 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with a stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
62104985|NCT06063330|EXPERIMENTAL|High Dose of RQ-01|Subjects in this arm will receive 10 mg per day (for 3 days) of RQ-01
62104986|NCT06063330|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive 0 mg per day (for 3 days) of RQ-01
62468817|NCT03912337|PLACEBO_COMPARATOR|Placebo|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
62468818|NCT03912337|EXPERIMENTAL|Erenumab|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
62468819|NCT03961425|ACTIVE_COMPARATOR|NO CO2|Traditional De Airing maneuver
62468820|NCT03961425|ACTIVE_COMPARATOR|CO2 Cannula|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by non specific needle cannula
62468821|NCT03961425|ACTIVE_COMPARATOR|CO2 Cardia|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by commercial diffuser Cardia
62468822|NCT03462524||Neoadjuvant chemotherapy|
62468823|NCT03462524||Neoadjuvant chemoradiation|
62667000|NCT00853047|EXPERIMENTAL|Placebo Core Phase|Placebo-matching telotristat etiprate capsules, orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to receive telotristat etiprate in the optional open-label extension period.
62667001|NCT00853047|EXPERIMENTAL|Telotristat Etiprate Open-Label Extension Phase|Telotristat etiprate at assigned dose level for 8 weeks in combination with stable-dose octreotide LAR depot therapy given once per month in the open-label extension period. Upon completion of the 8-week period, participants could enter an additional extension period of 172 weeks, receiving telotristat etiprate at the assigned dose or maximum tolerated dose (500 mg 3 times daily).
62667002|NCT05655988|ACTIVE_COMPARATOR|mesh migration after TEPP / fixation free mesh|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
62667003|NCT05655988|ACTIVE_COMPARATOR|mesh migration after TEPP / mesh with fixation|TEPP surgeries performed with mesh fixation
62667004|NCT05921500|EXPERIMENTAL|Internal bleaching of discolored primary anterior teeth by using sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
62667005|NCT00211939|EXPERIMENTAL|1|PhosLo + atorvastatin
62667006|NCT00211939|ACTIVE_COMPARATOR|2|Sevelamer + atorvastatin
62667007|NCT02560766|EXPERIMENTAL|HORIZANT 300 mg|HORIZANT 300 mg once daily
62667008|NCT02560766|EXPERIMENTAL|HORIZANT 600 mg|HORIZANT 600 mg once daily
62667009|NCT02560766|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62104987|NCT03425604||Endometriosis I y II, according to ASRM classification|Cycles were chosen for analysis only when all the following selection criteria were satisfied: \< 38 years old women, antral follicle count \> 6, basal FSH \< 10mUI/ml, BMI\<30, Infertility time \<4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, \< 3 previous IUI cycles, no male severe factor associated
62104988|NCT03425604||patients without endometriosis|Cycles were chosen for analysis only when all the following selection criteria were satisfied: \< 38 years old women, antral follicle count \> 6, basal FSH \< 10mUI/ml, BMI\<30, Infertility time \<4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, \< 3 previous IUI cycles, no male severe factor associated
62104989|NCT02485743|ACTIVE_COMPARATOR|Active Diet Products|A range of products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
62104990|NCT02485743|PLACEBO_COMPARATOR|Placebo Diet Products|A range of products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
62667010|NCT04981054||cystocele with repairment|women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
62104991|NCT02391246||Positron Emission Tomography Imaging|Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
62104992|NCT03781804|ACTIVE_COMPARATOR|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
62104993|NCT03781804|ACTIVE_COMPARATOR|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
62104994|NCT03781804|PLACEBO_COMPARATOR|Placebo|Matching Placebo BID x 24 Weeks
62104995|NCT06487468||HFpEF Group|"HFpEF (Heart failure with preserved ejection fraction): LVEF≥50%.~Non-endpoint events group versus Endpoint events (all-cause death,cardiovascular death or heart failure readmission) group"
62104996|NCT02118506|ACTIVE_COMPARATOR|Physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Physical practice: is the execution of the motor action."
62104997|NCT02118506|EXPERIMENTAL|Mental and physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Mental practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical practice: is the execution of the motor action."
62104998|NCT06629064|EXPERIMENTAL|Working Memory Training|Computer-administered working memory training program. WMT is a modified working memory capacity task designed to train working memory functioning. WMT is designed to contain high interference across trials and is adaptive to performance. As participants improve working memory, the task becomes more difficult.
62104999|NCT06629064|SHAM_COMPARATOR|Sham Training|The Sham condition requires participants to complete a similar computer task for the same length of time. The Sham Training is a modified working memory capacity task designed to place less demands on working memory.
62105000|NCT02957292|EXPERIMENTAL|Levonorgestrel IUD|13,5 mg Levonorgestrel intrauterine device
62105001|NCT02957292|ACTIVE_COMPARATOR|Copper IUD|Copper (380mm2) intrauterine device
62105002|NCT06630845|EXPERIMENTAL|Whole Body DWI plus FDG PET/MRI|Participants will receive 5 to 10 Megabecquerel (MBq) +/- 10% of 18F-fluorodeoxyglucose as an intravenous injection and undergo a FDG PET/MRI scan that will extend from the vertex to the mid-thighs. Imaging will be performed from vertex to mid-thighs using standard protocol. Participants may also obtain an optional second FDG PET/MRI with DWI within 6 months.
62105003|NCT04244318|EXPERIMENTAL|G1: DTP + Videofeedback 3.0|"Once a week, it will be offered a 5-session intervention of parental therapy (DTP). After that, a 5-session intervention of videofeedback.~Parental Therapy. S1: the therapist will talk with caregiver about her childhood and attachment figures. S2: family mandates and how they have influenced his life. S3: integration of painful memories and the inner child. S4: focus on the present time, and rearing. S5: exploring expectations and stimulating a commimment to positive parenting.~Videofeedback. S1: a play interaction between the child and the caregiver will be recorded for 10 minutes. S2: will be done between the therapist and caregivers, where they will watch different selected parts of the video and will provide feedback through a mentalization constructed framework. S3: another play interaction video will be recorded, that will be discussed on the S4 with the caregiver. S5: a final interaction video will be recorded."
62297345|NCT02639377|PLACEBO_COMPARATOR|Placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
62667011|NCT00810745|EXPERIMENTAL|rectal resection|
62105004|NCT04244318|EXPERIMENTAL|G2: Videofeedback 3.0 + DTP|"Once a week, it will be offered a 5-session intervention of videofeedback. After that, a 5-session intervention of parental therapy (DTP).~Videofeedback. S1: a play interaction between the child and the caregiver will be recorded for 10 minutes. S2: will be done between the therapist and caregivers, where they will watch different selected parts of the video and will provide feedback through a mentalization constructed framework. S3: another play interaction video will be recorded, that will be discussed on the S4 with the caregiver. S5: a final interaction video will be recorded.~Parental Therapy. S1: the therapist will talk with caregiver about her childhood and attachment figures. S2: family mandates and how they have influenced his life. S3: integration of painful memories and the inner child. S4: focus on the present time, and rearing. S5: exploring expectations and stimulating a commimment to positive parenting."
62297346|NCT04341779|EXPERIMENTAL|Intervention arm|Point-of-care adherence testing and Point-of-care viral load testing
62667012|NCT04370899||Familial hypercholesterolaemia children|FH diagnostic criteria were as follows: a positive genetic test or, if no genetic test results were available, LDL-C \>160 mg/dL and one parent with a DLCN score \>8.
62667013|NCT04370899||Unaffected children|The children evaluated for suspected FH who did not meet the FH criteria were included in the non-FH control group
62737213|NCT03569449|EXPERIMENTAL|Group 8- Dog|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and individually-tailored visits
62105005|NCT04244318|ACTIVE_COMPARATOR|Control Group|"Patients in control group will be placed as an active comparator group, as treatment as usual due to the nature of the psychosocial program from wich the cases were selected. After collecting the post-test data, they will be offered the same intervention than the experimental group."
62105006|NCT01913340|ACTIVE_COMPARATOR|Erythropoietin|1000 U/kg/dose x 5 doses
62105007|NCT01913340|PLACEBO_COMPARATOR|Normal saline|
62105008|NCT02501772|EXPERIMENTAL|Sanyinjiao acupressor group|In addition to maintain current treatment included oral anti-hyperglycemia agent and ACEI(angiotensin-converting enzyme inhibitor ) or ARB, subjects should wear ankle band at Sanyinjiao point ( calf , ankle on the foot tip 3 inch ), with the thumb pressing daily five minutes later and carry more than four hours for 8 weeks
62105009|NCT02501772|SHAM_COMPARATOR|Control Group|In the control group, ankle band was place as same as the those for the SA(Sanyinjiao acupressor) group, but was wearing at the acupoint of Sanyinjiao with anti- surface without pressure. It was applied four hours per day for 8 weeks
62105010|NCT04157166|OTHER|group 1 in pair week|In pair week, patients will inclued in group1: the conventional recording followed by complementary images SPECT/CT, will be realized in first intention and the procedure of recording in camera VERITON will be recorderd in second intention
62468824|NCT02625077|EXPERIMENTAL|Laparoscopic valvuloplasty|Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
62667014|NCT02429739|EXPERIMENTAL|Working Memory Training|Behavioral: Cogmed RM working memory training. After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start immediately and will have 6 weeks to perform the 25 training sessions.
62667015|NCT02429739|NO_INTERVENTION|Passive control group|"The control group will receive treatment as usual (Ordinary school days, special education if normally received)."
62105011|NCT04157166|OTHER|group 2 in odd week|in odd week, patients will inclued in group2: the procedure of recording of 25 minutes in camera VERITON-CT ™, will be realized in first intention and the procedure of conventional recording followed by complementary images SPECT/CT will be recorded in second intention
62105012|NCT03563521||Atopic, eosinophilic|
62105013|NCT03563521||Atopic, non-eosinophilic|
62105014|NCT03563521||Non-atopic, eosinophilic|
62468825|NCT02625077|ACTIVE_COMPARATOR|Laparoscopic Toupet fundoplication|Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
62468826|NCT02120547|EXPERIMENTAL|Cenicriviroc in mild liver impaired|Subjects with mild liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
62468827|NCT02120547|EXPERIMENTAL|Cenicriviroc in moderate liver impaired|Subjects with moderate liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
62468828|NCT00812162|EXPERIMENTAL|1|High protein diet.
62105015|NCT03563521||Chronic rhinosinusitis with/without nasal polyposis|
62105016|NCT03563521||Non-atopic, non-eosinophilic|
62105017|NCT03563521||Control|Without asthma, atopy and eosinophilia
62468829|NCT00812162|EXPERIMENTAL|2|Lower protein diet.
62468830|NCT03194139|EXPERIMENTAL|Sentinel Cohort|
62105018|NCT05687500|EXPERIMENTAL|Glibenclamide oral|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
62105019|NCT03556605|OTHER|Intervention Arm|A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
62297347|NCT04341779|NO_INTERVENTION|Standard-of-care arm|No adherence testing and lab-based viral load testing
62297348|NCT02536586|EXPERIMENTAL|LY3023414|LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
62468831|NCT03194139|EXPERIMENTAL|Crossover Design|
62468832|NCT05396859|EXPERIMENTAL|Treatment (ASTX727, entrectinib)|Patients receive entrectinib PO QD on days 1-28 and ASTX727 PO QD on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62105020|NCT03556605|OTHER|Control Arm.|A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
62105021|NCT04461106|ACTIVE_COMPARATOR|Social Marketing Campaign|Select egg hubs will receive social marketing campaign which aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (\<5yrs) and pregnant/lactating women.
62105022|NCT04461106|NO_INTERVENTION|No Social Marketing Campaign|Other egg hugs will not receive social marketing campaign.
62105023|NCT02086708|EXPERIMENTAL|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
62105024|NCT05623280||Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL; Achieve Intraoperative fluorescence images by Near-Infrared I ( NIR-I ) fluorescence imaging instrument.
62105025|NCT06630065|EXPERIMENTAL|Patients|Depressed patients treated with Esketamin
62105026|NCT06630065|OTHER|healthy volunteers|Healthy subjects
62667016|NCT04607759|EXPERIMENTAL|Experimental group (cucumber)|"Consumption for 90 days of cucumber extract (20mg/day)~Two capsules a day orally for 90 days."
62667017|NCT04607759|PLACEBO_COMPARATOR|control group Placebo (sucrose)|Two capsules a day orally for 90 days.
62105027|NCT02476773|EXPERIMENTAL|Group 1|"* 5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm.~* 5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
62667018|NCT01917773|EXPERIMENTAL|Octreotide|All patient received octreotide. We compared pre (fasting) and post octreotide colonic motility index.
61913011|NCT05987488|EXPERIMENTAL|ShigETEC vaccine|The vaccine will consist of a suspension of a live, attenuated Shigella bacterial strain (a clinical isolate of Shigella flexneri 2457T strain) into which the genes for nontoxic forms of the ETEC heatlabile toxin B subunit (LTB) and a mutant heat stable toxin (STm) have been inserted.
62105028|NCT02476773|EXPERIMENTAL|Group 2|"* 5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~* 5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
62105029|NCT02476773|EXPERIMENTAL|Group 3|"* 5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~* 5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
62105030|NCT02476773|EXPERIMENTAL|Group 4|"* 5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~* 5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
62105031|NCT02476773|EXPERIMENTAL|Group 5|"* 5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~* 5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
62297349|NCT04976452|EXPERIMENTAL|Group 1|Group 1 will include first year Physical Therapy students who will be trained for Blood Pressure (BP) measurement using a brief powerpoint lecture, completion of an interactive BP measurement module from the American Medical Association which includes a quiz assessment and certificate of completion, and a competency examination during the lab portion of class.
62297350|NCT04976452|NO_INTERVENTION|Group 2|Group 2 consists of second year PT students who only had a powerpoint lecture on Blood Pressure measurement that was done virtually with no lab component or American Medical Association interactive module training.
62297351|NCT03557021|EXPERIMENTAL|Individualized therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the followed therapy will be adjusted with in this setting available medications to the outcome of the resistance profile
62297352|NCT03557021|ACTIVE_COMPARATOR|standard therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the national defined standard therapy will be applied as second line treatment.
62297353|NCT05747989|ACTIVE_COMPARATOR|skin stitched with two-component skin adhesive|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
62468833|NCT05107323|EXPERIMENTAL|CMT-T|The CMT-T is a Compassionate Mind Training program tailored for teachers, delivered in a group format across eight sessions of approximately 2.5 hours each. In each session, besides presenting relevant theoretical constructs addressed in that session, participants are invited to complete experiential exercises, compassion and mindfulness meditation practices, and work in small groups to share their experiences, followed by a plenary session. There are six different modules addressed during the 8-sessions CMT-T
62468834|NCT05107323|NO_INTERVENTION|Waiting list|Participants in the waiting list control group were not offered an intervention.
62468835|NCT03105141|EXPERIMENTAL|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
62667019|NCT00683384||1|
62667020|NCT04042428|EXPERIMENTAL|Treatment group|Subjects receive a 14-day treatment. A 450 mL blood sample is extracted 6 hours after the last administration (day 14).
62667021|NCT04042428|NO_INTERVENTION|Control group|Subjects do not receive any treatment. A 450 mL blood sample is extracted at baseline.
62667022|NCT02868528|EXPERIMENTAL|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
62667023|NCT02868528|NO_INTERVENTION|control group|After blastocyst culture, blastocysts will be transferred
62667024|NCT05619419|EXPERIMENTAL|Mindfulness-enhanced positive affect induction (MPAI)|The MPAI is a method of bringing mindful (nonjudgmental) awareness to positive emotions, thoughts, and memories and is not expected to result in adverse experiences. It includes beginning with mindful awareness of the breath (i.e., meditation focusing on the breath) to draw attention away from negative aspects of pain. With continued awareness of the breath, smiling and gentle laughter are begun in order to initiate positive affect. With continued smiling and laughter, participants then imagine the smiles and laughter of those they are fond of, to allow a positive affect state to build upon itself and trigger state dependent positive memories, thoughts, emotions (e.g., gratitude) and self-efficacy of pain management.
62737214|NCT03569449|EXPERIMENTAL|Group 9- Donkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and structured visits
62297354|NCT05747989|PLACEBO_COMPARATOR|skin stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0. (Optilene® DSMP 19, 3/8 needle, thread size 4/0
62297355|NCT03263091|EXPERIMENTAL|Roxadustat|"Open-label, lead-in: Participants will receive sequential escalating roxadustat doses (1.5 milligrams/kilograms \[mg/kg\], 2.0 mg/kg and 2.5 mg/kg), three times a week (TIW) based upon their actual weight at the randomization visit to identify the starting dose for double-blind period.~Double-blind: Participants will receive roxadustat 2.5 mg/kg TIW based upon their body weight for a duration of 52 weeks.~Open-label: Participants with high serum erythropoietin levels (\>400 milli-international units \[mIU\]/milliliter \[mL\] mIU/mL) will receive roxadustat 2.5 mg/kg TIW based upon their body weight for a duration of 52 weeks."
62297356|NCT03263091|PLACEBO_COMPARATOR|Placebo|Double-blind: Participants will receive placebo matching to roxadustat for a duration of 52 weeks.
62297357|NCT04432038||General population of adults from about 30 countries|Data will be collected in general population of adults from about 30 countries. Questionnaires contain also questions about the occurrence of chronic illnesses, being a professional athlete, etc. to control all such aspects.
62667025|NCT05619419|ACTIVE_COMPARATOR|Breathing meditation (BM)|Breathing meditation is a method of bringing mindful (nonjudgmental) awareness to various aspects of the breath and is aimed toward attaining a neutral state of affect and is not expected to result in adverse experiences. It involves bringing present-moment focused, nonjudgmental awareness to aspects breathing, such as sensations of airflow with each inhalation and exhalation, as well noticing the rise and expansion of the chest and belly with each inhalation. The use of breathing mediation will serve as a comparison task for the MPAI.
62667026|NCT05619419|NO_INTERVENTION|Natural Response (NR)|Participants instructed to respond naturally to the cold pressor test will be instructed to not attempt to modify or control their experience (e.g., via distraction or use of meditation). Natural response will serve as a control comparator for the MPAI and is not expected to result in adverse experiences.
62667027|NCT01567085|EXPERIMENTAL|Eculizumab|"Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days."
62667028|NCT03100292|EXPERIMENTAL|bariatric surgery|"This trial is a single-arm study and the enrolled patients are going to undergo sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).~If the patient has Barrett's esophagus on the preoperative endoscopy, SG is not permitted. Inflammatory bowel disease and Helicobacter pylori infection on a rapid urease test are contraindications of RYGB."
62667029|NCT02184117||All patients|Entire cohort undergoes paired testing
62667030|NCT06007443|EXPERIMENTAL|patients with neck pain|conditioned pain modulation, temporal summation and two-point discrimination will be evaluated in all included participants. Average pain intensity will be asked
62667031|NCT01131585|EXPERIMENTAL|Active laser photocoagulation and ranibizumab|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
62667032|NCT01131585|ACTIVE_COMPARATOR|Active laser photocoagulation and sham injection|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
62667033|NCT03537677|EXPERIMENTAL|Sedentary Behavior Intervention|A behavioral intervention that targets prolonged sitting and encourages frequent activity breaks.
62667034|NCT05027282|EXPERIMENTAL|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces|
62667035|NCT01506076|EXPERIMENTAL|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
62297358|NCT04432038||General population of adults from Poland|
62667036|NCT01506076|ACTIVE_COMPARATOR|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
62297359|NCT04432038||General population of adults from Germany|
62297360|NCT04432038||General population of adults from China|
62667037|NCT02061592|ACTIVE_COMPARATOR|Etafilcon A Control Lens|etafilcon A
62667038|NCT02061592|EXPERIMENTAL|Etafilcon A Test Lens|etafilcon A
62667039|NCT06061159|EXPERIMENTAL|1-3years old|single intravenous bolus remimazolam about 5min before general anesthesia induction
62667040|NCT06061159|EXPERIMENTAL|3-6years old|single intravenous bolus remimazolam about 5min before general anesthesia induction
62667041|NCT06061159|EXPERIMENTAL|6-12years old|single intravenous bolus remimazolam about 5min before general anesthesia induction
62105032|NCT02476773|EXPERIMENTAL|Group 6|"* 5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~* 5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
62297361|NCT04432038||General population of adults from Vietnam|
62297362|NCT04432038||General population of adults from Spain|
62297363|NCT04432038||General population of adults from Brazil|
62297364|NCT04432038||General population of adults from Croatia|
62297365|NCT04432038||General population of adults from Ethiopia|
62297366|NCT04432038||General population of adults from France|
62297367|NCT04432038||General population of adults from Indonesia|
62297368|NCT04432038||General population of adults from Iran|
62297369|NCT04432038||General population of adults from Sri Lanka|
62297370|NCT04432038||General population of adults from USA|
62297371|NCT04432038||General population of adults from Italy|
62667042|NCT00890318|OTHER|1|Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole
62667043|NCT00890318|OTHER|2|Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.
62667044|NCT00890318|OTHER|3|Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.
62667045|NCT06179875|EXPERIMENTAL|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
62667046|NCT05348694|ACTIVE_COMPARATOR|Pendulum WBF-038|Pendulum WBF-038, a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
62667047|NCT05348694|PLACEBO_COMPARATOR|Pendulum Placebo|Pendulum Placebo containing Magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
62105033|NCT06047262|EXPERIMENTAL|Intervention Group|1000 mg dapansutrile (2 × 500mg tablets) administered twice a day from day 1 through the week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.
62667048|NCT04791826|EXPERIMENTAL|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of HF in diabetes and the lack of an active order for SGLT2i therapy.
62667049|NCT04791826|NO_INTERVENTION|No Alert|The CDS will not issue an on-screen alert.
62105034|NCT06047262|PLACEBO_COMPARATOR|Control Group|Matching placebo (2 tablets) administered twice a day from day 1 through the Week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.
62105035|NCT03822351|EXPERIMENTAL|Control Arm (Durvalumab monotherapy)|durvalumab IV
62105036|NCT03822351|EXPERIMENTAL|Arm A (durvalumab + oleclumab):|durvalumab IV and oleclumab IV
62667050|NCT00724503|EXPERIMENTAL|mFOLFOX6 + SIRT|A single injection of SIR-Spheres microspheres into the liver plus systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX)
62105037|NCT03822351|EXPERIMENTAL|Arm B (durvalumab + monalizumab)|durvalumab IV and monalizumab IV
62105038|NCT04290429|EXPERIMENTAL|SR-GI-GVHD|Analysis of patient's stool frequency, albumin serum levels and quantification of Paneth cell numbers in GI biopsies before and during teduglutide treatment.
62105039|NCT04296032|EXPERIMENTAL|virtual reality group|Standard treatment 30 minutes plus virtual reality game 30 minutes, twice a week for 9 weeks.
62105040|NCT04296032|ACTIVE_COMPARATOR|standard treatment group|Standard treatment 60 minutes, twice a week for 9 weeks.
62105041|NCT03383887|PLACEBO_COMPARATOR|Placebo|Placebo capsule 30 minutes before sleep
62105042|NCT03383887|ACTIVE_COMPARATOR|DAW1033D|DAW1033D capsule 30 minutes before sleep
62105043|NCT01250002|ACTIVE_COMPARATOR|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
62105044|NCT01250002|PLACEBO_COMPARATOR|Placebo|Placebo will receive the same volume of saline infusion.
62105045|NCT01740557|EXPERIMENTAL|Treatment (genetically modified T-cells, high-dose aldesleukin|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
62105046|NCT05402891|EXPERIMENTAL|Study population|Every patient will receive treatment: Lithiumcarbonate 300mg daily in oral tablet for six months. There will no control group included since patient represent their own control in the nontreatment-phase.
62105047|NCT02214108|EXPERIMENTAL|Phisical activity with Nintendo Wii|3 hours of weekly of physical activity, divided in 1 hour interday with Nintendo WII. games applied: Wii Boxing, Wii Tennis; Wii Bowling
62105048|NCT02214108|NO_INTERVENTION|phisical activity with phisiotherapist|3 hours of weekly physical activity, divided in 1 hour interday. applying cardiovascular and muscular endurance static exercises.
62105049|NCT05616559||Patient cohort (n=800)|All participants included will contribute with basic clinical, cognitive, psychometric, genetic and biochemical data.
62297372|NCT04432038||General population of adults from South Africa|
62105050|NCT05616559||Subcohort I (n=600)|Patients in Subcohort I undergo MRI and EEG in addition to expanded clinical, cognitive, psychometric, and biological data.
62297373|NCT04432038||General population of adults from Portugal|
62297374|NCT04432038||General population of adults from Norway|
62297375|NCT04432038||General population of adults from Lithuania|
62667051|NCT00724503|ACTIVE_COMPARATOR|mFOLFOX6|Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).
62667052|NCT04551924|EXPERIMENTAL|dose 1|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
62667053|NCT04551924|EXPERIMENTAL|dose 2|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
62667054|NCT04551924|EXPERIMENTAL|dose 3|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
62667055|NCT04551924|EXPERIMENTAL|dose 4|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
62667056|NCT04551924|ACTIVE_COMPARATOR|Naropin|Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
62667057|NCT02375997|EXPERIMENTAL|Standard oncology care plus palliative care|
62667058|NCT02375997|NO_INTERVENTION|Standard oncology care|
62667059|NCT02603029|PLACEBO_COMPARATOR|Placebo cream|Cream with 0% Silver fir wood extract (Belinal)
62667060|NCT02603029|ACTIVE_COMPARATOR|Belinal cream|Cream with 2% Silver fir wood extract (Belinal)
62667061|NCT05673850||NET|
62667062|NCT05673850||NCT|
62667063|NCT01586182|EXPERIMENTAL|Stereotactic Boost|Escalating doses of stereotactic body radiation therapy (SBRT)
62737215|NCT03569449|EXPERIMENTAL|Group 10- Bear|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and structured visits
62737216|NCT03569449|EXPERIMENTAL|Group 11- Tiger|Clinic and community visits, technology enhanced care coordination, standard pediatric surveillance, and structured visits
62737217|NCT03569449|EXPERIMENTAL|Group 12- Lion|Clinic and community visits, technology enhanced care coordination, enhanced pediatric surveillance, and structured visits
62105051|NCT05616559||Subcohort II - drug naive PET subgroup (n=60)|A subgroup of Subcohort I, including only patients who at inclusion do not receive any pharmacological treatment for their depression, undergo in addition Positron Emission Tomography imaging with \[11C\]-UCB-J for measurement of cerebral synaptic density.
62667064|NCT04874168|ACTIVE_COMPARATOR|In the TAP group (Group A )|"after completion of surgery, bilateral ultrasound-guided TAP block was performed .~Description of the intervention: a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used ;A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
62667065|NCT04874168|ACTIVE_COMPARATOR|In the infiltration group (Group B )|at the end of surgery, 40 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (20 mL in each of the upper and lower sides) by the obstetrician before skin closure.
62105052|NCT05658562|EXPERIMENTAL|MT-2111 dosing regimen|
62667066|NCT04874168|PLACEBO_COMPARATOR|In placebo group (Group C )|routine analgesic was administered and recorded .
62667067|NCT02845492|EXPERIMENTAL|Qigong intervention|Qigong meditative exercise intervention meets three times a week for 10 weeks. The qigong group (n=30) will meet at the Women's Medicine Collaborative, Miriam Hospital (146 W. River St., Providence, RI) for Qigong classes. The lesson will be taught by a validated Qi Gong master with over forty years of experience and the interventional protocol will be validated. Two and a half hours of weekly outside personal practice will also be required of participants.
62737218|NCT03569449|EXPERIMENTAL|Group 13- Monkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and individually-tailored visits
62105053|NCT05376605||lung transplant|Patients who have passed at least 3 months after lung transplantation
62105054|NCT05428345||Participants With UC or CD|Participants diagnosed with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist and have initiated treatment with vedolizumab in a routine clinical practical setting in South Korea, will be observed prospectively for 52 weeks.
62105055|NCT00731380|EXPERIMENTAL|ABI-007 escalation; then radiation + AUC|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-FU 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
62105056|NCT02785744||Patients receiving DEXA Scan|Gaucher patients referred for dual energy X-ray absorptiometry (DEXA scan), who were found to have T-score \<-1.0.
62297376|NCT04432038||General population of adults from Romania|
62105057|NCT04274751||Transaxillary|TAVI, transaxillary approach
62468836|NCT03105141|EXPERIMENTAL|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
62105058|NCT04274751||Transfemoral|TAVI, transfemoral approach
62105059|NCT03862170|ACTIVE_COMPARATOR|Ciprofloxacin|Patients in this arm will receive Ciprofloxacin 400mg IV 120mn (prophylactic antibiotic) before their HDR brachytherapy
62105060|NCT03862170|EXPERIMENTAL|Cefazolin|Patients in this arm will receive Cefazolin 2000mg IV 60mn (prophylactic antibiotic) before their HDR brachytherapy
62105061|NCT03862170|NO_INTERVENTION|No prophylactic antibiotics|Patients in this arm will not receive any prophylactic antibiotics before their HDR brachytherapy
62105062|NCT06049108|EXPERIMENTAL|[14C]-LY3871801|Single dose of \[¹⁴C\]-LY3871801 administered orally
62297377|NCT04432038||General population of adults from Pakistan|
62297378|NCT04432038||General population of adults from Ukraine|
62297379|NCT04432038||General population of adults from India|
62297380|NCT04432038||General population of adults from Japan|
62468837|NCT03105141|EXPERIMENTAL|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
62105063|NCT01564875|EXPERIMENTAL|Simvast CR|"* Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.~* Placebo with the same appearance and formulation as that of Zocor Tab, 1 tablet once daily to be administered between 6 and 9 p.m."
62297381|NCT04432038||General population of adults from Russia|
62297382|NCT04432038||General population of adults from Bangladesh|
62105064|NCT01564875|ACTIVE_COMPARATOR|Zocor|"* Placebo with the same appearance and formulation as that of Simvast CR Tab, 1 tablet once daily to be administered between 6 and 9 a.m.~* Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m."
62297383|NCT04432038||General population of adults from Nigeria|
62297384|NCT04432038||General population of adults from Egypt|
62297385|NCT03882918|EXPERIMENTAL|OV101|once daily at bedtime (gaboxadol)
62297386|NCT02747082|ACTIVE_COMPARATOR|1% sodium hypochlorite (NaOCl)|"Retreatment of root-filled teeth with infection with 1% NaOCl as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
62468838|NCT03105141|EXPERIMENTAL|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
62468839|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
62468840|NCT03544411|EXPERIMENTAL|Type 2 Diabetes Mellitus group 1|The group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
62105065|NCT06103734|ACTIVE_COMPARATOR|Zavegepant 10 mg|This is the active arm where the participant will receive 4 doses of the zavegepant 10mg intranasal
62105066|NCT06103734|PLACEBO_COMPARATOR|Placebo - Control 1|This is one of the two placebo arms where the participant will receive 3 doses of placebo and 1 dose of zavegepant 10mg intranasal. Participant will not know which dose will be zavegepant.
62667068|NCT02845492|ACTIVE_COMPARATOR|CHIP healthy wellness-exercise class|The Complete Health Improvement Program is a validated set of weekly classes designed to promote gentle exercise and wellness related activities in a supportive group setting led by an experienced trainer.
62667069|NCT01365611|EXPERIMENTAL|Ketorolac tromethamine|
62667070|NCT03763383||Free lateral arm flap|included patients who had free lateral Arm flap
62667071|NCT03763383||pedicled lateral arm flap|included patients who had pedicled lateral arm flap
62667072|NCT04396275|EXPERIMENTAL|Cooked whole navy beans|A meal consisting of cooked navy beans
62667073|NCT04396275|EXPERIMENTAL|Cooked whole yellow split peas|A meal consisting of cooked yellow peas
62667074|NCT04396275|EXPERIMENTAL|Cooked rice (control)|A meal consisting of cooked rice
62667075|NCT02745405|EXPERIMENTAL|Fat Suit Condition|Participants are randomly assigned to wear a fat suit and then walk across campus.
62105067|NCT06103734|PLACEBO_COMPARATOR|Placebo - Control 2|This is one of the two placebo arms where the participant will receive 3 doses of placebo and 1 dose of zavegepant 10mg intranasal. Participant will not know which dose will be zavegepant.
62105068|NCT01721564|EXPERIMENTAL|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
62105069|NCT04809402|OTHER|Telemonitoring|Subjects in the telemonitoring group will have post-operative follow-up measurements involving teleconsultations, remote eye exams and health questionnaires.
62105070|NCT04809402|NO_INTERVENTION|Usual care|Subjects in the usual care group will receive regular post-operative care, mostly involving in-hospital consultations.
62297387|NCT02747082|ACTIVE_COMPARATOR|2% chlorhexidine gluconate (CHX)|"Retreatment of root-filled teeth with infection with 2% CHX as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
62297388|NCT03293654|EXPERIMENTAL|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62667076|NCT02745405|OTHER|Control Condition|Participants are randomly assigned to wear the same clothing that is on the fat suit but in their own size and then walk across campus.
62667077|NCT00819195||RRMS|Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care
62105071|NCT01606384|PLACEBO_COMPARATOR|Placebo|Twice daily
62105072|NCT01606384|EXPERIMENTAL|SSR149415 - 100mg|Twice daily
62667078|NCT00819195||HC|Healthy control volunteers
62667079|NCT01028391|EXPERIMENTAL|Sitagliptin + Pioglitazone|
62667080|NCT01028391|ACTIVE_COMPARATOR|Pioglitazone + Placebo|
62667081|NCT04351971|EXPERIMENTAL|Intervention Group|The dorsal sliding technique C0-C1 will be applied to this group.
62105073|NCT01606384|EXPERIMENTAL|SSR149415 - 250mg|Twice daily
62105074|NCT03826602|EXPERIMENTAL|Tucatinib plus metformin|Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8
62667082|NCT04351971|SHAM_COMPARATOR|Placebo group|A placebo dorsal mobilization technique will be applied
62105075|NCT01954940|EXPERIMENTAL|Whole Body Vibration Therapy|Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
62105076|NCT01954940|NO_INTERVENTION|Control group|Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.
62105077|NCT04163458|EXPERIMENTAL|MENOPUR liquid|MENOPUR liquid (including placebo to MENOPUR powder) initiated at a fixed dose of 225 international units (IU) for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.
62105078|NCT04163458|ACTIVE_COMPARATOR|MENOPUR powder|MENOPUR powder (including placebo to MENOPUR liquid) initiated at a fixed dose of 225 IU for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.
62667083|NCT05404659|ACTIVE_COMPARATOR|Oscillatory Mobilizations|
62297389|NCT03293654|ACTIVE_COMPARATOR|US licenced Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62297390|NCT03293654|ACTIVE_COMPARATOR|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62297391|NCT02688413|EXPERIMENTAL|MindMotionPRO|MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
62297392|NCT02688413|ACTIVE_COMPARATOR|Self-Directed Prescribed Exercises|Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation
62297393|NCT00947349|EXPERIMENTAL|BI 201335 NA low TN|patient to receive a capsule containing low dose of BI 201335 NA/Drug for treatment-naive (TN) patients
62667084|NCT05404659|EXPERIMENTAL|Mckenzie Retraction Exercises|
62667085|NCT02161666||Patients|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
62667086|NCT02161666||Controls|Age, sex and BMI-matched healthy controls
62667087|NCT02950584|EXPERIMENTAL|Patients take titanium dioxide denture|Participants will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) for 1 month in the initial phase of the trial then in the later phase after one month they will receive (rapid heat cured acrylic resin) denture
62667088|NCT02950584|PLACEBO_COMPARATOR|Patients take rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles)
62105079|NCT06242834|EXPERIMENTAL|Treatment (pembrolizumab, tazemetostat)|Starting on day 14 after standard of care ASCT or CAR-T cell treatment patients receive pembrolizumab IV on day 1 of each cycle. Starting cycle 2, patients receive tazemetostat PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography during screening, CT scan, PET scan, and blood sample collection throughout the study.
62105080|NCT01501929|ACTIVE_COMPARATOR|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP \> 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
62105081|NCT01501929|ACTIVE_COMPARATOR|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP \> 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
62105082|NCT05191251||Full-term pregnant women with HEMSTOP|"Full-term pregnant women who have given birth vaginally or by cesarean section. Patients for whom a HEMSTOP questionnaire could be carried out in prepartum, during the pre-delivery anesthesia consultation.~Patients who received follow-up during pregnancy as recommended. Age over 18"
62297394|NCT00947349|EXPERIMENTAL|BI 201335 NA high TN|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-naive (TN )patients
62297395|NCT00947349|EXPERIMENTAL|BI 201335 NA high TE|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-experienced (TE) patients
62297396|NCT00947349|PLACEBO_COMPARATOR|Placebo in Treatment Naive (TN) Patients|
62297397|NCT01607892|EXPERIMENTAL|selinexor|
62297398|NCT06488677||High adherence|Participants with high adherence to the lifestyle intervention
62297399|NCT06488677||Low adherence|Participants with low adherence to the lifestyle intervention
62297400|NCT00681551|ACTIVE_COMPARATOR|Arm 1|
62297401|NCT00681551|EXPERIMENTAL|Arm 2|
62105083|NCT02329041|EXPERIMENTAL|McGrath Series 5|DLT intubation with McGrath Series 5 videolaryngoscope
62105084|NCT02329041|ACTIVE_COMPARATOR|Airtraq|DLT intubation with Airtraq videolaryngoscope
62105085|NCT04776486|EXPERIMENTAL|Critically ill patients with augmented renal clearance|ICU patients with estimated renal clearance over 130ml/min/1.73m2
62105086|NCT00573703|ACTIVE_COMPARATOR|Group A|
62297402|NCT01802281|ACTIVE_COMPARATOR|Hysteropexy|Uphold® LITE
62297403|NCT01802281|ACTIVE_COMPARATOR|Hysterectomy and USLS|Vaginal hysterectomy and uterosacral ligament suspension (USLS)
62297404|NCT06100432|EXPERIMENTAL|Treatment 1|DLBS5055 \& Placebo Multivitamin
62297405|NCT06100432|ACTIVE_COMPARATOR|Treatment 2|Multivitamin (Vitamin C 1000mg + Vitamin E 200IU + Beta Carotene 20000IU) \& Placebo DLBS5055
62297406|NCT06100432|EXPERIMENTAL|Treatment 3|DLBS5055 \& Multivitamin (Vitamin C 1000mg + Vitamin E 200IU + Beta Carotene 20000IU)
62297407|NCT06095830||Group 1|Patients that recovered from sepsis without complications
62297408|NCT06095830||Group 2|"Patients that didn't recover from sepsis.~Further subdivided into:~Group 2-A: developed complications Group 2-B: non-surviving"
62297409|NCT06095830||Group 3|Control group of healthy individuals
62297410|NCT03539432|EXPERIMENTAL|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily
62297411|NCT03539432|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose powder packaged in capsules identical to the experimental condition
62667089|NCT02092103|NO_INTERVENTION|Delayed Clamping|"The American Congress of Obstetricians and Gynecologists (ACOG) recommends delayed cord clamping for preterm infants. Infants randomized to this group will follow the protocol below:~1. Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~2. Once infant is delivered designated RN starts timer~3. Infant warming bag on delivery table~4. Infant placed into warming bag then wrapped in a towel~5. Assistant to deliver preps cord clamps~6. Registered Nurse (RN) notifies provider at 30 seconds~7. Cord clamped and cut~8. Infant handed off to waiting staff~9. Exceptions: Placental separation, cord stops pulsating, need for immediate resuscitation, all would result in clamping prior to 30 seconds"
62667090|NCT02092103|EXPERIMENTAL|Cord Milking|"Infants randomized to the cord milking group will follow the protocol below:~1. Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~2. Infant held and the cord is milked from perineum to infant four times~3. Assistant to deliver preps cord clamps~4. Cord clamped and cut~5. Infant handed off to waiting staff"
62667091|NCT03792997|ACTIVE_COMPARATOR|control|regular treatment with embryo transfer in the form of progesterone I.M. \& Supp. in addition to low dose aspirin \& folic acid
61913012|NCT05987488|PLACEBO_COMPARATOR|Placebo|A saline solution with corn starch
62105087|NCT00573703|EXPERIMENTAL|Group B|
62297412|NCT04279197|EXPERIMENTAL|FZHY Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~* Fuzheng Huayu tablets"
62297413|NCT04279197|PLACEBO_COMPARATOR|Placebo Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~* placebo"
62297414|NCT01561664|ACTIVE_COMPARATOR|volunteers|not overweight Volunteers responding to the study criteria
62468841|NCT03544411|EXPERIMENTAL|Type 2 Diabetes Mellitus group 2|this group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
62468842|NCT00887263|EXPERIMENTAL|A|
62468843|NCT00887263|PLACEBO_COMPARATOR|B|
62468844|NCT03886935||Fontan patients|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
61913013|NCT05909800|EXPERIMENTAL|Phenofibrate|Phenofibrate in capsules received orally, daily, for 12 months.
61913014|NCT05909800|PLACEBO_COMPARATOR|Placebo|Capsules containing Microcrystalline cellulose 102,594 mg (99%) and Magnesium stearate 6 mg (1%) identical to those of the active product received orally, daily, for 12 months.
61913015|NCT05823740|OTHER|Single Arm|Children with malignant diseases, receiving anti-cancer treatment and completed study interventions.
61913016|NCT04158193|EXPERIMENTAL|Acupuncture group|Subjects in the acupuncture group are given acupuncture treatment.
61913017|NCT04158193|EXPERIMENTAL|Sham acupuncture control group|Subjects in the sham acupuncture control group are given non-acupoint shallow acupuncture.
61913018|NCT04531774|EXPERIMENTAL|RECHARGE|4 1-hour sessions of RECHARGE are delivered online using Skype for Business within 2 weeks.
61913019|NCT04531774|ACTIVE_COMPARATOR|Online self-study of stress management strategies|Self study during 2 weeks.
61913020|NCT05449470|EXPERIMENTAL|CDSS and patient portal|The intervention includes the combined use of the clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction and a patient portal.
61913021|NCT05449470|NO_INTERVENTION|Care as usual|Care as usual
61913022|NCT02689102||ILD patients|ILD patients scheduled for diagnostic bronchoscopy with biopsy and/or broncho-alveolar lavage will undergo additional imagaing with probe based optical techniques.
62105088|NCT01007149|EXPERIMENTAL|Omalizumab|Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
62105089|NCT01007149|PLACEBO_COMPARATOR|Placebo|Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.
62105090|NCT04691544|ACTIVE_COMPARATOR|Fecal microbiota transplant from donor A|One FMT delivered by enema
62105091|NCT04691544|ACTIVE_COMPARATOR|Fecal microbiota transplant from donor B|One FMT delivered by enema
62105092|NCT04691544|ACTIVE_COMPARATOR|Fecal microbiota transplant from donor C|One FMT delivered by enema
62297415|NCT01561664|EXPERIMENTAL|overweight patients insulin sensitive|overweight patients insulin sensitive responding to the study criteria
62297416|NCT01561664|EXPERIMENTAL|overweight insulin resistant|overweight patients insulin resistant responding to the study criteria
62297417|NCT06656429|EXPERIMENTAL|TFESI|Lumbar Transforaminal Epidural Steroid Injections was administered, consisting of 4 mg dexamethasone and 0.33% lidocaine in a 3 ml solution.
62468845|NCT03886935||Healthy biventricular controls|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
62468846|NCT01372033|EXPERIMENTAL|CBT|Use of cognitive behavioral therapy focused on social skill development and interpersonal relationships
62468847|NCT03287310|EXPERIMENTAL|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
62297418|NCT04358458|EXPERIMENTAL|Monotherapy Arm|
62297419|NCT04358458|EXPERIMENTAL|Combination Arm|
62297420|NCT03458169|EXPERIMENTAL|LEAP usability|"* Therapist LEAP session feedback~* Participant LEAP session feedback~* LEAP risk control validation"
62297421|NCT01075087|PLACEBO_COMPARATOR|Placebo|(control group) will receive sterile normal saline in the block
62297422|NCT01075087|ACTIVE_COMPARATOR|Active comparator|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
62297423|NCT00748657|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62297424|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA \& stenting (possibly with additional endophlebectomy and AV-fistula)
62297425|NCT02290210|PLACEBO_COMPARATOR|Placebo|Placebo x 2weeks
62297426|NCT02290210|PLACEBO_COMPARATOR|URC102 0.25mg|0.25mg URC102 x 2weeks
62105093|NCT04691544|PLACEBO_COMPARATOR|Fecal microbiota transplant from autologous feces|One FMT delivered by enema
62105094|NCT03673709|NO_INTERVENTION|Individual Antenatal Care (usual care)|Women are provided antenatal care services on a first come, first serve basis and listen to a health lecture. They meet individually with a midwife for a physical assessment. Women complete laboratory tests (including HIV testing) at their first visit. Congruent with the new WHO recommendations, individual antenatal care consists of 8 antenatal care visits and 2 postnatal visits at 1 week and 6 weeks.
62105095|NCT03673709|EXPERIMENTAL|Group Antenatal Care (intervention)|Women have the same number of visits as those in individual care. Their first antenatal care (intake) and first postnatal visit is done individually (identical to individual care). Women in group care bypass the waiting area and have a 2-hour visit with the same provider in a group of 8-12 women at a similar stage of pregnancy. Women assess their blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
62105096|NCT06631456||PRP group|Patients who received intra-articular PRP due to gonarthrosis
62105097|NCT06631456||Ozone group|Patients who received intra-articular ozone therapy due to gonarthrosis
62297427|NCT02290210|EXPERIMENTAL|URC102 0.5mg|0.5mg URC102 x 2weeks
62297428|NCT02290210|PLACEBO_COMPARATOR|URC102 1.0mg|1.0mg URC102 x 2weeks
62297429|NCT02290210|PLACEBO_COMPARATOR|URC102 2.0mg|2.0mg URC102 x 2weeks
62297430|NCT05198648||Postoperative myocardial injury|
62297431|NCT05198648||Non postoperative myocardial injury|
62297432|NCT06479603|ACTIVE_COMPARATOR|NIntedanib|The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily.
62297433|NCT06479603|ACTIVE_COMPARATOR|Standard of care|The subjects will receive the standard-of-care immunosuppressive treatment alone.
62105098|NCT04622527|ACTIVE_COMPARATOR|A = Virtual Reality paradigm A|Begin with Paradigm A virtual reality headgear
62105099|NCT04622527|ACTIVE_COMPARATOR|B = Virtual Reality paradigm B|Begin with Paradigm B virtual reality headgear
62105100|NCT04622527|SHAM_COMPARATOR|C = Non-Virtual Reality paradigm A|Begin with Paradigm A without virtual reality headgear
62105101|NCT04622527|SHAM_COMPARATOR|D = Non-Virtual Reality paradigm B|Begin with Paradigm B without virtual reality headgear
62105102|NCT03006341||Dabigatran etexilate|NVAF patients initiating dabigatran etexilate
62105103|NCT03006341||Warfarin|NVAF patients initiating warfarin
62105104|NCT00100659|ACTIVE_COMPARATOR|Pegylated interferon/ribavirin|"Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.~Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets."
62297434|NCT01289613||Children|Children
62297435|NCT01289613||Adults|Adults
62297436|NCT01923025|EXPERIMENTAL|RO5545965|
62297437|NCT00836940|PLACEBO_COMPARATOR|1|
62297438|NCT00836940|EXPERIMENTAL|2|GRC 8200-25mg OD
62297439|NCT00836940|EXPERIMENTAL|3|GRC 8200-50mg OD
62297440|NCT00836940|EXPERIMENTAL|4|GRC 8200-50mg BD
62297441|NCT00836940|EXPERIMENTAL|5|GRC 8200-100mg OD
62297442|NCT03582358||Verrine|Patients served verrines
62297443|NCT03582358||CNO|Patients served wrapped supplements
62297444|NCT04881838|EXPERIMENTAL|High risk group|"1. Stage I, unresected; Stage I with B syndrome~2. Stage II~3. Stage III~4. Stage IV without CNS involvement"
62297445|NCT03934762|ACTIVE_COMPARATOR|Placebo|A placebo solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
62297446|NCT03934762|EXPERIMENTAL|Natural aloe vera|A natural aloe vera solution (peel and leaf) will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
62297447|NCT03934762|EXPERIMENTAL|Aloe vera soup|An aloe vera soup solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
62297448|NCT06253923|ACTIVE_COMPARATOR|MR-301|"On first day, patient will receive MR-301 at 100 mg intravenous infusion BID. On second day, the dose is elevated to 150 mg intravenous infusion BID.~On third day, the dose is further elevated to 200 mg intravenous infusion BID and maintained up to Day 21"
62297449|NCT06253923|PLACEBO_COMPARATOR|Placebo|
62105105|NCT00100659|PLACEBO_COMPARATOR|Pegylated interferon/placebo|Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).
62105106|NCT06630988||Hand infection|Description of whitlows, tendinous infections and septic arthritis diagnostic, management and outcome Descriptive study, no intervention
62105107|NCT06545175|EXPERIMENTAL|Intracochlear treatment with VSF1.01|
62105108|NCT02417311||Control group|40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
62667092|NCT03792997|EXPERIMENTAL|study|regular treatment with embryo transfer in the form of progesterone I.M. \& Supp. in addition to low dose aspirin \& folic acid but the investigators add in this arm lipid emulsion \& prednisolone \& LMWH
62667093|NCT03695796|OTHER|Single arm|Only one arm because diagnostic study evaluating non-invasive tests using liver biopsy as reference
62667094|NCT01284764|NO_INTERVENTION|midnight fasting|The patients in this group will have midnight fasting the day before endoscopic examination
62667095|NCT01284764|ACTIVE_COMPARATOR|Mosapride, low volume of water|The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.
62667096|NCT03361020||Hodgkin Lymphoma|Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
62667097|NCT03361020||Control Group|The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
62667098|NCT02162433|ACTIVE_COMPARATOR|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
62667099|NCT02162433|PLACEBO_COMPARATOR|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
62667100|NCT02162433|ACTIVE_COMPARATOR|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
62667101|NCT02162433|PLACEBO_COMPARATOR|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
62667102|NCT04914663|EXPERIMENTAL|All-extremity exercise|
62667103|NCT04914663|ACTIVE_COMPARATOR|Treadmill exercise|
62667104|NCT04914663|NO_INTERVENTION|Usual Care|
62667105|NCT01726686|ACTIVE_COMPARATOR|Ropivacaine in the pump|The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
62667106|NCT01726686|PLACEBO_COMPARATOR|Placebo in the pump|The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
62667107|NCT01799395||Lung Cancer|All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied.
61913023|NCT06206954|EXPERIMENTAL|MyHealthPath Tool|Receive MyHealthPath Tool intervention.
62105109|NCT02417311||DCM patients|20 patients with dilated cardiomyopathy
62105110|NCT02417311||HCM patients|20 patients with hypertrophic cardiomyopathy
62667108|NCT00315822|PLACEBO_COMPARATOR|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
62667109|NCT00315822|ACTIVE_COMPARATOR|80% oxygen|Subject undergoing surgery will receive supplemental oxygen
62667110|NCT02825459|EXPERIMENTAL|Abstinence from e-cigarettes|Participants abstain from e-cigarettes and other nicotine/tobacco products for 6 days
62667111|NCT02825459|NO_INTERVENTION|E-cigarette use|Participants use e-cigarettes and continue to abstain from tobacco/nicotine products as they normally would.
62667112|NCT06381284||Participants with undiagnosed neuromuscular symptoms|
62667113|NCT01258855|EXPERIMENTAL|Arm I (ziv-aflibercept and aldesleukin)|Patients receive ziv-aflibercept IV over at least 1 hour in weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62667114|NCT01258855|EXPERIMENTAL|Arm II (aldesleukin)|Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62667115|NCT00508846||HNPCC Patients|
62667116|NCT03128164|EXPERIMENTAL|Six arm including in dose expansion stage by following:|"* Arm A: patients with MZL (subtype including nodal, extra-nodal and splenic) who received ≥ 1 previous line of systematic treatment and at least one line included CD20-directed regimen~* Arm B: patients with CLL/SLL who received ≥ 1 previous line of systematic treatment and at least one of which included purine-based regimen or CD20-directed regimen~* Arm C: patients with FL (grade 1, 2, and 3a) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~* Arm D: patients with MCL who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~* Arm E: patients with DLBCL (including GCB and non-GCB, Richter' transformation) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~* Arm F: patients with PTCL who received ≥ 2 previous line of systematic treatment"
62667117|NCT03890939|EXPERIMENTAL|BiPAP AutoSV Advanced System One|
62667118|NCT03890939|EXPERIMENTAL|Dreamstation BiPAP AutoSV|
62667119|NCT03890939|ACTIVE_COMPARATOR|ResMed S7 VPAP Adapt device|
62667120|NCT01271829|NO_INTERVENTION|Control|While on the control arm subjects will be given a meal with no avocado.
62667121|NCT01271829|ACTIVE_COMPARATOR|Avocado supplement|While on the avocado supplement arm subjects will be given a meal in which a given amount of calories will be replaced by calories contributed by avocados.
62667122|NCT01271829|ACTIVE_COMPARATOR|Avocado included|While on the avocado included arm subjects will be given a meal in which the calories of avocado will be added to the calories of the control meal.
62667123|NCT04711577|EXPERIMENTAL|Condition 1|Track clinician-determined symptoms
62667124|NCT04711577|EXPERIMENTAL|Condition 2|Track clinician-determined and self-determined symptoms
62667125|NCT00215956|EXPERIMENTAL|Dose Escalation and Radiation, Followed by Surgery|Preoperative treatment with radiation and oral topotecan for up to 5 weeks, followed by surgery.
62667126|NCT01769443|NO_INTERVENTION|No Desensitization Therapy|Subject(s) randomized to no desensitization therapy pre-transplant.
62667127|NCT01769443|EXPERIMENTAL|Desensitization Therapy|"Subject(s) randomized to desensitization therapy pre-transplant.~Desensitization therapy regimen pre-transplant: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib."
62667128|NCT04517799|EXPERIMENTAL|cannabidiol|cannabidiol arm
62667129|NCT04517799|PLACEBO_COMPARATOR|placebo|placebo arm
62667130|NCT04710433|ACTIVE_COMPARATOR|Non-invasive Neuromodulation|"Application of non-invasive sacral nerve stimulation for 12 weeks, at least 8 hours per day.~Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field with a 15 Hz frequency for a duration of 210µs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).~Medical and behavioral therapy is to be continued as started before intervention."
62297450|NCT06645340|OTHER|previous smokers|All women at high risk for developing preeclampsia were divided into two groups based on reported smoking status: previous smokers who quit by the positive pregnancy test, and non-smokers.
62297451|NCT06645340|OTHER|non smokers|All women at high risk for developing preeclampsia were divided into two groups based on reported smoking status: previous smokers who quit by the positive pregnancy test, and non-smokers.
62297452|NCT05111314|EXPERIMENTAL|Diagnostic (embolization, 68Ga-PSMA, PET/CT)|Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1 hour.
62667131|NCT04710433|OTHER|Medical/behavioral Therapy|Patients receive an optimized conventional treatment for 12 weeks, including lifestyle changes, toilet training and weight-adjusted medication. Conventional medical options include oral laxative medication with polyethyleneglycol or rectal medication with saline enemas in possible combination with a stimulant laxative (glycerin or bisacodyl).
62667132|NCT04505111|EXPERIMENTAL|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
62667133|NCT04505111|ACTIVE_COMPARATOR|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
62667134|NCT01277068|ACTIVE_COMPARATOR|the adjustable gastric banding|
62667135|NCT01277068|ACTIVE_COMPARATOR|the sleeve gastrectomy|
62297453|NCT05461443|ACTIVE_COMPARATOR|Wild-type|Supplementation with the wild-type of the LGG strain
62297454|NCT05461443|EXPERIMENTAL|Low-pill|Supplementation with the low-pili LGG strain
62667136|NCT01277068|ACTIVE_COMPARATOR|the gastric bypass|
62667137|NCT01783938|EXPERIMENTAL|Cohort A: Nivolumab followed by Ipilimumab|"Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period."
61913024|NCT06206954|ACTIVE_COMPARATOR|MyHealthPath Guide|Receive MyHealthPath Guide intervention
61913025|NCT02225613|ACTIVE_COMPARATOR|Usual protocol|2 weeks conventional rehabilitation 3 weeks conventional rehabilitation
62297455|NCT05461443|EXPERIMENTAL|High-pili|Supplementation with the high-pili LGG strain
62468848|NCT03287310|PLACEBO_COMPARATOR|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
62667138|NCT01783938|EXPERIMENTAL|Cohort B: Ipilimumab followed by Nivolumab|"Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1."
62667139|NCT04639063||Cesarean sectioned|All females who treated in our hospital by Cesarean section operation during two-years-period
62667140|NCT04639063||Complicated with Abdominal wall endometriosis|All the surgically excised endometrioma cases during the same time period
62667141|NCT03621670|EXPERIMENTAL|MenB+PCV Group|Approximately 800 subjects enrolled in this group will receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prev-nar13) and other RIV (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6 and 12 months of age. Subjects who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose will either receive PCV13 or PCV20 at 12 months of age (Visit 5).
62667142|NCT03621670|PLACEBO_COMPARATOR|Placebo+PCV Group|Approximately 400 subjects enrolled in this group will receive PCV13 concomitantly with placebo and other RIV at 2, 4, 6 and 12 months of age. Subjects who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose will either receive PCV13 or PCV20 at 12 months of age (Visit 5).
62667143|NCT03398109|EXPERIMENTAL|Customized toric IOL|Customized toric IOL for post-Dalk atigmatism in cataract patients
62667144|NCT05501379||Cancer Patients|Patients with a verified diagnosis of lymphoma, colorectal or pancreatic cancer requiring surgical, chemo or radio therapy.
62667145|NCT01719094||Childhood Cancer Surviviors|
62667146|NCT01719094||Adolescent/young adults with no cancer history|
62667147|NCT01719094||Newly diagnosed cancer patients|
62667148|NCT02137460||Young normal controls|"* age : 20 \~ 55~* without dementia, MCI, or other major neurological/psychiatric illness"
62667149|NCT02137460||Elderly normal controls|"* age : 55 \~ 90~* without dementia, MCI, or other major neurological/psychiatric illness"
62667150|NCT02137460||MCI (Mild cognitive impairment)|"* age : 55 \~ 90~* without major neurological/psychiatric illness~* concern regarding a change in cognition, lower performance in episodic memory domains that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
62667151|NCT02137460||AD (Alzheimer's diseases)|"* age: 55 \~ 90~* National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia"
61913026|NCT02225613|ACTIVE_COMPARATOR|Spa protocol|2 weeks conventional rehabilitation 3 weeks aquatic rehabilitation
62667152|NCT06133166|EXPERIMENTAL|EG017 ointment 3%|60 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
62667153|NCT06133166|EXPERIMENTAL|EG017 ointment 5%|60 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
62667154|NCT06133166|EXPERIMENTAL|EG017 ointment 9%|60 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
61913027|NCT01191216|EXPERIMENTAL|Arm I|Patients receive oral 1-methyl-d-tryptophan twice daily on days 1-21 and docetaxel IV over 1 hour on day 1 (in course one patients receive 1-methyl-d-tryptophan once daily on days 1 and 3-21).
61913028|NCT01510288|EXPERIMENTAL|Ipilimumab and GVAX|
61913029|NCT03789409|EXPERIMENTAL|Intermittent Fasting|Over rehabilitation treatment during and admission (at least 1 week), intermittent fasting (IF) for more than 12 hours (water can be allowed). For subgroup assignment, participants can choose IF1 (eat early in the evening and late in the morning) or Post-IF2 (eat the remaining two meals without breakfast), depending on own their faver.
61913030|NCT03789409|NO_INTERVENTION|Ad libitium|Participants will be allowed to have hospital meals and all the desired intake without time limit.
62667155|NCT06133166|PLACEBO_COMPARATOR|Placebo A|40 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
62667156|NCT06133166|PLACEBO_COMPARATOR|Placebo B|20 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
62667157|NCT01656746|EXPERIMENTAL|Treatment (single incision laparoscopic surgery)|Patients undergo single incision laparoscopic surgery with GelPort® attachment.
61913031|NCT03526380|EXPERIMENTAL|Treatment|Participants receive the OPT-IN Brief Intervention.
61913032|NCT03526380|NO_INTERVENTION|Control|Participants will only complete the baseline and follow-up surveys.
62667158|NCT06466265|EXPERIMENTAL|Participant Group/Arm|"Experimental: Patients with advanced solid tumors~Dose escalation with patients having solid tumors. Patients receive escalating doses of DNP002 intravenously for 1 hour on Day 1 of each 14-day cycle (Q2W) or each 21-day cycle (Q3W).~This course will be repeated in the absence of disease progression or unacceptable toxicity."
62667159|NCT03687255|EXPERIMENTAL|cefepime/AAI101 combination|Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)
62667160|NCT03687255|ACTIVE_COMPARATOR|piperacillin/tazobactam|Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)
62667161|NCT06458400|EXPERIMENTAL|tegileridine|The loading iv dose: 0.75mg The PCIA dose：0.05mg Lockout time: 10min
62667162|NCT06458400|EXPERIMENTAL|oliceridine|The loading iv dose: 1.5mg The PCIA dose：0.35mg Lockout time: 6min
62667163|NCT06458400|ACTIVE_COMPARATOR|morphine|The loading iv dose: 3mg The PCIA dose：1mg Lockout time: 6min
62667164|NCT01756001||Control Arm|Arm 1 will be the Control arm, in which subjects will be instructed to use the GlowCap for their chronic disease medication but will not be provided with any specific incentive for taking the medication or with any aid in remembering to do so.
62667165|NCT01756001||Reminder Arm|Arm 2 will be the Reminder arm with daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
61913033|NCT01059929|ACTIVE_COMPARATOR|Dexmedetomidine|Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
62297456|NCT06656208|EXPERIMENTAL|Experimental Group|"Pubic symphysis manipulation with 5 repetitions hold for 10 sec and ask the patient to apply max. Contraction and then relax. Whereas, the therapist applies a rapid stretch to a new barrier and is held for 10 seconds.~SIJ mobilizations will be given with 30 Oscillations per set for 15 seconds, 3 sets on effected side along with"
61913034|NCT01059929|ACTIVE_COMPARATOR|Propofol|Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
61913035|NCT03257709|ACTIVE_COMPARATOR|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
62297457|NCT06656208|ACTIVE_COMPARATOR|Control Group|SIJ mobilizations will be given with 30 Oscillations per set for 15 seconds, 3 sets on effected side.
61913036|NCT03257709|ACTIVE_COMPARATOR|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
61913037|NCT03885167||Affected Individuals with Known SCA3|In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
61913038|NCT03885167||Healthy Individual Control Subjects|In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
62297458|NCT05109312|EXPERIMENTAL|Treatment Group 1 Cohort 1|HTX-011 + multimodal analgesic (MMA) regimen
62468849|NCT03287310|EXPERIMENTAL|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
62468850|NCT03287310|PLACEBO_COMPARATOR|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
62468851|NCT03287310|EXPERIMENTAL|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
62667166|NCT01756001||Incentives Arm|Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
62737219|NCT03569449|EXPERIMENTAL|Group 14- Zebra|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and individually-tailored visits
61913039|NCT02246712|ACTIVE_COMPARATOR|Control group|Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for the single nucleotide polymorphism (SNP) 516G\>T in CYP2B6 gene (CYP2B6 genotype).
61913040|NCT02246712|EXPERIMENTAL|T2DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G\>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 2 DM was performed according to the American Diabetes Association (2010)."
61913041|NCT02246712|EXPERIMENTAL|T1DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G\>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 1 DM was performed according to the American Diabetes Association (2010)."
62297459|NCT05109312|ACTIVE_COMPARATOR|Treatment Group 2 Cohort 1|Bupivacaine HCl + MMA
62297460|NCT05109312|EXPERIMENTAL|Treatment Group 1 Cohort 2|HTX-011 + MMA
62297461|NCT05109312|ACTIVE_COMPARATOR|Treatment Group 2 Cohort 2|Bupivacaine HCl + MMA
62297462|NCT01350869||Xience stent|Real world patients treated with XIENCE stents
62297463|NCT06036966|EXPERIMENTAL|Hetrombopag|single-arm
62297464|NCT02154750|ACTIVE_COMPARATOR|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
62297465|NCT02154750|EXPERIMENTAL|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled
62468852|NCT03287310|PLACEBO_COMPARATOR|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
62468853|NCT03287310|EXPERIMENTAL|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
62468854|NCT03287310|PLACEBO_COMPARATOR|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
62468855|NCT03287310|EXPERIMENTAL|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
62468856|NCT03287310|PLACEBO_COMPARATOR|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
62468857|NCT06233747|EXPERIMENTAL|I-CARE|I-CARE (Improving Care, Accelerating Recovery \& Education) is a quality improvement program designed to deliver evidence-based psychosocial skills to adolescents during mental health boarding. The program consists of 7 web-based animated videos and workbook exercises, facilitated by licensed nursing assistants/behavioral health technicians/safety attendants who provide one-on-one safety supervision during boarding. I-CARE will be offered to all eligible adolescents who are boarding and only those who agree to participate in a program evaluation will be involved in the research component.
62468858|NCT06233747|NO_INTERVENTION|Usual Care|"These hospitals currently offer basic safety supervision and medical monitoring for adolescents during mental health boarding. This is the usual care condition."
61913042|NCT01637519||Ureteral stone|Ten (10) patients with a unilateral, mid- or distal, ureteral (tube connecting kidney and bladder in the urinary system) stone will be enrolled and brought to completion in this study.
62105111|NCT04697069|EXPERIMENTAL|ANB019|Participants received a starting dose of 400 milligrams (mg) of imsidolimab on Day 1 followed by 200 mg imsidolimab every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
62105112|NCT04697069|PLACEBO_COMPARATOR|Placebo|Participants received imsidolimab matching placebo on Day 1 and thereafter, every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
62105113|NCT02162667|EXPERIMENTAL|CT-P6|
62105114|NCT02162667|ACTIVE_COMPARATOR|Trastuzumab|
62105115|NCT06305988|EXPERIMENTAL|intervention group（Transcranial direct current stimulation）|tDCS group participants will receive tDCS intervention stimulation for 1 week (1.5mA, 20min/ time, twice a day)
62105116|NCT06305988|PLACEBO_COMPARATOR|control group（Sham Transcranial direct current stimulation）|Placebo comparator group subjects will receive similar sites and the same frequency of spurials (0mA, 20min/ time, twice daily) for 1 week
62105117|NCT04162366|EXPERIMENTAL|Aprocitentan 25 mg|
62105118|NCT04162366|EXPERIMENTAL|Placebo|
62105119|NCT04162366|EXPERIMENTAL|Aprocitentan 25 mg or Placebo|
62105120|NCT03988062|EXPERIMENTAL|TrelliX Embolic Coil System|
62105121|NCT04007302|EXPERIMENTAL|walking with distraction|the patient walks in front of a screen with virtual reality simulation
62105122|NCT04007302|ACTIVE_COMPARATOR|Walking without distraction|the patient walks on a treadmill without virtual reality simulation
62105123|NCT06630182||Type 2 diabetic patients with foot wounds|Patients with type 2 diabetes referred for management of a new diabetic foot wound
62105124|NCT05995574|EXPERIMENTAL|Avatar training|One hundred physician learners will train with the avatar communication training tool as a behavioral intervention. Before the training (T0), the learners will complete a pre-survey to assess their baseline confidence. At the start of training, after a brief introduction and orientation to the tool, the learners will complete a 10-min uninterrupted scenario with a teen-parent avatar dyad about a contraception scenario. After the initial scenario (T1), the learner will pause and complete an assessment to evaluate use of SDM (Shared decision making) skills and PCCC (person-centered contraceptive counseling). Then, the learner will train for an hour with the tool. At the end (T2), the learner will complete another uninterrupted scenario and evaluate their confidence, SDM, and PCCC skills.
62297466|NCT01867489||Chemotherapy, Cancer|Adult cancer patients (with any type of cancer) being treated with chemotherapy
62297467|NCT04253132|ACTIVE_COMPARATOR|50 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
62297468|NCT04253132|ACTIVE_COMPARATOR|300 mg daily oral dose|300 mg daily, oral dose of tolfenamic acid
62297469|NCT04253132|ACTIVE_COMPARATOR|600 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
62297470|NCT04253132|PLACEBO_COMPARATOR|Placebo control - 50 mg daily oral dose|50 mg daily oral placebo control
62297471|NCT04253132|PLACEBO_COMPARATOR|Placebo control - 300 mg daily oral dose|300 mg daily oral placebo control
62297472|NCT04253132|PLACEBO_COMPARATOR|Placebo control - 600 mg daily oral dose|600 mg daily oral placebo control
62737220|NCT03569449|EXPERIMENTAL|Group 15- Elephant|Clinic and community visits, technology-enhanced care, standard pediatric surveillance, and individually-tailored visits
61913043|NCT01863654|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
61913044|NCT01863654|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
61913045|NCT02342093|ACTIVE_COMPARATOR|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
61913046|NCT02342093|ACTIVE_COMPARATOR|20EE+DRSP|Combined oral contraceptive containing 20 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
61913047|NCT05194566|ACTIVE_COMPARATOR|Real tACS|tACS 75Hz intervention combined with language tasks and breathing exercises. The device will operate in tACS research active stimulation mode.
61913048|NCT05194566|SHAM_COMPARATOR|Sham tACS|tACS sham intervention combined with language tasks and breathing exercises. The device will operate in tACS sham simulation research mode.
61913049|NCT03967691|PLACEBO_COMPARATOR|Saline infusion|Subjects will be infused with saline (placebo) on study day 1
61913050|NCT03967691|ACTIVE_COMPARATOR|Tocilizumab infusion|Subjects will be infused with tocilizumab on study day 2
61913051|NCT03967691|OTHER|Saline infusion under tocilizumab influence|Subjects will be infused withsaline (but still under the influence of tocilizumab) on study day 3
61913052|NCT05315011|EXPERIMENTAL|Whole-body cryotherapy|The exposure time will be 4 minutes and 30 seconds in -85°C.
62105125|NCT01704846|EXPERIMENTAL|Treatment sequence 1|Test - Reference - Reference - Test
62105126|NCT01704846|EXPERIMENTAL|Treatment sequence 2|Reference - Test - Test - Reference
62105127|NCT06631781|EXPERIMENTAL|GOLD-Cog+|The experimental group receives 6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).
62105128|NCT06631781|NO_INTERVENTION|Waiting period|The same participants will also participate in 6-weeks of no intervention before or after the 6-week experimental period (i.e. crossover study). This will be used as the 'control' group.
62297473|NCT04579549|EXPERIMENTAL|Repeat Testing for SARS-CoV-2|Anyone over the age of 5yrs old with consent to provide a saliva sample for SARS-CoV-2 assay will be eligible to participate. Assay takes 20 minutes.
62297474|NCT00751413|EXPERIMENTAL|1|MK0633
62308297|NCT03340805|EXPERIMENTAL|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
62308298|NCT03340805|ACTIVE_COMPARATOR|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
62105129|NCT00452465|EXPERIMENTAL|Intervention|A research nurse will meet with participants, complete a detailed nursing assessment and develop of a care plan to help connect participants with resources to allow them to stay in their homes longer.
62308299|NCT05459805|EXPERIMENTAL|group 1|those receive ICS/LABA plus traditional Chinese medicine
61913053|NCT05315011|PLACEBO_COMPARATOR|Placebo cryotherapy|The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
62468859|NCT04342559|EXPERIMENTAL|Group I|"Belamy with sinodor Vaginal Moisturizer with Odor Neutralizer - code: 062603-07~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
62667167|NCT01756001||Incentives and Reminders Arm|Arm 4 will be the financial incentives and reminders arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform. They will also receive daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
62105130|NCT00452465|NO_INTERVENTION|Control|Usual Care
62105131|NCT05117450|ACTIVE_COMPARATOR|HeprAN first|Each included patient will have hemodialysis sessions with HeprAN membrane and then HYDROLINK
62105132|NCT05117450|ACTIVE_COMPARATOR|HYDROLINK first|Each included patient will have hemodialysis sessions with HYDROLINK and then HeprAN membrane
62105133|NCT06204796|ACTIVE_COMPARATOR|Vitamin D+ Systemic steroids|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
62105134|NCT06204796|ACTIVE_COMPARATOR|Systemic steroids alone|systemic steroids only
61913054|NCT04260932|EXPERIMENTAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
61913055|NCT00577525||1|Case : Patients with steroid sensitive nephrotic syndrome
62308300|NCT05459805|ACTIVE_COMPARATOR|group 2|those receive ICS/LABA alone
62105135|NCT04884399|EXPERIMENTAL|CMAB818|0.5 mg by intravitreal injection once on the first day.
62105136|NCT04884399|ACTIVE_COMPARATOR|Lucentis®|0.5 mg by intravitreal injection once on the first day.
62105137|NCT06631898|EXPERIMENTAL|SaaTwae Bio-Natural Moisturizing Cream|A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
62105138|NCT03213678|EXPERIMENTAL|Treatment (samotolisib)|Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, CT, MRI, FDG-PET, and blood sample collection on study.
62105139|NCT03360396|EXPERIMENTAL|Endobronchial Coils|Treatment with PneumRx Endobronchial Coil System
62105140|NCT03360396|NO_INTERVENTION|Control|Medically-managed control group
62308301|NCT04698408|EXPERIMENTAL|high-protein, carbohydrate-reduced diet|
62308302|NCT04698408|ACTIVE_COMPARATOR|Dutch Nutritional Guidelines|
62308303|NCT06399549|EXPERIMENTAL|Dead bug exercise|
62308304|NCT06399549|EXPERIMENTAL|The McGill Curl Up|
62308305|NCT06456723|EXPERIMENTAL|[18F]-FET-βAG-TOCA-PET/CT|Radiotracer: \[18F\]-FET-βAG-TOCA Imaging Modality: PET/CT Max. Injected Dose: 370 megabecquerel (MBq) Total Effective Dose per Patient: 12 millisieverts (mSv) (cohort 1) and 14mSv (cohort 2)
62308306|NCT04031261||National Validation|All patients must have a diagnosis of severe asthma, be taking high dose inhaled corticosteroids (GINA step 4 \& 5), and be aged 16 years or over.
62308307|NCT04031261||Sensitivity to Change|Patients commencing a biologic treatment for their severe asthma (GINA step 4 \& 5), as per National Institute for Health and Care Excellence (NICE) guidelines.
62308308|NCT00149214|EXPERIMENTAL|A: Pemetrexed Plus Doxorubicin, Followed by Docetaxel|
62308309|NCT00149214|ACTIVE_COMPARATOR|B: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel|
62308310|NCT03283839|OTHER|Temporomandibular disorder|
62308311|NCT03283839|OTHER|Without temporomandibular disorder|
62308312|NCT04316481|OTHER|AngelMed Guardian System|All eligible subjects will have the AngelMed Guardian System implanted with alerting features turned ON; receive an external device which provides additional alerting; and receive training on system use.
62308313|NCT05387330||CP-CML patients|Twenty five newly diagnosed CP-CML patients. Plasma sCD62L and serum SPARC levels were measured using commercially available ELISA kits
62308314|NCT05387330||Control|Ten matched controls were enrolled. Plasma sCD62L and serum SPARC levels were measured using commercially available ELISA kits
62308315|NCT02066090|EXPERIMENTAL|Real acupuncture|manual acupuncture + electroacupuncture, twice a week, for 6 weeks
62308316|NCT02066090|SHAM_COMPARATOR|Sham acupuncture|sham acupuncture + placebo acupuncture without electrical stimulation, twice a week, for 6 weeks
62308317|NCT00643045|EXPERIMENTAL|1|Low dose (50-100mg/day)
62308318|NCT00643045|EXPERIMENTAL|2|High dose (150-200 mg/day)
62308319|NCT00643045|PLACEBO_COMPARATOR|3|
62308320|NCT06498375||On-pump cardiac surgery|Patients undergoing cardiac surgery with cardiopulmonary bypass
62297475|NCT05602428|EXPERIMENTAL|The observation group A|The use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block. The patients were subjected to local anesthesia and punctured through the left radial artery for invasive arterial blood pressure monitoring. Anesthesia induction: the observation group followed by intravenous injection of ketamine 0.2mg/kg, sufentanil 0.3μg/kg, Cyclophenol 0.3mg/kg, midazolam 2mg, rocuronium 0.6mg/kg. After the onset of the drug endotracheal intubation, connect anesthesia machine control breathing. Anesthesia was maintained with 1%\~2% sevoflurane inhalation, remifentanil infusion rate was 0.2\~0.3 μg/kg·min, sevoflurane was stopped 30 min before the end of the operation. Patient-controlled intravenous analgesia pump (PCIA) was given for postoperative analgesia. PCIA formula: sufentanil 100ug+ondansetron 8mg+ketorolac tromethamine 60mg+saline to 100ml, pump speed 2ml/h, automatic single dose 3ml, lock time 20min.
62105141|NCT06631352||GB cancer|Patients who were diagnosed with gallbladder cancer and underwent the hepatopancreatoduodenectomy.
62105142|NCT06631352||CCA|Patients who were diagnosed with cholangiocarcinoma and underwent the hepatopancreatoduodenectomy.
62105143|NCT03824899|EXPERIMENTAL|CRT group|Patients With Advanced Rectal Cancer receiving CPT-11-based CRT and blood concentration check
62105144|NCT01002443|ACTIVE_COMPARATOR|H. pylori eradication|
62105145|NCT01002443|PLACEBO_COMPARATOR|placebo|
62105146|NCT03772730||Group 1|Multiply injured patients having at least one operative orthopaedic injury to the pelvis, acetabulum, femur, or diaphyseal tibia with planned definitive fixation to occur prior to discharge.
62308321|NCT06498375||Off-pump cardiac surgery|Patients undergoing cardiac surgery without cardiopulmonary bypass
62468860|NCT04342559|EXPERIMENTAL|Group II|"Belamy without sinodor Vaginal Moisturizer without Odor Neutralizer - code: 062603-08~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
62468861|NCT05218772||Elderly people with moderate or severe haemophilia|
62468862|NCT06510634||endovascular thrombectomy group|The EVT group would include Stent retriever thrombectomy; Aspiration; Balloon angioplasty and/or stenting; Intra-arterial medication; Combination
62468863|NCT06510634||best medical treatment gruop|BMM consisted of IVT antiplatelet drugs, anticoagulation, or combinations of these treatment modalities according to institutional guidelines.
62468864|NCT04133623|EXPERIMENTAL|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
62468865|NCT04133623|ACTIVE_COMPARATOR|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
62468866|NCT03988803|EXPERIMENTAL|All subjects|
62468867|NCT04860804|ACTIVE_COMPARATOR|AOK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
62468868|NCT04860804|ACTIVE_COMPARATOR|OK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine
62468869|NCT04630327||Female Cancer Patients|Female cancer patients with no history of previously diagnosed depression or anxiety and who have been referred to or have been receiving treatment at Almaty Oncology Center or Kazakh Scientific Research Institute of Oncology and Radiology
62468870|NCT04370769||Women with Kidney Disease|Women with kidney disease
62468871|NCT02188953|EXPERIMENTAL|ACCS100|Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.
62667168|NCT00653562|EXPERIMENTAL|1|Patients will receive placebo in one part and zolpidem in the other part
62667169|NCT00770484|EXPERIMENTAL|Propranolol then placebo|Active treatment
62667170|NCT00770484|PLACEBO_COMPARATOR|Placebo then propranolol|Placebo Treatment
62468872|NCT02188953|PLACEBO_COMPARATOR|Calcium carbonate|Participants will consume 1 gram of calcium carbonate at each meal (up to three times per day) for seven days. The calcium carbonate will be administered by mixing a powder sachet into water.
62468873|NCT01624363||Patients undergoing EUS|Patients undergoing EUS for non-pancreatic treatment.
62468874|NCT05608447|ACTIVE_COMPARATOR|FMT capsules|FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 0 (randomization), Day 1, Day 2, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49.
62667171|NCT05849974|EXPERIMENTAL|Hight Myopa|Large Cohort of patients with hight Myopa
62667172|NCT04677166|EXPERIMENTAL|NPWT with Instillation|"NPWT coupled with instillation will be employed via use of V.A.C. VeraFlo device. The protocol to be used is as follows:~Instillation Solution: normal saline Dwell/Soak Time: 30 seconds Cycle Time: 4 hours Pressure: 125mmHg"
62667173|NCT04677166|ACTIVE_COMPARATOR|Standard NPWT|Standard NPWT with use of V.A.C. Ulta device employed at 125mmHg continuous suction.
62667174|NCT04508075|EXPERIMENTAL|SARS-CoV-2 Vaccine|Participants receive 2 doses of SARS-CoV-2 Inactivated Vaccine with 14 days interval, intramuscularly
62105147|NCT02467491|OTHER|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
62105148|NCT01500551|EXPERIMENTAL|Tofacitinib|All patients will be in tofacitinib treatment group.
62105149|NCT03076450|ACTIVE_COMPARATOR|Maximum Oxygenation|Using PVC to set the initial peep, check ABG real-time, and according to PaO2+PaCO2≥400mmHg whether or not to adjust maintain PEEP.
62105150|NCT03076450|EXPERIMENTAL|Lung Ultrasound Re-aeration Score|Combine POC-LUS with PVC in set the initial peep, and then dynamic record LUS-RAS to feedback regulate PEEP.
62308322|NCT04932590|EXPERIMENTAL|Patients|Patients less than 2 years old admitted in the pediatric intensive care unit of the Armand-Trousseau hospital, under invasive mechanical ventilation and in whom a volume expansion is planned by the attending physicians.
62308323|NCT06340412|EXPERIMENTAL|High-fat meal with intact MFGM|
62308324|NCT06340412|EXPERIMENTAL|High-fat meal with destroyed MFGM|
62308325|NCT06340412|EXPERIMENTAL|High-fat meal without MFGM|
62308326|NCT06511427||difficult laryngoscopy|patients with a cormack lehane classification after induction of anesthesia 3 or 4.
62105151|NCT05852366|EXPERIMENTAL|Group A (Experimental group): (n=25): Jasmate toothpaste preparation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Jasmate toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 8 weeks for assessment of the efficacy
62297476|NCT05602428|ACTIVE_COMPARATOR|the control group B|Esketamine subanesthetic dose combined with lumbar plexus block was used. The patient was placed in the healthy lateral decubitus position and ultrasound-guided puncture was performed 4 cm beside the 3rd and 4th lumbar vertebrae (Figure 1B、C). The frequency of the ultrasound probe was 2-5 MHz, and the probe was adjusted until the images below the transverse processes of the 3rd to 5th lumbar vertebrae and the psoas muscle were clearly displayed, and the needle was inserted close to the probe and retracted in the lumbar plexus, and sufentanil 0.5 μg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg were injected after no blood extraction. General anesthesia was then performed using a subanesthetic dose of esketamine and the same maintenance and postoperative analgesic measures were used as in group A.
62297477|NCT05602428|ACTIVE_COMPARATOR|the control group C|general anesthesia was performed with esketamine subanesthetic dose. The same maintenance and postoperative analgesia measures were used as in group A.
62297478|NCT06656806|ACTIVE_COMPARATOR|Determine the presence and concentration of CBD in Subject's plasma with inhaled CBD|Determine the presence and concentration of CBD in the plasma of male and female subjects with generalized anxiety disorder treated with inhaled CBD
62468875|NCT05608447|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 0 (randomization), Day 1, Day 2, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49.
62667175|NCT04508075|PLACEBO_COMPARATOR|Placebo|Participants receive 2 doses of placebo with 14 days interval, intramuscularly
62667176|NCT00357604|ACTIVE_COMPARATOR|A1|
62667177|NCT00357604|EXPERIMENTAL|A2|
62667178|NCT00639379|EXPERIMENTAL|senofilcon A|senofilcon A toric daily wear contact lenses
62667179|NCT00639379|ACTIVE_COMPARATOR|alphafilcon A|alphafilcon A toric daily wear contact lenses
62667180|NCT05389787|EXPERIMENTAL|TMS|
62667181|NCT05389787|SHAM_COMPARATOR|Sham|
62667182|NCT02845349|EXPERIMENTAL|Drug-Vortioxetine|The treatment group will receive vortioxetine 10 mg per day, which will be increased to 20 mg or decreased to 5 mg, if deemed clinically necessary, at week 4 or 8.
62667183|NCT02845349|PLACEBO_COMPARATOR|Placebo|Matching placebo will be used.
62297479|NCT06656806|ACTIVE_COMPARATOR|Measure concentrations of CBD is spot urine collections in subjects with inhaled CBD|Measure concentration of CBD in spot urine collections in subject's with generalized anxiety disorder treated with inhaled CBD
62297480|NCT01552434|EXPERIMENTAL|Group I (temsirolimus, bevacizumab, cetuximab)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62297481|NCT01552434|EXPERIMENTAL|Group II (temsirolimus, bevacizumab, valproic acid)|Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62297482|NCT01552434|EXPERIMENTAL|Group III (temsirolimus, bevacizumab)|Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62297483|NCT00743886|PLACEBO_COMPARATOR|2|saline
62297484|NCT00743886|EXPERIMENTAL|1|Plasma Rich in Growth Factors (PRGF)
62297485|NCT04430907||Vaccine Accepting|This group will receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
62468876|NCT02276339|EXPERIMENTAL|Single arm ankle exercise intervention|Chronic Ankle Instability Group assessed pre and post a 6 week eccentric - concentric exercise intervention
62667184|NCT04462679|EXPERIMENTAL|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
62667185|NCT03182712|EXPERIMENTAL|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
62667186|NCT03182712|PLACEBO_COMPARATOR|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
62667187|NCT01053936|EXPERIMENTAL|Bardoxolone methyl: 5 mg|
62667188|NCT01053936|EXPERIMENTAL|Bardoxolone methyl: 10 mg|
62667189|NCT01053936|EXPERIMENTAL|Bardoxolone methyl: 15 mg|
62667190|NCT01053936|EXPERIMENTAL|Bardoxolone methyl: 30 mg|
62667191|NCT01053936|EXPERIMENTAL|Bardoxolone methyl: 2.5 mg|
62667192|NCT03964129|EXPERIMENTAL|Avance Nerve Graft with autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested . Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained.
62737221|NCT03569449|EXPERIMENTAL|Group 16- Giraffe|Clinic and community visits, technology-enhanced care, enhanced pediatric surveillance, and individually-tailored visits
62297486|NCT04430907||Vaccine Rejecting|This group will not receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
62297487|NCT04515355|EXPERIMENTAL|People with MS (PwMS)|People with MS recruited to take part and will be randomised to receive the intervention of online programme of support.
62297488|NCT04515355|NO_INTERVENTION|People with MS (PwMS) - standard care|People with MS recruited to take part and will be randomised to receive the usual standard of care.
62297489|NCT01569581|EXPERIMENTAL|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
62737222|NCT02033629|ACTIVE_COMPARATOR|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
62297490|NCT01569581|EXPERIMENTAL|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
62297491|NCT01569581|EXPERIMENTAL|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
62105152|NCT05852366|ACTIVE_COMPARATOR|Group B (Positive Control): (n=25): Bioactive glass based BioMin F toothpaste preparation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Biomin F toothpaste (Bioactive glass with Calcium, Phosphate and Fluoride) onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 8 weeks for assessment of the efficacy
62667193|NCT03722888|EXPERIMENTAL|adolescents who have previously smoked|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, behaviors around smoking, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
62667194|NCT04317027|EXPERIMENTAL|All subjects|All subjects in this trial will receive the new fighting clothing while performing the study protocol
62667195|NCT01526369|ACTIVE_COMPARATOR|Paclitaxel and Trastuzumab|Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
62667196|NCT01526369|EXPERIMENTAL|Paclitaxel, Trastuzumab and Lapatinib|"Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)~+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal."
62667197|NCT02842671|EXPERIMENTAL|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the the procedure will serve as our intervention group. The participants will be assigned an Ambassador throughout the procedure and will complete a patient satisfaction survey afterwards. The investigators hope to enroll 25 controls.
62667198|NCT02842671|NO_INTERVENTION|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the patient's procedure will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the procedure. No ambassador will be assigned for the procedure day. The investigators hope to enroll 25 controls.
62667199|NCT01522027|EXPERIMENTAL|Nerve stimulator|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
62105153|NCT05852366|PLACEBO_COMPARATOR|Group C (Negative Control): (n=25): Placebo toothpaste without any active desensitizing agent|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Placebo toothpaste without any active desensitizing agent onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 8 weeks for assessment of the efficacy
62105154|NCT04908982|EXPERIMENTAL|Aspirin|Participants in this arm will be instructed to take 1 81mg aspirin daily beginning between weeks 12 and 16 of pregnancy and continuing until delivery.
62105155|NCT04908982|NO_INTERVENTION|No Aspirin|Participants in this arm will receive no aspirin.
62105156|NCT03738657||Screening|Olfactory screening
62667200|NCT03794063||Robson group 1|Nulliparous women, single cephalic, more than or equal to 37 weeks, in spontaneous labour
62667201|NCT03794063||Robson Group 2|Nulliparous women, single cephalic, more than or equal to 37 weeks, induced or Caesarean section before labour
62667202|NCT03794063||Robson Group 3|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more than or equal 37 weeks gestation in spontaneous labour
62667203|NCT03794063||Robson Group 4|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more or equal 37 weeks gestation who had labour induced or were delivered by Caesarean section before labour
62667204|NCT03794063||Robson Group 5|All Multiparous women with at least one CS with a single cephalic pregnancy, more or equal to 37 weeks gestation
62105157|NCT03738657||On Study|Taste testing
62105158|NCT05656092|EXPERIMENTAL|HIP0612|Taking HIP0612+HPP2202 once daily for 4 or 8 weeks.
62667205|NCT03794063||Robson Group 6|All nulliparous women with a single breech pregnancy
62667206|NCT03794063||Robson Group 7|Multiparous women with a single breech pregnancy including women with previous Caesarean section
62667207|NCT03794063||Robson Group 8|All women with multiple pregnancies including women with previous Caesarean sections
62667208|NCT03794063||Robson Group 9|All women with a single pregnancy with a transverse or oblique lie, including women with previous Caesarean Section (s)
62105159|NCT05656092|ACTIVE_COMPARATOR|RLD2204|Taking RLD2204+HPP2201 once daily for 4 or 8 weeks.
61913056|NCT00577525||2|Controls (matched for age and sexe with the first group)
62105160|NCT00886808|EXPERIMENTAL|1|110 microgram dose of iCo-007 Intravitreal Injection
62105161|NCT00886808|EXPERIMENTAL|2|350microgram dose of iCo-007 Intravitreal Injection
62468877|NCT06037772|EXPERIMENTAL|Subcutaneous injection practice game|After the subcutaneous injection was explained to the experimental group, the digital game developed for subcutaneous injection was explained and they were allowed to play the game for a week. Afterwards, the experimental group was shown the subcutaneous injection application on a low-reality model of the abdomen, and the students were allowed to practice the skill.
62667209|NCT03794063||Robson Group 10|All women with a single cephalic pregnancy less than 37 weeks gestation, including women with previous Caesarean section (s)
61913057|NCT00694538|ACTIVE_COMPARATOR|1|100 patients are being treated with a single laser beam over pain area.
61913058|NCT00694538|EXPERIMENTAL|2|100 patients are being treated with interferential laser from two independent sources
62105162|NCT00886808|EXPERIMENTAL|3|700microgram dose of iCo-007 Intravitreal Injection
62297492|NCT01569581|EXPERIMENTAL|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
62468878|NCT06037772|ACTIVE_COMPARATOR|Traditional education|The students in the control group were given the traditional education method (subcutaneous injection application on a low-reality abdominal model after the completion of the theoretical course on the subject of subcutaneous injection).
62105163|NCT00886808|EXPERIMENTAL|4|1,000microgram dose of iCo-007 Intravitreal Injection
62105164|NCT00556062|EXPERIMENTAL|1: Lot 1|
62105165|NCT00556062|EXPERIMENTAL|2: Lot 2|
62105166|NCT00556062|EXPERIMENTAL|3: Lot 3|
62105167|NCT00556062|ACTIVE_COMPARATOR|4: control vaccine|
62105168|NCT00623922|EXPERIMENTAL|1|Patient education
61913059|NCT04199702|OTHER|Same day discharge|
62297493|NCT01569581|NO_INTERVENTION|0U/0.5ml in infants (6-11 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 6-11 months old on day 0, 28
62468879|NCT04197765|SHAM_COMPARATOR|Sham|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
62468880|NCT04197765|ACTIVE_COMPARATOR|Active acTBS|"For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays."
62468881|NCT03696394|NO_INTERVENTION|Group I|Group I consists of 5 patients receiving a microfracture as per standard of care.
62468882|NCT03696394|ACTIVE_COMPARATOR|Group II|Group II consists of 10 patients receiving a microfracture with BioCartilage®.
62667210|NCT04627753|EXPERIMENTAL|Lenalidomide and Rituximab therapy|"The clinical trial drug is administered in one cycle for 28 days and is administered as follows.~Drug : Rituximab It will be administered 375 mg/m² IV infusion Day 1. (Rituximab: up to 6 cycles)~Drug : Lenalidomide It will be administred 20 mg PO day 1 -21.~The medication is taken for up to 2 years, and if there is no recurrence, it is stopped after 2 years~, Or stop when disease progression is confirmed during the administration period."
62297494|NCT01569581|NO_INTERVENTION|0U/0.5ml in infants (12-23 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 12-23 months old on day 0, 28
62105169|NCT00623922|NO_INTERVENTION|2|Usual care
62105170|NCT05633043||16-18 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110\*3 (age classes)\*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50\*3\*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
62297495|NCT01569581|NO_INTERVENTION|0U/0.5ml in children (24-35 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1500 children aged 24-35 months old on day 0, 28
62297496|NCT01569581|NO_INTERVENTION|0U/0.5ml in children (36-71 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1000 children aged 36-71 months old on day 0, 28
62297497|NCT04740229|EXPERIMENTAL|Moderate-intensity flow-based Yoga|The intervention will consist of participants engaging in a progressive series of moderate-intensity, flow-based yoga poses, along with breathing and relaxation, for eight weeks. The intervention will be titrated in terms of supervision, with first two weeks being completely supervised, followed by partial supervision for three weeks, and three weeks of unsupervised sessions. The sessions will be \~50 minutes long, 3 times/week. All supervised sessions will be conducted online through Google Meet (GM), which is a live video interaction platform. Videos will be provided to guide unsupervised sessions. Sessions will be led by a certified yoga instructor. An orientation will be provided in the first week, given that the participants will have no or minimal experience with yoga. The intervention will consist of basic sun salutations of hatha yoga sun salutation A, sun salutation B and flow sequences, and breathing exercises, and relaxation.
62297498|NCT04740229|NO_INTERVENTION|Waitlist control|Participants in this group will not receive the 8-week intervention during the course of the study, and will be asked to engage in their regular activities. They will be asked to not start any new activities during the study period. After they complete the study, they will be provided with the same intervention (live instruction, feedback and supportive videos).
62468883|NCT01633450|EXPERIMENTAL|Zinc biofortified rice|
62468884|NCT01633450|ACTIVE_COMPARATOR|Rice extrinsically fortified with zinc|
62468885|NCT04546282||Osimertinib treated patients|Patients with metastatic adenocarcinoma of the lung for whom a 3rd generation TKI therapy is proposed and a search for resistance mutation by blood analysis as part of the usual management.
62468886|NCT03212573|EXPERIMENTAL|ERAS protocol|ERAS protocol includes early oral intake (6 hours after surgery), early deambulation (6h after surgery) and multimodal analgesia (port-sites infiltration with Bupivacain 0.5% combined with postoperative intravenous analgesia)
62468887|NCT03212573|ACTIVE_COMPARATOR|Standard care|Oral intake and early deambulation begins 24h after surgery and analgesia consists in only intravenous drugs
62468888|NCT05396963|OTHER|Egg white - Whey protein - Maltodextrin|Participants will receive egg white, whey protein, and maltodextrin in this order.
62468889|NCT05396963|OTHER|Egg white - Maltodextrin - Whey protein|Participants will receive egg white, maltodextrin, and whey protein in this order.
62468890|NCT05396963|OTHER|Whey protein - Egg white - Maltodextrin|Participants will receive whey protein, egg white, and maltodextrin in this order.
62308327|NCT06511427||Easy laryngoscopy|patients with a cormack lehane classification after induction of anesthesia 1 or 2.
62105171|NCT05633043||16-18 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110\*3 (age classes)\*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50\*3\*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
62105172|NCT05633043||18-25 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110\*3 (age classes)\*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50\*3\*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
62105173|NCT05633043||18-25 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110\*3 (age classes)\*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50\*3\*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
62105174|NCT05633043||25-45 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110\*3 (age classes)\*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50\*3\*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
62297499|NCT02972827|EXPERIMENTAL|NICOM/FloTrac|500-1000ml Crystalloid fluid challenge (normal saline or plasmalyte) to be given for positive passive leg raise test by either device, and also will be given at baseline, regardless of baseline PLR response.
62297500|NCT06234904|EXPERIMENTAL|IBR733 Cell Injection|
62297501|NCT00816803|EXPERIMENTAL|BM transplant with physiotherapy|Autologous BM transplant
62297502|NCT00816803|ACTIVE_COMPARATOR|Physiotherapy only|conventional physical therapy for chronic spinal cord injury.
62468891|NCT05396963|OTHER|Whey protein - Maltodextrin - Egg white|Participants will receive whey protein, maltodextrin, and egg white in this order.
62297503|NCT05180812|EXPERIMENTAL|Experimental Group: Gravity Compensation|The participants will be wearing the ExoNet device tuned to gravity support.
62297504|NCT05180812|SHAM_COMPARATOR|Control Group: No Gravity Compensation|The participants will be wearing the ExoNet device, but it will not be tuned to gravity support.
62297505|NCT04318392||Patients with suspected sarcoidosis|Patients presenting with suspected sarcoidosis.
62297506|NCT04318392||Healthy controls|Healthy controls matched for age and gender. Recruitment of spouses and partners will also take place where possible.
62297507|NCT02748343|ACTIVE_COMPARATOR|allograft bone|traditional allograft bone
62297508|NCT02748343|EXPERIMENTAL|tissue-engineered bone|tissue-engineered bone
62468892|NCT05396963|OTHER|Maltodextrin - Egg white - Whey protein|Participants will receive maltodextrin, egg white, and whey protein in this order.
62667211|NCT03383939|EXPERIMENTAL|group A|"10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month.~Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month"
61913060|NCT02359175|ACTIVE_COMPARATOR|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
61913061|NCT02359175|ACTIVE_COMPARATOR|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
62297509|NCT03384329|EXPERIMENTAL|Resveratrol Pill|
61913062|NCT02916121|EXPERIMENTAL|folic acid 5 mg/cap|folic acid 5 mg/d and vitamin B12 500 ug/d
61913063|NCT02916121|PLACEBO_COMPARATOR|placebo|placebo
61913064|NCT02472509|EXPERIMENTAL|Open Label|32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
61913065|NCT01032473||GAD|Children between the ages of 7-11 years diagnosed with Generalized Anxiety Disorder (GAD)
61913066|NCT01032473||Control|Children between the ages of 7-11 years free of significant medical or behavioral problems (matched to children diagnosed with GAD based on age, gender, and ethnicity).
61913067|NCT06252077|EXPERIMENTAL|very low ketogenic diet|patients with overweight and obesity in treatment for weight loss
61913068|NCT00881543|PLACEBO_COMPARATOR|1|This arm will begin taking the placebo by a month, after a month will be tested the diets (the same caloric amount with different composition on fat, protein and carbohydrates)making curves of insulin, glucagon, C peptide and glp 1 and lipid when diets are tested (three acute tests with diets). After that, the patient will begin the drug by month (Januvia, 100 mg a day)and repeat all the three curves using the prepared diets to compare with the first month.
62105175|NCT05633043||25-45 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110\*3 (age classes)\*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50\*3\*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
62468893|NCT05396963|OTHER|Maltodextrin - Whey protein - Egg white|Participants will receive maltodextrin, whey protein, and egg white in this order.
62667212|NCT03383939|PLACEBO_COMPARATOR|group B|"9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month.~intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month."
62667213|NCT03383939|NO_INTERVENTION|Control|10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
62667214|NCT01170130|EXPERIMENTAL|Lidmyd|The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
61913069|NCT00881543|ACTIVE_COMPARATOR|2|Since the beginning they will use the drug. Then will make the three tests and after will stop the drug by 1 month and come back to do the tests. We objective to demonstrate the washout of the drug clinically.
61913070|NCT04367571|EXPERIMENTAL|Osteopathic Manipulative Treatment|
61913071|NCT04367571|PLACEBO_COMPARATOR|Manual Placebo|
61913072|NCT00767182||Pregnant patients with VPP antecedent|Pregnancy women consulting for an scan during their 12th week of amenorrhea at the University Hospital of Saint Etienne will be studied in this clinical trial. They have an history of VPP (Vascular Placental Pathology). They will have to give a blood sample.
62105176|NCT06076343|EXPERIMENTAL|Dialectical behavior therapy/Family Connections|Outpatients with a diagnosis of BPD will be assigned to DBT skills-training intervention (6-10 participants per group). Each DBT skills-training group will receive 24 sessions. Family members of people with BPD will be assigned to psychoeducational intervention. Each FC group (10-12 participants) will receive 12 sessions. Each session for BPD patients and for caregivers lasts 1.5 hours and it is conducted by a leader and a co-leader (two trained psychotherapists).
62468894|NCT00007722||1|
62667215|NCT05787509|EXPERIMENTAL|The Trial group|we will prolong the duration of vaginal progesterone treatment until 24 weeks of gestation.
62667216|NCT05787509|EXPERIMENTAL|The control group|we will use vaginal progesterone treatment until 12 weeks of gestation.
61913073|NCT05944328|EXPERIMENTAL|intervention group|
62105177|NCT05771090|EXPERIMENTAL|Study arm|Participants in the study arm will undergo the study procedure which are different induced glycaemic states.
62468895|NCT01935076||Obese mother/ Macrosomic baby|Obese mother that delivers a macrosomic neonate to understand the effects neonatal exposure to maternal obesity.
62468896|NCT01935076||Obese mother/ normal weight baby|Obese mother that delivers a normal weight neonate to understand effects neonatal exposure to maternal obesity.
62667217|NCT01610388|EXPERIMENTAL|Cohort A1|Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
62667218|NCT01610388|EXPERIMENTAL|Cohort A2|Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
62667219|NCT01610388|EXPERIMENTAL|Cohort B|Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days
62667220|NCT01610388|EXPERIMENTAL|Cohort C|Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days
62667221|NCT01610388|EXPERIMENTAL|Cohort D|Single dose 2000mg IV GSK1322322J/placebo
62667222|NCT01610388|EXPERIMENTAL|Cohort E|Single dose 3000mg IV GSK1322322J/placebo
62667223|NCT01610388|EXPERIMENTAL|Cohort F|1000mg IV GSK1322322J/placebo followed by BID for 4 days
61913074|NCT05944328|NO_INTERVENTION|control group|
61913075|NCT02507960|OTHER|Pilot Study|The patient will undergo a conventional CT simulation in supine position without the breast immobilization cup. The purpose of the CT simulation is-two-fold: 1) the investigators will see if the TB volume can be accurately delineated and if the TB volume is too large for Gamma Pod boost; and 2) the CT images are used for planning the patient's whole breast irradiation. If, after viewing the CT images and the patient is deemed a study candidate and consents, the participants will receive a second CT-sim and the Gamma Pod TB boost treatment on the same day as described below.
61913076|NCT00521300|EXPERIMENTAL|octreotide|6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
61913077|NCT00521300|ACTIVE_COMPARATOR|standard surgery|Standard transphenoidal surgery soon after the diagnosis of acromegaly
61913078|NCT01092832|EXPERIMENTAL|Active voriconazole|All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
61913079|NCT06086015|EXPERIMENTAL|Active group|
61913080|NCT06086015|PLACEBO_COMPARATOR|Sham group|
61913081|NCT05484687|EXPERIMENTAL|Lidocaine is used in radical resection of colorectal tumors.|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
61913082|NCT02535780|EXPERIMENTAL|TMS Treatment Group|15 sessions active Transcranial magnetic stimulation (TMS) treatment
62667224|NCT03609840||Pediatric Hematopoietic Stem Cell Transplant Recipients|Children undergoing hematopoietic stem cell transplant (HCT) at University of California, San Francisco Benioff Children's Hospital
62667225|NCT00387127|EXPERIMENTAL|Lapatinib|1500mg lapatinib orally daily
62667226|NCT00387127|PLACEBO_COMPARATOR|Placebo|orally daily
62737223|NCT02033629|ACTIVE_COMPARATOR|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
62737224|NCT02033629|PLACEBO_COMPARATOR|Ce 3 ng/ml|Remifentanil Ce 3 ng/ml
62468897|NCT01935076||Normal weight mother/ Macrosomic baby|Normal weight mother that delivers a macrosomic neonate
62667227|NCT02475837|ACTIVE_COMPARATOR|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
62737225|NCT05442723|OTHER|Case|Patients with extensive LAD disease treated with off-pump CABG
61913083|NCT02535780|SHAM_COMPARATOR|TMS Sham Group|15 sessions sham Transcranial magnetic stimulation (TMS) treatment
62105178|NCT02661568||Population with condition and with exposure|
62105179|NCT04699669|OTHER|Cohort 1: CBL-514 2 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2
62105180|NCT04699669|OTHER|Cohort 2: CBL-514 10 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2
62105181|NCT04699669|OTHER|Cohort 3: CBL-514 20 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2
62105182|NCT04699669|OTHER|Cohort 4: CBL-514 40 mg, 1.0 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2
62737226|NCT05442723|OTHER|Control|Patients with extensive LAD disease treated with on-pump CABG
62468898|NCT01935076||Normal weight mother/ Normal weight baby|Normal weight mother who delivered a normal weight neonate
62468899|NCT02350647|EXPERIMENTAL|HEALICOIL Regenesorb|Suture anchor for rotator cuff repair
62468900|NCT02350647|ACTIVE_COMPARATOR|Twinfix Ultra HA|Suture anchor for rotator cuff repair
62297510|NCT03384329|PLACEBO_COMPARATOR|Placebo|
62297511|NCT05628844||Healthy subjects|Healthy persons ≥ 18 yrs of age
62468901|NCT05223894|EXPERIMENTAL|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
62297512|NCT05628844||Critically ill patients|Critically ill patients ≥ 18 yrs of age admitted to the ICU
62297513|NCT05046288|EXPERIMENTAL|Group 1|Participants will participate to the 3-month cycle of virtual guided tour of the MMFA and will complete assessments at M0 and at M3
62297514|NCT05046288|NO_INTERVENTION|Group 2|Participants will not participate to the 3-month cycle of virtual guided tour of the MMFA but will complete assessments at M0 and at M3
62297515|NCT03737825|ACTIVE_COMPARATOR|Program 1|Computerized gaming rehabilitation Program 1.
62468902|NCT05223894|SHAM_COMPARATOR|Control|Coronary artery bypass grafting surgery only.
62468903|NCT01814930|NO_INTERVENTION|Routine Care|Routine postpartum contraceptive counseling
62468904|NCT01814930|EXPERIMENTAL|Individual counseling|Brief standardized contraceptive counseling intervention
61913084|NCT02535780|EXPERIMENTAL|tDCS Treatment Group|15 sessions active Transcranial direct current stimulation (tDCS) treatment
62468905|NCT04711980|EXPERIMENTAL|Mudan granule|"Based on the standard medical care, experimental group were treated with Mudan Granule 7g , 3 times/d.~Intervention: Drug: Mudan granule"
62468906|NCT04711980|PLACEBO_COMPARATOR|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 7g , 3 times/d Intervention: Drug: Placebo
62468907|NCT01517854|ACTIVE_COMPARATOR|Revatio|
61913085|NCT02535780|SHAM_COMPARATOR|tDCS Sham Group|15 sessions sham Transcranial direct current stimulation (tDCS) treatment
61913086|NCT02698995|PLACEBO_COMPARATOR|Group A|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+1 ml saline=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS \<3. After 2 h morphine was administered SC ½ of the total loading dose at request.
61913087|NCT02698995|ACTIVE_COMPARATOR|Group B|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+2 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS \<3. After 2 h morphine was administered SC ½ of the total loading dose at request.
61913088|NCT02698995|ACTIVE_COMPARATOR|Group C|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+4 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS \<3. After 2 h morphine was administered SC ½ of the total loading dose at request.
61913089|NCT02444624||not necrotizing enterocolitis group|not necrotizing enterocolitis preterm neonates matched with necrotizing enterocolitis preterm neonates
62468908|NCT01517854|PLACEBO_COMPARATOR|Placebo|
62468909|NCT05279040||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis who will be initiating Trikafta treatment
62105183|NCT04699669|OTHER|Cohort 5: CBL-514 40 mg, 2 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 2 cm\^2
62667228|NCT02475837|PLACEBO_COMPARATOR|Placebo intervention|"This arm will receive the matching placebo.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
62667229|NCT02355834|EXPERIMENTAL|Group 1 (IBD Nurse CONSULT + BOOKLET)|IBD nurse intervention-Will have 3-4 x 30 minute face-to-face sessions over 3 months with an IBD specialist nurse specifically focusing on bowel control. Participants completing at least 3 sessions will be considered to have completed the intervention. They will also be given a booklet and access to all usual care, including nurse-led IBD helpline
62667230|NCT02355834|NO_INTERVENTION|Group 2 (BOOKLET alone)|Will receive the same booklet and access to usual care as Group 1.
62667231|NCT04976972|EXPERIMENTAL|Robotic-Total Knee Replacement (R-TKR)|NAVIO/CORI Surgical System
62105184|NCT04699669|EXPERIMENTAL|Cohort 6: CBL-514 80 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2
62105185|NCT04699669|EXPERIMENTAL|Cohort 7: CBL-514 160 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2
62105186|NCT04699669|EXPERIMENTAL|Cohort 8: CBL-514 240 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2
62105187|NCT04699669|EXPERIMENTAL|Cohort 9: CBL-514 320 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2
62105188|NCT05602155||Group 1|weight bearing situation: patients with partial weight bearing after treatment
62105189|NCT05602155||Group 2|weight bearing: patients with full weight bearing after treatment
62297516|NCT03737825|PLACEBO_COMPARATOR|Program 2|Computerized gaming rehabilitation Program 2.
62297517|NCT06052748|EXPERIMENTAL|Test group|AD-223A+AD-223B+AD-223C Placebo
62297518|NCT06052748|ACTIVE_COMPARATOR|Control group 1|AD-223A+AD-223B Placebo+AD-223C Placebo
62297519|NCT06052748|ACTIVE_COMPARATOR|Control group 2|AD-223A Placebo+AD-223B+AD-223C Placebo
62667232|NCT04976972|ACTIVE_COMPARATOR|Conventional-Total Knee Replacement (C-TKR)|Non-robotic conventional instrumentation
62667233|NCT01312129|EXPERIMENTAL|Sulfasalazine|Sulfasalazine 1500 mg
62667234|NCT01312129|PLACEBO_COMPARATOR|Placebo|Placebo capsule x 3 doses 12 hours apart
62105190|NCT05038969|EXPERIMENTAL|A test|Test drug (Stomopral) 1 capsule contains 40 mg Enteric Coated Pellets of Esomeprazole
62297520|NCT06052748|ACTIVE_COMPARATOR|Control group 3|AD-223A Placebo+AD-223B Placebo+AD-223C
62297521|NCT04800380|NO_INTERVENTION|Routine training|Nursing students in the control group will receive training in routine metric and drug dose calculation in virtual environment.
62297522|NCT04800380|EXPERIMENTAL|Edpuzzle application|Students in the intervention group will watch the routine metric and drug dose calculation training in virtual environment, as well as interactive videos prepared by the first researcher and uploaded to the Edpuzzle application.
61913090|NCT02444624||necrotizing enterocolitis group|necrotizing enterocolitis preterm neonates of gestational age less than or equal to 31+6 weeks of amenorrhoea with confirmed NEC diagnosis (Bell stage II or III)
61913091|NCT05331079|EXPERIMENTAL|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
61913092|NCT05331079|NO_INTERVENTION|Control|20 minutes of rest
61913093|NCT05834595|EXPERIMENTAL|Sequence 1|"* Period 1: D064, D701 - A single oral dose of 2 tablets~* Period 2: CKD-828 - A single oral dose of 1 tablet~* Period 3: D064, D701 - A single oral dose of 2 tablets~* Period 4: CKD-828 - A single oral dose of 1 tablet"
61913094|NCT05834595|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-828 - A single oral dose of 1 tablet~* Period 2: D064, D701 - A single oral dose of 2 tablets~* Period 3: CKD-828 - A single oral dose of 1 tablet~* Period 4: D064, D701 - A single oral dose of 2 tablets"
62105191|NCT05038969|ACTIVE_COMPARATOR|B reference|Reference drug (Nexium) 1 capsule contains 40 mg Esomeprazole
62105192|NCT03717987|ACTIVE_COMPARATOR|Botulinum toxin A injection|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
62297523|NCT02101437|PLACEBO_COMPARATOR|control|normal subjects.
62297524|NCT02101437|ACTIVE_COMPARATOR|clopidogrel|subjects received clopidogrel 75mg qd.
62297525|NCT02101437|ACTIVE_COMPARATOR|ticagrelor|subjects received ticagrelor 90mg qd.
62297526|NCT02101437|ACTIVE_COMPARATOR|cilostazol|subjects received cilostazol 100mg bid.
62297527|NCT04702711||Patients with symptoms of generalized anxiety in primary health care|Patients (18 years or older) with symptoms of generalized anxiety at a primary health care center.
62297528|NCT04702711||Health care professionals|Health care professionals working with patients with symptoms of generalized anxiety in a primary health care center.
62667235|NCT05033457||unilateral biportal endoscopy technique group|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group
62667236|NCT05033457||percutaneous endoscopic transforaminal discectomy group|Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group
62667237|NCT03778333|EXPERIMENTAL|Open label single arm study|All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks.
62667238|NCT05644418|EXPERIMENTAL|Postcardiac surgery ICU-patients|After postcardiac surgery patients are brought to the ICU and are ventilated on PCV (Pressure Controlled Ventilation). Measurements of the lung volume (by Electrical Impedance Tomography; EIT), the minute volume and Mechanical Power/Dissipated energy are started and continued for the duration of the study. After a few minutes the patient is switched to FCV (Flow Controlled Ventilation) for 90 minutes and afterwards PCV is resumed with the measurements lasting for another 30 minutes (total study time 120 minutes).
62667239|NCT01535105||Obese Adolescents|
62667240|NCT01996995|EXPERIMENTAL|Nd:YAG laser pulse therapy|Nd:YAG laser pulse therapy Patients are treated with laser session in week 0, 2, 4, and 12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2, 5 Hz, power 10 W, pulse duration 132 millisecond. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.
62667241|NCT01996995|SHAM_COMPARATOR|Sham|Sham treatment Patients are treated with a sham session in week 0, 2, 4, and 12. The study settings are similar to the laser except the laser beam. Because the patient is also blinded, they can't see the procedure. The sound and the beeps are audible similar to the laser treatment.
62667242|NCT01815190||IgA-positive vasculitis|Patients with immune complex vasculitis who show perivascular deposits of IgA
62667243|NCT01815190||IgA-negative vasculitis|Patients with immune complex vasculitis who show no perivascular deposits of IgA
62667244|NCT03132272|EXPERIMENTAL|Immunoadsorption with Globaffin for Alzheimer Dementia|Immunoadsorption with Globaffin
62667245|NCT02370862|EXPERIMENTAL|Bowel Evacuation Study with NEO and GLY|The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
62667246|NCT00335075|EXPERIMENTAL|Temodal group|Subjects treated with temozolomide.
62667247|NCT00335075|ACTIVE_COMPARATOR|Semustine group|Subjects treated with semustine.
62667248|NCT01574560|ACTIVE_COMPARATOR|Control Group - Health Education|This group is provided with information regarding secondhand smoke and creating a healthy home environment.
62667249|NCT01574560|ACTIVE_COMPARATOR|Treatment Group - Counseling|This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
62667250|NCT01319370|PLACEBO_COMPARATOR|vehicle of 5% Minoxidl topical foam|vehicel foam in twice daily application in temple and vertex region
62667251|NCT01319370|ACTIVE_COMPARATOR|5% Minoxidil topical foam|5% Minoxidil topical in twice daily application in temple and vertex region
62297529|NCT02656472|ACTIVE_COMPARATOR|Tranexamic Acid Arm|TXA arm will include 10 subjects who will receive TXA for duration of surgery.
62667252|NCT00793065||1|Physicians that are using paper-based medical charts and who are not receiving Medical Home redesign incentives.
62667253|NCT00793065||2|Physicians that are using Electronic Health Records (EHRs) and who are not undergoing Medical Home redesign.
62667254|NCT00793065||3|Physicians that are using Electronic Health Records (EHRs) and undergoing Medical Home redesign.
62667255|NCT03812250|ACTIVE_COMPARATOR|ERCP assisted trans-papillary drainage|ERCP assisted trans-papillary drainage for malignant biliary obstruction
62667256|NCT03812250|ACTIVE_COMPARATOR|EUS-guide biliary drainage|EUS-guide biliary drainage for malignant biliary obstruction
62667257|NCT04541654||Variant in the TP53 Gene in blood or saliva|Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history
62297530|NCT02656472|ACTIVE_COMPARATOR|Epsilon Aminocaproic Acid Arm|EACA arm will include 10 subjects who will receive EACA for the duration of surgery.
62308328|NCT05036538|EXPERIMENTAL|Relaxation intervention with natural sounds|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
62667258|NCT03864562||Black African or Caribbean|Healthy individuals of black African or Caribbean descent
62667259|NCT03864562||White European|Healthy individuals of white European descent
62667260|NCT02345343||Drug: Apixaban|Patients with VTE who are being given apixaban for the treatment and/or prevention of recurrence of DVT and PE at the sentinel site
62667261|NCT05922085|EXPERIMENTAL|patient under mechanical ventilation for at least 48 hours|
62667262|NCT02123875|OTHER|Control arm|Routine hospital based physiotherapy
62667263|NCT02123875|OTHER|Physiotherapy intervention arm|Caregiver delivered, home based physiotherapy
62667264|NCT05229081|OTHER|Vaccine education|The intervention arm refers to the arm in which the pharmacist gives vaccination education.
62667265|NCT05229081|NO_INTERVENTION|Standard of Care|The control arm refers to the arm that includes patients who receive routine health care services without vaccination education provided by the pharmacist.
62667266|NCT01121926|EXPERIMENTAL|Trazodone HCl OAD|OAD: Once A Day
62667267|NCT01121926|ACTIVE_COMPARATOR|Trazodone HCl (Apotex Corp.)|
62667268|NCT03812328|EXPERIMENTAL|SelK2 and Enoxaparin|I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)
62667269|NCT03812328|ACTIVE_COMPARATOR|Enoxaparin|SC, QD for up to 10 ± 2 days
62667270|NCT03812328|EXPERIMENTAL|SelK2|I.V., single-dose
62297531|NCT06657144|EXPERIMENTAL|Arm A1: CHS-114 Dose A + Toripalimab|Participants will be treated with dose A of CHS-114 administered as an intravenous (IV) infusion in combination with toripalimab every 3 weeks (Q3W). Participants will remain on study treatment for approximately 2 years.
62667271|NCT02609633|ACTIVE_COMPARATOR|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
62297532|NCT06657144|EXPERIMENTAL|Arm A1: CHS-114 Dose B + Toripalimab|Participants will be treated with dose B of CHS-114 administered as an IV infusion in combination with toripalimab Q3W. Participants will remain on study treatment for approximately 2 years.
62297533|NCT02344810|EXPERIMENTAL|Arm A (AMG 337, mFOLFOX6)|Patients receive c-Met inhibitor AMG 337 PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
62297534|NCT02344810|ACTIVE_COMPARATOR|Arm B (placebo, mFOLFOX6)|Patients receive placebo PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
62297535|NCT05987215||CASE|Patients with surgically confirmed otosclerosis who initially consulted for conductive hearing loss with normal otoscopy, and with a high resolution computed tomography of temporal bone available
62297536|NCT05987215||CONTROL|Random patients with a high resolution computed tomography scan of temporal bone performed without suspicion of otosclerosis and considered normal
62297537|NCT05334979|OTHER|Kidney stone formers|25 stone-forming subjects will be enrolled in this arm.
62297538|NCT05334979|OTHER|Non-kidney stone formers|25 non-stone-forming subjects will be enrolled in this arm.
62297539|NCT05735899||Core Treatment Group|This is the only group in this study. Participants will receive full standard of care meniscal repair, followed by assessment interventions- ultrasound, MRI, and physical assessment to document healing progress. Participants will return for standard of care post-operative visits with the physician- 6 weeks, 6 months, and 1 year after the operation is performed- at which point the aforementioned interventions will be completed.
62297540|NCT01995890|EXPERIMENTAL|nepafenac|Nepafenac 0.1% eye drops, 3 times a day
62297541|NCT01995890|NO_INTERVENTION|control|No intervention in the control arm
62297542|NCT01478958|ACTIVE_COMPARATOR|high saturated fat diet|
62297543|NCT01478958|EXPERIMENTAL|high monounsaturated fat diet|
62297544|NCT01478958|EXPERIMENTAL|high n-6 polyunsaturated fat diet|
62297545|NCT01485874|EXPERIMENTAL|Doxil + BIBF 1120|
62468910|NCT02979522|EXPERIMENTAL|Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD|Brentuximab vedotin 48 mg/m\^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
62667272|NCT02609633|EXPERIMENTAL|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
62667273|NCT03501277|EXPERIMENTAL|Sequence I: ABCD|SYR-322-4833 BL (alogliptin 25 \[milligram\] mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 2 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 4 (Regimen D).
61913095|NCT01716871|ACTIVE_COMPARATOR|cryotherapy using Cold pack®|"patients with lateral ankle sprain who have been randomized in the cold packs® group.~Application of cryotherapy with Cold pack® or ice-cubes pack in the sprained ankle during 20 minutes 4 times a day, 3 days long."
61913096|NCT01716871|ACTIVE_COMPARATOR|cryotherapy using Neurocryostimulation|"Patient with lateral ankle sprain randomized in the neurocryostimulation group.~Application of neurocryostimulation with Duo-cryo® device during 1 minute on the sprained ankle, 2 times a day, 3 days long"
61913097|NCT02276027|EXPERIMENTAL|BYL719 350 mg QD|Patient's tumor must have molecular alteration of the PIK3CA gene.
61913098|NCT02276027|EXPERIMENTAL|INC280 400 mg BID tab/600 mg BID cap|Patient's tumor must have molecular alteration of the c-MET gene.
61913099|NCT02276027|EXPERIMENTAL|LDK378 750 mg QD|Patient's tumor must have ALK or ROS1 gene rearrangement.
61913100|NCT02276027|EXPERIMENTAL|MEK162 45 mg BID|Patient's tumor must have KRAS, NRAS or BRAF mutation.
61913101|NCT00222716|EXPERIMENTAL|Structured|Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
61913102|NCT00222716|NO_INTERVENTION|Usual Care|Control arm
61913103|NCT00222716|EXPERIMENTAL|Inidividualized|Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
61913104|NCT01407653|EXPERIMENTAL|virtual reality|
61913105|NCT01407653|OTHER|usual care|
61913106|NCT02447705|NO_INTERVENTION|Lamivudine group|continue Lamivudine
61913107|NCT02447705|EXPERIMENTAL|Telbivudine group|Telbivudine replaces Lamivudine
61913108|NCT01323920|EXPERIMENTAL|Velcade/Tac/MTX|"Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m\^2 IV~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid~Drug: Methotrexate. Methotrexate 15 mg/m\^2 IV"
61913109|NCT03703401||Women with recurrent miscarriage and no hydrosalpinx|
61913110|NCT03703401||Women with recurrent miscarriage and concurrent hydrosalpinx|
61913111|NCT03703401||Women with recurrent miscarriage and treated hydrosalpinx|
61913112|NCT04434378|PLACEBO_COMPARATOR|Placebo|Patients undergoing laparoscopic inguinal hernia repair will randomized to one dose of placebo in the preoperative holding area 2 hours before surgery.
61913113|NCT04434378|EXPERIMENTAL|Interventional|Patients undergoing laparoscopic inguinal hernia repair will be randomized to one dose of 0.4 mg tamsulosin in the preoperative holding area 2 hours before surgery.
62297546|NCT01403298|ACTIVE_COMPARATOR|Adolescent Only Health Promotion|An individual adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
62297547|NCT01403298|EXPERIMENTAL|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
62297548|NCT05555810|ACTIVE_COMPARATOR|Suture ligation of cystic duct and artery|The investigators will ligate cystic duct and artery by traditional sutures during laparoscopic cholecystectomy .
62297549|NCT05555810|ACTIVE_COMPARATOR|Application of clips|The investigators will put a clips on the cystic duct and artery during laparoscopic cholecystectomy.
62297550|NCT01162850|ACTIVE_COMPARATOR|Polypodium Leucotomos|Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
62297551|NCT01162850|PLACEBO_COMPARATOR|Placebo|Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
62297552|NCT00957853|EXPERIMENTAL|Group 1: Cetuximab|Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes
62297553|NCT00957853|EXPERIMENTAL|Group 2: IMC-A12|IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.
62297554|NCT00957853|EXPERIMENTAL|Group 3: Cetuximab + IMC-A12|"Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes.~IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3."
62297555|NCT03935971|EXPERIMENTAL|Subjects with Allergic Contact Dermatitis|Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks
62468911|NCT02979522|EXPERIMENTAL|Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD|Brentuximab vedotin 48 mg/m\^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
62667274|NCT03501277|EXPERIMENTAL|Sequence II: BCDA|Alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 1 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 3 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen A).
62667275|NCT03501277|EXPERIMENTAL|Sequence III: CDAB|SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 2 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 4 (Regimen B).
62737227|NCT02924441|EXPERIMENTAL|Right Breast Lidocaine and calming music|Group 1 - right breast lidocaine \& calming music
62737228|NCT02924441|EXPERIMENTAL|Right Breast Lidocaine and no music|Group 2 - right breast lidocaine \& no calming music
62297556|NCT00098787|EXPERIMENTAL|Arm A (High TS, IROX/bev)|Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
62297557|NCT00098787|EXPERIMENTAL|Arm B (High TS, FOLFOX/bev)|Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
62737229|NCT02924441|EXPERIMENTAL|Left Breast Lidocaine and calming music|Group 3 - left breast lidocaine \& calming music
62737230|NCT02924441|EXPERIMENTAL|Left Breast Lidocaine and no music|Group 4 - left breast lidocaine \& no calming music
62297558|NCT00098787|EXPERIMENTAL|Arm C (Low or intermediate TS, FOLFOX/bev)|Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.
62297559|NCT06159478|EXPERIMENTAL|Binimetinib|
62468912|NCT04591717|EXPERIMENTAL|Cohort 1: 0.5 mL of hAd5-S-Fusion+N-ETSD SC|0.5 mL of hAd5-S-Fusion+N-ETSD SC (5 × 10e10 VP/dose) on days 1 and 22
62468913|NCT04591717|EXPERIMENTAL|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) on days 1 and 22
61913114|NCT02819778|OTHER|Control group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
61913115|NCT02819778|OTHER|interventional group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
62297560|NCT06001606|EXPERIMENTAL|Shingrix|
61913116|NCT06505720|OTHER|Control Group|The child in this group will be treated for his\\ her acute septic hip infection using open surgery ( The Standard Method)
62297561|NCT06001606|PLACEBO_COMPARATOR|Placebo|
62468914|NCT04591717|EXPERIMENTAL|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
62468915|NCT04591717|EXPERIMENTAL|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; no vaccine on day 22
62468916|NCT04591717|EXPERIMENTAL|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
62667276|NCT03501277|EXPERIMENTAL|Sequence IV: DABC|Alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 1 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 3 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen C).
61913117|NCT06505720|OTHER|Intervention Group|The child in this group will be treated for his\\ her acute septic hip infection arthroscopically
62297562|NCT01591330|EXPERIMENTAL|LY2140023 Reference Form|LY2140023: 80 mg, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
62667277|NCT00424164|EXPERIMENTAL|Tamoxifen-lapatinib|Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
62297563|NCT01591330|EXPERIMENTAL|LY2140023 Test-Low|LY2140023: 80 mg, low particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
62468917|NCT04591717|EXPERIMENTAL|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on days 15 and 29
62667278|NCT00424164|EXPERIMENTAL|Lapatinib-tamoxifen|Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
62667279|NCT05752409|EXPERIMENTAL|Propofol + esketamin 0.5|1mg•kg-1propofol, 0.5 mg•kg-1esketamin, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
62667280|NCT05752409|EXPERIMENTAL|Propofol+ esketamin 0.75|1mg•kg-1propofol, 0.75 mg•kg-1esketamin, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
62667281|NCT05752409|ACTIVE_COMPARATOR|Propofol|2 mg•kg-1propofol, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
62667282|NCT02106273||Bronchial blocker|Pilot study to enroll ASA class I-III patients age between 18-70 years who undergoes thoracic surgery which require one-lung ventilation.
62667283|NCT00949663|EXPERIMENTAL|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
62667284|NCT00949663|EXPERIMENTAL|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
62667285|NCT00949663|EXPERIMENTAL|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
62667286|NCT05419258|EXPERIMENTAL|use of the device during hemodialysis sessions|use of the device during one month during hemodialysis sessions
62667287|NCT00523380|EXPERIMENTAL|A|
62667288|NCT01271166|EXPERIMENTAL|Glivec®, modified FOLFOX, Avastin®|
62667289|NCT06216340|PLACEBO_COMPARATOR|Control group|Placebo and diet-exercise therapy
62667290|NCT06216340|EXPERIMENTAL|Intervention group|10mg of Henagliflozin and diet-exercise therapy
62737231|NCT04325295|ACTIVE_COMPARATOR|Surgical treatment strategy:|
61913118|NCT04585009|EXPERIMENTAL|Cohort1:GSK3923868 50 micrograms (mcg)/ Placebo/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/Placebo/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
61913119|NCT04585009|EXPERIMENTAL|Cohort 1:GSK3923868 50 mcg/ 100 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
61913120|NCT04585009|EXPERIMENTAL|Cohort 1:GSK3923868 50mcg/ 100mcg/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
62297564|NCT01591330|EXPERIMENTAL|LY2140023 Test-Medium|LY2140023: 80 mg, medium particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
62667291|NCT05628350|EXPERIMENTAL|No UPF (Ultra-processed foods)|"Following a 2-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy) for 6 weeks. The controlled diet is eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.~Participants will consume a diet containing 0% total energy from UPF for 6 weeks"
62105193|NCT03717987|ACTIVE_COMPARATOR|Zinc supplementationj prior to Botulinum toxin A injection|"Patients in the intervention group will take zinc supplement tablets to increase zinc levels for 4 days before botulinum toxin injections. While patients in the control group will take placebo tablets 4 days prior to the injections. All tablets will be placed in envelopes for blinding the operator, and numbered by a supervisor to allocate patients again in their groups for statistical results. Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
62105194|NCT05533866|EXPERIMENTAL|EB participants|Visits will include screening, pre-treatment (week 0), weeks 4 and 8, followed by a visit without use of the APR-TD011 for 4 weeks (week 12) for microbiome assessment off of therapy.
62105195|NCT03098030|EXPERIMENTAL|Part 1: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m\^2 IV) + Irinotecan (350 mg/m\^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m\^2 increments per cycle if maximal pain is \<Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m\^2 IV.
62105196|NCT03098030|ACTIVE_COMPARATOR|Part 2: Irinotecan|Irinotecan (350 mg/m\^2 IV) on Day 1 of each q21d cycle.
62105197|NCT03098030|EXPERIMENTAL|Part 2: Dinutuximab + Irinotecan|Dinutuximab (16 mg/m\^2 IV) + Irinotecan (350 mg/m\^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m\^2 increments per cycle if maximal pain is \<Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m\^2 IV.
62105198|NCT03098030|ACTIVE_COMPARATOR|Part 2: Topotecan|Topotecan (1.5 mg/m\^2 IV) on Days 1 to 5 of each q21d cycle.
62105199|NCT01809964|EXPERIMENTAL|Dose 1|ANT-1401
62105200|NCT01809964|EXPERIMENTAL|Dose 2|ANT-1401
62297565|NCT01591330|EXPERIMENTAL|LY2140023 Test-High|LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
62297566|NCT01929070|EXPERIMENTAL|Group 1|"* R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state~* R2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet~* T1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state~* T2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet~R1 -\> T2 -\> R2 -\> T1"
62297567|NCT01929070|EXPERIMENTAL|Group 2|R2 -\> R1 -\> T1 -\> T2
62737232|NCT04325295|ACTIVE_COMPARATOR|Gonadotrophins treatment strategy|
62105201|NCT01809964|PLACEBO_COMPARATOR|Vehicle|Placebo Vehicle
62105202|NCT01805362|ACTIVE_COMPARATOR|MORNING|patients continue to take their treatments (RAS blockers and diuretics) on awaking
62105203|NCT01805362|EXPERIMENTAL|EVENING|Patients take their treatments(RAS blockers and diurectics)at bedtime
62105204|NCT03683862|EXPERIMENTAL|Thermoplastic Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
62105205|NCT03683862|ACTIVE_COMPARATOR|Hawley Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
62297568|NCT01929070|EXPERIMENTAL|Group 3|T1 -\> R2 -\> T2 -\> R1
62297569|NCT01929070|EXPERIMENTAL|Group 4|T2 -\> T1 -\> R1 -\> R2
62297570|NCT06656819||Healthy Females|
62297571|NCT06656819||Healthy Males (control)|
62667292|NCT05628350|EXPERIMENTAL|High UPF|Following a 2-week eucaloric lead-in diet, participants will be provided and consume a diet composed of 59% UPF for 6 weeks. The controlled diet is eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.
62667293|NCT05466253|EXPERIMENTAL|Group 1 EARLY|In experimental group Orthodontic treatment will be started (early) 10 days after periodontal surgery
62667294|NCT05466253|EXPERIMENTAL|Group 2 DELAYED|control group will receive orthodontic intervention(delayed) 3 months after periodontal surgery
62667295|NCT05587647|EXPERIMENTAL|Experimental: YEGEP group/Intervention|Mothers will be informed about the program and invited to work. In the phone call, information will be given about the purpose, duration, requirements and volunteering of the study. The planned training schedule will be applied to these mothers.
62667296|NCT05587647|NO_INTERVENTION|Control group|Annual care trainings are given to parents at the disabled center where the study will be conducted. There is no similar practice to these mothers on the same dates. place in the control group
62667297|NCT00710970|EXPERIMENTAL|Single Arm Receiving 25mg Tamoxifen|
62667298|NCT03243188||Participants|Cancer patients with palliative care needs (+/- their carers)
62667299|NCT03475563||Patients with coronary artery disease|(coronary artery disease)
61913121|NCT04585009|EXPERIMENTAL|Cohort 1:Placebo / GSK3923868 100 mcg/ GSK3923868 250 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 100 mcg/GSK3923868 250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
62297572|NCT05106530||Coronary Artery Ectasia patients|
62297573|NCT05106530||Normal coronary artery patients|
62297574|NCT01748071||Sufentanil group|Grouped by intravenous injection of sufentanil at the time of anesthesia induction
62667300|NCT01332201|EXPERIMENTAL|Advagraf|
62667301|NCT01332201|ACTIVE_COMPARATOR|Prograf|
62667302|NCT04667429|EXPERIMENTAL|Food effect|HEC83518 40mg will be administered fasted, or with high-fat meal for once.
62667303|NCT04667429|EXPERIMENTAL|Multiple Ascending Doses-HEC83518 20mg|HEC83518 20mg will be administered before sleep for 15 days .
62667304|NCT04667429|EXPERIMENTAL|Multiple Ascending Doses-HEC83518 40mg|HEC83518 40mg will be administered before sleep for 15 days .
62297575|NCT01748071||Fentanyl group|Grouped by intravenous injection of fentanyl at the time of anesthesia induction
62297576|NCT01748071||Saline group|Grouped by intravenous injection of saline before the time of anesthesia induction
62297577|NCT06006975||Subarachnoid hemorrhage (SAH) patients|Patients after aneurysmal subarachnoid hemorrhage who received routine treatment (aneurysm clipping surgery, post operative care and multimodal monitoring in ICU).
62297578|NCT03204344|EXPERIMENTAL|Intervention group|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking."
62297579|NCT03204344|SHAM_COMPARATOR|Control group|"For all patients, routine fasting (drinking water allowed) begins from 22:00 on the day before surgery， water fasting begins from 6:00 on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided from 6:00. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, magnesium sulfate) are added when becessary."
62667305|NCT04667429|EXPERIMENTAL|Multiple Ascending Doses-HEC83518 80mg|HEC83518 80mg will be administered before sleep for 15 days .
62105206|NCT03758625|EXPERIMENTAL|ARM A|a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
62105207|NCT03758625|EXPERIMENTAL|ARM B|a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
62105208|NCT03758625|ACTIVE_COMPARATOR|ARM C|a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
62297580|NCT01058603|ACTIVE_COMPARATOR|D3|
62667306|NCT04667429|PLACEBO_COMPARATOR|Multiple Ascending Doses-placebo|Placebo will be administered before sleep for 15 days .
62667307|NCT04086667|EXPERIMENTAL|Pain group|"The segment on the lower back marked as most painful"
62297581|NCT01058603|EXPERIMENTAL|D5|
62667308|NCT04086667|EXPERIMENTAL|Stiff group|"The segment on the lower back marked as most stiff"
62667309|NCT03066076|ACTIVE_COMPARATOR|Thyroidectomy|Total thyroidectomy
62667310|NCT03066076|ACTIVE_COMPARATOR|Antithyroid drug|Thiamazol, Propylthiouracil
62667311|NCT04145934|EXPERIMENTAL|training|The subjects receive the ADSTEP intervention
62667312|NCT04145934|NO_INTERVENTION|waitlist|These subjects receive two brochures on fall prevention and walking aid selection, and a letter is sent to their care provider informing them that the subject has reported falling. Subjects in this group will be offered the ADSTEP intervention once their study participation is complete.
62297582|NCT01525758|EXPERIMENTAL|SI000413 400mg|tablet, SI000413 200mg bid
62667313|NCT02933476|EXPERIMENTAL|Vibrotactile Stimulation Treatment|All patients will receive the vibrotactile stimulation treatment. No deception will be used.
62667314|NCT05249920|EXPERIMENTAL|Edaravone Dexborneol group|Patients in this arm will be given Edaravone Dexborneol Concentrated Solution for injection twice a day for 10 to 14 days.
62667315|NCT05249920|PLACEBO_COMPARATOR|Edaravone Dexborneol Placebo group|Patients in this arm will be given a placebo of Edaravone Dexborneol for injection twice a day for 10 to 14 days.
62105209|NCT03758625|EXPERIMENTAL|ARM D|pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
62667316|NCT05783219|EXPERIMENTAL|topical lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
62105210|NCT03758625|EXPERIMENTAL|ARM E|pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
62105211|NCT03758625|ACTIVE_COMPARATOR|ARM F|pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
62105212|NCT05241795|ACTIVE_COMPARATOR|Group A: Knee exercises then Ankle exercises|Patients will receive a rehabilitation protocol starting with knee training followed by ankle training.
62297583|NCT01525758|EXPERIMENTAL|SI000413 600mg|tablet, SI000413 200mg tid
62468918|NCT02054845|EXPERIMENTAL|Body awareness therapy|The experimental treatment: BEWARE
62667317|NCT05783219|PLACEBO_COMPARATOR|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
62667318|NCT01203371|EXPERIMENTAL|Naftopidil|0,25 mg (2 weeks) and 0,50 mg (10 weeks)
62667319|NCT01203371|ACTIVE_COMPARATOR|Tamsusolin|0,4 mg/day
62667320|NCT05992038|EXPERIMENTAL|Putty|The osteotomy gap will be filled with a synthetic ceramic material, Putty
62105213|NCT05241795|EXPERIMENTAL|Group B: Ankle exercises then Knee exercises|Patients will receive a rehabilitation protocol starting with ankle training followed by knee training.
62468919|NCT02054845|ACTIVE_COMPARATOR|Treatment as Usual|The new treatment is compared to this arm: Physical therapy
62667321|NCT05992038|PLACEBO_COMPARATOR|Conventional|Osteotomy performed according to the conventional method, without gap filler
62667322|NCT02323061|EXPERIMENTAL|BCI-robot (I)|EEG guided training based on ipsilesional EEG signals; Training for 20 sessions
62468920|NCT03067753|ACTIVE_COMPARATOR|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
62667323|NCT02323061|EXPERIMENTAL|BCI-robot (IC)|EEG guided training based on both ipsilesional and contralesional EEG signals; Training for 20 sessions
62667324|NCT02323061|PLACEBO_COMPARATOR|robot|Training for 20 sessions
62667325|NCT03309059|PLACEBO_COMPARATOR|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
62667326|NCT03309059|ACTIVE_COMPARATOR|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
62667327|NCT03309059|EXPERIMENTAL|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
62667328|NCT01159353|EXPERIMENTAL|insulin glulisine + insulin aspart|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
62667329|NCT01159353|EXPERIMENTAL|insulin aspart + insulin glulisine|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
62105214|NCT00731107|ACTIVE_COMPARATOR|1|Veress Needle laparoscopic entry
62105215|NCT00731107|ACTIVE_COMPARATOR|2|XCEL bladeless trocar laparoscopic entry
62737233|NCT00854724|ACTIVE_COMPARATOR|Puerarin|
62737234|NCT00854724|PLACEBO_COMPARATOR|Placebo|Sugar beet filler in capsule
62297584|NCT01525758|EXPERIMENTAL|SI000413 800mg|SI000413 200mg, 2T bid
62297585|NCT01525758|PLACEBO_COMPARATOR|placebo|placebo 2T tid for 8 weeks
62297586|NCT01938859|EXPERIMENTAL|Lithium combined with SGAs|SGAs (Second Generation Antipsychotics), quetiapine adjunctive to lithium therapy
62297587|NCT01938859|EXPERIMENTAL|lithium combined with TCM|TCM (Traditional Chinese Medicine), Shuganjieyu capsule adjunctive to lithium therapy.
62297588|NCT01938859|ACTIVE_COMPARATOR|Lithium monotherpy|Lithium monotherapy
62297589|NCT01476462||ALL diagnosed 1980-2007|Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
62297590|NCT05217914||r/r iNHL Patients: Copanlisib treatment|"The data in patients who received at least one dose of copanlisib before 01-May-2022 will be included for interim analysis. All study data collection will end in Q2 2024, or when the data collection of maximal 50 enrolled patients is completed, whenever comes first.~Subgroup analysis: r/r iNHL Patients: Copanlisib 2nd line treatment Subgroup analysis: r/r iNHL Patients: Copanlisib 3rd line treatment"
62297591|NCT04681092|EXPERIMENTAL|AKS-452 s.c.(A)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL) single-dose
62468921|NCT03067753|EXPERIMENTAL|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
62667330|NCT05379608|EXPERIMENTAL|intervention group|The patients with cardiovascular pathology who underwent confirmed by laboratory tests COVID-19 infection 1-3 months ago with the degree of lung lesion CT3, CT4, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University will be included in the study.
62667331|NCT05379608|PLACEBO_COMPARATOR|control group|The patients with cardiovascular pathology who underwent confirmed by laboratory tests COVID-19 infection 1-3 months ago with the degree of lung lesion CT3, CT4, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University will be included in the study.
62667332|NCT02112227|ACTIVE_COMPARATOR|Discharge planning services|Proven effective discharge-planning services will be grouped into 'patient-centered care transitions in heart failure' patients. This will be known as the PACT-HF model.
62667333|NCT02112227|NO_INTERVENTION|Standard Care|Standard of care will be provided to HF patients at discharge.
62667334|NCT04849832|EXPERIMENTAL|SIC|4mg of Fe will be given as 102 mg of SIC as a solution
62667335|NCT04849832|EXPERIMENTAL|SIC + tea|4 mg of Fe will be given as 102 mg of SIC as a solution along with 200 ml of black tea
61913122|NCT04585009|EXPERIMENTAL|Cohort 2:Placebo / GSK3923868 1000 mcg/ GSK3923868 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 1000 mcg/GSK3923868 3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
62105216|NCT03537573|ACTIVE_COMPARATOR|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
62105217|NCT03537573|EXPERIMENTAL|Guideline + Opioid Justification (OJ)|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
62105218|NCT03537573|EXPERIMENTAL|Guideline + Provider Comparison (PC)|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
62105219|NCT03537573|EXPERIMENTAL|Guideline + OJ + PC|This arm will include the guideline, opioid justification, and provider comparison described above.
62297592|NCT04681092|EXPERIMENTAL|AKS-452 s.c. (B)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL), two-dose
62297593|NCT04681092|EXPERIMENTAL|AKS-452 s.c. (C)|Subcutaneous injection of pre-defined dose (45 ug, 205 uL), single-dose
62297594|NCT04681092|EXPERIMENTAL|AKS-452 s.c. (D)|Subcutaneous injection of pre-defined dose (45 ug, 250 uL), two-dose
62297595|NCT04681092|EXPERIMENTAL|AKS-452 s.c. (E)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), single-dose
62297596|NCT04681092|EXPERIMENTAL|AKS-452 s.c. (F)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), two-dose
62297597|NCT04681092|EXPERIMENTAL|Phase 2, single-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (90 ug, 500 uL)
62297598|NCT04681092|EXPERIMENTAL|Phase 2, two-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (45 ug, 500 uL) twice.
62297599|NCT03122626|EXPERIMENTAL|Experimental Group|The intervention is a group, task-oriented exercise program involving two 1-hour exercise classes per week for 12 weeks. The class involves a seated warm-up, repetitive, progressive practice of functional balance and mobility tasks, and a seated cool down. The warm-up consists of active range-of-motion exercises, aerobic exercise, leg loading, stretching, and sit-to-stand training. The cool-down involves exercises with an emphasis on stretching and relaxation. Tasks are organized in a 3-station circuit completed by participants grouped by overall ability: Superstation 1: walking, aerobic training, and wall work (standing and reaching, wall push-ups); Superstation 2: standing weight shifts, coordinated with stepping and lunging; and Superstation 3: tap-ups, step-ups, and heel/toe raises, hamstring curls, marching-on-the-spot, and mini-squats. Participants are instructed to be physically active by walking in their neighbourhood, practicing the program exercises, or using the stairs.
62667336|NCT04849832|ACTIVE_COMPARATOR|FeSO4|4 mg of Fe will be given as Ferrous sulfate solution
62667337|NCT04849832|ACTIVE_COMPARATOR|FeSO4 + tea|4 mg of Fe will be given as Ferrous sulfate solution along with 200 ml of black tea
62667338|NCT02952677|EXPERIMENTAL|Experimental|"Participants receive Remind-to-move by means of vibration emitted through sensory cueing wristwatch devices, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period.They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities."
61913123|NCT04585009|EXPERIMENTAL|Cohort 2:GSK3923868 500 mcg/ Placebo/ 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/Placebo/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
62297600|NCT03122626|NO_INTERVENTION|Wait-listed Control Group|The control group will receive usual care which will be monitored and is expected to consist of provision of a home exercise program and information on community resources according to current best practices. At the end of the study period, participants in the control group will be offered to participate in the 3-month exercise program.
62297601|NCT01687790|EXPERIMENTAL|molecular breast imaging|
62297602|NCT01716819|OTHER|Abdominal obesity|"Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :~Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring"
62297603|NCT04325503|EXPERIMENTAL|Treatment|carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks
62468922|NCT02883413|EXPERIMENTAL|CRT +Teach the Parent|The Teach the Parent (TtP) addition to CRT is designed to increase parental understanding of their adolescents' thinking styles. We hypothesize that by doing so, parents will be more likely to challenge eating disorder behaviors and be less likely to accommodate behavioral symptoms of the eating disorder (e.g., make something low-fat for dinner because it will be easier). In this arm, adolescents will explain what they learned during CRT and walk their parents though at least 4 tasks during each TtP session. Parents and child will not be permitted to speak about the eating disorder during these sessions. TtP sessions will occur 3-4 times during hospitalization and will be guided by the adolescent.
62105220|NCT06189716|EXPERIMENTAL|Experimental|High flow oxygen through nasal cannula, oxygen and carbon dioxide measurement in the hypopharynx
62105221|NCT05822141|EXPERIMENTAL|Fish Oil (Omega-3 Fatty Acids)|15 subjects will ingest 6 capsules of fish oil of per day for 12 weeks
62105222|NCT05822141|PLACEBO_COMPARATOR|Olive Oil|15 subjects will ingest 6 capsules of olive oil per day for 12 weeks
62105223|NCT04226469||Subjects require canine retraction|Subjects require canine retraction during orthodontic tooth movement and their gingival crevicular fluid is collected during the tooth movement. The control is the initial timepoint.
62105224|NCT06492954|EXPERIMENTAL|Dose escalation|"Unilateral: Participants start with atezolizumab, followed ≤ 1 week later by SBRT at the assigned dose for a single lesion. After 2 cycles, those with unilateral disease undergo complete surgical resection, including all lung nodules, including the radiated one, as per osteosarcoma standard care. Atezolizumab resumes 14-28 days post-op, per protocol criteria, barring toxicity or disease progression.~Bilateral: Subjects first undergo surgery on the non-SBRT side. 7-14 days later, they start atezolizumab, followed ≤ 1 week later by SBRT on the other lesion. After 2 cycles of atezolizumab, surgery on the contralateral side removes all lung nodules, including the radiated one, per standard care. Atezolizumab resumes 14-18 days post-op, per protocol criteria, barring toxicity or disease progression"
62105225|NCT05091164|EXPERIMENTAL|Moderate obstructive sleep apnea syndrome patient under hypnosis|"Patients suffering from moderate obstructive sleep apnea syndrome. It is proposed to induce in the patient a hypnotic trance leading to intense muscle relaxation, capable of reproducing in the upper airways.~The type of collapsibility thus obtained, classified according to Kezirian (6), will allow specific management by OAM in the event of predominant anteroposterior stenosis."
62105226|NCT05848141|EXPERIMENTAL|Indoor Rowing|Research participants will be instructed how to use a Concept 2 RowErg and will be provided instruction on basic rowing skills for beginners. Exercise training will gradually progress to 50 min of moderate-intensity exercise, on 3 days per week, for 12 weeks.
62105227|NCT05848141|NO_INTERVENTION|Usual Care|Research participants in this group will have the opportunity to complete the supervised indoor rowing program after completing their post-intervention assessments.
62105228|NCT05933655|EXPERIMENTAL|Peer Coach|The research coordinator will set up a time for the subject to have a brief discussion with a peer coach from the study team approximately 1 week after randomization. During the coaching session, the peer coach will encourage the subject to mention their heart health goals to their primary care clinician during their next primary care appointment. The peer coach will also help the subject brainstorm ways to remove any barriers that may prevent them from having the discussion with their clinician. The peer coaching session and the subsequent medical appointment will be audio-recorded.
62105229|NCT05933655|NO_INTERVENTION|Control|The subject will not be asked to meet with the peer coach or anyone from the study team prior to their next visit with their primary care clinician. Their subsequent primary care appointment will be audio-recorded.
62105230|NCT04073355|EXPERIMENTAL|Physical Activity|Smartphone-delivered physical activity intervention
62667339|NCT02952677|SHAM_COMPARATOR|Sham treatment|Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
62667340|NCT02952677|OTHER|Control|Participants receive usual care only during the intervention period.
62667341|NCT03289000||ConforMIS PS Group|Patients who have undergone a total knee replacement with the ConforMIS iTotal PS Knee Replacement System
62297604|NCT04659993|EXPERIMENTAL|Telemental Group|The virtual group will be conducted within a secure platform such as Microsoft WebEx. Assessments (pre-, post-, mid-way) will be distributed through REDCap, a secure virtual platform, as will session handouts and forms.
62297605|NCT04811092|PLACEBO_COMPARATOR|Placebo plus background PAH therapy|Administered subcutaneously (SC) every 21 days plus background PAH therapy
62297606|NCT04811092|EXPERIMENTAL|Sotatercept plus background PAH therapy|Administered at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, subcutaneously (SC) every 21 days plus background PAH therapy
62667342|NCT03842800|OTHER|ASD Patients|This arm consists of patients diagnosed with Autism Spectrum Disorder (ASD) that will receive an MRI.
62667343|NCT03842800|OTHER|Schizophrenic Patients|This arm consists of patients diagnosed with Schizophrenia that will receive an MRI.
62297607|NCT01023282|EXPERIMENTAL|ACR325|
62297608|NCT01023282|PLACEBO_COMPARATOR|Placebo|
62297609|NCT02511522|ACTIVE_COMPARATOR|Best Supportive Care|Patients will be randomized 1:1 to receive best supportive care alone
62105231|NCT03049436||Patients with program of adapted physical activity|
62105232|NCT05753137|EXPERIMENTAL|Ophthalmic Acupoint Treatment Group|"Ophthalmic acupoint treatment group will receive a total of 6 courses of treatment, once a week, a total of six weeks, 20 minutes each time.~Acupuncture points: Fengchi(GB20), Cuanzhu(BL2), Sibai(ST2), Taiyang(EX-HN5), Hegu(LI4), Taichong(LR3), a total of six acupoints."
62105233|NCT05753137|PLACEBO_COMPARATOR|Non-ophthalmological Acupoint Control Group|"Non-ophthalmological acupoint control group will receive a total of 6 courses of treatment, once a week, a total of six weeks, 20 minutes each time.~Acupuncture points: Yinlingquan(SP9), Liangqiu (ST34),Xiajuxu(ST39), Yanglingquan (GB34), Shousanli(LI10), Sanyangluo(TE8), a total of six acupoints. The Non-ophthalmological acupoint control group points are not indicated for the treatment of ophthalmological related pathologies, and are not reported to improve ophthalmological function."
62297610|NCT02511522|EXPERIMENTAL|Best Supportive Care + RT 8 Gy/1|Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
62297611|NCT01122355|ACTIVE_COMPARATOR|niacin arm|
62297612|NCT01122355|ACTIVE_COMPARATOR|fenofibrate arm|
62297613|NCT04637867|OTHER|RT-PCR confirmed COVID-19 patients|RT-PCR confirmed patients included in the NOSO-COR study are invited six and 12 months after the initial infection to provide blood (41.5mL in total), salivary and nasopharyngeal samples and to complete a questionnaire. Each visit is expected to take about one hour.
62297614|NCT05653895|ACTIVE_COMPARATOR|Arm 1|Resveratrol (2 gm daily) 50 patients with PCOS will receive Resveratrol 1000mg BD daily
62297615|NCT05653895|ACTIVE_COMPARATOR|Arm 2|Metformin (1000mg daily),Resveratrol(2 gm daily) 50 patients with PCOS will receive Metformin 500mg,Resveratrol 1000 mg BD daily
62297616|NCT05653895|ACTIVE_COMPARATOR|Arm 3|L-Arginine(3 gm daily), Acetyl L-Carnitine (3 gm daily),CoQ10(200 mg daily) 50 patients with PCOS will receive L Arginine 1500mg,Acetyl L Carnitine 1500mg ,COQ10 100mg BD daily respectively
62297617|NCT05653895|ACTIVE_COMPARATOR|Arm 4|L-Arginine(3 gm daily), Acetyl L-Carnitine (3 gm daily),CoQ10(200 mg daily),Metformin (1000mg daily) 50 patients with PCOS will receive L Arginine 1500mg,Acetyl L Carnitine 1500mg,COQ10 100mg BD daily respectively
62297618|NCT03064464||CA-MRSA infection|None intervention
62297619|NCT03064464||HA-MRSA infection|None intervention
62468923|NCT02883413|ACTIVE_COMPARATOR|CRT + Family Fun Time|In order to assess for any non-specific effects of spending non-eating disorder driven time with family, adolescents in the CRT+ Contact Control condition will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). We refer to this condition as CRT + Family Fun Time (CRT+FFT). Adolescents will be asked to complete a series of fun tasks (some standardized, some are choice driven) with their parents. During these sessions, they will not be permitted to discuss CRT or the eating disorder.
62468924|NCT02883413|NO_INTERVENTION|Treatment as Usual (TAU)|Adolescents in this condition will not receive any additional treatment. They will have a standard hospital stay with all normal contact with health professionals.
62468925|NCT01666899|EXPERIMENTAL|Skin and blood vessel procedures|All patients will be placed into Arm 1. They will undergo punch biopsies of the breast skin at the time of mastectomy and at 2, 4, 6, 8 and 12 months after completion of radiation therapy. Three more biopsies will be taken at 3, 6, and 12 months after completion of reconstruction. Patients will also undergo skin blood flow studies with a laser imaging device prior to each biopsy procedure. Ultrasound studies of the chest vessels will be performed 4 times over the course of the study- once prior to radiation and at 2, 6 and 12 months after radiation.
62468926|NCT02973685|EXPERIMENTAL|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
62468927|NCT02973685|ACTIVE_COMPARATOR|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, with or without MMC), and embolization with polyvinyl alcohol particles (PVA).
62297620|NCT03064464||CA-MSSA infection|None intervention
62297621|NCT01933087|NO_INTERVENTION|Control with no hand hygiene promotion|no implementation of hand hygiene promotion
62297622|NCT01933087|EXPERIMENTAL|Hand hygiene promotion|Intervention to promote hand hygiene which is based on the WHO multimodal hand hygiene improvement strategy.
62297623|NCT04210479|EXPERIMENTAL|Filled-bladder|Bladder filling with 300ml diluted methylene blue.
62297624|NCT04210479|ACTIVE_COMPARATOR|non filled-bladder|
62297625|NCT02669693|PLACEBO_COMPARATOR|bread without olives|Intervention (no olives): Subjects will consume a meal of 109 g white bread and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
62297626|NCT02669693|ACTIVE_COMPARATOR|bread with olives|Intervention (olives 100 g): Subjects will consume a meal of 109 g white bread, 100 g of olives and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
62667344|NCT03842800|OTHER|Healthy Controls|This arm consists of healthy control volunteer participants that will receive an MRI.
62667345|NCT03842800|EXPERIMENTAL|Healthy Controls with Ketamine|This arm consists of healthy control volunteer participants that elect to receive ketamine prior to receiving an MRI.
62667346|NCT00452257|EXPERIMENTAL|A|
62105234|NCT06628596|PLACEBO_COMPARATOR|Placebo|"After qualifying for the study, subjects will be randomly assigned to receive a placebo, 200mg PXN, and 300mg PXN using a Latin Square design.~* Paraxanthine (200 mg)~* Paraxanthine (300 mg)~* Placebo (containing 300mg resistant starch) •Supplements will be provided in identical-looking capsules with label directions and Study Protocol Number."
62105235|NCT06628596|ACTIVE_COMPARATOR|Paraxanthine 200mg|"After qualifying for the study, subjects will be randomly assigned to receive a placebo, 200mg PXN, and 300mg PXN using a Latin Square design.~* Paraxanthine (200 mg)~* Paraxanthine (300 mg)~* Placebo (containing 300mg resistant starch) •Supplements will be provided in identical-looking capsules with label directions and Study Protocol Number."
62105236|NCT06628596|ACTIVE_COMPARATOR|Paraxanthine 300mg|"After qualifying for the study, subjects will be randomly assigned to receive a placebo, 200mg PXN, and 300mg PXN using a Latin Square design.~* Paraxanthine (200 mg)~* Paraxanthine (300 mg)~* Placebo (containing 300mg resistant starch) •Supplements will be provided in identical-looking capsules with label directions and Study Protocol Number."
62105237|NCT05160675||Group 1|Group 1: 690 healthy infants and their mother followed from birth to 12 months
62105238|NCT05160675||Group 2|Group 2: 690 healthy infants and their mother followed from 6 months to 3 years of age
62105239|NCT02431143|EXPERIMENTAL|Miltefosine|allometric dosing
62105240|NCT04497961|EXPERIMENTAL|Lenalidomide maintenance|"Arm A: Those randomized to lenalidomide maintenance will receive a maintenance dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.~Sub ARM A: The first 15 patients on each arm interested in this sub study will be enrolled during C10D1 visit to initiate whole food plant based diet (WFPBD) meals provided by Daily Harvest and nutrition counseling for 12 weeks. They will continue on their lenalidomide maintenance schedule per study calendar.~The patients who do not go on the nutrition sub study will continue on their lenalidomide maintenance schedule per study calendar."
62105241|NCT04497961|EXPERIMENTAL|Daratumumab maintenance|"ARM B: Those randomized to receive daratumumab maintenance will receive 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.~Sub ARM B: The first 15 patients on each arm interested in this sub study will be enrolled during C10D1 visit to initiate whole food plant based diet (WFPBD) meals provided by Daily Harvest and nutrition counseling for 12 weeks. They will continue on their daratumumab maintenance schedule per study calendar.~The patients who do not go on the nutrition sub study will continue on their daratumumab maintenance schedule per study calendar."
62105242|NCT04765943||Study population|Patients with LVEF equal to or less than 40% determined by echocardiogram on the 4th day after acute myocardial infarction.
62105243|NCT06056154||Patients undergoing routine clinical practice with ASQELIOTM monofocal LIO model QLIO130C.|Data will be extracted retrospectively from their medical records and prospectively in a single follow-up visit. All procedures performed are according to standard clinical practice.
62105244|NCT02221700|EXPERIMENTAL|Group I (leg massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks.
62105245|NCT02221700|EXPERIMENTAL|Group II (leg massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks.
62105246|NCT02221700|EXPERIMENTAL|Group III (head/neck/shoulder massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks.
62105247|NCT02221700|EXPERIMENTAL|Group IV (head/neck/shoulder massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks.
62105248|NCT00025714||Patients|Patients who have agreed to undergo brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
62105249|NCT06631365|EXPERIMENTAL|PrEPsmart intervention (N=40)|"Participants will be randomized in a 2:1 ratio to the intervention (N=40) For the pre-exposure prophylaxis (PrEP)smart intervention group, a study clinician will perform a medical history and limited physical exam to confirm eligibility to enroll in the study, a 4th generation rapid Human immunodeficiency virus (HIV) test will be performed, and labs drawn for creatinine, sexual transmitted infection (STI) testing (Neisseria gonorrhoeae/Chlamydia trachomatis (GC/CT)), syphilis), and hepatitis B testing.~For participants newly starting 2-1-1 PrEP (PrEPsmart intervention group), study drug will be offered to participants to ensure that they will have access to PrEP during the study to be able to adequately test the app."
62667347|NCT00066170|EXPERIMENTAL|Group 1.|Xyrem + Modafinil Placebo
62297627|NCT00534534|ACTIVE_COMPARATOR|1|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. In addition, they also will undergo repeated similar interventions at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
62297628|NCT00534534|NO_INTERVENTION|Standard|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
62297629|NCT05095935||Thoracic Adult|Use of Signia SDR for the transection of pulmonary arteries and veins in adult patients.
62667348|NCT00066170|PLACEBO_COMPARATOR|Group 2:|Xyrem Placebo + Modafinil Placebo
62667349|NCT00066170|ACTIVE_COMPARATOR|Group 3|Xyrem Placebo + Modafinil at established dose
62667350|NCT00066170|EXPERIMENTAL|Group 4:|Xyrem + Modafinil at established dose
62667351|NCT03457831||Status Epilepticus|Convulsive and Non-Convulsive Status Epilepticus ; and Pseudo Status Epilepticus
62105250|NCT06631365|NO_INTERVENTION|control (N=20)|"For the non-prescribed group, study staff will request documentation of an HIV-negative test within the last 3 months OR evidence of pre-exposure prophylaxis (PrEP) prescription within the last 6 months from medical records or pharmacy/provider communication. Additionally, study staff will confirm via self-report that the participant's 2-1-1 PrEP use will be clinically monitored by another clinician or clinic for the duration of the study. Any individual with a positive HIV test will have a confirmation test sent to the lab and be referred immediately for HIV care and initiation of treatment.~For participants already on PrEP (control group) may choose to continue to use their own supply of Truvada (tenofovir disoproxil fumarate/emtricitabine, or TDF/FTC)."
62297630|NCT05095935||Abdominal Adult|Use of Signia SDR for the transection of renal arteries and veins in adult patients.
62297631|NCT05095935||Abdominal Pediatric|Use of Signia SDR for the transection of the appendiceal stump and mesoappendix (simple acute appendicitis) in pediatric patients.
62297632|NCT04073745|EXPERIMENTAL|Treatment (SBRT)|Beginning at least 2 weeks after surgical resection, patients undergo 1 fraction (or 5 fractions every other day if R2 resection of central tumor) of SBRT.
62297633|NCT05437887|EXPERIMENTAL|Fucoidan|All patients are in the experimental group.
62297634|NCT01027689|ACTIVE_COMPARATOR|Alprazolam commercial immediate release oral tablet|
62297635|NCT01027689|EXPERIMENTAL|Alprazolam test sublingual tablet|
62297636|NCT05521165|EXPERIMENTAL|group A|The patients in group (A) (n=29) will receive an American physical therapy association (APTA) guided program consisting of stretching exercises for global trunk, back muscles, and hamstring muscles, strengthening exercises for abdominal and back muscles, and stabilizing exercises for trunk and pelvic muscles.
62297637|NCT05521165|EXPERIMENTAL|group B|The patients in group (B) (n=29) will receive treatment as in group (A) in addition to selected G Med strengthening exercises.
62667352|NCT05898880|EXPERIMENTAL|Self acupressure group|The first acupressure application will be administered and taught individually by the researcher to the oncology patients in the self-administered group. Afterwards, each patient who learns the application will be asked to apply acupressure on his own for three days. In the self-acupressure group, a questionnaire form consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied first (pre-test) before the acupressure application is taught to the group by the researchers. Afterwards, patients will apply acupressure on their own for three days, and at the end of this period (post-test), a questionnaire consisting of personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. Acupressure will be applied the large intestine meridian 4th Point (LI4), the pericardium meridian Neiguan (P6) and Yintang (EX-HN3).
62297638|NCT03660878|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|
62297639|NCT03660878|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.5%)|
62297640|NCT03660878|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62297641|NCT00499785||patients admitted with acute leukemia|
62297642|NCT03684655|EXPERIMENTAL|[18F]F-AraG|"radiofluorinated imaging agent, \[18F\]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
62297643|NCT05408858|EXPERIMENTAL|LGBTQ-affirmative cognitive behavioral group therapy|LGBTQ-affirmative cognitive behavioral group therapy consists of 10 weekly, 90-minute group therapy sessions, delivered remotely via Zoom. Intervention sessions and associated home practice will cover the following topics: Building and keeping motivation; Introduction to LGBTQ-related stress; Getting to know your emotions; Introduction to emotional behaviors and behavioral experiments; Awareness of physical sensations and introduction to flexible thinking; Being flexible in your thinking; Awareness of emotional experiences; Assertiveness; Situational exposures; Reviewing accomplishments and looking ahead. Participants will be taught intervention content through a range of teaching modalities including use of the Zoom whiteboard feature, videos, interactive activities, worksheets, and group discussion.
62297644|NCT05929599|PLACEBO_COMPARATOR|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~* Treatment medications: antipyretic paracetamol, antibiotics following the treatment protocol for community-acquired pneumonia in children by the Ministry of Health, and antibiotics with susceptibility results, such as Amoxicillin, Augmentin, or Benzylpenicillin. In cases of severe pneumonia, the following antibiotics may be used: Benzylpenicillin + Gentamicin; Cephalosporins (Cefotaxime, Ceftriaxone) + Amikacin; Oxacillin, Bristopen, Vancomycin if Staphylococcal pneumonia is suspected.~* Oxygen therapy: Indicated for all cases of severe pneumonia when SpO2 \<92%. Use an oxygen mask or nasal cannula."
62297645|NCT05929599|EXPERIMENTAL|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~* Treatment medications: antipyretic paracetamol, antibiotics following the treatment protocol for community-acquired pneumonia in children by the Ministry of Health, and antibiotics with susceptibility results, such as Amoxicillin, Augmentin, or Benzylpenicillin. In cases of severe pneumonia, the following antibiotics may be used: Benzylpenicillin + Gentamicin; Cephalosporins (Cefotaxime, Ceftriaxone) + Amikacin; Oxacillin, Bristopen, Vancomycin if Staphylococcal pneumonia is suspected.~* Oxygen therapy: Indicated for all cases of severe pneumonia when SpO2 \<92%. Use an oxygen mask or nasal cannula."
61913124|NCT04585009|EXPERIMENTAL|Cohort 2:GSK3923868 500 mcg/ 1000 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/Placebo. There will be at least 10 days of wash-out period between doses for each participant.
62105251|NCT06628648||canceled|Hypertensive patients proposed for minor abdominal surgery and canceled for high blood pressure numbers.
62105252|NCT06628648||not canceled|Hypertensive patients proposed for minor abdominal surgery not canceled: whose blood pressure figures are correct.
62297646|NCT05035420|EXPERIMENTAL|Healthy Volunteer|Healthy Volunteer
62297647|NCT05428709|EXPERIMENTAL|Acute exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
62297648|NCT01337401|EXPERIMENTAL|Blinded Cediranib|
62297649|NCT01337401|PLACEBO_COMPARATOR|Blinded Placebo|
62297650|NCT03614247|ACTIVE_COMPARATOR|RIRS|Patients underwent retrograde intrarenal surgery for lower calyceal stone between 1cm and 2cm in size
62297651|NCT03614247|ACTIVE_COMPARATOR|Micro-PNL|Patients underwent micro percutaneous nephrolithotomy (tract size \<10 F) for lower calyceal stone between 1cm and 2cm in size
62667353|NCT05898880|OTHER|Acupressure by therapist|In this group, acupressure will be administered to stage I, stage II, and stage III cancer patients receiving at least one course of chemotherapy for a total of three days by researchers with acupressure certification. Before the application (pre-test) by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied to the patients in the group in question. At the end of the three-day acupressure application (post-test) applied to the patients included in the study by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. In the acupressure group applied by the therapist, a total of three points will be applied to the upper extremity: the 4th point of the large intestine meridian (LI4), the Pericardium Meridian/Neiguan (P6), Yintang (EX-HN3) point.
62297652|NCT03614247|ACTIVE_COMPARATOR|Ultramini-PNL|Patients underwent ultra-mini percutaneous nephrolithotomy (tract size \<15 F) for lower calyceal stone between 1cm and 2cm in size
61913125|NCT04585009|EXPERIMENTAL|Cohort 2:GSK3923868 500mcg/ 1000mcg/ 3000mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
61913126|NCT04585009|EXPERIMENTAL|Cohort 3: Participants receivings repeated doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
61913127|NCT04585009|EXPERIMENTAL|Cohort 4: Participants receiving repeat doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
61913128|NCT04585009|EXPERIMENTAL|Cohort 5: Participants receiving repeat doses of GSK3923868|Participants with stable asthma will receive a planned repeat dosing of 3000 mcg (six capsules) GSK3923868 daily for 7 days
62105253|NCT04246697|ACTIVE_COMPARATOR|Standard of Care A|"Randomized controlled prospective trial to compare two standards of care for head and neck surgery pain management. Arm A, will include:~* Scheduled Tylenol 1000 mg IV one time dose intra-operatively, then 650 mg via PEG tube or PO Q4H to a max dose of 4gm/24 hrs~* Opioids prn based on Numeric Pain Scale (0-10, with 0 indicating no pain and 10 indicating worst pain ever):~* 0-3: no prn meds, reassurance, listen to music, watch TV.~* 4-7: Oxycodone 5 mg q4h prn via PEG tube or PO with a maximum of 30 mg/24 hours.~* 8-10 Morphine 2 mg IV q2h prn breakthrough pain."
62105254|NCT04246697|EXPERIMENTAL|Standard of Care B|"Arm B, will include:~* Arm A description with addition..~* Scheduled Ketorolac starting post-op day #1, 15 mg q6h (max 120 mg/day), for a total of 5 days~* Scheduled Gabapentin starting 7 days preoperatively to continue postoperatively~* Regional block per anesthesia protocol - Initial block: 0.5% bupivacaine, 20 ml Continuous infusion: 0.125% bupivacaine at 6 ml/hr with a 5 ml bolus available every 30 mins"
62105255|NCT05613257|ACTIVE_COMPARATOR|Free-hand/perfect circles|Patients in this group will have interlocking screw placement using a free-hand, perfect circles technique.
62105256|NCT05613257|EXPERIMENTAL|Distal targeting jig|Patients in this group will have interlocking screw placement using a proximally placed distal targeting jig
62105257|NCT03210402|ACTIVE_COMPARATOR|Elevated night pacing on|
62105258|NCT03210402|PLACEBO_COMPARATOR|Elevated night pacing off|
62105259|NCT06631950|EXPERIMENTAL|Fecundity knowledge intervention|In the experimental arm, participants receive a short (3 minutes) educational video on risk factors of importance for fecundity.
62105260|NCT06631950|NO_INTERVENTION|Control|In the no-intervention arm, the participants do not receive the intervention (a short educational video).
62105261|NCT00727584|ACTIVE_COMPARATOR|Arm I (multi-fraction radiotherapy)|Patients undergo 5 fractions of 20 Gy external-beam radiotherapy.
62105262|NCT00727584|EXPERIMENTAL|Arm II (single-fraction radiotherapy)|Patients undergo 1 fraction of 8 Gy external beam radiotherapy.
62105263|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
62105264|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
62468928|NCT06144918|EXPERIMENTAL|SBI-100 Ophthalmic Emulsion, 0.5%|All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
62105265|NCT02972008||patients with constitutional von Willebrand factor (vWF) deficiency|
62105266|NCT05923255|EXPERIMENTAL|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）group|In LISH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing a novel radical right hemicolectomy technique that allows for the preservation of the ileocecal region.
62105267|NCT05923255|ACTIVE_COMPARATOR|TRH （Traditional Right Hemicolectomy）group|In TRH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing the traditional radical right hemicolectomy.
62105268|NCT02322216|EXPERIMENTAL|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
62105269|NCT02322216|ACTIVE_COMPARATOR|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
62468929|NCT06144918|PLACEBO_COMPARATOR|SBI-100 Ophthalmic Emulsion Placebo|All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
62105270|NCT04474925|ACTIVE_COMPARATOR|Surgical Resection followed by SRS (Non-Experimental)|Surgical Resection followed by SRS within 3 weeks of surgery date.
62105271|NCT04474925|EXPERIMENTAL|SRS followed by Surgical Resection (Experimental)|SRS followed by surgery within 1 week of radiotherapy end date.
62297653|NCT03614247|ACTIVE_COMPARATOR|Mini-PNL|Patients underwent mini percutaneous nephrolithotomy (tract size \<20 F) for lower calyceal stone between 1cm and 2cm in size
62297654|NCT03614247|ACTIVE_COMPARATOR|Standard PNL|Patients underwent standard percutaneous nephrolithotomy (tract size \>25 F) for lower calyceal stone between 1cm and 2cm in size
62468930|NCT06144918|EXPERIMENTAL|SBI-100 Ophthalmic Emulsion, 1%|All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
62297655|NCT03193268|EXPERIMENTAL|High intensity agility group|Exercise therapy
62667354|NCT05898880|OTHER|Control group|The control group will receive the routine treatment applied in the hospital, and acupressure will not be applied to this group.
62667355|NCT03130322|EXPERIMENTAL|NightPP|Participants of the NightPP will be subjected to one MRI session and two MEG recording sessions: the first one before a physical practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
62667356|NCT03130322|EXPERIMENTAL|NightMI|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
62667357|NCT03130322|EXPERIMENTAL|NightCtrl|Participants of the NightCtrl will be subjected to one MRI session and two MEG recording sessions: the first one before a mental rotation practice session, a second MEG session right after practice,and second MEG session right after practice.
62667358|NCT03130322|EXPERIMENTAL|Day|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
62667359|NCT04822571|OTHER|Adolescent volunteers|Adolescent males aged 12-16 years old
62667360|NCT04822571|OTHER|Adult volunteers|Adult males aged 25-35 years old
62667361|NCT01542099|ACTIVE_COMPARATOR|Single lumen tube|Single lumen tube intubation during remifentanil infusion
62667362|NCT01542099|ACTIVE_COMPARATOR|Double lumen tube|Double lumen tube intubation during remifentanil infusion
61913129|NCT03811808||MSA patients|patients diagnosed with possible or probable multiple system atrophy
61913130|NCT00604370||1|Acutely ill medical and surgical patients who were hospitalized at BWH, and at-risk for VTE, but were not treated with prophylaxis at hospital discharge.
61913131|NCT00604370||2|Acutely ill medical and surgical patients who were at risk for VTE at time of hospital discharge and prescribed a prophylaxis strategy.
61913132|NCT02577393|EXPERIMENTAL|prophylactic EGCG group|
61913133|NCT02577393|EXPERIMENTAL|therapeutic EGCG group|
61913134|NCT02577393|PLACEBO_COMPARATOR|conventional therapy group|
61913135|NCT01251640|EXPERIMENTAL|Arm 1|
61913136|NCT04671472|EXPERIMENTAL|Aceneuramic acid tablets|Aceneuramic acid tablets 6 g/day, divided 3 times a day for 48 weeks
61913137|NCT04671472|PLACEBO_COMPARATOR|Aceneuramic acid placebo tablets|Matching placebo 3 times a day for 48 weeks
61913138|NCT04248959|EXPERIMENTAL|Multimodal Prehabilitation|Facility and home-based multimodal prehabilitation (aerobic exercise training, resistance exercise training, nutrition support, stress management and mindfulness training)
61913139|NCT04865523|EXPERIMENTAL|Manual Lymphatic Drainage|
61913140|NCT04865523|NO_INTERVENTION|No intervention|
61913141|NCT05622162|EXPERIMENTAL|Interventional and Comparator|The subject participation in the study consists from performing of one non-contrast enhanced PET/CT with Investigational Product (18F-JK-PSMA-7) and of one PET/CT with Comparator (18F-Fluorocholine) This sequence of administration is established in advance as the organizational model, linked to the availability and management of the radiopharmaceutical, not allow to perform a randomization.
61913142|NCT05869357|EXPERIMENTAL|cream containing 2.5% sericin and 2%turmeric|cream containing 2.5% sericin and 2%turmeric
61913143|NCT05869357|EXPERIMENTAL|cream containing 5%sericin and 2%turmeric|cream containing 5% sericin and 2%turmeric
61913144|NCT05869357|EXPERIMENTAL|cream containing 10%sericin and 2%turmeric|cream containing 10% sericin and 2%turmeric
61913145|NCT05869357|EXPERIMENTAL|cream base|cream base without sericin and tumeric
61913146|NCT01005121|EXPERIMENTAL|colchicine|patients will receive 2 mg of colchicine daily
61913147|NCT04064008||Primary Total Hip Arthroplasty|Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem
62297656|NCT03193268|EXPERIMENTAL|Non-agility cycling group|Parkinson's Bicycle Group, which takes 1 hour of exercise every day for 5 weeks
62667363|NCT04769401|EXPERIMENTAL|Normal Progesterone group|Progesterone level ≥ 10 ng/mL on ET day.
62667364|NCT04769401|ACTIVE_COMPARATOR|Low Progesterone group|Progesterone level \<10 ng/mL on ET day.
62667365|NCT03234452|EXPERIMENTAL|Lactoflorene plus|10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day
62667366|NCT03234452|PLACEBO_COMPARATOR|Placebo Lactoflorene plus|Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.
62297657|NCT03193268|NO_INTERVENTION|No-exercise control group|Control Parkinson's disease control group thad will not receive exercise treatment
62297658|NCT05003362|NO_INTERVENTION|usual care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician.
62297659|NCT05003362|ACTIVE_COMPARATOR|ACT|An 8-week mindfulness-based group therapy.
62297660|NCT03862456|EXPERIMENTAL|azythromycin + periodontal surgery.|Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days).
62105272|NCT04025905|EXPERIMENTAL|Social Cognition Training Program|This program is taken from two validated cognitive remediation programs: the SCIT program and the RC2S program : perception of social situations - emotional processes and social perception;interpretation of social situations - theory of mind and attributions;acting in social situations - social skills training
62105273|NCT04025905|SHAM_COMPARATOR|Informations program|Educational team Information will be given to participants about work environment, social environment, stress management, sleep management, treatments. It will also include socialization sessions with board games or cultural activities.
62105274|NCT01560949|EXPERIMENTAL|Chemotherapy + Radiation|"SYSTEMIC PHASE: Chemotherapy with Oxaliplatin followed by Irinotecan followed by 5-FU. m FOLFIRINOX - oxaliplatin 75 mg/m2 d1 + irinotecan 150 mg/m2 d1 + 5-FUl 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks).~CHEMORADIATION PHASE: This phase will start at least 2 weeks, but no more than 6 weeks after completion of the last cycle of mFOLFIRINOX. Chemoradiation with Gemcitabine: 350 mg/m2 IV over 35 minutes every week for 5 doses beginning day 1 (days 1, 8, 15, 22, 29)~Radiation: External beam radiation therapy will be delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions) to the GTV + 1.5 cm margin.~SURGERY- At least 4-6 weeks after last dose of Gemcitabine, if no local progression or distant metastasis. Patients whose scans show unequivocal local or distant progression are not candidates for surgery."
62105275|NCT05177341||Amputees with acceptable phantom sensation|
62105276|NCT05177341||Amputees with no phantom sensation|
62105277|NCT05177341||Control group|
62105278|NCT00635895|ACTIVE_COMPARATOR|1|Manual Lymph Drainage Therapy is a manual therapy method
62105279|NCT00635895|ACTIVE_COMPARATOR|2|Connective Tissue Massage
62105280|NCT06554171|EXPERIMENTAL|Hippotherapy group|In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
62105281|NCT06554171|EXPERIMENTAL|Control group|In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
62105282|NCT05887323||Left Bundle Branch Area Implant|Data included in this LBBAP data collection registry will be from subjects followed for 6 months (± 3 months) after attempted implant of LBBAP location. Data will be collected from previously occurring visits at pre-implant (baseline, required), implant (required), 6 months (±3 months, required), and 12 months (-2, +4months, optional).
62105283|NCT00931229|EXPERIMENTAL|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines.
62468931|NCT06388122||Group 1 (initiating 1st line CDK4/6 & endocrine therapy)|Blood will be drawn every 14 days starting from the first treatment cycle until the start of cycle 3; starting at cycle 3 blood will be drawn the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.
62667367|NCT00086307|ACTIVE_COMPARATOR|Pramipexole|Patients receive pramipexole and placebo. The dosage of pramipexole is 0.125 milligrams (mg) three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
62667368|NCT00086307|ACTIVE_COMPARATOR|Escitalopram|Patients receive escitalopram and placebo. The dosage of escitalopram is 10 milligrams (mg) per day.
61913148|NCT02778360|EXPERIMENTAL|Neurofeedback NFT|"Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game.~Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home"
61913149|NCT02778360|ACTIVE_COMPARATOR|Methylphenidate MPH|"Methylphenidate long acting preparation.~Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day).~Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day)."
61913150|NCT03040570|EXPERIMENTAL|Conservative oxygenation target|Children in the conservative oxygenation target group receive treatment targeting oxygen saturation values of 88-92%.
61913151|NCT03040570|ACTIVE_COMPARATOR|Liberal oxygenation target|Children in the liberal oxygenation target group receive treatment targeting oxygen saturation values of \>94%.
61913152|NCT00573287|EXPERIMENTAL|Clozapine|clozapine: clozapine--tablets, 12.5-100 mg, daily for 24 weeks
61913153|NCT00573287|ACTIVE_COMPARATOR|Risperidone|risperidone: risperidone--tablets, 0.5-5.0mg daily for 24 weeks
61913154|NCT00859638|EXPERIMENTAL|Intervention Group|Rehabilitation self-management group, on-line self monitoring of physical function, and organizational capacity building.
61913155|NCT00859638|NO_INTERVENTION|Case matched controls|Usual care in primary health care.
61913156|NCT00637143|EXPERIMENTAL|1|Oral
61913157|NCT00637143|ACTIVE_COMPARATOR|2|Oral
61913158|NCT02858544||Group1 - Validation Group|n=890 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
61913159|NCT02858544||Group 2 - Cross Validation Group|n=900 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
61913160|NCT02280122||gen. mod. to sev. chronic periodontitis|"* Sites with probing pocket depths (PPD) ≥ 3.5 mm~* Attachment loss (PAL-V) ≥ 3 mm \> 30% of sites~* no Intervention provided"
61913161|NCT02280122||periodontally healthy|"* PPD ≤ 3 mm~* PAL-V ≤ 2 mm at \< 30% of sites~* BOP \< 20%~* No radiographically detectable bone loss: distance cemento-enamel junction to provided~* no Intervention but aMMP-8 test"
61913162|NCT01961583|EXPERIMENTAL|Drug; 18F-Fluciclatide|18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
61913163|NCT03315091|EXPERIMENTAL|Treatment sequence 1 (Fasted-Fed)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
62297661|NCT03862456|ACTIVE_COMPARATOR|metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days).
62297662|NCT02054702|EXPERIMENTAL|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
62297663|NCT02054702|EXPERIMENTAL|Aripiprazole|Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally
62297664|NCT04728204|EXPERIMENTAL|Intervention group|8 module, 8 week long internet-based intervention for reducing burden of depression
62297665|NCT04728204|NO_INTERVENTION|Control group|Participants randomized to the control group will be instructed to wait until the intervention group finishes the treatment and that they will be able to use the same intervention afterwards.
62297666|NCT04474912||Control group|Healthy volunteers with no symptoms or signs of rheumatoid arthritis or osteoarthritis
62297667|NCT04474912||Rheumatoid arthritis group|Rheumatoid arthritis (RA) patients fulfilled 2010 American college of rheumatology (ACR) classification criteria. A patient is considered having definite RA if he/she scores at least 6 points in the established classification system
62297668|NCT04474912||Osteoarthritis group|Osteoarthritis (OA) patients fulfilled 1990 ACR criteria for the classification and reporting of osteoarthritis of the hand. A patient is considered having hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands
62297669|NCT05779891|EXPERIMENTAL|Interventional Group A|
62297670|NCT05779891|ACTIVE_COMPARATOR|Interventional Group B|
62297671|NCT00278525|EXPERIMENTAL|stem cell trasplantation|intervention as stem cell transplantation after conditioning regimen
62667369|NCT00086307|EXPERIMENTAL|Escitalopram and Pramipexole|Patients receive escitalopram and pramipexole. The dosage of escitalopram is 10 milligrams (mg) per day. The dosage of pramipexole is 0.125 mg three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
62667370|NCT05965934|EXPERIMENTAL|Direct Sodium Removal (DSR) Infusate 2.0|Participants will receive a peritoneal dialysis catheter implant. DSR is to be started 14 days after catheter implantation (= D1) for a period of 4 weeks (D28) on top of optimized usual care for HF, while loop diuretic treatment is suspended. Participants then enter enter a 3 month safety follow-up period (D29-D120) until the end of study (D120).
62105284|NCT00835016|EXPERIMENTAL|Early psychosocial stimulation (LTP)|The 10 session of Early psychosocial stimulation (LTP)will be delivered to depressed mothers in the intervention group
62105285|NCT00835016|ACTIVE_COMPARATOR|Waiting group|Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
62667371|NCT05965934|NO_INTERVENTION|Optimized Usual Care for HF|IV loop diuretic treatment is to be started (or continued) after a 14 days observation period (= D1) and can be continued for up to 4 weeks (D28). Participants then enter enter a 3 month safety follow-up period (D29-D120) until the end of study (D120).
62737235|NCT02111915|OTHER|Enhanced Usual Care (EUC)|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services
61913164|NCT03315091|EXPERIMENTAL|Treatment sequence 2 (Fed-Fasted)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
61913165|NCT00918008||Blood sample|the blood sample only collected prior to surgery
61913166|NCT05023369|EXPERIMENTAL|Dexamethasone group|Patient in this group will receive administration of 9 mg dexamethasone injected in the peri-articular tissues after the bone cut for hip endoprosthesis
62297672|NCT00278525|ACTIVE_COMPARATOR|standard of care|medication as standard of care will be given
61913167|NCT05023369|NO_INTERVENTION|Routine care|In this group only routinely performed anaesthesia protocol will be provided
61913168|NCT06008912|EXPERIMENTAL|Calisthenic + Aerobic Exercise Group|Patients will take aerobic exercise training in 3 days per week, and 7 days per week calisthenic exercises for upper extremity, lower extremity and trunk, for 8 weeks.
62105286|NCT02918916|EXPERIMENTAL|Active phototherapy group|"Phototherapy will be applied between sprint and squat training (exactly 10 minutes before squat training).~Active phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin.~The optical power will be calibrated before irradiation in each participant using a Thorlabs thermal power meter (Model S322C, Thorlabs, Newton, New Jersey, USA)."
62297673|NCT02491541|EXPERIMENTAL|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
62297674|NCT02491541|ACTIVE_COMPARATOR|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
62105287|NCT02918916|PLACEBO_COMPARATOR|Placebo phototherapy group|"Placebo will be applied between sprint and squat training (exactly 10 minutes before squat training). Placebo phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin. To receive active or placebo phototherapy the participant will be placed in the supine position.~The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled."
62105288|NCT02918916|NO_INTERVENTION|Control group|Passive recovery will be applied between sprint and squat training (exactly 10 minutes before squat training). During the period when the other groups are receiving recovery strategies, the control group participants will remain seated for passive recovery, supervised by an independent therapist.
62105289|NCT06200636|EXPERIMENTAL|Interventional group|This arm inclcudes all study participants.
62667372|NCT04919343|EXPERIMENTAL|BBC Tiny Happy People intervention|Parents will be sent links each month directing them to BBC Tiny Happy People content via SMS text message using the secure service FireText. This content will be aimed at supporting language development. Parents will be asked to watch the video content and incorporate it into their parenting practices. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits.
62105290|NCT04330443|EXPERIMENTAL|Ultrasound group|The neonatologist-researcher (NR) performed the lung ultrasound at admission during the first hour of life. The neonatologist-assistant (NA) of the baby was not blinded to the result of the lung ultrasound. If the patient had a lung ultrasound score higher than \>8 or when FiO2 exceeded 30% patient received surfactant therapy during in the first 72 hours of life
62105291|NCT04330443|NO_INTERVENTION|Chest X Ray|The NR performed the LUS at admission/suspicion during the first hour of life. The NA was not blinded to the result of the LUS. Patient received surfactant therapy only when FiO2 exceeded 30% during the first 72 hours of life
62105292|NCT01106729|OTHER|Cyanidin 3 glucoside|
62105293|NCT03425526|EXPERIMENTAL|Treatment (allogeneic adenovirus-specific CTLs)|Within two weeks of enrollment, patients receive allogeneic adenovirus-specific CTLs IV over 30 minutes. Patients may receive additional allogeneic adenovirus-specific CTL infusions at the discretion of the investigator in the absence of disease progression or unacceptable toxicity.
62105294|NCT02896894|EXPERIMENTAL|Immediate Treatment Group|The Immediate Treatment Group will receive access to the study intervention - the Big White Wall, immediately after consenting for a total duration of 3 months.
62105295|NCT02896894|OTHER|Delayed Treatment Group|The Delayed Treatment Group will have no access to the study intervention - the Big White Wall for the first 3 months, then receive access to the BWW for 3 consecutive months.
62105296|NCT02896894|EXPERIMENTAL|Immediate Treatment Group - Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to the The Immediate Treatment Group - Extension, will receive access to the Big White Wall for an additional 3 months (months 4-6), immediately after receiving the initial 3 months of access.
62105297|NCT02896894|NO_INTERVENTION|Immediate Treatment Group - No Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to The Immediate Treatment Group - No extension, will not receive extended access to the Big White Wall.
62105298|NCT06230874|EXPERIMENTAL|HOME Protocol|Will receive the HOME Protocol Intervention
62105299|NCT06230874|ACTIVE_COMPARATOR|Control Journaling Protocol|Will receive the Control Journaling Protocol
62105300|NCT03861949|NO_INTERVENTION|Conventional|preoxygenation done with 100% oxygen in supine position
62105301|NCT03861949|EXPERIMENTAL|Positive-pressure|preoxygenation done with 5 cmH2O CPAP (continuous positive airway pressure) in supine position with 100% oxygen
62105302|NCT03861949|EXPERIMENTAL|Head-up|preoxygenation done in 25 degree head-up position with 5 cmH2O CPAP with 100% oxygen
62105303|NCT01871818|EXPERIMENTAL|Combined program|"Combined program with physiotherapy, endurance training and resistance training.~120 patients will receive this combined program"
62105304|NCT01871818|ACTIVE_COMPARATOR|Physiotherapy|Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
62105305|NCT04241796|EXPERIMENTAL|Elevated Risk and Non-Elevated Risk Groups|"Two cohorts:~1. Elevated risk group (approximately 70% of the total enrollment) on the basis of history of smoking, documented genetic cancer predisposition, or personal history of invasive or hematologic malignancy.~2. Non-elevated risk group (approximately 30% of the total enrollment) with none of the conditions listed in the Elevated Risk Group."
62105306|NCT04668183||Pudendal Nerve Block|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
62105307|NCT04668183||Dorsal Penile Nerve Block|Ultrasound (US) guided dorsal penile nerve block with in plane technique was done. Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
62105308|NCT01353638|OTHER|Arm A|Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
62105309|NCT01353638|OTHER|Arm B|Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.
62105310|NCT03766438|EXPERIMENTAL|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care.
62105311|NCT03766438|NO_INTERVENTION|Control|The comparison group will receive usual clinical care.
62105312|NCT02652234|EXPERIMENTAL|Endostar-subcutaneous injection/Chemotherapy|
62105313|NCT05068713|EXPERIMENTAL|Hihg Target Mean Arterial Pressure|Target of mean arterial pressure of 85-90 mmHg in ther first 24h after liver transplant.
62105314|NCT05068713|ACTIVE_COMPARATOR|Low Target Mean Arterial Pressure|Target of mean arterial pressure of 65-70 mmHg in ther first 24h after liver transplant.
62297675|NCT02852226|EXPERIMENTAL|Study Intervention|Assess PrEP among women in the study. Assess the characteristics of women who enroll in the PrEP study. Assess the referral sources of women who enroll in the PrEP study
62297676|NCT06559839|EXPERIMENTAL|Fibromyalgia|Patients in this arm meet ACR 2011 criteria for Fibromyalgia.
62297677|NCT06559839|EXPERIMENTAL|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Long Covid, Post Treatment Lyme Disease Syndrome|Participants in this arm meet criteria for at least one of the following diseases: Myalgic-Encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID, or Post Treatment Lyme Disease Syndrome.
62297678|NCT02970617|ACTIVE_COMPARATOR|Group A (no bell after final radiation)|Patients undergo standard of care radiation therapy with or without chemotherapy.
62737236|NCT02111915|EXPERIMENTAL|THPP-P|Trial participant s who are in the THPP group will receive, in addition to EUC, 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
62105315|NCT04590989|EXPERIMENTAL|Personalized Plan (PP)|"Each subject in the PP group will be allocated to one of five clusters based on their metabolic and genetic health biomarkers from samples of urine, plasma, serum, and saliva. 58 biomarkers will be included to characterize the 5 metabolic clusters/processes in the PREVENTOMICS platform: 1) oxidative stress; 2) inflammation; 3) carbohydrate metabolism; 4) lipid metabolism; 5) microbiota-generated metabolites. Eurecat Nutrition Team has prepared a list of recommended food items to increase and food to exclude/limit from the diet for each cluster. The list will be adopted by Simple Feast in creating five different menus that will encompass the 12 meals/week of breakfasts and dinners for the five different metabolic clusters. Additionally, subjects will receive personalized actionable Do's push notifications by ONMI. The messages are personalized based on user reports from the behavioral questionnaire at V2 in addition to inputs from the nutritional recommendations of food to increase."
62105316|NCT04590989|PLACEBO_COMPARATOR|Control Group|"Dietary intervention:~The second group of 50 subjects will receive meals from Simple Feast, after integrating their metabolic profile and other blood biomarkers by PREVENTOMICS, which are based on the national dietary guidelines.~Behavioral intervention:~Subjects will also receive nudges, after filling out ONMI's behavioral questionnaire at V2, but that will not be personalized (i.e. basic information that is available online from NHS and WHO)."
62105317|NCT06629636|ACTIVE_COMPARATOR|NMN intervention|NMN capsules (total of 900mg/day) for 8 weeks
62105318|NCT06629636|PLACEBO_COMPARATOR|Placebo intervention|NMN-free placebo capsules for 8 weeks
62297679|NCT02970617|EXPERIMENTAL|Group B (ring bell after final radiation treatment)|On the final day of standard of care radiation therapy, patients ring a bell in the clinic.
62297680|NCT01512589|EXPERIMENTAL|Proton Beam Therapy (PBT)|"Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy (or at RBE (Relative Biologic Equivalence for PBT)) to be delivered to the periphery of the planning target volume (PTV)."
62105319|NCT01387490|EXPERIMENTAL|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
62297681|NCT01512589|ACTIVE_COMPARATOR|Intensity Modulated Radiation Therapy (IMRT)|Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy to be delivered to the periphery of the planning target volume (PTV).
62297682|NCT04740411|EXPERIMENTAL|Common Elements Toolbox (COMET)|
62297683|NCT04740411|NO_INTERVENTION|Wait-list control condition|
62297684|NCT00752986|EXPERIMENTAL|Vandetanib at the dose of 100 mg|vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
62297685|NCT00752986|EXPERIMENTAL|Vandetanib at the dose of 300 mg|vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
62297686|NCT00752986|PLACEBO_COMPARATOR|Placebo to match vandetanib 100 mg and 300 mg|placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3).
62297687|NCT05970887|EXPERIMENTAL|C group|Concomitant administration of bivalent mRNA COVID-19 booster and quadrivalent influenza vaccination
62297688|NCT05970887|PLACEBO_COMPARATOR|S group (COVID-19 vaccine only)|separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later
62297689|NCT05970887|PLACEBO_COMPARATOR|S group (influenza vaccine only)|separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later
62297690|NCT00596544||1|FSFI score \<= 26
62297691|NCT00596544||2|FSFI score \>26
62297692|NCT04154098|EXPERIMENTAL|NO-OA-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
62297693|NCT04154098|EXPERIMENTAL|NO-MA-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
62297694|NCT04154098|EXPERIMENTAL|OA-NO-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
62667373|NCT04919343|ACTIVE_COMPARATOR|Physical health control|Similar to the experimental condition, parents will be sent links each month via SMS text message using FireText. These links will direct them to publicly available web content with tips to promote the healthy development of their baby, focusing on things such as healthy eating, physical activities, and dental care. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits
62297695|NCT04154098|EXPERIMENTAL|OA-MA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
62297696|NCT04154098|EXPERIMENTAL|MA-NO-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
62297697|NCT04154098|EXPERIMENTAL|MA-OA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
62297698|NCT04868123|EXPERIMENTAL|Mindfulness Meditation|6 weeks of daily mindfulness meditation (guided by audio recordings) performed at home
62297699|NCT04868123|EXPERIMENTAL|Transcutaneous nerve stimulation (TENS)|6 weeks of daily TENS treatment performed at home
62297700|NCT04868123|NO_INTERVENTION|Usual Care|Usual care (no additional treatment)
62297701|NCT04355286|EXPERIMENTAL|Part 1, one-arm open label pilot study|Part 1 is an open label, 1-arm pilot study to evaluate the systemic absorption and effects of multiple applications of a market-image topical sunscreen formulation containing BEMT (6%) under maximum use conditions in healthy adult subjects.
62667374|NCT01257542|EXPERIMENTAL|Active|
62667375|NCT01257542|PLACEBO_COMPARATOR|Placebo|
62667376|NCT03017261|EXPERIMENTAL|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
62667377|NCT02350205|EXPERIMENTAL|Treatment (SASS)|Phase A: All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples sites A+ B). // Phase B: All patients will receive Self assembled skin subsitute (SASS)
62297702|NCT05413330|EXPERIMENTAL|IVTA group|Patients will receive an intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of surgery.
62297703|NCT05413330|NO_INTERVENTION|No injection group|Patients will receive no additional treatment to the standard phacoemulsification surgery.
62297704|NCT04709549|ACTIVE_COMPARATOR|Diabetes Prevention Program|The DPP is a behavioral obesity and diabetes prevention program run by the YMCA, over a 12-month period.
62297705|NCT04709549|EXPERIMENTAL|Diabetes Prevention Program + Job and Legal Services|Participants meet with service connectors to receive an individual assessment of your needs and create an individual service plan for job services and be referred to legal support services if also needed.
62667378|NCT00540267||Schizophrenia|Chronic schizophrenia with aged 18-80 years
62667379|NCT05910398|ACTIVE_COMPARATOR|continuous pyrotinib|pyrotinib 400 mg, orally once daily for one year
62667380|NCT05910398|EXPERIMENTAL|intermittent pyrotinib|pyrotinib 400 mg, 14 days on and 7 days off, every 21 days for 17 cycles
62667381|NCT01104012||All patients|Allergy patients, asthma and rhinitis
62667382|NCT03402087|EXPERIMENTAL|BMS-986165+Methotrexate+Leucovorin|Three treatments administered
62667383|NCT03688737|PLACEBO_COMPARATOR|control group|"A) Control group:~Has Surgical procedures von Langenbeck technique  to repair cleft palate and will come for follow up visit at day of surgery, 1st day and 3rd day for placebo device like LLL and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
62667384|NCT03688737|ACTIVE_COMPARATOR|study group|"B) Study group:~This group will be subjected to the same surgical procedure von Langenbeck technique to repair cleft palate but low level laser Therapy will be at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
62667385|NCT05565547||Patients with common eye diseases|Patients who have common eye diseases, including common anterior segment eye diseases (conjunctivitis, keratitis, corneal opacity, cataract) and fundus diseases (age-related macular degeneration, diabetic retinopathy) and refractive error (myopia, high myopia, hyperopia, anisometropia and presbyopia).
62667386|NCT01447472|EXPERIMENTAL|MDMA|One single dose of MDMA (1.5 mg/kg; range 75-100 mg)
61913169|NCT06008912|ACTIVE_COMPARATOR|Aerobic Exercise Group|Patients will take aerobic exercise training in 3 days per week, for 8 weeks.
62105320|NCT01387490|OTHER|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
62105321|NCT03028363|EXPERIMENTAL|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
62105322|NCT03028363|PLACEBO_COMPARATOR|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
62105323|NCT06631911|OTHER|Emotional Awareness and Expression Therapy|Please see description for intervention
62105324|NCT01335789|ACTIVE_COMPARATOR|Oxytocin|intranasal administration
62105325|NCT01335789|PLACEBO_COMPARATOR|saline|intranasal administration
62105326|NCT05447013|EXPERIMENTAL|For Phase II: Arm A|Standard of care (SOC) and Coronavirus-specific T cells (CoV-2-STs)
62105327|NCT05447013|ACTIVE_COMPARATOR|For Phase II: Arm B|Standard of care (SOC)
62105328|NCT03315390|EXPERIMENTAL|Intervention-group|Narrative Exposure Therapy (NET): for GP-practice adapted version of narrative exposure therapy during 3 sessions (à 45 minutes)
62297706|NCT00759629|EXPERIMENTAL|A|Interventional treatment group - Patients assigned to PCI will receive the loading dose of clopidogrel, aspirin plus a bolus of heparin and be transferred immediately for interventional treatment. They will receive abciximab as a bolus followed by a continuous infusion of for 12 hours.
62297707|NCT00759629|ACTIVE_COMPARATOR|B|Conservative treatment group - Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards.
62297708|NCT06653777|EXPERIMENTAL|pemigatinib|Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).
62667387|NCT01501513|EXPERIMENTAL|BLI800 approved preparation regimen|BLI800 approved preparation regimen
61913170|NCT06008912|NO_INTERVENTION|Control Group|Patients will take physical activity recommendations, and just screening after 8 weeks.
61913171|NCT03712709||Case Detection Group|Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled
61913172|NCT03712709||Drug Resistant TB Group|In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).
61913173|NCT04397666|EXPERIMENTAL|1|
61913174|NCT02311218|ACTIVE_COMPARATOR|Test group with L. reuteri|Subjects in the test group take one Lactobacillus reuteri DSM 17938 and PTA 5289 containing lozenge in the morning and one in the evening.
61913175|NCT02311218|PLACEBO_COMPARATOR|Placebo group without L. reuteri|Subjects in the placebo group take one placebo lozenges with same look, taste and smell as the test lozenge but lacking the Lactobacillii the morning and one in the evening.
61913176|NCT03893253|EXPERIMENTAL|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
61913177|NCT03893253|ACTIVE_COMPARATOR|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
61913178|NCT03893253|NO_INTERVENTION|Control group|The control group will receive no booster teaching at all.
61913179|NCT03906916|EXPERIMENTAL|Patients with suspicion of invasive candidiasis|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
62667388|NCT01501513|EXPERIMENTAL|BLI800 investigational preparation regimen|BLI800 investigational preparation regimen
62667389|NCT01501513|ACTIVE_COMPARATOR|PEG-3350 based bowel preparation|PEG-3350 based bowel preparation
62667390|NCT03632330||Dexmedetomidine|Dexmedetomidine group
62667391|NCT03632330||Midazolam|Midazolam group
62667392|NCT03632330||propofol|propofol group
62667393|NCT03632330||Midazolam/Propofol|Midazolam and Propofol group
62667394|NCT02451475|OTHER|Amitriptyline|Amitriptyline 25 mg/day
62667395|NCT02451475|ACTIVE_COMPARATOR|Venlafaxine|Venlafaxine 75 mg/day
62667396|NCT02451475|ACTIVE_COMPARATOR|Paroxetine|Paroxetine 25 mg/day
62667397|NCT01428128|EXPERIMENTAL|Arsenic Trioxide|
62667398|NCT02298283|EXPERIMENTAL|study treatment|"* induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks~* radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks~* Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg"
62667399|NCT03554109|EXPERIMENTAL|Group A|"NANT Neoadjuvant Triple Negative Breast Cancer Vaccine~A combination of agents will be administered to subjects in this study:~cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, avelumab, aldoxorubicin HCl, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-051 and ETBX-061"
62667400|NCT03554109|ACTIVE_COMPARATOR|Group B|Standard treatment with a combination of doxorubicin, cyclophosphamide and paclitaxel.
62667401|NCT02882984|ACTIVE_COMPARATOR|WBRT along with TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~3750Gy/15F~Other Name: WBRT"
62667402|NCT02882984|EXPERIMENTAL|HFSRS with EGFR TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~25 to 40 Gy/5F~Other Name: HFSRS"
62667403|NCT02043860|EXPERIMENTAL|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
62667404|NCT03267589|EXPERIMENTAL|Cohort A|Intervention: MEDI9447 (CD73) + durvalumab
62667405|NCT03267589|EXPERIMENTAL|Cohort B|Intervention: MEDI0562 (OX40) + durvalumab
62667406|NCT03267589|EXPERIMENTAL|Cohort C|Intervention: MEDI0562 (OX40) + tremelimumab combination
61913180|NCT05398081|EXPERIMENTAL|Cefuroxime|Cefuroxime (Zinnat®) will be used as prophylactic antibiotic in this arm
62667407|NCT03228576||TREVISE|
62105329|NCT03315390|ACTIVE_COMPARATOR|iTAU group|Improved Treatment-as-usual: 3 GP consultations with patients according to guidelines and adapted to patients' needs
62667408|NCT05796973|EXPERIMENTAL|Guided physical exercise arm|"20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit.~In addition, as a separate group, 20 patients from each type of cancer (altogether 80) who are already using statin medication are randomized to this arm."
62667409|NCT05796973|EXPERIMENTAL|Atorvastatin arm|20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise + atorvastatin (40 mg QD) arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit.
62667410|NCT05796973|ACTIVE_COMPARATOR|Non-guided physical exercise arm|"20 patients from each type of cancer (altogether 80) are randomized to a non-guided physical exercise arm. The patients' physical condition and body composition are measured at baseline. The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own. The physical condition and body composition of this group is also measured at three months and six months after baseline to detect changes. After that the patients are given advise to exercise regularly and this is asked during each follow-up visit.~In addition, as a separate group, 20 patients from each type of cancer (altogether 80) who are already using statin medication are randomized to this arm."
62667411|NCT01295892|PLACEBO_COMPARATOR|placebo|placebo (transdermal gel)
62667412|NCT01295892|EXPERIMENTAL|Estrogen|1mg of 17B-estradiol/day (transdermal gel)
62105330|NCT04344366||group A|children with low birth weight
62667413|NCT02289378|EXPERIMENTAL|Docetaxel, Oxaliplatin and 5-Fu|Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two weeks
62667414|NCT00999206|EXPERIMENTAL|1|
62667415|NCT00999206|EXPERIMENTAL|2|
62667416|NCT00999206|EXPERIMENTAL|3|
62667417|NCT00999206|ACTIVE_COMPARATOR|4|
61913181|NCT05398081|ACTIVE_COMPARATOR|Ceftriaxone|Ceftriaxone (Rocephin®) will be used as prophylactic antibiotic in this arm
61913182|NCT04104269||Mechanical Complications|Include free wall ventricular rupture and ventricular septal rupture
61913183|NCT04104269||Non-Mechanical Complications|Mechanical complications were not included in patients with AMI
61913184|NCT05073094|EXPERIMENTAL|Esmolol|1 mg/kg (max. 100 mg) as a bolus before aortic cross-clamping and 2 mg/kg (max. 200 mg) in the cardioplegia solution
61913185|NCT05073094|PLACEBO_COMPARATOR|Placebo|Equivalent volume of saline as a bolus before aortic cross-clamping and in the cardioplegic solution
62105331|NCT04344366||group B|children with normal birth weight
62297709|NCT04412304||thrombose prophylaxis|The dose used to prevent thromboembolic complication in critically ill
62297710|NCT04412304||double thrombose prophylaxis|Double the dose used to prevent thromboembolic complication in critically ill
62468932|NCT06388122||Group 2 (initiating 2nd or later line of CDK4/6 with or without endocrine therapy)|Blood will be drawn every 14 days starting from the first treatment cycle until the start of cycle 3; starting at cycle 3 blood will be drawn the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.
62468933|NCT06388122||Group 3 (currently receiving 1st line CDK4/6 and endocrine therapy)|Blood will be drawn on day 15 of the next cycle after enrollment and the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.
62468934|NCT06388122||Group 4 (initiating or currently receiving 1st or 2nd line endocrine therapy)|Blood will be drawn at baseline or the first day of the treatment cycle and the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.
62468935|NCT05855577|EXPERIMENTAL|Terazosine|Pharmacological Treatment of Pakinson's disease patients using Terazosin 2 mg
62105332|NCT04238104||sea level|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center of sea level were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
62105333|NCT04238104||altitude <1000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude less than 1000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
62667418|NCT05000437|EXPERIMENTAL|High Intensity Interval Training|single arm intervention, with high intensity interval training
62105334|NCT04238104||altitude 1000-2000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 1000-2000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
62297711|NCT04412304||full dose anticoagulant|Dose used to treat thromboembolic event
62468936|NCT05855577|PLACEBO_COMPARATOR|placebo T|Pharmacological Treatment of Parkinson's disease patients using Placebo
62667419|NCT05611736|EXPERIMENTAL|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
62667420|NCT05611736|ACTIVE_COMPARATOR|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal system will be performed using 20 milliliters of normal saline solution at room temperature.
62667421|NCT00456612|OTHER|Cyberknife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
62667422|NCT05331937|EXPERIMENTAL|real rTMS|verum rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
62297712|NCT06657027||AI-Guided Radiotherapy Cohort|This cohort includes patients with newly diagnosed IDH wild-type glioblastoma, grade 4, according to the 2021 WHO classification of Central Nervous System Tumors. Patients in this group will undergo personalized radiotherapy guided by artificial intelligence (AI) and multiparametric MRI, using predictive models to adjust treatment volumes and doses according to areas of tumor infiltration. The AI model, developed from radiomic characteristics of postoperative MRI, predicts tumor recurrence and infiltration, enabling targeted dose escalation to high-risk areas while minimizing radiation exposure to healthy tissues.
62297713|NCT00296322|ACTIVE_COMPARATOR|Mitomycin-C, Doxifluridine|Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
62297714|NCT00296322|ACTIVE_COMPARATOR|Mitomycin-C, Doxifluridine, Cisplatin|iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
62297715|NCT04568330|OTHER|Best support care (BSC)|Interventions for comparison group (group C) who received BSC alone were (1) informed of potential presentations of HFSR, (2) asked for wearing waterproof gloves before execute household or work with water, (3) provided the method of contacting with healthcare specialists for confirming early diagnosis of HFSR, and (4) asked for self-report when they occurred symptoms of HFSR.
62308329|NCT05036538|EXPERIMENTAL|Relaxation intervention with natural sounds and binaural beats|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
62667423|NCT05331937|SHAM_COMPARATOR|sham rTMS|sham rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
61913186|NCT01836874||Topiramate|
61913187|NCT01470989|EXPERIMENTAL|canakinumab|canakinumab 150 mg s.c.
61913188|NCT04924413|EXPERIMENTAL|L-TIL and Tislelizumab|L-TIL（3-10）x10\*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year
61913189|NCT04865874|EXPERIMENTAL|PPV-GDT|Intra-operative fluid-therapy based (lactated Ringer) on continous PPV monitoring (target ≤5.8%)
61913190|NCT04865874|ACTIVE_COMPARATOR|Zero balance|Intra-operative fluid-therapy (lactated Ringer) based on 1:1 compensation of urinary output
61913191|NCT02899078|EXPERIMENTAL|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
61913192|NCT05634447|EXPERIMENTAL|Sequence 1|"* Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~* Period 2: CKD-391 - A single oral dose of 1 tablet under fasting condition~* Period 3: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~* Period 4: CKD-391 - A single oral dose of 1 tablet under fasting condition"
61913193|NCT05634447|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-391 - A single oral dose of 1 tablet under fasting condition~* Period 2: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~* Period 3: CKD-391 - A single oral dose of 1 tablet under fasting condition~* Period 4: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition"
62667424|NCT05145894||Asthma|Asthma patients aged 3 years and older with confirmed asthma diagnosis treated by a monotherapy ICS or ICS plus LABA or other controllers and presenting with moderate or severe disease exacerbation
61913194|NCT01966432|OTHER|SBIRT|"This is a single arm, non-randomized study. However, based on participants' substance use status, participants will be categorized into three groups:~1. Screening group. Patients who screen for no use of cigarettes, alcohol, or other drugs. Patients are re-screened at followup visits.~2. Screening, Brief Intervention group. Patients who screen positive for cigarette, alcohol, or other drug use.~3. Screening, Brief Intervention, and Referral to Treatment group. Patients who screen positive for use and have a positive AUDIT-C and/or positive DAST-10 assessment for problematic alcohol or drug use."
62667425|NCT05145894||COPD|COPD patients aged 40 years and older with confirmed COPD diagnosis treated by a monotherapy long-acting muscarinic antagonist (LAMA), or LAMA plus long acting beta2-agonist (LABA), or inhaled corticosteroid (ICS) plus LABA, or LAMA plus LABA plus ICS and presenting with moderate or severe disease exacerbation
61913195|NCT00645255|OTHER|1|Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
61913196|NCT00645255|PLACEBO_COMPARATOR|2|Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
61913197|NCT05623865|EXPERIMENTAL|Experimental group|"After the initial evaluation, the patients will be randomly divided into two groups as the Experimental group and the control group.Experimental group will receive kinesiotape treatment in addition to those applied in the control group.~Kinesiotape to the kinesio tape group will be done by a PM\&R spesialist doctor who has a certificate of kinesiotaping, in accordance with the literature, using the lymphedema method."
61913198|NCT05623865|OTHER|Control group|Elevation and cold application, which is applied in the prevention and treatment of classical edema, will be recommended to the control group. In addition, wrist, elbow, finger range of motion and stretching exercises will be taught as a home exercise program.
62297716|NCT04568330|EXPERIMENTAL|BSC plus moisture cream|The A group with BCS plus moisturizing cream received the interventions as the comparison group, was given the moisturizing cream (dimethicone, fragrance free, Aveeno, United States) for 9 times and was instructed how to use the cream. The education of usage included (1) using the cream twice a day from 3 days before starting sorafenib and each week post starting sorafenib, (2) scooping out nut-sized cream with a unique spoon each time, (3) gently applied the cream evenly on symmetrical palms below wrists and symmetrical soles below ankles each time, (4) wore unique cotton gloves immediately after the appalment of cream for 30 minutes each time.
62297717|NCT04568330|ACTIVE_COMPARATOR|10% urea-based cream|The B group with BCS plus 10% urea-based cream had the similar interventions as the A group with BCS plus moisturizing cream except being given the cream container with different component (10% urea; Sipharr, Taiwan). The outlook of the containers with the two kinds of cream was the same. All the cream looks white and grey.
62297718|NCT05275114|EXPERIMENTAL|Hand Tasks + M1(1mA) & aIPS(1mA) tDCS|20 minutes of Hand Taks + applying 30 minutes of M1(1mA) \& aIPS(1mA) tDCS and fNIRS
62297719|NCT05275114|ACTIVE_COMPARATOR|Hand Tasks + Sham tDCS|20 minutes of Hand Tasks + 30 minutes of sham tDCS and fNIRS
62297720|NCT05098184|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced melanoma after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62297721|NCT01610921|EXPERIMENTAL|bronchial provocationtest|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
62667426|NCT05330377|EXPERIMENTAL|Gilteritinib (Dose Level -1: 40 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 40 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~* Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~* Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~* Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~* Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
62297722|NCT00541307|EXPERIMENTAL|GORE VIABHAN Endoprothesis|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
62297723|NCT06560359|EXPERIMENTAL|Trial Group|Participants in the Trial Group will receive a daily intervention consisting of a breakfast that includes one piece of fruits (e.g., an apple or a banana), vegetables (e.g., a carrot or a cucumber), and other regular diet. The fruit and vegetable will be provided as part of a standardized breakfast menu designed by nutrition experts. Participants will also receive an extra fruit box once a week at home. This intervention will be administered every morning, seven days a week, for a duration of 12 weeks. The goal is to increase the daily intake of fruits and vegetables among participants to assess the effects on cognitive performance, mood and attention.
61913199|NCT01486043|EXPERIMENTAL|Metformin and insulin therapy|Up to 30-40 patients will be in the prospectively recruited treatment group, which will receive both metformin and insulin therapy for transient hyperglycemia
61913200|NCT01595945|OTHER|Gastric bypass|Subjects with planned gastric bypass surgery are followed-up in regard of resting metabolic rate.
61913201|NCT01595945|OTHER|Caloric restriction|Caloric restriction calculated by an online weight management program (based on subject's starting weight, start BMI, age, target weight and time span). Subjects are followed-up in regard to resting metabolic rate.
61913202|NCT03523923|NO_INTERVENTION|Usual Care|If assigned to the Usual Care (UC) arm, participants receive the same care as they would normally received from the HMC or UWMC outpatient TBI clinics, which could include similar types of treatment (medication changes, referral to specialists, etc.).
61913203|NCT03523923|ACTIVE_COMPARATOR|Collaborative Care|If assigned to the Collaborative Care (CC) arm, participants receive up to 12 sessions (45-60 minutes) of scheduled contacts with a Collaborative Care Manager (CCM) over 16 weeks of treatment. The CCM meets weekly for supervision with a team of experts to determine appropriate care.
61913204|NCT01962168||Evolution® Biliary Stent - Uncovered|
62105335|NCT04238104||altitude 2000-3000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 2000-3000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
62297724|NCT06560359|PLACEBO_COMPARATOR|Control group|Participants in the Control Group will maintain their regular breakfast without any additional interventions related to fruit and vegetable intake. No changes will be made to their daily breakfast routine. No fruit box will be delivered to the Control Group.
62297725|NCT01661257|EXPERIMENTAL|TIM-3|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
62297726|NCT06543992|EXPERIMENTAL|Intrathecal chemotherapy group|Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
62297727|NCT05445193|EXPERIMENTAL|Module PEaters Choice™|Using module that will be develop
62297728|NCT05445193|NO_INTERVENTION|Standard nutrition information|No intervention done, just a standard information about nutrition.
62297729|NCT00403104|EXPERIMENTAL|E|ONO-2506PO in the presence of Riluzole
62297730|NCT00403104|PLACEBO_COMPARATOR|P|Placebo in the presence of Riluzole
62297731|NCT00684814|EXPERIMENTAL|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered after an overnight fast of at least 10 hours.
62297732|NCT00684814|EXPERIMENTAL|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered after an overnight fast of at least 10 hours.
62297733|NCT06657287||Healthy adults|Adults with postprandial symptoms
62297734|NCT03817918|EXPERIMENTAL|Determination of local pleural strain|The local pleural strain will be determined over three consecutive respiratory cycles using lung ultrasonography
62667427|NCT05330377|EXPERIMENTAL|Gilteritinib (Dose Level 1: 80 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 80 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~* Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~* Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~* Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~* Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
62667428|NCT05330377|EXPERIMENTAL|Gilteritinib (Dose Level 2: 120 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 120 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~* Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~* Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~* Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~* Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
62667429|NCT04439409||Patients with Cluster Headache (CH)|Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.
62105336|NCT04238104||altitude 3000-4000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 3000-4000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
62297735|NCT00367757|OTHER|PVI group|Trigger-based ablation guided by pulmonary vein antrum isolation
62297736|NCT00367757|OTHER|CFAE group|Substrate-based ablation using an approach targeting CFAEs
62297737|NCT00367757|OTHER|Combined group|Combined trigger and substrate based approach
62297738|NCT03475225|EXPERIMENTAL|Experimental Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level \<30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months
62297739|NCT03475225|PLACEBO_COMPARATOR|Control Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level\<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.
62297740|NCT00768560|ACTIVE_COMPARATOR|Nifedipine (Adalat CR, BAYA1040) 40 mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
62297741|NCT00768560|EXPERIMENTAL|Nifedipine (Adalat CR, BAYA1040) 40 mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
62667430|NCT00910741|EXPERIMENTAL|Nanoplatin|"Nanoplatin (NC-6004) had to be administered once every 3 weeks, on Day 1, Day 22 and Day 43 etc.~Gemcitabine had to be administered to every patient 2 times on Day 1 and Day 8 every 3 weeks after the infusion of Nanoplatin (NC-6004)."
62667431|NCT02094235|EXPERIMENTAL|1|E6005 0.2% ointment applied twice a day to eczema areas
62667432|NCT02094235|EXPERIMENTAL|2|E6005 0.05% ointment applied twice a day to eczema areas
62667433|NCT02094235|PLACEBO_COMPARATOR|3|Placebo ointment applied twice a day to eczema areas
62105337|NCT04238104||altitude 4000-5000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 4000-5000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
62105338|NCT01720446|EXPERIMENTAL|Semaglutide 0.5 mg|
62105339|NCT01720446|EXPERIMENTAL|Semaglutide 1.0 mg|
62105340|NCT01720446|PLACEBO_COMPARATOR|Semaglutide placebo 0.5 mg|
62105341|NCT01720446|PLACEBO_COMPARATOR|Semaglutide placebo 1.0 mg|
62105342|NCT03185663|PLACEBO_COMPARATOR|a pillow between the legs|
62105343|NCT03185663|EXPERIMENTAL|traction-stuck|
62105344|NCT04461756|EXPERIMENTAL|inhaled THC/CBD (PPP001)|
62105345|NCT01776294||prehypertensives|students will be classified as prehypertensives as per the JNC-7 (Joint National Commission) guidelines based on their Blood Pressure measurement
62105346|NCT01776294||normotensives|students will be classed as normotensives based on their BP measurement as per JNC-7 guidelines (systolic \<120 AND diastolic \<80)
62105347|NCT02867501||Aneurysmatic disease|Patients with dilatative arteriopathy (DA) the aortic diameter must be \> 3 cm or the popliteal artery diameter \> 1.5 cm
62105348|NCT02867501||Peripheral arterial occlusive disease|Patients with arterial occlusive disease (PAOD) defined with an Ankle brachial index (ABI) \< 0.9 and positive criteria in the Edinburgh questionnaire.
62105349|NCT02867501||Healthy|Control group of age matched persons without PAOD (ABI \> 0.9) and without DA.
62297742|NCT00768560|EXPERIMENTAL|Nifedipine (Adalat CR, BAYA1040) 80 mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
62297743|NCT01747902|OTHER|Biceps tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
62297744|NCT01747902|OTHER|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
62297745|NCT06247826|EXPERIMENTAL|Experimental arm|Patients presenting advanced NSCLC with EGFR ins20 already treated with amivantamab as monotherapy in France under Temporary Use Authorisation or Early Access Program who will accept to provide blood samples at disease progression.
62105350|NCT01195675|EXPERIMENTAL|BI 10773|single oral (high and low) dose per subject
62105351|NCT01195675|PLACEBO_COMPARATOR|Placebo|2 single oral doses per subject
62105352|NCT01195675|ACTIVE_COMPARATOR|Moxifloxacin|single oral dose per subject
62105353|NCT02104609||Normal weight women|Levonorgestrel 1.5mg by mouth once
62105354|NCT02104609||Obese women|Levonorgestrel 1.5mg by mouth once
62105355|NCT02104609||Extremely obese women|Levonorgestrel 1.5mg by mouth once
62105356|NCT01881243||Adult patients resuscitated from cardiac arrest|
62297746|NCT04629729|EXPERIMENTAL|FT819 Single-Dose Monotherapy, B-Cell Lymphoma|FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma
62297747|NCT04629729|EXPERIMENTAL|FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
62297748|NCT04629729|EXPERIMENTAL|FT819 Step Fractionated Monotherapy, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma
62667434|NCT02474706|EXPERIMENTAL|cefoxitin|Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
62667435|NCT02474706|ACTIVE_COMPARATOR|imipenem|Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
62667436|NCT00741949|EXPERIMENTAL|1|
62667437|NCT00741949|PLACEBO_COMPARATOR|2|
62105357|NCT03721016|EXPERIMENTAL|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the Glabellar Lines (GL) and Placebo into the Lateral Canthal Lines (LCL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
62105358|NCT03721016|EXPERIMENTAL|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the Glabellar Lines (GL) and MT10109L Dose 2 into the Lateral Canthal Lines (LCL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
62667438|NCT05807503||A with Cerebrolysin administration|Group of patients with TBI diagnosis, admitted to ICU for further treatment after or without neurosurgical craniotomy, treated with Cerebrolysin administration in addition to standard ICU protocols.
62667439|NCT05807503||B without Cerebrolysin administration|Group of patients with TBI diagnosis, admitted to ICU for further treatment after or without neurosurgical craniotomy, treated without Cerebrolysin administration according to standard ICU protocols.
62667440|NCT06158880|EXPERIMENTAL|Alcoholic beverage|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%.
62667441|NCT06158880|ACTIVE_COMPARATOR|Non-alcoholic beverage|Participants will receive a beverage that does not contain alcohol (fruit juice only).
62667442|NCT06158880|EXPERIMENTAL|Partner Negative Mood Manipulation|Participants receive an experimental manipulation describing negative emotions in a hypothetical sexual partner.
62667443|NCT06158880|ACTIVE_COMPARATOR|Partner Positive Mood Manipulation|Participants receive an experimental manipulation describing positive emotions in a hypothetical sexual partner.
62667444|NCT01419925|EXPERIMENTAL|Group A|Two Multimeric-001 administrations followed by TIV
62667445|NCT01419925|EXPERIMENTAL|Group B|One administration of Multimeric-001 followed by TIV
62667446|NCT01419925|EXPERIMENTAL|Group C|One administration of adjuvanted M-001 followed by TIV
62667447|NCT01419925|ACTIVE_COMPARATOR|Group D|One administration of placebo followed by TIV
62667448|NCT00350506|EXPERIMENTAL|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed by catheter coronary angiography (CATH).
62667449|NCT04987970|EXPERIMENTAL|Sequence 1|Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-386(2)- A single oral dose of 1 tablet under fasting condition
62105359|NCT03721016|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the Glabellar Lines (GL) and into the Lateral Canthal Lines (LCL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
62105360|NCT06392932|EXPERIMENTAL|QDOT Arm|Temperature-controlled very-high-power short-duration ablation using the QDOT Micro catheter.
62667450|NCT04987970|EXPERIMENTAL|Sequence 2|Period 1: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition
62105361|NCT06392932|ACTIVE_COMPARATOR|ST SF Arm|Conventional high-power short-duration ablation using the ThermoCool ST SF catheter.
62105362|NCT03947112||Norwegian population with Duchenne Muscular Dystrophy (DMD)|Boys with DMD.
62105363|NCT06630026||Parkinson Patients|Parkinson patients who are aged 18-80 years with Hoehn \& Yahr scale between 1-4 and able to speak and read Turkish, will recruit to the study.
62105364|NCT03627962|EXPERIMENTAL|gaze-directed oculomotor training|device: Tobii PCEye Treatment group went through the oculomotor training with a gaze-pointer interface (Tobii PC Eye) in reading in Chinese.
62105365|NCT03627962|NO_INTERVENTION|control|No intervention: participants in control read ordinary Chinese textbooks.
62105366|NCT02245854|EXPERIMENTAL|Colonic polyps|Exacto™
62105367|NCT03203798|ACTIVE_COMPARATOR|Training of pelvic floor muscles|
62105368|NCT03203798|EXPERIMENTAL|Hipopressive abdominal gymnastics|
62105369|NCT05835115||The training dataset|The training dataset was comprised of data from a school-based, prospective cohort (the Shanghai Time Outside to Reduce Myopia \[STORM\] trial) and data from another population-based, prospective study, the High Myopia Registration Study (SCALE-HM), with annual follow-up. Participants of the two studies were divided into a training set (70%), a tuning set (10%), and an internal test set (20%), which were not duplicated by each other at the participant level.
62297749|NCT04629729|EXPERIMENTAL|FT819 Single-Dose Monotherapy, CLL|FT819 single-dose monotherapy in adult subjects with r/r CLL
62297750|NCT04629729|EXPERIMENTAL|FT819 Single-Dose in Combination with IL-2, CLL|FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL
62297751|NCT04629729|EXPERIMENTAL|FT819 Step Fractionated Monotherapy, CLL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL
62297752|NCT04629729|EXPERIMENTAL|FT819 Single-Dose Monotherapy, B-ALL|FT819 single-dose monotherapy in adult subjects with r/r B-ALL
62667451|NCT00411658|EXPERIMENTAL|Investigational Device|
62667452|NCT00411658|ACTIVE_COMPARATOR|Cryopreserved|
62667453|NCT00940459|EXPERIMENTAL|Acuvue Oasys|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
62667454|NCT00940459|EXPERIMENTAL|Biofinity|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
62667455|NCT00940459|EXPERIMENTAL|Air Optix|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
62667456|NCT00940459|EXPERIMENTAL|PureVision|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
62667457|NCT00940459|ACTIVE_COMPARATOR|Acuvue 2|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
62667458|NCT03753477|EXPERIMENTAL|Test Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
62667459|NCT03753477|ACTIVE_COMPARATOR|Reference Drug|Sevikar and Crestor
62667460|NCT02714738|EXPERIMENTAL|Infraclavicular Block|The patient will be positioned supine. The operating limb may be positioned abducted or adducted by side depending on operator preference and patient factors. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. Local anaesthetic (lidocaine 2% with epinephrine 1:200.000) will be injected posterior to the artery with the intention achieving the U shape, cranio-postero-caudal spread. Local anaesthetic will be deposited to the lateral and medial cords as well, if required. The total dose of the local anaesthetic will be 20-30 ml, as clinically indicated.
62667461|NCT02714738|EXPERIMENTAL|Axillary Brachial Plexus Block|The patient will be positioned supine with the operative upper limb extended, flexed at the elbow, rested on a pillow to expose the axilla. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. All four nerves in the axillary region are being blocked. The local anesthetic (lidocaine 2% with epinephrine 1:200.000, 15-25 ml) will be divided among the four nerves as clinically indicated by the spread, but at least 3 ml applied to each nerve.
61913205|NCT01937104|EXPERIMENTAL|Group 1|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust minimum alveolar concentration (MAC) to maintain bispectral index (BIS) between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Trendelenburg position - 30 degree"
61913206|NCT01937104|EXPERIMENTAL|Group 2|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust MAC to maintain BIS between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Reverse Trendelenburg position - 30 degree"
61913207|NCT04850781|ACTIVE_COMPARATOR|Daily Meals|A lunch-time meal delivered to participants' homes multiple times per week with wellness check and socialization.
61913208|NCT04850781|EXPERIMENTAL|Frozen, Drop-shipped Meals|10 frozen meals that are mailed to participants every two weeks.
61913209|NCT01252693|EXPERIMENTAL|Ozarelix|
62105370|NCT05835115||The internal validation dataset|The internal validation dataset was comprised of data from a school-based, prospective cohort (the Shanghai Time Outside to Reduce Myopia \[STORM\] trial) and data from another population-based, prospective study, the High Myopia Registration Study (SCALE-HM), with annual follow-up. Participants of the two studies were divided into a training set (70%), a tuning set (10%), and an internal test set (20%), which were not duplicated by each other at the participant level.
62105371|NCT05835115||The external validation dataset|To test the extrapolation capabilities of the deep learning sysyem, two independent datasets, the Joint Five-site Fundus Test (JFFT) and the Hong Kong Children Eye Study (HKCES), were applied as external test sets. The JFFT study, a multi-site dataset, contains cross-sectional data from Shanghai, Yunnan, Inner Mongolia, Xinjiang and Guangzhou. HKCES, a population-based cohort study of eye conditions in children aged 6-8 years.
62105372|NCT03593070|EXPERIMENTAL|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
62105373|NCT03593070|NO_INTERVENTION|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
62105374|NCT02716909|EXPERIMENTAL|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
62105375|NCT02716909|NO_INTERVENTION|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
62105376|NCT03586544|EXPERIMENTAL|Albuterol first|Order albuterol and then interval warm up (IWU)
62105377|NCT03586544|EXPERIMENTAL|Interval warm-up first|Order is interval warm up (IWU) and then albuterol
62105378|NCT02634216|EXPERIMENTAL|Type 1 Diabetics using CGM|Type 1 diabetics using Continuous Glucose MonitoringCGM to take 500 mg daily of Capros supplement (250 mg twice a day) at lunch and dinner.
61913210|NCT01252693|ACTIVE_COMPARATOR|Goserelin|
61913211|NCT05201456||Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite pressure monitoring single use flexible scope, real-time pressure monitoring technology, which will provide surgeons with intraluminal pressure data in the kidneys and ureter.
61913212|NCT05201456||Non-Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite Non-pressure monitoring single use flexible scope.
62105379|NCT04310059|ACTIVE_COMPARATOR|Folic acid 5mg|
61913213|NCT01494389||SIRS|(1) temperature \> 38oC or \< 36oC; (2) pulse rate \> 90 beats/min; (3) ventilation rate \> 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) \< 32 mmHg; (4) white blood cell (WBC) count \>1 2,000μL-1 or \< 4000 μL-1 , or \> 10% immature cells.
62105380|NCT04310059|ACTIVE_COMPARATOR|Folic acid 0.5mg|
62105381|NCT04310059|ACTIVE_COMPARATOR|Materna|
62105382|NCT06063356|ACTIVE_COMPARATOR|Dextrose Prolotherapy|Intra-articular Injection: A total of 5 cc of 25% dextrose solution (4 cc of 30% dextrose + 1 cc of saline) will be administered to the patellofemoral joint space in each patient with the same technique using the supero-lateral technique using a sterile injector with a 20 gauge needle tip.
62667462|NCT05244837|EXPERIMENTAL|Arm A:Resectable Stage IIB-IIIA Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 3-4 cycles before surgical resection, followed by adjuvant intravenous tislelizumab monotherapy for 1 year ( 200 mg every 3 weeks for 2 cycles, followed by 200 mg every 4 weeks for 12 cycles).
62667463|NCT05244837|EXPERIMENTAL|Arm B：Unresectable Stage IIIA/IIIB/IIIC or IV Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 4-6 cycles , followed by adjuvant intravenous tislelizumab monotherapy ( 200 mg every 3 weeks )，until disease progression or intolerable toxicity If surgery is not possible；If surgery is possible after assessment, subsequent treatment at the discretion of the investigator
62667464|NCT05771623|EXPERIMENTAL|Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar|"The study group includes 38 postburn hypertrophic scar patients l receiving Botox iontophoresis once monthly for 3 months; in addition to their physical therapy program (Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.~Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session."
62667465|NCT05771623|ACTIVE_COMPARATOR|Traditional physical therapy for postburn hypertrophic scar|This group includes 38 patients with postburn hypertrophic scar who will receive the traditional PT (deep friction massage, stretching and pressure therapy).
62667466|NCT04318418||Cases|Patients who developed severe COVID-19 disease (including fatal events)
62667467|NCT04318418||Controls|Infected patients who did not develop severe COVID-19 respiratory disease (including individuals who recovered from the infection)
62667468|NCT02184247|EXPERIMENTAL|anhydrous theophylline, 350 mg|
62667469|NCT02184247|ACTIVE_COMPARATOR|anhydrous theophylline, 300 mg|
62667470|NCT00864513|EXPERIMENTAL|chemotherapy|pemetrexed
62667471|NCT06225752|EXPERIMENTAL|Probucol Group|The study drug should be started as soon as possible within 7 days after symptom onset.
62667472|NCT06225752|PLACEBO_COMPARATOR|Placebo Probucol Group|The study drug should be started as soon as possible within 7 days after symptom onset.
62667473|NCT01642316|EXPERIMENTAL|washback|students received 8 specific related formative test for that lesson plus a pre-test and post-test, Michigan English language proficiency test
62667474|NCT01642316|OTHER|control|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
62667475|NCT00376506|EXPERIMENTAL|Implanted Device|Implanted intramuscular neurostimulator device
62667476|NCT00376506|ACTIVE_COMPARATOR|External Device|External vibrotactile device
62667477|NCT05703776|EXPERIMENTAL|Nordic Walking|2 weekly sessions of supervised Nordic Walking in a city park with trees, grass, and ponds. Exercise intensity was set at 65%-75% of age-predicted maximal heart rate. The length of training was consecutive 10 weeks
62667478|NCT05703776|NO_INTERVENTION|control|no intervention
62667479|NCT02000037|ACTIVE_COMPARATOR|Dietary care|Treatment is composed of a dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).
62105383|NCT06063356|ACTIVE_COMPARATOR|Saline|Intra-articular Injection: Using a sterile syringe with a 20 gauge needle tip, a total of 5 cc of saline will be administered to the patellofemoral joint space in each patient with the same technique using the supero-lateral technique.
62667480|NCT02000037|EXPERIMENTAL|IR reflexotherapy + dietary care|"Treatment is composed of :~* IR reflexotherapy sessions given by a trained professional ;~* dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille)."
62667481|NCT02000037|EXPERIMENTAL|IR Reflexotherapy|Treatment is composed of IR reflexotherapy sessions given by a trained professional.
62667482|NCT03640182|EXPERIMENTAL|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
61913214|NCT01494389||sepsis|SIRS + infection
61913215|NCT01494389||Normal|not SIRS and have no infection
61913216|NCT03665818|EXPERIMENTAL|Oral appliance intervention|
61913217|NCT03665818|NO_INTERVENTION|Without oral appliance intervention|
61913218|NCT00594724|EXPERIMENTAL|1|
61913219|NCT01436162|EXPERIMENTAL|Antidepressant + SPD489|
61913220|NCT01436162|PLACEBO_COMPARATOR|Antidepressant + Placebo|
61913221|NCT05828810|ACTIVE_COMPARATOR|Chlorhexidine gluconate-alcohol solution|"Chlorhexidine gluconate-alcohol solution is a type of solution that has antiseptic properties, which means it helps to eliminate harmful bacteria on the skin at the time of surgery, and therefore, reduce the risk of infection.~For participants in this arm, their surgeons will use chlorhexidine-based skin preparation solutions at the time of surgery to sterilize the surgical area."
62297753|NCT04629729|EXPERIMENTAL|FT819 Single-Dose in Combination with IL-2, B-ALL|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL
62667483|NCT03605056|EXPERIMENTAL|CRD regimen|CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
62105384|NCT02824432|EXPERIMENTAL|TAK-085 2g|A dose of 2 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered once a day immediately after meal.
62667484|NCT04292886|ACTIVE_COMPARATOR|thin endometrium ,treatment,Tamoxifen|From the 2nd day of the menstrual cycle, the patient took tamoxifen and femoston
62105385|NCT02824432|EXPERIMENTAL|TAK-085 4g|A dose of 4 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered twice a day immediately after meal.
62105386|NCT04138433|EXPERIMENTAL|Real tDCS|fMRI task plus anodal tDCS
62105387|NCT04138433|SHAM_COMPARATOR|Sham tDCS|fMRI task plus sham tDCS
62105388|NCT02742142|PLACEBO_COMPARATOR|control|Distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) was painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.In addition, instructions on oral hygiene (OHI) tailored to the individual's condition was given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) was provided. The OHI and provision of toothpaste will be repeated at 6-month intervals.
62105389|NCT02742142|EXPERIMENTAL|silver diammine fluoride|the subjects received the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution was painted onto the exposed tooth root surfaces. This treatment was repeated after 12 and 24 months.
62105390|NCT01234532|EXPERIMENTAL|entinostat & anastrozole neoadjuvant|"Neoadjuvant entinostat daily on days 1, 8, 15, 22, and 29 + anastrozole daily on days 4-29 followed by surgery ie either lumpectomy or mastectomy.~Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
62105391|NCT01750554|EXPERIMENTAL|bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
62468937|NCT05855577|EXPERIMENTAL|Lisosan-G (Nutritional Supplement)|Treatment of Parkinson's disease patients using Lisosan-G
62297754|NCT04629729|EXPERIMENTAL|FT819 Step Fractionated Monotherapy, B-ALL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL
62297755|NCT04629729|EXPERIMENTAL|FT819 Step Fractionated Monotherapy in Combination with IL-2, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
62297756|NCT04629729|EXPERIMENTAL|FT819 Step Fractionated Monotherapy in Combination with IL-2, CLL|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r CLL
62297757|NCT04629729|EXPERIMENTAL|FT819 Step Fractionated Monotherapy in Combination with IL-2, B-ALL|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-ALL
62468938|NCT05855577|PLACEBO_COMPARATOR|Lisosan_G Placebo|Treatment of Parkinson's disease patients using Lisosan-G
62667485|NCT04292886|PLACEBO_COMPARATOR|thin endometrium ,treatment,Vitamin C|From the 2nd day of the menstrual cycle, the patient took Vitamin C and femoston
62667486|NCT00604383|EXPERIMENTAL|Ruboxistaurin|
62667487|NCT00604383|PLACEBO_COMPARATOR|Placebo|
62667488|NCT01053052|EXPERIMENTAL|Sonography with FemVue vs. HSG|FemVue sonography and HSG
62667489|NCT05265676|EXPERIMENTAL|Cohort 1 - AB treatment sequence|"Period 1 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India.~Period 2 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany."
62667490|NCT05265676|EXPERIMENTAL|Cohort 2 - BA treatment sequence|"Period 1 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany.~Period 2 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India."
62667491|NCT04947280|EXPERIMENTAL|Fractionated Stereotatic Radiation Therapy|
62468939|NCT04805411|EXPERIMENTAL|High-dose arm|600mg for 1st dose, and then 300 mg for 2-8nd doses, every 2 weeks, SC
62667492|NCT01599962|EXPERIMENTAL|Cinacalcet|
62667493|NCT01599962|PLACEBO_COMPARATOR|Sugar pill|
62468940|NCT04805411|EXPERIMENTAL|low-dose arm|300mg for 1st dose, and then 150 mg for 2-8nd doses, every 2 weeks, SC
62105392|NCT01750554|NO_INTERVENTION|No bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
62105393|NCT04511806||Primary Subjects|Children (age 0-21) with a cancer predisposition syndromes (CPS).
62667494|NCT01442636|EXPERIMENTAL|Xience Prime stent|Patients with critical limb ischemia due to below the knee arterial lesion between 30 and 100mm in length, treated with the XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
62105394|NCT04511806||Relatives of Children with CPS|Members of their Primary Family Unit will also be recruited for this study, including CPS-Affected Parents, Unaffected Parents and Siblings. Other adult family members (with documented or obligate CPS) are also eligible to enroll as Affected Family Members.
62667495|NCT00768859|EXPERIMENTAL|1|paclitaxel, trastuzumab and carboplatin
62297758|NCT06656416|EXPERIMENTAL|ALTO-100|Participants will receive ALTO-100 40 mg tablet twice daily, from Day 1 to Week 6 in the double blind (DB) treatment period. Eligible participants who enter the open label (OL) treatment period will receive ALTO-100 40 mg tablet twice daily from OL baseline until the end of OL period/early termination visit (Up to 7 weeks).
62297759|NCT06656416|PLACEBO_COMPARATOR|Placebo DB|Participants will receive matching placebo tablet twice daily, from Day 1 to Week 6 in the double blind (DB) treatment period.
62297760|NCT03135886|EXPERIMENTAL|HIV Testing Practice Coaching Intervention Group|The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.
62468941|NCT04805411|PLACEBO_COMPARATOR|placebo|placebo for 1-8 doses, every 2 weeks, SC
62667496|NCT00549328|EXPERIMENTAL|Pazopanib Open-label|Single-arm, non-randomised, single-stage pazopanib monotherapy.
62468942|NCT02284750|EXPERIMENTAL|Two-stenting technique|Percutaneous coronary intervention with DK crush, or culotte technique
62667497|NCT05333744|EXPERIMENTAL|Prednisone plus rhTPO|Prednisone 20mg per day, 2 weeks and rhTPO 300U/kg per day, 2 weeks
62667498|NCT05333744|ACTIVE_COMPARATOR|Prednisone|Prednisone 20mg per day, 2 weeks
62667499|NCT01941056|EXPERIMENTAL|Treatment (CMV-MVA Triplex vaccine)|Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
62667500|NCT01668537|EXPERIMENTAL|Group 1|LF formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
62667501|NCT01668537|EXPERIMENTAL|Group 2|FD formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
62667502|NCT00559715|EXPERIMENTAL|A|
62667503|NCT00559715|ACTIVE_COMPARATOR|B|
62667504|NCT00680173|ACTIVE_COMPARATOR|A|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin achieve a sustained virological response
62667505|NCT00680173|ACTIVE_COMPARATOR|B|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin did not achieve a sustained virological response
62667506|NCT03819699|EXPERIMENTAL|Cohort 1 - dose regimen 1|Cohort 1: encompasses patients enrolled prior to the PA1
62667507|NCT03819699|EXPERIMENTAL|Cohort 2 - dose regimen 2|Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
62667508|NCT03819699|EXPERIMENTAL|Cohort 2 - dose regimen 3|Cohort 2: 10 patients who will not receive a booster vaccine
62667509|NCT05737732|ACTIVE_COMPARATOR|Circadian Effective Lighting (CEL)|The CEL will be performed in hospital sites over a 2-month period.
62667510|NCT05737732|SHAM_COMPARATOR|Circadian Ineffective Lighting (CIL)|The comparator lighting will be performed identical to Arm 1, at specified lower levels of lighting.
62667511|NCT01108055|EXPERIMENTAL|pazopanib + paclitaxel|"Cycle of 28 days. Pazopanib: 800mg daily~Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15"
62667512|NCT03188705|EXPERIMENTAL|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
62667513|NCT01098578|EXPERIMENTAL|Floseal|Received 1 syringe of Floseal for treatment of posterior epistaxis.
62667514|NCT00872157|EXPERIMENTAL|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
62105395|NCT03906630||Shoulder patients|
62105396|NCT04816890|EXPERIMENTAL|M1 Pram P037|Multi daily administration of M1 Pram P037 by subcutaneous injection
62105397|NCT04816890|ACTIVE_COMPARATOR|Insulin lispro|Multi daily administration of insulin lispro (Humalog®) by subcutaneous injection
62105398|NCT01129778|EXPERIMENTAL|Received Zegerid (Ome-NaBic)|Administered Ome-NaBic 40 mg orally 1 h before breakfast and bedtime
62105399|NCT05384132|EXPERIMENTAL|Scaling and Root Planing (SRP) + Livfresh Dental Gel (LDG)|SRP at Baseline with use of LDG (test dentifrice) for twice daily brushing between study visits.
62468943|NCT02284750|ACTIVE_COMPARATOR|Provisional stenting technique|Percutaneous coronary intervention with Provisional stenting technique. Stenting of the side branch was required if TIMI flow was \<3, or ≥ type B dissection after kissing balloon inflation.
62468944|NCT03649594||TAVI and no therapeutic anticoagulation|Subjects in this group do not have an indication for therapeutic anticoagulation.
62468945|NCT03649594||TAVI and therapeutic anticoagulation|Subjects in this group have an indication for therapeutic anticoagulation such as atrial fibrillation.
62667515|NCT03188029|EXPERIMENTAL|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
62667516|NCT02396797|EXPERIMENTAL|The new atWork intervention|The intervention group will receive the new atWork intervention, which include a management course and workplace courses for all employees targeting mental health complaints and musculoskeletal complaints.
62667517|NCT02396797|ACTIVE_COMPARATOR|The original atWork intervention|The control group will receive the original atWork intervention, targeting musculoskeletal complaint, and peer support.
61913222|NCT05828810|ACTIVE_COMPARATOR|Povidone-iodine solution|"Povidone-iodine solution is a type of solution that has antiseptic properties, which means it helps to eliminate harmful bacteria on the skin at the time of surgery, and therefore, reduce the risk of infection.~For participants in this arm, their surgeons will use iodine-based skin preparation solutions at the time of surgery to sterilize the surgical area."
62105400|NCT05384132|ACTIVE_COMPARATOR|Scaling and Root Planing (SRP) + standard fluoride dentifrice|SRP at Baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits.
62105401|NCT02637544|ACTIVE_COMPARATOR|Verum|"Acupuncture therapy.~For this study arm following acupuncture points suitable for facial pain, according to traditional chinese medicine, were chosen:~F2, F3, F34, IT3, IT19, S7, T21 and temporomandibular joint ear acupuncture points. Only intervention is the acupuncture therapy."
62105402|NCT02637544|PLACEBO_COMPARATOR|Placebo|Placebo acupuncture therapy. For this study arm points outside of the meridians according to traditional chinese medicine, were chosen. Only intervention is the acupuncture therapy.
62297761|NCT03135886|EXPERIMENTAL|HIV and HCV Testing Practice Coaching Intervention Group|The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.
62297762|NCT03135886|OTHER|Information Control Group|The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.
62297763|NCT01967043|EXPERIMENTAL|Oraxol Arm 1|"HM30181AK-US tablet administered as a single oral dose of xmg on Days x, y, and z of each cycle~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
62297764|NCT01967043|EXPERIMENTAL|Oraxol Arm 2|"HM30181AK-US tablet administered as a single oral dose of xmg daily with each dose of Paclitaxel~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
62297765|NCT03652909||Adults with difficulty hearing in some daily listening situations|Patients listen to sounds with and without the personal sound amplification smartphone application
62297766|NCT03487445|EXPERIMENTAL|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
62297767|NCT03487445|EXPERIMENTAL|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
62297768|NCT04490629|OTHER|DURAFORM|DURAFORM was used in repairing cerebral dura mater.
62297769|NCT04490629|EXPERIMENTAL|Lyoplant Onlay|Lyoplant Onlay was used in repairing cerebral dura mater.
62308330|NCT05036538|EXPERIMENTAL|Relaxation intervention with natural sounds and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
62468946|NCT05203562|ACTIVE_COMPARATOR|Control group I|Patients with complete mole treated by evacuation of using suction curettage followed by conservative follow up
62468947|NCT05203562|EXPERIMENTAL|Prophylactic letrozole group II|Patients with complete mole treated by evacuation of using suction curettage followed by 5mg daily letrozole for 10 days followed by conservative follow up
62468948|NCT01184183||Accuseal patch|
62468949|NCT01184183||Bovine Pericardial patch|
62468950|NCT04295122|ACTIVE_COMPARATOR|Phacoemulsification + ECP laser|"Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. The viscoelastic will be washed-out of the capsular bag after IOL insertion. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment.~Intracameral cefuroxime and dexamethasone will be injected into the anterior chamber and sutures used to close the incisions as required."
62667518|NCT01896986||PRD patrients|"Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)~Subgroups:~1. receiving immunosuppressant therapy~2. not on immunosuppressant therapy"
61913223|NCT03066973|EXPERIMENTAL|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
61913224|NCT03066973|NO_INTERVENTION|Control group|control group that received standard care service.
62667519|NCT01896986||IBD patients|"Children/adolescent females 12-26 years diagnosed with IBD.~Subgroups:~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy"
62667520|NCT02381327|EXPERIMENTAL|Binge Eating Disorder|Patients with Binge Eating Disorder will use Mandometer as an intervention to reduce food intake and speed of eating.
62667521|NCT02381327|EXPERIMENTAL|Control|Normal weight, healthy control subjects will use Mandometer to obtain data for comparison with the patients with Binge Eating Disorder.
62667522|NCT01194700|EXPERIMENTAL|Evohaler|
62667523|NCT01194700|EXPERIMENTAL|Volumatic spacer|
62667524|NCT01194700|EXPERIMENTAL|Aerochamber Plus|
62667525|NCT01194700|EXPERIMENTAL|Synchro-Breathe|
62667526|NCT04078399|EXPERIMENTAL|patients with recurrence after allogeneic transplantat|One arm
62105403|NCT05090384|EXPERIMENTAL|Steroid Taper|All enrolled patients start on the same dose of steroids for treatment of GVHD, blood samples are taken at week 1 and 2 post study start and biomarkers plus clinical response determines how steroid treatment is continued
62667527|NCT05708664|EXPERIMENTAL|PBCS|patients enrolled in the PBCS group underwent precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction.
62667528|NCT05708664|NO_INTERVENTION|Control|patients enrolled in the Control group underwent palpation guided breast conserving surgery
62667529|NCT00899457||Healthy, non-smokers|
62667530|NCT05308693|NO_INTERVENTION|Control-Classical patient education|Before the operation, the stoma area is marked, the patient is educated with the classical method brochure
62667531|NCT05308693|EXPERIMENTAL|Experimental-Patient Compatible Stoma Educational Material|The stoma area is marked before the operation; A brochure is given to the patient. Practical training is given on the patient's own body with patient-compatible stoma training material.
62105404|NCT04966156|NO_INTERVENTION|Usual care group|No change to patient's usual care at Princess Margaret Cancer Centre.
62105405|NCT04966156|EXPERIMENTAL|CaRE-4-allBMT plus usual care|a longitudinal 6-month rehabilitation program that uses a person- centred strategy and a multidimensional approach targeting physical activity, nutrition, psychosocial distress and promoting self-management skills.
62105406|NCT00459264|ACTIVE_COMPARATOR|1|Folic Acid
62667532|NCT01797185|EXPERIMENTAL|SPARC1104 group 1|
62105407|NCT00459264|PLACEBO_COMPARATOR|2|Matching placebo for folic acid
62667533|NCT01797185|EXPERIMENTAL|SPARC1104 group 2|
62667534|NCT01797185|EXPERIMENTAL|SPARC1104 group 3|
62667535|NCT04764539|ACTIVE_COMPARATOR|Stimuli administered via 2D format on an iPad Pro|Participants were given the Video-Assisted Speech Therapy (VAST) video-modeling stimuli in a 2D format (iPad Pro). Three children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the tablet-based VAST application. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
62105408|NCT04452955|EXPERIMENTAL|PRL3-zumab|All patients will receive PRL3-zumab until clinical progression per RECIST v1.1 and iRECIST criteria, or unacceptable toxicity, or withdraws consent.
62105409|NCT01356134||Multiple sclerosis and or Ehlers-Danlos|Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis
62105410|NCT01356134||Age matched normals|Age matched normals
62667536|NCT04764539|ACTIVE_COMPARATOR|Stimuli administered in 3D format via VR goggles and bone conduction headphones|Participants were given the Video-Assisted Speech Therapy (VAST) video-modeling stimuli in a VR format paired with a custom 3D-printed VR headset. Three children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized a 3D VR-integrated VAST prototype with bone conduction audio. Sessions were held twice a week with each lasting approximately 15 min (i.e. +/- 5 minutes).
62667537|NCT03291015|OTHER|radiographic guided treatment|radiographic guided treatment of kienbock disease using plain x ray for determine treatment plan
62667538|NCT03291015|OTHER|arthroscopic guided treatment|arthroscopic guided treatment of kienbock disease using wrist arthroscopy for determine treatment plan (Wrist arthroscopy)
62667539|NCT01954173|EXPERIMENTAL|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
62105411|NCT05091593|EXPERIMENTAL|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
62667540|NCT06433063|EXPERIMENTAL|Treatment arm|Patients who underwent FMISO PET imaging before Lu-177 PSMA radionuclide treatment for CRPC
62667541|NCT04732585|EXPERIMENTAL|Patient with PFPS or ACL injury|Physiotherapy intervention Surgical intervention
62667542|NCT04732585|NO_INTERVENTION|Healthy control group|The healthy control group will not do any intervention
62105412|NCT05091593|ACTIVE_COMPARATOR|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
62105413|NCT03232268|EXPERIMENTAL|HLA-mismatched microtransplantation|HLA-mismatched microtransplantation without immunosuppressive treatment
62105414|NCT05872321||Per-operative Complication|
62105415|NCT06628635|EXPERIMENTAL|Aerobic exercise|30 minutes of moderate-intensity aerobic exercise on a cycle ergometer
62105416|NCT06628635|EXPERIMENTAL|Isometric exercise|30 minutes of isometric exercise (alternating hand-grip with wall-sitting)
62105417|NCT06628635|EXPERIMENTAL|Static stretching|30 minutes of static stretching of major muscle groups
62105418|NCT06628635|ACTIVE_COMPARATOR|Resting control|30 minutes of seated rest
62105419|NCT06548334|EXPERIMENTAL|Advanced Physiotherapy|
62105420|NCT06548334|ACTIVE_COMPARATOR|Conventional Physiotherapytechniques|
62105421|NCT02111343|EXPERIMENTAL|Computer-based auditory training (CBAT)|The CBAT programmes in the current study were specifically designed to improve speech-in-noise and dichotic listening skills of children diagnosed with CAPD. All the training programmes were designed to be installed on home-user's computer, and they were visually attractive and appealing to children. The development of the software (non commercial) for the speech-in-noise and dichotic listening training was done by two different teams in the United Kingdom and Singapore, respectively.
62105422|NCT02111343|NO_INTERVENTION|Control|No intervention other than participants' regular school activities
62105423|NCT04040543|EXPERIMENTAL|Daily|Daily supplementation with product containing markers
62105424|NCT04040543|EXPERIMENTAL|Intermittent|Daily supplementation with either the product containing markers or the product not containing markers
62105425|NCT04040543|PLACEBO_COMPARATOR|Control|Daily supplementation with product not containing markers
62105426|NCT01588015|EXPERIMENTAL|Arm I (vaccine therapy)|Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
62667543|NCT03869021|ACTIVE_COMPARATOR|Computer guided surgery|A surgical guide is 3d printed to guide through the surgery, the patients of this group will have the distraction surgery by a guide designed by Mimics 19.0, Materialise NV,Belgium
62667544|NCT03869021|OTHER|No surgical guide (free hand surgery)|control group added to investigate the effect of surgical guide
62105427|NCT01588015|ACTIVE_COMPARATOR|Arm II (control)|Patients undergo immune monitoring only.
62105428|NCT04083651|EXPERIMENTAL|Methylnaltrexone Bromide (MNTX)|Participants will receive methylnaltrexone bromide (MNTX) 450 mg (3 tablets of 150 mg each) QD orally. If the initial interim analysis suggests a lack of efficacy, subsequent participants will receive 450 mg MNTX twice daily (BID) or three times daily (TID). Treatment will continue until participant's death or early withdrawal from study or study completion at Day 168.
62105429|NCT04083651|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to MNTX until participant's death or early withdrawal from study or study completion at Day 168.
62105430|NCT04183166|EXPERIMENTAL|Arm A : Early study treatment initiation|TG4050 treatment initiation at completion of primary treatment
62105431|NCT04183166|EXPERIMENTAL|Arm B: Study treatment initiation at recurrence|TG4050 treatment initiation at the time of recurrence
62105432|NCT03704311|EXPERIMENTAL|Single|Evaluation of mitochondrial function after muscle biopsy and follow-up for surgical complications.
62105433|NCT00965536||1|Seroquel
62105434|NCT00965536||2|Seroquel Prolong
62105435|NCT03677206|SHAM_COMPARATOR|Exposure to white LED light.|Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks
62105436|NCT03677206|EXPERIMENTAL|Exposure to green LED light|Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks.
62105437|NCT03677206|OTHER|Cross over|Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks.
62105438|NCT03573362|EXPERIMENTAL|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
62468951|NCT04295122|ACTIVE_COMPARATOR|Phacoemulsification alone|Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. For this study, monofocal IOLs are required.
62667545|NCT01029821|OTHER|Low-Molecular-Weight Heparin for DVT|Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
62667546|NCT06398639|OTHER|Low Risk Cohort|Participants are placed into their arm after appropriate genetic testing has been conducted to determine their risk.
62667547|NCT06398639|OTHER|Intermediate Risk Cohort|Participants are placed into their arm after appropriate genetic testing has been conducted to determine their risk.
62667548|NCT06398639|OTHER|High Risk Cohort|Participants are placed into their arm after appropriate genetic testing has been conducted to determine their risk.
62667549|NCT04504760|EXPERIMENTAL|ONO-2910 (Part A and B)|
62667550|NCT04504760|PLACEBO_COMPARATOR|Placebo (Part A)|
62667551|NCT04504760|EXPERIMENTAL|ONO-2910 (Part C and D)|
62667552|NCT04504760|PLACEBO_COMPARATOR|Placebo (Part C and D)|
62667553|NCT06431659||Active group|"The S-PCG is a person-centered decision support to identify, assess, document and meet palliative care needs and increase patients' quality of life and participation in their health-care decisions. The purpose of the S-PCG is to ensure the quality of care in continuous dialogue between health care staff, patient, and family, from the transition from curative to palliative care, to the patient dying, and the care afterwards. In the Care Guide, the patients' plans and wishes are documented, and based on this care be prioritized, planned, and coordinated. The S-PCG is adapted to be used throughout the health and medical care and in municipal care. The S-PCG consists of three parts that can be used separately, the intervention in this study includes S-PCG part 2 and 2D.~In the active group the nursing homes will get our help to implement the S-PCG immediately, and data will be collected after the implementation."
62105439|NCT03573362|ACTIVE_COMPARATOR|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
62667554|NCT06431659||Control group|"The S-PCG is a person-centered decision support to identify, assess, document and meet palliative care needs and increase patients' quality of life and participation in their health-care decisions. The purpose of the S-PCG is to ensure the quality of care in continuous dialogue between health care staff, patient, and family, from the transition from curative to palliative care, to the patient dying, and the care afterwards. In the Care Guide, the patients' plans and wishes are documented, and based on this care be prioritized, planned, and coordinated. The S-PCG is adapted to be used throughout the health and medical care and in municipal care. The S-PCG consists of three parts that can be used separately, the intervention in this study includes S-PCG part 2 and 2D.~In the control group data will be collected before the implementation of S-PCG."
62667555|NCT04249739|EXPERIMENTAL|CapeOx+Pembrolizumab(HER2 negative)|"\<Cohort A\>: HER2 negative patients CapeOx+Pembrolizumab therapy (N=78)~* Cycle 1 CapeOX~* Cycle 2 up to Cycle 8 CapeOX + pembrolizumab therapy~* Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy~  * CapeOx + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~    1. Cycle: Day 1 through Day 21)"
62667556|NCT04249739|EXPERIMENTAL|Cape/Cis+Trastuzumab+Pembrolizumab (HER2 positive )|"Cape/Cis+Trastuzumab+Pembrolizumab therapy (N=15)~* Cycle 1 Capecitabine + cisplatin (Cape/Cis)~* Cycle 2 up to Cycle 8 Cape/Cis + Trastuzumab + pembrolizumab therapy~* Cycle 9 up to Cycle 35 Capecitabine + Trastuzumab + pembrolizumab therapy~  * Cape/Cis + Trastuzumab + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~    1. Cycle: Day 1 through Day 21)"
62667557|NCT06470724|EXPERIMENTAL|intervention of structural visual approach|"1. st visit): Intervensi: Successive approaches, T-S-F-D, visual pedagogy~2. nd visit): Intervensi: Successive approaches, T-S-F-D, visual pedagogy, audio-visual modelling~3. rd visit): Intervensi: Successive approaches, T-S-F-D, visual pedagogy, in vivo modelling~4. th visit): Intervensi: Successive approaches, T-S-F-D, visual pedagogy, behavioral trials~5. th visit): Intervensi: T-S-F-D, auto-modeling, behavioral trial"
62667558|NCT03936127|EXPERIMENTAL|Transperineal (TP) Ultrasound (US) Targeted Fusion Biopsy|Transperineal (TP) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
62297770|NCT02235818|ACTIVE_COMPARATOR|Kinesiotape (KT)|Kinesiotape was used only on the affected side as per the manufacturer instructions. With the elbow extended, wrist fully flexed and fingers pointed down 24, KT was applied with slight stretch (10-15%) and paper off tension to the lateral arm beginning just above the bony portion of lateral epicondyle. Once the top strand was anchored, KT was applied along the side of elbow such that hole in the tape was over lateral epicondyle of the elbow. Two strands of tape followed the lateral forearm and ended at around beginning of the distal one third of forearm. Once the support was applied, KT was gently rubbed to activate the glue.
62667559|NCT03936127|ACTIVE_COMPARATOR|Transrectal (TR) Ultrasound (US) Targeted Fusion Biopsies|Transrectal (TR) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
62667560|NCT01163656|ACTIVE_COMPARATOR|Direct Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Miller Laryngoscope.
62667561|NCT01163656|ACTIVE_COMPARATOR|Glidescope Cobalt Video Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Glidescope Cobalt Video Laryngoscope.
62667562|NCT04450875|EXPERIMENTAL|Experimental group (with diet)|It consisted in the administration of nutritional therapy with foods high in methionine according to the National Nutrient Database For Standard Reference (USDA) and adapted to the consumption and usual cost in the Mexican diet.
62667563|NCT04450875|NO_INTERVENTION|Control|The control group continued with their usual diet for the same period of 3 months as the experimental group.
62667564|NCT05122715|OTHER|OMNI PET/CT scan first|
62667565|NCT05122715|OTHER|DMI PET/CT scan first|
62667566|NCT05987280||Phase 1|We aim to use an online survey to collect data from participants. It is estimated that this survey will take 10 minutes to complete. The first part of the survey asks questions about the participant including what stakeholder group best describes them. The second part asks them about what outcomes are important in pharmacy research and in the management of kidney disease.
62468952|NCT03086473|OTHER|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
62105440|NCT02578212|PLACEBO_COMPARATOR|Control|"All participants will also be introduced to the control cream: This cream is a control cream."
62297771|NCT02235818|ACTIVE_COMPARATOR|Counterforce elbow brace|The counterforce brace was approximately 5cm wide with velcro attachment for adjustable girth. It had gel pack for extra support on extensor muscle mass. With the elbow extended, brace was applied 2.5cms below the lateral epicondyle. A feeling of comfortable compression, as reported by the patients was used to adjust the brace.
62468953|NCT03086473|OTHER|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
62667567|NCT05987280||Phase 2|"The outcomes generated in this survey will be supplemented by outcomes identified in an ongoing systematic review being performed by our group. We will take this long list of outcomes and aim to reach consensus on a COS using a 2-round Delphi process. The Delphi process is a structured process used for forming a consensus, where stakeholder groups provide their opinions in an iterative approach for answering questions over several rounds.~This will also take place using surveys online and we will submit an ethical amendment for each round with the questions and outcomes we will be seeking consensus on. In each Delphi round, participants will be asked to rate the importance of outcomes for inclusion or exclusion. Between each round, excluded outcomes will be removed. Included outcomes (those reaching consensus, defined as a minimum of 75% of participants who scored outcomes as agree or strongly agree or disagree or strongly disagree) will go into the COS."
62468954|NCT05812781|EXPERIMENTAL|Cohort 1|
62667568|NCT05328544|EXPERIMENTAL|ACL Reconstruction with the use of autogenous spongiform bone grafts|Stabilization of the tibial insertion with a bioabsorbable screw (Arthrex) with simultaneous application to the tibial canal of autogenous cancellous bone grafts taken during the drilling of this canal.
62667569|NCT05328544|ACTIVE_COMPARATOR|ACL Reconstruction without the use of autogenous spongiform bone grafts|Stabilization of the tibial attachment with a bioabsorbable screw (Arthrex) without simultaneous application of autogenous cancellous bone grafts to the tibial canal.
62667570|NCT05742750|EXPERIMENTAL|Camrelizumab + apatinib and chemotherapies (gemcitabine and cisplatin)|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
62667571|NCT02890888|EXPERIMENTAL|Hyperbaric oxygen treatment|HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks
62667572|NCT04831554|EXPERIMENTAL|single chest tube group|
62667573|NCT04831554|NO_INTERVENTION|multiple chest tubes group|
62667574|NCT04545138|EXPERIMENTAL|cognitive training during treadmill training group|Cognitive training combine treadmill training is an intervention that can challenge participants by practicing different tasks simultaneously.
62667575|NCT04545138|ACTIVE_COMPARATOR|treadmill training group|Treadmill training as an active control.
62667576|NCT05177263|PLACEBO_COMPARATOR|Supportive Positions + Oral Sterile Water|The enrolled premature infants will be administered 1ml of the sterile water a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of sterile water a second time.
62667577|NCT05177263|ACTIVE_COMPARATOR|Supportive Positions + 10% Oral Dextrose|"The enrolled premature infants will be administered 1ml of the 10% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 10% oral dextrose solution a second time.~(%10 oral dextrose solution: osmolarity= 550 mOsm/L, pH= 3.5-6.5, calorie=400 kcal/L)"
62667578|NCT05177263|ACTIVE_COMPARATOR|Supportive Positions + 20% Oral Dextrose|"The enrolled premature infants will be administered 1ml of the 20% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 20% oral dextrose solution a second time.~(%20 oral dextrose solution: osmolarity= 1010 mOsm/L, pH= 3.2-6.5, calorie= 680 kcal/L)"
62667579|NCT05177263|ACTIVE_COMPARATOR|Supportive Positions + 30% Oral Dextrose|"The enrolled premature infants will be administered 1ml of the 30% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 30% oral dextrose solution a second time.~(%30 oral dextrose solution: osmolarity= 1515 mOsm/L, pH= 3.2-6.5, calorie= 1020 kcal/L)"
62667580|NCT00852878|ACTIVE_COMPARATOR|Biofeedback|heart rate variability biofeedback
62667581|NCT00852878|ACTIVE_COMPARATOR|Behavioral|Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements
62667582|NCT02083211|EXPERIMENTAL|mAb Nimotuzumab + chemotherapy|
62667583|NCT02083211|PLACEBO_COMPARATOR|placebo + chemotherapy|
62667584|NCT04393428||COVID-19 patients with urinary samples|COVID-19 patients with urinary samples
62667585|NCT03010956||Patients with uncontrolled diabetes mellitus|Patients with uncotrolled tyre 1 or type 2 diabetes mellitus
62667586|NCT03010956||Patients with controlled diabetes mellitus|Patients with controlled type 1 or type 2 diabetes mellitus
62667587|NCT04631978||Underweight|Comprehensive ophthalmologic examination
62667588|NCT04631978||Control|Comprehensive ophthalmologic examination
62667589|NCT02912377|EXPERIMENTAL|Arm 1; B12019 / Neulasta|2 single doses of B12019 followed by one dose of Neulasta
62667590|NCT02912377|EXPERIMENTAL|Arm 2; Neulasta / B12019|2 single doses of Neulasta followed by one dose B12019
62667591|NCT00120874|EXPERIMENTAL|Group 1|Individualized Management including caregiver training and Memantine
62667592|NCT00120874|ACTIVE_COMPARATOR|Group 2|Only Memantine
62468955|NCT05812781|EXPERIMENTAL|Cohort 2|
62468956|NCT01464112|EXPERIMENTAL|001|
62297772|NCT01916395||Imitrex and Treximet|Imitrex 100mg as needed Treximet 85/500mg
62297773|NCT00002850|EXPERIMENTAL|Ciprofloxacin or ofloxacin|"Quinolone:~Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours."
62297774|NCT00002850|EXPERIMENTAL|TMP-SMX|TMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
62297775|NCT00002850|NO_INTERVENTION|No prophylaxis|The patient will receive no prophylactic antibiotics.
62468957|NCT02146118|EXPERIMENTAL|Erlotinib and Silibin|
62667593|NCT06544395|EXPERIMENTAL|Patients receiving non invasive neuromodulation treatment.|Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive non invasive neuromodulation treatment.
62105441|NCT02578212|SHAM_COMPARATOR|Placebo|"All participants will then be introduced to an analgesia expectation: This cream is a powerful pain killer, while receiving an inert cream. In this study participants will be told that they will receive a potent painkiller as well as a control cream. Making use of placebo cream is an established method to induce placebo expectations . Moreover, to increase the analgesic effect, heat pain stimuli intensity will be surreptitiously lowered for the placebo trials to a temperature corresponding to 30% of the VAS intensity and to 60% for the control trials. As the occurrence of a placebo response is highly dependent on expectations, the deceptive procedure described above is used in order to maximally enhance expectations and therefore placebo response. Participants will be debriefed after the completion of study participation."
62105442|NCT02954055|ACTIVE_COMPARATOR|Arm A|Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
62105443|NCT02954055|EXPERIMENTAL|Arm B|"Metronomic VEX:~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability."
62105444|NCT00618280|ACTIVE_COMPARATOR|1|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
62105445|NCT00618280|PLACEBO_COMPARATOR|2|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
62667594|NCT06544395|ACTIVE_COMPARATOR|Patients receiving traditional treatment.|Patients receiving only traditional therapy. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive treatment of traditional therapy.
62105446|NCT04745702|OTHER|Low-Calorie Control Group|The control group will receive for 2 calorie-restricted balanced meals per day, consisting of a portion of meat, a portion of vegetables, a portion of medium to high GI carbohydrates and prepared with refined corn oil. The control meals will be devoid of any whole legumes and will contain minimal amounts of spices. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by \~5%.
62105447|NCT04745702|ACTIVE_COMPARATOR|Low-Calorie Treatment Group|The treatment group will receive for 2 calorie-restricted (isocaloric with control group) meals per day containing 100 g cooked whole legumes (amounting to a total of 200 g cooked legumes, approximately 1 cup of cooked legumes)and/or certain meat analogues (textured vegetable \[soy\] proteins), and/or a portion of vegetables, low GI, wholegrain carbohydrates for their starch sources (rice/noodles/pasta), added spices (dried spice powder) at dietary and culinary acceptable doses and blended vegetable oil. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by \~5%.
62105448|NCT02694848|OTHER|Salvianolate injection group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
62105449|NCT02694848|ACTIVE_COMPARATOR|Aspirin group|Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
62105450|NCT02694848|EXPERIMENTAL|Salvianolate injection and aspirin group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
62105451|NCT05702294|EXPERIMENTAL|Control|"Adult females with no lower urinary tract symptoms will complete a 3-day paper bladder diary. After each void they will transfer their voided volume to the diary pod (vessel that calculates automatically the voided volume) for the duration of these three days.~After three days the reports of the paper diary versus the electronic diary will be compared."
62297776|NCT03560661||Amyotrophic lateral sclerosis (ALS) patients|
62667595|NCT06544395|PLACEBO_COMPARATOR|Patients receiving placebo treatment.|Patients receiving placebo. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; to those who will be administered placebo (device off, without emitting).
62667596|NCT00780039|EXPERIMENTAL|Single Arm|Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.
62297777|NCT03560661||Primitive Lateral Sclerosis (PLS) patients|
62667597|NCT03170921|EXPERIMENTAL|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
62667598|NCT03170921|EXPERIMENTAL|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
62297778|NCT03560661||Kennedy's disease (KD) patients|
62297779|NCT02226354|ACTIVE_COMPARATOR|Flaxseed oil|9.73ml Flaxseed oil once daily, for 28 days
62297780|NCT02226354|EXPERIMENTAL|Ahiflower oil|9.73ml Ahiflower oil once daily, for 28 days
62667599|NCT03170921|EXPERIMENTAL|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
62297781|NCT06084806|EXPERIMENTAL|Advanced non small cell lung cancer (NSCLC) patients|Patients will undergo two \[18F\]F AraG PET/CT scans within 7 days of each other prior to receiving treatment
61913225|NCT04687176|EXPERIMENTAL|Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)|"Induction: Oral arsenic trioxide 10mg daily (0.16mg/kg/day in patients \< 18 years-old, all-trans retinoic acid (ATRA) \[45mg/m\^2 (25mg/m\^2 per day in patients \< 18 years-old) in 2 divided doses) and ascorbic acid 1g daily (15mg/kg/day in patients \< 18 years-old) for 42 days Consolidation: Oral arsenic trioxide daily, ATRA, and ascorbic acid daily for 14 days every 28 days for 2 cycles.~Maintenance: Oral arsenic trioxide, ATRA and ascorbic acid daily for 2 weeks every 8 weeks for a total of 2 years (i.e. for 12 cycles in total)."
61913226|NCT00775203|EXPERIMENTAL|Trazodone Contramid Once A Day (OAD)|
61913227|NCT00775203|PLACEBO_COMPARATOR|Placebo|
61913228|NCT03702244|NO_INTERVENTION|Usual Care|For participants randomized to usual care, the participant's care team will select the specific noninvasive stress test (exercise electrocardiogram, stress nuclear imaging \[including PET\], stress MR, or stress echocardiogram); OR invasive test: (direct to diagnostic catheterization).
62105452|NCT05702294|EXPERIMENTAL|LUTS ( Lower urinary tract symptoms) arm|"Adult females with lower urinary tract symptoms will complete a 3-day paper bladder diary. After each void they will transfer their voided volume to the diary pod (vessel that calculates automatically the voided volume) for the duration of these three days.~After three days the reports of the paper diary versus the electronic diary will be compared."
61913229|NCT03702244|OTHER|Precision evaluation|Participants randomized to a precision strategy will be assigned to either guideline-recommended care without immediately planned testing (low risk) or cCTA with selective FFRct (elevated risk) using a risk tool based on pretest clinical characteristics derived from the PROMISE trial and validated in SCOT-HEART trial. Participants assigned to guideline-recommended care without planned testing will be treated with preventive and antianginal medical treatment per guideline recommendations and clinical judgment and followed without testing.
61913230|NCT04896450|EXPERIMENTAL|Test group|Test subjects receive GTR and early initiation of OTM.
61913231|NCT04896450|ACTIVE_COMPARATOR|Control group|Control subjects receive only GTR.
62667600|NCT05132452||adults living in the community|Healthy community dwelling participants, aged 20 year old and above, without dysphagia.
62667601|NCT02705157||Bone metastasis of the long bone|Patients with bone metastases of the long bone(s) receiving surgical stabilisation of a pathologic or impending fracture or receiving radiotherapy for a painful metastasis.
62667602|NCT01623752||Patients with Rheumatoid Arthritis|
61913232|NCT01405066|EXPERIMENTAL|Dose Reports and Educational Seminar|
61913233|NCT02506985|EXPERIMENTAL|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
61913234|NCT02506985|EXPERIMENTAL|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is \>= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
61913235|NCT01197443|EXPERIMENTAL|Parent-only Group|Treatment will be administered to parents of the overweight child. Parent-only group treatment will include all of the same skills and techniques to promote weight loss, but the information will be delivered only to the parent. Participation of the children assigned to the parent-only treatment arm will be limited to the baseline and follow-up assessments.
62105453|NCT01646502|EXPERIMENTAL|Esp-supplemented standard wound care|500 pmol Esp protein will be added to the standard wound care protocol.
62105454|NCT01646502|ACTIVE_COMPARATOR|Standard wound care|"The standard treatment protocol established at the Vancouver Wound Healing Clinic is based on the Best Clinical Practice Guidelines for Venous Leg Ulcers from the Canadian Association of Wound Care."
62667603|NCT01623752||Patients with Psoriasis Arthritis|
62667604|NCT06473428|EXPERIMENTAL|Inspiratory Muscle Training|Participants in this group will undergo a specific inspiratory muscle training program. The training consists of two sessions per day, each comprising five repetitions per session. Each repetition will involve a series of inspiratory exercises aimed at strengthening the respiratory muscles. The training will be conducted six days a week for eight weeks.
61913236|NCT01197443|ACTIVE_COMPARATOR|Parent + child Group|The treatment for participants in the parent + child arm will be administered in two separate groups, one for the parents and one for the child.
62105455|NCT05609578|EXPERIMENTAL|Cohort A: PD-L1 TPS≥ 1% (Closed)|Adagrasib 400 mg BID for 2 cycles followed by adagrasib 400 mg BID + pembrolizumab 200 mg every 3 weeks (Q3W) up to 35 cycles
61913237|NCT02956902|NO_INTERVENTION|Waiting list control|
61913238|NCT02956902|EXPERIMENTAL|Intervention|Clinician-supported smartphone application intervention
61913239|NCT00639743|EXPERIMENTAL|group A|tenecteplase (group A)
61913240|NCT00639743|PLACEBO_COMPARATOR|group B|placebo ( group B)
62105456|NCT05609578|EXPERIMENTAL|Cohort C|Adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + pembrolizumab 200 mg Q3W up to 31 cycles
62105457|NCT05609578|EXPERIMENTAL|Cohort E|Adagrasib 400 mg BID + pembrolizumab 200 mg Q3W + pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 4 cycles, followed by adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + pembrolizumab 200 mg Q3W (up to 31 cycles)
62297782|NCT06136858||healthy volunteers|participants of the Airway management Course in Copenhagen Denmark 2023
62468958|NCT02170506|EXPERIMENTAL|submental sensitive transcutaneous electrical stimulation.|Each Healthy subjects will be his own witness. Urostim 2 stimulation Arm
62667605|NCT06473428|EXPERIMENTAL|Combined Inspiratory and Expiratory Muscle Training|This group will participate in a combined inspiratory and expiratory muscle training regimen. Similar to the inspiratory group, training sessions will occur twice daily, with each session comprising five repetitions of both inspiratory and expiratory exercises. The training will also be conducted six days a week for eight weeks
61913241|NCT05974423|ACTIVE_COMPARATOR|Control - Narcotic Prescription|"1. Oxycodone 5 mg 1 tablet every 6 hours PRN~2. Tylenol 1000 mg every 8 hours~3. Ibuprofen 600 mg every 6 hours as needed for pain"
61913242|NCT05974423|EXPERIMENTAL|Experimental - Non-narcotic only|"This group will not be sent home with an oxycodone prescription. They will be sent home with the following prescriptions. If this does not manage their pain, they will call the resident on call who will reach out to the PI. The PI will then electronically send in a prescription of oxycodone to their pharmacy if required. The PI or operating surgeon (co-investigators) will be available 24/7 to do this. They will be sent home with these two prescriptions:~1. Tylenol 1000 mg every 8 hours~2. Ibuprofen 600 mg every 6 hours as needed for pain"
62667606|NCT06473428|PLACEBO_COMPARATOR|Placebo-Controlled Expiratory Muscle Training|Participants in this control group will receive placebo-controlled expiratory muscle training. The training sessions will be similar in structure to the experimental groups, consisting of two daily sessions with five repetitions each, conducted six days a week for eight weeks
62667607|NCT03985995|ACTIVE_COMPARATOR|CBD 800 mg p.o.|The study Investigational Medical Product (IMP) is a cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration.
62667608|NCT03985995|PLACEBO_COMPARATOR|Placebo p.o.|Participants in the control arm will be receiving a single dose of oral placebo solution 8 ml matched to the active comparator.
62667609|NCT03306121|EXPERIMENTAL|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
61913243|NCT00266877|EXPERIMENTAL|Prior Tarceva or Iressa With EGFR Mutation|HKI-272 administered to patients whose disease has progressed following \> or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening
62105458|NCT01107262||Poultry exposed adults|This seroepidemiological study proposes to compare adults with occupational exposure to poultry with non-poultry exposed adult controls for evidence of previous infections with AI viruses.In this study, any person with occupational exposure to poultry i.e. works in poultry production facility or raises a smaller number of poultry on his/her farm will be considered exposed. The questionnaire used in this study will capture poultry exposure data through a group of variables assessing type of occupational setting, length of time of exposure, flock size, type of work performed, and personal protective equipment (PPE) used.
62297783|NCT05700461|EXPERIMENTAL|Implantable microdevice (IMD) + Biopsy + Standard of Care Treatment|"Participants with confirmed or suspected metastatic Renal Cell Carcinoma (RCC) and who are candidates for standard of care metastatectomy or debulking/consolidative nephrectomy will be selected for study participation and will undergo study procedures as outlined:~* Placement of 1-6 microdevice(s) 72 +/- 24 hours prior to scheduled, standard of care surgery. The number of microdevices implanted into a tumor will be made on a case-by-case basis based on tumor and participant factors before and during the procedure.~* At the time of standard of care surgery, surgical removal of microdevice(s) along with surrounding tumor tissue.~* Monitoring for safety endpoints during inpatient stay and at a follow-up clinic visit."
62105459|NCT01107262||Poultry Non-exposed Adult Controls|Controls, adults who were never exposed to poultry, will be enrolled from urban areas such as the capital Beirut. Controls will be invited to volunteer by word of mouth at public/community sites.
62667610|NCT03306121|ACTIVE_COMPARATOR|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
62105460|NCT02213692||Crush-clamping Method (group A)|Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
62105461|NCT02213692||Harmonic Scalpel Method (group B)|Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (\<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
62105462|NCT03514199|EXPERIMENTAL|Mediterranean-type diet|Recommends high consumption of whole grains, vegetables, nuts, fruits, vegetables and olive oil as the main source of fat used for salads. Moderate to high fish consumption and low consumption of red and processed meats. Poultry and dairy products (such as yogurt or cheese) will be consumed in small quantities and moderate consumption of alcohol, usually in the form of red wine, will be recommended with meals for usual drinkers.
62667611|NCT00597675|PLACEBO_COMPARATOR|Placebo|Oat flour ingested daily as a placebo
62667612|NCT00597675|ACTIVE_COMPARATOR|Peanut OIT|Peanut flour ingested daily as oral mucosal immunotherapy
62105463|NCT03514199|ACTIVE_COMPARATOR|Low fat diet|It recommends reducing the intake of foods rich in fats, especially those saturated and hydrogenated.
62105464|NCT05709873|EXPERIMENTAL|Imagery rehearsal therapy (IRT)|Participants randomized to this group will receive 7 sessions of IRT.
62105465|NCT05709873|EXPERIMENTAL|Imagery rehearsal therapy and targeted dream control (IRT+TDC)|Participants randomized to this group will receive 7 sessions of IRT+TDC.
62105466|NCT02974010|EXPERIMENTAL|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
62667613|NCT00837330|EXPERIMENTAL|Ranibizumab 0.5 mg/ 0.05 cc|Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
62667614|NCT00837330|EXPERIMENTAL|Ranibizumab 0.3 mg/ 0.05 cc|Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab
62667615|NCT04794998||"Recommended schedule cohort"|COVID-19 patients who have applied the proposed treatment recommendation algorithm at the onset of or within few days from the beginning of symptoms.
62667616|NCT04794998||"control cohort"|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, and treated at home by their family doctors with drug regimens other than those proposed in the recommendations
62667617|NCT06261957|EXPERIMENTAL|Salbutamol Test Arm|
61913244|NCT00266877|EXPERIMENTAL|Prior Tarceva or Iressa w/o EGFR Mutation|HKI-272 administered to patients whose disease has progressed following \> or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening
61913245|NCT00266877|EXPERIMENTAL|No Prior EGFR Tyrosine Kinase Inhibitor Treatment|HKI-272 administered to patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, \< or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)
61913246|NCT05530018|EXPERIMENTAL|BCI group|Participants will be asked to participate in a brief contact intervention and to evaluate its feasibility, including the feasibility of recruitment, intervention resources, the appropriateness of data collection, and the acceptance of the intervention.
61913247|NCT04443595|EXPERIMENTAL|Experimental|Treatment of Acute Severe Pancreatitis with DPN
61913248|NCT02983097|EXPERIMENTAL|R²-DHAP|"Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide~Dosage:~Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.~peripheral stem cell collection after cycle 1 or 2"
62105467|NCT02974010|ACTIVE_COMPARATOR|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101
62667618|NCT06261957|ACTIVE_COMPARATOR|Salbutamol Reference Arm|
62667619|NCT05957120||Patients on local therapy|20 patients on local antipsoriatic therapy (either corticosteroid cream/ointment, calcipotriol or combination (corticosteroid and calcipotriol); duration of treatment varies in cohort of patients
61913249|NCT00998777|EXPERIMENTAL|Shoulder Strengthening|The shoulder strengthening program is a 6-week intervention aimed to improve shoulder and scapular stabilizer strength and scapular kinematics. The program includes 10 exercises: shoulder flexion, Ys,Ts,Ws, Throwing Acceleration, Throwing Deceleration, Low Rows, Dynamic Hug, IR @ 90, and ER @ 90. The program also includes 2 stretches: sleeper stretch and corner stretch.
61913250|NCT00647829|ACTIVE_COMPARATOR|Arm 1|
61913251|NCT00647829|ACTIVE_COMPARATOR|Arm 2|
62667620|NCT05957120||Patients on methotrexate|20 patients on methotrexate with dosage adjusted by weight; duration of treatment varies in cohort of patients
62667621|NCT05957120||Patients on biologic therapy with anti-tumor necrosis factor-alpha|20 patients on adalimumab - 40 mg every two weeks (or 40 mg weekly if the response was previously insufficient); duration of treatment varies in cohort of patients
62667622|NCT05957120||Patients on biologic therapy with anti-interleukin-17|20 patients on secukinumab - 300 mg monthly (or 300 mg every two weeks if the response was previously insufficient); duration of treatment varies in cohort of patients
61913252|NCT00647829|PLACEBO_COMPARATOR|Arm 3|
61913253|NCT00472758|ACTIVE_COMPARATOR|1|MEDI 545
61913254|NCT00472758|PLACEBO_COMPARATOR|2|Placebo IV
61913255|NCT02204761|EXPERIMENTAL|Treatment|Proton beam radiation therapy
61913256|NCT00695201|EXPERIMENTAL|1|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
61913257|NCT00695201|EXPERIMENTAL|2|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
61913258|NCT04280770|SHAM_COMPARATOR|Non retinal detachment group|35 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
62105468|NCT06494748||Anesthesiologists Decision|Intensive Care Unit Follow up need is decided by anesthesiologists.
62105469|NCT06494748||Artificial Intelligence Decision|Intensive Care Unit Follow up need is decided by Artificial Intelligence
62297784|NCT04176861|EXPERIMENTAL|Home based intervention|Participants using hBET technology at home (all participants).
62667623|NCT05957120||Patients on biologic therapy with anti-interleukin-23|20 patients on guselkumab - 100 mg every 8 weeks; duration of treatment varies in cohort of patients
62105470|NCT06178315|ACTIVE_COMPARATOR|Endoscopic ultrasound-guided celiac plexus block|EUS-guided celiac plexus block will be performed.
62105471|NCT06178315|SHAM_COMPARATOR|Sham|Celiac plexus block will not be performed.
62105472|NCT03572413|EXPERIMENTAL|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
62667624|NCT05957120||Controls|20 subjects who are age-matched
62667625|NCT02326090|ACTIVE_COMPARATOR|cis-UCA ophthalmic solution 1.0%|One drop in each eye
61913259|NCT04280770|ACTIVE_COMPARATOR|retinal detachment group|15 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
61913260|NCT04234633||SLE patients|Any SLE patients between 18 and 40 years old.
61913261|NCT01904773|PLACEBO_COMPARATOR|Placebo|
61913262|NCT01904773|EXPERIMENTAL|low dose AZD5213|
62667626|NCT02326090|ACTIVE_COMPARATOR|cis-UCA ophthalmic solution 2.5%|One drop in each eye
62667627|NCT02326090|PLACEBO_COMPARATOR|Placebo ophthalmic solution|One drop in each eye
62667628|NCT00508300|OTHER|A|Epidural Analgesia (EDA) An epidural catheter was inserted at thoracic level (Th8-Th10) before induction of anesthesia. A bolus of 5 mL of bupivacaine 0.5% was started as soon as the epidural catheter was in place, and a continuous perfusion of bupivacaine 0.5% at 5 mL/hr was initiated until the end of surgical procedure.
62667629|NCT00508300|OTHER|B|Patient controlled analgesia (PCA) was assured by fentanyl (morphine-based) as needed.
62667630|NCT05403073|NO_INTERVENTION|No Nerve Blocking|Pain management at ER Department will be as usually with iv drugs and 3 kilogram soft traction.
61913263|NCT01904773|EXPERIMENTAL|high dose AZD5213|
62667631|NCT05403073|ACTIVE_COMPARATOR|Ultrasound Nerve blocking|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
62667632|NCT03083379|ACTIVE_COMPARATOR|Volumetric Incentive Spirometry|Incentive Spirometry
61913264|NCT04505501|EXPERIMENTAL|N-803|N-803 at 6mcg/kg every 3 weeks for 3 doses plus ART (n=10)
61913265|NCT04505501|NO_INTERVENTION|Control|ART alone (n=5)
62105473|NCT03572413|ACTIVE_COMPARATOR|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
62105474|NCT04993963|EXPERIMENTAL|Cycle Ergometery Training (Prehabilitation)|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown) Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion \<13 on Borg scale
62105475|NCT04993963|ACTIVE_COMPARATOR|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
62667633|NCT03083379|EXPERIMENTAL|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
62667634|NCT05260632||no intervention|
62667635|NCT05260632||2 groups|
62667636|NCT02455180|EXPERIMENTAL|4x 1 gram bolus (q12H) dosage regimen|1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).
62667637|NCT02455180|EXPERIMENTAL|4x 5 grams bolus (q12H) dosage regimen|5 grams of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 20 grams).
62667638|NCT02455180|EXPERIMENTAL|4 gram continuous dosage regimen|1 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
62667639|NCT02455180|EXPERIMENTAL|20 gram continuous dosage regimen|5 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
62667640|NCT02201576|EXPERIMENTAL|Bortezomib|Five plasma exchanges, two cycles of bortezomib + dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
61913266|NCT01220544|EXPERIMENTAL|HaploTransplant with NK cells|Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2
61913267|NCT03824509||Patients with an echocardiagram who suffered a stroke or TIA|"1. Medical record number~2. Sex~3. Age~4. BMI~5. Body surface area~6. Smoking status~7. Congestive heart failure~8. Hypertension~9. Diabetes,~10. Previous history of heart attack or vascular disease~11. Previous history of stroke~12. Date of stroke~13. Type of stroke~14. CHA2DS2-VASc scores~15. On an anticoagulant yes/no at time of stroke~16. Date of atrial fibrillation diagnosis~17. Date of echocardiogram~18. Echocardiographic features:~a. Left atrial volume, indexed to body surface area (BSA) b. Left ventricular hypertrophy 4. Stroke outcome:~1. Mortality~2. NIH Stroke Scale~3. Modified Rankin Scale~4. Discharge placement:~i. Home ii. Long term care iii. Skilled nursing facility e. 6-month survival"
61913268|NCT03824509||Control Group - matched CHA2DS2-VASc score, age, and gender|"Controls from both PBMC and MMC will be obtained. Controls are patients from 2014-2017 with matched age (+/- 5 years), gender, and CHA2DS2-VASc score who had atrial fibrillation and had not had a documented stroke or TIA in EPIC or the Get with the Guidelines registry maintained at PBMC. Controls must have an echocardiogram on record and have a diagnosis of atrial fibrillation at the time of the echocardiogram."
61913269|NCT03633877|EXPERIMENTAL|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
61913270|NCT03633877|EXPERIMENTAL|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
62105476|NCT06629415|ACTIVE_COMPARATOR|Intravenous Injection Injection of Indocyanine Green (ICG)|7.5 mg (3 ml of a 25 mg/10 ml solution) of indocyanine green was injected intravenously in the pre-operative holding area at least 20 minutes before surgery to outline the biliary tree during laparoscopic cholecystectomy.
62667641|NCT02201576|ACTIVE_COMPARATOR|Control|Five plasma exchanges, dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
62667642|NCT02451319|ACTIVE_COMPARATOR|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w holmium laser device who have 1-2 cm diameter kidney stones
62667643|NCT02451319|ACTIVE_COMPARATOR|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser device (working over 20w power) who have 1-2 cm diameter kidney stones
61913271|NCT05792657|EXPERIMENTAL|HIGH dosage in-person exercise coaching|One in-person exercise session with an exercise professional/weekly. A total of 20 hours of in-person coaching during the 20 weeks of intervention.
61913272|NCT05792657|EXPERIMENTAL|MEDIUM dosage in-person exercise coaching|Two in-person exercise session with an exercise professional/monthly, and 15 minutes web-based behavioral support on the non-supervised weeks.A total of 10 hours in-person coaching during the 20 weeks intervention.
62105477|NCT06629415|ACTIVE_COMPARATOR|Transhepatic intracholecystic injection of Indocyanine Green (ICG)|Intracholecystic injection of ICG was done in 30 patients. Twenty 1.25 mg particles, one from a 25 mg ICG vial, were separated under aseptic conditions.
61913273|NCT05792657|EXPERIMENTAL|LOW dosage in-person exercise coaching|One in-person exercise session with the exercise professional/monthly, and 15 minutes web-based behavioral support on the non-supervised weeks.Total of five hours of in-person coaching during the 20 weeks intervention.
62105478|NCT03426072|EXPERIMENTAL|modified IHI breakthrough series|"The SCOPE intervention is a complex, high facilitation, multi-component intervention operating at the microsystem (resident care unit) level of the organization and is designed to engage, develop, and equip Health Care Aides to implement improvement initiatives."
61913274|NCT05792657|NO_INTERVENTION|CONTROL|"Will be asked to continuing with normal life, and will receive regular follow-up care from their GP. This group will be giving the Norwegian Directorate of Health's recommendations for physical activity and nutrition, and will have access to the ABEL-app in order to register physical activity and exercise, but will not be provided any coaching during the 20 weeks."
62105479|NCT03426072|NO_INTERVENTION|Control|The control units (propensity matched) have no intervention and form a naturalistic control
62297785|NCT03578679|EXPERIMENTAL|HEGOR/AZICUR shampoo solution|At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
62297786|NCT06447506|EXPERIMENTAL|GSK1070806 Dose 1|Participants will receive GSK1070806 Dose 1.
62297787|NCT06447506|EXPERIMENTAL|GSK1070806 Dose 2|Participants will receive GSK1070806 Dose 2.
62468959|NCT03834883|EXPERIMENTAL|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
62105480|NCT02271607|EXPERIMENTAL|moxibustion|A series of moxibustion sessions within four weeks from the baseline followed by observation period of four weeks.
62297788|NCT06447506|EXPERIMENTAL|GSK1070806 Dose 3|Participants will receive GSK1070806 Dose 3.
62297789|NCT06447506|EXPERIMENTAL|GSK1070806 Dose 4|Participants will receive GSK1070806 Dose 4.
62297790|NCT03502122|EXPERIMENTAL|VR rehabilitation|Virtual Reality based rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
62297791|NCT03502122|ACTIVE_COMPARATOR|control- conventional rehabilitation|conventional rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
62297792|NCT04788264|EXPERIMENTAL|Arm I (exercise training, behavior modification)|Beginning 1 week prior to start of intervention, patients receive a Fitbit to monitor physical activity for 13 weeks. Patients receive consultation and personalized exercise prescription from a physical therapist at baseline, and attend exercise training sessions with a physical therapist during weeks 1, 3, 6, 9, and 12. Patients also attend behavior modification sessions with a behavioral therapist that focus on goal setting and healthy behavior changes during weeks 2, 4, 5, 7, 8, 10, and 11.
61913275|NCT04278105|EXPERIMENTAL|HD-tCES & upper extremity rehabilitation|The experiment group will receive HD-tCES combined with upper extremity rehabilitation of affected side.
62297793|NCT04788264|ACTIVE_COMPARATOR|Arm II (Fitbit, consultation)|Patients receive a Fitbit to monitor physical activity for 12 weeks. Patients also receive consultation from a physical therapist to assess physical performance at weeks 1, 6, and 12.
62297794|NCT02954471||Participants With Breast Cancer|This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
62297795|NCT05211167|ACTIVE_COMPARATOR|Group A|Intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
62297796|NCT05211167|EXPERIMENTAL|Group B|Intravenous administration,50μg, once every two weeks, for 32 weeks
62297797|NCT04865848|EXPERIMENTAL|Mandibular infiltration dental anesthesia with Articaine|"Step-by-step:~* Reflect tissue to expose injection site.~* Orient bevel of the needle to be parallel to the bone and insert needle into mucobuccal fold~* Proceed to the depth that approximates the apices of the buccal roots of the primary molars.~* Aspirate.~* Deposit bolus of local anesthetic slowly at a rate of 1 ml/min.~* Remove needle.~* A subsequent lingual infiltration is delivered.~The armamentarium includes: 4% articaine HCl with 1:100,000 epinephrine (Septocaine ®, Septodont, Lancaster, Penn. USA) in 1.7 ml cartridges and 30-gauge short needle manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
62468960|NCT03834883|PLACEBO_COMPARATOR|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
62468961|NCT03834883|EXPERIMENTAL|Premenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
62468962|NCT03834883|PLACEBO_COMPARATOR|Premenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
62667644|NCT02451319|ACTIVE_COMPARATOR|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser(working under 20w power) device who have 1-2 cm diameter kidney stones
62667645|NCT03223194|EXPERIMENTAL|Cohort 1|1.5 x 10\^12 vg/kg of AT342 delivered intravenously one time
62667646|NCT03223194|EXPERIMENTAL|Cohort 2|6.0 x 10\^12 vg/kg of AT342 delivered intravenously one time
62667647|NCT03223194|EXPERIMENTAL|Cohort 3|1.5 x 10\^13 vg/kg of AT342 delivered intravenously one time
62667648|NCT03223194|NO_INTERVENTION|Delayed-Treatment Control|Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.
62667649|NCT04398914|EXPERIMENTAL|Pyrotinib, trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: pyrotinib, trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).~After surgery：~* if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.~* if tpCR: chemotherapy 0-4 cycles according to physician's choice, followed with pertuzumab and trastuzumab up to 1 year total."
62667650|NCT04398914|ACTIVE_COMPARATOR|Trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).~After surgery：~* if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.~* if tpCR: chemotherapy 0-4 cycles according to physician's choice; followed with pertuzumab and trastuzumab up to 1 year total."
62667651|NCT02369250|PLACEBO_COMPARATOR|OFD+ PLACEBO GEL|furcation defect site is surgically debrid and placed a placebo gel
62667652|NCT02369250|ACTIVE_COMPARATOR|OFD+ PRF + BONE GRAFT|Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft
62667653|NCT02369250|EXPERIMENTAL|RSV1.2% gel + PRF+ BG|Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed
61913276|NCT04278105|SHAM_COMPARATOR|Sham HD-tCES & upper extremity rehabilitation|The sham control group will receive sham HD-tCES combined with upper extremity rehabilitation of affected side.
62105481|NCT02271607|NO_INTERVENTION|waiting|Waiting period of four weeks followed by moxibustion therapy sessions on the same way with moxibustion group.
62105482|NCT00711646|EXPERIMENTAL|Sativex|
62105483|NCT00711646|PLACEBO_COMPARATOR|Placebo|
62105484|NCT03426514|EXPERIMENTAL|Three-port Laparoscopic Surgery|Patients with colorectal cancer undergo three-port laparoscopic surgery.
62105485|NCT03426514|EXPERIMENTAL|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（4 or more ports）.
62297798|NCT04865848|ACTIVE_COMPARATOR|Inferior Alveolar Nerve Block with Lidocaine|"Step-by-step:~* Dry injection site with gauze.~* The barrel of the syringe should be directed on a plane between the two primary molars on the opposite side of the arch. It is advisable to inject a small amount of the solution as soon as the tissue is penetrated and to continue to inject minute quantities as the needle is directed toward the mandibular foramen.~Insert to the depth that is adjacent to bone.~* Aspirate.~* Slowly inject bolus of anesthetic at a rate of 1 ml/min.~* Remove needle.~The armamentarium includes 2% lidocaine HCl with 1:100,000 epinephrine (Henry Schein ® Lidocaine, Novocol, Cambridge, Ontario, Canada) in 1.7 ml cartridges, as well as 27-gauge long needles manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
62667654|NCT03729479|EXPERIMENTAL|Experimental: DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
62105486|NCT01403792|EXPERIMENTAL|Up to 7mg P2G12|
62667655|NCT03729479|EXPERIMENTAL|Experimental: very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
61913277|NCT01440543|EXPERIMENTAL|Water/CO2|water immersion during colonoscope insertion and CO2 insufflation during colonoscope withdrawal
62105487|NCT01403792|EXPERIMENTAL|Up to 14mg P2G12|
62105488|NCT01403792|EXPERIMENTAL|Up to 28mg P2G12|
62105489|NCT01403792|PLACEBO_COMPARATOR|Placebo (saline solution)|
62105490|NCT01916889|EXPERIMENTAL|RACY test|"4-question RACY delirium screening tool"
62105491|NCT01122524||Chromosomal Abnormality|Fetus affected by chromosomal abnormality
62105492|NCT01122524||No Chromosomal Abnormality|Fetus not affected by chromosomal abnormality
62105493|NCT03852433|ACTIVE_COMPARATOR|Pegylated Interferon alfa-2a (PEG-IFN alfa)|Participants will receive PEG-IFN alfa 180 microgram (mcg) once a week subcutaneously for 48 weeks with additional 48 weeks follow-up.
62667656|NCT03729479|EXPERIMENTAL|Experimental: DASH diet and extra support|"Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
62667657|NCT03729479|EXPERIMENTAL|Experimental: very low carb, ketogenic diet and extra support|"Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
62667658|NCT05162911|ACTIVE_COMPARATOR|Ask, Advise, Assist (AAA) and Refer.|Patients will receive Ask, Advise, Assist (AAA) and refer to the quitline as the intervention.
62667659|NCT05162911|ACTIVE_COMPARATOR|AAA plus referral to onsite counselor (Counsel).|Patients will receive Ask, Advise, Assist plus referral to onsite counselor.
62667660|NCT05162911|ACTIVE_COMPARATOR|AAA+Counsel+N (Nicotine gum).|Patients will receive Ask, Advise, Assist, plus referral to onsite counselor and nicotine gum.
61913278|NCT01440543|EXPERIMENTAL|Water/Air|Water immersion during colonoscope insertion and air insufflation during colonoscope withdrawal
61913279|NCT01440543|EXPERIMENTAL|CO2/CO2|CO2 insufflation during both colonoscope insertion and withdrawal
61913280|NCT01440543|NO_INTERVENTION|Air/Air|room air insufflation during both colonoscope insertion and withdrawal
61913281|NCT00321087|EXPERIMENTAL|1|T2000 dose escalation
62105494|NCT03852433|EXPERIMENTAL|Bulevirtide 2 mg/day + PEG-IFN alfa|Participants will receive bulevirtide 2 mg once a day subcutaneously incombination with PEG-IFN alfa 180 mcg once a week subcutaneously for 48 weeks followed by bulevirtide 2 mg once a day for 48 weeks and additional 48 weeks follow-up.
62105495|NCT03852433|EXPERIMENTAL|Bulevirtide 10 mg/day + PEG-IFN alfa|Participants will receive bulevirtide 10 mg once a day subcutaneously in combination with PEG-IFN alfa 180 mcg once a week subcutaneously for 48 weeks followed by bulevirtide 10 mg once a day for 48 weeks and additional 48 weeks follow-up.
62105496|NCT03852433|EXPERIMENTAL|Bulevirtide 10 mg once a day|Participants will receive bulevirtide 10 mg once a day subcutaneously for 96 weeks with additional 48 weeks follow-up
61913282|NCT00321087|EXPERIMENTAL|2|Placebo followed by T2000 dose escalation
62297799|NCT06656858|ACTIVE_COMPARATOR|Static stretching|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
62667661|NCT02907827|EXPERIMENTAL|stage IV melanoma CR>3years|Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
61913283|NCT00321087|EXPERIMENTAL|3|Placebo followed by T2000 dose escalation
61913284|NCT02050178|EXPERIMENTAL|Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine|
61913285|NCT01335802||Subclinical hypothyroidim|Women having subclinical hypothyroidism and/or TPOab-positive.
61913286|NCT01335802||Controls|Women having normal levels of TSH and TPOab-negative.
61913287|NCT05662709|EXPERIMENTAL|L-PRF|Test group, alveolar ridge preservation with L-PRF after tooth extraction.
61913288|NCT05662709|NO_INTERVENTION|Spontaneous Healing (SH)|Control group, spontaneous healing of the socket after tooth extraction
61913289|NCT05117671||revision total hip or knee arthroplasties|THA/TKA patients that underwent revision surgery between 01.01.2013 until 31.12.2018
61913290|NCT00865423|EXPERIMENTAL|A|Gabapentin 800 mg Tablets, single dose
61913291|NCT00865423|ACTIVE_COMPARATOR|B|NEURONTIN® 800 mg Tablets, single dose
61913292|NCT00600145|EXPERIMENTAL|1|Mirtazapine
61913293|NCT00600145|PLACEBO_COMPARATOR|2|Placebo
61913294|NCT04474028||Hood group|The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood.
61913295|NCT04474028||Direct spray group|The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively.
62105497|NCT06631924||• Operative Cohort: Patients who undergo hand surgery at University of Colorado Hospital and Denver|• Operative Cohort: Patients who undergo hand surgery at University of Colorado Hospital and Denver Health Medical Center for surgical treatment of closed extraarticular metacarpal fracture(s). Fracture classification will be based off of AO Foundation/Orthopaedic Trauma Association guidelines and radiographic interpretation
62105498|NCT04443153|EXPERIMENTAL|De-escalation|Subjects randomized to this arm will proceed from DSS to PF to SAM
62468963|NCT06441097|EXPERIMENTAL|Pola-RCHP-X|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV) on Day2, rituximab 375 milligrams per square meter (mg/m²) IV on Day 1, cyclophosphamide 750 mg/m² IV on Day 2， doxorubicin 50 mg/m² IV on Day 2 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 2-6 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive Acalabrutinib 100 mg BID PO on days 1-21, or lenalidomide 25 mg/day PO on days 1-10, or decitabine 10 mg/m²/day IV on days -5 to -1 followed by standard Pola-RCHP of every 21-day cycle.
62667662|NCT02907827|EXPERIMENTAL|Stage III Melanoma|AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
62667663|NCT01264471||Gulf War Syndrome patients|Gulf War veterans who have been diagnosed with Gulf War Syndrome.
62667664|NCT01677065||Treatment A|Controlled release oxycodone test formulation 40 mg
62667665|NCT01677065||Treatment B|Immediate release oxycodone reference drug 20 mg
62667666|NCT02639026|EXPERIMENTAL|Cohort 1|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 1 tests 8 Gy x 3 fractions
62667667|NCT02639026|EXPERIMENTAL|Cohort 2|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 2 tests 17 Gy x 1 fraction.
62468964|NCT06441097|ACTIVE_COMPARATOR|Pola-RCHP|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV) on Day2, rituximab 375 milligrams per square meter (mg/m²) IV on Day 1, cyclophosphamide 750 mg/m² IV on Day 2， doxorubicin 50 mg/m² IV on Day 2 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 2-6 of every 21-day cycle for 6 cycles.
62667668|NCT01447771|EXPERIMENTAL|Lifestyle counseling|Decision control preference intervention
62667669|NCT00601107|EXPERIMENTAL|Doxercalciferol 2.5 mcg/day|Doxercalciferol 2.5 microgram (mcg) capsule orally once daily up to Week 24.
62667670|NCT00601107|EXPERIMENTAL|Doxercalciferol 5 mcg/day|Doxercalciferol 5 mcg capsules orally once daily up to Week 24.
62667671|NCT00601107|EXPERIMENTAL|Doxercalciferol 7.5 mcg/day|Doxercalciferol 7.5 mcg capsules orally once daily up to Week 24.
62667672|NCT00601107|PLACEBO_COMPARATOR|Placebo|Placebo matching to doxercalciferol capsules orally once daily up to Week 24.
62105499|NCT04443153|EXPERIMENTAL|Escalation|Subjects randomized to this arm will proceed from SAM to PF to DSS
62105500|NCT00763282|EXPERIMENTAL|SM+MI|Self Management (SM) + Motivational Interviewing (MI). Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. Motivational Interviewing (MI) is an evidence-based form of counseling to help individuals to engage in behavior change. Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
62667673|NCT05399342||LAAOS III Extended Follow-Up Cohort|Patients randomized into the LAAOS III trial who have consented to longer term observational follow-up. There is no intervention in this study.
61913296|NCT01073501|PLACEBO_COMPARATOR|Placebo|Placebo versus pregabalin
61913297|NCT01073501|EXPERIMENTAL|Pregabalin|Placebo versus pregabalin
62667674|NCT02473874||Skin Spect dermoscope|Skin mole
62667675|NCT02473874||Spatially modulated quantitative|Skin mole
61913298|NCT03505710|EXPERIMENTAL|Cohort 1: HER2 Overexpressing|Participants with HER2-overexpressing(immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
61913299|NCT03505710|EXPERIMENTAL|Cohort 1a: HER2 Overexpressing|Participants with HER2-overexpressing (immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
62105501|NCT00763282|ACTIVE_COMPARATOR|ED|Education (ED). An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures. The ED intervention will differ only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
62105502|NCT04566874|OTHER|Spira-A with HCT/p DBM|Single level Spira-A 3D printed Titanium ALIF Device with HCT/p DBM
62105503|NCT04566874|ACTIVE_COMPARATOR|Medtronic PEEK ALIF with Infuse|Single level Medtronic Divergent-L/Perimeter PEEK ALIF Device with Recombinant Bone Morphogenic Protein-2 (Infuse)
62105504|NCT06618898||oboe|Woodwind players in German professional orchestras who play the oboe
62297800|NCT06656858|ACTIVE_COMPARATOR|PNF stretching|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
61913300|NCT03505710|EXPERIMENTAL|Cohort 2: HER2 Mutated|Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
61913301|NCT02233478|ACTIVE_COMPARATOR|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
62105505|NCT06618898||flute|Woodwind players in German professional orchestras who play the flute
62468965|NCT04398745|EXPERIMENTAL|Part 1: Participants with normal/mild impaired renal function|Participants with normal or mildly impaired renal function (Normal: individual glomerular filtration rate \[iGFR\]: \>=90 milliliter per minute; Mild impairment: iGFR: 60-89 mL/min will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
62105506|NCT06618898||clarinet|Woodwind players in German professional orchestras who play the clarinet
62105507|NCT06618898||bassoon|Woodwind players in German professional orchestras who play the bassoon
62297801|NCT06656858|EXPERIMENTAL|Static stretching with BFR|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
62105508|NCT06618898||cello|musicians in German professional orchestras who play the cello
62105509|NCT02034149|OTHER|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
62105510|NCT02034149|EXPERIMENTAL|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc.With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
62297802|NCT06656858|EXPERIMENTAL|PNF stretching with BFR|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application
62297803|NCT06656858|OTHER|Control|No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
62105511|NCT02034149|EXPERIMENTAL|peer-assisted management|The peer-assisted management group received the peer oriented group activities followed, including group discussions to share experience and sports map etc. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
62105512|NCT04417556|EXPERIMENTAL|Sleep Measurement|Sleep Measurement arm, sleep are simultaneously measured using polosomgraphy, actigraphy and Thai-version Richards Campbell Sleep Questionnaire.
62297804|NCT03021902|EXPERIMENTAL|IV amino acid + in-bed cycle ergometry|Beginning within 96 hours of initiation of mechanical ventilation, participants will receive the combined intervention that includes IV amino acids supplementation and in-bed cycle ergometry exercise
62297805|NCT03021902|NO_INTERVENTION|Usual care|Participants randomized to the usual care arm will receive usual care protein and exercise.
62667676|NCT05349500|EXPERIMENTAL|OA CARE|Participants assigned to the OA CARE intervention will receive a 12-month Medical Membership to a local YMCA and participate in a 12-week weight loss program. Participants will also work with an OA CARE Navigator, who, in partnership with their primary care provider (PCP), will identify any additional programs or resources that may help them manage their osteoarthritis (OA) symptoms.
62667677|NCT05349500|PLACEBO_COMPARATOR|Usual Care|Participants assigned to this group will receive no additional treatment from the study for about 12 months.
62667678|NCT04077606|ACTIVE_COMPARATOR|ceramo-metallic crown|ceramo-metallic crown preparation
62667679|NCT04077606|ACTIVE_COMPARATOR|monolithic zirconia crown|monolithic zirconia crown preparation
62667680|NCT01139372|EXPERIMENTAL|FID 115958D|Lubricant eye drop
62105513|NCT06240039|EXPERIMENTAL|Evaluating the direct and indirect effect of amino acids on the regulation of hepatokines|Participants will be subjected to four experimental days
62105514|NCT04705857||test group|"bone reconstructive surgery with the use of Histograft bone substitute (gene-activated matrix based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) mixed with shredded autobone (in a ratio of 50/50) harvested during the surgery"
62297806|NCT05017545|EXPERIMENTAL|Cohort 1 (N=5 Subjects)|"The two investigational agents used in this study are carfilzomib and belatacept.~Per protocol, Carfilzomib administered intravenously:~* Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43).~* Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99).~Per protocol, Belatacept:~-Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert."
62468966|NCT04398745|EXPERIMENTAL|Part 1: Participants with severe renal impairment|Participants with severely impaired renal function (iGFR: 15-29 mL/min) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
62468967|NCT04398745|EXPERIMENTAL|Part 2: Participants with ESRD (not on dialysis)|Participants with ESRD (iGFR: \<15 mL/min) not on dialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
62667681|NCT04352530|ACTIVE_COMPARATOR|Rewind the Future|Fear appeal, video message to reduce sugar consumption or risk death
62105515|NCT04705857||control group|bone reconstructive surgery with the use of shredded bone autograft harvested from iliac crest
62105516|NCT05914558||TN cohort|The patient was diagnosed with trigeminal neuralgia which has active symptoms in the past 30 days.
62667682|NCT04352530|EXPERIMENTAL|Hear No|"Video of spoken word poem from The Bigger Picture project, Hear No by Joshua Merchant; images of African-American male poet interspersed with images of environment"
62667683|NCT04352530|EXPERIMENTAL|The Longest Mile|"Video of spoken word poem from The Bigger Picture Project, The Longest Mile by Tassiana Willis; images of African-American female poet interspersed with images of environment"
62667684|NCT04352530|EXPERIMENTAL|A Taste of Home|"Video of spoken word poem from The Bigger Picture Project, A Taste of Home by Monica Mendoza; images of Hispanic female poet interspersed with images of environment"
62667685|NCT04352530|EXPERIMENTAL|Lost in Translation|"Video of spoken word poem from The Bigger Picture Project, Lost in Translation by Yosimar Reyes; images of Hispanic male poet interspersed with images of environment"
62297807|NCT05017545|EXPERIMENTAL|Cohort 2 (N=10 Subjects)|"The enrollment of ten additional subjects and dosing regimen is dependent on the results in Cohort 1.°~Per protocol, Carfilzomib administered intravenously:~* Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43).~* Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99).~Per protocol, Belatacept:~-Belatacept will be administered intravenously on days 28 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert.~° May be modified based on the safety and efficacy analysis of Cohort 1."
62297808|NCT05511038|EXPERIMENTAL|Aflibercept|Participants will receive one aflibercept injection per month (every four weeks) for five consecutive doses, followed by one injection every alternate month (every 8 weeks) for rest of the duration
62667686|NCT04352530|EXPERIMENTAL|Bottled Up|"Video of spoken word poem from The Bigger Picture Project, Bottled Up by Eileen Torrez; images of Hispanic female poet interspersed with images of environment"
62667687|NCT04352530|EXPERIMENTAL|The Corner|"Video of spoken word poem from The Bigger Picture Project, The Corner by Jose Vadi; images of Hispanic male poet interspersed with images of environment"
62667688|NCT04352530|EXPERIMENTAL|Thin Line|"Video of spoken word poem from The Bigger Picture Project, Thin Line by Ivori Holson; images of African-American female poet interspersed with images of environment"
62667689|NCT04401293|EXPERIMENTAL|Full Dose LMWH anticoagulation therapy|Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and \< 30ml/min) during the course of their hospitalization.
62667690|NCT04401293|ACTIVE_COMPARATOR|Prophylactic/Intermediate Dose LMWH or UFH therapy|Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.
62667691|NCT06248528|EXPERIMENTAL|Liver resection-based group|Patients in the liver resection-based group received adjuvant PD-1 inhibitors plus targeted drugs following liver resection.
62667692|NCT06248528|ACTIVE_COMPARATOR|Locoregional treatment-based group|Patients in the locoregional treatment-based group received PD-1 inhibitors plus targeted drugs following locoregional therapy.
62105517|NCT03211325|EXPERIMENTAL|Healthy|"Two sequences of ten healthy volunteers each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
62667693|NCT03429205|EXPERIMENTAL|No heating - Study group|Patient will undergo bariatric surgery without utilization of external heating device.
62297809|NCT03310125|EXPERIMENTAL|Colchicine|Participants received over-encapsulated colchicine 0.5 mg tablet orally twice daily for 10 days.
62297810|NCT03310125|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo capsules orally twice daily for 10 days.
62297811|NCT03026387|OTHER|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are suicide attempters without psychotic features"
62297812|NCT01608152||Group I (focus group)|Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.
62105518|NCT03211325|EXPERIMENTAL|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
62105519|NCT03211325|EXPERIMENTAL|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
62297813|NCT01608152||Group II (access to the game)|Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.
62297814|NCT00503399|EXPERIMENTAL|Teriparatide|Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
62297815|NCT00503399|ACTIVE_COMPARATOR|Risedronate|Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)
62667694|NCT03429205|OTHER|Heating - Control group|Patient will undergo bariatric surgery with utilization of external heating device.
62667695|NCT03986268|ACTIVE_COMPARATOR|study group|The patients measured a total of 25 OH vitamin D3 levels, initial, 3'th month and 6'th month of neoadjuvant therapy with replacement treatment with vitamin D3 at least weekly 50000 IU for eight weeks.
62667696|NCT03986268|OTHER|control group|The patients had measured a total of 25 OH vitamin D3 levels, previously treated with neoadjuvant therapy without replacement treatment with vitamin D3.
62667697|NCT03268187|EXPERIMENTAL|Self-Alert Training|Biofeedback-based Self-Alert Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
62667698|NCT03268187|ACTIVE_COMPARATOR|Relaxation Training|Biofeedback-based Relaxation Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
62667699|NCT00550004|ACTIVE_COMPARATOR|Arm 1|RP101 and Gemcitabine
62667700|NCT00550004|PLACEBO_COMPARATOR|Arm 2|Placebo and Gemcitabine
62667701|NCT04097223||Subjects with Pulmonary Disease, Chronic Obstructive|
62667702|NCT03083041|EXPERIMENTAL|SHR-1210，200mg,q2w plus apatinib 250mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
62297816|NCT04239417|EXPERIMENTAL|The Study group A|graduated abdominal strengthening exercises group
62297817|NCT04239417|EXPERIMENTAL|The Study group B|Russian stimulation group
62297818|NCT04239417|EXPERIMENTAL|The Study group C|combination group
62297819|NCT04239417|NO_INTERVENTION|The Control group D|presume in normal activities of daily living.
62297820|NCT02585427|EXPERIMENTAL|low glycemic index rice with butter|50 g available low glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
62667703|NCT03083041|EXPERIMENTAL|SHR-1210，200mg,q2w plus apatinib 500mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
62667704|NCT03083041|EXPERIMENTAL|SHR-1210，200mg,q2w plus apatinib 375mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
62667705|NCT04482790|ACTIVE_COMPARATOR|Conventional celluloid matrix|Conventional celluloid matrix technique in management of black triangle
62667706|NCT04482790|EXPERIMENTAL|Bioclear cervical matrix|Bioclear cervical matrix with injection molding technique in management of black triangle
62667707|NCT02663440|EXPERIMENTAL|IMRT|Hypofractionated IMRT With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor
62297821|NCT02585427|EXPERIMENTAL|low glycemic index rice with olive oil|50 g available low glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
62297822|NCT02585427|EXPERIMENTAL|low glycemic index rice with grapeseed oil|50 g available low glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
62297823|NCT02585427|EXPERIMENTAL|high glycemic index rice with butter|50 g available high glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
62667708|NCT05900245|ACTIVE_COMPARATOR|Group H：IoC1 60-70|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg， following by mask pressurized oxygen supply，dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 60 and 70. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System，manufacturer：SOMATICS, USA；Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.
62105520|NCT05139160|EXPERIMENTAL|Whey protein isolate|Whey protein isolate is the 'gold standard' of protein supplements due to being rich in essential amino acids and leucine. Leucine is a key amino acid the is required to stimulate muscle protein synthesis. Muscle protein synthesis is the major mechanism the underpins muscle growth. The whey protein would ostensibly serve as a positive control.
62105521|NCT05139160|EXPERIMENTAL|Plant based protein isolate|Current plant-based protein isolates available contain insufficient amounts of leucine, and are less digestible, resulting in a reduced muscle protein synthesis responses. The plant based protein would ostensibly serve as a negative control.
62105522|NCT05139160|EXPERIMENTAL|Plant based protein isolate + leucine|Enriching plant-based protein with leucine will increase the 'quality' of said protein source and theoretically should have similar muscle protein synthetic responses to whey protein.
62105523|NCT00368719|NO_INTERVENTION|1|
62105524|NCT05464212|ACTIVE_COMPARATOR|USG Guided Greater Occipital Nerve Block (GONB)|
61913302|NCT02233478|ACTIVE_COMPARATOR|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
62105525|NCT05464212|ACTIVE_COMPARATOR|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency (GONB+PRF)|
62468968|NCT04398745|EXPERIMENTAL|Part 2: Participants with ESRD (on hemodialysis)|Participants with ESRD (iGFR: \<15 mL/min) on hemodialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
62105526|NCT04059562|EXPERIMENTAL|Treatment|Combination of Lonsurf® and Irinotecan
62105527|NCT04928872||Non-diabetic older adults|Non-diabetic older adults
62105528|NCT03966794|EXPERIMENTAL|Epidural Electrical Stimulation|
62105529|NCT03966794|EXPERIMENTAL|Functional scaffold & Epidural Electrical Stimulation|
62105530|NCT06631599|NO_INTERVENTION|control group|This group performed routine soccer training
62105531|NCT06631599|EXPERIMENTAL|sprint training group|This group performed, in addition to routine soccer training, sprint training with resistance
62105532|NCT06631599|EXPERIMENTAL|Functional training group|This group performed, in addition to routine football training, functional training
62105533|NCT01749787|EXPERIMENTAL|1.5 mcg/kg|PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks
62105534|NCT01749787|EXPERIMENTAL|3.0 mcg/kg|PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks
62105535|NCT01749787|EXPERIMENTAL|6.0 mcg/kg|PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks
62105536|NCT01749787|EXPERIMENTAL|12.0 mcg/kg|PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks
62105537|NCT01749787|EXPERIMENTAL|240 mcg|PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
62105538|NCT01749787|PLACEBO_COMPARATOR|Placebo|Placebo administered via infusion once per week for 5 weeks
62105539|NCT01749787|EXPERIMENTAL|420 mcg|PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
62105540|NCT01025869|OTHER|Stent System|Cinatra™ Corolimus Eluting Coronary Stent System
62468969|NCT02712086|NO_INTERVENTION|usual dietary management|Control group: usual dietary management Following the intervention, the stomach of patients underwent many changes
62105541|NCT02889822|EXPERIMENTAL|Alprostadil Liposomes for Injection|"1. Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~2. Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
62105542|NCT06245109|ACTIVE_COMPARATOR|Duloxetine|Duloxetine 60mg tablet, daily (with an initial and final 7-day titration at 30 mg, daily)
62105543|NCT06245109|ACTIVE_COMPARATOR|Celecoxib|Celecoxib 200 mg tablet, daily
62105544|NCT06245109|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet, daily
62105545|NCT05249179|EXPERIMENTAL|Group 1 (Oral stimulation)|The group that will receive oral stimulation with the Backman method once a day from the 29th week
62105546|NCT05249179|EXPERIMENTAL|Group 2 (Pacifier)|The group that will be given a pacifier three times a day from the 29th week
62105547|NCT05249179|EXPERIMENTAL|Group 3 (oral stimulation + pacifier)|Starting from the 29th week, the group will be given a pacifier three times a day and a Backman oral stimulation will be applied once a day.
62468970|NCT02712086|EXPERIMENTAL|care of with usual dietary protein supplementation|Intervention group: Usual dietary management with protein supplementation (30g) in addition to the usual inputs
62468971|NCT00111098|EXPERIMENTAL|darbepoetin alfa|
62667709|NCT05900245|ACTIVE_COMPARATOR|Group M: IoC1 50-60|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg， following by mask pressurized oxygen supply，dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 50 and 60. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System，manufacturer：SOMATICS, USA；Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.
62667710|NCT05900245|ACTIVE_COMPARATOR|Group L：IoC1 40-50|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg， following by mask pressurized oxygen supply，dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 40 and 50. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System，manufacturer：SOMATICS, USA；Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.
62297824|NCT02585427|EXPERIMENTAL|high glycemic index rice with olive oil|50 g available high glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
62297825|NCT02585427|EXPERIMENTAL|high glycemic index rice with grapeseed oil|50 g available high glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
62297826|NCT05152212|EXPERIMENTAL|LVGN7409|Monotherapy Dose Escalation
62297827|NCT04472689|ACTIVE_COMPARATOR|Lidocaine group|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
62105548|NCT05249179|NO_INTERVENTION|Group 4 (Enteral feeding by tube)|The group fed enterally by tube in routine practice, in which no intervention will be made.
62468972|NCT04881968|NO_INTERVENTION|Control: Usual Care|The control arm occurs prior to receipt of the video game intervention and reflects usual care. Each hospitalist 'crosses over' from control to intervention at a single time point.
62468973|NCT04881968|EXPERIMENTAL|Video Game Intervention|Each hospitalist 'crosses over' from control to intervention at a single time point by receiving a link to the Hopewell Hospitalist game via email and logging in to play the video game.
62468974|NCT05675735|EXPERIMENTAL|Cohort 1|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in group 1. Group 1 will start the six-month intervention at Baseline and end at Month 6.
62468975|NCT05675735|EXPERIMENTAL|Cohort 2|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 2. Cohort 2 will start the six-month intervention at Month 6 and end at Month 12.
62667711|NCT03885388|ACTIVE_COMPARATOR|control arm|single methotrexate multicourse treatment MTX:MTX 0.4mg/kg•d, intramuscular, every two weeks
62667712|NCT03885388|EXPERIMENTAL|experimental arm|combination of methotrexate and actinomycin multicourse treatment, every two weeks MTX+ACTD:Act-d 0.6mg/m2 Day1,2 intravenous (IV) MTX 100mg/m2 IV Day1(after Act-d) MTX 200mg/m2 Ivgtt Day1(after MTX,500mlNS)
62105549|NCT04766437|EXPERIMENTAL|Prasugrel or ticagrelor monotherapy|Once daily 10 mg prasugrel or twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 60 mg prasugrel or 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
62105550|NCT06286982||People aged 65 years and older with a Clinical Frailty Score (CFS) ≥5|The Oral Symptom Assessment Scale will be administered to participants. A feedback questionnaire will also be administered.
62297828|NCT04472689|PLACEBO_COMPARATOR|Control group|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation.
62667713|NCT00855478|EXPERIMENTAL|1|Cypher drug-eluting stent
62667714|NCT04574505|EXPERIMENTAL|NUT|1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks
62667715|NCT04574505|PLACEBO_COMPARATOR|Placebo|1 tablet of Placebo per day + standard diet for 8 weeks
62667716|NCT00901498|EXPERIMENTAL|Treatment A (Reference)|
62297829|NCT03325309||Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
62468976|NCT05675735|EXPERIMENTAL|Cohort 3|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 3. Cohort 3 will start the six-month intervention at Month 12 and end at Month 18.
62468977|NCT05675735|EXPERIMENTAL|Cohort 4|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 4. Cohort 4 will start the six-month intervention at Month 18 and end at Month 24.
62468978|NCT05675735|EXPERIMENTAL|Cohort 5|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 5. Cohort 5 will start the six-month intervention at Month 24 and end at Month 30.
62105551|NCT05939557|EXPERIMENTAL|Jones technique group|Performs Jones technique 12 participants.
62468979|NCT05675735|EXPERIMENTAL|Cohort 6|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 5. Cohort 5 will start the six-month intervention at Month 30 and end at Month 36.
62105552|NCT05939557|EXPERIMENTAL|kinesio tapping group|Performs kinesiotape 14 participants.
62105553|NCT05939557|EXPERIMENTAL|combined therapy group|Performs Jones technique and kinesiotape 12 participants.
62105554|NCT05022342||HR-positive HER2-negative ABC/MBC|Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC)/ metastatic breast cancer (MBC) patients
62105555|NCT05022342||PIK3CA mutation positive|Patients with Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) gene mutation positive
61913303|NCT02233478|ACTIVE_COMPARATOR|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
61913304|NCT05604183|EXPERIMENTAL|Subjects|"On all subjects included in the study (see inclusion / exclusion criteria and informed consent) both procedures will be performed.~The result of these procedures (retinal scan, result from cognitive test and blood sample) will be used to build diagnostic classification models."
61913305|NCT00559494|EXPERIMENTAL|Minocycline|
61913306|NCT00559494|PLACEBO_COMPARATOR|Placebo|
61913307|NCT00559494|EXPERIMENTAL|SCPP augmentation|
61913308|NCT00559494|SHAM_COMPARATOR|SCPP control|
61913309|NCT06221657|EXPERIMENTAL|TAF group|
62105556|NCT06629701|EXPERIMENTAL|Group A|Group A will consist of a group of patients who will be sutured with external support for vein grafts.
62105557|NCT06629701|NO_INTERVENTION|Group B|Group B will be without sewn-in external supports.
62297830|NCT06367322||Statin users|"Patients ≥ 18 years old scheduled for ERCP according to a medical indication, and willing to participate were included, who were receiving treatment with statins.~Excluded: patients with ongoing AP, surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy), or failure to reach the papilla as well as patients undergoing ERCP for stent removal or exchange were excluded."
62297831|NCT06367322||Non-statin users|"Patients ≥ 18 years old scheduled for ERCP according to a medical indication, and willing to participate were included, who were not receiving treatment with statins.~Excluded: patients with ongoing AP, surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy), or failure to reach the papilla as well as patients undergoing ERCP for stent removal or exchange were excluded."
62297832|NCT01986335|EXPERIMENTAL|DTP/HB/Hib Vaccine (Batch: A)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
62297833|NCT01986335|EXPERIMENTAL|DTP/HB/Hib vaccine (Batch: B)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
62297834|NCT01986335|EXPERIMENTAL|DTP/HB/Hib vaccine (Batch: C)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
62468980|NCT00269776|EXPERIMENTAL|001|OROS (methylphenidate HCl) Treatment A: 1 2 or 3 OROS methylphenidate 18-mg tablets + 0 1 or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
62468981|NCT00269776|EXPERIMENTAL|002|Ritalin (methylphenidate) Treatment B: 5 10 or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
62468982|NCT00269776|EXPERIMENTAL|003|Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
62468983|NCT01844674|EXPERIMENTAL|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
62105558|NCT02646670|ACTIVE_COMPARATOR|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml . This group will be five about patients about any age, with diabetic macular edema randomly chosen
62105559|NCT02646670|ACTIVE_COMPARATOR|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml. This group will be about five patients about any age, with diabetic macular edema randomly chosen
62105560|NCT02646670|ACTIVE_COMPARATOR|Ranibizumab and Aflibercept|- In this group will be held two applications of 0.1 ml Aflibercept(the first and the third doses) interspersed with one application of Ranibizumab 0.1 ml(the second dose). This group will be about five patients about any age, with diabetic macular edema randomly chosen
62105561|NCT02646670|ACTIVE_COMPARATOR|Aflibercept and Ranibizumab|- This group will be held two applications of Ranibizumab 0.1 ml(the first and the third doses) interspersed with one application of Aflibercept 0.1 ml(the second dose). This group will be five about patients about any age, with diabetic macular edema randomly chosen
62105562|NCT01278693|OTHER|placebo|it is as like as L-carnitine in shape
62105563|NCT01278693|OTHER|L-carnitine|it is kind of supplement
61913310|NCT06221657|ACTIVE_COMPARATOR|TDF group|
61913311|NCT04316702|ACTIVE_COMPARATOR|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
61913312|NCT04316702|ACTIVE_COMPARATOR|Pharmacotherapy|Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 2 weeks, patients will be evaluated and dose will be adjusted as necessary and tolerated, up to the maximum dosage recommended for FM. Patients may also be switched from one medication to the other according to clinical judgment of the physician.
62297835|NCT00558090|ACTIVE_COMPARATOR|A|patients receive 2,5 mg morphine iv, before the first intervention on the day after admission in the ICU
62297836|NCT03231514|PLACEBO_COMPARATOR|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
62297837|NCT03231514|ACTIVE_COMPARATOR|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate \& Placebo for effects of supplement. All participate in the exercise intervention.
62297838|NCT03231514|EXPERIMENTAL|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet \& placebo) and placebo control group (vs. ketogenic \& supplement). All participate in the exercise intervention.
62297839|NCT03231514|EXPERIMENTAL|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
62105564|NCT05634317|EXPERIMENTAL|Behavioral activation|The SD-BA, consisting of 16 sessions (30 minutes each) twice a week over 8 weeks, will be delivered by the trained instructor through a videoconference mobile app. Participants will be asked to review their daily activity patterns and then choose activity goals and review their successes and areas of improvement. They will also be taught how to fill out the daily monitoring record, which will involve noting down their activities on the day of the session for each hour before the session, and rating the importance and degree of enjoyment associated with each activity.
62105565|NCT05634317|ACTIVE_COMPARATOR|Mindfulness|A mindfulness instructor will deliver the program through a videoconference mobile app, and include various mindfulness practices (e.g., mindful walking, body scanning) and sharing. To standardize the interventions in this study, the previous approach will be changed from 7 weekly 120-minute sessions to 16 sessions (30 minutes each) twice a week over 8 weeks. The participants will also be encouraged to perform 30 minutes of mindfulness practice every day. All participants will be given an audio (mp3) recording of guided mindfulness activities to enhance their daily practice, and a logbook via a mobile app or in hardcopy (according to their preference) to record the frequency of their self-practice at home and monitor their compliance rate. Our volunteers will provide support via smartphone to answer questions and address difficulties.
62468984|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
62468985|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
62468986|NCT01912898||1|
62667717|NCT00901498|ACTIVE_COMPARATOR|Treatment B|
62667718|NCT00901498|ACTIVE_COMPARATOR|Treatment C|
62667719|NCT00901498|ACTIVE_COMPARATOR|Treatment D|
62667720|NCT00901498|ACTIVE_COMPARATOR|Treatment E|
62667721|NCT02337946|ACTIVE_COMPARATOR|Group A|Panitumumab (Pmab) 6 mg/kg, intravenous drip infusion (DIV), at Day 1, oxaliplatin (OXA) 85 mg/m\^2, DIV, at Day 1, levofolinate (l LV) 200 mg/m\^2, DIV, at Day 1, fluorouracil (5-FU) 400 mg/m\^2, intravenous (IV) at Day 1, 5-FU 2400 mg/m\^2, continuous intravenous infusion (CIV), at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m\^2, DIV, at Day 1, l LV 200 mg/m\^2, DIV, at Day 1, 5-FU 400 mg/m\^2, IV, at Day 1, 5-FU 2400 mg/m\^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
62667722|NCT02337946|EXPERIMENTAL|Group B|Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m\^2, DIV, at Day 1, l LV 200 mg/m\^2, DIV, at Day 1, 5-FU 400 mg/m\^2, IV, at Day 1, 5-FU 2400 mg/m\^2, CIV, at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, l LV 200 mg/m\^2, DIV, at Day 1, 5-FU 400 mg/m\^2, IV, at Day 1, 5-FU 2400 mg/m\^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
62667723|NCT05406895|EXPERIMENTAL|CBCT first|This group will receive the injection technique that is guided by pre-treatment measurements made from the 3D dental scan (CBCT) during implant placement surgery and if the implant is placed as a two-stage procedure, during the second stage implant uncovery will receive the standard injection technique. If the implant is placed as a one-stage procedure, the second visit will not apply.
62667724|NCT05406895|ACTIVE_COMPARATOR|Standard technique first|This group will receive the standard injection technique first at the implant placement surgery and if the implant is placed as a two-stage procedure, during the second stage implant uncovery will receive the injection technique guided by the 3D dental scan (CBCT). If the implant is placed as a one-stage procedure, the second visit will not apply.
62667725|NCT05788198|EXPERIMENTAL|Integrated care arm|Case management in primary care setting (integration at general practitioners' practices), Depression and population management education for general practitioners, shared care guidance protocol including a medication path (drug classes, no specific drugs specified, based on available depression guidelines in Belgium).
62667726|NCT00132483|EXPERIMENTAL|Intervention arm|
62667727|NCT00132483|NO_INTERVENTION|Control|
62105566|NCT03274102|EXPERIMENTAL|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
62468987|NCT03001063|EXPERIMENTAL|Intervention|This arm will receive the Supported Self- Management intervention, which consists of bibliotherapy that is provided with the regular support of health or social workers for a duration of two months.
62105567|NCT03274102|ACTIVE_COMPARATOR|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
62105568|NCT03274102|ACTIVE_COMPARATOR|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
62105569|NCT02702921|ACTIVE_COMPARATOR|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
62105570|NCT02702921|EXPERIMENTAL|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
62105571|NCT01532232||placebo|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
62105572|NCT01532232||varenicline|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
62105573|NCT03223883|EXPERIMENTAL|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
62105574|NCT03223883|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
62297840|NCT05334329|EXPERIMENTAL|Treatment (fludarabine, cyclophosphamide, COH06, atezolizumab)|Patients receive fludarabine IV on days -5 to -3, cyclophosphamide IV on days -5 to -3, and COH06 IV on days 0, 7, 14, and 21 in the absence of disease progression or unacceptable toxicity. Patients assigned to dose level 4 also receive atezolizumab IV over 60 minutes on days 0, 14, 28, and 42 in the absence of disease progression or unacceptable toxicity.
62297841|NCT04042480|EXPERIMENTAL|SGN-CD228A|SGN-CD228A monotherapy
62297842|NCT00125034|EXPERIMENTAL|Cetuximab Plus FOLFOX-4|
62297843|NCT00125034|ACTIVE_COMPARATOR|FOLFOX-4 Alone|
62468988|NCT03001063|OTHER|Control|This arm will receive enhanced treatment as usual, which consists of a leaflet with information about depression and regular care as provided by primary care centres. The control arm will receive the intervention after the intervention arm has completed the intervention period.
62667728|NCT05362539|EXPERIMENTAL|Hematuria patients|Voided urine was collected from consecutive patients presented with hematuria at our institute for urine cytology and DNA hypermethylation assay of the assigned genes using methylation-specific Polymerase Chain Reaction (PCR). Further assessment by office cystoscopy and imaging with subsequent inpatient cystoscopic biopsy for positive findings, was done. The diagnostic characteristics of DNA hypermethylation and urine cytology were assessed based on its capability to predict UBC noninvasively
62105575|NCT00470795|EXPERIMENTAL|A|Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
62105576|NCT00470795|PLACEBO_COMPARATOR|B|Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
62105577|NCT02898051||Venous Thromboembolism and cancer|"Patients hospitalized for Venous Thromboembolism and having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: three tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
62105578|NCT02898051||Venous Thromboembolism and non cancer|"Patients hospitalized for Venous Thromboembolism and not having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: 3 tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
62667729|NCT03052673|ACTIVE_COMPARATOR|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
62667730|NCT03052673|ACTIVE_COMPARATOR|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
62667731|NCT04806425|ACTIVE_COMPARATOR|IL group|receive 1.5 ml /kg intralipid 20% through Central venous line after sternotomy over 1 hour
62667732|NCT04806425|PLACEBO_COMPARATOR|NS group|recieve 1.5 ml /kg normal saline 0.9% through central venous line after sternotomy over 1 hour
62667733|NCT01058824|ACTIVE_COMPARATOR|Lincomycin - Active Comparative - Hard Gelatin Capsule|
62105579|NCT05905406|EXPERIMENTAL|S60|The Hip will be positioned at 80°, and knee positioned 60°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
62297844|NCT03107195||Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 4-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
62468989|NCT04152174|EXPERIMENTAL|Combined extracorporeal blood purification|CRRT with CVVHDF mode plus treatment with CytSorb adsorber
62468990|NCT04152174|ACTIVE_COMPARATOR|Control|CRRT with CVVHDF mode
62468991|NCT04967794|ACTIVE_COMPARATOR|Group Whatsapp|Will receive standardized brushing Teleorientation consultation through the Whatsapp communication platform
62667734|NCT01058824|EXPERIMENTAL|Lincomycin - Study Drug - Hard Gelatin Capsule|
61913313|NCT05602896|EXPERIMENTAL|Sepsis Education|The patient will receive a daily notification via their mobile phone and conduct the daily activity for 30 days. The program is interactive and aimed at measures that prevent exposure to infection sources in the environment, as well as recognition of early signs of infection and possible sepsis. Each session takes approximately 2 minutes or less. Each scenario or session has the user identify where germs may be present and then asks the user to perform a simple action to remove the germs (e.g. with an antiseptic wipe). The range of activities include cleaning of surfaces, proper mask use, and hand sanitizing. This includes areas of their home such as the kitchen, bathroom, living room/family room. The program also addresses common community areas such as public transit, grocery stores, and restaurants
61913314|NCT01890629|EXPERIMENTAL|Gemigliptin + Metformin|Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
61913315|NCT01890629|ACTIVE_COMPARATOR|Sitagliptin + Metformin|Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
61913316|NCT01890629|ACTIVE_COMPARATOR|Glimepiride + Metformin|Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
62297845|NCT04948996|EXPERIMENTAL|El Buen Consejo Móvil- Group (EBCM-G)|Participants in the group condition will be placed in groups of five participants within the app. Their version of EBCM will have the functionality to connect individuals to one another via a facilitator-guided chat room (EBCM-G), where they can respond to suggested strategies within the app and communicate with each other or their facilitator guide using voice or text.
62297846|NCT04948996|ACTIVE_COMPARATOR|El Buen Consejo Móvil- Individual (EBCM-I)|Participants randomized to EBCM-I will receive the same program contents without the group functionality.
62667735|NCT01640561|EXPERIMENTAL|MISC|The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein (consultant) has been used to enhance the development of children throughout the developing world, with the support of such international aid agencies as the World Health Organization (WHO), UNICEF, Norwegian Agency for Development Cooperation (NORAD), and Redd Barna (Norway).
62667736|NCT01640561|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|
61913317|NCT01768884|EXPERIMENTAL|Nitric oxide inhalation + standard treatment|Inhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
61913318|NCT01768884|PLACEBO_COMPARATOR|Standard treatment|Standard treatment
61913319|NCT01492543|EXPERIMENTAL|Aiyi®|Tegafur Gimeracil Oteracil Potassium Capsule
62105580|NCT05905406|EXPERIMENTAL|S20|The Hip will be positioned at 80°, and knee positioned 20°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
61913320|NCT05616689|EXPERIMENTAL|Bundled hyperpolypharmacy intervention|Eligible participants with physician authorization who are randomly assigned to intervention
61913321|NCT05616689|NO_INTERVENTION|Control|Eligible participants with physician authorization who are randomly assigned to usual care
61913322|NCT04591860|ACTIVE_COMPARATOR|Sutures only|"Patients with a large hiatal hernia undergo the cruroplasty with sutures only.~A large hiatal hernia is defined as \> 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
62105581|NCT05905406|EXPERIMENTAL|D60|The Hip will be positioned at 0°, and knee positioned 60°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
62297847|NCT00482963|EXPERIMENTAL|levonorgestrel, efavirenz|healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz
62667737|NCT02487485|EXPERIMENTAL|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
61913323|NCT04591860|ACTIVE_COMPARATOR|Absorbable Mesh|"Patients with a large hiatal hernia undergo the cruroplasty with mesh implantation.~A large hiatal hernia is defined as \> 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
61913324|NCT04591860|ACTIVE_COMPARATOR|Pledgeted sutures|"Patients with a large hiatal hernia undergo the cruroplasty with pledgeted sutures.~A large hiatal hernia is defined as \> 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
61913325|NCT00212017|ACTIVE_COMPARATOR|the voglibose group|Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.
61913326|NCT00212017|ACTIVE_COMPARATOR|the control group|Participants assigned to the control group were treated only with diet and exercise therapy.
62468992|NCT04967794|ACTIVE_COMPARATOR|Group Vídeo for Health|You will receive a standardized brushing Teleorientation consultation through the V4H Platform, created specifically for Teleconsultations
62667738|NCT02487485|PLACEBO_COMPARATOR|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
62667739|NCT01993758|ACTIVE_COMPARATOR|Conventional tourniquet pressure|The patients in this group will undertake total knee arthroplasty under conventional tourniquet pressure, which will be set as the pressure added by 150mmHg on the last systolic blood pressure just before tourniquet inflation.
62667740|NCT01993758|EXPERIMENTAL|Low tourniquet pressure|The patients in this group will undertake total knee arthroplasty under low tourniquet pressure, which will be set as the pressure added by 120mmHg on the last systolic blood pressure just before tourniquet inflation.
62667741|NCT06532916|EXPERIMENTAL|Group1|
61913327|NCT00871507|EXPERIMENTAL|001|
61913328|NCT00871507|EXPERIMENTAL|002|
62468993|NCT04967794|ACTIVE_COMPARATOR|Group de Orientação presencial|You will receive a standardized face-to-face brushing orientation consultation.
62468994|NCT01312415|EXPERIMENTAL|levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine (17.5 or 15 mg) without morphine, and will receive peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% at 8am the following morning.
62667742|NCT06532916|EXPERIMENTAL|Group 2|
62667743|NCT04230239|EXPERIMENTAL|CPX-351|
61913329|NCT00871507|PLACEBO_COMPARATOR|003|
61913330|NCT00871507|ACTIVE_COMPARATOR|004|
61913331|NCT04355728|EXPERIMENTAL|UC-MSCs Group|Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
61913332|NCT04355728|PLACEBO_COMPARATOR|Control Group|Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
62667744|NCT06283875||Surgical treatment queue (N=40)|Cervical cancer patients who meet the inclusion criteria and are eligible for radical surgical resection. Collect surgical tumor tissue samples from the screening stage of patients in this queue, as well as peripheral blood samples (20 ml/time) from baseline, postoperative, postoperative radiotherapy and chemotherapy end nodes, consolidation treatment end nodes (some patients with this treatment), and multiple nodes during the 6-month follow-up stage. Perform ctDNA MRD testing in a timely manner separately
61913333|NCT02739633|EXPERIMENTAL|Genexol-PM + Gemcitabine|Genexol-PM125 mg/m2 will be administered in combination with gemcitabine 1,000 mg/m2 weekly for 3 weeks followed by one week of rest. Each cycle is 28 days.
62105582|NCT05905406|EXPERIMENTAL|D20|The Hip will be positioned at 0°, and knee positioned 20°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
62105583|NCT04097899||Group A in preimplementation phase|Patient and antibiotic related data were collected to calculate and define; ventilator associated pneumonia incidence, mean ventilation days and mean length of stay, antibiotic selection, antibiotic cost, antibiotic susceptibility pattern, antibiotic consumption.
62105584|NCT04097899||Group B in postimplementation phase|The appropriateness of antibiotic use (selection, initiation, duration \& time of discontinuation) before and after implementing the educational program was compared, calculation of the change in the ventilator associated pneumonia incidence \& length of ICU stay, calculation of the change in the rate of antibiotic resistance and calculation of the cost change of antibiotics used after implementing the educational program.
62105585|NCT04989322|EXPERIMENTAL|Treatment|
62105586|NCT04282902|EXPERIMENTAL|Pirfenidone group|This study was designed to randomize approximately 147 adult subjects.The patients were stratified according to whether the onset time was less than 14 days, and randomly divided into groups at a ratio of 1:1. The group received pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer.
62105587|NCT04282902|NO_INTERVENTION|Standard treatment group|This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤ 14 days and randomly divided into groups of 1: 1. This group only receives standard treatment
62105588|NCT01348087|EXPERIMENTAL|AFQ056 100 mg (Bid)|All patients initiated treatment with AFQ056 at a starting dose of 25 milligram (mg) twice daily. The dose was titrated from 25mg bid to 50mg bid, 75mg bid and 100mg bid at weekly intervals. Dose adjustments (up- and down titrations) were permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose not to exceed 100mg bid.
62105589|NCT06047821||Children with Shigella Diarrhea|Children with Shigella identified by culture or quantitative PCR
62468995|NCT01312415|OTHER|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
61913334|NCT00369629|EXPERIMENTAL|Cohort 1|"Pemetrexed at a dose of 400 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
61913335|NCT00369629|EXPERIMENTAL|Cohort 2|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
61913336|NCT00369629|EXPERIMENTAL|Cohort 3|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1000 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
61913337|NCT00369629|EXPERIMENTAL|Cohort 4|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1200 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
61913338|NCT00729391|EXPERIMENTAL|1|Women's CoOp
61913339|NCT00729391|ACTIVE_COMPARATOR|2|Nutrition (Attention-Control)
62468996|NCT00401089|EXPERIMENTAL|Ginsana-115|Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
61913340|NCT00729391|ACTIVE_COMPARATOR|3|Voluntary Counseling and Testing
61913341|NCT04551313|EXPERIMENTAL|social skill training group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
61913342|NCT04551313|ACTIVE_COMPARATOR|control group|Regular therapy
61913343|NCT05677672|EXPERIMENTAL|Human TH-SC01 cell injection|Human TH-SC01 Cell Injection is a human expanded umbilical cord mesenchymal stem cells suspension
61913344|NCT05677672|PLACEBO_COMPARATOR|Placebo-control group|Saline solution
62105590|NCT06047821||Children without Shigella Diarrhea|Children without Shigella identified by culture or quantitative PCR
62105591|NCT01019616|EXPERIMENTAL|Chemotherapy|
62105592|NCT01019616|NO_INTERVENTION|Control|
62105593|NCT06629792|EXPERIMENTAL|Topical Treatment|Subjects received a topical facial treatment applied by a license esthetician in a series of 3 sessions at 1 month intervals, in combination with a cleanser, moisturizer, and sunscreen over the course of 12 weeks.
62105594|NCT00802919|EXPERIMENTAL|Varenicline|Varenciline 1-2 mg/day
62105595|NCT00802919|PLACEBO_COMPARATOR|Matched Placebo|placebo for varenicline
62105596|NCT01540929||Study Group|DoD Smallpox Screening Form 600 (2 part format)
61913345|NCT02593071|EXPERIMENTAL|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
61913346|NCT02593071|PLACEBO_COMPARATOR|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
61913347|NCT01556347|EXPERIMENTAL|Elimination of Immunologic Memory|A single arm multi-drug regimen is used to delete immunologic memory in order to reduce or eliminate alloreactive anti-HLA antibodies in highly sensitized heart transplant candidates. The intervention includes a protocol of Thymoglobulin, Rituximab, plasmapheresis and Bortezomib.
62105597|NCT01730274||patients|children operated on a cerebellar tumor
62105598|NCT01730274||healthy subjects|healthy volunteers
62105599|NCT02775981|EXPERIMENTAL|Active|RX0041-002
62105600|NCT05868226|EXPERIMENTAL|PRE1 ALX148 (Evorpacept) + Fam-Trastuzumab Deruxtecan-Nxki (T-DXd, Enhertu®)|The combination of T-DXd and ALX148 aims to explore the anti-tumoral effects of trastuzumab, of the topoisomerase inhibitor DXd and of the CD47-blocking agent ALX148. The rationale for this combination is that ALX148 is hypothesized, based on preclinical data, to facilitate antibody-dependent cellular phagocytosis (ADCP) of HER2 expressing (\>HER2 1+) breast cancer binding T-DXd while cancer cell intrinsic or bystander cytotoxicity of T-DXd will result in the release of neoantigens promoting immune mediated antitumor activity in the tumor microenvironment.
62297848|NCT03171922|EXPERIMENTAL|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
61913348|NCT01823588|NO_INTERVENTION|Usual care|Educational program and usual cardiovascular prevention.
61913349|NCT01823588|EXPERIMENTAL|Nurse-led reminder through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse-care manager (NCM)
61913350|NCT03235635||Preterm|newborn infants were born with a gestational age of less than 32 weeks
61913351|NCT03235635||Late preterm|newborn infants were born with a gestational age of greater than 32 weeks and less than 36 weeks
61913352|NCT03235635||full-term|newborn infants were born with a gestational age of greater than or equal to 37 weeks
62297849|NCT03171922|EXPERIMENTAL|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
61913353|NCT03812627|EXPERIMENTAL|Re-intervention of hip prosthesis made of ceramic or metal|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis with friction couples of: ceramic-on-ceramic or metal-on-metal~(25 patients by group)"
61913354|NCT03812627|EXPERIMENTAL|Re-intervention of hip prosthesis of stainless steel ball|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis of stainless steel ball."
61913355|NCT03812627|EXPERIMENTAL|Re-intervention of knee prosthesis|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 inpatient subjects for re-intervention of knee prosthesis polyethylene-on-metal."
61913356|NCT03812627|EXPERIMENTAL|Dead patients IMD holders autopsied|Autopsy: 80 dead patients IMD holders will be autopsied.
61913357|NCT03812627|ACTIVE_COMPARATOR|Dead patients non-IMD holders autopsied|Autopsy: dead patients non-IMD holders autopsied, 30 subjects in this arm.
61913358|NCT03812627|ACTIVE_COMPARATOR|patients before first prosthesis surgery|Before the initial prosthesis surgery: 30 patients Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections will be done
61913359|NCT02385227|EXPERIMENTAL|Cohort A1|Exclusive blu™ e-cigarette A1
62667745|NCT06283875||Radical radiotherapy and chemotherapy treatment cohort (N=40)|Cervical cancer patients who meet the inclusion criteria and are eligible for radical radiotherapy and chemotherapy. Collect baseline tumor tissue samples from patients during the screening phase, as well as peripheral blood samples (20 ml/time) from multiple nodes at baseline, mid-term of curative radiotherapy and chemotherapy, after curative radiotherapy and chemotherapy, after consolidation therapy (if any), and at 6 months/time during the follow-up phase. Perform ctDNA MRD testing in a timely manner separately
61913360|NCT02385227|EXPERIMENTAL|Cohort A2|Exclusive blu™ e-cigarette A2
61913361|NCT02385227|EXPERIMENTAL|Cohort A3|Exclusive blu™ e-cigarette A3
62297850|NCT02780791|ACTIVE_COMPARATOR|Transplantation into pelvic wall|Ovarian transplantation into the pelvic wall after cryopreservation of ovarian tissue before cytotoxic therapies
62297851|NCT02780791|ACTIVE_COMPARATOR|Transplantation into the ovary|Ovarian transplantation into ovary after cryopreservation of ovarian tissue before cytotoxic therapies
62297852|NCT00613626|PLACEBO_COMPARATOR|Arm A: ZD6474 Matched Placebo|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
62297853|NCT00613626|ACTIVE_COMPARATOR|Arm B: ZD6474|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
62297854|NCT00613626|EXPERIMENTAL|Safety Lead-In|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator. The safety lead-in will be conducted to determine the safety of the combination of ZD6474 and cisplation + etopiside. If this combination is found to be unsafe, no patients will be randomized in the Phase II portion of the trial. If the combination is deemed safe according to the protocol, participants from the safety lead-in cohort will not be included in the efficacy analysis.
62667746|NCT04808453|EXPERIMENTAL|CPI-300|Dose Escalation Group: CPI-300 will be administered via intravenous infusion once every 2 weeks for up to 6 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design
62667747|NCT03443544||Intestinal origin|Either perianal abcess or rectal carcinoma
62297855|NCT05731960|EXPERIMENTAL|Dexamethasone (Group SD)|10 mg IV dexamethasone x1
62667748|NCT03443544||Testicular Origin|Complicated epididymitis with fascitis,
61913362|NCT02385227|EXPERIMENTAL|Cohort B1|Dual blu™ e-cigarette and usual brand B1
61913363|NCT02385227|EXPERIMENTAL|Cohort B2|Dual blu™ e-cigarette and usual brand B2
61913364|NCT02385227|EXPERIMENTAL|Cohort B3|Dual blu™ e-cigarette and usual brand B3
61913365|NCT02385227|EXPERIMENTAL|Cohort C|Nicotine product cessation C
62667749|NCT03443544||Urinary Origin|From urinary tract infection or fistulae from urethral trauma
62667750|NCT03443544||Cutaneous Origin|mostly folliculitis, and skin infections
62105601|NCT05868226|EXPERIMENTAL|PRE2 Zanidatamab (ZW25, zani) + Tucatinib (TUKYSA®)|"Zanidatamab is a bispecific IgG1-like antibody directed against two distinct HER2 epitopes. It induces formation of receptor clusters and internalization resulting in downregulation. It also inhibits growth factor-dependent and -independent tumor cell proliferation as well as potently activating ADCC, ADCP, and CDC.~Tucatinib is a highly selective, small molecule tyrosine kinase inhibitor (TKI) of HER2 compared to other TKI's (i.e., EGFR). It is well tolerated, crosses the blood brain barrier and can treat CNS disease. It is FDA approved for HER2+ breast cancer.~Given the promising clinical data for each of these drugs which have different mechanisms, the effect of zanidatamab after T-DXd (Enhertu®) in breast cancer patients, and the favorable toxicity profile of both drugs, we hypothesize that the combination of tucatinib and zanidatamab will be well tolerated and more efficacious than either drug alone for the treatment of patients with HER2 positive breast cancer."
62105602|NCT01178242|EXPERIMENTAL|Salivary Gland and Labial Mucous Membrane Transplantation|
62667751|NCT05501405|EXPERIMENTAL|Schizophrenic patients|Electroencephalogram and eye-tracking recordings Behavorial tests
62667752|NCT05501405|EXPERIMENTAL|Autism Spectrum Disorder (ASD) patients|Electroencephalogram and eye-tracking recordings
61913366|NCT00245219|NO_INTERVENTION|Health Tracking (control)|Participants assigned to the health-tracking condition received usual care and did not attend any meetings.
61913367|NCT00245219|EXPERIMENTAL|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
62667753|NCT05501405|EXPERIMENTAL|22q11.2 DS patients|Electroencephalogram and eye-tracking recordings Behavorial tests
62667754|NCT05501405|EXPERIMENTAL|Williams syndrome patients|Electroencephalogram and eye-tracking recordings Behavorial tests
62667755|NCT05501405|EXPERIMENTAL|Präder Willi syndrome patients|Electroencephalogram and eye-tracking recordings Behavorial tests
62667756|NCT05501405|ACTIVE_COMPARATOR|Control participants|Electroencephalogram and eye-tracking recordings Behavorial tests
62667757|NCT05708378|EXPERIMENTAL|Rocker board training|"Stretching Exercises (Heel drop, heel raises, Hamstring stretch, quad stretch, half kneel, IT band stretch, half squats). Hold the stretch for 20 seconds and repeat 10 times.~Isometric Strengthening Exercises of calves, hamstrings, quads, hip flexors, gluteus, dorsiflexors and plantarflexors. Hold for 20 seconds and repeat 10 times.~Pelvic Bridging Exercises. Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between."
62667758|NCT05708378|OTHER|Stable surface training|"Stretching Exercises (Heel drop, heel raises, Hamstring stretch, quad stretch, half kneel, IT band stretch, half squats). Hold the stretch for 20 seconds and repeat 10 times.~Strengthening Exercises calves, hamstrings, quads, hip flexors, gluteus, dorsiflexors and plantarflexors. Hold for 20 seconds and repeat 10 times.~Pelvic Bridging Exercises. Trunk balance exercise (flexion, extension of lower and upper trunk, rotation of lower and upper trunk, forward and lateral reach) on plain surface."
62105603|NCT04392635|EXPERIMENTAL|TauTona Pneumoperitoneum Assist Device (TPAD)|Participants will receive investigational TPAD device during laparoscopic surgery. The TPAD was used to aid Veress needle insertion in place of surgical tools such as clamps. The TPAD was applied to the patient prior to Veress needle entry and removed after insufflation was completed.
62297856|NCT05731960|ACTIVE_COMPARATOR|Metoclopramide (Group SM)|10 mg IV metoclopramide x1
62297857|NCT03884075|EXPERIMENTAL|Arm A: Steatosis|Participants with steatosis on baseline biopsy
62667759|NCT00745160||1|Never-smokers with lung cancer
62667760|NCT02301091|EXPERIMENTAL|TACE-RFA|2 times TACE first, RFA for residual viable tumors and PVTT within 1 month.
62667761|NCT02301091|ACTIVE_COMPARATOR|TACE alone|repeated TACE and 1 to 2 months interval between two sessions of TACE.
62667762|NCT04041518|OTHER|Intervention|Autotransplantation and intra-operative extraoral apicoectomy of a permanent tooth.
62667763|NCT01192698|EXPERIMENTAL|IV interferon|IV interferon oral ribavirin
62667764|NCT01192698|NO_INTERVENTION|Standard of care|standard of care
62297858|NCT03884075|EXPERIMENTAL|Arm B: NASH|Participants with NASH on baseline biopsy
62667765|NCT00968968|EXPERIMENTAL|Arm 1: Lapatinib plus Trastuzumab|
62667766|NCT00968968|ACTIVE_COMPARATOR|Arm 2: Trastuzumab|
62667767|NCT04856618||Massive Transfusion Positive|Massive Transfusion Positive
62667768|NCT04856618||Massive Transfusion Negative|Massive Transfusion Negative
62297859|NCT03884075|NO_INTERVENTION|Arm C: Healthy|Healthy Volunteers
62297860|NCT05634499|EXPERIMENTAL|Giredestrant|
62297861|NCT02945982|PLACEBO_COMPARATOR|Entecavir/Carvedilol|Tablet with Entrcavir and Carvedilol
62297862|NCT02945982|EXPERIMENTAL|Entecavir/Carvedilol/ Fuzheng Huayu|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
62297863|NCT04628507||Patients undergoing IVF|
62297864|NCT04386889|OTHER|SLE Vasculitis|20 SLE Female patients will subjected to study of the all vasculitic pattern that may occur.
62105604|NCT04392635|PLACEBO_COMPARATOR|Standard of Care (SOC)|Participants will receive SOC included both direct (unassisted) entry and assisted entry using clamps, if needed, to aid in Veress needle insertion. Upon confirmation that the Veresss needle was in the correct location (e.g. drop test), insufflation was initiated.
62105605|NCT03503773|EXPERIMENTAL|Treatment Arm:|Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
62105606|NCT03503773|SHAM_COMPARATOR|Sham Control Arm|Only renal angiography performed
62105607|NCT02317705|EXPERIMENTAL|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
62105608|NCT04539951|ACTIVE_COMPARATOR|serotonin treatment|In experimental phase I, all recruited subjects provide written informed consent before any related procedures. Participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
62105609|NCT04539951|ACTIVE_COMPARATOR|sequenced treatment alternatives|If participants in In Experimental phase I do not achieve remission, they will be will be randomly assigned to the second-step treatment (Experimental phase II). The second-step therapy will consist of five treatment options including higher-than-usual-maximal dosage of sertraline, switching to fluvoxamine, switching to venlafaxine, augmentation with memantine, and augmentation with aripiprazole.
62105610|NCT02279342|NO_INTERVENTION|Non febuxostat treatment group|No febuxostat treatment
62667769|NCT05007444|PLACEBO_COMPARATOR|Placebo comparator|Patients in the placebo group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
62297865|NCT01948752|NO_INTERVENTION|Menu - no nutrition information (control)|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included a normal menu with no nutrition information."
62105611|NCT02279342|EXPERIMENTAL|Febuxostat treatment group|once daily after breakfast
62105612|NCT05753852|EXPERIMENTAL|Active treatment|
62105613|NCT02063607|ACTIVE_COMPARATOR|Peginterferon alfa 2a|Peginterferon alfa 2a 180 mcg
62105614|NCT02063607|EXPERIMENTAL|Peginterferon Lambda|Peginterferon Lambda 60,120,180 and 240 mcg
62105615|NCT01506843|ACTIVE_COMPARATOR|mite allergen drop|Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.
62105616|NCT01506843|ACTIVE_COMPARATOR|mite plus bacterial extracts|Vaccine constituted with mite and bacterial extracts will be compared to placebo.
62105617|NCT01506843|PLACEBO_COMPARATOR|Placebo|Placebo will be constituted by the same solution used to make dilution of the allergen extracts.
62297866|NCT01948752|EXPERIMENTAL|Calorie labels|Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with the calorie amounts displayed.
62297867|NCT01948752|EXPERIMENTAL|Calorie Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts in green/amber/red traffic lights to signify low/medium/high amounts."
62297868|NCT01948752|EXPERIMENTAL|Multi-Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts as well as sodium, fat, and sugar amounts in green/amber/red traffic lights to signify low/medium/high amounts."
62105618|NCT06064032|ACTIVE_COMPARATOR|cognitive behvioral therapy|The subjects in the control group will be given a 10 minute session of Progressive Muscle Relaxation (PMR) 2 minutes deep breathing exercises and 3 minutes training for life style modification which includes the use of planners, setting alarms, breaking a difficult task into parts, positive reinforcement and communication. This would be taught for 15 days at one day interval.
62105619|NCT06064032|EXPERIMENTAL|motor learning techniques|"The subjects in the experimental group will be given a 10 minute session of Progressive Muscle Relaxation (PMR), 2 minutes deep breathing exercises,3 minutes training for life style modification which includes the use of planners, setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with a 3 minute session of drawing a specific pattern with installing pegs on pegboard, 2 minutes session of balance board training, 3 min session of solving jigsaw puzzles, 1 minute session of squeezing a ball with maximum repetition and 1 minute session of finding beads in puttey.~This would be taught for 15 days at one day interval."
62105620|NCT02533167|EXPERIMENTAL|skin to skin|skin to skin initiated on all consented CS while in the operating room
62105621|NCT00370448|EXPERIMENTAL|1|Training gatekeeper recruited from students and tutors and counselors
62105622|NCT00370448|ACTIVE_COMPARATOR|2|
62105623|NCT00370448|NO_INTERVENTION|3|
62105624|NCT06475599|EXPERIMENTAL|Anlotinib hydrochloride capsules + TQB2450 injection|"Anlotinib hydrochloride capsule: 12 mg each time, once a day, oral administration before breakfast, continuous oral administration for 2 weeks and stop for 1 week.~TQB2450 injection: 1200mg/ time, once every 3 weeks, diluted to 250 mL with normal saline, infusion time was 60±10 minute."
62297869|NCT05239104||Children aged 1 month - 14 years 11 months with a severe illness/injury|"Children aged 1 month - 14 years 11 months presenting to hospital with symptoms of an acute severe illness/injury that started within the last 2 weeks. Severe defined as a child showing emergency signs or requiring hospital admission for treatment."
62667770|NCT05007444|ACTIVE_COMPARATOR|Active comparator P2Et|Patients in the P2Et group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
62667771|NCT00852982|EXPERIMENTAL|Exercise|Five hours of Nordic walking per week, during four months
62667772|NCT00852982|NO_INTERVENTION|Control|Control group asked not to alter lifestyle during study
62105625|NCT06475599|ACTIVE_COMPARATOR|Chemotherapy drug|"Based on each patient's condition and previous treatment history, the investigator will select one of the following chemotherapy drugs for treatment.~Paclitaxel: dose of 175 mg /㎡, Day 1, every 4 weeks (Q4W). Albumin-bound paclitaxel: dose of 125 mg /㎡, Day 1, Day 8, Day 15, every 4 weeks (Q4W).~Doxorubicin: dose 60mg/m ², Day1, every 3 weeks (Q3W). Doxorubicin liposome: dose 40mg/ m ²,Day 1, every 4 weeks (Q4W)."
62105626|NCT06619639|NO_INTERVENTION|Usual programming control (implement beyond 3:30 programming as usual)|Groups assigned to the usual programming control arm will deliver regular beyond 3:30 programming.
62105627|NCT06619639|EXPERIMENTAL|Social-emotional learning curriculum|The intervention is the EMPOWER social-emotional learning curriculum.
62297870|NCT03871907|ACTIVE_COMPARATOR|Digital technology|standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week
62297871|NCT03871907|NO_INTERVENTION|Control|standard cardiac rehabilitation program
62105628|NCT00535197|EXPERIMENTAL|CD34+ stem/progenitor cell therapy|Patients presenting within 7 days of onset with severe anterior circulation ischemic stroke (National Institutes of Health Stroke Scale \[NIHSS\] score≥8). CD34+ cells were collected from the bone marrow of the subjects before being delivered by catheter angiography into the ipsilesional middle cerebral artery.
62297872|NCT03943329|ACTIVE_COMPARATOR|Standard of Care|
62297873|NCT03943329|EXPERIMENTAL|Distal Targeting Treatment|
62297874|NCT04398732||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.
62297875|NCT04398901||Colombia ZIKV-exposed|Seventy children in Colombia were previously enrolled as part of a fetal-neonatal neuroimaging study in 2016-2017 and were from Department of Atlantico, Colombia on the Caribbean coast. Eligible children had prior normal fetal MRI and fetal US, normal birth head circumference, normal clinical exam, no more than mild non-specific postnatal imaging findings, and are thus without findings of CZS.
62667773|NCT05409638|EXPERIMENTAL|CBT intervention for cancer-related fatigue|Participants will receive 4 weekly sessions consisting of psycho-education around fatigue, pacing, journaling fatigue, relaxation training, CBT, and evidence-based tips to increase physical activity.
62667774|NCT05409638|NO_INTERVENTION|Wait-list control group|Participants assigned to this arm wait about 3-months to receive the intervention.
62667775|NCT03097315|EXPERIMENTAL|4 mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA
62667776|NCT00311168|EXPERIMENTAL|VIP On, Then VIP Off|Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.
62105629|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
62105630|NCT06285175|EXPERIMENTAL|Tele-REINVENT|All participants in this study are asked to use tele-REINVENT, a 6 week home tele-rehab program with EMG biofeedback.
62105631|NCT04878341|EXPERIMENTAL|Erector Spinae plane Block|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and the transverse process of T5-T7 vertebrae and Erector Spinae (ES) fascia will be located with a linear ultrasound probe. A 19G or 20G epidural needle (according to age) will be positioned under the ES muscle and a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered; after hydrodissection, the catheter will be threaded, followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
62105632|NCT04878341|ACTIVE_COMPARATOR|Thoracic Epidural Anesthesia|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and a 19G or 20G epidural needle (according to age) will be positioned at T5-T7 level with cathether placement; a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered and followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
62105633|NCT01981356|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT condition will be provided with the opportunity to attend 4 ACT sessions. The treatment protocol is adapted from and virtually identical to that presented in Gaudiano and Herbert (2006). Each ACT session will serve as a standalone session, with all essential elements of the treatment briefly presented. Participants in the ACT condition will also receive treatment as usual.
62105634|NCT01981356|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU consists of psychopharmacology, case management, and psychotherapy. Additionally, patients randomized to the TAU condition will meet with ACT facilitators for 15 minutes every other day to provide additional support and answer questions, while ensuring not to discuss or suggest the use of therapeutic techniques related to ACT.
62105635|NCT06357572||Hemophilia A patients prophylactically treated with FEIBA|
62105636|NCT03690856|EXPERIMENTAL|depressiv people|
62667777|NCT00311168|EXPERIMENTAL|VIP Off, Then VIP On|Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.
62667778|NCT06153121||Adult tennis players|tennis players between the age of 18 and 35
62667779|NCT06153121||Adult swimmers|swimmers between the age of 18 and 35
62667780|NCT06153121||Adolescent tennis players|tennis players between the age of 12 and 18
62105637|NCT05527483||[F-18]NaF|Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
62105638|NCT05527483||[Ga-68]PSMA|Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
62105639|NCT05903482||Diabetic, in GLP-1 RA|non-invasive, gastric ultrasound in children who are on GLP-1 RA medications and have type 2 diabetes mellitis (DM) and/or obesity and/or type 1 DM
62105640|NCT05903482||Diabetic, not on GLP-1 RA|non-invasive, gastric ultrasound in children who are not on GLP-1 RA medications and have type 2 diabetes mellitis (DM) and/or obesity and/or type 1 DM.
62105641|NCT05903482||Non-diabetic, not on GLP-1 RA|non-invasive, gastric ultrasound in non-diabetic children who are not on GLP-1 RA medications and do not have diabetes or obesity.
62105642|NCT05159141|NO_INTERVENTION|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
62297876|NCT04398901||Colombia Non-ZIKV exposed control|The investigators will enroll 70 non-ZIKV exposed children, age 4 to 5 years, in Department of Atlántico, Colombia with birth dates prior to March 31, 2016. Based on the arrival of ZIKV to Colombia in November 2015, this date would ensure a control cohort without congenital ZIKV exposure in the first half of gestation and unlikely during any of the pregnancy.
62667781|NCT06153121||Adolescent swimmers|swimmers between the age of 12 and 18
62667782|NCT06075290||Observation group|Intelligent jaundice instrument and Internet plus system for home monitoring and remote follow-up
62667783|NCT06075290||control group|follow-up by conventional methods ； hospital or community follow-up depending on arrangement
62667784|NCT01721239|NO_INTERVENTION|Control group|No intervention
62667785|NCT01721239|EXPERIMENTAL|Standardized Followup program|Standardized written information, patient photos and three follow-up consultations.
62667786|NCT02962557|NO_INTERVENTION|Control|The control group will receive no prompts by the recorded voice.
62667787|NCT02962557|EXPERIMENTAL|Experimental|The experimental group will receive playback of recorded verbal prompts to breathe with an optional shoulder shake.
62105643|NCT05159141|EXPERIMENTAL|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
62297877|NCT04398901||United States ZIKV-exposed|The US cohort either presented during pregnancy or after birth and sought clinical care with the Children's National Congenital Zika Program in Washington, DC and were ZIKV-exposed.
62667788|NCT01010620||Screening|Screening Assessment battery. Specific to study(or studies) the individual is screening for.
62297878|NCT04398901||United States Non-ZIKV exposed control|The investigators will enroll 32 non-ZIKV exposed children, age 4 years, in Washington, DC.
62297879|NCT05749731||post-COVID-19 patients in geriatric rehabilitation|Patients in European geriatric rehabilitation departments as the result of COVID-19 disease.
62667789|NCT01137812|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
62667790|NCT01137812|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
62667791|NCT01774370||Pradaxa group|
62667792|NCT05649774|ACTIVE_COMPARATOR|Myofascial Release (MFR)|The therapist will place its hands on the T12-L1 levels as well as on the sacrum. A cross handed hold will be performed along the fascia. Then for the gluteus Medius and maximus muscle, the therapist will stand facing the participant's leg and closed to the superior border of participant's pelvis. The therapist will place the palm of the hand on the anterior surface, allowing the fingers to rest on the outer fibers of the gluteal muscles stabilizing the pelvis of the participants. Allow the participant to flex its knee while applying adequate amount of stretch on the hip joint in an open pack position. Hold, wait for the release and stretch again. for tensor fascia Latae, The therapist will place several slightly adducted fingers of its one hand on the superior fibers proximal to the insertion on the anterior superior iliac crest and the thumb as well as the other fingers of the other hand on the distal muscle fibers. Hold, wait for the release and stretch again.
62105644|NCT06393569||Access to Specialized palliative outpatient clinic|Patients who have had access to specialized palliative outpatient clinic before admitted to ASiH
62105645|NCT02750397||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
62105646|NCT02750397||HIV D-/R+|HIV+ recipients who receive an organ transplant from an HIV- donor
62105647|NCT04950751|EXPERIMENTAL|SCB-2020S Standard Dose|Day 1 and 22: standard dose SCB-2020S with CpG 1018/alum adjuvant
62105648|NCT04950751|EXPERIMENTAL|SCB-2020S Low Antigen Dose|Day 1 and 22: low dose SCB-2020S with CpG 1018/alum adjuvant
62105649|NCT04950751|EXPERIMENTAL|SCB-2020S Low Adjuvant Dose|Day 1 and 22: standard dose SCB-2020S with low dose CpG 1018/alum adjuvant
62105650|NCT04950751|EXPERIMENTAL|SCB-2020S Mixed Series|Day 1 (Dose 1) standard dose SCB-2020S with CpG 1018/alum adjuvant and Day 22 Dose 2) standard dose SCB-2020S with alum adjuvant
62297880|NCT02978222|EXPERIMENTAL|FRα peptide plus adjuvant (GM-CSF)|FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
62297881|NCT02978222|PLACEBO_COMPARATOR|Adjuvant (GM-CSF) Alone|GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
62297882|NCT04288024|EXPERIMENTAL|Postural|During training, participants in this group are instructed to focus on their posture during weight-shifting.
62105651|NCT04950751|ACTIVE_COMPARATOR|SCB-2019|Day 1 and 22: standard dose SCB-2019 with CpG 1018/alum adjuvant
62105652|NCT03425539|EXPERIMENTAL|Lucerastat|
62105653|NCT03425539|PLACEBO_COMPARATOR|Placebo|
62105654|NCT05187767||Malignant GGOs|Patients with histologically proven malignant pulmonary ground glass opacities (GGOs)
62297883|NCT04288024|EXPERIMENTAL|Suprapostural|During training, participants in this group are instructed to focus on their suprapostural task during weight-shifting.
62297884|NCT00538642|NO_INTERVENTION|Stay on current antipsychotic|Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated.
62667793|NCT05649774|ACTIVE_COMPARATOR|Kinesio Taping (KT)|"Lumbar star correction technique was applied. 4 tape I strips will be cut. The paper from the center will be torn. The targeted area will be stretched as tolerated at the lumbar region. The therapist will apply 25% to 35% tension to the strip within the therapeutic zone over the target tissue. End the strip with no tension and activate the adhesive. For the second strip change the posture in order to change the stretch on the tissue, apply the second strip with 25% to 35% tension in the center of the tape and end with no tension. Activate the adhesive. Now flex the trunk and rotate on one side. Apply the third tape strip with 25% to 35% tension in the center of the tape. Apply the fourth tape strip with flexion and rotation on the opposite side again with 25% to 35% tension on the strip.~The tape will be changed 3 times per week."
62667794|NCT05649774|EXPERIMENTAL|Myofascial Release with Taping (MFKT)|Same Protocol of MFR followed by KT
62667795|NCT05649774|SHAM_COMPARATOR|Placebo Treatment|The control group received a sham myofascial release for 40 minutes per treatment session, three times a week for three weeks. The sham myofascial release was applied by gently placing the hands over the same areas treated in the MFR group,without sliding, just enough to maintain contact for the desired time.
62667796|NCT02038426|EXPERIMENTAL|the patients with SpA|
62667797|NCT02038426|EXPERIMENTAL|sports subjects|
62667798|NCT02038426|OTHER|control subjects|
62667799|NCT02346916|OTHER|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
62667800|NCT03447795|EXPERIMENTAL|autogenous tooth grafted sites|
62667801|NCT03447795|ACTIVE_COMPARATOR|autogenous demineralised dentin grafted sites|
62667802|NCT03096353|EXPERIMENTAL|Naloxone, then Placebo|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again."
62667803|NCT03096353|EXPERIMENTAL|Placebo, then Naloxone|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again."
62667804|NCT02980653|EXPERIMENTAL|Megestrol|Single arm
62667805|NCT05019053|EXPERIMENTAL|Coping Crew Intervention|Interested participants who meet the screening criteria will be assigned to receive COPING CREW. First, following informed consent, eligible participants will complete a baseline assessment appointment in the week prior to the group beginning. During the baseline appointment, participants will provide informed consent, be instructed in the use of Microsoft Teams, complete a battery of self-report measures, be given a semi-structured diagnostic interview, and follow instructions to install a mobile app that will be used to track their mood and homework. Then, 4 groups of COPING CREW, with 6 participants per group, will be run. Participants will complete four weekly 60-minute virtual intervention sessions followed by a booster session two weeks later. Participants will complete daily surveys and homework assignments on their mobile devices. Links to follow-up surveys will be sent to participants at 1- and 3-month follow-ups.
62667806|NCT01701648|ACTIVE_COMPARATOR|1|
62667807|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
62667808|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
62105655|NCT05187767||Benign GGOs|Patients with histologically or radiologically proven benign pulmonary ground glass opacities (GGOs)
62297885|NCT00538642|ACTIVE_COMPARATOR|ziprasidone treatment|Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.
62297886|NCT04007484|EXPERIMENTAL|HP+CPB/DHCA group|For patients randomized into the intervention group, a hemoperfusion device will be connected in series to the extracorporeal circulation machine in advance to ensure that every single patient will undergo continuous hemoperfusion from the beginning to the end of CPB.
62297887|NCT04007484|NO_INTERVENTION|CPB/DHCA group|For patients randomized into the CPB/DHCA group, no hemoperfusion device will be connect to the extracorporeal circulation machine. Patients will undergo CPB and DHCA without continuous hemoperfusion.
62468997|NCT00401089|PLACEBO_COMPARATOR|Sugar Pill|Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
62105656|NCT05585580|EXPERIMENTAL|Serplulimab, lenvatinib and paclitaxel/Paclitaxel for Injection (Albumin Bound)/Paclitaxel liposome|Patients will be treated with serplulimab combined with lenvatinib and paclitaxel/ Paclitaxel for Injection (Albumin Bound)/Paclitaxel liposomefor 6 cycles, followed by serplulimab combined with lenvatinib maintenance therapy until disease progression, intolerable adverse reactions, or withdrawal of treatment consent.
62105657|NCT06037681||Black cannabis users|African Americans that use cannabis at least once a week
62105658|NCT06037681||Black non-cannabis users|African Americans that do not use cannabis for at least 3 months prior to enrollment
62105659|NCT06037681||White cannabis users|Caucasians that use cannabis at least once a week
62105660|NCT06037681||White non-cannabis users|Caucasians that do not use cannabis for at least 3 month prior to enrollment
62105661|NCT06501079|ACTIVE_COMPARATOR|Normal saline|receiving erector spinae block with 27ml bupivacaine 0.25% + 3 ml NS
62105662|NCT06501079|ACTIVE_COMPARATOR|magnesium sulphate 10%|receiving erector spinae block with 27 ml bupivacaine 0.25% + 3 ml magnesium sulphate 10%
62105663|NCT06501079|ACTIVE_COMPARATOR|dexamethasone|receiving erector spinae block with 27 ml bupivacaine 0.25% + 8 mg dexamethasone (2 ml) + 1 ml NS.
62105664|NCT05165914|ACTIVE_COMPARATOR|Midazolam group|In the midazolam group, patients double blindly received 0.03 mg.kg-1 midazolam intravenously just before emergence from general anesthesia.
62105665|NCT05165914|PLACEBO_COMPARATOR|Placebo group|In the placebo group, patients double blindly received normal saline of similar volume to midazolam just before emergence from general anesthesia.
62105666|NCT04146818|EXPERIMENTAL|Adapted Tango Dancing arm|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months)
62105667|NCT04146818|PLACEBO_COMPARATOR|Control arm|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
62105668|NCT02540642|ACTIVE_COMPARATOR|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
62105669|NCT02540642|NO_INTERVENTION|antidiabetics|Only regular antidiabetic drugs will be given
62105670|NCT02760381|EXPERIMENTAL|Routine colonoscopy Cohort|Patients receiving routine colonoscopy receive the intervention: NBI + Acetic Acid (AA)
62105671|NCT01134419|EXPERIMENTAL|Computerized Handoff Tool plus training|Computerized handoff tool implemented together with team training for residents
62105672|NCT01134419|ACTIVE_COMPARATOR|Team training only|No computerized tool
62468998|NCT02767921|EXPERIMENTAL|Treatment (recombinant EphB4-HSA fusion protein, surgery)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
62105673|NCT01964859|EXPERIMENTAL|autologous skin fibroblasts|we are comparing 3 injection sites in the same individual
62105674|NCT05586451|OTHER|Resistance Trained|Resistance-trained individuals are considered those who report performing structured moderate to intense resistance exercise for at least three days per week for at least 2 years prior to study start.
62105675|NCT05586451|OTHER|Untrained|Untrained individuals are considered those that report less than two days per week of structured (\> 30 minutes) moderate to vigorous-intensity aerobic exercise and less than two days per week of structured resistance training for the 3 months prior to study start.
62105676|NCT04181931|EXPERIMENTAL|neo-TACE-HAIC with surgery|neoadjuvant TACE-HAIC with surgery for HCC patients with PVTT
62105677|NCT04181931|ACTIVE_COMPARATOR|surgery alone|surgery alone for HCC patients with PVTT
62105678|NCT02289560|EXPERIMENTAL|Transcranial ExAblate|Transcranial ExAblate
62105679|NCT06631807||Blind and severely visually impaired (BSI)|This group is composed of adults participants (ages of ≥ 18 and ≤ 85 years) with an impairment of the peripheral visual system (i.e., involving pre-chiasmatic structures, such as the retina and optic nerve). The visual deficit can be congenital (from birth) or have a late onset. Participants with visual impairment, classified according to the current diagnostic criteria, must have residual vision lower than 1.0 LogMAR. Participant of any gender and ethnicity are considered, provided they have a good knowledge of the Italian language.
62105680|NCT06631807||Control|Control group is composed of adult participants (without visual deficits) age and gender matched with the BSI group.
62105681|NCT04018417|EXPERIMENTAL|Amphotericin B|The eye bank will add amphotericin B 0.255 μg/mL to the Optisol-GS donor cornea storage solution.
62105682|NCT04018417|NO_INTERVENTION|Control|The donor cornea will be stored in Optisol-GS per the eye bank's standard procedure.
62105683|NCT06478043|EXPERIMENTAL|ivonescimab and irinotecan liposome|Subjects receive ivonescimab plus irinotecan liposome until progression.
62468999|NCT04184518|EXPERIMENTAL|Cediranib plus durvalumab|
62469000|NCT00749177|ACTIVE_COMPARATOR|2|Traditional Healing arm Provides Traditional Healing options only
62469001|NCT00749177|ACTIVE_COMPARATOR|3|Traditional Healing and usual standard of care arm Subjects will access both treatment options
62469002|NCT00749177|ACTIVE_COMPARATOR|1|Treatment as usual
62469003|NCT04198844||Warfarin user|
62105684|NCT02396979|EXPERIMENTAL|Methadone Maintenance|Methadone induction and management provided
62105685|NCT02396979|EXPERIMENTAL|Holistic Health Recovery Program|Administration of the Holistic Health Recovery Program (HHRP-M), which is an eight-session substance abuse relapse prevention and harm reduction program administered by a trained substance abuse counselor.
62297888|NCT00187590|EXPERIMENTAL|Intervention|Phone call after an ER visit.
62469004|NCT04198844||Apixaban user|
62469005|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
62469006|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
62469007|NCT04718506|EXPERIMENTAL|Exercise|Supervised exercise training
62105686|NCT02396979|EXPERIMENTAL|Methadone Maintenance and Holistic Health Recovery Prorgram|Methadone induction and management provided in combination with the Holistic Health Recovery Program (HHRP-M).
62105687|NCT02396979|NO_INTERVENTION|Standard of Care|Standard of care provided for substance abuse treatment. No methadone maintenance or holistic health recovery program intervention provided.
62105688|NCT00712166|PLACEBO_COMPARATOR|Placebo three times daily (TID)|
62297889|NCT00187590|NO_INTERVENTION|Control|No phone call after an ER visit.
62297890|NCT02811705||PFAPA group|Life quality for PFAPA patient report by themselves or parent
62297891|NCT02811705||FMF group|Life quality for FMF patient report by themselves or parent
62297892|NCT01088425||Spontaneous|Mothers with children conceived after spontaneous cycle
62297893|NCT01088425||Vitrificatíon|Mothers with children conceived after vitrification cycle
62297894|NCT01088425||slow- rate freezing|Mothers with children conceived after slow- rate freezing cycle
62469008|NCT04718506|EXPERIMENTAL|Inspiratory muscle training|Non-supervised inspiratory muscle training protocol
62469009|NCT04718506|ACTIVE_COMPARATOR|Controls|Non-supervised WHO exercise guidelines
62469010|NCT04928300|EXPERIMENTAL|Group D|Dexmedetomidine infusion IV for 5 days.
62469011|NCT04928300|EXPERIMENTAL|Group K|Ketamine infusion 2.5 µ/kg/min for 5 days.
62105689|NCT00712166|EXPERIMENTAL|AZLI 75 mg three times daily (TID)|
62105690|NCT01881919|EXPERIMENTAL|Treatment|Daily intake of Quercetin supplement 500mg tablet for 28 days with meal (breakfast preferred.)
62105691|NCT01881919|PLACEBO_COMPARATOR|Placebo|Daily intake of Placebo (lactose) tablet for 28 days with meal (breakfast preferred)
62469012|NCT04928300|PLACEBO_COMPARATOR|Group C|The same dose and duration of normal saline will be given.
62105692|NCT01483287|ACTIVE_COMPARATOR|Enzyme|Capsules with alpha-galactosidase (enzyme) (400 GaIU x 3) are ingested at breakfast, lunch and dinner.
62105693|NCT01483287|PLACEBO_COMPARATOR|Placebo|3 capsules with a non-active substance are ingested at breakfast, lunch and dinner
62297895|NCT01838135|NO_INTERVENTION|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
62297896|NCT01838135|EXPERIMENTAL|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
62297897|NCT05426148|EXPERIMENTAL|Bivalent HPV Vaccine Consistency Lot 1|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
62469013|NCT02942264|EXPERIMENTAL|Phase I Arm 1 Dose Dense Temozolomide plus Zotiraciclib (TG02)|dose dense (dd) Temozolomide (TMZ) 125 mg/m\^2 x 7 days on / 7 days off plus Zotiraciclib (TG02) dose escalation
62469014|NCT02942264|EXPERIMENTAL|Phase I Arm 2 Metronomic Temozolomide Plus Zotiraciclib (TG02)|metronomic Temozolomide (TMZ) 50 mg/ m\^2 daily plus Zotiraciclib (TG02) dose escalation
62469015|NCT02942264|EXPERIMENTAL|Phase II Arm 1 Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) Plus Temozolomide (TMZ)|"Maximum tolerated dose (MTD) of Zotiraciclib (TG02) from phase I plus and winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I"
62105694|NCT04266561|OTHER|lap. recurent inguinal hernia repair|After induction of general anesthesia, the patient was placed supine in Trendelenburg's position. Insertion of the main umbilical port. Laparoscopic hernia repair was done by intracorporeal insertion of purse string technique with some modifications
61913368|NCT00245219|EXPERIMENTAL|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
61913369|NCT01471431|EXPERIMENTAL|Spontaneous breathing trial|The spontaneous breathing trial will determine the extubation readiness of the subject.
61913370|NCT01471431|NO_INTERVENTION|Usual care|Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.
62105695|NCT02013986|EXPERIMENTAL|etomidate & midazolam|a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.
62297898|NCT05426148|EXPERIMENTAL|Bivalent HPV Vaccine Consistency Lot 2|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
62297899|NCT05426148|EXPERIMENTAL|Bivalent HPV Vaccine Consistency Lot 3|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
62297900|NCT02635204|EXPERIMENTAL|DFD-06 Cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
62297901|NCT02635204|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
62297902|NCT01696461|EXPERIMENTAL|Related donors receiving plerixafor|"Collection of sufficient CD34+ cells using plerixafor as the mobilizing agent.~Eligible donors determined according to institutional standards~* 18-65 years of age~* 6/6 HLA-matched sibling~* Fulfill individual Transplant Center criteria to serve as a mobilized blood cell donor~* Serum creatinine \<1.5 x institution upper limit of normal (ULN) or estimated creatinine clearance (CLCR) \>50 mL/min~Treatment Description:~* Receive subcutaneous plerixafor at 240 μg/kg and commence leukapheresis approximately 4 hours later.~* Leukapheresis will be performed up to two consecutive days. The target CD34+ cell dose is \> 4.0 x 106/kg with a minimum of \> 2.0 x 106/kg."
62297903|NCT01696461|NO_INTERVENTION|Recipients, myeloablative regimen|"Patients undergoing conditioning under a myeloablative regimen~Myeloablative (one of four general regimens):~Busulfan (\> 9 mg/kg po or iv total) with fludarabine Busulfan (\> 9 mg/kg po or iv total) with cyclophosphamide Total body irradiation (\> 1000 cGy) plus etoposide Total body irradiation (\> 500 cGy) plus cyclophosphamide"
62297904|NCT01696461|NO_INTERVENTION|Recipients, reduced intensity conditioning regimen.|"Patients undergoing conditioning using a reduced intensity conditioning regimen.~Reduced Intensity (one of three general regimens):~Busulfan (\< 9 mg/kg po or iv total) plus fludarabine Melphalan (100-140 mg/m2 iv total) plus fludarabine Fludarabine plus cyclophosphamide (\> 2000 mg/m2 total)"
62297905|NCT05381831|EXPERIMENTAL|NatestoTM|Participants in this group will receive Natesto for a 26 consecutive weeks treatment course
62297906|NCT01087554|EXPERIMENTAL|Arm A: Vorinostat + Sirolimus|"Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
62297907|NCT01087554|EXPERIMENTAL|Arm B: Vorinostat + Everolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
62297908|NCT01087554|EXPERIMENTAL|Arm C: Vorinostat + Temsirolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
62297909|NCT05974306|EXPERIMENTAL|ILR group|patients implanted with an implantable loop recorder to be monitored remotely.
62297910|NCT05974306|NO_INTERVENTION|in-hospital fup group|Patients that will be followed with in-hospital visits.
62297911|NCT02134886|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62297912|NCT05705726|EXPERIMENTAL|facia iliaca block|
62297913|NCT05705726|EXPERIMENTAL|Precedex and ketamine|
62297914|NCT04377945|EXPERIMENTAL|Part 1, JM-010 component Group A|Part 1, JM-010 component Group A
62105696|NCT02013986|ACTIVE_COMPARATOR|midazolam & propofol|During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.
62105697|NCT02359838|OTHER|Usual Care|Frail/pre-frail hematologic oncology patients receive usual care
62105698|NCT02359838|ACTIVE_COMPARATOR|Geriatrician Co-Management|Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician
62297915|NCT04377945|EXPERIMENTAL|Part 1, JM-010 component Group B|Part 1, JM-010 component Group B
62297916|NCT04377945|EXPERIMENTAL|Part 1, JM-010 component Group C|Part 1, JM-010 component Group C
62297917|NCT04377945|PLACEBO_COMPARATOR|Part 1, Placebo Group|Part 1, Placebo Group
62297918|NCT04377945|EXPERIMENTAL|Part 2, JM-010 combination Group A|Part 2, JM-010 combination Group A
62297919|NCT04377945|EXPERIMENTAL|Part 2, JM-010 combination Group B|Part 2, JM-010 combination Group B
62297920|NCT04377945|EXPERIMENTAL|Part 2, JM-010 component Group C|Part 2, JM-010 component Group C
62297921|NCT04377945|PLACEBO_COMPARATOR|Part 2, Placebo Group|Part 2, Placebo Group
62469016|NCT02942264|ACTIVE_COMPARATOR|Phase II Arm 2 Metronomic Temozolomide (TMZ)|"winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I alone"
62105699|NCT01771887|EXPERIMENTAL|education program|education program in 6 hours for groups of 10 people. The content will be divided into 2 sessions with an interval of 2 weeks, the duration of each session is 3 hours. Means active learning, teaching materials in Arabic accompany the content masterful discussions on flipcharts, situation analysis, computer-assisted presentation, demonstration, 150 photos of Lebanese dishes. After, patients receive a 10-page illustrated book, a logbook of diabetes control. 2 weeks after the second education session, each participant will receive 5 calls every 15 days in 2 months. During each call, the research assistant will ask the patient about diet, exercise and self-monitoring, medication and foot care and this according to a checklist.
62105700|NCT05695573||Controlgroup|25 healthy volunteer as a control
62105701|NCT05695573||diabetic patients with normoalbuminuria|Consisted of 25 type 2 diabetic patients with normoalbuminuria (levels \<30 mg/g creatinine)
62105702|NCT05695573||diabetic patients with microalbuminuria|Consisted of 25 type 2 diabetic patients with microalbuminuria (between 30-300 mg/g creatinine).
62105703|NCT05695573||diabetic patients with macrolbuminuria|Consisted of 25 type 2 diabetic patients with macroalbuminuria (levels \>300 mg/g creatinine)
62105704|NCT04091672|EXPERIMENTAL|All Participants (within patient control)|Each participant will serve as their own Control, receiving both Control and Investigational Interventions randomly allocated to treatment of a portion of a full-thickness skin defect.
62667809|NCT01953237|ACTIVE_COMPARATOR|Control|Individuals randomized to the control condition will be provided with a smartphone free of charge with unlimited use of the phone's voice and internet capabilities. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period. All participants will be contacted by research staff to trouble-shoot problems with the smartphone at the end of the first week, but will receive no additional contact from research staff until the end of the trial.
62105705|NCT01867580|EXPERIMENTAL|V.A.C.Ulta with Prontosan instillation|Treatment Arm
62105706|NCT01867580|ACTIVE_COMPARATOR|V.A.C.Ulta without instillation|Control Arm
62105707|NCT03817736|EXPERIMENTAL|START-FIT|"Single group assignment combining TACE and SBRT with immune checkpoint inhibitor as treatment in HCC patients.~Procedure of TACE will be standardized.~SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.~An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons."
62297922|NCT04128111||Acute Exacerbation|Exacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e. they represent a change from the patient's usual status that is sufficient to require a change in treatment.
62297923|NCT04128111||Non-acute exacerbation|Non-acute exacerbation of asthma includes chronic remission and clinical delays.Clinical remission stage refers to an absence of wheezing, chest tightness, cough and other symptoms for more than 1 year.Chronic duration refers to that symptoms, such as wheezing, chest tightness, cough and so on, attack at different frequency and different degrees every week.
62667810|NCT01953237|EXPERIMENTAL|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
62297924|NCT04128111||Healthy Volunteer|Health is not only the absence of disease or infirmity, but also a state of physical, mental, and social perfection.
62667811|NCT05639205|ACTIVE_COMPARATOR|Arm A|LFD testing for Covid-19 with sickness support payment. Care providers will receive funding to reimburse the costs of employing agency staff to cover sickness absence in asymptomatic staff who test positive for COVID.
62297925|NCT01059448|EXPERIMENTAL|Placebo Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered matching placebo in parent study 20090061 and were administered 210 mg subcutaneous (SC) AMG 827 at Day 1, Week 1, Week 2, and every other week thereafter (Q2WK). Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
62469017|NCT01447615|EXPERIMENTAL|Bridges|
61913371|NCT02620371|PLACEBO_COMPARATOR|(bupivacaine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine)
62105708|NCT01359371||Peer telephone cessation counseling|The cohort is 131 veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital follow up volunteer peer telephone cessation counseling
62105709|NCT02047461|EXPERIMENTAL|ORGN001 (formerly ALXN1101)|daily IV infusions
62105710|NCT05075031||300 Newborn feeding on Breast Milk or Artificial Milk Formula rom birth to about 2 months of age|The electronic patient record of 300 Newborn feeding on Breast Milk or Artificial Milk Formula from birth to about 2 months of age would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
62105711|NCT05075031||300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year|The electronic patient record of 300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
62105712|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year|The electronic patient record of 300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
62469018|NCT01447615|EXPERIMENTAL|Bridges PLUS|
62469019|NCT01447615|OTHER|Usual Care|
62667812|NCT05639205|NO_INTERVENTION|Arm B|Usual Care
62667813|NCT03514537|EXPERIMENTAL|Lipoaspiration|Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
62667814|NCT03514537|EXPERIMENTAL|Isolation & Concentration of cSVF|Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
62667815|NCT03514537|EXPERIMENTAL|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
62105713|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 5 year up to 15 year|The electronic patient record of 300 child feeding on Artificial Milk Formula or any source of DHA from 5 year up to 15 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
62105714|NCT05075031||Control Group|"1. The electronic patient record of 150 infant and child patients who feed on only cow's milk which does not provide a rich source of DHA and did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the cohorts that feed on Breast Milk or Artificial Milk Formula~2. The electronic patient record of 150 adult patients from 15 years to 25 years who did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021"
62105715|NCT04504903|EXPERIMENTAL|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will participate in 12 weekly group sessions to discuss thoughts, feelings, and behaviors that promote work success in the community
62105716|NCT04504903|ACTIVE_COMPARATOR|Psychoeducation|Veterans in the control group will participate in 12 weekly group sessions in which they will learn more about their mental health conditions.
62105717|NCT04384146|EXPERIMENTAL|Quad Shot Radiation|In this trial, patients with centrally located lung tumors will be treated with up to 3 cycles of Quad Shot Radiation. Radiation treatment will be given within 1 week of administration of chemotherapy. Quad Shot radiation will involve: 3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break. The first group of patients will be treated with 2 cycles of quad shot radiation, followed by a 3-month observation period post-RT to allow a complete evaluation of acute toxicity. The next group of patients will be treated with either 1 cycle or 3 cycles of quad shot radiation. The minimum accrual is 4 patients with an expected accrual of 16 patients. Twenty additional patients will be recruited to an expansion cohort.
62105718|NCT02772614|EXPERIMENTAL|Nebicapone (200 mg)|"Each subject was to receive one single dose of 2.5 MBq \[14C\]-labelled BIA 3-202 (200 mg) together with a total of 250 mL non-carbonated water.~The study drug was given after an overnight fast of at least 10 hours after the in-house stay. During waking hours on Day 1, subjects had to have a fluid intake of at least 150 mL per hour starting 1 hour before study drug administration."
62105719|NCT04392349|OTHER|NORMAL|Normal group includes eyes with healthy cornea.
62105720|NCT04392349|OTHER|IRREGULAR|Irregular goup includes eyes with irregular astigmatism or corneal scarring.
62105721|NCT03936829|EXPERIMENTAL|Interventional|Drug:Cyclophosphamide Dosage form: intravenous infusion Dosage: 500 mg/m2 of BSA Frequency: every 4 weeks Duration: 24 weeks
62105722|NCT04216823||Sevoflurane Group|sevoflurane is used for anesthetic induction
62105723|NCT04216823||Propofol Group|intravenous anesthetic propofol is used for anesthetic induction
62105724|NCT05702723|EXPERIMENTAL|Smart-3RP|"Survivors-caregivers will be randomized together (dyad), stratified by survivor status: curvivor (participants who have completed curative therapy) or metavivor (participants will metastatic disease), using a random plan generator with 1:1 randomization. Participants will complete study procedures as outlined:~* Baseline questionnaires.~* 9 virtual sessions of Smart-3RP.~* 3-month questionnaires.~* Optional collections of hair samples at enrollment and 6-month follow-up period to measure cortisol concentration.~* 6-month questionnaires.~* Optional exit interview with study staff."
62105725|NCT05702723|ACTIVE_COMPARATOR|Enhanced Usual Care|"Survivors-caregivers will be randomized together (dyad), stratified by survivor status (curvivor/metavivor), using a random plan generator with 1:1 randomization.~* Participants will be referred to a 14-week online support group."
62105726|NCT05763004|EXPERIMENTAL|IOS-1002 Monotherapy|
62105727|NCT05763004|EXPERIMENTAL|IOS-1002 Combination Therapy with KEYTRUDA® (pembrolizumab)|
62297926|NCT01059448|EXPERIMENTAL|70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered 70 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2 and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
62297927|NCT01059448|EXPERIMENTAL|140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK|Participants who were administered 140 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2, and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
62297928|NCT01059448|EXPERIMENTAL|210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered 210 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2, and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
61913372|NCT02620371|ACTIVE_COMPARATOR|(bupivacaine, ketamine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine plus ketamine 1 mg/kg) .
61913373|NCT03034668|EXPERIMENTAL|CS16-003 Full dose|350 mg capsule QD Rhodiola rosea L. \& Rhaptonticum carthamoides extracts
61913374|NCT03034668|EXPERIMENTAL|CS16-003 Half dose|175 mg capsule QD 50% Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + 50% Maltodextrin
61913375|NCT03034668|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62105728|NCT00668174|EXPERIMENTAL|1|Exercise
62105729|NCT00668174|NO_INTERVENTION|2|Control
62297929|NCT00876031|EXPERIMENTAL|O-TIE|oral maintenance therapy with trofosfamide, idarubicin, and etoposide
62297930|NCT00876031|NO_INTERVENTION|control|
62667816|NCT03902990|EXPERIMENTAL|Dual task|Treadmill training + cognitive tasks + standard exercise programme
62667817|NCT03902990|ACTIVE_COMPARATOR|Single task|Treadmill training + standard exercise programme
62667818|NCT03902990|ACTIVE_COMPARATOR|Control|Standard exercise programme
62105730|NCT06630520|ACTIVE_COMPARATOR|Periarticular injection|
62105731|NCT06630520|NO_INTERVENTION|Control group|
62105732|NCT00404079|EXPERIMENTAL|Glucosamine Sulphate|
62297931|NCT01769911|EXPERIMENTAL|Treatment (gene modified peripheral blood cell transplant)|"CONDITIONING: Patients receive carmustine IV over 3 hours on day -7, cytarabine IV over 2 hours BID and etoposide IV over 2 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.~TRANSPLANTATION: Patients receive an autologous PBSC infusion and/or infusion of autologous transduced hematopoietic cells on day 0.~Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. Patients achieving \> 10% gene marking and CD4 count of \>= 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection."
62105733|NCT00404079|PLACEBO_COMPARATOR|Placebo|
62105734|NCT03365609|EXPERIMENTAL|T-group|T-group(triple therapy)
62105735|NCT03365609|EXPERIMENTAL|S-group|S-group( sequential therapy)
62297932|NCT01282125||sleep apnea|100 patients suffering from obstructive sleep apnea syndrome
62297933|NCT01282125||controls|100 subjects matching cases to age, sex, and body weight
62297934|NCT03715465|ACTIVE_COMPARATOR|Estimated DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before estimated dim light melatonin onset.
62297935|NCT03715465|EXPERIMENTAL|Measured DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before measured dim light melatonin onset.
62297936|NCT02934607|ACTIVE_COMPARATOR|Treatment A|2 x 160/4.5 µg Symbicort pMDI administered with no spacer device; no activated charcoal (systemic exposure).
62297937|NCT02934607|EXPERIMENTAL|Treatment B|2 x 160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; no activated charcoal (systemic exposure).
62297938|NCT02934607|ACTIVE_COMPARATOR|Treatment C|160/4.5 µg Symbicort pMDI administered with no spacer device; with activated charcoal (lung exposure).
62297939|NCT02934607|EXPERIMENTAL|Treatment D|160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; with activated charcoal (lung exposure).
62297940|NCT01939379|ACTIVE_COMPARATOR|15ml ropivacaine|Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
62297941|NCT01939379|ACTIVE_COMPARATOR|30ml ropivacaine|If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
62297942|NCT04300348|ACTIVE_COMPARATOR|Heel2Toe Group|The Heel2Toe group will have 5 therapy sessions to learn to trigger the sensor with a strong heel strike and how to use device for home practice for 3 months. During the home practice, participants will be instructed to walk with the device for a minimum of 10 minutes per day in feedback mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
62297943|NCT04300348|OTHER|No-feedback Control Group (Control group)|The Control group will do the same 5 sessions of training and 3 months of practice but without the Heel2Toe device in feedback mode, just in data acquisition mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
62469020|NCT04960722|ACTIVE_COMPARATOR|Control|autogenous bone graft
62667819|NCT04099420||Italian university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
62105736|NCT03365609|EXPERIMENTAL|B-group|B-group( bismuth quadruple therapy )
62105737|NCT03365609|EXPERIMENTAL|C-group|C-group( concomitant therapy)
62105738|NCT03538054|EXPERIMENTAL|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
62105739|NCT03538054|PLACEBO_COMPARATOR|Placebo|Participants will take one placebo capsule in the morning and at night.
62105740|NCT06713941||Bone metatases|This study involves adults with bone metastases or who have had a bone event associated with a cancer diagnosis.
62105741|NCT01434303|EXPERIMENTAL|Treatment (entinostat, lapatinib ditosylate and trastuzumab)|Patients receive entinostat PO on days 1 and 15 and lapatinib tosylate PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in the Phase I Trastuzumab Cohort also receive maintenance dose of trastuzumab IV over 30-90 minutes every 3 weeks.
62105742|NCT02799095|EXPERIMENTAL|ALKS 4230|
62105743|NCT02799095|EXPERIMENTAL|ALKS 4230 + pembrolizumab|
62105744|NCT06628583||Rehabilitation Group|mild/non pain group with VAS\<3 at 3th months after PLIF.N=501
62105745|NCT06628583||Recurrent pain group|Recurrent pain group: recurrent pain group with VAS≥3 at 3th months after PLIF.N=435
62105746|NCT03837769|EXPERIMENTAL|Aktiia SA PulseWatch|Aktiia OBPM PulseWatch wrist device
62105747|NCT00637676|ACTIVE_COMPARATOR|1|Implantation of PleurX-Pleural catheter plus talc pleurodesis
62469021|NCT04960722|EXPERIMENTAL|1.5 mg/g OIF/β-TCP|1.5 mg/g OIF/β-TCP
62469022|NCT04960722|EXPERIMENTAL|2 mg/g OIF/β-TCP|2 mg/g OIF/β-TCP
62667820|NCT04099420||Spanish university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
62667821|NCT02422901||Vit C deficiency in acute diseases|Patients with vitamin C deficiency due to a acute underlying disease treated with Pascorbin® 7.5 g
62105748|NCT00637676|ACTIVE_COMPARATOR|2|talc pleurodesis, no implantation of PleurX-Pleural catheter
62105749|NCT04258774|ACTIVE_COMPARATOR|Healthy Adults|
62105750|NCT04258774|ACTIVE_COMPARATOR|Adults diagnosed with vascular pathology of the brain|
62105751|NCT05163756|EXPERIMENTAL|DW1903(Test)|once a day, q.d. PO / DW1903 + Placebo of DW1903-R1
62105752|NCT05163756|ACTIVE_COMPARATOR|DW1903-R1(Reference)|once a day, q.d. PO / Placebo of DW1903 + DW1903-R1
62105753|NCT03307980|EXPERIMENTAL|PF-06838435 Dose-Escalation|Single intravaneous infusion of PF-06838435. After 2 participants receive initial dose, data will be evaluated and a decision will be made to escalate or reduce the dose being evaluated, increase the number of participants receiving the dose, or stop dosing. Multiple iterations may be undertaken.
62105754|NCT03518541|ACTIVE_COMPARATOR|Goniometer|FDO: classic procedure with goniometer controlled derotation
62105755|NCT03518541|EXPERIMENTAL|EMT|FDO: procedure with electromagnetic tracking (EMT) controlling derotation
62105756|NCT04735939||morning dosing radiotherapy|
62105757|NCT04735939||evening dosing radiotherapy|
62105758|NCT01611909|EXPERIMENTAL|2% PMDO|
62297944|NCT03874234|EXPERIMENTAL|Part A: Subjects receiving GSK3186899 + placebo in Cohort 1|Subjects will receive 3 single ascending oral doses (SAD) of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 1 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
62297945|NCT03874234|EXPERIMENTAL|Part A: Subjects receiving GSK3186899 + placebo in Cohort 2|Subjects will receive 3 SAD of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 2 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
62297946|NCT03874234|EXPERIMENTAL|Part A: Subjects receiving GSK3186899 in Cohort 3|Subjects will receive GSK3186899 orally, under fasted condition and fed conditions on Day 1 of cohort 3 in each of the two treatment periods. There will be a wash out period of at least 10 days between each treatment period. A dose level will be determined based on the effect of food on the safety, tolerability and PK of a single dose of GSK3186899, with dose level selected from Cohorts 1 and 2.
62297947|NCT03874234|EXPERIMENTAL|Part B: Subjects receiving GSK3186899|Subjects will receive GSK3186899, orally, twice daily (BID) on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
62297948|NCT03874234|PLACEBO_COMPARATOR|Part B: Subjects receiving placebo|Subjects will receive placebo, orally, BID on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
62297949|NCT06642480|OTHER|Determination of Patients' Visual Analogue Scale (VAS)|Pain level was categorized into 0 (no pain), 1-3 (signifying mild), 4-6 (middle), and 7-10 ( heavy pain).
62297950|NCT03226093|EXPERIMENTAL|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
62297951|NCT06154629|EXPERIMENTAL|Botanical ingredient|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
62667822|NCT02422901||Vit C deficiency in chronic diseases|Patients with vitamin C deficiency due to a chronic underlying disease treated with Pascorbin® 7.5 g
62667823|NCT01604031|EXPERIMENTAL|B-CLL vaccine|Patients will receive doses of vaccine at 2 week intervals for 5 doses and at 4 week intervals for doses 6-16. The injection will be performed subcutaneously in the deltoid region of the upper arm.
62667824|NCT02971904||Human milk collection|Lactating mothers should have enough milk to provide enough maternal milk their preterm infant(s) require plus additional collection of samples (3mL). After consenting to the study, milk from lactating mothers of preterm infants in the local ICU will be analyzed daily from the moment they express sufficient milk volume beyond their child's requirement until discharge (from 4th day of admission until 15th day of hospitalization ). Three mL of sample milk will be collected every morning and analyzed, according to hospital routine. Personal details of mothers and their infants will be collected by applying a questionnaire on the first day of analysis. The nutritional composition of the last meal before the milk sample collection and also a nutrition questionnaire intake will be evaluated.
62105759|NCT01611909|EXPERIMENTAL|5% PMDO|
62105760|NCT01611909|ACTIVE_COMPARATOR|Mupirocin|
62105761|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
62105762|NCT03994471|EXPERIMENTAL|XyloCore peritoneal dialysis solution|Patients will receive 1, 2 or 3 daily (short-dwell) exchanges with XyloCore of an osmotic strength comparable to their pre-randomization prescription of glucose peritoneal dialysis solution (XyloCore Low, Medium and High Strenght have an osmotic strength comparable to Physioneal, Fixioneal or Dianeal 1.36%, 2.27%, 3.86% glucose, respectively, and Balance, Bicavera, Bicanova or Equibalance with 1.5%, 2.5%, 4.25% glucose, respectively). All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
62105763|NCT03994471|ACTIVE_COMPARATOR|Glucose peritoneal dialysis solution|Patients randomized to glucose solution will continue the 1, 2 or 3 daily (short-dwell) exchanges of Physioneal 40 or 35, Fixioneal 40 or 35 or Dianeal (1.36%, 2.27%, 3.86% glucose), Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.5%, 4.25% glucose) with the same osmotic strength of their pre-randomization prescription. All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
62105764|NCT03317353|EXPERIMENTAL|Vestibular rehabil.: CDP|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
62297952|NCT06154629|PLACEBO_COMPARATOR|Control Group|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
62469023|NCT04960722|EXPERIMENTAL|3 mg/g OIF/β-TCP|3 mg/g OIF/β-TCP
62469024|NCT06057922|EXPERIMENTAL|Phase 1 dose expansion stage|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
62105765|NCT03317353|EXPERIMENTAL|Vestibular rehabil.: optokinetic stimuli|Group B. Patient has to stand in a dark room, wiht optokinetic stimuli around him/her. Ten sessions (one per day, five per week, two weeks), with progressive increase of stimulus speed (from 30º/sec the first day to 100º/sec the last), duration of session (from 5 minutes the first day to 15 minutes the last), stimulus complexity (horizontal stimuli in the first sessions, progressively adding vertical and rotating stimuli) and support surface difficulty (initially hard surface, last sessions on foam).
62105766|NCT03317353|EXPERIMENTAL|Vestibular rehabil.: home exercises|Group C. The patient is given a list of exercises (and explained how to do them) to stabilise eye position and improve postural control. They are to be performed twice a day for two weeks. Approximate duration of each session: 15 minutes. The exercises must be supervised by a family member to verify adherence to the programme.
62105767|NCT03317353|NO_INTERVENTION|Control group|Group D. No vestibular rehabilitation is developed.
62105768|NCT03758339|EXPERIMENTAL|Tucatinib|
62105769|NCT05680012|EXPERIMENTAL|Gluten challenge group|Diagnosis of celiac disease by intestinal biopsy and serology for at least 12 months
62105770|NCT05680012|NO_INTERVENTION|Gluten de-challenge group|Suspected celiac disease either showing typical symptoms or positive celiac disease serology
62105771|NCT05680012|NO_INTERVENTION|Control group|No history or symptoms of celiac disease
62105772|NCT04808635||general surgery residents|
62105773|NCT04808635||orthopedic surgery residents|
62105774|NCT04808635||urology residents|
62105775|NCT04808635||OBGYN residents|
62667825|NCT05005143||Paroxysmal AF ablation|Patients with standard indications to paroxysmal AF ablation
62105776|NCT02934958|ACTIVE_COMPARATOR|FIT Positive|Referral to GI or Primary Care. Patients will be referred to MD for pre-colonoscopy vist.Standard of Care.
62105777|NCT02934958|EXPERIMENTAL|FIT Positive Choice|Offered Chioce of Direct referral. Patients will be given a choice to advance to directly having a colonoscopy screening.Colon Cancer Screening Navigation.
62105778|NCT02664376||Geriatric ward population|Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.
62667826|NCT00582452||2|Affected patients who are at high risk for metachronous colorectal tumors due to mutation status.
62667827|NCT00582452||1|Unaffected patients who are at high risk for developing colon cancer based on family history and/or mutation status.
62667828|NCT02457286|EXPERIMENTAL|Metformin|Metformin is being compared to exercise and diet modifications. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
62105779|NCT05132205|EXPERIMENTAL|Radiofrequency Ablation|Patients will receive RFA as a one-time intervention, with a possible second treatment after 6 months if adequate resolution is not noted on ultrasound.
62105780|NCT04179240|EXPERIMENTAL|audio and animated cartoon questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with audio and animated cartoon questionnaire. The animation was an 8-minute cartoon video divided into different parts according to different questions. The first part of the animation was the introduction of biospecific nonspecimen specimen and our survey, while the other parts showed the content of the questionnaire about donating biospecific nonspecimen specimen in a vivid way. The background music built a relaxed and pleasant atmosphere, and some cartoon pictures were made into question options to simplify the understanding and data analysis.
62105781|NCT04179240|NO_INTERVENTION|text questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
62105782|NCT04179240|OTHER|Parent group|After a brief introduction to our survey, participants(parent) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
62105783|NCT05275842|EXPERIMENTAL|Cognitive Processing Therapy-Lifesteps (CPT-L) [Group A]|
62105784|NCT05275842|ACTIVE_COMPARATOR|Lifesteps [Group B]|
62105785|NCT05092906|ACTIVE_COMPARATOR|Lumbar puncture with standard of care|
62105786|NCT05092906|EXPERIMENTAL|Lumbar puncture with hypnosis add-on therapy|
62105787|NCT00413491|EXPERIMENTAL|1|Comparison of MR and mammography
62105788|NCT01255033||Pulmonary surgical patients|Patients submitted for scheduled lung surgery requiring one-lung ventilation
62105789|NCT04509713||infected/positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
62105790|NCT04509713||uninfected/negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
62667829|NCT02457286|EXPERIMENTAL|Lifestyle modification|The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating participants condition or disorder. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
62105791|NCT00995709|EXPERIMENTAL|AIN457C 300 mg every 2 week dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
62105792|NCT00995709|EXPERIMENTAL|AIN457C 300 mg monthly dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
62105793|NCT00995709|PLACEBO_COMPARATOR|Placebo|Placebo was administered in 2 s.c. injections every 2 weeks
61913376|NCT02725489|EXPERIMENTAL|Part 1 Cohort 1: 1x10^6 cells Vigil|The first part will be a safety run-in comprised of 2 cohorts that will use a 3 + 3 design to determine the Vigil dose in Part 2. Cohort 1 will receive a low dose of Vigil (1x10\^6 cells/intradermal (ID) injection) in combination with durvalumab (1500 mg (if \> 30 kg) IV over 60 minutes) every 4 weeks.
62105794|NCT02491736|EXPERIMENTAL|ketoprofen|2.5% ketoprofen gel
61913377|NCT02725489|EXPERIMENTAL|Part 1 Cohort 2: 1x10^7 cells Vigil|Cohort 2 will receive Vigil at 1x10\^7 cells/ID injection and durvalumab (1500mg (if \> 30 kg) IV over 60 minutes) every 4 weeks.
61913378|NCT02725489|EXPERIMENTAL|Part 1 Cohort -1: 1x10^5 cells Vigil|If needed, Cohort -1 will be used which will receive Vigil at 1x10\^5 cells/ID injection and Durvalumab (1500mg (if \> 30 kg) IV over 60 minutes) every 4 weeks.
61913379|NCT01135563|EXPERIMENTAL|Vinblastine and Sirolimus|The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
61913380|NCT01138176|NO_INTERVENTION|Standard care|
62105795|NCT02491736|PLACEBO_COMPARATOR|Placebo|Placebo gel
61913381|NCT01138176|EXPERIMENTAL|Cooling|Reduction of rectal temperature to 33.5 C for 72 hours
62105796|NCT02923284||Imaged renal mass cohort|Subjects undergoing surgery for an kidney tumor identified radiologically.
62469025|NCT06057922|EXPERIMENTAL|Phase 2 stage with expanded sample size|Patients will be treated with YL201 intravenous (IV) infusion at PR2D once every 3 weeks (Q3W) as a cycle.
61913382|NCT06044766|OTHER|Surgical exatrction of impacted lower third molars|Clinical intervention: Surgical exatrction of impacted lower third molar to examine and classify the roots, then to compare it with radiographic classification
62469026|NCT00557752|ACTIVE_COMPARATOR|1|Addition to the standard therapy of non-invasive mechanical ventilation. Continuously for the first 24 hours, then trials to discontinuation every 24 hours. Interface adjusted for the associated injuries.
62469027|NCT00557752|NO_INTERVENTION|2|Standard therapy for severe post-traumatic hypoxia: pain control with epidural anesthesia and oxygen.
62469028|NCT03254771|NO_INTERVENTION|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
62469029|NCT03254771|EXPERIMENTAL|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
61913383|NCT05945862|EXPERIMENTAL|Nutrition-Physical activity Program|Participants within the nutrition education and physical activity program
61913384|NCT06080724|OTHER|Group A with intralesional injection of bleomycin with dexamethasone|Patients in the group A(n=57) were given intralesional bleomycin combined with dexamethasone and The intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose and similarly intralesional dexamethasone was given as 0.8-1.6 mg/kg/dose. The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=\<50% decrease, 2=50-75%, 3=75-90%, 4=\>90% but \<100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.
62105797|NCT02923284||control cohort|Subjects undergoing surgery for any kind of cancer other than kidney.
62105798|NCT04724369|EXPERIMENTAL|Study Cohort: Subjects with known or presumed neuroblastoma|"Drug: 18F-mFBG Positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for identification of neuroblastoma.~Other Names:~* meta-fluorobenzylguanidine~* IRP101"
62105799|NCT06629129|OTHER|EFFECT OF ANTI GLAUCOMA LATANOPROST 0.005 ON OPTIC NERVE PERFUSION|EFFECT OF ANTI GLAUCOMA PROSTAGLANDIN 0.005 ON OPTIC NERVE PERFUSION
62105800|NCT06194643||Pregnant people at high risk of preeclampsia (case group)|Investigators will collect a sample of blood (up to 50ml) at the time of a previously scheduled visit as part of routine prenatal care. Platelet phenotyping, measuring platelet activity, and the platelet transcriptome will be performed on samples. Plasma, serum, whole blood RNA and DNA will be collected.
62469030|NCT03171285||Less than 35 years old|Clinical and laboratory evaluations
62469031|NCT03171285||Greater than or equal to 35 years|Clinical and laboratory evaluations
62469032|NCT02682784|EXPERIMENTAL|Oxytocin/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to oxytocin.
62469033|NCT02682784|ACTIVE_COMPARATOR|Placebo/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to placebo.
62105801|NCT06194643||Pregnant people at low risk of preeclampsia (control group)|Investigators will collect a sample of blood (up to 50ml) at the time of a previously scheduled visit as part of routine prenatal care. Platelet phenotyping, measuring platelet activity, and the platelet transcriptome will be performed on samples. Plasma, serum, whole blood RNA and DNA will be collected.
62105802|NCT04293783|ACTIVE_COMPARATOR|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 two tablet by mouth 1 time per day
62105803|NCT04293783|PLACEBO_COMPARATOR|Placebo|Placebo two tablet by mouth 1 times per day
62105804|NCT01530009|ACTIVE_COMPARATOR|Amoxicillin|A liquid preparation of amoxicillin will be administered during the study through a nasoduodenal catheter after random patient assignment.
62105805|NCT01530009|PLACEBO_COMPARATOR|Placebo|A liquid placebo will be administered via a nasoduodenal catheter to patients based on random assignment.
62105806|NCT03768206|EXPERIMENTAL|PATH|PATH participants will receive Standard Outpatient Physical Therapy. In addition, physical therapist discuss physical activity \& assist with goal setting during therapy sessions.
62667830|NCT01198015||Rett syndrome girls|The study population (identical to the population in the preliminary research project) consists of a well-defined group of thirteen Dutch RTT girls with complete clinical, molecular, neurophysiological and metabolic work-up.
62105807|NCT03768206|ACTIVE_COMPARATOR|PATH-12|PATH-12 participants will receive Standard Outpatient Physical Therapy. In addition, PATH-12 participants will receive a Physical activity session (1-hour) focusing on physical activity and goal setting at 12 weeks after surgery.
62105808|NCT06620302|EXPERIMENTAL|Treatment (DT2216, irinotecan)|Patients receive DT2216 IV over 30 minutes on days 1, 4, 8, 11, 15, and 18 of each cycle and irinotecan IV over 90 minutes on days 2-6 of cycle 1, and on days 1-5 of remaining cycles. Cycles repeat every 21 days for up to 35 cycles (24 months) in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection throughout the trial.
62105809|NCT05891977|EXPERIMENTAL|Group AB (intervention / control)|After a 1-week washout period avoiding consumption of tomato, tomato-based products and other food sources of lycopene (watermelon, papaya, grapefruit and lycopene supplements), participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during 3 months (intervention). Then they will return to their regular dietary pattern during 3 weeks. At the beginning of the first 4 month, participants will be encouraged to move into the second phase (control), before a 1-week washout period. The second phase or control consists in following their regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during the next 3 months.
62105810|NCT05891977|EXPERIMENTAL|Group BA (control / intervention)|After a 1-week washout period avoiding consumption of tomato, tomato-based products and other food sources of lycopene (watermelon, papaya, grapefruit, and lycopene supplements), participants will start the control intervention which consists of following their regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during 3 months (control). Then they will return to their regular diet during 3 weeks. At the beginning of the first 4 month, participants will be encouraged to move into the second phase (intervention), before a 1-week washout period. The intervention consist in consuming a daily amount of 0.5 g of tomato paste / kg of body weight diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during the next 3 months.
62105811|NCT02024308|EXPERIMENTAL|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.
62105812|NCT02024308|ACTIVE_COMPARATOR|HD-Arac|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
62105813|NCT05463276||Patients with breast cancer|
62105814|NCT02004561||Gastric Banding|Patients chose Gastric banding
62105815|NCT02004561||Gastric Bypass|Patients chose gastric bypass surgical operation
62297953|NCT05040191|EXPERIMENTAL|Control Group|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Nursing Fundamentals Skills Laboratory. The laboratory consists of 3 practice rooms, 1 control room and 1 analysis room. A video prepared by the researcher on the Simple Nasogastric Tube Application Model in line with the steps of Checklist for Teaching Nasogastric Tube Application Skills was watched and preliminary information was given. The questions were answered by allowing the students to ask questions."
62469034|NCT02682784|EXPERIMENTAL|Oxytocin/Control|Healthy controls who are randomized to oxytocin.
62469035|NCT02682784|ACTIVE_COMPARATOR|Placebo/Control|Healthy controls who are randomized to placebo.
62667831|NCT06050993||Cirrhotic patients|Patients known to have a cirrhosis, with an invasive procedure scheduled at the Paul Brousse hospital
62667832|NCT06050993||Non-cirrhotic patients|Patients without cirrhosis, with an invasive procedure scheduled at the Paul Brousse hospital
62667833|NCT02154659|OTHER|postprandial reflux group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
62469036|NCT04394676|EXPERIMENTAL|Reduction in Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
62667834|NCT02154659|OTHER|normal group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
62667835|NCT05364489|EXPERIMENTAL|Bevacizumab combined with Oxaliplatin and TAS-102|Efficacy, safety and exploratory clinical study of Bevacizumab combined with Oxaliplatin and TAS-102 in first-line treatment of advanced colorectal cancer
62667836|NCT05242744||Metastatic prostate cancer|Men at least 18 years of age with metastatic prostate cancer may be eligible for this study .Volunteers that meet the eligibility criteria will be considered for study participation regardless of race or ethnic background. Only individuals who can understand and give informed consent will be eligible to participate in this study.
62667837|NCT06519149||Slow Wave UASD|Participants who wear the Slow Wave UASD oral device fora 90 day period and a Wellue O2 ring to measure daily sleep metrics
62105816|NCT03102242|EXPERIMENTAL|Treatment|"Induction immunotherapy: atezolizumab 1200 mg IV q 21 days x 4 cycles. Restaging after cycle 2 and cycle 4 induction: patients with progression of disease (PD) at the post-cycle 2 assessment will stop atezolizumab and go immediately to chemoradiotherapy if still stage III and eligible for curative intent therapy.~Chemoradiotherapy: carboplatin AUC = 2 + paclitaxel 50 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 60 Gy given in 2 Gy fractions daily M-F x 30 fractions~Consolidation chemotherapy: Carboplatin AUC = 6 + paclitaxel 200 mg/m2 IV q 21 days x 2 cycles beginning 3-5 weeks after completion of radiation.~Adjuvant immunotherapy: atezolizumab 1200 mg IV q 21 days to complete one year of therapy (from start of induction)."
61913385|NCT06080724|OTHER|Group B WITH INTRALESIONAL INJECTION OF BLEOMYCIN|Patients in the group B(n=57) intralesional bleomycin alone after taking aseptic and antiseptic measuresThe intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose.The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=\<50% decrease, 2=50-75%, 3=75-90%, 4=\>90% but \<100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.
62105817|NCT01391442|OTHER|family|each family, composed of 4 characters at least, is studied
62105818|NCT05873556|EXPERIMENTAL|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|Participants randomized to the Lab-based Cue Reactivity PFI condition will receive a link to the personalized feedback in the lab after completing the cue reactivity protocol. Participants view the feedback on their own during the lab session. The personalized feedback is delivered online and contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
62105819|NCT05873556|NO_INTERVENTION|Assessment-only control|Participants randomized to the control group will not receive any intervention. They complete all the survey assessments and the lab-based cue reactivity protocol without ever receiving any personalized feedback.
62105820|NCT00518362|EXPERIMENTAL|immunosuppressor|Valsartan,160mg/d,TW 120mg/d
62105821|NCT03971747|EXPERIMENTAL|C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
62105822|NCT01027286|EXPERIMENTAL|Vitagel|
62105823|NCT01027286|NO_INTERVENTION|Control|No Vitagel used.
62469037|NCT04394676|ACTIVE_COMPARATOR|Standard Amount of Pressure|This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
62469038|NCT03210480|EXPERIMENTAL|Group 1|Lithium sulphate prolonged-release 660 mg
62469039|NCT03210480|ACTIVE_COMPARATOR|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
62105824|NCT02272699|EXPERIMENTAL|Nimotuzumab with Chemotherapy|"Patients will receive neoadjuvant chemotherapy of paclitaxel and cisplatin with concurrent nimotuzumab.~Paclitaxel 175mg per square metre on day 1 and cisplatin 30mg per square metre on day 1 and day 2 every 3 weeks for 2 cycles. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
62105825|NCT02272699|EXPERIMENTAL|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent nimotuzumab. Intensity-modulated radiation therapy(IMRT) of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
62469040|NCT03326180|EXPERIMENTAL|Liposomal bupivacaine (EXPAREL)|266mg/20ml EXPAREL mixed with 80ml 0.9% normal saline and 100mg/20ml 0.5% plain bupivacaine hydrochloride. Administered as a single dose intra-operatively by periarticular infiltration.
62469041|NCT03326180|ACTIVE_COMPARATOR|Bupivacaine hydrochloride alone|"100ml 0.9% normal saline mixed with 100mg/20ml 0.5% plain bupivacaine hydrochloride.~Administered as a single dose intra-operatively by periarticular infiltration."
62469042|NCT04593134|EXPERIMENTAL|exercise group|A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a Week.
62667838|NCT02842996||Patient and carer study group|Patients having undergone hip fracture surgery and their care givers.
62105826|NCT02272699|ACTIVE_COMPARATOR|Surgery alone|Patients in this group will be given esophagectomy without any neoadjuvant treatment. Adjuvant radiotherapy is permit for patients with positive lymph nodes metastasis.
62105827|NCT06628414|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|TDCS will be delivered using a NeuroConn DC Stimulator Plus via two 35cm2 rubber electrodes covered in saline-soaked sponges. The anode electrode will be positioned over EEG 10-20 coordinate F4 and the cathode over F3. The current will be delivered at 2mA for 20 minutes with ramp-up and ramp-down of 10 seconds. Each participant will receive 10 daily stimulation sessions over 2 weeks.
62667839|NCT01109381|EXPERIMENTAL|Treatment with GT08|Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid
62667840|NCT00875667|EXPERIMENTAL|Lenalidomide|Lenalidomide
62105828|NCT06628414|PLACEBO_COMPARATOR|Sham|Same as intervention arm but the current will be delivered at 2mA for 30 seconds, after which the stimulation will be discontinued.
62105829|NCT02784379||The breast with mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast with mastalgia.
62105830|NCT02784379||The breast without mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast without mastalgia.
62469043|NCT04593134|NO_INTERVENTION|usual-care group|These participants follows the standard post-surgery follow-up consisting of counseling by dietitians, nurses and doctors.
62667841|NCT00875667|ACTIVE_COMPARATOR|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine
62667842|NCT05478746|OTHER|Routine Care|Participants enrolled in the control arm will undergo routine care for localized provoked vulvodynia according to the doctor's usual recommendations. These may include lidocaine cream, physical therapy, a compounded cream containing a blend of lidocaine, baclofen, amitryptyline, estradiol, testosterone, and bupivacaine, radiofrequency treatment, Naropin or botulinum toxin injections.
62667843|NCT05478746|EXPERIMENTAL|Flourish HEC|"Participants in the Flourish HEC arm will undergo routine care as described for the control arm. Instead of lidocaine cream, they will be given a 4% lidocaine gel (called Relief, to be used up to 4x/day as needed) in an iso-osmotic, pH-balanced gel base. In addition, they will be given 3 products to use as described here, comprising the Flourish HEC kit (HEC = hydroxyethylcellulose, the principal gelling compound in the vaginal gel, to distinguish from the original Flourish kit using aloe).~1. Balance - external vulvar wash to be used daily in the shower.~2. BioNourish - vaginal moisturizing gel to be used every day before bed. Iso-osmotic and pH-adjusted with lactic acid to match healthy vaginal fluid.~3. BiopHresh - vaginal homeopathic suppository with 7 vaginal probiotic strains, including Lactobacillus crispatus, to be used every 3rd day before bed."
61913386|NCT01467635|ACTIVE_COMPARATOR|EBUS-TBNA|Sampling using endobronchial ultrasound guided transbronchial needle aspiration
61913387|NCT01467635|EXPERIMENTAL|EBUS-TBNB|Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.
61913388|NCT00528541|ACTIVE_COMPARATOR|BOTOX®|botulinum toxin type A (BOTOX®)
61913389|NCT00528541|ACTIVE_COMPARATOR|Dysport®|botulinum toxin type A (Dysport®)
61913390|NCT06052098|EXPERIMENTAL|Transbronchial group|Subjects receive bronchoscopy-guided RFA and undergo follow-up.
62105831|NCT05972239|ACTIVE_COMPARATOR|Control|Educational interventions, aerobic and strenght training, flexibility exercises.
62105832|NCT05972239|EXPERIMENTAL|Intervention|Educational interventions, aerobic and strenght training, balance training.
62667844|NCT04171999|EXPERIMENTAL|Usual Care + Intervention (Case)|Cases will receive the CommunityRx Intervention.
62667845|NCT04171999|NO_INTERVENTION|Usual Care (Control)|Controls will receive the usual standard care, which consists of information about hospital food resources and access to Feed1st hospital food pantries prior to discharge.
62667846|NCT03451968|EXPERIMENTAL|critically ill|"amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive).~it is a single bolus, no other elements or drug will be administered."
61913391|NCT06052098|EXPERIMENTAL|Transthoracic group|Subjects receive CT-guided RFA and undergo follow-up.
61913392|NCT06114524|EXPERIMENTAL|binaural music group|Binaural music therapy was applied for 15 min before the procedure.
61913393|NCT06114524|NO_INTERVENTION|control|The control group was kept in a quiet room for 15 minutes before the procedure and then taken for the procedure.
61913394|NCT02496676|ACTIVE_COMPARATOR|Magnesium, then placebo|In phase 1, participants received oral magnesium L-threonate for 12 weeks then crossover to placebo for 12 weeks, followed by a 2-week washout period. In phase 2, all participants received 3 days of intravenous MgSO4 in 3 daily doses totaling 30 mg/kg/day followed by oral magnesium L-threonate for 24 weeks.
62105833|NCT01217554||age-matched healthy male participants|age-matched healthy male participants without LBP
62105834|NCT01217554||participants with non specific chronic LBP|male participants with non specific chronic LBP
62105835|NCT01953809|EXPERIMENTAL|Run-in Period|All subjects will receive EE/NE for first 21 days and EE/NE matching placebo for next 7 days before start of treatment phase
62105836|NCT01953809|EXPERIMENTAL|Group 1|Subjects upon completion of 28 days of run-in period will receive GSK1322322/Placebo + EE/NE in period 1 and only EE/NE in period 2 and 3 of treatment phase. Each period will be of 7 days
62105837|NCT01953809|EXPERIMENTAL|Group 2|Subjects upon completion of 28 days of run-in period will receive only EE/NE in period 1, GSK1322322/Placebo + EE/NE in period 2 and again EE/NE only in period 3 of treatment phase. Each period will be of 7 days
62105838|NCT01953809|EXPERIMENTAL|Group 3|Subjects upon completion of 28 days of run-in period will receive only OC in period 1 and 2, and GSK1322322/Placebo + EE/NE in period 3 of treatment phase. Each period will be of 7 days
62105839|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
62105840|NCT06015594|EXPERIMENTAL|Metformin group|Treated with metformin
62105841|NCT06015594|NO_INTERVENTION|Control group|not treated
62469044|NCT01880814|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Type of talk therapy that focuses on individual behavioral and cognitive skills.
62667847|NCT03451968|ACTIVE_COMPARATOR|control|amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive) it is a single bolus, no other elements or drug will be administered.
62105842|NCT01211665|EXPERIMENTAL|Pulsed IVMP|Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles). If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
62105843|NCT01211665|EXPERIMENTAL|IVMP with oral prednisolone taper|Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg). If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
62667848|NCT05603221||Endovascular Group|Patients who had successful endovascular revascularization
62105844|NCT00714636||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62105845|NCT00714636||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
62105846|NCT00643838|EXPERIMENTAL|A|Misture of 50% nitrous oxide and 50% oxygen
62105847|NCT02648529|EXPERIMENTAL|Patients with BCECTS|Patients with BCECTS on which MRI, fMRI and neuropsychological assessment will be performed
62105848|NCT02648529|OTHER|Healthy volunteers|Healthy volunteers on which MRI, fMRI and neuropsychological assessment will be performed
62105849|NCT06714487|NO_INTERVENTION|No intervention|Neuropsychological evaluation including pre and 6 months without cognitive stimulation through games.
62105850|NCT06714487|EXPERIMENTAL|Intervention with games|Neuropsychological evaluation including pre and 6 months with cognitive stimulation three times a week through games.
62105851|NCT02416674|EXPERIMENTAL|Transplant recipients|The intervention is transplantatoin of abdominal wall tissues from an organ donor who is deceased to a recipient with a large abdominal wall defect.
62105852|NCT03563053|EXPERIMENTAL|active drug|\~14-22 mg dexamethasone sodium phosphate (DSP) for 12 months. The duration of EryDex treatment could be extended further and continue until patients eventually withdrew consent, or the Investigator decided to discontinue treatment based on a risk / benefit assessment.
62469045|NCT01880814|EXPERIMENTAL|Caregiver-Child Treatment|Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
62469046|NCT02634437|EXPERIMENTAL|Normal Renal Function|Ulipristal acetate, 10 mg, oral administration
62469047|NCT02634437|EXPERIMENTAL|Moderate Renal Impairment|Ulipristal acetate, 10 mg, oral administration
62667849|NCT05967910||Early esophageal cancer patients with chronic psychological stress|
62667850|NCT05967910||Early esophageal cancer patients without chronic psychological stress|
62105853|NCT03404843|EXPERIMENTAL|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
62105854|NCT03404843|PLACEBO_COMPARATOR|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
62105855|NCT00196365|EXPERIMENTAL|1|
62105856|NCT00196365|ACTIVE_COMPARATOR|2|
62105857|NCT05425264|EXPERIMENTAL|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
62105858|NCT01267838|ACTIVE_COMPARATOR|T Stenting group|PCI of bifurcation lesion with modified T Stenting.
62105859|NCT01267838|ACTIVE_COMPARATOR|Culotte stenting group|PCI of bifurcation lesion with Culotte stenting
62105860|NCT06629883|EXPERIMENTAL|REPS w/BANDS|The intervention was delivered by certified personal trainers who connected with participants in their homes using SHVDs. Supervised training was individually delivered to participants in real time and incorporated low-cost, portable resistance equipment (i.e., resistance bands, stability ball). SDT-guided strategies (e.g., peer support, practice, encouragement, affirmations) were incorporated to help increase exercise motivation. Peer support was addressed by randomly assigning participants with a buddy. Personal trainers demonstrated proper exercise form and had participants practice each exercise. Participants were instructed on how to use an affirmation app on the SHVD and encouraged to use it at least weekly.
62105861|NCT03920163|ACTIVE_COMPARATOR|Control|Stable , penetrating trauma patients undergoing laparotomy who receive standard post operative care
62105862|NCT03920163|EXPERIMENTAL|ERATS|Stable penetrating trauma patients undergoing laparotomy who receive enhanced recovery measures post operatively .
62105863|NCT05378282||Diabetic patients without diabetic nephropathy|i. Patients with ≥ 20 years of T2D evolution with normoalbuminuria ii. Patients without a personal or family history of kidney disease in 1st degree relatives iii. Age ≥ 18 years
62105864|NCT05378282||Diabetic patients with diabetic nephropathy|"i. T2D diagnosed at least 5 years before initiating renal replacement therapy ii. Background or diabetic retinopathy by self-report to ensure that albuminuria was the consequence of diabetic nephropathy rather than a non-diabetic glomerulopathy iii. albuminuria ≥ 300 mg/24 h in at least two out of three sterile urine samples iv. no hematuria or signs (including cellular casts), history or predisposition to other kidney or urinary tract disease.~v. Age ≥ 18 years"
62469048|NCT02634437|EXPERIMENTAL|Severe Renal Impairment|Ulipristal acetate, 10 mg, oral administration
62469049|NCT06105034||Conservative management|150 patients
62469050|NCT06105034||CS hysterectomy|150 patients
62469051|NCT04680962|EXPERIMENTAL|MabionCD20 / MabionCD20|Patients receive one or two treatment courses of MabionCD20, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
62667851|NCT05967910||Advanced esophageal cancer patients with chronic psychological stress|
62667852|NCT05967910||Advanced esophageal cancer patients without chronic psychological stress|
62667853|NCT06169085|EXPERIMENTAL|young participates|16 young participants(between 18\~45 years old) will be given Leritrelvir. D1：400mg QD D3-D5:400mg TID D6:400mg QD
62105865|NCT03035656|EXPERIMENTAL|Experimental|Administration of epidural Ropivaciane
62105866|NCT03035656|PLACEBO_COMPARATOR|Control|Administration of saline
62667854|NCT06169085|EXPERIMENTAL|Elder participates|16 elder participants(Age≥65 years old) will be given Leritrelvir. 16 young participants(between 18\~45 years old) will be given Leritrelvir. D1：400mg QD D3-D5:400mg TID D6:400mg QD
62667855|NCT06460909|EXPERIMENTAL|Psychological support arm|Patients randomized with psychological intervention.
62667856|NCT06460909|NO_INTERVENTION|Without support|Patients with routine care with psychological support.
62105867|NCT03093792|PLACEBO_COMPARATOR|Control|(no diet or exercise intervention)
62105868|NCT03093792|EXPERIMENTAL|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
62105869|NCT03093792|ACTIVE_COMPARATOR|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
62105870|NCT03093792|ACTIVE_COMPARATOR|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
62105871|NCT00913328|ACTIVE_COMPARATOR|Montelukast|Oral montelukast 10 mg once daily for 12 weeks
62105872|NCT00913328|PLACEBO_COMPARATOR|Placebo|Oral placebo once daily for 12 weeks
62105873|NCT05664581|EXPERIMENTAL|Rapid Acoustic Pulse (RAP)|Participants will receive 3 separate RAP cellulite treatments sessions.
62105874|NCT02041676|EXPERIMENTAL|1: chest physiotherapy technique|Chest physiotherapy technique increasing inspiratory flow (IIF) 3 times per day
62105875|NCT02041676|ACTIVE_COMPARATOR|2: Usual surveillance|Usual surveillance of the non invasive ventilation
62105876|NCT06435468|EXPERIMENTAL|Patient with with a rare dysimmune disease|minors or adults of any age with a rare dysimmune disease characterized by autoimmunity, autoinflammation or early lymphoproliferation, with onset in childhood (\<18 years), or syndromic or familial.
62105877|NCT06435468|OTHER|Healthy volunteer participants|minor or adult participant without age restriction weighing more than 5 kg
62105878|NCT01568996|EXPERIMENTAL|Low dose BSE-SFN|BSE-SFN will be orally administered at 50 µmol SFN for 28 days.
62667857|NCT00476541|EXPERIMENTAL|1|Gemtuzumab 5 mg / m2 two courses with three week interval
62667858|NCT00476541|NO_INTERVENTION|2|No further therapy
62667859|NCT06500715|ACTIVE_COMPARATOR|Group A|Patients in Group A will undergo the acupuncture intervention at the 1st chemotherapy cycle; no acupuncture at the 2nd cycle; intervention at the 3rd; and so on.
62667860|NCT06500715|ACTIVE_COMPARATOR|Group B|No intervention at the 1st cycle; acupuncture intervention at the 2nd cycle; and so on.
62667861|NCT02236767|EXPERIMENTAL|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
62667862|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.~Patient may or may not be receiving terlipressin therapy."
62667863|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
62667864|NCT04834115|EXPERIMENTAL|Ivermectin|Ivermectin 200mcg/kg single dose, maximum dose 18mg
62667865|NCT04834115|PLACEBO_COMPARATOR|Placebo|Inactive medication tablets indistinguishable from ivermectin tablets
62667866|NCT00498485|PLACEBO_COMPARATOR|Placebo|Patients were randomized and these received placebo
62105879|NCT01568996|EXPERIMENTAL|Mid dose BSE-SFN|BSE-SFN will be orally administered at 100 µmol SFN for 28 days.
62105880|NCT01568996|EXPERIMENTAL|High dose BSE-SFN|BSE-SFN will be orally administered at 200 µmol SFN for 28 days.
62105881|NCT01107626|EXPERIMENTAL|Arm A (Induction then Maintenance with Bevacizumab)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm A receive bevacizumab IV over 30-90 minutes on day 1 of every cycle until progression or unacceptable toxicity."
62105882|NCT01107626|EXPERIMENTAL|Arm B (Induction then Maintenance with Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm B receive pemetrexed IV over 10 minutes on day 1 of every cycle until progression or unacceptable toxicity."
62308331|NCT05036538|EXPERIMENTAL|Relaxation intervention with natural sounds, binaural beats and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
62308332|NCT05036538|NO_INTERVENTION|Control without Intervention|
62667867|NCT00498485|ACTIVE_COMPARATOR|Sodium Oxybate|Patients were randomized and these received the active drug
62667868|NCT02234180|EXPERIMENTAL|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62667869|NCT02234180|PLACEBO_COMPARATOR|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62667870|NCT00962650|EXPERIMENTAL|NOTES Toolbox|Multiple devices designed for trans-orifice use during surgical procedures; used for transvaginal cholecystectomy in this trial
62667871|NCT06512233|ACTIVE_COMPARATOR|LMW Heparin 5000 U/ML-Aspirin 75 MG|Patients will receive 5000 unit of low molecular weight heparin subcutaneously once daily along with tablet aspirin 75 MG once daily, for additional thromboprophylaxis for free flap. The flaps of these patients will be monitored as standard clinical examination and outcome will be recorded until 4th post operative day.
62105883|NCT01107626|EXPERIMENTAL|Arm C (Induction then Maintenance with Bevacizumab & Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm C receive bevacizumab as in arm A and pemetrexed as in arm B."
62105884|NCT02680093||Cervical length in pregnant women.|"Pregnant Women beyond the date of birth in conservative monitoring and prenatal follow-up. will be followed while coming to routine monitoring.~physiological parameter of cervical length will be measured as the differential predictor to determine their due date."
61913395|NCT02496676|PLACEBO_COMPARATOR|Placebo, then magnesium|In phase 1, participants received oral placebo for 12 weeks then crossover to oral magnesium L-threonate for 12 weeks, followed by a 2-week washout period. In phase 2, all participants received 3 days of intravenous MgSO4 in 3 daily doses totaling 30 mg/kg/day followed by oral magnesium L-threonate for 24 weeks.
62105885|NCT04881799|PLACEBO_COMPARATOR|Placebo-Controlled Period|Participants in this phase of the study will be randomized 1:1 to receive either phentermine/topiramate or placebo.
62105886|NCT04881799|EXPERIMENTAL|Open Label Extension|Participants in this phase of the study will receive open label phentermine/topiramate.
62105887|NCT06713200|ACTIVE_COMPARATOR|Subjects treated with high-intensity percutaneous electrolysis.|
62105888|NCT06713200|ACTIVE_COMPARATOR|Subjects treated with low intensity percutaneous electrolysis.|
62105889|NCT06713200|SHAM_COMPARATOR|Subjects treated with simulated percutaneous electrolysis|
62105890|NCT03219502|EXPERIMENTAL|Group I (rTMS)|Patients undergo rTMS over 30 minutes for 10 sessions over 10 business days.
62105891|NCT03219502|SHAM_COMPARATOR|Group II (sham rTMS)|Patients undergo sham rTMS over 30 minutes for 10 sessions over 10 business days.
62105892|NCT03219502|ACTIVE_COMPARATOR|Group III (standard of care)|Patients receive standard of care.
62105893|NCT03810482|EXPERIMENTAL|The study population|"The study population as described by eligibility criteria.~Intervention: 6 minute walking test Intervention: pedometer"
62105894|NCT01219855|EXPERIMENTAL|Cohort 1: CTAP101 Capsules 60µg|
62105895|NCT01219855|EXPERIMENTAL|Cohort 1: CTAP101 Capsules 90µg|
62469052|NCT04680962|ACTIVE_COMPARATOR|EU-Rituximab / EU-Rituximab|Patients receive one or two treatment courses of MabThera®, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
62469053|NCT04680962|ACTIVE_COMPARATOR|US-Rituximab / MabionCD20|Patients receive a single treatment course of Rituxan®, consisting of two 1000 mg i.v. infusions at Day 1 and Day 15. After 24 weeks of follow-up, all patients eligible for re-treatment, are switched to receive a single treatment course of MabionCD20, consisting of two 1000 mg i.v. infusions at Week 24 and Week 26.
61913396|NCT02195414|EXPERIMENTAL|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
61913397|NCT02178839|EXPERIMENTAL|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
62105896|NCT01219855|PLACEBO_COMPARATOR|Cohort 1: Sugar Capsule|
62105897|NCT01219855|EXPERIMENTAL|Cohort 2: CTAP101 Capsules 30µg|
62105898|NCT01219855|PLACEBO_COMPARATOR|Cohort 2: Sugar Capsule|
62105899|NCT06714097|EXPERIMENTAL|Standard secondary prevention + digital twin|"Patients allocated to this arm will receive the standard secondary prevention and will also use the STRATIF-AI app, which will integrate digital twin (DT) technology to improve patient management during the secondary prevention phase and to assist patients in understanding key concepts, such as: Why should I care about a certain risk factor (e.g. blood pressure), and how can my lifestyle impact that risk factor? In other words, they will use the app to understand their medical situation, and to set personal goals."
62105900|NCT06714097|ACTIVE_COMPARATOR|Standard secondary prevention only|Patients allocated to this arm will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA.
62105901|NCT05582616|EXPERIMENTAL|Active tDCS with physiotherapy|Patients will engage in a six-week treatment protocol with 3 sessions per week (18 treatments). This was chosen to minimize discomfort and ensure the number of sessions is consistent with previous migraine literature. The primary motor cortex (M1) will be the treatment target to reduce pain sensitivity and improve motor learning. M1 will be found through measurements of the head: the point halfway between the nasion and inion and halfway between the left and right tragus will be found, we will then move down 20% of the inter-tragi distance and place the anode there. The cathode will then be placed over the super orbital region. Each electrode will be held in place with a strap and will make as much contact with the skin as possible. tDCS will be delivered via two 35cm2 surface sponge electrodes at an intensity of 2mA in the active group.
62105902|NCT05582616|SHAM_COMPARATOR|Sham tDCS with physiotherapy|In the sham condition, the number of sessions, placement of electrodes, and types of electrodes used will be the same, however, only a 30 second ramp up period will be administered to emulate active tDCS therapy. Patients will be able to hear the sounds of the device and will feel slight tingling for the first 30 seconds but will receive no active stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
62469054|NCT01959750|EXPERIMENTAL|Intervention Group|
62469055|NCT01959750|NO_INTERVENTION|Control Group|
62105903|NCT01703520||Male Finasteride Users|Male finasteride users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
62105904|NCT01703520||Male Finasteride Non-users|Country-matched male finasteride non-users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
62105905|NCT01703520||Men with Breast Cancer|Breast cancer cases among men aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
62105906|NCT01703520||Men without Breast Cancer|Country- and age-matched controls: men without breast cancer aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
62667872|NCT06512233|ACTIVE_COMPARATOR|LMW Heparin 5000 U/ML|Patients will receive 5000 unit of low molecular weight heparin subcutaneously once daily according to institutional protocol as routine practice for prevention of deep venous thrombosis in post operative period. The flaps of these patients will be monitored as standard clinical examination and outcome will be recorded until 4th post operative day.
62667873|NCT06282289|OTHER|6-month-old infants|
62667874|NCT06282289|OTHER|10-month-old infants|
62667875|NCT00611156|EXPERIMENTAL|A|Spice
62667876|NCT00611156|EXPERIMENTAL|B|Spice
62667877|NCT00611156|EXPERIMENTAL|C|Spice
62667878|NCT00611156|EXPERIMENTAL|D|Spice
62667879|NCT00611156|PLACEBO_COMPARATOR|E|Placebo
62667880|NCT01995435|EXPERIMENTAL|Telemedicine refraction before traditional refraction|We will first refract an individual using telemedicine refraction, and then refract them using a traditional refraction method.
62667881|NCT01995435|EXPERIMENTAL|Traditional refraction before telemedicine refraction|We will first refract an individual using a traditional refraction, and then refract them using a telemedicine refraction method.
62667882|NCT04205825|EXPERIMENTAL|New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
62667883|NCT04205825|NO_INTERVENTION|Habitual Practice|Patients randomized in this arm they will receive the habitual practice.
62667884|NCT02993341|EXPERIMENTAL|Tranexamic Acid Wash|Participants in the experimental arm will receive a wash of tranexamic acid topically at the site of surgery.
62667885|NCT02993341|PLACEBO_COMPARATOR|Saline Wash|Participants in the control arm will receive a wash of saline topically at the site of surgery.
61913398|NCT02178839|PLACEBO_COMPARATOR|Maltodextrin|8.5 g/d Maltodextrin
61913399|NCT00604214|EXPERIMENTAL|Drotrecogin alfa (activated)|
62105907|NCT03703479|EXPERIMENTAL|A-PRF group|Socket site that will receive A-PRF clot
62105908|NCT03703479|NO_INTERVENTION|control|socket site that will not receive any intervention
62105909|NCT00465985|EXPERIMENTAL|Part I, Part II-arm1, & Part III|
62105910|NCT00465985|PLACEBO_COMPARATOR|Part II - arm 2|
62105911|NCT03991949|EXPERIMENTAL|Experimental Infant Formula|Ready-to-feed, milk-based formula
62105912|NCT03134235|EXPERIMENTAL|Raw, plant-based diet|A raw, plant-based diet was prescribed for 4 weeks.
62105913|NCT05701592||Patients with PCL tear treated with DB-PCLR|Patients with PCL tear treated with DB-PCLR
62105914|NCT06173570|EXPERIMENTAL|Arm A|AZD0780, Dose 1
62105915|NCT06173570|EXPERIMENTAL|Arm B|AZD0780, Dose 2
62105916|NCT06173570|EXPERIMENTAL|Arm C|AZD0780, Dose 3
62105917|NCT06173570|EXPERIMENTAL|Arm D|AZD0780, Dose 4
62469056|NCT03226054|OTHER|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
62667886|NCT03219736|ACTIVE_COMPARATOR|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
62667887|NCT03219736|ACTIVE_COMPARATOR|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
62667888|NCT02087592|NO_INTERVENTION|Control|Usual standard of care
62105918|NCT06173570|PLACEBO_COMPARATOR|Arm E|Placebo, matched for appearance
62105919|NCT00013143|OTHER|Arm 1|
62105920|NCT03363061||Antithrombotics|The patients should be on antithrombotics on the day of colonoscopy arrangement
62105921|NCT03328117|ACTIVE_COMPARATOR|Intervention|
62105922|NCT03328117|PLACEBO_COMPARATOR|Placebo|
62469057|NCT06204991|EXPERIMENTAL|Tumor-infiltrating lymphocytes genemodified with IL-7 gene for IL-7 production upon Ag engagement|"Tumor-infiltrating lymphocytes grown ex-vivo from resected tumor tissue and reapplied to the patient via an intravenous infusion.~Drug: Cyclophosphamide: 2 doses (69 mg/kg) prior to infusion Drug: Fludarabinephosphat 5 doses (25 mg/m2, max. 50 mg) prior to infusion Drug: Proleukin 600.000 IU/kg/dose IL-2 a maximum of 6 doses"
62667889|NCT02087592|EXPERIMENTAL|Intervention|Usual standard of care plus structured physical exercise training plus mediterranean-style diet
62667890|NCT02776787||Patients|Patients with diverticulitis
62667891|NCT02776787||Surgeons|Surgeons who perform elective colon resections
62667892|NCT05698212|ACTIVE_COMPARATOR|Cohort 1|Endometriosis diagnosed at stage 1 or 2
62667893|NCT05698212|ACTIVE_COMPARATOR|Cohort 2|Endometriosis diagnosed at stage 3 or 4
62667894|NCT05698212|OTHER|Cohort 3|"Control--Not suspected of having and absence of endometriosis confirmed by diagnostic test.~This group has uterine tissue biopsy and laparoscopy for non-endometriosis indication, i.e. tubal ligation"
62105923|NCT03238482|ACTIVE_COMPARATOR|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
62105924|NCT03238482|EXPERIMENTAL|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
62105925|NCT03238482|EXPERIMENTAL|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
62105926|NCT03238482|EXPERIMENTAL|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
62105927|NCT05892913|ACTIVE_COMPARATOR|Efedrine Group|For sympathetic blockade (SBP\<90) if developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine would be used and repeated if necessary. In case of development of bradycardia (\<65/min) in this group, Atropine 0.5 mg/mL would be planned to be administered and repeated if necessary.
62105928|NCT05892913|EXPERIMENTAL|Preemptive Atropine Group|In the atropine group, it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia). In this group if SBP\<90 despite slow dose atropine administration; it will be planed to give efedrine as bolus of 5 mg/mL. And for bradicardia (HR\<65/min) it will be planed to give Atropine 0.5 mg/mL.
62105929|NCT06475807|EXPERIMENTAL|high-fermented food + high fiber supplementation|"Step 1: patients will consume high-fermented food~Step 2: High fiber supplementation"
62105930|NCT05671094|NO_INTERVENTION|Control group|Standard of care, i.e no specific program prior to surgery.
62105931|NCT05671094|EXPERIMENTAL|Prehabilitation group|A multimodal prehabilitation program including 4 different components (physical, cognitive, nutritional and stress reduction prehabilitation) will be proposed to patients in order for them to participate during four to two weeks pre-operatively.
62105932|NCT02683824|EXPERIMENTAL|pancreatic cancer patients|Patients receive \[18F\]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
62667895|NCT04261166|EXPERIMENTAL|Single dose|Single dose in fasted state of : A1, A2,A3, A4, A5, B1, B2, B3, B4
62105933|NCT02683824|EXPERIMENTAL|healthy patients|Patients receive \[18F\]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
62105934|NCT06630429||Cohort A|Includes patients with Stage IB-IV NSCLC receiving treatment with immune checkpoint inhibitors either alone or in combination with chemotherapy.
62105935|NCT06630429||Cohort B|Includes patients with metastatic RCC receiving first line combination with nivolumab and ipilimumab.
62105936|NCT06628570||HIV Positive MSM with high grade LGTN|At each study visit, participants will receive a digital anorectal examination followed by HRA, with directed biopsies of suspicious lesions. An HRA-certified physician will collect anal swabs and HRA-directed biopsies for histological confirmation of disease and biomarker assays.
62105937|NCT06628570||HIV Negative MSM with high grade LGTN|At each study visit, participants will receive a digital anorectal examination followed by HRA, with directed biopsies of suspicious lesions. An HRA-certified physician will collect anal swabs and HRA-directed biopsies for histological confirmation of disease and biomarker assays.
62105938|NCT06628570||HIV Positive women with high grade LGTN|At each study visit, participants will receive a digital anorectal examination followed by HRA, with directed biopsies of suspicious lesions. An HRA-certified physician will collect anal swabs and HRA-directed biopsies for histological confirmation of disease and biomarker assays.
62667896|NCT04261166|EXPERIMENTAL|Cross-Over food effect|2 doses: fasted and fed state with the same product: A1, A4, A5, B4
62667897|NCT04261166|EXPERIMENTAL|Cross-Over product comparison|2 doses: in fasted state comparing A1 to A4
62667898|NCT04261166|EXPERIMENTAL|Cross-over route of administration comparison|2 doses: in fasted state comparing oral administration to sublingual administration of A4
62667899|NCT01903044|EXPERIMENTAL|BM-MNC injection|Injection of autologous bone marrow-derived mononuclear cells
62667900|NCT04836130|ACTIVE_COMPARATOR|(ZMC) Fractures reduction Using Patient Specific Guide (PSG)|
62667901|NCT04836130|ACTIVE_COMPARATOR|(ZMC) Fractures reduction Using Conventional Technique|
62667902|NCT03134638|EXPERIMENTAL|Dose Escalation|Dose escalation phase to explore maximum tolerated dose across two dosing schedules. SY-1365 will be administered intravenously weekly and twice-weekly for 3 weeks of each 4-week cycle
62667903|NCT03134638|EXPERIMENTAL|Advanced Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
62667904|NCT03134638|EXPERIMENTAL|Relapsed Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatin)
62667905|NCT03134638|EXPERIMENTAL|Clear Cell Ovarian Cancer|Patients with clear cell ovarian cancer previously treated with ≥ 1 prior line of therapy (SY-1365 single agent)
62667906|NCT03134638|EXPERIMENTAL|Advanced Solid Tumors|Biopsy cohort of approximately 20-30 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained (SY-1365 single agent)
62667907|NCT03134638|EXPERIMENTAL|HR+ breast cancer|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy (SY-1365 + fulvestrant)
62667908|NCT06377085|EXPERIMENTAL|AZA 10mg/m^2|5-Azacytidine, subcutaneous injection, 10mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
62667909|NCT06377085|EXPERIMENTAL|AZA 20mg/m^2|5-Azacytidine, subcutaneous injection, 20mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
62667910|NCT06377085|EXPERIMENTAL|AZA 35mg/m^2|5-Azacytidine, subcutaneous injection, 35mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
62667911|NCT06377085|EXPERIMENTAL|AZA 75mg/m^2|5-Azacytidine, subcutaneous injection, 75mg/m\^2, one subcutaneous injection for duration of study (estimated at 46 - 76 days)
62667912|NCT06377085|PLACEBO_COMPARATOR|Placebo for 10mg/m^2|Placebo, subcutaneous injection, 10mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
62667913|NCT06377085|PLACEBO_COMPARATOR|Placebo for 20mg/m^2|Placebo, subcutaneous injection, 20mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
62667914|NCT06377085|PLACEBO_COMPARATOR|Placebo for 35mg/m^2|Placebo, subcutaneous injection, 35mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
62667915|NCT06377085|PLACEBO_COMPARATOR|Placebo for 75mg/m^2|Placebo, subcutaneous injection, 75mg/m\^2, one subcutaneous injection without the active treatment for duration of study (estimated at 46 - 76 days)
62469058|NCT04176094|EXPERIMENTAL|16 hour schedule|All residents assigned to an ICU randomized to a 16h overnight schedule will complete 16h overnight calls not preceded by an 8h daytime shift.
62667916|NCT06348212|EXPERIMENTAL|Probiotic group|They are given probiotic capsules of Lactobacillus paracasei PS23. Each capsule contains 100 mg of probiotic powder(10,000,000,000 CFU) Subjects should take two capsules per day for two months
62667917|NCT06348212|PLACEBO_COMPARATOR|Placebo group|They are given probiotic capsules of microcrystalline cellulose. Subjects should take two capsules per day for two months
62667918|NCT05935488||Early Liver Disease|A total of 30 subjects with fibroscan confirmed liver fibrosis likely due to non-alcoholic steatohepatitis (NASH) will be recruited.
62667919|NCT02617290|EXPERIMENTAL|Ticagrelor Arm|Ticagrelor is an oral antiplatelet agent which was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. It is available as round, yellow tablets (90 mg). The standard dose is 90 mg twice a day during the maintenance phase and 180 mg once for the loading dose. It is approved for duration of 12 month in ACS patients and will be used for duration of one month in the ALPHEUS Study.
62667920|NCT02617290|ACTIVE_COMPARATOR|Clopidogrel Arm|Clopidoprel is an oral antiplatelet agent which was approved for use in the European Union by the European Commission in 1997 and available as generic since 2007. The standard dose of clopidogrel is one 75 mg tablet once a day. The dosage for the loading dose is normally 300 mg but 600 mg is also used. Clopidogrel is the standard of care for PCI at the moment.
62667921|NCT06355349|OTHER|Sequence A|"Treatment A: Co-administration of 1 tablet of JW0101 and 1 tablet of C2101 Treatment B: Administration alone of 1 tablet of JW0102~Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration"
62667922|NCT06355349|OTHER|Sequence B|"Treatment A: Co-administration of 1 tablet of JW0101 and 1 tablet of C2101 Treatment B: Administration alone of 1 tablet of JW0102~Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration"
62667923|NCT01006408|ACTIVE_COMPARATOR|Low Level Laser|Low Level Laser twice a week for 8 weeks
62667924|NCT01006408|SHAM_COMPARATOR|Placebo and Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
62667925|NCT02508207|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
62667926|NCT02508207|EXPERIMENTAL|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
62667927|NCT06154473||Open heart surgery|Cohort of patient undergoing an open heart surgery. Open heart surgery is defined as a surgical procedure that involves making an incision in the chest to opening the chest wall to access and operate on the heart. The study will include patients who undergo valve repair, valve replacement, or coronary artery bypass grafting. In addition, combined surgery, define as valve surgery in combination with coronary artery bypass grafting, will also be included. Heart transplant will not be included.
62667928|NCT06154473||Percutaneous cardiovascular surgery|Cohort of patient undergoing a percutaneous cardiovascular surgery. Percutaneous cardiovascular surgery is defined as a surgical procedure that involves making an incision in the skin to use a catheter-based approach to access and operate on the heart. The study will include patients who undergo transcatheter aortic valve implantation, valve in valve transcatheter aortic valve implantation and transcatheter mitral-valve repair or replacement.
62667929|NCT02708173|EXPERIMENTAL|One dose Vaccine in aged 18-60 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 18-60 years old.
62667930|NCT02708173|EXPERIMENTAL|One dose Vaccine in aged 3-17 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 3-17 years old.
62667931|NCT03595891||Adult with acute PE before the introduction of apixaban|
62667932|NCT03595891||Adult with acute PE after the introduction of apixaban|
62667933|NCT00599313|EXPERIMENTAL|Sunitinib Malate|Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
62667934|NCT00739219|ACTIVE_COMPARATOR|eNO group|eNO measurement is used to inform asthma management decisions
62105939|NCT06628570||HIV Negative women with high grade LGTN|At each study visit, participants will receive a digital anorectal examination followed by HRA, with directed biopsies of suspicious lesions. An HRA-certified physician will collect anal swabs and HRA-directed biopsies for histological confirmation of disease and biomarker assays.
62105940|NCT06290089|OTHER|ETEC strain|Each enrolled subject will receive a single administration of the challenge dose
62105941|NCT01545674||Pregnant Women Blood Draw|Pregnant Women with elevated risk of trisomic pregnancy to donate a blood sample through one time blood draw
62105942|NCT05482386|EXPERIMENTAL|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
62105943|NCT05482386|NO_INTERVENTION|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
62667935|NCT00739219|NO_INTERVENTION|control group|Asthma is managed according to existing standard of care
62667936|NCT02957825|NO_INTERVENTION|Control|Routine monitoring
62667937|NCT02957825|EXPERIMENTAL|Continuous wireless monitoring|Continuous wireless monitoring
62105944|NCT04760301|EXPERIMENTAL|local tranexamic acid injection to cervix|1 gr of Tranexamic acid diluted in 10 ml saline
62667938|NCT02472093|ACTIVE_COMPARATOR|Physical exercises treatment|The types of exercises included: low-impact to moderate aerobic training (gradually starting from 50% of the Fc max to 70%-80% of Fc max); walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing.
62667939|NCT02472093|EXPERIMENTAL|Perceptive Rehabilitation Treatment|Perceptual surfaces is a therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips; usually, over 100 cones are used for each session. Patients were asked to lie down supine on the surface that was formed by the smoothed apex of these cones, creating reaction forces to the patient's weight, generated by the interaction with the cones.
62667940|NCT02472093|ACTIVE_COMPARATOR|Control group|The control group did brief educational sessions.
62667941|NCT03115970||Trauma patients|All patients having / suspected to have severe trauma injuries
61913400|NCT00604214|PLACEBO_COMPARATOR|Placebo|
62105945|NCT04760301|PLACEBO_COMPARATOR|local normal saline injection to cervix|20 ml of saline
62105946|NCT04760301|EXPERIMENTAL|IV 1 g tranexamic acid|1 gr of Tranexamic acid diluted in 100 ml saline- IV
62469059|NCT04176094|ACTIVE_COMPARATOR|24 hour schedule|All residents assigned to an ICU randomized to a 24h overnight schedule will complete 24h shifts when scheduled for overnight calls (8h daytime shift followed by a 16h overnight call).
62469060|NCT04380610||Pediatric SCA|We will develop a novel eGFR equation in 200 pediatric participants
62105947|NCT04760301|PLACEBO_COMPARATOR|IV 1 g normal saline|100 ml saline- IV
62469061|NCT04380610||Adult SCA|We will develop a novel eGFR equation in 200 adult participants
62667942|NCT02686255||Children 0-18 months post heart surgery|complete blood count for all children 0-18 months going through cardiac surgery
62667943|NCT04135001|EXPERIMENTAL|HBM Training|
62667944|NCT04135001|PLACEBO_COMPARATOR|Placebo Training|
62667945|NCT00371449||hearing aid users|hearing aid users
61913401|NCT03338959|EXPERIMENTAL|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
61913402|NCT01143389|ACTIVE_COMPARATOR|Riboflavin 0.1% eyedrops every 5 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
62105948|NCT02973243||Manual Respiration Rate Measurement|Patients with manually measured respiratory rate
62105949|NCT02973243||Automatic Respiration Rate Measurement|Patients with automatically measured respiratory rate
62667946|NCT01281306|EXPERIMENTAL|VAL + AHU 400 mg|Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
62667947|NCT01281306|EXPERIMENTAL|VAL + AHU 200 mg|Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
62667948|NCT01281306|EXPERIMENTAL|VAL + AHU 100 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
62667949|NCT01281306|EXPERIMENTAL|VAL + AHU 50 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
62667950|NCT01281306|EXPERIMENTAL|VAL 320 mg|Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
62667951|NCT01281306|EXPERIMENTAL|LCZ 400 mg|Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
62667952|NCT01281306|EXPERIMENTAL|Placebo|Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
62667953|NCT00004032|EXPERIMENTAL|Treatment (ALVAC-hB7.1, recombinant interferon gamma)|Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.
62667954|NCT03418675|PLACEBO_COMPARATOR|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
62667955|NCT03418675|EXPERIMENTAL|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
62667956|NCT01149551||Group 1|
62667957|NCT03289312||Sepsis|Diagnosis of new onset sepsis within 24h without history of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.
62667958|NCT03289312||Health control|Health vonlunteers
62667959|NCT03238469|EXPERIMENTAL|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
62667960|NCT03238469|NO_INTERVENTION|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
62667961|NCT04379180||Treatment(bosentan, sildenafil and tadalafil)|
62667962|NCT05720247|EXPERIMENTAL|Fibroscan|Screening and brief intervention with additional Fibroscan procedure and sharing of results with patient
62667963|NCT05720247|ACTIVE_COMPARATOR|Standard Care|Screening and brief intervention without Fibroscan
62667964|NCT02580552|EXPERIMENTAL|Part A, MF|Intratumoral Injection of cobomarsen
62667965|NCT02580552|EXPERIMENTAL|Part B, MF|Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy
62667966|NCT02580552|EXPERIMENTAL|Part C, MF|Subcutaneous or intravenous administration of cobomarsen as monotherapy
61913403|NCT01143389|ACTIVE_COMPARATOR|Riboflavin 0.1% eyedrops every 2 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
62105950|NCT05707052|EXPERIMENTAL|Neck-Trunk Stabilization exercises|First neck and trunk exercise involved lifting the head in a modified bridge exercise position so that lower abdominal muscles contracted when the neck was bent, thereby activating the neck flexor muscle and the lower abdominal muscles simultaneously. Second exercise involved pushing the neck backward in supine position to activate the erector muscles of the neck and the upper thoracic vertebrae through the extension of the muscles of the back of the neck. Third exercise activated the deep abdominal muscles in bridge exercise positions so that the participants would experience the posterior inclined movement of the pelvis. Keep each posture for 10 seconds at a time and repeat 10 times with a rest interval of 3 seconds per each.
62667967|NCT02580552|EXPERIMENTAL|Part D, CLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
61913404|NCT03680456|ACTIVE_COMPARATOR|Intervention|due to postoperative Hemoglobin Level intravenous iron Ferriccarboxymaltose is Infuses, dosage is based on the Ganzoni-Algorithm
62667968|NCT02580552|EXPERIMENTAL|Part E, DLBCL, activated B-cell (ABC) subtype|Subcutaneous or intravenous administration of cobomarsen as monotherapy
62667969|NCT02580552|EXPERIMENTAL|Part F, ATLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
62667970|NCT01101555|EXPERIMENTAL|COHORT 1: CUMULATIVE DOSE 1.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 3 days, dose 0.3, 0.5, 0.7, four patients in cohort, one of which is on placebo, escalation increment N/A
61913405|NCT03680456|PLACEBO_COMPARATOR|Placebo|Natriumchlorid is the placebo
62308333|NCT02440724|EXPERIMENTAL|winged stent group|participants who are assigned to winged-stent group will be treated with deployment of a winged stent(partially covered or uncovered SEMS).
62667971|NCT01101555|EXPERIMENTAL|COHORT 2: CUMULATIVE DOSE 3.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.5, 0.7, 1.0, 1.0 four patients in cohort, one of which is on placebo, escalation increment 2.3 fold.
62667972|NCT01101555|EXPERIMENTAL|COHORT 3: CUMULATIVE DOSE 6.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 7 days, dose 0.3, 0.7, 5 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.7 fold.
62667973|NCT01101555|EXPERIMENTAL|COHORT 4: CUMULATIVE DOSE 8.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.7, 1.0, 2 x 3.0 four patients in cohort, one of which is on placebo, escalation increment 1.33 fold.
62667974|NCT01101555|EXPERIMENTAL|COHORT 5: CUMULATIVE DOSE 10MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 10 days, dose 10 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.25 fold.
62667975|NCT01101555|EXPERIMENTAL|COHORT 6: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 15 days, dose 15 x 1.0 six patients in cohort, one of which is on placebo, escalation increment 1.5 fold.
62667976|NCT01101555|EXPERIMENTAL|COHORT 7: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 5 x 3.0 six patients in cohort, one of which is on placebo, escalation increment N/A
62667977|NCT03264950|OTHER|SIngle Arm|All patients undergo Elastography. This is a single arm study
62667978|NCT01098695|EXPERIMENTAL|EcoFIT offered|
62667979|NCT01098695|NO_INTERVENTION|No Feedback or services offered|
62667980|NCT01609192|EXPERIMENTAL|hydroxyurea|
62667981|NCT03599466|EXPERIMENTAL|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
62667982|NCT03599466|ACTIVE_COMPARATOR|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
62667983|NCT02945046|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo administered via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injection at Weeks 4 and 8, respectively.
62667984|NCT02945046|EXPERIMENTAL|Fremanezumab 675 mg/Placebo/Placebo|Participants will receive placebo as an approximately 1-hour intravenous infusion followed by fremanezumab at 675 milligrams (mg) administered as 3 subcutaneous injections (225 mg/1.5 milliliters \[mL\]) at Week 0 and placebo administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
62667985|NCT02945046|EXPERIMENTAL|Fremanezumab 900/225/225 mg|Participants will receive fremanezumab at 900 mg administered via an approximately 1-hour intravenous infusion followed by 3 placebo subcutaneous injections at Week 0 and fremanezumab at 225 mg administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
62667986|NCT05535088|EXPERIMENTAL|Virtual reality|Virtual reality
62667987|NCT06140641|PLACEBO_COMPARATOR|Placebo group|Daily administration of placebo for 8 weeks.
62667988|NCT06140641|EXPERIMENTAL|Probiotics group|Daily administration of Bifidobacterium Longum BL21 for 8 weeks.
62667989|NCT01160900|EXPERIMENTAL|multivessel revascularization|Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure
62667990|NCT01433588|ACTIVE_COMPARATOR|Calmer|This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
62667991|NCT01433588|PLACEBO_COMPARATOR|Standard Care|Standard of care during bloodwork is receiving a soother and facilitated tucking.
62667992|NCT04393844|PLACEBO_COMPARATOR|with obturator|A group using an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
62667993|NCT04393844|EXPERIMENTAL|without obturator|A group that does not use an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
61913406|NCT03007888|EXPERIMENTAL|IPX203 then Sinemet|Participants first received IPX203 ER CD-LD Capsules for 15 days After a Washout Period of 7 days; participants then received Sinemet (IR CD-LD) Tablet for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
62469062|NCT01049893|EXPERIMENTAL|AC220|Dose finding study. Number of arms dependant upon dose limiting toxicities.
62297954|NCT05040191|EXPERIMENTAL|Haptic Interactive Virtual Reality Simulation(Experiment 1 group)|Application in the Experiment-1 Group: After the theoretical lesson, the students in the Experiment-1 group were taken to the computer laboratory room where the haptic interactive virtual reality application was installed. The Nasogastric Tube Application with Haptic Interactive Virtual Reality Simulation was applied and explained by the researcher and preliminary information was given. The questions were answered by allowing the students to ask questions.
62308334|NCT06304441|EXPERIMENTAL|Group A|Intra-pemetrexed plus third-generation small molecule TKI drugs (e.g. 'osimertinib')
62469063|NCT06420986|EXPERIMENTAL|Hemorrhoidectomy|
62469064|NCT06420986|EXPERIMENTAL|Transanal Hemorrhoidal Dearterialization|
62469065|NCT05508932||Beta-thalassemia|Patients with Beta-thalassemia undergoing a cardiological evaluation
62469066|NCT02792426|ACTIVE_COMPARATOR|Group 1 AB|Smoker subject's own brand of combustion cigarette
62469067|NCT02792426|ACTIVE_COMPARATOR|Group 1 BA|Smoker subject's own brand of combustion cigarette
62469068|NCT02792426|ACTIVE_COMPARATOR|Group 2|E-cigarette user's own brand of electronic nicotine delivery system (ENDS)
62469069|NCT04325256||study group|All pregnant women who will attend the labor unit for induction of labour due to different indications during the study period will be invited to participate in the study.
62667994|NCT00401115|EXPERIMENTAL|1|Subconjunctival injection
62667995|NCT00401115|EXPERIMENTAL|2|Intraocular injection
62667996|NCT01270685||1|Veterans with spinal cord injuries and disorders
62667997|NCT01270685||2|Comparison group: general Veteran population (without spinal cord injuries or disorders)
62667998|NCT01270685||3|Health care providers with face-to-face contact with Veterans with SCI/D
62667999|NCT01270685||4|Infection control Chiefs/Officers
62668000|NCT04027946|EXPERIMENTAL|Mesothelin Expressing Non-Small Cell Lung Cancer Participants|LMB-100 + Pembrolizumab
62668001|NCT06174701|EXPERIMENTAL|Intervention|"Participants in the intervention arm will receive PST. Meetings via videoconferencing or phone will occur at a frequency of 1 time every week for an estimated 2-3 sessions before surgery and 6-7 sessions after surgery for a total of 9 sessions.~PST: Essential components of the PST that the patient will be taught include: (1) define the nature of the problem, (2) generate wide range of possible solutions, (3) systematically evaluate the potential solutions and select the most optimal ones to implement, (4) monitor and evaluate the actual solution outcome after implementation."
62668002|NCT06174701|NO_INTERVENTION|Enhanced Usual Care|"Participants in the control arm will receive enhanced usual care. They will receive additional mental health education in the form of educational handouts mailed or emailed to them."
62668003|NCT03833258|NO_INTERVENTION|Rehabilitation with precautions|Patients in this arm will continue with rehabilitation following routine care recommendations after total hip replacement; therefore following precautions.
62668004|NCT03833258|EXPERIMENTAL|Rehabilitation with no precautions|Patients in this arm will continue with rehabilitation after total hip replacement without precautions, being permitted to move within limits of their own pain only.
62469070|NCT02486900|EXPERIMENTAL|Neurofeedback training group|The neurofeedback group will perform 6 training sessions over a period of 4 months: 4 fortnightly sessions in the first two months will be followed by 2 monthly 'booster' sessions. Each session will include several behavioural assessments and fMRI-based neurofeedback training in an MRI scanner (1 h). The neurofeedback training phase will be be followed-up by two behavioural assessments 8 and 12 months after the first training.
62469071|NCT02486900|NO_INTERVENTION|Treatment-as-usual control group|The control group will receive treatment as usual (e.g. medication, counselling) but no neurofeedback training during the study period. Patients in the control group will be invited for four behavioural assessment sessions (baseline assessment, follow-up assessments 4/8/12 months after baseline).
62469072|NCT03525860|EXPERIMENTAL|Acupuncture Treatment|"20 subjects will be treated with standard of care and acupuncture.~Will complete Symptom and Pain questionnaire (VAS) and a Was It Worth It (WIWI) questionnaire each day of study participation (3 days)."
62469073|NCT03525860|NO_INTERVENTION|No Intervention|"20 subjects will be treated with standard of care only.~Will complete Symptom and Pain questionnaire (VAS) each day of study participation (3 days)."
62668005|NCT05176574||Physicians|Physicians from 12 different specialties (i.e. General Medicine, Endocrinologists, Neurologists, Cardiologists, Orthopedists, Pathologists, Rheumatologists, Phytochemists-Pneumonologists, Vascular Surgeons, Oncologists-Pathologists, Psychiatrists, Neurologists-Psychiatrists) who manage patients with non-communicable diseases.
62668006|NCT01673945|ACTIVE_COMPARATOR|EUS-FNA with the CLA-EUS|patients examined with the CLA-EUS
62469074|NCT01629381|EXPERIMENTAL|Rivaroxaban|Oral Rivaroxaban 10 mg od for 7 days
62469075|NCT01629381|PLACEBO_COMPARATOR|Placebo|oral placebo od for 7 days
62469076|NCT02601794|EXPERIMENTAL|App-based Mindfulness Training|12 week mindfulness training delivered remotely through mobile app
62469077|NCT02601794|NO_INTERVENTION|Waitlist Control|No intervention provided during study period. 12 week mindfulness training will be delivered through mobile app once all study assessments have been completed
62469078|NCT02246322|EXPERIMENTAL|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
62469079|NCT02246322|EXPERIMENTAL|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
62469080|NCT03261310|EXPERIMENTAL|Acetaminophen & Craniotomy|Drug: Acetaminophen 1000mg administered intravenously during craniotomy
62469081|NCT03261310|PLACEBO_COMPARATOR|Placebo & Craniotomy|Placebo administered intravenously during craniotomy.
62469082|NCT03261310|EXPERIMENTAL|Acetaminophen & Laminectomy|Acetaminophen 1000mg administered intravenously during laminectomy.
62469083|NCT03261310|PLACEBO_COMPARATOR|Placebo & Laminectomy|Placebo administered during laminectomy.
62469084|NCT05084066|EXPERIMENTAL|Experimental group|20 patients with PAD and claudication
62469085|NCT05084066|SHAM_COMPARATOR|Control group (sham)|20 patients with PAD and claudication
62297955|NCT05040191|EXPERIMENTAL|Haptic Interactive Computer Based Simulation(Experiment 2 group)|Application in the Experiment-2 Group: After the theoretical lesson, the students in the Experiment-2 group were taken to the laboratory room where the haptic interactive computer-based simulation was located. This computer-assisted simulation allows us to see the application on the computer screen while performing an application with a haptic arm. It gives feedback on hand manipulations similar to reality. It was explained by the researcher by applying the nasogastric tube application skill with haptic interactive computer-based simulation and preliminary information was given. The questions were answered by allowing the students to ask questions.
62469086|NCT02149693|EXPERIMENTAL|high-fidelity simulation and teamwork training|high-fidelity simulation and teamwork training
62469087|NCT02149693|ACTIVE_COMPARATOR|traditional resuscitation training|traditional resuscitation training
62469088|NCT02340897||Nontuberculous lung disease|Patients with Nontuberculous Mycobacteria satisfying American Thoracic Society and British Thoracic Society guidelines
62469089|NCT02340897||pulmonary tuberculosis|Patients with culture confirmed tuberculosis
62469090|NCT02340897||bronchiectasis|Patients with bronchiectasis based on chest CT findings as well as symptoms
62469091|NCT02453386|EXPERIMENTAL|Tozadenant 60 mg BID|"During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
62469092|NCT02453386|EXPERIMENTAL|Tozadenant 120 mg BID|"During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
62668007|NCT01673945|EXPERIMENTAL|EUS-FNA With the FV-EUS|patients examined with the FV-EUS
62668008|NCT02625740|EXPERIMENTAL|Study group|After crossing the lesion with a guidewire, patients will be treated with intravascular high intensity, low-frequency ultrasound followed by local administration of liquid mixture of Paclitaxel and Iopromide-370 with predetermined dosage of 1.0 µg/mm
62668009|NCT02625740|ACTIVE_COMPARATOR|Control group|After crossing the lesion with a guidewire, patients will be treated with drug eluting ballon angioplasty with the In.Pact Admiral ballon (Medtronic)
62668010|NCT00508508|EXPERIMENTAL|1|Behavioral: IVR
62668011|NCT00508508|EXPERIMENTAL|2|Behavioral: Nurse-Led Group Visits
62668012|NCT02817204|EXPERIMENTAL|Aerobic Exercise group|Cardio Pulmonary Exercise Test(CPET) Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
62105951|NCT05707052|EXPERIMENTAL|Bobath Therapy|"1. trunk-pelvic-hip neutral alignment with anterior-posterior weight shifts on the ball,~2. bilateral upper extremity abduction-traction for lateral weight shift,~3. prone extension on the ball,~4. forward weight shift for the trunk and hip extension and forward protective extension,~5. diagonal weight shifts in flexion-rotation direction,~6. lateral weight shift for simultaneous activation of flexors and extensors,~7. bilateral shoulder flexion for latissimus dorsi elongation,~8. pectoral elongation exercise for trunk extension,~9. preparatory trunk activities (with continuous and/or intermittent compression and intermittent support),~10. positioning and holding of the head-trunk Keep each posture for 10 seconds at a time with a rest interval of 3 seconds per each."
62469093|NCT02453386|PLACEBO_COMPARATOR|Placebo BID|"During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
62668013|NCT02817204|OTHER|Health Education Group|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol Cardio Pulmonary Exercise Test(CPET) No Cycle ergometer exercise
62105952|NCT03686813|PLACEBO_COMPARATOR|Placebo|Each participant will be studied with active drug and placebo.
62297956|NCT05152355|EXPERIMENTAL|Budesonide HFA MDI (Treatment A)|Participants assigned to Experimental arm will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks
62297957|NCT05152355|ACTIVE_COMPARATOR|Budesonide DPI (Turbuhaler) (Treatment B)|Participants assigned to Active Comparator arm will inhaled 4 puffs of budesonide 100 mcg powder for inhalation bid (am 08:00 and pm 16:00) for 4 weeks
62469094|NCT05857891|EXPERIMENTAL|Erythropoietin group|intravenous injection of 40000iu of rhEPO
62469095|NCT05857891|PLACEBO_COMPARATOR|0.9%NS|intravenous injection of the same volume of 0.9%NS as the test group
62469096|NCT02196766|ACTIVE_COMPARATOR|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
62469097|NCT02196766|ACTIVE_COMPARATOR|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
62668014|NCT06494956|EXPERIMENTAL|Single unit|An implantable computer fills the deep nervous system and turns it on for treatment
62668015|NCT01041079||Chronic marginal ulcer after RYGB|Patients with intractable or chronic marginal ulcer disease after gastric bypass complaining of abdominal pain, GI bleeding, obstruction, perforation and penetration. Sometimes with other associated diagnosis such as narcotic and tobacco dependence, protein-calorie malnutrition, excessive weight loss, poor pouch emptying syndrome, weight regain, inadequate initial weight loss, severe dumping syndrome among others.
62668016|NCT02732730|EXPERIMENTAL|PrEP Acceptor|"For those women who choose to accept PrEP (Truvada), the following adherence support package will be provided:~* Cognitive Behavioral Theory adherence support sessions~* Two-way SMS communications~* Optional monthly adherence support clubs Drug level counseling for those randomized to that extra intervention (1:1)"
62668017|NCT02732730|NO_INTERVENTION|PrEP Decliner|Standard of care
62105953|NCT03686813|ACTIVE_COMPARATOR|Sildenafil|Sildenafil 50 mg orally one hour (once) before immersed exercise
62105954|NCT01345292|EXPERIMENTAL|12027-027|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
62297958|NCT01941225|PLACEBO_COMPARATOR|Placebo|Nebulized normal saline. Single administration
62297959|NCT01941225|EXPERIMENTAL|Inhaled iloprost 5.0 mcg|Single administration
62297960|NCT05747690|EXPERIMENTAL|KIO015 - Cohort 1|One injection of KIO015 on the hemi-face. The untreated hemi-face is used as a comparator.
62297961|NCT05747690|EXPERIMENTAL|KIO015 - Cohort 2|3 injections at one month interval on the hemi-face. The untreated hemi-face is used as a comparator.
62297962|NCT02812511|EXPERIMENTAL|Skin biopsy|
62297963|NCT05170360||patient group|Patients who are recently diagnosed with CRC based on clinical and pathological examinations
62297964|NCT05170360||control group|Control subjects will be CRC-free, based on the clinical history and physical examination.
62469098|NCT04546074|EXPERIMENTAL|Treatment|
62469099|NCT03527147|EXPERIMENTAL|AZD9150 + Acalabrutinib|AZD9150 given in combination with acalabrutinib
62469100|NCT03527147|EXPERIMENTAL|AZD6738 + Acalabrutinib|AZD6738 in combination with acalabrutinib
62469101|NCT03527147|EXPERIMENTAL|Hu5F9-G4 + rituximab + Acalabrutinib|Hu5F9-G4/rituximab in combination with acalabrutinib
62469102|NCT03527147|EXPERIMENTAL|AZD5153 + Acalabrutinib|AZD5153 in combination with acalabrutinib
62469103|NCT04039594||ECMO|
62469104|NCT04186182|OTHER|CICI - Feasibility trial study group|The feasibility of the entire CICI-protocol will be evaluated. See details above.
62469105|NCT05494671|EXPERIMENTAL|conjunctival limbal autologous transplant|patients with unilateral stem cell deficiency due to chemical burn
62668018|NCT01793935|EXPERIMENTAL|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera
62668019|NCT01793935|PLACEBO_COMPARATOR|Placebo|Placebo
61913407|NCT03007888|EXPERIMENTAL|Sinemet then IPX203|Participants first received Sinemet Capsules for 15 days After a Washout Period of 7 days; participants then received IPX203 ER CD-LD Capsules for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
62105955|NCT01345292|ACTIVE_COMPARATOR|310158077046|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
62105956|NCT01345292|PLACEBO_COMPARATOR|037000003212|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
62297965|NCT01332708|EXPERIMENTAL|Obese and overweight subjects|The participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.
62297966|NCT00584974|EXPERIMENTAL|0.5 mg SEP-225289|0.5 mg SEP-225289
62297967|NCT00584974|EXPERIMENTAL|2.0 mg of SEP-225289|2.0 mg of SEP-225289
62297968|NCT00584974|ACTIVE_COMPARATOR|Venlafaxine|150 mg Venlafaxine
62297969|NCT00584974|PLACEBO_COMPARATOR|Placebo|placebo
62297970|NCT02707770|EXPERIMENTAL|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
62297971|NCT02707770|PLACEBO_COMPARATOR|Room air|Patient will breath on room air during pulmonary rehabilitation programme
62297972|NCT01939795|NO_INTERVENTION|Healthy People|Control group
62668020|NCT00513630|ACTIVE_COMPARATOR|metformin|
62297973|NCT01939795|EXPERIMENTAL|Untrained CRT|Untrained CRT patients
62297974|NCT01939795|EXPERIMENTAL|Exercise trained + CRT|Exercise-trained CRT patients
62668021|NCT00513630|ACTIVE_COMPARATOR|glipizide|
62668022|NCT00477724|PLACEBO_COMPARATOR|sedentary control group|patients are treated by conventional rehabilitation
61913408|NCT04774458|EXPERIMENTAL|Fluoroscopic-guided cervical epidural access|Cervical epidural access with loss of resistance technique using CLO view at 50 degree under fluoroscopic guidance.
62105957|NCT04545606|EXPERIMENTAL|In-person CBT for insomnia in children with autism|In-person cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted at the Thompson Center. In-person treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
62297975|NCT02179840|ACTIVE_COMPARATOR|Intravenous|Anesthesia is maintained via intravenous agents. Mechanical ventilation adjustment will be performed.
62297976|NCT02179840|ACTIVE_COMPARATOR|Inhalational|Anesthesia is maintained via inhalational agents. Mechanical ventilation adjustment will be performed.
62297977|NCT03051633|EXPERIMENTAL|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
62297978|NCT03051633|NO_INTERVENTION|Control|Assessment only
61913409|NCT01850576|EXPERIMENTAL|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
61913410|NCT01850576|NO_INTERVENTION|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
61913411|NCT00344942|EXPERIMENTAL|1|
61913412|NCT00344942|PLACEBO_COMPARATOR|2|
61913413|NCT04056767||Imaginal PE|
61913414|NCT04056767||Writing PE|
62297979|NCT03251547||NovoSeven|Non-hemophiliac patients experienced massive haemorrhage who was treated with recombinant activated factor VII
62297980|NCT05407623|EXPERIMENTAL|PAX Good Behavior Game|PAX Good Behavior Game (GBG) is based on its precursor programme Good Behavior Game (GBG) that trains teachers to use principles of social learning in order to maximize the childrens' task-oriented and prosocial behaviors and minimize the occurrence of disruptive and off-task behaviors.
62297981|NCT05407623|ACTIVE_COMPARATOR|Active control (choice between on of two active interventions)|"\[The project has two alternative control interventions for the schools to choose between, in order to increase their engagement in the control intervention. They are hence only provided with one of these interventions, not both.\]~Count On Me! is an adaptive application teaching fluency in addition and subtraction facts (i.e., math facts), equality, compose and decompose numbers and a few more basic mathematical skills taught in the first grades of schooling.~Collegial earning is based on five cyclical steps for professional learning for teachers."
62297982|NCT02946112||Shoulder pain|volleyball players with shoulder pain
62297983|NCT02946112||No shoulder pain|volleyball players without shoulder pain
62668023|NCT00477724|ACTIVE_COMPARATOR|exercise and respiratory therapy|rehabilitation with exercise and respiratory therapy
62668024|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
62668025|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
62668026|NCT01877954||IPDI Qvar|ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate
62668027|NCT01877954||IPDI FP|ICS initiation as fluticasone propionate
62668028|NCT02999321|EXPERIMENTAL|0% aspartame (water)|participants will not have any aspartame, this is a control.
62668029|NCT02999321|EXPERIMENTAL|5 mg aspartame|participants will receive 5 mg aspartame in a beverage.
62668030|NCT02999321|EXPERIMENTAL|15mg aspartame|participants will receive 5 mg aspartame in a beverage, and 10mg in capsules.
62668031|NCT01050842|EXPERIMENTAL|Arm I|Patients receive oral bicalutamide and oral raloxifene on days 1-28.
62105958|NCT04545606|EXPERIMENTAL|Remote CBT for insomnia in children with autism|Remote/videoconferenced cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
62105959|NCT04545606|EXPERIMENTAL|Remote behavioral SHARE for insomnia in children with autism|Remote/videoconferenced behavioral sleep hygiene and related education (SHARE) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep and related health related concerns/interests.
62105960|NCT04204330|EXPERIMENTAL|CardioQVARK group|"Inclusion criteria:~1. Males and females aged 20 to 96 years having one or more of the following risk factors:~   * hypertensive heart disease;~  * history of ischemic stroke or transient ischemic attacks;~  * type 1 and 2 diabetes;~  * class 1-3 obesity;~  * heart failure or decreased tolerance to physical activity due to dyspnea;~  * coronary artery disease (CAD) or chest pain without established CAD diagnosis;~  * peripheral artery atherosclerosis;~  * abnormal heart rhythms (episodes of palpitations, pauses in heartbeat).~2. A patient's consent to participate in the study and the ability to sign an informed consent form.~Exclusion criteria:~1. acute coronary syndrome;~2. acute ischemic or hemorrhagic stroke;~3. mental illness;~4. severe concomitant disease with life expectancy less than 2 years.~Withdrawal criteria:~1. Refusal to participate in the study."
62105961|NCT00469118|EXPERIMENTAL|DRX Treatment|20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000™ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles.
62105962|NCT00469118|NO_INTERVENTION|Conservative Care|Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment
62105963|NCT03396913|EXPERIMENTAL|IPL followed by Meibomian Gland Expression (MGX)|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
62105964|NCT03396913|SHAM_COMPARATOR|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
62297984|NCT03433625|EXPERIMENTAL|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
62297985|NCT03433625|NO_INTERVENTION|Waiting list|6 week wait (with assessments) before being transferred to the experimental condition.
62469106|NCT02261857|EXPERIMENTAL|Intervention Arm|Intervention: Subjects will undergo assessment and a personalized CPAP mask device will be manufactured using patient-specific computer-aided design and 3D printing. The subject will use the personalized CPAP mask for 1 month of consistent use and post-intervention data will be collected for compare to historical control (see other arm)
62469107|NCT02261857|NO_INTERVENTION|Historical Control Arm|Pre-interventional baseline data on subject OSA, CPAP compliance, and quality of life (QoL) measures will be collected to serve as historical controls.
62469108|NCT02758496||ASD Subjects|Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.
62469109|NCT02758496||Healthy Controls|Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group
62469110|NCT00260650|EXPERIMENTAL|Heart PACT Program|Heart PACT Program - patient activation intervention
62469111|NCT00260650|NO_INTERVENTION|Usual Care|Usual Care
62105965|NCT02174211|ACTIVE_COMPARATOR|Arm A: Ranibizumab (Lucentis)|Previous Vitrectomy
62297986|NCT03469076|EXPERIMENTAL|ACN Cream|Patients with mild to moderate acne using ACN Cream
62469112|NCT04272632|EXPERIMENTAL|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
62668032|NCT02512159|EXPERIMENTAL|drenovac handcrafted|Patients treatment with the handicraft topical device negative pressure therapy Economic craft
61913415|NCT00960583|EXPERIMENTAL|Exercise program|"Exercise program comprising muscle strengthening, cardiovascular training and stretching exercises.~Program duration : 12 weeks Sessions frequency : twice per week Session duration : 1h30"
62297987|NCT02000843|OTHER|perichondrium graft perforation|tympanoplasty -- conchal cavum approach is used.
62469113|NCT04272632|EXPERIMENTAL|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
62668033|NCT02512159|ACTIVE_COMPARATOR|Healing|"Patients who were managed with traditional conservative treatment."
62105966|NCT02174211|ACTIVE_COMPARATOR|Arm B: Ranibizumab (Lucentis)|Non-vitrectomised, PVD / no PVD
62105967|NCT02174211|ACTIVE_COMPARATOR|Arm C: Aflibercept (Eylea)|Non-vitrectomised, PVD / no PVD
62105968|NCT04898803||conventional gastroscopy training course|physicians receive the DGVS-recommended training, consisting of a 2-day course with 1 hour of simulator training
62105969|NCT04898803||extended simulator course|physicians receive a two-day simulator course with a minimum of 6 hours of simulator training per trainee, structured in stages in the sense of progressive or mastery learning. The initial part of the training will be part-task training.
62105970|NCT00567164|EXPERIMENTAL|Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
62668034|NCT04595019|ACTIVE_COMPARATOR|5 fraction|MRI-guided radiotherapy, 36.25 Gray (Gy) in 5 fractions (boost to 40 Gy over tumour/prostate CTV) over 10 days.
62668035|NCT04595019|EXPERIMENTAL|2 fraction|MRI-guided radiotherapy, 24 Gy in 2 fractions (boost to 27 Gy over tumour/prostate CTV) over 8 days.
62668036|NCT01328626|EXPERIMENTAL|Arm A (CLL/SLL subjects)|Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) subjects
62668037|NCT01328626|EXPERIMENTAL|Arm B (NHL subjects)|Non-Hodgkin lymphoma (NHL) subjects
61913416|NCT00960583|ACTIVE_COMPARATOR|Routine follow-up|Routine follow-up after functional multidisciplinary rehabilitation by attending physician (Advice to stay active)
61913417|NCT04381988|EXPERIMENTAL|Hydroxychloroquine|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of hydroxychloroquine 400mg daily.
62105971|NCT00567164|EXPERIMENTAL|Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
62668038|NCT03888690|ACTIVE_COMPARATOR|With and then without VR|Virtual Reality with standardized procedures for first intervention, Standardized procedures for second intervention, without VR.
62668039|NCT03888690|ACTIVE_COMPARATOR|Without and then with VR|Standardized procedures without VR for first intervention, Virtual Reality with standardized procedures for second intervention.
62668040|NCT03349047|ACTIVE_COMPARATOR|Behavioral Intervention|Behavioral Intervention Group - Education regarding nut allergy and will also have contact with nut.
62668041|NCT03349047|PLACEBO_COMPARATOR|Control|Education regarding nut allergy
62668042|NCT01566825|ACTIVE_COMPARATOR|Amitriptyline|
62105972|NCT00567164|ACTIVE_COMPARATOR|Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.
62105973|NCT02701361|ACTIVE_COMPARATOR|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
62469114|NCT04272632|EXPERIMENTAL|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
62469115|NCT01559324|EXPERIMENTAL|Bifrontal ECT (BF)|Formula-based low dose BF ECT
62469116|NCT01559324|EXPERIMENTAL|Right unilateral ECT (RU)|Formula-based high-dose RU ECT
62469117|NCT03600480|EXPERIMENTAL|NNC0174-0833+Semaglutide|Participants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
62668043|NCT01566825|PLACEBO_COMPARATOR|white 8 mm Lichtenstein®|
62668044|NCT02073617|EXPERIMENTAL|Real-time 3-dimensional DynaCT|Patients will undergo the standard CTA protocol and invasive coronary angiography performed as part of the pre-operative assessment for TAVR. Patients in this study will also undergo DynaCT during coronary angiography, utilizing 1 acquisition sweep and 20 to 35cc more of contrast media. Measurements of the major aortic annulus diameter, orthogonal minor aortic annulus diameter, aortic annulus perimeter, maximum ascending aorta diameter at 40mm above the annulus, sinus of Valsalva diameters, sinus of Valsalva heights, and aortic root angulation will be made using both the CTA and DynaCT protocols by a radiologist blinded to patient identity. Based on these measurements, a trained interventional cardiologist will select the appropriate TAVR size for the patient.
62668045|NCT01068912|EXPERIMENTAL|1: Experimental|Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days
62668046|NCT01068912|EXPERIMENTAL|2: Experimental|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
62668047|NCT01068912|PLACEBO_COMPARATOR|Placebo|Placebo
61913418|NCT04381988|PLACEBO_COMPARATOR|Placebo|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of placebo 400mg daily.
62105974|NCT02701361|EXPERIMENTAL|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
62105975|NCT02701361|EXPERIMENTAL|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
62297988|NCT02554305|ACTIVE_COMPARATOR|Fusion oxygenation system|Fusion oxygenation machine will be used during the operation.
62297989|NCT02554305|ACTIVE_COMPARATOR|Affinity oxygenation system|Affinity oxygenation machine will be used during the operation.
62297990|NCT02554305|NO_INTERVENTION|Peripheral vascular procedure|No oxygenation machine will be used in this group
62469118|NCT03600480|ACTIVE_COMPARATOR|Placebo (NNC0174-0833)+Semaglutide|Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
62668048|NCT00785941|EXPERIMENTAL|IMC-A12|"All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each Cohort. When all patients complete a cohort, dose escalation to the next Cohort will occur.~A treatment cycle will consist of IMC-A12 administered intravenously, once every other week for 4 weeks, for a total of 2 doses; followed by a 2-week observation period."
62105976|NCT02462655|EXPERIMENTAL|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
62105977|NCT02462655|EXPERIMENTAL|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
62105978|NCT05678296||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
62297991|NCT02554305|NO_INTERVENTION|percutaneous coronary intervention|No oxygenation machine will be used in this group
62668049|NCT00407030|EXPERIMENTAL|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection"
62297992|NCT01926587|EXPERIMENTAL|Oral rigosertib plus azacitidine|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle. Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
62297993|NCT00679887|EXPERIMENTAL|A|Ischemic compression on trigger points located around the shoulder. Active comparator. Ischemic compression, 5 weeks
62297994|NCT01477905|EXPERIMENTAL|Remi50 no prime|For using experimental target control infusion device (TCIs), targeting an effect-site concentration (Ceff) of 4.0 ng/ml, were randomly performed using 50 μg/ml (Remi50) of remifentanil, and without PRIMING,
62469119|NCT02360982||propofol and esmeron(rokuronyum)|In group G, anesthesia was induced with iv propofol (2 mg.kg-1) and maintained with 2% sevoflurane in a mixture of 65 % nitrous oxide and 35 % oxygen with a total gas flow rate of 6 L min-1. Neuromuscular relaxation was induced with iv rocuronium (esmeron) (0.5 mg.kg-1). Intravenous infusion of 0.9% saline was administered at a volume of 5 mL/kg/h. Patients received morphine (0.1mg/kg) for postoperative analgesia 30 minutes before the end of the operation. Anesthesia was terminated and neuromuscular blockade was antagonized with neostigmine (0.05 mg.kg-1)and atropine sulphate (0.01 mg.kg-1).
62668050|NCT00407030|EXPERIMENTAL|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection"
62105979|NCT05678296||group 1|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
62105980|NCT05678296||group 2|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
62105981|NCT00578214|ACTIVE_COMPARATOR|Randomized Midazolam|Single-dose midazolam
62105982|NCT00578214|PLACEBO_COMPARATOR|Placebo|
62105983|NCT00578214|EXPERIMENTAL|Prospective Midazolam|
62297995|NCT01477905|EXPERIMENTAL|Remi20 no prmie|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and without PRIMING
62105984|NCT06505824|EXPERIMENTAL|BL-M14D1|Participants receive BL-M14D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62297996|NCT00813995|EXPERIMENTAL|Sitagliptin|
62297997|NCT00813995|PLACEBO_COMPARATOR|Placebo|
62297998|NCT03142100||Hebrew speaking participants|Hebrew speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
62297999|NCT03142100||Arabic speaking participants|Arabic speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
62308335|NCT06304441|ACTIVE_COMPARATOR|Group B|Third-generation small molecule TKI drugs (e.g. 'osimertinib') alone
62298000|NCT05269355|EXPERIMENTAL|Unesbulin and Dacarbazine|Participants will receive unesbulin 300 milligrams (mg) tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/meter squared (m\^2) intravenously (IV) once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
62298001|NCT05269355|PLACEBO_COMPARATOR|Placebo and Dacarbazine|Participants will receive placebo matching to unesbulin tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/m\^2 IV once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
62298002|NCT04880811|EXPERIMENTAL|Afatinib plus toripalimab|
62298003|NCT01964248|EXPERIMENTAL|Lidocaïne/prilocaïne|"* Lidocaine/prilocaine eutectic mixture 5% incorporated in a cream base~* Single dose: 2 grams (one tube of cream)~* Cream applied 2 hours before blood sample"
62298004|NCT01964248|PLACEBO_COMPARATOR|Placebo|"* Single dose: 2 grams (one tube of cream)~* Cream applied 2 hours before blood sample"
62298005|NCT02406157|EXPERIMENTAL|577-MPL|577nm micropulse laser photocoagulation(577MPL) treatment to the macular area of retinal thickening with a focal or grid pattern
62298006|NCT02406157|ACTIVE_COMPARATOR|532-SLP|532nm subthreshold laser photocoagulation(532-SLP) treatment to the macular area of retinal thickening with a focal or grid pattern
62298007|NCT06557512|EXPERIMENTAL|Hypofractionated Stereotactic Radiosurgery (SRS)|Participants undergo hypofractionated stereotactic radiosurgery over 15-30 minutes QD on days 1-5 in the absence of disease progression or unacceptable toxicity.
61913419|NCT05216666|ACTIVE_COMPARATOR|Lateral approach|290 participants receive their hip prosthesis through a lateral approach. The anterior third of m. gluteus medius along with the corresponding part of m. vastus lateralis are detached from the greater trochanter and the anterior capsule is excised for the exposure of the hip joint. After implant insertion, the gluteus medius is reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
62668051|NCT00407030|PLACEBO_COMPARATOR|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection
62668052|NCT05872919|NO_INTERVENTION|Control group|will not receive the intervention
62668053|NCT05872919|EXPERIMENTAL|Study group|will receive the intervention
62668054|NCT01111292|EXPERIMENTAL|Arm I (inositol)|Beginning within 14 days after colonoscopy, patients receive inositol PO QD on days 1-14 and BID on days 15-90.
62668055|NCT01111292|PLACEBO_COMPARATOR|Arm II (placebo)|Beginning within 14 days after colonoscopy, patients receive placebo PO QD on days 1-14 and BID on days 15-90.
62105985|NCT03828695|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
62105986|NCT04653714|EXPERIMENTAL|Full mouth debridement|Supragingival plaque/calculus removal and scaling and root planing
62105987|NCT04653714|SHAM_COMPARATOR|Supragingival plaque/calculus removal|Supragingival plaque and calculus removal
62105988|NCT04653714|EXPERIMENTAL|Probiotic lozenges|Daily usage of probiotic lozenges
62105989|NCT04653714|ACTIVE_COMPARATOR|Placebo lozenges|Daily usage of placebo lozenges
62105990|NCT05215457||development set|50 cases are the development set, which is used to develop the prediction model of diquat acute poisoning. These patients are all from the First Affiliated Hospital of Nanjing Medical University.
62105991|NCT05215457||validation set|50 patients are the validation set, from more than ten tertiary a-level hospitals in the surrounding area, to verify the prediction model.
62308336|NCT02962635||Hemodialysis patients|"A total of 30 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
62105992|NCT01601314|EXPERIMENTAL|magnesium sulphate|The patients who are going to receive Magnesium Sulphate
62105993|NCT01601314|PLACEBO_COMPARATOR|Control|Patients who are going to receive Sodium Chloride 0.9%
62105994|NCT04206046|ACTIVE_COMPARATOR|General Anaesthesia|Patients will receive a general anaesthetic, together with a femoral nerve block.
62105995|NCT04206046|ACTIVE_COMPARATOR|Spinal Anaesthesia|Patients will receive a spinal anaesthetic
62105996|NCT05404230|ACTIVE_COMPARATOR|Fish oil|"4 capsules containing n-3 poly unsaturated fatty acids (EPA and DHA) with a total concentration of 3 g per day.~4 capsules per day for 8 months"
62105997|NCT05404230|PLACEBO_COMPARATOR|Corn oil|"4 capsules containing n-6 poly unsaturated fatty acids in a total concentration of 2 g per day.~4 capsules per day for 8 months.~Corn oil is regularly used in the kitchen and the daily dose in the study is the equivalent of adding an extra spoon of food oil when cooking. It has no known effect on the parameters we want to examine."
62105998|NCT05555108|EXPERIMENTAL|ACTCOM-I Intervention|
62105999|NCT05555108|ACTIVE_COMPARATOR|Standard CBT-I Intervention|
62106000|NCT03085017|ACTIVE_COMPARATOR|Ostene|Application of Ostene onto cut sternal site for hemostasis.
62106001|NCT03085017|EXPERIMENTAL|BoneSeal|Application of BoneSeal onto cut sternal site for hemostasis.
62106002|NCT00742573|ACTIVE_COMPARATOR|1 Texas Medication Algorithm|Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
62298008|NCT06642753|EXPERIMENTAL|immediate implant with buccal plate augmentation using sticky bone|"atraumatic extraction.~* The socket will be well irrigated with saline and debrided with a bone curette.~* placement of the implant.~* Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* sticky bone will be ready to be grafted.~* Sticky bone will be inserted into the pouch by a mean of a small periosteal elevator. Additional graft material will be added and compressed until adequate filling of the pouch is achieved without overstretching the soft tissues.~* the healing abutment will be screwed into the implant body ."
62469120|NCT02360982||marcaine and fentanyl|"We inserted a 18-G Tuohy needle at the L3/L4 or L2/L3 intervertebral epidural space using an epidural loss of resistance technique and thus performed needle-through-needle technique for subarachnoid injection of 2 mL bupivacaine (marcaine)(0.5%) and fentanyl (25 mcg) by 27-G spinal needle. After subarachnoid injection, epidural catheter was advanced and fixed.~At the end of the surgery 5 mL of bupivacaine 0.5% plus morphine (1 mg), adding to 4 mL saline was injected via epidural catheter for postoperative analgesia.Epidural catheter was removed at 24th hours"
62668056|NCT02090595|EXPERIMENTAL|MBCT-C|Mindfulness-Based Cognitive Therapy for Anxious Children (MBCT-C) is a 12-week manualized group therapy program for children with anxiety disorders. The program involves teaching children to pay attention to anxiety-related thoughts, emotions, and physical sensations with openness and non-judgment.
62668057|NCT02090595|OTHER|Waitlist Control|Education and Therapy
62668058|NCT02287519|EXPERIMENTAL|Support Group|"* One group educational session will include information on resources, self-help strategies, and relaxation techniques.~* One telephone coaching session after the group session Or~* Pilot webinar format of the educational session"
62668059|NCT01117545|EXPERIMENTAL|EFT|Six sessions of EFT (Emotional Freedom Techniques)
62106003|NCT00742573|EXPERIMENTAL|2 Patient Choice|Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
62106004|NCT01286402|EXPERIMENTAL|Bupropion SR (sustained release)|Group receiving bupropion SR medication
62106005|NCT01286402|PLACEBO_COMPARATOR|Placebo|
62106006|NCT00631475|EXPERIMENTAL|1|"For patients who were administered bosentan during BUILD 3 (NCT00391443):~Same dose will continue~For patients who were administered placebo during BUILD 3 (NCT00391443):~Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg"
62106007|NCT00814281|PLACEBO_COMPARATOR|1|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
62298009|NCT06642753|ACTIVE_COMPARATOR|immediate implant with sticky bone as a filling material in the jumping gap|"* atraumatic extraction.~* The socket will be well irrigated with saline and debrided with a bone curette.~* placement of the implant.~* Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* sticky bone will be ready to be grafted.~* The sticky bone graft will be condensed and adapted into the jumping gap as well as over the implants. Further, it will be covered with PRF membrane.~* the healing abutment will be screwed into the implant body"
62298010|NCT01993979|OTHER|Surveillance|Patients allocated to surveillance will be seen at 4, 7, 10 and 13 weeks post randomisation - equivalent to the end of cycle in patients receiving chemotherapy - in order to collect details of early treatment failure in this group and comparative data relating to toxicity and quality of life. Patients on surveillance will then be followed up for signs of recurrence at the same intervals as those who received chemotherapy
62298011|NCT01993979|EXPERIMENTAL|Chemotherapy|Patients allocated adjuvant chemotherapy will receive 4 x 21 day cycles of gemcitabine-cisplatin. Patients who have a sub-optimal renal function (GFR 30-49ml/min) will receive carboplatin instead of cisplatin.
62298012|NCT03246074|EXPERIMENTAL|Fostamatinib 100 mg bid and Paclitaxel|Participants will receive paclitaxel on Days 1, 8 and 15 of each cycle and fostamatinib at a fixed oral dose of 100mg twice daily throughout each 28-day cycle.
62298013|NCT03246074|EXPERIMENTAL|Fostamatinib 150 mg bid and Paclitaxel|Participants will receive paclitaxel on Days 1, 8 and 15 of each cycle and fostamatinib at a fixed oral dose of 150mg twice daily throughout each 28-day cycle.
62469121|NCT00613145|ACTIVE_COMPARATOR|A|Treatment with Capecitabine and Sorafenib
62469122|NCT00613145|ACTIVE_COMPARATOR|B|Treatment with Capecitabine and Sorafenib
62469123|NCT00800709|EXPERIMENTAL|Memantine|
62469124|NCT00934934|PLACEBO_COMPARATOR|Placebo|Saline will serve as the placebo solution since the active comparator is clear and colourless.
62469125|NCT00934934|ACTIVE_COMPARATOR|Antifungal|Patient will receive a dose daily for a total of 14 days
62469126|NCT01086254|EXPERIMENTAL|Iniparib/ Gemcitabine/ Cisplatin|"Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.~Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion."
62469127|NCT01086254|ACTIVE_COMPARATOR|Gemcitabine/ Cisplatin|Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
62668060|NCT01117545|NO_INTERVENTION|Wait List|One month wait period
62668061|NCT06414018|EXPERIMENTAL|Sufentanil group|The dose of sufentanil group is 0.2μg/kg
62668062|NCT06414018|EXPERIMENTAL|Alfentanil|The dose of aifentanil group is 10μg/kg
61913420|NCT05216666|ACTIVE_COMPARATOR|Posterior approach|290 participants receive their hip prosthesis through a posterior approach. The m. piriformis gemelli and obturator internus are detached from the greater trochanter and the posterior capsule is incised for the exposure of the hip joint. After implant insertion, the posterior capsule as well as m piriformis and the external rotators are reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
61913421|NCT01607203|ACTIVE_COMPARATOR|hCG|5000 IU Pregnyl SC
62106008|NCT00814281|PLACEBO_COMPARATOR|2|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
61913422|NCT01607203|ACTIVE_COMPARATOR|hCG and GnRH agonist|5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
61913423|NCT05022511|EXPERIMENTAL|Intervention group|"All women aged 50-69 years attending breast cancer screening in the intervention unit on an intervention day. They will all be offered to receive information on their screening status in cervical cancer og colorectal cancer screening.~Women aged 50-64 years, who have not had a cervical cytology sample taken within 5 years and 6 months will be offered to receive a self-sample device for high risk human papilloma virus (hrHPV) screening by mail, or reminded to see her general practitioner (GP) to have a conventional cervical cytology sample taken.~Women aged 50-69 years, who have not had a Faecal Immunochemical Test (FIT) within 2 years and 4.5 months will be offered to receive a new self-sampling kit for FIT."
61913424|NCT05022511|NO_INTERVENTION|Control group|Women in the control group will receive standard screening offers according to the national screening programme.
61913425|NCT00718562|EXPERIMENTAL|Nilotinib|
61913426|NCT05059899|EXPERIMENTAL|Exercise group|Home-based circuit and community walking exercise
62106009|NCT00814281|EXPERIMENTAL|3|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
62106010|NCT00814281|EXPERIMENTAL|4|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
62106011|NCT00743821||TBI Patients|Individuals who have suffered a mild traumatic brain injury and have persistent post-concussive symptoms (PCS)
62298014|NCT03246074|EXPERIMENTAL|Fostamatinib 200 mg bid and Paclitaxel|Participants will receive paclitaxel on Days 1, 8 and 15 of each cycle and fostamatinib at a fixed oral dose of 150mg twice daily throughout each 28-day cycle.
62298015|NCT02337842|EXPERIMENTAL|Cohort 1|N= 9 subjects will receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units and N=1 single oral dose Placebo.
62298016|NCT02337842|EXPERIMENTAL|Cohort 2|N=9 subjects will receive single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units and N=1 single oral dose of Placebo.
62469128|NCT00151047|EXPERIMENTAL|Docetaxel and Capecitabine|
62469129|NCT05184426||Exposed: Positive anti-HLA antibodies|Heart transplant patients who have developed antiHLA antibodies after transplant
61913427|NCT05059899|NO_INTERVENTION|Usual care|Usual activity/healthcare
61913428|NCT06457672|EXPERIMENTAL|group I|complete crown technique for superimposition of digital models
61913429|NCT03219463|EXPERIMENTAL|Regular Exercise Group|at least 30 minutes of moderate to vigorous activity at least 3 times per week. Will recieve 3 grams of ginger for 8 weeks.
61913430|NCT03219463|ACTIVE_COMPARATOR|Non Regular Exercise Group|at least 30 minutes of moderate to vigorous activity 1-2 times per week. Will recieve 3 grams of ginger for 8 weeks.
61913431|NCT01373827||MC1 Subjects|
61913432|NCT05242796|EXPERIMENTAL|12 sessions of magnet|
61913433|NCT05242796|EXPERIMENTAL|24 sessions of magnet|
61913434|NCT05242796|PLACEBO_COMPARATOR|Placebo magnet intervention|
61913435|NCT05463198|EXPERIMENTAL|Blood Loss|
61913436|NCT04486001|EXPERIMENTAL|Treatment Group|This is single arm study with only comparison to non-treated cohorts at site.
61913437|NCT02350751|EXPERIMENTAL|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
61913438|NCT02350751|PLACEBO_COMPARATOR|Placebo|Solution containing no active ingredients
61913439|NCT02097017|ACTIVE_COMPARATOR|lidocaine spray group|
61913440|NCT02097017|PLACEBO_COMPARATOR|placebo arm|
61913441|NCT01293565||HED Affected Males|
61913442|NCT01293565||Male Controls|
62106012|NCT00743821||Normals|Individuals of comparable age and education who have not suffered a traumatic brain injury
62106013|NCT05470374|EXPERIMENTAL|Ultrasound|Glioma resection with intraoperative sonography
62106014|NCT05470374|NO_INTERVENTION|Non-ultrasound|Glioma resection without intraoperative sonography
61913443|NCT00732043|EXPERIMENTAL|1|
61913444|NCT00732043|EXPERIMENTAL|2|
61913445|NCT00732043|PLACEBO_COMPARATOR|3|
61913446|NCT04240080|NO_INTERVENTION|Control Goup|Subjects will undergo clinically indicated facial injection procedures per standard of care without venous mapping
61913447|NCT04240080|EXPERIMENTAL|Intervention Group|Subjects will undergo clinically indicated facial injection procedure with pre-procedural facial venous mapping by Accuvein® Veinfinder
61913448|NCT05063071|EXPERIMENTAL|TAF monotherapy without HBIG|The standard dose of TAF 25mg daily was used. TAF can be used on the first day after orthotopic liver transplantation. No HBIG was used before, during, or after transplantation; and therapeutic vaccination was not routinely used.
61913449|NCT02969603|OTHER|Healthy volunteers- MRI|MRI scan for morphological assessment of muscle structures and anatomy
62106015|NCT06250816|EXPERIMENTAL|Children wearing the hospital gown with cartoon characters|The experimental group will have a preoperative visit, the investigator will meet the patient and assess the child's anxiety level using the modified Yale Preoperative Anxiety Scale (m-YPAS). Afterwards, the patient will be asked to choose one of the hospital gowns they want to wear and put it on with parental assistance.
62106016|NCT06250816|NO_INTERVENTION|Children with standard hospital gown|The control group will have a preoperative visit, the investigator will meet the patient and assess the child's anxiety level using m-YPAS. The patient will be asked to wear the hospital gown used in the hospital in routine practice with parental assistance.
62106017|NCT01573195||All prescribing MDs at UWHC|Observational for accept, reject, or accept with modification of Best Practice Alers
62469130|NCT05184426||Non-exposed: Negative anti-HLA antibodies|Heart transplant patients without antiHLA antibodies with similar transplant date to its correspondent case.
62668063|NCT04617327|EXPERIMENTAL|Experimental : Short Course Pre-operative RadiothErapy|"As part of the planning process, you need to undergo a CT Simulation.It is special type of CT scan used to measure and design the radiation fields to precisely target the tumor.It is done at the Radiation Oncology Department at the MUHC. Some patients may be asked to also undergo an MRI Simulation, and the CT simulation. You may asked to provide a blood sample to ensure good kidney function prior to the CT and MRI scans. Both CT and MRI simulations are considered standard of care.~Once the simulation studies are done, there is about a 2 week waiting period for radiation planning prior to starting the radiation treatments.~The hypofractionation technique will be delivering five fractions (one fraction delivered every 2nd day) of 7 Gy daily of external beam radiotherapy (EBRT) over a period of one and half weeks for a total of 35 Gy. The treatment should last approximately 30 minutes. Once treatments are done, there is a 4 to 6 week wait for surgery."
62298017|NCT02337842|EXPERIMENTAL|Cohort 4|N=36 subjects will receive single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units , N=4 subjects receive a single oral dose of Placebo
62298018|NCT02337842|EXPERIMENTAL|Cohort 3|N=18 subjects will receive single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units and N=2 single oral dose of Placebo
62298019|NCT06296264|OTHER|Standard ultrasound|Comparator
62668064|NCT03448029||Endovascular Patients|Patients undergoing endovascular interventions for symptomatic PAD
62668065|NCT01767389||Type 2 diabetes patients taking antidiabetic agents|Subjects should also have at least 1 claim of T2D diagnosis identified using ICD-9 codes 250.x0 or 250.x2 (excluding 250.x1 and/or 250.x3 - Type 1 diabetes and 648.0x - gestational diabetes).
62298020|NCT06296264|EXPERIMENTAL|Ultra-portable ultrasound|
62298021|NCT02906553|EXPERIMENTAL|Glyceryl Trinitrate|Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
62298022|NCT02906553|PLACEBO_COMPARATOR|Placebo|The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
62668066|NCT01484366|ACTIVE_COMPARATOR|intramedullary nailing and plating|intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
62668067|NCT01484366|ACTIVE_COMPARATOR|plating|plating of both the radius and ulna in the treatment of both bone forearm fractures
62668068|NCT05732545|EXPERIMENTAL|enteral nutrition program by intra-abdominal pressure|enteral nutrition program for patients with intra-abdominal hypertension guided by intra-abdominal pressure
62298023|NCT05817045|ACTIVE_COMPARATOR|Active|"RD-X19 Active Device~Investigational device that uses 32 J/cm2 of electromagnetic energy to target the oropharynx."
62298024|NCT05817045|SHAM_COMPARATOR|Sham|"RD-X19 Sham Device~Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV2 in vitro."
62298025|NCT06023108|EXPERIMENTAL|Orthokeratology group|Participants in OK lenses group will wear OK lenses at least 8 hours per day for 12 months.
62668069|NCT05732545|NO_INTERVENTION|Routine nursing measures|Routine nursing measures
62298026|NCT06023108|ACTIVE_COMPARATOR|Spectacles group|Participants in spectacles group will wear per day for 12 months.
62668070|NCT01951066|EXPERIMENTAL|Group 1 (dexamethasone implant/anti-VEGF)|Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
62668071|NCT01951066|EXPERIMENTAL|Group 2 (anti-VEGF/dexamethasone implant)|Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
62298027|NCT04294888|EXPERIMENTAL|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80% of a patient's active motor threshold. rTMS will be administered in an excitatory iTBS pattern. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
62298028|NCT04294888|SHAM_COMPARATOR|Sham stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80% of a patient's active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory performance, or whether practice effects or other non-specific effects are responsible for any changes in memory which may be observed.
62298029|NCT04567784|PLACEBO_COMPARATOR|Control|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
62668072|NCT03191201|ACTIVE_COMPARATOR|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
62668073|NCT03191201|PLACEBO_COMPARATOR|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
62298030|NCT04567784|EXPERIMENTAL|CBD 800mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
62298031|NCT04234217|NO_INTERVENTION|Untreated|Untreated condition (obstructive sleep apnea)
62298032|NCT04234217|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP) treatment|Continuous positive airway pressure (CPAP) treatment
62298033|NCT04234217|ACTIVE_COMPARATOR|Niacin|Untreated, pharmacological suppression of lipolysis by Niacin
62298034|NCT00635102|ACTIVE_COMPARATOR|Alcohol dependent|Alcohol dependent patients will receive 4 interventions
62668074|NCT03597555|EXPERIMENTAL|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
62668075|NCT03597555|PLACEBO_COMPARATOR|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
62668076|NCT01356810|PLACEBO_COMPARATOR|Standard Care|Delirium management defined by the attending physician.
62668077|NCT01356810|EXPERIMENTAL|Environmental Intervention|
62106018|NCT05143476||Observational group|Follow-up visits will be conducted at 4-6, 7-9, 12-16 and 26-32 weeks, from time of fracture. A participant's doctor will perform routine examination of fracture healing. The assessment will include evaluation of gross fracture site motion and presence or absence of radiographic healing, including a mRUST score.
62106019|NCT03315507|EXPERIMENTAL|PB1046 Injection|PB1046 Subcutaneous Injection
62106020|NCT04820101|EXPERIMENTAL|Every preterm newborns 26+0 -36+6 wGA with RDS needing surfactant therapy|Every preterm newborns 26+0-36+6 wGA who undergoes LISA procedure will receive sedation with dexmedetomidine in order to evaluate its efficacy in achieving pain control and comfort.
62106021|NCT02712866||Patients treated with vedolizumab|
62106022|NCT00104754|EXPERIMENTAL|liposomal SN-38|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response or patients with stable disease (SD) who were previously treated before study enrollment receive up to 4 additional courses of treatment. Patients with CNS-only disease progression receive whole brain radiotherapy (WBRT). After completion of WBRT, these patients also receive up to 4 additional courses of treatment. Patients with disease progression to sites other than the CNS or patients with SD who were previously untreated before study enrollment are removed from the study.~Quality of life is assessed at baseline, before each treatment course, and then annually for 3 years.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years."
62106023|NCT00422201|EXPERIMENTAL|Prospective, open-label, study of mifepristone|Eligible subjects will start study treatment at the dose of 600 mg/day (given as one 200 mg tablet tid, per os). Total duration of treatment will not exceed 12 months. At the end of 12-month treatment, investigators may petition to extend treatment on a case-by-case basis.
62106024|NCT02343744|EXPERIMENTAL|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
62106025|NCT06423313||Group TIVA|
62106026|NCT06423313||Group Inhalation|
62106027|NCT05846165|EXPERIMENTAL|Bladder tumours|Participants with muscle-invasive and non-muscle invasive bladder tumours of at least 3 cm in diameter will undergo one FCI scan.
62106028|NCT05200650|EXPERIMENTAL|TumoCure Treatment|Subjects will be treated with a single intra-tumor injection of TumoCure, containing the polymeric delivery system and the Cisplatin hemotherapy agent at a dose of 100mg.
62106029|NCT04542148|EXPERIMENTAL|Sliding Scale Insulin|Addition of supplemental sliding scale insulin to home insulin regimen for maximum of 5 days after antenatal corticosteroids
62298035|NCT00635102|ACTIVE_COMPARATOR|Healthy subjects|Healthy subjects will receive 4 interventions
62469131|NCT03152981|ACTIVE_COMPARATOR|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
62469132|NCT03152981|ACTIVE_COMPARATOR|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
62668078|NCT01675700|EXPERIMENTAL|Myofascial trigger point|Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point.
62668079|NCT03556176|ACTIVE_COMPARATOR|5-HTTLPR or BDNF polymorphisms|
62668080|NCT03556176|ACTIVE_COMPARATOR|Control ( without 5-HTTLPR or BDNF polymorphisms )|
62668081|NCT01366105|NO_INTERVENTION|Dry Dressing|Incisions that were dressed with a sterile dry dressing at end of operation.
62668082|NCT01366105|EXPERIMENTAL|Negative Pressure Wound Therapy|Incisions dressed with a V.A.C. (NPWT) postoperatively.
62668083|NCT01339182|EXPERIMENTAL|Pegylated-Somatropin, 10mcg/kg|
62668084|NCT01339182|EXPERIMENTAL|Pegylated-Somatropin, 30mcg/kg|
62668085|NCT01339182|EXPERIMENTAL|Pegylated-Somatropin, 60mcg/kg|
62106030|NCT04542148|EXPERIMENTAL|Up-Titration of Home Insulin|Increase in home insulin regimen based on standardized algorithm for maximum of 5 days after antenatal corticosteroids
62298036|NCT05631132|EXPERIMENTAL|BAL + NIV|Qualification for a specific type of ventilation (NIV or CPAP) will be carried out in a randomized manner by a specially created online platform. The procedure will be performed subsequently in the same segment of the opposite lung. Once the test is finished, the volume of BAL fluid that has been recovered will be measured.
62668086|NCT01339182|EXPERIMENTAL|Pegylated-Somatropin, 120mcg/kg|
62668087|NCT01339182|EXPERIMENTAL|Pegylated-Somatropin, 200mcg/kg|
62668088|NCT02852434|EXPERIMENTAL|Self-administered Gel|Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
61913450|NCT02969603|OTHER|Healthy Volunteers- PET/MRI|The volunteers will undergo a combined \[11C\]acetate PET/MRI scan
62298037|NCT05631132|EXPERIMENTAL|BAL + CPAP|Qualification for a specific type of ventilation (NIV or CPAP) will be carried out in a randomized manner by a specially created online platform. The procedure will be performed subsequently in the same segment of the opposite lung. Once the test is finished, the volume of BAL fluid that has been recovered will be measured.
62298038|NCT02042066|EXPERIMENTAL|Treated Group|This group will receive actual shockwave treatment
62298039|NCT06145230||Under 60 group|Colorectal cancer paitents aged under 60 years old ( do not include 60 years old)
62298040|NCT06145230||60-69 group|Colorectal cancer paitents aged 60-69 years old
62106031|NCT04542148|EXPERIMENTAL|Continuous Insulin Infusion|Discontinuation of home insulin regimen and receipt of continuous insulin infusion for maximum of 5 days after antenatal corticosteroids
62106032|NCT02582411||Group 1: 18-34 years|Patients in age group 18-34 years
62106033|NCT02582411||Group 2: 35-49 years|Patients in age group 35-49 years
62106034|NCT02582411||Group 3: 50-64 years|Patients in age group 50-64 years
62106035|NCT02582411||Group 4: 65-80 years|Patients in age group 65-80 years
62106036|NCT01496638|EXPERIMENTAL|"No side branch treatment group"|Implantation of coronary stent in bifurcation lesion
62298041|NCT06145230||70-79 group|Colorectal cancer paitents aged 70-79 years old
62298042|NCT06145230||80 and over group|Colorectal cancer paitents aged 80 and over 80 years old
62668089|NCT02852434|ACTIVE_COMPARATOR|Paracervical Block|Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement
61913451|NCT05476484||Allergic rhinitis patients with and without asthma treated with SQ SLIT-tablet|
61913452|NCT05476484||Allergic rhinitis patients with and without asthma not treated with SQ SLIT-tablet|
62106037|NCT01496638|EXPERIMENTAL|"Stenting of main vessel and side branch group"|Implantation of coronary stent in bifurcation lesion
62106038|NCT05112315|EXPERIMENTAL|Predigraft|Subjects will have a clinical follow-up based on site standard of care and benefit from follow-up using Predigraft in addition of the standard of care: the investigator will receive an alert every time there is a subject's instability, instability based on the following criteria: allograft survival assessed by iBox decreased by at least 5% in the last 12 months.
62298043|NCT00644267|ACTIVE_COMPARATOR|1|Subjects will use a telemedicine system for blood pressure control
62668090|NCT05312060|EXPERIMENTAL|Pneumatic Compression (PC)|The PC will undergo two daily 30-minute sessions of sequential pneumatic compression.
62668091|NCT05312060|ACTIVE_COMPARATOR|Antithromboembolic exercises (AE)|AE will perform two supervised antithromboembolic exercises sessions daily lasting 30 minutes.
62668092|NCT01363076|EXPERIMENTAL|Ketorolac Tromethamine (15 mg)|Ketorolac Tromethamine - single dose (15 mg) administered intranasally (IN) for subjects weighing \<50 kg.
62668093|NCT01363076|EXPERIMENTAL|Ketorolac Tromethamine (30 mg)|Ketorolac Tromethamine - single dose (30 mg) administered intranasally (IN) for subjects weighing ≥50 kg.
62106039|NCT05112315|NO_INTERVENTION|Standard of Care|Subjects will have a clinical follow-up based on site standard of care.
62106040|NCT02404454|EXPERIMENTAL|hysteroscopic metroplasty|women undergoing hysteroscopic metroplasty for uterine septum resection
62106041|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
62106042|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
62106043|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
62106044|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
62298044|NCT00644267|NO_INTERVENTION|2|Patients with hypertension receiving usual care by a primary care physician
62298045|NCT06456710|PLACEBO_COMPARATOR|Conventional IBS Health Education|Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.
62298046|NCT06456710|EXPERIMENTAL|Based on ACT Theory of Psychological Intervention|A psychological intervention program based on ACT theory was implemented on top of the control group.
62668094|NCT02384460|EXPERIMENTAL|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
61919863|NCT03843242|EXPERIMENTAL|Pacemaker with Fixed long AV delay|"1. Patients who meet the inclusion criteria and is implanted with a Biotronik Enitra 8 DR-T pacemaker are eligible.~2. The pacemaker was programmed with a long and fixed atrioventricular interval for the first 3 months.~3. Definition of fixed AV delay (than intrinsic AV conduction) • If P-wave exists: intrinsic AV conduction time = As \~ Vs interval in the marker channel sensed AV delay = intrinsic AV conduction time + 20 msec paced AV delay = sensed AV delay + 30 msec • If no P-wave exits: intrinsic AV conduction time = Ap \~ Vs interval in the marker channel paced AV delay = intrinsic AV conduction time + 20 msec sensed AV delay = paced AV delay - 30 msec • If the intrinsic AV conduction time is ≥ 300ms, make paced/sensed AV delay 350/320 msec"
62106045|NCT03970811|EXPERIMENTAL|Immediate implants with immediate temporization|Immediate implants with simultaneous immediate placement of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
62106046|NCT03970811|ACTIVE_COMPARATOR|Immediate implants without temporization|Immediate implants without the use of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
62106047|NCT01459549|NO_INTERVENTION|Control Group|Just clear the stone without choledochojejunostomy
62106048|NCT01459549|EXPERIMENTAL|Experimental Group|Clear the stone combined with Roux-en-y choledochojejunostomy
62106049|NCT05851417|EXPERIMENTAL|Live donors|Live kidney donors (healthy volunteers).
62106050|NCT05851417|EXPERIMENTAL|Native kidney damage|Patients with native kidney damage (suspected active glomerular or interstitial lesion).
62298047|NCT01886664|ACTIVE_COMPARATOR|Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
62298048|NCT01886664|EXPERIMENTAL|Desflurane|Performing liver transplantation under general anesthesia using desflurane
62298049|NCT05640648|ACTIVE_COMPARATOR|Standard Implementation Strategy Period|During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
62106051|NCT05851417|EXPERIMENTAL|Kidney transplants|Patients with kidney transplant.
62298050|NCT05640648|EXPERIMENTAL|Enhanced Contact Investigation Intervention Period|"The enhanced contact investigation strategy includes 4 implementation facilitation tools and 3 continuous quality improvement techniques and will be delivered as a branded package named for an inspirational Luganda phrase that is translated as We are together with you. Implementation facilitation tools include 1) a TB education pamphlet, 2) a contact identification algorithm, 3) an instructional video on sputum collection, and 4) community health riders who transport clients, community health workers, and sputum samples by motorcycle. The continuous quality improvement techniques delivered as the community of practice package include 1) community of practice meetings, 2) audit and feedback reports and 3) a group chat application."
62298051|NCT04791384|EXPERIMENTAL|Abemaciclib/Elacestrant|Abemaciclib and Elacestrant combination
62308337|NCT02962635||Peritoneal dialysis patients|"A total of 15 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
62469133|NCT02038621|EXPERIMENTAL|A|Capecitabine: 1000mg/m\^2 bid, days 1-14, every 3 weeks until progression/intolerance.
62668095|NCT02384460|PLACEBO_COMPARATOR|Placebo (SD-101-0.0) cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
62668096|NCT04545697|EXPERIMENTAL|Patient Decision Support|Instructions will be provided for installation and use of a smartphone recording app 7-60 days before an oncology consultation. Participants will share the recording with the Patient Support Corps (PSC), who will summarize the recording, send it to the participant's oncologist for review, then return an annotated summary to the participant within a week of the consultation.
62668097|NCT06432426|EXPERIMENTAL|Virtual Reality Training Group|Participants will undergo a postural balance rehabilitation program, utilizing a probed protocol for the elderly population with virtual reality via the Nintendo Wii Fit® and its peripheral Balance Board system. Supervised group sessions will be conducted twice a week for 9 weeks.
62668098|NCT06432426|ACTIVE_COMPARATOR|Standard physical exercise Group|Participants will undergo a standardized physical exercise program based on a validated protocol designed for elderly breast cancer survivors
62668099|NCT02495675|NO_INTERVENTION|No flow|Subjects will be spontaneously breathing in room air with no flow.
62668100|NCT02495675|EXPERIMENTAL|Conventional flow via nasal prongs|Subjects will be breathing with nasal prongs delivering 5 L/min of air (inspired fraction of oxygen: 0.21)
62668101|NCT02495675|EXPERIMENTAL|High flow nasal cannulas 20 L/min|Subjects will be breathing with high flow nasal cannulas delivering 20 L/min with an inspired fraction of oxygen of 0.21.
62668102|NCT02495675|EXPERIMENTAL|High flow nasal cannulas 40 L/min|Subjects will be breathing with high flow nasal cannulas delivering 40 L/min with an inspired fraction of oxygen of 0.21.
62106052|NCT06264830|ACTIVE_COMPARATOR|Conventional-binocular-microscope-assisted standard cataract operation|In this group, patients undergo standard modern cataract operation during which the surgeon use conventional binocular microscope
62106053|NCT06264830|EXPERIMENTAL|Alcon-NGENUITY® (NG)-System-assisted standard cataract operation|In this group, patients undergo standard modern cataract operation during which the surgeon use the Alcon NGENUITY® (NG) System
62106054|NCT03146351|EXPERIMENTAL|Early and moderate preterm group|Infants born before 34 weeks included in this group
62106055|NCT03146351|EXPERIMENTAL|Late preterm group|Infants born between 34 and 37 weeks included in this group
62668103|NCT02495675|EXPERIMENTAL|High flow nasal cannulas 60 L/min|Subjects will be breathing with high flow nasal cannulas delivering 60 L/min with an inspired fraction of oxygen of 0.21.
62106056|NCT01131247|EXPERIMENTAL|ofatumumab + bendamustine|
62106057|NCT04031417|OTHER|Placebo|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
62469134|NCT02038621|PLACEBO_COMPARATOR|B|Observation until progression
62469135|NCT00316186|EXPERIMENTAL|Single arm, open label|
62668104|NCT03458091|ACTIVE_COMPARATOR|Intubation|The patients will be intubated and ventilated
62668105|NCT03458091|EXPERIMENTAL|THRIVE|The patients will be oxygenated during apnea using THRIVE
62668106|NCT06195605|EXPERIMENTAL|Photodamaged skin|
62668107|NCT04033913||Adult patient learning self-catheterization|Patients who have successfully perform self-catheterization during a day hospital in a neuro-urology department complete a questionnaire validated by experts on the different criteria that guided the final choice of the catheter
62668108|NCT02663505||Group 1|Patients receiving either elective or emergency surgery.
62668109|NCT06081062|EXPERIMENTAL|Fabagal® (Agalsidase beta)|1 mg/kg, administered every 2 weeks for 12 months
62668110|NCT06081062|ACTIVE_COMPARATOR|Active Comparator (Agalsidase beta)|1 mg/kg, administered every 2 weeks for 12 months
62668111|NCT03345004|ACTIVE_COMPARATOR|Active arm|Patients will be assigned to receive i) three (3) intralymphatic injections with Recombinant human Glutamic Acid Decarboxylase adsorbed to Alhydrogel (Diamyd) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)
62668112|NCT03345004|PLACEBO_COMPARATOR|Placebo arm|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)
62106058|NCT04031417|OTHER|soy isoflavones|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
62106059|NCT04031417|OTHER|soy isoflavones & cocoa polyphenols|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
62106060|NCT02140554|EXPERIMENTAL|Group A|Participants who had rescue cells that were collected by bone marrow harvest method and had received treatment with lovo-cel which consists of autologous CD34+ hematopoietic stem cells (HSCs) and progenitor stem cells (PSCs) collected from participants with sickle cell disease (SCD) by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene (the original drug product manufacturing process for this study).
62298052|NCT01702116|EXPERIMENTAL|extralevator APR|"This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
62298053|NCT01702116|ACTIVE_COMPARATOR|standard APR|conventional abdominoperineal resection (APR)
62298054|NCT03888625|ACTIVE_COMPARATOR|Group A: Conventional ILM peeling|peeling with complete removal of the internal limiting membrane (ILM)
62298055|NCT03888625|ACTIVE_COMPARATOR|GroupB: Inverted ILM Peeling|the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
62298056|NCT00353977|EXPERIMENTAL|ALVAC-CMV (vCP260) Vaccinated group|Patients who were vaccinated with ALVAC-CMV (vCP260)
62298057|NCT06487052|EXPERIMENTAL|Standard Catheter-Directed Thrombolysis|Local, standard catheter-directed thrombolysis with a total alteplase dose of 10 mg (for unilateral lesion) or 20 mg (for bilateral lesion) administered over 9 hours
62298058|NCT06487052|ACTIVE_COMPARATOR|Standard Anticoagulation|Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed.
62298059|NCT02380131|EXPERIMENTAL|Herceptin|"drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.~To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis"
62298060|NCT05423379||XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System|Subjects who were implanted with XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System will be included.
61913453|NCT04982601|EXPERIMENTAL|Yoga Group|Yoga-based exercises were performed by a physiotherapist has Yoga training, by consisting of 10-person groups, 6 weeks, 3 days in a week for a total of 18 sessions. Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises and lasts about one hour. Especially combined movements with upper extremity and neck movements and breathing exercises were used in breathing exercises. In the warm-up exercises, the muscles were extended by giving exercises especially for stretching the muscles. In this way, asanas were prepared. Asanas Ardra kati cahkrasana, padahastasana, trikosana, sasankasana, varaksana poses have been performed. Asanas were modified and applied according to the patient's condition. Relaxation exercises were used both after breathing exercises and at the end of the exercise program. With relaxation, the patients were allowed to leave their muscles relaxed with the whole body relaxation
61913454|NCT04982601|NO_INTERVENTION|Control Group|No kind of intervention has been applied to control group they awaited for therapy procedure for 6 week. They have assessed at the end of the 6 weeks.
62106061|NCT02140554|EXPERIMENTAL|Group B|"Group B1 participant had rescue cells and drug product cells that were collected by bone marrow harvest method and drug product was manufactured with autologous CD34+ HSCs collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene. This participant's drug product was produced in 2 lots each using two different manufacturing processes (the original drug product manufacturing process and a refined drug product manufacturing process).~Group B2 Plerixafor mobilization and apheresis were used for collection of rescue cells and exploratory manufacturing development. A single Group B2 participant received treatment of lovo-cel manufactured with autologous CD34+ HSCs collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene (using only the refined drug product manufacturing process).~Note: Groups B1 and B2 are combined as Group B for results reporting purposes."
62106062|NCT02140554|EXPERIMENTAL|Group C|Plerixafor mobilization and apheresis were used for collection of rescue cells, and drug product. Participants received treatment of lovo-cel manufactured with autologous CD34+ HSCs collected by plerixafor mobilization and apheresis transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene using a further refined manufacturing process similar to commercial manufacturing.
62106063|NCT02282527|OTHER|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
62298061|NCT00442598|EXPERIMENTAL|Glufosfamide q21 days|1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycle
62298062|NCT00442598|EXPERIMENTAL|Glufosfamide q7 days low|1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
62298063|NCT00442598|EXPERIMENTAL|Glufosfamide q7 days high|1-hour infusion of glufosfamide at a dose of 2,500 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
62298064|NCT05001178||Class I horizontal grower|
62298065|NCT05001178||Class I normal grower|
62298066|NCT05001178||Class I vertical grower|
62298067|NCT05001178||Class II horizontal grower|
62298068|NCT05001178||Class II normal grower|
62298069|NCT05001178||Class II vertical grower|
62298070|NCT05001178||Class III horizontal grower|
62298071|NCT05001178||Class III normal grower|
62298072|NCT05001178||Class III vertical grower|
62298073|NCT01642355|NO_INTERVENTION|Usual Care|Usual care includes physician assistant and/or nurse based medical and lifestyle recommendations in consultation with cardiac catheterization attending or patient's clinical cardiologist to potentially improve the patient's medical and lifestyle regimen. Relevant educational material is routinely distributed to patients.
62298074|NCT01642355|ACTIVE_COMPARATOR|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
62298075|NCT01642355|ACTIVE_COMPARATOR|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
62298076|NCT03685448|EXPERIMENTAL|Experimental: Cabozantonib|Cabozantinib 60 mg/day for up to 12 cycles (one cycle is 28 days), taken orally
62106064|NCT02282527|OTHER|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
62106065|NCT04601311|EXPERIMENTAL|Guided self-determination|3 to 5 one-hour digital or analogue guided self-determination sessions
62106066|NCT04601311|ACTIVE_COMPARATOR|Personal support in goal-pursuing|Up to five personal goal pursuing support sessions
62298077|NCT03511365|EXPERIMENTAL|Probiotic administration|After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.
62298078|NCT04512261|EXPERIMENTAL|Tucatinib + Pembrolizumab + Trastuzumab|Patients will receive a combination therapy of tucatinib with pembrolizumab and trastuzumab during the treatment period until progression, treatment intolerance, or patient withdrawal from study. Tucatinib and pembrolizumab are administered as experimental use while trastuzumab is administered per standard use. Patients are expected to be on treatment for at least 12 weeks.
62298079|NCT03804151|EXPERIMENTAL|FitSpirit Intervention|FitSpirit physical activities and events are organized by participants' schools during the school year. Girl-only activities such as physical activity sessions, speaking engagements, turnkey running program and special events can be offered. The number, type and frequency of activities are decided by each school.
62298080|NCT04558502|EXPERIMENTAL|minocycline-based bismuth quadruple regimen for 14 days|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
62298081|NCT04558502|ACTIVE_COMPARATOR|clarithromycin-based bismuth quadruple regimen for 14 days|Esomeprazole 20 mg,clarithromycin 500 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
62298082|NCT04558502|EXPERIMENTAL|minocycline-based bismuth quadruple regimen for 10 days|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 10 days.
62469136|NCT00834795|EXPERIMENTAL|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
62469137|NCT00834795|ACTIVE_COMPARATOR|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
62469138|NCT01926912||Participants with schizophrenia|
62469139|NCT01190930|EXPERIMENTAL|Arm A (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
62106067|NCT03640273|EXPERIMENTAL|Prapchompoothaweep|Group 1 will be received Prapchompoothaweep remedy 1,000 mg for 3 times before meals (for 6 weeks).
62106068|NCT03640273|EXPERIMENTAL|Loratadine|Group 2 will be received Loratadine 10 mg per day before meals (for 6 weeks)
62106069|NCT05749029|EXPERIMENTAL|Intervention|
62106070|NCT05749029|NO_INTERVENTION|Waitlist Control|Control participants will receive no intervention during the study but will be given the option of accessing the online self-compassion intervention after the study is complete.
62106071|NCT06628882|ACTIVE_COMPARATOR|Infraclavicular Block|Patients were placed in the supine position with the head facing the opposite direction of the blocked side .After sterilizing the skin with povidone iodine, a linear ultrasound probe was sterilized and placed vertically over the infraclavicular fossa to visualize the axillary artery and the lateral, medial, and posterior cords of the brachial plexus. Using an 80 mm long 21G Stimuplex1 needle, a mixture of 10 cc 0.5% bupivacaine (BUPIVON® liquid 5%, On Pharma, Istanbul, Turkey)and 2% lidocaine(JETOKAIN® liquid Adeka Pharma, Istanbul, Turkey) was injected around the three cords with intermittent aspiration for control purposes.
62298083|NCT06603636||study group|cerebral palsy children aging from 5 to 8 years having problem in gait
62298084|NCT04932889||Change|the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19 (n=240)
62298085|NCT04932889||No change|the patients whose musculoskeletal symptoms did not change with Covid-19 (n=40)
62668113|NCT03695094|EXPERIMENTAL|Cohort 1|Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
62106072|NCT06628882|EXPERIMENTAL|Wide-Awake Local Anesthesia with No Tourniquet|The WALANT solution was prepared as follows: 50 mL of 1 mg/1 mL epinephrine + 2% lidocaine(JETOKAIN® liquid Adeka Pharma, Istanbul, Turkey) + 39 cc of 0.9% isotonic NaCl + 10 mL of 8.4% sodium bicarbonate . The surgical area was sterilized with polyvinyl iodine. Using a 27-gauge syringe, the solution was applied around the incision site, either from a single point or several different points, until whitening of the skin was observed. Care was taken not to exceed the maximum dose of 7 mg/kg. The surgical procedure began 20-30 minutes after the application of the WALANT technique.
62298086|NCT03596164|EXPERIMENTAL|Teduglutide 0.05 mg|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
62298087|NCT02520479|EXPERIMENTAL|sandwich protocols|"sandwich protocols: Patients with newly diagnosed ENKTL is given 2 cycles of P-CHOP\[cyclophosphamide(CTX), 750 mg/m2 day 1; vincristine(VCR), 1.4 mg/m2 day 1 (maximal dose 2 mg),adriamycin(ADM) 50 mg/m2 day 1; dexamethasone(DXM) 10 mg days 1-8; Pegaspargase 2500 international unit day 1\] before radiotherapy(RT) and then two consolidation cycles after RT."
62298088|NCT05426811|EXPERIMENTAL|Regorafenib combined with Raltitrexed|"Regorafenib:~120mg/d，Po，qd,d1-d21，Every 4 weeks~Raltitrexed:~3mg/㎡，ivgtt，d1，Every 3 weeks"
62298089|NCT02318602|EXPERIMENTAL|Infants|"Participants 1 to\<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
62298090|NCT02318602|EXPERIMENTAL|Children|"Participants 2 to \<12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
62308338|NCT02471417|EXPERIMENTAL|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
62469140|NCT01190930|EXPERIMENTAL|Arm B (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
62469141|NCT01190930|EXPERIMENTAL|Arm B-LLy (4-week cycle maintenance)|See Detailed Description.
62469142|NCT01190930|EXPERIMENTAL|Arm C (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
62469143|NCT01190930|EXPERIMENTAL|Arm D (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
62106073|NCT01874184|EXPERIMENTAL|Arm I (DEEM intervention)|Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.
62106074|NCT01874184|NO_INTERVENTION|Arm II (usual care)|Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.
62106075|NCT05245097|EXPERIMENTAL|Intervention Group|"The intervention group will be assigned a Tango Belt to be worn around the waist for up to 24 hours a day (removed for bathing, charging of device and upon request) for 6 months. The Tango Belt (the Device) is a wearable belt designed to enable safer mobility of geriatric individuals (≥ 65 years of age) at risk for fall injury by mitigating major hip injuries due to falls by deploying an airbag around the hips upon sensing a serious hip-impacting fall-in-progress to protect the hips from ground impact forces."
62106076|NCT05245097|NO_INTERVENTION|Control Group|The the clinical site's electronic medical record (EMR) database will be reviewed determine their long-term care patient population's initial eligibility for meeting the study inclusion criteria beginning at the time frame 6 months prior to the institutional review board (IRB) approval date. Subjects eligible for the control group must meet the requirements of the inclusion and exclusion criteria except for the waist circumference and need for consent. Eligible subjects' electronic health records will be mined for the baseline, midpoint, and final study metrics.
62469144|NCT01190930|EXPERIMENTAL|Arm LR-C (risk-adapted chemotherapy)|Patients receive consolidation, interim maintenance I, delayed intensification, interim maintenance II, and maintenance therapy. See detailed description.
62469145|NCT01190930|EXPERIMENTAL|Arm LR-M (risk-adapted chemotherapy)|Patients receive consolidation and maintenance therapy. See detailed description.
62469146|NCT01190930|EXPERIMENTAL|Arm SR DS (12-week cycle maintenance)|See Detailed Description
62469147|NCT03707171|ACTIVE_COMPARATOR|Liraglutide|12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
62469148|NCT03707171|PLACEBO_COMPARATOR|Placebo|12 weeks of Placebo treatment at adjusting dose Drug:Placebo
62469149|NCT04055584||Sputum spot|
62469150|NCT01467622||Study population|Patients undergoing elective pulmonary wedge resection, anatomic segmentectomy, or lobectomy.
62469151|NCT02096718|EXPERIMENTAL|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
62469152|NCT02096718|EXPERIMENTAL|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
62469153|NCT02096718|OTHER|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
62469154|NCT04799444||Adult patients with complications post COVID-19|
62469155|NCT04799444||Children with complications post COVID-19|
62469156|NCT01221922|EXPERIMENTAL|Acne treatment|Treatment of acne scars
62469157|NCT03888430||Standard Oxygen|preoxygenation methods : Standard Oxygen
62469158|NCT03888430||High flow Oxygen|preoxygenation methods : High flow Oxygen
61913455|NCT05856591|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|"Participants randomized to EUC will have access to existing usual primary care services. They will also be enrolled in Hypertension Self-Management Education and Support (SMES) class (Hypertension group), which is an existing CDC-endorsed program offered at Eskenazi Health to provide information and skills for managing hypertension (HTN). Classes are led by registered dietitians via Webex."
62469159|NCT03888430||Non invasive ventilation|preoxygenation methods : Non invasive ventilation
62469160|NCT05763147|EXPERIMENTAL|PosiFlush™ Pre-filled flush syringes (Suzhou Becton Dickinson Medical Devices Co., Ltd.)|PosiFlush™ Pre-filled flush syringes (Suzhou Becton Dickinson Medical Devices Co., Ltd.)
62469161|NCT05763147|ACTIVE_COMPARATOR|PosiFlush™ Pre-filled Flush Syringes (BD, USA)|PosiFlush™ Pre-filled Flush Syringes (BD, USA)
62668114|NCT03695094|EXPERIMENTAL|Cohort 2|Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
62668115|NCT00315575||1|Individuals with high risk for Alzheimer's disease
62668116|NCT00315575||2|Individuals with low risk for Alzheimer's disease
62668117|NCT06203795|EXPERIMENTAL|Hemodiafiltration with FX CorAL 800 dialyzer|"* Patients are dialyzed three consecutive dialysis sessions with an FX CorAL 800 dialyzer, starting on Saturday.~* On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~* Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
62668118|NCT06203795|EXPERIMENTAL|Hemodiafiltration with FX 800 Cordiax dialyzer|"* Patients are dialyzed three consecutive dialysis sessions with an FX 800 Cordiax dialyzer, starting on Saturday.~* On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~* Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
62668119|NCT06203795|EXPERIMENTAL|Hemodiafiltration with Solacea 19H dialyzer|"* Patients are dialyzed three consecutive dialysis sessions with a Solacea 19H dialyzer, starting on Saturday.~* On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~* Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
62668120|NCT06203795|EXPERIMENTAL|Hemodiafiltration with Xevonta Hi-20|"* Patients are dialyzed three consecutive dialysis sessions with a Xevonta Hi-20 dialyzer, starting on Saturday.~* On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~* Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
62668121|NCT02063269|EXPERIMENTAL|Rivastigmine|Rivastigmine
62668122|NCT03928327|EXPERIMENTAL|Part 1, Treatment Sequence AB|TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments.
62668123|NCT03928327|EXPERIMENTAL|Part 2, Treatment Sequence CD|TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
62668124|NCT03650075|PLACEBO_COMPARATOR|Single Ascending Dose (SAD)|
62668125|NCT03650075|PLACEBO_COMPARATOR|Multiple Ascending Dose (MAD)|
62668126|NCT03650075|EXPERIMENTAL|Food Effect Part|
62668127|NCT00575302|ACTIVE_COMPARATOR|300|administration of 300 IU Gonal-f® in a short agonist protocol.
62668128|NCT00575302|EXPERIMENTAL|450|administration of 450 IU Gonal-f® in a short agonist protocol.
62668129|NCT02365129|NO_INTERVENTION|Usual care group (control)|Participants randomly assigned to the usual care (control) group will receive general advices from the exercise-training specialist about the positive effects of physical activity at the start of the study. The investigators will prepare informative pamphlets describing the benefits of physical activity that the investigators group has prepared for the Region of Andalucía (Southern Spain),http://www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf.
62106077|NCT05765851|EXPERIMENTAL|Dose Escalation: DS-1103a + T-DXd|Participants with HER2-expressing or HER2-mutant advanced metastatic solid tumors who will receive an intravenous (IV) infusion of DS-1103a (starting dose of 100 mg) every 3 weeks (Q3W) starting on Cycle 1 Day 1. Starting on Cycle 2 Day 1 and on Day 1 of each subsequent cycle, participants will also receive T-DXd Q3W at a dose of 5.4 mg/kg.
62106078|NCT05765851|EXPERIMENTAL|Dose Expansion: DS-1103a + T-DXd|Participants with HER2-low expressing breast cancer who will receive an IV infusion of DS-1103a at the recommended dose for expansion (RDE) in combination with T-DXd 5.4 mg/kg Q3W starting on Cycle 1 Day 1.
62469162|NCT05748886||Period 1|00:00 30th Jan 2023 - 23:59 26th Feb 2023 (+ 30 Day Follow-up)
62469163|NCT05748886||Period 2|00:00 27th Feb 2023 - 23:59 26th Mar 2023 (+ 30 Day Follow-up)
62469164|NCT05748886||Period 3|00:00 27th Mar 2023 - 23:59 23th Apr 2023 (+ 30 Day Follow-up)
62469165|NCT05748886||Period 4|00:00 24th April 2023 - 23:59 21st May 2023 (+ 30 Day Follow-up)
62469166|NCT06139666|ACTIVE_COMPARATOR|Control- Bupivacaine Alone|patients will receive a standard interscalene block with bupivacaine alone (25 cc of bupivacaine)
62469167|NCT06139666|EXPERIMENTAL|Study- Exparel|patients will receive an interscalene block with Exparel solution, which is an extended-release formulation of bupivacaine consisting of 10cc liposomal bupivacaine mixed with 15cc bupivacaine. This is approved and used at the study institution
62668130|NCT02365129|EXPERIMENTAL|Moderate-intensity group|Exercise training based on recommendations for adults (WHO)
62668131|NCT02365129|EXPERIMENTAL|Vigorous-intensity group|Exercise training based on recommendations for adults (WHO)
62469168|NCT05497362|EXPERIMENTAL|Real tDCS|Group 1 (n = 5) received anodal tDCS stimulation and intensive speech and voice therapy; tDCS and speech therapy was applied in 10 daily sessions during a 2-week period, administered on Monday to Friday. The anodal stimulation was delivered to the primary motor cortex (SM1) of the orofacial area.
62469169|NCT05497362|SHAM_COMPARATOR|Sham tDCS|Group 2 (n = 4) received sham tDCS stimulation and intensive speech and voice therapy. For the sham tDCS group, the same setting of tDCS electrodes was applied on the scalp, but the stimulation only lasted for 30 sec in order to cause a similar sensation on the scalp. tDCS and speech therapy was applied in 10 daily sessions during a 2-week period, administered on Monday to Friday.
62469170|NCT06523114|EXPERIMENTAL|Lateral epicondylitis and plantar fascitis group|Among patients with lateral epicondylitis or plantar fascitis, pain refractory to at least 6 months of physician directed conservative therapy
61913456|NCT05856591|EXPERIMENTAL|Food Resources & Kitchen Skills (FoRKS)|"Participants randomized to FoRKS will attend weekly HTN SMES classes separately from EUC participants. SMES classes will include the EUC curriculum stated above and an introduction to the upcoming FoRKS intervention.~Following HTN SMES completion, FoRKS continues with home-delivered Mediterranean-style ingredient kits, food management lessons, and hands-on cooking classes in one's own kitchen. Classes are led by registered dietitians via Webex. Classes are held twice per week thru Week 12, then only once per week through Week 16."
61913457|NCT00002642|EXPERIMENTAL|chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery and post-surgery boost chemotherapy
61913458|NCT02257801|EXPERIMENTAL|Nutritional beverage fortified with 6mg lutein/day|
61913459|NCT02257801|EXPERIMENTAL|Nutritional beverage fortified with 12mg lutein/day|
61913460|NCT02257801|PLACEBO_COMPARATOR|Nutritional beverage fortified with 0mg lutein/day|
61913461|NCT00618553|EXPERIMENTAL|Pulmonary Rehabilitation|Pulmonary Rehabilitation - Rehabilitation treatment given over about 3-4 weeks. Questionnaire regarding quality-of-life that lasts about 30 minutes.
61913462|NCT03175055|EXPERIMENTAL|Phoenix|Phoenix
61913463|NCT03483922||chronic hepatitis B|This group will include 50 with hepatitis B subjects and the diagnoses will be based on AASLD practice guideline.
61913464|NCT03483922||HCC Cases|"This group will include 350 in stage 0, stage A, stage B, Stage C+D of hepatocellular carcinoma.~HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma"
61913465|NCT03483922||Healthy|This group will include 50 healthy sex and age matched controls.
61913466|NCT00167856|EXPERIMENTAL|1|Venlafaxine HCL (extended release)
62106079|NCT04268563|PLACEBO_COMPARATOR|Placebo|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
61913467|NCT00167856|ACTIVE_COMPARATOR|2|Benztropine Mesylate
61913468|NCT05062993|EXPERIMENTAL|study group|Patients with chronic radicular pain will be included in this study. Ultrasound guided caudal epidural pulse radiofrequency technique will be applied to the study group.
62106080|NCT04268563|EXPERIMENTAL|Metformin|Intervention group 1: received Metformin (Glucophage, Merck, West Drayton, UK; 500 mg ,two times daily
62106081|NCT04268563|EXPERIMENTAL|Sitagliptin|Intervention group2: received Sitagliptin (Januvia, Merck,West Drayton, UK. 50 mg, two times daily
61913469|NCT00040846|EXPERIMENTAL|Treatment (dose-escalation of alemtuzumab, HSCT)|"CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 2 hours on days -8 to -5 and fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~HSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156."
61913470|NCT01104376|EXPERIMENTAL|CYP2B6|"Healthy volunteers will receive Efavirenz and Vericonazole as follow:~In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
61913471|NCT02253927|EXPERIMENTAL|BILR 355 (dose escalation) + Ritonavir|escalating dose groups, for food effect evaluation lowest dose group (D1) with high fat meal breakfast after wash-out period
61913472|NCT03029637|EXPERIMENTAL|No preparation resin bonded bridges|RBBs with no or minimal preparation of their abutment teeth
62106082|NCT04268563|EXPERIMENTAL|sitagliptin/metformin|Intervention group3: received Sitagliptin/metformin (Janumet, Merck,West Drayton, UK. 50/500 mg), two times daily
61913473|NCT03029637|ACTIVE_COMPARATOR|Routine resin bonded bridges|RBBs with routine tooth preparation of their abutment teeth
61913474|NCT02398994|ACTIVE_COMPARATOR|Intravenous Methylprednisolone|"Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
61913475|NCT02398994|EXPERIMENTAL|Intravenous Immunoglobulin|"Paediatric patients \<41.2kg - total dose of 2g/kg in divided doses over 2 days.~All other patients - total dose of 2g/kg in divided doses over 5 days.~PLUS Intravenous Methylprednisolone~Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
61913476|NCT04125264|EXPERIMENTAL|Intense therapeutic Ultrasound|"During the trial two applications of 1000 pulses each one (day one and day thirty) will be applied. Pulse regulation could be modified from 4 to 5 joules depending the presence or not of pain.~Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching."
61913477|NCT04125264|NO_INTERVENTION|Control group|Non ITU application. Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching.
62106083|NCT03183232|EXPERIMENTAL|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
62106084|NCT03183232|EXPERIMENTAL|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
62106085|NCT03183232|EXPERIMENTAL|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
62469171|NCT01659580|EXPERIMENTAL|T89 high dose|T89 225mg bid
62469172|NCT01659580|EXPERIMENTAL|T89 low dose|T89 150mg bid
62668132|NCT03608085|EXPERIMENTAL|Pharmacist Heart failure MTM training|Community pharmacist who will receive heart failure medication therapy management training
62298091|NCT02318602|EXPERIMENTAL|Adolescents|"Participants 12 to \<17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
62298092|NCT06656169|EXPERIMENTAL|Case group|Patients with unilateral or bilateral arthritic hand, both genders, age of 60 years or older in treatment with subcutaneous polyvidone collagen.
62469173|NCT01659580|EXPERIMENTAL|Sanqi+Bingpian|225mg bid
62106086|NCT06267365||Adult Patients with Painful Chronic Pancreatitis|Participants with chronic pancreatitis scheduled for endoscopic therapy will undergo baseline assessments including EEG, quantitative sensory testing, and psychosocial questionnaires. Follow-up questionnaires will be completed at approximately 3, 6, 12 and 18 months post-procedure.
62106087|NCT06317883||CORALS|Children aged 3-6 years
62106088|NCT05512260|OTHER|Women aged 23 -74 and men aged 60 - 74 invited to population based cancer screening|Women aged 23 -74 targeted for breast cancer, cervical and bowel screening and men aged 60-74 targeted for bowel screening will be invited to the project. Efforts will be made to recruit participants who normally do not participate in research and screening, such as those with various disabilities, participants who live outside society and foreign born.
62106089|NCT00012987|OTHER|Arm 1|
62106090|NCT06433037|PLACEBO_COMPARATOR|Maltodextrin|
62106091|NCT06433037|EXPERIMENTAL|Chicory inulin|
62106092|NCT06433037|EXPERIMENTAL|Resistant dextrin|
62106093|NCT06433037|EXPERIMENTAL|Seaweed polysaccharide|
62106094|NCT02491931|ACTIVE_COMPARATOR|GLN group|All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
62106095|NCT02491931|PLACEBO_COMPARATOR|CONT group|All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
62106096|NCT01121783|ACTIVE_COMPARATOR|Lactisole-Glucose|
62106097|NCT01121783|ACTIVE_COMPARATOR|Lactisole-water|
62106098|NCT01121783|PLACEBO_COMPARATOR|Water-Glcuose|
62106099|NCT01121783|PLACEBO_COMPARATOR|Water-Water|
62469174|NCT01659580|PLACEBO_COMPARATOR|Placebo|225mg bid
62469175|NCT02195193|NO_INTERVENTION|Usual Care (UC)|"The standard interventions from Clinical Pathway for Acute Coronary Syndromes in China-Phase 3 (CPACS-3) study that are limited to in-patient ACS care (refer to Usual Care \[UC\]), will be implemented in the participating hospitals, and hence will be received by all patients in both intervention (IC) and control (UC) groups; standardized cardiovascular disease education also will be provided to all participants.CPACS-3 registration number is NCT01398228"
62668133|NCT03608085|EXPERIMENTAL|Patient Heart failure MTM intervention|Independently living community dwelling subjects who are prescribed at least 1 cardiovascular medication for HF and 3 additional chronic medications after discharge from the Hospital for an MTM consultation by a pharmacist trained in heart failure medication therapy management.
62668134|NCT03723486||Roux-en-Y gastric bypass surgery (RYGB)|Morbidly obese patients undergoing gastric bypass surgery
62668135|NCT06407440|ACTIVE_COMPARATOR|control|Ergonomics training will be provided and followed up
62668136|NCT06407440|EXPERIMENTAL|exercise|In addition to ergonomics training, exercise training will be provided.
62106100|NCT06457607|EXPERIMENTAL|Arm is composed of determined to need a forehead lift due to drooping upper eyelids|The participant will visit the clinical trial institution at 4, 8, 12, and 16 weeks after the application visit (Visit 2, Baseline) of the medical device for clinical trials. They will participate in the efficacy evaluation of the clinical trial medical device for a total of 16 weeks.
62106101|NCT02197871|NO_INTERVENTION|blank control|usual diet
62106102|NCT02197871|EXPERIMENTAL|nutrition supplementation|In addition to usual diet,the patients will be given enteral nutrition emulsion, which is a oral nutrition liquid composed of proteins,omega-3 fatty acids,carbohydrate,vitamins.Every package contains 200ml and provides 260 kcal energy.
62106103|NCT03893591||Body mass index below 35|
62106104|NCT03893591||Body mass index 35 and above|
62106105|NCT00069459|OTHER|Extended-release Bupropion Hydrochloride|Extended-release Bupropion Hydrochloride
62298093|NCT06656169|PLACEBO_COMPARATOR|Control group|Patients with unilateral or bilateral arthritic hand, both genders, age of 60 years or older
62298094|NCT00559338|ACTIVE_COMPARATOR|1|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
62298095|NCT00559338|PLACEBO_COMPARATOR|2|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
62308339|NCT02471417|PLACEBO_COMPARATOR|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
62668137|NCT03418480|EXPERIMENTAL|RNA Vaccine A|"Arm 1A: 15 (6+9) patients with previously treated HPV16+ head and neck squamous cell carcinoma receiving increasing doses of HPV vaccine.~- COMPLETE no longer recruiting"
62668138|NCT03418480|EXPERIMENTAL|RAN Vaccine B|"Arm 1B: 29 (15+14) patients with HPV16+ advanced disease receiving increasing doses of HPV vaccine.~OPEN to recruitment"
62668139|NCT05404841|EXPERIMENTAL|CoffeeBerry Supplement|Caffeine and polyphenol supplement
62668140|NCT05404841|PLACEBO_COMPARATOR|Placebo|Placebo
62668141|NCT01738178|PLACEBO_COMPARATOR|Control - Placebo|These participants will receive placebo tablets during the first 5 years
62668142|NCT01738178|ACTIVE_COMPARATOR|Caffeine group|This group of participants will receive caffeine tablets.
62668143|NCT03485456|EXPERIMENTAL|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
62668144|NCT03832088|EXPERIMENTAL|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated for sarcopenia and balance disorders
62668145|NCT05934253|EXPERIMENTAL|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
62668146|NCT05934253|ACTIVE_COMPARATOR|Tetracaine ophthalmic solution 0.5%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
62668147|NCT04488094|EXPERIMENTAL|Heart transplantation|Patients suspected of having acute heart allograft rejection after heart transplantation will receive a single IV injection of \[18F\]FSPG
62668148|NCT04488094|EXPERIMENTAL|Liver transplantation|Patients suspected of having acute liver allograft rejection after heart transplantation will receive a single IV injection of \[18F\]FSPG
62668149|NCT01716156|EXPERIMENTAL|Grazoprevir 100 mg + RBV 12 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 12 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 12 weeks. Participants with detectable HCV RNA at TW4 received an additional 12 weeks of study therapy for a total of 24 weeks of treatment.
62668150|NCT01716156|EXPERIMENTAL|Grazoprevir 100 mg + RBV 24 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 24 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 24 weeks.
62668151|NCT05586087|EXPERIMENTAL|Experimental group|Participants perform a 16-week of High-Speed Resistance Training program.
62668152|NCT05586087|NO_INTERVENTION|Control group|Participantes continued their usual activity without engaging in any strength training or beginning a new exercise program during the study.
62668153|NCT01311583|ACTIVE_COMPARATOR|usual care plus Teach Back intervention|Trained nurses will provide Teach Back to the intervention group. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
62668154|NCT01311583|NO_INTERVENTION|usual care|"All participants will experience the current practice of discharge teaching: daily interaction with the interdisciplinary team members via rounds, counseling on diet and medications with a dietician and pharmacist when referred, view the Heart Failure Discharge Video, and receive a Congestive Heart Failure education package which includes the Heart and Stroke Managing Congestive Heart Failure booklet."
62106106|NCT01575470|EXPERIMENTAL|bone marrow mononuclear cells|a bone marrow harvest will be performed within 36 hours of injury followed by a single intravenous infusion of autologous bone marrow mononuclear cells (BMMNCs)
62668155|NCT05406999|ACTIVE_COMPARATOR|ADT alone + prostatectomy|A total of 100 subjects receive ADT for 6 cycles (28 days per cycle) before prostatectomy. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62668156|NCT05406999|EXPERIMENTAL|ADT plus Abiraterone|A total of 150 subjects in this group received abiraterone acetate + prednisolone acetate daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62668157|NCT05406999|EXPERIMENTAL|ADT plus Enzalutamide|A total of 50 subjects in this group received enzalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62668158|NCT05406999|EXPERIMENTAL|ADT plus Apalutamide|A total of 150 subjects in this group received apalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62668159|NCT05406999|EXPERIMENTAL|ADT plus Darotamide|A total of 150 subjects in this group received darotamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62106107|NCT06290544|OTHER|Single arm study|Subjects with type 1 diabetes mellitus who meet all the inclusion and none exclusion criteria
62106108|NCT06096428||Pulsed-field group|Patients will undergo catheter ablation for atrial fibrillation using pulsed-field energy
62668160|NCT05406999|EXPERIMENTAL|ADT plus Rizvilutamide|A total of 150 subjects in this group received rizvilutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62106109|NCT06096428||Radiofrequency group|Patients will undergo catheter ablation using radiofrequency energx
62106110|NCT02771418|SHAM_COMPARATOR|TIVA with propofol|Induction and maintenance of general anesthesia using TIVA with propofol
62668161|NCT05406999|EXPERIMENTAL|PARP inhibitor + abiraterone + ADT|A total of 100 subjects in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor plus abiraterone along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62469176|NCT02195193|EXPERIMENTAL|Intervention Care (IC)|Besides of the UC, an nurse-coordinated integrated care model for Acute Coronary Syndromes(ACS) and depression will be delivered to intervention group, including ACS secondary prevention therapies at and after discharge, screening and treatment of depression during hospitalization and after discharge.
62469177|NCT02363803|PLACEBO_COMPARATOR|Normal saline infusion then lidocaine infusion|Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine \[5mg/kg\] over a 40 minute period.
62106111|NCT02771418|ACTIVE_COMPARATOR|VIMA with sevoflurane|Induction and maintenance of general anesthesia using VIMA with sevoflurane
62106112|NCT00067639|EXPERIMENTAL|Pegfilgrastim + Apheresis|12 mg Pegfilgrastim as subcutaneous injection on day 1 + Apheresis daily till target stem cell dose reached.
62106113|NCT06111508|EXPERIMENTAL|Continuous Glucose Monitoring (CGM) based Titration|The CGM-based titration algorithm will run on the Diabetes Assistant and Amazon Web Services (AWS) platform (DiAs-Cloud). DiAs-Cloud enables the seamless integration of a smart phone application and AWS server architecture to enable data capture, dose computation, review by the clinical team, and communication to study participants. For dose computation the algorithm is comprised of three components; titration glucose level, personalized target, and safety hypoglycemia feature.
62668162|NCT05406999|EXPERIMENTAL|PARP inhibitor + ADT|A total of 50 subjects in this group in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor along with ADT mentioned above. Enrolled patients carry homologous recombination repair (HRR) gene mutation verified by molecular testing. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
62668163|NCT05520047||COVID19-severe Patient|modified Medical Research Council dyspnea scale (mMRC), European Quality of Life 5 Dimensions and 5 Lines (EQ-5D-5L), the impact of event scale-revised (IES-R), The Hospital Anxiety and Depression Scale (HADS), the Montreal Cognitive Assessment (MoCA)- BLIND, Lawton instrumental activities of daily living (IADL) and Return to work scales
62668164|NCT05520047||family of COVID19-severe Patient|impact of event scale-revised (IES-R), The Hospital Anxiety and Depression Scale (HADS) scales
62668165|NCT04667169|EXPERIMENTAL|Laser Haemorrhoidoplasty|A stab incision was made at the ano-cutaneous junction and the anodermis was tunneled with artery forceps to the pedicle of the haemorrhoids. The laser catheter was introduced submucosally towards the pedicle guided by a visible beam to ascertain the exact location of the laser fibre. This was then followed by about six pulsed laser energy delivered at five mm interval, while gradually withdrawing the laser catheter.
62668166|NCT04667169|EXPERIMENTAL|Haemorrhoidal Artery Ligation|In addition to the delivery of laser energy as per the procedure described above, each identified pedicle was ligated with a suture, without Doppler guidance.
62668167|NCT04231006|EXPERIMENTAL|Single arm|Single arm
62668168|NCT04331405|EXPERIMENTAL|Pilot group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received hUCBMC infusions weekly (4 infusions overall) in addition to standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
62668169|NCT04331405|NO_INTERVENTION|Control group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
62668170|NCT01431846|NO_INTERVENTION|Discharge Patient|Eight patients who were being discharged from Denver VA Medical Center for cardiac care to their primary care providers were recruited at the time of discharge and completed an interview two weeks following their discharge. Patients were asked to describe their transition to home and identify barriers and facilitators of this process, their understanding of their medical condition, new medications prescribed, timeliness of follow-up visit with their PCP and knowledge of signs/symptoms in which they should seek medical attention.
62668171|NCT01431846|NO_INTERVENTION|Providers|Three providers who refer patients to the Denver VA Medical Center for cardiac care were interviewed to identify barriers and facilitators from their perspective of following-up with patients after their hospitalization at Denver VAMC. Additionally, the same information was asked of providers who participated in two focus groups in the Grand Junction VA.
62668172|NCT01431846|EXPERIMENTAL|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
62668173|NCT03854032|EXPERIMENTAL|Arm I (BMS986205, nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD. Beginning week 2, patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days.
62668174|NCT03854032|ACTIVE_COMPARATOR|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days.
62668175|NCT03709589||Group-A|Patients with Modified Early Warning Score of ≥ 5
62469178|NCT02363803|ACTIVE_COMPARATOR|Lidocaine infusion, then normal saline infusion|Intravenous infusion of lidocaine \[5mg/kg\] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.
62469179|NCT02589808|EXPERIMENTAL|Full TTE|Full echocardiogram.
62668176|NCT03709589||Group-B|Patients with Modified Early Warning Score of \< 5
62668177|NCT00127933|EXPERIMENTAL|HER2-NEU Positive|
62668178|NCT00127933|EXPERIMENTAL|HER2-NEU Negative|
62668179|NCT01981928|EXPERIMENTAL|ASP7962|Each dose level group will include 8 subjects, of which 6 will be randomized to receive active ASP7962
62668180|NCT01981928|PLACEBO_COMPARATOR|Placebo|Each dose level group will include 8 subjects, of which 2 will be randomized to receive placebo
62469180|NCT02589808|EXPERIMENTAL|VScan|Handheld echocardiogram.
62469181|NCT02045550|PLACEBO_COMPARATOR|Placebo Syrup|Placebo Syrup 2.5 ml twice daily for 4 weeks
62469182|NCT02045550|ACTIVE_COMPARATOR|Prospan Syrup|Prospan Syrup 2.5 ml twice daily for 4 weeks
62106114|NCT06111508|NO_INTERVENTION|Standard Self-Monitoring Blood Glucose (SMBG) Titration|The SMBG-based titration algorithm will run on the Diabetes Assistant and Amazon Web Services (AWS) platform (DiAs-Cloud). DiAs-Cloud enables the seamless integration of a smart phone application and AWS server architecture to enable data capture, dose computation, review by the clinical team, and communication to study participants. Participants in the standard SMBG based titration group will wear a blinded CGM during the whole study. The total daily basal insulin dose will be converted 1:1 to Degludec. Algorithm informed dose changes will be made once weekly and checked by study physician.
62668181|NCT01824004|EXPERIMENTAL|S-1,chemoradiotherapy, adjuvant treatment|Pts with radically D2 resected adenocarcinoma of the stomach or GEJ in AJCC stage Ib-IV (M0) were eligible for this study. Pts were treated with S-1 (40-60 mg depending on BSA) b.i.d. for 3 wks, and cisplatin (60 mg/m²) iv on day 1, followed by a 2-wk rest period, within a 5-wk cycle. Subsequently, radiotherapy (RT) started which consisted of 25 fractions of 1.8 Gy to a total dose of 45 Gy in 5 wks (5 fractions/wk). On RT days, S-1 (40-60 mg depending on BSA ) b.i.d., 5 days/wk was given. One month after the completion of RT, two 5-wk cycles of S-1/ciplatin chemotherapy were given.
62106115|NCT00282438|EXPERIMENTAL|Autologous hematopoietic stem cell transplantation|Autologous stem cells will be injected after conditioning
62106116|NCT00282438|EXPERIMENTAL|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
62106117|NCT04590651|EXPERIMENTAL|Standard PHACO cataract surgery|In this group normal phacoemulsification cataract surgery will be preformed.
62106118|NCT04590651|EXPERIMENTAL|PHACO + extra aspiration|In this group an extra one minute anterior chamber angle aspiration will be preformed at the end of a standard cataract operation.
62106119|NCT02469064|EXPERIMENTAL|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
62106120|NCT02469064|ACTIVE_COMPARATOR|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
62298096|NCT04636112||control group|Patients hospitalized and diagnosed as non-AMI during the same time period were matched. All patients underwent coronary angiography and CAD was defined as at least one main coronary artery with \> 50% narrowing of luminal diameter.
62298097|NCT04636112||AMI group|Patients were diagnosed as MI when a cardiac biomarker (preferably cardiac troponin) rose or fell at least one value in its 99th percentile upper reference limit and at least one of the following criteria was met, including ischemic symptoms, electrocardiogram (ECG) changes of new ischemia, pathologic Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, identification of an intracoronary thrombus by angiography or autopsy.
62298098|NCT02024776|ACTIVE_COMPARATOR|Prehabilitation|Prehabilitation program is defined as a tailored physical exercise program to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile. The intervention consisted of a standard 4-6 week supervised outpatient program including global endurance exercise training, or educational sessions followed by a self-management program supported by ICT during the follow-up period, or a combination of both.
62298099|NCT02024776|NO_INTERVENTION|No-intervention|Standard counseling and conventional pre-surgical measures
62298100|NCT00814931|EXPERIMENTAL|1|Treatment Group
62298101|NCT00814931|PLACEBO_COMPARATOR|2|
62298102|NCT01627145|EXPERIMENTAL|antimuscariniz drug|
62469183|NCT02409953|EXPERIMENTAL|Bath|
62469184|NCT02409953|PLACEBO_COMPARATOR|Bed|
62469185|NCT03106662|EXPERIMENTAL|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10\^8 cell/kg mesenchymal stem cells will be infused.
62469186|NCT01759940|EXPERIMENTAL|ropivacaine 0,375%|In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
62469187|NCT01759940|ACTIVE_COMPARATOR|ropivacaine 0,75%|In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
62106121|NCT01306669|ACTIVE_COMPARATOR|Trivalent influenza vaccine|Single dose administration of trivalent influenza vaccine prior to onset of influenza season
62106122|NCT01306669|PLACEBO_COMPARATOR|Normal saline|
62106123|NCT06629337|EXPERIMENTAL|Experimental: BFR exercise with histamine blockade|
62106124|NCT06629337|SHAM_COMPARATOR|Sham Comparator: BFR exercise without histamine blockade|
62298103|NCT06372977||1|(-ve OCB )(70 patients) Control group which include patients with inflammatory and non-inflammatory neurological diseases (such as cerebral small vessel disease or unspecific white matter lesion )
62298104|NCT06372977||2|(+ve OCBs )(70 patients) Patients presenting for the diagnostic workup, including CSF analysis , of clinical and/or MRI suspicion of MS or CIS.
62298105|NCT03467230||NoL Index|All patients will be monitored by PMD-200 device
62298106|NCT04708067|EXPERIMENTAL|Treatment (hypofractionated radiation, bintrafusp alfa)|Patients undergo hypofractionated radiation therapy QD on weekdays (Monday-Friday) for 15 fractions in the absence of disease progression or unacceptable toxicity. Beginning 1 week after completion of radiation therapy, patients receive bintrafusp alfa IV over 1 hour on day 1. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62298107|NCT03009357||thyrotoxicosis|patients with newly detected or recurrent thyrotoxicosis
62298108|NCT03009357||control|euthyroid, healthy adults
62298109|NCT01479972|EXPERIMENTAL|VPM1002|
62469188|NCT06145386|EXPERIMENTAL|COVID-19 positive|
62469189|NCT06145386|EXPERIMENTAL|COVID-19 negative|
62668182|NCT00943202|EXPERIMENTAL|Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine; Day 42: TIV.
62668183|NCT00943202|EXPERIMENTAL|Group 2: Day 0-H1N1+TIV; Day 21-H1N1|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine + TIV; Day 21: 15 mcg H1N1 vaccine.
62668184|NCT00943202|EXPERIMENTAL|Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1|150 subjects to receive-Day 0: TIV; Day 21: 15 mcg H1N1 vaccine; Day 42: 15 mcg H1N1 vaccine.
62668185|NCT00943202|EXPERIMENTAL|Group 3: Day 0-H1N1; Day 21-H1N1+TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine + TIV.
62106125|NCT03736785|EXPERIMENTAL|LY3209590 Algorithm 1|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of \<140 milligram per deciliter (mg/dL).
62298110|NCT01479972|ACTIVE_COMPARATOR|BCG|
62469190|NCT00861406|EXPERIMENTAL|Group 1|Pegylated Interferon alfa-2b (Once week x 4 weeks) + GP-100 Peptide
62106126|NCT03736785|EXPERIMENTAL|LY3209590 Algorithm 2|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous injection. Dose titration was done to maintain fasting blood glucose of \<120 mg/dL.
62106127|NCT03736785|ACTIVE_COMPARATOR|Insulin Degludec|Participants received same dose of Degludec as the total basal insulin dose already administered prior to randomization. Dose was titrated to maintain fasting blood glucose of ≤100 mg/dL to achieve glycemic goal of HbA1C \<7%.
62106128|NCT01068249|EXPERIMENTAL|Letrozole + RAD001|Letrozole and RAD001 (Everolimus)
62106129|NCT02304822|ACTIVE_COMPARATOR|Multiple-dose of ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
62106130|NCT02304822|EXPERIMENTAL|Single-dose of ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only
62106131|NCT02304822|EXPERIMENTAL|Zero-dose of ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
62298111|NCT03425903|ACTIVE_COMPARATOR|Whole Body Cryotherapy sessions|10 Whole Body Cryotherapy sessions administered on alternate days. Patient fills the questionaires and then comes into the cabin wearing only underwear. The door is closed and the session begins, with the release of nitrogen gas to the cabin indoors, which will be in contact with the patient's body surface for 3 minutes. The intervention is performed on alternate days, so 3 sessions per week are administered. Afterwards will be compared when intervening as an control group without sessions, and with 3 visits per week and fills in the questionnaires
62469191|NCT00861406|EXPERIMENTAL|Group 2|Pegylated Interferon alfa-2b (Once week x 8 weeks) + GP-100 Peptide
62668186|NCT04049565||Procalcitonin|septic patients who will receive Procalcitonin
62668187|NCT04049565||C-Reactive Protein|septic patients who will receive C-Reactive ptotein
62106132|NCT05795829|EXPERIMENTAL|Disposable Intravascular Ultrasound Ablation Catheter and Ultrasound Ablation Instrument|All subjects will receive treatment from the disposable intravascular ultrasound ablation catheter.
62106133|NCT06161064|OTHER|office-based injection laryngoplasty|office-based injection laryngoplasty by using hyaluronic acid
62106134|NCT04744597|EXPERIMENTAL|Real execution group|The real execution group will perform the acute intervention by the actual performance of the Fitt's law task.
62106135|NCT04744597|EXPERIMENTAL|Motor imagery group|The motor imagery group will perform the acute intervention by simulating (mental process) the Fitt's law task.
62106136|NCT04744597|ACTIVE_COMPARATOR|Control group|The control group will perform skip counting.
62106137|NCT01386086|EXPERIMENTAL|Aripiprazole|aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
62106138|NCT01989637|EXPERIMENTAL|Strawberry Meal|40 g freeze-dried strawberries included in test meal
62469192|NCT00861406|EXPERIMENTAL|Group 3|Pegylated Interferon alfa-2b (Once week x 12 weeks) + GP-100 Peptide
62469193|NCT02099747|ACTIVE_COMPARATOR|hATG + CsA|Control Arm
62469194|NCT02099747|EXPERIMENTAL|hATG + CsA + Eltrombopag|Experimental
62469195|NCT03955757|EXPERIMENTAL|Boot Camp Translation|Intervention communities will undergo the Boot Camp Translation process.
62668188|NCT04764604|EXPERIMENTAL|Muscle Tension Group|"10 participants with a diagnosis of muscle tension dysphonia will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~1. Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~2. Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
62469196|NCT03955757|ACTIVE_COMPARATOR|Control|Control communities will behave as usual
62469197|NCT02865850|EXPERIMENTAL|Vadadustat|
62469198|NCT02865850|ACTIVE_COMPARATOR|Darbepoetin alfa|
62469199|NCT02291263|ACTIVE_COMPARATOR|Arm A|Group A will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group A participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
62469200|NCT02291263|ACTIVE_COMPARATOR|Arm B|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group B participants will also receive inactivated polio vaccine (IPV) at 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
62469201|NCT02291263|ACTIVE_COMPARATOR|Arm C|Group C will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group C participants will also receive inactivated polio vaccine (IPV) at 6 and 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
62668189|NCT04764604|EXPERIMENTAL|Vocal Fold Palsy Group|"10 participants with a diagnosis of (unilateral) vocal fold palsy will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~1. Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~2. Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
62668190|NCT04764604|EXPERIMENTAL|Presbylaryngis Group|"10 participants with a diagnosis of presbylaryngis will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~1. Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~2. Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
62469202|NCT04768309|EXPERIMENTAL|CKD group|CKD adult patients stage 4-5 Without diabetes BMI between 18 and 30 kg/m2
62668191|NCT01696968|NO_INTERVENTION|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
62668192|NCT01696968|ACTIVE_COMPARATOR|Lung Screening|"Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as smokers undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial."
62668193|NCT04700462|EXPERIMENTAL|Sm-EMA|Participants will receive the Self-monitoring ecological momentary assessment behavior change tool.
62668194|NCT05673655|ACTIVE_COMPARATOR|transcutaneous injection|
62668195|NCT05673655|ACTIVE_COMPARATOR|intraoral injection|
62668196|NCT02993302|ACTIVE_COMPARATOR|PTU-Oral 1α-D3|patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
62106139|NCT01989637|PLACEBO_COMPARATOR|Control Meal|Control consisting of matched test meal with strawberry flavoring instead of freeze-dried strawberry powder
62668197|NCT02993302|PLACEBO_COMPARATOR|PTU-Placebos|patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
62668198|NCT01824147||CABG Patients|Patients undergoing surgery for coronary revascularization.
62106140|NCT06628505|ACTIVE_COMPARATOR|Speech in Noise Training (SPiN)|Young to middle-age mTBI patients (age 18-55 yrs.) with various degrees of central hearing impairment will be randomly assigned to this training group
62668199|NCT02838238|EXPERIMENTAL|X|Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles
62106141|NCT06628505|NO_INTERVENTION|SPiN Control Group Treatment as Usual (TAU)|Young to middle-age mTBI patients (age 18-55 yrs.) with various degrees of central hearing impairment will be randomly assigned to a treatment as usual group
62106142|NCT06628505|ACTIVE_COMPARATOR|Spatial Hearing Training|Young to middle-age mTBI patients (age 18-55 yrs.) with various degrees of central hearing impairment will be randomly assigned to this training group
62106143|NCT06628505|OTHER|Spatial Hearing Training Control Group Treatment as Usual (TAU)|Young to middle-age mTBI patients (age 18-55 yrs.) with various degrees of central hearing impairment will be randomly assigned to a treatment as usual group
62469203|NCT04768309|OTHER|Healthy volunteers group|Adult without chronic treatment, without renal dysfunction
62469204|NCT01708824|EXPERIMENTAL|dietary|"Dietary intervention to meet the target of~1.\<5 servings of red/processed meat weekly; \<2 servings would be processed meat 2.2 servings of refined grains daily"
62668200|NCT02838238|PLACEBO_COMPARATOR|Placebo|Placebo, bid, po, d1-14, every 3 weeks for 6 cycles
62298112|NCT03425903|NO_INTERVENTION|Control group|Without sessions. Patient attends a control visit weekly, for 3 consecutive weeks and fills in the questionnaires to control the variables while treatment is not applied. Afterwards will be compared when intervening as an intervention group receiving 3 sessions per week and fills in the questionnaires.
62298113|NCT02267486||Alzheimer Dementia (AD)|Patients with dementia caused by Alzheimer's disease
62298114|NCT02267486||Non-dementia|Patients with cognitive concern without dementia
62469205|NCT01708824|EXPERIMENTAL|physical activity|"Physical activity intervention with the following targets:~1. General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~2. Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
62469206|NCT01708824|EXPERIMENTAL|dietary and physical activity|Meeting both the dietary and physical activity targets
62469207|NCT01708824|NO_INTERVENTION|usual care|Follow the general lifestyle advice in accordance with the recommendations of the Department of Health in Hong Kong available in the public domain
61913478|NCT05599776|NO_INTERVENTION|Control group|The control group of this trial will receive standard postoperative care which includes physiotherapy appointments 4 weeks and 3 months after the surgery. The 4-week physiotherapy appointment will be at local health center, occupational health clinic or in private physiotherapy clinic and patients are instructed to book the appointments independently according to the standard of care in Coxa Hospital. The 3-month physiotherapy appointment in Coxa Hospital will be carried out by physiotherapists who are dedicated to research projects at Coxa outpatient clinic.
61919864|NCT03843242|EXPERIMENTAL|Pacemaker with VpS® algorithm on|Vp Suppression ON algorithm: This feature promotes the intrinsic AV conduction by only pacing the ventricle when intrinsic conduction becomes unstable or disappears. Depending on the presence or absence of AV conduction, the feature is implemented either in the ventricular pacing suppression state ADI(R), which promotes the intrinsic conduction, or in the DDD(R) ventricular pacing state Vp DDD(R), which provides ventricular pacing. Automatic switching capabilities between those two states promotethe intrinsic conduction as much as possible without harming the patient. Scheduled Vs searching tests look for intrinsic conduction using an extended AV delay of 450ms.
62106144|NCT06049524||Experimental group|Prior to surgery all included patients are asked to fill out questionnaires in written or electronic form to collect the information. Then the participating doctor conducts a test to determine the pain threshold for pressure pain. Further the scheduled surgical intervention is performed under spinal anesthesia.Intraoperative data are also entered to the database. After surgery the researcher provides the patient with a written or electronic form of a postoperative monitoring questionnaire. In the postoperative period, patients undergo analgesia according to the standard scheme. In case of ineffectiveness of the standard anesthesia regimen 100 mg of tramadol is administered to the patient. All patients are remotely monitored 30 days after surgery to collect postoperative data, and if there are any remaining symptoms or complaints, they are invited to the clinic for examination.
62469208|NCT03943238|EXPERIMENTAL|Combined kidney/stem cell transplants and recipient's Tregs|Preparatory regimen including TLI, TBI, ATG after kidney transplantation followed by infusion of donor CD34+, T cell and recipient Tregs
62469209|NCT04701541|OTHER|Obese Patients undergoing Bariatric Surgery|"Obesity is a progressively growing morbid condition in the world, and given the direct relationship between body mass index (BMI) and costs, this has a major impact on economic and health policy. Obese patients undergoing bariatric surgery are at high risk for postoperative respiratory complications. In these patients, postoperative respiratory complications are related to various pathophysiological mechanisms that include: decreased lung volumes, respiratory muscle dysfunction and atelectasis. Demographic (age, gender, BMI) and clinical features of the population included: ASA, comorbidity and pre and postoperative respiratory function \[PaO2/FiO2, haemogasanalysis (EGA)\]. Ultrasound evaluation of DIA was performed.~T0: preoperative within 24h before surgery: DIA, haemogasanalysis; T1: Post operation: 60 min after extubation: Aldrete Score, DIA, EGA; T2: Post operation: 240 min after extubation: Aldrete, EGA."
62469210|NCT01815879||Control Group|Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases
62469211|NCT01781325|ACTIVE_COMPARATOR|IBEHR|IBEHR
62668201|NCT01641432|EXPERIMENTAL|TAPAT|Computerized Tonic and Phasic Attention training consisting of visual, auditory, and spatial stimuli that requires sustained attention (24 minutes). Training is followed by a computerized cognitive exercise (12 minutes).
62668202|NCT01641432|ACTIVE_COMPARATOR|Active Comparator|Computerized conventional board-games that lack the therapeutic effect of the TAPAT exercises. Active control has stimulus parameters similar to the TAPAT exercises (eg. stimuli is presented on the computer, participant responses are collected, session time and improvement is measured).
62668203|NCT01297790||Asthma|Subjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
62668204|NCT01297790||Chronic obstructive pulmonary disease|Subjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
62668205|NCT01297790||Healthy Volunteers|Healthy non smoking adults.
62668206|NCT01297790||Healthy smokers|Current smokers with normal breath tests (spirometry)
62668207|NCT01297790||Chronic cough|Subjects with idiopathic chronic cough.
62668208|NCT01428141|EXPERIMENTAL|E7050|
62668209|NCT06144801|EXPERIMENTAL|CoolSense Group|The responsible researcher carried out the application of the CoolSense device and filled out the patient information form before the arteriovenous fistula cannulation. Meanwhile, the application of the VCS and GCS was conducted both before and after the CoolSense device's application, with the latter occurring after the arteriovenous fistula cannulation. The nephrology charge nurse was responsible for these measurements, using a single device located at the patient's bedside.
62668210|NCT06144801|NO_INTERVENTION|Control Group|Patients in the control group underwent routine HD arteriovenous fistula cannulation and received HD treatment following the hospital's established protocol. Data collection tools were only administered to the participants before and after the study.
62668211|NCT01458145|EXPERIMENTAL|Home visits|
62668212|NCT01458145|NO_INTERVENTION|routine primary care at community health center|
62668213|NCT02473601|EXPERIMENTAL|Mivacurium Chloride by liver dysfunction|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
62668214|NCT02473601|OTHER|Mivacurium Chloride by normal liver function|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
62668215|NCT02122523|EXPERIMENTAL|SLN identification with NIR-dye-subserosa injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
61919865|NCT03843242|EXPERIMENTAL|Pacemaker with IRSplus algorithm on|IRS plus algorithm: This algorithm incorporates two different functions: the first is scan hysteresis, which better enables the heart to pace on its own by periodically extending the search time for its natural pacing stimulus (the intrinsic AV conduction) over six consecutive atrial cycles. The second is the repetitive hysteresis, which recognizes when the heart is not pacing on its own (a consistent loss of intrinsic AV conduction lasting for six consecutive atrial cycles) and switches the mode of the device from extended to basic atrioventricular (AV) delay.
62298115|NCT06023212|EXPERIMENTAL|tranexamic acid group|injection of 2 bottles of tranexamic acid (1g/bottle) before making incision; tranexamic acid soaked gauze applied to the wound before closing the wound; Intravenous injection of tranexamic acid 3 times (every 8 hours）within 24 hours after operation；
62298116|NCT06023212|PLACEBO_COMPARATOR|SPSS group|injection of 2 bottles of stroke-physiological saline solution（SPSS）before making incision; SPSS soaked gauze applied to the wound before closing the wound; Intravenous injection of SPSS 3 times (every 8 hours）within 24 hours after operation；
62469212|NCT01781325|NO_INTERVENTION|Standard therapy|written instructions
62469213|NCT06035107||Comparing radar and auscultatory blood pressure|"25 participants will be recruited from a specialist hypertension clinic. These participants will undergo the following tests:~1. Questionnaire: The participant will be asked to complete a clinico-demographic questionnaire. This includes their demographic data and past medical history.~2. Measurement of height, weight and heart rate~3. Measurement of blood pressure using the radar device and using a cuff (called manual auscultation)~4. End of visit."
62469214|NCT06035107||Comparing radar and invasive blood pressure|"Participants will be recruited from a list of patients scheduled to attend the Royal Free Hospital catheterisation laboratory for a clinically-indicated invasive angiogram that was booked by their consultant. 50 participants aged 18 and over will be recruited.~The radar blood pressure measurements taken during the angiogram will not impact on the procedure or standard clinical care which the participant will receive. The duration of the visit is determined by the duration of the coronary angiogram and that is decided by the clinical care team. Participants will have the following tests:~1. Collection of baseline data including past medical history, current medication, height, weight and baseline ECG~2. Measurement of invasive blood pressure and radar blood pressure simultaneously before the rest of the procedure~3. End of visit."
62469215|NCT06035107||Testing if the radar device can measure blood pressure in the MRI scanner|"First we will develop a radar blood pressure device that can be used in the MRI scanner.~When this device has been proven to be safe, we will recruit 25 participants to have the following tests:~1. A questionnaire. The participant will be asked to complete a clinic-demographic questionnaire including their demographic data and past medical history.~2. Collection of blood test to assess kidney function. Additional blood tests will also be collected for storage and future analysis.~3. A cardiac MRI scan. Blood pressure will be measured at 5 minute intervals during the scan using an oscillometric cuff around the right upper arm. The radar device will measure blood pressure in a contactless way at the same time.~4. End of visit."
62469216|NCT06035107||Testing if the radar device can measure blood pressure during exercise|"We will recruit 50 participants the have the following tests:~1. Questionnaire: The participant will be asked to complete a clinico-demographic questionnaire. This includes their demographic data and past medical history.~2. Measurement of heart rate, breathing rate and oxygen saturations.~3. Recording a heart tracing called an ECG~4. Participants will then perform 5-10 minutes of exercise, either repeated sit-to-stand movements or using a bike ergometer. Blood pressure will be measured using a cuff and the radar device at regular intervals~5. Participants will then have a heart scan called an echocardiogram during which time the radar blood measurements will also be collected.~6. End of visit."
62469217|NCT02170922|EXPERIMENTAL|Sequence 1|BIBR 1048 MS tablet (fasted) - BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet after high fat meal
62469218|NCT02170922|EXPERIMENTAL|Sequence 2|BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet (fasted) - BIBR 1048 MS tablet after high fat meal
62668216|NCT02122523|ACTIVE_COMPARATOR|SLN identification with NIR-dye-submucosal injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
62668217|NCT02112552|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IP on day 1. Treatment repeats every 21 days for up to 6 courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.~RADIATION: At provider discretion, patients may undergo 3D conformal or IMRT 5 days a week for 5 weeks (weeks 19-23)."
62668218|NCT04257669||Iron sufficient|Haemoglobin ≥120g/L Serum ferritin \> 20μg/L
62668219|NCT04257669||Non-anaemic iron deficient|Haemoglobin ≥120g/L Serum ferritin ≤ 20μg/L
62668220|NCT04257669||Iron deficient anaemic|Haemoglobin \<120g/L Serum ferritin ≤ 20μg/L
62668221|NCT04257669||Anaemic without iron deficiency|Haemoglobin \<120g/L Serum ferritin \> 20μg/L
62668222|NCT04772131|EXPERIMENTAL|Desara® One|Single Incision Sling
62668223|NCT04772131|ACTIVE_COMPARATOR|Desara® Blue|Transobturator Sling
62668224|NCT03290729|EXPERIMENTAL|narrow ridge|edentulous site with crestal bone width comprised between 3,5 and 5 millimeters wedge shape implants insertion
62668225|NCT02263690|ACTIVE_COMPARATOR|Group Drops|"proparacaine 0.5% drops (Group Drops)~Patients from group Drops received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~Patients from Group Drops received a second drop of proparacaine 0.5%, 5 minutes after the drop of povidone iodine 5%."
62668226|NCT02263690|ACTIVE_COMPARATOR|Group SC|"proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC)~Patients from group SC received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~For the patients from Group SC, a subconjunctival bleb of anesthesia was created by injecting 0.4 ml of lidocaine 1% into the subconjunctival space, posteriorly to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-ml syringe."
62668227|NCT02263690|ACTIVE_COMPARATOR|Group Gel|"Lidocaine gel 2% on the eye (Group Gel)~Patients from Group Gel received 1 mL of 2% lidocaine gel on the eye before receiving the drop of povidone iodine 5%.~For the patients from Group Gel, 1 mL of 2% lidocaine gel was applied on the eye before receiving the drop of povidone iodine 5%."
61919866|NCT04695587||TakoTsubo|Patients hospitalized with TakoTsubo syndrome according to the INTERTAK criteria
62298117|NCT00817414|EXPERIMENTAL|Cohort A: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.
62298118|NCT00817414|EXPERIMENTAL|Cohort A: LCI699 1.0 mg QD|Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
62298119|NCT00817414|EXPERIMENTAL|Cohort B1: LCI699 1.0 mg BID|Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.
62298120|NCT00817414|EXPERIMENTAL|Cohort B1: LCI699 2.0 mg QD|Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
62298121|NCT00817414|PLACEBO_COMPARATOR|Placebo|Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.
62668228|NCT00869596|PLACEBO_COMPARATOR|1|Placebo
62668229|NCT00869596|ACTIVE_COMPARATOR|2|Fluticasone 440 mcg
62668230|NCT00869596|ACTIVE_COMPARATOR|3|Fluticasone 1980 mcg
62668231|NCT05995366|EXPERIMENTAL|ABBV-903|Participants will receive ABBV-903 on Day 1.
62668232|NCT00896233|EXPERIMENTAL|MRE|
62668233|NCT03995082|EXPERIMENTAL|Experimental Group|Patients will receive the results from the PROM survey in graphical form each time they complete a survey.
62668234|NCT03995082|NO_INTERVENTION|Normative Control|These patients will complete the PROM surveys, but will not be presented with the results of the survey.
62668235|NCT01460771|EXPERIMENTAL|Treatment|Active Transcranial Direct Current Stimulation (TDCS) at 1mA or highest tolerated current
62668236|NCT01460771|SHAM_COMPARATOR|sham|inactive Transcranial Direct current stimulation (TDCS) at 0mA
62668237|NCT02783859|EXPERIMENTAL|Active arm: Amoxicillin-clavulanic Acid|8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day)
62668238|NCT02783859|PLACEBO_COMPARATOR|Placebo arm|8 days of oral placebo (equivalent volume as the active arm)
62668239|NCT03228407|ACTIVE_COMPARATOR|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
62668240|NCT03228407|ACTIVE_COMPARATOR|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
62298122|NCT06602141|ACTIVE_COMPARATOR|Control (CTRL) group|
62469219|NCT06131086|EXPERIMENTAL|stabilization exercises|"Scapular stabilization exercise~Scapular Retraction Exercise:~2. Scapular Wall Slide: Stand with your back against a wall and your feet shoulder-width apart.Raise your arms to shoulder height with your elbows bent at a 90-degree angle, so that your hands are pointing up~* Slide your arms up the wall as high as you can, while keeping your shoulder blades pinched together and down~* Hold the position for 5-10 seconds, then slowly lower your arms back down to the starting position~* Repeat for 10-15 repetitions"
62668241|NCT03228407|PLACEBO_COMPARATOR|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
62668242|NCT05838170|EXPERIMENTAL|Lotilaner Gel, 2.0% (TP-04)|Participants will be randomized to a 2:1 ratio at baseline to apply Lotilaner Gel, 2.0% (TP-04) on the face BID for 12 weeks.
62668243|NCT05838170|PLACEBO_COMPARATOR|Vehicle-Controlled|Participants will be randomized to a 2:1 ratio at baseline to apply vehicle control gel on the face BID for 12 weeks.
62668244|NCT03927716|EXPERIMENTAL|SB206 12%|SB206 12% topically once daily
62668245|NCT03927716|PLACEBO_COMPARATOR|Placebo|Placebo topically once daily
62668246|NCT00430612||All Registry Participants|Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site.
62668247|NCT03123588|EXPERIMENTAL|Group A : Ruxolitinib and anagrelide placebo|Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.
62668248|NCT03123588|ACTIVE_COMPARATOR|Group B : Anagrelide and Ruxolitinib PLacebo|Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.
62668249|NCT01453647|EXPERIMENTAL|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
62668250|NCT01453647|NO_INTERVENTION|control|Participants in the control group will be instructed to maintain their FM treatment regimens as reported at baseline.
62668251|NCT04843904|EXPERIMENTAL|Venetoclax|"Participants will be separated into two cohorts: Cohort A: Patients at low risk for TLS. Cohort B: Patients with both median and high risk for TLS.~Five (5) participants from cohort A will be initially enrolled, if these first 5 participants tolerate the accelerated ramp-up, cohorts A and B will enroll simultaneously.~All participants will be hospitalized and receive venetoclax daily with accelerated dose increases over 5 days to reach full dose. After reaching full dose, participants will be discharged and continue daily venetoclax at home.~Per doctor assessment, some participants may also receive rituximab or obinutuzumab as part of the treatment regimen with venetoclax.~Rituximab: Given every 28 days starting on the second study cycle and continuing for up to 6 cycles as per standard of care.~Obinutuzumab: Days 1, 2, 8, and 15 of cycle 1 and once every 28 days there after for up to 6 cycles as per standard of care."
62668252|NCT02887586|EXPERIMENTAL|Auricular Needling group|Patients will receive auricular needling for 4 weeks .
62668253|NCT02887586|NO_INTERVENTION|control group|This group will receive no treatment. Subjects will be assessed at baseline and the 2th, 4th and 8th week.
62668254|NCT01750281|EXPERIMENTAL|Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
62668255|NCT01750281|EXPERIMENTAL|Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 60 mg/m2 intravenously administered on day 1 of each 21 day cycle.
62668256|NCT01750281|EXPERIMENTAL|Placebo twice daily + Docetaxel 75 mg/m2|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
62668257|NCT05838872|EXPERIMENTAL|Minuteful - Kidney Urine Analysis Test System|
62668258|NCT00607594|EXPERIMENTAL|Treatment (kinase inhibitor therapy)|Patients receive saracatinib PO, at a dose of 175 mg QD in the absence of disease progression or unacceptable toxicity.
61919867|NCT02749123|ACTIVE_COMPARATOR|Lidocaine5% v Lidocaine3.6%,Menthol1.25%|Daily patch Q12 followed by Q12 of no patch
61919868|NCT02749123|PLACEBO_COMPARATOR|Lidocaine 3.6%, menthol 1.25% v placebo|Daily patch Q12 followed by Q12 of no patch
61919869|NCT02005328|EXPERIMENTAL|cross-over|Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days.
61919870|NCT06391801|EXPERIMENTAL|Intervention group|Daily 15 Minutes of Neuroathletic training additional to traditional movement therapy in outpatient rehabilitation
62298123|NCT06602141|ACTIVE_COMPARATOR|Endurance exercise (EX) group|
62106145|NCT06073171|OTHER|Cutis Tricolor patient included in trio or duo|Cutis Tricolor patient included in trio (one affected parent, one unaffected parent) or duo (one of the two affected parents)
62668259|NCT03051009|EXPERIMENTAL|Desmopressin ODT 25 μg (female previous on 25 μg)|Subjects received 25 μg in trial 000129.
62668260|NCT03051009|EXPERIMENTAL|Desmopressin ODT 25 μg (female previously on placebo)|Subjects received placebo in trial 000129
62668261|NCT03051009|EXPERIMENTAL|Desmopressin ODT 25 μg (female)|New female subjects
62106146|NCT06475170|EXPERIMENTAL|λ+α double-tract anastomosis|
62106147|NCT06475170|ACTIVE_COMPARATOR|double-tract anastomosis|
62106148|NCT00555867||1|Standard routine care for breast cancer
62106149|NCT00555867||2|Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
62106150|NCT03261661|EXPERIMENTAL|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
62106151|NCT03261661|EXPERIMENTAL|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
62106152|NCT03261661|ACTIVE_COMPARATOR|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
62106153|NCT03261661|ACTIVE_COMPARATOR|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
62106154|NCT02664220|EXPERIMENTAL|Povidone-iodine irrigation|
62106155|NCT02664220|ACTIVE_COMPARATOR|No irrigation|
62106156|NCT00322699|EXPERIMENTAL|A single arm, non-randomized Phase II Study|Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
62106157|NCT03148938|EXPERIMENTAL|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
62106158|NCT03148938|ACTIVE_COMPARATOR|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
62106159|NCT03410667|OTHER|Standard Care|Standard of care arm
62106160|NCT03410667|EXPERIMENTAL|Intervention Arm|Intervention arm
62106161|NCT05550922|EXPERIMENTAL|Healthcare transition based education|The content of the education program and interviews include: the importance of transition readiness from pediatric to adult care; asthma, asthma management, asthma support groups and literature; asthma self-management skills (making appointments, taking medications regularly, knowing the risks and what to do during an asthma attack, visiting doctors alone, getting a prescription, communicating with health care professionals); filling out medical forms; insurance; decision making, autonomy, career plans; characteristics of adolescence; pediatrics and adult care differences; transition planning; discussions on case studies; knowledge and skills related to adult pulmonology service procedures; interview with pediatric and adult pulmonologists.
62106162|NCT05550922|NO_INTERVENTION|No Intervention|Control: Not all control group participants will receive health care transition-based training. The control group will receive standard outpatient clinic asthma treatment during this process.
62106163|NCT05186545|EXPERIMENTAL|Experimental|surufatinib + fulvestrant + chidamide
62668262|NCT03051009|EXPERIMENTAL|Desmopressin ODT 25 μg (male previous on 25 μg)|Subjects received 25 μg in trial 000130
62668263|NCT03051009|EXPERIMENTAL|Desmopressin ODT 50 μg (male previous on 50 μg)|Subjects received 50 μg in trial 000130
62106164|NCT01982643|EXPERIMENTAL|naltrexone plus bupropion|extended-release depot naltrexone (XR-NTX; as Vivitrol®)plus extended-release bupropion tablets (BRP; as Wellbutrin XL®)
62106165|NCT01549652|EXPERIMENTAL|Prevention of Opioid Withdrawal|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days, and then will be randomized to take either ondansetron 8 mg or matching placebo thirty minutes prior to naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will return to their titrated morphine dose for one week and then return for the opposite pre-treatment followed by naloxone-induced withdrawal in clinic. Participants will then taper back to their original dose of morphine for one week.
62106166|NCT01549652|EXPERIMENTAL|Prevention of Physical Dependence|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days; during morphine treatment, participants will be randomized to take either ondansetron 8 mg or matching placebo three times daily along with the oral morphine treatment. After thirty days, participants will return to the lab to undergo naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will then taper back to their original dose of morphine for one week.
62106167|NCT03684733||Arm 1: Cohort 1 - Retrospective Analysis|Participants attending MRI \& XRM for a clinical indication with at least one normal breast
62106168|NCT03684733||Arm 2: Cohort 2 - Retrospective Analysis|"BRCA1 or BRCA2 mutation carriers attending MRI \& XRM for breast screening:~Genetic risk of breast cancer"
62668264|NCT03051009|EXPERIMENTAL|Desmopressin ODT 50 μg (male previous on placebo)|Subjects received placebo in trial 000130
62668265|NCT03051009|EXPERIMENTAL|Desmopressin ODT 25 μg (male)|Subjects received placebo in trial 000130
62668266|NCT03051009|EXPERIMENTAL|Desmopressin ODT 50 μg (male)|New male subjects
62668267|NCT02528136|EXPERIMENTAL|Carbetocin|One minute injection of carbetocin 100 µg after the delivery of the baby
62668268|NCT02528136|ACTIVE_COMPARATOR|Oxytocin|One minute injection of oxytocin 2.5 U after the delivery of the baby
62668269|NCT04625972|EXPERIMENTAL|AZD7442|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
62106169|NCT03684733||Arm 2: Cohort 3 - Retrospective Analysis|"Participants attending MRI \& XRM for breast screening post mantle radiotherapy:~Environmental risk of breast cancer"
62668270|NCT04625972|PLACEBO_COMPARATOR|Placebo|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
62668271|NCT03019588|EXPERIMENTAL|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62668272|NCT03019588|ACTIVE_COMPARATOR|Paclitaxel 80 mg/m^2|Participants receive paclitaxel 80 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.
62668273|NCT03524144|OTHER|adult patients with Crohn's disease|All adult patients(18 years old or older) with Crohn's disease underwent gastroscopy; patients with diagnosed and treated Crohn's disease had gastroscopy performed during the re-examination, and patients diagnosed with Crohn's disease for the first time had gastroscopy performed during the initial consultation.
62668274|NCT04656431|EXPERIMENTAL|Cohort 1: Hyperpolarized pyruvate (13C)|Histologically proven relapsed PCNSL patients will receive hyperpolarized carbon C 13 pyruvate intravenously (IV) and undergo MRI at baseline. An optional second HP 13C pyruvate injection and MRI acquisition will be offered on same day following completion of the first scan.
62668275|NCT04656431|EXPERIMENTAL|Cohort 2: Hyperpolarized pyruvate (13C)|Newly diagnosed PCNSL participants with planned treatment of standard high-dose methotrexate,temozolomide plus rituximab (MT-R) regimen will receive hyperpolarized carbon C 13 pyruvate intravenously (IV) and undergo MRI at baseline and again after three cycles of of standard induction chemotherapy. An optional second HP 13C pyruvate injection and MRI acquisition will be offered on same day following completion of the first scan. Participants in Cohort 2 will also have option to undergo an additional imaging at a later time if the participant's cancer progresses.
62668276|NCT06485180|ACTIVE_COMPARATOR|Conservative surgery|"D\&C: A curette is inserted into the uterus through the dilated cervix. The curette is used to scrape the lining of the uterus and remove the pregnancy tissue.~Hysteroscopy: The procedure can be used for CSP with progression toward the uterine cavity or the bladder. The gestational sac is dissected free of the uterine wall through a natural entrance, and hemostasis can be achieved with electro-coagulation using a wire-loop or roller-ball. Hysteroscopy is a minimally invasive technique and is conducted under direct observation or combined with abdominal ultrasound."
62298124|NCT05549388|NO_INTERVENTION|No label|In this arm, participants will view images of packaged food or beverage products without a front-of-pack label and respond to questions about the products.
62668277|NCT06485180|ACTIVE_COMPARATOR|Resection surgery|"Transvaginal CSP excision: The bladder is dissected away through an incision in the anterior cervico-vaginal junction, and the CSP is identified in the anterior part of the lower uterine segment. The ectopic pregnancy tissue is removed through a transverse incision, and suction curettage through the incision on the uterus can be performed. Finally, the myometrial and vaginal defects are repaired.~Hysteroscopy-assisted laparoscopic CSP excision: Under the guidance of the light of hysteroscopy, position CSP accurately and excision is performed of the uterine scar that contains the ectopic pregnancy, with subsequent repair of the defect in the uterus. After laparoscopic CSP excision, hysteroscopy proved that the niche had disappeared.~Abdominal CSP excision: The ectopic pregnancy tissue is removed through an abdominal incision, and suction curettage through the incision on the uterus can be performed. Finally, the myometrial and abdominal defects are repaired."
62668278|NCT04088253|EXPERIMENTAL|cirrhotic patient|cirrhotic patient with umbilical hernia to be operated
62668279|NCT00527345||1|children riding retrofitted school buses or private cars
62668280|NCT00527345||2|children riding old buses who will change to retrofitted buses during the first or second year of the study
62668281|NCT00527345||3|children who ride old diesel buses through the study
62668282|NCT00182637|EXPERIMENTAL|bortezomib|
62106170|NCT03684733||Arm 2: Cohort 4 - Prospective|"General population attending XRM for breast investigation:~Population risk of breast cancer MRI"
62106171|NCT01548391|EXPERIMENTAL|HX-1171 20 mg (20mg 1T)|
62106172|NCT01548391|EXPERIMENTAL|HX-1171 40 mg (20mg 2T)|
62106173|NCT01548391|EXPERIMENTAL|HX-1171 80 mg (20mg 4T)|
62106174|NCT01548391|EXPERIMENTAL|HX-1171 160 mg (20mg 8T)|
62106175|NCT01548391|EXPERIMENTAL|HX-1171 300 mg (200mg 1T, 20mg 5T)|
62106176|NCT01548391|EXPERIMENTAL|HX-1171 600 mg (200mg 3T)|
62106177|NCT01548391|EXPERIMENTAL|HX-1171 1200 mg (500mg 2T, 200mg 1T)|
62106178|NCT01548391|EXPERIMENTAL|HX-1171 1500 mg (500mg 3T)|
62106179|NCT01548391|EXPERIMENTAL|HX-1171 2000 mg (500mg 4T)|
62106180|NCT00966966|EXPERIMENTAL|1|SAM-531_gemfibrozil
62106181|NCT04895566|EXPERIMENTAL|monoclonal antibody (Mab) sB24M|Therapy by injecting 200 mg of the monoclonal antibody (Mab) sB24M into the areas affected by pyoderma
62106182|NCT05257733||CIDP associated with systemic diseases|Patients with CIDP associated with systemic diseases
62106183|NCT05257733||CIDP without systemic diseases|Patients with CIDP without other systemic diseases
62106184|NCT05216237|EXPERIMENTAL|Treatment of HER-2 Negative MSS Advanced Gastric|Sintilimab Plus Apatinib and Chemotherapy in Patients with Previously Untreated HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer
62298125|NCT05549388|EXPERIMENTAL|Multiple Traffic Light (MTL)|In this arm, participants will view images of packaged food or beverage products which have multiple traffic light labels displayed on the front-of-pack and respond to questions about the products.
62298126|NCT05549388|EXPERIMENTAL|Nutri-Score|In this arm, participants will view images of packaged food or beverage products which have a Nutriscore front-of-pack label and respond to questions about the products.
62668283|NCT01635179|EXPERIMENTAL|Cricoid pressure|A cricoid pressure of 30 N is done to occlude esophagus under a rapid sequence induction.
62106185|NCT01756287|EXPERIMENTAL|Standardized Chinese ocular exercise|The participants are trained with standardized Chinese ocular exercise which contains accurate positions of acupuncture points and appropriate pressure on the points.
62106186|NCT01756287|SHAM_COMPARATOR|Nonstandardized ocular exercise|The participants are trained with nonstandardized ocular exercise performed on wrong positions where no acupuncture points at all.
62298127|NCT05549388|EXPERIMENTAL|Warning Label|In this arm, participants will view packaged food or beverage products which have front-of-pack warning labels if the product is high in one or more nutrients of concern and respond to questions about the products.
62668284|NCT02200575||Patients with non-secondary, essential hypertension|
62668285|NCT00882388|ACTIVE_COMPARATOR|ASA|aspirin only
62668286|NCT00882388|ACTIVE_COMPARATOR|Cele|
62668287|NCT00882388|EXPERIMENTAL|ASA + Cele|
62668288|NCT00882388|ACTIVE_COMPARATOR|ASA + Clo|
62298128|NCT02643550|EXPERIMENTAL|Dose escalation|Dose escalation of monalizumab in combination with cetuximab
62298129|NCT02643550|EXPERIMENTAL|Expansion cohort 1|monalizumab + cetuximab expansion cohort
62298130|NCT02643550|EXPERIMENTAL|Expansion cohort 2|monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers
62668289|NCT00882388|EXPERIMENTAL|ASA + Clo + Cele|
62668290|NCT04469283||caffeine efficacy|Collection of preliminary data on caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
62298131|NCT02643550|EXPERIMENTAL|Expansion cohort 3|monalizumab + cetuximab + anti-PD(L)1
62298132|NCT01819935||linezolid (Zyvox)|
62298133|NCT01819935||Vancomycin|
62668291|NCT00588276|EXPERIMENTAL|1|Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).
62668292|NCT03537430|OTHER|TNT Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent TNT uniportal VATS mediastinal tumor resection
62668293|NCT03537430|OTHER|Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent traditional uniportal VATS mediastinal tumor resection
62668294|NCT06309758|EXPERIMENTAL|Participants|3 month active use of the website. Receive bi-weekly update mails to nudge participants to use the website.
62668295|NCT01799278|EXPERIMENTAL|All Patients|MLN8237 at 50 mg twice daily for 7 days repeated every 21 days. Therapy will continue until disease progression, unacceptable toxicity as a result of MLN8237, or withdrawal of patient consent.
62668296|NCT00705822|EXPERIMENTAL|1|Docetaxel + Estramustine + Hydrocortisone
62668297|NCT00705822|ACTIVE_COMPARATOR|2|Docetaxel + Prednisone
62668298|NCT02635490||prophylactic antibiotics|
62469220|NCT06131086|EXPERIMENTAL|stabilization exercises along with pectoralis minor stretching|"pectoralis minor stretch: Stand facing a wall or a doorway. Raise your right arm to shoulder height and place your right forearm against the wall or doorway, with your elbow bent at a 90-degree angle.~Step forward with your right foot until you feel a stretch in your chest and shoulder.~Slowly lean forward, keeping your arm against the wall or doorway, until you feel a deeper stretch in your chest and shoulder.~Hold the stretch for 10-15 seconds, then release and repeat on the other side. Repeat the stretch 2-3 times on each side."
62106187|NCT01756287|NO_INTERVENTION|Eye closure|The participants are told to close eyes and don't do ocular exercise at all.
61913479|NCT05599776|EXPERIMENTAL|Intervention group|The patients in the intervention group will receive standard physiotherapy care but patients also use smart rings (Oura ring) 3 months postoperatively. Patients will be remotely monitored to follow their recovery from TKR surgery: the study group physiotherapists will follow the patients' activity and sleep and if necessary, make a contact with patient if there seems to low activity indicating difficulties with recovering from the surgery. If there is a constantly decreasing trends in these parameters or patient improvement plateaus, patient is contacted and their status is evaluated by telephone. Based on the information from this contact, the patients may be asked to visit the physiotherapist at the outpatient clinic to assess the situation, and also anesthetist may be consulted on the pain medication. Data collected with the Oura ring will also be used in physiotherapy appointments as a part of therapeutic treatment and guidance.
62469221|NCT04781205|EXPERIMENTAL|Intervention|Members of clinics randomized into intervention arm will be consented on a blood test for DNA evaluation (up to WGS), a single feces sample for microbiome analysis and tentative agreement to ware monitors of various vital signs of body function
62668299|NCT00026338|ACTIVE_COMPARATOR|OSI-774 plus Gemcitabine|
62668300|NCT00026338|ACTIVE_COMPARATOR|Placebo plus gemcitabine|
62668301|NCT05818787|EXPERIMENTAL|Training Protocol 1 - Intervention First|Participants will complete a roll tilt training protocol previously shown to reduce roll tilt thresholds. The training stimulus parameters are as follows: 0.5 Hz roll tilt motion, stimulus size will be adjusted based upon subject responses using a 2-down, 1-up (2D/1U) staircase, and only auditory feedback will be provided.The training protocol will be completed first, followed by the placebo intervention.
62668302|NCT05818787|EXPERIMENTAL|Training Protocol 1 - Placebo First|Participants will complete a roll tilt training protocol previously shown to reduce roll tilt thresholds. The training stimulus parameters are as follows: 0.5 Hz roll tilt motion, stimulus size will be adjusted based upon subject responses using a 2D/1U staircase, and only auditory feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
62668303|NCT05818787|EXPERIMENTAL|Training Protocol 2 - Intervention First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, three-down, one-up (3D/1U), or six-down, one-up (6D/1U) staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The training protocol will be completed first, followed by the placebo intervention.
61913480|NCT06391190|EXPERIMENTAL|treatment arm|with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation (EBRT followed by brachytherapy); followed by Sintilimab 200mg Q3W for 8 cycles.
62106188|NCT04018118||Eosinophilia/Hypereosinophilic syndrome|patient with eosinophilia and/or hypereosinophilic syndrome
62106189|NCT00798772|EXPERIMENTAL|A: Broad spectrum micronutrients|"The experimental treatment medications (micronutrients and antioxidants) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
62298134|NCT03550248|OTHER|Intervention group|Participants will receive the intervention - Healthy Together (HT).
62298135|NCT05836090|EXPERIMENTAL|Family Spirit Strengths (FSS)|FSS participants will receive 4-16 (average of 6-8) intervention visits covering topics related to their mental and behavioral health. The number of sessions each participant receives varies and depends on their unique needs. To guide this process, all intervention participants will take a brief, in-session survey to screen for current challenges they may be facing. Their answers will help determine the content and dose of future sessions.
62298136|NCT05836090|ACTIVE_COMPARATOR|Family Spirit Nurture|Participants enrolled in nutrition education comparison group will receive 6 educational lessons related to promoting early childhood healthy growth. Lessons will be delivered bi-weekly for no longer than 4-months total. The lessons are from the evidence-based Family Spirit Nurture curriculum.
62469222|NCT04781205|NO_INTERVENTION|Usual care|No intervention at all
62469223|NCT05838703|EXPERIMENTAL|Tiotropium bromide (Spiriva Respimat)|Images obtained using 129XeMRI will be obtained after one-time use of Spiriva Respimat
62469224|NCT05838703|ACTIVE_COMPARATOR|Tiotropium bromide inhalation powder (Spiriva HandiHaler)|Images obtained using 129XeMRI will be obtained after one-time use of Spiriva HandiHaler
62469225|NCT02108119|ACTIVE_COMPARATOR|Probiotics|
62469226|NCT02108119|PLACEBO_COMPARATOR|Control placebo|
62668304|NCT05818787|EXPERIMENTAL|Training Protocol 2 - Placebo First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, left anterior/right posterior (LARP) tilt, or right anterior/left posterior (RALP) tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
61913481|NCT00547001|ACTIVE_COMPARATOR|1|Group A will be tapered over 4 weeks, starting at baseline (week 0). Subjects in this group will take one tablet of ET daily (effective dose, 0.75 mg) for week 1, then one 0.50 mg tablet daily for week 2, then one 0.25 mg tablet daily for week 3, and finally one 0.125 mg tablet daily for week 4.
62106190|NCT00798772|ACTIVE_COMPARATOR|B: Identical appearing multivitamins|"The active comparator/control medications (identical appearing RDA multivitamins and minerals) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
62298137|NCT04657822|EXPERIMENTAL|Crizanlizumab|All participants will receive crizanlizumab (SEG101) at the same dose/schedule as in the parent study.
62469227|NCT06122363||Complete Novasure endometrial ablation|After treatment with novasure, the hysteroscopy showed no remains of endometrium, , so a complete novasure endomentrial ablation
62668305|NCT05818787|EXPERIMENTAL|Training Protocol 3 - Intervention First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, three-down, one-up (3D/1U), or six-down, one-up (6D/1U) staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The training protocol will be completed first, followed by the placebo intervention.
62668306|NCT05818787|EXPERIMENTAL|Training Protocol 3 - Placebo First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
62668307|NCT05818787|EXPERIMENTAL|Training Protocol 4 - Intervention First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds AND improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The training protocol will be completed first, followed by the placebo intervention.
62106191|NCT01779882|ACTIVE_COMPARATOR|BU-CY|Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
62298138|NCT04513158|EXPERIMENTAL|Treatment Arm|Study is single arm all patients hospitalized meeting inclusion/exclusion criteria and providing informed consent to receive one unit (approximately 200 mL) of convalescent plasma with data collected daily on routine (non-research) clinical assessments/physical exams and lab results.
62298139|NCT01746134||Cohort|
62106192|NCT01779882|EXPERIMENTAL|CY-BU|Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
61913482|NCT00547001|PLACEBO_COMPARATOR|2|Group B will be administered placebo. These tablets will appear identical to those administered to subjects in Group A, but the tablets will contain no estrogen. Subjects in this group will be instructed to take one pill every day for the 4 weeks. Thus, while patients will, in effect, be stopped abruptly from their therapy, there is still the potential of a placebo effect.
61919871|NCT06391801|ACTIVE_COMPARATOR|Control group|Traditional movement therapy in outpatient rehabilitation
62106193|NCT06630481||CAP grade 0|No viable cancer cells in pancreatic resection specimen with neoadjuvant therapy.
62106194|NCT06630481||CAP grade 1|Single cells or rare small groups of cancer cells in pancreatic resection specimen with neoadjuvant therapy.
61919872|NCT01066507||Breast cancer|Slides containing breast cancer paraffin embedded tissue sections.
62106195|NCT06630481||CAP grade 2|Residual cancer with evident tumor regression in pancreatic resection specimen with neoadjuvant therapy.
62298140|NCT05125653|EXPERIMENTAL|NIR/ICG Arm|Indocyanine Green Fluorescent Cholangiography and Intraoperative Angiography will be done during the Laparoscopic Cholecystectomy
62298141|NCT05125653|ACTIVE_COMPARATOR|WL Arm|Conventional white light was used for Laparoscopic Cholecystectomy
62298142|NCT05752448|EXPERIMENTAL|Intervention group|Group received care Using POSTCare process
62469228|NCT06122363||Incomplete Novasure endometrial ablation|After treatment with novasure, the hysteroscopy showed remains of endometrium, so an incomplete novasure endomentrial ablation
62469229|NCT02307981||Visual field defect with vision teacher|Patients With occipital ischemic stroke and Visual Field defect that live in a geographical region where training With vision teacher is an available service (vision Teachers are a Limited Resource in Norway)
62106196|NCT06630481||CAP grade 3|Extensive residual cancer with no evident tumor regression in pancreatic resection specimen with neoadjuvant therapy.
62106197|NCT06630481||pathological complete response|No viable cancer cells in pancreatic resection specimen with neoadjuvant therapy.
62106198|NCT06269874|ACTIVE_COMPARATOR|Intravenous Adenosine|Invasive microvascular function assessment will be conducted by administering intravenous hyperemic agent adenosine.
62106199|NCT06269874|EXPERIMENTAL|Intracoronary Adenosine|Invasive microvascular function assessment will be conducted by administering intracoronary hyperemic agent adenosine.
62298143|NCT05752448|NO_INTERVENTION|Usual Care|Group received usual care
62668308|NCT05818787|EXPERIMENTAL|Training Protocol 4 - Placebo First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds AND improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
62298144|NCT06656130|EXPERIMENTAL|Effects of Pranayama on cardiovascular parameters, stress and quality of life in pre-hypertension|This group will receive Pranayama. Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. You purposely inhale, exhale, and hold your breath in a specific sequence. Interventions will be performed for 30 minutes in a day, 3 days per week for 8 weeks. (total no. of sessions=24). Breathing exercises will be consist on Alternate Nostril Technique, Skull Shinning Technique, Bellow Breath, Bee Breath, Victorious Breath
62298145|NCT06656130|EXPERIMENTAL|effects of Jacobson's technique on CVS parameters, stress and QOL in Pre-hypertension|This group will receive Jacobson's Progressive Muscle Relaxation Technique. Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, you can become more aware of your body and physical sensations, The sessions will consist of 30 minutes in a day, 3 days per week for 8 weeks. (total no. of sessions=24).
62298146|NCT01397019|EXPERIMENTAL|FOLFIRINOX|
61913483|NCT00547001|NO_INTERVENTION|3|"Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the real life scenario of stopping medication abruptly."
61913484|NCT04058171||LSS group|Participants with a diagnosis of lumbar spinal stenosis
62106200|NCT02200952||Patients at risk of OHSS|Patients at risk of OHSS on the oocytes triggering day with an oestradiol \> 4000pg/ml or a number of follicles greater than 24 of a diameter greater than 12 mm
62106201|NCT05974072|ACTIVE_COMPARATOR|Usual Care (Pharmacological Control)|The subjects in the control group will be treated following a pharmacological approach according to the latest clinical guidelines for patients with chronic low back pain. Thus, the pharmacological options to be considered in each patient will be those included in the first and second analgesic steps of the WHO (preferably without including minor opioids).
62106202|NCT05974072|EXPERIMENTAL|PAINDOC Program|"The PAINDOC Program is a multidisciplinary treatment that integrates four parts provided by different health professionals and consists of 8 sessions carried out in the pain unit of the Hospital Clinic of Barcelona over two months.~It consists of a therapeutic education (Empowered Relief) session given by a physician from the unit, a pain psychology session given by a psychologist, an introductory mindfulness meditation session given by an advanced practice nurse, and two pain neuroscience education sessions and three therapeutic exercise sessions given by a physiotherapist. This program is already part of the pain unit's routine care practice, so it is considered that the sessions of this program do not represent an additional and specific visit for the patients."
62106203|NCT00789789||1|
61913485|NCT04058171||PAD group|Participants with a diagnosis of peripheral artery disease
61913486|NCT04058171||LBP group|Participants with a diagnosis of non specific low back pain
62298147|NCT06618651|EXPERIMENTAL|SHR-3821 injection|
62106204|NCT01174329|EXPERIMENTAL|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"Patient regulated (by a remote control) neuro-electrostimulation by Saliwell Crown"
62106205|NCT01174329|ACTIVE_COMPARATOR|"Automatic neuro-electrostimulation by Saliwell Crown"|No remote control used
62106206|NCT03302156|OTHER|Healthy Control Non-Dosimetry Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6
62106207|NCT03302156|OTHER|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40
62106208|NCT03302156|OTHER|Dosimetry Group|Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6
62106209|NCT01726023|EXPERIMENTAL|Ceftazidime-Avibactam plus metronidazole|
62106210|NCT01726023|ACTIVE_COMPARATOR|Meropenem|
62106211|NCT02718118|EXPERIMENTAL|1.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units \[U\]) at the Day 1 visit.
62308340|NCT04036565||The experimental group|The first post-test measurements were taken right after the participants completed the sunlight therapy (two to four weeks after the start of the intervention), and the second post-test measurements were taken one month after the intervention was completed (six to eight weeks after the start of the intervention).
62106212|NCT02718118|EXPERIMENTAL|2.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units \[U\]) at the Day 1 visit.
62106213|NCT05759819|EXPERIMENTAL|CLZ-BM3D group|"The cilostazol-coated BioMimics 3D stent on the delivery system is implanted into the target lesion and self-expands to maintain the vessel lumen diameter. Post-dilatation is performed as needed.~- CLZ is released from the surface of the implanted stent."
62106214|NCT00857480|EXPERIMENTAL|Reference|No pre-treatment
62106215|NCT00857480|EXPERIMENTAL|T1|Cloxacillin pre- and co-treatment
62106216|NCT00857480|EXPERIMENTAL|T2|UDCA pre-treatment
62106217|NCT03916926|EXPERIMENTAL|"A simple medical strategy consisting of SDF"|The treatment will be bi-annual application (at baseline and 26 weeks) of topical 38% silver diamine fluoride (Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL) following manufacturer's instructions and guidelines published by UCSF (2016).
62106218|NCT03916926|ACTIVE_COMPARATOR|"A typical dental strategy consisting of ART + FV"|Atraumatic Restorative Treatment (ART) will be a modification of the approach used by Lo and colleagues (2006), and the cavity restored at baseline with resin reinforced glass-ionomer cement (GIC) (GC Corporation, Japan). Participants in this arm will also receive biannual topical fluoride varnish application (FluoriMax, Elevate) according to manufacturer's instructions.
62106219|NCT01609894|EXPERIMENTAL|Individualized fortification of breast milk|"1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~2. Routine fortifier will be added to breast milk batches.~3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
62106220|NCT01609894|ACTIVE_COMPARATOR|Routine fortification of breast milk|"1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~2. Routine fortifier will be added to breast milk batches."
62106221|NCT05515770|EXPERIMENTAL|Injectable Cabitegravir|Participants that are interested in Cab long action injectable
62308341|NCT04036565||The control group|Standard care.The first and second post-test measurements were taken two and six weeks, respectively, after they started receiving standard care.
62106222|NCT04061408|EXPERIMENTAL|FSRT|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
62106223|NCT06629818|EXPERIMENTAL|Dara-VenD|Daratumumab combined with venetoclax and dexamethasone
62106224|NCT03972813|EXPERIMENTAL|cervical cancer - sexually transmitted (STD) - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
62106225|NCT03972813|EXPERIMENTAL|cervical cancer - STD - 12 years old (y.o.)|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
62106226|NCT03972813|EXPERIMENTAL|cervical cancer - STD - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
62106227|NCT03972813|EXPERIMENTAL|cervical cancer - infectious - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
62469230|NCT02307981||Visual field defect without vision teacher|Patients With occipital ischemic stroke and a Visual Field defect, who live in a geographical area where training With vision teacher is not an available service.
62106228|NCT03972813|EXPERIMENTAL|cervical cancer - infectious - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
62106229|NCT03972813|EXPERIMENTAL|cervical cancer - infectious - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
62106230|NCT03972813|EXPERIMENTAL|cervical cancer - blank - standard|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
62106231|NCT03972813|EXPERIMENTAL|cervical cancer - blank - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
62106232|NCT03972813|EXPERIMENTAL|cervical cancer - blank - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
62106233|NCT03972813|EXPERIMENTAL|many cancers - STD - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
62106234|NCT03972813|EXPERIMENTAL|many cancers - STD - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
62106235|NCT03972813|EXPERIMENTAL|many cancers - STD - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
62106236|NCT03972813|EXPERIMENTAL|many cancers - infectious - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
62308342|NCT02527304|EXPERIMENTAL|Treatment (adaptive staged SBRT)|Patients undergo adaptive staged SBRT. Within 14-21 days, patients may undergo a second treatment of adaptive staged SBRT at the discretion of the treating physician based on clinical parameters, diagnostic interval imaging, and achievement of spinal cord dose constraints.
62308343|NCT06104683|EXPERIMENTAL|Pirtobrutinib Dose 1|Participants will receive pirtobrutinib orally.
62308344|NCT06104683|EXPERIMENTAL|Pirtobrutinib Dose 2|Participants will receive pirtobrutinib orally.
62668309|NCT00038246|EXPERIMENTAL|Thalidomide, Taxol, Estramustine|Thalidomide starting dose 200 mg by mouth every day once a week; Taxol 100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10; Estramustine 140 mg by mouth three times a day on Days 1-5, 8-12.
62668310|NCT01120197|EXPERIMENTAL|Exercise group|"Exercise group with intervention~Subjects in the intervention group must participate in a training course consisted of 24 sessions over 3 months. The exercises include aerobic, stretching, balance and functional training, i.e. circuit exercises focus been on: the prevention of falls and fractures, improving balance and coordination, improving posture, and informing subjects about risk factors for falls and for osteoporosis and fractures. A 3-hour session of information and supervision will be hold for the intervention group by the same physiotherapist who leads the training sessions. The focus is on body awareness and ergonomic advice in specific, daily-life situations (e.g. lifting/carrying, resting positions)."
62668311|NCT01120197|OTHER|Control Group|"Control group with no intervention~Subjects in the control group are asked to maintain their current lifestyle. No restrictions are placed on their exercise activities. The control group is followed for the same duration as the intervention group."
62668312|NCT01371682|OTHER|Session 1|Ropinirole manufactued at Crawley will be compared to that manufactured at Aranda
62668313|NCT01371682|OTHER|Session 2|Ropinirole manufactured at Crawley will be compared to that manufactured at Aranda.
62668314|NCT05290298|EXPERIMENTAL|NITRATE|Multi-component nutritional formula (containing 1200 mg of potassium nitrate, 200 mg of magnesium, 50 mg of zinc, and 1000 mg of citric acid)
62668315|NCT05290298|PLACEBO_COMPARATOR|PLACEBO|Placebo (2.5 grams of inulin)
62668316|NCT06456268|ACTIVE_COMPARATOR|Standard Ice packs|Standard ice packs applied to knee for 20 minutes a day three times a day
61913487|NCT03986073|EXPERIMENTAL|Low dose group|Subjects in the low dose group administrated one TQ-F3083 capsule 10mg, one TQ-F3083 blank analog capsule and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
61913488|NCT03986073|EXPERIMENTAL|High dose group|Subjects in the high dose group administrated twoTQ-F3083 capsules 20mg and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
62106237|NCT03972813|EXPERIMENTAL|many cancers - infectious - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
62668317|NCT06456268|ACTIVE_COMPARATOR|Cryocompression device|Cryocompression device (Game Ready, Bregs) with ice placed into the device and applied to knee for 20 minutes a day, three times a day
61913489|NCT03986073|ACTIVE_COMPARATOR|Positive drug control group|Subjects in the positive drug control group administrated two TQ-F3083 blank analog capsules and one Linagliptin tablet orally, once daily for 12 weeks.
61913490|NCT03986073|PLACEBO_COMPARATOR|Placebo group|Subjects in the placebo group administrated two TQ-F3083 blank analog capsules and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
61913491|NCT04111978|EXPERIMENTAL|Letrozole (aromatase inhibitor)|Letrozole, 2.5 mg Femara tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease
61913492|NCT04111978|PLACEBO_COMPARATOR|Placebo|Placebo tablet of Femara (without aromatase inhibitor), 0 mg Femara tablet, administered once daily for 5 years or progression of underlying disease
62106238|NCT03972813|EXPERIMENTAL|many cancers - infectious - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
62668318|NCT06456268|EXPERIMENTAL|VibraCool|FDA-approved VibraCool mechanical stimulation and neuromodulatory therapeutic device with ice placed into it and applied to knee for 20 minutes a day, three times a day
61913493|NCT05337033|EXPERIMENTAL|Cannabidiol-enriched Cannabis Herbal Extract|CBD50 plus
62106239|NCT03972813|EXPERIMENTAL|many cancers - blank - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
62106240|NCT03972813|EXPERIMENTAL|many cancers - blank - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
62106241|NCT03972813|EXPERIMENTAL|many cancers - blank - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
62106242|NCT01943162|EXPERIMENTAL|SMART-CPT|CPT with additional elements of cognitive rehabilitation
62106243|NCT01943162|ACTIVE_COMPARATOR|CPT|Standard Cognitive Processing Therapy
62308345|NCT06104683|EXPERIMENTAL|Pirtobrutinib Dose 3|Participants will receive pirtobrutinib orally.
62668319|NCT01011283|ACTIVE_COMPARATOR|1|
62668320|NCT01011283|ACTIVE_COMPARATOR|2|
61913494|NCT01868919|EXPERIMENTAL|Positive Parenting Program|Level 3 or 4 of Triple P
61913495|NCT03557996|EXPERIMENTAL|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
61913496|NCT03557996|ACTIVE_COMPARATOR|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
61913497|NCT01464905|EXPERIMENTAL|NU100|
61913498|NCT01464905|PLACEBO_COMPARATOR|Placebo|
61913499|NCT01464905|ACTIVE_COMPARATOR|recombinant human interferon beta- 1b|
61913500|NCT01185301|ACTIVE_COMPARATOR|ADA + 2.5 mg MTX|2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
61913501|NCT01185301|ACTIVE_COMPARATOR|ADA + 5 mg MTX|5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
61913502|NCT01185301|ACTIVE_COMPARATOR|ADA + 10 mg MTX|10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
61913503|NCT01185301|ACTIVE_COMPARATOR|ADA + 20 mg MTX|MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
62308346|NCT06104683|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally.
62668321|NCT01297114||Participants aged 60-70|Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
62668322|NCT01297114||Participants aged 20-30|Younger participants will not undergo PET scanning that will be studied with other methods.
62668323|NCT06060886|EXPERIMENTAL|First episode of psychosis patients|"Operational definition for a first episode of psychosis included individuals with a non-affective psychosis who have not received previous antipsychotic treatment regardless of the duration of psychosis."
62668324|NCT05898373|EXPERIMENTAL|vedicitumomab|RC48 (2.5 mg/kg every two weeks) intravenously for 6-8 cycles
62668325|NCT05898373|EXPERIMENTAL|vedicitumomab in combination with pyrrolizidine|RC48 （2 mg/kg every two weeks) intravenously for 6-8 cycles in combination with oral HER2 TKI (pyrrolizidine 400 mg qd po)
62106244|NCT01884389|EXPERIMENTAL|Patient Navigation|"Patients are admitted to the navigation program, provided through a local community partner agency. Each of these subjects will be assigned an advanced practice nurse (APN) and licensed social worker (LSW) as co-case managers, with their relative contributions depending on the nature of the subject's needs. Level of need (1, 2 or 3) will be confirmed for each patient, and the level will inform the amount of in-person and phone call contacts made to provide on-going support and monitoring of patients. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
62106245|NCT01884389|NO_INTERVENTION|Usual Care|"The control group will receive usual care - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted social query (e.g. How are things going for you?). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
62106246|NCT02828683|EXPERIMENTAL|Ultimaster, Drug Eluting Stent|Primary PCI in patients with ST segment elevation myocardial infarction with a new Drug Eluting Stent, Ultimaster
62106247|NCT02828683|ACTIVE_COMPARATOR|Kaname, Bare metal stent|Primary PCI in patients with ST segment elevation myocardial infarction with a Bare Metal Stent - Kaname
62298148|NCT04425655|EXPERIMENTAL|Fludarabine and CPX351|"Induction 1:~Fludarabine 30 mg/m2/day IV on days 1-5 for 5 doses Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3, 5 (given 4 hours after fludarabine infusion) for 3 doses~Induction 2 (residual leukemia after Induction 1):~Fludarabine 30 mg/m2/day IV on days 1-3 for 3 doses~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3 (given 4 hours after fludarabine infusion) for 2 doses~Optional consolidation, up to 2 cycles:~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 29 mg/m2/day and cytarabine 65 mg/m2/day IV on days 1, 3 for 2 doses"
62469231|NCT06123130|EXPERIMENTAL|Single Arm|The study is a prospective single-arm multicenter clinical trial. Adult patients will be consented and enrolled in an outpatient cardiology office or Arrhythmia Clinic.
62106248|NCT02565056|ACTIVE_COMPARATOR|Self-help|Self-help book completed over 6 weeks with up to 30 minutes of telephone support per week.
62106249|NCT02565056|NO_INTERVENTION|Treatment as usual|Treatment as usual.
62106250|NCT03910478|EXPERIMENTAL|Self-collected Dried Blood Spot (DBS) monitoring|N=100 Subject collected DBS CMV monitoring with mobile technology support
62106251|NCT03910478|ACTIVE_COMPARATOR|Standard Monitoring Control|N=50 Standard care with office based testing
62106252|NCT05803967|EXPERIMENTAL|group number 1|Females with sub-clinical hypothyroidism exhibit cognitive problems (mild cognitive impairement), they will be elderly, will receive baduanjin training that will be applied 5 times per the week, under supervision for 12 weeks, number of patients will be 20), also women of this group will receive their prescribed daily one-dose medication tablet (levothyroxine).
62668326|NCT05898373|EXPERIMENTAL|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 (2 mg/kg every two weeks) in combination with a platinum-based chemotherapeutic agent of the physician's choice (carboplatin 200-250 mg/m2 every two weeks or cisplatin 50 mg/m2 every two weeks) administered intravenously for 6-8 cycles
62668327|NCT05898373|EXPERIMENTAL|RC48 in combination with teraplizumab|RC48(2 mg/kg every two weeks) in combination with an immune checkpoint inhibitor (teraplizumab, 3 mg/kg every two weeks)
62668328|NCT00557102|OTHER|cetuximab, FOLFIRI|
62106253|NCT05803967|NO_INTERVENTION|group number 2|Females with sub-clinical hypothyroidism exhibit cognitive problems (mild cognitive impairement), they will be elderly, will receive will receive their prescribed daily one-dose medication tablet (levothyroxine).
62106254|NCT03584295|ACTIVE_COMPARATOR|Conventional care|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
62298149|NCT05252689|ACTIVE_COMPARATOR|monolithic zirconia single posterior crowns with deep chamfer finish line|monolithic zirconia single posterior crowns with deep chamfer finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
62298150|NCT05252689|EXPERIMENTAL|monolithic zirconia single posterior crowns with vertical finish line|monolithic zirconia single posterior crowns with vertical finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
62298151|NCT01389245|EXPERIMENTAL|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
62298152|NCT01599559|EXPERIMENTAL|observation|Follow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
62668329|NCT01334853||Cohort 1|50 eosinophilic subjects to be evaluated
62668330|NCT01334853||Cohort 2|50 non-eosinophilic subjects to be evaluated
62668331|NCT02836106|EXPERIMENTAL|Healthy|Lean subjects (BMI\<25) with a waist circumference of \<94 cm for men and\<80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
62668332|NCT02836106|EXPERIMENTAL|Obese|Overweight and obese subjects (BMI≥25) with a waist circumference of ≥94 cm for men and ≥80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
62469232|NCT04829045|EXPERIMENTAL|Acupuncture plus diabetic routine care|Subjects will receive acupuncture treatment using press needles
62469233|NCT04829045|PLACEBO_COMPARATOR|Placebo plus diabetic routine care|Subjects are given placebo
62668333|NCT03321032|EXPERIMENTAL|Amphilimus-eluting stents|Polymer-free Amphilimus-eluting stents
61913504|NCT02677311|OTHER|Cases|Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
62668334|NCT03321032|ACTIVE_COMPARATOR|Zotarolimus-eluting stents|Biolinx Polymer-based zotarolimus-eluting stents
62106255|NCT03584295|EXPERIMENTAL|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (22-24Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-1.75 L/min.
62106256|NCT03685188|EXPERIMENTAL|Oxycodone group|PCIA is formulated at 0.4 mg/ml of oxycodone.
62106257|NCT03685188|ACTIVE_COMPARATOR|Sufentanil group|PCIA is formulated at 2 μg/ml of sufentanil.
62668335|NCT03828383|EXPERIMENTAL|In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
62668336|NCT03828383|SHAM_COMPARATOR|Limited In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
62668337|NCT02313597|PLACEBO_COMPARATOR|SETON|Silk suture will be used as SETON
62668338|NCT02313597|EXPERIMENTAL|VAAFT|Video assisted anal fistula treatment
62668339|NCT04899128||Observational Group|Patients receive pyrotinib-based therapy after lapatinib progression.
62668340|NCT00792389|EXPERIMENTAL|1|Patients receiving warmed, humidified gas
62668341|NCT00792389|ACTIVE_COMPARATOR|2|Patients receiving cool, day gas
62106258|NCT03722433|EXPERIMENTAL|probiotic plus 14-day sequential therapy|D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
62668342|NCT02546141|ACTIVE_COMPARATOR|skimmed milk (UHT)|portion size that contains 25 g of protein, oral, single administration
62668343|NCT02546141|ACTIVE_COMPARATOR|skimmed milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
62106259|NCT03722433|PLACEBO_COMPARATOR|placebo plus 14-day sequential therapy|D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
62106260|NCT02037243|EXPERIMENTAL|Water Treatment|Chlorine dispenser promotion and provision
62106261|NCT02037243|EXPERIMENTAL|Hand washing|Hand washing with soapy water promotion
62106262|NCT02037243|EXPERIMENTAL|Standard public health intervention|Health promotion using information about germs and disease
62106263|NCT02037243|EXPERIMENTAL|Disgust and shame intervention|Health promotion using disgust shame
62668344|NCT02546141|ACTIVE_COMPARATOR|skimmed yoghurt|portion size that contains 25 g of protein, oral, single administration
62668345|NCT02546141|ACTIVE_COMPARATOR|full-fat milk (UHT)|portion size that contains 25 g of protein, oral, single administration
62668346|NCT02546141|ACTIVE_COMPARATOR|non-homogenized full-fat milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
62106264|NCT06610344|EXPERIMENTAL|R-1,3-Butanediol|Participants will take 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
62106265|NCT00768131|EXPERIMENTAL|A1 FISH (+)|
62106266|NCT00768131|ACTIVE_COMPARATOR|B1 FISH (+)|
62106267|NCT00768131|EXPERIMENTAL|A2 FISH (-)|
62298153|NCT01599559|ACTIVE_COMPARATOR|mediastinal irradiation|Radiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.
62668347|NCT02546141|ACTIVE_COMPARATOR|full-fat cheese (semi-matured)|portion size that contains 25 g of protein, oral, single administration
62106268|NCT00768131|ACTIVE_COMPARATOR|B2 FISH (-)|
62106269|NCT00258518||1|ALI/ARDS patients
62106270|NCT04194502|OTHER|Pre-operative and intra-operative TEE|All patients enrolled in the study will undergo a pre-op research TEE and a intra-op clinical transesophageal echo.
62106271|NCT01176799|ACTIVE_COMPARATOR|Arm A: Control Arm|"Doxorubicin - 60mg/m2 day 1~Cyclophosphamide~-600mg/m2 day1, every 3 weeks x 4 cycles"
62106272|NCT01176799|EXPERIMENTAL|Arm B: Experimental|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
62668348|NCT02546141|ACTIVE_COMPARATOR|whey protein|portion size that contains 25 g of protein, oral, single administration
62298154|NCT03254056|ACTIVE_COMPARATOR|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
62668349|NCT02546141|ACTIVE_COMPARATOR|micellar casein|portion size that contains 25 g of protein, oral, single administration
62668350|NCT03300336|EXPERIMENTAL|Intervention|Implementation of STRIDE program
62298155|NCT03254056|ACTIVE_COMPARATOR|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
62668351|NCT03300336|NO_INTERVENTION|Usual Care|Pre-implementation before STRIDE program
62668352|NCT01279993|EXPERIMENTAL|Kerato refractive Surgery|
62668353|NCT02988557|EXPERIMENTAL|Treadmill|
62668354|NCT02622022|ACTIVE_COMPARATOR|Morphine|18 patients treated with oral morphine hydrochloride linctus 5 mg 4 four times daily and as needed up to 4 times daily
62668355|NCT02622022|PLACEBO_COMPARATOR|Placebo|18 patients treated with oral linctus corresponding to 5 mg morphine hydrochloride, four times daily and as needed up to 4 times daily
62106273|NCT05302843|EXPERIMENTAL|dose exploration and dose expansion|Patients receive BPI-28592 PO. Cycles repeat every 28 days.
62298156|NCT03483532||Lit Control pH Up without cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract without cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
62106274|NCT04550767||local infections|local infections
62106275|NCT04550767||systemic infections|systemic infections
62106276|NCT00832884|ACTIVE_COMPARATOR|Group 1A|Lacosamide, IV, 50 mg, once, 30 minutes
62106277|NCT00832884|ACTIVE_COMPARATOR|Group 2A|Lacosamide, IV, 100 mg, once, 30 min
62106278|NCT00832884|ACTIVE_COMPARATOR|Group 3A|Lacosamide, IV, 150 mg, once, 30 min
62106279|NCT00832884|ACTIVE_COMPARATOR|Group 4A|Lacosamide, IV, 200 mg, once, 30 min
62106280|NCT00832884|ACTIVE_COMPARATOR|Group 1B|Lacosamide, IV, 50 mg, once, 15 min
62106281|NCT00832884|ACTIVE_COMPARATOR|Group 2B|Lacosamide, IV, 100 mg, once, 15 min
62106282|NCT00832884|ACTIVE_COMPARATOR|Group 3B|Lacosamide, IV, 150 mg, once, 15 min
62106283|NCT00832884|ACTIVE_COMPARATOR|Group 4B|Lacosamide, IV, 200 mg, once, 15 min
62298157|NCT03483532||Lit Control pH Up with dry cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract with cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
62668356|NCT03873688|EXPERIMENTAL|Experimental Group|Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
62668357|NCT03873688|SHAM_COMPARATOR|Sham Group|In sham group, patients will perform expiratory muscle training at home for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device that the intensity of training will been setted 5 cm H₂O.
62106284|NCT01680276|EXPERIMENTAL|PBS based staff training|"The training, which will be supported by a treatment manual will comprise the following sections:~1. Functional Behavioural Assessment and formulation skills~   • Brief Behavioural Assessment Tool for brief functional analyses~2. Primary Prevention~3. Secondary Prevention and Reactive Strategies~4. Periodic Service Review and Problem Solving~   * Developing individualised periodic service reviews~  * Trouble shooting"
62106285|NCT01680276|OTHER|Treatment as usual|Most community intellectual disability services provide a range of health interventions that include but are not limited to psychiatric assessment and management, nursing support, psychology, speech and language therapy, occupational therapy and counselling. There may be some variation in resources but service users with challenging behaviour are likely to receive a range of broadly defined behavioural management and pharmacological interventions. Staff is routinely supervised by their clinical managers weekly.
62106286|NCT03965702|ACTIVE_COMPARATOR|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
62668358|NCT05381870|EXPERIMENTAL|Test preparation|Ezetimibe tablets: specification: 10mg; Package specification: 7 pieces / plate, 1 plate / box; Produced and provided by Changzhou Pharmaceutical Factory Co., Ltd.
62668359|NCT05381870|ACTIVE_COMPARATOR|Reference preparation|Ezetimibe Tablets：Ezetrol ®， Specification: 10mg, packaging specification: 10 pieces / plate, 1 plate / box; Licensee: MSD Pharma (Singapore) PTE. Ltd.
62668360|NCT01905683|EXPERIMENTAL|16-20 Units per kg body weight incobotulinumtoxinA|
62668361|NCT00714272|EXPERIMENTAL|A|Granulocytapheresis treatment
62668362|NCT00714272|PLACEBO_COMPARATOR|B|Sham device treatment
62106287|NCT03965702|EXPERIMENTAL|EV1000 monitoring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
62106288|NCT02667730|PLACEBO_COMPARATOR|Physiotherapy only|This group will receive non-pharmacological advice and physiotherapy only
62668363|NCT00923702|ACTIVE_COMPARATOR|3-dose|The participants received three doses of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) at days 1, 60 and 180+.
62106289|NCT02667730|EXPERIMENTAL|Acetaminophen + physiotherapy|This group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy
62106290|NCT02667730|EXPERIMENTAL|Naproxen + physiotherapy|This group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy
62106291|NCT02667730|EXPERIMENTAL|Celecoxib + physiotherapy|This group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy
62106292|NCT00099437|EXPERIMENTAL|1|Fulvestrant 500 mg
62106293|NCT00099437|EXPERIMENTAL|2|Fulvestrant 250 mg
62106294|NCT04716933|EXPERIMENTAL|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily.
62106295|NCT04716933|PLACEBO_COMPARATOR|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|Participants receive carboplatin AUC5 or cisplatin 75 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily.
62106296|NCT04231474||Demographic and clinical features of the patients|Number of patients Time from injury to hospitalization Time from injury to urodynamic evaluation Duration of hospitalization
62106297|NCT04231474||Comparison of urodynamic outcomes|Treatment options in patients with level SCI : cervical, thoracical and lumbar spinal cord injury
62106298|NCT01168453||neutral head position|supine with neutral head position
62668364|NCT00923702|EXPERIMENTAL|2-dose|The participants received two doses of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) at days 1 and 180+.
62668365|NCT00923702|EXPERIMENTAL|2 doses by default|The participants received two doses of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) at days 1 and 60 by default (incomplete doses)
62668366|NCT00923702|EXPERIMENTAL|Single-dose|The participants received one dose of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) by default (incomplete doses)
62668367|NCT00923702|NO_INTERVENTION|Unvaccinated|A cohort of unvaccinated women
62668368|NCT01590615||Participants with chronic HBV infection|Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
62668369|NCT03983005||Patients with suspected lung cancer|Patients with pulmonary parenchymal lesions suspected for malignancy in contact or adjacent to the esophagus which can be sampled by EUS-B-FNA
62668370|NCT04215575|ACTIVE_COMPARATOR|BGI model 101-350 placement (BGI group)|A 350 mm2 Baerveldt glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP \>16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits.The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures.
62668371|NCT04215575|EXPERIMENTAL|AGV model FP7 or S2 placement (AGV group)|A 184 mm2 Ahmed glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP \>16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits. The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures
62298158|NCT02913989||Doctors from Medical Specialities|Doctors from Medical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
62298159|NCT02913989||Doctors from Surgical Specialities|Doctors from Surgical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
62298160|NCT04102150|EXPERIMENTAL|DS-3201b|
62298161|NCT03040024|EXPERIMENTAL|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
62298162|NCT03040024|EXPERIMENTAL|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
62298163|NCT03040024|PLACEBO_COMPARATOR|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
62298164|NCT05302752|EXPERIMENTAL|Bilateral rapid magnetic stimulation of the phrenic nerves|Each participant will be tested on three different days with optimal settings for bilateral rapid magnetic stimulation of the phrenic nerves established on visit 1 and then repeated on visits 2 and 3.
62298165|NCT04468477|ACTIVE_COMPARATOR|Patients attending cardiac outpatient clinic|
62298166|NCT06190314||patients with ischemic stroke|measure serum vitamin b12 levels
62668372|NCT04694638|EXPERIMENTAL|HFNC and NIPPV|Combined use of prone positioning and non-invasive positive pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC)
62298167|NCT06190314||patients with hemorrhagic stroke|measure serum vitamin b12 levels
62106299|NCT01168453||head rotation|supine with 30° head rotation
62106300|NCT03069781|EXPERIMENTAL|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
62668373|NCT01784185|EXPERIMENTAL|virtual bronchoscopy guided transbronchial needle aspiration|virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
62668374|NCT04354571|EXPERIMENTAL|GROUP (Erector spinae block):|were given general anesthesia plus Erector spinae plane block
62298168|NCT03375385|OTHER|Hemodynamic parameters|
62298169|NCT03375385|OTHER|Ramsay sedation score|
62298170|NCT03375385|OTHER|Intraoperative side effects|
62298171|NCT03375385|OTHER|recovery of sedation|
62298172|NCT02712775|EXPERIMENTAL|Minocycline|Experimental group will receive an infusion of minocycline, the investigational drug, through a needle in a vein in the arm at the dose of 200 mg at 1 h prior to transplantation and 100 mg 12 h and 24 h after transplantation. In addition, the donated liver will be flushed with 200 mg minocycline 1 h prior to transplantation.
62298173|NCT02712775|PLACEBO_COMPARATOR|Saline|Placebo group will receive an infusion of saline, a placebo, through a needle in a vein in the arm according to the same schedule. In addition, the donated liver will be flushed with saline 1 h prior to transplantation.
62298174|NCT04508387|ACTIVE_COMPARATOR|Group HH (heated-humidified) patients|Group HH (heated-humidified) patients were administered 95% humidified CO2 insufflation at 37°C. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
62298175|NCT04508387|PLACEBO_COMPARATOR|Group CD (cold-dry) patients|Group CD (cold-dry) patients were administered dry CO2 via insufflator at room temperature (21°C). All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
62298176|NCT04266574|EXPERIMENTAL|Near Infrared Spectroscopy (NIRS)|
62298177|NCT04266574|ACTIVE_COMPARATOR|Standard Care|
62668375|NCT04354571|ACTIVE_COMPARATOR|GROUP (caudal block):|were given general anesthesia plus caudal block
62668376|NCT00328809|EXPERIMENTAL|Spirnolactone|
62668377|NCT05236751||Elective intracranial intervention patients|Adult patients (18-89 years at the time of surgery) scheduled for elective intracranial (open surgical or endoscopic) intervention and require general anesthesia and a hospital stay of at least one day post-procedure.
62298178|NCT01046188|EXPERIMENTAL|Web-based Teaching Group|Patients randomized to the intervention group will receive a unique login and password to a link on the Ottawa Fertility Centre website. This will allow them access to a secure site containing required teaching modules. They will then complete an interactive teaching tool that contains the same educational content as the traditional presentation. Patients will be able to access a module that is specific to their stimulation protocol. The teaching tool does not need to be completed all at one time. Once completed, the information can still be accessed as many times as required.
62106301|NCT03069781|PLACEBO_COMPARATOR|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
62106302|NCT05266144||atrial fibrillation|Atrial fibrillation patients who underwent radiofrequency ablation in Peking Union Medical College Hospital.
62298179|NCT01046188|ACTIVE_COMPARATOR|Control group|Participants randomized to the control arm of the study will participate in a traditional didactic teaching session. This session will be carried out by the nurse educator. This session will be attended by up to 10 other couples that may or may not be participating in the study. The nurse educator administering the session will not know which couples are participating in the study. Slides shown and information conveyed will be the same as that provided to the web-based group, however all three stimulation protocols will be presented to the participants regardless of their actual treatment protocol.
62668378|NCT03288831|ACTIVE_COMPARATOR|Normal Subjects, Gluten Drink|Normal subjects will drink a solution containing 6 grams of gluten one time.
62668379|NCT03288831|PLACEBO_COMPARATOR|Normal Subjects, Placebo Drink|Normal subjects will drink a solution without gluten one time.
62668380|NCT03288831|ACTIVE_COMPARATOR|Celiac Subjects, Gluten Drink|Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.
62668381|NCT03288831|PLACEBO_COMPARATOR|Celiac Subjects, Placebo Drink|Subjects with celiac disease will drink a solution without gluten one time.
62668382|NCT03288831|ACTIVE_COMPARATOR|Gluten Sensitivity, Gluten Drink|Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.
62106303|NCT05479539|EXPERIMENTAL|AOT|
62106304|NCT05479539|NO_INTERVENTION|Control|
62106305|NCT01280591|EXPERIMENTAL|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|
62106306|NCT01280591|EXPERIMENTAL|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|
62668383|NCT03288831|PLACEBO_COMPARATOR|Gluten Sensitivity, Placebo Drink|Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.
62668384|NCT05929586|NO_INTERVENTION|"Digital data linkage and scheduling ('C-it'): The C-it enhanced standard of care"|Linking facility to community digital data via linkage-app: Data between electronic Community Health Information System (eCHIS) and facility-based Kenya Electronic Medical Record (Kenya EMR) do not link. We do not have an existing digital data linkage module or app to track successful pregnancy referrals or allow the facility staff to view community contacts and vice versa. We will engage with national and county teams and software developers to build a digital data linkage module, linking eCHIS and Kenya EMR Maternal and Child Health (MCH) module.
62106307|NCT01280591|ACTIVE_COMPARATOR|Naproxen sodium 440 mg (BAYH6689)|
62106308|NCT01280591|ACTIVE_COMPARATOR|DPH 50 mg|
62106309|NCT03465007|ACTIVE_COMPARATOR|Hydrocortisone|100mg Hydrocortisone will be administered prior to hemodialysis
62106310|NCT03465007|PLACEBO_COMPARATOR|Placebo|100mg normal saline will be administered prior to hemodialysis
62106311|NCT01678196|EXPERIMENTAL|VA-CRAFT|Family participants complete an on-line training course (VA-CRAFT) over a 3 month period
62106312|NCT01678196|PLACEBO_COMPARATOR|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
62106313|NCT06631248|EXPERIMENTAL|Coordinative exercise protocol|coordinative exercise group
62469234|NCT04769622||patients affected by untreated Periodontitis|patients coming to the Unit of Periodontics at the University of Siena will be screened for the inclusion in the study. All patients eligible for the inclusion in the study will undergo non-surgical periodontal treatment and will be administered a questionnaire about lifestyles (adherence to mediterranean diet, sleep quality, physical activity, perceived stress). Patients will be then reevaluated at 3 months after the completion on non-surgical periodontal therapy.
62106314|NCT06631248|NO_INTERVENTION|control group|The control group continued the standard education curriculum in kindergarten and did not receive any intervention
62106315|NCT04950855||Pregnant Women|Healty pregnant women between 18-45 years,with no history of eye surgery and systemical disease.In 1st , 2nd and 3rd trimesters the measurements will be repeated
62106316|NCT04950855||Control Group|Healty non-pregnant women between 18-45 years with no history of eye surgery and systemical disease.
62106317|NCT03693755|ACTIVE_COMPARATOR|In-plane Group|In this Group the femoral nerve catheter will be placed with the in-plane technique.
62106318|NCT03693755|ACTIVE_COMPARATOR|Out-of-plane Group|In this Group the femoral nerve catheter will be placed with the out-of-plane technique.
62106319|NCT03864484|EXPERIMENTAL|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, participants watch a video using the iPad Application displaying positive word stimuli.
62106320|NCT03864484|ACTIVE_COMPARATOR|Usual rehabilitation|The control group receives usual rehabilitation.
62298180|NCT00123929|ACTIVE_COMPARATOR|1|doxorubicin
62106321|NCT03483337||recurrent or metastatic head and neck cancer patients|Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest DWI scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at Memorial Sloan Kettering's main campus, will also be imaged weekly during their course of treatment.
62106322|NCT03483337||head and neck cancer or thyroid cancers (differentiated and undifferentiated)|All patients, irrespective of treatment regimen, will be imaged on a 1.5T or 3T MR scanner prior to treatment initiation. Follow up imaging for patients undergoing surgery only will be as per clinical standard of care and not on this protocol. Patients undergoing treatment in radiation oncology and/or medicine will have imaging studies during week 2 of treatment. If patients receive 70Gy, they will also receive a scan during week 4 of treatment, if needed by treating physician. Scans will be performed to derive MRI biomarkers indicative of therapeutic mechanisms of action or efficacy will also be performed.
62106323|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
62106324|NCT03691961|EXPERIMENTAL|Medium dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
62106325|NCT03691961|EXPERIMENTAL|High dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
62106326|NCT00908947|EXPERIMENTAL|Overall Study|PTA plus stenting with the LifeStent® Vascular Stent System
62106327|NCT02512042|EXPERIMENTAL|Brinzolamide 1% Ophthalmic suspension|Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd
62106328|NCT02512042|ACTIVE_COMPARATOR|Azopt® 1% Ophthalmic suspension|Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc
62106329|NCT00217711|ACTIVE_COMPARATOR|Arm A|Oxaliplatin, Irinotecan, and Capecitabine
62469235|NCT02109250||all Belgian patients treated with Caprelsa® (vandetanib)|It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
62469236|NCT02313064|ACTIVE_COMPARATOR|CXA-10|single dose of CXA-10 oral formulation
62106330|NCT01327469|EXPERIMENTAL|Albendazole 400mg|albendazole, 1 x 400mg
62106331|NCT01327469|EXPERIMENTAL|Albendazole 2 x 400mg|albendazole, 2 x 400mg
62106332|NCT01327469|EXPERIMENTAL|Mebendazole 500mg|mebendazole, 1 x 500mg
62106333|NCT01327469|EXPERIMENTAL|Mebendazole 2 x 500mg|mebendazole, 2x 500mg
62106334|NCT01327469|EXPERIMENTAL|Pyrantel-oxantel + mebendazole|pyrantel-oxantel (10mg/kg)+ mebendazole (500mg)
62106335|NCT00612001|EXPERIMENTAL|dendritic cell vaccine|
62106336|NCT04835038|EXPERIMENTAL|Sodium Bicarbonate Ringer's Injection group|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
62106337|NCT04835038|ACTIVE_COMPARATOR|Sodium Lactated Ringer's Injection group|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
62106338|NCT01167036|EXPERIMENTAL|FascialEdge tool|A massage tool used to loosen adhesions in the superficial fascia
62106339|NCT01167036|PLACEBO_COMPARATOR|Placebo|Detuned electric point stimulation over the upper trapezius trigger point
62106340|NCT04414878|EXPERIMENTAL|Single arm clinical investigation|Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System
62106341|NCT04238234||study group|Participants will be adult patients (above 18 years), ASA I-II-III, scheduled for elective surgeries under general anesthesia.
62106342|NCT01511250|EXPERIMENTAL|Part I: TDV 21 to 45 Years (yrs)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 plaque forming units (PFU), 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
62106343|NCT01511250|PLACEBO_COMPARATOR|Part I: Placebo 21 to 45 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
62298181|NCT00123929|OTHER|2|docetaxel
62298182|NCT04721353|EXPERIMENTAL|Open-label prazosin treatment|Open-label administration of prazosin
62298183|NCT05117970|EXPERIMENTAL|Intervention|Patients randomized to intervention will have access to the screening tool.
62298184|NCT05117970|NO_INTERVENTION|Control|Patients randomized to control will continue routine practice.
62298185|NCT05824910|EXPERIMENTAL|Small group zoom meeting|2 groups of 6 participants will be asked to follow the exercise program with their peers in a zoom meeting 3 times a week for 45 min each time. This time includes 5 min before and 10 min after for free talk and chat between participants. There will also be a weekly zoom education session for 30min.
62298186|NCT04420793||ECT and Voice Recorded Group|This is an add-on study of voice samples to be gathered during ECT clinical treatments. The ONLY research procedures are four tasks on an online form, one text task and three voice recording tasks. These voice recordings will take place in a private room on the 5th floor of the Institute of Psychiatry on the same day of a patient's ECT treatment. The questionnaire will take less than 10 minutes.
62308347|NCT00003995|EXPERIMENTAL|Arm I|Patients receive a loading dose of trastuzumab IV over 90 minutes on week 1, and over 30-90 minutes weekly thereafter. Patients receive irinotecan IV over 90 minutes following trastuzumab weekly for 4 weeks. Courses are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
62469237|NCT02313064|PLACEBO_COMPARATOR|CXA-10 placebo|single oral doses of CXA-10 placebo
61913505|NCT02677311|OTHER|Controls|Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
62668385|NCT05929586|EXPERIMENTAL|"The combined C-it DU-it intervention: community data use for ANC"|"Combining C-it and work improvement teams (WITs) for community data use: We will establish and train integrated WITs in intervention sites consisting of community health members, health facility staff and community members and train them on how they will use linkage-app. The resultant combined C-it DU-it intervention has three building blocks:~We make the following assumptions about the building blocks at the bottom of figure 1.~1. Building block 1: We assume that high-quality digital data that can trace the entire journey through pregnancy is accessible to CHVs~2. Building block 2: We also assume that integrated work improvement teams (WITs) will have the right people around the table with clearly defined roles and responsibilities will use the data.~3. Building block 3: Community ANC contacts will be implemented."
62668386|NCT04769362|EXPERIMENTAL|β-blocker discontinuation arm|Discontinuation of β-blocker therapy after at least 1 year of β-blocker therapy after acute myocardial infarction
62668387|NCT04769362|NO_INTERVENTION|β-blocker maintenance arm|Continuation of β-blocker therapy after acute myocardial infarction
62668388|NCT03948386|ACTIVE_COMPARATOR|isobaric bupivacaine|"Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for \> 74 height"
62668389|NCT03948386|ACTIVE_COMPARATOR|hyperbaric bupivacaine|"hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for \> 74 height"
62668390|NCT03948386|ACTIVE_COMPARATOR|isobaric mepivacaine|"isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for \> 74 height"
62668391|NCT05447832||1/Children aged between 1-5 years from the emergency department|Children who have attended the emergency department at St Mary's Hospital, with an acute attack of wheezing. These families will be asked to use the lung function monitoring and the wheeze detection device every night for 2 weeks, while recording symptoms and medication use in the last 24 hours.
62668392|NCT05447832||2/Children aged between 1-5 years admitted electively for wheezing investigation|Children who have been admitted electively for investigations of their wheezing at the Brompton Hospital. These children/families will be asked to do the lung function monitoring and the wheeze detection device once per week for 4 months, while recording symptoms and medication use in the last 24 hours.
62668393|NCT05103592||Primary osteoprosis patients|patients older than 18 years with primary osteoporosis diagnosed by dxa scan . tartrate- resistant acid phosphatase 5b level will be measured.
62668394|NCT05103592||Rheumatoid arthritis patients|"patients older than 18 years with primary osteoporosis diagnosed by dxa scan and rhumatoid arthritis.~tartrate- resistant acid phosphatase 5b level will be measured."
62668395|NCT05103592||Ankylosing spondylitis patients|"patients older than 18 years with primary osteoporosis diagnosed by dxa scan and ankylosing spondylitis.~tartrate- resistant acid phosphatase 5b level will be measured."
62668396|NCT05103592||Control group|patients older than 18 years not complaining of any bone disease tartrate- resistant acid phosphatase 5b level will be measured.
61913506|NCT03567317|NO_INTERVENTION|CPAP|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP during the initial study visit, patients will resume CPAP use for one week before the second study visit.
61913507|NCT03567317|EXPERIMENTAL|CPAP withdrawal|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP at the second study visit, patients will withdraw CPAP one week before.
61913508|NCT01343823|ACTIVE_COMPARATOR|ecallantide 10mg|Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
62668397|NCT00932802||Group 1|
62668398|NCT06130202||NAFLD|
61913509|NCT01343823|PLACEBO_COMPARATOR|placebo|Administered as two SC 3 mL injections
61913510|NCT01343823|ACTIVE_COMPARATOR|ecallantide 60mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
61913511|NCT01343823|ACTIVE_COMPARATOR|ecallantide 30mg|Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.
61913512|NCT01413633|EXPERIMENTAL|cholecystectomy|single incision laparoscopic cholecystectomy
61913513|NCT00392379|EXPERIMENTAL|A|4 mg nicotine lozenges for 3 months
61913514|NCT00392379|PLACEBO_COMPARATOR|B|Placebo nicotine lozenges for 3 months
61913515|NCT02518880|OTHER|Plasma volume measurements|
62106344|NCT01511250|EXPERIMENTAL|Part I: TDV 12 to 20 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
62106345|NCT01511250|PLACEBO_COMPARATOR|Part I: Placebo 12 to 20 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
62106346|NCT01511250|EXPERIMENTAL|Part I: TDV 6 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
62106347|NCT01511250|PLACEBO_COMPARATOR|Part I: Placebo 6 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
62106348|NCT01511250|EXPERIMENTAL|Part I: TDV 1.5 to 5 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
62308348|NCT04704076|EXPERIMENTAL|Early, Small-Volume Supplementation (ESVS)|Breastfeeding with up to 59 mL formula daily until 30 days of age, followed by recommendation to breastfeed exclusively through 6 months of age
62668399|NCT01996540|EXPERIMENTAL|Interventional arm|Interventional arm
62668400|NCT01996540|NO_INTERVENTION|Standard arm|Standard arm
62668401|NCT01958684||Group 1|The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
62668402|NCT01958684||Group 2|Copper IUDs with different shape and with or without drugs
61913516|NCT05714319||MINOCA|"Patients undergoing clinically indicated CAG for suspected myocardial ischemia with angiographic evidence of non-obstructive CAD (angiographically normal coronary arteries or diffuse atherosclerosis with stenosis \<50% and/or fractional flow reserve \[FFR\] \>0.80 if coronary stenosis ranging from 40 to 49%) that underwent an intracoronary provocative test with ACh according to clinical practice and medical choice will be enrolled.~Patients with MINOCA will be diagnosed based on clinical evidence of acute myocardial ischemia, detection of raise and fall of serum troponin T levels with at least one value exceeding the 99th percentile of a normal reference population and at least one of the following: myocardial ischemia (1 or + episodes of chest pain at rest typical enough to suggest a cardiac ischemic origin in the previous 24 hours); new ischemic ECG changes; pathological Q waves; new loss of viable myocardium or regional wall motion abnormality consistent with an ischemic aetiology."
61913517|NCT05714319||INOCA|"All consecutive patients undergoing clinically indicated CAG for suspected myocardial ischemia with angiographic evidence of non-obstructive CAD (angiographically normal coronary arteries or diffuse atherosclerosis with stenosis \<50% and/or fractional flow reserve \[FFR\] \>0.80 if coronary stenosis ranging from 40 to 49%) that underwent an intracoronary provocative test with ACh as suggested in current guidelines and consensus and according to clinical practice and medical choice will be consecutively included in this study.~Patients with INOCA will be defined as those with a stable pattern of typical chest pain on exertion, at rest or both, without any sign of acute myocardial infarction (MI), and/or evidence of inducible myocardial ischemia undergoing a scheduled hospital admission for CAG."
61913518|NCT03426982|EXPERIMENTAL|Anti-Xa group|- Heparin was monitored by Anti-Xa activity, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 0.30 and 0.70 IU/mL
62106349|NCT01511250|PLACEBO_COMPARATOR|Part I: Placebo 1.5 to 5 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
62106350|NCT01511250|EXPERIMENTAL|Part II: TDV 1.5 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
62668403|NCT03516500|EXPERIMENTAL|Iron Sucrose injection group|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.
62668404|NCT01381588||Post menopausal women|Post menopausal women between 50 to 80
62668405|NCT04234542|EXPERIMENTAL|Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using a protocol developed in collaboration with BioFlexTM Laser. Each treatment will last approximately 45 minutes and will include the laser array first being applied to the skin overlying the sacral spine in a horizontal placement then in oblique placement bilaterally (red and infrared light) while a laser probe is applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light) and the focal probe will be applied to painful sites on the perineum. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. All the stages will involve use of the same array and probe placement, but at each stage the dosage will be increased according to the BioFlex protocol. During teach treatment session, women will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones.
62106351|NCT01511250|PLACEBO_COMPARATOR|Part II: Placebo 1.5 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
62106352|NCT01325870|EXPERIMENTAL|ACD-CPR +ITD|Active Compression Decompression CPR with the ResQPRO device and ResQPOD ITD device.
62106353|NCT01325870|EXPERIMENTAL|S-CPR + ITPR|
62106354|NCT01325870|ACTIVE_COMPARATOR|S-CPR|
61913519|NCT03426982|EXPERIMENTAL|APTT group|- Heparin was monitored by APTT, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 1.5 and 2.5 time the basiline.
62469238|NCT04025450|EXPERIMENTAL|Chidamide plus VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
62106355|NCT02653079||Study Cohort|Blood draw and Questionaire from patients suffering from chronic inflammatory diseases of the joints, namely painful shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia, Arthrosis (finger- and Rhizarthrosis, Gonarthrosis, Anklearthrosis), and Arthritis with an planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
62106356|NCT01004328|EXPERIMENTAL|Intervention Group 1|All participants
62106357|NCT00286741|EXPERIMENTAL|Medical group visits|Medical group visits
62106358|NCT00286741|NO_INTERVENTION|Treatment as Usual control|control
62106359|NCT02430181|EXPERIMENTAL|lonafarnib - I|lonafarnib 200 mg BID; n=3
62106360|NCT02430181|EXPERIMENTAL|lonafarnib - II|lonafarnib 300 mg BID; n=3
62106361|NCT02430181|EXPERIMENTAL|lonafarnib - III|lonafarnib 100 mg TID; n=3
62106362|NCT02430181|EXPERIMENTAL|lonafarnib/PEG IFN-a - I|lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3
62106363|NCT02430181|EXPERIMENTAL|lonafarnib/PEG IFN-a - II|lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3
62106364|NCT02430181|EXPERIMENTAL|lonafarnib/PEG IFN-a - III|lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=2
62106365|NCT02430181|EXPERIMENTAL|lonafarnib/ritonavir|lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3
62298187|NCT05918887|EXPERIMENTAL|E-cigarette arm|Participants will receive the commercially available NJOY ACE e-cigarette, nicotine pods (2 of each available flavor, for a total of 4 pods), and tailored instructions to switch. Participants will use the ACE ad libitum for 14 days, reporting their cigarette use, e-cigarette use, mood, and nicotine crazing every day via text message surveys.
62298188|NCT03246438|EXPERIMENTAL|Control|Colonoscopy only outreach and follow-up
62298189|NCT03246438|EXPERIMENTAL|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
62298190|NCT03246438|EXPERIMENTAL|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
62469239|NCT04025450|ACTIVE_COMPARATOR|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
62469240|NCT04357639||Protease inhibitor exposed|HIV patients treated with antiretroviral drugs including a protease inhibitor
61913520|NCT04814238||mini-David|
61913521|NCT04814238||mini-Yacoub|
61913522|NCT04814238||mini-Bentall|
62106366|NCT05167253|EXPERIMENTAL|UB-612 100 μg, 0.5 mL|All subjects will be enrolled to receive one dose of 100 μg UB-612 vaccine
62106367|NCT02600442||main and unique cohort|
62106368|NCT02593565||Intervention|Woman, 18 years of age or older, currently pregnant, and have a diagnosis of vasculitis.
62106369|NCT05997654|EXPERIMENTAL|Instrumental procedures and safety and efficacy assessments|"Group I: 23 participants who will undergo instrumental procedures, perceived efficacy questionnaires and clinical assessments of safety and efficacy.~Group II: 10 participants who will only perform perceived efficacy questionnaires and clinical assessments of safety and efficacy."
62106370|NCT03076736|ACTIVE_COMPARATOR|Resource pack|Aphasia resource pack
62106371|NCT03076736|EXPERIMENTAL|Singing group + resource pack|Singing group + Aphasia resource pack
62298191|NCT06260787||In Vitro Fertilisation|Patients undergoing in vitro fertilisation at our tertiary fertility center facility
62298192|NCT02028949|EXPERIMENTAL|Chemo-lipiodol|
62298193|NCT05984745|NO_INTERVENTION|Control group|Patients will receive the standard conventional care which is mainly therapeutic life changes
62298194|NCT05984745|EXPERIMENTAL|Test Group|Patients will receive Coenzyme Q10 Forte® (MEPACO Pharmaceutical Company, Cairo, Egypt) capsules in a dose of 100 mg twice per day 1 capsule every 12 hours for twelve weeks, in addition to the standard conventional care.
61913523|NCT05765773|EXPERIMENTAL|The study group consisted of 200 volunteers|The study group is planned to screen a maximum of 250 volunteers inclusive, of which it is planned to include 200 men and women aged 60 years and older who meet the criteria for inclusion in the study and do not have non-inclusion criteria.
61913524|NCT05765773|NO_INTERVENTION|Control group|Retrospective immunogenicity data obtained in the framework of clinical study № VKI-I/II-08/20 on healthy volunteers aged 18-60 years.
62298195|NCT06042686|OTHER|Repeated measures|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
62298196|NCT01315574|ACTIVE_COMPARATOR|Latanoprost (Xalatan)|7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
62298197|NCT01315574|ACTIVE_COMPARATOR|Travoprost (Travatan Z)|7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.
62469241|NCT04357639||Protease inhibitor non exposed|HIV patients treated with antiretroviral drugs without a protease inhibitor
62469242|NCT00807794|EXPERIMENTAL|1|MEDI-507
62469243|NCT00807794|EXPERIMENTAL|2|MEDI-507
62469244|NCT00807794|EXPERIMENTAL|3|MEDI-507
62469245|NCT00807794|EXPERIMENTAL|4|MEDI-507
62469246|NCT00807794|EXPERIMENTAL|5|MEDI-507
62469247|NCT01960374|EXPERIMENTAL|Japanese Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
62469248|NCT01960374|EXPERIMENTAL|Non-Japanese Asian Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
62469249|NCT01888822|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
62469250|NCT01888822|ACTIVE_COMPARATOR|Ampicillin-sulbactam|Intravenous infusion of 3gr ampicillin-sulbactam in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
62469251|NCT01888822|ACTIVE_COMPARATOR|Ciprofloxacin|Intravenous infusion of 400 mg ciprofloxacin in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
62469252|NCT03184753|EXPERIMENTAL|Single arm|OC-IgT cells to treat ovarian cancer.
61913525|NCT03315052|EXPERIMENTAL|Budesonide treatment arm|Patients treated with budesonide in place of prednisone as part of immunosuppressive regimen
61913526|NCT03315052|ACTIVE_COMPARATOR|Standard immunosuppression arm|Patients treated with standard immunosuppression after liver transplant
62106372|NCT03455361||Stark Implant with low primary stability|Patient who had received bone level V-Blast implants with low primary stability.
62106373|NCT03455361||Stark Implant with primary stability|Patient who had received bone level V-Blast implants and achieved primary stability.
62106374|NCT00941356|EXPERIMENTAL|1|Bio-K+ CL1285 contains 50 billion of live bacteria
62106375|NCT00941356|PLACEBO_COMPARATOR|2|placebo devoid of bacteria
62298198|NCT01106378||NEVO™ Sirolimus-eluting Coronary Stent System.|Subjects treated during routine clinical practice with the NEVO™ Sirolimus-eluting Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease.
62298199|NCT01106378||CYPHER Select® Plus Coronary Stent|Subjects treated during routine clinical practice with the CYPHER Select® Plus Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease
62298200|NCT05855356|EXPERIMENTAL|LoCoDiRe-Dys|Respiratory physiotherapy, personalized aerobic and strength training in parallel with standard of care
62298201|NCT05855356|ACTIVE_COMPARATOR|Standard of Care|Standard of care including behavioural and medical advice
62298202|NCT06386458|EXPERIMENTAL|Radiofrequency transseptal puncture needle|Utilizing Radiofrequency transseptal puncture system for left atrial access
62298203|NCT06386458|ACTIVE_COMPARATOR|Traditional mechanical transseptal puncture needle|Utilizing Traditional mechanical transseptal puncture needle for left atrial access
62298204|NCT00885443|ACTIVE_COMPARATOR|1|
62298205|NCT00885443|ACTIVE_COMPARATOR|2|
62469253|NCT01286922|EXPERIMENTAL|Interval Training|"The target intensity for the INT group is 2 min at about 95% of baseline VO2max followed by 2 min of recovery at 40-50% of VO2max. Regardless of the training method each participant will be locked into a weekly energy expenditure of 12 kilocalories per kilogram of body weight per week (KKW)."
62469254|NCT01286922|PLACEBO_COMPARATOR|Aerobic Conditioning|During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
62469255|NCT03727828||Patients with heart failure|Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
62469256|NCT03727828||healthy control|
62469257|NCT02308722|EXPERIMENTAL|5-fraction stereotactic body radiation therapy|See intervention
62469258|NCT04888819|EXPERIMENTAL|fed state group|just after a meal
62668406|NCT04234542|SHAM_COMPARATOR|Sham Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using the same protocol developed in collaboration with BioFlexTM Laser, but at an intensity of 1% output for all sites and at all stages. Each treatment will last approximately 45 minutes. At each visit, the laser array will first be applied to the skin overlying the sacral spine in a horizontal then oblique placement bilaterally (red and infrared light) concurrently with a laser probe applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light), followed by treatment at specific painful sites using the red light probe. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. Participants randomized to this group will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones while receiving the sham laser treatment.
62668407|NCT03637374|EXPERIMENTAL|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
62668408|NCT03637374|OTHER|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
62668409|NCT02729168|EXPERIMENTAL|Human rabies vaccines|Five doses 0.5 mL vaccine INDIRAB® on D0, D3, D7, D14, D28 using administered intramuscularly.
62106376|NCT03578523||Chronic Kidney Disease|"CKD stage 3-4 eGFR 59-20mls/min/1.73 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
62106377|NCT03578523||Acute Kidney Injury|"AKI stage 2-3 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
62106378|NCT03870360|EXPERIMENTAL|HOLA: A Culturally-Tailored Health Promotion Intervention|16 week, multicomponent, health promotion intervention
62106379|NCT03870360|ACTIVE_COMPARATOR|Healthy lifestyles education program|Educational material on mental health, physical activity, and information on community resources
62106380|NCT03279666|ACTIVE_COMPARATOR|tenaculum with intracervical blockage|
62106381|NCT03279666|NO_INTERVENTION|No tenaculum with intracercical blockage|
62106382|NCT03279666|ACTIVE_COMPARATOR|Tenaculum without intracervical blockage|
62106383|NCT03279666|NO_INTERVENTION|No Tenaculum without intracervical blockage|
62668410|NCT05389839|EXPERIMENTAL|Wechat program guidance group|Wechat program guidance group using insulin dose calculator
62106384|NCT02628691||HCV coinfection with no-to-moderate fibrosis|
62106385|NCT04075708||Case-group|The case group will consist of women diagnosed with PE after 34 weeks of gestation.
62106386|NCT04075708||Control-group|The control group will include 165 participants who were not diagnosed with PE in their pregnancies.
62106387|NCT01353482|ACTIVE_COMPARATOR|Phase II only - Arm I|If the patient is randomised into the Vorinostat arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle plus the dose of Vorinostat determined in the phase I study.
62106388|NCT01353482|PLACEBO_COMPARATOR|Phase II only - Arm 2|If the patient is randomised into the placebo arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle with the placebo for the same number of days as in the vorinostat arm.
62106389|NCT03426280|EXPERIMENTAL|Apple Watch|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
62106390|NCT03426280|NO_INTERVENTION|Usual Care|Usual care.
62106391|NCT00207129|EXPERIMENTAL|A|
62106392|NCT00207129|EXPERIMENTAL|B|
62469259|NCT04888819|EXPERIMENTAL|fasted state group|before a meal
62469260|NCT03543462|SHAM_COMPARATOR|Arm A: Chest tube positioning YES|Patients enrolled for chest tube positioning
62469261|NCT03543462|NO_INTERVENTION|Arm B: Chest tube positioning NO|Patients enrolled for diaphragm closure without chest tube positioning
62469262|NCT00984126|EXPERIMENTAL|Turoctocog alfa|
62469263|NCT02273622|EXPERIMENTAL|hydroxytyrosol 5 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
62106393|NCT04631549|EXPERIMENTAL|Healthy participants|Intervention: Drug: SHR3680 single dose
62106394|NCT04631549|EXPERIMENTAL|Mild liver impairment|Intervention: Drug: SHR3680 single dose
62106395|NCT04631549|EXPERIMENTAL|Moderate liver impairment|Intervention: Drug: SHR3680 single dose
62106396|NCT06081803|EXPERIMENTAL|Evolocumab group|Evolocumab 420mg subcutaneous injection before primary PCI
62106397|NCT06081803|NO_INTERVENTION|Control group|without Evolocumab 420mg before primary PCI
62106398|NCT05295082|EXPERIMENTAL|guided trephination-based protocol|"The drilling process will be performed by guided trephination protocol.~* An appropriate trephine drill (Helmut Zepf Medizintechnik GmbH, Germany) will be used to create an initial osteotomy.~* The guide will be removed, and the depth and angulation of this initial osteotomy will be evaluated.~* The final drill of the chosen implant system will be used to complete the osteotomy.~* The implant (NeoBiotech Implant System, Neobiotech Co. Ltd. Korea) then will be placed freehand in a conventional manner."
62106399|NCT05295082|ACTIVE_COMPARATOR|guided conventional drilling-based protocol|"The drilling process will be performed by a guided conventional drilling protocol.~* Drilling (Neo NaviGuide System - Neobiotech Co. Ltd. Korea) will be performed throughout the guiding sleeve from the first drill to the final drill.~* The guide will be removed.~* The implant (NeoBiotech Implant System, Neobiotech Co. Ltd. Korea) then will be placed freehand in a conventional manner."
62106400|NCT06037616|ACTIVE_COMPARATOR|gr A: powerpoint and tutor|teaching with powerpoint and tutor
62106401|NCT06037616|ACTIVE_COMPARATOR|gr B: powerpoint and tutor and video skill|teaching with powerpoint and tutor and video showing skill to perform a skin suture
62106402|NCT06037616|ACTIVE_COMPARATOR|gr C: powerpoint and tutor and video error|teaching with powerpoint and tutor and video showing errors
62106403|NCT06037616|ACTIVE_COMPARATOR|gr D: powerpoint and tutor and video skill and error|teaching with powerpoint and tutor and video showing skill to perform a skin suture and errors
62106404|NCT01861678|ACTIVE_COMPARATOR|High tie of IMA|In High tie group, IMA was transected at its origin from the abdominal aorta.
62106405|NCT01861678|EXPERIMENTAL|Low tie of IMA|In the low tie of the IMA, IMA was separated after branching to the left colic artery. The lymph node dissection around the IMA at its origin was performed.
62106406|NCT04483882|SHAM_COMPARATOR|Phase I- Visually Obscured Healthy Subjects|Tactile label to be evaluated by healthy subjects without visual defect. Subjects in visually obscuring lenses but without peripheral neuropathies or other tactile deficits will evaluate the tactile labeling product for efficacy in drug identity and dosing definition. .
62106407|NCT04483882|ACTIVE_COMPARATOR|Phase II- Low Vision Over 50 years of age|Subjects with documented Low Vision of 20/70 or less or visual field less than 20 degrees will be asked to evaluate tactile labeling product for efficacy in drug identity and dosing definition.
62668411|NCT05389839|ACTIVE_COMPARATOR|clinical experience treatment group|clinical experience treatment group using physician experience
62106408|NCT02916719|EXPERIMENTAL|Neo-adjuvant radiotherapy|Group of women having undergone a neo-adjuvant radiotherapy for early breast cancer.
62106409|NCT05590312||Low Flow Group - Group D|Vitamin D, Albumin, CRP, TAS and TOS values will be checked before and during the operation in 36 patients who will receive general anesthesia. Flow of 1 L/min will be given during the operation. The processed EEG values of all patients will be monitored and they will be ensured to be at the same anesthesia depth. Albumin, CRP, TAS and TOS values will be checked again from the blood taken postoperatively in the patients who were taken to the service after the operation and these values will be compared with the previous ones.
62106410|NCT05590312||High Flow Group - Group Y|Vitamin D, Albumin, CRP, TAS and TOS values will be checked before and during the operation in 36 patients who will receive general anesthesia. Flow of 4 L/min will be given during the operation. The processed EEG values of all patients will be monitored and they will be ensured to be at the same anesthesia depth. Albumin, CRP, TAS and TOS values will be checked again from the blood taken postoperatively in the patients who were taken to the service after the operation and these values will be compared with the previous ones.
62298206|NCT03118622||Pentax group|Intubation using Pentax
62469264|NCT02273622|EXPERIMENTAL|hydroxytyrosol 20 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
62469265|NCT02273622|PLACEBO_COMPARATOR|placebo|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
62668412|NCT06345820|EXPERIMENTAL|Evolux|Patient will receive the Enova IOL during cataract surgery
62106411|NCT06281080|EXPERIMENTAL|Treatment arm|Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
62106412|NCT05523258|EXPERIMENTAL|Intervention Group|Patients in this group will receive computerized cognition training, including processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning and problem solving. The training program and its difficulty are constantly adjusted with the patients' training performance.
62298207|NCT03118622||Macintosh group|Intubation using Macintosh
62298208|NCT04561180|PLACEBO_COMPARATOR|Arm 1: SOC + DEX + EG-009A placebo|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A placebo for 3 additional weeks.
62298209|NCT04561180|EXPERIMENTAL|Arm 2: SOC + DEX + Low Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A Low dose for 3 additional weeks.
62298210|NCT04561180|EXPERIMENTAL|Arm 3: SOC + DEX + High Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A High dose for 3 additional weeks.
62298211|NCT05356793|EXPERIMENTAL|Treatment|Active treatment with SCH-1
62668413|NCT06345820|EXPERIMENTAL|Tecnis Eyhance|Patient will receive the Tecnis Ehance IOL during cataract surgery
62668414|NCT04926662||Aim 1: Focus Groups|Focus groups will be conducted in 2 New Hampshire and 2 Vermont towns to better understand patient knowledge, attitudes, and preferences regarding access to lung cancer screening.
62106413|NCT05523258|SHAM_COMPARATOR|Control group|Patients in this group will receive basic training based on tablet computer, and the subjects will receive five training tasks of processing speed and attention, which are fixed in difficulty and scheme. The training methods and intensity are similar to the intervention group.
62668415|NCT04926662||Aim 2: Cross Sectional Survey|Based on focus group feedback, the investigators will visit each proposed site to survey on 2 separate dates to confirm days and times of high traffic. The investigators will also survey patrons at the proposed locations to further determine prospective patient mobile screening preferences and evaluate willingness to participate in screening.
62106414|NCT04477746||Standard Laparoscopy group (LS)|7 surgeons performing surgical procedures using the standard laparoscopic approach
62106415|NCT04477746||Robot- assisted laparoscopic group (RALS)|6 surgeons performing surgical procedures using the robot-assisted laparoscopic approach
62106416|NCT04094064|EXPERIMENTAL|CGM Use while on Hemodialysis Therapy|All subjects will use a CGM for 10 days. Subjects will continue their standard of care hemodialysis treatments during the study period.
62106417|NCT02064569|EXPERIMENTAL|GS010|
62106418|NCT04053829|EXPERIMENTAL|HOLOBalance|The experimental arm will use the HOLOBalance tele-rehabilitation system to provide the intervention. Participants will be required to use the HOLOBalance system on a daily basis for the duration of the 8 week study. Although participants will have daily interaction with the HOLOBalance system, they will be free to choose when to complete their exercises.
62106419|NCT04053829|ACTIVE_COMPARATOR|OTAGO Home Exercise Programme|The comparator for this study is the OTAGO home exercise programme. The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. The OTAGO is well-established and is widely used in clinical practice in the UK for the management of older adults who fall or have increased risk for falling. It has been shown to be well tolerated in older adults in community settings with good adherence rates, and reduces falls rate in older adults by 35%, with greatest effects observed in frailer older women
62106420|NCT00633412|EXPERIMENTAL|1|20mg Oral tablet daily
62106421|NCT00633412|EXPERIMENTAL|2|40mg Oral tablet daily
62668416|NCT04926662||Aim 3: Survey with follow up data|The investigators will pilot mobile lung cancer screening clinics at each chosen location using the knowledge acquired from focus group experience and local patient survey. Surveys will be conducted at these clinics, and patients will be followed for up to 5 years.
62106422|NCT00633412|ACTIVE_COMPARATOR|3|150mg oral twice daily
62106423|NCT01624636|PLACEBO_COMPARATOR|Placebo|
62106424|NCT01624636|EXPERIMENTAL|LFG316: 10 mg/kg (2 doses in cohort 1)|
62668417|NCT05469308|EXPERIMENTAL|questionary|
62668418|NCT05571488||Healthcare professionals|All type of healthcare professionals (HCPs), working in a variety of settings and across Switzerland
62668419|NCT05571488||Informal caregivers|All type of informal caregivers (ICs), assisting a person for health reasons across Switzerland
62668420|NCT02669537|EXPERIMENTAL|GOPRO resident|Residents will use the gopro during a vaginal procedure, review the case with the attending after, and perform a 2nd case of the same type. The VVSI and GRS will be used to assess any changes in surgical skill
61913527|NCT04929665|ACTIVE_COMPARATOR|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
62106425|NCT01624636|EXPERIMENTAL|LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).|
62106426|NCT00604006|EXPERIMENTAL|Group A|
62668421|NCT02669537|NO_INTERVENTION|Control Resident|Residents will use standard surgical education practices, direct instruction from attending, surgical atlas, online videos. They will perform 2 cases of the same type and the difference in VVSI and GRS will be assessed
62668422|NCT02669537|EXPERIMENTAL|GOPRO medical student|Medical students will be allowed to watch the surgery on an iPad with the GoPro app. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
62106427|NCT00604006|PLACEBO_COMPARATOR|Group B|
62106428|NCT04917432|ACTIVE_COMPARATOR|IVUS guided CTO revascularization|To assess the effects of IVUS usage in CTO revascularization compared to conventional non-IVUS guided CTO-PCI as regard technical success and procedural success, MACE within 6 months.
62106429|NCT04917432|ACTIVE_COMPARATOR|Non-IVUS guided CTO revascularization|To compare this conventional non-IVUS guided CTO-PCI arm with the other IVUS guided arm as regard technical success and procedural success, MACE within 6 months.
62106430|NCT05955599|EXPERIMENTAL|Pre-adolescent Intervention|11-13 year old female handball players complete a supervised ACL injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The ACL injury prevention training consists of three tracks focusing on 1) hamstring and hip external rotation strength; 2) medial hamstring activation; 3) single leg landing technique training with a special focus on knee control. The training is integrated in the players/team's normal handball practice.
62106431|NCT05955599|OTHER|Pre-adolescent Control|11-13 year old female handball players complete a supervised shoulder injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The shoulder injury prevention training consists of three tracks focusing on 1) external rotator cuff strength; 2) scapula stability; 3) core strength and trunk rotation. The training is integrated in the players/team's normal handball practice.
62106432|NCT05955599|EXPERIMENTAL|Adult Intervention|Adult (≥18 year old) female handball players complete a supervised ACL injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The ACL injury prevention training consists of three tracks focusing on 1) hamstring and hip external rotation strength; 2) medial hamstring activation; 3) single leg landing technique training with a special focus on knee control. The training is integrated in the players/team's normal handball practice.
62106433|NCT05955599|OTHER|Adult Control|Adult (≥18 year old) female handball players completed a supervised shoulder injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The shoulder injury prevention training consists of three tracks focusing on 1) external rotator cuff strength; 2) scapula stability; 3) core strength and trunk rotation. The training is integrated in the players/team's normal handball practice.
62106434|NCT04740359|ACTIVE_COMPARATOR|Control|Routine training; mat exercises and perturbation training
62106435|NCT04740359|EXPERIMENTAL|Study|Trunk training; Functional training, mat exercises and perturbation training
62106436|NCT02759731|EXPERIMENTAL|Baricitinib|"Single arm, intra-patient dose escalation. Arm 1 (starting dose) -Baricitinib starting at a dose of 2mg daily for 12 weeks. If the response at 12 weeks is a complete response (CR) and there has not been a dose-limiting toxicity (DLT), the dose will remain at 2mg daily for an additional 12 weeks. Arm 2 (dose escalation) - If the response is a partial response (PR) or stable disease (from cohort 1), the dose will be increased to 4mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks will have a dose reduction back to 2mg daily.~Each participant is exposed to both dose levels (with the exception of participants who developed toxicity or progressive disease that caused them to discontinue study early before they were able to undergo the per-protocol dose escalation at 12 weeks)."
62106437|NCT00639613||1|Patients with type 2 diabetes
62106438|NCT00639613||2|Healthy subjects
62469266|NCT02514941|EXPERIMENTAL|pre OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed within three days before the scheduled proximal Roux-en-Y gastric bypass surgery. A gastroduodenoscopy with biopsy of the lower duodenum will be performed before the first pharmacokinetic study period.
62106439|NCT04697251|OTHER|FOT measurements|FOT measurements in newborns and small infants
62106440|NCT06479018|EXPERIMENTAL|Patients with Bullous Pemphigoid|
62106441|NCT06479018|EXPERIMENTAL|Control subjects|
62106442|NCT06628856|EXPERIMENTAL|HOSPITAL CHILE|The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being. (N=286)
62298212|NCT05356793|PLACEBO_COMPARATOR|Placebo|Vehicle minus active components
62298213|NCT04702230||post-TAE|
62298214|NCT04702230||post-TARE|
62298215|NCT00370344|ACTIVE_COMPARATOR|Laparoscopic cholecystectomy|Operation by experts in laparoscopy.
62469267|NCT02514941|EXPERIMENTAL|post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
62469268|NCT02514941|EXPERIMENTAL|one year post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period and a gastrojejunoscopy with biopsy of the jejunum will be performed about one year after the scheduled proximal stomach bypass surgery.
62469269|NCT00312897|PLACEBO_COMPARATOR|corn oil|as stated
62469270|NCT00312897|EXPERIMENTAL|Omega 3 Fatty Acids|as stated
62469271|NCT05860647|EXPERIMENTAL|Intermittent theta burst stimulation|All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 8-10 weeks.
62668423|NCT02669537|NO_INTERVENTION|Control Medical Student|Medical students will be taught using standard practices, i.e instruction by residents/attendings. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
62668424|NCT03166956|EXPERIMENTAL|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
62668425|NCT03166956|PLACEBO_COMPARATOR|Control (C) group|"Placebo:~Subjects in the C group received isocaloric maltodextrin as placebo."
62668426|NCT05168982||Chronic liver disease (CLD) patients at stage A0 of liver inflammation|
61913528|NCT04929665|ACTIVE_COMPARATOR|Erector spinae block|Patients who are planned to have an erector spina block will be advanced to the interfacial area under the erector spinae muscle by ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
62298216|NCT00370344|ACTIVE_COMPARATOR|Small-incision open cholecystectomy|Operation by experts in small-incision cholecystectomy.
62298217|NCT00097539||Participants With Growth Disorders|Participants initiating therapy with Genentech GH products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) for the treatment of pediatric growth disorders as determined by their physician and who have consented to participate in the NCGS will be enrolled in the study and will be followed throughout their course of treatment, or until withdrawal from the NCGS.
62298218|NCT00462423|EXPERIMENTAL|Single Arm, Open Label|Single Arm, Open Label trial of Abraxane and Avastin
62298219|NCT02846519|EXPERIMENTAL|Esketamine|Participants in Cohort 1 (Han Chinese participants), Cohort 2 (Korean participants) and Cohort 3 (Japanese participants ) will receive 100-microliter (mcL) spray of 14 percent (%) esketamine solution (14 milligram \[mg\]) into each nostril at Time 0 and 5 minutes later for a total dose of 56 milligram (mg) in Period 1.
62106443|NCT06628856|EXPERIMENTAL|HOSPITAL SPAIN|The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being. (N=286)
62668427|NCT05168982||Chronic liver disease (CLD) patients at stage A1 of liver inflammation|
62668428|NCT05168982||Chronic liver disease (CLD) patients at stage A2 of liver inflammation|
62668429|NCT05168982||Chronic liver disease (CLD) patients at stage A3 of liver inflammation|
61913529|NCT04929665|ACTIVE_COMPARATOR|Thoracic Paravertebral block and Erector spinae Block|In patients who are planned to have combined erector spinae block and thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 10 ml of 0.25% bupivacaine will be given to this area. Then, with the same needle, return 1-2 cm from the paravertebral area and inject 10 ml of 0.25% bupivacaine into the interfacial area under the erector spinae muscle.
62668430|NCT05168982||Chronic liver disease (CLD) patients at stage F0 of liver fibrosis|
62668431|NCT05168982||Chronic liver disease (CLD) patients at stage F1 of liver fibrosis|
61913530|NCT03693729|EXPERIMENTAL|Active DLPFC during task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
62106444|NCT03379363||Pediatric Cushing Syndrome Patients|Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
62106445|NCT02434718|EXPERIMENTAL|Cohort 1|IV infusion in cohorts assigned to low dose 1; 1 participant per cohort will receive placebo
62668432|NCT05168982||Chronic liver disease (CLD) patients at stage F2 of liver fibrosis|
62668433|NCT05168982||Chronic liver disease (CLD) patients at stage F3 of liver fibrosis|
62668434|NCT05168982||Chronic liver disease (CLD) patients at stage F4 of liver fibrosis|
62106446|NCT02434718|EXPERIMENTAL|Cohort 2|IV infusion in cohorts assigned to low dose 2; 1 participant per cohort will receive placebo
62106447|NCT02434718|EXPERIMENTAL|Cohort 3|IV infusion in cohorts assigned to high dose; 1 participant per cohort will receive placebo
62298220|NCT02846519|EXPERIMENTAL|Esketamine+Rifampin|Participants in Cohort 4 (Caucasian participants) will receive a 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 1 followed by rifampin from Day -6 to Day -1 of treatment Period 2 and followed by 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 2.
62298221|NCT00492219|ACTIVE_COMPARATOR|1|Patients undergoing total knee replacement
62469272|NCT01334632|ACTIVE_COMPARATOR|Continuous interscalene block|Continuous interscalene block with bolus ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2% 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
62469273|NCT01334632|PLACEBO_COMPARATOR|PCA morphine|Patients with iv self-administration of morphine, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
62668435|NCT05168982||healthy subjects|
62668436|NCT00977561|EXPERIMENTAL|Arm A|Figitumumab (CP-751,871) Plus Chemotherapy \[Cisplatin (Or Carboplatin) And Etoposide\] All drugs to be administered on a 21 day cycle
62668437|NCT00977561|ACTIVE_COMPARATOR|Arm B|Chemotherapy \[Cisplatin (Or Carboplatin) And Etoposide\] All drugs to be administered on a 21 day cycle
62668438|NCT05863416|ACTIVE_COMPARATOR|Group Saline|Propofol-based total intravenous anesthesia with saline infusion
62668439|NCT05863416|EXPERIMENTAL|Group Dexmedetomidine|Propofol-based total intravenous anesthesia with dexmedetomidine infusion
62668440|NCT05849753||T1DM lower SES|Type 1 diabetes of lower SES, including AA and Latino racial/ethnic minorities, who are in suboptimal diabetes control.
62106448|NCT02434718|EXPERIMENTAL|Cohort 4|IV infusion in cohorts assigned to mid dose; 1 participant per cohort will receive placebo
62298222|NCT00492219|NO_INTERVENTION|2|Healthy volunteers that are not undergoing knee replacement surgery
62298223|NCT00492219|EXPERIMENTAL|3|Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
62298224|NCT00492219|EXPERIMENTAL|4|Patients undergoing partial knee replacement with the Vanguard M implant system
62298225|NCT06656091|EXPERIMENTAL|simmitinib|simmitinib 6mg,QD ,3 weeks on 1 week off
62298226|NCT06656091|ACTIVE_COMPARATOR|investigator's choice of chemotherapy|docetaxel injection 75mg/m\^2,d1,every 3 weeks；or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
62298227|NCT01903876|PLACEBO_COMPARATOR|General Health promotion|A 3-hour general mental health web-based program.
62298228|NCT01903876|EXPERIMENTAL|Bystander & Sexual Violence Prevention|A 3-hour web-based program designed to teach male college student bystanders to intervene.
62298229|NCT01810809|ACTIVE_COMPARATOR|Articular Lavage|Patients from Group Zero will receive articular lavage with saline injection
62668441|NCT04757584|ACTIVE_COMPARATOR|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers."
61913531|NCT03693729|ACTIVE_COMPARATOR|Active DLPFC after task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min after the memory and metamemory task and during a filler task.
61913532|NCT03693729|SHAM_COMPARATOR|Sham DLPFC during task|Sham HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
61913533|NCT04652739|EXPERIMENTAL|Lycopene|
61913534|NCT04652739|ACTIVE_COMPARATOR|Corticosteroids|
61913535|NCT01143233|ACTIVE_COMPARATOR|control formula group|infants are fed a commercial, hydrolysed formula during the first 4 month of life, according to protocol
61913536|NCT01143233|EXPERIMENTAL|intervention formula 1 group|infants are fed hydrolyzed infant formula with different protein content during the first 4 month of life, according to protocol
61913537|NCT01143233|EXPERIMENTAL|intervention formula 2 group|infants are fed hydrolyzed infant formula with different protein content with pro- and prebiotics during the first 4 month of life, according to protocol
61913538|NCT01143233|EXPERIMENTAL|intervention formula 3 group|infants are fed hydrolyzed instant formula with different protein content with pro- and prebiotics during the first 4 months of life, according to protocol
61913539|NCT01143233|NO_INTERVENTION|Reference group|infants are breast fed
62469274|NCT03217903|EXPERIMENTAL|Patients with High-risk MDS With Excess Blasts|
62469275|NCT00486395|ACTIVE_COMPARATOR|1|Mechanical ventilation
62469276|NCT00486395|EXPERIMENTAL|2|CPAP
62469277|NCT01518439|EXPERIMENTAL|neuromuscular patients|neuromuscular patients with cough inefficiency in a stable respiratory state upon inclusion
62469278|NCT02445339|ACTIVE_COMPARATOR|Intervention Arm: XR-NTX+CM|XR-NTX+CM (Extended Release Naltrexone + Care Management)
62469279|NCT02445339|NO_INTERVENTION|Standard Care Arm|Standard Care/Alcohol-Medical Management (MM) Only
62469280|NCT01348789|EXPERIMENTAL|Hair2Go (Mē)|Treatment with Hair2Go (Mē)device
62469281|NCT02344381|EXPERIMENTAL|Sucrose|Sucrose ingestion post-exercise
62469282|NCT02344381|ACTIVE_COMPARATOR|Glucose|Glucose ingestion post-exercise
62469283|NCT01969747|EXPERIMENTAL|Empagliflozin low|Empagliflozin low once daily
61913540|NCT01566812|EXPERIMENTAL|Breast feeding optimization|
62469284|NCT01969747|EXPERIMENTAL|Empagliflozin medium|Empagliflozin medium once daily
62469285|NCT01969747|EXPERIMENTAL|Empagliflozin high|Empagliflozin high once daily
62469286|NCT01969747|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62469287|NCT01446094|OTHER|single-arm|Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
62469288|NCT01950611|EXPERIMENTAL|Bortezomib in treatment|
62469289|NCT03968601||cohorte 1|Severe primary chronic mitral regurgitation with preserved left ventricular ejection fraction.
62469290|NCT00679640||1|Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
62469291|NCT02723721|EXPERIMENTAL|Picato gel|application on1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
62469292|NCT01324193|OTHER|Pre-diaylsis patients|Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
62469293|NCT01324193|OTHER|Dialysis patients|Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
61913541|NCT01566812|ACTIVE_COMPARATOR|Usual/routine care|
61913542|NCT02890615|EXPERIMENTAL|Depression Self-care Intervention (SCI)|"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.~The coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call."
61913543|NCT02890615|NO_INTERVENTION|Control group|"Members of both groups will continue to receive usual care for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment."
62737237|NCT04224831|ACTIVE_COMPARATOR|Before application|"The chronic CSCR cases included here meet one or more of the following criteria:~* Complaints of recurrent symptoms lasting longer than 3 months;~* Recalcitrant or unresponsive to all known current treatment modalities including PDT and MPL;~* Typical B-scan SD-OCT findings of chronicity such as elongation of photoreceptor outer segments indicating chronic nature of sub-macular fluid and/or the presence of serous flat-irregular RPED and focal areas of thickened RPE that lie below the collection of SRF;~* Widespread RPE/photoreceptor damage, RPE mottling and atrophy along with chronic submacular fluid;~* Widespread multifocal areas of chronic serous retinal detachment and/or flat-irregular RPEDs in those eyes that effective and reliable laser application is impossible."
61913544|NCT04732000|ACTIVE_COMPARATOR|N-acetyl cysteine|N-acetyl cysteine will be administered as follows: A loading dose of 50 mg/kg will be started as a 1-hour infusion before surgical incision, and will be followed by a maintenance dose of 50 mg/kg administered over 4 hours.
61913545|NCT04732000|PLACEBO_COMPARATOR|Normal Saline|Normal will be administered as follows: A normal saline infusion will administered at a rate and duration to mimic the N-acetyl cysteine administration.
61913546|NCT03707028|EXPERIMENTAL|Rivoceranib with Paclitaxel|Participants will receive oral daily doses of rivoceranib per 28-day cycle (as its mesylate salt) with a fixed dose of paclitaxel given intravenously on Day 1, Day 8, and Day 15 of the 28-day cycle.
62106449|NCT03092557|EXPERIMENTAL|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
62106450|NCT06631157||Coronary Artery Disease (CAD)|
62106451|NCT04167709|EXPERIMENTAL|Allocated CHS nurses|Primary and secondary baseline data are collected from the allocated CHS nurses before the study starts. The CHS nurses are then given the educational intervention and afterwards primary and secondary outcomes are collected again.
62106452|NCT03787875||Control|The control group included 10 periodontally healthy subjects without signs or symptoms of periodontal disease.
62469294|NCT03694782||Experimental group|Gardeners starting gardening in a community garden in Montpellier (France)
62469295|NCT03694782||Control Group|Volunteers living in the same neighborhoods but with no experience in community gardening.
62469296|NCT05041127|EXPERIMENTAL|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.
61913547|NCT05680805|EXPERIMENTAL|PCOS|Participants with PCOS
61919873|NCT06516341||UC patients|patients with histologically confirmed UC undergoing intestinal resection due to stricturing disease. These patients will be divided into two groups: patients with postoperative recurrence and 5 without (control arm)
62106453|NCT03787875||Study|"The study group included 15 subjects diagnosed with mild or advanced chronic periodontitis. Each periodontal patient had one non-affected single-rooted tooth (healthy site) and another single-rooted tooth with periodontitis (periodontitis site) with the following features:~Healthy site: a single-rooted tooth with probing depths below or equal to 3 mm without recession and without bleeding on probing.~Periodontitis site: another single-rooted tooth from the same patient with clinical attachment loss equal to or greater than 6 mm and bleeding upon probing."
62106454|NCT01061229|EXPERIMENTAL|Homeopathic drug, potency C12|
62106455|NCT01061229|PLACEBO_COMPARATOR|Placebo|
62106456|NCT04708743||CKD group|patients with CKD stage 3-5 including dialysis, followed tongue images by Automatic Tongue Diagnosis System
62469297|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
62469298|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
62668442|NCT04757584|ACTIVE_COMPARATOR|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers."
62668443|NCT04599218|EXPERIMENTAL|Males with Prostate Cancer|Each participant will receive standard of care ultrasound guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy.
62668444|NCT02713841|EXPERIMENTAL|Inhaled insulin (LOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a low output mesh (aerosol particles sized 3.5-4.0 μm)
62668445|NCT02713841|EXPERIMENTAL|Inhaled insulin (MOM1)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
62668446|NCT02713841|EXPERIMENTAL|Inhaled insulin (MOM2)|repeat of single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
62668447|NCT02713841|EXPERIMENTAL|Inhaled insulin (HOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a high output mesh (aerosol particles sized 5.0-5.5 μm)
62668448|NCT02713841|ACTIVE_COMPARATOR|subcutaneous insulin lispro (LIS)|single 6 unit dose of insulin lispro administered subcutaneously
62668449|NCT02388789|EXPERIMENTAL|active movement|use a light treadmill run to raise feet temperature
62298230|NCT01810809|EXPERIMENTAL|Group 1|Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
62469299|NCT01921062|NO_INTERVENTION|Control|Patients allocated to the control group only receive standard treatment.
61919874|NCT06516341||CD patients|patients with histologically confirmed CD undergoing intestinal resection due to stricturing disease. Divided into two groups: patients with postoperative recurrence and 5 without (control arm)
62106457|NCT04708743||Health group|patients who had no past history or systemic disease, CKD followed tongue images by Automatic Tongue Diagnosis System
62469300|NCT01921062|EXPERIMENTAL|Motor imagery|Patients allocated to this arm perform kinesthetic motor imagery during the immobilisation period.
62469301|NCT01950637||Patients with type 2 diabetes mellitus (T2DM)|
62668450|NCT01435915|EXPERIMENTAL|Subjects receiving ropinirole|Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
62668451|NCT06386549|EXPERIMENTAL|tele-rehabilitation|experimental group received an 12-week tele-rehabilitation program, which included face-to-face access to silicone pads, pressure garments, splint and other tools necessary for burn recovery. The tele-rehabilitation program was used for intervention and regular follow-up.
62668452|NCT06386549|ACTIVE_COMPARATOR|routine post-discharge rehabilitation|The control group also received an 12-week follow-up, but only on the basis of face-to-face access to silicone pads, pressure garments, splint and other tools necessary for burn recovery.
62737238|NCT04224831|ACTIVE_COMPARATOR|After application|The changes in SMT, CMT, DRCD, and BCVA before and after the interventions were compared.
62106458|NCT00588965|PLACEBO_COMPARATOR|1|Subjects are assigned to placebo.
62106459|NCT00588965|ACTIVE_COMPARATOR|2|Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.
62106460|NCT00466791|ACTIVE_COMPARATOR|Methylphenidate Transdermal System|Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
62106461|NCT00466791|PLACEBO_COMPARATOR|Placebo|Transdermal patch, 0mg, daily for 11 weeks
62106462|NCT06631495||HPV infection|patients with HPV infection
62298231|NCT01810809|EXPERIMENTAL|Group 2|Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
62298232|NCT01810809|EXPERIMENTAL|Group 3|Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
62298233|NCT01667848|EXPERIMENTAL|group B: Insufflation with warm gas|Insufflation with warmed, humidified carbon dioxide insufflation during laparoscopic cholecystectomy using the optitherm® device attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
62469302|NCT01950637||Healthcare professionals (HCPs)|
61913548|NCT03367247|EXPERIMENTAL|Bolster|"* Bolster provides participants with longitudinal nursing support across care settings,~* A smartphone-based symptom management app,~* A print and web-based symptom management toolkit,~* Advance care planning to ensure that the patient receives care that is congruent with her informed preferences~* BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks~* Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
61913549|NCT03367247|OTHER|Enhanced Discharge Planning (EDP)|"* Medication education,~* Self-management strategies for symptoms,~* Skills training,~* A list of red flag symptoms and numbers for who to call"
62106463|NCT04822129|ACTIVE_COMPARATOR|Treatment as usual|Intervention for TAU group: Actual participation in the intervention will begin with the first videoconference. The general format for each conference will be a brief presentation (10-15 minutes) by Dr. Ownby on a specific topic related to brain health, with the remainder of the time spent in discussion of the topic's importance and in answering participants' questions about the topic or about any other concerns they have related to developing a brain healthy lifestyle. The first videoconference will also provide participants with an overview of the daily log form, instructions for completing it and entering results every week in RedCap, and a reminder on the process of compensation for completion of the logs.
62668453|NCT01018953|EXPERIMENTAL|BIM 23A760|This dose adaptive study is planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed are 1, 2, 4, 6 and 8 mg, however, the maximum starting dose will be 4 mg. The starting dose of the first cohort will be 1 mg; the first cohort will include at least five patients. After the first fifteen patients have been treated for 4 weeks, the results will be reviewed by a Data Review Committee. An extension phase (Part B) is planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).
62668454|NCT04954820|EXPERIMENTAL|Experimental arm|2 additional infusions of Lutathera® according to the marketing authorization schema
62668455|NCT04954820|NO_INTERVENTION|Control arm|No treatment with active monitoring (clinical, biological and radiological follow-up) every 2 months.
61913550|NCT02558829|EXPERIMENTAL|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
62668456|NCT06413407|ACTIVE_COMPARATOR|Tai Chi Exercise Group|As an intervention for this group, only Tai Chi Exercise will be applied.
62668457|NCT06413407|ACTIVE_COMPARATOR|Receptive Music Therapy Group|As an intervention for this group, only Receptive Music Therapy Group will be applied.
61913551|NCT02558829|EXPERIMENTAL|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
61913552|NCT04426760||Women with submucosal leiomyoma(s)|Women with submucosal leimyomas undergoing hysteroscopical removal of the leiomyoma
62668458|NCT06413407|EXPERIMENTAL|Experimental|As an intervention, both Tai Chi Exercise and Receptive Music Therapy will be applied to this group.
62668459|NCT06413407|NO_INTERVENTION|Control|No intervention will be applied to this group.
61913553|NCT04426760||Women with intramural leiomyomas|Women with intramural leiomyomas undergoing myomectomy
61913554|NCT04426760||Infertility patients|Patients treated at the Department for Reproductive Medicine at the Oslo University hospital failing to conceive after 3 or more embryo transfers with good quality embryos.
62106464|NCT04822129|EXPERIMENTAL|Cogtrastim model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model. Early videoconference sessions will also focus on strategies for behavior change, including realistic goal setting, problem solving about possible difficulties, and assistance in formulating a written plan to improve brain health. Participants will be encouraged to develop a written program for brain health and to also develop self-monitoring habits.
62668460|NCT05141747|EXPERIMENTAL|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
62737239|NCT04033614|EXPERIMENTAL|Patients with Laparostoma|"Patients needing a laparostoma will be treated with the fasciotens abdomen device. The distance between the fasciae will be measured frequently using a ruler.~12 months after the treatment an ultrasound measurement will be performed to assess hernia formation"
61913555|NCT04426760||Fertile women|Healthy, volunteering women with proved fertility with 1 or more deliveries and no history of infertility
61913556|NCT06080672|EXPERIMENTAL|Group 1 (dental examination-training-tooth brushing)|Students, whose first records (plaque index, gingival index) are taken after the examination by the periodontology specialist, will be taught how to brush their teeth with the Modified Bass Technique and how to use dental floss/interdental brush. Students will then be asked to brush their teeth.
62106465|NCT04310579|NO_INTERVENTION|Lead-In|Read Rebreathing Reproducibility Assessment
61913557|NCT06080672|EXPERIMENTAL|Group 2 (dental examination-training-plaque disclosing-tooth brushing)|The students, whose initial records (plaque index, gingival index) are taken after the examination by the periodontology specialist, will be taught how to brush their teeth with the Modified Bass Technique and how to use dental floss/interdental brush. After staining the teeth with a plaque disclosing agent, they will be shown in the mirror. Then the students will then be asked to brush their teeth.
61913558|NCT04122456|EXPERIMENTAL|Day Shift Work Schedule|Day shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
61913559|NCT04122456|EXPERIMENTAL|Night Shift Work Schedule|Night shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
61913560|NCT01700868|EXPERIMENTAL|Vegan Group|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
61913561|NCT01700868|ACTIVE_COMPARATOR|American Diabetes Association guidelines|Participants will follow ADA diet according to ADA regulations. This group will also receive weekly nutrition classes.
62106466|NCT04310579|ACTIVE_COMPARATOR|Part 1 Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) tablets and intravenous (IV) placebo 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day.~Note: Initial doses of oxycodone will be 10 mg, but may be increased to 15 mg if necessary based on criteria specified in protocol. Initial doses of midazolam will be 0.0375 mg/kg but may be increased to 0.075 mg/kg based on criteria specified in protocol."
62298234|NCT01667848|EXPERIMENTAL|group A: Insufflation with cold gas|group A: Insufflation with cold gas during laparoscopic cholecystectomy, the use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A
62298235|NCT01851096|EXPERIMENTAL|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
62298236|NCT06129084||Metastatic Bladder Cancer|Patients with metastatic bladder cancer who will have archival tissue sent for FGFR testing.
62298237|NCT05157633||Controls|Children without eating difficulties
62106467|NCT04310579|ACTIVE_COMPARATOR|Part 2 Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
62668461|NCT03061019|ACTIVE_COMPARATOR|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
62668462|NCT03061019|EXPERIMENTAL|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
62668463|NCT03061019|NO_INTERVENTION|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
62106468|NCT06530030||Cohort|patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa
62298238|NCT05157633||Patients|Children with eating difficulties
62668464|NCT01873885|EXPERIMENTAL|Cohort 1: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 1 - Single 30 minute infusion Vasomera (PB1046) at 0.01 mg/kg diluted in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
62668465|NCT01873885|EXPERIMENTAL|Cohort 2: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 2 - Single 30 minute infusion Vasomera (PB1046) at 0.005mg/kg in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
61913562|NCT01940978|PLACEBO_COMPARATOR|Control|Methylphenidate ER QD placebo BID
61913563|NCT01940978|ACTIVE_COMPARATOR|Methylphenidate ER, cyproheptadine 2.5mg|Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID
61913564|NCT01940978|ACTIVE_COMPARATOR|Methylphenidate ER, cyproheptadine 5mg|Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID
62298239|NCT00960076|EXPERIMENTAL|1|Saxagliptin
62298240|NCT00960076|ACTIVE_COMPARATOR|2|Metformin Extended Release
61913565|NCT05172479||Positive qSOFA|Adult patients with suspected infection and a qSOFA score ≥ 2 at the triage in the ED who are planned for hospitalization
62298241|NCT02515240|ACTIVE_COMPARATOR|healthy controls|healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.
62298242|NCT02515240|ACTIVE_COMPARATOR|newly diagnosed HIV >200|Newly diagnosed HIV positive patients with CD4 count \>200, immunized with one shot of PPV23 vaccine.
62298243|NCT02515240|ACTIVE_COMPARATOR|newly diagnosed HIV <200|Newly diagnosed HIVpositive patients with CD4 count \<200, immediately immunized with one shot of PPV23 vaccine.
62298244|NCT02515240|ACTIVE_COMPARATOR|newly diagnosed HIV <200 delayed|Newly diagnosed HIV positive patients with CD4 count \<200 delayed immunization with one shot of PPV23 vaccine, treated for 6-12 months with Highly Active Anti-Retroviral Therapy (HAART) first.
62298245|NCT02515240|ACTIVE_COMPARATOR|HAART experienced HIV>200|HIV positive, on HAART treatment for 5 years, nadir CD4 count \<200, but at present CD4 count is \>200, immunized with one shot of PPV23 vaccine.
62298246|NCT02515240|ACTIVE_COMPARATOR|HAART experienced HIV<200|HIVpositive, on HAART treatment for 5 years, nadir CD4 count \<200, and at present CD4 count is \<200, immunized with one shot of PPV23 vaccine.
62298247|NCT06292897||obese individuals [Body Mass Index (BMI) > 30 affected by prostate cancer|
62298248|NCT06292897||normal-weight individuals [18 < BMI < 25] affected by prostate cancer|
62298249|NCT04299529|EXPERIMENTAL|HTM plus UPP|Urinary proteomic profiling administered on top of home blood pressure telemonitoring and guideline-endorsed non-pharmacological and pharmacological management of risk factors
62298250|NCT04299529|OTHER|HTM alone|Home blood pressure telemonitoring administered on top of non-pharmacological and pharmacological management of risk factors
62298251|NCT01818544|EXPERIMENTAL|BAY85-8501|
62298252|NCT01818544|PLACEBO_COMPARATOR|Placebo|
61913566|NCT05172479||Negative qSOFA|Adult patients with suspected infection and a qSOFA score \< 2 at the triage in the ED who are planned for hospitalization
62106469|NCT03581968|EXPERIMENTAL|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
62668466|NCT01873885|EXPERIMENTAL|Cohort 3: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 3 - Single 30 minute infusion Vasomera (PB1046) at 0.02mg/kg 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
61913567|NCT05172479||Positive SIRS|Adult patients with suspected infection and a SIRS criteria ≥ 2 at the triage in the ED who are planned for hospitalization
62298253|NCT04224363|EXPERIMENTAL|Downward Staining|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
62298254|NCT04224363|EXPERIMENTAL|Upward Staining|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
62469303|NCT03598374|EXPERIMENTAL|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
62469304|NCT03598374|PLACEBO_COMPARATOR|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
62106470|NCT03581968|EXPERIMENTAL|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
62106471|NCT06630351|EXPERIMENTAL|Supportive Care (MCP-C)|Caregivers participate in MCP-C virtual group discussion sessions over 90 minutes each and complete reading exercises and workbook assignments once weekly for 8 weeks throughout the study.
62106472|NCT02860260|EXPERIMENTAL|Patients with fibrinolysis|
62106473|NCT02860260|PLACEBO_COMPARATOR|Patients without fibrinolysis|
62106474|NCT05790941|EXPERIMENTAL|Topical Latanoprost/Minoxidil formulation|8 participants: Topical Latanoprost/Minoxidil formulation applied to both eyebrows once a day for 90 days
62106475|NCT05790941|PLACEBO_COMPARATOR|Control Group|4 participants: Vehicle applied to both eyebrows once a day for 90 days
62106476|NCT02144935||myelitis, transverse or acute flaccid myelitis|Observational study with online survey participation highlighting outcomes recovery. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks how the child is doing after hospitalization within 6 months of diagnosis, and every 4 months until study end in 2024.
62298255|NCT06417632|EXPERIMENTAL|Graded monolithic Zirconia Crowns|3Y-TZP/5Y-TZP zirconia crown
62469305|NCT06359847|EXPERIMENTAL|ST-1898|All participants will be administered with ST-1898 orally at 180mg once daily during the study, until disease progression or intolerable toxicity.
62469306|NCT02260830|EXPERIMENTAL|Treatment Period A|1 reference treatment (2 mg Lu AF11167 immediate release hard capsule) + 5 different test prototype formulations of Lu AF11167
62668467|NCT02763995|EXPERIMENTAL|Pharmaceutical care|Dader method. Health education for lifestyle modification. Improve adherence. Resolution of negative outcome associated with medication.
62106477|NCT05289830|EXPERIMENTAL|Participants receiving Escitalopram|
62106478|NCT05289830|PLACEBO_COMPARATOR|Participants receiving Placebo|
62298256|NCT06417632|ACTIVE_COMPARATOR|Conventional monolithic Zirconia Crowns|3Y-TZP zirconia crowns
62298257|NCT00337389|EXPERIMENTAL|1|CoFactor, 5-FU, Avastin
62298258|NCT00337389|ACTIVE_COMPARATOR|2|Leucovorin, 5-FU, Avastin
62469307|NCT02260830|EXPERIMENTAL|Treatment Period B|Food interaction and multiple dosing of Lu AF11167
62668468|NCT00922051|EXPERIMENTAL|Group 1|Application of Acu-TENS
61913568|NCT05172479||Negative SIRS|Adult patients with suspected infection and a SIRS criteria \< 2 at the triage in the ED who are planned for hospitalization
62106479|NCT01842971|EXPERIMENTAL|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
62668469|NCT00922051|PLACEBO_COMPARATOR|Group 2|
61913569|NCT05172479||Positive NEWS|Adult patients with suspected infection and a NEWS ≥ 5 or red score (i.e., a score of 3 in any one parameter) at the triage in the ED who are planned for hospitalization
62106480|NCT00751790|EXPERIMENTAL|Triptorelin|
62106481|NCT06172660||ARI Cases|Cases will be defined as infants ≤12 months old who had a clinical encounter for acute respiratory illness (ARI) and tested positive for RSV using polymerase chain reaction (PCR).
62106482|NCT06172660||Healthy Controls|Healthy controls will be individually matched to enrolled vaccine failures (immunized and RSV+) by date of birth (±1 month), sex, and immunoprophylactic agent received (i.e., maternal vaccine or monoclonal antibody).
62298259|NCT05195606|NO_INTERVENTION|Control group|There is no standard sensory stimulation program for comatose patients with head trauma in the hospitals where the research will be conducted. Therefore, the control group will receive routine practice.
62298260|NCT05195606|EXPERIMENTAL|Auditory stimulus (Intervention A)|Auditory stimulus for patients in this group
62298261|NCT05195606|EXPERIMENTAL|Tactile stimulus (Intervention B)|Tactile stimulus for patients in this group
62668470|NCT06380608||Local Anesthesia|Patients who will undergo a dental surgery under local anesthesia
62106483|NCT06172660||ARI Controls|Controls will be individuals with ARI who test negative for RSV and will be frequency matched based on time and clinical setting.
62668471|NCT06380608||General anesthesia|Patients who will undergo a dental surgery under general anesthesia
62668472|NCT04008186|EXPERIMENTAL|Omaveloxolone and Multiple Drugs (Part 1)|Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27
62668473|NCT04008186|EXPERIMENTAL|Omaveloxolone & Gemfibrozil (Part 2)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18
62668474|NCT04008186|EXPERIMENTAL|Omaveloxolone and Itraconazole (Part 3)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.
62106484|NCT03370406|NO_INTERVENTION|Control Group|Control group will receive neither 5-fluorouracil (5FU) injection nor topical Imiquimod 5% cream. This group will receive standard of care only. Lesion will be surgical resected on day 21 of study.
62298262|NCT04988373|EXPERIMENTAL|Single aligner appliance|Modified aligner appliance with NiTi springs
62298263|NCT04988373|ACTIVE_COMPARATOR|Traditional fixed appliances|MBT-prescription of metallic brackets.
62298264|NCT06125860|NO_INTERVENTION|Arm 1 (control arm)|In Arm 1 (control arm), participants will receive the standard of antenatal care including iron and folic acid supplementation.
62668475|NCT04008186|EXPERIMENTAL|Omaveloxolone and Verapamil (Part 4)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.
62668476|NCT05842291|EXPERIMENTAL|Active rTMS with short inter-session interval|Patients in this group will receive rTMS intervention with short inter-session intervals.
62668477|NCT05842291|SHAM_COMPARATOR|Sham rTMS with short inter-session interval|Patients in this group will receive sham rTMS intervention with short inter-session intervals.
62668478|NCT05842291|ACTIVE_COMPARATOR|Active rTMS with long inter-session interval|Patients in this group will receive rTMS intervention with long inter-session intervals.
62737240|NCT04169984|ACTIVE_COMPARATOR|Myofunctional Therapy|This therapy consists of the practice of isotonic, isokinetic and isometric exercises that improve mobility and coordination and increase the muscular strength of the orofacial structures that contribute to the obstructive sleep apnea etiopathogenesis.
61913570|NCT05172479||Negative NEWS|Adult patients with suspected infection and a NEWS \< 5 at the triage in the ED who are planned for hospitalization
62106485|NCT03370406|EXPERIMENTAL|5FU Group|5-fluorouracil (5FU) Group participants will receive a 1ml intralesional injection of 5FU 50mg/ml aqueous injectable solution. One injection will be administered weekly for 3 weeks. Injections will occur on d0, d7, and d14. Standard of care will be administered on d21 of study and lesion will be surgical resected.
62106486|NCT03370406|EXPERIMENTAL|5FU + Imiquimod 5% Group|5-fluorouracil (5FU) + Imiquimod 5% cream Group participants will receive intralesional 5FU as in the previous group, additionally participants will also receive three-times-weekly topical application of 5% imiquimod to the same lesion. Standard of care will be administered on d21 of study and lesion will be surgical resected.
62106487|NCT01227707|EXPERIMENTAL|Single Arm|
62106488|NCT05742984|EXPERIMENTAL|25 mg Linaprazan Glurate QD|25 mg ( one 25 mg oral tablet) Linaprazan Glurate QD for 14 days
62106489|NCT05742984|EXPERIMENTAL|50 mg Linaprazan Glurate QD|50 mg (two 25 mg oral tablets) Linaprazan Glurate QD for 14 days
62106490|NCT05742984|EXPERIMENTAL|75 mg Linaprazan Glurate QD|75 mg ( three 25 mg oral tablet) Linaprazan Glurate QD for 14 days
62106491|NCT05742984|EXPERIMENTAL|25 mg Linaprazan Glurate BID|25 mg ( one 25mg oral tablet) Linaprazan Glurate BID for 14 days
62298265|NCT06125860|EXPERIMENTAL|Arm 2 (Targeted BEP based on baseline nutritional status)|
62298266|NCT06125860|EXPERIMENTAL|Arm 3 (Targeted BEP by baseline nutritional status and monthly gestational weight gain monitoring)|
62298267|NCT06125860|EXPERIMENTAL|Arm 4 (universal BEP)|
62298268|NCT04242537|EXPERIMENTAL|High flow oxygen delivery|Oxygen delivery with high flow nasal cannula with head side elevation to 30 degrees
62298269|NCT04242537|EXPERIMENTAL|Low Flow oxygen delivery|Low flow oxygen delivery through nasal cannula with head side elevation to 30 degrees
62298270|NCT04242537|NO_INTERVENTION|Standard practice of care|No oxygen delivery either high flow or low flow through nasal cannula
62308349|NCT04704076|ACTIVE_COMPARATOR|Exclusive Breastfeeding|Recommendation to breastfeed exclusively for 6 months without any other food or fluid except vitamins, minerals and medications
62298271|NCT05418764|EXPERIMENTAL|Intervention group|Participants will receive standardized training by performing five hysterectomies on the Miya Model with a trainer who is a sub-PI at each Institution, with each of these training sessions filmed and then scored by blinded experts - Residents in the simulation arm will train until they reach a score of 27 on the modified Vagina Surgical Skills Index (VSSI)
62298272|NCT05418764|NO_INTERVENTION|Control group|The training will be whatever is standard at their Institution
62298273|NCT02320578|EXPERIMENTAL|3D Laparoscopy|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
62298274|NCT02320578|ACTIVE_COMPARATOR|Standard Laparoscopy|Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
62298275|NCT04837014|EXPERIMENTAL|Acetaminophen and naproxen only arm|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration.
62298276|NCT04837014|ACTIVE_COMPARATOR|Acetaminophen, naproxen and dilaudid arm|Patient allocated to the control group will be discharged home with a prescription for regular acetaminophen, naproxen, and 5 tabs of hydromorphone 1 mg, with instruction to prioritize non opioid analgesic as first line.
62668479|NCT03589053|EXPERIMENTAL|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
62668480|NCT03589053|SHAM_COMPARATOR|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
62298277|NCT03463330|EXPERIMENTAL|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
62469308|NCT04847323|ACTIVE_COMPARATOR|V-bend Bonded Retainer|"The V-bend retainer was bonded in the lingual surface of the anterior teeth. The retainer was constructed using 0.024 stainless steel wires. Differently from the conventional bonded retainers, this retainer presents V-bends in the sagittal direction, parallel to the occlusal plane in each interproximal contact point of the incisors and canines.~The retainers was bonded after adequate etching with phosphoric acid and application of adhesive with a low viscosity resin."
62668481|NCT04373070|EXPERIMENTAL|chatbot-based intervention programme (intervention)|"Participants randomised to the intervention group will receive a CAir desk and a chatbot-based intervention programme for a period of 12 weeks. The CAir desk is supplied to assess HrQoL, physical activity, and spirometry data. The first week is equal to the procedure in the control group (for details see paragraph below) and serves for baseline measurements of daily physical activity. Starting in week 2 of the study duration, participants receive feedback on their daily physical activity through the CAir chatbot application and aim to increase their daily step count by 15% from baseline. Furthermore, the CAir chatbot provides several components of the Living well with COPD programme (e.g. educational content, information on exercise training) to the patient."
62737241|NCT04169984|PLACEBO_COMPARATOR|Placebo|The placebo group will be instructed in simulation exercises that do not alter the function or morphology of the upper airway.
62106492|NCT05742984|EXPERIMENTAL|50 mg Linaprazan Glurate BID|50 mg ( two 25 mg oral tablets) Linaprazan Glurate BID for 14 days
62106493|NCT05742984|EXPERIMENTAL|75 mg Linaprazan Glurate BID|75 mg ( three 25 mg oral tablet) Linaprazan Glurate BID for 14 days
62106494|NCT06110195|EXPERIMENTAL|Escalation Group Dose Level -1|"Participants assigned to this cohort will receive xevinapant 50 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
62106495|NCT06110195|EXPERIMENTAL|Escalation Group Dose Level 0|"Participants assigned to this cohort will receive xevinapant 100 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
62106496|NCT06110195|EXPERIMENTAL|Escalation Group Dose Level 1|"Participants assigned to this cohort will receive xevinapant 150 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
62298278|NCT03463330|SHAM_COMPARATOR|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
61913571|NCT05172479||Positive NEWS2|Adult patients with suspected infection and a NEWS2 ≥ 5 or red score (i.e., a score of 3 in any one parameter) at the triage in the ED who are planned for hospitalization
62106497|NCT06110195|EXPERIMENTAL|Escalation Group Dose Level 2|"Participants assigned to this cohort will receive xevinapant 200 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
62308350|NCT05509608|EXPERIMENTAL|Electroretinogram Signal Quality|Electroretinogram Signal Quality: This Arm will participate in a comparative study using two ERG sensors, one commercially available (ERG Jet Electrode) and one seeking FDA approval (RM Electrode). This will be done by performing standard ERG test protocols with both electrodes worn one at a time, in one eye (random order) in ten healthy (normally-sighted) adult subjects.
62737242|NCT05132400||Pre-Training Arm (Control)|To receive physical therapy treatment as usual, before PiPT occurs
61913572|NCT05172479||Negative NEWS2|Adult patients with suspected infection and a NEWS2 \< 5 at the triage in the ED who are planned for hospitalization
61913573|NCT05172479||Positive MEWS|Adult patients with suspected infection and a MEWS ≥ 5 at the triage in the ED who are planned for hospitalization
61913574|NCT05172479||Negative MEWS|Adult patients with suspected infection and a MEWS \< 5 at the triage in the ED who are planned for hospitalization
61913575|NCT03521895||Treatment naïve wAMD|Treatment naïve patients with wAMD treated with IVT aflibercept from the two underlying studies PERSEUS and RAINBOW
61913576|NCT00634270|EXPERIMENTAL|Sirolimus|"Design~* Sirolimus oral solution will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment course) with pharmacokinetically-guided dosing.~* Disease status will be evaluated using volumetric MRI analysis at regular intervals.~* The plasma pharmacokinetics and pharmacodynamics of sirolimus will be evaluated, as will pharmacogenetic polymorphisms and their influence on the metabolism of sirolimus in this patient population.~* Pain reduction and quality of life outcomes will also be assessed.~* Toxicity of chronic sirolimus administered will be evaluated using physical and laboratory evaluations."
61913577|NCT00424255|EXPERIMENTAL|Lapatinib+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus lapatinib 1500 mg once daily for 6 to 7 weeks, followed by lapatinib 1500 mg once daily for one year.~Chemoradiotherapy=total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of radiotherapy. Lapatinib is also given at 1500 mg once daily for 3-7 days prior to the start of chemoradiotherapy."
61913578|NCT00424255|PLACEBO_COMPARATOR|Placebo+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus placebo once daily for 6 to 7 weeks, followed by placebo once daily for one year.~Chemoradiotherapy = total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of treatment. Placebo is also given once daily for 3-7 days prior to the start of chemoradiotherapy."
61913579|NCT06372743|NO_INTERVENTION|Control group|Control arm: Patients will be assigned to a consultation model of CKD care which consists of clinic reviews by a nephrologist, which is as per current standard of care. The frequency of reviews, which is at the discretion of the nephrologist, is typically scheduled at 4 to 6 monthly intervals. Each consultation lasts an average of 10 to 15 minutes.
61913580|NCT06372743|EXPERIMENTAL|INTEGREAT-CKD Intervention|Intervention arm: Patients will be assigned to a consultation model of CKD care which consists of 30-minute clinic reviews led by an advanced practice nurse (APN), with both on-site and remote support from a nephrologist, at 3 monthly intervals. Patients will be required to monitor certain clinical parameters (one of or a combination of blood pressure, glucose trend or weight trend) between clinic reviews, tapping on a telehealth platform for transmission of data to an assigned community-based nurse, who will provide oversight of these readings, with regular escalation to the APN/nephrologist. The on-site remote support, in the form of telehealth monitoring, will be concurrent between clinic consults, with frequency of monitoring individualized as per patient's needs.
61913581|NCT02925533|EXPERIMENTAL|B-701 and Pembrolizumab|"* B-701 will be administered every 3 weeks intravenously~* Pembrolizumab will be administered every 3 weeks intravenously"
61913582|NCT03330002||CE-marked MANTA vascular closure devices per IFU|Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.
61913583|NCT03768557|EXPERIMENTAL|Minocycline|single dose of minocycline (200mg)
61913584|NCT03768557|PLACEBO_COMPARATOR|Placebo|lactose pills (400mg)
61913585|NCT00481507|PLACEBO_COMPARATOR|Placebo|
61913586|NCT00481507|EXPERIMENTAL|Kefir|
61913587|NCT02294942|EXPERIMENTAL|RANCAD 500mg|RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.
61913588|NCT02294942|EXPERIMENTAL|RANCAD 1000mg|RANCAD 2 tabs (500 mg), twice daily
61913589|NCT02294942|ACTIVE_COMPARATOR|Placebo|2 tabs, twice daily
62668482|NCT04373070|OTHER|Usual care group (control)|Participants randomised to the control group receive usual care and a CAir desk for a period of 12 weeks. The CAir desk is supplied to assess daily symptom burden, physical activity, and spirometry data. In contrast to the intervention group, participants do not receive feedback or scores of the daily reported CAT and daily physical activity.
62668483|NCT02755090|EXPERIMENTAL|Nitrous oxide and IV saline|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
61913590|NCT04164693|EXPERIMENTAL|anticoagulant group|Patients in the anticoagulant group received low-dose subcutaneous injection of low molecular weight heparin for prevention of AVF thrombosis, starting 12-24 hours after surgery. For patients weighing less than 80kg, enoxaparin sodium 4000IU was administered once daily, while for those weighing over 80kg, enoxaparin sodium 4000IU was administered every 12 hours. After discharge, these patients were switched to oral low-dose warfarin for anticoagulation, with a daily dose of 1.25mg (half tablet) on dialysis days, and 2.5mg/day on non-dialysis days. Patients with significantly excessive body weight may be considered for a daily dose of 2.5mg, with a total treatment duration of 4 weeks.
62469309|NCT04847323|ACTIVE_COMPARATOR|Vacuum-formed Retainer|The removable Vacuum-formed retainers were made of acetate 1mm thickness. They were made at the same appointment of debonding using plaster models. The patients were instructed to use the retainers only during nights.
62469310|NCT06133725|EXPERIMENTAL|ESPB|erector spinae plane block
62668484|NCT02755090|NO_INTERVENTION|Standard Care (IV Sedation and Oxygen)|Within the IV sedation group, women will receive 100mcg fentanyl and 2mg midazolam at least two minutes prior to initiation of the procedure. This group will also receive 100% oxygen by a scented face mask. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
62469311|NCT06133725|ACTIVE_COMPARATOR|TAPB&RSB|transversus abdominis plane block combined with rectus sheath block
62469312|NCT04395677|EXPERIMENTAL|AB-106 （DS-6051b）|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106
62668485|NCT02342951|OTHER|LCI|Measure of lung clearance index
62668486|NCT05847400||CKD patients with T2DM on regular HD|CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD on regular HD at dialysis unit of Assuit University Hospital
62668487|NCT05847400||CKD patients with T2DM not on regular HD|CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD not on regular HD at dialysis unit of Assuit University Hospital
62106498|NCT06110195|EXPERIMENTAL|Dose Expansion|"Participants assigned to this cohort will receive xevinapant at the dose found during escalation phase of study for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
62298279|NCT03855072|EXPERIMENTAL|Customized plate fixation|"Customized Plate fixation of Vertical Ramus Osteotomy after Mandibular Setback~- intervention:~* All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together"
62308351|NCT05509608|EXPERIMENTAL|Ocular Irritation|Ocular Irritation: Ten healthy (normally-sighted) adult subjects will wear the RM Electrode in one eye and the ERG Jet Electrode in the other eye for a total of 60 minutes, in 20-minute sessions with short breaks in between. The eyes will be evaluated for irritation (standard clinical grading scales for bulbar redness, limbal redness, tarsal redness, and slit-lamp examination of corneal staining) after each 20-minute interval.
62668488|NCT04915300|ACTIVE_COMPARATOR|Apabetalone|100mg BID, 24-week (168±3 days) Treatment Period.
62668489|NCT04915300|PLACEBO_COMPARATOR|Placebo|24-week (168±3 days) period.
62668490|NCT00729001|EXPERIMENTAL|Group A|Human Rotavirus Vaccine - Formulation 1
62668491|NCT00729001|EXPERIMENTAL|Group B|Human Rotavirus Vaccine - Formulation 2
62106499|NCT06390891||Patients treated in high-volume pancreatic centers|Patients treated at a hospital performing at least 50 pancreatic resection procedures annually during 2010 to 2018
62668492|NCT00729001|PLACEBO_COMPARATOR|Group C|
62668493|NCT05332795|ACTIVE_COMPARATOR|group 1: gouty patients on metformin.|metformin users: include gouty patients, who will receive metformin tablets (1000 mg) once daily for about 3 months.
62668494|NCT05332795|PLACEBO_COMPARATOR|gouty patients on placebo.|placebo users: include gouty patients, who were on placebo tablets once daily for about 3 months.
62668495|NCT04114370|EXPERIMENTAL|Participants with Glioma|\[F18\]fluciclovine will be utilized to assess tumor viability compared with F-18 FDG PET or diagnostic MRI.
62106500|NCT06390891||Patients treated in low-volume pancreatic centers|Patients not treated at a hospital performing at least 50 pancreatic resection procedures annually during 2010 to 2018
62298280|NCT03855072|ACTIVE_COMPARATOR|maxillomandibular fixation|"Mandibular Setback by Vertical Ramus Ostotmy fixed with Maxillomandibular fixation~- intervention:~* All cases will undergo one surgery under general anesthesia~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint"
62308352|NCT00974779|EXPERIMENTAL|HCO dialyzer|Hemodialysis with the HCO1100 hemodialyzer membrane with high molecular weight cut off.
62668496|NCT01746160|EXPERIMENTAL|C1 Implant|Patient having C1 implant installed.
62668497|NCT04928586|EXPERIMENTAL|Pirfenidone group|CTD-ILD patients treated with DMARDs and pirfenidone
62668498|NCT04928586|ACTIVE_COMPARATOR|No-Pirfenidone group|CTD-ILD patients treated with DMARDs, without pirfenidone
62668499|NCT01182584||Graves' disease|
62668500|NCT01182584||Healthy volunteers|
62668501|NCT01609140|EXPERIMENTAL|A|
62668502|NCT01609140|EXPERIMENTAL|B|
62668503|NCT01609140|EXPERIMENTAL|C|
62308353|NCT00974779|ACTIVE_COMPARATOR|Placebo|Regular dialysis using a polyamide high-flux hemodialyzer
62308354|NCT01975025|EXPERIMENTAL|All study participants|Short daily dialysis for 2 weeks
62668504|NCT01609140|EXPERIMENTAL|D|
62668505|NCT01609140|EXPERIMENTAL|E|
62668506|NCT01609140|PLACEBO_COMPARATOR|F|
62668507|NCT02569983||Observational cohort|Observational study - all suspected or confirmed ovarian cancer patients
62668508|NCT05313464|EXPERIMENTAL|nutrition pushed by parents|enteral nutrition pushed by parents
62668509|NCT05313464|ACTIVE_COMPARATOR|syringe pump|Enteral nutrition with syringe pump
62668510|NCT02499315|EXPERIMENTAL|AMG 357|
62668511|NCT02499315|PLACEBO_COMPARATOR|Placebo|
62668512|NCT04777903||underweight woman with twin pregnancy|underweight (BMI \< 18.5 kg/m2)
62668513|NCT04777903||normal weight woman with twin pregnancy|normal (BMI: 18.5-23.9 kg/m2)
62668514|NCT04777903||overweight and obese woman with twin pregnancy|overweight and obese (BMI ≥24 kg/m2)
62668515|NCT03770975|ACTIVE_COMPARATOR|Delayed implant placement with immediate provisionalization|Single delayed implant placement in the esthetic zone with placing an immediate temporary crown placed within 48 hours after the surgery
62668516|NCT03770975|EXPERIMENTAL|Implant with immediate temporization and soft tissue graft|Single delayed implant placement in the esthetic zone with placing a subepithelial connective tissue graft buccal to the implant and immediate temporary crown within 48 hours after the surgery
62668517|NCT05954689|EXPERIMENTAL|Femoral artery block|An experienced Anesthesiologist will perform the femoral blocks, under ultrasound guidance with a linear probe and a 50mm (millimeters) or 80mm needle. No nerve stimulator will be used during the block. In both groups, femoral nerve block at the nerve sheath will be performed with 20mL (milliliters) 0.5% ropivacaine. In the interventional group, additionally to the previous block, the needle will be retracted and advanced to the antero-medial side of the femoral artery where 10mL 0.5% ropivacaine will be injected after negative aspiration.
62668518|NCT05954689|NO_INTERVENTION|No intervention|
62668519|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
62668520|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
62668521|NCT04705571|EXPERIMENTAL|MorpheusV Applicator (active)|
62668522|NCT03461861|EXPERIMENTAL|AGB101 220 mg, then Placebo|AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
62668523|NCT03461861|EXPERIMENTAL|Placebo, then AGB101 220 mg|Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.
62668524|NCT00696150|PLACEBO_COMPARATOR|loss of resistance|Anterior psoas compartment nerve block inserted using loss of resistance
62668525|NCT00696150|ACTIVE_COMPARATOR|nerve stimulator|Anterior psoas compartment nerve block inserted using nerve stimulator
62668526|NCT00696150|ACTIVE_COMPARATOR|ultrasound|Anterior psoas compartment nerve block inserted using ultrasound
61913591|NCT04164693|OTHER|control group|Patients in the control group did not receive anticoagulants postoperatively, but both groups routinely received antiplatelet therapy.
61913592|NCT02319356|ACTIVE_COMPARATOR|Beetroot juice (BRJ)|beetroot juice
62668527|NCT00327171|EXPERIMENTAL|Aflibercept 2.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
62668528|NCT00327171|EXPERIMENTAL|Aflibercept 4.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
62668529|NCT00993889|EXPERIMENTAL|VR during Physical Therapy|The subject will receive virtual reality during painful physical therapy sessions.
62668530|NCT00993889|EXPERIMENTAL|VR background pain|The subjects receives virtual reality, not during a physical therapy procedure, another time of the day for background pain.
62668531|NCT00993889|EXPERIMENTAL|No VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
62737243|NCT05132400||Post-Training Arm (Intervention)|
61913593|NCT02319356|PLACEBO_COMPARATOR|Placebo (PL)|placebo juice
61913594|NCT02528721|EXPERIMENTAL|Initial Diagnosis Subjects|Patients with clinical indication for H.pylori infection
61913595|NCT02528721|EXPERIMENTAL|Post Therapy Subjects|Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
61913596|NCT01223443|EXPERIMENTAL|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
61913597|NCT01223443|NO_INTERVENTION|Standard medical treatment|
62298281|NCT04855695|EXPERIMENTAL|Acalabrutinib, Venetoclax, and Obinutuzumab|"This study will consist of 3 parts (Parts A, B, and C). In the relapsed/refractory (R/R) MCL setting (Part A), the phase 1 portion consists of a dose finding stage to determine the recommended phase 2 dose (RP2D). It will follow a 3+3 dose finding schema, with a safety pause and evaluation after the first 3 participants have completed through cycle 5, day 1. If there are no dose limiting toxicities (DLTs), an additional 3 participants will be treated and if there are 0 or 1 DLTs seen, the RP2D will have been determined.11 participants will be enrolled in the Part A expansion cohort.~Part B will enroll 24 participants with untreated mantle cell lymphoma who are transplant ineligible and/or TP53 mutated.~Part C will enroll 12 participants with untreated mantle cell lymphoma who are transplant eligible and TP53 wild type.~Each study drug is given according to a different schedule. Each treatment cycle lasts 28 days (4 weeks).~* Acalabrutinib:~* Obinutuzumab:~* Venetoclax:"
62298282|NCT04986501|EXPERIMENTAL|MucoPEG|Arm being compared to against Biotene
62298283|NCT04986501|ACTIVE_COMPARATOR|Biotene|Arm being compared against MucoPEG
61913598|NCT00882570|EXPERIMENTAL|1|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
61913599|NCT00882570|ACTIVE_COMPARATOR|2|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
61913600|NCT05895799|ACTIVE_COMPARATOR|Clinical teaching from an expert after LC1|Medical students who had early intervention, i.e. teaching from an expert trainer, in the randomized controlled waitlist design.
61913601|NCT05895799|ACTIVE_COMPARATOR|Clinical teaching from an expert after LC2|Medical students who had a late intervention, i.e. teaching from an expert trainer, in the randomized controlled waitlist design.
61913602|NCT04352153|EXPERIMENTAL|Single-use group|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
61913603|NCT04352153|EXPERIMENTAL|Research group|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
61913604|NCT04668612|ACTIVE_COMPARATOR|Standard-bolus|Standard boluses for all meal
61913605|NCT04668612|EXPERIMENTAL|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m
61913606|NCT00280111|EXPERIMENTAL|1|116E AGMK
61913607|NCT00280111|EXPERIMENTAL|2|I321 AGMK
61913608|NCT00280111|PLACEBO_COMPARATOR|3|Placebo
61913609|NCT00576680|EXPERIMENTAL|Temozolomide with RAD001|
61913610|NCT04597060|EXPERIMENTAL|Split Keloid - first side|
61913611|NCT04597060|EXPERIMENTAL|Split Keloid - second side|
61913612|NCT03893344||Cases|patients with Multiple Sclerosis in different stages diagnosed clinically according to revised McDonald's criteria 2010
61913613|NCT03893344||Control|Healthy peaple
61913614|NCT04787523||Patients with pathological response to treatment|Response evaluated using the pathology report
61913615|NCT03393533|OTHER|Group I|Extraction third molar with pre and postoperative evaluation of edema, pain and trismus
61913616|NCT03393533|ACTIVE_COMPARATOR|Group II|Extraction third molar with therapeutic bandage pre and postoperative evaluation of edema, pain and trismus
61913617|NCT05832554|ACTIVE_COMPARATOR|Nasopharyngeal airway|Patients with nasopharygeal airway placed
61913618|NCT05832554|ACTIVE_COMPARATOR|Orophryngeal airway|Patients with oropharygeal airway placed
61913619|NCT03920904||Bupivacaine dosage in PIFB block|The pharmacokinetics of bupivacaine 0.25% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following a PIFB block will be determined by the collection of blood samples at predetermined time points.
61913620|NCT01525199||Case|
61913621|NCT01525199||Control|
61913622|NCT00177047|EXPERIMENTAL|Chemotherapy and Transplant Treatment|Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\^2). Post-transplant maintenance therapy is then prescribed if appropriate.
61913623|NCT06409793|EXPERIMENTAL|mHealth|"Participants will undertake a 3-month structured exercise and PA intervention, supported by an exercise specialist. Participants will have 5 exercise consultations. Participants will receive a personalised progressive exercise programme. The aim will be to increase exercise intensity and duration during the first 3-months; aiming to meet the aerobic training guidelines of 3-4 sessions of at least 40 minutes at 85-90% heart rate maximum or of vigorous intensity. During follow-up, the aim will be to at least maintain this level of exercise.~Participants will receive 1) a wrist worn fitness watch (Polar Ignite), featuring a 3d accelerometer and optical heart rate monitor, and 2) a smartphone app for participants (Polar Flow - Sync \& Analyse). These will be synced, allowing data to be transferred to the exercise specialist, who will created monitor pre-set exercise sessions."
61913624|NCT06409793|ACTIVE_COMPARATOR|Exercise Counselling|"Participants will undertake the same 3-month structured exercise and PA intervention, supported by an exercise specialist, but without the use of mHealth technology to support the prescription and adherence to the exercise.~Participants will be monitored using a wrist worn fitness watch, but will not receive feedback or have pre-set exercise sessions through the mHealth technology"
61913625|NCT06409793|NO_INTERVENTION|Active control|Participants will receive no exercise or PA intervention. Participants will continue with regular PA behaviours as an active control comparator. Participants in the control group will be monitored at the start and the end of the 3 months intervention period (2 weeks) to determine habitual PA and exercise levels
61913626|NCT05337904|ACTIVE_COMPARATOR|On-Stimulation|"Disease condition is assessed with stimulation turned on"
61913627|NCT05337904|PLACEBO_COMPARATOR|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
61913628|NCT00735189|EXPERIMENTAL|1|Patient continues to receive anticoagulation care from the Anticoagulation Management Service
61913629|NCT00735189|ACTIVE_COMPARATOR|2|Patient receives anticoagulation care from their usual primary care physician
61913630|NCT04607278|EXPERIMENTAL|Probiotic|Oral probiotic supplementation (Pro-Probiotic) was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
61913631|NCT04607278|ACTIVE_COMPARATOR|Prebiotic|The prebiotic (Inulin) was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
61913632|NCT04607278|PLACEBO_COMPARATOR|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
61913633|NCT05409378|EXPERIMENTAL|The HLT® Meridian® TAVR Valve|Transcatheter aortic valve replacement with the HLT Meridian TAVR Valve
62469313|NCT01961973|ACTIVE_COMPARATOR|Cultured chondrocytes|"Cultured chondrocytes:~This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery."
61913634|NCT00535574|PLACEBO_COMPARATOR|Bexarotene (Targretin LGD1069)|
61913635|NCT00535574|ACTIVE_COMPARATOR|placebo|
61913636|NCT01819818||Paliperidone palmitate|
62106501|NCT01052818||Stage IV NSCLC|Stage IV non small-cell lung cancer patients will be recruited for this protocol
62106502|NCT02380742|EXPERIMENTAL|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
62469314|NCT01961973|ACTIVE_COMPARATOR|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
62469315|NCT03557632|EXPERIMENTAL|TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)|Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
62668532|NCT03821532|NO_INTERVENTION|Control group|Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
62668533|NCT03821532|EXPERIMENTAL|Experimental group|Each family will receive a randomized packet containing educational information, rewards charts, an adult literacy test and a constipation action plan tool. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms, adherence to the treatment plan, and action plan utility.
61913637|NCT00075270|EXPERIMENTAL|Arm 1|Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
61913638|NCT00075270|PLACEBO_COMPARATOR|Arm 2|Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo
62106503|NCT02380742|PLACEBO_COMPARATOR|Placebo|4 mL of placebo cream
62106504|NCT05386758|EXPERIMENTAL|Panel A - Severe Renal Impairment Group|Participants with severe renal impairment will receive a single oral 800 mg dose of molnupiravir.
61913639|NCT02217072|NO_INTERVENTION|Control|Control
61913640|NCT02217072|EXPERIMENTAL|Parents as Tutors|Educational support intervention
62106505|NCT05386758|EXPERIMENTAL|Panel B - Healthy Control Group|Participants in the healthy mean matched control group will receive a single oral 800 mg dose of molnupiravir.
62106506|NCT04428554|NO_INTERVENTION|Control arm|Standard of care
62106507|NCT04428554|EXPERIMENTAL|Experimental arm|
62106508|NCT00554801|EXPERIMENTAL|Blast|The study group includes soldiers who have recently been exposed to a high-explosive blast while stationed in Iraq or Afghanistan. They will be recruited at Walter Reed Army Medical Center, Washington, DC. They will undergo audiological testing.
62106509|NCT00554801|ACTIVE_COMPARATOR|Control|Control group are subjects matched to the experimental group by age, gender, and hearing loss, but who have not been exposed to a blast. They will undergo the same audiological testing as the experimental group
62106510|NCT04312568|EXPERIMENTAL|Fadanafil|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
62106511|NCT04312568|PLACEBO_COMPARATOR|Placebo|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
62106512|NCT03126084|ACTIVE_COMPARATOR|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
62106513|NCT03126084|ACTIVE_COMPARATOR|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
62106514|NCT03126084|ACTIVE_COMPARATOR|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
62106515|NCT02488174|ACTIVE_COMPARATOR|Standard Care|The pre-intervention control condition will be usual care: that is, clinicians practice as usual without clinician notification of risk and without prompting on care practices as recommended by PROOFcheck.
62106516|NCT02488174|EXPERIMENTAL|PROOFcheck|The intervention for this study will consist of 3 parts: 1) Education of clinicians on prevention of severe ARF and MOF in and out of the ICU, and best practice with regards to patients with severe ARF; 2) Clinicians will be notified that a patient they are taking care of has been identified as being at high risk for developing severe ARF requiring prolong MV; 3) Notified clinicians will be directed to PROOFcheck with a bundle of recommendations for best care for patients with ARF.
62298284|NCT05265650|EXPERIMENTAL|Single Treatment Arm|"Treatment will consist of IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent with systemic administration of nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.~In the initial cohort A, BO-112 will be IT injected on a weekly basis during the first cycle on the accessible lesions, and every 2 weeks thereafter. The minimum dose to be injected per visit is 1 mg (unless injected lesion in case of response, if solitary, becomes smaller than 1.5 cm) and the maximum dose is 2 mg (3.4 mL), distributed in the different lesions.~Stereotactic ablative radiotherapy (SABR) will be initiated on week 3.~In the cohort B, BO-112 and SABR will be administered as described previously.~Nivolumab will be administered at the dose of 240 mg every 2 weeks in both cohorts, starting at cycle 4 (week 7) in cohort A and at cycle 3 (week 5) in cohort B."
62298285|NCT04207398|EXPERIMENTAL|TIPS|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver.
62298286|NCT04207398|ACTIVE_COMPARATOR|NSBB+EBL|Participants randomized to this group will receive the combination therapy of non-selective beta-blocker (NSBB) and endoscopic band ligation (EBL) . NSBB, including propranolol and carvidilol, will be started at day 5 after the index bleeding and elective EBL sessions started 2 weeks after the index bleeding.
62298287|NCT02421198|EXPERIMENTAL|face-to-face|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
62298288|NCT02421198|EXPERIMENTAL|face-to-face + mobile hybrid|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face and via a mobile platform by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
62668534|NCT02112175|EXPERIMENTAL|Lenalidomide|Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.
62668535|NCT02643784|EXPERIMENTAL|Rosuvastatin|Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
62668536|NCT02643784|NO_INTERVENTION|Control|Control group(don't take rosuvastatin until 14th day), as directed by the study physician.
62668537|NCT03632447|EXPERIMENTAL|Leva Arm|Subjects will undergo pelvic floor muscle training using the leva device (a vaginal probe) which provides immediate visual feedback via smartphone regarding the motion of pelvic floor muscles. Subjects will perform exercises 2 1/2 minutes twice daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later subjects will undergo pelvic floor muscle testing using the PFDx device and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device. They will be further randomized to receive reminder text messages or no messages over 10 months. Subjects will be asked to complete follow up surveys at 6- and 12-months.
62668538|NCT03632447|ACTIVE_COMPARATOR|Kegel Arm|Subjects in this arm will perform pelvic floor muscle exercises (Kegels) for the treatment of stress or mixed urinary incontinence. Subjects will be asked to perform exercises three times daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later, subjects will undergo pelvic floor muscle testing (using the PFDx device) and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device.
62668539|NCT04224051|EXPERIMENTAL|Metformin target dose of 2g daily|Metformin tablets taken orally with target dose of 2g daily plus standard care
61913641|NCT02217072|EXPERIMENTAL|school intervention|Educational support intervention
62668540|NCT04224051|ACTIVE_COMPARATOR|Standard care|Standard care includes help with smoking cessation if applicable; encouragement of physical activity and a healthy diet; blood pressure control; statin and anti-platelet therapy treatment if the patient have clinical manifestations of atherosclerotic disease.
62106517|NCT03635567|EXPERIMENTAL|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\^2 PLUS cisplatin 50 mg/m\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\^2 PLUS carboplatin Area Under the Curve (AUC) 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments are administered until disease progression or toxicity.
62668541|NCT06373939|EXPERIMENTAL|Children (>1 year old) and adult patients|Patients with various respiratory conditions, such as asthma or pneumonia, along with healthy individuals, will be targeted to assess the Pneumoscope's performance under clinical conditions. Additionally, patients with lower blood oxygen saturation levels, such as those with cyanotic heart defects like tetralogy of Fallot, will also be included
62106518|NCT03635567|PLACEBO_COMPARATOR|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\^2 PLUS cisplatin 50 mg/m\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\^2 PLUS carboplatin AUC 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments are administered until disease progression or toxicity.
62106519|NCT05251285||Prophylactic Nipple-Sparing Mastectomy|
62668542|NCT02826499|ACTIVE_COMPARATOR|Fluoroscopy|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy.
62668543|NCT02826499|EXPERIMENTAL|Fluoroscopy and Pediguard|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy, with the Pediguard system.
62668544|NCT06367179|EXPERIMENTAL|Experimental group|The experimental group will receive interventions of virtual reality and artificial intelligence wound detecting system.
62668545|NCT06367179|OTHER|Control group|The control group maintained the traditional pressure injury health education with oral introduction and health education leaflet.
62668546|NCT05991479|EXPERIMENTAL|(Pilates exercises plus traditional physical therapy programme)|"Pilates exercises: The Pilates training protocol will take 60 min per session, including 10 min of warm up prior to initiating the Pilates technique, 40 min for Pilates exercises and 10 min for cool down. The number of repetitions will be 10 times. The patient will perform the following Pilates exercises: (Hundred exercises, spine stretch, single leg stretch , double leg stretch, criss cross, swimming, one leg kick, side kick, clam, one leg circle, shoulder bridge, hip twist, roll up and down and standing footwork).Pilates training (3 sessions/week) for 8 weeks.~traditional physical therapy programme: consisting of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~1. Stretching exercises for calf and hamstring muscles.~2. Strengthening exercises for hip, knee, ankle, and foot muscles.~3. Deep friction massage for scar management:"
62668547|NCT05991479|EXPERIMENTAL|(traditional physical therapy programme)|"All patients will receive a traditional physical therapy programme consisting of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~1. Stretching exercises for calf and hamstring muscles.~2. Strengthening exercises for hip, knee, ankle, and foot muscles.~3. Deep friction massage for scar management:"
62668548|NCT06024265|EXPERIMENTAL|ER2001 Injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
62668549|NCT03183440|EXPERIMENTAL|PREBIOTICS|188 pregnant women
62668550|NCT03183440|PLACEBO_COMPARATOR|PLACEBO|188 pregnant women
62668551|NCT02196545|EXPERIMENTAL|Exercise|Exercise, patients train on a specifically programmed movement trainer three times a week for 30 minutes (total duration 12 weeks)
62668552|NCT02196545|NO_INTERVENTION|Treatment as usual|Treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without movement trainer exercise
62668553|NCT04322045|EXPERIMENTAL|participants|All tested serum PSA. Some conducted mpMRI with/without prostate biopsy under instruction.
62668554|NCT00748930||Cohort 1|Subjects previously enrolled in the ATTRACT trial from three Canadian sites.
62668555|NCT05789342|EXPERIMENTAL|The DDI of GP681 and Rosuvastatin Calcium Tablets|Subjects will receive a single dose of Rosuvastatin Calcium 10 mg on Day 1, then take a single doses of 40mg GP681, 10mg Rosuvastatin Calcium on Day 8.
62668556|NCT05789342|EXPERIMENTAL|The DDI of GP681 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take a single doses of 40mg GP681, 0.25mg Digoxin on Day 15.
62668557|NCT05789342|EXPERIMENTAL|The DDI of GP681 and Itraconazole Capsules|Subjects will receive a single dose of GP681 20mg on Day 1, then take Itraconazole 200 mg twice-daily on Day 22 and 200 mg once-daily on Day 23 through Day 36, and took a single dose of GP681 20 mg on Day 26.
61913642|NCT01247805|EXPERIMENTAL|Treatment A|Revatio: 1 x 20 mg IR oral tablet.
61913643|NCT01247805|EXPERIMENTAL|Treatment B|2 x 10 mg sildenafil citrate IR oral tablet.
62469316|NCT03557632|ACTIVE_COMPARATOR|Control: Relapse Prevention Drug Education|Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
62469317|NCT04111263|SHAM_COMPARATOR|PL+SHAM|Placebo intervention + sea level exposure
62469318|NCT04111263|PLACEBO_COMPARATOR|PL+HA|Placebo intervention + high altitude exposure
62469319|NCT04111263|EXPERIMENTAL|FP+HA|Fiber and polyphenol supplementation + high altitude exposure
62469320|NCT01118312|ACTIVE_COMPARATOR|Nasal Steroid|Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day
62668558|NCT05789342|EXPERIMENTAL|The DDI of GP681 and Oseltamivir Capsules|Subjects will receive all three treatments in a crossover fashion according to the randomized sequence. The treatments were as follows: single oral administration of GP681 at 40 mg on day 1 in the fasted state; single oral administration of oseltamivir at 75 mg on day 1 and day 5in the fasted state, followed by repeated twice-daily administration of oseltamivir at 75 mg until day 5 after each meal; co-administration of GP681 at 40 mg and oseltamivir at 75 mg simultaneously on day 1 in the fasted state, followed by repeated twice-daily administration of oseltamivir at 75 mg until day5 after each meal. There was an at least 21-day washout interval between each treatment.
62668559|NCT04063020||Reconstructive plastic surgery procedure|Minors with ear aplasia and initiating a reconstructive plastic surgery procedure
62668560|NCT04503200|ACTIVE_COMPARATOR|Double guidewire|
62106520|NCT03784963|EXPERIMENTAL|Primary Prevention Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
62106521|NCT03784963|PLACEBO_COMPARATOR|Primary Prevention Non-Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
62106522|NCT03784963|EXPERIMENTAL|Secondary Prevention Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
62106523|NCT03784963|PLACEBO_COMPARATOR|Secondary Prevention Non-Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
62106524|NCT02210702|EXPERIMENTAL|Ethinyl Estradiol 35mcg/Noethindrone 1mg|21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
62106525|NCT02210702|EXPERIMENTAL|Ethinyl Estradiol 20mcg/Norethindrone 1mg|21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
62106526|NCT02210702|NO_INTERVENTION|No hormonal contraception|Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).
62106527|NCT06076759|ACTIVE_COMPARATOR|Intrathecal morphine group (Group M):|• Patients in this group will receive intrathecal morphine (0.5 mg diluted in I ml of normal saline) prior to induction of general anesthesia.
62106528|NCT06076759|ACTIVE_COMPARATOR|Intrathecal dexmedetomidine group (Group D):|• Patients in this group will receive intrathecal dexmedetomidine (5 mcg diluted in 1 ml of normal saline) prior to induction of general anesthesia.
62106529|NCT03874156|ACTIVE_COMPARATOR|Intervention group|Atorvastatin 40 mg once daily
62106530|NCT03874156|PLACEBO_COMPARATOR|Placebo group|Matched placebo tablet once daily
62106531|NCT00994149|EXPERIMENTAL|Diazoxide|Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
62106532|NCT00994149|PLACEBO_COMPARATOR|Ora-plus|Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
62106533|NCT03778593|EXPERIMENTAL|mFOLFIRINOX|D1 Oxaliplatin 65 mg/m2 + 5% dextrose water (5DW) 200 mL mix IV over 2 hours followed by, D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1 liter (1L) continuous IV over 23 hours repeat every 2 weeks
62106534|NCT01939158|EXPERIMENTAL|ACWY1d group|Subjects will receive 1 dose of the MenACWY-TT vaccine
62469321|NCT01118312|PLACEBO_COMPARATOR|Placebo|Intranasal placebo, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day
62668561|NCT04503200|ACTIVE_COMPARATOR|Transpancreatic precut|
62469322|NCT01139034|EXPERIMENTAL|shoulder FES treatment|
62668562|NCT03403517|EXPERIMENTAL|Methylprednisolone|10 mg/kg, single preoperative infusion
62668563|NCT03403517|ACTIVE_COMPARATOR|Dexamethasone|8 mg dexamethasone, single preoperative infusion
62469323|NCT01113424|EXPERIMENTAL|NRT-2|2 mg single-dose of a new NRT product
62469324|NCT01113424|ACTIVE_COMPARATOR|GUM-2|2 mg single-dose of a marketed nicotine gum
62469325|NCT01113424|EXPERIMENTAL|NRT-4|4 mg single-dose of a new NRT product
62469326|NCT01113424|ACTIVE_COMPARATOR|GUM-4|4 mg single-dose of marketed nicotine gum
62106535|NCT01939158|EXPERIMENTAL|ACWY2d group|Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
62106536|NCT01939158|EXPERIMENTAL|Co-ad group|Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
62106537|NCT01939158|ACTIVE_COMPARATOR|PCV-13 group|Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later
62298289|NCT02886429|ACTIVE_COMPARATOR|Group A|Ultrasound guided paravertebral block with bupivacaine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) via paravertebral route.
62298290|NCT02886429|ACTIVE_COMPARATOR|Group B|Ultrasound guided paravertebral block with bupivacaine and dexmedetomidine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) via paravertebral route (Bupivacaine plus Dexmedetomidine)
62106538|NCT06629909|EXPERIMENTAL|Secretome Injection|patient will receive secretome injection every two weeks for four months
62298291|NCT05984927|EXPERIMENTAL|NG101 Gene Therapy Group 1|Single subretinal injection of 1x10\^9 vector genomes of NG101 AAV gene therapy
62298292|NCT05984927|EXPERIMENTAL|NG101 Gene Therapy Group 2|Single subretinal injection of 3x10\^9 vector genomes of NG101 AAV gene therapy
62106539|NCT06629909|NO_INTERVENTION|Best Treatment Practice|patient will receive hepatoprotector drugs and Urodeoxycolate acid for four months
62106540|NCT04565249|EXPERIMENTAL|PLN-74809 Dose Level1|Dose Level 1 of PLN-74809
62106541|NCT04565249|EXPERIMENTAL|PLN-74809 Dose Level 2|Dose Level 2 of PLN-74809
62106542|NCT04565249|EXPERIMENTAL|PLN74809 Dose Level 3|Dose Level 3 of PLN-74809
62106543|NCT04187157||Blue-light filtering intraocular lens (IOL)|Bilateral implantation of blue-filtering intraocular lens. Blue-IOL, in addition to ultraviolet, also impede the transmission of the lower visible blue spectrum between 400 and 500nm.
62106544|NCT04187157||Conventional intraocular lens (IOL)|Bilateral implantation of conventional ultraviolet light-blocking intraocular lens
62298293|NCT05984927|EXPERIMENTAL|NG101 Gene Therapy Group 3|Single subretinal injection of 8x10\^9 vector genomes of NG101 AAV gene therapy
62298294|NCT02589977|OTHER|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) \>60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
62298295|NCT02589977|OTHER|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \>60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
62668564|NCT05112588|EXPERIMENTAL|Individual and digital support Intervention (IDSI)|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit according to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
62668565|NCT05112588|NO_INTERVENTION|Care as usual|One arm including in women with gestational diabetes who will be subject to care as usual at the Health care unit.
61913644|NCT01247805|EXPERIMENTAL|Treatment C|2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
61913645|NCT06046352||Cohort|Non-documented, clinically-suspected PSVT
61913646|NCT00204243|EXPERIMENTAL|Naltrexone implant|Naltrexone implant (GoMedical Inc. 6 months implant)
62106545|NCT05931107|EXPERIMENTAL|Stress ball practice group (Stress ball squeezing)|Patient information form, IBS symptom severity score, IBS quality of life scale and Depression-Anxiety-Stress scale will be administered by the researcher using face-to-face interview technique (pre-test) to the patients in both groups.The patients in the experimental group will be told how to use the stress ball in the room in the outpatient clinic and each patient will be given a stress ball. The first sessions of the patients will be held together with the patient in the outpatient clinic. Patients will apply a stress ball (squeezing the stress ball) once a day at home. In order to ensure the continuity of the stress ball application, the phone numbers of the patients will be taken and a reminder message will be sent every day. The patients' IBS symptom severity score will be evaluated every week.The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
62298296|NCT02589977|OTHER|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) \>60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
62298297|NCT05527925||Congenital cataracts children (0~3 years)|Children with congenital cataracts between the ages of 0 and 3 years
62298298|NCT05527925||Normal children (0~3 years)|Children without congenital cataracts between the ages of 0 and 3 years
62298299|NCT05527925||Congenital cataracts children (6~18 years)|Children with congenital cataracts between the ages of 6 and 18 years
62298300|NCT05527925||Normal children (6~18 years)|Children without congenital cataracts between the ages of 6 and 18 years
62668566|NCT05112588|NO_INTERVENTION|Control|One arm with women with normal glucose tolerance as control. Will be examined carefully at the same time-point as women in the intervention.
62668567|NCT03925714|OTHER|life style|life style control only
62668568|NCT03925714|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg twice daily
62668569|NCT03925714|EXPERIMENTAL|Nigetella salivata|NS 450 mg twice daily
62106546|NCT05931107|NO_INTERVENTION|Control group|"Patients who come to the outpatient clinic will be met, information will be given about the research, and consent will be obtained from the patients who agree to participate in the research. The groups of the patients who meet the inclusion criteria will be determined according to the randomization list.~Patient information form, IBS symptom severity score, IBS quality of life scale and Depression-Anxiety-Stress scale will be administered by the researcher using face-to-face interview technique (pre-test) to the patients in both groups.~Stress ball attempts will not be made to the patients in the control group. Phone numbers of patients in this group will be taken. Patients' IBS symptom severity score will be evaluated every week.~Patients in both groups will continue to use routine treatments for 4 weeks. After the research is completed, the patients in the control group will be given a stress ball according to their wishes and will be informed about its application."
62106547|NCT02543216|EXPERIMENTAL|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
62106548|NCT02543216|EXPERIMENTAL|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
62106549|NCT03551132|EXPERIMENTAL|Group 1|"Experimental group A supervised progressive moderate-to-high RTC program designed to induce muscular hypertrophy was performed. EG followed a progressive moderate-to-high RTC program for 12-weeks. The training program incorporated resistance exercise of six major regions and consisted of 3 training sessions per week on non-consecutive days (Monday, Wednesday and Friday).~All subjects performed the sets with moderate-intensity (8 to 12 repetitions) in each exercise and 30-60 seconds rest between sets. The load was increased during the 12 weeks from 60% 1-RM to high-intensity 80% 1-RM. The training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions) followed the OMNI-RES scale and a hard effort perception level. Rest between sets was 1-2 minutes."
62106550|NCT03551132|NO_INTERVENTION|Group 2|Control group The CG not participated in the RTC program.
62106551|NCT05288517|NO_INTERVENTION|Control Arm|Control patients received three invitations for a survey only and were blind to the L2L intervention.
62298301|NCT00527202|EXPERIMENTAL|botulinum toxin A|active treatment arm using botulinum toxin A max 200 U injected into the painful area using SC injections 2 cm apart
62298302|NCT00527202|PLACEBO_COMPARATOR|placebo|saline injection with the same dosages injected using the same procedure as botulinum toxin A
62298303|NCT05553860|ACTIVE_COMPARATOR|Anterior Protrusive|use of anterior protrusive positioning technique
62469327|NCT00622414|EXPERIMENTAL|Treatment (ziv-aflibercept)|"PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined.~PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
62469328|NCT04123080|EXPERIMENTAL|EBL group|Removal of large long-stalked pedunculated colonic polyps using band ligations
62668570|NCT03808857|EXPERIMENTAL|GB226|Geptanolimab Injection,3mg/kg once per 2 weeks
62668571|NCT05124678|EXPERIMENTAL|Fast/intermediate acetylators|"Participants in this arm have fast/intermediate acetylator status from NAT2 genotyping.~In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 10mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
62668572|NCT05124678|NO_INTERVENTION|Slow acetylators|"Participants in this arm have a slow acetylator status from NAT2 genotyping. They will receive the standard of care. In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 5mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
62668573|NCT02794779|EXPERIMENTAL|Rule of three|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
61913647|NCT00204243|ACTIVE_COMPARATOR|Methadone|Methadone Maintenance Treatment
61913648|NCT00007007|EXPERIMENTAL|Whole brain radiation therapy + neurocognitive assessments|Whole brain radiation therapy (WBRT) with neurocognitive assessments done pre and post WBRT.
62298304|NCT05553860|EXPERIMENTAL|Speech Position|use of speech positioning technique
62298305|NCT04627740|EXPERIMENTAL|CART treatment|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
62298306|NCT06656065||IMR≥15|Heart trasplant patient with an index of microvascular resistance ≥ 15 measured in the first two months in the physiological study.
62469329|NCT06390501|EXPERIMENTAL|Semaglutide|Once-weekly injections of gradually increased doses of semaglutide
62469330|NCT06390501|PLACEBO_COMPARATOR|Placebo|Once-weekly injections of gradually increased volumes of saline placebo, to match the volumes of the semaglutide treated arm.
62469331|NCT00507663|EXPERIMENTAL|Atenolol|Atenolol given prior to and for up to 7 days after surgery
62469332|NCT00507663|NO_INTERVENTION|routine care|routine clinical care
62668574|NCT02794779|ACTIVE_COMPARATOR|Continuous infusion|Continuous infusion of variable rate if 0,4 UI of oxytocin until obstetrician determines that uterine tone is adequate.
62668575|NCT00668408|OTHER|LTOT group|Study group: optimal medical therapy plus LTOT = or \> 15 hours pro die
62106552|NCT05288517|ACTIVE_COMPARATOR|Lock to Live Intervention Arm|Patients in the Intervention Arm received the invitation to Lock to Live, including up to 3 EHR invitation messages plus three messages to complete a follow-up survey evaluating study outcomes.
62668576|NCT00668408|OTHER|Non LTOT group|control group: optimal medical therapy without LTOT
62106553|NCT03697772||multmorbid patients|patients with 2 chronic diseases (medical conditions requiring management for more than 6 months)
62106554|NCT04347135|EXPERIMENTAL|F-18 FES PET/MRI|16α-(18)F-fluoro-17β-estradiol (\[F-18\] FES)
62106555|NCT03089346|OTHER|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
62298307|NCT06656065||IMR<15|Heart trasplant patient with an index of microvascular resistance\<15 measured in the first two months in the physiological study.
62668577|NCT01643187|EXPERIMENTAL|Fortified beverage|A group of children with some degree of malnourishment considered by a Z-score \< -1 for weight for height, height for age or weight for age.
62668578|NCT01643187|ACTIVE_COMPARATOR|Group receiving lactose-free milk|A group of children with some degree of malnourishment considered by a Z-score \< -1 for weight for height, height for age or weight for age.
62668579|NCT01997255|EXPERIMENTAL|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
62668580|NCT01175720|EXPERIMENTAL|test and control|The test and control technique will be tested in a split-mouth design.
62298308|NCT03740334|EXPERIMENTAL|Ribociclib (RIBO) + Dexamethasone (DEX)|"* Ribociclib administered daily for 21 consecutive days~* Dexamethasone administered intravenously on days 1-5 and again on days 11-15"
62298309|NCT03740334|EXPERIMENTAL|RIBO + Everolimus (EVE) + DEX|"* Ribociclib administered daily for 21 consecutive days~* Dexamethasone administered intravenously on days 1-5 and again on days 11-15~* Everolimus administered daily for 21 consecutive days"
62298310|NCT03740334|EXPERIMENTAL|RIBO + EVE+ DEX (dose expansion)|"* Ribociclib administered daily for 21 consecutive days. Dosing at RDE~* Dexamethasone administered intravenously on days 1-5 and again on days 11-15~* Everolimus administered daily for 21 consecutive days. Dosing at RDE"
62298311|NCT03977779|EXPERIMENTAL|Prophylactic biodegradable pancreatic stent placement|
62298312|NCT01571492|EXPERIMENTAL|L2 Paravertebral peripheral nerve block|L2 paravertebral peripheral nerve block catheter will be placed.
62298313|NCT01571492|ACTIVE_COMPARATOR|Continuous Lumbar plexus peripheral nerve block|Continuous unilateral lumbar plexus peripheral nerve block catheter will be placed.
62298314|NCT03441126||Multicenter Quality Improvement program|Locally developed and reliably implemented ICU Quality Improvement program to reduce blood culture use.
62298315|NCT01178021|ACTIVE_COMPARATOR|Chloroquine|Standard arm
62298316|NCT01178021|EXPERIMENTAL|Chloroquine/Primaquine|Chloroquine combined with primaquine
62668581|NCT02685865|ACTIVE_COMPARATOR|FCSEM Stent|WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
62668582|NCT02685865|ACTIVE_COMPARATOR|Plastic Stents|WON is first identified using EUS, and punctured using a 19 gauge needle. 10 ml of the WON fluid is aspirated and sent for gram stain and culture with sensitivities. A 0.025 or 0.035 inch guidewire is inserted into the WON through the fine needle aspiration (FNA) needle. A transmural tract is created using an Endoscopic Retrograde Cholangiopancreatography(ERCP) catheter (with the use of a needle knife catheter ± cautery if needed), and then dilated using a 12-13.5-15mm Controlled Radial Expansion (CRE) balloon to a maximum size of 15mm if technically possible. Two or three 7 French plastic stents are inserted through the transmural tract into the WON cavity.
62106556|NCT00996372|EXPERIMENTAL|flibanserin 100mg|flibanserin 100mg po qd
62298317|NCT04426630|OTHER|mHealth|Heart failure patients enrolled in the mHealth program
61913649|NCT05421650|ACTIVE_COMPARATOR|Control group|Concurrent chemoradiation therapy (CCRT)
62106557|NCT00996372|PLACEBO_COMPARATOR|placebo|placebo one tablet po qd
62106558|NCT03829267|EXPERIMENTAL|eFIT Behavioral Intervention|Intervention: Participants randomized to the eFIT condition will join a 1-hour peer group meeting online each week, called eFIT intervention. They will learn about accountability partners, and use the group as an accountability partner to state and attain physical fitness goals.
62106559|NCT03829267|ACTIVE_COMPARATOR|eJournal Behavioral Intervention|Intervention: Participants in the eJournal condition will spend 1-hour online each week engaged in an active journaling activity, called eJournal Intervention. They will also receive the same psychoeducational materials online as the eFIT participants are presented in group.
62298318|NCT02560454|EXPERIMENTAL|Cogmed®|"Cogmed® : working memory training (unifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
62298319|NCT02560454|EXPERIMENTAL|Presco®|"Presco® : different cognitive function are trained (multifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
62298320|NCT02560454|NO_INTERVENTION|Control|Control ( waiting list)
62298321|NCT00466505|EXPERIMENTAL|Therapeutic Intervention|
62469333|NCT00441467|EXPERIMENTAL|Glufosfamide|Glufosfamide
62469334|NCT06237023|OTHER|pre-pandemic group|Patients who presented to the Orthopedics and Traumatology unit for any trauma-related reason during the one-year period prior to the pandemic
61913650|NCT05421650|EXPERIMENTAL|Experimental group|Surgical debulking of bulky or multiple lymph node followed by CCRT
62469335|NCT06237023|OTHER|post-pandemic group|Patients who presented to the Orthopedics and Traumatology unit for any trauma-related reason within one year from the start of the pandemic
62106560|NCT04358328|EXPERIMENTAL|Intervention group|The patients in the intervention arm will receive the same care and treatment as is provided to all patients in the clinical setting, including the ERAS-concept. In addition to this they will be individually assessed by a physician with geriatric profile, dietician, physiotherapist and nurse and thereafter undergo appropriate interventions (CGA and care). The intervention team will have weekly meetings regarding the patients included in the study to evaluate how long the intervention should continue before surgery, a maximum time of eight weeks will be allowed for the intervention.
62106561|NCT04358328|ACTIVE_COMPARATOR|Control group|The patients in the control group will standard care and treatment which include assessment of surgeons, anaesthesiologists and, if needed, other specialized physicians. They will be treated according to the ERAS-concept in the pre- peri- and post operative phase.
62106562|NCT06632145|EXPERIMENTAL|Cog Fun Ageing intervention|
62106563|NCT05825170|EXPERIMENTAL|FASY L|Subjects will be consecutively included to receive FASY L in lips at level of their scar
62106564|NCT02524444|ACTIVE_COMPARATOR|Mefloquine|Tabs Mefloquine 250mg 3 doses 4 weeks apart
62106565|NCT02524444|ACTIVE_COMPARATOR|Sulphadoxine-Pyrimethamine|500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses
62106566|NCT02661035|EXPERIMENTAL|Reduced Intensity Conditioning|Non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion
62298322|NCT05745129||Treatment cohort|"Surgical vs conservative treatment.~Surgery procedures are based on the NOMESCO Classification of Surgical Procedures (NCSP). Conservative treatment includes all non-surgical treatment methods such as pharmaceutical treatment, physical medicine and physiotherapy modalities (information, patient education, exercise, manual therapy etc), cognitive-behavioural therapy, multidisciplinary treatment, acupuncture, and others (e.g. chiropractic treatment, homeopathy, naprapathy, osteopathy). The results will be described for important spinal subgroups (specific diagnoses, nerve-root affections, and non-specific conditions)."
62298323|NCT03021837||all patients|Patient receiving antenatal corticosteroid course for fetal lung maturity consisting of betamethasone or dexamethasone Women without known gestational diabetes and women with non-insulin requiring gestational diabetes (A1GDM)
62469336|NCT06250491|EXPERIMENTAL|Active rTMS|Deep rTMS with H coil targeting the motor cortex bilaterally
62469337|NCT06250491|PLACEBO_COMPARATOR|Sham rTMS|Sham rTMS with H coil targeting the motor cortex bilaterally
62469338|NCT01802853|EXPERIMENTAL|A: RO6811135 s.c.|
62469339|NCT01802853|ACTIVE_COMPARATOR|B: RO6811135 i.v.|
62106567|NCT04936789|EXPERIMENTAL|Single arm|Single arm. All subjects will receive the intervention. Comparator device will be subjects' own prosthesis at baseline.
62106568|NCT05379127|OTHER|Standard follow-up|standard care during follow-up
62668583|NCT01155323|ACTIVE_COMPARATOR|etafilcon A/omafilcon A|etafilcon A contact lenses will be worn during the first week and omafilcon A contact lenses will be worn during the second. Lenses were replaced daily
61913651|NCT00105053|EXPERIMENTAL|vaccine group|
61913652|NCT06435559|EXPERIMENTAL|A-experimental group|Patient enrolled in a cognitive rehabilitation program using Neurotablet® and paper and pencil exercises
62298324|NCT03820492|OTHER|Patient with left-main stenosis|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
62469340|NCT00415363|EXPERIMENTAL|A|
62469341|NCT00415363|PLACEBO_COMPARATOR|B|
62469342|NCT01263860|EXPERIMENTAL|24-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
62469343|NCT01263860|ACTIVE_COMPARATOR|48-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
62469344|NCT01862627||Macular retinoschisis and detachment|
62469345|NCT02286817|EXPERIMENTAL|Single arm of 30 subjects|Subjects will be administered single dose of NFC-1 to assess safety, tolerability, and pharmacokinetics, then proceed to continuous, daily administration of NFC-1 for 4 weeks to assess safety, tolerability, and impact on ADHD severity.
62106569|NCT05379127|EXPERIMENTAL|Patient-empowered follow-up|
62106570|NCT01841827|ACTIVE_COMPARATOR|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
62106571|NCT01841827|PLACEBO_COMPARATOR|Placebo|A capsule of placebo containing starch are taken orally on each study day.
62298325|NCT01360203|NO_INTERVENTION|Current Care|Patients will receive the current care provided to heart failure patients at each of the study sites
62469346|NCT05710393||Affected|(Affected) persons with a medical history of symptoms related to Hidradenitis Suppurativa.
62469347|NCT05710393||Unaffected-control|(Unaffected) family of participants, having no history of symptoms related to Hidradenitis Suppurativa.
62469348|NCT04794283||Hand milking with Diabetes|93 women with DM1, DM2 and medically treated GDM who are patients in specialist maternity care at Soderhospital in Stockholm and who plan to hand milk are part of this group.
62469349|NCT04794283||Not hand milking with diabetes|A group of 93 women are then selected from 1 April 2021and back in the same number as the group1 (n=93) this group only gave milk substitute the first 24h.
62469350|NCT01229618|EXPERIMENTAL|1|0.14 ml/kg bw - hyperpolarized pyruvate
62469351|NCT01229618|EXPERIMENTAL|2|0.28 ml/kg bw - hyperpolarized pyruvate
62469352|NCT01229618|EXPERIMENTAL|3|0.43 ml/kg bw - hyperpolarized pyruvate
61913653|NCT06435559|OTHER|B-control group|Patient NOT enrolled in a cognitive rehabilitation program using Neurotablet® and paper and pencil exercises.
61913654|NCT05551442||In control group A,|In control group A, we adopted the conventional lateral position
62106572|NCT05605743|EXPERIMENTAL|Exercised group|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
62106573|NCT05605743|NO_INTERVENTION|control group|this will be a thirty-patient wait-list group that will no receive any shape of training
62106574|NCT04902586|EXPERIMENTAL|E group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）and TTFields therapy during RT. The TTFields therapy started on the day the radiotherapy started.
62106575|NCT04902586|NO_INTERVENTION|C group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）
62106576|NCT00759837|EXPERIMENTAL|1|
62106577|NCT03478501|EXPERIMENTAL|Decision Aid Group|Participants randomized to this arm will view the decision aid on a tablet in the emergency department.
62106578|NCT03478501|NO_INTERVENTION|Control Group|Participants randomized to this arm will be asked to review general suicide prevention information on a tablet in the emergency department.
62106579|NCT02155686|EXPERIMENTAL|Biosensors|Participants in this arm are equipped both with home telecare/automation and with biometric sensors
62106580|NCT02155686|ACTIVE_COMPARATOR|Automation|Participants in this arm are equiepd with home automation only
62298326|NCT01360203|EXPERIMENTAL|Care Transition Intervention|Care transition intervention beginning prior to discharge and through six months post-discharge.
62469353|NCT01268709|ACTIVE_COMPARATOR|doxepin|
62668584|NCT01155323|ACTIVE_COMPARATOR|omafilcon A/etafilcon A|omafilcon A contact lenses will be worn during the first week and etafilcon A contact lenses will be worn during the second. Lenses were replaced daily.
62106581|NCT04820582||Delphi Panel|A group of international experts comprising patients experts, gynecologists, radiologist, psychologists, nurses and researchers, were identified based on their expertise in the field or due to your active role in an endometriosis patient association that have accepted to participate to this study.
62106582|NCT06214468|OTHER|Tylenol and Nicotinamide Riboside|
62298327|NCT06655961|ACTIVE_COMPARATOR|Control Group|Children in this group will receive services within the scope of the routine treatment and nursing care protocol of the clinic during hospitalisation. No intervention will be applied to the control group of this study until the discharge process takes place. However, on the day of discharge, the children in the control group and their parents will be informed about the garden activities by the researcher. A single session gardening activity will be planned according to the request of the child and parent. During this session, children will be given the opportunity to choose a plant and a pot, and then planting, watering and creating a name card will be carried out.
62298328|NCT06655961|EXPERIMENTAL|Intervention Group|"Children in this group will have three sessions of gardening activities within the scope of the 'Gardening Activities Programme' during their hospitalisation. The sessions will take place only with the active participation of the child participant and the researcher (EB); there will be one child participant in each session. The duration of the sessions will be between 30-45 minutes. The sessions in the 'Garden Activities Programme' regarding the session planning of the activities to be carried out with children are as follows.~Session 1: Pot Preparation and Plant Selection Session 2: Creating a Plant Arrangement Session 3: Care and Illustration"
62298329|NCT03101072|ACTIVE_COMPARATOR|"Fixed long antibiotic course"|"Patients randomized to this group will receive a fixed long antibiotic course of 14 days."
62469354|NCT01268709|ACTIVE_COMPARATOR|nortriptyline|
62469355|NCT01268709|PLACEBO_COMPARATOR|placebo|
62668585|NCT06386120||EIT-PEEP group|The PEEP titration guided by EIT, decided by the responsible attending physician
62106583|NCT06214468|ACTIVE_COMPARATOR|Tylenol Only|
62106584|NCT01582945|EXPERIMENTAL|Ketamine IV|Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks
62106585|NCT00590850|NO_INTERVENTION|Closed|Closed Treatment
62668586|NCT06386120||Table-PEEP group|The PEEP setting with low FiO2-PEEP table, decided by the responsible attending physician
62668587|NCT02513082|EXPERIMENTAL|Femoral nerve block|Femoral nerve block will be performed just one time after total knee arthroplasty in general anesthesia state
62668588|NCT02513082|ACTIVE_COMPARATOR|Adductor canal block|Adductor canal block will be performed just one time after total knee arthroplasty in general anesthesia state
62668589|NCT01446653|EXPERIMENTAL|EARLY|Motivational Interviewing plus feedback counseling with information via video and brochures
62106586|NCT00590850|ACTIVE_COMPARATOR|ORIF|Open Reduction and Internal Fixation (ORIF) with Plate and Screws
62106587|NCT00590850|ACTIVE_COMPARATOR|Pin|Pin Fixation
62668590|NCT01446653|ACTIVE_COMPARATOR|Video Information|Providing FASD information via documentary video clips
62106588|NCT03543839|ACTIVE_COMPARATOR|Belimumab|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 2 years
62106589|NCT03543839|EXPERIMENTAL|Belimumab/Placebo|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 1 year and then placebo injections subcutaneously for 1 year.
62106590|NCT03543839|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive placebo for self administration subcutaneously weekly for 2 years
62106591|NCT00640666|EXPERIMENTAL|Physical activity intervention|Behavior change intervention
62298330|NCT03101072|EXPERIMENTAL|"Fixed short antibiotic course"|"Patients randomized to this group will receive a fixed short antibiotic course of 7 days."
62298331|NCT03101072|EXPERIMENTAL|"Individualized antibiotic course"|"Individualized antibiotic course: starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75%"
62298332|NCT01839474|EXPERIMENTAL|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
62668591|NCT01446653|ACTIVE_COMPARATOR|Informational Brochure|Participants will receive informational brochures on contraception, women and drinking, and cutting down your drinking.
62668592|NCT01846871|EXPERIMENTAL|Tivozanib|1.5 mg daily for 3 weeks, with 1 week off.
62668593|NCT02505971|ACTIVE_COMPARATOR|Nadolol group|40 study participants will take Nadolol (oral liquid suspension)
62668594|NCT02505971|ACTIVE_COMPARATOR|Propranolol group|40 study paticipants will take Propranolol (oral liquid suspension)
62668595|NCT01302171|EXPERIMENTAL|Peripheral|Half the patients will be randomised to the non-interventional part of the trial. In this subgroup of patients will be randomised 1:1 to 5 day course of subcutaneous placebo injections or a 5 day course of G-CSF(Granocyte™) subcutaneous injections
62106592|NCT00640666|NO_INTERVENTION|Standard of care with written materials|Written materials
62106593|NCT02887261|OTHER|Power Port|patients who received power injectable port
62106594|NCT02887261|ACTIVE_COMPARATOR|Conventional Port|patients who received conventional port ( not power injectable)
62106595|NCT05481502|EXPERIMENTAL|Patients receiving advanced therapy medicinal products|
62106596|NCT00243334|EXPERIMENTAL|1|Decision Support integrated with Order Entry
62106597|NCT00243334|NO_INTERVENTION|2|Decision Support Only (not integrated with order entry)
62106598|NCT04778410|EXPERIMENTAL|Safety Run-in Cohort 1 (1L Unfit AML Mag+Ven+Aza)|Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab, venetoclax and azacitidine.
62106599|NCT04778410|EXPERIMENTAL|Safety Run-in Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab and MEC.
62106600|NCT04778410|EXPERIMENTAL|Safety Run-in Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab and CC-486.
62106601|NCT04778410|EXPERIMENTAL|Phase 2 Cohort 1 (1L Unfit AML Mag+Ven+Aza)|Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, venetoclax and azacitidine.
62106602|NCT04778410|EXPERIMENTAL|Phase 2 Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and MEC.
62106603|NCT04778410|EXPERIMENTAL|Phase 2 Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 3 and CC-486.
62106604|NCT03284632||Smokers|
62668596|NCT01302171|EXPERIMENTAL|Interventional arm|In the subgroup of the interventional arm patients will be randomised 1:1 to receive a 5 day course of subcutaneous G-CSF (Granocyte™) injections and bone marrow aspiration at day 5, they will then receive either stem cells or placebo via intracoronary injection
62106605|NCT03284632||E-cigarette users|
62106606|NCT03284632||Non-smokers|
62106607|NCT04833192||experimental group|patients diagnosed with subclinical hypercortisolism as assessed by an endocrinologist.
62106608|NCT04833192||control grpup|patients diagnosed with nonfunctional adrenal adenoma as assessed by an endocrinologist.
62106609|NCT04570475|EXPERIMENTAL|vitamin D+multivitamin|
62106610|NCT04570475|ACTIVE_COMPARATOR|placebo+multivitamin|
62106611|NCT06059820||Conservative treatment group|The main group (prospective) will consist of patients who received conservative therapy. The expected number of observations in the main group will be 50 patients.
62106612|NCT06059820||Surgical treatment group|The control group (historical control) will be comprised of 50 patients who underwent surgery previously at the Sklifosovsky Research Institute for Emergency Medicine.
62106613|NCT06141577|EXPERIMENTAL|UI059|
62106614|NCT06141577|ACTIVE_COMPARATOR|UIC202201|
62298333|NCT01839474|NO_INTERVENTION|Control|Children will receive standard medical therapy.
62668597|NCT02843555||Leukodystrophy of unknown etiology|Subjects who may have an undiagnosed form of leukodystrophy
62668598|NCT02811978|EXPERIMENTAL|Group 1 : Intravenous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2) bortezomib intravenously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
62106615|NCT06057220||Group 1|Adult patients referred for oesophago-gastro-duodenoscopy (OGD) to investigate any of the following symptoms: difficulty swallowing, vomiting, reflux, anaemia, gastrointestinal (GI) bleeding, upper abdominal pain and weight loss.
62106616|NCT06057220||Group 2|Adult patients with known BO who are undergoing OGD for surveillance
62106617|NCT06057220||Group 3|Adult patients who have been diagnosed with OGc (Ac or SCc) and are having further investigations as part of the disease staging process such as a staging laparoscopy or further OGD
62298334|NCT05879133|EXPERIMENTAL|Group 1 (Behavioral)|"Participants are randomly assigned a study group, pariticipants will be given the following:~* A Fitbit to wear every day during the study. A Fitbit is a physical activity tracking device that will help measure your physical activity. Participants will also receive a Fitbit Aria weight scale. Participants need to create a Fitbit account on the Fitbit website, which will allow participants to track your physical activity and log your diet information and weight. A member of the study team will call you or help you in-person (if you are in the clinic) to help set up the Fitbit and scale.~* Resistance bands with an instructional video on how to use them.~* Educational materials, such as handouts about diabetes prevention, as well as written/verbal/video instructions on setting up the Fitbit and scale. This will also include information about online safety/privacy."
62469356|NCT04207203|OTHER|Single arm study|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
62469357|NCT01882647|EXPERIMENTAL|Active Arm|Topical lotion, applied twice daily
62469358|NCT01882647|PLACEBO_COMPARATOR|Vehicle Arm|Topical lotion, applied twice daily
62469359|NCT03660384|EXPERIMENTAL|SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
62668599|NCT02811978|EXPERIMENTAL|Group 2 : Subcutaneous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2) bortezomib subcutaneously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
62668600|NCT03111732|EXPERIMENTAL|1/Arm 1|Pembrolizumab plus Oxaliplatin plus Capecitabine
62668601|NCT01765621|EXPERIMENTAL|DDI+ and Pharmacogenetic data|DDI+ System and Pharmacogenetic data
62668602|NCT01765621|NO_INTERVENTION|Standard Care|Control
62668603|NCT04106037||Legionnaires' disease|All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.
62106618|NCT06057220||Group 4|Adult patients with OGc (Ac or SCc) who are having surgical resection of the cancer
62106619|NCT01834235|ACTIVE_COMPARATOR|Abraxane, gemcitabine|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
62106620|NCT01834235|EXPERIMENTAL|Abraxane, gemcitabine, NPC-1C|"Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.~Patients on arm B will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 4-week cycle. This will be administered 30minutes after completion of the gemcitabine infusion."
61913655|NCT05551442||control group B|control group B adopted the lumbar bridge cushion lateral position
61913656|NCT05551442||observation group C|observation group C adopted the modified javelin lateral position
61913657|NCT05905003||CHR|Clinical High Risk (CHR) for psychosis subjects meeting diagnostic criteria for CHR on the Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS).
62106621|NCT04495634|EXPERIMENTAL|Head Trauma or Brain Bleed|Medically stable patients who have undergone conventional head CT imaging undergo imaging within 24 hours using the s-HCT system.
62106622|NCT01530074|EXPERIMENTAL|Study Group|
62106623|NCT01432158|EXPERIMENTAL|PCV-13 group|1 dose of Prevenar-13
62106624|NCT01432158|EXPERIMENTAL|PPV-23 group|1 dose of Pneumovax-II
62106625|NCT05560828||Zio Cohort|Patients who have been prescribed Zio
61913658|NCT05905003||HC|Healthy Control (HC) Subjects
61913659|NCT00904410|EXPERIMENTAL|1|
61913660|NCT00081861|EXPERIMENTAL|Avastin + Rituximab|Avastin 10 mg/kg given intravenously every 2 weeks for 4 doses, and Rituximab 375 mg/m\^2 intravenously weekly for 8 doses.
62106626|NCT05560828||Holter Cohort|Patients who have been prescribed Holter
62106627|NCT03016130|ACTIVE_COMPARATOR|Liberalized Hospital Diet (Diet A)|Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
62106628|NCT03016130|ACTIVE_COMPARATOR|Neutropenic Diet (Diet B)|Diet B is the hospital neutropenic diet.
62106629|NCT06550193|EXPERIMENTAL|AR/VR|AR/VR technology for ultrasound-guided procedures.
61913661|NCT02582177|EXPERIMENTAL|Candicort®/ Nizoral®|Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.
61913662|NCT02582177|EXPERIMENTAL|Baycuten N®/ Canesten®|Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.
62668604|NCT06447896|EXPERIMENTAL|Arm A|In the experimental arm, the Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000, REEM (Shenzhen) Healthcare Co., Ltd) is used for both cardiovascular autonomic reflex tests (CARTs) and heart rate variability (HRV) analysis.
62668605|NCT06447896|ACTIVE_COMPARATOR|Arm B|In the active comparator arm, conventional method of CARTs and HRV analysis using a commercially available ambulatory holter station are conducted as control.
61913663|NCT06112873||The parents of allergic children 0 to 17 years|The parents of 200 eligible patients will complete the parent questionnaire comprising 15 questions
62106630|NCT05608499|EXPERIMENTAL|Duobrii|Duobrii is the study treatment drug. Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii.
62106631|NCT05608499|PLACEBO_COMPARATOR|Placebo|Placebo
62106632|NCT06053788|EXPERIMENTAL|PocDoc|All participants given PocDoc device
62106633|NCT04610294|EXPERIMENTAL|Aerus air sterilization|Aerus air sterilization system will be used in an operating room, in addition to routine room air filtration
62106634|NCT04610294|ACTIVE_COMPARATOR|Conventional air handling|Only routine room air filtration will be used in an operation room.
62106635|NCT05037851|EXPERIMENTAL|Opelconazole|14.8 mg opelconazole administered twice daily for 12 weeks
62469360|NCT03660384|EXPERIMENTAL|C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
62469361|NCT03934047|EXPERIMENTAL|Group A|Group A: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
61913664|NCT06112873||Allergic children aged 8 to 17 years|A total of 200 eligible patients aged 8 to 17 years will complete the children's self-reported questionnaire comprising 13 questions.
62106636|NCT05037851|ACTIVE_COMPARATOR|Standard of Care (SoC)|Mold-active SoC prophylaxis/pre-emptive therapy
62106637|NCT04789850|EXPERIMENTAL|Itacitinib|200mg of oral Itacitinib everyday for 360 days.
62106638|NCT04789850|PLACEBO_COMPARATOR|Placebo|Oral placebo everyday for 360 days.
62106639|NCT01243255||1|Patients with hypercholesterolemia on lipid lowering pharmacological treatment
62106640|NCT05652530|EXPERIMENTAL|BCMA CAR-NK|
62106641|NCT05169255|EXPERIMENTAL|Azithromycin|24 participants received azithromycin for 3 or 7 days
62106642|NCT05169255|EXPERIMENTAL|Amoxicillin|24 participants received amoxicillin for 3 or 7 days
62106643|NCT06479785|EXPERIMENTAL|Educational intervention program on machine workers|Use proper protective gears like mask, glasses, glove and proper foot wear. Maintain proper posture. Avoid repetitive movement.
62469362|NCT03934047|NO_INTERVENTION|Group B|Group B: No Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
62469363|NCT03325192|PLACEBO_COMPARATOR|Standard of care|Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
62668606|NCT01879657|EXPERIMENTAL|68Ga-DOTATATE PET scans|"This is an open-label, single-dose diagnostic study using DOTATATE peptide, labelled with the 68Ga tracer. The radiation (imaging) dose will be 111-185MBq (3 - 5 mCi) ±25%. Imaging will start 90 ±30 minutes after injection.~The diagnostic sensitivity, specificity and accuracy of the study drug are being compared with a predefined standard of truth (SOT) parameters. A comparative conventional scan, such as anatomical imaging modalities CT, ultrasound, and MRI or functional imaging using 18F-FDG and NaF PET/CT or bone scan is being used to evaluate the diagnostic efficacy of 68Ga-DOTATATE."
62668607|NCT01433770|EXPERIMENTAL|Alefacept action on memory T cells|
61913665|NCT06112873||Adults over 18|A total of 200 adult patients will complete the adult self-reported questionnaire comprising 14 questions.
62106644|NCT06479785|EXPERIMENTAL|Educational intervention program on manual workers|Use proper protective gears like mask, glasses, glove and proper foot wear. Maintain proper posture during heavy load lifting. Take breaks during prolong period of work.
62106645|NCT02715063|EXPERIMENTAL|High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
62469364|NCT03325192|EXPERIMENTAL|Rapid pleurodesis protocol|Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter
61913666|NCT02125604|EXPERIMENTAL|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
62106646|NCT02715063|ACTIVE_COMPARATOR|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
62106647|NCT02715063|ACTIVE_COMPARATOR|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached. Exercise will be performed at three sessions per week.
62106648|NCT02715063|PLACEBO_COMPARATOR|Usual clinical care|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
62106649|NCT03098290||Intermittent Claudication|Mild to severe claudication
62106650|NCT03098290||Ischaemic Rest Pain|
62106651|NCT03098290||Critical Limb Threatening Ischaemia|Ulcers, Necrosis, Gangrene
62106652|NCT05394402|EXPERIMENTAL|SHR0410 Injection High dose|
62106653|NCT05394402|EXPERIMENTAL|SHR0410 Injection Low dose|
62106654|NCT05394402|PLACEBO_COMPARATOR|Placebo for SHR0410 Injection|
61913667|NCT00169442|EXPERIMENTAL|Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
62668608|NCT00868270||Children with UTIs|
62668609|NCT05639868|ACTIVE_COMPARATOR|T-CPR|Participants perform telephone-assisted CPR based on the European Resuscitation Council (ERC) 2021 guidelines.
61913668|NCT00169442|EXPERIMENTAL|Tritanrix-HepB/Hiberix Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
61913669|NCT00169442|EXPERIMENTAL|HB Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine (with HepB at birth), received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
62469365|NCT04023461|NO_INTERVENTION|Clinical Treatment Group|
62668610|NCT05639868|EXPERIMENTAL|V-CPR|Participants perform video-assisted CPR based on the European Resuscitation Council (ERC) 2021 guidelines.
62668611|NCT05639868|NO_INTERVENTION|Unassisted CPR|CPR without dispatcher instructions.
62668612|NCT02134028|EXPERIMENTAL|dupilumab treatment|"For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1\* Dose every 2 weeks added to current controller medications.~For participants coming from other studies: dupilumab 1 \* Dose SC every 2 weeks added to current controller medications."
62668613|NCT05120232|ACTIVE_COMPARATOR|Unified Protocol (UP)|The Unified Protocol (UP) is a transdiagnostic, cognitive-behavioral therapy that has been shown to be effective for treating emotional disorders. The UP targets negative emotions and helps people respond to their emotions in ways that are more helpful for them and in line with their goals. This will be delivered entirely on an online platform.
62106655|NCT01611441||Patients with osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery.
62106656|NCT05528536|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT) and Exercise|This group receives eight weeks' Acceptance and Commitment Therapy (ACT) and exercise intervention.
62469366|NCT04023461|EXPERIMENTAL|Interventional Ablation Group|
62668614|NCT05120232|EXPERIMENTAL|Modified Unified Protocol (UP+)|A modified version of the UP (called the UP+) delivered entirely on an online platform that will include exercises specifically designed to enhance positive emotions.
62668615|NCT02271802|EXPERIMENTAL|Butyrate|Enema containing sodium butyrate
62668616|NCT02271802|PLACEBO_COMPARATOR|Placebo|Enema containing NaCl
62668617|NCT06548243|EXPERIMENTAL|Act with Nature Programme|A nature-based programme to promote well-being and pro-environmental behaviour. The programme is facilitated by a trained health care professional.
61913670|NCT00169442|EXPERIMENTAL|Tritanrix-HepB Kft.+Hiberix Group|Healthy male and female infants who were primed with Tritanrix™-HepB Kft. and Hiberix™ vaccines, were boosted with Tritanrix™-HepB Kft. vaccine administered intramuscularly into the right upper thigh and Hiberix™ vaccine, administered intramuscularly into the left upper thigh, at 15-18 months of age.
61913671|NCT00169442|EXPERIMENTAL|PRP Tritanrix-HepB Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
62106657|NCT05528536|SHAM_COMPARATOR|Art and Exercise|This group receives eight weeks' art workshops (skill-based) and exercise intervention.
62106658|NCT05528536|ACTIVE_COMPARATOR|Treatment as usual|This group receives treatment as usual in the local community setting.
62106659|NCT02722356|EXPERIMENTAL|Oxytocin|Oxytocin administered according to proposed protocol
62106660|NCT02722356|ACTIVE_COMPARATOR|Standard Practice|Oxytocin administered according to standard practice at facility
62298335|NCT05879133|EXPERIMENTAL|Group 2 (Waitlist)|"Participants are randomly assigned a study group, pariticipants will be given the following:~* A Fitbit to wear every day during the study. A Fitbit is a physical activity tracking device that will help measure your physical activity. Participants will also receive a Fitbit Aria weight scale. Participants need to create a Fitbit account on the Fitbit website, which will allow participants to track your physical activity and log your diet information and weight. A member of the study team will call you or help you in-person (if you are in the clinic) to help set up the Fitbit and scale.~* Resistance bands with an instructional video on how to use them.~* Educational materials, such as handouts about diabetes prevention, as well as written/verbal/video instructions on setting up the Fitbit and scale. This will also include information about online safety/privacy."
62106661|NCT04905316|EXPERIMENTAL|Canakinumab with Chemoradiation and Durvalumab|Treatment will consist of canakinumab (ACZ885) administered as a subcutaneous injection every 3 weeks for 3 cycles concurrent with standard of care concurrent chemoradiation, followed by canakinumab administered intravenously every 4 weeks for up to 12 total infusions concurrent with standard of care durvalumab. Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first. Patients that come off treatment for progression, or have progression after completion of all protocol-related therapy, can be followed for survival outcomes by chart review based on standard of care evaluations.
62106662|NCT03276039||25 patients with non-alcoholic fatty liver disease|
62106663|NCT03276039||25 patients with NAFLD and chronic HCV|
62106664|NCT03276039||20 healthy controls|
62668618|NCT06548243|NO_INTERVENTION|Control group|The participants in the control group continue life as usual.
62668619|NCT00629239|EXPERIMENTAL|1|AZD4818
62668620|NCT00629239|PLACEBO_COMPARATOR|2|Placebo
61913672|NCT00169442|EXPERIMENTAL|PRP Tritanrix-HepB Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
62469367|NCT01819597|OTHER|EDAS surgery|EDAS surgery is an established form of indirect revascularization. The study arm in this study will receive EDAS surgery
61913673|NCT05713669|EXPERIMENTAL|Residents meet ICU patients during follow-up visit (encounter)|Residents will be paired according to the patient that were cared.
61913674|NCT05713669|OTHER|Residents in the non-encounter group|Residents will not meet with patients that were in the ICU.
62469368|NCT04230083|EXPERIMENTAL|Dienogest Test Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
62469369|NCT04230083|ACTIVE_COMPARATOR|Dienogest Reference Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
62469370|NCT05783505|EXPERIMENTAL|Treatment group|Multicomponent intervention program
62469371|NCT05783505|NO_INTERVENTION|Control group|Standard care
62469372|NCT03555747|OTHER|Canine distalization by 75 g force|Canine was distalized using a continuous force of 75 g with nickel-titanium closed coil springs.
62668621|NCT05181657|EXPERIMENTAL|LinkUP Active intervention|"The counselor will present basic evidence-based COVID-19 information on SARS-CoV-2 biology and epidemiology, testing and the safety and efficacy of available COVID-19 vaccines. The counselor will also address COVID-19 misinformation (e.g., that COVID is no worse than the flu), and COVID-19 disinformation (e.g., that COVID vaccines include a tracking device).~The LinkUP active intervention combines education, motivational interviewing (MI), problem-solving, and ongoing support from peer counselors. Through an open discussion with one of OnPoint's peer counselors who are trained in MI, the counselor will present evidence-based COVID-19 information. Next, the counselor will attempt to identify the participant's concerns about COVID-19 and vaccination in an attempt to tip their decisional balance."
62668622|NCT05181657|PLACEBO_COMPARATOR|LinkUP Control Condition (didactic intervention)|As described above, the control condition is a one-way sharing of COVID-19 information presented by an OnPoint counselor. The counselor will be instructed to answer any questions the participant may have but will not engage in motivational interviewing counseling. The same educational materials used in the LinkUP intervention module will be used for this session and it will be completed within 45 minutes.
61913675|NCT00480948|ACTIVE_COMPARATOR|1|Infant formula with InFat™ oil(containing \~49% of C16:0 at sn-2 position).
62469373|NCT03555747|OTHER|Canine distalization by 150 g force|Canine was distalized using a continuous force of 150 g with nickel-titanium closed coil springs.
62469374|NCT00801970|EXPERIMENTAL|1 - Pregnant - Tokophobic|Psychoanalysis treatment.
61913676|NCT00480948|PLACEBO_COMPARATOR|2|Standard vegetable oil based infant formula
61913677|NCT03947554|EXPERIMENTAL|HRG80 Panax ginseng|Panax ginseng standardized to 63.4 mg of total ginsenosides taken orally once daily in the morning after a meal.
61913678|NCT03947554|ACTIVE_COMPARATOR|Panax ginseng|Panax ginseng standardized to 19.6 mg of total ginsenosides taken orally once daily in the morning after a meal.
61913679|NCT03947554|PLACEBO_COMPARATOR|Placebo|Placebo capsule containing brown sugar and rice flour, taken orally once daily in the morning after a meal.
61913680|NCT01532193|EXPERIMENTAL|Hipoxia|The low oxygen tension group
61913681|NCT01532193|NO_INTERVENTION|Control group|Conventional culture conditions
62106665|NCT00711542|ACTIVE_COMPARATOR|1|Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
62106666|NCT00711542|PLACEBO_COMPARATOR|2|Intracoronary infusion of Placebo after NSTEMI
62106667|NCT02313844|EXPERIMENTAL|Viralym-B|"Partially HLA-matched Viralym-B cells will be thawed and given by intravenous injection. Patients will receive 2 x 10\^7 partially HLA-matched Viralym-B/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
62106668|NCT00545844|EXPERIMENTAL|1|montelukast sodium
62106669|NCT02805244|EXPERIMENTAL|JTZ-951, 14C-JTZ-951|Single oral administration on Day 1; 10 mg JTZ-951, 100 μCi of 14C-JTZ-951
62106670|NCT03728725||TB case detection Group|Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.
62298336|NCT03732924|EXPERIMENTAL|Five minute rest|
62298337|NCT03732924|ACTIVE_COMPARATOR|Zero minute rest|
61913682|NCT03160547|ACTIVE_COMPARATOR|Usual Protein/Amino Acid Group|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
61913683|NCT03160547|ACTIVE_COMPARATOR|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
61913684|NCT01221740|EXPERIMENTAL|Milnacipran|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
62298338|NCT03567187|EXPERIMENTAL|Iovera|"The iovera° device consists of a reusable, portable hand-piece, along with a single-patient use sterile smart Tip (cryoprobe) and disposable nitrous oxide (N2O) cartridges (cryogen). The smart tip is composed of closed-tip stainless steel needles, thereby fully enclosing the cryogen. There are 2 types of smart tips that will be utilized during this study, depending on the depth of the nerves being treated. The shorter smart tip comes in 2 variants - three X 6.9 mm or 8.9 mm, 27-gauge needles, with an attached skin warmer to prevent damage to the underlying skin. The longer smart tip also comes in 2 variants - 55 mm 22-gauge needle or a 90 mm 20G needle.~The effect is by initiation of a cooling cycle, by fully inserting the smart tip into the procedure site and activating the cryogen flow. As the gas travels through the length of the needle, an ice ball develops around the needle freezing the surrounding tissue."
62298339|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
62298340|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
62298341|NCT05153343|EXPERIMENTAL|flonoltinib 25mg|1 case，The starting dose，Take the medicine once on D1 ，D 5 through 21.
62298342|NCT05153343|EXPERIMENTAL|flonoltinib 50mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62668623|NCT06163274|EXPERIMENTAL|Sequence: Placebo Intravaginal Ring A followed by Placebo Intravaginal Ring B|Placebo Intravaginal Ring A will be inserted and used for 28 days, Ring A will be removed and followed by no intravaginal ring use for 7-21 days. Then Placebo Intravaginal Ring B will be inserted and used for 28 days.
62298343|NCT05153343|EXPERIMENTAL|flonoltinib 100mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62298344|NCT05153343|EXPERIMENTAL|flonoltinib 150mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62298345|NCT05153343|EXPERIMENTAL|flonoltinib 225mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62298346|NCT05153343|EXPERIMENTAL|flonoltinib 325mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
62298347|NCT01588821|EXPERIMENTAL|Treatment Arm|Cabozantinib
62298348|NCT03742427|EXPERIMENTAL|effect of c-collar in optic nerve sheath diameter|Comparing the effect of c-collar in minor head trauma patients by using optic nerve sheath diameter ultrasonography
62298349|NCT04874272|NO_INTERVENTION|Pre-Intervention|Pre-intervention: participants complete research surveys about codes and are asked to participate in an interview with the research team.
62298350|NCT04874272|EXPERIMENTAL|Pilot (Single Unit Recruitment)|Pilot intervention: participants participate in a chaplain led post-code debrief, participants complete research surveys about codes.
62298351|NCT04874272|EXPERIMENTAL|Pilot (Hospital-wide Recruitment)|Pilot intervention: participants participate in a chaplain led post-code debrief, participants complete research surveys about codes.
62469375|NCT00801970|EXPERIMENTAL|2 - Pregnant - Tokophobic|Cognitive-Behavioral treatment.
61913685|NCT05958693||Patients detected with Plasmodium falciparum (Artemether-lumefantrine)|Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
61913686|NCT00586664|EXPERIMENTAL|Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%|
61913687|NCT00586664|EXPERIMENTAL|Bepotastine Besilate Ophthalmic Solution 1.0%|
61913688|NCT00586664|PLACEBO_COMPARATOR|Placebo|
61913689|NCT05860010|PLACEBO_COMPARATOR|control|Bupivacaine will be administered in the caudal space
61913690|NCT05860010|ACTIVE_COMPARATOR|dexmedetomidine|caudal with dexmedetomidine
62469376|NCT00801970|EXPERIMENTAL|3 - Non-pregnant - Tokophobic|Group Therapy
62106671|NCT03728725||RIF-resistance MTB Group|"An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.~/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations."
62106672|NCT03557385|OTHER|aFFR vs cFFR|All subjects will receive Fractional Flow Reserve Measurements with both adenosine (aFFR) and contrast (Iopamidol) (cFFR) using the Navvus® Catheter and CVi® Contrast Delivery System
62106673|NCT03234816|EXPERIMENTAL|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
62106674|NCT03234816|EXPERIMENTAL|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
62106675|NCT03234816|EXPERIMENTAL|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
62298352|NCT02979756|EXPERIMENTAL|Decentralized GDM screening and initial management|In this arm, the intervention consists of screening all pregnant women for GDM using the nationally recommended oral glucose tolerance test that will take place during antenatal care consultations in 10 randomly selected primary health care facilities. Overall, 80 women who are diagnosed with GDM and who consent to participate will receive initial nutritional counseling and will be closely followed up.
62298353|NCT02979756|NO_INTERVENTION|Standard GDM screening and management practice|In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
62298354|NCT04970706||Healthy Volunteers|Volunteers were healthy people without ACL rupture
62298355|NCT04970706||Patients with ACL Rupture|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
62298356|NCT05575310||No Persistent Post Surgical Pain|The grouping variable will be the presence or not of persistent post-surgical pain. This will be a dichotomous variable obtained from the evaluation of pain intensity at 3 months after surgery. The tool used will be a 100mm Visual Analog Scale (VAS) (0 = no pain, 100 = worst pain imaginable) (25). Those with a VAS \< 30 will be considered as patients with no persistent pain, while those with a VAS ≥ 30 will be considered as patients with persistent pain. This cut-off point has been determined by numerous authors in previous studies.
62298357|NCT05575310||Persistent Post Surgical Pain|While those with a VAS ≥ 30 will be considered as patients with persistent pain. This cut-off point has been determined by numerous authors in previous studies
62298358|NCT05716919|EXPERIMENTAL|Cohort 1 - 4|Cohort 1 : 50 mg/day Cohort 2 : 100 mg/day Cohort 3: 200mg/day \[Cohort 4: 300mg/day: based on the result of Safety Review Meeting (SRM)\]
62298359|NCT05716919|PLACEBO_COMPARATOR|Placebo|
62298360|NCT00312013|NO_INTERVENTION|No Nadroparin|Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
62469377|NCT00801970|NO_INTERVENTION|4 - Control|Pregnant and non-pregnant non-tokophobic women will answer questionnaires. Won't receive therapy.
62668624|NCT06163274|EXPERIMENTAL|Sequence: Placebo Intravaginal Ring B followed by Placebo Intravaginal Ring A|Placebo Intravaginal Ring B will be inserted and used for 28 days, Ring B will be removed and followed by no intravaginal ring use for 7-21 days. Then Placebo Intravaginal Ring A will be inserted and used for 28 days.
62668625|NCT01509105||Group1|
62106676|NCT02396056|SHAM_COMPARATOR|Occlusive Membrane (OM)|Five patients will be randomly assigned to the OM group.
62469378|NCT00961168|EXPERIMENTAL|Lung-Protective Ventilation|Lung-Protective Ventilation comparing volume vs. pressure control
61913691|NCT05860010|ACTIVE_COMPARATOR|epinephrine|caudal with epinephrine
62106677|NCT02396056|EXPERIMENTAL|Modified Perforated Membrane (MPM)|Five patients will be randomly assigned to the MPM group.
62106678|NCT00530335|EXPERIMENTAL|Atomoxetine|
62106679|NCT05082883||Cognitively Normal|No cognitive impairment, medically stable
62106680|NCT05082883||Mild Cognitive Impairment|Meets NIA-AA criteria for MCI
62106681|NCT05082883||Mild Dementia|Meets NIA-AA criteria for dementia
62106682|NCT02153606|ACTIVE_COMPARATOR|Glycerin Suppository|
62469379|NCT05951660|EXPERIMENTAL|INT1: Only patients are educated|
62106683|NCT02153606|SHAM_COMPARATOR|Sham Suppository|
62106684|NCT06118489||sevoflurane|
62106685|NCT06118489||desflurane|
62106686|NCT01793272|OTHER|Pentoxifylline|effect of pentoxifylline on ICSI outcome
62298361|NCT00312013|EXPERIMENTAL|Nadroparin|Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
62298362|NCT03031561|EXPERIMENTAL|Diagnostic (standard ultrasound, MicroPure, biopsy)|Patients undergo grayscale and MicroPure ultrasound imaging followed by sonographic or stereotactic guided core needle biopsy or surgical resection. Surgical specimens are then x-rayed.
62298363|NCT01686568|EXPERIMENTAL|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
62469380|NCT05951660|EXPERIMENTAL|INT2: Only Healthcare Professionals are educated|
62668626|NCT05480098|EXPERIMENTAL|Brimonidine intervention|We will compare hemostasis between 2 surgical sides of the same patient. One side will be randomized to receive Brimonidine (0.15% or 0.2%) in addition to standard hemostasis measures, while the other side will receive only standard hemostasis measures (preoperative discontinuation of blood thinners, preoperative injection of lidocaine with epinephrine).
62668627|NCT05480098|NO_INTERVENTION|Control Arm|We will compare hemostasis between 2 surgical sides of the same patient. One side will be randomized to receive Brimonidine (0.15% or 0.2%) in addition to standard hemostasis measures, while the other side will receive only standard hemostasis measures (preoperative discontinuation of blood thinners, preoperative injection of lidocaine with epinephrine).
62668628|NCT02553070||Pharmacy Students|Participants will be asked to indicate their perception of poisoning severity by answering a short survey.
62106687|NCT03426696||Thyroid Related Eye Disease|Survey about the psychological condition would done with the patients of Thyroid Related Eye Disease
62106688|NCT01888406|EXPERIMENTAL|Guided Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
62106689|NCT01888406|OTHER|Pure Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources.
62106690|NCT02680756|EXPERIMENTAL|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
62106691|NCT02680756|ACTIVE_COMPARATOR|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
62106692|NCT04470102|OTHER|isolated septal myectomy|Isolated extended septal myectomy
62298364|NCT01686568|PLACEBO_COMPARATOR|Placebo|Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
62106693|NCT04470102|ACTIVE_COMPARATOR|"Septal myectomy+ edge-to-edge"|advanced septal myectomy in combination with mitral valve repair using the edge-to-edge technique
62106694|NCT02882646|EXPERIMENTAL|Stroke/CP survivors & healthy subjects|"Part A: Stroke and CP survivors greater than 18 years of age with hemiplegia and varying levels of impairment. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. Healthy persons over the age of 18 with no upper limb impairment.~Part B: Low to mid functioning CP and stroke survivors greater than 18 years of age with hemiplegia. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. All will be asked to use the Bi-ADLER system."
62106695|NCT05711498|EXPERIMENTAL|Anodal thoracic tsDCS|Anodal tsDCS will be applied over the T12 vertebra
62668629|NCT00476788|EXPERIMENTAL|Omnipod Device|Patients will be placed on an Omnipod insulin pump
62106696|NCT05711498|EXPERIMENTAL|Cathodal thoracic tsDCS|Cathodal tsDCS will be applied over the T12 vertebra
62106697|NCT05711498|SHAM_COMPARATOR|Sham thoracic tsDCS|Sham tsDCS will be applied over the T12 vertebra
62106698|NCT01249092|EXPERIMENTAL|Pentoxifylline 400 mg TID|This study is an open label pilot with only one arm.
62668630|NCT03238872|EXPERIMENTAL|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
62668631|NCT03238872|ACTIVE_COMPARATOR|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
62106699|NCT04859595|EXPERIMENTAL|telephone follow-up arm|"The experimental arm corresponds to the patient benefiting from a monthly telephone follow-up during the first 6 months of their discharge from the reeducation center : CRIL (from M1 to M6). They will be contacted each month by CRIL's speech therapist for a telephone interview (20 to 30 minutes)."
62106700|NCT04859595|NO_INTERVENTION|control arm|The comparison group will follow the standard follow-up protocol. A technician will contact the patients in the control arm to obtain the TIMES score each month. No further telephone follow-up will be carried out.
62106701|NCT03321955|EXPERIMENTAL|Subjects with Painful Neuropathy|All subjects will be implanted with the Medtronic Synchromed II pump, and treated with the same algorithm for dose adjustment for painful neuropathy with Ziconotide 100 micrograms/ml.
62298365|NCT06107829|EXPERIMENTAL|Valbenazine|This an open-label study in which all participants will have their valbenazine dose titrated from 40 mg to 80 mg per day, which will remain the valbenazine dose through end of study, unless interrupted by adverse events. Participants taking valbenazine who are concurrently taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, duloxetine) will continue their valbenazine dose at 40 mg per day through end of study. Participants taking valbenazine who are concurrently taking strong CYP3A4 inhibitors (ketoconazole, fluconazole, cimetidine, verapamil) will continue their valbenazine dose at 40 mg per day through end of study.
62298366|NCT03545282|EXPERIMENTAL|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
62298367|NCT03545282|OTHER|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
62298368|NCT06657443|EXPERIMENTAL|Training material sharing and activity sessions|Eğitim materyali paylaşımı ve etkinlik oturumları
62298369|NCT05502289|EXPERIMENTAL|TEST/CONTROL|Eligible subjects will be randomized to the wear sequence (TEST/CONTROL) to wear the study lenses during each dispensing period (1 week) with a wash-out period (1 week) between wear periods.
62469381|NCT05951660|EXPERIMENTAL|INT3: Both patients and Healthcare Professionals are educated|
62668632|NCT01339013|ACTIVE_COMPARATOR|AnaConDa|
62668633|NCT00397930|EXPERIMENTAL|Yoga Intervention (YOCAS)|Standardized Yoga for Cancer Survivors (YOCAS)
61913692|NCT01498094|ACTIVE_COMPARATOR|Control|Standard low-flow oxygen therapy.
61913693|NCT01498094|EXPERIMENTAL|Intervention|High Flow Nasal Cannula Oxygen Therapy
62668634|NCT00397930|EXPERIMENTAL|Standard Care Control Condition|Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.
61913694|NCT01433276|EXPERIMENTAL|Totilac|
61913695|NCT01433276|ACTIVE_COMPARATOR|Ringer's lactate|
61913696|NCT04161768|ACTIVE_COMPARATOR|Norfloxacin|Norfloxacin 400 mg daily
61913697|NCT04161768|EXPERIMENTAL|Norfloxacin and Itopride|Norfloxacin 400 mg daily and Itopride 50 mg three times daily.
61913698|NCT01425047||Females ingesting mangosteen juice|
61913699|NCT01425047||Males ingesting mangosteen juice|
62106702|NCT00657280|EXPERIMENTAL|All subjects recieve Sitagliptin|All subjects are aware of what they are taking. Nobody is blinded in this study. study
62106703|NCT04874012|PLACEBO_COMPARATOR|Placebo|Participants into the placebo group will receive the same treatment regimen, but with packets of the same appearance and size containing only vehicle.
62106704|NCT04874012|ACTIVE_COMPARATOR|Taurine|Participants will receive 6 gy taurine divided into twice/day orally administration for 12 weeks.
62298370|NCT05502289|EXPERIMENTAL|CONTROL/TEST|Eligible subjects will be randomized to the wear sequence (CONTROL/TEST) to wear the study lenses during each dispensing period (1 week) with a wash-out period (1 week) between wear periods.
62668635|NCT02762604|EXPERIMENTAL|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
62668636|NCT02762604|ACTIVE_COMPARATOR|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
62668637|NCT02781194|EXPERIMENTAL|forced-air warming blanket|Forced-air warming blanket via 3M™ Bair Hugger™.
61913700|NCT02710162|EXPERIMENTAL|Screening|Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study. In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
62298371|NCT01989663|EXPERIMENTAL|1% vaginally applied tenofovir gel|1% vaginally applied tenofovir gel administered for 7 daily doses
62298372|NCT01989663|PLACEBO_COMPARATOR|HEC placebo vaginal gel|HEC placebo vaginal gel administered for 7 daily doses
62298373|NCT01989663|EXPERIMENTAL|Tenofovir film- 10mg|Tenofovir Film 10mg inserted vaginally, administered for 7 daily doses
62298374|NCT01989663|EXPERIMENTAL|Tenofovir Film-40 mg|Tenofovir Gel 40 mg inserted vaginally, administered for 7 daily doses
62298375|NCT01989663|PLACEBO_COMPARATOR|Placebo Film|Placebo Film inserted vaginally, administered for 7 daily doses
62668638|NCT02781194|EXPERIMENTAL|warmed, humidified insufflation|Warmed, humidified insufflation via the F\&P HumiGard™ Surgical Humidification System.
62668639|NCT02781194|EXPERIMENTAL|forced-air warming blanket & warmed, humidified insufflation|Combination of forced-air warming blanket via 3M™ Bair Hugger™ and warmed, humidified insufflation via the F\&P HumiGard™ Surgical Humidification System.
62668640|NCT00311805|ACTIVE_COMPARATOR|1|
62668641|NCT00311805|ACTIVE_COMPARATOR|2|
62668642|NCT00311805|PLACEBO_COMPARATOR|3|
61913701|NCT00782938||low SAA|
62106705|NCT05054062|EXPERIMENTAL|Healthy participants|
62298376|NCT02338986||Healthy Volunteers|Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases
62298377|NCT05720312|EXPERIMENTAL|Dorsolateral Prefrontal Cortex (DLPFC)|36 sessions of high frequency (10Hz) rTMS
62298378|NCT05720312|EXPERIMENTAL|Ventromedial Prefrontal Cortex (vmPFC)|36 sessions of low frequency (1Hz) rTMS
62298379|NCT03822910||Healthy Controls|Matched Healthy Controls
62298380|NCT03822910||Firt Episode Psychosis (FEP)|subjects before and after antipsychotic treatment
62298381|NCT00157300|EXPERIMENTAL|Epoetin beta|
62298382|NCT05516914|EXPERIMENTAL|LBL-007 & Tislelizumab|LBL-007 Injection; dose A or dose B; Q3W
62668643|NCT04033536|ACTIVE_COMPARATOR|Involved target SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined Involved Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
62668644|NCT04033536|ACTIVE_COMPARATOR|Elective target SSRS|SSRS with 16 Gy in single fraction to the defined Elective Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
62298383|NCT04109599|EXPERIMENTAL|PlaySmart Full Game|Adolescents, boys and girls, aged 16-19 participated in the pilot testing of the adapted game. PlaySmart is a digital intervention targeted towards preventing opioid misuse in older adolescents.
62106706|NCT05660395|EXPERIMENTAL|Arm A: Normal Hepatic Function|"Participants will receive loncastuximab tesirine 0.15 mg/kg once every 3 weeks (Q3W) for two cycles, then 0.075 mg/kg Q3W for subsequent cycles (1 cycle = 21 days).~Participants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3."
62298384|NCT04109599|EXPERIMENTAL|Trading Wisdom Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player receives an opioid prescription from their dentist. This storyline includes information about safe use of opioids and the difference between use and misuse.
62298385|NCT04109599|EXPERIMENTAL|Lean on Me Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player is offered opioids at a party. This storyline includes information about different forms of opioids and their effects.
62298386|NCT04109599|EXPERIMENTAL|Tough Love Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player navigates supporting their partner struggling with opioid misuse. This storyline includes information about treatment and recovery resources for opioid misuse \& Opioid Use Disorder.
62469382|NCT05951660|NO_INTERVENTION|Control|
62668645|NCT00762177|PLACEBO_COMPARATOR|A -Control|fluoride toothpaste
62668646|NCT00762177|EXPERIMENTAL|B Experimental toothpaste|Stannous fluoride toothpaste
62668647|NCT00762177|ACTIVE_COMPARATOR|C- positive control|fluoride/triclosan/copolymer toothpaste
62668648|NCT04832308|EXPERIMENTAL|SVS SET Program|Participants enroll in SVS Program which includes 1) educational information on PAD, exercise and nutrition, 2) weekly health coaching, and 3) walking therapy prescription.
62668649|NCT04832308|NO_INTERVENTION|Usual Care|This usual care arm will allow sites to direct patients as they usually do. This could include an in-person exercise therapy program or simply exercise instruction during an office visit.
62668650|NCT05599425|ACTIVE_COMPARATOR|Healthy Living Education|The basic healthy living education intervention is a 24-session program (two sessions/week for 12 weeks) designed to educate participants about major modifiable risk factors for Alzheimer's disease. The first session each week is didactic, intended to increase knowledge about each Alzheimer's disease risk factor. The second session involves repetition and practice of didactic material as well as strategizing cues to action
62668651|NCT05599425|EXPERIMENTAL|Enhanced Healthy Living Education|The enhanced healthy living education intervention will include the same didactic content as the basic HLE course for the first session each week. The second session will focus on personal health beliefs and how they affect specific health behaviors. This may include discussing perceived benefits, troubleshooting barriers to action, making specific action plans, and implementing natural reward systems to bolster self-efficacy.
62668652|NCT01952678||DaTscan™ - Non-Caucasian Participants|Non-Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
62668653|NCT01952678||DaTscan™- Caucasian Participants|Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
61913702|NCT00782938||high SAA|
61913703|NCT00216164|EXPERIMENTAL|1|Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
62668654|NCT04947787|EXPERIMENTAL|Intervention Group|Participants receive a physical activity referral scheme.
61913704|NCT00738036||Group P|Exposed to an acute painful phenomenon requiring an analgesic management
62106707|NCT05660395|EXPERIMENTAL|Arm B: Moderate Hepatic Impairment|"Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest dose possibly administered will be 0.15 mg/kg Q3W.~Participants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3."
62298387|NCT04109599|EXPERIMENTAL|Grandma's Pills Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player witnesses the sharing of an opioid prescription within their family. This storyline includes information about medication safety and opioid overdose identification and response.
62668655|NCT04947787|ACTIVE_COMPARATOR|Control Group|Participants receive physical activity advice from general practitioners.
62668656|NCT03679884|EXPERIMENTAL|Daridorexant 10 mg|Film-coated tablets administered orally, once daily in the evening
61913705|NCT00738036||Group C|Control, not exposed to acute pain
62668657|NCT03679884|EXPERIMENTAL|Daridorexant 25 mg|Film-coated tablets administered orally, once daily in the evening
62668658|NCT03679884|EXPERIMENTAL|Daridorexant 50 mg|Film-coated tablets administered orally, once daily in the evening
62668659|NCT03679884|PLACEBO_COMPARATOR|Placebo|Film-coated tablets administered orally, once daily in the evening
62668660|NCT03679884|EXPERIMENTAL|Ex-Placebo Daridorexant 25 mg|Film-coated tablets administered orally, once daily in the evening
62668661|NCT01491165|EXPERIMENTAL|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
61913706|NCT06070220|EXPERIMENTAL|client-centered intervention group|
61913707|NCT06070220|EXPERIMENTAL|control group|
61913708|NCT04875247||Single arm|All patients will be assigned to this cohort.
61913709|NCT00886652|EXPERIMENTAL|Exercise|"The patients of the Exercise group were submitted to a four-month physiotherapy protocol, with three weekly sessions of 60 minutes each, accompanied by a physiotherapist, and consisting of warm-up, aerobic exercise on an electric treadmill, and then winding down and relaxation.~Each patient in this group was therefore submitted to an average of 48 sessions of exercises, always carried out at the same physiotherapy center."
61913710|NCT00886652|NO_INTERVENTION|2|The patients of the control group were not submitted to any type of physical exercises. Like the patients submitted to the protocol, they were evaluated at the beginning, and again after four months.
61913711|NCT03288792|EXPERIMENTAL|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
61913712|NCT05651204||Dravet|
61913713|NCT05651204||Age-Matched Control|
61913714|NCT02261025|EXPERIMENTAL|Aspirin group|Aspirin 75-100mg,per day，oral
61913715|NCT02261025|NO_INTERVENTION|non-aspirin group|No interventions
62668662|NCT04723069|EXPERIMENTAL|Fuke Qianjin capsule|"Metronidazole tablets + Doxycycline Hyclate tablets simulant are consecutively taken for 14 days, while the Fuke Qianjin capsule is consecutively taken for 28 days.~Fuke Qianjin Capsules are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch, and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
61913716|NCT03976869|EXPERIMENTAL|Cohort 1|The study will include adolescent patients of 12 to 17 years of age, with subgroups of 12-14 years age and 15-17 years age.
62106708|NCT05660395|EXPERIMENTAL|Arm C: Severe Hepatic Impairment|"Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest dose possibly administered will be 0.15 mg/kg Q3W.~Participants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3."
62106709|NCT02551354|EXPERIMENTAL|Patients|"Pain assess by :~* Visual Analogic Scale (VAS).~* Portable video pupillometer"
62106710|NCT06620614|EXPERIMENTAL|Fractionated group arm|In this group ,participants are given 1.6 ml of Injection Heavy Bupivacaine 0.5% initially followed by 0.9ml after 60 seconds at a rate of 0.2ml/hr.
62106711|NCT06620614|PLACEBO_COMPARATOR|Bolus arm group|In this group ,participants are given Injection Heavy Bupivacaine 0.5% 2.5ml bolus at a rate of 0.2ml/hr
62106712|NCT05994092|EXPERIMENTAL|Experimental|
62106713|NCT05994092|NO_INTERVENTION|Control|
62298388|NCT04109599|EXPERIMENTAL|A Friend in Need Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player interacts with a friend that is in distress. This storyline includes information about how to navigate peer-to-peer support.
62298389|NCT04109599|EXPERIMENTAL|A New Direction Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player seeks out therapy as an option to manage stress. This storyline includes information about how to seek professional help for mental health.
62298390|NCT04109599|EXPERIMENTAL|Risk Sense All Levels|Adolescents, boys and girls, aged 16-19 participated in beta testing all levels of this PlaySmart mini game intended to increase perceived risk of harm of opioid misuse.
62298391|NCT04109599|EXPERIMENTAL|PlaySmart Full Game: Focus on Character Development|Adolescents, boys and girls, aged 16-19 participated in the pilot testing of the adapted game. PlaySmart is a digital intervention targeted towards preventing opioid misuse in older adolescents. Participants in this arm focused on beta testing character development aspects throughout the game.
62469383|NCT01537640|EXPERIMENTAL|SAR231893 (REGN668) Drug Product (DP) 1|SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection
62469384|NCT01537640|EXPERIMENTAL|SAR231893 (REGN668) Drug Product (DP) 2|SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection
62469385|NCT01886768|EXPERIMENTAL|Double pledget nasal anesthesia|All patients in the double pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to both the inferior nasal meatus and middle nasal meatus. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A preloaded biopsy forceps is protruded slowly into the middle meatus first under endoscope monitoring. The second gauze pledgetting procedure is performed two minutes after the first gauze pledgetting which serves to induce turbinate size reduction to both the INT and MNT. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
62106714|NCT01520350|EXPERIMENTAL|Mood stabilizer + Aripiprazole|
62106715|NCT01520350|PLACEBO_COMPARATOR|Mood stabilizer + placebo|
62298392|NCT05491122|NO_INTERVENTION|Habitual period|8 consecutive days where participants will drink fluids as they do habitually (habitually low TFI = ≤ 1.6 L/day, women ≤ 1.5 L/day, or habitually high TFI = men ≥ 2.9 L/day, women ≥ 2.5 L/day)
62298393|NCT05491122|EXPERIMENTAL|Intervention period|1-week where the fluid intake will be modified. Habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI.
61913717|NCT03551925|EXPERIMENTAL|Treatment as Usual Plus Occupational Therapy|The occupational therapy intervention will be guided by the Integrative Medication Self-Management Intervention (IMedS).The IMedS process guides the occupational therapist and client through an initial evaluation process and a three-step intervention plan to improve medication management.
62668663|NCT04723069|ACTIVE_COMPARATOR|Metronidazole tablets + Doxycycline hyclate tablets|"Metronidazole tablets + Doxycycline hyclate tablets are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.~Fuke Qianjin Capsules simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
62668664|NCT04419974||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
61913718|NCT03551925|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants will receive only the TAU intervention which is provided by a clinical pharmacist and is the protocol at Jordan Valley Community Health Center. The intervention seeks to improve medication adherence in individuals with hypertension.
61913719|NCT01574833|ACTIVE_COMPARATOR|PEMF|arm that receive PEMF treatment
61913720|NCT01574833|SHAM_COMPARATOR|Sham|arm that receive sham treatment
61913721|NCT04503915|EXPERIMENTAL|Constant group|Women will receive oral estradiol valerate (Progynova®; Bayer Schering Pharma AG, Berlin, Germany) 3 mg bid for 14 days for endometrial priming from the second or third day of the menstrual cycle.
62106716|NCT04519450||ICU patients without an with chronic respiratory diseases|The group will consist of \>50 patients admitted to the intensive care unit, of which at least 20 with chronic respiratory diseases. Patients of both sexes, patients with and without chronic respiratory diseases, and also patients requiring mechanical ventilation were included and their demographic characteristics and outcomes registered. All patients will sign an informed consent form before inclusion in the prospective observational study.
62298394|NCT01979107|EXPERIMENTAL|Proactive action by the general practitioner|Proactive action by the general practitioner inviting to preventive health check.
62298395|NCT01979107|NO_INTERVENTION|Control group|The participants will be treated as usual by the general practitioner.
62298396|NCT02739464|EXPERIMENTAL|Exercise + SOC PT/OT|SOC treatment plus a personalized, structured, and quantifiable exercise program (MP10) carried out soon after admission until hospital discharge (including during the BICU stay and time on ventilation.
62298397|NCT02739464|ACTIVE_COMPARATOR|SOC PT/OT|Only SOC for treating in-patient burn subjects
61913722|NCT04503915|ACTIVE_COMPARATOR|Step -up group|Women will receive estradiol valerate 2mg once daily for 4 days from the second to fifth day,followed by 2mg bid for 4 days from the sixth to ninth day and then 3mg bid for 6 days from tenth to fifteenth day of menstrual cycle.
61913723|NCT02849353|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
61913724|NCT02849353|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62106717|NCT01887041|ACTIVE_COMPARATOR|Stent|Arm B, after randomisation the biliary tract stents shall remain. The patients in study arm B will also receive chemotherapy and gemcitabine, according to the recommended palliative therapy for a pancreas carcinoma.
62298398|NCT06656481||1. Small for Gestational Age Babies (SGA)|Infants with birth weight below the 10th percentile are classified as small for gestational age (SGA
62298399|NCT06656481||2. Large for Gestational Age Babies (LGA)|infants above the 90th percentile are classified as large for gestational age (LGA)
62298400|NCT06656481||3. Appropriate for Gestational Age Babies (AGA)|between the 10th and 90th percentiles are classified as appropriate for gestational age
62298401|NCT06656481||4. GDM|babies of Mothers with gestational diabetes mellitus
62298402|NCT04177836|EXPERIMENTAL|MIndfulness|This arm was developed to increase attention towards and acceptance of current experiences.
62298403|NCT04177836|ACTIVE_COMPARATOR|Active Control|This arm is a relaxation-based active treatment comparison intervention, developed to parallel the structure of the mindfulness intervention without the attention towards or acceptance of present experiences.
62298404|NCT02955329|EXPERIMENTAL|Tobacco Arm|Participants will vape tobacco leaves with nicotine out of the PAX device.
62298405|NCT02955329|EXPERIMENTAL|Cannabis Arm|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
62668665|NCT04419974||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
61913725|NCT02426489|NO_INTERVENTION|Diagnostic accuracy with MRI alone|The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
61913726|NCT02426489|EXPERIMENTAL|Diagnostic accuracy with MRI + PEM image|The combined PEM/MRI image will be examined.
62298406|NCT02955329|EXPERIMENTAL|Combined Cannabis and Tobacco Arm|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
62668666|NCT04419974||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
62106718|NCT01887041|ACTIVE_COMPARATOR|Biliodigestive anastomosis|"Study arm A will, after randomisation, have a biliodigestive anastomosis inserted. After the healing of the wound (al least 14 days postoperative) the treatment using gemcitabine, according to the plan mentioned below.~Gemcitabine shall be administered on days 1, 8 and 15 of each 4 week cycle. The cycle is defined as a weekly, over a period of 3 consecutive weeks, applied infusions, followed by 1 week pause. On the day of therapy a dosage of 1000 mg/ml body surface shall be administered, intravenous, over a period of 30 minutes."
62106719|NCT06411405||Ugandan mother-baby cohort|Mother-baby pairs recruited antenatally or at delivery, with babies eligible for inclusion if they are born at 34 weeks gestational age and above. Used as primary data for modelling.
62298407|NCT02649634|EXPERIMENTAL|Motivational Interviewing|Two 45-60 minute motivational interviewing sessions focusing on exploring and resolving ambivalence towards change.
62298408|NCT02649634|ACTIVE_COMPARATOR|Attention Control|Two 45-60 minute semi-structured interviews, acting as a pseudo-intervention, ascertaining information relevant to health history, weight history, diet history, as well as dietary and physical activity habits.
62106720|NCT06411405||Zimbabwean mother-baby cohort|Mother-baby pairs with babies eligible for inclusion if they are born at 34 weeks gestational age and above, used as a validation cohort for the model.
62298409|NCT03759275||Stage 1|For the Baseline Investigation and Technical Preparation Stage
62298410|NCT05106361|EXPERIMENTAL|MOSAIC Plus|"Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
62668667|NCT02087683|OTHER|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months.
62668668|NCT02087683|PLACEBO_COMPARATOR|Control Group (Placebo)|Participants in this group will receive a placebo containing gelatin and corn oil per day for 12 months
62668669|NCT02541903|EXPERIMENTAL|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
62668670|NCT00267319|EXPERIMENTAL|single group|
62298411|NCT05106361|ACTIVE_COMPARATOR|MOSAIC|"Those in the active comparator will receive the Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV."
62298412|NCT03415230|EXPERIMENTAL|Therapeutic massage|Women will undertake sessions of therapeutic massage
62298413|NCT03415230|SHAM_COMPARATOR|Sham massage|Women will undertake sessions of sham massage
62298414|NCT04947137|EXPERIMENTAL|Subjects Free of Inflammatory Disease|The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
62298415|NCT04947137|EXPERIMENTAL|Healthy Controls and RA Subjects on Stable Therapy|The second arm is comprised of \[1\] disease-free HCs and \[2\] clinically diagnosed RA subjects on stable treatment.
62298416|NCT05747924|EXPERIMENTAL|AOC 1020 Regimen 1|Cohort A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months
62298417|NCT05747924|EXPERIMENTAL|AOC 1020 Regimen 2|Cohort B1: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months
62668671|NCT04281719|EXPERIMENTAL|Mobile App|Youth will be assigned to interact with a novel mobile application during a course of outpatient psychotherapy for substance use disorder(s) and co-occurring mental health disorder(s).
62668672|NCT00907114|ACTIVE_COMPARATOR|Ketorolac tromethamine|ocular topic ketorolac used 4 times a day during a week after panphotocoagulation
62668673|NCT00907114|PLACEBO_COMPARATOR|Polivynilic alcohol|ocular lubricant drops 4 times a day during one week after panphotocoagulation
62298418|NCT05747924|EXPERIMENTAL|AOC 1020 Regimen 3|Cohort C: AOC 1020 Dose Regimen 3; Eight doses administered intravenously over approximately 10 months
62298419|NCT05747924|PLACEBO_COMPARATOR|Placebo (Saline) Regimen 1|Cohort A \& B: Placebo; Five doses administered intravenously over 9 months
62298420|NCT05747924|PLACEBO_COMPARATOR|Placebo (Saline) Regimen 2|Cohort C: Placebo; Eight doses administered intravenously over approximately 10 months
62298421|NCT00030576|EXPERIMENTAL|OSI-774 and cisplatin|HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days
62668674|NCT04914000|EXPERIMENTAL|Self Help Materials|Participants will receive a smoking cessation booklet/pamphlet corresponding to their cancer type.
62668675|NCT03630887|NO_INTERVENTION|Control|Non-active prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
62106721|NCT05100472|EXPERIMENTAL|Hormone Therapy and Radiation|Patients enrolled in this study will receive ADT for 6 months which will consist of bicalutamide 50 mg PO daily starting approximately 1-2 weeks before leuprolide 22.5mg injected every 3 months. The HDR prostate brachytherapy procedure will be performed approximately 3 months after starting ADT to allow for potential radiosensitization and cytoreduction. Approximately 4 weeks after the HDR boost, patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
62469386|NCT01886768|ACTIVE_COMPARATOR|Single pledget nasal anesthesia|All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
62469387|NCT02543554||Pre-intervention group|mechanically ventilated patients before implementation of ED lung protective ventilation
62668676|NCT03630887|EXPERIMENTAL|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
62298422|NCT01355289|PLACEBO_COMPARATOR|Placebo (Core Study)|Placebo, will be administered orally, once daily for up to 21 days.
62298423|NCT01355289|ACTIVE_COMPARATOR|Avatrombopag 10 mg (Core Study)|Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.
62298424|NCT01355289|ACTIVE_COMPARATOR|Avatrombopag 20 mg (Core Study)|Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.
62298425|NCT01355289|ACTIVE_COMPARATOR|Avatrombopag 30 mg (Core Study)|Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.
62298426|NCT01355289|EXPERIMENTAL|Avatrombopag (Open-Label Extension)|Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
62668677|NCT03630887|EXPERIMENTAL|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
62668678|NCT03630887|EXPERIMENTAL|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
62668679|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 1|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 0.03 mg/kg"
62668680|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 2|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 0.1 mg/kg"
62298427|NCT05127486|EXPERIMENTAL|Galcanezumab|"Participants received a loading dose of 2 injections of 120 milligrams (mg) galcanezumab subcutaneously (SC) in the first month followed by 120 mg monthly for remaining 2 months.~1 placebo oral disintegrating tablet (ODT) every other day for 3 months was given to preserve blinding."
62298428|NCT05127486|ACTIVE_COMPARATOR|Rimegepant|"Participants received 75 mg Rimegepant oral disintegrating tablet (ODT) every other day for 3 months.~2 placebo SC injections loading dose, then 1 placebo SC injection monthly for remaining 2 months was given to preserve blinding."
62298429|NCT03456011|OTHER|BFA with Eufflexa injections|"BFA treatment before Sodium Hyaluronate injections.~Intervention: BFA"
62298430|NCT03456011|NO_INTERVENTION|Anesthetic with Eufflexa injections|"Receiving Standard of care determined by their provider~No interventions"
62469388|NCT02543554||Intervention group|mechanically ventilated patients after implementation of ED lung protective ventilation
62469389|NCT02466880|EXPERIMENTAL|Telemedicine|Diabetes education and support via telemedicine
62469390|NCT02466880|ACTIVE_COMPARATOR|Usual care|Diabetes education and support in person
62469391|NCT01638520|EXPERIMENTAL|Pascolizumab|The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.
62106722|NCT01760291|EXPERIMENTAL|WATCHMAN|WATCHMAN LAA Closure Technology
62469392|NCT01638520|PLACEBO_COMPARATOR|Placebo|For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.
62469393|NCT01393366|OTHER|Without AMA|Patient will be follow only like usual practice
62469394|NCT01393366|OTHER|With AMA|Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
62469395|NCT03243630|PLACEBO_COMPARATOR|Menthol e-liquid|Menthol Flavor + IV saline Menthol Flavor + IV nicotine (0.25mg/70kg) Menthol Flavor + IV nicotine (0.5mg/70kg)
62469396|NCT03243630|ACTIVE_COMPARATOR|green apple e-liquid|Green apple + IV saline Green apple + IV nicotine (0.25mg/70kg) Green apple + IV nicotine (0.5mg/70kg)
62469397|NCT03243630|ACTIVE_COMPARATOR|green apple and menthol e-liquid|Green apple and menthol + IV saline Green apple and menthol + IV nicotine (0.25mg/70kg) Green apple and menthol + IV nicotine (0.5mg/70kg)
62106723|NCT01191788|EXPERIMENTAL|Group CBT|Clients received up to 16 sessions of group CBT for depression
62469398|NCT05314023|EXPERIMENTAL|9 to 19 Years Old: Day 1, Months 2 and 6|Chinese males 9 to 19 years old will receive a 0.5 mL intramuscular (IM) injection of 9-valent HPV (9vHPV) vaccine on Day 1, Month 2 and Month 6
62469399|NCT05314023|EXPERIMENTAL|9 to 14 Years Old: Day 1, and Month 6|Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 6
62469400|NCT05314023|EXPERIMENTAL|9 to 14 Years Old: Day 1 and Month 12|Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 12
61913727|NCT03232125|EXPERIMENTAL|Ramosetron group|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
62298431|NCT03635944||Group A|Infants born in Lyon (France)
61913728|NCT03232125|PLACEBO_COMPARATOR|Placebo group|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
61913729|NCT01673152|PLACEBO_COMPARATOR|Maltodextrin|
62298432|NCT03635944||Group B|Infants born in Stockholm (Sweden)
62298433|NCT03435978||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
62298434|NCT03435978||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
62298435|NCT04333966|EXPERIMENTAL|Interactive PBI|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
62298436|NCT04333966|ACTIVE_COMPARATOR|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call toAction: A Guide for Families.
62298437|NCT04178590|EXPERIMENTAL|SRP + Injectable Platelet-Rich Fibrin|Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
62668681|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 3|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 0.3 mg/kg"
62668682|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 4|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 1.0 mg/kg"
61913730|NCT01673152|EXPERIMENTAL|Oligofructose|Orafti P95, Beneo-Orafti, Belgium,
62298438|NCT04178590|PLACEBO_COMPARATOR|SRP + placebo|Scaling and root planing in conjunction with saline
62298439|NCT05367661|EXPERIMENTAL|Part A: Healthy Volunteers: Single ascending doses|Six dose groups ranging from 15mg to 500mg, under fasting condition.
62298440|NCT05367661|EXPERIMENTAL|Part A: Healthy Volunteer: Single Ascending dose under fed condition|60mg under fed condition.
62469401|NCT04115150||self-gripping mesh|
62469402|NCT04115150||non-self-gripping mesh|
62668683|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 5|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 2.0 mg/kg"
61913731|NCT03024580|EXPERIMENTAL|Megestrol acetate|Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
61913732|NCT03024580|ACTIVE_COMPARATOR|Anastrozole|Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
61913733|NCT03024580|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
62668684|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 6|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 4.0 mg/kg"
61913734|NCT03024580|ACTIVE_COMPARATOR|Exemestane|Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
61913735|NCT03024580|ACTIVE_COMPARATOR|Tamoxifen|Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
61913736|NCT03024580|ACTIVE_COMPARATOR|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
61913737|NCT03515291|EXPERIMENTAL|iMP cell injection|iMP cells injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
62106724|NCT01191788|ACTIVE_COMPARATOR|Comparison|Treatment as Usual comparison condition
62298441|NCT05367661|EXPERIMENTAL|Part A: Otherwise Healthy volunteer with Class I or Class II obesity, Single Ascending dose|125mg, under fasting condition.
62298442|NCT05367661|EXPERIMENTAL|Part B: Healthy Volunteers: Multiple Ascending doses|5 dose groups with doses ranging from 30mg to 500mg. Given daily for 14 days, under fasting condition.
62298443|NCT02588378||Early dry AMD (no GA)|multi-modal cSLO imaging
62298444|NCT02588378||Late dry AMD (with GA)|multi-modal cSLO imaging
62298445|NCT02588378||Reticular Pseudodrusen (RPD)|multi-modal cSLO imaging
62298446|NCT02588378||Polypoidal Choroidal Vasculopathy (PCV)|multi-modal cSLO imaging
62298447|NCT02588378||Retinal Angiomatous Proliferaion (RAP)|multi-modal cSLO imaging
62298448|NCT02588378||Central Serous Retinopathy (CSR)|multi-modal cSLO imaging
62298449|NCT02588378||RPE Detachment (RPED)|multi-modal cSLO imaging
62298450|NCT02588378||New onset CNVM (wet AMD)|multi-modal cSLO imaging
62298451|NCT02588378||Healthy (non-AMD) controls|multi-modal cSLO imaging
62298452|NCT04101890|EXPERIMENTAL|Diaper care with Theraworx|Participants will be given a 4 week supply of Theraworx Spray Foam, an FDA-registered OTC drug (NDC 61594-000), to apply a thin layer to their infant's entire diaper area with every diaper change (2-4 foam pumps or 4-6 sprays depending on the infant's size) for 4 weeks.
62469403|NCT02995005|EXPERIMENTAL|Tenofovir Disoproxil Fumarate|Women early in pregnancy (end of first or beginning second trimester) will be treated with TDF to determine the efficacy of this strategy to bring \>=95% of women to undetectable HBV DNA levels at delivery.
62469404|NCT01280149|EXPERIMENTAL|substance P-low dose allergen|Substance P injections with 8 sequential, increasing doses of allergen
62668685|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 7|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 6.0 mg/kg"
62668686|NCT06028373|ACTIVE_COMPARATOR|ATG-031 dose level 8|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose level is 9.0 mg/kg"
62668687|NCT04668963|EXPERIMENTAL|INTENSIVE MIRROR THERAPY|The intensive therapy group participants received 5 Mirror Therapy (+physiotherapy) sessions /week for 6 weeks, which makes a total of 30 sessions.
61913738|NCT03515291|PLACEBO_COMPARATOR|Control injection|Control (cell suspension solution) injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
62106725|NCT03834753|EXPERIMENTAL|bevacizumab|ONS-5010
62106726|NCT03834753|ACTIVE_COMPARATOR|ranibizumab|
62106727|NCT05747599|EXPERIMENTAL|Intervention|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
62106728|NCT05747599|ACTIVE_COMPARATOR|Usual Care|Community treatment referrals
62106729|NCT03001986|EXPERIMENTAL|vaccine (3.0 EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
62106730|NCT02561403|EXPERIMENTAL|EVO multitask video game|
62106731|NCT02561403|EXPERIMENTAL|EVO words video game|
62106732|NCT02561403|NO_INTERVENTION|Assessment Only|
62106733|NCT04257851|ACTIVE_COMPARATOR|Group T (n=30)|Theophylline group
62106734|NCT04257851|ACTIVE_COMPARATOR|Group S (n=30)|Sumatriptan group
62106735|NCT05689216|EXPERIMENTAL|Awake timed prone and repositioning group|Patients' cumulative prone and repositioning time is encouraged to reach 8-10 hours per day for 4 days following a timed prone and repositioning strategy.
62106736|NCT05689216|NO_INTERVENTION|Standard care group|Patients can change their positions freely according to their own needs. Health providers do not take the initiative to give guidance on prone and repositioning.
62106737|NCT05532813|EXPERIMENTAL|Metformin arm|Patients randomized in Metformin arm will take metformin orally.
62106738|NCT05532813|PLACEBO_COMPARATOR|Placebo receivers|Patients randomized in placebo arm will take placebo orally in the same procedure as metformin taken.
62106739|NCT05644262|EXPERIMENTAL|T2:C100|
62106740|NCT05644262|PLACEBO_COMPARATOR|Placebo|
62298453|NCT04101890|NO_INTERVENTION|Routine diaper care|Participants continue their typical diaper care.
62668688|NCT04668963|ACTIVE_COMPARATOR|SPACED OVER TIME MIRROR THERAPY|The conventional therapy group received the same number of sessions but more spaced in time, consisting in 3 Mirror Therapy (+physiotherapy) sessions/week for 10 weeks.
62668689|NCT04429594|OTHER|volonteers|
62668690|NCT01531153|ACTIVE_COMPARATOR|Sugar Pill|Sugar Pill will be compared with the active medication Galantamine
62106741|NCT03595943|EXPERIMENTAL|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
62106742|NCT03595943|ACTIVE_COMPARATOR|Regular hospital diet|Moderate glycemic index diet based on hospital menus
62106743|NCT00825435|EXPERIMENTAL|1|Coronary CT angiogram plus Standard of care (CTA+SOC)
62106744|NCT00825435|NO_INTERVENTION|2|Standard of Care (SOC)
62668691|NCT01531153|ACTIVE_COMPARATOR|Galantamine|Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
62106745|NCT06277622|EXPERIMENTAL|Proximal Femoral Universal Nail (PFUN)|
62106746|NCT06277622|ACTIVE_COMPARATOR|Proximal Femoral Nail Antirotation (PFNA)|
62106747|NCT03780790|ACTIVE_COMPARATOR|Quadratus Lumborum Block|US-guided quadratus lumborum block will be performed with 0,5 ml/kg 0.25% Bupivacaine in the anterior layer of the thoracolumbar fascia between psoas major and quadratus lumborum muscles
62106748|NCT03780790|ACTIVE_COMPARATOR|Transversus Abdominis Plane Block|US- guided transversus abdominis plane block will be performed with 0,5 ml/kg 0.25% Bupivacaine into the fascial plane between internal oblique muscle and transversus abdominis muscle
62106749|NCT03780790|ACTIVE_COMPARATOR|Caudal Block|US-guided caudal epidural block will be applied to 0.7 ml/kg 0.25 % Bupivacaine up to a maximum of 20 mL
62106750|NCT01516892|EXPERIMENTAL|BOTOX®|Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
62106751|NCT04991259|EXPERIMENTAL|Preemptive CRRT|In patients randomized to early CRRT, CRRT would be initiated within 12 hours of randomization.
62106752|NCT04991259|ACTIVE_COMPARATOR|Standard Medical Treatment|"In patients randomized to SMT group, CRRT would be initiated as per the existing standard protocol.~1. in patients with worsening hyperammonemia despite two sessions of plasma-exchange~2. patients meeting renal indications (hyperkalemia, volume overload, oliguria or metabolic acidosis etc)."
62106753|NCT02952950|OTHER|Oralstimulation|Infants whose mothers is included in the cohort is randomized to receive oral stimulation when the infant's postnatal age is at least 32 + 0 weeks, as it is the time when the infant is able to coordinate sucking and swallowing reflex
62298454|NCT00577811||1|Patients from 6 different Special Need Plans
62298455|NCT00577811||2|
62298456|NCT01093495|EXPERIMENTAL|CPAP group|Subjects in this group will continue receiving CPAP until no oxygen requirement for 24 hours, then will be weaned off CPAP completely as long as they tolerate. CPAP will be re-instituted if subjects meet failing criteria. Another trial off CPAP will start 24 hours after failure and/or after being on 21% for 24 hours. CPAP will be weaned off directly to room air at all times.
62469405|NCT01280149|EXPERIMENTAL|substance P-moderate dose allergen|Substance P with sequential, increasing doses of allergen
62469406|NCT01280149|EXPERIMENTAL|substance P-low/moderate dose allergen|substance P with 16 sequential increasing doses of allergen
62668692|NCT03490383||patients without CBD calculi|patients without CBD calculi
61913739|NCT04925154||Group A: Patients|Recruitment for this group will take place at either the radiation-oncology department or at the colorectal surgery department, at the time of consultation or at the time of diagnosis, before the treatment setting. Once clinical staging is available, the surgeon and/or radiation-oncologist and/or research assistant should identify eligible patients. Patients that comply with selection criteria (inclusion/exclusion) will be approached by a research team member. For those patients interested in participating, the e-link to the consent form for this group will be sent by email. Once a patient decides to sign the consent form, the link for the questionnaire Q1 will be sent by email.
61913740|NCT04925154||Group B: Physicians|Health professionals will be approached by the research team. The study aim will be explained, and participants that agree to participate will be provided an e-link to consent for this group. Once the health care participant decides to sign the consent form, the link for the questionnaire Q1 will be sent by email.
62106754|NCT02952950|NO_INTERVENTION|Controlgroup|Families in the control group is not seeing the oralstimulation movie, do not receive the script or the supervision of occupational therapists and these infants do not get oral stimulation. Both groups receive instructions after usual practice i.e. guidance and elements that promote breastfeeding example, skin to skin contact and compression.
62106755|NCT00349908|EXPERIMENTAL|Group 1: Atherosclerosis Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
62106756|NCT00349908|ACTIVE_COMPARATOR|Group 2: Aneurysm Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
62106757|NCT03525041|ACTIVE_COMPARATOR|CABG+mitral valve annuloplasty|Participants will undergo CABG and mitral valve annuloplasty.
62106758|NCT03525041|ACTIVE_COMPARATOR|CABG|Participants will undergo CABG only.
62106759|NCT06388447|EXPERIMENTAL|Umbilical cord-mesenchymal stem cells|Injection of the UC-MSC into the interdental papilla using a standardised 1mL syringe will be done. 0.1mL (2millions cells) will be administered per black triangle. If there are three black triangles, only two black triangle will be treated, skipping the middle black triangle to avoid additive effect of the intervention
62106760|NCT06388447|PLACEBO_COMPARATOR|Physiological saline|Injection of the 0.9% Sodium chloride (NaCl) into the interdental papilla using a standardised 1mL syringe will be done. 0.1mL of 0.9% NaCl will be administered per black triangle. If there are three black triangles, only two black triangle will be treated, skipping the middle black triangle to avoid additive effect of the intervention
62106761|NCT00704756||Arm 1|Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium.
62106762|NCT06343584||Group 1|"Must hold the title of Nurse Manager or Interim Nurse Manager at Methodist Mansfield Medical Center. Upon receipt of informed consent, participants will be divided into two groups.~Group 1 will receive a list of suggested tools used to decrease the amount of smartphone interruptions after business hours"
62106763|NCT06343584||Group 2|"Must hold the title of Nurse Manager or Interim Nurse Manager at Methodist Mansfield Medical Center. Upon receipt of informed consent, participants will be divided into two groups.~Group 2 will receive a work-issued smartphone with instructions for use (Appendix C)."
62106764|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
62298457|NCT01093495|EXPERIMENTAL|Nasal Cannula Group|Subjects will be weaned from CPAP (when FiO2 \<0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
62668693|NCT03490383||CBD calculi without ERCP history|patients with CBD calculi without ERCP history
62106765|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
62106766|NCT02197299|EXPERIMENTAL|Carnitine|Oral administration of 4.5 g L-carnitine L-tartrate (containing 3 g L-carnitine; Carnipure, Lonza Ltd., Switzerland) once daily for 24 weeks
62106767|NCT02197299|PLACEBO_COMPARATOR|Sugar pill|Oral administration of placebo sugar pill
62106768|NCT04251351|EXPERIMENTAL|Arm 1|Paracetamol 15 mg/kg/dose 6 hourly for 72 hours
62298458|NCT03408132|EXPERIMENTAL|FE203799 5 mg|FE203799 5 mg subcutaneous injection
62298459|NCT00397150|EXPERIMENTAL|Intervention|Peer-support for exclusive breastfeeding
62298460|NCT00397150|NO_INTERVENTION|No intervention|No intervention
62106769|NCT04251351|SHAM_COMPARATOR|Arm 2|Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.
62106770|NCT04010643|ACTIVE_COMPARATOR|online cognitive behavioural therapy (oCBT)|"20 hours of online engagement with the oCBT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of of the MoodGym program, followed by 2 hours of practical online CBT homework. To equate time and type of engagement spent in doing oCBT and oCBT+NCRT, 1 final hour per week is dedicated to completing online puzzles."
62106771|NCT04010643|EXPERIMENTAL|online neurocognitively-enhanced CBT (oCBT+oNCRT)|"20 hours of online engagement with the oCBT+oNCRT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of the MoodGym program, followed by 1 hour of practical online CBT homework \& 3 hours of the online NCRT programme Cognifit targeting attention, memory, and planning ability."
62298461|NCT01009294|EXPERIMENTAL|Ataluren|Ataluren was provided as a vanilla-flavored powder to be mixed with water, apple juice, or milk. Study drug dosing was based on milligrams of drug per kilogram of body weight. The dose level for ataluren was 20 milligrams/kilograms (mg/kg) in the morning, 20 mg/kg at midday, and 40 mg/kg in the evening. Administration within 30 minutes after a meal was recommended. Study drug was taken for up to 50 days.
62298462|NCT06250387|EXPERIMENTAL|Patients with mediastinal lymphadenopathy|Patients with suspicion of lymphoma, sarcoidosis and tuberculosis, presenting with mediastinal lymphadenopathy confirmed by a CT scan and/ or PET scan and patients with previous negative EBUS-TBNA.
62668694|NCT03490383||CBD calculi with ERCP history|patients with CBD calculi and ERCP history
62668695|NCT00442156||Laser|People with diabetic macular edema involving the center of the macula (OCT central subfield thickness \>250 microns), who were already intended to receive focal photocoagulation
62668696|NCT03924297|EXPERIMENTAL|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
62668697|NCT05146765|EXPERIMENTAL|Intervention|The intervention group will receive treatment as usual along with the speech therapy app.
62668698|NCT05146765|NO_INTERVENTION|Control|The control group will receive treatment as usual only.
62668699|NCT01895647|EXPERIMENTAL|Biceps stimulation|EMS
62298463|NCT00277537|EXPERIMENTAL|1|
62298464|NCT00277537|OTHER|2|
62668700|NCT01895647|EXPERIMENTAL|Quadriceps stimulation|EMS
62106772|NCT02205151|OTHER|Treatment AB|"Treatment A (1 day) → wash-out(14days) → Treatment B (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
62298465|NCT02979314|EXPERIMENTAL|Galvanic Vestibular Stimulation|A standard placement of the electrodes will be used for GVS and sham, placed on the mastoids. Weak currents up to maximally 3 mA will be used (tested before in each participant individually, and expected mean current will be around 1.5 mA). Previous studies have used Magnetic Resonance (MR) compatible GVS without reporting any discomfort for the participants, however weak sensations of nausea could be possible and in case that they are disturbing for the participants the experiment will be aborted. Continuous stimulation for up to 30min with intensities of 1-1.5 mA is generally considered as safe and free of any considerable side effects.
62298466|NCT03036930|EXPERIMENTAL|Prevention (Gardasil 9 HPV vaccine)|Participants receive the first dose of the recombinant human papillomavirus nonavalent vaccine IM at baseline, at least 30 days prior to the kidney transplant surgery. The second dose is given at least one month after the first dose. The third dose is given at least five months after the first dose and at least three months after the second dose. The timing of the second and third doses is dependent on the scheduling of the kidney transplant surgery. Patients are followed up at 6- and 12-months after the kidney transplant surgery to measure vaccine-induced immune responses. Patients may receive either one, two, or all three vaccine doses prior to the kidney transplant surgery, and are offered additional visits at least one year after the surgery to complete any remaining doses of the three-dose vaccine series. Patients also undergo collection of blood samples and self-collection of cervical/vaginal samples (female participants only) on study.
62298467|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
62298468|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
62298469|NCT06656676|EXPERIMENTAL|Intervention group: Transgender women|Transgender women randomized to the intervention group will use WePrEP with a PrEP service provider. WePrEP will be stored on providers' tablets and will present oral PrEP and CAB-LA priority information points, identified during preliminary studies, and cue relevant discussions. Once a transgender woman assigned to the control group selects her preferred PrEP method, the provider will review the appropriate adherence strategies using WePrEP.
62298470|NCT06656676|ACTIVE_COMPARATOR|Control group: Transgender women|Transgender women randomized to the Control Group will receive a standard of care PrEP explanation from a PrEP services provider designated to deliver this trial condition. This explanation follows the 2021 CDC PrEP Clinical Guidelines, which have been updated to include information about CAB-LA.
61913741|NCT06531590||ketamine group|patients receiving ketamine as analgesic after shoulder dislocation
62668701|NCT01895647|NO_INTERVENTION|Control|Control group without electric muscle stimulation
62298471|NCT06656676|EXPERIMENTAL|Intervention group: PrEP service providers|During the study, PrEP service providers randomized to the intervention group will use WePrEP with transgender women participants in the intervention group who are potential PrEP patients. WePrEP will be stored on providers' tablets and will present oral PrEP and CAB-LA priority information points, identified during preliminary studies, and cue relevant discussions. Once the participant selects her PrEP method, the provider will review the appropriate adherence strategies. To ensure that they are able to provide feedback on WePrEP in IDIs, intervention group PrEP service providers will use WePrEP with a minimum of 8 different transgender women in this study.
62469407|NCT01280149|ACTIVE_COMPARATOR|substance P-placebo|Placebo injections of substance P and placebo
62668702|NCT04954235||Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia who received treatment with 2 infusions of 4 mg / Kg each of hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) separated by 48 hours
62668703|NCT04954235||Not Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia not exposed to hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) during hospitalization corresponding to the period prior to the approval of the hyperimmune anti-SARS-CoV-2 serum for its use.
62668704|NCT06135545|EXPERIMENTAL|T Group|The T group used liposomal bupivacaine for ultrasound-guided serratus anterior plane block.
62668705|NCT06135545|ACTIVE_COMPARATOR|C Group|The C group used traditional ropivacaine for ultrasound-guided paravertebral nerve block.
62668706|NCT06135909||PH Patients receiving targeted drugs treatment|Patients with pulmonary hypertension receiving targeted drugs treatment
62668707|NCT06210633||Endovascular thrombectomy|Patients in this group will be treated with medical management plus endovascular thrombectomy
62668708|NCT06210633||Medical management|Patients in this group will be treated with medical management alone
62668709|NCT02092428|EXPERIMENTAL|Image Quality|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to compare image quality between contrast and non-contrast scans.
62668710|NCT02092428|EXPERIMENTAL|Diagnostic Accuracy|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to assess the diagnostic accuracy of coronary MRI in detecting CAD as compared to conventional x-ray angiography
61913742|NCT06531590||intraarticular lidocaine injection group|patients receiving intraarticular lidocaine injection as analgesic after shoulder dislocation
61913743|NCT06531590||interscalene nerve block group|patients receiving interscalene nerve block group as analgesic after shoulder dislocation
61913744|NCT06531590||suprascapular nerve block group|patients receiving suprascapular nerve block group as analgesic after shoulder dislocation
62106773|NCT02205151|OTHER|Treatment BA|"Treatment B (1 day) → wash-out(14days) → Treatment A (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
62106774|NCT04036162|EXPERIMENTAL|Young group|Young Right-handed healthy volunteers
62668711|NCT02760511|PLACEBO_COMPARATOR|Control|Intake of placebo capsules
62668712|NCT02760511|ACTIVE_COMPARATOR|20 mg|Daily intake of 20 mg anthocyanin
62668713|NCT02760511|ACTIVE_COMPARATOR|40 mg|Daily intake of 40 mg anthocyanin
62668714|NCT02760511|ACTIVE_COMPARATOR|80 mg|Daily intake of 80 mg anthocyanin
62668715|NCT02760511|ACTIVE_COMPARATOR|160 mg|Daily intake of 160 mg anthocyanin
62668716|NCT02760511|ACTIVE_COMPARATOR|320 mg|Daily intake of 320 mg anthocyanin
62106775|NCT04036162|EXPERIMENTAL|Aged group|Aged Right-handed healthy volunteers
62106776|NCT03872869|ACTIVE_COMPARATOR|Hip School|The participants in the Hip School were required to attend three 1.5 hour classes which were conducted by specially trained physiotherapists in premise at Lund University.
62298472|NCT06656676|ACTIVE_COMPARATOR|Control group: PrEP service providers|PrEP service providers randomized to the Control Group will give transgender women enrolled in this study a standard of care PrEP explanation. This explanation follows the 2021 CDC PrEP Clinical Guidelines, which have been updated to include information about CAB-LA.
62298473|NCT04358757||Cesarean patients|participants undergoing elective cesarean will have measures of recovery assessed (patient-reported outcome measures and activity data from watch)
62298474|NCT04402502|EXPERIMENTAL|Healthy Population|Healthy Individuals with no presence of neurological disorders, rheumatoid arthritis or comorbid health conditions, and are not pregnant.
62298475|NCT06559709|EXPERIMENTAL|Supportive care (meal delivery service)|Patients receive 3 meals per day and snacks delivered twice weekly and meet with dietitian once weekly on days -7 to 28. Patients undergo blood and stool sample collection on study.
62298476|NCT04339868|ACTIVE_COMPARATOR|Terlipressin group|Terlipressin acetate 1 mg in 0.9% normal saline (NaCl) 50 mL (0.02 mg/mL) Initial dose 20 mcg/hr (1 mL/hr) titrate increase 1 mL/hr every 30 min to 100 mcg/hr (5 mg/hr) to keep mean arterial blood pressure (MAP) \> 65 mmHg If MAP \> 75 mmHg for \> 30 min, decrease epinephrine and norepinephrine until \< 0.15 mcg/kg/min, then decrease terlipressin until stop
62298477|NCT04339868|PLACEBO_COMPARATOR|Placebo group|Placebo 0.9% NaCl 50 mL Initial dose 1 mL/hr titrate increase 1 mL/hr every 30 min to 5 mg/hr to keep mean arterial blood pressure (MAP) \> 65 mmHg If MAP \> 75 mmHg for \> 30 min, decrease epinephrine and norepinephrine until \< 0.15 mcg/kg/min, then decrease placebo until stop
62298478|NCT04352920|EXPERIMENTAL|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
62668717|NCT01719302|EXPERIMENTAL|cohort 1|
62668718|NCT03467945|EXPERIMENTAL|Treatment Sequence 1|Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
62668719|NCT03467945|EXPERIMENTAL|Treatment Sequence 2|Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
62668720|NCT03467945|EXPERIMENTAL|Treatment Sequence 3|Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
62106777|NCT03872869|ACTIVE_COMPARATOR|Tai Chi for arthritis (TCA)|The treatment intervention with TCA was scheduled in a group setting. Class size for Tai Chi groups was 8- 10 individuals. The group was led by a physiotherapist, specially trained in the concept, in premise at Lund University. The participants in the Tai Chi group were required to attend classes for 12-16 one- hour sessions, twice a week for the first four weeks and then once a week.
62106778|NCT03872869|NO_INTERVENTION|Control group|
62106779|NCT02966743|EXPERIMENTAL|midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
62106780|NCT02966743|ACTIVE_COMPARATOR|dexmedetomidine|administration of dexmedeomidine during spinal anesthesia for target bispectral index 75-80
62106781|NCT01367912|NO_INTERVENTION|Progesterone only group|received a single daily application of vaginal progesterone gel beginning from the day of OPU and continued at least until pregnancy was ruled out by a negative serum ß-hCG measurement performed on the 14th day after embryo transfer with no E2 added
62106782|NCT01367912|ACTIVE_COMPARATOR|Progesterone+Early Estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
62106783|NCT01367912|ACTIVE_COMPARATOR|Progesterone+Late estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel
62106784|NCT04616365|EXPERIMENTAL|Semi-Elective Lung Transplantation|Planned Semi-Elective Lung Transplantation Using 10°C Cold Static Preservation
62106785|NCT01512966|EXPERIMENTAL|VTE 2Q4 first, then VTE 2Q8|VEGF Trap-Eye \[BAY86-5321; EYLEA (aflibercept) Injection\] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)
62298479|NCT06448988||Supine position|To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
62298480|NCT03102684|NO_INTERVENTION|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
62298481|NCT03102684|EXPERIMENTAL|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
62298482|NCT03102684|EXPERIMENTAL|High exposure|Secondhand exposure to e-cigarette aerosols (high)
62298483|NCT02897609||A simple questionary filled|
62298484|NCT01717248|EXPERIMENTAL|GCS-100|GCS-100 will be administered once weekly by a ten minutes injection.
62298485|NCT00942006|ACTIVE_COMPARATOR|LNB-doxycycline|
62298486|NCT00942006|ACTIVE_COMPARATOR|LNB-ceftriaxone|
62298487|NCT01639183|EXPERIMENTAL|Rotating-oscillating Power Toothbrush|Nursing home residents will be randomly assigned to receive power toothbrushing twice daily by their caregivers using a rotating-oscillating power toothbrush.
62298488|NCT01639183|ACTIVE_COMPARATOR|Standard Care|This arm comprises the control group where nursing home residents will receive standard daily oral care as usual.
62106786|NCT06630377|EXPERIMENTAL|Dietary intervention with GOS|Eligible subjects are instructed to take one pocket of galactooligosaccharide during the first week, followed by two pockets of galactooligosaccharide during the remaining 7 weeks.
62298489|NCT00900796||1|Patients diagnosed with active AS who start anti-TNF therapy according to standard clinical practice.
62298490|NCT02594501|EXPERIMENTAL|COBRA PzF|Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
62298491|NCT02594501|ACTIVE_COMPARATOR|Drug Eluting Stent|standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
62298492|NCT01617538|EXPERIMENTAL|Atorvastatin|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.
62298493|NCT01617538|NO_INTERVENTION|compare|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.
62298494|NCT03643692|EXPERIMENTAL|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
62469408|NCT01280149|EXPERIMENTAL|placebo-low dose allergen|Placebo injections with 8 sequential increasing low dose allergen injections
62106787|NCT06630377|PLACEBO_COMPARATOR|Dietary intervention with Placebo|Eligible subjects are instructed to take one pocket of maltodextrin during the first week, followed by two pockets of maltodextrin during the remaining 7 weeks.
62106788|NCT02387749|EXPERIMENTAL|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R\&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
62298495|NCT02941367|EXPERIMENTAL|Lyxumia|Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
62298496|NCT02941367|ACTIVE_COMPARATOR|Sulfonylurea|Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
62298497|NCT04205552|EXPERIMENTAL|Nivolumab|"Nivolumab 2 cycles, every two weeks (q2w)~o Nivolumab 240 mg i.v. over 30 min"
62298498|NCT04205552|EXPERIMENTAL|Nivolumab/Relatlimab (80 mg)|"Nivolumab/Relatlimab (80 mg) 2 cycles, every two weeks (q2w)~* Nivolumab 240 mg i.v. over 30 min~* Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)"
62298499|NCT04205552|EXPERIMENTAL|Nivolumab/Relatlimab (240 mg)|"Nivolumab/Relatlimab (240 mg) 2 cycles, every two weeks (q2w)~* Nivolumab 240 mg i.v. over 30 min~* Relatlimab 240 mg i.v. over 30 min (within 30 min of nivolumab)"
62298500|NCT04331301|ACTIVE_COMPARATOR|vapoenucleation group|Group A
62298501|NCT04331301|ACTIVE_COMPARATOR|needlescopic enucleation|group B
62469409|NCT01280149|PLACEBO_COMPARATOR|placebo-placebo|substance P placebo and allergen placebo (weekly)
62469410|NCT04267627|NO_INTERVENTION|Usual Care|No intervention.
62469411|NCT04267627|EXPERIMENTAL|CARING with telemedicine|Patients will receive the nurse-led supportive care intervention over telemedicine videoconferencing from home or from a satellite telemedicine site in Virginia.
62668721|NCT03467945|EXPERIMENTAL|Treatment Sequence 4|Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
62668722|NCT04680143|EXPERIMENTAL|Systemic erythropoietin injections|The study included 10 patients diagnosed as post papilledemic optic atrophy
62668723|NCT03158311|EXPERIMENTAL|QVM149 150/50/80 μg|QVM149 150/50/80 μg o.d. delivered via Concept1
62668724|NCT03158311|EXPERIMENTAL|QVM149 150/50/160 μg|QVM149 150/50/160 μg o.d. delivered via Concept1
62668725|NCT03158311|ACTIVE_COMPARATOR|Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
62668726|NCT04663672|EXPERIMENTAL|Exposure Therapy + Exposure Scent Cue During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of the exposure scent.
62106789|NCT05825079|EXPERIMENTAL|Weight-Bearing Feedback Delivered to Mobile Phone|The weight-bearing tracking system is attached to the patient's crutch and calculates how much weight is being put on the crutch. Feedback of this data can be delivered to the patient through a mobile phone application. For Arm A of the study, feedback is delivered to the patient's paired mobile phone, providing them information on how much weight they are exerting on their crutch/injured lower extremity.
62298502|NCT06065046|SHAM_COMPARATOR|Control group|Participants will receive standard treatment and care according to the current management guidelines for traumatic brain injury, e.g. the guideline made by U.S. Brain Trauma Foundation (BTF)
62298503|NCT06065046|EXPERIMENTAL|Baricitinib group|Besides receiving standard treatment and care, baricitinib will be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg, for consecutive 14 days after patients' brain injury.
62298504|NCT02687269|EXPERIMENTAL|Ranolazine|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, Ranolazine at a dose of 375 mg twice daily.
62298505|NCT02687269|PLACEBO_COMPARATOR|Placebo|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, placebo twice daily.
62298506|NCT04000646|OTHER|standard care|Standard care non-pharmacologic interventions during anesthesia induction
62298507|NCT04000646|EXPERIMENTAL|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
62298508|NCT05436249|OTHER|Real time neurofeedback with task|Participants will undergo a real-time fMRI scan during which two distinct tasks will be performed.
62298509|NCT05436249|OTHER|Overt tapping and/or motor imagery practice|Participants will undergo an overt tapping task at baseline. Participants are assigned to a group where they will then perform respective motor and/or imagery tasks at home for 3 weeks.
62298510|NCT06122584|EXPERIMENTAL|[18F]PSMA-1007|Single intravenous administration of \[18F\]PSMA-1007 for Positron Emission Tomography (PET) scan
62298511|NCT02795988|EXPERIMENTAL|Phase 1b|10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
62106790|NCT05825079|ACTIVE_COMPARATOR|No Weight-Bearing Feedback|The weight-bearing tracking system is attached to the patient's crutch and calculates how much weight is being put on the crutch. For Arm B, no feedback about weight-bearing status is delivered to the patient.
62106791|NCT02714803|EXPERIMENTAL|Connective tissue massage group|Connective tissue massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
62298512|NCT02795988|EXPERIMENTAL|Phase 2 - IMU 131 plus chemotherapy|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
62298513|NCT02795988|EXPERIMENTAL|Phase 2 - Chemotherapy only|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
62106792|NCT02714803|ACTIVE_COMPARATOR|Classic massage group|Classic massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
62298514|NCT06504381|EXPERIMENTAL|No MGMT Methylation (DB107-RRV, DB107-FC, Radiation therapy)|Participants receive a 4.0 x 10\^8 transduction units per milliliter (TU/mL)) dose of DB107-RRV intracranially (IC) at resection and a 1.4 x 10\^9 TU/mL dose IV prior to leaving surgery room. Participants have up to 6 weeks for surgical recovery. Unmethylated MGMT participants receive 300 mg/kg/day DB107-FC PO during RT over 5 days during weeks 1-2, \& 5-6. 2Gy/day standard of care (SOC) RT will be given for 5 consecutive days for 6 weeks. After RT, participants receive 1.4 x 10\^9 TU/mL of DB107-RRV IV on days 7 and 14 and continue during a 4-week rest period between RT and adjuvant therapy. Participants who begin adjuvant therapy receive 300 mg/kg/day DB107-FC PO on days 1-5 of a 28-day cycle up to 6 cycles or until PD. Participants with no PD during adjuvant treatment may receive additional cycles of DB107-FC until PD, withdrawal, death or study closure. Participants will be followed up for safety and survival status for up to 15 years.
62469412|NCT04267627|EXPERIMENTAL|CARING face-to-face|Patients will receive the nurse-led supportive care intervention in person.
62469413|NCT00448903|EXPERIMENTAL|A|Bemiparin
62469414|NCT00448903|PLACEBO_COMPARATOR|2|Placebo
62469415|NCT01764347|EXPERIMENTAL|Diagnostic (MRI-TRUS fusion image-guided biopsy)|Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies.
62469416|NCT00886275|EXPERIMENTAL|Dexmedetomidine|
61913745|NCT06485115|EXPERIMENTAL|Home-based Digital motor Telerehabilitation added to conventional therapy|All patients will receive an individualized ten sessions of an in-hospital rehabilitation program (1 hour/day, 3 days/week) by a qualified physiotherapist at each participating unit. Then, the EG will follow a 12-week individualized Digital Telerehabilitation program (1 hour/day, 3 days/week, EG).
62106793|NCT02714803|SHAM_COMPARATOR|Sham massage group|Sham massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
62106794|NCT02028130|EXPERIMENTAL|LAA electrical isolation + occlusion|Standard persistent AF ablation protocol + LAA electrical isolation + Watchman device implantation to occlude LAA
62106795|NCT05478772|EXPERIMENTAL|CTP-543 and Fluconazole Treatment|On Day 1, each subject will receive a single oral dose of 12 mg CTP-543. Following a washout on Day 2, each subject will receive an oral dose of 200 mg fluconazole once daily on Days 3 through to Day 8. On Day 7, approximately 1 hour after the 200 mg dose of fluconazole, each subject will receive a single oral dose of 12 mg CTP-543.
62106796|NCT06225999|EXPERIMENTAL|Irinotecan liposome Injection in combination with oxaliplatin, 5-FU and LLV|
62106797|NCT04672473|EXPERIMENTAL|Treatment|DAC combined with Ag-CTL
62106798|NCT00819884|EXPERIMENTAL|1|twice daily during 4 days
62106799|NCT00819884|EXPERIMENTAL|2|once daily during 4 days
62106800|NCT05502211|EXPERIMENTAL|Lidocaine|
62106801|NCT05502211|ACTIVE_COMPARATOR|Fentanyl|
62106802|NCT05954169|EXPERIMENTAL|Treatment group A in moderately renal insufficiency subjects|
62106803|NCT05954169|EXPERIMENTAL|Treatment group B in healthy subjects|
62106804|NCT02480335|EXPERIMENTAL|Usual care and bosentan|Usual care and also treatment with bosentan.
62106805|NCT02480335|NO_INTERVENTION|Usual care|Usual care only.
62106806|NCT03515720|EXPERIMENTAL|Study group|Painful points will be located in the path of the sensory nerves of the knee in which asepsis and antisepsis will be performed, and then 0.5-1 ml of 5% dextrose solution will be applied subcutaneously at a 45º angle along the way. of the nerve with a 27 gauge needle of ½ inch. The number of injections will vary according to the symptoms to be treated. The application will be made once a week for 6 weeks. After the first application of neuroprolotherapy, the patient will be trained to perform a rehabilitation therapy program based on thermotherapy, kinesitherapy and knee strengthening exercises. At the end of the 6 sessions, a new assessment will be made with the WOMAC, EVA and measurement of movement arcs to assess the evolution after treatment.
62106807|NCT03515720|NO_INTERVENTION|Control group|Physical therapy consisting of 10 sessions based on thermotherapy, kinesitherapy and muscle strengthening exercises to the knee. Subsequently, the patient will perform this therapy home until completing 6 weeks. At the end a new assessment will be made with measurement of movement arcs, WOMAC scale and EVA to assess the evolution after treatment.
62106808|NCT00658060||1|"* 1.Fulfilling the Tel Hashomer criteria for the diagnosis of FMF \[5\].~* 2.Suffering from episodes of exertional leg pain and or exertional ankle edema~* 3.18-45 years old~* 4.On a stable (≥ 2 weeks) dose of oral colchicine therapy~* 5.Non-smokers"
62668727|NCT04663672|PLACEBO_COMPARATOR|Exposure Therapy + Novel Scent During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of a novel scent.
62668728|NCT04663672|SHAM_COMPARATOR|Exposure Therapy + No-Scent Control During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of an odorless control vehicle.
62106809|NCT00658060||2|"Control group~* 1.Healthy subjects~* 2.18-45 years old~* 3.Non-smokers"
62106810|NCT06028113|EXPERIMENTAL|Treatment Group|The Teaching Healthy Responsive Parenting during Infancy to promote Vital growth and rEgulation (THRIVE 2.0) group will consist of 4 sessions delivered by the trained IBH provider, in conjunction with the 1, 2, 4, and 6 month well-child visit in primary care. The THRIVE curriculum teaches responsive parenting principles targeted to establish healthy eating, sleeping, and regulation habits for infants.
62298515|NCT06504381|EXPERIMENTAL|Low to High MGMT Methylation (DB107-RRV, DB107-FC, Temozolomide (TMZ), Radiation therapy)|Participants receive a 4.0 x 10\^8 TU/mL dose of DB107-RRV IC at resection and a 1.4 x 10\^9 TU/mL dose IV prior to prior to leaving surgery room. Participants have up to 6 weeks for surgical recovery. Low to high MGMT methylation participants receive 75 mg/m\^2 TMZ per SOC and 300mg/kg/day DB107-FC PO concurrent with 2Gy/day over 5 consecutive days during weeks 1-2, \& 5-6. After RT, participants receive 1.4 x 10\^9 TU/mL DB107-RRV IV on days 7 and 14. IV DB107-RRV occurs during a 4-week rest period between RT and adjuvant portions of the protocol. Participants who begin adjuvant therapy receive 300 mg/kg/day DB107-FC PO on days 1-5 of a 28-day cycle for up to 6 cycles or until PD with 150-200 mg/m\^2 adjuvant TMZ per SOC on days 1-5 of each cycle for up to 6 cycles. Participants with no PD may continue to receive additional cycles of DB107-FC PD, withdrawal, death or study closure. Participants will be followed up for safety and survival status for up to 15 years.
62469417|NCT00886275|ACTIVE_COMPARATOR|Midazolam|
61913746|NCT06485115|OTHER|Conventional therapy alone|All patients will receive an individualized ten sessions of an in-hospital rehabilitation program (1 hour/day, 3 days/week) by a qualified physiotherapist at each participating unit. Then, the CG will not receive any additional therapy except for general instructions for self- management according to the allocation group.
62469418|NCT00886275|EXPERIMENTAL|Dexmedetomidine, Midazolam|Combination
61913747|NCT05291468|ACTIVE_COMPARATOR|C Acnes present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
62106811|NCT06028113|NO_INTERVENTION|Control Group|Control arm: Usual Pediatric Care. The control condition is usual care delivered by pediatricians at 1, 2, 4, and 6 month well child visits.
62106812|NCT04767230|ACTIVE_COMPARATOR|A heart-healthy diet + Flaxseed + Olive oil|A heart-healthy diet with a specified number of food servings from different food groups (including vegetables, fruits, grains, dairy products, meats) + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil (equivalent to 4 tablespoons; 2 tablespoons for lunch and 2 tablespoons for dinner) for 3 months
62106813|NCT04767230|PLACEBO_COMPARATOR|A heart-healthy diet|Recommendations for a heart-healthy diet, such as those of the American Heart Association for 3 months. These include eating at least 5 servings of vegetables and fruits daily, reduction in the consumption of sources of saturated and trans fats by avoiding the consumption of high-fat red meats and replacing them with low-fat meat or with poultry and fish, replacing low-fat dairy sources with regular or high-fat ones; consumption of regular vegetable oils such as canola and sunflower; reduction in salt consumption; and reduction in the consumption of simple sugars for 3 months
61913748|NCT05291468|PLACEBO_COMPARATOR|C Acnes present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
61913749|NCT05291468|ACTIVE_COMPARATOR|C Acnes NOT present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
62298516|NCT02248376|EXPERIMENTAL|Gel +|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
62668729|NCT06296693|EXPERIMENTAL|POCUS-L|The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged \>12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
62668730|NCT04992286|EXPERIMENTAL|people aged 65 years or more|men or women, age Superior to 65 years
62668731|NCT01873833|EXPERIMENTAL|Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)|Patients receive capecitabine by mouth (PO) every day (QD), cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62668732|NCT01112007||prehypertension|Subjects with prehypertension, that is, individuals with systolic blood pressure in the range of 120-139 mmHg or diastolic BP between 80-89 mmHg.
61913750|NCT05291468|PLACEBO_COMPARATOR|C. Acnes NOT present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
61913751|NCT04897139|EXPERIMENTAL|treatment arm|treatment arm
62106814|NCT02175212|EXPERIMENTAL|Long term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* High dose conformal radiotherapy~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
62298517|NCT02248376|NO_INTERVENTION|Gel -|Patients aged of more than 18 years-old coming for a natural miscarriage who will not have the non-stick gel application at the end of the scraping surgery.
62298518|NCT04209738||Eurythmy Therapy (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified therapist: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by an eurythmy manual and an exercise video. This complements the regular care.
62298519|NCT04209738||Tai Chi (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified teacher: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by a Tai Chi manual and a practice video. This complements the regular care.
62298520|NCT04209738||Standard Care|"Brochure with detailed description of different evidence-based measures for fall prevention, created for the specific age group (Gleichgewicht \& Kraft - Trittsicher durchs Leben https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf) and recommendation to visit the family doctor and discuss fall prophylaxis with him."
62298521|NCT04475341|ACTIVE_COMPARATOR|BMS without BMAC|
62469419|NCT03606278|EXPERIMENTAL|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
62668733|NCT00746720|EXPERIMENTAL|A, 1|Study part 1 (n = 8)
62668734|NCT00746720|PLACEBO_COMPARATOR|A, 2|Study part 1 (n = 4)
62668735|NCT00746720|EXPERIMENTAL|B, 1|Study part 2 (n = 20)
62668736|NCT00746720|PLACEBO_COMPARATOR|B, 2|Study part 2 (n = 20)
62668737|NCT01197027|EXPERIMENTAL|Enhanced counseling|5 intensive counseling sessions following acute HIV infection
62668738|NCT01197027|ACTIVE_COMPARATOR|Standard counseling|Standard HIV counseling following acute HIV infection
62668739|NCT00574899||1|patients scheduled to receive standard of care with a Radical prostatectomy
62668740|NCT00574899||2|patients scheduled to receive standard of care with radiation therapy
62668741|NCT02830633|EXPERIMENTAL|LNTME|Laparoscopy-assisted nerve-preserved TME (LNTME) is conducted in rectal cancer patients
61913752|NCT03027284|EXPERIMENTAL|Merestinib (Part A Dose Level 1)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
61913753|NCT03027284|EXPERIMENTAL|Merestinib (Part A Dose Level 2)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
62469420|NCT03606278|ACTIVE_COMPARATOR|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
62469421|NCT01228461||AYA with Fatigue and Hodgkin Lymphoma|
62668742|NCT02830633|ACTIVE_COMPARATOR|OTME|Open TME (OTME) is conducted in rectal cancer patients
62668743|NCT00601237|EXPERIMENTAL|A|Participants will receive HIV-related text messages
62668744|NCT00601237|ACTIVE_COMPARATOR|B|Participants will receive nutrition-related text messages
62668745|NCT00601237|NO_INTERVENTION|C|Participants will attend a 90-minute focus group to develop messages for the cell-phone program
62106815|NCT02175212|ACTIVE_COMPARATOR|Short term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* High dose conformal radiotherapy"
62106816|NCT03384537|EXPERIMENTAL|Listerine total care zero|Listerine total care zero
62298522|NCT04475341|EXPERIMENTAL|BMS with BMAC|
62298523|NCT03050684|ACTIVE_COMPARATOR|vaginal lavage group|We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule
62298524|NCT03050684|PLACEBO_COMPARATOR|Control group|We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.
62298525|NCT04827238||Patients with Elevated Gradients Post Transcatheter Aortic Valve Replacement|Patients who have an echocardiographic transaortic mean gradient ≥ 20mmHg OR VARC-3 criteria for ≥ moderate hemodynamic valve deterioration post TAVR on any TTE \> 1 month post-TAVR
62298526|NCT04764188||Cohort 1|Participants starting alectinib treatment after (Arm A) or before (Arm B) study enrollment as first-line treatment will be followed up for up to 4 years.
62298527|NCT04764188||Cohort 2|Participants receiving alectinib as second-line treatment after study enrollment will be followed up for up to 2 years.
62298528|NCT05666089|EXPERIMENTAL|N-acetylcysteine|intracanal medication of NAC paste
62298529|NCT05666089|ACTIVE_COMPARATOR|Calcium hydroxide|intracanal medication of Ca(OH)2 paste
62298530|NCT05787704||Multiple Sclerosis|People with Multiple Sclerosis, 18 years or older
62469422|NCT04108572|EXPERIMENTAL|Infant feeding intervention|The intervention will be delivered to parents by practice nurses and/or GPs in MPHC at each of the vaccination visits, prior to administration of the vaccination. These vaccination visits take place at 2, 4, 6, 12 and 13 months. This intervention consists of 1) verbally delivered pre-specified infant feeding messages, and 2) provision of additional infant-feeding resources including an information leaflet, a magnet, an infant bib and access to an informational website.
61913754|NCT03027284|EXPERIMENTAL|Merestinib + Cisplatin + Gemcitabine (Part B)|Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
62469423|NCT02080845|PLACEBO_COMPARATOR|no caffeine & no theobromine|Drink 1
62469424|NCT02080845|EXPERIMENTAL|no caffeine & low theobromine|Drink 2
62469425|NCT02080845|EXPERIMENTAL|no caffeine & high theobromine|Drink 3
62106817|NCT03384537|ACTIVE_COMPARATOR|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
62298531|NCT04407767|EXPERIMENTAL|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
62469426|NCT02080845|EXPERIMENTAL|high caffeine & no theobromine|Drink 4
62469427|NCT05218486|ACTIVE_COMPARATOR|Isotretinoin group|Patients will be treated with Isotretinoin in a dose (from 20 to 40) for 3 months and serum YKL40 will be assessed before and after treatment
62668746|NCT02037074|EXPERIMENTAL|Experimental: EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 14
62106818|NCT00851942|EXPERIMENTAL|Synacthen 250 micrograms|IV injection of 250 micrograms of Synacthen in 1m
62106819|NCT06454773|ACTIVE_COMPARATOR|intervention|bioactive compound from black pepper and hemp hull
62106820|NCT06454773|PLACEBO_COMPARATOR|control|Placebo
62298532|NCT04407767|ACTIVE_COMPARATOR|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
62469428|NCT05218486|NO_INTERVENTION|Control group|Assessment of serum YKL40 in healthy individuals
62469429|NCT03337997|EXPERIMENTAL|Study group|All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
62469430|NCT03352518|EXPERIMENTAL|IMD data collection|Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators.
62469431|NCT04989374||CD patients treated with WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these CD patients treated with WMT
62668747|NCT02037074|EXPERIMENTAL|Experimental: EVP-6308; Arm 2|intermediate dose, Capsule, Once Daily, Day 1 through Day 14
62668748|NCT02037074|EXPERIMENTAL|Experimental: EVP-6308; Arm 3|high dose, Capsule, Once Daily, Day 1 through Day 14
62668749|NCT02037074|PLACEBO_COMPARATOR|Placebo Comparator; Arm 4|Placebo, Capsule, Once Daily, Day 1 through Day 14
62668750|NCT04135651|EXPERIMENTAL|Paralaryngeal pressure|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
62668751|NCT04135651|ACTIVE_COMPARATOR|Cricoid pressure|During the induction of anesthesia, cricoid pressure is applied by 30N force with three fingers.
62668752|NCT05135325|EXPERIMENTAL|No-blood-type message|This group will receive a message that does not mention the patient's blood type, or that the patient's blood type is in short supply.
62668753|NCT05135325|EXPERIMENTAL|Blood-type message|This group will receive a message that mentions the patient's blood type and that states their blood type is in short supply.
61913755|NCT03961477|ACTIVE_COMPARATOR|IF group|Interferential therpapy
61913756|NCT03961477|NO_INTERVENTION|Placebo|No intervention
62668754|NCT05135325|NO_INTERVENTION|Shortage control|This group will not receive a message.
62106821|NCT03296371||Ancillary-Correlative (biospecimen collection)|Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal mucosa is evaluated via whole exome sequencing.
62668755|NCT05135325|NO_INTERVENTION|No-shortage control|This group will not receive a message.
62106822|NCT01450878|EXPERIMENTAL|Graft with EPO|intravenous 1000 000UI beta-epoietin one hour before organe retrieval.
62106823|NCT01450878|NO_INTERVENTION|graft without EPO|no injection befoe organ retrieval
62106824|NCT06627439|EXPERIMENTAL|Web-based Comadres Saludables CHW Training|Experimental group participants will have access to the web-based Comadres Saludables training for three months.
62106825|NCT06627439|ACTIVE_COMPARATOR|HHS Promoting Healthy Choices and Community Changes|Control condition participants will receive information on how to access the HHS CHW Promoting Healthy Choices and Community Changes training. They will be asked to review for three months.
62106826|NCT01710514|ACTIVE_COMPARATOR|FE 999913 100 mg BID|FE 999913 100 mg vaginal tablet BID
62106827|NCT01710514|ACTIVE_COMPARATOR|FE 999913 100 mg TID|FE 999913 100 mg vaginal tablet TID
62106828|NCT03526081|EXPERIMENTAL|Chamomile Tea|Chamomile Tea in 300mL hot water
62106829|NCT03526081|EXPERIMENTAL|Parsley based drink|3.2 g dried parsley in 300mL hot water
62106830|NCT03526081|EXPERIMENTAL|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
62106831|NCT03526081|EXPERIMENTAL|Apigenin|Apigenin capsule mixed with 300mL hot water
62106832|NCT03526081|EXPERIMENTAL|Parsley-based drink (II)|3.2 g of dried parsley in 300 ml of hot water
62298533|NCT03756090|EXPERIMENTAL|Experimental group|Arm I: Palbociclib combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
62469432|NCT04989374||CD patients treated without WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these CD patients treated without WMT
62106833|NCT06630923|ACTIVE_COMPARATOR|IV Human Albumin + IV Furosemide|Continuous slow IV infusion of Human Albumin plus IV Furosemide
62106834|NCT06630923|PLACEBO_COMPARATOR|IV Furosemide alone|Continuous slow IV infusion of Furosemide
62298534|NCT03756090|PLACEBO_COMPARATOR|Control group|Arm II: Placebo combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
62469433|NCT04989374||UC patients treated with WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these UC patients treated with WMT
62668756|NCT01363271||complicated skin and skin structure infections (cSSSI)|Identified through a pre-specified list of ICD-9 codes in study protocol.
62668757|NCT01363271||Pneumonia|Identified through a pre-specified list of ICD-9 codes in study protocol.
62106835|NCT04768920|EXPERIMENTAL|Teletx|The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 \~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc).
62106836|NCT01253499|EXPERIMENTAL|TRx0037|Double blind placebo controlled study of TRx0037 in healthy elderly volunteers to assess safety, tolerability, bioavailability and pharmacokinetics
62106837|NCT05178758|EXPERIMENTAL|Virtual Reality (VR) Rehabilitation Training|Patients in the VR group will receive VR rehabilitation training in the hospital. The content of the training is the same as the control group. The only difference is that participants in the intervention group will use VR as a training platform. The VR system will include the training materials and tasks required for the patients to perform in the 3D environment. Demographic, clinical data and treatment costs will be collected before and after the rehabilitation training.
62298535|NCT05347615||EDOF|Eye after EDOF lens Implantation
62298536|NCT05347615||Monofocal|Eye after Monofocal lens Implantation
62298537|NCT00988390|OTHER|Intervention, mothers living with HIV|Mothers living with HIV, Cognitive-behavioral intervention delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions)
62298538|NCT00988390|NO_INTERVENTION|Control, mothers living with HIV|Mothers living with HIV, offered intervention at end of study (18 months after recruitment)
62668758|NCT02113215||Young Males|Males, age 18-35 years. 9-hour Stable isotope infusion
62668759|NCT02113215||Young Females|Females, age 18-35 years. 9-hour Stable isotope infusion
62298539|NCT00988390|NO_INTERVENTION|Control, non-HIV-infected mothers|Neighborhood control mothers not infected with HIV, did not receive any intervention
62298540|NCT04848805||liver recipients with hepatocellular and cohlangiocarcinoma diagnosis|liver recipients
62298541|NCT04469491|EXPERIMENTAL|Inhaled IFN arm|IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; +/- dexamethasone; + appropriate O2 support)
62298542|NCT04469491|ACTIVE_COMPARATOR|Control Arm:|Aerosol (WFI water and routine care (+/- antibiotics;+/- dexamethasone; + appropriate O2 support).
62298543|NCT03293680|EXPERIMENTAL|Pembrolizumab Arm|1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks
62298544|NCT05273151|OTHER|KOS treatment|Treatment with intranasal kinetic oscillation stimulation (KOS)
62469434|NCT04989374||UC patients treated without WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these UC patients treated without WMT
62469435|NCT02645409|EXPERIMENTAL|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
62668760|NCT02113215||Older Males|Males, age 60-75. 9-hour Stable isotope infusion
62668761|NCT02113215||Older Females|Females, age 60-75. 9-hour Stable isotope infusion
62668762|NCT02867826|EXPERIMENTAL|Cap-assisted endoscopy|forward-viewing endoscope with a Cap attached at the tip
62668763|NCT03280680|EXPERIMENTAL|Female+male group sessions|
62668764|NCT03280680|EXPERIMENTAL|Female group sessions|
62668765|NCT03280680|OTHER|No group sessions|
62298545|NCT05634577|EXPERIMENTAL|Lead-in Phase|Participants will first have a Lead-in Phase in which participants receive only mitotane. This will be 4 weeks long in most participants. Participants will then begin receiving pembrolizumab.
62668766|NCT03849989|EXPERIMENTAL|Hailey-Hailey disease|"Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy.~Skin biopsy specimens will be taken before and after lasertherapy at three time points.~Before treatment:~Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction~Immediately after treatment of the treated area:~2 mm punch for histopathology~Six weeks after treatment:~Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy~2mm punch biopsy of clinically uninvolved skin of the upper arm for electron microscopy~Patients without Hailey-Hailey disease:~2mm punch biopsy of skin of the upper arm for electron microscopy"
62298546|NCT05591833|ACTIVE_COMPARATOR|SASI|
62298547|NCT05591833|EXPERIMENTAL|SAS-J|
62298548|NCT06454864|EXPERIMENTAL|Guidelines-based physical activity|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
62298549|NCT06454864|EXPERIMENTAL|Guidelines-based physical activity and healthy eating|Arm Description: 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide.
62298550|NCT06454864|PLACEBO_COMPARATOR|Stretching exercise|Whole-body stretching.
62668767|NCT02534480|ACTIVE_COMPARATOR|NGP 555 25 mg|NGP 555 25 mg capsule and placebo by mouth once per day
62298551|NCT00826748|EXPERIMENTAL|Treated Smokers|The treatment with inhaled beclomethasone will be administered to this cohort from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days.
62298552|NCT00826748|NO_INTERVENTION|Non-Treated Smokers|This cohort will act as control and include healthy smokers who receive no treatment.
62298553|NCT00826748|NO_INTERVENTION|Non-Smokers|This cohort will act as control and include healthy non-smokers who receive no treatment.
62298554|NCT03370757|ACTIVE_COMPARATOR|3-hour bundled care|Infants in this group will have their diaper changed every 3 hours during 3-hour bundled care.
62298555|NCT03370757|ACTIVE_COMPARATOR|6-hour bundled care|Infants in this group will have their diaper changed every 6 hours.
62668768|NCT02534480|ACTIVE_COMPARATOR|NGP 555 50 mg|NGP 555 50 mg capsule and placebo by mouth once per day
61913757|NCT03978143|OTHER|Sequence 1|Receive treatments in the following order from Periods 1-6: A, B, C, D, E, G
62298556|NCT02456220|EXPERIMENTAL|Herbst Group|Patients treated with Herbst appliance.
62298557|NCT02456220|NO_INTERVENTION|Comparison Group|Patients that received only teeth movement (alignment and leveling before Herbst insertion), without any orthopedic intervention.
62668769|NCT02534480|ACTIVE_COMPARATOR|NGP 555 100 mg|NGP 555 100 mg capsule and placebo by mouth once per day
62668770|NCT02534480|ACTIVE_COMPARATOR|NGP 555 200 mg|NGP 555 200 mg capsule and placebo by mouth once per day
62668771|NCT02534480|ACTIVE_COMPARATOR|NGP 555 300 mg|NGP 555 300 mg capsule and placebo by mouth once per day
62668772|NCT02079870|EXPERIMENTAL|Sema|Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing
61913758|NCT03978143|OTHER|Sequence 2|Receive treatments in the following order from Periods 1-6: A, C, B, D, E, G
61913759|NCT03978143|OTHER|Sequence 3|Receive treatments in the following order from Periods 1-6: B, A, C, D, E, G
61913760|NCT03978143|OTHER|Sequence 4|Receive treatments in the following order from Periods 1-6: B, C, A, D, F, H
61913761|NCT03978143|OTHER|Sequence 5|Receive treatments in the following order from Periods 1-6: C, A, B, D, F, H
61913762|NCT03978143|OTHER|Sequence 6|Receive treatments in the following order from Periods 1-6: C, B, A, D, F, H
61913763|NCT04883723|EXPERIMENTAL|Experiment I (Shotblocker) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position. The determined injection site was cleaned with a cotton pad with alcohol, with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. The protruding surface of the Shotblocker was placed in the area just before the injection, so that the needle entry point would not be contaminated. It was lightly pressed into the shotblocker with fingertips and the injection was performed. ShotBlocker has been removed after removing the needle. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
61919875|NCT02477423|ACTIVE_COMPARATOR|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
61919876|NCT02477423|PLACEBO_COMPARATOR|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
61919877|NCT01097876|EXPERIMENTAL|Active PF-04447943|
62298558|NCT04770103|EXPERIMENTAL|Dynamic|Participants within the dynamic arm will receive either traditional balance training within ACSM guidelines or Dynamic Step training known as Perturbation based training (PBT). Outcome measures assessed will be Margin of Stability during dynamic step recovery when subjected to a forward loss of balance, along with static postural sway ( a measure of postural control not requiring a step recovery). Participants motivation, mental wellness, attitudes to exercise and fear of falling will be assessed prior to the intervention and 6 months following the intervention.
62298559|NCT04770103|EXPERIMENTAL|Static|Participants within the static arm will receive only traditional balance training within ACSM guidelines. The outcome measure within the static arm is limited to static postural sway. Participants motivation, mental wellness, attitudes to exercise and fear of falling will be assessed prior to the intervention and 6 months following the intervention.
62668773|NCT02079870|PLACEBO_COMPARATOR|Placebo|
62668774|NCT03428204|OTHER|180 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 180 seconds for percutaneous treatment of femoropopliteal artery stenosis
62668775|NCT03428204|OTHER|300 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 300 seconds for percutaneous treatment of femoropopliteal artery stenosis
62106838|NCT05178758|NO_INTERVENTION|Control - Conventional Rehabilitation Training|Patients in the control group will receive conventional rehabilitation training currently provided in the hospital. An instructor will assign each participant for training. Demographic, clinical data, and treatment costs will be collected before and after completing the rehabilitation training
62106839|NCT05794373||Pre-Education group|Patients in this group undergo rehabilitation for back pain in a municipality setting with physiotherapists before the physiotherapists have participated in an educational intervention
62298560|NCT05841472|EXPERIMENTAL|Camrelizumab, Pemetrexed and Carboplatin|
62668776|NCT04755725|ACTIVE_COMPARATOR|Epidural Group|epidural catheter inserted pre induction
62668777|NCT04755725|ACTIVE_COMPARATOR|Rectus sheath catheter Group|rectus sheath catheter inserted by the surgeon at the end of surgery
62668778|NCT03738748|EXPERIMENTAL|Ultrasound-guided Percutaneous Neuromodulation|This group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L3 (1 times/ 4 weeks).
62668779|NCT03738748|ACTIVE_COMPARATOR|TENS therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region (1 times/ 4 weeks).
62668780|NCT03413917||Control group|patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony
62668781|NCT03413917||Study group|Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery
62668782|NCT02357485|EXPERIMENTAL|Treatment arm|Single injection of ADSC
62668783|NCT01708525|EXPERIMENTAL|Ultherapy®-treated tissue|Heavy water labeled tissue receiving an Ulthera® System Treatment
62668784|NCT03072875|EXPERIMENTAL|CAMS-RAS|In this single-arm study design, all enrolled patient participants are asked to provide feedback on the CAMS-RAS prototype as it is developed for this study. Feedback will be gathered via survey measure and interview.
61919878|NCT01097876|PLACEBO_COMPARATOR|Placebo PF-04447943|
61919879|NCT02996643|NO_INTERVENTION|Traditional method|The traditional brace design method will be used to design a spinal brace.
62106840|NCT05794373||Post-Education group|Patients in this group undergo rehabilitation for back pain in a municipality setting with physiotherapists after they have participated in an educational intervention
62298561|NCT05988814|EXPERIMENTAL|FOLFIRINOX treatment|"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression."
62298562|NCT00283010|EXPERIMENTAL|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
62668785|NCT03837275|EXPERIMENTAL|humsfe|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique)
62298563|NCT00283010|ACTIVE_COMPARATOR|Active Control|Educational DVDs
62668786|NCT03837275|ACTIVE_COMPARATOR|closed sinus lift|transcrestal maxilllary sinus floor elevation
62668787|NCT01509924|EXPERIMENTAL|Physical activity on Prescription (PaP)|Intervention group receives a PaP for 12 month.
62668788|NCT01509924|NO_INTERVENTION|Control Group|The control group has the same monitoring as the experimental group but receives no PaP.
62668789|NCT01509924|NO_INTERVENTION|Cognitiv function in patients with TIA|"Before discharged from hospital cognitive function is assessed. At the first visit the patients fill in a self assessment questionnaire for mental fatigue.~If impaired at the previous assessment cognitive function will be assessed at 3, 6 and 12 month."
62668790|NCT01509924|NO_INTERVENTION|Controlgroup Cognitive function|In order to determine whether hospitalization in itself is associated with transient impaired cognition, a comparison group will be included. The comparison group will consist of patients with angina pectoris consecutively admitted to the Norrtälje Hospital. The patients with angina pectoris will be age and sex matched with the patients with TIA and assessed for cognitive function when their angina symptoms have subsided.
62668791|NCT03281915||high inguinal approch|Patients undergoing high inguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
62668792|NCT03281915||subinguinal approch|Patients undergoing subinguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
62668793|NCT02916329|EXPERIMENTAL|68Ga-ZEGFR: EGFR++|Patients in this group had EGFR-activating mutant and EGFR high expression tumors and did not receive any treatment before this study.
62668794|NCT02916329|EXPERIMENTAL|68Ga-ZEGFR: EGFR+|Patients in this group had EGFR-activating mutant and EGFR medium expression tumors and did not receive any treatment before this study.
62298564|NCT05620342|EXPERIMENTAL|iC9.GD2.CAR.IL-15 T Therapy|Experimental: Single Arm Subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy will receive iC9.GD2.CAR.IL-15 T cells were manufactured from their collected blood sample.
61919880|NCT02996643|ACTIVE_COMPARATOR|Intervention|A custom Providence brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
62298565|NCT03719599||Children|Children 6 -12 months of age presenting for routine clinic visits
62298566|NCT03719599||Pregnant Women|Pregnant Women 18 years and older presenting for routine clinic visits
62298567|NCT06651567|EXPERIMENTAL|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
62298568|NCT06651567|PLACEBO_COMPARATOR|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
62298569|NCT02544776|EXPERIMENTAL|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
62298570|NCT02544776|ACTIVE_COMPARATOR|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
62298571|NCT04396977|OTHER|Histamine and placebo skin pricks|Each subject will receive the same histamine (10 mg/ml) and control (saline) skin prick on the right and left forearm on both study visits, to allow an intra-individual comparison
62298572|NCT02886104|ACTIVE_COMPARATOR|CRLM resection group|Resection of both primary and secondary tumors in SCRLM and resection of MCRLM. Interventions: Simultaneous resection of both primary and secondary tumors in SCRLM and resection of MCRLM.
62298573|NCT02886104|EXPERIMENTAL|CRLM ablation group|"Ablation of CRLM after resection of primary tumor in SCRLM and ablation of MCRLM.~Interventions: Ablation of liver metastasis within 30 days after resection of primary tumor in SCRLM and ablation of MCRLM."
62298574|NCT03001544|EXPERIMENTAL|Experimental Ascending Dose Cohort|TS23
62298575|NCT00849550|EXPERIMENTAL|XELOX-A-Ev|
62298576|NCT00749606|EXPERIMENTAL|Individual Telephone Intervention|Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
62298577|NCT00749606|ACTIVE_COMPARATOR|Group Telephone Intervention|Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.
62298578|NCT03084523|EXPERIMENTAL|1|80 patients with intracranial atherosclerosis
62298579|NCT05766579|EXPERIMENTAL|K1, 18-21 mmHg|Use of elastic stockings at 18-21 mmHg after endovenous thermal ablation
62298580|NCT05766579|EXPERIMENTAL|K2, 23-32 mmHg|Use of elastic stockings at 23-32 mmHg after endovenous thermal ablation
62298581|NCT01916772||cherubism patients|no interventions
62298582|NCT04821284|EXPERIMENTAL|Arm I (sonazoid, ultrasound, chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity. Patients also receive sonazoid IV over 20 minutes and undergo CEUS. Patients undergo CT or PET/CT or MRI during screening and as clinically indicated on study.
62298583|NCT04821284|ACTIVE_COMPARATOR|Arm II (chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity. Patients undergo CT or PET/CT or MRI during screening and as clinically indicated on study.
62298584|NCT05537038|EXPERIMENTAL|BNT164a1|Escalating dose levels
62298585|NCT05537038|EXPERIMENTAL|BNT164b1|Escalating dose levels
62298586|NCT05537038|EXPERIMENTAL|Placebo|Isotonic NaCl solution (0.9%)
62298587|NCT01620125|OTHER|Lactobacillus reuteri|Dietary supplementation with Lactobacillus reuteri DSM 17938
62298588|NCT04459962|EXPERIMENTAL|Study Arm|Breath Test and Cheek Swab collection
62298589|NCT04246554|EXPERIMENTAL|Control|Patients receive oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for pain following ACL reconstruction surgery
62298590|NCT04246554|EXPERIMENTAL|Ketorolac|Patients receive IV ketorolac followed by ketorolac 10 mg every 6 hours for 3 days following ACL reconstruction surgery. Patients are additionally discharged with oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for additional pain control
62298591|NCT02582515|EXPERIMENTAL|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training.
62298592|NCT02582515|PLACEBO_COMPARATOR|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training.
62298593|NCT05794139|EXPERIMENTAL|Cohort 1|Experimental drug followed by placebo
62298594|NCT05794139|EXPERIMENTAL|Cohort 2|Placebo followed by experimental drug
61919881|NCT05846477||MySpine MC|spinal stabilization via cortical bone trajectory with the support of patient specific guide (MySpine MC technology)
62298595|NCT02789696|OTHER|Acromegaly|Diagnosis of acromegaly
61919882|NCT05846477||MySpine STD|spinal stabilization via standard pedicle screw positioning with the support of patient specific guide (MySpine std technology)
61919883|NCT03988959|OTHER|Control|Standard resection
62298596|NCT03588689|NO_INTERVENTION|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
62469436|NCT02645409|EXPERIMENTAL|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
62469437|NCT00578552|PLACEBO_COMPARATOR|Placebo|Non active placebo pill
62298597|NCT03588689|EXPERIMENTAL|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
62668795|NCT02916329|EXPERIMENTAL|68Ga-ZEGFR: EGFR-|Patients in this group had no EGFR expression tumors and did not receive any treatment before this study.
62298598|NCT05613270|EXPERIMENTAL|18F-FES PET/CT|Inject 18F-FES and then perform PET/CT scan.
62469438|NCT00578552|ACTIVE_COMPARATOR|Gabapentin - 1800 mg/day|Gabapentin - 1800 mg/day
62469439|NCT00578552|ACTIVE_COMPARATOR|Gabapentin - 2700 mg/day|Gabapentin - 2700 mg/day
62469440|NCT01645995|EXPERIMENTAL|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
62668796|NCT02916329|EXPERIMENTAL|68Ga-ZEGFR: EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
62668797|NCT02916329|EXPERIMENTAL|68Ga-ZEGFR:unknown EGFR status|Patients without the EGFR status measurement results and did not receive any treatments were classified in this group.
62469441|NCT01645995|EXPERIMENTAL|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
62668798|NCT02916329|EXPERIMENTAL|68Ga-ZEGFR: EGFR|Patients in this group had EGFR expression tumors and had receive some treatment before this study.
62298599|NCT05902585|NO_INTERVENTION|Usual care|In this arm, the analysis will be done in the usual way (for example, distracting with questions).
62298600|NCT05902585|ACTIVE_COMPARATOR|Virtual reality|In this arm, the analysis will be done while the children use virtual reality.
62298601|NCT04940923||Patients|Patients within 4 weeks of a whiplash injury.
62668799|NCT04947267|EXPERIMENTAL|3% mepivacaine|3% mepivacaine was administered via inferior alveolar nerve block.
62668800|NCT04947267|ACTIVE_COMPARATOR|2% mepivacaine with 1:100,000 epinephrine|2% mepivacaine with 1:100,000 epinephrine was administered via inferior alveolar nerve block.
62668801|NCT02158507|EXPERIMENTAL|Combination of Veliparib + Lapatinib|Lapatinib will be administered as a tablet at a dosage of 1250 mg/day continuously for 28 days starting on Day 1 of each cycle. Veliparib will be administered as a capsule at a dosage of 200 mg every 12 hours for 28 days starting on Day 2 of each cycle. A cycle of therapy is defined as 28 days. Treatment is administered on an outpatient basis. Patient response will be evaluated every 8 weeks according to the current Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and performance of relevant scans and/or x-rays.
62668802|NCT04706403|EXPERIMENTAL|Message 1|"Participants were randomized to receive version #1 of 5 different versions of a message from a physician regarding the COVID-19 vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 1, this statement was followed by a participatory-style recommendation (What do you think?)"
62668803|NCT04706403|EXPERIMENTAL|Message 2|"Participants were randomized to receive version #2 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 2, this statement was followed by a comparison of the COVID-19 vaccine to the flu shot and an explicit recommendation (I recommend that you get it)."
62668804|NCT04706403|EXPERIMENTAL|Message 3|"Participants were randomized to receive version #3 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 3, this statement was followed by a statement that millions of people have already received the COVID-19 vaccine and an explicit recommendation (I recommend that you get it)."
62668805|NCT04706403|EXPERIMENTAL|Message 4|"Participants were randomized to receive version #4 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 4, this statement was followed by an acknowledgment of concerns and reassurance that the physician personally reviewed the safety data and an explicit recommendation (I recommend that you get it)."
62668806|NCT04706403|EXPERIMENTAL|Message 5|"Participants were randomized to receive version #5 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 5, this statement was followed by an emphasis on protecting others an explicit recommendation (I recommend that you get it)."
62668807|NCT04193215|EXPERIMENTAL|V114|Participants will receive an intramuscular (IM) injection.
62668808|NCT04193215|OTHER|Control|
62106841|NCT06630780|EXPERIMENTAL|Trial Group|"All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.~(1) Tumor bed (CTVtb): It was delineated based on the tumor extent shown in laryngoscopy, enhanced CT/MRI, or PET CT before induction therapy49. For patients with significant anatomical changes due to tumor regression, the CTVtb was adjusted, taking into account the patient's anatomy after induction chemotherapy and the initial state of the tumor; if a cavity appeared due to tumor regression, it was adjusted according to natural anatomical boundaries.(2) High-risk clinical target volume (CTV1): CTVtb plus a 5-10mm margin, with a prescribed dose of at least 60Gy in 30 fractions.~(3) Low-risk clinical target volume (CTV2): CTV1 plus a 5-10mm margin. For hypo"
62106842|NCT04742751|EXPERIMENTAL|Treatment|Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With Metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
62668809|NCT06421766||3mm implant|Patients recieving a 3mm long implant
62106843|NCT03132324|EXPERIMENTAL|INCB059872 0.5 mg|INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.
62668810|NCT06421766||4mm implant|Patients recieving a 4mm long implant
62668811|NCT02211157|EXPERIMENTAL|BIBR 796 BS, fasted|dose escalation
62668812|NCT02211157|EXPERIMENTAL|BIBR 796 BS, fed|50 mg BIRB 796 BS (food effect)
62668813|NCT02211157|PLACEBO_COMPARATOR|Placebo|
62106844|NCT03132324|EXPERIMENTAL|INCB059872 1 mg|INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
62106845|NCT03132324|EXPERIMENTAL|INCB059872 2 mg|INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
62298602|NCT04940923||Healthy controls|Age and gender matched healthy controls
62668814|NCT02264041|EXPERIMENTAL|Cilobradine, low dose plus itraconazole|Pre-study
62668815|NCT02264041|ACTIVE_COMPARATOR|Cilobradine, low dose|Pre-study
62668816|NCT02264041|EXPERIMENTAL|Cilobradine, high dose plus itraconazole|main study
62668817|NCT02264041|ACTIVE_COMPARATOR|Cilobradine, high dose|main study
62668818|NCT05016336|EXPERIMENTAL|strategy-based cognitive training + social interaction|The experimental group received twelve 60 minutes sessions of strategy-based cognitive training. (i.e., training in mnemonic memory strategies). We chose to train multiple strategies instead of a single one in effort to reach larger training gains. each session began with engaging conversations between the researcher and participants. After each practice trial, participants were encouraged to share their ideas/stories/associations or visual images (mnemonic uses) in turn. All other participants were allowed to give feedback relating to what can be learned from each mnemonic use or give their own ideas on how they think it can be improved.
62668819|NCT05016336|ACTIVE_COMPARATOR|social interaction|The social interaction control group received the same number of group meetings but without the strategy training. Meetings content consisted of providing tools for making social connections, providing tools for interpersonal communication and raising the participant's sense of personal well-being through group contact.
62668820|NCT02147080|EXPERIMENTAL|Tailored Intervention|Subject has access to the tailored web intervention
62668821|NCT02147080|ACTIVE_COMPARATOR|Skin Cancer Foundation Website|Subject has access to the pre-existing Skin Cancer Foundation website
62106846|NCT03964285|ACTIVE_COMPARATOR|Rumination group|The patients will receive rumination induction. Rumination induction will follow a relevant activity for our patients: climbing steps. Rumination induction will be done right after climbing the steps.
62469442|NCT05839470|EXPERIMENTAL|Cadonilimab+ FOLFOXIRI+bevacizumab|Cadonilimab (6mg/kg, iv, Q2W, Day1)+irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1; oxaliplatin 85 mg/m² iv continue for 2 hours, D1; leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours, D1; 5-FU 2400 mg/m² cont. inf. 48h; repeat every 2 weeks (Q2W) + bevacizumab （5mg/kg，d 1）
62668822|NCT02147080|NO_INTERVENTION|Assessment Only Condition|Subjects will only complete assessments
62106847|NCT03964285|EXPERIMENTAL|distraction group|Distraction will follow a relevant activity for our patients: climbing steps. Distraction induction will be done right after climbing the steps.
62106848|NCT06630104|EXPERIMENTAL|Supportive care (bone marrow aspiration, CFU)|Patients undergo bone marrow aspiration and hair and saliva sample collection up to 14 days prior to LD therapy. Patients undergo CFU on day 90 post-CAR-T therapy. Patients with unexplained cytopenia also undergo bone marrow aspiration for sequencing analysis on day 90 and at development of MN-pCT during CFU. Patients also undergo bone marrow aspiration at determination of clonal evolution or myeloid neoplasm if not done during on day 90. Additionally, patients receive a genetic counselor consultation on study.
62106849|NCT01701154||Pompe|Adults and children with Pompe disease.
62106850|NCT02735915|EXPERIMENTAL|GSK1437173A vaccine Group|Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
62106851|NCT04784013|ACTIVE_COMPARATOR|Conventional group|
62106852|NCT04784013|ACTIVE_COMPARATOR|90W-group|
62106853|NCT05266365|EXPERIMENTAL|The Video-based exercise (VBE) group|Each subject in the video-based exercise group will receive a treatment protocol consisting of stretching exercises, strengthening exercises and functional exercises for knee and hip.
62469443|NCT05033847|EXPERIMENTAL|Subject last vaccination time is within 30-90 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days
62469444|NCT05033847|EXPERIMENTAL|Subject last vaccination time is within 91-180 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days
62469445|NCT05033847|EXPERIMENTAL|Subject last vaccination time more than 181 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days
62469446|NCT04713709|EXPERIMENTAL|FMXIN001 4 mg Naloxone microspheres powder,|Naloxone powder nasal spray from Nasus Pharma, Israel
62469447|NCT04713709|ACTIVE_COMPARATOR|Narcan® 4 mg/0.1 mL nasal spray|Naloxone solution nasal spray from Adapt Pharma, Inc., USA
62469448|NCT00003674|EXPERIMENTAL|dalteparin + standard therapy|Patients receive dalteparin by subcutaneous injection once daily plus standard therapy. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
62469449|NCT00003674|ACTIVE_COMPARATOR|standard therapy|Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
62469450|NCT01770262||Osteoporosis|Hospitalized subjects diagnosed with osteoporosis
62106854|NCT05266365|ACTIVE_COMPARATOR|The standard exercise group (SE)|Each subject in the standard exercise group will receive a treatment protocol consisting of stretching exercises, strengthening exercises and functional exercises for knee and hip.
62106855|NCT02687646|EXPERIMENTAL|Allogeneic Mesenchymal Cells|All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.
62106856|NCT02325050|EXPERIMENTAL|Group 1|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
62106857|NCT02325050|EXPERIMENTAL|Group 2|Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
62106858|NCT02325050|EXPERIMENTAL|Group 3|Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
62469451|NCT01770262||Healthy|
62469452|NCT00588874||1|men 50 yrs of age or older
62469453|NCT05879471|EXPERIMENTAL|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
62298603|NCT06637176||Group 1: Colon Surgery with Extracorporeal Anastomosis|All individuals over 18 years old undergoing elective colon surgery with the formation of an extracorporeal anastomosis are eligible to participate, regardless of indication, comorbidities, or other conditions.
62469454|NCT01148030||Single|3M Skin and Nasal Antiseptic
62298604|NCT01962220|NO_INTERVENTION|Standard of Care|"Routine ANC, Delivery and Postpartum Care: All consenting women will receive routine ANC/Delivery and Postpartum care offered to pregnant women in Kenya as per national guidelines at the MCH of the respective facility.~Routine PMTCT and HIV Care: All newly diagnosed HIV-infected pregnant women are enrolled into HIV care in the MCH and receive PMTCT/HIV care per Kenya national guidelines (Revised 2012 PMTCT Guidelines)."
62298605|NCT01962220|EXPERIMENTAL|Study Intervention for Retention (APFU)|Participants randomized to the experimental arm of the study will receive routine antenatal and HIV services as described above per Kenya national guidelines. In addition each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri), who will perform numerous tasks described in the intervention. In addition to the Mama Mshauri, this arm will receive phone/SMS appointment reminders, and default patient tracking if participants miss an appointment.
62298606|NCT06448793||Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC)|
62298607|NCT06448793||Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients|
62469455|NCT03429920|EXPERIMENTAL|Q CAN PLUS POWDER|QCAN PLUS POWDER:2 pouches per day, each pouch contains(12-15gms of fermented soy powder)
62469456|NCT03429920|PLACEBO_COMPARATOR|placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
62469457|NCT01019603|EXPERIMENTAL|1|Tazarotene foam 0.1%
62469458|NCT01019603|ACTIVE_COMPARATOR|2|Tazaroc Gel 0.1%
62298608|NCT01871506|EXPERIMENTAL|Standard Care (SC)|"Participants randomized to standard care (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice."
62298609|NCT01871506|EXPERIMENTAL|Intensive Counseling (IC)|"Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:~* Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).~* Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication \[varenicline, bupropion, or combination NRT (patch + lozenge)\] at no cost to the participant."
62469459|NCT01291121|ACTIVE_COMPARATOR|group 1|Intravitreal ranibizumab 0.5mg only group
62469460|NCT00431912|EXPERIMENTAL|Single-arm, trinomial 2-stage design|
62469461|NCT01471041|EXPERIMENTAL|Venous Window Needle Guide|Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula
62469462|NCT04513418|EXPERIMENTAL|Interventional group|Patients receive omega-3 fatty-acid enriched enteral nutritional emulsion during the neoadjuvant chemoradiotherapy. Patients are meanwhile encouraged to intake 25-30kcal/kg through regular food.
62469463|NCT04513418|NO_INTERVENTION|Control group|Patients are encouraged to intake 25-30kcal/kg through regular food without supplemental nutritional support before esophagectomy.
62469464|NCT04007640|OTHER|Volunteer patient|1st stage: To adjust the transducer, test and validate pancreatic MRI sequences on volunteers without history of known pancreatic disorders. Adjustment of MRI parameters is needed to optimize data acquisition, especially in obese patients. Moreover, an external material (transducer) has to be applied on the abdomen. The right position has to be tested and specified before stages 2 and 3 of the study. We aim to include volunteers without history of known pancreatic disorders for the Stage 1, meaning volunteers without personal history or symptoms suggesting pancreatic disorders.
62469465|NCT04007640|OTHER|Obese volunteers with indication for hepatic MRI|2nd stage: To validate and assess pancreatic MRI sequences on obese volunteers with indication for hepatic MRI , in relation with acceptable resolution and field of view criteria applicable to the typical anteroposterior diameters found in obese persons. For Magnetic Resonance Elastography (MRE), the amplitude setting of the MRE transducer will be adapted to the size of obese patients, in addition to the aforementioned adjustments to spatial resolution and field of view sizes. The effect of frequency on MRE data quality will be investigated. The effects of respiratory motion will be investigated; indeed in obese patients respiration amplitude is typically low and this enables to acquire data in free breathing mode over long periods of time, which offers more possibilities (notably in terms of averaging, spatial resolution, mechanical wave sampling rate) than when constraining acquisition parameters with a maximum breath hold time of less than 20s.
62298610|NCT03619915||Greater dependence|
62298611|NCT03619915||Less dependence|
62298612|NCT03619915||Independent|
62469466|NCT04007640|OTHER|Obese patient|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
62469467|NCT04007640|OTHER|Non obese patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
62469468|NCT04007640|OTHER|Overweight patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
62469469|NCT02377778|EXPERIMENTAL|Propofol|In this arm patients will be receiving propofol for anaesthesia at doses 3-5mg depending on the time needed to complete oocyte retrieval
62469470|NCT02377778|ACTIVE_COMPARATOR|Thiopental|In this arm patients will receive thiopental for anaesthesia at doses 7mg and a repeat dose of 2-3mg depending on the time needed to completed oocyte retrieval
62106859|NCT02325050|EXPERIMENTAL|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
62106860|NCT02325050|EXPERIMENTAL|Group 5|Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
62106861|NCT02325050|EXPERIMENTAL|Group 6|Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive MVA-BN-Filo (1\*10\^8 TCID50) on Day 360.
62106862|NCT02325050|EXPERIMENTAL|Group 7|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10\^10 vp) on Day 360.
62106863|NCT02325050|EXPERIMENTAL|Group 8|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (1x10\^11 vp) on Day 360.
62298613|NCT04827355|SHAM_COMPARATOR|Control|Participants allocated to the control arm will be fit with the UES Compression Device at a pressure known not to provide intervention.
62298614|NCT04827355|EXPERIMENTAL|Experimental|Participants allocated to the experimental arm will be fit with the UES Compression Device according to manufacturer guidelines.
62298615|NCT03696784|EXPERIMENTAL|Single Arm iC9.CAR19 T cells|"The safety of iC9-CAR19 cells will be investigated using the 3+3 design. Dose level (DL) Dose (#transduced cells/kg)~-1 1 x 10\^5~1. 1 x 10\^6~2. 2 x 10\^6 DL1 will enroll 3 subjects. If no toxicity within 4 weeks, then DL 2 will enroll 3 subjects. If toxicity in 1/3 subjects in DL 1, 3 more subjects will be enrolled. If DL 1 is not tolerable, a de-escalation to DL -1 will enroll 3 subjects. If 3 subjects at the higher dose do not have DLTs more will be enrolled at that dose to get more information about toxicity.~Lymphodepleting chemotherapy of IV bendamustine 70 mg/m2 and IV fludarabine 30 mg/m2/day for 3 consecutive days will be given within 2-14 days prior to cell infusion.~AP1903 (0.4 mg/kg), a dimerizing agent to engage and activate the caspase 9 safety switch to trigger iC9-CAR19 T cell death by apoptosis will be given to subjects who develop severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)."
62298616|NCT03696784|EXPERIMENTAL|Expansion Cohort iC9-CAR19 cells|After the tolerable cell dose (TCD) has been determined in adults, up to 18 additional subjects may be enrolled in an expansion cohort at the TCD. A TCD is defined as the dose at which approximately 0.20 of subjects experience dose limiting toxicity (0 - 1 out of 6 subjects).
62298617|NCT04820179|EXPERIMENTAL|Cabozantinib 40mg + Atezolizumab 1200mg|Cabozantinib 40 mg, tablets, oral administration, once daily, continuously. Atezolizumab 1200 mg, administered intravenously, on Day 1 of every 21 day cycle.
62298618|NCT02148029|ACTIVE_COMPARATOR|Control|Standard care: anticoagulation, compression, and ad-lib ambulation
62298619|NCT02148029|EXPERIMENTAL|Exercise|Standard care + Interventional Exercise therapy
62298620|NCT05332444|EXPERIMENTAL|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
62298621|NCT05332444|ACTIVE_COMPARATOR|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
62298622|NCT06601192|EXPERIMENTAL|zelicapavir Dose 1 (therapeutic dose)|All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.
62298623|NCT06601192|EXPERIMENTAL|zelicapavir Dose 2 (supratherapeutic dose)|All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.
62298624|NCT06601192|PLACEBO_COMPARATOR|placebo|All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.
62298625|NCT06601192|EXPERIMENTAL|moxifloxacin|All participants will receive 4 study interventions. The study interventions will be administered during separate treatment periods starting on Days 1, 9, 17, and 25.
62298626|NCT04126837|OTHER|Patient admitted for Ankle and foot injuries|Diagnosis and treatment of Ankle and foot injuries by an accelerated nursing branch in emergency department
62469471|NCT02832752|ACTIVE_COMPARATOR|ECPR Region|The ECPR region has incorporated ECPR therapy into the out-of-hospital cardiac arrest algorithm. Within the ECPR Protocol, full standard advanced cardiac life support treatments will continue up until the time of ECMO initiation. The anticipated enrolment in this group is 70 patients. All eligible patients in the region will be enrolled, regardless of whether the ECPR protocol is activated or whether the patient is actually treated with ECPR.
62106864|NCT02325050|EXPERIMENTAL|Group 9|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
62106865|NCT02325050|EXPERIMENTAL|Group 10|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
62106866|NCT00359619|ACTIVE_COMPARATOR|Cervarix Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62106867|NCT00359619|EXPERIMENTAL|Cervarix 1 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 1 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62298627|NCT06656728||Healthy subjects|Patients over the age of 40, without active cancer in the last 5 years, who come for a cancer screening (and sometimes other screenings) at the Integrated Cancer Prevention Center
62668823|NCT04696770|EXPERIMENTAL|Mindfulness Intervention|"Four face-to-face direct coachings on Mindfulness technique at weekly intervals. The following will be the broad theme of each coaching session~Week 1 - On the first encounter, the mothers will learn how to practice an introductory mindfulness technique to develop the awareness of any sensations felt in the body while holding their baby.~Week 2 - On the second encounter, the mothers will learn how to practice a second mindfulness technique to create positive feelings in the body while holding their baby.~During the third and fourth weekly encounters, the mothers will have a chance to ask their questions and explore further both mindfulness techniques as needed."
62298628|NCT00049127|EXPERIMENTAL|Phase II (Group 1)|Patients receive imatinib mesylate PO, at the MTD determined in phase I, BID for 4 weeks.
62298629|NCT00049127|EXPERIMENTAL|Phase II (Group 2)|Patients receive standard-dose imatinib mesylate PO BID for 4 weeks.
62298630|NCT02691000|EXPERIMENTAL|Bright White Light (BWL) Litebook|Participants will be instructed to use the BWL Litebook for an hour every day for 8 weeks.
62298631|NCT02691000|PLACEBO_COMPARATOR|Dim Red Light (DRL) Litebook|Participants will be instructed to use the DRL (comparison condition) Litebook for an hour every day for 8 weeks.
62298632|NCT04985565|EXPERIMENTAL|Treatment (dietary intervention, radical prostatectomy)|Patients participate in the Mediterranean diet for 6 days per week for 4 weeks before undergoing standard of care radical prostatectomy.
62298633|NCT03245879|ACTIVE_COMPARATOR|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
62298634|NCT03245879|ACTIVE_COMPARATOR|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
62298635|NCT03245879|ACTIVE_COMPARATOR|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
62469472|NCT02832752|NO_INTERVENTION|Control Region|"The control region will continue usual care as per current protocols which include standard advanced cardiac life support. Patients will be enrolled in the control region group at the same juncture of study eligibility. The anticipated enrolment in this group is 350 patients.~Within BCEHS practice, transport to hospital without prior return of spontaneous circulation is rare. Termination of resuscitation must be approved by an on-call physician and cannot occur prior to 30 minutes of resuscitation efforts."
62469473|NCT04407806|ACTIVE_COMPARATOR|Continuous Pulse Oximetry Monitoring of Oxygen Saturation|Continuous pulse oximetry to measure oxygen saturation
62298636|NCT00868387|EXPERIMENTAL|energy-restricted, CHO-restricted diet|Interventions: carbohydrate restriction of diet: 40% Frequency: daily Duration: 12 months
62298637|NCT00868387|ACTIVE_COMPARATOR|energy-restricted, CHO-rich diet|Comparator: carbohydrate content of diet: \> 55% Frequency: daily Duration: 12 months
62298638|NCT05564858|EXPERIMENTAL|Phase Ia Dose escalation|Phase Ia: Participants with locally advanced or metastatic tumor will be administered FDA022-BB05 intravenously once at escalated doses in each cycle (of 21 days) during Phase Ia part of the study until disease progression or intolerable toxicity.
62298639|NCT05564858|EXPERIMENTAL|Phase Ib Dose expansion|Phase Ib: is a dose expansion to examine the safety and efficacy of FDA022-BB05 and it is consist of multiple cohorts: in subjects with HER2 overexpressing breast cancer (Cohort A); HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Cohort B).
62298640|NCT05237388|EXPERIMENTAL|Baricitinib|Participants will take one pill of Baricitinib daily with their regular medications.
62298641|NCT05237388|PLACEBO_COMPARATOR|Placebo|Participants will take a Baricitinib placebo pill matching Baricitinib daily with their regular medications.
62298642|NCT03057444|EXPERIMENTAL|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
62298643|NCT01719757|EXPERIMENTAL|Oxycodone/naloxone|Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day
62298644|NCT05086315|EXPERIMENTAL|SAR443579|"Dose Escalation: SAR443579 administered intravenously at escalating dose levels.~Dose Expansion: SAR443579 administered intravenously at the recommended dose and schedule determined from the dose escalation."
62298645|NCT01021007|PLACEBO_COMPARATOR|A|control mouthrinse
62668824|NCT04696770|NO_INTERVENTION|Control|Standard of care will be offered to all mothers in the control group which includes kangaroo care but does not involve any mindfulness practices.
62668825|NCT01086475|EXPERIMENTAL|D-cycloserine|Subjects randomized to D-cycloserine will be administered 50 mg 30 minutes prior to each of ten Social Skills Training Sessions
62668826|NCT01086475|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo arm will receive placebo pill 30 minutes prior to each of ten Social Skills Training Sessions
62668827|NCT01392196|OTHER|Single arm|Renal Denervation
62298646|NCT01021007|EXPERIMENTAL|B|new prototype mouthrinse
62298647|NCT05887635|EXPERIMENTAL|Study arm- RF Vapor Ablation arm|This is a single arm study. All enrolled patients will be included in this arm
62298648|NCT04259502|EXPERIMENTAL|RIB Group|A single injection Rhomboid intercostal block will be performed under ultrasound guidance
62298649|NCT04259502|ACTIVE_COMPARATOR|ESP Group|A single injection Erector spinae plane block will be performed under ultrasound guidance
62298650|NCT01783665|EXPERIMENTAL|Aerobic Exercise|3x/week supervised moderate intensity aerobic exercise on recumbent stepper
62298651|NCT01783665|ACTIVE_COMPARATOR|Home exercise program|Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic
62298652|NCT01497392|EXPERIMENTAL|Treatment (dovitinib lactate, gemcitabine, and capecitabine)|Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62298653|NCT02714530|EXPERIMENTAL|Radiotherapy combined with erlotinib|Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
62668828|NCT06468020|EXPERIMENTAL|The Gather.town gaming intervention|"1. The Gather.town gaming intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 5 sessions.~Week 1: Introduction, identifying emotion (90 minutes). Introduction to the Gather.town gaming, emotional identification, and interpreting scenarios.~Week 2: Identifying irrational beliefs or negative thoughts (50 minutes). Presenting scenarios and identifying irrational beliefs or negative thoughts.~Week 3: Changing irrational beliefs or negative thoughts (50 minutes). Presenting scenarios, and matching irrational beliefs or negative thoughts with rational beliefs or positive thoughts Week 4: Finding a solution (50 minutes). Using the scenario to identify coping mechanisms and social support.~Week 5: Reinforcing happiness (90 minutes). Practice mindfulness and deep breathing techniques and identify emotions of happiness."
62668829|NCT06468020|NO_INTERVENTION|Control group|Routine care Participants received routine care in the health system including vital sign checkups, health assessments, and health education. They attended the antenatal care clinic eight times until delivery.
62668830|NCT00902525|EXPERIMENTAL|90Y-Ibritumomab Tiuxetan double dose|90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3
62668831|NCT05472298|EXPERIMENTAL|intervention arm|lifestyle modification, goal setting, coaching and peer support, problem-solving, and self-monitoring
62668832|NCT05472298|NO_INTERVENTION|control arm|education leaflet
62668833|NCT00661219|ACTIVE_COMPARATOR|Arm 1|
62668834|NCT00661219|PLACEBO_COMPARATOR|Arm 2|
62106868|NCT00359619|EXPERIMENTAL|Cervarix 2 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 2 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62106869|NCT00359619|EXPERIMENTAL|Cervarix 3 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 3 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62106870|NCT00359619|EXPERIMENTAL|Cervarix 4 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 4 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62106871|NCT00359619|EXPERIMENTAL|Cervarix 5 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 5 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62106872|NCT00359619|EXPERIMENTAL|Cervarix 6 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 6 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62106873|NCT05141890|EXPERIMENTAL|Probiotic|Participants will be given the probiotic supplement Lp299v. The supplement is taken by mouth in the form of capsules. Participants will undergo a screening visit. After 7-11 weeks of taking Lp299v, they will return for their final visit. Blood will be drawn before and after the 7- 11 week intervention.
62106874|NCT03094104|ACTIVE_COMPARATOR|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
62106875|NCT03094104|EXPERIMENTAL|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
62106876|NCT06631612|ACTIVE_COMPARATOR|daily dose of Iron Supplementation|daily dose of 3 mg/kg elemental Iron before bed
62106877|NCT06631612|EXPERIMENTAL|alternate day regimen|every other day dose of 3mg/kg elemental Iron before bed
62106878|NCT05019781|EXPERIMENTAL|KT group|Participants were received single session therapeutic tape application for one week.
62106879|NCT05019781|PLACEBO_COMPARATOR|Placebo group|Participants were received single session placebo tape application for one week.
62106880|NCT05019781|NO_INTERVENTION|Control group|No intervention.
62106881|NCT02989662|ACTIVE_COMPARATOR|Mifepristone|Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
62106882|NCT02989662|PLACEBO_COMPARATOR|Placebo - Cap|This is an inactive compound which appears physically identical to active medication.
62106883|NCT03601507|EXPERIMENTAL|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
62106884|NCT02358187|EXPERIMENTAL|HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|All subjects will receive vaccine plus Poly-ICLC. Injections will be given every 3 week for a total of 8 vaccines.
62469474|NCT04407806|ACTIVE_COMPARATOR|Intermittent Pulse Oximetry Monitoring of Oxygen Saturation|Intermittent pulse oximetry to measure oxygen saturation, measured every 4 hours
62469475|NCT06018532|EXPERIMENTAL|Intervention|
62668835|NCT05955833|EXPERIMENTAL|89Zr-DFO*-trastuzumab PET|Patients undergoing the 89Zr-DFO\*-trastuzumab PET-scans
62668836|NCT06195215|EXPERIMENTAL|peer counselling|"* Does not have any cognitive, affective and verbal problems that prevent communication~* It is planned to include nursing students with an Image Scale for Nursing Profession score of 143 and lower.~* The peer counselling process related to nursing image was applied to this group by 1 senior nursing student for 1 hour a week for 7 weeks. Before and immediately after the 7-week period, the nursing image scale is applied."
62668837|NCT06195215|NO_INTERVENTION|Control|"* Does not have any cognitive, affective and verbal problems that prevent communication~* It is planned to include nursing students with an Image Scale for Nursing Profession score of 143 and lower.~* No peer counselling process is applied to this group. Seven weeks after the first data collection, the final data are collected for the second time using the nursing image scale."
62668838|NCT01922609||Normal cerebrovascular reserve|Patients without preprocedural TCD signs of impaired cerebrovascular reserve
62668839|NCT01922609||Impaired cerebrovascular reserve|Patients with preprocedural TCD signs of impaired cerebrovascular reserve
62668840|NCT02664883||Group I (no cancer or hematuria)|Patients with no evidence of cancer and no hematuria undergo collection of blood and urine samples at baseline and 2 months for analysis via the Flow Cytometry MDSC Clinical Assay
62106885|NCT04416139|ACTIVE_COMPARATOR|Treated group|Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.
62106886|NCT04416139|NO_INTERVENTION|Control Group|The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables.
62298654|NCT02714530|ACTIVE_COMPARATOR|Radiotherapy alone|Radiotherapy 3 Gy x 10 alone
62469476|NCT00725803|EXPERIMENTAL|Cohort 1|Subjects randomized 3:1 (active:placebo) to receive GS-9450 10 mg/day or placebo.
62668841|NCT02664883||Group II (localized RCC)|Patients diagnosed with localized renal cell carcinoma undergo collection of blood and urine samples at baseline and after nephrectomy for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI within 30 days after nephrectomy.
62469477|NCT00725803|EXPERIMENTAL|Cohort 2|Subjects randomized 3:1 (active:placebo) to receive GS-9450 40 mg/day or placebo.
62469478|NCT00725803|EXPERIMENTAL|Cohort 3|Subjects randomized 3:1 (active:placebo) to receive GS-9450 80 mg/day or placebo.
62469479|NCT00725803|EXPERIMENTAL|Cohort 4|Subjects randomized 3:1 (active:placebo) to receive GS-9450 5 mg/day or placebo. Cohort may or may not be conducted pending blinded review of previous cohorts.
62469480|NCT02105779|EXPERIMENTAL|Targeted Cognitive Training|40 hours of BFP auditory training
62469481|NCT02105779|EXPERIMENTAL|Social Cognitive Training|40 hours of auditory training and 10 hours social exercises
62469482|NCT03015584||Septic patients admitted to the ICU|
62469483|NCT03958422|EXPERIMENTAL|Myocardin test group|Patients in cardiomyopeptidin group are given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) and intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI.
62469484|NCT03958422|NO_INTERVENTION|Blank test group|Patients in blank test group aren't given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) .
62469485|NCT05481320|EXPERIMENTAL|REACH VN Phone Intervention|A multicomponent behavioral intervention to support family caregivers of persons with dementia. The enrollment session (session 0) will be conducted face-to-face. Thereafter, participants will receive 4-6 intervention sessions by phone with either audio or video call over the course of 1-3 months. The sessions will occur every 1-2 weeks depending on the needs and availability of family caregivers.
62469486|NCT05481320|PLACEBO_COMPARATOR|Enhanced control|A single phone session focused on education about the nature of dementia.
62469487|NCT04598074|EXPERIMENTAL|Opioid Package Prototype (OPP)|Oxycodone 5mg tablets dispensed in the Opioid Package Prototype (OPP) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
62668842|NCT02664883||Group III (metastatic RCC)|Patients diagnosed with metastatic renal cell carcinoma undergo collection of samples prior to baseline and then after 4 months of systemic treatment for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI after completion of 4 months of systemic treatment.
62668843|NCT00354211||1|FLOTRAC™ SYSTEM
62668844|NCT00354211||2|Control Group
62298655|NCT01752283|EXPERIMENTAL|Hypnosis and local anesthesia|video-assisted thyroidectomy under hypnosis and local anesthesia.
62469488|NCT04598074|ACTIVE_COMPARATOR|Usual Care (standard amber vial)|Oxycodone 5mg tablets dispensed in the standard amber vial (usual care) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
62469489|NCT04100486||Healthy, Able-Bodied Individuals|This study will only enroll healthy, able-bodied individuals.
62668845|NCT05349370|EXPERIMENTAL|All patients|All patients receive the same intervention/sampling protocol
62668846|NCT05946772|PLACEBO_COMPARATOR|Placebo|A concealed 0.9% sodium chloride (NaCl) preparation will be applied intravenously at baseline, 12h, and 24h.
62106887|NCT00017004|EXPERIMENTAL|Arm I|Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
62668847|NCT05946772|EXPERIMENTAL|CsA|Cyclosporine A will be applied intravenously at baseline, 12h, and 24h.
62106888|NCT00017004|EXPERIMENTAL|Arm II|Patients undergo radiotherapy and chemotherapy as in arm I. Additionally, patients receive epoetin alfa subcutaneously once weekly concurrently with radiotherapy and chemotherapy.
62106889|NCT05223192|EXPERIMENTAL|Intervention group|Participants in this group will receive the ocean disc music therapy entrainment intervention
62668848|NCT03463447|EXPERIMENTAL|Hand strength|We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
62668849|NCT05930470|SHAM_COMPARATOR|Delayed intervention|Sham treatment first, then Magnetic Mitohormesis Therapy treatment
62106890|NCT05223192|NO_INTERVENTION|Control group|Participants in this group will not receive any intervention
62106891|NCT02192034|EXPERIMENTAL|Navigation Group|This group will receive standard clinic instructions for the colonoscopy and two additional phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure.
62106892|NCT02192034|PLACEBO_COMPARATOR|Control|This group will receive only clinic instructions without intervention from the patient navigator.
62106893|NCT03052946|ACTIVE_COMPARATOR|Bulking agent|Bulking agent in fecal incontinence
62106894|NCT03052946|PLACEBO_COMPARATOR|Endoanal electrostimulation|Endoanal electrostimulation in fecal incontinence
62106895|NCT05737784|EXPERIMENTAL|Preliminary Safety|Open-label PRAX-222
62106896|NCT05737784|EXPERIMENTAL|Dose Escalation - PRAX-222|Initial dose escalation consisting of double-blind ascending doses of PRAX-222
62106897|NCT05737784|PLACEBO_COMPARATOR|Dose Escalation - Placebo|Double-blind placebo procedure
62106898|NCT05737784|EXPERIMENTAL|Optional Dose Escalation - PRAX-222|Optional dose escalation consisting of double-blind ascending doses of PRAX-222
62469490|NCT02195050||Therapeutic target arm|Statin treated patients with and without raised triglycerides who do not have diabetes or dysglycemia. Statin treated patients with type 2 diabetes.Statin treated patients with CKD stages 4 and 5 (eGFR ≤30mL/min).
62668850|NCT05930470|EXPERIMENTAL|Immediate intervention|Magnetic Mitohormesis Therapy treatment first, then Sham treatment
62668851|NCT03780062|EXPERIMENTAL|S100B protein dosing|
62668852|NCT03041870|EXPERIMENTAL|Dominance|Healthy subjects
62106899|NCT05737784|PLACEBO_COMPARATOR|Optional Dose Escalation - Placebo|Double-blind placebo procedure
62106900|NCT05737784|EXPERIMENTAL|Confirmatory Dosing - PRAX-222|Double-blind fixed-dose PRAX-222
62106901|NCT05737784|EXPERIMENTAL|Confirmatory Dosing - Placebo|Double-blind placebo procedure
62106902|NCT05737784|EXPERIMENTAL|Open-label PRAX-222|Open-label PRAX-222
62106903|NCT01553513||Group 1 - STEMI|Patients with acute cardiovascular event and typical aberrations in the ECG(STEMI) and positive serum markers
62106904|NCT01553513||Group 2 - NSTEMI|Patients with acute coronary syndrome without typical aberrations in the ECG (NSTEMI) or without positive serum markers
62106905|NCT01553513||Group 3 - symptomatic CAD|Symptomatic patients with stable CAD, who are eligible for ICA
62106906|NCT01553513||Group 4 - STEMI|Patients eligible for ICA 6 months after STEMI and revascularization
62469491|NCT02195050||Nerve function arm|Patients with severe hypertriglyceridaemia (fasting TG \> 5.5mmol/l.) are recruited for nerve function assessment and corneal confocal microscopy.
62668853|NCT02726295|ACTIVE_COMPARATOR|E. coli Nissle 1917 (Mutaflor®)|Mutaflor® group will receive E. coli Nissle 1917 (Mutaflor®) 28mg 2T tid for initial 2 days, then E. coli Nissle 1917, Mutaflor® 4T qd for the next 26 days.
62668854|NCT02726295|PLACEBO_COMPARATOR|Matched placebo|Matched placebo group will receive placebo drug 28mg 2T tid for initial 2 days, then placebo 4T qd for the next 26 days. Placebo drug has same shape and size with E. coli Nissle 1917 (Mutaflor®).
62668855|NCT00720200|EXPERIMENTAL|1|
62668856|NCT00720200|ACTIVE_COMPARATOR|2|
62668857|NCT03739554|EXPERIMENTAL|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15 after the venetoclax ramp-up schedule is completed. Venetoclax will be taken daily at a dose that is deemed safe and tolerable after the ramp-up schedule. One cycle will be 28 days or 4 weeks.
62668858|NCT03808454|EXPERIMENTAL|Platelet rich plasma (PRP)|PRP injection only
62668859|NCT03808454|EXPERIMENTAL|PRP+Rehabilitation|PRP injection combined with rehabilitation
62668860|NCT03808454|ACTIVE_COMPARATOR|Rehabilitation|Rehabilitation treatment only
62106907|NCT03113487|EXPERIMENTAL|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
62298656|NCT01752283|ACTIVE_COMPARATOR|General anesthesia|Video-assisted thyroidectomy under general anesthesia
62668861|NCT05028088|EXPERIMENTAL|Child-Pugh A|"1. Diaphragm ultrasound scan before induction of anesthesia.~2. Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~3. When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~4. Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
62106908|NCT06279819|EXPERIMENTAL|intervention group|The intervention group will receive the gut microbiota-targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly health education videos for the same duration. The intervention will span three months, followed by a three-month follow-up period.
62106909|NCT06279819|NO_INTERVENTION|control group|The control group will continue routine follow-up and health education practices.
62106910|NCT01715909|EXPERIMENTAL|Oseltamivir: Standard dose|Participants will receive standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight. Infants \<1 year of age will receive oseltamivir at a dose of 3 milligrams per kilogram (mg/kg).
62106911|NCT01715909|EXPERIMENTAL|Oseltamivir: Triple dose|Participants will receive three times the standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight and age. Infants \<1 year will receive standard dose at 3 mg/kg.
62106912|NCT04518930|EXPERIMENTAL|high fat|26 participants will be provided with (35) g of roasted, not salted peanuts as snack.
62106913|NCT04518930|EXPERIMENTAL|high protein|26 participants will be provided with (380) g of Plain Greek yogurt after as snack.
62298657|NCT03202654|EXPERIMENTAL|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
62298658|NCT03202654|ACTIVE_COMPARATOR|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
62298659|NCT01770340|SHAM_COMPARATOR|Control group|Radical prostatectomy without implantation of allograft
62298660|NCT01770340|EXPERIMENTAL|Treatment group|Radical prostatectomy with implantation of allograft
62469492|NCT02195050||Genetic screening arm|For LAL deficiency screening, patients will be recruited over a 5 year period with a documented triglyceride level of more than 10 mmol/l at any time, low HDLC, raised ALT, combined hyperlipidaemia, or non-alcoholic fatty liver disease. Patients recruited from Manchester will be offered additional genetic testing for familial hypercholesterolaemia.
62106914|NCT05060679||Non-sepsis|Non-septic patients receive supportive treatment at the ICU.
62106915|NCT05060679||Sepsis|Patients receive sepsis therapy.
62298661|NCT02081963|EXPERIMENTAL|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
62298662|NCT02081963|OTHER|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
62298663|NCT02712502||Study group (OG).|"50 patients c and acute exacerbation of chronic bacterial rhinosinusitis in the study group (OG).~The treatment regimen in the study group.~* Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
62106916|NCT05060679||Sepsis-related organ dysfunction|Patients receive sepsis therapy and advanced supportive treatment based on the occurrence of specific sepsis-related organ dysfunctions.
62106917|NCT00717743||1|Patients diagnosed with RCC.
62106918|NCT06629545|EXPERIMENTAL|Passive ultrasonic irrigation|The irrigation solution was agitated by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device.
62106919|NCT06629545|EXPERIMENTAL|Sonic activated irrigation|The irrigation solution was agitated by a suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA).
62469493|NCT02184026|EXPERIMENTAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
62469494|NCT01381653|EXPERIMENTAL|Motivational Interviewing|Eight 30-minute sessions utilizing Motivational Interviewing will be delivered to reduce substance use and sexual risk in a group of high risk young men who have sex with men.
62106920|NCT06629545|NO_INTERVENTION|Control group|Pre-treatment GCF (preGCF) samples were collected for all participants
62106921|NCT02338739|ACTIVE_COMPARATOR|REC; Outreach if Failure|
62106922|NCT02338739|ACTIVE_COMPARATOR|REC; SMS + Voucher if Failure|
62106923|NCT02338739|ACTIVE_COMPARATOR|REC; Navigator if Failure|
62298664|NCT02712502||Control group (CG).|"50 patients c and acute exacerbation of chronic rhinosinusitis in the control group (CG).~The treatment regimen of the control group. Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
62298665|NCT05446948|EXPERIMENTAL|beveled 27G+ group|The group of patients underwent vitrectomy with a beveled 27G+ vitrectomy system.
62298666|NCT05446948|ACTIVE_COMPARATOR|25G+ group|The group of patients underwent vitrectomy with a standard 25G+ vitrectomy system.
62298667|NCT04609748|ACTIVE_COMPARATOR|The group that received nimesulide|
62298668|NCT04609748|EXPERIMENTAL|The group that received CBD Oil|
62106924|NCT02338739|ACTIVE_COMPARATOR|SMS; Outreach if Failure|
62106925|NCT02338739|ACTIVE_COMPARATOR|SMS; Outreach if Failure; Stop SMS if Success|
62106926|NCT02338739|ACTIVE_COMPARATOR|SMS; SMS+Voucher if Failure|
62106927|NCT02338739|ACTIVE_COMPARATOR|SMS; SMS+Voucher if Failure; Stop SMS if Success|
62106928|NCT02338739|ACTIVE_COMPARATOR|SMS; Navigator if Failure|
62106929|NCT02338739|ACTIVE_COMPARATOR|SMS; Navigator if Failure; Stop SMS if Success|
62106930|NCT02338739|ACTIVE_COMPARATOR|Voucher; Outreach if Failure|
62106931|NCT02338739|ACTIVE_COMPARATOR|Voucher; Outreach if Failure; Stop Voucher if Success|
62106932|NCT02338739|ACTIVE_COMPARATOR|Voucher; SMS+Voucher if Failure|
62106933|NCT02338739|ACTIVE_COMPARATOR|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|
62106934|NCT02338739|ACTIVE_COMPARATOR|Voucher; Navigator if Failure|
62106935|NCT02338739|ACTIVE_COMPARATOR|Voucher; Navigator if Failure; Stop Voucher if Success|
62106936|NCT03674190|EXPERIMENTAL|Anterior Lumbar Interbody Fusion|Surgical treatment Anterior Lumbar Interbody Fusion
62106937|NCT03674190|ACTIVE_COMPARATOR|Total disc replacement|Surgical treatment total disc replacement in the lumbar spine
62106938|NCT04973852|EXPERIMENTAL|Exoskeleton|5 sessions of overground ambulation with wearable exoskeleton where heart rate is monitored over each session.
62106939|NCT04304534|EXPERIMENTAL|BAY 2433334 high dose|
62106940|NCT04304534|EXPERIMENTAL|BAY 2433334 medium dose|
62106941|NCT04304534|EXPERIMENTAL|BAY 2433334 low dose|
62106942|NCT04304534|PLACEBO_COMPARATOR|BAY2433334 matching placebo|
62106943|NCT04371926|ACTIVE_COMPARATOR|HCQ arm|"COVID-19 positive cases will receive receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff randomized to this group will receive HCQ sulfate 400 mg/week for 4 weeks"
62106944|NCT04371926|NO_INTERVENTION|No-HCQ arm|Will receive standard treatment as needed, but no HCQ
62106945|NCT06101030||Signal On|Patient Signals ON
62106946|NCT06101030||Signal Off|Patient Signals Off
62106947|NCT02057354|ACTIVE_COMPARATOR|Healthy Sedentary Young Adults|Participants 18-35 years of age will be randomized to either aerobic or non-aerobic exercise training.
62106948|NCT02057354|EXPERIMENTAL|Healthy Sedentary Older Adults|Participants 55-85 years of age will be randomized to either aerobic or non-aerobic exercise training.
62298669|NCT00691171||1|GERD: Patients with established diagnoses of GERD based on ICD-9 codes
62106949|NCT04985487||Brolucizumab|Patients prescribed with brolucizumab in the approved indication
62106950|NCT02873676|EXPERIMENTAL|nutritional intervention|This group received multi-dimensional intensive nutritional intervention for 3 month, which included whey (30g/d,plus three times every week ),vitamin D (1000IU) and omega-3 fatty acid (DHA 1200mg and EPA 800mg).
62106951|NCT02873676|EXPERIMENTAL|resistance training program|This group received resistance training program which is made up warm-up exercise, muscle strength training and relaxing.
62106952|NCT02873676|EXPERIMENTAL|lifestyle modification project|This group receive multi-dimensional intensive nutritional intervention and resistance training program.
62106953|NCT02873676|PLACEBO_COMPARATOR|control|This group receive nutritional consulting,which involve dietary pattern modification and protein intake standardization.
62106954|NCT04008420||Adults who are scheduled to undergo robotic esophagectomy|Adults who are scheduled to undergo robotic esophagectomy
62106955|NCT03967925|ACTIVE_COMPARATOR|Belimumab|Weekly 200mg SC injections of belimumab for 12 months
62106956|NCT03967925|PLACEBO_COMPARATOR|Belimumab placebo|Weekly SC injections of belimumab placebo for 12 months
62106957|NCT04178343|EXPERIMENTAL|Group A|Meningeal Metastases, with or without brain metastases
62106958|NCT06082076|ACTIVE_COMPARATOR|Group D (dexmedetomidine group)|
62106959|NCT06082076|ACTIVE_COMPARATOR|Group K (ketamine group)|
62106960|NCT06082076|PLACEBO_COMPARATOR|Group C (control group)|
62106961|NCT02556034||Disease evaluation|Rheumatoid arthritis evaluations.
62106962|NCT02328820|OTHER|All patients|All lesions undergo simultaneous assessment with a combined pressure and flow sensor
62106963|NCT03189134|EXPERIMENTAL|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
62106964|NCT06165549|EXPERIMENTAL|Light therapy|about 30 individuals with internet gaming disorder will be randomly assigned to the light therapy group
62298670|NCT00691171||2|Atypical GERD: Patients without an established diagnosis of GERD with atypical symptoms that could be due to GERD (e.g., asthma)
62298671|NCT00691171||3|Chronic NSAID users: Patients using chronic NSAIDs who are at increased risk of GI complications (defined as previous diagnosis of peptic ulcer disease; age 75 or older; or concomitant use of corticosteroids, anticoagulants, or aspirin)
62298672|NCT00668005|EXPERIMENTAL|Arm 1|
62298673|NCT00668005|PLACEBO_COMPARATOR|Arm 2|
62298674|NCT03058484|NO_INTERVENTION|Control|Standard of care, i.e. regular clinic services are provided prior to the study.
62298675|NCT03058484|EXPERIMENTAL|Community Health Worker Intervention|This arm is a four-part behavioral intervention that includes: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
62298676|NCT06460350|EXPERIMENTAL|NEUROCUPLE™ Group|This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 2-weeks following their TKA surgery.
62298677|NCT06460350|PLACEBO_COMPARATOR|Placebo Group|This arm of subjects will receive the placebo (non-active, sham) patch to wear for 2-weeks following their TKA surgery.
62298678|NCT01583348||Women with gallstones|30 women with symptomatic gallstone disease with an indication for elective cholecystectomy
61913764|NCT04883723|EXPERIMENTAL|Experiment II (Manual Pressure) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
62106965|NCT06165549|PLACEBO_COMPARATOR|Light placebo|about 30 individuals with internet gaming disorder will be randomly assigned to the light placebo group
62106966|NCT06165549|OTHER|EABM training group|about 30 individuals with internet gaming disorder will be randomly assigned to the EABM training group
62298679|NCT02144649|NO_INTERVENTION|Group I (control, no juice)|Patients consume no tomato juice.
62469495|NCT03252509|EXPERIMENTAL|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
62469496|NCT03119025|EXPERIMENTAL|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
62469497|NCT01332864|ACTIVE_COMPARATOR|OMT to the head and rest of body|OMT is the intervention that will be applied to areas of somatic dysfunction as well as to the head using a compression of the fourth ventricle (CV4) technique.
62469498|NCT01332864|PLACEBO_COMPARATOR|Light touch|Light touch will be applied to the head region for 10 minutes with the patient at rest in the supine position.
62469499|NCT01332864|EXPERIMENTAL|OMT with CV4 to head|OMT is the intervention using the CV4 technique to the head region for 10 minutes with patient at rest.
62469500|NCT01332864|ACTIVE_COMPARATOR|OMT to the body except the head region|OMT is the intervention that will be applied to areas of somatic dysfunction in any region except the head.
62469501|NCT03067818|EXPERIMENTAL|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
62469502|NCT03067818|EXPERIMENTAL|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
62469503|NCT03067818|ACTIVE_COMPARATOR|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
62469504|NCT03596944||Statin|History of statin use for primary prevention
62298680|NCT02144649|EXPERIMENTAL|Group II (tangerine tomato juice)|Patients will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks)
62298681|NCT02144649|EXPERIMENTAL|Group III (red tomato juice)|Patients consume two cans of red tomato juice daily until their scheduled surgery (approximately 4 weeks).
62469505|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
62469506|NCT05668780|EXPERIMENTAL|Intervention - Nominal Group Technique, Training, Coaching|Each group of clinics will receive the same intervention in a step-wedge design, starting every 6-months.
62469507|NCT02508883||Upper gastrointestinal bleeding|patients with cancer who presented or were admitted in the emergency room, wards or intensive care units of the Cancer Institute of São Paulo (ICESP), with a recent episode of upper gastrointestinal bleeding.
62469508|NCT06350669|EXPERIMENTAL|App-assisted vestibular rehabilitation|The patients in this group will undergo standard vestibular rehabilitation treatment with the addition of a phone app that support the treatment program, e.g., providing reminders for exercise, documentation of exercise performance, communication with the therapist, etc.
62106967|NCT00957086|ACTIVE_COMPARATOR|Nimotuzumab|Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab
62106968|NCT00957086|PLACEBO_COMPARATOR|Placebo|Comprising Adjuvant Cisplatin, Concurrent RT and Placebo
62298682|NCT06004804|EXPERIMENTAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
62298683|NCT06004804|EXPERIMENTAL|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
62298684|NCT06004804|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
62298685|NCT00706732|ACTIVE_COMPARATOR|T1|
62298686|NCT00706732|ACTIVE_COMPARATOR|T2|
62298687|NCT00706732|PLACEBO_COMPARATOR|C1|
62298688|NCT00706732|PLACEBO_COMPARATOR|C2|
62298689|NCT05048290|EXPERIMENTAL|Group I (communication workshops, video, surveys)|Participants complete 2 communication workshops about conversational skills and development of a video about the summer student's research experience over 3 hours each during the second week of the summer research experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
62298690|NCT05048290|ACTIVE_COMPARATOR|Group II (generic communication workshops, surveys)|Participants complete 2 generic communication workshops about networking and presentation skills over 3 hours each during the second week of the summer experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
62298691|NCT06346522|ACTIVE_COMPARATOR|-Group G (40 patients): Gabapentin|After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
62298692|NCT06346522|ACTIVE_COMPARATOR|-Group T (40 patients): Trospium chloride slow release|After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
62298693|NCT03006783||Cross-face nerve graft treated|People treated by a solitary cross-face nerve graft or in combination with another procedure.
62298694|NCT03006783||Hypoglossal-facial treated|People treated with a solitary hypoglossal-facial anastomosis.
62298695|NCT03234114|EXPERIMENTAL|1-month TAT|Randomized experimental group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg q.d. and aspirin 100 mg q.d.) for 1 month (30 days) then quit aspirin till 12 months after PCI
62298696|NCT03234114|EXPERIMENTAL|6-month TAT|Randomized control group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg q.d. and aspirin 100 mg q.d.) for 6 months (180 days）then quit aspirin till 12 months after PCI
62298697|NCT03234114|EXPERIMENTAL|12-month DAT-1|Randomized experimental group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg q.d. for 12 months after PCI
62298698|NCT03234114|EXPERIMENTAL|12-month DAT-2|Randomized control group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI
62469509|NCT06350669|NO_INTERVENTION|Standard vestibular rehabilitation (no app)|The patients in this group will undergo standard vestibular rehabilitation treatment, without using the app.
62469510|NCT04048317|EXPERIMENTAL|drug eluting bead trans arterial chemo embolization|the international arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Hepasphere
62469511|NCT04048317|PLACEBO_COMPARATOR|conventional trans arterial chemo embolization|the control arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Lipiodol
62106969|NCT00454792|ACTIVE_COMPARATOR|Exercise and advise to stay active|The exercise group received exercises for the stabilising muscles in the low back and abdomen together with dynamic exercises, exercises for postural instability and light physical fitness training.
62106970|NCT00454792|EXPERIMENTAL|Rest and use of flexible lumbar belt|The rest group was instructed to avoid hard physical activity and to rest twice daily for one hour, by lying down
62298699|NCT04486560|EXPERIMENTAL|Single Arm: Cryoprobe|Everyone who enrolls in this study will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe.
62298700|NCT03865472|EXPERIMENTAL|Arm I (rTMS)|Patients undergo rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
62298701|NCT03865472|SHAM_COMPARATOR|Arm II (sham rTMS)|Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
62298702|NCT03075839|EXPERIMENTAL|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
62469512|NCT01786785||Stroke Patients|Subjects between 2 and 17 years of age with a confirmed arterial ischemic stroke.
62469513|NCT01786785||Controls|Age and Gender Matched Controls
62106971|NCT03152799|EXPERIMENTAL|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
62298703|NCT02555800|EXPERIMENTAL|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
62469514|NCT04808557|ACTIVE_COMPARATOR|Trial Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Biorepair Total Protection for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
62469515|NCT04808557|ACTIVE_COMPARATOR|Control Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Sensodyne Repair \& Protect for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
62469516|NCT04430569|EXPERIMENTAL|Alteplase|
62469517|NCT04430569|PLACEBO_COMPARATOR|Placebo|
62469518|NCT00657553|ACTIVE_COMPARATOR|Bortezomib/Treatment Arm|Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
62106972|NCT03152799|SHAM_COMPARATOR|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
62106973|NCT05946824|EXPERIMENTAL|1 - Prostate bed only recurrence|Patients with confirmed radiologic recurrence of their prostate cancer in the defined region of the previous prostate surgery - commonly referred to as the prostate surgical bed.
62298704|NCT02555800|EXPERIMENTAL|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
62106974|NCT05946824|EXPERIMENTAL|2- Pelvic nodal with or without a prostate bed recurrence|Patients who have a radiologic recurrence of prostate cancer in the pelvic node region
62106975|NCT04081506|EXPERIMENTAL|Group A|Individualized care
62106976|NCT04081506|NO_INTERVENTION|Group B|Conventional care
62106977|NCT00479180|EXPERIMENTAL|AVG1|Vascugel
62106978|NCT00479180|PLACEBO_COMPARATOR|AVG2|Gelfoam
62106979|NCT00479180|EXPERIMENTAL|AVF3|Vascugel
62298705|NCT02555800|PLACEBO_COMPARATOR|Saline|Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.
62298706|NCT01133743|EXPERIMENTAL|Lenalidomide and Dexamethasone|Lenalidomide target dose of 25 mg PO OD continuously (28-day cycle) using an initial dose escalation period. Oral dexamethasone 12 mg daily on days 1-7, 14 and 21 of each cycle.
62298707|NCT04078750|SHAM_COMPARATOR|Phase I. Control group|"1. The standard of care will be provided to the control group pre- and post-transplant. This does not involve any direct pre-transplant assessment of medication adherence or risk factors for non-adherence.~2. Tacrolimus capsules will be dispensed in Medication Event Monitoring System (MEMS) caps for 3 months post-transplant for the purpose of measuring adherence after transplantation.~3. Patients will be asked to complete Basel Assessment of Adherence to Immunosuppressive Medication instrument (BAASIS) questionnaire and Long-term Medication Behaviour Self-efficacy Scale at 3 months after transplantation."
62106980|NCT00479180|PLACEBO_COMPARATOR|AVF4|Gelfoam
62668862|NCT05028088|EXPERIMENTAL|Child-Pugh B|"1. Diaphragm ultrasound scan before induction of anesthesia.~2. Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~3. When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~4. Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
62106981|NCT02451943|EXPERIMENTAL|Doxorubicin + Olaratumab|75 milligrams per meter squared (mg/m\^2) doxorubicin administered intravenously (IV) on day 1 of each 21-day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21-day cycle until documented progressive disease (PD) or discontinuation for any other reason.
62106982|NCT02451943|PLACEBO_COMPARATOR|Doxorubicin + Placebo|75 mg/m\^2 doxorubicin administered IV on day 1 of each 21-day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21-day cycle until PD or discontinuation for any other reason.
62106983|NCT00603356|EXPERIMENTAL|1|Dose Escalation
62298708|NCT04078750|EXPERIMENTAL|Phase II. Intervention group|Patients will be given lactose containing white- and yellow-colored gelatin capsules stored in (MEMS®) bottles for a 1-month adherence trial. Yellow-colored gelatin capsules represent tacrolimus 0.5mg capsules while white-colored gelatin capsules represent tacrolimus 1mg capsules. MEMS® is designed to record the date/time of opening and closure of the drug vial. Patients will be asked to take a certain dose and expected to remove the correct number of white and yellow capsules from respective vial at the correct time each day. Phone calls will be made to patients to change the 'dose' at various times throughout the month to mimic the frequent need to make tacrolimus dosing changes early post-transplant.Pill count and MEMS record will be reviewed at the end of the 1-month trial period to assess adherence. Patients will also undergo health literacy, cognition testing, self-efficacy tests, with a customized post-transplant plan.
62298709|NCT01051739||Group 1|glaucoma
62298710|NCT01051739||Group 2|normal
62298711|NCT03097887|ACTIVE_COMPARATOR|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
62298712|NCT03097887|ACTIVE_COMPARATOR|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
62469519|NCT00657553|NO_INTERVENTION|Observation Arm (watchful waiting)|monitor myeloma parameters every 3-6 months
62469520|NCT02289963|PLACEBO_COMPARATOR|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
62298713|NCT04634578|EXPERIMENTAL|Bevacizumab- 0.063 mg|Participants will receive a single intravitreal injection of 0.063 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
62106984|NCT06434051|EXPERIMENTAL|Traditional Chinese cervical manipulation|The CMP will first palpate the transverse processes of C1 and C2. The transverse process with apparent tenderness will be regarded as the pain side. The right side will be the painful side for the following example). During the manipulation, the CMP will use his left hand to support the lower jaw and passively rotate the neck to the left side by 70-75 degrees (or to the maximum angle without discomfort). The physician's right-hand fingers will support the left-side transverse processes of C1 and C2, and the thumb and thenar muscle will be placed on the spinous process and occipital area. While maintaining a passive left neck rotation, the physician will increase the rotation angle by 5-10 degrees with both hands under a sudden pulling force. The above procedure will be repeated on the right side (pain side).
62106985|NCT06434051|SHAM_COMPARATOR|Sham manipulation|The posture and position of the participant and the practitioner and the procedure are the same as the CCM technique. The right side will be regarded as the pain side once again. When performing the sham technique, the CMP uses the left hand to support the lower jaw position and passively rotates the neck to the left side by 70-75 degrees or to the maximum angle. The right hand presses the upper inner corner of the right scapula. While maintaining the passive left rotation of the neck, the right hand slowly exerts force downwards and outwards on the inner side of the scapula. The left hand only maintains the left rotation of the neck without any pulling force. After completion, repeat the above actions on the right side. After the technique is completed, participants can get up after resting for 5-10 minutes.
62298714|NCT04634578|EXPERIMENTAL|Bevacizumab- 0.25 mg|Participants will receive a single intravitreal injection of 0.25 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
62106986|NCT04439513|EXPERIMENTAL|Dual Artery Compression|time to hemostasis and incidence of radial artery occlusion will be monitored while using a dual artery compression device (Terry-2-band) to achieve hemostasis.
62106987|NCT04439513|ACTIVE_COMPARATOR|Radial Artery-Only|time to hemostasis and incidence of radial artery occlusion will be monitored while using the device currently approved by the institution (Hemo-Stop) and following institutional protocols for hemostasis.
62298715|NCT02247869|EXPERIMENTAL|dose dense ABVD|1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)
62298716|NCT00407355|ACTIVE_COMPARATOR|RBZ 0.3|RBZ at the 0.3 mg dose intravitreal injection
62298717|NCT00407355|ACTIVE_COMPARATOR|RBZ 0.5|RBZ dose level .5 for ITV injection
62298718|NCT04693871||high-flow rate group|
62298719|NCT04693871||low-flow rate group|
62298720|NCT03510793||Balanced anesthesia|Patients receiving balanced anesthesia (desflurane + remifentanil) according to the attending physician's decision
62298721|NCT03510793||Total intravenous anesthesia|Patients receiving total intravenous anesthesia (TIVA) using propofol + remifentanil with target-controlled infusion according to the attending physician's decision.
62106988|NCT01805349|OTHER|X-Rays|patients with digital arthrosis and hip/knee arthrosis will practice hand X-rays
62106989|NCT01379287|EXPERIMENTAL|Patients with Advanced Solid Tumors|The trial was initially designed as a 3 hour IV infusion of iso-fludelone every 3 weeks with three dose-escalation stages (12 patients), however it has been amended to study iso-fludelone administered over 6 hours (+/- 30 minutes) every 3 weeks schedule.
61913765|NCT04883723|NO_INTERVENTION|Control Group|The patients in the Manual Pressure group were given detailed information about the procedure and the research, and the patients who agreed to participate in the study were signed by an informed consent form. Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Injection was given using the normal intramuscular injection procedure. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
62106990|NCT05320913|EXPERIMENTAL|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|Participants receiving pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)
62298722|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
62298723|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
62298724|NCT05154474||Standard|Standard follow-up MNA, IPAQ, SARC-F and SarQOL questionnaire
62298725|NCT01420133|EXPERIMENTAL|Normal regimen|without special regimen for corticosteroid therapy
62298726|NCT01420133|ACTIVE_COMPARATOR|Standard arm|with diet low in salt and sugar
62469521|NCT02289963|PLACEBO_COMPARATOR|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
62298727|NCT05316896|EXPERIMENTAL|Internal perturbation|The people included in this group did 6 internal perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
61913766|NCT06388044|EXPERIMENTAL|Acceptance and Commitment Therapy|For those that enroll in the study, the therapist will see patients for 12 therapy sessions in the fertility clinic, with sessions lasting between 50 and 60 minutes. The therapist will offer both in-person and virtual sessions.
61913767|NCT03235180|EXPERIMENTAL|Crohn's Disease Subjects|"Subjects will receive ultrasound exams of the bowel with 2 different machines (Ultrasound Elastography and Ultrasound Vascularity) at three time points: baseline, 4 weeks, and 6 months. The ultrasound exams will be performed at first with no contrast agent, and then ultrasound measurements will be repeated with 1-2 ml of Sulfur Hexafluoride, a contract agent.~Subjects also will receive Magnetic Resonance Enterography (MRE) exams at baseline and 6 months as part of their clinical care."
62106991|NCT05320913|ACTIVE_COMPARATOR|isolated periarticular multimodal drug injection (PMDI)|Arm Description: Participants receiving isolated periarticular multimodal drug injection (PMDI)
62106992|NCT05528380|EXPERIMENTAL|Open Trial Intervention|Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
62106993|NCT04087746|ACTIVE_COMPARATOR|AFLIBERCEPT|Intra-vitreal injection of AFLIBERCEPT
62106994|NCT04087746|ACTIVE_COMPARATOR|RANIBIZUMAB|Intra-vitreal injection of RANIBIZUMAB
62106995|NCT02528591|EXPERIMENTAL|renal transplant patient|
62298728|NCT05316896|EXPERIMENTAL|Eksternal perturbation|The individuals included in this group performed 6 external perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
62298729|NCT06275217|EXPERIMENTAL|Mindful yoga group|The participants in experimental group will receive a 10-week mindfulness-based yoga program, one session per week with 1.5 hours in each session.
62469522|NCT04395222|EXPERIMENTAL|ATG Group I|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen.~* Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~* Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~* Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~* Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
62469523|NCT04395222|EXPERIMENTAL|ATG Group II|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen.~* Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~* Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~* Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~* Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
62469524|NCT04395222|EXPERIMENTAL|ATG Group III|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen.~* Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~* Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~* Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~* Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
62469525|NCT04395222|EXPERIMENTAL|ATG Group IV|"* Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~* Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~* Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~* Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
62469526|NCT03682263|EXPERIMENTAL|Full Service Treatment|The Full Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services, as well as Medication Management Support (MMS) from a Nurse Care Coordinator (NCC).
62469527|NCT03682263|EXPERIMENTAL|Basic Service Treatment|The Basic Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services.
61913768|NCT05853796||Patients with acute ischemic stroke at young age (18-50 years)|Patients aged 18 to 50 years with first-ever ischemic stroke or transient ischemic attack.
62106996|NCT06628544|EXPERIMENTAL|BCG vaccination with taking metformin on the day 85|
62106997|NCT06628544|EXPERIMENTAL|BCG vaccination without metformin|
62106998|NCT06628544|PLACEBO_COMPARATOR|Placebo|
62106999|NCT06628544|EXPERIMENTAL|BCG vaccination with taking metformin on the day 0|
62107000|NCT06628544|EXPERIMENTAL|BCG vaccination with taking metformin on the day 9|
62469528|NCT03682263|NO_INTERVENTION|Usual Services|Members of the Usual Service group seek services as they normally would (or would not) in their community. At the time of randomization, each Usual Services group member receives a comprehensive manual describing mental health and employment services in their local community, as well as state and national resources.
62469529|NCT06225076|EXPERIMENTAL|The observation group|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 20 days.
62469530|NCT06225076|ACTIVE_COMPARATOR|The control group|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 20 days.
62469531|NCT01688609|EXPERIMENTAL|Treatment (lapatinib, trastuzumab, paclitaxel, surgery)|"Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.~Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30 minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy or mastectomy."
62107001|NCT01967030||Women with recent GDM pregnancy|The study cohort includes women who had gestational diabetes mellitus (GDM) in their index pregnancy for study enrollment. There are two pre-defined groups: 1) women who breastfeed intensively during the first 4 months postpartum, and 2) women who mostly fed formula during the first 4 months postpartum. The study enrolled women into these pre-defined groups, but some women transitioned into mixed feeding groups after enrollment.
62107002|NCT03359031|NO_INTERVENTION|No patient education|This group of patients will not receive any additional information beyond standard of care educational pamphlets provided by the hospital.
62107003|NCT03359031|OTHER|Patient education|This group of patients will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
62107004|NCT03832660|ACTIVE_COMPARATOR|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
62107005|NCT03832660|ACTIVE_COMPARATOR|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
61913769|NCT05853796||Healthy controls|Healthy controls (aged 18 to 50 years) without cardiovascular diseases in their medical history. Subjects age- and gender-matched to patients
62298730|NCT06275217|ACTIVE_COMPARATOR|Psychoeducation group|The participants in the psychoeducation group will receive a 10-week psychoeducation program, one session per week with 1.5 hours in each session.
62298731|NCT05595525|EXPERIMENTAL|Group A = right side face treated with 1064nm and left with 755nm|subject will have their right half of their face treated with the 1064nm picosecond laser with diffractive lens array. Then the contralateral, left half will be treated with the 755nm picosecond laser with diffractive lens array. Subjects will receive three (3) treatments, four (4) weeks ± 7 days apart to each facial half.
62298732|NCT05595525|EXPERIMENTAL|Group B = left side face treated with 1064nm and right with 755nm|subject will have their left half of their face treated with the 1064nm picosecond laser with diffractive lens array. Then the contralateral, right half will be treated with the 755nm picosecond laser with diffractive lens array. Subjects will receive three (3) treatments, four (4) weeks ± 7 days apart to each facial half.
62298733|NCT01748227|OTHER|Peer-Coached Pain Self-Management|Participants (n=20) were assigned to a peer coach, who delivered self-management instruction one-on-one over a 4-month period.
62298734|NCT01966510|EXPERIMENTAL|Cord blood transplantation|Two cord blood units containing both together more than 3x10\^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
62298735|NCT04585685|EXPERIMENTAL|2 week baseline, CPT + SC|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
62469532|NCT01082523|ACTIVE_COMPARATOR|Text message reminders|
62469533|NCT01082523|NO_INTERVENTION|Control|
62469534|NCT04826874|EXPERIMENTAL|Affect Labeling_direct|Randomized to immediate two-week, internet delivered psychoeducative course in affect labeling
62469535|NCT04826874|NO_INTERVENTION|Wait-list|Randomized to a two-week wait-list control
61913770|NCT03680742|EXPERIMENTAL|Treated|All eligible patients who underwent an attempt with the Contour device.
62469536|NCT03374462|EXPERIMENTAL|Telemedicine Intervention|All participants will receive the study intervention, which consists of home-based telemedicine visits with a diabetes specialist, at a frequency determined by the patient's degree of glycemic control (every 4, 6, or 8 weeks).
62469537|NCT05638971|EXPERIMENTAL|Sensor Group|The first half sample size Peripheral intravenous canula will be enrolled in a non-alarming group. ivWatch will monitor the Peripheral intravenous canula insertion site collecting data without notifications. The goals of the study on the nonalarming group are: a) to evaluate ivWatch sensitivity to detect infiltration in comparison with nurse standard of care; b) to estimate the difference in terms of time to detection of ivWatch in comparison with nurse standard of care
62469538|NCT04910425|EXPERIMENTAL|Diagnostic (18F-DCFPyL PET/MRI, mpMRI)|Patients receive fluorine F 18 DCFPyL IV and undergo PET/MRI. Patients also receive either gadobutrol IV or gadobenate dimeglumine IV (per radiologist preference), and undergo mpMRI. Within approximately 60 days after PET/MRI and mpMRI, patients undergo TRUS guided prostate biopsy per standard of care.
62469539|NCT04847544|EXPERIMENTAL|ADX-629 300 mg administered orally twice daily (BID) for up to 28 days.|
62469540|NCT04847544|PLACEBO_COMPARATOR|Placebo administered orally BID for up to 28 days.|
62469541|NCT03426722|ACTIVE_COMPARATOR|L-carnitine|L-carnitine 500mg three times daily (per oral)
62469542|NCT03426722|PLACEBO_COMPARATOR|Placebo|Placebo 500mg three times daily (per oral)
62107006|NCT03832660|NO_INTERVENTION|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
62107007|NCT01202851|EXPERIMENTAL|Relaxation Group 1|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
62298736|NCT04585685|EXPERIMENTAL|2 week baseline, SC + CPT|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
62298737|NCT04585685|EXPERIMENTAL|4 week baseline, CPT + SC|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
62298738|NCT04585685|EXPERIMENTAL|4 week baseline, SC + CPT|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
62469543|NCT03967223|EXPERIMENTAL|Substudy 1: lete-cel in previously untreated advanced (metastatic or unresectable) SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
62469544|NCT03967223|EXPERIMENTAL|Substudy 2: lete-cel in advanced (metastatic or unresectable) SS or MRCLS post anthracycline chemo|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
62469545|NCT05312827|EXPERIMENTAL|Telehealth|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
62469546|NCT02914600|EXPERIMENTAL|Filgotinib 200 mg|"Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg.~Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study.~Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks)."
62298739|NCT06600906||Cohort A (HP 13C pyruvate, MRI)|Participants with advanced/non-resectable pancreatic ductal adenocarcinoma (PDA) receive HP 13C pyruvate intravenously (IV) and undergo MRI scans prior to receiving standard-of-care (SOC) treatment and again at 4 weeks after starting SOC treatment. Participants may optionally undergo an additional HP 13C pyruvate MRI scan at 8 weeks after starting SOC treatment. Participants who have excellent response and deemed candidates for surgical resection may be switched to Cohort B. Participants also undergo CT and additional MRI scans throughout the study.
62469547|NCT02914600|EXPERIMENTAL|Filgotinib 100 mg|"Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg.~Male participants from the US \& Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study.~Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks)."
62469548|NCT02914600|PLACEBO_COMPARATOR|Placebo|"Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After unblinding of the parent study, participants on placebo treatment discontinued study drug and study participation.~Treatment was administered orally once a day until unblinding of the parent study (up to 308 weeks)."
62469549|NCT04975334|EXPERIMENTAL|naloxone|one period of frequent blood sampling with no medication administered; one period of frequent blood sampling with IV administration of naloxone (one bolus and an infusion over an up to 12-hour period.)
62298740|NCT06600906||Cohort B (HP 13C pyruvate, MRI)|Participants with localized PDA who are deemed candidates for neoadjuvant therapy (NAT) receive HP 13C pyruvate IV and undergo MRI scans prior to starting NAT and again at 4 weeks after starting NAT. Participants may optionally undergo an additional HP 13C pyruvate MRI scan at 8 weeks after starting NAT. Participants who develop rapidly progressive disease and are deemed non-resectable may be switched to Cohort A. Participants also undergo CT and additional MRI scans throughout the study.
62298741|NCT00701987|EXPERIMENTAL|1|ALS-357 applied topically twice weekly for four weeks.
62298742|NCT00701987|EXPERIMENTAL|2|ALS-357 applied topically every other day for four weeks.
62469550|NCT04616066|EXPERIMENTAL|Dates Arm|Consumption of Khalas dates (3 dates =30g undried dates) twice daily (phytoestrogen content 329ug/100g)
62469551|NCT04616066|EXPERIMENTAL|Raisins Arm|Consumption of Raisins (30g twice daily, phytoestrogen content of 9.6ug/100g)
62469552|NCT06162793|EXPERIMENTAL|RehaPlus+|Customized motivational text messages twice weekly for six months
62469553|NCT06162793|NO_INTERVENTION|Usual care|"Standard care (Six-month German outpatient program IRENA)"
62469554|NCT06147596||Soccer|Healthy volunteers that participate in the study by playing a regular soccer game for the sake of the HEADLINE study
62107008|NCT01202851|EXPERIMENTAL|Relaxation Group 2|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
62107009|NCT01202851|OTHER|Waitlist Control Group (WLC)|Participants in this group given the option to take part in one of the two forms of relaxation (off study) after they finish their last questionnaire packet. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
62107010|NCT02455687|ACTIVE_COMPARATOR|Hi-Mg + Bud|Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.
62107011|NCT02455687|PLACEBO_COMPARATOR|Hi-Mg + P|Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.
62298743|NCT00701987|EXPERIMENTAL|3|ALS-357 applied topically once daily for four weeks.
62298744|NCT00701987|EXPERIMENTAL|4|ALS-357 applied topically twice daily for four weeks.
62298745|NCT06258525|EXPERIMENTAL|Single Arm|
62469555|NCT02089685|EXPERIMENTAL|Pembrolizumab + PegIFN-2b|Participants in Part 1A receive pembrolizumab intravenously (IV) 200 mg every three weeks (Q3W) + PEG-IFN at assigned dose subcutaneously (SC) once a week for up to \~2 years.
62469556|NCT02089685|EXPERIMENTAL|Pembrolizumab + IPI Q3W|Participants in Parts 1A and 1B receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 1 mg/kg Q3W for up to \~12 weeks.
62298746|NCT05493514||People with neurological disease according to inclusion criteria|People with neurological disease (Multiple Sclerosis, Parkinson Disease, Stroke and acquired brain injuries) will be recruited according to inclusion and exclusion criteria.
62298747|NCT04705467|OTHER|Patients|Device: Gynecological brachytherapy requiring an Interstitial or ring and tandem insert involves insertion of the needle and applicators with no standard real-time image guidance. Occasionally 2-dimensional ultrasound is used, but it greatly limited by its flat nature, preventing a volumetric view of the needle pathways. Interstitial brachytherapy is done under general anesthesia. The trans-abdominal and trans-rectal standard 2D ultrasound that are used in some cases, will be expanded to 3D dimensional imaging through the use of an investigational device. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning.
62469557|NCT02089685|EXPERIMENTAL|Pembrolizumab + IPI Q6W|Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 50 mg every 6 weeks (Q6W) for up to \~24 weeks.
62469558|NCT02089685|EXPERIMENTAL|Pembrolizumab + IPI Q12W|Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 100 mg every 12 weeks (Q12W) for up to \~48 weeks.
62469559|NCT03916497||Group 1 : kidney transplant recipients (KTR)|
62469560|NCT03916497||Group 2 : hemodialysis patients|
62469561|NCT03916497||Group 3 : Control patients|
62469562|NCT02864615|EXPERIMENTAL|Stereotactic Body Radiation Therapy|Patients with stable disease on targeted or IO therapy will receive SBRT on first metastasis of clear cell renal cell carcinoma. Second metastasis will be as a control. In case of safety and 50% reduction in size of first metastasis, up to 10 metastasis will be treated with SBRT.
62469563|NCT02042664|EXPERIMENTAL|treatment BYETTA|
62469564|NCT02042664|ACTIVE_COMPARATOR|metformine|
62469565|NCT00906594|ACTIVE_COMPARATOR|Latanoprost|Latanoprost mono therapy
62469566|NCT00906594|EXPERIMENTAL|Latanoprost + Fixed combination|Latnoprost + Fixed combination
62298748|NCT06657729||Extremely preterm infants|Extremely preterm infants born before 29 weeks.
62298749|NCT02830802|EXPERIMENTAL|Group A|Active Agent
62107012|NCT02455687|ACTIVE_COMPARATOR|Std-Mg + Bud|Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.
62298750|NCT02830802|PLACEBO_COMPARATOR|Group B|Placebo
62298751|NCT02053805|OTHER|screening tests|The screening will include: DRE, PSA , a multiparametric prostate MRI and a trans-rectal ultra-sound guided prostate biopsy/ MRI-US fusion , IPSS questionnaire, trans-rectal US assessment of prostate size, urine flow and residual.
62298752|NCT04108507|EXPERIMENTAL|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP)operation
62298753|NCT04108507|NO_INTERVENTION|without posterior branch block of spinal nerve|without posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
62298754|NCT02432807|EXPERIMENTAL|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1% dosed approximately 1 cm of ointment QID for 7 days
62469567|NCT01630733|EXPERIMENTAL|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
62469568|NCT01630733|ACTIVE_COMPARATOR|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
62107013|NCT02455687|PLACEBO_COMPARATOR|St-Mg + P|Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline
62107014|NCT04621539||Infected without an SMO|Defined as an acute infection not associated with admission to the intensive care unit (ICU), mechanical ventilation, or the use of vasopressors.
62469569|NCT05239819|EXPERIMENTAL|Intervention group|We conducted a fully engaged inspiratory muscle training (IMT) program. The exercise group received the intervention threshold IMT from preoperative to postoperative undergoing upper abdominal surgery. The IMT was started before 3 weeks of operation and surveyed in the followed 4 weeks.
62469570|NCT05239819|ACTIVE_COMPARATOR|Usual care group|The Usual care group will receive regulated education.
62668863|NCT05028088|EXPERIMENTAL|Child-Pugh C|"1. Diaphragm ultrasound scan before induction of anesthesia.~2. Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~3. When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~4. Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
62668864|NCT06122064|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients attend a standard of care visit with their clinician on study.
62107015|NCT04621539||Infected with an SMO|defined as an acute infection associated with intensive care unit (ICU) admission, mechanical ventilation, or vasopressor use.
62107016|NCT04826055|ACTIVE_COMPARATOR|loop bypass with fixed biliary limb length|in all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
62668865|NCT06122064|EXPERIMENTAL|Arm II (standard of care, conversation aid)|Patients attend a standard of care visit with the use of the shared decision-making conversation tool by the clinician on study.
62668866|NCT06433726|EXPERIMENTAL|BY101921|Dose Escalation: Multiple doses of BY101921 for oral administration
62107017|NCT04826055|EXPERIMENTAL|loop bypass with a biliary limb is a percentage of the small intestine|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
62107018|NCT06185400|EXPERIMENTAL|Arm1: Treatment Naive NSCLC|RC48+third-generation EGFR TKIs in treatment-naive patients harboring EGFR mutation and HER2 alterations
62298755|NCT02432807|PLACEBO_COMPARATOR|Placebo|Vehicle (placebo) ophthalmic ointment dosed approximately 1 cm of ointment QID for 7 days
62298756|NCT02634866||Group N|The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
62298757|NCT02634866||Group D|The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
62298758|NCT02634866||Group D_HF|The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
62298759|NCT00679861|EXPERIMENTAL|3|A practitioner delivered counselling and an expert system intervention is implemented in practices allocated to this arm
62298760|NCT00679861|EXPERIMENTAL|1|A practitioner delivered counselling intervention was implemented in practices allocated to this arm
62298761|NCT00679861|EXPERIMENTAL|2|A computer expert system intervention was implemented in practices allocated to this arm
62298762|NCT00283387|EXPERIMENTAL|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
62298763|NCT00283387|PLACEBO_COMPARATOR|Placebo|Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
62298764|NCT02593929|EXPERIMENTAL|ruxolitinib|Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
62298765|NCT06338787|EXPERIMENTAL|Iron/yeast complex (FeSC)|Iron Supplement
62469571|NCT04609722|EXPERIMENTAL|intervention group|Solution-Focused Support Program will apply to the participants.
62107019|NCT06185400|EXPERIMENTAL|Arm2: Locally Progressed|This cohort includes ERBB2 altered patients after third-generation EGFR-TKIs treatment with locally or slowly progressed disease, who may continue to benefit from third-generation EGFR-TKIs treatment under investigators' evaluation.
62107020|NCT06185400|EXPERIMENTAL|Arm3: Extensively Progressed|This cohort includes ERBB2 altered patients after third-generation EGFR-TKIs treatment with extensively progressed disease, who may be less likely to benefit from third-generation EGFR-TKIs treatment under investigators' evaluation.
62107021|NCT00771667|PLACEBO_COMPARATOR|Placebo (IP)|
62107022|NCT00771667|EXPERIMENTAL|Ustekinumab 1mg/kg (IP)|
62107023|NCT00771667|EXPERIMENTAL|Ustekinumab 3 mg/kg (IP)|
62107024|NCT00771667|EXPERIMENTAL|Ustekinumab 6 mg/kg (IP)|
62107025|NCT00771667|PLACEBO_COMPARATOR|Placebo IV - Responder - Placebo SC (MP)|
62107026|NCT00771667|PLACEBO_COMPARATOR|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC|
62298766|NCT03469011|EXPERIMENTAL|Imatinib oral100mg tablets|"A standard 3+3 trial design will be utilized for the imatinib dosing. In general, patients will be treated in cohorts of 3-6 with escalating doses of imatinib using oral 100mg tablets.~Dose Level -1=100mg, +1=200mg (starting dose for cohort 1), +2=300mg, +3=400mg, +4=600mg (if needed)."
62469572|NCT04609722|NO_INTERVENTION|control group|No intervention will be applied to the parents in the control group.
62469573|NCT02561585|EXPERIMENTAL|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
62107027|NCT00771667|PLACEBO_COMPARATOR|Ustekinumab IV - Responder - Placebo SC (MP)|
62107028|NCT00771667|EXPERIMENTAL|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|
62107029|NCT00771667|PLACEBO_COMPARATOR|Ustekinumab IV - Nonresponder - Placebo SC (MP)|
62107030|NCT00771667|EXPERIMENTAL|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|
62107031|NCT01130064|EXPERIMENTAL|QAX576|QAX576
62107032|NCT01130064|PLACEBO_COMPARATOR|Placebo|Placebo
62107033|NCT05015868|EXPERIMENTAL|IDENTIFICATION OF THE CAUSE OF THE EPILEPSY AND OF THE EPILEPTOGENIC ZONE (sequential approach)|"Step1: standard of care.~* acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data~* complete neuropsychological assessment~* genetic tests through Next generation sequencing epilepsies panel, or exome~Step 2: experimental~- combined Electroencephalogram-Functional brain magnetic resonance imaging registration.~Step 3: experimental~In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~* execution of High Density-Electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~* 7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone(PI, Italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
62298767|NCT06656039||Training cohort|
62668867|NCT02930447|EXPERIMENTAL|Treatment group|Autologous glue will be prepared from the patient's own blood with RegenKit®-Surgery device and applied per-operatively by spraying in the undermining region space between fascia and skin.
62107034|NCT00608907|EXPERIMENTAL|VELCADE|Control arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
62107035|NCT00608907|EXPERIMENTAL|VELCADE + rifampicin|Treatment Arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
62107036|NCT00608907|EXPERIMENTAL|VELCADE + dexamethasone|Treatment arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
62107037|NCT06631313|EXPERIMENTAL|PureWick System|
62107038|NCT01942967||Preterm ≤ 32 weeks GA, on CPAP|Preterm infants less than 32 weeks gestational age requiring CPAP as a mode of respiratory support and admitted in the NICU.While the baby is on CPAP,tissue oxygen saturation monitoring will be started by applying NIRS(Near Infrared Spectroscopy Monitoring) sensors to the forehead and the abdomen. After 3 hours,echocardiography(including Superior Mesenteric Artery Doppler) will be done while the baby is on CPAP. Then, using the same machine, the mode of respiratory support will be changed to TrPA. After another three hours,another echocardiography will be done,then NIRS monitoring will be stopped and the mode of respiratory support will be changed back to CPAP.
62107039|NCT01188629|PLACEBO_COMPARATOR|Safety Training|
62107040|NCT01188629|EXPERIMENTAL|Personal Health Partner and Counseling (PHP+C)|
62107041|NCT05939648|EXPERIMENTAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, One booster dose 1.0mL IM injection of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021).
62107042|NCT05939648|PLACEBO_COMPARATOR|Saline|One booster dose 1.0mL IM injection of saline.
62107043|NCT04245319|OTHER|NbUVB|Group A: patients will receive three NB-UVB sessions per week for 48 sessions.
62298768|NCT06656039||Validation cohort|
62298769|NCT06656039||Test cohort|
62298770|NCT02499952|EXPERIMENTAL|Experimental Arm|Pembrolizumab
62298771|NCT01563601|EXPERIMENTAL|Obatoclax mesylate, Carboplatin and Etoposide (CEO)|
62298772|NCT01563601|ACTIVE_COMPARATOR|Carboplatin and Etoposide (CE)|
62298773|NCT02730559|EXPERIMENTAL|Intervention Group|Group A (Parent-adolescent dyads)
62298774|NCT02730559|ACTIVE_COMPARATOR|Control Group - Active Comparator|Group B (Adolescents only)
62298775|NCT00812669|EXPERIMENTAL|Fludarabine, Cylophosphamide and Rituximab|
62469574|NCT02561585|PLACEBO_COMPARATOR|Vehicle|LEO 124249 ointment vehicle twice daily
62469575|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
62469576|NCT00773253|ACTIVE_COMPARATOR|standard EMG-guided Botox injection|All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.
62469577|NCT00773253|EXPERIMENTAL|Multi-channel EMG-guided Botox injection|Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.
61913771|NCT04340219||Cancer patients|Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (CPDI, DASS-21, and WHOQOL-BREF).
61913772|NCT03725423|EXPERIMENTAL|experimental group|Oral administration of 250mg of apatinib daily, with or without chemotherapy
61913773|NCT03014882|OTHER|Antioxidant treatment|
62668868|NCT02930447|NO_INTERVENTION|Control group|Patient from the control group will undergo abdominoplasty according to an identical procedure, but without application of autologous glue or any other treatment product before wound closure.
62668869|NCT04889651|EXPERIMENTAL|A(TRTR)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) \& Sequence B (RTRT)).~\* Sequence A: T-R-T-R~* T: BR9004, oral single-dose administration, 1 tablet per day~* R: BR9004-1, oral single-dose administration, 1 tablet per day~* Washout interval between periods: 7 days"
61913774|NCT00734955|EXPERIMENTAL|Reduction Mammoplasty|Patients undergoing reduction mammoplasty
61913775|NCT00734955|EXPERIMENTAL|Mastectomy|Patients undergoing mastectomy
61913776|NCT00734955|EXPERIMENTAL|Lumpectomy|Patients undergoing a lumpectomy
61913777|NCT03889301|EXPERIMENTAL|E-E Video|Watch E-E video that incorporates health and educational messages
61913778|NCT03889301|ACTIVE_COMPARATOR|Discussion|Structured discussion about depression and anxiety
61913779|NCT01534182|EXPERIMENTAL|Fingolimod|Participants received 0.5 mg orally once a day.
61913780|NCT01534182|ACTIVE_COMPARATOR|Standard Disease Modifying Therapy (DMT)|Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
61913781|NCT00708253|ACTIVE_COMPARATOR|SBE|
61913782|NCT00708253|ACTIVE_COMPARATOR|DBE|
61913783|NCT02325973|OTHER|IMR evaluation|Assessment of IMR index in coronaries through PressureWire Certus guidewire
61913784|NCT06236191|EXPERIMENTAL|Intervention|Intervention group is transcranial pulse electrical stimulation
62107044|NCT04245319|EXPERIMENTAL|Combined nbUVB and Acitretin|Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3mg/kg/day daily.
62107045|NCT03465254||Cohort|Recruited members of the cohort are children aged 9-14 years old and eligible to receive the dengue vaccine at the time of the initiation of community-based dengue immunization program of the Department of Health.
62107046|NCT00083499||Group 1|Index cases
62107047|NCT00083499||Group 2|Relatives of Index Cases
62298776|NCT02204865||Pacemaker/ICD with ApneaScan|Patients with HFREF due to receive a pacemaker or ICD with ApneaScan function
62298777|NCT06657573|EXPERIMENTAL|Influenza Vaccine Chatbot Intervention group|In this arm, participants will receive a vaccine chatbot intervention for one and a half months. The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers, where people can ask any questions related to the influenza vaccine and get previously validated answers from the chatbot immediately. The chatbot is available for use at their convenience during the 1.5-month intervention, with invitations sent every ten days to reinforce the engagement.
62298778|NCT06657573|NO_INTERVENTION|Control group|The control group will not use the chatbot during the intervention duration.
62107048|NCT00083499||Group 3|Fetal tissue
62107049|NCT00816829|PLACEBO_COMPARATOR|1|Fenofibrate-matching placebo tablet
62298779|NCT03198221|ACTIVE_COMPARATOR|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
61913785|NCT06236191|ACTIVE_COMPARATOR|Comparator|comparator is Melatonin
61913786|NCT02758379|EXPERIMENTAL|Shockwave Coronary Lithoplasty System|Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
61913787|NCT00821509|ACTIVE_COMPARATOR|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent hand washing in office and at home
61913788|NCT00821509|ACTIVE_COMPARATOR|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
61913789|NCT00821509|NO_INTERVENTION|Control|No change in hygiene behaviour
61913790|NCT00693862|EXPERIMENTAL|Stalevo|
61913791|NCT00693862|ACTIVE_COMPARATOR|levodopa/carbidopa|
61913792|NCT05843227||paediatric orthopaedic surgeons|"paediatric orthopaedic surgeons in the national territory who routinely treat idiopathic scoliosis in children and adolescents and who are members of the Société Française d'Orthopédie Pédiatrique (SoFOP) will be included.~questionnaire will be completed. ."
61913793|NCT04093063|EXPERIMENTAL|Intervention Group|Subjects in the intervention group were tasked with building a micro-stellated icosahedron using a detailed instruction manual. They were each provided with a dissecting microscope and necessary materials to complete the task at home at their leisure. They were given two weeks to complete the task. They were asked to return for a second in-person meeting two weeks.
61913794|NCT04093063|NO_INTERVENTION|Control Group|Subjects in the non-intervention control group were not given any task or any materials. They were asked to return for a second in-person meeting in two weeks.
61913795|NCT05675683||Asymptomatic Brain Metastases|Patients with Asymptomatic Brain Metastases
61913796|NCT05675683||Symptomatic Brain Metastases|Patient with Symptomatic Brain Metastases
61913797|NCT02844686|EXPERIMENTAL|Cardiac Dynamic SPECT|
61913798|NCT03460743|EXPERIMENTAL|Study group|single or two doses of quadrivalent recombinant 180 ugm hemagglutinin influenza vaccine
61913799|NCT03460743|ACTIVE_COMPARATOR|Control group|single or two doses of quadrivalent inactivated influenza vaccine.
61913800|NCT02540889|EXPERIMENTAL|trial arm|100 hours of therapy.
61913801|NCT02540889|NO_INTERVENTION|Normal therapy arm|12 weeks of normal therapy.
61913802|NCT05112276|ACTIVE_COMPARATOR|Control Diet|Average Swedish diet
62107050|NCT00816829|EXPERIMENTAL|2|145 mg NanoCrystal fenofibrate tablet
62469578|NCT04694586|EXPERIMENTAL|High-dose rifampicin and pyrazinamide|"rifampicin 35 mg/kg for 4 months provided as a combination of fixed drug combination tablets (HRZE for 8 weeks and HR Week 9-16) and single drug tablets of rifampicin (R)~AND~pyrazinamide 40 mg/kg the first 2 months provided as a combination of fixed drug combination tablets (HRZE) and single drug tablets of pyrazinamide (Z)~fixed drug combination tablets are: isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 16 (total treatment duration 4 months)"
62668870|NCT04889651|EXPERIMENTAL|B(RTRT)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) \& Sequence B (RTRT)).~\* Sequence B: R-T-R-T~* T: BR9004, oral single-dose administration, 1 tablet per day~* R: BR9004-1, oral single-dose administration, 1 tablet per day~* Washout interval between periods: 7 days"
61913803|NCT05112276|EXPERIMENTAL|Intervention Diet|The intervention diet will be based on food items that have shown a beneficial effect on gut microbiota associated with cardiometabolic risk factors.
62107051|NCT04622150|EXPERIMENTAL|Customized Adherence Enhancement (CAE)|This arm will receive the experimental intervention, Customized Adherence Enhancement (CAE).
62107052|NCT04622150|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (eTAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (eTAU).
62107053|NCT05818306|EXPERIMENTAL|Cohort A Dose 1|Oral, daily administration of BL-001 Dose 1 or Placebo randomized 3:1 (BL-001: Placebo)
62107054|NCT05818306|EXPERIMENTAL|Cohort B Dose 2|Oral, daily administration of BL-001 Dose 2 or Placebo randomized 3:1 (BL-001: Placebo)
62107055|NCT05818306|EXPERIMENTAL|Cohort C Dose 3|Oral, daily administration of BL-001 Dose 3 or Placebo randomized 3:1 (BL-001: Placebo)
62469579|NCT04694586|NO_INTERVENTION|Standardized TB treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9-26 (total treatment duration 6 months)
62469580|NCT02989233|ACTIVE_COMPARATOR|Brochure-Female-8/10|Female 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62668871|NCT01529216|EXPERIMENTAL|Electrical signal ON|Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
62668872|NCT01529216|SHAM_COMPARATOR|Sham|"Subjects randomized to this group (Group B) will have their device in turned off mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study."
62668873|NCT00837460|EXPERIMENTAL|rehabilitation|Bilateral and unilateral prehension oriented rehabilitation to enhance prehension.
62668874|NCT01271972|EXPERIMENTAL|Cohort 1|Dose 1
62668875|NCT01271972|EXPERIMENTAL|Cohort 2|Dose 2
62668876|NCT01271972|EXPERIMENTAL|Cohort 3|Dose 3
62668877|NCT01271972|EXPERIMENTAL|Cohort 4|Dose 4
62668878|NCT01271972|EXPERIMENTAL|Cohort 5|Dose 5
62668879|NCT01271972|EXPERIMENTAL|Expansion Cohort 1|Dose 4
62668880|NCT01271972|EXPERIMENTAL|Expansion Cohort 2|Dose 5
62668881|NCT04833608|ACTIVE_COMPARATOR|Vktory Carbon fiber insoles|VKTRY insoles were initially designed to increase ground force leading to a harder push off for faster running or higher jumping. To enable energy return the insole needed to be extremely rigid and therefore consists out of a full length Carbon-Fiber base. Unexpectedly the Carbon fiber base makes this a highly rigid construct which will likely benefit those patients with MTP arthritis as it will take away much movement of the MTP joint, without having an uncomfortable shape, i.e. patients can use this insole in their own shoes, possibly leading to a higher patient compliance and, simultaneously, to better outcome
62668882|NCT04833608|ACTIVE_COMPARATOR|Morton's extension insoles|Based on expert opinions, it seems the Morton extensions may alleviate pain but are also poorly tolerated by patients due to its uncomfortable shape, coincidently leading to a low patient compliance rate.
62107056|NCT05818306|EXPERIMENTAL|Cohort D Dose 4|Oral, daily administration of BL-001 Dose 4 or Placebo randomized 3:1 (BL-001: Placebo)
62107057|NCT02082366|ACTIVE_COMPARATOR|conventional irrigated ablation catheter|"TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
62107058|NCT02082366|ACTIVE_COMPARATOR|nMARQ circumferential irrigated catheter|"TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
62107059|NCT01649791|EXPERIMENTAL|Treatment (lenalidomide as chemoprevention)|Patients receive lenalidomide PO once daily for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62469581|NCT02989233|ACTIVE_COMPARATOR|Brochure-Male-8/10|Male 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62668883|NCT05192876||Data Base of Patient Records 2000-2025|Analysis of outcomes and adverse events
62668884|NCT01780194||Lumbar fusion group|
61913804|NCT04840836||Telehealth-supported LARC provision|"Patients who receive care at the SBHC provide informed consent for care, as well as record review for quality assurance purposes. Analyses will include female patients who have a reproductive health visit, which includes contraceptive counseling, contraceptive management, or contraceptive method initiation, during the study period. Patients who have a telehealth consultation with a SBHC medical provider for LARC services (conservatively estimated n=113) will be considered enrolled patients once the data are extracted from the EHR."
62107060|NCT06631742|EXPERIMENTAL|Exergaming|Individual active dance game training on Dividat Senso
62107061|NCT06631742|OTHER|Usual Care|Customised care and support as required
62107062|NCT00630513|EXPERIMENTAL|E|3 days regimen with Ertapenem
62668885|NCT01780194||Conservative treatment group|
62668886|NCT03400553|EXPERIMENTAL|non-traumatic thoracic pain|Patients with out-of-hospital non-traumatic thoracic pain admitted to the emergency unit via ambulance or MUG will be screened for enrolment. Blood analysis for troponin-T will be performed by 3 different devices as explained earlier.
62668887|NCT04243837|EXPERIMENTAL|LYT-100 in patients with BCRL|LYT-100 BID for 6 months
62668888|NCT04243837|PLACEBO_COMPARATOR|Placebo in patients with BCRL|Placebo BID for 6 months
62469582|NCT02989233|ACTIVE_COMPARATOR|Model-Female-8/10|Female 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62469583|NCT02989233|ACTIVE_COMPARATOR|Model-Male-8/10|Male 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62107063|NCT00630513|ACTIVE_COMPARATOR|AS|3 days treatment with Ampicillin-Sulbactam
62469584|NCT02989233|ACTIVE_COMPARATOR|Video-Female-8/10|Female 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62668889|NCT05037383|OTHER|Study group|Each participant will be part of the same group, since the study is focusing on the motion and viewing of the operating staff. There are no patient records collected.
62668890|NCT02547987|EXPERIMENTAL|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
62107064|NCT05381662|EXPERIMENTAL|Cohort 1|This cohort will determine the safety and efficacy of CD19 CAR-T cells and CD19 positive feeder T cells for CD19+ acute lymphoblastic leukemia without Chemotherapy pretreatment
62107065|NCT05381662|EXPERIMENTAL|Cohort 2|This cohort will determine the safety and efficacy of CD19 CAR-T cells and CD19 positive feeder T cells for CD19+ acute lymphoblastic leukemia with Chemotherapy pretreatment
62107066|NCT05937906|EXPERIMENTAL|Phase I - Level 1|"Mirdametinib 4 mg twice/day for 7 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
62107067|NCT05937906|EXPERIMENTAL|Phase I - Level 2|"Mirdametinib 4 mg twice/day for 14 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
62107068|NCT05937906|EXPERIMENTAL|Phase I - Level 3|"Mirdametinib 6 mg twice/day for 7 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
62107069|NCT05937906|EXPERIMENTAL|Phase I - Level 4|"Mirdametinib 6 mg twice/day for 14 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
62668891|NCT05186298|EXPERIMENTAL|AcrySof® IQ PanOptix® (Alcon Laboratories, Inc., Fort Worth, TX)|The subject will be implanted bilaterally during cataract surgery
62107070|NCT05937906|NO_INTERVENTION|Phase II - Standard arm|Carboplatin / Pemetrexed / Pembrolizumab for the first 4 cycles
62107071|NCT05937906|EXPERIMENTAL|Phase II - Experimental arm|Carboplatin / Pemetrexed / Pembrolizumab + mirdametinib for the first 4 cycles
62107072|NCT02689349|EXPERIMENTAL|Esteem Implant Prospective Subjects|Subjects followed through 1 year for both Safety and Efficacy endpoints
62107073|NCT02689349|OTHER|Esteem Implant Retrospective Chart Review Subjects|Subjects providing Safety-only endpoint data through retrospective chart review, to be added to Prospective Subjects' Safety data
62107074|NCT03762330|ACTIVE_COMPARATOR|COPD structured self-management plan|Participants will receive usual care for COPD and in addition, a structured self-management education plan.
62469585|NCT02989233|ACTIVE_COMPARATOR|Video-Male-8/10|Male 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62668892|NCT05186298|EXPERIMENTAL|Synergy® (Johnson & Johnson Surgical Vision, Santa Ana, CA)|The subject will be implanted bilaterally during cataract surgery
62668893|NCT06122493|OTHER|chemotherapy-immunotherapy-radiotherapy|Carboplatin (AUC = 5, d1) and nab-paclitaxel (175 mg/m², day1) will be administered every 3 weeks for four cycles.Tislelizumab (200 mg) will be administered every 3 weeks for up to 12 months. Radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy over 28 fractions will be delivered.
62469586|NCT02989233|ACTIVE_COMPARATOR|Brochure-Female-11/13|Female 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62469587|NCT02989233|ACTIVE_COMPARATOR|Brochure-Male-11/13|Male 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62668894|NCT01090206|OTHER|Hemophilia, Vitamin D deficiency|"1. Hemophilia, Rickets - Vitamin D per endocrine consult~2. Hemophilia, Vitamin D deficient - Vitamin D 2000 units daily plus calcium~3. Hemophilia, Normal Vitamin D - no intervention - observation only"
62668895|NCT03472677|EXPERIMENTAL|Cohort 1|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
62668896|NCT03472677|EXPERIMENTAL|Cohort 2|Controlled cooling wrap versus ice pack cooling.
62668897|NCT03472677|EXPERIMENTAL|Cohort 3|Controlled cooling parameters will be determined after evaluation of data from prior cohorts.
62668898|NCT03472677|EXPERIMENTAL|Cohort 4|Controlled cooling with knee device versus no cooling (determined after evaluation of data from previous cohorts).
61913805|NCT00830076|EXPERIMENTAL|Sitagliptin + placebo metformin|
62469588|NCT02989233|ACTIVE_COMPARATOR|Model-Female-11/13|Female 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62469589|NCT02989233|ACTIVE_COMPARATOR|Model-Male-11/13|Male 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
61913806|NCT00830076|EXPERIMENTAL|Metformin + placebo sitagliptin|
62107075|NCT03762330|NO_INTERVENTION|Usual care|COPD participants receiving only usual care
62107076|NCT01664104||RA Participants|Participants with moderate or severe RA who are under tocilizumab treatment in routine clinical practice (in accordance with the local label) will be observed for 6 months from the start of treatment.
62107077|NCT01173614||Normal subjects|Subjects with two normal eyes.
62107078|NCT06157879|EXPERIMENTAL|WVI-MIS-01-2022|Healthy volunteers
62107079|NCT02267980|ACTIVE_COMPARATOR|Group SK|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.
62668899|NCT03786575|EXPERIMENTAL|NGS detection group|Before treatment, the patients in the study group underwent NGS detection of ctDNA and formulated endocrine treatment plan according to the test results. After 2 months of endocrine therapy, all patients underwent NGS detection of ctDNA, and the efficacy was evaluated according to RECIST v1.1 standard.
62668900|NCT03380741||Group1|Tumour present on histology and MRI following biopsy/LLETZ
61913807|NCT00830076|EXPERIMENTAL|Sitagliptin + metformin|Co-administration of sitagliptin and metformin
61913808|NCT00830076|PLACEBO_COMPARATOR|Placebo sitagliptin + placebo metformin|Co-administration of placebo to sitagliptin and placebo to metformin
62668901|NCT03380741||Group 2|Tumour absent on MRI following biopsy/LLETZ
61913809|NCT03920540|EXPERIMENTAL|GC1111|"In part 1, all participants who randomized into GC1111 arm should receive the GC1111 for 52 weeks.~In part 2, all enrolled participants should receive the GC1111 for 52 weeks."
61913810|NCT03920540|ACTIVE_COMPARATOR|Comparator (Part 1)|In Part 1, all participants who randomized into comparator arm should receive the GC1111 for 52 weeks.
61913811|NCT04382664|EXPERIMENTAL|UV1 vaccination + nivolumab and ipilimumab|UV1 vaccination + nivolumab and ipilimumab
62107080|NCT02267980|PLACEBO_COMPARATOR|Group SS|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.
62107081|NCT04637750|EXPERIMENTAL|Educational intervention|Randomised GPs will receive the low cost informative intervention composed by a practitioner-focused letter plus leaflet for patients
62107082|NCT04637750|NO_INTERVENTION|Control group|GPs not receiving any informative intervention
62107083|NCT03054220|EXPERIMENTAL|CYP2D6 gene score 1|carriers of 1 fully functional and 1non functional CYP2D6 alleles
62469590|NCT02989233|ACTIVE_COMPARATOR|Video-Female-11/13|Female 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62469591|NCT02989233|ACTIVE_COMPARATOR|Video-Male-11/13|Male 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
62668902|NCT03380741||Group 3|Tumour recurrence present at the vaginal vault on MRI
62668903|NCT03380741||Group 4|Tumour recurrence absent at the vaginal vault on MRI
62668904|NCT03380741||Group 5|Normal cervix at colposcopy
62469592|NCT00448019|EXPERIMENTAL|FCR + Bevacizumab|FCR = Fludarabine 25 mg/m\^2 intravenous (IV) , Cyclophosphamide 250 mg/m\^2 IV daily for 3 days, Rituximab 375 mg/m\^2 IV Day 1, followed by 500 mg/m\^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.
62469593|NCT05371392||patient group|
62668905|NCT02715752||Herpes Simplex Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
61913812|NCT04382664|ACTIVE_COMPARATOR|Nivolumab and ipilimumab|nivolumab and ipilimumab
62469594|NCT05371392||control group|
62668906|NCT02715752||Human Papillomavirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
62668907|NCT02715752||Epstein-Barr Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
62668908|NCT02715752||Cytomegalovirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
62668909|NCT02715752||Varicella Zoster Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
62668910|NCT03461809||Ocular motor nerve palsy treated by ocular acupuncture|Ocular motor nerve palsy patients who received ocular acupuncture treatment
61913813|NCT05008978|EXPERIMENTAL|Test 1|
61913814|NCT05008978|EXPERIMENTAL|Test 2|
61913815|NCT05008978|EXPERIMENTAL|Test 3|
61913816|NCT05008978|EXPERIMENTAL|Test 4|
61913817|NCT05008978|EXPERIMENTAL|Test 5|
61913818|NCT05700643|EXPERIMENTAL|Intervention|500 mg cherry supplement
61913819|NCT05700643|PLACEBO_COMPARATOR|Control|Placebo
61913820|NCT02417493|EXPERIMENTAL|Simulation of Epinephrine Self-Injection|The patient will self-inject an empty syringe into his/her thigh simulating a self-injection of epinephrine during a routine outpatient visit to the allergist.
61913821|NCT02417493|NO_INTERVENTION|Control Group|The patient will be encouraged to speak to their physician about self-injection, but will not undergo the self-injection protocol during a routine outpatient visit to the allergist.
62107084|NCT03054220|EXPERIMENTAL|CYP2D6 gene score 2|carriers of 2 fully functional CYP2D6 alleles
62668911|NCT04453254|ACTIVE_COMPARATOR|Whole Food Meal|A whole meal consisting of 1 cup 2% milk, 1 cup Kashi Go Lean Original cereal, ¼ cup of almonds, ¼ cup of strawberries, and ¼ cup of raspberries.
61913822|NCT01456975|EXPERIMENTAL|Valsalva|Reimplantation procedure using Valsalva prosthesis
61913823|NCT04061993|EXPERIMENTAL|Intervention Group OBV|Intervention Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
61913824|NCT04061993|ACTIVE_COMPARATOR|Control Group OBV|Control Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
61913825|NCT04061993|EXPERIMENTAL|Intervention Group SBNM|Intervention Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
61913826|NCT04061993|ACTIVE_COMPARATOR|Control Group SBNM|Control Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
62107085|NCT00465751|ACTIVE_COMPARATOR|A|chenodeoxycholic acid treatment
62107086|NCT00465751|PLACEBO_COMPARATOR|B|placebo treatment
62107087|NCT06165926|EXPERIMENTAL|15% hypertonic dextrose and physical therapy|The patient receives a single ultrasound-guided injection of 15% hypertonic dextrose into the shoulder joint (3 ml of 50% Dextrose + 1 ml of 2% xylocaine + 6 ml of normal saline). Subsequent evaluations occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection treatment, totally two sessions. Simultaneously, the patient undergoes an 8-week physical therapy program, attending sessions twice a week. Each session, lasting approximately 30 minutes, includes joint activities, stretching, and muscle-strengthening exercises under the guidance and supervision of a physical therapist.
62107088|NCT06165926|PLACEBO_COMPARATOR|normal saline and physical therapy|The patient undergoes a single ultrasound-guided normal saline injection for shoulder joint distension (1 ml of 2% xylocaine + 9 ml of normal saline). Subsequent assessments occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection treatment, totally two sessions. Simultaneously, the patient is undergoing an 8-week physical therapy program, with sessions held twice a week. Each session, lasting approximately 30 minutes, includes joint activities, stretching, and muscle-strengthening exercises under the guidance and supervision of a physical therapist.
62107089|NCT05139095|EXPERIMENTAL|Cohort A|Population: ultra high-risk gestational trophoblastic neoplasia
62107090|NCT05139095|EXPERIMENTAL|Cohort B|Population: high-risk chemo-refractory or relapsed gestational trophoblastic neoplasia
62107091|NCT05644652|EXPERIMENTAL|control group|15 Children in this group will receive a designed physical therapy program for 60 minutes per session, three times a week, for three consecutive months.
62107092|NCT05644652|EXPERIMENTAL|Nordic walking group|Children in this group will receive the same designed physical therapy program for 60 minutes per session, three times a week, for three consecutive months. while the Nordic walking training for 20 minutes will replace the functional gait training.
62107093|NCT05778071|EXPERIMENTAL|eneboparatide|Starting dose of 20 mcg; Administered once daily by subcutaneous injection
62107094|NCT05778071|PLACEBO_COMPARATOR|Placebo|Administered once daily by subcutaneous injection
62107095|NCT04551417|ACTIVE_COMPARATOR|Dorsal onlay graft urethroplasty|
62107096|NCT04551417|EXPERIMENTAL|Ventral onlay graft urethroplasty|
62107097|NCT06460363|EXPERIMENTAL|Transcranial alternating current stimulation (TACS)|Experimental intervention is alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes. One electrode is placed with the center over Pz position according to the 10-20 international EEG coordinates (an area overlying the medial parietal cortex and the precuneus) and the other over the right deltoid muscle.
62107098|NCT06460363|SHAM_COMPARATOR|Sham TACS|The same electrodes are connected to the patient as in trial intervention. In sham treatment, a few seconds of actual current is provided and then the device automatically turns off. This is to ensure that patients cannot distinguish between real and sham treatments based on possible tingling of skin when starting the electrical current.
62107099|NCT05268198|EXPERIMENTAL|Intervention/Treatment|Single dose, oral inhalation (nebuliser solution)
62107100|NCT05268198|PLACEBO_COMPARATOR|Placebo|Placebo
62107101|NCT04702503|EXPERIMENTAL|10% WP1220 ointment|10% WP1220 ointment topically applied 2x day for 84 days
62107102|NCT01396109|ACTIVE_COMPARATOR|Group I|Intervention: Procedure: TVH and GYNECARE PROSIMA\* Pelvic Floor Repair System
62107103|NCT01396109|ACTIVE_COMPARATOR|Group II|Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with Mesh
62107104|NCT04124068|EXPERIMENTAL|GLO Science Professional Chairside Teeth Whitening|
62107105|NCT04124068|EXPERIMENTAL|GLO Science Professional At-Home Teeth Whitening Device|
62107106|NCT04124068|EXPERIMENTAL|GLO Brilliant At-Home Teeth Whitening Device|
62107107|NCT04124068|EXPERIMENTAL|GLO Lit At-Home Teeth Whitening Device|
62308355|NCT02558023|EXPERIMENTAL|Urapidil|"Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
62668912|NCT04453254|ACTIVE_COMPARATOR|Supplement Food Meal|A supplemental meal equivalent consisting of 1 cup 2% milk, 20 g whey protein, ½ EAS Myoplex bar, and ½ Balance bar.
62107108|NCT04124068|EXPERIMENTAL|GLO Lit Whitening GLO Vials|
62107109|NCT04598529|ACTIVE_COMPARATOR|A2 milk|A2 milk, organic, 200ml, twice daily
62107110|NCT04598529|PLACEBO_COMPARATOR|Conventional milk|Pasteurized semi-skimmed milk, organic, 200ml, twice daily
62668913|NCT06094829||Smokers|Healthy subjects having smoked 100 cigarettes or more during their life.
62107111|NCT01632930|EXPERIMENTAL|Results of urinary PCA3 test will be available|In this arm, physicians will have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion is likely to be influenced by urinary PCA3 test results
62107112|NCT01632930|ACTIVE_COMPARATOR|Results of urinary PCA3 test will not be available|In this arm, physicians will not have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion will therefore not be influenced by urinary PCA3 test results
62107113|NCT03921489||Subchondroplasty in treating bone marrow edema|These patients will have calcium phosphate mineral compound injected into the bone marrow lesions.
62668914|NCT06094829||Non-smokers|Healthy subjects having smoked less than 100 cigarettes during their life.
62668915|NCT03159949|EXPERIMENTAL|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
62668916|NCT03159949|EXPERIMENTAL|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
62668917|NCT00800384|EXPERIMENTAL|1|ICD implant without defibrillation testing
62668918|NCT00800384|ACTIVE_COMPARATOR|2|ICD implant with defibrillation testing
62668919|NCT04760457|ACTIVE_COMPARATOR|IL-FLS|Immediate loading (IL) and Flapless surgery (FLS)
62668920|NCT04760457|ACTIVE_COMPARATOR|IL-FPS|Immediate loading (IL) and Flapped surgery (FPS)
62668921|NCT04760457|ACTIVE_COMPARATOR|DL-FLS|Delayed loading (DL) and Flapless surgery (FLS)
62668922|NCT04760457|ACTIVE_COMPARATOR|DL-FPS|Delayed loading (DL) and Flapped surgery (FPS)
62668923|NCT05257044|EXPERIMENTAL|CBG|Participants will ingest 20 mg of CBG tincture in this arm
62668924|NCT05257044|PLACEBO_COMPARATOR|Placebo|Participants will ingest 20 mg of placebo tincture in this arm
62668925|NCT05787223|ACTIVE_COMPARATOR|Control Group|
62308356|NCT02558023|ACTIVE_COMPARATOR|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
62668926|NCT05787223|EXPERIMENTAL|Experimental Group|
62668927|NCT04630262|ACTIVE_COMPARATOR|ATTUNE Cementless CR Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Cruciate Retaining Configuration.
62668928|NCT04630262|ACTIVE_COMPARATOR|ATTUNE Cementless PS Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Posterior Stabilizing Configuration.
62668929|NCT01898130|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62668930|NCT06403501|EXPERIMENTAL|Clascoterone Cream 1%|Clascoterone Cream 1% (Winlevi)
62668931|NCT06403501|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
62668932|NCT05957341|EXPERIMENTAL|active rTMS: 20min inter-session interval|Three sessions of active rTMS would be delivered, with 1800 pulse/session and 20 min inter-session intervals.
62668933|NCT05957341|ACTIVE_COMPARATOR|active rTMS: 50min inter-session interval|Three sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
62668934|NCT05957341|SHAM_COMPARATOR|sham rTMS: 20min inter-session interval|Three sessions of sham rTMS would be delivered, with 1800 pulse/session and 20 min inter-session intervals.
62668935|NCT05957341|SHAM_COMPARATOR|sham rTMS: 50min inter-session interval|Three sessions of sham rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
62668936|NCT05119465||Group|Hospitalized Patients with Corona virus disease
62668937|NCT00200083|ACTIVE_COMPARATOR|A|"All subjects enrolled will be implanted with an IGS system. The active group are those randomized to on and will receive active stimulation for 12 months."
62668938|NCT00200083|PLACEBO_COMPARATOR|B|"All subjects enrolled will be implanted with an IGS system. The placebo group are those randomized to off and will receive no stimulation for 12 months."
61913827|NCT02846220|EXPERIMENTAL|Health coaching|"Two-hour in-person group counseling session led by health coach, involving development of personalized immunity maps that lay out adherence goal, behaviors that distract from goal, hidden motives that compete with achieving goal, and underlying assumptions~Eight 50-minute individual telephone counseling sessions every three weeks with a health coach, focusing on uncovering hidden motives and challenging assumptions with the goal of overturning nonadherence mindsets"
61913828|NCT02846220|NO_INTERVENTION|Usual care|
61913829|NCT03989869|EXPERIMENTAL|VEMA|Immediate medical abortion treatment
61913830|NCT03989869|NO_INTERVENTION|Standard of Care|Delayed care until an intrauterine pregnancy has been confirmed with ultrasound.
61913831|NCT04964193|EXPERIMENTAL|Elzsa film-coated tablet|Participants received Elzsa film-coated tablet (2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
61913832|NCT04964193|ACTIVE_COMPARATOR|Diane-35 Sugar-coated tablet|Participants received Diane-35 Sugar-coated tablet ( 2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
61913833|NCT04598399|EXPERIMENTAL|MBRP program:|
61913834|NCT04598399|ACTIVE_COMPARATOR|Standard care|
61913835|NCT04764266|EXPERIMENTAL|Normothermic Machine Perfusion|Blood sampling at 5 time points after transplantation Perfusate collection at 3 time points during normothermic machine perfusion prior to transplantation
61913836|NCT03109912|NO_INTERVENTION|Control|At the baseline fitness assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. Throughout the study, these 30 participants will receive generic, non-personalized encouragement and recommendations (if requested by the participant) for PA at routine clinic visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.
61913837|NCT03109912|EXPERIMENTAL|Exercise Intervention|The baseline fitness assessment includes an additional 30-minutes for exercise prescriptions; participant FitBit daily step goal is set based on a collaborative review between the participant and PT and participants receive individualized exercise prescriptions based on their assessment. Throughout the study, these 30 participants will receive customized encouragement and personalized fitness recommendations for PA at routine visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, study team members meet again with the participant for an additional 30-45 minutes to reinforce exercise through exercise prescriptions and individualized encouragement, export FitBit data and review any missing data concerning for equipment failure or user error and address any specific exercise concerns. FitBit daily step goals may be adjusted based on collaborative review between the participant and PT.
62308357|NCT02409498|ACTIVE_COMPARATOR|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.
62668939|NCT01140139|EXPERIMENTAL|HIV DNA + Hydroxyurea|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption. The patients also received 500 mg of hydroxyurea daily.
62668940|NCT01140139|EXPERIMENTAL|HIV DNA|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
62668941|NCT01140139|PLACEBO_COMPARATOR|Placebo|PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
62668942|NCT02487706|EXPERIMENTAL|Dolutegravir 50mg/day per 5 days|Dolutegravir 50mg/day per 5 days
62668943|NCT02096536|OTHER|Vancomycin|All included patients receive vancomycin for medical reasons. Decision for start of therapy is made by the treating physician.
62668944|NCT05756907|EXPERIMENTAL|Dose Level 1|SON-1010 Dose Level 1 + Atezolizumab
62668945|NCT05756907|EXPERIMENTAL|Dose Level 2|SON-1010 Dose Level 2 + Atezolizumab
62668946|NCT05756907|EXPERIMENTAL|Dose Level 3|SON-1010 Dose Level 3 + Atezolizumab
62668947|NCT05756907|EXPERIMENTAL|Dose Level 4|SON-1010 Dose Level 4 + Atezolizumab
62668948|NCT05756907|EXPERIMENTAL|Dose Level 5|SON-1010 Dose Level 5 + Atezolizumab
61913838|NCT04599179||Group 1|Patients underwent placement of a self-expandable metal stent (SEMS)
61913839|NCT04599179||Group 2|Patients underwent to stomach-partitioning gastrojejunostomy
61913840|NCT05421884|EXPERIMENTAL|Cancer Patient and their significant other|The intervention will implemented in all cancer patients and their significant others
61913841|NCT01722695|OTHER|Revaclear followed by FX|
62308358|NCT02409498|PLACEBO_COMPARATOR|no pudendal block|Saline
62668949|NCT05756907|EXPERIMENTAL|RP2D Expansion in Patients with Platinum-resistant Ovarian Cancer|RP2D Dose of SON-1010 + Atezolizumab
62668950|NCT05756907|EXPERIMENTAL|Randomized Arm #1 in Patients with Platinum-resistant Ovarian Cancer|SON-1010 @ RP2D Alone
61913842|NCT01722695|OTHER|FX followed by Revaclear|
62107114|NCT04656002|EXPERIMENTAL|Paclitaxel, Ramucirumab + TEW-7197|"Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours~-Paclitaxel, Ramucirumab Intravenous (IV) Ramucirumab injection, provided as a single-use 500-mg/50-mL vial containing 10 mg/mL of product in histidine buffer, with disease progression, toxicity requiring discontinuation, or without interruption for any reason. After diluting to 8 mg/kg every 2 weeks, IV It is administered by infusion.~Paclitaxel is administered at a dose of 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle, with disease progression, toxicity requiring discontinuation, or without interruption for any reason."
62107115|NCT04618913||VTE and history of cancer|VTE and history of cancer
62107116|NCT04618913||VTE and active cancer|VTE and active cancer
62107117|NCT00454662|ACTIVE_COMPARATOR|1|olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
62107118|NCT00454662|ACTIVE_COMPARATOR|2|AT1 subtype angiotensin II receptor antagonist/low dose diuretic
62107119|NCT02013037|EXPERIMENTAL|Eculizumab|Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.
62107120|NCT02793297|EXPERIMENTAL|refined wheat crisp bread|refined wheat crisp bread was served as part of a complete standardized breakfast
62107121|NCT02793297|EXPERIMENTAL|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread was served as part of a complete standardized breakfast
62107122|NCT02793297|EXPERIMENTAL|unfermented rye crisp bread|Unfermented rye crisp bread was served as part of a complete standardized breakfast
62107123|NCT01735240|EXPERIMENTAL|First AZD5069, then Ketoconazole + AZD5069|AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone (on 2 days)
62107124|NCT02909699||Dose 1|1,000mg of resveratrol per day (1 pill 3 times per day). This ancillary study will be observational without drug administration.
62107125|NCT02909699||Dose 2|1,500mg of resveratrol per day (1 pill 3 times per day)
62107126|NCT02909699||Placebo|Alike looking 1 pill 3 times per day
62107127|NCT02050958|EXPERIMENTAL|OXP001|OXP001
62107128|NCT02050958|ACTIVE_COMPARATOR|Ibuprofen|Brufen
62107129|NCT03114722|ACTIVE_COMPARATOR|heparin 10U/ml|Heparinised saline (10U/ml) lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
62107130|NCT03114722|EXPERIMENTAL|citrate 4%|4% citrate lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
62107131|NCT02584517||GCA|Patients referred with suspected GCA, whose final diagnosis is GCA
62107132|NCT02584517||Not GCA|Patients referred with suspected GCA, whose final diagnosis is another disorder
62107133|NCT02376036|EXPERIMENTAL|MGD010|Subjects will receive MGD010 through IV infusion.
62107134|NCT02376036|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo through IV infusion.
62668951|NCT05756907|EXPERIMENTAL|Randomized Arm #2 in Patients with Platinum-resistant Ovarian Cancer|SON-1010 @ RP2D + Atezolizumab
62298780|NCT03198221|ACTIVE_COMPARATOR|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
62668952|NCT05756907|NO_INTERVENTION|Randomized Arm #3 in Patients with Platinum-resistant Ovarian Cancer|Standard of Care
62298781|NCT03198221|ACTIVE_COMPARATOR|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
62668953|NCT00746161|ACTIVE_COMPARATOR|1|Roux-en-Y
62668954|NCT00746161|EXPERIMENTAL|2|double tract reconstruction
62668955|NCT02769052|ACTIVE_COMPARATOR|Follow-up/Treatment - Control Group|Composed of two phases of 8 weeks each (follow-up - treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
62298782|NCT03198221|ACTIVE_COMPARATOR|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
62668956|NCT02769052|ACTIVE_COMPARATOR|Treatment Group|Composed of one phase of 8 weeks (treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
62668957|NCT04094636|NO_INTERVENTION|No intervention: Control|Control group
62668958|NCT04094636|EXPERIMENTAL|In-bed cycling|Supervised in-bed cycling
62668959|NCT04094636|EXPERIMENTAL|Exercise booklet|Supervised physical training with exercises from exercise booklet
62107135|NCT02376036|EXPERIMENTAL|MGD010 and HepA vaccine|Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.
62107136|NCT02376036|PLACEBO_COMPARATOR|Placebo and HepA vaccine|Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.
62107137|NCT03092440||"Nursing students group"|nursing students
62298783|NCT05928806|EXPERIMENTAL|Arm A (botensilimab and balstilimab)|Arm A subjects will receive 2 cycles of induction treatment with each cycle lasting 6 weeks. Cycle 1 will consist of botensilimab 75mg IV in combination with balstilimab 450mg IV on Day 1 and Day 22. Cycle 2 will consist of balstilimab 450mg IV ONLY on Day 1 and Day 22. Botensilimab will NOT be given in Cycle 2. Subjects will receive 7 cycles of maintenance treatment with each cycle lasting 12 weeks. Cycles 3 and 4 will consist of botensilimab 75mg IV on Day 1 in combination with balstilimab 450mg IV on Day 1, 22, 43 and 64. Cycles 5-9 will consist of balstilimab alone 450 mg IV on Day 1, 22, 43 and 64.
62298784|NCT05928806|ACTIVE_COMPARATOR|Arm B (ipilimumab and nivolumab)|Arm B subjects will receive 2 cycles of induction treatment with each cycle lasting 6 weeks. Cycle 1 and 2 will consist of ipilimumab 1 mg/kg IV and nivolumab 3 mg/kg on Day 1 and 22. Subjects will receive 7 cycles of maintenance treatment with each cycle lasting 12 weeks. Nivolumab 480mg IV will be given on Day 1, 29 and 57 of each cycle (every 4 weeks).
62298785|NCT05222139||Solid organ transplant recipients|Solid organ transplant recipients
62298786|NCT05222139||People living with HIV|People living with HIV
62668960|NCT03432689|EXPERIMENTAL|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
62668961|NCT03432689|PLACEBO_COMPARATOR|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
62668962|NCT01507389|EXPERIMENTAL|Mild|
62668963|NCT01507389|EXPERIMENTAL|Moderate|
62668964|NCT01507389|EXPERIMENTAL|Severe|
62668965|NCT01507389|EXPERIMENTAL|Normal|
62668966|NCT02037113||Patient underwent PAD-Stent|Patient who underwent angioplasty and/or atherectomy with stent placement for Femoro-popliteal disease and Intravascular ultrasound was performed after stent deployment.
62668967|NCT04184908|EXPERIMENTAL|GROUP EXPERIMENTAL|Gel xerostomia Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
62107138|NCT03092440||"New nurses group"|Nurses with \< 2 years experience
62107139|NCT03092440||"Expert nurses group"|Intensive nurses (with ≥ 4 years experience post graduate)
62107140|NCT05407129|NO_INTERVENTION|Usual care|This arm is the usual care arm of parents and providers who are randomized to proceed with usual care and are not given the family safety reporting intervention.
62107141|NCT05407129|EXPERIMENTAL|Experimental: Intervention arm|This arm is the intervention arm of parents and providers who are randomized to the family safety reporting intervention on the study units.
62107142|NCT04584021||Stress study participants|Adults who reported stress problems derived from work
62107143|NCT04904757|OTHER|CESM Pre and Post Survey|"Subject will be asked to complete a questionnaire that will ask you about your general attitude toward Contrast-Enhanced Spectral Mammography (CESM). Questions will include:~* Thoughts regarding risk of breast cancer~* Concerns regarding contrast procedures such as the CESM~* Past mammogram/breast imaging experience"
62298787|NCT05222139||Patients with oncological diseases|Patients with oncological diseases
62469595|NCT04018365|EXPERIMENTAL|Treatment of empagliflozin|Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of \<7.0%, 10 mg will be continued: in case of \>=7.0%, it will be increased to 25 mg.
62469596|NCT06279910||Patients treated with calcifediol|Patients admitted to the GAI Hospital Complex of Albacete, due to COVID-19 (respiratory infection confirmed by radiographic pattern of viral pneumonia and positive PCR/antigen for SARS-CoV-2) treated with calcifediol
62469597|NCT06279910||Patients not treated with calcifediol|Patients admitted to the GAI Hospital Complex of Albacete, due to COVID-19 (respiratory infection confirmed by radiographic pattern of viral pneumonia and positive PCR/antigen for SARS-CoV-2) not treated with calcifediol
62469598|NCT04446559|EXPERIMENTAL|Sitting in a chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
62469599|NCT04446559|NO_INTERVENTION|Semi-recumbent in bed position|The patient will benefit from conventional positioning techniques in the ICU bed. With the help of the medical monitoring software present in the wards, we will note the different nursing care given to the patient during the 3 hours following the morning arterial gasometry.
62469600|NCT06151730||Observational|Patients attend hypertension clinic visits, undergo blood pressure monitoring, electrocardiograms, impedance cardiography testing and blood sample collection and have medical records reviewed throughout study.
62469601|NCT04564560||Patients treated with Zenith Alpha Spiral-Z®|Patients that from January 2017 until December 2019 received endovascular aortic repair with the Zenith Alpha Spiral-Z® at St. Olavs Hospital
62469602|NCT04526782|EXPERIMENTAL|Cohort 1 (1st line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
62107144|NCT02729272|EXPERIMENTAL|Ultrasonic ESD|Laparoscopic colpotomy by ultrasonic ESD (Harmonic Synergy Hook Blade; Ethicon Endo-Surgery) during total laparoscopic hysterectomy.
62469603|NCT04526782|EXPERIMENTAL|Cohort 2 (2nd line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
62469604|NCT01510262|EXPERIMENTAL|Tailored Socio-Contextual Intervention|"1. Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, \& piloting.~2. Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~3. After subjects receive STI diagnosis, treatment,\& partner notification services, randomly assign subjects to:~   A. The STI strengths-based prevention case management, or B. Standard care.~4. Assess participants' risk behavior, determinants of behavior \& quality of life. Investigators will assess the incidence of new STI \& test the efficacy of the intervention relative to control.~5. Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~6. Conduct cost effectiveness analyses of intervention compared to the standard."
62469605|NCT01510262|ACTIVE_COMPARATOR|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes \& 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners \& number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms \& testing/treatment resources. Referral information is provided when needed \& more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
62298788|NCT05222139||Patients with hematological diseases|Patients with hematological diseases
62298789|NCT05222139||Patients with cystic fibrosis|Patients with cystic fibrosis
62469606|NCT06517979||Patients with cancer undergoing LND|Patients undergo radical tumor resection and lymph node dissection (LND)
62469607|NCT04624620|EXPERIMENTAL|Pilot|Participants will participate in a 16 week, culinary intensive study that will consist of 2 hour virtual classes taught by a chef, a dietitian, and a health coach that focus on diet, culinary competency, daily physical activity, mindfulness and support for behavior change.
62469608|NCT03851939|EXPERIMENTAL|treatment group|Transarterial Chemoinfusion (TAI) Combine Toripalimab
62469609|NCT04914962|ACTIVE_COMPARATOR|monolithic glazedcrowns|glazed Celtra due crowns
62107145|NCT02729272|ACTIVE_COMPARATOR|Monopolar ESD|Laparoscopic colpotomy by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany) during total laparoscopic hysterectomy.
62107146|NCT01353092|EXPERIMENTAL|Active PEMF twice daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
62107147|NCT01353092|ACTIVE_COMPARATOR|Active PEMF once daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
62298790|NCT05222139||Patients with Parkinson Disease|Patients with Parkinson Disease
62298791|NCT05222139||Patients with rheumatological diseases|Patients with rheumatological diseases
62298792|NCT05222139||Pregnant women/ New-borns|Pregnant women/ New-borns
62298793|NCT05222139||Children|Children
62298794|NCT00373074|ACTIVE_COMPARATOR|15 cc|15 cc of blood used for Epidural Blood Patch
62298795|NCT00373074|ACTIVE_COMPARATOR|20 cc|20 cc of blood used for Epidural Blood Patch
62298796|NCT00373074|ACTIVE_COMPARATOR|30 cc|30cc of blood used for Epidural Blood Patch
62298797|NCT04604327|ACTIVE_COMPARATOR|Prophylactic bemiparin (3,500 IU/day)|Bemiparin 3,500 IU daily for 10 days
62298798|NCT04604327|EXPERIMENTAL|Full therapeutic bemiparin (weight adjusted)|Bemiparin at full therapeutic dose, adjusted to body weight, for 10 days
62298799|NCT06113081||Patients enrolled|Patients affected by relapsed/refractory Cutaneous T cell Lymphoma who have received Mogamulizumab in real life setting
62298800|NCT05805501|EXPERIMENTAL|Arm A (Tobemstomig + Axitinib)|Participants will receive intravenous (IV) tobemstomig every three weeks (Q3W) on Day 1 of each 21-day cycle. Participants will also receive oral (PO) axitinib twice daily (BID).
62469610|NCT04914962|EXPERIMENTAL|monolithic polished crowns|polished Celtra due crowns
61913843|NCT04048733|EXPERIMENTAL|Patchy type-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using patchy-type 12-lead ECG device as a doctor's order. This device will be automatically record 12-lead ECG 3 times in 1 minutes at a time by its algorithm."
61913844|NCT04048733|NO_INTERVENTION|Standard 12-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using standard 12-lead ECG device as a doctor's order. Interns and ECG technicians will perform 12-lead ECG as they perform as usual."
62107148|NCT04547348|EXPERIMENTAL|Denosumab treated group|Participants will receive a 60 mg subcutaneous injection of Prolia upon randomization and on week 28 after the first injection provided remission of the Charcot foot has not been achieved by then
62107149|NCT04547348|PLACEBO_COMPARATOR|Placebo treated group|Participants will receive an injection of placebo (saline) instead of Prolia
62298801|NCT05805501|EXPERIMENTAL|Arm B (Tobemstomig + Tiragolumab + Axitinib)|Participants will receive IV tobemstomig followed by IV tiragolumab Q3W on Day 1 of 21-day cycle. Participants will also receive axitinib PO BID.
62298802|NCT05805501|ACTIVE_COMPARATOR|Control Arm (Pembrolizumab + Axitinib)|Participants will receive IV pembrolizumab Q3W on Day 1 of each 21-day cycle. Participants will also receive axitinib PO BID.
62298803|NCT05144425|ACTIVE_COMPARATOR|group A|underwent TKA with using pneumatic tourniquet
62107150|NCT03014102|EXPERIMENTAL|TPOqd|Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization
62107151|NCT03014102|ACTIVE_COMPARATOR|TPOqod|Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization
62469611|NCT04100733|ACTIVE_COMPARATOR|Control|Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.
62107152|NCT02908464|EXPERIMENTAL|Lumosity (CT Group)|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
62469612|NCT04100733|EXPERIMENTAL|Intervention|Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.
62107153|NCT02908464|NO_INTERVENTION|Usual Care (Control Group)|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
62107154|NCT04958811|EXPERIMENTAL|Tiragolumab plus atezolizumab and bevacizumab|Tiragolumab 600mg IV will be administered together with atezolizumab 1200mg IV and bevacizumab 15mg/kg IV every 3 weeks (q3w) until progressive disease or unacceptable toxicity.
62107155|NCT03162887|EXPERIMENTAL|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
62298804|NCT05144425|PLACEBO_COMPARATOR|group B|underwent TKA without using pneumatic tourniquet
62469613|NCT01560767|ACTIVE_COMPARATOR|Femoral Nerve Block|levobupivacaine
62668968|NCT04184908|PLACEBO_COMPARATOR|CONTROL GROUP|Gel placebo Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
62668969|NCT04568772|ACTIVE_COMPARATOR|Atovaquone/Proguanil 250/100 mg|A single oral administration of atovaquone/proguanil 250/100 mg
61913845|NCT02095132|EXPERIMENTAL|Treatment (irinotecan hydrochloride, adavosertib)|Patients receive irinotecan hydrochloride PO and adavosertib PO on days 1-5. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
61913846|NCT02331160|EXPERIMENTAL|Rebozo|Intervention by Rebozo
61913847|NCT02331160|NO_INTERVENTION|Control|Standard
62298805|NCT06382090|EXPERIMENTAL|Laughter yoga|Premenstrual syndrome scale will be applied to adolescents as a pre-test. 34 randomly selected students who pass the cutoff score on this scale will form the experimental group. A total of 10 sessions of laughter yoga will be performed for this group, twice a week for 5 weeks. At the end of the tenth session, the premenstrual syndrome scale will be re-applied to the experimental group as a post-test.
62298806|NCT06382090|NO_INTERVENTION|Control|Premenstrual syndrome scale will be applied to adolescents as a pre-test. 34 randomly selected students who pass the cutoff score on this scale will form the control group. No intervention will be applied to this group. At the end of five weeks, the premenstrual syndrome scale will be applied again to the control group as a post-test.
62298807|NCT01170689||Inpatient schizophrenia or schizoaffective disorder|
62298808|NCT01028352|OTHER|Duloxetine|
62107156|NCT04338165|EXPERIMENTAL|Evolocumab, 420 milligrams|Single injection of 420 milligrams of evolocumab (REPATHA®) one month before coronary angiography and coronary microcirculation (IMR) measurement.
62107157|NCT04338165|NO_INTERVENTION|Control arm|Measurement of coronary microcirculation (IMR) during coronary angiography, without prior evolocumab injection.
62107158|NCT06313138|EXPERIMENTAL|Interventional group|"The Individual and Family Enhancement Program Session 1(1st week): Assessment and exchange information and building trusting relationship between researcher and participants; Session 2-3(1st-2nd week): Information sharing based on PITS model (Pathophysiology, Symptoms, or signs) and evaluation participants' understanding based on UPP scale.~Session 4-5(2nd-3rd week): Information sharing based on PITS model (treatment) and health maintenance skills.~Session 6 (3rd week): Information sharing based on PITS model (specifics) and family role in self-management.~Session7(4th week): Evaluation and summary. Session 8(5th week): Assess health literacy and information provision"
62107159|NCT06313138|OTHER|control group|Community nurses provide usual care
62107160|NCT03919617|EXPERIMENTAL|Open-Label REMD-477|
62107161|NCT05903807|EXPERIMENTAL|Ovarian cancer or high risk of ovarian cancer|Patients with newly diagnosed ovarian cancer or high risk of ovarian cancer undergo FAPI PET/CT in addition to conventional imaging
62107162|NCT03049202||Never-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that have never smoked. Definition of never-smoker: Lifetime consumption of \<100 cigarettes. No cigarettes the past 2 years.
62298809|NCT05308212|EXPERIMENTAL|FLU-M Tetra w/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (with preservative) intramuscularly
62298810|NCT05308212|EXPERIMENTAL|FLU-M Tetra w/o/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (without preservative) intramuscularly.
62298811|NCT05308212|ACTIVE_COMPARATOR|Ultrix|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Ultrix vaccine.
62469614|NCT01560767|ACTIVE_COMPARATOR|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
62107163|NCT03049202||Ex-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that stopped smoking. Definition of smoking: \> 10 pack years. Definition of ex-smoker: \> 2 years since smoke cessation.
62107164|NCT03049202||Current-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that are currently smoking. Definition of smoking: \> 10 pack years. Definition of current-smoker: \> 10/cigarettes/dat the past 6 months.
62107165|NCT03049202||Current-smoker healthy controls|Current-smokers that are otherwise healthy, with normal lung function. Definition of smoking: \> 10 pack years. Definition of current-smoker: \> 10/cigarettes/dat the past 6 months.
62298812|NCT02300129|EXPERIMENTAL|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
62298813|NCT02300129|EXPERIMENTAL|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
62469615|NCT05908266||PD|Patients with Parkinson disease
61913848|NCT04482023||Nurses COVID 19|Nurses from any unit of the Consortium Parc Taulí Corporation who have been in direct care of patients diagnosed with COVID 19 between March 9, 2020 and May 15, 2020
61913849|NCT05955976||Patients suffering of knee ostheoarthritis undergoing a surgery for a total knee prosthesis.|
61913850|NCT04303923||Male group|Male patients who performed transthoracic echocardiography with arterial ultrasonography
62298814|NCT02300129|EXPERIMENTAL|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
62298815|NCT02300129|EXPERIMENTAL|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
62107166|NCT03049202||Never-smoker healthy controls|Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of \<100 cigarettes. No cigarettes the past 2 years.
62107167|NCT06234280||Eluvia|Patients treated with Eluvia stent
62107168|NCT04720781|ACTIVE_COMPARATOR|Vonoprazan|Vonoprazan (20mg/day) is prescribed for patients with erosive esophagitis
62107169|NCT04720781|PLACEBO_COMPARATOR|Esomeprazole|Esomeprazole (20mg/day) is prescribed for patients with erosive esophagitis
62298816|NCT02281812|EXPERIMENTAL|RFA group|A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
62469616|NCT05908266||Control|Healthy volunteers
62107170|NCT05691179||COVID-19 infection group|the patients with IMN and COVID-19 infection
62107171|NCT06279429|EXPERIMENTAL|Sideral® Sucrosomial Iron|The study subjects continued to take Sucrosomial Iron 30mg supplements every day, 2 capsules a day, one 30 minutes after breakfast and dinner, for 12 consecutive weeks. During the study period, none of them used erythropoiesis stimulating agent (ESA).
62107172|NCT06279429|ACTIVE_COMPARATOR|Placebo|The study subjects continued to take Iron chewable tablet 100mg supplements every day, 2 capsules a day, one 30 minutes after breakfast and dinner, for 12 consecutive weeks. During the study period, none of them used erythropoiesis stimulating agent (ESA).
62107173|NCT01624558|EXPERIMENTAL|Treatment (filter in circuit)|After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
62298817|NCT02281812|NO_INTERVENTION|Control group|Normal excision of the tumor according to the protocol
62298818|NCT05280561|EXPERIMENTAL|DHM group|This arm is to evaluate DHM effects on the intervention of stress-induced insomnia during the pandemic. DHM granular preparation contains DHM 200 mg plus same excipients as placebo. The 244 participants were taken DHM granular preparation, which was dissolved in \~100 ml water for oral administration, once daily for 20 days.
62469617|NCT01853657|ACTIVE_COMPARATOR|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
62469618|NCT01853657|NO_INTERVENTION|Routine monitoring|Immunological and clinical monitoring
62469619|NCT04718025|EXPERIMENTAL|Low-dose ticagrelor with aspirin (LDTA)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, and will receive the following antiplatelet therapy:~1. ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~2. ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until 12 months after ACS."
62107174|NCT01624558|NO_INTERVENTION|No Intervention Control|After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
62668970|NCT04568772|EXPERIMENTAL|Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day
62668971|NCT04568772|EXPERIMENTAL|Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day
62107175|NCT01159158|EXPERIMENTAL|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
62107176|NCT01159158|ACTIVE_COMPARATOR|Starlix|Starlix Tablets 120 mg of Novartis
62107177|NCT00093795|ACTIVE_COMPARATOR|Group 1: TAC X 6|Doxorubicin, cyclophosphamide, and docetaxel.
62107178|NCT00093795|ACTIVE_COMPARATOR|Group 2: AC X 4 then P X 4|Doxorubicin, cyclophosphamide, and paclitaxel
62107179|NCT00093795|EXPERIMENTAL|Group 3: AC X 4 then PG X 4|Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
62298819|NCT05280561|PLACEBO_COMPARATOR|Control group|The placebo contained excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
62298820|NCT00728546|EXPERIMENTAL|INA dose adjustment, NAT2|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
62298821|NCT02966314|PLACEBO_COMPARATOR|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
62308359|NCT06170255|EXPERIMENTAL|Depression treatment|Participants receive behavioral therapy for depression
62668972|NCT04568772|EXPERIMENTAL|Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day
62107180|NCT02814266|OTHER|difficult intubation|Intubation difficulty score \>5
62107181|NCT02814266|OTHER|Easy intubation|Intubation difficulty score \>5
62298822|NCT02966314|ACTIVE_COMPARATOR|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
62298823|NCT03698734|ACTIVE_COMPARATOR|Evening primrose oil|
62107182|NCT02873884||case-management|Patients will meet the case-manager 5 times per month during 1h30 in community living
62107183|NCT02873884||traditional nursing|Patients will meet the case-manager 2 times per month during 1h00 in hospital
62107184|NCT00669461|EXPERIMENTAL|Patients|
62107185|NCT04518566|NO_INTERVENTION|Placebo|Patients in control arm will have FitBit. However, there are no personalised nudges given to the patients in the control arm. Occasional reminders to encourage adherence to wearing of the FitBit will be sent.
62107186|NCT04518566|EXPERIMENTAL|Nudges|Patients in the intervention arm will be given a FitBit device and will be encouraged to wear it as often as possible. Using FitBit built-in tracking technologies such as PurePulse and SmartTrack54, patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the adaptive intervention platform as developed in Phase 2 for real-time tracking.
62107187|NCT06628791|EXPERIMENTAL|BK329 group|This group takes BK329 for 12 weeks.
62107188|NCT06628791|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks.
62107189|NCT04286165|ACTIVE_COMPARATOR|BPS webSTAIR 6 Levels with Peer Support|Participants in BPS webSTAIR will complete a baseline, posttreatment and 2-month follow-up assessment. In the BPS webSTAIR condition, participants will first complete a welcome module to orient them to the program. After randomization, participants will have 10 weeks to complete the 6 modules. Every time the Veteran logs on they will have the opportunity to engage with a Veteran peer for support through the web program. Contacts can last for up to an hour. Veterans will receive a series of automated reminders and engagement emails that the Vets Prevail program sends at various points in the program.
62107190|NCT04286165|NO_INTERVENTION|Wait List|In Wait list, participants will be asked to go about their life as usual. They will be asked not to participate in any other programs for PTSD or depression symptoms for 10 weeks. After the 10 weeks, WL participants can begin any other program for PTSD or depression. They will also be given the option of participating in BPS webSTAIR or be provided with information about other web-based programs that might be of interest or relevant to them.
62107191|NCT06158958|EXPERIMENTAL|ABBV-303 Dose Escalation: Part 1A Monotherapy|Participants with (R)/refractory (R) solid tumors will receive ABBV-303 in escalating doses as a monotherapy until the maximum tolerable dose (MTD) is determined as part of the 3 year study duration.
62298824|NCT03698734|PLACEBO_COMPARATOR|placebo|
62469620|NCT04718025|EXPERIMENTAL|Low-dose ticagrelor with placebo (LDTP)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, followed by discontinuation of aspirin after 3 months post-ACS, and will receive the following antiplatelet therapy:~1. ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~2. ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until day 90 after ACS;~3. ticagrelor 2x60mg + placebo starting from day 91 until 12 months after ACS."
62469621|NCT04718025|ACTIVE_COMPARATOR|Standard-dose ticagrelor with aspirin (SDTA)|Patients with ACS in this arm will receive standard dual antiplatelet therapy including ticagrelor 2x90mg + aspirin 1x100mg during the whole 12 months after ACS.
62469622|NCT02214615|ACTIVE_COMPARATOR|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
62469623|NCT02214615|PLACEBO_COMPARATOR|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
62469624|NCT00651820|EXPERIMENTAL|Collagenase Santyl Rate of Wound Closure|Dermatome-induced skin wounds treated with drug active (collagenase).
62668973|NCT01975480|EXPERIMENTAL|Desvenlafaxine|At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.
62107192|NCT06158958|EXPERIMENTAL|ABBV-303 Dose Expansion: Part 2A Monotherapy|Participants with R/R NSCLC will receive ABBV-303 at the recommended phase 1 expansion dose (RP1ED) as a monotherapy as part of the 3 year study duration.
62298825|NCT03406026|EXPERIMENTAL|Balance System Protocol Stroke|Balance System Protocol Stroke differentiates 2 levels of difficulty in relation to the patient's condition and progressively according to their evolution. If the patient maintains stability in standing for at least 30 s, he starts in Level 2 and otherwise he will remain in Level 1 until he acquires it. In level 1 the progression of exercises is: 1.Pressure stimulation of the foot support points; 2.Proprioceptive ankle work; 3.Sit-to-stand work and vice versa; 4.Sit-to-stand work with delayed affection. In level 2, the progression of exercises is: 1.Standing unbalances; 2.Standing on Balance-pad; 3.Work to get monopodal support; 4.Balance pad in monopodal support; 5.Monopodal support work with closed eyes.
62469625|NCT00651820|PLACEBO_COMPARATOR|Vehicle Rate of Wound Closure|Dermatome-induced skin wounds treated with Vehicle alone.
62469626|NCT02069080|EXPERIMENTAL|1|All subjects are administered the study drug
62469627|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
62107193|NCT06158958|EXPERIMENTAL|ABBV-303 Dose Expansion: Part 3A Monotherapy|Participants with R/R RCC will receive ABBV-303 at the RP1ED as a monotherapy as part of the 3 year study duration.
62107194|NCT06158958|EXPERIMENTAL|ABBV-303 Dose Expansion: Part 4A Monotherapy|Participants with R/R HNSCC will receive ABBV-303 at the RP1ED as a monotherapy as part of the 3 year study duration.
62298826|NCT03406026|ACTIVE_COMPARATOR|Control Stroke|The program of Control Stroke arm is based on an integral and rehabilitative approach in which the patient follows a personalized plan of exercises and therapies according to the deficits of each patient, the previous situation, the personal concerns with In order to perform a person-centered approach.
62298827|NCT02984462|EXPERIMENTAL|screw fixation|Surgical Percutaneous Akin osteotomy with fixation by a percutaneous cannulated screw and forefoot surgery dressing.
62298828|NCT02984462|NO_INTERVENTION|No fixation|Surgical Percutaneous Akin osteotomy non-fixed, hold by forefoot surgery dressing.
62668974|NCT02164188|NO_INTERVENTION|control|Initially this control group will not receive an intervention (wait list). After 8 weeks this goup will receive the Flourishing protocol (cross over).
62298829|NCT01802359||Mirodenafil|
62298830|NCT06392815|OTHER|Neuroborreliosis|25 patients with possible or confirmed neuroborreliosis
62298831|NCT06392815|OTHER|controls|25 patients investigated for neuroborreliosis but with normal CSF examination
62107195|NCT06158958|EXPERIMENTAL|ABBV-303 Dose Expansion: Part 5A Monotherapy|Tissue agnostic with R/R participants with MET amplification by any commercially available test will receive ABBV-303 at the RP1ED as a monotherapy as part of the 3 year study duration.
62107196|NCT06158958|EXPERIMENTAL|ABBV-303 Dose Escalation: Part 1B Combination|Participants with R/R solid tumors will receive ABBV-303 in combination with budigalimab at or below the MTD as part of the 3 year study duration.
62107197|NCT06158958|EXPERIMENTAL|ABBV-303 Dose Expansion: Part 2B Combination|Participants with R/R NSCLC will receive ABBV-303 at or below the MTD in combination with budigalimab as part of the 3 year study duration.
62107198|NCT05301556|EXPERIMENTAL|Experimental Product|Food for Special Medical Purpose (FSMP) is a special medical food for patients with tumors
62107199|NCT05301556|ACTIVE_COMPARATOR|Control Product|Nutrition Emulsion (TPF-T) TPF-T is a tumor-specific enteral nutrition therapy
62298832|NCT06556108|EXPERIMENTAL|Arm 1|"This clinical study consists of 4 dose groups, with dose groups 1 and 2 using an accelerated titration dose escalation method, and dose groups 3 and 4 using a 3+3 dose escalation method.~Interventions:~Biological: CAR-T cells Drug: Fludarabine Drug: Cyclophosphamide"
62298833|NCT03840876|EXPERIMENTAL|Group J|Jet ventilation was achieved via supraglottic jet oxygenation and ventilation with WEI NASAL JET (WNJ).
62668975|NCT02164188|EXPERIMENTAL|Flourishing protocol|This group will receive the intervention Flourishing protocol and after that it will not receive any other intervention (cross over).
62668976|NCT06139458|EXPERIMENTAL|Cryotherapy|
62107200|NCT01769391|EXPERIMENTAL|Necitumumab +Paclitaxel+Carboplatin|"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.~Paclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.~Carboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle.~The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles. Necitumumab may continue until Progressive Disease (PD), toxicity requiring cessation, protocol noncompliance, or withdrawal of consent."
62298834|NCT03840876|NO_INTERVENTION|Group I|Patients were ventilated with a small size endotracheal tube.
62298835|NCT06656832|EXPERIMENTAL|Randomised Arm 1: Heart Failure Network Care|Patients will receive three follow-up visits during the vulnerable period (three month after hospital discharge) in the HF network (either cardiologist in private practice or HF outpatient clinic)
62298836|NCT06656832|NO_INTERVENTION|Randomised Arm 2: Usual care|Patients will receive usual care by their primary physician or cardiologist
62668977|NCT06139458|EXPERIMENTAL|Compression with Cryotherapy|
62668978|NCT01967875|ACTIVE_COMPARATOR|H-A: ERCC1 High Expression Group A|XP：Capecitabine+Cisplatin
62668979|NCT01967875|EXPERIMENTAL|H-B: ERCC1 High Expression Group B|DX：Docetaxel+Capecitabine
62668980|NCT01967875|ACTIVE_COMPARATOR|L: ERCC1 Low Expression Group|XP：Capecitabine+Cisplatin
62668981|NCT01371760|EXPERIMENTAL|Intervention|The patients will undergo PTA of the extracranial cerebral veins
62668982|NCT01371760|SHAM_COMPARATOR|Controls|The patients will undergo sham procedure
62298837|NCT06656832|NO_INTERVENTION|Registry Arm for non-randomised patients|Patients not willing to be randomised will be followed in a registry.
62298838|NCT01217775|EXPERIMENTAL|PH80 intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
62298839|NCT01217775|PLACEBO_COMPARATOR|Placebo intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
62298840|NCT04340050|EXPERIMENTAL|Treatment with anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
62298841|NCT05089708|EXPERIMENTAL|Trifarotene (CD5789) 50 mcg/g Cream|
62298842|NCT05089708|PLACEBO_COMPARATOR|Trifarotene Vehicle Cream|
62298843|NCT03771625||single-group studies|All the patients received chemotherapy and radiotherapy.
62668983|NCT03235414|EXPERIMENTAL|Normals|Will receive an MRI and a blood draw
62668984|NCT03827642|EXPERIMENTAL|Cohort 1: Treatment Sequence A-D-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment D on Day 1 of Period 2, Treatment C on Day 1 of Period 3 and Treatment B on Day 1 of Period 4.
62668985|NCT03827642|EXPERIMENTAL|Cohort 2: Treatment Sequence B-C-D-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, Treatment D on Day 1 of Period 3 and Treatment A on Day 1 of Period 4.
62668986|NCT03827642|EXPERIMENTAL|Cohort 3: Treatment Sequence C-A-B-D|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, Treatment B on Day 1 of Period 3 and Treatment D on Day 1 of Period 4.
62668987|NCT03827642|EXPERIMENTAL|Cohort 4: Treatment Sequence D-B-A-C|Participants received Treatment D on Day 1 of Period 1, Treatment B on Day 1 of Period 2, Treatment A on Day 1 of Period 3 and Treatment C on Day 1 of Period 4.
62668988|NCT01946802||Frontal 4 channel EEG|Consecutive comatose patients admitted to the emergency ICU for postresuscitation care following successful cardiopulmonary resuscitation after nontraumatic out-of-hospital and in-hospital cardiac arrest.
62668989|NCT00179179|ACTIVE_COMPARATOR|1|nutritional supplement plus resistance exercise
62107201|NCT01769391|ACTIVE_COMPARATOR|Paclitaxel + Carboplatin|Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles. After completion of chemotherapy, participants will be followed until radiographic documentation of PD.
62107202|NCT02119624||1|Healthy non-treatment-seeking heavy drinkers
62668990|NCT00179179|ACTIVE_COMPARATOR|2|nutritional supplement only (resistance exercise will not be performed)
62668991|NCT05932030|OTHER|patients and health professionals|The intervention is a survey administered to patients and health professional. The two questionnaires are identical, with only the socio-demographic section differing. The questionnaire is composed of closed questions, scale scores and short-answer questions.
62668992|NCT04259242|EXPERIMENTAL|premenopausal women with periodontitis|Experimental: premenopausal women with periodontitis premenopausal women with chronic periodontitis will be evaluated after SRP for serum bone resorption markers - CTX and inflammatory markers IL-6
62668993|NCT00884065|EXPERIMENTAL|Intervention Group|The intervention group was treated with a single session of DF following the procedure as described by the authors.
62298844|NCT04261543|EXPERIMENTAL|High Protein and Early Exercise|High protein is defined as a protein prescription of ≥2.2 gram/kg body weight; Early exercise is defined as exercise by using cycle ergometry for 45 minutes per day within 24 hours of randomization
62668994|NCT00884065|PLACEBO_COMPARATOR|Control Group|The control group was treated with a single placebo session of DF.
62668995|NCT02555098|EXPERIMENTAL|Sapphire contact lenses|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
62107203|NCT02119624||2|Healthy light drinkers
62107204|NCT03403699||nondiabetics|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must be a healthy control and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
62107205|NCT03403699||Diabetic|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) carry the diagnosis of diabetes and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
62469628|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
61913851|NCT04303923||Female group|Female patients who performed transthoracic echocardiography with arterial ultrasonography
61913852|NCT01829243|EXPERIMENTAL|Milnacipran|Eligible subjects will receive milnacipran (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
61913853|NCT01829243|PLACEBO_COMPARATOR|Placebo|Eligible subjects will receive placebo (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
61913854|NCT03952390||control|healthy volunteers
61913855|NCT03952390||sepsis|patients with sepsis
61913856|NCT02550977|EXPERIMENTAL|Gestodene/EE Patch|
62107206|NCT04587479|EXPERIMENTAL|JAB-8263|Monotherapy, dose escalation
62107207|NCT01010165||septic arthritis|
62107208|NCT01010165||crystal arthritis|
62107209|NCT01010165||rheumatismal disease|
62107210|NCT01236989|EXPERIMENTAL|Anatomical resection|
62107211|NCT01236989|ACTIVE_COMPARATOR|Non-anatomical resection|
62298845|NCT04261543|ACTIVE_COMPARATOR|Usual Care|Usual care has a protein prescription of ≤1.2 gram/kg body weight and exercise prescription as per the discretion of attending clinicians
62298846|NCT05122130|EXPERIMENTAL|Melatonin group|Melatonin loaded Carbopol hydrogel will be synthesized as follows: 1 gm of Carbopol will be dissolved in 100 ml deionized water while stirring at 600 rpm for 25°C. Melatonin (3gm) will be dissolved in 1 ml ethanol and added to the formed gel while stirring at 600 rpm at 25 °C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed and it will be loaded on gelatin sponge and will be applied to the donor site.
62469629|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
62668996|NCT02555098|ACTIVE_COMPARATOR|senofilcon A|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
62107212|NCT05518487|EXPERIMENTAL|Kidney transplant recipients|This single-arm trial will administer a single dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine to kidney transplant recipients who demonstrate a persistently low (=\< 2500 u/mL) anti-spike antibody response after completion of primary series and bivalent booster of either the Moderna COVID-19 Vaccine or the Pfizer-BioNTech Vaccine, as described in their respective Food and Drug Administration (FDA) Emergency Use Authorizations (EUAs)
62298847|NCT05122130|PLACEBO_COMPARATOR|Placebo group|•Topical placebo carbopol gel will be prepared as follows: 1 gm of Carbopol will be dissolved in 100ml deionized water while stirring at 600 rpm for 25°C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed
62469630|NCT01016028||Questionnaire + Sensory Tests + Interview|
62107213|NCT01761396|EXPERIMENTAL|CBT|Cognitive behavioral therapy
62107214|NCT01761396|ACTIVE_COMPARATOR|UC|Usual care
62107215|NCT03735771|EXPERIMENTAL|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
62107216|NCT03735771|EXPERIMENTAL|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
62107217|NCT03735771|EXPERIMENTAL|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
62107218|NCT03735771|EXPERIMENTAL|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
62107219|NCT04820621|EXPERIMENTAL|Participants with mild hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
62107220|NCT04820621|EXPERIMENTAL|Participants with moderate hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
62107221|NCT04820621|EXPERIMENTAL|Participants with normal hepatic function|All participants will receive a single oral dose in the fasted state on Day 1.
62107222|NCT00964314|EXPERIMENTAL|five elements music|Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
62107223|NCT00964314|ACTIVE_COMPARATOR|western music|Listening western music based on conventional therapy in China.
62107224|NCT00964314|NO_INTERVENTION|Without music|no music therapy will be done in the arm.
62107225|NCT03007758|ACTIVE_COMPARATOR|robotic ventral hernia repair (VHR)|Robotic VHR
62107226|NCT03007758|ACTIVE_COMPARATOR|open ventral hernia repair (VHR)|Open VHR
62107227|NCT05954507|OTHER|Prospective cohort of patients|Patients with suspected cardiac sarcoidosis
62107228|NCT01668342|EXPERIMENTAL|SMS assessments & feedback|Daily symptom assessments of headaches, trouble ocncentrating and irritability/anxiety with self-care feedback based on response severity.
62469631|NCT03909945|EXPERIMENTAL|Interventional arm|The intervention consisted in the daily administration, during 60 days, of a 796 mg tablet of aqueous extracts of leaves of Annona muricata between 08:00 AM and 09:00 AM.
62469632|NCT03135834|EXPERIMENTAL|Group 1 (ACWY Naive subjects, MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
62469633|NCT03135834|EXPERIMENTAL|Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)|ACWY Naive subjects, rLP2086/MenACWY-CRM
62668997|NCT00326495|EXPERIMENTAL|BAY 43-9006 & Cetuximab|BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID). Cetuximab will be given intravenously (IV) at a dose of 400 mg/m\^2 initially as a loading dose on week 2, followed by 250 mg/m\^2 weekly starting on week 3
62107229|NCT01668342|NO_INTERVENTION|Control|Standard of care
62107230|NCT06421948|EXPERIMENTAL|Orally administered, targeted therapy|Participants will receive a combination of linperlisib in combination with chidamide orally.
62668998|NCT00581997|EXPERIMENTAL|1|QAX576
62668999|NCT00581997|PLACEBO_COMPARATOR|2|Placebo
62107231|NCT06421948|ACTIVE_COMPARATOR|Intravenously chemotherapy|Participants will receive standard CHOP regimen chemotherapy including cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone.
62107232|NCT02741167||CRS and HIPEC|Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy
62107233|NCT02584153|EXPERIMENTAL|Myoseal|The fibrin sealant and silver microparticles are sprayed onto the surface of the sutured myofascial incision following abdominal surgery.
62298848|NCT01491087|EXPERIMENTAL|PENTAXIM® vaccine group|
62298849|NCT04785612|EXPERIMENTAL|RSVPreF|A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume
62298850|NCT04785612|PLACEBO_COMPARATOR|Placebo|A single intramuscular injection of Placebo to match active vaccine
62469634|NCT03135834|EXPERIMENTAL|Group 3 (ACWY Experienced subjects, MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
62469635|NCT03135834|EXPERIMENTAL|Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)|ACWY Experienced subjects, rLP2086/MenACWY-CRM
62669000|NCT02487355|ACTIVE_COMPARATOR|group (MG)|Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine
62298851|NCT06376149|OTHER|Experimental: Intervention Group|"Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.~Interventions:~Behavioural: Making Mindfulness Matter© (M3)"
61913857|NCT01797770||Mechanical bowel preperation|mechanical bowel preparation with polyethylene glycol one day prior to surgery
62107234|NCT01976689||Patients with New-onset Diabetes|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
62298852|NCT06376149|OTHER|Other: Waitlist Control|"Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete Follow-up questionnaire and extended follow up questionnaires at comparable times to families in the intervention arm. With one extra set of questionnaires at the completion of the intervention. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session.~Interventions:~Behavioural: Making Mindfulness Matter© (M3)"
62669001|NCT02487355|ACTIVE_COMPARATOR|group (D)|Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
62669002|NCT02487355|ACTIVE_COMPARATOR|group (MD)|50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
62669003|NCT02487355|ACTIVE_COMPARATOR|group (C)|1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline
61913858|NCT01444092|EXPERIMENTAL|Entocort|Study Medication
61913859|NCT06515535|EXPERIMENTAL|Study group (n=28)|The topical tranexamic acid group will receive topical tranexamic acid after placental delivery applied on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%, in addition to the IV infusion of 1g tranexamic acid (2 ampules 500ug) diluted with 20ml of 5% glucose administered just after delivery of the fetus.
62298853|NCT01295125|EXPERIMENTAL|XenMATRIX|Use of XenMATRIX mesh to repair hernia
62298854|NCT04800315|EXPERIMENTAL|Dose 1: CC-93538 SC QW|Administration of CC-93538 Subcutaneous (SC) Once weekly (QW) for 16 weeks.
62669004|NCT01346553|EXPERIMENTAL|ESVV treatment|using ESVV device
62669005|NCT03243890|EXPERIMENTAL|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
62669006|NCT03243890|PLACEBO_COMPARATOR|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
62669007|NCT03030209||Distal Pancreatectomy|Patients undergoing distal pancreatectomy
62669008|NCT00583804|EXPERIMENTAL|Stimulation ON|Individuals implanted with stimulator/sensor device. Stimulator is turned on and is active.
62669009|NCT00583804|ACTIVE_COMPARATOR|Stimulation OFF|Function with stimulation turned off.
62669010|NCT04218851|EXPERIMENTAL|Posaconazole|On Day 1 participants receive 2 administrations of posaconazole (POS) 6 mg/kg body weight by intravenous (IV) infusion. On Days 2 through 7, participants receive POS 6 mg/kg body weight once daily by IV infusion. Beginning at Day 8 up to Day 84, participants may transition to receiving an oral formulation, or they may remain on the IV formulation.
62669011|NCT01049672|ACTIVE_COMPARATOR|Alfentanil|Hospice in-patients who require subcutaneous strong opioid administration will be given alfentanil
62669012|NCT01049672|ACTIVE_COMPARATOR|Diamorphine|Hospice in-patients who require strong opioids will be given diamorphine
61913860|NCT06515535|ACTIVE_COMPARATOR|Control group (n=28)|The intravenous tranexamic acid group will receive only an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
61913861|NCT01695876|EXPERIMENTAL|AMG 357|AMG 357 is a small molecule for treatment of inflammatory disease
62469636|NCT01162694|ACTIVE_COMPARATOR|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
62469637|NCT01162694|ACTIVE_COMPARATOR|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the uploaded data and receive feedback from their endocrinologist every 2 weeks.
62107235|NCT01976689||Patients without NODAT|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
62469638|NCT00683098||1|patients, who had a endoscopic total extraperitoneal repair of recurrent inguinal hernia between 1995 and 2008
62469639|NCT04000386|EXPERIMENTAL|zinc oxide nanoparticles coated socks|62 patients with zinc oxide nanoparticles coated socks
62469640|NCT04000386|PLACEBO_COMPARATOR|placebo|62 patients with placebo socks
62469641|NCT04481815|EXPERIMENTAL|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
62469642|NCT04481815|SHAM_COMPARATOR|R-MTX|Control arm will be treated with R-MTX regimen(Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved CR or PR with additional WBRT, they processed to Lenalidomide maintenance for 4 cycles.
62107236|NCT06092931|EXPERIMENTAL|Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate)|Participants will receive a single oral dose of the 2-probe substrate cocktail (midazolam and repaglinide) on Day 1. From Day 4 through Day 8, participants will receive twice-daily (BID) oral doses of DC-806 and a single oral dose of the 2-probe substrate cocktail on Day 7. DC-806 BID dosing will continue until the end of Day 8.
62107237|NCT06092931|EXPERIMENTAL|Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)|Participants will receive a single oral dose of the 2-probe substrate cocktail (digoxin and rosuvastatin) on Day 1. From Day 5 through Day 9, participants will receive twice daily oral doses of DC-806 and a single oral dose of the 2-probe substrate cocktail on Day 8. DC-806 BID dosing will continue until the end of Day 9.
62107238|NCT05158192|EXPERIMENTAL|Diosmin/Hesperidin (90/10) Test Product|Participants received one tablet of the test formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.
62107239|NCT05158192|ACTIVE_COMPARATOR|Diosmin/Hesperidin (90/10) Reference Product|Participants received one tablet of the marketed reference formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.
62107240|NCT06555224|NO_INTERVENTION|High Risk Standard of Care|OSFI \>= 0.3, NSAID 2x daily for 4 weeks
62107241|NCT06555224|EXPERIMENTAL|High Risk Treatment Group|OSFI \>= 0.3, NSAID 2x daily for 4 weeks, Systane Hydration MDPF 4x daily for 3 months
62107242|NCT06555224|NO_INTERVENTION|Low Risk, Reference Group|OSFI \< 0.3, NSAID 2x daily for 4 weeks
62469643|NCT05860686|ACTIVE_COMPARATOR|No rinsing|
62107243|NCT04893980|EXPERIMENTAL|Low-dose interleukin-2 treatment group|Use Interleukin-2 to treat CSU during day1-day28.
62107244|NCT04893980|OTHER|Control group|Use Interleukin-2 to treat CSU during day15-day28.
62298855|NCT04800315|EXPERIMENTAL|Dose 2: CC-93538 SC Q2W and Placebo alternating every other week SC Q2W|Starting at the baseline visit, active IP will be administered. On the alternate weeks, placebo will be administered to maintain the blind.
62298856|NCT04800315|EXPERIMENTAL|Dose 3: CC-93538 SC Q2W and Placebo SC weekly|"Starting at the baseline visit, active IP and matching placebo will be administered.~On the alternate weeks, placebo will be administered weekly to maintain the blind."
62298857|NCT04800315|PLACEBO_COMPARATOR|Placebo SC QW|Administration of placebo each week.
62298858|NCT02426814|SHAM_COMPARATOR|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: inhaler sensor"
62469644|NCT05860686|EXPERIMENTAL|Monoject rinsing|
62469645|NCT01804270|ACTIVE_COMPARATOR|Part 1 Active|Blinded, active repetitive transcranial magnetic stimulation
62469646|NCT01804270|SHAM_COMPARATOR|Part 1 Sham|Blinded, sham repetitive transcranial magnetic stimulation
62469647|NCT01940341|EXPERIMENTAL|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
62469648|NCT01940341|ACTIVE_COMPARATOR|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
62669013|NCT01527981|EXPERIMENTAL|CBT-AD|Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.
61913862|NCT01695876|PLACEBO_COMPARATOR|Placebo|Matching placebo to AMG 357 containing no active drug
61913863|NCT00893620|OTHER|1|Treatment
62298859|NCT02426814|EXPERIMENTAL|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application with reminders to allow self-management of medication use.~Interventions: inhaler sensor and mobile application for asthma adherence"
62669014|NCT02271542|EXPERIMENTAL|between 1-10 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
62669015|NCT02271542|EXPERIMENTAL|under 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
62669016|NCT02271542|EXPERIMENTAL|upper 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
62669017|NCT00152230|EXPERIMENTAL|1|UFT (uracil, tegafur)
62669018|NCT00152230|OTHER|2|Surgery alone
62107245|NCT04571333|EXPERIMENTAL|Mi2000 Cochlear Implant surgery|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
62107246|NCT04300933|EXPERIMENTAL|Neurofeedback therapy|Fifty participants conduct neurofeedback daily for 5 days.
62107247|NCT03308487|ACTIVE_COMPARATOR|vitamin D3 (1000 IU)|group 1
62469649|NCT01940341|EXPERIMENTAL|Open-label TAF|"All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.~After the end of study treatment, participants can either switch to commercially available anti-HBV treatments in their country or will be followed every 4 weeks, for up to 24 weeks off treatment (treatment-free follow-up (TFFU)) for safety assessment."
62669019|NCT03648970|EXPERIMENTAL|Pravastatin Treatment Group|In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
62669020|NCT03648970|NO_INTERVENTION|Control Group|"In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.~In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group"
62669021|NCT04037956|EXPERIMENTAL|Tubeless NOSES|Patients receive Tubeless NOSES.
62107248|NCT03308487|ACTIVE_COMPARATOR|vitamin D3 (2000 IU)|group 2
62107249|NCT06278064||Gastric cancer group|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
62107250|NCT06278064||esophagus cancer group|Patients diagnosed with esophagus cancer, including early esophagus cancer and advanced esophagus cancer
62107251|NCT06278064||Non-cancer group|Patients diagnosed with benign upper gastrointestinal diseases or healthy controls
62107252|NCT00589212|EXPERIMENTAL|1|Patients with 1-3 brain metastases
62298860|NCT03628157|EXPERIMENTAL|intervention|using a bio-oss bovine bone alone
62298861|NCT03628157|ACTIVE_COMPARATOR|control|using a bio-oss bovine bone with autogenous bone ratio 1:1
62107253|NCT04035512|EXPERIMENTAL|Expressive writing|The expressive writing group will perform the writing task, for 3 consecutive days, 20 minutes each day
62298862|NCT04091217|EXPERIMENTAL|Atezolizumab + Bevacizumab|
62298863|NCT05878028|EXPERIMENTAL|L-TIL plus Tislelizumab and Docetaxel|Tislelizumab, 200mg, ivgtt, d1, Q3W for one year L-TIL cells, （3-10）x10\^9/m2, ivgtt, d14, Q3W for 4 or 6 cycles Docetacel, 75mg/m2, ivgtt, d1, Q3W for 4 cycles
62469650|NCT05703438|EXPERIMENTAL|Nutritionally balanced low-calorie diet|Experimental study with pre and post design
62469651|NCT03397056||The study population|"The target population corresponds to patients with a respiratory disease already included in a biomedical research protocol.~Intervention: Questionnaire"
62669022|NCT04037956|ACTIVE_COMPARATOR|traditional laparoscopic|Patients receive traditional laparoscopic radical resection.
62669023|NCT00793611|ACTIVE_COMPARATOR|Behavioral therapy|"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)"
62669024|NCT00793611|EXPERIMENTAL|hypnotherapy|patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder
62669025|NCT02674087||Expectant women|
62669026|NCT01084564||1|moderate to severe uncontrolled asthma
62669027|NCT04764253|EXPERIMENTAL|Modified Sodium Watcher Program + Digital Self-Monitoring|
62107254|NCT04035512|NO_INTERVENTION|Control group|Any intervention
62107255|NCT00757718|ACTIVE_COMPARATOR|CPAP treatment|Subjects will have repeat polysomnography on the second night, while wearing a continuous positive airway pressure (CPAP) device. Morning bloodwork will be drawn for inflammatory mediators.
62107256|NCT00757718|EXPERIMENTAL|Oral appliance|Subjects will have repeat polysomnography on the second night, while wearing an oral appliance, as well as a Breathe-Right nasal strip. Morning bloodwork will be drawn for inflammatory mediators.
62107257|NCT06113939|ACTIVE_COMPARATOR|Standard of Care|IV ceftriaxone/24 hours 3 doses
62669028|NCT04764253|ACTIVE_COMPARATOR|Usual care + Digital Self-Monitoring|
62669029|NCT01145222|EXPERIMENTAL|A. Remimazolam (CNS 7056)|"Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
62669030|NCT01145222|EXPERIMENTAL|B. Remimazolam (CNS 7056)|"Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
62669031|NCT01145222|EXPERIMENTAL|C. Remimazolam (CNS 7056)|"Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
62669032|NCT01145222|ACTIVE_COMPARATOR|D. Midazolam|"Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses"
62669033|NCT02370394|EXPERIMENTAL|ROSE Program|Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
62669034|NCT02370394|NO_INTERVENTION|Control Condition|Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
62669035|NCT04190095|EXPERIMENTAL|User Interaction with Device|A user will wear motion sensors and VR device to interact with object or another user in VR environment
62669036|NCT04040673||Normal benign|participants with normal benign nodules (no cancer)
62107258|NCT06113939|EXPERIMENTAL|Subglottic aspiration|Continuos aspiration of subglottic secretions
62669037|NCT04040673||Follicular thyroid cancer|participants with follicular thyroid cancer
62669038|NCT04040673||Papillary thyroid cancer|participants with papillary thyroid cancer
62107259|NCT06113939|EXPERIMENTAL|Cough Simulator|Mechanical exsufflator
62107260|NCT03201614|EXPERIMENTAL|A-CP HA|Patients randomized in this group will be treated with a combination of platelet-rich plasma plus hyaluronic acid prepared with A-CP HA Kit.
62107261|NCT03201614|ACTIVE_COMPARATOR|ArthroVisc 40|Patients randomized in this group will be treated with hyaluronic acid only (ArthroVisc 40); hyaluronic acid is the same as the one contained in the A-CP HA Kit.
62107262|NCT03201614|PLACEBO_COMPARATOR|Placebo|Patients randomized in this group will be treated with a saline solution.
62669039|NCT04040673||Anaplastic thyroid cancer|participants with anaplastic thyroid cancer
62669040|NCT04040673||Medullary thyroid cancer|participants with medullary thyroid cancer
62298864|NCT06294028|ACTIVE_COMPARATOR|Implantation of an automatic defibrillator|Implantation of an automatic defibrillator
62669041|NCT03319121|EXPERIMENTAL|Empirical therapy group|Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
62669042|NCT03319121|EXPERIMENTAL|Guided therapy group|Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
62669043|NCT01535066|EXPERIMENTAL|Arm I|Patients receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
62107263|NCT02648425|EXPERIMENTAL|Regimen A / Amended Regimen A|"Regimen A: Cisplatin + 5-fluorouracil~ASLAN001 daily in combination with:~Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles.~Or~Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin~ASLAN001 daily in combination with:~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles."
62107264|NCT02648425|EXPERIMENTAL|Regimen B|"Regimen B: Cisplatin + capecitabine~ASLAN001 daily in combination with:~Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles."
62298865|NCT06294028|EXPERIMENTAL|Percutaneous catheter ablation|Percutaneous catheter ablation
62469652|NCT00724191||A|Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
62469653|NCT01216839|EXPERIMENTAL|Everolimus|
62669044|NCT01535066|SHAM_COMPARATOR|Arm II|Patients receive sham acupuncture twice weekly for 6 weeks and then once weekly for 6 weeks.
62669045|NCT01535066|NO_INTERVENTION|Arm III|Patients are assigned to a waiting list for 12 weeks with standard follow-up care.
62669046|NCT03723239|EXPERIMENTAL|TricValve® System Single-Arm|Minimally invasive catheter-supported, bicaval tricuspid valve (self-expanding) replacement
62298866|NCT03216629|EXPERIMENTAL|Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will say sorry repeatedly. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
62669047|NCT06163638|EXPERIMENTAL|Intergenerational movement program|This group will receive the intergenerational physical activity program. There are 4 components, which consist of an educational session for grandparents and parents (1), group-based movement sessions for grandparents and grandchildren once a week during 8 weeks (2), home-based physical activities for both grandparents and grandchildren (3) and community-based activities for both grandparents and grandchildren (4).
62669048|NCT06001307|EXPERIMENTAL|Program STARS (Supporting Trans Affirmation, relationships, and Sex)|"STARS is an HIV prevention intervention for trans women/femmes with recent intimate partner violence (IPV). Delivered by peer counselors, STARS consists of two one-hour sessions held one week apart and two brief 20-30 minute booster sessions held two- and four-weeks after the 2nd hour long session. Requirements for peer counselors include identifying as trans women or trans feminine and having leadership roles in the trans community.~STARS is an empowerment-based intervention that integrates trauma-informed and gender affirmation approaches. The first session emphasizes education and discussion around HIV and IPV, as well as the interaction between IPV and HIV risk. The second session focuses on identifying partners where HIV/IPV risk exists and developing an empowerment plan to address those risks. Participants create an empowerment plan in session 2 and this plan is reviewed and updated in the booster sessions."
62669049|NCT06001307|ACTIVE_COMPARATOR|Relaxation and Stress Reduction|"The Relaxation and Stress Reduction Program is structured to mirror STARS (time matched, attention-controlled). Delivered by peer counselors, the Relaxation and Stress Reduction Program consists of two one-hour sessions held one week apart and two brief 20-30 minute booster sessions held two- and four-weeks after the 2nd hour long session. Requirements for peer counselors include identifying as trans women or trans feminine and having leadership roles in the trans community.~The relaxation and stress reduction protocol is an attention and time-matched control condition. The intervention focuses on providing both education and opportunities to practice various relaxation strategies. In addition, education is provided on healthy eating as an additional tool for reducing stress. Booster sessions focus on providing participants with additional practice of relaxation strategies."
62669050|NCT06150443|EXPERIMENTAL|Group 1 - OMT Only|Osteopathic manipulative treatment will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. The cervical spine will also be treated, with particular attention to the C5-7 levels, all the way to the wrist and hand as the physician sees fit based on the findings of the osteopathic structural exam.
62298867|NCT03216629|NO_INTERVENTION|Not Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will remain silent. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
62298868|NCT04767425|EXPERIMENTAL|Experimental|
62298869|NCT00297414||Patients with mild cognitive impairment|Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
62107265|NCT05484024|EXPERIMENTAL|iTNT group|The intervention of iTNT group is Short-course radiotherapy followed by neoadjuvant chemotherapy and PD-1 inhibitor, which consists of a short-course radiotherapy(SCRT, 5 Gy x 5 alone), then after 14 days of radiotherapy completed, four cycles of PD-1 inhibitor and four cycles of CAPOX or six cycles of mFOLFOX will be performed. The regimen of PD-1 inhibitor and CAPOX treatment includes Sintilimab 200 mg IV, day 1，Oxaliplatin 130 mg/m2 IV day 1，Capecitabine 1000 mg/m2 twice daily PO for 14 days(3 weeks per cycle). The regimen of PD-1 inhibitor and mFOLFOX treatment includes Sintilimab 200 mg IV day 1(3 weeks per cycle), Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion(2 weeks per cycle), then followed by a total mesorectal excision(TME) or Watch \& Wait strategy for clinical complete remission voluntary patients.
62107266|NCT05484024|ACTIVE_COMPARATOR|TNT group|The intervention of TNT group is Short-course radiotherapy followed by neoadjuvant chemotherapy, which consists of a short-course radiotherapy(SCRT, 5 Gy x 5 alone), then after 14 days of radiotherapy completed, four cycles of CAPOX or six cycles of mFOLFOX will be performed. The regimen of CAPOX treatment includes Oxaliplatin 130 mg/m2 IV day 1，Capecitabine 1000 mg/m2 twice daily PO for 14 days(3 weeks per cycle). The regimen of mFOLFOX treatment includes, Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion(2 weeks per cycle), then followed by a total mesorectal excision(TME) or Watch \& Wait strategy for clinical complete remission voluntary patients.
62107267|NCT04791124||Typical Developing Subjects|EEG evaluation of typical developing subjects
62107268|NCT04791124||Down Syndrome Subjects|EEG evaluation of DS subjects
62298870|NCT03678974|EXPERIMENTAL|Exercise|Subjects will receive metabolic testing, exercise prescription, YMCA memberships, and physician based on Intensive Behavioral Therapy for Obesity utilizing CardioCoach app.
62298871|NCT01665638|EXPERIMENTAL|Treatment Sequence Group AB|
62298872|NCT01665638|EXPERIMENTAL|Treatment Sequence Group BA|
62298873|NCT00162773|PLACEBO_COMPARATOR|Placebo|water injection
62298874|NCT00162773|EXPERIMENTAL|Omalizumab|"Other Names:~Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE."
62298875|NCT03668756||Computer-Assisted Navigation TKA|the patients who were received CAS TKA in one limb
61913864|NCT02915874|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:~1. Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;~2. Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
61913865|NCT02915874|NO_INTERVENTION|Control|Subjects randomized to not receive treatment.
61913866|NCT03957460||continuous and noninvasive hemoglobin monitoring|Group receive the continuous and noninvasive hemoglobin monitoring during laparoscopic gastrectomy.
61913867|NCT03096041|EXPERIMENTAL|Experimental arm|Auriculotherapy for analgesic use
61913868|NCT03096041|PLACEBO_COMPARATOR|Controle arm|Placebo auriculotherapy
61913869|NCT01976988|ACTIVE_COMPARATOR|Post-op Heparin|Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder of the patients hospital course
62669051|NCT06150443|ACTIVE_COMPARATOR|Group 2 - OMT + Conservative Treatment|Will receive Osteopathic manipulative treatment in addition to conservative treatment. Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical and Occupational therapy will be excluded from the conservative therapy regimen. Osteopathic manipulative treatment will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. The cervical spine will also be treated, with particular attention to the C5-7 levels, all the way to the wrist and hand as the physician sees fit based on the findings of the osteopathic structural exam.
62107269|NCT03380975|EXPERIMENTAL|Montelukast 10 mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.
62107270|NCT06164249|EXPERIMENTAL|Nordic|Training regimens composed of nordic exercise
61913870|NCT01976988|EXPERIMENTAL|Pre-op Heparin|Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
62107271|NCT06164249|EXPERIMENTAL|Deadlift|Training regimens composed of deadlift exercise
62107272|NCT06164249|NO_INTERVENTION|Control|Training regimens composed of no exercise
62107273|NCT02923128|ACTIVE_COMPARATOR|Dexmedetomidine+routine PCIA|PCIA pump was provided after surgery, which consisted of 3 ug/kg sufentanil and 3 ug/kg dexmedetomidine, total amount 150ml, 2 mL bolus dose with a lock-out of 10 minutes and background infu-sion rate 2 mL/h.
62107274|NCT02923128|SHAM_COMPARATOR|Routine PCIA|3 ug/kg sufentanil without dexmedetomidine, total amount 150ml, 2 mL bolus dose with a lock-out of 10 minutes and background infu-sion rate 2 mL/h.
62107275|NCT02777879||Chronic Obstructive Pulmonary Disease (COPD)|Case of early COPD (GOLD 1-2, FEV1/FVC\<70 and FEV1\>50%)
62107276|NCT02777879||Control|No obstruction (FEV1/FVC\<70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).
62107277|NCT03677154|EXPERIMENTAL|Consolidation Therapy (Cohort A)|Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
62107278|NCT03677154|EXPERIMENTAL|Elderly/Unfit Previously Untreated Monotherapy (Cohort B)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
62107279|NCT03677154|EXPERIMENTAL|Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
61913871|NCT04942197|EXPERIMENTAL|Arm 1|Participants who received three dimensional ultrasound with pregnancy application
61913872|NCT04942197|PLACEBO_COMPARATOR|Arm 2|Participants who received three dimensional ultrasound without pregnancy management application
61913873|NCT03716570|EXPERIMENTAL|Cohort 1: BIIB054 Dose A|Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
61913874|NCT03716570|EXPERIMENTAL|Cohort 2: BIIB054 Dose B|Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
61913875|NCT03716570|EXPERIMENTAL|Cohort 3: BIIB054 Dose C|Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
62107280|NCT03608670|EXPERIMENTAL|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
62107281|NCT00651885|PLACEBO_COMPARATOR|2 arm|
62669052|NCT06150443|ACTIVE_COMPARATOR|Group 3 - Conservative Treatment Only|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical and Occupational therapy will be excluded from the conservative therapy regimen.
62107282|NCT00651885|EXPERIMENTAL|1 arm|treprostinil dienthalomine
62107283|NCT02903836|EXPERIMENTAL|Nafithromycin 800 mg 3 days|PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind
62107284|NCT02903836|EXPERIMENTAL|Nafithromycin 800 mg 5 days|PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind
62107285|NCT02903836|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind
62107286|NCT02888431||Arterial blood sample|0.5 mL blood sample from arterial line which is clinically indicated
62107287|NCT02888431||peripheral venous blood sample|0.5 mL blood sample drawn simultaneously with arterial sample from clinically indicated peripheral line
62107288|NCT06375356|EXPERIMENTAL|Shorter Resistance Training: Stronger Snacks|"Home-based strength training exercises would be broken up into shorter segments throughout the day or week (e.g. a snack might be 3 sets of body-weight or band-based squats)."
62107289|NCT06375356|EXPERIMENTAL|Single Session Resistance Training: Stronger Sessions|Home-based strength training exercises would be broken up into 3 weekly sessions throughout the week.
62107290|NCT03462199|PLACEBO_COMPARATOR|Placebo|
62669053|NCT02077647||Conservative|Conservative treatment of osteoarthritis of the knee
62669054|NCT02700256||Patients undergoing a procedure|Patients will be asked to complete a baseline survey after enrollment. After surgery, enrollees who opt for the email/online access will receive an email upon discharge with a link to the WebCore site. Email will be sent at 9 am on postoperative day (POD) 2 to the email address the patient provided at consent. On post-operative days 2 through 6 the patient will be asked to complete a symptom inventory, they will receive an email with a link to the WebCore website, where they will be able to complete that day's survey. Enrollees who opt for the automated phone calls will complete their surveys via Interactive Voice Response (IVR), which will be automatically set-up to call the patient at 9 am on POD 2. Patients will complete phone surveys daily for 5 days. If the first phone call does not connect to the patient, a second phone call will be made at 10:00am. If the second call is unsuccessful a third \& final call for that day will be placed at 11:00am.
62669055|NCT06156267|EXPERIMENTAL|Part A: Dose Escalation, Part B: Dose Expansion|
62669056|NCT03712852|ACTIVE_COMPARATOR|PRF+CAF treated patients|The clot collected from the blood samples is pressed through a calibrated compression system into the PRF box the folded membrane is measured and adjusted to 1,5 mm, then transferred on a sterile gauze. A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the PRFs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
62669057|NCT03712852|ACTIVE_COMPARATOR|SCTG+ CAF treated patients|SCTG is taken from the opposite palate area of gingival defect. The graft is collected with a single incision technique and it is measured and adjusted to 1,5 mm by measuring with a standard caliper.A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the SCTGs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
62669058|NCT03712852|ACTIVE_COMPARATOR|CAF treated patients|A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the flap is sutured over the enamel in a tension free position.
62669059|NCT03331562|ACTIVE_COMPARATOR|pembrolizumab & paricalcitol|pembrolizumab 200 mg IV q 3 weeks and paricalcitol 25 mcg IV 3 xs per week
62669060|NCT03331562|PLACEBO_COMPARATOR|pembrolizumab & placebo|pembrolizumab 200 mg IV q 3 weeks \& placebo- normal saline IV 3 xs per week
62669061|NCT03522168||Risperidone group|Risperidone, n=350, including 30 children 3 - \<6 years old and 320 children 6 - \<18 years old. \~50% - \~80% of the entire group will have \<90 days of prior treatment with any antipsychotic.
62669062|NCT03522168||Aripiprazole group|Aripiprazole group, n=350, including 30 children 3 - \<6 years old and 320 children 6 - \<18 years old. \~50% - \~80% of the entire group will have ≤90 days of prior treatment with any antipsychotic.
62669063|NCT04126668|EXPERIMENTAL|Period 1: fasted control → Period 2: fed control|Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast
62107291|NCT03462199|EXPERIMENTAL|Actazin High Dose|
62107292|NCT03462199|EXPERIMENTAL|Actazin Low Dose|
62107293|NCT03462199|ACTIVE_COMPARATOR|Control Formula|
62298876|NCT03668756||Conventional TKA|the patients who were received conventional TKA in one limb
62298877|NCT05819229||Oral antibiotic therapy|Clinically stable (see eligibility criteria) children without any past high-risk medical history (see eligibility criteria) will initiate oral antibiotic therapy.
62298878|NCT03677570||Female athletes|A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
62107294|NCT03462199|EXPERIMENTAL|Livaux High Dose|
62107295|NCT03462199|EXPERIMENTAL|Livaux Low Dose|
62107296|NCT00728637|EXPERIMENTAL|1|Participants took part in the Family Passport to Heart Health Program.
62107297|NCT00728637|ACTIVE_COMPARATOR|2|Participants took part in a control group.
62107298|NCT02490982||Teriflunomide|Patient-reported outcomes and clinical assessment
62107299|NCT03404336|EXPERIMENTAL|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
62669064|NCT04126668|EXPERIMENTAL|Period 1: fed control → Period 2: fasted control|Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast
61913876|NCT03716570|PLACEBO_COMPARATOR|Cohorts 1-3: Placebo|Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
62469654|NCT01549080||research|biological research on the effects of yisuishengxuegranule
62669065|NCT05937282|PLACEBO_COMPARATOR|Control group|Patients will receive infusion of 25 ml normal saline in 50 ml syringe pump.
62669066|NCT05937282|ACTIVE_COMPARATOR|Dexmedetomidine group|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
62669067|NCT05937282|ACTIVE_COMPARATOR|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. (12) 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump
61913877|NCT03821844|EXPERIMENTAL|Music and Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
61913878|NCT03821844|NO_INTERVENTION|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
61913879|NCT04575597|EXPERIMENTAL|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
61913880|NCT04575597|EXPERIMENTAL|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
61913881|NCT04575597|EXPERIMENTAL|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
61913882|NCT04575597|PLACEBO_COMPARATOR|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
61913883|NCT04575597|EXPERIMENTAL|Part 2: Molnupiravir 800 mg|800 mg Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
61913884|NCT04575597|PLACEBO_COMPARATOR|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
61913885|NCT05251129|EXPERIMENTAL|Higher Intensity Statin|Atorvastatin 80 mg daily
61913886|NCT05251129|ACTIVE_COMPARATOR|Lower Intensity Statin|Pravastatin 40 mg daily
62107300|NCT03404336|PLACEBO_COMPARATOR|Control condition|The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.
62107301|NCT01398930|ACTIVE_COMPARATOR|Group I was treated with etoricoxib|
62107302|NCT01398930|ACTIVE_COMPARATOR|Group II was treated with acupuncture and etoricoxib|
62107303|NCT01398930|SHAM_COMPARATOR|Group III was treated with sham acupuncture and etoricoxib.|
62107304|NCT05761509||Single arm|"200 subjects exposed to HIV, leading to prescription of 28-day doravirine based post exposure prophylaxis (PEP).~The study referred to treatments that are using routinely in the medical care of subjects under PEP. These treatments are the following:~* Delstrigo®: Fixed-dose combination containing 100mg of doravirine, 245 mg of tenofovir disoproxil and 300 mg of lamivudine, one tablet to be taken orally once daily, with or without food.~* Pifeltro®: doravirine dosed at 100 mg, on tablet to be taken orally once daily, with or without food, in combination with tenofovir disoproxil/emtricitabine."
62107305|NCT02414919||HERC|Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
62107306|NCT06494124|EXPERIMENTAL|tACS group|10 Hz 2 mA peak-to-peak stimulation will be for 20 minutes, at zero-degree phase difference and zero offset current
62107307|NCT06494124|ACTIVE_COMPARATOR|tDCS group|tDCS stimulation: 2 mA stimulation will be applied for 20 minutes
62107308|NCT06494124|SHAM_COMPARATOR|sham controlled group|1mA current will be applied for the first 30 seconds, to provide the initial sensation of real stimulation and then the current will be stopped, thus minimizing the stimulatory effects
62469655|NCT01549080||clinical research|clinical research on thalassemia
62469656|NCT05707962|EXPERIMENTAL|intervention group|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
62669068|NCT05937282|ACTIVE_COMPARATOR|Lidocaine|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr. (15) 25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
62107309|NCT06514105|ACTIVE_COMPARATOR|High intensity laser group|In addition to the physiotherapy program, high intensity laser application will be applied to the high intensity laser group.
62669069|NCT03246854|EXPERIMENTAL|DBPR112|
62669070|NCT05895500||Tablet|Tablets (50mg/tablet), oral
62669071|NCT05895500||Injection|Injection for SC administration (120mg/syringe)
62669072|NCT00676052|EXPERIMENTAL|Arm 1|GSK233705 12.5mcg
62669073|NCT00676052|EXPERIMENTAL|Arm 2|GSK233705 25mcg
62669074|NCT00676052|EXPERIMENTAL|Arm 3|GSK233705 50mcg
62669075|NCT00676052|EXPERIMENTAL|Arm 4|GSK233705 100mcg
61913887|NCT00782587|EXPERIMENTAL|Arm 1|Single arm, open label, single dose, intravesical instillation of Chemophase (combination of rHuPH20 and mitomycin) for appropriate superficial bladder cancer patients within 6 hours of TURBT.
61913888|NCT00105365|PLACEBO_COMPARATOR|walking shoes|walking shoes
61913889|NCT00105365|EXPERIMENTAL|walking shoes + shoe insert|walking shoes + shoe insert
61913890|NCT01325792||GORE® BIO-A® Tissue Reinforcement|Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
62669076|NCT00676052|EXPERIMENTAL|Arm 5|GSK233705 200mcg
62107310|NCT06514105|ACTIVE_COMPARATOR|Control group|In addition to the physiotherapy program, sham high intensity laser application will be applied to the control group.
62298879|NCT03677570||Healthy Control|15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
62298880|NCT04697225|EXPERIMENTAL|weight loss program|
61913891|NCT04661098|EXPERIMENTAL|Postpubertal patients with imperforate hymen|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
61913892|NCT03357939|EXPERIMENTAL|HLX03|There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
61913893|NCT03357939|ACTIVE_COMPARATOR|Humira|There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.
61913894|NCT02772198|EXPERIMENTAL|Single Arm|All patients will be treated on this single arm
61913895|NCT05461573|EXPERIMENTAL|Part A - An investigation of the efficacy, safety, and tolerability of LPRI-CF113|All subjects enrolled in the study will participate in Part A of the study. Part A of the study will investigate the efficacy, safety, and tolerability of LPRI-CF113.
61913896|NCT05461573|EXPERIMENTAL|Part B - The effect of LPRI-CF113 on bone mineral density in a subgroup age 18-45|A subgroup of subjects from Part A that are age 18-45 and without further exclusion criteria to Part B will be enrolled in Part B of the study. Part B of the study will investigate the effects of LPRI-CF113 on bone mineral density.
61913897|NCT02879396|EXPERIMENTAL|Study Participants|A maximum of 50 participants will be enrolled in the study per the inclusion and exclusion criteria. The participants will be residents of SLH who are 55 years old or older. They will have had one or more EMS calls made, ED visit or hospital admission in the past year, as determined by the incidence report at SLH. The study participants will receive PA4LE program.
61913898|NCT00716833|ACTIVE_COMPARATOR|Preemptive|Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
62107311|NCT02580812|EXPERIMENTAL|MONALISA 5-years old children|Clinical and neuropsychological evaluation procedure 90 children
62298881|NCT03947229|ACTIVE_COMPARATOR|Clopidogrel mono-therapy|After randomization, patients will receive clopidogrel monotherapy after DES implantation for 24 months.
62298882|NCT03947229|ACTIVE_COMPARATOR|Dual-antiplatelet therapy|Patients will receive dual antiplatelet consisting of aspirin and clopidogrel.
62298883|NCT06201143|EXPERIMENTAL|BREATHING EXERCISE AND MOBILIZATION TRAINING GROUP|"Breathing exercise and mobilization training will be given in the patient\&#39;s room during the preoperative period. Each training is planned to last approximately 20 minutes. Respiratory and mobilization training for patients during training techniques will be taught in practice, they will be shown how to mark the breathing exercise and mobilization tracking chart, and their questions will be answered.~Individuals in this group will be given breathing exercise and mobilization training. VAS form will be filled in at the 10th, 24th, 48th and 72nd hours of postpartum. The patient\&#39;s total mobilization time and the number of breathing exercises will be recorded. The postpartum comfort scale will be filled in at the 10th and 72nd hours."
62669077|NCT00676052|PLACEBO_COMPARATOR|Arm 6|Placebo
62669078|NCT04048083|EXPERIMENTAL|Patients-MT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training (MT) of reaching to grasp movements
61913899|NCT00716833|PLACEBO_COMPARATOR|Postoperative|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.
61913900|NCT00880464|EXPERIMENTAL|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
61913901|NCT01699971|ACTIVE_COMPARATOR|Lichtenstein|Hernia repair with lichtenstein propylene mesh
61913902|NCT06129357||Diagnosis of gingivitis|60
62107312|NCT02580812|ACTIVE_COMPARATOR|EPIPAGE 5 -years old children|Cohort of prematurely borne children and their controls Clinical and neuropsychological evaluation procedure 270 children
62107313|NCT02620072|EXPERIMENTAL|oral insulin capsule (dose escalation using 2 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 67.5 mg rH-insulin crystals. Insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) contained in hard gelatine capsules given orally.
62669079|NCT04048083|EXPERIMENTAL|Patients-CAT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in computer-aided training (CAT) of reaching to grasp movements using virtual environment with visual-feedback.
62298884|NCT06201143|EXPERIMENTAL|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING GROUP|Participants in this group will be given kinesiology taping, breathing exercise and mobilization training. Kinesiological taping will be done at the 10th hour postoperatively. The VAS form will be filled out at the 10th, 24th, 48th and 72nd postoperative hour. The patient\&#39;s total mobilization time and the number of breathing exercises will be recorded. The postpartum comfort scale will be filled in at the 10th and 72nd hours.
62298885|NCT06201143|NO_INTERVENTION|CONTROL GROUP|No intervention will be made to individuals participating in this group. The VAS form will be filled out at the 10th, 24th, 48th and 72nd postoperative hour. The patient\&#39;s total mobilization time and the number of breathing exercises will be recorded. The postpartum comfort scale will be filled in at the 10th and 72nd hours.
62669080|NCT04048083|EXPERIMENTAL|Patients-CAMT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training of reaching to grasp movements supplemented by virtual environment (patients that received both types of training).
61913903|NCT06129357||Diagnosed as periodontal healthys|60
62107314|NCT02620072|PLACEBO_COMPARATOR|Placebo capsule|Daily administration of placebo capsules containing filling substance (microcrystalline cellulose).
62669081|NCT04048083|ACTIVE_COMPARATOR|Healthy-controls|9 Healthy, age and gender-matched subjects, without any kind of training
62669082|NCT04501575|EXPERIMENTAL|Osteopathic consultation|It consists of 1 session. Each osteopathic session is based on a structural evaluation and treatment tailored to the participant-specific complains
62107315|NCT04550416|EXPERIMENTAL|ProMark Information and Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
62298886|NCT04725656|ACTIVE_COMPARATOR|Active arm, low concentration (18 mg/mL) nicotine salt e-liquids|
62298887|NCT04725656|ACTIVE_COMPARATOR|Active arm, high concentration (59 mg/mL) nicotine salt e-liquids|
62669083|NCT04501575|SHAM_COMPARATOR|Osteopathic sham consultation|Osteopathic Sham treatment was applied using manual contact on specific bony surfaces using very light pressure. The practitioner was counting the seconds up to 1 minute between the areas where to apply the light touch without any intention to treat or diagnose.
62669084|NCT04501575|NO_INTERVENTION|Usual Care|Participants will be on a waiting list, and meanwhile, they are advised to deal with their pain in the way they would, but without using any sort of Manual Therapy.
62669085|NCT02958527||venlafaxine|Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first
61913904|NCT06129357||Diagnosis of periodontitis|60
61913905|NCT01858818||healthy 18 year old males|
61913906|NCT06029517|OTHER|Aim 1 - interview, focus group|Participants complete interviews over 60 minutes and attend focus groups over 90 minutes in support of intervention adaptation and refinement
61913907|NCT06029517|EXPERIMENTAL|Aim 2 - Indigenous SIPin|Participants receive the Indigenous SIPin intervention over 6 months, which includes in-person and/or virtual educational sessions weekly over 30 minutes for 12 weeks and text message communications BIW for 12 weeks and then monthly thereafter up to month 6.
61913908|NCT01109056|EXPERIMENTAL|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
61913909|NCT01109056|PLACEBO_COMPARATOR|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
61913910|NCT04905498|PLACEBO_COMPARATOR|Control|Children were exposed to food commercials without narratives.
61913911|NCT04905498|EXPERIMENTAL|Intervention|Children were exposed to narrative statements that were shown and read aloud in between commercials played.
61913912|NCT04098055|EXPERIMENTAL|Custom-made foot orthoses|
61913913|NCT04098055|PLACEBO_COMPARATOR|Control Group|
61913914|NCT02312687|EXPERIMENTAL|KRN23|KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.
61913915|NCT06409832||Episodic migraine|Patients affected by an episodic pattern migraine(\< 15 monthly headache days) with or without aura according to ICHD-III criteria.
61913916|NCT06409832||Chronic migraine|Patients affected by chronic migraine (\> 15 monthly headache days with at least 8 days with migraine features) according to ICHD-III criteria.
61913917|NCT04957433||Cohort A|Patients new to The Lung Health Check (TLHC) pilot who are attending their first lung health check
61913918|NCT04957433||Cohort B (Nodule Suveillance)|Patients who have already undergone one lung health check as part of the TLHC programme, and are now being followed up at 3 months (B1), 12 months (B2) or other (BX) due to an indeterminate finding (e.g. lung nodule)
61913919|NCT04957433||Cohort C (Incident Scan)|Patients who are already part of TLHC attending for routine 'incident' round follow-up scanning (usually at approximately 24 months)
61913920|NCT04957433||Cohort D|Participants with interstitial lung abnormalities (ILAs) identified as part of TLHC, who are referred to the interstitial lung disease (ILD) unit at Royal Brompton Hospital.
62107316|NCT04550416|NO_INTERVENTION|Standard Practice|Physicians will care for online virtual patients as they normally would in practice.
62669086|NCT05194488|EXPERIMENTAL|Low level laser therapy|
61913921|NCT02262182|EXPERIMENTAL|KP group|PEP delivery by EzPAP® device with manual chest physiotherapy .
62107317|NCT06629051||berberine|post-intervention of berberine
62669087|NCT05194488|EXPERIMENTAL|Botulinum toxin type A|
62669088|NCT05194488|ACTIVE_COMPARATOR|Anterior repositioning appliance|
62669089|NCT03968627||Protocol application|The study describes the method and the criteria used in the development of the protocol, the steps followed in its implementation in two Don Gnocchi Foundation Pilot Hospitals
62669090|NCT00727337|EXPERIMENTAL|LACE-DVD|Participants will complete the LACE training, however, not in an interactive computer mode but through a static DVD mode
62669091|NCT00727337|EXPERIMENTAL|LACE-COMPUTER|Participants will complete a computer-based auditory training program (i.e., LACE)
62669092|NCT00727337|ACTIVE_COMPARATOR|PLACEBO-DIRECTED LISTENING|Participants will complete a directed listening to books on CD treatment
62669093|NCT00727337|ACTIVE_COMPARATOR|CONTROL|Participants will be provided with hearing aids
62669094|NCT02588755|ACTIVE_COMPARATOR|TACE+ Tegafur|Patients will be treated with Tegafur after resection soon, and TACE in 4 or 8 weeks after resection.
62669095|NCT02588755|EXPERIMENTAL|TACE|Patients will be treated with TACE alone in 4 or 8 weeks after resection.
62669096|NCT00309244|EXPERIMENTAL|TI + Insulin glargine|Technosphere® Insulin Inhalation Powder + insulin glargine
62669097|NCT00309244|ACTIVE_COMPARATOR|BPR 70/30|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
61913922|NCT02262182|PLACEBO_COMPARATOR|KM group|Manual chest physiotherapy only;
61913923|NCT03935113|EXPERIMENTAL|KT group|The paretic upper limb is a common consequence of stroke that increases activity limitation.
61913924|NCT03243708|NO_INTERVENTION|Usual Care|Control: Standard order set without risk calculator (usual care)
61913925|NCT03243708|ACTIVE_COMPARATOR|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
61913926|NCT06173310|EXPERIMENTAL|borderline-resectable pancreatic cancer (BRPC)|
62669098|NCT02127515|EXPERIMENTAL|Non Invasive Prenatal Testing|Blood sample
62669099|NCT02127515|ACTIVE_COMPARATOR|Invasive Prenatal Testing|CVS or amniocentesis
62669100|NCT06500728||GCA patients|Patients older than 18 years with clinically suspected or confirmed giant cell arteritis, who experience newly diagnosed visual impairment with suspected or confirmed correlation with vasculitis.
61913927|NCT05606003|EXPERIMENTAL|Multi-level Multi-Component Intervention (MLI)|Individuals receive COVID-19 CHW-delivered education and navigation, 2-1-1 helpline referrals, and social marketing messaging.
61913928|NCT05606003|EXPERIMENTAL|Community Just-in-Time-Adaptive Intervention (JITAI)|Individuals receive MLI intervention components that are informed by real-time data and community stakeholder feedback.
62107318|NCT06629051||placebo|post-intervention of placebo tablets
62107319|NCT02759029|ACTIVE_COMPARATOR|Susceptibility-guided group|Drugs according to antimicrobial susceptibility-guided treatment
62107320|NCT02759029|SHAM_COMPARATOR|triple therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
62107321|NCT02759029|SHAM_COMPARATOR|concomitant therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
62107322|NCT03521323|EXPERIMENTAL|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
62107323|NCT03521323|PLACEBO_COMPARATOR|Control|Sham operation and 10ml saline as placebos, once a month for 4 months
62107324|NCT03997006|ACTIVE_COMPARATOR|Group A (n=30)|Aminophylline group
62107325|NCT03997006|ACTIVE_COMPARATOR|Group NA (n=30)|Neostigmine/Atropine group
62107326|NCT05949203||All participants|All participants will receive standard-of-care through the tele-PrEP program and home infusion pharmacy.
62669101|NCT06500728||Non arteritis patients|Patients over 18 years of age who experience newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology.
62669102|NCT05539508||Primary open-angle glaucoma (POAG) group|
62669103|NCT05539508||Age-matched normally sighted control group|
62669104|NCT02971189|OTHER|Librata endometrial ablation|Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
62669105|NCT01945242||Alogilptin 25mg, tablets, orally, once daily, up to 12 months|
61913929|NCT05606003|NO_INTERVENTION|Comparison Condition|Individuals receive standard exposure to ongoing city and county COVID-19 communication and testing.
62669106|NCT03745469||Young-age group|Patient between the age of 18 and 30 years old, with a confirmed diagnosis of chronic mechanical neck pain
62669107|NCT03745469||Middle-age group|Patients between 30 and 60 years old, with a confirmed diagnosis of chronic mechanical neck pain.
62107327|NCT06526949|EXPERIMENTAL|Intervention group|Reiki application will be applied to the patients for 2 consecutive days or 2 times (1st and 3rd day) for 30 minutes every other day. Pain, anxiety and haemodynamic parameters will be recorded on data collection forms before and at the end of the application. The duration of intubation, intensive care unit stay and haemodynamic stability of the patients will be limited due to the rapid changes.
62107328|NCT06526949|PLACEBO_COMPARATOR|Placebo Control Group:|In the sham (Sham Reiki) group, sham practitioners (not involved in the study) who have no experience in energy work will prepare screens and headphones for the patients as in the intervention group. Then, they will place their hands gently on or above the patient's head and eyes, upper body from the neck to the pelvic region, arms and legs (standard reiki hand positions) for 30 minutes every other day for 2 days in a row or 2 times (Day 1 and Day 3) like the practitioner in the intervention group. Patient data will be recorded on forms before and after placebo administration as in the intervention group.
62669108|NCT02410876||Controls|No lower urinary tract symptoms undergoing cystoscopy in anesthesia for stone treatment or microhematuria assessment.
61913930|NCT05256706|EXPERIMENTAL|SomaSignal Informed Medical Management SSCVD|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will be sent to the providers and participants approximately 2-4 weeks after testing.
61913931|NCT05256706|ACTIVE_COMPARATOR|Standard of Care (Uninformed Arm)|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will not be provided to the provider or participant until the 6-month visit.
61913932|NCT01031420|EXPERIMENTAL|dose dense MVAC|standard doses of MVAC given every 14 days x 3.
61913933|NCT02402738|EXPERIMENTAL|Interpersonal and Social Rhythm Therapy|Participants may be randomized to receive up to 20 outpatient sessions of Interpersonal and Social Rhythm Therapy, provided as an adjunct to community treatment as usual. Intervention sessions begin during pregnancy and continue through 8 weeks postpartum.
62107329|NCT04596579||Participants age 18-34|Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.
62107330|NCT04596579||Participants age 35-54|Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
62298888|NCT04725656|OTHER|Control group|Receive only smoking cessation counseling
62298889|NCT02354950|EXPERIMENTAL|Part 1 Cohort 1 (Moderate hepatic impairment subjects)|Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
62669109|NCT02410876||Spinal cord injury/acontractile|"Patients with traumatic spinal cord injury (SCI) with no (neither spontaneous nor provoked) detrusor activity during the filling phase of urodynamics.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
61913934|NCT02402738|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a monthly standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
62107331|NCT04596579||Participants age 55-64|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
61913935|NCT04057989||Battlefield Injury with ketamine treatment|Patients who received ketamine infusions to treat pain from January 2007 to December 2013.
61913936|NCT00126880|EXPERIMENTAL|600mg BID ATC|600mg BID ATC
62107332|NCT04596579||Participants 65 and over|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
62298890|NCT02354950|EXPERIMENTAL|Part 1 Cohort 2 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
62298891|NCT02354950|EXPERIMENTAL|Part 2 Cohort 3 (Mild hepatic impairment subjects)|Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
62298892|NCT02354950|EXPERIMENTAL|Part 2 Cohort 4 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
61913937|NCT00126880|EXPERIMENTAL|800mg BID ATC|800mg BID ATC
62107333|NCT03079882||Living Donor Recipients|Recipients of renal transplants with the transplanted organ originating from living donors
62298893|NCT06061445|EXPERIMENTAL|treatment group|Radiotherapy Combined with TKI and Anti-PD-1 Antibody
62298894|NCT06037876|EXPERIMENTAL|IVM (200 µg/kg) + ALB (400 mg)|A single tablet of albendazole (400mg) plus 200 µg/kg of ivermectin, provided as single oral dose.
62669110|NCT02410876||Spinal cord injury/Detrusor overactivity|"SCI patients with proven detrusor (urodynamics) overactivity during the filling phase.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
62669111|NCT02410876||Prostatic obstruction/acontractile|"Low flow to no flow, no measurable detrusor activity on urodynamic evaluation, cystoscopy in line with obstruction.~Bladder biopsy at TURP (transurethral resection prostate) 3 months later urodynamic study and bladder biopsy"
62669112|NCT02410876||Prostatic obstruction/ obstructed|Obstruction according to Schäfer nomogram on urodynamic evaluation. Bladder biopsy at TURP 3 months later urodynamic study and bladder biopsy
62669113|NCT06251427|PLACEBO_COMPARATOR|Low dose multiple micronutrient fortification|Maize, milk plus low multiple micronutrient fortification
62669114|NCT06251427|ACTIVE_COMPARATOR|Moderate dose multiple micronutrient fortification|Maize, milk plus moderate multiple micronutrient fortification
62669115|NCT06251427|ACTIVE_COMPARATOR|High dose multiple micronutrient fortification|Maize, milk plus high multiple micronutrient fortification (double the moderate level)
62669116|NCT06459973|EXPERIMENTAL|Phase Ia: Dose escalation portion|YL205 is provided as the lyophilized powder, 160 mg/vial. Adcanced solid tumors patients will be given YL205 by intravenously once every 3 weeks (Q3W) as a cycle at several dose levels.
62669117|NCT06459973|EXPERIMENTAL|Phase Ib: Dose expansion portion|YL205 is provided as the lyophilized powder, 160 mg/vial. Adcanced solid tumors patients will be given YL205 by intravenously once every 3 weeks (Q3W) as a cycle at no less than two dose levels.
62669118|NCT06459973|EXPERIMENTAL|Phase II: Cohort expansion portion|YL205 is provided as the lyophilized powder, 160 mg/vial. Adcanced solid tumors patients will be given YL205 by intravenously once every 3 weeks (Q3W) as a cycle at RP2D.
62669119|NCT02242110|EXPERIMENTAL|Nightmare Treatment|The nightmare treatment, Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder (ERRT-Bipolar Disorder), is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
62669120|NCT02345577|ACTIVE_COMPARATOR|Physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
62669121|NCT02345577|SHAM_COMPARATOR|Sham physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.
62669122|NCT05299450|EXPERIMENTAL|Exercise intervention|12 week personalised exercise intervention with personal trainer and gym membership, fitbit
62669123|NCT05299450|EXPERIMENTAL|Beetroot juice|12 weeks daily Beet It (beetroot shots) containing nitrate, fitbit
62669124|NCT05299450|EXPERIMENTAL|Exercise and Beetroot|12 week personalised exercise intervention with personal trainer and gym membership and daily Beet It (beetroot shots) containing nitrate, fitbit
62669125|NCT05299450|ACTIVE_COMPARATOR|Control group|No intervention, fitbit
61913938|NCT00126880|ACTIVE_COMPARATOR|150mg BID 3TC|150mg BID 3TC
61913939|NCT03056599|EXPERIMENTAL|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
62298895|NCT06037876|ACTIVE_COMPARATOR|ALB (400mg)|A single tablet of albendazole (400mg), provided as single oral dose.
62298896|NCT04435340|OTHER|Retrospective|All patients in the retrospective cohort are contacted at least 1 year after surgery and/or 3 years after surgery via phone call or letter, informed about the study and asked to participate. In case of informed consent, they are invited to the study site. They are asked to complete the questionnaires and they undergo a Sonography of the ventral abdomen.
61913940|NCT00268580|EXPERIMENTAL|Intervention|Asthma care provided using care pathway
61913941|NCT00268580|NO_INTERVENTION|Control|Standard of care provided
61913942|NCT01894412|EXPERIMENTAL|HD 203|prefilled syringe
61913943|NCT01894412|ACTIVE_COMPARATOR|Enbrel|prefilled syringe
62107334|NCT03079882||Deceased Donor Recipients|Recipients of renal transplants with the transplanted organ originating from deceased donors
62669126|NCT05858229|EXPERIMENTAL|Treatment|Patients will receive RP1 via direct intratumoral (IT) injection into superficial cutaneous solid tumors to assess the safety and tolerability as well efficacy of RP1 treatment. The primary efficacy population is up to 12 evaluable patients with resectable CSCC.
62669127|NCT04411407|OTHER|Group WT|PROM registration via the DANBIO WebApp and thereafter the outpatient touchscreen
62669128|NCT04411407|OTHER|Group TW|PROM registration via the outpatient touchscreen and thereafter the DANBIO WebApp
61913944|NCT05767476||Newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia|
61913945|NCT04555967||Transcatheter aortic valve implantation|
61913946|NCT05519995||Sensate II Users|Users will be adults (18+ years of age) who have been using the Sensate II device for stress management for a minimum of 30-days or 1-month
61913947|NCT05143710||PRES in PE or E|patients diagnosed with PRES in PE or E
61913948|NCT01262352|EXPERIMENTAL|Treatment Sequence 1|Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2.
61913949|NCT01262352|EXPERIMENTAL|Treatment Sequence 2|Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2.
61913950|NCT02603796||Newborns requiring ncpap|3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks.
61913951|NCT05504876|EXPERIMENTAL|Midazolam Syrup HEC74647PA HEC110114|Subjects will receive 5mg Midazolam Syrup on Day 1,100 mg HEC74647PA and 600 mg HEC110114 on Day3\~8, 5mg Midazolam Syrup co-administered with 100 mg HEC74647PA and 600 mg HEC110114 on Day9.
62107335|NCT04966572|EXPERIMENTAL|Presurgical vacuum formed nasoalveolar molding aligners group|In this group, all patients will receive 1-2 VF-NAM aligners incorporated with palatal screw in addition to taping from day 1 for 4-6 Months with follow-up every 3 weeks
62669129|NCT06177353||EBDR patients|
62669130|NCT06177353||Healthy control|
62669131|NCT00541775|EXPERIMENTAL|Sitagliptin|sitagliptin 100 mg
62669132|NCT00541775|ACTIVE_COMPARATOR|Rosiglitazone|rosiglitazone 8 mg
62669133|NCT00541775|PLACEBO_COMPARATOR|Placebo|placebo
62669134|NCT05756478|OTHER|Medication Review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria) .
62669135|NCT05315258|EXPERIMENTAL|Cutaneous melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
62107336|NCT04966572|EXPERIMENTAL|conventional Grayson acrylic formed nasoalveolar molding appliances group|This group will receive conventional Grayson acrylic formed nasoalveolar molding appliances without taping except some cases, with follow up every week for activation.
61913952|NCT00998062||1|Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
61913953|NCT05268627|ACTIVE_COMPARATOR|Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections|
62107337|NCT01809808||Acromegaly Subjects|People who have a biochemical diagnosis of acromegaly, and will or have already undergone surgery for acromegaly and will be taking medications for acromegaly . Subjects will undergo blood sampling, metabolic rate measurement, adipose tissue biopsy and total body magnetic resonance imaging before and over time after either surgery or medical therapy for acromegaly.
62669136|NCT05315258|EXPERIMENTAL|Uveal melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
62669137|NCT00837447|ACTIVE_COMPARATOR|NexGen CR knee prosthesis|side of knee operated with total knee replacement with Nexgen CR prosthesis
62669138|NCT00837447|ACTIVE_COMPARATOR|NexGen CR-Flex knee prosthesis|side of knee operated with total knee arthroplasty using Nexgen CR-flex prosthesis
62669139|NCT00448357|EXPERIMENTAL|GVHD prophylaxis|"Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine .~Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus."
62669140|NCT01051167|EXPERIMENTAL|Cetuximab + Folfox-6-regime|"Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h."
62669141|NCT03478995|EXPERIMENTAL|GX-I7|Determined dose of GX-I7 on Day1 of each cycle
62669142|NCT05582603|EXPERIMENTAL|Computerized Cognitive Training|Individuals enrolled in Phase I and II will complete a Computerized Cognitive Training (CCT) based on an intervention with 15 different cognitive tasks in the form of games aimed at enhancing memory, attention, reasoning, perception and coordination skills. The CCT will be implemented in an app designed by CogniFit (CogniFit Inc., San Francisco, USA) to be used in tablets or mobile phones.
62107338|NCT01809808||Healthy Subjects|People who are not diagnosed with acromegaly, responding to flyer or by word of mouth for participation, without medical problems, not taking medications, and with a stable weight for 3 months prior to study. Subjects will undergo blood sampling, total body MRI and adipose tissue biopsy once.
62107339|NCT04037735|EXPERIMENTAL|ATTUNE|Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
62107340|NCT04037735|ACTIVE_COMPARATOR|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
62107341|NCT06328946|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding+Basic treatment|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure."
62669143|NCT04599257|EXPERIMENTAL|Hip and thigh circumference changes|"The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits. All of the study subjects will receive the treatment with the subject device.~At the baseline visit, MRI imaging will be performed; the subject's weight and hip and thigh circumference will be recorded. Photos of the treated area will be taken.~The treatment administration phase will consist of four (4) treatments, delivered once a week. The applicator of the device will be applied over the treatment area. The device will induce visible muscle contractions along with heating of the subcutaneous fat.~At the last therapy visit, the subject's weight and hip and thigh circumference will be recorded, and photos of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire to fill in."
62669144|NCT05009550|ACTIVE_COMPARATOR|Erector spinae plane block group (ESP)|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group. Then standard sedation method is applied to all patients.
62669145|NCT05009550|OTHER|Control Group|This Group was received no intervention.Standard sedation method is applied to all patients.
62107342|NCT06328946|ACTIVE_COMPARATOR|Nasogastric Tube Feeding+Basic treatment|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding."
62669146|NCT04286958|EXPERIMENTAL|Camrelizumab|All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.
62669147|NCT02507999|EXPERIMENTAL|Goal Directed Therapy - Flotrac Use Arm|This arm will employ the use of the Flotrac device to monitor cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure management.
61913954|NCT05268627|ACTIVE_COMPARATOR|liraglutide|
61913955|NCT04998136|EXPERIMENTAL|Semaglutide 2.4 mg|
61913956|NCT04998136|PLACEBO_COMPARATOR|Placebo|
61913957|NCT05047445|EXPERIMENTAL|COVIDITY administered via needle-free intradermal injection (PharmaJet Tropis)|
61913958|NCT05047445|EXPERIMENTAL|COVIDITY administered via needle-free intramuscular injection (PharmaJet Stratis)|
61913959|NCT04382820||Families of rare chronically ill children|Clinical study participants for the diagnostic study are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf due to a rare pediatric surgical disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
62669148|NCT02507999|NO_INTERVENTION|Non-Goal Directed Therapy|In this arm, patients will have the Flotrac machine attached to their arterial catheter but the screen that displays the monitor readings will be covered and machine alarms will be turned off. The anesthesiologist will not be aware of the Flotrac monitor readings.
62669149|NCT01851304|PLACEBO_COMPARATOR|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
62107343|NCT03278288|EXPERIMENTAL|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
62107344|NCT03278288|NO_INTERVENTION|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
62107345|NCT06567743|EXPERIMENTAL|Experimental: Cohort A, Arm 1|Cretostimogene (1 x 1012 vp) and DDM (0.1%) will be administered intravesically via the current instillation method
62107346|NCT06567743|EXPERIMENTAL|Experimental: Cohort A, Arm 2|Cretostimogene (1 x 1012 vp) and DDM (0.1%) will be administered intravesically via an alternative instillation method.
62107347|NCT00973141|EXPERIMENTAL|JNJ-42160443 1mg every 4 weeks|
62669150|NCT01851304|EXPERIMENTAL|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
62669151|NCT01851304|EXPERIMENTAL|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
62669152|NCT01851304|EXPERIMENTAL|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
62669153|NCT01851304|PLACEBO_COMPARATOR|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
62107348|NCT00973141|EXPERIMENTAL|JNJ-42160443 3mg every 4 weeks|
62107349|NCT00973141|EXPERIMENTAL|JNJ-42160443 3mg every 8 weeks|
62107350|NCT00973141|EXPERIMENTAL|JNJ-42160443 6mg every 8 weeks|
62669154|NCT01851304|EXPERIMENTAL|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
62669155|NCT01851304|EXPERIMENTAL|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
62669156|NCT00663351|ACTIVE_COMPARATOR|Reflection Ceramic-Ceramic Hip System (IP)|Investigational: Reflection Ceramic-Ceramic Hip System. Ceramic femoral head component and the ceramic acetabular cup insert are composed of Biolox forte aluminum oxide material.
62669157|NCT00663351|ACTIVE_COMPARATOR|Reflection FSO V (5 hole) (Control)|Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
62669158|NCT04374552|EXPERIMENTAL|Hydroxychloroquine & Azithromycin|Hydroxychloroquine sulfate 400 mg po BID for day one and then 400 mg QD for 4 days Azithromycin 500 mg po on day one, followed by 250 mg po QD X 4 days
62669159|NCT04374552|PLACEBO_COMPARATOR|Placebo|Placebo for Hydroxychloroquine sulfate (2 pills bid day one and then 2 tablets QD for 4 days) Placebo for Azithromycin (2 pills on day one and followed by 1 pill po QD x 4 days)
62107351|NCT00973141|EXPERIMENTAL|JNJ-42160443 10mg every 8 weeks|
62669160|NCT02955927|EXPERIMENTAL|ortho-k and 0.01% atropine eye drops|participants will receive treatment of ortho-k and 0.01% atropine eye drops
62107352|NCT00973141|PLACEBO_COMPARATOR|Matching placebo every 4 or 8 weeks|
62107353|NCT06293547|EXPERIMENTAL|Single arm|Following a standard dental examination, which may have included intraoral radiographs as needed, the application of 38% SDF (Riva Star, SDI Australia) was conducted on carious lesions identified in primary teeth. The application procedure of SDF adhered to the protocol recommended in the literature and the instructions provided by the manufacturer. One and experienced researcher applied SDF to each patient. Initially, the affected teeth were isolated and dried using gauze and cotton rolls. Subsequently, the SDF solution was applied directly to the lesions using a microbrush, with an absorption time ranging from a minimum of 30 seconds to a maximum of 120 seconds, depending on the child's behavior (30-60-90-120 seconds). Any excess solution was carefully removed using gauze. Parents were instructed to ensure that the child refrained from eating or drinking for at least one hour following the application of SDF.
62669161|NCT02955927|ACTIVE_COMPARATOR|ortho-k|participants will receive treatment of ortho-k alone
62669162|NCT00471107|SHAM_COMPARATOR|Sham TDCS|
62669163|NCT00471107|EXPERIMENTAL|Surface-anodal direct current|0.08 mA/cm2
62669164|NCT00471107|ACTIVE_COMPARATOR|Surface-cathodal direct current|0.08 mA/cm2
62669165|NCT01660685|EXPERIMENTAL|Tracking + Journaling + Website|In addition to standard care, participants will complete daily tracking and journaling and receive weekly feedback based on their individual entries.
62669166|NCT01660685|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants receive standard care
62107354|NCT03391908||MP - SG 01|Patients with unstable angina type acute coronary syndrome: patients aged at least 18 years, who have signed the informed consent, and present an unstable angina-type acute coronary syndrome with maximum 48h before presentation, defined as the presence of typical angina pain, with duration of more than 5 minute, accompanied by ECG changes.
62107355|NCT03391908||MP - SG 02|Patients with acute myocardial infarction (STEMI or NSTEMI) that occurred 30 days before randomization: patients aged at least 18 years, who have signed the informed consent, and present with acute myocardial infarction (STEMI or NSTEMI) defined as typical changes on the ECG (ST elevation of minimum 1 mm in at least 2 consecutive leads - STEMI; ST-T changes for NSTEMI) accompanied by increased levels of cardiac troponin I or T, or CK-MB of more than 2x the normal reference value of the laboratory.
62669167|NCT01446588|EXPERIMENTAL|Yoga|Yoga group
62669168|NCT01857154|ACTIVE_COMPARATOR|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
62669169|NCT01857154|ACTIVE_COMPARATOR|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
62107356|NCT00853424|ACTIVE_COMPARATOR|M|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
62669170|NCT01857154|ACTIVE_COMPARATOR|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
62669171|NCT01857154|ACTIVE_COMPARATOR|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
62669172|NCT01926639|EXPERIMENTAL|Radiotherapy , rituximab and DC|Treatment repeated 3 times and targeting different lymph nodes
62669173|NCT02982109||Postop pain level 1|Minor postoperative pain anticipated
62669174|NCT02982109||Postop pain level 2|Might experience postoperative pain
62669175|NCT02982109||Postop pain level 3|Moderate pain/substantial surgery performed
62669176|NCT02982109||Postop pain level 4|Severe postoperative pain expected/major surgery
62669177|NCT03934307|EXPERIMENTAL|Part A: SAD: ALN-AGT01|Participants will be administered a single dose of ALN-AGT01.
62669178|NCT03934307|PLACEBO_COMPARATOR|Part A: SAD: ALN-AGT01-Matching Placebo|Participants will be administered a single dose of ALN-AGT01-matching placebo.
62669179|NCT03934307|EXPERIMENTAL|Part B: SD: ALN-AGT01|Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
62669180|NCT03934307|PLACEBO_COMPARATOR|Part B: SD: ALN-AGT01-Matching Placebo|Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
62669181|NCT03934307|EXPERIMENTAL|Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo|Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
62669182|NCT03934307|ACTIVE_COMPARATOR|Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan|Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
62669183|NCT03934307|EXPERIMENTAL|Part E: Open Label: ALN-AGT01 + Irbesartan|Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
62669184|NCT04763408||Lenvatinib|Participants with advanced or unresectable HCC will initiate treatment with lenvatinib capsules based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
62669185|NCT04763408||Sorafenib|Participants with advanced or unresectable HCC will initiate treatment with sorafenib tablets based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
62669186|NCT03242733||Hip fracture patients|Fasted elderly patients scheduled for hip fracture surgery except exclusion criteria are enrolled.
62669187|NCT00373087|ACTIVE_COMPARATOR|L-dopa + entacapone|L-dopa + entacapone
62669188|NCT00373087|EXPERIMENTAL|L dopa / placebo|L dopa / placebo
62669189|NCT03366415|EXPERIMENTAL|Induction chemotherapy+IMRT+adjuvant chemotherapy|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), followed by gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles.
62669190|NCT03366415|ACTIVE_COMPARATOR|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 30 mg/m² every week.
62669191|NCT02130011|NO_INTERVENTION|without feeding/fluid instructicon|Ten patients treated with preoperative chemoradiotherapy without feeding/fluid instructions
62669192|NCT02130011|EXPERIMENTAL|with feeding/fluid instructions|Ten patients treated with preoperative chemoradiotherapy with feeding/fluid instructions
62669193|NCT00472381|EXPERIMENTAL|2|Insulin
62669194|NCT03492112|EXPERIMENTAL|People attending needle syringe programs in Australia|Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.
62669195|NCT04743596||Sarcoidosis group|Consecutive patients with clinical and radiological (CT scan) suspect of sarcoidosis as assessed by a respiratory physician.
62107357|NCT00853424|EXPERIMENTAL|I|subjects receive an islet cell transplant in addition to all recommended medical treatment for diabetes and diabetic eye disease
62107358|NCT00611832|ACTIVE_COMPARATOR|Standard|"Standard information-only version of the television series that includes only modeling and demonstration of the targeted parenting skills"
62298897|NCT04435340|OTHER|Prospective|All patients in the prospective cohort are informed about the study and asked to participate in the outpatient clinic before surgery. In case of informed consent, they are invited to the study site at least one year and three years, respectively, after surgery. They are asked to complete the questionnaires and they undergo an ultrasound of the ventral abdomen.
62469657|NCT05707962|NO_INTERVENTION|non intervention group|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
62469658|NCT04540523|EXPERIMENTAL|Exergaming intervention group|30 minutes of exergaming per session and 5 sessions of exergaming play per week for a 6-month period.
62469659|NCT04540523|ACTIVE_COMPARATOR|Traditional Physical Activity|Phone consultations and workshops for parents to offer 5 times, 30 minutes per session; traditional physical activity at home for 6 months.
62469660|NCT04540523|NO_INTERVENTION|Attention control group|Continue with usual activities at home with emailed physical activity tips.
62469661|NCT03128905|ACTIVE_COMPARATOR|Colchicine|Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.
62107359|NCT00611832|EXPERIMENTAL|Enhanced|"Enhanced behavior activation version of the television series that includes all of the content of the standard information-only version, but is also designed to actively promote parental behavior change, through additional content elements addressing attributions, self-efficacy and expectancies, social support, and emotional reactivity."
62107360|NCT00611832|NO_INTERVENTION|Control|Waitlist control
62107361|NCT06632002|EXPERIMENTAL|Experimental Product|
62298898|NCT00994617|EXPERIMENTAL|Combination Therapy|Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
61913960|NCT04382820||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-21 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
61913961|NCT06298682||subjects without known pathologies|
61913962|NCT04559529|EXPERIMENTAL|Levetiracetam (LEV), then Placebo|Participants will first receive two 250mg LEV capsules on the same day. After one week, they will receive two placebo capsules on the same day.
61913963|NCT04559529|EXPERIMENTAL|Placebo, then Levetiracetam (LEV)|Participants will first receive two placebo capsules on the same day. After one week, they will receive two 250mg LEV capsules on the same day.
61913964|NCT01874678|EXPERIMENTAL|TS-1/Cisplatin|single arm
61913965|NCT03487692|EXPERIMENTAL|2018 Training Cohort|10 health centers will be randomized to the 2018 Training Cohort. Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
61913966|NCT03487692|OTHER|2020 Training Cohort|10 health centers will be randomized to the 2020 Training Cohort. Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group. After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
61913967|NCT03757013||Patients treated with Apremilast|Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).
61913968|NCT02785237|ACTIVE_COMPARATOR|Coroflex® ISAR Drug-eluting stent in first lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
61913969|NCT02785237|ACTIVE_COMPARATOR|Ultimaster® Drug-eluting stent in first lesion|Patients with Ultimaster® Drug-eluting stent in first lesion
61913970|NCT02785237|ACTIVE_COMPARATOR|Coroflex® ISAR Drug-eluting stent in second lesion|Patients with with Ultimaster® Drug-eluting stent in first lesion
61913971|NCT02785237|ACTIVE_COMPARATOR|Ultimaster® Drug-eluting stent in second lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
61913972|NCT00956098|PLACEBO_COMPARATOR|placebo|
62107362|NCT06632002|OTHER|Control Product|
62107363|NCT06630208|EXPERIMENTAL|Myofascial release + Breathing exercises + Pharmacological treatment|It will include 30 patients, who will receive myofascial release for 5 days, with breathing exercises in addition to pharmacological treatment.
62107364|NCT06630208|ACTIVE_COMPARATOR|Pharmacological treatment|It will include 30 patients, who will receive pharmacological treatment only.
62298899|NCT00994617|ACTIVE_COMPARATOR|Monotherapy|Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
62298900|NCT01784887|ACTIVE_COMPARATOR|Bioelectric Dressing|SOC + Bioelectric Dressing
62469662|NCT03128905|EXPERIMENTAL|Prednisone (corticoids)|Patients assigned to this group will receive Prednisone : Cortancyl 20mg.
61913973|NCT00956098|EXPERIMENTAL|oltipraz|
61913974|NCT00631761|EXPERIMENTAL|1|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas of the human bladder.
62298901|NCT01784887|NO_INTERVENTION|SOC|Standard of Care
62469663|NCT01244620|EXPERIMENTAL|Treatment A|sitaxsentan 100 mg QD for 6 days (Treatment A)
61913975|NCT00631761|PLACEBO_COMPARATOR|2|The control group will be instructed to read a urethrocystoscopy textbook chapter at home
61913976|NCT03956719|EXPERIMENTAL|Autologous adipose-derived mesenchymal stem cells|Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells
61913977|NCT03652623|EXPERIMENTAL|TDF/FTC and cs-HT|Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.
62298902|NCT01819792|OTHER|patient with Acute Myeloïd Leukemia|
62298903|NCT02698410|EXPERIMENTAL|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
62469664|NCT01244620|EXPERIMENTAL|Treatment B|tadalafil 40 mg QD for 6 days
62298904|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.~* ECG: 12 lead electrocardiogram that visualizes cardiac activity~* history and physical: background information about athlete's and their family history~* ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
61913978|NCT06425627|EXPERIMENTAL|spinal anesthesia|Patients underwent real-time ultrasound guided spinal anesthesia. The maximum attempts of skin piercings are 3, and the total redirections of each skin piercings should not exceed 6 times. General anesthesia was considered if three skin piercings were unsuccessful.
61913979|NCT06425627|EXPERIMENTAL|general anesthesia|Rapid sequential induction was performed with sufentanil 0.5 ug /kg, etomidate 0.3 mg /kg, cisatracurium 0.15 mg /kg, and then laryngeal mask was applyed. Parameter settings: tidal volume: 6-10 mL/kg, 1.5 \~ 2.0% sevoflurane inhalation, remifentanil 0.1 \~ 0.2 ug/ kg.min-1. Mechanical driving pressure was applyed by PEEP titration method.
61913980|NCT05720754|EXPERIMENTAL|DQS+HEM|Participants in the DQS+ group used DQS 1 drop 3 times/per day with heated eye mask for 2 weeks
62107365|NCT05716542|EXPERIMENTAL|Physical Activity Intervention|"* Participants will complete a primarily home-based PA intervention, with the goal of safely increasing their steps/day by incorporating moderate-to-vigorous physical activity (MVPA)~* Participants will receive Fitbits with heart rate capabilities to support maintenance of the prescribed intensity during home exercise sessions and participants' self-monitoring of daily steps.~* Participants will strategize aerobic MVPA behaviors with the intervention PT to identify preferable and enjoyable PA modalities (e.g., walking, cycling), while also identifying alternative options to allow for flexibility if life- or cancer-specific barriers arise~* During the first Zoom coaching session, the intervention PT will train participants on using the Fitbit and completing home exercise logs. The PT will continue to meet with participants to support exercise maintenance, review home exercise sessions, strategize new exercises, and troubleshoot emerging chemotherapy-related health declines."
62107366|NCT05716542|NO_INTERVENTION|Usual care, wait-list control condition|-Participants in the control group will proceed with their treatment regimen as prescribed by their oncologist(s). To prevent drop out and high attrition rates as well as promote healthy behavior, control group participants will receive a Fitbit at the initial set-up meeting to wear during chemotherapy, as well as an individualized home exercise program and up to two Zoom coaching sessions with a PT after chemotherapy completion.
62107367|NCT02588482|EXPERIMENTAL|electroencephalography recording|Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously
62298905|NCT06656182|EXPERIMENTAL|Cervical and Thoracic SNAGs|Cervical and Thoracic SNAGs with 6 reps and 1 set along with cervical and shoulder muscle stretching and scapular mobilizations
62298906|NCT06656182|ACTIVE_COMPARATOR|traditional physical therapy and scapular mobilizations|cervical and shoulder muscle stretching and scapular mobilizations
61913981|NCT05720754|ACTIVE_COMPARATOR|DQS|Participants in the DQS group used DQS 1 drop 3 times/per day for 2 weeks
61913982|NCT05720754|ACTIVE_COMPARATOR|HEM|Participants in the HEM group used heated eye mask 3 times/per day for 2 weeks
62469665|NCT01244620|EXPERIMENTAL|Treatment C|sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
62298907|NCT04927312|EXPERIMENTAL|PF-06947386 + Metronidazole|Multiple intravenous infusion of ceftazidime-avibactam followed by intravenous infusion of metronidazole, repeated every 8 hours for 5-14 days.
62298908|NCT03577990|EXPERIMENTAL|Interactive Technology Enhanced Coaching (ITEC)|Fitbit Plus monitoring will include BP, weight measurements, daily food intake, self-report medication-taking, and physical activity plus weekly Interactive Technology-Enhanced Coaching (ITEC) for 3 months, then biweekly ITEC for 3 months, followed by another 3 months with no coaching to assess for sustainability.
62298909|NCT03577990|ACTIVE_COMPARATOR|Interactive Technology-No Coaching (IT)|Participants will receive usual care for 3 months followed by 6 months of only Fitbit Plus monitoring (with no ITEC) of BP, weight measurements, daily food intake, self-report medication-taking, and physical activity to be used for comparative data with the treatment arm.
62298910|NCT04200612|EXPERIMENTAL|Intervention Group|Participants in the intervention group will go through the 5-week EAP program consisting of the clinical processing following some activities found in EAP manuals.
62669196|NCT01051752||NTM infection|Patients with NTM infection are generally middle aged or higher aged, white males with COPD or bronchiectasis. They will be recruited from the outpatient clinics of University Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients with NTM disease will be recruited.
62669197|NCT03277274|EXPERIMENTAL|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
61913983|NCT04139746|ACTIVE_COMPARATOR|Scleral Buckling|Scleral Buckling represents the gold standard for retinal detachment in young phakic patients.
62298911|NCT04200612|ACTIVE_COMPARATOR|Active-control group|Participants in the active-control group will undergo a 5-week program that only involves interactions with horses without any clinical input (i.e. commonly coined as animal-assisted activities).
62298912|NCT04200612|PLACEBO_COMPARATOR|Placebo-control group|Participants in the placebo-control group will undergo a 5-week movie screening of 1 hour each session that is related to horses.
62469666|NCT01244620|EXPERIMENTAL|Treatment D|sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
62469667|NCT05565053|ACTIVE_COMPARATOR|Bilateral Erector Spinae Plane Block|Bilateral Erector Spinae Plane Block
62469668|NCT05565053|ACTIVE_COMPARATOR|Trigger Point Injection|Trapezius muscle Trigger Point Injection
62669198|NCT03277274|EXPERIMENTAL|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
62107368|NCT01105572|EXPERIMENTAL|Intel Home Health Guide|Participants in the intervention group will receive the use of the Intel Healthguide, an Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback when transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager. Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
62669199|NCT03277274|EXPERIMENTAL|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
62669200|NCT03277274|EXPERIMENTAL|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
62669201|NCT00363467|OTHER|Autologous Hematopoietic Progenitor Cell Transplantation|G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
62669202|NCT06420908|EXPERIMENTAL|PET-CT responders|SUV (PETr) reduction \>35%
62669203|NCT06420908|EXPERIMENTAL|PET-CT non-responders|SUV (PETr) reduction ≤35%
62669204|NCT02919631|ACTIVE_COMPARATOR|triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
62669205|NCT02919631|PLACEBO_COMPARATOR|placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day
62669206|NCT05565404|EXPERIMENTAL|Test group|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
62669207|NCT05565404|ACTIVE_COMPARATOR|Control group|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
62669208|NCT00554580|ACTIVE_COMPARATOR|A|Usual care of pulmonary acute oedema
61913984|NCT04139746|EXPERIMENTAL|Drainage-Injection-Pneumoretinopexy|Drainage-Injection-Pneumoretinopexy is a modified pneumatic retinopexy technique, in which, before injecting the gas, the drainage of the subretinal fluid is performed with a simultaneous injection of balanced salt solution (BSS) in the vitreous chamber.
62298913|NCT00597649|EXPERIMENTAL|1|Bicifadine 800 mg/day for a year
62298914|NCT00597649|EXPERIMENTAL|2|Bicifadine 1200 mg/day for a year
62669209|NCT00554580|EXPERIMENTAL|B|CPAP + usual care of pulmonary acute oedema
62669210|NCT06305546|EXPERIMENTAL|group A|
62669211|NCT06305546|EXPERIMENTAL|GROUP B|
62669212|NCT06305546|EXPERIMENTAL|GROUP C|
62669213|NCT06305546|PLACEBO_COMPARATOR|GROUP D|
62107369|NCT01105572|NO_INTERVENTION|Case Management Only|All participants in the comparison group, are identified for outreach and assistance by a nurse case manager. Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
62298915|NCT02209506|EXPERIMENTAL|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
62298916|NCT02209506|EXPERIMENTAL|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
62298917|NCT02209506|EXPERIMENTAL|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
62298918|NCT02209506|EXPERIMENTAL|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
62469669|NCT04444479|EXPERIMENTAL|PICC catheter placement|Study subjects in whom placement of the PICC catheter is indicated
62669214|NCT04259489|NO_INTERVENTION|Traditional therapy group|All patients in the control group will receive routine diabetes management, including lifestyle education, health guidance, blood glucose monitoring and medicine adjustment and other treatments which conducted by the endocrinology medical team. After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
62669215|NCT04259489|ACTIVE_COMPARATOR|Shared Care group|The Patients download the Shared Care mobile application and connect with the smart-glucometer BG1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
62669216|NCT00593437||1|diagnosed with normal bone density by Norland Excel
62107370|NCT01768143||Nurse Trainees|unexperienced endoscopy nurses
62107371|NCT01768143||Nurse Experts|Educated endoscopy Nurses
62107372|NCT02772315||Hypertensive patients|Diagnostic procedures in patients with hypertension applying omics results
62298919|NCT02209506|EXPERIMENTAL|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
62298920|NCT02209506|EXPERIMENTAL|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
62469670|NCT00868374|EXPERIMENTAL|1|Quetiapine XR
62669217|NCT00593437||2|diagnosed with osteopenia by Norland Excel densitometer
62669218|NCT00593437||3|diagnosed with osteoporosis by Norland Excel densitometer
62107373|NCT05963308|EXPERIMENTAL|"Online group intervention Healthy Minds"|
62669219|NCT03313193|EXPERIMENTAL|Arm A|Acupressure for Children in Treatment for a Childhood Cancer + usual care
62669220|NCT03313193|NO_INTERVENTION|Arm B|Usual care alone
62669221|NCT03880890|ACTIVE_COMPARATOR|sphenoidotomy (group A)|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus
62298921|NCT02209506|EXPERIMENTAL|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
62298922|NCT02209506|EXPERIMENTAL|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
62469671|NCT00868374|PLACEBO_COMPARATOR|2|
62469672|NCT01453465||Ancillary-Correlative (gene expression profile, miRNA profile)|Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
62669222|NCT03880890|ACTIVE_COMPARATOR|sphenoid nasalization (group B)|sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
62669223|NCT04422873||in-centre|Currently dialysing in-centre
62107374|NCT05963308|NO_INTERVENTION|Control group|"Like the intervention group, the control group will complete an online set of questionnaires at the following time points:~* Baseline~* First follow-up (2 months after baseline)~* Second follow-up (6 months after baseline)~* Third follow-up (12 months after baseline)~The questionnaires will cover the following domains:~* Sociodemographic and biopsychosocial factors~* Symptoms associated with the primary mood disorder~* Cognitive difficulties and distortions~* Self-efficacy in relation to returning to work~* Work accommodations and natural supports~* Relationship with immediate supervisor~* Work functioning~* Return-to-work time (number of days away from work)"
62107375|NCT02947815|EXPERIMENTAL|NABOTA|Single-dose
62107376|NCT02947815|ACTIVE_COMPARATOR|BOTOX|Single-dose
62107377|NCT03594331|EXPERIMENTAL|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
62107378|NCT03594331|EXPERIMENTAL|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
62107379|NCT03594331|EXPERIMENTAL|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
62107380|NCT00296426|NO_INTERVENTION|Usual Care|control patients admitted to hospital floors received usual care
62107381|NCT00296426|EXPERIMENTAL|Intervention|computerized medication reconciliation tool and process redesign involving physicians, nurses, and pharmacists
62298923|NCT02209506|EXPERIMENTAL|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
62298924|NCT02209506|EXPERIMENTAL|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
62298925|NCT02765841|EXPERIMENTAL|Lomitapide|
62298926|NCT01737775|EXPERIMENTAL|Abdominal laparoscopic surgery (C group)|
61913985|NCT02900144|EXPERIMENTAL|Modified CBIT Treatment Arm|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
62107382|NCT01003015|EXPERIMENTAL|Arm 1|
62107383|NCT06458127|EXPERIMENTAL|Tele-PC Intervention|Participants (individuals with moderate to severe chronic Graft-versus-Host Disease) will receive a monthly at home consultation with a specialty palliative care clinician via a video-conference tele-health visit.
62107384|NCT04836793||Patients with cancer|"* Patients with active treatment in adjuvant/induction setting,~* Patients with active treatment in metastatic/relapse setting,~* Patients without active treatment (last treatment above 6 months)."
62107385|NCT04836793||Patients without cancer but aged above 70 years|
62107386|NCT04836793||Healthy person|
62107387|NCT03243656|NO_INTERVENTION|historical group|Immunosuppressive therapy (cyclosporine alone ),
62107388|NCT03243656|ACTIVE_COMPARATOR|case arm|cyclosporine plus an oral dose of Eltrombopag
62107389|NCT03771885|EXPERIMENTAL|Group A|4 weeks place followed by 4 weeks IMP
62107390|NCT03771885|EXPERIMENTAL|Group B|4 weeks IMP followed by 4 weeks placebo
62107391|NCT04564313|EXPERIMENTAL|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
62107392|NCT03416751|EXPERIMENTAL|Fecal Microbial transplantation|Patients will get one-dose of 90ml of FMT enema on day 1 that has been received from OpenBiome using a rational donor
62298927|NCT01737775|EXPERIMENTAL|Abdominal surgery by laparotomy (L group)|
62298928|NCT01737775|EXPERIMENTAL|Head and neck surgery (O group)|
62298929|NCT03116880||Image registration|
62298930|NCT05660122||Treatment group|patients with gastroesophageal reflux disease
62298931|NCT00391599|EXPERIMENTAL|Study Group|a fleet enema (250 cc of sodium biphosphate 16 gr and sodium phosphate 6 gr per 100 cc) the night before cesarean section
62298932|NCT00391599|ACTIVE_COMPARATOR|Control Group|no preoperative intestinal preparation.
62298933|NCT01501487|ACTIVE_COMPARATOR|HER2 negative patients|"In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:~1. TAC chemotherapy~2. TC chemotherapy~3. Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy"
62298934|NCT01501487|ACTIVE_COMPARATOR|Her2 positive patients|The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
62669224|NCT04422873||home|Currently dialysing at home
62107393|NCT03416751|PLACEBO_COMPARATOR|Placebo|Patients will get one-dose of 90ml of saline enema on day 1
62107394|NCT06631989|EXPERIMENTAL|Dose escalation (WSD0922-FU)|Patients receive WSD0922-FU PO QD on C0D1 to C0D3, then BID on C1D1 to C1D21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study.
61913986|NCT02900144|ACTIVE_COMPARATOR|Standard CBIT Treatment Arm|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
61913987|NCT03419975|EXPERIMENTAL|TJO-002|
61913988|NCT03419975|ACTIVE_COMPARATOR|latanoprost|
61913989|NCT01022827|EXPERIMENTAL|posterior shoulder stiffness massage group|The inclusion criteria of patients with glenohumeral internal rotation limitation and posterior shoulder stiffness were: \[1\] limitation of internal rotation ROM compared to the sound side; \[2\] mild glenohumeral joint hypomobility according to joint play assessment; \[3\] stiffness in the posterior shoulder region.
61913990|NCT01022827|PLACEBO_COMPARATOR|posterior shoulder stiffness placebo group|
62298935|NCT06573853||PFA group|A retrospective analysis was conducted on 214 patients with PSVT recieving PFA who met the inclusion and exclusion criteria and visited at the First Affiliated Hospital of Ningbo University, the Third People's Hospital of Chengdu, the Xiamen Cardiovascular Hospital of Xiamen University, the First Hospital of Jilin University, the Seventh People's Hospital of Zhengzhou, Shanghai General Hospital, and Jiangxi Provincial People's Hospital from October 2022 to June 2024. These patients were included in the PFA group. Basic clinical information, procedural data, and the efficiency and safety post 1-year follow-up were collected and analyzed.
61913991|NCT04999852|EXPERIMENTAL|Psychotherapy + SSP|All subjects enrolled in this study will receive the SSP intervention
62107395|NCT06631989|EXPERIMENTAL|Dose expansion (WSD0922-FU)|Patients receive WSD0922-FU PO BID on C1D1 to C1D21 using dosage selected from Dose escalation. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study.
62107396|NCT06631989|EXPERIMENTAL|Dose extension (WSD0922-FU)|Patients receive WSD0922-FU PO BID on C1D1 to C1D21 using RP2D. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study.
62298936|NCT06573853||RFA group|A retrospective analysis for control group was conducted on patients with PSVT reciecing RFA who met the inclusion and exclusion criteria and visited at the First Affiliated Hospital of Ningbo University the Third People's Hospital of Chengdu, the Xiamen Cardiovascular Hospital of Xiamen University, the First Hospital of Jilin University, the Seventh People's Hospital of Zhengzhou, Shanghai General Hospital, and Jiangxi Provincial People's Hospital from October 2022 to June 2024. 214 patients approached by RFA were matched 1:1 by propensity score to a similar population treated by PFA. Basic clinical information, procedural data, as well as the efficiency and safety of 1-year follow-up were collected and analyzed.
62298937|NCT03693872|OTHER|Apomorphine|Withdrawal of dopaminergic agonists at pump initiation
62669225|NCT03989570|EXPERIMENTAL|Group I (A group)|31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
61913992|NCT04999852|ACTIVE_COMPARATOR|Psychotherapy (treatment as usual)|Subjects who are receiving psychotherapy but not the SSP intervention
61913993|NCT05033990||Healthy Controls|Participants with no smoking history (\< 100 cigarettes in lifetime); pre-bronchodilator FEV1/FVC ≥ 0.70; pre-bronchodilator FEV1 ≥ 80% predicted; and pre-bronchodilator FVC ≥ 80% predicted.
61913994|NCT05033990||Gold 0|"Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted.~GOLD stands for the Global initiative for Chronic Obstructive Lung Disease."
61913995|NCT05033990||Preserved Ratio Impaired Spirometry (PRISm)|Participants with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 \< 80% predicted.
61913996|NCT05033990||GOLD 1 - 2|Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \< 0.70 and FEV1 ≥ 50% predicted.
62669226|NCT03989570|ACTIVE_COMPARATOR|Group II (B group)|31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
61913997|NCT04739176|EXPERIMENTAL|One-on-one rehabilitation program|
62669227|NCT03989570|PLACEBO_COMPARATOR|Group III (C group)|31 patients anesthetized with the protocol followed by Minia University Hospital
61913998|NCT04998201|EXPERIMENTAL|ARO-APOC3 10 mg, Day 1 and Week 12|2 doses of ARO-APOC3 by subcutaneous (sc) injection
61913999|NCT04998201|EXPERIMENTAL|ARO-APOC3 25 mg, Day 1 and Week 12|2 doses of ARO-APOC3 by subcutaneous (sc) injection
61914000|NCT04998201|EXPERIMENTAL|ARO-APOC3 50 mg, Day 1 and Week 12|2 doses of ARO-APOC3 by subcutaneous (sc) injection
61914001|NCT04998201|EXPERIMENTAL|ARO-APOC3 50 mg, Day 1 and Week 24|2 doses of ARO-APOC3 by subcutaneous (sc) injection
61914002|NCT04998201|PLACEBO_COMPARATOR|Placebo, Day 1 and Week 12 or Week 24|calculated volume to match active treatment by sc injection
61914003|NCT02110602|EXPERIMENTAL|Initial Diet - high in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin high amino acid diet~Visit 3 (4 days after Visit 2): Completion of high amino acid diet~Visit 4 (3 days after Visit 3): Begin low amino acid diet~Visit 5 (4 days after Visit 4): Completion of low amino acid diet, completion of study"
61914004|NCT02110602|EXPERIMENTAL|Initial Diet - low in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin low amino acid diet~Visit 3 (4 days after Visit 2): Completion of low amino acid diet~Visit 4 (3 days after Visit 3): Begin high amino acid diet~Visit 5 (4 days after Visit 4): Completion of high amino acid diet, completion of study"
61914005|NCT04930380||Cases|"* male and female aged 25 years or more~* diagnosis of defined MS~* written informed consent must be obtained before the enrolment."
61914006|NCT04930380||Controls|"* male and female aged 25 years or more~* written informed consent must be obtained before the enrolment no history of MS"
61914007|NCT06520969|OTHER|prevalance and anatomical variations of superficial and deep veins|Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients
61914008|NCT05988502|EXPERIMENTAL|auricular acupressure (AA) group|the auricular acupressure (AA) group was given auricular acupressure for two weeks
61914009|NCT05988502|NO_INTERVENTION|control group|all participants received the same routine care which was general heart failure care and medications for constipation therapy provided by the study hospital professionals. Prior to the study, every participant was assessed by the cardiologist and identified as being appropriate and safe.
62298938|NCT03693872|OTHER|Dopaminergic Agonist + Apomorphine|Continuation of dopaminergic agonists at pump initiation
62469673|NCT03222063|EXPERIMENTAL|Experimental group|"Experimental Group:~Experimental group consists of 30 hospitalized children.In Experimental group after taking pretest on 1st day play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. Though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. The play interventions were administered for 1 hour daily for continuous 5 days.Post test assessment of anxiety was done on 5th day."
62469674|NCT03222063|NO_INTERVENTION|Comparison group|Comparison Group: 30 hospitalized children were selected by purposive sampling in comparison group. Pretest anxiety was measured on 1st day . No intervention was administered. only usual medical and nursing care was administered to the hospitalized children. Post test assessment of anxiety was done on 5th day.
62469675|NCT04425447|ACTIVE_COMPARATOR|Group C|30 patients will receive bilateral tumescent local anesthesia as a control group
62669228|NCT02285309||Cardiac surgery|
62669229|NCT06194994|EXPERIMENTAL|Parent Training|Behavioral parent training intervention. Individual sessions.
62669230|NCT06194994|EXPERIMENTAL|Child directed treatment|Child directed cognitive behavioral therapy. Individual sessions.
62669231|NCT02036723|EXPERIMENTAL|BCD-021|"BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia.~In this arm 72 patients will receive BCD-021 at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months."
62669232|NCT02036723|ACTIVE_COMPARATOR|Lucentis®|Lucentis® is ranibizumab drug produced by Novartis Pharmaceuticals Canada Inc. In this arm 36 patients will receive Lucentis® at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
61914010|NCT06312696|NO_INTERVENTION|No treatment group|No Treatment: participants will be placed in a similar position to the other groups for the same duration, but no treatment or touch will be administered.
61914011|NCT06312696|SHAM_COMPARATOR|Pseudo sham group|Light massage group
61914012|NCT06312696|EXPERIMENTAL|Experimental group|Spinal Manipulative therapy group
61914013|NCT01311869|ACTIVE_COMPARATOR|EGCG ( Green Tea extract)|40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
61914014|NCT01311869|PLACEBO_COMPARATOR|Brown Rice pills|40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months
62469676|NCT04425447|EXPERIMENTAL|Group TPVB|30 patients will receive bilateral US guided thoracic paravertebral block.
62469677|NCT04425447|EXPERIMENTAL|Group TIPB|30 patients will receive bilateral US guided thoracic interfascial plane block
62469678|NCT05844553||Healthy Volunteers|Healthy Volunteers
62298939|NCT05648474||Adult undergoing 1- or 2-level lateral lumbar interbody fusion surgery, inclusive of the L4-5 level|
62298940|NCT05715216|EXPERIMENTAL|Etigilimab plus Nivolumab|Participants will receive the study drugs on Days 1 and 15 of each study cycle,Cycle 1, Participants will receive the drugs on separate days (etigilimab on Day 1 and nivolumab on Day 2). Starting with Cycle 2, you will receive both drugs on Day 1 (separated by 2 hours).
62298941|NCT05065112|ACTIVE_COMPARATOR|PVI only|Patients in this arm will undergo only standard pulmonary veins isolation with radiofrequency (RF) energy to treat their AF.
62669233|NCT03879109|EXPERIMENTAL|Arm A: Induction Chemotherapy followed by Pelvic reirradiation|"Protocol of chemotherapy FOLFIRINOX\*, 6 cycles :~* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)~Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week."
62669234|NCT03879109|ACTIVE_COMPARATOR|Arm B: Chemotherapy alone|"Protocol of chemotherapy FOLFIRINOX\*, 6 cycles :~* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)"
62669235|NCT02694250|OTHER|DTRAX Cervical Cervical Cage with DTRAX Bone Screw|
62669236|NCT04027387|EXPERIMENTAL|TMB-365 400 mg- Group 1|Single dose of TMB-365 400 mg or matching placebo by intravenous infusion
62669237|NCT04027387|EXPERIMENTAL|TMB-365 800 mg- Group 2|Single dose of TMB-365 800 mg or matching placebo by intravenous infusion
62669238|NCT04027387|EXPERIMENTAL|TMB-365 1600 mg- Group 3|Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion
62669239|NCT00356590|OTHER|1|
62669240|NCT00625378|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Participants receive single-agent sorafenib at the same dose and schedule as in their original clinical trials.
62669241|NCT05415111|ACTIVE_COMPARATOR|Subepithelial connective tissue group (SCTG)|"A SCTG will be harvested from the patient's palate with a dimension dependent on the size of the peri-implant osseous defect. The technique of harvesting a soft tissue grafting is well described and established in the literature. Following the administration of local anesthesia, the SCTG will be harvested using a single incision technique. The periosteum will be left intact. The thickness of the SCTG will be at least 1.5mm. A cross suture will be used to close the palatal incision.~The SCTG will be placed on the buccal exposed implant threads (above the DBBM-C) exceeding 1mm in a coronal and apical direction, 3mm in a mesial and distal direction and then immobilized using a horizontal mattress connecting it to the lingual or palatal flap. The flaps are then closed primarily and tension-free following a horizontal periosteal releasing incision."
62669242|NCT05415111|ACTIVE_COMPARATOR|Volume stable Collagen Matrix group (VCMX)|A VMCX (FibroGide®) will be hydrated in sterile saline, trimmed and adjusted to a dimension dependent on the size of the osseous peri-implant defect. The VCMX will then be placed as described above and then immobilized using a horizontal mattress connecting it to the lingual or palatal flap. The flaps are then closed primarily and tension-free following a horizontal periosteal releasing incision.
62669243|NCT05415111|SHAM_COMPARATOR|No soft tissue augmentation (GBR)|No barrier membranes will be placed. After filling the defect with the bone substitute, the flaps are closed primarily and tension-free following a horizontal periosteal releasing incision.
62669244|NCT06413771|ACTIVE_COMPARATOR|Conventional Only Gonadotropin|The Conventional Only Gonadotropin (COG) group received recombinant FSH based on body mass index (BMI)
62669245|NCT06413771|ACTIVE_COMPARATOR|Combined Letrozole-Gonadotropin group|The combined Letrozole-Gonadotropin (CLG) group received letrozole followed by gonadotropin with dose adjustments based on BMI.
62669246|NCT01522547|EXPERIMENTAL|Cohort 1: 0.5 mg pomalidomide|0.5 mg pomalidomide orally daily for 84 days
62298942|NCT05065112|EXPERIMENTAL|PVI + IM|Patients in this arm will undergo standard wide area circumferential pulmonary veins isolation along with radiofrequency energy and additional RF ablation guided by individualised mapping with Cartofinder to treat their AF.
62298943|NCT05133986|EXPERIMENTAL|Onion feeding first, couscous feeding second|Participants will report to the laboratory at 8am in a fasted state (water consumption is permitted) and provide a spot baseline urine sample. Participants will then be served a 120g portion of onions (experimental condition), prepared under standardized conditions. Participants shall remain supervised in the laboratory and will only consume water (100mL per hour) for the subsequent 6 hours, after which participants are free to consume their habitual diet (except alcohol, tea coffee, and FVs). In the 24-hour postprandial test period, participants will obtain urine samples at several time-points. Urine collection vessels will be used to obtain samples at 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 hours. This experimental protocol shall be repeated following a 4-day washout period (habitual diet consumption with no restrictions imposed on participants) with 120g of couscous consumed instead of onions, as a control condition.
62669247|NCT01522547|EXPERIMENTAL|Cohort 2: 1.0 mg pomalidomide|1.0 mg pomalidomide orally daily for 84 days
62107397|NCT06252727|EXPERIMENTAL|Aminolevulinic acid (5-ALA)|20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgical resection. 5-ALA fluorescence will be used to evaluate the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.
62107398|NCT03523962|EXPERIMENTAL|First pre-op antiseptic skin solution|The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
62107399|NCT03523962|EXPERIMENTAL|Crossover - Second pre-op antiseptic skin solution|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
62107400|NCT06630715||Rheumatoid Arthritis|Patients diagnosed with RA according to the ACR/EULAR 2010 classification criteria with active disease starting Upadacitinib
62107401|NCT06630715||Psoriatic Arthritis|Patients diagnosed with peripheral Psoriatic Arthritis according to the CASPAR criteria or with axial Psoriatic Arthritis according to ASAS criteria with active disease starting Upadacitinib
62107402|NCT00290706|EXPERIMENTAL|Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds|Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
62298944|NCT05133986|EXPERIMENTAL|Couscous feeding first, onion feeding second|Participants will report to the laboratory at 8am in a fasted state (water consumption is permitted) and provide a spot baseline urine sample. Participants will then be served a 120g portion of couscous (control condition), prepared under standardized conditions. Participants shall remain supervised in the laboratory and will only consume water (100mL per hour) for the subsequent 6 hours, after which participants are free to consume their habitual diet (except alcohol, tea coffee, and FVs). In the 24-hour postprandial test period, participants will obtain urine samples at several time-points. Urine collection vessels will be used to obtain samples at 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 hours. This experimental protocol shall be repeated following a 4-day washout period (habitual diet consumption with no restrictions imposed on participants) with 120g of onions consumed instead of couscous, as an experimental condition.
62298945|NCT05133986|OTHER|Onion supplementation period|This dose-dependent biomarker validation intervention will include three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised. Participants will be asked to avoid onion intake throughout the supplementation periods, other than the portions provided by researchers. First morning void urine samples will be collected by participants on the morning after the supplementation period and obtained by researchers.
62298946|NCT01936038|PLACEBO_COMPARATOR|Control Group|CPAP
62669248|NCT01522547|EXPERIMENTAL|Cohort 3: 2.0 mg pomalidomide|2.0 mg pomalidomide orally daily for 84 days
62669249|NCT01522547|EXPERIMENTAL|Cohort 4: 3.0 mg pomalidomide|3.0 mg pomalidomide orally daily for 84 days
62669250|NCT01522547|EXPERIMENTAL|Cohort 5: 4.0 mg pomalidomide|4.0 mg pomalidomide orally daily for 84 days
62669251|NCT01312675|EXPERIMENTAL|Group A|S.A.F.E.BT plus Standard of Care therapy
62107403|NCT06629896|EXPERIMENTAL|CONtrast enhanced mammography|women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
62107404|NCT06629896|ACTIVE_COMPARATOR|MRI|women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.
62107405|NCT04033237|EXPERIMENTAL|Very low nicotine content cigarettes|
62107406|NCT04033237|NO_INTERVENTION|Usual Brand|
62107407|NCT03960255||Normal adiposity group|Body fat \< 25% and \<32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
62298947|NCT01936038|EXPERIMENTAL|EXPERIMENTAL GROUP|Upper Airway Toning for Improve the Compliance of CPAP
62298948|NCT04724889||Patients with underlying AF|Patients that will have AF detected by ILR will be compared with patients without AF.
62669252|NCT01312675|NO_INTERVENTION|Group B|Standard of Care therapy alone
62669253|NCT04761354||University Medical Center Utrecht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669254|NCT04761354||University Medical Center Groningen|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669255|NCT04761354||Vu University Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669256|NCT04761354||University Medical Center Maastricht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669257|NCT04761354||Academic Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669258|NCT04761354||Istituto di Semeiotica Chirurgica Roma|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669259|NCT04761354||University of California San Francisco|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669260|NCT04761354||Northwestern Memorial Hospital|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62107408|NCT03960255||High adiposity group|Body fat ≥ 25% and ≥32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
62107409|NCT02672813|EXPERIMENTAL|Pectoral Nerve I and II block|Under Ultrasound guidance, Pectoral nerve I block is given for every breast surgery using 10ml of 0.25 % Ropivacaine ( without added preservatives). Similarly Pectoral nerve II block is also given using 20 ml of 0.25% Ropivacaine ( without added preservative) in same group of patient.
62107410|NCT02672813|NO_INTERVENTION|No block|Pectoral nerve block is not given in this group of patients undergoing breast surgery
62298949|NCT04724889||Patients without AF|Patients that will have AF detected by ILR will be compared with patients without AF.
62298950|NCT05745662||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
62298951|NCT05638321|EXPERIMENTAL|Treatment Arm 1|Eyes of subjects with uncontrolled (IOP \> 20 mmHg) open-angle glaucoma (OAG), where IOP is not controlled when using maximum tolerated glaucoma medications
62669261|NCT04761354||Weill Cornell Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669262|NCT04761354||Columbia University Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62298952|NCT05638321|EXPERIMENTAL|Treatment Arm 2|Eyes of subjects with uncontrolled (IOP \> 20 mmHg) open-angle glaucoma (OAG), who failed prior filtering procedure or had uncontrolled IOP on tolerated glaucoma medications \[Treatment Arm 2 and Treatment Arm 3\].
62298953|NCT05638321|EXPERIMENTAL|Treatment Arm 3|Two (2) inferonasal sclerostomies will be performed by the MIMS® system in the eyes of subjects who failed prior filtering procedure or had uncontrolled IOP on tolerated glaucoma medications (i.e., refractory glaucoma).
62669263|NCT04761354||University of Chicago Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669264|NCT04761354||M.D. Anderson Cancer Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669265|NCT04761354||Boston Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669266|NCT04761354||University Health Network Toronto|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669267|NCT04761354||Montreal General Hospital - McGill University|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
62669268|NCT04761354||University of Sydney|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
61914015|NCT05795478|EXPERIMENTAL|Combined group|Oxycodone+Pregabalin
62107411|NCT02971306|ACTIVE_COMPARATOR|Standard Medical therapy|standard medical therapy
62107412|NCT02971306|EXPERIMENTAL|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
62107413|NCT02971306|EXPERIMENTAL|G-CSF and NAC|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days plus NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution)
62107414|NCT03095209||Standard of care concurrent chemo-radiation therapy|
62107415|NCT01901770|EXPERIMENTAL|Arm I-HPV vaccine education|"The educational intervention is that parents and providers receive materials about HPV by mail including HPV/ cervical cancer videos and brochures, fact sheets, HPV/cervical cancer resource lists. Clinics receive posters, brochures, tabletop/reminder cards, resource lists, newsletters, and invitation to be vaccinated letters for parents."
62669269|NCT02246985|EXPERIMENTAL|Plain bread with plain mayonnaise|Control meal. The bread and mayonnaise in this meal does not have vegetable powders incorporated into them, hence this meal does not contain carotenoids
62669270|NCT02246985|EXPERIMENTAL|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids
62669271|NCT02246985|EXPERIMENTAL|Vegetable bread with plain mayonnaise|A vegetable powder (carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids.
61914016|NCT05795478|OTHER|Oxycodone group|Oxycodone+placebo capsules
61914017|NCT05795478|OTHER|Pregabalin group|NS+Pregabalin
62107416|NCT01901770|ACTIVE_COMPARATOR|Arm II- Flu vaccine education|The educational intervention is that parents and providers receive materials about Flu by mail including Flu brochures, fact sheets, Flu resource lists. Clinics receive posters and brochures.
62107417|NCT02841891|EXPERIMENTAL|Test|Test group will receive Sylys® Surgical Sealant as an adjunct to standard closure of stapled anastomosis in colectomy procedure.
62107418|NCT02841891|ACTIVE_COMPARATOR|Control|Control group will receive standard of care closure of stapled anastomosis in colectomy procedure without Sylys® Surgical Sealant.
62107419|NCT05779514|EXPERIMENTAL|The growth of brown adipose tissue|
62298954|NCT06282692|EXPERIMENTAL|Experimental:|"INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg~Study product are provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given 1 dose (0.5 ml) twice."
62298955|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
62298956|NCT05718401||Intervention group|Patients With Multiple Myeloma Myocardial Amyloidosis
62298957|NCT05718401||Control group|Patients With Multiple Myeloma but without Myocardial Amyloidosis.
62298958|NCT02522819|EXPERIMENTAL|obstructive sleep apnea in the acute phase of stroke|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke
62669272|NCT02246985|EXPERIMENTAL|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
62298959|NCT00646893|NO_INTERVENTION|1|Control: assisted hatching, without Preimplantation Genetic Diagnosis
62298960|NCT00646893|EXPERIMENTAL|2|Test: embryo biopsy with Preimplantation Genetic Diagnosis
62298961|NCT04755556|OTHER|Experimental group|Intensive bimanual training with routine physical therapy
62298962|NCT04755556|OTHER|control group|routine physical therapy
62469679|NCT02381834|EXPERIMENTAL|Bladder stimulation technique|This is a two-person technique. A health care aide or nurse (RN) begins by holding the infant under the axillae with its legs dangling. A second RN or physician then performs bladder stimulation by gentle finger tapping on the lower abdomen in the midline just above the pubic symphysis at a frequency of 100 taps/min. If this is unsuccessful after 30 seconds, lower back stimulation in the lumbar paravertebral zone is performed by light massage in a circular motion using both thumbs. This too is performed for 30 seconds maximum. These two manoeuvres are repeated in succession, for a maximum of 5 minutes total, until urination occurs. Unsuccessful attempts at midstream urine collection will be followed by further feeding/fluid administration and bladder catheterization.
62298963|NCT05385562|ACTIVE_COMPARATOR|Formulated Posterior Sub Tenon Triamcinolone|
62298964|NCT05385562|ACTIVE_COMPARATOR|Posterior Sub Tenon Triamcinolone alone|
62298965|NCT05416892||Patients of Geriatric Wards SU06 and SU13 of the CHU Brugmann Hospital|
62298966|NCT05274750|EXPERIMENTAL|Participants receiving depemokimab (GSK3511294)|
62469680|NCT05552833|EXPERIMENTAL|COPD patients|This arm will consist of only COPD patients.
62469681|NCT05552833|EXPERIMENTAL|Healthy controls|This arm will consist of age and BMI matched healthy controls.
62469682|NCT02469805|ACTIVE_COMPARATOR|stimulated intrauterine insemination (IUI)|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
62469683|NCT02469805|ACTIVE_COMPARATOR|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
62669273|NCT03324009|EXPERIMENTAL|2-stage screen|All patients will be enrolled in the two-stage cervical cancer screening protocol
62669274|NCT00578058|OTHER|1|Counseling plus everyday noise type 1
62669275|NCT00578058|OTHER|2|Counseling plus static noise type 2
62669276|NCT00578058|OTHER|3|Counseling plus static noise type 3
62669277|NCT00578058|OTHER|4|Hearing aid and counseling plus everyday noise type 1
61914018|NCT05795478|PLACEBO_COMPARATOR|Control group|NS+placebo capsules
61914019|NCT05898997|EXPERIMENTAL|Normal (Visual Field Defects: >-2.00 dB)|Do the formal acupressure
61914020|NCT05898997|EXPERIMENTAL|Mild (Visual Field Defects: -2.00~-6.00 dB)|Do the formal acupressure
61914021|NCT05898997|EXPERIMENTAL|Moderate (Visual Field Defects: -6.01~-12.00 dB)|Do the formal acupressure
61914022|NCT05898997|EXPERIMENTAL|Severe (Visual Field Defects: -12.01~-20.00dB)|Do the formal acupressure
61914023|NCT05898997|EXPERIMENTAL|Profound (Visual Field Defects: <-20 dB)|Do the formal acupressure
61914024|NCT05371873||Anatomical resection group|Anatomical resection of liver cancer tissue
62298967|NCT05274750|PLACEBO_COMPARATOR|Participants receiving placebo|
62298968|NCT04152759|EXPERIMENTAL|BAT2506 injection|50mg ；subcutaneous injection
62298969|NCT04152759|ACTIVE_COMPARATOR|Sinponi(EU-licensed)|50mg ；subcutaneous injection
62298970|NCT06069791|EXPERIMENTAL|Group 1|bupivacaine 0.0%, 0.01%, and 0.05% in random order, one week apart each
62298971|NCT06069791|EXPERIMENTAL|Group 2|bupivacaine 0.1%, 0.05%, and 0.1% in random order, one week apart each
62298972|NCT06069791|EXPERIMENTAL|Group 3|bupivacaine 0.0%, 0.1%, and 0.5% in random order, one week apart each
62298973|NCT06069791|EXPERIMENTAL|Group 4|bupivacaine \[0.01% or 0.05%\], \[0.05% or 0.1%\], and 0.05% in random order, one week apart each
62298974|NCT02580734|PLACEBO_COMPARATOR|placebo|tablet without melatonin
62298975|NCT02580734|EXPERIMENTAL|melatonin|tablet with melatonin
62298976|NCT00603005|EXPERIMENTAL|1|
62298977|NCT00603005|EXPERIMENTAL|2|
62298978|NCT00603005|EXPERIMENTAL|3|
62298979|NCT00603005|EXPERIMENTAL|4|
62298980|NCT05902728|EXPERIMENTAL|HLX208 in the fast state|HLX208 900mg in the fast state
62298981|NCT05902728|EXPERIMENTAL|HLX208 in the fed state|HLX208 900mg in the fed state
62298982|NCT05902728|EXPERIMENTAL|HLX208 + Itraconazole group|HLX208 + Itraconazole group
62298983|NCT05902728|EXPERIMENTAL|HLX208 + rifampicin group|HLX208 + rifampicin group
62298984|NCT04212000|EXPERIMENTAL|Levoketoconazole|Levoketoconazole 150 mg
62298985|NCT04212000|ACTIVE_COMPARATOR|Ketoconazole|Ketoconazole 200 mg
62669278|NCT00578058|OTHER|5|Hearing aid and counseling plus static noise type 2
62107420|NCT04241653|ACTIVE_COMPARATOR|Spontaneous Ventilation|Patients will spontaneously ventilated. Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
62107421|NCT04241653|ACTIVE_COMPARATOR|Unparalyzed Controlled Ventilation|Patients will be mechanically ventilated without muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
62469684|NCT02469805|ACTIVE_COMPARATOR|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
62107422|NCT04241653|ACTIVE_COMPARATOR|Paralyzed Controlled Ventilation|Patients will be mechanically ventilated with muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
62107423|NCT01304394|OTHER|parenteral nutrition solution|
62107424|NCT02396992|OTHER|Minimal-Massive Intervention|The minimal/basic intervention for a massive number of hospitalized patients.
62107425|NCT06389318|EXPERIMENTAL|buccal midazolam group|Children received oral placebo syrup, intranasal 0.9 % normal saline at 0.03 ml/kg and buccal midazolam at 0.1 mg/ kg mixed with simple syrup
62107426|NCT06389318|EXPERIMENTAL|oral chloral hydrate and intranasal dexmedetomidine group|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline.
62298986|NCT06269848||Junior boxers|Junior category boxers aged 15 to 16 years old
62298987|NCT06269848||Youth boxers|Youth category boxers aged 17 to 18 years old
62298988|NCT00961532|EXPERIMENTAL|DDAVP|DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes
62298989|NCT02379858|EXPERIMENTAL|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
62469685|NCT04561622||Bipolar patients|Bipolar patients (type I,II, NOS) of the bipolar disorder expert center of CHU Grenoble Alpes.
62469686|NCT04561622||Healthy controls|Volunteers without any psychiatric disease matching inclusion criteria
62469687|NCT06560515|EXPERIMENTAL|Vaginal Dinoprostone|received 3 mg vaginal Dinoprostone of maximum 2 doses 6 hours apart.
62469688|NCT06560515|ACTIVE_COMPARATOR|Vaginal Misoprostol|received 50μg of vaginal misoprostol of maximum 2 doses 6 hours apart.
62469689|NCT00171886|EXPERIMENTAL|octrotide|
62469690|NCT06020924||UFs with infertile patients|Uterine fibroids combined with infertile women
62469691|NCT06020924||UFs with non-infertile patients|Uterine fibroids combined with non-infertile women
62469692|NCT03113786|NO_INTERVENTION|Standard of Care|Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
62469693|NCT03113786|ACTIVE_COMPARATOR|CLARIX™100|Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
62469694|NCT03113786|ACTIVE_COMPARATOR|CLARIX CORD 1K|Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
62469695|NCT03190005||group 1|placebo control without medication.
62469696|NCT03190005||group 2|hyper-reactive responser after clopidogrel.
61914025|NCT05371873||Non-anatomical resection group|Non-anatomical resection of liver cancer tissue
62469697|NCT03190005||group 3|hypo-reactive responser after clopidogrel.
62669279|NCT00578058|OTHER|6|Hearing aid and counseling plus static noise type 3
62669280|NCT02904356|EXPERIMENTAL|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
62669281|NCT03883854||1 group|"Complete iron profile~* serum iron~* serum ferritin~* total iron binding capacity~* transferrin saturation (TSAT)"
61914026|NCT01254942|ACTIVE_COMPARATOR|Usual Care|Usual care following hip fracture
61914027|NCT01254942|EXPERIMENTAL|Intervention|Follow-up Fracture Clinic
61914028|NCT00527488|EXPERIMENTAL|Degarelix 16+16 mg|
61914029|NCT00527488|EXPERIMENTAL|Degarelix 32 mg|
61914030|NCT00527488|EXPERIMENTAL|Degarelix 32+32 mg|
61914031|NCT00527488|EXPERIMENTAL|Degarelix 64 mg|
62107427|NCT05688280|EXPERIMENTAL|Colorectal Cancer (CRC)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
62107428|NCT05688280|EXPERIMENTAL|Non-Small Cell Lung Cancer (NSCLC)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
62107429|NCT05688280|EXPERIMENTAL|Soft Tissue Sarcoma (STS)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
62107430|NCT02540135|EXPERIMENTAL|Arm A|Flourescein plus intraoperative MRI
62107431|NCT02540135|ACTIVE_COMPARATOR|Arm B|intraoperative MRI alone
62107432|NCT01025206|EXPERIMENTAL|BI-505|
62107433|NCT05356403|EXPERIMENTAL|Difelikefalin 1 mg Oral Tablet|Patients receive oral difelikefalin 1 mg once daily
62107434|NCT05356403|PLACEBO_COMPARATOR|Placebo Oral Tablet|Patients receive oral placebo once daily
62107435|NCT01521585|EXPERIMENTAL|SEN0014196 50 mg oral tablet|
62107436|NCT01521585|EXPERIMENTAL|SEN0014196 200 mg oral tablet|
62107437|NCT01521585|PLACEBO_COMPARATOR|Placebo tablet|
62107438|NCT02242162||neuromuscular diseases|
62107439|NCT01358916|NO_INTERVENTION|Usual information policy|No specific intervention
62107440|NCT01358916|OTHER|Antibiotic therapy guidelines|
62107441|NCT06473519|EXPERIMENTAL|RSVpreF multidose vial (MDV)|RSVpreF with 2-PE formulated in an MDV
62298990|NCT02379858|PLACEBO_COMPARATOR|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
62298991|NCT04193683|SHAM_COMPARATOR|Sham-Ultrasound|Intervention will include one session sham-ultrasound application to both lower extremities of participant. The total time will be 15 minutes.
62107442|NCT06473519|EXPERIMENTAL|RSVpreF single-dose vial (SDV)|RSVpreF without 2-PE formulated in an SDV
62107443|NCT03645174|ACTIVE_COMPARATOR|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
62107444|NCT03645174|EXPERIMENTAL|Long tube|Fiberoptic-guided intubation through LMA, using long tube
62107445|NCT01051583|EXPERIMENTAL|Avastin , diode laser cyclophotcoagulation|Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
62107446|NCT01051583|ACTIVE_COMPARATOR|Diode Laser cyclophotocoagulation|Diode laser cyclophotocoagulation to control intraocular pressure
62107447|NCT01649635|EXPERIMENTAL|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3
62107448|NCT00005113|EXPERIMENTAL|1|Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
62107449|NCT00005113|EXPERIMENTAL|2|Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
62107450|NCT04444180||Clinical high risk for psychosis (CHR)|No intervention. Just use virtual hand illusion (VHI) paradigm to observe the outcome of individuals with CHR at one-year follow-up node and analyze the predictive role of self-representation in transition into psychosis.
61914032|NCT01945710|EXPERIMENTAL|Eribulin-LF Schedule 1|"Schedule 1: Eribulin-LF administered as IV infusion on Day 1 of a 21-day cycle starting at 1 mg/m\^2 escalating up to 3.5 mg/m\^2.~Schedule 1a: Eribulin-LF administered as IV infusion on Day 1 of a 28-day cycle starting at 1 mg/m\^2 escalating up to 3.5 mg/m\^2 (only to be investigated in the event that a 21-day cycle is considered inappropriate)."
62107451|NCT04444180||First episode of schizophrenia (FES)|In contrast to FES, it is anticipated to observe CHR individuals with similar behavioral performance to FES may presented higher risk of transition.
61914033|NCT01945710|EXPERIMENTAL|Eribulin-LF Schedule 2|Schedule 2: Eribulin-LF administered as IV infusion on Day 1 and Day 15 of a 28-day cycle starting at 1 mg/m\^2 escalating up to 3.5 mg/m\^2 (only to be investigated in the event that a 21-day cycle is considered appropriate).
61914034|NCT04241679|EXPERIMENTAL|Intervention Group|Patients undergoing a translabyrinthine approach for vestibular schwannoma resection will have the health of their auditory nerve monitored during tumor dissection. If the auditory nerve is visually confirmed to be intact, then concurrent cochlear implantation will be performed.
61914035|NCT03549793|EXPERIMENTAL|dance thrapy|4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
61914036|NCT03549793|ACTIVE_COMPARATOR|exercises without dance|4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)
62107452|NCT04444180||Healthy control (HC)|In contrast to HC, it is anticipated to observe CHR individuals with similar behavioral performance to HC may presented lower risk of transition.
62107453|NCT01695317|ACTIVE_COMPARATOR|Acetyl-L-carnitine|Acetyl-L-carnitine tablets
62107454|NCT01695317|PLACEBO_COMPARATOR|Sugar pills|Glucose with lemon acid
62107455|NCT05300451|EXPERIMENTAL|HLA Desensitization Group|Subjects awaiting cardiac transplantation with high levels of circulating Human Leukocyte Antigen (HLA) antibodies will receive daratumumab/hyaluronidase-fihj.
61914037|NCT03779243|EXPERIMENTAL|5mg Melatonin and Sleep Education|Participants will take 5mg Melatonin nightly, 1 hour before bedtime and be provided educational materials to improve sleep hygiene. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits.
61914038|NCT03779243|PLACEBO_COMPARATOR|Placebo Control|"Participants will be given placebo pills to be taken daily 1 hour before bedtime and are a sleep aid. Participants will not receive any sleep education materials. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits."
61914039|NCT04438070|PLACEBO_COMPARATOR|Daily active screening only|
61914040|NCT04438070|EXPERIMENTAL|Daily active screening and self-collected nasal swab|
61914041|NCT04438070|EXPERIMENTAL|Daily active screening and self-collected oral-nasal swab|
61914042|NCT04438070|EXPERIMENTAL|Daily active screening and nurse collected nasopharyngeal swab|
62107456|NCT02856711|EXPERIMENTAL|Trauma-informed group|These groups will use the enhanced Centering Pregnancy curriculum.
62107457|NCT02856711|NO_INTERVENTION|Control group|These groups will use the standard CenteringPregnancy curriculum.
62107458|NCT04074551|EXPERIMENTAL|Experimental|HCP1701
62107459|NCT04074551|ACTIVE_COMPARATOR|Active Comparator 1|HGP0904, HGP0608
62107460|NCT04074551|ACTIVE_COMPARATOR|Active Comparator 2|HGP0608, HCP1306
62107461|NCT00677248|PLACEBO_COMPARATOR|1|Ezetimibe and placebo
62107462|NCT00677248|EXPERIMENTAL|2|Eprotirome dose 1 and ezetimibe
62107463|NCT00677248|EXPERIMENTAL|3|Eprotirome dose 2 and ezetimibe
62107464|NCT00677248|EXPERIMENTAL|4|Eprotirome dose 3 and ezetimibe
62107465|NCT02780362|EXPERIMENTAL|A Test|Test drug (Prodactariv)1 tablet contains 60 mg Daclatasvir
62107466|NCT02780362|ACTIVE_COMPARATOR|B Reference|Reference drug (Clatazev) 1 tablet contains 60 mg Daclatasvir
62107467|NCT04666337|ACTIVE_COMPARATOR|Group B (bupivacaine group)|patients received 20 ml bupivacaine 0.5% plus normal saline (2ml)
62107468|NCT04666337|ACTIVE_COMPARATOR|Group F (fentanyl group)|patients received 20 ml bupivacaine 0.5% plus fentanyl (100µg-2 ml)
62107469|NCT04666337|ACTIVE_COMPARATOR|Group T (tramadol group)|patients received 20 ml bupivacaine 0.5% plus tramadol (100mg-2 ml)
62107470|NCT05737550|EXPERIMENTAL|Subjects with confirmed SUD|Evaluation of the usability of Previct Drugs when used in the intended population (patients with SUD).
62107471|NCT00601029||1|Winter Phase - Observational
62107472|NCT00601029||2|Summer Phase - Observational
62107473|NCT03737669|EXPERIMENTAL|Mirasol-treated Fresh Whole Blood|Standard Fresh Whole Blood, treated with Mirasol Pathogen Reduction Technology
62107474|NCT03737669|PLACEBO_COMPARATOR|Standard Fresh Whole Blood|Standard-issue fresh whole blood
62107475|NCT04655118|EXPERIMENTAL|Cohort 1a, Relapsed/Refractory Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
62669282|NCT02568254|ACTIVE_COMPARATOR|Lens 1/ Lens 2/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
62669283|NCT02568254|ACTIVE_COMPARATOR|Lens 1 / Lens 3 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
62669284|NCT02568254|ACTIVE_COMPARATOR|Lens 2/ Lens 3/ Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
62669285|NCT02568254|ACTIVE_COMPARATOR|Lens 2 / Lens 1/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
62669286|NCT02568254|ACTIVE_COMPARATOR|Lens 3 / Lens 1 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
62107476|NCT04655118|EXPERIMENTAL|Cohort 1b, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
62107477|NCT04655118|EXPERIMENTAL|Cohort 1c, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
62107478|NCT04655118|EXPERIMENTAL|Cohort 1d, Relapsed/Refractory Myelofibrosis|450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
62107479|NCT04655118|EXPERIMENTAL|Cohort 2a, JAKi Intolerant Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
62669287|NCT02568254|ACTIVE_COMPARATOR|Lens 3 / Lens 2 / Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
62107480|NCT04655118|EXPERIMENTAL|Cohort 2b, JAKi Intolerant Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
62107481|NCT04655118|EXPERIMENTAL|Cohort 3a, JAKi Ineligible Myelofibrosis with platelet count of ≥ 25 and < 50 × 109/L|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
62298992|NCT04193683|EXPERIMENTAL|Myofascial Release Technique+Sham-Ultrasound|In addition to one session sham-ultrasound, the intervention will include one session myofascial release technique to both lower extremities of participant. The total time will be 30 minutes.
62298993|NCT04644718|EXPERIMENTAL|Anodal-tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with real tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
62669288|NCT03850587|EXPERIMENTAL|YYC301-1 & Celocoxib placebo|"YYC301-1 one capsule and Concomitant Drug Celocoxib placebo.~\*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex)."
62669289|NCT03850587|EXPERIMENTAL|YYC301-2 & Celocoxib placebo|"YYC301-2 one capsule and Concomitant Drug Celocoxib placebo.~\*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)"
62669290|NCT03850587|EXPERIMENTAL|YYC301-3 & Celocoxib placebo|"YYC301-3 one capsule and Concomitant Drug Celocoxib placebo.~\*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)"
62669291|NCT03850587|ACTIVE_COMPARATOR|YYC301 placebo & Celecoxib|Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
62669292|NCT04516200|EXPERIMENTAL|Transcranial direct current stimulation|Transcranial direct current stimulation will be applied to study group only . Anodal transcranial stimulation will be applied on left somatosensory cortex while the cathodal one will be applied on right supra-orbital area with frequency of 2m.A for 20 minutes.Stimulation will be applied three times per week for two months.
62669293|NCT04516200|PLACEBO_COMPARATOR|traditional physical therapy program|traditional physical therapy program will be applied to both the control group and study group. It will be consist of sensory re-education training and balance training.Exercises will be applied three times per week for two months
62669294|NCT04717583|EXPERIMENTAL|IPL-treated side|For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits, the IPL-treated side of the face will be treated with IPL, once every 4 weeks for 3 consecutive times.
61914043|NCT05027295|ACTIVE_COMPARATOR|Continuous UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of continuous UVA light for 7.5 minute exposure time
62107482|NCT04655118|EXPERIMENTAL|Cohort 3b, JAKi Ineligible Myelofibrosis with platelet count of ≥ 25 and < 50 × 109/L|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
62107483|NCT04655118|EXPERIMENTAL|Cohort 5a, Indolent Systemic Mastocytosis|TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle in combination with best supportive care (BSC).
62107484|NCT04655118|EXPERIMENTAL|Cohort 5b, Indolent Systemic Mastocytosis|TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle in combination with BSC.
62107485|NCT04655118|EXPERIMENTAL|Cohort 5c, Indolent Systemic Mastocytosis|TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle in combination with BSC.
62107486|NCT04655118|EXPERIMENTAL|Cohort 5d, Indolent Systemic Mastocytosis|TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle in combination with BSC.
62107487|NCT04655118|PLACEBO_COMPARATOR|Cohort 5e, Indolent Systemic Mastocytosis|Placebo to match TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle in combination with BSC.
62298994|NCT04644718|SHAM_COMPARATOR|sham tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with sham tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
62298995|NCT05929495|EXPERIMENTAL|Metformin|"25 patients with GBM will take 1g/day of Metformin (2 tablets of 500 mg) for two weeks and then take 2g/day of Metformin for a total of 6 weeks. At the end of 6 weeks, treatment with Metformin alone will be continued for 4 weeks.~Thereafter, the second-phase Stupp protocol (adjuvant TMZ) + metformin is resumed continuously until the end of the enrollment period, i.e., 58 weeks from the start of treatment, for each patient."
62298996|NCT01053312|EXPERIMENTAL|1 flutemetamol|
62298997|NCT00476086|EXPERIMENTAL|Oxaliplatin/ Gemcitabine Then Radiation|Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed.
62669295|NCT04717583|NO_INTERVENTION|Control side|"For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits (before Week 12), the control side of face will not be treated by IPL.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
62669296|NCT04775134||Subjects with earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
62669297|NCT04775134||Subjects WITHOUT earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
62669298|NCT06301152|EXPERIMENTAL|high intensive laser|high-intensity laser was applied 3 times in a week, for three weeks, total of 9 sessions
62298998|NCT03728049|EXPERIMENTAL|CT-ADP group|PVR assessment with the standard methods and with the CT-ADP that will be provided to the operator in real-time during TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator and based on the results of the CT-ADP on top of the standard methods of PVR assessment.
62298999|NCT03728049|OTHER|Control group|PVR assessment with standard methods only (at discretion of the operator excluding CT-ADP and transesophageal echocardiography). CT-ADP will not be provided to the operator at the time of TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator according to the results of the standard methods of PVR assessment.
62299000|NCT01682044|EXPERIMENTAL|Treatment (colony-stimulating factor and monoclonal antibody)|Patients receive pegfilgrastim SC followed by rituximab IV 3 days later in weeks 1, 3, 5, 7, 15, 23, 31, and 39. Treatment continues in the absence of disease progression or unacceptable toxicity.
62669299|NCT06301152|EXPERIMENTAL|extracorporeal shock wave therapy|extracorporeal shock wave therapy was applied once a week, for three weeks total of 3 sessions
62669300|NCT02440399|EXPERIMENTAL|Fix protocol - Oral treatment|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
62669301|NCT02440399|EXPERIMENTAL|Spinal morphine|The women will receive 150 mcg morphine with the spinal anesthesia given in the cesarean section
61914044|NCT05027295|ACTIVE_COMPARATOR|Pulsed UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of pulsed UVA light for 15 minute exposure time
61914045|NCT02475824|EXPERIMENTAL|MMD arm|Both midazolam® (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea) are given intravenously at the initiation of sedation. In addition, a continuous IV infusion of dexmedetomidine (1ug/kg/h, Precedex; Hospira, Seoul, Republic of Korea) is administered 15 min before the ERCP till complete procedure
61914046|NCT02475824|ACTIVE_COMPARATOR|BPS arm|IV bolus dose of midazolam® (0.06mg/kg, 50% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea). Repeated doses of 10-20 mg propofol® are titrated to achieve the target level of sedation. 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
62107488|NCT05880316|EXPERIMENTAL|Intermittent Fasting Group|IF regime: 3 fasting day: 4 non-fasting day. On fasting day - allows to eat restricted calorie diet (up to 70% total daily calorie intake) for 8 hours.
62107489|NCT05880316|NO_INTERVENTION|Non-Fasting Group|Usual care. Not allowed to fast
62299001|NCT06657404|EXPERIMENTAL|experimental group|use Amiodarone, Bisoprolol and Digoxin
62299002|NCT06657404|ACTIVE_COMPARATOR|control group|use Bisoprolol and Digoxin
62469698|NCT03190005||group 4|normo-reactive responser after clopidogrel.
62469699|NCT03190005||group 5|reaction after OPC-13013
62469700|NCT03190005||group 6|reaction after AR-C
62107490|NCT01117441|ACTIVE_COMPARATOR|R1 control arm|see detailed protocol description
62107491|NCT01117441|EXPERIMENTAL|R1 experimental arm|see detailed protocol description
61914047|NCT04276727|ACTIVE_COMPARATOR|Menthol|Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
62107492|NCT01117441|ACTIVE_COMPARATOR|R2 control arm|see detailed protocol description
62107493|NCT01117441|EXPERIMENTAL|R2 experimental arm|see detailed protocol description
62107494|NCT01117441|ACTIVE_COMPARATOR|R-HR control arm|see detailed protocol description
62107495|NCT01117441|EXPERIMENTAL|R-HR experimental arm|see detailed protocol description
62107496|NCT01921140|OTHER|Fasted|Olaparib tablets following no breakfast
62107497|NCT01921140|OTHER|High-fat meal|Olaparib tablets after high-fat breakfast
62107498|NCT03210727|OTHER|single arm|This arm will be used to pilot test the Ready to CARE program (with the caregivers) and measure outcomes (in the patients).
62107499|NCT05159128|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD) Cohorts|Healthy Japanese participants will receive JNJ-75105186 or matching placebo orally in Cohorts 1-3.
61914048|NCT04276727|PLACEBO_COMPARATOR|Placebo|Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
62107500|NCT05159128|EXPERIMENTAL|Part 2: Single Dose (SD) Cohort|Healthy Chinese participants will receive JNJ-75105186 or matching placebo orally in Cohort 4.
62107501|NCT00781690|EXPERIMENTAL|1|Treatment with Evodial with reduction of heparin across study period
62107502|NCT05046158|ACTIVE_COMPARATOR|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using Transforming Powder Dressing and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to other standard of care dressings used to treat diabetic foot ulcers.Surveys regarding pain and quality of life will be completed at each study visit.
62299003|NCT02956655|EXPERIMENTAL|Fasting therapy|Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs.
62299004|NCT02956655|ACTIVE_COMPARATOR|Insulin intensive therapy|Insulin intensive therapy, receive continuous subcutaneous insulin infusion. (Human Insulin (Novolin-R, Novo Nordisk) Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland). The insulin dose used will be adjusted everyday according to their glucose by a physician until a target blood glucose level been reached.
62299005|NCT02494141|EXPERIMENTAL|Curcumin|25/mg/kg per day for 1 year.
62299006|NCT02494141|PLACEBO_COMPARATOR|Placebo|Equivalent placebo for 1 year.
62299007|NCT05893134||Main|Information from entomological, housing condition, and sociodemographic surveys of the El Vergel neighborhood, Tapachula, Chiapas, obtained during the period from November to December 2019, will be used
62299008|NCT05418712|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to VX-150.
62299009|NCT05418712|EXPERIMENTAL|VX-150|Participants will be randomized to receive a single dose of one of different dose levels VX-150.
62737244|NCT02471118|EXPERIMENTAL|1st 50 subjects to Enter the Study|"At Baseline, subjects will be randomized (1:1) to receive study drug (Adalimumab or placebo). The study drug will be provided as a subcutaneous injection (pre-filled syringe) either Adalimumab (ADA) 40 mg/0.8 mL,every other week (EOW) or matching placebo for Adalimumab every other week for 16 weeks. Efficacy will be assessed at Week 16 while the safety of the study drug will be monitored throughout the study.~At Week 16 all subjects will begin to receive open label ADA 40 mg EOW and will continue to receive open label ADA up to Week 50. An End of Study visit will be done at Week 52. A Telephone Follow-up will be done at Week 62 to review Adverse Events and Concomitant Medications."
61914049|NCT01375283||lung cancer surgery|
62107503|NCT05046158|ACTIVE_COMPARATOR|Standard of Care Dressing|Half of the subjects will be randomized to receive standard of care wound dressings to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using standard of care wound products, and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to transforming powder dressings used to treat diabetic foot ulcers. Surveys regarding pain and quality of life will be completed at each study visit.
62107504|NCT05866510|EXPERIMENTAL|Utidelone and Anlotinib|The treatment group will be treated with Utidelone and Anlotinib until the presence of progressive disease or unacceptable toxicity.
62107505|NCT00618319|EXPERIMENTAL|1|BIIB021
62299010|NCT05139030|EXPERIMENTAL|Cohort 1: EXPAREL admix arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
62299011|NCT05139030|ACTIVE_COMPARATOR|Cohort 1: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
62299012|NCT05139030|EXPERIMENTAL|Cohort 2: EXPAREL admix arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
62299013|NCT05139030|ACTIVE_COMPARATOR|Cohort 2: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
62299014|NCT05742386|EXPERIMENTAL|HPV vaccine communication training|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.
62469701|NCT03190005||group 7|reaction after simastatin
61914050|NCT03894722|PLACEBO_COMPARATOR|Group I (control; saline only)|Control Group: Intraoperative irrigation with saline solution only.
62107506|NCT03058783|EXPERIMENTAL|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
62107507|NCT03058783|ACTIVE_COMPARATOR|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
62107508|NCT03284749|EXPERIMENTAL|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
62107509|NCT03284749|PLACEBO_COMPARATOR|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
62107510|NCT03284749|EXPERIMENTAL|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
61914051|NCT03894722|EXPERIMENTAL|Group II (0.5% concentration of PVP-I )|Experimental Group: Intraoperative irrigation with 0.5% concentration of PVP-I solution.
62107511|NCT03284749|PLACEBO_COMPARATOR|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
62107512|NCT02809300|EXPERIMENTAL|ankylosing spondylarthritis|
62107513|NCT01360190|ACTIVE_COMPARATOR|fluoxetine|
62107514|NCT01360190|PLACEBO_COMPARATOR|placebo|
62107515|NCT04554823|PLACEBO_COMPARATOR|Control Group|Will attend lectures on health education.
62107516|NCT04554823|EXPERIMENTAL|Exercise Group|Will be subjected to a supervised training program of combined exercises for 24 weeks, with a frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week and Will attend lectures on health education.
62107517|NCT04579510|ACTIVE_COMPARATOR|nOPV2 only|Participants in this arm will receive nOPV2 at 6, 10, and 14 weeks of age
62299015|NCT05742386|EXPERIMENTAL|HPV vaccine communication training and standing orders optimization|Staff in clinics randomized to this arm will receive the AAT and conduct a set of activities to optimize use of HPV vaccine standing orders.
61914052|NCT03894722|EXPERIMENTAL|Group III (1% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 1% concentration of PVP-I solution.
61914053|NCT03894722|EXPERIMENTAL|Group IV (3% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 3% concentration of PVP-I solution.
62299016|NCT04700267|EXPERIMENTAL|GLPG3970|One dose level of GLPG3970
62299017|NCT04700267|PLACEBO_COMPARATOR|Placebo|One dose level of Placebo
62737245|NCT02471118|EXPERIMENTAL|2nd group of 50 subjects|At Baseline, subjects will be randomized (1:1) to receive either adalimumab 40 mg every other week or placebo for 16 weeks. All subjects will begin to receive open label adalimumab 40 mg every other week from week 16-week 30, with An End of Study visit at Week 32. A Telephone Follow-up will be done at Week 42 to review Adverse Events and Concomitant Medications.
61914054|NCT04321785|PLACEBO_COMPARATOR|Placebo|
61914055|NCT04321785|EXPERIMENTAL|Caffeine|
61914056|NCT00476671||1|HIV infected adults with viral load \< 50 copies/ml on NNRTI based HAART
61914057|NCT00674154|EXPERIMENTAL|Vitamin D group|Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
61914058|NCT00674154|PLACEBO_COMPARATOR|Placebo group|Placebo, two tablets daily in 52 weeks.
62107518|NCT04579510|ACTIVE_COMPARATOR|nOPV2 and bOPV|Participants in this arm will receive both nOPV2 and bOPV at 6, 10, and 14 weeks of age
62107519|NCT04579510|ACTIVE_COMPARATOR|bOPV only|Participants in this arm will receive bOPV at 6, 10, and 14 weeks of age
62107520|NCT01672320||Phase II|An evaluation of long-term outcomes, patient reported outcomes, and radiographic analysis will be conducted prospectively on 500 patients
61914059|NCT03443947|EXPERIMENTAL|D group|
62107521|NCT01672320||Phase I|An analysis of post-operative component positioning will be evaluated for 500 patients, retrospectively.
62107522|NCT06199687|EXPERIMENTAL|Experimental group|The patients in the experimental group were shown a virtual reality video called 'Turkey 4K - Scenic Relaxation Film With Calming Music', containing images of nature and sea with music, for 15 minutes using virtual reality glasses.
62107523|NCT06199687|NO_INTERVENTION|Control Group|Patients received standard care.
62107524|NCT04164524||Group; A|Open technique Hernioplasty for abdominal hernia in which 160 mg Gentamycin spray applied over the mesh
62107525|NCT04164524||Group; B|Open technique Hernioplasty for abdominal hernia in which no Gentamycin spray applied over the mesh
62107526|NCT06607705|EXPERIMENTAL|Surgery required glaucoma|Treatment group
62107527|NCT06607705|EXPERIMENTAL|Medically controlled glaucoma|Control group
62107528|NCT05317793||Professionals|150 knowledge workers from three Finnish companies.
62107529|NCT03072355|ACTIVE_COMPARATOR|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
62107530|NCT03072355|ACTIVE_COMPARATOR|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
62299018|NCT00909272||US-guided lumbar medial branch block|Patients who have low back pain and/or leg pain due to possible lumbar facet joint disease .
62299019|NCT00909272||Cadavers for Ultrasound landmarks|Cadavers donated to the Department of Anatomy in McMaster University will be used to determine the landmarks for ultrasound.
62299020|NCT02590393|EXPERIMENTAL|Nicotine + NNTAs|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain tobacco extract with nicotine + NNTAs in a vehicle of propylene glycol and vegtable glycerin, with tobacco or menthol flavor matched to each participant's preference. The yields of nicotine and NNTAs will be in the range of typical commercial cigarettes.
62299021|NCT04269551|EXPERIMENTAL|BIVV020 IV|Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.
62299022|NCT03384992|EXPERIMENTAL|Group 1|Participants were exposed to the following conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
62469702|NCT02109692|OTHER|cohort|blood sample : doage of miRNA
62669302|NCT04715100||Experimental group|"The inclusion criteria to participate in the present study are patients: with a diagnosis of hemophilia A and B; adults; and on a prophylactic or on-demand treatment regimen with FVIII / FIX concentrates.~For their part, patients with: neurological or cognitive alterations that impede understanding of the questionnaires will be excluded from the study; Dependent patients who require help from a third person to get around; patients who have developed a hemarthros in the 4 weeks prior to the study; and those who have not signed the informed consent document.~For inclusion in the study, patients will continue to be administered the dose of FVIII / FIX concentrates, following the guidelines of the medical criteria established by their reference hematologist. Throughout this study, the medical criteria for drug treatment, the dosage, and the replacement treatment periods will not be changed."
62299023|NCT03384992|EXPERIMENTAL|Group 2|Participants were exposed to the one of the following usual care conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3.
62299024|NCT03384992|EXPERIMENTAL|Group 3|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
62299025|NCT03384992|EXPERIMENTAL|Group 4|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
62299026|NCT03384992|EXPERIMENTAL|Group 5|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
62299027|NCT03384992|EXPERIMENTAL|Group 6|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
62299028|NCT03384992|EXPERIMENTAL|Group 7|Participants were exposed to the following conditions: cognitive restructuring for week 1, worry practice for week 2, and General Health and Diet (General and BCSS) for week 3. Telephone coaching was given.
62299029|NCT03384992|EXPERIMENTAL|Group 8|Participants were exposed to the following conditions: cognitive restructuring for week 1, scheduled worry practice for week 2, and General Health and Diet (General and BCSS) for week 3.
62669303|NCT00647023|EXPERIMENTAL|A|
62669304|NCT04971824|EXPERIMENTAL|Physiotherapeutic arm|"There will be the physiotherapeutic intervention, total duration for each participant is three months.~The participants will be asked to fill three validated questionnaires in the beginning and in the end of study and keep records of their exercises, period and ovulation in their diaries."
62669305|NCT00682838|EXPERIMENTAL|Self-Management (SM)|Active Intervention - Self-management: Self-management Educational component focused on sleep apnea and CPAP from a self-management perspective
62669306|NCT00682838|ACTIVE_COMPARATOR|Telemonitored Care (TC)|Active Comparator - Telemonitored care: Telemonitored care Consists of CPAP therapist actively monitoring care at a distance, and acting on that data per a set protocol
61914060|NCT00278915|EXPERIMENTAL|Fulvestrant|Participants will receive intramuscular injection of fulvestrant 2 mg/kg or 4 mg/kg (First 10 participants will be dosed at 2 mg/kg then increased to 4 mg/kg. All subsequent participants will be dosed at 4 mg/kg) into the buttock or thigh monthly for 12 months or until the participant demonstrates lack of efficacy based upon one or more of the primary endpoints or experiences a serious drug-related toxicity requiring treatment discontinuation.
61914061|NCT01373671|OTHER|Mammography exam|Siemens DBT scan
61914062|NCT04441762|ACTIVE_COMPARATOR|intravenous|30 mg intravenous ketorolac in 10 ml syringe + 1 mL Normal Saline 9% using an intranasal device (0.5 ml in each nostril).
61914063|NCT04441762|EXPERIMENTAL|Intranasal|30 mg intranasal ketorolac in 1 ml intranasal device (0.5 ml in each nostril) + 10 ml Intravenous Normal Saline 9%.
61914064|NCT06354556|EXPERIMENTAL|Single arm|
61914065|NCT01278654|ACTIVE_COMPARATOR|Personal incentive|If participants attain their walkstation usage goal, they are entered into bi-weekly lotteries to win money.
61914066|NCT01278654|ACTIVE_COMPARATOR|Token incentive|Participants who attain their walkstation usage goal will be entered into a bi-weekly prize to win a token reward.
61914067|NCT03306797|EXPERIMENTAL|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
61914068|NCT03306797|OTHER|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
61914069|NCT01649453||Cancer of uncertain primary|
61914070|NCT05711303|ACTIVE_COMPARATOR|Superba Boost|One 1000 mg capsule per day Superba Boost for 12 weeks
61914071|NCT05711303|PLACEBO_COMPARATOR|Placebo|One 1000 mg capsule per day placebo for 12 weeks
61914072|NCT04050020|ACTIVE_COMPARATOR|Group A|
62107531|NCT01066741|EXPERIMENTAL|Homeodent®|Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.
62107532|NCT01066741|ACTIVE_COMPARATOR|1.4 % Sodium Bicarbonate solution|"Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.~In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis."
62107533|NCT02840994|EXPERIMENTAL|CV301 + Pembrolizumab|CV301 + Pembrolizumab (Phase 1b portion of the trial)
62107534|NCT02840994|EXPERIMENTAL|CV301 + Nivolumab|CV301 + Nivolumab (Phase 1b portion of the trial)
62107535|NCT06425237|NO_INTERVENTION|standard care|
62107536|NCT06425237|EXPERIMENTAL|standard care and music therapy|
62107537|NCT06425237|EXPERIMENTAL|standard care and aromatherapy|
62107538|NCT06425237|EXPERIMENTAL|standard care ansd music therapy and aromatherapy|
62107539|NCT06259448|EXPERIMENTAL|urine self-sampling|urine self-sampling
62107540|NCT06125678|EXPERIMENTAL|Small intestinal contrast enhanced ultrasound followed by cross sectional imaging|Patients shall be undergoing small intestinal contrast enhanced ultrasound followed by cross sectional imaging
62107541|NCT00982254|EXPERIMENTAL|Oral Insulin|oral insulin capsule formulation
62107542|NCT00982254|ACTIVE_COMPARATOR|Subcutaneous Insulin|Subcutaneous injection of regular human insulin
62107543|NCT03045692|ACTIVE_COMPARATOR|Control group|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
62107544|NCT03045692|EXPERIMENTAL|Study group|4 hour creatinine clearance is used to decide colistin maintenance dosage.
62107545|NCT02823496|EXPERIMENTAL|Arm 1|All subjects are patched with the same product
62107546|NCT05657327||Group with postoperative complications|Postoperative complications such as pancreatic fistula, postoperative bleeding and delayed gastric emptying
62299030|NCT03384992|EXPERIMENTAL|Group 9|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3. Telephone coaching was given.
62299031|NCT03384992|EXPERIMENTAL|Group 10|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3.
62107547|NCT05657327||Group without postoperative complications|No postoperative complications such as pancreatic fistula, postoperative bleeding and delayed gastric emptying
62107548|NCT01227642|EXPERIMENTAL|pre-implant transrectal ultrasound images and planning|Transrectal ultrasound session will be performed at a separate session prior to the implant.
62107549|NCT01816113|EXPERIMENTAL|Group 1|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly
62107550|NCT01816113|EXPERIMENTAL|Group 2A|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly
62107551|NCT01816113|EXPERIMENTAL|Group 2B|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10\^8 pfu 8 weeks later intramuscularly
62107552|NCT01816113|EXPERIMENTAL|Group 2C|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10\^8 pfu 8 weeks later intramuscularly
62107553|NCT01343654|EXPERIMENTAL|Text messaging|Participants randomized to this arm will receive a mobile phone if needed, and the 12 week personalized text messaging/EMA intervention
62107554|NCT01343654|ACTIVE_COMPARATOR|Treatment as usual|Participants randomized to this arm will receive treatment as usual in the ID clinics and in the communities for nonadherence and drug use problems
62107555|NCT05108896|OTHER|Aspiration in Acute Respiratory Failure Survivors|All participants will receive a tracheal ultrasound within 72 hours prior to extubation, collection of demographic and hospital clinical information, administration of 3 screening tests (study defined algorithm test, 3-ounce water swallow test, TOR-BSST) addressing swallowing function within 24 hours post-extubation, and a fiberoptic endoscopic examination of swallowing (FEES) exam.
62107556|NCT06628726|EXPERIMENTAL|Neonates|Neonates with persistent neonatal jaundice underwent liver biopsy
62107557|NCT03237936|EXPERIMENTAL|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
62107558|NCT05717686|EXPERIMENTAL|Part A: SAD in healthy participants|Part A: Single ascending doses of up to 450 mg AHB-137 by subcutaneous (SC) injection in healthy participants.
62107559|NCT05717686|EXPERIMENTAL|Part B: MD in healthy participants|Part B: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in healthy participants.
62107560|NCT05717686|EXPERIMENTAL|Part C: MD in CHB patients (open label)|Part C: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients.
62107561|NCT05717686|EXPERIMENTAL|Part D: MD in CHB patients in multiple centers|Part D: Multiple doses of 200 mg or 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients (Multiple centers across multiple regions).
62107562|NCT05386602||Prior trial patients|In stage III, patients who have been on an experimental cancer medicine trial for less than six weeks will complete a draft PREM-ECM (less than six weeks), the EORTC PATSATC33 and HAD questionnaires at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 patients will be asked to repeat the draft of the PREM-ECM (less than six weeks) approximately one week later at time point 2 (T2). In stage IV, the PREM-ECM will be administered alone.
62299032|NCT03384992|EXPERIMENTAL|Group 11|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
62299033|NCT03384992|EXPERIMENTAL|Group 12|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3.
61914073|NCT04050020|PLACEBO_COMPARATOR|Group B|
61914074|NCT06144762|EXPERIMENTAL|Blood sample and tissue sample|Blood sample and tissue sample
61914075|NCT04300959|EXPERIMENTAL|Experimental group|Anlotinib in combination with Sintilimab with Gemcitabine plus(+)Cisplatin
62669307|NCT00682838|EXPERIMENTAL|SM + TC|Self-management and Telemonitored care: Combination of both SM + TC intervention
62107563|NCT05386602||On trial patients|In stage III, patients who have been on an experimental cancer medicine trial for more than six weeks will complete a draft PREM-ECM (more than six weeks), the EORTC PATSATC33 and HAD questionnaires at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 patients will be asked to repeat the draft of the PREM-ECM (more than six weeks) approximately one week later at time point 2 (T2). In stage IV, the PREM-ECM will be administered alone.
62299034|NCT03384992|EXPERIMENTAL|Group 13|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
62669308|NCT00682838|NO_INTERVENTION|Usual care (UC)|Control Group
62669309|NCT03581747||Subjects with atopic dermatitis|
62669310|NCT03581747||Controls|
62669311|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
62737246|NCT04732442|EXPERIMENTAL|Immuno-group|The immuno-group will consist of patients who, as part of preoperative nutritional support, used immunonutrition ONS (2x Impact Oral® Nestle, Switzerland per day) for 2 weeks before surgery.
62737247|NCT04732442|SHAM_COMPARATOR|Control-group|The control group will consist of patients who, as part of preoperative nutritional support, used standard ONS (3x Fortimel Compact Protein® Nutricia, United Kingdom per day) for 2 weeks before surgery.
61914076|NCT04300959|ACTIVE_COMPARATOR|Control group|Standard platinum-based chemotherapy
61914077|NCT01613976|EXPERIMENTAL|Panobinostat and Azacitidine|combination regimen
61914078|NCT01701518|OTHER|Ozurdex|Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
61914079|NCT02767362|EXPERIMENTAL|Single Arm|Patients will undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgery. At the time of hysterectomy and surgical staging, women will undergo repeat endometrial biopsy in the operating room under general anesthesia.
61914080|NCT01535664||dalfampridine-ER 10mg|Subjects with MS taking dalfampridine-ER 10mg and considered to be responders
61914081|NCT02166671|EXPERIMENTAL|HBV booster vaccination|
61914082|NCT02052765|EXPERIMENTAL|ajmaline test|All patients underwent ajmaline test for ST shift recording
61914083|NCT02355873|EXPERIMENTAL|AN69ST|AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter
61914084|NCT02355873|ACTIVE_COMPARATOR|AN69|AN69:original Polyacrylonitrile Membrane Hemofilter
61914085|NCT06092047|EXPERIMENTAL|UTAA09 cells for infusion|Off-the-shelf γδT cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day-7\~Day-2.
61914086|NCT06177275|EXPERIMENTAL|Thin vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal|In Thin vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
61914087|NCT06177275|ACTIVE_COMPARATOR|Thin vertical soft tissue biotype, Placement of BLX implants equicrestal|In Thin vertical soft tissue biotype, Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
61914088|NCT06177275|EXPERIMENTAL|Thick vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal|In Thick vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
61914089|NCT06177275|ACTIVE_COMPARATOR|Thick vertical soft tissue biotype, Placement of BLX implants equicrestal|In Thick vertical soft tissue biotype, Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
61914090|NCT03553966|EXPERIMENTAL|Tooth Brushing HAP+Restorative dentistry|"Arm Intervention: HA-Toothpaste Tooth Brushing HA Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite 3x daily over the duration of the study (336 days).~Procedure: Tooth Brushing HA"
61914091|NCT03553966|ACTIVE_COMPARATOR|Tooth Brushing F+Restorative dentistry|"Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (500 ppm F-), (three times daily over the duration of the study (336 days).~Intervention:~Procedure: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated toothpaste."
61914092|NCT02691598|EXPERIMENTAL|Group A|Dexmedetomidine Hydrochloride 4ug/ml；0.05ml/kg.h infusion for 24hours
61914093|NCT02691598|PLACEBO_COMPARATOR|Group B|Normal Saline 0.05ml/kg.h infusion for 24hours
61914094|NCT01284257||Enteric coated mycophenolate sodium (EC-MPS) arm|Patients to whom EC-MPS is prescribed by their practitioner.
61914095|NCT01284257||MMF arm|Patients to whom MMF is prescribed by their practitioner.
61914096|NCT01111929|ACTIVE_COMPARATOR|Counseling for LAM|"Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.~Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires."
61914097|NCT01111929|EXPERIMENTAL|Counseling for LAM+ LNG-EC|LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills
62107564|NCT05386602||Carers of patients|In stage III, carers of patients recruited on an experimental cancer medicine trial will be asked to complete a draft PREM-ECM-carers, the Adult Carer Quality of Life Questionnaire (AC-QOL), the EQ5D-5L, and the Hospital Anxiety and Depression Scale (HADS) at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 carers will be asked to repeat the draft of the PREM-ECM-carers approximately one week later at time point 2 (T2). In Stage IV, the PREM-ECM-carer will be administered alone.
62107565|NCT00477100||Observational (biospecimen and medical data collection)|Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
61914098|NCT05557318|EXPERIMENTAL|Bacterial infections|"The subject is infected with at least one of the following pathogens:~Bacterial vaginosis (BV) / Escherichia coli / Trichomonas / Group B streptococcus / Chlamydia trachomatis / Neisseria gonorrhoeae"
61914099|NCT05557318|EXPERIMENTAL|Fungal infection :|The subject is infected with Candida albicans only.
61914100|NCT05557318|EXPERIMENTAL|Mixed infection|Bacterial and fungal infections coexist.
62107566|NCT01912495|EXPERIMENTAL|Boceprevir, peginterferon ribavirin|All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.
62107567|NCT06631703|EXPERIMENTAL|Group receiving Oral Colostrum Administiration|In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued.
62107568|NCT06631703|NO_INTERVENTION|Routine Feeding Care|According to the NICU guidelines, The control group continued to receive the routine feeding plan. Within the scope of the study, infants in both groups received colostrum, the only difference being the route of administration. The control group received colostrum by gavage, and the study group received colostrum using an oropharyngeal route.
62107569|NCT00606866|PLACEBO_COMPARATOR|I|placebo pill
62107570|NCT00606866|ACTIVE_COMPARATOR|II|Sorafenib, 200 mg bid
62107571|NCT00606866|ACTIVE_COMPARATOR|III|Sorafenib, 400 mg bid
62469703|NCT04036422|EXPERIMENTAL|Computer based exercise group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week to a total of twenty hours over a four week period. In addition to this, these patients will receive half an hour of conventional occupational therapy and half an hour of Rejoyce computerized exercise seven days a week to a total of twenty eight hours over a four weeks period.
62669312|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
61914101|NCT05557318|EXPERIMENTAL|No infection|Healthy participant
61914102|NCT00562900|ACTIVE_COMPARATOR|A, robotic|
61914103|NCT00562900|ACTIVE_COMPARATOR|B, laparoscopic|
61914104|NCT02967380|EXPERIMENTAL|Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI)|Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.
61914105|NCT05046444||Unclear diagnosis via conventional methods|The study population consists of carefully chosen patients with potential hematological malignancy, for which current diagnostic methods were not sufficient to provide clear-cut diagnosis and definitive clinical guidance. SIRIUS will be conducted for a total number of 110 patients with inconclusive diagnosis by gold standard techniques for a total of up to nine months after the first enrollment.
61914106|NCT01884727|ACTIVE_COMPARATOR|ASEA water|Subjects to consume 4-ounces of ASEA water at 9:00 am before breakfast and 4-ounces of ASEA water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
61914107|NCT01884727|PLACEBO_COMPARATOR|Salt water|Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
62107572|NCT05627557|EXPERIMENTAL|Obinutuzumab (Group A)|Participants in Group A will receive obinutuzumab 1000 milligrams (mg) (or 20 mg/ kilogram \[kg\] for participants \<45 kg) administered by intravenous (IV) infusion on Days 1, 15, 168 (Week 24), and 182 (Week 26).
62107573|NCT05627557|ACTIVE_COMPARATOR|MMF (Group B)|Participants in Group B will receive oral MMF 600 mg/m\^2 twice a day (BID) (target 1200 mg/m2/day in divided doses, maximum 2 g/day) to Week 52.
62669313|NCT05864014|EXPERIMENTAL|Hetrombopag|
62107574|NCT03650322|EXPERIMENTAL|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
62299035|NCT03384992|EXPERIMENTAL|Group 14|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and General health and Diet (General and BCSS) for week 3.
62299036|NCT03384992|EXPERIMENTAL|Group 15|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and cognitive restructuring for week 3. Telephone coaching was given.
62299037|NCT03384992|EXPERIMENTAL|Group 16|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and cognitive restructuring for week 3.
62469704|NCT04036422|ACTIVE_COMPARATOR|Conventional treatment group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week, to a total of twenty hours over a four week period. In addition to this, patients in this group will receive one hourly sessions of conventional occupational therapy seven days a week to a total of twenty eight hours over a four week period.
62469705|NCT06234358||Calcanail cohort|Patients implanted with medical device under study between January 2012 and January 2020.
62469706|NCT06025188||training set|To determine potential predictive factors, the training set was subjected to LASSO regression analysis, which effectively eliminated several irrelevant or multicollinearity independent variables to reduce high-dimensional data
62669314|NCT05864014|EXPERIMENTAL|Hetrombopag plus Placebo|
62669315|NCT05864014|PLACEBO_COMPARATOR|Placebo|
62669316|NCT02102828|PLACEBO_COMPARATOR|Aspirin only|Patients receive aspirin therapy
62669317|NCT02102828|EXPERIMENTAL|extended compression|aspirin and extended compression therapy in combination
61914108|NCT05576974|ACTIVE_COMPARATOR|Part 1 - Cohort A|In Part 1 the single dose of 1 mg/kg of pegsitacianine given 6-100 hours prior to surgery will be used to image primary tumors in patients with HNSCC to evaluated to verify the diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes.
61914109|NCT05576974|ACTIVE_COMPARATOR|Part 2 - Cohort B|In Part 2, pegsitacianine the single dose of 1 mg/kg of given 6-100 hours prior to surgery will be used to in patients with unknown primary cancer of the head and neck. These patients typically undergo exam under anesthesia with a laryngoscopy as well as panendoscopy for identifying the source of the metastatic cancer found in the cervical nodes. The diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes in these patients will be evaluated. All the available data to date will be used to decide the additional tumor type(s), number of patients per tumor type, and number of Group(s) to be enrolled.
61914110|NCT04829578|OTHER|Hypnosis|hyspnosis treatment
61914111|NCT05048550|NO_INTERVENTION|A (control)|First visit assessments at 8 weeks corrected gestational age. No glasses prescribed.
61914112|NCT05048550|EXPERIMENTAL|B1 (intervention)|First visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed.
61914113|NCT05048550|EXPERIMENTAL|B2 (intervention)|First visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed.
61914114|NCT01211431|ACTIVE_COMPARATOR|Reference|Intrathécale morphine is used for post-cesarean pain control
61914115|NCT01211431|EXPERIMENTAL|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
61914116|NCT03010436|OTHER|Open-Label|All subjects will receive the study medication- benralizumab
62469707|NCT06025188||validation set|The multivariable logistic regression analysis was applied to determine the variables of soiling in patients with HSCR following surgery over one year of age. Finally, a nomogram was created based on the training set and validated in the validation set.
62469708|NCT03141671|EXPERIMENTAL|GnRH + Bicalutamide|"* GnRH agonist injection monthly or every 3 months for 6 months~* Bicalutamide by mouth once/day for 6 months~* Salvage radiation (starting 4-10 weeks after initiation of ADT)"
62669318|NCT01272778|EXPERIMENTAL|Lorazepam 0.2 mg|All subjects receive lorazepam 0.2 mg in this crossover design.
62669319|NCT01272778|EXPERIMENTAL|Lorazepam, 0.5 mg|All subjects receive lorazepam 0.5 mg in this crossover design.
62669320|NCT01272778|EXPERIMENTAL|Lorazepam, 1.0 mg|All subjects receive lorazepam 1.0 mg in this crossover design.
62107575|NCT03650322|ACTIVE_COMPARATOR|Stretching and Toning|This 12 week, progressive stretching and toning course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
62107576|NCT03650322|EXPERIMENTAL|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
62107577|NCT05080595|EXPERIMENTAL|Transportation assistance, reports unreliable transportation|Lyft rides provided to transplant-related appointments
62107578|NCT05080595|NO_INTERVENTION|No transportation assistance, reports unreliable transportation|No intervention, standard-of-care
62669321|NCT01272778|EXPERIMENTAL|Lorazepam, 2.0 mg|All subjects receive lorazepam 2.0 mg in this crossover design
62669322|NCT01272778|PLACEBO_COMPARATOR|Sugar pill|All subjects receive a sugar pill in this crossover design.
62299038|NCT05863247||pseudophakic patients with post-operative dysphotpsias|Patients who report dyshoptsias after bilateral in-the-bag implantation of a trifocal intra-ocular lens (AT LISA 839mp)
62669323|NCT02990143|NO_INTERVENTION|Glaucoma Drainage implant no Ologen|The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
62107579|NCT05080595|NO_INTERVENTION|Transportation assistance, control|No intervention, standard-of-care
62669324|NCT02990143|ACTIVE_COMPARATOR|Glaucoma Drainage implant with Ologen|the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
62107580|NCT06428786||Phenotype A|PHENOTYPE A: Hyperandrogenism + Ovulatory Dysfunction + Polycystic ovary morphology 44 participants
62107581|NCT06428786||Phenotype B|PHENOTYPE B: Hyperandrogenism + Ovulatory Dysfunction 44 participants
62107582|NCT06428786||Phenotype C|PHENOTYPE C: Hyperandrogenism + Polycystic ovary morphology 44 participants
62107583|NCT06428786||Phenotype D|PHENOTYPE D: Ovulatory Dysfunction + Polycystic ovary morphology 44 participants
62107584|NCT06256445|EXPERIMENTAL|AYP-101|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments
62669325|NCT03421080|ACTIVE_COMPARATOR|MoodGYM Only|The MoodGYM only Internet intervention will consist of a popular, automated, self-help cognitive behavioral therapy program for depression comprising five modules to be completed over five weeks and an online workbook incorporating 29 exercises. A series of published research trials has shown MoodGYM to be effective in reducing depressive symptoms in users in a range of settings (e.g., schools, universities, Lifeline suicide prevention, U.K. NHS Choices online), for different aspects of the mental health service spectrum (e.g., prevention vs treatment), and different age groups (adults, adolescents).
62299039|NCT05863247||pseudophakic patients without post-operative dysphotpsias|Patients who don't report dyshoptsias after bilateral in-the-bag implantation of a trifocal intra-ocular lens (AT LISA 839mp)
62299040|NCT00393822|EXPERIMENTAL|Palifermin|50 subjects to receive palifermin 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
62299041|NCT00393822|PLACEBO_COMPARATOR|Control Group|50 subjects to receive matched placebo 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
62299042|NCT04141696|EXPERIMENTAL|Ketamine|Given intravenously over 40 minutes
62299043|NCT04141696|ACTIVE_COMPARATOR|Midazolam|Given intravenously over 40 minutes
62299044|NCT00124306|ACTIVE_COMPARATOR|1|Amitryptiline
62669326|NCT03421080|EXPERIMENTAL|MoodGYM + CYD|The MoodGYM + CYD intervention condition will consist of the MoodGYM only intervention and an online intervention providing feedback on quantity and frequency of drinking, severity of hazardous drinking, and provides recommendations for safe levels of alcohol consumption (Check Your Drinking - CYD). The CYD Final Report will be provided as part of the participant's MoodDYM dashboard.
61914117|NCT04879602|EXPERIMENTAL|Bronchoscopy group|patients receive suction before extubation by bronchoscopy in PACU
62107585|NCT06256445|PLACEBO_COMPARATOR|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments
62107586|NCT05576051||All TNFi initiations|
62107587|NCT05576051||TNFi initiations after 11/6/2012 for comparisons with Tofacitinib initiators|
62107588|NCT05576051||RA patient in Corrona with initiation Tofacitinib during follow-up in Corron|
62107589|NCT01472536|EXPERIMENTAL|3-day sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms
62107590|NCT01472536|NO_INTERVENTION|Control|No intervention
62107591|NCT02199145|OTHER|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria /creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
62107592|NCT04726046|EXPERIMENTAL|Antibiotic treatment group|They were Antibiotic treatment group (AG, cefotetan 1g, 1 dose/prophylactic) before surgery.
62107593|NCT04726046|NO_INTERVENTION|Non-antibiotic treatment group|They were Non-antibiotics treatment such as cefotetan 1g before surgery.
62107594|NCT02594215|EXPERIMENTAL|Experimental|Experimental
62107595|NCT04428320|EXPERIMENTAL|Bupivicaine pelvic floor muscle injection|Five injections at pre-specified locations at pelvic floor muscle bilaterally after induction of general anesthesia for vaginal pelvic prolapse surgery
62107596|NCT04428320|NO_INTERVENTION|Standard of care (no injection) preoperatively|No injection - standard analgesia
62107597|NCT02135809|EXPERIMENTAL|FCSEMS|Patients will receive the WallFlex Pancreatic Stent.
62107598|NCT02801929|EXPERIMENTAL|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62107599|NCT05787444||symptomatic|Subject is currently exhibiting fever, or one or more symptoms associated with COVID-19 or influenza (such as, but not limited to, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea) and must present within 6 days of symptom onset. Subject must still be exhibiting symptoms on the day of sample collection.
62299045|NCT00124306|PLACEBO_COMPARATOR|2|Placebo will be dosed exactly as active arm.
62299046|NCT02993978||Control group|Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
62107600|NCT01723436|NO_INTERVENTION|DLST Only|Surrogates will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
62299047|NCT02993978||Case group|Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
62299048|NCT03500744|EXPERIMENTAL|Erector spinae plane block|"The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
62299049|NCT03500744|SHAM_COMPARATOR|Shame block|"A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
61914118|NCT04879602|NO_INTERVENTION|Control group|patients receive routine ordinary suction in PACU
62299050|NCT06653621|EXPERIMENTAL|adductor block+ Bupivacaine liposomes and bupivacaine mixture|The patient underwent ultrasound-guided bupivacaine liposome mixture single adductor block during anesthesia induction room for analgesia after total knee arthroplasty .
62299051|NCT06653621|ACTIVE_COMPARATOR|adductor block+ bupivacaine|The patient underwent ultrasound-guided bupivacaine single adductor block during anesthesia induction room for analgesia after total knee arthroplasty
62669327|NCT01438944|OTHER|Nicabate 21mg transdermal NRT|21mg Transdermal NRT applied for 24hrs over a 14day period.
62107601|NCT01723436|EXPERIMENTAL|Contemplate only|Surrogates will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
62669328|NCT03654079|ACTIVE_COMPARATOR|Simulation Arm|Subjects in this arm will participate in Interventions (In- Utero Simulation, Cesarean Section Simulation, and Pushing Simulation).
62107602|NCT01723436|EXPERIMENTAL|Decide with advice|Surrogates will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, surrogates will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
61914119|NCT06396182|EXPERIMENTAL|Group A (Study group):|The program of treatment will be 3 times a week lasting for 8 weeks. A standardized 5- min warm-up phase will precede each session and 10-min cooling down phase after each session with the actual time of each session is 30 minute. 30 minutes of virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).
62107603|NCT01723436|EXPERIMENTAL|Decide without advice|Surrogates will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
62299052|NCT06653621|EXPERIMENTAL|femoral triangle block + Bupivacaine liposomes and bupivacaine mixture|The patient underwent ultrasound-guided bupivacaine liposome mixture single femoral triangle block during anesthesia induction room for analgesia after total knee arthroplasty .
62107604|NCT02458534|EXPERIMENTAL|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
62669329|NCT03654079|NO_INTERVENTION|Control Arm|Subjects in this arm will not participate in any simulations.
62669330|NCT00907088|ACTIVE_COMPARATOR|1|
62299053|NCT06653621|ACTIVE_COMPARATOR|femoral triangle block + bupivacaine|The patient underwent ultrasound-guided bupivacaine single femoral triangle block during anesthesia induction room for analgesia after total knee arthroplasty .
62669331|NCT00907088|EXPERIMENTAL|2|
62737248|NCT04747236|EXPERIMENTAL|AZA and ROMI|Oral Azacytidine (AZA) (300 mg daily on days 1-14) plus Romidepsin (ROMI) (14 mg/m2 as an intravenous infusion over 4 hours +/- 30 minutes on days 8, 15 and 22 of a 35-day cycle.
62107605|NCT02458534|EXPERIMENTAL|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
62107606|NCT02458534|ACTIVE_COMPARATOR|Macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
62107607|NCT02955498|EXPERIMENTAL|R-T|First period: administration of reference drug, Second period: administration of test drug
62107608|NCT02955498|EXPERIMENTAL|T-R|First period: administration of test drug, Second period: administration of reference drug
62669332|NCT04807296|ACTIVE_COMPARATOR|TFLEP|Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.
62107609|NCT01872429||Short-term group|Patients with postoperative 6-month laboratory data were included in the short-term group
62107610|NCT01872429||Long-term group|Patients with postoperative more than 6-month laboratory data were included in the long-term group
62107611|NCT02750709|EXPERIMENTAL|Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62107612|NCT02750709|EXPERIMENTAL|Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62107613|NCT02750709|EXPERIMENTAL|Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62107614|NCT02750709|EXPERIMENTAL|Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62107615|NCT02750709|EXPERIMENTAL|Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62107616|NCT02750709|EXPERIMENTAL|Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
62107617|NCT05925842||Participants with PsA without Axial Involvement|
62299054|NCT05370911|EXPERIMENTAL|Immediate Treatment|Participants randomized to this condition will receive treatment immediately, facilitated by two study staff members, and which consists of two preparatory sessions, followed by the first dosing session and two integration sessions, then the second dosing session and two integration sessions. This is followed by follow-up and long-term follow-up visits up to 12 months post-second dose.
62107618|NCT05925842||Participants with PsA with Axial Involvement|
62107619|NCT05173493||Amoxicillin-Furazolidone-containing quadruple group|Patients in amoxicillin-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
62107620|NCT05173493||Amoxicillin-Levofloxacin-containing quadruple group|Patients in amoxicillin-Levofloxacin-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
62299055|NCT05370911|NO_INTERVENTION|Waitlist Control/Delayed Treatment|Participants randomized to this condition will first enter a waitlist phase that lasts for 7 weeks, after which rater unblinding will occur, and participants will be rescreened. If participants remain eligible at this time, they will begin their treatment phase. During their treatment phase, participants in this condition will receive the same treatment as described for participants in the immediate treatment group. This is followed by follow-up and long-term follow-up visits up to 12 months post-second dose.
62737249|NCT04747236|ACTIVE_COMPARATOR|Investigator's Choice|Investigator's choice to include: ROMI, 14 mg/m2 IV infusion on days 1, 8, and 15 of a 28 day cycle, belinostat,1000 mg/m2 IV infusion on days 1-5 every 21 days, pralatrexate, 30 mg/m2 IV push once weekly for 6 weeks of a 7-week treatment cycle, or gemcitabine, 1000 mg/m2 IV infusion on days 1, 8, and 15 of a 28-day cycle.
62737250|NCT03886194|ACTIVE_COMPARATOR|Thrombolytic group|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip
62107621|NCT05173493||Tetracycline-Furazolidone-containing quadruple group|Patients in tetracycline-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), tetracycline 500 mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
62299056|NCT06586489|EXPERIMENTAL|Virtual Reality Group (VR)|Participants in this group will engage with immersive virtual reality (VR) natural landscapes.
62299057|NCT06586489|ACTIVE_COMPARATOR|Tablet Screen Group (Tab)|Participants in this group will view natural landscapes on a tablet screen.
62299058|NCT06586489|NO_INTERVENTION|Control Group (C)|Participants in this group will continue their usual care routine without additional exposure to virtual or screen-based natural environments.
62299059|NCT04756934|EXPERIMENTAL|Ia: LP002 dose escalation-1mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 1mg/kg, Q3W for up to 1 year.
62299060|NCT04756934|EXPERIMENTAL|Ia: LP002 dose escalation-3mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 3mg/kg, Q3W for up to 1 year.
62299061|NCT04756934|EXPERIMENTAL|Ia: LP002 dose escalation-5mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 5mg/kg, Q3W for up to 1 year.
62299062|NCT04756934|EXPERIMENTAL|Ib: Expansion|Approximately 30 participants will receive HX008 of 200mg, Q3W plus LP002 of the recommended dose, Q3W for up to 1 year.
62299063|NCT04756934|EXPERIMENTAL|Ib: Control|Approximately 15 participants will receive LP002 of recommended dose, Q3W for up to 1 year.
62299064|NCT04147949|EXPERIMENTAL|AV-101|1440 mg of L-4-chlorokynurenine administered twice a day orally
62669333|NCT04807296|ACTIVE_COMPARATOR|m-HoLEP|The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.
62669334|NCT05981807||Transgender population|Cohort of transgender people (man to woman and woman to man)
62669335|NCT01021917||Other Dieters (OD)|Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
62669336|NCT01021917||Take Shape For Life (TSFL)|Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
61914120|NCT06396182|ACTIVE_COMPARATOR|Group B (Control group):|"The program of treatment will be 3 times a week lasting for 8 weeks. A standardized 5- min warm-up phase will precede each session and 10-min cooling down phase after each session with the actual time of each session is 30 minute. 30 minutes of cycling session by traditional stationary bike.~- Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020)."
62299065|NCT04147949|PLACEBO_COMPARATOR|Placebo|Matching capsules of placebo
62299066|NCT04285918||Cohort A|Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature)
62669337|NCT01021917||Medifast Direct (MD)|Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.
61914121|NCT04465136|EXPERIMENTAL|Received CES intervention|CES with the frequency of 0.5 Hertz; current of 100\~600micro-ampere, for 60 minutes, everyday for 6 weeks, total 42 sessions intervention
61914122|NCT05357729|EXPERIMENTAL|MultiSense® remote monitoring|The patients included will be equipped with the MultiSense® solution prior to the hospital discharge. The device will be used for 6 days from the date of actual deployment.
61914123|NCT03539809|EXPERIMENTAL|BCAA Ratio|Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.
61914124|NCT01450904|EXPERIMENTAL|Group A|The length of Quadriceps incision was less than 2 cm.
61914125|NCT01450904|EXPERIMENTAL|Group B|The length of Quadriceps incision was 2 to 4 cm.
61914126|NCT01450904|EXPERIMENTAL|Group C|The length of Quadriceps incision was more than 4 cm.
62299067|NCT04285918||Cohort B|Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO
62299068|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
62299069|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
62299070|NCT02922764|EXPERIMENTAL|Recurrent NSCLC (2nd/3rd Line Lung Cancer). Expansion|"RGX-104 in combination docetaxel~RGX104 120 mg BID (5day on/2days off)"
62299071|NCT02922764|EXPERIMENTAL|Newly dignosed NSCLC Cohort Expansion|"RGX104 + pembrolizumab + carboplatin/pemetrexed~RGX104 120 mg BID (5day on/2days off)"
62299072|NCT02922764|EXPERIMENTAL|Recurrent/Relapsed Small Cell Lung Cancer (SCLC) Expansion|"RGX-104 + docetaxel~RGX104 120 mg BID (5day on/2days off)"
62299073|NCT02922764|EXPERIMENTAL|Recurrent/Relapsed Endometrial Cancer Expansion|"RGX-104 combined with ipilimumab~RGX104 120 mg BID (5day on/2days off)"
62299074|NCT02830165|EXPERIMENTAL|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
62299075|NCT01973283|EXPERIMENTAL|Medication Treatment|Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.
62299076|NCT02240862||Carotid Artery Disease|Patients undergoing carotid artery stenting for high grade carotid artery stenosis with or without neurologic symptoms and with or without a high risk for carotid endarterectomy.
62299077|NCT05239689|EXPERIMENTAL|Treatment of CD38-positive Hematological Malignancies|Administration of CD38 CAR T-cells A dose levels of 2-8\*10E6/kg are administrated for each subject.
62299078|NCT06620107|ACTIVE_COMPARATOR|Noninvasive high frequency oscillation ventilation|preterm neonates with GA of 32 to 36 weeks ready for extubation
62299079|NCT06620107|ACTIVE_COMPARATOR|Noninvasive intermittent positive pressure ventilation|preterm neonates with GA of 32 to 36 weeks ready for extubation
62299080|NCT05607134|SHAM_COMPARATOR|Physical and occupational therapy group|The group will receive a Physical and occupational therapy program
62669338|NCT02794805|EXPERIMENTAL|HCC positive|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
62669339|NCT02794805|EXPERIMENTAL|HCC negative|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
62669340|NCT04131192|EXPERIMENTAL|z650 and Gemcitabine|Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles
62669341|NCT03769974|EXPERIMENTAL|Motor imagery|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-person kinesthetic motor imagery training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of motor imagery will be 2 series of 30 seconds for each of the 12 manual positions to remember
62299081|NCT05607134|ACTIVE_COMPARATOR|Shock Wave group|The group will receive a radial Extracorporeal Shock Wave sessions
62669342|NCT03769974|EXPERIMENTAL|Action observation|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-personaction observation training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of action observation will be 2 series of 30 seconds for each of the 12 manual positions to remember in video format.
62669343|NCT03769974|PLACEBO_COMPARATOR|Placebo group|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which an imagery training and placebo observation, inspired by a rural landscape, will be given for four consecutive days. This group will carry out the observation and imagination of a landscape during 2 series of 30 seconds for each manual motor sequence to remember.
62669344|NCT03237091|EXPERIMENTAL|bihemispheric transcranial pulsed current stimulation (tPCS)|
62469709|NCT03141671|EXPERIMENTAL|GnRH+Abiraterone+Apalutamide+Prednisone|"* GnRH agonist injection monthly or every 3 months for 6 months~* Abiraterone acetate by mouth once/day for 6 months~* Prednisone by mouth once/day for 6 months~* Apalutamide by mouth once/day for 6 months~* Salvage radiation (starting 4-10 weeks after initiation of ADT)"
62469710|NCT00950989|PLACEBO_COMPARATOR|Placebo|Placebo on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
62669345|NCT03237091|EXPERIMENTAL|unihemispheric transcranial pulsed current stimulation (tPCS)|
61914127|NCT05615935|EXPERIMENTAL|Get a learning material and a experiential HIV Testing|These participants in the experimental group will be provided a learning material about HIV testing, then an experiential HIV Testing, which includes HIV testing and counselling, education and discussion, and a post-test interviews will be provided.
61914128|NCT05615935|NO_INTERVENTION|Get a learning material only|These participants in the control group will be provided a learning material about HIV testing only. After the post-test, the experiential HIV Testing will be provided to them.
61914129|NCT04244812|OTHER|CSAP group|"Participants in the CSAP group will receive examination of laser doppler flowmetry(LDF).~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian"
62299082|NCT05607134|ACTIVE_COMPARATOR|Peripheral Magnetic Stimulation group|The group will receive a Peripheral Magnetic Stimulation sessions
62299083|NCT03808155|ACTIVE_COMPARATOR|Tamsulosin|The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation.
62299084|NCT03808155|PLACEBO_COMPARATOR|Placebo Oral Tablet|The placebo is taken once a day per os five days prior to the operation and two days after the operation.
62469711|NCT00950989|EXPERIMENTAL|Brodalumab 70 mg|70 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
62469712|NCT00950989|EXPERIMENTAL|Brodalumab 140 mg|140 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexateand folic acid supplementation (at least 5 mg per week).
62469713|NCT00950989|PLACEBO_COMPARATOR|Brodalumab 210 mg|210 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
62107622|NCT02932293|EXPERIMENTAL|SOF+DCV+SMV 3-4 wks|Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is \<500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is \>500 IU/ml.
62107623|NCT02932293|EXPERIMENTAL|SOF+DCV+SMV 6-8 wks|Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is \<500 IU/ml or (b) 8 weeks if HCV VL on day 2 is \>500 IU/ml.
62107624|NCT02756104|OTHER|Volunteers|Healthy People on each collecting blood for phenotyping Tcells
62107625|NCT02756104|OTHER|Patients with ALS|"Patients with ALS deficient or not in Vitamin D on each collecting blood for phenotyping Tcells.~The patients who are deficient in Vitamin D will have supplementation in vitamin D"
62107626|NCT04732039|EXPERIMENTAL|LVAD recipients|Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients
62107627|NCT04732039|EXPERIMENTAL|Healthy controls|Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls.
62107628|NCT03907007|NO_INTERVENTION|Sole Medication|Monitoring under current prescribed medication
62107629|NCT03907007|ACTIVE_COMPARATOR|Combined stimulation & medication|Concurrent usage of stimulation with the prescribed medication
62107630|NCT03907007|ACTIVE_COMPARATOR|Sole Stimulation|Alternating usage of stimulation to the prescribed medication
62107631|NCT00470743|EXPERIMENTAL|Ibuprofen|Compare ibuprofen
62107632|NCT00470743|PLACEBO_COMPARATOR|Normal saline|Compared against ibuprofen -- placebo
62669346|NCT03237091|EXPERIMENTAL|bihemispheric transcranial direct current stimulation (tDCS)|
62669347|NCT03237091|EXPERIMENTAL|unihemispheric transcranial direct current stimulation (tDCS)|
62669348|NCT03237091|ACTIVE_COMPARATOR|sham-control|
62669349|NCT02245373||Antidepressants|Naturalistic assignment: Patients whose physician decides to indicate antidepressants.
62669350|NCT02245373||Active Monitoring|Naturalistic assignment: Patients whose physician considers starting an Active Monitoring intervention.
62669351|NCT01651598|EXPERIMENTAL|BI 144807|Subjects receive multiple BID doses of BI 144807 solution
62669352|NCT01651598|PLACEBO_COMPARATOR|Placebo|Subjects receive multiple BID doses of Placebo solution
61914130|NCT04244812|OTHER|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
62107633|NCT04663802|NO_INTERVENTION|Usual care|This arm will have no interventions and standard of care practices will be in place.
62299085|NCT05546489|EXPERIMENTAL|Lymfit intervention|Participants will receive a Fitbit wearable tracker, expert guidance, and a personalized exercise prescription to optimize physical activities among lymphoma survivors. The intervention is 12 weeks long, participants are meeting with a kinesiologist every 2 weeks.
62669353|NCT03594370||control|Limbal image by OCT in normal subjects.
62669354|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
62669355|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
61914131|NCT04244812|EXPERIMENTAL|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
61914132|NCT01843647|EXPERIMENTAL|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
62107634|NCT04663802|ACTIVE_COMPARATOR|Default order set|This arm will have the default order set implementation strategy
62107635|NCT04663802|ACTIVE_COMPARATOR|Physician-targeted accountable justification|This arm will have the physician-targeted accountable justification implementation strategy
62107636|NCT04663802|ACTIVE_COMPARATOR|Default order set + RT-targeted accountable justification|This arm will have the default order set and respiratory therapist-targeted accountable justification
62107637|NCT04663802|ACTIVE_COMPARATOR|Physician-targeted accountable justification + RT-targeted accountable justification|This arm will have the default order set and respiratory therapist-targeted accountable justification
62107638|NCT04716803|EXPERIMENTAL|Bone marrow aspiration concentrate using the Angel System|"Bone marrow aspirate concentrate (BMAC) will be administered via injection to the knee of interest on day 14 of the study.~Bone marrow aspiration will be concentrated using the Angel System."
62107639|NCT04785066|EXPERIMENTAL|Study treatment|Administration of dornase alfa during intervention of thrombectomy
62107640|NCT06629935|EXPERIMENTAL|Nievert osteotomy group|lateral nasal wall osteotomy has been performed with single guided Nievert osteotome.
62107641|NCT06629935|ACTIVE_COMPARATOR|Blade osteotomy group|lateral nasal wall osteotomy has been performed with blade osteotome.
62299086|NCT00862602|EXPERIMENTAL|1|Stepping Up to Health
62299087|NCT00862602|NO_INTERVENTION|2|Usual care group
62669356|NCT05904366|OTHER|Patients|Participants will undergo an MRI with MR Spectroscopy (MRS) and MR Elastography (MRE) measurements
62669357|NCT05904366|OTHER|Healthy controls|Participants will undergo an MRI with MR Spectroscopy (MRS) and MR Elastography (MRE) measurements
62669358|NCT02679092|ACTIVE_COMPARATOR|Dilapan (14wks 0days-15wks, 6days)|The clinician will place 1 to 2 osmotic cervical dilators (Dilapan-S) (4mm x 65mm) the day before the participant's procedure.
62669359|NCT02679092|ACTIVE_COMPARATOR|Dilapan (16wks 0days-18wks, 6days)|The clinician will place 3 to 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
62737251|NCT03886194|EXPERIMENTAL|Interventional treatment group|Interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
62107642|NCT06629805|EXPERIMENTAL|Aureobasidium pullulans produced β-glucan group|This group takes Aureobasidium pullulans produced β-glucan for 12 weeks.
62299088|NCT06203002|EXPERIMENTAL|LX9211 Low Dose|LX9211 low dose, orally, once daily during a blinded treatment period.
62299089|NCT06203002|EXPERIMENTAL|LX9211 High Dose|LX9211 high dose, orally, once daily during a blinded treatment period.
62299090|NCT06203002|EXPERIMENTAL|LX9211 High Dose Followed by Low Dose|LX9211 high dose followed by LX9211 low dose, orally, once daily during a blinded treatment period.
62299091|NCT06203002|PLACEBO_COMPARATOR|LX9211 Placebo|LX9211 matching placebo, orally, once daily during a blinded treatment period.
62299092|NCT01117376|ACTIVE_COMPARATOR|Erythromycin|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
62299093|NCT01117376|ACTIVE_COMPARATOR|Methylnaltrexone|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
62299094|NCT02353949|EXPERIMENTAL|Flutmetamol Group|PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose
62299095|NCT06165588||Cyclists|Elite cyclists participating in the Tour de France
62669360|NCT02679092|EXPERIMENTAL|Mifepristone (14wks 0days-15wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
62669361|NCT02679092|EXPERIMENTAL|Mifepristone (16wks 0days-18wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
62669362|NCT00167947|ACTIVE_COMPARATOR|A|
62669363|NCT00167947|EXPERIMENTAL|B|
62669364|NCT01657500|ACTIVE_COMPARATOR|Life 4°C media for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
62669365|NCT01657500|ACTIVE_COMPARATOR|Optisol GS|Donor cornea is stored in the Optisol GS media prior to implantation.
62669366|NCT02470377|EXPERIMENTAL|Target 1: Occipital Cortex|After determination of the motor threshold, the TMS coil will be positioned over the midline occipital cortex using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
62669367|NCT02470377|EXPERIMENTAL|Target 2: Cerebellar Vermis|After determination of the motor threshold, the TMS coil will be positioned over the midline cerebellar vermis using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
62107643|NCT06629805|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks.
62107644|NCT00698802|EXPERIMENTAL|A|
62107645|NCT00698802|ACTIVE_COMPARATOR|B|
62107646|NCT00427557|EXPERIMENTAL|Cellular Therapy with Cord Blood Cells|Fludarabine 30 mg/m\^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m\^2 IV for 1 Day + Rituximab 375 mg/m\^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion
62107647|NCT04962100|EXPERIMENTAL|Study population|Male patients and donors who provide a sample of fresh ejaculated semen will be the population of this study, as well as female patients undergoing artificial insemination with their partner's semen or frozen donor semen.
62107648|NCT00820118|EXPERIMENTAL|Intermittent treatment|6 months on antiretroviral treatment and 6 months off treatment
62107649|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
62107650|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
62107651|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
62107652|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
62107653|NCT03737175|EXPERIMENTAL|Carotid Artery Stenting group|Carotid Artery Stenting
62107654|NCT03737175|ACTIVE_COMPARATOR|Carotid Endarterectomy group|Carotid Endarterectomy
62107655|NCT04259632|EXPERIMENTAL|Time Restricted Eating (TRE)|For the TRE group, we will restrict the eating window to 8 hours, where they will eat ad libitum. This is the same interval established by Dr. Panda and by our preliminary data. This interval will be entered into the mCC app and participants will be asked to adhere to this eating window during the intervention. All eating occasions will be logged using the mCC app. Only water and medications will be allowed outside of the eating window.
62107656|NCT04259632|ACTIVE_COMPARATOR|Caloric Restriction (CR)|Participants randomized to CR will meet with the study dietitian prior to the intervention and be counseled on options to reduce their caloric intake by 15%, while maintaining their eating window. The 15% reduction was selected as our preliminary data and recent literature suggest that TRE with ad libitum intake reduces caloric intake by \~270 to 300 cal/day. The 15% CR is similar to the 11.9% CR achieved by the CALERIE-2 study, which is a 2 year study of CR.26 All eating occasions will be logged using the mCC app. The weekly dietitian review of the mCC information will include maintenance of the eating window and examination of dietary intake to determine compliance with the 15% CR.
62107657|NCT04259632|NO_INTERVENTION|Unrestricted Eating (non-TRE)|For the unrestricted eating (non-TRE) group, participants will eat ad libitum per their usual habits. They will receive initial counseling about mCC logging. All eating occasions will be logged using the mCC app.
62107658|NCT00683410||1|
62107659|NCT00789906||1|350 healthy women , aged from 18 to 89
62107660|NCT00789906||2|350 healthy men, aged from 18 to 89
62107661|NCT06369090|EXPERIMENTAL|Healthy female volunteers|Data were obtained at two phases at supine horizontal position during spontaneous and forced breathing of the volunteers. First, with electrode belt placed over the breast tissue and second, with the electrode belt under the breast tissue.
62107662|NCT02107014|OTHER|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
62669368|NCT02470377|ACTIVE_COMPARATOR|Target 3: Cerebellar Hemisphere|After determination of the motor threshold, the TMS coil will be positioned over the lateral cerebellar hemisphere using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
62107663|NCT01403519||Alzheimer's disease patients|Patients blood and CSF samples
62669369|NCT03269006|EXPERIMENTAL|Inesfly Paint|Inesfly 5AIGRNG TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%). The formulation is vinyl paint with an aqueous base, with the active ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of active ingredients. Microcapsules range from one to several hundred micrometers in size.
62669370|NCT03269006|EXPERIMENTAL|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies.
62669371|NCT03269006|EXPERIMENTAL|ITN (KO-Tab 123)|impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin.
62669372|NCT03269006|EXPERIMENTAL|IRS (Delthamethrin)|indoor residual spraying with Delthamethrin in the living rooms
62107664|NCT01403519||Control group|Blood and CSF samples
62669373|NCT03269006|NO_INTERVENTION|Control|without any study interventions
62107665|NCT01403519||FTD patients|Blood ad CSF samples
62669374|NCT05015179|NO_INTERVENTION|Control|Laparoscopic partial nephrectomy is performed with an intraoperative ultrasound (US) control
62107666|NCT03728738|EXPERIMENTAL|Zero Degree HOB|Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy
62469714|NCT05229445|EXPERIMENTAL|CGM insulin bolus calculator arm|All participants will receive the CGM insulin bolus calculator
62107667|NCT03728738|ACTIVE_COMPARATOR|Thirty Degree HOB|Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy
62107668|NCT00434278|PLACEBO_COMPARATOR|Placebo|
62107669|NCT00434278|EXPERIMENTAL|Dornase alfa|
62107670|NCT00371566|EXPERIMENTAL|Lapatinib|
62107671|NCT00371566|PLACEBO_COMPARATOR|Placebo|
62107672|NCT03910543|EXPERIMENTAL|Patients with Cutaneous Sarcoidosis|Patients with cutaneous sarcoidosis that may also have also have internal organ sarcoidosis
62107673|NCT03910543|EXPERIMENTAL|Patients with Granuloma Annulare|Patients with granuloma annulare that is long-standing and/or widespread
62107674|NCT00929591|ACTIVE_COMPARATOR|tamoxifen for five years|tamoxifen for five years
62107675|NCT00929591|EXPERIMENTAL|CAF followed by tamoxifen for five years|intermittent CAF X 6 courses followed by tamoxifen for five years
62107676|NCT00929591|EXPERIMENTAL|CAF with concurrent tamoxifen for five years|intermittent CAF X 6 courses with concurrent tamoxifen for five years
62107677|NCT06492356|EXPERIMENTAL|Group A|Consists of 20 patients with acne scars and will receive medical treatment by a dermatologist and tripolar radiofrequency (RF) therapy once a week for 12 weeks, each session for 15 minutes.
62469715|NCT02043327||Experienced in Colonoscopy|two tests on two different modalities of colonoscopy simulators
62469716|NCT02043327||Novices in colonoscopy|Two tests on each of trw colonoscopy simulators
62469717|NCT01425060|EXPERIMENTAL|Contraceptive management program|
62469718|NCT01425060|ACTIVE_COMPARATOR|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
62469719|NCT01223820|EXPERIMENTAL|Capsaicin|
62669375|NCT05015179|EXPERIMENTAL|Experimental|Underwent Laparoscopic partial nephrectomy with the aid of the mixed reality model
62669376|NCT04116047|ACTIVE_COMPARATOR|Arm 1 (control): chemoradiotherapy|Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.
62107678|NCT06492356|ACTIVE_COMPARATOR|Group B|consists of 20 patients with acne scars and will receive medical treatment by a dermatologist
62107679|NCT06286163||Chronic Cough|"History of chronic cough of at least 8 weeks' duration and should have been followed in the Cough Clinic for at least 6 months.~Undergone a protocol with a diagnostic pathway as recommended by the ERS guidelines for management of cough.~Would have either an identifiable cause for their cough that have failed therapies targeted towards the identified cause or classed as having chronic idiopathic cough where no identifiable cause has been found."
62107680|NCT06286163||Healthy|Healthy individuals, free of significant disease No history of asthma/rhinitis, No therapies, Baseline FEV1 ≥80% predicted with FEV1/FVC ratio \>70% Non-smoker for at least the past 12 months with a pack history of ≤5 pack-years
62299096|NCT01876589|ACTIVE_COMPARATOR|Bioresorbable vascular scaffold|Paritcipants will receive a bioresorbable vascular scaffols (BVS)
62107681|NCT03729804|EXPERIMENTAL|KRD Arm|Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary
62107682|NCT03729804|EXPERIMENTAL|VRD Arm|Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary
62669377|NCT04116047|EXPERIMENTAL|Arm 5: Durvalumab + Arm 1|One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months
62669378|NCT02194686|ACTIVE_COMPARATOR|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
62299097|NCT01876589|ACTIVE_COMPARATOR|Xience Prime|Participant will receive a Xience Prime stent
62299098|NCT02012010|EXPERIMENTAL|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
62669379|NCT02194686|PLACEBO_COMPARATOR|Dummy Placebo|One tablet twice per day for 12 weeks
62669380|NCT02520440||GIF and/or MOF patients|Development during the ICU stay of gastro-intestinal failure and/or multiple organ failure. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
62669381|NCT02520440||Controls|patients admitted to ICU without gastrointestinal failure and/or multiple organ failure during the intensive care unit stay. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
62669382|NCT01495728|EXPERIMENTAL|Thrust Manipulation -Thoracic Spine|Mid and Upper Thoracic Spine
62669383|NCT01495728|PLACEBO_COMPARATOR|Sham Manipulation|Mid and Upper Thoracic Spine
62107683|NCT00436137|EXPERIMENTAL|1|Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach
62299099|NCT02012010|ACTIVE_COMPARATOR|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
62299100|NCT04447547|EXPERIMENTAL|SL1904B CAR-T|Patients will be treated with CD19 CAR-T cells
62669384|NCT02697422|EXPERIMENTAL|Peer health coach intervention group|Eligible participants will be randomly assigned to receive a home-visit peer health coach intervention to promote health outcomes and behavior change among Veterans with multiple cardiovascular disease (CVD) risk factors.
62669385|NCT02697422|NO_INTERVENTION|Control group|Participants who meet the same eligibility criteria as participants in the intervention group will be randomly assigned to receive no intervention. Participants will continue to receive their regular, usual primary care.
62669386|NCT06367114|EXPERIMENTAL|ssCART-19 Cells|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to ssCART-19 cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62299101|NCT00566306|EXPERIMENTAL|A|PHMG will be introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets will be coated with biocide coating (PHMG) as well as bed frames in investigational wards.
62299102|NCT00566306|NO_INTERVENTION|B|Three wards will be control wards and continue using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines.
62299103|NCT04691258|ACTIVE_COMPARATOR|Restricted Group (RG)|Intervention with the movement technique traditional of squat exercise.
62299104|NCT04691258|EXPERIMENTAL|Complete Group (CG)|Intervention with the squat exercise technique prioritizing the full range of motion.
62299105|NCT01931865|EXPERIMENTAL|IncobotulinumtoxinA|The total dose will depend on the extent of the area involved by pain. The injections will be carried out through a 1cc syringe using a ½ to 1 inch needle intramuscularly or subcutaneously (or both). The ttoal dose will not exceed 100 units.
62469720|NCT01604902||Psoriasis vulgaris|Patients with psoriasis vulgaris who are going to be treated with biological drugs independent of this project(according to national guidelines).
62669387|NCT04079725|EXPERIMENTAL|Experimental : Infants with primary congenital glaucoma|
62669388|NCT04240847|ACTIVE_COMPARATOR|Midline incision|Skin incision at the midline, 1 cm medial to tibial tubercle
62669389|NCT04240847|EXPERIMENTAL|Lateral incision|Skin incision at 1 cm lateral to tibial tubercle
62107684|NCT04168814||Oncology patients (Immunotherapy alone or in combination))|"1. Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~2. Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: PD1, PDL1 inhibitors. At least 12 weeks of treatment."
62107685|NCT04168814||Oncology Patients (Chemo-Radiotherapy group).|"1. Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~2. Patients under active treatment either in combination with chemotherapy or radiotherapy. At least 12 weeks of treatment."
62107686|NCT03124108|PLACEBO_COMPARATOR|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
62107687|NCT03124108|ACTIVE_COMPARATOR|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
62107688|NCT03124108|ACTIVE_COMPARATOR|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
62107689|NCT05564325|EXPERIMENTAL|Deflectable guidewire|
62107690|NCT05564325|ACTIVE_COMPARATOR|Standard of care guidewire|
62107691|NCT01317134|ACTIVE_COMPARATOR|Therapy-naive|"This group consists of patients with a newly diagnosed PH (Class I or IV). First blood sampling takes place before initiation of PH therapy (0 months), the following measurements will be performed after 3, 6, 9 and 12 months under specific therapy.~Initiation of standard therapy is performed directly after baseline visit / study inclusion. No special study medication will be used.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood Test"
62469721|NCT02137135|EXPERIMENTAL|follicular phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
62469722|NCT02137135|ACTIVE_COMPARATOR|luteal phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
61914133|NCT01843647|ACTIVE_COMPARATOR|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
61914134|NCT04617431|EXPERIMENTAL|Intervention group|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
62469723|NCT00381225|EXPERIMENTAL|Ultra-sound guided radio-frequency ablation|
62669390|NCT02857920|EXPERIMENTAL|Bevacizumab and NK immunotherapy|In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
61914135|NCT04617431|NO_INTERVENTION|Control group|"The participants of control group had a wearable device and could upload their dietary diary to the health management platform every day. But no LINE group was created, and no reminding."
61914136|NCT04304547|ACTIVE_COMPARATOR|Sequence A|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
62107692|NCT01317134|ACTIVE_COMPARATOR|Under therapy|"This group consists of patients under ERA monotherapy at timepoint of inclusion. Observation period is one year to detect intraindividual changes in endothelial dysfunction measured by L-arginine/NO-metabolites after 0, 3, 6, 9 and 12 months under investigation.~Specific PAH therapy has been started prior to the study for medical reasons and will be continued throughout.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood"
62107693|NCT01317134|ACTIVE_COMPARATOR|Healthy controls|This group consists of healthy individuals. Sex and age matching is intended. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood
62107694|NCT04265625|NO_INTERVENTION|blind tracheotomy|no endoscopic guidance tracheotomy
62107695|NCT04265625|EXPERIMENTAL|endoscopic guidance tracheotomy|With endoscopic guidance tracheotomy
62107696|NCT00673296|OTHER|A|Patients receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
62299106|NCT04008017||stable Chronic obstructive pulmonary disease|clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity \<70%) post bronchodilator
62299107|NCT04008017||acute exacerbation of Chronic obstructive pulmonary disease|patients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity \<70%) post bronchodilator
62299108|NCT01306981|EXPERIMENTAL|Ranibizumab|
62469724|NCT04472156|EXPERIMENTAL|Transfer of mosaic embryo|Women will have a mosaic embryo transferred to their uterus after in vitro fertilization (IVF) with pre implantation genetic testing completed at Colorado Center for Reproductive Medicine.
61914137|NCT04304547|ACTIVE_COMPARATOR|Sequence B|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
61914138|NCT04304547|ACTIVE_COMPARATOR|Sequence C|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
61914139|NCT01376440|EXPERIMENTAL|Household water treatment|household water treatment with 1.25% sodium hypochlorite
61914140|NCT01376440|NO_INTERVENTION|control|"Usual practice (the use of Jerrican for water storage, which is considered as safe storage)"
61914141|NCT02093351|EXPERIMENTAL|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
62107697|NCT05067127|EXPERIMENTAL|Group 1: Pegcetacoplan administration|Subcutaneous infusion of 20mL (1080 mg), twice weekly (for adults or adolescents \>50kg), and the three other weight-based doses either of 10mL (540mg), 12mL (648mg), or 15mL (810mg)
62107698|NCT05067127|PLACEBO_COMPARATOR|Group 2: Placebo administration|Subcutaneous infusion of either 10mL, 12mL, 15mL, or 20mL, twice weekly
62107699|NCT06104969||Diabetic Foot Ulcer|Adult individuals with at least one diabetic foot ulcer who meet inclusion/exclusion criteria
62107700|NCT02175290||Spinocerebellar Ataxia 3 Yemenite Jews patients|
62107701|NCT04395755||Infertile women who had the IVF treatment postponed or delayed|
62107702|NCT02438800|NO_INTERVENTION|Standard Counseling|Women in this arm will receive standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
62107703|NCT02438800|EXPERIMENTAL|Video Counseling|Women in this arm will receive LARC First video-based contraceptive counseling in addition to standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
62107704|NCT05543811|EXPERIMENTAL|Product for special dietary use|Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid will be given to the subjects enrolled to this arm, 20 gram twice daily with breakfast and supper (instead of butter)
62107705|NCT05543811|PLACEBO_COMPARATOR|control|This group will receive standard spread, without theanine, gamma-aminobutyric acid and 5-hydroxytryptophan, twice daily with breakfast and supper with food (instead of butter)
62107706|NCT04122807|ACTIVE_COMPARATOR|Mapping|Standard treatment involving ablation of the slow pathway with cryotherapy
62107707|NCT04122807|EXPERIMENTAL|Ablation|Mapping and ablation of the retrograde fast pathway with cryotherapy
62669391|NCT02857920|ACTIVE_COMPARATOR|Bevacizumab|In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62107708|NCT02072122||women during fertility treatment|
62107709|NCT06445231|EXPERIMENTAL|Echocardiographic screening arm|Participants from nursing homes allocated to echocardiographic screening group will benefit of one echocardiography at inclusion.
62669392|NCT03780725|EXPERIMENTAL|Part 1: Ezabenlimab 240mg + BI 754111 600mg|
62669393|NCT03780725|EXPERIMENTAL|Part 2: Ezabenlimab 240mg + BI 754111 40mg|
62669394|NCT01684592|ACTIVE_COMPARATOR|Standard care|Standard care for smokers during pregnancy and referral to 24/7 quitline postpartum (passive)
62107710|NCT06445231|NO_INTERVENTION|Usual care|Participants from nursing homes allocated to no-screening group. Participants will be followed for medical management and care as usual.
62669395|NCT01684592|EXPERIMENTAL|Standard care plus PPCC|Standard care for smoking during pregnancy and proactive phone-based postpartum continuing care (PPCC) for 6 months postpartum
62669396|NCT02372084|EXPERIMENTAL|osilodrostat (LCI699)|Each participant will undergo a 28-day screening/baseline period (day -28 to day -1), followed by a 5 day treatment period (a single 30 mg dose of LCI699 ( Day 1) with 5 days of PK sample collection).
62669397|NCT02347007|EXPERIMENTAL|Almond|
62669398|NCT02347007|ACTIVE_COMPARATOR|Cereal Bar|
62669399|NCT02096224|EXPERIMENTAL|Sevoflurane|Sevoflurane will be administered as the maintenance agent of general anesthesia.
61914142|NCT02093351|EXPERIMENTAL|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
61914143|NCT02093351|EXPERIMENTAL|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
61914144|NCT06078800|EXPERIMENTAL|YL-17231|YL-17231 will be administrated orally from 0.25mg QD, 0.5mg BID to 10mg BID in sequence during dose excalation part and selected doses in dose expansion part,for 21 consecutive days as a treatment cycle
61914145|NCT04138979||Control group|20 healthy volunteers were included in the healthy control group
62107711|NCT04606251|EXPERIMENTAL|Arm 1: Exercise Group|This group will consist of the subjects taken for 6 weeks of exercise.
62107712|NCT04606251|NO_INTERVENTION|Arm 2: Control Group|This group will consist of the subjects who did not receive any intervention for 6 weeks and were evaluated before and after 6 weeks.
62107713|NCT06437002||anorexia nervosa restrictive/ANr|
62107714|NCT06437002||anorexia nervosa binge-purging/ANbp|
62107715|NCT06437002||bulimia nervosa/bn|
62107716|NCT06437002||Health control/Hc|
62107717|NCT04102449|OTHER|Treatment with Apremilast|"Single group:~Apremilast will be prescribed according to the patient information leaflet, i.e.:~Dosage form: Oral pill Dosage and Frequency: First 6 days titration phase, followed by 30mg twice daily (in case of kidney problems 30mg once daily in the morning). Treatment duration at the discretion of the treating physician."
62107718|NCT06611163|EXPERIMENTAL|Tildrakizumab 100 mg|
62107719|NCT06611163|PLACEBO_COMPARATOR|Placebo|
62107720|NCT05542342|EXPERIMENTAL|Experimental arm|Patients will receive Sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until progression of disease, unacceptable toxicity, death, or consent withdrawal, whichever occurs first. Treatment may be continued after progression according to physician criteria (with previous consultation with Coordinating investigator) until patients no longer receive clinical benefit.
62107721|NCT01895517|ACTIVE_COMPARATOR|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
62107722|NCT01895517|EXPERIMENTAL|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
61914146|NCT04138979||Disease group|First chemotherapy for breast cancer
62107723|NCT03037190|EXPERIMENTAL|Group A|Group A:withdrawal of gluten from the diet, Group A will have a gluten free diet for a year after the onset of diabetes
62299109|NCT01306981|PLACEBO_COMPARATOR|Saline|
62299110|NCT01501643|ACTIVE_COMPARATOR|Spirometry|Spirometry
62669400|NCT02096224|ACTIVE_COMPARATOR|Desflurane|Desflurane will be administered as the maintenance agent of general anesthesia.
62669401|NCT05428228|EXPERIMENTAL|TP1|Participants will be administered TP1 during one of the experimental visits.
62669402|NCT05428228|EXPERIMENTAL|TP2|Participants will be administered TP2 during one of the experimental visits.
62669403|NCT05428228|PLACEBO_COMPARATOR|Placebo|Participants will be administered placebo during one of the experimental visits.
62669404|NCT05080270|EXPERIMENTAL|tolerogenic fibroblasts administered via intravenous infusion|A single dose of 100 million tolerogenic fibroblasts administered via intravenous infusion.
62299111|NCT01501643|EXPERIMENTAL|Non invasive positive pressure ventilation|Non invasive positive pressure ventilation
62299112|NCT02561156|EXPERIMENTAL|Part 1 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62669405|NCT04011709|OTHER|Visit 1 and Visit 2, Test Arm 2A|Subjects who carried out 3 attempts at Visit 1, failed to achieve nebulization success and subsequently were included in Test Arm 2A for Visit 2
62107724|NCT03037190|NO_INTERVENTION|B normal diet|Group B will have normal not glutenfree diet, no planned intervention
62107725|NCT02703155|OTHER|Home Oral Glucose tolerance test kit|Providing children with Cystic Fibrosis between 10 and 17 years of age with Home Oral glucose tolerance test kit to screen Cystic fibrosis related Diabetes.
62107726|NCT04729296|EXPERIMENTAL|Golimumab|Golimumab for subcutaneous use
62669406|NCT04011709|OTHER|Visit 1 and Visit 2, Test Arm 2B|Subjects who carried out 3 attempts at Visit 1, achieved nebulization success and were subsequently included in Test Arm 2B for Visit 2
62669407|NCT02468700|EXPERIMENTAL|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
62669408|NCT02468700|PLACEBO_COMPARATOR|PV|PV (placebo drug delivery vehicle)
62669409|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 4 mg|4 uncoated tablets of 1 milligram (mg) BI 764122 (total: 4 mg) were administered as single oral dose with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h). Single rising dose (SRD) part.
62669410|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 12 mg|1 film-coated tablet of 10 mg and 2 uncoated tablets of 1 mg BI 764122 (total: 12 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
62669411|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 25 mg|2 film-coated tablets of 10 mg and 5 uncoated tablets of 1 mg BI 764122 (total: 25 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
62107727|NCT04729296|PLACEBO_COMPARATOR|Placebo|Placebo syringes and vials matching active drug
62107728|NCT05189587|EXPERIMENTAL|TES group|Intervention: Device (transcranial electrical stimulation, TES)
62107729|NCT05189587|SHAM_COMPARATOR|sham TES group|Intervention: Device (transcranial electrical stimulation, TES)
62107730|NCT05189587|NO_INTERVENTION|Control group|Intervention: none
62107731|NCT02057718|EXPERIMENTAL|LUM001 (Maralixibat)|Participants will receive LUM001, also known as Maralixibat (MRX) twice a day (BID).
62299113|NCT02561156|EXPERIMENTAL|Part 1 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62299114|NCT02561156|EXPERIMENTAL|Part 1 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62299115|NCT02561156|EXPERIMENTAL|Part 1 Cohort 4: TAK-653 5.0 mg|TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62299116|NCT02561156|EXPERIMENTAL|Part 1 Cohort 5: TAK-653 9.0 mg|TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
62299117|NCT02561156|EXPERIMENTAL|Part 1 Cohort 6: TAK- 653 18 mg|TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
62299118|NCT02561156|EXPERIMENTAL|Part 1 Additional Cohorts: TAK- 653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
62299119|NCT02561156|EXPERIMENTAL|Part 2 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
62299120|NCT02561156|EXPERIMENTAL|Part 2 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
62107732|NCT04332757|EXPERIMENTAL|Training Intervention|18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation.
62107733|NCT04332757|NO_INTERVENTION|Usual care control|Usual care acting as a control group.
62107734|NCT00343824|EXPERIMENTAL|aquacel AG hydrofiber|
62107735|NCT00343824|EXPERIMENTAL|Acticoat burn dressing|
62107736|NCT04617600|ACTIVE_COMPARATOR|Mineral trioxide aggregate (MTA)|Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)
62469725|NCT05640531|EXPERIMENTAL|WCK 771|WCK 771 600mg, 800mg, and 1000mg WCK 771 BID. Dosage form : IV Infusion
62107737|NCT04617600|EXPERIMENTAL|TheraCal PT|Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)
62299121|NCT02561156|EXPERIMENTAL|Part 2 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
62299122|NCT02561156|EXPERIMENTAL|Part 2 Cohort 4: TAK-653 6 mg|TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
61914147|NCT05891756||CD patients requiring surgical treatment (ileocecal resection)|
62107738|NCT06631300|EXPERIMENTAL|Prednisone group|A prednisone taper will be given to the subjects.
62299123|NCT02561156|EXPERIMENTAL|Part 2 Cohort 5: TAK-653 9 mg|TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
62107739|NCT06631300|PLACEBO_COMPARATOR|Placebo group|A placebo taper will be given to match the number of pills being tapered in the prednisone group.
62107740|NCT04228055|EXPERIMENTAL|CLIPP2|24 Week Lifestyle Modification Intervention
62299124|NCT02561156|EXPERIMENTAL|Part 2 Additional Cohorts: TAK-653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
62299125|NCT03534648|EXPERIMENTAL|Effect of PF-05221304 on PF-06865571 PK|
62469726|NCT05640531|PLACEBO_COMPARATOR|Placebo infusion|Matching Placebo administered as IV infusion
62299126|NCT03534648|EXPERIMENTAL|Effect of PF-06865571 on PF-05221304 PK|
62469727|NCT02128386||Renal sympathetic denervation|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus renal sympathetic denervation
62469728|NCT02128386||Intensified antihypertensive treatment|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus second-line antihypertensive agents (e.g. mineralocorticoid receptor antagonists or alpha-1-blockers)
62469729|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
62469730|NCT00942318|EXPERIMENTAL|PPE|PPE : CSII +/- Metformin.
62669412|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 50 mg|5 film-coated tablets of 10 mg BI 764122 (total 50 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
62669413|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 100 mg|1 film-coated tablet of 100 mg BI 764122 (total: 100 mg) was administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
62669414|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 200 mg|2 film-coated tablets of 100 mg BI 764122 (total: 200 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
61914148|NCT05891756||Control group|Patients requiring an ileocecal resection for a cause other than CD
62299127|NCT03354845|NO_INTERVENTION|Control (usual care) group|In the control group, doctors maintained the usual practice of medication review, altering and discontinuing medications as necessary, without receiving deprescribing recommendations from pharmacists.
62299128|NCT03354845|OTHER|Deprescribing intervention group|The five-step patient-centred deprescribing process was utilized in the intervention group.
62299129|NCT05301244|EXPERIMENTAL|laughter yoga practice|Laughter yoga practiced by a researcher with a laughter yoga practitioner certificate
62107741|NCT04201119|EXPERIMENTAL|With Oxiris|
62107742|NCT04201119|NO_INTERVENTION|Without Oxiris|
62107743|NCT01813903|EXPERIMENTAL|Nutrition|Intensified dietary counseling and use of web application.
62107744|NCT01813903|EXPERIMENTAL|Flexible mind|Use of mobile applications.
62107745|NCT01813903|NO_INTERVENTION|Normal maternity clinic visits|In control maternity clinics, nurses continue their usual counseling.
62107746|NCT03719209|PLACEBO_COMPARATOR|Standard Practice|Patients and families will be shown images of their endoscopic procedure per standard practice.
62107747|NCT03719209|EXPERIMENTAL|Virtual Reality|Patients and families will be showed the results of their endoscopic procedure via a virtual reality application called HealthVoyager, in addition to standard practice images.
62299130|NCT05301244|EXPERIMENTAL|Laughter yoga session parts-1|Deep breathing exercises (5 minutes)
62299131|NCT05301244|EXPERIMENTAL|Laughter yoga session parts-2|Warm-up exercises (10 minutes)
62299132|NCT05301244|EXPERIMENTAL|Laughter yoga session parts-3|Childish games (10 minutes)
62107748|NCT03269019||HIT-group|The patients with heparin-induced thrombocytopenia.
62107749|NCT03269019||HITTs-group|The patients with heparin-induced thrombocytopenia with thrombosis.
62107750|NCT03269019||Control group|The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.
62107751|NCT01846169|EXPERIMENTAL|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
62107752|NCT06130878|NO_INTERVENTION|Control Group (CG)|This group does not receive any treatment.
62469731|NCT00942318|ACTIVE_COMPARATOR|injections|INJ: basal/bolus MDI +/- Metformin
62469732|NCT02010320|EXPERIMENTAL|Computer dosed|Patients for which the computer model will calculate the individual doses
62469733|NCT02010320|ACTIVE_COMPARATOR|Control|Patients which will get their tacrolimus doses determined by experience transplant physicians
62469734|NCT02704286|SHAM_COMPARATOR|Generic Osteoarthritis Risk Information|Participants in this arm received generic osteoarthritis information that was not personalized.
62469735|NCT02704286|EXPERIMENTAL|Personalized Osteoarthritis Risk|Participants in this arm obtained their personalized osteoarthritis risk from the internet-based Osteoarthritis Risk Calculator.
61914149|NCT03486275|ACTIVE_COMPARATOR|Hygie game|Prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
62299133|NCT05301244|EXPERIMENTAL|Laughter yoga session parts-4|Laughter exercises (15 minutes)
62469736|NCT02035306|EXPERIMENTAL|non-invasive Haemaglobin|Measuring haemaglobin using non-invasive co-oximetry device
62669415|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 300 mg|3 film-coated tablets of 100 mg BI 764122 (total: 300 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
62669416|NCT03794323|EXPERIMENTAL|SRD part: BI 764122 400 mg|4 film-coated tablets of 100 mg BI 764122 (total: 400 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
62669417|NCT03794323|EXPERIMENTAL|FE part: BI 764122 50 mg fasted/ BI 764122 50 mg fed|5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) were administered as single oral dose with 240 mL water after an overnight fast of at least 10 h, followed by wash-out period of at least 7 days followed by 5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) administered as single oral dose with 240 mL water after a standardized high-fat, high-calorie breakfast. Food effect (FE) part.
62107753|NCT06130878|EXPERIMENTAL|EXPERIMENTAL GROUP (EG)|People assigned to this group will undergo a 12-week physical training intervention
62669418|NCT03794323|EXPERIMENTAL|FE part: BI 764122 50 mg fed/ BI 764122 50 mg fasted|5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) were administered as single oral dose with 240 mL water after a standardized high-fat, high-calorie breakfast, followed by wash-out period of at least 7 days followed by 5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) administered as single oral dose with 240 mL water after an overnight fast of at least 10 h. FE part.
62669419|NCT03794323|PLACEBO_COMPARATOR|Placebo|placebo matching in size and weight to corresponding uncoated or film-coated BI 764122 tablets were administered as single oral dose with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h). Single rising dose (SRD) part.
62107754|NCT03552770|ACTIVE_COMPARATOR|IVIBx1|Patients treated with a single intra-vitreous injection of bevacizumab (1.25 mg in 0.05 ml of solution) pro-re-nata repeated after monthly periodic monitoring of each patient
62107755|NCT03552770|ACTIVE_COMPARATOR|IVIBx2|Patients treated with two combined intra-vitreous injections of bevacizumab, (1.25 mg in 0.05 ml of solution) spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of each patient
62107756|NCT05866081|OTHER|Randomized cohort- No stent placement|"Participants that are eligible and consent for the randomization cohort of the trial will not have a stent placed.~If participants are found to be ineligible (see below) at the end of ureteroscopy the participants will not be randomized and taken off the study.~In randomization cohort, second stage eligibility criteria: ureteral perforation, unanticipated anatomic abnormality, greater than expected bleeding, ureteral dilation greater than 12 French, ureteral access sheath utilized, failed ureteroscopy, no or incomplete lithotripsy performed, unable to complete case due to medical or anesthetic event."
62107757|NCT05866081|EXPERIMENTAL|Randomized cohort- Stent placement|"Participants that are eligible and consent for the randomization cohort trial will have a stent placed.~If participants are found to be ineligible (see below) at the end of ureteroscopy the participants will not be randomized and taken off the study.~In randomization cohort, second stage eligibility criteria: ureteral perforation, unanticipated anatomic abnormality, greater than expected bleeding, ureteral dilation greater than 12 French, ureteral access sheath utilized, failed ureteroscopy, no or incomplete lithotripsy performed, unable to complete case due to medical or anesthetic event."
62107758|NCT05866081|OTHER|Observational participants - not randomized|Patients that do not consent to the randomization trial that elect to be on the observational cohort. Stent placement in the observational cohort will be decided by the surgeon intraoperatively, as per routine clinical practice.
62107759|NCT03095508|EXPERIMENTAL|Angal S (Arm A)|Patients received Angal S, topical spray \[Menthol\], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
62107760|NCT03095508|ACTIVE_COMPARATOR|ANTI-ANGIN® FORMULA (Arm B)|"Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
62107761|NCT00885508|EXPERIMENTAL|Aracytidine, Daunaurubicine, Lenalidomide|
62107762|NCT05811728|EXPERIMENTAL|Low level laser therapy|
62107763|NCT05811728|PLACEBO_COMPARATOR|Control|
62107764|NCT04830254|ACTIVE_COMPARATOR|study group(A)|Group (A) included 20 patients who received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs) for 45 min per session, three times per week, and for 12 weeks.
62107765|NCT04830254|SHAM_COMPARATOR|Control group(B)|The control group(B) included 20 patients who received placebo TENS stimulation but with a voltage level falling to zero after 10 s of stimulation
62107766|NCT05181579|EXPERIMENTAL|Manuel therapy and exercise group|Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week. And home exercises will be given and told. Each patient will do exercise 4 days a week for 4 weeks.
62299134|NCT00455637|EXPERIMENTAL|Dysport 5 units|
62299135|NCT00455637|EXPERIMENTAL|Dysport 10 units|
62299136|NCT00455637|EXPERIMENTAL|Dysport 15 units|
62669420|NCT05488353|EXPERIMENTAL|Single Arm|Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection.
62669421|NCT02584296|NO_INTERVENTION|Usual care control|Phase 1 will be observation only, and will be considered a usual care control group, activity at home.
62669422|NCT02584296|EXPERIMENTAL|Biobehavioral self management approach|Phase 2 participants will receive the Biobehavioral self management approach (BSMA) intervention aligned with the IMB model; introduced over three days of each five-day consolidation chemotherapy hospital admission.
62299137|NCT03815175|EXPERIMENTAL|XIENCE|XIENCE + 1 month DAPT
62299138|NCT00975091|ACTIVE_COMPARATOR|Entecavir 0.5|
62299139|NCT00975091|ACTIVE_COMPARATOR|Entecavir 1.0|
62299140|NCT05581043|PLACEBO_COMPARATOR|0 gram 3-OHB 30 minutes before an OGTT|0 gram 3-OHB 30 minutes before an OGTT
62299141|NCT05581043|EXPERIMENTAL|10 gram 3-OHB 30 minutes before an OGTT|10 gram 3-OHB 30 minutes before an OGTT
62299142|NCT05581043|EXPERIMENTAL|20 gram 3-OHB 30 minutes before an OGTT|20 gram 3-OHB 30 minutes before an OGTT
62669423|NCT06025383|EXPERIMENTAL|L-Citrulline|L-Citrulline: 6 grams/day divided in 2 equal doses
62299143|NCT05581043|EXPERIMENTAL|40 gram 3-OHB 30 minutes before an OGTT|40 gram 3-OHB 30 minutes before an OGTT
62669424|NCT06025383|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose: 8 capsules/day divided into 2 equal doses
62299144|NCT05581043|EXPERIMENTAL|20 gram 3-OHB 0 minutes before an OGTT|20 gram 3-OHB 0 minutes before an OGTT
62669425|NCT02524678|PLACEBO_COMPARATOR|Placebo|Placebo
62669426|NCT02524678|ACTIVE_COMPARATOR|URC102|URC102
62669427|NCT00997815|EXPERIMENTAL|Botulinum toxin A|The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.
62669428|NCT00997815|PLACEBO_COMPARATOR|Placebo|Using normal saline
62669429|NCT02818062||Endophthalmitis|The diagnosis of endophthalmitis was made on the basis of clinical features including pain, decreased visual acuity (VA), diffuse bulbar conjunctival hyperaemia, chemosis, inflammation of the anterior segment and posterior segment inflammation (all patients had vitreous infiltration diagnosed by biomicroscopy or ophthalmic ultrasound).
62669430|NCT02818062||Cataract (Control)|Controls were patients who underwent cataract surgery.
62669431|NCT00787488|EXPERIMENTAL|1|Chemotherapy plus Hyperthermia
62669432|NCT04338997|EXPERIMENTAL|IZD174|Intra subject dose escalation of IZD174
62669433|NCT05291481|EXPERIMENTAL|CAPAS Youth Parenting Intervention|11-week CAPAS-Youth culturally adapted intervention
62299145|NCT05581043|EXPERIMENTAL|20 gram 3-OHB 60 minutes before an OGTT|20 gram 3-OHB 60 minutes before an OGTT
62299146|NCT03949673|OTHER|Knee or Hip Joint Arthroplasty|Patients with OA of the knee or hip who are participating in an ongoing fasinumab phase 3 parent study
62669434|NCT05291481|NO_INTERVENTION|Wait-list control|Participants allocated to this condition receive the intervention until all assessments are completed for both arms in each cohort
62669435|NCT03175458|EXPERIMENTAL|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
62669436|NCT03175458|ACTIVE_COMPARATOR|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
62669437|NCT06450561||Patients hospitalized due to a cardiovascular event|Patients hospitalized due to a cardiovascular event including stroke, acute coronary syndrome, ischemic heart disease, or peripheral arterial disease
62669438|NCT03017287|EXPERIMENTAL|GlucoMe App|Self monitoring of glucose blood measurements using the GlucoMe glucose monitoring glucose device and App
62669439|NCT00443326|EXPERIMENTAL|AMG 714|AMG 714 will be given as a multiple dose regimen
62669440|NCT00804479||no treatment|Available 301 subjects enrolled in CALM-PD Available 82 subjects enrolled in CALM-PD imaging substudy
62299147|NCT04516681|EXPERIMENTAL|Combined Ascorbic Acid with Adebrelimab and chemotherapy group|Ascorbic Acid with Adebrelimab and FOLFOX ± bevacizumab. Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
62299148|NCT04516681|ACTIVE_COMPARATOR|Chemotherapy alone group|standard FOLFOX treatment
62299149|NCT02468193|EXPERIMENTAL|Osilodrostat|Patients in this arm took the study drug, osilodrostat.
62669441|NCT04132466|EXPERIMENTAL|Enrolled Subjects|Adult subjects who met eligibility criteria and provided written informed consent to participate
62669442|NCT02391584|EXPERIMENTAL|XprESS|Balloon dilation of the Eustachian tube
62669443|NCT02391584|OTHER|Control|Continued medical management
62669444|NCT04835753|EXPERIMENTAL|study group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training plus shock wave on the muscle belly of the planter flexor hypertonic muscles.
62669445|NCT04835753|OTHER|control group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training .these traditional therapy had been approved by previous studies its effectiveness in management cerebral palsy child
62669446|NCT03752801||Script Review Parents/Caregivers|will have script reviewed and evaluated by parents/caregivers in groups of 5 up to 40 participants until 4/5 parents/caregivers demonstrate that script is understandable and acceptable.
62299150|NCT05649176|ACTIVE_COMPARATOR|Diet without soy|Participants receive a diet to moderate the blood glucose response that does not include soy
62669447|NCT03752801||Video Review Parents/Caregivers|review and evaluation of the developed educational videos by parents/caregivers up to 20 parents who have not participated in the script review
62669448|NCT04137887|EXPERIMENTAL|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) high dose quadrivalent influenza vaccine (QIV-HD), intramuscularly (IM) at Day 0.
62669449|NCT04137887|ACTIVE_COMPARATOR|Group 2: QIV-SD|Participants received a single injection of 0.5 mL standard-dose quadrivalent influenza vaccine (QIV-SD), IM at Day 0.
62669450|NCT00954655||Group 1|Tumor samples are used for polymorphism and mutation analysis.
62669451|NCT01699685|PLACEBO_COMPARATOR|Sequence A|Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
62299151|NCT05649176|EXPERIMENTAL|Diet with soy|Participants receive a diet to moderate the blood glucose response that includes soy
62669452|NCT01699685|ACTIVE_COMPARATOR|Sequence B|Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
62669453|NCT01617967|EXPERIMENTAL|Patisiran (ALN-TTR02)|Two administrations of patisiran will be administered once every 4 weeks \[Q4W\]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks \[Q3W\]), and an alternative premedication regimen.
61914150|NCT03486275|ACTIVE_COMPARATOR|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva)
61914151|NCT05036473|EXPERIMENTAL|25/100mg treatment group|25/100mg WD-1603
61914152|NCT05036473|EXPERIMENTAL|25/150mg treatment group|25/150mg WD-1603
62299152|NCT00986349|EXPERIMENTAL|Diabetes|Single Arm
62299153|NCT06071312|EXPERIMENTAL|. Single FMT|Patients enrolled in this arm will receive a single infusion of donor FMT
62299154|NCT06071312|ACTIVE_COMPARATOR|Sequential FMT|Patients enrolled in this arm will receive sequential infusions of donor FMT
62669454|NCT01558570||Schizophrenia|
61914153|NCT05036473|EXPERIMENTAL|2x25/100mg treatment group|2x25/100mg WD-1603
61914154|NCT05036473|PLACEBO_COMPARATOR|placebo group|placebo are tablets-matching with the same active groups.
62299155|NCT01215084|EXPERIMENTAL|Chinese Subpopulation: Fampridine-PR 10 mg|Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
62299156|NCT01215084|EXPERIMENTAL|Japanese Subpopulation: Fampridine-PR 10mg|Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
62669455|NCT04626336||Patients who undergo a cystectomy|Patients who undergo a cystectomy for cancer or not, since 2010 to 2020
61914155|NCT05503667|EXPERIMENTAL|Furmonertinib Plus Bevacizumab|Furmonertinib Plus Bevacizumab
61914156|NCT05503667|ACTIVE_COMPARATOR|Furmonertinib|Furmonertinib monotherapy
61914157|NCT01481129|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62299157|NCT01215084|EXPERIMENTAL|Caucasian Subpopulation: Fampridine-PR 10mg|Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs
62299158|NCT05018286|EXPERIMENTAL|Apraglutide subcutaneous (SC) injections, once weekly|Peptide analogue of Glucagon-like Peptide 2 (GLP-2)
62669456|NCT00870155|EXPERIMENTAL|Dirucotide|
62669457|NCT00623376|ACTIVE_COMPARATOR|1|first on treatment then on Placebo
62669458|NCT00623376|PLACEBO_COMPARATOR|2|first on placebo then on treatment
62669459|NCT01495273|EXPERIMENTAL|Nerve stimulator|Experimental group; will undergo transtracheal injection with needle connected to nerve stimulator.
62669460|NCT01495273|ACTIVE_COMPARATOR|Standard needle/syringe|Control group; will undergo transtracheal injection with standard needle/syringe assembly.
62669461|NCT01717859|OTHER|Tocilizumab|All subjects will receive tocilizumab.
62299159|NCT05297565|EXPERIMENTAL|Arm A: Subcutaneous Nivolumab|
62299160|NCT05297565|ACTIVE_COMPARATOR|Arm B: Intravenous Nivolumab|
62469737|NCT03075553|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62469738|NCT02481830|EXPERIMENTAL|Arm A Nivolumab|Nivolumab intravenous infusion as specified
62299161|NCT05270603||ICARUS Calculator Raters (Intervention Group)|Surgeons and anesthesiologists will be asked to use the ICARUS Calculator to grade a subset of 10 clinical scenarios selected from a list of the clinical scenarios and examples from the publications of the 5iAE systems
62469739|NCT02481830|ACTIVE_COMPARATOR|Arm B Chemotherapy Topotecan|Topotecan as specified
62469740|NCT02481830|ACTIVE_COMPARATOR|Arm B Chemotherapy Amrubicin|Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
62469741|NCT02071797|ACTIVE_COMPARATOR|Arm A - Blanketroll lll|Cutaneous Cooling Blanket, Blanketroll lll, applied to cool patient to 32C. Standard care
62469742|NCT02071797|ACTIVE_COMPARATOR|Arm B - RhinoChill|Intra nasal cooling system, RhinoChill, to cool patient to 32C - Standard care
62469743|NCT04657965|EXPERIMENTAL|Administration of LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
62469744|NCT01884519|EXPERIMENTAL|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
62469745|NCT01884519|EXPERIMENTAL|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
61914158|NCT03937635|EXPERIMENTAL|Arm I (daratumumab, lenalidomide, dexamethasone)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 in courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
61914159|NCT03937635|EXPERIMENTAL|Arm II (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
61914160|NCT03320694|EXPERIMENTAL|metformin|Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
62469746|NCT00938951|EXPERIMENTAL|Systane® Ultra|Systane® Ultra
62469747|NCT00328926|ACTIVE_COMPARATOR|Luveris® 75 IU|
62469748|NCT00328926|ACTIVE_COMPARATOR|Luveris® 25 IU|
62469749|NCT00328926|PLACEBO_COMPARATOR|Placebo|
62469750|NCT04012112|EXPERIMENTAL|single-arm trials|longitudial study of the thoracolumbar brace in the neuromuscular scoliosis for 6 months
62469751|NCT04215822||acute myeloid leukemia patients - control group|acute myeloid leukemia
62469752|NCT06141317|EXPERIMENTAL|PASC transplantation (25 million PASCs/patient)|Pluripotent Adipose-Derived Stem Cells will be delivered intravenously
62469753|NCT06141317|PLACEBO_COMPARATOR|Control|Saline solution will be delivered intravenously
62469754|NCT01751048|EXPERIMENTAL|Group #1|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE)
62299162|NCT05270603||Cognitive Grading Raters (Control Group)|Surgeons and anesthesiologists will be asked to use the ICARUS Calculator to grade a subset of 10 clinical scenarios (same as the Intervention group) selected from a list of the clinical scenarios and examples from the publications of the 5iAE systems
62299163|NCT05227729||Patients undergoing abdominal surgery|Inclusion criteria: \> 18 years old, American Society of Anesthesiologists physical status 1-3, abdominal surgery of \> 1,5 hrs estimated duration, no contraindications to the use of oesophageal ultrasound.
62299164|NCT00618150|EXPERIMENTAL|A|
62299165|NCT02038062|EXPERIMENTAL|Sevoflurane|Sevoflurane Preconditioning
62299166|NCT02038062|NO_INTERVENTION|No Sevoflurane|No Sevoflurane Preconditioning
62469755|NCT01751048|EXPERIMENTAL|Group #2|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 10 mcg Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE)
62469756|NCT01751048|EXPERIMENTAL|Group #3|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + Stable oil-in-water Emulsion (SE)
62469757|NCT01644253|EXPERIMENTAL|Cohort 1 - Previously Untreated CLL|20 mg/kg TRU-016 + Rituximab
62469758|NCT01644253|EXPERIMENTAL|Cohort 2 - Relapsed CLL|20 mg/kg TRU-016 + Rituximab
62469759|NCT01644253|EXPERIMENTAL|Cohort 3 - Previously Untreated CLL|10 mg/kg TRU-016 + Rituximab
62469760|NCT01644253|EXPERIMENTAL|Cohort 4 - Previously Untreated CLL|20 mg/kg TRU-016 20 + Obinutuzumab
62469761|NCT01644253|EXPERIMENTAL|Cohort 5 - Relapse CLL|20 mg/kg TRU-016 + idelalisib + rituximab
62469762|NCT01644253|EXPERIMENTAL|Cohort 6 - With CLL on ibrutinib with no complete response|20 mg/kg TRU-016 + ibrutinib
62469763|NCT01644253|EXPERIMENTAL|Cohort 7 - With CLL on ibrutinib with stable disease|20 mg/kg TRU-016 + ibrutinib
62469764|NCT01644253|EXPERIMENTAL|Cohort 8 - With relapsed or refractory PTCL|20 mg/kg TRU-016 + 90 mg/m2 bendamustine
62469765|NCT02095782|EXPERIMENTAL|chemotherapy and erlotinib|Intercalated combination of chemotherapy and erlotinib in 1st line setting for patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation
62737252|NCT05829005|ACTIVE_COMPARATOR|Active arm|The location and number of pulses will be set. The intensity of stimulation will be felt by the subject. 120 stimuli - including at least 20 supra (motor) threshold stimuli causing movement of the affected limb.
62669462|NCT03128060|EXPERIMENTAL|Home-based Palliative Care|Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
62669463|NCT03128060|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced usual care refers to: 1) usual primary care provided by a primary care physician who has been offered special training in the core elements of palliative care; 2) case management services; and 3) provider support through palliative care consultation.
62669464|NCT03990688|EXPERIMENTAL|AK3280 (Cohort 1)|Subjects in Cohort 1 are administered with an oral dose of 100 mg AK3280 b.i.d from Day 1 to Day 14.
62669465|NCT03990688|EXPERIMENTAL|AK3280 (Cohort 2)|Subjects in Cohort 2 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 2 will be based on the emerging data from previous cohort.
62107767|NCT05181579|EXPERIMENTAL|Sacroiliac injection and exercise group|"To patients in the injection group corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine)will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy).~And home exercises will be given and told. Each patient will do exercise 4 days a week for 4 weeks."
62669466|NCT03990688|EXPERIMENTAL|AK3280 (Cohort 3)|Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.
62669467|NCT03990688|PLACEBO_COMPARATOR|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose cohort.
62669468|NCT04268212|EXPERIMENTAL|Bitter Melon|The participants were asked to consume 100 ml of bitter melon juice 15 minutes prior to the 75-g oral glucose intake. Participants drank the juice within 5 minutes. Participants remained seated throughout the following 2 hours.
62669469|NCT04268212|EXPERIMENTAL|Exercise|Participants performed 30 minutes of treadmill walking at 65% of the age-predicted maximum heart rate. The exercise started 15 minutes after the 75-g oral glucose intake.
62669470|NCT01667614|NO_INTERVENTION|ACE/ARB|In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
62669471|NCT01667614|ACTIVE_COMPARATOR|Spironolactone/ARB|spironolacone 25 mg tablets added to losartan
62669472|NCT02428153|EXPERIMENTAL|cases|static and dynamic stretching exercises
62669473|NCT05309889||high exposure level|Patients have a high level of exposure factors
62669474|NCT05309889||low exposure level|Patients have a low level of exposure factors
62669475|NCT02580344|OTHER|Ibuprofen|
62299167|NCT00544739||1|323 women with established coronary artery disease before 55 year of age
62469766|NCT03904563|EXPERIMENTAL|Bevacizumab|All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
61914161|NCT03320694|ACTIVE_COMPARATOR|Insulin|Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
62669476|NCT04645056|EXPERIMENTAL|Intervention group|"a. Intervention Group: Neck stretching and movement~The patient starts the stretching exercises the morning after surgery with instructions from a trained professional at the department. The patient is informed that the stretching exercises will not affect the surgical wound. The patient is instructed in performing five repetitions of each of the following nine exercises three times each day in four weeks:~1. Relax shoulders and neck sufficiently~2. Look down - Stretching and movement~3. Look to each side - movement~4. Lower the head to each side - stretching~5. Lower the head diagonally to each side - stretching~6. Small nod movements~7. Lift the shoulders - movement~8. Roll the shoulders - movement~9. Lift the arms - movement~The first stretching session is observed by the instructor who gives feedback and correct the exercises, if necessary. Furthermore, the patient is given a training brochure."
62669477|NCT04645056|NO_INTERVENTION|Control group|b. Control group The patients in the control group are not instructed in any intervention but are answering completely similar questionnaires as the intervention group.
61914162|NCT00559832|NO_INTERVENTION|Normoxia|Sleeping in normoxia for 14 nights prior to one night at 4500 m
61914163|NCT00559832|EXPERIMENTAL|Hypoxia|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
62669478|NCT05877612||Burst stimulation|Patients treated by Spinal Cord Stimulation in Burst Mode for their Complex Regional Pain Syndromes (CRPS) Type 1 of the Upper Limbs
62669479|NCT01316900|EXPERIMENTAL|GSK573719/GW642444 125/25|125/25 mcg once-daily
62669480|NCT01316900|EXPERIMENTAL|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
62669481|NCT01316900|EXPERIMENTAL|GW642444|25 mcg once-daily
62669482|NCT01316900|ACTIVE_COMPARATOR|tiotropium bromide|18 mcg once-daily
62669483|NCT04216004|EXPERIMENTAL|Full-fat dairy|3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
62669484|NCT04216004|ACTIVE_COMPARATOR|Non-fat diary|3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.
62669485|NCT04216004|PLACEBO_COMPARATOR|Non-dairy control|3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.
62669486|NCT02296801|ACTIVE_COMPARATOR|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
62107768|NCT02589210|EXPERIMENTAL|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
62107769|NCT04543162||patients with Mild Traumatic Brain Injury|patients with Mild Traumatic Brain Injury
62669487|NCT02296801|EXPERIMENTAL|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
62107770|NCT03239925|EXPERIMENTAL|Experimental group|all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
62299168|NCT00544739||2|347 clinically healthy, age matched women selected from the National Health Survey WOBASZ study with negative history of CVD or negative exertional chest pain.
62299169|NCT04547257|EXPERIMENTAL|Treatment|Extracorporeal therapy with Seraph 100 blood filter
62107771|NCT03239925|PLACEBO_COMPARATOR|Control group|these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode
62107772|NCT06306365|EXPERIMENTAL|Experimental|Subjects belonging to this group perform a modern board game-based learning.
62107773|NCT06306365|NO_INTERVENTION|Control (no intervention)|Subjects belonging to this group not perform intervention.
62299170|NCT04547257|NO_INTERVENTION|Control|patients receive antibiotics only as standard of care
62299171|NCT04695977|EXPERIMENTAL|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
62299172|NCT04695977|EXPERIMENTAL|Nivolumab Monotherapy|All enrolled subjects will receive nivolumab monotherapy IV according to the treatment schedule until a reason for treatment discontinuation is reached.
62299173|NCT04957173|OTHER|Intensive lifestyle intervention|Participants will undergo an intensive lifestyle intervention, implemented virtually by a medical team with expertise in the management of T2DM. This team will be made up of an endocrinologist, a nutritionist and a nurse.
62669488|NCT02296801|EXPERIMENTAL|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
62299174|NCT03834948|EXPERIMENTAL|AO-176 Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
62299175|NCT03834948|EXPERIMENTAL|AO-176 Dose Expansion|Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
62469767|NCT02002754|ACTIVE_COMPARATOR|Eosinophilic bronchitis|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
62669489|NCT02296801|EXPERIMENTAL|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
61914164|NCT02490761||Study cohort|Patients aged 65 years or over admitted to a geriatric ward in 2 hospitals for more than 3 days
62107774|NCT06142240|ACTIVE_COMPARATOR|programe at the health centre|Subjects who are included in the study will perform a therapeutic exercise programme which will have a duration of 8 weeks and 2 sessions per week of 1h duration. Participants assigned to the supervised group will perform the programme at the health centre
62299176|NCT03834948|EXPERIMENTAL|AO-176 + Paclitaxel Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
62299177|NCT03834948|EXPERIMENTAL|AO-176 + Paclitaxel Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + paclitaxel.
62669490|NCT02296801|OTHER|Combined Groups B+D+C|Combined data
62669491|NCT02857959|EXPERIMENTAL|single dose benzathine penicillin G.|single dose benzathine penicillin G.
62299178|NCT03834948|EXPERIMENTAL|AO-176 + Pembrolizumab Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
62469768|NCT02002754|ACTIVE_COMPARATOR|cough variant asthma|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
62469769|NCT04642274|EXPERIMENTAL|ERAS|
62469770|NCT04642274|NO_INTERVENTION|Control|
62469771|NCT05974163||Model reconstruction cohort|8000 patients were recruited retrospectively from January 2023 to December 2025 as discovering group.
62469772|NCT05974163||External Validation cohort 1|1000 patients were recruited retrospectively from January 2023 to December 2025 as internal validation group.
62669492|NCT02857959|ACTIVE_COMPARATOR|three doses of benzathine penicillin G.|three doses of benzathine penicillin G.
62669493|NCT01030575|EXPERIMENTAL|Inositol low volume|10 mg/kg/day Intravenous inositol 5%
61914165|NCT01875224|EXPERIMENTAL|Belatacept and CellCept|Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
62107775|NCT06142240|EXPERIMENTAL|programe at the health home|Subjects who are included in the study will perform a therapeutic exercise programme which will have a duration of 8 weeks and 2 sessions per week of 1h duration. Participants assigned to the to the home group will receive telematic supervision (via videoconference).
62107776|NCT02540044|EXPERIMENTAL|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
62299179|NCT03834948|EXPERIMENTAL|AO-176 + Pembrolizumab Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + pembrolizumab.
62299180|NCT05167201|EXPERIMENTAL|Nasal High Flow|"The Nasal High Flow device is an integrated flow generator that delivers warmed and humidified air to spontaneously breathing patients through a variety of patient interfaces.~Flow rates up to 60 litres/minute are available to the user, depending on the patient interface and mode of operation."
62299181|NCT04265391|EXPERIMENTAL|Snakehead fish cookies|Subjects who were given intervention of snakehead fish cookies during the study period
62469773|NCT05974163||External validation cohort 2|1000 patients will be recruited prospectively during the period from January 2023 to December 2025 as external validation group
62469774|NCT04742283|EXPERIMENTAL|DE-126 Opthalmic Solution 0.002% QD and Vehicle QD|DE-126 Ophthalmic Solution 0.002% is administered once daily (QD)
62469775|NCT04742283|ACTIVE_COMPARATOR|Timolol Maleate Opthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution 0.5% is administered twice daily (BID)
62469776|NCT01218672|EXPERIMENTAL|GreenLight XPS|Photoselective vaporization of the prostate using GreenLight XPS laser system.
62107777|NCT02540044|ACTIVE_COMPARATOR|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
62299182|NCT04265391|PLACEBO_COMPARATOR|Standard cookies|Subjects who were in control group and received standard cookies
62299183|NCT02478684|ACTIVE_COMPARATOR|30 seconds of DCC|30 Seconds of placental blood transfusion
62299184|NCT02478684|ACTIVE_COMPARATOR|60 seconds DCC|60 Seconds of placental blood transfusion
62469777|NCT01218672|ACTIVE_COMPARATOR|Transurethral Resection of the Prostate|Monopolar and bipolar Transuretheral resection of the prostate (TURP)
62469778|NCT00863083|ACTIVE_COMPARATOR|1|Multifamily group weight management intervention plus rewards for program attendance
62469779|NCT00863083|ACTIVE_COMPARATOR|2|Multifamily group weight management intervention plus rewards for attendance and goal attainment
62469780|NCT01613040|EXPERIMENTAL|Treatment A|
62669494|NCT01030575|EXPERIMENTAL|Inositol mid-level volume|40 mg/kg/day Intravenous inositol 5%
62669495|NCT01030575|EXPERIMENTAL|Inositol high volume|80 mg/kg/day Intravenous inositol 5%
61914166|NCT01875224|ACTIVE_COMPARATOR|Tacrolimus and CellCept|Tacrolimus and CellCept taken twice daily based on patient response.
61914167|NCT01315821|EXPERIMENTAL|Saccharomyces boulardii|Saccharomyces boulardii 5 million unit/day for 3 months
61914168|NCT01315821|PLACEBO_COMPARATOR|control|Placebo- for 3 months
62669496|NCT01030575|PLACEBO_COMPARATOR|Placebo|Glucose 5% given in volumes equal to that of the comparator drug
62669497|NCT02360501|EXPERIMENTAL|treatment arm|docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks
62669498|NCT03024164||Young adult stroke patients|Young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke
62669499|NCT00218894||post cataract surgery|
62469781|NCT01613040|EXPERIMENTAL|Treatment B|
62669500|NCT04391907|ACTIVE_COMPARATOR|IPL group|Subject who have intense pulsed light (IPL) laser 2 twice 1-6 weeks before cataract surgery
62107778|NCT04570644|OTHER|Part A|"24 subjects randomized to receive treatment: (A-B) = Single 17.1 mg oral inhaled dose of ALZT-OP1a (cromolyn) via dry powder inhaler and a single oral 10 mg tablet of ALZT-OP1b (ibuprofen) on Day 1. On Day 2, subjects would receive two 17.1 mg doses of ALZT-OP1a via dry powder inhaler and two 10 mg tablets of ALZT-OP1b (ibuprofen), within two minutes of each other.~(B-A) = Two 17.1 mg doses of ALZT-OP1a (cromolyn) and two doses of 10 mg ALZT-OP1b (ibuprofen) on Day 1 and single 17.1 mg dose of ALZT-OP1a cromolyn 17.1 mg and a single 10 mg dose of ALZT-OP1b (ibuprofen) on Day 2.~All subjects will have plasma and CSF collected for PK analysis."
62107779|NCT04570644|OTHER|Part B|"PD - 32 subjects (AD only) will be enrolled in the PD portion of the study. Twenty-four (24) subjects will be assigned to Treatment Group 1 to receive a single (17.1 mg) inhaled dose of ALZT-OP1a (cromolyn) plus a single (10 mg) oral dose of ALZT-OP1b (ibuprofen) daily for 60 days.~All subjects will have plasma and CSF collected for PD biomarker analysis. Eight (8) A subjects will be assigned to Treatment Group 2 (Control Group) and will not be administered study drug."
62299185|NCT06422182|EXPERIMENTAL|Erector Spinae Plane Block group|Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
62299186|NCT06422182|ACTIVE_COMPARATOR|Intravenous patient-controlled analgesia group|Patients received Intravenous patient-controlled analgesia (IV-PCA) by morphine
62299187|NCT01617044|EXPERIMENTAL|Treatment|"1. iron 3 mg/kg/day elemental iron FeSO4 up to 45 mg (dose to be determined by PI)~2. + vitamin C-250 mg chewable tab~3. + probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)"
62299188|NCT01617044|PLACEBO_COMPARATOR|Control|"1. iron 3 mg/kg/day elemental iron FeSO4 to 45 mg~2. + vitamin C-250 mg chewable tab~3. + placebo (identical capsule)"
62299189|NCT03599661||Fertilit-e|Participants review Fertilit-e content, undergo interviews about issues of content, functionality, and ease of use, and complete questionnaires over 45-60 minutes.
62299190|NCT05832762|EXPERIMENTAL|Endovascular treatment + best medical treatment|Endovascular treatment associated with the best medical treatment.
62299191|NCT05832762|ACTIVE_COMPARATOR|best medical treatment|Best medical treatment alone
62299192|NCT02603523|EXPERIMENTAL|Senior Dance|The intervention group will attend a single educational class on fall risk factors and prevention, and will participate in a 12-week, twice-weekly group-based program of Senior Dance. Each dance class will last for an hour, and the number of participants per class will range from 10 to 15. Senior Dance-certified instructors will lead the classes. The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups.
62299193|NCT02603523|NO_INTERVENTION|Control group|Participants in the control group will attend the same educational class on fall risk factors and prevention that intervention group participants will receive, and will be instructed not to take part in any regular exercise programs such as supervised group exercise, Tai Chi, Yoga, or any dance activity during the study period. At the end of the study, they will be offered Senior Dance classes, twice a week, during 12 weeks.
62299194|NCT06483477|EXPERIMENTAL|Arm A|Standard skin care supported by a reminder app
62299195|NCT06483477|ACTIVE_COMPARATOR|Arm B|Standard skin care alone
62299196|NCT06378827|EXPERIMENTAL|Experimental|Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
62107780|NCT02260739|OTHER|chronic myelomonocytic leukemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
62107781|NCT02260739|OTHER|essential thrombocytemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
62107782|NCT02260739|OTHER|myelofibrosis|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
62107783|NCT05392738||Vivity with i-Stent|Patients with Glaucoma or Ocular Hypertension undergoing simultaneous cataract and i-Stent implantation, with Vivity intraocular lens
62107784|NCT05392738||Glaucoma with Vivity|Patients with Glaucoma or Ocular Hypertension undergoing isolated phacoemulsification with Vivity intraocular lens
62107785|NCT05392738||Healthy with Vivity|Patients with undergoing isolated phacoemulsification with Vivity intraocular lens
62107786|NCT03836417||Idiopathic interstitial pneumonias|Patients with idiopathic interstitial pneumonias undergoing surgical lung biopsy
62299197|NCT06378827|PLACEBO_COMPARATOR|Control|Patients in the control group will receive the same volume of saline solution.
62299198|NCT01530490|NO_INTERVENTION|Hemoes|
62299199|NCT01530490|EXPERIMENTAL|Cabergoline|cabergoline
62299200|NCT01104220|NO_INTERVENTION|Lean, metabolically normal|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
62299201|NCT01104220|NO_INTERVENTION|Obese, metabolically normal|Subjects with body mass index ≥30.0 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
62469782|NCT01613040|PLACEBO_COMPARATOR|Treatment C|
62469783|NCT01613040|PLACEBO_COMPARATOR|Treatment D|
62669501|NCT04391907|NO_INTERVENTION|Non-IPL group|Subject who do not have intense pulsed light (IPL) laser before cataract surgery
62669502|NCT04935515|EXPERIMENTAL|Mild|Patients with mild symptoms and normal CRP.
62669503|NCT04935515|EXPERIMENTAL|Moderate|Patients with mild symptoms and less than 10 fold increase in CRP.
62669504|NCT04935515|EXPERIMENTAL|Severe|Patients with high grade fever persisting even on the third or fourth day after onset of symptoms or 10 fold or more increase in CRP.
62669505|NCT05815927|ACTIVE_COMPARATOR|Arm 1 : Standard of Care|Pembrolizumab at a dose of 400mg every 6-weeks (Q6W) for a duration of 2 years (i.e 17 cycles) as per Standard of Care treatment of oligometastatic HNSCC disease. Palliative radiotherapy to oligometastatic disease is allowed if necessary as per standard of care to relieve symptomatic disease and prevent complications. Recommended dose regimens are 1x 8 Gy, 5x 4 Gy and 10x 3 Gy. Planning technique and target volume definition should be according to institutional standards.No ablative-stereotactic dose and no boost techniques are allowed with the exception of CNS-metastases treatment.
62669506|NCT05815927|EXPERIMENTAL|Arm 2 : Standard of Care + stereotattic ablative radiation (SABR)|The Experiemnt Arm consists of pembrolizumab at a dose of 400mg every 6-weeks (Q6W) for a duration of 2 years (i.e 17 cycles) as per Standard of Care treatment of oligometastatic HNSCC disease in combination with SABR. For each oligometastatic lesion treatment, specific SABR fractions and targeted dose(Gy) should be used depending on the location of the lesion. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
62299202|NCT01104220|NO_INTERVENTION|Obese, metabolically abnormal|Subjects with body mass index ≥30.0 kg/m² and impaired fasting or oral glucose tolerance and increased liver fat.
62669507|NCT01598220|EXPERIMENTAL|Computer-assisted cognitive remediation therapy|
62669508|NCT01598220|PLACEBO_COMPARATOR|attentional task|
62669509|NCT05695430|EXPERIMENTAL|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|
62669510|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
62669511|NCT03018938|EXPERIMENTAL|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
62299203|NCT01104220|EXPERIMENTAL|Obese, scheduled for bariatric surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing bariatric surgery
62669512|NCT03018938|EXPERIMENTAL|Basal Insulin Analog|Basal insulin analog given SC.
62299204|NCT01104220|NO_INTERVENTION|Obese, scheduled for gallbladder surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing gallbladder surgery
62299205|NCT01104220|NO_INTERVENTION|Lean, scheduled for inguinal hernia, hysterectomy or myomectomy surgery|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
62299206|NCT02506530|ACTIVE_COMPARATOR|intensive decongestive treatment (IDT)|Patients will receive an intensive decongestive treatment for 5 days
62299207|NCT02506530|EXPERIMENTAL|IDT + Cellu M6|Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days
62299208|NCT02506530|ACTIVE_COMPARATOR|Cellu M6 + bandages|Patients will receive an bandages + Cellu M6 for 5 days
62669513|NCT03434366|EXPERIMENTAL|ketamine and dexmedetomidine group|intranasal ketamine and dexmedetomidine was treated in the children
62669514|NCT03434366|EXPERIMENTAL|ketamine group|intranasal ketamine was treated in the children
62669515|NCT03434366|PLACEBO_COMPARATOR|control group|intranasal insaline was used in the children
62669516|NCT02565472|EXPERIMENTAL|Apple Juice|12 oz apple juice
62669517|NCT02565472|EXPERIMENTAL|Grape Juice|12 oz grape juice
62299209|NCT01322828|ACTIVE_COMPARATOR|Single incision repair of distal bicep tendon rupture|In this treatment arm patients will have a single incision technique used to repair their distal bicep tendon rupture
62299210|NCT01322828|ACTIVE_COMPARATOR|Double incision repair of distal bicep tendon rupture|In this treatment arm, patients will have a double incision technique used to repair their distal bicep tendon rupture.
62669518|NCT02385357|PLACEBO_COMPARATOR|Control|330 ml of commercial protein-enriched drink (2.5 g/100 ml of protein)
62669519|NCT02385357|EXPERIMENTAL|Experimental|330 ml of protein-enriched drink (6 g/100 ml of protein)
62669520|NCT04656080||transplant recipients <1year without AMR|20 recent transplant recipients (\<1 year) without antibody-mediated rejection (AMR);
62669521|NCT04656080||3 months post-heart transplant with AMR|• 7 transplant recipients, at least 3 months post-transplant, with antibody-mediated rejection
62469784|NCT01328093|EXPERIMENTAL|LY2140023|Double Blind Phase: 40 milligrams (mg) administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
62669522|NCT05845190|EXPERIMENTAL|aerobic exercises group (group A )|"20 male patients with diabetes mellites Attended the program of walking on treadmill for 12 weeks according to the following parameters.~Exercise prescription:~Intensity: started by 60-75% of target heart rate according to each patient response.~Duration: Each session consisted of five minutes warming up firstly then 25-30 minutes time of session ended by five minutes cool down exercises Frequency: Three times / week (day after day) for 12 weeks"
62669523|NCT05845190|EXPERIMENTAL|resistance exercises group (group B)|"20 male patients with diabetes mellites will participate in resistance training exercises 30-45 mins. The subject will warm up and cool down for at least five to seven minutes each, (before and after exercise) with initial load of 60% of 1 repetition maximum.~This program consists of 3 sets of 8 to 12 repetitions, then increasing load when subject was able to complete 12 repetitions. A rest period of 1.5 min was established between each set.~Mode: 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 leg exercises (leg press, extension, and flexion), abdominal crunches and back extensions. with the individualized workloads at 60% of 1RM.~Duration: 30 min-45 min (total session). Frequency: Three times / week (day after day). Intensity: increased load was established when subject was able to complete 12 repetitions."
61914169|NCT05704127|EXPERIMENTAL|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
61914170|NCT05704127|EXPERIMENTAL|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
61914171|NCT00789412||Expected ICU|Patients with expected postoperative admission to the ICU. Baseline measurement of SSI. Exploration prior to weaning.
62469785|NCT01328093|ACTIVE_COMPARATOR|Aripiprazole|Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
62469786|NCT05672433|ACTIVE_COMPARATOR|Cafestol|Participants in this arm ingest 6 mg cafestol capsules twice daily with breakfast and dinner.
61914172|NCT00789412||Unexpected ICU|Patients with unexpected stay at the ICU. No baseline measurement of SSI. Exploration in 'steady state' of analgosedation.
62107787|NCT02833155|EXPERIMENTAL|Entinostat and Exemestane|"Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.~Exemestane wil be orally administered once daily for up to six months."
62107788|NCT00667693|ACTIVE_COMPARATOR|Macintosh laryngoscope|Intubation with a Macintosh laryngoscope
62107789|NCT00667693|ACTIVE_COMPARATOR|Pentax AWS|Intubation with a Pentax AWS
62107790|NCT04536077|EXPERIMENTAL|CDX-1140 Monotherapy|Patients randomized to the CDX-1140 monotherapy arm will receive a single IV infusion at a dose of 1.5 mg/kg, with surgery to follow 7-12 days after administration of CDX-1140.
62107791|NCT04536077|EXPERIMENTAL|CDX-1140 + CDX-301|Patients randomized to the CDX-301 + CDX-1140 arm will receive CDX-301 at 75 mcg/kg/day as a subcutaneous injection every day for 5 days (Days 1-5) with CDX-1140 IV at 1.5 mg/kg on Day 8 +/-1 day. Surgery will be 7-12 days after administration of CDX-1140.
62107792|NCT01839877|EXPERIMENTAL|HIA DEBIRI + systemic FOLFOX|Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX
62107793|NCT03096184|EXPERIMENTAL|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
62107794|NCT03821922||pregnancy-induced pregnancy|Those women (subjects) with pregnancy-induced pregnancy.
62107795|NCT03821922||Control|Those healthy pregnant women
62107796|NCT02523872||Acute respiratory failure|Patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration
62107797|NCT05193630|EXPERIMENTAL|Treatment|The subjects in the treatment arm will be given Milnutri Sure TM product with dietary counselling
62107798|NCT05193630|ACTIVE_COMPARATOR|Control|The subjects in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator.
61914173|NCT01932892||Transhumeral prosthesis user|Transhumeral body-powered prosthesis user
62107799|NCT06234865|ACTIVE_COMPARATOR|Control Group|Patients in the control group will receive the routine care of the orthopaedic clinic and education with a brochure about preventing constipation.
62107800|NCT06234865|EXPERIMENTAL|Video Education Group|Patient in the experimental group will receive the routine care of the orthopaedic clinic and a video education about preventing constipation.
62107801|NCT01626274|EXPERIMENTAL|Device: in-ear sensor|Patients who routinely undergo a polysomnography night (1 night) are monitored via in-ear sensor which will be embedded in the auditory canal. During this night vital signs parameters are monitored, processed and subsequently compared to the polysomnography data.
62107802|NCT01565928|EXPERIMENTAL|MDV3100|
62107803|NCT04642261|EXPERIMENTAL|Empagliflozin group|Empagliflozin 10mg daily for 52 weeks
62107804|NCT04642261|PLACEBO_COMPARATOR|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks
61914174|NCT00677053|EXPERIMENTAL|TAK-442 10 mg BID|Added with standard care for recurrent ischemic events.
61914175|NCT00677053|EXPERIMENTAL|TAK-442 20 mg BID|Added with standard care for recurrent ischemic events
62107805|NCT00988286|EXPERIMENTAL|CEP|
62107806|NCT06492889|EXPERIMENTAL|Levonorgestrel plus mifepristone|Women randomized to take one pill containing 1.5 mg levonorgestrel followed one to two days later by 200 mg mifepristone.
62107807|NCT06492889|EXPERIMENTAL|Placebo plus mifepristone|Women randomized to take one placebo pill followed one to two days later by 200 mg mifepristone.
62299211|NCT04341571|EXPERIMENTAL|Probiotics|15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.
62299212|NCT04341571|EXPERIMENTAL|Metformin|15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.
61914176|NCT00677053|EXPERIMENTAL|TAK-442 40 mg QD|Added with standard care for recurrent ischemic events
61914177|NCT00677053|EXPERIMENTAL|TAK-442 40 mg BID|Added with standard care for recurrent ischemic events
61914178|NCT00677053|EXPERIMENTAL|TAK-442 80 mg QD|Added with standard care for recurrent ischemic events
62469787|NCT05672433|PLACEBO_COMPARATOR|Placebo|Participants in this arm ingest placebo capsules twice daily with breakfast and dinner.
62669524|NCT06455254|EXPERIMENTAL|Treatment arm|Candonilimab (AK104) + Regorafenib
62299213|NCT01561287|EXPERIMENTAL|Dermal Autograft|
62299214|NCT01561287|EXPERIMENTAL|AlloDerm|
62669525|NCT00517062|ACTIVE_COMPARATOR|A|Growth hormone
62669526|NCT00517062|PLACEBO_COMPARATOR|B|Placebo
62669527|NCT00129896|EXPERIMENTAL|Myocet+Taxotere+Herceptin|Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg
62469788|NCT06334445||Control group|Wearables/sensors and ePsycHeart App
62469789|NCT06334445||Intervention group|Wearables/sensors and ePsycHeart App and eHealtHeart
62469790|NCT02388191|EXPERIMENTAL|Naproxen sodium|550 mg naproxen sodium
61914179|NCT00677053|EXPERIMENTAL|TAK-442 80 mg BID|Added with standard care for recurrent ischemic events
62669528|NCT03637829|PLACEBO_COMPARATOR|Control|250 mL of water
62669529|NCT03637829|ACTIVE_COMPARATOR|White Chocolate|White chocolate (40 g)
61914180|NCT00677053|EXPERIMENTAL|TAK-442 160 mg QD|Added with standard care for recurrent ischemic events
61914181|NCT00677053|EXPERIMENTAL|TAK-442 120 mg BID|Added with standard care for recurrent ischemic events
61914182|NCT00677053|PLACEBO_COMPARATOR|Placebo|Added with standard care for recurrent ischemic events
61914183|NCT04785690|EXPERIMENTAL|CureSight|eye-tracking-based
61914184|NCT04785690|ACTIVE_COMPARATOR|Patching|occlusive deprivation
62299215|NCT00779168|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive white button mushroom extract PO twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
62299216|NCT01771783|EXPERIMENTAL|ACEI-ARB-RI|angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
62299217|NCT01771783|EXPERIMENTAL|ARB-RI-ACEI|ARB-RI-ACEI
62299218|NCT01771783|EXPERIMENTAL|RI-ACEI-ARB|RI-ACEI-ARB
61914185|NCT00499057|OTHER|single arm study|single arm study
61914186|NCT03787979|EXPERIMENTAL|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
61914187|NCT03787979|ACTIVE_COMPARATOR|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
61914188|NCT05997394|EXPERIMENTAL|Experimental Group|Participants in this group will be given a prayer concert for a month. At the end of one month, the severity of dyspnea, anxiety and spiritual well-being levels experienced by the participants will be re-checked.
61914189|NCT05997394|NO_INTERVENTION|Control Group|There will be no prayer audience for participants in this group.
61914190|NCT01528540|PLACEBO_COMPARATOR|Placebo|This group will contain a placebo for antioxidant cocktail and pregabalin
61914191|NCT01528540|EXPERIMENTAL|Antioxidant plus pregabalin|This group will contain antioxidant cocktail and pregabalin
61914192|NCT00235170|EXPERIMENTAL|1|Cypher Sirolimus-eluting Coronary stent
62299219|NCT01374698|ACTIVE_COMPARATOR|Aspirin|All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
62299220|NCT01374698|NO_INTERVENTION|No intervention|No intervention
62299221|NCT04619407||teacher|"* Employed in a school in Mecklenburg-Vorpommern~* Age between 18 to 67 years~* Willing and able to provide informed consent~* Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
62299222|NCT04619407||pupils|"* Attending school in Mecklenburg-Vorpommern~* Age between 6 to 17 years~* Agreement to participate~* Legal representative willing and able to provide informed consent~* Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
62299223|NCT04619407||childcare educators|"* Employed in a kindergarten in Mecklenburg-Vorpommern~* Age between 18 to 67 years~* Willing and able to provide informed consent~* Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
62469791|NCT02388191|PLACEBO_COMPARATOR|Placebo|Placebo
62469792|NCT05294471||Healthy participants|70 healthy participants will be recruited, across substudies 1, 2, 4, and 5
62469793|NCT05294471||Participants with known or suspected iron overload|30 Participants with known or suspected iron overload will be recruited, to substudy 3
62469794|NCT05294471||Participants with elevated levels of liver fat|30 participants with elevated levels of liver fat will be recruited, to substudy 3
62469795|NCT05294471||Participants referred for clinical abdominal MRI|60 participants referred for clinical abdominal MRI will be recruited, to substudy 6
62469796|NCT06012097|ACTIVE_COMPARATOR|active comparator|Diclofenac gel Splint of the thumb and wrist
62469797|NCT06012097|EXPERIMENTAL|Experimental Group|Aromatherapy Gel Splint of the thumb and wrist
62469798|NCT04927208|EXPERIMENTAL|Improved skeletal muscle function due to protein supplementation|Experimental: Intervention group Improved skeletal muscle function due to protein supplementation
62669530|NCT03637829|EXPERIMENTAL|Dark chocolate 1|Dark chocolate (40 g)
62669531|NCT03637829|EXPERIMENTAL|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
62669532|NCT05560906||Control group|Healthy patients under 18 years of age.
62669533|NCT05560906||MIS-C group|Patients with MIS-C diagnosed, based on WHO diagnostic criteria.
62669534|NCT02782468|EXPERIMENTAL|Arm 1, Cohort 1: Pevonedistat 25 mg/m^2|Pevonedistat, 25 milligram per square meter (mg/m\^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
62669535|NCT02782468|EXPERIMENTAL|Arm 1, Cohort 2: Pevonedistat 44 mg/m^2|Pevonedistat, 44 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
62669536|NCT02782468|EXPERIMENTAL|Arm 2, Cohort 1: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 10 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m\^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
62669537|NCT02782468|EXPERIMENTAL|Arm 2, Cohort 2: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m\^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
62299224|NCT04619407||preschoolers|"* Attending kindergarten in Mecklenburg-Vorpommern~* Age between 3 to 6 years~* Agreement to participate~* Legal representative willing and able to provide informed consent~* Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
62469799|NCT01633047|EXPERIMENTAL|Electrical stimulation|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training) associated with electrostimulation.
62469800|NCT01633047|ACTIVE_COMPARATOR|Physical therapy exercises|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training).
62669538|NCT02845427|ACTIVE_COMPARATOR|A(drain group)|patients of primary THA will have closed suction drain introduced intraoperative at surgical site
62669539|NCT02845427|PLACEBO_COMPARATOR|B(No drain group)|patients of primary THA will have the surgical wound be closed with no suction drain
62669540|NCT03368430|EXPERIMENTAL|Melatonin|10 mg melatonin capsule was given to participants in the test group once per day for only 2 months after performing scaling and root planing (SRP) during the whole 6- month period of the study.
62669541|NCT03368430|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule was given to the control group once daily for 2 months after receiving scaling and root planing (SRP) during the whole 6- month period of the study.
62469801|NCT03978923||the drill-inserted implants (G1)|
62469802|NCT03978923||the ultrasonic device- inserted implants (G2)|
62469803|NCT01376167|EXPERIMENTAL|Tafenoquine 50mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 50mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
62469804|NCT01376167|EXPERIMENTAL|Tafenoquine 100mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 100mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
62669542|NCT04941911|ACTIVE_COMPARATOR|Intervention group|Octreotide intravenous infusion, 100mcg bolus with a subsequent infusion of 100mcg per hour during surgery.
62669543|NCT04941911|PLACEBO_COMPARATOR|Placebo group|Sodium chloride 0.9% w/v
62669544|NCT01475500||Screening|These high-risk subjects will undergo screening for lung cancer. All subjects will undergo all listed interventions
62669545|NCT01210443|EXPERIMENTAL|Sitaxentan treatment|
62669546|NCT00532857|EXPERIMENTAL|Paclitaxel/Gemcitabine/Trastuzumab|
62299225|NCT02120417|EXPERIMENTAL|Treatment A - Capecitabine and ruxolitinib|
62299226|NCT02120417|ACTIVE_COMPARATOR|Treatment B - Capecitabine and placebo|
62299227|NCT02532231|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle.
62469805|NCT01376167|EXPERIMENTAL|Tafenoquine 300mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
62469806|NCT01376167|EXPERIMENTAL|Tafenoquine 600mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 600mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
62669547|NCT03464981||Advanced HF patients scheduled to undergo LVAD implantation|
62669548|NCT02002208|EXPERIMENTAL|OC000459 Tablets|50 mg orally once a day
62669549|NCT02002208|PLACEBO_COMPARATOR|Placebo Tablets|Orally once a day
62669550|NCT06319443|EXPERIMENTAL|Liquid vinegar|Liquid vinegar (6% acidity) consumed at a dosage of 2 tablespoons (diluted in water and consumed at mealtime) twice daily (4 tablespoons total per day).
62669551|NCT06319443|PLACEBO_COMPARATOR|Vinegar pill|One pill consumed daily in the morning.
62669552|NCT03338686|ACTIVE_COMPARATOR|Free Gingival Graft|Free Gingival Graft (FGG)
62669553|NCT03338686|EXPERIMENTAL|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft (CTG) followed by Laser Gingivoplasty
62669554|NCT05911386||MYOCARDITIS|No intervention Study of available clinical, biological, and echocardiographic data
62669555|NCT05911386||KAWASAKI|No intervention Study of available clinical, biological, and echocardiographic data
62669556|NCT05911386||PIMS|No intervention Study of available clinical, biological, and echocardiographic data
61914193|NCT04816409|EXPERIMENTAL|(Neurodevelopmental therapy)|"Starting Posture Start and evaluate the supreme effective posture to move from(usually straight) Reassemble to mid plane (head/trunk)~•Neutral position of body Identify the Missing Components Detect starting posture and compare to normal.~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.~Developmental movement patterns training:~Obstacle crawl, hold swing's ropes in kneeling anhalf kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of sustaining exercise positions in children.4. Ambulation training, suitable to the motor"
62669557|NCT02025036|EXPERIMENTAL|Capecitabine-oxaliplatin-radiotherapy|"oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
62669558|NCT02025036|ACTIVE_COMPARATOR|cisplatin with 5-FU and radiotherapy|"cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
62669559|NCT02025036|EXPERIMENTAL|Capecitabine and radiotherapy|capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
62669560|NCT02353663||All study participants|Schoolgoing children 5 to 16 years of age
62669561|NCT00430859|EXPERIMENTAL|1|BIAP
61914194|NCT04816409|ACTIVE_COMPARATOR|Conventional treatment|Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,
61914195|NCT01701752|ACTIVE_COMPARATOR|Group 1|Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
61914196|NCT01701752|ACTIVE_COMPARATOR|Group 2|Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
62469807|NCT01376167|ACTIVE_COMPARATOR|Primaquine 15mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15.
62469808|NCT01376167|PLACEBO_COMPARATOR|Chloroquine only|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered.
61914197|NCT01701752|ACTIVE_COMPARATOR|Group 3|Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
61914198|NCT01701752|ACTIVE_COMPARATOR|Group 4|Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
62469809|NCT01376167|EXPERIMENTAL|Tafenoquine 300mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
62669562|NCT00430859|PLACEBO_COMPARATOR|Placebo|Placebo, saline
61914199|NCT01701752|ACTIVE_COMPARATOR|Group 5|Day 1: Adjuvant + TIV ; Day 29: Placebo
61914200|NCT01701752|ACTIVE_COMPARATOR|Group 6|Day 1: Placebo + TIV ; Day 29: Placebo
61914201|NCT00796887|EXPERIMENTAL|Niaspan® 500mg|
61914202|NCT00796887|EXPERIMENTAL|Niaspan® 1000mg|
62669563|NCT03512886|ACTIVE_COMPARATOR|Single task training|The exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
61914203|NCT00796887|PLACEBO_COMPARATOR|Placebo|
61914204|NCT03700541|ACTIVE_COMPARATOR|Morphine|Morphine-based perioperative analgesia
61914205|NCT03700541|ACTIVE_COMPARATOR|Piritramid|Piritramid-based perioperative analgesia
61914206|NCT04434170||Heart failure|outpatients with heart failure with reduced ejection fraction in treatment with sacubitril/valsartan according to guidelines
62299228|NCT01492010|EXPERIMENTAL|25 g protein|25 g whey protein
62299229|NCT01492010|EXPERIMENTAL|6.25 g protein supplemented with leucine|6.25 g protein supplemented with leucine
62669564|NCT03512886|EXPERIMENTAL|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
62669565|NCT03512886|NO_INTERVENTION|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
62669566|NCT00669331|EXPERIMENTAL|Mannitol|Inhaled mannitol 400mg
62669567|NCT00669331|PLACEBO_COMPARATOR|Control|Matched control - inhaled mannitol 50mg
62299230|NCT01492010|EXPERIMENTAL|6.25 g whey protein with EAA|6.25 g protein supplemented with a mixture of essential amino acids devoid of leucine
62669568|NCT02506036|ACTIVE_COMPARATOR|Control then Social Cognitive Training|Patients assigned to this arm will first receive a control therapy on a laptop followed by the Brain HQ social-cognitive training.
62669569|NCT02506036|EXPERIMENTAL|Social Cognitive Training then Control|Patients assigned to this arm will first receive the Brain HQ social-cognitive training and then undergo a control therapy.
62669570|NCT02727959||Patients newly diagnosed with IBD|
62469810|NCT01376167|ACTIVE_COMPARATOR|Primaquine 15mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15
62469811|NCT01376167|PLACEBO_COMPARATOR|Chloroquine only (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered
62469812|NCT05206344|OTHER|Without Clowns - Clowns (WC-C)|Firstly a painful act without the presence of the clown duo, then in a second time the same painful act in the presence of the clown duo
62469813|NCT05206344|OTHER|Clowns- Without clowns (C-WC)|Firstly a painful act with the presence of the clown duo, then in a seconde time, the same painful act without the presence of the clown duo
62669571|NCT02727959||Symptomatic non IBD-controls|Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.
62469814|NCT00437658|EXPERIMENTAL|Elagolix 75 mg BID|Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
62669572|NCT05189197|EXPERIMENTAL|Experimental: Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg bis in die（BID） administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved complete response （CR）will continue to receive zanubrutinib 160mg BID for 1 year."
62469815|NCT00437658|EXPERIMENTAL|Elagolix 150 mg QD|Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
62669573|NCT01260753|EXPERIMENTAL|UR-63325|
62469816|NCT00437658|ACTIVE_COMPARATOR|DMPA-SC|Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.
62469817|NCT02406898|EXPERIMENTAL|hysteroscopic surgery with morcellation technic|"The hysteroscope with the MH system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter ."
62469818|NCT02406898|ACTIVE_COMPARATOR|conventional hysteroscopy technic with resection.|"The hysteroscope with conventional resection system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter (4 )."
62469819|NCT06036498||Preoperative Assessment of Trail Group|
62669574|NCT01260753|ACTIVE_COMPARATOR|Fluticasone propionate nasal spray|
62669575|NCT01260753|PLACEBO_COMPARATOR|Placebo|
62669576|NCT00115531|EXPERIMENTAL|Arm 1|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
62669577|NCT00115531|EXPERIMENTAL|Arm 2|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
62669578|NCT00973973|EXPERIMENTAL|Elagolix 150 mg|Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.
62669579|NCT00973973|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.
62669580|NCT05924230|ACTIVE_COMPARATOR|RL 10|Patients of this group will receive Ringer's lactate (RL) 10ml/kg
62669581|NCT05924230|ACTIVE_COMPARATOR|RL 15|Patients of this group will receive 15ml/kg of Ringer's lactate solution
62669582|NCT05130983|EXPERIMENTAL|15ml at Day 0, 2, 4, 30 ml at Week 2, Week 6, and every 4 weeks after to week 46|IV administration of 15 mL study agent at Day 0, Day 2, Day 4 and 30 mL at Week 2, Week 6 and every 4 weeks thereafter to week 46 (total # doses = 15).
62107808|NCT03603418|EXPERIMENTAL|Group D (Study group-Dexamethasone group)|Forty patients undergoing induction of labor will receive 8 mg (2ml) of the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product from Epico-Egypt, and labor induction will be performed according to the American College of Obstetricians and Gynecologists protocol, i.e, starting by 25 mcg of PGE1 vaginally, in the form of Vagiprost, every 3-6 hours according to patient response, Dexamethasone will be given one hour before the first dose of Vagiprost, when bishop score reaches 6 to 8, oxytocin will be added by 5 drops/minute of 500 cc saline + 5 units of oxytocin with the dose increasing by 5-10 drops / minute every 30 minute till optimal contractions are reached which are three uterine contractions in 10 minutes and each lasting for 40-50 seconds
62299231|NCT05149196|EXPERIMENTAL|Targeted blood pressure management|"During anesthesia, hemodynamic managements include active hydration (\>10 ml/kg/h), use of inotropes (dobutamine), and forced diuresis; the targets are to maintain pulse pressure variation \<9%, mean arterial pressure ≥85 mmHg, and urine output \>200 ml/h (3ml/kg/h).~During the first 48 hours after surgery, systolic blood pressure is maintained ≥110 mmHg or within 20% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or vasoactive infusion."
62299232|NCT05149196|ACTIVE_COMPARATOR|Routine care|"During anesthesia, hemodynamic managements are conducted according to routine practice and usually include fluids infusion at a rate of 6-8 ml/kg/h without inotropics; the targets are to maintain mean arterial pressure ≥60 mmHg and urine output \>0.5 ml/kg/h.~During the first 48 hours after surgery, hemodynamic management is performed according to routine practice."
62469820|NCT06036498||Post-Anaesthetic Induction Assessment of Trial Groups|
62469821|NCT06036498||After Pneumoperitoneum Assessment of Trial Groups|
61914207|NCT02473692||Online MigraineTreatment Optimization|After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
61914208|NCT01335022|EXPERIMENTAL|Cardiovascular Disease Education|6 lectures on cardiovascular disease were given over a 2 month time period
61914209|NCT00641316|EXPERIMENTAL|1|Teeth extraction followed by natural healing
62107809|NCT03603418|PLACEBO_COMPARATOR|Group C (Control group)|Forty patients undergoing induction of labor will receive 2ml of distilled water intramuscular one hour before the initiation of labor induction, and labor induction will be performed by the same protocol as above.
62299233|NCT05587881||donor with vaccine, patient without vaccine|Patients don' t receive COVID-19 vaccine before allo-HSCT but whose donors receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.
62299234|NCT05587881||donor without vaccine, patient with vaccine|Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT but whose donors don't receive COVID-19 vaccine before stem cell collection.
62299235|NCT05587881||donor with vaccine, patient with vaccine|Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT and whose donors also receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.
62469822|NCT06036498||Within Head-up Tilt Position Assessment of Trial Groups|
62469823|NCT06036498||Neuralized Position Assessment of Trial Groups|
62469824|NCT06036498||Within Deflation of Abdomen Assessment of Trial Groups|
62469825|NCT06036498||Awaking Period from Anaesthesia Assessment of Trial Groups|
62469826|NCT00451412|EXPERIMENTAL|Certoparin|
62469827|NCT00451412|ACTIVE_COMPARATOR|Unfractionated Heparin|
62469828|NCT06558877|EXPERIMENTAL|intervention group|
62469829|NCT06558877|OTHER|control group|
62669583|NCT05372939|ACTIVE_COMPARATOR|AMT-101 and Humira (adalimumab)|AMT-101 Tablet
62669584|NCT05372939|PLACEBO_COMPARATOR|Placebo and Humira (adalimumab)|Placebo Tablet
62737253|NCT05829005|SHAM_COMPARATOR|Inactive/control arm|The location and number of pulses have been set at the same as the active treatment. The intensity of stimulation will necessarily be less but will still result in a stimulus that is felt by the subject to maximise chances of successful blinding. 120 stimuli - no stimuli of sufficient intensity to produce movement.
62469830|NCT04459585|EXPERIMENTAL|Dabigatran + Quizartinib|Participants who will receive a single oral dose of 150mg dabigatran etexilate on Day 1 of Period 1 and then will receive a single oral dose of 60mg quizartinib 2 hours prior to the administration of a single oral dose of 150mg dabigatran etexilate on the morning of Day 5 of Period 2.
62669585|NCT02606539|ACTIVE_COMPARATOR|surgery and methotrxate|The patient will be treated by total abdominal hystrectomy(after written consent laparatomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg alternating with calcium folinate 0.1 mg/kg until normalization of B-HCG
62107810|NCT03973424|EXPERIMENTAL|Simple|This arm uses a simplified form of dietary tracking that involves tracking only high-calorie, high-fat foods, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
62107811|NCT03973424|EXPERIMENTAL|Standard|This arm uses standard calorie tracking, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
62107812|NCT03706963|EXPERIMENTAL|Phone Call|"* Patients will be provided with a Fitbit wristband \& assistance to set up on smart phone~* Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery~* The group will receive a phone call 7 days into their preoperative period to identify barriers, provide available resources, \& encourage continuation of prehabilitation activities~* The physician extender will talk with the patient to identify barriers to prehabilitation activities that the patient may have experienced during the first 7 days of activity tracking \& provide recommendations \& resources to overcome those barriers when possible. The physician extender will encourage the patient to continue prehabilitation activities until the day of operation to meet goals. Following surgery, we will analyze Fitbit data to determine if the intervention had an impact on the patient's prehabilitation activity with the non-intervened patient group used as a control"
62107813|NCT03706963|NO_INTERVENTION|No Phone Call|"* Eligible patients will be provided with a Fitbit wristband \& assistance to set up on smart phone~* Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery"
62107814|NCT03172208|EXPERIMENTAL|Group 1: Japanese - Caplacizumab Dose 1 iv (SD)|Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants
62107815|NCT03172208|PLACEBO_COMPARATOR|Group 1: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
62107816|NCT03172208|EXPERIMENTAL|Group 2: Japanese - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants
62107817|NCT03172208|EXPERIMENTAL|Group 2: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
62107818|NCT03172208|EXPERIMENTAL|Group 2: White - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants
62107819|NCT03172208|PLACEBO_COMPARATOR|Group 2: White - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to White participants
62107820|NCT03172208|EXPERIMENTAL|Group 3: Japanese - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
62107821|NCT03172208|PLACEBO_COMPARATOR|Group 3: Japanese - Placebo sc (SD)|Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants
62107822|NCT03172208|EXPERIMENTAL|Group 3: White - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants
62107823|NCT03172208|PLACEBO_COMPARATOR|Group 3: White - Placebo sc (SD)|Single dose (SD) Placebo administered subcutaneously (sc) to White participants
62469831|NCT01757886||ST-elevation acute coronary syndrome|ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty
62107824|NCT03172208|EXPERIMENTAL|Group 4: Japanese - Caplacizumab Dose 2 sc (MD)|Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
62299236|NCT05587881||donor without vaccine, patient without vaccine|Patients don' t receive COVID-19 vaccine before allo-HSCT and whose donors also don't receive COVID-19 vaccine before stem cell collection.
62669586|NCT02606539|ACTIVE_COMPARATOR|methotrxate|The patient will be treated by multiple courses of methotrexate( antifolate) 1mg/kg every 14 days each one alternating in every otherday with calcium folinate 0.1 mg/kg till normalization of B-HCG
62737254|NCT00692744||Randomized microsurgical|After randomization, this group was constituted of patients treated by microsurgical clipping.
62299237|NCT05990803|EXPERIMENTAL|Study treatment|Participants received BL-B01D1, SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62469832|NCT01414972|ACTIVE_COMPARATOR|patients with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
62469833|NCT01414972|PLACEBO_COMPARATOR|patients with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
62469834|NCT01414972|ACTIVE_COMPARATOR|people without athrosclerosis/ vitamin a|people in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
62737255|NCT00692744||Randomized endovascular|After randomization, this group was constituted of patients treated by endovascular coiling.
62469835|NCT01292590|EXPERIMENTAL|High fat meal|
62469836|NCT04920929|ACTIVE_COMPARATOR|Hydrophilic BioMaterial|Hydrophilic BioMaterial- HydroPICC
62469837|NCT04920929|ACTIVE_COMPARATOR|Thermoplastic Polyurethane|TPU- 4 French Single Lumen PowerPICC
62299238|NCT04919629|EXPERIMENTAL|Cohort 2A-1 (pegcetacoplan, pembrolizumab)|Patients receive pegcetacoplan IV over 20-40 minutes on day 1 of cycle 1 and then SC BIW of each cycle. Patients also receive pembrolizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive pembrolizumab for up to 35 21-day cycles in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy and blood sample collection throughout the study.
62669587|NCT04849052|EXPERIMENTAL|MASTERY Intervention|Participants will complete a positive psychology activity, work towards a physical activity goal, and use a stress reduction technique, then will complete weekly text message sessions. In the first six weeks, participants will review the activities they performed the prior week, be introduced to new material, choose activities to perform that week, and set a new physical activity goal during the text message sessions. In the final 6 weeks, participants will review progress towards prior goals, set new physical activity goals, and choose positive psychology and stress reduction skills to use that week. Finally, over the course of the program participants will complete three brief calls with a study trainer to discuss progress.
62669588|NCT04849052|ACTIVE_COMPARATOR|Attentional control|Participants will receive the same physical activity component noted in MASTERY along with added messages providing education and guidance about physical activity, from our past work. Control participants will not receive PP or midlife-related content.
62669589|NCT02368236|OTHER|Intervention Group|Patients randomized to the intervention group will use CRIS. Then intervention group patients and their physicians will receive a tailored printout generated by the CRIS recommending risk-appropriate colorectal testing and ways to overcome perceived barriers to testing. A member of the research team will hand the patient a printout and will deliver the other printout to the physician.
62107825|NCT03172208|PLACEBO_COMPARATOR|Group 4: Japanese - Placebo sc (MD)|Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants
62107826|NCT00603538|EXPERIMENTAL|CP-751,871|
62107827|NCT02410291|EXPERIMENTAL|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
62107828|NCT02410291|NO_INTERVENTION|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
62107829|NCT02186405|EXPERIMENTAL|LEVOTHYROXINE|administration of levothyroxine
62107830|NCT05483374||epithelial tumours of nasal cavity and paranasal sinus|adult patients diagnosed with nasal cavity and paranasal sinus cancers (any stage of disease)
62107831|NCT05483374||epithelial tumours of nasopharynx|adult patients diagnosed with nasopharyngeal cancers (any stage of disease)
62107832|NCT05483374||minor and major salivary gland tumours|adult patients diagnosed with minor or major salivary gland cancers (any stage of disease)
62669590|NCT02368236|NO_INTERVENTION|Comparison Group|Patients randomized to the comparison group will use CRIS, but receive a non-tailored standard information about multiple types of cancer screening (e.g., content from an American Cancer Society cancer screening brochure) while physicians receive standard electronic chart prompts indicating the patients were age-eligible but not currently adherent for colorectal cancer screening.
62669591|NCT02368236|NO_INTERVENTION|True No-contact Control Group|A screening baseline for the true no-contact group will be established by conducting a retrospective chart review for patients who did not receive an invitation to participate in this study. The same randomization procedure will be used as the comparison and intervention groups. The purpose is to conduct analysis with the comparison and intervention group to see if individuals who participate in CRIS have a higher screening rate for colorectal cancer compared to the non-contact group.
62107833|NCT05483374||middel ear tumours|adult patients diagnosed with cancers of the middle ear (any stage of disease)
62107834|NCT03679962|EXPERIMENTAL|Triple Chronotherapy|Four-day intervention, with 24-hour total sleep deprivation, 3-days of sleep phase advancement and daily bright light therapy.
62107835|NCT03679962|ACTIVE_COMPARATOR|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
62107836|NCT06630728|EXPERIMENTAL|Smoking session|All participants will undergo three smoking sessions: one using their own usual brand cigar, one with a normal nicotine study cigar, and one with a reduced nicotine study cigar
62107837|NCT00281918|EXPERIMENTAL|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
62107838|NCT00281918|ACTIVE_COMPARATOR|Fludarabine+Cyclophosphamide (FC)|
62299239|NCT04919629|EXPERIMENTAL|Cohort 2A-2 (pegcetacoplan, pembrolizumab, bevacizumab)|Patients receive pegcetacoplan IV over 20-40 minutes on day 1 of cycle 1 and then SC BIW of each cycle. Patients also receive pembrolizumab IV and bevacizumab IV on day 1of each cycle. Treatment repeats every 3 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive pembrolizumab for up to 35 21-day cycles in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy and blood sample collection throughout the study.
61914210|NCT00641316|EXPERIMENTAL|2- FDBA/TCP|
62107839|NCT04527614|OTHER|COVID+|Participants with a previous SARS-CoV-2 infection
62107840|NCT04527614|OTHER|COVID-|Participants without a previous SARS-CoV-2 infection
62299240|NCT04919629|EXPERIMENTAL|Cohort 2B-1 (pegcetacoplan, pembrolizumab)|(Expansion) Patients receive pegcetacoplan IV over 20-40 minutes on day 1 of cycle 1 and then SC BIW of each cycle. Treatment repeats every 3 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles, followed by every 42 days for up to 35 total cycles in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy and blood sample collection throughout the study.
62299241|NCT04919629|EXPERIMENTAL|Cohort 2B-2 (pegcetacoplan, pembrolizumab, bevacizumab)|Patients receive pegcetacoplan IV over 20-40 minutes on day 1 of cycle 1 and then SC BIW of each cycle. Patients also receive pembrolizumab IV and bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive pembrolizumab for up to 35 21-day cycles in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy and blood sample collection throughout the study.
62107841|NCT05349097|EXPERIMENTAL|SAD cohort 1 active treatment|30mg
62107842|NCT05349097|EXPERIMENTAL|SAD cohort 2 active treatment|100mg.
62107843|NCT05349097|EXPERIMENTAL|SAD cohort 3 active treatment|200mg
62107844|NCT05349097|EXPERIMENTAL|SAD cohort 4 active treatment|400mg.
62299242|NCT04919629|EXPERIMENTAL|Cohort 2B-3 (bevacizumab)|Patients receive bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy and blood sample collection throughout the study.
61914211|NCT00641316|EXPERIMENTAL|3 FDBA/TCP+PRP|
61914212|NCT00641316|EXPERIMENTAL|4 FDBA/TCP + PDGF|
62107845|NCT05349097|EXPERIMENTAL|SAD cohort 5 active treatment|600mg.
62107846|NCT05349097|PLACEBO_COMPARATOR|SAD cohort 1 placebo|30mg
62107847|NCT05349097|PLACEBO_COMPARATOR|SAD cohort 2 placebo|100mg.
62107848|NCT05349097|PLACEBO_COMPARATOR|SAD cohort 3 placebo|200mg.
62107849|NCT05349097|PLACEBO_COMPARATOR|SAD cohort 4 placebo|400mg.
62107850|NCT05349097|PLACEBO_COMPARATOR|SAD cohort 5 placebo|600mg.
62107851|NCT05349097|EXPERIMENTAL|MAD cohort 1 active treatment|50mg
62107852|NCT05349097|PLACEBO_COMPARATOR|MAD cohort 1 placebo|50mg
62107853|NCT05349097|EXPERIMENTAL|MAD cohort 2 active treatment|150mg
62107854|NCT05349097|PLACEBO_COMPARATOR|MAD cohort 2 placebo|150mg
62107855|NCT05349097|EXPERIMENTAL|MAD cohort 3 active treatment|300mg
62107856|NCT05349097|PLACEBO_COMPARATOR|MAD cohort 3 placebo|300mg
62669592|NCT01982227||patients|Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal
62669593|NCT00584285||Corneal Topographer Fluorescein Patterns|Use corneal topography to evaluate fluorescein pattern of rgp contact lens. Used corneal topography to develop theoretical fluorescein patters on a virtual eye. Theoretical lens developed by the topographer was ordered to compare to the actual fluorescein pattern on the actual eye.
62669594|NCT02456558|EXPERIMENTAL|Intravenous deferiprone, 1.5 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 1.5 g, twice-daily
62669595|NCT02456558|EXPERIMENTAL|Intravenous deferiprone, 2 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 2 g, twice-daily
62669596|NCT02456558|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive an infusion of placebo twice-daily for 10 days, at a volume equivalent to that of the active product in the respective cohort
62669597|NCT05523739|EXPERIMENTAL|Part 1: Cohort 1|Participants will receive a single 300 mg dose of STI-1558 or placebo. Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
62669598|NCT05523739|EXPERIMENTAL|Part 1: Cohort 2|Participants will receive a single 600 mg dose of STI-1558 or placebo. Cohort 2 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
62669599|NCT05523739|EXPERIMENTAL|Part 1: Cohort 3|Participants will receive a single 1200 mg dose of STI-1558 or placebo. Cohort 3 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
62669600|NCT05523739|EXPERIMENTAL|Part 1: Cohort 4|Participants will receive a single 2000 mg dose of STI-1558 or placebo. Cohort 4 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
62669601|NCT05523739|EXPERIMENTAL|Part 2: Cohort 1|"Participants will receive a 300 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo."
62669602|NCT05523739|EXPERIMENTAL|Part 2: Cohort 2|"Participants will receive a 600 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 2 will dose 16 subjects to STI-1558 and 8 subjects to placebo."
62669603|NCT05523739|EXPERIMENTAL|Part 2: Cohort 3|"Participants will receive a 800 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 3 will dose 16 subjects to STI-1558 and 8 subjects to placebo."
62669604|NCT06028737|ACTIVE_COMPARATOR|Perioperative 4+4 FLOT cycles|4 cycles of neoadjuvant FLOT chemotherapy scheme, followed by surgery and 4 cycles of adjuvant FLOT chemotherapy scheme.
62669605|NCT06028737|EXPERIMENTAL|Total Neoadjuvant ChemoTherapy (TNT) 8 FLOT cycles|8 cycles of total neoadjuvant FLOT chemotherapy scheme, followed by surgery.
62669606|NCT05065827||Normal oxygenation|Normal oxygenation based on the BERLIN criteria for ARDS
62669607|NCT05065827||Mild deficit in oxygenation|Mild deficit in oxygenation based on the BERLIN criteria for ARDS
62669608|NCT05065827||Moderate deficit in oxygenation|Moderate deficit in oxygenation based on the BERLIN criteria for ARDS
62669609|NCT05065827||Severe deficit in oxygenation|Severe deficit in oxygenation based on the BERLIN criteria for ARDS
62669610|NCT02278237|EXPERIMENTAL|VME Group|Pre and post VME education group. The Intervention is the use of the virtual education module rather than the interpersonal educational strategy.
62669611|NCT00848315|NO_INTERVENTION|1|Usual Care that the Type 2 Diabetes Patients usually receive at the health centers.
62669612|NCT00848315|EXPERIMENTAL|2|Cognitive Behavioral Intervention
62669613|NCT03033043|EXPERIMENTAL|Experimental: Relay Pro|The Relay Pro arm includes subjects who receive the device. The Relay Pro Stent Graft System is administered to treat complicated Type B aortic dissections.
62299243|NCT04083495|EXPERIMENTAL|ATLCAR.CD30 cells|The cellular product consisting of ATLCAR.CD30 cells will be administered via intravenous injection over 5 - 10 minutes through either a peripheral or a central line. The volume of infusion will depend upon the concentration of the cells when frozen and the size of the subject. Administration to eligible subjects will occur within 2 - 14 days after completing the lymphodepleting chemotherapy regimen
62669614|NCT04517058||epilepsy patients with depression group|the score of HAMD-17\>7
62669615|NCT04517058||epilepsy patients without depression group|the score of HAMD-17≤7
62669616|NCT00888849|EXPERIMENTAL|Stapling|
62669617|NCT00888849|ACTIVE_COMPARATOR|Suturing|4 layered hand-sutured anastomosis
62669618|NCT06134414|EXPERIMENTAL|Arm 1 MY008211A low dose|Participants will receive MY008211A at a dose of 400 mg orally b.i.d
62469838|NCT02433639|EXPERIMENTAL|treatment|single arm study: TH-302 monotherapy is given
62669619|NCT06134414|EXPERIMENTAL|Arm 2 MY008211A high dose|Participants will receive MY008211A at a dose of 600 mg orally b.i.d
62669620|NCT03177850|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
62669621|NCT03177850|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
62669622|NCT01158768||Violence, Comorbidity|
62669623|NCT05486702|EXPERIMENTAL|Early Time Restricted Eating|8-hour eating period from 7 am to 3 pm with exercise
62669624|NCT05486702|EXPERIMENTAL|Late Time Restricted Eating|8-hour eating period from 3 pm to 11 pm with exercise
62669625|NCT04937530|EXPERIMENTAL|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
62669626|NCT04937530|PLACEBO_COMPARATOR|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
62669627|NCT01149785|EXPERIMENTAL|1|There should be at least 14-day washout period between treatment A and B.
62669628|NCT01926392|EXPERIMENTAL|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
62669629|NCT01926392|ACTIVE_COMPARATOR|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
62469839|NCT03313622||OCD group|"Day 1: Questionnaires/Assessments~Day 2: Tasks"
62107857|NCT05349097|EXPERIMENTAL|Food Effect cohort|150mg
62107858|NCT05198089|EXPERIMENTAL|Arm I (MyInspiration)|Patients use MyInspiration for spiritual and/or religious guidance for 30 days.
62107859|NCT02997618|ACTIVE_COMPARATOR|Control|"1. Usual care (control)~Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to:~Smoking Exercise Weight Diet"
62107860|NCT02997618|EXPERIMENTAL|Community Based Exercise Programme|"Community based-exercise (in addition to usual care) with the choice of either:~1. Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment.~2. Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises.~Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks."
62107861|NCT03879642|EXPERIMENTAL|REDCHiP|10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
62299244|NCT01612234|EXPERIMENTAL|High palmitate or high oleate diet.|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
62299245|NCT01612234|EXPERIMENTAL|high palmitate or high oleate diet|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
62299246|NCT04407169||Patients without chronic respiratory disease|All patients hospitalized for severe CoVid-19 without chronic respiratory disease
62299247|NCT04407169||Patients with chronic respiratory diseas|Patients hospitalized for severe CoVid-19 with one chronic respiratory disease
62299248|NCT03525873|EXPERIMENTAL|ARM I (methylphenidate, physical activity)|Patients receive methylphenidate PO BID for up to 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete physical activity consisting of walking and resistance exercise over 25-40 minutes QD 4 days a week. After 2 weeks, patients may continue methylphenidate at the discretion of the treating physician for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
62299249|NCT03525873|PLACEBO_COMPARATOR|ARM II (placebo, physical activity)|Patients receive a matched placebo PO BID and complete physical activity as in Arm I. Treatment continues for up to 2 weeks in the absence of disease progression or unacceptable toxicity.
62299250|NCT01287663|PLACEBO_COMPARATOR|no permethrin|
62669630|NCT03017664||RFG|Retrospective review of enteral feeding in pediatric ICU patients for up to 5 days
62107862|NCT03879642|NO_INTERVENTION|Waitlist|10 week no intervention to provide waitlist control condition
62669631|NCT03017664||PFG|Pediatric ICU population to be fed a peptide-based enteral formula with higher protein and higher calories for up to 5 days
62669632|NCT02352142|NO_INTERVENTION|Standard Care|Mothers are given infant care instruction as part of standard care
62669633|NCT02352142|EXPERIMENTAL|Facilitated infant care|Family Nurture Intervention
62669634|NCT02352142|OTHER|Full Term EEG|Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants
62669635|NCT02919345|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg in addition to Metformin 1500 mg
62669636|NCT02919345|ACTIVE_COMPARATOR|Glibenclamide|Glibenclamide 5mg in addition to Metformin 1500 mg
62669637|NCT01968785|ACTIVE_COMPARATOR|Radiation dose 25 Gy|• 25 Gy: Subjects will be treated with beta radiation dosage of 25 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
62669638|NCT01968785|ACTIVE_COMPARATOR|Radiation dose 50 Gy|• 50 Gy: Subjects will be treated with beta radiation dosage of 50 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
62107863|NCT05542953|EXPERIMENTAL|Alzheimer's Disease|AD subjects will undergo PET imaging using \[18F\]APN-1607.
62107864|NCT05542953|EXPERIMENTAL|Mild Cognitive Impairment Due to Alzheimer's Disease|MCI subjects will undergo PET imaging using \[18F\]APN-1607.
62299251|NCT01287663|EXPERIMENTAL|permethrin|
62299252|NCT05363917|EXPERIMENTAL|Natrunix with MTX placebo (+Folate)|Natrunix 400mg, subcutaneous injection with oral MTX placebo (+Folate). This arm will enroll 100 subjects.
62299253|NCT05363917|ACTIVE_COMPARATOR|Natrunix Placebo with MTX(+Folate)|Natrunix Placebo, subcutaneous injection with oral MTX(+Folate). This arm will enroll 50 subjects.
62299254|NCT02145130|EXPERIMENTAL|denovoDerm|Autologous tissue-engineered dermal substitute
62299255|NCT02145130|EXPERIMENTAL|denovoSkin|Autologous tissue-engineered dermo-epidermal skin substitute
62299256|NCT03006211|ACTIVE_COMPARATOR|corneal endothal|Evaluate the effects of nitrogen protoxide to corneal endothal and compare with oxygen.
62299257|NCT03006211|ACTIVE_COMPARATOR|Cell density|Evaluate the effects of nitrogen protoxide to Cell density and compare with oxygen.
62299258|NCT05886361||ASD|Diagnosed with DSM-5 autism spectrum disorder
62299259|NCT05886361||Clinical|Patients with anxiety, depression, somatic symptoms which are non-psychotic and non-organic
62669639|NCT00005940|EXPERIMENTAL|Treatment (radiolabeled BC8, chemotherapy, PBSCT)|"RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.~CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.~GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
62107865|NCT05542953|EXPERIMENTAL|Healthy Volunteers|Healthy control subjects will undergo PET imaging using \[18F\]APN-1607.
62107866|NCT00580801|EXPERIMENTAL|Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection \[injected under the skin by way of a needle\], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 2 to 50.
62107867|NCT00580801|EXPERIMENTAL|Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
62107868|NCT00580801|ACTIVE_COMPARATOR|Placebo+Pegylated-interferon-alfa-2a+Ribavirin|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa 2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
62299260|NCT05886361||Control|Healthy control without psychiatric disorder or chronic somatic symptoms
62299261|NCT02469246|EXPERIMENTAL|F/TAF (Double-Blind)|"F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
62299262|NCT02469246|ACTIVE_COMPARATOR|ABC/3TC (Double-Blind)|"ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
62299263|NCT02469246|EXPERIMENTAL|Open-Label F/TAF|After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
62299264|NCT06651411|EXPERIMENTAL|Intervention group|The intervention group will get a 10-session chatbot-based stress management intervention.
62469840|NCT05287061|EXPERIMENTAL|Cardiac Rehabilitation (CR) + Multicomponent Psychological Program (MPP):|The patients who are assigned to this treatment arm will have access to a psychological intervention program, which will use techniques from the positive psychology and motivational interviewing to work on several modules: Health pills (phase I), CR in phase II identical to the standar, and MPP interspersed in Phase II of the conventional program. An individualized program will be included in this branch, which will be added to the follow-up carried out in primary care. It will contain a post-traumatic growth module, an emotion management module, and an intention consolidation module.
62107869|NCT03199417|EXPERIMENTAL|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
62107870|NCT03199417|PLACEBO_COMPARATOR|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
62107871|NCT03152149|ACTIVE_COMPARATOR|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
62107872|NCT03152149|ACTIVE_COMPARATOR|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
62299265|NCT06651411|OTHER|Control group|The control group will get basic psychoeducation.
62299266|NCT00885911||Extraglottic device|The laryngeal mask airway (LMA) used during pediatric anesthesia for routine and difficult airway management.
62299267|NCT05014178||Adult CKD stage 1-5 participants|"* Age greater than or equal to 18 years~* Estimated GFR \< 90 mL/min/1.73m²"
62469841|NCT05287061|NO_INTERVENTION|Cardiac Rehabilitation (CR)|The patient will follow the usual process of cardiac rehabilitation.
62469842|NCT05930964||Hemodialysis patients|They will fill 3 questionnaires and will do some functional tests.
62299268|NCT05014178||Adult transplanted participants|• Age greater than or equal to 18 years
62299269|NCT05014178||Adult dialysis participants|"* Age greater than or equal to 18 years~* More than 3 months duration of therapy"
62299270|NCT05014178||Adult ADPKD|• Age greater than or equal to 18 years
62469843|NCT05357417|EXPERIMENTAL|cohort 1|HER2-negative advanced breast cancer with brain metastases who have received at least one prior anthracycline and one prior taxane
62469844|NCT05357417|EXPERIMENTAL|cohort 2|HER2-positive advanced breast cancer with brain metastases who have failed trastuzumab and pyrotinib
62669640|NCT05573360|OTHER|Sequence 1|NGF5-A/NGF4-B/NGF6-B/NGF6-E/Systane, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
62669641|NCT05573360|OTHER|Sequence 2|NGF4-B/NGF6-B/NGF6-E/Systane/NGF5-A, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
62669642|NCT05573360|OTHER|Sequence 3|NGF6-B/NGF6-E/Systane/NGF5-A/NGF4-B, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
62669643|NCT05573360|OTHER|Sequence 4|NGF6-E/Systane/NGF5-A/NGF4-B/NGF6-B, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
62669644|NCT05573360|OTHER|Sequence 5|Systane/NGF5-A/NGF4-B/NGF6-B/NGF6-E, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
62669645|NCT04483947|EXPERIMENTAL|Cohort 1|15 participants will receive AZD2693 dose 1 and 5 participants will receive placebo
62669646|NCT04483947|EXPERIMENTAL|Cohort 2|15 participants will receive AZD2693 dose 2 and 5 participants will receive placebo
62669647|NCT04483947|EXPERIMENTAL|Cohort 3|15 participants will receive AZD2693 dose 1 and 5 participants will receive placebo
62669648|NCT04483947|EXPERIMENTAL|Cohort 4|15 participants will receive AZD2693 dose 3 and 5 participants will receive placebo
62669649|NCT06354088|EXPERIMENTAL|Placebo then alpelisib (Insulin Sensitive group)|On Study Visit 1, participants in the Insulin Sensitive (IS) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of placebo. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of alpelisib 300 mg.
62669650|NCT06354088|EXPERIMENTAL|Alpelisib then placebo (Insulin Sensitive group)|On Study Visit 1, participants in the Insulin Sensitive (IS) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of alpelisib 300 mg. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of placebo.
62669651|NCT06354088|EXPERIMENTAL|Placebo then alpelisib (Insulin Resistant group)|On Study Visit 1, participants in the Insulin Resistant (IR) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of placebo. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of alpelisib 300 mg.
62299271|NCT05014178||Adults treated for nephrolithiasis|• Age greater than or equal to 18 years
62299272|NCT05014178||Adult healthy controls including kidney donors|"* Age greater than or equal to 18 years~* Lack of kidney disease, heart failure, liver cirrhosis and peripheral"
62299273|NCT03315429|OTHER|Stress testing arm|Stress testing of patients with functional mitral regurgitation.
62299274|NCT02490657|EXPERIMENTAL|Iloprost group|
62299275|NCT02490657|PLACEBO_COMPARATOR|normal saline|
62299276|NCT05240261|OTHER|ESRAD on regular haemodialysis|30 ESRD Patients with sleep \< 6 hours on regular haemodialysis . Before and after taking medications for 3 month.
62299277|NCT05240261|OTHER|CKD patients (predialydsis)|30 CKD Patients (predialysis) with sleep \< 6 hours . Before and after taking medications for 3 month.
62469845|NCT03429634|EXPERIMENTAL|Balloon-Stent Kissing technique|randomly, patients with bifurcation lesion treated by Balloon-Stent Kissing intervention technique in this group.For procedure,stent in main vessel and balloon protect of side branch,final kiss-balloon was performed.
62469846|NCT03429634|SHAM_COMPARATOR|Jailed Wire technique|randomly,patients with bifurcation lesion treated by Jailed Wire intervention technique in this group.For procedure,stent in main vessel and only wire protect of side branch.If need,post-stent rewire of branch,and balloon dilation of side branch was performed.
62469847|NCT05075798||group patients|Patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR neuropathy with proven mutation, having benefited from a brain MRI.
62469848|NCT00665145|EXPERIMENTAL|1|Cohort 1
62737256|NCT00692744||Prospective observational microsurgical|The randomization was ethically unsuitable because of the aneurysm predisposed to the microsurgical clipping after discussion into the neurovascular interdisciplinary team.
62107873|NCT03298464|EXPERIMENTAL|NGM313|
62107874|NCT03298464|ACTIVE_COMPARATOR|Pioglitazone|
62469849|NCT00665145|EXPERIMENTAL|2|Cohort 2
62469850|NCT00665145|PLACEBO_COMPARATOR|3|Cohort 3
62469851|NCT00665145|EXPERIMENTAL|4|Cohort 4
62107875|NCT06629116|EXPERIMENTAL|Albumin group|Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).
62107876|NCT06629116|NO_INTERVENTION|Control group|Follow the current guidelines for standard conventional treatment.
62107877|NCT04408287|EXPERIMENTAL|Intervention|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
62107878|NCT03256344|EXPERIMENTAL|Talimogene Laherparepvec with Atezolizumab: Triple Negative Breast Cancer (TNBC)|Participants with TNBC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10\^6 plaque-forming units/milliliter (PFU/mL) on Day 1 of Cycle 1 and 10\^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
62737257|NCT00692744||Prospective observational endovascular|The randomization was ethically unsuitable because of the aneurysm morphology predisposed to the endovascular coiling after discussion into the neurovascular interdisciplinary team.
61914213|NCT00354185|EXPERIMENTAL|Treatment (tanespimycin, belinostat)|"Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, and 11 and PXD101 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 17-AAG and PDX101 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.~Patients undergo blood collection on days 1 and 4 of course 1 for pharmacokinetic studies."
61914214|NCT01303003|EXPERIMENTAL|Treatment Arm 1|Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
61914215|NCT01303003|ACTIVE_COMPARATOR|Treatment Arm 2|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
62107879|NCT03256344|EXPERIMENTAL|Talimogene Laherparepvec with Atezolizumab: Colorectal Cancer (CRC)|Participants with CRC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10\^6 PFU/mL on Day 1 of Cycle 1 and 10\^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
62107880|NCT02485834|ACTIVE_COMPARATOR|Arm A - surgery, chemotherapy and radiation therapy|Patients undergo surgery within 42 days of completion of pre-registration chemotherapy. Beginning within 49 days of surgery, patients receive 5-FU IV continuously and capecitabine PO BID on days 1-7, and undergo 3D-CRT or IMRT QD on days 1-5. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
62107881|NCT02485834|EXPERIMENTAL|Arm B - surgery, chemotherapy and FDG-PET|Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
62107882|NCT00438555|EXPERIMENTAL|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
62107883|NCT00438555|EXPERIMENTAL|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
62107884|NCT00438555|NO_INTERVENTION|Control group|control group, no intervention, medical follow up only
62107885|NCT02165891|OTHER|Urokinase|insertion of a chest drain with urokinase instillation
62107886|NCT02165891|OTHER|VATS|primary video-assisted thorascopic surgery Other interventions except drainage procedure are the same in both arms
62107887|NCT03646669|EXPERIMENTAL|Asthma education and PEF feedback|Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
62469852|NCT00641420|EXPERIMENTAL|Fractional Laser 10mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 10mJ.
62469853|NCT00641420|EXPERIMENTAL|Fractional Laser 40mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 40mJ.
62107888|NCT03646669|PLACEBO_COMPARATOR|Asthma education|No PEF feedback arm
62107889|NCT04066751|ACTIVE_COMPARATOR|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
62107890|NCT04066751|PLACEBO_COMPARATOR|Placebo|Placebo, 150 mg PO every 12 hrs for 84 days
62299278|NCT05363007|EXPERIMENTAL|Upfront SI|Upfront nanoliposomal irinotecan + 5-FU/leucovorin plus SI
62469854|NCT02442063|EXPERIMENTAL|Radium Ra 223 dichloride|Radium Ra 223 dichloride (Xofigo, BAY88-8223)
62469855|NCT04934618|EXPERIMENTAL|Carelizumab Combined With Irinotecan and Apatinib|Second-line treatment of advanced gastric cancer with three-drug regimen（Carelizumab Combined With Irinotecan and Apatinib ）
61914216|NCT01076127|EXPERIMENTAL|Ketllebell group|Basic ketllebell training 3 x 20 min a week for 8 weeks
61914217|NCT01076127|SHAM_COMPARATOR|Control group|Control group. Receives a health examination before and after the intervention period, and are advised to stay active.
61914218|NCT02592642|EXPERIMENTAL|Group 1|Self-management Program, Workbook, Video, Pedometer
61914219|NCT02592642|ACTIVE_COMPARATOR|Group 2|Instructional Workbook, Video, and Pedometer
61914220|NCT02592642|EXPERIMENTAL|Group a|Para-spinal TENS
61914221|NCT02592642|PLACEBO_COMPARATOR|Group b|Para-spinal Placebo TENS
61914222|NCT02592642|EXPERIMENTAL|Group c|Prototype Spinal Stenosis Belt
61914223|NCT02592642|SHAM_COMPARATOR|Group d|Sham spinal stenosis belt
61914224|NCT02616601|EXPERIMENTAL|Generic Fluorouracil Cream|Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
62299279|NCT05363007|EXPERIMENTAL|Add-on SI|Add-on SI following limited progression to nanoliposomal irinotecan + 5-FU/leucovorin
62669652|NCT06354088|EXPERIMENTAL|Alpelisib then placebo (Insulin Resistant group)|On Study Visit 1, participants in the Insulin Resistant (IR) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of alpelisib 300 mg. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of placebo.
62669653|NCT02056132||Cystic Fibrosis patients.|Patients with Cystic Fibrosis. Results of Exhaled Breath Condensate lab.
62299280|NCT04960358||Chronic LBP|Will be applied Surface Electromyography
62299281|NCT00762346|EXPERIMENTAL|1|
62299282|NCT04708587|ACTIVE_COMPARATOR|dual anti-platelet therapy at least 6 months|
62299283|NCT04708587|EXPERIMENTAL|dual anti-platelet therapy 3months or less|
62299284|NCT01209858|EXPERIMENTAL|Experimental 1|
62299285|NCT01209858|EXPERIMENTAL|Experimental 2|
62299286|NCT06498921||metastatic Hormone Sensitive Prostate Cancer (mHSPC)|All adult men with a diagnosis of mHSPC, treated with darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel.
62299287|NCT01365221|EXPERIMENTAL|Patients who have received loading dose of clopidogrel|
62299288|NCT01365221|ACTIVE_COMPARATOR|Patients who have not received loading dose of clopidogrel|
62299289|NCT03818269|OTHER|Septic shock|
62469856|NCT03459807|EXPERIMENTAL|Home systolic blood pressure (SBP) <140 mmHg|"Participants will be asked to take morning and evening blood pressures every two weeks on a non-dialysis day.~Participants will be asked to transmit these measures to the study team at minimum every 2 weeks either via Bluetooth technology, a manual log, telephone call, text message, e-mail, or verbal communication.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
62299290|NCT03818269|OTHER|Control|
62299291|NCT06528431|EXPERIMENTAL|Single arm trial|Single arm trial in patients with established RA who achieved clinical remission with subcutaneous injection of adalimumab in combination with MTX (methotrexate). Patients will undergo a tapering strategy based only on the clinical status (flare /no flare) during 12 months.
62299292|NCT06528431|NO_INTERVENTION|Maintenance arm|Maintenance arm: the same adalimumab regimen
62299293|NCT06528431|EXPERIMENTAL|Optimized tapering adalimumab|An optimized tapering adalimumab strategy based on the disease activity and the adalimumab trough concentration. The tapering strategy will rely on the adalimumab trough concentration. Spacing will be performed only if adalimumab trough concentration is above the pre-specified concentration threshold
61914225|NCT02616601|ACTIVE_COMPARATOR|Carac® (Fluorouracil) Cream|Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
62299294|NCT01012661|EXPERIMENTAL|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).
62299295|NCT01012661|ACTIVE_COMPARATOR|Radiesse® without Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face.
62299296|NCT01744561|EXPERIMENTAL|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
62299297|NCT01744561|NO_INTERVENTION|Control|Keep activity level constant
62669654|NCT02056132||Control Subjects|Individuals without Cystic Fibrosis or signs of current respiratory infection. Results of Exhaled Breath Condensate lab.
62299298|NCT00428168|EXPERIMENTAL|Betahistine 24 mg|
62299299|NCT00428168|PLACEBO_COMPARATOR|Placebo|
62669655|NCT01028053|EXPERIMENTAL|Flutemetamol (18F) Injection|Flutemetamol (18F) Injection
62737258|NCT00692744||Prospective observational conservative|This group was constituted of patients whom no curative treatment of the aneurysm sac could not be proposed.
62737259|NCT03931850|EXPERIMENTAL|Dual guidance (ultrasound and neurostimulation)|This arm : patients will be received pudendal nerve block by dual guidance technique ( ultrasound and neurostimulation)
62737260|NCT03931850|ACTIVE_COMPARATOR|ultrasound-guided only|This arm : patients will be received pudendal nerve block by ultrasound-guided only.
62737261|NCT05584488||Inherited diseases of allergic inflammation or immune dysregulation|Patients and blood relatives with disorders of allergic inflammation and immune dysregulation.
62737262|NCT03333928|ACTIVE_COMPARATOR|HTD1801 500 mg BID|
62737263|NCT03333928|ACTIVE_COMPARATOR|HTD1801 1000 mg BID|
62737264|NCT03333928|PLACEBO_COMPARATOR|Placebo BID|
62669656|NCT02015715|EXPERIMENTAL|RO6864018|Asian participants will receive a single oral dose of RO6864018 capsule on Day 1. The first dose escalation cohort will receive a single 400 mg oral dose. Dose will be escalated in subsequent cohorts (up to Cohort 4) up to a maximum of 1600 mg, based on safety, pharmacokinetic, and pharmacodynamic data available from lower dose cohorts. The Cohort 5 will include Caucasian participants who will receive a single 1200 mg (or the highest dose well-tolerated by Asian participants, if lower than 1200 mg) oral dose of RO6864018 capsules on Day 1.
62669657|NCT02015715|PLACEBO_COMPARATOR|Placebo|Participants will receive a single oral dose of placebo matching to RO6864018.
62669658|NCT03298100||Postmenopausal women|
62107891|NCT02710968|EXPERIMENTAL|11540KE and Balt Goldbal 2 balloon|"Patients meeting inclusion criteria will receive fetoscopic tracheal occlusion using the fetoscopy sheath 11540 KE and the Balt Goldbal2 detachable balloon.~Participants with an O/E LHR \<25% (severe group) will have FETO completed at 27 weeks + 0 days to 29 weeks + 6 days gestation. Balloon removal is 4-5 weeks after that.~Participants with an O/E LHR 25 to \<30% (less severe group) will have FETO completed at 30 weeks + 0 days to 31 weeks + 6 days gestation. Balloon removal is 3 - 4 weeks after that."
62299300|NCT06187506|EXPERIMENTAL|RC48+BCG|Disitamab Vedotin (2.0 mg/kg, administered intravenously every three weeks); BCG therapy: Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
62299301|NCT06656767||Chronic Liver Disease|A comprehensive atlas of somatic mutation present in chronic liver disease, spanning disease aetiologies and stages.
62299302|NCT04046861|ACTIVE_COMPARATOR|Vitamin C|2g vitamin C (ascorbic acid) iv before cardiopulmonary bypass, 2 g vitamin C iv before removing the aortic clamp, 1g vitamin C iv 8 h after aortic clamp removal and every 8 h thereafter(2 times)
62299303|NCT04046861|PLACEBO_COMPARATOR|Placebo (saline)|placebo (saline) iv before cardiopulmonary bypass, placebo before removing the aortic clamp, placebo iv 8 h after aortic clamp removal and every 8 h (2 times)
62469857|NCT03459807|ACTIVE_COMPARATOR|Pre-dialysis SBP <140 mmHg|"Blood pressures taken in the clinical setting at prior to start of dialysis treatment will be recorded.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
62669659|NCT04180878|NO_INTERVENTION|Control Arm|Participants in this group were informed to continue to receive usual care.
62669660|NCT04180878|EXPERIMENTAL|Intervention Arm|Received an interactive physical activity monitoring system (the Gruve®).
62669661|NCT04180878|EXPERIMENTAL|Intervention Arm 2|Received an interactive physical activity monitoring system (the Gruve®) and group based phone counseling (GBPC).
62669662|NCT02510482||Aortic valve stenosis|Individuals with clinically stable moderate aortic valve stenosis
62299304|NCT02262403|EXPERIMENTAL|Hookworm infected|The amount, phenotype and function of Treg will be explored at several time points. Cultures with environmental antigen will be subsequently performed.
62299305|NCT02262403|ACTIVE_COMPARATOR|Non infected (hookworms) healthy subjects|All the tests done in the experimental hookworm infected group will be also done in the comparator non infected group.
62669663|NCT00294567|ACTIVE_COMPARATOR|1|Amlodipine
62669664|NCT00294567|ACTIVE_COMPARATOR|2|Azelnidipine
62669665|NCT05079087|EXPERIMENTAL|PENG BLOCK arm|The first arm will consist of patients that undergo PENG block administering a mixture of Ropivacaine 0.5% + Dexamethasone 4 mg in a volume of 20 ml before performing the spinal anaesthesia.
62299306|NCT02926339|EXPERIMENTAL|Teens Against Tobacco Use presentation|Students in the intervention group will receive anti-tobacco presentations from Teens Against Tobacco Use Members
62299307|NCT02926339|NO_INTERVENTION|Control|Students in this group will receive a control presentation from their physical education teachers on a topic unrelated to tobacco.
62299308|NCT00742781|EXPERIMENTAL|Dietary supplement|Dietary supplement of vitamin D
62107892|NCT05553145||Patients Seen by their Endocrinologist|Patients whose diabetes is managed by their Endocrinologist
62107893|NCT05553145||Patients Seen by their Primary Care Provider|Patients whose diabetes is managed by their Primary Care Provider
62469858|NCT04742790|EXPERIMENTAL|Patients|The study will recruit volunteers (1) suffering from disabling post-operative pain for more than two weeks following surgery (thoracotomy, sternotomy and breast cancer surgery), (2) currently being treated for their post-operative pain with an opioid analgesic - along with possible other treatments - and (3) for which the treating physician is about to introduce an additional non-opioid drug for the treatment of their pain (e.g. an antiepileptic or an anti-depressant).
62669666|NCT05079087|ACTIVE_COMPARATOR|Ketamine- Midazolam arm|The second arm consist in Patients that will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
62669667|NCT01727154||Sipuleucel-T|
62669668|NCT04935619|OTHER|Non-Contingency Reinforcement Group|Subjects assigned to the NCR group with self-reported abstinence verified by urinary THC-COOH level \<20 ng/ml will not receive contingency monetary reinforcement at Day 28 of the study.
62669669|NCT04935619|EXPERIMENTAL|Contingency Reinforcement Group|Subjects assigned to the CR group with self-reported abstinence verified by urinary THC-COOH level \<20 ng/ml will receive contingency monetary reinforcement at Day 28 of the study.
62669670|NCT05687565|PLACEBO_COMPARATOR|Control group|Dietary supplementation
62669671|NCT05687565|EXPERIMENTAL|Experimental group 1|1.5 grams once daily during 48 weeks
62669672|NCT05687565|EXPERIMENTAL|Experimental group 2|3 grams once daily during 48 weeks
62107894|NCT06631664|EXPERIMENTAL|Study group|Twenty children suffering from Obstetric brachial plexus injury limited to nerve roots C5, C6, with/without involvement of C7
62107895|NCT06631664|OTHER|Control group|Twenty children suffering from Obstetric brachial plexus injury limited to nerve roots C5, C6, with/without involvement of C7
62107896|NCT04362501|EXPERIMENTAL|dupilumab treatment group|dupilumab treatment group
62299309|NCT05142241|EXPERIMENTAL|Treatment (talazoparib, temozolomide)|Patients receive talazoparib PO QD on days 1-28 and temozolomide PO QD on days 2-6 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and may optionally undergo biopsy and/or blood sample collection at baseline and on the trial.
62469859|NCT05719922|EXPERIMENTAL|Low-load blood flow restriction training (LL-BFR)|Twice daily LL-BFR for 3 weeks
62469860|NCT05719922|ACTIVE_COMPARATOR|Heavier load resistance training (HL-RT)|Three sessions per week for 3 weeks
62469861|NCT03610035|EXPERIMENTAL|Experimental|NPT189
62107897|NCT04362501|PLACEBO_COMPARATOR|placebo group|placebo group
62107898|NCT05025124||Method comparison|400 samples to be compared directly against the reference method. This is to get the bias estimate.
62469862|NCT03610035|PLACEBO_COMPARATOR|Placebo Comparator|Placebo
62469863|NCT02364063|EXPERIMENTAL|Children with CP - Therapy|Children receive incontinence treatment during one year, after which a follow-up period of 6 months will be applied. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
62469864|NCT02364063|NO_INTERVENTION|Children with CP - Control|Children are followed for 6 months, not receiving any treatment. After this follow-up period, children also receive incontinence treatment for 6 months.
62469865|NCT02364063|ACTIVE_COMPARATOR|Children without CP|Children receive incontinence treatment during 1 year. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
62469866|NCT03226522|EXPERIMENTAL|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
62469867|NCT03226522|ACTIVE_COMPARATOR|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
62669673|NCT02413346|EXPERIMENTAL|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
62669674|NCT02413346|EXPERIMENTAL|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
62737265|NCT01891396|PLACEBO_COMPARATOR|Saline|Single injection of 0.9% saline supplied as a 4 milliliter (mL) unit dose in a 5mL glass syringe
62737266|NCT01891396|EXPERIMENTAL|Hyaluronic Acid and TH (Cingal®)|Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
62737267|NCT01891396|ACTIVE_COMPARATOR|Hyaluronic Acid (Monovisc®)|Single injection of sodium hyaluronate supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
62737268|NCT03153891|EXPERIMENTAL|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
62107899|NCT05025124||Precision|30 samples will be each split into 10 individual samples to evaluate the precision of the Entia Liberty devices.
62299310|NCT06657807|EXPERIMENTAL|Internet-CBT|Internet-CBT including 8 weekly modules
62299311|NCT03158402|SHAM_COMPARATOR|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
62299312|NCT03158402|EXPERIMENTAL|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
62299313|NCT01209715|PLACEBO_COMPARATOR|Matching Placebo|Participants will be treated with placebo twice a day for 3 weeks.
62299314|NCT01209715|ACTIVE_COMPARATOR|Fluticasone/salmeterol|Participants will be assigned to inhaled fluticasone/salmeterol twice a day for 3 weeks.
62469868|NCT03226522|PLACEBO_COMPARATOR|Placebo|Placebo tablets taken by mouth for 5 weeks.
62469869|NCT04678882|EXPERIMENTAL|Dupilumab|Double dose on day1 and followed by single dose every 2 weeks or single dose every 4 weeks
62469870|NCT04678882|PLACEBO_COMPARATOR|Placebo|Double dose on day1 and followed by single dose every 2 weeks or single dose every 4 weeks
62469871|NCT02071303|ACTIVE_COMPARATOR|Tramadol|Women will receive Tramadol 100mg 1 hour before the procedure.
62469872|NCT02071303|ACTIVE_COMPARATOR|Celecoxib|Women will receive Celecoxib 200mg 1 hour before the procedure.
62299315|NCT04846114|ACTIVE_COMPARATOR|Control group (Cg)|"The control group (Cg) comprised 20 procedures performed in patients not on OAT.~Buccal and palatal-lingual flaps were repositioned and sutured with simple stitches using 5/0 monofilament nylon yarn, and a dry gauze was applied for 30 minutes."
62299316|NCT04846114|EXPERIMENTAL|Tranexamic acid group (TXAg)|TXAg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound for 30 minutes using a gauze soaked in the contents of a 500mg ampoule of TXA, after which a new gauze soaked in the contents of a 500mg ampoule of TXA was applied for two hours.
62469873|NCT02071303|PLACEBO_COMPARATOR|Placebo|Women will receive a placebo 1 hour before the procedure.
62469874|NCT06264024|ACTIVE_COMPARATOR|CXL|Treatment with CXL alone
62469875|NCT06264024|EXPERIMENTAL|CXL and t-PTK|Treatment with t-PTK combined with CXL
62469876|NCT02462317|ACTIVE_COMPARATOR|botulinum A toxin|Patients are injected with botulinum toxin in a standardized protocol and received placebo baclofen tablets (120 patients)
62669675|NCT01486394|EXPERIMENTAL|Focused sonography|Intervention group: After the primary evaluation by a physician in the emergency department, focused sonography of the patients heart, lungs and deep veins in the legs are performed. Hereafter the further examinations and treatment are done according to hospital guidelines.
62669676|NCT01486394|NO_INTERVENTION|Usual treatment and diagnostic work-up|Control group: After the primary evaluation by a physician in the emergency department. Hereafter the further examinations and treatment are done according to hospital guidelines.
62669677|NCT00999011|ACTIVE_COMPARATOR|One 20 minute period of activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
62107900|NCT04559724|EXPERIMENTAL|Indego-Assisted Gait Rehabilitation|"Every session of Indego-assisted gait rehabilitation will last 30 minutes, excluding preparation times (dressing, measurements, and adaptation of the brace to the anthropological measures of the various patients). The Indego program will be set based on the patient's ambulatory abilities, assessed by the Functional Ambulation Classification (FAC):~* subjects unable to walk or high-.assistance needed (FAC = 0-2): Motion + program;~* Subjects able to walk with mid/mini assistance or with supervision only (FAC = 3-5): Therapy + program.~* During the treatment, the program change from Motion + to Therapy + is allowed based on the experts' opinion."
62107901|NCT04103736|EXPERIMENTAL|Beet Juice Supplement|A single, acute dose of Beet It Sport Shot containing \~12.6mmol naturally occurring dietary nitrates.
62107902|NCT04103736|PLACEBO_COMPARATOR|Placebo juice|A single, acute dose of nitrate-depleted Beet It Sport Shot
62107903|NCT04002128|PLACEBO_COMPARATOR|Group air|"Group air was mechanically ventilated using 35% oxygen in 65% air during the whole surgical procedure.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
62107904|NCT04002128|ACTIVE_COMPARATOR|Group nitrous oxyde (N2O)|"Group N2O was mechanically ventilated using 35 % oxygen and 65 % of nitrous oxyde during the surgical procedure.~Nitrous oxyde may increase cuff pressure during the general endotracheal anesthesia and result in the respiratory symptoms like sore throat, hoarseness and postoperative cough.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
62107905|NCT01645111|ACTIVE_COMPARATOR|Clevidipine|
62107906|NCT01556256|EXPERIMENTAL|Arm I (TMV)|See detailed description.
62469877|NCT02462317|ACTIVE_COMPARATOR|Baclofen|Patients are injected with placebo in a standardized protocol and received baclofen tablets (120 patients)
62669678|NCT00999011|ACTIVE_COMPARATOR|Two periods of 20 minute activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
62669679|NCT01298466|EXPERIMENTAL|Pregabalin|Open label study. All patients fulfilling the protocol inclusion/exclusion criteria will receive pregabalin in a flexible-dosing regimen.
62469878|NCT02462317|PLACEBO_COMPARATOR|double Placebo|Patients are injected with placebo in a standardized protocol and received placebo baclofen tablets (60 patients)
62669680|NCT02717962|EXPERIMENTAL|VAL-083, Dianhydrogalactitol (Group 1)|Patients with recurrent/progressive GBM
62299317|NCT04846114|EXPERIMENTAL|Bismuth subgallate group (BSg)|BSg group comprised 20 procedures performed in patients OAT. At the moment of surgery, the contents of an anestube (1.8 ml) were mixed with a sufficient amount of BS powder to obtain a paste similar in consistency to tooth-paste (29). A thin layer of the paste was applied on the bone ridge, and buccal and palatal-lingual flaps were then repositioned and sutured as in the Cg. compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
62299318|NCT04846114|EXPERIMENTAL|Dry gauze group (DGg)|DGg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
62469879|NCT02134964|EXPERIMENTAL|OLT1177 Capsules|"A total of 5 patients in each cohort will receive OLT1177 Capsules:~* Cohort 1 will receive a single 100 mg dose of OLT1177~* Cohort 2 will receive a single 300 mg dose of OLT1177~* Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart)~* Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days~* Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days~* Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days"
62469880|NCT02134964|PLACEBO_COMPARATOR|Placebo Capsules|"A total of 1 patient in each cohort will receive Placebo Capsules:~* Cohort 1 will receive a single placebo capsule~* Cohort 2 will receive three placebo capsules~* Cohort 3 will receive ten placebo capsules (seven days apart)~* Cohort 4 will receive a single placebo capsule QD for 8 days~* Cohort 5 will receive three placebo capsules QD for 8 days~* Cohort 6 will receive ten placebo capsules QD for 8 days"
62469881|NCT03407781|EXPERIMENTAL|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
62669681|NCT02717962|EXPERIMENTAL|VAL-083, Dianhydrogalactitol (Group 2)|Newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide
62469882|NCT04612140|EXPERIMENTAL|Radiosurgery|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
62469883|NCT04612140|ACTIVE_COMPARATOR|Repeated catheter ablation|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
62469884|NCT06007781|PLACEBO_COMPARATOR|Placebo|One dose of placebo on Day 1 and one dose of placebo between Day 29 and Day 57
62107907|NCT01556256|EXPERIMENTAL|Arm II (TMV+P)|See detailed description.
62107908|NCT03460574|EXPERIMENTAL|INFORMATION|"Participants in this condition receive a manipulation suggesting that the performance test TEMINT, they previously worked on, has been shown to be highly relevant for daily life and professional success. We anticipated that after receiving this fake information about the TEMINT, it would be difficult for participants to engage in cognitive immunization processes because the validity and utility of the expectation-disconfirming experience is explicitly highlighted."
62107909|NCT03460574|EXPERIMENTAL|SALIENCE|Participants in this condition are asked to think about how well they performed on this really difficult performance test. We anticipated that this manipulation would enhance expectation change, as the salience of the expectation-disconfirming experience was explicitly increased.
62107910|NCT03460574|EXPERIMENTAL|ATTENTION|Before working on the performance test, participants in this conditions receive the instruction to attentionally focus on their personal result in the performance test. Further, they are asked to specify what would be personally good result for them. We anticipated that after receiving this instruction, the expectation-disconfirming performance feedback should be salient for the participants, hence making it difficult for them to engage in cognitive immunization strategies.
62107911|NCT03460574|EXPERIMENTAL|CONTROL|Participants in this condition receive no further information. Therefore, they are passing through the standard procedure of the previously developed experimental paradigm.
62107912|NCT03631199|EXPERIMENTAL|Part 1: Cohort A|Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed.
62107913|NCT03631199|EXPERIMENTAL|Part 1: Cohort B|Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed.
62107914|NCT03631199|EXPERIMENTAL|Part 1: Cohort C|Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel.
62299319|NCT02601417|NO_INTERVENTION|Antibiotics change is based on both blood and bile cultures|"Empirical antibiotic therapy was initially conducted for patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance.~Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians."
62299320|NCT02601417|EXPERIMENTAL|Antibiotics change is based only on the blood culture|"Empirical antibiotic therapy was initially conducted for patients. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group.~Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians."
62299321|NCT02339948|ACTIVE_COMPARATOR|SBRT only|Patients assigned to this arm receive 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
62299322|NCT02339948|ACTIVE_COMPARATOR|IMRT plus SBRT Boost|Patients assigned to this arm receive 1.8 Gy per fraction for 25 fractions over 5 weeks for a total of 45.0 Gy followed by an SBRT boost of 5.5 Gy per fraction for 4 fractions after IMRT for a total of 22.0 Gy
62299323|NCT01734343|OTHER|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
62299324|NCT01734343|OTHER|PhysIOL microAY|eyes with implanted intraocular lens PhysIOL microAY
62299325|NCT04782622||Apatinib+Camrelizumab|treated with apatinib+camrelizumab
62299326|NCT04424576||Regular Menstrual Cycles|22 adolescents with regular menstrual cycles (i.e., once every 4-6 weeks) will be enrolled within 11 months of menarche.
62299327|NCT04424576||Irregular Menstrual Cycles|26 adolescents with irregular menstrual cycles (i.e., \< 4 weeks or \> 6 weeks between periods) will be enrolled within 11 months of menarche.
62299328|NCT03830281|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Participants received individual dose of 100 U/mL insulin lispro (Humalog) by CSII; where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
62299329|NCT03830281|EXPERIMENTAL|Ultra-Rapid Lispro|Participants received individual dose of 100 units per milliliter (U/mL) ultra rapid lispro by continuous subcutaneous insulin infusion (CSII); where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
62469885|NCT06007781|EXPERIMENTAL|Experimental|One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 29 and Day 57
62299330|NCT02951052|EXPERIMENTAL|CAB LA + RPV LA every 4 weeks|Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
62469886|NCT03011294|ACTIVE_COMPARATOR|CPAP (in the partner)|Positive airway pressure for treating OSA in the bed partner.
61914226|NCT02616601|PLACEBO_COMPARATOR|Vehicle Cream|Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
61914227|NCT04438564|OTHER|cancer of breast, colorectal, ovarian and endometrial|Patient who diagnostic of Breast cancer, Colorectal cancer, cancer of Ovary, and cancer of Endometrial are can recruit.
61914228|NCT06036602|EXPERIMENTAL|cAD3-Sudan Ebolavirus Vaccine|Single dose of cAd3-Sudan Ebolavirus vaccine (1x10\^11 PU) administered intramuscularly (IM) with needle and syringe.
61914229|NCT06036602|PLACEBO_COMPARATOR|Placebo|0.9% NaCl solution for injection)administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL
61914230|NCT06391528|NO_INTERVENTION|Group Control|
62107915|NCT03631199|EXPERIMENTAL|Part 2: Canakinumab+pembro+CTx|Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy.
61914231|NCT06391528|ACTIVE_COMPARATOR|Group FTB|
61914232|NCT00591578|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD|
62107916|NCT03631199|OTHER|Part 2: Placebo+pembro+CTx|Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy.
62299331|NCT02951052|ACTIVE_COMPARATOR|Current antiretroviral regimen|Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
62469887|NCT03011294|PLACEBO_COMPARATOR|Nasal strips (in the partner)|Nasal dilator as a placebo for treating OSA in the bed partner.
61914233|NCT00591578|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD|
61914234|NCT00591578|ACTIVE_COMPARATOR|Valsartan 320 mg QD|
61914235|NCT03821662|EXPERIMENTAL|OT Diabetes Self-Management Intervention|The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
61914236|NCT03415386|EXPERIMENTAL|aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)|
62469888|NCT02486445|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours.
61914237|NCT03415386|EXPERIMENTAL|aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid|
62107917|NCT03171896|EXPERIMENTAL|Intervention|Medical clown
62107918|NCT03171896|SHAM_COMPARATOR|No Intervention|No clown in the room
62107919|NCT03564626|NO_INTERVENTION|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
62107920|NCT03564626|EXPERIMENTAL|Health IT +/- Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
62107921|NCT04204837|EXPERIMENTAL|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
62299332|NCT02562729|EXPERIMENTAL|Nerve-Sparing Radical Hysterectomy (NSRH)|Type C1 Hysterectomy
62469889|NCT02012153|EXPERIMENTAL|Mesenchymal Stromal Cells|"A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
62469890|NCT00849901|PLACEBO_COMPARATOR|Placebo|
61914238|NCT03415386|EXPERIMENTAL|aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)|
61914239|NCT03415386|EXPERIMENTAL|aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid|
62469891|NCT00849901|ACTIVE_COMPARATOR|Fluoxetine|
62469892|NCT00849901|EXPERIMENTAL|Duloxetine|
61914240|NCT04608461|EXPERIMENTAL|pumpkin seeds extract containing cream|Intervention-pumpkin seeds extract containing cream, dose-twice daily for 12 weeks
61914241|NCT03571945|ACTIVE_COMPARATOR|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
61914242|NCT03571945|ACTIVE_COMPARATOR|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
61914243|NCT05778383|NO_INTERVENTION|Standars of Care|Standard of Care of treatment for SARS-coV-2 infection
61914244|NCT05778383|EXPERIMENTAL|Zinc Supplementation +Standard of Care|Standard of care + ( 240mg zinc acetate Zinc (75mg Zn element) +NM QD) during 14 days
61914245|NCT03222492|EXPERIMENTAL|Cohort 1: 0.6 mg/kg brentuximab vedotin|"This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
62469893|NCT06082791||COPD|
62469894|NCT06082791||other respiratory disease without COPD|
62469895|NCT06082791||healthy people without respiratory disease|
61914246|NCT03222492|PLACEBO_COMPARATOR|Cohort 1: placebo|"0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
61914247|NCT03222492|EXPERIMENTAL|Cohort 2: 1.2 mg/kg brentuximab vedotin|"This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
62299333|NCT04073550|EXPERIMENTAL|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
62299334|NCT04073550|PLACEBO_COMPARATOR|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
62299335|NCT05045040|EXPERIMENTAL|Mobile-based empathetic communication support program group|Patients are provided a mobile-based empathetic communication support program to promote ACP discussion for patients with advanced cancer and physicians. The experimental group also receives the usual care as is standard practice.
62669682|NCT06389162|EXPERIMENTAL|tDCS|Transcranial direct current stimulation applied to the left dorsolateral prefrontal cortex
62669683|NCT06389162|SHAM_COMPARATOR|SHAM|SHAM transcranial direct current stimulation applied to the left dorsolateral prefrontal cortex
62669684|NCT01420978|EXPERIMENTAL|High volume CSF diversion|The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
62669685|NCT01420978|ACTIVE_COMPARATOR|Conventional CSF diversion|The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician. Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
62669686|NCT04257617|EXPERIMENTAL|Single arm, ZL-1201|Single arm, ZL-1201
62669687|NCT01854112||T-cell lymphoma|
62669688|NCT02006446||VATES|men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
62669689|NCT05738889||Group 1: Patients with fixed lingual retainers applied with Bis-GMA containing composite|In the maxilla and mandible, the lingual surfaces of the anterior six teeth, including the canines, were roughened and bonded by applying 37.5% phosphoric acid for 30 seconds. Then, the retainer wire was adhered to the lingual surfaces of the teeth between the canine-canines in the maxilla and mandible, where a fixed lingual retainer will be applied, with a flowable composite adhesive containing Bis-GMA, with 10 seconds of illumination for 60 seconds for each tooth.
62669690|NCT05738889||Group 2: Patients with fixed lingual retainers applied with Bis-GMA-free composite|The lingual surfaces of the anterior six teeth, including the canines, in the maxilla and mandible were roughened by the application of 37.5% phosphoric acid for 30 seconds. Since the applied composite system is one-stage, no additional bond application was done. Fixed lingual retainer wire was applied with a Bis-GMA-free flowable composite adhesive with 60 seconds exposure for 10 seconds for each tooth.
62669691|NCT05738889||Group 3: Patients with vacuum-formed retainers|Impressions were taken with alginate impression material from the maxilla and mandible of the volunteers whose treatment was completed, and a model was obtained with a hard cast. On the models obtained, vacuum formed retainers were prepared with a vacuum forming machine. The use and care instructions of vacuum formed retainers were explained to the patient orally. vacuum formed retainers were used by the patient for 22 hours.
62669692|NCT05738889||Group 4: Patients with hawley retainers|Impressions were taken with alginate impression material from the volunteers in the Hawley retainers group and a model was obtained with hard plaster. Wire elements were made on the model obtained and the appliance was prepared from transparent acrylic material. After the leveling and polishing processes were completed, the hawley retainers was attached to the mouth. It is stated that the appliance is used for 22 hours in 1 day. The use and care instructions of the Hawley retainers are explained to the patient.
62669693|NCT04942210|EXPERIMENTAL|vYF|1 injection of vYF at Day 1
62669694|NCT04942210|ACTIVE_COMPARATOR|YF-VAX|1 injection of YF-VAX at Day 1
62669695|NCT05378542|ACTIVE_COMPARATOR|1. group|participants will receive information about cervical cancer with the developed mobile application.
62669696|NCT05378542|NO_INTERVENTION|2. group|No Intervention: control group (non-education) Routıne care
62669697|NCT00731536||Patients with Hepatosplenic T-cell Lymphoma (HSTCL)|
62669698|NCT02242006||piperacillin/tazobactam|Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
61914248|NCT03222492|PLACEBO_COMPARATOR|Cohort 2: placebo|"1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
61914249|NCT03222492|EXPERIMENTAL|Cohort 3: 1.8 mg/kg brentuximab vedotin|"This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
62669699|NCT02242006||meropenem|Serial serum sampling of patients receiving meropenem and SLED simultaneously
62669700|NCT02242006||vancomycin|Serial serum sampling of patients receiving vancomycin and SLED simultaneously
62669701|NCT00586547|EXPERIMENTAL|Treatment|After patients have completed preparation to receive cells, they will be treated at one of five dose levels.
62669702|NCT00303628|ACTIVE_COMPARATOR|Arm I|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses.
62669703|NCT00303628|EXPERIMENTAL|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I.
61914250|NCT03222492|PLACEBO_COMPARATOR|Cohort 3: placebo|"1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
62669704|NCT00945620|PLACEBO_COMPARATOR|right side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
61914251|NCT02835053||Emergency General Surgery|All patients having emergency general surgery procedures as defined by Scott et al (JAMA Surgery 2016)
61914252|NCT00663442|EXPERIMENTAL|1|OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose)
61914253|NCT05612412|EXPERIMENTAL|Morning Exercise|Morning exercise session
61914254|NCT05612412|EXPERIMENTAL|Evening Exercise|Evening exercise session
62669705|NCT00945620|PLACEBO_COMPARATOR|Left side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
61914255|NCT05436873|EXPERIMENTAL|Treatment Arm|This is a single arm study
61914256|NCT03857347|EXPERIMENTAL|Brief Psychoeducation Intervention|2 group session psychoeducation intervention feasibility study
61914257|NCT02557074|EXPERIMENTAL|IL2 - Group A|"Patient will received IL2 low doses (1.5 to 3MUI/d) -~* IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment~* IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses"
62107922|NCT04204837|EXPERIMENTAL|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
62669706|NCT01374789|EXPERIMENTAL|Arm A (GemCis + Panitumumab)|gemcitabine + cisplatin + panitumumab
62107923|NCT03492632||Women with Psoriasis|Reproductive age women newly diagnosed with psoriasis
62107924|NCT03492632||Women without Psoriasis|Reproductive age women without psoriasis to serve as control
62299336|NCT05045040|NO_INTERVENTION|Usual care group|Patients receive the usual care. The usual care includes routine medical treatment and care by physicians, nurses, pharmacists, and others as well as support from the palliative care team and others as per the patient's situation.
62299337|NCT01552343|EXPERIMENTAL|Female - Desmopressin 25 μg|Female participants took 1 tablet of 25 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
62669707|NCT01374789|ACTIVE_COMPARATOR|Arm B (GemCis)|gemcitabine + cisplatin
61914258|NCT02557074|PLACEBO_COMPARATOR|Placebo - Group B|NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
61914259|NCT03654573|EXPERIMENTAL|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
61914260|NCT05324488||Type 1 Diabetes|Patients with diagnosed type 1 diabetes mellitus
61914261|NCT05324488||Type 2 Diabetes|Patients with diagnosed type 2 diabetes mellitus
61914262|NCT05324488||Adipositas|Obese patients with a BMI \> 30kg/m2
61914263|NCT05324488||Lipid metabolism disorder|Patients with disorder of lipid metabolism
62299338|NCT01552343|PLACEBO_COMPARATOR|Female - Placebo|Female participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
62299339|NCT01552343|EXPERIMENTAL|Male - Desmopressin 75 μg|Male participants took 1 tablet 75 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
61914264|NCT05324488||Type 3 Diabetes Mellitus|Patients with diagnosed type 3 diabetes mellitus
61914265|NCT05324488||Maturity onset diabetes of the young (MODY)|Patients with diagnosed MODY
62299340|NCT01552343|PLACEBO_COMPARATOR|Male - Placebo|Male participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
62299341|NCT01390740||Echocardiography|patients with echocardiography
62299342|NCT01905956|ACTIVE_COMPARATOR|IQP-AK-102|2 capsules per dose, three times daily
62299343|NCT01905956|PLACEBO_COMPARATOR|Placebo|2 capsules per dose, 3 times daily
62299344|NCT00982566|EXPERIMENTAL|Sequence I|
62299345|NCT00982566|EXPERIMENTAL|Sequence II|
61914266|NCT05324488||Late onset diabetes of the adult (LADA)|Patients with diagnosed LADA
61914267|NCT02817477|EXPERIMENTAL|IN Ketamine|A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
61914268|NCT02817477|ACTIVE_COMPARATOR|IM Morphine|A single administration of 0.15 mg/kg intramuscular morphine
61914269|NCT02817477|ACTIVE_COMPARATOR|IV Morphine|A single administration of 0.1 mg/kg slow intravascular bolus of morphine.
61914270|NCT01653379|EXPERIMENTAL|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
61914271|NCT00164944||FDR of CRC patient|First degree relatives of patients having CRC
61914272|NCT00164944||FDR of normal colonoscopy|First degree relatives of patients having normal colonoscopy
61914273|NCT03660085|EXPERIMENTAL|Arm A - Early Intervention|For 180 days participants in this arm will be exposed to the intervention and 180 days afterwards they will be exposed to the standard of care.
61914274|NCT03660085|ACTIVE_COMPARATOR|Arm B - Late Intervention|For 180 days participants in this arm will be exposed to the standard of care and 180 days afterwards they will be exposed to the intervention.
61914275|NCT04718844|EXPERIMENTAL|1.0mg/kg - Thalassaemia|
61914276|NCT04718844|EXPERIMENTAL|3.0mg/kg - Thalassaemia|
62299346|NCT00982566|EXPERIMENTAL|Sequence III|
62669708|NCT00189514|EXPERIMENTAL|1|
62669709|NCT00189514|EXPERIMENTAL|2|
62669710|NCT00189514|EXPERIMENTAL|3|
62669711|NCT00189514|PLACEBO_COMPARATOR|4|
62669712|NCT01646216|EXPERIMENTAL|Split-belt treadmill training|Split-belt treadmill exercise
62669713|NCT03338023|EXPERIMENTAL|LY2963016 + Insulin Lispro|Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
61914277|NCT04718844|EXPERIMENTAL|6.0mg/kg - Thalassaemia|
61914278|NCT04718844|PLACEBO_COMPARATOR|Placebo - Thalassaemia|
62669714|NCT03338023|ACTIVE_COMPARATOR|Lantus® + Insulin Lispro|Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
61914279|NCT04718844|EXPERIMENTAL|Xmg/kg - Thalassaemia|
61914280|NCT04718844|EXPERIMENTAL|1.0mg/kg - Myelodysplastic Syndrome|
61914281|NCT04718844|EXPERIMENTAL|3.0mg/kg - Myelodysplastic Syndrome|
62299347|NCT00982566|EXPERIMENTAL|Sequence IV|
62299348|NCT00982566|EXPERIMENTAL|Sequence V|
62669715|NCT01155609|EXPERIMENTAL|Supportive care (oral complications management)|Patients receive L-Lysine PO QD until completion of radiotherapy and resolution of mucositis in the absence of disease progression or unacceptable toxicity.
61914282|NCT04718844|EXPERIMENTAL|10.0mg/kg - Myelodysplastic Syndrome|
61914283|NCT04718844|EXPERIMENTAL|Xmg/kg - Myelodysplastic Syndrome|
62469896|NCT02422264|EXPERIMENTAL|dTpa Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 \[DTPA (BOOSTRIX)-047\] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
62669716|NCT03123107|EXPERIMENTAL|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
61914284|NCT04718844|EXPERIMENTAL|3.0mg/kg - Thalassaemia multi dose|
61914285|NCT04718844|EXPERIMENTAL|10.0mg/kg - Thalassaemia multi dose|
61914286|NCT04718844|EXPERIMENTAL|Xmg/kg - Thalassaemia multi dose|
61914287|NCT04718844|EXPERIMENTAL|3.0mg/kg - Myelodysplastic Syndrome multi dose|
61914288|NCT04718844|EXPERIMENTAL|10.0mg/kg - Myelodysplastic Syndrome multi dose|
62299349|NCT00982566|EXPERIMENTAL|Sequence VI|
62299350|NCT00982566|EXPERIMENTAL|Sequence VII|
62299351|NCT00982566|EXPERIMENTAL|Sequence VIII|
61914289|NCT04718844|EXPERIMENTAL|Xmg/kg - Myelodysplastic Syndrome multi dose|
61914290|NCT04718844|PLACEBO_COMPARATOR|Placebo - Thalassaemia multi dose|
61914291|NCT04718844|PLACEBO_COMPARATOR|Placebo - Myelodysplastic Syndrome|
61914292|NCT04718844|PLACEBO_COMPARATOR|Placebo - Myelodysplastic Syndrome multi dose|
61914293|NCT02251522||ConforMIS iTotal Knee Replacement System|Patients who have had an iTotal knee replacement at least 6 months prior to testing
61914294|NCT02251522||Off-the-Shelf Knee Replacement System|Patients who have had an off-the-shelf knee replacement at least 6 months prior to testing
61914295|NCT06001411|EXPERIMENTAL|Prone Position Training group (PPT group)|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
61914296|NCT06001411|PLACEBO_COMPARATOR|Control group (C group)|Patients in the control group (C group) received standard perioperative care without any prone position training.
61914297|NCT00938886|EXPERIMENTAL|Naltrexone|50 mg daily naltrexone for 10 weeks
61914298|NCT00938886|PLACEBO_COMPARATOR|Placebo|Daily matched placebo pill
61914299|NCT04544215|EXPERIMENTAL|MPCs-derived exosomes Dosage 1|low-dose group
61914300|NCT04544215|EXPERIMENTAL|MPCs-derived exosomes Dosage 2|high-dose group
61914301|NCT04544215|PLACEBO_COMPARATOR|No exosomes|No MPCs-derived exosomes
61914302|NCT05444140|EXPERIMENTAL|Experimental group|Health coaching
61914303|NCT04320641|EXPERIMENTAL|acupressure|
61914304|NCT04320641|EXPERIMENTAL|music|
61914305|NCT04320641|NO_INTERVENTION|control|
61914306|NCT04403009||the nonsevere Coronavirus Disease 2019 Patients|
61914307|NCT04403009||the severe Coronavirus Disease 2019 Patients|
61914308|NCT02166177|EXPERIMENTAL|Autologous Regulatory T cell therapy|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose)
61914309|NCT01174433|EXPERIMENTAL|Tryton bifurcation stent system|
61914310|NCT00722085||Observational|
62299352|NCT00982566|EXPERIMENTAL|Sequence IX|
62299353|NCT00982566|EXPERIMENTAL|Sequence X|
62299354|NCT00982566|EXPERIMENTAL|Sequence XI|
62299355|NCT00982566|EXPERIMENTAL|Sequence XII|
62299356|NCT00982566|EXPERIMENTAL|Sequence XIII|
62299357|NCT00982566|EXPERIMENTAL|Sequence XIV|
62299358|NCT00982566|EXPERIMENTAL|Sequence XVI|
62299359|NCT00982566|EXPERIMENTAL|Sequence XV|
62299360|NCT05344547||PCOS Patient|
62299361|NCT05344547||Non-PCOS Patient|
62299362|NCT00986531|EXPERIMENTAL|1|80 mg AZD8529
62299363|NCT00986531|PLACEBO_COMPARATOR|2|Placebo
62669717|NCT05142085|EXPERIMENTAL|Efficacy of nano-PSO on motor and non-motors symptoms of Parkinson´s disease.|"It is the clinical trial itself where more than 140 subjects will be included:~84 under active treatment and 56 under placebo"
62669718|NCT05142085|EXPERIMENTAL|Effect of nano-PSO on molecular images of PD patients|In this group, the study implicates performing a multitracer PET-scan before treatment, and at 6 months, to 25 subjects in the clinical trial : 15 under active treatment and 10 in the placebo group.
62669719|NCT05241210|EXPERIMENTAL|Testing of degree of mucosal inspection|AI provides real-time feedback related to circumferential views during endoscope removal
62669720|NCT05241210|EXPERIMENTAL|Testing of clearing of fecal debris|AI provides real-time feedback related to removal of remaining fecal debris
62107925|NCT02454205|ACTIVE_COMPARATOR|Conventional treatment 21-24 months|"Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.~In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol."
62107926|NCT02454205|EXPERIMENTAL|Interventional treatment 6-9 months|"Participants will receive six to nine months of oral:~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (\<50kg) or 1000mg (\>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures."
62469897|NCT02422264|ACTIVE_COMPARATOR|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 \[DTPA (BOOSTRIX)-047\], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
62299364|NCT05391438|OTHER|Meal-timing|All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period.
62469898|NCT00234286|EXPERIMENTAL|Arm 1|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
62469899|NCT00436163|EXPERIMENTAL|Peginterferon Alfa-2a|Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.
62469900|NCT01868191|PLACEBO_COMPARATOR|Placebo for benfotiamine|Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
62299365|NCT01076179||Human Immunodeficiency Virus (HIV)-Infected Participants|HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists
62469901|NCT01868191|EXPERIMENTAL|Benfotiamine|Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months
62469902|NCT02957097|EXPERIMENTAL|Medication - Gabapentin|Participants of this group will be administered either Gabapentin 900 milligram PO 2-3 hours prior to the surgical procedure.
62669721|NCT04111783|EXPERIMENTAL|POU ultrasound intervention test group|The experimental group used POU protocol ultrasound to perform a heart scan and a standard scan, a large vascular scan under the xiphoid, a body cavity scan, a standard section, and a lung scan in 10 minutes. Comprehensive preoperative circulation and assessment of systemic conditions, and guided intraoperative anesthesia management with assessment results.
62469903|NCT02957097|PLACEBO_COMPARATOR|Medication - Placebo|Participants of this group will be administered either Placebo PO 2-3 hours prior to the surgical procedure.
62469904|NCT03069586|OTHER|Low pressure pneumoperitoneum|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg).
62669722|NCT04111783|NO_INTERVENTION|Control group|the anesthesiologist performed according to the existing preoperative evaluation program and existing experience, and guided the anesthesia management with the evaluation results.
62669723|NCT02369926|ACTIVE_COMPARATOR|Group 1|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
62669724|NCT02369926|ACTIVE_COMPARATOR|Group 2|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
62669725|NCT04767412|ACTIVE_COMPARATOR|aerobic exercise|
62107927|NCT05821127|EXPERIMENTAL|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|Patient education was provided in 3 sessions via telerehabilitation method, and exercises were provided with virtual reality support. It was requested that the exercises be done in 6 sets (30 repetitions) every day. Participants were given a splint, exercise brochure, and exercise diary for use at night.
62107928|NCT05821127|ACTIVE_COMPARATOR|Neurodynamic Exercises and Patient Education with Traditional Method|Participants were given a single session of face-to-face training on the same topics, and were given a splint, exercise brochure and exercise diary to be used at night.
62299366|NCT05212051|EXPERIMENTAL|JS005 150 mg|30 patients will be enrolled in this arm.
62299367|NCT05212051|PLACEBO_COMPARATOR|Placebo 150 mg|10 patients will be enrolled in this arm.
61914311|NCT02660008|EXPERIMENTAL|ZP4207|ZP4207 (peptide analogue of human glucagon) Planned doses: 0.1, 0.3, 0.6, 1.0 mg s.c.
61914312|NCT02660008|ACTIVE_COMPARATOR|GlucaGen|GlucaGen (native glucagon) Planned doses: 0.5, 1.0 mg s.c.
62107929|NCT03332134|EXPERIMENTAL|Married Couple Dyad|Husband-wife dyads will receive the intimate partner violence (IPV) intervention program over the course of six weeks.
62299368|NCT05212051|EXPERIMENTAL|JS005 300 mg|30 patients will be enrolled in this arm.
62299369|NCT05212051|PLACEBO_COMPARATOR|Placebo 300 mg|10 patients will be enrolled in this arm.
62299370|NCT05212051|EXPERIMENTAL|JS005 450 mg|30 patients will be enrolled in this arm.
62299371|NCT05212051|PLACEBO_COMPARATOR|Placebo 450|10 patients will be enrolled in this arm.
62299372|NCT04168086|EXPERIMENTAL|Right Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to motor area of the right cerebellum prior to completing a motor learning task.
62299373|NCT04168086|EXPERIMENTAL|Non-Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to a non-motor area of the right cerebellum prior to completing a motor learning task.
62299374|NCT04168086|SHAM_COMPARATOR|Control|Participants will have the Focused Ultrasound transducer placed on their neck without stimulation as a Sham present prior to completing a motor learning task.
62299375|NCT02083276|EXPERIMENTAL|Pivmecillinamhydrochlorid|Selexid 400 mg x 3 , 7 days
62299376|NCT03323749|EXPERIMENTAL|Part 1: Elamipretide|40 mg (0.5mL) elamipretide subcutaneous (SC) daily
62299377|NCT03323749|PLACEBO_COMPARATOR|Part 1: Placebo|Placebo SC daily
62299378|NCT03323749|EXPERIMENTAL|Part 2: Elamipretide open label|Elamepretide 40 mg (0.5 mL) SC daily
62469905|NCT03069586|ACTIVE_COMPARATOR|low pressure peritoneum and pulmonary recruitment|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg) and at the end of surgery a manual pulmonary recruitment manoeuver (2 x 5sec max 40cmH2O) will be done
62469906|NCT02480322||Sleeve group|Patients undergoing gastric sleeve resection.
62469907|NCT02480322||Proximal RYGB group|Patients undergoing proximal gastric bypass surgery.
62669726|NCT04767412|ACTIVE_COMPARATOR|aerobic exercise and inspiratory muscle training|
62669727|NCT01787903|ACTIVE_COMPARATOR|Real-time continuous glucose monitor|16 weeks use of a real-time continuous glucose monitor
62669728|NCT01787903|PLACEBO_COMPARATOR|Continuous glucose monitor|16 weeks use of a (blinded, retrospective) continuous glucose monitor
62737269|NCT03153891|EXPERIMENTAL|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
62737270|NCT03153891|NO_INTERVENTION|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
62737271|NCT06429046|NO_INTERVENTION|CONTROL|"For patients in the control group, Personal Information Form will be applied before the procedure and pain will be evaluated with Numeric Pain Scale.~NPS will be applied at the beginning of the procedure when the ultrasound probe is placed (NPS-1), 5 minutes after the procedure (NPS-2) and at the end of the procedure when the probe is removed (NPS-3).~However, no treatment will be performed on control group patients."
61914313|NCT02589600|EXPERIMENTAL|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
62469908|NCT02480322||Distal RYGB group|Patients undergoing distal gastric bypass surgery.
62469909|NCT02480322||BMI-matched control group|
62469910|NCT02480322||Normal-weight control group|
62469911|NCT02803398|EXPERIMENTAL|Patient at risk of venous thrombosis|
62737272|NCT06429046|EXPERIMENTAL|LIDOCAINE GEL (LG)|"Data will be collected in two stages. To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum. Patients in the LG group will be administered a Personal Information Form before the procedure, and their pain will be evaluated with the Numeric Pain Scale. NPS will be applied at the beginning of the procedure when the ultrasound probe is placed (NPS-1), 5 minutes after the procedure (NPS-2) and at the end of the procedure when the probe is removed (NPS-3)."
61914314|NCT02589600|PLACEBO_COMPARATOR|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
62107930|NCT03332134|NO_INTERVENTION|Control Group|Husband-wife dyads in the control group will not receive an intervention.
62107931|NCT06632158|EXPERIMENTAL|MindBoba|Participants will be given access to the MindBoba app for 12 weeks.
62299379|NCT03404362|ACTIVE_COMPARATOR|MRgFUS|"The treatment process begins with the physician acquiring a set of MR images, identifying target volume(s) of tissue to ablate, and then drawing the treatment contours.~The therapy planning software computes the type and number of sonications required to treat the defined region while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment"
62299380|NCT03404362|ACTIVE_COMPARATOR|EBRT|Patient would undergo single fraction of external beam radiation to a dose of 8Gy or a session of 10 fractions of external beam radiations at 3Gy per fraction for two weeks.
62107932|NCT06632158|ACTIVE_COMPARATOR|Mindshift CBT|Participants will be given access to the Mindshift CBT app for 12 weeks.
62107933|NCT06632158|NO_INTERVENTION|Business-as-Usual|
62299381|NCT05912023||Vaping patients|Includes patients that actively vape that are undergoing general anesthesia
62299382|NCT05912023||Non-vaping patients|Includes patients that do not actively vape that are undergoing general anesthesia
62107934|NCT01282437|EXPERIMENTAL|Prophylactic Cranial Irradiation|
62107935|NCT01282437|NO_INTERVENTION|Observation|Patients will not receive PCI, but will be observed and the same items will be measured as in the PCI-arm.
61914315|NCT02575066|OTHER|radiotherapy combined with pazopanib|patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg). The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
61914316|NCT02165839|ACTIVE_COMPARATOR|Healthy Eating Education Learning (HEAL)|Control group.
62107936|NCT04153344||Infrared hyperreflective area|Patients with neurofibromatosis type 1 and with infrared hyperreflective areas
62107937|NCT04153344||No infrared hyperreflective areas|Patients with neurofibromatosis type 1 and with no infrared hyperreflective areas
62299383|NCT00896961|EXPERIMENTAL|Observational (EF5)|Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
62299384|NCT01312194|EXPERIMENTAL|One vist group|All patients included in this treatment group will receive the complete endodontic treatment in a single visit.
62299385|NCT01312194|ACTIVE_COMPARATOR|Two-vist group|All patients included in this treatment group will receive treatment in two visits. The first will be done chemo mechanical root canal preparation, the placement of the intracanal medication the basis of calcium hydroxide and coronal sealing. Ten to twelve days later, this medication is removed and the root canal will be permanently filled.
62299386|NCT04288245|EXPERIMENTAL|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
62107938|NCT04153344||Controls|Patients with no neurofibromatosis type 1
62107939|NCT04858425|EXPERIMENTAL|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
61914317|NCT02165839|EXPERIMENTAL|Brief Behavioral Therapy for Insomnia (BBT-I)|
62107940|NCT04858425|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets 3 times daily for 14 days
62107941|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
62107942|NCT02293421|OTHER|STOP BANG|STOP BANG screening questionnaire and a snore question
62107943|NCT01155869|EXPERIMENTAL|XR-NTX|Depot naltrexone (Vivitrol) 380 mg. IM monthly
62107944|NCT01155869|ACTIVE_COMPARATOR|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
62107945|NCT05444179|ACTIVE_COMPARATOR|Intervention group|"The participant will be provided an educational module entitled Mommies can Eat and Exercise with No Stress (MomEENS), in which the module will be delivered through a booklet and video. The MomEENS module consist of five key recommendations: 1. Eat healthy foods ;2. Eat foods rich in iron and folic acid; 3. Eat foods rich in omega-3 fatty acids; 4. Increase steps in a day and; 5. Increase body flexibility and strength. All the key recommendations will be explained in the booklet, while the video will provide full guidance on how to exercise during postpartum at home, explaining key recommendations 4 and 5. Face-to-face consultation with the participants will be held during baseline and 4th week to enhance the participation. Besides, Whatsapp and Facebook page group is developed as a step to enhance the compliance of participants. All the participants will be contacted once for every two weeks, lasting for about 5 to 10 minutes for each call to monitor the participant's progress."
62107946|NCT05444179|NO_INTERVENTION|Control group|The participants in the control group will be received advice on the standardised Malaysian food pyramid and be instructed to follow their usual standard care as suggested by their healthcare provider. Postpartum women in Malaysia typically attend postpartum healthcare visits with an exam on day 30 after childbirth but receive no other routine care following this appointment unless a specific health problem has been identified. Participants in the control group performed the same evaluations. They received the same incentives as those in the intervention group, but they did not receive any educational module and contact from the investigator during the 8 weeks follow-up.
61914318|NCT02955251|EXPERIMENTAL|Arm 1|ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).
62107947|NCT01643291|EXPERIMENTAL|Ultrasound|
62107948|NCT01972152|EXPERIMENTAL|G-Pen(TM) 1 mg|G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection
62299387|NCT04288245|PLACEBO_COMPARATOR|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
62469912|NCT03620747|EXPERIMENTAL|Dupilumab|Participants received subcutaneous (SC) dose of dupilumab 300 milligrams (mg) every 2 weeks (q2w) from Week 0 up to Week 132. Participants who discontinued treatment for greater than or equal to (\>=) 6 weeks after study LTS12551 (NCT02134028), received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose inhaled corticosteroid (ICS) as maintained in study LTS12551 in combination with controllers (and/or oral corticosteroid \[OCS\] for those participants from the original parent study EFC13691 \[NCT02528214\]). Salbutamol/albuterol hydrofluoroalkane pressurized metered dose inhalers (MDI) or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study.
62469913|NCT00505570|NO_INTERVENTION|Medical Management|
62469914|NCT00505570|EXPERIMENTAL|PFO Closure|
62669729|NCT04002557||Focus group|"This is a qualitative study using focus group discussions with young people aged 12-18 who are receiving consultation summaries.~Patients attending a single diabetes service will be invited to enrol. This service serves a population from a wide geographic area and socio-economic backgrounds.~Interviews will be conducted by a qualitative researcher with relevant experience. They will be held on the day of a participant's clinic appointment within the same hospital or on the day agreed with the participant."
62669730|NCT00756834||Mammography Image Collection|Acquired images
62669731|NCT00756834||CAD Radiologist Reader|Retrospective reader study
62669732|NCT01293877|OTHER|LGP|Patient underwent surgery for morbid obesity treatment between 18 to 60 years, and BMI of 40 ore more will divided in two groups, one hundred will be schedule for laparoscopic gastric plication. Our theory for this arm is that the procedure can offer the same results than the second arm with less cost and safety, reversibility included.
62669733|NCT01293877|OTHER|LSG|The patients in a total of one hundred will be schedule for laparoscopic sleeve gastrectomy. The is our control for development of the study.
62669734|NCT06376227||with or without Left Colic Artery Preservation|
62669735|NCT06376227||low ligation (LL) group and high ligation (HL) group|low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
62669736|NCT03529149|EXPERIMENTAL|Accurate blood pressure control|Implementing accurate blood pressure management under TCD monitoring
61914319|NCT02955251|EXPERIMENTAL|Arm A, B, and C|Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.
61914320|NCT02955251|EXPERIMENTAL|Arm D|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.
62299388|NCT05634603|ACTIVE_COMPARATOR|Intervention|Lactose-free milk formula (Frisolac LF ®)
62299389|NCT05634603|PLACEBO_COMPARATOR|Placebo|Regular infant milk formula
62299390|NCT04964258|PLACEBO_COMPARATOR|Part 1: Placebo|TAK-105-a matching-placebo, injection, subcutaneously, once on Day 1.
62469915|NCT02897375|EXPERIMENTAL|Arm A (palbociclib, cisplatin)|Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62469916|NCT02897375|EXPERIMENTAL|Arm B (palbociclib, carboplatin)|Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62469917|NCT05690217||COPD group|There are 40 chronic obstructive pulmonary disease (COPD) patients in the COPD group.
62469918|NCT05690217||Healthy control group|There are 40 age-matched healthy participants in the healthy control group.
62469919|NCT03769922|EXPERIMENTAL|Extensive mesenteric resection|Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
62469920|NCT03769922|ACTIVE_COMPARATOR|Limited mesenteric excision|"Mesentery is retained, i.e. Close shave or 3 cm from the border of bowel (using whatever approach - clips, or haemostatic vessel sealing device)."
62669737|NCT03529149|ACTIVE_COMPARATOR|Guideline blood pressure control|Control blood pressure according to guidelines
62669738|NCT03661580|EXPERIMENTAL|Behavioural Activation|Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
62669739|NCT03661580|ACTIVE_COMPARATOR|Treatment as Usual|Participants in this arm will receive no change to the care they usually receive at the CDAT service.
62669740|NCT06341283||BCOOS-A1|The patients in this array are treated with Abemaciclib and Letrozole/Anastrozole.
62669741|NCT06341283||BCOOS-A2|The patients in this array are treated with Letrozole or Anastrozole.
62669742|NCT06341283||BCOOS-B1|The patients in this array are treated with Abemaciclib and Fulvestrant.
61914321|NCT02955251|EXPERIMENTAL|Arm 2|ABBV-428 plus nivolumab.
62107949|NCT01972152|EXPERIMENTAL|G-Pen(TM) 0.5 mg|G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
62107950|NCT01972152|ACTIVE_COMPARATOR|Lilly Glucagon(TM) 1 mg|Lilly Glucagon(TM) \[glucagon for injection (rDNA origin)\], single 1 mg SC injection
62107951|NCT06631859|EXPERIMENTAL|Volunteers who recieved tested product|Volunteers who recieved tested product
62107952|NCT06631859|PLACEBO_COMPARATOR|Volunteers who recieved base product|Volunteers who recieved base product
62107953|NCT06138951|PLACEBO_COMPARATOR|Nonexercised rested day|Athlete will not exercise on trial day.
62669743|NCT06341283||BCOOS-B2|The patients in this array are treated with Fulvestrant only.
62669744|NCT04869930||Autism Spectrum Disorder (ASD)|Early childhood (pre-diagnosis) OR existing diagnosis of moderate/severe ASD
62669745|NCT04869930||Fragile X Syndrome (FXS)|Existing diagnosis of Fragile X Syndrome
62669746|NCT04869930||Healthy Controls|No diagnosed chronic conditions
62299391|NCT04964258|EXPERIMENTAL|Part 1: TAK-105 Dose 1|TAK-105-a Dose 1, injection, subcutaneously, once on Day 1.
62299392|NCT04964258|EXPERIMENTAL|Part 1: TAK-105 Dose 2|TAK-105-a Dose 2, injection, subcutaneously, once on Day 1.
62669747|NCT01556100|EXPERIMENTAL|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
62107954|NCT06138951|EXPERIMENTAL|Recovery from 10KM run|Athlete will run 10km on trial day.
62107955|NCT06138951|EXPERIMENTAL|Recovery from 20KM run|Athlete will run 20km on trial day.
62107956|NCT01769781|EXPERIMENTAL|anastrazole|women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
62107957|NCT01769781|ACTIVE_COMPARATOR|GnRH analog alone|women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
62669748|NCT00057070|OTHER|Arm 1|
61914322|NCT05585281|EXPERIMENTAL|Participants receiving Fluzoparib+ QL1101|Participants will be administered QL1101 7.5 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Fluzoparib will be administered orally twice daily continuously throughout each 21-day cycle. On Day 1 of each cycle, fluzoparib will be administered upon completion of QL1101 infusion. The starting dose of fluzoparib will be based on the participant's Baseline actual body weight or platelet count.
61914323|NCT04232709|NO_INTERVENTION|After-hours care|Patients in the after-hours care (AH) group will receive the usual (telemedicine) care. That is, they will have the option to call the after-hours centre and receive help from the oncology nurses using the COSTaRS practice guides to manage their after-hours symptoms.
62107958|NCT06629922||Young Adults|a) aged between 18 to 35 years old and, b) have never been diagnosed with somatosensory, visual, and vestibular deficits as reported by the participants
62107959|NCT06629922||Older Adults|a) are 65 years old and over and, b) have not fallen in the last 12 months will also be invited to participate
62107960|NCT06713213|EXPERIMENTAL|Concomitant comparison of respiratory volumes using FRNDS device with Plethysmography belts|"FRNDS is a novel cannula device that can both measure tidal volume (VT) in real time while simultaneously delivering air to the patient.~Study subjects with undergo continuous measurement of a patient's VT while simultaneously delivering variable volumes of air to the patient and comparing these results with VTs captured with conventional technology (RIP belts)"
62107961|NCT06631040|EXPERIMENTAL|Acute lymphocytic leukemia, in relapse|
62669749|NCT01594268|OTHER|Kidney transplantation patient|Kidney transplantation patient; single arm
62669750|NCT05193396|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62669751|NCT05193396|ACTIVE_COMPARATOR|Hydrocortisone|hydrocortisone tablets
62669752|NCT05166642|ACTIVE_COMPARATOR|Bandgrip Micro-Anchor Skin Closure|
62669753|NCT05166642|ACTIVE_COMPARATOR|Standard of Care wound closure|Standard Monocryl suture closure
62669754|NCT03705611|NO_INTERVENTION|Standard of care|Provide personalised clinic invitation slips (letters) to partners to come for HIV testing, and to access post-test services
62669755|NCT03705611|EXPERIMENTAL|HIV self-testing only|HIV self-testing only
62299393|NCT04964258|EXPERIMENTAL|Part 1: TAK-105 Dose 3|TAK-105-a Dose 3, injection, subcutaneously, once on Day 1.
62299394|NCT04964258|EXPERIMENTAL|Part 1: TAK-105 Dose 4|TAK-105-a Dose 4, injection, subcutaneously, once on Day 1.
62299395|NCT04964258|EXPERIMENTAL|Part 1: TAK-105 Dose 5|TAK-105-a Dose 5, injection, subcutaneously, once on Day 1.
62299396|NCT04964258|EXPERIMENTAL|Part 1: TAK-105 Dose 6|TAK-105-a Dose 6, injection, subcutaneously, once on Day 1.
62669756|NCT03705611|EXPERIMENTAL|HIV self-testing secondary accuracy|HIV self-testing secondary accuracy
62669757|NCT00806026|EXPERIMENTAL|PBO/PGB 300 mg|
62669758|NCT00806026|ACTIVE_COMPARATOR|PBO/PPX 0.25 mg|
62669759|NCT00806026|ACTIVE_COMPARATOR|PBO/PPX 0.5 mg|
62669760|NCT00806026|EXPERIMENTAL|PGB 300 mg|
62669761|NCT00806026|ACTIVE_COMPARATOR|PPX 0.25 mg|
62107962|NCT03526835|EXPERIMENTAL|MCLA-158|"In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days.~In the expansion phase, 2 doses (1100 mg and 1500 mg) of MCLA-158 will be evaluated in a cohort of head and neck squamous cell carcinoma patients"
62107963|NCT03526835|EXPERIMENTAL|MCLA-158 + Pembrolizumab|MCLA-158 in combination with pembrolizumab will be explored first in head and neck squamous cell carcinoma patients eligible to receive pembrolizumab as first-line monotherapy.
62299397|NCT04964258|EXPERIMENTAL|Part 1: TAK-105 Dose 7|TAK-105-a Dose 7, injection, subcutaneously, once on Day 1.
62469921|NCT02345395|EXPERIMENTAL|Transpalpebral Approach|Aneurysm Clipping - Patients will be submitted to a Transpalpebral Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
62669762|NCT00806026|ACTIVE_COMPARATOR|PPX 0.5 mg|
62107964|NCT03526835|EXPERIMENTAL|MCLA-158 + FOLFIRI combination chemotherapy|MCLA-158 in combination with FOLFIRI combination will be explored first in metastatic colorectal cancer patients (mCRC) in the 2L setting.
62107965|NCT01494662|ACTIVE_COMPARATOR|Cohort 1|"Patients With Progressive Brain Metastases~Intervention: HKI-272 (Neratinib)340 mg orally, once daily."
62107966|NCT01494662|ACTIVE_COMPARATOR|Cohort 2|"Patients Who Are Candidates For Craniotomy.~Intervention: HKI-272 (Neratinib) 240 mg orally, once daily.~Surgical resection (biopsy).~Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib."
62107967|NCT01494662|ACTIVE_COMPARATOR|Cohort 3a/3b|"Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.~Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest."
62107968|NCT01494662|ACTIVE_COMPARATOR|Cohort 4a/4b/4c|"Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks."
62107969|NCT02842658|ACTIVE_COMPARATOR|A high-intensity interval exercise group|Supervised exercise training with be carried out at the Mayo Clinic Cardiac rehabilitation center on cycle ergometers using EKG telemetry. Treatment will begin one week prior to chemotherapy and is tailored around 8 weeks.
62107970|NCT02842658|OTHER|An attention-control group|Patients will receive counseling regarding physical activity during chemotherapy. Patients will receive a weekly phone call to maintain physical activity during chemotherapy and compliance will be verified using physical activity diaries and pedometers.
62107971|NCT02389192|EXPERIMENTAL|OPEN|healthy volunteers between the ages of 18-50 to receive a one-time infusion of Zmapp at a dose of 50mg/kg.
62299398|NCT04964258|PLACEBO_COMPARATOR|Part 2: Placebo|TAK-105-a matching-placebo, injection, subcutaneously, once weekly for 4 weeks.
62299399|NCT04964258|EXPERIMENTAL|Part 2: TAK-105 Dose 1A|TAK-105-a Dose 1A, injection, subcutaneously, once weekly for up to 4 weeks.
62299400|NCT04964258|EXPERIMENTAL|Part 2: TAK-105 Dose 2A|TAK-105-a Dose 2A, injection, subcutaneously, once weekly for 1 week.
62469922|NCT02345395|EXPERIMENTAL|NanoPterional Approach|Aneurysm Clipping - Patients will be submitted to a Modified MiniPterional Approach (Nanopterional) to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
62469923|NCT02345395|SHAM_COMPARATOR|Classical Pterional Craniotomy|Aneurysm Clipping - Patients will be submitted to a Classical Pterional Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital 4-5 days after the procedure.
62469924|NCT00115128||Filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
62469925|NCT01083784|EXPERIMENTAL|Prophylactic group|the group that used prophylactic anticonvulsants (valproate, clonazepam)
62469926|NCT01083784|NO_INTERVENTION|Control group|control group
62469927|NCT01900626|ACTIVE_COMPARATOR|single epidural catheter|
62669763|NCT04753177|EXPERIMENTAL|Neoadjuvant combined hormone therapy|Ribocyclib, fulvestrant, triptorelin
62669764|NCT04753177|ACTIVE_COMPARATOR|Chemotherapy (the control)|doxorubicin, cyclophosphamide, paclitaxel
62107972|NCT03523091|EXPERIMENTAL|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
62107973|NCT03523091|EXPERIMENTAL|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
62107974|NCT06106659|EXPERIMENTAL|forearm|Mini midline catheter forearm placement.
62107975|NCT06106659|OTHER|upper arm|Mini midline catheter upper arm placement
62107976|NCT00768066|EXPERIMENTAL|1|Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).
62107977|NCT00768066|EXPERIMENTAL|2|Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).
62107978|NCT00768066|PLACEBO_COMPARATOR|3|Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS).
62107979|NCT01043471|EXPERIMENTAL|Chewing gum|
62107980|NCT01043471|PLACEBO_COMPARATOR|Water|
62107981|NCT06629571|EXPERIMENTAL|Experimental|Patient education
62299401|NCT03731793|PLACEBO_COMPARATOR|Placebo Group|Placebo. For 90 days one capsule/day.
62299402|NCT03731793|EXPERIMENTAL|Intervention Group|600 mg/day of non-animal Chondroitin Sulphate. One capsule/day for 90 days.
62107982|NCT06629571|NO_INTERVENTION|Control|No patient education
62107983|NCT03879967|EXPERIMENTAL|Allograft block graft|For lateral alveolar ridge augmentation, all patients will be treated with allograft block with guided bone regeneration. After a minimal healing phase of six months, implants would be placed in the augmented site. After a healing phase of about 4months, the implants would be loaded and then followed until the control appointment approximately 3 years later.
62107984|NCT04977128|EXPERIMENTAL|Experimental：89Zr-KN035 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
62107985|NCT03569683|EXPERIMENTAL|Interventional Single arm|"Group A- Diode laser biostimulation on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group B- Hyaluronic acid (Gengigel) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group C- Herbal gel (Hiora SG) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery."
62469928|NCT01900626|ACTIVE_COMPARATOR|double epidural catheter|
62107986|NCT01183533|EXPERIMENTAL|off label rt-PA used|off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.
62107987|NCT05826444||microvascular cardiac allograft vasculopathy|Heart transplant recipients with microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.
62107988|NCT05826444||control|Heart transplant recipients without microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.
62107989|NCT02315885|PLACEBO_COMPARATOR|placebo alcohol|\<0.05% alcohol
62107990|NCT02315885|ACTIVE_COMPARATOR|alcohol middle dose|alcohol dose=0.45g/kg for women and 0.5g/kg for men
62107991|NCT02315885|ACTIVE_COMPARATOR|alcohol high dose|alcohol dose=0.90g/kg for women and 1.0g/kg for men
62107992|NCT05129982|EXPERIMENTAL|Intervention|The reflex response will be recorded during whole-body vibration.
62107993|NCT00079482|ACTIVE_COMPARATOR|1|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of 1 to 6 months, the induction regimen will be MEC.
62107994|NCT00079482|ACTIVE_COMPARATOR|2|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of more than 6 months to 24 months, the induction regimen will be HiDAC.
62469929|NCT03644693|EXPERIMENTAL|Investigational|Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
62107995|NCT00651378|EXPERIMENTAL|Rosuvastatin|
62107996|NCT00651378|ACTIVE_COMPARATOR|Ezetimibe + Atorvastatin|
62107997|NCT00651378|ACTIVE_COMPARATOR|Double Atorvastatin|
62469930|NCT03644693|PLACEBO_COMPARATOR|Placebo|Subjects assigned to this arm will receive the Placebo Formulation.
62469931|NCT04694391||Recurrence|The period of recurrence was within 2 years after radiotherapy. Pathologic diagnosis was squamous cell carcinoma same with preradiotherapy.
62469932|NCT04694391||No recurrence|The period was more than 3 years after radiotherapy and no recurrence signs were observed.
62469933|NCT06093802|EXPERIMENTAL|DISE-guided treatment group|"DISE findings will be documented and obstruction scored per pediatric DISE criteria. Clinically relevant obstruction is defined as \>50% at minimum one site. (Adeno-)tonsillotomy will be performed if corroborative DISE suggests tonsil/adenoid obstruction; if not, no surgery will be performed.~This approach is maintained despite other identified obstruction sites, which will be assessed at a later stage."
62107998|NCT04517331|ACTIVE_COMPARATOR|Group S (single injection TPVB group)|Patients received bilateral single injection ultrasound-guided TPVB at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
62107999|NCT04517331|ACTIVE_COMPARATOR|Group D (double injection TPVB group)|Patients received bilateral double injection ultrasound-guided TPVB at the level of T2-T3 and T4-T5 with 10 mL bupivacaine 0.375% per injection (20 mL bupivacaine 0.375% per side as the single injection group).
62108000|NCT05603650|PLACEBO_COMPARATOR|Water rinse|rinse twice daily for 1 min with water
62108001|NCT05603650|EXPERIMENTAL|Lumineux Oral Essentials rinse|rinse twice daily for 1 min with Lumineux Oral Essentials rinse
62108002|NCT05603650|EXPERIMENTAL|Listerine rinse|rinse twice daily for 1 min with Listerine rinse
62108003|NCT02020018|EXPERIMENTAL|Prospective group|Negative pressure wound therapy (Prevena Incision Management System) applied immediately postoperatively.
62108004|NCT02020018|ACTIVE_COMPARATOR|Retrospective arm|Conventional sterile dry wound dressing applied immediately postoperatively.
62108005|NCT04280913||COVID-19 patients|Hospitalized patients with COVID-19
62108006|NCT03338218|EXPERIMENTAL|Volulyte 6%|Volulyte 6% solution for infusion
62108007|NCT03338218|ACTIVE_COMPARATOR|Ionolyte|Ionolyte solution for infusion
62108008|NCT04758897|EXPERIMENTAL|Single Arm|"1. 5.0\*10\^7 on D1~2. 1.0\*10\^8 on D1~3. 2.0\*10\^8 on D1~4. 2.0\*10\^8 on D1 and D2~5. 2.0\*10\^8 on Days 1 to 3~6. 2.0\*10\^8 on Days 1 to 4~7. 2.0\*10\^8 on Days 1 to 5"
62108009|NCT03198546|OTHER|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 and TGFβ targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
62108010|NCT04628858||Primary group|
62108011|NCT05381701||Group I|Minimal Flow Anesthesia (0.25L/dk oxygen, 0,25 L/min air)
62108012|NCT05381701||Group II|Low Flow Anesthesia (0.5L/dk oxygen, 0,5 L/min air)
61914324|NCT04232709|EXPERIMENTAL|After-hours care w/personal health info|Patients in the after-hours care with personal health information (AH-PHI) group will also receive the usual (telemedicine) care. However, if they call the telemedicine service, the oncology nurses will have access to some of their personal health information from the cancer centre (i.e., a shared electronic patient record) via the MedChart platform.
62469934|NCT06093802|ACTIVE_COMPARATOR|Non-DISE-guided treatment group|"DISE findings will be documented, and video material will be saved for later assessment.~Patients will be operated according to current guidelines (s.o.), regardless of perioperative DISE findings, i.e. tonsillotomy +/- adenoidectomy."
62469935|NCT00304603||Patients from previous topiramate obesity and diabetes studies|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study.
62469936|NCT03723993|PLACEBO_COMPARATOR|Control group|control group will have non inflated cuff around the arm.
62469937|NCT03723993|ACTIVE_COMPARATOR|RIPC group|Inflated cuff will be done systematically and regularly
62669765|NCT06103682|EXPERIMENTAL|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
62669766|NCT02869139|EXPERIMENTAL|Package of mentholated measures|Package of mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
62669767|NCT02869139|ACTIVE_COMPARATOR|Package of non-mentholated measures|Package of non-mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
62669768|NCT03752931|ACTIVE_COMPARATOR|Celiprolol|receiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
62669769|NCT03752931|ACTIVE_COMPARATOR|Diltiazem|receiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.
62669770|NCT01127061|EXPERIMENTAL|Exercise Training|Participants in the exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The protocol will be custom designed in consultation with an exercise physiologist based on data from the initial cardiopulmonary stress test. Exercise regimen will begin at a low level of intensity then increase in duration and training intensity to a goal of 60 minutes a day and 70% of the heart rate reserve during the 1st month of the study protocol with maintenance of the program thereafter. There is no need to come to a participating site for actually doing the exercise regimen. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
62669771|NCT01127061|NO_INTERVENTION|Usual Activity|Participants in this group are not restricted in their activities. They simply are not guided in their physical activities by the study team. At the end of the 4 month study period, they will also receive an individualized exercise prescription for personal use.
62108013|NCT05381701||Group III|Medium Flow Anesthesia (1L/dk oxygen, 1 L/min air
62108014|NCT05455346|EXPERIMENTAL|Romanian Deadlift|The training intervention groups will undergo the same program with the only difference being the interventional hamstring exercise. The program will consist of a 2-week acclimatization period followed by 4-weeks of progressive training. The RDL will be performed with a 6 second eccentric component with the athlete returning to the start position with a maximal concentric hip extension.
62299403|NCT01455350|ACTIVE_COMPARATOR|Lidocaine|10 week treatment of daily application of topical lidocaine
62669772|NCT04995107|EXPERIMENTAL|Electro-Press Needle group|Body acupoints of Yintang (GV29), Dazhui (GV14), Guanyuan (CV4), bilateral Zigong (EX-CA1), and bilateral Sanyinjiao (SP6) and auricular acupoints of Heart (CO15), Chuiqian (LO4) and Shenmen (TF4) will be selected for treatment. Auricular acupoints on right and left ear will be stimulated alternatively, one side on each time.The treatment will last 40mins for each session, 3 sessions a week (ideally every other day) for a succession of 6 weeks.
62669773|NCT04995107|NO_INTERVENTION|Waiting-list group|Participants in the waiting-list group will receive no intervention for 6 weeks and be followed up till weeks 30.
62669774|NCT05998499||EuroLatin HIV Cohort (ELHC)|Cohort of Latin American migrants living with HIV who were seeking international protection in Spain (Europe)
62669775|NCT02636491|EXPERIMENTAL|investigational device|"MD-Logic-Automated Insulin Delivery System, Version 01.05.02~The device is being used continuously over 60 hours for insulin therapy"
62669776|NCT02636491|PLACEBO_COMPARATOR|MiniMed Paradigm® Veo™ System|"sensor augmented insulin pump~The device is being used continuously over 60 hours for insulin therapy"
62669777|NCT02544724|EXPERIMENTAL|NM-IL-12|NM-IL-12 will be administered subcutaneously
62669778|NCT05363800|EXPERIMENTAL|HRS-3738|"In dose Escalation:~HRS-3738 will be taken in oral. Seven dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
62669779|NCT06093659|EXPERIMENTAL|Product use sequence ABECD|Subjects use Product A on Day 1, Product B on Day 2, Product E on Day 3 and Product C on Day 4 and Product D on Day 5.
61914325|NCT04564768|EXPERIMENTAL|Intervention group|Online Mindfulness-Based Cancer Recovery
61914326|NCT04564768|NO_INTERVENTION|Control group|Treatment as usual
61914327|NCT05428189|EXPERIMENTAL|Guided Biofilm Therapy (GBT)|The subjects receive professional oral hygiene guided by plaque a disclosing agent, using air-polishing and a ultrasonic device
62299404|NCT01455350|EXPERIMENTAL|Multimodal physiotherapy|10 weeks of weekly multimodal physiotherapy treatments
62469938|NCT02265783|OTHER|Nellcor USB Pulse Oximeter Monitor Interface Cable Sensor Test|
62469939|NCT01602419||Patients using Wilate as standard of care treatment|This patient population is being treated with Wilate as standard of care treatment
62669780|NCT06093659|EXPERIMENTAL|Product use sequence BCADE|Subjects use Product B on Day 1, Product C on Day 2, Product A on Day 3 and Product D on Day 4 and Product E on Day 5.
62669781|NCT06093659|EXPERIMENTAL|Product use sequence CDBEA|Subjects use Product C on Day 1, Product D on Day 2, Product B on Day 3 and Product E on Day 4 and Product A on Day 5.
62669782|NCT06093659|EXPERIMENTAL|Product use sequence DECAB|Subjects use Product D on Day 1, Product E on Day 2, Product C on Day 3 and Product A on Day 4 and Product B on Day 5.
62669783|NCT06093659|EXPERIMENTAL|Product use sequence EADBC|Subjects use Product E on Day 1, Product A on Day 2, Product D on Day 3 and Product B on Day 4 and Product C on Day 5.
61914328|NCT05428189|ACTIVE_COMPARATOR|Air Polishing and Ultrasonic Debridment|The subject receive professional oral hygiene using air-polishing and a ultrasonic device
62299405|NCT03607227|ACTIVE_COMPARATOR|Local anesthetic|Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
62299406|NCT03607227|PLACEBO_COMPARATOR|Saline|Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as in the active substance arm.
62669784|NCT05474677|EXPERIMENTAL|intervention group|intervention group with the abdomen will be closed with continuous PDS 2\\0 sutures
62669785|NCT05474677|EXPERIMENTAL|control group|the abdomen will be closed with continuous sutures size zero
62669786|NCT02785705|EXPERIMENTAL|cIPV-bOPV-bOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two bivalent types 1 and 3 oral poliovirus vaccine sequentially.
62669787|NCT02785705|EXPERIMENTAL|cIPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
61914329|NCT03121976|EXPERIMENTAL|Ultrasound|Femoral catheters inserted using ultrasound only
61914330|NCT03121976|ACTIVE_COMPARATOR|Ultrasound + Nerve Stimulation|Femoral catheters inserted using ultrasound with nerve stimulation
61914331|NCT02940106|PLACEBO_COMPARATOR|closed device|Standard cryopreservation system.
61914332|NCT02940106|ACTIVE_COMPARATOR|open device|New cryopreservation system.
61914333|NCT02814500|EXPERIMENTAL|A group|Amlodipine and Rosuvastatin, DP-R212
61914334|NCT02814500|EXPERIMENTAL|B group|DP-R212, Amlodipine and Rosuvastatin
61914335|NCT05999162||Minimally invasive surgery (MIS)|The patients underwent minimally invasive surgery for the treatment of colorectal cancer.
61914336|NCT05999162||Traditional open surgery (TOS)|The patients underwent traditional open surgery for the treatment of colorectal cancer.
61914337|NCT01903252|EXPERIMENTAL|TP05 (Mesalazine) 1600mg|week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
61914338|NCT01903252|ACTIVE_COMPARATOR|Asacol 400 mg (Tillotts Pharma)|week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
61914339|NCT03513081|EXPERIMENTAL|Educative Session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child tasted it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
61914340|NCT03513081|NO_INTERVENTION|Control|Children in the control group don´t receive an educative session. Before the study starts children are asked to eat a salad. After 9 weeks, all children in the control group will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
61914341|NCT05409560||Cold water swimmers|swimmers participating in the 6-hour cold water swim, qualifying for the English Channel Swim
61914342|NCT01670578|EXPERIMENTAL|PRP Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
61914343|NCT01670578|ACTIVE_COMPARATOR|Hyaluronan Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
62469940|NCT02424097|EXPERIMENTAL|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
61914344|NCT03814421|EXPERIMENTAL|Low dose intermittent|Pantoprazole 40mg as a bolus injection daily for 72hours
61914345|NCT03814421|ACTIVE_COMPARATOR|High dose continous|Pantoprazole 40mg as a bolus injection followed by continuous infusion at 8mg/hr for 72hours
61914346|NCT01082822|SHAM_COMPARATOR|standard of care|In the first step, the patient was periodontally treated until the inflammation was eliminated through control of bacterial biofilm and oral hygiene for about 6 months. Then the rigid fixed appliances were placed on the diseased teeth, reverse beveled open-flap surgery was performed in the buccal and palatal maxillary sides of the periodontitis-caught teeth to allow granulation tissue debridement and proper root preparation. The roots were completely scaled, and 17%EDTA was applied for 2 minutes to demineralize the root surfaces and bone wall defects, the flap was sutured.
61914347|NCT01082822|EXPERIMENTAL|PDLSC cell sheet transplantion|Periodontal ligament stem cell derived cell sheet or pellet with carrier such as Bioss was implanted into periodontal defect area at post surgical treatment.
61914348|NCT01082822|EXPERIMENTAL|the bio-ss implantation|implantation of Bioss at post surgical treatment
62108015|NCT05455346|ACTIVE_COMPARATOR|Nordic Hamstring Exercise|The training intervention groups will undergo the same program with the only difference being the interventional hamstring exercise. The program will consist of a 2-week acclimatization period followed by 4-weeks of progressive training. During the acclimatization period, the relative intensity will be lower compared to the 4-week progressive training to ensure each participant performs the exercise with proper technique. During the subsequent progressive training weeks, the participants will perform the NHE without the bands.
62108016|NCT02611414|EXPERIMENTAL|anodal tDCS|TDCS will be delivered with two saline-soaked sponge electrodes. The main electrode to anodal stimulation will be placed over the motor cortex, M1. The second electrode is neutral and will be placed on the skin overlying the supraorbital region The current will be delivered at the intensity of 2mA for 20 minutes. The procedure will be repeated at five consecutive days.
62108017|NCT02611414|SHAM_COMPARATOR|Sham tDCS|Two electrodes are positioned at M1 and supra-orbital área. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. The procedure will be repeated at five consecutive days.
62108018|NCT04208243|EXPERIMENTAL|Oncology Patient|Any Oncology patient in the CCBD who has not previously received more than two sessions of CAT in the outpatient unit and who will be receiving approximately weekly infusions of at least one hour in the infusion center will be identified by a research assistant.
62108019|NCT03317639|EXPERIMENTAL|an intervention arm|Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model
61914349|NCT04250077|EXPERIMENTAL|CRAFT-A|"Participants assigned to the CRAFT-A will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1)Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.~CRAFT-A participants also attend a weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations."
61914350|NCT04250077|EXPERIMENTAL|CRAFT-C|"Participants assigned to the CRAFT-C groups will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.~CRAFT-C participants attend a weekly 60-minute individualized on-on-one coaching session with a CRAFT certified coach. During weekly individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations. One-on-one sessions involve role-plays that are tailored to the participants' specific circumstances"
61914351|NCT04250077|ACTIVE_COMPARATOR|PEER|"Participants assigned to the PEER group will participate in an online peer support forum with other CSOs.~Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully. This individual also will report any adverse or severe adverse events that members mention online."
61914352|NCT02250833|EXPERIMENTAL|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
61914353|NCT02250833|ACTIVE_COMPARATOR|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
61914354|NCT01371032|ACTIVE_COMPARATOR|Video-Miller laryngoscope|using the screen (Video laryngoscopy group)
61914355|NCT01371032|ACTIVE_COMPARATOR|Direct laryngoscopy|without use the screen (Direct laryngoscopy group)
61914356|NCT00130312|EXPERIMENTAL|Sulodexide|Also known as KRX-101. These patients are also on ACEs and ARBs (irbesartin and/or losartan).
61914357|NCT00130312|PLACEBO_COMPARATOR|Placebo|These patients are also on ACEs and ARBs (irbesartin and/or losartan).
61914358|NCT05232370|NO_INTERVENTION|Control Group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to control group (Without losartan or enalapril)"
61914359|NCT05232370|EXPERIMENTAL|Enalapril group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to Enalapril group"
61914360|NCT05232370|EXPERIMENTAL|Losartan group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to Losartan group"
61914361|NCT00311298|PLACEBO_COMPARATOR|No micronutrients|Biscuit without additional micronutrients
61914362|NCT00311298|EXPERIMENTAL|Micronutrients|Biscuit with additional micronutrients
61914363|NCT00311298|ACTIVE_COMPARATOR|1 biscuit|1 biscuit with micronutrients
61914364|NCT00311298|EXPERIMENTAL|6 biscuits|1 biscuit with micronutrients, plus 5 biscuits without additional micronutrients
62299407|NCT06656195|EXPERIMENTAL|experimental group A|In week 1 SIJ Mobilization along with ,Single leg bridge ,alternating leg lifts ,clam Exercise,Prone hip extension with knee flexion. In week 2 SIJ Mobilization along with Side-squats,Star excursion exercise,Forward step-down.In week 3 SIJ Mobilization along with bilateral squat ,single leg squat ,split squat/lunge ,frontal step up ,lateral step up.In week 4 SIJ mobilization along with bilateral squat with a band and hip extension against resistance was done.Three times a week for 4 weeks In each session, a total of two sets of 12 repetitions each were carried out, with a 1 min rest time between sets.
62669788|NCT02785705|EXPERIMENTAL|cIPV-cIPV-bOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one bivalent types 1 and 3 oral poliovirus vaccine sequentially.
62108020|NCT03317639|NO_INTERVENTION|a control arm|hospitals in the control arm will receive no intervention and maintain existing care
62108021|NCT01245439|EXPERIMENTAL|1|
62108022|NCT00722215|PLACEBO_COMPARATOR|1|Placebo control arm of study
62108023|NCT00722215|EXPERIMENTAL|2|BQ-123 arm of study
62108024|NCT00722215|ACTIVE_COMPARATOR|3|Nifedipine arm of study
62108025|NCT03180905|EXPERIMENTAL|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
62108026|NCT03180905|ACTIVE_COMPARATOR|Test/Re-Test|ImPACT Online will be administered at 2 time points
62299408|NCT06656195|ACTIVE_COMPARATOR|experimental group B|SIJ mobilization and Soft tissue mobilization along with Static Hamstrings stretching (3 sets, 15 repetitions with a holding time of 15 seconds ,3 times a week for 4 week) and Dynamic hamstrings stretching(3 set, 15 repetitions with a holding time of 1 second, 3 times a week for 4 weeks.
62669789|NCT02785705|EXPERIMENTAL|cIPV-cIPV-tOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
62669790|NCT02785705|EXPERIMENTAL|cIPV-cIPV-cIPV poliovirus vaccine|Participants would be vaccine with three shots of trivalent conventional inactivated poliovirus vaccine.
62108027|NCT04895007||Group, vaccinated with Inactive Vaccine (Sinovac Life Sciences, Beijing, China).|- Any person, male or female, over 18 years of age, were vaccinated with Inactive Vaccine.
62108028|NCT04895007||Group, vaccinated with recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V).|- Any person, male or female, over 18 years of age, were vaccinated with recombinant human adenovirus serotype number 26.
62108029|NCT04895007||Group, vaccinated with mRNA Vaccine (Pfizer/BionTEC).|- Any person, male or female, over 18 years of age, were vaccinated with mRNA Vaccine.
62299409|NCT01475955|EXPERIMENTAL|Broad Area ALA 1-hour incubation|Broad Area ALA 1-hour incubation
62299410|NCT01475955|EXPERIMENTAL|Broad Area ALA 2-hour incubation|Broad Area ALA 2-hour incubation
62299411|NCT01475955|EXPERIMENTAL|Broad Area ALA 3-hour incubation|Broad Area ALA 3-hour incubation
62299412|NCT01475955|EXPERIMENTAL|Spot ALA 2-hour incubation|Spot ALA 2-hour incubation
62299413|NCT01475955|PLACEBO_COMPARATOR|Vehicle PDT|VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
62469941|NCT02424097|ACTIVE_COMPARATOR|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
62469942|NCT00029198|EXPERIMENTAL|1|15 minute massage tid
62669791|NCT02785705|EXPERIMENTAL|tOPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with three times of trivalent types 1, 2 and 3 oral poliovirus vaccine .
62669792|NCT02500355|ACTIVE_COMPARATOR|Group A|Carpal Tunnel Release via limited approaches with 2 years follow-up.
62669793|NCT02500355|ACTIVE_COMPARATOR|Group B|Carpal Tunnel Release via standard approach with 2 years follow-up.
62669794|NCT02500355|PLACEBO_COMPARATOR|Group C|Endoscopic Carpal Tunnel Release with 2 years follow-up.
62669795|NCT01802671|EXPERIMENTAL|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways: a web tool named TEO (Emotional Therapy Online) and SMS that will send to the patients' mobile phone with reminders and reinforcements.
62669796|NCT01802671|ACTIVE_COMPARATOR|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment and information
61914365|NCT06294743|EXPERIMENTAL|Group-1|Posterior tibial nerve neuroprolotherapy will be administered during the first two menstrual cycles, followed by oral acetaminophen (500mg) for the subsequent two menstrual cycles
62669797|NCT01802671|EXPERIMENTAL|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT.
62669798|NCT03061851|EXPERIMENTAL|conventional treatment|given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
62669799|NCT03061851|EXPERIMENTAL|conventional treatment + maltose app|the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.
62669800|NCT06302361|EXPERIMENTAL|Lymphovenous anastomosis (LVA)|Intervention with lymphovenous anastomosis (LVA) surgery of the affected arm.
62108030|NCT04451889|EXPERIMENTAL|Confocal laser endomicroscopy diagnostic study|"Cohort 1: COVID-19 patients. Cohort 2: patients with lung diseases unrelated to COVID-19.~All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special Alveoflex miniprobe during the hospitalisation period. Records will be done and analysed prospectively with the included software for the endomicroscopic system.~Using Alveoflex is a minimally invasive intervention."
62108031|NCT00944801|EXPERIMENTAL|Pegylated Liposomal Doxorubicin|Radiotherapy is planned with dedicated computed tomography and three-dimensional planning systems and delivered to the gross tumor volume with a 2 to 3 cm margin for the clinical target volume. After a 4-week break, patients receive adjuvant TMZ 150 to 200 mg/m2 day 1 to 5 in 28 days until tumor progression or up to at least 12 cycles. In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
62669801|NCT01168180|EXPERIMENTAL|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
61914366|NCT06294743|EXPERIMENTAL|Group-2|Oral acetaminophen (500mg) will be given during the initial two menstrual cycles, followed by a transition to posterior tibial nerve neuroprolotherapy for the last two menstrual cycles.
62469943|NCT00029198|SHAM_COMPARATOR|2|non-massage touch
62669802|NCT01168180|ACTIVE_COMPARATOR|Ultrasound therapy and hot pack|The participants will receive thirty minutes session of Ultrasound therapy and hot pack for 9 sessions over a period of 3 weeks
62469944|NCT01768533||Survey|A lifestyle survey was administered to primary-care givers or legal guardians who take their children 4-10 y/o to the pediatric well-child visits.
62299414|NCT03311126|EXPERIMENTAL|Bendamustine + Obinutuzumab (BO)|"Induction chemoimmunotherapy (28 day cycles):~Bendamustine 90 mg/m2 IV days 1 \& 2 every 28 days X 4-6 cycles~Obinutuzumab:~* Cycle 1: 100 mg IV day 1, 900 mg IV day 2, 1000 mg IV days 8 \& 15~* Cycles 2-6: 1000 mg IV day 1~Consolidation phase:~Obinutuzumab 1000 mg IV weekly X 4 doses~Maintenance phase (8 week cycles):~Obinutuzumab 1000 mg IV on day 1 of cycles 1-8"
62299415|NCT01596491||patients with peripheral nerve injury|10 patients with neuropathic pain, because of peripheral nerve injury will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
62669803|NCT03519607|ACTIVE_COMPARATOR|Treatment Group|Participants who are in the intervention group will receive the FertiStrong app downloading instructions as soon as they have been randomized. They will have access to this app for a period of 30 days during the intervention phase of the study.
62669804|NCT03519607|NO_INTERVENTION|Control Group|Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
62669805|NCT06326918||Functional dyspepsia|"1. Patients who are 18 years old or more and exhibit at least one of the following four symptoms for the last 3 months, with symptom onset occurring at least 6 months prior to diagnosis.~   1.1 Postprandial distress syndrome (symptoms occurring at least 3 days per week), including:~  * Postprandial fullness and/or~  * Early satiation~   1.2 Epigastric pain syndrome (symptoms occurring at least 1 day per week), including:~  * Epigastric pain and/or~  * Epigastric burning~2. Participants undergo esophago-gastro duodenoscopy (EGD) to confirm the absence of any structural abnormalities."
62669806|NCT06326918||Control|"* Patients with no or minimal upper GI symptoms (not match the criteria of FD) and current EGD appear normal or insignificant gastritis~* Age- and sex-matched to the functional dyspepsia (FD) patient group."
62669807|NCT04687397||Disorders of consciousness|Patients diagnosed as either in a Vegetative State or in a Minimally Conscious State
62669808|NCT01666600|EXPERIMENTAL|BIBF 1120 + reirradiation|2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
62669809|NCT01666600|ACTIVE_COMPARATOR|reirradiation alone|radiotherapy (2 Gy / fraction; 36 Gy in total)
62669810|NCT02503930|EXPERIMENTAL|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
62669811|NCT02503930|SHAM_COMPARATOR|Sham tDCS|The Sham tDCS - an inactive stimulation.
62669812|NCT03751787|EXPERIMENTAL|cranial osteopathy|The group will receive treatment with osteopathic cranial osteopathy
62669813|NCT03751787|PLACEBO_COMPARATOR|comfort massage|The group will benefit from a placebo manipulation by an osteopathic student who has not yet been trained in cranial osteopathy.
62669814|NCT01828684|EXPERIMENTAL|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
62669815|NCT01828684|SHAM_COMPARATOR|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
62669816|NCT01604200||Dentists|Dentists in practice
62669817|NCT06444100|EXPERIMENTAL|Intervention|The intervention arm will undergo training on child abuse led by an expert group, while the control arm will not receive this training. Both groups will undergo pre-testing before the intervention, followed by post-testing two weeks after the training period.
62669818|NCT06444100|NO_INTERVENTION|Control|The control arm will not get any training.
62669819|NCT00689988|EXPERIMENTAL|SG|Study Group: five children with Down syndrome submitted to speech-language intervention with AAC intervention
62299416|NCT01596491||patients with postherpetic neuralgia|10 patients with neuropathic pain, because of postherpetic neuralgia will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
62299417|NCT05135364|EXPERIMENTAL|Camrelizumab+HAIC+TKI*|\*For patients who have not received molecular targeted therapy in the past, lenvatinib is recommended; For patients who have received sorafenib or lenvatinib in the past, regorafenib is recommended.
62299418|NCT01650805|EXPERIMENTAL|ponatinib|
62299419|NCT01650805|ACTIVE_COMPARATOR|imatinib|
62299420|NCT06310369|EXPERIMENTAL|Radiotherapy arm|Radiation therapy will be given covering the whole bladder over 4 weeks. The use of a radiosensitizing agent is mandatory.
62669820|NCT02571231|EXPERIMENTAL|HFV+vg|volume guarantee given
62669821|NCT02571231|EXPERIMENTAL|HFV-VG|Volume guarantee not given
62669822|NCT02569242|EXPERIMENTAL|Nivolumab Arm|Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62669823|NCT02569242|ACTIVE_COMPARATOR|Active Comparator Arm （Docetaxel/Paclitaxel）|"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~OR~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
62669824|NCT03362593|EXPERIMENTAL|MEDI7219|Experimental Drug
62669825|NCT03362593|PLACEBO_COMPARATOR|Placebo|Placebo
62669826|NCT03362593|PLACEBO_COMPARATOR|Formulation without Active Drug|Formulation without Active Drug
62669827|NCT03364010|EXPERIMENTAL|Dyslexic and non dyslexic Children|Children aged 10-12 Evaluation of proprioception Evaluation of motor learning Evaluation of written language
62108032|NCT06555471|EXPERIMENTAL|combination therapy sintilimab combined with chemotherapy and radiotherapy|"Sintilimab (200mg iv q3w d1) combined with chemoradiation. The application of chemotherapy based on investigator's assessment, and if so, S-1 (po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time) or capecitabine （1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.); Radiotherapy：once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy.~Maintenance therapy with sintilimab in combination with S-1 (po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time) or capecitabine （1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.) up to 2 years."
62108033|NCT05250817||Cohort 1|Participants with early stage and advanced/metastatic non-small cell lung cancer (NSCLC)
62108034|NCT05250817||Cohort 2|Participants from the general population
62108035|NCT03764943|EXPERIMENTAL|Immunonutrition Intervention|Participants will consume 3 'Impact Advanced Recovery' shakes daily for 5 days prior to surgery 2 hours prior to surgery.
62108036|NCT03357224|EXPERIMENTAL|Experimental: Atezolizumab|The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
62299421|NCT06189443|NO_INTERVENTION|Traditional lifestyle changes and kegel exercise recommended group|Patients with stress urinary incontinence will be given a brochure that will be prepared similar to the brochure given to the Intervention group.
62669828|NCT03930108||Mortality outcome|
62669829|NCT05872399||Physiotherapy students|The group will consist of Greek physiotherapy undergraduate students.
62669830|NCT04086459|ACTIVE_COMPARATOR|Active repetitive transcranial magnetic stimulation|
62669831|NCT04086459|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation|
62108037|NCT01111903|EXPERIMENTAL|lenalidomide|Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
62108038|NCT04667065|OTHER|Physical activity with smartwatch before bronchial cancer surgery|
62108039|NCT06345612|EXPERIMENTAL|1. exercise in hypoxia with creatine supplementation|"* training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above sea level (indoor air composition: 15,4% of O2 and 84,7% of N)~* with creatine supplementation"
62669832|NCT04086459|NO_INTERVENTION|No repetitive transcranial magnetic stimulation|
62108040|NCT06345612|EXPERIMENTAL|2. exercise in hypoxia without creatine supplementation|"* training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above sea level (indoor air composition: 15,4% of O2 and 84,7% of N)~* without creatine supplementation"
62108041|NCT06345612|EXPERIMENTAL|3. exercise in normoxia with creatine supplementation|"* the same training program in normoxic conditions~* with creatine supplementation"
62108042|NCT06345612|EXPERIMENTAL|4.exercise in normoxia without creatine supplementation|"* the same training program in normoxic conditions~* without creatine supplementation"
62108043|NCT06554067|EXPERIMENTAL|Group +/+|Group +/+ will receive ten minutes of active tDCS followed by ten minutes of active VNS.
62669833|NCT05157763|EXPERIMENTAL|EscharEx 5%|The powder of EX-02 (4 g per vial) should be reconstituted with 10 ml water for injection (WFI) to obtain 5% EX-02 gel. The EX-02 powder and the WFI are to be mixed up to 15 min prior to use. EX-02 5% gel will be topically applied in a thick layer of 2-3 mm on the lesion surface including margin of 5-10 mm for 8-12 hours (preferable over-night) and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
62669834|NCT06235541|EXPERIMENTAL|GENA104|80 patients in total with histologically/cytologically confirmed unresectable, recurrent, or metastatic advanced solid tumors, for who no standard therapy exists, or standard therapy has failed will be enrolled in this study.
62669835|NCT01243125|EXPERIMENTAL|NVC-422|
62669836|NCT01243125|PLACEBO_COMPARATOR|Saline|
62669837|NCT03688113|EXPERIMENTAL|Treatment|
62669838|NCT03688113|OTHER|Wait list|
62669839|NCT01087450||Stage1|1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
62669840|NCT01087450||Stage 2 Randomized, blinded trial|Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment
62669841|NCT02923180|EXPERIMENTAL|Enoblituzumab|Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.
62669842|NCT05018559|EXPERIMENTAL|Intervention group nursing care|Participants receive a co-created physical activity intervention called BuG lesson (German: 'Bewegt und Gesund'-Stunde; English: PA and health lesson).
62669843|NCT05018559|NO_INTERVENTION|Control group nursing care|Participants do not receive any treatment in addition to their vocational education and training curriculum.
62669844|NCT05018559|EXPERIMENTAL|Intervention group automotive mechatronics|Participants receive a co-created physical activity intervention called tutoring system.
62669845|NCT05018559|NO_INTERVENTION|Control group automotive mechatronics|Participants do not receive any treatment in addition to their vocational education and training curriculum.
62669846|NCT03899597|EXPERIMENTAL|artificial contractions (ARTCON) group|All participating patients in the intervention (ARTCON) group will undergo oxytocin exposure in the form of a continuous intravenous infusion according to dosage guidelines of The Czech Society of Obstetrics and Gynaecology. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed in order for the assumed effects of physiological stress associated with labor to occur.
62669847|NCT03899597|PLACEBO_COMPARATOR|standard approach (SA) group|All participating patients in the control (SA) group will undergo placebo exposure in the form of a continuous intravenous infusion. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed.
62669848|NCT03682081|NO_INTERVENTION|Usual care|Usual care groups will receive standard swallowing interventions identified by the Speech-Language Pathologist as appropriate to treat the patient's dysphagia and common in clinical practice. Such treatment would likely consist of dietary (e.g., thickened liquids or pureed foods) or postural compensatory strategies (e.g., chin down posture while swallowing). No progressive lingual strengthening approaches or regimented salivary substitute protocols are utilized.
62669849|NCT03682081|EXPERIMENTAL|Saliva Substitute Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied to the oral cavity regularly for 8 weeks.
62669850|NCT03682081|EXPERIMENTAL|Lingual Strengthening Intervention|Patient-caregiver dyads will be trained in the lingual strengthening protocol and patients will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
62669851|NCT03682081|EXPERIMENTAL|Saliva Substitute and Lingual Strengthening Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied regularly to the oral cavity for 8 weeks. Each dyad will also be trained in the lingual strengthening protocol and will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
62669852|NCT04319536||Healthy individuals|
62669853|NCT05399355|ACTIVE_COMPARATOR|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
62108044|NCT06554067|ACTIVE_COMPARATOR|Group +/-|Group +/- will receive ten minutes of active tDCS followed by ten minutes of sham VNS.
62108045|NCT06554067|ACTIVE_COMPARATOR|Group -/+|Group -/+ will receive ten minutes of sham tDCS followed by ten minutes of active VNS.
62669854|NCT05399355|SHAM_COMPARATOR|Sham Treatment|Application of 7-30 days of a nonfunctional sham device.
62669855|NCT03192020|EXPERIMENTAL|Percutaneous needle fasciotomy (PNF)|PNF is a treatment in which the Dupuytren's contracture cord causing the contracture is not excised, but only divided with a hypodermic needle.
62669856|NCT03192020|EXPERIMENTAL|Collagenase clostridium histolyticum (CCH)|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times. One injection is performed normally at least to three different places in the cord.
62108046|NCT06554067|SHAM_COMPARATOR|Group -/-|Group -/- will receive ten minutes of sham tDCS followed by ten minutes of sham VNS.
62669857|NCT03192020|ACTIVE_COMPARATOR|Limited fasciectomy (LF)|In LF, the thickened part of the palmar fascia causing the contracture is excised through skin incision.
62669858|NCT01574521||Only father carrier|fetuses whose fathers were HBV carriers whereas mothers negatively.
62669859|NCT01574521||only mother carrier|fetuses whose mothers were HBV carriers whereas fathers negatively.
62669860|NCT01574521||both parents carriers|fetuses whose both parents were HBV carriers
62669861|NCT01793922|ACTIVE_COMPARATOR|PD|pneumodilation
62108047|NCT00964366|EXPERIMENTAL|Clindamycin/BPO gel|Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
62108048|NCT00964366|ACTIVE_COMPARATOR|Dapsone gel|Twice-daily applications of dapsone gel to one side of the face.
62108049|NCT02048709|EXPERIMENTAL|GDC-0919 Dose Escalation|GDC-0919 to be given on an outpatient basis as a single agent. Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour. Patients will receive the study drug daily for 21 days followed by 7 days off for a cycle length of 28 days; or on 28 consecutive days of a 28-day cycle
62669862|NCT01793922|ACTIVE_COMPARATOR|POEM|peroral endoscopic myotomy
62669863|NCT02663167|EXPERIMENTAL|Internet-delivered Cognitive-Behavioral Therapy|
62669864|NCT01839266||acute PE survivor, acute PE nonsurvivor|acute PE survivor, acute PE nonsurvivor (in-hospital death)
62669865|NCT01263379|EXPERIMENTAL|LEAES treatment|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
62669866|NCT04359615|EXPERIMENTAL|Favipiravir|
62669867|NCT04359615|ACTIVE_COMPARATOR|Control|
62669868|NCT04920994|ACTIVE_COMPARATOR|Group A (M-TAPA )|Ultrasound-guided M-TAPA block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
62669869|NCT04920994|ACTIVE_COMPARATOR|Group B (SCTAP)|Ultrasound-guided SCTAP block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
62669870|NCT01023464|OTHER|Period 1|FID 114657 or SootheXP
62108050|NCT05579886|ACTIVE_COMPARATOR|Control Lens|All participants wore the Control Lens for 2 weeks (Period 1)
62108051|NCT05579886|EXPERIMENTAL|Test Lens|All participants wore the Test Lens for 2 weeks (Period 2)
62108052|NCT06281821|EXPERIMENTAL|Mobile App Intervention|Mobile health intervention delivered through an app
62108053|NCT06281821|NO_INTERVENTION|Control|Assessment Only Control condition
62108054|NCT00183638|EXPERIMENTAL|1|Participants will receive Internet-based tailored prevention messages
62669871|NCT01023464|OTHER|Period 2|FID 114657 or SootheXP
62669872|NCT04831385|EXPERIMENTAL|CBT-i|
62669873|NCT04831385|NO_INTERVENTION|Control (Usual Care)|Control
62669874|NCT02247856|ACTIVE_COMPARATOR|Control Group|Noninvasive ventilation+ jet nebulizer
62669875|NCT02247856|EXPERIMENTAL|Experimental Group|Noninvasive ventilation+ Vibrating Mesh Nebulizer (VMN)
62669876|NCT03297827||Patients with stroke|Adult stroke patients with the stroke diagnosis will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
62669877|NCT03297827||Patients without stroke|Age/Sex matched adult control patients without the diagnosis of stroke, myocardial infarction, inflammatory flare, acute trauma, neurodegenerative or neuroinflammatory disease (AD, PD, TM, PSP, etc.) except MS will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
62669878|NCT05860530|OTHER|Test-reference|Administration order: The test olaparib tablets for 7 days, then the reference olaparib tablets for 7 days.
62108055|NCT00183638|ACTIVE_COMPARATOR|2|Participants will receive non-tailored messages containing information on reproductive health
62108056|NCT00003656|EXPERIMENTAL|All subjects|Weekly ATRA-IV with recombinant interferon alfa
62669879|NCT05860530|OTHER|Reference-test|Administration order: The reference olaparib tablets for 7 days, then the test olaparib tablets for 7 days.
62669880|NCT02846727||Sepsis Group|This group will consist of surgical intensive care patients with diagnosis of sepsis, severe sepsis, or septic shock.
62669881|NCT02846727||Control Group|This group will consist of patients that serve as controls who do not have diagnosis of sepsis, severe sepsis, or septic shock.
62669882|NCT02056522||Suspicious skin lesions.|No intervention is administered.
62669883|NCT04626778|ACTIVE_COMPARATOR|Peroxyl|1.5% Hydrogen Peroxide mouthwash
62669884|NCT04626778|PLACEBO_COMPARATOR|placebo mouthwash|0.0% Hydrogen peroxide mouthwash
62669885|NCT00971503|SHAM_COMPARATOR|saline injection|
62669886|NCT00971503|EXPERIMENTAL|Autologous bone marrow implantation|
62669887|NCT01196234|EXPERIMENTAL|Paclitaxel/Carboplatin/Gefitinib|Paclitaxel/Carboplatin/Gefitinib
62669888|NCT01196234|ACTIVE_COMPARATOR|Paclitaxel/Carboplatin|Paclitaxel/Carboplatin
62108057|NCT00197015|ACTIVE_COMPARATOR|HAV Group|Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)
62669889|NCT01827943|EXPERIMENTAL|Temsirolimus|Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.
62669890|NCT03150797|EXPERIMENTAL|Melatonin 3mg|Melatonin 3mg
62669891|NCT03150797|EXPERIMENTAL|Melatonin 6mg|Melatonin 6mg
62108058|NCT00197015|EXPERIMENTAL|HAV+MMR+V Group|Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9
62108059|NCT00197015|ACTIVE_COMPARATOR|MMR+V→HAV Group|Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)
62108060|NCT00009984|EXPERIMENTAL|Arm I (thalidomide)|Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
62108061|NCT00009984|EXPERIMENTAL|Arm II (thalidomide, fludarabine phosphate)|Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
62669892|NCT03150797|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo
62108062|NCT02989961|EXPERIMENTAL|A-Resticutis|Autologous, Activated-Platelets type of preparation.
62108063|NCT02989961|PLACEBO_COMPARATOR|C-Platelet-Poor Plasma PPP|Platelet-Poor Plasma type of preparation achieved by centrifugation of blood samples at high speed conditions. Resticutis is administered instead if the patient doesn't achieve full healing after 6 injections.
62108064|NCT02786693||FUO and SII patients|Patients with fever \> 38,3°C for more than a week, OR CRP\> 5mg/L, without diagnosis after a first step clinical examination and paraclinical exams.
62669893|NCT00509600|EXPERIMENTAL|Etanercept|0.8 mg/kg subcutaneously weekly for 90 days
62669894|NCT01762007||6Mo-2Yr old penile hypospadias patients before operation|
62108065|NCT00678158|EXPERIMENTAL|1|Patients with metastatic disease to soft tissue.
62108066|NCT00678158|EXPERIMENTAL|2|Patients with metastatic disease to lymph nodes.
62108067|NCT00678158|EXPERIMENTAL|3|Patients with metastatic disease to the bone.
62108068|NCT01465243|EXPERIMENTAL|Icotinib|This is a single arm study.
62108069|NCT04044664|PLACEBO_COMPARATOR|Placebo|
62108070|NCT04044664|EXPERIMENTAL|NYX-783 Low Dose (10 mg QD)|
62108071|NCT04044664|EXPERIMENTAL|NYX-783 High Dose (50 mg QD)|
62108072|NCT06630559|EXPERIMENTAL|CT-P55|
62108073|NCT06630559|ACTIVE_COMPARATOR|EU-approved Cosentyx|
62108074|NCT05640817|ACTIVE_COMPARATOR|Group 1 as control group|cisplatin with standard hydration with normal saline
62669895|NCT01762007||6Mo-2Yr old male patients without hypospadias|
62669896|NCT01762007||penile hypospadias patients under the age of 5 Yr|penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed
62669897|NCT01762007||2Yr-5Yr old male patients without hypospadias|
62108075|NCT05640817|ACTIVE_COMPARATOR|Group two as Pentoxifylline|receive cisplatin with standard hydration with normal saline and Pentoxifylline 400 mg SR tablets twice daily for three cycles.
62299422|NCT06189443|ACTIVE_COMPARATOR|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
62669898|NCT04797728|EXPERIMENTAL|Elacestrant|400 mg given orally (PO), once a day, in a continuous schedule (QD). 4 weeks (+/- 2 days) of elacestrant treatment
62669899|NCT05105932||EIT group|patients went through EIT detection
62669900|NCT05105932||CTPA group|patients went through CTPA detection
62669901|NCT01653262|EXPERIMENTAL|Brivaracetam|"The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily.~Based on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed.~At the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks."
62669902|NCT01362270|EXPERIMENTAL|Verum Acupuncture|Subjects will receive acupuncture using real acupuncture needles.
62669903|NCT01362270|SHAM_COMPARATOR|Sham acupuncture|Subjects will receive sham acupuncture therapy using the Streitberger needle at the same points and on the same schedule as patients in the treatment group. Streitberger needles are blunt tipped and retract into themselves rather than penetrating the skin.
62299423|NCT02086227|EXPERIMENTAL|A Glucagon for Injection, Fresenius Kabi USA|The subjects will be administered the test (A) (Glucagon for Injection, Fresenius Kabi USA)or reference (B) product (GlucaGen® for Injection, Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
62669904|NCT01183286|ACTIVE_COMPARATOR|CFFONE|
62669905|NCT01183286|PLACEBO_COMPARATOR|CF website|
62108076|NCT05639023|EXPERIMENTAL|Manipulation Techniques Group|Subjects will be received orthopedic manipulation and Physiotherapy Scoliosis-Specific Exercise(PSSE). For orthopedic manipulation, Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week. For PSSE, subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
62669906|NCT06388213||Non GLP-1 RA group|Patient aged 18 years or older in healthy condition with no gastroparetic treatment and without history of gastro-intestinal pathology, respecting fasting period of 6 hours for solid or thick liquid (juice, milk, sparkling water and soda) and 2 hours for clear liquid (still water, black coffee or tea).
62299424|NCT02086227|ACTIVE_COMPARATOR|B GlucaGen® (Bedford Laboratories)|The subjects will be administered the test (A) Glucagon for Injection, Fresenius Kabi USA; or reference (B) product, GlucaGen® (Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
62669907|NCT06388213||GLP-1 RA group|Patients aged 18 years or older, treated with GLP-1 receptor agonists, respecting fasting period of 6 hours for solid or thick liquid (juice, milk, sparkling water and soda) and 2 hours for clear liquid (still water, black coffee or tea).
62669908|NCT01981993||patients at ICU with sepsis|
62669909|NCT01229553|EXPERIMENTAL|Decolonization group|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
62669910|NCT05036460|ACTIVE_COMPARATOR|Ultrasonography + direct visualization|To detect using ultrasonography assisted direct visualization.
62299425|NCT05153382|EXPERIMENTAL|Youth with and/or at familial risk for bipolar disorder|60 youth aged 13 to 23 with and/or at familial risk for bipolar disorder will be enrolled in the dialectical behavioral therapy intervention.
62299426|NCT05215522|EXPERIMENTAL|The BCI-FES Intervention|The BCI-FES device will be used by all participants.
62299427|NCT02207907|EXPERIMENTAL|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
62299428|NCT02207907|ACTIVE_COMPARATOR|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
62669911|NCT05036460|EXPERIMENTAL|Direct visualization|To detect using direct visualization.
62669912|NCT05838313|EXPERIMENTAL|Decision Support Tool|Participants will interact with the decision support tool prior to making their decision regarding whether to have an induction of labor without a medical indication
62669913|NCT01959971|EXPERIMENTAL|Placebo - Alirocumab|Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
62669914|NCT05427916|EXPERIMENTAL|Negative Pressure Wound Therapy|Negative pressure to the incision site and managing exudate generated by the incision.
62669915|NCT05427916|ACTIVE_COMPARATOR|Optifoam|This foam is standard of care and is currently stocked by the operating rooms at Mount Sinai hospital and indicated for use in high risk wounds
62669916|NCT06520423|ACTIVE_COMPARATOR|Urinary catheter drainage|These patients will undergo urinary catheter drainage for seven days following urethroplasty
62669917|NCT06520423|EXPERIMENTAL|Urethral stent tube irrigation (combined with urinary catheter drainage)|These patients will undergo urinary catheter drainage (combined with urinary catheter drainage) for seven days following urethroplasty
62669918|NCT00693303|EXPERIMENTAL|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
62669919|NCT04591132|EXPERIMENTAL|kinematic analysis|each patient with a diagnosis of parkinsonism, ataxia, chorea, dystonia or tremor will be asked to perform some motor tasks routinely used in clinical evaluation wearing inertial sensors.
62669920|NCT01956942|EXPERIMENTAL|Micropulse Laser Trabeculoplasty|Patient's randomized to MLT would be treated with the following settings: 300 micron spot size, 0.3 second duration, 15% duty cycle, and 1000 milliWatt power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative intraocular pressure (IOP) spikes as per standard pre-laser trabeculoplasty protocol.
62669921|NCT01956942|ACTIVE_COMPARATOR|Selective Laser Trabeculoplasty (SLT)|Patient's randomized to SLT would be treated with the following settings: 400 micron spot size, 0.3 second duration, and 1.00 milliWatt (mW) power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative IOP spikes as per standard pre-laser trabeculoplasty protocol.
62669922|NCT01177488|EXPERIMENTAL|BATE-T|Behavioral Activation Therapeutic Exposure done while the patient is at home via videoconferencing technology
62669923|NCT01177488|ACTIVE_COMPARATOR|BATE-IP|Behavioral Activation Therapeutic Exposure done in the therapist's office
62669924|NCT00559351|ACTIVE_COMPARATOR|S|esophagectomy
62669925|NCT00559351|EXPERIMENTAL|CHTS|neoadjuvant chemotherapy followed by esophagectomy
62669926|NCT00559351|EXPERIMENTAL|CHRTS|neoadjuvant chemoradiotherapy followed by esophagectomy
62669927|NCT04242602|OTHER|Study Subjects|
62669928|NCT02774720|EXPERIMENTAL|Centre-based physical activity|People with Mild Cognitive Impairment (MCI) and early dementia will receive centre-based physical activity for one hour each week for three months, plus at-home prescribed exercise.
62669929|NCT02774720|EXPERIMENTAL|Home-based exercise|People with Mild Cognitive Impairment (MCI) and early dementia be prescribed at-home prescribed exercise and will received monthly support phone calls.
62669930|NCT03168087||0% dilution|Blood specimen which was diluted with 0% level using a plasmalyte-148 solution
62669931|NCT03168087||20% dilution|Blood specimen which was diluted with 20% level using a plasmalyte-148 solution
62299429|NCT00519077|EXPERIMENTAL|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
62669932|NCT03168087||40% dilution|Blood specimen which was diluted with 40% level using a plasmalyte-148 solution
62669933|NCT03168087||60% dilution|Blood specimen which was diluted with 60% level using a plasmalyte-148 solution
62108077|NCT05639023|EXPERIMENTAL|Control Group|Subjects will be received sham orthopedic manipulation and Physiotherapy Scoliosis-Specific Exercise(PSSE). For orthopedic manipulation, Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week. For PSSE, subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
62299430|NCT03486314|EXPERIMENTAL|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m\^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.
62469945|NCT02642367|EXPERIMENTAL|no use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection without use of stylet with McGrath videolaryngoscope after endotracheal tube was rolled up circularly for 3 min
62469946|NCT02642367|ACTIVE_COMPARATOR|use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection using a styletted endotracheal tube with McGrath videolaryngoscope
62469947|NCT06561022|EXPERIMENTAL|SNF 1 safety lead-in phase|Everolimus plus Fulvestrant and Abemaciclib in patients with HR+ HER2-advanced breast cancer of SNF1 subtype who have progressed after CDK4/6 inhibitor treatment.
62469948|NCT06561022|ACTIVE_COMPARATOR|SNF 1 Phase II Control|Fulvestrant and Abemaciclib in patients with HR+ HER2-advanced breast cancer of SNF1 subtype who have progressed after CDK4/6 inhibitor treatment.
62669934|NCT06194669||Controls|Healthy volunteers; patients referring to San Raffaele Hospital for renal/urological conditions other than VHL
62669935|NCT06194669||VHL-disease patients|Individuals with genetic diagnosis of Von Hippel Lindau disease
62669936|NCT02492776|EXPERIMENTAL|Gefapixant + Omeprazole|Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days
62469949|NCT06561022|EXPERIMENTAL|SNF 1 Phase II Experimental|Everolimus plus Fulvestrant and Abemaciclib in patients with HR+ HER2-advanced breast cancer of SNF1 subtype who have progressed after CDK4/6 inhibitor treatment.
62469950|NCT06561022|EXPERIMENTAL|SNF 3 safety lead-in phase|Fluzoparib plus Fulvestrant and Abemaciclib in patients with HR+ HER2-advanced breast cancer of SNF3 subtype who have progressed after CDK4/6 inhibitor treatment.
62469951|NCT06561022|ACTIVE_COMPARATOR|SNF 3 Phase II Control|Fulvestrant and Abemaciclib in patients with HR+ HER2-advanced breast cancer of SNF3 subtype who have progressed after CDK4/6 inhibitor treatment.
62469952|NCT06561022|ACTIVE_COMPARATOR|SNF 3 Phase II Experimental|Fluzoparib plus Fulvestrant and Abemaciclib in patients with HR+ HER2-advanced breast cancer of SNF3 subtype who have progressed after CDK4/6 inhibitor treatment.
62669937|NCT04279600|EXPERIMENTAL|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
62669938|NCT04279600|ACTIVE_COMPARATOR|Taurine supplementation associated to exercise training|"Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
62669939|NCT04279600|PLACEBO_COMPARATOR|Placebo supplementation associated to exercise training|"Placebo supplementation composed of capsules of starch powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
62669940|NCT03024632||trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a trial of labor
62669941|NCT03024632||No trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a a repeat cesarean section
62669942|NCT05492903|EXPERIMENTAL|Intervention|Intervention during weeks 0-10 (10 weekly group sessions). Follow-up with no treatment during weeks 11-20.
62669943|NCT05492903|OTHER|Waitlist Control|Usual practice during weeks 0-10. Intervention during weeks 11-20 (10 weekly group sessions).
62669944|NCT04719923||Subjects with autism spectrum disorders|Children affected by autism spectrum disorders
62669945|NCT04719923||Healthy controls|Healthy children
62669946|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
62669947|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
62669948|NCT02011997|EXPERIMENTAL|segmentectomy|Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy
62669949|NCT02011997|ACTIVE_COMPARATOR|Lobectomy|Patients undergo cVATS lobectomy
62669950|NCT01181765|EXPERIMENTAL|Infliximab infusions (5 mg/kg) at weeks 0, 2, 6, 14 and 22|
62108078|NCT04467515|EXPERIMENTAL|Dose Escalation and Expansion|"The dose escalation phase of the study will be an open label 3 + 3 design, where at least 3 patients are treated at each dose level. Dose escalation will be done via increases of the nominal activity of CAM-H2 in cohorts of 3 to 6 patients.~In the dose expansion phase of the study, the patients will be given the RDP2 determined in the dose escalation phase. Similar to the dose escalation phase, all patients will receive at least 1 cycle of CAM-H2."
62669951|NCT00560638|EXPERIMENTAL|Loteprednol Etabonate TID|loteprednol etabonate ophthalmic suspension, 0.5%, TID
62108079|NCT06630884|EXPERIMENTAL|Polysaccharide typhoid vaccine|Participants in this condition will receive an injection of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA), which contains 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection.
62669952|NCT00560638|EXPERIMENTAL|Loteprednol Etabonate QID|loteprednol etabonate ophthalmic suspension, 0.5%, QID
62669953|NCT00560638|PLACEBO_COMPARATOR|Vehicle|vehicle of loteprednol etabonate
62669954|NCT04362150||COVID-19 positive, recovered|Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).
62669955|NCT01320098|EXPERIMENTAL|Home-Based Parenting Program|
62669956|NCT01320098|EXPERIMENTAL|Clinic-Based Parenting Program|
62669957|NCT01320098|OTHER|Wait-List Control Group|
62669958|NCT01573793|ACTIVE_COMPARATOR|Intervention|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
62669959|NCT01573793|SHAM_COMPARATOR|Control|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
62669960|NCT00776997|OTHER|Magnetic Sphincter Augmentation|Single-arm study: all subjects were treated with magnetic sphincter augmentation. A subject's baseline measurements prior to sphincter augmentation were compared to post-sphincter augmentation measurements. Subjects served as their own control.
62469953|NCT05321446|EXPERIMENTAL|GoHand Feedback Group|"Both groups will receive a standardized home practice program, the GRASP (Graded Repetitive Arm Supplementary Program). This is a program that has a standard set of arm and hand movements to be practiced 45 minutes per day over a one month period. The person manipulates objects to practice different hand movements. These are everyday objects and each person will be given a set of these to take home and to keep.~For the Experimental Group, the person will be taught the GRASP program and how to move the wrist and hand optimally to activate the GoHand sensor to hear the sound."
62469954|NCT05321446|SHAM_COMPARATOR|GoHand Measurement Group|For Group 2, the person will be taught GRASP program and how to wear the sensor so it measures movement but does not emit a sound.
62669961|NCT06193967|NO_INTERVENTION|BASIC|Children will be asked to track their intake of fruits, vegetables, sweet and salty snack foods, and sugary drinks in the web-based dietary self-monitoring (DSM) log for 4 weeks. Each child will be provided with a personal URL to access their log, which can be accessed from any internet-capable device (computer, phone, etc.). Caregivers will be asked to review their child's log each day and complete a caregiver check-in in the DSM log.
62669962|NCT06193967|EXPERIMENTAL|PRAISE|In addition to conditions of the BASIC group, caregivers will also be asked to provide praise to their child for engaging in DSM over the 4 weeks. Additionally, when the caregiver completes caregiver check-ins in the DSM log, they will receive a prompt to also complete a praise check-in.
62669963|NCT06193967|EXPERIMENTAL|GAME|In addition to the conditions of the BASIC group, the child's log will also include a virtual pet that evolves over time as he/she uses the log. As the child earns points, the pet will level up and grow over time.
62669964|NCT06193967|EXPERIMENTAL|PRAISE+GAME|In addition to conditions of the BASIC group, caregivers will also be asked to provide praise to their child for engaging in DSM over the 4 weeks. Additionally, when the caregiver completes caregiver check-ins in the DSM log, they will receive a prompt to also complete a praise check-in. The child's log will also include a virtual pet that evolves over time as he/she uses the log. As the child earns points, the pet will level up and grow over time.
62108080|NCT06630884|PLACEBO_COMPARATOR|Saline Placebo Arm|Participants in this condition will receive and injection of 0.5ml of saline.
62108081|NCT06213051||Cohort of sexually active adult females with an abnormal cervical cancer screening result.|"Multi-center, prospective, paired, comparative diagnostic accuracy study To compare the performance of self-collected vaginal samples transported dry to those transported wet for detection of hrHPV DNA.~Interventions:~COPAN floq swab transported wet and dry evaluated on Roche COBAS and Cepheid Xpert HPV tests"
62669965|NCT00856102|EXPERIMENTAL|Exercise|
62669966|NCT00856102|NO_INTERVENTION|Control|
62108082|NCT04950218||Psoriasis patients|Eligible psoriasis patients will be identified from the daily outpatient program, at the Department of Dermato-Allergology, that is the department will provide the patient's contact information to the project group. As most outpatient clinic psoriasis is classified as moderate to severe, in order to approximate a random sample as accurate as possible including patients with mild psoriasis, all people with a diagnosis of psoriasis will a general invitation to participate in the study through appropriate channels such as the Danish Psoriasis Foundation's newsletter.
62469955|NCT03700944|EXPERIMENTAL|YOG|The yoga group (YOG) was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week
62469956|NCT03700944|NO_INTERVENTION|CON|The control group (CON) had normal life.
62669967|NCT03168997|OTHER|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
62669968|NCT03168997|OTHER|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
62669969|NCT03168997|OTHER|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
62669970|NCT01899703|EXPERIMENTAL|GSK2330672|Subject will receive GSK2330672 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either (i) GSK2330672 followed by placebo; OR (ii) placebo followed by GSK2330672.
62669971|NCT01899703|EXPERIMENTAL|Placebo|Subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either GSK2330672 followed by placebo; OR placebo followed by GSK2330672.
62669972|NCT00290238|EXPERIMENTAL|PNT|
62669973|NCT00290238|SHAM_COMPARATOR|TENS|
62669974|NCT01411371|EXPERIMENTAL|Catheter Ablation|Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.
62469957|NCT03333616|EXPERIMENTAL|Nivolumab+Ipilimumab|"* Nivolumab and Ipilimumab are administered intravenously every 3 weeks for a total of 4 maximum doses. After combination therapy, nivolumab will be administered as monotherapy every 4 weeks.~* Doses are determined per protocol."
62469958|NCT03157362|ACTIVE_COMPARATOR|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62469959|NCT03157362|ACTIVE_COMPARATOR|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62669975|NCT01411371|ACTIVE_COMPARATOR|Medical treatment alone|Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
62669976|NCT02765971|ACTIVE_COMPARATOR|chewing gum group|180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval
62669977|NCT02765971|ACTIVE_COMPARATOR|laxatives group|180 women will receive laxatives after their operating room discharge by 3 hours
62469960|NCT03157362|ACTIVE_COMPARATOR|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62669978|NCT02765971|PLACEBO_COMPARATOR|control|they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds
62669979|NCT02636283|ACTIVE_COMPARATOR|Entresto|oral route
62669980|NCT02636283|PLACEBO_COMPARATOR|Placebo group|Oral placebo
62669981|NCT01280500|PLACEBO_COMPARATOR|Group A - Usual Care Controls|Group A will consist of 20 primary care clinics who are part of the Carolinas Healthcare System network but have not yet adopted the Electronic Medical Record System. These practices do use the same billing databases as the remaining clinics, allowing easy identification of asthma patients and their health services utilization patterns. Data from the billing systems will be used to retrospectively populate a database for these clinics from January 2009 forward.
62669982|NCT01280500|ACTIVE_COMPARATOR|Group B - EMR Control Practices|There are currently 65 primary care practices within the Carolinas Healthcare System network that have electronic medical record with decision support (EAP)access at baseline. These practices will serve as a second level of control for comparison with the intervention groups. Each of these practices is currently using Cerner PowerChart and at the start of the study and will have access to the asthma decision support tools; an electronically generated Asthma Action Plan (AAP); and a built-in system of population management reports which will be pushed to the practices on an on-going basis to help in patient recall and management. The EAP approach to care has been developed with input from clinicians, hospital administrators, hospital information services personnel, and Cerner consultants.
62669983|NCT01280500|ACTIVE_COMPARATOR|C Integrated Approach to Care|There are 10 practices within the Carolinas Healthcare System (CHS) network that have already received additional training for improving outcomes for patients with chronic diseases termed the Integrated Approach to Care (IAC). This IAC approach developed by CHS is based on the Chronic Care Model (CCM). The IAC approach includes a heavy emphasis on the use of health information technology that practices receive during the initial EAP rollout.
62469961|NCT03157362|ACTIVE_COMPARATOR|Time 4|Participant will complete the remaining intervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62299431|NCT03486314|EXPERIMENTAL|Part B: Pevonedistat|Pevonedistat 25 mg/m\^2 intravenously in combination with docetaxel 75 mg/m\^2 or at 20 mg/m\^2 in combination with carboplatin +paclitaxel 175 mg/m\^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
62469962|NCT04664621|EXPERIMENTAL|HepQuant Testing|
62469963|NCT00734019||P.F.C. Sigma Knee System|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
62299432|NCT06475404|EXPERIMENTAL|verenafusp alfa 6 mg/kg intravenously|Single intravenous administration
62299433|NCT06475404|EXPERIMENTAL|verenafusp alfa 9 mg/kg intravenously|Single intravenous administration
62299434|NCT06475404|EXPERIMENTAL|verenafusp alfa 12 mg/kg intravenously|Single intravenous administration
62469964|NCT05197634||Children with Autism Spectrum Disorder|The orofacial trauma history, dietary habits and lifestyle changes of children aged 3-14 years diagnosed with autism in Istanbul University Department of Child Psychiatry evaluated through a questionnaire to be applied to their families.
62299435|NCT00372918|OTHER|1|Transnasal Esophagoscopy
62299436|NCT01363843|EXPERIMENTAL|treatment|"Induction therapy - Modified FOLFOX6 - Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours - Repeat q14 days x 8 cycles~Concurrent Chemoradiation~50.4 Gy Radiation in 28 fractions (45 Gy IMRT, 5.4 Gy 3D conformal boost)~Surgery"
62469965|NCT05197634||Healthy children|The orofacial trauma history, dietary habits and lifestyle changes of healthy children aged 3-14 years applying to Istanbul University Faculty of Dentistry Department of Pediatric Dentistry will be evaluated through a questionnaire to be applied to their families.
62469966|NCT06561399||Triple Therapy sequential Radiotherapy|
62469967|NCT01236677||Community acquired pneumonia,age≥14 ys|Patients with community acquired pneumonia,age≥14 ys and less than one week after the onset of symptoms, without pregnancy,breast-feeding,HIV infection,recent 90-day hospitalized history and in nursing homes or rehabilitation hospitals
62469968|NCT04334174|EXPERIMENTAL|Single Arm|Brentuximab vedotin (SGN-35), intravenous infusion, 1.8 milligrams (mg) per kilogram (kg), day one of each twenty- one day cycle with a total of ten cycles planned.
62469969|NCT02409979|ACTIVE_COMPARATOR|Carbon dioxide method|Colonoscopy performed as usual, with the minimal CO2 insufflation required to aid insertion and adequate distension during withdrawal for exploration. Washing allowed as needed. Considered to be standard procedure.
62669984|NCT01280500|ACTIVE_COMPARATOR|Group D - Shared Decision Making (SDM)|This approach has great potential for improved patient outcomes and provides an additional step in the successful implementation of patient self-management. The research team will develop the SDM intervention during the first 6 months of the study. In particular, the Shared decision making (SDM) intervention will be designed to be deployed within the 4 large clinics that care for the majority of the community's underserved and disadvantaged patients. The SDM intervention development will be overseen by the study advisory board and actively recruit providers from within the clinics for feedback about the intervention.
62669985|NCT01280500|ACTIVE_COMPARATOR|School Based Care (SBC)|Activities included: spending individual time with students to assess, treat, and monitor and to educate students in proper asthma management; facilitate access to health care and medicine; and communicate with parents.
62669986|NCT00812097|OTHER|Primary Augmentation|The Primary Augmentation cohort will include patients who wish general breast enlargement receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel \[CPG\]) Breast Implants.
62669987|NCT00812097|OTHER|Primary Reconstruction|The Primary Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel \[CPG\]) Breast Implants.
62669988|NCT00812097|OTHER|Revision Augmentation|The Revision Augmentation cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel \[CPG\]) Breast Implants during a revision surgery to correct or improve the result of a primary breast augmentation surgery.
62669989|NCT00812097|OTHER|Revision Reconstruction|The Revision Reconstruction cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel \[CPG\]) Breast Implants during a revision surgery to correct or improve the result of a primary breast reconstruction surgery.
62299437|NCT03474367||Unplanned Peritoneal Dialysis|CKD patients stage 5 (eGFR \< 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate peritoneal dialysis (PD) in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home. The patient must not have any absolute contraindications to initiate PD, which include: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2\> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
62299438|NCT03474367||Unplanned Hemodialysis|CKD patients stage 5 (eGFR \< 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).
62108083|NCT04950218||Control group|The control group will consist of a retrospective random sample of around 1.000 patients from the general population examined in the 4th and 5th Copenhagen City Heart Study, 2001-2003 and 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
62108084|NCT01636206|PLACEBO_COMPARATOR|Placebo|Placebo
62108085|NCT01636206|EXPERIMENTAL|Lifitegrast|Active
62108086|NCT02716324|ACTIVE_COMPARATOR|ADHD Portal|In this arm, the ADHD Portal was used alone as an electronic communication tool.The ADHD portal is considered standard of care at our institution for communicating information between clinicians, teachers, and parents.
62299439|NCT05038761||Type 1 or type 2 diabetes mellitus participants|Participants will be enrolled after the decision to initiate venous blood glucose testing and Continuous Glucose Monitoring (CGM) system as per investigator's routine treatment practice.
62469970|NCT02409979|EXPERIMENTAL|Water Exchange-CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using carbon dioxide insufflation.
62469971|NCT02409979|EXPERIMENTAL|Water Exchange-AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using air insufflation.
62469972|NCT05612867||PO Vitamin C|Patients who got PO vitamin C
62108087|NCT02716324|EXPERIMENTAL|ADHD Portal plus Care Manager (CM)|In this arm, the ADHD Portal was combined with the CM. Clinicians, teachers, and parents used the ADHD Portal as standard of care. In addition, clinicians, teachers, parents, and any external mental health providers interacted with a CM, who had access to information contained in the ADHD Portal.
62108088|NCT06435338|EXPERIMENTAL|Patient decision aid|Patient decision aid on HPV vaccination on webpage.
62108089|NCT06435338|ACTIVE_COMPARATOR|Control|Vaccine information sheet on HPV vaccination view on webpage.
62108090|NCT03982199|EXPERIMENTAL|Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, and 1C to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, and 3 years respectively after the first vaccination.
62108091|NCT03982199|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, and 2C, and will first receive Ad26.RSV.preF based vaccine at years 1, 2, and 3. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.
62108092|NCT05230680|EXPERIMENTAL|Arm ACHOP|"1. Phase I Azacitidine D1-3 + CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone)~   * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~2. Phase II~   * Azacitidine D-2, -1, 1 + CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone)~  * 6 cycles in total"
62108093|NCT04480593|ACTIVE_COMPARATOR|Control|standard care.
62299440|NCT02114190|EXPERIMENTAL|Adolescent Mindful Eating Group|Adolescents will participate in a 8 week mindful eating programs tailored for adolescents.
62299441|NCT02114190|EXPERIMENTAL|Parent Intergrated Group|This intervention incorporates a family systems perspective into mindful eating interventions for adolescents. This intervention will consist of 11 sessions in an 8 week period, with sessions 2,7, and 11 incorporating family sessions. The purpose of the family sessions are to increase overall family motivation for behavior change, involve family members in identifying specific targets of change and establishing agreed upon strategies.
62469973|NCT05612867||IV Vitamin C|Patients who got IV vitamin C
62469974|NCT02583763||Fetuses/Children with IUGR|"The moving sequences of the heart movement are collected at the regular ultrasound examinations during pregnancy. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyse the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
62108094|NCT04480593|EXPERIMENTAL|EPP-AF 400mg/day|Green propolis extract (EPP-AF) at a dose of 400mg / day in addition to the standard treatment.
62299442|NCT03542682|ACTIVE_COMPARATOR|Individuals given Standard Bolus first, then quick bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
62108095|NCT04480593|EXPERIMENTAL|EPP-AF 800mg/day|Green propolis extract (EPP-AF) at a dose of 800mg / day in addition to the standard treatment.
62108096|NCT00570869|ACTIVE_COMPARATOR|CPR Class|mothers who are currently certified in CPR (i.e., have taken the traditional CPR class, or have been recertified in CPR by classroom instruction, within the past two years).
62108097|NCT05996757|ACTIVE_COMPARATOR|Wet clothing removal|
62108098|NCT05996757|NO_INTERVENTION|Vapor barrier|
62108099|NCT03012919|OTHER|active decision support system (GDT protocol)|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
62108100|NCT01186848|ACTIVE_COMPARATOR|1550-nm erbium-doped fractionated laser|
62108101|NCT01186848|ACTIVE_COMPARATOR|Combination treatment|"micro-focused ultrasound and 1550nm-fractionated laser"
62108102|NCT02323386|EXPERIMENTAL|ATTUNE knee system|The patients will undergo primary Total Knee Arthroplasty (ATTUNE knee system)
61914367|NCT01190735|EXPERIMENTAL|Caffeine|Each patient will take pills twice per day containing 100-200 mg of caffeine (as synthetic caffeine alkaloid). Patients will be instructed to take whatever caffeine-containing beverages they are accustomed to taking, without changing their habitual schedule (note that all will be taking \<200 mg per day). Caffeine intake will be assessed at each visit. Patients will continue their usual PD medications, without change in dose or timing for the entire duration of the study. Medication will be provided in pre-packaged dosettes.
62108103|NCT01930019|EXPERIMENTAL|OE|OE - obese patients (BMI\>40) in which etomidate was used,
62108104|NCT01930019|OTHER|NE|NE - patients with normal body mass (BMI\<25), in which etomidate was used,
62108105|NCT01930019|EXPERIMENTAL|OT|OT - obese patients in which thiopental was used,
62108106|NCT01930019|OTHER|NT|NT - patients with normal body mass, in which thiopental was used
62108107|NCT03211637|EXPERIMENTAL|INTERVENTION GROUP|This group comprises 6 healthcare units equipped with a Family Health Strategy, where patients are seen by coordinating nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
62108108|NCT03211637|ACTIVE_COMPARATOR|CONTROL GROUP|This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
62108109|NCT02611232|ACTIVE_COMPARATOR|Victoza®|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
62299443|NCT03542682|ACTIVE_COMPARATOR|Individuals given Quick bolus first, then standard bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
61914368|NCT00728143|ACTIVE_COMPARATOR|1|Healthy subjects
61914369|NCT00728143|EXPERIMENTAL|2|Diabetic subjects
62108110|NCT02611232|PLACEBO_COMPARATOR|Placebo|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
62108111|NCT06018194||Low FFR|Invasive FFR \<= 0.80
62108112|NCT06018194||High FFR|Invasive FFR \> 0.80
62108113|NCT04005313|EXPERIMENTAL|Comparison between unisensory and multisensory stimulation|The same person receive unisensory and multisensory stimulation on separate day.
62108114|NCT04005313|EXPERIMENTAL|The treatment effect of multisensory stimulation|The persons living in long-term care facility would receive multisensory stimulation for one month.
62108115|NCT04005313|EXPERIMENTAL|Multisensory stimulation and virtual reality.|The subjects would receive vibroacoustic therapy or virtual reality.
62469975|NCT02583763||Healthy Controls|"The moving sequences of the heart movement are collected at two occasions approximately 4 weeks apart. This takes place during gestational weeks 28-36. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyze the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
62735921|NCT06513130|ACTIVE_COMPARATOR|Group without geriatric assessment|"At the end of the ICU stay or in the 7 days following, will be collect:~* Medical and surgical history, Charlson comorbidity index,~* Living place~* Regular treatment (number and class)~* ICU trajectory: ICU length of stay, reason for ICU admission, severity scores (SOFA and SAPS 2 score), organ supports requirement and duration~* Limitation of life-sustaining therapy decision~At 6 month after ICU discharge, patients will be evaluated during a post-ICU consultation, where will be recorded:~* Living conditions (home, proxy, home support)~* Quality of life (SF-36)~* Covi test and 4-item Geriatric Depression Scale~* Katz-ADL and IADL~* History of fall, mobility assessment~* Nutritional status (BMI, albuminemia, Mini Nutritionnal Assesment)~* Cognitive assessment (Mini-mental State Examination)~* Regular treatment (number and class)~* Hospitalizations between ICU discharge and M6~* Additional comorbidity~* Family burden assessment (mini-Zarit)"
61914370|NCT00911885|EXPERIMENTAL|High Fiber Diet|A single dietary change condition that focuses exclusively on increasing fiber.
62108116|NCT04005313|EXPERIMENTAL|Vibroacustic therapy on neck pain.|The subjects would receive either vibroacustic therapy or music therapy.
62108117|NCT05040750||moderate to severe COVID 19 patients|moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed
62108118|NCT03141658|EXPERIMENTAL|TS-134 20 mg|
62108119|NCT03141658|EXPERIMENTAL|TS-134 60 mg|
62108120|NCT03141658|EXPERIMENTAL|Placebo|
62108121|NCT00942149|EXPERIMENTAL|Daptomycin cohort|
62108122|NCT03155152|EXPERIMENTAL|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
62108123|NCT03155152|ACTIVE_COMPARATOR|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
62108124|NCT01364519|EXPERIMENTAL|Arm 1|
62108125|NCT01364519|PLACEBO_COMPARATOR|Arm 2|
62108126|NCT05971355|EXPERIMENTAL|Treatment group|LimpiAD cream 2,5% plus to be applied twice a day (morning and evening) for 4 weeks.
62108127|NCT05971355|ACTIVE_COMPARATOR|Control group|Vehicle of LimpiAD cream 2,5% plus to be applied twice a day (morning and evening) for 4 weeks.
62108128|NCT05971355|ACTIVE_COMPARATOR|Emollient group|Emollient cream to be applied twice a day (morning and evening) for 4 weeks.
62108129|NCT05950113|EXPERIMENTAL|Treatment (CART-BCMA/CS1)|Patients undergo leukapheresis on 35 to 21 days before Infusion Day (I-Day -35 to I-Day -21) and receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on I-Days -5, -4, and -3. Patients then receive CART-BCMA/CS1 IV on I-Day-0 on study. Patients undergo ECHO, ECG and MRI during screening. Patients undergo bone marrow biopsy and/or bone marrow aspirate screening, between I-Day -28 to I-Day -5, I-Day 30, and at 1 year post CART-BCMA/CS1 infusion. Patients also undergo FDG PET/CT during screening, between I-Day -28 to I-Day -5, I-Day 90 and I-Day 180 and every 3 months thereafter.
62469976|NCT03919058|ACTIVE_COMPARATOR|Regime 1: control regime|All participants start with the control regime, where baseline activity will be measured.
62108130|NCT04810884||Living kidney donors|"Aim 1: A survey about fractures and general bone health will be sent to 3000 prior living kidney donors.~Aim 2: Out of these 3000 subjects, 200 prior living kidney donors who are ≥10 years post kidney donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
62108131|NCT04810884||Matched Controls|"Aim 1: A survey about fractures and general bone health will be sent to 3000 age, sex, race, and comorbidity-matched subjects who would have been eligible to donate but did not donate a kidney.~Aim 2: Out of these 3000 subjects, 200 control subjects who would be eligible to donate, but have not donated, and are matched by age, sex, race, and comorbidity to donors at the time of donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
62469977|NCT03919058|EXPERIMENTAL|Regime 2: Sit regime/sit less regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
61914371|NCT00911885|ACTIVE_COMPARATOR|AHA Diet|The AHA Diet is the current recommendation for patients with the metabolic syndrome.
62108132|NCT06530875|EXPERIMENTAL|Arms|The experimental group will be trained on hesitations in childhood vaccines.
62108133|NCT06530875|NO_INTERVENTION|Control|there will be no interference
62108134|NCT02944955|EXPERIMENTAL|BLEX 404 Oral Liquid|"Part I:~Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part II:~Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.~BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine."
61914372|NCT05672667|EXPERIMENTAL|Oxytocin Administration (Intravenous, then Intranasal)|Oxytocin 14 micrograms infusion over 30 minutes on first study day. Oxytocin 102 micrograms by intranasal spray on second study day.
62669990|NCT05621980|EXPERIMENTAL|Functional electrical stimulation (FES) + AVK group|This group will use the AVK system in combination with targeted FES to provide training of independent movement of each digit of the paretic hand. This training has two modes: Key Combination and Song. In the Key Combination mode, the subject will attempt to play the discrete key or key combinations specified on the computer screen to practice difficult movements and combinations. In the Song mode, sequential, rhythmic movements will be practiced as the participant is guided to play a series of keys, specified as falling keys, constituting five-note songs. Key Combination will be employed at the beginning and end of each training session to practice discrete movements that proved troubling during the current or previous session. Most of the session will be spent in the Song mode to emphasize the transitions from one movement to the next. In both modes the AVK system will trigger FES for the finger matching the desired key and signal the PneuGlove to resist movement of other digits.
62735922|NCT03073083|ACTIVE_COMPARATOR|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
62735923|NCT03073083|ACTIVE_COMPARATOR|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
61914373|NCT02195011|EXPERIMENTAL|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
62108135|NCT04900155|ACTIVE_COMPARATOR|Atorvastatin 80 mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
62108136|NCT04900155|ACTIVE_COMPARATOR|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
62108137|NCT01193153|EXPERIMENTAL|001|paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
62108138|NCT01193153|PLACEBO_COMPARATOR|002|Placebo monthly by i.m. injection for 15 months
62108139|NCT06141980|EXPERIMENTAL|Study group (DWP16001 0.3 mg)|DWP16001 0.3mg, Tablets, Orally, Once daily
62469978|NCT03919058|EXPERIMENTAL|Regime 3: Sit less regime/sit regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
62108140|NCT04448717||Children and adolescents|Children and adolescents in primary and secondary schools (aimed sample size: 2500)
62108141|NCT04448717||Parents|Parents of participating children (aimed sample size: 3000)
62108142|NCT04448717||School personnel|School personnel (teaching, administrative, maintenance, etc.) (aimed sample size: 2500)
62108143|NCT04460898||Breast Cancer Patients|HR+/HER2- metastatic breast cancer patients in the US.
62108144|NCT00099515|EXPERIMENTAL|A|
62735924|NCT03073083|ACTIVE_COMPARATOR|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
62735925|NCT01389726|EXPERIMENTAL|Behavioral Parenting Training|Triple-P Parenting Training Program (group level)
61914374|NCT02195011|EXPERIMENTAL|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
62108145|NCT00099515|EXPERIMENTAL|B|
62108146|NCT06351280|OTHER|Functionality Assessment|Each participant will be provided with an informed consent form detailing the purpose of the study. After obtaining written consent, baseline data will be collected, including demographic information, medical history, and any pre-existing conditions. The participants will then undergo the post-laparotomy interventions as described. Throughout the intervention period, data will be collected using the tools mentioned: 6 minute Walk Test, 5 Times Sit to Stand test, 2 Minute walk Test, and Timed Up and GO to determine any changes in their functionality and overall well-being on post operative day 1 and before discharge. For reliability, tests will be conducted twice a day with a minimum gap of 2 hours, both on day 1 and on the day of discharge.
62108147|NCT02355535|EXPERIMENTAL|Open label|Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
62108148|NCT02442466|EXPERIMENTAL|Endothelin receptor B inhibitor BQ-788|Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)
62108149|NCT02442466|EXPERIMENTAL|PBS|Intra-lesion administration of vehicle
62469979|NCT03919058|EXPERIMENTAL|Regime 4: Exercise regime|The exercise regime is the final regime for all participants. This is comparable with the sit regime, but 1h of sitting is replaced with 1 exercise bout.
62669991|NCT05621980|ACTIVE_COMPARATOR|OT Group|An occupational therapist will provide therapy of matching duration to the OT subject group. This will consist of 10 minutes of stretching of the finger muscles, particularly of the extrinsic finger flexors. This stretching will be followed by two 20-minute sessions of therapy focused on active task practice, object manipulation, and individuated movement of the digits. The Canadian Occupational Performance Measure (COPM) will be administered to identify goals that incorporate dexterous use of the paretic hand. Part of each training session will be used to practice these tasks, while the remainder will be used to practice component skills. Active practice will be followed by a final 10 minutes of stretching of muscles of the digits.
62669992|NCT04120675|EXPERIMENTAL|Experimental group|"Experimental Group 20 patients on Early Harvest Extra Virgin Olive Oil Aluminum bottle with 500 ml of early harvest extra virgin olive oil (3 tablespoons per day).~Dietary Supplement: Early Harvest Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
62669993|NCT04120675|ACTIVE_COMPARATOR|Control group|10 patients will not receive treatment with Extra Virgin Olive Oil
62669994|NCT04949295||the hemodialysis group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
62669995|NCT04949295||the normal group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
62669996|NCT04863807||Thoracic epidural for rib fracture management|Patients aged \> 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare National Health Service (NHS) Trust 'Invasive rib fracture management pathway'
62669997|NCT04863807||Erector Spinae block for rib fracture management|Patients aged \> 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
62669998|NCT04863807||Serratus Anterior block for rib fracture management|Patients aged \> 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
61914375|NCT00622778||1|Patients from daily practice
62108150|NCT02261688|OTHER|Subjects in study|All subjects in study are in a cross-over study with 3 interventions sequentially (low salt diet, low salt diet + IV normal saline, liberal salt diet)
62108151|NCT06220058|EXPERIMENTAL|Group Bites|"Closure of the midline laparotomy using the small bites technique"
62108152|NCT06220058|EXPERIMENTAL|Group Mesh|"Closure of the midline laparotomy using the small bites technique adding a suprapubic polypropylene mesh."
62108153|NCT04553302||Psoriatic Arthritis|Patients diagnosed with PsA according to CASPAR criteria by the rheumatologist were included.
62108154|NCT04553302||Rheumatoid Arthritis|Patients diagnosed with RA according to ACR / EULAR 2010 criteria by the rheumatologist were included.
62108155|NCT04553302||Asymptomatic Healthy Group|Participants had any neurological and/or rheumatological diseases, no complaints about the upper extremity. Participants diagnosed with OA according to traditional clinical criteria were excluded from the study.
62108156|NCT00464672|EXPERIMENTAL|Influenza virus vaccine|
62469980|NCT02026635||Optivol® Device in CareLink|A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital
61914376|NCT01686802|ACTIVE_COMPARATOR|ibuprofen|ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
62108157|NCT00464672|ACTIVE_COMPARATOR|Comparator influenza vaccine|
62108158|NCT02280655|ACTIVE_COMPARATOR|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
62108159|NCT02280655|ACTIVE_COMPARATOR|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
62469981|NCT03738605|EXPERIMENTAL|Laser Group|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
61914377|NCT01686802|ACTIVE_COMPARATOR|oral morphine|oral morphine 0.5 mg/kg (max 20 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
61914378|NCT00912444|EXPERIMENTAL|TAC Arm|six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide
62469982|NCT03738605|PLACEBO_COMPARATOR|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
62669999|NCT01451788|NO_INTERVENTION|Conventional group|conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)
62670000|NCT01451788|EXPERIMENTAL|Floseal|Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)
62670001|NCT02455011|EXPERIMENTAL|REMD-477 Treatment A|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
62670002|NCT02455011|PLACEBO_COMPARATOR|Matching placebo|Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes
61914379|NCT00912444|EXPERIMENTAL|TC Arm|six cycles of neoadjuvant Docetaxel and Cyclophosphamide
61914380|NCT05926076||Kidney Transplant Recipients Group (KTR)|
61914381|NCT05926076||Non-Kidney Transplant Recipients Group（NKTR）|
61914382|NCT05524116|ACTIVE_COMPARATOR|Group TX (Telehealth Exercise)|Participants in this group will receive a supervised and group-based exercise program once a week for 8 weeks via telehealth.
61914383|NCT05524116|EXPERIMENTAL|Group TMX (Telehealth Exercise and Mindfulness)|Participants in this group will receive a supervised, group-based integrated mindfulness and exercise program once a week for 8 weeks via telehealth.
61914384|NCT02111278|EXPERIMENTAL|lumbar Manipulation|Patients randomized to this treatment group will receive lumbar manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
61914385|NCT02111278|PLACEBO_COMPARATOR|Sham Manipulation|Patients randomized to this treatment group will receive a sham manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
61914386|NCT03302364||risperidone patients|patients that are in accordance with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychological Interview(MINI)
61914387|NCT04733794|EXPERIMENTAL|Surgery for Stoma Reversal|All study participants will receive stoma reversal, complete baseline questionnaire, pelvic floor training and follow up questionnaires
62469983|NCT03541941|EXPERIMENTAL|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
62670003|NCT02455011|EXPERIMENTAL|REMD-477 Treatment B|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
61914388|NCT05202938||Septic shock with SIMD: SIMD+|8 patients in septic shock (Sepsis-3-) with SIMD: ejection fraction (LVEF) \< 45% in the first 48 hours of admission into the intensive care unit. No prior cardiac ultrasound or normal cardiac ultrasound values less than 2 years ago , or an ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine) required to obtain a LVEF ≥ 45%, or a drop of ≥ 20% compared to the LVEF value record ed less than 2 years ago.
62670004|NCT02455011|EXPERIMENTAL|REMD-477 Treatment C|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
61914389|NCT05202938||Septic shock without SIMD: SIMD-|8 patients in septic shock (Sepsis-3) without SIMD. Ejection fraction (LVEF) ≥ 45% with or without ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine), or similar to the LVEF recorded less than 2 years ago.
61914390|NCT05202938||Acute Heart Failure with reduced Ejection Fraction: HFrEF|8 patients with acutely reduced ejection fraction (LVEF) \< 50%. with or without ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine) No prior cardiac ultrasound, or normal cardiac ultrasound values less than 2 years ago, or a drop of ≥ 20% compared to the LVEF recorded less than 2 years ago. No evidence of sepsis or septic shock.
62108160|NCT02939495|EXPERIMENTAL|Study drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet
62108161|NCT01243801|ACTIVE_COMPARATOR|Epidural ketamine|"* Bolus of epidural ketamine during the induction of anesthesia~* Epidural infusion of ketamine during the first 48 h after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
62108162|NCT01243801|ACTIVE_COMPARATOR|Intravenous ketamine|"* Bolus of intravenous ketamine administered during the induction of anesthesia~* Intravenous infusion during the first 48 hours after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine plus fentanyl"
62108163|NCT01243801|PLACEBO_COMPARATOR|Placebo|"Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
62108164|NCT00470106|ACTIVE_COMPARATOR|Cognitive Remediation|cognitive remediation
62108165|NCT00470106|EXPERIMENTAL|Social Cognitive Skills Training|social cognitive skills training
62108166|NCT00470106|ACTIVE_COMPARATOR|Hybrid Intervention|combined social cognitive and cognitive remediation training
62670005|NCT02455011|EXPERIMENTAL|REMD-477 Treatment D|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
61914391|NCT05202938||Acute Heart Failure with preserved Ejection Fraction: HFpEF|8 patients with acute heart failure and a preserved ejection fraction (ejection fraction (LVEF ≥ 50% or similar to normal cardiac ultrasound values recorded less than 2 years ago). No evidence of septic shock.
62108167|NCT00470106|OTHER|Skills Training|control training
61914392|NCT06401213|EXPERIMENTAL|MTX-463|
62469984|NCT03541941|ACTIVE_COMPARATOR|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
62469985|NCT03541941|PLACEBO_COMPARATOR|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
61914393|NCT06401213|PLACEBO_COMPARATOR|Placebo|
62108168|NCT03990220||Treatment|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of yoghurt containing Lactobacillus rhamnosus, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
62108169|NCT03990220||Control|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of milk, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
62108170|NCT02225600|OTHER|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
62108171|NCT02225600|ACTIVE_COMPARATOR|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
62299444|NCT04697563|ACTIVE_COMPARATOR|Laser|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions."
62299445|NCT04697563|PLACEBO_COMPARATOR|Placebo Laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
62299446|NCT04332237||Hypothermia group|Hypothermic trauma patients or hypothermic patients with traumatic brain injury specifically.
62299447|NCT04332237||Normothermia group|Normothermic trauma patients or normothermic patients with traumatic brain injury specifically.
62299448|NCT00363415|EXPERIMENTAL|A|
62299449|NCT00363415|ACTIVE_COMPARATOR|B|
62299450|NCT02284724|EXPERIMENTAL|Needling|Insertion of solid mono-filament needle into lumbar multifidus muscle at both sides of L4/5 segment
62670006|NCT02455011|EXPERIMENTAL|REMD-477 Treatment E|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
62670007|NCT04607616|EXPERIMENTAL|3 baselines sessions Treatment As Usual (TAU)|Patients received 3 baseline sessions before interactive guidance therapy
61914394|NCT01358188||Gaucher disease group|Subjects will include individuals with GD
62299451|NCT02284724|OTHER|Sham|The plastic tube containing the mono-filament needle will be pressed into the skin over the lumbar multifidus muscle at both sides of L4/5 segment - without insertion through the skin
61914395|NCT01358188||Control group|Controls will include healthy individuals and individuals with primary immune dysfunction
62299452|NCT00156663|OTHER|Arm 1|
62299453|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
62299454|NCT02248779||treated < 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
62469986|NCT02613260|NO_INTERVENTION|Usual Care|Patients in this study arm will receive usual care from their primary care clinic.
62469987|NCT02613260|EXPERIMENTAL|FIT Outreach + Usual Care|Patients in this study arm will receive usual care at their primary care clinic and the intervention.
62670008|NCT04607616|EXPERIMENTAL|4 baselines sessions TAU|Patients received 4 baseline sessions before interactive guidance therapy
62670009|NCT04607616|EXPERIMENTAL|5 baselines sessions TAU|Patients received 5 baseline sessions before interactive guidance therapy
61914396|NCT00635076|PLACEBO_COMPARATOR|Placebo group|
61914397|NCT00635076|ACTIVE_COMPARATOR|Alprazolam XR group|
62108172|NCT01316978|EXPERIMENTAL|Experimental|Experimental Ibuprofen
62108173|NCT01316978|ACTIVE_COMPARATOR|Nurofen|Nurofen Meltlets Orodispersible Tablet
62108174|NCT01316978|ACTIVE_COMPARATOR|Motrin|Junior Strength Motrin Chewable Tablet
62108175|NCT05060562||Post COVID 19 symptoms Positive|The presence of persistent COVID-related symptoms after being cured.
62108176|NCT05060562||Post COVID 19 symptoms Negative|No persistent COVID-related symptoms after cured
62108177|NCT00943605|ACTIVE_COMPARATOR|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
62108178|NCT00943605|EXPERIMENTAL|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
62108179|NCT04092985||Patients suspected with Cardiac Arrhythmia|iECG + 12-lead ECG recording in patients suspected with any type of cardiac arrhythmias at the time of recruitment
61914398|NCT06514534|EXPERIMENTAL|Asciminib (Scemblix®)|Asciminib will be administered 200 mg twice a day orally. The minimum dose is 200 mg, and maximum dose is 400 mg.
61914399|NCT06047184|EXPERIMENTAL|Monotherapy group 1|BEBT-209 capsules, 25mg once daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
61914400|NCT06047184|EXPERIMENTAL|Monotherapy group 2|BEBT-209 capsules, 25mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
61914401|NCT06047184|EXPERIMENTAL|Monotherapy group 3|BEBT-209 capsules, 50mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
62108180|NCT01749761|PLACEBO_COMPARATOR|Hemodialysis without biofeedback|Patients will be randomized to receive hemodialysis without biofeedback for a period of 8 weeks.
62670010|NCT04607616|EXPERIMENTAL|6 baselines sessions TAU|Patients received 6 baseline sessions before interactive guidance therapy
62670011|NCT04607616|EXPERIMENTAL|7 baselines sessions TAU|Patients received 7 baseline sessions before interactive guidance therapy
62670012|NCT04607616|EXPERIMENTAL|8 baselines sessions TAU|Patients received 8 baseline sessions before interactive guidance therapy
62670013|NCT05008770||Older adults without sarcopenia|Healthy volunteers aged 65+ years who do not fulfill diagnostic criteria for sarcopenia, according to the revised European Working Group on Sarcopenia in Older People (EWGSOP2)
61914402|NCT06047184|EXPERIMENTAL|Monotherapy group 4|BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
62108181|NCT01749761|ACTIVE_COMPARATOR|BioLogic RR biofeedback|Patients will receive 8 weeks of HD with BioLogic RR Blood pressure guided biofeedback.
62108182|NCT04058743|ACTIVE_COMPARATOR|TKA with standard cobalt chromium components|Patients randomized to this group will receive the standard cobalt chromium components in their total knee arthroplasty
62108183|NCT04058743|EXPERIMENTAL|TKA with nickel free components|Patients randomized to this group will receive nickel free components in their total knee arthroplasty
62469988|NCT05034055|EXPERIMENTAL|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
62469989|NCT04446676|ACTIVE_COMPARATOR|Stem stabilization|Group of patients with stem endoprosthesis stabilization
62469990|NCT04446676|ACTIVE_COMPARATOR|Sleeve stabilization|Group of patients with sleeve endoprosthesis stabilization
62670014|NCT04898465|EXPERIMENTAL|Social Paediatric Intervention|Multiprofessional social paediatric meeting with the family.
62670015|NCT04898465|NO_INTERVENTION|Control group|Normal post-DGA dental programme.
62670016|NCT06308445|EXPERIMENTAL|Rapamycin|
62670017|NCT01078428|ACTIVE_COMPARATOR|Silicone gel|Gel containing silicone gel
62670018|NCT01078428|PLACEBO_COMPARATOR|Vaseline|Gel containing petrolatum gel
62670019|NCT00350220|ACTIVE_COMPARATOR|1|High Hemoglobin group; goal Hb \>13g/dl. 10cc/kg RBCs are transfused for any hemoglobin value under 13g/dl regardless whether clinical indication for transfusion exists.
62670020|NCT00350220|ACTIVE_COMPARATOR|2|Low Hb transfusion group; goal to not transfuse unless the Hb \<9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
62670021|NCT04456283||Incomplete pathological response with less than 12 LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
62670022|NCT04456283||Incomplete pathological response with 12 or more LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
61914403|NCT06047184|EXPERIMENTAL|Monotherapy group 5|BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
61914404|NCT06047184|EXPERIMENTAL|Monotherapy group 6|BEBT-209 capsules, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
61914405|NCT06047184|EXPERIMENTAL|BEBT-209 combined with the letrozole group 1|"BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle."
61914406|NCT06047184|EXPERIMENTAL|BEBT-209 combined with the letrozole group 2|"BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle."
61914407|NCT06047184|EXPERIMENTAL|BEBT-209 combined with the Fulvestrant Group 1|"BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle"
61914408|NCT06047184|EXPERIMENTAL|BEBT-209 combined with the Fulvestrant Group 2|"BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle"
61914409|NCT00217464|EXPERIMENTAL|Fulvestrant|Fulvestrant will be provided as 250 mg in 5 mL as a pre-tilled syringe. Fulvestrant will be administered as 500 mg, that is, 2 injections of 5 mL, one into each buttock im on day 0. A single 250 mg in 5 mL injection will be administered on day 14 followed by a single 250 mg in 5 mL dose on day 28 and monthly thereafter.
61914410|NCT01792570|EXPERIMENTAL|RPV + DRV/r|switch to RPV + DRV/r
61914411|NCT01792570|ACTIVE_COMPARATOR|continue the PI/r-containing HAART.|continue the PI/r-containing HAART
61914412|NCT00667173|EXPERIMENTAL|1|
61914413|NCT00667173|PLACEBO_COMPARATOR|2|
61914414|NCT00667173|PLACEBO_COMPARATOR|3|
61914415|NCT02412488|EXPERIMENTAL|Out of CathLab setting|Out of cathlab insertion
61914416|NCT05472701|EXPERIMENTAL|Whole Food Plant-Based (WFPB)|2 meals/day of traditional plant proteins (tofu, quinoa, black beans) and minimized intake of processed food, eggs, and dairy
62469991|NCT01370317|EXPERIMENTAL|MK-1029|
62670023|NCT04456283||Complete pathological response with less than 12 LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
61914417|NCT05472701|EXPERIMENTAL|Plant-Based Meat Alternatives (PBMA)|2 servings/day of plant-based meat alternatives (Beyond Beef, Impossible Burger, Gardein Chick'n)
61914418|NCT05472701|EXPERIMENTAL|Animal|2 servings/day of traditional meat products (beef burger, pork, chicken)
62108184|NCT03682328|ACTIVE_COMPARATOR|vertebroplasty|Patients will be managed by equipment of vertebroplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
62670024|NCT04456283||Complete pathological response with 12 or more LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
62670025|NCT05581888|OTHER|839MP group|Patients in this group were binocularly implanted with the AT LISA tri 839MP trifocal intraocular lens.
62108185|NCT03682328|ACTIVE_COMPARATOR|kyphoplasty|Patients will be managed by equipment of kyphoplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
62469992|NCT01370317|PLACEBO_COMPARATOR|Placebo|
62670026|NCT05581888|OTHER|TFNT00 group|Patients in this group were binocularly implanted with the AcrySof IQ PanOptix TFNT00 trifocal intraocular lens.
62670027|NCT02655809|OTHER|Physica KR|Patients who have received a Physica KR total knee implant.
62670028|NCT04061499||Hip OA|Individuals with diagnosed hip osteoarthritis
61914419|NCT01141062|EXPERIMENTAL|Treated leiomyomas|Philips MR-guided HIFU
61914420|NCT03344523|EXPERIMENTAL|standard treatment + Iron succinylate|1 bottle orally, twice daily, take orally before meals
61914421|NCT03344523|PLACEBO_COMPARATOR|standard treatment + placebo|1 bottle orally, twice daily, take orally before meals
61914422|NCT02102256|EXPERIMENTAL|Experimental|Device Implantation
61914423|NCT06297252|EXPERIMENTAL|Pregnant adults|Adults women with an ongoing pregnancy who are scheduled for a T2 ultrasound, regardless of known history or pregnancy context (normal or pathological).
61914424|NCT04762901|EXPERIMENTAL|Stage 1 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles, followed by AC IV every 21 days
61914425|NCT04762901|EXPERIMENTAL|Stage 1 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
61914426|NCT04762901|EXPERIMENTAL|Stage 1 Arm 3|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, 15, and 22 every 28 days
61914427|NCT04762901|EXPERIMENTAL|Stage 1 Arm 4|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, and 15 every 21 days and carboplatin IV every 21 days
62108186|NCT01006746||ICD patient and Home Monitoring|Patients primo implanted with ICD
62108187|NCT00768781|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction|
62108188|NCT00768781|ACTIVE_COMPARATOR|Mindfulness-Based Therapy for Insomnia|
62108189|NCT00768781|OTHER|Behavioral Therapy for Insomnia (Delayed treatment condition)|
62469993|NCT05875597|EXPERIMENTAL|Experimental Group Exercise|Participants will be required to undertake a strength oriented physical therapy exercise programme.
62670029|NCT04061499||Control|Individuals without diagnosed hip osteoarthritis
62670030|NCT02489773||Group 1|HbA1c values ranged from 7.5% to 12% (or higher)
62670031|NCT02489773||Group 2|HbA1c values \<7.5%
62670032|NCT01084486|EXPERIMENTAL|Metformin, Adiponectine, Arterial Compliance|
62670033|NCT03367585|EXPERIMENTAL|Experimental|The experimental group, which will supplement vitamin D3 50,000 IU / week, being in two capsules (25,000 IU / week each),
62670034|NCT03367585|PLACEBO_COMPARATOR|Placebo|The placebo group will inject two capsules of equal size, volume and coloration, composed of lactose, without the vitamin D3 supplement.
61914428|NCT04762901|EXPERIMENTAL|Stage 2 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles
61914429|NCT04762901|EXPERIMENTAL|Stage 2 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
61914430|NCT00081510|EXPERIMENTAL|Lonafarnib plus Anastrozole|Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
61914431|NCT00081510|ACTIVE_COMPARATOR|Placebo plus Anastrozole|Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
61914432|NCT00473980|EXPERIMENTAL|Drug|Treatment with indomethacin or celecoxib
61914433|NCT00473980|SHAM_COMPARATOR|SHAM|Sham treatment
61914434|NCT01597115|ACTIVE_COMPARATOR|Duplex|Patients in this group will be examed by duplex ultrasonography at 2 and 4 weeks after surgery
61914435|NCT01597115|NO_INTERVENTION|physical exam|According to the K/DOQI guideline, patients will be examed by vascular access surgeon at 2 and 4 weeks after surgery
61914436|NCT06272097|EXPERIMENTAL|Intervention group|The intervention group will receive an intervention plan based on the TIME CDST tool led by wound specialist nurses at each dressing change.
62469994|NCT05875597|NO_INTERVENTION|Control Group|Participants will not engage in a strength oriented therapeutic physical exercise programme.
62670035|NCT01841853|EXPERIMENTAL|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
62670036|NCT01841853|NO_INTERVENTION|Control group|The control group will receive conventional care on their own initiative.
62670037|NCT00996177|EXPERIMENTAL|IONSYS|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
62670038|NCT00996177|ACTIVE_COMPARATOR|Patient-Controlled Analgesia|IV Morphine Patient-Controlled Analgesia (IV PCA)
62670039|NCT03211832|NO_INTERVENTION|Control|The control group will conduct usual public health practice.
62735926|NCT01389726|EXPERIMENTAL|Cognitive Behavioral Therapy|CBT group-level intervention (Designed by Larry Thompson \& Dolores Gallagher Thompson)
62735927|NCT01389726|ACTIVE_COMPARATOR|Psychosocial-Informational Support|Standard of Care informational support group
61914437|NCT06272097|OTHER|Control group|The control group receives a routine wound care program of wound cleaning and dressing changes at each dressing change.
61914438|NCT04014374||Transplant Arm|Patients with CTCL or ATLL who received mogamulizumab within one year prior or up to 18 months after alloHCT
61914439|NCT04014374||Control Arm|Patients who have undergone alloHCT without exposure to mogamulizumab pre- or post-alloHCT
61914440|NCT03603327|OTHER|Treatment|All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
61914441|NCT01998984|EXPERIMENTAL|2 days placebo and 2 days drug|Placebo and drug
61914442|NCT01998984|EXPERIMENTAL|1 day placebo and 3 days drug|Placebo and drug
62108190|NCT00864812|EXPERIMENTAL|1|tiotropium with fluticasone propionate/salmeterol (FSC)
62108191|NCT00864812|ACTIVE_COMPARATOR|2|tiotropium
62108192|NCT05085496|EXPERIMENTAL|Treatment (SBRT, atezolizumab)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 of cycle 1. Beginning 1-2 days after SBRT, patients also receive atezolizumab IV on day 1. Treatment repeats every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
62108193|NCT00685893|NO_INTERVENTION|Control Arm|6 Community hospital ICUs receiving delayed intervention activities after the completion of the randomized trial
62108194|NCT00685893|EXPERIMENTAL|Intervention Arm|6 community hospital ICUs receiving 5-component intervention.
62108195|NCT01156116|ACTIVE_COMPARATOR|Continuous positive airway pressure|2 weeks of continuous positive airway pressure (CPAP) treatment which includes wearing the CPAP mask for 8 hours each night
62108196|NCT01156116|PLACEBO_COMPARATOR|Placebo|2 weeks of oral administration of a placebo tablet 30min before bedtime
62108197|NCT06630975|EXPERIMENTAL|Comparative Study between Growth guided Correction By ( 8 Plate )|Coronal angular deformities of lower limb in children are a common finding in pediatric orthopedic surgery.
62299455|NCT02248779||treated ≥ 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
61914443|NCT01998984|PLACEBO_COMPARATOR|4 days placebo|Placebo
62108198|NCT06630975|OTHER|Clinical ,Radiological of Comparison the Result of Growth guided Correction to Osteoclasis in mana|These angular deformities can be idiopathic in origin, or they can emerge secondary to congenital and acquired abnormalities. Valgus deformities in excess of 10\* can cause anterior knee pain, circumduction gait, and occasionally patellofemoral instability. Varus deformities may result in lateral thrust, ligamentous laxity, and a waddling gait , meniscal tears, collateral ligament laxity, cartilage degeneration, and early osteoarthritis due to gradual mechanical axis disruption
61914444|NCT01998984|EXPERIMENTAL|4 days drug|Drug
61914445|NCT05915039|EXPERIMENTAL|Group A|This is the initial experimental group who will be exposed to the CAL module 48 hours before the first retesting period 2 months out from initial baseline measurement.
61914446|NCT05915039|NO_INTERVENTION|Group B|This is the initial control group who will not be exposed to the CAL module 48 hours before the first retesting period 2 months out from initial baseline measurement.
62299456|NCT02420886|ACTIVE_COMPARATOR|Cytokines supplemented In Vitro single culture media|We will add Cytokines (LIF, HB-EGF and GM-CSF) to LIFEGLOBAL culture media and assess the embryogenesis and pregnancy.
62299457|NCT02420886|NO_INTERVENTION|Traditional Single step culture media|
62299458|NCT01152853|EXPERIMENTAL|single arm|PF00299804 treatment arm
61914447|NCT03199443||Overactive bladder patients|
61914448|NCT03199443||Non Obstructive Urinary Retention patients|
62299459|NCT04706572|EXPERIMENTAL|Patients with Golden Rhythm|Administration of an external auditory cue based on Golden Rhythm
62108199|NCT06630975|ACTIVE_COMPARATOR|Comparison the Result of Growth guided Correction to Osteoclasis|These angular deformities can be idiopathic in origin, or they can emerge secondary to congenital and acquired abnormalities. Valgus deformities in excess of 10\* can cause anterior knee pain, circumduction gait, and occasionally patellofemoral instability. Varus deformities may result in lateral thrust, ligamentous laxity, and a waddling gait , meniscal tears, collateral ligament laxity, cartilage degeneration, and early osteoarthritis due to gradual mechanical axis disruption
62108200|NCT06630975|ACTIVE_COMPARATOR|Genu Varum|These angular deformities can be idiopathic in origin, or they can emerge secondary to congenital and acquired abnormalities. Valgus deformities in excess of 10\* can cause anterior knee pain, circumduction gait, and occasionally patellofemoral instability. Varus deformities may result in lateral thrust, ligamentous laxity, and a waddling gait , meniscal tears, collateral ligament laxity, cartilage degeneration, and early osteoarthritis due to gradual mechanical axis disruption
62108201|NCT02869958|ACTIVE_COMPARATOR|1: Written action plan|Written action plan
62108202|NCT02869958|EXPERIMENTAL|2: Digital action plan|Written action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
62108203|NCT01559480|ACTIVE_COMPARATOR|Desogestrel|
62108204|NCT01559480|PLACEBO_COMPARATOR|Placebo|
62108205|NCT04813393||Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire Group|The CPHP-Q was administered as a caregiver-report questionnaire. It aims to measure home program adherence of parents of children with CP. Parents applied this instrument in the study.
62108206|NCT00215306|EXPERIMENTAL|Lumbar TDR|CHARITÉ Artificial Disc
62108207|NCT00215306|ACTIVE_COMPARATOR|ALIF|Anterior Interbody Fusion with BAK Cage
62108208|NCT00975806|EXPERIMENTAL|Cohort A|Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
62108209|NCT00975806|EXPERIMENTAL|Cohorts F and G|Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle
62108210|NCT03992495||Neck pain|People suffering from neck pain at the time of recruitment
62670040|NCT03211832|ACTIVE_COMPARATOR|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
62670041|NCT05354258|PLACEBO_COMPARATOR|Vitamin A + Zinc supplements on Day 0, followed by SMC course on Day 1,2 & 3|
62108211|NCT03992495||Healthy|Participants with no significant past neck pain, chronic pain or other relevant medical disorders.
62108212|NCT05460806|EXPERIMENTAL|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
62108213|NCT05460806|NO_INTERVENTION|Control|
62108214|NCT05512949|EXPERIMENTAL|Arm 1|0.1 mL of 2 x 10\^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
62108215|NCT05512949|EXPERIMENTAL|Arm 2|0.05 mL of 1 x 10\^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
62108216|NCT05512949|ACTIVE_COMPARATOR|Arm 3|0.5 mL of 1 x 10\^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on Days 1 and 29. N=70
62108217|NCT01190150|EXPERIMENTAL|0.65 g / 1.3 g tranexamic acid|Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.
62108218|NCT01190150|EXPERIMENTAL|1.3 g / 0.65 g tranexamic acid|Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.
62108219|NCT01821586|EXPERIMENTAL|Modified ORS-1|Modified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
62108220|NCT01821586|EXPERIMENTAL|Modified ORS-2 (ReSoMal)|Modified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
62108221|NCT01821586|EXPERIMENTAL|Modified ORS-3 (Benefibre)|Modified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
62108222|NCT04868799||ATRT|Patients \<18 years with an ATRT having frozen samples
62299460|NCT04706572|PLACEBO_COMPARATOR|Patients with Metronome|Administration of an external auditory cue based on metronome binary rhythm
62108223|NCT03234621|EXPERIMENTAL|conventional tidal group|provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
62108224|NCT03234621|EXPERIMENTAL|low tidal group|provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
62299461|NCT00590161|EXPERIMENTAL|1|Pentoxifylline (PTX) 400 mg by mouth (PO) three times daily (TID)
62299462|NCT00590161|PLACEBO_COMPARATOR|2|Placebo three times daily (TID)
62469995|NCT01654458|EXPERIMENTAL|Immediate Treatment Condition|Receives the 12-week GyneGals Support Group within a month of completing the baseline assessment.
62670042|NCT05354258|EXPERIMENTAL|Praziquantel + Vitamin A on Day 0, followed SMC course on Days 1,2 & 3|
62670043|NCT05354258|EXPERIMENTAL|Albendazole + Praziquantel on Day 0, followed by SMC course on Days 1, 2 & 3|
62670044|NCT01971593|OTHER|Eplerenone after drug free period|Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
62670045|NCT01971593|OTHER|Eplerenone before drug free period|Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
62670046|NCT05431907|EXPERIMENTAL|Cohorts 1-2|Escalating doses of Allocetra-OTS up to 10 x 10\^9 cells.
62670047|NCT05431907|EXPERIMENTAL|Cohorts 3-4|Allocetra-OTS at the maximal tolerated dose.
62670048|NCT06144086|EXPERIMENTAL|Foscenvivint|Foscenvivint 280 mg/m2, twice a week for 24 weeks
62670049|NCT01560130|ACTIVE_COMPARATOR|Shape Up Rhode Island + Online Weight Loss + Incentives|
62299463|NCT04030195|EXPERIMENTAL|Dose Level 1 of PBCAR20A CAR T cells|"1 x 10\^6 chimeric antigen receptor (CAR) T cells per kg body weight.~In this study, PBCAR20A, allogeneic anti-cluster of differentiation (CD20) CAR T Cells, is used to treat patients with relapsed or refractory (r/r) CD20+ Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).~Route of Administration: Intravenous infusion (IV)~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR20A infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62670050|NCT01560130|ACTIVE_COMPARATOR|Shape Up Rhode Island + Online weight loss program|
62670051|NCT01560130|ACTIVE_COMPARATOR|Shape Up Rhode Island + Online weight loss program + groups|
62670052|NCT03640026|EXPERIMENTAL|Tacrolimus treatment|
62670053|NCT05436912|EXPERIMENTAL|Healthy participants with normal hepatic function|Selpercatinib administered orally to healthy participants.
62670054|NCT05436912|EXPERIMENTAL|Participants with mild hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per Child-Pugh \[CP\] classification (CP Class A, score of 5 or 6).
62670055|NCT05436912|EXPERIMENTAL|Participants with moderate hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per CP classification (CP Class C, score of 10 to 15).
62670056|NCT05436912|EXPERIMENTAL|Participants with severe hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per CP classification (CP Class B, score of 7 to 9)).
62670057|NCT05343429|ACTIVE_COMPARATOR|Benzydamine hydrochloride (BN)|15 ml of 0.15 % Benzydamine hydrochloride (BN) to dissolved in 15 ml plain water in a sterile container
62670058|NCT05343429|ACTIVE_COMPARATOR|Aspirin (Ap)|600 mg Aspirin tablets dissolved in 30 ml of plain water
62670059|NCT03517007|EXPERIMENTAL|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
62670060|NCT03517007|NO_INTERVENTION|Standard of Care|Provider continues routine, standard of care on the patient.
62670061|NCT01716195|EXPERIMENTAL|Response Adapted Chemoradiation|Paclitaxel 175 mg/m2 + Carboplatin area under curve (AUC) 6 followed by response adapted Radiation Therapy (5 - 6 weeks) + Paclitaxel
62670062|NCT05434676|EXPERIMENTAL|IVL group|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 or S4
62670063|NCT03713788|EXPERIMENTAL|Experimental pain group|subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. They were instructed to immerse it to wrist-level and keep the hand open.
62670064|NCT03713788|NO_INTERVENTION|Control group|Participants rested in a seated position for 5 minutes.
62670065|NCT00651807|ACTIVE_COMPARATOR|Arm 1|etonogestrel
62670066|NCT00651807|PLACEBO_COMPARATOR|Arm 2|Placebo
62670067|NCT02722135|EXPERIMENTAL|Volasertib|
61914449|NCT06451731|EXPERIMENTAL|PHOLEXSEM|"Each session lasted 30 minutes, and comprised three sections, each lasting 10 minutes: Repetition, Semantic Feature Analysis (SFA), and Lexical retrieval.~Repetition: 50 items for different kind of stimuli including: syllables, 2-syllable words and non-words; 2-syllable words and non-words with one consonant cluster; 3-syllable words and non-words; 3-syllable words and non-words with one consonant cluster, nuclear phrases.~SFA: stimuli were 46 pictures of nouns, including living and non-living objects, controlled for frequency of use.~Lexical retrieval phase: the patient was given three fluency tasks: a) 4 min of phonemic recall, b) 4 min of semantic recall, and c) 2 min of verb recall."
62670068|NCT01011296|EXPERIMENTAL|Single IV Dose 1|
62670069|NCT01011296|EXPERIMENTAL|Single IV Dose 2|
62670070|NCT01011296|EXPERIMENTAL|Single IV Dose 3|
62670071|NCT04891653|EXPERIMENTAL|5-65mg QD|
62670072|NCT04623060|EXPERIMENTAL|Intervention|3 sessions/week for 6 weeks
62670073|NCT00527878|EXPERIMENTAL|Placebo/Ranitidine crossover|Patients took placebo for 12 months and then ranitidine for 12 months
62670074|NCT00527878|EXPERIMENTAL|Ranitidine/placebo crossover|Ranitidine for one year followed by placebo for one year
62670075|NCT04561531|EXPERIMENTAL|Intermittent bolus|In intermittent bolus of 3%NaCl group ,patients will receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and then follow plasma sodium,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
62670076|NCT04561531|EXPERIMENTAL|Traditional continuous drip|In traditional continuous drip of 3%NaCl group ,patients will receive 3%NaCl adjust rate start from 1 ml/kg/hr and follow plasma sodium every 1 hour,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
62735928|NCT05225077|ACTIVE_COMPARATOR|Dapagliflozin 10mg group|Dapagliflozin 10 mg once a day for 1 month after the procedure.
62735929|NCT05225077|NO_INTERVENTION|Non-intervention group|No intervention.
62735930|NCT03956992|EXPERIMENTAL|Mouth gel|A mouth gel with hydroxyapatite
62735931|NCT00106119|ACTIVE_COMPARATOR|Liothyronine and Levothyroxine|Hypothyroid patients treatment with Levothyroxine and Liothyronine in 2 crossover, randomized phases
61914450|NCT06451731|ACTIVE_COMPARATOR|PACE|Three decks of cards - diversified by frequency of use - depicting nouns, were presented in sets of 4 cards each. In an exchange modality, the task consisted in understanding the noun chosen by the patient and, in turn, by the rehabilitator. Any communicative modality (oral, gestural, verbal, graphic) was allowed. Word difficulty was graded based on the frequency of use and semantic proximity or distance between target and distractors.
61914451|NCT04772742|EXPERIMENTAL|Eptinezumab|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
61914452|NCT04772742|PLACEBO_COMPARATOR|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
62469996|NCT01654458|NO_INTERVENTION|Waitlist Control Condition|Waitlist control group receives the 12-week GyneGals Support Group only after its involvement in the study has ended, as a courtesy.
62670077|NCT03074643|PLACEBO_COMPARATOR|RecProt|Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
62670078|NCT03074643|ACTIVE_COMPARATOR|6-mon HiProt|Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
61914453|NCT01145638|EXPERIMENTAL|iron isomaltoside 1000|Iron isomaltoside intravenously as bolus or infusion
61914454|NCT01145638|ACTIVE_COMPARATOR|iron sulphate|oral iron sulphate twice a day
62670079|NCT03074643|ACTIVE_COMPARATOR|18-mon HiProt|"Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
62670080|NCT02767245|ACTIVE_COMPARATOR|Thiamine|Thiamine intravenously 100 mg/day for 3 days
61914455|NCT02364401|EXPERIMENTAL|Impedance Guided Ablation Group|Impedance guided ablation group performs pulmonary vein(PV) isolation guided by annotation criteria with minimum time of 10 seconds, maximum range of 2 mm, and minimum impedance decrease over 5 Ohms instead of CF parameters. In the impedance guided group, operators are blinded to contact force data during PV isolation.
61914456|NCT02364401|ACTIVE_COMPARATOR|Contact Forced Guided Ablation Group|Contact force(CF) guided ablation group performs pulmonary vein (PV) isolation guided by automated annotation criteria with minimum time of 10 seconds, maximum range of 2mm, CF over time of 50% and minimum CF of 10 g.
62670081|NCT02767245|NO_INTERVENTION|No thiamine|No thiamine was given to the patient
61914457|NCT02004639|ACTIVE_COMPARATOR|Mastictors sparing group|Using IMRT or HT to do masticators sparing techniques and physical therapy to prevent trismus.
61914458|NCT02004639|NO_INTERVENTION|Masticators not sparing group|The patients do not receive masticators sparing technique as traditional techniques but still receive physical therapy after radiotherapy to prevent trismus.
62670082|NCT05926193|EXPERIMENTAL|Nutrition Workshops|
62670083|NCT05926193|NO_INTERVENTION|No Workshops|
62670084|NCT02305459||Patients treated with Radioembolisation|"All Patients treated with Radioembolisation with yttrium-90 loaded SIR-Spheres microspheres are asked to be enrolled. In no way will participation in the registry influence the way in which the patient is treated or will it influence the quality of the treatment.~In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with the Hepatocellular carcinoma (HCC) Module to measure changes in the quality of life of the patient."
61914459|NCT02004639|ACTIVE_COMPARATOR|EA group|Using masticators sparing techniques and electro-acupunture stimulation to prevent trismus
61914460|NCT02004639|SHAM_COMPARATOR|Sham-EA group|Using masticators sparing techniques but with sham EA stimulation.
61914461|NCT00828373|PLACEBO_COMPARATOR|Placebo|
62108225|NCT03234621|EXPERIMENTAL|high tidal group|provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
62108226|NCT03761654||"Patients with a non-severe subarachnoid hemorrhage"|
62108227|NCT05993949|EXPERIMENTAL|Dasatinib|Oral dasatinib 100mg
62108228|NCT01180621|EXPERIMENTAL|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
62670085|NCT02521194|EXPERIMENTAL|Caregiver Questionnaire|Questionnaire completion regarding opinion on the inpatient occupational therapy session person being cared for received.
62670086|NCT02521194|EXPERIMENTAL|Patient Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
61914462|NCT00828373|ACTIVE_COMPARATOR|Lidocaine|
61914463|NCT05049720|EXPERIMENTAL|Experimental|Patients will be implanted with an Extravascular ICD and undergo requisite electrical testing.
62108229|NCT04594330|ACTIVE_COMPARATOR|Group 1 - 30 COVID-19 patients aged ≥ 18 years old receiving the investigational drug|Group 1 - 30 COVID-19 patients receiving standard therapy and the investigational drug (Virgin Coconut Oil)
62108230|NCT04594330|PLACEBO_COMPARATOR|Group 2 - 30 COVID-19 patients aged ≥ 18 years old receiving placebo|Group 2 - 30 COVID-19 patients receiving standard therapy and placebo
62299464|NCT04030195|EXPERIMENTAL|Dose Level 2 of PBCAR20A CAR T cells|240 x 10\^6 CAR T cells (flat dose)
62469997|NCT01331538||adolescents with TMD|adolescents with temporomandibular dysfunction
62469998|NCT01331538||No TMD|adolescents without temporomandibular dysfunction
62670087|NCT06210295||Anemia and Systemic lupus erythematosus|Systemic lupus patients with anemia and searching for causes of anemia and what is the most common and what are the causes of refractory anemia and relation of bone marrow affection
62469999|NCT02139839|PLACEBO_COMPARATOR|Gelatin pill first|
62470000|NCT02139839|EXPERIMENTAL|Lactobacillus capsules first|
62670088|NCT03748563|EXPERIMENTAL|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically maneuvered capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
62670089|NCT01846143|EXPERIMENTAL|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
62670090|NCT01846143|EXPERIMENTAL|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
62670091|NCT01846143|EXPERIMENTAL|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
62670092|NCT00007501|EXPERIMENTAL|Arm 1|varicella-zoster vaccine
62670093|NCT00007501|PLACEBO_COMPARATOR|Arm 2|vaccine placebo
62670094|NCT05797090|EXPERIMENTAL|crystalloid cardioplegia with modified del Nido cardioplegia|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
62670095|NCT01932580|OTHER|FLOT chemotherapy|"Chemotherapy to be administered every 2 weeks for 4 cycles, before surgery. Then 4 more cycles will be given after surgery, at 2-week intervals.~5-FU 2600 mg IV/m2 in continuous infusion Leucovorin 200 mg IV/m2 Oxaliplatin 85 mg IV/m2 Docetaxel 50 mg IV/m2"
62670096|NCT01307735||Myocarditis negative on CMR|Patients with suspected myocarditis referred for CMR and not fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
62670097|NCT01307735||Myocarditis positive on CMR|Patients with suspected myocarditis referred for CMR and fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
62670098|NCT02423720|OTHER|Study Intervention|Audio-based mindfulness intervention A 8-week single arm pilot study will be conducted among Helen Diller Famiily Comprehensive Cancer Center (HDFCCC) patients with metastatic colorectal cancer receiving chemotherapy and their caregivers (44 participants, total). Participants will receive an informational booklet containing a practice log and an MP3 player containing an introductory lecture and guided meditations. Practice reminders will be sent via text messages. Weekly emails will contain practice instructions and links to validated questionnaires.
62670099|NCT00289900|EXPERIMENTAL|MK-0524B 2g/20 mg|Co-administration of one tablet of MK-0524A (Extended Release \[ER\] niacin/laropiprant \[LRPT\] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
62108231|NCT04458831||Cohort 1|Patients with multiple myeloma (MM) and are considered as RRMM according to the International Myeloma Working Group (IMWG) criteria
62108232|NCT05001906|NO_INTERVENTION|Control group|The control group (CG) will consist of pregnant women with standard prenatal care, who attending theoretical classes on childbirth (CG, n = 35). The control group will not exercise. The sedentary participants will continue their regular daily activities and life habits.
62470001|NCT01762618|EXPERIMENTAL|Cognitive Behavioral Therapy Group|14 therapy sessions, once a week for one and a half hours.
62470002|NCT01762618|NO_INTERVENTION|Control Group|Social support for caregiver (through the social worker) as usual. The social worker gives information when they considered that there is a social economic risk or upon request by the caregiver.
62470003|NCT03921294|EXPERIMENTAL|Single Arm|Patients with hemophilic pseudotumor will be treated with prophylactic emicizumab and assessed for improvement.
62470004|NCT03331445|EXPERIMENTAL|160 ppm Nitric Oxide|
62470005|NCT04306107|EXPERIMENTAL|NIV with prone position|Use of prone position during NIV
62670100|NCT00289900|EXPERIMENTAL|MK-0524B 2g/40mg|Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
62470006|NCT04306107|PLACEBO_COMPARATOR|NIV (conventional)|NIV on conventional position
62670101|NCT00289900|ACTIVE_COMPARATOR|Atorvastatin 10 mg|Atorvastatin 10 mg, orally, once daily for 12 weeks
62108233|NCT05001906|EXPERIMENTAL|Exercise group|The exercise group (EG) will consist of pregnant women who will attend theoretical classes and prenatal exercises in the program of psychophysical preparation for childbirth (EG, n = 35). The experimental group will exercise for 45 minutes, three times a week.
62108234|NCT03942042|EXPERIMENTAL|Ixekizumab|"Induction Dosing Period:~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.~Maintenance Dosing Period:~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1."
62108235|NCT02404337|EXPERIMENTAL|100 mg/kg of Betaine|Dose 1 : 100 mg/kg of Betaine
62108236|NCT02404337|EXPERIMENTAL|250 mg/kg of Betaine|Dose 2 : 250 mg/kg of Betaine
62108237|NCT05779007||Pirfenidone initiators|Patients who initiated pirfenidone treatment
62470007|NCT04306107|EXPERIMENTAL|HFNC on prone position|Prone position during HFNC
62470008|NCT04306107|PLACEBO_COMPARATOR|HFNC (conventional)|HFNC on conventional position
62470009|NCT03921463||caesarean section|
62470010|NCT03921463||vaginal delivery|
62470011|NCT05957263|EXPERIMENTAL|Biofeedback training and Osteopathy procedure|"the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.~The osteopathy techniques involved a combination of myofascial, visceral, and articular techniques aimed at restoring and rebalancing internal tensions and improving visceral mobility."
62470012|NCT05957263|ACTIVE_COMPARATOR|Biofeedback training|he biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.
62470013|NCT05957263|ACTIVE_COMPARATOR|Osteopathy procedure|The osteopathy techniques involved a combination of myofascial, visceral, and articular techniques aimed at restoring and rebalancing internal tensions and improving visceral mobility.
62470014|NCT04135027||CD group|no interventions
62470015|NCT05122286|EXPERIMENTAL|Bailout angioplasty|If the patient is randomized into the bailout angioplasty arm, the choice of balloon dilation or stenting will be left to the discretion of the interventionalist.
62470016|NCT05122286|ACTIVE_COMPARATOR|Standard therapy|If the patient is randomized into the standard therapy arm, the interventionalist will decide whether to stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters.
62470017|NCT00599664|EXPERIMENTAL|1|Drug
62470018|NCT00599664|PLACEBO_COMPARATOR|2|Vehicle
62470019|NCT05746897|EXPERIMENTAL|NM1F Injection/pembrolizumab Injection|NM1F monotherapy dose escalation(Phase 1a) NM1F dose escalation in combination with a fixed dose of pembrolizumab(Phase 1b)
62670102|NCT00289900|ACTIVE_COMPARATOR|Atorvastatin 20 mg|Atorvastatin 20 mg, orally, once daily for 12 weeks
62670103|NCT00289900|ACTIVE_COMPARATOR|Atorvastatin 40 mg|Atorvastatin 40 mg, orally, once daily for 12 weeks
62670104|NCT00289900|ACTIVE_COMPARATOR|Atorvastatin 80 mg|Atorvastatin 80 mg, orally, once daily for 12 weeks
62108238|NCT05779007||Nintedanib initiators|Patients who initiated nintedanib treatment
62299465|NCT04030195|EXPERIMENTAL|Dose Level 3 of PBCAR20A CAR T cells|480 x 10\^6 CAR T cells (flat dose)
62299466|NCT06366373|EXPERIMENTAL|an exhibition group|those who attend the offline art exhibition
62299467|NCT06366373|ACTIVE_COMPARATOR|an education group|those who are unable to attend the offline art exhibition but will be provided with printed/online education materials
62299468|NCT03038022|EXPERIMENTAL|MGL-3196|Study Drug
62670105|NCT01732211|EXPERIMENTAL|PD 0360324|
62670106|NCT01732211|PLACEBO_COMPARATOR|Placebo|
62670107|NCT01898091|EXPERIMENTAL|Neem Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
62299469|NCT03038022|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62299470|NCT06041750||OSAS patients with postoperative pulmonary complication|American Society of Anesthesiologists (ASA) physical status I-III adult patients age between 18-65 years undergoing elective surgery with general anesthesia and diagnosis of OSAS will be recruited in this study. In this patient group, the incidence of postoperative early-period and long-term pulmonary complications will be investigated.
62299471|NCT02716376|EXPERIMENTAL|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
62299472|NCT02716376|NO_INTERVENTION|No treatment|Observation: No treatment.
61914464|NCT06418464|EXPERIMENTAL|AP-A Dosage Decision Support System|The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
61914465|NCT06418464|ACTIVE_COMPARATOR|Physician decision-making|The injection dose of the control group was determined by the doctor solely.
61914466|NCT03130647|EXPERIMENTAL|Focused ultrasound|Repeated measures sham control
61914467|NCT01849887|ACTIVE_COMPARATOR|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
62108239|NCT05803330|NO_INTERVENTION|PXB combined with venous dilation group|Use of PXB combined with intravenous volume expansion during preoperative preparation in patients with pheochromocytoma
62470020|NCT05132933|EXPERIMENTAL|Shunt-group|Test of three different levels of positive end-expiratory pressure (PEEP)
62670108|NCT01898091|PLACEBO_COMPARATOR|Placebo Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
62670109|NCT00478140|EXPERIMENTAL|Trastuzumab|Participants receive trastuzumab loading dose 8 mg/kg intravenous (IV) over 30-90 minutes on day 1 and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62670110|NCT05698628|EXPERIMENTAL|Preemptive distal perfusion group|Distal perfusion catheterization will be done within 1 hour after VA-ECMO application.
62670111|NCT05698628|ACTIVE_COMPARATOR|Conventional distal perfusion group|The conventional group will undergo distal perfusion catheterization at the time of limb ischemia sign.
62670112|NCT05903742||Hepatitis delta cohort|hepatitis delta patients aged ≥18 years
62670113|NCT01272687||Observation|Adults (\>18 years) with a confirmed diagnosis of Parkinson's disease
62670114|NCT04506710||Patients with low-risk prostate cancer|Histologically confirmed low-risk prostate cancer (PSA up to 10 ng / ml; Gleason (3 + 3) = 6 (ISUP 1); tumor stage T2a (low- risk according to the D'Amico scale))
62670115|NCT02441114|EXPERIMENTAL|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.~The periods were separated with a washout period of 14 days."
62670116|NCT02898389||Group 1: With cardiovascular risk factors|Patients fall within this group when they have at least one of the cardiovascular risk factors listed in the eligibility criteria section.
62670117|NCT02898389||Group 1: Without cardiovascular risk factors|Patients fall into this group when they do not have any of the cardiovascular risk factors listed in the eligibility criteria section.
62670118|NCT05644964||Group 1:|Anemic pregnancies under the age of 18 (study group),
61914468|NCT01849887|PLACEBO_COMPARATOR|Placebo|Placebo
61914469|NCT05287360|EXPERIMENTAL|Treatment Sequence 1|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 1; Period 2: Formulation 2; Period 3: Formulation 3; Period 4: Formulation 4~There will be a washout period of 5 days between each dosing."
61914470|NCT05287360|EXPERIMENTAL|Treatment Sequence 2|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 2; Period 2: Formulation 4; Period 3: Formulation 1; Period 4: Formulation 3~There will be a washout period of 5 days between each dosing."
62670119|NCT05644964||Group 2:|Anemic pregnancies over the age of 35 (study group)
62108240|NCT05803330|EXPERIMENTAL|PXB group|PXB alone during preoperative preparation in patients with pheochromocytoma
62299473|NCT04322708|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive 6 monthly doses of placebo.
62670120|NCT05644964||Group 3:|Pregnant women under the age of 18 are not anemic (control group)
62670121|NCT05644964||Group 4:|Non-anemic pregnant women over the age of 35 (control group)
62670122|NCT04948632|ACTIVE_COMPARATOR|Complete LeoMed application|LeoMed application with integrated artificial intelligence
62670123|NCT04948632|PLACEBO_COMPARATOR|Basic LeoMed application|LeoMed application without artificial intelligence
62670124|NCT00871000|EXPERIMENTAL|BOOSTRIX POLIO GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Boostrix Polio™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Boostrix Polio™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
62670125|NCT00871000|ACTIVE_COMPARATOR|TETRAVAC GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Tetravac™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Tetravac™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
62670126|NCT02227264|EXPERIMENTAL|Cinacalcet|"Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.~Second intervention: Parathyroid adenomectomy."
62670127|NCT04302259|EXPERIMENTAL|SCI Patient|Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10
62670128|NCT06035198||Stroke patients|Patients diagnosed with stroke at four hospitals in Korea
62670129|NCT04874441|NO_INTERVENTION|blood culture-based diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy
62670130|NCT04874441|EXPERIMENTAL|C. glabrata / krusei PCR diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata / krusei PCR
62670131|NCT03439514|EXPERIMENTAL|Part 1 Double-blind Treatment|ARRY-371797 (PF-07265803) tablet orally OR matching placebo tablet orally
62670132|NCT03439514|EXPERIMENTAL|Part 2 Open-label Treatment|ARRY-371797 (PF-07265803) tablet orally
62670133|NCT05320588|EXPERIMENTAL|Single agent BIO-106|Escalating doses followed by expansion targeting advanced cancers
62670134|NCT05320588|EXPERIMENTAL|Combination BIO-106 plus pembrolizumab|Escalating doses followed by expansion targeting advanced cancers
62670135|NCT02856373|OTHER|CPVT|catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
62670136|NCT02856373|OTHER|long QT syndrome|long QT syndrome patients
62670137|NCT02856373|OTHER|ARVC|arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
62299474|NCT04322708|EXPERIMENTAL|1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).
62670138|NCT02856373|OTHER|HCM|hypertrophic cardiomyopathy (HCM) patients
62670139|NCT02856373|OTHER|DCM|dilated non-ischemic cardiomyopathy (DCM) patients
62670140|NCT02856373|OTHER|ICM|ischemic cardiomyopathy (ICM) patients
62670141|NCT02449447|EXPERIMENTAL|Blended treatment|10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.
62670142|NCT02449447|ACTIVE_COMPARATOR|Treatment as usual|Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).
62670143|NCT00560599|NO_INTERVENTION|1: Standard of care|Standard of care (no body decolonization regimen) and Standard of care (no environmental decolonization regimen)
62299475|NCT04322708|EXPERIMENTAL|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.
62470021|NCT04167332||NMIBC|"Patients diagnosed with primary non-muscle-invasive bladder (NMIBC) cancer.~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.~The clinical (demographic, operative and follow-up) and pathological data, and biosamples (blood, urine, bladder cancer tissue) of the patients will be collected in a completely anonymous way."
62470022|NCT00318383|EXPERIMENTAL|1|200 mcg NicVAX in each of 4 doses
62470023|NCT00318383|EXPERIMENTAL|2|200 mcg NicVAX in each of 5 doses
62470024|NCT00318383|EXPERIMENTAL|3|400 mcg NicVAX in each of 4 doses
62470025|NCT00318383|EXPERIMENTAL|4|400 mcg NicVAX in each of 5 doses
62670144|NCT00560599|EXPERIMENTAL|2: Body decolonization regimen|Body decolonization regimen and Standard of care (no environmental decolonization regimen)
62670145|NCT00560599|EXPERIMENTAL|3 Environmental decolonization regimen|Standard of care (no body decolonization regimen) and Environmental decolonization regimen
62670146|NCT00560599|EXPERIMENTAL|4 Body and Environmental decolonization regimens|Body decolonization regimen and Environmental decolonization regimen
62670147|NCT06091605|EXPERIMENTAL|Omega roll envelope flap (OREF) technique|"Patients will undergo peri-implant soft tissue augmentation procedures accompanied by the placement of healing abutments at the uncovering of the inserted osseo-integrated implants, 12 weeks after the initial stage of implant placement.~Omega roll envelope flap (OREF) technique will be done around the placed healing abutment, then suturing will be done."
62735932|NCT04115774||Osteogenesis Imperfecta patients|The group comprises all patients affected by Osteogenesis Imperfecta, including prenatal and fetal diagnosis of Osteogenesis Imperfecta
62735933|NCT01159678|EXPERIMENTAL|online psychoeducation|
62735934|NCT04931797|EXPERIMENTAL|Video|Video decision aid and advance care planning discussion
62735935|NCT04931797|ACTIVE_COMPARATOR|Control arm|Usual advance care planning services provided at the study site.
62735936|NCT05783128||Spontaneous breathing|1) Spontaneous breathing, with no airway management, in surgeries performed under regional anesthesia
62670148|NCT06091605|ACTIVE_COMPARATOR|Envelope flap combined with a sub-epithelial connective tissue graft|"Patients will undergo peri-implant soft tissue augmentation procedures accompanied by the placement of healing abutments at the uncovering of the inserted osseo-integrated implants, 12 weeks after the initial stage of implant placement.~An envelope split thickness flap will be made at the concerned implant site and a connective tissue graft will be harvested from the tuberosity and then adapted to the placed healing abutment at the surgical site and suturing will be done."
62670149|NCT05515640||Karolinska Cohort|Observational cohort corresponding to patients treated at the Neurointensive Care Unit, Karolinska University Hospital, Stockholm, Sweden.
62670150|NCT03912805|PLACEBO_COMPARATOR|Vehicle|Vehicle, topical liniment, administered once at baseline
62670151|NCT03912805|EXPERIMENTAL|ET-01 1610U|botulinum toxin, Type A, topical liniment, administered once at baseline
62670152|NCT06162234||entire cohort|entire cohort made up of high myopia patients（observational study）
62670153|NCT05391074|EXPERIMENTAL|patients with GA secondary to AMD, myopia or angioid streaks|postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)
62670154|NCT06131593|EXPERIMENTAL|Group TAPB-D (n=25)|Patients in this group will receive TAPB with dexamethasone as an adjuvant to local anesthetic.
62670155|NCT06131593|ACTIVE_COMPARATOR|Group TAPB-M (n=25)|Patients in this group will receive TAPB with methylprednisolone as an adjuvant to local anesthetic.
62670156|NCT02261142|EXPERIMENTAL|Multifocal TENS|Multifocal TENS given in the garment Mollii® (Elektrodress) 1 hour every second day together with individualized training exercises. The steering unit counts down 60 minutes visible for the patient
62670157|NCT02261142|SHAM_COMPARATOR|Sham treatment|Use of the garment Mollii® (Elektrodress) but without the electrical stimulation combined with the individualized training exercises. The steering unit counts down 60 minutes visible for the patient
62670158|NCT04993911|EXPERIMENTAL|Balance training + conventional exercises|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~Walking forward Walking backward Side stepping Walk heel to toe Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises. ROM and active stretching of the hamstring and quadriceps muscle. Active ankle pump. Squats,step-up, sit to stand, calf raises Straigh leg raising exercise in crook lying position"
62670159|NCT04993911|ACTIVE_COMPARATOR|Only conventional|"CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises. ROM and active stretching of the hamstring and quadriceps muscle. Active ankle pump. Squats,step-up, sit to stand, calf raises Straigh leg raising exercise in crook lying position"
62670160|NCT04855812|EXPERIMENTAL|MyoPro|Receiving MyoMo training in-clinic and at home for 6-weeks
62670161|NCT04855812|ACTIVE_COMPARATOR|Myo-SB|Receiving MyoMo training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
62670162|NCT04855812|ACTIVE_COMPARATOR|Control|Receiving conventional therapy/training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
62670163|NCT00371631|OTHER|Arm 1|insertion of E. coli coated catheter
62670164|NCT02361684|EXPERIMENTAL|Blended CBT treatment|
62670165|NCT02361684|ACTIVE_COMPARATOR|Treatment as usual|
62670166|NCT05564923||group 1|Advanced cancer patients over 65 years of age receiving nivolumab
62670167|NCT04802915|OTHER|epiretinal membrane group|Patient with epiretinal fibrosis confirmed by OCT with BCVA\< 0,6 and complaints of metamorphopsies
62670168|NCT02793778|EXPERIMENTAL|CROWN|CROWN: A nutritionally based therapy with a high protein content, formulated as a powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
62299476|NCT02149992|EXPERIMENTAL|Myo-inositol, folic acid|"1. myo-inositol, oral, 2g, two times per day for 5 total days~2. folic acid, oral 200 micrograms, two times per day for 7 days~3. Continuous Glucose Monitoring Surveillance device for 7 days during study period~4. Capillary glucose monitoring 4 times per day"
62470026|NCT00318383|PLACEBO_COMPARATOR|5|Placebo in 4 or 5 doses
62470027|NCT00318383|EXPERIMENTAL|6|200 mcg NicVAX formulation 2 in each of 5 doses
62670169|NCT02793778|PLACEBO_COMPARATOR|CROWN Placebo|Placebo: An appearance and volume matched formulated powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
62670170|NCT00454142|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28."
62670171|NCT00501085||LAP-BAND|Patients who receive the LAP-BAND AP Adjustable Gastric Banding System.
62670172|NCT05942989|EXPERIMENTAL|Intervention group that given education|Reiki group
62670173|NCT05942989|NO_INTERVENTION|Control group|Group with no intervention
62670174|NCT03767894|EXPERIMENTAL|MyHand orthosis|Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.
61914471|NCT05287360|EXPERIMENTAL|Treatment Sequence 3|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 3; Period 2: Formulation 1; Period 3: Formulation 4; Period 4: Formulation 2~There will be a washout period of 5 days between each dosing."
61914472|NCT05287360|EXPERIMENTAL|Treatment Sequence 4|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 4; Period 2: Formulation 3; Period 3: Formulation 2; Period 4: Formulation 1~There will be a washout period of 5 days between each dosing."
62670175|NCT03583866|EXPERIMENTAL|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
61914473|NCT04449731||Adult population (> 18 years old)|Around 30000 adults (\> 18 years old) from 22 different countries.
62670176|NCT03583866|PLACEBO_COMPARATOR|Placebo|Endothelial function will be determined following a seven day treatment of placebo
62670177|NCT04819620|EXPERIMENTAL|Single Dose|Single dose administration
62670178|NCT04819620|EXPERIMENTAL|Multiple Dose|Multiple dose administration
61914474|NCT05662566||Chronic pain|Patients with chronic pain and fixed opioid use, undergoing laparotomy with epidural anesthesia as a part of the postoperative analgesic strategy
61914475|NCT05662566||No chronic pain|Patients without chronic pain and without fixed opioid use, undergoing laparotomy with epidural anesthesia as a part of the postoperative analgesic strategy
62670179|NCT04819620|EXPERIMENTAL|Solid Dose Comparison|Solid dose administration
62670180|NCT02825537|EXPERIMENTAL|With use of compression stocking|Use of compression stocking during 3 consecutives days
62299477|NCT02812004|EXPERIMENTAL|Study Eye|Ultra Q Reflex YAG laser (Ellex)
62470028|NCT01804985|EXPERIMENTAL|De-escalated Treatment|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
62470029|NCT00845715|OTHER|Early motion|
62470030|NCT00845715|OTHER|Standard motion|
62470031|NCT00091260|EXPERIMENTAL|revlimid|lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
62670181|NCT02825537|OTHER|Without use of compression stocking|No use of compression stocking during 3 consecutives days
62670182|NCT06523946||Pacific Islander (PcI) Adults|The investigators will enroll 150 sedentary Pacific Islander (PcI) adults. The investigators will first use an evidence-based physical activity (PA) program tool on all participants to stimulate their PA levels, and then study how contextual and psychosocial factors influence PA initiation and maintenance. The investigators will assess participants for 5 separate weeks during a 20-month span using real-time, field-based, state-of-the-art methodologies consisting of MotionSense (a well-validated on-body mobile sensor system), ecological momentary assessment (EMA), and the Global Positioning System (GPS).
62670183|NCT05643144|EXPERIMENTAL|Patient-Caregiver Dyads|Participants will wear a continuous glucose monitor
62670184|NCT05643144|NO_INTERVENTION|Patient-Caregiver Dyads & Clinicians (first iteration)|Participants will participate in the first iteration of the user-centered design process.
62470032|NCT06016361|SHAM_COMPARATOR|Standard of Care|Standard of Care
62470033|NCT06016361|ACTIVE_COMPARATOR|Investigational Product|Investigational product
62470034|NCT05334173|ACTIVE_COMPARATOR|RYGB TYPE 1 - LONGER ALIMENTARY LIMB (LAL-GB)|150 cm alimentary limb and 70 cm biliopancreatic limb
62470035|NCT05334173|ACTIVE_COMPARATOR|RYGB TYPE 2 - LONGER BILIOPANCREATIC LIMB (LBPL-GB)|70 cm alimentary limb and 150 cm biliopancreatic limb
62670185|NCT05643144|NO_INTERVENTION|Patient-Caregiver Dyads & Clinicians (second iteration)|Participants will participate in the second iteration of the user-centered design process.
62670186|NCT00327132|EXPERIMENTAL|Experimental Arm|
62670187|NCT01304719|EXPERIMENTAL|Computer Assisted home visitation|Home visitation with computer modules added
62670188|NCT01304719|EXPERIMENTAL|Home Visitation TAU|Home Visitation Treatment as Usual
62670189|NCT01304719|NO_INTERVENTION|Community Referral|Community Referral
62735937|NCT05783128||Endotracheal intubation - Macintosh laryngoscope|2) Assist control ventilation, after intubation through the mouth, with the use of a Macintosh laryngoscope
62670190|NCT04574700|EXPERIMENTAL|knee joint mobilization and traction|Tibiofemoral, Tibiofibular joint anterioposterior mobilization, keltonborn knee traction Transcutaneous electrical nerve stimulation(TENS) and quadriceps strengthening
62670191|NCT04574700|ACTIVE_COMPARATOR|Post isometric relaxation|Post isometric relaxation on hamstring, TENS and quadriceps strengthening.
62670192|NCT01029483|EXPERIMENTAL|Low carbohydrate diet|6 week ad libitum low carbohydrate diet; research diet provided at 120% of estimated energy requirement for weight maintenance; carbohydrate intake limited to 28g/d
62670193|NCT01029483|ACTIVE_COMPARATOR|High Carbohydrate Diet-ad libitum|High complex carbohydrate diet (55% carbohydrate, 18% protein, 27% fat. 120% of estimated energy needs for weight maintenance provided, participants allowed to eat as much or as little as desired to satisfy appetite
61914476|NCT00958997||Type 1 diabetic subjects|Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician
62670194|NCT01029483|ACTIVE_COMPARATOR|High Carbohydrate Diet-Energy-matched|High carbohydrate diet (55% carbohydrate, 18% protein and 27% fat). Energy intake restricted to \~68% of energy needs for weight maintenance. Participants required to eat all food provided and nothing else
62670195|NCT00710554|EXPERIMENTAL|Sativex|
62108241|NCT00016913|EXPERIMENTAL|Neo-Adj ChemoTx + ablation prior to RT|Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m\^2 intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77.4 gray \[Gy\] in 1.8-Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.
62670196|NCT00710554|PLACEBO_COMPARATOR|Placebo|
62670197|NCT00875459|EXPERIMENTAL|VIAject™|Single injection
62108242|NCT04621708|EXPERIMENTAL|Left DLPFC iTBS rTMS|
62108243|NCT00770978|EXPERIMENTAL|Ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
62670198|NCT04294238|EXPERIMENTAL|Post-exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage of peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
62670199|NCT02027194|EXPERIMENTAL|Cure-Allergic Rhinitis Syrup|In syrup form, 20 ml once daily for 4 weeks
62670200|NCT02027194|ACTIVE_COMPARATOR|Yu-ping-fung San|In syrup form, 20ml once daily for 4 weeks
62670201|NCT02027194|PLACEBO_COMPARATOR|Placebo group|In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks
62670202|NCT06423027|NO_INTERVENTION|Control|
62670203|NCT06423027|EXPERIMENTAL|Experiment|
62670204|NCT01986751|EXPERIMENTAL|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
61914477|NCT00958997||Healthy control subjects|Age-weight-BMI matched to the subjects with type-1 diabetes
61914478|NCT02201550||Liraglutide|Patients with type 2 diabetes undertaking treatment with liraglutide
61914479|NCT04507373|PLACEBO_COMPARATOR|Placebo|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
61914480|NCT04507373|ACTIVE_COMPARATOR|Simvastatin 40mg|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
61914481|NCT02409108|EXPERIMENTAL|Exatherm-TBH system|One treatment of Total Body Hyperthermia
62108244|NCT00770978|EXPERIMENTAL|Ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
62108245|NCT00647205|SHAM_COMPARATOR|1|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count \> 350/mm3
62108246|NCT00647205|SHAM_COMPARATOR|2|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 \< 350/mm3)
62108247|NCT00647205|SHAM_COMPARATOR|3|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 \< 350/mm3)
62108248|NCT00647205|SHAM_COMPARATOR|4|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 \> 350/mm3)
62108249|NCT00647205|SHAM_COMPARATOR|5|HIV infected patients with active TB
62108250|NCT00647205|SHAM_COMPARATOR|6|HIV negative patients with active TB
62108251|NCT04975243|EXPERIMENTAL|Unwanted Fine Facial Hair|Up to three (3) treatments with GentleMax Pro/ GentleMax Pro Plus TM for Laser Hair Removal
62108252|NCT02596035|EXPERIMENTAL|Nivolumab|Nivolumab dose as specified
62299478|NCT02812004|SHAM_COMPARATOR|Contralateral Eye|Short light impulse is simulated
62470036|NCT01555086|EXPERIMENTAL|Limited pelvic Lymphadenectomy|
62470037|NCT01555086|EXPERIMENTAL|Extended pelvic Lymphadenectomy|
62299479|NCT04491279|EXPERIMENTAL|Neuropilates class.|"Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (chartered physiotherapist and pilates instructor).~Pitched at a beginner level focused on the core elements of neuropilates and progressing week on week as appropriate.~Includes a warm up, cool down and neuropilates exercises in line with the teaching of APPI (the Australian Physiotherapy and Pilates Institute). Exercises may be completed on mats, chairs, gym balls, plinths and in standing, depending upon the ability level of the participant.~Two classes running with 8 participants in each based on their initial assessment into the higher and lower functionally independent participants.~Participants will be given a home exercise programme weekly based on exercises from the class and will be asked to complete these independently at home twice more during the week and to keep a training diary."
62470038|NCT04019834|EXPERIMENTAL|regional nerve block with local anesthesia|Treatment Arm (n=55) will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes and perform regional nerve blocks. A block needle will be passed into the fascial plane an injectate will be deposited . The injectate in the active arm will contain a local anesthestic and dexamethasone.
62470039|NCT04019834|PLACEBO_COMPARATOR|regional nerve block with normal saline|Placebo Comparator Arm (n=55). Patients will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue.
62470040|NCT06405009||patients with omental metastases|
62470041|NCT06405009||patients without omental metastases|
62470042|NCT06485869|EXPERIMENTAL|With virtual reality session|Arm A patients will benefit from a 20-minute virtual reality session per chemotherapy session, for the first 3 cycles, with each session lasting more than 30 minutes.
62470043|NCT06485869|OTHER|Without virtual reality session|Patients in arm B will receive conventional care without hypnotic support.
62670205|NCT01986751|ACTIVE_COMPARATOR|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
62670206|NCT01703221|EXPERIMENTAL|Omarigliptin 25 mg (Phase A+B)|Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
62670207|NCT01703221|ACTIVE_COMPARATOR|Sitagliptin (Phase A) switching to Omarigliptin (Phase B)|Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
62670208|NCT01703221|PLACEBO_COMPARATOR|Placebo (Phase A) switching to Omarigliptin (Phase B)|Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
61914482|NCT04510636|EXPERIMENTAL|Pembrolizumab and Bendamustine|"The study drugs will be given in 3 week periods called cycles.~Pembrolizumab is available in powder form or as a liquid for infusion. Pembrolizumab at a dose of 200 mg will be given over 30 minutes, once every cycle for up to 35 cycles (approximately 24 months).~Bendamustine is available in powder form for injection. Bendamustine at a dose of 90 mg/m2 will be given over 60 minutes, on Days 1 and 2 of every cycle for up to 6 cycles."
62470044|NCT01586611|ACTIVE_COMPARATOR|Gemcitabine|Cycles to be 4 weeks in length Gemcitabine 1000 mg/m2 IV weekly for 3 weeks then one week off
62470045|NCT01586611|EXPERIMENTAL|FOLFOX|Cycles to be 2 weeks in length Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
62108253|NCT00781612|EXPERIMENTAL|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine either as a single agent or in combination with other anti-cancer therapy (atezolizumab, paclitaxel, trastuzumab and docetaxel). Participants will receive the same dose and schedule on Cycle 1, Day 1 at which it was given at the end of the parent study. Study drug will be administered in 21-day cycles or weekly, depending on the schedule used in the parent study. Participants will receive study treatment until disease progression or unacceptable toxicity.
62108254|NCT01191086|EXPERIMENTAL|Open-label USL255|Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day
62108255|NCT06431035|EXPERIMENTAL|caffeine gum|Chewing caffeine Gum (CAF trial, containing 5 mg/kg of caffeine) for 10 minutes before test.
62470046|NCT00688363|EXPERIMENTAL|1|No blood-glucose self-control, no HbA1c
62470047|NCT00688363|EXPERIMENTAL|2|Blood-glucose self-control, no HbA1c
62470048|NCT00688363|EXPERIMENTAL|3|No blood-glucose self-control, HbA1c
62470049|NCT00688363|EXPERIMENTAL|4|Blood-glucose self-control, HbA1c
62470050|NCT03828981|ACTIVE_COMPARATOR|fast-track recovery program|"Pre-operative Verbal and video information Tobacco cessation Daily physical activity Light meal 6 hours and clear liquids up to 2 hours before surgery No bowel preparation A warm blanket Premedication paracetamol 1g and tematsepam 20mg~Intraoperatively For nausea and voimiting dexamethasone 10mg, dehydrobensperidol 1mg and ondancetron 4mg before emergence Analgesia: ropivacain at port sites before incision and at vaginal vault Opioids intravenously at discretion of anesthesiologist supplemented with Dexketoprofen 50mg Urinary catheter early removal Postoperative Pain: tramadol 50mg and ketoprofen100mg i.v., oral opioid if needed; patients with normal pain control receive oral pregabalin 25mg every 8 hours, paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours until discharge Out of bed after 2 hours from the end of surgery A liquid diet, if tolerated regular normal diet. For emesis ondansetron 4mg"
62670209|NCT01663831|EXPERIMENTAL|Topical Repellent & LLIN|
62670210|NCT01663831|NO_INTERVENTION|Long Lasting Insecticidal Nets|"Brand Name LLIN: Olyset Net~Active ingredient: permethrin"
62670211|NCT04453007|PLACEBO_COMPARATOR|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Any follow-up emails sent to them later contain only a reminder to participate in follow-up surveys.
62735938|NCT05783128||Endotracheal intubation - C-MAC video-laryngoscope|3) Assist control ventilation, after intubation through the mouth, with the use of a C-MAC video-laryngoscope
62735939|NCT05783128||Supraglottic Airway Device|4) Assist control ventilation, after the insertion of an LMA (laryngeal mask airway) supreme supraglottic device
62470051|NCT03828981|NO_INTERVENTION|conventional recovery program|"Preoperative preparation Verbal and written information Cessation of oral intake after previous midnight. Premedication paracetamol 1g+ diatsepam 5mg.~Intraoperative A warm blanket at the start of procedure. Prophylaxis for nausea and vomiting: Dexamethasone 5mg at induction, and Dehydrobenzperidol 1mg, ondancetron 4mg before emergence. Analgesia: injection of ropivacain 5% 20ml at port sites at the end of surgery, Opioids i.v. (oxycodone)~Postoperative Pain medication:Opioids i.v. (oxycodone), paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours Urinary catheter removal on next morning. Prolonged bowel and bed rest and gradual reintroduction of feeding."
62470052|NCT01777347|EXPERIMENTAL|3% Saline|Nebulized 3% Saline
62670212|NCT04453007|ACTIVE_COMPARATOR|Intervention plus 2-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 2 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
62670213|NCT04453007|ACTIVE_COMPARATOR|Intervention plus 6-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 6 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
62670214|NCT04453007|ACTIVE_COMPARATOR|Intervention plus 10-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 10 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
62108256|NCT06431035|PLACEBO_COMPARATOR|placebo|Chewing placebo gum (without caffeine) for 10 minutes before test.
62108257|NCT02007499||Cardiac Arrest, Out of hospital|Pre-arrival Cardiopulmonary Resuscitation (CPR) instruction for bystander.
62299480|NCT04491279|ACTIVE_COMPARATOR|Generalised exercise class.|"Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility.~Exercises will be more functional and generic than in the pilates classes and will be conducted in a circuit style, including mobility practice, sit to stand practice, cycling with the motomed, and general upper and lower limb strengthening. Warm up and cool downs will also be a feature of this class.~Participants will be also be given a home exercise programme based on exercises completed in the class and will be asked to complete these exercises twice more during the week and to keep a training diary."
62299481|NCT04199923|EXPERIMENTAL|15 Day immobilisation|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 15 continuous days
62299482|NCT04199923|EXPERIMENTAL|5 Day immobilisation young|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
62299483|NCT04199923|EXPERIMENTAL|5 Day immobilisation old|The dominant leg of aged patients (65-80 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
62470053|NCT01777347|PLACEBO_COMPARATOR|0.9% Normal Saline|Nebulized 0.9% normal saline
62670215|NCT04453007|ACTIVE_COMPARATOR|Intervention plus 14-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 14 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
62670216|NCT04453007|ACTIVE_COMPARATOR|Intervention plus repeated feedback boosters|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the multiple feedback booster emails, 2, 6, 10, and 14 weeks later. Each time, the email contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
62108258|NCT05901558|EXPERIMENTAL|STAR intervention group|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities. The structure of the STAR model is with 2 modules and 16 sessions. Module I derives from our previous offline parent-tutoring courses with 8 intervention strategy topics combining academic instruction and real child demonstration but modified into on-line version. Module II is designed specifically for long-term consolidation of parents' intervention skills containing 8 biweekly sessions of distance coaching with parents practicing intervention with their children in real time at home.
62108259|NCT05901558|OTHER|community intervention group|This group will have community interventions parents can choose.
62108260|NCT02959957|EXPERIMENTAL|Temocillin|Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
62299484|NCT02101008|OTHER|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
62299485|NCT06417515|EXPERIMENTAL|Xiao-Yao-San group|Received Xiao-Yao-San for 28 days
62299486|NCT06417515|OTHER|weight loss class group|The control group were those who didn't receive any Chinese medicine but attended the weight loss class.
62299487|NCT04122196|EXPERIMENTAL|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
62299488|NCT04122196|PLACEBO_COMPARATOR|Placebo|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
62299489|NCT03947541|ACTIVE_COMPARATOR|No Brace|Patients randomized to the no-brace group will not be required to wear a brace, postoperatively.
62735940|NCT05971368|ACTIVE_COMPARATOR|Group A: Patients will receive ultrasound guided thoracic paravertebral block|Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.
61914483|NCT05402033||Survey / Interview Group|"All patients (or parent / caregiver, if relevant) who provide informed consent will be asked to complete baseline assessments utilizing validated questionnaires administered through the phone or video call. The clinical research coordinator will input responses into REDCap. Alternatively, patients may request assessments be sent through secure email.~Baseline assessment consisting of sociodemographic items and study eligibility questions (call #1)~In addition, each patient will complete the Comprehensive Score for financial Toxicity Patient Reported Outcome Measure (COST PROM) and Short Assessment of Health Literacy (SAHL) survey measures."
62108261|NCT02959957|ACTIVE_COMPARATOR|Cefotaxime|Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
61914484|NCT01227824|EXPERIMENTAL|GSK1349572 (N=~394)|GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
61914485|NCT01227824|ACTIVE_COMPARATOR|raltegravir (N=~394)|raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily
61914486|NCT05420753|EXPERIMENTAL|TIPS|Patients in this arm will undergo TIPS creation in addition to their current management.
62108262|NCT03613129|ACTIVE_COMPARATOR|D0.20|Subcutaneous infusion of CT38 at 0.20 μg/kg/hour, for 3 hours on each of 2 days
62108263|NCT03613129|ACTIVE_COMPARATOR|D0.03|Subcutaneous infusion of CT38 at 0.03 μg/kg/hour, for 3.5 hours on each of 3 days
62108264|NCT03613129|ACTIVE_COMPARATOR|D0.06|Subcutaneous infusion of CT38 at 0.06 μg/kg/hour, for 3.5 hours on each of 3 days
62108265|NCT03613129|ACTIVE_COMPARATOR|D0.01|Subcutaneous infusion of CT38 at 0.01 μg/kg/hour, for 3.5 hours on each of 3 days
62108266|NCT05541263|EXPERIMENTAL|MBSR group|The MBSR group participants will receive an Mindfulness Based Stress Reduction training programme over 2 months.
62108267|NCT05541263|NO_INTERVENTION|Wait-list group|The wait-list control group participants will wait while the experimental group is participating in the Mindfulness Based Stress Reduction training. This group will follow the training at the end of the study (7 months after baseline), after all relevant measurements are concluded.
62108268|NCT01638624|ACTIVE_COMPARATOR|Propofol|Propofol infusion group: Under spinal anesthesia, a continuous intravenous infusion (2mg/kg/h) of propofol will be use during the operation
62108269|NCT01638624|PLACEBO_COMPARATOR|Control group|Placebo group: Under spinal anesthesia, a continuous intravenous infusion of volume-equivalent placebo will use during the operation
62108270|NCT02968004|EXPERIMENTAL|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
62108271|NCT02968004|ACTIVE_COMPARATOR|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
62299490|NCT03947541|EXPERIMENTAL|Brace|Patients randomized to the brace group will wear the brace when out of bed and will be allowed to remove the brace when in bed. This intervention will continue through their 6-week postoperative visit, after which point, patients will be allowed to wear the brace for comfort.
62108272|NCT05357365||Doctor|Doctors of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
62108273|NCT05357365||Nurses|Nurses of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
62108274|NCT01876654|EXPERIMENTAL|TruMatch® patient specific cutting guide|In patients randomized to experimental arm, TKR components will be implanted using TruMatch® patient specific cutting guides.
61914487|NCT05420753|NO_INTERVENTION|Standard of care|Patients in this arm will continue to be treated with their current management
61914488|NCT05066555||Advanced-stage Hodgkin Lymphoma patients (1)|All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Comparator arm).
61914489|NCT05066555||Advanced-stage Hodgkin Lymphoma patients (2)|All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Experimental arm).
61914490|NCT00386971|ACTIVE_COMPARATOR|1|L-carnitine
61914491|NCT00386971|PLACEBO_COMPARATOR|2|Placebo
61914492|NCT02847572|OTHER|Surgery Patient|All patients to be implanted bilaterally with a Tecnis Extended Range Lens in the Dominant eye and a Low Add Multifocal in the non dominant
61914493|NCT02924415|EXPERIMENTAL|Tele-care support|Online psychoeducation treatment using new technologies
61914494|NCT02924415|ACTIVE_COMPARATOR|Control group|Standard care
61914495|NCT00832910||Rheumatoid Arthritis group1|This group had patients with rheumatoid arthritis
61914496|NCT00832910||2|
61914497|NCT03340103|EXPERIMENTAL|Experimental group A|Group A (18 newborns) will be treated with LUTEIN ofta 0,5 drops, (1 ml per Kg equal to 0,5 mg of lutein and 0,05 of zeaxantin) additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
61914498|NCT03340103|PLACEBO_COMPARATOR|Control group B|Group B (18 newborns) treated with Placebo solution additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
61914499|NCT02747433|ACTIVE_COMPARATOR|ALPS + Robot-Assisted Therapy (RT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 1 hr sessions 3x week for 6 weeks plus ALPS training
62299491|NCT04554576|EXPERIMENTAL|6-week self-management and remote feedback for 6 months|All participants will receive the 6-week self-management program and after, half the group will be randomized to an every 6th week healthcare provider feedback phone or video visit session for 6 months (4 visits over 24 months).
61914500|NCT02747433|ACTIVE_COMPARATOR|ALPS + Robot + Task-Oriented Training (RT-TOT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 30 mins, 3x week for 6 weeks plus ALPS training. Task oriented training will be provided for remaining 30 min of each treatment session
61914501|NCT03934814|EXPERIMENTAL|Part 1A - TJ011133 Monotherapy|TJ011133 alone will be administered at up to 7 dose levels (0.3, 1, 3, 10, 20, 30, 45 mg/kg) once weekly (Q1W) (the 0.3 mg/kg dose level cohort will be enrolled if a DLT in 1 out of 3 subjects is observed following the 1 mg/kg dose level).
61914502|NCT03934814|EXPERIMENTAL|Part 1B - Combination therapy of TJ011133 with pembrolizumab|TJ011133 will be administered Q1W, starting at 20 mg/ kg, in combination with pembrolizumab.
61914503|NCT03934814|EXPERIMENTAL|Part 1C - Combination therapy of TJ011133 with rituximab|TJ011133 will be administered Q1W, starting at 20 mg/kg, in combination with rituximab.
62108275|NCT01876654|NO_INTERVENTION|Conventional cutting guide|In patients randomized to control arm, TKR components will be implanted using Attune® instrumentation (femoral intra-medullary guide, tibial extra-medullary guide), without TruMatch® patient specific cutting guides.
62108276|NCT05171218|EXPERIMENTAL|Music & Auditory Beat Stimulation|Participants listened to calm music with theta auditory beat stimulation for 24 minutes
62299492|NCT04554576|ACTIVE_COMPARATOR|6-week self-management and control group for 6 months|All participants will receive the 6-week self-management program and after, half will be randomized to a 6 month control grup
62670217|NCT00003812|EXPERIMENTAL|chemotherapy + radiation therapy|Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.
61914504|NCT03934814|EXPERIMENTAL|Part 2 - Dose Expansion|30 participants (with DLBCL or indolent lymphoma) in the TJ011133 combination therapy with rituximab expansion and 20 participants with solid tumors in the TJ011133 combination therapy with pembrolizumab expansion.
61914505|NCT01476202|EXPERIMENTAL|Nicotine mouth strip|single dose
61914506|NCT01476202|ACTIVE_COMPARATOR|nicotine lozenge|single dose
61914507|NCT01476202|ACTIVE_COMPARATOR|nicotine gum|single dose
61914508|NCT01027273|EXPERIMENTAL|Peer-Led Stroke Recurrence Prevention Education|The intervention group will participate in a 6-session course held over a 6-week period. The Prevent Return of Stroke Workshop, led by trained peer educators, aims to help participants control the risk factors for stroke, thereby preventing recurrence of strokes.
61914509|NCT01027273|PLACEBO_COMPARATOR|Usual Care (Delayed Intervention)|The control group will be offered the chance to take part in the 6-week session intervention after 12 months after enrollment into the trial.
61914510|NCT03134079|ACTIVE_COMPARATOR|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
62108277|NCT05171218|ACTIVE_COMPARATOR|Music Alone|Participants listened to calm music for 24 minutes
62108278|NCT05171218|ACTIVE_COMPARATOR|Auditory Beat Stimulation|Participants listened to theta auditory beat stimulation for 24 minutes
62670218|NCT06235970|EXPERIMENTAL|Device: Transcranial electrical stimulation (tES) including SHAM|healthy adults
62299493|NCT04401059|EXPERIMENTAL|Elemene plus First or Third generation EGFR-TKIs|Elemene Injectable Emulsion sequentially with Elemene Oral Emulsion plus First -generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib) or Third-generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib).
62108279|NCT05171218|SHAM_COMPARATOR|Pink Noise|Participants listened to pink noise for 24 minutes
62108280|NCT02373228|EXPERIMENTAL|Compressive signal processing algorithm|Participants compare music signals with preprocessing to the same music signals without compressive preprocessing.
62108281|NCT02783157|EXPERIMENTAL|Transcutaneous low-level vagal nerve stimulation (LLVNS)|n=100 patients will be randomized to transcutaneous low-level vagal nerve stimulation (LLVNS), via a clip applied to the ear. Stimulation will be delivered throughout the procedure.
62108282|NCT02783157|SHAM_COMPARATOR|Sham LLVNS|n=100 patients will be randomized to sham LLVNS, with the clip applied but no stimulation delivered.
62108283|NCT00610753|EXPERIMENTAL|Family Behavioral Therapy|This intervention focuses on counseling the parents (and other family members) on refeeding their child. When weight is being steadily regained the focus of therapy shifts to allow the child more independence.
62108284|NCT00610753|ACTIVE_COMPARATOR|Systems Family Therapy|This therapy focuses primarily on clarifying psychological processes within the family.
61914511|NCT03134079|EXPERIMENTAL|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
62299494|NCT04401059|ACTIVE_COMPARATOR|First or third generation EGFR-TKIs only|First-generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib) or third-generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib).
62670219|NCT06548958|EXPERIMENTAL|40 patients with malignant hematological diseases who undergo SCT2|patients undergo SCT2 using TBI + BUMEL as a conditioning regimen
61914512|NCT03134079|EXPERIMENTAL|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
62670220|NCT01129895|EXPERIMENTAL|Health promotion|5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
62670221|NCT01129895|NO_INTERVENTION|Promoting Health|No intervention follow-up only
62670222|NCT01002391|EXPERIMENTAL|Postoperative day 1|Dressing is removed on the first postoperative day
62670223|NCT01002391|EXPERIMENTAL|Postoperative day 6|Dressing is removed on the sixth postoperative day
61914513|NCT06402994||Infants & toddlers|Children between 0 and 2,5 years of age
62670224|NCT03676725|EXPERIMENTAL|All subjects|All subjects get the lidocaine taste test
62670225|NCT01678690|EXPERIMENTAL|Gemcitabine HCl Oral Formulation|Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
62670226|NCT05505890||SFIPB|"suprainguinal fascia iliaca plane block with 50ml of %0.25 bupivacaine will be used for postoperative analgesia~."
61914514|NCT06402994||Kindergartners|Children between 2,5 and 6 years of age
61914515|NCT06402994||Primary school children|Children between 6 and 12 years of age
61914516|NCT04935671|ACTIVE_COMPARATOR|Allopathic + Herbal|"20mg of chamomile and 1 mg saffron in form of teabag for preparation of herbal decoction in dose of two teabags per day for a month as an ADJUVANT THERAPY with standard allopathic treatment for depression."
61914517|NCT04935671|NO_INTERVENTION|Allopathic only|Only allopathic medication for depression.
61914518|NCT01787344|EXPERIMENTAL|Botulinum toxin type A (Botulax®)|Botulinum toxin type A (Botulax®)
61914519|NCT01787344|ACTIVE_COMPARATOR|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
61914520|NCT05535218|OTHER|Single Arm|Single Arm treatment
61914521|NCT05272436|EXPERIMENTAL|Patients IVR for Upper Limb Motor Impairment Rehabilitation in children and at home trial|"For the purpose of the trial, patients had their usual OT/PT appointments but were asked to use the IVR games to do the prescribed home exercises. Before consenting to participate, each patient was offered a 5-10 minute experience of the game to familiarise themselves with how it worked and to check for problems. Written and verbal consents were taken from parents and children.~The pre-trial PedsQL was administered in the initial OT/PT appointment. Children were then asked to use the IVR system for approximately 15 minutes twice a day. Trial participation lasted three weeks during the prescribed treatment weeks.~Following the at-home trial, patients and parents returned the equipment to the clinic in the final appointment and the SUS and the post-trial Peds QL were administrated by OT/PT in person. In addition, they participated in semi-structured interviews as described above."
62299495|NCT01834495|EXPERIMENTAL|Balloon expandable stent|study design is 1:1 randomization design. Patients will be randomized in a 1:1 manner according to different two (balloon expandable versus Self expandable)stents. Randomization procedure will be performed using a web-based program
62299496|NCT01834495|ACTIVE_COMPARATOR|Self expandable stent|same to Balloon expandable stent
62299497|NCT01668277|EXPERIMENTAL|3 ml/kg 7.2% NaCl|The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
62670227|NCT05505890||control|Fascia iliac block will not be applied to this group. Postoperative analgesia will be provided with other analgesia modalities.
62670228|NCT05431179|EXPERIMENTAL|Oral Ibrutinib|Open Label Ibrutinib Monotherapy Phase (16 weeks)
62670229|NCT05431179|EXPERIMENTAL|Arm A: IV Infusion of Ziloveramab and Oral Ibrutinib|Randomized, Double-Blind Treatment Phase
62670230|NCT05431179|PLACEBO_COMPARATOR|Arm B: IV Infusion of Placebo and Oral Ibrutinib|Randomized, Double-Blind Treatment Phase
62670231|NCT04902144|EXPERIMENTAL|Screening (medical records, coaching)|"PHASE I: Patients' medical data are collected.~PHASE II: Patients complete questionnaires and their medical data is collected. SCCA subject matter experts and OMC providers review patients' medical data at bi-monthly virtual conferences. OMC providers receive coaching from SCCA subject matter experts for guidance on providing genetic counseling and testing to their patients."
61914522|NCT05272436|OTHER|Occupational Therapist perceptions of the effectiveness of the IVR|"She recruited the patients, gave out devices, administered the outcome measures and provided us with feedback about their experience with the VR game.~At the end of the trial, an interview (10 minutes) with the OT was conducted by a research nurse."
61914523|NCT05993013|NO_INTERVENTION|Conventional exercise|Normally physiotherapist-recommended, tailored strength and balance exercises. These exercises are given in printed handouts and demonstrated by our physiotherapist with the patients during their initial clinic visit. Exercise is recommended to be done at least 3 times per week.
61914524|NCT05993013|EXPERIMENTAL|Game-based exercise|Strength and balance exercises using the LudoFit game-based exercise software. Participants will be registered on the platform. Exercise is recommended to be done at least 3 times per week.
61914525|NCT02735499|EXPERIMENTAL|Treatment with Botox|Onabotulinum toxin A. 200 units of Botox installed into the bladder by catheter.
61914526|NCT06271473|ACTIVE_COMPARATOR|subjecting to vitrectomy + ILM peeling only|
62108285|NCT04854993|EXPERIMENTAL|Increased dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
62299498|NCT01668277|ACTIVE_COMPARATOR|3 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
61914527|NCT06271473|ACTIVE_COMPARATOR|subjecting to vitrectomy + ILM peeling + planned foveal detachment|
62299499|NCT01668277|ACTIVE_COMPARATOR|20 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
61914528|NCT02760043|EXPERIMENTAL|Dexamethasone|LIA mixture with the addition of 8mg Dexamethasone.
62670232|NCT06494982|ACTIVE_COMPARATOR|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy|
62670233|NCT06494982|ACTIVE_COMPARATOR|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy|
62670234|NCT00615316|EXPERIMENTAL|A|
62670235|NCT00615316|PLACEBO_COMPARATOR|B|
62670236|NCT03813251|EXPERIMENTAL|Assigned Interventions|ForConti Contix Fecal Incontinence Management System (FIMS)
62670237|NCT01885234|EXPERIMENTAL|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
61914529|NCT02760043|SHAM_COMPARATOR|Saline|LIA mixture with the addition of 2mL of 0.9% NaCl Saline.
61914530|NCT05937776||Diagnostic (¹⁸FDG PET, MRI)|Patients receive ¹⁸FDG IV, then 60 minutes later undergo simultaneous MRI and PET scanning. During this scanning period, patients will receive gadoterate meglumine IV to obtain post-contrast MRI. Total scanning time will take 45-60 minutes.
61914531|NCT06522984|ACTIVE_COMPARATOR|Group A|About 15 cases will receive sessions with fractional Er: YAG laser every 3 weeks followed by application of topical 4% (HQ) cream.
61914532|NCT06522984|ACTIVE_COMPARATOR|Group B|About 15 cases will receive sessions of intradermal injection of tranexamic acid on the melasma site every 3 weeks concurrently with the application of topical 4% HQ cream every night. The injections will be done using an insulin syringe with a dilution of the tranexamic acid
61914533|NCT06522984|ACTIVE_COMPARATOR|Group C|About 15 cases will receive oral tranexamic acid 500mg tablet once daily for three months. And will also be asked to apply a thin layer of topical HQ 4% cream on the hyperpigmented areas once every night.
61914534|NCT05519332|EXPERIMENTAL|PVDP group|Patients underwent percutaneous vertebral-disc plasty
61914535|NCT05519332|NO_INTERVENTION|PVP group|Patients underwent conventional percutaneous vertebroplasty
61914536|NCT03189381|EXPERIMENTAL|Cohort A|Standard PCI dose
61914537|NCT03189381|EXPERIMENTAL|Cohort B|Low PCI dose
61914538|NCT04390932|EXPERIMENTAL|Enhanced TA|Therapeutic exercise protocol accompanied by an enhanced TA.
61914539|NCT04390932|ACTIVE_COMPARATOR|Neutral therapeutic alliance|Therapeutic exercise protocol accompanied by an limited TA
61914540|NCT04440423|EXPERIMENTAL|Clotiazepam Test Product|
61914541|NCT04440423|ACTIVE_COMPARATOR|Clotiazepam Reference Product|
61914542|NCT00348933|EXPERIMENTAL|1|Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.
62108286|NCT04854993|ACTIVE_COMPARATOR|Standard dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
62108287|NCT04921423|EXPERIMENTAL|situational simulation teaching|Clinical case role play and empathy skill practice
62108288|NCT04921423|NO_INTERVENTION|Clinical Case (Problem Based Learning)|Clinical Case discuss (Problem Based Learning)
62108289|NCT03126409|EXPERIMENTAL|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
62670238|NCT01885234|PLACEBO_COMPARATOR|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
62670239|NCT02018887|EXPERIMENTAL|LY2969822 (Part A)|Single dose of LY2969822 administered orally in 2 of 3 study periods.
62670240|NCT02018887|PLACEBO_COMPARATOR|Placebo (Part A)|Single dose of placebo administered orally in 1 of 3 study periods.
62670241|NCT02018887|EXPERIMENTAL|LY2969822 (Part B)|LY2969822 administered orally for 14 days.
62670242|NCT02018887|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered orally for 14 days.
62670243|NCT02018887|EXPERIMENTAL|LY2969822 (Part C)|LY2969822 administered orally for 14 days.
62670244|NCT02018887|PLACEBO_COMPARATOR|Placebo (Part C)|Placebo administered orally for 14 days.
62670245|NCT04756284||Bladder Tumor Positive|Patients with previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy or suspected bladder tumor undergoing surveillance cystoscopy.
62670246|NCT04756284||Bladder Tumor Negative|Patients with no suspected bladder tumor.
62670247|NCT04258098||OA+MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
62108290|NCT03126409|ACTIVE_COMPARATOR|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
62108291|NCT02098902|EXPERIMENTAL|Smart Moms Intervention|This arm will receive the Smart Moms intervention immediately following randomization.
62670248|NCT04258098||MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. No oral antibiotics was administered to the patients.
62670249|NCT01215240|EXPERIMENTAL|Prophylactic peritoneal dialysis|Prophylactic peritoneal dialysis
62670250|NCT01215240|NO_INTERVENTION|Standard care without PDC|
62670251|NCT01659541|EXPERIMENTAL|Procedure & Device|Procedure/Surgery: Implantation of device; Device: Expiratory Muscle Stimulator
62670252|NCT05838040|ACTIVE_COMPARATOR|General Exercises|This exercise activates paravertebral and abdominal muscles. Because this exercise impose extra loading on the spinal tissues, the general exercise was selected on the basis of maximizing the contraction benefit/spinal loading ratio.
62670253|NCT05838040|EXPERIMENTAL|General exercises with TA contraction|This exercise activates paravertebral and abdominal muscles. Because this exercise impose extra loading on the spinal tissues, the general exercise was selected on the basis of maximizing the contraction benefit/spinal loading ratio. The patients will be asked to contract TA will doing these exercises.
62670254|NCT04165980|SHAM_COMPARATOR|Sham transcranial direct current stimulation (sham tDCS)|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
62670255|NCT04165980|ACTIVE_COMPARATOR|Active transcranial direct current stimulation (activetDCS)|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
62670256|NCT02633657|EXPERIMENTAL|HORIZANT 300 mg|HORIZANT 300 mg once daily
62670257|NCT05225168|ACTIVE_COMPARATOR|laparoscopic burch colposuspension group|this group will only have laparoscopic burch colposuspension
61914543|NCT01728233|EXPERIMENTAL|Dacomitinib (PF-00299804)|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
61914544|NCT05959980|EXPERIMENTAL|Surgical arm|Will undergo posterior cervical fixation surgery within 4 weeks of randomization
62670258|NCT05225168|ACTIVE_COMPARATOR|Minisling Suburethral Sling group|this group will only have Minisling Suburethral Sling
62299500|NCT00246259|EXPERIMENTAL|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following initiation of Risperidone LAI, and for a maximum of 3 weeks following a dose increase.
62299501|NCT00246259|ACTIVE_COMPARATOR|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg. Participants will be switched to another oral therapy as per Investigator's discretion.
62299502|NCT06060301|EXPERIMENTAL|study group (S group)|The patients will use topical sulfasalazine prepared by dissolving one tablet of commercially available in 100 ml of distilled water 4 times per day as a mouth wash combined with topical corticosteroids 4 times per day as a topical gel in an alternate sequence.
62670259|NCT00672269||1|Families with carcinoid in multiple family members
62670260|NCT03295448|ACTIVE_COMPARATOR|Fat - Sugar - Fiber|Intervention: consuming diets rich in fat, rich in sugar, and rich in fibers during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
62670261|NCT03295448|ACTIVE_COMPARATOR|Fat - Fiber - Sugar|Intervention: consuming diets rich in fat, rich in fiber, and rich sugar during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
62670262|NCT03295448|ACTIVE_COMPARATOR|Sugar - Fiber - Fat|Intervention: Consuming diets rich in sugar, rich in fiber, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
62670263|NCT03295448|ACTIVE_COMPARATOR|Sugar - Fat - Fiber|Intervention: Consuming diets rich in sugar, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
62670264|NCT03295448|ACTIVE_COMPARATOR|Fiber - Sugar - Fat|Intervention: Consuming diets rich in fiber, rich in sugar, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
61914545|NCT05959980|NO_INTERVENTION|Cervical collar arm|Will be given cervical collar for regular use
61914546|NCT00713232||test construction|university student living in Taiwan for more than 5 years No known neurological, psychiatric or speech language disorders
61914547|NCT00713232||normative data|normal subjects 20-80 y/o Living in Taiwan for at least 5 years No know neurological, psychiatric and speech-language disorders
61914548|NCT05054660|EXPERIMENTAL|caring chatbot|The investigators will enroll participants aged over 55 in the psychiatric outpatient department. The participants will get a one-month caring chatbot and can interact with the chatbot freely.
62108292|NCT02098902|NO_INTERVENTION|Waitlist control group|This arm will receive a modified version of the Smart Moms intervention after the 6-month assessment.
62108293|NCT06631560|EXPERIMENTAL|Oncological disease|Serum was taken from each patient before treatment initiation and during treatment follow-up. In addition, oncological participants completed a questionnaire consisting of eight questions focusing on quantitative aspects, to identify risk factors for HEV infection.
62108294|NCT06631560|EXPERIMENTAL|Healthy controls|Serum samples were analysed retrospectively using HEV ELISAs
62108295|NCT06631560|EXPERIMENTAL|Control hospitalized due to SARS-CoV-2 infection|Serum samples were analysed retrospectively using HEV ELISAs
62108296|NCT01043406|EXPERIMENTAL|Single Arm, Device Implant|
62108297|NCT01103973|PLACEBO_COMPARATOR|Control (Spa Certificate)|For every three months in the study control subjects received $50 spa gift certificates.
62670265|NCT03295448|ACTIVE_COMPARATOR|Fiber - Fat - Sugar|Intervention: consuming diets rich in fiber, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
62299503|NCT06060301|ACTIVE_COMPARATOR|Control group (C group)|The 23 patients categorized as control group (C group) will receive topical corticosteroids gel only 4 times per day. The treatment regimen will be continued for 4 weeks.
62299504|NCT04957888||training group|the observational group to find out the potential biomarker
62299505|NCT04957888||validation group|the validation group to validate the parameters used for early diagnosis
62299506|NCT04049279|ACTIVE_COMPARATOR|BiMobile standard cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
62299507|NCT04049279|ACTIVE_COMPARATOR|BiMobile larger cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
61914549|NCT05587946|EXPERIMENTAL|Intervention/treatment|"1. Implementation steps 1-4 of the Control Group will be done.~2. The patient will be informed about the virtual reality application.~3. The patient will be told that they can remove their glasses at any time and stop participating in the study.~4. 2 minutes before the endoscopy process starts, the previously determined video will be started by putting on the Virtual Reality Glasses.~5. Glasses will be worn from the beginning to the end of the procedure.~6. The patient will be observed during the procedure. The data obtained during the observation will be noted.~7. After the endoscopy procedure; State Anxiety Scale, Visual Comparison Scale will be re-applied and vital signs will be measured and recorded in the Patient Follow-up Form.~8. After the endoscopy procedure, patients will be given an interview appointment on the same day to collect the data of the qualitative part of the study.~9. Semi-Structured Interview Form will be applied in the interview."
62108298|NCT01103973|EXPERIMENTAL|Mind/Body Program|Ten week group mind/body program. Skills include relaxation training, cognitive strategies, and lifestyle modifications.
62108299|NCT00569738||A|patients with neuroendocrine tumors
62299508|NCT04049279|ACTIVE_COMPARATOR|Avantage standard cement|25 patients will receive a cemented THA with an Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
62108300|NCT02601053|ACTIVE_COMPARATOR|Dull (boring) movie|Participants will be exposed to a dull (i.e. boring) movie followed by a scary (i.e. horrifying) movie.
62299509|NCT02580058|EXPERIMENTAL|avelumab|Arm A: avelumab alone
62299510|NCT02580058|EXPERIMENTAL|avelumab plus pegylated liposomal doxorubicin (PLD)|Arm B: avelumab plus PLD
62299511|NCT02580058|ACTIVE_COMPARATOR|PLD|Arm C: PLD alone
62299512|NCT06012669|EXPERIMENTAL|Low Dose|0.34 g Recombinant Human Lactoferrin
62299513|NCT06012669|EXPERIMENTAL|High Dose|3.4 g Recombinant Human Lactoferrin
62299514|NCT06012669|ACTIVE_COMPARATOR|Active Control|3.4 g Bovine Lactoferrin
62299515|NCT04701307|EXPERIMENTAL|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21 of cycles 1-4, and on days 1-42 of subsequent cycles. Patients also receive dostarlimab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-4 and every 42 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
62299516|NCT06657378||Fycompa|
62299517|NCT03451448||Healthy volunteers|Healthy volunteers to undergo MRI using USPIO contrast
62108301|NCT02601053|EXPERIMENTAL|Scary (horrifying) movie|Participants will be exposed to a scary (i.e. horrifying) movie followed by a to a dull (i.e. boring) movie.
62299518|NCT03451448||Stable coronary artery disease|Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
62299519|NCT03451448||Recent acute coronary syndrome|Patients with recent (3 months) type 1 myocardial infarction
62299520|NCT06657235|EXPERIMENTAL|Early Enrollment|Participants enrolled around the time of discharge from the hospital immediately following an ischemic stroke.
62299521|NCT06657235|EXPERIMENTAL|Late Enrollment|Participants enrolled mainly between 3-5 months after their discharge from the hospital following an ischemic stroke.
62299522|NCT05773456|EXPERIMENTAL|Sushi and wakame salad|231 microgram of iodine per serving
62299523|NCT05773456|ACTIVE_COMPARATOR|Potassium iodide supplement|225 microgram of iodine per tablet
62299524|NCT01018407|EXPERIMENTAL|Discrete Trial Training|Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
62299525|NCT01018407|EXPERIMENTAL|Interpersonal Developmental Approach|Targets Joint Attention and Symbolic Play. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
62299526|NCT05066685||All Participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
62299527|NCT05839561|ACTIVE_COMPARATOR|Tubal pregnancy treated with MTX|MTX in a single dose of 100 mg intravenously on day 0
62299528|NCT05839561|ACTIVE_COMPARATOR|Tubal pregnancy treated with letrozole|Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0
61914550|NCT05587946|NO_INTERVENTION|Control group|"1. Hands will be washed.~2. The right patient will be determined, the procedure will be explained to the patient and permission will be obtained.~3. A Patient Identification Form will be applied to the individual before the endoscopy procedure.~4. Before the endoscopy procedure; State Anxiety Scale will be applied in the first 10 minutes, and Visual Comparison Scale will be applied in the first 5 minutes. Vital signs will be measured within the first 5 minutes and recorded on the Patient Follow-up Form. Then the individual will be taken to the endoscopy procedure.~5. The patient will be observed during the procedure. The data obtained during the observation will be noted.~6. After the endoscopy procedure; State Anxiety Scale, Visual Comparison Scale will be applied again and vital signs will be measured and recorded in the Patient Follow-up Form."
61914551|NCT00859261|EXPERIMENTAL|Breast imaging using Ultrasound and Photoacoustic|Evaluating 3D ultrasound for breast abnormalities/masses/cysts. This includes ultrasound imaging and possibly photoacoustic imaging.
61914552|NCT04363398|EXPERIMENTAL|Comprehensive|Coaches from schools randomized to the comprehensive follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a trained research team member will monitor the team weekly for injuries, participation, and adherence, and provide support to the school coaches regarding the warm-up.
61914553|NCT04363398|ACTIVE_COMPARATOR|Standard|Coaches from schools randomized to the standard follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a research team member will monitor the team weekly for injuries, participation, and adherence, however will not provide support to the school coaches regarding the warm-up.
61914554|NCT01514786|NO_INTERVENTION|Control|Same information is presented in the control website as is found in the intervention website, but no interactive component: preferences and risk assessment.
61914555|NCT01514786|ACTIVE_COMPARATOR|Intervention with Colorectal Website|Intervention website includes an interactive component including preferences and risk assessment.
61914556|NCT06208930|EXPERIMENTAL|FMT group|
62299529|NCT03849729|ACTIVE_COMPARATOR|Phentermine|Low-calorie diet + Phentermine Capsules 15 mg po by 6 weeks, one time a day before bariatric surgery.
62470054|NCT01615198|EXPERIMENTAL|LCZ696|Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd.
61914557|NCT02430129|ACTIVE_COMPARATOR|Total knee arthroplasty/Persona|Total knee arthroplasty with Zimmer Persona posterior cruciate retaining prosthesis (Zimmer, Warsaw, IN)
62299530|NCT03849729|PLACEBO_COMPARATOR|Placebo|Low-calorie diet + Placebo Capsules po by 6 weeks, one time a day before bariatric surgery.
62299531|NCT05523180|EXPERIMENTAL|Probiotic|1 capsule of 15 Billion CFU proprietary probiotic blend with 120 mg herbal extracts, taken twice daily.
62299532|NCT05523180|PLACEBO_COMPARATOR|Placebo|1 capsule of placebo, taken twice daily.
62299533|NCT01245244|EXPERIMENTAL|Morphine|
62299534|NCT01245244|PLACEBO_COMPARATOR|Placebo|
62299535|NCT03560362|ACTIVE_COMPARATOR|Bupivacaine with epinephrine|Patients will receive intraoperative intercostal nerve block with bupivacaine
62299536|NCT03560362|EXPERIMENTAL|Lipossomal extended release bupivacaine|Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
62470055|NCT01615198|ACTIVE_COMPARATOR|Olmesartan|Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd.
62670266|NCT04867330|EXPERIMENTAL|conventional treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
62670267|NCT00221923||Healthy individuals|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
62299537|NCT04836286|EXPERIMENTAL|single group repeated design|The Emotive Intelligent Spaces (EIS) leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
62470056|NCT01537861|EXPERIMENTAL|Arm 1|"Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.~Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.~Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.~PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen."
62470057|NCT02829762|EXPERIMENTAL|Interventional arm PS-DR|The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24).
62670268|NCT00221923||Persons at risk for or with primary open angle glaucoma|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
62670269|NCT03471949|EXPERIMENTAL|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
62670270|NCT02383485|EXPERIMENTAL|After-school exercise program|40 min/day vigorous aerobic games after school
62670271|NCT02383485|ACTIVE_COMPARATOR|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
62670272|NCT03139630||HIV-infected patients|HIV-infected adult male or female patients who are HIV treatment naive and initiate antiretroviral therapy including a protease inhibitor during the follow up period.
62670273|NCT03139630||HIV-uninfected patients|HIV-uninfected adult male or female patients.
62670274|NCT02737059|PLACEBO_COMPARATOR|Codeine/naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and placebo tablet matching naloxegol q.d."
62108302|NCT02570295|EXPERIMENTAL|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
62108303|NCT02570295|NO_INTERVENTION|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
62108304|NCT01175707|EXPERIMENTAL|Daptomycin|500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted
61914558|NCT02430129|EXPERIMENTAL|Unicompartment knee arthroplasty/Oxford|Unicompartmental knee arthroplasty with Biomet Oxford mobile-bearing unicompartmental knee prosthesis (Biomet, Warsaw, IN)
62299538|NCT03482661|NO_INTERVENTION|Control|The patients swallowed the capsule with water in the supine position. When the capsule reached the stomach, the capsule was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After completing the stomach examination, the capsule moved automatically without magnetic control and entered the duodenum under physiological conditions. The position of the capsule was verified through real-time viewer.
62670275|NCT02737059|PLACEBO_COMPARATOR|Naloxegol/ codeine placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Naloxegol tablet 25 mg q.d and placebo tablet matching codeine q.i.d."
62670276|NCT02737059|ACTIVE_COMPARATOR|Codeine/ naloxegol|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and naloxegol tablet 25 mg q.d."
62108305|NCT01175707|ACTIVE_COMPARATOR|Vancomycin|Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician
62108306|NCT02321748|OTHER|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
62108307|NCT02321748|OTHER|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
62108308|NCT02191852|EXPERIMENTAL|Seresis®|2 capsules per day for a period of 16 consecutive weeks
62108309|NCT01461213|EXPERIMENTAL|Dose 1|Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
61914559|NCT06275529|EXPERIMENTAL|MSU Classification 1A|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 1A
61914560|NCT06275529|EXPERIMENTAL|MSU Classification 1B|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 1B
61914561|NCT06275529|EXPERIMENTAL|MSU Classification 1C|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 1C
61914562|NCT06275529|EXPERIMENTAL|MSU Classification 2A|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2A
61914563|NCT06275529|EXPERIMENTAL|MSU Classification 2B|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2B
61914564|NCT06275529|EXPERIMENTAL|MSU Classification 2C|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2C
62470058|NCT02829762|NO_INTERVENTION|Reference Arm|In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team.
62670277|NCT02737059|ACTIVE_COMPARATOR|codeine placebo/ naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Placebo tablet matching codeine q.i.d., and placebo tablet matching naloxegol q.d."
62670278|NCT03591536|OTHER|pentoxifylline oral|50 adult patient underwent elective CABG intervention to be administered will be receiving main drug (pentoxifylline )oral 400 mg' every 8 hours from three days before surgery and on the day of surgery effect of intervention regarding antioxidant
62670279|NCT03591536|PLACEBO_COMPARATOR|placebo|50 adult patient underwent elective CABG received oral placebo pill resembling completely to pentoxifylline 400 mg, every 8 hours from three days before surgery and on the day of surgery
61914565|NCT06275529|EXPERIMENTAL|MSU Classification 3A|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 3A
61914566|NCT06275529|EXPERIMENTAL|MSU Classification 3B|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 3B
61914567|NCT06275529|EXPERIMENTAL|MSU Classification 2AB|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2AB
62470059|NCT04985474||Pulmonary resection|
61914568|NCT06275529|EXPERIMENTAL|MSU Classification 3AB|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 3AB
61914569|NCT03304444|ACTIVE_COMPARATOR|Bupivacaine HCl in TAP block|"When performing a bilateral TAP with Bupivicaine 0.25% and the incision is below the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials).~When performing a bilateral TAP with Bupivicaine 0.25% and the incision extends above the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials). A 3rd vial of 30 ml 0.25% bupivacaine will be drawn up and is directly infiltrated into the surgical site (above and below the fascia prior to closure of fascia) extending above the umbilicus by the surgeon."
62108310|NCT01461213|EXPERIMENTAL|Dose 2|Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
62108311|NCT01254981|EXPERIMENTAL|Nobori|Percutaneous coronary intervention with implantation of coronary stent (Nobori)
62470060|NCT06309225|EXPERIMENTAL|Experimental|"Cisplatin: 30-40 mg/m2/week, every week during radiation. Dose should be based on actual body weight. The first cisplatin infusion should be started within 24 hours before or after the first scheduled radiation treatment.~Intensity Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT) are mandatory for this study.~55 Gy radiation in 5 weeks using 5 fractions per week + Cisplatin every week"
62470061|NCT05599074|EXPERIMENTAL|AOB adults|adult patients over 18 years having an anterior open bite of more than 2 mm, requiring incisors extrusion
62470062|NCT00627419|EXPERIMENTAL|1|IPI-504
62470063|NCT00817661|EXPERIMENTAL|1|Vitamin A group
62470064|NCT00817661|PLACEBO_COMPARATOR|2|Placebo group
62670280|NCT05349266|EXPERIMENTAL|ThisCART19A 2×10^6 cells/kg for dose level 1|Patients will receive 2×10\^6 cells/kg of ThisCART19A
62670281|NCT05349266|EXPERIMENTAL|ThisCART19A 3×10^6 cells/kg as dose level 2|Patients will receive 3×10\^6 cells/kg of ThisCART19A
62670282|NCT05349266|EXPERIMENTAL|Patients will receive 4×10^6 cells/kg as dose level 3|Patients will receive 4×10\^6 cells/kg of ThisCART19A
62670283|NCT00981175|EXPERIMENTAL|Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo|Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
62470065|NCT06156644|OTHER|PFA strategy|PFA will be performed based on a specific protocol
62670284|NCT00981175|EXPERIMENTAL|Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine|Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
62670285|NCT04958590||1 （asymptomatic）|the middle-aged and elderly Chinese asymptomatic population who underwent the whole spine X-ray in standing and sitting positions.
62670286|NCT04958590||2 （patients）|the patients who underwent posterior lumbar fusion surgery for lumbar degenerative disease has been followed up for three months.
62670287|NCT01016015|EXPERIMENTAL|Treatment (cixutumumab and temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
61914570|NCT03304444|EXPERIMENTAL|Liposomal Bupivicaine in TAP block|When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
61914571|NCT00657410|EXPERIMENTAL|ARM A - PDN|PDN is administered orally at the daily dose of 1 mg/Kg for 4 consecutive weeks (from day 0 to day 28), then, therapy is tapered within 14 days. The patients considered NOT RESPONDER at day 42 or WHO HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be crossed to ARM B.
61914572|NCT00657410|EXPERIMENTAL|ARM B - DXM|"DXM is administered orally at single fixed daily doses of 40 mg for 4 consecutive days, every 14 days, for 3 consecutive courses. If platelet count is £ 20x109/L or bleeding symptoms related to thrombocytopenia are present, lowdose DXM (0.035 mg/Kg/day) between courses is given. The patients (either from ARM A+B or from ARM B) considered NOT RESPONDER at day 46 or who HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be considered OFF TREATMENT.~For these patients a second line therapy will be considered, according to the medical practice of the Centre (splenectomy or other)."
61914573|NCT02605044|EXPERIMENTAL|Masitinib + FOLFIRI|masitinib + FOLFIRI
62108312|NCT01254981|EXPERIMENTAL|Cypher|Percutaneous coronary intervention with implantation of coronary stent (Cypher)
62670288|NCT01886157|ACTIVE_COMPARATOR|Corticosteroid injection|Standard corticosteroid injection.
62670289|NCT01886157|EXPERIMENTAL|Corticosteroid Injection and Trigger Splint|Corticosteroid Injection + Trigger Splint + Education + Home Exercises
62299539|NCT03482661|EXPERIMENTAL|Magnetic steering|After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis.
62299540|NCT06196502|EXPERIMENTAL|Gentle human touch (GHT)|Experimental: Gentle human touch (GHT) Group 1: Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior.
62670290|NCT04664088|EXPERIMENTAL|Acupuncture group|Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions).
62670291|NCT04664088|ACTIVE_COMPARATOR|Medication group|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks.
62670292|NCT04549428|EXPERIMENTAL|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1,200 mg by intravenous infusion every 21 days on an outpatient basis until progression, intolerance or loss of clinical benefit, according to the its approved prescribing information. Palliative radiation therapy will be delivered concomitant to the 2nd dose of atezolizumab as a single fraction of 8 Gy
62670293|NCT02492919|EXPERIMENTAL|Medixair®|Cardiac reanimation unit bed with Medixair®
62670294|NCT02492919|NO_INTERVENTION|NO Medixair®|Cardiac reanimation unit bed with NO Medixair®
61914574|NCT02605044|PLACEBO_COMPARATOR|Placebo + FOLFIRI|Placebo + FOLFIRI
61914575|NCT03726554|EXPERIMENTAL|Comp. Rev. Porous Augmented Glenoid|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Porous Augmented Glenoid.
62670295|NCT03889262|ACTIVE_COMPARATOR|Control Group|Participants in this group will receive only Neurodevelopmental therapy (NDT) based rehabilitation for 45 minutes in each session, twice a week, during 8 weeks, 16 sessions in total. Number of participants in this group is anticipated to be 20.
62299541|NCT06196502|ACTIVE_COMPARATOR|Kangaroo Care|Experimental: Kangaroo Care Group 2: Kangaroo care is a comforting technique that strengthens and bonds the baby and parent, increases the production of milk by the mother, and lessens the stress and anxiety of both parties. Kangaroo care between parent and baby is a method that regulates vital values, reduces the possibility of hypoglycemia and prevents hypothermia.
61914576|NCT03726554|EXPERIMENTAL|Comp. Rev. Mini Humeral Tray|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Mini Humeral Tray
61914577|NCT02732197||Sedation (S)|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
61914578|NCT02732197||No sedation (NS)|Parturients who did not receive any sedative agent after the spinal anesthesia performance.
62670296|NCT03889262|ACTIVE_COMPARATOR|Study Group|After 16 sessions (8 weeks) of only Neurodevelopmental therapy (NDT) based rehabilitation, simulated hippotherapy treatment will be added to rehabilitation program of the same participants. Their NDT treatment will be reduced to 25 minutes whereas hippotherapy will be applied for 20 minutes in each session, 2 sessions a week, 8 weeks in total.
61914579|NCT01136200|EXPERIMENTAL|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
62299542|NCT06196502|ACTIVE_COMPARATOR|Lactation|Breastfeeding will begin 5 minutes before the Hepatitis-B vaccine administration and will continue during and after the procedure. It is planned to last 10 minutes in total.
62299543|NCT05670977|ACTIVE_COMPARATOR|Study product plus collagen supplement|"5g/bag, containing the following ingredients per 5g serving:~* Collagen tripeptide 1500 mg~* Elastin peptide 150 mg"
62670297|NCT05210946|EXPERIMENTAL|Pemigatinib in Advanced Non-Small Cell Lung Cancer Patients with FGFR Gene Alterations|"This study is a prospective single-arm clinical study. Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to"
62670298|NCT01552889|NO_INTERVENTION|Usual Care (UC)|Patients will receive only the care provided by their primary care physicians or other medical professionals outside of the study.
61914580|NCT01136200|NO_INTERVENTION|Control|Patients not receiving infectious disease specialist advice
61914581|NCT03279627||Hypoglycemia|This group will be those who experience a BG \< 70 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
62670299|NCT01552889|EXPERIMENTAL|Collaborative Care (CC)|Patients randomized to the Collaborate Care (CC) arm of this study will receive brief screening, consultative, and referral services. This collaborative approach includes the patient, the patient's PCP, the cardiologist, and the nurse case manager (NCM), using evidence based recommendations for depression treatment and follow-up care.
61914582|NCT03279627||Hyperglycemia|This group will be those who experience a BG \> 250 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
61914583|NCT03279627||Glycemic control|This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
62299544|NCT05670977|PLACEBO_COMPARATOR|Study product without collagen supplement|"5g/bag, containing the following ingredients per 5g serving:~* Peach juice 8 mg~* Erythritol 10 mg"
62299545|NCT00768222|ACTIVE_COMPARATOR|Chinese Silk Suture|Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
62299546|NCT00768222|EXPERIMENTAL|VICRYL* Plus Suture|Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
62299547|NCT01549990||Sevoflurane group|donors who went through donor nephrectomy under general anesthesia with sevoflurane
62299548|NCT01549990||desflurane group|donors who went through donor nephrectomy under general anesthesia with desflurane
62299549|NCT06170645|EXPERIMENTAL|Patients with active tVNS|Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid will be included.
62299550|NCT06170645|SHAM_COMPARATOR|Patients with sham tVNS|Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid will be included.
62299551|NCT00811252|PLACEBO_COMPARATOR|Placebo|
62299552|NCT00811252|EXPERIMENTAL|Vortioxetine 5 mg|
62299553|NCT00811252|OTHER|Duloxetine 60 mg|Active reference
62299554|NCT01122329|PLACEBO_COMPARATOR|inactive food packet|
62299555|NCT01122329|ACTIVE_COMPARATOR|Axona®|
62299556|NCT05206643||A cohort as an area probability sample of Shanghai City|
62670300|NCT03362957|EXPERIMENTAL|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
62670301|NCT03362957|SHAM_COMPARATOR|Sham Procedure|Patients will be randomized to a sham procedure.
62670302|NCT03362957|EXPERIMENTAL|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
62670303|NCT03536377|EXPERIMENTAL|very low calorie liquid diet|Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence
62670304|NCT01183637|EXPERIMENTAL|Treatment|Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
62670305|NCT01183637|ACTIVE_COMPARATOR|Control|Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
62299557|NCT04351659||Blood donors|Donors who had tested positive for SARS-CoV-2 in the past and have recovered from COVID-19 and are now suitable for blood donation.
62670306|NCT05099445|EXPERIMENTAL|Group 1: Normal Renal Function|Participants with normal levels of renal function will receive a single oral dose of INCB000928 200 mg on Day 1.
62670307|NCT05099445|EXPERIMENTAL|Group 2: Mild Renal Impairment|Participants with mild levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
62670308|NCT05099445|EXPERIMENTAL|Group 3: Moderate Renal Impairment|Participants with moderate levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
62299558|NCT06441630|EXPERIMENTAL|Co-administration of AD-227A and AD-227B|AD-227A + AD-227B + Placebo of AD-227C
62670309|NCT05099445|EXPERIMENTAL|Group 4: Severe Renal Impairment|Participants with severe levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
62670310|NCT05099445|EXPERIMENTAL|Group 5: Kidney Failure|Group 5 participants with ESRD maintained on HD will receive a single dose of INCB000928 on Day 1 of each of 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB000928.
62670311|NCT02499536|EXPERIMENTAL|Study participants|After general anesthesia development of the atelectasis will be investigated by the lung ultrasound
62670312|NCT04242134|EXPERIMENTAL|PS-DCB|"For PS-DCB group~1. NC balloon dilating ostial side branch (SB) (1:1 ratio).~2. DCB dilating SB. Specifically, the DCB, which had to be 2-3 mm longer on each side than the predilatation balloon, was inflated at nominal pressure for 30\~ 60 s. The ratio of the DCB diameter to the nominal diameter of the SB was recommended to be between 0.8 and 1.0. DCB should be delivered to the lesion within 2 min after entering human body.~3. Kissing inflation using 2 noncomplian balloons.~4. Stenting side branch with T and protrusion (TAP) technique if any of the following issues was observed after kissing balloon inflation: \>type C dissection or thrombolysis in myocardial infarction (TIMI) flow \<3.~5. Final kissing inflation and proximal optimal technique (POT)."
62670313|NCT04242134|ACTIVE_COMPARATOR|PS-NCB|"For PS-NCB group~1. NC balloon dilating ostial SB (1:1 ratio).~2. Kissing inflation using 2 NC balloons.~3. Stenting side branch with TAP technique if any of the following issues was observed after kissing balloon inflation: \>type C dissection or thrombolysis in myocardial infarction (TIMI) flow \<3.~4. Final kissing inflation and proximal optimal technique (POT)."
62670314|NCT04573530|EXPERIMENTAL|We Walk Plus Intervention|The intervention group will receive a Fitbit, SMS and will be assigned to a private Fitbit community (4-5 participants per group) for 12 weeks. During the intervention, participants will receive weekly personalized SMS on their mobile phones including encouraging messages, reminders, and tips to increase steps, and weekly step goals. The investigators will use a secure, web-based platform, iCardia, to support continuous real-time remote monitoring of activity data from Fitbit devices and personalized communication via SMS based on incoming data. The investigators will set up the Fitbit networking settings on participants' phones to give notifications when there are posts to this group. Individual goals and a weekly team goal of steps will be set up by the research team. Each member will be awarded a badge upon reaching each individual's weekly goal. Teams will also be awarded badges when all team members reach their individual weekly goals.
62670315|NCT04573530|NO_INTERVENTION|Attention control group|The attention control group will also receive a Fitbit and will be asked to continue with normal daily activities. During the initial in-person session, they will receive the same PA recommendations as the intervention group to walk at least 30 minutes for 5 days or more a week or 10,000 steps a day. However, a plan for improving PA will not be discussed.
62670316|NCT02400580|EXPERIMENTAL|Intravenous IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
62670317|NCT02400580|PLACEBO_COMPARATOR|Normal Saline|The patients in the placebo arm will receive normal saline.
62670318|NCT04934072|EXPERIMENTAL|FKS518|
62670319|NCT04934072|ACTIVE_COMPARATOR|US-licensed Prolia|
62670320|NCT04085003||Intact abdominal aortic aneurysm|
62670321|NCT04085003||Ruptured abdominal aortic aneurysm|
62670322|NCT03904186|EXPERIMENTAL|QUIT Treatment for Smoking Cessation and Distress Tolerance|Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
62299559|NCT06441630|ACTIVE_COMPARATOR|AD-227A|AD-227A + Placebo of AD-227B + Placebo of AD-227C
62670323|NCT03904186|ACTIVE_COMPARATOR|Time and Intensity-Match Control|Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.
61914584|NCT01138878||Patient pre-study group|A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
61914585|NCT01138878||Staff pre-study group|A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
61914586|NCT01138878||Patient intra-study group|A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
62299560|NCT06441630|ACTIVE_COMPARATOR|Co-administration of AD-227A and AD-227C|AD-227A + Placebo of AD-227B + AD-227C
62299561|NCT02490852|EXPERIMENTAL|Investigational Infant formula|Healthy term infants fed exclusively the investigational Infant Formula
62670324|NCT03904186|NO_INTERVENTION|Standard of Care|At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
62670325|NCT00977184|EXPERIMENTAL|Real rTMS|
62670326|NCT00977184|SHAM_COMPARATOR|Sham rTMS|
62670327|NCT05516095|ACTIVE_COMPARATOR|Active iTBS|iTBS will be delivered with 120% of resting motor threshold, triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays). Each patient will start treatment at the same time between 9 am and 3 pm during the 10-day treatment period.
61914587|NCT01138878||Post-study staff group|A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
62108313|NCT03511885||high cardiovascular risk patients|"Coronary patients~* Elective coronary artery bypass surgery (CABG).~* Elective percutaneous coronary intervention (PCI) .~* Acute coronary syndromes (acute myocardial infarction with ST elevation (STEMI) and Non ST elevation MI (Non- STEMI) including those treated with primary PCI and/or CABG, and unstable angina).~People at high risk of cardiovascular disease (CVD) who have been prescribed one or more of the following medications: (i) blood pressure and/or (ii) lipid and/or (iii) glucose lowering (diet and/or oral hypoglycaemic agents and/or insulin) treatments prescribed by a physician."
62108314|NCT00728845|EXPERIMENTAL|Hydroxychloroquine, Carboplatin, Paclitaxel, Bevacizumab|Cohort 1: Bevacizumab Eligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
62108315|NCT00728845|EXPERIMENTAL|Hydroxychloroquine, Carboplatin, Paclitaxel|Cohort 2: Bevacizumab Ineligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
61914588|NCT00184171|EXPERIMENTAL|Budesonide|Budesonide 9mg
62670328|NCT05516095|PLACEBO_COMPARATOR|Sham iTBS|The sham system has an identical look, weight and sound compared to the true coil, and delivers electrical stimulation that can be felt at the skin but without penetrating the skull and thus not inducing any treatment effect. The sham stimulation will be given with the same procedure as the active stimulation; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s.
62670329|NCT05515263|EXPERIMENTAL|Intervention snack|The intervention group will receive a snack food believed to be beneficial for immune function (high content of immunoregulatory nutrients).
62670330|NCT05515263|PLACEBO_COMPARATOR|Control snack|The control group will receive an isocaloric, commercially available snack food (low content of immunoregulatory nutrients).
62670331|NCT05593640||ThroboxaneOA|Patient with osteoarthritis and knee effusion
62670332|NCT04151498|EXPERIMENTAL|Intervention Group|This group will complete an HIV health reengagement intervention on a mobile van, in addition to a pre- and post-intervention qualitative interview.
62670333|NCT04151498|OTHER|Usual Care Reengagement Group|This group will complete a qualitative interview about barriers and facilitators to HIV care.
61914589|NCT00184171|EXPERIMENTAL|bismuth|Bismuth mixture
61914590|NCT00184171|SHAM_COMPARATOR|Fiber|Fiber preparation
61914591|NCT05814354|EXPERIMENTAL|SHR-A1811|
61914592|NCT05814354|ACTIVE_COMPARATOR|Physician's Choice|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
61914593|NCT01294527|EXPERIMENTAL|Implant|Implant of the WiCS-LV system
61914594|NCT02106923|EXPERIMENTAL|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
61914595|NCT02106923|EXPERIMENTAL|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
61914596|NCT02106923|EXPERIMENTAL|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
61914597|NCT01149954|EXPERIMENTAL|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
61914598|NCT01149954|ACTIVE_COMPARATOR|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
61914599|NCT01599143|EXPERIMENTAL|Mindfulness-based Stress Reduction group|All eligible participants attend a 3-hour weekly session, for 8 consecutive weeks, to learn meditation and simple Hatha Yoga techniques, and incorporate them into their daily lives.
61914600|NCT01640327|EXPERIMENTAL|TIVf|
61914601|NCT02700503|EXPERIMENTAL|Intervention|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
62108316|NCT00315055|EXPERIMENTAL|Group 1: DTaP-IPV-Hep B-PRP-T|Participants will receive 3 vaccinations with Diphtheria (D) and tetanus (T) toxoids, acellular pertussis (2-component) (aP), recombinant Hepatitis B surface antigen (HBsAg), inactivated poliomyelitis virus (IPV), and Hemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (DTaP-IPV-Hep B-PRP\~T); One dose each at 2, 3, and 4 months of age.
62108317|NCT00315055|ACTIVE_COMPARATOR|Group 2: PENTAXIM™ and ENGERIX B® PEDIATRIC|Participants will receive 3 vaccinations with DTaP-IPV-PRP\~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines. One dose each at 2, 3, and 4 months of age.
62108318|NCT06556134|ACTIVE_COMPARATOR|GROUP IV|Group IV received intravenous iron-hydroxide sucrose complex (marketed as Fermed® 100mg), administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 month
61914602|NCT02763969|EXPERIMENTAL|Part A: Single Ascending Dose|BMS-986202 or Placebo specified dose on specified days
61914603|NCT02763969|EXPERIMENTAL|Part B: Multiple Ascending Dose|BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
61914604|NCT02763969|EXPERIMENTAL|Part C: Multiple Ascending Dose-Japanese descent|BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent
61914605|NCT02763969|EXPERIMENTAL|Part D: Relative Bioavailability|BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days
61914606|NCT02763969|EXPERIMENTAL|Part E: Proof of Mechanism|BMS-986202 or Placebo + Ustekinumab specified dose on specified days
61914607|NCT04636853|EXPERIMENTAL|Affected Individual|A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
62470066|NCT05306639|EXPERIMENTAL|Spinal magnetic stimulation|Spinal magnetic stimulation group will receive repetitive spinal magnetic stimulation sessions for a total of 12 sessions. Using the Neuro-MS/D machine, circular coil will be used to stimulate S2,3 and 4 sacral roots. The outer rim of the coil will be positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2) Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 15 Hz, burst length = 10 seconds, inter-burst interval = 30 seconds with a total of 1500 pulses
61914608|NCT03785093||Chinese Family|Chinese parents and their offsprings
61914609|NCT04729400|EXPERIMENTAL|Experimental group|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
61914610|NCT04729400|EXPERIMENTAL|CONTROL GROUP|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
61914611|NCT01565343|EXPERIMENTAL|AD Subjects|Two bolus IV injections followed by brain PET scan up to 4 weeks apart
61914612|NCT01565343|EXPERIMENTAL|AD Subjects: Slow vs. Fast Bolus|"Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.~The first injection given as a rapid bolus (\< 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration)."
61914613|NCT01565343|EXPERIMENTAL|Healthy controls|Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart
62108319|NCT06556134|ACTIVE_COMPARATOR|GROUP OS|Group OS received one oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid (marketed as Lisofer® 30mg), for the same 3-month duration
62108320|NCT01230346|EXPERIMENTAL|Arm I|Patients receive a culturally-informed adapted motivational interviewing telephone call.
62108321|NCT01230346|EXPERIMENTAL|Arm II|Patients participate in a controlled condition comprising a health habits intervention group.
62108322|NCT01230346|ACTIVE_COMPARATOR|Arm III|Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
62108323|NCT03921684|EXPERIMENTAL|Neoadjuvant Treatment|All subjects will receive chemoradiation followed by chemotherapy and nivolumab as neoadjuvant treatment
62670334|NCT04151498|NO_INTERVENTION|Non-enrolling Group|This group will not be enrolled in the intervention, and will include de-identified data from clinic patients referred to bridge counselors during the study time period that do not participate in the intervention.
62670335|NCT03116269|EXPERIMENTAL|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
62670336|NCT03116269|ACTIVE_COMPARATOR|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
62670337|NCT04772547|EXPERIMENTAL|Open label|4500 mg of vigabatrin administered enterally
62470067|NCT05306639|EXPERIMENTAL|Neuromodulation|Neuromodulation group will receive 12 sessions of bilateral transcutaneous posterior tibial neuromodulation using (Myomed 632®, Enraf Nonius, Delft, Netherlands) machine, the active rubber surface was placed behind the medial malleolus and the reference electrode was placed 10 cm proximal. Adjustment of the electric current was as follows: continuous current, pulse duration 200 ms, frequency 20 Hz; each session lasts for 30 min. The current intensity was adjusted according to the tolerance of the patient or until the big toe curls into plantar flexion
62470068|NCT05275985|EXPERIMENTAL|68Ga-FAPI PET/CT examination|Patients with suspected pancreatic lesions underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The clinicians decided the treatment methods based on the results of 68Ga-FAPI PET/CT.
62108324|NCT00908336|EXPERIMENTAL|Docetaxel and Erlotinib|"Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.~After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment."
62108325|NCT00908336|ACTIVE_COMPARATOR|Erlotinib|Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
62108326|NCT00939848|EXPERIMENTAL|B|The experimental arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with cediranib 20mg oral daily (continuous dosing).
62108327|NCT00939848|PLACEBO_COMPARATOR|Arm A|The control arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with a matching placebo 20mg oral daily (continuous dosing)
62299562|NCT02490852|ACTIVE_COMPARATOR|Commercially available Infant formula|Healthy term infants fed exclusively a commercially available Infant Formula
62299563|NCT02490852|ACTIVE_COMPARATOR|Human milk|Healthy term infants fed exclusively human milk
62108328|NCT03872297|PLACEBO_COMPARATOR|Placebo supplement|Consumption of a non active food complement during 3 months.
62108329|NCT03872297|ACTIVE_COMPARATOR|Naticol supplement|Consumption of the active food complement during 3 months containing Naticol.
62299564|NCT01440725|EXPERIMENTAL|PRP|Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
62470069|NCT02272647|EXPERIMENTAL|IM Plac - Oral Plac - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
62470070|NCT02272647|EXPERIMENTAL|IM Plac - Oral Prog - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
62470071|NCT02272647|EXPERIMENTAL|IM E2 - Oral Plac - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)
62470072|NCT02272647|EXPERIMENTAL|IM E2 - Oral Prog - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
62670338|NCT00976391|ACTIVE_COMPARATOR|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
62670339|NCT00976391|ACTIVE_COMPARATOR|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
62108330|NCT06628934||Spinocerebellar Ataxia|Individuals with genetically-confirmed diagnosis of SCA
62108331|NCT06628934||Healthy Controls|Healthy Controls
62108332|NCT05655442|EXPERIMENTAL|early APM|early APM within 3 and 6 month knee pain symptoms
62299565|NCT01440725|ACTIVE_COMPARATOR|Evacuation of haematoma|Evacuation of the hematoma, and simulation of the administration of PRP
62299566|NCT01779609|EXPERIMENTAL|Bosentan + Exercise|2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise
62299567|NCT01779609|PLACEBO_COMPARATOR|Placebo + Exercise|2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise
62299568|NCT01779609|OTHER|Exercise|3x/week supervised exercise for 8 weeks
62108333|NCT05655442|ACTIVE_COMPARATOR|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
62299569|NCT05973409|EXPERIMENTAL|Habitual Soft Lens Wearers|Each group will be a prospective, randomized, double masked, cross-over, 1-month per arm, daily wear study. Each participant will be active in the study for at least 2 months.
62299570|NCT05973409|EXPERIMENTAL|Non Contact Lens Wearers|Each group will be a prospective, randomized, double masked, cross-over, 1-month per arm, daily wear study. Each participant will be active in the study for at least 2 months.
62299571|NCT03810989|EXPERIMENTAL|infra-red sauna|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
62670340|NCT01794975|ACTIVE_COMPARATOR|Ketamine|Ketamine will be administered intravenously using a pseudo steady state infusion approach with a target plasma concentration of 300 ng/ml starting 15 minutes before the PET scan and continued throughout the scan.
62670341|NCT01794975|ACTIVE_COMPARATOR|Atomoxetine and the cold pressor test|An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
62670342|NCT01794975|PLACEBO_COMPARATOR|Placebo|Placebo capsules are given to mimic the atomoxetine treatment at each treatment visit except the atomoxetine visit. A baseline PET scan with \[11C\]ORM-13070 will be performed for all subjects with the placebo treatment only.
62670343|NCT04692051|EXPERIMENTAL|Nab-paclitaxel + Cisplatin|Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin
62670344|NCT04692051|ACTIVE_COMPARATOR|Gemcitabine + Cisplatin|Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin
62670345|NCT01058005|EXPERIMENTAL|Natalizumab|
62670346|NCT01058005|ACTIVE_COMPARATOR|Interferon Beta-1a|
62670347|NCT01058005|ACTIVE_COMPARATOR|Glatiramer Acetate|
62670348|NCT03780387|EXPERIMENTAL|Inhaled Allergen Challenge|Felis Catus sensitive, mild asthmatics will undergo inhaled allergen challenge.
62670349|NCT01077895|EXPERIMENTAL|CVVH with fluid removal|
62670350|NCT01077895|ACTIVE_COMPARATOR|CVVH without fluid removal|
62670351|NCT02042001|EXPERIMENTAL|Immediate Switch|Immediate switch to TDF/FTC/RPV
62670352|NCT02042001|ACTIVE_COMPARATOR|Deferred Switch|Switch to TDF/FTC/RPV after 24 weeks
62670353|NCT01696214|PLACEBO_COMPARATOR|Ipratropium|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
62299572|NCT03810989|EXPERIMENTAL|argometer and treadmill|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
62299573|NCT03810989|EXPERIMENTAL|combination of sauna and hot bath|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
62670354|NCT01696214|PLACEBO_COMPARATOR|Theophylline|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
62670355|NCT01696214|PLACEBO_COMPARATOR|Montelukast|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
62670356|NCT01696214|PLACEBO_COMPARATOR|fluticasone 250 mg/salmeterol 50mg|Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
62670357|NCT02549378|EXPERIMENTAL|patients with a hypercapnia test|confocal microscopy patients with a hypercapnia test
62670358|NCT04055662||Cannabis users|
62670359|NCT04055662||Cannabis naive|
62670360|NCT00142597|ACTIVE_COMPARATOR|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
62670361|NCT00142597|SHAM_COMPARATOR|Sham Treatment|Sham acupuncture is used.
62670362|NCT04055389|EXPERIMENTAL|AT-III treatment|
62670363|NCT04055389|PLACEBO_COMPARATOR|Placebo|
62670364|NCT04345432|EXPERIMENTAL|Gabapentin|"The experiment will be divided into the following phases:~* Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~* 7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~* 7 day drug washout phase - no medication will be taken~* 7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~* Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
62670365|NCT04345432|PLACEBO_COMPARATOR|Placebo|"The experiment will be divided into the following phases:~* Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~* 7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~* 7 day drug washout phase - no medication will be taken~* 7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~* Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
62670366|NCT03081923|EXPERIMENTAL|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
62670367|NCT03081923|EXPERIMENTAL|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
61914614|NCT00943943|EXPERIMENTAL|G-CSF and Plerixafor with Sorafenib|G-CSF 10 mcg/kg adjusted body weight subcutaneous injection. Plerixafor fixed dose of 240 mcg/kg adjusted body weight subcutaneous injection in abdomen. Patients will receive the 1st doses of G-CSF and Plerixafor on day 1. G-CSF and Plerixafor every other day for 7 total doses, repeated every 28 days. Sorafenib starting dose 400 mg twice daily orally after G-CSF/Plerixafor injections.
61914615|NCT05609812|EXPERIMENTAL|Atacicept Dose|Atacicept Dose once weekly subcutaneous (SC) Injection
61914616|NCT05609812|PLACEBO_COMPARATOR|Placebo to match Atacicept|Placebo to match Atacicept once weekly subcutaneous (SC) injection
61914617|NCT05587049||Venetoclax + Azacitidine Participants|Participants treated with venetoclax in combination with azacitidine in accordance with approved local label.
61914618|NCT02715297|EXPERIMENTAL|Arm A: SRT to the resection cavity|Postoperative stereotactic fractionated radiotherapy (SRT) to the resection cavity to a Total Dose of 46 Gy, 2 Gy single dose, or 36 Gy in 3 Gy single dose 5 fractions/week, depending on the volume and location of the treatment region.
61914619|NCT02715297|NO_INTERVENTION|Arm B: Observation|Observation without adjuvant radiotherapy.
62108334|NCT02145182|EXPERIMENTAL|Active|Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours \[h\] later).
62108335|NCT02145182|PLACEBO_COMPARATOR|Placebo|Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
62108336|NCT01971892|EXPERIMENTAL|Non invasive ventilation (NIV)|Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
62108337|NCT01971892|ACTIVE_COMPARATOR|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute with in order to maintain peripheral oxygen saturation above 94%.
62108338|NCT05104905|EXPERIMENTAL|Renal cell intervention 1.0 mg/kg|
62108339|NCT05104905|EXPERIMENTAL|Renal cell intervention 3.0 mg/kg|
62108340|NCT05104905|EXPERIMENTAL|Renal cell intervention 10 mg/kg|
62470073|NCT05081466||United Kingdom Women's Cohort|United Kingdom Women's Cohort Study. No interventions are to be administered in this observational prospective cohort study.
61914620|NCT00703703|EXPERIMENTAL|1|Darifenacin
61914621|NCT00703703|ACTIVE_COMPARATOR|2|Tolterodine
61914622|NCT00703703|PLACEBO_COMPARATOR|3|Placebo
61914623|NCT03025100||Prospective|A sample of 120 patients aged 60 years or older admitted to General Medicine at Duke University Hospital will be enrolled in the prospective cohort study. A convenience sample will be derived from a randomized daily list of general medicine admissions; weekend admissions will be excluded as these patients will not be captured within 24 hours of hospital admission.
61914624|NCT02756988|EXPERIMENTAL|Coppertone (BAY987704)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61914625|NCT04731857||Genetic diseases|For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.
61914626|NCT00591461||1|Study participants must be older than 18 years of age who are having an endoscopy performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth, dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.
61914627|NCT05982951|ACTIVE_COMPARATOR|Shoulder PENG block group|Ultrasound-guided peri-capsular nerve block of the shoulder with 20ml of 0.25% bupivacaine between the supraspinatus muscle and deltoid muscle.
61914628|NCT05982951|ACTIVE_COMPARATOR|Shoulder block|ultrasound guided axillary nerve block and suprascapular nerve block posterior approach with 10 ml 0.25% bupivacaine (total 20ml)
62108341|NCT05104905|NO_INTERVENTION|Renal cell Observation|
62470074|NCT05531422|EXPERIMENTAL|Inhaled fentanyl aerosol|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with Inhaled fentanyl aerosol (25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25µg) in a random sequence
61914629|NCT02827656|EXPERIMENTAL|Decapeptyl support|S.C single luteal Decapeptyl 0.1 mg on days 3, 6,9 post ovulation triggering
61914630|NCT02827656|ACTIVE_COMPARATOR|hCG luteal support|S.C single luteal S.C recombinant hCG 50 micrograms on days 3 ovulation triggering
62108342|NCT05104905|EXPERIMENTAL|Colon cancer intervention 1.0 mg/kg|
62108343|NCT05104905|EXPERIMENTAL|Colon cancer intervention 3.0 mg/kg|
62108344|NCT05104905|EXPERIMENTAL|Colon cancer intervention 10 mg/kg|
62108345|NCT05104905|NO_INTERVENTION|Colon cancer Observation|
62108346|NCT03985917|EXPERIMENTAL|Intervention Singing Group Program|Singing group intervention program that includes six components: (1) vocal warm-up exercises; (2) vocal technique; (3) rehearsal of repertoire; (4) break for socialization; (5) creation and presentation of a show; (6) assessment of participants performance (vocal tuning).
62108347|NCT03985917|ACTIVE_COMPARATOR|Alternative Social and Leisure Activities|While the experimental group is participating in the intervention program, the control group will participate in the other activities proposed by the day care centers, which will be registered.
62470075|NCT05531422|PLACEBO_COMPARATOR|Placebo|Participants were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence
62470076|NCT04755985|EXPERIMENTAL|ARM 1|Period 1 : Reference Drug(AD-2132) Period 2 : Test Drug(AD-213-B)
62470077|NCT04755985|EXPERIMENTAL|ARM 2|Period 1 : Test Drug(AD-213-B) Period 2 : Reference Drug(AD-2132)
62470078|NCT03110120|ACTIVE_COMPARATOR|serratus|Serratus plane block and local control
61914631|NCT02219243|NO_INTERVENTION|Waitlist Control|This is a 1-month waitlist control to be compared with the active online interpretation training interventions. This is a no intervention control group
61914632|NCT02219243|EXPERIMENTAL|Active Interpretation Training|Online Interpretation Training Condition 2 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
61914633|NCT02219243|EXPERIMENTAL|Placebo Interpretation Training|Online Interpretation Training Condition 1 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
61914634|NCT03416062|EXPERIMENTAL|Remaxol® 400 ml + Placebo 400 ml|Treatment with Remaxol® 400 ml IV + Ringer solution 400 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
62108348|NCT02934035||Placebo|The placebo group includes participants in eligible clinical trials who have been assigned to placebo medication.
62108349|NCT02934035||Antidepressant|The antidepressant group includes participants in eligible clinical trials who have been assigned to antidepressant medication.
62299574|NCT03810989|EXPERIMENTAL|combination of sauna and hot bath in CKD|During the ﬁrst month (control phase), S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be calculated. During the next two months (intervention phase) the patient will be subjected to three session of sauna of 15 minutes duration separated by ten minutes rest outside the sauna then the patients will be immersed up to neck for one hour in water at 37 -43 C .
62299575|NCT02095561|EXPERIMENTAL|HPV Self testing|HPV self testing offered by CHWs during home visits
62670368|NCT03949231|EXPERIMENTAL|PD1/PDL1/CTLA4 inhibitor or their combinations hepatic artery infusion|Interventional technique to place microcatheter in hepatic artery to infuse PD1/PDL1/CTLA4 inhibitor or their combinations in 30 minutes.
62670369|NCT03949231|EXPERIMENTAL|PD1/PDL1/CTLA4 inhibitor or their combinations vein infusion|Regular IV infusion of PD1/PDL1/CTLA4 inhibitor or their combinations in 30 minutes.
62670370|NCT01770730|EXPERIMENTAL|LAM plus standard care|Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site
62670371|NCT01770730|NO_INTERVENTION|Standard care|Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site
62670372|NCT04786925|PLACEBO_COMPARATOR|Control diet|A conventional diet based on the current Spanish Mediterranean dietary guidelines: Spanish Society of Community Nutrition (SENC).
61914635|NCT03416062|EXPERIMENTAL|Remaxol® 800 ml|Treatment with Remaxol® 800 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
61914636|NCT03416062|PLACEBO_COMPARATOR|Control|Treatment with Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
62108350|NCT01909336|ACTIVE_COMPARATOR|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
62108351|NCT01909336|ACTIVE_COMPARATOR|Group 2: 0.45% Saline in 5% dextrose (intravenous)|Group 2: 0.45% Saline in 5% dextrose (intravenous)
62108352|NCT01909336|ACTIVE_COMPARATOR|Group 3: 0.9% Saline in 5% dextrose (intravenous)|Group 3: 0.9% Saline in 5% dextrose (intravenous)
62108353|NCT04180267|NO_INTERVENTION|Control Group|Subject assigned to Control Group will not receive LMHFV
61914637|NCT04877509||Over 50 year's COVID-19 patients hospitalized at HCL from 1st March to 29th May 2020.|
62108354|NCT04180267|ACTIVE_COMPARATOR|LMHFV group|Subject assigned to LMHFV group will receive LMHFV (35Hz, 0.3g, 20min/day, at least 3 times/week) for half year.
62299576|NCT02095561|NO_INTERVENTION|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
62299577|NCT03114033|EXPERIMENTAL|Targeted therapeutic mild hypercapnia|Target arterial carbon dioxide range of 50-55 mmHg for 24 hours following randomisation
62299578|NCT03114033|ACTIVE_COMPARATOR|Targeted normocapnia (Standard care)|Target arterial carbon dioxide range of 35-45 mmHg for 24 hours following randomisation
62670373|NCT04786925|EXPERIMENTAL|Nutriprecision diet|A Mediterranean, balanced diet based on the inclusion of precision foods designed and developed within the framework of Nutriprecision project. A mobile application to empower and support the management of the dietary prescription. A digital tool for cognitive stimulation.
62670374|NCT05099406|ACTIVE_COMPARATOR|Transcranial direct current stimulation (tDCS)|Fifteen stimulation sessions applied with a daily frequency during an uninterrupted period of time which comprises just over two weeks. Current intensity of 2mA is applied during 20 minutes at the left M1, with anodal electrode placed in C3 and cathodal in FP2, following the International 10-20 EEG System. Ramp-up and ramp-down comprises 15 seconds at the beginning and end of the stimulation period.
62735941|NCT05971368|ACTIVE_COMPARATOR|Group B: Patients will receive ultrasound guided serratus anterior muscle block|Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.
61914638|NCT03726398|EXPERIMENTAL|Opsumit|Opsumit 10 mg tablet by mouth once daily
61914639|NCT06367218|EXPERIMENTAL|OSB|"Anesthesia was induced by intravenous injection of Sufentanil 0.1 µg/kg and propofol 2 mg /kg. The patient was placed with a laryngeal mask airway, connected to an anesthetic ventilator with spontaneous breathing mode. Anesthesia was maintained with propofol (5 mg/kg/h) and remifentanil (0.01 µg/kg/min) first, and then adjusted according to the depth of anesthesia.~Paravertebral nerve blocks were performed at T4 and T6 levels with ropivacaine (0.5%, 10 ml) under ultrasound guidance. A mixture of 5 ml of 2% lidocaine and 5 ml of 0.5% ropivacaine was sprayed on the surface of the visceral pleura after thoracic cavity opening. The vagal and phrenic nerve trunks were blocked with 2 ml of the mixture."
62108355|NCT04073914|ACTIVE_COMPARATOR|Intervention|Type 1 Teamwork program
62108356|NCT04073914|NO_INTERVENTION|Control|Standard of care
62299579|NCT03312218|EXPERIMENTAL|Intervention|Intervention site residents will receive alerts through an app to adaptively reinforce the learning of clinical content based on cases and test questions (spaced education).
62299580|NCT03312218|NO_INTERVENTION|Control|Residents in the control group will receive the same app providing identical clinical cases and test questions-on-demand, but with alerts inactivated (no spaced education).
62470079|NCT03110120|SHAM_COMPARATOR|local|serratus control and local anesthesia
62670375|NCT05099406|ACTIVE_COMPARATOR|Transcranial alternant current stimulation (tACS)|Fifteen stimulation sessions applied with a daily frequency during an uninterrupted period of time which comprises just over two weeks. Two electrodes will be placed at F3 and F4 and connected together for 10-Hz tACS (or the frequency which shows best sensitivity or specificity), and one electrode at Pz will be the return electrode. This setting is used to stimulate the somatosensory cortical region. Stimulation will last for 20 minutes, with a ramp-up and ramp-down of 15 seconds at the beginning and end of the session.
61914640|NCT06367218|EXPERIMENTAL|KSB|"Anesthesia was induced by intravenous injection of Sufentanil 0.1 µg/kg and propofol 2 mg /kg. The patient was placed with a laryngeal mask airway, connected to an anesthetic ventilator with spontaneous breathing mode. Anesthesia was maintained with propofol (5 mg/kg/h) and remifentanil (0.01 µg/kg/min) first, and then adjusted according to the depth of anesthesia.~Paravertebral nerve blocks were performed at T4 and T6 levels with ropivacaine (0.5%, 10 ml) under ultrasound guidance. A mixture of 5 ml of 2% lidocaine and 5 ml of 0.5% ropivacaine was sprayed on the surface of the visceral pleura after thoracic cavity opening. The vagal and phrenic nerve trunks were blocked with 2 ml of the mixture."
62108357|NCT03658499|EXPERIMENTAL|Experimental|"Those assigned to the experimental condition will be provided with treatment as usual (the two day skills group) and exposure to the video intervention adjuncts.~two day skills group plus treatment adjuncts"
62108358|NCT03658499|OTHER|control|"Those in the control condition will be provided with treatment as usual (the two day skills group) without access to the video intervention adjuncts.~two day skills group control group"
62108359|NCT04417270|OTHER|Freestyle Libre 14-day CGM|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
62108360|NCT04417270|OTHER|Accuchek Inform II meter|ACCU-CHEK INFORM II system quantitatively measures glucose in fresh venous, arterial, neonatal heel stick and capillary whole blood from the finger and is used as an aid in monitoring the effectiveness of glucose control
62108361|NCT01090024|EXPERIMENTAL|BI 671800 AM and PM|Patients receiving two capsules twice daily
62108362|NCT01090024|EXPERIMENTAL|BI 671800 AM|Patients receiving four capsules in the morning
62108363|NCT01090024|EXPERIMENTAL|BI 671800 PM|Patients receiving four capsules in the evening
62108364|NCT01090024|PLACEBO_COMPARATOR|Placebo|Patients receiving four capsules twice a day
62108365|NCT03517579|EXPERIMENTAL|Pilot Project|It is a Pilot study of 10 persons
62108366|NCT00333541|EXPERIMENTAL|Treatment|follow-up via e-mail link to survey
62108367|NCT00333541|NO_INTERVENTION|Control|standard follow-up by phone and in-person interview
62108368|NCT02793427|EXPERIMENTAL|Type 1 diabetes|
62108369|NCT02793427|EXPERIMENTAL|control|
62108370|NCT05990569|EXPERIMENTAL|Arm A|Bupivacaine
62108371|NCT05990569|EXPERIMENTAL|Arm B|Bupivacaine with methylene blue
62108372|NCT03552913||2015 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2015
62108373|NCT03552913||2017 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2017
62108374|NCT03552913||2015 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2015
62108375|NCT03552913||2017 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2017
62108376|NCT01501006||Patient Roles|Physician communication styles will be evaluated with different patient roles.
62108377|NCT05147506|EXPERIMENTAL|CBT DTx|Participants randomized to active intervention will access a structured, cognitive behavioral therapy (CBT) intervention.
62108378|NCT05147506|ACTIVE_COMPARATOR|Psychoeducations DTx|Participants randomized to the comparison group will access an unstructured educational DTx.
62108379|NCT02271048|EXPERIMENTAL|Group I|"The raters in this group one firstly review ultrasound images numbered from one to 50 using LCD monitor of ultrasound machine and after mandatory rests of 20 minutes, review the remaining ultrasound examinations numbered from 51 to 100 using iPhone display with CubeView at their first visit.(Remote ultrasonography interpretation using the smartphone)~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
62108380|NCT02271048|EXPERIMENTAL|Group II|"The raters in this group II firstly review the ultrasound images numbered from one to 50 using iPhone with CubeView (Remote ultrasonography interpretation using the smartphone) and 51 to 100 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
62108381|NCT00048828|ACTIVE_COMPARATOR|1|
62108382|NCT00048828|ACTIVE_COMPARATOR|2|
62108383|NCT01612754|NO_INTERVENTION|Reference group - cloaked noise meters|"Reference group or phase 1~Theatre equipped with multiple sound meters disguised as CO2 meter for sound probing in the absence of a research clerk with personnel completely unaware of sound measurements."
62108384|NCT01612754|SHAM_COMPARATOR|Control Noise AND Stress measurements|"Control Group - Phase 2~No intervention but research clerk is present in theatre to protocoll the operation and test for stress by collecting saliva cortisol and probing electrodermal activity"
62108385|NCT01612754|EXPERIMENTAL|Noise Reduction Intervention Group|"Intervention Group - Phase 3~A panel of noise reduction measures (staff workplace rules, technical devices as optical noise warners, optical telephones) is put into effect. Surgeons are monitored by biometry, psychometry and the outcome."
62108386|NCT04822155||Children|Children between 11-17 years of age will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect their physical, emotional, or mental well-being (BRIEF-II and CBCL questionnaires). The child will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality.
62299581|NCT03991247|EXPERIMENTAL|Internet Behavioral therapy program + spa therapy|Patient following a program of computerized behavioral therapy for insomnia management during a 3 weeks spa treatment.
62299582|NCT03991247|ACTIVE_COMPARATOR|Internet Behavioral therapy program at home|Patient following a program of computerized behavioral therapy for insomnia management during 3 weeks at home.
62735942|NCT03654924|EXPERIMENTAL|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
62299583|NCT03212261|EXPERIMENTAL|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
62299584|NCT02793284|EXPERIMENTAL|Intervention 18F-DCFPyL PET/CT|18F-DCFPyL PET/CT scan obtained at the time of restaging for biochemical recurrence after primary radiotherapy
62299585|NCT06108661|EXPERIMENTAL|Group A|"Treatment protocol given to both groups will be carried out for 3 sessions per week for 2 weeks.~It will comprise of hot pack for 10 minutes in prone position. Stretching protocol for shortened muscles. Frequency would be: 3 times per week (alternatively) for 1st week and 2nd week.~ELDOA. As per the tolerance of the patient. (Max hold time=60sec) For 2 weeks (alternatively)."
62470080|NCT03401086|ACTIVE_COMPARATOR|Study group|Kinesio Taping
62470081|NCT03401086|NO_INTERVENTION|Control group|No intervention
62108387|NCT04822155||Adults|Adults, 18 years and older will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect your physical, emotional, or mental well-being (BRIEF-A and ABCL questionnaires). The adult will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality. Additionally, the adult will need to take their blood pressure 3 times per day for 14 days and record measurements.
62108388|NCT01457560|EXPERIMENTAL|Group A|
62299586|NCT06108661|ACTIVE_COMPARATOR|Group B|"Treatment protocol given to both groups will be carried out for 3 sessions per week for 2 weeks.~It will comprise of hot pack for 10 minutes. Stretching protocol for shortened muscles. Frequency would be: 3 times per week (alternatively) for 1st week and 2nd week.~Slump Stretching: Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed"
62299587|NCT04328480|ACTIVE_COMPARATOR|Local standard of care plus colchicine|Local standard of care plus colchicine (specific dosage schedule)
62299588|NCT04328480|OTHER|Local standard of care|Local standard of care for COVID-19 SARS moderate / high-risk patients
62299589|NCT00000264|PLACEBO_COMPARATOR|0 g/Kg ethanol +/- 30% nitrous oxide|
62470082|NCT01205425|EXPERIMENTAL|CT|Procedure of stent implantation will be planed on the basis of both angiography and computed tomography results.
62108389|NCT05753644|EXPERIMENTAL|SGB group|The subjects will accept ultrasound guided SGB in the right side of the neck in a supine position. The drug is 5 ml of 0.5% ropivacaine.
62299590|NCT00000264|ACTIVE_COMPARATOR|0.35 g/Kg ethanol +/- 30% nitrous oxide|
62299591|NCT00000264|ACTIVE_COMPARATOR|0.7 g/Kg ethanol +/- 30% nitrous oxide|
62299592|NCT03571464|EXPERIMENTAL|Immediate use GGRO Mobile App|The group starts using the GGRO Mobile App immediately after the first assessment (T1) for 15 days.
62299593|NCT03571464|ACTIVE_COMPARATOR|Delayed use GGRO Mobile App|Delayed use GGRO Mobile App group started using the App 15 days after the first assessment (T2).
62299594|NCT03220412|EXPERIMENTAL|Experimental Condition|Intervention was guns in movies. Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition Intervention is m
62299595|NCT03220412|NO_INTERVENTION|Control Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
62299596|NCT05464095|ACTIVE_COMPARATOR|mHealth Intervention|Patients will be randomized to the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
62470083|NCT01205425|ACTIVE_COMPARATOR|Angio|Procedure of stent implantation will be planned only on the basis of diagnostic coronary angiography.
62470084|NCT01465581||Neurogenic incontinence|The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.
62470085|NCT01207986|OTHER|CT screening|CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
62108390|NCT05753644|PLACEBO_COMPARATOR|control group|The subjects will accept sham block in the right side of the neck in a supine position. A sham block is performed by subcutaneous infiltration (1 mL1% lidocaine) on the site.
62299597|NCT05464095|OTHER|Usual Care|Routine medical care
62299598|NCT03423355|ACTIVE_COMPARATOR|Dapagliflozin (Forxiga®)|Treatment with the SGLT2 inhibitor dapagliflozin 10 mg once daily for 28 days.
62299599|NCT03423355|PLACEBO_COMPARATOR|Placebo matching Dapagliflozin|Treatment with the Dapagliflozin matching placebo once daily for 28 days.
62299600|NCT03423355|OTHER|Hydrochlorothiazide|Treatment with the Hydrochlorothiazide 25 mg once daily for 28 days
62299601|NCT00744289|NO_INTERVENTION|Arm 1|Participants in Arm 1 will not receive any financial incentive after the second and third dose of hepatitis B vaccine have been administered.
62299602|NCT00744289|OTHER|Arm 2|Participants in Arm 2 will receive a small financial incentive after the second and third dose of the hepatitis B vaccine
62470086|NCT04690881|EXPERIMENTAL|Psychodrama group psychoteraphy|Psychodrama is not just a training but also a treatment technique where an individual is offered a potential cure, as well as improvement and awareness for his or her ongoing relationships within the group. In psychodrama, the participant is given an opportunity to re-experience of earlier incidents for a second time so that the person could be free from the impacts of that earlier experience. All of this happens simultaneously with joy, tears, laughter, and depth of feeling.Prenatal psychodrama is held by psychodrama psychotherapists in individual and group therapy sessions. In these sessions the pregnant mother encounters herself, her baby, her partner, her mother, her fear of childbirth and the moment of birth; she may act as protagonist in some scenes and in this way she closes any unfinished business from the past and rehearses the future in a safe therapeutic environment. In this study, 90-minute psychodrama practice was conducted in addition to pregnancy training for 6 weeks.
62470087|NCT04690881|NO_INTERVENTION|Childbirth-antenatal education|Childbirth is one of the most significant events in a parent's life and has the potential to be an exhilarating and fulfilling experience for some or a frightening anxiety provoking experience for others. Structured antenatal classes have developed worldwide as traditional methods of information sharing have declined and expectant parents look for strategies to prepare for childbirth. In this study, routine pregnancy training was conducted for 6 weeks.
62470088|NCT06228963|EXPERIMENTAL|Experimental group|Triple therapy for eradication of Helicobacter Pylori+Orelabrutinib
62470089|NCT06228963|ACTIVE_COMPARATOR|Control group|Triple therapy for eradication of Helicobacter Pylori
62299603|NCT04990570||Pediatric day-case surgical patients, encountered via Virtual clinic from June 2020 till July 2021|"Pediatric patients, with age ranging from 1 month-14 years, with day-case surgical problems, encountered during the era of Covid-19 pandemic.~Telemedicine, in the form of Virtual clinic, was utilized to address this distressing problem, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter."
62299604|NCT04990570||Control group comprising of patients scheduled to the OPD clinic from June 2019 till June 2020|Cases of office OPD appointments in the period from June 2019 till June 2020 will be included as a control group
62299605|NCT01729689|EXPERIMENTAL|Supportive care (cognitive behavioral therapy)|Participants undergo cognitive behavioral therapy over 1 hour once weekly for a total of 6 sessions. Sessions are tailored to patient and caregiver cognitions and approach and avoidance behaviors.
62299606|NCT02251743|EXPERIMENTAL|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
62299607|NCT02251743|PLACEBO_COMPARATOR|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
62299608|NCT06657417|EXPERIMENTAL|Standard before AI support|
62670376|NCT05099406|PLACEBO_COMPARATOR|Sham stimulation|The electrode montage will be either the tDCS (for half of the participants) or the tACS montage (for the other half), and we will just apply the current at the ramps terms, but no current in the interval between the ramps which practically comprises the whole session. As for the two other group, fifteen sham stimulation sessions will be daily scheduled in a non-interrupted period of two weeks.
62670377|NCT03233685|EXPERIMENTAL|Experimental Group|Subjects will perform a visual training for 12 weeks
62299609|NCT06657417|EXPERIMENTAL|AI support before standard|
62470090|NCT02304211|EXPERIMENTAL|Intra-Arterial Microdose Insulin|Healthy volunteers will receive microdose insulin intra-arterially into the radial artery.
62670378|NCT03233685|ACTIVE_COMPARATOR|Control Group|Subjects will perform the normal training routine for 12 weeks
62670379|NCT02614014|EXPERIMENTAL|Psychological intervention|Cognitive-behavior interventional program
62108391|NCT04590794||covid 19|Patients admitted with covid 19
62299610|NCT05261217|EXPERIMENTAL|The motion 3D II appliance|using The motion 3D II appliance on treating Class II orthodontic
62108392|NCT06111690|EXPERIMENTAL|Preoperative Exercises|Intervention is blood flow restriction training (BFRT)
62299611|NCT03022461||Ongoing HM3 CE Mark study patients|The study will include the ongoing HM3 CE Mark study patients that have consented to continue the long term follow-up data collection.
62299612|NCT04708990|EXPERIMENTAL|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
62299613|NCT04708990|NO_INTERVENTION|control group|
62670380|NCT02614014|NO_INTERVENTION|Control|No intervention
62108393|NCT04899323||Cohort|Perform a 250cc vascular filling over 10 minutes and then perform a cardiac ultrasound. Repeat the vascular filling followed by the ultrasound as long as the patient is responsive.
62670381|NCT01559285|ACTIVE_COMPARATOR|0.375% ropivacaine|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
62670382|NCT01559285|ACTIVE_COMPARATOR|0.75% ropivacaine|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
62670383|NCT01559285|ACTIVE_COMPARATOR|0.2% ropivacaine|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
62670384|NCT03830411|EXPERIMENTAL|Arm A: Sintilimab|Participants will receive Sintilimab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
62670385|NCT03830411|ACTIVE_COMPARATOR|Arm B: Chemotherapy (Docetaxel or Pemetrexed)|Participants randomized to the chemotherapy arm will receive docetaxel or pemetrexed until disease progression per standard RECIST v1.1 or unacceptable toxicity.
62299614|NCT04681326|EXPERIMENTAL|Biological prosthesis|The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia to allow the positioning of the transfix stitches necessary to the mesh fixation. Successively the retro-muscular rectum muscles plane will be prepared by the separation of the rectum muscles from the posterior rectum-muscles fascia. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched placed at the cardinal and inter-cardinal points. The prosthesis will be placed with a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt (JP) 10 suction drain will be placed under the prosthesis. A JP 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate- reabsorbable-time suture. Another JP 10 suction drain will be placed over the anterior fascia. No subcutaneous suture. Skin stapler or interrupted stitches will be used to close.
62670386|NCT05007509|EXPERIMENTAL|COVID-19 vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
62670387|NCT05007509|ACTIVE_COMPARATOR|Commercial COVID-19 vaccine|Subjects will receive 2 injections of commercial COVID-19 vaccine administered 21 days apart.
62108394|NCT05086809|ACTIVE_COMPARATOR|AAB|Starts with Device A in first and second trial period and change to Device B in third trial period.
62108395|NCT05086809|ACTIVE_COMPARATOR|ABA|Starts with Device A in first trial period, wears Device B in second trial period and change to Device A in third trial period.
62299615|NCT04681326|NO_INTERVENTION|Standard of care|Normal abdominal wall closure
62299616|NCT04912167|EXPERIMENTAL|ARNI-Sacubitril-Valsartan|patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.
62299617|NCT04912167|ACTIVE_COMPARATOR|ACEI-Enalapril|patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril
62299618|NCT06018883|EXPERIMENTAL|Ascorbate|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 900 mg/day, three times a day, orally.
62470091|NCT02304211|ACTIVE_COMPARATOR|Systemic Insulin|Healthy volunteers will receive full-dose insulin intra-venously.
62470092|NCT03430830|EXPERIMENTAL|GROUP 1|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.
62470093|NCT03430830|EXPERIMENTAL|GROUP 2|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
62670388|NCT05983406|EXPERIMENTAL|Intervention|Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions
62108396|NCT01352507|EXPERIMENTAL|Tadalafil then Sildenafil|"20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED)."
62108397|NCT01352507|ACTIVE_COMPARATOR|Sildenafil then Tadalafil|"100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED."
62299619|NCT06018883|OTHER|Control|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
62299620|NCT05172011||Extant, Clinical and De Novo Cohort -- INFECTED|SARS-CoV-2 infected children and young adults with and without current or prior PASC-like symptoms, including infected individuals with history of multisystem inflammatory syndrome in children (MIS-C), and infants born in the context of maternal SARS-CoV-2 infection during pregnancy
62299621|NCT05172011||Extant, Clinical and De Novo Cohort -- UNINFECTED|SARS-CoV-2 uninfected children and infants born to uninfected mothers
62299622|NCT05172011||Acute Cohort -- INFECTED|Newly SARS-CoV-2 infected individuals (≤4 weeks since onset of symptoms or positive laboratory testing)
62299623|NCT05172011||Acute Cohort -- UNINFECTED|Contemporaneous SARS-CoV-2 uninfected individuals selected from the same population as newly SARS-CoV-2 infected individuals
62299624|NCT05172011||Post-acute cohort -- INFECTED|Post-acute infected individuals (\>4 weeks after initial symptoms or positive laboratory testing) in the extant, clinical and de novo cohorts, including infants born in the context of maternal SARS-CoV-2 infection during pregnancy, will be enrolled 1-24 months after initial SARS-CoV-2 infection.
62299625|NCT05172011||Post-acute cohort -- UNINFECTED|Uninfected individuals will be derived from a similar population with respect to age, sex, race and ethnicity, geographic origin, sociodemographics, and time of enrollment as the infected individuals.
62670389|NCT04803435|ACTIVE_COMPARATOR|Adult patients with acute gastrointestinal infection - telemedicine before face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have undergone telemedicine consultation before face-to-face evaluation
62670390|NCT04803435|ACTIVE_COMPARATOR|Adult patients with acute gastrointestinal infection - only face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have only face-to-face evaluation
62299626|NCT05172011||Post-COVID Vaccine Myocarditis|Individuals with history of myocarditis after receiving COVID-19 vaccine.
62670391|NCT01724190|ACTIVE_COMPARATOR|Vitamin D|Subjects will receive oral vitamin D supplementation, 3000 IU daily over the course of 9 months.
62670392|NCT01724190|PLACEBO_COMPARATOR|Placebo|Subjects will receive a placebo solution daily over the course of 9 months.
62670393|NCT02843386|EXPERIMENTAL|A : Chemotherapy|Adjuvant chemotherapy by Fotemustin 100mg/m²
62670394|NCT02843386|OTHER|B : Surveillance|Intensive surveillance
62108398|NCT06360042|EXPERIMENTAL|1|Adebrelimab（1200mg iv q3w） plus Apatinib(250mg po qd)
62108399|NCT06360042|EXPERIMENTAL|2|Adebrelimab（1200mg iv q3w）plus Bevacizumab(15mg/kg iv q3w)
62108400|NCT06360042|EXPERIMENTAL|3|Camrelizumab (200mg iv q2w) plus Apatinib(250mg po qd)
62108401|NCT05012644||Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
62108402|NCT05012644||Aromatase inhibitor alone|Aromatase inhibitor alone
62108403|NCT01189006|EXPERIMENTAL|dextromethorphan|Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study
62108404|NCT00646308||I|Adult patients with GH deficiency due to a nonsecreting pituitary tumor
62108405|NCT00646308||2|Adult patients with a nonsecreting pituitary tumor but without GH deficiency
62108406|NCT01213706|EXPERIMENTAL|Whole Body Periodic Acceleration (WBPA)|All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.
62108407|NCT01213706|EXPERIMENTAL|Sham WBPA|"Sham WBPA :~All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge."
62108408|NCT00238316|ACTIVE_COMPARATOR|Letrozole|
62108409|NCT00238316|PLACEBO_COMPARATOR|Placebo|
62299627|NCT05172011||Primary Caregivers|The primary caregiver of the child or young adult may optionally participate in the study.
62299628|NCT05172011||Biological Parent|If the primary caregiver is a biological parent, the other biological parent may optionally participate in the study
62299629|NCT04854655|ACTIVE_COMPARATOR|Control|Conventional resin composite
62670395|NCT05821595|EXPERIMENTAL|JYB1907 Dose 1|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
62670396|NCT05821595|EXPERIMENTAL|JYB1907 Dose 2|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
62670397|NCT05821595|EXPERIMENTAL|JYB1907 Dose 3|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
62670398|NCT05821595|EXPERIMENTAL|JYB1907 Dose 4|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
62108410|NCT02559258|EXPERIMENTAL|Cohort 1|
62108411|NCT02559258|EXPERIMENTAL|Cohort 2|
62108412|NCT02559258|EXPERIMENTAL|Cohort 3|
62108413|NCT02559258|EXPERIMENTAL|Cohort 4|
62108414|NCT02559258|EXPERIMENTAL|Cohort 5|
62108415|NCT04303182|ACTIVE_COMPARATOR|Standard 3 port TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
62108416|NCT04303182|ACTIVE_COMPARATOR|LESS TEP|Group B will undergo laparoscopic TEP inguinal hernia repair with a single skin incision 2-3cm.
62108417|NCT02885350|ACTIVE_COMPARATOR|Spinal fentanyl|20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
62299630|NCT04854655|EXPERIMENTAL|Intervention 1|Activa Presto
62299631|NCT04854655|EXPERIMENTAL|Intervention 2|Giomer
62299632|NCT04563364|EXPERIMENTAL|Hospital-Home|This group will receive an interdisciplinary intervention of education to parents for get better outcomes of motor development.
62299633|NCT04563364|ACTIVE_COMPARATOR|Control Intervention|Control group will receive a conventional treatment given by the institutions
62299634|NCT00839111|EXPERIMENTAL|A|Sorafenib plus FOLFIRI regimen
61914641|NCT06367218|EXPERIMENTAL|OMV|"Anesthesia was induced by intravenous sufentanil injection of 0.5 μg/kg. Propofol 2 mg/kg and rocuronium 0.9 mg/kg were subsequently administered intravenously. After rocuronium took effect, double-lumen bronchial tube intubation was performed under the guidance of video laryngoscope, and fixed after the bronchoscopic examination, anesthesia ventilator was connected for mechanical ventilation, tidal volume was 6 mL/kg (ideal body weight), respiratory rate was 12-16 times /min, and end-expiratory partial pressure of carbon dioxide was maintained at 35-45 mmHg. Intraoperative anesthesia was maintained with initial intravenous pump of propofol (5 mg/kg/h) and remifentanil (0.1 μg/kg/min) first , and then adjusted according to the depth of anesthesia.~Paravertebral nerve blocks were performed at T4 and T6 levels with ropivacaine (0.5%, 10 ml) under ultrasound guidance."
61914642|NCT06367218|EXPERIMENTAL|KMV|Anesthesia was induced by intravenous injection of esketamine 0.5 mg/kg. Propofol 2 mg/kg and rocuronium 0.9 mg/kg were subsequently administered intravenously. After rocuronium took effect, double-chamber tracheal tube intubation was performed under the guidance of video laryngoscope, and fixed after the bronchoscopic examination, anesthesia ventilator was connected for mechanical ventilation, tidal volume was 6 mL/kg (ideal body weight), respiratory rate was 12-16 times /min, and end-expiratory partial pressure of carbon dioxide was maintained at 35-45 mmHg. Intraoperative anesthesia was maintained with the initial intravenous pump of propofol (5 mg/kg/h) and esketamine (0.5 mg/kg/h) first , and then adjusted according to the depth of anesthesia. Paravertebral nerve blocks were performed at T4 and T6 levels with ropivacaine (0.5%, 10 ml) under ultrasound guidance.
61914643|NCT03149601||Healthy Weight|Participants with BMI \< 95th percentile
61914644|NCT03149601||Obese|Participants with BMI \> or = 95th percentile
62299635|NCT01883570|EXPERIMENTAL|trained visual search strategy|An expert's visual search strategy for reading the chest x-ray was recorded using a gaze tracking device. This strategy was reproduced using a dynamic cursor and will be made available to participants in the experimental group using an interactive website.
62470094|NCT03430830|EXPERIMENTAL|GROUP 3|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
62670399|NCT05821595|EXPERIMENTAL|JYB1907 Dose 5|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
61914645|NCT06095622|NO_INTERVENTION|Typical rice pulao without and herbal intervention|Normal chickpea rice pulao was used as the main arm. The control group does not contain fenugreek and Indian rennet extract.
61914646|NCT06095622|EXPERIMENTAL|Chickpea Pulao Using Fenugreek Seeds and Indian Rennet|Chickpea rice pulao added with herb (Fenugreek Seeds and Indian Rennet).
61914647|NCT01820260|EXPERIMENTAL|Part 1A: Ingenol mebutate gel 0.005%|Open-label, dose escalation, 3 days treatment
62108418|NCT02885350|EXPERIMENTAL|Epidural fentanyl|100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
62108419|NCT02885350|ACTIVE_COMPARATOR|Spinal sufentanil|5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
62470095|NCT03430830|EXPERIMENTAL|GROUP 4|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
62470096|NCT03430830|EXPERIMENTAL|GROUP 5|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
62470097|NCT03430830|EXPERIMENTAL|GROUP 6|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
62470098|NCT04710381|EXPERIMENTAL|IMUNOR|Study subjects in this arm will receive IMUNOR preparation as prevention against COVID-19 disease.
62470099|NCT01854463|EXPERIMENTAL|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
62470100|NCT01854463|PLACEBO_COMPARATOR|placebo|administered elemental calcium 200mg daily for 24 weeks
62470101|NCT00813592|EXPERIMENTAL|All participants|
62470102|NCT01202734|EXPERIMENTAL|001|Methylphenidate HCl Period 1: One tablet oral 36 mg once daily single-dose on Day 1 Period 2: Three tablets oral 18 mg once daily single-dose on Day 1 Period 3: Two tablets oral 36 mg once daily single-dose on Day 1. (Each treatment period will be separated by 3-7 days)
62108420|NCT02885350|EXPERIMENTAL|Epidural sufentanil|20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.
62108421|NCT02727972|OTHER|Cognitive Testing|Cognitive assessments
62299636|NCT01883570|ACTIVE_COMPARATOR|not trained in visual search strategy|Participants will learn to read chest x-rays by having access to a library of chest x-rays identical to the one used by the experimental arm, but without the search strategy.
62299637|NCT06003959|EXPERIMENTAL|Breastfeeding Support System|The intervention group was given breastfeeding support system care
62299638|NCT06003959|NO_INTERVENTION|Control group|Routine nursing care was given to the pretrms in this groups without any breastfeeding support system care
62470103|NCT01045161|EXPERIMENTAL|1|Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
62470104|NCT01045161|EXPERIMENTAL|2|Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
62470105|NCT01045161|PLACEBO_COMPARATOR|3|Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks
62470106|NCT02159183|EXPERIMENTAL|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
61914648|NCT01820260|ACTIVE_COMPARATOR|Part 2: Ingenol mebutate gel 0.018% for 3 days treatment|Randomized, 3 days treatment
61914649|NCT01820260|ACTIVE_COMPARATOR|Part 2: Ingenol mebutate gel 0.018% for 2 days treatment|Randomized 2 days treatment
61914650|NCT01820260|ACTIVE_COMPARATOR|Part 2: Ingenol mebutate gel 0.027% for 3 days treatment|Randomized 3 days treatment
61914651|NCT01820260|ACTIVE_COMPARATOR|Part 2: Ingenol mebutate gel 0.027% for 2 days treatment|Randomized 2 days treatment
61914652|NCT01820260|PLACEBO_COMPARATOR|Part 2: Placebo for 3 days treatment|Randomized 3 days treatment
61914653|NCT01820260|PLACEBO_COMPARATOR|Part 2: Placebo for 2 days treatment|Randomized 2 days treatment
62108422|NCT02727972|ACTIVE_COMPARATOR|Magnetic Resonance Imaging|All subjects will have one MRI with a possibility of one functional MRI (fmri).
62108423|NCT02727972|ACTIVE_COMPARATOR|Positron Emission Tomography|All subjects will have PET scan using FPEB or ABP688.
62108424|NCT01063023|ACTIVE_COMPARATOR|Arm A - Ortho Tri-Cyclen®|1 to 28 days
62108425|NCT01063023|ACTIVE_COMPARATOR|Arm B - Ortho Tri-Cyclen®|29 to 56 days
62108426|NCT01063023|ACTIVE_COMPARATOR|Arm C - Ortho Tri-Cyclen® + BMS-650032|"Ortho Tri-Cyclen®: 57 to 77 days~BMS-650032: 68 to 77 days"
62108427|NCT02988596|ACTIVE_COMPARATOR|Enhanced Graded Exertion|At the time of the injury, participants will be given guided activity instructions regarding what activities to consider and how to observe for increases in symptoms. The focus will be on guided activity and not on restriction. Symptoms will be assessed at the end of each day. Once the patient has been asymptomatic for 24 hours or within 85% of their baseline symptom score (BSS) they will begin the enhanced graded exertion progression (Zurich/Berlin protocol). This protocol will follow the Zurich/Berlin guidelines, but will be enhanced to include sports and skill specific activities. Each step will be completed on a separate day. A medical professional will determine the symptom status of the athlete and when the graded exertion will begin.
61914654|NCT01820260|EXPERIMENTAL|Part 1A: Ingenol mebutate gel 0.008%|Open-label, dose escalation, 3 days treatment
61914655|NCT01820260|EXPERIMENTAL|Part 1A: Ingenol mebutate gel 0.012%|Open-label, dose escalation, 3 days treatment
61914656|NCT01820260|EXPERIMENTAL|Part 1A: Ingenol mebutate gel 0.027%|Open-label, dose escalation, 3 days treatment
61914657|NCT01820260|EXPERIMENTAL|Part 1A: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 3 days treatment
62108428|NCT02988596|EXPERIMENTAL|Multidimensional Active Rehabilitation|At injury, participants are given instructions regarding guided activities to consider and how to observe for symptom increase. Focus is on guided activity, not restriction. The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and sport specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements. Participants are required to spend at least 2 days in Phase 1; subsequent phases are completed on separate days. Once asymptomatic for 24 hours or within 85% of their BSS they begin the enhanced graded exertion progression (Zurich/Berlin protocol).
62108429|NCT02882048|EXPERIMENTAL|Medication management & NADA Protocol|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens, and NADA protocol administered biweekly
62108430|NCT02882048|ACTIVE_COMPARATOR|Medication management|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens.
61914658|NCT01820260|EXPERIMENTAL|Part 1B: Ingenol mebutate gel 0.06%|Open-label, dose escalation, 2 days treatment
61914659|NCT01820260|EXPERIMENTAL|Part 1A: Ingenol mebutate gel 0.018%|Open-label, dose escalation, 3 days treatment
61914660|NCT01820260|EXPERIMENTAL|Part 1B: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 2 days treatment
61914661|NCT00130442|EXPERIMENTAL|Arm 1- PI-88 plus dacarbazine|PI-88 (muparfostat) 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
61914662|NCT00130442|ACTIVE_COMPARATOR|Arm 2- dacarbazine alone|dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
62108431|NCT02735486|EXPERIMENTAL|Ginger drink|Experimental: Ginger drink (300 ml) to be consumed during the study visit
62108432|NCT02735486|PLACEBO_COMPARATOR|Placebo: Super pure water|Super Pure water low in nitrate content
62108433|NCT05787730|OTHER|Patients operated with TOT|The study is a retrospective cohort study. Between 2005 and 2008, a total of 54 patients were examined with ultrasound before and after TOT surgery. The collected data has not been previously published. Now these same patients are to be examined again with a more advanced ultrasound device.
62108434|NCT02287649|OTHER|patients with rituximab treatment|blood sample intake
62108435|NCT03107611|EXPERIMENTAL|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
62108436|NCT03107611|ACTIVE_COMPARATOR|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
62108437|NCT03107611|PLACEBO_COMPARATOR|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
61914663|NCT05541588|ACTIVE_COMPARATOR|ESPB|Erector Spinae Plane Block group
61914664|NCT05541588|ACTIVE_COMPARATOR|QLB|Quadratus Lumborum Block group
61914665|NCT03271983|OTHER|metronidazole gel 1|RLD gel
61914666|NCT03271983|OTHER|metronidazole gel 2|generic gel
61914667|NCT03271983|OTHER|metronidazole cream|generic cream
61914668|NCT01351870|ACTIVE_COMPARATOR|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
61914669|NCT01351870|EXPERIMENTAL|Hyperfractionated radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
61914670|NCT05470257|EXPERIMENTAL|Elbow Flexion Cast|This cohort will be placed in a long arm flexion cast.
61914671|NCT05470257|EXPERIMENTAL|Elbow Extension Cast|This cohort will be placed in a long arm extension cast.
61914672|NCT06437704|EXPERIMENTAL|Experimental|Brain training game (Lumosity)
61914673|NCT06437704|ACTIVE_COMPARATOR|Control|Simulation game (Simcity buildit)
61914674|NCT03462901|EXPERIMENTAL|Elastic rod fixation|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures
62108438|NCT04089046|EXPERIMENTAL|TEAM-UP for Teens Intervention|TEAM-UP for Teens pairs school-based and video-supported directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
61914675|NCT06246955|EXPERIMENTAL|Supportive care (group therapy sessions)|Patients attend acceptance and commitment virtual group therapy sessions over 1.5 hours each, once a week for 6 weeks.
62299639|NCT06518629|PLACEBO_COMPARATOR|Placebo|Only in-office tooth whitening will be performed. Patients will not undergo additional treatments, however, a simulation of the application of FBM will be performed before and after each CD session. The low-power laser (Therapy EC, DMC, São Carlos, SP, Brazil) will be positioned perpendicularly, in contact, over the cervical and apical region of each tooth included in the whitening treatment. During the simulation, the equipment will not be activated, that is, irradiation will not be carried out.
62299640|NCT06518629|EXPERIMENTAL|FBM-Before|Low power laser will be used immediately before CD. The energy supplied to each tooth will be 4J, using infrared light (IF) at 808 nm (± 10 nm) at two perpendicular points (located in the apical and cervical region) on the buccal surface of the incisors, canines and premolars. The laser will be operated in continuous mode and an energy of 2J will be applied to each point. The protocol that will be used to treat tooth sensitivity was recommended by the equipment manufacturer. Immediately after each whitening treatment session, a FBM simulation will be performed, in the same way as described for the Placebo group.
61914676|NCT00035347|EXPERIMENTAL|Azithromycin plus ceftriaxone group (AZY+CEF group)|IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
61914677|NCT00035347|EXPERIMENTAL|Levofloxacin group (LEV group)|IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.
62299641|NCT06518629|EXPERIMENTAL|FBM-After|The low-power laser will be used immediately after tooth whitening. The FBM protocol will occur in the same way as described for the FBM-Before group. The FBM simulation will occur before the CD session begins and will occur in the same way as described for the Placebo group.
62299642|NCT05196893|EXPERIMENTAL|Immediate Student Intervention Group|Eligible students who were randomized into an immediate intervention group, and received intervention from school staff who received specialized intervention training starting in the fall semester of the academic year. Students from two clusters of schools received staggered intervention (Cluster 1 starting in year 1, and Cluster 2 starting in year 2). School staff recorded details of intervention sessions in a case management tool, and administrative records were maintained by the school district, for evaluation purposes.
62299643|NCT05196893|EXPERIMENTAL|Wait-list Student Intervention Group|Eligible students who were randomized into a wait-list intervention group, and received intervention from school staff who received specialized intervention training starting in the spring semester of the academic year. Students from two clusters of schools received staggered intervention (Cluster 1 starting in year 1, and Cluster 2 starting in year 2). School staff recorded details of intervention sessions in a case management tool, and administrative records were maintained by the school district, for evaluation purposes.
62299644|NCT05196893|NO_INTERVENTION|Within School Student Control Group|Eligible students who were randomized into either the immediate or wait-list intervention groups, but did not receive intervention from school staff. This was used as a control group instead of an intended 3rd Cluster, which ultimately was not a comparable control based on enrollment and demographic characteristics.
62299645|NCT05200988|EXPERIMENTAL|Induction with heckpoint inhibition followed by consolidative chemoradiation|Checkpoint inhibition and chemoradiation
62299646|NCT00042809|EXPERIMENTAL|Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)|See detailed description.
62470107|NCT02159183|ACTIVE_COMPARATOR|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
62470108|NCT00979303|NO_INTERVENTION|Control Group|Control Patients - Undergo ablation procedures with radiation/fluoroscopy only
62470109|NCT00979303|EXPERIMENTAL|Study Group|Study Group Patients - Undergo ablation procedures using intracardiac echocardiography and 3D navigational system in addition to radiation.
62470110|NCT05718245|EXPERIMENTAL|HEPA first and sham|This group of participants will be assigned an intervention of HEPA filters with the capacity to reduce PM2.5 levels at their residence for 6 months. After 6-month wash-out period, will be assigned to sham filters for 6 months.
62470111|NCT05718245|SHAM_COMPARATOR|Sham first and HEPA|This group of participants will be assigned an intervention of sham filters without the capacity to reduce PM2.5 levels at their residence for 6 months. After 6-month wash-out period, will be assigned to HEPA filters for 6 months.
62470112|NCT05538052|ACTIVE_COMPARATOR|2% lidocaine|The first group will receive intraligamentary injections of 2% lidocaine with 1: 80 000 epinephrine. The injections will be administered using a pressure-type syringe (Osung Deosy, Pearland, Tx, USA) and 30 gauge short needles (Septojet needles, Septodont).
62670400|NCT02974426|EXPERIMENTAL|Arm I (PORT-first strategy)|Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
61914678|NCT06397521|EXPERIMENTAL|Scalpel crown lengthening|Crown lengthening will be performed utilizing double periodontal surgical guide with scalpel.
61914679|NCT06397521|EXPERIMENTAL|Laser crown lengthening|Crown lengthening will be performed utilizing double periodontal surgical guide with diode laser.
61914680|NCT06397521|EXPERIMENTAL|Electrosurgery crown lengthening|Crown lengthening will be performed utilizing double periodontal surgical guide with electrosurgery.
61914681|NCT02915328|EXPERIMENTAL|Stent Roadsaver® +Filterwire EZ™|The arm assess the efficacy of the combination of the stent Roadsaver® with the Filterwire EZ™ protection
61914682|NCT02915328|EXPERIMENTAL|Stent Roadsaver® + MO.MA Ultra|The arm assess the efficacy of the combination of the stent Roadsaver® with the MO.MA Ultra protection
62670401|NCT02974426|ACTIVE_COMPARATOR|Arm II (PORT-last strategy)|Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
62670402|NCT04484181|EXPERIMENTAL|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
62670403|NCT04484181|ACTIVE_COMPARATOR|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer was based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
62670404|NCT04935294|EXPERIMENTAL|Group 1: Matched Control Group Of Healthy Participants|Participants received a single 200-milligram (mg) treatment on Day 1.
62670405|NCT04935294|EXPERIMENTAL|Group 2: Severe RI And Not On Dialysis|Participants received a single 200-mg treatment on Day 1.
62299647|NCT03622645|EXPERIMENTAL|Range of motion in hand|Assessment of Wrist flexion/extension, radial/ulnar deviation, supination/pronation, 1.-5. DIP, PIP and MCP flexion/extension ROM measurements of the fingers with universal goniometer and Leap motion sensor
62470113|NCT05538052|EXPERIMENTAL|2% lidocaine plus tramadol hydrochloride|The second group will receive intraligamentary injections of 2% lidocaine with 1:80 000 epinephrine plus tramadol hydrochloride (50 mg, 1:1 v/v ratio). The injections will be administered using a pressure-type syringe (Osung Deosy, Pearland, Tx, USA) and 30 gauge short needles (Septojet needles, Septodont).
61914683|NCT02915328|EXPERIMENTAL|Carotid Wallstent +MO.MA Ultra|The arm assess the efficacy of the combination of the Carotid Wallstent with the MO.MA Ultra protection
62108439|NCT04089046|ACTIVE_COMPARATOR|Enhanced Care Comparison|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
62299648|NCT03976089|EXPERIMENTAL|Recipe 4 Success intervention|10 lessons delivered across 10 successive weeks within Early Head Start infrastructure by families' regular Early Head Start home visitors. Lessons involved active coaching in which parents and children prepared healthy snacks or meals. Lessons also included information on children's self-regulation skills and healthy eating habits.
62299649|NCT03976089|ACTIVE_COMPARATOR|Treatment as usual Early Head Start|Regular Early Head Start home visitors continued to implement evidence-informed developmentally appropriate curriculum designed to promote children's physical health, cognitive skills, and social-emotional functioning as well as parents' capacities to support their children's development.
62299650|NCT03162289|ACTIVE_COMPARATOR|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
62670406|NCT02774174||METS Proximal Humeral system|Implanted with METS Proximal Humerus
62670407|NCT05331482|EXPERIMENTAL|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
62670408|NCT05331482|ACTIVE_COMPARATOR|Conventional training protocol-|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
62670409|NCT05331482|NO_INTERVENTION|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
62670410|NCT02148770|EXPERIMENTAL|Neurofeedback|Neurofeedback training: Up-regulation of DLPFC.
62670411|NCT02148770|SHAM_COMPARATOR|Neurofeedback SHAM|Neurofeedback training: Sham-regulation of DLPFC.
62670412|NCT01127477|EXPERIMENTAL|1|
62670413|NCT00332098|EXPERIMENTAL|1|Family-Focused Treatment Plus Pharmacotherapy
62670414|NCT00332098|ACTIVE_COMPARATOR|2|Enhanced Care Plus Pharmacotherapy
62670415|NCT04280315||Cases|"Cases are patients with type 1 diabetes in three age strata:~* 20 participants in the age of 2-10 years~* 20 participants in the age of 11-20 years~* 10 participants with more than 30 years of diabetes duration"
61914684|NCT02915328|EXPERIMENTAL|Carotid Wallstent + Filterwire EZ™|The arm assess the efficacy of the combination of the Carotid Wallstent with the Filterwire EZ™ protection
61914685|NCT05849285||TLC Patient|Patients of the TLC program with CP/SB/DD
61914686|NCT05849285||Control Patient|Adults with CP/SB/DD that are not patients of the TLC Program
61914687|NCT05849285||TLC Caregiver|Caregiver of Patients of the TLC program with CP/SB/DD
61914688|NCT05849285||Control Caregiver|Caregiver of Adults with CP/SB/DD that are not patients of the TLC Program
61914689|NCT05849285||Healthcare Providers|Healthcare Providers who care for patients in the TLC clinic
62108440|NCT02337010|ACTIVE_COMPARATOR|Control|In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
62108441|NCT02337010|EXPERIMENTAL|CeVOX|In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.
62299651|NCT03162289|ACTIVE_COMPARATOR|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
62299652|NCT01870466|EXPERIMENTAL|C -> C + S|cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2
62299653|NCT01870466|EXPERIMENTAL|C + S -> C|cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2
62299654|NCT01870466|EXPERIMENTAL|S -> S + C|simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2
62299655|NCT01870466|EXPERIMENTAL|C + S -> S|cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2
62470114|NCT05538052|EXPERIMENTAL|tramadol hydrochloride|The second group will receive intraligamentary injections of tramadol hydrochloride (25mg/ mL). The injections will be administered using a pressure-type syringe (Osung Deosy, Pearland, Tx, USA) and 30 gauge short needles (Septojet needles, Septodont).
62299656|NCT01870466|EXPERIMENTAL|R -> C + R|rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2
62670416|NCT04280315||Controls|Controls are age and sexmatched with the cases and are recruited from the neuropediatric clinic at Herlev Hospital as well as relatives and parents of patients in the whole Pediatric Department
62670417|NCT01890005|EXPERIMENTAL|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
62670418|NCT01890005|PLACEBO_COMPARATOR|Placebo|Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
62670419|NCT01925820|EXPERIMENTAL|Arm 1|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks
62108442|NCT05567952|EXPERIMENTAL|nirmatrelvir plus ritonavir for 5 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
62108443|NCT05567952|OTHER|placebo plus ritonavir for 5 days|placebo (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
62108444|NCT05128305|EXPERIMENTAL|group 1|traditional chinese medicine 1 and traditional chinese medicine 2 simulant
62670420|NCT01925820|ACTIVE_COMPARATOR|Arm 2|Entecavir daily for 144 weeks.
62670421|NCT01925820|ACTIVE_COMPARATOR|Arm 3|180 mcg Peg-IFN alfa-2a once a week for 48 weeks
62670422|NCT06449248||Case Group|"1. Patients of both sexes, consecutively enrolled in a 1:2 ratio~2. Age over 18 yo~3. Previous clinical and histological diagnosis of OLP"
62670423|NCT06449248||Control Group|"1. Patients of both sexes, consecutively enrolled in a 1:2 ratio~2. Age over 18 yo"
62670424|NCT01769365|EXPERIMENTAL|7-day quadruple therapy|"1. pantoprazole 40 mg twice daily for 7 days,~2. clarithromycin 500 mg twice daily for 7 days,~3. amoxicillin 1 g twice daily for 7 days,~4. metronidazole 500 mg twice daily for 7 days"
62670425|NCT01769365|EXPERIMENTAL|10-day sequential therapy|"1. pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by~2. pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days."
62670426|NCT01769365|ACTIVE_COMPARATOR|7-day standard triple therapy|"1. pantoprazole 40 mg twice daily for 7 days,~2. clarithromycin 500 mg twice daily for 7 days,~3. amoxicillin 1 g twice daily for 7 days."
62670427|NCT05414773|EXPERIMENTAL|Corneal Topography with IOLMaster and Sirius topography.|The experimental group will have the two exams: the topography with the IOLMAster and the topography with Sirius topography.
62670428|NCT01324180|EXPERIMENTAL|VLPD Regimen|Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.
62108445|NCT05128305|EXPERIMENTAL|group 2|traditional chinese medicine 1 simulant and traditional chinese medicine 2
62108446|NCT05128305|EXPERIMENTAL|group 3|traditional chinese medicine 1 and traditional chinese medicine 2
62108447|NCT05128305|PLACEBO_COMPARATOR|group 4|traditional chinese medicine 1 simulant and traditional chinese medicine 2 simulant
62108448|NCT03086512|ACTIVE_COMPARATOR|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
62108449|NCT03086512|SHAM_COMPARATOR|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
62108450|NCT02931851|PLACEBO_COMPARATOR|Placebo|Standard Information
62108451|NCT02931851|ACTIVE_COMPARATOR|Intervention|Professionally developed website for relatives of ICU patients
62299657|NCT01870466|EXPERIMENTAL|C + R -> R|cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2
62299658|NCT04808687|EXPERIMENTAL|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 2-4 cycles
62299659|NCT01146925|EXPERIMENTAL|CRMD-001-Deferiprone|
62299660|NCT01146925|PLACEBO_COMPARATOR|Placebo|
62299661|NCT05281523|EXPERIMENTAL|Participants receiving depemokimab (GSK3511294)|
62299662|NCT05281523|PLACEBO_COMPARATOR|Participants receiving Placebo|
62470115|NCT01523730|ACTIVE_COMPARATOR|Repetitive Transcranial Magnetic Stimulation (rTMS)|
62470116|NCT01523730|PLACEBO_COMPARATOR|Sham rTMS|
62670429|NCT01835756|ACTIVE_COMPARATOR|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light.
62670430|NCT01835756|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia MLS but does not emit any therapeutic light.
62470117|NCT01232426|EXPERIMENTAL|Operative|operative treatment of a Mallet fracture with a biodegradable Meniscus Arrow®
62670431|NCT04299620|EXPERIMENTAL|Diagnostic (TRUS)|Patients may undergo TRUS prior to standard-of-care radical prostatectomy. Following radical prostatectomy, removed glands are scanned and micro-US, standard of care mpMRI, and whole mount images are analyzed and compared.
62670432|NCT03336866|PLACEBO_COMPARATOR|Placebo|Normal saline
62108452|NCT05457478|ACTIVE_COMPARATOR|Cohort 2 (no weighing)|"Patients do not weigh themselves using the Smart scale during standard radiation therapy."
62108453|NCT05457478|EXPERIMENTAL|"Cohort I ('Smart scale weighing)"|"Patients weigh themselves daily using the Smart scale over 5-8 weeks during standard radiation therapy."
62108454|NCT00882635|EXPERIMENTAL|Enoxaparin|
62670433|NCT03336866|EXPERIMENTAL|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
62670434|NCT00894920|PLACEBO_COMPARATOR|placebo|
62670435|NCT00894920|ACTIVE_COMPARATOR|biotin|
62670436|NCT02848352|EXPERIMENTAL|Positive placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
62670437|NCT02848352|EXPERIMENTAL|Negative placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it sensitizes for experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
62108455|NCT00882635|ACTIVE_COMPARATOR|Unfractionated heparin|
62108456|NCT00605033|ACTIVE_COMPARATOR|Suboxone|Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
62108457|NCT00605033|ACTIVE_COMPARATOR|Subutex|Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
62108458|NCT04472338||Screening (biospecimen collection)|Participants undergo collection of blood, urine, and/or tissue samples every 12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 12 months after completion of curative therapy.
62108459|NCT06366594|OTHER|Group of first-line nurse managers|First-line nurse managers received an authentic leadership training program
62108460|NCT06366594|OTHER|Intervention Group|First-line nurse managers received an authentic leadership training program
62299663|NCT06559501|EXPERIMENTAL|Integrated case manager care|comprises 8 sessions delivered by case managers. Case managers will provide up to 6 low-intensity sessions in the hospital or the community (if the patient is discharged before completing the required sessions), with content and duration tailored to patient preferences. Post-discharge, patients will receive 2 follow-up sessions with case managers to ensure a smooth transition into the community.
62470118|NCT01232426|ACTIVE_COMPARATOR|Conservative|Conservative treatment of a Mallet fracture with a Mallet splint
62470119|NCT04587557|EXPERIMENTAL|ASD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for children with Autism Spectrum Disorder
62470120|NCT04587557|ACTIVE_COMPARATOR|ASD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for children with Autism Spectrum Disorder
62670438|NCT02848352|PLACEBO_COMPARATOR|Placebo control group|Participants receive a nasal spray that is a placebo and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
62670439|NCT02848352|OTHER|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
62108461|NCT03235349|EXPERIMENTAL|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
62108462|NCT04995887||C-Section Delivery with EBL ≥ 1500 mL|Patients with ≥ 1500 mL estimated blood loss (EBL) at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
62108463|NCT04995887||C-Section Delivery with EBL < 1500 mL|Patients with \< 1500 mL EBL at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
62108464|NCT04995887||Vaginal Delivery with EBL ≥ 1000 mL|Patients with ≥ 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
62108465|NCT04995887||Vaginal Delivery with EBL < 1000 mL|Patients with \< 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
62108466|NCT00335023|ACTIVE_COMPARATOR|Red blood cell transfusion|At least one unit of red blood cells will be administered.
62108467|NCT00335023|NO_INTERVENTION|Control|No red blood cell transfusion. Iron suppletion is allowed and can be administered according to local protocol. If suppletion is prescribed, the type and duration will be registered
62108468|NCT04247711|EXPERIMENTAL|OTCH|OTCH is based on OTNY, a Coordinated Specialty Care program for people with first-episode psychosis. The program is implemented by a multidisciplinary team, who provide coordinated, evidence-based services based on the interests, needs, and preferences of each participant.
62108469|NCT04247711|PLACEBO_COMPARATOR|Usual FEP services|This is generally provided in mental health outpatient clinics which serve a population enrolled in the public health care system.
62108470|NCT02129933|EXPERIMENTAL|Tracer bevacizumab-IRDye800CW|"Two days prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform), all patients will receive the fluorescent tracer bevacizumab-IRDye800CW intravenously.~\*amendement June 2015: topical administration of bevacizumab-800CW"
62108471|NCT00161447|ACTIVE_COMPARATOR|1|Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
62108472|NCT00161447|ACTIVE_COMPARATOR|2|Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 \& at month 3) + Acyline (SQ) every two weeks for the first 12 weeks
62299664|NCT06559501|NO_INTERVENTION|Enhanced care as usual|includes their standard care, and all treatments recommended by attending physicians will be provided, plus a written self-help booklet
62299665|NCT04489238||Young onset Colorectal Cancer Participants|(Stool collection on newly diagnosed patients in this cohort) Participants will include patients under the age of 50 who are diagnosed with colorectal adenocarcinoma.
62299666|NCT04489238||Average onset Colorectal Cancer Participants|"(Stool collection cohort only) 166 colorectal cancer patients 50 year-old or older will serve as controls.~Stool collection cohort only."
62470121|NCT04587557|EXPERIMENTAL|TD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for typically developed children
62470122|NCT04587557|ACTIVE_COMPARATOR|TD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for typically developed children
62108473|NCT02987335||Lean Diabetes Subjects|N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.
62299667|NCT01377493|PLACEBO_COMPARATOR|placebo|
62299668|NCT01377493|ACTIVE_COMPARATOR|POs-Ca|
62108474|NCT02987335||Type 2 Diabetes Mellitus Subjects|N=13 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp
62108475|NCT02987335||Type 1 Diabetes Mellitus Subjects|N=15 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp
62108476|NCT02987335||Lean Nondiabetic Subjects|N=16 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
62108477|NCT02987335||Obese Nondiabetic Subjects|N=9 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the Type 2 diabetes Mellitus group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
62108478|NCT00810550|OTHER|LV systolic dysfunction|Diagnostic Testing
62108479|NCT03662399|EXPERIMENTAL|Insole A|Investigational product - Insole A
62108480|NCT03662399|EXPERIMENTAL|Insole B|Investigational product - Insole B
62108481|NCT03662399|EXPERIMENTAL|Insole C|Investigational product - Insole C
62108482|NCT03662399|EXPERIMENTAL|Insole D|Investigational product - Insole D
62299669|NCT01377493|ACTIVE_COMPARATOR|POs-Ca+F|
62299670|NCT00427414|EXPERIMENTAL|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
62299671|NCT05746624|EXPERIMENTAL|Arm 1 Long COVID left handed|Long COVID left handed
62299672|NCT05746624|EXPERIMENTAL|Arm 1 Long COVID right handed|Long COVID right handed
62470123|NCT03941925|EXPERIMENTAL|Prebiotic fructans|Prebiotic fructans. Prebiotic will be mixed into foods or drinks and consumed twice daily.
62470124|NCT03941925|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin. Maltodextrin will be mixed into foods or drinks and consumed twice daily.
62299673|NCT05746624|EXPERIMENTAL|Arm 2 Healthy Controls left handed|healthy left handed
62299674|NCT05746624|EXPERIMENTAL|Arm 2 Healthy Controls right handed|healthy right handed
62299675|NCT03609164|EXPERIMENTAL|Suture-spanning augmentation of single-row repair|
62470125|NCT02544672|EXPERIMENTAL|Myoelectric Elbow-Wrist-Hand Orthosis|
62470126|NCT05858463|EXPERIMENTAL|Intervention group|High Intensity Interval training: 1 min at maximal workload followed by 1 min rest, repeated during a maximum of 40 min.
62670440|NCT02746380|EXPERIMENTAL|LBAL|Adalimumab
62108483|NCT03662399|EXPERIMENTAL|Insole E|Investigational product - Insole E
62108484|NCT03662399|EXPERIMENTAL|Insole F|Investigational product - Insole F
62108485|NCT03662399|EXPERIMENTAL|Insole G|Non-Investigational product - Standard shoe
62108486|NCT00624546||1|gerd patients
62108487|NCT00624546||2|non gerd controls
62108488|NCT02577484||Participants|Subjects who satisfy both general and angiographic inclusion/exclusion criteria, and who have the pressure measurement taken with the Navvus catheter.
62108489|NCT01923948|ACTIVE_COMPARATOR|Pregabalin|Single, 150 mg pre-operative oral dose of Pregabalin
62108490|NCT01923948|PLACEBO_COMPARATOR|Sugar Pill|Single, placebo pre-operative dose
62670441|NCT02746380|ACTIVE_COMPARATOR|Humira®|Adalimumab
62670442|NCT00016302|EXPERIMENTAL|Regimen A|See detailed description.
62670443|NCT00016302|EXPERIMENTAL|Regimen B|"Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.~Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses."
62735943|NCT04251234|EXPERIMENTAL|Healthy controls|"* No co-morbid medical or psychiatry diagnoses~* No family history of mental illness~* No current medication use~* Non-smoking"
62108491|NCT01205750|EXPERIMENTAL|Glucose clamp|
62108492|NCT00514332|EXPERIMENTAL|A|primary surgery group
62108493|NCT02023372|OTHER|NuCel with Autograft|NuCel will be used with local autograft during surgical treatment of one, two or three level degenerative disease of the lumbar spine
62108494|NCT06116812|EXPERIMENTAL|the laughter yoga group|Women diagnosed with breast cancer who meet the inclusion criteria and are receiving chemotherapy will receive laughter therapy twice a week for an average of 40-60 minutes for 8 weeks.
62108495|NCT06116812|EXPERIMENTAL|the mindfulness based stress reduction group|Women diagnosed with breast cancer who meet the inclusion criteria and are receiving chemotherapy will receive an average of 40-60 minutes of mindfulnes therapy twice a week for 8 weeks.
62108496|NCT06116812|NO_INTERVENTION|the control group|Women diagnosed with breast cancer who meet the inclusion criteria and are receiving chemotherapy will receive standard hospital care only.
62108497|NCT01191619|EXPERIMENTAL|McIvor group|groups in which proseal laryngeal mask airway is inserted with McIvor retractor.
62108498|NCT04729244|ACTIVE_COMPARATOR|CBD(hemp oil) cream|cream 2000mg/1oz (50mg/dose) once daily dosing for a total of 4 weeks to area of most pain.Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
62108499|NCT04729244|ACTIVE_COMPARATOR|CBD (Hemp oil) Tincture|1500mg CBD/30ml (50mg/dose) once daily dosing for total of 4 weeks. Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
62735944|NCT04251234|EXPERIMENTAL|Bipolar I disorder|"* Clinical diagnosis of Bipolar I disorder~* Can be (not required, not exclusionary) taking lithium and/or sodium valproate and/or antidepressants~* Can be (not required, not exclusionary) light smokers"
62735945|NCT00727545|EXPERIMENTAL|1|
62108500|NCT02678624|EXPERIMENTAL|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
62108501|NCT02678624|NO_INTERVENTION|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
62108502|NCT06112119||cohort|patients \>16y with sepsis associated with disturbance in conscious level, the first braun CT scan will be routinely performed on admission, the second further brain CT Scan will be obtained whenever prolonged disturbance of consciousness will be detected.
62108503|NCT01976754|OTHER|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
62108504|NCT01573858|EXPERIMENTAL|Acupuncture treatment 1 plus CC|
62108505|NCT01573858|ACTIVE_COMPARATOR|Acupuncture treatment 2 plus CC|
62108506|NCT01573858|ACTIVE_COMPARATOR|Acupuncture treatment 1 plus CC placebo|
62108507|NCT01573858|ACTIVE_COMPARATOR|Acupucture treatment 2 and CC placebo.|
62108508|NCT06217354|ACTIVE_COMPARATOR|Group A: Parturient with BMI ≥ 30 kg/m2.|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).
62299676|NCT03609164|ACTIVE_COMPARATOR|single-row repair|
62108509|NCT06217354|OTHER|Group B: Parturients with BMI < 30kg/m2 (control group)|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[Pabal, Ferring , Baar, Switzerland\]).
62108510|NCT04830722|ACTIVE_COMPARATOR|Sculptra Aesthetic Side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.
62108511|NCT04830722|PLACEBO_COMPARATOR|Placebo side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side
62108512|NCT06630091|EXPERIMENTAL|Golidocitinib + CHOP|Golidocitinib will be administered at 150 mg PO daily as monotherapy unless dose modified per toxicity chart; when in combination with CHOP, the maximum dose of golidocitinib is 150 mg PO every other day
62470127|NCT05858463|ACTIVE_COMPARATOR|Control group|Low intensity continuous exercise training set at the level of the ventilatory threshold, lasting for a maximum of 40 min
62470128|NCT00817960|EXPERIMENTAL|Methylphenidate|
61914690|NCT06167343|EXPERIMENTAL|Semitendinosus tendon graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus tendon (ST).~The ST graft is harvested through a 4-5 cm incision at the pes anserinus. The semitendinosus is identified and harvested. The tendon is prepared and folded to a four-stranded graft with a total diameter of 8-11 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The quadrupled ST graft is fixed proximally with the RIGIDLOOP® adjustable cortical system (DePuy Synthes) and distally with the RIGIDLOOP® XL adjustable cortical system."
61914691|NCT06167343|EXPERIMENTAL|Quadriceps tendon graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon (QT) without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The QT graft is fixed proximally with the RIGIDLOOP® adjustable cortical system (DePuy Synthes) and distally with the RIGIDLOOP® XL adjustable cortical system"
61914692|NCT04357301|EXPERIMENTAL|Closed-loop|Closed-loop administration of norepinephrine
62299677|NCT03138564|EXPERIMENTAL|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
62299678|NCT03138564|ACTIVE_COMPARATOR|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
62299679|NCT02372617||Group A|bone graft - autologous
62299680|NCT02372617||Group B|bone graft - ceramic
62299681|NCT01708226|EXPERIMENTAL|Attention Modification Program|Attention Modification Program
62470129|NCT06038019||Group 1|Patients with suspected or confirmed food allergy
62470130|NCT03325426|NO_INTERVENTION|Usual care|No physical activity tracker or feedback x 6 months, then crossover to physical activity tracker x 6 months
62470131|NCT03325426|EXPERIMENTAL|Physical activity tracker|Physical activity tracker x 12 months (6 months with study feedback and 6 months without)
62735946|NCT05206214|EXPERIMENTAL|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver
62735947|NCT05206214|EXPERIMENTAL|mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver
62735948|NCT05824663|EXPERIMENTAL|HBM1020|HBM1020 is a recombinant fully human anti-B7H7 monoclonal antibody
62735949|NCT03863379||Neurodisabled persons|Persons with various neurodisabilities
62735950|NCT03863379||Control group|Able bodied persons
62299682|NCT01725165|EXPERIMENTAL|Arm I (immediate LCT)|Patients undergo ablation of all residual local and metastatic sites of disease by surgery and/or EBRT. After completion of LCT, patients undergo either surveillance or maintenance treatment at the discretion of the treating physician.
62670444|NCT00016302|EXPERIMENTAL|Regimen C|"Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.~If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.~Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.~Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B."
62670445|NCT00016302|EXPERIMENTAL|Regimen D|See detailed description.
62670446|NCT00016302|EXPERIMENTAL|Regimen E|Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
62299683|NCT01725165|ACTIVE_COMPARATOR|Arm II (delayed/no LCT)|Patients undergo standard maintenance therapy or clinical observation, based on physician choice. Patients may cross-over to Arm I due to RECIST progression or toxicity at the treating physician's discretion.
62299684|NCT05170737|EXPERIMENTAL|PART I: SINGLE ASCENDING DOSE (FIH-SAD)|Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-group, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in single ascending doses.
62670447|NCT00016302|EXPERIMENTAL|Regimen F|Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
62108513|NCT01291004|EXPERIMENTAL|28-day Desogestrel Oral Contraceptive|
61914693|NCT03286127||PCU (unit)|Those patients who received specialised palliative care on a palliative care unit.(palliative care unit)
62670448|NCT03590327|NO_INTERVENTION|Apathy +, rTMS -|This arm will be followed without intervention
61914694|NCT03286127||IPCC (hospital)|"Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team.~(inpatient palliative care consultation team)"
62299685|NCT05170737|EXPERIMENTAL|PART II: MULTIPLE ASCENDING DOSES (FIH-MAD)|Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-groups, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in multiple ascending doses.
62299686|NCT05170737|EXPERIMENTAL|PART III: FOOD EFFECT (FIH-FE)|Prospective, open-label single dose, two-condition (fed versus fasting), two sequences, crossover phase I investigation to assess the effects of food on the bioavailability of AEF0217.
62299687|NCT03139292|EXPERIMENTAL|ProSeal Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for PLMA insertion
62108514|NCT01291004|ACTIVE_COMPARATOR|28-day Drospirenone Oral Contraceptive|
62299688|NCT03139292|EXPERIMENTAL|AmbuAuraGain Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for AmbuAuraGain Laryngeal Mask Airway insertion
62299689|NCT01670500|ACTIVE_COMPARATOR|Doxorubicin-Cyclophosphamide|Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4
62299690|NCT01670500|ACTIVE_COMPARATOR|Cisplatin|Cisplatin q 3 wk x 4
62299691|NCT06656780|EXPERIMENTAL|SIT + Damage Control Assessment & Firefighting (DCA-FF)|
62299692|NCT06656780|ACTIVE_COMPARATOR|DCA-FF|
62108515|NCT01291004|ACTIVE_COMPARATOR|28-day Levonorgestrel Oral Contraceptive|
62108516|NCT00731211|EXPERIMENTAL|Pazopanib|800 mg of pazopanib orally each day continuously
62108517|NCT01303835|EXPERIMENTAL|Naltrexone|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
62108518|NCT01303835|PLACEBO_COMPARATOR|Placebo|Randomized patients received placebo to be taken every night before bed.
62108519|NCT04096144|EXPERIMENTAL|Neostigmine|This is the standard Neuromuscular reversal drug that has been in standard care for the past thirty years. Dose: -Neostigmine: 0.03-0.07 mg/kg by intravenous route.
62299693|NCT06418542|OTHER|END|patients who have chronic renal disease
61914695|NCT03286127||OPCC (outpatient)|Those patients who received specialised palliative care at home from an outpatient palliative care consultation team. (outpatient palliative care consultation team)
62108520|NCT04096144|EXPERIMENTAL|Sugammadex|"Used for Neuromuscular reversal; Sugammadex is devoid of the parasympathetic effects caused by Neostigmine.~Dose: -Sugammadex: 2-4 mg/kg (4 mg/kg if no twitch responses after initial stimulation), intravenous route."
62108521|NCT04709744||SLE patients|SLE patients were presented to chest outpatient clinic and emergency hospital, Mansoura University with manifestation suggesting COVID-19 infection. Vit D was measured in serum by ELISA. Vit D was added to anti COVID-19.
62299694|NCT06418542|OTHER|END free|patients who don't have chronic renal disease
62299695|NCT04082247|EXPERIMENTAL|Experimental group|The education and training of early childhood educators (developed by the researchers) and their intervention on children.
62670449|NCT03590327|ACTIVE_COMPARATOR|rTMS|This group will be randomized to receive rTMS treatment
62670450|NCT03590327|SHAM_COMPARATOR|Sham|This group will be randomized to receive sham treatment
62299696|NCT04082247|NO_INTERVENTION|Control group|Receive the standard care.
62670451|NCT03631121|EXPERIMENTAL|Basalin to Lantus|the patients who are using Basalin treatment will use isodose of Lantus instead
62670452|NCT03203512|ACTIVE_COMPARATOR|Intervention|Fish oil capsules
62670453|NCT03203512|PLACEBO_COMPARATOR|Placebo|High-oleic safflower oil capsules
62735951|NCT05147532|OTHER|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI with \[18F\]-Florbetaben and PET-MRI with \[18F\]-DPA-714
62108522|NCT05126329|EXPERIMENTAL|Participants with mild hepatic impairment|Amcenestrant 200 mg single dose on Day 1 in fed condition
62108523|NCT05126329|EXPERIMENTAL|Participants with moderate hepatic impairment|Amcenestrant 200 mg single dose on Day 1 in fed condition
61914696|NCT01146860|EXPERIMENTAL|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
61914697|NCT01146860|PLACEBO_COMPARATOR|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days
62108524|NCT05126329|EXPERIMENTAL|Participants with normal hepatic function|Amcenestrant 200 mg single dose on Day 1 in fed condition
62108525|NCT02795650|EXPERIMENTAL|Experimental arm|Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.
62108526|NCT02795650|ACTIVE_COMPARATOR|Control|Investigators are allowed to chose the best option of standard treatment for patients.
62108527|NCT02165605|EXPERIMENTAL|HylaCare|HylaCare cream Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily, but not within 4 hours prior to radiation treatment.
62108528|NCT02165605|PLACEBO_COMPARATOR|Placebo|The patient is her own control.
62108529|NCT04164537||Latina adolescents and parents|Latina adolescent young women experiencing depression and their parents will be recruited from community and primary care settings for one-time individual interviews.
62108530|NCT04164537||Healthcare providers|Primary care and mental health providers who commonly work with Latina adolescent patients will be recruited for focus groups from an integrated primary care clinic.
62108531|NCT04923139||Japanese VTE patients including Ca-VTE patients|Include a large number of adult VTE patients (including Ca-VTE patients) prescribed rivaroxaban who visited facilities covered by the MDV database
62108532|NCT05885828|EXPERIMENTAL|Plant-based diet|Participants in this arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. All participants are instructed not to modify their exercise habits during the intervention period.
62108533|NCT05885828|EXPERIMENTAL|Conventional diabetic diet|Participants in this arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. All participants are instructed not to modify their exercise habits during the intervention period.
62108534|NCT00004192|EXPERIMENTAL|Single Dose Filgrastim (SD/01)|Participants receive etoposide IV over 1 hour on days 1-4, cisplatin IV continuously on days 1-4, methylprednisolone IV over 15 minutes on days 1-5, and cytarabine IV over 2 hours on day 5. Treatment is repeated every 21 days for up to 4 courses. Arm I: Participants receive filgrastim-SD/01 subcutaneously (SQ) on day 6.
62108535|NCT00004192|EXPERIMENTAL|Daily Filgrastim (G-CSF)|Participants receive etoposide IV over 1 hour on days 1-4, cisplatin IV continuously on days 1-4, methylprednisolone IV over 15 minutes on days 1-5, and cytarabine IV over 2 hours on day 5. Treatment is repeated every 21 days for up to 4 courses. Arm II: Participants receive filgrastim (G-CSF) SQ daily beginning on day 6 and continuing for 12 days or until blood counts recover.
62108536|NCT03797235|EXPERIMENTAL|Dominant Arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the dominant forearm
62108537|NCT03797235|ACTIVE_COMPARATOR|Non-dominant arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the non-dominant forearm.
62108538|NCT03178396|EXPERIMENTAL|Young, intervention|patients ages 18-45, taking melatonin
62108539|NCT03178396|NO_INTERVENTION|Young, control|patients ages 18-45, usual care
62108540|NCT03178396|EXPERIMENTAL|Older, intervention|patients ages 60 and older, taking melatonin
62108541|NCT03178396|NO_INTERVENTION|Older, control|patients ages 60 and older, usual care
62108542|NCT02535624|ACTIVE_COMPARATOR|ANGIO|Patients with persistent hemodynamic instability (systolic blood pressure (SBP) \<90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography. These patients had to tolerate transfer to the suite. Patients receiving primarily angioembolization therapy were defined as the ANGIO group.
62108543|NCT02535624|ACTIVE_COMPARATOR|PACKING|Indication for pelvic packing was persistent SBP\<90 mmHg during the initial resuscitation period with 3000 ml of intravenous (IV) crystalloids and transfusion of 4 PRBC units. These patients were treated primarly with retroperitoneal packing, while angioembolization OR staff was unavailable (5pm-7am), and were defined as the PACK group.
62108544|NCT04756050|EXPERIMENTAL|corner pocket|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
62299697|NCT00520598|ACTIVE_COMPARATOR|1|Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
62737273|NCT06429046|EXPERIMENTAL|COLD LIDOCAINE GEL (CLG)|"Similarly, patients in the CLG group will be administered Personal Information Form before the procedure and pain will be evaluated with Numeric Pain Scale. In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.NPS will be applied at the beginning of the procedure when the ultrasound probe is placed (NPS-1), 5 minutes after the procedure (NPS-2) and at the end of the procedure when the probe is removed (NPS-3)."
62108545|NCT04756050|EXPERIMENTAL|corner+intracluster|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) 10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
62108546|NCT04756050|EXPERIMENTAL|multi|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
62108547|NCT03724370|EXPERIMENTAL|TES+ VHA-SRM|Telehealth monitoring system (TES) will be added to the VA suicide risk management system (VHA-SRM)
62108548|NCT03724370|ACTIVE_COMPARATOR|VHA-SRM|VHA-SRM will be active comparator
62108549|NCT06477926|EXPERIMENTAL|ABBV-668 Regimen A|Participants will receive ABBV-668 Immediate Release (IR) capsules on Day 1 under fasting conditions
62108550|NCT06477926|EXPERIMENTAL|ABBV-668 Regimen B|Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fasting conditions
62108551|NCT06477926|EXPERIMENTAL|ABBV-668 Regimen C|Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fed conditions
62108552|NCT06477926|EXPERIMENTAL|ABBV-668 Regimen D|Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fasting conditions
62108553|NCT06477926|EXPERIMENTAL|ABBV-668 Regimen E|Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fed conditions
62108554|NCT06477926|EXPERIMENTAL|ABBV-668 Regimen F|Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fasting conditions
62299698|NCT00520598|EXPERIMENTAL|2|Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
62299699|NCT00520598|EXPERIMENTAL|3|Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
62299700|NCT00520598|EXPERIMENTAL|4|Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
62299701|NCT00520598|EXPERIMENTAL|5|Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
62299702|NCT05240144|EXPERIMENTAL|IHG group|Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% Maximal Voluntary Contraction (MVC) on both hands with the frequency of 3 days per week for a period of 6 weeks.
62299703|NCT05240144|ACTIVE_COMPARATOR|Aerobic training group|Aerobic Exercises include walk for 50 min with the frequency of 3 days per week. This exercise will be done for a 6-week period.
62299704|NCT05240144|SHAM_COMPARATOR|IHG + Aerobic exercises group|"Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% MVC on both hands with the frequency of 3 days per week for a period of 6 weeks.~Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% MVC on both hands with the frequency of 3 days per week for a period of 6 weeks."
62108555|NCT06477926|EXPERIMENTAL|ABBV-668 Regimen G|Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fed conditions
62108556|NCT01513642|OTHER|Incentive spirometry|
62108557|NCT01513642|NO_INTERVENTION|Breath Stacking|
62108558|NCT03061513|ACTIVE_COMPARATOR|Ubiquinol|600mg ubiquinol daily for 24 weeks
62108559|NCT03061513|PLACEBO_COMPARATOR|Placebo|Placebo daily for 24 weeks
62108560|NCT02116855|EXPERIMENTAL|tertiary prophylaxis prophy on Hemophilia A patiets|A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.
62108561|NCT05599399|ACTIVE_COMPARATOR|Patients receiving gum acacia|Group one will receive gum acacia extract as an add-on therapy on daily basis
62108562|NCT05599399|NO_INTERVENTION|Patients receiving no intervention|Group two will not receive add-on therapy; they will receive standard care only.
62108563|NCT05264467|NO_INTERVENTION|Control|
62299705|NCT05240144|SHAM_COMPARATOR|Sham IHG group|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period.
62670454|NCT05337748|EXPERIMENTAL|Experimental : Lexie Self Test and Fit Group (Lexie STF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
62670455|NCT05337748|ACTIVE_COMPARATOR|Control: Lexie Professional Test and Fit Group (Lexie PTF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
62299706|NCT01380899||PD Parkinson´s Disrease|We are studying the presence of alpha-synuclein in the epidermis and dermis besides the end nerve terminal. We have several reports until now, and we are following the study because we wish to convince the academic and scientific society over the utility of this study to be close to the molecular diagnosis of this kind of disease.
62670456|NCT01713127|PLACEBO_COMPARATOR|Placebo|5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
62670457|NCT01713127|ACTIVE_COMPARATOR|remifentanil|0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth
62670458|NCT02595554|ACTIVE_COMPARATOR|Concurrent chemoirradiation (CCRT)|Concurrent chemoirradiation
62670459|NCT02595554|EXPERIMENTAL|NACT+Surgery|Neoadjuvant chemotherapy with Paclitaxel and Cisplatin (3 cycles), followed by radical surgery
62108564|NCT05264467|EXPERIMENTAL|PRF|
62108565|NCT03176030||Fortified foods|Fortified foods will be delivered to this group for 3 consecutive days mainly on a mid-meal trolley three times a day (between breakfast and lunch around 10am, between lunch and dinner around 3 pm, and in the evening). However, fortified foods will be available 24 hours and patients will be encouraged to order as many as they like anytime during the day.
62108566|NCT03176030||Baseline|Prior to implementing the intervention, dietary intake among eligible patients offered the standard hospital menu will be measured on the study wards for 24 hours during three days in each of the study wards to estimate the energy and protein intake.
62108567|NCT03999021|EXPERIMENTAL|Experimental Arm|All participants to receive study intervention.
62108568|NCT02824367|OTHER|Parkinsonian|Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation
62108569|NCT02824367|OTHER|Dystonic|Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation
62108570|NCT06341491||Participants of the Pé-de-Meia Program|
62299707|NCT01380899||AP Atypical Parkinsonism|with neurodegenerative disease (proteinopathies) and secondary AP.
62299708|NCT01380899||Control group|Subjects without neurodegenerative disease and apparently good health status with an age that matches the problems groups
62299709|NCT06464211|EXPERIMENTAL|experimental group|There were 6 face-to-face sessions with students for 50- 60 minutes/week, and 2 sessions with internet-based video programs with students' families. Cognitive Behavioral Model-Based Family Counseling Program was conducted. At least one parent was asked to participate in the family sessions. After the implementation of the intervention group was completed, the final tests of the scales used in the research were applied again to both the intervention and the control group. After the data of the study were collected, a focus group interview, one of the interview methods used in qualitative research on the effectiveness and organization of a Cognitive Behavioral Model-Based Family Counseling Program, was conducted for 5 students selected from the initiative group and the effectiveness of the program was evaluated.
62299710|NCT06464211|NO_INTERVENTION|control group|no intervention
62299711|NCT00940706|EXPERIMENTAL|Physical activity in groups|Exercises of physical activity
62299712|NCT00940706|EXPERIMENTAL|Activity monitoring with accelerometers|Each subject will wear the accelerometer 24 hours a day for 4 days The activity will be recorded and analyzed
62299713|NCT00940706|ACTIVE_COMPARATOR|Treadmill|Treadmill with safety adaptations for handicapped persons
62108571|NCT00149630|EXPERIMENTAL|Disulfiram, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
62299714|NCT05330039||Patients with IEM|Collection of biological samples (stool and urine) and health-related data at two timepoints, three to six months apart.
62299715|NCT05330039||Healthy Siblings|Collection of biological samples (stool) and health-related data at two timepoints, three to six months apart.
62299716|NCT04345185||Project Viva|Project Viva (1999-present) enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age.
62299717|NCT04345185||Infant Feeding Practices Study II|The Infant Feeding Practices Study II (IFPS II, 2005-2007) enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (N=2,552) to 12 months of infant age, and at 6 years.
62299718|NCT01553799||US check tube|
62670460|NCT00811109|NO_INTERVENTION|Standard|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity
61914698|NCT02919384|EXPERIMENTAL|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
61914699|NCT02919384|NO_INTERVENTION|Control|Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.
61914700|NCT01535300||Elective pediatric surgery|
61914701|NCT05658523|ACTIVE_COMPARATOR|Bivalent Moderna (mRNA-1273.214)|"Participants who have received three doses of COVID-19 vaccine, with the last dose at least 6 months prior to the study, will receive a booster dose of bivalent mRNA Moderna COVID-19 vaccine (mRNA-1273.214)~The mRNA-1273.214 encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\])."
61914702|NCT05658523|ACTIVE_COMPARATOR|Novavax|"Participants who have received three doses of COVID-19 vaccine, with the last dose at least 6 months prior to the study, will receive a booster dose of Novavax COVID-19 protein subunit vaccine.~Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms)."
61914703|NCT05658523|NO_INTERVENTION|Control group- no vaccine|Participants who have received three doses of COVID-19 vaccine, with the last dose at least 6 months prior to the study, will be recruited but will not receive any COVID-19 vaccine.
61914704|NCT02789319|OTHER|FreeStyle Lite|Blood Glucose Meter type
61914705|NCT02789319|OTHER|Contour Next|Blood Glucose Meter type
62670461|NCT00811109|ACTIVE_COMPARATOR|2|With Blood Volume on-line monitoring only
62670462|NCT00811109|ACTIVE_COMPARATOR|3|With Blood volume and Blood temperature on-line monitoring
61914706|NCT02789319|OTHER|OneTouch Ultra2|Blood Glucose Meter type
61914707|NCT02789319|OTHER|ACCU-CHEK AVIVA Plus|Blood Glucose Meter type
61914708|NCT02789319|OTHER|Prodigy Auto Code|Blood Glucose Meter type
61914709|NCT02789319|OTHER|Walmart ReliOn Prime|Blood Glucose Meter type
61914710|NCT02789319|OTHER|Embrace|Blood Glucose Meter type
62299719|NCT01553799||US check tube, Endobronchial|
62299720|NCT02700529|EXPERIMENTAL|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
62670463|NCT05907499|EXPERIMENTAL|Arm A|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
62670464|NCT05907499|ACTIVE_COMPARATOR|Arm B|The hematologic growth factors (granulocyte-colony stimulating factor, thrombopoietin receptor agonists, recombinant human erythropoietin)
61914711|NCT02789319|OTHER|True Result|Blood Glucose Meter type
61914712|NCT02789319|OTHER|True Track|Blood Glucose Meter type
61914713|NCT02789319|OTHER|Walmart ReliOn Confirm|Blood Glucose Meter type
61914714|NCT02789319|OTHER|Advocate Redi-Code +|Blood Glucose Meter type
61914715|NCT02789319|OTHER|CVS Advanced|Blood Glucose Meter type
61914716|NCT02789319|OTHER|OneTouch Verio|Blood Glucose Meter type
61914717|NCT02789319|OTHER|Contour|Blood Glucose Meter type
61914718|NCT02789319|OTHER|Accu-Chek Nano|Blood Glucose Meter type
61914719|NCT02789319|OTHER|Walmart ReliOn Ultima|Blood Glucose Meter type
61914720|NCT02789319|OTHER|Gmate Smart|Blood Glucose Meter type
61914721|NCT02789319|OTHER|SolusV2|Blood Glucose Meter type
62670465|NCT05628272|EXPERIMENTAL|Experimental group|granulocyte stimulating factor(5ug/kg/d) +infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10\^8, once a week
61914722|NCT00555425|ACTIVE_COMPARATOR|1|Buprenorphine/naloxone maintenance (Mtn) is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services.
61914723|NCT00555425|EXPERIMENTAL|2|Buprenorphine/naloxone detoxification (Dtx) is identical to Mtn for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Buprenorphine/naloxone.
61914724|NCT03272269|EXPERIMENTAL|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
61914725|NCT03272269|EXPERIMENTAL|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
62299721|NCT02700529|PLACEBO_COMPARATOR|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
62299722|NCT04273724|EXPERIMENTAL|Geriatric assessment guided interventions|
62299723|NCT00587223|EXPERIMENTAL|1|Apligraf (a living bilayered cell therapy product)
62299724|NCT00587223|ACTIVE_COMPARATOR|2|Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.
62299725|NCT02948894|EXPERIMENTAL|MAD|Mandibular advancement device. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
62299726|NCT02948894|PLACEBO_COMPARATOR|Sham-MAD|Mandibular advancement device (non-advanced device). A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
62299727|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
62299728|NCT03406962|EXPERIMENTAL|MGTA-456|MGTA-456 is an expanded CD34+ cell therapy investigational product used in replacement of single umbilical cord blood transplantation.
62299729|NCT05069038|EXPERIMENTAL|Treatment|"The following drugs will be taken for six cycles:~Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days and 7 days off schedule (meaning: on Days 1-21 of each 28-day cycle).~Letrozole should be taken daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.~Goserelin is given as subcutaneous injection every 28 days at a dose of 3.6 mg. It is to be given on Day 1 of each cycle. Goserelin will only be administered to pre-menopausal subjects."
62299730|NCT04354454|ACTIVE_COMPARATOR|Fitbit|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit only group.~-- Participants will track their daily steps for 4.5 months with use of a Fitbit~The study interventions involved in this research are:~* Fitbit (also known as a wearable accelerometer or fitness tracker)~* Way to Health platform~* Surveys/Interviews"
62299731|NCT04354454|EXPERIMENTAL|Fitbit + Game + Support from a Teammate|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit + Game + Support from a Teammate.~* Participants will select a step goal, use a Fitbit to track daily activity, and select a teammate (e.g. family member or friend) who they think will help them achieve their goals.~* Participants will participate a 3-month game designed to increase activity and then followed for another 1.5 months to see if their increased activity can be maintained without the game.~The study interventions involved in this research are:~* Fitbit (also known as a wearable accelerometer or fitness tracker)~* Help from a Teammate (i.e. friend or family member chosen to help reach goals, if applicable~* Way to Health Platform~* Surveys/Interviews"
62299732|NCT03206502|EXPERIMENTAL|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
62670466|NCT05628272|PLACEBO_COMPARATOR|control group|granulocyte stimulating factor 5ug/kg/d
62108572|NCT00149630|ACTIVE_COMPARATOR|Placebo, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
61914726|NCT03272269|EXPERIMENTAL|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
61914727|NCT01030601|NO_INTERVENTION|Control|Diabetics undergoing routine cataract surgery
62108573|NCT05547750|EXPERIMENTAL|vitamin K2 arm|The vitamin K2 arm takes vitamin K2 180 μg/day at bedtime for 8 weeks.
62299733|NCT01041092|PLACEBO_COMPARATOR|sugar pill|
62299734|NCT01041092|ACTIVE_COMPARATOR|raloxifene hydrochloride|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
62299735|NCT05155098||secukinumab|Patients receiving secukinumab in real world practice
62299736|NCT05418049|EXPERIMENTAL|Experimental Study Participants|Participants received, in random order, a single dose of placebo, baclofen, roflumilast or memantine with a two-week washout period between doses.
62299737|NCT05418049|PLACEBO_COMPARATOR|Control Study Participants|Participants received, in random order, a single dose of placebo, baclofen, roflumilast or memantine with a two-week washout period between doses.
62299738|NCT05831085|EXPERIMENTAL|Imaging- and Physiology-Guided State-of-the-Art Percutaneous Coronary Intervention|
62299739|NCT05831085|ACTIVE_COMPARATOR|Coronary-Artery Bypass Grafting|
62299740|NCT02363179|NO_INTERVENTION|Non Music Group|500 non-intervention patients will be consented to serve as the control group
62299741|NCT02363179|EXPERIMENTAL|Music Intervention Group|500 intervention patients will be consented to participate in the live preferential music intervention
62299742|NCT01606462|EXPERIMENTAL|Oxytocin|one application of 24 IU oxytocin per volunteer
62299743|NCT01606462|PLACEBO_COMPARATOR|Placebo|sodium chloride solution, intranasal application, 3 puffs per nostril one application per volunteer
62670467|NCT03331406|EXPERIMENTAL|12-week physical activity program|"The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week.~* At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity.~* Exercise Trainer --A exercise trainer will be assigned to design a physical activity program."
62108574|NCT05547750|PLACEBO_COMPARATOR|Placebo|The placebo group takes a placebo at bedtime for 8 weeks.
61914728|NCT01030601|EXPERIMENTAL|Treatment|Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
62299744|NCT06145750|NO_INTERVENTION|Arm A1|Arm A practices will be further randomized 1:1 into two groups (A1:A2) to observe lung cancer screening standard of care. Practices in A1 will be observed.
62299745|NCT06145750|ACTIVE_COMPARATOR|Arm A2|Arm A practices will be further randomized 1:1 into two groups (A1:A2) to observe lung cancer screening standard of care. Practices in A2 will receive standard education on lung cancer screening for CME credit.
62299746|NCT06145750|EXPERIMENTAL|Arm B|Arm B (intervention) practices will receive education on FirstLook™ and have access to order FirstLook™ at the providers' discretion;
62299747|NCT01925703|EXPERIMENTAL|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
62299748|NCT05056831|EXPERIMENTAL|Group I (physical activity intervention)|Patients attend face-to-face mind-body sessions focused on stretching, breathing, and relaxation twice a week and receive targeted text messages daily on their smartphone for 8 weeks.
62108575|NCT03425890|EXPERIMENTAL|SURE Program Group|The intervention group will receive a SURE program booklet and will perform individualized daily self-exercise and functional use of the arm and hand on their own outside of therapy for 60 minutes/day, 6 days/week for 4 weeks. These self-exercises and upper limb functional use will be performed in addition to usual care. Three SURE program booklets have been developed which relate to the affected upper limb motor capability using individual Fugl Meyer (ULFM) score. Each SURE program booklet consists of warm-up exercises, strengthening exercises and motor tasks. The SURE program booklet also includes selected functional motor tasks to be performed by the participants using their affected upper limb. The performance of the exercises and functional motor tasks will be reviewed three times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.
62108576|NCT03425890|EXPERIMENTAL|Education Group|The control group will receive an education booklet with 10 modules. The education booklet will contain information on stroke, recovery and management strategies after stroke. Participants are to complete 2-3 modules per week and answer 1-2 simple questions after each module. Each module including answering questions takes approximately 5-10 minutes to complete. CPI will review the information with the participants 3 times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.The participants in the control group will continue with their usual care in the hospital.
62108577|NCT02276131|EXPERIMENTAL|Usability testing|Patients will participate in summative human factors testing of the Vigilant Diabetes Management Application in a controlled environment and during home use testing. Clinicians will participate in summative human factors testing in a controlled environment.
62108578|NCT04470193|EXPERIMENTAL|MyChildCMC Intervention Group|Parents/patients randomized into the MyChildCMC Intervention Group will use the MyChildCMC app to monitor their child's daily symptoms for the duration of the study period (3 months). The MyChildCMC app includes a daily form consisting of 12 questions assessing child's vitals, pain, seizures, mood, and feeding as well as caregiver worry for the day. Daily reminders are sent to the parent to fill out the vitals form in the app. Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
62108579|NCT04470193|NO_INTERVENTION|Standard of Care Group|Parents/patients randomized into the Standard of Care Group do not use the MyChildCMC app to monitor their child's daily symptoms and are instructed to continue with regular care for their child and to continue monitoring their child's symptoms on their own without the use of the app for the duration of the study period (3 months). Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
62108580|NCT00586014|EXPERIMENTAL|I|High-dose sequential cyclophosphamide and VP-16 followed by myeloablation with high-dose BCNU and melphalan with autologous stem cell transplant
62108581|NCT00699686|ACTIVE_COMPARATOR|Glargine|During this arm/phase patients take subcutaneous glargine daily for 3 months.
62108582|NCT00699686|EXPERIMENTAL|Detemir|During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.
62108583|NCT04089618|EXPERIMENTAL|Baseline 10 Days|10 days baseline before intervention starts.
62299749|NCT05056831|ACTIVE_COMPARATOR|Group II (usual care)|Patients receive usual care.
62299750|NCT02602509|EXPERIMENTAL|Celecoxib plus rifampicin group|Visit 1: Celecoxib 400mg Visit 2: Rifampicin 10mg/kg Visit 3: Celecoxib 400mg PLUS rifampicin 10mg/kg
62299751|NCT02602509|EXPERIMENTAL|Celecoxib plus pyrazinamide group|Visit 1: Celecoxib 400mg Visit 2: Pyrazinamide 25mg/kg Visit 3: Celecoxib 400mg PLUS pyrazinamide 25mg/kg
62299752|NCT03754933|EXPERIMENTAL|Ad/PNP + fludarabine phosphate, 5 cycles|
61914729|NCT01197001|EXPERIMENTAL|Amlodipine plus Losartan|
61914730|NCT01197001|ACTIVE_COMPARATOR|Amlodipine, Losartan|
62670468|NCT04524117||Group A(vulnerable plaque group)|Lipid plaques with fibrous cap thickness less than 65um, erosion and coronary artery dissection detected by OCT are defined as vulnerable plaque.
62108584|NCT04089618|EXPERIMENTAL|Baseline 17 Days|17 days baseline before intervention starts.
62108585|NCT04089618|EXPERIMENTAL|Baseline 24 Days|24 days baseline before intervention starts.
62108586|NCT02181348|ACTIVE_COMPARATOR|Intervention (Vitamin E supplementation)|Vitamin E 400 mg once daily for 3 months
62108587|NCT02181348|PLACEBO_COMPARATOR|placebo (edible oil)|
62299753|NCT03285815|EXPERIMENTAL|Proton Therapy 60 CGE|60 CGE (3CGE X 20) for 4wks
62299754|NCT03285815|EXPERIMENTAL|Proton Therapy 47 CGE|47 CGE (4.7CGE X 10) for 2wks
62299755|NCT02318004|EXPERIMENTAL|Home monitoring|Home monitoring via the EarlySense non-invasive nocturnal monitoring system. Movement, heart rate and respiratory rates will be monitored while subject is in his bed. The trends of monitored values will be daily reported to a central repository. No intervention will be attempted and care will be coordinated by the family physician and treating cardiologist as usual.
62299756|NCT04727515|EXPERIMENTAL|General anesthesia|Patients will receive general anesthesia
62299757|NCT04727515|EXPERIMENTAL|Axillary Block|Patients will receive axillary nerve block
62670469|NCT04524117||Group B(stable plaque group)|Lipid plaques with fibrous cap thickness more than 65um detected by OCT are defined as vulnerable plaque.
62670470|NCT00530075|EXPERIMENTAL|1|Gusperimus
61914731|NCT06053710|OTHER|Patients with chronic kidney failure|Patients with chronic kidney failure will wear bioimpedance sensors at the upper back and lower anterior leg for three weeks.
62108588|NCT03476109|ACTIVE_COMPARATOR|Omalizumab|"Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).~Non responders will be switched to mepolizumab arm."
62108589|NCT03476109|ACTIVE_COMPARATOR|Mepolizumab|"Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).~Non responders will be switched to omalizumab arm."
62299758|NCT05219812|EXPERIMENTAL|Group 1 (BAY2395840 - placebo)|Participants will be randomly assigned to treatment regimen of double-blind BAY2395840, and after an interim single blind period for washout will switch to double-blind placebo.
62108590|NCT00062062|EXPERIMENTAL|gefitinib|"Patients receive oral gefitinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
62108591|NCT00062062|EXPERIMENTAL|paclitaxel + carboplatin + gefitinib|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy and in the absence of disease progression, patients receive oral gefitinib as in group I.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
62299759|NCT05219812|EXPERIMENTAL|Group 2 (Placebo - BAY2395840)|Participants will start with a treatment regimen of double-blind placebo, and after an interim single blind period for washout will switch to double-blind BAY2395840.
62299760|NCT02249715|EXPERIMENTAL|rDTMS|
62299761|NCT04281797||Kidney transplant recipients|Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
62299762|NCT04281797||HSCT-recipients|Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
62299763|NCT04281797||MSCT-recipients|Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
62299764|NCT04281797||Liver transplant recipients|Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
62737274|NCT03992781||Newly prescribed tofacitinib|patients who were newly prescribed tofacitinib at baseline and who scored at least 11 points on CUDOS scale
62737275|NCT02966288|EXPERIMENTAL|Toradol injection|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
61914732|NCT06053710|OTHER|Patients with severe overhydration|Patients with severe overhydration will wear bioimpedance sensors at the upper back, lateral thorax, anterior thigh, and lower anterior leg throughout an intensive dialysis treatment regime (\~2-10 days).
62108592|NCT04175886||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with an indication for tofacitinib: 5mgx2 per day
62108593|NCT04175886||Healthy subjects|Healthy subjects matched to cases (1:1) on age (±5 years), sex, and menopausal status for women and body mass index (BMI, ±3 kg/m²)
62108594|NCT02209740||Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
62108595|NCT06476925|PLACEBO_COMPARATOR|Control group|Sonar guided stellate ganglion injection of 8 ml of sterile saline 0.9% using high frequency probe as a placebo. Stellate ganglion is identified at the level of C6 just under the pulsation of the ipsilateral carotid artery
62108596|NCT06476925|ACTIVE_COMPARATOR|Stellate ganglion|Sonar guided stellate ganglion injection of 8ml bupivacaine 0.25% using high frequency probe. . Stellate ganglion is identified at the level of C6 just under the pulsation of the ipsilateral carotid artery
62108597|NCT04163471||VasoStat|Randomized to use of VasoStat radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
62108598|NCT04163471||TR Band|Randomized to use of TR Band radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
62108599|NCT00336232|EXPERIMENTAL|Diet Intervention|28 day diet low vitamin K, 28 day diet high vitamin K
62108600|NCT01360840|PLACEBO_COMPARATOR|Placebo + Standard of care (SoC)|
62108601|NCT01360840|EXPERIMENTAL|EMD 525797 750 mg + SoC|
62108602|NCT01360840|EXPERIMENTAL|EMD 525797 1500 mg + SoC|
62108603|NCT02081898|NO_INTERVENTION|control group|weight maintenance diet
62108604|NCT02081898|EXPERIMENTAL|low calorie diet (LCD) group|approximate 100 kcal/d calorie deficit
62108605|NCT00470626|EXPERIMENTAL|1|Vena Cava Filter
62108606|NCT04311229|EXPERIMENTAL|Negative-Pressure Wound Therapy group|NPWT was applied three times for Class III and pressure ulcers. An initial pre-treatment measurement was used as a baseline, followed by three post-treatment measurements after each round to evaluate wound healing. A total of four measurements were performed for each subject. Wound healing was measured using the PUSH Tool and the 3DWM device in both groups.
62108607|NCT04311229|OTHER|CONTROL GROUP|wet to dry dressing group
62108608|NCT04251143||Ectasia|Keratoconus, Keratoconus suspects
62299765|NCT04775823|EXPERIMENTAL|Hybrid composite nano-ceramic|
62299766|NCT04437264|EXPERIMENTAL|Intermittent feed|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
62299767|NCT04437264|EXPERIMENTAL|Continuous feeds|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
62299768|NCT00863616|EXPERIMENTAL|HFCWO|HFCWO twice a day delivered by SmartVest device at 13Hz FOR 20min x2. Duration 4 weeks in each phase with a 2week washout.
62299769|NCT00863616|NO_INTERVENTION|Placebo/Control|Self-administered breathing exercises
62299770|NCT06468371|ACTIVE_COMPARATOR|Dopamine agonist|"* Ropinirole administration was begun with a dose of 0.25 mg, taken orally once daily, two hours before bedtime.~* The dose was adjusted based on symptomatology at weekly intervals, with an increment of 0.5 mg, targeting a maximum dose of 2.0 mg, which was maintained for the remaining duration of the 12 weeks"
62299771|NCT06468371|EXPERIMENTAL|Excercise training|"* Exercise sessions involved using a pedal bicycle twice a week for 12 weeks, integrated into the patient's hemodialysis schedule.~* Each exercise session lasted 20 minutes, scheduled between the second and third hours of dialysis.~* The first 5 minutes were served as a warm-up, consisting of slow pedaling.~* This was followed by 10 minutes of more intense pedaling.~* After the initial 15 minutes, the pace was slow again for another 5 minutes for a cool-down period, helping to gradually reduce the heart rate."
61914733|NCT02694432|ACTIVE_COMPARATOR|GOALS|Participants will use for approximately four months an online platform, GOALS, consisting of weekly lessons designed to enhance blood pressure control. Recommended lifestyle changes for hypertension, including a low-sodium diet, physical activity, weight loss (if appropriate) and behavioral self-management skills will be offered. Attention to medication adherence and pharmacist support as well as that of a dedicated online health coach and ongoing collaboration with the primary care physician are also provided.
61914734|NCT02694432|EXPERIMENTAL|Minding GOALS|Participants in this arm will also use the GOALS standard tools for blood pressure control. To further maximize success, they will receive additional online behavioral training throughout the 4-month intervention that focuses on mind-body approaches. Weekly topics, for example, will include meditation lessons, mindfulness-based stress reduction and mindfulness-based eating awareness.
61914735|NCT04649580||Online Survey|
62108609|NCT00045916|EXPERIMENTAL|High dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
62108610|NCT00045916|EXPERIMENTAL|High dosage ECT + venlafaxine|Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
62108611|NCT00045916|PLACEBO_COMPARATOR|High dosage ECT + placebo|Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
62108612|NCT00045916|EXPERIMENTAL|Low dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
62108613|NCT00045916|EXPERIMENTAL|Low dosage ECT + venlafaxine|Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
62108614|NCT00045916|EXPERIMENTAL|Low dosage ECT + placebo|Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
62108615|NCT03606005||Group 1: Allogeneic-HSCT recipients|Dyspnea \[Modified Medical Research Council dyspnea scale (MMRC)\], submaximal exercise capacity \[6-minute walk test (6-MWT)\], physical activity level \[metabolic holter\], quality of life \[European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)\] and pulmonary functions \[spirometry\] were evaluated in allogeneic-HSCT recipients (.Vital signs, dyspnea and fatigue perception \[Modified Borg Scale\] were recorded as pre-post measurements of 6-MWT.
62108616|NCT03606005||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
62299772|NCT03002506|EXPERIMENTAL|ceftolozane/tazobactam|One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
62470132|NCT06007937|EXPERIMENTAL|Lorlatinib and ramucirumab|The phase 1 safety portion of the study will assess whether a dose of lorlatinib 100 mg orally daily and ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose. Six patients will be enrolled at this dose level and assessed for dose limiting toxicities (DLTs) for one full cycle (21 days). Once the phase 1 portion of the study is complete, patients will be enrolled in the phase 2 portion of the study, cohort expansion at the MTD. Patients will be enrolled in two patient cohorts: cohort 1, treatment-naïve and cohort 2, patients who have progressed on prior second-generation ALK TKI. A cycle will be 21 days in length. Response to therapy will initially be assessed by interval imaging every 2 cycles.
62108617|NCT05498337|OTHER|Examiner|Examiner
62108618|NCT05498337|NO_INTERVENTION|Patient|Patient
62108619|NCT03917329|OTHER|ACT and PBS group workshop|The intervention in this study is an Acceptance and Commitment Therapy (ACT) and Positive Behaviour Support (PBS) group workshop for parents and education staff of children with intellectual disabilities.
62299773|NCT05241652|ACTIVE_COMPARATOR|Intervention group|Sixteen patients are assigned an IMT exercise program that included inspiratory muscle strengthening exercises thrice a week at a 50% MIP intensity, five sets per time, ten breathing repetitions per set, for an estimated duration of 20 minutes each using Threshold IMT for 12 weeks.
62470133|NCT05470972|EXPERIMENTAL|Ovarian Endometrioma|Ovarian endometrioma (OE) is in women of reproductive age
62470134|NCT03331497|EXPERIMENTAL|Tonsillotomy|The patients diagnosed with PFAPA will have tonsillotomy performed in one month from randomisation.
62470135|NCT03331497|NO_INTERVENTION|Follow up|The patients diagnosed with PFAPA will be monitored for 3 months time. If the symptoms still persist, tonsillectomy will be performed
62470136|NCT05519683|EXPERIMENTAL|TEA at location A|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
62670471|NCT04034680|EXPERIMENTAL|Home care services - Intervention group|Totally 5 municipalities (25 persons with dementia) will be included in the intervention group, and will receive training in the TIME model. This includes two hours of lectures about dementia and neuropsychiatric symptoms (NPS) and three hours of training and roleplay in using the TIME model. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational and information files. From each municipality, three staff members, called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
62108620|NCT04682756||CNN model|Electronic health information of NSTEMI and UA patients in two chest pain centers from 2017 to 2019 was collected，After manual labeling, the characteristics of patient admission records were selected, and through the construction of one-dimensional convolution (CNN) model. Taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
62108621|NCT04682756||XG boost|Through the construction of XG boost model,taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
62108622|NCT01022489|EXPERIMENTAL|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
62108623|NCT01022489|PLACEBO_COMPARATOR|placebo (sham coil) treatment|
62108624|NCT01756417|EXPERIMENTAL|Metformin + canagliflozin (JNJ-28431754)|Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
62108625|NCT04744779|NO_INTERVENTION|Observation|Observation only.
62108626|NCT04744779|EXPERIMENTAL|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
62108627|NCT03467724|EXPERIMENTAL|Fractional radiofrequency (FRF)|Subjects received 3 FRF treatments (monthly) over their scar following breast augmentation, abdominoplasty or face lift surgery.
62108628|NCT05273281|EXPERIMENTAL|TAQLA|Transabdominal plain block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
62108629|NCT05273281|EXPERIMENTAL|TAQLB|Quadratus lumborum block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
62108630|NCT05273281|NO_INTERVENTION|TAQLC|Control group. Pain relief only with intravenous and peroral drugs.
62108631|NCT05838664||AF patients unexposed to oral anticoagulants|
62108632|NCT05838664||AF patients exposed to VKA|
62108633|NCT05838664||AF patients exposed to apixaban|
62108634|NCT05838664||AF patients exposed to rivaroxaban|
62108635|NCT05838664||AF patients exposed to dabigatran|
62108636|NCT05511454|EXPERIMENTAL|Group of patients with periodontitis (cases)|Patients with periodontitis according to the Chicago 2018 classification criteria
62108637|NCT05511454|OTHER|Control group|Patients with periodontal health according to the 2018 Chicago Classification
62108638|NCT01209039|EXPERIMENTAL|Part A, cohort 1 and 2|Part A, Cohorts 1 and 2, will investigate escalating multiple daily doses of GSK1144814 in 19 subjects
62108639|NCT01209039|EXPERIMENTAL|Part A, cohort 3|Cohort 3 will investigate safety, tolerability and PK of a dose of GSK1144814 over a repeat treatment period of 28 days in 18 subjects and a potential drug drug interaction between GSK1144814 and the CYP3A4 sensitive substrate midazolam (in 15 subjects).
62108640|NCT01209039|EXPERIMENTAL|Part B|Part B will assess NK1 receptor occupancy following repeated administration of GSK1144814 given once daily until steady state is obtained
62299774|NCT05241652|PLACEBO_COMPARATOR|Control group|Sixteen patients are assigned an IMT exercise program that included inspiratory muscle strengthening exercises thrice a week at a 10% MIP intensity, five sets per time, ten breathing repetitions per set, for an estimated duration of 20 minutes each using Threshold IMT for 12 weeks.
62737276|NCT02966288|ACTIVE_COMPARATOR|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
62737277|NCT00830375|EXPERIMENTAL|Memantine|10-30mg, memantine
62108641|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
62108642|NCT03809299|OTHER|Ad libitum meal timing first|This arm will receive the ad libitum meal timing intervention first, followed by the twice a day feeding intervention.
62108643|NCT03809299|OTHER|Twice a day meals first|This arm will receive the twice a day feeding intervention first, followed by the ad libitum meal timing intervention.
62108644|NCT01221337|OTHER|haemodialyzer EVODIAL-haemodialyzer VIE|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
62108645|NCT01221337|OTHER|haemodialyzer VIE-haemodialyzer Evodial|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
62108646|NCT01705249|EXPERIMENTAL|estradiol / norethisterone acetate|
62108647|NCT03897309|EXPERIMENTAL|Monovalent GI.1|Monovalent GI.1 tableted vaccine group
62108648|NCT03897309|EXPERIMENTAL|Monovalent GII.4|Monovalent GII.4 tableted vaccine group
62108649|NCT03897309|EXPERIMENTAL|Bivalent GI.1 and GII.4 vaccine group|Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine
62108650|NCT03897309|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62108651|NCT04240730||extremely obese patients with early-stage endometrial cancer|
62108652|NCT04993391|EXPERIMENTAL|40mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
62299775|NCT06158139|EXPERIMENTAL|CAR-T Cell Therapy|Single Arm Subjects with Refractory Pancreatic Ductal Adenocarcinoma (PDAC) cancer will receive iC9.CAR.B7-H3 T cells manufactured from their collected blood sample.
62470137|NCT05519683|SHAM_COMPARATOR|TEA at location B|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
62670472|NCT04034680|ACTIVE_COMPARATOR|Home care services - Control group|Totally 5 municipalities (25 persons with dementia) will be included in the Control group. The municipalities in the control group will receive the same two hours lectures about dementia and NPS as the intervention group. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
62670473|NCT01309191|EXPERIMENTAL|Minoxidil|Patients received Minoxidil (same strength as sold over the counter) twice a day for 8 weeks.
62670474|NCT01309191|PLACEBO_COMPARATOR|Placebo|Placebo arm
62670475|NCT06494813|ACTIVE_COMPARATOR|controls|apparently healthy individual with no chronic illness
62108653|NCT04993391|EXPERIMENTAL|80mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
62299776|NCT00561353|EXPERIMENTAL|TMC435 25 mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B).
62299777|NCT00561353|EXPERIMENTAL|TMC435 75mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily for 21 days with PegIFNα-2a (P) and ribavirin (R) OR TMC435 75 mg once daily coadministered with PR for 28 days (Panel B).
62299778|NCT00561353|PLACEBO_COMPARATOR|Placebo (Cohort 1/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 25/75 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR and Placebo once daily coadministered with PR for 28 days (Panel B).
62670476|NCT06494813|ACTIVE_COMPARATOR|cases|patients with rheumatoid arthritis who fulfilled the EULAR/ACR Criteria 2010 for the Classification of RA
62670477|NCT03174275|EXPERIMENTAL|Low Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive adjuvant durvalumab (750 mg) once every two weeks x 3 cycles"
62108654|NCT04993391|EXPERIMENTAL|160mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
62108655|NCT04993391|EXPERIMENTAL|240mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
62108656|NCT04993391|EXPERIMENTAL|320mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
62108657|NCT02030028|OTHER|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
62108658|NCT03068637|EXPERIMENTAL|Care planning platform usage|This intervention will focus on the use of the Carevive care planning software for multiple myeloma patients age 65 and older who are at a treatment decision-making timepoint.
62299779|NCT00561353|EXPERIMENTAL|TMC435 200 mg (Cohort 2, Panel A and B)|Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 200 mg once daily coadministered with PR for 28 days (Panel B).
62299780|NCT00561353|PLACEBO_COMPARATOR|Placebo (Cohort 2/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR placebo once daily coadministered with PR for 28 days (Panel B).
62299781|NCT00561353|EXPERIMENTAL|TMC435 75 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
62299782|NCT00561353|EXPERIMENTAL|TMC435 150 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
62108659|NCT03883438|ACTIVE_COMPARATOR|Coronally advanced flap and acellular dermal graft|In CAF group, after local anesthesia oblique beveled vertical incisions were made at the most mesial and distal line angles of the recessions. These two incisions were connected with an intra-sulcular and interdental sub-marginal incisions in order to create the external surgical papillae. Then the flap was elevated as a split-full-split approach. The apical portion of the flap was reflected as close to the periosteum as possible by mesio-distal and apical sharp dissection parallel to the mucosa to release residual muscle tension and extended beyond the muco-gingival junction to facilitate the passive coronal replacement of the flap over the defects. In both groups ADMG was used as a sub-epithelial graft considering the manufacturer's instructions. The graft was positioned at the level of cemento-enamel junction and extended to the surrounding bone in the apical direction with full closure of the exposed root surfaces.
62108660|NCT03883438|EXPERIMENTAL|Modified coronally advanced flap and acellular dermal graft|Test group received CAF avoiding vertical releasing incisions (mCAF).
62108661|NCT05739513|OTHER|Patients with COVID-19|blood sampling for miRNA analysis
62108662|NCT05739513|OTHER|Patients without COVID-19|blood sampling for miRNA analysis
62108663|NCT02026076|EXPERIMENTAL|manual unloading|All subjects will first undergo a manual unloading test, followed by a single application of mechanical lumbar traction to determine predictive effect
62108664|NCT01477619|EXPERIMENTAL|Smokers|Split into BMI categories
62108665|NCT01477619|EXPERIMENTAL|Non-Smokers|Gender, age, and BMI matched to Smokers
62108666|NCT01477619|EXPERIMENTAL|Elderly|
62108667|NCT04688268||deep neuromuscular blockade|patients who underwent surgery with deep neuromuscular blockade
62108668|NCT06630637|EXPERIMENTAL|Personalized Health Intervention Arm|This arm involves the the single participant following a personalized regimen that includes intermittent fasting, exercise routines, heat/cold interventions, diet modifications, and supplementation. The participant will engage in continuous monitoring of metabolic changes using wearable technology, continuous glucose monitoring, and ketone measurements, along with blood, saliva, and stool lab tests. The goal is to assess the effects of these interventions on metabolic health and overall well-being, identifying potential trends and correlations throughout the study period.
62108669|NCT02733250|OTHER|Pembrolizumab + Nab-Paclitaxel|"Phase I will determine the recommended Phase II dose (RP2D) of nab-paclitaxel when given in combination with pembrolizumab. Escalation for nab-paclitaxel will be conducted following a 3+3 design. First cohort of 3 patients will receive nab-paclitaxel on Days 1 and 8 at a dose of 100 mg/m2 intravenous (IV) in combination with pembrolizumab at 200 mg IV every 3 weeks. If no dose limiting toxicities (DLT) occur, the dose of nab-paclitaxel will be escalated to 100 mg/m2 on Days 1, 8 and 15 every 3 weeks. The dose of pembrolizumab will remain the same. If no DLTs occur, dose level 2 will be defined as the RP2D. In the Phase II, pembrolizumab will be administered at 200 mg IV every 3 weeks and nab-paclitaxel will be administered at the RP2D."
62108670|NCT05490654|EXPERIMENTAL|Abdominal Massage|Study participants who will receive abdominal massage by manual or device delivered for 6 weeks
62108671|NCT05490654|NO_INTERVENTION|Control|Participants who will have no change to their normal treatment regime
62299783|NCT00561353|EXPERIMENTAL|TMC435 200 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
62299784|NCT00561353|PLACEBO_COMPARATOR|Placebo (Cohort 4/Panel C)|Treatment-experienced non-responders received placebo once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
62108672|NCT06022536|EXPERIMENTAL|1mg dose group|The 1mg dose group is a low dose group and only safety and tolerability will be evaluated, pharmacokinetics and immunogenicity will not be evaluated, therefore one subject is planned to be enrolled.1mg SSS40 was injected subcutaneously on day1.
62108673|NCT06022536|EXPERIMENTAL|3mg dose group|Four subjects were included in the 3mg dose group (trial group: 3:1 placebo group).3mg SSS40/Placebo was injected subcutaneously on day1.
62108674|NCT06022536|EXPERIMENTAL|10mg、20mg、30mg、 45mg、60mg or 80mg dose group|Sentinel dosing was used starting with the 10 mg group, with two subjects first enrolled and randomized 1:1 (test drug:placebo) for sentinel dosing, with sentinels participating in blinding, and then after the sentinel group had completed the 72-h safety assessment, the rest of the subjects in the group were randomized to receive dosing according to the test drug group versus the placebo group.10mg、20mg、30mg、 45mg、60mg or 80mg SSS40/Placebo was injected subcutaneously on day1.
62108675|NCT06469840||Parents|Parents of a child aged 18 to 42 months with a diagnosis of delayed motor development
62108676|NCT06469840||Expert group|Pediatric rehabilitation professionals
62108677|NCT03890640|EXPERIMENTAL|Ultrasound-guided TECI|After assessment of the epidural space using the loss of resistance technique with saline under ultrasound guidance, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
62108678|NCT06630663|ACTIVE_COMPARATOR|standard care|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
62299785|NCT00561353|EXPERIMENTAL|TMC435 200 mg (Cohort 5/Panel D)|Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
62299786|NCT01011257|ACTIVE_COMPARATOR|Aspirin 81 mg, 1 tab twice daily|All participants to take one aspirin (81mg per tab) twice daily.
61914736|NCT04649580||One-to-one interviews|
61914737|NCT03003299|EXPERIMENTAL|TAVR - Failing surgical or transcatheter valve|Patients with a failing surgical or transcatheter bioprosthetic valve will undergo transcatheter aortic valve replacement (TAVR).
61914738|NCT02057042|EXPERIMENTAL|PS-cCBT|peer-assisted computerized CBT
61914739|NCT02057042|ACTIVE_COMPARATOR|EUC|Enhanced usual care
61914740|NCT02542930|EXPERIMENTAL|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
61914741|NCT05054842|EXPERIMENTAL|treatment group A|
61914742|NCT05054842|PLACEBO_COMPARATOR|treatment group B|
61914743|NCT01663077|EXPERIMENTAL|Clozapine|Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month
61914744|NCT02068768||Operated Subjects|Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1
62108679|NCT06630663|EXPERIMENTAL|A Wearable Device and AI-Supported Diet and Exercise intervention|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
62108680|NCT04367376|EXPERIMENTAL|manual therapy|The control group will receive central postero-anterior grade III mobilization through the pisiform grip method at the level of pain in the lumbar spine.
62108681|NCT04367376|EXPERIMENTAL|instrumental manual therapy|the intervention groub rcieved central postero-anterior mobilization with a force of 20-30 N through physiotherapy instrument mobilization at the level of pain in the lumbar spine.
62108682|NCT02375516|EXPERIMENTAL|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions.
62108683|NCT02375516|NO_INTERVENTION|Control group|Youths assigned to the control arm will receive no intervention.
62670478|NCT03174275|EXPERIMENTAL|Medium Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive ipsilateral involved field radiation concurrent with weekly cisplatin 30mg/m2. Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
62108684|NCT01249300||Dysphagia|Patients with CVA which causes dysphagia
61914745|NCT03168529|ACTIVE_COMPARATOR|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
61914746|NCT03168529|PLACEBO_COMPARATOR|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
62108685|NCT00587288|EXPERIMENTAL|Reslizumab 3 mg/kg|Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
62470138|NCT05519683|EXPERIMENTAL|TEA at location C|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
62670479|NCT03174275|EXPERIMENTAL|High Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- All patients will be treated with intensity modulation radiation therapy (IMRT) concurrent with weekly cisplatin 30mg/m2 or other standard of care chemoradiotherapy regimen.Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
62108686|NCT00587288|PLACEBO_COMPARATOR|Placebo|Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
62108687|NCT05593042|ACTIVE_COMPARATOR|Heterologous group receiving CoronaVac®|General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of CoronaVac®
62108688|NCT05593042|EXPERIMENTAL|Heterologous group receiving Omicron vaccine|General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of Omicron vaccine
62299787|NCT01011257|ACTIVE_COMPARATOR|Clopidogrel 75 mg 1 tab daily|Only stable CAD participants will take Clopidogrel (75mg per tab) daily.
61914747|NCT03472443|EXPERIMENTAL|Sinew Acupuncture|
61914748|NCT03472443|NO_INTERVENTION|Waitlist|
61914749|NCT06416995||Control Group|Pregnant women who do not have any pregestational disease, who gave a blood sample in the first trimester for the study, who did not develop any pregnancy-related disease during their pregnancy, and who gave birth at term.
61914750|NCT06416995||Adverse Perinatal Outcome Group|Pregnant women who do not have any pregestational disease and who gave a blood sample in the first trimester for the study and who develop preeclampsia, gestational hypertension, preterm birth, fetal growth restriction, and gestational diabetes mellitus in the later weeks of pregnancy.
62108689|NCT05593042|EXPERIMENTAL|Heterologous group receiving a trivalent vaccine|General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of trivalent vaccine
62299788|NCT01856673|EXPERIMENTAL|ARM 1: Component-Based Intervention|Common Elements Treatment Approach (CETA) only
62299789|NCT01856673|EXPERIMENTAL|ARM 2: Community Group Therapy|Narrative Community Group Therapy (NCGT) only
62299790|NCT01856673|OTHER|ARM 3: Standby group|Standby group without intervention, but under monthly monitoring.
62470139|NCT05519683|EXPERIMENTAL|Escitalopram treatment|This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
62470140|NCT05810753|EXPERIMENTAL|SPOONful|Participants will be asked to consume one ONS with their breakfast, and one with their lunch, daily for three weeks.
62470141|NCT05810753|NO_INTERVENTION|Control|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks without any precise instruction regarding when to consume the ONS during the day (standard care).
62670480|NCT05507684|EXPERIMENTAL|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group 9 times for once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
62670481|NCT05507684|NO_INTERVENTION|Control|The control arm will receive individually usual care in assisted living facility (e.g. the existing social prescription as available) Usual care is the appropriate comparison rather than a placebo for complex interventions.
62108690|NCT05593042|EXPERIMENTAL|Homologous group receiving Omicron vaccine|Participants of the CoronaVac03CL study who have received the primary regimen and two booster doses with CoronaVac® vaccine; and who receive a booster dose of Omicron vaccine
62108691|NCT05593042|EXPERIMENTAL|Homologous group receiving a trivalent vaccine|Participants of the CoronaVac03CL study who have received the primary regimen and two booster doses with CoronaVac® vaccine and who receive a booster dose of trivalent vaccine
62108692|NCT00614406|EXPERIMENTAL|1|
62108693|NCT00614406|PLACEBO_COMPARATOR|2|
62108694|NCT00920296|EXPERIMENTAL|Cohort 1|All subjects
62108695|NCT04490148|ACTIVE_COMPARATOR|remote PFT (rPFT) longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment.
62108696|NCT04490148|EXPERIMENTAL|remote PFT (rPFT) + Nurse Coaching longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment, and receive monthly coaching from an ALS nurse.
62108697|NCT04727723||Lutathera®|Lutathera® will be administered according to the local label and according to the recommended treatment regimen in adults consisting of four equally divided doses of Lutathera® for a total of 29.6 GBq (800 mCi).
62108698|NCT03013348||Adults (22-99),|Male or female subject between the ages of 22-99, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
62108699|NCT03013348||Adolescents (13-21)|Male or female subject between the ages of 13-21, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
62299791|NCT01938183|PLACEBO_COMPARATOR|Full-mouth PD+placebo gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.
62299792|NCT01938183|ACTIVE_COMPARATOR|Full-mouth PD+Metronidazole tablet|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.
62299793|NCT01938183|ACTIVE_COMPARATOR|Full-mouth PD+Metronidazole benzoate gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.
62299794|NCT06205030|ACTIVE_COMPARATOR|NOSHIN SHAHD drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
62470142|NCT02188303|PLACEBO_COMPARATOR|Placebo (Single Dose, Cohorts 1-3)|Single dose of placebo matching LY2944876 administered subcutaneous (SC) on Day 1
62470143|NCT02188303|EXPERIMENTAL|LY2944876 (Single Dose, Cohorts 1-3)|Single dose of 10 milligrams (mg) of LY2944876 administered SC on Day 1
62470144|NCT02188303|PLACEBO_COMPARATOR|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1-7
62470145|NCT02188303|EXPERIMENTAL|LY2944876 (Multiple Dose, Cohort 4)|40 mg LY2944876 administered once daily SC on Days 1-7
62470146|NCT02188303|PLACEBO_COMPARATOR|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
62470147|NCT02188303|EXPERIMENTAL|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses of 15 mg on Day 1, 30 mg on Day 4, up to 60 mg on Day 6, and up to 80 mg on Days 8, 10 and 12 administered once daily SC
62299795|NCT06205030|PLACEBO_COMPARATOR|placebo|The placebo with the same appearance as the herbal syrup will be drinking nectar. All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received placebo 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
62470148|NCT00520234|ACTIVE_COMPARATOR|1 prophylaxis|Caspofungin 50 mg Intravenous (IV) daily up to 28 days of therapy
62670482|NCT04893031||Tocilizumab treatment group|Symptoms of hypoxia and systemic inflammation (SpO2 \<90% on room air with accompanying elevation of any two of the systemic inflammatory markers such as CRP, LDH and Ferritin) and / or acute bilateral infiltrations on chest radiography or rapid progression of existing infiltrations, but who did not need mechanical ventilation at admission and were given tocilizumab treatment.
62670483|NCT04893031||Standard treatment group|Patients who did not require mechanical ventilation in intensive care admission and did not receive tocilizumab treatment during any period of hospitalization.
62670484|NCT05357079|EXPERIMENTAL|Topical TXA Treatment|2 gm TXA/100 ml of normal saline
62108700|NCT03013348||Children (2-12)|Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
62108701|NCT04653350|EXPERIMENTAL|HIT-MMEX Group|In this group Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
62108702|NCT04653350|ACTIVE_COMPARATOR|Control Group|In this Group Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
62108703|NCT02817217|OTHER|SP2086 and Valsartan|
62108704|NCT00906620|EXPERIMENTAL|QPR intervention|"QPR intervention (Question, Persuade \& Refer): The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
62108705|NCT00906620|EXPERIMENTAL|Awareness program|The awareness programme is comprised of a leaflet, six posters and four seminars. The seminars are made up of one introductory lesson, and two interactive follow-up lessons with role play and one final meeting as a closing/debriefing lesson.
62299796|NCT01320228|PLACEBO_COMPARATOR|Control|Alli treatment plus placebo (rice flour)
62299797|NCT01320228|EXPERIMENTAL|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
62299798|NCT01320228|EXPERIMENTAL|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
62299799|NCT01320228|EXPERIMENTAL|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
62299800|NCT02636309|NO_INTERVENTION|control group|control group only filled up the questionnaires. They didn't receive intervention
62299801|NCT02636309|EXPERIMENTAL|intervention group|physical therapy at work
62299802|NCT06427447|EXPERIMENTAL|adjuvant chemoradiotherapy|"Chemotherapy: Gemcitabine plus capecitabine Gemcitabine, 1000mg/m2，d1, 8, every 3 weeks as a cycle. Capecitabine, 825-1000mg/m2，bid, d1-14, every 3 weeks as acycle. A total of 6 cycle should be delivered.~Chemoradiotherapy: 2-3 weeks after chemotherapy, adjuvant chemoradiotherapy is given. Radiation dose: 50-54Gy (1.8-2.0Gy per fraction). Concurrent capecitabine, 825mg/m2，bid."
62299803|NCT06427447|ACTIVE_COMPARATOR|adjuvant chemotherapy|Gemcitabine, 1000mg/m2，d1, 8, every 3 weeks as a cycle. Capecitabine, 825-1000mg/m2，bid, d1-14, every 3 weeks as acycle. A total of 6 cycle should be delivered.
62470149|NCT00520234|PLACEBO_COMPARATOR|2 placebo|Normal Saline 100 cc IV daily
62470150|NCT00904345|EXPERIMENTAL|Treatment|
62108706|NCT00906620|EXPERIMENTAL|ProfScreen|The program's primary objective is to help young people and their parents through the early identification of mental health problems, such as anxiety, depression, substance abuse, and suicide. Screening strategies are based on the valid premise that suicidal adolescents are under-identified, suffer from an active, often treatable mental illness such as depression and exhibit identifiable risk factors (Gould et al. 2003). A potential shortcoming of screening programs is that asking about suicide could increase suicidal ideation and behaviour. About this issue a recent study (Gould et al . 2005) on over 2300 students reported no evidence of iatrogenic effects of suicide screening and that screening in high schools is a safe component of youth suicide prevention efforts.
62299804|NCT06487377|EXPERIMENTAL|IX001 TCR-T cells|IX001 TCR-T cells targeted for KRAS mutation
62470151|NCT00127946|ACTIVE_COMPARATOR|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
62470152|NCT00127946|NO_INTERVENTION|placebo|This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
62470153|NCT05180253||Healthy Subjects|
62670485|NCT05357079|PLACEBO_COMPARATOR|No Topical Treatment|Normal saline
62670486|NCT01913470|EXPERIMENTAL|Losartan then Placebo|0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
62670487|NCT01913470|EXPERIMENTAL|Sugar pill|placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks
62670488|NCT03372915|ACTIVE_COMPARATOR|Standard Exposure|This arm will receive exposure therapy conducted according to standard care practices.
62670489|NCT03372915|EXPERIMENTAL|Exposure + Inhibitory Learning|This arm will receive exposure therapy conducted according to principles of inhibitory learning.
62670490|NCT03753542|EXPERIMENTAL|Intervention|The Intervention group will received multimedia education, booklet and weekly tele-nursing follow-up about chemotherapy and side effects management
62670491|NCT03753542|NO_INTERVENTION|Control|The Control group will receive routine care
62670492|NCT05654207|EXPERIMENTAL|WeCare|WeCare system of care - universal screening, ED-based intervention, text message follow-up.
62108707|NCT00906620|EXPERIMENTAL|Control group|The control group will comprise 250 subjects. After the baseline assessment, subjects will be randomized in one of the three intervention arms or in the control group. Individuals in the control group will undergo the same baseline and follow-up evaluations as subjects in the intervention arms and will receive the same leaflet about healthy lifestyles with information about the possibility to seek help for unhealthy, suicidal behaviour and mental health problems. In this arm, no additional intervention will be performed although the possibility of seeking help from mental health resources will be available.
62108708|NCT05903963|ACTIVE_COMPARATOR|Midazolam group|
62108709|NCT05903963|ACTIVE_COMPARATOR|dexmedetomidine group|
62108710|NCT01899872|EXPERIMENTAL|Patients with type 1 diabetes|Patients with type 1 diabetes
62108711|NCT04043767||Pediatric patients aged between 1-8 years|Pediatric patients aged between 1-8 years who scheduled for general anesthesia in elective surgery. Additional physical examinations which were including thyromental distances, hyomental distances and neck circumferences, was performed at one day prior surgery. Intubation was done by general anesthesiologist in order to grade the laryngoscopic view.
62108712|NCT05506709|EXPERIMENTAL|Test|Subjects receive only the test product (medical device/nasal pump containing moderately hypertonic solution produced based on 100% natural sea water rich of marine trace elements with added manganese and calcium)
62299805|NCT05177796|EXPERIMENTAL|Treatment (panitumumab,pembrolizumab,neoajuvant chemotherapy)|"CYCLES 1-4: Patients receive pembrolizumab IV over 30 minutes and panitumumab IV over 30-60 minutes on day 1 of cycle 0. Cycle 0 continues for 7 days in the absence of disease progression or unacceptable toxicity. Patients then receive panitumumab IV over 30-60 minutes on days 1, 8, and 15 of cycles 1-3 and days 1 and 8 of cycle 4, pembrolizumab IV over 30 minutes on day 1 of cycles 2-4, paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1, 8 and 15 of cycles 1-4. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CYCLES 5-8: Patients receive standard of care treatment, including pembrolizumab IV over 30 minutes, doxorubicin IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
62299806|NCT02528344|EXPERIMENTAL|HIIT - RA|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
62299807|NCT05049785|ACTIVE_COMPARATOR|Arm I (counseling)|Patients attend 13 nutrition counseling sessions over 45 minutes each for 1 year. Patients may receive nutrition handouts.
61914751|NCT00829985|EXPERIMENTAL|Glycerinated German Cockroach Allergenic Extract|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume \[w/v\]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
61914752|NCT00829985|PLACEBO_COMPARATOR|Placebo|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered daily doses of placebo placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The placebo was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 weight per volume \[w/v\]) was achieved.
62299808|NCT05049785|EXPERIMENTAL|Arm II (nutrition and PA intervention)|Patients attend 2 tasting sessions for low-fat and low-sugar recipes and complete 2 PA sessions over 1 hour for each session.
62108713|NCT05452993|EXPERIMENTAL|1 - Retinophotography for diabetic retinopathy screening|Patients who accepted to participate to this study and had retinophotography for diabetic retinopathy screening.
62108714|NCT05452993|NO_INTERVENTION|2 - No screening|Patients who did not meet inclusion criteria and/or refused the retinophotographies screening.
62670493|NCT05654207|NO_INTERVENTION|Usual Services|Usual care for youth presenting to the ED will be the control condition.
62108715|NCT02677974||On-X Aortic Heart Valve replacement|Patients with On-X Aortic Valve maintained on low dose warfarin anticoagulation with an INR target of 1.5 to 2.0, with or without home monitoring.
62108716|NCT06112717|EXPERIMENTAL|Nursing Care|Seven home visit was made to adolescent in the intervention group. In the first and last visits only self-care knowledge and skills of adolescents were evaluated. In the 2.,3.,4.,5. and 6. home visits they received supportive-educational individualised nursing care based on Orem's Self Care Deficit Nursing Theory. The applied nursing interventions varied based on the individual needs and the level of assistance required by each adolescent. Each home visit lasted 30-60 minutes. Adolescents were given an educational booklet containing information about self-care in cystic fibrosis.
62108717|NCT06112717|NO_INTERVENTION|Control Group|Adolescents in the control group received no intervention by the researcher.
62108718|NCT02357784|EXPERIMENTAL|Current Perception Threshold Testing|The subjects in this study will undergo Current Perception Threshold Testing and fill out several questionnaires both before their Sacral Nerve Modulator device implantation and again 3 months after the device implantation.
62299809|NCT04791943|EXPERIMENTAL|Experimental Treatment - Melatonin|Premedication for three nights with 10mg melatonin
62299810|NCT04791943|PLACEBO_COMPARATOR|Control Treatment - Lactose|Premedication for three nights with lactose capsules
62299811|NCT04390685|EXPERIMENTAL|Tacrolimus ointment|Apply whole arm, in a thin layer, once daily for one year
62670494|NCT03409458|EXPERIMENTAL|PT-112 in combination with avelumab|"PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion~Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study."
62670495|NCT02898831|NO_INTERVENTION|Control/No Intervention|Standard clinical procedure with intrauterine device insertion involving no heated/cold compresses on the abdomen during insertion.
62670496|NCT02898831|EXPERIMENTAL|Cold Compress/Experimental|Cold compress (intervention) placed on abdomen just before IUD insertion and remains throughout insertion. Pain scale and survey completed following insertion regarding pre-procedure and intra-procedure pain.
62670497|NCT01294072|EXPERIMENTAL|Arm 1: Curcumin alone|Subjects take curcumin orally.
62108719|NCT02703727||OAC|Patients on oral anticoagulation therapy (OAC) will receive a pharmacists led medication review with a focus on anticoagulation therapy (extended polymedication check)
62108720|NCT03669562|EXPERIMENTAL|Alprostadil liposome|
62108721|NCT03669562|PLACEBO_COMPARATOR|Placebo|
62108722|NCT03265717|EXPERIMENTAL|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
62108723|NCT03265717|EXPERIMENTAL|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as \<0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
62299812|NCT04390685|NO_INTERVENTION|Control|
62299813|NCT04214080|EXPERIMENTAL|Study Group (SG)|"In addition to feeding and oral motor intervention strategies, intensive neck and trunk stabilization exercises based on Neurodevelopmental treatment-Bobath (NDT-B) concept principles were applied to this group.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
62299814|NCT04214080|PLACEBO_COMPARATOR|Control Group (CG).|"(NDT-B) concept approaches and feeding and oral motor intervention strategies were applied to this group in routine treatment.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
62670498|NCT01294072|EXPERIMENTAL|Arm 2: Curcumin with plant exosomes|Subjects take curcumin conjugated with plant exosomes.
62670499|NCT01294072|EXPERIMENTAL|Arm 3: no treatment|subjects will not take curcumin or plant exosomes
61914753|NCT01652300|EXPERIMENTAL|test group|For test group intervention was two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
62108724|NCT05887310||Patients with drug-resistant psychiatric disorders|
62108725|NCT05027087|EXPERIMENTAL|Treatment|Participants receive the blueberry gummy supplement
62108726|NCT05027087|PLACEBO_COMPARATOR|Placebo|Participant receive the placebo gummy supplement
62299815|NCT03386708|EXPERIMENTAL|hUC-MSC intrauterine injection group|Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)
62670500|NCT03389750|ACTIVE_COMPARATOR|Intravenous Challenge Drug: Oxymorphone|Intravenous (IV) Dose Range: 1.8, 3.2, 5.6, 10 mg/70kg of the participant's body weight
62670501|NCT03389750|ACTIVE_COMPARATOR|Intravenous Challenge Drug: Oxycodone|IV Dose Range: 10, 18, 32, 56 mg/70kg of the participant's body weight
62670502|NCT03389750|ACTIVE_COMPARATOR|Intravenous Challenge Drug: Hydromorphone|IV Dose Range: 3.2, 5.6, 10, 18 mg/70kg of the participant's body weight
62670503|NCT03389750|PLACEBO_COMPARATOR|Intravenous Challenge Drug: Placebo|IV saline
62670504|NCT03248804|EXPERIMENTAL|Soy Group|Subjects in the soy group were asked to participate in the Colorado Diet program and to consume 3 soy food items per day.
61914754|NCT01652300|OTHER|control|received no education
61914755|NCT02317146|EXPERIMENTAL|Six Hours Postpartum|The woman received magnesium sulfate for 6 hours after delivery as prophylaxis to eclampsia.
61914756|NCT02317146|ACTIVE_COMPARATOR|Twenty-four hours Postpartum|The woman received magnesium sulfate for 24 hours after delivery as prophylaxis to eclampsia.
62108727|NCT05245851|EXPERIMENTAL|Opportunistic screening for low BMD|Outpatients aged over 50 years undergoing x-ray of the thoracic spine, lumbar spine, chest, pelvis, hand or knee will have their x-rays screened for low BMD by the software-as-a-medical device. If low BMD is identified by the software, a radiologist reviewing the x-ray may choose to incorporate this as an incidental finding in their report to the referring physician.
62299816|NCT05420766|EXPERIMENTAL|Shortened Sleep|In this 4-week sleep protocol, children in this experimental condition follow a Stabilized Sleep schedule (i.e., their usual bed time) during weeks 1, 3 and 4. During week 2, they follow a Shortened Sleep schedule, during which they go to bed 90 later than is typical.
62299817|NCT05420766|ACTIVE_COMPARATOR|Usual Sleep Schedule|In this control arm of the 4-week sleep protocol, children follow the Stabilized Sleep schedule for all 4 weeks.
62299818|NCT06341231||Elderly patients with pulmonary thromboembolism|
62299819|NCT06341231||Pulmonary thromboembolism patients with renal insufficiency|
62299820|NCT06341231||Pulmonary thromboembolism patients with co-existing malignancy|
62299821|NCT00004980|EXPERIMENTAL|active rTMS|1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
62299822|NCT00004980|PLACEBO_COMPARATOR|sham stimulation|Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
62299823|NCT06623981|EXPERIMENTAL|Enhanced IPT-B|Enhanced Brief Interpersonal Psychotherapy
62299824|NCT06623981|ACTIVE_COMPARATOR|Supplemented Usual Care|Short-term care coordination
62299825|NCT05520879|EXPERIMENTAL|To provide Sharnali-1 to severe acute malnourished children|We will provide Sharnali-1 among 225 severe acute malnourished children to assess the proportion of children graduating from SAM to non-acute malnutrition status (MUAC ≥ 125 mm or WLZ/WHZ ≥ -2 for two consecutive weeks) by 90 days of intervention.
62299826|NCT05520879|EXPERIMENTAL|To provide Sharnali-2 to severe acute malnourished children|We will provide Sharnali-2 among 225 severely acute malnourished children to assess the proportion of children graduating from SAM to non-acute malnutrition status (MUAC ≥ 125 mm or WLZ/WHZ ≥ -2 for two consecutive weeks) by 90 days of intervention.
62299827|NCT06203431|EXPERIMENTAL|Drug ET-26|
62670505|NCT03248804|OTHER|Non-soy Group|Subjects in the non-soy group were asked to participate in the Colorado Diet program and to avoid soy food products.
62670506|NCT05659420|EXPERIMENTAL|High intensity interval training|
62670507|NCT05659420|ACTIVE_COMPARATOR|Moderate intensity continous training|
62670508|NCT05659420|PLACEBO_COMPARATOR|Control|
62670509|NCT03961035||25% cycle ratio|Patients group treated with CPCTSI at a 25% cycle ratio
61914757|NCT01537107|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62670510|NCT03961035||31.3% cycle ratio|Patients group treated with CPCTSI at a 31.3% cycle ratio
61914758|NCT05438901|EXPERIMENTAL|before and after application|Before the hirudotherapy application, it was planned to study the oxidant and antioxidant parameters in the venous blood of the patient. In addition, it was planned to study the oxidant and antioxidant parameters in the patient's venous blood after 2 sessions of Hirudotherapy, 1 month apart.
61914759|NCT02692898||1|Archived CNS neoplasm specimens, in which primary diagnostic studies are complete, and for which there is excess tissue for analysis in the form of unstained slides or paraffin blocks
62108728|NCT04101123||Children and adolescents with cancer|Children and adolescents between 10-18 years with newly diagnosed leukemia, brain tumors, and sarcomas
62108729|NCT03248011|EXPERIMENTAL|Flexibility|Stretching exercise
62108730|NCT03248011|EXPERIMENTAL|Strength|Eccentric hamstring strengthening exercise
62108731|NCT03248011|EXPERIMENTAL|Neuromuscular|Balance exercise
62108732|NCT03248011|NO_INTERVENTION|Control|No exercise
62108733|NCT01947179|NO_INTERVENTION|Physical Health Training|The Physical Health Training condition will include information on the importance and benefits of a healthy lifestyle. Additionally, the program will discuss guidelines for a healthy lifestyle including information on diet, water consumption, exercise, and sleep.
62108734|NCT01947179|EXPERIMENTAL|Anxiety Risk Reduction|The anxiety risk reduction intervention will include psychoeducation focused on the nature of stress and its effect on the body. Interoceptive exposure exercises that were designed to correct the conditioned fear of bodily sensations will be explained and practiced.
62108735|NCT05112718|EXPERIMENTAL|Platelet Rich Plasma|The patients who receive PRP injections
62108736|NCT05112718|SHAM_COMPARATOR|Normal Saline|The patients who receive normal saline
62108737|NCT00137605|EXPERIMENTAL|Pneumovax/immediate|
62108738|NCT00137605|EXPERIMENTAL|Pneumovax/delayed|
62108739|NCT00137605|EXPERIMENTAL|Prevnar/immediate|
62299828|NCT06203431|ACTIVE_COMPARATOR|Drug Etomidate|
62670511|NCT06243159|EXPERIMENTAL|JY231 injection for the treatment of refractory autoimmune diseases (ADs) Early exploratory clinica|Infusion of JY231 Injection by dose of 1-10×10\^6 transducing units(TU)/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
62670512|NCT04799665||All Participants|
62670513|NCT03684057|EXPERIMENTAL|TAU + App-Delivered Mindfulness Training (MT)|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
62670514|NCT03684057|OTHER|Treatment as Usual (TAU)|Individuals in the TAU group will complete the assessments without an intervention. (Note: participants will be transitioned to the Unwinding Anxiety program following the 2-month wait list control period)
62670515|NCT01641783|EXPERIMENTAL|nanoparticle Albumin-bound paclitaxel|evaluate one dose level of nab-paclitaxel:125mg/m2
62108740|NCT00137605|EXPERIMENTAL|Prevnar/delayed|
62108741|NCT02061111||Subclinical thyroid disease|26 pregnant women with subclinical hypothyroidism and/orTPO-antibodies, and their offspring.
62108742|NCT02061111||Healthy controls|51 pregnant women without thyroid disease or any other metabolic disorders, and their offspring.
62108743|NCT05070104|EXPERIMENTAL|Single Arm|CPI-613 mFFX Bevacizumab
62108744|NCT04816825|EXPERIMENTAL|Exergaming|The combination of 1) game-console based exercise programs, 2) specifically designed by professional physiotherapists with focus on subjects with a chronic lung disease and 3) weekly distant monitoring with close supervision by a physiotherapist. Individually prescribed exercise program based on tests of patient's physical fitness.
62108745|NCT04816825|ACTIVE_COMPARATOR|Standard rehabilitation|Standard rehabilitation at the COPD-Center. This includes recommendations about physical activity according to the general guidelines, however, individualized after each subject's physical fitness level.
62108746|NCT04420286||Hospital having ICU beds|Hospital having ICU beds during COVID-19 outbreak in France
62108747|NCT02930343|ACTIVE_COMPARATOR|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
62299829|NCT02261441||Group 1|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study
62670516|NCT00412451|EXPERIMENTAL|Ocriplasmin 25µg|25µg ocriplasmin intravitreal injection versus sham injection
61914760|NCT06092060|EXPERIMENTAL|the group GS|probiotic treatment group, ca. 20 participants
61914761|NCT06092060|PLACEBO_COMPARATOR|the group GP|placebo group, ca. 20 participants
61914762|NCT03443557||oral nutrition supplement group|hospitalized malnourished patients who were received oral nutrition supplement during hospital course
62299830|NCT04442607|EXPERIMENTAL|AI arm|Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis
62299831|NCT01044355|ACTIVE_COMPARATOR|auto-titrating|Patients being treated for 6 weeks with auto-titrating continuous airway pressure.
62299832|NCT01044355|ACTIVE_COMPARATOR|Fixed|Patients receiving 6 weeks of treatment with fixed continuous positive airway pressure.
62670517|NCT00412451|EXPERIMENTAL|Ocriplasmin 75µg|75µg ocriplasmin intravitreal injection versus sham injection
61914763|NCT03443557||control group|hospitalized malnourished patients who were received only hospital food during hospital course
61914764|NCT03932006|EXPERIMENTAL|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
62108748|NCT02930343|ACTIVE_COMPARATOR|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
62108749|NCT02837237|EXPERIMENTAL|KBP-5074|Single oral dose
62108750|NCT01428349|EXPERIMENTAL|Attention to Context|
62108751|NCT01428349|EXPERIMENTAL|Affective Cognitive Control|
62108752|NCT06629649|EXPERIMENTAL|The Federally Qualified Health Centers (FQHCs)|Eight FQHCs will participate in this project. Four FQHCs will implement a glaucoma screening protocol and a protocol for detecting diabetic retinopathy, cataract, and visual acuity impairment, while the other four will be standard of care without the above screening protocol.
62108753|NCT06629649|NO_INTERVENTION|Primary Standard of Care|Primary care provider asks participants if they are having symptoms or problems with their eyes or vision.
62108754|NCT06140680|EXPERIMENTAL|LifelongU|"Four modules that performed face-to-face physical education lessons:~1. health-related fitness knowledge~2. fitness test and training~3. motor skill training~4. behavior change techniques (habit formation and implementation intention)"
62108755|NCT06140680|ACTIVE_COMPARATOR|Physical education|Classic physical education lessons: physical fitness training and skill training
62108756|NCT03746418|PLACEBO_COMPARATOR|Group I|received 20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.
62108757|NCT03746418|ACTIVE_COMPARATOR|Group II|received 20 ml of 0.25% bupivacaine with supplementation of 1 mL containing 100µg dexmedetomidine bilaterally
62108758|NCT00764413|ACTIVE_COMPARATOR|1|Both study arms receive both active treatment = methylprednisolone and an inactive treatment = Sodium chlorid (dummy)
62108759|NCT00764413|ACTIVE_COMPARATOR|2|Both arms receives both active treatment and inactive treatment = dummy. Active treatment is methylprednisolone, inactive treatment is sodium chlorid.
62470154|NCT06561100|EXPERIMENTAL|Sub-symptomatic Adaptable Exercise Treatment (SAET)|Participants will attend two in-clinic sessions per week with either a licensed Physical Therapist or Exercise Physiologist and complete three sessions per week independently outside of the clinic. Each session will be 1 hour in duration, 5 days a week for 8 weeks, for a total of 40 hours. Participants will complete a combination of aerobic and resistance training exercises prescribed and adapted to the participant's personal needs based on evaluations by the Physical Therapist and Exercise Physiologist. Exercise will be adjusted to maintain sub-symptomatic levels, meaning that if a participant's neurobehavioral symptoms increase with activity, the intensity and/or exercise will be modified. Furthermore, participants will be asked to fill out an Exercise Habits Questionnaire (EHQ) in order to capture the exercises they are currently doing.
62470155|NCT06561100|ACTIVE_COMPARATOR|Stretching Control Group (SCG)|Participants will attend two in-clinic sessions per week with either a licensed Physical Therapist or Exercise Physiologist and complete three sessions per week independently outside of the clinic. Each session will be 1 hour in duration, 5 days a week for 8 weeks, for a total of 40 hours. The stretching exercises are designed not to increase heart rate or have excessive head motion consist of static stretching and yoga based movements.
62108760|NCT04300335|EXPERIMENTAL|High Risk - Individual Exercise|Patients who show an increased fracture risk and/or increased risk of fall in the screening assessments and are therefore allocated to an individualized personal training.
62108761|NCT04300335|EXPERIMENTAL|Low Risk - Group Exercise|Patients who show neither increased fracture risk nor increased risk of fall in the screening assessments and are therefore allocated to the exercise group.
62470156|NCT05975697|EXPERIMENTAL|Experimental group to be applied FES|FES treatment to the deltoid, triceps, extensor carpi radialis muscles for a total of 10 sessions, 30 minutes twice a day (in the morning and in the evening), for 5 days after the first 24th hour after the thrombectomy procedure in the experimental group patients (Program duration is 15 minutes and resting time is 15 minutes). minutes) will be applied.
61914765|NCT03932006|EXPERIMENTAL|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
62108762|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
62108763|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
62108764|NCT02700867|EXPERIMENTAL|Proximal tibia|Assumption of intraosseous access into the proximal tibia. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
62108765|NCT02700867|EXPERIMENTAL|Proximal humerus|Assumption of intraosseous access into the proximal humerus. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
62108766|NCT02008734|NO_INTERVENTION|Control|
62108767|NCT02008734|EXPERIMENTAL|PD0332991|Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.
61914766|NCT03932006|ACTIVE_COMPARATOR|Imrecoxib|Imrecoxib 0.1g twice a day,orally
62670518|NCT00412451|EXPERIMENTAL|Ocriplasmin 125µg|125µg ocriplasmin intravitreal injection versus sham injection
62670519|NCT00412451|SHAM_COMPARATOR|sham injection|Sham injection
62670520|NCT04253860|EXPERIMENTAL|TENS|Transcutaneous electrical neurostimulation will be applied for 30 minutes three times a week during 90 days
62670521|NCT04253860|SHAM_COMPARATOR|Sham|A sham comparator will be applied for 30 minutes three times a week during 90 days. The device does not emit electrical impulses
62670522|NCT01172301|EXPERIMENTAL|Oral EAA vs total AA supplement|
62670523|NCT00875901|EXPERIMENTAL|Peripherally located lung tumor|12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent
62108768|NCT04157257|EXPERIMENTAL|QL-007 +TDF|QL-007 200 mg BID +TDF 300 mg QD
62108769|NCT04157257|EXPERIMENTAL|QL-007 +Entecavir|QL-007 200 mg BID +Entecavir 0.5 mg QD
62108770|NCT04157257|ACTIVE_COMPARATOR|TDF monotherapy|TDF tablet 300 mg QD
62108771|NCT04157257|ACTIVE_COMPARATOR|Entecavir monotherapy|Entecavir tablet 0.5 mg QD
62108772|NCT04763213||Invasive treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
62108773|NCT04763213||Medically treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
62108774|NCT06465667|EXPERIMENTAL|Group 1 dashboard (3 months) then dashboard with Precision feedback (12 months)|Months 0-3 dashboard only, months 3-15 months dashboard with Precision feedback.
62108775|NCT06465667|EXPERIMENTAL|Group 2 dashboard (6 months) then dashboard with Precision feedback (6 months)|Months 0-6 dashboard only, months 6-15 months dashboard with Precision feedback.
62108776|NCT06465667|EXPERIMENTAL|Group 3 dashboard (9 months) then dashboard with Precision feedback (6 months)|Months 0-9 dashboard only, months 9-15 months dashboard with Precision feedback.
62108777|NCT06465667|EXPERIMENTAL|Group 4 dashboard (12 months) then dashboard with Precision feedback (3 months)|Months 0-12 dashboard only, months 12-15 months dashboard with Precision feedback.
62108778|NCT03709446|EXPERIMENTAL|Leflunomide|"Women with HER2-negative metastatic and/or locally advanced, inoperable breast cancer.~Leflunomide tablet orally daily"
62108779|NCT00927823|EXPERIMENTAL|PF-04691502 Treatment|
62108780|NCT02246621|EXPERIMENTAL|Abemaciclib + NSAI|150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
62108781|NCT02246621|PLACEBO_COMPARATOR|Placebo + NSAI|Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
62108782|NCT04564391|ACTIVE_COMPARATOR|Whey protein group, 60g/day|Three weeks, daily supplementation with 60 g of whey protein
62108783|NCT04564391|ACTIVE_COMPARATOR|Casein protein group, 60 g/day|Three weeks, daily supplementation with 60 g of casein protein
62108784|NCT04564391|ACTIVE_COMPARATOR|pea protein group, 60g/day|Three weeks, daily supplementation with 60 g of pea protein
62108785|NCT04564391|PLACEBO_COMPARATOR|placebo arm|Three weeks, daily supplementation with placebo
62670524|NCT00875901|EXPERIMENTAL|Centrally located lung tumor|6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent
62108786|NCT03925194|EXPERIMENTAL|Anakinra|
62108787|NCT03925194|PLACEBO_COMPARATOR|Placebo|
62108788|NCT03168646|ACTIVE_COMPARATOR|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
62108789|NCT03168646|ACTIVE_COMPARATOR|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
62108790|NCT05972694|EXPERIMENTAL|Freeze-dried Grape powder intervention|participants will be supplemented with 46g/d freeze-dried grape powder consumed as 22.5g packets twice daily for 21 days.
62299833|NCT02400125||1|Patients underwent isolated or combined coronary artery bypass grafting surgery
62299834|NCT02400125||2|Patients underwent isolate or combined surgical treatment for heart valve disease
62299835|NCT03417765|EXPERIMENTAL|Cohort A: 5 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
62299836|NCT03417765|EXPERIMENTAL|Cohort B: 10 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
62670525|NCT04270786|EXPERIMENTAL|Early de-escalation|In the experiment arm, empirical antibiotics will be stopped and levofloxacin prophylaxis will be resumed in case of afebrile after 72 hours.
62670526|NCT04270786|OTHER|Standard|In the control group, empirical antibiotics will be continue until recovery of neutropenia or at least 7 days as standard clinical practice.
62670527|NCT02961725|EXPERIMENTAL|UCMSC treatment|UCMSC: umbilical cord mesenchymal stem cells
62670528|NCT02813720||Patients with peripheral PsA|
62670529|NCT02813720||Patients with psoriatic nail onycholysis|
62670530|NCT02813720||Patients with PsO only|
62670531|NCT02813720||Healthy match control subjects|
62670532|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA\<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
62670533|NCT03492268|EXPERIMENTAL|BCMA-CART|Autologous T cells transduced to express anti-BCMA chimeric antigen receptor (CAR)
62670534|NCT02781701|EXPERIMENTAL|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
61914767|NCT04415970|EXPERIMENTAL|Flotation Therapy|Participants will utilize flotation sensory deprivation tanks.
62108791|NCT04148937|EXPERIMENTAL|Phase 1a Cohort A LY3475070 (dose escalation)|Participants received 150 milligram (mg) once daily or 300 mg once daily or 300mg twice daily or 600mg once daily oral LY3475070 on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
62299837|NCT03417765|EXPERIMENTAL|Cohort C: 25 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
62670535|NCT03398382|PLACEBO_COMPARATOR|Magnesium citrate tablet group|In this group patients will take magnesium citrate tablets 3 days postoperatively, so 400 mg magnesium citrate tbl (Solgar) /per day will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
62670536|NCT03398382|PLACEBO_COMPARATOR|Placebo tablet group|"In this group patients will take placebo tablets 3 days postoperatively, so 400 mg /per day placebo tbl will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.~Placebo tablets will be identical to the right drug (Magnesium citrate tbl.Solgar)"
62670537|NCT03398382|PLACEBO_COMPARATOR|Magnesium citrate lozenge group|In this group patients will take 100 mg. magnesium citrate lozenge (Diasporal) 30 min. before the procedure and continue to take up to 4 lozenges per day over the next 3 days in the same time intervals as it was on the day of surgery.
62670538|NCT03398382|PLACEBO_COMPARATOR|Placebo lozenge group|"In this group patients will take 100 mg. placebo lozenge 30 min. before the procedure and continue to take up to 4 pastilles per day over the next 3 days in the same time intervals as it was on the day of surgery.~Placebo lozenges will be identical to the right drug (Magnesium citrate tbl.(Diasporal)"
62670539|NCT02827708|EXPERIMENTAL|Semaglutide|
62670540|NCT02827708|PLACEBO_COMPARATOR|Placebo|
62299838|NCT06185920||Patients with severe infection.|Patients with severe infection treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
62470157|NCT05975697|NO_INTERVENTION|control group|In the control group patients; From the first 24 hours after the thrombectomy procedure, the routine of the clinic (such as not performing a non-pharmacological procedure) is applied for 5 days, and no other procedure will be performed.
62470158|NCT05663411|EXPERIMENTAL|Treatment group A: SHR6508|
62470159|NCT05663411|EXPERIMENTAL|Treatment group B: SHR6508|
62470160|NCT05663411|ACTIVE_COMPARATOR|Treatment group C: Cinacalcet|
62470161|NCT03568565|EXPERIMENTAL|ePREP Program|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
62470162|NCT03568565|EXPERIMENTAL|ePREP Program plus Coach|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Couples also have four, brief video or phone calls with a coach throughout the program.
62470163|NCT03568565|EXPERIMENTAL|OurRelationship Program|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner.Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
62470164|NCT03568565|EXPERIMENTAL|OurRelationship Program plus Coach|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s). Couples also have four, brief video or phone calls with a coach throughout the program.
62470165|NCT03568565|NO_INTERVENTION|Waitlist|Participants are assessed at 1, 2, 4, and 6 months after randomization; however, no active intervention is given during the waitlist period.
62470166|NCT03552744|EXPERIMENTAL|Intervention group|
62470167|NCT03552744|NO_INTERVENTION|Control group|
62670541|NCT03250195|OTHER|PET/MRI|All participants will have a PET/MRI performed
62670542|NCT01390935||systolic heart failure|EF under 45%
62108792|NCT04148937|EXPERIMENTAL|Phase 1a Cohort B LY3475070 + Pembrolizumab (dose escalation)|Participants received 150 mg once daily or 150 mg twice daily or 300 mg once daily or 300mg twice daily oral LY3475070 on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.
62108793|NCT04148937|EXPERIMENTAL|Phase 1b Cohort C1 LY3475070 + Pembrolizumab (dose expansion)|"LY3475070 administered orally and pembrolizumab administered IV.~Based on Sponsor decision, Phase 1b expansion cohorts were not initiated."
62108794|NCT04148937|EXPERIMENTAL|Phase 1b Cohort C2 LY3475070 (dose expansion)|"LY3475070 administered orally.~Based on Sponsor decision, Phase 1b expansion cohorts were not initiated."
61914768|NCT04415970|ACTIVE_COMPARATOR|Sleep Pod|Participants will utilize sleep pods with partial sensory deprivation (no light and silence).
61914769|NCT02513147|EXPERIMENTAL|2 NRTI+ Dolutegravir|22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks
61914770|NCT02513147|ACTIVE_COMPARATOR|2 NRTI + PI|22 patients will be treated with 2 NRTI + PI during 24 weeks
62670543|NCT03662971|EXPERIMENTAL|0.0005% single-dose|Two subjects will be treated with Germinal peptide eye drops 0.0005% single dose.
62108795|NCT04148937|EXPERIMENTAL|Phase 1b Cohort D1 LY3475070 + Pembrolizumab (dose expansion)|"LY3475070 administered orally and pembrolizumab administered IV.~Based on Sponsor decision, Phase 1b expansion cohorts were not initiated."
62299839|NCT06217991|EXPERIMENTAL|PTST anastomose group after proximal gastrectomy|"Standard procedure: Patient placed in a supine position and proximal gastrectomy performed under general anesthesia.~1. Lymph node dissection~2. Cut the esophagus~3. Gymnosis of gastric curvature greater and gastric curvature lesser~4. The specimen removed from the stomach(5cm away)~5. Preparation of serosa-muscle flap: Mark two straight lines, A and B, about 3cm long, with methylene blue on the anterior wall of the stomach about 2cm and 6cm from the gastric stump. The electrocoagulation and cutting power of the electrotome were adjusted to 10 watts, and the serosa-muscle layer of the gastric wall was cut along the marked line with the electrotome. With the help of the assistant, the surgeon separated the gastric parietal serosa-muscle layer from the submucosa along line B to line A. When the dissociation reached the middle point of the tunnel, it should be dissociated along line A to line B, completely dissociated the gastric parietal serosa-muscle layer from the submucosa."
62299840|NCT03395678|EXPERIMENTAL|Microneedling|Participants in this arm will receive 5 treatments of microneedling.
62299841|NCT03395678|ACTIVE_COMPARATOR|Fractional non-ablative 1,540nm laser|Participants in this arm will receive 5 treatments of fractional non-ablative1,540nm laser.
62299842|NCT06411821|EXPERIMENTAL|Mitogen-activated protein kinase (MAPK) pathway mutation (primary cohort)|Patients in this study will receive ulixertinib, starting at 300 mg twice daily, for every 28-day cycle.
62299843|NCT06411821|EXPERIMENTAL|No Mitogen-activated protein kinase (MAPK) pathway mutation identified (exploratory cohort)|Patients in this study will receive ulixertinib, starting at 300 mg twice daily, for every 28-day cycle.
62299844|NCT03027167|ACTIVE_COMPARATOR|Aspirin and MCDs|ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
62670544|NCT03662971|EXPERIMENTAL|0.001% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.001% single dose (eight treatment and two placebo).
62108796|NCT04148937|EXPERIMENTAL|Phase 1b Cohort D2 LY3475070 (dose expansion)|"LY3475070 administered orally.~Based on Sponsor decision, Phase 1b expansion cohorts were not initiated."
62108797|NCT04148937|EXPERIMENTAL|Phase 1b Cohort E LY3475070 + Pembrolizumab (dose expansion)|"LY3475070 administered orally and pembrolizumab administered IV.~Based on Sponsor decision, Phase 1b expansion cohorts were not initiated."
62108798|NCT02784704|EXPERIMENTAL|Eravacycline|
62108799|NCT02784704|ACTIVE_COMPARATOR|Meropenem|
62108800|NCT06554132||Scleroderma group|Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
62670545|NCT03662971|EXPERIMENTAL|0.002% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% single dose (eight treatment and two placebo).
62670546|NCT03662971|EXPERIMENTAL|0.004% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% single dose (eight treatment and two placebo).
62670547|NCT03662971|EXPERIMENTAL|0.008% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% single dose (eight treatment and two placebo).
62670548|NCT03662971|EXPERIMENTAL|0.002% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% multiple dose (eight treatment and two placebo).
62108801|NCT06554132||Healthy group|Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
62299845|NCT03027167|EXPERIMENTAL|Aspirin only|ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital. ASA 325mg BID will be prescribed for a period of 6 weeks.
62299846|NCT01496664|EXPERIMENTAL|Result of combined CABG and PCI treatment|The registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.
62299847|NCT02983084|EXPERIMENTAL|Multiforce|Variable modulus version of a current orthodontic archwire
62299848|NCT02983084|ACTIVE_COMPARATOR|CuNiTi A|".016 current orthodontic archwire"
62299849|NCT02983084|ACTIVE_COMPARATOR|CuNiTi B|"0.014 and 0.018 current orthodontic archwire sequence"
62470168|NCT04792450||ED Patients|Patients presenting in Emergency Department
62670549|NCT03662971|EXPERIMENTAL|0.004% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% multiple dose (eight treatment and two placebo).
62670550|NCT03662971|EXPERIMENTAL|0.008% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% multiple dose (eight treatment and two placebo).
62670551|NCT01718990||Patients with Idiopathic Pulmonary Fibrosis (IPF)|Sixty patients with IPF will be included in this prospective cohort;15 IPF patients per year for years 1-4.
62670552|NCT01718990||Healthy Volunteers|Sixty normal controls will be recruited from volunteers.
62670553|NCT03175588|EXPERIMENTAL|virtual rehabilitation|video based exercise
62670554|NCT03175588|NO_INTERVENTION|physical Activity|different type of physical Activity
62670555|NCT03540940|EXPERIMENTAL|zero positive end expiratory pressure|
62670556|NCT03540940|EXPERIMENTAL|Positive end expiratory pressure|
62670557|NCT01116843|EXPERIMENTAL|PF-00299804|Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
62670558|NCT01116843|PLACEBO_COMPARATOR|Placebo arm|Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
62670559|NCT03865251|EXPERIMENTAL|experimental group|Kinesiology tape application to dominant leg during lying and standing positions
62670560|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
62670561|NCT01333566|EXPERIMENTAL|Intervention Group|
62670562|NCT01333566|PLACEBO_COMPARATOR|Control Group|
62670563|NCT04288557||Sleep clinic patients|All adult patients, from 18 years and up to and including 65 years of age, on the waiting list for overnight polysomnography (PSG) recording at Leicester General Hospital.
62670564|NCT04288557||Healthy volunteers|All adults, from 18 and up to and including 65 years of age without a known sleep disorder.
62670565|NCT03868566|EXPERIMENTAL|SNP-612 dose1|dose1 once a day orally for 12 weeks
62670566|NCT03868566|EXPERIMENTAL|SNP-612 dose2|dose2 once a day orally for 12 weeks
62108802|NCT05255718|PLACEBO_COMPARATOR|Control|The placebo supplement will have no polyphenol content and will consist of 100 mL of the following mixture: black cherry Koolaid, blue and red food coloring, sucrose and sorbitol. This placebo will match the sugar content of the chokeberry juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
62108803|NCT05255718|EXPERIMENTAL|Aronia|100 mL of Aronia juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
62108804|NCT02155829|EXPERIMENTAL|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
62108805|NCT02155829|PLACEBO_COMPARATOR|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
62108806|NCT01673113|EXPERIMENTAL|Cryolipolysis|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device, which is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks. Sensory testing was done before and after the procedure.
62108807|NCT01673113|NO_INTERVENTION|Control|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device. The untreated flank served as the internal control for each subject.
62299850|NCT05229965|ACTIVE_COMPARATOR|Paracétamol Group|"In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracétamol Caféine Group) .~In Paracetamol group , the patients will receive a pill containing 1000 mg of paracetamol 3 times a day for 7 days .~Paracétamol 1000 mg : 1 pill \*3 / day"
62299851|NCT05229965|ACTIVE_COMPARATOR|Paracétamol Codéine Group|"In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) .~In Paracetamol codéine group , the patients will receive a pill containing an association of paracetamol and codéine ( 500mg / 30mg ) 3 times a day for 7 days .~-Association of Paracétamol and Codéine ( 500mg / 30 mg) : 1 pill \*2 /day"
62299852|NCT05229965|ACTIVE_COMPARATOR|Paracétamol Caféine Group|"In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) .~In Paracetamol caféine group , the patients will receive a pill containing an association of paracetamol and caféine ( 500mg / 65 mg ) 3 times a day for 7 days .~-Association of Paracétamol and Caféine ( 500mg / 65 mg) : 1 pill \*3 /day"
62299853|NCT01241786|EXPERIMENTAL|response to Vidaza + Revlimid|response to combination of azacitidine + lenalidomide A Phase II, Single Arm Study Examining the Combination of Revlimid (Lenalidomide) and Vidaza (Azacitidine) (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
62299854|NCT03751384|EXPERIMENTAL|Capsules|Dietary Supplement: Möllers Omega-3 Ekstra Sterk
62299855|NCT03751384|ACTIVE_COMPARATOR|Drink|Dietary Supplement: Nutrifriend Cachexia
62670567|NCT04095936|EXPERIMENTAL|AMG531|
62670568|NCT05520177|EXPERIMENTAL|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
62670569|NCT05520177|ACTIVE_COMPARATOR|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
62670570|NCT03745456||Subarachnoid Hemorrhage patients|Patients with severe subarachnoid hemorrhage (Hunt and Hess 4-5, Fisher 3-4) will be included initially in the first 6 hours after the onset of symptoms.
62670571|NCT04837742|EXPERIMENTAL|ESPB group|ESPB injection at T10 region with levobupivacaine 100mg (20 ml)+ Omnipaque10 ml
62670572|NCT04837742|SHAM_COMPARATOR|Control group|ESPB injection at T10 region with 0.9% normal saline 20ml + Omnipaque10ml
62670573|NCT03215615|ACTIVE_COMPARATOR|Group NF + TE|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with nanofilled resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
62670574|NCT03215615|ACTIVE_COMPARATOR|Group NF + UA|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with nanofilled resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
62299856|NCT01816087|EXPERIMENTAL|brief assessment tool (BAT)|all participants will have a brief assessment tool (BAT) for the identification of geriatric syndromes performed by their general practitioner. Afterwards, all participants will have a full geriatric assessment performed by geriatricians
62670575|NCT03215615|ACTIVE_COMPARATOR|Group MH + TE|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with micro-hybrid resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
62670576|NCT03215615|ACTIVE_COMPARATOR|Group MH + UA|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with micro-hybrid resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
62108808|NCT05174286|EXPERIMENTAL|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|"Participants randomized to this arm will receive:~1. SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~2. Culturally-adapted Alive! Program, which is a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
62108809|NCT05174286|ACTIVE_COMPARATOR|Referral as Usual (RAU)|Participants randomized to this arm will receive Referral as Usual (RAU), which will involve distributing CRC health educational materials (e.g. NCI or Centers For Disease Control brochures that include new guidelines) and contact information for screening service providers in our target community.
62108810|NCT01559506|NO_INTERVENTION|No device|Subject does not receive ABS system
62108811|NCT01559506|EXPERIMENTAL|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
62108812|NCT01549379|ACTIVE_COMPARATOR|Surgical patients|This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
62108813|NCT01549379|ACTIVE_COMPARATOR|Chemoradiation Patients|This group will consist of 15 patients with locally advanced HNSCC with lymph nodes ≥3 cm in which chemoradiotherapy is the primary treatment as per standard of care. This group will be composed of patients with a primary malignancy originating in the nasopharynx, oropharynx, hypopharynx or larynx. Pre-treatment DCE-CT of neck will be obtained. The standard therapy, radiation and chemotherapy, will be administered and the patients will have standard follow up. A post-treatment DCE-CT of neck will be obtained 8-10 weeks after treatment along with standard CT neck.
62108814|NCT05125367||multivessel coronary artery disease|From BEST trial study population_NCT00997828
62299857|NCT04057170|EXPERIMENTAL|mulligan method|Mulligan mobilization with mowement method every three days for six weeks
62299858|NCT04057170|EXPERIMENTAL|accelerated protocol|accelerated rehabilitation protocol every three days for six weeks
62299859|NCT05098483|ACTIVE_COMPARATOR|Conventional root canal treatment|The caries will be removed. An excavator will be used to remove the coronal portion of the dental pulp while the radicular portion will be cleaned using k- files. 2.5% Sodium hypochlorite will be used as irrigant solution.The canals will be filled with ZOE cement and a stainless-steel crown will be inserted to restore the tooth.
62299860|NCT05098483|EXPERIMENTAL|Regenerative endodontic treatment using MTA|"Access cavity will be prepared in each primary molar then each canal will be copiously irrigated by sodium hypochlorite. Triple antibiotic paste will be inserted in eash canal then sealed with temporary restoration till the second visit.~In the second visit canals will be irrigated with EDTA, after that induction of bleeding will be created by overinstumentation inside each canal. Finally sealed with MTA under the GIC restoration and S.S.C"
62299861|NCT05098483|EXPERIMENTAL|Regenerative endodontic treatment using Biodentine|"Access cavity will be prepared in each primary molar then canals will be copiously irrigated by sodium hypochlorite. Mixture of Triple antibiotic paste will be introduced in eash canal then cavity will be sealed with temporary restoration till the second visit.~In the second visit canals will be irrigated with EDTA, after that bleeding will be created by overinstumentation inside each canal. Finally sealed with biodentine under the GIC restoration and S.S.C"
62670577|NCT03004456|EXPERIMENTAL|Distraction|"Patients randomized to the Distraction group will be permitted to choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw."
62670578|NCT03004456|NO_INTERVENTION|Standard of care|"Patients randomized to the Standard of Care group will not be provided with an iPad."
62670579|NCT01370642|EXPERIMENTAL|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
62670580|NCT01370642|EXPERIMENTAL|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
62670581|NCT01370642|ACTIVE_COMPARATOR|Control Arm|Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
61914771|NCT01155479|EXPERIMENTAL|Preladenant 2 mg|Preladenant 2 mg oral tablet and placebo for rasagiline taken in the morning (AM) followed by preladenant 2 mg oral tablet taken in the evening (PM) for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
61914772|NCT01155479|EXPERIMENTAL|Preladenant 5 mg|Preladenant 5 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 5 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
62299862|NCT03511339|NO_INTERVENTION|Control|Brain rest
62670582|NCT03664141|PLACEBO_COMPARATOR|Placebo group|1 drop of regular oil for food labeled as 3% cannabis oil once a day during 3 months
61914773|NCT01155479|EXPERIMENTAL|Preladenant 10 mg|Preladenant 10 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 10 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
61914774|NCT01155479|PLACEBO_COMPARATOR|Placebo|Placebo for preladenant and placebo for rasagiline taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).
61914775|NCT01155479|ACTIVE_COMPARATOR|Rasagiline|Rasagiline 1 mg oral capsule and placebo for preladenant taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
62108815|NCT05688956|EXPERIMENTAL|(i) ONS + Exercise group|This group will consume whey protein ONS enriched with leucine and vitamin D, twice a day for 12 weeks. The optimal time to consume the ONS on non-exercise days will be based on each participants 24-hour dietary recall. On exercise days, participants will be asked to consume the ONS after breakfast and after the exercise class. Participants will participate in a resistance-based exercise programme twice a week for 12 weeks which will be carried out over Zoom. Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to this group by the research nutritionist.
62299863|NCT03511339|EXPERIMENTAL|TecTraum Device|Treatment with study device
62299864|NCT03655028|EXPERIMENTAL|RAS-music group|Home-based, exercise program augmented with rhythmically auditory stimulation enhanced music
62299865|NCT03655028|ACTIVE_COMPARATOR|Control group|Home-based, exercise program without rhythmically auditory stimulation enhanced music
62470169|NCT04792450||ED Staff|Staff working within the Emergency Department
61914776|NCT05421143||Quantitative study with medication reconciliation|The data collection will continue consecutively until the goal of 150 patients is reached. If it is feasible, we will try to reach 200 patients. We think 150-200 patients will give good insight into different types of medication discrepancies, since studies have shown that up to 90% of patients have at least one medication discrepancy in primary care.
61914777|NCT05421143||Qualitative semi-structured interviews with patients and next of kin|A selection of patients from the quantitative study described above will be chosen purposively and step by step along the way to ensure the informational strength in the selection. When possible, we will include next of kin in the interviews together with the patient. We aim to include around 20-30 patients, without counting in next of kin. The part will be accomplished together with the quantitative part. Every new interview will be compared with previous interviews to identify similarities and differences. Characteristics it is important to ensure variability for; women and men, different ethnicities, education type, spread in age, number of medications and help from next of kin/homecare nurses or not. It is also important to ensure variability in number and type of medications and diagnoses.
62299866|NCT05819892|EXPERIMENTAL|Adjuvant Therapy During Radiation|Participants will receive an active treatment for 6 cycles. Participants will be on maintenance for 14 cycles, as long as the disease does not get worse. Follow-up will then occur every 6 months for 5 years (from your enrollment date).
62299867|NCT05819892|EXPERIMENTAL|Adjuvant Therapy After Radiation|Participants will receive an active treatment for 6 cycles. Participants will be on maintenance for 14 cycles, as long as the disease does not get worse. Follow-up will then occur every 6 months for 5 years (from your enrollment date).
62299868|NCT05819892|EXPERIMENTAL|Immunotherapy after Radiation and Chemo|Participants will receive an active treatment for 6 cycles. Participants will be on maintenance for 14 cycles, as long as the disease does not get worse. Follow-up will then occur every 6 months for 5 years (from your enrollment date).
62299869|NCT03989830|EXPERIMENTAL|Second-line chemotherapy combined with Endostar|Second-line chemotherapy+Endostar
62299870|NCT04007276|EXPERIMENTAL|Lumify Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
62299871|NCT04007276|SHAM_COMPARATOR|Control Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
62299872|NCT02322762||One single cohort.|One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
62299873|NCT04969913||19 + years|Healthy adults over the age of 19 years
62470170|NCT06089382|EXPERIMENTAL|Sintilimab Plus Lenvatinib|
62470171|NCT06089382|ACTIVE_COMPARATOR|TACE(one cycle) + active surveillance|
62470172|NCT00429234|EXPERIMENTAL|Dasatinib + Gemcitabine|Dasatinib starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks. Gemcitabine starting dose of 800 mg/m\^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
62670583|NCT03664141|EXPERIMENTAL|Cannabis oil group|1 drop of 3% cannabis oil once a day during 3 months
62670584|NCT00835978|OTHER|A|Randomized arm
62670585|NCT00835978|OTHER|B|Randomized arm
62670586|NCT00835978|OTHER|C|Non-randomized arm
62670587|NCT06155214||autism spectrum disorder children|100 children with autism spectrum disorder who met the inclusion criteria and signed informed consent forms were included. Among them, there are 30 cases of children with regressive autism spectrum disorder.
61914778|NCT05421143||Qualitative semi-structured interviews with HCP|HCP will be recruited purposively along the quantitative study to ensure the informational strength in the selection. We aim to include around 15-20 HCP. The HCP recruited are involved in the patients medication regime or management, this to ensure that they have knowledge about patients with multiple long term conditions. Every new interview will be compared with previous interviews to identify similarities and differences. Characteristics it is important to ensure variability for; woman and men, physicians and homecare nurses, spread in age, years of working experience, different ethnicities and number of medications the patients they care for use.
62299874|NCT04969913||Ages 11 - 18 years|Healthy children between the ages of 11 and 18 years
62108816|NCT05688956|ACTIVE_COMPARATOR|(ii) Exercise-alone group|Participants will participate in a resistance-based exercise programme twice a week for 12 weeks which will be carried out over Zoom. Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to this group by the research nutritionist. The participants will not be provided with a placebo ONS.
62108817|NCT01037530|EXPERIMENTAL|Ramipril|
62299875|NCT04969913||Ages 5 - 10 years|Healthy children between the ages of 5 and 10 years
62299876|NCT04969913||Ages 6 months - 4 years|Healthy infants between the ages of 6 months and four years
62299877|NCT03642184|ACTIVE_COMPARATOR|Empagliflozin|Jardiance 10mg/25mg Film-coated tablets， once daily
62299878|NCT03642184|ACTIVE_COMPARATOR|Linagliptin|Trajenta 5mg Film-coated tablets， once daily
62299879|NCT01974323|EXPERIMENTAL|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
62299880|NCT01974323|PLACEBO_COMPARATOR|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
62299881|NCT00446030|EXPERIMENTAL|Stratum 1: TAC + Bevacizumab|"Human epidermal growth factor receptor-2 (HER2) negative participants stratified at registration, were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
62299882|NCT00446030|EXPERIMENTAL|Stratum 2: TCH + Bevacizumab|"HER2 positive participants stratified at registration, were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
62299883|NCT06357221|EXPERIMENTAL|Skincare Product Treatment|Subjects will use topical skincare products to assigned side of the body, per randomization.
62108818|NCT05638204|EXPERIMENTAL|Intervention Group|Participants in the intervention group received the Suicidal Crisis Intervention( SCI) in addition to their treatment as usual.
62299884|NCT01393587|EXPERIMENTAL|Experimental|
62299885|NCT01994343|EXPERIMENTAL|Experimental group|Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
62299886|NCT01994343|NO_INTERVENTION|Control group|Adult women aged over 18 years old without chronic pain. will receive no intervention.
62299887|NCT02451956|EXPERIMENTAL|AZD5363 in combination with paclitaxel|AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.If paclitaxel therapy is stopped then AZD5363 can be given on a 4on/3off continuous schedule.
62108819|NCT05638204|NO_INTERVENTION|Control Group|Participants in the control group received their treatment as usual.
62299888|NCT06362785|EXPERIMENTAL|virtual reality|The intervention group will perform immersive virtual reality sessions with interactive activities involving functional movements of the spine and limb region in a virtual environment using Meta Quest 3 goggles.
62108820|NCT03701230|EXPERIMENTAL|low temperature rota-flush solution|A total of 66 patients are assigned to low temperature rota-flush solution group after randomization schedule.
62108821|NCT03701230|NO_INTERVENTION|room temperature rota-flush solution|A total of 66 patients are assigned to room temperature rota-flush solution group after randomization schedule.
62108822|NCT00683735|ACTIVE_COMPARATOR|Treatment A|sitagliptin and placebo
62108823|NCT00683735|ACTIVE_COMPARATOR|Treatment B|placebo and metformin
62108824|NCT00683735|ACTIVE_COMPARATOR|Treatment C|sitagliptin and metformin
62108825|NCT00683735|PLACEBO_COMPARATOR|Treatment D|placebo
62108826|NCT02667418|OTHER|Fidaxomicin|Standard 10-day fidaxomicin treatment for Clostridium difficile
62108827|NCT02667418|OTHER|Vancomycin T/P|Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile
62108828|NCT02667418|OTHER|Vancomycin|Standard 10-day vancomycin treatment for Clostridium difficile
62108829|NCT05529589||control group|Diabetic macular edema patient with inner limit membrane
62299889|NCT06362785|NO_INTERVENTION|Control|The control group will not receive any type of intervention.
62299890|NCT03893292||Preoperative cooled radiofrequency ablation|Patients who undergo cooled radiofrequency ablation within 4-8 weeks of their scheduled total knee replacement.
62299891|NCT04888611|EXPERIMENTAL|Neoadjuvant PD-1 inhibitor plus DC vaccine|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, DC vaccines and further PD-1 inhibitor treatment until toxicity or progression.
62299892|NCT04888611|ACTIVE_COMPARATOR|Neoadjuvant PD-1 inhibitor plus Placebo|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, placebo and further PD-1 inhibitor treatment until toxicity or progression.
62108830|NCT05529589||experimental group|Diabetic macular edema patient with inner limit membrane peeling
62108831|NCT03651531|ACTIVE_COMPARATOR|insulin|
62299893|NCT05983393|SHAM_COMPARATOR|Control group|No block was performed
62299894|NCT05983393|ACTIVE_COMPARATOR|Erector spinae plane block|Erector spinae plane block was performed, morphine was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
62108832|NCT03651531|ACTIVE_COMPARATOR|insulin and metformin|
62108833|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
62108834|NCT00094809|ACTIVE_COMPARATOR|Pegfilgrastim|6 mg pegfilgrastim
62108835|NCT00094809|PLACEBO_COMPARATOR|Placebo|6 mg placebo
62108836|NCT01405235|ACTIVE_COMPARATOR|Arm B: Cisplatin/Topotecane|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
62108837|NCT01405235|EXPERIMENTAL|Arm A: Paclitaxel/Topotecan|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
62108838|NCT04301687|EXPERIMENTAL|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
62108839|NCT04301687|PLACEBO_COMPARATOR|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
62108840|NCT06185192|NO_INTERVENTION|Placebo|Participants with HbA1c levels between 6.5-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
62108841|NCT06185192|EXPERIMENTAL|Viome's Precision Nutrition Program (VPNP)|Participants with HbA1c levels between 6.5-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
62108842|NCT05723991|EXPERIMENTAL|Vidiximab and Gemcitabine Neoadjuvant therapy|Vidiximab (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every 2 weeks
62108843|NCT05283044|OTHER|Biopsy liquid contributive|Patients presenting for whom ct DNA sequencing
62108844|NCT04572672|ACTIVE_COMPARATOR|Purse lip breathing with number counting arm|"1) Position: The patient lies down in a semi-supine position, the bed is adjusted by 45-60 degrees, 2) Pursed-lip breathing and number counting one and two during inspiration, and 3) Number counting, one, two, three, and four during exhalation for the first 15 minutes (min) of each hour, total study time was 3 hours or until the patient was discharged from the ER."
62108845|NCT04572672|NO_INTERVENTION|Control arm|The patients who were allocated to the control group received usual nursing care i.e. bed rest in a supine position in a quiet area. Patients were advised to limit their activity. The frequency of the vital signs monitoring and pharmacologic treatment were the same as the intervention group.
62108846|NCT06317688|NO_INTERVENTION|Pre-Screening|Pre-Screening to meet qualifications and conditions of study.
62108847|NCT06317688|NO_INTERVENTION|Demographic Data Stage I|Data information gathered for enrollment
62108848|NCT06317688|NO_INTERVENTION|Demographic Data StageII|Data gathered after delivery
62108849|NCT06317688|EXPERIMENTAL|Clinical Data|50%Administration of Extra-Virgin Coconut Oil/ 50% HPA Lanolin
62108850|NCT06553573|ACTIVE_COMPARATOR|Parasternal Block and Recto-İntercostal Fascial Plane Block|Before surgery, patients will receive a combination of bilateral PSB and RIFPB with 0.25% bupivacaine (total volume 60 ml) for postoperative pain control.
62299895|NCT04228419|ACTIVE_COMPARATOR|Total Shoulder Arthroplasty (anatomic)|TSA procedure involves replacing the worn-out ball and socket joint with prosthetic components.
62299896|NCT04228419|ACTIVE_COMPARATOR|Reverse Shoulder Arthroplasty|RSA procedure is similar to a TSA, however the orientation of the ball and socket joint is placed in the reverse position
62299897|NCT06007612|EXPERIMENTAL|Behavioral: Context Sensitivity in Emotion Regulation|
62299898|NCT00921869|EXPERIMENTAL|1|
62299899|NCT04925570|EXPERIMENTAL|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
62299900|NCT04925570|OTHER|Digitally-delivered Psychoeducation|"Psychoeducation delivers weekly fact sheets that include information on:~1. Alcohol-specific topics;~2. Drug-specific topics;~3. General addiction topics;~4. Statistics relating to alcohol and substance use."
62670588|NCT06155214||global developmental delay children|100 children with global developmental delay who met the inclusion criteria and signed informed consent forms were included. Among them, there are 30 cases of children with regressive global developmental delay.
62670589|NCT06155214||normally developing children|Included 100 children with normal development.
62670590|NCT04066244|OTHER|Cohort 1|Dose 1 of BLZ945
62670591|NCT04066244|OTHER|Cohort 2|Dose 2 of BLZ945
62108851|NCT06553573|ACTIVE_COMPARATOR|Parasternal Block and Erector Spinae Plane Block|Before surgery, patients will be given 0.25% bupivacaine (total volume 60 ml) with a combination of bilateral PSB and ESPB for postoperative pain control.
62108852|NCT05396976|EXPERIMENTAL|Yoga Group|Yoga practice will be done two days a week for 10 weeks.
62108853|NCT05396976|NO_INTERVENTION|control group|no intervention
62108854|NCT05396976|EXPERIMENTAL|Muscle Relaxation Exercise Practices Group|Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
62108855|NCT05396976|EXPERIMENTAL|Yoga and Muscle Relaxation Exercise Practices Group|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
62108856|NCT03758651||Williams syndrome - Onsite participation|Individuals with Williams syndrome who will participate in the study at Massachusetts General Hospital (MGH)
62108857|NCT03758651||Williams syndrome - Convention participation|Individuals with Williams syndrome (WS) who will have a more limited evaluation at a convention focusing on WS, such as the WS Association convention.
62299901|NCT05163665|EXPERIMENTAL|Through-the-Scope clip group|Through the scope Dual Action Tissue Clip (DAT) clipping equipment and technique performed in closure of GI defect area after polyp removal.
62299902|NCT05163665|ACTIVE_COMPARATOR|X-Tack suturing group|Use of Endoscopic Helix Tacking System (X-Tack) by Apollo Endosurgery for the closure of GI defect after polyp removal.
62299903|NCT01961427|ACTIVE_COMPARATOR|sodium Nitrate 12mmol|Ingestion of a solution of inorganic nitrate, dosage: 12mmol
62108858|NCT03758651||Williams syndrome - Remote participation|Individuals with Williams syndrome (WS) who will participate in the study remotely by filling out a questionnaire and providing information by mail.
62108859|NCT03758651||Healthy Controls|Healthy individuals without Williams syndrome who will participate in the study at the Massachusetts General Hospital
62108860|NCT00921739|EXPERIMENTAL|IMRT concurrent with chemotherapy|6 fractions of esophageal sparing IMRT weekly for 5-6 weeks (dependent on dose cohort) concurrent with standard chemotherapy: Cisplatin 50 mg/m2 /d intravenously (IV) on days 1, 8, 29, and 36. Etoposide 50 mg/m2 /d IV on days 1 through 5 and 29 through 33.
62108861|NCT00370799|ACTIVE_COMPARATOR|local anesthetic|Group 1. local anesthetics only
62108862|NCT00370799|ACTIVE_COMPARATOR|Local anesthetic with generic Celestone|Group 2. local anesthetic with 6mg of non-particulate Celestone
62108863|NCT00370799|ACTIVE_COMPARATOR|Local anesthetic with Celestone|Group 3. local anesthetic with 6 mg of brand nameCelestone
62108864|NCT00370799|ACTIVE_COMPARATOR|Local anesthetic with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
62299904|NCT01961427|ACTIVE_COMPARATOR|sodium Nitrate (6mmol)|ingestion of inorganic nitrate (6mmol solution)
62299905|NCT01961427|ACTIVE_COMPARATOR|sodium nitrate 3mmol|ingestion of inorganic nitrate (3mmol solution)
62299906|NCT01961427|ACTIVE_COMPARATOR|sodium nitrate (0mmol)|Ingestion of water as a placebo
62299907|NCT01961427|ACTIVE_COMPARATOR|Beetroot juice (12mmol)|ingestion of 170ml of concentrated beetroot juice (12mmol)
62299908|NCT01961427|ACTIVE_COMPARATOR|beetroot juice (6mmol)|ingestion of 85ml concentrated beetroot juice (6mmol)
62299909|NCT01961427|ACTIVE_COMPARATOR|Beetroot juice (3mmol)|Ingestion of 42.5ml of concentrated beetroot juice (3mmol)
62670592|NCT04066244|OTHER|Cohort 3|Dose 3 of BLZ945
62670593|NCT04066244|OTHER|Cohort 4|Dose 4 of BLZ945
62670594|NCT04066244|OTHER|Cohort 5 Arm #1|Dose 4, Regimen 1 of BLZ945
62670595|NCT04066244|OTHER|Cohort 5 Arm #2|Dose 4, Regimen 2 of BLZ945
62670596|NCT04066244|OTHER|Cohort 5 Arm #1 extended treatment period|Dose 4, Regimen 1 of BLZ945
62670597|NCT04066244|OTHER|Cohort 5 Arm #2 extended treatment period|Dose 4, Regimen 2 of BLZ945
62670598|NCT06257121|EXPERIMENTAL|SGRT|Patient position will be managed by optical surface management system (OSMS). Equipment for this procedure includes an IMRT board, a long head cushion (with transparent Timo, moldcare, and shim), anatomical markers the cushion (shoulders, under the chin, etc.), a kneefix and arm plates. Every day, prior to treatment, there will be (1) A lateral kilo voltage (kV) image for jaw positioning and (2) a CBCT with standard match (3D column then 3D GTV/PTV). During treatment, patients will undergo real-time monitoring with the VisionRT system (SGRT). A second CBCT will de carried mid-treatment (after the 2nd of 3 arcs) and patient's position will be adjusted if deemed necessary.
62670599|NCT02287025|EXPERIMENTAL|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
62670600|NCT02287025|ACTIVE_COMPARATOR|Standard of Care|Investigators were supported with standard prescribing information.
62670601|NCT01528774||Melanoma|Patients with histologically confirmed melanoma
62670602|NCT01528774||Prostate|Patients with histologically confirmed prostate cancer
62670603|NCT01528774||Solid tumors - other|Patients with histologically confirmed solid tumor cancers other than melanoma and prostate
62670604|NCT01528774||Benign Hematologic Conditions|Patients diagnosed with non-cancerous hematologic conditions
62670605|NCT01528774||Healthy Volunteers|Family members of patients undergoing treatment at Comprehensive Cancer Centers of Nevada, or other healthy volunteers
62670606|NCT05474820|OTHER|Saliva and serum collection of patients and samples molecules analysis|After periodontal examination, samples were collected from all patients via informing them about procedures. Then all samples were stored at -80 C unto analyses.
62670607|NCT05474820|OTHER|Periodontal examination|All periodontal indices were measured in six sites in each tooth present in the arch by one calibrated periodontist
62670608|NCT01972984|EXPERIMENTAL|Anastrozole|All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery
62670609|NCT04162275|EXPERIMENTAL|pre-trial, fasting administration|2 cases were given 150mg Finamine tablets（pre-trial，fasting administration）
61914779|NCT02788877|EXPERIMENTAL|treat-and-extend|Aflibercept 2mg is injected into the vitreous cavity. An injection is given every 4 weeks five times and then the Treat-and-Extend process begins. If 1mm central subfield macular thickness (CSMT) improved (10% or more reduction) compared to the previous visit, the next treatment will be performed at the same interval. If CSMT is maintained (less than 10% changes), the next interval will be extended by two weeks (up to 12 weeks). If CSMT is worsened (10% or more increase), the next interval will be shortened by two weeks (minimum 4 weeks). If CSMT is stable two times at 12 weeks-interval, the injection will be deferred, and the next visit will be 8 weeks later. These process will be continued for 2 years.
61914780|NCT02378805||no-T: untreated patients|untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)
62470173|NCT05622422|EXPERIMENTAL|Body Knowleging Program Pilot Study|There will be three groups of 10 participants with a chronic disease that will receive the Body knowledging Program. The intervention aims to activate patients' inherent resources and by this, facilitate empowerment, patient activation, and self-care management of their chronic disease. The participants will include people 18 years and older that have been diagnosed with a chronic disease. This pilot study will use a pre-post design. Some of the data will be collected initially, then the intervention will be provided in seven sessions the first three face-to-face at a local community center and then the last four sessions through video conferencing that will be facilitated by three researchers. Data collection will take place at the first session and then again at the seventh session. The participants will be invited back in week nine to attend a video conference focus group to obtain qualitative data. Both qualitative and quantitative data will be analyzed.
62470174|NCT05132985|EXPERIMENTAL|Icotinib+chemotherapy|"Neoadjuvant chemotherapy (pemetrexed + carboplatin/cisplatin ) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.~Icotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of Icotinib is 125mg 1tt(Take 1 tablet 3 times a day) orally.~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 2 of neoadjuvant treatment.~Adjuvant treatment: Patients receive additional 2 cycles of platinum-based doublet chemotherapy(Researcher decide) on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity"
62470175|NCT01424293|EXPERIMENTAL|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
62670610|NCT04162275|EXPERIMENTAL|pre-trial,after high fat meal|2 cases were given 150mg Finamine tablets (pre- trial，after high fat meal)
62670611|NCT04162275|PLACEBO_COMPARATOR|formal trial-150mg|4 cases were given 150mg Finamine tablets 2 cases were given placebo
62670612|NCT04162275|PLACEBO_COMPARATOR|formal trial-300mg|6 cases were given 300mg Finamine tablets 2 cases were given placebo
62670613|NCT04162275|PLACEBO_COMPARATOR|formal trial-600mg|6 cases were given 600mg Finamine tablets 2 cases were given placebo
62670614|NCT04162275|PLACEBO_COMPARATOR|formal trial-1200mg|6 cases were given 1200mg Finamine tablets 2 cases were given placebo
62670615|NCT00126737|ACTIVE_COMPARATOR|Arm 1|Group assigned to both a Weight Control Nutritional Program and home-based exercise program (Ex+WC).
62670616|NCT00126737|ACTIVE_COMPARATOR|Arm 2|Group assigned to a Weight Control Nutritional Program (WC).
62670617|NCT00126737|ACTIVE_COMPARATOR|Arm 3|Group assigned to a home-based exercise program (Ex).
62670618|NCT00126737|NO_INTERVENTION|Arm 4|Usual care and non- specific health information (C).
62670619|NCT01975584|EXPERIMENTAL|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
61914781|NCT02378805||T-III: late therapy in patients|patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).
61914782|NCT02378805||T-II: early therapy in patients|therapy starts at patients with proteinuria \>0.3 g/day or per gCreatinine
61914783|NCT02378805||T-I: very early tharpy in patients|starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).
62108865|NCT00127647|EXPERIMENTAL|1|montelukast sodium 5 mg, QD 2-weeks
62108866|NCT00127647|EXPERIMENTAL|2|montelukast sodium 10 mg QD 2-weeks
62670620|NCT03528850|EXPERIMENTAL|Telehealth|The Telehealth arm will receive daily biometric measurement of blood pressure, heart rate, oxygen saturation and weight. The Telehealth arm will also have weekly virtual visits for the first month after hospital discharge. The Telehealth arm will answer surveys weekly for the first 30 days.
62108867|NCT00127647|ACTIVE_COMPARATOR|3|Pranlukast 225 mg BID 2-weeks
62670621|NCT03528850|NO_INTERVENTION|Standard of Care|The Standard of Care will receive no interventions but will conduct surveys at enrollment and at the end of 30 days.
62670622|NCT05290974|ACTIVE_COMPARATOR|In-person group|Conventional in-person standardized teaching
62108868|NCT01886014|EXPERIMENTAL|oxytocin|application of intranasal oxytocin 40IE
62108869|NCT01886014|PLACEBO_COMPARATOR|placebo|"application of intranasal saline~Both sprays (saline/oxytocin) are delivered in identical containers manufactured by the University pharmacy to assure blinding."
62670623|NCT05290974|EXPERIMENTAL|Online group|Independent learning with online educational material
62670624|NCT00924482|OTHER|Single Arm - Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
62670625|NCT04479384|EXPERIMENTAL|Intervention group|Thoracic manipulation T1-T5 if somatic dysfunction. Intrathoracic fascia stretch x 3. Recoil sternum x 3. Cranial base release - 4 steps.
62670626|NCT04479384|NO_INTERVENTION|Control group|Supine position 10 minutes on the bench.
62670627|NCT04508985|EXPERIMENTAL|Intervention|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
62670628|NCT04508985|OTHER|Continuation of standard of care|No intervention, Continuation RAAS inhibitor \[continued standard of care\].
62670629|NCT06469853|EXPERIMENTAL|MBF-015 16 mg oral multiple dose|Drug: MBF-015 16 mg oral capsules. Single daily dose. One hard gelatin capsule during 28 days.
62108870|NCT03121950|EXPERIMENTAL|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
62108871|NCT03121950|ACTIVE_COMPARATOR|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
62108872|NCT05580796|EXPERIMENTAL|TCR-T cells|TCR-T cell injection
62108873|NCT01076335|EXPERIMENTAL|Neoadjuvant Hormones + Docetaxel|Neoadjuvant Hormonal Therapy plus Docetaxel followed by Radical Prostatectomy
62108874|NCT03370055|ACTIVE_COMPARATOR|LeucoPatch®|Usual wound care and LeucoPatch® treatment for 8 weeks, with the offer of additional 8 weeks treatment with LeucoPatch®
62108875|NCT03370055|PLACEBO_COMPARATOR|Control|Usual wound care for 8 weeks, with the offer of 8 weeks of LeucoPatch® treatment after the first 8 weeks
62108876|NCT04957654|EXPERIMENTAL|VST with collagen plug soaked in blood|
62108877|NCT04957654|ACTIVE_COMPARATOR|VST with Allograft Demineralized bone matrix Grafton|
62108878|NCT04957654|ACTIVE_COMPARATOR|VST with autogenous cortical chips and bovine deprotinzed particles|
62108879|NCT04747457|EXPERIMENTAL|Adults and pediatric patients, all etiologies combined|
62108880|NCT02521116|OTHER|Healthy subjects|healthy study subjects, age 18-80 years
62108881|NCT04533139||Vaccine, pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
62108882|NCT04533139||Vaccine, post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
62108883|NCT04533139||Vaccine, not receiving transplant|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
62108884|NCT02980380||Locked-in and complete locked-in state patients|Amyotrophic lateral sclerosis patients in complete locked-in state as well as in transition from locked-in to complete locked-in state who have no means of communication.
62470176|NCT04188197|EXPERIMENTAL|e-Cigarette Matched to Usual Brand Cigarette|"JUUL and cigarette flavor matched (Mint for menthol smokers and Virginia Tobacco for non-menthol smokers);"
62670630|NCT06469853|EXPERIMENTAL|MBF-015 32 mg oral multiple dose|Drug: MBF-015 16 mg oral capsules. Single daily dose. Two hard gelatin capsules during 28 days.
62670631|NCT05231941|EXPERIMENTAL|Lidocaine Group|After induction of anaesthesia, a bolus of 2mg/kg intravenous lidocaine will be given followed by Lidocaine infusion at the rate of 1.5 mg/kg/hour which will be stopped at the end of surgery.
62670632|NCT05231941|EXPERIMENTAL|TAP group|After completion of procedure and before extubation, bilateral ultrasound guided subcoastal transversus abdominis plane (TAP) block will be performed by the primary anaesthetist. After taking aseptic measures, with patient in supine position a high frequency (6-13 MHz) linear ultrasound probe will be placed obliquely just inferior to the costal margin over the anterior abdominal wall. With the help of a 21G or 22G, 100 mm needle, 20 ml of 0.375% Ropivacaine will be injected between rectus sheath and fascia of transversus abdominis muscle, bilaterally.
62108885|NCT04178395|EXPERIMENTAL|real tDCS group|Patients allocated to the real tDCS group (11 patients) received one daily session of bihemispheric transcranial direct stimulation and repetitive peripheral stimulation for 5 consecutive days.
62108886|NCT04178395|SHAM_COMPARATOR|sham group|Patients allocated to the sham tDCS group (9 patients) received sham tDCS + rPNS also daily, for 5 consecutive days.
62108887|NCT03030950|EXPERIMENTAL|Dexmedetomidine group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
62299910|NCT00659295||Type 1 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
62670633|NCT05231941|NO_INTERVENTION|Control group|No additional intervention will be given to this group
61914784|NCT02378805||no therapy in heterozygous carriers|heterozygous carriers without therapy
61914785|NCT02378805||therapy in heterozygous carriers|heterozygous carriers with RAAS-blockade
61914786|NCT05532696|EXPERIMENTAL|ABT-101|"Part 1- dose-escalation: ABT-101 in patients with advanced cancer disease~Part 2- dose expansion: ABT-101 in patients with NSCLC with confirmed HER2 mutations"
61914787|NCT04707443||enteral nutrition|Infants, undergo enterostomy for various reasons within the age range of 0-6 months.The enteral nutrition can be administered orally or via enteral nutrition, including breast milk, preterm formula, infant formula, extensive hydrolyzed formula or amino acid formula et al .To observe and study the efficacy, safety and tolerance of enteral nutrition in infants after enterostomy.
62299911|NCT00659295||Type 2 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
62299912|NCT04714372|EXPERIMENTAL|Dose Level 1: FT538 at 1 x10^8 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
62670634|NCT04076137|EXPERIMENTAL|Targeted T-cell|This study is a pre-phase I immunotherapy trial in 10 people with malignant solid tumor consisting of 9 infusions of bispecific antibody armed anti-CD3-Actibated T cells(ATC) to determine safety, maximum tolerated dose (MTD), technical feasibility, immune responses.
62670635|NCT04599985|EXPERIMENTAL|Star excursion balance training (SEBT)|Received star excursion balance training (SEBT) program. Performed 3-trials in all 8 directions of the SEBT grid.
62670636|NCT04599985|ACTIVE_COMPARATOR|Simplified star excursion balance training (SSEBT)|Received simplified star excursion balance training (SSEBT) program. Performed 3-trials in all 3 directions of SSEBT grid.
61914788|NCT03687164|EXPERIMENTAL|Group Medical Visits|Group visits which will provide aspects of support, empowerment, education and medical care.
61914789|NCT03687164|NO_INTERVENTION|Usual Care|Usual clinical office visits
61914790|NCT02447783|PLACEBO_COMPARATOR|Control, Flavanol-free intervention|Intake of flavanol-free, macro- and micro-nutrient matched control capsules
61914791|NCT02447783|ACTIVE_COMPARATOR|CF intervention|Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
61914792|NCT00825773|ACTIVE_COMPARATOR|Excel|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
61914793|NCT00825773|SHAM_COMPARATOR|Cypher|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
61914794|NCT05080244|EXPERIMENTAL|Probiotics|Two probiotic strains will constitute the experimental arm (Probiotics). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
61914795|NCT05080244|PLACEBO_COMPARATOR|Placebo|Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
61914796|NCT01544088|EXPERIMENTAL|Arm 1: GCBT|Group Cognitive Behavioral treatment (GCBT)
61914797|NCT01544088|ACTIVE_COMPARATOR|Arm 2: Group Treatment|Present Centered Group Treatment
61914798|NCT00627146|PLACEBO_COMPARATOR|B|
61914799|NCT00627146|ACTIVE_COMPARATOR|A|ChAgly CD3
61914800|NCT01654913|EXPERIMENTAL|surgical patients|patients studied just before induction of anesthesia
61914801|NCT01119937|EXPERIMENTAL|NVA237|50µg once daily
61914802|NCT01119937|EXPERIMENTAL|Tiotropium|18µg once daily
61914803|NCT00409175|EXPERIMENTAL|1.|Fx-1006A
61914804|NCT00409175|PLACEBO_COMPARATOR|2.|Placebo
62299913|NCT04714372|EXPERIMENTAL|Dose Level 2: FT538 at 3 x10^8 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
62299914|NCT04714372|EXPERIMENTAL|Dose Level 3: FT538 at 1 x10^9 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
62670637|NCT05845593||Group 1|Adult male and female patients with a clinical diagnosis of SLE or incomplete lupus
61914805|NCT05703633|EXPERIMENTAL|uDCD arm|Patients enroled in the study will receive a kidney from a uDCD donor, after the kidney has been subjected to a reconditioning procedure, preventing ischemia/reperfusion-injury, confirming large animal data using the same protocol.
61914806|NCT00159497|ACTIVE_COMPARATOR|1|Standard porouscoated Trilogy Cup
61914807|NCT00159497|EXPERIMENTAL|2|HA coated Trilogy cup
61914808|NCT03584945|EXPERIMENTAL|Obsessive Compulsive Disorder|
61914809|NCT03584945|OTHER|Subclinical Obsessive-Compulsive symptoms (OCS)|
61914810|NCT03584945|NO_INTERVENTION|Healthy Control|
61914811|NCT03403387|EXPERIMENTAL|GlutenShield|3 capsules of GlutenShield supplement/day for 28 days
61914812|NCT03403387|PLACEBO_COMPARATOR|Placebo|3 capsules of the placebo (Avicel and bentonite powder (for color))/ day for 28 days
62299915|NCT04714372|EXPERIMENTAL|Dose Level 4: FT538 at 1.5 x10^9 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
62299916|NCT03419793|EXPERIMENTAL|physical therapy intervention and segmental muscle vibration|physiotherapy intervention and segmental muscle vibration device
62299917|NCT03419793|SHAM_COMPARATOR|physical therapy intervention|physical therapy intervention alone
62299918|NCT02038322|NO_INTERVENTION|The Stork|Device - The Stork - complete kit (Conceptacle and Applicator)
62670638|NCT06274021|EXPERIMENTAL|Transcutaneous spinal stimulation in combination of baclofen/tizanidine/placebo|"Each participant will receive five distinct interventions:~* Transcutaneous spinal stimulation at 100 Hz for 30 minutes with a placebo~* Transcutaneous spinal stimulation at 50 Hz for 30 minutes with a placebo~* Transcutaneous spinal stimulation at 50 Hz for 30 minutes with a single-dose baclofen~* Transcutaneous spinal stimulation at 50 Hz for 30 minutes with a single-dose tizanidine~* Transcutaneous spinal stimulation (sham) for 30 minutes with a placebo"
62670639|NCT05919056|EXPERIMENTAL|Intervention arm|The interventions include cardiovascular risk assessment, dynamic risk monitoring, and regular general practitioner (GP) visits. The frequency of risk assessment, risk monitoring, and automatic mobile texting will be once per month, while regular GP visits will be once per three months.
62670640|NCT05919056|NO_INTERVENTION|Control arm|Current regular management (usual care) will be kept in the control arm. The management objectives are for patients with hypertension or diabetes mellitus. The frequency of follow-up is at least once per three months.
62670641|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN60D3 IOL)|No Intervention: Multifocal Spheric IOL implantation
62670642|NCT01763411||Monofocal Spheric Intraocular Lens (AcrySof SN60AT IOL)|No Intervention: Monofocal Spheric IOL implantation
62670643|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMA00 IOL)|No intervention Multifocal IOL implantation
62670644|NCT01763411||Monofocal Aspheric Intraocular Lens (AcrySof SN60WF IOL)|No Intervention: Monofocal IOL implantation
62670645|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMB00 IOL)|No intervention Multifocal IOL implantation
62299919|NCT01849133|EXPERIMENTAL|ELIOT|intraoperative radiotherapy
62670646|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN6AD1 IOL)|No intervention Multifocal IOL implantation
61914813|NCT01687374|PLACEBO_COMPARATOR|Placebo|
62108888|NCT03030950|PLACEBO_COMPARATOR|Control group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
62108889|NCT00728286||Type 2 diabetes mellitus|We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
62299920|NCT01849133|ACTIVE_COMPARATOR|EXTERNAL RT|external fractionated radiotherapy
62470177|NCT04188197|EXPERIMENTAL|e-Cigarette Unmatched to Usual Brand Cigarette|"JUUL and cigarette flavor unmatched (Virginia Tobacco for menthol smokers and Mint for non-menthol smokers)."
62670647|NCT01496443|EXPERIMENTAL|TAK-875 & Glimepiride QD|TAK-875 50 mg, tablets, orally and glimepiride 2 mg, capsules, orally and glimepiride placebo matching capsules, orally, once daily on dosing days for up to 19 days.
61914814|NCT01687374|EXPERIMENTAL|Parathyroid hormone|
61914815|NCT03916107|EXPERIMENTAL|Levator muscle and tarsus resection|
61914816|NCT03916107|ACTIVE_COMPARATOR|Frontal muscle flap|
61914817|NCT02425189||LQT Positive (Group 1)|"* Gene-positive LQTS patients~* Gene negative LQTS patients with confirmed phenotypic diagnosis of LQTS (Schwartz score ≥4)"
62299921|NCT06387615|EXPERIMENTAL|Active cTBS|Active cTBS will be administered to the left supramarginal gyrus
62299922|NCT06387615|SHAM_COMPARATOR|Sham stimulation|Sham stimulation will be administered to the left supramarginal gyrus
62470178|NCT03706794|EXPERIMENTAL|Clinical Decision Support Tool|Tailored education provided via a smartphone application
62470179|NCT03706794|ACTIVE_COMPARATOR|Headache Education|Non-tailored education provided via a smartphone application.
62670648|NCT03149861|EXPERIMENTAL|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
62670649|NCT03149861|EXPERIMENTAL|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
62670650|NCT00096408|ACTIVE_COMPARATOR|1|Total Abdominal Hysterectomy
62670651|NCT00096408|EXPERIMENTAL|2|Total Laparoscopic Hysterectomy
62670652|NCT06302283||Family Members or Informal Caregivers|family members or informal caregivers that have cared for a patient with Covid-19 or of a patient who has died in the first phase of the pandemic (March to December 2021)
61914818|NCT02425189||Asyptomatic Patients (Group 2)|Asymptomatic patients, those free of syncope on beta blocker, or gene negative unaffected family members
61914819|NCT00005866|EXPERIMENTAL|treatment|
61914820|NCT01155882||Whipple Surgery at the Splenic Artery|Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
62670653|NCT05481281|EXPERIMENTAL|Group Dexmedetomidine|Group Dexmedetomidine receiving I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion till surgery completion
62670654|NCT05481281|EXPERIMENTAL|Group Ketamine|Group Ketamine receiving 0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion till surgery completion
62670655|NCT01601977|EXPERIMENTAL|Intervention|AVAPS-AE
62670656|NCT01601977|ACTIVE_COMPARATOR|Usual care|Non-invasive ventilation
62670657|NCT05125939||Screening indication|Screening indication includes asymptomatic patients aged ≥50 years with no prior colonoscopy and at average risk of CRC. Screening indication also includes asymptomatic patients with negative prior colonoscopy.
62670658|NCT05125939||Surveillance indication|Surveillance indication includes patients with prior colon neoplasms, including conventional adenomas and clinically significant serrated polyps.
62670659|NCT05125939||Diagnostic indication|Diagnostic indication includes patients who report symptoms (e.g., abdominal pain, a change in bowel habits, or rectal bleeding) before their first screening examination and undergo evaluation of an abnormality on other image study, unexplained anemia and/or unexplained weight loss.
61914821|NCT00924170|EXPERIMENTAL|Fludarabine and Cyclophosphamide/LMB-2|Administer cycle 1 with Fludarabine and Cyclophosphamide (FC) alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
62670660|NCT05125939||Positive fecal immunochemical test|FIT+ indication includes patients who undergo colonoscopy for positive FIT results in screen-eligible individuals. FIT+ indication also applies to those with a positive FIT result and a recent colonoscopy.
62670661|NCT05866328|EXPERIMENTAL|Intervention|Experimental Group (e-Motional Training and Individual Placement and Support)
61914822|NCT02140502||Men undergoing prostate biopsy|
61914823|NCT01879579|EXPERIMENTAL|Mobile Insulin Titration Intervention|Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
62108890|NCT06631209|ACTIVE_COMPARATOR|Active Stimulation - Posterior Cingulate Cortex|Active Stimulation targeted at the Posterior Cingulate Cortex
62108891|NCT06631209|ACTIVE_COMPARATOR|Active Stimulation - Inferior Parietal Lobule|Active Stimulation targeted at the Inferior Parietal Lobule
61914824|NCT01879579|NO_INTERVENTION|Current Best Practice|Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.
61914825|NCT00129298|EXPERIMENTAL|1|Tiagabine
61914826|NCT00129298|PLACEBO_COMPARATOR|2|Matching placebo
61919884|NCT05635058|EXPERIMENTAL|Reminisence Therapy|The participants in the intervention group received reminiscence therapy which was implemented by the researcher as one session per week for eight weeks. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher.
62108892|NCT06631209|ACTIVE_COMPARATOR|Active Stimulation - Dorsomedial Prefrontal Cortex|Active Stimulation targeted at the Dorsomedial Prefrontal Cortex
62108893|NCT06631209|SHAM_COMPARATOR|Sham Stimulation|The TMS device will be placed to the head but no energy will be emitted.
62108894|NCT05864482|EXPERIMENTAL|Experimental|Brief Cognitive behavioral therapy intervention will be interviewed by the researcher as part of psychosocial care, with two sessions pre-operative and two post-operative sessions. In the postoperative period, an eye mask and ear plug will be applied to the patient by the researcher on the 3rd and 4th days of the short CBT post-op and between 23:00 and 07:00 at night. Visual Analogue Scale, State Anxiety Inventory, Richmond Agitation-Sedation Scale, Confusion Evaluation Scale in Intensive Care, Richard Campbell Sleep Quality Scale, Daily Follow-up Form will be applied after open heart surgery.
62670662|NCT05866328|NO_INTERVENTION|Control|Control Group (Individual Placement and Support)
62670663|NCT03667729|EXPERIMENTAL|progressive muscle relaxation|The experimental group received PMR once a week for a total of 12 weeks. Subjects completed measures at baseline, 3-month, and 3-month follow-up.
62670664|NCT03667729|NO_INTERVENTION|Control group|treatment-as-usual(TAU)
62670665|NCT03302663|OTHER|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
62670666|NCT03302663|OTHER|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
62670667|NCT03302663|OTHER|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
62670668|NCT03302663|OTHER|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
62670669|NCT00985790|EXPERIMENTAL|GSK2321138A Group|"Subjects aged between 18 and 47 months received the GSK2321138A. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm."
62670670|NCT00985790|ACTIVE_COMPARATOR|Fluarix Group|"Subjects aged between 18 and 47 months received the Fluarix™ vaccine. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm."
62670671|NCT06501937|EXPERIMENTAL|Experimental group|Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities
61914827|NCT05009433|EXPERIMENTAL|Pregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). The program will be also based on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise."
62108895|NCT05864482|NO_INTERVENTION|Control|Patients who meet the research criteria and agree to participate in the study will be informed about the research process (purpose of the research, assignment to the intervention and control group, etc.), written informed consent and contact information of the patients will be obtained, and the contact information of the researcher will be given to the patient. Only routine nursing care will be given to the patient. will be applied by the researcher
62670672|NCT06501937|ACTIVE_COMPARATOR|Control group|Videos featuring influencers promoting e-cigarettes alone
62670673|NCT04981561|EXPERIMENTAL|100 microgram GATE-251|GATE-251, 100 microgram tablet, PO, Single Dose with 28 day follow up
62670674|NCT04981561|EXPERIMENTAL|1 mg GATE-251|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up
62670675|NCT04981561|EXPERIMENTAL|3 mg GATE-251|GATE-251, 3 mg tablet, PO, Single Dose with 28 day follow up
62670676|NCT04981561|EXPERIMENTAL|10 mg GATE-251|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up
62670677|NCT04981561|EXPERIMENTAL|25 mg GATE-251|GATE-251, 25 mg tablet, PO, Single Dose with 28 day follow up
62670678|NCT04981561|EXPERIMENTAL|50 mg GATE-251|GATE-251, 50 mg tablet, PO, Single Dose with 28 day follow up
62670679|NCT04981561|EXPERIMENTAL|100 mg GATE-251|GATE-251, 100 mg tablet, PO, Single Dose with 28 day follow up
62670680|NCT04981561|EXPERIMENTAL|1 mg GATE-251 with CSF collection|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
62670681|NCT04981561|EXPERIMENTAL|10 mg GATE-251 with CSF collection|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
62670682|NCT04981561|PLACEBO_COMPARATOR|Placebo|Placebo tablet, PO, Single Dose with 28 day follow up
62670683|NCT05484167|ACTIVE_COMPARATOR|Natesto|Natesto™ is a testosterone nasal gel that is FDA approved to treat low testosterone. It delivers testosterone through the nasal passages and it is then absorbed into the blood stream. The nasal pump is placed at the opening of each nostril and then the participant would press down on the nasal pump to apply the gel. Each application takes about 10 seconds and the nasal pump applies a thin layer of gel that absorbs through the lining of the nose.
62670684|NCT05484167|PLACEBO_COMPARATOR|Placebo|This study involves a placebo. The placebo will look like the Natesto™ nasal pump and will contain a nasal gel, but without any active ingredients.
62670685|NCT03158597||AMI|
62670686|NCT03158597||Control|
62670687|NCT04678310||Intervention Group|A patient will be assessed as 'eligible' for participation in the iLIVE Volunteer Study if they have an advanced, incurable illness that is unlikely to be cured, and they have been assessed by their clinical team as being in the last month of life. If patients meet this criteria, they will be offered support from the hospital palliative and end of life care volunteer service (developed for this study). Patients who agree to support will be recruited to the 'Intervention Group'.
62108896|NCT03944343|SHAM_COMPARATOR|Reference product|Commercial cereals and a commercial yogurt
62108897|NCT03944343|EXPERIMENTAL|Test product A|Specific designed cereals A and yogurt
62108898|NCT03944343|EXPERIMENTAL|Test product B|Specific designed cereals B and yogurt
62670688|NCT04678310||Case Control Comparison Group|If a patient is 'eligible' to receive support from the hospital palliative and end of life care volunteer service (see 'Intervention Group'), but declines involvement, they will be approached for inclusion in the study, as part of the 'Case Control Comparison' group for comparative analysis to assess the 'impact' of the volunteer service.
62670689|NCT02712242|EXPERIMENTAL|Platelet Rich Fibrin|PRF was laid directly on the palatal wound immediately after harvesting the tissue graft and stabilized
62670690|NCT02712242|ACTIVE_COMPARATOR|Butyl cyanoacrylate|Butyl cyanoacrylate was directly applied on the palatal wound after harvesting the tissue graft
62670691|NCT02712242|PLACEBO_COMPARATOR|Wet Gauze|Wet Gauze was placed for 1 minute on the palatal wound after harvesting the tissue graft
62108899|NCT03944343|EXPERIMENTAL|Test product C|Specific designed cereals C and yogurt
62470180|NCT04941586|EXPERIMENTAL|Education in pain, Manual Therapy and Exercises|The therapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 60 minutes, for one month. Each therapy will last 20 minutes.
62670692|NCT02874131|EXPERIMENTAL|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
62470181|NCT04941586|ACTIVE_COMPARATOR|Manual Therapy and Exercises|The terapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 40 minutes, for one month. Each therapy will last 20 minutes.
62470182|NCT03205241|EXPERIMENTAL|n-3 PUFA|Omega-3 polyunsaturated fatty acid - 5.7g/ day for 4 weeks
62670693|NCT02874131|ACTIVE_COMPARATOR|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
62670694|NCT00950092|OTHER|Treatment|
62670695|NCT01532375|EXPERIMENTAL|Kochujang(32g)|
62670696|NCT01532375|PLACEBO_COMPARATOR|placebo(32g)|
62470183|NCT03205241|PLACEBO_COMPARATOR|Placebo|Olive Oil - 6g/ day for 4 weeks
62470184|NCT05212285||Early-stage NSCLC with sarcopenia|Patients diagnosed with NSCLC meeting Stage IA-IIIA as well as sarcopenia by the enrollment
62470185|NCT05212285||Early-stage NSCLC without sarcopenia|Patients diagnosed with NSCLC meeting Stage IA-IIIA but without sarcopenia by the enrollment
62108900|NCT03944343|EXPERIMENTAL|Test product D|Specific designed cereals D and yogurt
62108901|NCT02952053|EXPERIMENTAL|Dry Needling into MTrPs.|MTrP Group: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
62108902|NCT02952053|ACTIVE_COMPARATOR|Dry Needling within Taut Band|TB Group: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band; out of MTrPs).
62108903|NCT00522756|EXPERIMENTAL|Intervention|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
62108904|NCT00522756|ACTIVE_COMPARATOR|Control|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
62108905|NCT04118374|EXPERIMENTAL|Standard Carb Diet then Low Carb Diet|
62108906|NCT04118374|EXPERIMENTAL|Low Carb Diet then Standard Carb Diet|
62670697|NCT04294849|EXPERIMENTAL|Venous Thromboembolism Arm|This will be a cohort of patients age 8- ≤ 21 years old with objectively diagnosed DVT and/or PE.
62108907|NCT06421090|ACTIVE_COMPARATOR|Transauricular Vagal Nerve Stimulation|
62108908|NCT06421090|SHAM_COMPARATOR|Transauricular Vagal Nerve sham Stimulation|
62108909|NCT01006551|EXPERIMENTAL|Ziprasidone|
62108910|NCT04308746|EXPERIMENTAL|Individualistic|Participants write 3 statements to 3 questions relating to his/her differences from his/her immediate community
62108911|NCT04308746|EXPERIMENTAL|Collectivistic|Participants write 3 statements to 3 questions relating to his/her similarities with his/her immediate community
62108912|NCT04591301|EXPERIMENTAL|HEC113995 PA•H2O 2.5mg|Healthy subjects are given HEC113995 PA•H2O 2.5 mg in a single dose.
62108913|NCT04591301|ACTIVE_COMPARATOR|HEC113995 PA•H2O 5mg|Healthy subjects are given HEC113995 PA•H2O 5 mg in a single dose.
62670698|NCT02383173|ACTIVE_COMPARATOR|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
62670699|NCT02383173|EXPERIMENTAL|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
62670700|NCT01283386|EXPERIMENTAL|FCR-lite|Rituximab, fludarabine, and cyclophosphamide
62670701|NCT01283386|ACTIVE_COMPARATOR|LR Therapy|Rituximab and chlorambucile
62670702|NCT02541487||Nutritional/Physical Activity (NuPA) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
61914828|NCT05009433|ACTIVE_COMPARATOR|Pregnant MICT group|The moderate intensity continuous training (MICT) program will be implemented based on the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the MICT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise.
61914829|NCT05009433|SHAM_COMPARATOR|Pregnant standard care group|During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to taking part in the study tests.
62108914|NCT04591301|ACTIVE_COMPARATOR|HEC113995 PA•H2O 10mg|Healthy subjects are given HEC113995 PA•H2O 10 mg in a single dose.
62108915|NCT04591301|ACTIVE_COMPARATOR|HEC113995 PA•H2O 20mg|Healthy subjects are given HEC113995 PA•H2O 20 mg in a single dose.
62108916|NCT04591301|ACTIVE_COMPARATOR|HEC113995 PA•H2O 40mg|Healthy subjects are given HEC113995 PA•H2O 40 mg in a single dose.
62108917|NCT04591301|ACTIVE_COMPARATOR|HEC113995 PA•H2O 60mg|Healthy subjects are given HEC113995 PA•H2O 60 mg in a single dose.
62108918|NCT04591301|ACTIVE_COMPARATOR|HEC113995 PA•H2O 80mg|Healthy subjects are given HEC113995 PA•H2O 80 mg in a single dose.
62108919|NCT04591301|PLACEBO_COMPARATOR|placebo|Healthy subjects are given placebo in a single dose.
62108920|NCT03034915|EXPERIMENTAL|UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
62108921|NCT03034915|EXPERIMENTAL|UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
62470186|NCT05518890|EXPERIMENTAL|Diet Only|Reduced calorie intake by 5000kcals per week over a 4 week period
62470187|NCT05518890|EXPERIMENTAL|Diet plus Exercise|Reduced calorie intake by 5000kcals per week over 4 weeks with the addition of five 30 minute exercise sessions per week on a cycle ergometer. The exercise in intensity will be progressive and perceptually based and monitored by the investigators.
62108922|NCT03034915|EXPERIMENTAL|Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA|Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
61914830|NCT05009433|EXPERIMENTAL|Nonpregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
61914831|NCT05009433|ACTIVE_COMPARATOR|Nonpregnant MICT group|"The moderate intensity continuous training program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
62108923|NCT00300456|ACTIVE_COMPARATOR|A|ABT-335 + 20 mg simvastatin
62108924|NCT00300456|ACTIVE_COMPARATOR|B|ABT-335 + 40 mg simvastatin
62108925|NCT00300456|PLACEBO_COMPARATOR|C|ABT-335 monotherapy
62108926|NCT00300456|PLACEBO_COMPARATOR|D|20 mg simvastatin monotherapy
62108927|NCT00300456|PLACEBO_COMPARATOR|E|40 mg simvastatin monotherapy
62108928|NCT00300456|PLACEBO_COMPARATOR|F|80 mg simvastatin monotherapy
62108929|NCT05982041||idiopathic inflammatory myopathy|
62470188|NCT04171570|OTHER|Distal Transradial Access|Distal Transradial Access
62470189|NCT04171570|OTHER|Conventional Transradial Access|Conventional Transradial Access
62470190|NCT01433718|EXPERIMENTAL|ACL prevention training|
62470191|NCT02241434|EXPERIMENTAL|Stem Cell|bone marrow mononuclear cell transplantation
62108930|NCT01700790|EXPERIMENTAL|Lopinavir/ritonavir and ritonavir|Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.
62670703|NCT02541487||Physical Activity only (PAo) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the exercise only arm that achieve pregnancy.
62670704|NCT02541487||Infertile, non-lifestyle intervention controls|Obese women (60) with unexplained infertility who meet the inclusion/exclusion criteria for FIT-PLESE but decline participation in the trial and who elect to undergo CC-IUI treatment and achieve pregnancy without prior diet and exercise interventions.
62670705|NCT02476682||Normal subjects|blood or stool samples will be collected from people referred for screening colonoscopy
62670706|NCT02476682||Colorectal cancer|blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
62670707|NCT02476682||Polyps <10mm and no high risk features|blood or stool samples will be collected from people with no polyps or low risk polyps (\<10mm, no villous component or dysplasia) detected at colonoscopy
62670708|NCT02476682||Advanced Mucosal Neoplasia|blood or stool samples will be collected from people with AMN detected at resection
62670709|NCT02476682||Sessile Serrated Adenoma|blood or stool samples will be collected from people with SSP detected at resection
62670710|NCT02476682||non-colorectal neoplastic disease|Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.
62670711|NCT01623154|OTHER|BreathTek UBT|Comparison of Urea hydrolysis rate (UHR) values derived from Delta over Baseline (DOB)values obtained from the POCone and UBiT-IR300
62670712|NCT04268966|EXPERIMENTAL|CMX001|Initial dose of 200mg followed by 4 doses of 100mg
62670713|NCT01027416|NO_INTERVENTION|No Intervention|
62670714|NCT01027416|ACTIVE_COMPARATOR|Tamoxifen|Tamoxifen 20 mg orally 1x/day for 4 weeks
62670715|NCT02313272|EXPERIMENTAL|HFSRT with Pembrolizumab and Bevacizumab|Hypofractionated Stereotactic Irradiation (HFSRT). Pembrolizumab intravenous (IV) infusion every 3 weeks. Bevacizumab administered intravenously every 2 weeks.
62670716|NCT01979094||spinal arthrodesis and/or arthroplasty procedures|
62670717|NCT03514225|OTHER|Metacognitive Therapy for Social Anxiety|Exact sessional content of the MCT intervention is likely to involve attention training and situational attentional refocussing techniques, verbal reattribution strategies aimed to facilitate a reduction of self-processing strategies and to challenge metacognitive beliefs, and between-session tasks for participants to practice at home.
62670718|NCT04264962|EXPERIMENTAL|Yang Yin Fu Zheng Jie Du therapy|
62670719|NCT04264962|PLACEBO_COMPARATOR|Routine medical care|
62108931|NCT06442254|EXPERIMENTAL|Virtual Reality Group|In the intervention group, virtual reality application will be applied in addition to conventional treatment. In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched. To evaluate the effectiveness of the application, vital signs, respiratory muscle strength, grip strength, blood gas analysis, dyspnea and fatigue will be evaluated. Additionally, Richmond Agitation Sedation Scale (RASS), Non-Verbal Pain Scale, Glaskow coma scale, Physical Function Test in Intensive Care (PFIT)- CPax (Chelsea Critical Care Physical Assessment Tool) scales will be used.
62470192|NCT00925054|EXPERIMENTAL|rAvPAL-PEG 0.001 mg/kg|Subjects will start on rAvPAL-PEG 0.001 mg/kg
62670720|NCT02902315|ACTIVE_COMPARATOR|1ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
62670721|NCT02902315|ACTIVE_COMPARATOR|2ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
62470193|NCT00925054|EXPERIMENTAL|rAvPAL-PEG 0.003 mg/kg|Subjects will start on rAvPAL-PEG 0.003 mg/kg
62470194|NCT00925054|EXPERIMENTAL|rAvPAL-PEG 0.01 mg/kg|Subjects will start on rAvPAL-PEG 0.01 mg/kg
62670722|NCT02902315|ACTIVE_COMPARATOR|3ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
62670723|NCT02902315|ACTIVE_COMPARATOR|4ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
62670724|NCT01960842|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour)."
61914832|NCT05009433|SHAM_COMPARATOR|Nonpregnant standard care group|During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests.
62299923|NCT05641649|EXPERIMENTAL|Test formulation group of volunteers|"Sixteen healthy subjects aged between 18 and 60 years who satisfy the inclusion/ exclusion criteria will be enrolled in the study. Volunteers will be assigned to take particular formulation by a method of randomization on the first study day.~Half of the volunteers falling in the test formulation arm will be given a tablet of test formulation with 200 ml of water in an empty stomach on the first study day. In the second study day, these volunteers will be exchanging the formulations."
61914833|NCT00718237|EXPERIMENTAL|1|RotaTeq™
62108932|NCT06442254|NO_INTERVENTION|Control Group|Conventional treatment will be applied in the control group. Participants' vital signs, respiratory muscle strength, grip strength, blood gas analysis, dyspnea and fatigue will be evaluated. Additionally, Richmond Agitation Sedation Scale (RASS), Non-Verbal Pain Scale, Glaskow coma scale, Physical Function Test in Intensive Care (PFIT)- CPax (Chelsea Critical Care Physical Assessment Tool) scales will be used.
62470195|NCT00925054|EXPERIMENTAL|rAvPAL-PEG 0.03 mg/kg|Subjects will start on rAvPAL-PEG 0.03 mg/kg
62470196|NCT00925054|EXPERIMENTAL|rAvPAL-PEG 0.1 mg/kg|Subjects will start on rAvPAL-PEG 0.1 mg/kg
62470197|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
62470198|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
62470199|NCT01216566|EXPERIMENTAL|I. Patients with chronic neck pain|
62470200|NCT02775812|EXPERIMENTAL|Treatment (cisplatin, pembrolizumab, IMRT)|Patients receive cisplatin IV over 1-2 hours once weekly for weeks 1-6 and pembrolizumab IV over 30 minutes every 3 weeks in weeks 9, 12, 15, 18, and 21. Patients also undergo IMRT in weeks 1-6. Patients may also receive pembrolizumab IV over 30 minutes in weeks 3, 6, 24, and 27.
62470201|NCT02050685||All patients for PSG at SLBO|All patients incoming in the sleep study centre for a PSG. At the arrival the screening score will be recorder. AHI will be recorded next morning after analysis of the PSG.
62470202|NCT05331261|EXPERIMENTAL|Patients who have had knee replacement surgery|
61914834|NCT00718237|PLACEBO_COMPARATOR|2|Placebo
62108933|NCT03485859|EXPERIMENTAL|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
62108934|NCT03485859|PLACEBO_COMPARATOR|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
62470203|NCT05538416||Open PLIF|Patients undergoing conventional open posterior lumbar interbody fusion (PLIF) surgery. A long midline skin incision (10-15 cm) is made, after which the paravertebral muscles are detached from the midline and retracted laterally in order to expose the facet joints and pedicle entry point. After the pedicle screws are positioned, the disc will be removed bilaterally and packed with autogenous bone chips, followed by bilateral placement of polyetheretherketone (PEEK) PLIF cages.
62470204|NCT05538416||CBT-PLIF|Patient undergoing minimal access PLIF surgery with cortical bone trajectory (CBT-PLIF). The CBT-PLIF uses more medialized entry points, closer to the spinal process. Due to the medial approach of this technique, a smaller incision is needed and the need to retract muscles laterally is minimalized.
62108935|NCT04411836|NO_INTERVENTION|Control|Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)
62108936|NCT04411836|EXPERIMENTAL|PQ Intervention|Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
62108937|NCT04411836|EXPERIMENTAL|TQ Intervention|Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)
62108938|NCT04335591|EXPERIMENTAL|Linzagolix 75 mg|
62470205|NCT05538416||MI-PLIF|Patients undergoing minimal invasive PLIF surgery. A small midline incision (3-5 cm) will be made to perform mini-open decompression and placement of bilateral PEEK PLIF cages. In addition, two small paramedian incisions will be made on both sides for percutaneous pedicle screw fixation.
62470206|NCT04110236|EXPERIMENTAL|Immediate PriCARE|Caregiver-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 1-2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
62470207|NCT04110236|NO_INTERVENTION|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
62670725|NCT02171208|ACTIVE_COMPARATOR|Reference, Test, Reference (RTR)|Doses will be separated by a washout period
62670726|NCT02171208|ACTIVE_COMPARATOR|Test, Reference, Reference (TRR)|Doses will be separated by a washout period
62670727|NCT05396781|EXPERIMENTAL|Augmented Reality High Resolution Microendoscope (HRME) imaging|All study subjects will receive White Light Imaging and Lugol's Chromoendoscopy (LCE) which is the current standard of care procedure. The investigators will record any LCE abnormal areas and record the clinician's plan of action. Following LCE, all subjects will receive Mobile, Augmented Reality High Resolution Microendoscope (marHRME) imaging with the study contrast agent (Proflavine) of any LCE-identified abnormal areas as well as LCE normal areas. The investigators will record the subjective clinician read and confidence level in the investigators' diagnosis, and plan of action. Then the investigators will image the same abnormal and normal areas with the marHRME and record the software read, clinician confidence level, and plan of action. Finally, the imaged areas will be biopsied or resected and evaluated by a pathologist. All subjects will receive both standard of care and marHRME imaging.
62670728|NCT01713738|EXPERIMENTAL|rituximab|
62670729|NCT04613869|EXPERIMENTAL|High-dose esketamine group|After the operation, 5 mg esketamine was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 45mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/kg , Background dose 2ug/kg/h, single dose 4ug/kg/time
62670730|NCT04613869|EXPERIMENTAL|Low-dose esketamine group|After the operation, esketamine 2.5mg was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 22.5mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/ kg, background dose 2ug/kg/h, single dose 4ug/kg/time
62670731|NCT04613869|PLACEBO_COMPARATOR|Control group|PCIA formula: 6mg of hydromorphone + 10mg of tropisetron into 100ml of 0.9% sodium chloride injection, the first dose is 20ug/kg, the background dose is 2ug/kg/h, and the single dose is 4ug/kg/time.
62670732|NCT06211790|EXPERIMENTAL|FuDan-GP1 subtype|FuDan-GP1 subtype is targeted sensitive type. Treatment regimen：anlotinib 12 mg PO, QD, 14 days on - 7 days off.
62670733|NCT06211790|EXPERIMENTAL|FuDan-GP2 subtype|FuDan-GP2 subtype is Cold tumor type. Treatment regimen：anlotinib 12 mg PO, QD, 14 days on - 7 days off combined with everolimus 5 mg PO, QD.
62670734|NCT06211790|EXPERIMENTAL|FuDan-GP3 subtype|FuDan-GP3 subtype is progenitor infiltrating type. Treatment regimen：anlotinib 12 mg PO, QD, 14 days on - 7 days off combined with tislelizumab 200 mg, IV, Q3W.
62108939|NCT04335591|EXPERIMENTAL|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
62108940|NCT01368406|EXPERIMENTAL|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
62108941|NCT01368406|NO_INTERVENTION|treatment as usual|patients were on regular visits on psychiatrist
62108942|NCT03714750|ACTIVE_COMPARATOR|DK crush|Percutaneous revascularization of true coronary bifurcation stenosis (Medina 1,1,1 or 0,1,1) with double kissing and crush technique
62108943|NCT03714750|EXPERIMENTAL|Reverse TAP|Percutaneous revascularization of true coronary bifurcation Stenosis (Medina 1,1,1 or 0,1,1) with reverse T and protrusion technique
62108944|NCT02183246|EXPERIMENTAL|Porfiromycin + Radiotherapy|
62108945|NCT02183246|PLACEBO_COMPARATOR|Placebo + Radiotherapy|
62108946|NCT04473950|EXPERIMENTAL|Pain Group|Patients with chronic pain who are maintained on methadone for opioid use disorder
62108947|NCT04473950|PLACEBO_COMPARATOR|No Pain Group|Patients who are maintained on methadone for opioid use disorder but who do not have chronic pain.
62108948|NCT05453864|EXPERIMENTAL|CMAP Plus TFCBT|This intervention is a manual-assisted intervention, which will include two existing culturally adapted psychological interventions 1) Culturally Adapted Manual Assisted Psychological (CMAP), 2) Self-help manual for trauma - BASID Ki Kahani. Both interventions are based on the principles of Cognitive behavioural therapy (CBT).
62670735|NCT04665791|EXPERIMENTAL|Challenge|Challenge participants will be inoculated intranasally with reconstituted, previously lyophilised Neisseria lactamica (LyoNlac). The initial dose will be 10\^5 colony forming units and will be escalated to a maximum of 10\^7 colony forming units to find the dose which successfully colonises at least 70% of volunteers.
62670736|NCT02371252|NO_INTERVENTION|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
62670737|NCT02371252|ACTIVE_COMPARATOR|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
62670738|NCT00090402|PLACEBO_COMPARATOR|Fish Oil Placebo & Lipoic Acid Placebo|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram placebo-lipoic acid per day. Placebo fish oil capsules consisted of soybean oil flavored with lemon flavor and 5% fish oil to match fish oil capsules. LA placebo contained no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate.
62670739|NCT00090402|ACTIVE_COMPARATOR|Fish Oil Only|Three 1-gram fish oil concentrate capsules in triglyceride form (675 milligrams DHA and 975 milligrams EPA), 2 in the morning and 1 in the evening, plus one 600 milligram placebo-lipoic acid (containing no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate) per day.
62108949|NCT05453864|NO_INTERVENTION|Treatment As Usual (TAU)|This will be already receiving local medical, psychiatric and primary care services providing standard routine care to the participants.
62108950|NCT05424159|EXPERIMENTAL|Patients with locally advanced unresectable pancreatic cancer|Patients with locally advanced unresectable pancreatic cancer without invasion of the gastrointestinal tract, cT4N0-2M0 Stage III (AJCC/UICC Version 8).
62670740|NCT00090402|EXPERIMENTAL|Fish Oil Plus Lipoic Acid|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram lipoic acid (LA) capsule in the racemic form per day.
62670741|NCT03950388|NO_INTERVENTION|Treatment as Usual|
62670742|NCT03950388|EXPERIMENTAL|Intervention|
62670743|NCT03832452|EXPERIMENTAL|Part A: Treatment 1|A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
62670744|NCT03832452|PLACEBO_COMPARATOR|Part A: Treatment 2|A single oral dose of placebo on Day 1 and 3
62670745|NCT03832452|ACTIVE_COMPARATOR|Part B: Treatment A|A single oral dose of 400 mg moxifloxacin
62670746|NCT03832452|EXPERIMENTAL|Part B: Treatment B|A single oral dose of 1000 mg lucerastat
61914835|NCT00635024|EXPERIMENTAL|Anti-thymocyte Globulin/Melphalan|Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)
61914836|NCT04566445|EXPERIMENTAL|GT005 Medium Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 Medium Dose.
61914837|NCT04566445|EXPERIMENTAL|GT005 High Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 High Dose.
62108951|NCT06183710|NO_INTERVENTION|Integrated care only (control group)|The integrated care comprises of standard treatment offered at the Integrated Treatment Clinic at King's College Hospital and includes addiction and liver follow-up as well as facilitation of psychosocial sessions
62108952|NCT06183710|EXPERIMENTAL|Integrated care + CM|The integrated care comprises of standard treatment offered at the Integrated Treatment Clinic at King's College Hospital and includes addiction and liver follow-up as well as facilitation of psychosocial sessions. The adjunctive CM aims to reinforce attendance to integrated alcohol and liver care services from KCH over the course of 3 months
62108953|NCT03328949|EXPERIMENTAL|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
62108954|NCT01137266|ACTIVE_COMPARATOR|skin resistence|1) the location with the lowest resistance
62299924|NCT05641649|EXPERIMENTAL|Innovator formulation group of volunteers|"Sixteen healthy subjects aged between 18 and 60 years who satisfy the inclusion/ exclusion criteria will be enrolled. Volunteers will be assigned to take particular formulation by a method of randomization on the first study day.~Half of the volunteers falling in the innovator formulation arm will be given a tablet of innovator formulation with 200 ml of water in an empty stomach on the first study day. In the second study day, these volunteers will be exchanging the formulations."
62299925|NCT04925115|EXPERIMENTAL|Interventional group|"Interventional group:~1. Warm up and cool down (10 minutes before physical activity)~2. Brisk walking ( 30 minutes each session for 5 days in a week)~3. Week 1 to week 6 same protocol"
62299926|NCT04925115|NO_INTERVENTION|Control group|Routine activity of daily life
62299927|NCT02626377|EXPERIMENTAL|Interventional arm|'Support provided by social worker'
62299928|NCT02626377|OTHER|Non-interventional arm|'Information booklet receipt'
62299929|NCT06273163|EXPERIMENTAL|Medically tailored meals|Participants will receive 10 medically tailored meals per week (40 meals per month) for four-months.
62299930|NCT06273163|EXPERIMENTAL|Noom®|Participants will receive a paid Noom® subscription for four-months. Noom® is a subscription-based mobile application that provides food intake and exercise tracking and uses principles from psychology to motivate behavior change.
62299931|NCT06273163|PLACEBO_COMPARATOR|Usual care|Participants will receive usual care from their provider.
62299932|NCT05829057|EXPERIMENTAL|Arm of P-IL-2|Ia:Subjects will be dosed with single dose of P-IL-2
62299933|NCT05829057|EXPERIMENTAL|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib:Subjects will be dosed with dose of P-IL-2 plus Anti-PD-1 Monoclonal Antibody
62670747|NCT03832452|EXPERIMENTAL|Part B: Treatment C|A single oral dose of 4000 mg lucerastat
62670748|NCT03832452|PLACEBO_COMPARATOR|Part B: Treatment D|A single oral dose of placebo
62670749|NCT03997201|OTHER|Ripple Mapping guided ischaemic VT ablation|Patients referred for ablation of ischaemic VT undergo Ripple Mapping guided procedure.
62670750|NCT01083472|ACTIVE_COMPARATOR|Strattice(TM) TM repair|Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
62670751|NCT01083472|ACTIVE_COMPARATOR|Standard of Care repair|Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh
62670752|NCT05103735||PROPOFOL-REMIFENTANYL|"Awake craniotomy under propofol-remifentanil sedation. Propofol and remifentanyl was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.~Propofol dosage: 0.2-2 mk/kg/h Remifentanyl dosage: 0.01-0.1 mcg/kg/min"
62670753|NCT05103735||DEXMEDETOMIDINE|"Awake craniotomy under dexmedetomidine sedation. Dexmedetomidine was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.~Dexmedetomidine dosage: 0.2-1 mcg/kg/h In this group, remifentanyl administration was allowed."
62108955|NCT01137266|ACTIVE_COMPARATOR|irradiation|2) the site that causes an irradiation sensation
62108956|NCT01137266|ACTIVE_COMPARATOR|random|3) a random stimulation site.
62108957|NCT06262919||Tafinlar/Mekinist|Patients with BRAF V600E mutation positive unresectable advanced or recurrent solid tumors treated with dabrafenib and trametinib as per Japanese Package Insert.
62108958|NCT02794064|EXPERIMENTAL|Tri-modal imaging|Ultrasound and photoacoustic imaging of breast and adjacent lymph nodes. Imaging time: Approximately 30 minutes
62108959|NCT03097237|EXPERIMENTAL|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
62108960|NCT03097237|ACTIVE_COMPARATOR|Refined wheat|Refined wheat products with a low content of dietary fiber
62108961|NCT04648436|OTHER|Early surgery|
62108962|NCT04648436|OTHER|Initial conservative treatment|
62108963|NCT05222750||Pre-COVID-19|
62108964|NCT05222750||COVID-19|
62108965|NCT05222750||COVID-19 vaccination roll - out|
62108966|NCT03978533|EXPERIMENTAL|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
62108967|NCT06126536|EXPERIMENTAL|Group 1: Crestal Maxillary Sinus Floor Elevation using Osseodensification:|A crestal incision will be made towards the palate for better wound closure. A conservative flap will be raised, extending beyond the alveolar crest to minimize complications. In cases with 4-6mm ridge height and a need for 3mm vertical depth, a narrow densifying bur will be used, followed by wider burs to elevate the sinus membrane. The Densah® Bur will compact graft material to lift the membrane without penetrating the sinus floor. The osteotomy will be filled with bone graft substitute, and the final bur will apically propel the graft for vertical augmentation. Implant placement follows confirmation via radiography.
62108968|NCT06126536|EXPERIMENTAL|Group 2: Lateral Maxillary Sinus Floor Elevation|"In the Lateral technique, a crestal incision and mucoperiosteal flap will expose the sinus's lateral wall. A bony window is created, and when removable, sinus elevation curettes are used to elevate the sinus floor cautiously. Membrane perforations are covered with a resorbable collagen membrane if needed. Implant osteotomies follow standard protocol.~Graft material mixed with saline is gently packed into the sinus to achieve the desired bone height. A resorbable membrane is placed on the window's outer surface, and the flap is sutured for primary closure."
62108969|NCT01837641|EXPERIMENTAL|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
62108970|NCT01837641|EXPERIMENTAL|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
62670754|NCT02273466|ACTIVE_COMPARATOR|Desipramine alone|
62670755|NCT02273466|EXPERIMENTAL|Desipramine with Crobenetine|
62670756|NCT01763957|ACTIVE_COMPARATOR|Pelvic Floor Muscle Training (PFMT)|
62670757|NCT01763957|ACTIVE_COMPARATOR|Paula Method|
62670758|NCT03650608|EXPERIMENTAL|Cohort 1: HL217 Ophathalmic Solution QD|HL217 3mg/mL, Ophthalmic solution, two drop once a day
62670759|NCT03650608|EXPERIMENTAL|Cohort 2: HL217 Ophathalmic Solution BID|HL217 3mg/mL, Ophthalmic solution, two drop twice a day
62670760|NCT03650608|EXPERIMENTAL|Cohort 3: HL217 Ophthalmic Solution QID|HL217 3mg/mL, Ophthalmic solution, two drop four times a day
62670761|NCT03650608|PLACEBO_COMPARATOR|Placebo Ophthalmic solution|Placebo Ophthalmic solution, two drop once or twice or four times a day
61914838|NCT04566445|NO_INTERVENTION|Untreated control|Approximately 83 subjects are planned, with subjects randomised to untreated control.
62108971|NCT01837641|EXPERIMENTAL|LY3002813-Single 1 mg/kg in Healthy Participants|1 mg/kg single dose LY3002813 given once by IV infusion.
62108972|NCT01837641|EXPERIMENTAL|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
62108973|NCT01837641|EXPERIMENTAL|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
62108974|NCT01837641|EXPERIMENTAL|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
62108975|NCT01837641|PLACEBO_COMPARATOR|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
62108976|NCT01837641|EXPERIMENTAL|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
62108977|NCT01837641|EXPERIMENTAL|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
62670762|NCT02117817|EXPERIMENTAL|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
62670763|NCT00469027|EXPERIMENTAL|eNOS transfected EPCs|eNOS transfected EPCs will be delivered by injection via a PA line, incremental doses over three days
62670764|NCT02792946|EXPERIMENTAL|Sulfolase CR (200mg, QD)|for 7 days with or without meal
62670765|NCT02792946|ACTIVE_COMPARATOR|Sulfolase Capsule (100mg, BID)|for 7 days with or without meal
62670766|NCT06258291|EXPERIMENTAL|Treatment arm|The REBOOT Hemosystem will be tested in the treatment arm for a maximum of 5 treatments, the treatment will be applied in addition to standard of care alone.
61914839|NCT04739371|EXPERIMENTAL|Insulin|40 participants will receive 40 IUs of intranasal insulin about 30 minutes before consuming an ad libitum lunch.
61914840|NCT04739371|PLACEBO_COMPARATOR|Placebo|40 participants will receive 40 IUs of intranasal saline about 30 minutes before consuming an ad libitum lunch.
61914841|NCT06309394|EXPERIMENTAL|INCB099280|Participants will be administered INCB099280 tablet orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
61914842|NCT00459056|EXPERIMENTAL|Carvediolol CR + Lisinopril, then Lisinopril + HCTZ|Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months.
62470208|NCT04110236|EXPERIMENTAL|Immediate PriCARE Positive Discipline Module|A subset of participants (up to 40 caregiver-child pairs) who were assigned to the immediate PriCARE group will be offered to participate in the PriCARE Positive Discipline Module if they attended at least 4 PriCARE sessions and completed both main study interviews. If they are randomized to the immediate PriCARE Positive Discipline group, they will attend an additional 4-6 sessions 4-6 weeks after completion of the 6-week PriCARE intervention. This module teaches techniques related to behavior reward charts, appropriate timeout protocol, and other positive discipline techniques for handling persistent behaviors not addressed by the other PriCARE skills.
62670767|NCT06258291|NO_INTERVENTION|Standard of care|Best standard of care will be applied to these patients.
62670768|NCT01186419|EXPERIMENTAL|SPD602 (16mg)|
62670769|NCT01186419|EXPERIMENTAL|SPD602 (32mg)|
62670770|NCT01121575|EXPERIMENTAL|Arm 1|PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
62670771|NCT01121575|EXPERIMENTAL|Arm 2|PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
62670772|NCT03826004|PLACEBO_COMPARATOR|Placebo|Saline solution 2ml before anesthetic induction
62670773|NCT03826004|EXPERIMENTAL|Clemastine|Clemastine fumarate 2mg/2ml before anesthetic induction
62670774|NCT02000271|OTHER|Vaginal packing|Vaginal packing will be placed as is typical following vaginal reconstructive surgery.
62670775|NCT02000271|EXPERIMENTAL|No vaginal packing|No vaginal packing will be used following vaginal reconstructive surgery.
62670776|NCT05424809|EXPERIMENTAL|Shared decision-making model|In the intervention group, the shared decision-making model will be carried out. This model was proposed and designed through a participatory and deliberative process.
62670777|NCT05424809|NO_INTERVENTION|Usual care|Information without an estructured shared decision-making model
62670778|NCT00202995|EXPERIMENTAL|1|Glatiramer Acetate 20 mg s.c. daily
62670779|NCT00202995|ACTIVE_COMPARATOR|2|Betaseron 250 ug every other day or Rebif 44 ug 3 times a week
62670780|NCT00066937|EXPERIMENTAL|Nortriptyline Oral Capsule/CBT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.
62670781|NCT00066937|EXPERIMENTAL|Benztropine Oral Product/CBT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.
61914843|NCT00459056|ACTIVE_COMPARATOR|Lisinopril + HCTZ, then Carvedilol CR + Lisinopril|Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and then were given Carvedilol CR + Lisinopril for the final three months.
61914844|NCT00914303|EXPERIMENTAL|AZD3241|AZD3241 Tablets
61914845|NCT00914303|EXPERIMENTAL|Placebo|Placebo Tablets
62670782|NCT00066937|EXPERIMENTAL|Nortriptyline Oral Capsule/Disease MGT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.
61914846|NCT00306111|EXPERIMENTAL|Pegfilgrastim|Pegfilgrastim for stem cell mobilization (single arm)
61914847|NCT03256890|EXPERIMENTAL|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
62108978|NCT05082649|EXPERIMENTAL|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
62108979|NCT05082649|ACTIVE_COMPARATOR|Face to Face Exercises|Face to face (in clinic) progressive spinal stabilization exercises.
62670783|NCT00066937|ACTIVE_COMPARATOR|Benztropine Oral Product/Disease MGT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.
62670784|NCT01349621||Standard and polarized light colposcopy|Standard and polarized light colposcopy
62670785|NCT00947388|EXPERIMENTAL|Bendamustine plus Alemtuzumab|
62670786|NCT05003999|EXPERIMENTAL|Intermittent catheterization starting with a hydrophilic catheter (HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter i.e. SpeediCath ® (Coloplast A/S, Humlebæk, Denmark)
62670787|NCT05003999|ACTIVE_COMPARATOR|Intermittent catheterization starting with a non-hydrophilic catheter (non-HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter i.e. Self-Cath ® (Coloplast A/S, Humlebæk, Denmark); Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
62670788|NCT02460380|ACTIVE_COMPARATOR|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
62670789|NCT02460380|PLACEBO_COMPARATOR|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
62670790|NCT01457430|EXPERIMENTAL|Icatibant|Open-label study
62108980|NCT05708066|EXPERIMENTAL|Lavender Aromatherapy Tab|If part of the experimental group, participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations. After the lavender patch has been in place for 5 minutes, participants will receive the same visual analogue scale (VAS) anxiety questionnaire.
62108981|NCT05708066|PLACEBO_COMPARATOR|Non-scented Tab|If part of the placebo comparator group, participants will have an unscented tab placed on the chest, according to manufacturer recommendations. Participants in this group will only receive the initial visual analogue scale (VAS) anxiety questionnaire.
62108982|NCT04009070|ACTIVE_COMPARATOR|Acupuncture|"Group A: Acupuncture group:Group A: Acupunctur will be applied to the Acupunctur group 24 hours prior to bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally on the tibia) . The tape (Needle Press) will stay for 24 hours.~Needle Press: Pres Needle: 0.22x1.5 mm needle"
62108983|NCT04009070|NO_INTERVENTION|Control Group|Group C: Control group
62299934|NCT04982133|ACTIVE_COMPARATOR|Fortification adjusted according to urea|Fortification adjusted according to urea with FM 85 at 4% and oligopeptides. In this arm, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.
62299935|NCT04982133|EXPERIMENTAL|Individualized fortification according to the nutritional characteristics of breast milk|"Individualized fortification according to the nutritional characteristics of the mother's own milk or pasteurized milk taken by the premature infant.~In this arm, fortification is adjusted based on the macronutrient analysis of breast milk or donated twice weekly."
62299936|NCT04549987|EXPERIMENTAL|Without changing working archwire|Extraction space closed using the same working archwire throughout 3 visits after insertion
62670791|NCT05873621|EXPERIMENTAL|ICG-guided lymphadenectomy|Patients will intraoperatively receive a transanal local administration of ICG. During laparoscopic total mesorectal excision, ICG-fluorescent lymph nodes beyond the mesorectum will be separately excised and sent for pathology
62670792|NCT06136234|EXPERIMENTAL|Experimental Condition with intensive assessment|Caring Contacts plus best available resources, with monthly EMAs during study year
62670793|NCT06136234|ACTIVE_COMPARATOR|Control Condition with intensive assessment|Best available resources, with monthly EMAs during study year
62670794|NCT06136234|EXPERIMENTAL|Experimental Condition without intensive assessment|Caring Contacts plus best available resources, without monthly EMAs during study year
62670795|NCT06049277|EXPERIMENTAL|Mulligan techniques with manual traction|Mulligan techniques with manual traction
62670796|NCT06049277|ACTIVE_COMPARATOR|McKenzie extension exercises with manual traction|McKenzie extension exercises with manual traction
62670797|NCT03055195|EXPERIMENTAL|Mepolizumab|Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
62670798|NCT03055195|PLACEBO_COMPARATOR|Placebo|Eligible subjects will receive matching placebo subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
62470209|NCT04110236|NO_INTERVENTION|Delayed PriCARE Positive Discipline Module|The delayed Positive Discipline group will not receive the Positive Discipline Module intervention until after their third interview data collection is complete (in 2-3 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
62470210|NCT03925532|EXPERIMENTAL|Supportive Care (denosumab)|Patients receive 2 doses of denosumab SC between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
62670799|NCT03750669|EXPERIMENTAL|Neoadjuvant Chemotherapy|Patients receive the sequential neoadjuvant chemotherapy of AG regimen (nab-paclitaxel plus gemcitabine) and mFOLFIRINOX before resection.
62670800|NCT03750669|NO_INTERVENTION|control|Patients receive surgical treatment without any neoadjuvant treatments.
62670801|NCT01452789|EXPERIMENTAL|sublingual buprenorphine|This is the group that received active sublingual buprenorphine and placebo for oral morphine
62670802|NCT01452789|ACTIVE_COMPARATOR|oral morphine|This is the group that received active oral morphine and placebo for sublingual buprenorphine
62670803|NCT02237274|EXPERIMENTAL|Patients with Fontan circulation|High altitude exposition
62670804|NCT02237274|OTHER|Age and gender-matched healthy volunteers|High altitude exposition
62670805|NCT05017636|ACTIVE_COMPARATOR|Treatment groupThorck Shock Wave Ibramed (terapia ESWT)- fat cell death|The shock wave treatment was performed on the left side of the abdomen
62670806|NCT05017636|NO_INTERVENTION|Without intervention.|no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group without intervention.
62299937|NCT04549987|EXPERIMENTAL|With changing working archwire|The extraction space closed having the working archwire changed monthly.
62108984|NCT04814043|EXPERIMENTAL|PD-1 antibody and lenvatinib plus TACE-HAIC|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
62108985|NCT05356923||Healthy volunteers|Age- and sex- matched to participants, those aged 50 or over without known heart disease. n=20
62108986|NCT05356923||Acute myocardial infarction - multi-timepoint imaging|Those aged 50 or over with recent myocardial infarction who will be imaged using PET/MR at 1,2,4, and 12 weeks post-MI. n=20
62299938|NCT05204563|EXPERIMENTAL|Imipenem/Cilastatin/XNW4107|Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg, Q6h (0.5h Infusion)
62299939|NCT05204563|ACTIVE_COMPARATOR|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25g Q6h (0.5h Infusion)
62299940|NCT02568436|NO_INTERVENTION|Conventional Decrowding|Crowded upper incisors will be treated in the conventional manner with a fake irradiation without using low level laser therapy.
61914848|NCT03256890|ACTIVE_COMPARATOR|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
62108987|NCT05356923||Acute or chronic myocardial infarction - single timepoint imaging|Those aged 50 or over with recent (n=20) or prior established (\>24 months, n=20) myocardial infarction who will be imaged at a single timepoint (1,2,4, or 12 weeks post-MI for acute, at the time of enrolement to the study for chronic).
62108988|NCT03244787|EXPERIMENTAL|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
62108989|NCT03244787|NO_INTERVENTION|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
62108990|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
62108991|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
62670807|NCT01936974|EXPERIMENTAL|Platinum, Gemcitabine and Bevacizumab|"Platinum:~1. Carboplatin\* on day 1~   \*If a patient is allergic to carboplatin, then give~2. Cisplatin\*\* on day 1~   \*\*If a patient is allergic to cisplatin and carboplatin, then give~3. Oxaliplatin on day 1~Gemcitabine on day 1 only~Bevacizumab on day 1"
62670808|NCT01936974|ACTIVE_COMPARATOR|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8~Bevacizumab on day 1"
62670809|NCT01629940||Male HED-Affected Individuals|Male subjects affected by HED
62670810|NCT01629940||Male controls|Male subjects not affected by HED
62670811|NCT06107673|EXPERIMENTAL|neoadjuvant endocrine group|"Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks.~AI: Take according to the instructions provided."
62670812|NCT06107673|ACTIVE_COMPARATOR|neoadjuvant chemotherapy group|"Docetaxel for injection: Administered as a 75 mg/m2 intravenous infusion Epirubicin hydrochloride for injection: Administered as a 75 mg/m2 intravenous infusion.~Cyclophosphamide for injection: Administered as a 500 mg/m2 intravenous infusion."
61914849|NCT05154370||MS/CIS|Diagnosis of MS and CIS based on the 2017 McDonald MS diagnostic criteria.
62108992|NCT02971930||Prophylaxis treatment of BAY94-9027_1|2 infusions per week during the extension study
62670813|NCT04852653||Patients with adenocarcinoma of rectum histologically proven|
62670814|NCT04129801||Prospective analysis|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).~Evaluation of Muscle Strength was used The Biodex Multi-joint System 3 dynamometer (Biodex Medical Systems, Inc., Shirley, New York, USA) to measure isokinetic extension (Ext) and flexion (Flex) MVC torques for both legs."
62108993|NCT02971930||Prophylaxis treatment of BAY94-9027_2|infusion every 5 days during the extension study
62108994|NCT02971930||Prophylaxis treatment of BAY94-9027_3|every 7 days during the extension study
62108995|NCT04117451|SHAM_COMPARATOR|Chlorhexidine|Chlorhexidine mouthwash will be provided to participants for a week to rinse the mouth twice a day.
61914850|NCT05154370||ADEM|Diagnosis of ADEM based on the 2012 IPMSSG diagnostic criteria for ADEM
61914851|NCT05154370||MOGAD|Diagnosis of MOGAD based on the 2020 Chinese Expert Consensus.
62108996|NCT04117451|EXPERIMENTAL|Propolis|Propolis mouthwash will be provided to participants for a week to rinse the mouth twice a day.
62108997|NCT00208104|EXPERIMENTAL|Motivational Interview Condition|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
62108998|NCT00208104|NO_INTERVENTION|Non-supportive Counseling|A non-supportive counseling session will consist of regular nurse-patient interaction.
62108999|NCT01469949||Kinesthetic Imagery group|Subjects receiving Kinesthetic Imagery
62109000|NCT01469949||Visual Imagery Group|Subjects receiving visual imagery
62109001|NCT01469949||Control group|Subjects receiving measurement with intervention
62670815|NCT05998239|EXPERIMENTAL|Bootle Boot Camp with movement tracking feedback (virtual Coach Botley present)|Bootle Boot Camp exercise sessions offered with movement tracking feedback through the presence of virtual coach Botley.
62670816|NCT05998239|EXPERIMENTAL|Bootle Boot Camp without movement tracking feedback (virtual Coach Botley absent)|Bootle Boot Camp exercise sessions offered without movement tracking feedback through the absence of virtual coach Botley.
62670817|NCT04261595|ACTIVE_COMPARATOR|Dates group 1|For the group of the date 1, Diagnosed autistic patients will be given three pieces of Dates will be given on daily basis for 12 weeks as follow: Three pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
62109002|NCT00290732|EXPERIMENTAL|Intraductal arm|Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.
62109003|NCT00290732|ACTIVE_COMPARATOR|Intravenous arm|Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.
62109004|NCT06607731||Study population|Patients who have undergone percutaneous gel ethanol sclerosis for aggressive bone angioma at Saint-Etienne University Hospital.
62109005|NCT01424579|EXPERIMENTAL|Actual Diacutaneous Fibrolysis|The group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of actual Diacutaneous Fibrolysis.
62299941|NCT02568436|EXPERIMENTAL|Low Level Laser Therapy|Each maxillary incisor will be subjected to low level laser therapy at specific times in order to accelerate tooth movement
62299942|NCT05679882|ACTIVE_COMPARATOR|Outdoor Environment|Exposure to outdoor environmental noise
62299943|NCT05679882|EXPERIMENTAL|Outdoor Environment with Machine-Learning Selected Masking Sounds|Exposure to outdoor environmental noise and masking sounds
62299944|NCT03939208|EXPERIMENTAL|Intervention (BRISC) Group|Clinicians randomly assigned to BRISC will implement a flexible intervention that, over four sessions, aims to assess and engage student clients, and identify and address student identified difficulties that are distressing and impacting academic performance/behavior, social, and overall functioning. BRISC uses an explicit, problem-solving structure and a range of techniques common to evidence-based practices (EBP) tailored to the identified needs of the student.
62299945|NCT03939208|ACTIVE_COMPARATOR|Services as Usual (SAU) Group|"Clinicians in the SAU condition will use a diverse array of treatment as usual strategies over four sessions that may include some directive, skill-building techniques common in EBPs, but, given findings from pilot studies and studies of mental health services as usual in community and school settings, are likely to be provided at an overall lower rate, and at lower intensity, than in BRISC or other EBP."
62299946|NCT02363829|EXPERIMENTAL|Treatment|Nelfinavir and Cisplatin
62670818|NCT04261595|ACTIVE_COMPARATOR|Dates group 2|For the group of the date 2, Diagnosed autistic patients matched for age and sex will be given five pieces of Dates will be given on daily basis for 12 weeks as follow: five pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
62670819|NCT04261595|ACTIVE_COMPARATOR|Group 3|Group 3 (no- Dates fruit group): Diagnosed autistic patients matched for age and sex will not receive any dates
62670820|NCT04582643|EXPERIMENTAL|6P intervention|6P assessment along with education provided based on the 6P components.
62670821|NCT00483509|EXPERIMENTAL|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
62670822|NCT05023005|EXPERIMENTAL|Piriformis Strain-Counterstrain|The treatment group will receive strain-counterstrain for the piriformis muscle.
62670823|NCT05023005|SHAM_COMPARATOR|Hamstring Strain-Counterstrain|The sham group will receive strain-counterstrain treatment for the hamstring muscle.
62670824|NCT02623270|EXPERIMENTAL|Noninvasive Ventilation|After induction of anesthesia, checking of ability to bag mask ventilating the patient, the manual bag ventilation will be replaced by a Noninvasive Ventilator, V60 (Philips)
62670825|NCT01751841||Spinal fusion patients with minimally invasive spine surgery|Spinal fusion patients for whom Silicate-Substituted Calcium Phosphate Ceramic has been used as the Bone Graft
62670826|NCT02663570|EXPERIMENTAL|open|therapy with melatonin 2 mg daily for six months
62670827|NCT02744547|EXPERIMENTAL|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
62670828|NCT02744547|NO_INTERVENTION|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
62670829|NCT01684033|OTHER|PureMoist - Biotrue|Opti-Free® PureMoist® MPDS used first, followed by Biotrue™ MPS. Each product used as indicated for 30 days with participant's habitual contact lenses.
62670830|NCT01684033|OTHER|Biotrue - PureMoist|Biotrue™ MPS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
62670831|NCT05111769|EXPERIMENTAL|rhBNP in the treatment of sepsis complicated with heart failure|Recombinant human brain natriuretic peptide (rhBNP) on sepsis complicated with heart failure
62670832|NCT05111769|NO_INTERVENTION|Conventional treatment group|Do not use recombinant human brain natriuretic peptide (rhBNP) to treat sepsis with heart failure
62670833|NCT02797535|OTHER|GI fluids samples collection|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
62670834|NCT00881244|EXPERIMENTAL|1|AS1411
62670835|NCT04108260|EXPERIMENTAL|Single arm_Idelvion treated|
62299947|NCT02844361|EXPERIMENTAL|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
62299948|NCT02844361|ACTIVE_COMPARATOR|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
62299949|NCT02704962|EXPERIMENTAL|trifluoperazine plus olanzapine|trifluoperazine 5mg/day + olanzapine 5mg/day
62670836|NCT03993678|EXPERIMENTAL|Ablation + IP-001|"Ablation + IP-001 will be administered every 4 weeks for up to 6 treatment visits.~Trial treatment will stop in case of tumor progression according to RECIST 1.1 or iRECIST or unacceptable toxicity.~In all cases, toxicity assessment will continue for at least 100 days after discontinuing the last treatment of Ablation + IP-001 or until resolution of Ablation + IP-001-associated toxicity."
62670837|NCT02216162|EXPERIMENTAL|A: Interventional adapted physical activity + enhanced geriatr|Geriatric (functionality, gait, nutrition) follow-up, biological tests, anti-aromatase agents blood dosing, clinical assessment. Weekly Taï-Chi exercises.
62670838|NCT02216162|OTHER|Arm B: control|Clinical follow-up according to the Guidelines, annual geriatric and nutritional assessment
61914852|NCT05154370||NMOSD|diagnosis of NMOSD according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria.
61914853|NCT00534469|EXPERIMENTAL|HD ARA-C with or without Idarubicin|"This study was designed as a single-arm study.~Strata were:~HD ARA-C w/ Idarubicin, CR\<6 months N = 24 patients. HD ARA-C w/ Idarubicin, CR\>6 months N=1. HD ARA-C consolidation, CR\<6 months N=5. HD ARA-C consolidation, CR\>6 months N= 0."
61914854|NCT01847807|ACTIVE_COMPARATOR|High-dose Astragalus group|treatment with 10 gram astragalus
61914855|NCT01847807|ACTIVE_COMPARATOR|Low-dose Astragalus group|treatment with 5 gram astragalus
61914856|NCT01847807|NO_INTERVENTION|MS control|
61914857|NCT04559711|EXPERIMENTAL|Intervention arm|Strengthening coverage and quality of nutrition services including MMS during ANC
61914858|NCT04559711|NO_INTERVENTION|Comparison arm|Existing provision of nutrition services during ANC.
61914859|NCT04644731||Pediatric patients who require fluid removal|Pediatric patients who require fluid removal with the Aquadex™ System per local standard of care
61914860|NCT02067052||Advanced vulvar cancer|Patients with advanced-stage tumors.
61914861|NCT02067052||Early-stage vulvar cancer|Patients with early-stage tumors
61914862|NCT04959071|EXPERIMENTAL|Group A|Group A included participants who underwent VAC therapy for diabetic Foot ulcers
62109006|NCT01424579|PLACEBO_COMPARATOR|Placebo Diacutaneous Fybrolisis|This group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of placebo Diacutaneous Fibrolysis.
62109007|NCT01424579|OTHER|No Diacutaneous Fibrolysis|This group received only tree weeks of a daily protocolized treatment.
62109008|NCT03773861|OTHER|Participants|Active BLS- Instructors at the Bern Simulation and CPR- Center (BeSiC), at the Bern University Hospital, Bern, Switzerland. Participants have to oversee a BLS instructional session, where standardized errors are performed by trained volunteers.
61914863|NCT04959071|ACTIVE_COMPARATOR|Group B|Group B included participants who underwent conventional dressings for diabetic foot ulcers
61914864|NCT00356837|EXPERIMENTAL|A|Those with extremity fractures.
62109009|NCT03360422|ACTIVE_COMPARATOR|Survey group|Collect alcohol and sexual activity data via web survey from 683 young MSM to yield normative data for the alcohol and HIV preventive intervention in a follow-up study
62109010|NCT03360422|ACTIVE_COMPARATOR|Focus Group|30 young MSM who drink regularly to inform the content of the alcohol and HIV preventive intervention tested in the UH3 phase and ensure the intervention is culturally appropriate for MSM.
62109011|NCT03360422|ACTIVE_COMPARATOR|Usability Study|10 young adult MSM will test the mobile intervention in development for 30 days in order to establish usability, acceptability and correct any functionality issues.
62109012|NCT05283460|EXPERIMENTAL|mandala|As in the case of previous studies, to prevent confusion and make the mandala drawing process easier, a few videos describing what a mandala is were shown to the patients, and information was provided. Next, each patient was given a set of felt-tip pens (in 24 different colors) and ready-to-use mandala papers, and they were asked to complete the mandala activity. The patients were given empty mandala books with enough pages for them to draw mandalas every day, they were asked to perform the mandala activity regularly in a time interval of their own choice every day, and whether they performed the activity was checked daily without them noticing (so that they would not have the feeling of being checked on or inspected).
62299950|NCT02704962|ACTIVE_COMPARATOR|full-dose olanzapine|olanzapine 10mg/day
62299951|NCT00942162|EXPERIMENTAL|GSK2132231A GS+ Group|Patients with the pre-specified gene signature (GS), who received intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
61914865|NCT00539760|EXPERIMENTAL|Subjects receiving GSK 1827771 in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive GSK1827771 with the starting dose of 0.3 milligram (mg)
62299952|NCT00942162|EXPERIMENTAL|GSK2132231A GS- Group|Patients without the pre-specified gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
61914866|NCT00539760|PLACEBO_COMPARATOR|Subjects receiving placebo in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
61914867|NCT00539760|EXPERIMENTAL|Subjects receiving GSK 1827771 in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
61914868|NCT00539760|PLACEBO_COMPARATOR|Subjects receiving placebo in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
62109013|NCT05283460|NO_INTERVENTION|control group|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
62299953|NCT00942162|EXPERIMENTAL|GSK2132231A GS-unknown Group|Patients with unknown gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE_A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
62299954|NCT05842798|EXPERIMENTAL|Cohort 1: TNM002 35 μg/kg or placebo|Eight subjects will be randomly assigned to receive either TNM002 35 μg/kg or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo)
62299955|NCT05842798|EXPERIMENTAL|Cohort 2: TNM002 100 μg/kg or placebo|Eight subjects will be randomly assigned to receive either TNM002 100 μg/kg or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo)
62470211|NCT02308475|EXPERIMENTAL|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
62299956|NCT05842798|EXPERIMENTAL|Cohort 3：TNM002 250 μg/kg or placebo|Eight subjects will be randomly assigned to receive either TNM002 250 μg/kg or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo)
61914869|NCT00539760|EXPERIMENTAL|Subjects receiving GSK 1827771 in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
61914870|NCT00539760|PLACEBO_COMPARATOR|Subjects receiving placebo in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
61914871|NCT02680678|ACTIVE_COMPARATOR|Colloid preload|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) 15 minutes before spinal anesthesia.
61914872|NCT02680678|ACTIVE_COMPARATOR|Colloid Co-load|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) beginning with spinal anesthesia.
62109014|NCT00695006|SHAM_COMPARATOR|II|Sham Traction
62109015|NCT00695006|ACTIVE_COMPARATOR|I|Traction
62109016|NCT01372163|EXPERIMENTAL|2 mg PF-05190457 or Placebo BID|
61914873|NCT02680678|ACTIVE_COMPARATOR|Crystalloid Preload|20 patients each patient receives 20 ml/kg of Ringer's lactate solution 15 minutes before spinal anesthesia.
61914874|NCT02680678|ACTIVE_COMPARATOR|Crystalloid Co-load|20 patients each patient receives 20 ml/kg of Ringer's lactate solution beginning with spinal anesthesia.
61914875|NCT00374205|EXPERIMENTAL|AL|Artemether plus Lumefantrine 6 dose 3 days treatment
61914876|NCT00374205|ACTIVE_COMPARATOR|ASAQ|Artesunate plus Amodiaquine
61914877|NCT00969280|EXPERIMENTAL|Standardized Acupuncture group|
61914878|NCT00969280|PLACEBO_COMPARATOR|Non-acupoint shallow penetration group|
61914879|NCT03997578|ACTIVE_COMPARATOR|NIPSA|Patients will be treated with only NIPSA technique.
61914880|NCT03997578|EXPERIMENTAL|NIPSA plus Connective tissue graft|Patients will be treated with NIPSA technique associated to a connective tissue graft.
61914881|NCT02864485|EXPERIMENTAL|transplantation|Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases
61914882|NCT01584570|ACTIVE_COMPARATOR|Control|fentanyl 1 mcg/kg before induction
61914883|NCT01584570|EXPERIMENTAL|D 0.5 group|Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium
61914884|NCT01584570|EXPERIMENTAL|D 1.0 group|Dexmedetomidine 1.0 ug/kg + Propofol + Sevoflurane+ Vecuronium
61914885|NCT03381157||Cystic Fibrosis Group|
61914886|NCT03381157||Control Group|
61914887|NCT01081548|EXPERIMENTAL|Generic|
61914888|NCT01081548|ACTIVE_COMPARATOR|Lipitor|
62109017|NCT01372163|EXPERIMENTAL|10 mg PF-05190457 or Placebo BID|
62109018|NCT01372163|EXPERIMENTAL|40 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
62670839|NCT05830643|EXPERIMENTAL|Social skills group psychotherapy|Originally designed to meet the needs of patients with ASD or ASPD, this group is now popular with patients who want to work on issues involving their relationships with their probation or parole officers or in establishing health romantic relationships.
62109019|NCT01372163|EXPERIMENTAL|150 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
62109020|NCT01372163|EXPERIMENTAL|5 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
62670840|NCT05830643|ACTIVE_COMPARATOR|Adult interest group psychotherapy|The adult interest group has dual aims to (1) stop illegal sex acts and (2) enhance noncriminal sexual interests. The group focuses on respect for informed, voluntary, revocable, consent by examining various cognitive distortions that group members may endorse.
62670841|NCT01082055||Currently receiving antiarrythmic drugs|
62670842|NCT02708706|EXPERIMENTAL|physical therapy and hyaluronic acid|patient received ultrasound-guided hydrodilatation with hyaluronic acid plus physical therapy
62299957|NCT06489288|EXPERIMENTAL|ERAS group|It is necessary to remove the urinary catheter before the patient awakens from anesthesia, drink water orally in the early postoperative period, and remove the drainage tube and nutrition tube in the early postoperative period
62299958|NCT06489288|OTHER|control group|According to conventional treatment measures, there is no need for Enhanced Recovery After Surgery
62109021|NCT01372163|EXPERIMENTAL|50 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
62109022|NCT01372163|EXPERIMENTAL|xxx mg PF-05190457 or Placebo|Dose and dose frequency to be determined based on emerging safety and PK data.
62109023|NCT03795701|PLACEBO_COMPARATOR|Placebo|Subjects in placebo group will receive placebo plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will also be asked to maintain physical activity.
62109024|NCT03795701|EXPERIMENTAL|Liraglutide 3.0|Subjects in Liraglutide 3.0 group will receive Saxenda® plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will be asked to maintain physical activity. The dose of Saxenda® will be increased weekly in the first 4 weeks (.6; 1.2; 1.8; 2.4 mg) and maintained on 3 mg for 12 weeks.
62109025|NCT03046290|ACTIVE_COMPARATOR|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
62109026|NCT03046290|ACTIVE_COMPARATOR|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
62109027|NCT00782639|ACTIVE_COMPARATOR|Iopamiro-370|
62109028|NCT00782639|ACTIVE_COMPARATOR|Visipaque 320|
62109029|NCT03355053|ACTIVE_COMPARATOR|Dexmedetomidine, continuous very-low-dose overnight infusion|Patients randomized to this study arm will receive dexmedetomidine, given as a very-low-dose (0.1 mcg/kg/hour group; rate of 0.075 mL/kg/hour at a concentration of 1.33 mcg/mL) continuous overnight infusion. Study drug will be provided by the MGH research pharmacy as a clear liquid and delivered by the research staff directly to the patient's ICU nurse, in a 60 mL syringe/bag (s). Nursing will then administer the study drug intravenously each night (11 hours; 8PM through 7AM) until either discharge from the ICU or up to 7 consecutive nights, whichever occurs first.
62109030|NCT03355053|ACTIVE_COMPARATOR|Dexmedetomidine, continuous low-dose overnight infusion|Patients randomized to this study arm will receive dexmedetomidine, given as a low-dose (0.3 mcg/kg/hour group; rate of 0.075 mL/kg/hour at a concentration of 4 mcg/mL) continuous overnight infusion. Study drug will be provided by the MGH research pharmacy as a clear liquid and delivered by the research staff directly to the patient's ICU nurse, in a 60 mL syringe/bag (s). Nursing will then administer the study drug intravenously each night (11 hours; 8PM through 7AM) until either discharge from the ICU or up to 7 consecutive nights, whichever occurs first.
62109031|NCT03355053|PLACEBO_COMPARATOR|Usual care and placebo (normal saline)|Patients randomized to this study arm will receive standard ICU care plus a normal saline placebo, given as a continuous overnight infusion, at a rate of 0.075 mL/kg/hour. Study drug will be provided by the MGH research pharmacy as a clear liquid and delivered by the research staff directly to the patient's ICU nurse, in a 60 mL syringe/bag (s). Nursing will then administer the study drug intravenously each night (11 hours; 8PM through 7AM) until either discharge from the ICU or up to 7 consecutive nights, whichever occurs first.
62299959|NCT01901224|EXPERIMENTAL|Metformin 1000 mg|metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
62670843|NCT02708706|ACTIVE_COMPARATOR|physical therapy only|patient received physical therapy only
62470212|NCT03500003|EXPERIMENTAL|Milk acute intake|14 adult and 14 elderly volunteers will consume 600mL of milk. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
62470213|NCT03500003|EXPERIMENTAL|Yogurt acute intake|14 adult and 14 elderly volunteers will consume 600mL of yogurt. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
61914889|NCT03252600|EXPERIMENTAL|Arm I (lenalidomide, dexamethasone, elotuzumab)|"Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8, 15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
62109032|NCT00392678|PLACEBO_COMPARATOR|Placebo|Placebo, appearance matched to active drug
62109033|NCT00392678|ACTIVE_COMPARATOR|3 gram|Salsalate 3.0 grams daily, divided
62109034|NCT00392678|ACTIVE_COMPARATOR|3.5 gram|Salsalate 3.5 g daily, divided
62109035|NCT00392678|ACTIVE_COMPARATOR|4 gram|Salsalate 4.0 g daily, divided
62299960|NCT01901224|PLACEBO_COMPARATOR|Control|placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
62299961|NCT03091023|ACTIVE_COMPARATOR|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
62299962|NCT03091023|ACTIVE_COMPARATOR|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
62299963|NCT03335501|ACTIVE_COMPARATOR|Rapid-acting Aspart|Rapid-acting Aspart will be used to regulate glucose levels
62299964|NCT03335501|ACTIVE_COMPARATOR|Faster insulin Aspart|Faster insulin Aspart will be used to regulate glucose levels
62670844|NCT04870970||Tobacco Users|Participants in this group use some form of tobacco.
62109036|NCT06630702|EXPERIMENTAL|SCS implantation|
62109037|NCT04423484||Children with Nephroblastoma|All children coming into the participating units with suspected Nephroblastoma.
62109038|NCT00831792|EXPERIMENTAL|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day). Following an initial 4-week cycle at a starting dose of 400 mg 5 days- on and 2 days off, TKI258 may be escalated to 500 mg/day 5 days-on/2 days off if no significant Grade3/4 AEs or laboratory abnormalities are observed.
62109039|NCT04431206|EXPERIMENTAL|Oxytocin|Oxytocin administered by IV infusion
62109040|NCT06556069|NO_INTERVENTION|Standard Care|Standard of care will occur during the baseline/pre-implementation phase and no quality improvement programs or interventions related to agitation management will occur during this time period.
62109041|NCT06556069|EXPERIMENTAL|PACT Implementation|Implementation of the PACT intervention. After a site is randomized to implement PACT, trained peers will be assigned to work ED shifts alongside the structured code team. ED patients with behavioral needs will receive peer-led TIC, including empathic listening, therapeutic relationship building, understanding of patient needs and goals for the visit, and informing of patients and family about the evaluation process in real-time.
62299965|NCT00013052|OTHER|Arm 1|
62299966|NCT04710108|NO_INTERVENTION|No treatment control|No treatment; no intervention (survey only)
62670845|NCT04870970||Non-Tobacco Users|Participants in this group do not use tobacco products.
62670846|NCT05415787||adult patients with metastatic prostate cancer|
62109042|NCT06374056||Depressed|All study participants will undergo the same study procedures. All individuals will complete brief online assessments about their emotional and physical wellbeing, provide audio recorded voice responses to prompts, and complete the SCID-5-CT with a clinician licensed in their state of residence while being audio and video recorded for quality assurance purposes.
62109043|NCT04841733|EXPERIMENTAL|Protocol I: Foam Roller (FR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Cold-Water Immersion (CWI)
62109044|NCT04841733|EXPERIMENTAL|Protocol II: Stretching (STR) + Cold-Water Immersion (CWI)|Stretching (STR) Cold-Water Immersion (CWI)
62299967|NCT04710108|EXPERIMENTAL|Video|A Taste of Home video, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
62670847|NCT02468375|EXPERIMENTAL|mirabegron 50mg|about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
62670848|NCT03315559|EXPERIMENTAL|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of \[14C\] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
62109045|NCT04841733|EXPERIMENTAL|Protocol III: Foam Roller (FR) + Stretching (STR)|Foam Roller (FR) Stretching (STR)
62109046|NCT04841733|EXPERIMENTAL|Protocol IV: Foam Roller (FR) + Stretching (STR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Stretching (STR) Cold-Water Immersion (CWI)
62109047|NCT06196190||Post Conization HR HPV positive|Women with a Post Conization cervical test positive for HR HPV
62109048|NCT06196190||Post Conization HR HPV negative|Women with a Post Conization cervical test negative for HR HPV
62299968|NCT04710108|EXPERIMENTAL|Print|A Taste of Home comic book, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
62299969|NCT01412437|EXPERIMENTAL|Diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
62299970|NCT01412437|EXPERIMENTAL|sapropterin dihydrochloride|Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months
62670849|NCT03315559|EXPERIMENTAL|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive \[14C\]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
62670850|NCT01232907|EXPERIMENTAL|L-Carnitine|This study has a single subject design. Each subject acts as its own control. All subjects will go through intervention phase (treatment with L-Carnitine).
62670851|NCT05714397|EXPERIMENTAL|Cingal Injection|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
62670852|NCT05916066|OTHER|Healthy controls|Healthy controls
62670853|NCT05916066|OTHER|Pseudoexfoliative glaucoma|PEXG
62670854|NCT05916066|OTHER|POAG|POAG
62670855|NCT05916066|OTHER|NTG|NTG
62670856|NCT05592288|EXPERIMENTAL|Intervention group|The study universe will consist of adults of the ages 45-65 who have received a diagnosis of prediabetes and are registered at the Family Health Center No. 9. PREDIABE-TR mobile app usage (six months).
62109049|NCT06196190||No Conization HR HPV positive|Women who did not go through Conization prior to surgery and had a cervical test positive for HR HPV
62109050|NCT06196190||No Conization HR HPV negative|Women who did not go through Conization prior to surgery and had a cervical test negative for HR HPV
62109051|NCT01372852||T2DM patients|newly diagnosed T2DM patients and untreated with any drugs.
62470214|NCT04916418|PLACEBO_COMPARATOR|G1, Placebo|Intravenous saline (NaCl 0,9%) will be administered. G1 group will be administered an initial dose of placebo (20ml) per catheter bilaterally (total volume 40ml) after TTP has been placed. This is followed by 20ml doses of placebo per catheter every 8 hours until 72 hours from the first dose has passed.
62670857|NCT05592288|NO_INTERVENTION|Control grup|The study universe will consist of adults of the ages 45-65 who have received a diagnosis of prediabetes and are registered at the Family Health Center No. 9. Routine practice (Brochures of the Public Health Directorate, Mobile apps of the Ministry of Health, etc.)
62670858|NCT02438085||ACS patients|prospective collection of data and follow-up
62670859|NCT06543290|ACTIVE_COMPARATOR|Azithromycin Arm|Administration of 2 grams oral azithromycin (4 tablets of 500 mg) prior to the start of induction , once.
62670860|NCT06543290|PLACEBO_COMPARATOR|Placebo Arm|Administration of 4 magnesium oxide tablets prior to the start of induction , once.
62670861|NCT06178913|EXPERIMENTAL|Exercise intervention|
62670862|NCT05803512||experimental group|urinary incontinence females with sexual dysfunction
62670863|NCT05803512||control group|Normal females
62670864|NCT00943904|EXPERIMENTAL|Interstim stimulation|Patients who receive the interstim implant in order to evaluate effectiveness of treatment
62670865|NCT05803993|EXPERIMENTAL|FMT from healthy donor|Subjects receiving a single infusion FMT via colonoscopy from healthy donor
62670866|NCT05803993|PLACEBO_COMPARATOR|Autologous FMT|Subjects receiving a single infusion autologous FMT via colonoscopy
62670867|NCT02105870|EXPERIMENTAL|Intracoronary abciximab (Reopro)|Intracoronary abciximab (Reopro)
62670868|NCT02105870|PLACEBO_COMPARATOR|Control group|Intracoronary Reopro
62109052|NCT01372852||Non-diabetic Control Group|
62109053|NCT03408860|OTHER|2-week baseline|Patients complete assessment only for a duration of 2-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
62109054|NCT03408860|OTHER|4-week baseline|Patient complete assessment only for a duration of 4-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
62109055|NCT05318950|NO_INTERVENTION|Control|No intervention
62109056|NCT05318950|EXPERIMENTAL|E-learning|E-learning: 8 lessons about nutrition and lifestyle
62670869|NCT03580187|OTHER|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still\> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.~morphine (+) group: good response to morphine in nebulization after 30 min if VAS \> than 4 we conclude to morhine (-)"
62670870|NCT06318286|EXPERIMENTAL|Lenvatinib, Pemetrexed, Cisplatin/Carboplatin, and Pembrolizumab|In induction treatment, study interventions include oral lenvatinib, 8 mg quaque die (QD), and pembrolizumab, 200 mg, carboplatin (AUC 5 mg/mL/min) or cisplatin (75 mg/m2), and pemetrexed, 500 mg/m2 all given by intravenous (IV) infusion on Day 1 of a 21-day cycle. Lenvatinib, pembrolizumab, carboplatin/cisplatin, and pemetrexed combination treatment will be given for 4-6 cycles, after which participants may receive maintenance treatment with Lenvatinib, 20 mg QD, and pembrolizumab, 200 mg. Lenvatinib and Pembrolizumab may be given for up to a total of 35 cycles.
62670871|NCT04382079|EXPERIMENTAL|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
62670872|NCT04382079|EXPERIMENTAL|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
62670873|NCT04382079|NO_INTERVENTION|control|Routine care to encourage oral care three times a day.
62670874|NCT04179149|EXPERIMENTAL|Environmental enrichment|Subjects randomized to the intervention condition will receive the EE intervention (social support, open spaces, novel stress relief activities) as an adjuvant to standard gynecological care consisting of hormonal, analgesic or surgical treatment as necessary according to their symptoms during the study period.
62670875|NCT04179149|NO_INTERVENTION|Controls|Participants randomized to the control condition will receive only standard care as necessary according to their symptoms during the study period PLUS an online patient training module.
61914890|NCT03252600|EXPERIMENTAL|Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)|"Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
61914891|NCT00817687|EXPERIMENTAL|1|
61914892|NCT00817687|NO_INTERVENTION|2|
61914893|NCT04918901||Severe COVID-19|Comparative Analysis of Clinical Parameters and Radiographic Changes
61914894|NCT00584740|EXPERIMENTAL|AIN457|AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
61914895|NCT00584740|PLACEBO_COMPARATOR|Placebo|Matching placebo to AIN457 was given as an infusion at day 1 and day 22.
61914896|NCT00870233||GYN pts undergoing surgery|This study will assess patient use of WEBCORE, an online system designed for cancer patients to self-record toxicity-related symptoms based on NCI Common Terminology Criteria for Adverse Events and global quality of life (QoL) by European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).
61914897|NCT00794027|OTHER|Yoga group|Patients with heart failure
61914898|NCT00256282|EXPERIMENTAL|Docetaxel & Vinorelbine + Sargramostim|Docetaxel, Vinorelbine, and Sargramostim
61914899|NCT02007538||Thin Prep|Samples obtained from this group will be tested with thin prep
61914900|NCT02007538||Control Group|Samples obtained from this group will be tested with conventional procedure.
61914901|NCT02676128|EXPERIMENTAL|Mobile Health ART Adherence Application (mARTAA)|mARTAA will use a smartphone-delivered application developed by Twine Health, Inc.
61914902|NCT02676128|ACTIVE_COMPARATOR|Face-to-Face ART Adherence Intervention|A single face-to-face ART adherence intervention will be administered.
61914903|NCT02962375|EXPERIMENTAL|Active Treatment|100% orange juice with orange pomace fiber
61914904|NCT02962375|PLACEBO_COMPARATOR|Control Treatment|100% orange juice
62470215|NCT04916418|ACTIVE_COMPARATOR|G2, Ropivacaine|Ropivacaine 0.5%. G2 group will be administered an initial dose of ropivacaine (20 ml) per catheter bilaterally (total volume 40ml) after the TTP has been placed. This is followed by 20 ml doses of ropivacain per catheter every 8 hours until 72 hours from the first dose has passed.
62470216|NCT04649593|NO_INTERVENTION|according to clinical guidlines|Dystocic progress and an observed low AFL value (\< 12.0 mmol/l).
62470217|NCT04649593|EXPERIMENTAL|intevention|"At dystocic labor and an observed high AFL value, the woman is randomized to one of the intended two study groups.~Group 1) Delivery according to the clinic's guidelines in case labor dystocia, i.e., oxytocin stimulation Group 2) Two bags of Samarin mixed in a glass of water. After an hour, In case of lack of progress, oxytocin stimulation is started."
61914905|NCT01437800|EXPERIMENTAL|Glimepiride / Extended release Metformin|Pharmaceutical Form: Tablets Dosage: (4/850 mg). Administration way: Oral On fasting conditions
61914906|NCT02179138|OTHER|TFV 1% Gel|TFV 1% gel with the user-filled paper applicator
61914907|NCT02821143|EXPERIMENTAL|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
61914908|NCT02821143|OTHER|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
62299971|NCT04937270|EXPERIMENTAL|High frequency application time is 5 minutes|The group which treats for 5 minutes by using the high-frequency therapy device
62299972|NCT04937270|EXPERIMENTAL|High frequency application time is 7 minutes|The group which treats for 7 minutes by using the high-frequency therapy device
62470218|NCT05931315|ACTIVE_COMPARATOR|CaroRite™|One capsule to be taken immediately post-dinner / with dinner
62470219|NCT05931315|PLACEBO_COMPARATOR|Placebo|One capsule to be taken immediately post-dinner / with dinner
62470220|NCT05105945|EXPERIMENTAL|Single port inflatable mediastinoscope and synchronized laparoscopic radical resection|"Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
62470221|NCT05105945|ACTIVE_COMPARATOR|Thoracoscopy combined with laparoscopic radical resection|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
61914909|NCT01246466|EXPERIMENTAL|AtriCure Bipolar System combined with a catheter ablation|procedure using the AtriCure Bipolar System plus a catheter ablation
62470222|NCT00392665|ACTIVE_COMPARATOR|Erlotinib + Bevacizumab|erlotinib plus bevacizumab
61914910|NCT06094985||Patient with head and neck cancer|Patient diagnosed with head and neck cancer
61914911|NCT02299401|EXPERIMENTAL|Buccal|Women randomized to receive three 800 mcg doses of misoprostol taken buccally in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
62109057|NCT05318950|EXPERIMENTAL|Diet A|MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids)
61914912|NCT02299401|EXPERIMENTAL|Sublingual|Women randomized to receive three 800 mcg doses of misoprostol taken sublingually in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
62109058|NCT05318950|EXPERIMENTAL|Diet B|MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
62109059|NCT00219999||HCV infection|current HCV infection, including intravenous drug users
62109060|NCT00219999||cryoglobulinemia|cryoglobulinemia and without HCV infection
62109061|NCT00219999||chronic liver disease|chronic liver disease not due to hepatitis C virus infection
62299973|NCT04937270|EXPERIMENTAL|High frequency application time is 9 minutes|The group which treats for 9 minutes by using the high-frequency therapy device
62470223|NCT00392665|ACTIVE_COMPARATOR|Erlotinib + Sulindac|erlotinib plus sulindac
62470224|NCT02255097|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
62470225|NCT03427164|EXPERIMENTAL|TIPS|Participants will have measurements taken of spleen stiffness before and after TIPS. Participation will last about 12 months, with visits at 1-2 weeks post-TIPS, 3 months, 6 months, and 12 months.
62109062|NCT00219999||Sustained Virologic responders|successfully treated for HCV infection
62109063|NCT00219999||normal|normal, healthy volunteers
62299974|NCT04937270|ACTIVE_COMPARATOR|Superficial heat therapy|Group treated with superficial heat therapy for 20 minutes
61914913|NCT00645710|EXPERIMENTAL|Arm I|"Patients receive floxuridine as a continuous hepatic arterial infusion on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 9 and 11. Patients also receive yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV over 25 minutes on day 9. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive an additional course of floxuridine in combination with systemic therapy at the discretion of the treating physician."
62670876|NCT00120250|EXPERIMENTAL|Eszopiclone|Subjects received 3mg eszopiclone nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of placebo, followed by another 1 week washout.
61914914|NCT01847131|ACTIVE_COMPARATOR|oxymetazoline|0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
61914915|NCT01847131|PLACEBO_COMPARATOR|placebo|placebo nasal spray 2 sprays in each nostril twice daily
61914916|NCT06254196|NO_INTERVENTION|Control group: current clinical practice|
62109064|NCT01805921|EXPERIMENTAL|Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|"Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
62109065|NCT01805921|EXPERIMENTAL|Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|"Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.~Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks."
62299975|NCT03456115|EXPERIMENTAL|Mechanical Nasal Dilator|All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
62670877|NCT00120250|PLACEBO_COMPARATOR|Placebo|Subjects received placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of 3mg eszopiclone, followed by another 1 week washout.
61914917|NCT06254196|EXPERIMENTAL|Experimental group: Telenursing intervention|
61914918|NCT05635188||Open Surgery|
62299976|NCT05059132|EXPERIMENTAL|Tele-rehabilitation|Participants in the tele-rehabilitation arm will receive a home-based, remotely delivered rehabilitation program.
62670878|NCT05548777||Patients hospitalized for an anticoagulation-related major bleed|
62670879|NCT05130021|EXPERIMENTAL|Part 1;50mg|
61914919|NCT05635188||Laparoscopic Surgery|
61914920|NCT05635188||Trephine Surgery|
62299977|NCT05059132|ACTIVE_COMPARATOR|Education only|Participants in the education arm will receive educational materials only, delivered through telecommunication messages.
62299978|NCT03723447|ACTIVE_COMPARATOR|Bupivacaine/epinephrine/dexamethasone TAP block|For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
62299979|NCT03723447|ACTIVE_COMPARATOR|Liposomal bupivacaine TAP block|For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.
62670880|NCT05130021|EXPERIMENTAL|Part 1;70mg|
62670881|NCT05130021|EXPERIMENTAL|Part 2;MAX-40279-01|
62670882|NCT05130021|EXPERIMENTAL|Part 2;regorafenib|
62670883|NCT02475057|EXPERIMENTAL|Degarelix (LHRH antagonist)|Degarelix (LHRH antagonist) EndoPAT2000
62670884|NCT02475057|ACTIVE_COMPARATOR|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist EndoPAT2000
62670885|NCT04677036||TUH Staff|Staff within Tallaght University Hospital - anonymised
62670886|NCT04677036||ASIT Members|Members of the Association of Surgeons in Training - anonymised
61914921|NCT05955573||knee osteoarthritis|Knee osteoarthritis
61914922|NCT01552733|EXPERIMENTAL|Robotic Therapy|Robotic Therapy using 'Inmotion' device plus standard care. Participants randomised to robotic therapy will receive up to 12 sessions (approximately 1 hour each) performing tasks (including circle drawing, reaching targets and holding/moving against moderate resistance.
61914923|NCT01552733|PLACEBO_COMPARATOR|Standard Care|Rehabilitation therapy according to local guidelines.
62670887|NCT01928576|EXPERIMENTAL|Arm C|Nivolumab 3mg/kg every 2 weeks until progression
62470226|NCT02477202|EXPERIMENTAL|Mirena® IUD|This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (\<30/30+ kg/m\^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
62470227|NCT05900635|EXPERIMENTAL|Control|Patients in this group will initiate treatment with oral ferrous glycine sulfate (100mg) every other day for 3 months
62109066|NCT01805921|EXPERIMENTAL|Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|"Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
62109067|NCT01805921|EXPERIMENTAL|Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)|"Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
62299980|NCT02039557||NiCord®/CordIn™ (omidubicel) transplanted|Anyone who signed the consent for this study received a NiCord®/CordIn™ (omidubicel) infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
62470228|NCT05900635|ACTIVE_COMPARATOR|Intervention|Patients in this group will initiate treatment with oral lactoferrin (one sachet that contains 100mg) with oral ferrous glycine sulfate (100mg) every other day for 3 months
62470229|NCT03019367|ACTIVE_COMPARATOR|Umbilical cord milking UCM|Milking the umbilical cord 4 times towards the infant at a speed of 20cm/2seconds.
62470230|NCT03019367|ACTIVE_COMPARATOR|Delayed cord clamping DCC|Delayed clamping of the umbilical cord for at least 60 seconds.
62670888|NCT01928576|EXPERIMENTAL|Arm D|"Anti-PD-1/PD-L1 treatment naïve patients only~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
62299981|NCT02493179|ACTIVE_COMPARATOR|Serodase 5 mg|Serodase ( Serratiopeptidase) 5 mg
62470231|NCT02927119||Non-users|Pregnant women who had not taken dietary iodine supplement before and during pregnancy.
62470232|NCT02927119||Users|Pregnant women who had taken dietary iodine supplement before and/or during pregnancy.
62670889|NCT01928576|EXPERIMENTAL|Arm E|"Patients must have had refractory (Arm E=less than 24 weeks from first dose of anti-PD-1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
62670890|NCT01928576|EXPERIMENTAL|Arm F|"Patients must have had recurrent (Arm F=more than 24 weeks from first dose of anti-PD1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
61914924|NCT05959642|EXPERIMENTAL|Controlled Flow Delivery Dentapen|Controlled Flow Delivery Dentapen - infiltration upper d according to the manufacturer instructions it works with standardised 1.8 ml local anaesthetic carpules . 1)we raise the lip a little 2) we use dentapen for anaesthesia 3) class 1 cavity preparation Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected.The dentist will wait 5 seconds
62109068|NCT01805921|NO_INTERVENTION|Arm 5. No vaccine|Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.
62109069|NCT01805921|EXPERIMENTAL|Arm 6. MVA-RSV (IM)|Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.
62109070|NCT01805921|EXPERIMENTAL|Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.
62299982|NCT02493179|PLACEBO_COMPARATOR|Placebo|Placebo
62299983|NCT00432198|EXPERIMENTAL|1|Oral
62299984|NCT00432198|EXPERIMENTAL|2|Oral
62299985|NCT00432198|PLACEBO_COMPARATOR|3|Oral
62299986|NCT05723146|EXPERIMENTAL|Spatial cognition assessment|A single session of spatial cognition assessment (baseline) will be proposed to participants. This assessment will be based on paper-and-pencil tasks and immersive virtual reality tasks (with an HTC Vive Pro Head-Mounted-Display). The assessment will last around 1 hour.
62670891|NCT01928576|EXPERIMENTAL|Arm A|"Anti-PD-1/PD-L1 treatment naïve patients only Every 28 days for 2 cycles Azacitidine 40mg/m2 subcutaneous days 1-6 and 8-10 Entinostat 7mg by mouth Days 3 and 10~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg"
61914925|NCT05959642|ACTIVE_COMPARATOR|Traditional metal Syringes|Traditional metal Syringes we raise the lip a little 2) infiltration upper d we use traditional syringes 3)class 1 cavity preparation with composit filling works with standardised 1.8 ml local anaesthetic carpules . we use Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected.The dentist will wait 5 seconds
61914926|NCT01824797||Roux-en-Y Gastric Bypass|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
61914927|NCT01824797||Sleeve Gastrectomy|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
61914928|NCT02727543|NO_INTERVENTION|Control|Participants randomized to this arm will not receive the intervention.
61914929|NCT02727543|EXPERIMENTAL|Intervention|Participants randomized to this arm will receive the intervention, Medisafe, a smartphone application.
62299987|NCT00047411|ACTIVE_COMPARATOR|1|Intervention: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines.
62470233|NCT04724941||REM behavior disorder +|"Individuals with REM Sleep Behavior Disorder:~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
62670892|NCT01928576|EXPERIMENTAL|Arm B|"Every 28 days for 2 cycles CC-486 300 mg by mouth days 1 - 21~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
62670893|NCT01243424|EXPERIMENTAL|linagliptin|patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
62670894|NCT01243424|ACTIVE_COMPARATOR|glimepiride 1-4 mg QD|patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)
62670895|NCT02661373|EXPERIMENTAL|Treatment Arm|Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.
62670896|NCT03434509|EXPERIMENTAL|Tai Chi|Ongoing, continuous Tai Chi and mindful movement instruction, 1 hour, twice per week
62670897|NCT04527250|EXPERIMENTAL|Experimental:1mg|ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
62670898|NCT04527250|EXPERIMENTAL|Experimental:2mg|ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
61914930|NCT06453057|EXPERIMENTAL|GT307 injection treatment group|
61914931|NCT05204303||Patients with symptoms of LPR and objective evidence of GORD|
61914932|NCT05204303||Patients with symptoms of LPR and no objective evidence of GORD|
62299988|NCT00047411|EXPERIMENTAL|2|Use of the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
62670899|NCT04527250|EXPERIMENTAL|Experimental:5mg|ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
62670900|NCT04527250|EXPERIMENTAL|Experimental:10mg|ASC41 two tablets (10mg) single oral dose at Day 1.
62670901|NCT04527250|EXPERIMENTAL|Experimental:20mg|ASC41 four tablets (20mg) single oral dose at Day 1.
62670902|NCT04527250|PLACEBO_COMPARATOR|Placebo:1mg|ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
62670903|NCT04527250|PLACEBO_COMPARATOR|Placebo:2mg|ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
62670904|NCT04527250|PLACEBO_COMPARATOR|Placebo:5mg|ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
62670905|NCT04527250|PLACEBO_COMPARATOR|Placebo:10mg|ASC41 placebo two tablets (10mg) single oral dose at Day 1.
61914933|NCT05204303||Healthy volunteers|
61914934|NCT02583659||Combined chemotherapy|AGC patients treated with first-line combined chemotherapy
61914935|NCT03725254|ACTIVE_COMPARATOR|radical surgery|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.
61914936|NCT03725254|EXPERIMENTAL|radical chemoradiotherapy|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.
61914937|NCT03742648|ACTIVE_COMPARATOR|Control physiotherapy group|Basic standard medical and nursing care along with standard chest physiotherapy involving steam inhalation and nebulization for 15-20 minutes and 10-15 cycles of incentive spirometry twice daily
61914938|NCT03742648|EXPERIMENTAL|Experimental physiotherapy group|Basic standard medical and nursing care along with chest physiotherapy involving any of the deep breathing exercises as per patients ease with 5-10 repetitions each, twice daily
61914939|NCT04601454|EXPERIMENTAL|Spinal Cord Stimulation|Enrolled subjects are implanted with a rechargeable spinal cord stimulation system that is activated and programmed to on-label parameters.
61914940|NCT04613778|EXPERIMENTAL|Laser acupuncture|Laser acupuncture with knee-chest position
61914941|NCT04613778|NO_INTERVENTION|No intervention|usual care with knee-chest position
62299989|NCT00934609|EXPERIMENTAL|Training|12 weeks of endurance training on the cycle ergometer under supervision on a physician
62299990|NCT00934609|NO_INTERVENTION|Control|Control condition
62670906|NCT04527250|PLACEBO_COMPARATOR|Placebo:20mg|ASC41 placebo four tablets (20mg) single oral dose at Day 1.
62670907|NCT01783782|EXPERIMENTAL|DIET|Group A followed the standard regime consisting of a clear liquid diet for 12 hours on the day before CE, followed by an overnight fast.
61914942|NCT02407652|EXPERIMENTAL|cognitive control training|internet-delivered, 2 weeks
61914943|NCT02407652|ACTIVE_COMPARATOR|low cognitive load training|internet-delivered, 2 weeks
61914944|NCT01444807|EXPERIMENTAL|Sorafenib|Active Arm
62109071|NCT01805921|EXPERIMENTAL|Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
62109072|NCT01805921|EXPERIMENTAL|Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
62109073|NCT01570660|NO_INTERVENTION|control group|parallel group without intervention
62109074|NCT05575895||Energy Drink|"Ingestion of 250 ml of the energy drink (Red Bull®)~- Evaluation of systemic skin microvascular endothelial function Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function."
62299991|NCT04290182|EXPERIMENTAL|Single arm: MSC administration to vocal fold scar|1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)
62299992|NCT04317807|ACTIVE_COMPARATOR|Study Drug group|Participants in this group will receive 500 mg of levetiracetam twice daily for 12 weeks. After 12 weeks, levetiracetam will be gradually decreased and stopped over the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
62299993|NCT04317807|PLACEBO_COMPARATOR|Placebo Group|Participants in this group will receive a placebo that looks like the levetiracetam pill twice daily for 12 weeks. After 12 weeks, the levetiracetam dose will be tapered for the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
62299994|NCT06657677|EXPERIMENTAL|40 mg|single dose of 40 mg oral iron
62299995|NCT06657677|EXPERIMENTAL|100 mg|single dose of 100 mg oral iron
62299996|NCT06657677|EXPERIMENTAL|180 mg|single dose of 180 mg oral iron
62299997|NCT03979729||3D + 2D-Mammogram Recipients (Patient Group A)|Women presenting for mammographic screening who selected 3D + 2D- mammogram. These women will undergo in-person or telephone interviews.
62299998|NCT03979729||2D-Mammogram Recipients (Patient Group B)|Women presenting for mammographic screening who selected 2D- mammogram alone (declined 3D + 2D- mammogram). These women will undergo in-person or telephone interviews.
62299999|NCT03979729||Women Who Have Never Received a Mammogram (Patient Group C)|Women who have never undergone recommended mammographic screening. These women will participate in a onetime facilitated focus group.
61914945|NCT01444807|NO_INTERVENTION|Best Supportive Care|Comparator
61914946|NCT00627614|EXPERIMENTAL|breast imaging study|
62300000|NCT03979729||Providers|Primary care providers (physicians, physicians assistants, and advanced nurse practitioners) working in clinics providing primary care for underserved patient populations in New Mexico, including primary care providers at a RIOSNET-affiliated and UNM-affiliated clinics
62470234|NCT04724941||REM behavior disorder -|"Individuals without REM Sleep Behavior Disorder with increased risk for PD:~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
61914947|NCT02842554|OTHER|DPA|Drug Placebo Administration
61914948|NCT02842554|OTHER|C|Control
61914949|NCT02842554|OTHER|EPT|Evoked Pain Training
61914950|NCT05733403|ACTIVE_COMPARATOR|Stroke Volume Variation (SVV) Group|"When SVV value ≥ 14%, 250cc isotonic will be given within 10min. 250cc isotonic boluses will be repeated until the SVV drops below 14%. If MAP\< 65 mmHg despite the SVV falling below 14%, a bolus of 4mcg noradrenaline(NA) will be administered. During the operation, if the SVV is below 14% and the MAP is \< 65mmHg, a bolus of 4mcg NA will be administered.~Intraoperative balance, amount of bleeding, number of fluid boluses and NA administrations, total additional fluid and NA amount, total number of hypotensive episodes will be recorded.~The times when the breast tissue was removed, the weights of the removed tissues and the amount of bleeding will be recorded.~Basal and 3 more arterial blood gases will be taken when the breast tissue is removed and early postoperatively, and Hgb, lactate, and base excess values will be recorded. iNOS values in blood will be recorded after basal iNOS and breast tissue are removed.~The creatinine value will be recorded on the 1st postoperative day."
61919885|NCT05635058|NO_INTERVENTION|Control Group|"Interviews were conducted with the individuals in the control group on a designated day of the week, at a designated place in the nursing home. The researcher interviewed the individuals in the control group once a week for eight weeks. During these meetings, daily issues and events such as health, sports, and weather were discussed. Each of the mentioned interviews lasted 45-60 minutes. At the end of eight weeks, SMMT and the Multidimensional Observation Scale for Elderly Individuals were implemented again to the participants in the intervention and control groups."
62109075|NCT05575895||Control|"Ingestion of 250 ml of mineral water (Minalba®)~- Evaluation of systemic skin microvascular endothelial function Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function."
62109076|NCT00087269|EXPERIMENTAL|Treatment (erlotinib)|Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
62109077|NCT01407601|EXPERIMENTAL|45 µg MK-7|45 µg MK-7 daily over 6 weeks
62109078|NCT01407601|EXPERIMENTAL|135 µg MK-7|135 µg MK-7 daily over 6 weeks
62109079|NCT01407601|EXPERIMENTAL|360 µg MK-7|360 µg MK-7 daily over 6 weeks
62109080|NCT04218669|ACTIVE_COMPARATOR|T-tube drainage|The T-tube was placed for biliary drainage
61914951|NCT05733403|ACTIVE_COMPARATOR|Mean Arterial Pressure (MAP) Group|"If MAP value under below 65mmHg, 250ml isotonic will be given within 10 min. However, if MAP is still below 65mmHg, a bolus of 4mcg NA will be administered, if no response, 4mcg NA will be repeated. If MAP falls below 65mmHg again, 250 ml isotonic will be administered again in 10 min; if it does not improve, 4mcg of NA will be given iv.~Intraoperative balance, amount of bleeding, number of fluid boluses and NA administrations, total additional fluid and NA amount, total number of hypotensive episodes will be recorded.~The times when the breast tissue was removed, the weights of the removed tissues and the amount of bleeding will be recorded.~Basal and 3 more arterial blood gases will be taken when the breast tissue is removed and early postoperatively, and Hgb, lactate, and base excess values will be recorded. iNOS values in blood will be recorded after basal iNOS and breast tissue are removed.~The creatinine value will be recorded on the 1st postoperative day."
61914952|NCT01687647|OTHER|Screening|Paired-design: low-dose CT scan, sputum sample and blood test will be performed on all subjects.
62670908|NCT01783782|EXPERIMENTAL|HIGH PEG|Group B received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed always by an overnight fast.
62670909|NCT01783782|EXPERIMENTAL|LOW PEG|Group C, defined as a low volume regime, received 25 mL/Kg (up to 1Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed by an overnight fast.
61914953|NCT01671943|EXPERIMENTAL|Breast carcinoma up to 2.0 cm|
62109081|NCT04218669|EXPERIMENTAL|Roux-en-Y Hepaticojejunostomy|biliary-enteric anastomosis was performed
62109082|NCT05043818||IBD patients with depression|IBD patients with depression
62109083|NCT05043818||IBD patients without depression|IBD patients without depression
61914954|NCT04140227|EXPERIMENTAL|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
62670910|NCT01783782|EXPERIMENTAL|SIMETHICONE|Group D received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion.
62670911|NCT01783782|EXPERIMENTAL|SIMETH+PEG|Group E received 25 mL/Kg (up to 1 Lt/die) of polyethylene glycol 4000 solution with simethicon solution followed by an overnight fast plus 20mL oral simethicone and 200mL water 30 minutes before capsule ingestion.
61914955|NCT04112589|EXPERIMENTAL|Level dose 1 - 40mg, 14 days|Patients will receive an induction cycle (40mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) \[with or without allogenic stem cell transplantation\]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
61914956|NCT04112589|EXPERIMENTAL|Level dose 2 - 60mg, 14 days|Patients will receive an induction cycle (60mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) \[with or without allogenic stem cell transplantation\]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
61914957|NCT04112589|EXPERIMENTAL|Level dose -1 - 60mg 7days|Patients will receive an induction cycle (60mg Quizartinib for 7 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) \[with or without allogenic stem cell transplantation\]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
61914958|NCT04112589|EXPERIMENTAL|Level dose -2 - 40mg 7 days|Patients will receive an induction cycle (40mg Quizartinib for 7days) followed by 1-3 consolidation cycles (Quizartinib at day 6) \[with or without allogenic stem cell transplantation\]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
61914959|NCT01467778|ACTIVE_COMPARATOR|ELAPR001|Tropoelastin 0.1ml SC implant
62109084|NCT00586339|EXPERIMENTAL|HIV+/Cervarix Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm, according to a 0, 1, 6-month schedule.
62470235|NCT00064974|EXPERIMENTAL|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
62670912|NCT01163877|OTHER|Symptomatic malaria infection|
62670913|NCT01163877|OTHER|Asymptomatic malaria infection|
62670914|NCT01163877|OTHER|Hookworm infection|
62470236|NCT02167386|EXPERIMENTAL|Enhanced PrEP Adherence|Enhanced PrEP Adherence: peer navigators, PrEP support group, on-line support group, text message reminders
62670915|NCT01163877|OTHER|Schistosoma haematobium infection|
62670916|NCT02167360|EXPERIMENTAL|Single Arm|
62670917|NCT03699800|EXPERIMENTAL|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
62670918|NCT03699800|NO_INTERVENTION|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
62470237|NCT02167386|ACTIVE_COMPARATOR|Standard PrEP Adherence|Standard PrEP Adherence: support groups, case management
61914960|NCT01467778|ACTIVE_COMPARATOR|ELAPR002|Tropoelastin 0.1ml SC implant
61914961|NCT01467778|ACTIVE_COMPARATOR|ELAPR003|Tropoelastin 0.1ml SC implant
61914962|NCT01467778|PLACEBO_COMPARATOR|Saline|Normal Saline 0.9%
61914963|NCT05535010|EXPERIMENTAL|Those with active trigger points before TFESI|Transforaminal epidural steroid injection
61914964|NCT05535010|ACTIVE_COMPARATOR|Those who do not have an active trigger point before TFESI|Transforaminal epidural steroid injection
61914965|NCT05392933|EXPERIMENTAL|Piriformis syndrome with lumbar radiculopathy (PSWLR)|All patients (n=39) will be evaluated with detailed physical examination and special clinical tests for both lumbar radiculopathy and piriformis syndrome. If patients have lumbar magnetic resonance imaging or electromyography results, they will be recorded to confirm the diagnosis of lumbar radiculopathy. The patients who have the final diagnosis of lumbar radiculopathy and prediagnosis of piriformis syndrome will be evaluated for the pain scores (pain at resting, sitting, standing, lying, at night and during activity) using numeric rating scale. Then, an ultrasound guided piriformis muscle injection will be performed. The patients will be kept under observation for 30 minutes afterwards and the percentage of their pain relief will be recorded. The patients whose pain resolves at least 50% from the baseline after the injection will be diagnosed as piriformis syndrome and will be reevaluated one week and one month after the injection and the changes in the pain scores will be recorded.
61914966|NCT00560521|ACTIVE_COMPARATOR|1|
61914967|NCT02871882|ACTIVE_COMPARATOR|Ox bile extract|Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
61914968|NCT02871882|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
61914969|NCT02636140|EXPERIMENTAL|Light|Randomized amount and color of light
61914970|NCT04692727|ACTIVE_COMPARATOR|Exercise grup|An exercise program that includes stretching, strengthening and balance exercises accompanied by physiotherapist in the clinic will be applied to all individuals participating in the study for 6 weeks, 2 times a week (12 sessions). Each session will take approximately 40 minutes and patients will be asked to repeat the exercises at least 2 sets a day at home when they are not in the clinic (other 5 days a week). The home program will be followed by the exercise daily form.
61914971|NCT04692727|EXPERIMENTAL|McConnell patellar taping grup|McConnell patellar taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group. The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
61914972|NCT04692727|EXPERIMENTAL|Femoral rotational taping grup|Femoral lateral rotation taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group.The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
61919886|NCT05753397|EXPERIMENTAL|Single injection|1x21ml Ropivacaine (7.5mg/ml) at ITTC T4. Including two sham injections at ITTC T2 and ITTC T6
62470238|NCT06009471|ACTIVE_COMPARATOR|Control group|All participants were treated with routine treatment in Neurology.
62670919|NCT06461559|NO_INTERVENTION|Control|
62670920|NCT06461559|ACTIVE_COMPARATOR|Ileostomy infusion|perform infusion if ileostomy prior to takedown operation
62670921|NCT01953354|EXPERIMENTAL|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period
61919887|NCT05753397|EXPERIMENTAL|Multiple injection|3x7ml Ropivacaine (7.5mg/ml) at ITTC T2, T4 and T6.
61914973|NCT06442631|NO_INTERVENTION|Standard stroke education|Participants in this arm of the study will receive institutional standard stroke education during the course of the hospitalization, standardized across the 5 participating sites. Standard education consists of non-standardized verbal bedside education by the care team, a standardized stroke educational booklet, and standardized verbal instructions by the bedside nurse addressing stroke risk factors and medications.
61914974|NCT06442631|EXPERIMENTAL|MyStroke + standard stroke education|Participants in this arm of the study will receive institutional standard stroke education in addition to access to MyStroke, a personalized video-based education platform. Each participant will receive their personalized page via email or SMS, as per their preference, and they will receive automated nudges to visit educational material after hospital discharge.
61914975|NCT04259723|EXPERIMENTAL|Intervention|
61914976|NCT04259723|NO_INTERVENTION|Control|
62670922|NCT01953354|PLACEBO_COMPARATOR|Placebo|Six doses of TSO placebo orally over a ten-week period
61914977|NCT02040727|ACTIVE_COMPARATOR|Non-Resistance Trained|No Participation in Resistance Training
62300001|NCT00275080|EXPERIMENTAL|Treatment (enzyme inhibitor, chemotherapy)|"Regimen 1 (sequential dosing): Patients receive oral vorinostat two or three times daily on days 6-21 or days 6-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Regimen 2 (concurrent dosing): Patients receive oral vorinostat two or three times daily on days 1-21, days 1-14 (patients with hematological malignancies only), or two times daily on days 1-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5."
61914978|NCT02040727|EXPERIMENTAL|Resistance Trained|Participation in Resistance Training
61914979|NCT02634476|EXPERIMENTAL|cognitive bias modification training|Participants complete four sessions of the alcohol approach/avoidance task.
61914980|NCT02634476|SHAM_COMPARATOR|sham training|Participants complete four sessions of the sham approach/avoidance task.
61914981|NCT05748652|EXPERIMENTAL|Digital CBT|digitally-delivered CBT for anxiety accessed via mobile app
61914982|NCT05748652|ACTIVE_COMPARATOR|Psychoeducation|psychoeducation delivered via digital written materials
61914983|NCT02770209|EXPERIMENTAL|the experimental group|Patients in the experimental group will be treated with the biomimetic cartilage matrix combined with autologous chondrocytes. The entire course of treatment includes two surgeries. The first surgery will be performed to observe articular cartilage damage by arthroscopy and assess treatment potential. If the patient's condition meets the surgical requirement, we will extract cartilage from the fossa intercondylar non-weight-bearing area during the first surgery. Chondrocytes will be in vitro-amplified and inoculated into the cartilage scaffold. The fully prepared seeded scaffold will be implanted into the site of injury during the second surgery.
62300002|NCT02135536|EXPERIMENTAL|NGM282 Dose 1|NGM282 Dose 1
61914984|NCT02770209|EXPERIMENTAL|the control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
61914985|NCT02100709|NO_INTERVENTION|Control Arm|This arm will perform the pulmonary rehabilitation as specified with no respiratory assistance.
61914986|NCT02100709|ACTIVE_COMPARATOR|Intervention Arm|This arm will conduct the pulmonary rehabilitation program with BiLevel Noninvasive Ventilation assistance from a ResMed ventilator.
62300003|NCT02135536|EXPERIMENTAL|NGM282 Dose 2|NGM282 Dose 2
61914987|NCT05504772||High-risk cancers|"One of the following two criteria must be met:~1. Confirmed or suspected high-risk malignancy defined as expected overall survival \< 30% based on current literature for the specific cancer~2. Cancers for which standard therapy would result in unacceptable and severe morbidity (e.g., infantile fibrosarcoma where definitive surgery would require amputation of limb) Note: This does not include HR neuroblastoma at diagnosis as this group of patients have an overall survival ≥30% and belongs to Cohort 4A."
61914988|NCT05504772||Rare tumors|"At least one of the following three criteria must be met:~1. A rare tumor of uncertain prognosis due to rarity of disease~2. A rare tumor with no established treatment strategy~3. A cancer where routine histopathological examination has not been able to establish a diagnosis~4. Confirmed histiocytic disorder AND molecular profiling may facilitate diagnosis and/or treatment~5. Confirmed proliferative vascular or lymphatic malformation AND has failed conventional treatment, e.g., surgery or embolization, OR no appropriate treatment is available AND the disease is organ, limb or life threatening, or debilitating"
62300004|NCT02135536|EXPERIMENTAL|NGM282 Dose 3|NGM282 Dose 3
62300005|NCT06059885|EXPERIMENTAL|Tislelizumab combined with tyrosine kinase inhibitor (TKI) treatment group|
62300006|NCT06059885|NO_INTERVENTION|No-intervention group|
62300007|NCT03295305|EXPERIMENTAL|Action Based Cognitive Remediation|
62300008|NCT03295305|ACTIVE_COMPARATOR|Unstructured support group|
62670923|NCT00341939||1/Cancer Patients|Cancer patients previously enrolled on IRB approved clinical trials at NCI
62670924|NCT03396458||Hepatitis B group|Hepatitis B serology and questionnaire
61914989|NCT05504772||Primary central nervous system (CNS) tumours|Patient is suspected or confirmed to have a primary CNS tumor, including low and high-grade tumors
61914990|NCT05504772||Neuroblastoma|Patient is suspected or confirmed to have neuroblastoma 4A: HR neuroblastoma at diagnosis 4B: Non-HR neuroblastoma
61914991|NCT05504772||Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL|Patient is confirmed by flow cytometry to have acute myeloid leukemia (AML) or other leukemias (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)
61914992|NCT05504772||Acute lymphoblastic leukemia (ALL)|Patient is confirmed to have acute lymphoblastic leukemia by flow cytometry (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)
62670925|NCT04055298|OTHER|Patients|"The study will be performed at the Walk-in-Clinic (WIC) and Interdisciplinary Emergency Department (ED) of the cantonal hospital of Baden, Switzerland. During their stay at the WIC or ED the patients will be invited to use the triage-symptom-checker SMASS-Triage.~In this study, the patient's self-triage using a symptom checker will be compared with the urgency assessments conducted by three interdisciplinary panels of physicians (panel A, B and C). In order to appropriately reflect the complex interaction in medical decision-making, which usually leads to a low inter-rater reliability, the cases assessed to be undertriaged by panel A, are subsequently assessed a second time by two panelist of panel B. Cases which are adjudged to be undertriaged by all panelist (panel A and B), are assessed for a risk to health or life by panel C. The risk assessments of panel C will be based on the structured reports generated by the symptom-checker and the discharge summaries of the WIC/ED."
62109085|NCT00586339|ACTIVE_COMPARATOR|HIV+/Aluminium Hydroxide Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of control Aluminium Hydroxide \[Al(OH)3\], administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
62109086|NCT00586339|EXPERIMENTAL|HIV-/Cervarix Group|Human immunodeficiency virus negative (HIV-) subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
62300009|NCT05383820|PLACEBO_COMPARATOR|Placebo|Placebo (calcined magnesia) in capsules, one capsule every 8 hours for 5 days.
62300010|NCT05383820|EXPERIMENTAL|Ketorolac|Ketorolac 10 mg capsules, one capsule every 8 hours (30 mg daily) for 5 days.
61914993|NCT05504772||Lymphomas|Patient is suspected or confirmed to have a lymphoma
61914994|NCT05504772||Sarcomas|Patient is suspected or confirmed to have a sarcoma Includes gastrointestinal stromal tumour (GIST), malignant peripheral nerve sheath tumour (MPNST), desmoplastic small round cell tumour (DSRCT)
61914995|NCT05504772||Renal tumors|Patient is suspected or confirmed to have a renal tumor Includes clear cell sarcoma of kidney
61914996|NCT05504772||Hepatic and biliary tree tumors|Patient is suspected or confirmed to have a liver or biliary tree tumor
61914997|NCT05504772||Thyroid and endocrine tumors|Patient is suspected or confirmed to have a thyroid or endocrine cancer
61914998|NCT05504772||Other tumors|Patient is suspected or confirmed to have a tumor which does not fit into any of the above
62109087|NCT06221332|ACTIVE_COMPARATOR|SACRAL EREKTÖR SPİNAE PLANE BLOK|Pregnant women in Group S will be given 10 cc bupivacaine solution of 0.25% bupivacaine on both sides.
62109088|NCT06221332|ACTIVE_COMPARATOR|control group|Pregnant women in Group K will be injected with 10 cc of saline on both sides.
62109089|NCT03252106|EXPERIMENTAL|Contour augmentation|
62300011|NCT05383820|ACTIVE_COMPARATOR|Paracetamol|Paracetamol capsules of 500 mg, one capsule every 8 hours (1.5 g per day) for 5 days.
61914999|NCT05504772||Germline only|"One of the following two criteria must be met:~1. Patients whose submitted tumor sample could not yield sufficient DNA for any molecular analysis AND participants/parents have consented to return of germline findings.~2. Patients who do not have appropriate tumor sample to be submitted for molecular profiling may be considered for germline only analysis. Obtaining tumor samples wherever possible will be encouraged."
61915000|NCT05694221|EXPERIMENTAL|Group A: Digoxin combined with Supaglutide group|"Subjects will receive a single oral dose of 0.25 mg digoxin tablets on Day 1. And will received subcutaneous injection of sulpalutide QW for five weeks（D5-D33）.~Then receive another single oral dose of 0.25 mg digoxin tablets on Day 35."
62670926|NCT02917499|EXPERIMENTAL|TMS|The experimental group will be treated with transcranial magnetic stimulation for 4 weeks.
61915001|NCT05694221|EXPERIMENTAL|Group B: Metformin combined with Supaglutide Group|"Subjects will receive multiple oral dose of Metformin tablets on Day 1-3. And will received subcutaneous injection of sulpalutide QW for five weeks（D5-D33）.~Then receive another round of Metformin tablets on Day 32-34."
61915002|NCT02324543|EXPERIMENTAL|Dose level 1 - Phase 1|"* Gemcitabine - 400 mg/m\^2~* Taxotere - 20 mg/m\^2~* Xeloda - 500 mg/twice daily (BID)~* Cisplatin - 15 mg/m\^2~* Irinotecan - 20 mg/m\^2"
61915003|NCT02324543|EXPERIMENTAL|Dose Level 2 - Phase 1|"* Gemcitabine - 400 mg/m\^2~* Taxotere - 20 mg/m\^2~* Xeloda - 500 mg/BID~* Cisplatin - 15 mg/m\^2~* Irinotecan - 40 mg/m\^2"
61915004|NCT02324543|EXPERIMENTAL|Dose Level 3 - Phase 1|"* Gemcitabine - 400 mg/m\^2~* Taxotere - 20 mg/m\^2~* Xeloda - 500 mg/BID~* Cisplatin - 15 mg/m\^2~* Irinotecan - 60 mg/m\^2"
62109090|NCT05537766|EXPERIMENTAL|Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel|"Participants will receive fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2 × 10\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg.~This arm is no longer recruiting."
62109091|NCT05537766|EXPERIMENTAL|Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel|"Participants will receive fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2×10\^6 anti-CD19 CAR T cells/kg.~This arm is no longer recruiting."
62109092|NCT05537766|EXPERIMENTAL|Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel|Participants will receive fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2x10\^6 anti-CD19 CAR T cells/kg.
62670927|NCT02917499|NO_INTERVENTION|noTMS|The control (no intervention) group will be treated as usual (with pharmacotherapy). These patients will receive TMS treatment after data collection is ended.
62670928|NCT05018819|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62670929|NCT04584983|ACTIVE_COMPARATOR|usual prescribed intralipid (UL) regimen|
62670930|NCT04584983|EXPERIMENTAL|restricted prescribed intralipid (RL) regimen|
62670931|NCT02924116|EXPERIMENTAL|Bioboosti|Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.
62670932|NCT02924116|EXPERIMENTAL|Sustained Efficacy|"Treatment with Bioboosti device for a year. In order to see if the device has sustained efficacy in treating insomnia.~Subjects will use it once a day for about one hour, before habitual sleep time."
62670933|NCT02924116|EXPERIMENTAL|Insomnia and migraine|Treatment with the Bioboosti device for a month. Subjects will use it once a day for about one hour, before habitual sleep time.
62670934|NCT05282407|EXPERIMENTAL|Experimental group|Tenolid Tab
62670935|NCT05282407|ACTIVE_COMPARATOR|Control group|Viread Tab
62670936|NCT03058016|EXPERIMENTAL|Personalized recommendations for diet|"After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built.~Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month."
62670937|NCT05496738|EXPERIMENTAL|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously
62670938|NCT05496738|EXPERIMENTAL|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously
61915005|NCT02324543|EXPERIMENTAL|Dose Level 1a - Phase 1|"* Gemcitabine - 500 mg/m\^2~* Taxotere - 20 mg/m\^2~* Xeloda - 500 mg/BID~* Cisplatin - 20 mg/m\^2~* Irinotecan - 20 mg/m\^2"
61915006|NCT02324543|EXPERIMENTAL|Dose level 1b - Phase 1|"* Gemcitabine - 500 mg/m\^2~* Taxotere - 20 mg/m\^2~* Xeloda - 500 mg/BID~* Cisplatin - 20 mg/m\^2~* Irinotecan - 40 mg/m\^2"
61915007|NCT02324543|EXPERIMENTAL|Phase 2|"* Gemcitabine - 500 mg/m\^2~* Taxotere - 20 mg/m\^2~* Xeloda - 500 mg/BID~* Cisplatin - 20 mg/m\^2~* Irinotecan - 20 mg/m\^2"
62109093|NCT05537766|EXPERIMENTAL|Substudy D (Relapsed/Refractory hairy cell leukemia): Brexucabtagene Autoleucel|"Participants will receive fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2 × 10\^6 anti-CD19 CAR T cells/kg.~This arm is no longer recruiting."
61915008|NCT03088085|EXPERIMENTAL|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
61915009|NCT03088085|ACTIVE_COMPARATOR|Sleep Education|Education on sleep hygiene with tips for improving sleep.
61915010|NCT01348009|EXPERIMENTAL|Tesetaxel-capecitabine-cisplatin|
61915011|NCT02655770|ACTIVE_COMPARATOR|Liraglutide arm|Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks.
62300012|NCT00093236|EXPERIMENTAL|Early Periodontal Treatment|Subjects will receive scaling, root planing and if needed periodontal surgery
62300013|NCT00093236|ACTIVE_COMPARATOR|Usual Dental Hygiene|Subjects will receive routine oral hygiene
62670939|NCT05496738|PLACEBO_COMPARATOR|Intravenous placebo|Placebo will be administered intravenously
61915012|NCT02655770|PLACEBO_COMPARATOR|Placebo arm|Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
62109094|NCT01167426|ACTIVE_COMPARATOR|20 mg/0.5 mL Glatiramer Acetate|Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).
62109095|NCT02085356|EXPERIMENTAL|Intervention women with partners|Women will enroll with male partners and both members of the couple will attend the Protect your Family intervention
61915013|NCT03748043|EXPERIMENTAL|lactoferrin+ferric hydroxide polymaltose|lactoferrin 100 mg /day plus ferric hydroxide polymaltose 6 mg /kilogram body wight for 3 months
61915014|NCT03748043|EXPERIMENTAL|ferric hydroxide polymaltose|6 mg /kilogram body wight of ferric hydroxide poly maltose per day for 3 months
61915015|NCT06259851|EXPERIMENTAL|rTMS-DBT group|Patients receiving combined DBT and active prefrontal rTMS treatment
61915016|NCT06259851|ACTIVE_COMPARATOR|Sham-DBT group|Patients receiving combined DBT and sham rTMS treatment
61915017|NCT06259851|ACTIVE_COMPARATOR|rTMS-only group|Patients receiving only active prefrontal rTMS treatment
61915018|NCT06259851|SHAM_COMPARATOR|sham-only group|Patients receiving only sham rTMS treatment
61915019|NCT03748615|EXPERIMENTAL|Computer Guided ridge splitting in posterior mandible|fabrication of a computer aided surgical guide and performing ridge splitting in posterior mandible using piezosurgery
61915020|NCT02532166|OTHER|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and chromoendoscopy with Lugol for detection of esophageal lichen.
61915021|NCT01718977|EXPERIMENTAL|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
61919888|NCT03368573|NO_INTERVENTION|Control Arm|Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person.
62109096|NCT02085356|EXPERIMENTAL|Intervention women without partners|Women will enroll alone and will attend the Protect your Family Intervention without a partner
62109097|NCT02085356|NO_INTERVENTION|Control women with partners|Women will enroll with male partners and both members of the couple will attend time-matched video sessions
62109098|NCT02085356|NO_INTERVENTION|Control women alone|Women will enroll alone and will attend time-matched video sessions
62300014|NCT01476930|EXPERIMENTAL|cupping serkangabin|migraine cases treated by cupping and serkangabin syrup
62300015|NCT01476930|ACTIVE_COMPARATOR|conventional|migraine cases treated by conventional drug treatment protocols
62670940|NCT05496738|PLACEBO_COMPARATOR|Subcutaneous Placebo|Placebo will be administered subcutaneously
62670941|NCT01065155||Median central blood pressure|Median central blood pressure, lower median group 1 and higher group 2.
62470239|NCT06009471|EXPERIMENTAL|Experimental group|"All participants were treated with routine treatment in Neurology and rTMS treatment.~rTMS parameters were set to stimulate the site: bilateral primary motor cortex; Stimulus frequency :5Hz; Pulse number: 1000 pulses per day, 500 on the left and 500 on the right; Stimulus intensity :90% resting threshold; Coil: 70mm round coil; Once a day, 30 minutes each time, 5 days a week for 4 weeks"
62109099|NCT03802786|EXPERIMENTAL|Moderate hepatic impairment|Single dose of Imeglimin
62109100|NCT03802786|EXPERIMENTAL|Normal hepatic function|Single dose of Imeglimin
62109101|NCT01365403|EXPERIMENTAL|Single Arm|
62300016|NCT02790489|EXPERIMENTAL|Valedia|Dose 1 : 2,5 g (4 capsules) Valedia per day during 4 weeks Dose 2 : 5 g (8 capsules) Valedia per day during 4 weeks 2 weeks (wash-out period) between the 2 doses
62300017|NCT01014715|OTHER|Single Arm|Phase II-Preoperative Radiation followed by Lumpectomy
62300018|NCT04084392|ACTIVE_COMPARATOR|Usual Care|Participants randomized to this arm will receive care as usual.
62300019|NCT04084392|ACTIVE_COMPARATOR|Bridge Clinic|Participants randomized to this arm will be referred to the Bridge Clinic to facilitate identification and referral to an outpatient provider for addiction treatment.
62300020|NCT02863848|PLACEBO_COMPARATOR|Placebo|Maltodextrin 2g, twice per day, 6 weeks
62300021|NCT02863848|ACTIVE_COMPARATOR|Inulin-type fructans|Orafti inulin-type fructans 2g, twice per day, 6 weeks
62300022|NCT05526534|EXPERIMENTAL|HFNC group|HFNC group was given heated humidified high flow nasal cannula oxygen therapy on the day of surgery and the first day after surgery to maintain oxygen saturation at 92% \~ 95%.Chest CT was reviewed 36-48 hours after surgery.
62300023|NCT05526534|OTHER|Control group|The control group was given conventional nasal catheter oxygen inhalation on the day of surgery and the first day after surgery, and oxygen flow was adjusted to maintain oxygen saturation at 92% \~ 95%.Chest CT was reviewed 36-48 hours after surgery.
62300024|NCT02631304||Patients undergoing cardiac surgery|Elderly patients scheduled to undergo elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery) with the use of cardiopulmonary bypass.
62300025|NCT05305716|EXPERIMENTAL|online pilates group|Online pilates training was done for a total of 8 weeks, 2 days a week for 1 hour. Microsoft Teams program was used to perform the exercises online. The investigators divided the individuals in the online pilates exercise group into seven smaller groups of 3 or 4 to verify whether they correctly did the exercises. A program including 15 minutes of warm-up, 30 minutes of Pilates exercises and 15 minutes of cooling and stretching exercises was arranged for the online pilates group and the exercises were performed as 10 repetitions. The exercise program recommended by the Australian Pilates and Physiotherapy Institute during pregnancy was used in the online training.
62300026|NCT05305716|ACTIVE_COMPARATOR|control group|The control group was given breathing and relaxation exercises, which they would do two days a week for eight weeks, in the form of a home program. Diaphragmatic breathing and respiratory control were given as breathing exercises.
62300027|NCT01769521|EXPERIMENTAL|Triggerfish|Device: Sensimed Triggerfish
62300028|NCT05200039||Study group|Older men who were treated for localized or locally advanced prostate cancer with curative intent at the age of 70 years or more
62300029|NCT05200039||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019, matched on age and education
62300030|NCT06042140|EXPERIMENTAL|NEOX Cord 1K applied fetoscopically|Patients intending to undergo open in-utero spina bifida repair will be offered to be screened for an alternative minimally invasive approach. All eligible pregnant mothers' fetuses within the trial will receive NEOX Cord 1K® as a spinal cord cover to close the developmental defect. In some cases, at the discretion of the Pediatric Neurosurgeon, NEOX Cord 1K® may be required to cover the skin. All eligible subjects meeting all inclusion criteria but none of the exclusion criteria may be enrolled.
62109102|NCT01670110|ACTIVE_COMPARATOR|Pasireotide LAR (SOM230)|Active Pasireotide LAR
62109103|NCT01670110|PLACEBO_COMPARATOR|placebo injection|
62109104|NCT04330430|EXPERIMENTAL|T-VEC + Nivolumab|Patients will receive pre-surgically 4 courses T-VEC (up to 4ml; first dose 10\^6 PFU per mL, subsequent doses at 10\^8 PFU per mL). Patients will also receive a flatdose of 240mg Nivolumab every 2 weeks after the first T-VEC injections (starting at 2nd T-VEC course at week 3, followed by the next doses at week 5 and 7).
62300031|NCT00601978|ACTIVE_COMPARATOR|1|Immediate-Release Carbidopa/Levodopa
62300032|NCT00601978|ACTIVE_COMPARATOR|2|Carbidopa/Levodopa/Entacapone
62109105|NCT05216419|EXPERIMENTAL|case group|"One dose of 30,000 IU of D-mac is taken once 15 days prior to surgery."
62109106|NCT05216419|NO_INTERVENTION|control group|"There is no 30,000 IU of D-mac to be taken."
62109107|NCT01735474|PLACEBO_COMPARATOR|Placebo|30 people are recruited in order to the inclusion criteria for the study. Placebo controlled.
62300033|NCT00187083|EXPERIMENTAL|1|Native asparaginase
61915022|NCT01718977|ACTIVE_COMPARATOR|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
61915023|NCT01457976||Members of the US public, non-probability sample|
61915024|NCT01457976||Members of the German public, non-probability sample|
62300034|NCT00187083|EXPERIMENTAL|2|PEG-asparaginase
61915025|NCT01457976||Members of the US public, probability sample|
62470240|NCT02937415|EXPERIMENTAL|Waterpipe smokers group|Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
62470241|NCT02937415|ACTIVE_COMPARATOR|Control group|The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
62670942|NCT02737787|EXPERIMENTAL|WT1 Vaccine and Nivolumab|Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab every two weeks over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.This cohort has completed recruitment.
61915026|NCT05763355|OTHER|Transrectal biopsy using KOELIS fusion system|Transrectal procedure will be performed with the patient in the left lateral position with a completely free-hand technique utilising the KOELIS fusion system.
61915027|NCT05763355|OTHER|Transperineal biopsy using KOELIS perine grid|"Transperineal biopsy will be performed in the lithotomy position. KOELIS Perine Grid needle guidance device and Steady Pro free-hand probe arm will be utilised (free-hand assisted technique)."
61915028|NCT03431272|EXPERIMENTAL|Treatment|lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day
62109108|NCT01735474|ACTIVE_COMPARATOR|Manual technique|30 people are recruited in order to the inclusion criteria for the study. Experimental group.
62109109|NCT04753463||Residents of Ophthalmology working on COVID-19 departments|Residents of ophthalmology working on COVID-19 departments and dealing with SARS-CoV-2 positive patients
62109110|NCT04753463||Residents of Ophthalmology working on general ophthalmic departments|Residents of Ophthalmology working on general ophthalmic departments and not dealing with SARS-CoV-2 positive patients
62109111|NCT03999554|EXPERIMENTAL|Low dose Sing2016 M2SR|Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29
62300035|NCT01656642|EXPERIMENTAL|Cohort 1 (C1): Ate+Vem - No Run-in|Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.
62470242|NCT01996527|EXPERIMENTAL|3-Tesla magnetic resonance imaging|Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment.
62670943|NCT02737787|EXPERIMENTAL|ESO-1 Vaccine and Nivolumab|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
61915029|NCT05954104|ACTIVE_COMPARATOR|Group A|About 20 patients suffering from Alopecia areata , they will receive topical vit D3 analogue (calcipotriol) 0.005% twice daily for 3 months with follow up
61915030|NCT05954104|ACTIVE_COMPARATOR|Group B|About 20 patients suffering from Alopecia areata , they will be injected by PRP intra lesional for 3 consecutive sessions 4weeks apart.
62109112|NCT03999554|EXPERIMENTAL|Medium dose Sing2016 M2SR|Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29
62109113|NCT03999554|EXPERIMENTAL|High dose Sing2016 M2SR|High dose Sing2016 M2SR will be administered intranasally on days 1 and 29
62109114|NCT03999554|ACTIVE_COMPARATOR|Low dose Bris10 M2SR|Low dose Bris10 M2SR will be administered intranasally on days 1 and 29
62109115|NCT03999554|PLACEBO_COMPARATOR|Placebo|Saline will be administered intranasally on days 1 and 29
61915031|NCT05954104|ACTIVE_COMPARATOR|Group C|About 20 patients suffering from Alopecia areata they will receive combined therapy ( PRP and topical vit D3 analogue).
61915032|NCT05954104|ACTIVE_COMPARATOR|Group D|About 20 of Healthy control group .
61915033|NCT04492215|EXPERIMENTAL|Physicians trained in motivational interviewing|Patients followed by general practitioners trained in motivational interviewing
61915034|NCT04492215|NO_INTERVENTION|Physicians did not trainned in motivational interviewing|Patients followed by general practitioners who did not receive motivational interviewing.
62109116|NCT06401018|ACTIVE_COMPARATOR|Patients who do not undergo noise cancellation during surgery|Patients who do not undergo noise cancellation during knee replacement surgery
62109117|NCT06401018|ACTIVE_COMPARATOR|Patients undergoing noise cancellation during surgery|Patients undergoing noise cancellation with the help of an over the head earmuff with noise cancelling properties during knee replacement surgery
62470243|NCT04278391|EXPERIMENTAL|A (RT)|Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)
61915035|NCT05045950|EXPERIMENTAL|WBRT-PRDR plus memantine.|Study patients will receive WBRT-PRDR within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique. Memantine should ideally start two days (or one day) prior to WBRT PRDR and must start no later than the fourth WBRT PRDR treatment and will continue for a maximum of 24 weeks (≈six months). Memantine will be administered as per standard institutional guidelines.
61915036|NCT03947411|EXPERIMENTAL|Oseltamivir Phosphate+Xiyanping injection|Oseltamivir Phosphate+Xiyanping injection treatment for 7-10 days
61915037|NCT03947411|ACTIVE_COMPARATOR|Oseltamivir Phosphate treatment only|Oseltamivir Phosphate treatment for 7-10 days
61915038|NCT01761071|EXPERIMENTAL|group KO|(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)
61915039|NCT01761071|ACTIVE_COMPARATOR|group DO|(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)
61915040|NCT05582954|EXPERIMENTAL|EsteemUp|Participants assigned to this arm will receive a 4 week-guided e-health application - EsteemUp - to improve their self-esteem
61915041|NCT05582954|ACTIVE_COMPARATOR|EsteemUp -G|This group will receive the same intervention (EsteemUp) with the addition of gamification elements.
61915042|NCT02282878|EXPERIMENTAL|High/Low Sodium Diet|All MS patients will receive 2 weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
61915043|NCT02282878|ACTIVE_COMPARATOR|High/Low Sodium Diet Control|Age matched controls will receive two weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
61915044|NCT06363188||intervention group|"Firstly the patient is generally anesthetized by the anesthesiologist. Intermaxillary fixation (IMF) screws has been inserted in case of there is no arch bar is used.~The transoral or extraoral approach is utilized to expose the fracture line separating the two segments.~Fixation of the bony segments with two plates one Compression 2.3 plate at the inferior border and Tension 2.0 plate five millimeter superiorly to the compression plate.~or 1 plate2.0 (champy) Then suturing the incision layers Postoperative evaluation with cone beam computed tomography (CBCT). These procedures will be done for both groups. This group will be subjected to shockwave by the usage of extracorporeal shockwave device at the third day postoperative.~Then follow up at the first and fourth month with another CBCT to compare the bone healing at the fracture site."
62300036|NCT01656642|EXPERIMENTAL|Cohort 2 (C2): Ate+Vem (56 Day Run-in)|Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
62300037|NCT01656642|EXPERIMENTAL|Cohort 3 (C3): Ate+Vem (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
62470244|NCT04278391|EXPERIMENTAL|B (TR)|Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)
62470245|NCT02911792|EXPERIMENTAL|Dapagliflozin/Hyperfiltration|Subjects with eGFR above 125 ml/min per 1.73 m2 will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day, Subjects who are taking Metformin at time of randomization will have Dapagliflozin added to current metformin.
62470246|NCT02911792|ACTIVE_COMPARATOR|Metformin/Hyperfiltration|Subjects who Drug naïve we will give Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization will have Metformin- XR, 1000 mg/day added. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
61915045|NCT06363188||control group|"Firstly the patient is generally anesthetized by the anesthesiologist. Intermaxillary fixation (IMF) screws has been inserted in case of there is no arch bar is used.~The transoral or extraoral approach is utilized to expose the fracture line separating the two segments.~Fixation of the bony segments with two plates one Compression 2.3 plate at the inferior border and Tension 2.0 plate five millimeter superiorly to the compression plate.~or 1 plate2.0 (champy) Then suturing the incision layers Postoperative evaluation with cone beam computed tomography (CBCT). The control group with no adjuvant intervention will stop at this point. Then follow up at the first and fourth month with another CBCT to compare the bone healing at the fracture site."
62470247|NCT02911792|EXPERIMENTAL|Dapagliflozin/Normofiltration|Subjects with eGFR below 124 ml/min per 1.73 m2 will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day, Subjects who are taking Metformin at time of randomization will have add Dapagliflozin added to current metformin.
61915046|NCT06036446|EXPERIMENTAL|Cerclage|Cervical cerclage placement with removal during the 36th week of gestation or earlier if clinically indicated.
62109118|NCT06401018|ACTIVE_COMPARATOR|Patients who were played music during the operation|Patients who were played music that has been shown to reduce anxiety during surgery.
62109119|NCT00280033|PLACEBO_COMPARATOR|9|Saline administered on days 0 and 28.
62109120|NCT00280033|EXPERIMENTAL|8|45 mcg alone administered on days 0 and 28.
61915047|NCT06036446|OTHER|Control|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
62109121|NCT00280033|EXPERIMENTAL|7|30 mcg plus aluminum hydroxide administered on days 0 and 28.
62109122|NCT00280033|EXPERIMENTAL|6|30 mcg alone administered on days 0 and 28.
61915048|NCT01659554|EXPERIMENTAL|Out-Patient Intraperitoneal Chemotherapy|Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 \& 8 during a 3 week cycle.
61915049|NCT02320903|EXPERIMENTAL|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
61915050|NCT05820659|EXPERIMENTAL|stress inducing task|Adolescents will complete an adapted peer rejection task on the computer to elicit the experience of subtle racial discrimination from White peers, as well as an impossible puzzle task to elicit cognitive stress.
62109123|NCT00280033|EXPERIMENTAL|5|15 mcg plus aluminum hydroxide administered on days 0 and 28.
62109124|NCT00280033|EXPERIMENTAL|4|15 mcg plus MF59 administered on days 0 and 28.
62109125|NCT00280033|EXPERIMENTAL|3|15 mcg alone administered on days 0 and 28.
62109126|NCT00280033|EXPERIMENTAL|2|7.5 mcg plus aluminum hydroxide administered on days 0 and 28.
62470248|NCT02911792|ACTIVE_COMPARATOR|Metformin/Normofiltration|Subjects with eGFR below 124 ml/min per 1.73m2 drug naïve will receive Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization we will add Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
61915051|NCT01548144|EXPERIMENTAL|Crizotinib + Pazopanib - Group A|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
62109127|NCT00280033|EXPERIMENTAL|1|7.5 mcg plus MF59 administered on days 0 and 28.
62109128|NCT01819038|EXPERIMENTAL|High NGAL and early RRT|NGAL level \> 400 ng/ml and start continuous renal replacement therapy early
62109129|NCT01819038|EXPERIMENTAL|High NGAL and late RRT|NGAL \> 400 ng/ml and start continuous renal replacement therapy late
62109130|NCT01819038|ACTIVE_COMPARATOR|Low NGAL|NGAL \< 400 ng/ml and starting continuous renal replacement therapy follow with absolute indication
62470249|NCT00752973|EXPERIMENTAL|Treatment arm|MALG treatment
62109131|NCT01850992|ACTIVE_COMPARATOR|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
62109132|NCT01850992|PLACEBO_COMPARATOR|Sham CPAP|This is placebo CPAP
62109133|NCT04437056|OTHER|Stroke patients with upper limb spasticity|Patients with post-stroke upper limb spasticity will be operated for cognitive nerve transfers to spastic muscles to allow for volitional muscle reinnervation and disrupture of spasticity. Adequate healthy nerve donors from the ipsilateral arm will be determined clinically and electrophysiologically.
62109134|NCT02699801|ACTIVE_COMPARATOR|Propofol|Patients received propofol for post-operative sedation
62109135|NCT02699801|ACTIVE_COMPARATOR|Dexmedetomidine|Patients received dexmedetomidine for post-operative sedation
62109136|NCT04431934|NO_INTERVENTION|CONTROL|No intervention arm
62109137|NCT04431934|ACTIVE_COMPARATOR|PROBIOTIC|
62109138|NCT04431934|ACTIVE_COMPARATOR|FMT REGIMEN|
62109139|NCT04880733|EXPERIMENTAL|Acupuncture|This arm will receive acupuncture for pain management, and any pain medications will be delayed until after receipt of acupuncture.
62109140|NCT04880733|ACTIVE_COMPARATOR|Usual Care|This arm will receive usual care for pain management.
62109141|NCT02675972||patient with poor outcome|modified Rankin scale≥3
62109142|NCT02675972||patients with favorable outcome|modified Rankin scale\<3
62109143|NCT01247558||Test Cohort|100 randomized subjects administered Metanx®
62109144|NCT01247558||Control Cohort|400 subjects with diabetes mellitus meeting the same inclusion and exclusion criteria as the test cohort who have not been treated with Metanx®.
62109145|NCT04381494|OTHER|Observational/Other|Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions.
62300038|NCT01656642|EXPERIMENTAL|Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.
62470250|NCT05855785|EXPERIMENTAL|The exercise group|The exercise group underwent 8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks. The exercise group also performed moderate-intensity home aerobic exercises for at least 60 minutes per week.
62470251|NCT05855785|OTHER|The control group|The control group performed 60-minute light intensity home exercise, 4 times a week for 8 weeks.
62670944|NCT05788354|ACTIVE_COMPARATOR|conventional method|IFirst, we Performed time out and verify that there were no contraindications to IUD placement:, Second, after package opening we Removed the IUD from the introducer and trimmed IUD threads to 12 cm, Third, we Grasped the IUD firmly along the stem of the device, Fourth we Stabilized the uterus using the non-dominant hand or with the aid of an assistant and advanced the IUD through the hysterotomy to the fundus, Fifth, we Removed hand and directed the IUD threads into the cervix and finally we Closed the uterine incision, took care not to incorporate the IUD strings.
61915052|NCT01548144|EXPERIMENTAL|Crizotinib + Pemetrexed - Group B|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
61915053|NCT01548144|EXPERIMENTAL|Pazopanib + Pemetrexed - Group C|"Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Expansion group starting dose: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion group starting dose: MTD from Phase 1."
61915054|NCT01548144|EXPERIMENTAL|Crizotinib + Pazopanib + Pemetrexed - Group D|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
61915055|NCT04490928||complete revascularization|All patients who underwent complete myocardial revascularization
61915056|NCT04490928||incomplete revascularization|All patients who did not complete myocardial revascularization
61915057|NCT04490928||without revascularization|All patients who were not revascularized
62109146|NCT04245501|EXPERIMENTAL|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized 16-session intervention aimed at reducing interpretation bias. In this study, CBM-I is personalized to youth anxiety symptoms. During CBM-I sessions, youth indicate whether word-sentence pairs are related, and are provided with feedback aimed to reduce bias.
61915058|NCT00570232|OTHER|Tarceva|All patients will be prescribed erlotinib 150mg daily
62109147|NCT04245501|PLACEBO_COMPARATOR|Interpretation Control Condition (ICC)|"Computerized 16-session intervention that is not believed to significantly modify bias. In this study, youth see stimuli personalized to their anxiety symptoms. During ICC sessions, youth see word-sentence pairs and are required to indicate whether word and sentence are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
62109148|NCT02891629|EXPERIMENTAL|Device use in Healthy volunteers|10 healthy volunteers will be recruited
62109149|NCT02891629|EXPERIMENTAL|Device use in ALS patients|5 ALS patients in early stages will be recruited
62109150|NCT00762333||Myocardial Infarction|
62109151|NCT03080792|EXPERIMENTAL|Exercise|Exercise Intervention, moderate to high-intensity endurance and resistance exercise
62109152|NCT03461991|OTHER|Patients scheduled for corneal transplantation|
62109153|NCT02113488||Control: P|Patients who did attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
62737278|NCT03244709|EXPERIMENTAL|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.~Week 24. TCZ tapering every 8 weeks as follows:~* 1 injection every 2 weeks~* 1 injection every 3 weeks~* 1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
62109154|NCT02113488||Case: A|Patients who did not attend (A) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
62737279|NCT02467127|NO_INTERVENTION|control group|Patients without headache. No drugs will be administered
62737280|NCT02467127|EXPERIMENTAL|Chronic Headache|Patients with headache \> 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
62737281|NCT02467127|EXPERIMENTAL|Chronic headache with drug overuse|Patients with headache \> 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
62470252|NCT02408302|ACTIVE_COMPARATOR|oral midazolam|oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.
61915059|NCT03817450|EXPERIMENTAL|Daily Mouth Care|The intervention consists of training in Mouth Care Without a Battle (MCWB) techniques and support in established quality improvement techniques. MCWB is a system-level, evidence based, tested approach to person-centered daily mouth care, which includes tooth-brushing, flossing, care of the gums, and denture care. MCWB provides training to all certified nursing assistants (CNAs) and nursing supervisors, and also supports the designation and specialized training of a CNA to serve as a dedicated, full-time Oral Care Aide (OCA) to provide mouth care to the residents who are at greatest risk for pneumonia and require specialized support to achieve good oral hygiene.
61915060|NCT03817450|NO_INTERVENTION|Standard Mouth Care|Nursing homes will continue to provide standard mouth care to all residents. Nursing home staff will not receive training or supplies in the control condition.
61915061|NCT04861402||Non-intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h Non-intubated during the monitoring carried out in the study Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
62470253|NCT02408302|ACTIVE_COMPARATOR|intranasal midazolam|intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
61915062|NCT04861402||Intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h For intubated group time between IUC admission and study inclusion ≤ 72h Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
61915063|NCT04861402||Health control group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring No symptoms of COVID-19 on the last 15 days~• For healthy group: No previous neurological disease No chronic disease as Diabetes Mellitus Type 2, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure, hypertension or Chronic Kidney Disease (CKD) No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
61915064|NCT04861402||Non-COVID-19 and non-neurological disease intubated group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring~• For intubated group: ICF signed by the participant or his/her legal representative\* Intubated patients for others causes than COVID-19 or neurological diseases IUC admission and study inclusion ≤ 72h No symptoms of COVID-19 on the last 15 days No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
61915065|NCT03544788|EXPERIMENTAL|Cirvo™ Therapy|
61915066|NCT06234332||Exposure group|Group with environmental, nutritional or lifestyle exposures
61915067|NCT06234332||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
61915068|NCT05184439||Study group after surgery|33 children and adolescents (39 knees) with recurrent patellar dislocation were treated with MPFL reconstruction using the adductor magnus tendon between 2010 and 2012. The group is under clinical observation with evaluation being made.
62109155|NCT02113488||Control: C|Patients who cancelled (C) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
62109156|NCT02907593|EXPERIMENTAL|0.025 mg/kg Budesonide|0.025 mg/kg Budesonide in Calfactant
62109157|NCT02907593|EXPERIMENTAL|0.050 mg/kg Budesonide|0.050 mg/kg Budesonide in Calfactant
62109158|NCT02907593|EXPERIMENTAL|0.10 mg/kg Budesonide|0.10 mg/kg Budesonide in Calfactant
62109159|NCT02907593|EXPERIMENTAL|0.15 mg/kg Budesonide|0.15 mg/kg Budesonide in Calfactant
62109160|NCT05302791|EXPERIMENTAL|Muscle Cooling|The intervention will be applying a cooling wrap during the bilateral resistance exercise.
62109161|NCT05302791|PLACEBO_COMPARATOR|Control|There will be no temperature alteration for this leg during bilateral resistance exercise.
62109162|NCT03636451|EXPERIMENTAL|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|40c buffered 0.5% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
62109163|NCT03636451|ACTIVE_COMPARATOR|20cc 1% lidocaine with 2 units of vasopressin paracervical block|20cc 1% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
62300039|NCT01656642|EXPERIMENTAL|ECA: Ate+Vem+Cob (Mandatory Biopsy PD)|Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
62300040|NCT01656642|EXPERIMENTAL|ECB: Ate+Vem+Cob (Mandatory Biopsy)|Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
62300041|NCT01656642|EXPERIMENTAL|ECC: Ate+Vem+Cob (No Mandatory Biopsy)|Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
61915069|NCT05527938|EXPERIMENTAL|web-based intervention|"1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance."
61915070|NCT05527938|NO_INTERVENTION|the control group|"1. Routine care.At each visit to the hospital, in this time, the child and his parents are given health education on diet and exercise booklets, and the parents supervise the child's daily life.~The team members will review the child's condition every month for feedback."
62300042|NCT00538681|EXPERIMENTAL|Enzastaurin + Pemetrexed + Cisplatin|
62300043|NCT00538681|PLACEBO_COMPARATOR|Placebo + Pemetrexed + Cisplatin|
62300044|NCT04990076||Patients planned for hysterectomy with a myometrial lesion of more than 1 cm.|
62300045|NCT00676507|EXPERIMENTAL|Treatment|Treatment Arm: This course of therapy is Best Support Care (BSC) plus monthly intradermal (ID) injections of Lucanix™ (belagenpumatucel-L) consisting of 25,000,000 cells in a volume of 0.40 mL.
62300046|NCT00676507|PLACEBO_COMPARATOR|Control Arm|Control Arm: This course of therapy is Best Support Care (BSC) plus a placebo injection that consists of 0.15% Intralipid® in solution composed of the cryopreservation formulation minus the gene modified cells and dimethyl sulfoxide (DMSO) in a volume of 0.40 mL.
62300047|NCT04516304|PLACEBO_COMPARATOR|Placebo|Placebo
61915071|NCT04054427|EXPERIMENTAL|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF
62109164|NCT03203018|EXPERIMENTAL|Women participating in HL intervention|Groups of women from disadvantaged communities will participate in a three session health literacy workshop
62109165|NCT06627426|EXPERIMENTAL|VR-based patient informed consent|"The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model and enable them to use the VR system by themselves."
62109166|NCT06627426|NO_INTERVENTION|Standard of care group|Group that will receive standard written informed consent
62109167|NCT06627205|EXPERIMENTAL|Sleep Restriction Therapy|Participants attend telehealth sessions once per week for three weeks and implement sleep restriction therapy in between sessions and for 4 weeks during a follow-up period.
62300048|NCT04516304|EXPERIMENTAL|Experimental|S-equol
62470254|NCT02408302|ACTIVE_COMPARATOR|buccal midazolam|buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
62470255|NCT04408794|EXPERIMENTAL|Zavegepant (BHV-3500)|10 mg intranasal (IN) up to 8 times per month, up to 1 year
61915072|NCT02241096|EXPERIMENTAL|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
61915073|NCT03177629|EXPERIMENTAL|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
61915074|NCT03177629|NO_INTERVENTION|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
61915075|NCT03177629|ACTIVE_COMPARATOR|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
61915076|NCT03479645|NO_INTERVENTION|Control|Control arm - usual practice. Simple SMS reminder that informs patients they are overdue for CRC screening and requests they contact the clinic.
61915077|NCT03479645|EXPERIMENTAL|Intervention|Serial text messages and mailed FIT kit
61915078|NCT04096183|OTHER|Ventilation of healthy volunteers|
61915079|NCT00695734||Hemodialysis|Patients under chronic hemodialysis for chronic end stage renal failure
61915080|NCT02095496|EXPERIMENTAL|Intellivent-ASV|Patients will receive Intellivent-ASV ventilation during 12 hours
61915081|NCT02095496|ACTIVE_COMPARATOR|Conventional ventilation|Patients will receive pressure support ventilation during 12 hours
61915082|NCT02078076|EXPERIMENTAL|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
61915083|NCT01710267||Observation group|This group includes all volunteers of this observation study.
61915084|NCT00458874|EXPERIMENTAL|Receive CIMT Results (R-CIMT)|This group will receive visual feedback of their CIMT results on a weekly basis.
61915085|NCT00458874|NO_INTERVENTION|Withhold CIMT Results (W-CIMT)|The W-CIMT group will not receive their CIMT results until the end of their study participation.
61915086|NCT03121651|EXPERIMENTAL|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).~Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications."
61915087|NCT00911001||Group 1|
61915088|NCT05252260|EXPERIMENTAL|Diode Laser|Vestibuloplasty operation was performed via diode laser
61915089|NCT05252260|OTHER|Diode laser + Low-level laser therapy|Vestibuloplasty operation was performed via diode laser and following low-level laser therapy was applied
62109168|NCT00605904|EXPERIMENTAL|Acamprosate|Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.
62300049|NCT06656988|ACTIVE_COMPARATOR|Standard angiography using iodinated Contrast Medium (CM)|"For patients randomised in the control group, a planned infrainguinal peripheral vascular intervention (PVI, not subject to the trial) will be performed with iso-osmolar or low-osmolar iodinated CM as contrast agent.~The trial sites may use iodinated CM as defined per local routine. In line with current recommendations , the use of high-osmolar CM will be prohibited in the trial."
62470256|NCT02259283|EXPERIMENTAL|Achalasia|Patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will undergo POEM with the hybrid knife.
62470257|NCT00440453|NO_INTERVENTION|1|Normal hospital food
61915090|NCT05252260|ACTIVE_COMPARATOR|Conventional surgery|Vestibuloplasty operation was performed via scalpel
61915091|NCT05252260|OTHER|Conventional surgery + Low-level laser therapy|Vestibuloplasty operation was performed via scalpel and following low-level laser therapy was applied
61915092|NCT05340270|EXPERIMENTAL|PD-1 inhibitor + GP Group|PD-1 inhibitor plus GP chemotherapy as Neoadjuvant Therapy followed by IMRT combined with cisplatin concurrent chemotherapy
61915093|NCT05340270|ACTIVE_COMPARATOR|GP Group|GP chemotherapy as Neoadjuvant Therapy chemotherapy followed by IMRT combined with cisplatin concurrent chemotherapy
61915094|NCT02230527|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75mg by mouth daily
61915095|NCT02230527|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg by mouth twice daily
61915096|NCT03255330|EXPERIMENTAL|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
61915097|NCT03255330|ACTIVE_COMPARATOR|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
61915098|NCT04187287|ACTIVE_COMPARATOR|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will be given for 3 weeks, 1 days in a week. Moreover 10-12 minutes cold pack will apply for every session.
61915099|NCT04187287|ACTIVE_COMPARATOR|Deep Friction Massage|Deep Friction Massage treatment will be given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
62109169|NCT00605904|PLACEBO_COMPARATOR|Placebo|Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.
62109170|NCT02970708|EXPERIMENTAL|EFG group|amblyopia in EFG group will receive Eyetronix Flicker Glassess treatment.
62109171|NCT02970708|ACTIVE_COMPARATOR|Patching group|amblyopia in patching group will receive patching treatment.
62109172|NCT06632106||HAIC plus TKIs and ICIs|Each patient should receive at least 2 cycles of HAIC and 1cycles of TKIs plus ICIs. The interval between HAIC and TKIs plus ICIs should be within 2 weeks.
62109173|NCT06632106||TKIs plus ICIs|Each patient should receive at least 2 cycles of ICIs. The interval between TKIs and ICIs should be within 2 weeks.
62109174|NCT00887640|EXPERIMENTAL|Temsirolimus 25 mg|Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion.
62109175|NCT05227469|EXPERIMENTAL|Skeletal class II twinblock + myofunctional therapy|Myofunctional exercises will be prescribed in addition to the standart twin block therapy. Movements will be taught to this group, for which we have prescribed the exercises. It will be ensured that the exercises are done more properly and regularly by taking video recordings every other day from the group that does the exercises twice a day. Incorrect exercises will be corrected by providing feedback.
61915100|NCT03229460|ACTIVE_COMPARATOR|standard low flow therapy|In the standard low flow therapy is applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more.
62109176|NCT05227469|NO_INTERVENTION|Control|Standard twin block therapy will be used for Class II patients. Patients will be informed that they are involved in a study that follows growth and development, and they will receive feedback on whether they use their devices properly, but no myofunctional exercise.
62470258|NCT00440453|EXPERIMENTAL|2|Nutritional treatment
62737282|NCT02467127|EXPERIMENTAL|Acute Headache|Patients without chronic headache but with an history of headache \< 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
62737283|NCT04259437|EXPERIMENTAL|High Protein, Energy Dense Nutritional Supplement|2 servings per day
62737284|NCT02368093|EXPERIMENTAL|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast\]
62737285|NCT02368093|PLACEBO_COMPARATOR|Placebo|placebo pills with the same appearance as Detosiv tablets.
62737286|NCT06403553||non-SALD group|"patients does not fulfill any of the following conditions during ICU stay:~1. Serum aminotransaminase levels \> 800 IU/L, including alanine aminotransferase and aspartate aminotransferase;~2. Total bilirubin \> 2 mg/dL."
62737287|NCT06403553||SALD group|"when patients meet either of the following two criteria under sepsis condition during ICU stay:~1. Serum aminotransaminase levels \> 800 IU/L, including alanine aminotransferase and aspartate aminotransferase;~2. Total bilirubin \> 2 mg/dL."
62737288|NCT02574078|EXPERIMENTAL|Group A Nivolumab|Opdivo specified dose on specified days
62737289|NCT02574078|EXPERIMENTAL|Group A Nivolumab + SOC maintenance therapy|"Opdivo/Bevacizumab specified dose on specified days~Opdivo/Pemetrexed specified dose on specified days"
62737290|NCT02574078|ACTIVE_COMPARATOR|Group A SOC maintenance therapy|"Bevacizumab specified dose on specified days~Pemetrexed specified dose on specified days"
62737291|NCT02574078|EXPERIMENTAL|Group B Nivolumab|Opdivo specified dose on specified days
62737292|NCT02574078|OTHER|Group B Best supportive care|Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
62737293|NCT02574078|ACTIVE_COMPARATOR|Group C Investigator's choice chemotherapy|"Carboplatin/nab-paclitaxel specified dose on specified days~Carboplatin/paclitaxel specified dose on specified days~Carboplatin/pemetrexed specified dose on specified days~Carboplatin/docetaxel specified dose on specified days~Carboplatin/gemcitabine specified dose on specified days~Paclitaxel specified dose on specified days~Docetaxel specified dose on specified days~Gemcitabine specified dose on specified days~Pemetrexed specified dose on specified days"
62737294|NCT02574078|EXPERIMENTAL|Group C Nivolumb|Opdivo specified dose on specified days
62737295|NCT02574078|ACTIVE_COMPARATOR|Group D Erlotinib|Erlotinib specified dose on specified days
62737296|NCT02574078|EXPERIMENTAL|Group D Nivolumab + Erlotinib|Opdivo/Erlotnib specified dose on specified days
62737297|NCT02574078|EXPERIMENTAL|Group E Nivolumab + Crizotinib|Opdivo/Crizotinib specified dose on specified days
62737298|NCT04188834|EXPERIMENTAL|Sensory Flicker Stimulation|"Participants will be exposed for about 10 to 60 minutes at a time, to a sequence of sensory flicker trials each lasting a few seconds to 5 minutes, while their eyes are open or closed. Each trial may include the following modalities and frequencies of flicker:~* Modalities: auditory only, visual only, or audiovisual combined.~* Frequencies: random, or anywhere from 3Hz to 200Hz.~Additionally, subjects may be exposed to individual pulses of light and/or sound, i.e. around or less than 1 pulse /second, for up to 20 minutes at a time."
62737299|NCT04188834|ACTIVE_COMPARATOR|Electrical Flicker Stimulation|"Participants will be exposed to direct electrical brain stimulation with low-amplitude current, at given flicker frequencies. Participants will be exposed to frequencies ranging from 5-100Hz, for up to 10 seconds at a time. Initially, frequencies of 5.5Hz and 40Hz will be tested.~During brain stimulation sessions, bipolar electrical stimulation will be applied to one or more areas of the brain at a time either with or without associated memory tasks. Stimulation in the absence of any memory task will be applied to assess the subject's neurophysiological response to stimulation and to identify the optimal stimulation parameters for use during memory tasks. Stimulation during behavioral tasks will be applied in an attempt to affect the subject's memory."
62300050|NCT06656988|EXPERIMENTAL|Contrast medium sparing strategy using CO2 injection as contrast agent, bailout option iodinated CM|"For patients randomised in the intervention group, a planned infrainguinal peripheral vascular intervention (PVI, not subject to the trial) will be performed with CO2 as contrast agent.~For the CO2 injection the Angiodroid® Injector will be used according to the recent user manual. The use of the Angiodroid® system allows a fully automatic injection with digital control. Automatic CO2 injection enhances patient tolerability as the gas injection is performed in a less explosive, more controlled manner.~Iodinated CM (as described in the above section) is used as bailout option in case of inadequate image quality or intraprocedural intolerance of CO2 angiography by the patient. The reasons for use and the amount of CM must be carefully recorded."
62300051|NCT05462093|OTHER|Additional sequences with MRCP+ and LiverMultiscan|PSC patients that undergo annual, standard care, MRI of the liver and MRCP will undergo additional Liver Multiscan sequences, taking approximately 15 minutes. After the MRI is performed, post-processing analysis named MRCP+ and LiverMultiscan will be performed without patient involvement.
62109177|NCT05825950||HR NMIBC group|"High Risk (HR) NMIBC group of participants studied include ones with American Urological Association (AUA) / Society of Urologic Oncology (SUO) criteria such as : high grade T1, recurrent high grade Ta, high grade Ta \>3 cm, multifocal high grade Ta, any Carcinoma in-situ (CIS), any BCG failure in high grade disease, any variant histology, any lymphovascular invasion.~Note: Ta means the cancer is just in the innermost layer of the bladder lining. T1 means the cancer has started to grow into the connective tissue beneath the bladder lining."
62300052|NCT04622852||Group A: ALPS-PHP device|Patients operated with angular stable plate for displaced PHF with an ALPS plate
62300053|NCT04622852||Group B: Philos device|Patients operated with angular stable plate for displaced PHF with a Philos plate
62300054|NCT02762058|EXPERIMENTAL|Experimental Group|Patients receiving Virtual Reality Mirror Therapy
62109178|NCT05825950||IR NMIBC group|Intermediate Risk (IR) NMIBC group of participants studied include ones with AUA/SUO criteria such as : recurrence within 1 year low grade Ta, solitary low grade Ta \>3 cm, multifocal low grade Ta, high grade Ta ≤3 cm, low grade T1 Note: Ta means the cancer is just in the innermost layer of the bladder lining. T1 means the cancer has started to grow into the connective tissue beneath the bladder lining.
62109179|NCT03807102|EXPERIMENTAL|Tumor Vaccine|Injection of NeoAntigen Tumor Vaccine
62735952|NCT05371158|EXPERIMENTAL|Online intervention|The experimental condition includes an online psychological intervention with therapist email guidance based on Acceptance \& Commitment Therapy (ACT). ACT is a form of Cognitive Behavioral Therapy, which focuses on acceptance of chronic pain in order to be able to perform valuable activities, instead of attempts of avoidance and controlling (Hayes et al., 2012). The main goal of ACT is increasing psychological flexibility, which includes the ability to act effectively according to personal values, with pain. ACT can thereby play a role in creating more realistic expectations regarding expectations of future pain relief. The intervention can be worked through in the participant's own living environment. It consists of 6 modules which can be worked through in 8 weeks.
62109180|NCT00921830|EXPERIMENTAL|Ibuprofen|ibuprofen
62300055|NCT02762058|EXPERIMENTAL|Control Group|Patients receiving Traditional Mirror Therapy
62300056|NCT06380244|NO_INTERVENTION|Opioid|general anesthesia (using remifentanil infusion intraoperatively). Standard monitoring during anaesthesia included arterial oxygen saturation, ECG, and non-invasive arterial blood pressure. Premedication was not used. The standard anaesthesia consisted of propofol (1.5-2 mg / kg body weight iv) and for induction. Infusion of remifentanil in a plasma target control infusion with a calculated plasma level of 1-6 ng/ml. Rocuronium (0.6 mg / kg body weight iv) was administered prior to intubation. AThe painkillers used would be metamizole, acetaminophen and oxycodone.
62300057|NCT06380244|EXPERIMENTAL|OFA|completely anesthetized without opioids (infusion of Ketamine, Lignocaine and Dexmedetomidine. Standard monitoring during anaesthesia included arterial oxygen saturation, ECG, and non-invasive arterial blood pressure. Premedication was not used. The standard anaesthesia consisted of propofol (1.5-2 mg / kg body weight iv) and for induction. Rocuronium (0.6 mg / kg body weight iv) was administered prior to intubation. The painkillers used would be metamizole, acetaminophen and oxycodone.
62300058|NCT00375245|EXPERIMENTAL|Rapamycin + Grapefruit juice|
62300059|NCT02220387||occupational COPD|"Consists of 2 subgroups~1. COPD patients with history of exposure to respirable silica dust~2. COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust"
62300060|NCT02220387||smokers with COPD and healthy control|"Consists of 2 subgroups~1. patients with COPD, history of tobacco smoke and no history of occupational exposure~2. healthy subjects"
62300061|NCT04320095|EXPERIMENTAL|Bizact device for one tonsil|Bizact tonsillecotmy device which is an advanced bipolar device using radiofrequency and pressure to ligate the encountered vessels during tonsillectomy.
62300062|NCT04320095|ACTIVE_COMPARATOR|Electrocautery for second tonsil|Electrocautery is the standard technique used at our institution.
62300063|NCT04320095|EXPERIMENTAL|Bizact device for both tonsils|Consecutive cases of tonsillectomy will be done using Bizact device and compare the operative time collectively for those cases and compare it to same number of cases done using the standard procedure ( Electrocautery)
62300064|NCT04320095|ACTIVE_COMPARATOR|Electrocautery for both tonsils|As explained on the above arm description
62109181|NCT01407900|PLACEBO_COMPARATOR|5% Dextrose in Water|Infusion of D5W
62109182|NCT01407900|ACTIVE_COMPARATOR|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
62109183|NCT03700658|EXPERIMENTAL|TV-46046 Undiluted|Participants will receive TV-46046 undiluted (120 mg/0.3 mL of 400 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
62109184|NCT03700658|EXPERIMENTAL|TV-46046 Diluted|Participants will receive TV-46046 saline-diluted (60 mg/0.3 mL of 200 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
62109185|NCT03700658|PLACEBO_COMPARATOR|TV-46046 Placebo|Participants will receive TV-46046 placebo (0.3 mL) SC injection in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
62300065|NCT04062955|EXPERIMENTAL|Prevention (dietary intervention)|"DIETARY INTERVENTION: Participants receive dietary counseling with a dietitian in person or via telephone to support adherence to a diet based on the AHEI guidelines once weekly for up to 12 weeks.~DXA ONLY STUDY: Participants undergo DXA scan for breast density measurement at baseline and at 12 weeks."
62300066|NCT01346800|EXPERIMENTAL|Prasugrel 10mg po|
62300067|NCT01346800|EXPERIMENTAL|Prasugrel 10mg po + ritonavir 100mg po|
62300068|NCT05294900|EXPERIMENTAL|paclitaxel/carboplatin|paclitaxel+carboplatin
62300069|NCT03903471|EXPERIMENTAL|22G-ProCore Group|The experimental group with 22G-ProCore needle is expected to enroll 300 patients. The 22G-ProCore needle has a 1.5mm long groove 2.5mm above the needle tip, which is expected to have the advantage of taking more biopsy tissues than the 22G-Standard needle.
62300070|NCT03903471|ACTIVE_COMPARATOR|22G-Standard Group|The control group of 22G-Standard needle is expected to include 300 patients, and there is no groove above the needle tip compared with 22G-ProCore needle.
62300071|NCT06108284|NO_INTERVENTION|Conventional Arm|Patients will be placed on Non invasive positive pressure ventilation per current standard of care.
62470259|NCT00001703|EXPERIMENTAL|Group A-VHL peptide and ISA-51 adjuvant|Patients are vaccinated with 1000 micrograms of the mutant Von Hipple-Lindau (VHL) peptide administered subcutaneously along with ISA-51 adjuvant (Montanide ISA-51 adjuvant, Incomplete Freund's adjuvant) and injected subcutaneously every four weeks for a total of four vaccinations.
62470260|NCT01521481|EXPERIMENTAL|Triple inguinal nerve block|Ropivacaine 5 mg/ml
61915101|NCT03229460|EXPERIMENTAL|high flow nasal oxygen therapy|In the high-flow-oxygen group is passed through a heated humidifier and applied continuously through large-bore binasal prongs, with a gas flow rate of 30-60 liters per minute . The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an Spo2 of 92% or more.
62109186|NCT03700658|ACTIVE_COMPARATOR|Depo-subQ 104|Participants will receive Depo-subQ 104 (medroxyprogesterone acetate injectable suspension; 104 mg/0.65 mL) SC injection as a reference formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
62109187|NCT02163915|EXPERIMENTAL|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
62109188|NCT02163915|EXPERIMENTAL|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
62109189|NCT02163915|EXPERIMENTAL|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
62109190|NCT02163915|EXPERIMENTAL|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
62109191|NCT02163915|EXPERIMENTAL|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
62109192|NCT02163915|EXPERIMENTAL|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
62109193|NCT03861221|EXPERIMENTAL|Conebeam Breast Computed Tomography|
62300072|NCT06108284|ACTIVE_COMPARATOR|Intervention Arm|Patient in this arm will be placed on Biphasic Cuirass Ventilation
62300073|NCT00904124|PLACEBO_COMPARATOR|Control|No regular flour replaced
62300074|NCT00904124|EXPERIMENTAL|5% Cellulose|5% regular flour is replaced by cellulose
62300075|NCT00904124|EXPERIMENTAL|2.5% Alginate|2.5% regular flour is replaced by Alginate
62300076|NCT00904124|EXPERIMENTAL|5% Alginate|5% regular flour is replaced by Alginate
62300077|NCT00904124|EXPERIMENTAL|2.5% Guar gum|2.5% regular flour is replaced by Guar gum
62300078|NCT00904124|EXPERIMENTAL|1.25% Guar gum|1.25% regular flour is replaced by Guar gum
62300079|NCT05207267|EXPERIMENTAL|testing arm|ventilated with different VT using an EIT monitor (PulmoVista® 500, Dräger, Lübeck, Germany)
62470261|NCT01521481|ACTIVE_COMPARATOR|Unilateral subarachnoid anesthesia|Bupivacaine 10 mg/ml
62109194|NCT06335836||SI group (social isolation group)|"The LSNS-6 was used for assessing social networks among older Chinese. Lubben suggested using a score of less than 12 as a clinical cutoff point of the LSNS-6 to indicate social isolation, which meant, on average, the respondents had less than two people to perform social integration functions.~0≤LSNS-6≤12"
62735953|NCT05371158|NO_INTERVENTION|Control condition|The control condition includes a waiting list group that can receive treatment-as-usual. Participants are placed on a waiting list and receive the online psychological ACT intervention without email guidance directly after the first follow-up measurement. Participants placed on the waiting list will not receive the ACT intervention immediately. Participants do have the opportunity to access treatment as usual (TAU). Directly after the first, 3-month follow-up measurement these participants receive the opportunity to follow the intervention without email guidance by a therapist.
62109195|NCT06335836||nonSI group (non-social isolation group)|LSNS-6\>12
62109196|NCT00130637|EXPERIMENTAL|Daclizumab|IV daclizumab
62109197|NCT05701111|EXPERIMENTAL|Mindfulness Curriculum|Participants will undergo a mindfulness curriculum in the classroom for 6-8 weeks and complete surveys before the start and after completion.
62109198|NCT05701111|EXPERIMENTAL|Teachers|Participants will be trained in the mindfulness curriculum and implement it in the classroom for 6-8 weeks. They will complete surveys before training and after implementation.
62470262|NCT05293886|ACTIVE_COMPARATOR|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
62109199|NCT05701111|EXPERIMENTAL|Counselors|Participants will be trained in Cue-Centered Therapy and implement the treatment with student clients for 15-18 weeks. They will complete surveys before training and after 3 months after the start of implementation.
62109200|NCT05701111|EXPERIMENTAL|CCT|Participants that report PTSD symptomatology during the mindfulness curriculum surveys will be eligible to participate in Cue-Centered Therapy treatment for 15-18 weeks. They will complete surveys before and after treatment.
62109201|NCT05701111|OTHER|iSWAB-DNA|Students that give prior consent to participating in DNA buccal swabs and the mindfulness curriculum are randomly selected to give buccal swabs prior to and after the mindfulness curriculum intervention. A subset of those students that qualify for CCT will give another buccal swab after CCT completion. DNA will be sent to Dr. Urban's lab for analysis of genetic resilience markers.
62109202|NCT01188252|EXPERIMENTAL|Roniciclib|
62109203|NCT00897637||Observational|Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
62109204|NCT03939572|ACTIVE_COMPARATOR|Accurate step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will simply display their accurate step count."
62109205|NCT03939572|EXPERIMENTAL|Deflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display a deflated step count."
62470263|NCT05293886|EXPERIMENTAL|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
62470264|NCT03374605|EXPERIMENTAL|Active tDCS|
62470265|NCT03374605|SHAM_COMPARATOR|Sham tDCS|
62735954|NCT00740441|EXPERIMENTAL|A|AS1411 treatment
62735955|NCT03383250|EXPERIMENTAL|Meal ingestion|
62470266|NCT05270733|EXPERIMENTAL|Treatment|Patients will be treated with ustekinumab (90mg at week 0 and week 4 by subcutaneous injection) for 8 weeks followed by treatment with guselkumab (100mg at week 0 and week 4 by subcutaneous injection) or risankizumab (150mg at week 0 and week 4 by subcutaneous injection)
62470267|NCT03647215||All Participants|Participants with CML and Ph+ALL who are being treated with their first or subsequent TKI therapy. CML patients must meet the ELN criteria for warning and failure ) or have high SOKAL score (\>0.8) or presence of additional chromosomal abnormalities (ACAs) and have detectable BCR-ABL levels. Ph+ALL patients need detectable BCR-ABL levels only.
62470268|NCT01093053|EXPERIMENTAL|Mind-Body Skills Groups|
62109206|NCT03939572|EXPERIMENTAL|Inflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display an inflated step count."
62109207|NCT03939572|EXPERIMENTAL|Accurate feedback + mindset intervention|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display their accurate step count. Additionally, participants in this arm will receive a meta-mindset intervention."
62470269|NCT01093053|ACTIVE_COMPARATOR|Standard Treatment|
62470270|NCT03059628|EXPERIMENTAL|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
62670945|NCT05788354|EXPERIMENTAL|new method|First we Performed time out and verified that there were no contraindications to IUD placement, Second, after package opening we Removed IUD from the introducer and trimmed the IUD threads to 12 cm and also trimmed the introducer to 12 cm, Third, we Loaded the IUD again inside the introducer (through the trimmed end) and kept the arms of the IUD unfolded, Forth, we removed the shoulders of the introducer, Fifth, we held the uterus and stabilized it by the non-dominant hand and guided the introducer containing the IUD strings first through the cervix then we advanced the introducer with the IUD arms unfolded to the fundus and kept the IUD their by pressing on the fundus, then we pushed the introducer gently through the cervix to the vagina, Finally, we Closed the uterine incision, took care not to incorporate the introducer or the threads and then we removed the introducer gently manually from the vagina after closure of the skin and ceiling of the wound.
62670946|NCT02491450|EXPERIMENTAL|A Test|Test drug (Heterosofir)1 tablet contains 400 mg Sofosbuvir
62670947|NCT02491450|ACTIVE_COMPARATOR|B Reference|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
62470271|NCT03059628|OTHER|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
62670948|NCT01111188|EXPERIMENTAL|all subjects|Subjects will receive PD 0332991 plus bortezomib. The dose of each agent will be dependent on the time point the subject enters the trial.
62109208|NCT00807430|EXPERIMENTAL|1|24 patients receiving active treatment
62109209|NCT00807430|PLACEBO_COMPARATOR|2|Placebo treatment
62300080|NCT02814773||AD group|group suffering from Alzheimer-type dementia (mild to moderate dementia)
62300081|NCT06545604|EXPERIMENTAL|CYT - Prehab Yoga Intervention + ERAS|
62300082|NCT06545604|EXPERIMENTAL|WLC - Wait List Control + ERAS|
62300083|NCT06655922||Patients with at least one untreated CTO at basal angiography|Total occlusion in any major coronary vessel or relevant side branches \[reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists\], with TIMI 0 in the distal segment and at least 3 months old
62300084|NCT05006053||Qualitative study with healthcare professionals|Healthcare professionals working in Child and Adolescent Mental Health Services, Sexual Assault Referral Centres or with e-therapy providers
62670949|NCT05319405|ACTIVE_COMPARATOR|Sana plus Treatment as Usual|Subjects will be loaned a Sana Device to use for 28 days and will also receive mental health care through the Ralph H. Johnson VA Medical Center.
61915102|NCT03229460|PLACEBO_COMPARATOR|Noninvasive ventilation|In the noninvasive-ventilation group is delivered to the patient through a face mask that was connected to an ICU ventilator,with pressure support applied in a noninvasive ventilation mode. The Fio2 or PEEP level (or both) were then adjusted to maintain an Spo2 of 92% or more.
61915103|NCT01470443|ACTIVE_COMPARATOR|GEMOX|"* Gemcitabine 1,000 mg/㎡, day 1 and 8, every 3 weeks~* Oxaliplatin 100 mg/㎡, day 1, every 3 weeks"
62300085|NCT01960010|ACTIVE_COMPARATOR|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
62300086|NCT01960010|PLACEBO_COMPARATOR|Vehicle|Vehicle
62300087|NCT01151072|EXPERIMENTAL|IDeg i.m. thigh|
62300088|NCT01151072|EXPERIMENTAL|IDeg i.v.|
62300089|NCT01151072|EXPERIMENTAL|IDeg s.c. abdomen|
62300090|NCT01151072|EXPERIMENTAL|IDeg s.c. deltoid|
62300091|NCT01151072|EXPERIMENTAL|IDeg s.c. thigh|
62300092|NCT00584662|ACTIVE_COMPARATOR|1|Oxymetazoline Hydrochloride
62300093|NCT02262637||Hypertensive patients - Cardiologists|
62670950|NCT05319405|NO_INTERVENTION|Treatment as Usual|Subjects will receive mental health care at the Ralph H. Johnson VA Medical Center or community-based outpatient clinic (CBOC).
62670951|NCT02003027|EXPERIMENTAL|BT injection|
62109210|NCT00966199|EXPERIMENTAL|Hypertensive elderly|community dwelling hypertensive elderly from general practices
62670952|NCT03399123|EXPERIMENTAL|Low tidal volume group|Use a low tidal volume(6'8ml/kg) ventilation mode during liver segmentation。
62670953|NCT03399123|ACTIVE_COMPARATOR|Standard tidal volume group|Use a standard tidal volume(10'12ml/kg) ventilation mode during operation.
62300094|NCT02262637||Hypertensive patients - Nephrologists|
62300095|NCT02262637||Hypertensive patients - Diabetologists|
62300096|NCT02395835||Normal weight (NW) pregnant women|"Pregnant women with Body Mass Index (BMI) \> = 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
62670954|NCT04275414|EXPERIMENTAL|bevacizumab plus standard care|Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.
62670955|NCT03607058|ACTIVE_COMPARATOR|Kinect + Exercise Training|Xbox Kinect and exercise training will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. A treatment session in this arm will consist of Kinect games for 40 minutes and exercise training for 20 minutes. In this arm, patients will play each game as two repetitions. Each game lasts about 3-4 minutes, and patients will be seated for resting between the games. After 10 weeks washout period only exercise training will be applied for 8 weeks.
62670956|NCT03607058|ACTIVE_COMPARATOR|Exercise Training|Exercise training will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 10 weeks washout period exercise training and Xbox Kinect will be applied together for 8 weeks.
62670957|NCT01260792||Children|Children between 5 and 18 years old.
62670958|NCT01260792||Adults|Parents of children between 5 and 18 years old
62670959|NCT05628415|ACTIVE_COMPARATOR|Procedure: non-powered AEON™ Endostapler|Bilateral or unilateral lung-volume-reduction-surgery (LVRS) by video-assisted thoracic surgery (VATS) or open method with use of the non-powered AEON™ Endostapler for left and/or right side of the lung. By randomization it is specified on which side and with which method the lung tissue will be closed. If bilateral surgery is planned, the other side is automatically closured using the other method. In cases of a unilateral surgery a random stapler as stated in the envelop would be allocated for that side in question.
62670960|NCT05628415|ACTIVE_COMPARATOR|Procedure: Echelon FLEX™ Powered plus Stapler|Bilateral or unilateral lung-volume-reduction-surgery (LVRS) by video-assisted thoracic surgery (VATS) or open method with use of the Echelon FLEX™ Powered plus Stapler for left and/or right side of the lung. By randomization it is specified on which side and with which method the lung tissue will be closed. If bilateral surgery is planned, the other side is automatically closured using the other method. In cases of a unilateral surgery a random stapler as stated in the envelop would be allocated for that side in question.
62670961|NCT02344095|EXPERIMENTAL|weekly paclitaxel with oncothermia|Paclitaxel group are treated with weekly paclitaxel and oncothermia for 4-cycles.
62109211|NCT02664194|ACTIVE_COMPARATOR|Control Group|Primary percutaneous coronary intervention only
62109212|NCT02664194|EXPERIMENTAL|03 Hours Hypothermia Group - Proteus® Cooling System|03 hours of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
62670962|NCT02344095|EXPERIMENTAL|weekly cisplatin with oncothermia|Cisplatin group are treated with weekly cisplatin and oncothermia for 4-cycles.
62670963|NCT01796444|ACTIVE_COMPARATOR|Axillary Lymph Node Dissection|After sentinel lymph node biopsy, surgery for standard axillary lymph node dissection. Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
62109213|NCT02664194|EXPERIMENTAL|01 Hour Hypothermia Group - Proteus® Cooling System|01 hour of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
62109214|NCT06441656|EXPERIMENTAL|Flip and fix ILM flap|In the (Flip and Fix) technique group, the (flipped) ILM flap was secured in place and flattened over the macular surface using a 1.5 cc bubble of PFCL (Arcaline; Arcadophtha, Toulouse, France) injected over the flipped ILM flap. Then fluid air exchange with removal of the PFCL bubble was done followed by (fixing) the ILM flap over the macular surface using two drops of autologous non-heparinized blood -collected by the attending nurse or anaesthesiologist from one of the veins on the dorsum of the hand- one dropped over the superior-nasal and another at the inferior-nasal edges of the ILM flap (away from the MH center).
62109215|NCT06441656|ACTIVE_COMPARATOR|classic temporal ILM flap|PFCL and blood were not used to fix the ILM flap
62109216|NCT01514734|EXPERIMENTAL|AZARGA|Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks
62300097|NCT02395835||Overweight (OW) pregnant women|"Pregnant women with Body Mass Index (BMI) \< 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
62300098|NCT05057351|EXPERIMENTAL|Active ingredient|Isopentenyltheophylline 0.44% + Glycerin 4.56%
62300099|NCT05057351|PLACEBO_COMPARATOR|Placebo|Glycerin 4.56%
62300100|NCT01589731||Allergic group|The first group (group A) included 45 patients (17 males; mean age: 46.2 years, SD: 12.2 years) with convincing clinical histories of reproducible adverse reactions to bovine milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.
62300101|NCT01589731||Non Allergic group|The second group (group B) was used as a control for the immunoblotting analysis performed in the first group and included 20 individuals selected based on an evident tolerance to cow's milk, an absence of βs-IgE by ImmunoCAP assay and SPT non-reactivity to β-Lg or TgPolβ-Lg (6 males; mean age: 21.9 years, SD: 17.6 years).
62109217|NCT02504970||Anesthesia Group Type|AQI collects data from anesthesia groups. The groups are classified according to practice type
62300102|NCT01589731||Atopic group|The third group (group C) included 49 subjects with atopic respiratory and/or dermatological diseases (19 males; mean age: 28.7 years, SD: 20.6 years) regardless of βs-IgE status. This group was used to compare the ex vivo cell-mediated immunoreactivity between β-Lg and TgPolβ-Lg by comparing the mean ex vivo antigenic challenge results determined using the leukocyte adherence inhibition test (LAIT).
62109218|NCT01429779|EXPERIMENTAL|Movicol|Administration of 1 sachet of Movicol® daily during one week preoperatively (experimental care) and 2 sachets of Movicol® daily postoperatively (standard care).
62109219|NCT01429779|NO_INTERVENTION|Control|Control group; standard postoperative care (administration of 2 sachets of Movicol® postoperatively daily)
62109220|NCT05689047|EXPERIMENTAL|Part A: Safety Run-in Cohort M5717+Pyronaridine|M5717 and pyronaridine once daily in a single day treatment regimen at low dose of 330 milligrams (mg) and 360 mg respectively.
62109221|NCT05689047|EXPERIMENTAL|Part B: Dose escalation cohort; M5717+Pyronaridine|After completion of Part A, if dose will be considered safe and well tolerated, the Internal Data Monitoring Committee (IDMC) will have the option to recommend dose adjustments. M5717 and pyronaridine once daily will be administered in an escalated dose in a single day or 2-day treatment regimen.
62109222|NCT05689047|ACTIVE_COMPARATOR|Pyronaridine-artesunate|Pyronaridine-artesunate (Pyramax) once daily in a 3-day treatment regimen.
62109223|NCT03644537|OTHER|heavy force 100gm|heavy intrusive force is to be applied on a first premolar on one side
62109224|NCT03644537|OTHER|medium force 25 gm|medium intrusive force is to be applied on a first premolar on one side
62109225|NCT03644537|OTHER|light force 10 gm|light intrusive force is to be applied on a first premolar on one side
62109226|NCT05242926|EXPERIMENTAL|ModraDoc006/r|Six evaluable patients will be included for collection of plasma, faeces and urine samples during 168 hours after one day of bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir.
62670964|NCT01796444|EXPERIMENTAL|Non-Axillary Lymph Node Dissection|After sentinel lymph node biopsy, no surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial). Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
62109227|NCT01535989|EXPERIMENTAL|intravenous|dose escalation
62109228|NCT02785978|EXPERIMENTAL|Parkinson Disease Patients Group #1|PD patients with programmed levodopa challenge
62300103|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
62300104|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
62300105|NCT02213718|EXPERIMENTAL|Desflurane|desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)
62300106|NCT02213718|ACTIVE_COMPARATOR|propofol|intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).
62300107|NCT01403077|EXPERIMENTAL|Scaffold Treatment|
62470272|NCT06131437|EXPERIMENTAL|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 72 weeks.
62470273|NCT06131437|ACTIVE_COMPARATOR|Tirzepatide 15 mg|Participants will receive 15 mg tirzepatide subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 72 weeks.
62470274|NCT00450190|EXPERIMENTAL|Saizen® E-Device|
62670965|NCT02619656|EXPERIMENTAL|Treatment|"Patients randomized to insufflation with CO2.~Intervention: CO2 Insufflation with CO2Efficient Endoscopic Insufflator on managed flow setting at 3.4 L/min"
62670966|NCT02619656|ACTIVE_COMPARATOR|Control|"Patients randomized to insufflation with ambient air.~Intervention: Ambient air insufflation with Evis Exera 111 CLV-190 on medium air flow setting 0.68 L/min"
62109229|NCT02785978|EXPERIMENTAL|Parkinson Disease Patients Group #2|PD patients without programmed levodopa challenge
62109230|NCT02785978|EXPERIMENTAL|Healthy volunteers|Healthy volunteers
62109231|NCT00906282|EXPERIMENTAL|Pemetrexed/Carboplatin|"4 cycles of preoperative treatment (1 Cycle = 21 days):~Pemetrexed: 500 mg/m2 intravenously (IV) for 10 minutes on Day 1 each cycle; Carboplatin: AUC 6.0 by IV on Day 1 each cycle."
62109232|NCT03143309|EXPERIMENTAL|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
62109233|NCT03143309|ACTIVE_COMPARATOR|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
62109234|NCT03705819|EXPERIMENTAL|Healthy Volunteers|In Stage 1, five healthy volunteers will receive a microdose of \[11C\]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes post-administration. These image sets will be used to evaluate \[11C\]-NOP46 biodistribution and derive dosimetry estimates.
62109235|NCT03705819|EXPERIMENTAL|Individuals with Focal Pain|In Stage 2, up to 30 subjects with focal pain will receive a microdose of \[11C\]-NOP46 and undergo PET/CT scans for up to 60 minutes in length. The results of Stage 1 will inform the scanning parameters (uptake period, scan length, reconstruction parameters, etc.) for Stage 2.
62109236|NCT05252871|EXPERIMENTAL|Experimental: The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
62670967|NCT04200209|EXPERIMENTAL|Hospital|Twelve wards of the hospital will be evaluated at the same time.
62470275|NCT05732857|SHAM_COMPARATOR|trocar standard|patients in whom the standard trocar will be used to perform robot-assisted complex partial nephrectomy surgery
62470276|NCT05732857|ACTIVE_COMPARATOR|trocar valveless|patients in whom the valveless trocar will be used to perform robot-assisted complex partial nephrectomy surgery
62670968|NCT04546620|ACTIVE_COMPARATOR|Arm A Control|6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy every 21 days.
62670969|NCT04546620|EXPERIMENTAL|Arm B Experimental|1 cycle of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy followed by 5 cycles of R-CHOP + acalabrutinib taken twice daily for 21 day cycles.
62109237|NCT05252871|ACTIVE_COMPARATOR|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
62109238|NCT03313206|EXPERIMENTAL|Cohort A|The cohort A (Pembrolizumab only) will be opened in a first study step. Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks (4 injections maximum over 12 weeks), monotherapy
62470277|NCT03733158|EXPERIMENTAL|Normal airway|intubation in normal aurway condition
62470278|NCT03733158|EXPERIMENTAL|Tongue edema|intubation in Tongue edema condition
62670970|NCT01975649|EXPERIMENTAL|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
62670971|NCT01975649|PLACEBO_COMPARATOR|Placebo|patients will use placebo for 120 days
61915104|NCT01470443|EXPERIMENTAL|XELOX|Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks Oxaliplatin 130mg/㎡, day 1, every 3 weeks
61915105|NCT04240678|EXPERIMENTAL|HBV Alert Group|
61915106|NCT04240678|NO_INTERVENTION|Control Group|
61915107|NCT05573412||All Particpants|Group contains all participants as this is a systemic review of stem cell cryopreservation techniques
62109239|NCT03313206|EXPERIMENTAL|Cohort B|Up to 26 evaluable patients will be treated in the cohort B (Pembrolizumab with Lenvatinib) if they do not have any contraindication for receiving lenvatinib treatment, otherwise they will be treated in the cohort A if slots are available. In the cohort B, the neo-adjuvant anti-PD1 immunotherapy will be combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
62470279|NCT03733158|EXPERIMENTAL|Pharyngeal obstruction|intubation in Tongue edema condition
62470280|NCT03733158|EXPERIMENTAL|Manual cervical inline stabilization|intubation in Manual cervical inline stabilization condition
62109240|NCT00778804|EXPERIMENTAL|telemedicine|Web-based monitoring in addition to usual clincial care with quarterly visits
62109241|NCT00778804|NO_INTERVENTION|Control|Ususal care with quarterly visits
62109242|NCT05890521|EXPERIMENTAL|Population Ⅰ|
62470281|NCT03733158|EXPERIMENTAL|Cervical collar stabilization|intubation in Cervical collar stabilization condition
62470282|NCT03733158|EXPERIMENTAL|Cervical collar stabilization and pharyngeal obstruction|intubation in Cervical collar stabilization and pharyngeal obstruction condition
62470283|NCT05125211|EXPERIMENTAL|Single dose-escalation of GB001 recombinant peptide spray|Each subject will receive one single administration of GB001 recombinant peptide. The dosage of each group is 0.054mg, 0.108mg, 0.216mg, 0.432mg and 0.864mg, respectively.
62670972|NCT05182892|EXPERIMENTAL|Part 1: All participants|All participants who will participate in part 1.
62670973|NCT05182892|NO_INTERVENTION|Part 2: All participants|All participants who participated in part 1
62670974|NCT05182892|NO_INTERVENTION|Part 3: All participants|All participants who will participate in part 3
62670975|NCT00739570|NO_INTERVENTION|1|
62670976|NCT00739570|ACTIVE_COMPARATOR|2|Activator chiropractic technique basic scan protocol
62670977|NCT03701087|NO_INTERVENTION|normal serum vitamin D|normal serum vitamin D
62670978|NCT03701087|EXPERIMENTAL|low serum level of vitamin D|this arm will intake vitamin D 2800 IU daily
62670979|NCT03701087|PLACEBO_COMPARATOR|low serum vitamin D|this arm will intake placebo omega 3
61915108|NCT06427343|EXPERIMENTAL|High dose|"Participants randomized to this arm will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up.~Iron to be administered as ferric derisomaltose. Ferric derisomaltose will be administered according to the dosing schedule determined by the patient's body weight and hemoglobin value.~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg."
62470284|NCT05125211|EXPERIMENTAL|Oral retention time test for a single dose|Each subject will receive one single administration of GB001 recombinant peptide. The dosage of the group is 0.108mg.
62670980|NCT01590966|EXPERIMENTAL|Patients with an active inflammatory joint disease|In total there will be 20 patients included: 5 patients with active rheumatoid arthritis, 5 patients with active early axial spondyloarthritis, 5 patients with active early peripheral spondyloarthritis and 5 patients with active ankylosing spondylitis.
62109243|NCT04041999|EXPERIMENTAL|Daily Cognition Training Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment."
62109244|NCT04041999|ACTIVE_COMPARATOR|Traditional Cognitive Stimulation Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are performed to work various cognitive functions."
62109245|NCT04373187|EXPERIMENTAL|CC-93538, 180mg/mL|26 healthy subjects will receive one injection of 2mL, 180mg/mL CC-93538
62109246|NCT04373187|EXPERIMENTAL|CC-93538, 150mg/mL|26 healthy subjects will receive 2 injections of 1.2mL, 150mg/mL CC-93538
62109247|NCT02706067|EXPERIMENTAL|Orlistat|Participants will receive intermittent orlistat for up to 4 years, with the dose determined according to body weight changes.
62470285|NCT05125211|EXPERIMENTAL|Multiple Ascending Dose of GB001 recombinant peptide spray|Each subject will be dosed with oral spray of GB001 recombinant peptide ten times per day for four days. GB001 recombinant peptide will be administrated, and the dosage of each group is 0.108mg, 0.216mg and 0.432mg, respectively.
62670981|NCT01647685|ACTIVE_COMPARATOR|Nanocort|Two weekly IV infusions of 144 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
62470286|NCT02504138|EXPERIMENTAL|Desflurane balanced anesthesia group|
62470287|NCT02504138|ACTIVE_COMPARATOR|Propofol total intravenous anesthesia group|
62470288|NCT02598323|EXPERIMENTAL|patients with active singleton pregnancy between 16 and 26 SA|
62470289|NCT04042363|EXPERIMENTAL|Active Transorbital electrical stimulation|Transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks
62470290|NCT04042363|SHAM_COMPARATOR|Sham Transorbital stimulation|Sham stimulation - 10 sessions during 2 consecutive weeks
62670982|NCT01647685|ACTIVE_COMPARATOR|Methylprednisolone|Methylprednisolone sodium succinate 125 mg infusion.
62670983|NCT01647685|PLACEBO_COMPARATOR|Saline|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
62670984|NCT05316987|OTHER|Active vitiligo patients|NBUVB
62670985|NCT00890721|EXPERIMENTAL|SKY0402|During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.
62670986|NCT00890721|PLACEBO_COMPARATOR|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
62670987|NCT03868800|OTHER|SDM-DC|All adult patients with kidney failure referred to a department of renal medicine at one of the four hospitals from the 1st of October 2016 to the 31st of May 2018 were offered the intervention and invited to participate in the study. The inclusion criterion was an estimated glomerular filtration rate below 20 ml/min and based on a clinical judgement made by the contact doctor and/or the contact nurse about the decline in the Estimated glomerular filtration rate to continue. Exclusion criteria were patients who had decided on conservative management, patients with a living donor and a set date for transplantation and patients not able to participate in the intervention due to cognitive impairment. The use of an interpreter was not an exclusion criterion.
62109248|NCT02205762|EXPERIMENTAL|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
62300108|NCT04074486||Injured and Matched Control Subjects|Head Injured subjects are defined as those who sustained a closed head injury and meet specified protocol inclusion/exclusion criteria. Matched Control subjects are enrolled based on matching criteria (for e.g. age, gender, and same population i.e. sports vs non-sports) to the head injured subjects. For all head injured and matched control group subjects, the full battery of tests will be performed. The injured pool will begin test procedures when a subject sustains a concussion injury. The matched control pool will follow the same time point/date interval as their matched injured subject. The matched control will be assigned by site to an injured subject and matched by age, gender, and sport (if applicable) or from the same population (if non-sport).
62670988|NCT04197960|EXPERIMENTAL|microwave ablation|ablate all tumors including at least 2mm safe margin except for tumors adjacent to thyroid capsule.
62109249|NCT02205762|EXPERIMENTAL|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
62670989|NCT04197960|ACTIVE_COMPARATOR|surgical resection|lobectomy + central lymph node dissection
62670990|NCT03694652|EXPERIMENTAL|PACE+DApp|Participants in this group will receive combined intervention and a mobile phone app.
62470291|NCT03876769|EXPERIMENTAL|Single dose of CTL019|"Based on the subject's weight one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects \> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
62470292|NCT01262469|EXPERIMENTAL|Lapatinib + Capecitabine|lapatinib 1250 mg/day (once daily) Capecitabine 2x850 mg/m2/day, days 1-14 during the first cycle and 2x1000 mg/m2/day, days 1-14, every 21 days for following cycles ( if no unacceptable toxicity is observed).
62109250|NCT02205762|EXPERIMENTAL|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
62109251|NCT02205762|EXPERIMENTAL|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
62109252|NCT02205762|EXPERIMENTAL|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
62109253|NCT02205762|EXPERIMENTAL|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.~* Treatment Options- Management (mostly wait \& see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.~* Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.~* Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
62109254|NCT02167243|EXPERIMENTAL|Reinforcement for performing BG testing|Subjects will receive reinforcement for BG testing. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
62670991|NCT03694652|ACTIVE_COMPARATOR|PACE+Dface-to-face|Participants in this group will receive combined intervention and in person/phone communication.
62109255|NCT02167243|ACTIVE_COMPARATOR|No reinforcement for BG testing|Subjects will receive standard of care without reinforcement for Self Monitoring Blood Glucose
62109256|NCT01145456|EXPERIMENTAL|Treatment (RO4929097 and gemcitabine hydrochloride)|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62109257|NCT02979899|EXPERIMENTAL|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
62109258|NCT02979899|ACTIVE_COMPARATOR|votrient|standard dose votrient by mouth, once daily
62109259|NCT04555044|EXPERIMENTAL|Clinolipid|Dosing based on American Academy of Pediatrics (AAP), American Academy Society for Parenteral and Enteral Nutrition (ASPEN), European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)/ European Society for Parenteral and Enteral Nutrition (ESPEN)/ European Society of Paediatric Research (ESPR)/ Chinese Society for Parenteral and Enteral Nutrition (CSPEN) guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
62109260|NCT04555044|ACTIVE_COMPARATOR|Intralipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
62109261|NCT06628817|EXPERIMENTAL|Experimental Arm|Hospitals assigned to the experimental group will receive a combined management intervention based on self-feedback from the online platform, including: a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
62109262|NCT06628817|NO_INTERVENTION|No intervention|Hospitals in the control group only received self-feedback from the online platform in the neurology department, without receiving combined management intervention. / The neurology department of the control group hospitals only received self-feedback from the online platform, without receiving combined management intervention.
62109263|NCT02526680|EXPERIMENTAL|Glaucoma Subjects|27 glaucoma subjects will be given the OrCam low vision aid device to use for 1 month.
62109264|NCT04671108|EXPERIMENTAL|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
62470293|NCT02847650|PLACEBO_COMPARATOR|Placebo|
62470294|NCT02847650|EXPERIMENTAL|PF-06649751|
62470295|NCT05247463||Women invited to Breast Cancer Screening in England|Women invited to Breast Cancer Screening in England up to 31st March 2018
62470296|NCT05247463||Women attending Breast Cancer Screening in England|Women attending mammography screening to examine the effect of screening test threshold on outcomes, up to 31st March 2018
62109265|NCT04671108|ACTIVE_COMPARATOR|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
62109266|NCT02875665|EXPERIMENTAL|geko device arm|geko™ devices (acting on the posterior tibial nerve) to be used on alternate days over seven days, for an hour per day
62109267|NCT06523855|EXPERIMENTAL|bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation|"in bilateral alveolar cleft, the cancellous particulate bone graft from anterior iliac crest will be used to fill the defect, 8-hole microplates will be used to fix the premaxilla using screws.~The microplates are to be removed 6 to 9 months postoperatively."
62109268|NCT06523855|ACTIVE_COMPARATOR|bilateral alveolar cleft grafting using iliac crest particulate|in bilateral alveolar cleft, the cancellous particulate bone graft from anterior iliac crest will be used to fill the defect.
62300109|NCT04074486||Healthy Volunteer Subjects|Healthy Volunteer subjects are defined as those who are normal subjects i.e. not head-injured meeting specified protocol inclusion/exclusion criteria.This group of subjects are recruited only for the purpose of collecting data for norming the electronic near point convergence measurement (eNPC). These subjects will only perform a limited battery of BrainScope tests at a single visit and will include data collection regarding their demographics, concussion history, signs and symptoms, sports information, etc. These subjects will not undergo EEG or neurocognitive assessment.
62300110|NCT04074486||Non-Concussed Head Injured Subjects|A secondary group of non-concussed head-injured controls shall be also recruited who were observed to have a head impact/injury but were not restricted from play within the same game or deemed non-concussed following on-field/sideline evaluation by the standard of care at each site. They will perform the entire BrainScope battery of tests within 5 days after the incident and defined as Day 0 and a follow-up assessment at 15 Days following Day0
62300111|NCT02792257|EXPERIMENTAL|Dronabinol|Study medication will be administered twice daily. Capsules of dronabinol will contain 2.5 mg per dose (5mg daily) during Week 1, then increase to 5 mg per dose (10mg daily) for Weeks 2 and 3.
62300112|NCT02792257|PLACEBO_COMPARATOR|Placebo|Placebo medication will be administered twice daily.
62300113|NCT03716726|EXPERIMENTAL|Intervention-WE CARE|"The WE CARE SDoH Screening Survey will be given at all visits by the front desk staff to all parents of Sickle Cell Anemia patients who present to the pediatric hematology clinic. They will also be provided the Family Resource Book.~Clinical team members (i.e. medical assistants and providers) will be trained to review the WE CARE Social Determinants of Health survey at visits and to provide community resource information sheets to parents with needs. The completed surveys will be scanned into the electronic health record (EHR)."
62300114|NCT03716726|EXPERIMENTAL|Control-Standard of Care|Standard of care for pediatric patients with sickle cell anemia will be delivered.
61915109|NCT06427343|ACTIVE_COMPARATOR|Low dose|"Participants randomized to this arm will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \<20% during follow-up.~Iron to be administered as ferric derisomaltose in analogy to high-dose arm."
62670992|NCT01901588|EXPERIMENTAL|Dexmedetomidine|dexmedetomidine/precedex
62670993|NCT01901588|PLACEBO_COMPARATOR|Placebo|patients receive saline solution.
62300115|NCT06656598|ACTIVE_COMPARATOR|Arm A (neoadjuvant chemotherapy only)|Patients will receive neoadjuvant chemotherapy alone with carboplatin AUC 5 D1 and paclitaxel 80mg/m² D1 D8 D15 (3 cycles of 4 weeks). Patients will subsequently receive curative hypofractionated radiotherapy (55 Gy/20fr). After radiotherapy, patients will receive maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks for a period of 12 months.
62470297|NCT00487565|OTHER|LCS Complete Posterior Stabilized knee implant|Total knee arthroplasty with a posterior stabilized implant
62470298|NCT02937870|EXPERIMENTAL|Test Product 1|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
62470299|NCT02937870|EXPERIMENTAL|Test Product 2|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
62470300|NCT02937870|ACTIVE_COMPARATOR|Reference Product|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
62470301|NCT02937870|OTHER|Negative Control|
62470302|NCT01677494||heart failure with preserved ejection fraction|- Inclusion Elevated BNP EF \> 50%
62670994|NCT05371197|EXPERIMENTAL|PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab)
62670995|NCT03863301|EXPERIMENTAL|MR-guided single dose preoperative PBI|
62670996|NCT00520715||Patients at hospital admission|Patients at hospital admission in medical wards on our tertiray care hospital (Hôpital Beaujon, Clichy, France).
61915110|NCT03375073|EXPERIMENTAL|Positive communication|Positive communication during medical transmission
61915111|NCT03375073|NO_INTERVENTION|Non-optimized communication|Medical transmission with non-optimized communication.
61915112|NCT03894176||PTX3 concentration|First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL
62109269|NCT05460663|EXPERIMENTAL|In-person SMART training|"The two-hour VTC or in-person will be provided SMART synchronously to a maximum of 10 individuals. A study team member will contact participants in the VTC group to provide available dates and times of scheduled classes, and these participants will be scheduled for a class they would like to attend. Participants in the VTC group will be provided a web-link prior to the session, and each session will have a unique password to access the training. Participants in the on-line training group will be provided a code to access the training website. If local conditions permit in-person group meetings (i.e. Health Protection Condition \[HPCON\] Alpha or Bravo), in-person group SMART training in a classroom will be offered as an alternative to VTC sessions. VTC and in-person sessions were provided using the same materials and methods, with the same instructors. Therefore, these are considered to be 'In-Person."
62300116|NCT06656598|EXPERIMENTAL|Arm B (neoadjuvant chemo-immunotherapy)|Patients will receive neoadjuvant chemotherapy alone with carboplatin AUC 5 D1 and paclitaxel 80mg/m² D1 D8 D15 and cemiplimab 350 mg D1-D21 (3 cycles of 4 weeks). Patients will subsequently receive curative hypofractionated radiotherapy (55 Gy/20fr). After radiotherapy, patients will receive maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks for a period of 12 months.
61915113|NCT01368718|OTHER|Active/Sham CPAP|
61915114|NCT01771185|ACTIVE_COMPARATOR|Best medical treatment|Metformin 2 g/day; gliclazide 30 mg
61915115|NCT01771185|ACTIVE_COMPARATOR|Duodenal jejunal bypass plus sleeve gastrectomy|Duodenal jejunal bypass plus sleeve gastrectomy is a metabolic surgical procedure
61915116|NCT05918198|EXPERIMENTAL|Ven+CAG|Venetoclax plus CAG regimen
61915117|NCT05774392||Disease Cohort|
61915118|NCT05774392||Engaged Cohort|
61915119|NCT00781352|ACTIVE_COMPARATOR|group 1|Colorectal surgery with 65% nitrous oxide administration
61915120|NCT00781352|ACTIVE_COMPARATOR|group 2|Colorectal surgery with nitrogen administration
61915121|NCT01930331|EXPERIMENTAL|ARCO treatment|Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
62109270|NCT05460663|EXPERIMENTAL|CBT SMART training|SMART will be provided via completion of a self-paced, on-line version completed over a period of four to eight weeks.
62109271|NCT01565161|EXPERIMENTAL|Home-Based Health Coaching|Intervention delivered in the home.
62109272|NCT01565161|ACTIVE_COMPARATOR|Control Arm|Mailed educational materials
62300117|NCT00650923|EXPERIMENTAL|Arm 1|See Detailed Description
62300118|NCT05036278|EXPERIMENTAL|Damoctocog alfa-pegol prophylaxis regimens|Prophylaxis regimens: All participants will begin with prophylaxis 2x/week (40 IU/kg/dose (recommended maximum dose 6,000 IU)) Participants with a high risk score (\> 4) continue on prophylaxis 2x/week (40 IU/kg/dose). Participants with a medium risk score (2 to 4) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose). Participants with a low risk score (\< 2) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose) and then after 4 weeks to a less frequent (e.g. Q7D) regimen (60 IU/kg/dose).
62300119|NCT01401569|ACTIVE_COMPARATOR|Control|All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
62470303|NCT04739384|EXPERIMENTAL|Standard dose of ticagrelor (90 mg twice daily).|Standard dose of ticagrelor (90 mg twice daily) followed by lower dose of ticagrelor (60 mg twice daily).
62470304|NCT04739384|EXPERIMENTAL|Low dose of ticagrelor (60 mg twice daily).|Low dose of ticagrelor (60 mg twice daily) followed by standard dose of ticagrelor (90 mg twice daily).
62470305|NCT02485522||Fecal incontinence|Women age \>18 years old with a diagnosis of fecal incontinence
62470306|NCT02485522||Controls|Women age \>18 without a diangosis of fecal incontinence
61915122|NCT01930331|ACTIVE_COMPARATOR|Eurartesim treatment|Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.
62109273|NCT00628940|EXPERIMENTAL|1|18F-fluoromethylcholine
62109274|NCT03423394|EXPERIMENTAL|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment.
62109275|NCT03423394|ACTIVE_COMPARATOR|Treatment as Usual|The treatment as usual (TAU) condition was selected to mirror the existing process in the military for identifying and encouraging treatment for personnel who screen positive for PTSD.
62109276|NCT00299702|ACTIVE_COMPARATOR|002|
62470307|NCT06243835|EXPERIMENTAL|Kindolor Cohort 1|"Kindolor Tosylate~1 tablet dose 100mg NPO for 8hrs x1 AM PO ex aq"
61915123|NCT04662827|EXPERIMENTAL|Palmithylethanolamid|Probands receive PEA 3xday for 28 days, 8 weeks wash out will follow, then they receive placebo for 28 days
61915124|NCT04662827|PLACEBO_COMPARATOR|placebo|Probands receive placebo 3xday for 28 days, 8 weeks washout will follow, then they receive PEA for 28 days
61915125|NCT03274375|EXPERIMENTAL|IA session|"* 4 Rituximab injections~* 10 IA sessions"
61915126|NCT00817128|EXPERIMENTAL|1|PEPT after randomization
61915127|NCT00817128|EXPERIMENTAL|2|CBO after randomization
61915128|NCT01889095|EXPERIMENTAL|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
62109277|NCT00299702|EXPERIMENTAL|001|
62109278|NCT02520570||general department|Patients using ulinastatin in department beyond ICU would be labelled as general department group.
61915129|NCT01889095|ACTIVE_COMPARATOR|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
62670997|NCT03494192|EXPERIMENTAL|scapula retraction exercise group|"* Manual Therapy~* Stretching Exercises~* Exercise training focus on scapulothoracic muscles will be applied two times per week total 12 week After 12 week follow-up, patients will proceed to reduced exercise program until the 6-month follow-up."
61915130|NCT03390101|EXPERIMENTAL|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
61915131|NCT03390101|EXPERIMENTAL|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
61919889|NCT03368573|EXPERIMENTAL|Experimental Arm|Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
62109279|NCT02520570||ICU|Patients using ulinastatin in ICU would be labelled as ICU group.
62109280|NCT02638415|EXPERIMENTAL|HVPG group|HVPG-guided therapy
62109281|NCT02638415|OTHER|non-HVPG group|routine therapy
62300120|NCT01401569|EXPERIMENTAL|physical activity program|Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.
62670998|NCT03494192|EXPERIMENTAL|Scapula Retraction +Glenohumeral Rotational Exercise Group|"* Manual Therapy~* Stretching Exercises~* Exercise training focus on scapulothoracic muscles~* Exercise training focus on rotator cuff muscles will be applied two times per week total 12 week After 12 week follow-up, patients will proceed to reduced exercise program until the 6-month follow-up."
62109282|NCT01177852|EXPERIMENTAL|Notuss® syrup|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
62300121|NCT04278131|EXPERIMENTAL|Cohort 1|BSO1 Cohort 1 dose
62300122|NCT04278131|EXPERIMENTAL|Cohort 2|BS01 Cohort 2 dose
62300123|NCT04278131|EXPERIMENTAL|Cohort 3|BS01 Cohort 3 dose
62670999|NCT03494192|NO_INTERVENTION|Control Group|Age-sex and hand-dominancy matched healthy controls will be included as a control group (CG) for acromiohumeral distance (AHD) normative data
62671000|NCT04978831|EXPERIMENTAL|Respiratory exercise device group|
62671001|NCT04978831|EXPERIMENTAL|Reading aloud group|
62109283|NCT01177852|ACTIVE_COMPARATOR|Dropropizine + Pseudoephedrine and brompheniramine|Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
62300124|NCT04278131|EXPERIMENTAL|Cohort 4|BS01 Cohort4 dose
62300125|NCT02757495|NO_INTERVENTION|Traditional|This will utilize the traditional method of performance of single dose caudal epidural block
62671002|NCT04978831|NO_INTERVENTION|Control group|
62109284|NCT03255018|EXPERIMENTAL|Participants with Gray-zone Lymphoma (GZL) or Extranodal Diffuse Large B-cell Lymphomas (DLBCL)|Participants with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
62109285|NCT00957229|PLACEBO_COMPARATOR|Sugar pill|placebo pill by mouth once daily
62109286|NCT00957229|EXPERIMENTAL|GDC-0449|vismodegib 150MG by mouth once daily
62109287|NCT01161719|EXPERIMENTAL|Videoconference|Parent training through videoconference
62109288|NCT01161719|ACTIVE_COMPARATOR|Control|Parent training through face to face conference
62109289|NCT05000450|EXPERIMENTAL|ALLO-605, ALLO-647|
62109290|NCT05522699|EXPERIMENTAL|Cough suppressive therapy|"The cough suppressive therapy consists of four one-to-one treatment sessions, 45 minutes per session, over a 2 months period. The sessions include patient education about chronic cough; negative effects of repeated cough as well as patient education of voluntary control of cough; identification of cough triggers and learning cough suppression techniques, and psychoeducational counselling including patient self-motivation, repetition of aims and techniques, behavior modification regarding over-awareness of the need to cough.~The sessions will be conducted by a specially trained physiotherapist or speech and language therapist. All components of the cough suppressive therapy will be delivered to each participant but the focus and emphasis on individual techniques will be individually tailored for each participant, determined by the physio- or speech and language therapist together with the participant."
62109291|NCT05522699|ACTIVE_COMPARATOR|Healthy lifestyle instructions|The Healthy lifestyle instructions consists of four one-to-one treatment sessions, 30 minutes per session, over a 2 months period. The sessions will be conducted by a specially trained physiotherapist or speech and language therapist. The sessions include patient education and motivational conversation about healthy eating habits, physical activity, stress and relaxation.
62109292|NCT04312776||Patients infected with CA-MRSA|It is an observational study, no interventions to any of the two study arms.
62109293|NCT04312776||Healthy people without any infection|It is an observational study, no interventions to any of the two study arms.
62109294|NCT04885595|ACTIVE_COMPARATOR|Forceps-Cryo 1.1 mm|Forceps biopsy following cryobiopsy with a 1.1mm cryoprobe are obtained within the same session
62109295|NCT04885595|ACTIVE_COMPARATOR|Forceps-Cryo 1.7 mm|Forceps biopsy following cryobiopsy with a 1.7mm cryoprobe are obtained within the same session
62109296|NCT02886897|EXPERIMENTAL|D-CIK and anti-PD-1 Immunotherapy|D-CIK was incubated with anti-PD-1 antibody before infused back into participants
62109297|NCT05658198||Unvaccinated patients|Patients who are unvaccinated against HPV when they arrive at Plan A.
62671003|NCT06101407||MG stage I|
62109298|NCT05481294|EXPERIMENTAL|Intervention with Transpersonal Supportive Coaching|PLWHA is given coaching using standard operating procedures (SOP) for Transpersonal Supportive Coaching to encourage or guide patients in obtaining support. The necessary tool is a representative room for two people with two chairs.
62109299|NCT05481294|ACTIVE_COMPARATOR|Intervention with Standard Support|PLWHA is given standard support provided by peer support foundations
62109300|NCT05481294|NO_INTERVENTION|No Support|PLWHA is not given any kind of support
62109301|NCT02877199||HCV triple therapy|Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy
62109302|NCT02380729||Index patients|"Children between birth and 18 years of age manifesting with a suspected genetic disorder.~Investigation: First Gene Panel Sequencing and if no mutation ist found \> Whole Genome Sequencing (WGS)"
62109303|NCT02380729||Parents of the index patient|"Both parents of the index patient.~Investigation: Whole Genome Sequencing (WGS) if no mutation is found by Gene Panel Sequencing of the index patient."
62109304|NCT03154944|EXPERIMENTAL|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
62109305|NCT03154944|EXPERIMENTAL|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
62109306|NCT03154944|EXPERIMENTAL|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
62109307|NCT03881358|ACTIVE_COMPARATOR|ortho-k lenses and thinner spectacles|participants using conventionally designed ortho-k lenses (target for 4.00D) and thinner spectacles during day time
62109308|NCT03881358|EXPERIMENTAL|newly designed ortho-k lenses|participants using newly designed ortho-k lenses for high myopia (target for full correction)
62671004|NCT06101407||MG stage IIA|
62671005|NCT06101407||MG stage IIB|
62671006|NCT04331379|EXPERIMENTAL|Nasal Elevator|
62671007|NCT04331379|ACTIVE_COMPARATOR|Taping Alone|
62671008|NCT04688944||patients|(1) age ≥ 45 years, (2) diagnosed LSS through a combination of clinical history, physical examination and radiological changes showing spinal canal stenosis on magnetic resonance imaging
62300126|NCT02757495|EXPERIMENTAL|Caudal dexmedetomidine|In this arm, single dose caudal epidural injection will be done patients in this arm will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%
61915132|NCT03390101|PLACEBO_COMPARATOR|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
61915133|NCT01341392|EXPERIMENTAL|CKD-501 0.5mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
61915134|NCT01341392|EXPERIMENTAL|CKD-501 Amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
62300127|NCT05124275|EXPERIMENTAL|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
62470308|NCT06243835|EXPERIMENTAL|Kindolor Cohort 2|"Kindolor Tosylate tablet~1 tablet dose 300mg NPO for 8hrs x1 AM PO ex aq"
61915135|NCT01341392|EXPERIMENTAL|Amlodipine 10mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
61915136|NCT06530186|EXPERIMENTAL|pH subset|This subset of patients (n=100) will be checking their vaginal pH at various time intervals (before, 2-6 hours after, and 10-14 hours after sex).
62671009|NCT04688944||healthy people|(1) age ≥ 45 years; (2) without chronic low back pain (LBP)
62300128|NCT05124275|EXPERIMENTAL|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
62300129|NCT05124275|EXPERIMENTAL|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
62671010|NCT05834153|EXPERIMENTAL|kinesiotaping|
62671011|NCT05834153|ACTIVE_COMPARATOR|electrical muscle stimulation|
62671012|NCT06530095||Group A|Patients who have been in prone positioning for 16-24 hours
62671013|NCT06530095||Group B|Patients who have been in prone positioning for 24-48 hours
61915137|NCT06530186|EXPERIMENTAL|Main Cohort|This subset of patients (n=900) will be providing user feedback on the study device, and will not be checking their vaginal pH
61915138|NCT01653132|EXPERIMENTAL|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
61915139|NCT01653132|PLACEBO_COMPARATOR|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
61915140|NCT00484185||1|
61915141|NCT01518738|EXPERIMENTAL|breath attention training|
61915142|NCT01518738|ACTIVE_COMPARATOR|working memory attention training|
61915143|NCT01518738|NO_INTERVENTION|no training|
61915144|NCT01363414|EXPERIMENTAL|Artificial tear|One drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
61915145|NCT01363414|PLACEBO_COMPARATOR|Control|one drop of sterile 0.9% sodium chloride solution in the other eye
62300130|NCT05124275|PLACEBO_COMPARATOR|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
62300131|NCT02188095||Excia T®|
62470309|NCT06243835|EXPERIMENTAL|Kindolor Cohort 3|"Kindolor Tosylate~3 tablets dose 300mg NPO for 8hrs x1 AM PO ex aq"
62671014|NCT03604627|OTHER|Patients treated for cancer during childhood or adolescence|Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg/m\^²)
62671015|NCT06121232|EXPERIMENTAL|Treatment Group|Group 1 will receive neuromodulation.
62671016|NCT06121232|EXPERIMENTAL|Control Group|Group 2 will not receive neuromodulation.
62671017|NCT00140114|OTHER|A|A: Vaginal misoprostol (cytotec)
61915146|NCT01447680||Blood samples, low risk population|
61915147|NCT01447680||Blood samples, high risk population|
61915148|NCT01447680||Blood samples, known HIV positive|
61915149|NCT04617873|EXPERIMENTAL|Deep bain stimulation and Spinal cord stimulation therapy|The patients in this group will receive bilateral STN-DBS and SCS stimulation
61915150|NCT00941434|EXPERIMENTAL|RUTF|Children with Severe malnutrition will be treated with Ready to use therapeutic food (RUTF) till their weight for age z scores are no longer in severe malnutrition group
62470310|NCT06243835|EXPERIMENTAL|Kindolor Cohort 4|"Kindolor Tosylate~6 tablets dose 300mg NPO for 8hrs x1 AM PO ex aq"
62470311|NCT06243835|PLACEBO_COMPARATOR|Placebo Comparator|Placebo to Match tablet(s) NPO for 8hrs x1 AM PO ex aq
62671018|NCT00140114|OTHER|B|Sublingual misoprostol (Cytotec)
61915151|NCT02539615|EXPERIMENTAL|ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection|Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
61915152|NCT01758445|EXPERIMENTAL|Proton Radiotherapy|Proton Radiotherapy
61915153|NCT03442868|EXPERIMENTAL|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
61915154|NCT02273739|EXPERIMENTAL|Enasidenib|During the dose escalation phase, consented eligible participants will be enrolled into sequential cohorts of increasing doses of enasidenib.The starting dose for this study is 100 mg administered every 24 hours,
61915155|NCT00817479|ACTIVE_COMPARATOR|Dexamethasone|20 mg of dexamethasone
61915156|NCT00817479|PLACEBO_COMPARATOR|Placebo [Saline]|Saline
61915157|NCT04739865|EXPERIMENTAL|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
61915158|NCT05106790|NO_INTERVENTION|Standard care arm|The first group will be on standard care as usually being practiced in hospitals.
62671019|NCT02024009|EXPERIMENTAL|Arm A|"12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX\* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir\*\* + 50.4 Grays (Gy) in 28# (arm A closed on 26Feb2020 due to lack of efficacy of nelfinavir)~\*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
61915159|NCT05106790|ACTIVE_COMPARATOR|Ed-counseling arm|The second group will receive monthly educational support ( booklets) with peer counseling sessions in addition to standard care.
61915160|NCT05106790|ACTIVE_COMPARATOR|mHealth|The third group will receive daily written and voice reminders, and once weekly an education-led video in addition to standard care.
61915161|NCT05106790|ACTIVE_COMPARATOR|Combined arm|The fourth group will receive educational support (booklets)and counseling sessions every month, daily written and voice reminders, and once weekly an education-led video in addition to standard care.
61915162|NCT00134784|EXPERIMENTAL|Assess [123I]B-CIT SPECT imaging|To assess\[123I\]B-CIT SPECT imaging in early Parkinson's disease subjects on placebo compared to early verses later Levodopa. Subjects on Levodopa 150mg/day, Levodopa 300 mg/day, and Levodopa 600 mg/day will be assessed.
61915163|NCT01773447|ACTIVE_COMPARATOR|Set-back suture|Wound to be close by set-back suture technique.
61915164|NCT01773447|ACTIVE_COMPARATOR|Vertical mattress suture technique|Wound to be closed by vertical mattress technique.
61915165|NCT04698850|ACTIVE_COMPARATOR|aflibercept|Patients with RAP who will be receiving aflibercept.
61915166|NCT04698850|EXPERIMENTAL|brolucizumab|Patients with RAP who will be receiving brolucizumab.
61915167|NCT05996991|EXPERIMENTAL|G1 - Positive Expectation Group + Spinal Manipulative Therapy|The participants of G1 will watch a short video (no more than 3 minutes) delivering a positive message regarding SMT. Secondly, a physiotherapist will administer one session of SMT and participants will be re-assessed to investigate the immediate effect of the videos on the pain intensity, global perceived effect of improvement, and expectations. Ultimately, patients will be submitted to a semi-structured interview in which their perceptions about the videos will be investigated.
61915168|NCT05996991|ACTIVE_COMPARATOR|G2 - Neutral Expectation Group + Spinal Manipulative Therapy|The participants of G1 will watch a short video (no more than 3 minutes) delivering a neutral message regarding SMT. Secondly, a physiotherapist will administer one session of SMT and participants will be re-assessed to investigate the immediate effect of the videos on the pain intensity, global perceived effect of improvement, and expectations. Ultimately, patients will be submitted to a semi-structured interview in which their perceptions about the videos will be investigated.
61915169|NCT05996991|ACTIVE_COMPARATOR|G2 - Negative Expectation Group + Spinal Manipulative Therapy|The participants of G1 will watch a short video (no more than 3 minutes) delivering a negative message regarding SMT. Secondly, a physiotherapist will administer one session of SMT and participants will be re-assessed to investigate the immediate effect of the videos on the pain intensity, global perceived effect of improvement, and expectations. Ultimately, patients will be submitted to a semi-structured interview in which their perceptions about the videos will be investigated.
61915170|NCT04307875||Rohingya refugee camp population|A sample of 1500 randomly selected individuals aged 18 years and above living in the Rohingya refugee camp 1E.
61915171|NCT04307875||Shamlapur refugee hosting community population|A sample of 1500 randomly selected individuals aged 18 years and above living in the refugee hosting community Shamlapur neighbouring the Rohingya refugee camps.
61915172|NCT04047927|EXPERIMENTAL|EpiFinder|Eligible subjects will be included to this group to receive an epidural injection of steroids to treat their chronic back pain. The investigational device will be used in conjugation to the standard practice of epidural injections, to assist the investigator to identify the epidural space.
61915173|NCT03513848|EXPERIMENTAL|Bright Light|
61915174|NCT03513848|PLACEBO_COMPARATOR|Dim Light|
62671020|NCT02024009|EXPERIMENTAL|Arm B|"12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX\* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#~\*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
62109309|NCT01467700|EXPERIMENTAL|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual (SL) \[dissolved under the tongue\], once daily (QD), every night at bedtime for up to 8 weeks.
62109310|NCT01467700|EXPERIMENTAL|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
62109311|NCT01467700|EXPERIMENTAL|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
62109312|NCT01467700|PLACEBO_COMPARATOR|Placebo|Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
62671021|NCT02024009|EXPERIMENTAL|Arm C|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX\* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir\*\* + 60Gy in 30# (arm C closed on 26Feb2020 due to lack of efficacy of nelfinavir)~\*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15"
62671022|NCT02024009|EXPERIMENTAL|Arm D|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX\* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#~\*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
62671023|NCT05338580|EXPERIMENTAL|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
62671024|NCT01676350|NO_INTERVENTION|Standard of care|If you are assigned to this group, ultrasound-guided IV will be used to obtain vascular access.
62671025|NCT01676350|EXPERIMENTAL|IO access using EZ-IO®|If you are assigned to this group, you will receive an IO line in the humeral head of the shoulder. IO lines are placed using an FDA-approved device called an EZ-IO®.
62671026|NCT02282384|EXPERIMENTAL|oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
61919890|NCT01603238|EXPERIMENTAL|[14C]-LC15-0444|A single oral dose of \[14C\]-LC15-0444 50 mg , containing 4.9 MBq \[14C\] (batch number 110372/C/01).
61919891|NCT01931670|PLACEBO_COMPARATOR|Placebo|Placebo twice daily (BID) for the 6-month Treatment Period
61919892|NCT01931670|EXPERIMENTAL|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
61919893|NCT01931670|EXPERIMENTAL|Elagolix 200 mg BID|Elagolix 200 mg BID for the 6-month Treatment Period
61919894|NCT00453960|EXPERIMENTAL|Genistein|Genistein 54 mg/day
61919895|NCT00453960|ACTIVE_COMPARATOR|Norethisterone Acetate|Norethisterone Acetate 10mg/day
61919896|NCT00453960|PLACEBO_COMPARATOR|Placebo|Placebo tablets, daily
61919897|NCT01456273|PLACEBO_COMPARATOR|A2- Medical consultation + placebo|Traditional medical interview + placebo
61919898|NCT01456273|ACTIVE_COMPARATOR|B1 - Therapeutic Encounter / Omeprazol|
61919899|NCT01456273|PLACEBO_COMPARATOR|B2 - Therapeutic Encounter / Placebo|
61919900|NCT01456273|ACTIVE_COMPARATOR|A1- Medical consultation + omeprazole|Traditional medical interview + omeprazole
61919901|NCT05779436||Patients undergoing cholangioscopy for evaluation biliary stricture|
61919902|NCT02355977|ACTIVE_COMPARATOR|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
61919903|NCT02355977|ACTIVE_COMPARATOR|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
61919904|NCT02355977|EXPERIMENTAL|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
61919905|NCT03682575||Infants WITH diagnosis of bronchopulmonary dysplasia (BPD)|Preterm infants who were on oxygen at 28 days of life.
61919906|NCT03682575||Infants WITHOUT diagnosis of bronchopulmonary dysplasia (BPD|Preterm infants who were not on oxygen at 28 days of life.
61919907|NCT05684432||Prostate and rectal cancer patients|Curative EBRT
61919908|NCT00946400||Suspected HIT|Those who are clinically suspected of having HIT will be enrolled in this study.
61919909|NCT00583479|OTHER|A|subjects who get one medication injection into the celiac ganglion during the EUS
61919910|NCT00583479|OTHER|B|subjects who get divided dose of the medication injected into two locations within the celiac ganglion during the EUS
61919911|NCT02182648|EXPERIMENTAL|etomidate group|infusion of etomidate at 2 minutes before anesthesia induction
61919912|NCT02182648|ACTIVE_COMPARATOR|propofol group|infusion of propofol at 2 minutes before anesthesia induction
61919913|NCT02182648|ACTIVE_COMPARATOR|sevoflurane group|inhale sevoflurane for anesthesia induction and maintenance
61919914|NCT01422967|ACTIVE_COMPARATOR|Osteoarthritis group|
61919915|NCT01422967|ACTIVE_COMPARATOR|without osteoarthritis|
61919916|NCT05843773|EXPERIMENTAL|Low Load Strength Training under Blood Flow Restriction|Low Load Strength Training under blood flow restriction
61919917|NCT02160483|EXPERIMENTAL|Magnetic resonance imaging|Functional magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance spectroscopy to evaluate women with chronic pelvic pain and/ or endometriosis
61919918|NCT05478954|EXPERIMENTAL|Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)|Children aged 3-59 months will receive SPAQ during the study period.
61919919|NCT03348787|EXPERIMENTAL|Behavioral and Cognitive Therapies|Chronic psychotic patients will have Behavioral and Cognitive Therapies
61919920|NCT06387433|EXPERIMENTAL|mobile app users|
62300132|NCT06169215|EXPERIMENTAL|Arm I (Dara-SVD)|Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, \& 22 for cycles 1-2, then days 1 \& 15 for cycles 3-4, and selinexor PO, bortezomib SC, and dexamethasone PO on days 1, 8, 15, \& 22 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET, MRI, or CT, and bone marrow aspiration and biopsy, and collection of blood and urine samples throughout the study.
62300133|NCT06169215|ACTIVE_COMPARATOR|Arm II (Dara-RVD)|Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, \& 22 for cycles 1-2, then days 1 \& 15 for cycles 3-4, lenalidomide PO QD on days 1-21 of each cycle, and bortezomib SC and dexamethasone PO on days 1, 8, 15, \& 22 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET, MRI, or CT, and bone marrow aspiration and biopsy, and collection of blood and urine samples throughout the study.
62300134|NCT03468608||Phase 1: Instrument Development|An initial set of questionnaire items will be created based on the questionnaires noted in the literature review as well as the semi-structured interviews conducted with parents and healthcare team members in our facility.
62300135|NCT03468608||Phase 2: Pre-Test Evaluation|Parents and healthcare team members will be asked to comment on the quality of the draft questionnaire created in phase 1 of this study.
62300136|NCT03468608||Phase 3: Pilot|"Parents will be asked to complete the questionnaire developed during phase 2 of this study. Upon completing the questionnaire, parents will be asked to rate the overall face validity of the tool using a 5-point Likert scale.~Healthcare team members will be asked to rate the content validity of each item on the questionnaire."
62300137|NCT03468608||Phase 4: Validation|Parents will be asked to complete the questionnaire developed during phase 3 of this study.
62300138|NCT02665689|ACTIVE_COMPARATOR|Regular Glycemic Control|Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
62671027|NCT02282384|PLACEBO_COMPARATOR|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
61915175|NCT02555501|EXPERIMENTAL|PDT + Low level laser|"PDT (photosensitizer and low level laser) and low level laser~Photosensitizer: aqueous solution of 0.005% methylene blue; Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)"
61915176|NCT02555501|ACTIVE_COMPARATOR|Low level laser|Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)
61915177|NCT03835728|ACTIVE_COMPARATOR|Treatment Arm|Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
61915178|NCT03835728|PLACEBO_COMPARATOR|Treatment Placebo Arm|Saline will be used as the matching placebo
61915179|NCT01367080|EXPERIMENTAL|A Group|"1. 1st administration - DWETR10~2. 2nd administration - DWETR25"
61915180|NCT01367080|EXPERIMENTAL|B Group|"1. 1st administration - DWETR25~2. 2nd administration - DWETR10"
61915181|NCT06309888||spinal cord injury|Individuals living with a spinal cord injury
61915182|NCT06309888||non spinal cord injury|able-bodied individuals
61919921|NCT06387433|NO_INTERVENTION|mobile app non-users|
61919922|NCT01465191|EXPERIMENTAL|50 micrograms (mcg) spinal morphine|Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section
62109313|NCT01489176|EXPERIMENTAL|Regadenoson; Optison|Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography.
62671028|NCT06132750||SELENON-related myopathy or LAMA2-related muscular dystrophy|"Participants diagnosed with congenital myopathy/muscular dystrophy due to mutations in the SEPN1 (SELENON) or LAMA2 gene~Interventions: No intervention"
62671029|NCT02968394|EXPERIMENTAL|NEVIT|Co treatment with omalizumab during another attempt of immunotherapy introduction
62671030|NCT03363438||martinique|
62671031|NCT03363438||guadeloupe|
62671032|NCT02659228|PLACEBO_COMPARATOR|Control 1 (negative control)|Individuals with a diagnosis of UWS without neural markers of consciousness
62300139|NCT02665689|EXPERIMENTAL|Intensified Glycemic Control|"Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level \< 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake."
62671033|NCT02659228|ACTIVE_COMPARATOR|Control 2 (positive control)|Individuals with a diagnosis of MCS, who are behaviourally responsive and who present neural markers of consciousness
62671034|NCT02659228|EXPERIMENTAL|Target Population|Individuals with a clinical diagnosis of UWS, but who possess some neurophysiological signatures of conscious awareness
62671035|NCT01034527|EXPERIMENTAL|Neuromuscular Training|Combination of exercises and phases designed to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
62671036|NCT01034527|NO_INTERVENTION|Speed Training|Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
62671037|NCT01307618|EXPERIMENTAL|Arm I (vaccine therapy)|Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
61919923|NCT01465191|EXPERIMENTAL|100 micrograms spinal morphine|Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section
61919924|NCT01465191|EXPERIMENTAL|150 micrograms spinal morphine|Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section
62671038|NCT01307618|EXPERIMENTAL|Arm II (vaccine therapy, IL-12)|Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
62671039|NCT00662701|ACTIVE_COMPARATOR|1|Catheter RF ablation with complete circumferential ablation around the right and PVs, and additional lines between the lower and upper PVs, and towards the mitral valve ring.
61919925|NCT05072470|EXPERIMENTAL|Experimental|Participants with bilateral moderate to severe sensorineural hearing loss
62671040|NCT00662701|ACTIVE_COMPARATOR|2|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
62300140|NCT05425771|EXPERIMENTAL|Mucosa Ablation Arm|Treatment group
61919926|NCT02943902|EXPERIMENTAL|Group 1a (1+1, 6 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
61919927|NCT02943902|EXPERIMENTAL|Group 1b (1+1, 6 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
61919928|NCT02943902|EXPERIMENTAL|Group 2a (1+1, 14 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
62300141|NCT00783627||1|Patient with sickle cell disease
62300142|NCT00783627||2|Healthy volunteers
62470312|NCT06339515|OTHER|The research is a mixed method including quantitative and qualitative.|"Quantitative part of the research;Experimental:~The curriculum, which will be prepared with the principles of the universal design model, will be implemented for 10 weeks, 3 lesson hours a weeks.~The data of pre-invention study will be collected. Descriptive Characteristics Form, Critical Thinking Disposition Scale,Communication Skills Scale, Healthy Living Awareness Scale.~Post-intervention data will be collected with Critical Thinking Disposition Scale,Communication Skills Scale, Healthy Living Awareness Scale.~Qualitative part of the research:~Experiences of Nursing Students: Student opinions will be taken weekly (Learning Diary) to determine the experiences of the students during the implementation process and at the end of the implementation.~Reflective Diary: At the end of each session, the teacher will make a self-evaluation of the session."
62300143|NCT04636918|OTHER|Single arm|Ikervis (cyclosporine 0.1%), emulsion, one drop into both eyes, once at night.
62470313|NCT03235388|EXPERIMENTAL|Intervention|Audit filter implementation in hospital
62300144|NCT03214835|EXPERIMENTAL|Brush biopsy for laryngeal lesion|Brush biopsy of the larynx - in addition to the standard biopsy
62300145|NCT03214835|EXPERIMENTAL|Brush biopsy for LPR|Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
62300146|NCT02495779|EXPERIMENTAL|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
62470314|NCT03235388|NO_INTERVENTION|Control|Routine care
62470315|NCT01667627|ACTIVE_COMPARATOR|BIO-25, Probiotic-mixture|Two capsules a day.
62109314|NCT05449002|EXPERIMENTAL|Practicing the Opposite (PTO) intervention|This 30-45 minutes Qualtrics-based, digital program uses stories, interactive activities, and engaging graphics to teach youths one core principle: by practicing the positive opposite of unhelpful behaviors (e.g., engaging with rather than avoiding feared stimuli), one can, over time, change their mood, thoughts, and actions. The intervention is comprised of four main sections: 1) An introduction to PTO; (2) Testimonials from young people who have been helped by PTO; (3) Learning how to Practice the Opposite through online activities. (4) Planning how to continue to Practice the Opposite in the participant's life. Of note, after being removed from the waitlist at the clinic and contacted to begin treatment, participants will still receive treatment as usual from the clinic.
61919929|NCT02943902|EXPERIMENTAL|Group 2b (1+1, 14 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
62109315|NCT05449002|OTHER|Usual waitlist control group|Usual waitlist procedures involve watchful waiting for a therapist to become available, sometimes complemented by periodic check-ins from the family with clinic administrators. After being removed from the waitlist and contacted to begin treatment, participants in both study conditions will receive treatment as usual in the clinic.
62109316|NCT02503202|EXPERIMENTAL|V920 Consistency Lot A|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
62300147|NCT05811312||Cohort 1-individuals who are na�ve to SCS|Individuals with chronic neuropathic pain who are na�ve to SCS and were selected for SCS trial period as part of their clinical care will participate in two study visits: before the beginning of the SCS trial and the end of the trial period. Data collection will be consistent across all data collection timepoints (T1 - T3) and include rs-fNIRS/EEG and clinical pain measures.
61919930|NCT02943902|ACTIVE_COMPARATOR|Group 3a (2+1)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
62470316|NCT01667627|PLACEBO_COMPARATOR|Placebo|Identical to the Bio-25 capsule: same taste, same colour, same appearance
62470317|NCT01275469|EXPERIMENTAL|GFT505 80mg|
62470318|NCT01275469|PLACEBO_COMPARATOR|Matching placebo|
62470319|NCT05048004||QMODE intervention|catheter ablation performed using high-power with a maximum of up to 50 W (QMODE) and
62470320|NCT05048004||QMODE+ intervention|catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +)
62109317|NCT02503202|EXPERIMENTAL|V920 Consistency Lot B|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
62109318|NCT02503202|EXPERIMENTAL|V920 Consistency Lot C|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
62109319|NCT02503202|EXPERIMENTAL|V920 High-dose Lot|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
62109320|NCT02503202|PLACEBO_COMPARATOR|Placebo to V920|Participants received a 1.0 mL intramuscular injection of placebo on Day 1
62300148|NCT05811312||Cohort 2-individuals with effective implanted SCS 6 months|Cohort 2: Participants with effective implanted SCS 6 months will participate in three study visits conducted 24-48 hours apart. Data will be collected during SCS use and following an SCS washout period. Data collection will be consistent across all data collection timepoints(T1-T4) and include rs-fNIRS/EEG and clinical pain measures. Both cohorts will receive paresthesia based SCS.
62671041|NCT06141681||Healthy volunteers|\>18 years old healthy
62109321|NCT05911256|ACTIVE_COMPARATOR|Pharmacist Only|Participants will receive clinical pharmacist management of diabetes. Those participants who meet their HbA1c goal at 6 months will continue with maintenance diabetes management. This includes routine primary care with the primary care provider, routine medication management, and traditional home glucose monitoring. For those not meeting goals in HbA1c they will be randomized again to receive Pharmacist + CGM or receive Pharmacist + CGM + Community Health Worker (CHW) support.
62300149|NCT02993237|EXPERIMENTAL|Group 1: DRV/COBI Placebo followed by D/C/F/TAF Placebo|Participants will receive fixed dose combination (FDC) of darunavir/cobicistat (DRV/COBI) matching placebo tablets (Intake 1) and FDC of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
62109322|NCT05911256|EXPERIMENTAL|Pharmacist + CGM|Participants receive clinical pharmacist + CGM support. Those participants who meet their HbA1c goal at 6-months will continue with maintenance diabetes management. This includes routine primary care with the primary care provider, routine medication management, and traditional home glucose monitoring. For those not meeting goals in HbA1c, they will be randomized again to continue with pharmacist + CGM or receive additional CHW support (Pharmacist + CGM + CHW).
62109323|NCT05911256|EXPERIMENTAL|Pharmacist + CGM + CHW|A second randomization step occurs at 6-months. Participants randomized to this condition receive clinical pharmacist, CHW, and CGM support.
62109324|NCT04288492|EXPERIMENTAL|biofeedback|Respiratory exercise using biofeedback device(ResCalm) 2-3 times / day for 3 minutes until discharge from hospital, once in recovery room before surgery
62109325|NCT04288492|NO_INTERVENTION|general|General surgical schedule without control exercise
62109326|NCT05722652|EXPERIMENTAL|Intervention Condition|
62470321|NCT01181622|EXPERIMENTAL|denufosol tetrasodium Inhalation Solution|
62470322|NCT01181622|PLACEBO_COMPARATOR|Placebo|
62671042|NCT06141681||Patients in critical care unit|patient in ICU with requirement for hemodynamic monitoring
62109327|NCT05722652|ACTIVE_COMPARATOR|Waitlist Condition|Clinics in this condition will receive the intervention approximately 12 months after the intervention condition.
62109328|NCT00608348|EXPERIMENTAL|1|Hyperinsulinemic euglycemic or hypoglycemic clamp with Muscle and skin sympathetic nerve activity recording in arm and/or leg
62671043|NCT06141681||Patients with ventilatory support in the operating room or critical care unit|patient in the ICU or operating room with a requirement for hemodynamic monitoring and ventilatory support
62671044|NCT05711407||Peri-implantitis|Group Case
62671045|NCT05711407||Healthy|Group Control
62671046|NCT04675281||Critically-ill adult patients who died in the Intensive Care Unit from a documented COVID-19|
62109329|NCT00608348|EXPERIMENTAL|2|Exercise with insulin or no insulin infused with muscle and skin sympathetic nerve activity measurements
62109330|NCT04401917|OTHER|HIV positive (HIV+) subjects with Opioid Use Disorder (OUD)|HIV positive (HIV+) subjects with Opioid Use Disorder (OUD): HIV+/OUD+
62109331|NCT04401917|OTHER|HIV negative (HIV-) subjects with OUD|HIV negative (HIV-) subjects with OUD: HIV-/OUD+
62671047|NCT06550453|EXPERIMENTAL|pembrolizumab + bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)|"all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity."
62109332|NCT04401917|OTHER|HIV Positive (HIV+) subjects with OUD negative|HIV+ subjects who may have been opioid-exposed but do not have current or past OUD
62300150|NCT02993237|EXPERIMENTAL|Group 2: D/C/F/TAF Placebo followed by DRV/COBI Placebo|Participants will receive FDC of D/C/F/TAF matching placebo tablets (Intake 1) and FDC of DRV/COBI matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
62671048|NCT01482286|EXPERIMENTAL|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
62671049|NCT01482286|EXPERIMENTAL|Dietary Restriction|Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
62109333|NCT04401917|OTHER|Healthy volunteer|HIV-, OUD- healthy controls who have been opioid-exposed but do not have current or past OUD
62109334|NCT03667547|EXPERIMENTAL|Raltegravir|Participants will receive a single oral dose of raltegravir 1200 mg (600 mg tablet X 2) in a fasted state on Day 0 and will be followed up to 2 weeks
62109335|NCT03087539|EXPERIMENTAL|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
62109336|NCT03087539|PLACEBO_COMPARATOR|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
62470323|NCT05665062|EXPERIMENTAL|SYNCAR-001 + STK-009 Cohort A|"Dose escalation: A single fixed dose of autologous SYNCAR-001 CAR-T intravenously (IV) will be administered in combination with repeated sequential ascending doses of STK-009 subcutaneously (SC)~Dose expansion: A single fixed dose of autologous SYNCAR-001 CAR-T IV will be administered in combination with repeated doses of STK-009 SC at the RP2D"
62671050|NCT01482286|EXPERIMENTAL|Exercise|Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
62671051|NCT01482286|NO_INTERVENTION|Control|Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.
62671052|NCT05366647|ACTIVE_COMPARATOR|Canaloplasty|Canaloplasty ab externo
62671053|NCT05366647|ACTIVE_COMPARATOR|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
62109337|NCT06532760|EXPERIMENTAL|Patients with Spinal cord injury|
62109338|NCT06532760|ACTIVE_COMPARATOR|Patients with Brain Injury|
62109339|NCT06532760|ACTIVE_COMPARATOR|Healthy volunteers|
61919931|NCT02943902|ACTIVE_COMPARATOR|Group 3b (2+1)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
62109340|NCT01549314||Subjects with CF taking ivacaftor|Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months
62109341|NCT01549314||Subjects with CF not taking ivacaftor|Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1
62109342|NCT01549314||Healthy subjects|Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.
62109343|NCT00590603|EXPERIMENTAL|1|Dose escalation study with two cohorts. A standard dose of Arsenic Trioxide will be given with escalating dose of Bortezomib.
62109344|NCT03333655|OTHER|Checkpoint Inhibitor Therapy|Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.
62109345|NCT01276990|PLACEBO_COMPARATOR|Placebo|Matching placebo in dosing regimen 1-8
62300151|NCT04641286||Stroke|Individuals admitted to the Hyper Acute Stroke Unit.
62671054|NCT00582829||1|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
62109346|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 1|Dosing regimen 1
62109347|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 2|Dosing regimen 2
62109348|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 3|Dosing regimen 3
62109349|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 4|Dosing regimen 4
62109350|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 5|Dosing regimen 5
62109351|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 6|Dosing regimen 6
62109352|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 7|Dosing regimen 7
62109353|NCT01276990|EXPERIMENTAL|BI 224436 dosing regimen 8|Dosing regimen 8
62109354|NCT04376814|EXPERIMENTAL|Test Group|In this group, Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days, plus 200mg of Hydroxychloroquine two times per day will be given to patients for 7 days.
62109355|NCT04376814|ACTIVE_COMPARATOR|Control Group|In this group, Patients will be given a stat dose of 400mg Hydroxychloroquine tablets plus 200/50 mg of Lopinavir/Ritonavirtwo times per day for seven days.
62671055|NCT00582829||2|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
62109356|NCT00496379|EXPERIMENTAL|ZK219477|
62300152|NCT04180605|ACTIVE_COMPARATOR|Standard of care treatment arm|"When patients are randomized to the standard treatment arm, patients will be treated according to the participating site's routine practice. As pre-procedural imaging, a cardiac CT-scan has to be performed; this can also be complemented with TEE at the discretion of the operator. The LAA closure procedure should be performed according to routine practice of the participating site - either in general or local anesthesia.~For those cases randomized to the standard treatment arm, the pre-procedural CT-scans will still be collected at completion of the study and FEops HEARTguideTM simulations will be generated, blinded for the procedural images and outcome. These simulations will be compared with the final device size and implant position and will be used for an additional comparative PREDICT-LAA sub-study."
62671056|NCT00582829||3|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
62671057|NCT02545127|EXPERIMENTAL|Merotocin (a selective oxytocin-receptor agonist)|
62671058|NCT02545127|PLACEBO_COMPARATOR|Placebo|
62671059|NCT01119222|ACTIVE_COMPARATOR|Gabapentin 1200mg|
62671060|NCT01119222|ACTIVE_COMPARATOR|Diphenhydramine 50 mg|
62671061|NCT01119222|ACTIVE_COMPARATOR|Morphine 10 mg|
62671062|NCT01119222|PLACEBO_COMPARATOR|Placebo formulations|
62671063|NCT02368509|EXPERIMENTAL|Bronchial cancer|Patients with bronchial cancer will perform sensory tests before and after a 6-week period of chemotherapy.
62671064|NCT02368509|PLACEBO_COMPARATOR|Control group|Healthy individuals will perform sensory tests before and after a 6-week period without chemotherapy.
62671065|NCT00656812|EXPERIMENTAL|Treatment Arm|Combination therapy Rituximab plus 2CdA
62671066|NCT06166823|EXPERIMENTAL|EMR Alert|
62671067|NCT06166823|NO_INTERVENTION|Usual Care|
62671068|NCT01837888|NO_INTERVENTION|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
62671069|NCT01837888|EXPERIMENTAL|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
62671070|NCT04621786|EXPERIMENTAL|Experimental arm|All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
62671071|NCT00874809|OTHER|Insulin Treatment|There is only one arm for this study using lispro insulin administered by insulin pump.
62671072|NCT01891838|ACTIVE_COMPARATOR|Volume controlled ventilation|Volume controlled ventilation: tidal volume of 7 mL/kg ideal body weight, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Ventilatory frequency is changed if necessary to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg.
62671073|NCT01891838|EXPERIMENTAL|Pressure-controlled ventilation|initial pressure of 15 cm H2O, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Pressure is modified to maintain a tidal volume of 7 mL/kg of ideal body weight and frequency ventilation is modified to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg
62671074|NCT06197516|EXPERIMENTAL|Integrated Neuromuscular Inhibition Technique|Individuals in Group A, After palpating the trigger point ischemic compression were applied for 20-60 sec while strain counterstain for 60-90 sec and MET is for 7-10 sec. This technique was repeat 3-4 time per session Conventional treatment include Hot Pack for 5mins, AROM exercises ,Home plans include stretching exercise of glutes,hamstring and calf (5-7 reps x 10 sec hold, each).
62671075|NCT06197516|ACTIVE_COMPARATOR|Neuromuscular Reeducation Technique|Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required (depend upon thickness of scar) per session, 10 sec rest b/w pressure. This technique given 5 time per session. Conventional treatment include Hot Pack for 5mins, AROM exercises ,Home plans include stretching exercise of glutes,hamstring and calf (5-7 reps x 10 sec hold, each).
62109357|NCT01119950|EXPERIMENTAL|NVA237 12.5 µg q.d.|NVA237 12.5 µg once daily
62671076|NCT06199999|NO_INTERVENTION|Group GA: General anesthesia only|This group receives general anesthesia only and surgical procedure will follow standard conditions.
62671077|NCT06199999|ACTIVE_COMPARATOR|Group ESP: Erector Spinae Block|This group receives general anesthesia with regional pain block (Erector Spinae Block) prior to incision.
62671078|NCT06199999|ACTIVE_COMPARATOR|Group LIA: Local Infiltration|This group receives general anesthesia and surgical procedure will take place as planned. Prior to being awakened, the area of procedure will be infiltrated.
62671079|NCT06151938||Standardised allergen extract from house dust mites (ACARIZAX®)|Observational study to collect real-world data: patients will be treated with ACARIZAX house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet for one tablet per day.
62671080|NCT01494974|ACTIVE_COMPARATOR|FP7 implant|
62671081|NCT01494974|ACTIVE_COMPARATOR|FP8 implant|
62671082|NCT01993368|OTHER|chronic periodontitis|biopsy of periodontal granulation tissue (surgical waste)
62109358|NCT01119950|EXPERIMENTAL|NVA237 25.0 µg q.d.|NVA237 25.0 µg once daily
62109359|NCT01119950|EXPERIMENTAL|NVA237 12.5 µg b.i.d.|NVA237 12.5 µg twice daily
62109360|NCT01119950|EXPERIMENTAL|NVA237 50.0 µg q.d.|NVA237 50.0 µg once daily
62671083|NCT01993368|OTHER|aggressive periodontitis (AP)|biopsy of periodontal granulation tissue (surgical waste)
61915183|NCT04656483|EXPERIMENTAL|Telemedicine Video Feedback Arm|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
61915184|NCT04656483|ACTIVE_COMPARATOR|Psychoeducational booklet arm|Mothers assigned to condition B will receive an informative booklet addressing the same themes discussed in the experimental intervention (i.e., responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant or specific parenting challenges.
61915185|NCT01687556|ACTIVE_COMPARATOR|Topical EGCG 1%|Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
61915186|NCT01687556|EXPERIMENTAL|topical EGCG 5%|Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
61915187|NCT01167985|EXPERIMENTAL|Root canal sealer group+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
62109361|NCT01119950|EXPERIMENTAL|NVA237 25.0 µg b.i.d.|NVA237 25.0 µg twice daily
62109362|NCT01119950|EXPERIMENTAL|NVA237 100.0 µg q.d.|NVA237 100.0 µg once daily
62109363|NCT01119950|EXPERIMENTAL|NVA237 50.0 µg b.i.d.|NVA237 50.0 µg twice daily
62470324|NCT05665062|EXPERIMENTAL|SYNCAR-001 + STK-009 Cohort B|"Dose escalation: A single fixed dose of autologous SYNCAR-001 CAR-T intravenously (IV) will be administered in combination with repeated sequential ascending doses of STK-009 subcutaneously (SC)~Dose expansion: A single fixed dose of autologous SYNCAR-001 CAR-T IV will be administered in combination with repeated doses of STK-009 SC at the RP2D"
62470325|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
62671084|NCT01993368|OTHER|controls|necessitating an extraction of wisdom teeth
62109364|NCT01119950|PLACEBO_COMPARATOR|Placebo|Placebo to NVA237 once daily
62109365|NCT03456817|EXPERIMENTAL|Treatment Arm - High dose ATG, Low dose CSA|High dose ATG will be infused on days -4, -3, -2, -1 and 0. Before each infusion of ATG (thymoglobulin), patient will receive medications preventing side effects from the ATG, including diphenhydramine (Benadryl), an antipyretic (ibuprofen or acetaminophen) and methylprednisolone (Solumedrol). The high dose ATG will be given into patient's vein via central venous catheter. Each infusion of ATG will take 4-8 hours. CSA (cyclosporine A) will be given from day 21. Standard dose methotrexate will be given.
62109366|NCT03456817|OTHER|Control Arm - Standard of care|Low dose ATG (thymoglobulin) will be infused on days -2, -1 and 0, and CSA (cyclosporine A) will be given from day -1 through day 84. Standard dose methotrexate will also be given.
62300153|NCT04180605|EXPERIMENTAL|Computational simulation arm|When patients are randomized to the computational simulation arm, the procedure will still be performed according to the participating site's routine practice - however, the procedure will only be performed after careful review of the FEops HEARTguideTM simulation results. The only prerequisite is that all patients randomized to this arm will have to undergo a pre-procedural cardiac CT-scan that will be uploaded into the FEops HEARTguideTM platform. Following this upload, a pre-procedural simulation plan will be provided to the operator, containing a set of optimal and suboptimal closure device sizes and implant positions. Software and technology upgrades of the FEops HEARTguideTM platform will be allowed during the course of the study.
62300154|NCT01033994|EXPERIMENTAL|AS902330|
62300155|NCT01033994|PLACEBO_COMPARATOR|Placebo|
62470326|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
62671085|NCT03483090|EXPERIMENTAL|Treatment A|4000mg Swisse High Strength Deep Sea Krill Oil (Superba BOOST) (4 capsules containing 1000mg each)
62671086|NCT03483090|PLACEBO_COMPARATOR|Treatment B|4 capsules of matching Placebo orally daily (1000mg each of mixed vegetable Oil)
62671087|NCT04692688|EXPERIMENTAL|APX3330|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
62109367|NCT02904707||Questionary EQ-5D|"The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.~Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient."
62109368|NCT02664337|EXPERIMENTAL|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
62300156|NCT02043574|OTHER|Stretching (Control)|Six months of stretching
62300157|NCT02043574|EXPERIMENTAL|Treadmill Exercise|Six months of treadmill training
62300158|NCT02910440|EXPERIMENTAL|DCL-101|
62300159|NCT02910440|ACTIVE_COMPARATOR|GoLytely|
62671088|NCT04692688|PLACEBO_COMPARATOR|Placebo|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
62300160|NCT05386914|EXPERIMENTAL|Carrier APOE4|
62300161|NCT05386914|OTHER|Non-Carrier APOE4|
62300162|NCT03624569|SHAM_COMPARATOR|Bagel diet|Bagel consumed daily for 2 weeks
62300163|NCT03624569|EXPERIMENTAL|Potato diet|Potato consumed daily for 2 weeks
62671089|NCT03022630|OTHER|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
62671090|NCT03022630|OTHER|Usual hepatic care|Usual hepatic care
61915188|NCT01167985|EXPERIMENTAL|Provisional restoration material+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
62109369|NCT02664337|ACTIVE_COMPARATOR|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
62109370|NCT02428088|EXPERIMENTAL|Dasotraline 2 mg|Dasotraline 2 mg
62671091|NCT06391515||Covid +|At baseline, a blood sample was collected and centrifuged for serological analysis. Then, sera were stored at -20°C until the end of the enrolment phase when all samples were centralized at the coordinating center for SARS-CoV-2 IgG measurements. IgG against the spike protein (anti-S IgG) and against nucleocapside (anti-N IgG) were tested. Anti-N IgG increase only after natural infection since the nucleocapsid protein is not contained in the vaccines, while anti-S IgG increase is induced either by vaccination or infection 21. Thus, we subdivided patients according to their serological status: i) group Covid+ included those patients who had both positive anti-S and anti-N IgG demonstrating a contact with SARS-CoV-2 before the diagnosis of SAT; ii) group Covid- consisted of patients with only anti-S IgG positivity (due to vaccine) or negative anti-N/anti-S IgG.
62671092|NCT06391515||Covid -|At baseline, a blood sample was collected and centrifuged for serological analysis. Then, sera were stored at -20°C until the end of the enrolment phase when all samples were centralized at the coordinating center for SARS-CoV-2 IgG measurements. IgG against the spike protein (anti-S IgG) and against nucleocapside (anti-N IgG) were tested. Anti-N IgG increase only after natural infection since the nucleocapsid protein is not contained in the vaccines, while anti-S IgG increase is induced either by vaccination or infection 21. Thus, we subdivided patients according to their serological status: i) group Covid+ included those patients who had both positive anti-S and anti-N IgG demonstrating a contact with SARS-CoV-2 before the diagnosis of SAT; ii) group Covid- consisted of patients with only anti-S IgG positivity (due to vaccine) or negative anti-N/anti-S IgG.
62671093|NCT05233059|ACTIVE_COMPARATOR|Walking|The walking group will receive a tailored FitEx for endometrial cancer survivors, including cancer specific newsletters.
62671094|NCT05233059|EXPERIMENTAL|Walking Plus Yoga|The walking group will receive a tailored FitEx for endometrial cancer survivors with yoga cuing and yoga-based newsletters.
62671095|NCT05082155|EXPERIMENTAL|Right sided catheter bupivacaine 0.25% and left sided catheter normal saline|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Bupivacaine 0.25 will be administered through the right-sided catheter while normal saline will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
62671096|NCT05082155|EXPERIMENTAL|Right sided catheter normal saline and left sided catheter bupivacaine 0.25%|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Normal saline will be administered through the right-sided catheter while bupivacaine 0.25% will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
62671097|NCT05328895|EXPERIMENTAL|taVNS group|taVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the cymba conchae and concha around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
62671098|NCT05328895|PLACEBO_COMPARATOR|Control Group|tnVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the antihelix around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
62671099|NCT04784403||Students and workers at the University of Barcelona|"The study population will be randomly selected from the different groups of the University:~* Students from the different centers and type of studies (undergraduate / graduate).~* Administrative and service personnel.~* Teaching and Research Staff."
62109371|NCT02428088|EXPERIMENTAL|Dasotraline 4 mg|Dasotraline 4 mg
62109372|NCT02428088|PLACEBO_COMPARATOR|Placebo|Placebo
62109373|NCT03183024|PLACEBO_COMPARATOR|placebo|placebo for benralizumab sc given during run-in phase
62109374|NCT03183024|EXPERIMENTAL|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
62109375|NCT04704102|EXPERIMENTAL|Muscle energy technique group|Use one of the muscle energy technique methods -- postisometric relaxation technique(PIR) as the intervention method.
62109376|NCT04704102|EXPERIMENTAL|Strain-counterstrain group|Use the Strain-counterstrain technique as the intervention method.
62109377|NCT04704102|SHAM_COMPARATOR|Control group|Use the modified Strain-counterstrain technique as the intervention method.
62109378|NCT02749045|OTHER|Image acquisition arm|Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.
62109379|NCT02092844|EXPERIMENTAL|CBT for Menopausal Insomnia (CBTMI)|CBTMI is a combination of Cognitive Behavioral Therapy for Insomnia (CBTI) and Cognitive Behavioral Therapy for Hot Flashes (CBTH).
62109380|NCT02092844|PLACEBO_COMPARATOR|Enhanced Treatment as Usual|In the Enhanced Treatment as Usual/Information Control group, participants continue with clinical care of their choosing, but will be enhanced by the provision of 3 American Academy of Sleep Medicine (AASM) brochures.
62109381|NCT02834689|EXPERIMENTAL|Walking|Walking on a treadmill at 3.5 metabolic equivalents (METS) for 50 minutes
62109382|NCT02834689|EXPERIMENTAL|Seated Control|Sitting for 50 minutes
62109383|NCT04542369|EXPERIMENTAL|LS-SCLC|"Induction therapy: Tislelizumab 200mg, i.v., q3w, 4 cycles; cisplatin 75mg/m2, d1-3 or carboplatin AUC5, d1+ etoposide 100mg/m2, q3w, 4 cycles.~Regional therapy: Candidates for complete resection will receive surgery otherwise they will receive radiotherapy.~Adjuvant therapy: Patients received surgery will receive adjuvant Tislelizumab plus platinum-etoposide therapy for four cycles."
62109384|NCT00584051||1|
62300164|NCT01413269|EXPERIMENTAL|hypofractionation radiotherapy|irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
62300165|NCT01413269|ACTIVE_COMPARATOR|conventional fractionation radiotherapy|irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
62300166|NCT05771428|EXPERIMENTAL|ABBV-552 Dose A|Participants will receive ABBV-552 Dose A once daily (QD) for 12 weeks.
62671100|NCT05970211|EXPERIMENTAL|Hearing Intervention Group|Adults aged 55-75 with hearing loss who have little/no prior experience with hearing aids will be enrolled in the hearing intervention group.
62671101|NCT03186924|EXPERIMENTAL|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
62671102|NCT03186924|NO_INTERVENTION|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
62671103|NCT01052142|EXPERIMENTAL|Lipovaxin-MM|
62671104|NCT02981693|EXPERIMENTAL|iRoot SP sealer|iRoot SP sealer was used as root canal sealer in root canal obturation.
62300167|NCT05771428|EXPERIMENTAL|ABBV-552 Dose B|Participants will receive ABBV-552 Dose B QD for 12 weeks.
62671105|NCT02981693|ACTIVE_COMPARATOR|AH Plus sealer|AH Plus sealer was used as a gold standard to be compared with iRoot SP sealer in root canal obturation.
62671106|NCT05301699||training cohort|The training cohort was used for data analysis.
62671107|NCT05301699||validation cohort|The validation cohort was used for validating the nomogram
62671108|NCT02834897|EXPERIMENTAL|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
62671109|NCT04641039|ACTIVE_COMPARATOR|Anterior annulus removal|In these patients the anterior portion of the annulus fibrosus will be removed when inserting a complete lumbar disc prosthesis
62671110|NCT04641039|ACTIVE_COMPARATOR|Anterior annulus replacement|In these group of patients the anterior portion of the annulus fibrosus will be opened up in to flaps hinged lateraly and replaced once the complete lumbar disc prosthesis is inserted
62671111|NCT03251105|ACTIVE_COMPARATOR|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
62671112|NCT03251105|ACTIVE_COMPARATOR|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
62671113|NCT02942407|EXPERIMENTAL|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
62671114|NCT02942407|EXPERIMENTAL|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
62671115|NCT04783727|EXPERIMENTAL|Experimental arm|The individualised treatment durations defined by the RNA transcriptomic signature-based model
62671116|NCT04783727|NO_INTERVENTION|Control arm|The locally accepted standard duration of treatment based on the WHO recommendation for treatment of MDR-TB patients
62109385|NCT00584051||2|
62109386|NCT00584051||3|
62109387|NCT04173572|EXPERIMENTAL|Walking Group|Participants will be walking two times a week in supervised virtual walking groups on a secure online platform (Zoom) and will also participate in independent walks done at a location of their own choosing outside group participation.
62109388|NCT04173572|ACTIVE_COMPARATOR|Fitbit Alone|Participants will be provided with a Fitbit wristband and instructed how to use it. Participants will also be given information on current recommended physical activity guidelines and told that study staff may be contacting them on a weekly basis if it looks like participants are not wearing their Fitbit for a certain number of days or to troubleshoot any issues.
62109389|NCT02111148|ACTIVE_COMPARATOR|urea and creatinine|urea and creatinine detected in vaginal fluid wash after injecting of 5 ml saline intavaginally
62109390|NCT02111148|ACTIVE_COMPARATOR|Nitrazine|Biochemical description of Nitrazine in the vaginal wash
62109391|NCT02111148|ACTIVE_COMPARATOR|saline|5ml saline will be injected in vagina of each patient in both groups within 24 hours of membrane rupture.
62300168|NCT05771428|EXPERIMENTAL|ABBV-552 Dose C|Participants will receive ABBV-552 Dose C QD for 12 weeks.
62300169|NCT05771428|PLACEBO_COMPARATOR|Placebo for ABBV-552|Participants will receive placebo for ABBV-552 QD for 12 weeks.
62671117|NCT00326040|EXPERIMENTAL|A|
62671118|NCT06438952|ACTIVE_COMPARATOR|Addition of lumbar sympathetic blockade to transforaminal steroid injection|The patient will receive both transforaminal steroid injection and lumbar sympathetic blockade.
62671119|NCT06438952|PLACEBO_COMPARATOR|Transforaminal steroid injection only|The patient will only receive transforaminal steroid injection.
62671120|NCT01619449|EXPERIMENTAL|Renal replacement therapy|Liver transplant recipients who receive continuous renal replacement therapy intra-operatively.
62671121|NCT01619449|ACTIVE_COMPARATOR|No CRRT|This arm consists of standard of care without CRRT in the OR for OLT
62300170|NCT04804215|EXPERIMENTAL|The experimental group in Intraductal transanastomotic stent|"Inclusion criteria~* 19 years old or older \~ under 70 years old~  * Patients eligible for liver transplantation ③ Patients who have consented to written consent~Intraductal transanastomotic stent was used during biliary reconstruction"
62300171|NCT04804215|EXPERIMENTAL|The controled group in non-Intraductal transanastomotic stent|"Inclusion criteria~* 19 years old or older \~ under 70 years old~  * Patients eligible for liver transplantation ③ Patients who have consented to written consent~No stent was used during biliary reconstruction"
62300172|NCT01841151|ACTIVE_COMPARATOR|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
62671122|NCT04267328||Patients having surgery|Older adults undergoing elective orthopedic surgery.
62671123|NCT01776203|ACTIVE_COMPARATOR|medroxyprogesterone acetate|
62300173|NCT01841151|ACTIVE_COMPARATOR|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
62671124|NCT01776203|NO_INTERVENTION|control|
62671125|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
62671126|NCT02040064|EXPERIMENTAL|Treatment|"* Cohort 1: Tremelimumab 3 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 3 mg/kg is the MTD)~* Cohort 2: Tremelimumab 6 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 6 mg/kg is the MTD)~* Cohort 3: Tremelimumab 10 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 10 mg/kg is the MTD)"
62671127|NCT06535737|EXPERIMENTAL|cabozantinib|Open-labelled
62671128|NCT00565760|EXPERIMENTAL|1|
62671129|NCT00565760|PLACEBO_COMPARATOR|2|
62671130|NCT00924651|EXPERIMENTAL|Standard Care + EXCAP|Personalized exercise prescription
62109392|NCT01662180||Subfertile couples|"Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles~All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle."
62300174|NCT01841151|ACTIVE_COMPARATOR|WM training|Working Memory training (WMt)
62300175|NCT01841151|NO_INTERVENTION|Waiting-list|Treatment as usual only
62300176|NCT02140125|EXPERIMENTAL|ASP2408 low dose group|
62300177|NCT02140125|EXPERIMENTAL|ASP2408 middle dose group|
62300178|NCT02140125|EXPERIMENTAL|ASP2408 high dose group|
62671131|NCT00924651|NO_INTERVENTION|Standard Care|Wait list control
62671132|NCT02102737|EXPERIMENTAL|6-DIG and clamp|injection of 6-DIG and hyperinsulinemic euglycemic clamp
62109393|NCT02235857|EXPERIMENTAL|Liposorber® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using Liposorber® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
62109394|NCT03231436|EXPERIMENTAL|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
62300179|NCT02140125|PLACEBO_COMPARATOR|Placebo group|
62300180|NCT05026073||Group 1 Endometrial Cancer:|Women with histological diagnosis of cancer of the endometrium (any type) undergoing hysterectomy
62300181|NCT05026073||Group 2 Endometrial Hyperplasia:|Women with histological diagnosis of endometrial hyperplasia (with or without atypia) undergoing hysterectomy
62300182|NCT05026073||Group 3 Controls:|Healthy women undergoing hysterectomy for a benign reason
62300183|NCT02265328|EXPERIMENTAL|Bovine colostrum + prednisolone|"1. Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.~2. Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. If Lilli score \> 0.45 after 7 days, then GC would be stopped and patients will be counselled for liver transplantation.~3. Oral Bovine colostrum (200 ml (20 gram) TDS × 2 months."
62300184|NCT02195843|ACTIVE_COMPARATOR|Emperical|Anatomical optimization of device and leads
62300185|NCT02195843|ACTIVE_COMPARATOR|Electrical|Electrical optimization by RVLV Conduction Time with VectSelect
62300186|NCT02607527|OTHER|Device Implantation|Transcatheter IRIS placement
62300187|NCT03414879|ACTIVE_COMPARATOR|Ketamine group|Nebulization with ketamine
62300188|NCT03414879|ACTIVE_COMPARATOR|Lidocaine group|Nebulization with with lidocaine
62300189|NCT04939155||Patients infected with SARS-CoV-2|The first part of this study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after they contracted SARS-CoV-2
62300190|NCT04939155||Patients who have received an mRNA vaccination|The second part of the study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after SARS CoV-2 mRNA vaccine injection.
62671133|NCT05690191||Chidamide in combination with rituximab and lenalidomide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses); Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle; Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
62671134|NCT00899847|EXPERIMENTAL|Autologous-Allogeneic Peripheral Blood Stem Cell Transplant|Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
62671135|NCT02205138|EXPERIMENTAL|ALLOB® cells with ceramic scaffold|ALLOB® cells with ceramic scaffold Implantation
62671136|NCT01415115||Type 1 Diabetes|Must have been diagnosed with type 1 diabetes. Subject group will be measured on SCOUT and compared to Type 2 diabetes cohort.
62671137|NCT01415115||Type 2 Diabetes|Must have been diagnosed with Type 2 diabetes. This group will be compared to the Type 1 cohort.
62671138|NCT04419350|EXPERIMENTAL|treatment|microneedling.
62671139|NCT04419350|NO_INTERVENTION|No treatment|No treatment will be done to these hypopigmented lesions
62671140|NCT06235957|OTHER|Group A|Three weeks of cast immobilisation
62671141|NCT06235957|OTHER|Group B|One week of brace immobilisation
62671142|NCT05880030|ACTIVE_COMPARATOR|Vitamin D|Vigantol 10 000 IU/day (20 droplets) two weeks supplementation (vitamin D3)
62671143|NCT05880030|PLACEBO_COMPARATOR|Control|sunflower oil, (20 droplets) two weeks supplementation.
62671144|NCT03994120|ACTIVE_COMPARATOR|Motor Cortex rTMS|Motor Cortex rTMS
62671145|NCT03994120|ACTIVE_COMPARATOR|PPC rTMS|PPC rTMS
62671146|NCT03994120|PLACEBO_COMPARATOR|vertex rTMS|vertex rTMS
62300191|NCT05187117|EXPERIMENTAL|Open Label Pilot|"The Open Label Pilot (Phase 4) will include testing the CAPABLE Family intervention with 6 individuals with MCI or early-stage dementia. At least 5 of the 6 older adults will be required to have a family member involved. Assuming all have a family member involved (though one may not), 12 participants will be enrolled in the open label pilot.~Open label pilot participants will be asked to provide feedback halfway through the intervention and at the end via phone conversations with the research study team, allowing the study team to make changes accordingly."
62300192|NCT05187117|EXPERIMENTAL|Randomized Control Pilot - Intervention Arm|After the open label pilot, 17 older adults (and if available, care partners) will be randomized to the CAPABLE Family intervention. They will be assessed at baseline, after the 4 month intervention, and after the waitlist control arm.
62300193|NCT05187117|ACTIVE_COMPARATOR|Randomized Control Pilot - Waitlist Control Arm|The waitlist control group, 17 older adults and if available, care partners, will receive the intervention after they have served as controls to the immediate treatment group, ensuring all participants have access to the intervention.
62300194|NCT05877677|PLACEBO_COMPARATOR|Placebo drink|consume 1 bottle per day
62470327|NCT03122015|EXPERIMENTAL|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
62470328|NCT03122015|NO_INTERVENTION|Standard care|
62671147|NCT03942055||B-line score ≥7|"Patients with B-line score ≥7 at the end of the surgical procedure.~The Sonosite Edge II Ultrasound device will be used.~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
62109395|NCT03231436|ACTIVE_COMPARATOR|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
62671148|NCT03942055||B-line score <7|"Patients with B-line score \<7 at the end of the surgical procedure.~The Sonosite Edge II Ultrasound device will be used.~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
62671149|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
62300195|NCT05877677|EXPERIMENTAL|Polygonatum kingianum extract drink|consume 1 bottle per day
62300196|NCT05844384|EXPERIMENTAL|Nanodroper|"* Patients are given a Nanodropper to use with their IOP-lowering eyedrops.~* Patient returns for a safety check 1 month following the start of Nanodropper use.~* At 3 months, the patient returns for clinical assessment and starts using IOP-lowering eyedrops without Nanodropper for 3 months.~* The patient returns at 6 months for final clinical assessment"
62671150|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
62671151|NCT05253235|EXPERIMENTAL|SAAF Intervention|Parents and youth will receive an online, family-centered intervention consisting of 7 weekly sessions.
62671152|NCT05253235|OTHER|Control Group|Control group members will receive a book entitled, Parenting for Liberation: A Guide for Raising Black Children
62470329|NCT03848507|EXPERIMENTAL|20% Albumin|Administration of 3ml per kg bodyweight of 20% albumin within 30 min during cystectomy.
62671153|NCT00948935|EXPERIMENTAL|Chemotherapy|Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
62671154|NCT04147741|EXPERIMENTAL|Pre-Workout Supplement|A 60 g dose of a commercially available pre-workout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine 1 g, yerba mate 0.3 g and caffeine 0.4 g. With 250 ml of water.
62671155|NCT04147741|PLACEBO_COMPARATOR|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 250 ml of water.
62671156|NCT02027493|ACTIVE_COMPARATOR|Reiferon R weekly plus ribavirin|patients who continued treatment on weekly basis (7-day schedule). This group included patients who were HCV-RNA negative at week 12 and those who had \< 1 log decrease in HCV-RNA viremia
62671157|NCT02027493|ACTIVE_COMPARATOR|Reiferon R (every 5-day) plus ribavirin|patients who continued treatment on a 5-day schedule. This group included patients who had ≥ 1 log decrease in viremia (compared to pre-treatment level) at week 12
62109396|NCT03386929|EXPERIMENTAL|Avelumab, Axitinib, Palbociclib|"For the Phase 1:~Avelumab is administered intravenously (IV) on Day 1 and Day 15 of a 28 day cycle in combination with axitinib po bid (every day of a 28 day cycle) and palbociclib po (on days 8-28 of a 28 day cycle).~For the Phase 2:~Avelumab, axitinib and palbociclib are administered at the recommended phase 2 dose (RP2D) as determined during the phase 1 part of the study."
62671158|NCT00393380|EXPERIMENTAL|Parathyroid Hormone (teriparatide)|Parathyroid hormone after double umbilical cord blood transplant.
62671159|NCT02823561|ACTIVE_COMPARATOR|Garcinia mangostana (treatment group)|Balanced low-calorie diet and regular exercise in combination with integration
62671160|NCT02823561|OTHER|Control group|balanced low-calorie diet and regular exercise
62735956|NCT03451513|EXPERIMENTAL|Pride Body Project (PBP)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
62300197|NCT05844384|ACTIVE_COMPARATOR|Regular Dropper|"* Patient continues using current IOP-lowering eyedrops without Nanodropper adaptor.~* At 3 months, the patient returns for clinical assessment and starts using IOP-lowering eyedrops with Nanodropper for 3 months.~* Patient returns for a safety check 1 month following the start of Nanodropper use.~* The patient returns at 6 months for final clinical assessment"
62300198|NCT02224430||schizophrenia/schizoaffective disorder|Participants with schizophrenia/schizoaffective disorder.
62671161|NCT05428917|EXPERIMENTAL|Near infrared spectroscopy|This method allows (like fMRI) to study cerebral neurovascular coupling. It is based on the fact that an activated brain region increases its local blood flow. Oxygenated (HbO) and deoxygenated (HbR) hemoglobin absorb infrared light and it is then possible to identify the cerebral cortical regions involved in a given task. This technique therefore makes it possible to study cerebral activation under more ecological conditions than fMRI and is thus particularly suitable for exploring rehabilitation techniques.
62300199|NCT05591911||Patients over 60 years old presenting with acute urinary tract infection symptoms|
62300200|NCT03784378|EXPERIMENTAL|Participants previously enrolled on Study of RXDX-105|Participants were previously enrolled on Study of RXDX-105
62671162|NCT03093168|EXPERIMENTAL|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
62671163|NCT00760071||1CF-patients<6|Patients with diagnoses of cystic fibrosis from birth to the age of 6 years
62671164|NCT00760071||2 controls|age matched controls
62671165|NCT01178411|EXPERIMENTAL|Tivantinib (Monotherapy or Combination Therapy)|Tivantinib 360 mg will be administered twice daily, orally, with meals, as a monotherapy or in combination with other drug therapies.
62671166|NCT04601909|ACTIVE_COMPARATOR|FX-322|FX-322, 1 dose (N=24)
62671167|NCT04601909|PLACEBO_COMPARATOR|Placebo|Placebo, 1 dose (n=6)
62671168|NCT02739646|EXPERIMENTAL|Females|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
62671169|NCT02739646|EXPERIMENTAL|Males|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
62109397|NCT02577523|EXPERIMENTAL|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours.
62671170|NCT00564070|ACTIVE_COMPARATOR|Enhanced treatment as usual|Enhanced treatment as usual plus single-session life-steps treatment
62671171|NCT00564070|EXPERIMENTAL|CBT-AD|Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)
62671172|NCT03180502|ACTIVE_COMPARATOR|Arm I (photon-based IMRT, temozolomide)|Patients undergo photon-based IMRT QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
62300201|NCT03591887|EXPERIMENTAL|ABY-035 2 mg|2 mg ABY-035 SC
62300202|NCT03591887|EXPERIMENTAL|ABY-035 20 mg|20 mg ABY-035 SC
62470330|NCT02159950|EXPERIMENTAL|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
62671173|NCT03180502|EXPERIMENTAL|Arm II (proton beam radiation therapy, temozolomide)|Patients undergo proton beam radiation therapy QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
62671174|NCT04000711|EXPERIMENTAL|Outpatient oral antibiotic treatment group.|After randomization, participants assigned to receive outpatient treatment with oral cefixime at a dose of 8 mg/kg/day were discharged. Treatment was provided by the researchers. Subjects were evaluated daily at the outpatient clinic of the hospital. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed in the outpatient group, they were re-admitted to the hospital to receive intravenous antibiotics. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
62671175|NCT04000711|ACTIVE_COMPARATOR|Inpatient intravenous antibiotic treatment group.|After randomization, participants continued intravenous inpatient antibiotic with cefepime 150 mg/kg/day according to local standard of care guidelines. Subjects were evaluated daily. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed, treatment was changed according to clinical guidelines. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
62671176|NCT04342585|ACTIVE_COMPARATOR|Vaginal progestogen|200mg of vaginal progestogen will be inserted before bedtime every day from time of recruitment until 34 weeks gestation.
62671177|NCT04342585|ACTIVE_COMPARATOR|Vaginal pessary|Vaginal pessary with an internal diameter size of 32 or 35 mm will be inserted at the time of recruitment and kept until 34 weeks gestation.
62109398|NCT02577523|EXPERIMENTAL|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours. Infusion started at wake-up time supplemented with an oral IR LD/CD tablet.
62109399|NCT02033096||Cohort 1: Stannsoporfin 1.5 mg/kg|Cohort 1: Received one 1.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
62109400|NCT02033096||Cohort 2: Stannsoporfin 3.0 mg/kg|Cohort 2: Received one 3.0 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
62109401|NCT02033096||Cohort 3: Stannsoporfin 4.5 mg/kg|Cohort 3: Received one 4.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
62300203|NCT03591887|EXPERIMENTAL|ABY-035 80 mg|80 mg ABY-035 SC
62300204|NCT03591887|EXPERIMENTAL|ABY-035 160 mg|160 mg ABY-035 SC
62300205|NCT03591887|PLACEBO_COMPARATOR|Placebo|Placebo, switching to 80 mg ABY-035 after 12 weeks
62300206|NCT01379625|ACTIVE_COMPARATOR|Medium Chain Triglyceride (MCT)|Subjects randomized to consume 20% of energy from MCT
62300207|NCT01379625|EXPERIMENTAL|Triheptanoin|Subject randomized to consume 20% of energy from triheptanoin.
62300208|NCT04863716|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered to this group.
62671178|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
62671179|NCT01477047||Patients receiving primary hip or knee arthoplasty|
62671180|NCT01184118|NO_INTERVENTION|FP Discontinued|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
62671181|NCT01184118|ACTIVE_COMPARATOR|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
62671182|NCT06417411|ACTIVE_COMPARATOR|Aspirin in First trimester|Participants who will start the study medication (Aspirin) during the first trimester
62671183|NCT06417411|EXPERIMENTAL|Aspirin in Second trimester|Participants who will start the study medication (Aspirin) during the second trimester
62671184|NCT02875600|EXPERIMENTAL|Nutri drink|MRI flow measurements of mesenterial vessels and portal vein before and after stimulation with nutritional drink
62300209|NCT04863716|ACTIVE_COMPARATOR|Control Group|No regional anesthesia technique will be applied to the control group.
62671185|NCT01359384||affected patients|25 patients suffering from severe immune deficiency under immunoglobulin therapy
62671186|NCT01359384||non-affected patients|25 matched controls not suffering from severe immune deficiency
62671187|NCT04730375|ACTIVE_COMPARATOR|( Group A)|: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery
62671188|NCT04730375|ACTIVE_COMPARATOR|(Group B)|Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
62671189|NCT01984060|OTHER|HOME-EX|"Motivational Counseling: Six patient-centered motivational counseling sessions based on the self-determination theory (SDT) of behavior change will be conducted with the patients in the HOME-EX group over 12 weeks.~Exercise Intervention: an individually tailored home-based exercise program performed 5-7 days a week that consists of walking prescription, and individualized strength training exercise designed to provide moderately intense progressive resistance exercise. Subjects will be given a set of 3 color-coded therapeutic resistance bands representing varying levels of resistance and they will start with a number of sets which is customized for each individual and they will be encouraged to progressively increase from their individual baseline sets."
62671190|NCT01984060|NO_INTERVENTION|Control|Subjects are instructed to maintain their usual activities during the study period. This group did not receive any PA counseling or recommendations.
62671191|NCT01536327||Observation|Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
62671192|NCT02227966|EXPERIMENTAL|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
62671193|NCT02227966|SHAM_COMPARATOR|sham-YBand (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
62671194|NCT02573467|EXPERIMENTAL|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
62671195|NCT02573467|EXPERIMENTAL|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
62671196|NCT02573467|EXPERIMENTAL|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
62671197|NCT02573467|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
62671198|NCT03478787|EXPERIMENTAL|Risankizumab|Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
62671199|NCT03478787|ACTIVE_COMPARATOR|Secukinumab|Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.
62671200|NCT02229292|ACTIVE_COMPARATOR|Tranexamic acid|The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.
62671201|NCT02229292|PLACEBO_COMPARATOR|Saline|The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.
62671202|NCT03946410|ACTIVE_COMPARATOR|Screening|Invitation to cardiovascular screening
62109402|NCT02033096||Cohort 4: Placebo Control|Cohort 4: Received one sterile saline injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
62300210|NCT04225598|EXPERIMENTAL|XR-BUP|Injectable buprenorphine
62300211|NCT04225598|ACTIVE_COMPARATOR|Standard SL-BUP|Sublingual buprenorphine
62300212|NCT01898663|EXPERIMENTAL|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DCs + CIK cells
62671203|NCT03946410|PLACEBO_COMPARATOR|Control|No invitation to cardiovascular screening
62671204|NCT05753475||hypotension|
62671205|NCT05753475||normotension|
62671206|NCT00215553|EXPERIMENTAL|A.1 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours.
62671207|NCT00215553|EXPERIMENTAL|A.2 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
62671208|NCT00215553|EXPERIMENTAL|A.3 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
62671209|NCT00215553|EXPERIMENTAL|A.4 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
62109403|NCT00109967|EXPERIMENTAL|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 only of courses 3, 5, 7, 9, and 11. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of course 3, patients undergo reevaluation. Patients achieving a CR or an unconfirmed CR (CRu) receive 2 additional courses of treatment for a total of 5 courses. Patients achieving a PR or stable disease continue study treatment as outlined above for up to 12 courses. Patients achieving a PR or stable disease who subsequently achieve a CR or CRu between courses 3 and 10 receive 2 additional courses of treatment.
62671210|NCT00215553|EXPERIMENTAL|B.1 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
62671211|NCT00215553|EXPERIMENTAL|B.2 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
62671212|NCT00215553|OTHER|B.3 SoC|Received standard ARDS management and ICU care (Standard of Care \[SOC\]). Included, but was not limited to, support with oxygen, conventional mechanical ventilation, sedations, and paralysis.
62671213|NCT00640432|ACTIVE_COMPARATOR|A|
62671214|NCT00640432|EXPERIMENTAL|B|
62671215|NCT05220995||100 patients with minimal|In advancing maternal age (AMA) women, minimal stimulation protocol (MSP) with the new combination of human menopausal gonadotrophin (hMG) and clomiphene citrate (CC) were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
62671216|NCT05220995||100 patients with recombinant FSH antagonist protocol|In advancing maternal age (AMA) women, flexible antagonist protocol with recombinant FSH were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
62671217|NCT05467137|EXPERIMENTAL|Standard of care + MSOT|Standard of care + MSOT
62671218|NCT06236997|EXPERIMENTAL|Treatment (etoposide, carboplatin, radiation, Adebrelimab)|Participants receive etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
62671219|NCT03855371|EXPERIMENTAL|Decitabine plus arsenic trioxide|decitabine: 20mg/m2/d, intravenously, d1-d5, q4w arsenic trioxide: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
62671220|NCT05257213|ACTIVE_COMPARATOR|Heparin solution|Administration of 3 ml heparin solution into the uterine cavity via a syringe immediately post operative hysteroscopy.
62671221|NCT05257213|ACTIVE_COMPARATOR|Anti-adhesion barrier gel|Intrauterine application of 2 ml biodegradable anti-adhesion barrier gel immediately post operative hysteroscopy.
62671222|NCT02919605|EXPERIMENTAL|Single dose of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg will be included, in a single dose.
62671223|NCT02919605|EXPERIMENTAL|Two doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during two weeks.
62671224|NCT02919605|EXPERIMENTAL|Three doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during three weeks.
61915189|NCT01167985|EXPERIMENTAL|Experimental- Different root canal sealer+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
62671225|NCT05067244|EXPERIMENTAL|MDMA assisted psychotherapy|Participants will undergo a 2-month course of CPT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered ini two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
62671226|NCT03520569|ACTIVE_COMPARATOR|Octreotide- Euglycemia|octreotide is 30 ng/kg/min x 240 min insulin 0.15mU/kg/min x 240 min Dextrose 20% at variable rate to maintain euglycemia for 240 min
62671227|NCT03520569|ACTIVE_COMPARATOR|Octreotide - Euglycemia- insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 330 min
62671228|NCT03520569|ACTIVE_COMPARATOR|Octreotide- hyperglycemia|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 330 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
62671229|NCT03520569|ACTIVE_COMPARATOR|Octreotide- hyperglycemia - insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
62671230|NCT01454557|EXPERIMENTAL|Acquired Brain Injury|auditory stimuli for ABI group
62671231|NCT01454557|EXPERIMENTAL|Controls|Auditory stimuli for control group
62735957|NCT03451513|ACTIVE_COMPARATOR|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
61915190|NCT02045953|EXPERIMENTAL|Sequence 1|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): ABCD, where A= FLIXOTIDE 250 Hydrofluoroalkane (HFA) with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
61915191|NCT02045953|EXPERIMENTAL|Sequence 2|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): BDAC, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
62671232|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
61915192|NCT02045953|EXPERIMENTAL|Sequence 3|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): CADB, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
61915193|NCT02045953|EXPERIMENTAL|Sequence 4|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): DCBA, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
61915194|NCT00084461|EXPERIMENTAL|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
62109404|NCT05386446||Drug: Interferon Gamma|Ingaron (INN: recombinant human interferon gamma, lyophilisate for solution for intranasal administration 100,000 IU) in the regime of 3 drops in each nasal passage intranasally every other day for 10 days with a break of 7 days (2 10-day cycles)
62109405|NCT05386446||Control: No intervention|Любой профилактический метод, включающий различные фармакологические методы лечения COVID-19, наряду с применением противовирусных и иммуномодулирующих средств, за исключением препаратов, назначаемых не по назначению или в исследовательских целях, а также IFN-G.
62109406|NCT06315400|EXPERIMENTAL|Ingavirin®, capsules, 60 mg|Ingavirin® will be administered once a day (60 mg/day) for 5 days on top of standard therapy.
62109407|NCT06315400|PLACEBO_COMPARATOR|Placebo|Placebo will be administered once a day for 5 days on top of standard therapy.
62109408|NCT00857363||Constipated|Adult subjects with functional constipation as define by Rome II criteria
62109409|NCT03018119|ACTIVE_COMPARATOR|Anesthesiologists|Total: 11 Intervention: Survey
62109410|NCT03018119|ACTIVE_COMPARATOR|Obstetricians|Total: 11 Intervention: Survey
62109411|NCT03018119|ACTIVE_COMPARATOR|Registered Nurses|Total: 10 Intervention: Survey
62671233|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
62671234|NCT03986541||Retrospective cohort|Patients with advanced colorectal cancer previously treated with an anti-EGFR agent (panitumumab or cetuximab).
62109412|NCT03018119|ACTIVE_COMPARATOR|Surgical Technicians|Total: 6 Intervention: Survey
62109413|NCT01985399||EFV containing ARV regimen|Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
62470331|NCT02159950|EXPERIMENTAL|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
62109414|NCT01985399||Non -EFV ontaning ARV regimen|Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
62109415|NCT04278820|EXPERIMENTAL|Climbing group|
62109416|NCT04278820|EXPERIMENTAL|Titration group|
62109417|NCT04278820|EXPERIMENTAL|Extension group|
62109418|NCT04127058|OTHER|CYP2D6 non-poor metabolizers|titrated up to 24 mg daily (12 mg b.i.d.)
62109419|NCT04127058|OTHER|CYP2D6 poor metabolizers|titrated up to 12 mg daily (6 mg b.i.d.)
62671235|NCT03986541||Prospective cohort|Patients with advanced colorectal cancer newly starting treatment with an anti-EGFR agent (panitumumab or cetuximab).
62300213|NCT03431012|EXPERIMENTAL|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
62671236|NCT04617223|OTHER|Treatment|
62671237|NCT01543503||Cohort|
62671238|NCT01444170|PLACEBO_COMPARATOR|Sugar pill|"Placebo sugar pill was used as a sham control"
62671239|NCT01444170|EXPERIMENTAL|dicreatinol sulfate|
62671240|NCT04424680|NO_INTERVENTION|Control|"Patients will be followed in heart failure outpatients units according to the usual established protocol. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.~Treatment for heart failure will be the same in both groups."
62109420|NCT04159636|NO_INTERVENTION|Fasting group|Participants will be remained fasted until surgery
62109421|NCT04159636|EXPERIMENTAL|Carbohydrate group|Participants will be allowed to drink carbohydrate beverage before 2 hours of surgery
62109422|NCT01813825||Female >=45 years, negative margins, DCIS|
62109423|NCT06249633|EXPERIMENTAL|iNOMAX|
62109424|NCT05014529||Control group|Polysomography show AHI less than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
62470332|NCT03127826|ACTIVE_COMPARATOR|Usual Care|"* Managing Low Back Pain pamphlet from DoD/VA~* No specific guidance regarding physical therapy (PT) or other referrals, thus decision to refer or not will be made by the primary care manager (PCM) according to their preference"
62109425|NCT05014529||OSA without CPAP group|Polysomography show AHI greater than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
62109426|NCT05014529||OSA with CPAP group|Polysomography show AHI greater than 15 events/h and participants receive CPAP more than 6 months.
62109427|NCT00697411||Experimental|Individuals with Aicardi syndrome and their first-degree relatives
62109428|NCT04443452||Prevalent Central Sensitisation|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
62109429|NCT04443452||Non-prevalent Central Sensitisation|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
62109430|NCT06253130|EXPERIMENTAL|Cohort 1|IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial.
62109431|NCT02465086|EXPERIMENTAL|Training|This arm, which is a half of the sample size, will be receiving training of linguistic recursion
62109432|NCT02465086|NO_INTERVENTION|No training|The no intervention group, which is a half of the sample size, will not be recieving training in linguistic recursion.
62671241|NCT04424680|EXPERIMENTAL|Intervention|"Patients will participate in the Advanced Care Planning Program. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.~Treatment for heart failure will be the same in both groups."
62671242|NCT00156130||1|Accelerated whole breast irradiation
62671243|NCT00156130||2|Conventional whole breast irradiation
62671244|NCT01441414|EXPERIMENTAL|ARM A|PF-04856884 in combination with AG-013736
62671245|NCT01441414|ACTIVE_COMPARATOR|ARM B|AG-013736 alone
62671246|NCT04648241|EXPERIMENTAL|≥16 Years Old|TBE vaccine 0.5 mL (intramuscular injection).
62671247|NCT04648241|EXPERIMENTAL|1 to <16 Years Old|TBE vaccine 0.25ｍL (intramuscular injection).
62470333|NCT03127826|EXPERIMENTAL|Risk Stratified Care|"* Managing Low Back Pain pamphlet from DoD/VA~* Self-management education and tools~* 2-item spinal manipulation screening/delivery if indicated~Low Risk:~* Home Exercise Program as indicated~* No referral for ongoing physical therapy~Medium Risk and High Risk~* Referral to physical therapy for ongoing care at physical therapists discretion~* Managed by a psychologically informed physical therapy trained physical therapist"
62671248|NCT04557761|EXPERIMENTAL|Closure with microMend® Arm|The microMend® wound closure product will be used to close the Subject's laceration. The wound will be covered with a non-stick dressing.
62671249|NCT04557761|ACTIVE_COMPARATOR|Closure with Sutures Arm|The Subject's laceration will be closed with sutures. The standard method for suture closed wounds will be followed in accordance with regular institutional policies and procedures.
62671250|NCT01691092|EXPERIMENTAL|Ketamine|All subjects will receive ketamine
62109433|NCT01654705|EXPERIMENTAL|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
62300214|NCT03431012|EXPERIMENTAL|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
62300215|NCT03431012|EXPERIMENTAL|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
62300216|NCT03431012|EXPERIMENTAL|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
62300217|NCT03758937|ACTIVE_COMPARATOR|volume-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
62671251|NCT02387879||Group 1|"Subjects should be chosen among relapse/refractory multiple myeloma patients who have received at least one prior antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with adequate dose and duration (≥2 cycles) or who have relapse/refractory multiple myeloma after stem cell transplantation.~Patients who are eligible for the study will be consecutively enrolled in the study until the targeted patient number is reached. The responsible investigator will be requested to keep a log of subjects who are invited to enter the study. In the case of any of these subjects will not be enrolled in the study, this information will be documented together with its reason"
62671252|NCT04781985|EXPERIMENTAL|suprapubic cystolithotomy|Extraction of the vesical stone via open exploration of the bladder.
62470334|NCT04140877|OTHER|Visu OD, Control OS|Contralateral eye study
62109434|NCT01654705|ACTIVE_COMPARATOR|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
62109435|NCT05427890|ACTIVE_COMPARATOR|Usual Care|
62109436|NCT05427890|EXPERIMENTAL|Relative Risk|
62109437|NCT05427890|EXPERIMENTAL|Metabolic Age|
62109438|NCT02699970||Selected features|"No intervention is administered to the selected features. They only need to be observed by the pathologist.~The features are part of tissue that is present on a slide. This slide is fully scanned and the digital image is than viewed by the pathologist who indicates if he can see the feature. By repeating the scan three times and having the pathologist view three times, the consistency of the feedback can be monitored. The consistency is a measure on how repeatable and reproducible the scanner is. To be very clear: the scanner does not do anything to the tissue. It only takes a digital 'photo' of the tissue. It is no treatment or intervention. It just takes a picture."
62470335|NCT04140877|OTHER|Control OD, Visu OS|Contralateral eye study
62671253|NCT01354535|ACTIVE_COMPARATOR|Cable plating with strut|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
62735958|NCT05031299|ACTIVE_COMPARATOR|Control group (Standard care)|Participants in the control group will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors for 3 months.
62300218|NCT03758937|ACTIVE_COMPARATOR|pressure-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
62671254|NCT01354535|ACTIVE_COMPARATOR|isolated plating|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
62300219|NCT02107144|EXPERIMENTAL|trimetazidin|Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI- Paients that are TMZ naïve and randomized to TMZ group will be given oral loading of 70mg TMZ.
62109439|NCT01942083|EXPERIMENTAL|OPB-111077|orally, once daily
62109440|NCT01859312|EXPERIMENTAL|Continuous Subcutaneous Hydrocortisone Infusion|Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.
62671255|NCT03807167|EXPERIMENTAL|Patients|
62671256|NCT03807167|ACTIVE_COMPARATOR|healthy controls|
62671257|NCT03757676|EXPERIMENTAL|No Play|This 'no play' group functioned as the control group.
62671258|NCT03757676|EXPERIMENTAL|At Will Play|This group functioned as 1 of the 2 play groups.
62671259|NCT03757676|EXPERIMENTAL|Goal Oriented Play|This group functioned as 1 of the 2 play groups.
62671260|NCT05226689|OTHER|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert.
62671261|NCT00008333|EXPERIMENTAL|vinorelbine|Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
62671262|NCT01160744|EXPERIMENTAL|IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin|IMC-1121B + Pemetrexed + Carboplatin \[Area Under the Concentration Time Curve 6 (AUC 6)\] or Cisplatin
62671263|NCT01160744|ACTIVE_COMPARATOR|Pemetrexed + Carboplatin (AUC 6) or Cisplatin|Pemetrexed + Carboplatin (AUC 6) or Cisplatin
62671264|NCT01160744|EXPERIMENTAL|IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin|IMC-1121B + Gemcitabine + Carboplatin \[Area Under the Concentration Time Curve 5 (AUC 5)\] or Cisplatin
62671265|NCT01160744|ACTIVE_COMPARATOR|Gemcitabine + Carboplatin (AUC 5) or Cisplatin|Gemcitabine + Carboplatin (AUC 5) or Cisplatin
62671266|NCT04757857|ACTIVE_COMPARATOR|Rivaroxaban 10 mg|Participants will receive, from the 1st to the 14th day, a dose of 10 mg of rivaroxaban - OA (Oral Administration).
62671267|NCT04757857|NO_INTERVENTION|Best locally standardized care|According to the study protocol, participating investigators are advised to follow the best available local practice in each participating site. There is no formal recommendation for any particular COVID-19 treatment, except symptomatic therapies.
62671268|NCT02516111|ACTIVE_COMPARATOR|Open flap debridement group|SRP with Open flap debridement (OFD) alone for treating intrabony defect
62671269|NCT02516111|ACTIVE_COMPARATOR|PRF group|SRP with Open flap debridement (OFD) with autologous Platelet rich fibrin (PRF) placement into intrabony defect
62671270|NCT02516111|ACTIVE_COMPARATOR|Alendronate group|SRP with Open flap debridement (OFD) with 1% Alendronate (ALN) placement into intrabony defect
62671271|NCT02516111|ACTIVE_COMPARATOR|Atorvastatin group|SRP with Open flap debridement (OFD) with 1.2% Atorvastatin (ATV) placement into intrabony defect
62671272|NCT06124677||Patients|Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.
62671273|NCT02585167|ACTIVE_COMPARATOR|Operation|"the fistula will be excised after dividing the sphincter and primary reconstruction~."
62671274|NCT02585167|EXPERIMENTAL|VAAFT|the fistula tract will be visualized by scope, closing the internal opening with absorbable sutures.
62671275|NCT03811873|OTHER|Vertebral fracture assessment|Study participants undergoing evaluation for liver transplant and deemed to early for transplant will receive standard of care bone mineral density and vertebral fracture assessment..
62671276|NCT02149160|EXPERIMENTAL|FRM-0334; Arm 1|low dose, Capsule, Once Daily, Day 1 through Day 28
62671277|NCT02149160|EXPERIMENTAL|FRM-0334; Arm 2|high dose, Capsule, Once Daily, Day 1 through Day 28
62671278|NCT02149160|PLACEBO_COMPARATOR|Placebo Comparator; Arm 3|Placebo, Capsule, Once Daily, Day 1 through Day 28
62671279|NCT02466581|ACTIVE_COMPARATOR|Arm 1|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~1. Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~2. Cimzia plus Methotrexate and steroids~3. Orencia plus Methotrexate and steroids~4. RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting at randomization."
62735959|NCT05031299|EXPERIMENTAL|Intervention group 1 (Application)|Participants will will be additionally provided with a health-promotion application for self-management for 3 months.
62109441|NCT00548964|EXPERIMENTAL|Ketamine + Lithium|All participants receive the study drug, IV ketamine, open-label
62109442|NCT00548964|ACTIVE_COMPARATOR|Ketamine + Placebo|All participants receive the study drug, IV ketamine, open-label
62109443|NCT01967407|EXPERIMENTAL|renal tumor <4cm, suspected RCC|Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.
62300220|NCT02107144|NO_INTERVENTION|Control|Patients, who are TMZ naïve, will be randomly assigned to receive just previous cardiac medication (Control group).
62300221|NCT01740362|OTHER|Healthy volunteers|Healthy volunteers
62300222|NCT01740362|EXPERIMENTAL|Mild renal impairment|patients with mild (\>50 and ≤80 mL/min) renal impairment
62300223|NCT01740362|EXPERIMENTAL|Moderate renal impairment|patients with moderate (≥30 and ≤50 mL/min) renal impairment
62300224|NCT01740362|EXPERIMENTAL|severe renal impairment|patients with severe (\<30 mL/min) renal impairment
62671280|NCT02466581|ACTIVE_COMPARATOR|Arm 2|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~1. Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~2. Cimzia plus Methotrexate and steroids~3. Orencia plus Methotrexate and steroids~4. RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting 24 weeks after randomization."
62671281|NCT05331833||study group|CTV-omitted IMRT under PET-CT guidance
61915195|NCT06382883|EXPERIMENTAL|SEMC-protocol|Assigned participants will receive CPAP-therapy and one year individually tailored lifestyle intervention at the Sports Medicine Outpatient Clinic of The Wellbeing Services County of Central Finland (SEMC).
62109444|NCT05663619|EXPERIMENTAL|Virtual Reality distraction (VRD)|In the VRD group, participants wore a VRD device and watched a previously selected favorite cartoon during the prophylactic dental treatment.
62109445|NCT05663619|ACTIVE_COMPARATOR|control group|In the control group, participants received their treatment while watching a previously selected favorite cartoon on a regular screen.
62109446|NCT04577170||Fabry disease|
62109447|NCT04577170||Healthy|age and sex matched
62109448|NCT00920686|EXPERIMENTAL|NXN-188|NXN-188, 600 mg, PRN
62109449|NCT00920686|ACTIVE_COMPARATOR|sumatriptan succinate 100 mg|Sumatriptan, 100 mg, PRN
62109450|NCT00920686|PLACEBO_COMPARATOR|placebo|matching, PRN
62109451|NCT03142646|EXPERIMENTAL|IM19 CART|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.
62109452|NCT03045900|ACTIVE_COMPARATOR|Translucent bulk-fill resin composite|\*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
62109453|NCT03045900|EXPERIMENTAL|Shaded bulk-fill resin composite|\*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
62109454|NCT06386913|EXPERIMENTAL|Clinician|Mental health providers at Carilion Clinic completed Measurement-Base Care (MBC) training
62109455|NCT01923857|EXPERIMENTAL|Healthy Volunteers|Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m\^2.
62109456|NCT01923857|EXPERIMENTAL|Mild Renal Impairment|Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m\^2 (creatinine clearance 50-80 mL/min).
62109457|NCT01923857|EXPERIMENTAL|Moderate Renal Impairment|Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m\^2 (creatinine clearance 30-50 mL/min).
62109458|NCT01923857|EXPERIMENTAL|Severe renal impairment|
62109459|NCT00706693|ACTIVE_COMPARATOR|Glucose|BD glucose tablets (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
62671282|NCT05331833||control group|CTV-delineated IMRT under PET-CT guidance
62671283|NCT00834587|EXPERIMENTAL|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip™ 5/500 mg Tablet (reference) dosed in second period
62671284|NCT00834587|ACTIVE_COMPARATOR|Metaglip™|Metaglip™ 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
62109460|NCT00706693|ACTIVE_COMPARATOR|Fructose|Fruit to Go (TM) is taken PO in response to a hypoglycemic event by participants randomized to this arm
62109461|NCT00706693|ACTIVE_COMPARATOR|Sucrose|Skittles (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
62109462|NCT03641950|EXPERIMENTAL|Botulinum Toxin Type A (Botulax)|Botulinum Toxin Type A (Botulax)
62109463|NCT06331754|EXPERIMENTAL|Technology-enabled blood pressure management|The intervention will consist of a technology-enabled remote hypertension management program. Participants will be given a cellular blood pressure (BP) cuff and patients with heart failure and chronic kidney disease stage 3b-5 will be given a scale also. Patients will undergo a series of protocolized software-driven medication initiation and titration steps until they reach a blood pressure target of systolic blood pressure \< 130 mmHg and diastolic blood pressure \< 80 mmHg. Patients will be subsequently monitored for up to 12 more months. If their blood pressure increases, they can re-enter active management.
62109464|NCT06331754|NO_INTERVENTION|No intervention|Patients meeting inclusion care undergoing usual care in control clinics.
62109465|NCT02460484|EXPERIMENTAL|Cord Blood Infusion|Autologous cord blood infusion
62300225|NCT05059353|EXPERIMENTAL|Patients with MCI|
62300226|NCT05059353|EXPERIMENTAL|Cognitively Normal Subjects|
62300227|NCT05059353|NO_INTERVENTION|Caregivers of Patients with MCI|
62671285|NCT03343886||Cohort 2011|A nationally representative sample of 4753 non-institutionalized adults aged 18 years or older from the Spanish population was collected (with an over-sampling of people aged 50+ years). A multi-stage clustered design was employed. A total of 2528 individuals were re-interviewed in 2014. In 2018, 1577 were again evaluated. Finally, in 2022, 963 participants took part of another study's evaluation.
62735960|NCT05031299|EXPERIMENTAL|Intervention group 2 (Devices)|"Participants will be additionally provided with wearables and devices for 3 months including:~* A weighing scale (assessing also body composition) device~* A smartwatch/wristband to assess physical activity but also sleep pattern."
62300228|NCT04751643|EXPERIMENTAL|TPE + usual treatments in intensive care unit according to the current state of knowledge.|"TPE + usual treatments in intensive care unit according to the current state of knowledge : 3 TPE sessions i.e. one per day during 3 consecutive days on day 1-3 (day 0 = inclusion Visit date)) + usual treatments in intensive care unit.~Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)"
61915196|NCT06382883|EXPERIMENTAL|SEMC-protocol + EBS intervention|Assigned participants will receive CPAP-therapy, SEMC-protocol as described above and enhanced behavioral support -intervention (EBS). The EBS-intervention will apply a patient-centered self-regulatory approach to support (motivation for) changes in behavior (CPAP-use, physical activity (PA), and sedentary behavior (SB)).
61915197|NCT06382883|NO_INTERVENTION|Control group|Assigned participants will receive CPAP-therapy, receive written information on healthy lifestyle but will not receive any extra support.
61915198|NCT05679427|ACTIVE_COMPARATOR|Arm A|Single fraction radiosurgery on bone metastases (21-24Gy x 1 fraction)
61915199|NCT05679427|ACTIVE_COMPARATOR|Arm B|Multi-fractioned stereotactic ablative radiotherapy (5 fractions delivered in 5 consecutive working days) with SIB on bone metastases (5Gy x 5 fractions + SIB up to 40-50Gy)
61915200|NCT06506370||Control group: Patients without periodontitis and with diabetes.|"Periodontitis was diagnosed in patients who presented with attachment losses due to inflammatory problems greater than or equal to 2 mm at the interproximal level or greater than or equal to 3 mm at the buccal or lingual/palatal level in two or more nonadjacent teeth.~The diagnosis of diabetes was made at the endocrinology service of the Hospital Virgen de la Arrixaca in Murcia."
61915201|NCT06506370||Test group: Patients with periodontitis and diabetes.|"Periodontitis was diagnosed in patients who presented with attachment losses due to inflammatory problems greater than or equal to 2 mm at the interproximal level or greater than or equal to 3 mm at the buccal or lingual/palatal level in two or more nonadjacent teeth.~The diagnosis of diabetes was made at the endocrinology service of the Hospital Virgen de la Arrixaca in Murcia."
61915202|NCT01126671|ACTIVE_COMPARATOR|Low Dose Vitamin D|Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
61915203|NCT01126671|ACTIVE_COMPARATOR|High Dose Vitamin D|Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
61915204|NCT03190642|ACTIVE_COMPARATOR|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
61915205|NCT03190642|ACTIVE_COMPARATOR|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
61915206|NCT03563144|EXPERIMENTAL|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1~A combination of agents will be administered to subjects in this study:~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
62109466|NCT05233137|EXPERIMENTAL|PA coaching and exercise training|Patients in this group will receive physical activity telecoaching as well as an exercise training program provided by a physiotherapist in primary care
62109467|NCT05233137|ACTIVE_COMPARATOR|PA coaching|Patients in this group will receive physical activity telecoaching
62109468|NCT02404064|OTHER|Antibiotics perioperative|dose of perioperative antibiotics (cefamezin 1g IV; metronidazole 500 mg IV) This is the standard of care of the department
62671286|NCT03343886||Cohort 2019|3002 participants from the regions of Madrid and Barcelona were brought in between 2019 and 2021. They are now under a second evaluation (2023). In 2020, during the first Coronavirus (COVID-19) lockdown, 1166 of the participants from the first wave of the cohort was telephonically interviewed, a lateral sub-study evaluation.
61915207|NCT03563144|ACTIVE_COMPARATOR|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
61915208|NCT03563144|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
61915209|NCT03450980|OTHER|EyeTurn App|All participants will have their eye alignment measured with both the experimental device (EyeTurn app) and the clinical gold standard tests or ground truth (simulated strabismus gaze angles).
61915210|NCT04329689|EXPERIMENTAL|septal myectomy alone versus septal myectomy|"The aims of the present study is to:~1. Compare the results of adequate septal myectomy alone versus septal myectomy + mitral repair in patients with HOCM.~2. Effect of mitral repair on outcome of patients with systolic anterior motion that accompanies HOCM."
61915211|NCT05061680|ACTIVE_COMPARATOR|short sphincterotomy +Short duration papillary large balloon dilation|Patients with short sphincterotomy
61915212|NCT05061680|ACTIVE_COMPARATOR|full sphincterotomy + short duration papillary balloon dilation|Patients with full lenght sphincterotomy
61915213|NCT05061680|ACTIVE_COMPARATOR|previous sphincterotomy + short duration papillary balloon dilation|Patients with previous sphincterotomy
61915214|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
62109469|NCT02404064|PLACEBO_COMPARATOR|placebo - No Antibiotics perioperative|The intervention is No Antibiotics perioperative
62109470|NCT05903027||Episodic migraine|Patients affected by an episodic pattern migraine(\< 15 monthly headache days) with or without aura according to ICHD-III criteria.
62109471|NCT05903027||Chronic migraine|Patients affected by chronic migraine according to ICHD-III criteria.
62671287|NCT01879852|ACTIVE_COMPARATOR|Standard Rehabilitation|Standard meniscectomy rehabilitation including knee range of motion and strengthening exercises.
62300229|NCT04751643|ACTIVE_COMPARATOR|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
62671288|NCT01879852|EXPERIMENTAL|Standard Rehabilitation + Quadriceps intensive strengthening|The intervention includes high-intensity neuromuscular electrical stimulation and eccentric exercises for the quadriceps muscle in addition to the standard rehabilitation protocol.
62109472|NCT05130060|EXPERIMENTAL|Treatment (PolyPEPI1018, TAS-102)|Patients receive PolyPEPI1018 SC at 4 injection sites on days 1 and 15 and trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-15. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
62109473|NCT05826704|EXPERIMENTAL|PS23|2 capsule daily
62109474|NCT05826704|PLACEBO_COMPARATOR|Placebo|2 capsule daily
62109475|NCT03603717|EXPERIMENTAL|CBT-I|Four individual sessions that will last approximately 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
62109476|NCT03603717|ACTIVE_COMPARATOR|Sleep Hygiene|Four individual sessions that will last 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
62109477|NCT03396835|EXPERIMENTAL|INVSENSOR00009 Sensor|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
62109478|NCT02135458|EXPERIMENTAL|Telemonitoring|Home-based patient management using AUTONOM@DOM telemonitoring system to record and transmit heart rate, blood pressure and weight; along side conventional care (patient therapeutic education or personalised care program)
62109479|NCT02135458|ACTIVE_COMPARATOR|Conventional care|Conventional care including patient therapeutic education or personalised care program
62109480|NCT05337657|EXPERIMENTAL|GB491+Letrozole|
62109481|NCT03553446|EXPERIMENTAL|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
62109482|NCT05518201|EXPERIMENTAL|The 9vHPV Recombinant Vaccine among 18-45yrs|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5mL/each dose).
62109483|NCT05518201|EXPERIMENTAL|The 9vHPV Recombinant Vaccine among 9-17 yrs|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5mL/each dose).
62109484|NCT00431808|EXPERIMENTAL|I, AMA1 vaccine|20 volunteers will receive 3 doses of the vaccine
62109485|NCT00580073|EXPERIMENTAL|1|FOLFOX4 + Cetuximab
62671289|NCT02228122|EXPERIMENTAL|Aquacel® Ag+ Extra|
62671290|NCT02887326||age 15-25 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
62671291|NCT02887326||age 25-35 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
62671292|NCT02887326||age 35-45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
62671293|NCT02887326||> age 45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
62671294|NCT04489056||Study group|This group will consist of 50 pregnant women, who experienced pPROM between 22+5 and 28+0 gestational weeks, either presenting at the primary study site, or being referred from other hospitals, and delivered at preterm by cesarean section.
62671295|NCT04489056||Control group|This group will consist of 50 pregnant women, who are scheduled for elective cesarean section at the outpatient department of the primary study site, between a 32+0 and 37+0 gestational weeks, and delivered at term by cesarean section.
62671296|NCT03148925|EXPERIMENTAL|SELA-070|
62671297|NCT03148925|PLACEBO_COMPARATOR|Saline|
62671298|NCT03796130|EXPERIMENTAL|(A)Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomlyallocated intotwo groups.~In group (A): myomectomy will be performed before ART~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
62671299|NCT03796130|NO_INTERVENTION|(B) No myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (B):women will have their trial of ART without myomectomy"
61915215|NCT02065271|EXPERIMENTAL|herbal supplements|500mg, 3 per day, 4weeks
62109486|NCT04741971|EXPERIMENTAL|Probiotics group|Will give Probiotics with Vit.D 3
61915216|NCT02065271|PLACEBO_COMPARATOR|placebo|500mg, 3 per day, 4 weeks
62109487|NCT04741971|PLACEBO_COMPARATOR|Non-probiotics group|Will give Vit. D3 as placebo
62109488|NCT06630910|ACTIVE_COMPARATOR|A double-layered, end-to-side pancreaticojejunostomy without stenting and omental patch|
62109489|NCT06630910|ACTIVE_COMPARATOR|A double-layered, end-to-side pancreaticojejunostomy with stenting and omental patch|
61915217|NCT05343533|EXPERIMENTAL|Active Probiotic|A mixture of probiotic strains (2.5 gram daily doses of 4 x 109 CFU/packet) of the following species (Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium longum).
62109490|NCT00866554|ACTIVE_COMPARATOR|LHRH agonist|Administration of a 3-month treatment with an LHRH agonist (chosen by the treating radiation oncologist) and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
62300230|NCT03217760||Patients|The main aim of the study is to examine the patient's induced stress during endodontic treatment in order to offer customised solutions to lessen stress. The other aims is also to evaluate the patient's pain and discomfort during endodontic treatment.
62300231|NCT03217760||Young dentists practitioners.|The other aims are to evaluate the young dentist's induced stress and to examine and compare the patient's induced stress and the young dentist's induced stress.
62300232|NCT01689558|EXPERIMENTAL|Recombine Endostatin|Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
62300233|NCT05200767||COVID-19|Adults aged 18 at the least of any sex and race hospitalized for SARS-CoV-2 infection
62109491|NCT00866554|EXPERIMENTAL|Dutasteride, Bicalutamide, Tamoxifen|"Administration of Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
62109492|NCT01085279|EXPERIMENTAL|Non-ablative fractional laser|"In each patient, one side of the face was treated with non-ablative fractional laser in four-five sessions.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
62109493|NCT01085279|ACTIVE_COMPARATOR|Triple topical therapy|"In each patient, one side of the face was treated with triple topical therapy (Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1%) during 15 weeks.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
62109494|NCT01178762|EXPERIMENTAL|Observation|
62300234|NCT06434168|EXPERIMENTAL|Yoga intervention|
62300235|NCT06434168|PLACEBO_COMPARATOR|Control condition|
62300236|NCT05278234|EXPERIMENTAL|Intervention arm|Participants will engage in a 7-week multicomponent chronic pain self-management program.
62300237|NCT05278234|NO_INTERVENTION|Usual care control arm|After completing the 12 month telephone survey, control group participants will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a workshop that provides key intervention content and individualized goal-setting guidance.
62109495|NCT04333069|OTHER|Uncorrected and best corrected visual acuity|Measuring of uncorrected and best corrected visual acuity after phaco emulsification and irrigation aspiration cataract surgery
62109496|NCT05586230|EXPERIMENTAL|Group 1 (≥ 31 kg)|"≥40 kg (Adult Formulation)~31-\<40 kg (Dispersible Pediatric Formulation)"
62109497|NCT05586230|EXPERIMENTAL|Group 2 (20-<31 kg)|20-\<31 kg (Dispersible pediatric Formulation)
62300238|NCT04905862||Hemodialyzed patients|Hemodialyzed patients vaccinated with BNT162b2 - mRNA vaccine against COVID-19
61915218|NCT05343533|PLACEBO_COMPARATOR|Placebo|Maltodextrin capsule
61915219|NCT06245551|EXPERIMENTAL|A/B - Treatment with PT027 (BUDESONIDE/ALBUTEROL) 160/180 μg followed by treatment with Placebo|Subjects randomized to receive a single dose of PT027 160/180 μg in treatment Period 1, and a single dose of Placebo in treatment Period 2.
62109498|NCT05586230|EXPERIMENTAL|Group 3 (12-<20 kg)|12-\<20 kg (Dispersible pediatric Formulation)
62109499|NCT05586230|EXPERIMENTAL|Group 4 (4-<12 kg)|"8-\<12 kg (Dispersible pediatric Formulation)~6-\<8 kg (Dispersible pediatric Formulation)~4-\<6 kg (Dispersible pediatric Formulation)"
62300239|NCT04905862||Patients treated with peritoneal dialysis|Patients treated with peritoneal dialysis vaccinated with BNT162b2 - mRNA vaccine against COVID-19
62300240|NCT04905862||Patients without chronic kidney disease|Patients without chronic kidney disease vaccinated with mRNA BNT162b2 - vaccine against COVID-19
62300241|NCT04905862||Kidney transplant recipients|Kidney transplant recipients vaccinated with mRNA vaccine against COVID-19
62300242|NCT02153840|EXPERIMENTAL|PSORI-CM01（YXBCM01）granule|PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
62300243|NCT02153840|EXPERIMENTAL|PSORI-CM01（YXBCM01）granule low dose group|PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
62671300|NCT01707121||Surgical patients|Patients with planned surgery for breast cancer, colorectal cancer and gall bladder disease
62300244|NCT02153840|PLACEBO_COMPARATOR|placebo|Placebo granule 1.1g os once a day for 12weeks.
62300245|NCT01714921||ICD patients|Patients with an indication for an ICD implantation according to the guidelines treated with a Protecta™, Protecta™ XT or any equivalent following product
62300246|NCT01640847|EXPERIMENTAL|Arm RT: HIFU plus ThermoDox|Index lesion has been treated with EBRT and is currently painful, but these subjects have already received their maximum cumulative EBRT dose.
62671301|NCT04828733|EXPERIMENTAL|OAGB + SCP + FundoRing|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty
62671302|NCT04828733|ACTIVE_COMPARATOR|OAGB + SCP + NF|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty
62671303|NCT04828733|ACTIVE_COMPARATOR|OAGB + SCP|laparoscopic one anastomosis gastric bypass without excluded stomach fundoplication and only suture cruroplasty
62671304|NCT01426451|EXPERIMENTAL|Theatre intervention|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
62671305|NCT01426451|EXPERIMENTAL|Group tutoring intervention|In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes weekly). Individualized student objectives on reading fluency and math will be implemented (one in math and one in reading per student).
62671306|NCT01426451|NO_INTERVENTION|No intervention|Classes not participating neither in drama workshops nor in group tutoring activities will fill out a questionnaire as a basis for comparison.
62671307|NCT02815956|EXPERIMENTAL|percutaneous tibial nerve stimulation (ST)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The protocol of stimulation is the same, that the one performed for fecal incontinence."
62671308|NCT02815956|PLACEBO_COMPARATOR|placebo (P)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The device delivers ineffective impulses."
62109500|NCT05969860|EXPERIMENTAL|Arm A (at-home treatment)|Patients continue receiving their SOC chemotherapy regimen at home for approximately 24 weeks in the absence of disease progression or unacceptable toxicity. This includes drug administrations, injections/infusions and routine clinical laboratory tests in the home from the HHNP, overseen by Mayo Clinic's home health program CCBW Command Center. Patients are also provided biometric devices for health monitoring vital signs, as well as a computer tablet for video visits with the Mayo Clinic care team.
62109501|NCT05969860|EXPERIMENTAL|Arm B (clinic & at-home treatment)|Patients continue receiving their SOC chemotherapy regimen in the clinic for approximately 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then begin receiving their SOC chemotherapy regimen at home as in Arm I for an approximate additional 16 weeks in the absence of disease progression or unacceptable toxicity.
62109502|NCT02588638||Adult patients|Unclear movement disorder, unclear cognitive decline
62671309|NCT00673114|OTHER|Transplant Recipients|
61915220|NCT06245551|EXPERIMENTAL|B/A - Treatment with Placebo followed by treatment with PT027 (BUDESONIDE/ALBUTEROL) 160/180 μg|Subjects randomized to receive a single dose of Placebo in treatment Period 1, and a single dose of PT027 160/180 in treatment Period 2.
61915221|NCT02483533|EXPERIMENTAL|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
62109503|NCT02588638||Patients < 18 years|Patients with (penetrating) suspected cerebral neurogenetic diseases
62109504|NCT02317016|EXPERIMENTAL|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
62109505|NCT06009419|EXPERIMENTAL|Intervention Group|In addition to the program given to the control group, the dual task program will be progressively given to the study group as previously described (Silsupadol et al., 2006). These applications will be explained to the patients or their relatives face-to-face in the clinical environment after the initial evaluation and then sent and followed up by telerehabilitation method and patients will always have access to programs and education. In addition, both groups will be told that they can contact the researcher upon request.
62109506|NCT06009419|ACTIVE_COMPARATOR|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
62109507|NCT02906306|EXPERIMENTAL|Individual Occupational therapy|In Individual Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT).
62109508|NCT02906306|EXPERIMENTAL|Group Occupational therapy|In group Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT) and psychosocial skills training.
62109509|NCT03875248|OTHER|Arm 1. Blood pressure measurement compared to arterial line|Comparative blood pressure measurement with the investigational device and the invasive reference method (arterial line).
62671310|NCT02822287|EXPERIMENTAL|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
62671311|NCT04361045|EXPERIMENTAL|Intervention Condition|Participants in this condition were delivered 8 weeks of online intervention modules and then were invited to complete a posttest survey.
62671312|NCT04361045|NO_INTERVENTION|Waitlist Condition|Participants in this condition received no intervention content nor communications for 8 weeks and then were invited to complete a posttest survey.
62671313|NCT05586360|EXPERIMENTAL|Simvastatin|Patients randomized to the statin group will receive 40 mg oral simvastatin QD for eight weeks prior to prostatectomy, including the day of surgery.
62671314|NCT05586360|NO_INTERVENTION|Control|Patients randomized to the control group receive no intervention prior to prostatectomy.
62671315|NCT01395537|EXPERIMENTAL|Lapatinib With Carboplatin and Paclitaxel|
62671316|NCT02866266||All commercially insured patients in the HIRD|
62671317|NCT02866266||All Medicaid patients in a participating state Medicaid plan|
62735961|NCT05066750|EXPERIMENTAL|Mindful breathing video|Participants watch a 10 minute mindful breathing video
62109510|NCT03875248|OTHER|Arm 2. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in hypertensive patients with the investigational device and the non-invasive reference method (manual cuff).
62109511|NCT03875248|OTHER|Arm 3. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in pregnant women with the investigational device and the non-invasive reference method (manual cuff).
62109512|NCT03100162|PLACEBO_COMPARATOR|Placebo|Individuals receive a placebo daily, for 3 months.
62300247|NCT01640847|EXPERIMENTAL|Arm NRT: HIFU plus ThermoDox|Subjects have no yet received any radiation to the index lesion.
61915222|NCT02483533|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
62671318|NCT05372900|EXPERIMENTAL|Test - Control product|Subject will start with consuming the test product daily for total 14 days (during intervention 1 period). After the 4 - 6 weeks wash out, subject will then consume the control product daily for total 14 days (during intervention period 2).
62300248|NCT04752280|EXPERIMENTAL|Arm A: Proton irradiation|Irradiation applied with protons
61915223|NCT01891045|NO_INTERVENTION|Control|Patients merely monitored on background variables to function as a baseline of comparison
61915224|NCT01891045|ACTIVE_COMPARATOR|Prediction|Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
62300249|NCT04752280|ACTIVE_COMPARATOR|Arm B: Photon IMRT|Photon irradiation applied as intensity-modulated radiotherapy
62300250|NCT00525252|PLACEBO_COMPARATOR|2|A total of 42 alcoholic patients with liver cirrhosis treated with placebo
62300251|NCT00525252|ACTIVE_COMPARATOR|1|a total of 42 alcoholic patients with liver cirrhosis treated by baclofen
62109513|NCT03100162|ACTIVE_COMPARATOR|Probiotic 2g|Individuals receive 2 g of probiotic daily, for 3 months.
62109514|NCT03100162|ACTIVE_COMPARATOR|Probiotic 4g|Individuals receive 4 g of probiotic daily, for 3 months.
62109515|NCT02770040|ACTIVE_COMPARATOR|Intensified Infliximab Induction|Infliximab 10mg/kg at Week 0 and Week 1
62109516|NCT02770040|ACTIVE_COMPARATOR|Accelerated Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 1 and Week 3
62300252|NCT03711383|PLACEBO_COMPARATOR|Placebo|isocaloric maltodextrin the day before CIDs
62300253|NCT03711383|ACTIVE_COMPARATOR|Inulin|12 g of inulin + isocaloric maltodextrin the day before CID
62300254|NCT03711383|EXPERIMENTAL|Inulin and Resistant Starch|12 g inulin + 7.5 g resistant starch the day before CID
62671319|NCT05372900|EXPERIMENTAL|Control - Test product|Subject will start with consuming the control product daily for total 14 days (during intervention 1 period). After the 4 - 6 weeks wash out, subject will then consume the test product daily for total 14 days (during intervention period 2).
62735962|NCT05066750|ACTIVE_COMPARATOR|Control video|Participants watch a 10 minute control video
61915225|NCT01891045|EXPERIMENTAL|Intervention|Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
62109517|NCT02770040|ACTIVE_COMPARATOR|Standard Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 2 and Week 6
61915226|NCT05883826|EXPERIMENTAL|PLISSIT Group|Nursing students in this group will be given sexual health training. The training will last for 4 weeks. The training is 16 hours in total. During the training, students will learn the PLISSIT model and evaluate cases involving using this model. Questionnaire will be applied before the training, immediately after the training and 3 months after the training.
62109518|NCT06502769|EXPERIMENTAL|TE+PNE group|patients with TMD who are going to combine therapeutic exercise with education in pain neurophysiology
62109519|NCT06502769|OTHER|TE group|patients with TMD who are going to perform isolated therapeutic exercise
62109520|NCT02390557|NO_INTERVENTION|Control - Standard Practice|Standard measures of quality at baseline. No intervention reports sent to providers
62109521|NCT02390557|EXPERIMENTAL|Survey|Persons with Disabilities Quality Survey.PDQS Survey Reports Intervention.reports sent to providers of OneCare enrollees
62109522|NCT02390557|EXPERIMENTAL|YESHealth|Arm 3: YESHealth Reports and PDQS Survey Reports sent to providers of OneCare enrollees
62109523|NCT02333630|EXPERIMENTAL|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
62109524|NCT02333630|ACTIVE_COMPARATOR|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
62109525|NCT02308358||Allograft Transplantation|Subjects with femoral condyle osteochondral defects ≥10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for allograft transplantation.
62300255|NCT03247400|ACTIVE_COMPARATOR|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
62300256|NCT03247400|ACTIVE_COMPARATOR|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
62300257|NCT03247400|PLACEBO_COMPARATOR|Vehicle ointment|Placebo ointment applied onto limbs opposite to treated with active substances
62300258|NCT00469937|EXPERIMENTAL|Therapeutic Intervention|
62300259|NCT03615092|ACTIVE_COMPARATOR|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
62300260|NCT03615092|PLACEBO_COMPARATOR|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
62300261|NCT04372264|EXPERIMENTAL|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
62300262|NCT04372264|EXPERIMENTAL|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
62109526|NCT02308358||Microfracture Treatment|Subjects with femoral condyle osteochondral defects \<10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for microfracture treatment.
62109527|NCT00329732|ACTIVE_COMPARATOR|Lidocaine/Bupivicaine|
62109528|NCT00329732|PLACEBO_COMPARATOR|saline|matching volume of saline injected
62109529|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
62109530|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
62109531|NCT02586454|EXPERIMENTAL|Transmuscular quadratus lumborum (QL) block|Bilateral QL block using 20 ml 0.375% ropivacaine in each side (to a maximum dose 3 mg/kg) plus patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
62109532|NCT02586454|ACTIVE_COMPARATOR|Control|Patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
62109533|NCT01608971||Weight based protamine group|In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)
62109534|NCT01608971||Heparin level based protamine group|In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.
62109535|NCT00423007|EXPERIMENTAL|Bromfenac|Ophthalmic Solution
62109536|NCT00423007|PLACEBO_COMPARATOR|Placebo|Vehicle ophthalmic solution
61915227|NCT05883826|NO_INTERVENTION|Control group|Nursing students in this group will not be subjected to any application and will continue their routine nursing lessons. The questionnaire will be administered to the control group before the training given to the experimental group, immediately after the training and 3 months after the training.
62109537|NCT03955640|EXPERIMENTAL|Treatment (olaparib, hyperthermia)|Patients receive olaparib PO BID. Treatment continues for 4 weeks in the absence of disease progression and unacceptable toxicity. Beginning week 2, patients also undergo hyperthermia treatment over 1 hour twice weekly for 3 weeks in the absence of disease progression and unacceptable toxicity.
62109538|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
62300263|NCT04372264|EXPERIMENTAL|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
61915228|NCT00162955|EXPERIMENTAL|ARB administration|80mg/day from the day of the start of 1st CHOP until the completion of all the evaluations
61915229|NCT00162955|NO_INTERVENTION|non-administration|ARB non-administration group
61915230|NCT00777218|ACTIVE_COMPARATOR|1|
61915231|NCT00777218|ACTIVE_COMPARATOR|2|
61915232|NCT00777218|ACTIVE_COMPARATOR|3|
62109539|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
62109540|NCT02364518|EXPERIMENTAL|Snoreplasty|Treatment of Snoring and/or mild obstructive sleep apnea with snoreplasty.
62109541|NCT01322919|EXPERIMENTAL|Myopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a myopic condition of the eye in conjunction with a presbyopic condition
62109542|NCT01322919|EXPERIMENTAL|Hyperopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a hyperopic condition of the eye in conjunction with a presbyopic condition
62300264|NCT02655484|OTHER|COPD patients|Oxygen was delivered to the face mask by a tube at a constant rate (5L/min) to keep the fingertip oxygen saturation at 90% or above. Ventilatory assistance was delivered using a BiPAP® Vision® ventilator (Respironics, Murrysville, Pennsylvania, USA) in BiPAP mode applied via a tightly fitting full face mask (Curative, Suzhou, China). A symptom-limited cycle exercise test was performed while assisted by non-invasive ventilation (NIV). All measurements were recorded at inspiratory pressure of 14 cmH2O, expiratory pressure of 4 cmH2O during rest and exercise. Breathing pattern, mean exhalation flow, mean plateau exhalation valve flow, the mean inspiratory fraction of CO2 (tidal FiCO2) reinsufflated from the circuit between the mask and the exhalation valve was measured for each breath.
62300265|NCT04551443|PLACEBO_COMPARATOR|Placebo PBS|Standard therapy+Intravenous infusion PBS in patients with AMI
62671320|NCT00964678|EXPERIMENTAL|carvedilol|Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI
62109543|NCT04097626|EXPERIMENTAL|experimental|This group will receive nutrition education during the first week of the study. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
62300266|NCT04551443|ACTIVE_COMPARATOR|WJMScs|Standard therapy+Intravenous infusion WJMSCs in patients with AMI
62300267|NCT01000103|ACTIVE_COMPARATOR|1: Real rTMS treatment|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
62300268|NCT01000103|SHAM_COMPARATOR|2: Sham rTMS treatment|Simulation of rTMS
62109544|NCT04097626|ACTIVE_COMPARATOR|control|This group will receive no nutrition education. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
62109545|NCT02642419|EXPERIMENTAL|Rivaroxaban|
62300269|NCT04403867||Endometrial cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
62300270|NCT04403867||Cervical cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
62300271|NCT01478555|EXPERIMENTAL|Dose 1 of Bromfenac in DuraSite|
62300272|NCT01478555|EXPERIMENTAL|Dose 2 of Bromfenac in DuraSite|
62671321|NCT04695626||Greenhouse Group|The patients in this group will be underwent Greenhouse tec to repair tendon tears.
62300273|NCT01478555|EXPERIMENTAL|Dose 3 of Bromfenac in DuraSite|
62300274|NCT01478555|ACTIVE_COMPARATOR|DuraSite|
62300275|NCT01478555|ACTIVE_COMPARATOR|Vehicle|
62300276|NCT03607370|NO_INTERVENTION|Group 1|The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy
62300277|NCT03607370|EXPERIMENTAL|Group 2|The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy
62300278|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
62671322|NCT04695626||Traditional Single Row Group|The patients in this group will be underwent traditional single row repair to repair tendon tears.
62671323|NCT05144282||premature baby without ROP (Group 1)|ROP: retinopathy of prematurity
61915233|NCT02734901|ACTIVE_COMPARATOR|400 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
61915234|NCT02734901|ACTIVE_COMPARATOR|200 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
62109546|NCT02642419|EXPERIMENTAL|Rivaroxaban and single antiplatelet drug|
62109547|NCT02685280|EXPERIMENTAL|DBS for psychiatric disorders patients|Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention
62109548|NCT06103240|ACTIVE_COMPARATOR|Probiotic group|Bacterial count：100 billion CFUs Take one sachet per day for 4 weeks.
62109549|NCT06103240|PLACEBO_COMPARATOR|Placebo group|maltodextrin
62109550|NCT02156635|EXPERIMENTAL|Active tdcs / CIMT|Participants in the acute post-stroke stage will receive active tDCS associate to rehabilitation (CIMT)
62300279|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
62300280|NCT05220150|EXPERIMENTAL|Alzheimer's patients|Patient diagnosed with early onset Alzheimer's disease.
62300281|NCT05220150|ACTIVE_COMPARATOR|Control|Healthy volunteers that do not have Alzheimer's disease.
62671324|NCT05144282||ROP without treatment (Group 2)|ROP: retinopathy of prematurity
62671325|NCT05144282||ROP with anti-VEGF treatment (Group 3)|ROP: retinopathy of prematurity
62671326|NCT05144282||ROP with laser photocoagulation treatment (Group 4)|ROP: retinopathy of prematurity
62671327|NCT03422718|EXPERIMENTAL|Arm 1|No healthy behavior texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
62671328|NCT03422718|EXPERIMENTAL|Arm 2|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
62671329|NCT03422718|EXPERIMENTAL|Arm 3|No healthy behavior texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
62671330|NCT03422718|EXPERIMENTAL|Arm 4|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
62671331|NCT03422718|EXPERIMENTAL|Arm 5|No healthy behavior texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
62109551|NCT02156635|SHAM_COMPARATOR|Sham stimulation / CIMT|Participants in the acute post-stroke stage will receive sham stimulation associate to rehabilitation (CIMT)
62109552|NCT04409210|EXPERIMENTAL|Intervention Group|The intervention group will receive establishment of individual health records, cardiovascular risk assessment, popularization of medical knowledge, personalized reminders and routine treatment.
62300282|NCT06286722|EXPERIMENTAL|Progressive, individualized and structured exercise program|"Individualized, progressive, structured exercise program. Participants will receive 12-weeks of either home-based and/or at a healthcare center intervention.~The at home intervention will consist of 3 visits/sessions per week (approximately 30-60 min.) for 12 weeks (maximum of 36 sessions in total) delivered in the participants own home, temporary home (e.g. 24- hour rehabilitation facility), nursing home or assisted living facilities.~The at a healthcare center intervention will be suggested to the participant when the physiotherapist and the participant feel confident that the participant can handle the transportation to/from the healthcare center, and will benefit from the higher intensity of the at a healthcare center intervention. This intervention consists of 2 visits/sessions per week (approximately 45-60 min.) for 12 weeks (total maximum of 24 sessions)."
62109553|NCT04409210|OTHER|Control Group|The control group just receive routine treatment and routine management.
62300283|NCT03034941|ACTIVE_COMPARATOR|metformin group|Drug: metformin
62300284|NCT03034941|ACTIVE_COMPARATOR|COMBI group|Drug: liraglutide + metformin
62300285|NCT03034941|NO_INTERVENTION|CONTROL group|control group of obese PCOS patients without therapy
62671332|NCT03422718|EXPERIMENTAL|Arm 6|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
62671333|NCT03422718|EXPERIMENTAL|Arm 7|No healthy behavior texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
62671334|NCT03422718|EXPERIMENTAL|Arm 8|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
62300286|NCT06655077|NO_INTERVENTION|Control phase|Any patient visits that occur before the time at which clinicians are granted access to the RA PRO dashboard will be part of the control phase (usual care).
62300287|NCT06655077|EXPERIMENTAL|Intervention phase|"Any patient visits that occur after the time at which clinicians are granted access to the RA PRO dashboard will be part of the intervention phase. The RA PRO dashboard will automatically launch into a new tab when the EHR is opened for any RA patient with at least 1 CDAI documented."
62300288|NCT06487949|EXPERIMENTAL|valsartan- Amlodipine fix dose combination pill|Patients with hypertension eligible receiving valsartan- Amlodipine 80/5 mg fix dose combination (FDC) pill
62671335|NCT03148639|EXPERIMENTAL|Avatar therapy|Immediate Avatar therapy.
62671336|NCT03148639|OTHER|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
62671337|NCT02285972|PLACEBO_COMPARATOR|saline|
62671338|NCT02285972|ACTIVE_COMPARATOR|dexketoprofen|
62671339|NCT02285972|ACTIVE_COMPARATOR|tenoxicam|
62109554|NCT04800302|EXPERIMENTAL|Continuous QLB group|U/S-guided continous QLB III
62109555|NCT04800302|ACTIVE_COMPARATOR|Single dose QLB group|U/S-guided single dose QLB III
62109556|NCT04800302|ACTIVE_COMPARATOR|Morphine group|IV Morphine
62109557|NCT04831684|PLACEBO_COMPARATOR|Group A|
62109558|NCT04831684|EXPERIMENTAL|Group B|
62109559|NCT02242929|ACTIVE_COMPARATOR|Standard surgical excision|"Standard surgical elliptical excision including a 3-mm clinically tumour-free margin according to the current local hospital arrangements."
62300289|NCT06487949|ACTIVE_COMPARATOR|Valsartan- Amlodipine free dose combination|Patients with hypertension eligible receiving valsartan 80 mg and amlodipine 5 mg as free dose of drugs separately
62300290|NCT06587256|EXPERIMENTAL|Simple snorers or Mild Sleep Apnea|Patients with snoring and a prior sleep study showing an AHI \< 15.
62300291|NCT05781048|EXPERIMENTAL|HRS-6209|
62300292|NCT01564979|EXPERIMENTAL|preseptal|
62300293|NCT01564979|EXPERIMENTAL|pretarsal|
62300294|NCT00872066|ACTIVE_COMPARATOR|1) SmartSet® HV Bone Cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
62300295|NCT00872066|ACTIVE_COMPARATOR|2) SmartSet® GHV Bone Cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
62671340|NCT03750227|ACTIVE_COMPARATOR|Arm A (Post-operative SRS)|Patients undergo surgery on day 1. Within 2 weeks, patients undergo stereotactic radiosurgery.
62671341|NCT03750227|EXPERIMENTAL|Arm B (Pre-operative SRS)|Patients undergo stereotactic radiosurgery on day 1. Within 4 weeks, patients undergo surgery.
62671342|NCT01889563|EXPERIMENTAL|Physical exercise training program|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
62671343|NCT01889563|NO_INTERVENTION|No Physical Exercise Training Program|No Physical Exercise Training Program
62671344|NCT04311580|EXPERIMENTAL|urothelial high risk non-muscle invasive bladder cancer|patients with urothelial high risk non-muscle invasive bladder cancer after failed intravesical bacillus Calmette-Guérin treatment.
62671345|NCT04106765||: epileptic LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom~Evaluated items:~* Number of seizures~* Type of seizures~* Presence of EEG abnormalities~* Presence of IRM abnormalities~* Time before cognitive disorders"
62671346|NCT04106765||cognitive LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom~Evaluated items:~* Presence of EEG abnormalities~* Presence of IRM abnormalities~* Time before epileptic seizures"
62671347|NCT05045599|EXPERIMENTAL|Integration of Family planning in Maternal, Newborn and Child Health|Strengthening of capacity of LHWs and Health care provider in providing integrated services Ensure Sustained supplies are available Community Mobilization Infrastructure support to ensure privacy and confidentiality Improvement of data recording, reporting and use
62671348|NCT05045599|ACTIVE_COMPARATOR|Standard of care|
62671349|NCT02170012|EXPERIMENTAL|Cohort 1-PF-06743649 or placebo|
62671350|NCT02170012|EXPERIMENTAL|Cohort 2-PF-06743649 or placebo|
62671351|NCT02170012|EXPERIMENTAL|Cohort 3-PF-06743649 or placebo|
62300296|NCT03717922|EXPERIMENTAL|Amygdala first, then Entorhinal Cortex|Low Intensity focused ultrasound pulsation (LIFUP) will be administered to the amygdala while participants are in the MRI scanner. Then, 2 weeks later, entorhinal cortex LIFUP will be administered.
62300297|NCT03717922|EXPERIMENTAL|Entorhinal Cortex first, then Amygdala|Low Intensity focused ultrasound pulsation (LIFUP) will be administered to the entorhinal cortex while participants are in the MRI scanner. Then, 2 weeks later, amygdala LIFUP will be administered.
62671352|NCT02170012|EXPERIMENTAL|Cohort 4-PF-06743649 or placebo|
62671353|NCT02170012|EXPERIMENTAL|Cohort 5-PF-06743649 or placebo|
62671354|NCT01111370|EXPERIMENTAL|CGM|continuous glucose monitoring system
61915235|NCT02734901|PLACEBO_COMPARATOR|Placebo control|Raspberry deprived supplement Acute intake of 600 mL (1x daily)
62109560|NCT02242929|EXPERIMENTAL|Imiquimod 5% cream with prior curettage|Tumours will be partially debulked under local anaesthesia by removing all tumour tissue until normal dermis remains with a blunt curette. After curettage patients will receive an instruction sheet to apply imiquimod 5% cream once daily, 5 days a week, during 6 weeks, starting one week after the curettage procedure. Patients will be instructed to apply a thin layer to the tumour including 5-10mm of the surrounding skin at least 1 hour before going to bed at night. The lesion will not be covered (unless needed because of weeping or bleeding). Participants will be asked to wash their hands after applying the cream, and to wipe the cream off after 8 hours (in the morning).
62109561|NCT01362491|EXPERIMENTAL|Treatment A|
62300298|NCT04746040|EXPERIMENTAL|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
62300299|NCT04746040|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS 250/50
62300300|NCT03615222||SERVE assessment only|Eligible veterans will complete 4 assessments over a two year period of time.
61915236|NCT04340427|EXPERIMENTAL|TQB3455 Tablets|TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
61915237|NCT05353803|EXPERIMENTAL|People older than 60 years with heart failure and living at home.|People older than 60 years with heart failure and living at home.
62109562|NCT01362491|ACTIVE_COMPARATOR|Treatment B|
62109563|NCT01362491|PLACEBO_COMPARATOR|Treatment C|
62109564|NCT05043987|EXPERIMENTAL|Part A|"Part A will follow the standard 3+3 dose-escalation design and will be enrolled at dose levels of CPO102 at (0.5, 1, 1.8, 2.5, 3.5, 4.5, 5.5 mg/kg).~Each subject group will receive one dose of CPO-102 every 3 weeks (1 cycle=21 days=1 treatment). For each cohort, the decision whether to dose-escalate will be made once all patients have been enrolled into the cohort and the last patient enrolled has been followed for 21 days (3-week DLT observation period)."
62300301|NCT02186392|NO_INTERVENTION|Control department|The control department where the conventional light is installed.
62671355|NCT03941886|NO_INTERVENTION|Non-intervention group|Participants receive routine prenatal care
62671356|NCT03941886|EXPERIMENTAL|Intervention group|Participants receive first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis in high-risk women.
62671357|NCT04322695|EXPERIMENTAL|Rehabilitation Education Care Program (RECP)|Cancer rehabilitation program and patients education can improve disability and promote return to work.
61915238|NCT00706849|EXPERIMENTAL|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
61915239|NCT00706849|PLACEBO_COMPARATOR|Placebo|Participants received a placebo subcutaneous injection once a week for 26 weeks.
61915240|NCT00740051|EXPERIMENTAL|Linagliptin|52 week treatment
62671358|NCT04322695|OTHER|Usual care|Usual care
62671359|NCT02082483|EXPERIMENTAL|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
62671360|NCT02082483|NO_INTERVENTION|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
61915241|NCT00740051|PLACEBO_COMPARATOR|Placebo|First 18 weeks of treatment
62671361|NCT00652613|ACTIVE_COMPARATOR|1|3 dimensional conformal radiotherapy
62671362|NCT00652613|EXPERIMENTAL|2|Intensity Modulated Radiation Therapy (IMRT)
62671363|NCT01164969||H. pylori eradication failure|People who are not able to eradicate H. pylori although the appropriate antibiotic therapy taken.
62671364|NCT03880409|ACTIVE_COMPARATOR|2% lidocaine with 1:000,000 epinephrine|supplemental intraseptal injections using 0.8 mL 2% lidocaine with 1:000,000 epinephrine
62671365|NCT03880409|ACTIVE_COMPARATOR|4% articaine with 1:000,000 epinephrine|buccal infiltration of 1.8 ml 4% articaine with 1:000,000 epinephrine
62735963|NCT02173483|OTHER|Quadriceps graft|Proximally from patella the Quadriceps graft is harvested and used as a knew anterior cruciate ligament after rupture.
61915242|NCT00740051|ACTIVE_COMPARATOR|Glimepiride|Placebo patients switch to glimepiride week19-52
62109565|NCT05043987|EXPERIMENTAL|Part B-Arm 1|Upon attaining a RP2D, Part B-Arm 1 will include approximately 15 patients with pancreatic cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
62109566|NCT05043987|EXPERIMENTAL|Part B-Arm 2|Upon attaining a RP2D, Part B-Arm 2 will include approximately 15 gastric (including gastric esophageal junction) cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
62109567|NCT00846313|ACTIVE_COMPARATOR|Dietary counseling|Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary.
62109568|NCT00846313|NO_INTERVENTION|Control|
62109569|NCT03635112|ACTIVE_COMPARATOR|Active Treatment TD-1473 with Dose A|"1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
61915243|NCT03705273|EXPERIMENTAL|Dexamethasone IV for PO|Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
62300302|NCT02186392|EXPERIMENTAL|Circadian Light luminaries|The department where the special circadian light is installed. The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
62109570|NCT03635112|ACTIVE_COMPARATOR|Active Treatment TD-1473 with Dose B|"1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks."
62109571|NCT03635112|PLACEBO_COMPARATOR|Placebo|"1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
62109572|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
62671366|NCT05039385|EXPERIMENTAL|ESATRAL Group|They will perform the supervised physical exercise program. The supervised exercise program (ESATRAL) will last 24 weeks with 2-3 non-consecutive weekly sessions. The duration of each session will be 30 minutes and will progressively increase depending on the phase in which we are until reaching 60 minutes.
62109573|NCT01306331|ACTIVE_COMPARATOR|Conceptrol|100 mg (4% concentration) of nonoxynol-9 in 2.5 mL volume of gel
62109574|NCT01306331|EXPERIMENTAL|Amphora|Citric acid USP, potassium bitartrate USP, and L-lactic acid USP
62671367|NCT05039385|NO_INTERVENTION|Control Group|They will follow their daily treatment without added exercise
62671368|NCT01529151|ACTIVE_COMPARATOR|OMT Group|Participants will receive Osteopathic Manipulative Treatment (OMT) with the objective of treating diagnosed somatic dysfunction and this will entail the use of specific indirect and direct techniques, including soft tissue, inhibitory, myofascial release, articulatory and high-velocity / low-amplitude (HVLA) techniques.
62671369|NCT01529151|ACTIVE_COMPARATOR|VRT Group|Participants will receive Vestibular Rehabilitation Therapy (VRT), which includes balance exercises in sitting and standing positions that include gaze stabilization, kinesthetic and proprioceptive retraining.
62671370|NCT01529151|ACTIVE_COMPARATOR|OMT - VRT Group|Participants will receive both Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT).
61915244|NCT03705273|ACTIVE_COMPARATOR|Dexamethasone crushed tablets|Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally
62671371|NCT01529151|NO_INTERVENTION|Control Group|
62671372|NCT04992741|EXPERIMENTAL|Experimental|Health Belief Model Based Motivational Interview Group The application will be made by the researcher who has been trained in motivational interviewing techniques. Motivational interviews based on Health Belief Model will be made by telephone to mothers who have daughters studying in high school. There will be 3 interviews with mothers based on the benefits, barriers, sensitivity and severity perception structures of the Health Belief Model regarding HPV infection and vaccination, and each interview will last 15-20 minutes. One week after each interview, the questionnaire/scale forms will be sent via whatsapp and applied.
62671373|NCT04992741|NO_INTERVENTION|other|The control group will remain subject to the routine process without any intervention.
62671374|NCT00302666|SHAM_COMPARATOR|Arm 1|
62109575|NCT01496209|SHAM_COMPARATOR|Placebo control|
62109576|NCT01496209|EXPERIMENTAL|Group: Cardiosphere Treatment|Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)
62109577|NCT06003608||Healthy control (HC)|25 neurotypical controls, age-matched to the Parkinson's disease group
62109578|NCT06003608||Parkinson's disease (PD)|75 Parkinson's disease patients
62109579|NCT04837313|EXPERIMENTAL|Parkinson's Disease with Constipation|Fecal microbiota transplantation will be performed.
62109580|NCT02347163|EXPERIMENTAL|Zoledronate|Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery
62109581|NCT04386733||Cancelled|all adult patients whose surgery was cancelled on the day of the planned procedure
62109582|NCT04386733||Non-cancelled|all adult patients whose surgery was not cancelled on the day of the planned procedure
62671375|NCT00302666|SHAM_COMPARATOR|Arm 2|
61915245|NCT02173028||Optimal beta blocker titration|We will compare the efficacy of two management strategies for beta-blocker up-titration: Standard in-office visits vs. Remote follow-up.
61915246|NCT02173028||Without optimal titration of beta blocker|This analysis will be conducted within the Cardiac Resynchronization Therapy observational study Modular Registry (CRT MORE - ClinicalTrials.gov Identifier: NCT01573091).
61915247|NCT02651181|EXPERIMENTAL|Closed Loop System|
62671376|NCT03818932|EXPERIMENTAL|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
62671377|NCT03818932|ACTIVE_COMPARATOR|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
62671378|NCT06106373|EXPERIMENTAL|Pediatric Cochlear Implant Recipient|Pediatric subjects receiving a cochlear implant between the ages of 9 months and under 12 years of age.
62300303|NCT00384956|EXPERIMENTAL|Azacitidine|Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
62300304|NCT01879020|EXPERIMENTAL|TA-8995 1 mg|
62300305|NCT01879020|EXPERIMENTAL|TA-8995 2.5 mg|
62300306|NCT01879020|EXPERIMENTAL|TA-8995 5 mg|
62300307|NCT01879020|EXPERIMENTAL|TA-8995 10 mg|
62300308|NCT01879020|EXPERIMENTAL|TA-8995 25 mg|
62300309|NCT01879020|PLACEBO_COMPARATOR|Placebo (TA-8995 1mg)|
62300310|NCT01879020|PLACEBO_COMPARATOR|Placebo (TA-8995 2.5mg)|
62300311|NCT01879020|PLACEBO_COMPARATOR|Placebo (TA-8995 5mg)|
62671379|NCT01935505||Consulting group|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
62671380|NCT01935505||Drug intervention group|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
62300312|NCT01879020|PLACEBO_COMPARATOR|Placebo (TA-8995 10mg)|
62300313|NCT01879020|PLACEBO_COMPARATOR|Placebo (TA-8995 25mg)|
62300314|NCT01662089|EXPERIMENTAL|Chelate zinc suppliment|15mg Chelate zinc suppliment : additional to standard 5% minoxidil
62300315|NCT01662089|PLACEBO_COMPARATOR|Placebo drug|Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil
62300316|NCT04907851|EXPERIMENTAL|Module 1 - RNF43 Mutated Advanced (unresectable)/Metastatic Pancreatic Cancer (Stage III/IV)|Patients (Karnofsky performance status ≥70) will be recruited and dosed with RXC004 (2 mg once daily \[QD\], orally) within 6 weeks of progression following 1st line SoC treatment.
62300317|NCT04907851|EXPERIMENTAL|Module 2 -Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage III/IV)|Patients (Eastern Cooperative Oncology Group \[ECOG\] performance status 0-1) will be recruited and dosed with RXC004 within 6 weeks of progression, following 1st line SoC treatment.
62300318|NCT04907851|EXPERIMENTAL|Module 3-Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage Ill/IV) Combination Therapy|Patients (ECOG performance status 0-1) will be recruited and dosed with RXC004 (1.5 mg QD, orally) in combination with pembrolizumab 400 mg IV infusion every 6 weeks (q6w) within 6 weeks of progression, following 1st line Soc treatment.
62300319|NCT03347214||1|People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study
62300320|NCT05659732|EXPERIMENTAL|PEP07 Monotherapy (Arm A)|"The dose finding of PEP07 monotherapy consists of an accelerated dose escalation followed by a standard 3+3 dose escalation. Accelerated titration will continue until 1 patient experiences a DLT, or ≥ grade 2 AE related to PEP07 (except for hematologic toxicities) at any dose level, after which, additional 2 patients will be enrolled in the same cohort, and the study will be switched to a 3+3 scheme.~Expansion cohorts with 12 patients will be opened for Arm A at the RP2D once efficacy signal is observed at this level."
62300321|NCT02037126|EXPERIMENTAL|Psilocybin administration|Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
62300322|NCT02037126|ACTIVE_COMPARATOR|Diphenhydramine administration|Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.
62300323|NCT03728244|EXPERIMENTAL|test group Hyaluronic acid|Patients scheduled for free gingival graft harvesting will receive Hyaluronic acid gel 0.2%
62300324|NCT03728244|EXPERIMENTAL|test group MEBO ointment|Patients scheduled for free gingival graft harvesting will receive MEBO ointment
62671381|NCT01935505||Telephone intervention group|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
62671382|NCT01935505||Consulting+Telephone+Drug intervention|All the interventions above are include in this group
62671383|NCT02665455|EXPERIMENTAL|Intervention|FreeStyle Libre Flash Glucose Monitoring System
62671384|NCT04320082||Elderly cohort|Patients \>70 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
62300325|NCT03728244|NO_INTERVENTION|negative control group|Patients scheduled for free gingival graft harvesting
62300326|NCT03808961|ACTIVE_COMPARATOR|Group 1 ? Niacin Arm|Oral 100 mg fixed dose twice daily x 18-months (200 mg total / day) with assessments @ baseline, 6 month, 12 month and 18 months
62300327|NCT03808961|ACTIVE_COMPARATOR|Group 2 ? Niacinamide Arm|Oral 100 mg fixed dose twice daily (200 mg total / day) x 18-months with assessments @ baseline, 6 month, 12 month and 18 months
62671385|NCT04320082||Young cohort|Patients between 18 and 30 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
62671386|NCT04228653|EXPERIMENTAL|No Arm|As this is the follow up study, there are no arms
62671387|NCT02072993|EXPERIMENTAL|AZD1979|Single ascending doses of oral solution AZD1979
62671388|NCT02072993|PLACEBO_COMPARATOR|Placebo|Placebo to match single ascending doses of oral solution AZD1979
62300328|NCT03808961|PLACEBO_COMPARATOR|Group 3 ? Placebo Wait-listed Arm|Oral placebo twice daily x 18- months with assessments @ baseline, 6 month, 12 month and 18 months
62300329|NCT04342065|ACTIVE_COMPARATOR|Group (G)|received gabapentin 300 mg capsule 2 hours preoperative and the same dose 6 hours postoperative.
62300330|NCT04342065|ACTIVE_COMPARATOR|Group (C)|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
62671389|NCT06114966|EXPERIMENTAL|titanium framework manufactured by dry milling technique|All patients will have titanium framework manufactured by dry milling technique and occlusal material made from PMMA FPD
62300331|NCT02397252|EXPERIMENTAL|Eve Medical self-collection system©|Device: Self-sampling swab from Eve Medical for collection of vaginal cells.
62300332|NCT02397252|PLACEBO_COMPARATOR|cobas® PCR Female swab self-sampling|Device: Regular polyester swab for collection of vaginal cells.
62300333|NCT02397252|PLACEBO_COMPARATOR|Physician-collected sampling|Routine colposcopy sample collected by a physician.
62671390|NCT06114966|EXPERIMENTAL|metal framework manufactured by dry milling/post sintering of Co-Cr soft metal blocks|All patients will have metal framework manufactured by dry milling/post sintering of Co-Cr soft metal blocks and occlusal material made from PMMA FPD
62671391|NCT00855582|EXPERIMENTAL|Tadalafil 2.5 mg|
62671392|NCT00855582|EXPERIMENTAL|Tadalafil 5 mg|
62671393|NCT00855582|PLACEBO_COMPARATOR|Placebo|
62671394|NCT02346370|EXPERIMENTAL|PEGPH20 + Docetaxel|PEGylated recombinant human hyaluronidase PH20 (PEGPH20) (1.6, 3.0, or 2.2 micrograms per kilogram (ug/kg)) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m\^2)) was administered on Day 2 of each 21-day cycle.
62671395|NCT01330524|ACTIVE_COMPARATOR|Avastin and Triamcinolone|
62671396|NCT01330524|PLACEBO_COMPARATOR|Placebo|
62671397|NCT01903200|EXPERIMENTAL|FK949E Fed Group|FK949E is administered after breakfast
62300334|NCT02534649|OTHER|Experimental|Newly obtained biopsy and Blood samples collection
62300335|NCT04265612|EXPERIMENTAL|Negative Pressure dressing|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
62300336|NCT04265612|ACTIVE_COMPARATOR|Aquacel hydrogel dressing|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
62300337|NCT05233995|EXPERIMENTAL|Intervention group|The patients included in the experimental group will be operated on, performing the resection of the intestinal segment affected by the dehiscence, the sectioned intestinal ends will be left without anastomosis, and open abdomen therapy will be established. After surgery, the patient will be cared for in the intensive care unit where intensive resuscitation will be carried out in order to improve the general conditions of the patient. After 48 ± 24 hours, a second surgical procedure will be performed where local conditions will be evaluated and the possibility of performing a delayed anastomosis will be evaluated.
62300338|NCT05233995|ACTIVE_COMPARATOR|Control group|The patients included in the control group will be operated on with a resection of the affected intestinal segment and a stoma with or without associated mucosal fistula will be performed at the same surgical time. After the procedure, the patient will be cared for in the intensive care unit in order to improve the general conditions of the patient.
62671398|NCT01903200|EXPERIMENTAL|FK949E Fasted Group|FK949E is administered in the morning under fasting conditions
62671399|NCT04607447|ACTIVE_COMPARATOR|Atorvastatin plus Dexamethasone tablets|
62671400|NCT04607447|EXPERIMENTAL|drugs+low intracranial pressure strategy treatment|Drugs means treatment with Atorvastatin plus Dexamethasone tablets
62671401|NCT05099276|EXPERIMENTAL|Oral TXA|1,950 mg oral tranexmic acid (three capsules of 650 mg) administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
62671402|NCT05099276|PLACEBO_COMPARATOR|Oral placebo|Three capsules of cellulose administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
62671403|NCT02054195|EXPERIMENTAL|IUD new technique|Training
62671404|NCT02054195|EXPERIMENTAL|No Training|No Training
62671405|NCT03408145|PLACEBO_COMPARATOR|Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml and 1ml of Saline) comprising a total volume of 8.5ml fluid during one procedure.
62671406|NCT03408145|ACTIVE_COMPARATOR|Hyaluronic Acid & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Saline) comprising a total of 8.5mL fluid during one procedure.
62671407|NCT03408145|ACTIVE_COMPARATOR|Amniotic Tissue & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Saline and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
62671408|NCT03408145|EXPERIMENTAL|Amniotic Tissue & Hyaluronic Acid|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
62671409|NCT05471661|EXPERIMENTAL|Penta-STs|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
62671410|NCT04726488|EXPERIMENTAL|Periareolar Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
62671411|NCT04726488|ACTIVE_COMPARATOR|Inframammary Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
62671412|NCT04718389|EXPERIMENTAL|Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatment|Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active comparator (participant's anti-Interleukin-5/ 5 receptor \[anti-IL-5/5R\] treatment prior to randomization): either placebo matching mepolizumab or placebo matching benralizumab. All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
62671413|NCT04718389|ACTIVE_COMPARATOR|Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab)|Participants will receive active comparator (participant's anti-IL-5/5R treatment prior to randomization): either mepolizumab or benralizumab, plus placebo matching GSK3511294 (Depemokimab). All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
62671414|NCT01133106|EXPERIMENTAL|In-person behavioral intervention|behavioral counseling plus antidepressant treatment prescribed by participant's own provider; consisted of orientation session plus 6 counseling sessions in person with a psychosocial nurse practitioner
62671415|NCT01133106|EXPERIMENTAL|Telephone behavioral intervention|This arm is identical to the in-person Arm except that the intervention is delivered by telephone instead of in-person.
62671416|NCT01133106|ACTIVE_COMPARATOR|Standard care|participants have orientation to the study with the same written materials given those in the experimental arms. Keep a medication log and keep appointments with their own post-stroke provider
62671417|NCT01814332|EXPERIMENTAL|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
62671418|NCT01814332|PLACEBO_COMPARATOR|Placebo|Placebo compound treatment for comparison with IP
62671419|NCT01845415|ACTIVE_COMPARATOR|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
62671420|NCT01845415|NO_INTERVENTION|No treatment Control|two communities receive no intervention
62671421|NCT01845415|ACTIVE_COMPARATOR|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
62671422|NCT06353516|ACTIVE_COMPARATOR|Intravenous Anesthesia|The anesthesia is maintained with intravenous anesthetics
62671423|NCT06353516|SHAM_COMPARATOR|Inhaled Gas Anesthesia|The anesthesia is maintained with inhaled gas anesthetics
62671424|NCT05708222||Self Reported Assessment|This group of patients will self report their answers to the MINI assessment.
62671425|NCT05708222||Clinician Interview Assessment|This group of patients will complete the MINI assessment via an interactive interview conducted by a qualified clinician.
62671426|NCT04071483|EXPERIMENTAL|Moderate stenosis|Moderate cervical neural foraminal stenosis is narrowest width of the neural foramen was \>50% of the width of the width of the extraforaminal nerve root at the level of the anterior margin of the superior articular process.
62671427|NCT04071483|ACTIVE_COMPARATOR|Severe stenosis|Severe cervical neural foraminal stenosis is narrowest width of the neural foramen was ≤50% of the extraforaminal nerve root width
62671428|NCT00552058|EXPERIMENTAL|Certolizumab pegol|Certolizumab pegol 400 mg for subcutaneous (sc) injection
62671429|NCT00552058|PLACEBO_COMPARATOR|Placebo|Placebo, saline solution for sc injection
62671430|NCT04411095|EXPERIMENTAL|Stretching of intrathoracic fascia|A technique will be used to stretch the intrathoracic fascia. The subject lies in his/her back, and a flexion of the upper cervical spine is combined with a retraction movement of the lower cervical and upper thoracic spine, this in combination with inspiration.
62671431|NCT04411095|PLACEBO_COMPARATOR|Test without stretching|A placebo technique is performed by positioning the hands of the therapist on the thorax without pressure or performing a technique. Similar as the stretching technique, a deep inspiration is performed by the patient, for each of the intrathoracic cilinders. This without performing a retraction of the lower cervical and upper thoracic spine.
62735964|NCT02173483|OTHER|Hamstrings Graft|The Hamstrings graft is harvested and used as a knew anterior cruciate ligament after rupture.
62470336|NCT06065150|ACTIVE_COMPARATOR|Standard support|"Initial medical treatment: placement of a nasogastric tube associated with hydration and vascular filling for hypovolaemic patients. Other medical treatments for occlusive small bowel syndrome on adhesion or flange can be performed but are not systematically recommended. Their use is left to the discretion of the surgeon. Medical treatment is carried out over 72 hours from admission.~In case of resumption of a transit by gas and/or stools associated with a tolerance to the food, the exit is authorized without resorting to surgery. In the absence of a resumption of transit by gas and/or stools associated with tolerance to food, semi-urgent surgical management is proposed 72 hours from the start of management. In the event of deterioration of the clinical condition during hospitalization, urgent surgery will be proposed, according to the recommendations for use."
62470337|NCT06065150|EXPERIMENTAL|Early surgery proposed according to the radiological score|Patients included in the experimental arm have treatment adapted to the radiological score. The radiological score described by Berge et al. (Berge et al. Eur J Trauma Emerg Surg 2021) is calculated after patient inclusion.
62470338|NCT05048017|EXPERIMENTAL|Regorafenib plus PD-1 inhibitor|"Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF).~Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma.~Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers.~Pembrolizumab (Keytruda) the programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells."
62671432|NCT06265805|EXPERIMENTAL|the observation group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62109583|NCT04107129||Known Endometriosis|Known Endometriosis undergoing IVF with PGTA
62671433|NCT06265805|ACTIVE_COMPARATOR|the control group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
62671434|NCT04465149|EXPERIMENTAL|Patients|Patients who required germectomy of mandibular third molars. Each patient received local anaesthesia on one side with articaine inoculated with plexus technique while on the other side with mepivacaine using inferior alveolar nerve block technique.
62671435|NCT05172336||Assisted reproductive technology (Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
62671436|NCT05172336||Assisted reproductive technology (Non-Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
62109584|NCT04107129||Unexplained Infertility|Unexplained Infertility undergoing IVF with PGTA
62109585|NCT04107129||Low Risk Controls|Low Risk Controls undergoing IVF with PGTA
62109586|NCT04265703|ACTIVE_COMPARATOR|Internal jugular vein site|Ultrasound-guided central venous catheterization at internal jugular vein site
62109587|NCT04265703|ACTIVE_COMPARATOR|Subclavian vein site|Ultrasound-guided central venous catheterization at subclavian vein site
62671437|NCT05172336||Spontaneous conception (SC)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
62109588|NCT04265703|ACTIVE_COMPARATOR|Innominate vein site|Ultrasound-guided central venous catheterization at innominate vein site
62109589|NCT06631014|EXPERIMENTAL|Early Rehab Group|
62671438|NCT04333654|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine, loading dose on day 1 followed by a daily maintenance dose during 9 days
62109590|NCT06631014|ACTIVE_COMPARATOR|Delayed Rehab Group|
62470339|NCT06097819|EXPERIMENTAL|Mobile app-based game group|The mobile app-based game group will receive the Becure mobile game program in addition to occupational therapy interventions and the sensor-based game application. This program will be implemented for 10 minutes a day, 5 days a week, for a duration of 6 weeks.
62109591|NCT02116829|EXPERIMENTAL|Danish butter, dairy|
62109592|NCT02116829|ACTIVE_COMPARATOR|Olive oil, refined|
62109593|NCT01233154|EXPERIMENTAL|L. paracasei|L. paracasei
62109594|NCT01233154|EXPERIMENTAL|L. acidophilus + B. lactis|L. acidophilus + B. lactis
62109595|NCT04923984|EXPERIMENTAL|Embolization of Middle Meningeal Artery for Subdural Hematoma|All patients with CSDH will undergo embolization of Middle Meningeal artery
62109596|NCT04455009|EXPERIMENTAL|100mg Caffeine Formula|10kcal drink containing a total of 100 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
62109597|NCT04455009|EXPERIMENTAL|140mg Caffeine Formula|10kcal drink containing a total of 140 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
62109598|NCT04455009|PLACEBO_COMPARATOR|Placebo Formula|non-caloric/non-caffeinated drink
62109599|NCT02533908|ACTIVE_COMPARATOR|Fentanyl intranasal|Fentanyl Sintetica 0.1mg/2ml: 1.5ug/kilogram intranasal= 0.03ml/kg once
62671439|NCT04333654|PLACEBO_COMPARATOR|Placebo|Matching placebo
62109600|NCT02533908|PLACEBO_COMPARATOR|NaCl 0.9% intranasal|NaCl 0.9% Sintetica 18mg/2ml: same dosage as fentanyl= 0.03ml/kg
62109601|NCT02814305|NO_INTERVENTION|Control|Patient receives neither educational nor financial interventions
62109602|NCT02814305|EXPERIMENTAL|Financial intervention only|Patient receives financial (pharmacy offer) intervention only
62109603|NCT02814305|EXPERIMENTAL|Educational intervention only|Patient receives educational (narrative) intervention only
62109604|NCT02814305|EXPERIMENTAL|Both interventions|Patient receives both educational and financial interventions
62109605|NCT04603014|EXPERIMENTAL|Interdialytic peritoneal ultrafiltration|Will receive incremental interdialytic peritoneal ultrafiltration with a 10% dextrose solution, twice a week for three consecutive weeks
62671440|NCT02636322|EXPERIMENTAL|RLI WITH EPOCH|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
62671441|NCT02636322|EXPERIMENTAL|RLI WITH R-CHOP|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
62300339|NCT06478953|EXPERIMENTAL|FA Pneumonia Panel Guided Group|Patients in the FA Pneumonia Panel guided group will have a BioFire® FilmArray® Pneumonia Panel assay performed as soon as possible but within 24 hours of new antibiotic prescription for suspected respiratory infection in addition to all the investigations performed in standard care. Based on the rapid test results, antimicrobial therapy will be adjusted according to a pre-determined treatment algorithm and antimicrobial guidelines. The treatment algorithm and antimicrobial guidelines were based on the latest hospital antibiogram, procalcitonin protocol, and consensus recommendations from microbiologists, infectious disease experts and intensive care physicians at our hospital. The treating clinical team will also be given the standard microbiological culture with sensitivity results when available. The treating clinical team may override the pre-determined antimicrobial algorithm for any clinical reason at any time and the rationale will be recorded.
62300340|NCT06478953|NO_INTERVENTION|Standard Care Group|Patients in the standard care group will receive antimicrobial therapy guided by conventional microbiological cultures and standardized procalcitonin protocol. Choice of antimicrobial agent is based on use of the narrowest-spectrum antimicrobial agent possible according to culture sensitivity. Current standard investigations for any patient mechanically ventilated for suspected pneumonia in our ICU includes two sets of blood cultures, daily procalcitonin, respiratory specimen of tracheal aspirate or bronchoalveolar lavage for bacterial gram stain and cultures, respiratory viral PCR and urine streptococcus and legionella antigen. FA Pneumonia Panel will be performed from concurrent respiratory samples in the standard care group at the end of the study and the results will not be used by the treating clinical team for treatment decisions. Blinded results will only be available to the antimicrobial review panel for outcome assessment.
62300341|NCT06640114|NO_INTERVENTION|Baseline therapy|Patients who received only standard therapy according to the underlying disease (topical therapy, systemic therapy, phototherapy).
62300342|NCT06640114|EXPERIMENTAL|Baseline therapy + Efferon CT|Patients with moderate to severe psoriasis who were receiving standard therapy for the treatment of the underlying disease and who also received a single course of haemoperfusion with Efferon CT
61915248|NCT02274038|EXPERIMENTAL|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
62300343|NCT02485392|ACTIVE_COMPARATOR|Single-Site robot-assisted cholecystectomy|Single-Site robot-assisted cholecystectomy
62300344|NCT02485392|ACTIVE_COMPARATOR|Single-incision laparoscopic cholecystectomy|Single-incision laparoscopic cholecystectomy
61915249|NCT04906915|EXPERIMENTAL|Ketamine|The experimental group was continuously pumped with remifentanil + ketamine for analgesia, and the control group was continuously pumped with remifentanil + placebo (normal saline) for analgesia. RASS and CPOT scores were performed to evaluate the pain degree of the patients.
62109606|NCT00015457|EXPERIMENTAL|cervical dystonia|cervical dsytonia patinets
62109607|NCT00208507|ACTIVE_COMPARATOR|Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System|Total hip replacement with a 28 mm ceramic head and liner.
62109608|NCT00208507|ACTIVE_COMPARATOR|Pinnacle™ Acetabular Cup with Marathon® Polyethylene|Total hip replacement with 28 mm ceramic head with a polyethylene liner.
62109609|NCT05266352|EXPERIMENTAL|Supervised exercise group|The group received the supervised exercise program
62109610|NCT05266352|ACTIVE_COMPARATOR|Home exercise group|The group received the home exercise program
62109611|NCT03429855|EXPERIMENTAL|study group|Bobath based trunk exercises
62109612|NCT03429855|OTHER|control group|conventional physiotherapy approaches
62109613|NCT01225939|EXPERIMENTAL|1|Single Oral dose AZD8329 tablet (fasting)
62109614|NCT01225939|EXPERIMENTAL|2|Single Oral dose AZD8329 solution (fasting)
62109615|NCT01225939|EXPERIMENTAL|3|Single Oral dose AZD8329 tablet (Fed)
62109616|NCT05999864|EXPERIMENTAL|Intervention Group|In addition to the program given to the control group, proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
61915250|NCT04991818|EXPERIMENTAL|Pregnant women or children 0-5 years of age|Pregnant women in third trimester or children 0-5 years of age
61915251|NCT01326325|EXPERIMENTAL|Ketamine|Ketamine PANFARMA
61915252|NCT01326325|PLACEBO_COMPARATOR|Not Ketamine|NaCl
61915253|NCT00360152|ACTIVE_COMPARATOR|Positive Axillary Ultrasound|Positive Axillary Ultrasound -\> Fine Needle Aspiration Biopsy -\> Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -\> Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -\> Pathology
61915254|NCT00360152|ACTIVE_COMPARATOR|Negative Axillary Ultrasound|Negative Axillary Ultrasound -\> Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -\> Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology
61915255|NCT03505827||TECNIS Monofocal|This group of patients has chosen to undergo implantation of a TECNIS monofocal ZCB00 lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 Humphrey visual field test prior to surgery, and a 24-2 SITA standard Humphrey visual field test after surgery at 1 month post-operatively.
61915256|NCT03505827||TECNIS Symfony|This group of patients has chosen to undergo implantation of a TECNIS Symfony extended depth of focus lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 SITA standard Humphrey visual field test prior to surgery, and a 24-2 Humphrey visual field test after surgery at 1 month post-operatively.
62109617|NCT05999864|ACTIVE_COMPARATOR|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
62109618|NCT02204618|EXPERIMENTAL|cochlear implantation|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
62109619|NCT02204618|OTHER|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
62109620|NCT00383188|PLACEBO_COMPARATOR|1|
62109621|NCT00383188|EXPERIMENTAL|2|
62109622|NCT00383188|EXPERIMENTAL|3|
62109623|NCT00383188|EXPERIMENTAL|4|
61915257|NCT03486145|EXPERIMENTAL|FVS (fruit and vegetable juice supplement)|The supplement contained ≈ 260-280 mg or 4 mmoles nitrate per two-ounce serving along with ≈ 51 mg total polyphenols. The FVS contains 7880 mg of a proprietary blend of beet root extract (Beta vulgaris), celery stem and leaf extract (Apium graveolens), red spinach leaf extract (Amaranthus dubius), stevia leaf extract (Stevia rebaudiana), and a fruit and vegetable extract blend (green tea leaf, red grape, white grape, bilberry, carrot, grapefruit, papaya, pineapple, strawberry, apple, apricot, cherry, orange, broccoli, green cabbage leaf, onion, garlic, black current, asparagus, tomato, olive and cucumber). Virtually all of the nitrates in FVS derive from the beet, celery, and red spinach extracts.
61915258|NCT03486145|PLACEBO_COMPARATOR|PRU (prune juice)|The placebo supplement was prune juice (Sunsweet brand 100% prune juice) (PRU). Prune juice was selected based on its very similar caloric and sugar content, its high antioxidant and phenolic profile, but low nitrate content. The prune juice contained \<0.6 mg nitrates and 133 mg total polyphenols per two-ounce serving.
61915259|NCT02485678|EXPERIMENTAL|Proactive Telephone Toxicity Management|Proactive Telephone Toxicity Management
62109624|NCT00383188|EXPERIMENTAL|5|
62109625|NCT05819450|EXPERIMENTAL|Sonography-guided hand|One hand of the participant will be treated with sonography-guided filler injection in random
62109626|NCT05819450|NO_INTERVENTION|Blinded injected hand|One hand of the participant will be treated with filler injection by physician's experience without sonography-guidance in random
62109627|NCT02458599|EXPERIMENTAL|Test product|One ready-to-drink beverage of 500 milliliter (mL) volume, containing 20 gram (g) protein will be administered orally, twice daily for four days.
62300345|NCT01670201|EXPERIMENTAL|Mepilex Transfer Ag|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
62300346|NCT03735940|NO_INTERVENTION|Control phase|no intervention, i.e. care as usual
62470340|NCT06097819|EXPERIMENTAL|Supervised combined sensor-based game group|A supervised combined sensor-based game intervention based on occupational therapy will be applied to this group. For this group, a supervised combined sensor-based game program was designed in addition to 12 sessions of occupational therapy interventions over 6 weeks, with 2 sessions per week and each session averaging 30 minutes
62671442|NCT00177489|EXPERIMENTAL|Treatment|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
62671443|NCT00177489|OTHER|Control|"Caregivers in the control group received 2 brief check-in telphone calls during the 6 month intervention."
61915260|NCT02485678|ACTIVE_COMPARATOR|Control Arm|Control
61915261|NCT05124418|OTHER|Palatal masticatory mucosa thickness measurement|
61915262|NCT03521804|OTHER|SoundBite™ Crossing System-Coronary|Crossing of coronary chronic total occlusions.
62109628|NCT02458599|ACTIVE_COMPARATOR|Reference product 1|One ready-to-drink beverage of 500 mL volume, containing 20 g carbohydrate will be administered orally, twice daily for four days.
62300347|NCT03735940|EXPERIMENTAL|Intervention phase|experimental intervention: spot monitoring device, i.e. use of DeltaScan
62300348|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
61915263|NCT04506762|NO_INTERVENTION|Control|Standard of care for peri operative analgesia
61915264|NCT04506762|EXPERIMENTAL|Intervention|Bilateral ESP catheters for peri operative regional analgesia
61915265|NCT00559182|EXPERIMENTAL|Parts A and B: MK-8033|Dose Escalation Study
62300349|NCT01958567|EXPERIMENTAL|Patients with clinical signs of scleritis or episcleritis|Optical Coherence Tomography for patients with scleral inflammation
62300350|NCT01958567|EXPERIMENTAL|Normal subjects with normal sclera|Optical Coherence Tomography on eyes with normal scleral
61915266|NCT00559182|EXPERIMENTAL|Part C: MK-8033 +/- omeprazole|Crossover Study
61915267|NCT06520475|ACTIVE_COMPARATOR|Bupivacaine + Magnesium|
61915268|NCT06520475|PLACEBO_COMPARATOR|Bupivacaine + Normal saline|
62109629|NCT02458599|PLACEBO_COMPARATOR|Reference product 2|One ready-to-drink beverage of 500 mL volume, containing 0 g carbohydrate will be administered orally, twice daily for four days.
62300351|NCT01783834|ACTIVE_COMPARATOR|pemetrexed|pemetrexed
62470341|NCT06097819|EXPERIMENTAL|Individualized occupational therapy group|Individualized occupational therapy group will receive occupational therapy sessions. During these sessions, activities that involve weight transfer, balance, fine motor skills, neuromuscular function, and cognitive skills will be implemented. Treatment will be administered for 2 days a week over a period of 6 weeks. Each session will last an average of 30 minutes. A total of 12 occupational therapy sessions will be conducted
62470342|NCT02128997|EXPERIMENTAL|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
62470343|NCT02128997|NO_INTERVENTION|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
62300352|NCT01783834|ACTIVE_COMPARATOR|gefitinib|gefitinib
62671444|NCT02372032|EXPERIMENTAL|PLD combined with ozone|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy combined with ozone therapy.
62671445|NCT02372032|ACTIVE_COMPARATOR|pure PLD|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy(PLD).
62671446|NCT01104272|EXPERIMENTAL|Energy Level 1|Subcutaneous Adipose Tissue Treated With Energy Level 1.
61915269|NCT06364293||the cohort with or without unfavorable imaging outcome|Cohorts will be divided into the favorable imaging outcome group and unfavorable imaging outcome group according to the interpretation of the imaging outcome of the postoperative follow-up of intravascular interventional therapy for intracranial aneurysms
61915270|NCT05117957|EXPERIMENTAL|Sorafenib|Sorafenib will be administered orally at a dose of 600mg (3 tablets; 400mg orally in the morning and 200mg orally in the evening about 12 hours apart or 200mg orally in the morning and 400mg orally in the evening about 12 hours apart) daily without food (at least 1 hour before or 2 hours after a meal).
61915271|NCT05098275|EXPERIMENTAL|Sequence A|
61915272|NCT05098275|EXPERIMENTAL|Sequence B|
61915273|NCT02678598||Micafungin group|
61915274|NCT04034953|OTHER|Colorectal Cancer Screening|"Potential screening participants will firstly be briefed about the CRC screening pilot program launched by the Department of Health (DH).~This project will offer screening referrals to the government pilot program or FIT screening tests for a total of 10,000 consecutive visitors."
62300353|NCT02914392||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
62300354|NCT02914392||Matched Controls for fetal congenital heart disease cases|Gravidas without fetal congenital heart disease
62671447|NCT02746731|EXPERIMENTAL|Prehabilitation|'Cardiorespiratory and resistance training.
62671448|NCT02746731|ACTIVE_COMPARATOR|Reference|Usual care.
62671449|NCT05365464|ACTIVE_COMPARATOR|Progesterone|Women receive prometrium 200 mg qhs for up to 8 weeks
62671450|NCT05365464|ACTIVE_COMPARATOR|hCG|A single shot of hCG (ovidril 250 ug) will be given as a subcutaneous injection 1 week after ovulation
61915275|NCT04034953|OTHER|Prostate Cancer Screening|A blood test for Prostate Specific Antigen (PSA) will then be performed. Subsequently, for subjects with serum PSA 4-10 ng/ml, additional blood tests for Prostate Health Index (PHI) will be performed for the further assessment of risk of prostate cancer. Subjects with serum PSA \> 10 ng/ml; or PHI ≥ 35 will be referred for Trans-rectal Ultrasound-guided Prostatic Biopsy (TRUS+PB). Subjects with serum PSA \< 4 ng/ml or with PHI level \< 35 will be invited to repeat the prostate screening tests every 2-years. We aim to screen not more than 5,000 subjects. For all patients recruited for prostate cancer screening, the study team will continue follow the subjects, by phone or mail or other means, for the long term clinical outcome for up to 10 years.
61915276|NCT04034953|OTHER|Breast Cancer Screening|Up to 5,000 eligible female subjects will receive a mammography on a 2-yearly basis. Individuals with abnormal findings on mammography will be referred for subsequent follow-up by the Jockey Club Breast Health Centre (BHC) run by the Hong Kong Breast Cancer Foundation (HKBCF).
62300355|NCT01451515|EXPERIMENTAL|Treatment|"Patients will undergo treatment as described in the intervention section. Interventions include:~* Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine~* Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine~* Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine, methotrexate~* Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide~* All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22."
62300356|NCT02566512|OTHER|Tracheostomy cuff inflated|The tracheostomy cuff will be inflated.
62300357|NCT02566512|OTHER|Tracheostomy cuff deflated|The tracheostomy cuff will be deflated.
62300358|NCT00997074|EXPERIMENTAL|ibuprofen|the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
62300359|NCT00997074|NO_INTERVENTION|placebo|this group will receive 2 placebo tablets together with the misoprostol
62300360|NCT02509208|EXPERIMENTAL|SurgiClot|All qualified subjects will be treated with the SurgiClot haemostatic dressing
62300361|NCT04232449|ACTIVE_COMPARATOR|Intervention group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of 40 mg (2 tablets of 20 mg) of prednisone (intervention group) are provided by General Physicians (GPs) to participants. PREDNISON Galepharm Tabl. 20 mg are manufactured according to Good Manufacturing Practice (GMP)-guidelines.~The prednisone medication is manufactured by Galepharm AG, 8700 Küsnacht (ZH) and packaged and labelled by the Hospital Pharmacy of the University Hospital Basel. The PREDNISON tablets' active substance is Prednisonum; the tablets also contain Excipiens pro compresso. Swissmedic authorization 50821"
62300362|NCT04232449|PLACEBO_COMPARATOR|Control group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of placebo (control group) are provided by General Physicians (GPs) to participants.~The content of the placebo tablets is as follows: Lactose monohydrate 140 mg, microcrystalline cellulose 68 mg, Croscarmellose sodium 5 mg, Magnesium stearate 2mg. The placebo tablets were manufactured by Apotheke Hotz, Zürichstrasse 176, CH- 8700 Küsnacht."
62300363|NCT06219538|EXPERIMENTAL|Interventional|Ten women in whom the Daisy Drain is placed.
62671451|NCT06021444|EXPERIMENTAL|DKM420|Injecting to one side knee.
62671452|NCT06021444|ACTIVE_COMPARATOR|Conjuran|Injecting to one side knee.
62671453|NCT02594878|EXPERIMENTAL|Pamidronatdinatrium 3mg/ml|Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.
61915277|NCT03673904||Prediabetics|Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
62300364|NCT00235157|EXPERIMENTAL|1|Sirolimus-eluting Palmaz Genesis peripheral stent
62470344|NCT04414917|EXPERIMENTAL|Twin Block local anesthetic|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s
62671454|NCT02594878|PLACEBO_COMPARATOR|Natrium chloride 9 mg/ml|Natrium chloride 9 mg/ml volume equals experimental drug
62671455|NCT04957524|ACTIVE_COMPARATOR|Set Amplitude|This arm is to test a specific amplitude. Participants will be instructed to set the amplitude to 20 mA, frequency to 20 Hz, and pulse duration to 5 mS. The parameters will stay the same for the entire session. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
62671456|NCT04957524|EXPERIMENTAL|Customizable Amplitude|In this arm, the participant will set the frequency to 12 Hz and pulse duration to 1 millisecond. The participant will be instructed to increase the amplitude gradually and set it at the maximal tolerable amplitude. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
62671457|NCT05712382|ACTIVE_COMPARATOR|Coping with emotions, Parent handbook, Problem-solving risky situations, and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62671458|NCT05712382|ACTIVE_COMPARATOR|Coping with negative emotions, Parent handbook , and Problem-solving for risky situations|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
62671459|NCT05712382|ACTIVE_COMPARATOR|Coping with negative emotions, Parent handbook , and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62671460|NCT05712382|ACTIVE_COMPARATOR|Coping with negative emotions and Parent handbook|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use.
62671461|NCT05712382|ACTIVE_COMPARATOR|Coping with negative emotions, Problem-solving for risky situations , and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62671462|NCT05712382|ACTIVE_COMPARATOR|Coping with negative emotions and Problem-solving for risky situations|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
62671463|NCT05712382|ACTIVE_COMPARATOR|Coping with negative emotions and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62671464|NCT05712382|ACTIVE_COMPARATOR|Coping with negative emotions|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions.
62671465|NCT05712382|ACTIVE_COMPARATOR|Parent handbook , Problem-solving for risky situations , and Recovering from slips|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62671466|NCT05712382|ACTIVE_COMPARATOR|Parent handbook and Problem-solving for risky situations|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62300365|NCT00934895|EXPERIMENTAL|Phase I / Phase II|"Phase I:~* Abraxane will be given by IV for 30 minutes on the first day of the first three weeks of each 28 day cycle.~* RAD001 will be given by tablet. The first group of patients will receive RAD001 once daily depending on side effects seen drug could be increased later to twice a day for a 28 day cycle.~Once a safe and effective drug range is established, the study moves into Phase II.~Phase II:~The maximum tolerated dose (established in Phase I) will be given as scheduled below and we will measure the effectiveness of the study drug combination.~* Abraxane will be given by IV (intravenous infusion) for 30 minutes on the first day of the first three weeks of each 28 day cycle (Day 1, Day 8, and Day 15 of each cycle).~* RAD001 will be given by tablet based on the dose established in the Phase I part of the study."
62300366|NCT06033443|EXPERIMENTAL|Experiment group|The experimental group will be given collaborative learning-based nursing education for twelve weeks.
62300367|NCT05706714||Patients with urea cycle disorder|Patients with inborn errors of metabolism resulting from defects in one of the enzymes or transporter molecules involved in the hepatic removal of ammonia from the bloodstream
62300368|NCT05706714||Patients with lysinuric protein intolerance|Patients with disorder caused by the body's inability to digest and use certain protein building blocks (amino acids), namely lysine, arginine, and ornithine
62300369|NCT05706714||Healthy control|Children without any comorbidity and chronic diseases.
62470345|NCT04414917|SHAM_COMPARATOR|Control|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block injection but with no medication administered/dispensed from the syringe, on the side/s of their extraction/s
62671467|NCT05712382|ACTIVE_COMPARATOR|Parent handbook and Recovering from slips|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62109630|NCT03038399|EXPERIMENTAL|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
62470346|NCT05249634|EXPERIMENTAL|treatment|JATENZO daily for 6 months
62300370|NCT02201940|EXPERIMENTAL|SOF/VEL|SOF/VEL for 12 weeks
62470347|NCT06002230||Patients treated with individualized homeopathy|Patients suffering from symptoms of Long COVID-19 were treated with individualized homeopathy.
62671468|NCT05712382|ACTIVE_COMPARATOR|Parent handbook|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use.
62671469|NCT05712382|ACTIVE_COMPARATOR|Problem-solving for risky situations and Recovering from slips|Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62109631|NCT03038399|EXPERIMENTAL|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
62109632|NCT03038399|EXPERIMENTAL|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
62109633|NCT03038399|EXPERIMENTAL|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
62109634|NCT05001919|PLACEBO_COMPARATOR|collagen membrane|10 sites treated with surgery and bone graft and collagen membrane as GTR
62109635|NCT05001919|EXPERIMENTAL|Concentrated growth factor membrane|10 sites treated by surgery +bone graft and concentrated growth factor membrane as GTR
62109636|NCT01991912|EXPERIMENTAL|irrigation endoscopic decompression|endoscopic decompression is performed for cases of lumbar spinal stenosis.Portals 0.5cm in size are used for the introduction of the instruments and the endoscope. Saline under pump pressure is used to open a potential working space. This is followed by performing an ipsilateral hemilaminotomy and contralateral decompression under the midline structure
62109637|NCT00329979||1|Radial access
62109638|NCT00329979||2|Femoral access
62109639|NCT03055767|OTHER|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
62109640|NCT03055767|OTHER|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
62109641|NCT05711095|EXPERIMENTAL|Fortified plant protein blend|20g of plant-based protein blend fortified with 2 g leucine
62300371|NCT02201940|PLACEBO_COMPARATOR|Placebo|SOF/VEL placebo for 12 weeks
62300372|NCT00932087||type 2 diabetics with metabolic syndrome|
62300373|NCT00932087||metabolic syndrome without diabetes|
62470348|NCT05294081|EXPERIMENTAL|Exposure (EXP)|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
61915278|NCT03673904||Newly diagnosed type 2 diabetes|Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level \>126 mg/dl A 2-hour blood glucose level \> 200 mg/d Hb A1C \> 6.5%
62300374|NCT00932087||type 1 diabetes|
62671470|NCT05712382|ACTIVE_COMPARATOR|Problem-solving for risky situations|Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
62671471|NCT05712382|ACTIVE_COMPARATOR|Recovering from slips|To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
62671472|NCT05712382|NO_INTERVENTION|Assessment only control condition|Participants in this condition will complete assessments but will not receive any additional intervention content.
62671473|NCT01472835|EXPERIMENTAL|Sedation|Pt will receive sedation with their procedure
62671474|NCT01472835|NO_INTERVENTION|Control|Patient will not receive sedation during procedure
62671475|NCT01060111|EXPERIMENTAL|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
62109642|NCT05711095|EXPERIMENTAL|Normal plant protein blend|20g of plant-based protein blend
62671476|NCT01060111|EXPERIMENTAL|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
62109643|NCT05711095|ACTIVE_COMPARATOR|Whey protein|20g of whey protein
62109644|NCT00983164|NO_INTERVENTION|group I|group I - controls
62109645|NCT00983164|EXPERIMENTAL|group II|group II - patients with hepatitis C without treatment
62109646|NCT00983164|EXPERIMENTAL|group III|group III - patients with hepatitis C treated weekly with pegylated interferon combined with daily ribavirin
62109647|NCT05976243|EXPERIMENTAL|Remibrutinib, symptomatic dermographism group|Remibrutinib oral twice daily in participants with symptomatic dermographism
62109648|NCT05976243|PLACEBO_COMPARATOR|Placebo, symptomatic dermographism group|Placebo oral twice daily, symptomatic dermographism
62109649|NCT05976243|EXPERIMENTAL|Remibrutinib, cold urticaria group|Remibrutinib oral twice daily, cold urticaria
62109650|NCT05976243|PLACEBO_COMPARATOR|Placebo, cold urticaria group|Placebo oral twice daily, cold urticaria
62109651|NCT05976243|EXPERIMENTAL|Remibrutinib, cholinergic urticaria group|Remibrutinib oral twice daily, cholinergic urticaria
62109652|NCT05976243|PLACEBO_COMPARATOR|Placebo, cholinergic urticaria|Placebo oral twice daily, cholinergic urticaria
62300375|NCT00932087||control|
62671477|NCT01060111|EXPERIMENTAL|Topiramate Slow and Propranolol Booster|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion. Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
62671478|NCT00937911|EXPERIMENTAL|YM150 group|
62671479|NCT04787458|EXPERIMENTAL|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
62671480|NCT04787458|NO_INTERVENTION|Control group|subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
62671481|NCT02502071|EXPERIMENTAL|Sodium Bicarbonate|All participants will receive 2 doses of 1950mg Sodium Bicarbonate
62735965|NCT02583633|ACTIVE_COMPARATOR|Group one have received Transdermal nitroglycerin|transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
62109653|NCT06238375||Premature Acute Coronary Syndrome (ACS) Patients in Africa|This cohort includes individuals diagnosed with premature Acute Coronary Syndrome (ACS), including subtypes like unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and myocardial infarction with persistent ST-segment elevation (STEMI). These participants are under 55 years (men) or 65 years (women) and have been admitted to various cardiac facilities in Africa (Urban and rural) due to ACS-related symptoms.
62671482|NCT00686738||A|"Study group will be made up of patients hospitalized to National Cancer Center, Korea, aged between 5 and 40 years, and diagnosed with high grade osteosarcoma by histological exam.~In this group, TGF-b1 measurement, PET/CT and MRS examination at diagnosis, after 1st cycle chemotherapy, and 2nd or 3rd chemotherapy (just before surgery) will be made.~In addition, evaluation of NF-kB expression status in tumor specimens at diagnostic biopsy and tumor removing surgery will be done.~The results of above studies will be correlated with the necrosis fractions of the tumor tissues removed by surgery."
62109654|NCT02857283|EXPERIMENTAL|Filtered Air, then Ozone|Participants in this arm will first receive filtered clean air followed by ozone
62470349|NCT05294081|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
61915279|NCT01028690|ACTIVE_COMPARATOR|Lactobacillus reuteri|L. reuteri is one species of lactobacillus that naturally inhabits the gastrointestinal tract of humans
61915280|NCT01028690|PLACEBO_COMPARATOR|placebo|Placebo will be delivered in a chewable tablet form (1.5g per dose)
61915281|NCT02484859|ACTIVE_COMPARATOR|remifentanil|Following an intravenous bolus dose of 0.5 µg/kg remifentanil administered just before the induction of anaesthesia, patients will receive an intravenous infusion of remifentanil at a dose of 0.25-0.5 µg/kg/min throughout the surgery. The rate of infusion will be adjusted to maintain a mean blood pressure within %70-80 of the baseline value. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
61915282|NCT02484859|ACTIVE_COMPARATOR|tramadol + metoprolol|Just before the induction of anaesthesia, an intravenous infusion of 1 mg/kg of tramadol in 100 ml isotonic fluid will be started. The infusion will be completed in 30 minutes using a perfusor. Additionally, following the administration of the neuromuscular blocking agent, 0.1 mg/kg of intravenous metoprolol will be administered within 5 minutes.
61915283|NCT01224782||Chronic Kidney Disease, Secondary Hyperparathyroidism|All eligible participants with chronic kidney disease stage 3 and 4 and secondary hyperparathyroidism treated with Zemplar (paricalcitol) capsules according to the local marketing authorization
61915284|NCT05184751||50 years and over|patients who underwent colonoscopic examination aged 50 years and over
61915285|NCT05184751||under 50 years|patients who underwent colonoscopic examination aged under 50 years
61915286|NCT01505647|EXPERIMENTAL|ZOSTAVAX™ (AMP)|ZOSTAVAX™ manufactured with an alternative process
62109655|NCT02857283|EXPERIMENTAL|Ozone, then Filtered Air|Participants in this arm will first receive ozone followed by filtered clean air
62109656|NCT01451814|EXPERIMENTAL|Positive psychotherapy|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
62109657|NCT01451814|ACTIVE_COMPARATOR|Standard treatment|6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition
62109658|NCT06007144|EXPERIMENTAL|Treatment Group|SPIRION Laryngeal Pacemaker System Implantation and follow-up
62109659|NCT06406101|EXPERIMENTAL|Floor|
62109660|NCT06406101|ACTIVE_COMPARATOR|Bed|
62109661|NCT04573374|ACTIVE_COMPARATOR|Biodentine|Biodentine (BD; Septodont, St Maur-des-Fosses, France) is a calcium silicate capping material. Biodentine is mixed according to manufacturer's instructions and placed in a 2-3 mm layer above the pulp tissue using an amalgam carrier and gently packed using a condenser. Initial setting is achieved after 12 minutes.
62300376|NCT02717507|EXPERIMENTAL|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
62300377|NCT02717507|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
62470350|NCT01787786||Irritable Bowel Disease|Infliximab administered according to current FDA and EMS approved doses and intervals.
61915287|NCT01505647|ACTIVE_COMPARATOR|ZOSTAVAX™|ZOSTAVAX™ manufactured with the current process
61915288|NCT01663753|EXPERIMENTAL|18F-FDG-PET|The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)
61915289|NCT05413577|EXPERIMENTAL|Experimental Group|The experimental group was invited to listen to a 15-minute mindfulness instructional recording delivered daily through an instant messaging application and to practice accordingly for 14 consecutive days at their own choice of time and place.
61915290|NCT05413577|NO_INTERVENTION|Waitlist control group|The waitlist control group was only be required to complete the demographic information, pre, post experiment and follow-up questionnaires before they receive the mindfulness training intervention.
61915291|NCT01781169|EXPERIMENTAL|Obese group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
62737300|NCT05256888|EXPERIMENTAL|Time-restricted eating|Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times). Participants will also receive weekly tips to encourage a healthy lifestyle in cancer survivorship.
61915292|NCT01781169|EXPERIMENTAL|Normal-weight group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
61915293|NCT03167450||Adults|Adults have sickle cell disease
61915294|NCT03167450||Parents|Parents with children/adults who have sickle cell disease
61915295|NCT03167450||Physicians|Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
61915296|NCT01910311|EXPERIMENTAL|Baricitinib|Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
61915297|NCT01910311|EXPERIMENTAL|Baricitinib + Rifampicin|Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
61915298|NCT05553054||Intravenous (IV) drugs|Patient and prepared/administrated/discarded IV drugs data will be collected during 24 hours.
61915299|NCT03794882|EXPERIMENTAL|QLB + Medical Management|Subjects will undergo Intervention: Procedure/Surgery: Quadratus Lumborum Block and receive Intervention: Procedure: Standard Medical Management as needed.
61915300|NCT03794882|ACTIVE_COMPARATOR|Standard Medical Management|Subjects will receive Intervention: Procedure: Standard Medical Management as needed.
62109662|NCT04573374|ACTIVE_COMPARATOR|Portland cement|Preparation of Portland cement: Industrial Portland cement is mixed with Bisthmus oxide or Barium sulphate radio-opacifier in a 3:1 ratio. The mix is sieved through silk sieve then sterilized in hot air oven at 135 ֯C for 2 hours. Portland cement is mixed in a 3:1 powder: distilled water ratio and placed in the pulp chamber and condensed against a moist cotton pellet. A small cotton pellet moistened with saline is placed in the pulp chamber against PC for 5 seconds to ensure water uptake then removed
62109663|NCT03775447||Parkinson's Disease Patients|"* A diagnosis of Parkinson's disease in the opinion of the enrolling investigator~* Disease duration: any~* Male or female age 18 years or older at time of PD diagnosis."
62109664|NCT03775447||Healthy Control (HC) Subjects|• Male or female age 18 years or older at Screening.
62109665|NCT05420168||Patient who received antibiotic prophylaxis|Patient who received antibiotic prophylaxis to assess appropriateness and consumption of treatment.
62109666|NCT03161691||Ischemic Stroke|Percutaneous neurovascular treatment of acute ischemic stroke patients.
62109667|NCT03533036|EXPERIMENTAL|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
62109668|NCT03533036|NO_INTERVENTION|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
62109669|NCT04943380||patients with hematuria undergoing investigation for UC|Patients will be recruited from those presenting with hematuria and undergoing investigative cystoscopy for the determination of possible urothelial carcinoma. This includes patients referred via imaging or from other departments for assessment of hematuria. Microscopic hematuria is defined as \> 3 red blood cells per high-powered microscopy field for a properly collected urine sample.
62737301|NCT05256888|OTHER|Control|Participants will receive weekly tips to encourage healthy lifestyle behaviors in cancer survivorship.
61915301|NCT02239705||Fluid challenge|Patients whose clinical conditions require bolus of fluids infusion to correct blood pressure and cardiac output
61915302|NCT02239705||Inotropic infusion|Patient whose clinical conditions require inotropic agents infusion to correct blood pressure and cardiac output
61915303|NCT06198140|EXPERIMENTAL|Myofascial Release and Quick icing|Experimental group will receive myofascial release \& quick icing.
61915304|NCT06198140|ACTIVE_COMPARATOR|Myofascial Release|In control group the individuals will receive only myofascial release on ankle planterflexors.
61915305|NCT00704665|PLACEBO_COMPARATOR|2|Placebo
61915306|NCT00704665|EXPERIMENTAL|A|10ug/kg/day or 25/ug/kg/day
61915307|NCT01644370|OTHER|HIV positive with aeroallergen|positive for aeroallergen at baseline
61915308|NCT01644370|OTHER|HIV positive without aeroallergen|negative for aeroallergen at baseline
61915309|NCT01644370|NO_INTERVENTION|control|HIV negative children (n=10)
61915310|NCT02044497|EXPERIMENTAL|oral oxycodone|An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines at Boston Children's Hospital.
61915311|NCT04272138|EXPERIMENTAL|Calm Meditation|Participants in the intervention group will be exposed to 10 minutes per day of meditation via a smartphone application for 4 weeks. Participants will log their meditation participation in an online weekly log.
61915312|NCT04272138|ACTIVE_COMPARATOR|Educational Podcast Control|Participants in the control group will be exposed to 10 minutes per day of health education podcasts via a smartphone application for 4 weeks. Participants will log their podcast participation in an online weekly log.
62300378|NCT02302495|OTHER|Carfilzomib weekly+Melphalan+Prednisone|one arm, two steps and two parts.In the first step of the study: 5 cohorts of 6 patients with Carfilzomib weekly administrated at different dose regimen will be opened one after the other to determine Maximum tolerated dose of Carfilzomib based on definition of Dose-limiting toxicities.In the second step of the study:expanded Cohort, 50 patients received Carfilzomib at the MTD. In Part 1. Induction.Nine 5 weeks cycles of weekly CMP are plannedCarfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route . Patients will start the first cycle day 1 with 20mg/m². In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.Part 2. Maintenance.Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year.
61915313|NCT03044574|EXPERIMENTAL|Experimental group (SCD + GCS + LMWH)|"SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
61915314|NCT03044574|ACTIVE_COMPARATOR|Control group (GCS + LMWH)|"GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
61915315|NCT06154681|EXPERIMENTAL|World Digital Detox Family Program|The 4-week Self-Help World Digital Detox Family and Society Program is a comprehensive program, with variety of self-guided activities, discussions, and reflection exercises. The intervention encompasses both individual and collective components.
62470351|NCT03514420|EXPERIMENTAL|AKCEA-ANGPTL3-LRx 20 mg|Participants received AKCEA-ANGPTL3-LRx 20 milligrams (mg) administered every week for 26 weeks by subcutaneous (SC) injection.
61915316|NCT06154681|NO_INTERVENTION|Wait-list Control|Wait-list control group underwent the standard assessment and screening process but not engaged in the intervention during the 4-week period.
62109670|NCT06309342|EXPERIMENTAL|PREVFUNKTION|Medical examination. Functional examination. Measurement of physical activity. Questionnaires on health, function and lifestyle. Feedback and advice based on medical examination. Feedback and advice based on functional examination. Functional profile. Support in setting goals for lifestyle changes.
62109671|NCT06309342|ACTIVE_COMPARATOR|Control|Medical examination. Functional examination. Measurement of physical activity. Questionnaires on health, function and lifestyle. Feedback and advice based on medical examination.
62109672|NCT00666939|EXPERIMENTAL|A|
61915317|NCT02451618||Epidermal Electronic System|EES, wireless tattoo electrode
62300379|NCT05095389|EXPERIMENTAL|Standard Care plus ARDCs|"* All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.~* All patients will receive standard care for their Diabetic Foot Ulcer.~* Additionally, patients randomized to the ADRC arm will receive ADRCs"
61915318|NCT02451618||Hydrogel electrode|EKG electrode, looking at hairline placement of electrodes.
61915319|NCT02128100|EXPERIMENTAL|Folririnox with SBRT|"Folfirinox~* Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours~SBRT 5 treatments of stereotactic body radiation therapy (SBRT) over the course of two weeks with a minimum of 36 hours in between each treatment."
62109673|NCT00666939|EXPERIMENTAL|B|
62109674|NCT00666939|PLACEBO_COMPARATOR|C|
62109675|NCT04691973||Access to tool|Access to the digital tool. Participants use the tool at their own in addition to usual care and do the different themes that are available. They are recommended to use it at least every other week.
62109676|NCT04691973||No access to tool|Participants are followed by their ordinary healthcare provider and are not exposed to the tool.
62109677|NCT03926819|ACTIVE_COMPARATOR|Single Ascending Dose|
62109678|NCT03926819|ACTIVE_COMPARATOR|Multiple Ascending Dose|
61915320|NCT03584529|EXPERIMENTAL|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 \< 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
61915321|NCT03584529|NO_INTERVENTION|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 \< 20 ng/ml)and uterine fibroids receive regular follow-up.
61915322|NCT03584529|EXPERIMENTAL|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 \< 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
61915323|NCT03584529|NO_INTERVENTION|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 \< 30 ng/ml)and uterine fibroids receive regular follow-up.
61915324|NCT02724670|OTHER|Radiation|IGRT 5x 2Gy/week, total dose: 78 Gy
61915325|NCT06459232||Multiple Sclerosis (MS) Cohort|Adult MS patients with at least 1 claim of siponimod or an MS-related FDA-approved DMT.
61915326|NCT06255366|EXPERIMENTAL|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
61915327|NCT06255366|EXPERIMENTAL|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
61915328|NCT06255366|PLACEBO_COMPARATOR|0.9% Sodium chloride injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
61915329|NCT05632744|EXPERIMENTAL|CG-100 Intraluminal Bypass Device|Subjects will be treated with CG-100 Intraluminal Bypass Device
62470352|NCT01289262|ACTIVE_COMPARATOR|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture.
61915330|NCT06229314|EXPERIMENTAL|IMT Group|The IMT group received IMT at 60% of the measured MIP value. IMT was administered using the Powerbreathe device (Powerbreathe Plus, Warwickshire, England) twice a day with 30x2 breaths. The device was adjusted weekly based on the patient's current MIP value, and training continued at 60% of the MIP value.
61915331|NCT06229314|SHAM_COMPARATOR|Control Group|The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks.
61915332|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
61915333|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
61915334|NCT05204875||Functional lung imaging|Assess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning.
61915335|NCT04937400||Pediatric Stem Cell Transplant Patients|A consecutive cohort of children admitted to the hospital for stem cell transplantation
61915336|NCT02368925|EXPERIMENTAL|Ultherapy™ System|Ultherapy™ System
62109679|NCT02814825||ViviGen|Patients undergoing a two or three level ACDF using ViviGen Cellular Bone Matrix in conjunction with cervical allograft spacers and DePuy Synthes anterior cervical plate systems.
62470353|NCT01289262|ACTIVE_COMPARATOR|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked closure technique.
62109680|NCT06001372|EXPERIMENTAL|Arm 1|Three 2.5-3 hour Ketamine Assisted Psychotherapy sessions, each 2-7 days apart
62109681|NCT03437642||Tako-Tsubo - STP|Short term psychotherapy + Classic cardiological therapy
62109682|NCT03437642||Tako-Tsubo - Control|Classic cardiological therapy only
62109683|NCT03437642||Oncologic - STP|Short term psychotherapy + Classic oncological therapy
62109684|NCT03437642||Oncologic - Control|Classic oncological therapy only
62109685|NCT03437642||AMI - STP|Short term psychotherapy + Classic cardiological therapy
62109686|NCT03437642||AMI - Control|Classic cardiological therapy only
62300380|NCT05095389|ACTIVE_COMPARATOR|Standard Care plus Placebo|"* All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.~* All patients will receive standard care for their Diabetic Foot Ulcer.~* Additionally, patients randomized to the Control arm will receive Placebo"
62300381|NCT03050125|EXPERIMENTAL|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
62300382|NCT03050125|EXPERIMENTAL|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
62470354|NCT04519749|EXPERIMENTAL|4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A|Single IV administration of 4D-310 Dose Level 1 - AAV NAb Titer Group A patients
61915337|NCT02456480|EXPERIMENTAL|CLS001 topical gel, 2.5%|
61915338|NCT02456480|EXPERIMENTAL|CLS001 topical gel 1%|
61915339|NCT02456480|PLACEBO_COMPARATOR|Vehicle gel|
62109687|NCT03437642||Healthy Subjects|No therapy
62109688|NCT03558204||CMC denervation|Patients will undergo denervation of the thumb CMC joint
62109689|NCT03558204||trapeziectomy with ligament reconstruction (LRTI)|Patients will undergo excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
62109690|NCT04968119|EXPERIMENTAL|Arm A (telehealth intervention)|Patients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
62109691|NCT04968119|ACTIVE_COMPARATOR|Arm B (delayed exercise intervention)|Patients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
62120019|NCT04549532|EXPERIMENTAL|T-MD Intervention Group|Participants will be prescribed 1+ interventions tailored to affected domains.Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.Autonomic-Graded aerobic exercise. Perform daily aerobic exercise, goal 80% HR max on a stationary bike/treadmill/walking/jogging.
62120020|NCT04549532|ACTIVE_COMPARATOR|Behavioral Management|Participants in control group will receive standardized behavioral management strategies including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion. Clinicians will discuss and review a behavioral strategies handout with each participant and answer any questions they may have about the information in the handout. Contact time between clinicians and patients will be similar to avoid effects associated with more or less contact time.
62120021|NCT04010318||Corrected group|The patients in which the PVI will corrected by fluid to level below 15
62120022|NCT04010318||Uncorrected group|Patients in which intravenous fluid administration didn't result any change in PVI or changed but still higher than 15
62120023|NCT05715268|EXPERIMENTAL|WeB and pelvic floor physical therapy group|This group will receive standard PFPT as well as WeB device for 12 weeks, and MS-symptom (including bladder bother) related questionnaires at baseline, 12 weeks and 6 months post intervention. Participants will also be provided with a remote activity monitor to use during the study.
62300383|NCT03050125|EXPERIMENTAL|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
62470355|NCT04519749|EXPERIMENTAL|4D-310 Dose Level 1 - AAV NAb Titer Group B|Single IV administration of 4D-310 Dose Level 1 - AAV NAb titer Group B patients
62470356|NCT04519749|EXPERIMENTAL|4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B|Single IV administration of 4D-310 at Dose Level 2 in AAV NAb titer Group A and/or B patients
62470357|NCT04519749|EXPERIMENTAL|4D-310 Dose Expansion|Dose expansion cohort of single IV administration of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients
62470358|NCT01038947|EXPERIMENTAL|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
61915340|NCT02483871|EXPERIMENTAL|Rosuvastatin|Two Cohorts, one at 20 mg and one at 40 mg will enroll in a dose escalation of rosuvastatin
61915341|NCT04617301||Group 1. Internal root resorption (IRR)|Internal root resorption is the progressive destruction of intraradicular dentin and dentinal tubules along the middle and apical thirds of the canal walls as a result of clastic activities. It is seen as a radiolucent area around the pulpal cavity, usually of incisors and mandibular molars. The various etiological factors suggested for internal root resorption include traumatic injury; infection and orthodontic treatment.
61915342|NCT04617301||Group 2. external cervical resorption (ECR)|"Cementum is considered to protect the underlying root dentin from being resorbed. It is broadly accepted that damage to or deficiency of this protective cementum layer below the epithelial attachment exposes the root surface to osteoclasts, which then resorb the dentin.~Clinical sign; Located in cervical region of tooth Pink spot might be noted by patient/dentist Tooth usually responds positively to vitality tests unless there is pulpal involvement (in very advanced cases) Spontaneous and profuse bleeding on probing Sharp, thinned out edges around the resorptive cavity"
61919932|NCT02959164|EXPERIMENTAL|Decitabine and Gemcitabine|"Decitabine, Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Gemcitabine fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle."
61919933|NCT00056056|EXPERIMENTAL|Bexarotene and PUVA|
62300384|NCT03593694|OTHER|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
62300385|NCT03593694|ACTIVE_COMPARATOR|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
62300386|NCT03593694|EXPERIMENTAL|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
62300387|NCT02010203|EXPERIMENTAL|Phase I: HS-410 Low Dose|In the open label Phase 1 portion, HS-410 is given as 1\*10\^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
62300388|NCT02010203|EXPERIMENTAL|Phase II: HS-410 Low-Dose Plus BCG|In the Phase 2 portion, HS-410 is given as 1\*10\^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
62300389|NCT02010203|EXPERIMENTAL|Phase II: High-Dose HS-410 Plus BCG|In the Phase 2 portion, HS-410 is given as 1\*10\^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
62300390|NCT02010203|PLACEBO_COMPARATOR|Phase II: Placebo Plus BCG|In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
62300391|NCT02010203|EXPERIMENTAL|Phase II: High-Dose HS-410|In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1\*10\^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
62300392|NCT03530449||Subjects with Normal Eyes|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects without ophthalmic pathology
62300393|NCT03530449||Subjects with Retinal Vascular Pathology|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects with retinal vascular ophthalmic pathology
62300394|NCT04661696|EXPERIMENTAL|single-arm|Paclitaxel (albumin-bound) 130 mg/m2, i.v., d1, 8; Carboplatin AUC 5, i.v. d1; repeat every 21days, 6 cycles.
62300395|NCT03835663||Patients with non erosive reflux|Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
61919934|NCT00056056|ACTIVE_COMPARATOR|PUVA|
62109692|NCT01315886|EXPERIMENTAL|SL Fentanyl conversion|"* Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication~* Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes."
62300396|NCT03835663||Patients with erosive reflux|Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
62109693|NCT05372094|EXPERIMENTAL|Experimental|Participants will be fit with a commercially available hearing aid and tested using various strengths of the noise reduction feature.
62109694|NCT03518112|EXPERIMENTAL|Treatment (blinatumomab, combination chemotherapy)|See detailed description.
62300397|NCT03835663||Patients with no reflux|Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
62300398|NCT03971981|EXPERIMENTAL|100% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
62470359|NCT03422770|OTHER|Mild aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. All undergoing 1 year control.
61919935|NCT05513131|EXPERIMENTAL|Venetoclax combined with Azacitidine and Harringtonine|Venetoclax 100mg d1，200mg d2，400mg d3\~d14； Azacitidine 75mg/m2/d，d1\~d7； Homoharringtonine 2mg/d d1\~d7
62109695|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
62109696|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
62109697|NCT04694573||POST-TX Covid-19 Serum Study Case|Kidney or liver-transplanted patients being hospitalized due to an infection with SARS-CoV-2
62109698|NCT04694573||POST-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection after TX; matching according to~* age (18-34, 35-59, 60-75 years)~* sex~* type of transplantation~* time after transplantation (0-180, 181-365, 366-1095, 1096-2555, \>2555 days after TX)"
62109699|NCT04694573||PRE-TX Covid-19 Serum Study Case|Patients being kidney or liver-transplanted after having had an infection with SARS-CoV-2
62109700|NCT04694573||PRE-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection prior to TX; matching according to~* age(18-34, 35-59, 60-75 years)~* sex~* type of transplantation"
62300399|NCT03971981|EXPERIMENTAL|22% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
62300400|NCT01262430|ACTIVE_COMPARATOR|OtisMed|
62300401|NCT01262430|ACTIVE_COMPARATOR|Computer Assisted Surgery (CAS)|
62300402|NCT04704180|EXPERIMENTAL|Experimental Group: Facilitation Tuchking Group|The experimental group neonates received facilitated tucking under the radiant heater after birth of the NICU as well as the routine interventions.
61915343|NCT04617301||Grup 3. external replacement resorption (ERR)|external replacement resorption also known as trauma-induced resorption - and this resorption may occur in teeth that also have external inflammatory resorption. This review will not discuss external replacement resorption in detail but it will be mentioned where relevant as both types of resorption may occur in some cases. This is because replacement resorption is a consequence of the same injuries that typically cause external inflammatory resorption - such as intrusion and avulsion where there is significant damage to the external root surface during the injury, as well as sometimes during the repositioning/ replantation of the tooth.
61915344|NCT05542277|EXPERIMENTAL|ClearPlasma|Investigational Group (A): one-time infusion (up to 12 hours after surgery) of unlimited plasminogen depleted plasma PDP units generated by ClearPlasma™ device.
61915345|NCT05542277|PLACEBO_COMPARATOR|Control|Control Group (B): one-time infusion (up to 12 hours) of unlimited regular plasma, Fresh frozen plasma (FFP) with mock ClearPlasma™ device.
62109701|NCT02299635|EXPERIMENTAL|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
62300403|NCT04704180|NO_INTERVENTION|Control Group|The control group underwent the routine interventions of the observation unit of the NICU. The group did not receive any other intervention
62300404|NCT05288088||Tumor craniotomy patients|Patients undergoing elective brain tumor craniotomy
62300405|NCT02072629|EXPERIMENTAL|Training of VHVs in iCCM|In these villages VHVs will be provided with iCCM training and equipped to support iCCM in their villages
62470360|NCT03422770|OTHER|Moderate aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. All undergoing 1 year control.
62470361|NCT03422770|OTHER|Severe aortic stenosis|50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. All undergoing 1 year control.
61919936|NCT03055858|EXPERIMENTAL|PDA closure|
61919937|NCT03272789|OTHER|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
61915346|NCT02508298|ACTIVE_COMPARATOR|Indocyanine green retention test|A baseline venous sample of 5 ml of venous will be drawn for pre-infusion measurement. Under sterile conditions 0.5 mg/kg body weight of ICG will be injected into vein. Further blood samples (5 ml each) will be collected at 5, 10, 15 and 20 minute intervals after the injection from a peripheral vein in the opposite arm using another intravenous catheter. After serum is separated by centrifugation, optical densities will be measured at 804 nm using a calibrated method for measurement of ICG level s. ICG retention at 15 minutes and elimination rate constant will be calculated by fitting the serum disappearance curve to a single exponential decay equation.This will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
61915347|NCT02508298|ACTIVE_COMPARATOR|Liver stiffness measurement|ARFI measurements of the liver will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
62109702|NCT02449499||therapy|patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy
62470362|NCT03422770|OTHER|Controls|31 subjects, all undergoing echocardiography and blood test and MRI.
62737302|NCT00632775|ACTIVE_COMPARATOR|1|Subjects in this arm will receive hypotonic (0.45% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
62109703|NCT02449499||control|patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints
62109704|NCT00652119|EXPERIMENTAL|Paclitaxel + Carboplatin + Avastin|"Paclitaxel Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.~Carboplatin Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.~Avastin Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle."
62109705|NCT00516503|EXPERIMENTAL|Arm I|Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel\> topically to each\> area of pain,\> numbness,\> and/or tingling\> on the\> feet and/or hands twice daily\> for\> 4 weeks.
62109706|NCT00516503|PLACEBO_COMPARATOR|Arm II|Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks.
62737303|NCT00632775|ACTIVE_COMPARATOR|2|Subjects in this arm will receive isotonic (0.9% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
62109707|NCT03684096|ACTIVE_COMPARATOR|non-estrogenic pollen extract PCC-100|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
62109708|NCT03684096|PLACEBO_COMPARATOR|placebo|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
62109709|NCT04026620|OTHER|Pamphlet-only|Pamphlet-only women will be provided with two (2) informational pamphlet(s) (both in Afrikaans).
62470363|NCT06181175|ACTIVE_COMPARATOR|ARM 1: PEAPROSTIL 600 mg + Tamsulosin 0.4 mg|"PEAPROSTIL 600 is a food supplement based on Palmitoylethanolamide and Serenoa Repens, respectively for each sachet there are 600 mg of PEA and 320 mg of Serenoa oil. The net content of a sachet is 2.45 g and can be orodispersible without the need for the use of water. The drug does not contain gluten or lactose.~• Tamsulosin 0.4 mg is a drug belonging to the category of alpha-blocker drugs used as first choice drugs (according to European Urology association guidelines) for the treatment of LUTS/BPH. The recommended dose is 0.4 mg per day (1 administration), to be taken preferably at the same time during the day, indifferently with or without meals."
61915348|NCT02508298|ACTIVE_COMPARATOR|Spleen stiffness measurement|ARFI measurements of the spleen will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
61915349|NCT00480987|EXPERIMENTAL|Oxaliplatin + Cytarabine + Fludarabine|Oxaliplatin 30 mg/m\^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m\^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m\^2 IV days 2-6
61915350|NCT06335901||2|
61915351|NCT04959656||X-ray|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
61919938|NCT01951859|EXPERIMENTAL|Topical Neuropathy/Ulcer Cream|an anti-inflammatory topical cream that contains homeopathic ingredients
61919939|NCT01951859|PLACEBO_COMPARATOR|Placebo Cream|
62109710|NCT04026620|OTHER|MET Group|MET women will be provided with a one (1) hour and 30 minute session of Motivational Enhancement Therapy (MET) and informational pamphlet(s) (both in Afrikaans).
62109711|NCT06037135|EXPERIMENTAL|dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery.
62109712|NCT06037135|ACTIVE_COMPARATOR|Control group|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
62109713|NCT03311958|EXPERIMENTAL|Nivolumab|
62470364|NCT06181175|ACTIVE_COMPARATOR|ARM 2: PEAPROSTIL 600 mg|PEAPROSTIL 600 is a food supplement based on Palmitoylethanolamide and Serenoa Repens, respectively for each sachet there are 600 mg of PEA and 320 mg of Serenoa oil. The net content of a sachet is 2.45 g and can be orodispersible without the need for the use of water. The drug does not contain gluten or lactose.
62109714|NCT00907218|EXPERIMENTAL|1|Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.
62109715|NCT06417450|EXPERIMENTAL|Non-invasive Neuromodulation|Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62109716|NCT06417450|PLACEBO_COMPARATOR|Placebo Non-invasive Neuromodulation|Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62300406|NCT05909891|EXPERIMENTAL|Experimental Group|"Patient selection will be made according to the planned randomization after examining the inclusion and exclusion criteria.~Introductory Form, Morisky Scale and Fatigue Scale will be applied to the individuals in the experimental group included in the study. The same forms will be applied to the patients included in the control group. Individuals in the control group will be followed up by the hospital routinely.~In addition to the routine follow-ups for the patients in the experimental group, the training material created by the researchers will be individually presented as an average of 35-40 minutes, and a session will be given in the form of mutual question and answer. After the training, a sample booklet, which is the training material, will be given to the patient as a reminder.~Adaptation and fatigue tests will be re-applied at the first control of the patients after the training."
62109717|NCT01597128|ACTIVE_COMPARATOR|Flex HD|Mesh Type
61915352|NCT04959656||CT|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
61915353|NCT04959656||MRI|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
61915354|NCT04461600|EXPERIMENTAL|AL101|The study included a lead-in cohort with 6 subjects at 6mg AL101 weekly. 13 additional patients were treated with 4mg AL101 weekly.
61915355|NCT06148194|PLACEBO_COMPARATOR|Control|The control group receives 0.9% NaCl physiological saline. Caregivers will spray the children twice daily (morning and afternoon), administering 2 sprays in each nostril and 2 sprays in the throat each time (totally 6 sprays each time) for a continuous period of 4 weeks, starting from the time of study participation.
61915356|NCT06148194|EXPERIMENTAL|Probiotic 1|The Probiotic 1 group receives LiveSpo® Navax product which is NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL. Caregivers will spray the children twice daily (morning and afternoon), administering 2 sprays in each nostril and 2 sprays in the throat each time (totally 6 sprays each time) for a continuous period of 4 weeks, starting from the time of study participation.
61915357|NCT06148194|EXPERIMENTAL|Probiotic 2|The Probiotic 2 group receives LiveSpo® Navax Kid product which is NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL. Caregivers will spray the children twice daily (morning and afternoon), administering 2 sprays in the nose and 2 sprays in each nostril, and 2 sprays in the throat each time (totally 6 sprays each time) for a continuous period of 4 weeks, starting from the time of study participation.
62109718|NCT01597128|ACTIVE_COMPARATOR|Strattice|Use of a second mesh type
62109719|NCT04172948|EXPERIMENTAL|Virtual reality arm|This arm will receive diaphragmatic breathing teaching by a medical professional and virtual reality module that teaches diaphragmatic breathing. This arm will be sent home with the virtual reality equipment and practice this breathing technique through the virtual reality module for 8 weeks.
62109720|NCT04172948|PLACEBO_COMPARATOR|Control|This arm will receive diaphragmatic breathing teaching by a medical professional only. They will practice this breathing technique with a paper handout of diaphragmatic breathing technique instructions for 8 weeks.
62109721|NCT06137846|EXPERIMENTAL|Peri-mucositis|Dental implant has peri-implant mucositis
62109722|NCT06137846|PLACEBO_COMPARATOR|Healthy|Dental implant does not have peri-implant mucositis
62300407|NCT05909891|NO_INTERVENTION|Control Group|
62109723|NCT03495284|EXPERIMENTAL|Potato treatment|Participants will be provided with one potato-based side dish, equivalent to one medium sized potato, every day for 4 weeks for incorporation into their self-selected diet. The potato-based side dish will be prepared at the Penn State Metabolic Kitchen. The potato side dish will consist of commonly consumed potato-based sides in the U.S. and there will be limited inclusion of ingredients high in saturated fat, refined sugars or sodium. French fries will not be provided. The variety of potatoes will represent consumption patterns in the U.S. including white, russet, yellow and red potatoes.
62109724|NCT03495284|ACTIVE_COMPARATOR|Refined grain treatment|Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet. The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used. These will be sides commonly eaten in the U.S. (e.g. pasta made with white flour and white rice, white bread rolls). During this treatment, participants will be told not to consume potatoes.
62109725|NCT01979913|EXPERIMENTAL|Patients with POAG or OHT|Patients with primary open angle glaucoma or ocular hypertension
62300408|NCT03195101|EXPERIMENTAL|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
62109726|NCT02170636|EXPERIMENTAL|Period 1: BIBR 1048 MS + Pantoprazole|"Five treatments with oral administration of 50 mg BIBR 1048 MS (bid for 3 days) and 40 mg Pantoprazole (bid). Randomised sequence.~BIBR 1048 MS Capsule E with pantoprazole; BIBR 1048 MS Capsule F with pantoprazole; BIBR 1048 MS Capsule G with pantoprazole; BIBR 1048 MS Tablet H with pantoprazole; BIBR 1048 MS Drinking solution with pantoprazole"
62109727|NCT02170636|EXPERIMENTAL|Period 2: BIBR 1048 MS|"Three treatments (fixed sequence) with oral administration of 50 mg BIBR 1048 MS (bid for 3 days).~1. BIBR 1048 MS Capsule E without pantoprazole;~2. BIBR 1048 MS Tablet H without pantoprazole;~3. BIBR 1048 MS Drinking solution without pantoprazole"
62300409|NCT03183570|EXPERIMENTAL|[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers|"Arm1: 7mCi (range 6-9 mCi) \[18F\]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the lungs in the FOV is followed by two vertex-to-thigh PET/CT scans.~NOTE: If the patient cannot tolerate lying down for an extended period of time at the time of imaging, the patient may be switched to scanning protocol Option B, which does not include an initial 60-minute dynamic PET/CT scan.~IPF Patients will have a repeat \[18F\]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan (within 12-24 months post initial scan for previously scanned IPF patients if they are willing to be re-consented)."
62300410|NCT03183570|EXPERIMENTAL|[18F]FP-R01-MG-F2 PET/CT in PSC Patients|"Arm 2: 7mCi (range 6-9 mCi) \[18F\]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the liver in the FOV is followed by two vertex-to-thigh PET/CT scans.~Patients will have the option for a repeat \[18F\]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan."
62300411|NCT03183570|EXPERIMENTAL|[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients|Arm 3: 7mCi (range 6-9 mCi) \[18F\]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
62300412|NCT01583036|EXPERIMENTAL|Session 1 digoxin alone, Session 2 retigabine plus digoxin|Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.
62300413|NCT05307471||neuropathic pain|This study will be proposed to patients undergoing thoracotomy or thoracoscopy for partial or total lung resection in the service of Thoracic Surgery of Centre Jean Perrin (Prof. M. Filaire), the objective is to recruit 120 patients (for 100 evaluable patients) over a period of 18 months of inclusion
62300414|NCT02224950|PLACEBO_COMPARATOR|Control|"Non-medicated Emollient with no Clothing Covering Upper Limb - Baseline/Control Cells"
62300415|NCT02224950|ACTIVE_COMPARATOR|Sleeve 2|Non-medicated Emollient plus Lyocell/Chitosan Sleeve
62300416|NCT02224950|PLACEBO_COMPARATOR|Placebo Sleeve|Non-medicated Emollient plus Cotton Sleeve
62300417|NCT06596304|EXPERIMENTAL|Resistance training with blood flow restriction|
62300418|NCT06596304|ACTIVE_COMPARATOR|Resistance training without blood flow restriction|
62300419|NCT06596304|NO_INTERVENTION|No exercise or blood flow restriction|
62470365|NCT06181175|ACTIVE_COMPARATOR|ARM 3: Tamsulosin 0.4 mg|Tamsulosin 0.4 mg is a drug belonging to the category of alpha-blocker drugs used as first choice drugs (according to European Urology association guidelines) for the treatment of benign prostatic hyperplasia. The recommended dose is 0.4 mg per day (1 administration), to be taken preferably at the same time during the day, indifferently with or without meals.
62470366|NCT06181006|EXPERIMENTAL|Cohort 1 (Treatment A): Pirtobrutinib|A single oral dose of pirtobrutinib will be administered.
62470367|NCT06181006|EXPERIMENTAL|Cohort 2 (Treatment B): Pirtobrutinib|A single oral dose of pirtobrutinib will be administered.
62470368|NCT06181006|EXPERIMENTAL|Cohort 3 (Treatment C): Pirtobrutinib|A single oral dose of pirtobrutinib will be administered.
62470369|NCT06559423|EXPERIMENTAL|Laser + HITS|"The treatment involved three consecutive Er:YAG laser sessions (TimeWalker® Intima Laser™, Fotona) followed by six HITS treatments (StarFormer® IntimaWave®, Fotona).~The laser sessions were spaced one month apart, following the IncontiLase® protocol using the G-Runner robotic handpiece. The protocol included three steps: (i) intravaginal laser treatment of the anterior vaginal wall, (ii) treatment of the entire vaginal canal, and (iii) treatment of the vestibule and introitus. Each session lasted 20 minutes.~Six weeks after the final laser treatment, patients received six HITS treatments, with two sessions per week. The HITS protocol involved increasing stimulation frequencies, each for 10 minutes, with the total session lasting 30 minutes."
62470370|NCT06328491|EXPERIMENTAL|Erdafitinib in metastatic steroid-cell tumor of the ovary|Erdafitinib, 8 mg, orally, once daily. Dose increase to 9 mg once daily may be considered based on serum phosphate levels and tolerability.
62120024|NCT05715268|ACTIVE_COMPARATOR|Control pelvic floor physical therapy group|"This group will receive standard PFPT for 12 weeks. MS-symptom (including bladder bother) related questionnaires at baseline, 12 weeks and 6 months after the last PFPT visit.~Patients will be invited to use WeB devices after this time."
62120025|NCT05803850|EXPERIMENTAL|HNC1058 Capsules|HNC1058 Capsules, single ascending doses
62671483|NCT01665378|EXPERIMENTAL|Multiple micronutrient - 1|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
62671484|NCT01665378|ACTIVE_COMPARATOR|Iron and folic acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
62671485|NCT01665378|PLACEBO_COMPARATOR|Folic Acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
61915358|NCT04484168|ACTIVE_COMPARATOR|Terminal Interruption of the Reflux Source (TIRS|These patients will have foam sclerotherapy of the veins in the immediate vicinity of their venous ulcer and thereafter be managed in compression bandaging and followed up fro 6 months or until the ulcer has healed
61915359|NCT04484168|ACTIVE_COMPARATOR|Axial Ablation|These patients will undergo endovenous ablation of the great or small saphenous veins, or other large superficial veins exhibiting significant reflux
61915360|NCT01015001|ACTIVE_COMPARATOR|Active rTMS|1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects
61915361|NCT01015001|PLACEBO_COMPARATOR|Sham rtms|Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region
61915362|NCT02777749|ACTIVE_COMPARATOR|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~Adductor Canal Block (ACB)"
62120026|NCT05803850|PLACEBO_COMPARATOR|HNC1058 Placebos|HNC1058 Placebos, single ascending doses
61915363|NCT02777749|ACTIVE_COMPARATOR|Periarticular SB|50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
62671486|NCT01665378|EXPERIMENTAL|Multiple Micronutrient - 2|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
62120027|NCT05803850|EXPERIMENTAL|HNC1058 Capsules FED|HNC1058 Capsules, food effect, Single dose
61915364|NCT02777749|ACTIVE_COMPARATOR|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
62120028|NCT05803850|PLACEBO_COMPARATOR|HNC1058 Placebos FED|HNC1058 Placebos, food effect, Single dose
61915365|NCT03744143|OTHER|Group A (vaginal technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through vaginal technique
61915366|NCT03744143|OTHER|Group B (laparoscopic technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through laparoscopic technique. Closure of the vagina with a transverse suture or a longitudinal suture.
61915367|NCT03889483|OTHER|NeuroCatch™ Platform Assessment|All participants will undergo two NeuroCatch™ Platform Assessments.
61915368|NCT02927405|PLACEBO_COMPARATOR|TAP Block plus placebo|Patients will only receive a TAP block procedure and then morphine consumption will be recorded.
61915369|NCT02927405|EXPERIMENTAL|TAP Block plus gabapentin|Patients will receive a TAP block procedure and take pre-operative oral Gabapentin and morphine consumption will me recorded after surgery.
61915370|NCT04637009|EXPERIMENTAL|Part 1 (dose escalation)|Oral administration of TAS1553 once daily at specific time points.
61915371|NCT04637009|EXPERIMENTAL|Part 2 (dose expansion)|Oral administration of TAS1553 once daily at specific time points.
61915372|NCT03553030||prediabetics|patients with diagnosed of prediabetes.
62109728|NCT02247063|SHAM_COMPARATOR|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
62109729|NCT02247063|EXPERIMENTAL|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
61915373|NCT03553030||normo glycemics (controls)|patients without diagnosed of prediabetes.
61915374|NCT01569243|OTHER|Usual care group|Subjects in this group will receive the usual standard of care available at MGH.
62109730|NCT03621761|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|8 weekly telephone-based sessions and 2 booster sessions
62671487|NCT01665378|ACTIVE_COMPARATOR|Iron and Folic Acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
61915375|NCT01569243|EXPERIMENTAL|Text messaging group|Subjects in this group will be enrolled to receive text messages aimed at providing bite-sized coaching based on measured step count to help improve activity levels and providing reminder, educational and motivation messages aimed at helping patients to meet their diabetes self-management goals.
61915376|NCT04779749||COVID positive <20 weeks|Case groups 1 will include pregnant patients infected by SARS-CoV2 before 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
61915377|NCT04779749||COVID positive >20 weeks|Case groups 2 will include pregnant patients infected by SARS-CoV2 after 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
61915378|NCT04779749||Control|Patients not infected by SARS-CoV2 during pregnancy during the period starting on February 1st 2020 and ending on November 30th 2020
61915379|NCT06022484||People with acute low back pain|No intervention.
61915380|NCT06022484||General practitioners who treat people with acute low back pain|No intervention.
61915381|NCT03054129|EXPERIMENTAL|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program. Balance training will be non-supervised program."
61919940|NCT03551340||Traditional methods|Patients, who consulted for gastro-intestinal symptoms between July 2016 and May 2017, and were investigated by traditional methods (stool microscopy and/or culture).
62470371|NCT04930796|EXPERIMENTAL|VER-01 following overnight fast (Day 1) and a high-fat breakfast (Day 4)|The PK profile of VER-01 is investigated after oral intake of a single dose VER-01 (corresponding to 10 mg THC) in the morning after a 10-hour fasting period on day 1, and 30 minutes after the intake of a standardised high-fat breakfast has been started on day 4 (Group 1).
62300420|NCT04488822|EXPERIMENTAL|Pexidartinib|
62109731|NCT03621761|ACTIVE_COMPARATOR|Modafinil|50-400 mg per day (oral)
62109732|NCT03621761|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy + Modafinil|Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)
62109733|NCT02560519|ACTIVE_COMPARATOR|Ringers acetate solution|Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
62109734|NCT02560519|EXPERIMENTAL|Albumin solution|Albuman® 200g/L (Sanquin, the Netherlands) is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.The solution contains 100 mmol/l of sodium (2.3 g/L). Pharmacodynamic properties: Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Pharmacokinetic properties. Under normal conditions, the average half-life of albumin is about 19 days. Albuman® 40g/L is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin. The solution contains 140 mmol/l of sodium (3.2 g/L).
62109735|NCT00959920|ACTIVE_COMPARATOR|Indwelling foley catheter|Insertion of an indwelling foley catheter when bladder emptying is necessary. The indwelling catheter will remain in place until the time of delivery.
62109736|NCT00959920|ACTIVE_COMPARATOR|Intermittent straight catheterization|Intermittent straight catheterization will be performed as needed during labor.
62109737|NCT03829410|EXPERIMENTAL|Onvansertib + FOLFIRI + Bevacizumab|"Phase 1b: Onvansertib escalating starting dose of 12 mg/m\^2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab. This Phase 1b portion of the study has been completed.~Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) of 15 mg/m\^2 orally Day 1 through Day 5 and Day 15 through Day 19 of every 28-day cycle in combination with FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m\^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle."
62300421|NCT01144273|ACTIVE_COMPARATOR|0.5% Ropivacaine|group receiving TAP block (0.5% ropivacaine at TAP plane)
62300422|NCT01144273|PLACEBO_COMPARATOR|normal saline|group receiving placebo (saline) at TAP plane
62300423|NCT04140487|EXPERIMENTAL|Treatment (azacitidine, venetoclax, gilteritinib)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles, and gilteritinib PO QD on days 1-28. Treatment of azacytidine and venetoclax repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Cycles of gilteritinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62300424|NCT05162157||at-home spirometry|This group performs spirometry at home with the Nuvoair spirometer
62470372|NCT04930796|EXPERIMENTAL|VER-01 following a high-fat breakfast (Day 1) and overnight fast (Day 4)|The PK profile of VER-01 is investigated after oral intake of a single dose VER-01 (corresponding to 10 mg THC) in the morning 30 minutes after the intake of a standardised high-fat breakfast has been started on day 1 and after a 10-hour fasting period on day 4 (Group 2).
62470373|NCT01874561|EXPERIMENTAL|Group 1|"Group 1: investigational product (custirsen) will receive:~* 320 mg of custirsen + 5 mg of dexamethasone on day 1~* 480 mg of custirsen + 5 mg of dexamethasone on day 3~* 640 mg of custirsen + 3 mg of dexamethasone on day 5~* 640 mg of custirsen on day 7 under fasting conditions"
62671488|NCT01665378|PLACEBO_COMPARATOR|Folic acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
62109738|NCT05324631|EXPERIMENTAL|Treatment group A|SHR0302
62109739|NCT05324631|PLACEBO_COMPARATOR|Treatment group B|SHR0302 Placebo
61915382|NCT03054129|ACTIVE_COMPARATOR|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program."
61915383|NCT04745273|ACTIVE_COMPARATOR|Ondansetron|Participants will receive Kemoset 4 mg iv intraoperatively
61915384|NCT04745273|PLACEBO_COMPARATOR|Salin solution|Participants will receive Salin solution 2ml (iv) intraoperatively
61915385|NCT06086262||Athletic group|twenty basketball and tennis players
61915386|NCT06086262||Non athletic group|were recruited from undergraduate students
61915387|NCT00744354|EXPERIMENTAL|Non-Randomized Open Label Single Arm|Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
61915388|NCT01072565|ACTIVE_COMPARATOR|SMBG Only|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
61915389|NCT01072565|ACTIVE_COMPARATOR|SMBG and CGM|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
61915390|NCT02739737|EXPERIMENTAL|Blinded Reviewers|Subjects receiving randomized sham manuscript for review
62109740|NCT06258980||heavily menstruating females with glanzmannns Thrombaesthenia|
62109741|NCT03663218|OTHER|Single Arm|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
62109742|NCT00855153|EXPERIMENTAL|treatment|Subjects receive 50mg DCS prior to 90 min session with graded VRE treatment
62109743|NCT03693742|EXPERIMENTAL|18F-DCFPyL PET/CT scan with MSG drink|Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
62671489|NCT01035307||Genomic and Proteomic Profiling|
62671490|NCT03055507|ACTIVE_COMPARATOR|Control|Standard pain regimen of acetaminophen 650 mg q6hrs while awake until cessation of need for scheduled pain medication with the addition of oxycodone 5 mg q3 hrs PRN (as needed) pain.
62671491|NCT03055507|EXPERIMENTAL|Ibuprofen|Alternating every 3 hours acetaminophen 650 mg and ibuprofen 400 mg while awake until cessation of need for schedule pain medication with the addition of oxycodone 5 mg q3hr PRN pain.
62671492|NCT04449809|EXPERIMENTAL|Exercise|Exercise program
61915391|NCT02739737|EXPERIMENTAL|Unblinded Reviewers|Subjects receiving randomized sham manuscript for review
61915392|NCT02673047||Botox®|Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.
61915393|NCT05778643|EXPERIMENTAL|TaKeTiNa|Participants receive TaKeTiNa Music therapy
61915394|NCT05778643|NO_INTERVENTION|Waiting|Participants receive no additional therapy
62109744|NCT03693742|PLACEBO_COMPARATOR|18F-DCFPyL PET/CT scan with placebo drink|Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.
62109745|NCT02982213|NO_INTERVENTION|No companion present|No companion is present during the placement of the epidural catheter.
62109746|NCT02982213|ACTIVE_COMPARATOR|Companion present|A companion will be present during the placement of the epidural catheter.
62120029|NCT00765934|OTHER|Rapydan|Internal control. Blood from both arms will be drawn. Only one arm of the subject is treated with Rapydan.
62671493|NCT02830087|ACTIVE_COMPARATOR|220 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 220 mmHg.
62671494|NCT02830087|ACTIVE_COMPARATOR|250 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 250 mmHg
62671495|NCT02830087|ACTIVE_COMPARATOR|275 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 275 mmHg
62671496|NCT02830087|ACTIVE_COMPARATOR|300 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 300 mmHg
61915395|NCT02003274|OTHER|Clamp-Mixed Meal Arm|Twenty adult patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
61915396|NCT02003274|OTHER|IVGTT-Mixed Meal Arm|Twenty healthy adult volunteers will be recruited.
62671497|NCT02830087|ACTIVE_COMPARATOR|325 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 325 mmHg
62300425|NCT05627245|EXPERIMENTAL|Treatment (tazemetostat, belinostat)|"Patients receive tazemetostat PO BID on days 2-21 of cycle 1 and days 1-21 of subsequent cycles, and belinostat IV over 30-180 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients may undergo a tumor biopsy during screening and on study (dose-expansion only). Patients undergo blood sample collection while on study and PET/CT scan throughout the study. Patients may also undergo CT scan alone throughout the study."
62300426|NCT03446677|EXPERIMENTAL|Asymptomatic persons with HIV|
62300427|NCT02514538|EXPERIMENTAL|Non-effervescent tablets|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
62300428|NCT02514538|ACTIVE_COMPARATOR|Effervescent Paracetamol|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
62300429|NCT00967941||Ancef|
62300430|NCT00967941||Vancomycin and Cefazolin|
62300431|NCT00967941||Daptomycin and Cefazolin|
62470374|NCT01874561|PLACEBO_COMPARATOR|Group 2|"Group 2: placebo (normal saline) will receive:~* placebo + 5 mg of dexamethasone on day 1~* placebo + 5 mg of dexamethasone on day 3~* placebo + 3 mg of dexamethasone on day 5~* placebo on day 7 under fasting conditions"
62671498|NCT02830087|ACTIVE_COMPARATOR|350 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 350 mmHg
61915397|NCT00466687|EXPERIMENTAL|Therapeutic Intervention|"Tarceva and Avastin:~* Tarceva: 150mg PO, days 1-28~* Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course"
62109747|NCT00001575|EXPERIMENTAL|Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)|"10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).~Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body"
61915398|NCT06321341|EXPERIMENTAL|Vespireit, prolonged-release tablets, 15 mg|Dosage regimen: 1 tablet once a day at approximately the same time in the morning after meals for 28 days. The drug is taken orally, whole, without breaking and not chewing.
61915399|NCT06321341|ACTIVE_COMPARATOR|Arlevert, tablets, 40 mg + 20 mg|Dosage regimen: 1 tablet 3 times a day at approximately the same time after meals for 28 days. The drug is taken orally, whole, without breaking and not chewing.
62109748|NCT06430125|NO_INTERVENTION|Control group|this group will include 23 patients who will receive metformin 2gm/day. The initial dose of metformin will be 1 g/day taken orally with the meal. After 7 days (week 1), the dose will be up titrated to daily dose of 2,000 mg/day. Treatment duration will be 12 weeks .
62109749|NCT06430125|ACTIVE_COMPARATOR|Nicorandil group|this group will include 23 patients who will receive a combination of metformin 2g/day and nicorandil 10 mg twice daily. The initial dose of metformin will be 1 g/day taken orally with the meal. After 7 days (week 1), the dose will be uptitrated to daily dose of 2,000 mg/day. Treatment duration will be 12 weeks .
62300432|NCT02351115|EXPERIMENTAL|Sequence BEADC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
62300433|NCT02351115|EXPERIMENTAL|Sequence CDAEB|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
62300434|NCT02351115|EXPERIMENTAL|Sequence DEBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
62470375|NCT01874561|ACTIVE_COMPARATOR|Group 3|"Group 3: positive control (moxifloxacin) will receive:~* placebo + 5 mg of dexamethasone on day 1~* placebo + 5 mg of dexamethasone on day 3~* placebo + 3 mg of dexamethasone on day 5~* 400 mg of moxifloxacin + placebo (immediately after moxifloxacin administration) on day 7 under fasting conditions"
62470376|NCT02287051||colonoscopy population|
62470377|NCT02925247|OTHER|patient with atrial fibrillation|
62470378|NCT04535076|EXPERIMENTAL|Transcatheter Aortic Valve Implantation|
62671499|NCT05311410|ACTIVE_COMPARATOR|Control group|
62671500|NCT05311410|ACTIVE_COMPARATOR|Study group|
61915400|NCT03167567|EXPERIMENTAL|intervention|These women will have a medical clown present in the room during their labor
61915401|NCT03167567|NO_INTERVENTION|Control|These women will not have a medical clown in the room during their labor
61915402|NCT02026570|NO_INTERVENTION|Control|Persons with unilateral transtibial amputation receiving standard physical therapy.
61915403|NCT02026570|EXPERIMENTAL|Motor Control Internal Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with motor control internal focus of attention instructions.
61915404|NCT02026570|EXPERIMENTAL|Motor Control External Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with external focus of attention instructions.
61915405|NCT05683431|EXPERIMENTAL|Cognitive Control of Emotion (CCE) Training|"Mobile (iphone/ipad) App with game-like exercises designed to improve Cognitive Control of Emotion (CCE), i.e. the ability to control the influence of emotional information on behavior. Participants do 20 sessions (approximately 30min each), over 4 weeks."
62671501|NCT01123564|EXPERIMENTAL|Lucentis (ranibizumab)|
62470379|NCT04535076|ACTIVE_COMPARATOR|Surgical Aortic Valve Replacement|
62470380|NCT04992611|EXPERIMENTAL|Circadian-Aligned Sleep Extension|A sleep extension period that roughly conforms to a given participant's circadian phase (i.e., fits the schedule of a Morning Lark vs. Night Owl).
62470381|NCT04992611|EXPERIMENTAL|Circadian-Misaligned Sleep Extension|A sleep extension period that does not conform to a given participant's circadian phase. In other words, this condition asks Morning Larks to extend their sleep by sleeping in later, or asks Night Owls to extend their sleep by going to bed earlier.
62470382|NCT02129491||Pediatric Stroke and Hemiplegia|Any infant or child with acute stroke or hemiplegia
62671502|NCT01123564|ACTIVE_COMPARATOR|Laser|
62671503|NCT05539170|EXPERIMENTAL|"micro parenting intervention"|"Parents will be instructed to bring the completed questionnaires with them to the university lab. Then, in the lab, parents will be observed interacting with their child. Following these baseline conditions, half of the parents will receive the micro parenting intervention-in the form of individual positive feedback concerning their parenting and their child's behavior."
62671504|NCT05539170|NO_INTERVENTION|care-as-usual condition|Participants in the care-as-usual control condition receive no immediate positive parenting feedback but will also be taken aside without their child, receiving only the instructions of the experiment.
62671505|NCT01220063|OTHER|Radiation + Irinotecan|"Irinotecan will be administered :~- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy~Radiotherapy (RSHF) will be administered :~* at D1, D3, D8 and D10~* 48 Gy, 12 Gy by fractions twice a week"
62671506|NCT05023655|EXPERIMENTAL|Tazemetostat|tazemetostat 800 mg po twice daily in continuous 28- day cycles
61915406|NCT03541876||children with H. pylori infection|
61915407|NCT02554279|EXPERIMENTAL|menotropin|menotropins for injection
61915408|NCT02554279|ACTIVE_COMPARATOR|recombinant FSH|
61915409|NCT03055377|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
61915410|NCT03055377|PLACEBO_COMPARATOR|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
62109750|NCT03015974||corticosteroid|pediatric IgA nephropathy treated with only corticosteroid
62109751|NCT03015974||corticosteroid and cyclophosphamide|pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
62470383|NCT01452802||HM II (HeartMate II LVAD)|Subjects who elect to, and receive HM II LVAD therapy at baseline
62470384|NCT01452802||OMM (Optimal Medical Management)|Subjects who elect to remain on optimal medical management
62470385|NCT04123808|EXPERIMENTAL|IpsiHand Treatment|All participants will receive treatment with IpsiHand device
62671507|NCT02975453||Rivaroxaban|Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
62470386|NCT05324098|EXPERIMENTAL|Health services research (STAND-T, text messages)|Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.
62470387|NCT02974556|ACTIVE_COMPARATOR|Standard surgical treatment group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
61915411|NCT04652414|EXPERIMENTAL|Prednisone|Patients randomized to the intervention arm will receive prednisone 50mg PO daily for 7 days.
61915412|NCT04652414|PLACEBO_COMPARATOR|Placebo|Patients will receive matching placebo PO daily for 7 days.
61915413|NCT03611842||Healthy eardrum|OME (otitis media with effusion)with normal tympanic membrane
62300435|NCT02351115|EXPERIMENTAL|Sequence EDBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
62300436|NCT02351115|EXPERIMENTAL|Sequence CABED|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
62300437|NCT05377632|ACTIVE_COMPARATOR|Hybrid-Group|Laparoscopic and Robotic-assisted combined (partial) nephrectomy via the hybrid (trans-peritoneal and retroperitoneal) access route
62300438|NCT05377632|ACTIVE_COMPARATOR|Retroperitoneal-Group|Robotic-assisted laparoscopic (partial) nephrectomy via the retroperitoneal access route
62300439|NCT06457126|EXPERIMENTAL|Attention Training Technique|An audio-recorded 12-minute version will be used and administered with permission and training from the creator of the Attention Training Technique (Professor Adrian Wells). At least four to eight sessions will be administered, given the minimally effective dose is four. Administration will continue until stable effects in the data are observed.
62671508|NCT04690647|PLACEBO_COMPARATOR|Opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia without preoperative regional anaesthesia and dexamethasone.
61915414|NCT03611842||Atrophic eardrum|OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket
61915415|NCT00776685|EXPERIMENTAL|learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
61915416|NCT00776685|EXPERIMENTAL|learning to cope with your sensation seeking|cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
61915417|NCT00776685|EXPERIMENTAL|learning to cope with your anxiety sensitivity|cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
61915418|NCT00776685|EXPERIMENTAL|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
62300440|NCT03308851|EXPERIMENTAL|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
62300441|NCT03308851|NO_INTERVENTION|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
62671509|NCT04690647|EXPERIMENTAL|Regional anaesthesia, opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and without preoperative dexamethasone.
62470388|NCT02974556|EXPERIMENTAL|Proactive management group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. At the end of surgical procedure HIPEC will be performed with oxaliplatin 460 mg/m2 and before the beginning of HIPEC an intravenous infusion of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin will be administered.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
62470389|NCT04975035|EXPERIMENTAL|Zolodine group|
62470390|NCT03914183|OTHER|Control|Standard of care arm - using insulin pen needles as previously prescribed
62671510|NCT04690647|EXPERIMENTAL|Regional anaesthesia, dexamethasone, opioid and non opioid postoperative analgesia|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and dexamethasone.
62109752|NCT03015974||corticosteroid and mycophenolate mofetil|pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
62109753|NCT03931044|EXPERIMENTAL|Image-Guided Robotic Gastrectomy|"The day before surgery, the ICG will be injected endoscopically into the submucosa of the four quadrants around the tumor (1.25mg/mL, 0.6mL x 4).~A modified total D2 gastrectomy - including the following lymph node stations: 1 - 7 + 8a, 9, 11p, 12a - will be performed in each patient.~The lymph node dissection will be performed using the Da Vinci Xi robotic system and the assistance of the near infrared technology to detect ICG fluorescence.~Even the resulting fluorescent lymph nodes outside the standard dissection plane will be retrieved. The lymph node stations will be sent to the pathologist in different containers and further subdivided according to fluorescence."
62109754|NCT03931044|NO_INTERVENTION|Robotic Gastrectomy|Data from patients undergoing the same surgery without the ICG imaging procedure will be collected during the same study period.
61915419|NCT04545944|EXPERIMENTAL|Midazolam single doses / Vonoprazan multiple doses|Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10
62109755|NCT00585455||A|Chronic heart failure patients with concomitant depression
62109756|NCT06552390|EXPERIMENTAL|Intervention Group - HRN4HTx|Cardiac rehabilitation as previously described.
62300442|NCT06521489|ACTIVE_COMPARATOR|Study Group 1, Asymmetrical HFNCO|"The intervention involves implementing the Asymmetrical High Flow Oxygenation Nasal Cannula as an oxygen treatment at Study Group 1. In contrast, oxygen supply was provided via conventional High Flow Nasal Cannula as a standard oxygen patients' treatment~The first Study Group will include patients on Asymmetrical High Flow Nasal Cannula Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
62671511|NCT03786055|EXPERIMENTAL|Somatic Yoga and Meditation (SYM)|Participants will engage in 16 sessions of somatic yoga and meditation with appropriate props as needed over 8 weeks and continue with a home practice. Application of SYM throughout activities of daily living is reinforced. All sessions are facilitated by trained yoga therapists.
62671512|NCT03251599|SHAM_COMPARATOR|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
62300443|NCT06521489|ACTIVE_COMPARATOR|Study Group 2, Conventional HFNCO|"The intervention involves implementing High Flow Nasal Cannula Oxygenation as an oxygen treatment in Study Group 2.~The second Study Group will include patients on Conventional High Flow Nasal Cannula Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
62671513|NCT03251599|ACTIVE_COMPARATOR|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
62120030|NCT04271410|EXPERIMENTAL|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
62671514|NCT01538407|NO_INTERVENTION|Control group|No intervention group
62671515|NCT01538407|ACTIVE_COMPARATOR|Strength training group|The knee extension strength training intervention period is 12 weeks with training sessions three times per week.
62109757|NCT03121963|EXPERIMENTAL|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
61919941|NCT03551340||Gastro-intestinal panel by PCR|Patients, who consulted for gastro-intestinal symptoms between July 2017 and May 2018,and were investigated by a gastro-intestinal panel by PCR
61919942|NCT03206905|EXPERIMENTAL|Endoscopic Sleeve Gastroplasty|
62109758|NCT03121963|ACTIVE_COMPARATOR|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
62109759|NCT02732678|EXPERIMENTAL|Cohort of a dose of Propranolol 80 mg/day|
62109760|NCT02732678|EXPERIMENTAL|Cohort of a dose of Propranolol 120 mg/day|
62109761|NCT02732678|EXPERIMENTAL|Cohort of a dose of Propranolol 160 mg/day|
62671516|NCT00770094|ACTIVE_COMPARATOR|Group 1|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the AMO/VISX CustomVue™ wavefront guided Excimer Laser System performed on the contralateral eye
62671517|NCT00770094|ACTIVE_COMPARATOR|Group 2|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System performed on the contralateral eye
62109762|NCT01648140|EXPERIMENTAL|T40|Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm
62109763|NCT01648140|EXPERIMENTAL|T60|Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
62109764|NCT01648140|ACTIVE_COMPARATOR|PRT|Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm
62109765|NCT01648140|EXPERIMENTAL|G4|Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
62109766|NCT04124263|EXPERIMENTAL|Medication Time Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
62109767|NCT04124263|EXPERIMENTAL|Educational Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
61919943|NCT03206905|ACTIVE_COMPARATOR|Diet and exercise only.|
61919944|NCT02503345|PLACEBO_COMPARATOR|Placebo|Placebo capsules (1, 2 or 5) PO TID
61919945|NCT02503345|EXPERIMENTAL|ALLN-177 low dose|ALLN-177 1,500 units/meal PO TID
61919946|NCT02503345|EXPERIMENTAL|ALLN-177 mid dose|ALLN-177 3,000 units/meal PO TID
61919947|NCT02503345|EXPERIMENTAL|ALLN-177 high dose|ALLN-177 7,500 units/meal PO TID
61919948|NCT00719264|EXPERIMENTAL|bevacizumab, RAD001 (everolimus)|Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks
61919949|NCT00719264|ACTIVE_COMPARATOR|bevacizumab, interferon alfa-2a (IFN)|Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks
62109768|NCT02087306|EXPERIMENTAL|Brincidofovir|"Subjects who weighed \<50 kg received 2 mg/kg (not to exceed 100 mg) BCV twice weekly administered orally as the appropriate volume of 10-mg/mL liquid suspension.~Subjects who weighed ≥50 kg received 100 mg BCV twice weekly administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine)."
62109769|NCT05591001|ACTIVE_COMPARATOR|Ketamine-dexmedetomidine group|Dexmedetomidine( 0.4 -0.6 μg/.kg /.h r)) ketamine,( 1-2m/.kg/.hr) infusion and giving bolus of fentanyl,( 1-2μg/.kg/ ) with keeping mean arterial blood pressure and heart rates changes within 25% of the baseline.
62671518|NCT00770094|ACTIVE_COMPARATOR|Group 3|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment in one eye of the subject and the Bausch and Lomb Planoscan™ Excimer Laser System performed on the contralateral eye
62671519|NCT01551823|EXPERIMENTAL|Team 1|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
62671520|NCT01551823|EXPERIMENTAL|Team 2|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
62671521|NCT04251936|EXPERIMENTAL|Exercise training plus smoking cessation group program|
62671522|NCT04251936|ACTIVE_COMPARATOR|Smoking cessation group program|
62671523|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
62671524|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
62671525|NCT00245570|EXPERIMENTAL|1|Montelukast - Salmeterol - Placebo
62671526|NCT00245570|EXPERIMENTAL|2|Montelukast - Placebo - Salmeterol
62671527|NCT00245570|EXPERIMENTAL|3|Salmeterol - Montelukast - Placebo
62671528|NCT00245570|EXPERIMENTAL|4|Salmeterol - Placebo - Montelukast
62671529|NCT00245570|EXPERIMENTAL|5|Placebo - Montelukast - Salmeterol
62671530|NCT00245570|EXPERIMENTAL|6|Placebo - Salmeterol - Montelukast
62671531|NCT03996460|PLACEBO_COMPARATOR|Placebo powder|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1). Fifteen (15) patients in arm 1 (group 1) will receive the matching placebo powder orally once daily for 12 weeks (90 days).
62671532|NCT03996460|ACTIVE_COMPARATOR|192 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 2 (group 2) will receive the 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally once daily for 12 weeks (90 days).
62671533|NCT03996460|ACTIVE_COMPARATOR|384 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 3 (group 3) will receive the 384 mg powder of K0706 (equivalent to 192 mg capsule of K0706) orally once daily for 12 weeks(90 days).
62671534|NCT04405388|OTHER|Spermidine first|First treatment period (8 weeks) will be 4 mg spermidine per day orally. Afterwards 4 weeks of wash-out followed by 8 weeks of placebo treatment.
62671535|NCT04405388|OTHER|Placebo first|First treatment period (8 weeks) will be placebo. Afterwards 4 weeks of wash-out followed by 8 weeks of 4 mg spermidine per day orally.
62671536|NCT04697992|EXPERIMENTAL|group A|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
62671537|NCT04697992|EXPERIMENTAL|group B|one eye was treated with tranexamic acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
62671538|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
62671539|NCT02159404||Healthy controls|
62671540|NCT04821011||Newborn birth between 28 and 40 Weeks of Gestational Age (wGA)|"Newborn birth between 28 and 40 Weeks of Gestational Age (wGA) will be included. The mother's newborn will be have a record of her heartbeats.~The newborn will be have an acoustic listening of their mother's heartbeat and a record of their own heartbeats."
62671541|NCT05713370|PLACEBO_COMPARATOR|no exercise, no SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be no exercise the night before the study day, normal sleep (8 h))
62671542|NCT05713370|EXPERIMENTAL|no exercise, SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be no exercise the night before the study day, 4 h of sleep the previous night)
62671543|NCT05713370|EXPERIMENTAL|Exercise, no SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be 45 min of exercise the night before the study day, normal sleep (8 h))
61919950|NCT05646472||≥ 65 Community-dwelling older adults|
61919951|NCT03926546|EXPERIMENTAL|Individual ERP|Individual Exposure and Response Prevention for OCD
61919952|NCT03926546|EXPERIMENTAL|Group ERP|Group Exposure and Response Prevention for OCD
62671544|NCT05713370|EXPERIMENTAL|Exercise, SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be 45 min of exercise the night before the study day, 4 h of sleep the previous night)
62671545|NCT01131650||diabetic retinopathy|
62671546|NCT01131650||diabetica retinopathy prevalence|
62671547|NCT02828085|OTHER|Infective Pericarditis|In patient prescribed with a pericardite kit for an etiological diagnosis of a pericardial syndrome, an additional nasal swab will be performed in order to perform a specific diagnosis with PCR technique.
62671548|NCT04225520|ACTIVE_COMPARATOR|Treatment recommendation based on guidelines|Treatment of the patient assigned to this arm will be based on the current guidelines for CRT implantation, as issued by the European Society of Cardiology. All patients will receive CRT implantation, with bi-ventricular pacing ON.
62671549|NCT04225520|EXPERIMENTAL|Treatment recommendation based on mechanical dyssynchrony|Treatment of the patients assigned to this arm will be based on the presence of mechanical dyssynchrony. All patients will receive CRT implantation. Bi-ventricular pacing will be either turned ON or OFF, based on respectively the presence or absence of mechanical dyssynchrony.
62671550|NCT01408498|NO_INTERVENTION|Placebo Control|Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
62671551|NCT01408498|EXPERIMENTAL|Testosterone administration group|Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
61915420|NCT02630199|EXPERIMENTAL|AZD6738 + paclitaxel|The PART A will be in combination with paclitaxel; the starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity. The PART B will be an independent parallel PK expansion cohort with cycle 0 of AZD6738 on D1, D8\~D21 monotherapy followed by combination therapy with weekly paclitaxel from cycle 1.
61915421|NCT03475953|EXPERIMENTAL|Phase 1 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915422|NCT03475953|EXPERIMENTAL|Phase 2 : cohort A Regorafenib + Avelumab|Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915423|NCT03475953|EXPERIMENTAL|Phase 2 : cohort B Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915424|NCT03475953|EXPERIMENTAL|Phase 2 : cohort C Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915425|NCT03475953|EXPERIMENTAL|Phase 2 : cohort D Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915426|NCT03475953|EXPERIMENTAL|Phase 2 : cohort E Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915427|NCT03475953|EXPERIMENTAL|Phase 2 : cohort F Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915428|NCT03475953|EXPERIMENTAL|Phase 2 : cohort G Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915429|NCT03475953|EXPERIMENTAL|Phase 2 : cohort H Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915430|NCT03475953|EXPERIMENTAL|Phase 2 : cohort I Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915431|NCT03475953|EXPERIMENTAL|Phase 2 : cohort A' Regorafenib low-dose + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915432|NCT03475953|EXPERIMENTAL|Phase 2 : cohort J Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915433|NCT03475953|EXPERIMENTAL|Phase 2 : cohort K Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915434|NCT03475953|EXPERIMENTAL|Phase 2 : cohort L Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915435|NCT03475953|EXPERIMENTAL|Phase 2 : cohort M Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915436|NCT03475953|EXPERIMENTAL|Phase 2 : cohort N Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915437|NCT03475953|EXPERIMENTAL|Phase 2 : cohort O Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
62109770|NCT05591001|ACTIVE_COMPARATOR|propofol group|propofol (100 ug/kg/min) -giving a bolus of fentanyl, (1-2μg/.kg/ ) with keeping mean arterial blood pressure and heart rate changes within 25% of the baseline.
62109771|NCT02606409|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine intravenous sedation at 0.2-0.7 µg/kg/h for \>24h.
61915438|NCT03475953|EXPERIMENTAL|Phase 2 : cohort P Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
61915439|NCT02126748|EXPERIMENTAL|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
61915440|NCT02126748|ACTIVE_COMPARATOR|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
61915441|NCT02126748|NO_INTERVENTION|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
62109772|NCT02606409|ACTIVE_COMPARATOR|Propofol|Propofol sedation at 10-70µg/kg/h for \>24h.
62109773|NCT02797249|EXPERIMENTAL|aspirin|Low dose aspirin (100 mg) starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy, taking at night.
62109774|NCT02797249|OTHER|blank|Routine examination during pregnancy.
61915442|NCT05045066|EXPERIMENTAL|Treatment (cholecalciferol)|Patients with low vitamin D3 levels receive cholecalciferol PO daily for 8 weeks in the absence of unacceptable toxicity. Patients undergo blood sample collection throughout the study.
62470391|NCT03914183|ACTIVE_COMPARATOR|mCPN intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened The current research study has accordingly been designed to determine if a pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles."
61915443|NCT01077375|PLACEBO_COMPARATOR|Placebo|Placebo tablets, twice a day, oral administration
61915444|NCT01077375|EXPERIMENTAL|Milnacipran|Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses.
62300444|NCT06521489|NO_INTERVENTION|Control Group|"No Intervention: Control group In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 12L/min.~In this group, all patients will receive the usual standard of care, with no other interventions included"
62470392|NCT05093309|EXPERIMENTAL|Intervention|The intervention group received naloxone resources + monthly reminders + educational webinar.
62671552|NCT05688709|ACTIVE_COMPARATOR|Control group|"Psychosocial services (PSS) are offered by a trained health worker in a designated space within the health facility. They assess youth for PSS needs and depending on the identified needs, health workers determine the relevant approach for providing PSS. Health workers refer PSS they cannot offer to established referral networks. Specifically, for ART adherence, health workers use the 5As principles to offer adherence psychosocial support. These are;~* Assess patient psychosocial concerns and needs that may hinder adherence to ART.~* Advise on the benefits of disclosure and support systems to adherence.~* Assist patients identify the support systems that will enable them to adhere to treatment.~* Agree on family and community support systems (expert client in the community).~* Arrange for the patient to join psychosocial support groups and use support systems."
62470393|NCT05093309|NO_INTERVENTION|Control|The control group received naloxone resources + monthly reminders + delayed educational webinar (after the 3-month study period).
62470394|NCT02393417|EXPERIMENTAL|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
62470395|NCT02393417|EXPERIMENTAL|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
62470396|NCT02393417|EXPERIMENTAL|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
62470397|NCT02393417|PLACEBO_COMPARATOR|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
62470398|NCT03673670|EXPERIMENTAL|1.5 mg RPL554 and tiotropium/olodaterol|1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
62470399|NCT03673670|EXPERIMENTAL|6 mg RPL554 and tiotropium/olodaterol|6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
62470400|NCT03673670|EXPERIMENTAL|Placebo and tiotropium/olodaterol|Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
62300445|NCT02015819|EXPERIMENTAL|Treatment (neural stem cells, flucytosine, leucovorin)|"Patients receive CD-expressing neural stem cells intracranially on days 1 and 15. Flucytosine is taken orally every 6 hours on days 4-10 and 18-24. Depending on when a subject enters the study, they may also be given leucovorin orally every 6 hours on days 4-10 and 18-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation used the following dose levels:~Dose Level 1 (NSC 5x10\^7 and 5-FC 37.5 mg/kg)~Dose Level 2 (NSC 1x10\^8 and 5-FC 37.5 mg/kg)~Dose Level 3 (NSC 1.5x10\^8 and 5-FC 37.5 mg/kg)~Dose Level 4 (NSC 1.5x10\^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis"
62109775|NCT04213560|EXPERIMENTAL|Weighted waist-hooping|Participants weighted waist-hooping on their own for ten minutes a day, four days a week, for six weeks resulting in a total of 40 minutes of weighted waist-hooping each week. Participants weighted waist-hooped with a three-pound weighted hula hoop at the waist for ten minutes. Half time hooping to the left and the other half hooping to the right. If discomfort while hooping occurred participants were instructed to take breaks, change directions more frequently, or where thicker clothing to lessen the impact of the hoop around their waists. The investigators would check in on the participants weekly to provide feedback on technique and answer all questions throughout the six-week intervention.
62109776|NCT04213560|NO_INTERVENTION|Control|No Intervention
62109777|NCT00886054||Neurocritical patients|Neurocritical patients including those sustaining head injury, cerebrovascular events (such as intracerebral hemorrhage, subarachnoid hemorrhage, etc.), brain tumor, or hydrocephalus.
62300446|NCT03184870|EXPERIMENTAL|Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI|FOLFIRI: FOL (folinic acid \[leucovorin\]) F (fluorouracil \[5-fluorouracil\]) IRI (irinotecan \[CAMPTOSAR\])
62300447|NCT03184870|EXPERIMENTAL|Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel|
62470401|NCT01353664|EXPERIMENTAL|Romidepsin|This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
62470402|NCT00479258|EXPERIMENTAL|Inhaled insulin (Exubera)|
62671553|NCT05688709|EXPERIMENTAL|Intervention|In addition to MOH standard care, we will enrol YLHIVA on a WhatsApp PSG and assign them trained peer counsellors. We will allocate YLHIVA to a WhatsApp group depending on their age and the health facility where they seek care (12). YLHIVA will interact with each other and their peer counsellors through one-on-one private communications and on the group chat.
62109778|NCT02884583|EXPERIMENTAL|Pulmonary function test|Patients hospitalized for Oral Food Challenge realize pulmonary function test
62470403|NCT00479258|ACTIVE_COMPARATOR|Subcutaneous Insulin (subject's prescribed)|
62470404|NCT04555889|EXPERIMENTAL|lung recruitment maneuver (LRM) group|The lung recruitment maneuver (LRM) will be done by increasing of PEEP 0,2 cm H2O every 3 minutes, until reach the opening pressure. After that PEEP decrease gradually until get the closing pressure. Than the investigators will back to the opening pressure for 3 minutes, and the final PEEP will be put backo 0,2 above closing pressure.
62109779|NCT00765492|EXPERIMENTAL|1|
62109780|NCT00765492|PLACEBO_COMPARATOR|2|
62300448|NCT03184870|EXPERIMENTAL|Part 1 Arm C [2L Pancreatic & 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab|2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable
62470405|NCT04555889|NO_INTERVENTION|without lung recruitment maneuver (LRM) group|Another group get standart protocol only.
62470406|NCT00398515|EXPERIMENTAL|Treatment (antiangiogenesis, chemotherapy, enzyme inhibitor)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62671554|NCT04624997||Patient suspected COVID-19|"Follow-up of patients as usual in care for infection. No specific puncture. Blood sample collect at admission and every 72h during hospitalisation for hemostasis evaluation, DNA extraction, Circulating endothelial cells measuring.~Sampling can be delayed for 24h to match a planned blood collection for care or other research."
62671555|NCT00817102|OTHER|CorCTA|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures
62470407|NCT02713321||Health Home patients|The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
62109781|NCT05768932|EXPERIMENTAL|Part 1: Substudy 1, Dose-escalation substudy of BAL0891 monotherapy|Increasing doses of BAL0891 will be administered IV on D1 and D8 Q3W (Regimen A). BAL0891 will be investigated in a dose range of 5-480 mg with Regimen A. Optionally, and based on cumulative safety, PK, and PD data, BAL0891 may be administered on D1 Q3W (Regimen B), D1 and D15 Q4W (Regimen C), or on D1, D8, and D15 Q4W (Regimen D).
62109782|NCT05768932|EXPERIMENTAL|Part 1: Substudy 2, Dose-escalation substudy of BAL0891 in combination with carboplatin|Carboplatin will be dosed at AUC5 Q3W, with an option to use AUC6 (either instead of, or after exploring, AUC5) if the cumulative data collected at that time support a higher dose of carboplatin.
62109783|NCT05768932|EXPERIMENTAL|Part 1: Substudy 3, Dose-escalation substudy of BAL0891 in combination with paclitaxel|Paclitaxel will be dosed at 70 mg/m2 on D1, D8, and D15 Q4W, with an option to use 80 mg/m2 (either instead of, or after exploring, 70 mg/m2) if the cumulative data collected at that time support a higher dose of paclitaxel.
62109784|NCT05768932|EXPERIMENTAL|Part 2 : Dose expansion, cohorts 1 TNBC (BAL0891 monotherapy)|BAL0891 will be administered intravenously on D1 and D8, Q3W for cohorts 1. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 1 will utilize the RP2D established in substudy 1 of the dose escalation phase.
62109785|NCT05768932|EXPERIMENTAL|Part 2 : Dose expansion, cohorts 2 GC (BAL0891 monotherapy)|BAL0891 will be administered intravenously on D1 and D8, Q3W for cohorts 2. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 2 will utilize the RP2D established in substudy 1 of the dose escalation phase.
62470408|NCT02713321||non-Health Home patients|The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
62470409|NCT02060760||UTROPIA study cohort|At least two cTnI data points available (including baseline) with blood samples available for hs-cTnI testing. No intervention.
62109786|NCT05768932|EXPERIMENTAL|Part 2 : Dose expansion, cohorts 3 TNBC (BAL0891 + Paclitaxel)|BAL0891 will be administered intravenously on D1 and D15, Q4W for cohorts 3 . The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 3 will utilize the RP2D established in substudy 3 of the dose escalation phase.
62109787|NCT05768932|EXPERIMENTAL|Part 2 : Dose expansion, cohorts 4 GC (BAL0891 + Paclitaxel)|BAL0891 will be administered intravenously on D1 and D15, Q4W for cohorts 4. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 4 will utilize the RP2D established in substudy 3 of the dose escalation phase.
62470410|NCT03324594|ACTIVE_COMPARATOR|Group A|Participants will be first given (1) WONDALEAF-CAP, followed by (2) WONDALEAF-ON-MEN, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
62671556|NCT06457932|EXPERIMENTAL|Biofeedback training|An 8-week intervention based on daily 10-minute HRV biofeedback training at rest using the Pulse HRV smartphone application.
62300449|NCT03184870|EXPERIMENTAL|Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI|
62300450|NCT03184870|EXPERIMENTAL|Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI|
62300451|NCT03184870|EXPERIMENTAL|Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI|
62470411|NCT03324594|ACTIVE_COMPARATOR|Group B|Participants will be first given (1) WONDALEAF-CAP, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
62470412|NCT03324594|ACTIVE_COMPARATOR|Group C|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
62671557|NCT06457932|ACTIVE_COMPARATOR|Meditation|An 8-week intervention based on daily 10-minute guided meditation sessions led by an instructor with over 20 years of experience in teaching meditation.
62109788|NCT05602857|EXPERIMENTAL|Balance Training|Participants will follow a home-based BT intervention specifically designed by the investigators to improve postural control and balance in children. The BT program will consist of training sessions every other day (3 days a week) and a total of up to 45 minutes of balance exercises per week (15 minutes or less per session), addressing static balance (i.e., standing on one foot) and dynamic balance (i.e., balancing a book on your head while walking).
62671558|NCT06457932|NO_INTERVENTION|Control|Passive, waitlist control group.
62671559|NCT01786109|EXPERIMENTAL|Dronabinol 2.5 mg|One dose of dronabinol 2.5 mg was taken orally with water.
62671560|NCT01786109|EXPERIMENTAL|Dronabinol 5 mg|One dose of dronabinol 5 mg was taken orally with water.
62671561|NCT01786109|PLACEBO_COMPARATOR|Placebo|One dose of placebo was taken orally with water.
62671562|NCT03006575|EXPERIMENTAL|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose at the initial course: 40-51Gy/10-17f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 15-24 Gy/5-8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
62671563|NCT00408447|OTHER|SCD group|Sickle Cell Disease patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
62671564|NCT00408447|OTHER|BT group|Beta Thalassemia patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
62671565|NCT05696158|EXPERIMENTAL|MHNA-003|MHNA-003 is a self-guided digital program for people living with tinnitus
62671566|NCT06342349|EXPERIMENTAL|SIBP-V03-I|Quadrivalent influenza virus split vaccine (MDCK cells)
62671567|NCT06342349|ACTIVE_COMPARATOR|QTV (chicken embryo)|Quadrivalent influenza virus split vaccine (chicken embryo)
62671568|NCT06342349|PLACEBO_COMPARATOR|Placebo|Phosphate buffer solution
62671569|NCT03304587|EXPERIMENTAL|Arm 1: Bright blue-green light|"* Bright blue-green light (\~515nm; 12,000 lux) for 30 minutes once a day.~* For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~* Light therapy will be self-administered using a light visor cap~* Each participant will make (3) overnight visits to the sleep laboratory~* On 2 randomly selected days, the participants will wear a light meter during wake time"
62671570|NCT03304587|ACTIVE_COMPARATOR|Arm 2: Dim red light|"* Dim red light (5 lux) (control group) for 30 minutes once a day.~  --For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~* Light therapy will be self-administered using a light visor cap~* Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
62671571|NCT04080934|EXPERIMENTAL|Experimental Group|In the experimental group, patients allocated to the swimming/experimental group will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum. They will be asked to undergo a range of motion (ROM) assessment by a registered kinesiologist, as well as a few short questionnaires administered over the phone by a research assistant, once at the onset of the intervention and once a month for 3 months during the intervention.
62737304|NCT04119804||septic loosening|Septic loosening of primary hip implants according to the 2014 CDC criteria (as routinely performed in the clinical setting), adding another major and necessary criterion: at least 3 positive intraoperative tissue samples (same micro-organism).
62300452|NCT03184870|EXPERIMENTAL|Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel|
62300453|NCT03184870|EXPERIMENTAL|Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel|
62109789|NCT05602857|ACTIVE_COMPARATOR|Music Training|Participants will follow a home-based MT intervention designed to provide enjoyable experiences to the child participants. The sessions will occur every other day (3 days a week) for a total of up to 45 minutes per week (15 minutes or less per session) for 12 weeks. The MT program will consist of a different selection of music videos each week, including a mix of familiar and new tunes.
62109790|NCT05602857|NO_INTERVENTION|Business as usual|Children assigned to this control group will follow their usual activities during the 12 weeks between initial assessment and the second assessment.
62470413|NCT03324594|ACTIVE_COMPARATOR|Group D|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) WONDALEAF-CAP, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
62470414|NCT03324594|ACTIVE_COMPARATOR|Group E|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-ON-MEN, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
62109791|NCT05676294|EXPERIMENTAL|Olanzapine|olanzapine oral tablet, 5mg, once prior to surgery
62109792|NCT05676294|PLACEBO_COMPARATOR|Placebo|placebo oral tablet once prior to surgery
62109793|NCT03917706||Congenital Heart Disease|Adults suffering from congenital heart disease, followed within the CHU Brugmann hospital, operated during childhood.
62109794|NCT06345833|EXPERIMENTAL|Group 1|"1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.~Each face is treated as a split face and one half gets randomized to a TXA containing treatment group, so that each participant serves as his/her own control."
62109795|NCT06345833|EXPERIMENTAL|Group 2|"3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control~Each face is treated as a split face and one half gets randomized to a TXA containing treatment group, so that each participant serves as his/her own control."
62737305|NCT04119804||aseptic loosening|aseptic loosening of primary hip implants not meeting the CDC 2014 criteria
62109796|NCT06345833|EXPERIMENTAL|Group 3|"1% TXA with local plus 3% TXA-soaked pledgets with saline as the control~Each face is treated as a split face and one half gets randomized to a TXA containing treatment group, so that each participant serves as his/her own control."
62109797|NCT00639015|EXPERIMENTAL|1|Phenylephrine
62109798|NCT00639015|ACTIVE_COMPARATOR|2|Norepinephrine
62109799|NCT01071967|EXPERIMENTAL|Community-based nurse care management|Participants randomized to receive the intervention worked with a nurse care manager who provided them with a comprehensive set of geriatric and chronic disease preventive services.
62109800|NCT01071967|NO_INTERVENTION|Usual care|Participants randomized to the control group received usual care without the involvement of a nurse care manager.
62109801|NCT01109095|EXPERIMENTAL|HER.CAR CMV-specific CTLs|Subject will be assigned a dose level at study entry.
62300454|NCT03184870|EXPERIMENTAL|Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel|
62470415|NCT03324594|ACTIVE_COMPARATOR|Group F|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-CAP, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
62470416|NCT05474365|EXPERIMENTAL|Medical students|
62470417|NCT05474365|EXPERIMENTAL|Surgical trainees|
62470418|NCT05474365|NO_INTERVENTION|Attending Surgeons|
62671572|NCT04080934|NO_INTERVENTION|Control Group|The control group will include patients who receive standard of care. This includes the recommendation to undertake exercise and physiotherapy; however, no formal exercise program will be provided. In the control group, participants will be asked to answer a few short questionnaires administered over the phone by a research assistant once per month for 4 months.
62671573|NCT01978574|ACTIVE_COMPARATOR|Documentary videos|In the placebo control condition, participants watch daily videos.
62671574|NCT01978574|EXPERIMENTAL|Intellectual Enrichment|Daily activities that encourage intellectual enrichment, including games, reading/writing, and hobby activities.
62671575|NCT00385229|EXPERIMENTAL|Induction|induction of labor at gestational age 289(41 weeks+2 days)
62671576|NCT00385229|NO_INTERVENTION|expectant management|expectant management at gestational age 289(41 weeks+2 days)
61915445|NCT03819907|NO_INTERVENTION|Control|"15 participants will be randomly assigned to the control group. They will receive no intervention other than the injection (which is not a part of the trial).~Pre-injection they will receive all baseline measures and questionnaires. Post injection they will receive the primary outcome measures: 1) Numeric Pain Rating Scale and 2) Anxiety thermometer"
61915446|NCT03819907|ACTIVE_COMPARATOR|Audiovisual (AV) Guided Relaxation|Combination Product: Audiovisual Guided Relaxation Five-minute guided relaxation delivered via a computer screen and speakers
62300455|NCT03184870|EXPERIMENTAL|Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab|
62300456|NCT03184870|EXPERIMENTAL|Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab|
62300457|NCT03184870|EXPERIMENTAL|Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy|
62300458|NCT03184870|EXPERIMENTAL|Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy|
62470419|NCT04465864|OTHER|Insertion visit 4 days prior|Intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
62671577|NCT04249635||Reference Group|Healthy term (\> 37 weeks of gestation) newborns of women with pregestational body mass index (BMI) ≥18,5 and \<24,9 in the first prenatal visit.
62671578|NCT04249635||Maternal obesity (MO) Group|Newborns of women with pregestational BMI ≥30 that received 200 mg/dayDHA supplementation.
62671579|NCT04249635||MO+DHA Group|Newborns from women with pregestational BMI ≥30 that received 800 mg/day DHA supplementation.
62671580|NCT03400189|OTHER|Single arm|"Single oral dose of sulthiame (Ospolot® tablets)~* Period I: 50 mg~* Period II: 100 mg~* Period III: 200 mg given 3 weeks apart"
62671581|NCT02985281|ACTIVE_COMPARATOR|Arm 1|"20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (\> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
62300459|NCT06276387|EXPERIMENTAL|Mindfulness Program|Individuals in the mindfulness group will complete an 8-week mindfulness course that has been adapted for individuals with rheumatic diseases (MBSR-RD).
62300460|NCT06276387|NO_INTERVENTION|Treatment as Usual (TAU)|Individuals in the TAU group will continue engaging in routine care and be asked to refrain from participating in mindfulness programs during the trial.
62300461|NCT02568904||Alcohol binge|Healthy volunteers receive 2ml vodka 40% per kg bodyweight as a binge
62300462|NCT02568904||Fructose|75 g Fructose orally
62300463|NCT02568904||Glucose|75 g Glucose orally
62300464|NCT02568904||Vehicle|2ml tap water per kg body weight
62300465|NCT04406038||Healthy adults|Healthy adults randomly sampled from the population of Saint Petersburg
62300466|NCT00762151|PLACEBO_COMPARATOR|Negative Control|Regular Toothpaste
62300467|NCT00762151|ACTIVE_COMPARATOR|Positive Control|Standard anti-plaque and anti-bacterial toothpaste.
62300468|NCT00762151|ACTIVE_COMPARATOR|Prototype|AN0128 Toothpaste
62300469|NCT01636037|EXPERIMENTAL|L-Dopa (Sinemet)|Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
62300470|NCT04637451|EXPERIMENTAL|Gingival Unit Graft|For test group, gingival recessions were treated with gingival unit graft.
62300471|NCT04637451|OTHER|Connective Tissue Graft|For Control group, gingival recessions were treated with connective tissue graft.
62671582|NCT02985281|ACTIVE_COMPARATOR|Arm 2|"20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration.~Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (\> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
62671583|NCT04995926|EXPERIMENTAL|Labial mucosa epithelium grafting for corneal limbus substitution.|Surgery for treating limbal stem cell deficiency using a strip of the lip oral mucosa with trimmed off the substantia propria and grafted as a circular corneal limbus substitute.
62671584|NCT00312962|ACTIVE_COMPARATOR|1|Participants will use commercially available computer games
62671585|NCT00312962|EXPERIMENTAL|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
62671586|NCT05374993|EXPERIMENTAL|3TBA Procedure|
62671587|NCT00406237|EXPERIMENTAL|1|
62671588|NCT05855642||Patients|All patients presented with degenerative or traumatic cervical spine matched the inclusion criteria will enrolled in our study from April 2023 to April 2024.
62671589|NCT06482424|EXPERIMENTAL|intervention group|Actions to be taken to the Intervention Group The state-trait anxiety scale and Pittsburg Sleep Quality Index score will be recorded on the patient follow-up chart-researcher form by the researcher at the patient's home at the beginning of the first week and at the end of the fourth week. The aromatic oil given to patients in the intervention group will be placed in 10ml dark glass bottles with droppers and a numbered label will be attached to the bottle.
62671590|NCT06482424|EXPERIMENTAL|placebo group|Procedures to be Performed on the Placebo Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. Sesame oil given to patients in the placebo group will be placed in 10 ml dark glass bottles with droppers and a label with number two will be attached to the bottle.
62671591|NCT05152095|EXPERIMENTAL|Intervention|Self-administered Vaccaria seed tapes on auricular acupoints with pressure applied
62671592|NCT05152095|SHAM_COMPARATOR|Sham|Self-administered plain tapes (without Vaccaria seed) on auricular acupoints without applying pressure.
62671593|NCT01784536|EXPERIMENTAL|Oritavancin|Single-Dose IV Oritavancin Diphosphate
61915447|NCT03819907|EXPERIMENTAL|Virtual Reality (VR) Guided Relaxation|"Combination Product: Virtual Reality Guided Relaxation Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.~Other Names:~• Samsung Galaxy 7s/Samsung adaptable VR headset"
61915448|NCT05130671|ACTIVE_COMPARATOR|Standard of care|This arm will receive the standard of care as per the hospital guidelines.
62300472|NCT02226484|EXPERIMENTAL|Quercetin|Two 250 mg capsules of oral quercetin (Q) twice-a-day (BID) one hour before meals with a glass of water for 6 weeks.
62300473|NCT02017444|PLACEBO_COMPARATOR|Placebo|Matched placebo tablet B.D for 12 weeks
62671594|NCT01037465|ACTIVE_COMPARATOR|N-acetylcysteine|N-acetylcysteine
62671595|NCT01037465|PLACEBO_COMPARATOR|Placebo|Placebo
62300474|NCT02017444|ACTIVE_COMPARATOR|AZD4017 (11b-HSD1 inhibitor)|AZD4017 400mg tablet B.D. for 12 weeks
62300475|NCT00794287||1|Hymenoptera allergic patients before allergen specific immunotherapy
62300476|NCT00794287||2|Hymenoptera allergic patients after allergen specific immunotherapy
62300477|NCT04902287|EXPERIMENTAL|TIES Engagement Strategies|Participants in this arm will receive a 30-minute TIES engagement intervention during their referral phone call.
62300478|NCT04902287|NO_INTERVENTION|Referral as Usual|Participants in this arm will receive a standard call to schedule an intake appointment by an administrative assistant with no clinical training.
62300479|NCT04017403|EXPERIMENTAL|Probiotic group|The probiotic group was treated with Bifidobacterium tripleis,one day before surgery to the sixth day after surgerythe drug is taken orally, 4 capsules at a time, 2 times a day.
62300480|NCT04017403|PLACEBO_COMPARATOR|Placebo group|The control group was given the same package of placebo,one day before surgery to the sixth day after surgery. The drug is taken orally, 4 capsules at a time, 2 times a day.
62300481|NCT01904487|EXPERIMENTAL|PET scans|Both alcoholics and healthy controls will undergo two \[11C\]flumazenil PET scans: one at baseline and one post administration of 0.2 mg/kg Tiagabine.
62300482|NCT06073262||Non-specific low back pain individual with chronic consipation|
62300483|NCT06073262||Individual without low back pain with chronic consipation|
62671596|NCT02692612||Young|
62671597|NCT02692612||Middle-Aged|
62671598|NCT02692612||Old|
62671599|NCT02197988|ACTIVE_COMPARATOR|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block Exparel 1.33% (20ml Volume)
62300484|NCT06480734|EXPERIMENTAL|Elderly patients with lung cancer and risk of pneumonitis|Elderly patients (65 years or older) irradiated for lung cancer who receive a mean radiation dose to the ipsilateral lung \>13 Gy and, therefore, have an increased risk of developing radiation pneumonitis.
62109802|NCT03935308|EXPERIMENTAL|MR-guided SBRT With SIB to the DILs to Prostate Cancer|Dose escalation to the DIL(s) will be performed in the traditional Phase I 3+3 design. Patients will be treated in four cohorts (three patients per dose level) starting with a dose of 9 Gy to the DIL(s). If no dose limiting toxicity (DLT), defined below, is observed after 90 days, then an additional three patients will be entered at the next dose level. Dose to the DIL(s) will be escalated at 1 Gy increments until DLT is observed or if maximum dose level (60 Gy in 5 fractions of 12 Gy) is reached with no observed DLT. If one of the three patients experience a DLT at a particular dose level an additional three patients will be enrolled at that level. If two or more patients experience a DLT a lower dose level will be explored to define the maximum tolerated dose (MTD). The three patients within any cohort can be enrolled simultaneously or sequentially without any waiting period among them.
62109803|NCT02526641||AbbVie|
62109804|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
62109805|NCT03356665|EXPERIMENTAL|Clinical suspect|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
62109806|NCT05539248|EXPERIMENTAL|Dose escalation CAN106 in cohort 1|Subjects are administered CAN106 20 mg/kg IV maintenance dosing.
62109807|NCT05539248|EXPERIMENTAL|Dose escalation CAN106 in cohort 2|Subjects are administered CAN106 40 mg/kg IV maintenance dosing.
62109808|NCT05539248|EXPERIMENTAL|Dose escalation CAN106 in cohort 3|Subjects are administered CAN106 80 mg/kg IV maintenance dosing.
62300485|NCT01154101|ACTIVE_COMPARATOR|Cohort 2 - 500mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 2 will commence after Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 2 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
62470420|NCT04465864|OTHER|Surgical 1 visit day 0|Intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
62470421|NCT02982356|OTHER|Fetal Selective Reduction Technology|Potassium chloride fetal heart injection in the dichorial twins with abnormal chromosome and structure
62671600|NCT02197988|ACTIVE_COMPARATOR|Thoracic Epidural Anesthesia|Thoracic Epidural Anesthesia 0.125% bupivicaine with 2 mcg/ml Fentanyl
62671601|NCT02714959|EXPERIMENTAL|Proleukin|Proleukin (subcutaneous injection) 1.5 MIU/day from day 1 to 5 at W1 3 MIU/day from day 1 to day 5 at W3, W6, and W9
62671602|NCT00901563|ACTIVE_COMPARATOR|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
62671603|NCT00901563|PLACEBO_COMPARATOR|Saline|Saline will be infused through-out the study.
62671604|NCT04626362|EXPERIMENTAL|Experimental: Cranberry juice consumption|Participants will be provided cranberry juice to consume for 21 days
62671605|NCT04626362|EXPERIMENTAL|Placebo juice consumption|Participants will be provided placebo juice to consume for 21 days
62671606|NCT00523666|ACTIVE_COMPARATOR|1|
62671607|NCT00523666|PLACEBO_COMPARATOR|2|
62671608|NCT00832962||1|Adult Rh negative pregnant patients from 7 selected centers (SAINT ANTOINE hospital, CHU Marseille, CHU Nantes, CHU Lille, LOUIS MOURIER Hospital, SAINT VINCENT-PAUL Hospital, CH POISSY)
62671609|NCT00832962||2|Adult Rh negative pregnant patients from 6 selected centers (Tenon hospital, Jean VERDIER Hospital, La Pitie-Salpetriere Hospital, Cochin Hospital, Robert Debre Hospital, BICHAT Hospital)
62671610|NCT03068520|OTHER|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
62671611|NCT03068520|OTHER|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.~will be followed with PET MRI"
62671612|NCT03068520|OTHER|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.~will be followed with PET MRI"
62671613|NCT04759755||Study participants|18-60 year olds who demonstrate habitual sleep onset time between 10:00 pm-3:00 am and BMI 25-39.9.
62671614|NCT05583058||Hormone Overdose and Misuse Group|Transgender and gender non-conforming individuals who have been identified as hormone overdose and misuse (HODM) at start of the cohorts according to the criteria established by the study.
62300486|NCT01154101|ACTIVE_COMPARATOR|Cohort 3 - 1000mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 3 will commence after Cohort 2 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 3 will be administered four SRT2104 capsules at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
62109809|NCT05054400|OTHER|F18 Fluciclovine|"radioactive imaging agent help researchers better see how the disease is responding to laser interstitial thermal therapy (LITT)"
62300487|NCT01154101|ACTIVE_COMPARATOR|Cohort 1 - 250mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 1 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff.~Dosing for Cohort 2 will not commence until Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee."
62300488|NCT03437187|OTHER|Cholecystectomy without nerve blocks|Cholecystectomy, enteral and parenteral analgesics
62300489|NCT03437187|PLACEBO_COMPARATOR|Cholecystectomy with placebo nerve block|Cholecystectomy, NaCl as a placebo Quadratus lumborum block
62300490|NCT03437187|ACTIVE_COMPARATOR|Cholecystectomy with naropin nerve block|Cholecystectomy, Quadratus lumborum block with naropin
62671615|NCT05583058||Non-Hormone Overdose and Misuse Group|Transgender and gender non-conforming individuals who have been identified as without hormone overdose or misuse (HODM) at start of the cohorts according to the criteria established by the study.
62470422|NCT02982356|NO_INTERVENTION|control group|normal dichorial twins without any intervention
62109810|NCT02286765|ACTIVE_COMPARATOR|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
62671616|NCT06329336|EXPERIMENTAL|Preventive Behavioral Parenting Program|This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
62671617|NCT04599335|EXPERIMENTAL|HA + Lidocaine|
62671618|NCT04599335|NO_INTERVENTION|Negative|
62109811|NCT02286765|ACTIVE_COMPARATOR|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
62109812|NCT04258410|PLACEBO_COMPARATOR|Placebo|Blinded subjects in this arm will receive 2 placebo (blank) soft chews, twice daily, orally for 20 weeks.
61915449|NCT05130671|EXPERIMENTAL|Investigational treatment|This arm will receive combination of nutritional supplements quercetin and curcumin as add-on to the standard of care.
62109813|NCT04258410|EXPERIMENTAL|Active Drug|Blinded subjects in this arm will receive 1 g/day of Quercetin delivered in 2 soft chews (250 mg/chew), twice daily, orally, for 20 weeks.
62109814|NCT06450977|EXPERIMENTAL|MIND Diet|Participants in the active MIND diet group will be asked to consume one ready-to-eat meal per day from Daily Harvest® meal delivery service. The treatment meals will follow MIND diet guidelines and include leafy green vegetables, nuts, legumes, whole grains, berries, and extra virgin olive oil.
62109815|NCT06450977|ACTIVE_COMPARATOR|Control Diet|Participants in the control diet group will be asked to consume one ready-to-eat meal per day from Daily Harvest® meal delivery service. The Control group will receive daily meals that are isocaloric with the active/experimental meals but will follow a general diet based on the average American diet and Dietary Guidelines for Americans (i.e., vegetables, fruits, nuts, whole grains, and unsaturated fats).
62109816|NCT01639638|PLACEBO_COMPARATOR|Placebo|
62109817|NCT01639638|EXPERIMENTAL|CIGB-300 - 5 mg|
62109818|NCT01639638|EXPERIMENTAL|CIGB-300 - 15 mg|
62671619|NCT03879577|EXPERIMENTAL|Docetaxel|Investigators will give patients docetaxel through drip every 3 weeks for four doses for 12 weeks before a repeat breast ultrasound. After breast ultrasound, if the investigator feels the injection is good, surgery will be done.
62671620|NCT03879577|OTHER|Herceptin|Herceptin will be given to patients under the skin of the thigh every 3 weeks for 18 times if they are HER2-positive
62671621|NCT03879577|OTHER|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with a poor response to docetaxal will receive FEC injection by drip every 3 weeks.
62671622|NCT03879577|OTHER|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years every 3 months for contraception and fertility preservation.
62671623|NCT03879577|OTHER|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
62671624|NCT01618708|EXPERIMENTAL|Synvisc-One|Single intraarticular (IA) injection of Synvisc-One (48 mg of Hylan G-F 20 polymer) at Day 1. Participants were observed for 26 weeks in follow up period.
62109819|NCT03402711||Bleeding Risk in Chinese ACS II|1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
62109820|NCT05100329|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Patients will receive mitoxantrone hydrochloride liposome injection every 3 weeks (q3w, a cycle).
62671625|NCT01618708|PLACEBO_COMPARATOR|Placebo|Single IA injection of placebo matched to Synvisc-One at Day 1. Participants were observed for 26 weeks in follow up period.
62671626|NCT02217007|EXPERIMENTAL|SNC-102 sustained release tablet|SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
61915450|NCT01489384||3 months: Discontinue vs continue DMARDS|At 3 months those patients who achieved a change in DAS28 of 1.2 or greater will be randomized to discontinue versus continue DMARDs and will be followed for an additional 15 months
61915451|NCT01489384||6 months: discontinue vs continue DMARDs|(Protocol amendment 4.0)At 6 months, those patients still on Cimzia and DMARD therapy who were not randomized at month 3 AND achieve a change in DAS28\> 1.2 will be randomized to discontinue versus continue DMARDs and will be followed for an additional 12 months.
62109821|NCT05845242||Risk 0|Very low ulcer risk: No LOPS (loss of peripheral sensation) and No PAD (peripheral arterial disease)
62109822|NCT05845242||Risk 1|Low ulcer risk: LOPS or PAD
62671627|NCT05298501||AMYWEB-Normative|This cohort assessed over six recruitment and test phases, will be sampled to be as closely representative of the demographic population as possible.
62671628|NCT05298501||AMYWEB-Diversity|This cohort assessed over two recruitment and test phases will oversample participants from minority and mixed ethnic and racial backgrounds as well as participants from lower educational backgrounds.
62109823|NCT05845242||Risk 2|Moderate ulcer risk: LOPS + PAD, or LOPS + foot deformity or PAD + foot deformity
62109824|NCT05845242||Risk 3|"High ulcer risk: LOPS or PAD, and one or more of the following:~* history of a foot ulcer~* a lower-extremity amputation (minor or major)~* end-stage renal disease"
62470423|NCT06223464||Adenomyosis-Case Group|The study will include those diagnosed with adenomyosis who were evaluated by gynecological examination and ultrasonographic imaging after the application to Etlik City Hospital Gynecology and Obstetrics Clinic, aged 18-45 reproductive period, pregnancy status excluded, without cervical infection, pathology and anomaly, without systemic disease findings and diagnoses, without chronic drug use.
62109825|NCT06187480||group 1|underwent total parathyroidectomy
62109826|NCT06187480||group 2|underwent subtotal parathyroidectomy
62109827|NCT04910919|ACTIVE_COMPARATOR|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
62109828|NCT04910919|EXPERIMENTAL|Honey Intervention|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
62109829|NCT01558921|EXPERIMENTAL|B: 5x5Gy -> CAPOX -> surgery|experimental group (arm B) M1 scheme
62109830|NCT01558921|ACTIVE_COMPARATOR|A: 5 weeks chemoradiation -> surgery|control group (arm A) standard long course chemoradiotherapy
62109831|NCT00431795|EXPERIMENTAL|1|Epi
62109832|NCT00431795|EXPERIMENTAL|2|Cael
62109833|NCT03147456|EXPERIMENTAL|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
62109834|NCT03147456|PLACEBO_COMPARATOR|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
62109835|NCT01490112||IAsp|
62470424|NCT06223464||Healthy patients-Control|The study will include those who have been gynecologically examined and evaluated with ultrasonographic imaging after the application to Etlik City Hospital Gynecology and Obstetrics Clinic, aged 18-45 reproductive period, pregnancy status excluded, without cervical infection, pathology and anomaly, without systemic disease findings and diagnoses, without chronic drug use, without adenomyosis diagnosis.
62470425|NCT01152840|EXPERIMENTAL|RAD001|RAD001 daily po medication
62671629|NCT05298501||AMYWEB-MCI|This cohort assessed and recruited over one test phase, will include participants with a reported diagnosis of mild cognitive impairment or dementia.
62671630|NCT03828669||Usual Care|Prior to the roll-out of the Recovery Toolkit program, all post-surgical patients receiving current standard of care are given pain care surveys at hospital discharge. Survey questions ask about pain, and satisfaction with pain care. The investigators will conduct chart review for pain and opioid use.
62671631|NCT03828669||Recovery Toolkit|After launch of the Recovery Toolkit program on Jan 25, all post-surgical patients will be offered a Recovery Toolkit by a unit nurse. A pain survey will be administered at hospital discharge to assess about pain in the hospital, satisfaction with pain care, whether they received a Toolkit, use of the Toolkit, and likelihood to recommend the Toolkit. The investigators will conduct chart review for pain and opioid use.
62671632|NCT01666314|OTHER|Placebo + Orteronel 200 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 (28 days) followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
62671633|NCT01666314|EXPERIMENTAL|Orteronel 200 mg (Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
62300491|NCT04990739|EXPERIMENTAL|Part A Dose-Escalation and Part B RP2D Dose-Expansion|"Study has two parts:~1. Part A Dose-Escalation will evaluate MTB-9655 monotherapy administered in 21 days cycle,and will be conducted in 2 stages (accelerated titration and dose-escalation).~   The first stage will consist of accelerated titration in single-patient cohorts for the initial two dose levels.~   In the second stage, a conventional 3+3 schema using a modified Fibonacci dose titration strategy will be implemented. The first dose at every dose level and in every patient will be administered under close medical supervision, and the patients will be hospitalized for approximately 24 hours.~   Up to 30 participants will participate in this dose escalation arm.~2. Part B dose-expansion will further explore the safety, PK and preliminary efficacy of MTB-9655 at the RP2D. The RP2D level will be no higher than the MTD identified in Part A."
62300492|NCT03650504|EXPERIMENTAL|Above Artery Group|
62109836|NCT06552533|EXPERIMENTAL|Resistance Exercises with Plyometric exercises|We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week). Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). While controlling the time that a maximal contraction will maintained, the therapist will assure that the targeted musculature will being maximally loaded. Resistance will be applied to the dorsum of the foot just above the toes to resist dorsiflexion and to the plantar surface of the foot at the metatarsals to resist plantar flexion. After resistance training the athletes will go for plyometric exercises and will follow the following guidelines.Tubing Exercises and Plyometric Ankle Jumps Ankle Circles. Move just your foot and ankle, not your leg. Vary the stretch by tracing out the letters of the alphabet with your big toe.
62300493|NCT03650504|ACTIVE_COMPARATOR|Between Artery and Vein Group|
62300494|NCT01089192|EXPERIMENTAL|Torrent's Metformin tablets 750 mg|
62300495|NCT01089192|ACTIVE_COMPARATOR|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
62300496|NCT03702725|EXPERIMENTAL|Dose Escalation|"Dose escalation will consist of three different drug levels of Ibrutinib, Lenalidomide, and Dexamethasone.~Dose Escalation (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
62300497|NCT03702725|EXPERIMENTAL|Dose Expansion|"Dosage of the combination will depend on the determine of maximum tolerated dose learned from the Dose Escalation phase.~Dose Expansion (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
62671634|NCT01666314|OTHER|Placebo + Orteronel 300 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
62671635|NCT01666314|EXPERIMENTAL|Orteronel 300 mg (Japan)|Orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
62671636|NCT01666314|OTHER|Placebo + Orteronel 200 mg (Ex-Japan)|"Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles outside of Japan (Ex-Japan) for up to 3.1 years.~Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study."
62300498|NCT04548310||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
62300499|NCT04548310||Healthy group|Healthy individuals without chronic disease
62300500|NCT03071718|EXPERIMENTAL|Med-D|Subjects will follow a Mediterranean diet for two months
62300501|NCT03071718|ACTIVE_COMPARATOR|Cont-D|Subjects will follow a control diet for two months
61915452|NCT01489384||6 months: D/C vs Cont'd DMARDs if change in DAS28|(Protocol amendment 4.0)At 6 months, if the change in DAS28 is at least 0.6 and there is a decision to continue Cimzia, then the patients will be randomized to discontinue versus continue DMARDs with Cimzia and will be followed for an additional 12 months.
62109837|NCT06552533|ACTIVE_COMPARATOR|Resistance Exercises without Plyometric exercises|We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week).We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). Active weight bearing exercises in the form of heel rise and toe rise will performed for ten repetitions each. Towel curl and marble pick up was performed at the end of the session for ten repetitions.
61915453|NCT01489384||3 or 6 months: stop CIMZIA and treat as per SOC|(Protocol amendment 4.0)If a change in DAS28 of \<0.6 occurs at 6 months (at 3 months for protocol amendment 6.1)in patients not randomized at month 3 then the patient will stop Cimzia and treatment will be standard of care. However, patient will still be followed until the end of study.
61915454|NCT04616742|EXPERIMENTAL|[14C]SHR6390|
62109838|NCT02488317|OTHER|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
62109839|NCT02488317|NO_INTERVENTION|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
62109840|NCT04534712||PROGRESSION|Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
62109841|NCT04534712||NON PROGRESSION|Cohort B with those who improved by two points on the ordinal scale without any further progression
62109842|NCT01272648|ACTIVE_COMPARATOR|Rehabilitation|note intervention
62109843|NCT01272648|PLACEBO_COMPARATOR|Control|same radiotherapy but no rehabilitation
62109844|NCT04855513|NO_INTERVENTION|standard care|The control group will receive standard care treatment including aspirin according to ACOG guidelines. The control group estimated number of enrollment is 207 patients.
62109845|NCT04855513|EXPERIMENTAL|Metformin|The intervention group will be give metformin 500 mg orally three times daily in addition to standard of care. The estimated number to be enrolled are 207 patients.
62109846|NCT04696250||Adverse Events associated with Antineoplastic and Immunomodulating Agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by anticancer drugs, with a chronology compatible with the drug toxicity
62109847|NCT05172154||15 subjects testing themselves|15 subjects 14 years of age and older
62300502|NCT05714930|EXPERIMENTAL|Treat-to-target|T2T will be implemented based on shared decision-making (SDM), tight control and remission as a validated treatment target (disease activity score clinical SLEDAI-2k = 0 \& glucocorticoids (GC) ≤ 5 mg prednisolone equivalent \& physician global assessment (PGA 0-3) \< 0.5 ± immunomodulatory therapy); All intervention centers will receive T2T/SDM trainings. Patients not meeting their target criterion at study entry or at any time during the trial will be included in a tight control T2T loop of 24 weeks with assessments every 6 weeks to reach the target by adjustments of their immunomodulatory treatments. Patients in target will be assessed every 12 weeks as it is standard in clinical routine care.
61915455|NCT02661711|EXPERIMENTAL|Aflibercept (Eylea)|All patients recruited to the study will receive 3 loading intravitreal injections of Aflibercept (Eylea) at monthly intervals followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up will occur when there is evidence of OCT stability in the view of the investigator i.e. there is no further reduction in macular fluid compared to the previous visit. All patients will receive 5 injections before considering them non-responders.
61915456|NCT04661254|OTHER|Lymphapheresis|Blood is drawn from one of the patient's two arms and passes through a separation circuit. After removing the white blood cells, it is reinjected into the other arm.
61915457|NCT05697978|OTHER|Monofocal lens|Eyes of patients with implanted monofocal aspheric lens Clareon (Alcon LLC)
61915458|NCT01622283|EXPERIMENTAL|Levocetirizine oral solution 5 mg|Levocetirizine oral solution 5 mg
61915459|NCT01622283|ACTIVE_COMPARATOR|Cetirizine dry syrup 10 mg|Cetirizine dry syrup 10 mg
61915460|NCT03603171||DM2 group|Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.
61915461|NCT03603171||Healthy controls group|A group of gender and age-matched healthy controls.
61915462|NCT02239120|EXPERIMENTAL|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
62109848|NCT05172154||15 subjects testing someone else|15 adult subjects testing individuals ages 2-13
61915463|NCT02239120|ACTIVE_COMPARATOR|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
61915464|NCT06098677|EXPERIMENTAL|Carotenoids group|Participants in the intervention group receive oral supplementation of 10 mg L, 10 mg MZ and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Each capsule contains 22 mg of carotenoids (10+10+2mg), thus each participant in the intervention group will receive a total of 22 mg of carotenoids per day.
61915465|NCT06098677|PLACEBO_COMPARATOR|Placebo group|Participants in the control group receive one soft gel capsule of placebo oil per day.
61915466|NCT05834855|NO_INTERVENTION|Ocrelizumab|The standard group will receive ocrelizumab (600 mg, the first dosage given in two infusion of 300 mg with a two week interval) following the current treatment protocol
61915467|NCT05834855|EXPERIMENTAL|Rituximab|The experimental group will receive rituximab (1000 mg). Rituximab will be given intravenously. To ensure blinding of treatment allocation two dosages of 500 mg with a two week interval will be given instead of one initial dosage of 1000 mg of rituximab to mimic the ocrelizumab protocol
61915468|NCT00278408|ACTIVE_COMPARATOR|Interventional: 6 R-CHOP-21|Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61915469|NCT00278408|ACTIVE_COMPARATOR|Interventional: 6 R-CHOP-21 + radiotherapy|Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
61915470|NCT00278408|ACTIVE_COMPARATOR|Interventional: 6 R-CHOP-14|Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61915471|NCT00278408|ACTIVE_COMPARATOR|Interventional: 6 R-CHOP-14 and radiotherapy|Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.
61915472|NCT05043376|ACTIVE_COMPARATOR|Standard of care|In this arm patients will receive the standard COVID-19 care as per the hospital guidelines.
61915473|NCT05043376|EXPERIMENTAL|BLIS K12|In this arm patients will receive the BLIS K12 as add-on to the standard COVID-19 care
61915474|NCT03467152|EXPERIMENTAL|Irsenontrine|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of Irsenontrine for 12 weeks.
61915475|NCT03467152|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of Irsenontrine-matched placebo for 12 weeks.
61915476|NCT01599364|EXPERIMENTAL|Switch|Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
61915477|NCT01599364|NO_INTERVENTION|continue|Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone
61915478|NCT05793229||improving frailty|Class 1
61915479|NCT05793229||maintaining frailty|Class 2
62671637|NCT01666314|EXPERIMENTAL|Orteronel 200 mg (Ex-Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
62300503|NCT05714930|NO_INTERVENTION|Standard of Care|In the standard of care (SoC) arm, patients receive 3-to 6-monthly controls and treatment adjustments according to their physician's discretion.
61915480|NCT05793229||deteriorating frailty|Class 3
62300504|NCT05307744|EXPERIMENTAL|PS128|Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.
61915481|NCT01995045|EXPERIMENTAL|Bupivicaine & Triamcinolone|Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide
61915482|NCT01995045|ACTIVE_COMPARATOR|Bupivicaine|Retrobulbar anesthesia with Bupivicaine Hydrochloride
61915483|NCT00746408||Main 1|Insurants of the health insurance company BARMER using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
61915484|NCT00746408||Main 2|Insurants of the health insurance company BARMER using search engines and portals to gather internet information about the type of headache they suffer from.
61915485|NCT00746408||Online 1|Internet users using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
62300505|NCT05307744|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.
62300506|NCT05307744|NO_INTERVENTION|Normal control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
62470426|NCT04264130|ACTIVE_COMPARATOR|artemisinin-based combination therapies|subjects given Artemisinin-based combined therapies according to the study instruction
61915486|NCT00746408||Online 2|Internet users using search engines and portals to gather internet information about the type of headache they suffer from.
61915487|NCT01711385|NO_INTERVENTION|Standard practice|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the basic/control intervention, are informed that it is important to follow-up with their physician regarding their test results. They are contacted by phone once to schedule their 6-month recall visit."
61915488|NCT01711385|EXPERIMENTAL|Enhanced intervention|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit."
62470427|NCT04264130|SHAM_COMPARATOR|non-artemisinin drugs|subjects given non artemisinin based combined therapies like describe in the study protocol
61915489|NCT03761797||Subjects with type 2 Diabetes Mellitus|
61915490|NCT01602133|EXPERIMENTAL|one intervention arm|
62470428|NCT01123694||Xeroderma Pigmentosum patients|Xeroderma Pigmentosum patients who attend Camp Sundown, a camp for children with this condition.
61915491|NCT06531044||1 of children with cerebral palsy|Children with spastic cerebral palsy will be enrolled in this study upon fulfilling the following inclusion criteria: They were scored Level I on the Gross Motor Function Classification System (GMFCS).
62470429|NCT04533893||BLS Training Group (Students without prior BLS Training)|"1. After completing training mode of the serious game module, participants were asked to choose the self-test mode of the serious game module.~2. the participants were asked to practice their hands-on skills in simulation center under the supervision of educators. After familiarization with the system using self-training mode, the participants were asked to proceed the BLS Hands-on training app with the simulator under the supervision of the educator.~3. Conventional OSCE score of each participant was obtained by watching the recorded sessions of BLS trainings."
61915492|NCT02692651|ACTIVE_COMPARATOR|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
61915493|NCT02692651|ACTIVE_COMPARATOR|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
61915494|NCT01293578|NO_INTERVENTION|Usual Care|Clinicians will present diabetes medication options to patients, in their usual way.
62470430|NCT01401647|ACTIVE_COMPARATOR|Amiodarone|Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.
62470431|NCT01401647|ACTIVE_COMPARATOR|Lidocaine|IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.
62470432|NCT01401647|PLACEBO_COMPARATOR|Normal saline|IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.
61915495|NCT01293578|EXPERIMENTAL|Diabetes Medication Decision Aid|In the decision aid arm, clinicians will use the diabetes medication decision aid cards (if they choose) when discussing diabetes medication options with their patients.
61915496|NCT03627390|EXPERIMENTAL|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
61915497|NCT03627390|EXPERIMENTAL|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
61915498|NCT02258984|OTHER|Open physician access to Venus 1000 CVP data|
62109849|NCT05079061|ACTIVE_COMPARATOR|Misoprostol group|At delivery of baby, routine uterotonics (syntometrine 1ml intramuscular or syntocinon 5 units intravenous bolus followed by 40 units in 500ml normal saline infusion over 4 hours in women contraindicated for syntometrine) will be given as routine practice, and sublingual misoprostol will be given to women in misoprostol group.
62671638|NCT01666314|OTHER|Placebo + Orteronel 400 mg (Ex-Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
62109850|NCT05079061|NO_INTERVENTION|Control group|At delivery of baby, routine uterotonics (syntometrine 1ml intramuscular or syntocinon 5 units intravenous bolus followed by 40 units in 500ml normal saline infusion over 4 hours in women contraindicated for syntometrine) will be given as routine practice, and no additional sublingual misoprostol will be given to women in control group.
62109851|NCT06202118|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62109852|NCT06629324|ACTIVE_COMPARATOR|BM MNC transplantation and Rehabilitation|Patients in group A will receive two autologous BM MNC administrations at baseline and 6 months ± 21 days (T6)
62470433|NCT01111864|EXPERIMENTAL|MixMe powder (iron & micronutrients)|
62671639|NCT01666314|EXPERIMENTAL|Orteronel 400 mg (Ex-Japan)|Orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
61915499|NCT02258984|OTHER|No open physician access to Venus 1000 CVP data|
62470434|NCT01111864|PLACEBO_COMPARATOR|MixMe powder (micronutrients, no iron)|
62470435|NCT01111864|EXPERIMENTAL|Sprinkles (iron and micronutrients)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Iron 12.5 mg; Zinc 5 mg
62470436|NCT01111864|PLACEBO_COMPARATOR|Sprinkles (micronutrients, no iron)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Zinc 5 mg
62470437|NCT03622801||Intra-arterial administration|Patients with intra-arterial administration of Iopromide
62470438|NCT03622801||Intravenous administration|Patients with intravenous administration of Iopromide
62470439|NCT00972218|EXPERIMENTAL|Enteropathic spondyloarthritis|Patients have concomitant inflammatory spinal symptoms and inflammatory bowel disease.
62470440|NCT02160925|EXPERIMENTAL|Preoperative 99mTc-Sestamibi SPECT/CT|
62470441|NCT03850795|EXPERIMENTAL|HC-1119|Oral dose of 80 mg/day
62470442|NCT03850795|ACTIVE_COMPARATOR|enzalutamide|Oral dose of 160 mg/day
62470443|NCT03965091|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to fremanezumab SC on Days 1, 29, 57, and 85.
62470444|NCT03965091|EXPERIMENTAL|Fremanezumab Dose A|Participants will receive fremanezumab SC on Days 1, 29, and 57 and placebo matched to fremanezumab SC on Day 85.
62470445|NCT03965091|EXPERIMENTAL|Fremanezumab Dose B|Participants will receive fremanezumab SC on Days 1, 29, and 57 and placebo matched to fremanezumab SC on Day 85.
62470446|NCT03202238|ACTIVE_COMPARATOR|Conventional|Venepuncture without the use of any venepuncture assistive device
62671640|NCT04107363|EXPERIMENTAL|Experimental group:|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes.~After the oropharyngeal aspiration was completed, the patient's position was changed."
62671641|NCT04107363|OTHER|Control group|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
62671642|NCT04060745|EXPERIMENTAL|Cooling|Participants will be cooled using an individualized cooling protocol with a water-perfused vest for two hours while resting. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
62671643|NCT04060745|EXPERIMENTAL|Thermoneutrality|Participants will rest for one hours. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
61915500|NCT04900064|EXPERIMENTAL|Diagnostic Assessment - Given self-help CBT|"The diagnostic assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview (MINI - International Neuropsychiatric Interview) and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).~In the primary analysis, only patients receiving treatment with self-help CBT are included."
61915501|NCT04900064|ACTIVE_COMPARATOR|Contextual Assessment - Suitable for self-help CBT but given brief interventions|"The contextual assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.~In the primary analysis, only patients suitable for self-help CBT are included. This is decided by an algorithm based on data from their screening, which takes into account symptom severity and type, patient preference and known variables that make self-help CBT a worse fit."
61915502|NCT04900064|EXPERIMENTAL|Diagnostic Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they receive treatment with self-help CBT or brief interventions."
61915503|NCT04900064|ACTIVE_COMPARATOR|Contextual Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they are deemed suitable for self-help CBT or not."
61915504|NCT01325220|ACTIVE_COMPARATOR|STX209 5 mg BID|
61915505|NCT01325220|ACTIVE_COMPARATOR|STX209 10 mg BID|
61915506|NCT01325220|ACTIVE_COMPARATOR|STX209 10 mg TID|
61915507|NCT01325220|PLACEBO_COMPARATOR|Placebo|
61915508|NCT06298344|EXPERIMENTAL|Thiamine|Patients with left to right shunt congenital heart disease who undergone transcatheter closure Intervention: Daily Thiamine 100 mg in 28 days.
62109853|NCT06629324|PLACEBO_COMPARATOR|Placebo with Rehabilitation, then BM MNC transplantation|Group B will receive BM MNCs at 9 months ± 21 days (T9) and 15 months ± 21 days (T15), with outcomes evaluated at 18 months ± 21 days (T18) compared to baseline.
62109854|NCT03143192|EXPERIMENTAL|Aflibercept with Micropulse Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Micropulse Laser at initial visit and reassessed every 12 weeks.
62470447|NCT03202238|ACTIVE_COMPARATOR|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
62470448|NCT03202238|EXPERIMENTAL|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
62671644|NCT05706285||Erector Spina Plane Block and Intravenous Patient Controlled Analgesia|
62671645|NCT05706285||Intrathecal Morphine and Intravenous Patient Controlled Analgesia|
62671646|NCT02496429|OTHER|BrownieForSymphony use|Each participant will use the BrownieForSymphony pumpset
62671647|NCT02201082|EXPERIMENTAL|Nebulization and airway clearance technique|nebulization combined to airway clearance
62671648|NCT02201082|ACTIVE_COMPARATOR|Nebulization|nebulization
62671649|NCT02706548|EXPERIMENTAL|Occupational Therapy Intervention Group|Thirty-minute intervention in which the participant and interventionist discuss past medication taking performance, medication-related goals, and strategies to meet goals. Intervention is enhanced with motivational interviewing and therapeutic use of self.
62671650|NCT02706548|ACTIVE_COMPARATOR|Standard Care Intervention Group|Thirty-minute educational intervention in which the participant and interventionist review a pamphlet on adherence to medication.
62671651|NCT04688996||Malagasy Participants|Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
62109855|NCT03143192|SHAM_COMPARATOR|Aflibercept with Sham Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Sham Laser at initial visit and reassessed every 12 weeks.
62671652|NCT04688996||USN Health Research Center|USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
61915509|NCT06298344|NO_INTERVENTION|Placebo|Patients with left to right shunt congenital heart disease who undergone transcatheter closure Interventions: Daily Placebo oral (Manufactured to mimic Thiamine) in 28 days.
62109856|NCT05481333|EXPERIMENTAL|IV Cohort 1|Single dose REGN7999 or Placebo; randomized 3:1
61915510|NCT04318145|EXPERIMENTAL|Part A: PL-3994 Dose Ascension|Dose ascension: up to 15 subjects with HFpEF. N = 3 per dose level, up to 5 dose levels.
61915511|NCT04318145|EXPERIMENTAL|Part B: PL-3994 Single Dose|Up to 40 subjects with HFpEF (20 Females, 20 Males) will receive a single dose of PL-3994.
61915512|NCT05329038|EXPERIMENTAL|Adult group|90 subjects aged 18-59 years received two dose inactivated COVID-19 vaccine in primary immunization will receive the booster immunization (the third dose )of inactivated COVID-19 vaccine.
62109857|NCT05481333|EXPERIMENTAL|IV Cohort 2|Single dose REGN7999 or Placebo; randomized 3:1
62109858|NCT05481333|EXPERIMENTAL|IV Cohort 3|Single dose REGN7999 or Placebo; randomized 3:1
62109859|NCT05481333|EXPERIMENTAL|IV Cohort 4|Single dose REGN7999 or Placebo; randomized 3:1
62109860|NCT05481333|EXPERIMENTAL|IV Cohort 5|Single dose REGN7999 or Placebo; randomized 3:1
62470449|NCT06192095|NO_INTERVENTION|Without skin barrier film|Routine care without skin barrier film around the insertion site of a vascular indwelling catheter
61915513|NCT05329038|EXPERIMENTAL|Elderly group|90 elderly aged 60 year and older received two dose inactivated COVID-19 vaccine in primary immunization will receive the booster immunization (the third dose )of inactivated COVID-19 vaccine.
61915514|NCT04689438||Healthy control groups|clinically healthy gingiva BOP score less than 10%
61915515|NCT04689438||Gingivitis groups|BOP score of 10% or greater
61915516|NCT04689438||Periodontitis groups|interdental AL ≥5 mm, PD≥6 mm
61915517|NCT00400153|EXPERIMENTAL|COMBIVENT Respimat 20/100 mcg|
61915518|NCT00400153|EXPERIMENTAL|COMBIVENT CFC-MDI 36/206 mcg|
62109861|NCT05481333|EXPERIMENTAL|SC Cohort 1|Single dose REGN7999 or Placebo; randomized 3:1
62109862|NCT05481333|EXPERIMENTAL|SC Cohort 2|Single dose REGN7999 or Placebo; randomized 3:1
62109863|NCT05481333|EXPERIMENTAL|SC Cohort 3|Single dose REGN7999 or Placebo; randomized 3:1
62109864|NCT05702710||Neonates Undergoing PIRS|All children \<28 days of age undergoing PIRS for inguinal hernia repair
62109865|NCT03663101|EXPERIMENTAL|Pre-Randomization, Run-In period (part A)|Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
62109866|NCT03663101|EXPERIMENTAL|Dysport dose 1 (part B)|Dysport dose 1 as a single-dose, intradermal injection.
62470450|NCT06192095|EXPERIMENTAL|With skin barrier film|Routine care with preventive use of skin barrier film around the insertion site of a vascular indwelling catheter
61915519|NCT00400153|EXPERIMENTAL|Ipratropium Respimat 20 mcg|
61915520|NCT06099145|NO_INTERVENTION|Standard care|Patient who received inhaled treatment with Innovair® or Trimbow® as a part standard care for 6 months
61915521|NCT06099145|EXPERIMENTAL|Hephai|Patient using the Hephaï medical device as a tool who received inhaled treatment with Innovair® or Trimbow® as a part standard care for 6 months
61915522|NCT00941577|EXPERIMENTAL|AIR645|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
62109867|NCT03663101|EXPERIMENTAL|Dysport dose 2 (part B)|Dysport dose 2 as a single-dose, intradermal injection.
61915523|NCT00941577|PLACEBO_COMPARATOR|Physiologic saline solution|Physiologic saline solution
61915524|NCT02553668|EXPERIMENTAL|Hyperoxia|Participants receive 100% oxygen
62109868|NCT03663101|EXPERIMENTAL|Dysport dose 3 (part B)|Dysport dose 3 as a single-dose, intradermal injection.
62470451|NCT02967107|ACTIVE_COMPARATOR|Cold snare polypectomy|Cold snare resection, if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
61915525|NCT00511225|ACTIVE_COMPARATOR|1|Will receive 10,000 IU of cholecalciferol weekly
61915526|NCT00511225|PLACEBO_COMPARATOR|2|Will receive a identical appearing placebo weekly
61915527|NCT00830869|EXPERIMENTAL|Part 1: Ixazomib 0.125 milligram per square meter (mg/m^2)|Ixazomib (MLN9708) 0.125 mg/m\^2, injection, intravenously (IV), once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
61915528|NCT00830869|EXPERIMENTAL|Part 1: Ixazomib 0.25 mg/m^2|Ixazomib (MLN9708) 0.25 mg/m\^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
62470452|NCT02967107|ACTIVE_COMPARATOR|Endoscopic mucosal resection|Endoscopic mucosal resection (EMR), if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
61915529|NCT00830869|EXPERIMENTAL|Part 1: Ixazomib 0.5 mg/m^2|Ixazomib (MLN9708) 0.5 mg/m\^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
61915530|NCT00830869|EXPERIMENTAL|Part 1: Ixazomib 1 mg/m^2|Ixazomib (MLN9708) 1 mg/m\^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
62109869|NCT03663101|PLACEBO_COMPARATOR|Placebo (saline solution) (part B)|Placebo single-dose, intradermal injection.
62470453|NCT01273779|PLACEBO_COMPARATOR|Placebo|
62109870|NCT05395832|EXPERIMENTAL|TAU + multicomponent treatment VIRTUAL FIBROWALK at sea|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session at sea will be added to solve doubts and emphasize the most important points of therapy
61915531|NCT00830869|EXPERIMENTAL|Part 1: Ixazomib 1.33 mg/m^2|Ixazomib (MLN9708) 1.33 mg/m\^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
61915532|NCT00830869|EXPERIMENTAL|Part 1: Ixazomib 1.76 mg/m^2|Ixazomib (MLN9708) 1.76 mg/m\^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
61915533|NCT00830869|EXPERIMENTAL|Part 1: Ixazomib 2.34 mg/m^2|Ixazomib (MLN9708) 2.34 mg/m\^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study. Once the MTD will be established, participants with NSCLC, Head and Neck Cancer (H\&N), Soft Tissue Sarcoma (STC) or Prostate Cancer (PC) will be included in MTD disease expanded cohort. An additional tumor pharmacodynamics expansion cohort (TPEC) will enroll participants with any type of solid tumor that can be biopsied for tissue analysis before and after treatment with ixazomib.
62470454|NCT01273779|EXPERIMENTAL|Talactoferrin alfa|
61915534|NCT00830869|EXPERIMENTAL|Part 2:Ixazomib 1.76 mg/m^2-NSCLC|Ixazomib (MLN9708) 1.76 mg/m\^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with NSCLC during Part 2 of the study.
61915535|NCT00830869|EXPERIMENTAL|Part 2: Ixazomib 1.76 mg/m^2-H&N|Ixazomib (MLN9708) 1.76 mg/m\^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with H\&N during Part 2 of the study.
61915536|NCT00830869|EXPERIMENTAL|Part 2: Ixazomib 1.76 mg/m^2-STC|Ixazomib (MLN9708) 1.76 mg/m\^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with STC during Part 2 of the study.
61915537|NCT00830869|EXPERIMENTAL|Part 2: Ixazomib 1.76 mg/m^2-PC|Ixazomib (MLN9708) 1.76 mg/m\^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with PC during Part 2 of the study.
61915538|NCT00830869|EXPERIMENTAL|Part 2: Ixazomib 1.76 mg/m^2-TPEC|Ixazomib (MLN9708) 1.76 mg/m\^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with various types of solid tumors suitable for biopsy in tumor pharmacodynamic expansion cohort (TPEC) during Part 2 of the study.
62470455|NCT01845298|EXPERIMENTAL|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
62470456|NCT02491905|EXPERIMENTAL|low dose HL tablet|HL tablet which contains 66.7mg of active compound by oral administration, twice daily in an hour after meal
62470457|NCT02491905|EXPERIMENTAL|high dose HL tablet|HL tablet which contains 200mg of active compound by oral administration, twice daily in an hour after meal
62470458|NCT02491905|PLACEBO_COMPARATOR|placebo group|Placebo by oral administration, twice daily in an hour after meal
62470459|NCT04029272|ACTIVE_COMPARATOR|Metformin|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d."
62470460|NCT04029272|EXPERIMENTAL|Metformin+EQW|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d.~EQW: Participants will receive long-acting Exenatide once a week for 12 weeks"
62470461|NCT01457716|EXPERIMENTAL|Budesonide/Formoterol Easyhaler A|
62470462|NCT01457716|EXPERIMENTAL|Budesonide/Formoterol Easyhaler B|
61915539|NCT00004190|EXPERIMENTAL|gemcitabine + oxaliplatin|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.
61915540|NCT01920035|EXPERIMENTAL|Local cooling/hypothermia|These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
61915541|NCT01920035|NO_INTERVENTION|Control Group: RARP without hypothermia|These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.
61915542|NCT05958173|ACTIVE_COMPARATOR|Capsaicin|Natural TRPV1 agonist at a concentration of 10mcM. Posology: 10 mL every 8h for 6 month.
61915543|NCT05958173|ACTIVE_COMPARATOR|Piperine|Natural TRPA1/V1 agonist at a concentration of 150mcM. Posology: 10 mL every 8h for 6 month.
62671653|NCT03777176|EXPERIMENTAL|Standard of Care + dasiglucagon|4 weeks (Treatment Period 1) + 4 weeks (Treatment Period 2) of dasiglucagon treatment as an SC infusion starting at 10 µg/hr on top of standard of care
62671654|NCT03777176|OTHER|Standard of Care Only|4 weeks (Treatment Period 1) of standard of care only + 4 weeks (Treatment Period 2) of dasiglucagon treatment as an SC infusion starting at 10 µg/hr on top of standard of care
62671655|NCT03883451|EXPERIMENTAL|Helmet type|football player helmet model
61915544|NCT05958173|PLACEBO_COMPARATOR|Placebo|Deionized water + the same preservatives as in the active treatments
61915545|NCT02523612|EXPERIMENTAL|Patients with atypical lesions|
61915546|NCT02820701|NO_INTERVENTION|Control|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. After the ultrasound assessment, the control group will wait in another room for approximately 30 minutes.
61915547|NCT02820701|EXPERIMENTAL|Treatment|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. Participants in the Treatment group will receive OMT to address sacral base asymmetry after the initial ultrasound assessment.
61915548|NCT01987947|PLACEBO_COMPARATOR|Placebo|
61915549|NCT01987947|ACTIVE_COMPARATOR|Quilizumab|
61915550|NCT03139942|EXPERIMENTAL|Imaging using OPTIC probe|Single arm study to test the feasibility of a new device - the OPTIC imaging probe. All participants enrolled in the study may be imaged using optical spectral reflectance and autofluorescence imaging during their endoscopy procedure.
61915551|NCT01625533||SA group|Patients using SA for the diagnosis of coronary artery disease are assigned to the SA group.
61915552|NCT01625533||DARCA group|Patients using DARCA for the diagnosis of coronary artery disease are assigned to the DARCA group.
61915553|NCT03386877|EXPERIMENTAL|Dental pulp stem cells|Test sites (n=15) Periodontal regeneration using micro-grafts of Dental pulp stem cells seeded onto collagen sponge
62671656|NCT03707080||Prospective|"The prospective DAA-PASS cohort will include a subset of HCV RNA positive participants in the TARGET-HCC study who meet entry criteria including hepatitis C (with no prior history of DAA therapy) and newly diagnosed Barcelona Clinic Liver Cancer (BCLC) Stage A HCC.~Participants will be enrolled in the countries participating in TARGET-HCC which will include: United States (US), France, Germany, Italy, and Spain."
62109871|NCT05395832|ACTIVE_COMPARATOR|TAU + multicomponent treatment VIRTUAL FIBROWALK in nature|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session in nature will be added to solve doubts and emphasize the most important points of therapy
62109872|NCT05395832|ACTIVE_COMPARATOR|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
62671657|NCT03707080||Historical|The historical cohort will be derived from the ITA.LI.CA database, which includes data on all consecutive patients with HCC who were managed within participating centers in Italy. The historical cohort will include patients from the ITA.LI.CA database who have active HCV infection who were not treated for HCV (IFN-based or DAA-based regimens) during the followup period, with initial HCC diagnosis BCLC Stage A, and subsequent successful treatment of HCC with curative therapy.
62671658|NCT02216877|PLACEBO_COMPARATOR|Placebo|Oral placebo twice daily for 8 weeks. 12 subjects.
62671659|NCT02216877|EXPERIMENTAL|Mablet 360 mg once daily|Oral Mablet 360 mg once daily and oral placebo once daily for 8 weeks. 12 subjects.
62671660|NCT02216877|EXPERIMENTAL|Mablet 360 mg twice daily|Oral Mablet 360 mg twice daily for 8 weeks. 12 subjects.
62671661|NCT05839509|EXPERIMENTAL|GH001 Individualized Dosing Regimen|GH001 (Mebufotenin, 5-Methoxy-N,N-Dimethyltryptamine) is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience \[PE\]) at the previously administered dose.
62671662|NCT02266862||Study Group|The purpose of this study is to evaluate the location within the renal artery of maximal angular displacement before and after fenestrated endovascular aortic repair (FEVAR) using CT with end-inspiration and end-expiration CT images before and after repair.
62109873|NCT01008670||Device Implant Recipients|Patients undergoing CRT implantation, or candidates for future CRT devices currently undergoing ICD or pacemaker implantation.
62109874|NCT02889341|PLACEBO_COMPARATOR|Placebo|Placebo
62671663|NCT02968290|ACTIVE_COMPARATOR|Hydrofobic material-Alcon AcrySof SA60AT|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrofobic material.
62671664|NCT02968290|ACTIVE_COMPARATOR|Hydrophilic material-Bausch Lomb AkreosA|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrophilic material.
61915554|NCT03386877|ACTIVE_COMPARATOR|coagulum|control sites (n=14) Periodontal regeneration using coagulum and collagen sponge alone
61915555|NCT01060345|EXPERIMENTAL|Women with Ductal Carcinoma in Situ|Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E
62109875|NCT02889341|ACTIVE_COMPARATOR|500 mg DHA/day|500 mg DHA/day
62109876|NCT02889341|ACTIVE_COMPARATOR|1g DHA/day|1g DHA/day
62109877|NCT02889341|ACTIVE_COMPARATOR|2g DHA/day|2g DHA/day
62109878|NCT00145041|EXPERIMENTAL|VSLI|Single armed study; all subjects received VSLI
62109879|NCT00595218|NO_INTERVENTION|1|Patients whose radiation oncologist are blinded to their patient preference survey results
62109880|NCT00595218|ACTIVE_COMPARATOR|2|Patients whose radiation oncologist are not blinded to their patient preference survey results
62109881|NCT02118935|ACTIVE_COMPARATOR|Previously marketed cow's milk-based infant formula|
62109882|NCT02118935|EXPERIMENTAL|Marketed cow's milk-based infant formula with prebiotics|
62109883|NCT00762619|PLACEBO_COMPARATOR|A -|fluoride toothpaste (Ultrabrite)
62109884|NCT00762619|ACTIVE_COMPARATOR|B - Postive control|fluoride/triclosan/copolymer toothpaste
62109885|NCT03640455|PLACEBO_COMPARATOR|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; dummy stimulation will be given.
62470463|NCT01457716|EXPERIMENTAL|Budesonide/Formoterol Easyhaler C|
62470464|NCT01457716|ACTIVE_COMPARATOR|Budesonide/Formoterol Turbohaler Forte|
62470465|NCT03476265|EXPERIMENTAL|Ineffective Esophageal Motility and GERD|Patients with gastroesophageal reflux disease (GERD) refractory to proton pump inhibitors (PPI) and ineffective esophageal motility (IEM) according to the Chicago classification v3.0.
62300507|NCT00351715|EXPERIMENTAL|Pharmacokinetic|One episode of breakthrough pain was to be evaluated per patient. Clinical status and bloodwork was evaluated prior to entering into this phase of the trial, and patients were eligible if bloodwork demonstrated a HgB of \>90 g/L with no concurrent bleeding. A peripheral intravenous catheter was inserted and saline locked. When breakthrough pain was experienced, methadone was administered, and the patient completed a pain intensity numeric rating scale at time 0 and every 10 minutes for one hour. A 10 cc specimen of blood was collected prior to administration of methadone, and again every 10 minutes for one hour. Blood was collected without anticoagulant, allowed to clot, separated by centrifugation, and serum samples flash frozen. Serum methadone levels were quantified by LC/MS/MS with comparison to isotopically labeled internal standards
62671665|NCT02014454|EXPERIMENTAL|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularization, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP Cooperative Group."
62300508|NCT00913146||index|child with fever and a negative malaria RDT
62300509|NCT00913146||control|apparently healthy child with a negative RDT
62300510|NCT04036084||Patients|Patients with CADASIL disease : Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL
62300511|NCT04036084||Control|
61915556|NCT01574742|EXPERIMENTAL|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
61915557|NCT02592811|ACTIVE_COMPARATOR|ESLBD|"Endoscopic Sphincterotomy plus Large Balloon Dilatation +/- lithotripsy~1. ERCP with deep cancellation of BDS~2. Endoscopic large sphincterotomy~3. Large Balloon Dilatation of Oddi Sphincter: with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)~4. Stone extraction with dormia basket or extraction balloon~5. Mechanical Lithotripsy if needed"
62470466|NCT05316428|EXPERIMENTAL|alcohol plus TPN171H|0.5 g/Kg alcohol plus 10 mg TPN171H tablet
62470467|NCT05316428|EXPERIMENTAL|alcohol|0.5 g/kg alcohol
62470468|NCT05316428|EXPERIMENTAL|TPN171H|10 mg TPN171H tablet
61915558|NCT02592811|ACTIVE_COMPARATOR|CONV|"Conventional treatment associating Endoscopic Sphincterotomy +/- Mechanical Lithotripsy (ES+/-LM)~1. ERCP with deep cancellation of BDS~2. Endoscopic large sphincterotomy~3. Stone extraction with dormia basket or extraction balloon~4. Mechanical Lithotripsy if needed"
62671666|NCT03917264|ACTIVE_COMPARATOR|Tooth-borne treatment|Titanium curettes
62671667|NCT03917264|EXPERIMENTAL|Implant-specific treatment|Implant brush
61915559|NCT06339671||NF (Non fumatori)|Non-smoker
61915560|NCT06339671||FT (Fumatori di tobacco)|Tobacco smokers
62671668|NCT02453191|EXPERIMENTAL|Treatment|"Talimogene Laherparepvec in combination with radiotherapy~Talimogene Laherparepvec Dose Levels:~• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL"
62671669|NCT01093885|OTHER|open label: medication Ambrisentan|"Open label study of Ambrisentan.~Ambrisentan will begin at 5mg daily for the first month.~Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week. Subjects will continue their present dose and schedule of disease modifying/antifibrotic medication for the duration of the study.~\*\* Dose escalation was attempted however none of the patients were able to increase. Therefore all subjects remained on 5 mg daily throughout the study. 12 patients on mycophenolate mofetil, 2 on mycophenolic acid and one on methotrexate"
61915561|NCT06339671||NRT (Nicotine replacement therapy)|Nicotine replacement therapy
61915562|NCT04095637|EXPERIMENTAL|Mako medial UKA|Mako medial unicondylar knee arthroplasty
61915563|NCT04095637|ACTIVE_COMPARATOR|Oxford media UKA|Oxford unicompartmental knee arthroplasty with navigation control
61915564|NCT05883670||Cohort 1|"The medication plan is determined by gynecological oncology or oncology physician. Select the treatment plan containing serplulimab (single drug and/or combination), the other anti-tumor treatment schemes without intervention.~The recommended dose of serplulimab is 300 mg IV, Day1 of each cycle. Apply the drug on the first day of each cycle until the disease progresses or intolerable toxicity occurs.The combined drugs is decided by the doctor.~In this non-interventive study, do not change or interfere with the current medical treatment of the recruited patients."
61915565|NCT00208546|EXPERIMENTAL|1Capecitabine + bevacizumab + oxaliplatin + cetuximab|
61915566|NCT00208546|ACTIVE_COMPARATOR|21Capecitabine + bevacizumab + oxaliplatin|
61915567|NCT05200819||COVID 19 Patients|Patients who have survived COVID-19 infection, including those included in the Michigan Medicine COVID-19 Cohort (M2C2) will be eligible to participate.
61915568|NCT03396757|ACTIVE_COMPARATOR|Standard strategy|RRT will be initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours (identical to the delayed strategy in AKIKI).
61915569|NCT03396757|EXPERIMENTAL|Delayed strategy|RRT will be considered only if one potentially severe following situation occurs (noticeable hyperkalemia, or acidosis or pulmonary edema due to fluid overload resulting in severe hypoxemia which do not respond rapidly to medical treatment) or if serum urea concentration reaches 50 mmol/L.
62671670|NCT00600782|EXPERIMENTAL|Group A|These subjects were further stratified into 3 groups according to the size of their PPD skin test reactions
62671671|NCT06328231|EXPERIMENTAL|Systematic simple swallowing training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
61915570|NCT02648828||Intern|Interns are in their first year of residency.
61915571|NCT02648828||Residents|Residents are in their 2nd or 3rd year of residency.
61915572|NCT02648828||Attendings|Attendings are physicians who have completed their residency.
61915573|NCT02394197|ACTIVE_COMPARATOR|14-day treatment (T14)|"The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)"
62671672|NCT06328231|NO_INTERVENTION|Blank Group|This group received no intervention but were requested to do mild physical activities by themselves
62671673|NCT01359280|EXPERIMENTAL|Adherence Counseling + Text Messages|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
62671674|NCT01359280|EXPERIMENTAL|Adherence Counseling Only|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building.
62671675|NCT01359280|PLACEBO_COMPARATOR|General Health Counseling Only|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building.
62671676|NCT01359280|PLACEBO_COMPARATOR|General Health Messages + Text Messages|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
62671677|NCT02773628|PLACEBO_COMPARATOR|control group|stable asthmatics receiving an Acar'up placebo system
62671678|NCT02773628|ACTIVE_COMPARATOR|treatment group|stable asthmatics receiving Acar'up system
62671679|NCT00831207||G1|15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ \< 350 cells/mm3.
62109886|NCT03640455|EXPERIMENTAL|Anodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in anodal polarity.
62671680|NCT00831207||G2|31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).
62109887|NCT03640455|EXPERIMENTAL|Cathodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in cathodal polarity.
62470469|NCT03452319|EXPERIMENTAL|Pretraining|Increased physical activity daily Daily strength training Daily inspiratory and expiratory muscle training Standard care during hospital stay and continued training after discharge.
62671681|NCT00831207||G3|43 HIV-1+ individuals undergoing HAART with TF.
62470470|NCT03452319|ACTIVE_COMPARATOR|Usual care treatment|Standard care including preoperative information and postoperative breathing exercises and mobilization during hospital stay.
62671682|NCT00831207||G4|20 normal individuals who served as controls for serum cytokines.
62671683|NCT02105142|ACTIVE_COMPARATOR|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
61915574|NCT02394197|EXPERIMENTAL|Intermittent single doses (ISD)|"The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html)."
61915575|NCT02697110|EXPERIMENTAL|A: Edutainment based intervention|This group receives the usual routine immunization at 6, 10, 14 weeks and 9 months and an Edutainment intervention package of limited group (i.e., 3-5 women) drama based video session (Edutainment) followed by a Question and Answer session with mothers on early brain development, parenting skills, communication and negotiating skills at 6 weeks. Mothers will be encouraged to train fathers and other caregivers at home with reinforcement of key messages at subsequent clinic visits. Key messages will be delivered through the use of flip charts at 14 weeks and given to mothers as take home for use in engaging the fathers partners and other caregivers for their child. Reinforcement of key messages at subsequent visits will be through the use of videos and flip chart.
62109888|NCT02476890|EXPERIMENTAL|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.
61915576|NCT02697110|NO_INTERVENTION|B|This group receives routine immunization care (usually includes group health talk) at 6, 10, 14 weeks and 9 months.
61915577|NCT00297024|EXPERIMENTAL|MRI for brain mets|
61915578|NCT02029690|EXPERIMENTAL|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol
61915579|NCT00924625|EXPERIMENTAL|Neuromuscular electrical stimulation|NMES will be used as in clinical practice based on an evidence-based approach. NMES will be applied at the participant's maximum tolerance. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions.
62109889|NCT02476890|EXPERIMENTAL|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.
62109890|NCT02476890|EXPERIMENTAL|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.
62671684|NCT02105142|ACTIVE_COMPARATOR|ADHD Group visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
62671685|NCT02105142|ACTIVE_COMPARATOR|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Online discussion portal access granted to parent participants and will allow parents to communicate with each other in between in-person group visits
62470471|NCT02410486||EOS infant / mother with chorio|Infant with EOS (Gram-positive or Gram-negative) and mother with Chorioamnionitis
62671686|NCT02882516|EXPERIMENTAL|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62671687|NCT02882516|EXPERIMENTAL|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62671688|NCT02882516|EXPERIMENTAL|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62671689|NCT02882516|EXPERIMENTAL|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62671690|NCT02882516|NO_INTERVENTION|darkness|The participants will not be exposed to any light but stay in darkness for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62671691|NCT06093503|EXPERIMENTAL|Telisotuzumab Vedotin and Osimertinib|Participants will receive telisotuzumab vedotin every 2 weeks in combination with osimertinib, until disease progression or unacceptable toxicity.
62671692|NCT06093503|EXPERIMENTAL|Standard of Care|Participants will receive standard of care chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed as prescribed by the physician), until disease progression or unacceptable toxicity.
62671693|NCT02645708|OTHER|Retrograde Intrarenal Surgery (RIRS)|Patients in Group 1 undergo Retrograde Intrarenal Surgery
62671694|NCT02645708|OTHER|EPVL after RIRS|"Patients in Group 2 undergo external physical vibration lithecbole after Retrograde Intrarenal Surgery.~with the help of changing the position and direction of the extracorporeally physical vibration machine, the urinary stone was discharged from the urinary collecting system"
61915580|NCT00924625|ACTIVE_COMPARATOR|Volitional exercises|VE will be used as in clinical practice based on an evidence-based approach. VE program will be the one shown to positively affect muscle hypertrophy and will follow the resistance training principles. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions
62671695|NCT04984408|EXPERIMENTAL|Arm 1: BBIBP-CorV|Study Arms 1 will have two groups: group 1 - HIV-uninfected receiving BBIBP-CorV; group 2 - HIV-infected receiving BBIBP-CorV .
62470472|NCT02410486||EOS infant / mother without chorio|Infant with EOS (Gram-positive or Gram-negative) and mother without Chorioamnionitis
62470473|NCT02410486||EOS Gram-neg infant / mother with chorio|Infant with Gram-negative EOS and mother with Chorioamnionitis
62470474|NCT02410486||Gram-neg infant / mother without chorio|Infant with Gram-negative EOS and mother without Chorioamnionitis
62470475|NCT02410486||Gram-pos infant / mother with chorio|Infant with Gram-positive EOS and mother with Chorioamnionitis
62470476|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
62671696|NCT04984408|EXPERIMENTAL|Arm 2: Flu Quadrivalent|Study Arms 2 will have two groups: group 1 - HIV-uninfected receiving Flu Quadrivalent; group 2 - HIV-infected receiving Flu Quadrivalent. The Flu Quadrivalent is recommended as a single dose for adults, the second and the booster doses for Arm 2 will be placebo.
62671697|NCT04984408|EXPERIMENTAL|Arm 3: BBIBP-CorV and Flu Quadrivalent (Co-administration)|Arm 3 will have 1 group - HIV-uninfected co-administration group receiving both study vaccines.
62671698|NCT01557816|ACTIVE_COMPARATOR|Naproxen|
62671699|NCT01557816|SHAM_COMPARATOR|Placebo|
62671700|NCT05020522|OTHER|MRI scan|Mp-MRI, LI-MRI, plasma DNA methylation signature (optional)
62671701|NCT01305343||Surgical treatment|This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity.
62671702|NCT02585102|OTHER|Recommended Vegetables|Diet provided consisting of recommended vegetable intake per Dietary Guidelines for Americans amounts for 8 weeks.
62671703|NCT02585102|OTHER|Usual Vegetables|Diet consisting of usual vegetable intake amounts for 8 weeks.
62671704|NCT03592992|EXPERIMENTAL|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
62671705|NCT03592992|ACTIVE_COMPARATOR|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
62671706|NCT02887599|OTHER|Patient Group|Pancreatic cancer patients
62671707|NCT02887599|OTHER|Control Group|Healthy people without evidence of malignancy
62671708|NCT03685240|EXPERIMENTAL|Intervention|AI-enabled camera fall detection with Human-in-the-Loop (HIP) review
62671709|NCT03685240|NO_INTERVENTION|Control|No camera detection
62671710|NCT00842036|ACTIVE_COMPARATOR|ANft|12- step Al/Nar-Anon Facilitation
62671711|NCT00842036|EXPERIMENTAL|TEnT|Treatment Entry Training
62671712|NCT00842036|EXPERIMENTAL|CRAFT|Community Reinforcement and Family Training
62671713|NCT01691742|PLACEBO_COMPARATOR|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
62671714|NCT01691742|ACTIVE_COMPARATOR|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
62671715|NCT06468475|EXPERIMENTAL|Magnesium Sulphate Group|
62671716|NCT06468475|NO_INTERVENTION|Control|
62671717|NCT05963919||Asthma Group|6 minute walk test, Pulmonary function test, Respiratory muscle strength test, Lower extremity muscle strength test
62671718|NCT05963919||Control Group|6 minute walk test, Pulmonary function test, Respiratory muscle strength test, Lower extremity muscle strength test
62671719|NCT03374904|ACTIVE_COMPARATOR|Control Group|Patients in control group will attend to four session of Play Therapy plus inpatient treatment as usual during four weeks
62671720|NCT03374904|EXPERIMENTAL|Video Feedback|Once a week, after play therapy, individual or group video feedback session will be done.
62671721|NCT03975114|ACTIVE_COMPARATOR|Chemo first|Standard chemotherapy followed at progression by durvalumab
62671722|NCT03975114|EXPERIMENTAL|Immuno Monotherapy first|Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
62671723|NCT03975114|EXPERIMENTAL|Immuno Combination Therapy first|experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
62671724|NCT02732145|PLACEBO_COMPARATOR|Normal vulva|"The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
62671725|NCT02732145|PLACEBO_COMPARATOR|Impaired vulvar skin|"The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
62671726|NCT02732145|PLACEBO_COMPARATOR|Vulvodynia|"The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
62671727|NCT02732145|ACTIVE_COMPARATOR|Vulvar dermatosis|"The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
62671728|NCT04508959||Screened patients|All individuals screened using the hospital's microbiology laboratory.
62671729|NCT04508959||Outpatient (Emergency Department) cases|All individuals seen in the emergency department who test positive for COVID-19.
62671730|NCT04508959||Inpatient (General Medical or Intensive Care) cases|All individuals admitted to a general or intensive care bed who test positive for COVID-19.
62671731|NCT00001082|EXPERIMENTAL|1|Participants will receive adefovir dipivoxil and L-carnitine
62671732|NCT00001082|EXPERIMENTAL|2|Participants will receive adefovir dipivoxil placebo and L-carnitine.
62671733|NCT03115658|EXPERIMENTAL|Exercise Intervention|"Participants met with a PhD level psychologist experienced with health behavior change, to set a personalized exercise goal and plan. Participants were told the studies' goal to engage in 150 minutes of moderate intensity or greater physical activity each week, based on the ACSM recommendations, but participants were allowed to set any personal goal. Participants were also instructed on how to self-monitor their physical activity.~After the initial meeting all other intervention components were sent through the mail. The intervention consists of three types of print material that were mailed: stage-matched manuals, tailored feedback report, and tip sheets."
62470477|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
62671734|NCT04162314|EXPERIMENTAL|Experimental|This group received combination of mycelium extract of Ganoderma lucidum capsule containing 180 mg Beta-1,3/1,6-D-Glucan with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
62671735|NCT04162314|PLACEBO_COMPARATOR|Control|This group received combination of placebo capsules with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
62671736|NCT03744975|PLACEBO_COMPARATOR|Placebos|Control Intervention will be 1 Placebo Capsule given orally, one time
62671737|NCT03744975|ACTIVE_COMPARATOR|LCZ 696|1st Experimental Arm will be 1 capsule of LCZ 696 given orally, one time
62671738|NCT02277860|EXPERIMENTAL|Exercise|Aerobic and strength training using the Wii Fit Plus for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
62671739|NCT00337194|EXPERIMENTAL|Arm I (SGN-30, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 \& 8, vinorelbine: 20 mg/m\^2 IV days 1 \& 8, gemcitabine: 1000 mg/m\^2 IV days 1 \& 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 \& 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 \& 8, vinorelbine: 15 mg/m\^2 IV days 1 \& 8, gemcitabine: 800 mg/m\^2 IV days 1 \& 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 \& 8."
62671740|NCT00337194|ACTIVE_COMPARATOR|Arm II (placebo, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 \& 8, vinorelbine: 20 mg/m\^2 IV days 1 \& 8, gemcitabine: 1000 mg/m\^2 IV days 1 \& 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 \& 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 \& 8, vinorelbine: 15 mg/m\^2 IV days 1 \& 8, gemcitabine: 800 mg/m\^2 IV days 1 \& 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 \& 8."
62671741|NCT02994277|EXPERIMENTAL|UVa and ITBA/UNLP algorithm arm|To control glycaemia in T1DM patients through UVa and ITBA/UNLP algorithm
62470478|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
62470479|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
62671742|NCT00863460|ACTIVE_COMPARATOR|A|MTX-based chemotherapy followed by WBRT
62671743|NCT00863460|EXPERIMENTAL|B|MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue
62671744|NCT02998099|EXPERIMENTAL|Aged 18-45 years|A single dose of IV rivipansel over 20 minutes.
62671745|NCT02998099|EXPERIMENTAL|Aged 65 and older|A single dose of IV rivipansel over 20 minutes.
62671746|NCT03092843||No functional capacity testing|6 minute walk Quality of life Questionaire
62671747|NCT03092843||Functional Capacity Testing|6 minute walk Quality of Life Questionnaire Metabolic stress test
62671748|NCT02347956|EXPERIMENTAL|Reduced port group|
62671749|NCT04604093||SMBG, self-monitoring of blood glucose|Subjects will be randomized to continue use traditional SMBG, self-monitoring of blood glucose, to manage their diabetes.
62671750|NCT04604093||FreeStyle Libre 2|Subjects will be randomized to use the FreeStyle Libre 2 Flash Glucose Monitoring System to manage their diabetes.
62109891|NCT02476890|EXPERIMENTAL|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.
62671751|NCT02056288|ACTIVE_COMPARATOR|Ultrasound Guided Supraclavicular block|Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
62671752|NCT02056288|ACTIVE_COMPARATOR|IV Opioids|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
62671753|NCT03115632||Obese asthmatic & lean asthmatic|men and women with asthma and either obese or lean BMI
62671754|NCT03115632||Obese non-asthmatic & lean non-asthmatic|men and women without asthma and either obese or lean BMI
62671755|NCT03115632||Asthmatic undergoing bariatric surgery|Obese asthmatic men and women undergoing bariatric surgery
62671756|NCT03115632||Non-asthmatic undergoing bariatric surgery|Obese men and women undergoing bariatric surgery
62671757|NCT00574951|EXPERIMENTAL|AMG 706|AMG 706 daily
62671758|NCT05187637||Intervention|Patients on the waiting list for liver transplantation with haemoglobin less than 11.5g/dL and transferrin saturation index less than 40% with ferritin less than 800mcg/L, which are considered iron deficiency susceptible to respond to intravenous iron administration.
62671759|NCT05187637||Control|Patients on the waiting list for liver transplantation in the same period of the intervention cohort, with haemoglobin less than 11.5g/dL and transferrin saturation index more than 40%, which are considered of non susceptibles for iron supplement alone.
62671760|NCT02614768|EXPERIMENTAL|Glucose Sensor|Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).
62671761|NCT02959606|EXPERIMENTAL|Sarpogrelate SR 300mg + ASA|"Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Anplone SR"
62671762|NCT02959606|ACTIVE_COMPARATOR|Clopidogrel + ASA|"Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Plavix"
62671763|NCT03435406||cirrhosis with HPS|Diagnosed as HPS
62671764|NCT03435406||cirrhosis without HPS|Not Diagnosed as HPS
62671765|NCT02548364|EXPERIMENTAL|Calcifediol|One capsule with 15,690 IU p.o. every two weeks
62671766|NCT02548364|PLACEBO_COMPARATOR|Placebo|One capsule with placebo p.o. every two weeks
62671767|NCT00193947||women initiating ARV therapy during pregnancy with neveripine|
62671768|NCT05747547||mild disease|asymptomatic or paucisymptomatic patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV2-infection) who received outpatient care
62671769|NCT05747547||moderate disease|patients with laboratory-confirmed SARS-CoV2-infection and radiology-confirmed pneumonia who did not require extracorporeal membrane oxygenation
62671770|NCT05747547||severe disease|patients with laboratory-confirmed SARS-CoV2-infection and acute respiratory distress syndrome who required extracorporeal membrane oxygenation
62109892|NCT00303836|EXPERIMENTAL|Arm I|Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.
62671771|NCT03799120|PLACEBO_COMPARATOR|tamsulosin QD + Placebo|0.4 mg tamsulosin QD + Placebo QD
62671772|NCT03799120|EXPERIMENTAL|tamsulosin BID|0.4 mg tamsulosin BID
62671773|NCT01758081|ACTIVE_COMPARATOR|vitamin D + fish oil|vitamin D3 + Omacor
62109893|NCT00303836|EXPERIMENTAL|Arm II|Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62109894|NCT03439904|EXPERIMENTAL|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care
62109895|NCT03439904|NO_INTERVENTION|control group|Patients will receive usual medical care
62109896|NCT05401916|ACTIVE_COMPARATOR|Intravenous paracetamol|Intravenous paracetamol 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Tramadol with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
61915581|NCT04089800|EXPERIMENTAL|Intervention|For 9 months, each of the 40 women in the intervention condition will use their phones to access the multimedia-based antenatal videos and audios tailored to their pregnancy stages. Participants will use the prototype until six weeks after giving birth. The intervention implementation is estimated to take 9 months including a 6 weeks follow-up after delivery, which implies that the implementation will be completed by November/ December 2019. The investigators will install the final prototype on a phone and give each participant in the intervention group a phone with a prototype installed, and explain how it works. Women will get support in resolving technical issues that may arise with the application between March and May 2019.
62109897|NCT05401916|ACTIVE_COMPARATOR|Intravenous ibuprofen|"800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery.~All administrations will be applied through IV infusion over 30 minutes. Patients will be received Tramadol with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min."
62109898|NCT06145854||Cisgender Females|
62109899|NCT04016818|EXPERIMENTAL|18-F FDG Study using Breast-Dedicated PET Camera|Breast-Dedicated PET Camera will be used with standard PET 18-F FDG tracer dose
62109900|NCT00684528|ACTIVE_COMPARATOR|a|This group will receive Metformin and placebo.
62300512|NCT02923271|EXPERIMENTAL|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
62300513|NCT02923271|EXPERIMENTAL|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
62300514|NCT00418288|ACTIVE_COMPARATOR|A|
62300515|NCT00418288|PLACEBO_COMPARATOR|P|
62300516|NCT02704104|EXPERIMENTAL|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
62671774|NCT01758081|ACTIVE_COMPARATOR|vitamin D + fish oil placebo|vitamin D3 + fish oil placebo
62671775|NCT01758081|ACTIVE_COMPARATOR|vitamin D placebo + fish oil|vitamin D placebo + Omacor
62671776|NCT01758081|PLACEBO_COMPARATOR|vitamin D placebo + fish oil placebo|vitamin D placebo + fish oil placebo
62671777|NCT00962455|EXPERIMENTAL|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
62671778|NCT00962455|ACTIVE_COMPARATOR|Usual practice|Usual practice regarding spirometry execution in family practice
62109901|NCT00684528|EXPERIMENTAL|2|The second arm will receive Metformin and Januvia
62109902|NCT03450278|NO_INTERVENTION|control|canine retraction without any means of acceleration.
62109903|NCT03450278|EXPERIMENTAL|micro-osteoperforation|canine retraction accelerated with micro-osteoperforation
62109904|NCT02128789|NO_INTERVENTION|Control Condition|Subjects receive usual care and support. No study intervention provided
62671779|NCT02585492|ACTIVE_COMPARATOR|head-of-bed elevated 15°|Mother's head-of-bead elevated 15°. Intervention: Head-of-bed elevated 15° during 2 hours after the delivery.
62671780|NCT02585492|EXPERIMENTAL|head-of-bed elevated 45°|Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
62109905|NCT02128789|EXPERIMENTAL|Elder Tree Condition|Elder Tree website. Subjects receive usual care, support and access to the study intervention website.
62109906|NCT05906225|EXPERIMENTAL|Electroencephalogram|Adjustment of concentration of sevoflurane according to EEG
62671781|NCT05823077|EXPERIMENTAL|Bergamot|In addition to 4 weeks of conventional treatment, Bergamot oil diluted with 1.5% sweet almond oil (4 drops of aromatic oil to 10 cc of sweet almond oil) will be used on the participants. After the oil is diluted, it will be heated up to 36oC. The participant will sit on the stretcher directly opposite the therapist, with the affected knee semi-flexed. The therapist will massage the affected knee for 15 minutes. After the massage, the knees will be wrapped with a towel for 5 minutes.
62109907|NCT05906225|ACTIVE_COMPARATOR|Conventional|Adjustment of concentration of sevoflurane according to vital signs
62109908|NCT01671644||Eeva Test Group|Day 3 embryo transfers that used Eeva predictions with morphology grading.
62109909|NCT01671644||Matched case control group|Day 3 embryo transfers using morphology grading only (from a matched concurrent control group).
62109910|NCT04588285|EXPERIMENTAL|Ambroxol|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
62109911|NCT04588285|EXPERIMENTAL|Placebo|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
62109912|NCT00930813|EXPERIMENTAL|Lutonix Catheter|Paclitaxel coated Balloon Catheter
62470480|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
62470481|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
62470482|NCT00944424|EXPERIMENTAL|Arm A|Arm A = Docetaxel + High dose Vitamin D2
62470483|NCT00944424|ACTIVE_COMPARATOR|Arm B|Docetaxel + Standard dose Vitamin D2
62470484|NCT01350557|NO_INTERVENTION|Control group|Patients receive only usual hospital care
62671782|NCT05823077|PLACEBO_COMPARATOR|Placebo|In addition to 4 weeks of conventional treatment, Pure sweet almond oil will be used for the participants. Sweet almond oil will be heated to 36oC. The participant will sit on the stretcher directly opposite the therapist, with the affected knee semi-flexed. The therapist will massage the affected knee for 15 minutes. After the massage, the knees will be wrapped with a towel for 5 minutes.
62671783|NCT05823077|NO_INTERVENTION|Control|4 weeks of conventional treatment.
62671784|NCT02053584|EXPERIMENTAL|Dario BGMS|
62671785|NCT02948075|EXPERIMENTAL|Quisinostat 12 mg & Paclitaxel & Carboplatin|One 3-weeks course includes 6 doses of Quisinostat 12 mg at Days 1, 3, 5, 7, 9 and 11 and Paclitaxel 175 mg/m2 and Carboplatin (mg/ml x min) x \[GFR (ml/min) + 25\] on Day 7 up to 6 cycles.
62470485|NCT01350557|OTHER|Subacute care group|Patients receive hospital usual care and subacute care. Subacute care consisted of geriatric consultation, a rehabilitation program, and early discharge planning.
62470486|NCT01350557|EXPERIMENTAL|Comprehensive care group|Patients receive not only the subacute care (geriatric consultation, rehabilitation program, and discharge planning), but also health-maintenance interventions to prevent falls, consult on nutrition, and manage depression.
62470487|NCT04553133|EXPERIMENTAL|PF-07104091|CDK2 monotherapy dose escalation
62470488|NCT04553133|EXPERIMENTAL|PF-07104091 + palbociclib + fulvestrant|CDK2 + palbociclib + fulvestrant
62671786|NCT00153920|EXPERIMENTAL|bortezomib|Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.
62671787|NCT06252337|EXPERIMENTAL|Thermafil AH Plus bioceramic test group|Test Group_ A premixed CaSi-containing bioceramic sealer (Ah Plus Bioceramic, Dentsply, Konstanz, Germany) was used in association with a warm carrier-based technique (Thermafil, Dentsply, Konstanz, Germany). AH Plus Bioceramic is mostly composed of zirconium dioxide (50-70%) as a radiopacifier and tricalcium silicate (10-15%) as a bioactive component. Dimethyl sulfoxide and traces of lithium carbonate and thickening agents are also reported by the manufacturer.The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
62109913|NCT00930813|ACTIVE_COMPARATOR|Standard uncoated Balloon Angioplasty Catheter|uncoated angioplasty balloon
62470489|NCT04553133|EXPERIMENTAL|PF-07104091 + palbociclib + letrozole|CDK2 + palbociclib + letrozole
62470490|NCT04553133|EXPERIMENTAL|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 monotherapy dose expansion (SCLC)
62470491|NCT04553133|EXPERIMENTAL|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 monotherapy dose expansion (ovarian)
62470492|NCT04553133|EXPERIMENTAL|PF-07104091 + fulvestrant (post CDK4/6) dose expansion|PF-07104091 + fulvestrant (post CDK4/6) dose expansion
62470493|NCT04553133|EXPERIMENTAL|PF-07104091 + fulvestrant (post CDK 4/6) dose escalation|CDK2+ fulvestrant (post CDK 4/6) dose escalation
62470494|NCT06456580|EXPERIMENTAL|Telitacicept|Telitacicept
62470495|NCT06456580|PLACEBO_COMPARATOR|Placebo|Placebo
62109914|NCT02791217||Diffused Large B cell Lymphoma|
62109915|NCT02791217||Follicular Lymphoma|
62109916|NCT02791217||Multiple Myeloma|
62470496|NCT02409472|OTHER|minimal surveillance|Minimal program for colon cancer: Office visit and CEA at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, and 48 months. Liver echography\* at 8, and 20 months.
62671788|NCT06252337|OTHER|Thermafil AH Plus control group|Control Group_ an epoxy resin based sealer (Ah Plus, Dentsply, Konstanz, Germany) was used in association with a warm carrier-based technique (Thermafil, Dentsply, Konstanz, Germany). The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
62671789|NCT04225832|EXPERIMENTAL|CBT Coping Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP among Latinx sexual minority men (SMM). The intervention sessions will address topics such as: understanding and coping with intersectional stigma, multiple identities (e.g., race/ethnicity, sexual orientation), medical mistrust, social support, and structural stigma. Intervention groups will be led by a trained facilitator (with expertise in group therapy with Latinx SMM) and a trained peer co-facilitator matched in identities with participants (Latinx SMM).
62671790|NCT04225832|NO_INTERVENTION|Control|Participants who are randomized to the control condition will be referred to the standard of care program at Bienestar, which includes an ongoing weekly open wellness-oriented support group available to all clients.
61915582|NCT04089800|NO_INTERVENTION|Control|The 40 women in the control condition will receive the usual standard care of antenatal check-up and counselling but no multimedia intervention.
62109917|NCT02791217||Hodgkin Lymphoma|
62109918|NCT02791217||Healthy individuals|
62109919|NCT05527236|EXPERIMENTAL|Breathing Exercise Group|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercise again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
62300517|NCT02704104|PLACEBO_COMPARATOR|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
62671791|NCT01663987|ACTIVE_COMPARATOR|18 mcg tiotropium|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
62671792|NCT01663987|PLACEBO_COMPARATOR|Placebo|Patient to receive one placebo capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
62671793|NCT04867590|EXPERIMENTAL|EndoRotor|"The ENDOROTOR is a new system for the resection of superficial lesions within the digestive tract and composed of a reusable generator, a single-use probe and additional accessories.~The device is used in the resection of mucosa in the digestive tract: flat or slightly raised lesions in the digestive mucosa, or treatment of the lateral margins following a resection carried out using another technique.~Resected tissue is aspirated away through a rotating catheter: the cutting and removal of tissue as well as the collection of specimens are combined into one act."
61915583|NCT01927471||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles. We will aim to recruit 120 women in this category.
61915584|NCT01927471||Irregular menstrual cycles, no PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, without a pre-existing diagnosis of PCOS. We will aim to recruit 120 women in this category.
62109920|NCT05527236|EXPERIMENTAL|Virtual Reality Group|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
62300518|NCT06118528|EXPERIMENTAL|Blur Obfuscation|
62300519|NCT06118528|EXPERIMENTAL|Edge Obfuscation|
62300520|NCT06118528|EXPERIMENTAL|Cartoon Obfuscation|
62300521|NCT06118528|EXPERIMENTAL|No Obfuscation (Raw)|
62300522|NCT00596505||1|Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
61915585|NCT01927471||Irregular menstrual cycles, with PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
62109921|NCT05527236|NO_INTERVENTION|Control Group|"Descriptive information form was filled out at 36th week of pregnancy in a quiet pregnant outpatient clinic in the hospital. After participants were admitted to the delivery room of Gaziantep Cengiz Gökçek Obstetrics and Pediatrics Hospital at the 40th week of pregnancy, and taken to their beds, in labour observation form, the labour section and the birth evaluation section which is used to evaluate the second and third stages of labour were filled out. Then, VAS was applied when cervical dilatation was 4 cm (the beginning of the active phase). Birth satisfaction was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.~No application was made to pregnant women in this group, except for routine practices in the pregnant outpatient clinic at the hospital and in the delivery room."
62109922|NCT01762241|EXPERIMENTAL|Intervention group|12 weeks systematically home based training 3 times per week one hour at the time using the Xbox Kinect system.
62109923|NCT01762241|NO_INTERVENTION|Control group|No systematically training/standard of care
62109924|NCT03264456|EXPERIMENTAL|[18F] Fluciclovine PET/MRI|\[18F\] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer
62109925|NCT02232178|EXPERIMENTAL|2 100mg Xaracoll implants|Bupivacaine HCl implant
62109926|NCT02232178|EXPERIMENTAL|3 100mg Xaracoll implants|Bupivacaine HCl implant
62109927|NCT02232178|ACTIVE_COMPARATOR|150mg Bupivacaine HCl injection|Bupivacaine HCl
62109928|NCT00269399|EXPERIMENTAL|Rifaximin Treatment Arm|rifaximin 400mg taken 3 times a day
62109929|NCT00269399|ACTIVE_COMPARATOR|Vancomycin Comparator Arm|vancomycin 125mg taken 4 times a day
62109930|NCT06030908||Study Population|Patients who underwent surgical reconstruction of the Achilles tendon insertion using a knotless, double-row anchor system.
62109931|NCT05969730|EXPERIMENTAL|A|Baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream
62109932|NCT05969730|EXPERIMENTAL|B|Azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream
62109933|NCT00494442|EXPERIMENTAL|KU-0059436 (AZD2281) 100 mg BID|
62109934|NCT00494442|EXPERIMENTAL|KU-0059436 (AZD2281) 400 mg BID|
62109935|NCT01985061|ACTIVE_COMPARATOR|BX2|Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2
62109936|NCT01985061|EXPERIMENTAL|BX3|Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
62300523|NCT00596505||2|Group 2 will not receive bevacizumab pretreatment
62109937|NCT01985061|ACTIVE_COMPARATOR|BX4-Suspended|Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
62109938|NCT05302713|EXPERIMENTAL|Ionic Calcium|Ionic calcium (IC) is a calcium in a free ionic state. Participants will be instructed to take 8mg of IC/60kg body weight dissolved into approximately 500ml of purified water. Participants will titrate their dose at the start of the study as follows: days 1-3: 1 dose per day 30 min prior to a meal; Days 4-6: twice per day, 30 minutes before meals; from day seven onward, the full dosage of three times per day, 30 minutes before meals.
62109939|NCT05302713|ACTIVE_COMPARATOR|Calcium Carbonate|Participants will be instructed to take 8mg of calcium carbonate/60kg body weight dissolved into approximately 500ml of purified water. Participants will titrate their dose at the start of the study as follows: days 1-3: 1 dose per day 30 min prior to a meal; Days 4-6: twice per day, 30 minutes before meals; from day seven onward, the full dosage of three times per day, 30 minutes before meals.
62109940|NCT04806113|OTHER|Vaccine|Study participants (People with rheumatic diseases and age matched controls).
62109941|NCT03245060|EXPERIMENTAL|Intervention: immediate SFBT|The Intervention arm will receive up to six Adapted Solution Focused Brief Therapy (SFBT) sessions immediately post randomisation. The sessions will be spaced over 3 months. Participants will also receive all usual care.
62300524|NCT02137668|EXPERIMENTAL|Oral Vancomycin|Every participant with PSC or BA will received the same Arm of Oral Vancomycin
62300525|NCT02090543||Group 1|300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
61915586|NCT03381742|EXPERIMENTAL|ticagrelor 45mg bidpo.|To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
61915587|NCT03381742|EXPERIMENTAL|ticagrelor 90mg qdpo.|To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
61915588|NCT03381742|ACTIVE_COMPARATOR|ticagrelor 90mg bidpo.|To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
61915589|NCT03381742|ACTIVE_COMPARATOR|clopidogrel 75mg qdpo.|To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
62671794|NCT04867590|ACTIVE_COMPARATOR|Radiofrequency|Endoscopic treatment using the HALO® 360 or 90 system is a thermal ablation system for superficial mucosa. First and foremost, the examination includes an endoscopy to locate the upper limits of the BE and its distribution, so as to choose the most appropriate type of probe. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.
62671795|NCT01834651|EXPERIMENTAL|Treatment (cabozantinib)|Cabozantinib 60mg orally daily until disease progression
62671796|NCT04394832|EXPERIMENTAL|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.~In the intervention phase the participant was offered around five intervention sessions with a researcher. Each session the participant chose which intrusive memory they would like to focus on and the cognitive task was completed. The intervention included a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants were given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary."
62671797|NCT01261377|ACTIVE_COMPARATOR|Bi-level positive airway pressure (BPAP)|bi-level will be titrated to optimize oxygenation and ventilation.
61915590|NCT01642121||Observational|Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by single-cell PCR analysis, flow cytometry, and reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice. Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed for human lymphoid- and myeloid-lineage cells by FACS.
61915591|NCT03089762|EXPERIMENTAL|SVF and PRP|
61915592|NCT04651101||vitamin D deficient|those patient with vitamin D level below 30 ng/dl
61915593|NCT04651101||non vitamin D deficient|those patient with vitamin D above 30 ng/dl
61915594|NCT03780400|EXPERIMENTAL|Osteoarthritis Physical Activity Care Pathway|4 month physical activity (PA) counseling intervention
61915595|NCT04334538|ACTIVE_COMPARATOR|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready to use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
61915596|NCT04334538|EXPERIMENTAL|oat-RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
61915597|NCT03699475|EXPERIMENTAL|single-arm Phase II: 3 x 10E6 BPX-501 cell/kg|"Determining the safety of maximum allowable Dose for BPX-501 starting at 3 x 10E6 cells/kg~Rimiducid will be administered to inactivate rivogenlecleucel in the event of GVHD not responsive to standard of care treatment"
61915598|NCT03699475|EXPERIMENTAL|phase 3 Arm A: Dose Determined in phase 2 group (never completed)|αβ T cell and CD19+ B cell-depleted, related haploidentical hematopoietic stem cell transplantation (haplo-HSCT) plus rivogenlecleucel
62109942|NCT03245060|OTHER|Intervention: delayed SFBT|The wait-list control arm will receive the same intervention (Adapted Solution Focused Brief Therapy, SFBT) as the intervention arm, but after a delay of six months. Participants will also receive all usual care.
62109943|NCT05977933||PAH Patients|Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality. Moreover, PH disease progression can be rapid; pharmaceutical intervention in early-stage PH can improve symptoms and functional capacity, and delayed diagnosis and treatment of PH likely reduces survival.
62109944|NCT04972812||Usual care|Acute stroke patients receiving usual care
62109945|NCT06024564|EXPERIMENTAL|Interventional|Participants will receive Acoustic Resonance Therapy using the Sonu headband and App, twice a day, for 90 days
62109946|NCT02987543|EXPERIMENTAL|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
62109947|NCT02987543|ACTIVE_COMPARATOR|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary."
62109948|NCT00829751|ACTIVE_COMPARATOR|ReNu Multiplus|Purevision lenses will be soaked in ReNu Multiplus
62109949|NCT00829751|ACTIVE_COMPARATOR|OptiFree RePlenish|PureVision lenses will be soaked in OptiFree RePlenish
62671798|NCT01261377|ACTIVE_COMPARATOR|Nocturnal oxygen|oxygen will be provided as per standard of care.
62671799|NCT01261377|ACTIVE_COMPARATOR|Continuous positive airway pressure|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
62671800|NCT05102838||Hepatitis B cohort|"1. Patients with HBsAg and/or HBV DNA positive;~2. Patients without cirrhosis."
62671801|NCT05102838||Hepatitis C cohort|"1. Patients with anti-HCV and/or HCV RNA positive;~2. Patients without cirrhosis."
62671802|NCT05102838||Cirrhosis cohort|"1. Patients diagnosised with cirrhosis;~2. Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive."
62671803|NCT05102838||Liver cancer cohort|"1. Patients diagnosised with liver cancer;~2. Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive."
62671804|NCT00353015|EXPERIMENTAL|Irinotecan plus Cisplatin|Irinotecan 65 mg/m2 and Cisplatin 25 mg/m2 intravenous (IV) days 1, 8 of a 21-day cycle
62671805|NCT01347957|EXPERIMENTAL|Nitric Oxide (NO) Gel|
62671806|NCT01347957|PLACEBO_COMPARATOR|Placebo Gel|
62671807|NCT04228315|EXPERIMENTAL|Early primaquine group|Thirty (30) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and 15 mg/day of oral primaquine for 14 days
62671808|NCT04228315|ACTIVE_COMPARATOR|Delayed Primaquine group|Sixty (60) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and the primaquine regimen (15 mg/day for 14 days) not given until 42 days after enrollment
62671809|NCT04228315|NO_INTERVENTION|Healthy control group|Ten (10) age- and gender-matched controls will be enrolled for one day to obtain biological samples to be compared to the 2 intervention arms
61915599|NCT03699475|ACTIVE_COMPARATOR|phase 3 Arm B: dose determined in the phase 2 group (never completed)|haplo-HSCT followed by post-transplant cyclophosphamide (PTCy) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
61915600|NCT01817517|EXPERIMENTAL|Deep Brain Stimulation implant|Unblinded treatment arm, thalamic DBS for Tourette syndrome.
61915601|NCT05301712|EXPERIMENTAL|Naloxone hydrochloride 5.0mg/5ml|Naloxone hydrochloride 60mg (However, the dose may be appropriately increased or decreased according to the judgement of the investigator)
62109950|NCT04687553|EXPERIMENTAL|Patients with vegetative state|Patients with vegetative state were assessed by the SECONDs and CRS-R for two days.
62109951|NCT04687553|EXPERIMENTAL|Patients with minimally conscious state|Patients with minimally conscious state were assessed by the SECONDs and CRS-R for two days.
62109952|NCT00964184|EXPERIMENTAL|Drug|1 gm metformin per day
62109953|NCT00964184|OTHER|control|lifestyle intervention
62109954|NCT05943652||Parkinson Disease|
62109955|NCT05943652||Idiopathic Dystonia|
62109956|NCT05943652||Essential Tremor|
61915602|NCT05301712|PLACEBO_COMPARATOR|Placebo|Placebo 60ml (However, the dose may be appropriately increased or decreased according to the judgement of the investigator)
61915603|NCT02199327|ACTIVE_COMPARATOR|Mitomycin C|Mitomycin C 0.04% 4 times daily for 7 days and 7 days off until resolution of neoplasia (3-6 cycles).
61915604|NCT02199327|ACTIVE_COMPARATOR|Interferon alfa 2b|Interferon alfa-2b 1 million IU/ml 4 times daily until complete resolution of the tumor
62109957|NCT05943652||Functional Neurological Disorder|
62109958|NCT05943652||Functional Cognitive Disorder|
62671810|NCT01975285|ACTIVE_COMPARATOR|Dexamethasone group|Dexamethasone 4mg(1 ml) per 20cc
62671811|NCT01975285|PLACEBO_COMPARATOR|Saline group|Saline 1 ml per 20cc
62671812|NCT05551221|ACTIVE_COMPARATOR|Tamsulosin Hydrochloride Capsules combine with Ningmitai Capsules placebo|Patients take tamsulosin hydrochloride capsules (1 tablet each time, once daily) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid.)
62671813|NCT05551221|EXPERIMENTAL|Silodosin Capsules combine with Ningmitai Capsules placebo|Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid).
62109959|NCT05943652||Alzheimer Disease|
62109960|NCT02754011|EXPERIMENTAL|combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
62109961|NCT05155371|EXPERIMENTAL|Optimal Positive End-expiratory Pressure obtained with Titration of Fraction of Inspiratory Oxygen|Obtained Optimal Positive End-expiratory Pressure obtained with Titration of Fraction of Inspiratory Oxygen and sustained the PEEP intraoperatively
62109962|NCT05155371|EXPERIMENTAL|Optimal Positive End-expiratory Pressure obtained with electrical impedance tomography|Obtained Optimal Positive End-expiratory Pressure obtained with EIT and sustained the PEEP intraoperatively
62109963|NCT00076180|EXPERIMENTAL|1|One dose of Hu-MiK Beta-1
62109964|NCT06629441|EXPERIMENTAL|Probiotic group|10B CFU/Sachet/Day BC99, before meals, Storage: Store in cool and dry place without sun exposure.
62109965|NCT06629441|PLACEBO_COMPARATOR|Placebo|Maltodextrin Sachet/Day, before meals, Storage: Store in cool and dry place without sun exposure.
62109966|NCT06495424||Study group|All subjects will receive repeat applications of the capsaicin 8% topical system every 12 weeks (up to 3 applications).
62109967|NCT04851730|EXPERIMENTAL|Orthopedic Intervention|All subjects are receiving an orthopedic intervention that is specific to their presentation but made up of all intervention categories: Manual therapy, dry needling, deep breathing, stretching, strengthening, and progressive overload.
62109968|NCT05679037|PLACEBO_COMPARATOR|Placebo group who received insulin only plus placebo tablets|(Placebo group; n=22) which will receive insulin plus placebo tablets once daily for 6 months.
62109969|NCT05679037|ACTIVE_COMPARATOR|ALA group who received Alpha lipoic acid plus insulin|(alpha-lipoic acid group; n=22) which will receive insulin plus ALA 600mg once daily for 6 months.
62109970|NCT05122312|OTHER|Totally removed smear layer|Smear layer is completely removed by etchant of phosphoric acid
62109971|NCT05122312|OTHER|Partially removed smear layer|Smear layer is partially removed by etchant of phosphoric acid
62109972|NCT04046965||Region XI Head Start children and families - Fall 2019 to Spring 2020|children (720) parents (720) classrooms/teachers (85) program directors (22) center directors (40)
62109973|NCT03319017||Multiple-trauma patients|The patients who are diagnosed with multiple-trauma and have blood test in an emergency room. The patients with multiple-trauma are defined as the patients who have trauma in more than two regions.
62109974|NCT01105884|ACTIVE_COMPARATOR|Group 1|
62109975|NCT01105884|ACTIVE_COMPARATOR|Group 2|
62109976|NCT01105884|ACTIVE_COMPARATOR|Group 3|
62671814|NCT05551221|EXPERIMENTAL|Silodosin Capsules combine with Ningmitai Capsules|Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules (Ningmitai®, 0.38 g/capsule, 4 capsules/time, tid).
62109977|NCT01105884|ACTIVE_COMPARATOR|Group 4|
62109978|NCT01105884|ACTIVE_COMPARATOR|Group 5|
62109979|NCT04208802||Smokers|Volunteers smoking at least 10 cigarettes per day
62109980|NCT04208802||Non-smokers|Non-smoking volunteers
62109981|NCT03490851|EXPERIMENTAL|Oatmeal + OatWell28XF Intervention 1|2g β-glucan
62109982|NCT03490851|EXPERIMENTAL|Oatmeal + OatWell28XF Intervention 2|4g β-glucan
62109983|NCT03490851|EXPERIMENTAL|Oatmeal + OatWell28XF Intervention 3|4g β-glucan plus β-glucanase
62109984|NCT03490851|PLACEBO_COMPARATOR|Cream of Rice|27 grams of cream of rice
62109985|NCT06054269|EXPERIMENTAL|FLUAD Quadrivalent|Participants administered a single dose of adjuvanted egg-based quadrivalent influenza vaccine (FLUAD Quadrivalent by Seqirus, 15 µg of HA from each strain).
62109986|NCT06054269|ACTIVE_COMPARATOR|FluQuadri|Participants administered a single dose of standard dose egg-based quadrivalent influenza vaccine (FluQuadri by Sanofi-Pasteur, 15 µg of HA from each strain).
62300526|NCT02090543||Group 2|300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
62300527|NCT04226352|EXPERIMENTAL|Dose 1|60 mg DXM a day for 28 days
62671815|NCT01327365|EXPERIMENTAL|Sheathless group|patient randomized to the sheathless guiding catheter group
62671816|NCT01327365|ACTIVE_COMPARATOR|Conventional group|patients randomized to the conventional guiding catheter group
62671817|NCT06279403|EXPERIMENTAL|Experimental|Experimental arm
62671818|NCT03830970|EXPERIMENTAL|1 cup of canned beans of multiple varieties|Consumption of 1 cup of canned beans of multiple varieties each day for 4 weeks
61915605|NCT00791076|PLACEBO_COMPARATOR|Saline Placebo|Saline
61915606|NCT00791076|ACTIVE_COMPARATOR|Pancreatic Polypeptide|Pancreatic Polypeptide
61915607|NCT04148872|ACTIVE_COMPARATOR|Neuromuscular Retraining Therapy|Neuromuscular retraining therapy alone for four months, with botulinum toxin injection added during an additional four month period.
61915608|NCT04148872|ACTIVE_COMPARATOR|Chemodenervation|Ipsilateral chemodenervation with botulinum toxin injections alone for four months (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin, Merz), with neuromuscular retraining therapy added for an additional four months.
61915609|NCT04265495||DUAL TRIGGERING|PATIENTS WILL RECEIVE DUAL TRIGGERING
61915610|NCT04265495||URINARY HCG|PATIENTS WILL RECEIVE URINARY HCG
61915611|NCT04265495||RECOMBINANT HCG|PATIENTS WILL RECEIVE RECOMBINANT HCG
61915612|NCT00822809|EXPERIMENTAL|A|"Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.~Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter."
61915613|NCT00822809|OTHER|B|Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.
62300528|NCT04226352|EXPERIMENTAL|Dose 2|300 mg DXM every 2 weeks for 28 days.
61915614|NCT04626141|EXPERIMENTAL|Abaloparatide group|Patients in the experimental group will receive abaloparatide after their surgery.
61915615|NCT04626141|PLACEBO_COMPARATOR|Control group|Patients in the control group will receive a placebo after their surgery.
61915616|NCT00675207|ACTIVE_COMPARATOR|1|Brimonidine purite 0.15%
62671819|NCT03830970|EXPERIMENTAL|1/2 cup of canned beans of multiple varieties|Consumption of 1/2 cup of canned beans of multiple varieties each day for 4 weeks
61915617|NCT00675207|ACTIVE_COMPARATOR|2|Dorzolamide 2%
61915618|NCT00675207|ACTIVE_COMPARATOR|3|Brinzolamide 1%
61915619|NCT00641927|EXPERIMENTAL|1|Antidepressant
61915620|NCT00641927|ACTIVE_COMPARATOR|2|Drug
61915621|NCT00612898|EXPERIMENTAL|1|800mg BID apricitabine plus optimised background
61915622|NCT00612898|ACTIVE_COMPARATOR|2|150mg BID lamivudine plus optimised background
61915623|NCT06388928||This study was assigned as a single group.|All participants, assigned as one group, were assessed as regards the manual dexterity at three different phases of the menstrual cycle (menstrual phase, ovulation phase, and mid-luteal phase).
61915624|NCT04508543||Minority (Case)|Self-identified as being a member of group traditionally underrepresented in the medical profession relative to the proportion in the general population: African-American/Black, Mexican-American, Native American (American Indians, Alaska Natives, and Native Hawaiians), and mainland Puerto Rican.
61915625|NCT04508543||Caucasian (Control)|Self-identified as Caucasian and Non-Hispanic
61915626|NCT02183103|ACTIVE_COMPARATOR|meloxicam rapid release tablet after an overnight fast|
61915627|NCT02183103|EXPERIMENTAL|meloxicam rapid release tablet after high fat breakfast|
62300529|NCT04226352|EXPERIMENTAL|Dose 3|300mg DXM once, with 60mg DXM daily afterwards
62300530|NCT00504257|EXPERIMENTAL|Avastin and Docetaxel|Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m\^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
62300531|NCT06656871|NO_INTERVENTION|Control group|The control group received lettuce (control lettuce 100 grams/day) that was without any biostimulation with Ecklonia Maxima algae but with the same characteristic of SwE lettuce (soil, water, harvesting time) for 4 weeks.
62671820|NCT03830970|OTHER|1 cup of White rice|Consumption of 1 cup of white rice each day for 4 weeks
62671821|NCT01787968||TcI, TcII|TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping
62671822|NCT06288178|EXPERIMENTAL|Types of bread|The three breads (whole wheat bread, buckwheat bread, and cornmeal bread) contained 30 grams of digestible carbohydrates. Participants consumed these breads when they were hungry. Blood glucose was measured with a glucometer at 0 (fasting), 30, 60, 90, and 120 minutes. Anthropometric measurements were measured by BIA method and weight classification (obesity and normal weight) was made.
61915628|NCT05577273|EXPERIMENTAL|Antibiotic prophylaxis|Single dose of p.o. antibiotic given 1 hour before catheter removal. The antibiotic of choice is Cefuroxime axetil 500 mg. For penicillin allergy, trimethoprim/sulfamethoxazole 160mg/800mg.
61915629|NCT05577273|NO_INTERVENTION|No treatment|
61915630|NCT02571738|ACTIVE_COMPARATOR|CHAM|Cryopreserved Human Amniotic Membrane
61915631|NCT02571738|PLACEBO_COMPARATOR|Control|Standard of Care
61915632|NCT05336344|EXPERIMENTAL|ENCODE Group|The intervention consists of three weekly video-conferencing sessions scheduled at the caregiver's convenience. Each session is scheduled to last approximately 40 minutes. The ENCODE intervention is manualized and has related curriculum designed specifically for caregivers of patients with ADRD. The agenda for the first session (week 1) includes an assessment of caregivers' pain management challenges and concerns. Once the barriers or challenges are identified, the interventionist works specific problem solving therapy steps covered over the three sessions.
61915633|NCT05336344|NO_INTERVENTION|Attention Control Group|"Caregivers in the attention control group will receive standard hospice services and complete the same measures and receive the same number of contacts as participants in the intervention group. Three video-conferencing calls will be scheduled based on the caregiver's availability following, if possible, a timeline between days 5 and 30 of the hospice admission. During these calls, the interventionist will allow caregivers in the attention control group to discuss their feelings, thoughts, and relationships. This friendly call intervention controls for the nonspecific aspects of treatment, i.e., the passage of time, amount of contact with a researcher, and the general support of an empathic, concerned and skilled professional and is based on the principles of nondirective supportive therapy."
61915634|NCT00829933|EXPERIMENTAL|1|DU-176b low dose
61915635|NCT00829933|EXPERIMENTAL|2|DU-176b intermediate dose
61915636|NCT00829933|EXPERIMENTAL|3|DU-176b high dose
61915637|NCT00829933|ACTIVE_COMPARATOR|4|Warfarin
62671823|NCT06288178|EXPERIMENTAL|Reference bread (White bread)|Control group. Blood glucose comparison of all breads was determined according to white bread. The measurement method used was the same as for the other breads.
62671824|NCT04771871|EXPERIMENTAL|Epirubicin-Cyclophosphamide plus Paclitaxel- Carboplatin|Epirubicin 60mg/m2 with cyclophosphamide 600/m2 every three weeks for four courses followed by paclitaxel 120mg/m2 and carboplatin 6 AUC every three weeks for four courses
61915638|NCT06301243|EXPERIMENTAL|Inactive|Subjects will be asked to be sedentary prior to an acute exercise bout (\<5,000 steps as measured by a physical activity monitor).
61915639|NCT06301243|PLACEBO_COMPARATOR|Normal activity|Subjects will be asked to have normal activity prior to an acute exercise bout (\>8,500 steps as measured by a physical activity monitor).
61915640|NCT04573647||Treatment group|All participants in this trial will be in the treatment group. They will administer Oxervate following the FDA approved guidelines: 1 drop to the affected eye 6 times per day for 8 weeks.
61915641|NCT00064298|EXPERIMENTAL|Arm I - JuicePlus|Patients receive oral fruit and vegetable extracts twice daily.
61915642|NCT00064298|PLACEBO_COMPARATOR|Arm II - Control|Patients receive oral placebo twice daily.
61915643|NCT01511055|EXPERIMENTAL|Folate-FITC|
61915644|NCT01905423||Paga (annual MDA)|"This group includes eligible residents of the village of Paga. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Paga received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
62109987|NCT05824377|EXPERIMENTAL|Bolus Feeding|"Intermittent bolus feeding will be defined as delivering enteral nutrition multiple times, usually every 2-3 hours over 15 - 30 minutes by gravity or an electric pump.~It will be further stratified as per weight ( less than 1000 g, 1000-1500 g, \>1500 g)."
62109988|NCT05824377|EXPERIMENTAL|Continuous Feeding|"Continuous feeding will be defined as delivering enteral nutrition with constant speed for 24 hours via a nutritional pump.~It will be further stratified as per weight ( less than 1000 g, 1000-1500 g, \>1500 g)."
62300532|NCT06656871|EXPERIMENTAL|Biostimulated SwE lettuce intervention group|The SwE lettuce intervention group received lettuce biostimulated with Ecklonia Maxima algae (SwE lettuce, 100 grams/day) for 4 weeks
62671825|NCT02677285||Skin graft|The bioimpedance measurement is done with a purpose built patch that has electrodes in contact with the wound and reference electrodes.
62671826|NCT02677285||Operation wound|The bioimpedance measurement is done with commercial electrodes places in healthy skin surrounding the wound.
62671827|NCT04776876|EXPERIMENTAL|Treatment (retifanlimab, telotristat ethyl)|Patients receive retifanlimab IV over 30-60 minutes on day 1 and telotristat ethyl PO TID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62671828|NCT02552654|EXPERIMENTAL|Hydrocortisone and Stress Film|Administration of 10mg hydrocortisone before the trauma film.
61915645|NCT01905423||Lewomada (annual MDA)|"This group includes eligible residents of the village of Lewomada. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Lewomada received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
61915646|NCT01905423||Pruda (semiannual MDA)|"This group includes eligible residents of the village of Pruda. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.~Pruda received a total of five rounds of MDA over a period of 24 months (once every 6 months)."
62671829|NCT02552654|EXPERIMENTAL|Placebo and Stress Film|Administration of placebo before the trauma film.
61915647|NCT01905423||Pekalongan (annual MDA)|"This group includes the villages of Banyurip Ageng and Jenggot. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
61915648|NCT01905423||Pekalongan (semiannual MDA)|"This group includes the villages of Kertoharjo and Pabean. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
61915649|NCT02117206|ACTIVE_COMPARATOR|L-Arginine|Femoral arterial infusion of 2 g L-Arginine for 30 min
62109989|NCT06553807|EXPERIMENTAL|Intervention|The intervention group will consist of women who score 21 points or less on the Genital Self-Image Scale.
62109990|NCT06553807|NO_INTERVENTION|Control|The control group will consist of women who score 21 points or less on the Genital Self-Image Scale.
62109991|NCT05984641|EXPERIMENTAL|Group A|Active treatment CONAN® (Medical Device, Omikron Italia Srl) a proctological cream containing 2.5% glycerin macerate from horse chestnut buds (escin), 1% hesperidin, 0.1% hyaluronic acid, 0.1% centella asiatica and 2.5% glycerinic extract of mallow; Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
62109992|NCT05984641|NO_INTERVENTION|Group B|No intervention. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
62109993|NCT05192707||Healthy Volunteers|TcPO2 measurement in the upper limb of healthy volunteers
62300533|NCT06656871|EXPERIMENTAL|Iron tablet intervention group|The iron tablet intervention group received iron supplementation (30 mg, 1 tablet/day of iron) for 4 weeks
62300534|NCT02473796|EXPERIMENTAL|Home based child care|The home based child care included treatment of various various childhood illnessed by locally avialable trained village health workers, improving hygiene and nutrition among children and women throgh health education. This care was in adiition to the local health care provided by the Government's primary health care services.
62671830|NCT00674232|EXPERIMENTAL|Misoprostol|Group 1 randomized to take single dose of 600 mcg oral misoprostol
62671831|NCT00674232|OTHER|Surgical treatment|Group 2 randomized to receive standard surgical treatment as per local protocol (D\&C or MVA)
62671832|NCT04853290|EXPERIMENTAL|Intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
62671833|NCT04853290|ACTIVE_COMPARATOR|Control group|Conventional peripheral venipuncture performed by a registered nurse from a clinical inpatient unit.
62109994|NCT05192707||Patients with arterial disease in the upper limb and wound|Patients with arterial disease in the upper limb and wound (retrospective setting, research on data)
62671834|NCT05937100|ACTIVE_COMPARATOR|control: Formocresol|Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute then removed and pulp stumps will be dressed with a layer of zinc oxide-eugenol (ZOE) paste.
62671835|NCT05937100|EXPERIMENTAL|Group A : (Biodentine)|The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps, and allowed to set.
62109995|NCT05038072|EXPERIMENTAL|4 mg Triamcinolone Acetonide (TA)/ Suprachoriodal Injection|Suprachoroidal injection of 4 mg in 100 μL of TA was administered as a single injection.
62109996|NCT02628093|OTHER|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
62109997|NCT02628093|OTHER|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
62109998|NCT00147355|OTHER|A|Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
62109999|NCT00147355|OTHER|B|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
62300535|NCT02473796|NO_INTERVENTION|control|The control arm included population where the home based neonatal care was not implimented. The health services were provided by the Government run primary health care services. Vital statistics data was collected by VHWs.
62300536|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
62671836|NCT05937100|EXPERIMENTAL|Group B : (Hyaluronic acid gel)|Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes. Then the pulp stumps will be dressed with a layer of zinc oxide-eugenol (ZOE) paste.
62671837|NCT06473818||Normotensive pregnant women|Singleton pregnancy ≥37 weeks, American Society of Anesthesiologists physical status classification I to II scheduled for cesarean section under spinal anesthesia
62671838|NCT03693508|EXPERIMENTAL|Arm 1|Naive HIV patients with severe immunosuppression.
62671839|NCT04289298|EXPERIMENTAL|Engage-A|Participants receive 9 individual in-person or remote therapy sessions. Each session will last approximately 60 minutes. During the sessions, the therapist will encourage the participant to engage in physical and social activities that are pleasurable or rewarding.
62110000|NCT00147355|OTHER|D|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
62300537|NCT03459040|EXPERIMENTAL|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
62110001|NCT00147355|OTHER|C|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
62110002|NCT03771027|EXPERIMENTAL|Low FODMAP diet group|four weeks of the low FODMAP diet based on Monash University low FODMAP diet App.
62110003|NCT03771027|ACTIVE_COMPARATOR|Control group|four weeks of the diet based on NICE guidelines and contained products with different FODMAP content
62300538|NCT03822884|EXPERIMENTAL|Hemax® PFS 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
62300539|NCT03822884|EXPERIMENTAL|Hemax® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
62300540|NCT03822884|ACTIVE_COMPARATOR|Erypo ® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
62300541|NCT05116969|EXPERIMENTAL|Stage 1: PTX-35 Dose Level 1|Dose Level 1: PTX-35 0.1 mg/kg
62300542|NCT05116969|EXPERIMENTAL|Stage 1: PTX-35 Dose Level 2|Dose Level 2: PTX-35 0.3 mg/kg
62300543|NCT05116969|EXPERIMENTAL|Stage 1: PTX-35 Dose Level 3|Dose Level 3: PTX-35 1.0 mg/kg
62300544|NCT05116969|EXPERIMENTAL|Stage 1: PTX-35 Dose Level 4|Dose Level 4: PTX-35 3.0 mg/kg
62671840|NCT04289298|EXPERIMENTAL|Clinician|Clinicians will be trained in Engage-A and supervised while utilizing the therapy.
62671841|NCT00666471|EXPERIMENTAL|1|MICE
62300545|NCT05116969|EXPERIMENTAL|Stage 1: PTX-35 Dose Level 5|Dose Level 5: PTX-35 10.0 mg/kg
62300546|NCT05116969|EXPERIMENTAL|Stage 2 Multiple Ascending Dose Regimen 6|4 doses of PTX-35 with each dose separated by 7 days
62300547|NCT05116969|EXPERIMENTAL|Stage 2 Multiple Ascending Dose Regimen 7|3 doses of PTX-35 with each dose separated by 14 days
62671842|NCT00666471|ACTIVE_COMPARATOR|2|SPA ligation
62671843|NCT00884598|EXPERIMENTAL|Cilengitide|
62671844|NCT00728182|EXPERIMENTAL|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
62671845|NCT00728182|PLACEBO_COMPARATOR|Placebo|
62110004|NCT02545062|EXPERIMENTAL|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
62110005|NCT02545062|EXPERIMENTAL|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
62300548|NCT05463133|ACTIVE_COMPARATOR|Arm 1 / Group 1 Standard Risk|Group 1 (Standard group) will receive tociluzumab at Day -10, Alemtuzumab on Day -9,-8,-7,-6,-5; Busulfan on Day -4, and -3, TBI, matched donor PBSC infusion, and Post transplant Cyclophosphamide.
62671846|NCT03295357||Patients with extubation while on ECLS|
62671847|NCT03295357||Patients without extubation|
62110006|NCT00607503|EXPERIMENTAL|1|
62110007|NCT02777632||HCV patients following living donor liver transplantation|single infection episode group
62110008|NCT02777632||patients following living donor liver transplantation|recurrent Infections episode group
62110009|NCT01872819|EXPERIMENTAL|Treatment (chemotherapy, biological therapy)|Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
62110010|NCT01187576|EXPERIMENTAL|Intervention|Multi-professional team intervention with PAR, lifestyle brochure
62110011|NCT01187576|ACTIVE_COMPARATOR|Conventional treatment|Ordinary recommendations on health behaviours, lifestyle brochure
62110012|NCT01187576|NO_INTERVENTION|retrospective med history comparison|Treatment as usual (retrospective data collection)
62110013|NCT02009358|EXPERIMENTAL|Mental health promotion group|
62110014|NCT03583021|EXPERIMENTAL|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
62110015|NCT03583021|PLACEBO_COMPARATOR|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
62110016|NCT05246956|EXPERIMENTAL|Intradialytic exercise in hemodialysis patients ( Experimental Group)|Intradialytic exercise group
62110017|NCT05246956|NO_INTERVENTION|Control Group|No intervention
62110018|NCT06489860|EXPERIMENTAL|SARS-CoV-2|"SARS-CoV-2. Directions: For adults and for Children 1-12 years old. Indication: Severe Acute Respiratory Syndrome Coronavirus 2 Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.~Participants: Use 4 to 5 packets, use one pack each time after two hours. Use within two years from the manufacturing date. Humidification: \<5%. Dosage Form: Powder form. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C. Store in a dry environment (75% humidity). 20 -1 g Packets. Net Weight 0.70 oz (20 g)"
62110019|NCT01566513|NO_INTERVENTION|Treatment as usual|
62110020|NCT01566513|EXPERIMENTAL|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
62110021|NCT01566513|EXPERIMENTAL|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
62110022|NCT01566513|EXPERIMENTAL|Peer Case Manager|If a participant is randomized into this condition, they are offered the chance to work with a Case Manager, who is trained in strengths-based case management.
62671848|NCT04333459|ACTIVE_COMPARATOR|Group 1 - Full Dose Hataan|"Group 1 will be vaccinated with the Full Dose of HTNV DNA vaccine, 2 mg of pWRG/HTN-M(co) with 0.5 mg/each deltoid."
62110023|NCT06345534|OTHER|FAST-FORWARD schedule|The first group is treated according to the FAST-FORWARD schedule, consisting of 5 radiation sessions on 5 consecutive working days (e.g. Monday to Friday). 2 rest days are allowed in the schedule, so that the treatment lasts a maximum of 7 days.
62110024|NCT06345534|OTHER|HAI5 schedule|The second group is treated according to the HAI5 schedule, developed by the radiotherapy department of Ghent University Hospital. In this schedule, at least 1 day of rest is scheduled between each treatment session, so the treatment is administered over 10-14 days.
62300549|NCT05463133|EXPERIMENTAL|Arm 2 / Group 2 High Risk.|Group 2 (High risk group will receive tociluzumab at day -24, a repeat dose at day -19, Alemtuzumab at day -9,-8,-7,-6,-5; Busulfan at day -4 and -3, Emapalumab at Day -1, matched donor PBSC infusion, and post transplant cyclophosphamide at Day +3 and +4
62470497|NCT02409472|OTHER|intensive surveillance|Intensive program for colon cancer: Office visit, complet blood count (CBC), CEA+ Carbohydrate Antigen (CA) 19.9 at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, 24, 36, 48,and 60 months. Liver echography\* at 4,8,12,16,24,36,48, and 60 months. Chest X-ray at 12,24,36,48,and 60 months.
62671849|NCT04333459|ACTIVE_COMPARATOR|Group 2 - Half Dose Hataan|"Group 2 will be vaccinated with the Half Dose of HTNV DNA vaccine, 1 mg of pWRG/HTN-M(co) with 1.0 mg/each deltoid."
62671850|NCT04333459|ACTIVE_COMPARATOR|Group 3 - Full Dose Puumala|"Group 3 will be vaccinated with the Full Dose of PUUV DNA vaccine, 2 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
62110025|NCT06062706||Open|Open donor hepatectomy approach: a portion of the liver is resected from a living donor using the traditional open surgical technique, involving a large incision to access the liver directly. This method is most commonly used in living donor liver transplantation nowadays.
62671851|NCT04333459|ACTIVE_COMPARATOR|Group 4 - Half Dose Puumala|"Group 4 will be vaccinated with the Half Dose of PUUV DNA vaccine, 1 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
61915650|NCT02117206|PLACEBO_COMPARATOR|Nacl|Femoral arterial infusion of Nacl for 30 min
62300550|NCT06657469|EXPERIMENTAL|Attention Functions Training (AFT) Group|The AFT group used two training tasks from the Cogmission software: A Conjunctive Continuous Performance Task (CCPT) designed to practice sustained attention, and a Go/No-go task, designed to practice response inhibition. This group also used three training tasks from the Computerized Progressive Attention Training (CPAT) program: (1) Conjunctive Visual Search Task, designed to improve selective-spatial attention; (2) Combined Orienting and Flanker Task, designed to improve orienting of attention; and, (3) Global-Local Task, designed to improve executive attention - conflict resolution. Each of the tasks consists of a broad hierarchy of difficulty levels, and the transition between them occurs after consistent improvement was obtained and performance reached a plateau at a given difficulty level.
62300551|NCT06657469|EXPERIMENTAL|Executive Functions Training (EFT)|The EFT group used a computerized version of the Set game. Set is a pattern-recognition card game where players must identify sets of three cards that share or differ in specific attributes, such as color, shape, or number. It was used to train cognitive flexibility. In addition, this group used four computer games to train problem-solving. Three of them were designed by Leo De Sol Games and were based on familiar games: (1) Rush Hour; (2) Pipes/Plumber; and (3) Sliding Puzzle. The fourth game, Thinkrolls Kings \& Queens by Avokiddo, is a challenging adventure puzzle game that incorporates logic and physics, requiring players to navigate mazes and overcome obstacles using reasoning. Additionally, three games developed by Mindware Consulting Inc. were used to train working memory based on well-known paradigms in the field.
61915651|NCT02702245|PLACEBO_COMPARATOR|Placebo comparator: Control|OGTT without thylakoids.
61915652|NCT02702245|EXPERIMENTAL|Experimental: Thylakoids 5 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 5 g. Intervention: OGTT at one occasion.
62110026|NCT06062706||Laparoscopic|Laparoscopic donor hepatectomy is a minimally invasive surgical approach where a portion of the liver is resected from a living donor using small incisions and specialized instruments.
62110027|NCT06062706||Robotic|Robotic donor hepatectomy is an advanced, minimally invasive surgical technique where a portion of the liver is resected from a living donor using robotic instruments. This method is known to provide enhanced precision, improved ergonomics, and superior 3D visualization.
62300552|NCT06657469|NO_INTERVENTION|Passive Control Group|Participants in this group did not receive any active intervention during the study period. They were assessed at the same time as the other groups-before the intervention and immediately after. This group enabled us to rule out spontaneous developmental effects, as well as learning and familiarity effects that may result from repeated exposure to the assessment tasks.
62300553|NCT00361530|ACTIVE_COMPARATOR|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
62300554|NCT00361530|NO_INTERVENTION|No intervention|Patient has no intervention.
62300555|NCT02265913|EXPERIMENTAL|Test Product|acyclovir cream
62300556|NCT02265913|ACTIVE_COMPARATOR|Reference Product|acyclovir cream
62300557|NCT02265913|PLACEBO_COMPARATOR|Placebo Product|Placebo cream
62300558|NCT00673855|EXPERIMENTAL|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye one time
62300559|NCT00673855|ACTIVE_COMPARATOR|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye 1 time
61915653|NCT02702245|EXPERIMENTAL|Experimental: Thylakoids 10 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 10 g. Intervention: OGTT at one occasion.
61915654|NCT00103727|EXPERIMENTAL|talnetant|200mg, 400mg, 600mg) twice a day
61915655|NCT00103727|PLACEBO_COMPARATOR|placebo|placebo
61915656|NCT00103727|ACTIVE_COMPARATOR|risperidone|3mg twice a day
61915657|NCT05381337|EXPERIMENTAL|the sideburns mini incision group|Forty patients (the sideburns mini incision group) were treated with sideburns mini incision.
61915658|NCT05381337|OTHER|the coronal scalp incision group|Forty patients (the coronal scalp incision group) were treated with coronal scalp incision.
61915659|NCT03281993||CPAP-AT|After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.
61915660|NCT05980767|ACTIVE_COMPARATOR|Experimental Intervention|Standard of care plus therapy, which consists of a single, 1 hour dose of electrical stimulation.
61915661|NCT05980767|NO_INTERVENTION|Control|Standard of care only.
62110028|NCT00741988|EXPERIMENTAL|Cohort A|ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
62110029|NCT00741988|EXPERIMENTAL|Cohort B|ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
62110030|NCT01570751|EXPERIMENTAL|IDeg followed by IGlar|
62110031|NCT01570751|EXPERIMENTAL|IGlar followed by IDeg|
62110032|NCT03554902||Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
62110033|NCT01168011|EXPERIMENTAL|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day every day of 21-day cycles.
62110034|NCT05305989|EXPERIMENTAL|Arm A: belumosudil 200 mg QD|The assigned arm is per the previous study KD025-213 or study KD025-208
62110035|NCT05305989|EXPERIMENTAL|Arm B: belumosudil 200 mg BID|The assigned arm is per the previous study KD025-213 or study KD025-208
61915662|NCT04178356|EXPERIMENTAL|Experimental-Study Group|In addition to the conservative treatment of the control group, proprioceptive neuromuscular facilitation techniques will be applied for 4 weeks.
61915663|NCT04178356|ACTIVE_COMPARATOR|Control Group|Conservative treatment of low back pain will be applied for 4 weeks.
62110036|NCT05305989|EXPERIMENTAL|Arm C: belumosudil 400 mg QD|The assigned arm is per the previous study KD025-213 or study KD025-208
62300560|NCT03191786|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.
62300561|NCT03191786|ACTIVE_COMPARATOR|Single Agent Chemotherapy (Vinorelbine or Gemcitabine)|Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.
62300562|NCT02868892|EXPERIMENTAL|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
62110037|NCT05279092|ACTIVE_COMPARATOR|Bupivacaine-Liposomal Bupivacaine (B-LB)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an Interspace between the popliteal artery and capsule of the posterior knee (iPACK) block.
62110038|NCT05279092|EXPERIMENTAL|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (B-DEX-MPA)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
62110039|NCT05817331||Patient|Patients with MDS
62110040|NCT05817331||Carer|Carers of patients with MDS
62110041|NCT05817331||Clinician|Clinicians who treat MDS
62110042|NCT02563704|ACTIVE_COMPARATOR|ARTES|"* Injectable Artesunate.Each vial contained 60 mg anhydrous artesunic acid, which was dissolved in 1 ml of 5% sodium bicarbonate (provided with the drug) and then mixed with 5 ml saline solution (provided with the drug) before injecting into an indwelling intravenous catheter.~* Patients received 2.4 mg/kg bw of parenteral artesunate at H0, H12, H24 and thereafter once daily, for a minimum of 24 hours.~* Patients exited from the protocol if they had clinically recovered and parasitaemia was negative."
62110043|NCT02563704|ACTIVE_COMPARATOR|QLD|"* Injectable quinine. Each vial contained 250 mg or 500 mg QB.~* Patients received a loading dose of 16.6 mg/kg bw of QB by intravenous (IV) infusion over 4 hours followed 8 hours after the start of the loading dose, with a maintenance dose of QB at 8.3 mg/kg bw over 4 hours every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~* Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
62110044|NCT02563704|ACTIVE_COMPARATOR|QNLD3|"* Injectable quinine. Each vial contained 250 mg or 500 mg QB.~* Patients received 8.3 mg/kg bw of QB over 4 hours by IV infusion every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~* Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
62110045|NCT02563704|ACTIVE_COMPARATOR|QNLD2|"* Injectable quinine. Each vial contained 250 mg or 500 mg QB.~* Patients received 12.5 mg/kg bw of QB over 4 hours by IV infusion every 12 hours diluted in 10 ml/kg bw of 10% dextrose solution.~* Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
62110046|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
62110047|NCT01847248||Severe sepsis|Patients with severe sepsis
62110048|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
62110049|NCT01847248||Control|Healthy volunteers
62110050|NCT01369589|EXPERIMENTAL|P-552 on Day 1 and Placebo on Day 2|Randomly assigned subjects will receive a single dose of P-552 on Day 1 followed by a single dose of Placebo on Day 2
62110051|NCT01369589|EXPERIMENTAL|Placebo on Day 1 and P-552 on Day 2|Randomly assigned subjects will receive a single dose of Placebo on Day 1 followed by a single dose of P-52 on Day 2
62110052|NCT02061332|EXPERIMENTAL|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
62110053|NCT02061332|EXPERIMENTAL|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
62110054|NCT02061332|EXPERIMENTAL|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
62110055|NCT00768651|EXPERIMENTAL|One arm: Sitagliptin + Pantoprazole|"Intervention Details:~Sitagliptin 100 mg daily and Pantoprazole 40 mg bid for 6 months, followed by a three-month washout."
62300563|NCT02715271||Retrospective cohort|Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.
62300564|NCT02715271||Prospective cohort|Tuberculosis patients prospectively submitted to therapeutical surgery.
62300565|NCT01713062||Vitelene|Plasmacup DC® with Vitelene® inlay manufactured by UHMWPE-XE (Ultra High Molecular Weight Polyethylene highly cross-linked with 0.1% Vitamin E) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
62300566|NCT01713062||XLPE|Plasmacup DC® with a standard polyethylene inlay manufactured by UHMWPE-X (Ultra High Molecular Weight Polyethylene highly cross-linked) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
62671852|NCT01968408|ACTIVE_COMPARATOR|L. reuteri DSM 17938|"Lactobacillus reuteri DSM 17938,10(9)CFU/daily (for the duration of hospitalization)~ARM I: Rotavirus vaccinated patients~ARM II: Non-rotavirus vaccinated patients"
62671853|NCT01968408|PLACEBO_COMPARATOR|Placebo|"Placebo consists of an identical formulation in all respects except that the live probiotic bacteria were excluded~for the duration of hospitalization"
62300567|NCT05147246|EXPERIMENTAL|Intervention Schools - School Staff|
62300568|NCT05147246|EXPERIMENTAL|Intervention Schools - Parent-Child Pairs|
62300569|NCT05147246|NO_INTERVENTION|Wait-List Control Schools - School Staff|
62671854|NCT06195111||Trifluridine/Tipiracil|Patients with metastatic colorectal cancer plan to recieve Trifluridine/Tipiracil-containing treatment will be enrolled in this study. The prescription all determined by doctor based on patient's situation.
62110056|NCT00868595|EXPERIMENTAL|Dose escalation|"Cohort 1: BPX-101, 4 x 10\*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10\*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10\*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10\*6 cells administered every 4 weeks for 3 cycles~At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours."
62110057|NCT02418806|EXPERIMENTAL|Therapy group with follow up sessions|Weekly psychotherapy groups during 4 months with a monthly follow up period (12 months)
62110058|NCT02418806|EXPERIMENTAL|Therapy group without follow up sessions|Weekly psychotherapy groups during 4 months
62110059|NCT02418806|ACTIVE_COMPARATOR|Active comparator group|Weekly self-help groups during 4 months with a monthly follow up period (12 months)
62110060|NCT00828672|ACTIVE_COMPARATOR|AXE (ARM 1)|Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
62110061|NCT00828672|ACTIVE_COMPARATOR|AX (ARM 2)|Bevacizumab and Capecitabine concurrently with radiotherapy
62300570|NCT05147246|NO_INTERVENTION|Wait-List Control Schools - Parent-Child Pairs|
62300571|NCT05918510||Group 1|High miR value
62110062|NCT00209443|EXPERIMENTAL|Gadodiamide Injection|All subjects received a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide Injection) at a dose of 0.1 mmol/kg
62110063|NCT02770248|EXPERIMENTAL|SIMBRINZA|Brinzolamide 1% / Brimonidine 0.2% tartrate ophthalmic suspension, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
62110064|NCT02770248|ACTIVE_COMPARATOR|Vehicle|Vehicle, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
62300572|NCT05918510||Group 2|Control group
62300573|NCT05666154|ACTIVE_COMPARATOR|Real diet|Diet excluding the trigger nutrient identified by an acute mucosal reaction in CLE
62300574|NCT05666154|SHAM_COMPARATOR|Sham diet|Diet excluding a sham nutrient without acute mucosal reaction in CLE
62300575|NCT05666154|ACTIVE_COMPARATOR|Wheat exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
62300576|NCT05666154|ACTIVE_COMPARATOR|Soy exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
62300577|NCT05779163|EXPERIMENTAL|LBL-033|LBL-033 for Injection; Initial dose - MTD; Q2W
62300578|NCT04711681|EXPERIMENTAL|PBS1|"This group will recieve an enhanced PBS intervention."
62300579|NCT04711681|ACTIVE_COMPARATOR|PBS 2|"This group will receive standard PBS with fewer training and coaching sessions than PBS 1."
62300580|NCT05654415|EXPERIMENTAL|Deprivation group|Sleep deprivation of 50% of physiological sleep
62300581|NCT05654415|EXPERIMENTAL|Melatonin group|Melatonin oral solution 5 mg 30 minutes before EEG performing
62300582|NCT05169671|EXPERIMENTAL|ATH-1020|ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5).
62300583|NCT05169671|PLACEBO_COMPARATOR|Placebo|Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo.
62300584|NCT00526201|EXPERIMENTAL|Exercise|Subjects will be randomized to exercise (12 week EnhanceFitness class) or a wait-list control group.
62671855|NCT05038371||Patients with neovascular age-related macular degeneration|This will include 10 subjects with a diagnosis of age-related macular degeneration.
62671856|NCT05038371||Controls|This group will comprise 10 participants who plan to undergo vitrectomy for macular hole, macular pucker, or vitreomacular traction, vitreous floaters or another condition unrelated to scarring.
62671857|NCT02588534|ACTIVE_COMPARATOR|Treatment A-etanercept (ENBREL®) via auto-injector device|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
62671858|NCT02588534|OTHER|Treatment B-etanercept (ENBREL®) via Manual injection|single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
62300585|NCT00526201|OTHER|Control|Wait-list control group will receive intervention after 12-weeks.
62470498|NCT02236494|ACTIVE_COMPARATOR|General Health Information Pamphlet|This group will not receive a brief intervention in the ED. They will receive a pamphlet with general health information for older adults, as well as contact information for an outpatient alcohol treatment center where they have the option to follow-up for alcohol treatment at their discretion. The patient's readiness to change their alcohol habits will be measured using a 1-10 scale with a visual cue.
62110065|NCT03318536||No Granisetron|120 Patients prior to changes of intern standards of caesarean section. Before march 2017 no patient undergoing elective caesarean section received Granisetron as a matter of routine.
62110066|NCT03318536||With Granisetron|120 Patients after changes of intern standards of caesarean section. After march 2017 all patient undergoing elective caesarean section received Granisetron as a matter of routine.
62110067|NCT05225935|EXPERIMENTAL|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
62110068|NCT05225935|ACTIVE_COMPARATOR|conventional VT ablation strategy|Catheter ablation performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
62110069|NCT05534100||Healthy Control|
62110070|NCT05534100||PTSD|
62110071|NCT05824442|EXPERIMENTAL|Biological sample|Blood sample
62110072|NCT06175923||MDS patients|"Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization:~* one or more cytopenias,~* and/or dysplasia of one or more lines,~* and/or bone marrow blastosis~* and/or sideroblasts in medullary crowns~* and/or genetic/cytogenetic abnormalities characteristic of MDS.~* Whatever the R-IPSS stage (Revised International Prognostic Scoring System)~* No history of cytotoxic treatment (hydroxycarbamide, azacytidine)"
62300586|NCT03025412|EXPERIMENTAL|Endoscopic surgery|Ambulatory surgery. Postoperative rehabilitation. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
62300587|NCT03025412|ACTIVE_COMPARATOR|Conservative treatment|Physiotherapy and exercise. First physiotherapy consultation: Information, advice, instructions. Exercise regime during 12 weeks in three phases.
62300588|NCT01726361|EXPERIMENTAL|MTFC|Out of home placement in MTFC family program
62300589|NCT01726361|ACTIVE_COMPARATOR|TAU|Other kind of out of home placement
62110073|NCT06175923||AML patients|Adult patients with suspected de novo acute myeloid leukemia at initial management
62300590|NCT03748927||1/ Cohort 1|Subjects with FL-HCC.
62300591|NCT05804331||Patient with Gastrointestinal neoplasm|Pt referred for resection of gastrointestinal neoplasm. Observational data collected from endoscopic submucosal dissection (ESD), submucosal-tunnelling endoscopic resection (STER) or endoscopic full-thickness resection (EFTR) of gastrointestinal neoplasm
62300592|NCT01929252|ACTIVE_COMPARATOR|Dexmedetomidine|%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.
62300593|NCT01929252|ACTIVE_COMPARATOR|Levobupivacaine|%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.
62300594|NCT00892437|EXPERIMENTAL|ATV+COBI+FTC/TDF|COBI + RTV placebo +ATV+FTC/TDF for 48 weeks
62300595|NCT00892437|ACTIVE_COMPARATOR|ATV+RTV+FTC/TDF|RTV + COBI placebo +ATV+FTC/TDF for 48 weeks
62671859|NCT04614779|EXPERIMENTAL|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) or higher dose (15 mg/kg bw, bid) for 24 or 48 weeks, according to the administration plan.~All subjects will be given the lower (15 mg/kg bw, bid) or higher dose (20 mg/kg bw, bid) for 49 or 96 weeks, according to the administration plan.~The dosage form is tablets."
62300596|NCT05957640|EXPERIMENTAL|Yttrium-90 carbon microspheres|Single dose of yttrium-90 carbon microspheres injection. Patients will be assessed by SPECT-CT imaging within 24 hours for yttrium-90 distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.Six Patients will be tested for the radioactivity of yttrium-90 in blood, urine, and feces (if available).
62300597|NCT06357286|NO_INTERVENTION|Control|The Control arm will not be hired by the cash-for-work program but will be surveyed.
62300598|NCT06357286|EXPERIMENTAL|Stable income arm|The Stable Income arm will work the same number of hours (36) and earn the same amount (108 cedis) every period.
62300599|NCT06357286|EXPERIMENTAL|Predictable Instability Arm|The hours and earnings of the Predictable Instability arm will vary over time. In three periods, the participant will work longer hours (60) and will earn more (180 cedis). In the remaining three periods, she will work fewer hours (12) and will earn less (36 cedis). Crucially, she will be able to predict all swings in her study earnings in the future-i.e., she will know her hours and earnings in each future period.
62300600|NCT06357286|EXPERIMENTAL|Unpredictable Instability Arm|The hours and earnings of the Unpredictable Instability arm will vary unpredictably over time. In any given period, there will be a 50% chance that she works longer hours (60) and earns more (180 cedis) and a 50% chance that she works fewer hours (12) and earns less (36 cedis).
62300601|NCT01295333|OTHER|conventional approach|conventional traitment
62110074|NCT03675139|EXPERIMENTAL|Medroxyprogesterone Acetate|EH patients will take MPA (Medroxyprogesterone Acetate) 10mg daily from tenth day of menstruation for 15 days for 3months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium. All of the findings will be recorded.
62110075|NCT03675139|EXPERIMENTAL|dydrogesterone|EH patients will take dydrogesterone 10 mg, 2 tablets twice daily from tenth day of menstruation for 15 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3-month to examine the endometrium. All of the findings will be recorded.
62110076|NCT01808807||cesarean section rate after audit|cesarean section rate after audit
62110077|NCT00866762|EXPERIMENTAL|1|Treatment with study drug approximately 6 months and follow-up for 3 months
62110078|NCT02555631|EXPERIMENTAL|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
62110079|NCT03392558|EXPERIMENTAL|Nature-Based Sensitive Skin Regimen|"Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):~1. Burt's Bees Sensitive Facial Cleanser (to be used day and night)~2. Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)~3. Burt's Bees Sensitive Night Cream (to be used at night)"
62110080|NCT03392558|ACTIVE_COMPARATOR|Control Regimen|"Control Skin Care Regimen (Control Regimen, CR):~1. Cetaphil Gentle Skin Cleanser (to be used day and night)~2. Cetaphil Moisturizing Lotion (to be used day and night)"
62110081|NCT01616654|EXPERIMENTAL|CD5789 25 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
62110082|NCT01616654|EXPERIMENTAL|CD5789 50 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
62110083|NCT01616654|ACTIVE_COMPARATOR|CD5789 100 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
62110084|NCT01616654|PLACEBO_COMPARATOR|Tazarotene 0.1% Gel|Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
62110085|NCT01616654|EXPERIMENTAL|Vehicle Cream|Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.
62110086|NCT05565391||Elranatamab|Patients treated with elranatamab from the MagnetisMM-3 trial
62110087|NCT05565391||Standard of care|Patients treated with standard-of-care therapies from real-world data sources
62300602|NCT01295333|EXPERIMENTAL|experimental approach|early and systematic traitment
62300603|NCT02976506|EXPERIMENTAL|Unsupervised exercise program|To verify the interference of an unsupervised exercise program on blood pressure, physical fitness, quality of life and safety in elderly hypertensive patients. Participants were divided into the study group or control group
62300604|NCT02976506|EXPERIMENTAL|Physical fitness and quality of life|To verify the interference of a walking program on physical fitness and quality of life.
62300605|NCT01121016|ACTIVE_COMPARATOR|combination therapy|combination therapy with inhaled budesonide and oral montelukast
62300606|NCT01121016|PLACEBO_COMPARATOR|monotherapy|monotherapy with inhaled budesonide and placebo of montelukast
62110088|NCT01814644|ACTIVE_COMPARATOR|Standard Care|Individual assessment Lifestyle counseling
62300607|NCT03832387|EXPERIMENTAL|Non-invasive mechanical ventilation|"Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.~The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
62671860|NCT04679818|ACTIVE_COMPARATOR|PMD-200 NOL group|Clinicians will titrate fentanyl to keep PMD-200 (Pain Monitoring Device) Nociception level (NOL) under 25 - always using good clinical judgement for individual patients
62110089|NCT01814644|EXPERIMENTAL|TRIMM Intervention|Individual assessment Lifestyle counseling Text messages
62110090|NCT00643708||A|14 cases
62110091|NCT00643708||B|14 cases
62110092|NCT00643708||C|14 cases
62110093|NCT00643708||D|14 Cases
62110094|NCT00629200|EXPERIMENTAL|SSG + Intron A|Sodium Stibogluconate (SSG) 400 mg/m\^2 intravenous (IV) daily on days 1-5 + Interferon Alfa-2b (Intron A) 3x10\^6 units subcutaneously three times weekly
62110095|NCT05725018|EXPERIMENTAL|EB-101 Surgical application of RDEB wounds|New or Previously Treated RDEB Patients
62300608|NCT03832387|ACTIVE_COMPARATOR|Venturi mask|"For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.~The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
62671861|NCT04679818|ACTIVE_COMPARATOR|Control Group|Clinicians will be blinded to PMD-200 Nociception level (NOL) monitoring and use clinical judgement to determine how much fentanyl should be given, and when.
62110096|NCT04915599|EXPERIMENTAL|Intervention group|Patients are assigned to using the Cooral® MCD after radiotherapy for 60 min. along with general oral care (GOC). The MCD will be placed into the subjects' mouth and remain intraorally for 60 minutes. After each fraction, i.e. session of RT, the subjects insert the MCD inside their mouth and can start the Cooral ® thermostat system themselves when they feel comfortable. The stopwatch will be started by the patient as soon as thermostat is running. The patient is asked to write down the starting and the stopping time of the 60-minute procedure. Thereafter the subject will receive a questionnaire to record the tolerance for the device. Patients will be also informed about standard of care (SOC) that should be regularly performed.
62300609|NCT02687308|ACTIVE_COMPARATOR|1Retrograde radical prostatectomy RRP|This opem surgical prostatectomy techniques described by Patrick Walsh is made through prostatic dissection, from apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
62671862|NCT06337409|EXPERIMENTAL|Empagliflozin 25 mg film-coated tablets|The test product, generic empagliflozin 25 mg film-coated tablets, will be formulated using the same active ingredient with the same strength as the reference product, JARDIANCE®. The test product to be used in this bioequivalence study is prepared in accordance with GMP regulations.
62110097|NCT02639429|EXPERIMENTAL|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
62110098|NCT02639429|ACTIVE_COMPARATOR|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score \> 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
62110099|NCT02534441|EXPERIMENTAL|Skin patch testing to 6 known and 3 novel surfactants|
62300610|NCT02687308|EXPERIMENTAL|2Anterograde radical prostatectomy RRP2A|This opem surgical prostatectomy techniques dissect the prostate, bladder neck and the neurovascular bundle, in an antegrade way, from bladder neck to the apex. With careful bladder neck dissection and preservation, careful nervesparing procedures with meticulous retroprostatic dissection of the posterior layer of Denonvilliers' fascia, and urethrovesical anastomosis performed through a monofilament running suture.
62300611|NCT02441530|EXPERIMENTAL|vitamin D|667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
62300612|NCT02441530|EXPERIMENTAL|vitamin E|200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
62110100|NCT05678491|EXPERIMENTAL|Endoscopic mucosal band ligation|All 12 patients with GERD will undergo the same procedure. Multiple rubber bands will be used to ligate mucosa in the gastroesophageal junction and cardia in 3/4 of the circumference.
62110101|NCT05425836|ACTIVE_COMPARATOR|Oxygen supplementation in the conventional arm|will be delivered by nasal cannula. At 5 minutes prior to sedation the flow rate would be kept a 5 L/minute.; The flow will be increased to 6-8 L/minute to maintain SPO2 ≥92% during the procedure, up to a maximum of 15 L/minute, depending on the patient tolerance.
62110102|NCT05425836|EXPERIMENTAL|Oxygen supplementation in HFNC arm|HFNC (OptiFlowTM; Fisher \& Paykel, Auckland, New Zealand) will be started 5 minutes before the sedation at a flow rate of 30 Litres/minute and at a fraction of inspired oxygen (FiO2) of 0.30, which will be titrated by increments of 10 liters/minute depending on oxygen demand to keep SPO2 ≥92% during the procedure. The flow rate will be maintained between 30- and 70-liters minute, depending on the patient tolerance.
62110103|NCT01524536|OTHER|Steroid Challenge|A single oral dose of prednisone (1 mg/kg rounded to the nearest 5mg) was administered to all participants. The following day, participant began glucocorticoid therapy of prednisone 30 mg oral daily for one week followed by a standardized taper until a minimally effective dose was achieved or participant tapered to prednisone 5 mg oral daily.
62110104|NCT05140564|EXPERIMENTAL|STEADY intervention group|
62110105|NCT05140564|NO_INTERVENTION|Treatment as usual group (control)|
62110106|NCT04701294|EXPERIMENTAL|Giomer Beautifil flow plusF03 Shofu-Japan|Giomer beautifil flow plusF03 shofu-Japan an application of flowable resin with sprg as a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the experiment.
62110107|NCT04701294|ACTIVE_COMPARATOR|Tetric N flow ivoclar vivadent-Germany|Tetric N flow ivoclar vivadent-Germany an application of flowable resin a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the comparator.
62110108|NCT00756743|EXPERIMENTAL|PF-04802540|
62110109|NCT00756743|PLACEBO_COMPARATOR|Placebo|
62300613|NCT02441530|EXPERIMENTAL|ibuprofen|400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.
62300614|NCT02112968|EXPERIMENTAL|Proscan|Ametropia Lasik treatment of virgin eyes.
62300615|NCT02112968|EXPERIMENTAL|Zyoptix|Wavefront based ametropia Lasik treatment of virgin eyes.
62671863|NCT06337409|ACTIVE_COMPARATOR|Empagliflozin 25 mg film-coated tablets, JARDIANCE|Empagliflozin 25 mg film-coated tablets, JARDIANCE®, has been registered with Food and Drug Administration, Thailand (TFDA).
62671864|NCT03888482|OTHER|DDT2, then Clariti|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
62671865|NCT03888482|OTHER|Clariti, then DDT2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
62671866|NCT03811405|EXPERIMENTAL|Patients with Essential Tremor|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time. The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation. The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off. A 30-minute washout period will be applied between each of the random conditions. Therefore, each patient will serve as their own control.
62300616|NCT02112968|EXPERIMENTAL|Supracor|Ametropia Lasik treatment of virgin eyes with presbyopia.
62300617|NCT01492673|EXPERIMENTAL|Cyclophosphamide, Topotecan, and Bevacizumab (CTB)|This is a multi-center, open label phase II study evaluating the safety and efficacy of the novel combination of agents consisting of bevacizumab, cyclophosphamide, and topotecan.
62300618|NCT04373603|EXPERIMENTAL|Intervention: HA plus TXA|HA will be diluted with TXA using a Leur-Lok hub in a ratio of 1.0 mL HA filler to 0.2 mL TXA (100mg/mL)
62300619|NCT04373603|PLACEBO_COMPARATOR|Control: HA plus Saline|HA will be diluted with saline in a ratio of 1.0 mL HA filler to 0.2 mL saline
62300620|NCT01645761|EXPERIMENTAL|PPI-based triple therapy with endonase|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.
62671867|NCT00222261|ACTIVE_COMPARATOR|1, aspirin|Aspirin 160 mg
62671868|NCT00222261|ACTIVE_COMPARATOR|2, clopidogrel|Clopidogrel 75 mg
62671869|NCT02172599|EXPERIMENTAL|multi-component intervention|"Sit-stand workstation provision~The multi-component intervention will align with the World Health Authority's promotion of a healthy workplace model, which emphasises that best-practice workplace health interventions should involve an integrated approach involving organisation and individual level approaches to behaviour change (WHO, 2010). Thus, participants will receive a sit-stand workstation with additional support to use the sit-stand workstation."
62671870|NCT02172599|EXPERIMENTAL|Sit-stand workstation only|"Sit-stand workstation provision~Participants in this arm will receive a sit-stand workstation. They will not receive any support to use the sit-stand workstation, except some health and safety advice upon installation."
62671871|NCT02172599|NO_INTERVENTION|Usual practice (seated workstation)|This arm is the control group. They will continue to use their usual seated workstation for the duration of the study.
62671872|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
62671873|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
62671874|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
62671875|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
62671876|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
62671877|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
62671878|NCT03874403|EXPERIMENTAL|NIVATS|Patients receiving Non-intubated VATS with DSA changes
62671879|NCT03874403|OTHER|Intubated VATS|Patients receiving intubated VATS with DSA changes
62110110|NCT05818800|OTHER|Solution 1 - HSmartBPM (developed by a supplier consortium led by GNOMON)|Solutions consist of devices (e.g., blood pressure monitors, body composition scales) working together in an ecosystem enabled by a user-facing service and associated interfaces. Users are invited to a dedicated training session at the pilot site to officially become enrolled and begin using the solution for an extended period of time. During that time, users are instructed to use the solutions based on recommendations by their treating physicians (e.g., regular measurement of blood pressure using the solution, or scheduling of regular visits via the solution interface). Questionnaires are administered via the solution's interface at the beginning and end of the trial duration. At the end of the trial, the user is asked to return the devices to the pilot site.
62110111|NCT05818800|OTHER|Solution 2 - HyperHealth (developed by a supplier consortium led by TECH4CARE)|Solutions consist of devices (e.g., blood pressure monitors, body composition scales) working together in an ecosystem enabled by a user-facing service and associated interfaces. Users are invited to a dedicated training session at the pilot site to officially become enrolled and begin using the solution for an extended period of time. During that time, users are instructed to use the solutions based on recommendations by their treating physicians (e.g., regular measurement of blood pressure using the solution, or scheduling of regular visits via the solution interface). Questionnaires are administered via the solution's interface at the beginning and end of the trial duration. At the end of the trial, the user is asked to return the devices to the pilot site.
62300621|NCT01645761|NO_INTERVENTION|PPI-based triple therapy|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week)
62300622|NCT04972383|EXPERIMENTAL|Platelet Rich Plasma group|single injection platelet rich plasma
62671880|NCT05240885||Controls|"Study subjects that are eligible based on inclusion/exclusion criteria~Screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~Study day(s): may include combinations of stable tracer infusions and with blood draws, cognitive and muscle performance testing"
62671881|NCT00300495|EXPERIMENTAL|1 - Amiodarone|Perioperative amiodarone
62671882|NCT00300495|ACTIVE_COMPARATOR|2 - Control|Control arm, standard care with no perioperative amiodarone
62300623|NCT04972383|EXPERIMENTAL|Hyaluronic Acid group|single injection of hyaluronic acid
62300624|NCT06435507|EXPERIMENTAL|Cohort 1|6 participants
62300625|NCT06435507|EXPERIMENTAL|Cohort 2|6 participants
62300626|NCT06435507|EXPERIMENTAL|Cohort 3|6 participants
62300627|NCT06435507|EXPERIMENTAL|Cohort 4|6 participants
62300628|NCT00775021|ACTIVE_COMPARATOR|etafilcon A/nelfilcon A|etafilcon A contact lens worn first and nelfilcon A contact lens worn second
62300629|NCT00775021|ACTIVE_COMPARATOR|nelfilcon A/etafilcon A|nelfilcon A contact lens worn first and etafilcon A contact lens second.
62300630|NCT00648986|EXPERIMENTAL|1|Uncontrolled, Open-Label Pilot Study
61915664|NCT02694718|EXPERIMENTAL|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m\^2) on Days 1-14, and 825 mg/m\^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m\^2/once a day (d) on Day 1 and 50 mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
62470499|NCT02236494|EXPERIMENTAL|Brief Negotiated Interview|The BNI will follow standard steps (7, 63): 1. The research assistant (RA) will ask permission to discuss the patient's alcohol use with them. 2. They will provide feedback regarding the patient's alcohol use, and will review guidelines drinking in older adults. Where relevant, the RA will discuss how the patient's current visit may relate to their alcohol use. 3. The RA will assess the patient's readiness to change using a 1-10 scale, and will enhance motivation. 4. The RA will negotiate a goal for the patient's drinking and give advice. The patient will be asked to sign a drinking agreement.
62470500|NCT02435823|EXPERIMENTAL|PulseRider|Endovascular treatment of intracranial aneurysms
62110112|NCT05818800|OTHER|control|the control group where they will be followed according to standard care
62110113|NCT04369534|ACTIVE_COMPARATOR|First group|The patients randomized into the first group will be given the newer P2Y12 receptor inhibitor ticagrelor during the 12 months.
62110114|NCT04369534|ACTIVE_COMPARATOR|Second group|The second group of patients will be given ticagrelor initially, and after the first 30 days it will be replaced with clopidogrel, that will be given for the remaining time period (up to 12 months). Clopidogrel dosing will be modified according to the results of the aggregometry using the ADP test.
62671883|NCT05695482|EXPERIMENTAL|Neuromuscular exercise training (NMT)|"The 6-week exercise intervention consists of group sessions of Neuromuscular training supervised by a researcher 3 times per week. Participants will be familiarized with the exercises on a separate day prior to testing.~Each session consists of a 5-minute submaximal warm-up followed by 25 minutes of NM training with closed kinetic chain exercises.~Every 2 weeks, there will be a progression that will be achieved by increasing the level of difficulty of each the exercise. We will take into consideration when an exercise is performed with appropriate sensorimotor control, quality of the performance, minimal exertion and control of the movement. Participants will be given special equipment including a step measuring 20 cm in height, an uneven surface, a slider and an elastic tubing medium load (green) from Thera BandTM, (Akron, Ohio, USA)."
62110115|NCT02117843|EXPERIMENTAL|AVI® Arsenic trioxide drug eluting stent|The Arsenic trioxide as AVI eluting drug, biodegradable polylactic acid as drug carrier.
62110116|NCT03852836|OTHER|1.5T magnetic field|For each patient who undergo a 1.5T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
62110117|NCT03852836|OTHER|3T magnetic field|For each patient who undergo a 3T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
62110118|NCT05541393|EXPERIMENTAL|COVID-19 Education Group|Participants randomized to the intervention will be engaged over a three-week period in discussions by their health ministries; any identified concerns or barriers around the initial vaccination series and/or booster vaccinations will be addressed and the importance of continued COVID-19 testing will be emphasized. Evidence-based vaccine strategies that focus on positive framing will be employed
62110119|NCT05541393|NO_INTERVENTION|Delayed Control Group|Participants in the delayed intervention control group will not receive any outreach during the three-week control period. Subsequent to completing the follow-up questionnaire, they will then be invited to join the intervention for the next three weeks. A follow-up questionnaire will be administered following their intervention period to be used in later analyses.
62110120|NCT06106087|OTHER|QI Training|Frontline staff in personal care homes will receive quality improvement training from an experienced quality advisor and support staff in making changes aimed to improve the quality of care for residents in the home.
62300631|NCT03787069|EXPERIMENTAL|Lignocaine group|This group will be given 1.5 mg/kg I/V lignocaine before intubation
62300632|NCT03787069|PLACEBO_COMPARATOR|Placebo|This group will be given 6 ml normal saline before intubation
62300633|NCT00816036|NO_INTERVENTION|Arm 1|Baseline Period
62300634|NCT00816036|EXPERIMENTAL|Arm 2|Intervention Period
62300635|NCT01591980|EXPERIMENTAL|Pregabalin 100 mg|
62300636|NCT01591980|EXPERIMENTAL|pregabalin 150 mg|
62300637|NCT01591980|SHAM_COMPARATOR|Placebo|
62470501|NCT01502254|EXPERIMENTAL|Copy of audio recording|Patients receive a copy of the audio recorded information about the clinical trial directly after the clinical visit. This makes it possible to repeat the information before a decision is made to participate in the clinical trial or not.
62470502|NCT01502254|NO_INTERVENTION|No copy of audio recording|Patients in the control arm receive no copy of the audio recording.
62470503|NCT03522545|EXPERIMENTAL|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
62470504|NCT03522545|PLACEBO_COMPARATOR|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
62470505|NCT03595917|EXPERIMENTAL|ABL001, Dasatinib, Prednisone, Blinatumomab|"- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D)~* Dasatinib-Fixed doses oral once a day per cycle~* ABL001 is administered orally daily per cycle~* Prednisone-Fixed doses oral once a day per cycle.~  --- Prednisone will be tapered and stop during cycle 2.~* Blinatumomab - intravenous continuous infusion beginning no earlier than cycle 2 day 1~* Blinatumomab - Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles"
62470506|NCT01746017|PLACEBO_COMPARATOR|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 4 study periods in Part A
62300638|NCT01531725|EXPERIMENTAL|BMS implantation|Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.
62110121|NCT02385669|EXPERIMENTAL|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
62110122|NCT06155253|ACTIVE_COMPARATOR|Single-level ESP group (1ESP)|Subjects in 1ESP group will receive a single-shot single-level erector spinae plane block at L1 level under ultrasound guidance immediately before surgery.
62110123|NCT06155253|ACTIVE_COMPARATOR|Bi-level ESP group (2ESP)|Subjects in this group will receive a single-shot single-level erector spinae plane block at T12 and L1 levels under ultrasound guidance immediately before surgery.
62300639|NCT03604666||Health care process with Nurse Navigator|"A Nurse Navigator will:~* Be present at the announcement consultation~* Give information on the outpatient circuit~* Offer assistance for patients over 75 years~* Complete onco-geriatric orientation questionnaires~* Take care of patients on the ambulatory circuit"
62300640|NCT03604666||Health care process|Health care process
62300641|NCT01664026|NO_INTERVENTION|Control|Subjects assigned to the usual care group will receive general lifestyle recommendations as per their country standards of care.
62110124|NCT03692520|EXPERIMENTAL|SCT200|Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression
62110125|NCT05485129|EXPERIMENTAL|Intervention|
62300642|NCT01664026|EXPERIMENTAL|Web|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
62110126|NCT03906734|EXPERIMENTAL|alfieri technique + Septal myectomy|Septal myectomy plus mitral valve repair using alfieri stich
62300643|NCT01664026|EXPERIMENTAL|Web+|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
62300644|NCT04048577|EXPERIMENTAL|Dose Interruption|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days) except during the pre-planned dose interruption of 2 consecutive skipped doses.
62300645|NCT04048577|NO_INTERVENTION|Standard Treatment|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days).
62470507|NCT01746017|EXPERIMENTAL|LY2922470 (Part A)|Single ascending dose of LY2922470 \[starting at 1 milligram (mg)\] administered orally to healthy participants in up to 3 of 4 study periods in Part A
62470508|NCT01746017|PLACEBO_COMPARATOR|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
62470509|NCT01746017|EXPERIMENTAL|LY2922470 (Part B)|Single ascending dose of LY2922470 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
62470510|NCT02440308|EXPERIMENTAL|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
61915665|NCT02302430|EXPERIMENTAL|Treatment|Treatment group will receive either 20IU or 40IU intranasal oxytocin
61915666|NCT02302430|PLACEBO_COMPARATOR|Placebo|Placebo group will receive a saline nasal spray
61915667|NCT05325710|ACTIVE_COMPARATOR|TD2 standard|Standard TD2 follow-up
61915668|NCT05325710|EXPERIMENTAL|TD2+ study Nurse|Specific study nurse follow-up every 4 months in addition of standard FU.
61915669|NCT00877773|EXPERIMENTAL|Temsirolimus|Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
61915670|NCT01830023||cardiac ultrasound examination|
61915671|NCT01952782|EXPERIMENTAL|Naloxone, Kisspeptin, GnRH|Intravenous (IV) administration of kisspeptin 112-121, GnRH, and naloxone
62470511|NCT02822326|EXPERIMENTAL|CD19-CAR-T2 T Cells|The subject's T cells will be modified to those which could identify and kill the tumor cells (CD19+ cells). These CD19-CAR-T2 T cells will be infused over 10-15 minutes on days Day 1, 2 and 3 tentatively according to the response to infusion.
62671884|NCT05695482|EXPERIMENTAL|Progressive Resistance Training (PRT)|"The 6-week exercise intervention consists of group sessions of progressive resistance training supervised by a researcher 3 times per week. Participants will be familiarized with the exercises on a separate day prior to testing.~Each session consists of a 5-minute submaximal warm-up followed by 20 minutes of PRT with an open kinetic chain (no weight-bearing exercises) targeting the abductors' muscles of the hip joint. The exercise intensity will be monitored by the researcher, as determined by the patient's ability to complete three sets of 8-12 repetitions for a given exercise and a Borg Rating of Perceived Exertion (RPE) of 6-8.~Every 2 weeks, there will be a progression achieved by changing the resistance in line with guidelines provided by the American College of Sports Medicine with an elastic tubing heavy load (grey) from Thera BandTM, (Akron, Ohio, USA)"
62110127|NCT03906734|ACTIVE_COMPARATOR|Subvalvular intervention + Septal myectomy|Septal myectomy plus subvalvular mitral valve intervention
62300646|NCT04937699|ACTIVE_COMPARATOR|Standard-DAPT of Ticagrelor plus aspirin (DAPT)|"Patients will receive Standard-DAPT of Ticagrelor plus aspirin for 1month after PCI and continue to receive standard-DAPT till 1 year in this arm after as followed:~Ticagrelor 90mg bid+Aspirin 100mg qd for 1month; Ticagrelor 90mg bid+Aspirin 100mg qd for another 11 months;"
62300647|NCT04937699|EXPERIMENTAL|Sequential monotherapy of Ticagrelor and Clopidogrel (SAPT)|"Patients will receive Standard-DAPT of Ticagrelor plus aspirin for 1month after PCI and switch to ticagrelor monotherapy in the following 5 months, and then further de-escalated to clopidogrel monotherapy till 1 year in this arm as followed:~Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month; Ticagrelor 90mg bid, for 5 months; clopidogrel 75mg qd, for 6 months."
62110128|NCT05426538||Interview group|A selection of patients will be interviewed, mapping the craving for the next biologic administration. These interviews will be used to develop a questionnaire to quantify the craving for the next administration in the total population.
62110129|NCT05426538||Questionnaire group|The remaining patients will be asked to fill in a questionnaire, based on the interviews from Group 1.
62110130|NCT05384392|EXPERIMENTAL|Intervention|All patients included in the study will be required to complete the examinations specified in the protocol.
62110131|NCT01228851|EXPERIMENTAL|Balance Training|Balance training using Wii Fit Balance Board
62110132|NCT05381571|EXPERIMENTAL|Reminiscence-based physical therapy|Participants will use the reminiscence-based technology (jDome BikeAround) for 10-minute sessions for three times per week during the 12 week study enrolment period.
62300648|NCT01330290||Neupro® Treatment|Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
62300649|NCT05548634|OTHER|Part 1 Cohort 0|IV infusion of TAVO412
62300650|NCT05548634|OTHER|Part 1 Cohort 1|IV infusion of TAVO412
62300651|NCT05548634|OTHER|Part 1 Cohort 2|IV infusion of TAVO412
62300652|NCT05548634|OTHER|Part 1 Cohort 3|IV infusion of TAVO412
62300653|NCT05548634|OTHER|Part 1 Cohort 4|IV infusion of TAVO412
62300654|NCT05548634|OTHER|Part 1 Cohort 5|IV infusion of TAVO412
62300655|NCT05548634|OTHER|Part 2 Cohorts|IV infusion of TAVO412
62300656|NCT06091501|EXPERIMENTAL|Lev Livet|The participants will receive the 9 weeks of Lev Livet intervention
62671885|NCT05391087|ACTIVE_COMPARATOR|Mean Arterial Pressure (MAP) Group|Target MAP: Baseline MAP +/- 20% and MAP\>65mmHg Baseline MAP: MAP average in the ward at rest the day before surgery Low MAP intervention If PPV\>14, apply 500ml crystalloid If PPV\>9 and any additional finding regarding hypovolemia, apply 500ml crystalloid If PPV\<10, start/titrate noradrenaline infusion
62671886|NCT05391087|ACTIVE_COMPARATOR|Cardiac Index (CI) Group|"CI: Baseline CI +/- 20% and CI \> 2.2 L/m2/min Baseline CI: CI calculated by MostCare monitor before the anesthesia induction starts Low CI intervention If PPV\>9, apply mini fluid challenge (MFC). If MFC is positive, apply 500ml crystalloid.~If MFC is negative, evaluate MAP. If MAP is elevated start/titrate remifentanil. If MAP is not elevated start/titrate dopamine/dobutamine in accordance with systemic vascular resistance index (SVRI)"
62671887|NCT02141724||neuromuscular patients|neuromuscular patients using wheelchair
62671888|NCT02852733||Residents in end-of-life situation|"Residents in end-of-life situation the day of the survey, as determined by the physician coordinator of nursing homes (we will use the definition of terminal condition contained in the guide of the CNSA (coding PATHOS - April 2011))."
62300657|NCT06091501|NO_INTERVENTION|Lev Livet control|The participants will attend 5 months of waiting list
62300658|NCT06091501|EXPERIMENTAL|Lev Livet + HiiT|The participants will receive the 9 weeks of Lev Livet intervention AND 9 weeks of HiiT training
62300659|NCT06091501|NO_INTERVENTION|Lev Livet + HiiT control|The participants will attend 5 months of waiting list
62300660|NCT00803556|EXPERIMENTAL|Arm 1|"Patients whose last dose is \> 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin~Patients whose last dose is \< 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin"
62470512|NCT04568785|EXPERIMENTAL|Brief Intervention group|Intervention consisted of a standardized Brief Intervention, which varied depending on the reason the patient had given for refusing the vaccination.
62110133|NCT03109886|EXPERIMENTAL|Milciclib maleate|milciclib maleate ,10, 50 and 100 mg hard gelatine capsules , 100 mg once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles)
62470513|NCT04568785|ACTIVE_COMPARATOR|Control group|the control group intervention was the normal advice that professionals used to give their patients
62671889|NCT02852733||dead residents|dead residents in the quarter preceding the date of the survey
62300661|NCT00803556|EXPERIMENTAL|Arm 2|"Patients whose last dose is \> 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin~Patients whose last dose is \< 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin"
62110134|NCT00804778||CABG,general anesthesia|their CO and CI was measured with USCOM and Swan-ganz cco respectively.
62300662|NCT04578210|EXPERIMENTAL|Arm A: allogeneic T memory cells|patients will receive memory T cells
62300663|NCT04578210|EXPERIMENTAL|Arm B: allogeneic NK cells|patients will receive NK cells
62300664|NCT01956981|PLACEBO_COMPARATOR|Magnesium|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
62300665|NCT01956981|ACTIVE_COMPARATOR|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
62300666|NCT01748383|EXPERIMENTAL|Transplantation of BMMCs|Autologous BMCs aspiration and transplantation of these cells
62470514|NCT03155425|EXPERIMENTAL|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion.
62671890|NCT05931900|EXPERIMENTAL|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
62671891|NCT01666652|EXPERIMENTAL|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62671892|NCT01666652|EXPERIMENTAL|TDENV-PIV AS01E1|1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62671893|NCT01666652|EXPERIMENTAL|TDENV-PIV AS03B1|1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62671894|NCT01666652|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
62671895|NCT01666652|EXPERIMENTAL|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
62671896|NCT03819205|EXPERIMENTAL|kinesiotaping group(before/after)|"* Hemiplegic CP:Kinesiotaping on the affected side~* Diplegic, tetraplegic CP: side of upper extremity which children have been used to but have obstacles in daily life~* intervention Duration: For 1 week at least 2-3 hours a day, renewing if it's necessary.~* Note:Patients will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day.~* Evaluation: In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion"
62671897|NCT00732693|EXPERIMENTAL|1|Treatment with standard sex steroid replacement regimen
62671898|NCT00732693|EXPERIMENTAL|2|Treatment with physiologic sex steroid regimen
61915672|NCT03733431|ACTIVE_COMPARATOR|Standard dose vagal stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
62300667|NCT01748383|EXPERIMENTAL|Transplantation of CD 133+ cells|Autologous CD 133+ BMCs aspiration and transplantation of CD 133+ cells
62470515|NCT03644264|EXPERIMENTAL|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
62470516|NCT03644264|ACTIVE_COMPARATOR|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
62470517|NCT03332485|EXPERIMENTAL|ECP Colon Prep Kit|
62671899|NCT05786755||Healthy Control|Total number of 52 Healthy Control Included in the study
62671900|NCT05786755||Alcoholic Control|Total number of 46 Alcoholic Control Included in the study
62671901|NCT05786755||Only Cirrhosis|Total 10 patients with only cirrhosis (n= 10, age 66.66±13.51 years) are included in this study
62671902|NCT05786755||Cirrhosis+ HCC|Total 26 patients with Cirrhosis+ hepatocellular carcinoma (HCC) (n= 26, age 61.61±9.85 years) are included in this study
62671903|NCT05786755||Cirrhosis+ Varices|Total 7 patients with Cirrhosis+ Varices (n= 7, age 48.42±15.80 years) are included in this study
62110135|NCT00804778||group 1|co measured with swan-ganz cco combined with vigilance
62110136|NCT01277445|PLACEBO_COMPARATOR|Placebo|15g/day maltodextrin for 28 days
62110137|NCT01277445|ACTIVE_COMPARATOR|Prebiotic|Consumption of 15g/day of inulin-fructan for 28 days
62110138|NCT00531518|NO_INTERVENTION|Control group|This is the control arm. Participants will be offered only case management. Participants may seek outside treatment, without guidance from study staff.
62300668|NCT01748383|ACTIVE_COMPARATOR|stenting of IRA|The only stenting of IRA
62300669|NCT01217606|EXPERIMENTAL|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
62470518|NCT03332485|ACTIVE_COMPARATOR|MoviPrep®|
62671904|NCT05786755||Cirrhosis+ Ascites|Total number of 26 patients with Cirrhosis+ Ascites (n= 26, age 55.96±8.51years) are included in this study
62671905|NCT05786755||Cirrhosis+ 2 Complications|Total number of 44 patients with cirrhosis with 2 complications (n=44, age 57.84±9.18 years) are included in this study
62671906|NCT05786755||Cirrhosis+ 3 Complications|Total number of 29 patients with cirrhosis and 3 or more complication (n=29, aged 59.64±12.61 years) are included in this study
62671907|NCT01972971|OTHER|pharmacist care|
62110139|NCT00531518|EXPERIMENTAL|Family-aided Assertive Community Treatment|This is the experimental intervention arm for high-risk-for-psychosis participants. The intervention includes psychiatric drugs (aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine), psychoeducational multifamily group treatment and supported employment and education .
62110140|NCT05465811|EXPERIMENTAL|Baseline|Before the intervention period, the following tests will be applied: SARC-F, Short Physical Performance Battery, hand-grip dynamometry, Geriatric Anxiety Inventory, Geriatric Depression Scale and Pittsburgh Sleep Quality Index.
62110141|NCT05465811|EXPERIMENTAL|Follow-up|After the intervention period, the following tests will be applied: SARC-F, Short Physical Performance Battery, hand-grip dynamometry, Geriatric Anxiety Inventory, Geriatric Depression Scale and Pittsburgh Sleep Quality Index.
62110142|NCT04588480|EXPERIMENTAL|BNT162b2|BNT162b2 (intramuscular injection)
62110143|NCT04588480|PLACEBO_COMPARATOR|Placebo|Placebo (intramuscular injection)
62110144|NCT01409512||Women with OAB|Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
62671908|NCT01391949|EXPERIMENTAL|Detailed feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
62671909|NCT01391949|ACTIVE_COMPARATOR|Basic feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
62671910|NCT03600428|EXPERIMENTAL|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
62110145|NCT00324038|EXPERIMENTAL|buprenorphine transdermal system|Buprenorphine transdermal 7 day analgesic patch
62110146|NCT00324038|ACTIVE_COMPARATOR|codeine paracetamol tablets|codeine paracetamol combination tablets
62110147|NCT05918159||Elderly|Group of 274 elderly
62110148|NCT01651949|ACTIVE_COMPARATOR|Females|Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
62110149|NCT01651949|EXPERIMENTAL|Heterosexual Males|Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
62110150|NCT01651949|EXPERIMENTAL|Men who have Sex with Men|Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
62110151|NCT05857358|EXPERIMENTAL|Adult patients suffering from xerostomia and autoimmune disease|"Xerostomia treatment consist of 3 steps (including 2 surgical steps) in the Hospital de la Conception of Marseille, in the same ward :~* The plastic/maxillofacial surgeon : collects the adipose tissue, and transfers it to the cell therapy unit;~* The cell therapy unit processes and controls the experimental product (adipose-derived stromal vascular fraction; AD-SVF) from the harvested adipose tissue. The AD-SVF batch is nominatively transported to the surgeon;~* The maxillofacial surgeon injects the AD-SVF without delay under local anesthesia."
62110152|NCT04747106|EXPERIMENTAL|plasma exchange|when ADP inhibition \>30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
62110153|NCT04747106|NO_INTERVENTION|standard medical treatment|standard medical treatment
62110154|NCT00730002|ACTIVE_COMPARATOR|1- Healthy Subjects|Healthy Subjects- receive MRA
62110155|NCT00730002|ACTIVE_COMPARATOR|2 - patients with SLE, no neuropsych|Systemic Lupus Erythematosus(SLE) patients without neuropsychiatric symptoms - receive MRA
62671911|NCT03600428|ACTIVE_COMPARATOR|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
62671912|NCT05769595|EXPERIMENTAL|MK-2060|Participants receive MK-2060 50 mg via a single intravenous (IV) infusion over 60-minutes.
62671913|NCT05769595|PLACEBO_COMPARATOR|Placebo|Participants receive a single IV saline infusion over 60 minutes.
62671914|NCT01216280|PLACEBO_COMPARATOR|2 x 10 mg placebo capsule|2 x 10 mg placebo capsules, administered orally with water, b.i.d.
62671915|NCT01216280|EXPERIMENTAL|10mg Natura-alpha + 10 mg placebo|10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
62671916|NCT01216280|EXPERIMENTAL|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
62671917|NCT01208051|EXPERIMENTAL|Arm A (cediranib maleate)|Patients receive cediranib maleate 30 mg PO QD on days 1-28. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62671918|NCT01208051|EXPERIMENTAL|Arm B (cediranib maleate plus lenalidomide thru April 10, 2015)|Patients receive cediranib maleate 30 mg PO and lenalidomide 15 mg PO on days 1-21. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. NOTE: As of April 10, 2015, patients assigned to this arm are discontinued lenalidomide and continued on cediranib alone.
62671919|NCT05208632||BLOCK SİDE|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
62671920|NCT05208632||UNBLOCK SİDE|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
62300670|NCT01217606|ACTIVE_COMPARATOR|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
62470519|NCT05167760|EXPERIMENTAL|Treatment Group|Participants will receive the study drug, apraclonidine, per its FDA-approved package labelling
61915673|NCT03733431|ACTIVE_COMPARATOR|High dose vagal stimulation|A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
61915674|NCT03733431|SHAM_COMPARATOR|Sham stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
61915675|NCT04485065|EXPERIMENTAL|IBI188+azacitidine|
61915676|NCT04422275|ACTIVE_COMPARATOR|Budesonide & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
62470520|NCT03195205|OTHER|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
62671921|NCT05438420|EXPERIMENTAL|Dose escalation of Q702 in combination with fixed dose of pembrolizumab|Give one week on/one week off at selected dose level
62671922|NCT05438420|EXPERIMENTAL|Dose expansion of Q702 in combination with fixed dose of pembrolizumab|Give intravenously once every three week at 200 mg
62671923|NCT03220555|EXPERIMENTAL|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
61915677|NCT04422275|ACTIVE_COMPARATOR|Placebo & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
61915678|NCT04422275|ACTIVE_COMPARATOR|Budesonide & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
61915679|NCT04422275|PLACEBO_COMPARATOR|Placebo & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
61915680|NCT02218476|OTHER|APS Patient|
61915681|NCT03272984|EXPERIMENTAL|ERAS group|Patients will undergo the ERAS programs.
61915682|NCT03272984|OTHER|SC group|Patients will undergo the SC group.
61915683|NCT04643301|EXPERIMENTAL|Adding Liraglutide to current treatment program|Adding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.
62110156|NCT00730002|ACTIVE_COMPARATOR|3 - patients with SLE with neuropsych|20 symptomatic neuropsychiatric systemic lupus erythematosus(NPSLE) patients.
62110157|NCT00730002|ACTIVE_COMPARATOR|4- healthy patients from other cohort|10 Healthy Controls (HC) from an existing cohort as part of another sponsored study.
62110158|NCT00362206|EXPERIMENTAL|1|
62110159|NCT00362206|EXPERIMENTAL|2|
62110160|NCT00362206|ACTIVE_COMPARATOR|3|
62110161|NCT05895760|EXPERIMENTAL|Multi-component physical exercise online intervention (MPE)|The exercise program included endurance, strength, coordination, balance, and flexibility exercises which were carried out for 3 months.
62110162|NCT05895760|NO_INTERVENTION|Control group|The control group received educational sessions on health prevention related to physical exercise.
62110163|NCT02206386|EXPERIMENTAL|MentalHealthTraining-Net|MHTraining-Net is an implementation strategy that uses a web-based platform with several long distance tools (e.g. e-learning modules, consultation, telephone calls, toolkits, and discussion boards) to deliver four types of implementation activities: infrastructure development, training and education, quality improvement, and social networking.
61915684|NCT00400478|ACTIVE_COMPARATOR|A|Treatment
61915685|NCT00400478|NO_INTERVENTION|B|Observation
61915686|NCT00828438|EXPERIMENTAL|Lorcaserin 10mg|
61915687|NCT02281097|ACTIVE_COMPARATOR|Vagal Stimulation First|"Vagal stimulation to improve upright heart rate modulation and symptoms is given on first tilt study day.~Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on second tilt study."
61915688|NCT02281097|PLACEBO_COMPARATOR|Placebo First|"Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on first tilt study day.~Vagal stimulation to improve upright heart rate modulation and symptoms is given on second tilt study day."
61915689|NCT05838989|EXPERIMENTAL|Group A: Stretching and Prefabricated Orthoses|Participants in this arm will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks, as well as prefabricated wrist orthoses.
61915690|NCT05838989|EXPERIMENTAL|Group B: Orthoses Alone|Participants in this arm will receive prefabricated wrist orthoses only.
61915691|NCT05838989|PLACEBO_COMPARATOR|Group C: Placebo Treatment|Participants in this arm will receive placebo treatment consisting of gentle wrist and hand movements.
62110164|NCT02206386|ACTIVE_COMPARATOR|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded trainings in the use of the protocol and depression screening posted by Brightree.
62110165|NCT01958541|EXPERIMENTAL|Behavioral Intervention I|This non-medication group treatment (Sleep Intervention I) consists of four 90-minute sessions.
62671924|NCT03220555|ACTIVE_COMPARATOR|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
61915692|NCT02385136|EXPERIMENTAL|WBRT plus TMZ arm|whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)
62110166|NCT01958541|ACTIVE_COMPARATOR|Behavioral Intervention II|This non-medication group treatment (Sleep Intervention II) consists of four 90-minute sessions.
61915693|NCT02385136|NO_INTERVENTION|WBRT|whole brain radiotherapy (WBRT)
61915694|NCT02547883|EXPERIMENTAL|Patients stopping statin|
62110167|NCT05912751|OTHER|Exercise Then Foam Roll|This arm (sequence) will first complete the exercise intervention promoting muscular engagement resisting gravitational collapsing tendencies, then the control intervention involving self-myofascial release of muscle groups not thought to resist gravitational collapse.
62110168|NCT05912751|OTHER|Foam Roll Then Exercise|This arm (sequence) will first complete the control intervention involving self-myofascial release of muscle groups not thought to resist gravitational collapse, then the exercise intervention promoting muscular engagement resisting gravitational collapsing tendencies.
62110169|NCT04277689|EXPERIMENTAL|Brain signal data collection|Collection of brain data during deep brain stimulation
62110170|NCT00504114||1|Healthy volunteers without knee pain.
62110171|NCT00504114||2|Patients with mild arthritic symptoms and radiographic changes (Kellgren Lawrence score of 1, 2)
62110172|NCT00504114||3|Patients with severe pain and functional limitations associated with knee arthritis (Kellgren Lawrence score of 3, 4).
62110173|NCT00504114||4|Patients with acute anterior cruciate ligament (ACL) injuries with associated osseous contusion.
62110174|NCT00504114||5|Patients with posttraumatic knee injury or degenerative condition and will have cartilage resurfacing procedures.
61915695|NCT02547883|NO_INTERVENTION|Patients continuing statin|
61915696|NCT05944978|EXPERIMENTAL|Study treatment|Participants receive GNC-035 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
61915697|NCT04801940|NO_INTERVENTION|Standard Care|Participant receives usual post-hospital care.
61915698|NCT04801940|ACTIVE_COMPARATOR|Apixaban|Intervention: Drug: Apixaban.
61915699|NCT04801940|ACTIVE_COMPARATOR|Atorvastatin|Intervention: Drug: Atorvastatin.
61915700|NCT00624884||A|Patients with moderate-to-severe aortic regurgitation having normal left ventricular ejection fraction
61915701|NCT00624884||B|Age, sex and bodymass index matched healthy subjects
61915702|NCT04396184|EXPERIMENTAL|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 288 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once every two weeks for 3 times.
61915703|NCT04396184|ACTIVE_COMPARATOR|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
61915704|NCT01211587|EXPERIMENTAL|100mg safinamide|Two 50mg tablets of safinamide once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
61915705|NCT01211587|PLACEBO_COMPARATOR|Placebo|Two 50mg tablets of placebo once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
61915706|NCT02598336|OTHER|Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing followed by a forced respiratory manoeuvre. This sequence is repeated twice.
61915707|NCT02598336|OTHER|Agreement and repeatability Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing. This sequence is repeated one further time at rest, and once further time after an exercise test to elevate respiratory rate.
61915708|NCT01286831|EXPERIMENTAL|[14C]GW642444|Single 200μg dose of \[14C\]GW642444 given on Day 1.
61915709|NCT04676971|EXPERIMENTAL|100 mg hzVSF-v13 IV + SOC|100 mg hzVSF-v13 IV + SOC
62110175|NCT00606580|EXPERIMENTAL|WR 279,396 Topical Treament|WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
62110176|NCT00606580|EXPERIMENTAL|Paromomycin Alone Topical treatment|Paromomycin Alone topical cream (15% paromomycin topical cream)
62110177|NCT00606580|PLACEBO_COMPARATOR|Vehicle Placebo Cream|The cream base without the addition of paromomycin or gentamicin
62110178|NCT02165137||trauma patients|type and severity of patients, circumstances and trauma pre- and post-injury / -quality initiative
62110179|NCT01158196|EXPERIMENTAL|infra-red diode laser|one session, one dose
62110180|NCT03489317||No metabolic syndrome|Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
61915710|NCT04676971|EXPERIMENTAL|200 mg hzVSF-v13 IV + SOC|200 mg hzVSF-v13 IV + SOC
61915711|NCT04676971|PLACEBO_COMPARATOR|Placebo (saline) IV + SOC|Placebo (saline) IV + SOC
62110181|NCT03489317||Metabolic syndrome- partial|Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
62671925|NCT03889795|EXPERIMENTAL|Dose Escalation|C3 (Metformin, Simvastatin and Digoxin) will be dosed each day of a 28 calendar day cycle. The starting dose level will be increased with each cohort. There are 3 cohorts. Upon reaching maximum tolerated dose, an expansion cohort will be opened. Cohort 1 - Metformin 850mg po/day, Simvastatin 5mg po/day, Digoxin 0.0625 mg po/day. Cohort 2 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 20 mg po/day, Digoxin 0.25 mg po/day. Cohort 3 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 40 mg po/day, Digoxin 0.25 mg po/day for two weeks, 0.375 mg po/day for the next two weeks for cycle 1. Subjects will receive 0.50 mg po/day in Cohort 3, Cycle 2 and beyond. Metformin to be taken at Breakfast and Dinner time (as applicable), Simvastatin at Bed time and Digoxin once daily.
62671926|NCT04093700||SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
61915712|NCT02968589|EXPERIMENTAL|@ctiveHip intervention|"A training session for caregivers of patients with hip fracture on patient management.~The @ctiveHip tele-rehabilitation system. This system includes a 3-months occupational therapy and exercise-based program, recommendations for patients and their caregivers and the option of chats and videoconferences.~The program consists of 5 sessions/week of 50-60 minutes that patients will do at home. Each session includes videos with the prescribed activities and exercises that the patients will find in the private site of www.activehip.es."
62110182|NCT03489317||Metabolic syndrome- full|Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
62110183|NCT06250270|EXPERIMENTAL|PRO pm, PRO am|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
62110184|NCT06250270|EXPERIMENTAL|PRO pm, PLAC am|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
62671927|NCT01248390|EXPERIMENTAL|Interactive Metronome therapy|Fifteen one-hour training sessions using Interactive Metronome system, in addition to treatment as usual.
62671928|NCT01248390|NO_INTERVENTION|Treatment as Usual|Standard of care symptom management.
62671929|NCT02164721|OTHER|CRT-D (Defibrillator)|Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
62671930|NCT06040450||All subjects with impairments|
62671931|NCT06040450||All subjects without impairments|
62671932|NCT03436420|EXPERIMENTAL|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
62671933|NCT05395780|EXPERIMENTAL|High-dose MAX-40279 group|High-dose MAX-40279 capsule group (10-15 subjects, 70 mg, BID, PO)
61915713|NCT02968589|ACTIVE_COMPARATOR|Other training|"A training session for caregivers of patients with hip fracture on patient management.~The usual care for hip fracture patients at hospital discharge. In addition, patients and their families will receive a triptych with information on recommendations and exercises to do at home."
62300671|NCT06497738||Daratumumab + lenalidomide + dexamethasone|"Drug: Daratumumab Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks. The total induction cycle is 8.~Drug: Lenalidomide Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 21 of each 28-day cycle.~Drug: Dexamethasone Dexamethasone 20 mg orally or intravenously on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 21-day cycle for Cycles 1-8. For participant\>75, dexamethasone will be reduced to 10mg twice a week.~Then according to the risk stratification, standard risk participants will receive lenalidomide maintenance therapy while high risk participants will receive daratumumab combined with lenalidomide until progression."
62110185|NCT06250270|EXPERIMENTAL|PLAC pm, PRO am|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
62110186|NCT06250270|PLACEBO_COMPARATOR|PLAC pm, PLAC pm|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
62110187|NCT06553248|EXPERIMENTAL|GZR4|s.c., once weekly
62110188|NCT06553248|ACTIVE_COMPARATOR|Insulin Degludec|s.c., once daily
61915714|NCT04837677|EXPERIMENTAL|PRT1419|PRT1419 will be administered by intravenous infusion
62110189|NCT00697229|EXPERIMENTAL|Group A|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
62110190|NCT00697229|EXPERIMENTAL|Group B|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
62110191|NCT00697229|EXPERIMENTAL|Group C|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
62110192|NCT00697229|EXPERIMENTAL|Group D|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
62110193|NCT00697229|EXPERIMENTAL|Group E|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
62110194|NCT00697229|EXPERIMENTAL|Group F|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
62110195|NCT00697229|EXPERIMENTAL|Group G|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
62110196|NCT00697229|EXPERIMENTAL|Group H|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
62300672|NCT06497738||Modified Bortezomib+Lenalidomide+dexamethasone|"Drug: Bortezomib Bortezomib 1.3 mg/m\^2 will be administered by subcutaneous(SC) injection injection weekly on Days 1, 8, 15, 22 of each 21-day cycle for Cycles 1-8.~Drug: Dexamethasone Dexamethasone 20 mg orally or intravenously on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 21-day cycle for Cycles 1-8. For participant\>75, dexamethasone will be reduced to 10mg twice a week.~Then according to the risk stratification, standard risk participants will receive lenalidomide maintenance therapy while high risk participants will receive bortezomib combined with lenalidomide until progression."
62110197|NCT06327919|EXPERIMENTAL|Intervention|"Probiotic supplementation with a weight loss program and ten one-hour online individual sessions cognitive behavioral therapy for 12 weeks.~multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks."
62671934|NCT05395780|EXPERIMENTAL|Low-dose MAX-40279 group|Low-dose MAX-40279 capsule group (10-15 subjects, 50 mg, BID, PO)
62671935|NCT01694394||Cohort|Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
62671936|NCT04387214||Veterinary students and researchers|
62671937|NCT01691313|EXPERIMENTAL|vanoxerine 200mg|vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
62671938|NCT01691313|PLACEBO_COMPARATOR|placebo|placebo to match vanoxerine oral capsule
61915715|NCT03590431|OTHER|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
62110198|NCT06327919|PLACEBO_COMPARATOR|Placebo|"Placebo supplementation with a weight loss program and ten one-hour online individual sessions cognitive behavioral therapy for 12 weeks.~The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks"
62110199|NCT04188028|EXPERIMENTAL|CYP2D6 gene score 0|CYP2D6 gene score 0: carrier of two non-functional alleles
62110200|NCT04188028|EXPERIMENTAL|CYP2D6 gene score ≥1|CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles
62671939|NCT01691313|EXPERIMENTAL|vanoxerine 300mg|vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
62671940|NCT01691313|EXPERIMENTAL|vanoxerine 400mg|vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)
62671941|NCT04877639|ACTIVE_COMPARATOR|Esmketamine group|Intravenous injection of 1.0mg/kg esmketamine was given, and nasal endoscopy was started 3 minutes later to maintain 1.0mg/kg/h esmketamine
62671942|NCT04877639|ACTIVE_COMPARATOR|Dexmedetomidine group|Dexmedetomidine 1 μg/ kg at least 10 min after intravenous injection + maintain 1 μ After intravenous injection of dexmedetomidine 1 ug / kg, sufentanil 0.05 mg / kg was given 5 minutes
62671943|NCT03612700|EXPERIMENTAL|CPFA-rich diet|Free living diet controlled in CPFA intake
62671944|NCT05223712||Development Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
62671945|NCT05223712||Development Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
62671946|NCT05223712||Validation Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
62671947|NCT05223712||Validation Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
62110201|NCT01137292||Active Treatment|Patients who are eligible for voriconazole treatment according to their physician decision.
62671948|NCT05223712||Test Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
62671949|NCT05223712||Test Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
62671950|NCT04784975||Preclinical Type 1 Diabetes|"Adolescents and young adults with preclinical diabetes (having at least 2 positive diabetes autoantibodies but who do not meet criteria for clinical diagnosis of type 1 diabetes).~There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health."
62671951|NCT04784975||New Onset Type 1 Diabetes|Adolescents and young adults with a diagnosis of clinical type 1 diabetes. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
62671952|NCT04784975||Long standing Type 1 Diabetes|Adolescents and young adults with type 1 diabetes for at least 2 years. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
62671953|NCT04784975||Control|Adolescents and young adults without any evidence of diabetes or hyperglycemia. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
62671954|NCT01960478|OTHER|bood test|
62671955|NCT00133211|ACTIVE_COMPARATOR|1|Antiarrythmic drug treatment
62671956|NCT00133211|EXPERIMENTAL|2|
62671957|NCT03281538|EXPERIMENTAL|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
62671958|NCT03426007|EXPERIMENTAL|Uterine Lavage|Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
61915716|NCT03590431|OTHER|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
61915717|NCT03590431|OTHER|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
61915718|NCT01706900|PLACEBO_COMPARATOR|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
62110202|NCT03114020|EXPERIMENTAL|Hyaluronic Acid inhalation solution|3mL of 0.03% Hyaluronic Acid inhalation solution BID for 28 days
62110203|NCT03114020|PLACEBO_COMPARATOR|Placebo Inhalation Solution|3mL matching placebo inhalation solution BID for 28 days
62110204|NCT01103219|PLACEBO_COMPARATOR|Control|Participants in this group will receive nutrition from birth and during the hospital stay until discharge according to the routines of the participating institutions.
62110205|NCT01103219|ACTIVE_COMPARATOR|Intervention|The participants in this group will receive increased supply of energy, protein, vitamin A, docosahexaenoic acid, and arachidonic acid from birth and during the hospital stay until discharge.
62671959|NCT01574404|EXPERIMENTAL|Polar Body Biopsy with PGS|Polar Body Biopsy with Pre implantation genetic screening
62110206|NCT01875484||High miR-126 group|
62110207|NCT01875484||Moderate miR-126 group|
62671960|NCT06516731|EXPERIMENTAL|pH Balanced Cleanser|Participants will use the pH Balanced Cleanser daily during showers. The study will evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
62671961|NCT05666856|EXPERIMENTAL|CRAFT|Participants assigned to CRAFT will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules that are unlocked weekly include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Problem-solving; 6) Withdrawing Reinforcement; 7) Allowing Natural Consequences; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills. Two additional modules (domestic violence and opioid overdose precautions) are available at any time. CRAFT participants also attend weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group or individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations.
62671962|NCT05666856|ACTIVE_COMPARATOR|PEER|"Participants assigned to the PEER condition will participate in an online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs.~Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully."
62671963|NCT01192360|EXPERIMENTAL|Cardiac Patients|In addition to the routine clinical MRI, we will conduct the DCE MR perfusion imaging research component. For this, we will measure native pre-contrast T1 and then inject a tight bolus of gadolinium (0.1mmol/kg) while acquiring high temporal resolution T1-weighted 3D contrast dynamics information over the whole thorax while the patient is holding his / her breath. Overall, the research component will prolong the clinical study by approximately 5 minutes.
62671964|NCT01192360|EXPERIMENTAL|Pulmonary Patients|Patients in this group will receive a full cardiac and pulmonary MRI assessment, with the DCE pulmonary perfusion scan added as described above. Overall, the investigation will take approximately 45 minutes
62671965|NCT00620035|EXPERIMENTAL|Radiopaque Etonogestrel Implant|"Radiopaque Etonogestrel Implant (drug) inserted with the Next Generation Applicator (NGA)~The Radiopaque Implant is a single rod contraceptive implant of 4 cm length and~2 mm in diameter which is placed at the inner side of the non-dominant upper-arm~about 8-10 cm above the medial epicondyle. The Radiopaque Implant contains~approximately 68 mg etonogestrel (ENG) dispersed in a matrix of ethylene vinyl acetate (EVA) copolymer and barium sulfate, surrounded by an EVA membrane. The barium-sulfate provides radio-opacity and allows detection by X-ray.~The ENG dose released from the implant amounts to about 60-70 mcg/day shortly after insertion and decreases to about 40 mcg/day at the start of the second year, and to about 25-30 mcg/day at the end of the third year."
62671966|NCT00249041|EXPERIMENTAL|Etanercept liquid|
61915719|NCT01706900|EXPERIMENTAL|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
62110208|NCT01875484||Low miR-126 group|
62110209|NCT00548119|EXPERIMENTAL|NeoCart|
62110210|NCT00548119|ACTIVE_COMPARATOR|microfracture|
62110211|NCT04826536||Cohort 1|Participants with psoriasis
61915720|NCT00611871|EXPERIMENTAL|1|Propranolol following traumatic memory
61915721|NCT00611871|ACTIVE_COMPARATOR|2|Propranolol following neutral memory
61915722|NCT00611871|PLACEBO_COMPARATOR|3|Placebo following traumatic memory
61915723|NCT01763242|ACTIVE_COMPARATOR|EMAN|Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required
62110212|NCT01285258|OTHER|peripartum|patients whom underwent peripartum hysterectomy
62110213|NCT03645850|EXPERIMENTAL|Investig. device:Vismed Gel Multi 0.3%|Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
62110214|NCT03645850|ACTIVE_COMPARATOR|Comparative device: Vismed Multi 0.18%|Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
62110215|NCT00344019|ACTIVE_COMPARATOR|atorvastatin 80 mg|80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
62110216|NCT00344019|PLACEBO_COMPARATOR|placebo oral tablet|placebo on average of 2-4 hours pre angio/PCI for ACS
62110217|NCT00344019|NO_INTERVENTION|Screening|Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
62110218|NCT04482205||precovid group|those who were operated from fJanuary first to March 15
62110219|NCT04482205||covid|those operated from March 16, to May 31, 2020
62110220|NCT06413940|NO_INTERVENTION|Control group|Subjects in the control group will receive usual care(On-site healthy lifestyle promotion)
62110221|NCT06413940|EXPERIMENTAL|Physical therapy group|Subjects in the physical therapy group will receive myofunctional therapy and inspiratory muscle training
62300673|NCT03420638|EXPERIMENTAL|Adjunct Exparel|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\], i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension on each side.
62671967|NCT05267002|EXPERIMENTAL|Suture removal at 1 week|Cutaneous nylon suture removal of half of the split-scar at one week.
62671968|NCT05267002|EXPERIMENTAL|Suture removal at 2 weeks|Cutaneous nylon suture removal of half of the split-scar at two weeks.
62671969|NCT06469268|NO_INTERVENTION|Group A|This was the routine observation group, 50 patients were enrolled in the group. After receiving antineoplastic drug treatment, they were discharged home, and the treatment-related adverse reactions were observed and intervention according to the routine process.
62671970|NCT06469268|EXPERIMENTAL|Group B|This was the ePRO study group: A total of 50 patients were enrolled in this group. After receiving anti-tumor drug treatment, the ePRO system was installed through the mobile phone. After training, the patients could skillfully use the ePRO system.
62671971|NCT03787160|ACTIVE_COMPARATOR|CDH Group|10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
62671972|NCT03787160|OTHER|Control Group|10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).
62671973|NCT03896360|EXPERIMENTAL|Food order behavioral intervention plus standard care|Subjects will receive standard nutrition counseling and additional carbohydrate-last food order behavioral counseling.
62671974|NCT03896360|OTHER|Standard care|Subjects will receive standard nutrition counseling.
62671975|NCT05033535|EXPERIMENTAL|S086|
62671976|NCT05033535|PLACEBO_COMPARATOR|Olmesartan medoxomil|S086 PLCEBO
62671977|NCT01578720|OTHER|IVT injection once every 8 weeks after 3 initial monthly doses|"Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).~Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit."
62300674|NCT03420638|OTHER|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
61915724|NCT01763242|NO_INTERVENTION|Control|Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy
62300675|NCT01967225|EXPERIMENTAL|Tedizolid Phosphate (Sivextro, BAY1192631)|Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
62671978|NCT03406052|EXPERIMENTAL|Smartphone-Assisted MB-CBT|Online intervention accessed through smartphone or online accessed computer comprised of Mindfulness-Based Cognitive Behaviour content
62671979|NCT03406052|NO_INTERVENTION|Control|Standard psychiatric care
61915725|NCT04716556|EXPERIMENTAL|Standard Therapy+Convalescent Plasma|Patients will receive standard therapy + 200-300 ml of convalescent plasma for a maximum of 3 times in 5 days, according to clinical conditions.
61915726|NCT04716556|NO_INTERVENTION|Standard Therapy|Patients will receive standard therapy for the treatment of SARS-CoV2 infection, according to AIFA indications
62300676|NCT01967225|ACTIVE_COMPARATOR|Linezolid|Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))
62300677|NCT00278629|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation in CIDP|Autologous hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide 200 mg/kg/intravenously(IV), rATG(thymoglobulin) 5.5 mg/kg/IV and rituximab 1000mg/IV.
62300678|NCT04457440|ACTIVE_COMPARATOR|Intensive Lifestyle Intervention (ILI)|The ILI will consist of 8 group-based 90-min sessions focusing on modifying dietary and exercise habits with the goal of reducing 450kcal of daily calories and increasing physical activity to 150 minutes of exercise per week.
62300679|NCT04457440|EXPERIMENTAL|ILI enhanced with cognitive behavioral sleep intervention|The ILI+Sleep intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session.
61915727|NCT04002570||GROUP I/GROUP I bis|20 breast cancer patients who performed radiotherapy treatment
62300680|NCT03268798|EXPERIMENTAL|Wrist extension training|
62300681|NCT05207150|ACTIVE_COMPARATOR|LINQ II/Apple Watch Series 6|
62300682|NCT05207150|ACTIVE_COMPARATOR|LINQII/SkyLabs CART-I ring|
62300683|NCT05087030|EXPERIMENTAL|RGB-14-P (Main period)|Randomized participants will receive subcutaneous (SC) injection of RGB-14-P, on Day 1 of Treatment periods 1 and 2.
62300684|NCT05087030|ACTIVE_COMPARATOR|Prolia® (Main period)|Randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment periods 1 and 2.
62300685|NCT05087030|EXPERIMENTAL|RGB-14-P (Transition period)|Re-randomized participants will receive SC injection of RGB-14-P, on Day 1 of Treatment period 3.
62470521|NCT06202794|EXPERIMENTAL|Experimental group|TENS will be initiated one hour after surgery. A portable device with two channels will be used (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil). This device will deliver a biphasic, asymmetrical, balanced current, with a frequency of 100 Hz and pulse duration of 100 μs. Four electrodes (5x5 cm) will be positioned on the left and right sides of the spine according to the indicated instructions. The assessor will increase the intensity to promote a strong tingling sensation, reaching the patient's maximum tolerance level without causing discomfort. Emission will be applied in a single session of one continuous hour and the patients will be informed that the sensation may decrease over time. Every 10 minutes, the assessor will ask the patient if there is habituation to the current and will increase the intensity if necessary. TENS will be administered only once for one hour.
62671980|NCT02738697|EXPERIMENTAL|Adjuvant chemotherapy|8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
62671981|NCT02738697|OTHER|Follow-up|Routine follow-up were performed instead of adjuvant chemotherapy
62671982|NCT00581789|EXPERIMENTAL|1|Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
62671983|NCT00362323|EXPERIMENTAL|1|
62671984|NCT00362323|ACTIVE_COMPARATOR|2|
61915728|NCT04002570||GROUP II|maximum 10 patients who performed radiotherapy and chemotherapy and/or immunotherapy and/or neo-adjuvant hormone therapy or/and adjuvant immunotherapy/hormone therapy.
62110222|NCT06413940|EXPERIMENTAL|Combined Exercise Group|Subjects in the combined exercise group will receive myofunctional therapy ,inspiratory muscle training and aerobic training
62110223|NCT03353467|EXPERIMENTAL|Group in endoscopic surgery|Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
62110224|NCT03353467|ACTIVE_COMPARATOR|Group in IMRT|Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.
62300686|NCT05087030|ACTIVE_COMPARATOR|Prolia® (Transition period)|Re-randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment period 3.
62300687|NCT05087030|EXPERIMENTAL|RGB-14-P (Continued till transition period)|Randomized participants will continue to receive SC injection of RGB-14-P from the main period till Day 1 of Treatment period 3.
62300688|NCT01241539|EXPERIMENTAL|Dabigatran etexilate 110 mg|Capsule, oral
61915729|NCT04002570||CONTROLS GROUP|healthy women with +/- 5 years compared to breast cancer patients age
62110225|NCT04546997||Patients with ocular blunt trauma|Patients with previous ocular blunt trauma in one eye.
62110226|NCT04546997||Control Group|Healthy fellow eyes without actual and previous ocular trauma
62671985|NCT02783989|ACTIVE_COMPARATOR|White wine|Two glasses of a market white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14 g in women). It is estimated that wine will contain about 8-9 mg/l of tyrosol. Therefore the dose of tyrosol ingested in two glasses would be 2-2.5 mg (1-1.25 mg in women).
62671986|NCT02783989|EXPERIMENTAL|White wine plus tyrosol capsules|Two glasses of white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14g in women), in combination with capsules of 25 mg of TYR (each one to be ingested with a glass of wine), two capsules along the day for men (at lunch and at dinner) and one for woman (at lunch).
62671987|NCT02783989|NO_INTERVENTION|Water|Drinking water along with meals
62671988|NCT04588363||SARS-CoV-2 positive children|"Individuals less than 21 years of age who fulfill one or more of the following criteria:~* SARS-CoV-2 detection from a respiratory specimen, and/or~* Meets criteria for MIS-C, and/or~* Meets criteria for MIS-C, except has involvement of only 1 organ system"
62300689|NCT01241539|EXPERIMENTAL|Dabigatran etexilate 75 mg|Capsule, oral
62300690|NCT01241539|EXPERIMENTAL|Dabigatran etexilate 150 mg|Capsule, oral
62300691|NCT03449888||St. Louis VA Healthcare System stress testing referrals|St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
62300692|NCT00543647|EXPERIMENTAL|1|
62300693|NCT00543647|PLACEBO_COMPARATOR|2|
62300694|NCT04237649|EXPERIMENTAL|Arm A|KAZ954
62300695|NCT04237649|EXPERIMENTAL|Arm B|KAZ954 + PDR001
62300696|NCT04237649|EXPERIMENTAL|Arm C|KAZ954 + NIR178
62300697|NCT04237649|EXPERIMENTAL|Arm D|KAZ954 + NZV930
62300698|NCT04535063|OTHER|severe pneumonia arm|patients with severe COVID19 pneumonia defined by: spontaneous breathing patients with respiratory failure requiring O2 nasal cannula more than 3 L/min or reservoir oxygen mask and SaO2 less than 95% or patients with critical pneumonia define by mechanical ventilation with less than 300 mmHg PaO2/FiO2 or shock or multi-organic dysfunction
62110227|NCT00525850|OTHER|1|high saturated fat diet
62110228|NCT00525850|OTHER|2|low calorie low saturated fat low trans fat high fiber diet
62300699|NCT02591615|ACTIVE_COMPARATOR|Arm A|"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
62671989|NCT04918797|EXPERIMENTAL|Study vaccine|SARS-COV2 vaccine
62671990|NCT05381168|EXPERIMENTAL|Calcium from fish bone|The volunteer will receive calcium from fish bone 4 capsules per day for 6 months.
62110229|NCT04940676|ACTIVE_COMPARATOR|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
62110230|NCT04940676|PLACEBO_COMPARATOR|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding of 5 minutes after breakfast and dinner for 7 days
62110231|NCT04461418|ACTIVE_COMPARATOR|Dexamethasone|Dose starting at 4 mg daily (for patients randomized to the Dexamethasone arm).
62671991|NCT05381168|ACTIVE_COMPARATOR|Calcium carbonate|The volunteer will receive calcium carbonate 2 tablets per day for 6 months.
62671992|NCT01907178||Postoperative pain management|The postoperative pain level will be assessed during hospitalization and at home, in patients undergoing total knee replacement
62671993|NCT02874352|OTHER|intensive care patients|intensive care patients with tracheostomy/ high resolution impedance manometry with Automated Impedance Manometry analysis
61915730|NCT02146144|NO_INTERVENTION|no peeling|where the ILM peeling will not be made
61915731|NCT02146144|ACTIVE_COMPARATOR|active peeling|where the ILM peeling will be made
62110232|NCT04461418|ACTIVE_COMPARATOR|Prednisone|Dose starting at 25 mg/day (a calculation of equipotent steroid equivalencies will be used).
62671994|NCT02874352|OTHER|healthy volunteers|control group with healthy volunteers/ high resolution impedance manometry with Automated Impedance Manometry analysis
61915732|NCT04184986||inflammatory bowel disease|100-150 pts with dg. inflammatory bowel disease
61915733|NCT04184986||unspecific GI symptoms|100-150 pts unspecific GI symptoms
61915734|NCT01173887|ACTIVE_COMPARATOR|mLSG15|
61915735|NCT01173887|EXPERIMENTAL|mLSG15 + KW-0761|
61915736|NCT04520269|EXPERIMENTAL|Patient with (cfDNA) 1q21.3 copy number amplification|The phase Ib segment will be carried out in a standard 3+3 design. In the phase II portion, 2 parallel cohorts will be enrolled (Cohort A: 1q21.3 amplified breast cancers, Cohort B: 1q21.3 amplified other solid tumors).
61915737|NCT01673347|EXPERIMENTAL|MENISCAL ALLOGRAFT|The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe.
61915738|NCT00259129|EXPERIMENTAL|Arm 1|
61915739|NCT02480140|EXPERIMENTAL|Self-regulated constraint-induced movement therapy|Self-regulated constraint-induced movement therapy (SR-CIMT) - participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days) (CIMT) (the same CIMT protocol as in the CIMT group described under 'comparator/control treatment'); participants were taught using the self-regulation (SR) strategy to relearn the tasks; SR strategy involved participants self reflecting on their abilities and deficits in performing the tasks, identifying problems and solutions in achieving the most independence in the tasks, and then actually carrying out the tasks.
61915740|NCT02480140|ACTIVE_COMPARATOR|Constraint-induced movement therapy|In the constraint-induced movement therapy group (CIMT), participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days); therapist provided demonstration on the adapted task performance with one arm (the side of participants' hemiplegic arm), and participants to practice the tasks with the unrestrained hemiplegic arm under supervision.
62671995|NCT00862901|EXPERIMENTAL|1|100 J / cm2 over 24 hours
62671996|NCT00862901|EXPERIMENTAL|2|200 J / cm2 over 24 hours
61915741|NCT02480140|ACTIVE_COMPARATOR|Conventional occupational therapy|It involved therapist to demonstrate the adapted task performance followed by patient's practice under supervision.
62671997|NCT00862901|EXPERIMENTAL|3|400 J / cm2 over 24 hours
62671998|NCT00862901|EXPERIMENTAL|4|800 J / cm2 over 24 hours
61915742|NCT01935427||Volunteer test subjects|Healthy volunteer with no cardiovascular disease
61915743|NCT02324127|EXPERIMENTAL|liver cancer|Detect plasma Hsp90α concentration of liver cancer patients
61915744|NCT00991068|EXPERIMENTAL|Synera|Synera topical patch
61915745|NCT06401187|ACTIVE_COMPARATOR|Co-Cr conventional technique cast bar attachments|conventional technique cast bar attachments
61915746|NCT06401187|EXPERIMENTAL|Co-Cr CAD/CAM milled bar attachments|Co-Cr CAD/CAM milled bar attachments
61915747|NCT06401187|EXPERIMENTAL|Co-Cr CAD/CAM 3D bar attachments|Co-Cr CAD/CAM 3D bar attachments
61915748|NCT01915329|EXPERIMENTAL|Verum-RSS|RSS Stimulation with high frequency electric pulses
61915749|NCT01915329|SHAM_COMPARATOR|Sham-RSS|Sham RSS Stimulation (no pulses are transmitted)
61915750|NCT05553743||Main Study|The purpose of this project is to collect and store breast milk samples and health information about moms and their babies in a Human Milk Biorepository at UCSD. Through these studies, researchers hope to understand more about the benefits of breast milk, and how it prevents or treats child health problems.
61915751|NCT05553743||Sub-study 100: COVID-19 Exposure|The purpose of this substudy is to learn how exposures to COVID-19 and breastfeeding may affect the development of the child. Women who contact the UCSD Human Milk Biorepository will be screened for possible COVID-19 infection or exposure. Women will be eligible to enroll in the COVID-19 sub-study if they are confirmed positive, are presumptive positive, are symptomatic but not tested, or have confirmed exposure but are asymptomatic.
62671999|NCT01197274||Mite-sensitized person|
62672000|NCT02726269|ACTIVE_COMPARATOR|CLA (Clarithro+Lanso+Amoxi)|Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
62672001|NCT02726269|EXPERIMENTAL|PLA (Panto+Levoflox+Azithro)|Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.
62672002|NCT01135056|ACTIVE_COMPARATOR|Sorafenib, Multikinase Inhibitor, Tablet|"Sorafenib tosylate:~Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.~Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma."
62672003|NCT01135056|ACTIVE_COMPARATOR|SIR-Spheres, Microspheres, Device|"SIR-Spheres:~SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.~SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver."
61915752|NCT05553743||Sub-study 101: Antibiotic Exposure|The purpose of this substudy is to learn more about maternal use of antibiotics in women who do or do not breastfeed, and how this may influence infant and child health. Women who contact or are referred to the UCSD Human Milk Biorepository will be screened to participate in the Antibiotic Exposure sub-study. Women will be eligible to enroll in the Antibiotic Exposure sub-study if they are 18 years of age or older, have a singleton infant who is \<3 months of age at the time of recruitment, and agree to all requirements of the study.
61915753|NCT05113303||navigation assisted knee revision surgery|
61915754|NCT05113303||manual procedure|
62110233|NCT05850130|EXPERIMENTAL|Arm A|6 weeks of acupuncture once a week. At week 7, patients will be assessed for the primary endpoint Then ,the patient may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist.
62110234|NCT05850130|ACTIVE_COMPARATOR|Arm B|"6 weeks without acupuncture. At week 7, patients will be assessed for the primary endpoint.~Then, the patient will receive or not acupuncture intervention:~* A mandatory acupuncture once a week if the patient' NRS global score at week 7 is ≥ 4 .~* No acupuncture if the patient' NRS global score at week 7 is \<4,"
62110235|NCT00917358|EXPERIMENTAL|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
61915755|NCT03025789|EXPERIMENTAL|Inpatients|Participants received fexinidazole orally for 10 days as inpatients (at the hospital)
61915756|NCT03025789|EXPERIMENTAL|Outpatients|Participants received fexinidazole orally for 10 days as outpatients (at home)
61915757|NCT04168710|EXPERIMENTAL|erector spinae plane block (ESP block) with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
61915758|NCT04168710|PLACEBO_COMPARATOR|ESP block with saline/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
61915759|NCT00821444|ACTIVE_COMPARATOR|Geodon fed|Commercial Geodon (ziprasidone) capsules given with food
61915760|NCT00821444|EXPERIMENTAL|B16 Fasted|Experimental reduced food effect formulation given without food
61915761|NCT00821444|EXPERIMENTAL|B16 Fed|Experimental reduced food effect formulation given with food
62110236|NCT00917358|NO_INTERVENTION|Observation|Retrospectively chart review of dialysis patients with acute hepatitis C who did not receive any intervention
62110237|NCT01137903|OTHER|Patients undergoing medical treatment|"Antibiotic treatment within 90 days with:~Ciprofloxacin Amoxicillin /Clavulanic acid. Trimethoprim /Sulfamethoxazole."
62110238|NCT01137903|OTHER|Patients undergoing surgical treatment|Conservative surgical Minor amputation 7 days antibiotic after surgical
62110239|NCT04167917|EXPERIMENTAL|NTX-301|
62110240|NCT05827354||Family Members|Family members of patients admitted to the ICU between the 1st of May 2025 and the 30th of May 2023, who survived ICU stay and are still alive up to 6 months after hospital discharge.
62110241|NCT06081829|EXPERIMENTAL|Open-Label Ivosidenib|250 mg Tablets
62110242|NCT04683159|NO_INTERVENTION|Control|No intervention, only routine pre-operative drops
62110243|NCT04683159|EXPERIMENTAL|Brimonidine 0.15%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.15% in the operating eye
62110244|NCT04683159|EXPERIMENTAL|Brimonidine 0.025%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.025% in the operating eye
62110245|NCT00862680||Diagnostic (4D PET/CT)|Participants undergo 4D PET/CT scan over up to 12 minutes.
62110246|NCT04408274|EXPERIMENTAL|Computerized Tests|
62110247|NCT04408274|PLACEBO_COMPARATOR|Placebo Control|
62110248|NCT05836935|EXPERIMENTAL|Participants|
62110249|NCT04601467|EXPERIMENTAL|AZD5718|Patients will receive once daily oral dose of AZD5718 for 12 months
62110250|NCT04601467|PLACEBO_COMPARATOR|Placebo|Patients will receive once daily oral dose of placebo matched to AZD5718 for 12 months
62110251|NCT01833832|EXPERIMENTAL|Cytoreductive surgery followed by HIPEC|Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
62110252|NCT01376141||Subjects prescribed IMIGRAN|Subjects with migraine disorders prescribed IMIGRAN during study period
62110253|NCT01598948|EXPERIMENTAL|Mipomersen|Patients randomized to this arm will receive mipomersen 200 mg weekly
62110254|NCT01598948|NO_INTERVENTION|Control|patients randomized to this arm will receive no additional drug
62470522|NCT06202794|SHAM_COMPARATOR|Control group|Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
62470523|NCT03796949||threatened preterm birth|Women with either preterm labor or preterm prelabor rupture of the membranes. Blood samples taken at time of inclusion in the study.
62470524|NCT03796949||Controls|Women with normal pregnancies. Blood samples taken at time of inclusion in the study, either prelabor (during pregnancy) or during active phase of labor.
62470525|NCT00987103|EXPERIMENTAL|Sublingual - Rectal - Oral|Administration order of rank: Sublingual - Rectal - Oral
61915762|NCT00813176|ACTIVE_COMPARATOR|Double Lumen Endotracheal Tube|We used a device called a double lumen tube ( DLT Broncho-Cath®). It is a bifurcated endotracheal tube designed to independently collapse the operated lung.
62110255|NCT06368609|OTHER|RDT (Rapid Diagnostic Test) arm|"The sera will be selected from the database of the Tropica biobank, based on the given exclusion/inclusion criteria.~The samples will be tested after thawing shortly before the procedures. Each serum sample will be used for running the two RDTs (IgG and IgG4). Two independent readers will report the test results blinded from each other. In case of discrepancies, a third reader will be involved."
62300700|NCT02591615|ACTIVE_COMPARATOR|Arm B|"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles~Patients with CR, PR, or SD by irRC will then be treated with:~For Squamous Carcinoma:~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
62300701|NCT00227357||Buprenorphine|Study patients receiving buprenorphine treatment
62300702|NCT00227357||Comparison|Study patients receiving methadone or no agonist treatment
62672004|NCT02587364|EXPERIMENTAL|Gemcabene 50 mg|Gemcabene 50 mg
62110256|NCT01491698|EXPERIMENTAL|pts undergoing Roux-en-Y pouch reconstruction (RYP)|This is a pilot randomized controlled trial comparing changes in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
62110257|NCT01491698|ACTIVE_COMPARATOR|pts undergoing conventional Roux-en-Y reconstruction (RYC)|This is a pilot randomized controlled trial comparing change in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
62110258|NCT02983370|EXPERIMENTAL|Blind volunteer|Blind volunteers will be implanted with our existing vision neuroprosthetic system, which utilizes a FDA cleared microelectrode array, using a minicraniotomy. The array will be implanted near the occipital pole or in extra striate areas. The investigators will collect descriptive feedback regarding thresholds, evoked perceptions and stimulation parameters leading to recognizable patterns.
62300703|NCT00811629||control group|
62300704|NCT01999673|EXPERIMENTAL|bavituximab plus docetaxel|Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
62300705|NCT01999673|PLACEBO_COMPARATOR|placebo plus docetaxel|Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
62300706|NCT06188832|EXPERIMENTAL|Fiber Supplementation|The active powder contained 1g glucomannan, 1g inulin, and 3g psyllium per bag.
62300707|NCT06188832|PLACEBO_COMPARATOR|Placebo group|The placebo powder composed of maltodextrin and rice flour, carefully selected to mimic the texture and volume of the active powder without providing any active dietary fiber
62300708|NCT05505422|EXPERIMENTAL|On demand ECMO (study group)|
62672005|NCT02587364|EXPERIMENTAL|Gemcabene 150 mg|Gemcabene 150 mg
61915763|NCT00813176|ACTIVE_COMPARATOR|Arndt Bronchial Blocker|We used a device called a bronchial blocker (9 Fr Arndt® blocker) along with a standard single-lumen tracheal tube (8.0-9.0 mm ID). The Arndt bronchial blocker is a single device, with a distal balloon that is passed thru the single lumen endotracheal once the patient is intubated. The Arndt bronchial blocker is designed to collapse the operated lung.
61915764|NCT01295268|ACTIVE_COMPARATOR|Emu Oil|
61915765|NCT01295268|PLACEBO_COMPARATOR|inert oil|
61915766|NCT01309893|EXPERIMENTAL|Investigational Lens|Bausch \& Lomb investigational silicone hydrogel contact lens for 1 week; then issued Air Optix Aqua Lens for 1 week.
61915767|NCT01309893|ACTIVE_COMPARATOR|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens for 1 week; then issued Investigational Lens for 1 week.
61915768|NCT01723696|PLACEBO_COMPARATOR|placebo tablet+prenatal vitamin|A daily placebo tablet
61915769|NCT01723696|ACTIVE_COMPARATOR|Vitamin C +prenatal vitamin|500 mg vitamin C /day
61915770|NCT02963844|EXPERIMENTAL|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
61915771|NCT02963844|SHAM_COMPARATOR|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
61915772|NCT06345196|EXPERIMENTAL|Motivational Interviewing|Motivational interviewing will be conducted in four sessions and the session duration will be maximum 40 minutes. The session will be conducted individually and online once a week. For the individual interview, the appropriate day and time will be determined with the individuals with diabetes and the researcher before the first session and the sessions will continue on the same day and time every week. The researcher will remind the participant about the time of the session by calling the participant by phone one day before each session. Motivational interview sessions will be held online on the Whatsapp platform.
61915773|NCT06345196|NO_INTERVENTION|Control|"The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. The patients were followed for four weeks. Before the study, data collection tools were applied to the patients. Again, after the study started and the study ended, all other data collection tools were applied, except the Patient Information Form."
61915774|NCT01677390|EXPERIMENTAL|Arm 1|SGN-75, everolimus
61915775|NCT04719832|EXPERIMENTAL|GSK3511294|Participants received a 100 milligram (mg) dose of GSK3511294 SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma SOC treatment throughout the study.
62110259|NCT00686517|EXPERIMENTAL|PEG-IFN 24|pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
62300709|NCT05505422|ACTIVE_COMPARATOR|Routine ECMO (control group)|
61915776|NCT04719832|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous (SC) injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.
61915777|NCT05629000||Carotid artery stenosis|patient with carotid artery stenosis
61915778|NCT04284150|EXPERIMENTAL|dexmedetomidine or Midazola treat supraventricular tachycardia|Comparison of efficacy of dexmedetomidine and Midazolam in the treatment of SVT
61915779|NCT05324865|EXPERIMENTAL|Experimental Group|Information about the experimental group was given. Progressive muscle relaxation (PMR) for 6 weeks to patients with schizophrenia will be heard. At the end of 6 weeks, psychiatric evaluation and mental well-being scale will be used.
61915780|NCT05324865|NO_INTERVENTION|Control Group|Patient identification form, psychological evaluation form and mental health form were filled in for the control group. At the end of 6 weeks, the psychological evaluation form and the mental well-being form were filled again without any intervention.
62110260|NCT00686517|EXPERIMENTAL|PEG-IFN 12|pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
62110261|NCT00686517|EXPERIMENTAL|PEG-IFN + RVB 12|pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
61915781|NCT00124839|OTHER|1|Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
61915782|NCT00124839|OTHER|2|Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
61915783|NCT00124839|OTHER|3|Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
61915784|NCT00124839|OTHER|4|Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)
61915785|NCT06054204|EXPERIMENTAL|lateral bony window in maxillary sinus|a displaced root in maxillary sinus which will be removed through a rectangular bony window will be done on the lateral wall of sinus using piezo-electric device after elevation of a full thickness mucoperiosteal flap, then the bony window will be repositioned, and the flap will be sutured.
61915786|NCT01254955||organ transplant patients|
61915787|NCT01254955||healthy controls|
61915788|NCT03455907||Patients|patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
61915789|NCT04013399|EXPERIMENTAL|Continuous Positive Airway Pressure|Women will receive Continuous Positive Airway Pressure (CPAP) for one month.
61915790|NCT04013399|NO_INTERVENTION|Control|Women will receive standard prenatal care.
61915791|NCT00912561|NO_INTERVENTION|Sedentary|patients who train after an 8 week observational period
61915792|NCT00912561|ACTIVE_COMPARATOR|patients who train immediately after enrollment|patients who train immediately after enrollment
61915793|NCT04368247||Nevi undergoing biopsy per SOC|Subjects with Nevi who will as part of their standard of care, will undergo biopsy.
61915794|NCT06371183|OTHER|Patients with lower GI manifestations|Patients with lower GI manifestations will undergo total colonoscopy with biopsy
61915795|NCT00540371||Port wine stain Birthmark|Port wine stain Birthmark
61915796|NCT03754231|EXPERIMENTAL|Aingeal|All recruited patients will wear the Aingeal device as a form of heart rate monitoring and respiratory rate monitoring in a paediatric outpatient clinic setting.
61915797|NCT04845529|EXPERIMENTAL|1 tDCS Parietal|Anodal tDCS applied to the right inferior parietal cortex
61915798|NCT04845529|EXPERIMENTAL|2 tDCS Frontal|Anodal tDCS applied to the medial frontal cortex
62110262|NCT04322643|EXPERIMENTAL|CPI therapy|Patients will be treated with CPI therapy for at least 24 weeks (+/- 4 weeks) as per standard of care (SOC), at which time those with a tumor burden reduction of 10% or greater will suspend CPI therapy.
62300710|NCT03069573||Eosinophilic Esophagitis - EoE|Diagnosis of pediatric EoE under current guidelines.
62300711|NCT03069573||Gastroesophageal reflux disease - GERD|Diagnosis of pediatric GERD under current guidelines.
62110263|NCT00641381|EXPERIMENTAL|Treatment (high-dose chemotherapy, anti-HIV therapy)|Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
62110264|NCT05593822|OTHER|patient with STEMI|
62300712|NCT03069573||Control|Exclusion diagnosis of EoE or GERD, with non specific gastrointestinal general complaints.
62110265|NCT03854006|ACTIVE_COMPARATOR|Freeze cycle: 240 s - TTI <75 s or 2x240 s - >75 s|"In the first group freeze duration is 240s if TTI (time-to-isolation) is \< 75 s. In case of TTI\>75s a 240s bonus freeze is applied.~If no TTI could be documented, a single 240 s freeze cycle is applied in this group in case of balloon temperature -40°C (degrees Celsius) after 60 s."
62110266|NCT03854006|ACTIVE_COMPARATOR|Freeze cycle: TTI+120 s|In the second group freeze duration is TTI (time-to-isolation) +120 s. If no TTI could be documented, a single 180 s freeze cycle is applied in this group in case of balloon temperature -40 °C after 60 s.
62110267|NCT06353243|EXPERIMENTAL|Bilateral alternating Stimulation|positive touch intervention provided by parent to infant using alternating stimulation
62110268|NCT04073732||family physician team|Family physician team in four regions (Beijing, Shanghai, Hangzhou and Xia'men), including general practitioners, nurses and public health personnel.
62110269|NCT04442984|ACTIVE_COMPARATOR|FOLFOX6|5FU 400mg/m2 iv bolus d1, 5-FU 2400 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
62300713|NCT03815890|EXPERIMENTAL|1A; LumB|Nivolumab
62300714|NCT03815890|EXPERIMENTAL|1B; TNBC|Nivolumab
62470526|NCT00987103|EXPERIMENTAL|Sublingual - Oral - Rectal|Administration order of rank: Sublingual - Oral - Rectal
62300715|NCT03815890|EXPERIMENTAL|2A; LUMB|Nivolumab and ipilimumab
62300716|NCT03815890|EXPERIMENTAL|2B; TNBC|Nivolumab and ipilimumab
62300717|NCT03815890|EXPERIMENTAL|3B; TNBC, High TIL|Nivolumab and ipilimumab
62300718|NCT06488781|ACTIVE_COMPARATOR|Prophylactic antibiotics|Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
62300719|NCT06488781|PLACEBO_COMPARATOR|Placebo|Placebos, similar in appearance, in place of azithromycin and cefazolin
62300720|NCT06152887|ACTIVE_COMPARATOR|Active tDCs|Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. An anodal electrode is placed above the primary motor cortex, M1, while a cathode is placed above the contralateral supraorbital area.
62300721|NCT06152887|SHAM_COMPARATOR|Sham tDCS|Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 30 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
62300722|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
62300723|NCT03794986|EXPERIMENTAL|Motivational Interviewing|Sexual and gender minority males who are sexual abuse survivors.
62110270|NCT04442984|EXPERIMENTAL|mFOLFIRINOX|Irinotecan 180mg/m2 d1, 5FU 250mg/m2 iv bolus d1, 5-FU 2200 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
62110271|NCT03202849|EXPERIMENTAL|Vitamin D and A Supplementation|Participants receive a single dose of vitamin D and a single dose of vitamin A prior to HSCT.
62110272|NCT03202849|ACTIVE_COMPARATOR|Vitamin D Supplementation with Placebo|Participants receive a single dose of vitamin D and a single dose of placebo prior to HSCT.
62110273|NCT03673943|EXPERIMENTAL|PET/CT imaging with 64Cu-DOTATATE|64Cu-DOTATATE is an investigational radioactive drug that binds to somatostatin receptors on neuroendocrine cancer cells.
62110274|NCT05633199|EXPERIMENTAL|cytoreduction surgery followed by chemotherapy|
62110275|NCT05633199|NO_INTERVENTION|chemotherapy alone|
62672006|NCT02587364|EXPERIMENTAL|Gemcabene 450 mg|Gemcabene 450 mg
62672007|NCT02587364|EXPERIMENTAL|Gemcabene 750/600 mg|Gemcabene 750/600 mg
62300724|NCT03794986|ACTIVE_COMPARATOR|MI with trauma-informed SGM affirmative care|MI w/trauma-informed SGM affirmative care
62300725|NCT05718362|EXPERIMENTAL|Intervention Group|Ayres Sensory Integration Therapy and Home Program
62300726|NCT05718362|ACTIVE_COMPARATOR|Control Group|Home Program
62110276|NCT02511639|EXPERIMENTAL|Arm A: Everolimus & Aromatase inhibitors|Everolimus 10 mg po daily + Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
62300727|NCT00805207|EXPERIMENTAL|Progesterone - PCOS|Women with obesity and polycystic ovary syndrome
62300728|NCT00805207|EXPERIMENTAL|Testosterone - premenopausal women|Healthy premenopausal women.
62300729|NCT00805207|EXPERIMENTAL|Continuous positive airway pressure|Women and men with obesity and obstructive sleep apnea
62300730|NCT00805207|EXPERIMENTAL|Glucocorticoid|Lean and obese healthy women, and obese men
62300731|NCT00805207|EXPERIMENTAL|Estrogen|Postmenopausal women
62470527|NCT00987103|EXPERIMENTAL|Oral - Sublingual - Rectal|Administration order of rank: Oral - Sublingual - Rectal
62110277|NCT02511639|ACTIVE_COMPARATOR|Arm B: Aromatase inhibitors|Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
62110278|NCT03844854|NO_INTERVENTION|Control Group|Without intervention.
62110279|NCT03844854|EXPERIMENTAL|Research Group|With providing stabilization occlusal splint and manual therapy.
62300732|NCT00805207|OTHER|control|Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits
62300733|NCT00805207|NO_INTERVENTION|control - baseline testing only|Healthy men and women
62672008|NCT02587364|EXPERIMENTAL|Gemcabene 900 mg|Gemcabene 900 mg
62110280|NCT06269536|EXPERIMENTAL|Heart-rate variability (HRV) biofeedback intervention + standard of care|Deep paced breathing with the HRV monitoring performed three times a day for seven minutes during three months with standard of care.
62300734|NCT00805207|EXPERIMENTAL|Progesterone - Postmenopausal women|Postmenopausal women
62672009|NCT02587364|PLACEBO_COMPARATOR|Placebo|Placebo
62672010|NCT00474968||Arm 1 - Experimental|e2 Cell Collector \[SoftPAP(R)\]
62672011|NCT00474968||Arm 2 - Control|Brush/spatula
62672012|NCT03865680|EXPERIMENTAL|MI varnish|MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
62672013|NCT03865680|ACTIVE_COMPARATOR|Duraphat Fluoride varnish|Duraphat Fluoride: varnish 5% sodium fluoride varnish (Colgate, New York, N.Y.). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
62672014|NCT03197688||Notapplicable|Not applicable as non-interventional study
62470528|NCT00987103|EXPERIMENTAL|Oral - Rectal - Sublingual|Administration order of rank: Oral - Rectal - Sublingual
62470529|NCT00987103|EXPERIMENTAL|Rectal - Sublingual - Oral|Administration order of rank: Rectal - Sublingual - Oral
62672015|NCT02965976|EXPERIMENTAL|Arm I (botulinum toxin type A, esophagectomy)|Patients receive botulinum toxin type A injection IM while undergoing standard minimally invasive esophagectomy.
62300735|NCT00805207|EXPERIMENTAL|Testosterone - Postmenopausal women|Postmenopausal women
62470530|NCT00987103|EXPERIMENTAL|Rectal - Oral - Sublingual|Administration order of rank: Rectal - Oral - Sublingual
62300736|NCT00824564|EXPERIMENTAL|A|Tranexamic Acid plus standard of care
62470531|NCT02042365||ERAS (Enhanced recovery after surgery)|This observational study evaluates the feasibility of ERAS pathway in six French departments of surgery located at Clermont-Ferrand, Bordeaux, Montpellier, Amiens, Strasbourg and Aurillac
62470532|NCT03037697|EXPERIMENTAL|TheraTogs Arm|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day, to allow the children to become acclimated to the system+ Traditional treatment 3 months
62672016|NCT02965976|ACTIVE_COMPARATOR|Arm II (esophagectomy)|Patients undergo standard minimally invasive esophagectomy.
62300737|NCT00824564|OTHER|B|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss.
62300738|NCT05244772|EXPERIMENTAL|Remote monitoring|At discharge, patients in the remote monitoring group receive verbal and paper care- and recovery instructions from a day care ward nurse and in adittion they will have a monitoring application installed on theirpersonal smartphone. Once they are back home, they can start recording pain and nausea and ask questions about their recovery with the application and report back the anaesthesia backoffice.
62300739|NCT05244772|NO_INTERVENTION|Standard care|At discharge, patients in the standard care group receive verbal and paper care- and recovery instructions from a day care ward nurse.
62300740|NCT01449825||Prescriber compliance group|Adult (18+ years) new users of pazopanib with an indication of RCC evaluated for prescriber compliance
62300741|NCT01449825||Incidence of liver chemistry test (LCT) elevation group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib in monotherapy who have a baseline LCT evaluated for LCT elevations
62672017|NCT01622335|PLACEBO_COMPARATOR|General anesthesia with oxygen|General anesthesia and Air
62672018|NCT01622335|EXPERIMENTAL|nitrous oxide and general anesthesia|General anesthesia with Nitrous Oxide
62672019|NCT05025917|EXPERIMENTAL|Shatavari|1000 mg per day shatavari root powder (2 x 500 mg opaque capsules; equivalent to 26,500 mg fresh weight shatavari). Ingested in the morning, daily for 6 weeks.
62672020|NCT05025917|PLACEBO_COMPARATOR|Placebo|1000 mg per day magnesium stearate powder (2 x 500 mg opaque capsules). Ingested in the morning, daily for 6 weeks.
62672021|NCT04785807|EXPERIMENTAL|Evaluation arm|
62672022|NCT05451888|EXPERIMENTAL|Celestial Floatation Pool|
62672023|NCT05451888|EXPERIMENTAL|Dead Sea Salt Pool|
62672024|NCT05451888|ACTIVE_COMPARATOR|Balneotherapy Control Pool|
62672025|NCT04199039|EXPERIMENTAL|ET fixation with ET holder|ET fixation of the patients in the study group was performed with an ET holder when they arrived at the CVS ICU
62110281|NCT06269536|NO_INTERVENTION|Standard of care|Gemcitabine 1000 mg/m2 + Cisplatin 70 mg/m2 day 1 (new course day 22) or Methotrexate 30 mg/m2 day 1, Doxorubicin 30 mg/m2 day 2, Vinblastine 3 mg/m2 day 2, Cisplatin 70 mg/m2 day 2 with Pegfilgrastim 6 mg s.c. day 4 (new course day 15) up to 4 courses followed by radical cystectomy or irradiation with cisplatin 70 mg/m2 weekly.
62110282|NCT00320489|EXPERIMENTAL|Olanzapine Pamoate Depot|Olanzapine pamoate depot
62300742|NCT01449825||Incidence of drug induced liver injury (DILI) cases group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of LCT elevations consistent with Hy's Law to evaluate for drug-induced liver injury
62110283|NCT00320489|ACTIVE_COMPARATOR|Olanzapine|Oral olanzapine
62110284|NCT02046616|EXPERIMENTAL|Tocilizumab Alone or Combined with Methotrexate or Other DMARD|All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
62300743|NCT01449825||Incidence of cases of ALF group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of ICD-9 codes indicative of possible ALF to evaluate for drug-induced liver injury
62672026|NCT04199039|NO_INTERVENTION|ET fixation with plaster|ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted.
62672027|NCT00919490|EXPERIMENTAL|Group 1|Single dose of 400 mg
62672028|NCT00919490|EXPERIMENTAL|Group 2|Single dose of 800 mg after safety evolution of Group I
62672029|NCT00919490|EXPERIMENTAL|Group 3|Single dose of 1200 mg after safety evolution of Group 2
62672030|NCT00919490|EXPERIMENTAL|Group 4|Single dose of 1600 mg after safety evolution of Group 3
62672031|NCT00919490|PLACEBO_COMPARATOR|Group 5|Single dose of placebo
62672032|NCT02269488|EXPERIMENTAL|MEDI3250|MEDI3250 Nasal spray
62300744|NCT03481530||Blinded|Continuing Glucose Monitoring System will be blinded
61915799|NCT04845529|SHAM_COMPARATOR|3 Sham|Sham tDCS (control, no stimulation delivered). Following a standard sham protocol, in this condition the tDCS will be active the first 30seconds and the last 30seconds of the session, but silent during the other 19minutes
61915800|NCT02502006|EXPERIMENTAL|High Dose|During each treatment phase, subjects will receive celecoxib (200 mg by mouth twice daily), naproxen (500 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
62672033|NCT06417307|EXPERIMENTAL|Supervised exercise training|Moderate intensity continuous cycling training.
62300745|NCT03481530||Unblinded|Continuing Glucose Monitoring System will be open. Participant can review results if they choose.
62300746|NCT03366389||Case|patients with irritable bowel syndrome
62672034|NCT06417307|EXPERIMENTAL|Control group|Recieve no intervention but only maintain daily lifestyle.
61915801|NCT02502006|EXPERIMENTAL|Low dose|During each treatment phase, subjects will receive celecoxib (100 mg by mouth twice daily), naproxen (250 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
61915802|NCT06209385|EXPERIMENTAL|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally quaque die (QD) for 21 days
61915803|NCT00976508|EXPERIMENTAL|1|
61915804|NCT01643980|EXPERIMENTAL|Vaginal micronized progesterone|200 mg vaginal route per day
61915805|NCT01643980|ACTIVE_COMPARATOR|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
61915806|NCT01216371|ACTIVE_COMPARATOR|Sunitinib|one year adjuvant treatment with sunitinib
61915807|NCT01216371|PLACEBO_COMPARATOR|Placebo|one year treatment with placebo
61915808|NCT04370483|EXPERIMENTAL|Treatment (leflunomide)|Patients receive leflunomide PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61915809|NCT04770077||Group S|Spray before intubation
62300747|NCT03366389||Control|Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.
62300748|NCT03672318|EXPERIMENTAL|CAR138 T cells|The first 3 subjects enrolled in the study will receive 5x10\^6 CAR138 T-cells/m\^2 via infusion. The number of cells for the infusion will be increased to 1x10\^7 CAR138 T-cells/m\^2 and then, 2.5x10\^7 CAR138 T-cells/m\^2, 5x10\^7 CAR138 T-cells/m\^2, 1x10\^8 CAR138 T-cells/m\^2 and 2x10\^8 CAR138 T-cells/m\^2 in subsequent cohorts of 3 subjects provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each subject to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another subject is allowed to enroll in the cohort.
62300749|NCT03792503|EXPERIMENTAL|Apatinib，Pemetrexe|Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
62672035|NCT02113566|PLACEBO_COMPARATOR|Placebo|2 capsules identical to comparator, 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
62672036|NCT02113566|ACTIVE_COMPARATOR|Ibuprofen|2oomg capsules (400 mg per dose), 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
62672037|NCT00291226|EXPERIMENTAL|Glycine|Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing \> 100 kg were limited to a total daily dose of 80 g daily. Glycine was dispensed under IND 33,515 (DCJ).
62300750|NCT01162525|EXPERIMENTAL|pTNS treatment|
62672038|NCT00291226|PLACEBO_COMPARATOR|Placebo Group|Placebo was dispensed as a proprietary formulations developed by Glytech, Inc, consisting of microencapsulated sucrose. Recommended administration of the sprinkles was to spoon them onto pudding or applesauce and swallow them with minimal chewing. Since earlier product testing by Glytech revealed that a few individuals did not like the somewhat granular texture of the sprinkles, subjects could switch to a second Glytech placebo formulation, consisting of proprietary pre-flavored sugar powders to be dissolved in 8 ounces of water.
62110285|NCT04749433|EXPERIMENTAL|Participants with diagnosis of ALS|Participants with a diagnosis of ALS will receive a single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
61915810|NCT04770077||Group C|Intubation directly
61915811|NCT05326724|EXPERIMENTAL|Acupuncture|
61915812|NCT01692847||RRT calls prior to IGS use|Patients who triggered ACT/RRT calls prior to the installation of the IGS (Intellivue Guardian System)
62110286|NCT04749433|EXPERIMENTAL|Healthy Participants without a diagnosis of ALS|Healthy participants (without a diagnosis of ALS) will receive a single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
62110287|NCT00219687|ACTIVE_COMPARATOR|1|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions only
62110288|NCT00219687|ACTIVE_COMPARATOR|2|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions and breaths
62110289|NCT03434392|ACTIVE_COMPARATOR|Healthy Controls|"Subjects with no pancreatic disease and no abdominal pain.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
62110290|NCT03434392|ACTIVE_COMPARATOR|Suspected CP|"Suspected Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
62110291|NCT03434392|ACTIVE_COMPARATOR|Definite CP|"Definite Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires.~A subset of these patients who undergo endotherapy as per clinical recommendation from clinical provider independent of this study will be followed for 6 months after their clinical intervention for repeat Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3 and questionnaires."
62110292|NCT03434392|ACTIVE_COMPARATOR|Sphincter of Oddi Dysfunction or Functional Dyspepsia|"Patients with Sphincter of Oddi Dysfunction Type 1 or Type 2, or who have a prior diagnosis of Functional Dyspepsia.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
62110293|NCT05237219|EXPERIMENTAL|Passive heating|Patients will be randomized to receive whole-body passive heating via 38°C natural thermal mineral water baths.
62300751|NCT03156530|EXPERIMENTAL|Auricular acupuncture|Stimulated with needles at three joint points of the lower limb, knee and ankle. Balance assessments will be performed prior to (initial) pacing, 20 minutes after the initiation of the pacing protocol (second evaluation) and after 5 minutes the final evaluation.
62300752|NCT03156530|PLACEBO_COMPARATOR|Control|Not receive stimulation.
62300753|NCT03394222|EXPERIMENTAL|Budesonide inhalation group|This group of participants were to receive 2mg/4ml of preoperative budesonide inhalation (Khartoum Road NORTH RYDE NSW 2113 Australia. AstraZeneca Pty Ltd) for 10 to 15min.
62300754|NCT03394222|PLACEBO_COMPARATOR|Normal saline inhalation group|This group of participants were to receive4ml of preoperative normal saline inhalation for 10 to 15min.
62300755|NCT05859854||Adult patients diagnosed treated with adjunctive cenobamate in Italy.|"Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy.~A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below"
61915813|NCT01692847||RRT calls during IGS use|Patients who triggered ACT/RRT calls after the installation of IGS. All patients on the study ward receive the same care in both groups. The only difference is the system used to collect vital signs and to inform the staff about patient deteriorations. In Group 2, the IGS (FDA approved and CE marked) is the vital signs collection and information system.
61915814|NCT02045329||Staphylococcus aureus nasal carriers|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus
61915815|NCT05780268|EXPERIMENTAL|LY3819253 plus SOC|"* LY3819253 7000 mg solution (10 vials of 20 mL solution containing 700 mg each); administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
61915816|NCT05780268|PLACEBO_COMPARATOR|Placebo plus SOC|"* Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
61915817|NCT03710018||A Patient who underwent open cavity BCS|Patients undergoing Open cavity Breast Conservative Surgery
62110294|NCT05237219|ACTIVE_COMPARATOR|Thermoneutral|Patients randomized to the comparator group will dip in thermoneutral natural thermal mineral water (30-32°C).
61915818|NCT03710018||B Patient who underwent close cavity BCS|Patients undergoing Close cavity Breast Conservative Surgery
62110295|NCT02246816|EXPERIMENTAL|All Subjects|Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
62110296|NCT02444013|ACTIVE_COMPARATOR|Folic acid|Oral folic acid (5 mg, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
62110297|NCT02444013|PLACEBO_COMPARATOR|Placebo|Oral placebo (1 tablet, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
62110298|NCT02079714||Questionnaire|All STREAM Study participants will be complete a series of computer adaptive testing (CAT) questions covering all core and exploratory domains, once written informed consent is obtained. Administration of these surveys will follow completion of all other follow-up activities related to the main METRC study in which they were originally enrolled. Identical surveys will be repeated at the 6 month study visit. At the final 12 month study visit, participants will complete the CAT survey for the six core domains, and will also complete a randomly assigned subset of items from the total item bank across these six core domains. At any visit, if the CAT cannot be administered, respondents will instead complete paper surveys of the short form for each domain.
62110299|NCT05662891|EXPERIMENTAL|blood flow restriction + Nordic hamstring exercise|
62110300|NCT05662891|EXPERIMENTAL|Nordic hamstring exercise|
62110301|NCT02590913|EXPERIMENTAL|group fructose|Volunteer was randomized into either group fructose or glucose
62110302|NCT02590913|EXPERIMENTAL|group glucose|After one-week washout period, volunteer was crossed over for either group glucose or fructose.
62300756|NCT06656273|EXPERIMENTAL|FT LCP|
62300757|NCT06656273|NO_INTERVENTION|Standard LCP|
62300758|NCT04654507|ACTIVE_COMPARATOR|Adjuvant dexamethasone|Drug: Dexamethasone
62300759|NCT04654507|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62300760|NCT06056973|EXPERIMENTAL|Trials group|PPI treatment for 8 weeks, ( d1-d56 ), Jinghua weikang capsules 2 tid, 28 days of treatment.
61915819|NCT03710018||C Patient who underwent oncoplasty|Patients undergoing oncoplasty for breast cancer
61915820|NCT01758289||Paricalcitol IV|Eligible participants with diagnosis of chronic kidney disease stage V undergoing hemodialysis, treated with paricalcitol IV per routine clinical practice according to prescribing information approved in Venezuela and clinical criteria.
62110303|NCT02414906|EXPERIMENTAL|Intervention group|Goal-directed therapy
62110304|NCT02414906|NO_INTERVENTION|Control group|Control group
62110305|NCT04297982|EXPERIMENTAL|Intervention group (Mandala activity)|Scales were applied to the experimental group in the first encounter with the adolescent (pre-test). Then, a total of two sessions of individual mandala activities were performed at least 48 hours apart. Each adolescent freely drawn and painted the unstructured mandala on white paper, starting from the center and expanding. The same scales were reapplied last (post-test).
62110306|NCT04297982|OTHER|Control group|Scales were applied to the control group with an interval of 5 days and received routine nursing care (pre-test, post-test).
62110307|NCT01803646|EXPERIMENTAL|AM-101 injection|AM-101
62110308|NCT01803646|PLACEBO_COMPARATOR|Placebo injection|Placebo
62300761|NCT06056973|ACTIVE_COMPARATOR|Control group|Control group ( 130 cases ) : PPI treatment for 8 weeks, ( d1-d56 ), PPI treatment for 28 days.
62300762|NCT05514665||Neonates with perinatal hypoxic-ischemic brain injury|Neonates who are admitted to the Level III Neonatal Intensive Care Unit with a diagnosis of hypoxic ischemic encephalopathy will undergo diffuse optical tomography measurements prior to discharge from Neonatal Intensive Care Unit . Their developmental assessment will be performed at 6 months and 12 months postmenstrual age.
62110309|NCT06544382||Intervention group|Patients from Aarhus Municipality, Central Denmark Region, Denmark, receiving The Long COVID Rehabilitation Intervention.
61915821|NCT01129024|EXPERIMENTAL|Lusutrombopag|Participants received lusutrombopag 0.5 mg administered orally once a day for up to 3 years or until study termination. The dose was adjusted based on platelet counts. If a subject's platelet count remained \< 50,000/μL, the dose could have been increased by 0.25 mg up to a maximum dose of 2.0 mg.
62110310|NCT06544382||Control group|Patients from the other municipalities of Central Denmark Region, Denmark, receiving a less structured rehabilitation programme with individual session and few group options with patients with long COVID or mixed diagnoses.
62110311|NCT05663918|ACTIVE_COMPARATOR|Exercise Training in Individuals with Mild Cognitive Impairment|Individuals will participate in 3 sessions of Self Determined Intensity Interval training per week for 4 weeks, using a stationary bike at an intensity whereby their Ratings of Perceived exertion (RPE) is challenging. RPE will be measured using a Borg's 6-20 scale. (44). The cycling protocol will include a 3-minute warm-up, five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery. and a 2-minute cool-down. The RPE will be acquired by asking the participant to provide their rating at the end of the last interval.
62300763|NCT05041738|EXPERIMENTAL|Intraoral Cryotherapy|
62470533|NCT03037697|ACTIVE_COMPARATOR|Traditional Treatment Arm|"Traditional Treatment Arm~1-Trunk control exercises 2-Core stability training 3-Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board~3 months"
62110312|NCT05663918|NO_INTERVENTION|Individuals with Mild Cognitive Impairment and No exercise|Group B: Participants in this arm will not experience any intervention during a 4 week period of time.
62110313|NCT05663918|ACTIVE_COMPARATOR|Exercise Training in age and sex matched healthy controls|Individuals will participate in 3 sessions of Self Determined Intensity Interval training per week for 4 weeks, using a stationary bike at an intensity whereby their Ratings of Perceived exertion (RPE) is challenging. RPE will be measured using a Borg's 6-20 scale. (44). The cycling protocol will include a 3-minute warm-up, five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery. and a 2-minute cool-down. The RPE will be acquired by asking the participant to provide their rating at the end of the last interval.
62110314|NCT03908424||CONTROL|Parturients who gave birth to a normal birth and did not receive epidural anesthesia.
62110315|NCT03908424||Normal Epidural|Parturients who gave birth to a normal birth with epidural anesthesia without an unintentional dural puncture.
62300764|NCT05041738|ACTIVE_COMPARATOR|Intracanal Cryotherapy|
62300765|NCT01588223|EXPERIMENTAL|Lipids|
62300766|NCT01745003|EXPERIMENTAL|Fibromyalgia|Investigate biochemical, functional, and structural neuroimaging changes following non-invasive brain stimulation in patients with chronic widespread pain: fibromyalgia (FM). We will be using tDCS as intervention.
62300767|NCT03904927|EXPERIMENTAL|Experimental Arm|The arm will be treated with combined systemic therapy and local therapy such as radiation, surgery or radiofrequency ablation.
62300768|NCT03904927|ACTIVE_COMPARATOR|Control Arm|The arm will be treated with systemic therapy alone.
62300769|NCT00995371|ACTIVE_COMPARATOR|Vertos mild® Minimally-Invasive Lumbar Decompression|Patients in the Vertos mild® treatment group will be treated by appropriately trained physicians in accordance with the product labeling and indications for use.
62300770|NCT00995371|ACTIVE_COMPARATOR|Epidural Steroid Injection|Patients in the Epidural Steroid Injection (ESI) group will have ESI performed by appropriately trained physicians in accordance with product labeling and indications for use.
62300771|NCT02676258|EXPERIMENTAL|Si-Hy soft contact lens|olifilon B daily disposable soft contact lens
62300772|NCT02676258|ACTIVE_COMPARATOR|Vistakon soft contact lens|narafilcon A daily disposable soft contact lens
61915822|NCT06091072|EXPERIMENTAL|Patients scheduled for sentinel node procedure|This is a single-center observational feasibility study to evaluate the overall performance of the surgical navigation system during robotic surgery, without impact on the surgical procedure itself. The duration of this study will be approximately 2.5 years. Patients scheduled for a sentinel node procedure at the NKI are eligible for inclusion. Patients are informed about the study before the planned surgery and, after being provided with the necessary information regarding participation in the study, will be asked for informed consent. No additional risk is expected using the NDI navigation setup. Patients will receive some additional radiation due to the CT scan during surgery; a perioperative CBCT scan (\~ 4 mSv) is acquired. This extra dose is low, considering other standard imaging in these patients like, pre-operative imaging with SPECT/CT scans. After surgery, no further participation or cooperation of the patient is required.
62300773|NCT04980547|EXPERIMENTAL|ACUMED® Scapholunate Repair System|All participants in this trial will undergo the surgical RASL procedure using the ACUMED® Scapholunate Repair System.
62300774|NCT02580162|ACTIVE_COMPARATOR|Pro.Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Professionals interventionists and parents are NOT Peer Interventionists
62300775|NCT02580162|EXPERIMENTAL|Pro.Treatment, Peer|Families receive FBT for Pediatric Weight Management by Professionals and parents ARE Peer Interventionists
62110316|NCT03908424||PDPH conservative treatment|Parturients who gave birth to a normal birth with epidural anesthesia and had an unintentional dural puncture, these women were treated conservatively.
62110317|NCT03908424||PDPH treated with Blood Patch|. Parturients who had a normal birth with epidural anesthesia and had an unintentional dural puncture and were treated with a blood patch following PDPH.
62110318|NCT04620018|ACTIVE_COMPARATOR|Pre and post op Antibiotic|subjects received prophylactic antibiotic orally (Amoxicillin 2mg ,1 hour before surgery) and post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
62110319|NCT04620018|ACTIVE_COMPARATOR|Pre-op antibiotic|subjects received only prophylactic antibiotic (Amoxicillin 2mg ,1 hour before surgery)
62110320|NCT04620018|ACTIVE_COMPARATOR|Post-op antibiotic|subjects received post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
62110321|NCT02274493|EXPERIMENTAL|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
62110322|NCT06359054|EXPERIMENTAL|Breast Cancer Patient|
62110323|NCT01387113||Acute ischemic stroke patients|All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
62300776|NCT02580162|EXPERIMENTAL|Peer Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Peers and parents are NOT Peer Interventionists
62300777|NCT02580162|EXPERIMENTAL|Peer Treatment, Peer|Families receive FBT for Pediatric Weight Management by Peers and parents ARE Peer Interventionists
62110324|NCT02633358|EXPERIMENTAL|Therapeutic hypothermia group|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
62110325|NCT02633358|NO_INTERVENTION|Control group|No therapeutic hypothermia for controlled data.
62300778|NCT02561897|EXPERIMENTAL|Edoxaban|Edoxaban 30 or 60 mg
62300779|NCT02561897|ACTIVE_COMPARATOR|Warfarin|Warfarin 1 -1 0 mg
62110326|NCT01803516||Breast cancer survivors with radiation-induced Telangiectasias|A quality of life assessment will also be completed by the patient using the Skindex-16 and a subscale of the BREAST-Q Breast Conserving Module questionnaire.
62300780|NCT00390832|ACTIVE_COMPARATOR|A|recombinant human erythropoietin beta
62300781|NCT00390832|PLACEBO_COMPARATOR|B|0.9% NaCl solution
62300782|NCT01161225|EXPERIMENTAL|peer-led asthma self-managment program|
62300783|NCT01161225|ACTIVE_COMPARATOR|Adult-led asthma self-management program|
62300784|NCT06037954|EXPERIMENTAL|Open Door for Cancer (OD-C)|OD-C includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded.
62300785|NCT06037954|ACTIVE_COMPARATOR|Usual Care|Participants assigned to Usual Care (n=50) will receive standard care. MSK's current usual care for distress screening is that all patients are screened for distress when they initiate care at MSK. Additional distress screening is conducted based on the determination of the oncology team. In addition, patients are referred to social work, psychology, and/or psychiatry based on the judgment of the oncology team.
61915823|NCT05682573||covid-19 Inpatients|Participant is diagnosed with symptomatic COVID-19 by a positive polymerase chain reaction(PCR) or rapid antigen detection for SARS-CoV-2 and with treatment in hospital
61915824|NCT02741180|OTHER|Patients with Arrhythmias|
61915825|NCT02741180|OTHER|Healthy Control|
61915826|NCT03539796|EXPERIMENTAL|Dural puncture epidurals (DPE)|Dural puncture epidurals for cesarean section.
61915827|NCT03539796|ACTIVE_COMPARATOR|Traditional epidurals (EPI)|Traditional epidurals (EPI) for cesarean section.
62470534|NCT01986491|EXPERIMENTAL|Part 1; Period 1|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.
61915828|NCT03539796|ACTIVE_COMPARATOR|Combined-spinal epidural technique (CSE)|Combined-spinal epidural technique (CSE) for cesarean section.
61915829|NCT02205554|ACTIVE_COMPARATOR|Omnitram-Tramadol-Placebo|Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.
61915830|NCT02205554|ACTIVE_COMPARATOR|Tramadol-Placebo-Omnitram|Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.
61915831|NCT02205554|ACTIVE_COMPARATOR|Placebo-Omnitram-Tramadol|Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.
61915832|NCT01752036|OTHER|Treatment|Post-Operative Stereotactic Radiosurgery
62110327|NCT00798122|EXPERIMENTAL|Women|IVUS and MRI performed in women with no obstructive CAD at angiography
62110328|NCT01550978|EXPERIMENTAL|Study Group|Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
62110329|NCT01550978|NO_INTERVENTION|Control Group|Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator
62110330|NCT03206554|ACTIVE_COMPARATOR|LIA|Local infiltration analgesia
61915833|NCT00697580|NO_INTERVENTION|1|Control (C)
61915834|NCT00697580|EXPERIMENTAL|2|Nutrition (N)
61915835|NCT00697580|EXPERIMENTAL|3|Strength Training \& Nutrition (ST + N)
61915836|NCT00697580|EXPERIMENTAL|4|Circuit Training \& Nutrition (CT + N)
61915837|NCT02290431|EXPERIMENTAL|LBH589 + bortezomib + dexamethasone|Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
61915838|NCT01864356|EXPERIMENTAL|NT100 Dose 1|NT100 Dose 1
61915839|NCT01864356|EXPERIMENTAL|NT100 Dose 2|NT100 Dose 2
61915840|NCT01864356|PLACEBO_COMPARATOR|Placebo|Placebo
61915841|NCT06403475|EXPERIMENTAL|Transcutaneous Vagus Nerve Stimulation|The intervention will take place for up to 45 minutes per day, 5 days per week for 6 weeks. The stimulation device will be worn whilst completing computer-based Speech and Language Therapy.
62110331|NCT03206554|SHAM_COMPARATOR|sham LIA|Saline injections
62470535|NCT01986491|EXPERIMENTAL|Part 1; Period 2|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.
61915842|NCT06403475|SHAM_COMPARATOR|Sham Transcutaneous Vagus Nerve Stimulation|The sham intervention will take place for up to 45 minutes per day, 5 days per week for 6 weeks. The device will be in 'sham' mode (attached to the earlobe). The stimulation device will be worn whilst completing computer-based Speech and Language Therapy.
61915843|NCT01063933|EXPERIMENTAL|Cohort I|Cohort I: \>/= 12 years to \< 18 years. Peramivir administered daily for five days or until the day of hospital discharge, whichever comes first.
61915844|NCT01063933|EXPERIMENTAL|Cohort II|Cohort II: \>/= 6 years to \< 12 years
61915845|NCT01063933|EXPERIMENTAL|Cohort III|Cohort III: \>/= 2 years to \< 6 years
61915846|NCT01063933|EXPERIMENTAL|Cohort V|Cohort V: \>/= 91 days to \< 181 days
61915847|NCT01063933|EXPERIMENTAL|Cohort VII|Cohort VII: birth to \< 31 days
61915848|NCT01063933|EXPERIMENTAL|Cohort VI|Cohort VI: \>/= 31 days to \< 91 days
61915849|NCT01063933|EXPERIMENTAL|Cohort IV|Cohort IV: \>/= 181 days to \< 2 years
61915850|NCT01358279|EXPERIMENTAL|migraine|
61915851|NCT04195191|PLACEBO_COMPARATOR|Placebo|The usual practice by community pharmacies
61915852|NCT04195191|EXPERIMENTAL|ANM|This is an intervention based on pharmaceutical-patient communication through an open and fluid conversation, aimed at evaluating the patient's relationship with their new prescription, detecting possible problems, concerns and false beliefs or visual expectations.
61915853|NCT03739788|EXPERIMENTAL|BMS-986165|Oral and intravenous administration
61915854|NCT01908400|OTHER|BMMNCs|Intravenous transfer of (BMMNCs)
62110332|NCT05975788|EXPERIMENTAL|Staphylococcus and Neisseria group|Experimental group will receive Staphylococcus and Neisseria Tablets (0.3mg/tablet) and standard care. Administration Staphylococcus and Neisseria is 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months.
62110333|NCT05975788|NO_INTERVENTION|Standard care group|Standard care based on clinical experience without interventions.
62110334|NCT04462107||Surveys|All participants will complete questionnaires at several time points, ranging from baseline to 3 months post partum.
62110335|NCT04138862|ACTIVE_COMPARATOR|Sensory Matched/Unlabelled|Sensory-matched covert calorie reduction, unlabelled
62300786|NCT05008328|EXPERIMENTAL|Music Therapy plus Standard Care|Music therapy intervention in addition to standard hospital care during an SBT.
62300787|NCT05008328|ACTIVE_COMPARATOR|Standard Care|Standard hospital care during an SBT.
62300788|NCT03932240|EXPERIMENTAL|Fibrinogen Concentrate (FC)|"Neonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who are randomized to receive platelets and FC after separation from bypass. The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
62470536|NCT01986491|EXPERIMENTAL|Part 1; Period 3|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.
62300789|NCT03932240|ACTIVE_COMPARATOR|Cryoprecipitate|"Neonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who are randomized to receive platelets and cryoprecipitate. Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL (based on findings by Downey et al., published in Anesthesia and Analgesia in 2020).~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
62300790|NCT01672892|EXPERIMENTAL|Intensity-Modulated Radiation Therapy|intensity-modulated radiation therapy (IMRT) to the pelvis of either 45 Gy or 50.4 Gy
62110336|NCT04138862|EXPERIMENTAL|Sensory Matched/Labelled|Sensory-matched explicit calorie reduction, labelled
62110337|NCT04138862|EXPERIMENTAL|Sensory Reduced/Labelled|Sensory-reduced explicit calorie reduction, labelled
62300791|NCT01672892|ACTIVE_COMPARATOR|Standard Radiation Therapy|Standard radiation therapy (4-field) to the pelvis of either 45 Gy or 50.4 Gy
62470537|NCT01986491|EXPERIMENTAL|Part 1; Period 4|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.
62110338|NCT04138862|EXPERIMENTAL|Sensory Enhanced/Labelled|Sensory-enhanced explicit calorie reduction, labelled
62300792|NCT03797560|EXPERIMENTAL|Ba-Duan-Jin group|"Ba-Duan-Jin therapy: The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital.~Placebo pregabalin capsules: Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks."
62470538|NCT01986491|EXPERIMENTAL|Part 2; Period 1|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.
62470539|NCT01986491|EXPERIMENTAL|Part 2; Period 2|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.
62470540|NCT01986491|EXPERIMENTAL|Part 3|Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.
62470541|NCT02449265|EXPERIMENTAL|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
62470542|NCT02449265|ACTIVE_COMPARATOR|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5,repeated at 21-day intervals ).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
61915855|NCT01753778|EXPERIMENTAL|Treatment|Treatment with Cryo-Touch III Device at Day 0
61915856|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
61915857|NCT02269189|EXPERIMENTAL|BIIL 284 BS, high dose in adult patients|
61915858|NCT02269189|EXPERIMENTAL|BIIL 284 BS, low dose in pediatric patients|
61915859|NCT02269189|PLACEBO_COMPARATOR|Placebo|
62110339|NCT02470936|EXPERIMENTAL|Group 1- Lifestyle Intervention|Men will receive a web-based, personalized lifestyle program. They will receive personalized prostate cancer-specific lifestyle recommendations on specific habits based on their eligibility survey responses. They will have access to the website composed of four topic areas (get active, eat well, stop smoking, and find support), receive a Fitbit and access to a Fitbit account and community group, and receive text messages and refrigerator magnet to reinforce behaviors. The website will be updated frequently with new tips and material and two weekly blogs will be maintained. Final content is reviewed by study investigators and patient advocates. Men will complete an intervention acceptability survey (acceptability of the website and intervention components) at 3 months.
62110340|NCT02470936|NO_INTERVENTION|Group 2 - Control|Men randomized to the control group will receive standard of care. They will receive access to the website and personalized lifestyle recommendations on the 8 healthy habits targeted in the study after the 3 month trial.
62110341|NCT06161051||Capmatinib|
62110342|NCT06161051||IO monotherapy|
62110343|NCT06161051||Chemotherapy alone|
62110344|NCT06161051||IO + chemotherapy|
62110345|NCT03683628|ACTIVE_COMPARATOR|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb, Aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
62470543|NCT00933686|ACTIVE_COMPARATOR|Saizen®|
62470544|NCT00933686|ACTIVE_COMPARATOR|Placebo + Saizen®|
62470545|NCT06094517||Observed Group|Patients with persistent lower back pain awaiting Physiotherapy care, undergoing interviews to assess their views of sleep health within and musculoskeletal outpatient Physiotherapy setting.
62470546|NCT05212766||Vaccinated or unvaccinated uninfected South Asian ethnicity|Participants will have not experienced infection (positive test) - we will aim to recruit both vaccinated and unvaccinated individuals although the latter may be harder to recruit. They will identify as of South Asian ethnicity. Uninfected subjects, will be recruited by advertisement within KCL or social media, from non-COVID in-patients or outpatients or attending A\&E at GSTT and at SARS-CoV2 antigen testing centres and vaccination centres and at PIC sites.
62470547|NCT05212766||Asymptomatic / mild infected South Asian ethnicity|Participants will have experienced asymptomatic or mild infection (positive test). They will identify as of South Asian ethnicity. Volunteers or subjects attending SARS-CoV2 testing centres who are found to be antigen positive or In-patients who have positive Covid tests and designated as asymptomatic/mild but admitted for non-covid reasons or those attending A\&E with COVID but designated as mild/asymptomatic
62470548|NCT05212766||Symptomatic infected South Asian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission). They will identify as of South Asian ethnicity. Patients either seen at GSTT or admitted as in-patients to GSTT or KCH and found to be SARS-CoV2 positive by RT-PCR in nasopharyngeal samples and designated as moderate/severe on the NIH/NIMR COVID severity scale.
62470549|NCT05212766||Infected recovered South Asian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission) and recovered. They will identify as of South Asian ethnicity.
61915860|NCT02695212|EXPERIMENTAL|Apremilast ( open label)|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
62110346|NCT03683628|ACTIVE_COMPARATOR|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
62110347|NCT03036735|EXPERIMENTAL|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
62110348|NCT01765686|ACTIVE_COMPARATOR|Harmonic|Harmonic scalpel uses ultrasound technology to coagulate and to cut tissues.
62110349|NCT01765686|ACTIVE_COMPARATOR|Small Jaw|Small Jaw device uses bipolar electrical energy and pressure to form a seal and a micro blade to divide the sealed tissues.
62110350|NCT06081231||open-source APS|open-source APS consisted of an insulin pump, a CGM system, and a heuristic algorithm on an Android smartphone.
62300793|NCT03797560|ACTIVE_COMPARATOR|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
62470550|NCT05212766||Vaccinated or unvaccinated uninfected Caucasian ethnicity|Participants will have not experienced infection (positive test) - we will aim to recruit both vaccinated and unvaccinated individuals although the latter may be harder to recruit. They will identify as of Caucasian ethnicity. Uninfected subjects, will be recruited by advertisement within KCL or social media, from non-COVID in-patients or outpatients or attending A\&E at GSTT and at SARS-CoV2 antigen testing centres and vaccination centres and at PIC sites.
62470551|NCT05212766||Asymptomatic / mild infected Caucasian ethnicity|Participants will have experienced asymptomatic or mild infection (positive test). They will identify as of Caucasian ethnicity. Volunteers or subjects attending SARS-CoV2 testing centres who are found to be antigen positive or In-patients who have positive Covid tests and designated as asymptomatic/mild but admitted for non-covid reasons or those attending A\&E with COVID but designated as mild/asymptomatic
62470552|NCT05212766||Symptomatic infected Caucasian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission). They will identify as of Caucasian ethnicity. Patients either seen at GSTT or admitted as in-patients to GSTT or KCH and found to be SARS-CoV2 positive by RT-PCR in nasopharyngeal samples and designated as moderate/severe on the NIH/NIMR COVID severity scale.
62300794|NCT04444570||Control group|14 days before the date of the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom)
62470553|NCT05212766||Infected recovered Caucasian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission) and recovered. They will identify as of Caucasian ethnicity
62110351|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
62110352|NCT00914823|EXPERIMENTAL|kisspeptin, GnRH|Intravenous (IV) or subcutaneous (SC) administration of kisspeptin 112-121 and/or administration of GnRH
62110353|NCT01322958||At Risk of Ectopic Pregnancy|Women who present to the emergency department at UCSF who are at risk of ectopic pregnancy.
62300795|NCT04444570||Study group|Right after the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
62300796|NCT03487224||Hoarding Disorder|Adults diagnosed with Hoarding Disorder
62300797|NCT03487224||Healthy Controls|Adults without mental illness
62300798|NCT05145465|EXPERIMENTAL|Telerehabilitation group|"Participants will undertake the first training session in the University of Thessaly under the supervision of a specialized physiotherapist in order to precept the exercises. All the other sessions will proceed via telerehabilitation program at their home. Participants will undergo an exercise home based program 3 times/week.~The program will start with 10 minutes warm up exercise , 20 minutes continuous aerobic exercise ( 60-80% of target heart rate), 20 minutes resistance training exercise ( 30-50% 1RM), 5 minutes cool down and breathing exercises. For their safety patients will monitor glucose, blood pressure, pulse-oxygen and heart rate via, blood pressure monitor, pulse oximeter and smart-watch devices. They will be assessed at the beginning of the study and after the intervention ( at 6 weeks)"
62470554|NCT03609866|ACTIVE_COMPARATOR|control|will be performed inferior limbs passive mobilization
62470555|NCT03609866|EXPERIMENTAL|experimental|rapid thoracic compression technique will be applied
62110354|NCT06629662|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy|Patients undergoing traditional sleeve gastrectomy
62110355|NCT06629662|ACTIVE_COMPARATOR|Robotic sleeve gastrectomy|Sleeve gastrectomy with DaVinci robot
62110356|NCT05301400|ACTIVE_COMPARATOR|Overcast implant single restauration|
62110357|NCT05301400|ACTIVE_COMPARATOR|Cad/cam direct implant restauration|
62110358|NCT05301400|ACTIVE_COMPARATOR|Cad/cam implant restauration with transepithelial pilar|
62300799|NCT05145465|NO_INTERVENTION|control group|The participants in this group will just receive the education session and they will continue their current medical therapies.They will be assessed at the beginning of the study and after the intervention ( at 6 weeks).
62300800|NCT01671904|EXPERIMENTAL|1L CLL BR+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
62300801|NCT01671904|EXPERIMENTAL|1L CLL BG+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and obinutuzumab (BG). Participants received six 28-day cycles of BG+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
62300802|NCT01671904|EXPERIMENTAL|R/R CLL BR+V|Participants with relapsed/refractory (R/R) CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with R/R CLL continued single-agent venetoclax until disease progression, death, or unacceptable toxicity.
62300803|NCT02707029||Persons, with or without pain disorders|Adults and adolescents with or without pain disorders.
62300804|NCT02216565|OTHER|Medical treatment|Conventional medical non-interventional treatment
62300805|NCT02216565|OTHER|Endovascular treatment|Conventional medical treatment plus endovascular treatment
62300806|NCT05718102|ACTIVE_COMPARATOR|Pharmacist led|Pharmacists will conduct population health management for patients with COPD
62300807|NCT05718102|ACTIVE_COMPARATOR|Pulmonologist led|Pulmonologists will conduct population health management for patients with COPD
62300808|NCT06656585|EXPERIMENTAL|Food selectivity Group (2)|15 children in the comparator group who will undergo the treatment perform the procedure individually using the traditional method.
62300809|NCT06656585|EXPERIMENTAL|Food selectivity group (1)|15 children in the experimental group who will undergo the treatment perform the procedure individually with exposure to foods through Oculus
62300810|NCT00310310|PLACEBO_COMPARATOR|Usual Care|Usual sleep apnea and cpap care
62300811|NCT00310310|EXPERIMENTAL|Self-Management|sleep apnea self-management program - 4 sessions, group-based
62300812|NCT00201539|ACTIVE_COMPARATOR|double dose once|double dose immediate-release oral morphine at bedtime in cancer patients, placebo after 4 hours
62300813|NCT00201539|EXPERIMENTAL|single dose twice|single dose immediate-release oral morphine at bedtime in cancer patients, second single dose after 4 hrs
62300814|NCT06011486|EXPERIMENTAL|Lymphocyte infusion|Patients with CMV disease or reactivation will be included for receiving donor-CMV-specific cells
62300815|NCT05303493|EXPERIMENTAL|Camu-camu (intervention) in addition to standard-of-care ICI|"Camu-camu (intervention) will be added to standard-of-care ICI in:~Cohort 1. For patients with advanced NSCLC, treatment will consist of single-agent pembrolizumab in combination with physician's choice platinum-doublet chemotherapy in combination with CC.~Cohort 2. For patients with advanced cutaneous melanoma, treatment will consist of single-agent anti-PD-1 either nivolumab or pembrolizumab at the discretion of the treating physician.~Cohort 3. For patients with advanced melanoma receiving standard-of-care ICI (either single-agent anti-PD-1 or combination anti-CTLA-4 plus anti-PD-1) who experience progressive disease (PD), their current regimen will continue unchanged and they will receive CC at 1500 mg for 3 months or until confirmed progression if progression occurs earlier."
62300816|NCT01750918|EXPERIMENTAL|Part 1: Dabrafenib and Panitumumab|In Part 1 subjects will be assigned to escalation cohort of the doublet of dabrafenib and panitumumab based on the monotherapy doses of dabrafenib (150 milligrams \[mg\] twice daily) and panitumumab (6 milligrams per kilogram \[mg/kg\] every-2-week \[Q2W\]). Dose escalation will follow a 3+3 dose escalation procedure. If the initial combination dose of dabrafenib and panitumumab in Cohort 1 (starting dose) is not tolerable, lower dose combination(s) may be evaluated.
62300817|NCT01750918|EXPERIMENTAL|Part 1: Dabrafenib, Trametinib and Panitumumab|In Part 1 after the dabrafenib/panitumumab combination dose is defined, subsequent cohorts will evaluate the addition of trametinib based on a panitumumab dose that is one dose level lower than the dabrafenib/panitumumab dose defined in Cohort 1. Trametinib starting at 1.5 mg once daily will be added to the combination of dabrafenib and panitumumab. Dose escalation will follow a 3+3 dose escalation procedure until the full monotherapy doses of all agents are evaluated or the maximum tolerated dose is determined.
62300818|NCT01750918|EXPERIMENTAL|Part 2: Dabrafenib and panitumumab|In Part 2, subjects will be assigned to expansion cohorts at a selected dose of dabrafenib in combination with panitumumab
62300819|NCT01750918|EXPERIMENTAL|Part 2: Dabrafenib, Trametinib and Panitumumab|In Part 2, subjects will be assigned to expansion cohorts at selected dose of trametinib plus dabrafenib in combination with panitumumab.
62300820|NCT01750918|EXPERIMENTAL|Part 4a: Trametinib and Panitumumab|Subject will be administered starting dose of Trametinib 2 mg once daily and Panitumumab 6mg/kg Q2W. If the initial combination dose of trametinib and panitumumab in Cohort 1 (starting dose) is not tolerable, the lower dose combination defined in de-escalation cohorts (Cohort -1A, -1B and/or -1C) may be evaluated. Cohort -1A: Trametinib 1.5 mg once daily and Panitumumab 6 mg/kg Q2W; Cohort -1B: Trametinib 2 mg once daily and Panitumumab 4.8 mg/kg Q2W; Cohort-1C: Trametinib 1.5 mg once daily and Panitumumab 4.8 mg/kg Q2W
62300821|NCT01750918|EXPERIMENTAL|Part 4b: Trametinib and Panitumumab|In Part 4B cohort expansion, subjects will be assigned to expansion cohorts at a selected dose of trametinib in combination with panitumumab. Enrollment in expansion cohorts will be initiated once dose escalation for the trametinib /panitumumab combination has been completed. Subjects with advanced/metastatic CRC with either a BRAF-mutation (Cohort 1E) or who developed secondary resistance to prior anti-EGFR therapy (Cohort 2E).
62300822|NCT01750918|EXPERIMENTAL|Part 3a: Dabrafenib and Panitumumab|Subjects will be randomized to receive dabrafenib plus panitumumab. Dose levels for dabrafenib, and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
62300823|NCT01750918|EXPERIMENTAL|Part 3b: Dabrafenib, Trametinib and Panitumumab|Subjects will be randomized to receive study treatment as dabrafenib plus trametinib plus panitumumab. Dose levels for dabrafenib, trametinib and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
62300824|NCT01750918|EXPERIMENTAL|Part 3c: Chemotherapy comparator|Subjects will be randomized to receive chemotherapy comparator. The chemotherapy comparator will consist of a standard chemotherapy regimen with or without the addition of a biological agent, based on local practice preferences. The available chemotherapy regimens includes 5-fluorouracil-based chemotherapy
62300825|NCT03921112|ACTIVE_COMPARATOR|lung ultrasound|
62300826|NCT03921112|ACTIVE_COMPARATOR|x-ray, ABG, RSBI, Vetilator parameters|
62300827|NCT05415579||DDC patients with Traditional Chinese medicine (TCM) treatment|"TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.~This study does not limit Western medical treatment methods. Patients commonly applied high dose of intravenous steroid treatment in the acute phase, which usually referred to intravenous administration of 1g or 500mg of glucocorticoid daily for 3 consecutive days and reduced by half every 3 days. In addition, plasma exchange and immunoabsorption are also optional treatment for the acute phase. Immunomodulatory therapies including low dose of steroid, immunosuppressants (Azathioprine, Mycophenolate, etc.), and disease-modifying therapy (fingolimod, Teriflunomide, Rituximab, Satralizumab, etc.) are necessary for the remission phase."
62300828|NCT00826514|EXPERIMENTAL|Tanezumab|
62300829|NCT00826514|PLACEBO_COMPARATOR|Placebo|
62300830|NCT04007614||Patients|Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.
62300831|NCT05374343|ACTIVE_COMPARATOR|Group A and C (normal kidney function)|Each subject will receive a single dose of rongliflozin on Day 1
62300832|NCT05374343|EXPERIMENTAL|Group B (mild renal impairment)|Each subject will receive a single dose of rongliflozin on Day 1
62110359|NCT03895788|EXPERIMENTAL|niraparib and brivanib|Subjects will be assigned into niraparib 100mg+brivanib 200mg, niraparib 200mg+brivanib 200mg, niraparib 200mg+brivanib 400mg, niraparib 200mg+brivanib 600mg dose group at the first day of the first cycle.
62110360|NCT01346930|EXPERIMENTAL|Macitentan|Macitentan tablet, 10 mg, once daily
62110361|NCT01072357|ACTIVE_COMPARATOR|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 milliliter (mL) (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
62110362|NCT01072357|PLACEBO_COMPARATOR|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% sodium chloride (NaCl). Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
62110363|NCT00394069|EXPERIMENTAL|Montelukast sodium|Participants receive montelukast sodium for 14 days.
62110364|NCT05042193||Unvaccinated SARS-CoV-2 positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated
62300833|NCT05374343|EXPERIMENTAL|Group D (moderate renal impairment)|Each subject will receive a single dose of rongliflozin on Day 1
62300834|NCT02063529|EXPERIMENTAL|A (FOLFOXIRI + Cetuximab)|FOLFOXIRI + Cetuximab
62300835|NCT02063529|ACTIVE_COMPARATOR|B (FOLFOXIRI)|FOLFOXIRI
62300836|NCT04194229||Group 1|Patients that receive Cytoflavin® medication i/v drop infusion at a dose of 10 ml of solution for injection per 200 ml of 0.9 % sodium chloride solution for 10 days in addition to a set of neurorehabilitation activities
62110365|NCT05042193||Vaccinated|Participants who were vaccinated against SARS-CoV-2
62110366|NCT05759585|EXPERIMENTAL|Person-centered lifestyle intervention group|"Intervention group: Volunteers who were diagnosed with RA by a rheumatologist according to the 2010 criteria of the American College of Rheumatology (ACR)/European Rheumatology Association (ACR/EULAR) will be included in the study.~Person-centered lifestyle intervention in individuals with rheumatoid arthritis is planned as 2 sessions per week, for a total of 4 weeks."
62300837|NCT04194229||Group 2|Patients that subjected to the standard set of neurorehabilitation activities for 10 days without being prescribed Cytoflavin® medication
62300838|NCT05574153||Patient Participant|Participants with known Metabolic Syndrome (MetS)
62300839|NCT05574153||Healthy Volunteers|NonS-moking participants with no known pre-existing conditions and who do not take any medications
62300840|NCT02126488|EXPERIMENTAL|treadmill perturbation|treadmill slip perturbation
62300841|NCT02126488|PLACEBO_COMPARATOR|treadmill placebo|treadmill training placebo
62300842|NCT02126488|SHAM_COMPARATOR|observation|observation training
62300843|NCT01186432|EXPERIMENTAL|Active|ranibizumab sustained delivery implant
62300844|NCT01774916|OTHER|patients|
62300845|NCT01774916|OTHER|volunter|
62300846|NCT05878509||patients with traumatic hand-forearm injuries|The patients between the ages of 18-65 who were referred to the hand rehabilitation unit due to traumatic hand and forearm injuries, those who did not have any neurological, orthopedic, rheumatological disease or surgery history in the relevant extremity and those who did not have communication problems were eligible to participate in the study.
62300847|NCT00687453|EXPERIMENTAL|Insulin glargine injected at bedtime|Insulin glargine injected at bedtime
61915861|NCT06420258|EXPERIMENTAL|Deeper endotracheal intubation|After general anesthesia, endotracheal intubation was conducted using an ultrafine endoscope (GIF-XP260NS, Olympus Corp., Japan), which allows observation of the exact position and avoids blindness caused by laryngoscopy. To prevent balloon compression of the CE after inflating, the endotracheal intubation tube was inserted above the tracheal carina, roughly the upper thoracic esophagus
61915862|NCT06420258|NO_INTERVENTION|Conventional endotracheal intubation|
61915863|NCT04710771|EXPERIMENTAL|Group-A|Patient performed prone lying position for three hours.
61915864|NCT04710771|ACTIVE_COMPARATOR|Group-B|along with Prone lying position, patients also performed alternate nostril breathing for ten minutes.
61915865|NCT00827931|EXPERIMENTAL|A|end of the operation and on the mornings of the first, second, fourth and seventh postoperative days.
62110367|NCT05759585|EXPERIMENTAL|Control group|"Control group: Volunteers who were diagnosed with RA by a rheumatologist according to the 2010 criteria of the American College of Rheumatology (ACR)/European Rheumatology Association (ACR/EULAR) will be included in the study.~For the control group, they will be called twice a week for 4 weeks and inquired about their general condition."
61915866|NCT00827931|OTHER|B|Standard of Care
61915867|NCT01934543|EXPERIMENTAL|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
61915868|NCT01934543|EXPERIMENTAL|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
61915869|NCT03797313||Patient's expectations met at Hospital discharge|ARF survivors whose expectations for recovery at hospital discharge are fully met 6 months later.
61915870|NCT03797313||Patient's with unmet expectations at Hospital Discharge|ARF survivors whose expectations for recovery at hospital discharge are not fully met 6 months later.
61915871|NCT00779272||1|Without preoperative chemotherapy
62110368|NCT04765163||physician group with assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group using assistive equipment
62110369|NCT04765163||Physician group without assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group without assistive equipment
62110370|NCT04370782|EXPERIMENTAL|Experimental Arm 1|"Hydroxychloroquine~Azithromycin~Zinc sulfate"
62110371|NCT04370782|EXPERIMENTAL|Experimental Arm 2|"Hydroxychloroquine~Doxycycline~Zinc sulfate"
62110372|NCT01212757|EXPERIMENTAL|Apremilast 20mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
61915872|NCT00779272||2|With preoperative chemotherapy
61915873|NCT03415529||4500 patients with ARDS|This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.
62300848|NCT00687453|ACTIVE_COMPARATOR|NPH insulin injected twice-daily|NPH insulin injected twice-daily, before breakfast and at bedtime
62672039|NCT00612768|EXPERIMENTAL|T.R.U.E. Test allergens Fragrance Mix and Thimerosol|"Concordance (agreement) between positive patch reactions to~1. fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)~2. thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)~3. fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)~4. thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)~will be measured"
62672040|NCT00587262||1|Two pediatric participants with high frequency hearing loss post cochlear implant with either long or short electrode array.
62672041|NCT00587262||2|Eight participants with high frequency hearing loss post cochlear implant with either short or long electrode array.
62110373|NCT01212757|EXPERIMENTAL|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
62300849|NCT05837754|ACTIVE_COMPARATOR|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP
62300850|NCT05837754|PLACEBO_COMPARATOR|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP
62300851|NCT03553173|ACTIVE_COMPARATOR|Control|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.~Prescribed treatments:~* Bupropion pills + Psychological advice~* Varenicline pills + Psychological advice"
62672042|NCT00587262||3|Fifteen participants from the existing Cochlear Implant data base.
62672043|NCT00580294|EXPERIMENTAL|oxymorphone|participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed
62672044|NCT01992471||history of breast cancer who have undergone BRCA1/2 testing|This is a single-arm observational study. Subjects with a history of breast cancer who have undergone BRCA1/2 testing and have received uninformative findings will enroll in this study, and then receive pre-test counseling for multiplex testing.
62672045|NCT00138294|EXPERIMENTAL|Intervention Cities|Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.
62672046|NCT00138294|ACTIVE_COMPARATOR|Comparison Cities|Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites will received their influenza vaccines (live attenuated or inactivated influenza vaccines) by the local healthcare providers.
62672047|NCT01511237|EXPERIMENTAL|Perinatal intensification|"Perinatal antiretroviral intensification (study treatment):~* Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks~The standard of care in Thailand is defined as:~* Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor~* Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants)."
62672048|NCT02331121|ACTIVE_COMPARATOR|Text-only Online Training|Text-only evidence-based training content on CPR, choking relief \& first aid
62672049|NCT02331121|EXPERIMENTAL|Family First Aid Online Training|Interactive multimedia evidence-based training content on CPR, choking relief \& first aid
62672050|NCT04968145|NO_INTERVENTION|Control Group|Participants in the control group receive routine follow up care which consists of (i) written instructions regarding potential complications and the contact information of their treating surgeon, (ii) a follow up telephone call 4 weeks following discharge by a member of the health care team and (iii) an in-person follow up visit in clinic with the treating surgeon 4-6 weeks following discharge.
62672051|NCT04968145|EXPERIMENTAL|Intervention Group|The participants in the intrevention group receive the same routine care as the control group in addition to post discharge monitoring with the Home to Stay app
62672052|NCT02717715|EXPERIMENTAL|Intervention group|Stroke patients from the intervention group will be, on top of usual care, offered a holistic home based and semi-supervised stroke rehabilitation program followed by a period of tele-supervision.
61915874|NCT03216928|EXPERIMENTAL|Group 1|patients with good response to anti-TNF had a blood test
62110374|NCT01212757|PLACEBO_COMPARATOR|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
62300852|NCT03553173|EXPERIMENTAL|Intervention|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.~Prescribed treatments:~* Bupropion pills + Psychological advice + So-Lo-Mo~* Varenicline pills + Psychological advice + So-Lo-Mo"
62300853|NCT01349738||Positive Group|Positive for ASB
62300854|NCT01349738||Negative Group|Negative for ASB
61915875|NCT03216928|EXPERIMENTAL|Group 2|patients with moderate or non-response to anti-TNF had a blood test
61915876|NCT00724880|EXPERIMENTAL|1|Clopidogrel is stopped 5 days prior to surgery
62300855|NCT05635708|EXPERIMENTAL|Sub-study 1: Experimental Arm 1A|Tislelizumab + BGB-A445
62300856|NCT05635708|EXPERIMENTAL|Sub-study 1: Experimental Arm 2A|Tislelizumab + LBL-007
62300857|NCT05635708|EXPERIMENTAL|Sub-study 1: Experimental Arm 3A|Tislelizumab + BGB-15025
62300858|NCT05635708|EXPERIMENTAL|Sub-study 1: Reference Arm Tislelizumab alone|Tislelizumab alone
62300859|NCT05635708|EXPERIMENTAL|Sub-study 2: Experimental Arm 1B|Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
62300860|NCT05635708|EXPERIMENTAL|Sub-study 2: Experimental Arm 2B|Tislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
62300861|NCT05635708|EXPERIMENTAL|Sub-study 2: Experimental Arm 3B|Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
62300862|NCT05635708|ACTIVE_COMPARATOR|Sub-study 2: Reference Arm|Tislelizumab + investigator's choice of histology-appropriate chemotherapy
62672053|NCT02717715|NO_INTERVENTION|Control group|The participants in the control group will only receive usual care.
62672054|NCT06419309|EXPERIMENTAL|Gluten- lactose free diet|People will be given a healthy diet by eliminating gluten-free lactose-containing foods from their diet. It will continue for 8 weeks.
62672055|NCT06419309|EXPERIMENTAL|Aronia Melanocarpa added and Gluten- lactose free diet|In addition to a healthy diet, people will be given aronia melanocarpa fruit juice daily (high in anthocyanins, 69.24 mg/100 mL cyanidin-3-glucoside) and a gluten-free-lactose-free diet.It will continue for 8 weeks.
62672056|NCT06419309|EXPERIMENTAL|Aronia Melanocarpa added diet|People will be given aronia melanocarpa fruit juice daily (high in anthocyanins, 69.24 mg/100 mL cyanidin-3-glucoside).It will continue for 8 weeks.
61915877|NCT00724880|EXPERIMENTAL|2|Clopidogrel is stopped 3 days prior to surgery
61915878|NCT00724880|EXPERIMENTAL|3|Clopidogrel is stopped 0 days prior to surgery
62110375|NCT01212757|PLACEBO_COMPARATOR|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
62110376|NCT02319785|EXPERIMENTAL|RAT-NMES|The combined treatment of robot-assisted therapy and neuromuscular electrical stimulation.
61915879|NCT05056285||Down syndrome less than four years Group|
61915880|NCT03396042||Group 1|5 Patient target, ages 3 to 5 yr, with visual acuity Light Perception (LP) to \<=20/200
61915881|NCT03396042||Group 2|5 Patient target, ages 3 to 5 yr, with visual acuity \>20/200 to \<=20/50
61915882|NCT03396042||Group 3|5 Patient target, ages 6 to 11 yr, with visual acuity LP to \<=20/200
62110377|NCT02319785|EXPERIMENTAL|RAT-MT|The combined treatment of robot-assisted therapy and mirror therapy.
62110378|NCT02319785|ACTIVE_COMPARATOR|Mirror therapy|Patients practice motion in a mirror box, and look into mirror while practicing.
62110379|NCT02319785|EXPERIMENTAL|Unilateral RAT|Unilateral robot-assisted therapy provided by InMotion Isokinetic Testing and Evaluation System.
62110380|NCT02319785|ACTIVE_COMPARATOR|Bilateral RAT|Bilateral robot-assisted therapy provided by Bi-Manu-Track.
62110381|NCT02319785|ACTIVE_COMPARATOR|Conventional rehabilitation|Conventional rehabilitation provided by therapist.
62110382|NCT00484575|ACTIVE_COMPARATOR|propofol|propofol for sedation minimum 2 hours in CTICU after CABG
62110383|NCT00484575|EXPERIMENTAL|sevoflurane|Sevoflurane via AnaConDa for minimum 2 hours in CTICU after CABG
62300863|NCT01068561|EXPERIMENTAL|Test group|open-label study of retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200.
62110384|NCT03082430|OTHER|knee osteoarthritis patients.|therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
62110385|NCT02466048|EXPERIMENTAL|SurgiFill™ on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
62110386|NCT02466048|ACTIVE_COMPARATOR|Autograft on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
62110387|NCT06357169|EXPERIMENTAL|Healthy-experimental|Healthy participants who have not been diagnosed with scalp or hair disease will be followed over a period of 2 weeks to assess their scalp microbiome and see how well the investigational device works on decreasing the microbe burden of the scalp.
62110388|NCT01343173|EXPERIMENTAL|Patients|
62300864|NCT04971590||Participants with Lupus Nephritis|
62300865|NCT05087888||Observational (MRI, questionnaire, blood collection)|Patients undergo multiparametric MRI with contrast at baseline, 3 weeks during radiotherapy, and at 1, 3, 6, 12, and 24 months post-radiotherapy. Patients undergo multiparametric MRI without contrast at 1, 2, 4, 5, and 6 weeks during radiotherapy. Patients may undergo functional MRI at baseline and 6 months post-radiotherapy. Patients also complete questionnaires and undergo collection of blood samples at baseline, weekly through week 6 during radiotherapy, and at 1, 3, 6, 12, and 24 months post radiotherapy.
61915883|NCT03396042||Group 4|5 Patient target, ages 6 to 11 yr, with visual acuity \>20/200 to \<=20/50
62110389|NCT00513734|ACTIVE_COMPARATOR|1|Geliperm Hydrogel Dressing
62300866|NCT04392986|NO_INTERVENTION|Baseline|Baseline measurement
62300867|NCT04392986|EXPERIMENTAL|Intervention|Sunlight intervention
62672057|NCT06419309|EXPERIMENTAL|Healthy eating group|Healthy diet patterns with an average macronutrient content of 10-20% protein, 20-35% fat and 45-60% carbohydrate will be followed for 8 weeks.
62672058|NCT04209842|EXPERIMENTAL|gastric ballon placement|will receive gastric balloon placed via endoscopy
62672059|NCT02569905|ACTIVE_COMPARATOR|Groups Parecoxib sodium|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
62672060|NCT02569905|ACTIVE_COMPARATOR|Groups Flurbiprofen|Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
62110390|NCT00513734|ACTIVE_COMPARATOR|2|Lacrilube ointment
62110391|NCT02925052|EXPERIMENTAL|GTG|Gastric tube placement using the Gastric Tube Guide
62110392|NCT02925052|OTHER|Conventional|Gastric tube placement using a conventional method, according to local protocol.
62110393|NCT04324242||Group1|visual feedback
62672061|NCT02569905|PLACEBO_COMPARATOR|Group Saline|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
62470556|NCT06541886|ACTIVE_COMPARATOR|Standard CBT-I|Standard CBT-I involves up to 5 different parts of the therapy: 1) improving sleep habits; 2) adjusting the sleep schedule; 3) only using the bed for sleep; 4) relaxation training to relax the mind and body for sleep; and 5) managing thoughts that may make it hard to go to sleep. Teens in this treatment condition will have an intake session and 6 treatment sessions (one for each unit listed above and one for a maintenance session). Treatment will include visual aids (e.g., a powerpoint) to convey didactic or psychoeducational material. The treatment protocol we will follow has already been tested and published and is publicly available (Edinger \& Carney Treatments that Work: A Cognitive Behavioral Approach to Overcoming Insomnia).
62672062|NCT04366583|EXPERIMENTAL|Argon plasma coagulation plus distilled water injection|The patients in this group received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
62672063|NCT04366583|ACTIVE_COMPARATOR|Hemoclipping plus distilled water injection|The patients in this group received hemoclipping (Olympus HX 110/610, Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
62470557|NCT06541886|EXPERIMENTAL|Teen CBT-I|Teen CBT-I The second of the two treatments with a therapist is similar to CBT-I but adapted for teens. Teens in this treatment condition will similarly have an intake session and 6 treatment sessions. The first session will include an introduction to Sleep Science and Insomnia Treatment. Middle sessions will include Healthy Sleep Habits, Setting a Sleep Schedule, Preparing the Mind and Body for Sleep, and Distinguishing the Sleep Space and Wake Space. The final session will be be centered on maintenance of treatment gains. Treatment will also similarly include visual aids (e.g., slides) to convey didactic or psychoeducational material.
62672064|NCT00468000|EXPERIMENTAL|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
62672065|NCT00468000|PLACEBO_COMPARATOR|Placebo|The control arm of the study will receive placebo injections.
62672066|NCT01732523||No treatment|No intervention
62672067|NCT05001503|EXPERIMENTAL|Intervention Group|The clinical team has access to the Stability UO software. All other care is given as standard.
62672068|NCT05001503|NO_INTERVENTION|Control Group|Standard care given.
62672069|NCT00741221|EXPERIMENTAL|1|Pemetrexed/Bevacizumab
62672070|NCT01259024|EXPERIMENTAL|doxorubicin-eluting LC Bead|transarterial chemoembolization using doxorubicin-eluting LC Beads
61915884|NCT03396042||Group 5|5 Patient target, ages 12 to 17 yr, with visual acuity LP to \<=20/200
61915885|NCT03396042||Group 6|5 Patient target, ages 12 to 17 yr, with visual acuity \>20/200 to \<=20/50
61915886|NCT03396042||Group 7|5 Patient target, ages 18yr and older, with visual acuity LP to \<=20/200
62300868|NCT01770184|EXPERIMENTAL|Intervention Group|The intervention group will receive the rehabilitation services and support that is recommended and provided in the current health care structure. The intervention group will also receive the Chronic Disease Self-Management Program (CDSMP). The CDSMP is an education program based on the concept of self-management. Self-management refers to the ability of an individual to manage the day-to-day responsibilities of living with a chronic condition. The CDSMP will be delivered in two and a half hour sessions, once a week, for six weeks, in group format.
62300869|NCT01770184|NO_INTERVENTION|Usual Care Group|The usual care group for this study will receive the rehabilitation services and support that is recommended and provided in the current health care structure. No additional intervention will be provided to the usual care group within this study.
62110394|NCT04324242||Group2|traditional feedback
62672071|NCT02425488|EXPERIMENTAL|Nursing therapeutics education|People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
62672072|NCT02425488|NO_INTERVENTION|Non NET|People who receive basic information without follow the educational program but clinically controlled
62672073|NCT04249193||Transfusion|
62672074|NCT02126202|NO_INTERVENTION|Conservative therapy|Optimized medical therapy
62672075|NCT02126202|EXPERIMENTAL|Invasive therapy|Coronary angiography and revascularization if feasible
62110395|NCT02012166|EXPERIMENTAL|MK-0893 40 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
62672076|NCT04213638|EXPERIMENTAL|Group：1|Intervention: Other：Single Microneedle Radiofrequency therapy
62672077|NCT04213638|ACTIVE_COMPARATOR|Group：2|Intervention: Other：Photodynamic therapy
62672078|NCT01867476||Healthy Normals|
62672079|NCT05268120|ACTIVE_COMPARATOR|A|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
62672080|NCT05268120|ACTIVE_COMPARATOR|B|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.
62672081|NCT00768638|ACTIVE_COMPARATOR|Atorvastatin 10mg|
62672082|NCT00768638|ACTIVE_COMPARATOR|Atorvastatin 40mg|
61915887|NCT03396042||Group 8|5 Patient target, ages 18yr and older, with visual acuity \>20/200 to \<=20/50
62300870|NCT05072405|OTHER|simvastatin 20 mg (Zocor®, MSD)|simvastatin 20 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases.
62470558|NCT06541886|NO_INTERVENTION|Waitlist|Teens in the waitlist condition will still complete the same study measures and receive the same payment for taking part in the study, but they will not receive treatment from a therapist. Their treatment will begin after they have completed the second round of measures (i.e., 8 weeks after they complete the baseline assessment). After they have completed the second round of measures, they will be given free access to an app that provides guided insomnia treatment. While no live therapist is involved, the approach is similar to traditional CBT-I.
61915888|NCT03690336||Patients with haemophilia B|Patients with haemophilia B treated with nonacog beta pegol who report adverse events to the PedNet and EUHASS, and possibly other national or international registries.
61915889|NCT05258669|ACTIVE_COMPARATOR|BBV152|BBV152
61915890|NCT05258669|PLACEBO_COMPARATOR|Placebo|0.9% normal saline
61915891|NCT02780323|EXPERIMENTAL|CELBESTA® and CELEBREX® placebo|CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks
62110396|NCT02012166|EXPERIMENTAL|MK-0893 200 mg→placebo→MK-0893 10 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
62110397|NCT02012166|EXPERIMENTAL|Placebo→MK-0893 10 mg→MK-0893 40 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
62672083|NCT02269449|EXPERIMENTAL|6Fr Glidesheath Slender sheath|TRI will be performed using a new 6Fr sheath (Glidesheath slender: GSS).
62110398|NCT02012166|EXPERIMENTAL|MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
62110399|NCT02012166|EXPERIMENTAL|Placebo→MK-0893 1000 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
62110400|NCT02012166|EXPERIMENTAL|MK-0893 200 mg→placebo→MK-0893 1000 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
62300871|NCT05072405|OTHER|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases
62470559|NCT00770822|EXPERIMENTAL|Device, HIFU|High Intensity Focused Ultrasound
62470560|NCT00770822|ACTIVE_COMPARATOR|Device, brachytherapy|Brachytherapy
62470561|NCT05133817|PLACEBO_COMPARATOR|Control group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
62672084|NCT02269449|ACTIVE_COMPARATOR|5Fr contemporary sheath|TRI will be performed using a contemporary safety of 5Fr sheath.
61915892|NCT02780323|ACTIVE_COMPARATOR|CELEBREX®|CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks
61915893|NCT03170232|EXPERIMENTAL|Subjects receiving danirixin|Following screening and assessment of rescue medication use, subjects will receive one tablet of danirixin 35 mg (as hydrobromide hemihydrate salt) orally twice daily with food for 52 weeks during treatment period. Study treatment will be dispensed to subjects at the study visits.
61915894|NCT03170232|PLACEBO_COMPARATOR|Subjects receiving placebo|Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
61915895|NCT05025748|EXPERIMENTAL|Health services research (ASQ brochure)|Patients receive ASQ brochure and complete questionnaires over 30 minutes at baseline, over 10 minutes pre-clinic visit, and over 30 minutes post-clinic visit.
61915896|NCT05198544|EXPERIMENTAL|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Subjects will receive weekly application of Ham along with standard of care therapy for eight (8) weeks unless healing occurs prior to 8 weeks.
61915897|NCT02149771|EXPERIMENTAL|TACE&Stents|chemoembolization combined with endovascular stents and iodine-125 seed strand implantation
61915898|NCT02149771|ACTIVE_COMPARATOR|TACE|Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
61915899|NCT00266565|EXPERIMENTAL|Anti-IL5 (Mepolizumab)|The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.
62300872|NCT02347293|EXPERIMENTAL|+ ind. CHO|Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables
62300873|NCT02347293|EXPERIMENTAL|- ind. CHO|Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables
62300874|NCT00488631|PLACEBO_COMPARATOR|Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
62300875|NCT00488631|EXPERIMENTAL|GLM-I-Rsp-Golimumab 50 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
62470562|NCT05133817|EXPERIMENTAL|0.025 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.025 μg/kg/min) by IV infusion.
62470563|NCT05133817|EXPERIMENTAL|0.05 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.05 μg/kg/min) by IV infusion.
62672085|NCT02269449|EXPERIMENTAL|Hemostasis with TR band|Hemostasis is achieved by randomization of using TR band (TERUMO) Patent hemostasis.
62110401|NCT02012166|EXPERIMENTAL|MK-0893 1000 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
62672086|NCT02269449|ACTIVE_COMPARATOR|Any hemostasis procedure|Hemostasis is achieved by randomization of any hemostasis of each hospital's routine procedure.
62672087|NCT02493855|EXPERIMENTAL|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
62110402|NCT05756998|ACTIVE_COMPARATOR|classic technique|
62110403|NCT05756998|EXPERIMENTAL|new technique|
62110404|NCT02772653||Severe trauma patients|"No interventions are done. It's a prospective and descriptive observational study where different markers are analyzed:~* Blood Lactate levels~* Blood Base Excess levels~* Blood B-type Natriuretic Peptide levels~* Blood Thromboelastometry (ROTEM) alterations~* Near-infrared spectroscopy alterations~* Sublingual videomicroscopy alterations~All these markers are analyzed at the 1rst, 8th and 24th hour from hospital admission."
62300876|NCT00488631|EXPERIMENTAL|GLM-I-Rsp-Golimumab 100 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
62300877|NCT00488631|PLACEBO_COMPARATOR|Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance|Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
62300878|NCT00488631|EXPERIMENTAL|PBO-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
62470564|NCT05133817|EXPERIMENTAL|0.075 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.075 μg/kg/min) by IV infusion.
62470565|NCT05133817|EXPERIMENTAL|0.1μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.1μg/kg/min) by IV infusion.
62672088|NCT02493855|EXPERIMENTAL|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
62672089|NCT02493855|EXPERIMENTAL|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
61915900|NCT02802670|EXPERIMENTAL|GDC-0810|GDC-0810 300-mg dose administered as oral solution, containing approximately 100 microcuries of \[14C\]-labeled GDC-0810.
61915901|NCT04575792||C group|C group: control group, children who do not practice oral habits.
61915902|NCT04575792||E group|E group: exposed group, children who practicing oral habits.
62735966|NCT02583633|ACTIVE_COMPARATOR|Group two have received nifedipine|"For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below;~1. One softgel every 20 min (4 doses)~2. Two softgel every 6 hr (4 doses)~3. One softgel every 6 hr (4 doses)~4. One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied."
61915903|NCT00937885|EXPERIMENTAL|Implementation of reminiscence|Individual and group reminiscence sessions held with residents, supplemented by reminiscence boxes, posters and exhibitions.
61915904|NCT00937885|NO_INTERVENTION|Usual nursing care|
62110405|NCT03414710|EXPERIMENTAL|Intervention group|"Health education booklet plus video plus brief counseling~In addition to the educational booklet received by the control group, the intervention group will receive the following health promotion:~1. Watch a 10-minute video promoting VMMC~2. Receive a brief counseling promoting VMMC If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
62110406|NCT03414710|ACTIVE_COMPARATOR|Control group|"Health education booklet only After randomization took place, the control group will receive an education booklet introducing voluntary medical male circumcision.~If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
62110407|NCT01936753|EXPERIMENTAL|Mentor Mother Peer Support|This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
61915905|NCT00219544|EXPERIMENTAL|1|
62110408|NCT01936753|NO_INTERVENTION|Routine Peer Support|Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.
62110409|NCT03771846|EXPERIMENTAL|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin
62110410|NCT03771846|ACTIVE_COMPARATOR|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and oxaliplatin
62110411|NCT01552304|EXPERIMENTAL|Oxygen treatment group|Besides routine care, patients in this group will receive postoperative oxygen therapy with nasal prolong at 3 liters/min during the first 3 nights after surgery.
62110412|NCT01552304|OTHER|Control group|Patients will be managed by the anesthesiologists and surgeons as per routine practice.
62110413|NCT02452294|EXPERIMENTAL|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events.
62300879|NCT00488631|EXPERIMENTAL|GLM-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
61915906|NCT00219544|EXPERIMENTAL|2|
61915907|NCT00219544|EXPERIMENTAL|3|
61915908|NCT00219544|PLACEBO_COMPARATOR|4|
61915909|NCT03656471||Clear aligner group|Patients receiving clear aligner treatments for their malocclusions
61915910|NCT03656471||Fixed appliance group|Patients receiving fixed appliance treatments for their malocclusions
62110414|NCT01596725|EXPERIMENTAL|Group A|
62110415|NCT01596725|EXPERIMENTAL|Group B|
62110416|NCT01596725|EXPERIMENTAL|Group C|
62110417|NCT01596725|EXPERIMENTAL|Group D|
62110418|NCT01596725|EXPERIMENTAL|Group E|
62110419|NCT01596725|EXPERIMENTAL|Group F|
62110420|NCT02780947|ACTIVE_COMPARATOR|Prophylactic substrate ablation group|Prophylactic substrate ablation group will undergo substrate mapping and ventricular tachycardia substrate ablation
62110421|NCT02780947|NO_INTERVENTION|Control group|Control group will undergo substrate mapping
62110422|NCT00627874|EXPERIMENTAL|1|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
62110423|NCT00627874|NO_INTERVENTION|2|
62110424|NCT06394791|EXPERIMENTAL|Experimental group|Tislelizumab with Interleukin-2+CAPOX
62300880|NCT00761215|EXPERIMENTAL|TR-701 200 mg|
62300881|NCT00761215|EXPERIMENTAL|TR-701 300 mg|
62300882|NCT00761215|EXPERIMENTAL|TR-701 400 mg|
62300883|NCT05650957||Non-COVID-19 ARDS|To be included in this analysis the cause for ARDS was a pulmonary infection other than COVID-19 and meeting all aspects of the Berlin definition.
62300884|NCT05650957||COVID-19 ARDS|To be included in this analysis the cause for ARDS was COVID-19 and meeting all aspects of the Berlin definition.
62300885|NCT05735054||endoscopic group|the patients who underwent endoscopic transaxillary thyroidectomy
62300886|NCT05735054||open group|the patients who underwent open thyroidectomy
61915911|NCT02315443|EXPERIMENTAL|Nerinetide (NA-1)|2.60 mg/kg of nerinetide (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
62110425|NCT02313441|ACTIVE_COMPARATOR|RIPC (Remote Ischemic Pre-Conditioning)|Patients used RIPC had a blood pressure cuff placed around their upper arm at \< 2 hours before the PCI procedure. The blood pressure cuff was inflated to for 5 minutes, followed by 5 minutes of deflation. This procedure was repeated 3 times
62110426|NCT02313441|PLACEBO_COMPARATOR|Control|Control participants did not experience this procedure of transient upper-limb ischemia.
62110427|NCT01130818|EXPERIMENTAL|1|single ascending doses
62110428|NCT01130818|PLACEBO_COMPARATOR|2|single dose placebo
62110429|NCT01130818|EXPERIMENTAL|3|single dose, oral solution, 50 mg
62110430|NCT01130818|EXPERIMENTAL|4|single dose, capsules (fasting)
61915912|NCT02315443|PLACEBO_COMPARATOR|Placebo|Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
62110431|NCT01130818|EXPERIMENTAL|5|single dose, capsules (fed)
62110432|NCT01020838|EXPERIMENTAL|Florbetaben (BAY94-9172)|
62110433|NCT03888755|EXPERIMENTAL|Icatibant|Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.
62110434|NCT01434563||HIV positive|Subjects must have documented HIV, be english speaking, with life expectancy greater than 6 months, and must have adequate information available in their medical record to apply HAND predictive algorithm (HIV-associated neurological disease)
61915913|NCT02728973||ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
61915914|NCT02728973||conventional treatment program|conventional treatment
61915915|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
61915916|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
62110435|NCT01434563||HIV negative|Must have documented negative HIV test within 12 months of study entry, have no traumatic brain injury or history of chronic neurological illness/psychiatric conditions (such as bipolar or depression),be english speaking and have no history of drug or alcohol abuse.
62110436|NCT02517307|EXPERIMENTAL|glycerol/saline FAOD|Glycerol/Saline co-infusion hyperinsulinemic euglycemic clamp among subjects with a fatty acid oxidation disorder (FAOD)
61915917|NCT03726567|ACTIVE_COMPARATOR|Bariatric surgery group|Patients who are undergoing bariatric surgery for weight loss
62110437|NCT02517307|EXPERIMENTAL|intralipid FAOD|Intralipid/Heparin co-infusion hyperinsulinemic euglycemic clamp among subjects with a fatty acid oxidation disorder (FAOD)
62110438|NCT02517307|EXPERIMENTAL|glycerol/saline Control|Glycerol/Saline co-infusion hyperinsulinemic euglycemic clamp among normal matched control subjects (control)
62110439|NCT02517307|EXPERIMENTAL|intralipid Control|Intralipid/Heparin co-infusion hyperinsulinemic euglycemic clamp among normal matched control subjects (control)
62300887|NCT02848547||Intervention - SMS|Participants in the intervention group received periodic text messages on healthy lifestyle throughout the study period.
62300888|NCT02848547||Control - Standard Care|Participants in the control group received standard one time advice at entry in the study.
62300889|NCT05413681|ACTIVE_COMPARATOR|metabolic myopathy|a supra-maximal exercise test on a cycloergometer.
62300890|NCT05413681|PLACEBO_COMPARATOR|Control : Healthy volonteers|a supra-maximal exercise test on a cycloergometer.
61915918|NCT03726567|NO_INTERVENTION|Non bariatric surgery group|Patients who are undergoing abdominal surgery for non-weight loss reasons
61915919|NCT02538861||ARM-A|Arm-A patients will receive the standard of care diagnostic test at Baptist Hospital, which includes SPECT imaging
62470566|NCT00239577|EXPERIMENTAL|DENGUE FORMULATION 17A GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Dengue vaccine Formulation 17a, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
62672090|NCT06553469||SNM group|After screening according to the inclusion and exclusion criteria, the subjects were enrolled in the study. The sacral nerve regulation treatment was divided into two phases. Phase I was the testing phase, during which sacral nerve stimulation electrode component implantation was performed. After electrode implantation, testing was conducted for 2-4 weeks. According to the urine diary and scale scores, if the symptoms improved by ≥ 50%, or if the patient requested to continue with phase II and was evaluated by the researcher as suitable for implantation, phase II (permanent implantation phase) treatment was performed, and sacral nerve stimulation pulse generator component implantation was performed.During the trial period, all patients in the intervention group received routine care for neurogenic lower urinary tract dysfunction, including regular clean interval catheterization (CIC), in addition to sacral nerve regulation therapy
62672091|NCT05089175||Women at high risk for preeclampsia|Using FIGO recommended preeclampsia screening model for the first-trimester which combined maternal risk factors, mean arterial pressure, placental growth factor, uterine artery pulsatility index to evaluate pregnant's risk for preeclampsia. Risk value≥1/100 is defined as screened high risk.
61915920|NCT02538861||ARM-B (Group-1)|Group-1 will receive CT Angiography and CT myocardial perfusion with new Revolution CT scanner.
61915921|NCT02538861||ARM-B (Group-2)|The Group-2 of arm B will receive SPECT imaging test.
61915922|NCT03239665|ACTIVE_COMPARATOR|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
62470567|NCT00239577|EXPERIMENTAL|DENGUE FORMULATION 17B GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 17b, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6, and one booster dose approximately 5-12 months after the second dose.
61915923|NCT03239665|EXPERIMENTAL|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
61915924|NCT06052215|EXPERIMENTAL|Solomon-1|
61915925|NCT06052215|EXPERIMENTAL|Solomon-2|No pretest measurement
61915926|NCT06052215|NO_INTERVENTION|Solomon-3|
61915927|NCT06052215|NO_INTERVENTION|Solomon-4|No pretest measurement
61915928|NCT05860101|OTHER|1 week waitlist|
61915929|NCT05860101|OTHER|2 week waitlist|
62110440|NCT04611360|EXPERIMENTAL|Anodal Transcranial Direct Current Stimulation Group|Anodal Transcranial Direct Current Stimulation and Conventional training exercises
62110441|NCT04611360|ACTIVE_COMPARATOR|Conventional Training Exercises Group|Conventional Training Exercises : Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk
61915930|NCT01925989|EXPERIMENTAL|Insulin Peglispro/Insulin Glargine|Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin.
61915931|NCT01925989|ACTIVE_COMPARATOR|Insulin Glargine/Insulin Peglispro|Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin. Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen.
61915932|NCT01925989|NO_INTERVENTION|Control|Control Arm. Untreated healthy participants.
61915933|NCT05088239||PAD|In prophylactic antibiotics for drain group (PAD) (n = 15), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative for 10-14 days when the drains were removed from the breast and abdomen.
61915934|NCT05088239||PA3|In the 3-day prophylactic antibiotics group (PA3) (n = 11), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in peri-operative period, and 6-hourly thereafter for 3 days.
61915935|NCT05088239||PA1|In the 1-day prophylactic antibiotics group (PA1) (n = 82), patients received prophylactic cefazolin 1000 mg 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative period and antibiotics were discontinued within 24 hours of surgery.
61915936|NCT03067233|EXPERIMENTAL|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
61915937|NCT01445626||All participants|Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.
61915938|NCT04456153|EXPERIMENTAL|standard of care therapy with atovaquone|The first treatment group will receive continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days.
61915939|NCT04456153|PLACEBO_COMPARATOR|standard of care therapy with matching placebo|The second treatment group will receive continued standard of care therapy together with matching placebo.
61915940|NCT05911282|EXPERIMENTAL|NAC|NAC group was given 1.2 g of N-acetylcysteine before and 1.2 g after drinking alcohol
61915941|NCT05911282|PLACEBO_COMPARATOR|PLACEBO|Placebo group was given lemon juice before and after drinking alcohol
61915942|NCT04941742||Active eosinophilic esophagitis|
61915943|NCT04941742||Eosinophilic esophagitis in remission|
61915944|NCT04941742||No eosinophilic esophagitis|
61915945|NCT01503112||Patients starting incretin treatments|Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
61915946|NCT02208778|EXPERIMENTAL|Duloxetine|Duloxetine 30 mg a day (2 weeks), then 60 mg a day (4weeks), taken by mouth
61915947|NCT02208778|PLACEBO_COMPARATOR|Placebo (for Duloxetine)|Sugar pill: 1 capsule a day (2 weeks), then 2 capsules a day (4 weeks) taken by mouth
61915948|NCT02208778|EXPERIMENTAL|Remifentanil|Intravenous infusion with maximum estimated plasma target of 1.0 ng/ml, during less than 20 minutes
62110442|NCT05904535||All patients|Cerebrospinal fluid will be collected from all study subjects and analyzed with sequencing techniques, Optotracing, and REDOX. All methods will compared with CSF bacterial cultures which is the current golden standard.
62300891|NCT03322800|EXPERIMENTAL|AK0529 100 mg, Pilot|This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.
61915949|NCT02208778|PLACEBO_COMPARATOR|Placebo (for Remifentanil)|Intravenous infusion of normal saline, during less than 20 min
61915950|NCT05898269|EXPERIMENTAL|Trendelenburg maneuver-EE OCC-EI OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62110443|NCT00844571||E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
62110444|NCT00844571||control group|
62110445|NCT05720546||Outpatient treatment center|Subjects received an infusion in an outpatient infusion center.
62110446|NCT05720546||Inpatient Infusion Center|Subjects received an infusion in an inpatient infusion center.
62110447|NCT04038229|NO_INTERVENTION|Standard of care|Prospective derived data from children and adolescents undergoing spinal fusion due to idiopathic scoliosis
61915951|NCT05898269|EXPERIMENTAL|Trendelenburg maneuver-EE OCC-Tidal volume challenge-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915952|NCT05898269|EXPERIMENTAL|Trendelenburg maneuver-Tidal volume challenge-EI OCC-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915953|NCT05898269|EXPERIMENTAL|Trendelenburg maneuver-Tidal volume challenge-EE OCC-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62110448|NCT04038229|EXPERIMENTAL|Enhanced recovery pathway|Children and adolescents undergoing spinal fusion due to idiopathic scoliosis using the pre -per and postoperative enhanced recovery protocol
62300892|NCT03322800|EXPERIMENTAL|AK0529 100 mg|Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
61915954|NCT05898269|EXPERIMENTAL|Trendelenburg maneuver-EI OCC-Tidal volume challenge-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915955|NCT05898269|EXPERIMENTAL|Trendelenburg maneuver-EI OCC-EE OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62110449|NCT02881125|EXPERIMENTAL|Treatment (paclitaxel, nortriptyline hydrochloride)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nortriptyline hydrochloride PO QD on days 1-7, BID on days 8-14, and TID on days 15-28 of course 1 and TID on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62110450|NCT01393912|OTHER|Stratum A Patients|The patients are newly diagnosed Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 3 (170 mg/m\^2).
62110451|NCT01393912|OTHER|Stratum B Patients|The patients are recurrent, refractory or progressive high-grade glioma including Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 4 (220 mg/m\^2).
62110452|NCT02438124|EXPERIMENTAL|Patient|Patient with Parkinson's Disease with walking test and neuropsychological evaluation
62110453|NCT02438124|EXPERIMENTAL|Contrôle|normal control with walking test and neuropsychological evaluation
62110454|NCT05154942|EXPERIMENTAL|DOXO+electroacupuncture|EA is given every day for the first three days before DOXO pumping, and EA is given when DOXO is pumped for 30 minutes each time
62300893|NCT03322800|EXPERIMENTAL|AK0529 300 mg, food effect|A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.
62300894|NCT03322800|EXPERIMENTAL|AK0529 600 mg|Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.
62110455|NCT05154942|NO_INTERVENTION|Non-electroacupuncture|Compared to the experimental group without EA treatment
62110456|NCT02028637|EXPERIMENTAL|toll like receptor (TLRs)|TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters
62300895|NCT03322800|EXPERIMENTAL|AK0529 300 mg, MAD|Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.
62300896|NCT03322800|OTHER|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.
62300897|NCT00181298|ACTIVE_COMPARATOR|1|
62300898|NCT00181298|PLACEBO_COMPARATOR|2|
62300899|NCT03633331|EXPERIMENTAL|Treatment (palbociclib, letrozole or fulvestrant)|Patients receive palbociclib PO QD on days 1-21. Patients also receive letrozole PO QD on days 1-28 or fulvestrant IM on days 1 and 15 of course 1 and on day 1 of subsequent courses per MD discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62470568|NCT00239577|EXPERIMENTAL|DENGUE FORMULATION 19 GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 19, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6 and one booster dose approximately 5-12 months after the second dose.
61915956|NCT05898269|EXPERIMENTAL|EE OCC-EI OCC-Tidal volume challenge-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915957|NCT05898269|EXPERIMENTAL|EE OCC-EI OCC-Trendelenburg maneuver-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62110457|NCT04836624|EXPERIMENTAL|Co-designing personalised aids of daily living|Participants will be involved in up to 6 interactive sessions spread over 3 months with the researcher. Participants will work with the researcher to help develop their own assistive device to overcome challenges of daily living they experience.
62110458|NCT04179227||Observational (focus group)|Participants attend a focus group session and review printed copies of planned posts for the to-be-developed Facebook intervention over 90 minutes to 2 hours.
62110459|NCT04480814||Metastatic Breast Cancer|"The study population are subjects with a confirmed diagnosis of ER+/HER2 metastatic Breast Cancer patient before the treatment initiation.~The selected inclusion/exclusion criteria have been set to include in the performance study appropriate population of interest, as broad as possible, but to exclude these subjects that have another current malignancy or any history of recent malignancy within 3 years."
62110460|NCT04480814||Healthy volunteers|In case of healthy volunteers only peripheral blood samples will be collected.
62110461|NCT03860220|ACTIVE_COMPARATOR|NEWSTATIN TS|Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)
62110462|NCT03860220|PLACEBO_COMPARATOR|CADUET|Dual therapy (Amlodipine + Atorvastatin 5/10mg)
62110463|NCT04767828|EXPERIMENTAL|One arm exploratory research|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition. Pyrrotini: 400 mg once a day, oral within 30 minutes after breakfast for 21 days. Cassitabine: twice a day, 800 mg / m2 orally within 30 minutes after each meal (one morning and one night, 12 hours apart, equivalent to a daily dose of 1600 mg / m2, one dose in the morning and one dose in the morning)
62300900|NCT03885921|EXPERIMENTAL|Ezetimibe+Atorvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with atorvastatin 40 mg (starting dose) via oral tablet once daily in the morning (may be titrated up to a maximum daily dose of 80 mg for atorvastatin, if needed) for up to 24 months.
62470569|NCT00239577|PLACEBO_COMPARATOR|PLACEBO GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Placebo, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
62470570|NCT01450189|ACTIVE_COMPARATOR|Standard Counseling Arm|The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
62110464|NCT03612804|NO_INTERVENTION|Unstructured care|Providers in this arm will continue to provide care as usual during lung cancer screening, with no intervention from the study team.
62110465|NCT03612804|EXPERIMENTAL|Proactive care|Providers in this arm will receive guidance from the study team about offering lung cancer screening patients proactive cessation care, including cessation medications and behavioral telephone counseling.
62110466|NCT02742896||Restoration of Erectile dysfunction|The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.
62110467|NCT00363116|ACTIVE_COMPARATOR|5 Dose Daclizbumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
62470571|NCT01450189|ACTIVE_COMPARATOR|Behavioral Intervention Arm only|Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
62300901|NCT03885921|EXPERIMENTAL|Ezetimibe+Simvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with simvastatin 40 mg (starting dose) via oral tablet once daily in the evening (may be titrated up to a maximum daily dose of 80 mg for simvastatin, if needed) for up to 24 months.
62300902|NCT01120626|ACTIVE_COMPARATOR|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
62300903|NCT01120626|PLACEBO_COMPARATOR|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
62300904|NCT03016611|ACTIVE_COMPARATOR|Chewing Ticagrelor|
62300905|NCT03016611|EXPERIMENTAL|Chewing Prasugrel|
62300906|NCT02607215|EXPERIMENTAL|Vinorelbine Plus DDP|"Vinorelbine:25 mg/m2, D1, D8 every 21 days~DDP:75 mg/m2, D1 every 21 days"
62300907|NCT02607215|ACTIVE_COMPARATOR|Vinorelbine|Vinorelbine:30 mg/m2, D1, D8 every 21 days
62300908|NCT02426606|EXPERIMENTAL|White bread|
62300909|NCT02426606|EXPERIMENTAL|Lentil 1 + white rice|
62300910|NCT02426606|EXPERIMENTAL|Lentil 2 + white rice|
61915958|NCT05898269|EXPERIMENTAL|EE OCC-Tidal volume challenge-Trendelenburg maneuver-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62110468|NCT00363116|ACTIVE_COMPARATOR|2 Dose Daclizaumab|daclizumab 2 mg/kg/dose every 14 days for 2 doses
62110469|NCT00363116|ACTIVE_COMPARATOR|Control|no antibody induction
62110470|NCT04142788|NO_INTERVENTION|Standard dose MRA|Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
62110471|NCT04142788|EXPERIMENTAL|Patiromer and high dose MRA|Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).
62110472|NCT05652322|ACTIVE_COMPARATOR|Group 1|prolonged intravenous loop diuretic treatment - furosemide
62110473|NCT05652322|EXPERIMENTAL|Group 2|Early (48 hrs) change to oral loop diuretic - furosemide - 150% eqivalent iv dose
62110474|NCT05652322|EXPERIMENTAL|Group 3|Early (48 hrs) change to oral loop diuretic - furosemide - 200% eqivalent iv dose
62110475|NCT03002844|EXPERIMENTAL|EGFR-TKI and Chemotherapy|gefitinib with pemetrexed/gemcitabine and carboplatin
62110476|NCT03002844|EXPERIMENTAL|EGFR-TK Inhibitor|Gefitinib
62110477|NCT03718793|EXPERIMENTAL|All subjects with asthma|In addition to normal diagnostic work out we will measure small airway inflammation based on peripheral exhaled nitric oxide and assess small airway dysfunction using impulse oscillometry. In addition, inflammatory markers in peripheral blood and genotype will be assessed.
62300911|NCT02426606|EXPERIMENTAL|Lentil 3 + white rice|
62300912|NCT02426606|EXPERIMENTAL|White rice|
61915959|NCT05898269|EXPERIMENTAL|EE OCC-Tidal volume challenge-EI OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915960|NCT05898269|EXPERIMENTAL|EE OCC-Trendelenburg maneuver-Tidal volume challenge-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915961|NCT05898269|EXPERIMENTAL|EE OCC-Trendelenburg maneuver-EI OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915962|NCT05898269|EXPERIMENTAL|EI OCC-Tidal volume challenge-EE OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915963|NCT05898269|EXPERIMENTAL|EI OCC-Tidal volume challenge-Trendelenburg maneuver-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62300913|NCT02426606|EXPERIMENTAL|Lentil 1 + potato|
62300914|NCT02426606|EXPERIMENTAL|Lentil 2 + potato|
61915964|NCT05898269|EXPERIMENTAL|EI OCC-Trendelenburg maneuver-EE OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915965|NCT05898269|EXPERIMENTAL|EI OCC-Trendelenburg maneuver-Tidal volume challenge-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915966|NCT05898269|EXPERIMENTAL|EI OCC-EE OCC-Trendelenburg maneuver-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915967|NCT05898269|EXPERIMENTAL|EI OCC-EE OCC-Tidal volume challenge-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915968|NCT05898269|EXPERIMENTAL|Tidal volume challenge-EI OCC-EE OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915969|NCT05898269|EXPERIMENTAL|Tidal volume challenge-EI OCC-Trendelenburg maneuver-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915970|NCT05898269|EXPERIMENTAL|Tidal volume challenge-Trendelenburg maneuver-EE OCC- EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915971|NCT05898269|EXPERIMENTAL|Tidal volume challenge-Trendelenburg maneuver- EI OCC-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62110478|NCT03059264||CDM|Children with Congenital Myotonic Dystrophy
62110479|NCT03059264||Control|Healthy Children
62110480|NCT01128530|EXPERIMENTAL|JNJ-32729463|JNJ-32729463 250 mg tablet and matching linezolid placebo twice daily
62110481|NCT01128530|ACTIVE_COMPARATOR|linezolid|linezolid 600 mg tablet and matching JNJ-32729463 placebo twice daily
62110482|NCT02920359|EXPERIMENTAL|LEUPRORELIN ACETATE|
62110483|NCT02169102|OTHER|Control|
62110484|NCT02169102|SHAM_COMPARATOR|Sham Laser|
62110485|NCT02169102|EXPERIMENTAL|Laser 1|Low Power Laser applied at 0.16 Joules/point. 2 points of laser irradiation
62110486|NCT02169102|EXPERIMENTAL|Laser 2|Low Power Laser applied at 16 Joules/point. 2 points of laser irradiation
62110487|NCT01989624||Pancreatic Adenocarcinoma|
62110488|NCT02454244|EXPERIMENTAL|Amygdala Retraining Technique (ART) with Mindfulness|Consists of 10 weekly sessions, followed by 3 monthly sessions
62300915|NCT02426606|EXPERIMENTAL|Lentil 3 + potato|
62300916|NCT02426606|EXPERIMENTAL|Potato|
62300917|NCT04617288|EXPERIMENTAL|Mean and standard deviations of age and height between group A and B|100 subjects with a mean age of 30.82±6.75 (group A, 31.42±6.67; group B, 30.82±6.82) ranging from 20 to 45 years, with a mean height of 165.52±7.85 (group A, 164.92±7.79; group B, 166.12±7.87) centimeters
62470572|NCT01450189|ACTIVE_COMPARATOR|Behavioral Intervention plus ARV|The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
61915972|NCT05898269|EXPERIMENTAL|Tidal volume challenge-EE OCC-Trendelenburg maneuver- EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
61915973|NCT05898269|EXPERIMENTAL|Tidal volume challenge-EE OCC- EI OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
62672092|NCT05089175||Women at low risk for preeclampsia|Using FIGO recommended preeclampsia screening model for the first-trimester which combined maternal risk factors, mean arterial pressure, placental growth factor, uterine artery pulsatility index to evaluate pregnant's risk for preeclampsia. Risk value\<1/100 is defined as screened low risk.
62672093|NCT04786574|EXPERIMENTAL|Tolvaptan (OPC-41061)|
62672094|NCT02614664||Single ventricle|Patients with single ventricle physiology presenting for laparoscopic procedures.
62672095|NCT00842374||Non-STEMI ACS|
62110489|NCT02454244|EXPERIMENTAL|Mindfulness Compassion|Includes the attentional training aspect of mindfulness and meditation practices, proved to bring benefits in relation to fibromyalgia and CFS symptoms, as fatigue and pain. Compassion training focuses on the ability to be kind to participants and their own experience, specifically to their experience of suffering. The protocol consists of 10 weekly sessions, followed by 3 following monthly sessions
62110490|NCT02454244|ACTIVE_COMPARATOR|Relaxation|Consists of 10 weekly sessions, followed by 3 monthly sessions
62110491|NCT00430300|EXPERIMENTAL|150mcg, 450mcg or 1350mcg|Active treatment given BID via a double pin monodose capsule inhaler device
62672096|NCT01447147|PLACEBO_COMPARATOR|Placebo (Group A)|
62672097|NCT01447147|EXPERIMENTAL|CCX140-B (Group B)|
62672098|NCT01447147|EXPERIMENTAL|CCX140-B (Group C)|
62672099|NCT05154162|EXPERIMENTAL|Experimental|Pelvic PSMA PET ± transperineal targeted prostate biopsy
62672100|NCT05154162|OTHER|Control|No pelvic PSMA PET + transperineal template prostate biopsy
62672101|NCT00169390||pregnant smokers|
62672102|NCT00169390||pregnant non smokers|
62672103|NCT03720171|EXPERIMENTAL|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb.
62672104|NCT03428555|EXPERIMENTAL|Integrate Care Pathway|"The intervention is an Integrated Care Pathway with 3 key components.~1. Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People.~2. Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol.~3. Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD)."
61915974|NCT01606878|EXPERIMENTAL|Part A (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (oral solution) PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
61915975|NCT01606878|EXPERIMENTAL|Part B (crizotinib, vincristine, dexrazoxane, doxorubicin)|Patients receive crizotinib (oral solution) PO BID as in Part A. Patients also receive vincristine sulfate IV on day 1, dexrazoxane hydrochloride IV on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
61915976|NCT01606878|EXPERIMENTAL|Part C (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (capsule formulation) PO BID, cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62110492|NCT00430300|PLACEBO_COMPARATOR|Placebo|Placebo treatment given BID via a single pin monodose inhaler device
62110493|NCT05098340||AIS group|This group includes patients with acute ischemic stroke (AIS).
61915977|NCT01606878|EXPERIMENTAL|Part D (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (microsphere formulation) PO BID, cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
61915978|NCT05178745||Cohort 1|Patients with metastatic colorectal cancer and liver metastases treated with FOLFIRI plus aflibercept after failure of an oxaliplatin-based regimen
62110494|NCT05098340||HC group|This group includes healthy controls (HC).
62110495|NCT05416671|EXPERIMENTAL|Treatment group|
62110496|NCT05416671|NO_INTERVENTION|Control group|
62110497|NCT02722668|EXPERIMENTAL|No ATG|Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
62110498|NCT02722668|EXPERIMENTAL|ATG|Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
62110499|NCT06067178|EXPERIMENTAL|Health Dialogue Intervention|
62110500|NCT06067178|EXPERIMENTAL|Opportunistic Screening|
62110501|NCT00680537|NO_INTERVENTION|1|Control group
62110502|NCT00680537|EXPERIMENTAL|2|Exercise group
62470573|NCT04132011|ACTIVE_COMPARATOR|Shortened interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals less than every 12 hours.
62470574|NCT04132011|ACTIVE_COMPARATOR|Standard interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals every 12 hours
61915979|NCT06185270||Patients undergoing minimally invasive distal gastrectomy for early gastric cancer|
61915980|NCT04671953|EXPERIMENTAL|Arm 1: BMS-986165 Dose 1 + Metformin|
61915981|NCT04671953|EXPERIMENTAL|Arm 2: BMS-986165 Dose 2 + Metformin|
61915982|NCT04291001|ACTIVE_COMPARATOR|ENG Implant alone|Participants will receive a contraceptive implant in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
62110503|NCT05451199|EXPERIMENTAL|ICP-488|Single ascending doses of ICP-488 tablet; Multiple ascending doses of ICP-488 tablet; Part3 Patients with Psoriasis:ICP-488 tablet.
62110504|NCT05451199|PLACEBO_COMPARATOR|Placebo|Single ascending doses of placebo; Multiple ascending doses of placebo; Part3 Patients with Psoriasis of placebo.
62110505|NCT00880906|ACTIVE_COMPARATOR|A|Group A receives steroids and PPI, (SOC) and esophageal dilation.
62110506|NCT00880906|SHAM_COMPARATOR|B|Receives steroids and PPI only- Does not have esophageal dilation.
62110507|NCT01070251|ACTIVE_COMPARATOR|Existing state-sponsored PA program|standard children-focused gym lessons approach
62110508|NCT01070251|ACTIVE_COMPARATOR|Participatory intervention plus state-sponsored PA program|Participatory parent-focused intervention over nine months in addition to state-sponsored PA program
62110509|NCT03651713|EXPERIMENTAL|GLU+EX|Subjects will consume a 75g glucose beverage three times daily for seven days while participating in five structured aerobic exercise sessions throughout the experimental protocol.
62110510|NCT03651713|ACTIVE_COMPARATOR|GLU|Subjects will consume a 75g glucose beverage three times daily for seven days without participating in structured aerobic exercise.
62110511|NCT06020651|EXPERIMENTAL|ICIs alone|Participants on ICIs alone
62110512|NCT06020651|EXPERIMENTAL|ICIs + VEGF inhibitors|Participants on ICIs + VEGF inhibitors
62110513|NCT06020651|EXPERIMENTAL|ICIs + chemotherapy|Participants on ICIs + chemotherapy
61915983|NCT04291001|ACTIVE_COMPARATOR|ENG Implant plus oral UPA|Participants will receive a contraceptive implant and oral UPA the same day in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
61915984|NCT03493659|NO_INTERVENTION|Sit-Sit|The participants will sit during the tutorials, and sit during the concept tests given to measure their learning.
62470575|NCT05132166|ACTIVE_COMPARATOR|BAT|anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
62470576|NCT05132166|EXPERIMENTAL|DSC|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
61915985|NCT03493659|ACTIVE_COMPARATOR|Sit-Stand|The participants will sit during the tutorials. Intervention: Behavioral: Standing during Concept Test will be administered
61915986|NCT03493659|ACTIVE_COMPARATOR|Stand-Stand|The participants will stand during the tutorials, and stand during the concept tests given to measure their learning. Intervention: Behavioral: Standing during Concept Test and regular tutorial session will be administered.
61915987|NCT03493659|ACTIVE_COMPARATOR|Stand-Sit|"The participants will stand during the tutorials. Intervention: Behavioral: Standing during regular tutorial session will be administered.~However, participants will sit during the concept tests given to measure their learning."
61915988|NCT01692795||MI patients|
62110514|NCT06020651|SHAM_COMPARATOR|Controls|Participants on other than ICIs cancer therapies
62110515|NCT06628375||Case Group|Biological mother and son with hypospadias
62110516|NCT06628375||Control Group|Biological mother and son without hypospadias
62110517|NCT01295918|NO_INTERVENTION|Placebo, antibiotic, diarrhea|
62470577|NCT05857085|ACTIVE_COMPARATOR|GLP 1 agonist|semaglutide in titrating doses 0,25 to 1,0 mg - duration of treatment12 weeks adding to insulin sheme (MDI or CII)
62470578|NCT05857085|ACTIVE_COMPARATOR|SGLT 2 inhibitor|empagliflozin 25 mg - duration of treatment 12 weeks adding to insulin sheme (MDI or CII or hybride system)
62672105|NCT03428555|ACTIVE_COMPARATOR|Treatment As Usual|Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
62672106|NCT05752331|EXPERIMENTAL|Physical activity behavioural modification|The 8-week PA behavioural modification intervention will focus on engaging participants in ADL and lowering sedentary time. Each participant will receive one semi-structured motivational interview at baseline to discuss favourite activities and barriers and facilitators to PA. Participants will produce an individualised action plan following the interview that will be followed throughout the intervention to allow an individualised approach to take place. Participants will then be provided with a low-cost pedometer and PA diary to self-monitor and record daily PA. The PA diary will provide examples of various activities that can be done in and around the house, with an emphasis placed on simple, effective movements to reduce sedentary time. Following this, a researcher will conduct weekly virtual meetings with the participant to discuss the past weeks PA levels and provide future individualised goals to promote ADL.
62672107|NCT05752331|NO_INTERVENTION|Usual Care|All participants will be notified of the government 'your Covid recovery' programme (usual care) which provides details and support on managing long term symptoms of Covid-19.
62470579|NCT05857085|NO_INTERVENTION|comparator|continuing treatment only with insulin sheme (MDI or CII or hybride system)
62110518|NCT01295918|PLACEBO_COMPARATOR|L. reuteri, Antibiotic, diarrhoea|L. reuteri will be ingested by patients on antibiotic therapy, effect of probiotic on AAD will be assessed.
62110519|NCT01896258||Regional emergency centers|
62110520|NCT01896258||Local emergency centers|
62110521|NCT04103671|EXPERIMENTAL|Group A|Prompt panretinal photocoagulation
62672108|NCT01774539||Physeal Injury - Distal Radius|Patients who suffer a physeal fracture of the distal radius will be scanned and compared to their healthy contralateral limb.
62672109|NCT01718106|ACTIVE_COMPARATOR|Single long bioabsorbable polymer DES|Patients with long coronary stenosis treated by a single long bioabsorbable polymer DES
62672110|NCT01718106|ACTIVE_COMPARATOR|Two bioabsorbable polymer DES in overlapping|patients with long coronary artery stenosis tretaed by 2 bioabsorbable polymer DES with minimal overlapping
62672111|NCT04785885||Transcatheter Aortic Valve Replacement|Patients receive 100U/Kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
61915989|NCT01804829|NO_INTERVENTION|Observational Control|Subjects who attain HCV RNA \<100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 34 week period.
61915990|NCT01804829|EXPERIMENTAL|Civacir® 10% at 200 mg/kg dose|Subjects who attain HCV RNA \<100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
61915991|NCT01804829|EXPERIMENTAL|Civacir® 10% at 300 mg/kg dose|Subjects who attain HCV RNA \<100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
62110522|NCT04103671|EXPERIMENTAL|Group B|Micro-invasive Pars-plana vitrectomy
62110523|NCT02351180|EXPERIMENTAL|Inhaled beclomethasone|Inhaled beclomethasone 320 mcg twice daily for 180 days.
62110524|NCT02351180|PLACEBO_COMPARATOR|Placebo|Inhaled placebo twice daily for 180 days.
62110525|NCT01413113|EXPERIMENTAL|Treatment (enzyme inhibitor and radioactive drug therapy)|Patients receive iodine I 131 IM QD 5 days a week in weeks 5-6. Patients also receive pazopanib hydrochloride PO QD beginning in week 1 and continuing for 8 weeks post-radioactive iodine therapy.
62110526|NCT02054299|EXPERIMENTAL|Drug application|6 treatment periods. On each period one of the following interventions
62110527|NCT06031350||Diseased eyes|The 30 diseased eyes of the patients were considered the case group.
62672112|NCT04785885||Cardiac Valve Annuloplasty|Patients receive 300U/kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
62110528|NCT06031350||Fellow eyes|The 30 fellow eyes of the patients were considered the control group.
62110529|NCT01670058||Belatacept treated adult kidney-only transplant recipients|All adult kidney-only transplant recipients treated with Nulojix (Belatacept)
62110530|NCT01670058||CNIs at transplantation|
62470580|NCT02294253|EXPERIMENTAL|Buprenorphine/naloxone stabilization|Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
62672113|NCT00025233|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62672114|NCT01249443|EXPERIMENTAL|Treatment (carboplatin, paclitaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Before February 1, 2013, patients also received vorinostat PO once daily on days 1-5 with paclitaxel and carboplatin."
62110531|NCT01145885|EXPERIMENTAL|BI 6727|BI 6727 cycles in every 21 days
62110532|NCT05339971|EXPERIMENTAL|block perforation|
62110533|NCT06343987|EXPERIMENTAL|Intervention Arm|14 participants
62110534|NCT06343987|NO_INTERVENTION|Observational Arm|7 participants
62300918|NCT04617288|EXPERIMENTAL|Between group comparison of VAS, NDI and ROM|VAS, NDI and Neck ROM between two groups were compared at pretest (0 day) and posttest (end of two weeks)
62300919|NCT00765765|EXPERIMENTAL|Ixabepilone and hydroxychloroquine|
62470581|NCT01202422|EXPERIMENTAL|Pregabalin controlled release, 165 mg|
62470582|NCT01202422|EXPERIMENTAL|Pregabalin controlled release, 330 mg|
62470583|NCT01202422|OTHER|Pregabalin immediate release, 150 mg|Reference Treatment
62470584|NCT01773590|OTHER|Asthmatics|Rhinovirus Infection
62300920|NCT04057443|EXPERIMENTAL|Intervention group|Patients in the intervention group will follow the standard treatment and follow-uo according to the clinical protocol of the institution and will participate in an intervention program with physical exercise and nutritional support during the period in which they are receiving oncological treatment or for a maximum period of 6 months.
62300921|NCT04057443|ACTIVE_COMPARATOR|Control group|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
62300922|NCT05182736|EXPERIMENTAL|TRAIL intervention|"The TRAIL program is comprised of a multi-tier system of strategies:~1. Universal Strategies (delivered school-wide),~2. Targeted Strategies (delivered to the target grade level in the evaluation sample)~3. Intensive Strategies (delivered to select at-risk students)"
62470585|NCT01773590|OTHER|Healthy Volunteers|Rhinovirus Infection
61915992|NCT01845987|PLACEBO_COMPARATOR|Placebo|
62470586|NCT04739020|ACTIVE_COMPARATOR|PCR SARS-CoV-2 Negative Adults|Healthy adults with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of parents of participating children and other healthy volunteers.
62470587|NCT04739020|ACTIVE_COMPARATOR|PCR SARS-CoV-2 Positive Adults|Adults with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic parents that are in the hospital with their children and symptomatic adults that are admitted to the infectious disease ward.
61915993|NCT01845987|EXPERIMENTAL|CNTO 1959|
62300923|NCT05182736|NO_INTERVENTION|Control|"Students in the comparison schools receive the normal ninth grade health curriculum, Reproductive and Health Safety Education."
62470588|NCT04739020|ACTIVE_COMPARATOR|PCR SARS-CoV-2 Negative Children|Children with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of children admitted to the Children's Hospital or presenting for planned diagnostic testing or follow up.
62470589|NCT04739020|ACTIVE_COMPARATOR|PCR SARS-CoV-2 Positive Children|Children with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic children that are admitted to the Children's Hospital for reasons other than COVID-19 and symptomatic children.
62470590|NCT04797195|EXPERIMENTAL|CKD-PD app user group|Patients on peritoneal dialysis using the CKD-PD app and home monitoring equipment to measure and record blood pressure, body weight, and dialysis fluid removed
62300924|NCT01823211||ischaemic cardiomyopathy|EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation
62300925|NCT01823211||non-ischaemic cardiomyopathy|EP study,magnetic resonance imaging with LGE, ICD implantation
62672115|NCT00349076|EXPERIMENTAL|1|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil und Oxaliplatin:~Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours; repeat day 15, 8 cycles"
62672116|NCT00349076|ACTIVE_COMPARATOR|2|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; 5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
62672117|NCT05202431|EXPERIMENTAL|Adherence|Participants received training, telefollow-up and daily text messages for 6 months.
62672118|NCT05202431|NO_INTERVENTION|Standart care|The standard follow-up applied in the dispensary for this group was performed.
62672119|NCT02415803|EXPERIMENTAL|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with non-ST-elevation acute coronary syndrome
62672120|NCT02415803|ACTIVE_COMPARATOR|conventional-dose ticagrelor|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose ticagrelor.
62672121|NCT02415803|ACTIVE_COMPARATOR|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
62672122|NCT04614272|EXPERIMENTAL|active prayer group|the active prayer group will mediate over an active type of prayer
62672123|NCT04614272|EXPERIMENTAL|passive prayer group|the passive prayer group will mediate over a passive type of prayer
62672124|NCT04614272|SHAM_COMPARATOR|control group|the control group will read a poem
62672125|NCT00738517|ACTIVE_COMPARATOR|1|Immunoadsorption with subsequent immunoglobulin substitution
62672126|NCT00738517|NO_INTERVENTION|2|
62672127|NCT05655897|EXPERIMENTAL|A single set of test|The GeminiOne Transcatheter Valve Edge-to-Edge Repair System consists of a transcatheter valve clamping system and an adjustable curved introducer catheter.
62672128|NCT00415259|EXPERIMENTAL|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
62672129|NCT00415259|OTHER|Flat control insoles|
62672130|NCT05178979|EXPERIMENTAL|Intervention|The intervention arm will receive up to 4 sessions of training. Trained intervention facilitator experienced in health professional trainings will lead the training. The intervention content delivered is aimed to increase HIV providers' knowledge, motivation, skills, and empathy to: 1) equitably deliver ART program guidelines (i.e., quality of care) and 2) provide gender sensitive counseling to address ART patients' gendered barriers to HIV care engagement, increasing patient satisfaction, retention, and ART adherence, and reducing gender disparities in HIV outcomes.
62672131|NCT05178979|NO_INTERVENTION|Control|The control arm will receive no training.
62672132|NCT04214236|EXPERIMENTAL|ciNPT group|Subjects will receive post-operative incisional wound care by ciNPT (125 mmHg, continuous suction) for the first 7 days after surgery.
62672133|NCT04214236|SHAM_COMPARATOR|Control group|Subjects will receive post-operative incisional wound care by standard non-adherent surgical dressing (vaseline petrolatum gauze),
62672134|NCT03815604|EXPERIMENTAL|RCT-IHS|Behavioral: At the Zurich site, the experimental intervention is called Independent Housing and Support
62672135|NCT03815604|ACTIVE_COMPARATOR|RCT-RCS/TAU|Behavioral: At the Zurich site, the comparator is usual residential care
62672136|NCT03815604|EXPERIMENTAL|OSD-IHS|Behavioral: At the Berne site, the experimental intervention is called Independent Housing and Support
62672137|NCT03815604|ACTIVE_COMPARATOR|OSD-RCS/TAU|Behavioral: At the Berne site, the comparator is usual residential care
62672138|NCT00576342|OTHER|AL-3862+timolol, then COSOPT|AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
62672139|NCT00576342|OTHER|COSOPT, then AL-3862+timolol|Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
61915994|NCT05346445|ACTIVE_COMPARATOR|Fluoxetine group|Participants received fluoxetine, 20 mg tablets, once a day for six months.
61915995|NCT05346445|EXPERIMENTAL|Citalopram group|Participants received citalopram, 20 mg tablets, once a day for six months.
61915996|NCT04647487|EXPERIMENTAL|LY3484356 Dose Level 1|Administered orally.
61915997|NCT04647487|EXPERIMENTAL|LY3484356 Dose Level 2|Administered orally.
61915998|NCT04647487|EXPERIMENTAL|LY3484356 Dose Level 3|Administered orally.
62672140|NCT03475043|EXPERIMENTAL|Auditory training: temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in a temporal (timing/duration) cue for 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear sentences that vary in speech rate for 6, 1-hour training sessions and will receive correct-answer feedback."
62672141|NCT03475043|ACTIVE_COMPARATOR|Auditory training: non-temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in either stimulus intensity or stimulus frequency during 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear speech in varying levels of noise during 6, 1-hour training sessions and will receive correct-answer feedback."
62672142|NCT03475043|NO_INTERVENTION|Passive control group (Aims 1 and 2)|Listeners will be evaluated on pre-training and post-training tests, but will receive no training at all.
62672143|NCT03696667|ACTIVE_COMPARATOR|Affective BCI training|15 participants in the intervention group will undergo 24 sessions of BCI-based emotion regulation training over an 8-week period. Each session will take about 30-minute to complete where participants will listen to music with audio feedback to regulate emotions toward positive affect.
62300926|NCT02999503|EXPERIMENTAL|Nutritional intervention|Patients subject to nutritional education by CINUSA group protocol
62300927|NCT02999503|NO_INTERVENTION|No intervention|Patients not subject to nutritional education
62672144|NCT03696667|NO_INTERVENTION|Control group|15 participants in the control group will take part in 24 music sessions (with no audio feedback) over an 8-week period. Each session will take about 30-minute to complete.
62672145|NCT01276418|EXPERIMENTAL|Treatment|
62672146|NCT06070532|EXPERIMENTAL|Intervention group|12 female or male patients suffering from aging frailty
62672147|NCT02985710|OTHER|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
62672148|NCT02985710|OTHER|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
62672149|NCT03356561|EXPERIMENTAL|Group 1: Ad26.ZIKV.001 5*10^10 Viral Particles (vp)|Participants will receive Ad26.ZIKV.001 at 5\*10\^10 viral particles (vp) via intramuscular (IM) route on Days 1 and 57.
62672150|NCT03356561|EXPERIMENTAL|Group 2: Ad26.ZIKV.001 5*10^10 vp and Placebo|Participants will receive Ad26.ZIKV.001 5\*10\^10 vp on Day 1 and placebo on Day 57 via IM route.
62672151|NCT03356561|EXPERIMENTAL|Group 3: Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at 1\*10\^11 vp via IM route on Days 1 and 57.
62672152|NCT03356561|EXPERIMENTAL|Group 4: Ad26.ZIKV.001 1*10^11 vp and Placebo|Participants will receive Ad26.ZIKV.001 1\*10\^11 vp on Day 1 and placebo on Day 57 via IM route.
62672153|NCT03356561|PLACEBO_COMPARATOR|Group 5: Placebo|Participants will receive placebo via IM route on Days 1 and 57.
62672154|NCT05033600|EXPERIMENTAL|Interventional - PEMF Therapy Recipients|90-minute sessions rendered twice weekly over three consecutive weeks. PEMFs are administered through electrodes attached to wrists, ankles and forehead of participant.
62672155|NCT00239980|ACTIVE_COMPARATOR|A|50 IU/kg
62672156|NCT00239980|ACTIVE_COMPARATOR|B|100 IU/kg
62672157|NCT00239980|ACTIVE_COMPARATOR|C|150 IU/kg
62672158|NCT06375720|EXPERIMENTAL|Tai Chi Chuan Group1|12 weeks of Tai Chi Chuan, 3x/week
62672159|NCT06375720|EXPERIMENTAL|Tai Chi Chuan Group2|12 weeks of Tai Chi Chuan, 5x/week
62672160|NCT06375720|EXPERIMENTAL|Tai Chi Chuan Group3|24 weeks of Tai Chi Chuan, 3x/week
62672161|NCT06375720|EXPERIMENTAL|Tai Chi Chuan Group4|24 weeks of Tai Chi Chuan, 5x/week
62672162|NCT06375720|SHAM_COMPARATOR|Control|Participants would take standard health education 0.5hour/ session, 2 sessions/month for 6 months.
62672163|NCT00504231|EXPERIMENTAL|0.3 mL Influenza Vaccine ID|60% dose - 0.3 mL delivered intradermally with needle and syringe
62300928|NCT00644592|ACTIVE_COMPARATOR|1-Fenofibrate then Placebo|4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
62300929|NCT00644592|ACTIVE_COMPARATOR|2 Placebo then Fenofibrate|4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.
62672164|NCT00504231|EXPERIMENTAL|0.15 mL twice Influenza Vaccine ID|60% dose - 0.15 mL delivered twice intradermally with needle and syringe
62672165|NCT00504231|ACTIVE_COMPARATOR|0.5 mL Influenza Vaccine by IM|100% dose - 0.5mL delivered intramuscularly with needle and syringe
62672166|NCT00504231|EXPERIMENTAL|0.3 mL Influenza Vaccine IM|60% dose - 0.3 mL delivered intramuscularly with needle and syringe
62672167|NCT01791296|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
62672168|NCT01791296|PLACEBO_COMPARATOR|Placebo|Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
62672169|NCT04555369|EXPERIMENTAL|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
62672170|NCT00705276|EXPERIMENTAL|I|
62672171|NCT05452512|SHAM_COMPARATOR|Self monitoring arm using smart clinical trial application|The subjects in this arm will take vitamin D for 3 months and keep track of drug administration using smart clinical trial application (self monitoring).
62672172|NCT05452512|EXPERIMENTAL|Active monitoring using smart watch coupled with self monitoring|The subjects in this arm will take vitamin D for 3 months and keep track of drug administration using smart watch and smart clinical trial application (self monitoring).
62672173|NCT01666613|EXPERIMENTAL|1|AZD8683 iv
62672174|NCT01666613|EXPERIMENTAL|2|AZD8683 oral
62672175|NCT01666613|EXPERIMENTAL|3|AZD8683 inhalation New Dry Powder Inhaler
62672176|NCT01666613|EXPERIMENTAL|4|AZD8683 inhalation Turbuhaler™
62672177|NCT05249400|EXPERIMENTAL|Off-site assistance group|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom. The trainer was not allowed to enter the procedure room and touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
62735967|NCT06430242|EXPERIMENTAL|Group A|In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months and the treatment will be monitored.
62110535|NCT02236559|ACTIVE_COMPARATOR|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 \> 88%."
62300930|NCT01723189||Central Apnoeas Patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of central apnoea (central apnoea index\> 10 / h, or Cheyne-Stokes breathing for more than 30% of total sleep time or mixed apneas with central apnoeas\> 50% of total apneas)
62300931|NCT01723189||Obstructive apnoea patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of obstructive sleep apnea (apnea-hypopnea index\> 20 / h)
62300932|NCT01723189||No SDB patients|* • 30 patients diagnosed with TIA / stroke within 7 days of admission and no evidence of sleep respiratory disorders at polysomnography
62300933|NCT01723189||Healthy controls|• 30 healthy controls matched for age, sex, race and BMI.
62300934|NCT04286932||5-12y|
62300935|NCT05662644|ACTIVE_COMPARATOR|Feasibility of Esophagectomy Esophageal Cancer|Minimally Invasive Surgery for Esophageal Cancer: feasibility
62300936|NCT05662644|ACTIVE_COMPARATOR|Outcome of Esophagectomy Esophageal Cancer|Minimally Invasive Surgery for Esophageal Cancer: outcome
62300937|NCT03476239|EXPERIMENTAL|Blinatumomab|"Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders.~In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for Days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). This is followed by two weeks without blinatumomab treatment.~In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks."
62300938|NCT03289689|EXPERIMENTAL|Whole body vibration|"The subjects in the WBV group performed one series of five consecutive repetitions of 60 sec unsynchronised multidimensional WBV (Zeptoring, Scisen GmbH, Germany; 4 Hz, amplitude 3mm) with a 1-min pause between administrations, three times a week. The construction of this device is designed to perform a nonharmonious generation of oscillating movements in vertical and horizontal planes in order to prevent occurrences of resonance and habituation of receptors.~During the intervention, subjects wore thin-soled gymnastic-type shoes, carrying out in a squatting standing position, with slight flexion at the hips, knees and ankle joint, on the vibration platform."
62300939|NCT03289689|NO_INTERVENTION|Control|The controls did not receive any training.
62300940|NCT03282396|EXPERIMENTAL|Treatment (ibrutinib)|Participants receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for 5 years in the absence of disease progression or unacceptable toxicity.
62300941|NCT01025635|EXPERIMENTAL|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
61915999|NCT00188708|EXPERIMENTAL|hypoxia measurement|Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
61916000|NCT02519855|EXPERIMENTAL|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
62110536|NCT02236559|EXPERIMENTAL|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 \> 88%."
62110537|NCT04030559|EXPERIMENTAL|Treatment (niraparib)|Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
62110538|NCT02306564|EXPERIMENTAL|Group A|Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation
62110539|NCT02306564|NO_INTERVENTION|Group B|Group B will include patients AT RISK of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline.
62300942|NCT01025635|PLACEBO_COMPARATOR|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
62300943|NCT00184587|EXPERIMENTAL|candesartan|candesartan cilexetil 16 mg (one tablet/day) in week 1 and 32 mg (2 tablets/day) in week 3, provided for the study by AstraZeneca
62300944|NCT00184587|PLACEBO_COMPARATOR|placebo|placebo one tablet/day in week 1 and 2 tablets/day in week 3, provided for the study by AstraZeneca. Same size, weight, taste and appearance as experimental drug
62300945|NCT01829048|EXPERIMENTAL|PF-02545920|
62110540|NCT02306564|NO_INTERVENTION|Group C|Group C will serve as a control group and will include age \& BMI matched patients NOT AT RISK of OHSS, and not receiving cabergoline.
62110541|NCT03532191|EXPERIMENTAL|PrEP-OI Intervention|All clinics that have crossed over to initiate the intervention at this time. The order of crossover is determined at random.
62110542|NCT03532191|NO_INTERVENTION|Control until randomized for intervention|All clinics that have not yet initiated the intervention at this time (i.e., control clinics). A new clinic will cross over to receive the intervention each month, with the order of clinic crossover determined at random, until all clinics are receiving the intervention.
62110543|NCT04374708||trans men|fMRI: body morph test and neurocognitive testing
62110544|NCT04374708||trans women|fMRI: body morph test and neurocognitive testing
62110545|NCT04374708||homosexual cisgender men|fMRI: body morph test and neurocognitive testing
62110546|NCT04374708||homosexual cisgender women|fMRI: body morph test and neurocognitive testing
62672178|NCT05249400|NO_INTERVENTION|On-site assistance group|The trainer supervised the trainee's cannulation operation in the procedure room. The trainer was allowed to provide unlimited verbal instructions to the trainee on-site. The trainer was not allowed to touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
62672179|NCT05137145|EXPERIMENTAL|The control group|The control group was given 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestines
62110547|NCT04374708||cisgender women|fMRI: body morph test and neurocognitive testing
62672180|NCT05137145|EXPERIMENTAL|the observation group 1|the observation group 1 was given Linaclotide(290 ug) in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine
62110548|NCT04374708||cisgender men|fMRI: body morph test and neurocognitive testing
62110549|NCT00387465|EXPERIMENTAL|Phase I - 30mg/m2 Azacitidine|Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
62110550|NCT00387465|EXPERIMENTAL|Phase I - 40mg/m2 Azacitidine|Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
62110551|NCT00387465|EXPERIMENTAL|Phase II Arm|Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62110552|NCT04074148|EXPERIMENTAL|Diabetes Prevention Education Program|Diabetes Prevention Education Program
62110553|NCT04074148|EXPERIMENTAL|control|Diabetes Prevention Education brochure
62110554|NCT04850482|EXPERIMENTAL|Intervention Arm|Participants get immediate access to the intervention on completion of baseline assessment.
62110555|NCT04850482|NO_INTERVENTION|Wait list control Arm|Participants get access to the intervention in 10 weeks after completion of the baseline and follow up assessment.
62672181|NCT05137145|EXPERIMENTAL|the observation group 2|the observation group 2 was given Linaclotide(290 ug) in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine
62672182|NCT05137145|EXPERIMENTAL|the observation group 3|the observation group 3 was given Linaclotide(290 ug) in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine.
61916001|NCT02519855|EXPERIMENTAL|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
62110556|NCT01126632||Cap Assisted Colonoscopy|Patients receiving colonoscopies where scope is fitted with cap
62110557|NCT01126632||Standard Colonoscopy|Patients receiving standard colonoscopy without the cap on the scope
62672183|NCT06190665|EXPERIMENTAL|Visualable microspheres|DEB-TACE with visualable microspheres
62672184|NCT06190665|ACTIVE_COMPARATOR|PVA microspheres|DEB-TACE with polyvinyl alcohol microspheres
61916002|NCT01955798|EXPERIMENTAL|Trocar|Pyramidal tip reusable 11mm trocar
61916003|NCT01955798|ACTIVE_COMPARATOR|Veress needle|Veress needle
62300946|NCT01829048|PLACEBO_COMPARATOR|Placebo|
62672185|NCT03189433|ACTIVE_COMPARATOR|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures \[ice packs, evaporative cooling(application of room temperature water via mist with use of a fan\], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities\]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
62672186|NCT03189433|NO_INTERVENTION|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures\[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan\], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities\].
62672187|NCT00552500|ACTIVE_COMPARATOR|Schizophrenics|i) meets DSM-IV criteria for schizophrenia, any type, treated with atypical or high potency typical neuroleptics for at least 3 months; ii) aged 18 to 60 years; iii) able to give informed consent; iv) no antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.
62672188|NCT00185900|ACTIVE_COMPARATOR|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate.
62672189|NCT00185900|ACTIVE_COMPARATOR|Nifedipine|Preterm labor treatment with Nifedipine.
62672190|NCT02355470|EXPERIMENTAL|Intervention|Participants will receive the GIFTSS intervention provided by college health center staff and clinicians
62672191|NCT02355470|ACTIVE_COMPARATOR|Control|Participants will receive a brief alcohol use reduction intervention based on NIAAA guidelines provided by college health center staff and clinicians
62672192|NCT01766089|ACTIVE_COMPARATOR|Dexmedetomidine|dexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
62672193|NCT01766089|PLACEBO_COMPARATOR|Remifentanil|remifentanil intravenous infusion rate of 0.1 µg/kg/min
62110558|NCT06086899|EXPERIMENTAL|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
62110559|NCT06086899|ACTIVE_COMPARATOR|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
62110560|NCT04898322|EXPERIMENTAL|2.5mg SY-005|
62110561|NCT04898322|EXPERIMENTAL|5mg SY-005|
62672194|NCT00929097|EXPERIMENTAL|Implementation aids|
62672195|NCT00929097|ACTIVE_COMPARATOR|Control|
62672196|NCT01530256|EXPERIMENTAL|ALD518|
61916004|NCT03603366||Primary prevention|"Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC.~Subgroups:~* Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD~* Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD"
62110562|NCT04898322|EXPERIMENTAL|10mg SY-005|
62110563|NCT04898322|PLACEBO_COMPARATOR|Placebo|
62672197|NCT06006221|EXPERIMENTAL|experimental group|After the morning meeting, the initiative group will be given 40 minutes of Qigong relaxation exercise.
62672198|NCT06006221|NO_INTERVENTION|control group|No application will be made to the control group. The control group will continue their routine treatment in the clinic.
61916005|NCT03603366||Secondary prevention|"Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC.~Subgroups:~* Patients eligible for and using low-dose aspirin for secondary prevention of CVD~* Patients eligible for and not using low-dose aspirin for secondary prevention of CVD"
61916006|NCT03603366||Physicians|Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.
61916007|NCT04519177|EXPERIMENTAL|Experimental (Early Education)|Firefighters in station randomized to the experimental (early education) will receive the sleep health education program (SHEP) including screening for common sleep disorders. Those found at high risk will be given information about seeking further evaluation, diagnosis and treatment, if necessary.
61916008|NCT04519177|NO_INTERVENTION|Control (Later education)|Firefighters in station randomized to the control condition will not receive SHEP prior to the data collection.
61916009|NCT05320497|EXPERIMENTAL|Transparent cap-assisted SpyGlass|Add a transparent cap to the end of the SpyGlass choledochoscopy
62672199|NCT02142621|ACTIVE_COMPARATOR|transpyloric tube feeds|Continuous transpyloric tube feeds administered through an oral/nasal feeding tube.
62672200|NCT02142621|ACTIVE_COMPARATOR|gastric tube feeds|Continuous gastric tube feeds administered through an oral/nasal feeding tube.
62110564|NCT03264248|EXPERIMENTAL|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
62470591|NCT04797195|NO_INTERVENTION|Usual care group|Patients on peritoneal dialysis using handwritten notebook to record record blood pressure, body weight, and dialysis fluid removed; measurements obtained through usual method
62470592|NCT06303726|ACTIVE_COMPARATOR|Single bundle ACL reconstruction|In this group we chose to do surgery of ACL reconstruction with single bundle (patellar ligament).
62470593|NCT06303726|ACTIVE_COMPARATOR|Double bundle ACL reconstruction|In this group we chose to do surgery of ACL reconstruction with double bundle - hamstring ligament.
62470594|NCT00132262|EXPERIMENTAL|1|Patients randomized to this arm received an intervention based in the motivational interviewing style
62470595|NCT00132262|ACTIVE_COMPARATOR|2|Patients randomized to this arm received standard hospital care
62470596|NCT05408884|ACTIVE_COMPARATOR|Miracle Friends|"Participants selected to receive a social support phone buddy program."
61916010|NCT02793843|ACTIVE_COMPARATOR|Ondansetron|
61916011|NCT02793843|EXPERIMENTAL|Ondansetron+ dexamethasone|
61916012|NCT02020720|EXPERIMENTAL|Diagnostic (18F-DOPA-PET)|Within 1 week of biopsy or resection, patients undergo 18F-DOPA PET/CT scan and pMRI and DTI at baseline. Patients then undergo stereotactic craniotomy or image-guided biopsy.
61916013|NCT04653896|EXPERIMENTAL|Knee OA group|Individuals who are over 18 years and have medical diagnosis of Grade 3 or 4 knee OA
62470597|NCT05408884|NO_INTERVENTION|waitlist|"Waitlisted for the social support phone buddy program."
62470598|NCT05408884|EXPERIMENTAL|Miracle Money|Participants who receive $750 monthly income for 12 months based on having engaged in the Miracle Friends program
62672201|NCT03513146|EXPERIMENTAL|OPAMM group|"During the pre-feeding period, infants will receive mother's colostrum (to the maximum of 0.2 ml) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 2 to 4 hours.~When an infant fits the criteria to start enteral feeding, 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
61916014|NCT02115126|ACTIVE_COMPARATOR|LMP2A-loaded conventional DC vaccine|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine
61916015|NCT02115126|EXPERIMENTAL|LMP2A-loaded DC vaccine + DUK-CPG-001|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001
61916016|NCT01908881|ACTIVE_COMPARATOR|Control (usual care)|"This arm receives usual care (control group) consisting in: home visits, evaluation by social worker and planning interventions according to multidisciplinary team usually done en Family Primary Health Care Centers"
62110565|NCT02853474|SHAM_COMPARATOR|Arm A: Chemotherapy (CT) alone|"The medical oncologists (or gastro enterologist physician) are in charge of the patient for CT administration, and for the management of symptoms related to the disease and/or the treatment, in accordance with professional practices. If needed (any time), a PC (Palliative consultation) visit could be performed.~Interventions are :~* EORTC-QLQ-C30 questionnaire for the assessment of quality of life~* HADS score for anxiety and depression assessment"
62470599|NCT06192303||CIP cohort|
62470600|NCT06192303||non CIP cohort|
62470601|NCT00581139|ACTIVE_COMPARATOR|1|
62470602|NCT00581139|ACTIVE_COMPARATOR|2|
62470603|NCT00581139|ACTIVE_COMPARATOR|3|
62470604|NCT00581139|ACTIVE_COMPARATOR|4|
62470605|NCT02209571|EXPERIMENTAL|Cystic Fibrosis|Breath test and venous blood markers in cystic fibrosis patients
62470606|NCT02209571|ACTIVE_COMPARATOR|Control|Breath test and venous blood markers in healthy subjects
62470607|NCT05047822||Concurrent Controls|
61916017|NCT01908881|EXPERIMENTAL|Intervention (group workshop+usual care)|Group intervention (group workshop) described elsewhere
61916018|NCT06104839|EXPERIMENTAL|NXC736|
61916019|NCT06104839|PLACEBO_COMPARATOR|Placebo|
61916020|NCT01226121|ACTIVE_COMPARATOR|Day 1 manipulation|Finger manipulation one day following Clostridial collagenase injectable
61916021|NCT01226121|ACTIVE_COMPARATOR|Day 2 manipulation|Finger manipulation two days following Clostridial collagenase injectable
61916022|NCT01226121|ACTIVE_COMPARATOR|Day 4 manipulation|Finger manipulation four days following Clostridial collagenase injectable
61916023|NCT02599051|ACTIVE_COMPARATOR|Monarc|Placement of a transobturator monarc sling for stress urinary incontinence
61916024|NCT02599051|EXPERIMENTAL|Mini-arc|Placement of a single incision mini-arc sling for stress urinary incontinence
61916025|NCT04896645|EXPERIMENTAL|Patients 8 to <19 years of age with a diagnosis of asthma|Patients 8 to \<19 years of age with a diagnosis of asthma as ICD-9 code 493 or ICD-10 code J45 seen in the allergy clinic at CHLA who have an albuterol rescue inhaler already prescribed and access to a personal smartphone will be eligible for recruitment.
61916026|NCT05290376|ACTIVE_COMPARATOR|Control group|Group I (control): patients who would be delivered mandibular implant overdenture retained by two RTx locator attachments using conventional loading protocol
61916027|NCT05290376|ACTIVE_COMPARATOR|Study group|Group II (study): patients who would be delivered mandibular overdenture retained by two RTx locator attachments using early loading protocol.
61916028|NCT05023824|EXPERIMENTAL|alpha-blocker withdrawal|receives 5-ARI monotherapy
61916029|NCT05023824|EXPERIMENTAL|5-ARI withdrawal|receives alpha-blocker monotherapy
61916030|NCT05023824|ACTIVE_COMPARATOR|combination therapy|receives alpha-blocker and 5-ARI
61916031|NCT01166243|EXPERIMENTAL|Fibrin Pad|Biologic
61916032|NCT01166243|OTHER|Standard of Care|Procedure
61916033|NCT05384951|EXPERIMENTAL|HMB + Vitamin D3 Supplement|Supplement delivery will be a tablet containing both HMB \& Vitamin D3. HMB will be administered in its calcium salt form. One tablet will contain 750 mg HMB + 250 IU of Vitamin D3. The target dosage is 3 g HMB + 1000 IU of Vitamin D3 per day.
62110566|NCT02853474|EXPERIMENTAL|Arm B: CT + Early Palliative care(EPC)|"Standard oncology care as for arm A plus early PC visits.~Interventions are :~* EORTC-QLQ-C30 questionnaire for the assessment of quality of life~* HADS score for anxiety and depression assessment~* Early palliative care visits"
62110567|NCT03610750|ACTIVE_COMPARATOR|Specialty Care|Psychiatric medications and evidence-based psychotherapies to be provided at a specialty mental clinic facilitated by psychiatric technicians, the mental health specialty workforce already in place in Mozambique.
62470608|NCT05047822||Vaccinated Cohort|
62110568|NCT03610750|EXPERIMENTAL|Integrated Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers.
62110569|NCT03610750|EXPERIMENTAL|Community Clinic Stepped Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers and community health workers, respectively.
62110570|NCT02794948|EXPERIMENTAL|Chinese Medicine intervention|Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months
62110571|NCT02794948|ACTIVE_COMPARATOR|Western intervention|DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.
62110572|NCT02228408|EXPERIMENTAL|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
62470609|NCT01330576|PLACEBO_COMPARATOR|Standard treatment of care at normothermia|Control group: Standard treatment of care at normothermia
62110573|NCT02228408|ACTIVE_COMPARATOR|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
61916034|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
61916035|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
61916036|NCT05002920||cleft patients received alveolar bone grafting|alveolar bone grafting was performed when the cleft patients were aged around 9 years old. CBCT was used to analyze the bone mineral density of grafted tissue.
61916037|NCT05512468|OTHER|Experimental: Tattooing of biopsied node|Prior to NST, suspicious axillary lymph nodes were biopsied by core needle or fne needle aspiration. The largest and/or biopsy-confrmed metastastic node was then injected with highly purifed carbon suspension either at the time of biopsy or at a separate session.
61916038|NCT00541190|EXPERIMENTAL|cystic fibrosis|Cystic fibrosis patients
61916039|NCT00541190|EXPERIMENTAL|healthy controls|Healthy control subjects
61916040|NCT00445809||1|High Risk population for developing AKI during/after CABG surgery.
61916041|NCT00445809||2|Medium Risk population for developing AKI during/after CABG surgery.
61916042|NCT01795066|EXPERIMENTAL|EUS-FNB with 25-gauge|
61916043|NCT03808987|EXPERIMENTAL|CHW+CPP brief prenatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
61916044|NCT03808987|EXPERIMENTAL|CHW+CPP brief postnatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning postnatally, in addition to services from a Community Health Worker (CHW)
62110574|NCT01235949|EXPERIMENTAL|Group IIBU|Immediate ibuprofen group: subjects receiving immediate ibuprofen treatment after each primary vaccine dose
62110575|NCT01235949|ACTIVE_COMPARATOR|Group DIBU|Delayed ibuprofen group: subjects receiving delayed ibuprofen treatment after each primary vaccine dose
62110576|NCT01235949|ACTIVE_COMPARATOR|Group NIBU|No ibuprofen group: subjects receiving no prophylactic ibuprofen treatment after each primary vaccine dose
62470610|NCT01330576|EXPERIMENTAL|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
61916045|NCT03808987|EXPERIMENTAL|CHW+CPP 12 months|Participants will receive Child-Parent Psychotherapy (CPP) for 12 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
61916046|NCT03808987|EXPERIMENTAL|CHW only|Participants will receive services from a Community Health Worker (CHW) without Child-Parent Psychotherapy (CPP)
61916047|NCT05950243||Urban population Africa|Urban population in sub-Saharan Africa
61916048|NCT03361644|EXPERIMENTAL|High-Intensity Interval Training|Brief periods of vigorous physical activity separated by short periods of rest.
61916049|NCT03361644|ACTIVE_COMPARATOR|Moderate-Intensity Continuous Training|Physical activity at a sustained moderate heart rate.
61916050|NCT05304091||Patients with bradykinin-mediated angioedema|Patients with bradykinin-mediated angioedema, aged 18 years or older, followed in the internal medicine department of the Lille University Hospital
62110577|NCT01235949|EXPERIMENTAL|Group IPARA|Immediate paracetamol group: subjects receiving immediate paracetamol treatment after each primary vaccine dose
62110578|NCT01235949|EXPERIMENTAL|Group DPARA|Delayed paracetamol group: subjects receiving delayed paracetamol treatment after each primary vaccine dose
62110579|NCT01235949|ACTIVE_COMPARATOR|Group NPARA|No paracetamol group: subjects receiving no prophylactic paracetamol treatment after each primary vaccine dose
62110580|NCT01235949|EXPERIMENTAL|Group IIBU-IIBU|1/3 of the subjects from the primary IIBU group receiving immediate ibuprofen treatment after booster vaccination
62110581|NCT01235949|EXPERIMENTAL|Group IIBU-DIBU|1/3 of the subjects from the primary IIBU group receiving delayed ibuprofen treatment after booster vaccination
62110582|NCT01235949|EXPERIMENTAL|Group IIBU-NIBU|1/3 of the subjects from the primary IIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
62672202|NCT03513146|NO_INTERVENTION|Control Group|"During the pre-feeding period, preterm infants will remain NPO. When an infant fits the criteria to start enteral feeding, own mother's colostrum or milk will be given by the regular gavage feeding on intervals regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
61916051|NCT04489901|EXPERIMENTAL|Extra Virgin Olivei oil group|The women in the experimental (olive oil) group were asked to apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
61916052|NCT04489901|NO_INTERVENTION|Control group|The women in the control group did not undergo any intervention.
61916053|NCT03976180|ACTIVE_COMPARATOR|standard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;
61916054|NCT03976180|EXPERIMENTAL|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
62110583|NCT01235949|EXPERIMENTAL|Group DIBU-IIBU|1/3 of the subjects from the primary DIBU group receiving immediate ibuprofen treatment after booster vaccination
62110584|NCT01235949|EXPERIMENTAL|Group DIBU-DIBU|1/3 of the subjects from the primary DIBU group receiving delayed ibuprofen treatment after booster vaccination
62110585|NCT01235949|EXPERIMENTAL|Group DIBU-NIBU|1/3 of the subjects from the primary DIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
62110586|NCT01235949|EXPERIMENTAL|Group NIBU-IIBU|1/3 of the subjects from the primary NIBU group receiving immediate ibuprofen treatment after booster vaccination
62110587|NCT01235949|EXPERIMENTAL|Group NIBU-DIBU|1/3 of the subjects from the primary NIBU group receiving delayed ibuprofen treatment after booster vaccination
62110588|NCT01235949|ACTIVE_COMPARATOR|Group NIBU-NIBU|1/3 of the subjects from the primary NIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
62110589|NCT01235949|EXPERIMENTAL|Group IPARA-NPARA|subjects from the primary IPARA group receiving no paracetamol treatment after booster vaccination
62110590|NCT01235949|EXPERIMENTAL|Group DPARA-IPARA|subjects from the primary DPARA group receiving immediate paracetamol treatment after booster vaccination
62110591|NCT01235949|EXPERIMENTAL|Group NPARA-IPARA|subjects from the primary NPARA group receiving immediate paracetamol treatment after booster vaccination
62110592|NCT04045743|EXPERIMENTAL|Bermekimab (MABp1)|
62672203|NCT00500110|EXPERIMENTAL|Hormonal Ablation, Imatinib + Docetaxel|Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m\^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months
62110593|NCT04045743|EXPERIMENTAL|Placebo|
62110594|NCT02711982|ACTIVE_COMPARATOR|Optic nerve decompression|Optic canal and optic nerve sheath decompression within 5 days from trauma occur.
62110595|NCT02711982|ACTIVE_COMPARATOR|methylprednisolone|a maximum daily dose of 1 g of methylprednisolone
62110596|NCT05451017|EXPERIMENTAL|AEF0117 1.0 mg in fasted condition|16 participants receive 1 dose of AEF0117 1 mg in fasted condition
62672204|NCT01245049|EXPERIMENTAL|BOOSTRIX POLIO GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
61916055|NCT03976180|EXPERIMENTAL|HFNO with intermediate FiO2 (50%)|HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
62735968|NCT06430242|ACTIVE_COMPARATOR|Group B|Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
61916056|NCT03976180|EXPERIMENTAL|HFNO with high FiO2 (100%)|HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
62110597|NCT05451017|EXPERIMENTAL|AEF0117 1.0 mg once daily (QD) in fed condition|16 participants receive 1 dose of AEF0117 1 mg fed condition
62110598|NCT05754281||Study Cohort|60 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the 2nd Gen LabPatch Continuous Glucose Sensing will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
62110599|NCT01087684|ACTIVE_COMPARATOR|Argon laser trabeculoplasty|Patients received standard argon laser treatment
62110600|NCT01087684|ACTIVE_COMPARATOR|Selective laser trabeculoplasty|Patients received a standard selective laser treatment
62110601|NCT05708014|EXPERIMENTAL|Intervention|From baseline to 16-months, participants randomized to the intervention arm will have access to the LuvHub web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessments that will occur every 4 months (4, 8, 12, \& 16-months).
62110602|NCT05708014|EXPERIMENTAL|Waitlist Control|"From baseline to 8-months, participants in the waitlist control condition will have access to the LuvHub web app for post-baseline assessments of 4 and 8 months, and the resources section.~From 8-months to 16-months, participants randomized to the waitlist control arm will then have access to the LuvHub web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessments that will occur every 4 months (12 \& 16-months)."
62110603|NCT01672840|EXPERIMENTAL|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
61916057|NCT04306679|EXPERIMENTAL|Interventional arm|The intervention, which was aimed to educate children on how to use pain scales and provide reliable pain assessments was based on a two short animation clips, lasting approximately 5 min each, and a short (5 min) guided interaction between the study nurse and the participants, in between the two clips.
61916058|NCT04306679|OTHER|Control|Children underwent the routine pre-operative preparations, which included a section on pain assessment.
61916059|NCT01818947||Gefitinib|
61916060|NCT04648969|EXPERIMENTAL|Experimental: kisspeptin, GnRH|• Intravenous administration of kisspeptin 112-121; 20 boluses in a 40-hour period. Intravenous administration of GnRH; one bolus.
61916061|NCT01740505|EXPERIMENTAL|Timing and Coordination|
61916062|NCT01740505|EXPERIMENTAL|Aerobic Walking|
61916063|NCT01740505|ACTIVE_COMPARATOR|Stretching and Relaxation|
61916064|NCT01923168|EXPERIMENTAL|Alpelisib + Letrozole|Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.
61916065|NCT01923168|EXPERIMENTAL|Buparlisib + Letrozole|Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.
62300947|NCT06653218||PRP+Lidocaine group|Patients will be placed in the supine position, with slightly excessive neck extension to receive stellate ganglion block (SGB). And 2.5 ml of PRP combined with 2.5 ml of 1.0% lidocaine will be injected slowly into the ipsilateral stellate ganglion under the guide of ultrasound visualization technology
62470611|NCT02708693|EXPERIMENTAL|experimental: steroid injection and splinting|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine) and a customized volar thermoplastic wrist splint
61916066|NCT01923168|PLACEBO_COMPARATOR|Placebo + Letrozole|Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.
61916067|NCT01927939||Histological proven breast cancer with bone lesion|
61916068|NCT00925743|EXPERIMENTAL|1|"* 5, 15, 20 or 25 mg/m2~* one injection of cabazitaxel on day 1 of each cycle (3 weeks)"
61916069|NCT01920646|EXPERIMENTAL|ALV|"300 gram cooked African leafy vegetables and school meal starch as daily school meal (5 days/weeks) for 3 months.~Selected African leafy vegetables:Amaranthus cruentus (amaranth), Vigna unguiculata (cowpea), Cleome gynandra (spiderplant), and Cucurbita maxima (pumpkin)."
61916070|NCT01920646|NO_INTERVENTION|Control|normal school meal as daily meal (5 days/weeks) for 3 months
62300948|NCT06653218||Lidocaine group|Patients will be placed in the supine position, with slightly excessive neck extension to receive stellate ganglion block (SGB). And 5 ml of 1.0% lidocaine will be injected slowly into the ipsilateral stellate ganglion under the guide of ultrasound visualization technology
62300949|NCT00284115|EXPERIMENTAL|Mechanical gait repetitive training|Body weight support treadmill training technique enabling nonambulatory patients to have the repetitive practice of a gate-like movement
62300950|NCT00284115|ACTIVE_COMPARATOR|Conventional rehabilitation program|Physiotherapeutic conventional rehabilitation program
62300951|NCT02588456|EXPERIMENTAL|Single Arm|
62300952|NCT01663441|EXPERIMENTAL|A1|"Patients in this treatment group will receive NL201(5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(7.5μg/kg).~Only for Dose-finding in Phase Ⅲa."
62300953|NCT01663441|EXPERIMENTAL|A2|"Patients in this treatment group will receive NL201(7.5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(5μg/kg).~Only for Dose-finding in Phase Ⅲa."
62300954|NCT01663441|ACTIVE_COMPARATOR|A|"Patients in this treatment group will receive NL201（optimal dosing dose）in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive rhIL-11(25μg/kg).~Only in Phase Ⅲb."
62300955|NCT01663441|ACTIVE_COMPARATOR|B|"Patients in this treatment group will receive rhIL-11(25μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201（optimal dosing dose）.~Only in Phase Ⅲb."
62300956|NCT01009411||Control|Patients in active phase of labor not augmented
62672205|NCT01245049|ACTIVE_COMPARATOR|REPEVAX GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
62672206|NCT04633304|OTHER|AVF|Single arm study using primary and secondary end points as comperators between subjects.
62672207|NCT03532490|ACTIVE_COMPARATOR|Roflumilast 500 mcg oral tablet|500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
62110604|NCT01672840|EXPERIMENTAL|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
62110605|NCT02951117|EXPERIMENTAL|Arm A Venetoclax QD + ABBV-838 Q3W + Dexamethasone|ABBV-838 administered at cohort-defined doses every 3 weeks (Q3W; starting dose 4.0 mg/kg) in combination with venetoclax (400 mg or 800 mg once daily \[QD\]) and dexamethasone (40 mg once weekly \[Q1W\]); once the maximum-tolerated-dose (MTD) and recommended phase two dose (RPTD) are determined, ABBV-838 in combination with venetoclax and dexamethasone at RPTD will be administered in a dose expansion phase of the study.
62110606|NCT02951117|EXPERIMENTAL|Arm B Venetoclax QD + ABBV-838 Q1W or Q2W + Dexamethasone Q1W|"Dose escalation portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax (400 or 800 mg QD) and dexamethasone (40 mg Q1W).~The dose expansion portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax and dexamethasone at the RPTD combination defined from the Dose Escalation portion."
62110607|NCT05015517|ACTIVE_COMPARATOR|ESPB Group|This group will receive ultrasound-guided erector spinae plane block and subarachnoid block.
62110608|NCT05015517|ACTIVE_COMPARATOR|FIB Group|This group will receive supra-inguinal fascia iliaca block and subarachnoid block .
62110609|NCT00931593|EXPERIMENTAL|volunteers|"This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control.~The date of perfused manometry is randomized to avoid bias due to examinations' order."
62110610|NCT05126719|EXPERIMENTAL|MRG003|"Part A: On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or 2.3 mg/kg calculated based on the actual body weight.~Part B: On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.3 mg/kg calculated based on the actual body weight."
62110611|NCT05126719|ACTIVE_COMPARATOR|Capecitabine tablets/Docetaxel injection|Part B: Capecitabine tablets: 1000 mg/m2, bid, d1-14, po, Q3W, or Docetaxel injection: 75 mg/m2, d1, IV, Q3W
62300957|NCT01009411||Augmented|Augmentation leading to normal progress
62470612|NCT02708693|ACTIVE_COMPARATOR|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
62672208|NCT03532490|PLACEBO_COMPARATOR|Placebo oral tablet|500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
62110612|NCT02089243|EXPERIMENTAL|Vagus nerve stimulation therapy|Surgical follow-up typically occurred 2 weeks postoperatively and, subsequently, on a variable schedule as indicated. The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes. Retrospective chart review was performed to collect follow-up and outcome data. At the time of last available clinical follow-up, the following data were collected: mean weekly seizure frequency (from seizure logs kept by caretakers or patient or caretaker report averaged of the last 3 months prior to ﬁnal follow-up), complications of VNS therapy, duration of VNS therapy, timing and all subsequent surgical procedures.
62300958|NCT01009411||Caesarean section|Augmentation leading to Caesarean section
62300959|NCT00968266|EXPERIMENTAL|Group intervention|"In short, the intervention consists of two group sessions moderated by a pharmacist. During these sessions, patients' self-perceived needs to take medication ('necessity beliefs'), concerns about taking medication ('concern beliefs'), and practical barriers are discussed. To explore a patient's individual ambivalence regarding his/her beliefs and barriers, the pharmacist uses Motivational Interviewing techniques. In between the sessions, participants make a homework assignment about their own beliefs and barriers, and eight weeks after the second session, a follow-up call to the individual patients is made by the pharmacist.~Patients in the experimental arm also receive a brochure about the DMARDs they currently use (see: control arm)"
62300960|NCT00968266|ACTIVE_COMPARATOR|Control arm: usual care|In the control arm, patients receive a brochure about the DMARDs they are currently using.
61916071|NCT03721770||Relatives|Relative or adult companion (age \<18 years) of a patient who died of cardiac arrest after organ removal request. A parent is defined as a close relative of the first degree: husband-wife, father-mother, son-daughter. Only one loved one is included per patient. Inclusion order of priority is husband-wife / father-mother / son-daughter.
61916072|NCT03398278|EXPERIMENTAL|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
62300961|NCT03352440|EXPERIMENTAL|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
62300962|NCT03352440|EXPERIMENTAL|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
62300963|NCT03352440|ACTIVE_COMPARATOR|Control Group - Kinect|Group with typical development that will perform the task on Kinect
62300964|NCT03352440|ACTIVE_COMPARATOR|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
62470613|NCT02987439|NO_INTERVENTION|Standard care group|"* Standard medical treatment for the exacerbation of COPD~* Standard medical treatment of COPD according to GOLD~* A visit by a pulmonary nurse at the patients own home 3-5 days after discharge. Lung function and smoking history is recorded. Correct use of inhaler is instructed.~* Visit in the outpatient clinic within the next 2-6 months after discharge as follow-up~* In the outpatient clinic they will receive an offer of pulmonary rehabilitation"
62672209|NCT01634750|EXPERIMENTAL|ManNac|
62672210|NCT01634750|PLACEBO_COMPARATOR|Placebo|
61916073|NCT03398278|ACTIVE_COMPARATOR|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
61916074|NCT03403842|ACTIVE_COMPARATOR|PERIDURAL|Peridural catheter positioning with a continuous infusion of ropivacaine 0,2% 99 ml+ sufentanil 50 mcg at an infusion rate of 4-6 ml/h
61916075|NCT03403842|ACTIVE_COMPARATOR|PCA MORPHINE|Patient controlled analgesia of endovenous morphine, injection dose 1 mg, lock-out time 10 minutes, maximum dosage for hour 4 mg
61916076|NCT03403842|EXPERIMENTAL|SSTS|Patients controlled analgesia of sublingual sufentanil tablet system, 15 mcg sufentanil tablets, lock out time 20 minutes
62110613|NCT02089243|EXPERIMENTAL|Resective surgery|The type of surgery performed consisted of standard anterior temporal lobectomy, electrocorticography tailored temporal lobectomy, anteromedial temporal lobectomy, transcortical or transsylvian or subtemporal selective amygdalohippocampectomy, temporal lobe disconnection and hippocampal transection.
62300965|NCT06657664|ACTIVE_COMPARATOR|control Group|all occlusal contacts are reduced by 1 mm
62300966|NCT06657664|ACTIVE_COMPARATOR|intracanal cryotherapy|the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes
62470614|NCT02987439|EXPERIMENTAL|Rehabilitation group|"The group will begin pulmonary rehabilitation during hospital admission. Afterwards a rehabilitation program twice weekly for 7 weeks.~Beside rehabilitation they will receive same treatment as the standard care group"
61916077|NCT01449695|EXPERIMENTAL|Lifestyle counseling|Group consultation and individual nurse consultation
61916078|NCT01449695|EXPERIMENTAL|e health|An individual web based entry
61916079|NCT01449695|NO_INTERVENTION|usual care|Usual care
61916080|NCT04450810||Control|Evaluation of serum and salivary NLRP3
62110614|NCT02082405|EXPERIMENTAL|Treatment (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC or IV over 3-5 seconds on days 1, 8, and 15; cyclophosphamide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62110615|NCT06628895|EXPERIMENTAL|Frail elderly living in community|Adult above 60 years old, frailty level based on Fried frailty phenotype, without having diabetes mellitus and cardiac disease
62110616|NCT03610997|OTHER|Photorefractive keratectomy|The children will undergo PRK in the affected eye(s) using previously derived formulas for PRK.
62300967|NCT06657664|ACTIVE_COMPARATOR|intraoral cryotherapy group|ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezing sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes
62300968|NCT06657664|ACTIVE_COMPARATOR|Both intracanal and intraoral cryotherapy|the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes , the canal is obturated and then ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezing sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes.
62300969|NCT06657664|ACTIVE_COMPARATOR|Low Level Laser Therapy|laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively.
62300970|NCT05029622|EXPERIMENTAL|Triptorelin formulation for Intramuscular injection (IM).|
61916081|NCT04450810||Periodontitis|Evaluation of serum and salivary NLRP3
61916082|NCT04450810||Diabetes|Evaluation of serum and salivary NLRP3
61916083|NCT04450810||Periodontitis + diabetes|Evaluation of serum and salivary NLRP3
61916084|NCT02879149||Group 1|Standard Rigid Fixation plus autograft
62110617|NCT00105820|OTHER|Arm 1|
62672211|NCT03607695|EXPERIMENTAL|Gait training|1 hour walking exercise on a treadmill
61916085|NCT02879149||Group 2|Standard rigid fixation plus AUGMENT® Bone Graft
62110618|NCT03254394|PLACEBO_COMPARATOR|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
62110619|NCT03254394|ACTIVE_COMPARATOR|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
62110620|NCT00640029|EXPERIMENTAL|1|Cervical - Arthroplasty
62110621|NCT00640029|ACTIVE_COMPARATOR|2|Cervical - Arthrodesis
62110622|NCT00640029|EXPERIMENTAL|3|Lumbar - Over 50 years - Arthroplasty
62110623|NCT00640029|ACTIVE_COMPARATOR|4|Lumbar - Over 50 years - Arthrodesis
62110624|NCT00640029|EXPERIMENTAL|5|Lumbar - Under 50 years - Arthroplasty
62110625|NCT05076656|EXPERIMENTAL|Probiotics arm|Individuals who receive a probiotics pill daily: Lactobacillus fermentum D3 (PCT/EP 2012058214)
62110626|NCT05076656|EXPERIMENTAL|FMT arm|Individuals who receive a FMT in the form of pills with fecal material from a healthy donor.
61916086|NCT05579171|EXPERIMENTAL|Left Side Treatment with picosecond 755nm Alexandrite laser|Subjects will have their left side of face treated with picosecond 755nm Alexandrite laser then will undergo full face radiofrequency microneedling.
61916087|NCT05579171|EXPERIMENTAL|Right Side Treatment with Picosecond 755NM Alexandrite laser|Subjects will have their right side of face treated with picosecond 755nm Alexandrite laser then will undergo full face radiofrequency microneedling.
61916088|NCT01673282||Vimpat + Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
61916089|NCT01673282||Vimpat + Non-Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.
61916090|NCT04074239|EXPERIMENTAL|Video triage|The sick child will be triaged on video by the operator.
61916091|NCT04074239|NO_INTERVENTION|Telephone triage|The sick child will be triaged solely on telephone by the operator.
61916092|NCT00534261|EXPERIMENTAL|1|patients received Avonex IM injections and be evaluated for quality of life criteria
61916093|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
61916094|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
61916095|NCT01667705||SkyCeiling during CT-Suite visit|Patients in the trial group are exposed to the SkyCeiling during their procedure.
61916096|NCT01667705||No SkyCeiling during CT-Suite visit|Patients in the trial group are not exposed to the SkyCeiling during their procedure.
62110627|NCT05076656|PLACEBO_COMPARATOR|Control arm|Individuals who receive a probiotics pill daily of placebo (milk powder)
62300971|NCT03319199|ACTIVE_COMPARATOR|Primary treatment Arm|"patients with a diagnosis of NAFDL will be randomly receive trial product SLIM WATER that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks."
62470615|NCT02372149|EXPERIMENTAL|IVIg--Washout--0.9% NaCl (CROSSOVER)|"1. 10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)~2. Washout period~3. 0.9% sodium chloride in water - equal volume to IVIg - Monthly x4"
61916097|NCT06505811|EXPERIMENTAL|Treated Group ($500 GI for 18 months)|Treated Group will receive $500 per month for 18 months (anticipated n=250)
61916098|NCT06505811|ACTIVE_COMPARATOR|Comparison Group ($20 GI for 18 months)|Comparison Group will receive $20 per month for 18 months (anticipated n=350)
61916099|NCT04707547|EXPERIMENTAL|Radiofrequency Ablation|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy
61916100|NCT04707547|PLACEBO_COMPARATOR|Radiofrequency Ablation combine with Nivolumab|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy, and improving immune systems by Nivolumab
62110628|NCT06020131|EXPERIMENTAL|Thoracic Mobility Group|Thoracic Mobility Exercises Ankle Strengthening Home Exercises with resistive band
62110629|NCT06020131|EXPERIMENTAL|Lumbopelvic Stability Group|Lumbopelvic stabilization exercises Ankle Strengthening Home Exercises with resistive band
62110630|NCT00412230||no treatment|
61916101|NCT00738621|ACTIVE_COMPARATOR|1|Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia
61916102|NCT00738621|PLACEBO_COMPARATOR|A,2|Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia
61916103|NCT04597151|EXPERIMENTAL|Supportive care (diet education)|Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).
61916104|NCT01073371|ACTIVE_COMPARATOR|liposome-encapsulated 3% prilocaine|
61916105|NCT01073371|ACTIVE_COMPARATOR|3% plain prilocaine|
61916106|NCT01073371|ACTIVE_COMPARATOR|3% prilocaine with 0,03IU/mL felypressin|
61916107|NCT06020729|EXPERIMENTAL|Occlusion Training|
61916108|NCT06020729|ACTIVE_COMPARATOR|General exercises without occlusion|
61916109|NCT01489111|EXPERIMENTAL|Surgery|
61916110|NCT05592873||Patients with locally advanced rectal adenocarcinoma|Patients with histollogically confirmed locally advanced rectal adenocarcinoma (clinical T3-T4N0M0 or T(any) N+M0) treated with neoadjuvant CRT followed by curtive intent elective surgery.
61916111|NCT01877733|EXPERIMENTAL|Maximal strenght training|Training maximal strength training 3 times a week/1 physiotherapy session for 8 weeks
61916112|NCT01877733|NO_INTERVENTION|Standard rehabilitation|2-3 physiotherapy sessions a week for 8 weeks/telephone contact by project leader once a week/writing training diary
62110631|NCT00412230||2|
62110632|NCT02012543|EXPERIMENTAL|Agar jelly, constipation|Subjects eat a cap of agar jelly (180g) shortly before eating dinner every day for 4 weeks.
62110633|NCT04538248||Continuous|Continuous
62110634|NCT04538248||Discontinuous|Discontinuous
62110635|NCT05784688|EXPERIMENTAL|TU2218 + Pembrolizumab Phase 1b|Escalating doses of TU2218 orally and Pembrolizumab intravenously administered daily for two weeks followed by one week to determine RP2DC.
62300972|NCT03319199|PLACEBO_COMPARATOR|Placebo Arm|"patients with a diagnosis of NAFDL will be randomly receive placebo for the initial 8 weeks and continue another 8 weeks with the trial product SLIM WATER."
62300973|NCT04273984|ACTIVE_COMPARATOR|1- Group 1 (misoprostol 200 mcg|"Group 1 :will take 1 tablet (200 mcg) of misoprostol and 1 placebo tablet,~.,"
62110636|NCT05784688|EXPERIMENTAL|TU2218 + Pembrolizumab in Biliary Tract Cancer (BTC) expansion cohort Phase 2a|A RP2DC of TU2218 + Pembrolizumab administered, orally BID, for 2 weeks followed by 1 week of rest in 3-week cycles for TU2218 and intravenous 200mg once every 3 weeks for Pembrolizumab to patients with BTC to see whether TU2218 has potential to reverse resistance to an anti-PD-(L)1 agent.
62110637|NCT05784688|EXPERIMENTAL|TU2218 + Pembrolizumab in Cervical Cancer (CC) expansion cohort Phase 2a|A RP2DC of TU2218 + Pembrolizumab administered, orally BID, for 2 weeks followed by 1 week of rest in 3-week cycles for TU2218 and intravenous 200mg once every 3 weeks for Pembrolizumab to patients with CC to see whether TU2218 has potential to reverse resistance to an anti-PD-(L)1 agent.
62300974|NCT04273984|ACTIVE_COMPARATOR|2- Group 2 (misoprostol 100 mcg)|Group 2: will take1 tablet (100 mcg) of misoprostol and 1 placebo tablet,
62300975|NCT04273984|PLACEBO_COMPARATOR|3- Group 3 (placebo group)|Group 3 ): will take2 placebo tablets
62672212|NCT00887588|EXPERIMENTAL|LCZ696|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
62672213|NCT00887588|ACTIVE_COMPARATOR|Valsartan|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.
62300976|NCT05966818|ACTIVE_COMPARATOR|Dapagliflozin group and Standard therapy which include either ACEI or ARB|- The first group (45 patients) will receive Dapagliflozin (Diglifloz) 10 mg orally once daily at any time of day with or without food. Tablets are to be swallowed whole with half a cup of water for 24 weeks and standard therapy which include either angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB).
62300977|NCT05966818|ACTIVE_COMPARATOR|Standard therapy which include either ACEI or ARB|- The second group (45 patients); will receive the standard therapy (ACEI or ARB).
62300978|NCT05440825|EXPERIMENTAL|VRelax|Participants will be using Virtual Reality relaxation (VRelax) in addition to treatment as usual
62300979|NCT05440825|ACTIVE_COMPARATOR|Relaxation exercises|Participants will be using relaxation exercises in addition to treatment as usual
62300980|NCT02175550|EXPERIMENTAL|NR CC|
62300981|NCT04363216|EXPERIMENTAL|Treatment|Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) will be added to each liter of sterile wate,r plus 1 g/L magnesium chloride to reduce burning sensation, and given parenterally over a 2-hour period. On the day of enrollment (Day 0), 0.3 g/kg will be given; Day 1 - 0.6 g/kg; Day 2 - 0.9 g/kg; Day 3 - 0.9 g/kg; Day 4 - 0.9 g/kg; Day 5 - 0.9 g/kg. After the first dose, each subsequent dose will be given 24 +/- 4 hours following the previous dose.
62470616|NCT02372149|EXPERIMENTAL|0.9% NaCl--Washout--IVIg (CROSSOVER)|"1. 0.9% sodium chloride in water - equal volume to IVIg - Monthly x4~2. Washout period~3. 10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)"
62470617|NCT06406608|EXPERIMENTAL|Organoid-Guided therapy|All patients will be included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation and drug sensitivity tests.
62470618|NCT04904120|ACTIVE_COMPARATOR|[203Pb]VMT01 first|Participants randomized to this arm will receive imaging agent \[203Pb\]VMT01 and undergo SPECT/CT imaging first. Later, participants in this arm will receive \[68Ga\]VMT02 and undergo PET/CT imaging.
62470619|NCT04904120|ACTIVE_COMPARATOR|[68Ga]VMT02 first|Participants randomized to this arm will receive imaging agent \[68Ga\]VMT02 and undergo PET/CT imaging first. Later, participants in this arm will receive \[203Pb\]VMT01 and undergo SPECT/CT imaging.
62470620|NCT01401803|OTHER|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass.
61916113|NCT04722055||Study group|Single arm of continuously enrolled participants. All eligible participants will be included in the study according to the inclusion criteria. In addition to giving stool samples for multigene methylation test, eligible participants need to undergo colonoscopy examination and have their biopsies taken when necessary (gold standard).
62470621|NCT04064892|EXPERIMENTAL|Exercise Intervention|Participants will receive a 12-week, individually-tailored, video conference-based physical activity intervention
62470622|NCT04979429|EXPERIMENTAL|PePS|4 sessions of telephone CBT-based pain self-management in addition to standard perioperative care.
62470623|NCT04979429|NO_INTERVENTION|Standard Care|Standard perioperative care.
61916114|NCT00716950|EXPERIMENTAL|1|valsartan/amlodipine
62300982|NCT04363216|NO_INTERVENTION|Routine care|These subject will follow routine care and their clinical courses will be recorded only.
62470624|NCT02895763||Neuro Muscular disease patients|French Patients, young adults and adults, with a diagnosed neuromuscular disease, of any known form.
62300983|NCT01760434|OTHER|Long-Term Outcomes|Patients will be recruited who were diagnosed with adolescent idiopathic scoliosis prior to age 18 and before 1994 (minimum 20 year outcomes) with available xrays. Patients will be included who were treated with surgery, observation, or bracing. Patients will return for a one-time visit for new xrays, physical exam, health-related quality of life surveys, and pulmonary function testing.
61916115|NCT00716950|ACTIVE_COMPARATOR|2|losartan/amlodpine
61916116|NCT01781091|EXPERIMENTAL|FULLY CLOSED-LOOP VENTILATION|IntelliVent-ASV automatic mode
61916117|NCT01781091|ACTIVE_COMPARATOR|Conventional modes ventilation|Conventional modes
61916118|NCT05399576|EXPERIMENTAL|Nicorandil and verapamil|intracoronary of 2mg Nicorandil and 500ug verapamil
61916119|NCT05399576|PLACEBO_COMPARATOR|saline|intracoronary of 4ml saline
61916120|NCT02340273|EXPERIMENTAL|Therapeutic ultrasound device|Patients receive treatment from the long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62300984|NCT00499265|ACTIVE_COMPARATOR|Gemcitabine|
62300985|NCT00499265|EXPERIMENTAL|Gemcitabine plus 200 mg WX-671|
62300986|NCT00499265|EXPERIMENTAL|Gemcitabine plus 400 mg WX-671|
62300987|NCT04314687|EXPERIMENTAL|UCMSCs + CM|UCMSCs + CM is administered via intrathecal injection
62300988|NCT04314687|EXPERIMENTAL|UCMSCs|UCMSCs is administered via intrathecal injection
62300989|NCT04314687|ACTIVE_COMPARATOR|Standard Therapy|Physiotherapy
62300990|NCT04357171|ACTIVE_COMPARATOR|Ileostomy|Loop protective ileostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
62300991|NCT04357171|ACTIVE_COMPARATOR|Colostomy|Loop protective transverse colostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
62300992|NCT04126148||Age matched Healthy participants (150)|Healthy Participants Age: \> 40y No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system
61916121|NCT02340273|PLACEBO_COMPARATOR|Placebo therapeutic ultrasound device|"Patients receive the sham long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound."
61916122|NCT00564538|EXPERIMENTAL|1|Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
61916123|NCT00564538|ACTIVE_COMPARATOR|2|patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
61916124|NCT00533091|ACTIVE_COMPARATOR|1|MEDI-545
62110638|NCT05784688|EXPERIMENTAL|TU2218 + Pembrolizumab in Colorectal Cancer (CRC) expansion cohort Phase 2a|A RP2DC of TU2218 + Pembrolizumab administered, orally BID, for 2 weeks followed by 1 week of rest in 3-week cycles for TU2218 and intravenous 200mg once every 3 weeks for Pembrolizumab to patients with CRC to see whether TU2218 has potential to reverse resistance to an anti-PD-(L)1 agent.
62110639|NCT01712594|ACTIVE_COMPARATOR|Closed Loop Procedure AB|Closed loop procedure with normal calibration first followed by closed loop procedure B with calibration error induced.
62470625|NCT04175808|EXPERIMENTAL|Part A|After an overnight fast of at least 10 hours participants received a single oral dose of 25 mg omecamtiv mecarbil on Day 1.
61916125|NCT00533091|OTHER|2|Placebo
61916126|NCT03171428||TAA|Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach
61916127|NCT03171428||AA|Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)
61916128|NCT04106414|EXPERIMENTAL|Nivolumab alone|Nivolumab 480 mg every 4 weeks.
61916129|NCT04106414|EXPERIMENTAL|Nivolumab with IDO-inhibitor, BMS- 986205|Nivolumab 480 mg every 4 weeks with BMS-986205 100 mg.
61916130|NCT00983398|EXPERIMENTAL|Treatment (mannitol, melphalan, carboplatin, STS)|Patients receive mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats every 4-6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
61916131|NCT04514302|PLACEBO_COMPARATOR|Placebo|Single dose of a 150 mL saline solution administered intravenously as an infusion over 40 min.
61916132|NCT04514302|EXPERIMENTAL|INOSARS dose 1|Single dose of 5 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.
61916133|NCT04514302|EXPERIMENTAL|INOSARS dose 2|Single dose of 15 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.
61916134|NCT04514302|EXPERIMENTAL|INOSARS dose 3|Single dose of 30 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.
61916135|NCT02013583||Glucose Transporter Type I Deficiency|No interventions
61916136|NCT04570059|EXPERIMENTAL|Intervention program|Intervention group
61916137|NCT04570059|ACTIVE_COMPARATOR|Usual Care|Control group
61916138|NCT02353143|EXPERIMENTAL|MEN1112|Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
62110640|NCT01712594|ACTIVE_COMPARATOR|Closed loop Procedure BA|Closed loop procedure with an induced calibration error first followed by closed loop procedure with normal calibration.
62110641|NCT06429670||Azacytidine and venetoclax treated patients|Adult patients with acute myeloid leukemia treated by AZACYTIDINE and VENETOCLAX in frontline and relapse/refractory settings
62110642|NCT05005819|EXPERIMENTAL|[18F]APN-1607|Participants will receive an IV bolus injection of \[18F\]APN-1607, followed by PET brain imaging.
62110643|NCT01806714|EXPERIMENTAL|Text-based reminder for HPV vaccine/WCC|Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
61916139|NCT05193227|EXPERIMENTAL|Treatment (ST-01)|Administration of ST-01 as single-dose into the cutaneous, subcutaneous and fascia region of the surgical site and/or as nerve block.
61916140|NCT05193227|ACTIVE_COMPARATOR|Control (Standard of Care)|Administration of Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®) as single-dose into the cutaneous, subcutaneous and fascia region of the surgical site and/or as nerve block.
61916141|NCT05911555||Non-Dry Eye Subjects|Subjects with no reported history of dry eye disease will be enrolled
62110644|NCT01806714|ACTIVE_COMPARATOR|Control arm|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
62110645|NCT01689519|ACTIVE_COMPARATOR|Placebo + Vemurafenib|Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
62110646|NCT01689519|EXPERIMENTAL|Cobimetinib + Vemurafenib|Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
61916142|NCT05911555||Dry Eye Disease|Subjects who have been diagnosed with dry eye disease in a previous trial will be enrolled.
61916143|NCT00101829|EXPERIMENTAL|Rituximab Treatment|Participants will receive rituximab at study entry and at Week 2
61916144|NCT01181401|ACTIVE_COMPARATOR|TPF standard|"TPF version 1 (standard)~1. Induction chemotherapy:~   Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles~2. Antibody therapy with:~   cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~3. RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
61916145|NCT01181401|EXPERIMENTAL|TPF experimental|"TPF version 2 (experimental)~1. Induction chemotherapy:~   Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles~2. Antibody therapy with:~   cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~3. RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
62110647|NCT05298111|ACTIVE_COMPARATOR|Formulation 3|Formulated MMT peel powder (provide 5 g dietary fiber per day)
62110648|NCT05298111|PLACEBO_COMPARATOR|Control|Glucose
62110649|NCT06223529|EXPERIMENTAL|Music intervention|Music-based exercises for arm/hand coordination, range of movement and dexterity using a selection of hand percussion, stand-mounted percussion and tablet with touchscreen instruments.
62110650|NCT03223090|EXPERIMENTAL|Tool training group|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
62110651|NCT03223090|ACTIVE_COMPARATOR|Hand training group|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
62672214|NCT06358677|EXPERIMENTAL|Tretinoin half of face (left) and Placebo/Moisturizer other half of the face (right)|Randomized, double-blind, split-face. Randomization will determine which side of the face Tretinoin will be applied to (left or right). The other side of the face (left or right) will have placebo applied. All participants will receive both treatment and placebo.
62110652|NCT02943993||Patients treated with Edoxaban|Patients with established initial or recurrent acute symptomatic VTE treated with edoxaban according to the Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
62300993|NCT04126148||Coronary Artery Disease (CAD) Patients (200)|Coronary Artery Disease (CAD) Patients Age \> 18 y Patients with an Indication for invasive coronary angiography based on symptoms and a test positive for inducible coronary ischemia, or previous coronary angiography.
62300994|NCT06167161|ACTIVE_COMPARATOR|Screening, intake and first fit (either clinician-fitting or self-fitting )|This clinical trial compares two methods of fitting individuals who suffer from hearing loss with a hearing aid device. Subjects will wear the hearing aid after receiving the clinician-fitting (device fitted by a clinician according to standard clinical best practice procedures) and self-fitting (device fitted by the user directly without assistance from a clinician following an automated assessment and fitting process) for two weeks each, totaling to approximately 1 month of wear throughout the trial. During the first visit, all individuals will go through intake procedures and a basic audiologic evaluation. After this is completed, individuals will be randomly assigned into one of two arms of the study. Individuals in the first visit of the study, will receive either the clinician-fitting or the self-fitting method for the first two weeks, then will switch to the experimental self-fitting or the clinician-fitting method for the last half. The order of the fitting will be randomized.
62300995|NCT06167161|SHAM_COMPARATOR|Second fit (either clinician-fitting or self-fitting )|In the second visit of the study, individuals who randomly received the conventional clinician-fitting for the first two weeks (first period) will switch to the experimental self-fitting for the remainder of the study (second period). Conversely, individuals who received the experimental self-fitting method for the first two weeks (first period) will switch to the clinician-fitting method for the last two weeks (second period). The same within-subject crossover design will be followed in both clinical sites and for all individuals who were enrolled in the study.
62300996|NCT06430892|OTHER|POP Protocol|Patients in this arm will be treated according to the POP protocol for stent deployment
62672215|NCT06358677|EXPERIMENTAL|Tretinoin half of face (right) and Placebo/Moisturizer other half of the face (left)|Randomized, double-blind, split-face. Randomization will determine which side of the face Tretinoin will be applied to (left or right). The other side of the face (left or right) will have placebo applied. All participants will receive both treatment and placebo.
62300997|NCT06430892|OTHER|Conventional method|Patients in this arm will be treated with conventional method (rapid inflation-deflation protocol) for stent deployment
62672216|NCT01291875|EXPERIMENTAL|Intensive periodontal treatment|
61916146|NCT01181401|ACTIVE_COMPARATOR|Standard RCT|"Standard RCT:~1. HART (72 Gy), IMRT or 3D-conformal techniques~2. with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5"
61916147|NCT02828891|EXPERIMENTAL|Experimental|Intervention: transcranial Doppler device will be utilized to measure CSF pressure.
61916148|NCT03473418|EXPERIMENTAL|Ketoconazole gel|use of Ketoconazole in situ gel for treatment of vaginal candidiasis
62300998|NCT05809310|EXPERIMENTAL|Interventional group|Percutaneous intervention for PA stenosis
62110653|NCT05380505|EXPERIMENTAL|Condition 1: Race Congruent Ads|Participants will complete a 15-minute survey in which they will be randomized to view and rate Facebook food ads associated with their condition. Then they will complete a food purchasing task in which they will shop in an online store that will display six food items and six beverages. Finally, they will answer demographic questions (e.g., self-reported height and weight) and view a debriefing summary that describes the full purpose of the study.
62300999|NCT05809310|NO_INTERVENTION|Control group|Conservative management (percutaneous intervention for PA stenosis 6 months postponed)
62301000|NCT02609399|EXPERIMENTAL|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
62301001|NCT02609399|EXPERIMENTAL|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
62672217|NCT01291875|ACTIVE_COMPARATOR|Supragingival biofilm control|
62672218|NCT06293950|EXPERIMENTAL|WJMSC|- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
62301002|NCT06432777||Recurrent Campylobacter bacteraemia|"Patients presenting at least two distinct episodes of Campylobacter bacteraemia separated by minimum 60 days and an immunodeficiency (innate or acquired)~and followed by a French hospital"
62301003|NCT02415725|EXPERIMENTAL|lymphofluoroscopy|Indocyanine Green intradermal injection before surgery, and after 3, 6 and 12 monthes
62301004|NCT00460993|EXPERIMENTAL|Group 1|Lunesta Active drug (eszopiclone) 1 mg during 1st week of active drug. If sleep efficiency does not improve does increases to 2 mg for 2nd week of active drug administration.
62672219|NCT05509374|EXPERIMENTAL|A study of carfilzomib, pomalidomide and dexamethasone administration after KRd administration|Patients with RRMM who progressed after receiving lenalidomide monotherapy for at least 6 months after administration of KRd will receive KPD therapy every 4 weeks until disease progression.
62672220|NCT03360487|SHAM_COMPARATOR|Sham photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the laser will be placed for 10 minutes, without being turned on.
61916149|NCT03473418|ACTIVE_COMPARATOR|terconazole cream|use of terconazole 0.8 cream for treatment of vaginal candidiasis
62110654|NCT05380505|EXPERIMENTAL|Condition 2: Race Incongruent Ads|Participants will complete a 15-minute survey in which they will be randomized to view and rate Facebook food ads associated with their condition. Then they will complete a food purchasing task in which they will shop in an online store that will display six food items and six beverages. Finally, they will answer demographic questions (e.g., self-reported height and weight) and view a debriefing summary that describes the full purpose of the study.
62301005|NCT00460993|PLACEBO_COMPARATOR|Group 2|"Sugar pill packaged and supplied by Sepracor. One pill weeks one and two of intervention.~Weeks 3 and 4 this Placebo group crosses over to active drug. 1 mg week 3 increasing to 2mg week 4 if sleep efficiency does not improve."
61916150|NCT04288232|EXPERIMENTAL|Intravitreal aflibercept|Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.
61916151|NCT00476567|EXPERIMENTAL|exercise|Regular exercise 45-60 minutes minimum three times per week
61916152|NCT00476567|ACTIVE_COMPARATOR|control|standard antenatal care
61916153|NCT01047098|EXPERIMENTAL|Iron with meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken with meals
61916154|NCT01047098|EXPERIMENTAL|Iron between meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken between meals
61916155|NCT01047098|PLACEBO_COMPARATOR|Placebo|Prenatal vitamin without iron plus capsule containing calcium carbonate (placebo) taken between meals
61916156|NCT05841173|EXPERIMENTAL|The Product Group|The Product group is prescribed with the investigated product - exogeneous ketone bodies.
61916157|NCT05841173|ACTIVE_COMPARATOR|The Combined Intervention Group|The Combined Intervention Group is prescribed with the investigated product -in combination with regular physical trainings.
62110655|NCT03835572|EXPERIMENTAL|CircaHealth|The CircaHealth group will receive access to an online educational module on circadian rhythms and health as their intervention. Every week for six weeks, these participants will receive a new module that contains videos, quizzes, behavioral modification checklists, and journal prompts.
62110656|NCT03835572|ACTIVE_COMPARATOR|Sleep hygiene materials|The control group will receive publicly available materials about sleep hygiene from the National Sleep Foundation and/or the American Academy of Sleep Medicine every week for six weeks as their intervention.
62110657|NCT04290585|EXPERIMENTAL|Health Services Research (text message reminder)|Patients receive 1-2 text messages a few weeks before and 1 text message 24 hours before their mammography screening appointment. Patients also receive a phone call reminder as per standard practice.
62301006|NCT01079767|OTHER|Temsirolimus|Temsirolimus
62301007|NCT01172314|EXPERIMENTAL|EAA+LEU vs total AA|
62672221|NCT03360487|ACTIVE_COMPARATOR|Photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the region will be irradiated for 10 minutes.
62672222|NCT03360487|SHAM_COMPARATOR|Sham photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be pretended on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be wakely irradiated for 30 seconds (total treatment time: 10 minutes).
62672223|NCT03360487|ACTIVE_COMPARATOR|Photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
62110658|NCT03743246|EXPERIMENTAL|Administration of JCAR017|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
62110659|NCT02168335|EXPERIMENTAL|Treatment group|"OrasaltsTM~1 level scoop of OrasaltsTM will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
62672224|NCT03360487|SHAM_COMPARATOR|Sham Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific turned-off bracelet of the DMC laser Therapy EC model.
62672225|NCT03360487|ACTIVE_COMPARATOR|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
62672226|NCT04621760|EXPERIMENTAL|HIV Prevention DST Intervention|Participants in this arm will receive the HIV prevention DST intervention and will receive the intervention immediately before their provider visit.
62672227|NCT04621760|ACTIVE_COMPARATOR|Standard Counseling|Participants in this arm will receive usual care.
62672228|NCT03422471|EXPERIMENTAL|Hypoglycemia|Participants are exposed to two 90 minute episodes of hypoglycemia (50 mg/dl) through a hyperinsulinemic hypoglycemic clamp. Baroreflex sensitivity will be assessed before, during, and 16 hours after the hypoglycemia.
62672229|NCT01031615|EXPERIMENTAL|Child and Family Traumatic Stress Interv|4-session secondary prevention model that focuses on family communication about symptoms of a child aged 7-16.
62672230|NCT01031615|ACTIVE_COMPARATOR|Psychoeducational Comparison|4-sessions focused on individual child using psychoeducation and relaxation skills
62110660|NCT02168335|PLACEBO_COMPARATOR|Control group|"Sea salt~1 level scoop of sea salt will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
62301008|NCT01172314|EXPERIMENTAL|Total AA vs EAA+LEU|
62301009|NCT01571713||Study|Pediatric patients with pulmonary hypertension
62301010|NCT01651923|OTHER|Group A|"First periody: Heparin Test Drug (Blau Farmacêutica S/A)~Secundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
62672231|NCT02427217||Fibrinogen Concentrate, Human (FCH)|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding, routine prophylaxis and/or use in surgery, and who may continue to prospectively receive FCH at the discretion of the treating physician.
61916158|NCT05841173|PLACEBO_COMPARATOR|The Placebo Group|The Placebo Group is prescribed with the Placebo.
62301011|NCT01651923|OTHER|Group B|"First periody: Heparin Comparator Drug (APP Pharmaceuticals)~Secundy periody: Heperin Test Drug (Blau Farmacêutica S/A)"
62301012|NCT06488950|EXPERIMENTAL|GC203 TIL(gene-edited TIL)|2x10\^8-1x10\^10 in vitro expanded GC203 TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62301013|NCT06488950|EXPERIMENTAL|autologous TILs|\>1x10\^9 in vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62110661|NCT03478696|EXPERIMENTAL|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
62301014|NCT05194319||1/Children with diparetic cerebral palsy|Children with diparetic cerebral palsy
62470626|NCT04175808|EXPERIMENTAL|Part B|"Participants with a maximum observed plasma OM concentration ≤ 350 ng/mL in Part A were randomly assigned to receive a single dose of each the following 3 treatments in one of six treatment sequences:~* Placebo~* 50 mg omecamtiv mecarbil~* 400 mg moxifloxacin Each treatment was separated by a washout of at least 7 days."
62470627|NCT03500120||Primary Aldosteronism|Aldosterone/renin concentration ratio(ARR)≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST≥6 ng/dl
62470628|NCT03500120||non Primary Aldosteronism|1. ARR≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST\<6 ng/dl
62470629|NCT01569269|EXPERIMENTAL|Yoga|See intervention description
62470630|NCT01569269|EXPERIMENTAL|Meditation|See intervention description
62470631|NCT01569269|EXPERIMENTAL|Reiki|see intervention description
62470632|NCT01569269|ACTIVE_COMPARATOR|Holistic Education|see intervention description
62110662|NCT03478696|ACTIVE_COMPARATOR|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
62110663|NCT00237107|EXPERIMENTAL|curettage|
62110664|NCT03182036|EXPERIMENTAL|Study group|Portable pulsed oxygen
62110665|NCT02572024|ACTIVE_COMPARATOR|Baroreflex activation therapy|BAT ON
62110666|NCT02572024|PLACEBO_COMPARATOR|Placebo|BAT OFF
62110667|NCT04034901|EXPERIMENTAL|Monitoring of cardiorespiratory parameters|Monitoring of cardiorespiratory parameters with BORA Band
62110668|NCT05026034||Training Cohort|Inpatients with HF requiring \>24 hours IV diuretics
62110669|NCT05026034||Cohort A|Patients undergoing serial, clinically indicated RHC. To investigate if measures derived by the CPM wearable device correlate with invasive measures of cardiopulmonary haemodynamics (PCWP).
62301015|NCT05194319||2/Healty control|Children with healty peer ages of cerebral palsy children.
62470633|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
62470634|NCT01838941|EXPERIMENTAL|Betaine|Betaine will be given orally to all participants and dose will be adjusted to body weight.
62470635|NCT00891800|EXPERIMENTAL|1|All patients will be treated with SIR-Sphere therapy.
62110670|NCT05026034||Cohort B|Patients receiving haemodialysis. To investigate if changes in measures derived by the CPM wearable device correlate with B-lines on LUS and changes in B-lines before and after haemodialysis and with volume of fluid removed during haemodialysis
62301016|NCT00322114|EXPERIMENTAL|Arm I|Participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks.
62301017|NCT00322114|EXPERIMENTAL|Arm II|Participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks.
62301018|NCT00322114|PLACEBO_COMPARATOR|Arm III|Participants receive oral placebo twice daily for 3 weeks.
62470636|NCT04123769|EXPERIMENTAL|Drug group|
62301019|NCT05319964|EXPERIMENTAL|anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~Participants were provided 30 minutes anti-gravity treadmill sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
62301020|NCT05319964|ACTIVE_COMPARATOR|conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
62301021|NCT05319964|OTHER|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks
62301022|NCT05227352|EXPERIMENTAL|Biophilic experience|Healthcare workers will experience the biophilic-designed room
62301023|NCT02602067|EXPERIMENTAL|131I-Tenatumomab|"Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl / min).~Therapeutic: each patient will receive one single i.v. infusion, escalating 131I-Tenatumomab dose starting at 2.5 GBq±10%,with escalation steps of 1 GBq, up to 5.5 GBq±10% in 10 ml of saline, (conveyed by 10 ±10% , 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333° µl / min)"
62110671|NCT05026034||Cohort C|Patients receiving inpatient intravenous diuretic treatment for heart failure. To investigate if changes in measures derived by the CPM wearable device system correlate with B-lines on lung ultrasound and weight before and after treatment for HF.
62470637|NCT00833651||tacrolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
62470638|NCT00833651||sirolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
62470639|NCT00833651||Healthy controls|Age, gender- and race-matched individuals, not on immunosuppressive medications
62470640|NCT02647177||Pancreatic Cyst Group|Only the eligible participant in the study are considered for inclusion in this group.
62470641|NCT01188850|EXPERIMENTAL|6mg of DNA/dose|Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
62470642|NCT03620175|ACTIVE_COMPARATOR|5 Percent TolaSure Topical Gel|
62470643|NCT03620175|ACTIVE_COMPARATOR|1.5 Percent TolaSure Topical Gel|
62470644|NCT03620175|ACTIVE_COMPARATOR|0.5 Percent TolaSure Topical Gel|
62110672|NCT01679262|OTHER|Optimal size of OPAs|
62470645|NCT03620175|PLACEBO_COMPARATOR|Topical Vehicle Gel|
62470646|NCT01581658|EXPERIMENTAL|BI10773 medium dose group 1|BI10773 medium dose tablet single dose group 1
62470647|NCT01581658|EXPERIMENTAL|BI10773 medium dose group 2|BI10773 medium dose tablet single dose group 2
62470648|NCT01581658|EXPERIMENTAL|BI10773 Medium dose group 3|BI10773 medium dose tablet single dose group 3
62470649|NCT01581658|EXPERIMENTAL|BI10773 Medium dose group 4|BI10773 medium dose tablet single dose group 4
62110673|NCT02967016|EXPERIMENTAL|normal spontaneous vaginal delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
62110674|NCT02967016|EXPERIMENTAL|Cesarean Delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
62110675|NCT00117988|EXPERIMENTAL|Arm I|Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease regression after completion of 8 courses may receive 2 additional courses of treatment beyond their maximal response. After completion of study treatment, patients are followed every 3 months until disease progression.
62470650|NCT00900718|EXPERIMENTAL|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
62470651|NCT00900718|ACTIVE_COMPARATOR|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
62470652|NCT02646124|EXPERIMENTAL|Diazepam|Naproxen +Diazepam
62470653|NCT02646124|ACTIVE_COMPARATOR|Placebo|Naproxen + Placebo
62470654|NCT06225609|EXPERIMENTAL|Ghost ileostomy|Laparoscopic or robotic surgery with ghost ileostomy
62470655|NCT06225609|ACTIVE_COMPARATOR|No ileostomy|Laparoscopic or robotic surgery with no ileostomy
62470656|NCT00732082|ACTIVE_COMPARATOR|Dose Level 0|Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
62470657|NCT00732082|EXPERIMENTAL|Dose Level 1|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 3 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free period."
62110676|NCT05053009|EXPERIMENTAL|Ibuprofen sustained release|Single dose of 800 mg Brufen Retard oral premedication will be administered 1 hour before local anesthesia
62110677|NCT05053009|PLACEBO_COMPARATOR|Placebo|1 capsule of 500 mg of glucose oral premedication will be adminstered 1 hour before local anesthesia
62110678|NCT03920371|EXPERIMENTAL|gamma camera imaging|hand held camera
62110679|NCT03265210|EXPERIMENTAL|Relief|Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
62110680|NCT03265210|NO_INTERVENTION|Referral|Referral for mental health based on clinical indication.
62110681|NCT04422535||Critical care patients|Patients admitted to critical care units for COVID-19, where ECG records and relevant clinical information are available to assess the impact of the disease and its concomitant treatment on electrocardiographic parameters of ventricular repolarization
62470658|NCT00732082|EXPERIMENTAL|Dose Level 2|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 6.5 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
62110682|NCT05612659|EXPERIMENTAL|Transcranial Electrical stimulation|Subjects will receive transcranial electrical stimulation.
62110683|NCT05612659|EXPERIMENTAL|Transcutaneous direct current stimulation|Subjects will receive Transcutaneous direct current stimulation
62470659|NCT00732082|EXPERIMENTAL|Dose Level 3|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 13 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
62301024|NCT04298411|EXPERIMENTAL|Experimental Arm|Participants will take part in 12 one-hour rehabilitation sessions over 12 weeks in the clinic at Holland Bloorview Kids Rehabilitation Hospital and Institut de réadaptation en déficience physique de Québec, during which they will play games developed for the Novint Falcon.
62110684|NCT05253339|ACTIVE_COMPARATOR|Standard administration method|"Drug: Cefoxitin, Device: not applicable (standard method)~Two grams of cefoxitin (JW Pharmaceutical Co., Ltd., Seoul, South Korea) was dissolved in 50 mL of normal saline and administered for about 10 min before skin incision."
62301025|NCT05903664||Single group assignment|The participant will undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.
62301026|NCT03574207|OTHER|Arm A: Stimulation then Sham|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm A, transcranial magnetic stimulation (TMS) will be applied in the first week of participation, and sham stimulation will be applied in the second week of participation.
62301027|NCT03574207|OTHER|Arm B: Sham then Stimulation|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm B, sham stimulation will be applied in the first week of participation, and transcranial magnetic stimulation (TMS) will be applied in the second week of participation.
62301028|NCT05388357|EXPERIMENTAL|AI -guided PCI|based on AI-QCA measurement, a drug eluting stent of an appropriate size is inserted and then high-pressure balloon dilatation is additionally actively performed in all patients.
62301029|NCT05388357|ACTIVE_COMPARATOR|OCT-guided PCI|In the OCT group, the size of the stent is determined using intravascular optical coherence tomography, and balloon dilatation is additionally performed if necessary.
62301030|NCT03802721|EXPERIMENTAL|50 ng dose|Capsule containing 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene (BaP)
62301031|NCT03802721|EXPERIMENTAL|Brussels sprouts before 50 ng dose|Subjects will consume 50 g (about 1/2 cup) of lightly steamed Brussels sprouts each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene (BaP)
62301032|NCT03802721|EXPERIMENTAL|DIM supplement before 50 ng dose|Subjects will consume 300 mg DIM supplement ( 2 capsules of BioResponse DIM® 150) each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene (BaP). A 300 mg DIM dose will be co-administrated with the 50 ng BaP dose
62301033|NCT00326820|EXPERIMENTAL|Ibandronic Acid|50mg tablet once daily over 96 weeks
62301034|NCT00326820|ACTIVE_COMPARATOR|Zoledronic Acid|4 mg via intravenous infusion (iv) over a minimum of 15 minutes in at least 100mls of saline every 4 weeks over 96 weeks
62301035|NCT06182631|EXPERIMENTAL|Vapocoolant|Will have nurse spray vapocoolant on the skin before IV insertion, will then videotape patient and ask them and parent to fill out FACES form.
62301036|NCT06182631|EXPERIMENTAL|Buzzy Bee|Will have nurse put Buzzy Bee on arm before, and leave it on during IV insertion. Will then videotape patient and ask them and parent to fill out FACES form.
62301037|NCT06182631|PLACEBO_COMPARATOR|Placebo|Will have nurse place a rubber band around arm before IV insertion. Will then videotape patient and ask them and parent to fill out FACES form.
62110685|NCT05253339|EXPERIMENTAL|Target controlled infusion (TCI)|"Drug: Cefoxitin, Device: TCI Syringe pump~Two grams of cefoxitin were dissolved in 50 mL of normal saline to give a concentration of 40 mg/mL. Before skin incision, cefoxitin was infused with a TCI syringe pump (Pilot Anesthesia 2, Fresenius vial, France), which was connected to a personal computer by an RS232c cable and controlled with TCI software (Asan pump, version 2.1.3; Bionet Co. Ltd., Seoul, Korea, http://www.fit4nm.org/download, last accessed: 27 August, 2012). Target concentrations of total concentrations were set to 80 μg/mL."
62301038|NCT06509061|EXPERIMENTAL|PASD Intervention|6 week 30-45 minute psychoeducation sessions that delivered content on the variables within the Physical Activity Self-Definition Model. The first session was an introductory session and each one that followed focused on one of the direct or indirect determinants of the model: perceived enjoyment, perceived wanting, perceived commitment, perceived trying, perceived ability (all relating to physical activity). Group activities such as worksheets and discussion were carried out during the session.
62301039|NCT06509061|ACTIVE_COMPARATOR|Attention Control|6 week 30-45 minute educational sessions that delivered content on general health behaviour. After the introductory session, each week, one of five general health behaviours were covered: balanced diet, sleep, reducing sedentary behaviour, mental/spiritual health and self-compassion/cultivating positive health behaviours. Group activities such as worksheets and discussion were carried out during the session.
62301040|NCT05495464|EXPERIMENTAL|Acalabrutinib and Rituximab (Part 1)|Participants may receive acalabrutinib and rituximab for up to 12 cycles. Each cycle is 28 days.
62301041|NCT05495464|EXPERIMENTAL|Brexucabtagene Autoleucel (Part 2)|Participants will have a procedure called leukapheresis to collect enough T cells.
62301042|NCT05895513|EXPERIMENTAL|Pimavanserin|One single dose of pimavanserin (34 mg oral)
62301043|NCT05895513|PLACEBO_COMPARATOR|Placebo|One single dose of matching placebo
62301044|NCT02079727|EXPERIMENTAL|Condrosulf (Chondroitin 4&6 sulfate)|1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days
62470660|NCT00732082|EXPERIMENTAL|Dose Level 4|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 26 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
61916159|NCT05841173|ACTIVE_COMPARATOR|The Diet Group|The Diet Group is prescribed with the Diet designed with 500 kcal reduction from daily energy expenditure.
62301045|NCT02079727|PLACEBO_COMPARATOR|Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule|1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days
62301046|NCT02079727|ACTIVE_COMPARATOR|Celebrex 200 mg capsule|1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days
62110686|NCT00300040|EXPERIMENTAL|1|Hemoglobin glutamer 250 - bovine
62470661|NCT04628117|NO_INTERVENTION|Control|Nutritional counselling by individualized nutritional plan for 8 weeks.
62672232|NCT01691482|ACTIVE_COMPARATOR|Albuterol/salbutamol followed by ipratropium|Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
62672233|NCT01691482|ACTIVE_COMPARATOR|Ipratropium followed by albuterol/salbutamol|Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium
62672234|NCT05740384|EXPERIMENTAL|Sonotubometry Assessment|All participants will be measured 8 times using sonotubometry. 2 times without applying any sound and 2 times while applying sound. This is done for both the left and right ear.
62110687|NCT00300040|ACTIVE_COMPARATOR|2|6% Hydroxyethylstarch
62110688|NCT00444613|EXPERIMENTAL|E0302 25 mg|
62110689|NCT00444613|EXPERIMENTAL|E0302 50 mg|
62110690|NCT00444613|PLACEBO_COMPARATOR|3|
62110691|NCT03646006|EXPERIMENTAL|Pre-sacral nerve block|10 mL bupivacaine (5mg/mL)
62110692|NCT03646006|SHAM_COMPARATOR|Sham block|10 mL normal saline
62110693|NCT02138331|EXPERIMENTAL|Exosomes|The exosomes have exosome-associated proteins such as the tetraspanin proteins, CD9 and CD81, Alix, Tsg101, and RNA that consists primarily of short RNAs of less than 300 nm. Some of these RNAs are microRNAs that are predominantly pre-microRNAs..Additionally, CB-SC displayed very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes.
62470662|NCT04628117|EXPERIMENTAL|Oral nutritional supplementation|Nutritional counselling by individualized nutritional plan plus oral nutritional supplementation for renal disease (237 mls per day) for 8 weeks.
62672235|NCT04279678||patients undergone mitral repair|includes all patients undergone repair of mitral valve with CABG
61916160|NCT05841173|NO_INTERVENTION|The Control Group|The Control Group is prescribed with standard recommendations for weight loss.
62470663|NCT04279353|EXPERIMENTAL|Mindfulness Based Intervention|Participants was asked to answer PSS-10 questionnaire to measure their stress level, then they received Mindfulness Based Intervention program for 4 weeks and did the PSS-10 test again after 4 weeks.
62672236|NCT04279678||patients with no mitral repair|includes all patients where no repair done for mitral valve , only CABG
62672237|NCT01506375|EXPERIMENTAL|gpASIT|grass pollen peptides alone
62672238|NCT01506375|EXPERIMENTAL|gpASIT/adjuvant|grass pollen peptides + adjuvant
62735969|NCT02684617|EXPERIMENTAL|rrCLL Cohort|Participants with refractory chronic lymphocytic leukemia (rrCLL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m\^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m\^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m\^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m\^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
61916161|NCT02492737|EXPERIMENTAL|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
61916162|NCT04879524||Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|100 units of Botulinum toxin type A (Botox, Allergan, Ireland) injection into the puborectalis muscle to each side of the midline, achieving a total of 200 units
62110694|NCT02139449||ICD/CRT registry|ICD / CRTregistry in Severance or Ewha Womans University Medical Center
62110695|NCT03949686|SHAM_COMPARATOR|Saline + Placebo|Ultrasound guided 0.5 ml/kg saline injection to erector spinae plane
62110696|NCT03949686|ACTIVE_COMPARATOR|ultrasound guided erector spinae plane block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection to erector spinae plane
62110697|NCT04548011|EXPERIMENTAL|Three times a week group|Twenty participants in three times a week group will receive acupuncture treatment 3 times per week (every other day) for 4 weeks, 12 sessions totally. The acupuncture operation as above. Participants will not be not allowed to take any other medication or accept any treatment for FD. should not be accepted during the study. In case of unbearable symptoms, the assistant researchers will detailly document.
62110698|NCT04548011|EXPERIMENTAL|Once a week group|Twenty participants in once a week group will receive acupuncture treatment 1 time per week for 4 weeks (Weekly fixed day), 4 sessions totally. Other inventions will be same as the Three times a week group.
62110699|NCT04548011|NO_INTERVENTION|Waiting for treatment group|After the health education（such as dietary adjustment for FD patients）, the participants will be followed up for 4 weeks. At the end of the follow-up, the patients could be given free acupuncture treatment (the invention will be similar with that of the Three times a week group) for 4 weeks at will.
62110700|NCT00750750|ACTIVE_COMPARATOR|1|MFNS once daily
62110701|NCT00750750|EXPERIMENTAL|2|MFNS twice daily
62110702|NCT00750750|ACTIVE_COMPARATOR|3|Amoxicillin
62110703|NCT00750750|PLACEBO_COMPARATOR|4|Placebo
62110704|NCT04643405|EXPERIMENTAL|APG1387 in combination with Gemcitabine and Nab-Paclitaxel|
62110705|NCT02023554|EXPERIMENTAL|Theophylline with azithromycin|steady-state plasma concentration of theophylline in the presence of azithromycin
62110706|NCT02023554|ACTIVE_COMPARATOR|Theophylline alone|steady-state plasma concentration of theophylline alone
62110707|NCT01959412|EXPERIMENTAL|Treatment Period Sequence 1|Indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcgin the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening
62110708|NCT01959412|EXPERIMENTAL|Treatment Period Sequence 2|Indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later 37.5 in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening
62110709|NCT01959412|EXPERIMENTAL|Treatment Period Sequence 3|Indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 55mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo n the evening, 14 days later placebo in the morning + matching placebo in the evening
62110710|NCT01959412|EXPERIMENTAL|Treatment Sequence Period 4|Indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening
62110711|NCT01959412|EXPERIMENTAL|Treatment Period Sequence 5|Indacaterol 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later 150mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening
62470664|NCT01780870|NO_INTERVENTION|Control Group|Obese, otherwise healthy people who are not receiving any nutritional,surgical or behavioral therapy
62470665|NCT01780870|ACTIVE_COMPARATOR|Weight loss group|Full Meal replacement Protocol
62470666|NCT04907838|EXPERIMENTAL|Type 2 diabetics|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
62470667|NCT04907838|EXPERIMENTAL|Healthy controls|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
62470668|NCT01790386||Surgical Patients Group|Patients undergoing cardiovascular surgery and cardiology procedures
62470669|NCT01790386||Reference Ranges Group|Healthy volunteer subjects for determination of normal hemostasis parameter results
62110712|NCT01959412|EXPERIMENTAL|Treatment Period Sequence 6|Placebo in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening
62110713|NCT04593797||Patients undergoing major upper abdominal surgery|major open upper abdominal surgery eg pancreatic, liver surgery
62110714|NCT05037266|EXPERIMENTAL|55 - 64 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
62110715|NCT05037266|EXPERIMENTAL|At least 65 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
62110716|NCT05936892|EXPERIMENTAL|upper extremity aerobic training|upper extremity aerobic training
62110717|NCT05936892|EXPERIMENTAL|upper extremity resistance training|upper extremity resistance training
62110718|NCT00565708|EXPERIMENTAL|acetylsalicylic acid|200mg OD for 3 years
62110719|NCT00565708|PLACEBO_COMPARATOR|Placebo|200mg OD for 3 years
62110720|NCT01455051|EXPERIMENTAL|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
62110721|NCT05629364|EXPERIMENTAL|0.15% KIO-101|.15% KIO-101 eyedrops
62110722|NCT05629364|EXPERIMENTAL|0.3% KIO-101|0.3% KIO-101 eyedrops
62110723|NCT05629364|PLACEBO_COMPARATOR|Vehicle|Vehicle eyedrops
62110724|NCT00890786|EXPERIMENTAL|HGG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the intervention section.
62110725|NCT00890786|EXPERIMENTAL|DIPG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the interventions section.
62110726|NCT02120313|ACTIVE_COMPARATOR|inpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in a rehabilitation hospital.
62470670|NCT02330380||Methotrexate|Methotrexate will be dosed weekly. Methotrexate is given as a single, weekly dose and is will be started at 15mg after a first week test dose of 2.5 mg to minimize side effects and achieve efficacy. Weekly dosages will be 15mg.
62301047|NCT02835729|EXPERIMENTAL|Phase 1a|"Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (freebase formulation). These patients will additionally receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.~All current subjects will transition from indoximod freebase capsules over to indoximod HCL F2 tablets. All new subjects enrolled will also receive indoximod HCL F2 tablets."
62470671|NCT02330380||Ustekinumab|Ustekinumab is given as a subcutaneous injection of 45mg if the patient is \<100Kg or 90mg if the patient is \>100Kg at weeks 0, 4, 16, and every 12 weeks thereafter.
62470672|NCT02330380||Etanercept|Etanercept will be given in the first 3 months of treatment as 50 mg twice a week (3 or 4 days apart). After 3 months, a reduced dose of 50 mg will be given once per week.
62470673|NCT02330380||Adalimumab|Adalimumab will be given in a dose of 40 mg subcutaneously every other week.
62470674|NCT02330380||Acitretin|Acetretin will be prescribed as daily with 25mg if the patient is \<80Kg or 35mg if the patient is \>80Kg.
62301048|NCT02835729|EXPERIMENTAL|Phase 1b (CLOSED TO ACCRUAL)|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (HCL F1 formulation). These patients will receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
62301049|NCT02427061|EXPERIMENTAL|Intervention Program (Manhood 2.0)|"Curricular Content: The 18 hour content will be spread over 3 to 6 sessions (3 weeks duration up to a 2 month period). Youth are guided to explore social constructions of masculinity, describe healthy relationships, discuss healthy sexual behaviors, identify coercive and disrespectful behaviors, and practice skills to intervene when witnessing peers' disrespectful and harmful behaviors, with repeated reflection on gender norms throughout these sessions.~Module One focuses on themes of gender and masculinity. Module Two focuses on themes of violence and sexual consent. Module Three focuses on themes of sexual health and decision making."
62301050|NCT02427061|ACTIVE_COMPARATOR|Control Program (Job Skills Training)|"Youth in the control arm receive the same amount of time with an intervention -- 18 hours of curriculum divided into 3 to 6 sessions, over 3 weeks up to 2 months duration.~The control intervention focuses on job skills development."
62301051|NCT02913625|EXPERIMENTAL|Ultrasound guided retroclavicular block|Patients assigned to this group will receive an ultrasound guided retroclavicular brachial plexus block
62672239|NCT01390584|EXPERIMENTAL|ABVD + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.~ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks."
62301052|NCT02913625|ACTIVE_COMPARATOR|Ultrasound guided infraclavicular block|Patients assigned to this group will receive an ultrasound guided infraclavicular brachial plexus block
62301053|NCT01547338||Breast reconstruction patient|Unilateral breast reconstruction patients
62301054|NCT00820105|EXPERIMENTAL|ADX10059 25 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
62301055|NCT00820105|EXPERIMENTAL|ADX10059 50 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
62301056|NCT00820105|EXPERIMENTAL|ADX10059 100 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
62672240|NCT01390584|EXPERIMENTAL|ABVD + BEACOPP + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.~BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks."
62672241|NCT03958487|EXPERIMENTAL|executive/monitoring training|All participants will be part of the same group and their performance after treatment will be compared to their own performance prior to treatment (baseline)
62672242|NCT02731859||EndoBarrier|All patients with EndoBarrier treatment
62672243|NCT05897554|EXPERIMENTAL|Successful mechanical thrombectomy plus intra-arterial alteplase group|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed after intra-arterial thrombolysis.
62470675|NCT02330380||UVB Excimer Laser|Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
62672244|NCT05897554|NO_INTERVENTION|Successful mechanical thrombectomy only group|For patients in the successful MT only group, the choice of MT strategy will be made by the qualified neurointerventionalist, including stent retriever, aspiration and a combination technology. Patients who underwent more than 3 thrombectomy procedures were excluded from the study. Rescue therapy was performed at the discretion of the neurointerventionalist in case of the grade of stenosis at the occlusion site was presented to be more than 70% after MT.
62672245|NCT01902303|PLACEBO_COMPARATOR|Matching Placebo|Matching Placebo
62672246|NCT01902303|EXPERIMENTAL|BTL-TML-HSV|Experimental Product
61916163|NCT01813045||Chronic Coronary Occlusion group|"We will also recruit 10 patients with an angiographically documented chronic (\>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.~We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan."
62110727|NCT02120313|EXPERIMENTAL|outpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in an outpatient rehabilitation center.
62110728|NCT05823181||Early laparoscopic exploration of common bile duct|Early laparoscopic exploration of common bile duct after failure of extraction of common bile duct stones by ERCP
62110729|NCT05823181||Late laparoscopic exploration of common bile duct|late laparoscopic exploration of common bile duct after failure of extraction of common bile duct stones by ERCP
62110730|NCT03831529||ICU older patient|Older patient (\> 65 years old) admitted to ICU with severe acute cholangitis
62110731|NCT02709616|EXPERIMENTAL|Personalized cellular vaccine|DC based cellular vaccine
62110732|NCT01179243||intensive care patients|no interventions
62110733|NCT01703130|EXPERIMENTAL|Local Anesthestic Dose|
62110734|NCT00479141|EXPERIMENTAL|1|HIV infected participants and their families
62110735|NCT00479141|EXPERIMENTAL|2|Popular Opinion Leaders (POL) participants
62110736|NCT02931435|ACTIVE_COMPARATOR|Nerve Block with Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
62110737|NCT02931435|SHAM_COMPARATOR|Nerve Block with Sham Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.
61916164|NCT01813045||MI (non-revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
62110738|NCT04330469|EXPERIMENTAL|Periodontal therapy|Patients offered periodontal therapy in 2-4 sittings (n=40), Dental hygiene advised
62110739|NCT04330469|SHAM_COMPARATOR|Control|Patients given standard medical treatment (n=40), Dental hygiene advised
62301057|NCT00820105|PLACEBO_COMPARATOR|ADX10059 Matching Placebo|Weeks 1-2: once daily Weeks 3-12: twice daily
62301058|NCT04438655|EXPERIMENTAL|Oral + Parenteral prophylaxis|"Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.~Systemic antibiotic drugs:~* Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~* in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
62301059|NCT04438655|SHAM_COMPARATOR|Only parenteral prophylaxis|"* Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~* in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
62301060|NCT03739970|EXPERIMENTAL|Investigational Group- Silk Peptide|"* Ingredient: Silk Peptide~* Type: Yellow granule stick~* Weight: Silk Peptide 9g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
62301061|NCT03739970|PLACEBO_COMPARATOR|Control Group - Placebo Product|"* Ingredient: Microcrystalline Cellulose~* Type: Yellow granule stick~* Weight: Silk Peptide 0g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
62301062|NCT02365428|EXPERIMENTAL|Control: Group 1|The control group will receive three standard Text4Baby messages per week at noon on Mondays, Wednesdays, and Fridays.
62301063|NCT02365428|EXPERIMENTAL|Group 2|Intervention group 1 will receive two physical activity messages and one standard Text4Baby message each week at noon on Mondays, Wednesdays, and Fridays.
62470676|NCT02330380||Narrowband UVB|Narrowband UVB (311nm) will be used to treat patients 3X per week with 311nm of UVB light. Uninvolved areas of skin will be covered where possible to minimize excess sun exposure. Patients will be tested for their minimal erythemal dose (MED), after which, based upon Fitzpatrick Scale skin type, a patient will typically beginning with 1-2 minutes based on skin type and gradually increased by 10-15% per treatment dose as tolerated.
62470677|NCT05305430||Prospective|All patients for whom the decision has been made to have the Synergy Disc implanted at participating investigative centers and give informed consent to participate in the prospective segment of this protocol, per country-specific requirements, will be enrolled in the prospective portion of this protocol.
62470678|NCT05305430||Retrospective|Patients who have previously had a Synergy Spine Solutions Synergy Disc implanted will be eligible for inclusion in the retrospective data collection; a waiver of consent, or informed consent, for retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations as applicable.
62470679|NCT04427748||congenital cataract group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and IOL implantation are perfomed ERG
62110740|NCT03172533|ACTIVE_COMPARATOR|verum group|approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks
62110741|NCT03172533|PLACEBO_COMPARATOR|placebo group|placebo
62110742|NCT00646451|ACTIVE_COMPARATOR|Pregabalin (Lyrica)|Pregabalin (Lyrica) 75 mg bid to a maximum dose of 300 mg bid
62110743|NCT00646451|PLACEBO_COMPARATOR|Placebo|Placebo to 4 capsules bid
62110744|NCT03904199|EXPERIMENTAL|Basal-Prandial-Correctional Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization. Adjustments will be made in real time to reach the target range.
62110745|NCT03904199|ACTIVE_COMPARATOR|Standard of Care Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.
62110746|NCT04582344|EXPERIMENTAL|SARS-COV-2 Vaccine|600 SU of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 14 days apart.
62110747|NCT04582344|PLACEBO_COMPARATOR|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, intramuscular injection, two doses given 14 days apart.
62110748|NCT02509780|EXPERIMENTAL|Vichy|
62110749|NCT01425983|ACTIVE_COMPARATOR|amino acid composition (asn01)|Dietary supplement: specific amino acid composition with micronutrients
62110750|NCT01425983|PLACEBO_COMPARATOR|Sugar powder|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties.
62110751|NCT02993471|EXPERIMENTAL|Drug Cocktail|Drug cocktail (caffeine, warfarin \[plus vitamin K\], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1 (day 1).
62301064|NCT02365428|EXPERIMENTAL|Group 3|Intervention group 2 will receive six physical activity messages and one standard Text4Baby message per week at a random time per day.
62301065|NCT02365428|EXPERIMENTAL|Group 4|Intervention group 3 will receive six physical activity messages and one standard Text4Baby message per week at a time of the participant's choice per day.
62470680|NCT04427748||age-matched normal children group|age-matched normal children are perfomed ERG
62470681|NCT05034757|EXPERIMENTAL|Hyaluronate|HA injection
62110752|NCT02993471|EXPERIMENTAL|Drug Cocktail + Ixekizumab|Drug cocktail (caffeine, warfarin \[plus vitamin K\], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.
62470682|NCT05034757|EXPERIMENTAL|HA + ESWT|HA + ESWT
62470683|NCT01868971|OTHER|Colonoscopy procedure with the EndoRings|Colonoscopy procedure using an add-on device (EndoRings) that is attached to the distal tip of the endoscope
62470684|NCT03250286|EXPERIMENTAL|EUS-ERCP group|EUS is performed first, and when the examiner finds bile duct stone in the EUS examination, ERCP is performed to remove the stone.
62470685|NCT03250286|ACTIVE_COMPARATOR|ERCP group|ERCP without EUS is performed in all patients.
62301066|NCT01059149|EXPERIMENTAL|receive real rTMS|For real rTMS, pulses will be delivered at a frequency of 5 Hz for 6s with a 54s interval, with an intensity equal of 90% of the motor threshold as established at Baseline. 20-min real stimulation sessions will be administered 5 days a week for a period of 2 weeks
62301067|NCT01059149|PLACEBO_COMPARATOR|sham rTMS|For sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo procedures will be used administered 5 days a week for a period of 2 weeks.
62470686|NCT04253366|OTHER|Single arm|All patients perform standard breast screening and also MammoWave exam.
62470687|NCT03789994|EXPERIMENTAL|Affective touch group|"Survivors in the intervention group will receive a total of 36 sessions of a 15-minute affective touch intervention performed by their family caregivers in their homes. Sessions will be scheduled for every alternate weekday (three times a week) for 12 weeks. A trained research nurse (RN) will conduct three 30-minute caregiver training sessions to support the caregivers in delivering the affective touch.~To put caregivers in a more relaxed mood for delivering the intervention, the RN will work with them to identify a time that they feel less burdensome, and teach them to perform deep breathing for relaxation before the affective touching begins. Also, the survivor-caregiver dyad will be asked to sit in a comfortable position and switch off television or radio during the intervention."
62470688|NCT03789994|OTHER|Fine motor group|To address the additional attention given by caregivers during affective touch, the control group will be asked to sit beside the survivors when they go through the fine motor exercises which are commonly used for rehabilitation. Caregivers will be instructed to provide only necessary help in preparing the equipment, and to avoid touching or talking to the survivors during the 15-minute exercise session. Two such sessions will be arranged for survivors to master the skills needed, and for caregivers to practise the required level of interaction during the exercise training. Participants will be instructed to do the exercise three times a week (every alternate weekday) over 12 weeks.
62470689|NCT01352091|EXPERIMENTAL|Switch to Zoladex + AI for 3-2 years|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
62110753|NCT04454892||Amyotrophic lateral sclerosis patients|Although previous studies have provided reference for the diagnosis and treatment of ALS, the etiology of ALS is still unknown, and the relevant clinical features and natural history of ALS still lack the verification of large samples. Therefore, the research on the natural history of ALS is of great significance to further increase the understanding of ALS and provide new evidence for the diagnosis and treatment of ALS
62110754|NCT01320436|ACTIVE_COMPARATOR|Treatments arm|Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
62110755|NCT01320436|PLACEBO_COMPARATOR|Control arm|Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.
62110756|NCT04075357|NO_INTERVENTION|Control|The patients underwent conventional CTS surgery
62110757|NCT04075357|EXPERIMENTAL|Experimental|The patients underwent conventional CTS surgery and transplantation of amniotic membrane
62301068|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
62301069|NCT06263712|EXPERIMENTAL|ASSIP Group|Patients in the ASSIP Group will receive 3-4 sessions of the Attempted Suicide Short Intervention Program (ASSIP) which is a specific therapy for patients with a suicide attempt in their personal history. Each ASSIP session takes approximately 50 minutes.
62301070|NCT06263712|ACTIVE_COMPARATOR|STAR Group|Patients in the STAR group will receive the standard of care plus resource interview (STAR) which will be a risk assessment interview, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the sessions are focused on activation of existing resources and the patients' social environment is discussed.
62301071|NCT02718820|EXPERIMENTAL|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression.
62470690|NCT01352091|EXPERIMENTAL|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
62470691|NCT05498857|ACTIVE_COMPARATOR|Ephedrine group|Patients will receive intramuscular ephedrine 0,5 mg/kg before spinal anesthesia
62470692|NCT05498857|PLACEBO_COMPARATOR|Placebo group|Patients will receive intramuscular saline before spinal anesthesia
61916165|NCT01813045||MI (revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
62110758|NCT06632015|ACTIVE_COMPARATOR|CALCIUM HYDROXIDE|"The working length was determined using a 15 K type file and apex locator (Morita Root ZX, Tokyo, Japan) and checked by radiography. The chemomechanical preparation was completed using the R25 (Resiproc, VDW, Munich, Germany) file in the mesial root canals and the R25, R40 files in the distal root canals, respectively, at the WL. During the chemomechanical preparation, the root canals were irrigated with 2.5% NaOCl after every three pecking motions; and total volume of NaOCl was 10 ml. In the final irrigation, the root canal was irrigated with 5 ml 17% Ethylene diamine tetraacetic acid (EDTA), for 1 minute, following with 2 ml distilled water. Following the retention of 5 ml of 2.5% NaOCl in the root canal for 1 minute, 5 ml of distilled used to neutralize the effect of NaOCl in the root canal.Subsequently, the root canals were dried with paper points, and the selected intracanal medicament was placed in the root canals.~• Group 1: 1 mL of distilled water with 1 g of Ca(OH)2 powder"
62110759|NCT06632015|EXPERIMENTAL|DICLOFENAC SODIUM|"The working length was determined using a 15 K type file and apex locator (Morita Root ZX, Tokyo, Japan) and checked by radiography. The chemomechanical preparation was completed using the R25 (Resiproc, VDW, Munich, Germany) file in the mesial root canals and the R25, R40 files in the distal root canals, respectively, at the WL. During the chemomechanical preparation, the root canals were irrigated with 2.5% NaOCl after every three pecking motions; and total volume of NaOCl was 10 ml. In the final irrigation, the root canal was irrigated with 5 ml 17% Ethylene diamine tetraacetic acid (EDTA), for 1 minute, following with 2 ml distilled water. Following the retention of 5 ml of 2.5% NaOCl in the root canal for 1 minute, 5 ml of distilled used to neutralize the effect of NaOCl in the root canal.Subsequently, the root canals were dried with paper points, and the selected intracanal medicament was placed in the root canals.~• Group 2: 1 mL of distilled water with 1 g of sodium diclofenac"
62110760|NCT06632015|EXPERIMENTAL|CALCIUM HYDROXIDE+DICLOFENAC SODIUM|"The working length was determined using a 15 K type file and apex locator (Morita Root ZX, Tokyo, Japan) and checked by radiography. The chemomechanical preparation was completed using the R25 (Resiproc, VDW, Munich, Germany) file in the mesial root canals and the R25, R40 files in the distal root canals, respectively, at the WL. During the chemomechanical preparation, the root canals were irrigated with 2.5% NaOCl after every three pecking motions; and total volume of NaOCl was 10 ml. In the final irrigation, the root canal was irrigated with 5 ml 17% Ethylene diamine tetraacetic acid (EDTA), for 1 minute, following with 2 ml distilled water. Following the retention of 5 ml of 2.5% NaOCl in the root canal for 1 minute, 5 ml of distilled used to neutralize the effect of NaOCl in the root canal.Subsequently, the root canals were dried with paper points, and the selected intracanal medicament was placed in the root canals.~• Group 3: 1 mL of distilled water with 950 mg of Ca(OH)2 powder"
62110761|NCT02796976|NO_INTERVENTION|healthy older active|only cross-sectional
62110762|NCT02796976|NO_INTERVENTION|healthy older sedentary|only cross-sectional
62110763|NCT02796976|ACTIVE_COMPARATOR|older sedentary at risk|cross-sectional and training or control condition
62110764|NCT04848649|EXPERIMENTAL|Arm 1|
62110765|NCT05515042|ACTIVE_COMPARATOR|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine|"Description: The Ad26.COV2.Sis a recombinant, replication-defective adenovirus type 26 (Ad26) vector vaccine encoding the SARS-CoV-2 spike (S) glycoprotein.~Dose: The Ad26.COV2.S drug product (DP) is supplied as a single-dose or multi-dose suspension (target DP titer is 1×1011 virus particles \[vp\]/mL or 2×1011 vp/mL) for intramuscular (IM) injection.~Dosage Form: Sterile liquid suspension for injection Colourless to slightly yellow, clear to very opalescent suspension (pH 6-6.4).~Packaging: The vaccine will be provided as a multi-dose vial with 5 doses per vial with a total volume of 2.5ml.~Administration: Vaccination (5x10\^10 vp dose) is given as a 0.5mL intramuscular injection into the deltoid muscle in the upper arm."
62301072|NCT00481481|EXPERIMENTAL|1|
62301073|NCT02424149|NO_INTERVENTION|Control|No preoperative phenazopyridine
62301074|NCT02424149|EXPERIMENTAL|Phenazopyridine|Preoperative phenazopyridine
62301075|NCT00540215|ACTIVE_COMPARATOR|1|450 nmol GLP-2 SC
61916166|NCT03743974|ACTIVE_COMPARATOR|Interscalene block|Site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled of extra-plexus injection of the mixture posterior to the C6 root
61916167|NCT03743974|EXPERIMENTAL|Supraclavicular block|"Site of injection for SCB was superficial and lateral to the trunks of the brachial plexus, and not directly deep inside the corner pocket zone, with neurostimulation control and visualization of the lung"
61916168|NCT05401396|EXPERIMENTAL|Swimming immediately after eating|Two arms but all participants are performing both the intervention and the comparison.
61916169|NCT05401396|NO_INTERVENTION|Swimming 30 minutes after eating|Two arms but all participants are performing both the intervention and the comparison.
62301076|NCT00540215|PLACEBO_COMPARATOR|2|1 ml isotonic saline SC
62301077|NCT03431610|EXPERIMENTAL|SB414 2%|SB414 2% topically twice daily
62301078|NCT03431610|EXPERIMENTAL|SB414 6%|SB414 6% topically twice daily
62301079|NCT03431610|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Cream topically twice daily
62301080|NCT04681131|EXPERIMENTAL|CAB-AXL-ADC (BA3011)|CAB-AXL-ADC (BA3011) alone
62301081|NCT04681131|EXPERIMENTAL|CAB-AXL-ADC (BA3011)+PD-1 inhibitor|CAB-AXL-ADC (BA3011) with PD-1 inhibitor
62301082|NCT06116383||Patients undergoing laparoscopic cholecystectomy.|Basal rSO2 values will be recorded by placing NIRS probes under the 10-11th intercostal space in the bilateral posterior lateral flank region. Age, gender, BMI, ASA scores, Hb/Htc values, intraoperative hemodynamic parameters, NIRS values, N-GAL (preoperative, 2nd hour and 24th hour), urea/creatinine (preoperative, postoperative 24th hour) values of the patients will be recorded. .
62301083|NCT04662593|EXPERIMENTAL|Intervention Group|"The intervention group participates in a 17-week whole health program including:~1. Weekly, small group online meetings with a health coach;~2. Supportive social media including a private Facebook group and selective text messaging;~3. Exposure to community tree planting and stewardship (through live streaming or in-person if COVID-19 public health guidance at the time, permits."
62470693|NCT03439982|EXPERIMENTAL|FMT|Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema
62470694|NCT06560242|EXPERIMENTAL|Speech Sounds|Participants listen to speech sounds while the investigators measure electrical and hemodynamic changes in the brain.
62301084|NCT04662593|NO_INTERVENTION|Control Group|The control group participates only in questionnaire data collection at baseline, 4 months, and 6 months as well as daily weighing. Control group participants will be offered 3 web-based seminars (webinars) highlighting the effective lifestyle approaches demonstrated in the study and intervention group health education materials. The webinars and materials will be provided after the 6-month data collection which concludes the study.
62470695|NCT04006522|EXPERIMENTAL|Cohort 1|Patients with Localized RCC prior to nephrectomy.
62470696|NCT04006522|EXPERIMENTAL|Cohort 2|Patients with Unresectable/Metastatic RCC prior to treatment with an immune checkpoint inhibitor.
61916170|NCT05301374|EXPERIMENTAL|Cartoon Group|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended. Parent was with their children during the procedure in both groups.
61916171|NCT05301374|NO_INTERVENTION|Control Group|No intervention was performed to reduce anxiety and pain for children in the control group. Parent was with their children during the procedure in both groups.
62470697|NCT00500591||Obese Women|
62470698|NCT02700750|OTHER|OCT exam|OCT exam No Arm No Intervention
62110766|NCT05515042|ACTIVE_COMPARATOR|SARS-CoV-2 rS (CovovaxTM)|"Description - SARS-CoV-2 rS (CovovaxTM): is a recombinant protein nanoparticle vaccine constructed from the SARS-CoV-2 full-length spike (S) glycoprotein co-formulated with Matrix-M1 adjuvant.~Dose: Each 0.5ml of SARS-CoV-2 rS consists of 5μg of a recombinant nanoparticle spike protein plus 50 μg of Matrix-M1 adjuvant.~Dosage Form: Suspension for injection COVOVAX™ is colourless to slightly yellow, clear to mildly opalescent, free to practically free from visible particles.~Packaging: The vaccine will be supplied as a multi-dose vial containing 10 doses per vial Administration: Vaccinations are given as a 0.5mL intramuscular injection into the deltoid muscle in the upper arm"
62301085|NCT06112925|EXPERIMENTAL|Medication Therapy Management|The patients attending hospitals assigned to interventional group received medication therapy management services in addition to usual care. The medication therapy management services was provided by the clinical pharmacists. The study participants and attending healthcare providers were blinded of participants' treatment group. The intervention was done at initial visit and repeated at 3rd and 6th month of the initial visit.
62301086|NCT06112925|NO_INTERVENTION|No Medication Therapy Management|The patients attending hospitals assigned to controlled group received usual care only. The usual care is patients' discussion with the attending physician, and nurse regarding their disease, medications, and subsequent appointments which may take approximately 5 minutes. Two consecutive follow-up visits were scheduled for 3rd month and 6th of initial visit for each patients in similar to interventional group.
62301087|NCT00838487|ACTIVE_COMPARATOR|condroflex and exercise|assent arm
62301088|NCT00838487|PLACEBO_COMPARATOR|sugar pill and exercise|sugar pill arm
62301089|NCT03128463||significantly effective group|visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
62301090|NCT03128463||effective group|visual improvement ≥5 letters and \<15 letters in EDTRS table after intravitreal injection of conbercept
62672247|NCT02211742|ACTIVE_COMPARATOR|dapagliflozin|10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)
62672248|NCT02211742|PLACEBO_COMPARATOR|placebo sugar pills|placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)
61916172|NCT03811275|EXPERIMENTAL|Sequence #1|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention A followed by nine 30 minute sessions (over 3 weeks) of intervention B.
61916173|NCT03811275|EXPERIMENTAL|Sequence #2|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention B followed by nine 30 minute sessions (over 3 weeks) of intervention B.
61916174|NCT00178880||Healthy volunteers|
61916175|NCT00178880||Depressed patients|
61916176|NCT05138471|EXPERIMENTAL|tDCS Active vs TENS Active|
61916177|NCT05138471|EXPERIMENTAL|tDCS Active vs TENS Placebo|
61916178|NCT05138471|PLACEBO_COMPARATOR|tDCS Placebo vs TENS Placebo|
61916179|NCT01067443|EXPERIMENTAL|Amb+SSG|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
62735970|NCT02684617|EXPERIMENTAL|rrMM Cohort|Participants with relapsed or refractory multiple myeloma (rrMM) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m\^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m\^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m\^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m\^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
62672249|NCT06328894|EXPERIMENTAL|comprehensive rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
61916180|NCT01067443|EXPERIMENTAL|Amb+Milt|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
61916181|NCT01067443|EXPERIMENTAL|Milt|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
61916182|NCT01067547|EXPERIMENTAL|iron sulfate|Oral iron sulfate 300mg tid
61916183|NCT01067547|ACTIVE_COMPARATOR|intravenous iron sulfate|intravenous iron sulfate 300 mg
61916184|NCT04501029|EXPERIMENTAL|Gimatecan group|In Phase Ib study, patients will receive gimatecan at different dose level (0.4mg/m2, 0.6mg/m2,0.8mg/m2, oral, every 4 weeks) until progressive disease (PD).In Phase II study, patients will receive gimatecan at recommended phase II dose level.
62301091|NCT03128463||invalid group|visual improvement \<5 letters and visual reduction\<5 letters in EDTRS table after intravitreal injection of Combercept
62301092|NCT03128463||deterioration group|visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
62301093|NCT04543500|EXPERIMENTAL|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
62735971|NCT02684617|EXPERIMENTAL|rrDLBCL Cohort|Participants with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m\^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m\^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m\^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m\^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
62735972|NCT02974140|EXPERIMENTAL|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
62735973|NCT02974140|ACTIVE_COMPARATOR|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
62735974|NCT05723692|EXPERIMENTAL|ALTB-268|Subcutaneous dose in healthy volunteers
62735975|NCT05723692|PLACEBO_COMPARATOR|Placebo|Subcutaneous dose in healthy volunteers
62735976|NCT02634775|EXPERIMENTAL|CKD - no dialysis|Change in treatment strategy: Start on dialysis, transplantation
62735977|NCT02634775|EXPERIMENTAL|Patients on PD|Change in treatment strategy: Change of PD prescription, start on HD, transplantation
62735978|NCT02634775|EXPERIMENTAL|Patients on HD|Change in treatment strategy: Change of HD prescription, transplantation
62735979|NCT00268944|EXPERIMENTAL|1|
62735980|NCT05969639|EXPERIMENTAL|Intervention|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
62735981|NCT05969639|NO_INTERVENTION|Control|
62735982|NCT05382741|EXPERIMENTAL|DURVALUMAB + REGORAFENIB|"Durvalumab 1500 mg (120-minute IV infusion) every 28 days, Regorafenib 90 mg/die orally once daily for 21 days in a 28-day cycle.~Treatment will be administred up to 1 year."
62735983|NCT05382741|NO_INTERVENTION|CONTROL ARM|"Observation (follow-up).~Crossover to the experimental arm is allowed in case of relapse."
62735984|NCT00068315|EXPERIMENTAL|Treatment (bortezomib, fludarabine, rituximab)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62735985|NCT04042597|EXPERIMENTAL|Arm A: anlotinib arm|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
62735986|NCT04042597|ACTIVE_COMPARATOR|Arm B: imatinib arm|Imatinib was given at dose of 400 mg twice daily continuously
62735987|NCT01812213|EXPERIMENTAL|[18F]NAV4694|Intravenous \[18F\]NAV4694 (8.1 mCi) administered once every 18 months
62735988|NCT01550406|ACTIVE_COMPARATOR|Tachocomb|Tachocomb will be applicated on the cut surface of distal pancreatectomy
62735989|NCT01550406|ACTIVE_COMPARATOR|PGA|PGA will be applicated on the cut surface of distal pancreatectomy
62735990|NCT01550406|NO_INTERVENTION|Control|No mesh will be applicated on the cut surface of distal pancreatectomy
62735991|NCT06091124|EXPERIMENTAL|Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin Followed by Radical Cystectomy|"The study population will include male and female patients over the age of 18 with invasive (cT1-cT4) neuroendocrine carcinoma of the bladder, with or without urothelial component (neuroendocrine component should be \>50%). Patients with resectable N1-3 disease (judged by investigators) are eligible. Patients should be fit to undergo cystectomy with normal function of vital organs.~Participants will be intravenously treated with adebrelimab (1200mg, day 1) in combination with etoposide (0.1g, day 1-3) and cisplatin (35mg/m2, day 1-2) every 21 days for a maximum of 4 cycles. Radical cystectomy, lymph node dissection and urine diversion will be performed after the completion of therapy."
62735992|NCT06380725|PLACEBO_COMPARATOR|control group|Subjects sit comfortably in a recliner and receive FDA-approved transcranial alternating current stimulation (sham stimulation) with trained operators following standardized instructions. Subjects are advised to relax, drink water, and even sleep, and not communicate with the operator as much as possible.
62735993|NCT06380725|EXPERIMENTAL|treatment group|Subjects sit comfortably in a recliner and receive FDA-approved transcranial alternating current stimulation (real stimulation) with trained operators following standardized instructions. Subjects are advised to relax, drink water, and even sleep, and not communicate with the operator as much as possible.
62735994|NCT06353633|ACTIVE_COMPARATOR|exclusion diet along with formula|
62735995|NCT06353633|ACTIVE_COMPARATOR|A group that receives only exclusion diet|
62735996|NCT00662831|EXPERIMENTAL|Active|Active study treatment
62735997|NCT00662831|PLACEBO_COMPARATOR|Placebo|Placebo
62735998|NCT00563082||1|SLE participants positive for both APA and CHD
62735999|NCT00563082||2|Normal participants with a high titer of APA
62736000|NCT05101733||Alternaria allergy sufferers|50 people suffering from an allergy to Alternaria. These participants receive a questionnaire, a Skin-Prick-Test, a blood draw and nasal provocation with collection of nasal secretion
62736001|NCT05101733||Non-allergic participants|Non allergic participants (20) receive a questionnaire, a blood draw and collection of nasal secretion
62736002|NCT04528550|EXPERIMENTAL|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection in acute phase. Each included patient will receive a single dose of 100 million autologous bone marrow-derived mononuclear cells.
62110767|NCT05515042|ACTIVE_COMPARATOR|BNT162b2 (Pfizer) (Comirnaty)|"Description: is a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2. Vaccinations 30mcg (0.3mL) will be given as an intramuscular injection into the deltoid muscle in the upper arm.~Dose: Each dose (0.3 mL) contains 30 micrograms of COVID-19 mRNA Vaccine. Dosage Form: White to off-white frozen suspension for Intramuscular (IM) injection Packaging: This vaccine will be supplied as a multidose vial and must be diluted with 0.9% Sodium Chloride USP before use. Each vial (0.45 mL) contains 6 doses of 0.3 mL after dilution.~Administration: Comirnaty should be administered intramuscularly after dilution. Each dose must contain 0.3 mL of vaccine. The preferred site is the deltoid muscle of the upper arm"
62110768|NCT02321306|EXPERIMENTAL|LUM001|LUM001 administered orally once each day.
62110769|NCT00786448||Group 1|
62110770|NCT04800224|PLACEBO_COMPARATOR|Placebo|Patients in the Placebo group will receive an identical number of capsules containing 900 mg / day of placebo (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
62110771|NCT04800224|ACTIVE_COMPARATOR|Propolis|Participants in the Propolis group will receive propolis EPP-AF at a dose of 900 mg / day (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
62672250|NCT06328894|ACTIVE_COMPARATOR|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
62672251|NCT05760677|ACTIVE_COMPARATOR|Pioglitazone group|All participants were treated with lifestyle intervention+ metformin(0.5g bid po)+ orlistat (0.12g bid po) (obese patients)+ pioglitazone (15mg qd po)
62672252|NCT05760677|EXPERIMENTAL|Chiglitazar group|All participants were treated with lifestyle intervention+ metformin(0.5g bid po)+ orlistat (0.12g bid po) (obese patients)+ Chiglitazar (32mg QD)
62110772|NCT05461547|OTHER|Usual Care|
62110773|NCT05461547|EXPERIMENTAL|Lung Ultrasound|
62110774|NCT00578617|ACTIVE_COMPARATOR|Pharmacologic Therapy|Pharmacologic Therapy Rate and/or Sinus Rhythm Control: Patients without other heart disease will receive beta or calcium channel blockers as first line rate control therapy. Patients with underlying coronary artery disease will receive beta-blockers, patients with limited ventricular hypertrophy not warranting exclusion would receive either beta- or calcium channel blockers, while patients with heart failure would be expected to receive carvedilol or metoprolol. Patients randomized to drug therapy may be started on a membrane active drug, in an approach consistent with the recommended Guidelines for Management of Subjects with AF. Each patient will be placed on an anti-arrhythmic drug for an appropriate period and the patient cardioverted to sinus rhythm if necessary. Patients will then be followed for a period of up to 3 months, during which dosage adjustment can be made or the drug replaced with a different anti-arrhythmic drug.
62110775|NCT00578617|ACTIVE_COMPARATOR|Ablation Therapy|Left Atrial Catheter Ablation: The specific choice of ablation catheters will be left to the investigator from the following list: Lifewire TC XLS, Therapy Dual/Thermocouple, NAVI-STAR/NAVI-STAR DS, Celsius Braided Tip, NAVI-STAR Thermo-Cool, Freezor/FreezorMax, Stinger, Blazer II RF/RPM/SteeroCath /XP, Chilli Cooled.
62110776|NCT05421988|EXPERIMENTAL|Individual EFT Therapy|Personal EFT instruction and practice group
62110777|NCT05421988|EXPERIMENTAL|Group EFT Therapy|Group EFT instruction and practice group
62110778|NCT05421988|NO_INTERVENTION|Wait List|Wait list control group
62110779|NCT02575235|EXPERIMENTAL|1.5mg Cetylpyridinium Chloride (CPC)|1.5mg CPC will be taken daily for four weeks.
62110780|NCT02575235|EXPERIMENTAL|4.5mg Cetylpyridinium Chloride (CPC)|4.5mg CPC will be taken daily for four weeks.
62110781|NCT02575235|PLACEBO_COMPARATOR|Control|Placebo will be taken daily for four weeks
62672253|NCT03331588|ACTIVE_COMPARATOR|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted thoracic surgery, no use of rib-spreader.
62672254|NCT03331588|ACTIVE_COMPARATOR|Intercostal uniportal VATS|Standard Intercostal single-port video assisted thoracic surgery, no use of rib-spreader.
62672255|NCT03410537|EXPERIMENTAL|Taurine Supplementation|Taurine 2.4mg/d for 12 weeks
62672256|NCT03410537|PLACEBO_COMPARATOR|Placebo|Placebo 2.4mg/d for 12 weeks
62672257|NCT04723368|EXPERIMENTAL|Automated flying Drone carrying an Automated external defibrillator (AED)|Five drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating time benefit of drone delivery of AEDs in suspected OHCA.
62672258|NCT01507727|EXPERIMENTAL|Drug: Tolvaptan|
62672259|NCT01507727|PLACEBO_COMPARATOR|Drug: Placebo|
62672260|NCT02216851|EXPERIMENTAL|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
62672261|NCT02216851|NO_INTERVENTION|No-treatment control|No-treatment control group do not receive any treatment during the main study period
62672262|NCT05202496|EXPERIMENTAL|Experimental: oral vitamin D supplementation during orthodontic treatment|"The biological methods include using various chemicals like parathyroid hormone, thyroid hormone, prostaglandins, corticosteroids, relaxin and vitamin D.~Due to its important role in bone remodeling, vitamin D is hypothesized to play an important role in accelerating orthodontic tooth movement.~experimental group subjects with serum vitamin D levels in the range of 30-40 ng/ml are enrolled"
62672263|NCT05202496|ACTIVE_COMPARATOR|control : Orthodontic treatment with no intervention|control group subjects with serum vitamin D levels in the range of (30-40 ng/ml) are enrolled
62672264|NCT01712464|OTHER|Cross over Oxytocin and Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
62672265|NCT01712464|OTHER|Cross over Placebo and Oxytocin|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
62672266|NCT04922762|EXPERIMENTAL|Moderate Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, normal volume exercise training
62672267|NCT04922762|EXPERIMENTAL|High Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of high intensity, normal volume exercise training
62672268|NCT04922762|EXPERIMENTAL|Moderate Intensity, High Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, high volume exercise training
62672269|NCT03864549|EXPERIMENTAL|probiotic femina II|research group will receive the probiotic formula Femina II (2 capsules/day) until delivery.
62672270|NCT03864549|PLACEBO_COMPARATOR|Placebo|control group will receive a placebo (2 capsules/day) until delivery.
62672271|NCT00992394|OTHER|Arm 1|Subjects randomized to arm 1 stop their etanercept treatment on entry into the study and may be retreated by etanercept 50 mg once weekly after medical review and agreement between the subject and the investigator
62672272|NCT00992394|OTHER|Arm 2|Subjects randomized to arm 2 in which subjects continue on treatment with etanercept at 25 mg once weekly, but with the option to have their drug treatment increased to 50 mg once weekly after medical review and agreement between the subject and the investigator
62672273|NCT00472641|EXPERIMENTAL|Ziprasidone/Geodon|Ziprasidone/Geodon up to 320 mg per day
62672274|NCT02696577|ACTIVE_COMPARATOR|Low dose aspirin|Received aspirin 81mg once daily for 6 weeks
62672275|NCT02696577|ACTIVE_COMPARATOR|Low dose aspirin plus omega 3 group|Received aspirin 81mg and omega 3 once daily for 6 weeks.
62672276|NCT02443129|EXPERIMENTAL|control group|"18-99 year old male + female~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
62672277|NCT02443129|EXPERIMENTAL|mydramide only|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
62672278|NCT02443129|EXPERIMENTAL|mydramide and ephrine 10%|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
62672279|NCT02443129|EXPERIMENTAL|All patients presenting with RD|"Patients with retinal detachment~Intervention:~RD surgery DRI-1 Swept source OCT, Atlantis, Topcon"
62672280|NCT02443129|EXPERIMENTAL|Impact of previous grid treatment|"Patients after grid laser~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
62672281|NCT02443129|EXPERIMENTAL|Effect of glaucoma medications|"Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment~Intervention:~If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon"
62672282|NCT02443129|EXPERIMENTAL|Effect of arteritic/non-arteritic AION|"About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).~Longitudinal arm with newly diagnosed patients for 2 years follow-up~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
62672283|NCT02443129|EXPERIMENTAL|NVAMD poorly responsive to Rx|"Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
62672284|NCT02443129|EXPERIMENTAL|Retrospective analysis|"All patients pictured with DRI-OCT~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
62672285|NCT01778985|EXPERIMENTAL|Premarin|Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
62672286|NCT01778985|PLACEBO_COMPARATOR|Placebo|Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
61916185|NCT02372214|NO_INTERVENTION|Group 1|30 patients/5 vascular surgery residents The residents of the last year of vascular surgery will perform the procedure under supervision of a senior surgeon
61916186|NCT02372214|EXPERIMENTAL|Group 2|30 patients/5 vascular surgery residents Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
61916187|NCT02073266|ACTIVE_COMPARATOR|SF6 vitrectomy|The first group included 31 patients who had undergone MH surgery using SF6 gas and who were advised to stay in face-down position for 7 days postoperatively (SF6 group). Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
61916188|NCT02073266|ACTIVE_COMPARATOR|C3F8 vitrectomy|The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
61916189|NCT04037878|EXPERIMENTAL|TAP block group|Patients in this arm will be given Transversus Abdominal Plane(TAP) block after the induction of anesthesia. They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
61916190|NCT04037878|EXPERIMENTAL|Local infiltration|Patients in this arm will be given local and intraperitoneal infiltration of local anesthetic before closure.They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
62301094|NCT04543500|ACTIVE_COMPARATOR|Sham Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left postcentral gyrus. Participants in this arm will receive sham feedback while attempting to modulate their neural activity during an emotional cognitive control task.
61916191|NCT04037878|OTHER|Control group|These patients will be given post operative analgesia in the form of patient controlled intravenous analgesia(PCIA) using tramadol. Neither local infiltration nor TAP block will be administered
61916192|NCT02380690|EXPERIMENTAL|Peer Coach Assignment|Veteran participants will be assigned to a peer coach, who delivered self-management instruction one-on-one over a 6-month period.
62301095|NCT03707561||Group 1 - IPAH and heritable PAH|Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)
62301096|NCT03707561||Group 2- PAH associated with CHD|Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)
62301097|NCT03707561||Group 3- PAH associated with CTD|Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)
62301098|NCT03707561||Group 4- portoPH|Portopulmonary hypertension
62301099|NCT03707561||group 5- PAH-HIV|Pulmonary arterial hypertension associated with HIV infection
62301100|NCT03707561||group 6- operable CTEPH|Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
62301101|NCT03707561||group 7- non-operable CTEPH|Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
62301102|NCT05846633|EXPERIMENTAL|VR treadmill|"The intervention of this study will be C-Mill virtual reality treadmill (Motekforce Link, Amsterdam/Culemborg, The Netherlands).~Sixteen participants will be included in the c-mill treadmill program for 50 minutes per session / two sessions per week, over six successive weeks (a total of 12 sessions).~Every participant will be trained for (50 minutes) as follows: warming up by walking on the treadmill with a comfortable walking speed upon individual's capability for 5 minutes. The speed should be determined for each one. Then participants continue training on the treadmill for 20 minutes. Visually guided stepping exercises will be applied. Participants should get a (5-min break) and then resume training on the treadmill for 25 minutes. Obstacle avoidance exercises and Walking area practice will be applied."
62672287|NCT03548792|OTHER|RSA radiostereometric analysis|30 patients in each Group Persona or Nexgen will receive tantalus beads to achieve RSA analysis comparing micromevements in radiographs.
62672288|NCT03548792|OTHER|Clinical comparison|Clinical comarison using different patient reported outcome measures and objective measures (ActivePAL, walking speed)
62672289|NCT04015687|EXPERIMENTAL|AG-881 (Group 1)|On Day 1 of Period 1, Group 1 participants will receive a single 50-milligram (mg) oral dose of lamotrigine at Hour 0. In Period 2, they will receive 50-mg oral doses of AG-881 once daily (QD) for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14.
62672290|NCT04015687|EXPERIMENTAL|AG-881 (Group 2)|Following a safety and tolerability review of the data from at least 7 days of AG-881 dosing of Group 1 participants in Period 2, Group 2 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1, and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
62672291|NCT04015687|EXPERIMENTAL|AG-881 (Group 3)|Following a safety and tolerability review of the data from Group 1 participants, and from at least 7 days of AG-881 dosing of Group 2 participants in Period 2, Group 3 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1; and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15) with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
62672292|NCT03614988|ACTIVE_COMPARATOR|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
62672293|NCT03614988|EXPERIMENTAL|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
62672294|NCT04100187|EXPERIMENTAL|experimental:3|Leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
62672295|NCT00665886|EXPERIMENTAL|1|"Experimental Group (Closed System):~Nexiva® Safety IV Catheter from BD (Becton Dickinson). The catheter has wings, a passive safety feature, an integrated Y extension tubing integrated and needle-less access using a split septum BD QSyte®. In order to completely close the Y connector a second Q-Syte® is added from the moment of catheter insertion"
62672296|NCT00665886|ACTIVE_COMPARATOR|2|"Control group (Open System):~A 'mounted' system consisting of the Vasocan® Safety catheter of B. Braun Medical, SA. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3, from BD) is added. This comes as one unit (tap and tubing are integrated). When not in use the three-way tap ('stopcock') remains closed using a red cork Luer/Luer-Lock Sollner®, made by Amebil, SA."
62672297|NCT06493942|ACTIVE_COMPARATOR|Control group (A)|Fluoride releasing filled resin based pit and fissure sealant using UltraSeal XT™ plus by Ultradent
62110782|NCT04743128|NO_INTERVENTION|Control group|The control group received written recommendations to exercise three times per week, for a period of 12 weeks but they did not attend the training sessions.
62110783|NCT04743128|EXPERIMENTAL|Exercise group|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
62110784|NCT02612571||Wind instrument players|A wind instrument is defined as any instrument that contains a resonator, in which a column of air is set into resonation by the player blowing into a mouthpiece at one end of the resonator.
62110785|NCT02612571||Non-wind instrument players|A non-wind instrument is defined as any instrument that does not contain a resonator.
62110786|NCT06629727|EXPERIMENTAL|VR group|Use of VR glasses during the procedure
62301103|NCT05846633|ACTIVE_COMPARATOR|Conventional group|Like group I, each participant will be trained on a conventional treadmill for (50 minutes) as follows: warming up by walking on the treadmill belt with a comfortable walking speed suitable for each participant for 5 minutes. The speed should be determined Then participants continue training on the treadmill for 20 minutes; no VR will be used or applied. Participants should get a 5-min break and then resume training on the treadmill again for 25 minutes.
62672298|NCT06493942|EXPERIMENTAL|Interventional group (B)|Bioactive pit and fissure sealant using BioCoat® by Premier®
62672299|NCT01309880|ACTIVE_COMPARATOR|Air Optix Aqua|Ciba Vision daily wear contact lens
62672300|NCT01309880|EXPERIMENTAL|Test Lens|Investigational silicone hydrogel contact lens
62672301|NCT05664815|EXPERIMENTAL|Application of human amniotic membrane (hAM)|After conventional/standard treatment, hAM will be applied in a single layer against the bone defect before closure.
62672302|NCT05664815|ACTIVE_COMPARATOR|Conventional/standard treatment|Conventional/standard surgery.
61916193|NCT02380690|NO_INTERVENTION|Control|"Veteran participants will attend a 2-hour class in pain basics and pain self-management. Veterans will aso be given a set of pamphlets related to pain self-management."
62672303|NCT05038514|EXPERIMENTAL|music therapy|Music therapy intervention, bluetooth headphones will be applied in the intensive care unit and will be disinfected after the application. The intervention consists of a 30-minute, single-session, nature-based music concert. the music concert is calibrated by the audiologist (60 decibels). During nature-based music listening, patients will be asked to close their eyes, rest and follow the sound flow.
62672304|NCT05038514|NO_INTERVENTION|control|The control group will be given the prone position and music therapy will not be applied.
61916194|NCT01312623|EXPERIMENTAL|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
61916195|NCT01312623|NO_INTERVENTION|Control|No ischemic preconditioning
62110787|NCT06629727|ACTIVE_COMPARATOR|Control Group|Standart care group
62110788|NCT01949909|EXPERIMENTAL|Alhydrogel CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
62110789|NCT01949909|EXPERIMENTAL|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
62110790|NCT01949909|PLACEBO_COMPARATOR|Control rabies vaccine Verorub TM TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
62110791|NCT01949909|EXPERIMENTAL|Alhydrogel TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
62672305|NCT03665168||Patients in the palliative stage|Adult patients in various settings will be included (General Practioners practices, home care facilities, general and academic hospitals, hospices) and with any underlying life-limiting disease.
62672306|NCT03640377|ACTIVE_COMPARATOR|Praziquantel 40 mg/kg dose only baseline treatment|150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
62672307|NCT03640377|ACTIVE_COMPARATOR|Praziquantel 80 mg/kg dose only baseline treatment|150 children will receive 80 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
62672308|NCT03640377|ACTIVE_COMPARATOR|Praziquantel 40 mg/kg dose at baseline and 6 months|150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.
62672309|NCT03640377|ACTIVE_COMPARATOR|Praziquantel 80 mg/kg dose at baseline and 6 months|150 children will receive 80 mg/kg Praziquantel at baseline and again six months later.
62110792|NCT01949909|EXPERIMENTAL|GLA-SE TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
62110793|NCT01949909|EXPERIMENTAL|GLA-SE TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
62110794|NCT01949909|EXPERIMENTAL|GLA-SE TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
62110795|NCT05422716|EXPERIMENTAL|Surgically implanted epidural stimulation for spasticity|"The epidural stimulation (ES) group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity. In each subsequent 6 months we will enroll cohorts of (n=5) voluntary research participants to allow for the final cohort to complete their 6 month follow up with a remaining 3 months for final data analyses and dissemination for the grant period.~Spinal cord epidural stimulation is administered by a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord."
62110796|NCT05422716|EXPERIMENTAL|Surgically implanted Intrathecal baclofen pump, the standard of care control group|"Individuals randomized to the baclofen pump (BP) group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments).~The Baclofen pump will be surgically implanted by a member of the clinical SCI medical team."
62110797|NCT04769609||Concentrated growth factor (CGF) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CGF
62110798|NCT04769609||Collagen membrane (CM) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CM
62672310|NCT03545841|EXPERIMENTAL|HIT training|6 weeks of high-intensity interval training (HIT)
62672311|NCT03545841|EXPERIMENTAL|Moderate intensity training|6 weeks of moderate-intensity continuous training (MICT)
62672312|NCT02205359|EXPERIMENTAL|aCRT ON|The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise
62110799|NCT02621593|EXPERIMENTAL|Treatment of dry eye secondary to MGD|Intervention: Treatment of dry eye symptoms secondary to MGD with the M22-IPL system
62672313|NCT02205359|ACTIVE_COMPARATOR|aCRT OFF|Standard CRT
62672314|NCT02255695|NO_INTERVENTION|Control group|Control group
62110800|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
62672315|NCT02255695|EXPERIMENTAL|School-based exercise program|School-based exercise program
62672316|NCT05832814|EXPERIMENTAL|Integrated training|Rhythm-guided walking exercise coordinated with singing training as training activity in pulmonary rehabilitation: 12 weeks, three times a week for 1 hour, leading to a total of 36 sessions
62672317|NCT05832814|EXPERIMENTAL|Rhythm-guided exercise training|Rhythm-guided walking exercise as training activity in pulmonary rehabilitation: 12 weeks, three times a week for 1/2 hour, leading to a total of 36 sessions
62672318|NCT05832814|NO_INTERVENTION|Usual care|The usual care is the comparator in the trial, consisting of standard medical treatment and educational sessions including physical training, smoking cessation and vaccination. And after the trial, the patients in this group will also be offered standard pulmonary rehabilitation according to the national guideline.
62672319|NCT01089543|EXPERIMENTAL|Rabeprazole 10 mg|
62672320|NCT01089543|EXPERIMENTAL|Rabeprazole 20 mg|
62672321|NCT01089543|EXPERIMENTAL|Rabeprazole 40 mg|
62110801|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
62110802|NCT02684565|ACTIVE_COMPARATOR|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
62110803|NCT02684565|ACTIVE_COMPARATOR|BCAA Low Protein Supplement|Subjects will be randomly assigned to take low BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
62110804|NCT04243213|EXPERIMENTAL|Vibration Group|Intervention group I receives a unit of 10 minutes daily on the vibrating plate with an upright posture of 15 ° postoperatively from the 2nd to the 7th day
62110805|NCT04243213|EXPERIMENTAL|15° Tilt Group|Intervention group II is positioned postoperatively from day 2 to day 7 for 15 minutes at 15 degrees, but without vibration
62110806|NCT04243213|PLACEBO_COMPARATOR|Control Group|The control group only receives standard physiotherapy and no further treatments
62110807|NCT04715373|EXPERIMENTAL|DR-LISA|"Experimental:~Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs. A trained physician will perform LISA using Hobart method. Infants requiring FiO2 \>0.8 on CPAP 8 cm H2O to maintain SpO2 88-94% by 20 minutes of life will be intubated prior to transport. After admission to the NICU, CPAP will be titrated 5-8 cm H20."
62110808|NCT04715373|ACTIVE_COMPARATOR|NICU-LISA|Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs and transported to NICU on CPAP. After admission to NICU, CPAP will be escalated every 30 minutes up to a maximum level of 7 cm H2O at which point infant would qualify for LISA if the FiO2 requirement is ≥0.3. LISA will be performed using Hobart method. Infants requiring FiO2 \>0.8 to maintain SpO2 88-94% by 20 minutes of life will be intubated in the DR.
62110809|NCT01805414|EXPERIMENTAL|Intervention Breakfast|40-45g carbs (300-350 kcal)
62110810|NCT01805414|ACTIVE_COMPARATOR|Control Breakfast|These patients received the usual hospital breakfast which contained 40-45 g carbs.
62110811|NCT00591838|EXPERIMENTAL|Phase I Dose Level A: SBRT 9Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
62110812|NCT00591838|EXPERIMENTAL|Phase I Dose Level B: SBRT 10Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
62110813|NCT00591838|EXPERIMENTAL|Phase I Dose Level C: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
62110814|NCT00591838|EXPERIMENTAL|Phase I Dose Level D: SBRT 12Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
62301104|NCT03916068|EXPERIMENTAL|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO2) - 100% oxygen at 2.4 atmospheres ATA for 90 minutes, Monday-Friday for 30 sessions (six weeks)
62301105|NCT03916068|ACTIVE_COMPARATOR|Trental and Vitamin E|Trental (pentoxifylline), 400 milligrams three times a day in combination with Vitamin E, 400 international units orally twice daily for six months
62110815|NCT00591838|EXPERIMENTAL|Phase II: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
62110816|NCT02161653|NO_INTERVENTION|Prednisone|Prednisone 40 mg daily by mouth during 30 days.
62110817|NCT02161653|NO_INTERVENTION|Pentoxifylline|Pentoxifylline 400 mg thrice in day by mouth during 30 days
62110818|NCT02161653|EXPERIMENTAL|Prednisone plus metadoxine|Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
62110819|NCT02161653|EXPERIMENTAL|Pentoxifylline plus metadoxine|Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
62110820|NCT04658615|OTHER|group with rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
62110821|NCT04658615|OTHER|group without rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
62672322|NCT01089543|PLACEBO_COMPARATOR|Placebo|
62672323|NCT00038415|EXPERIMENTAL|Vaccine|
62736003|NCT04528550|PLACEBO_COMPARATOR|Control|Included patients will receive the same amount of saline through lumbar injection.
62736004|NCT04626284|EXPERIMENTAL|Donors After Circulatory Determined death|Recipients receiving an organ from donors after circulatory determined death
62736005|NCT00681395|EXPERIMENTAL|1|ABT-143 capsules 20/135 mg
62736006|NCT00681395|ACTIVE_COMPARATOR|2|ABT-335 135mg and rosuvastatin 20mg
62736007|NCT00681395|EXPERIMENTAL|3|ABT-143 capsules 5/45mg
62736008|NCT00681395|ACTIVE_COMPARATOR|4|ABT-335 45mg and rosuvastatin 5mg
62736009|NCT05628285|EXPERIMENTAL|Sentio 1 sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
62736010|NCT01890590|EXPERIMENTAL|Cyberknife|You will receive a series of Cyberknife Radiosurgery treatments, with the amount of radiation dosing adjusted for the size of your tumor. The treatment will ideally take place over the course of 3-4 days, but not more than 14 days overall. (3 or 4 fractions of radiation therapy delivered by cyberknife)
62736011|NCT02388464|EXPERIMENTAL|Low dose|
62736012|NCT02388464|EXPERIMENTAL|Intermediate dose|
62736013|NCT02388464|EXPERIMENTAL|High dose|
62672324|NCT05020912|EXPERIMENTAL|Photodynamic therapy (PDT)|"Each participant will serve as their own control, receiving PDT for one tumor, no PDT for the second tumor (untreated control).~Visit 1:~* Informed consent~* Blood draw~* Lesion(s) Photographed~* (ALA) applied for4 hours~* PpIX measured in lesions (PpIX buildup monitored every 30 minutes over a 4 h period)~* PDT with blue light~Visit 2 (scheduled for within one of the following time intervals: 1-3 days, 4-7 days, or 8-14 days post-PDT):~* Blood draw~* Lesion(s) Photographed~* Mohs surgery~* After procedure, excess frozen BCC tissue will be saved for analysis"
62672325|NCT06468917|ACTIVE_COMPARATOR|Drain removal on POD 1|in case of POD 1 DFA\< 300 U/L
62672326|NCT06468917|ACTIVE_COMPARATOR|Drain removal on POD 3|in case of POD 1 DFA\< 300 U/L
62672327|NCT03004092|EXPERIMENTAL|Total cohort|
62110822|NCT05380583|EXPERIMENTAL|CRAFT-EP + TAU|Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) with 8 weekly sessions of 60-90-minute coaching + Treatment as Usual (TAU).
62110823|NCT05380583|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual
62672328|NCT05915169|EXPERIMENTAL|topical haemoglobin spray care group|Patients with stage 2 pressure ulcers in the sacrum area will be treated with topical haemoglobin spray every 3 days for 2 months.
62672329|NCT05915169|NO_INTERVENTION|group of gas dressings with saline solution|Patients with stage 2 pressure ulcers in the sacrum area will receive routine saline gas dressing for 2 months.
62672330|NCT00069329|EXPERIMENTAL|NOMID treatment arm|All patients enrolled received daily doses of subcutaneous injection of increased doses of anakinra starting at 0.5mg/kg/day up to a maximum 10mg/kg/day to achieve disease remission.
62110824|NCT06548880|EXPERIMENTAL|Study group|Participants in the study group have received an online exercise training with a structured exercise program including range of motion, stretching, and, to train full body, low intensity aerobic exercises, once a week for 10 weeks, each lasting 60 minutes.
62110825|NCT06548880|NO_INTERVENTION|Control group|Participants in the control group were asked to maintain their daily physical activity routine.
62110826|NCT04249388||Decliners of Pulmonary Rehabilitation|No intervention, just observation
62110827|NCT04833491||Senile cataract|
62110828|NCT04833491||Traumatic cataract|
62110829|NCT04833491||Congenital cataract|
62672331|NCT01521364|OTHER|0mg, 250mg, and 500mg claritromycin|"Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.~After this, there is a wash-out period of one week during which no claritromycine is administered."
62672332|NCT00400205|EXPERIMENTAL|Recipients of Docetaxel, Cisplatin, 5-Fluorouracil|Participants with squamous cell carcinoma receiving chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil.
62672333|NCT03593447|EXPERIMENTAL|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
62672334|NCT03593447|EXPERIMENTAL|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
62672335|NCT03593447|EXPERIMENTAL|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
62672336|NCT03593447|EXPERIMENTAL|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
61916196|NCT03575481||Post stroke patients|
61916197|NCT01426789|EXPERIMENTAL|Secukinumab|10 mg/kg intravenous (I.V.)
61916198|NCT01426789|PLACEBO_COMPARATOR|Placebo|Placebo I.V.
62110830|NCT04833491||Lens dislocation group|
62110831|NCT04833491||Complicated cataract|
62110832|NCT04927143|ACTIVE_COMPARATOR|Control|Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.
62110833|NCT04927143|EXPERIMENTAL|Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The Low group will receive incentives worth $2-$8."
62110834|NCT04927143|EXPERIMENTAL|Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The High group will receive incentives worth $4-$16."
62110835|NCT04927143|EXPERIMENTAL|De-Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The Low group will receive incentives worth $6-12."
62672337|NCT03593447|EXPERIMENTAL|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
62736014|NCT02388464|EXPERIMENTAL|Placebo|
62736015|NCT04314024|EXPERIMENTAL|Evobrutinib: Treatment Sequence 1: A-B-C|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
62736016|NCT04314024|EXPERIMENTAL|Evobrutinib: Treatment Sequence 2: A-C-B|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
61916199|NCT02898584|OTHER|BP Track|The study participants will be asked to monitor their blood pressure twice daily at home for twelve weeks, and sync the data to the mobile intervention so that a clinical pharmacist can review and incorporate the data into ongoing hypertension management.
61916200|NCT01522885|ACTIVE_COMPARATOR|KatGuide|Chest tube insertion is performed by using the KatGuide
61916201|NCT01522885|ACTIVE_COMPARATOR|Conventional group|Chest tubes are inserted by using conventional method (forceps) for large bore chest tube insertion.
62110836|NCT04927143|EXPERIMENTAL|De-Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The High group will receive incentives worth $10-$20."
62110837|NCT04927143|EXPERIMENTAL|Constant High|"In the Constant groups, incentive amounts will remain unchanged across time. The High group will receive incentives worth $16."
62110838|NCT04927143|EXPERIMENTAL|Constant Low|"In the Constant groups, incentive amounts will remain unchanged across time. The Low group will receive incentives worth $8 every test."
62672338|NCT03593447|EXPERIMENTAL|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
61916202|NCT06119022|EXPERIMENTAL|CT-MPI guided without myocardial ischemia|There was no evidence of myocardial ischemia in patients with coronary heart disease by CT-MPI
61916203|NCT06119022|EXPERIMENTAL|CT-MPI guided with myocardial ischemia|There was positive evidence of myocardial ischemia in patients with coronary heart disease by CT-MPI
61916204|NCT06119022|ACTIVE_COMPARATOR|SPECT-MPI guided without myocardial ischemia|There was no evidence of myocardial ischemia in patients with coronary heart disease by SPECT-MPI
61916205|NCT06119022|ACTIVE_COMPARATOR|SPECT-MPI guided with myocardial ischemia|There was positive evidence of myocardial ischemia in patients with coronary heart disease by SPECT-MPI
61916206|NCT04690062|EXPERIMENTAL|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
61916207|NCT05880823||Prospective|All patients for whom the decision has been made to have the Synergy Disc system implanted and give informed consent will be enrolled in this study, following country-specific requirements.
62110839|NCT01094041|EXPERIMENTAL|Gluten free diet|
62110840|NCT01094041|EXPERIMENTAL|Gluten rich diet|
61916208|NCT05880823||Retrospective|Patients who have previously received the Synergy Disc system in the last ten years are eligible for inclusion in the retrospective data collection; a waiver of consent, or an informed consent, for the retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations.
61916209|NCT02850133|EXPERIMENTAL|Spinal cord injury|Cardio-pulmonary exercise testing and aerobic exercise training
61916210|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
61916211|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
61916212|NCT04691947|EXPERIMENTAL|Low dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 3 µg/0.5 ml Vaccine Intervention Description:Two applications on Days 0 and 21
62110841|NCT06553222|EXPERIMENTAL|Interventional|Participants receives Injectable bone putty - Minimally invasive debridement periodontal flap plus putty bone graft in three osseous wall defect
62110842|NCT06553222|PLACEBO_COMPARATOR|Control group|- Participants receive No graft (No drug) Minimally invasive debridement periodontal flap
62672339|NCT03065738|EXPERIMENTAL|osteoarthritis knee ,severe varus deformity|reduction osteotomy in total knee replacement
62672340|NCT05302232|EXPERIMENTAL|Lidocaine plus steroid|
62672341|NCT05302232|PLACEBO_COMPARATOR|Steroid only|
62672342|NCT05326100|ACTIVE_COMPARATOR|Conventional Therapy (CPT) Group|Each session will include vestibular exercises, customized to address the participant's symptoms of vestibular dysfunction and functional ability.
62672343|NCT05326100|ACTIVE_COMPARATOR|CAREN Group|The CAREN group will undergo vestibular physical therapy that will include virtual environment (VE) applications on the CAREN.
62672344|NCT05326100|EXPERIMENTAL|Augmented Reality (AR) Group|The AR group will undergo vestibular physical therapy that will include VE applications on the AR HMD.
62672345|NCT04102111|EXPERIMENTAL|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily for 12 weeks.
61916213|NCT04691947|EXPERIMENTAL|Medium dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 6 µg/0.5 ml Vaccine Intervention Description: Two applications on Days 0 and 21
62110843|NCT02294643|ACTIVE_COMPARATOR|aspirin, clopidogrel & sarpogrelate|the triple anti-platelet treatment group will receive aspirin 100mg, clopidogrel 75mg and sarpogrelate (Anplag®, Yuhan Corporation, Seoul, South Korea) 100mg twice daily
62110844|NCT02294643|PLACEBO_COMPARATOR|aspirin, clopidogrel & placebo|the dual anti-platelet group will receive aspirin 100mg and clopidogrel 75mg daily plus placebo twice daily
62470699|NCT04362566|ACTIVE_COMPARATOR|Bupivicaine|Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
62470700|NCT04362566|PLACEBO_COMPARATOR|Placebo saline|Saline in the same volume as described above for bupivicaine
62672346|NCT04102111|PLACEBO_COMPARATOR|Placebo|Participants will receive oral tablets of matching placebo twice daily for 12 weeks.
62110845|NCT04697576|EXPERIMENTAL|Cohort I (resectable Stage I-III melanoma)|Patients receive an influenza vaccine IM on day 0 and intratumorally on days 2 and 14 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on day 28.
62110846|NCT04697576|EXPERIMENTAL|Cohort II (unresectable Stage IV)|Patients receive an influenza vaccine IM on day 0 and intratumorally on days 2, 14, 28, 42, 56, 70, 84, and 98 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care (single- or dual-agent) ipilimumab, nivolumab, relatlimab, or pembrolizumab.
62110847|NCT03923725|EXPERIMENTAL|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
62110848|NCT03923725|ACTIVE_COMPARATOR|artemether-lumefantrine+placebo (AL+PBO)|ACTs
62672347|NCT06272682|EXPERIMENTAL|Branch A: Local corticosteroid infiltration under ultrasound|One dose. 1 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6mg/2ml
62672348|NCT06272682|EXPERIMENTAL|Branch B: treated with intramuscular corticosteroid injection|One dose. 2 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6m/2ml.
62672349|NCT02979054|EXPERIMENTAL|T4020|1 drop every other day during 5 days
62672350|NCT02979054|PLACEBO_COMPARATOR|Saline solution|1 drop every other day during 5 days
61916214|NCT04691947|PLACEBO_COMPARATOR|Placebo|Placebo Vaccine, containing 0.9 % saline Intervention Description: Two applications on Days 0 and 21
62110849|NCT03923725|EXPERIMENTAL|Artesunate-mefloquine+Piperaquine (AS-MQ+PPQ)|Triple ACTs
62110850|NCT03923725|ACTIVE_COMPARATOR|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs
62110851|NCT06235606|ACTIVE_COMPARATOR|To receive supraclavicular BPB using liposomal bupivacaine with standard bupivacaine|10ml of 0.5% plain bupivacaine and 10ml of 1.33% liposomal bupivacaine will be injected.
62470701|NCT05886101|ACTIVE_COMPARATOR|Intervention|"Intervention factory with health education program~1. Health education will be provided on menstrual hygiene management and improve health literacy.~2. Behavior change communications program"
62470702|NCT05886101|NO_INTERVENTION|Control|No health education will be provided. However, health information material will be distributed among the participants
62672351|NCT04332185|EXPERIMENTAL|Vestibulart socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
62672352|NCT00801268|ACTIVE_COMPARATOR|emodin|
62672353|NCT00801268|EXPERIMENTAL|Triptolide Woldifii|TW60mg/d
62672354|NCT05417256|ACTIVE_COMPARATOR|Tappa Blocker Group|After orotracheal intubation, Tappa endobronchial blocker will be inserted using a broncoscope by an experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.
62672355|NCT05417256|ACTIVE_COMPARATOR|Arndt Blocker Group|After orotracheal intubation, Arndt endobronchial blocker will be inserted using a broncoscope by the experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.
62672356|NCT00003456|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62672357|NCT02070991|EXPERIMENTAL|Macitentan|oral tablet, 10 mg once daily.
62672358|NCT02070991|PLACEBO_COMPARATOR|Placebo|Matching placebo, once daily.
62672359|NCT02421965|EXPERIMENTAL|FOCUS (Smartphone Application)|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
62672360|NCT02421965|ACTIVE_COMPARATOR|WRAP (Wellness Recovery Action Planning)|WRAP is a clinic-based intervention designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It is conducted in group sessions that are delivered by trained facilitators with lived experience, using lecture, group discussion, and exercises.
62672361|NCT01795755|EXPERIMENTAL|Treat as usual + Horse assisted therapy ( HAT)|Treatment as usual means mentalization based inpatient treatment. Horse assisted therapy(HAT) is a structured program of 12 X 90 minute sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists.
62672362|NCT01795755|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual means mentalization based inpatient treatment.
62672363|NCT01864096|EXPERIMENTAL|Metformin|Metformin 850 mg, twice daily for 36 months
62672364|NCT01864096|PLACEBO_COMPARATOR|Placebo|Placebo tablets, 2teice daily for 36 months
62672365|NCT04091308|ACTIVE_COMPARATOR|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
62672366|NCT04091308|EXPERIMENTAL|Usual Care with Protein Supl.|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
62672367|NCT04091308|EXPERIMENTAL|Individualized Physical Exercise Training with Protein Supl.|This group is also called EXER group, and will receive individually tailored physical exercise programs, based on their strength and weaknesses from the baseline testing.
62672368|NCT00747071|EXPERIMENTAL|1|Hospitalized patients with Clostridium difficile associated diarrhea.
62672369|NCT00747071|EXPERIMENTAL|2|Close hospital contacts of each index case
62672370|NCT03276481||Multiple Myeloma|Participants with multiple myeloma undergoing autologous hematopoietic cell transplantation (HCT) after a high dose melphalan conditioning regimen
62672371|NCT06488001|PLACEBO_COMPARATOR|Placebo|This arm receives the placebo drug. This medication is taken the night before, 2 hours before surgery, and the night after surgery.
62470703|NCT03727620|EXPERIMENTAL|doxycycline group|Drug Longamycine 200 mg the first day , then 100 mg per day for 14 days
62470704|NCT03727620|ACTIVE_COMPARATOR|amoxicillin plus metronidazole group|Drug Dispamox 500 mg, 3 times a day for 7 days Flagyl 250 mg, 3 times a day for 7 days
62672372|NCT06488001|ACTIVE_COMPARATOR|Active|This arm receives the pantoprazole 40mg tablet. This medication is taken the night before, 2 hours before surgery, and the night after surgery.
62672373|NCT02051283||patients with HCC eligible for RFA|patients with HCC eligible for RFA
62672374|NCT06295146|EXPERIMENTAL|Active intervention (intervention A)|Active intervention (intervention A) which will include training through peer coaching
62672375|NCT06295146|ACTIVE_COMPARATOR|Waitlist control group|Waitlist control group that will receive the same intervention A but at 6 months
62672376|NCT06295146|ACTIVE_COMPARATOR|Self-study intervention|Self-study intervention with review of educational materials
62672377|NCT04303403|EXPERIMENTAL|Dose Escalation and Expansion|"Dose Escalation:~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb (2mg starting dose) daily and oral ruxolitinib (5mg starting dose) twice daily at assigned doses.~Dose Expansion:~Combination oral trametinb daily and oral ruxolitinib twice daily at the maximum tolerated dose (MTD) established at the Dose Escalation phase.~A cycle of therapy will comprise of 28 days of combination trametinib and ruxolitinib treatment."
62672378|NCT02483273||Brain dead patients|Brain dead patients certified by cerebral angiography.
62672379|NCT02483273||Healthy volunteers|Any person with no known cerebral pathology.
62672380|NCT06328621||Observational (survey, biospecimen, medical record, CT)|"Participants complete a survey over 40-45 minutes at baseline. Participants' medical records are also reviewed. Participants who have lung cancer but have not undergone treatment and participants not diagnosed with lung cancer (i.e., unaffected), undergo collection of blood samples at a scheduled clinical or research blood draw. Participants not diagnosed with lung cancer (i.e. unaffected), undergo a low-dose CT scan over 20 minutes."
62470705|NCT02371343|ACTIVE_COMPARATOR|Fish-Oil|"The pregnants with gestational diabetes given fish oil:~(Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, German) During third trimester of pregnancy, Once in a day"
62470706|NCT02371343|PLACEBO_COMPARATOR|Sunflower oil|"The pregnants with gestational diabetes given sunflower oil:~Sunflower oil capsules will be prepared in the pharmacy as the same size and colour with fish oil capsules During third trimester of pregnancy, Once in a day"
62672381|NCT02603627||With lung cancer|Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
62470707|NCT02296008|OTHER|surgery for Hirschsprung's disease|children after surgery for Hirschsprung's disease will undergo 3D high resolution anorectal manometry procedure
62672382|NCT02603627||Without lung cancer|Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
62672383|NCT02458300|PLACEBO_COMPARATOR|Control Arm|Nebulized hypertonic saline. Aspiration of secretions
62672384|NCT02458300|ACTIVE_COMPARATOR|Intervention Arm.|Nebulization of hypertonic saline. Application of Prolonged slow expiration technique (PSE) expiratory volume. Patient coughing Provocation (TP) Inspiratory maneuver to rhinopharyngeal cleaning DRR Aspiration of secretions
62672385|NCT03169972||Previously treated patients (PTPs)|PTPs: patients who had 4 or more days to other Factor VIII (FVIII) products
62672386|NCT03169972||Previously untreated patients (PUPs)|PUPs: patients who had 3 or less previous exposure days to other products
61916215|NCT04970953||Patients with intermediate risk for HFpEF at rest|Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.
62672387|NCT06499220|EXPERIMENTAL|ECAP Recording|
62672388|NCT04739436|OTHER|Bilateral hearing aid fitting group|
62672389|NCT04739436|ACTIVE_COMPARATOR|Unilateral hearing aid fitting group|
62672390|NCT00265642|EXPERIMENTAL|group verum|Drug: Irbesartan
62672391|NCT00265642|PLACEBO_COMPARATOR|group placebo|
62672392|NCT00425854|EXPERIMENTAL|BIBW 2992|high dose once daily
61916216|NCT06254820|EXPERIMENTAL|Part A Dose Arm 1|Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
62672393|NCT00754286|EXPERIMENTAL|Aromatherapy|Participants will be given aromatherapy wand at the onset of their chemotherapy treatment.
62110852|NCT06235606|ACTIVE_COMPARATOR|To receive supraclavicular BPB using dexmedetomidine with standard bupivacaine|19.5ml of 0.5% plain bupivacaine and 0.5ml (50mcg) of dexmedetomidine will be injected.
62110853|NCT02499471|OTHER|Before levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure 6.8 ± 2.8 weeks after thyroidectomy, when plasma free T4-levels were at the minimum, before daily levothyroxine therapy 137.75 ± 25.75 μg.
62470708|NCT02296008|OTHER|surgery for anorectal malformation|children after surgery for anorectal malformation will undergo 3D high resolution anorectal manometry procedure
62672394|NCT00754286|PLACEBO_COMPARATOR|Placebo|Participants will be given the placebo wand at the onset of their chemotherapy treatment. Placebo wands will look identical to the scented wands but will not contain a scent.
61916217|NCT06254820|EXPERIMENTAL|Part A Dose Arm 2|Dose Arm 2: High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)
61916218|NCT06254820|EXPERIMENTAL|Part B Dose Extension:|Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR
61916219|NCT06254820|EXPERIMENTAL|Part B Dose Arm 3|Addition of a 3rd dose, TBD depending on outcome of Part A
61916220|NCT06177574|EXPERIMENTAL|study group|HIV-1 infected adults, ART-naive subjects, who start BIC/FTC/TAF using test and treat strategy recruited at infectious diseases units from various Spanish public healthcare centers.
61916221|NCT02000154|EXPERIMENTAL|SyB L-1101|
62110854|NCT02499471|OTHER|After levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure four to six months after the initial measurements, after daily levothyroxine therapy 137.75 μg (fT4 levels 23.1 ± 3.9 pmol/L, TSH 0.5 ± 0.6 mU/L)
62110855|NCT05860140|EXPERIMENTAL|Intervention group|will get access to a six-minute educational video five days after being discharged from the hospital. The video is focusing on protein and energy meals for older adults.
62110856|NCT05860140|NO_INTERVENTION|Control group|Control group, not given any intervention
62110857|NCT02637908|EXPERIMENTAL|Mindfulness training|The mindfulness training (experimental condition) will receive 6-weeks of mindfulness training for parents provided in a group setting.
62470709|NCT02296008|OTHER|surgery for other disorders|children after surgery for other disorders will undergo 3D high resolution anorectal manometry procedure
62470710|NCT01381848|EXPERIMENTAL|001|Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients \<8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients \>=8 weeks CA.
62672395|NCT03967314|ACTIVE_COMPARATOR|Group T = TLIP block group|After the induction of anesthesia and placement of the patient in a prone position, US-guided mTLIP block was performed via the lateral approach in group T. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
62672396|NCT03967314|ACTIVE_COMPARATOR|Group W = Wound infiltration group|After the induction of anesthesia and placement of the patient in a prone position wound infiltration was performed in group W. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
62672397|NCT03222609|EXPERIMENTAL|Navitoclax + ruxolitinib|Participants will be administered navitoclax once daily (QD) at various doses and a dose greater than or equal to 10 mg of ruxolitinib twice daily (BID).
62672398|NCT03222609|EXPERIMENTAL|Navitoclax|Participants will be administered various doses of navitoclax once daily (QD)
62672399|NCT00927186|EXPERIMENTAL|Teriparatide|
62672400|NCT00927186|ACTIVE_COMPARATOR|Zoledronic Acid|
62110858|NCT02637908|NO_INTERVENTION|Wait-list control|The wait-list control group will receive no intervention during the course of the study. The control group will be offered training following the completion of the study.
62672401|NCT06636591|EXPERIMENTAL|Triple-negative Breast Cancer with Non-immunomodulatory Subtype|
62672402|NCT06636591|EXPERIMENTAL|Hormone Receptor-positive (HR+) and HER2-negative (HER2-)|
62672403|NCT04999293||The Elderly Undergoing Percutaneous Coronary Intervention|Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
62672404|NCT03802929||Derivation Cohort|"Derivation Cohort of Diagnostic Prediction Model:~Participants will be recruited from the emergency department of five general urban hospitals in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; from March 1, 2019. The investigators will randomly assign 70% participants to a derivation cohort.~Derivation Cohort of Prognostic Prediction Model:~Patients with VTE from 5 thrombosis centers in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; between January 2014 and December 2018."
62672405|NCT03802929||Validation Cohort|"Validation Cohort of Diagnostic Prediction Model:~The investigators plan to randomly assign 30% participants for developing the diagnostic prediction model to a Validation cohort.~Validation Cohort of Prognostic Prediction Model:~New individuals selected by the same inclusion and exclusion criteria as the derivation cohort of prognostic prediction model from the same institutions as a validation cohort of prognostic prediction model will be recruited from January 2019."
62672406|NCT05039593|EXPERIMENTAL|first group|The patients in the first group will be given oral care with 0.12% chlorhexidine twice a day.
62672407|NCT05039593|EXPERIMENTAL|second group|The patients in the second group will be given oral care with 0.12% chlorhexidine 3 times a day.
62672408|NCT05039593|EXPERIMENTAL|third group|The patients in the third group will be given oral care with 0.12% chlorhexidine 4 times a day.
62672409|NCT02783937|ACTIVE_COMPARATOR|Filgrastim arm|Intervention: Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days
62672410|NCT02783937|PLACEBO_COMPARATOR|Placebo arm|Intervention: Injection of saline SC injection twice daily for five consecutive days.
61916222|NCT00079131|EXPERIMENTAL|Treatment (oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61916223|NCT06245278|EXPERIMENTAL|Clinical Healthy|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. TIM-3 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the clinically healthy group.
62110859|NCT03677999||Brain tumor patients with Glioma|"1. Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.~2. Passed the safety screen for MRI~3. Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI."
62110860|NCT02931656|EXPERIMENTAL|GDM aquatic exercise|GDM Diagnosis criteria accordance with to IADPSG / WHO
62110861|NCT02931656|ACTIVE_COMPARATOR|Control Group aquatic exercise|No change in blood glucose levels Group, investigated between 24-28 weeks of gestation.
62110862|NCT05309980||Without Shock Team|Before January 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device without involvment of a dedicated shock team
62110863|NCT05309980||With Shock Team|After April 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device following a collegial meeting of a shock team (cardiac surgeon, cardiologist, intensivist) using a common algorythm.
62110864|NCT01099891|EXPERIMENTAL|EGF|
62110865|NCT01099891|PLACEBO_COMPARATOR|Placebo|
62110866|NCT04135209||Healthy controls|Healthy individuals of age-matched
62110867|NCT04135209||Myopic patients|Patients with myopia who meet the inclusion criteria
62110868|NCT01890889|ACTIVE_COMPARATOR|Ad-Chol-Pre|A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
62110869|NCT01890889|ACTIVE_COMPARATOR|Half-dose Ad-Chol-Pre|A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
62110870|NCT01890889|PLACEBO_COMPARATOR|Capsule containing inactive component of defatted egg yolk|Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
62110871|NCT01122420|EXPERIMENTAL|Goal-Setting Tool|
62110872|NCT01122420|ACTIVE_COMPARATOR|Health Web Sites|
62110873|NCT02160106|EXPERIMENTAL|TEW-7197|Dose Escalation of TEW-7197: TEW 7191 tablets will be given once daily (QD) or twice daily (BID) for 5 days followed by 2 days without treatment in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
62110874|NCT06631222|ACTIVE_COMPARATOR|control group|the participants will receive a conventional standard physical therapy program (sub-occipital inhibitory pressure, Spinal manipulation, deep friction massage and corrective exercises)
62110875|NCT06631222|EXPERIMENTAL|experimental group|the participants will be treated with behavior change model in addition to a conventional standard physical therapy program for tension-type headache.
62672411|NCT01666080|OTHER|Reduced Intensity Conditioning|Includes patients receiving a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using reduced intensity conditioning (RIC). Patients will receive busulfan, fludarabine, total body irradiation and stem cell transplant. Keppra will be given for seizure prophylaxis.
62672412|NCT06569264|EXPERIMENTAL|Alveolar ridge preservation using vitamin C with dentin graft and i-PRF|Pure vitamin C will be added to the fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes and extraction socket will be filled with the corresponding graft material and dentin graft. Adding vitamin C to dentin graft and i-PRF might aid in reducing the dimensional changes and marginal bone loss, since it increases osteoblast proliferation and viability during socket preservation. Layers of osteoblast cell morphology can be seen at day 11 with the presence of 25mM of vitamin C. By adding vitamin C to i-PRF we can add the advantages of improving soft tissue quality as well.
62672413|NCT06569264|ACTIVE_COMPARATOR|Alveolar ridge preservation using autogenous demineralized denting graft combined with i-PRF.|Autogenous demineralized dentin graft combined with i-PRF and extraction socket will be filled with the corresponding graft material. This mix provided promising clinical outcomes and considered an ideal bioactive graft material for hard tissue regeneration. Autogenous particulate dentin and platelet rich fibrin mix assist healing and counteract pronounced resorption of alveolar process.It can be used as an excellent autogenous graft material to replace other autogenous graft materials, and has shown an ability to maintain the alveolar ridge dimensions because of its osteo-conductive properties. Moreover, dentin graft is used as a cost-effective grafting material during socket preservation.
62672414|NCT05803343|EXPERIMENTAL|Regulating Together-Canine (RT-Canine)|Participants in this Arm will receive the Regulating Together-Canine intervention.
62672415|NCT05803343|ACTIVE_COMPARATOR|Regulating Together-Standard (RT-Standard)|Participants in this Arm will receive the Regulating Together-Standard intervention.
62672416|NCT06579248|EXPERIMENTAL|Intraoral Hypothermia Device|An intraoral hypothermia device will be used to cool the oral cavity while subject's receive radiation therapy.
62736017|NCT04314024|EXPERIMENTAL|Evobrutinib: Treatment Sequence 3: B-A-C|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
62110876|NCT06188962|OTHER|3-8 week baseline wait period followed by CBT-informed school-based counselling|All participants undergo a baseline wait period but are randomized to different baseline lengths (3-8 weeks)
62110877|NCT02169154|EXPERIMENTAL|Diclofenac Sodium/Menthol Gel|1% diclofenac sodium + 3% menthol
62110878|NCT02169154|ACTIVE_COMPARATOR|Diclofenac Gel|1% diclofenac sodium + 0.09% menthol
62110879|NCT02169154|ACTIVE_COMPARATOR|Menthol Gel|3% menthol
62110880|NCT02169154|PLACEBO_COMPARATOR|Placebo Gel|0.09% menthol
62110881|NCT02169154|ACTIVE_COMPARATOR|Voltaren Gel|1% diclofenac sodium
62110882|NCT02169154|PLACEBO_COMPARATOR|Sodium lauryl sulfate|0.2% Sodium lauryl sulfate
62110883|NCT02169154|PLACEBO_COMPARATOR|Saline|0.9% saline
62110884|NCT01740570|EXPERIMENTAL|Cabazitaxel|"Cabazitaxel by vein on day 1 of each 3 week cycle.~Phase I: Up to 5 dose levels of cabazitaxel tested. Two (2) dose levels will be given over 60 minutes, and 3 will be given over 30 minutes. First group of participants receive the lowest dose level. Each new group receives a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.~Phase II: Cabazitaxel at the highest dose that was tolerated in Phase I."
62110885|NCT01141933|OTHER|Usual care|Subjects in this group receive the usual treatment only.
62110886|NCT01141933|EXPERIMENTAL|Individual intervention|Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.
62110887|NCT01141933|EXPERIMENTAL|Group intervention|Consisting in a 12 weekly sessions with two therapists. Number of subjects in each group is from 5 to 10. Each session lasts 2 hours.
62110888|NCT03896828|EXPERIMENTAL|Sedentary|Sedentary (SED): Participants will remain seated in the lab all-day (7.5 hr).
62110889|NCT03896828|EXPERIMENTAL|Walking Breaks|Walking breaks (WALK): Participants will perform 2-minute walking breaks at 3.1 mph on a treadmill every 30 minutes (7.5 hr).
62110890|NCT03896828|EXPERIMENTAL|Resistance-exercise breaks|"Resistance exercise breaks (RE): Participants will perform 15 squats (1-minute) every 30 minutes. To reduce the risk of injury, standardize squat-depth, and recruit similar muscle groups as walking, the squats performed will be a chair-stand with calf-raise (7.5 hr)."
62110891|NCT00288691|EXPERIMENTAL|Arm 1|
62110892|NCT00288691|EXPERIMENTAL|Arm 2|
62110893|NCT00288691|EXPERIMENTAL|Arm 3|
62110894|NCT00288691|PLACEBO_COMPARATOR|Arm 4|
62110895|NCT03313128||Historic intervention|Infants born into the historic intervention arm of sanitation trial (NCT02362932)
62110896|NCT03313128||Historic control|Infants born into the historic control arm of sanitation trial (NCT02362932)
62110897|NCT05019729|EXPERIMENTAL|Group 1: L9LS (1 mg/kg IV)|L9LS (1 mg/kg) administered by intravenous (IV) infusion (Day 0)
62110898|NCT05019729|EXPERIMENTAL|Group 2: L9LS (5 mg/kg IV)|L9LS (5 mg/kg) administered by IV infusion (Day 0)
62110899|NCT05019729|EXPERIMENTAL|Group 3: L9LS (5 mg/kg SC)|L9LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
62110900|NCT05019729|EXPERIMENTAL|Group 4: L9LS (20 mg/kg IV)|L9LS (20 mg/kg) administered by IV infusion (Day 0)
62110901|NCT05019729|OTHER|Group 5: CHMI Controls|Control participants who did not receive L9LS and were enrolled to complete the controlled human malaria infection (CHMI)
62110902|NCT05019729|EXPERIMENTAL|Group 6: L9LS (5 mg/kg IM)|L9LS (5 mg/kg) administered by intramuscular (IM) injection (Day 0)
62110903|NCT05593952|EXPERIMENTAL|Dual task|"The dual task will be self-regulated and will consist of subtracting 3 by 3 from 100, and performing the maximum number of repetitions possible.~exercise with dual task + usual treatment;"
62110904|NCT05593952|ACTIVE_COMPARATOR|Single task|exercise without dual task + usual treatment.
62110905|NCT01724788|EXPERIMENTAL|Furosemide PO - IV|Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)
62470711|NCT01648582|EXPERIMENTAL|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
62736018|NCT04314024|EXPERIMENTAL|Evobrutinib: Treatment Sequence 4: B-C-A|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
62736019|NCT04314024|EXPERIMENTAL|Evobrutinib: Treatment Sequence 5: C-A-B|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
62736020|NCT04314024|EXPERIMENTAL|Evobrutinib: Treatment Sequence 6: C-B-A|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
62736021|NCT06496425|EXPERIMENTAL|Exercise and music|The strength training (ST) program incorporates single-leg exercises for balance training and training with resistance bands and body weight. During the ST, participants will be asked to synchronize their concentric and eccentric muscle contractions in time with the tempo of BMS playlists at a specific music tempo. For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week. Participants will be trained to walk in synchrony with the beats. Participants will receive individualized music playlists to match individual walking cadence and music preference.
62736022|NCT06496425|NO_INTERVENTION|Exercise|The ST program incorporates single-leg exercises for balance training and training with resistance bands and body weight. For AE, participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week.
62736023|NCT04238091|ACTIVE_COMPARATOR|Antibiotics prior to FMT|Participants will take a standardized regimen of antibiotics for three days prior to fecal transplant.
62736024|NCT04238091|ACTIVE_COMPARATOR|No Antibiotics prior to FMT|Participants will not take antibiotics before the transplant.
62736025|NCT06404333|EXPERIMENTAL|Ivermectin (200 µg/kg)|
62736026|NCT06404333|EXPERIMENTAL|Ivermectin (400 µg/kg)|
62736027|NCT02561481|ACTIVE_COMPARATOR|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to \~ 15 µmol SF). The total dose per day will depend on participants' body weight:~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
62736028|NCT02561481|PLACEBO_COMPARATOR|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
62736029|NCT04186533|EXPERIMENTAL|Default Intervention|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
62736030|NCT04186533|ACTIVE_COMPARATOR|Nutrition Education|Participants in the nutrition education condition were instructed to read brief nutrition education handouts before online grocery shopping.
62736031|NCT05970536|EXPERIMENTAL|Apple vinegar group|After hemostasis of the exposed pulp is achieved, Apple vinegar will be used for dentin conditioning for 5 mins then 1-2 mm thickness of MTA placed on the exposed pulp chamber.
62736032|NCT05970536|ACTIVE_COMPARATOR|EDTA 17% group|After hemostasis of the exposed pulp is achieved, EDTA 17 % will be used for dentin conditioning then 1-2 mm thickness of MTA placed on the exposed pulp chamber.
62301106|NCT01731015|EXPERIMENTAL|Normal Subject|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
62301107|NCT01731015|EXPERIMENTAL|Subjects with Lung/or Airway Disease|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
62672417|NCT03934879|EXPERIMENTAL|Gateway Academy|For this study, Gateway Academy students will participate in the FitClub intervention. They will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
62110906|NCT01724788|EXPERIMENTAL|Furosemide IV - PO|IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)
62110907|NCT01928004|EXPERIMENTAL|implant placement|insertion of 2 interforaminal mandibular implants and conversion of the lower complete denture to an implant-overdenture
62301108|NCT03301857|EXPERIMENTAL|Denosumab|"Participants who are still being treated with denosumab when 20062004 completes: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).~For participants undergoing retreatment with denosumab: 120 mg administered SC on Days 1, 8, 15 and 28 then every 4 weeks subsequently."
62301109|NCT03301857|NO_INTERVENTION|Safety Follow-up|Participants who completed denosumab treatment and were in safety follow-up at the conclusion of 20062004 will have follow-up visits performed every 6 months via telephone or in-person clinic visit.
62301110|NCT00332904|ACTIVE_COMPARATOR|beta|patients with liver cirrhosis, treated with betablocker
62672418|NCT03934879|ACTIVE_COMPARATOR|Control School|Other comparable school will be added as a control school, in which regular school activities will be provided.
62672419|NCT02182700|EXPERIMENTAL|Combivent® aerosol|
62110908|NCT01928004|ACTIVE_COMPARATOR|denture reline|conventional reline of mandibular complete denture
62110909|NCT00891618|EXPERIMENTAL|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
62110910|NCT04481386|EXPERIMENTAL|Active arm|Participants with a diagnosis of retinal detachment or vitreous haemorrhage, who are scheduled for vitrectomy surgery with a vitreous substitute
62110911|NCT03979651|EXPERIMENTAL|Patients with NRAS Melanoma (Dose 1)|Patients with NRAS Melanoma receiving the 1st dose of the treatment (400 milligrams)
62672420|NCT02405065|EXPERIMENTAL|HM95573|single arm
62672421|NCT03120039||Healthy adults|Healthy adults without any limitations in upper extremity movement or function.
62672422|NCT01801527|EXPERIMENTAL|Telerehabilitation group|
62110912|NCT03979651|EXPERIMENTAL|Patients with NRAS Melanoma (Dose 2)|Patients with NRAS Melanoma receiving the 2nd dose of the treatment (800 milligrams)
62110913|NCT03979651|EXPERIMENTAL|Patients with NRAS Melanoma (Dose 3)|Patients with NRAS Melanoma receiving the 3rd dose of the treatment (600 milligrams twice a day)
62110914|NCT04419181|EXPERIMENTAL|Pathologic complete response (pCR)|Participants will receive four cycles of TCHP \[docetaxel (Taxotere®), carboplatin, trastuzumab (Herceptin®), pertuzumab\], followed by surgery. Participants who achieve pathologic complete response will receive infusions of trastuzumab every 3 weeks for a total of 12 cycles/infusions.
62110915|NCT04419181|EXPERIMENTAL|Residual Disease|Participants will receive four cycles of TCHP \[docetaxel (Taxotere®, carboplatin, trastuzumab (Herceptin®), pertuzumab\], followed by surgery. Participants who have residual disease may be offered two more cycles of TCHP in the adjuvant settings (optional) per treating oncologist's discretion and then will receive infusion of Trastuzumab Emtansine (TDM1) plus pertuzumab every three weeks for a total of 12 cycles/infusions.
62110916|NCT01992354|EXPERIMENTAL|Single Arm|Evaluation of PET MR device for image assessment and device performance
62110917|NCT03753152|EXPERIMENTAL|Investigational medical device|Neuramis® Deep Lidocaine
62110918|NCT03753152|ACTIVE_COMPARATOR|Comparator device|YVOIRE® Volume Plus
62301111|NCT00332904|ACTIVE_COMPARATOR|spiron|patients with liver cirrhosis, treated with aldosterone antagonist
62301112|NCT00332904|NO_INTERVENTION|control|patients with liver cirrhosis, no treatment
62301113|NCT04740957|NO_INTERVENTION|Observational cohort|"100 patients undergoing elective left colonic or rectal resection with a primary anastomosis will be recruited pre-operatively throughout the study period. This study will not affect or delay the intended treatment for study participants.~Patients will undergo serial endoscopic examination of the anastomosis post-operatively. Blood, urine, stool, and mucosal biopsies will be serially collected."
62672423|NCT01801527|NO_INTERVENTION|Control group|Information about usual care
62672424|NCT04568512|PLACEBO_COMPARATOR|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
62110919|NCT03692949|EXPERIMENTAL|LY3451838 Part A|Single ascending doses, administered intravenously (IV)
62110920|NCT03692949|EXPERIMENTAL|LY3451838 Part B|Single doses administered subcutaneously (SC)
61916224|NCT06245278|EXPERIMENTAL|Periodontitis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. TIM-3 analysis will be performed by ELISA in saliva and serum of individuals. TIM-3 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
61916225|NCT06245278|EXPERIMENTAL|Periodontitis with İnflammatory Bowel Disease|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. TIM-3 analysis will be performed by ELISA in saliva and serum of individuals. TIM-3 levels will be examined to evaluate before and after treatment in periodontitis with İnflammatory Bowel Disease. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
61916226|NCT06245278|EXPERIMENTAL|Healthy individuals with İnflammatory Bowel Disease|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. TIM-3 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the healthy individuals with İnflammatory Bowel Disease group.
61916227|NCT03303027|EXPERIMENTAL|6-0 fast absorbing gut suture|6-0 fast absorbing gut used to suture wound
61916228|NCT03303027|EXPERIMENTAL|5-0 fast absorbing gut suture|5-0 fast absorbing gut used to suture wound
61916229|NCT02726308|ACTIVE_COMPARATOR|Dexamethasone Group|I.V. Dexamethasone 5 mg just before induction plus intra-operative 10 ml/kg Ringer's lactate solution.
61916230|NCT02726308|ACTIVE_COMPARATOR|Dexamethasone and super-hydration Group|I.V. Dexamethasone 5 mg just before induction of anesthesia plus intraoperative 30 ml/kg Ringer's lactate solution
62110921|NCT03692949|PLACEBO_COMPARATOR|Placebo Part A|Matching single doses administered intravenously (IV)
62110922|NCT03692949|PLACEBO_COMPARATOR|Placebo Part B|Matching single doses administered subcutaneously (SC)
62110923|NCT01585038|ACTIVE_COMPARATOR|Efavirenz|Efavirenz 600mg given nightly without food for 30 days
62110924|NCT01585038|ACTIVE_COMPARATOR|Rilpivirine|Rilpivirine 25mg given daily with meals for 30 days
62110925|NCT01228513|ACTIVE_COMPARATOR|0.01% ointment|Lowest concentration
62110926|NCT01228513|ACTIVE_COMPARATOR|0.03% ointment|Middle concentration
62110927|NCT01228513|ACTIVE_COMPARATOR|0.1% ointment|Highest concentration
62110928|NCT01228513|PLACEBO_COMPARATOR|Placebo (vehicle without active)|No active ingredient
62110929|NCT02372019|EXPERIMENTAL|CBM With Active Fear Reactivation|
62110930|NCT02372019|ACTIVE_COMPARATOR|CBM With Inert Fear Reactivation|
62110931|NCT02372019|PLACEBO_COMPARATOR|Inert CBM With Inert Fear Reactivation|
62110932|NCT00339469|OTHER|2|Controlled feeding study.
62470712|NCT01648582|EXPERIMENTAL|0.75 mg Dulaglutide|0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
62736033|NCT05369377|EXPERIMENTAL|Zanubrutinib and eltrombopag|Zanubrutinib 80mg po qd 6 weeks and eltrombopag 50 mg qd for up to 6 weeks.
62110933|NCT05670951|ACTIVE_COMPARATOR|ELGN-2112|
62110934|NCT05670951|PLACEBO_COMPARATOR|Placebo|
61916231|NCT01789918|EXPERIMENTAL|Percutaneous renal denervation|PARADISE percutaneous renal denervation
62301114|NCT04740957|EXPERIMENTAL|Distal limb feeding cohort|"This interventional arm will demonstrate the safety of re-introducing ileostomy effluent into the downstream (distal) limb of an ileostomy. The preliminary data will enable exploration of the association between microbiome and post-operative function and enable adequate powering of future interventional studies.~A subgroup of 20 patients undergoing a resection with a covering ileostomy will be recruited to the intervention arm. Complete healing of the colorectal anastomosis will first be confirmed by water-soluble contrast enema 8 weeks post-operatively (this is standard practice). Patients will be taught how to inject the output from the proximal ileostomy limb into the distal limb (this connects to the colon and thus the colorectal anastomosis) daily until the ileostomy closure date."
62301115|NCT04227691|ACTIVE_COMPARATOR|Long-pulsed Nd YAG laser treatment|Ten patients will be randomized to receive Long-pulsed Nd:YAG in either left or right axilla. (The other axilla will serve as within-person control)
62672425|NCT04568512|ACTIVE_COMPARATOR|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
62672426|NCT05951842|ACTIVE_COMPARATOR|TIVA group|"In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion.~Other names: fresofol MCT 1% inj®; Fresenius kabi, Seoul, Korea, Ultian inj®; Hanlim, Seoul, Korea"
61916232|NCT06505408|PLACEBO_COMPARATOR|Placebo|
61916233|NCT06505408|EXPERIMENTAL|Multivitamin|
62110935|NCT05341518|EXPERIMENTAL|Subscapularis repair|Patients will undergo standard of care reverse total shoulder arthroplasty with subscapularis repair
62110936|NCT05341518|NO_INTERVENTION|No repair|Patients will undergo standard of care reverse total shoulder arthroplasty. The subscapularis will not be repaired.
62110937|NCT04358640||Employees of Nîmes University Hospital (France)|Employees of Nîmes University Hospital (France)
62110938|NCT05554692|EXPERIMENTAL|Enrolled Participants - Older adults with cochlear implants|Individuals who already use at least one cochlear implant.
62110939|NCT05554692|OTHER|Enrolled Participants - Adults with typical hearing|Control group to provide baseline or comparison data
62110940|NCT01064765||Heart failure|Outpatients with heart failure, age 75 or less, left ventricular ejection fraction 40% or less, english speaking with no known dementia
62110941|NCT05623384|EXPERIMENTAL|Stellate ganglion block combined with facial and glossopharyngeal nerve block group|
62110942|NCT05623384|EXPERIMENTAL|Stellate ganglion block group|
62110943|NCT05623384|OTHER|Control group|
62301116|NCT04227691|ACTIVE_COMPARATOR|IPL treatment|Ten patients will be randomized to receive IPL treatment in either left or right axilla. (The other axilla will serve as within-person control)
62301117|NCT01451333|EXPERIMENTAL|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
62672427|NCT05951842|EXPERIMENTAL|Balanced anesthesia group.|"Anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.~Other names: Sojourn®, Kyongbo, Seoul, Korea, Ultian inj®; Hanlim, Seoul, Korea,"
62110944|NCT04166682|PLACEBO_COMPARATOR|Control Group|Routine care
62110945|NCT04166682|EXPERIMENTAL|Interventional Group|Home-based cardiac rehabilitation
62110946|NCT03163953|EXPERIMENTAL|TPAG with long break|PA coaching based on TPAG and long break or break 15 minutes for every 2 hours (TPAG with LB)
62110947|NCT03163953|EXPERIMENTAL|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
62110948|NCT03163953|OTHER|Control|No intervention
62110949|NCT06628453|EXPERIMENTAL|Continuous Glucose Monitoring|Real-time continuous glucose monitoring
62110950|NCT06628453|NO_INTERVENTION|Self-Monitoring of Blood Glucose|Self-monitoring of blood glucose (standard of care)
62110951|NCT01514903|ACTIVE_COMPARATOR|viagra,anti-erectile dysfunction agent|
62110952|NCT01514903|EXPERIMENTAL|HIP0908|
62110953|NCT04316234|NO_INTERVENTION|A. Clean Air|Clean air - no vaping was done.
62110954|NCT04316234|EXPERIMENTAL|B. Passive vaping|E-cigarette users were present in an adjacent chamber during both exposures, but only in situation B they were vaping and the vape-polluted air was passed on to the exposure chamber.
62301118|NCT01451333|ACTIVE_COMPARATOR|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
62301119|NCT01160731|EXPERIMENTAL|Cisplatin, Etoposide & Panobinostat|
62301120|NCT06656546|EXPERIMENTAL|Tracheal Ultrasound|The success of endotracheal intubation (ETI) will be checked by tracheal ultrasonography. The primary outcome will be the placement of the endotracheal tube (ETT) in the trachea or esophagus. The secondary outcome will assess the duration of the ultrasound procedure. The time measurement will begin immediately after the placement of the ETT and will continue until a decision is made, via ultrasound, regarding whether the intubation is tracheal or esophageal.
62301121|NCT06656546|EXPERIMENTAL|Lung Ultrasound|The success of ETI will be checked by lung ultrasonography. The primary outcome will be the placement of the ETT in the trachea or esophagus. The secondary outcome will assess endobronchial intubation and the duration of the ultrasound procedure. The time measurement will begin immediately after the placement of the ETT and will continue until a decision is made, via ultrasound, regarding whether the intubation is tracheal or esophageal.
62301122|NCT06656546|EXPERIMENTAL|Diaphragm Ultrasound|The success of ETI will be checked by diaphragm ultrasonography. The primary outcome will be the placement of the ETT in the trachea or esophagus. The secondary outcome will assess endobronchial intubation and the duration of the ultrasound procedure. The time measurement will begin immediately after the placement of the ETT and will continue until a decision is made, via ultrasound, regarding whether the intubation is tracheal or esophageal.
61916234|NCT03696927|EXPERIMENTAL|User Focus Group Participants|Target user population will be human subjects with spinal cord injury at levels C3 to C5, and ASIA Impairment Scale (AIS) A, B, or C.
62672428|NCT01301001|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
61916235|NCT04042935|EXPERIMENTAL|Alpha Lipoic Acid (ALA) during chemoradiation|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation as standard of care will receive ALA before, during, and after treatment. The drug will have dose escalation in a 3+3 design. The first group of 3 patients will receive 600 mg twice a day. If there are no DLTs, the next 3 patients will receive the highest dose of 600 mg three times a day. If one or more patients develop a DLT at any of the dosing levels, the group will either be expanded or dropped to a lower dose level.
61916236|NCT05134532|EXPERIMENTAL|intervention|"Potential subjects will be screened to determine if they meet the eligibility criteria. The screening period is 21 days.~Subjects who meet all the eligibility criteria will be commenced regorafenib 160mg once daily for the first 3 weeks of each 4-week cycle."
61916237|NCT05249218|ACTIVE_COMPARATOR|Group starting intervention with vegetable protein|Phase A followed by Phases B, C, D, E.
62110955|NCT01847651|ACTIVE_COMPARATOR|LOLA|"Other Names:~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
61916238|NCT05249218|ACTIVE_COMPARATOR|Group starting intervention with animal protein|Phase A followed by Phases D, E, B, C.
61916239|NCT00824070|EXPERIMENTAL|Besifloxacin|Besifloxacin ophthalmic suspension
62110956|NCT01847651|PLACEBO_COMPARATOR|Placebo|
61916240|NCT00824070|ACTIVE_COMPARATOR|Moxifloxacin|Vigamox (moxifloxacin ophthalmic solution, 0.5%)
62110957|NCT00751491|ACTIVE_COMPARATOR|III|
62301123|NCT01854177|ACTIVE_COMPARATOR|Aprepitant|Aprepitant 125 mg
61916241|NCT00824070|ACTIVE_COMPARATOR|Gatifloxacin|Zymar (gatifloxacin ophthalmic solution, 0.3%)
62110958|NCT00751491|ACTIVE_COMPARATOR|A|
62110959|NCT00751491|PLACEBO_COMPARATOR|placebo|
62110960|NCT06412406|ACTIVE_COMPARATOR|Transversus abdominis plane (TAP) block|Group A will include 31 patients to receive TAP block with 20 ml volume on each side (0.25 % bupivacaine)
62110961|NCT06412406|ACTIVE_COMPARATOR|External Oblique intercostal (EOI) block|Group B will include 31 patients to receive EOI block with 20 ml volume on each side ( 0.25% bupivacaine)
62110962|NCT02377505|ACTIVE_COMPARATOR|On-Stimulation|"Disease condition is assessed with stimulation turned on"
62301124|NCT01854177|PLACEBO_COMPARATOR|Placebo|Inert capsule
62672429|NCT01301001|ACTIVE_COMPARATOR|Gabapentin|Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
62672430|NCT01498666|EXPERIMENTAL|L. reuteri protectis tablets|one tablet a day for 4 weeks
62672431|NCT01498666|PLACEBO_COMPARATOR|Placebo tablet|one tablet a day for 4 weeks
62301125|NCT05541315|EXPERIMENTAL|JNJ-88260237|Participants will be randomized into 6 cohorts to receive single oral dose of JNJ-88260237 on Day 1. The doses in each cohort (Cohorts 2 to 4 and 6) will be escalated based on the safety and pharmacokinetics (PK) data of the previous cohort. For Cohort 5, participants will receive a single-dose of JNJ-82260237 in fasted conditions and a single dose of JNJ-82260237 in fed conditions with dosing sequence determined by randomization.
61916242|NCT04498494||myocarditis|The diagnosis of acute myocarditis was confirmed by a recent history of gastrointestinal/upper respiratory tract infection and/or complaints of cardiac symptoms and increasing cardiac markers and/or presentation with a new abnormality of the 12-lead ECGcombined with at least one of the following: ⅰ) Active or borderline biopsy according to the Dallas criteria (13); ⅱ) positive infectious origin of ventricular dysfunction; ⅲ) delayed enhancement on cardiac MRI consistent with myocarditis; or ⅳ) serological tests, ECGs, ultrasonic cardiogram (UCG), coronary angiography and ventriculography to exclude acute myocardial infarction (AMI), stress cardiomyopathy, congenital heart disease, myocarditis secondary to sepsis, valve disease, hyperthyroidism, autoimmune disease and rheumatic fever
62301126|NCT05541315|PLACEBO_COMPARATOR|Placebo|Participants in Cohorts 1 to 4 and 6 will receive single oral dose of matching placebo on Day 1.
62110963|NCT02377505|PLACEBO_COMPARATOR|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
62301127|NCT03116113|EXPERIMENTAL|Part 1: BIIB112 Dose 1|Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
61916243|NCT04498494||fulminant myocarditis|In patients with acute myocarditis, a diagnosis of FM was determined upon identification of one or more of the following: Haemodynamic instability due to cardiogenic shock or arrhythmia; left ventricular dysfunction and low cardiac output syndrome requiring inotropes or mechanical circulatory support; mechanical ventilation; and/or cardiac arrest (CA)
61916244|NCT04411862|EXPERIMENTAL|Intervention Group|50 Participants with NAFLD that receive lifestyle modification by Clinical Pharmacist plus Phosphatidylcholine two soft capsules 3 times daily(2.1 g per day) for 6 month
61916245|NCT04411862|ACTIVE_COMPARATOR|Control Group|50 Participants with NAFLD that receive only lifestyle modification by Clinical Pharmacist
62110964|NCT04299360||standard BIV|the following group describes the effects of the left ventricular stimulation involving a dipole of two electrodes located inside a suitable vessel branch of the coronary sinus (CS). Standard BIV pacing modality can be achieved by either a quadripolar electrode implanted in the CS, of which only two poles will be used for cardiac resynchronization therapy, or by a bipolar electrode equipped with just two electrodes. The latter describes the old technology, requiring a change into typology of generator which has to display an IS-1 connection (due to different distal terminal of the electrode itself), instead of the new one IS-4 connection that has been developed for quadripolar electrodes.
62301128|NCT03116113|EXPERIMENTAL|Part 1: BIIB112 Dose 2|Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
62301129|NCT03116113|EXPERIMENTAL|Part 1: BIIB112 Dose 3|Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
62301130|NCT03116113|EXPERIMENTAL|Part 1: BIIB112 Dose 4|Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
62301131|NCT03116113|EXPERIMENTAL|Part 1: BIIB112 Dose 5|Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
62301132|NCT03116113|EXPERIMENTAL|Part 1: BIIB112 Dose 6|Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
62301133|NCT03116113|EXPERIMENTAL|Part 2: BIIB112 High Dose|Participants will receive a single high dose of BIIB112 by sub-retinal injection.
62301134|NCT03116113|EXPERIMENTAL|Part 2: BIIB112 Low Dose|Participants will receive a single low dose of BIIB112 by sub-retinal injection.
62301135|NCT03116113|NO_INTERVENTION|Part 2: Untreated Group|Participants will receive no intervention to allow for a controlled comparison.
62301136|NCT05430867|EXPERIMENTAL|Memantine monotherapy group|Memantine 20mg once-daily
62301137|NCT05430867|EXPERIMENTAL|GV-971 monotherapy group|GV-971 450mg twice a day
62301138|NCT05430867|EXPERIMENTAL|Memantine combined with GV-971 group|Memantine 20mg once-daily plus GV-971 450mg twice a day
62301139|NCT01439958|EXPERIMENTAL|L-CsA|Twice daily inhalation of L-CsA
62301140|NCT06314750||Well T-downstage|After receiving neoadjuvant therapy, the postoperative pathological stage of patients with primary cT4 rectal cancer was pT2 or less.
62301141|NCT06314750||Poor T-downstage|After receiving neoadjuvant therapy, the postoperative pathological stage of patients with primary cT4 rectal cancer was pT3 or above.
62301142|NCT06027801|EXPERIMENTAL|Iron fortification group|Participants assigned to this group will receive iron-fortified cookies daily for the whole study duration
62301143|NCT06027801|PLACEBO_COMPARATOR|Control group|Participants assigned to this group will receive the same cookies containing no iron daily for the whole study duration
62301144|NCT01021111|EXPERIMENTAL|Activity Training with Feedback|Subject is tested prior to training and retested with feedback training designed to modify the mechanics of landing during jumping and running activities
62301145|NCT05639764|EXPERIMENTAL|specific Immersive virtual reality (VRi) software|"Intervention group will perform active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~The intervention will last 3 sessions / week of 15 minutes, therefore carrying a total duration of two weeks of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study."
62301146|NCT05639764|ACTIVE_COMPARATOR|non specific Immersive virtual reality (VRi) software|"The control group will perform a VRi intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces. This intervention will attempt to assess the influence of the immersive context and the playful component compared to the intervention group. This treatment will last 3 sessions / week of 15 minutes, therefore taking a total duration of two weeks of treatment with a total of 6 sessions."
62301147|NCT02252861||Left Atrial Appendage Closure|Patients with atrial fibrillation and counter-indication to anticoagulant therapy referred for percutaneous Left Atrial Appendage Closure in routine care
62301148|NCT00730236|EXPERIMENTAL|AEGR-733|
62672432|NCT04716309|ACTIVE_COMPARATOR|VLP|Open reduction and volar locking plate
61916246|NCT03375229|ACTIVE_COMPARATOR|Group On|This group was composed of 15 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.
61916247|NCT03375229|ACTIVE_COMPARATOR|Group Off|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
62301149|NCT06498141||Diseased|patients with interstitial lung diseases fulfilling the inclusion criteria.
62301150|NCT06498141||Control|Healthy subjects
62301151|NCT02945592|EXPERIMENTAL|Intervention|"* adaptive, therapeutic cueing during reading tasks~* adaptive, therapeutic cueing during visuo spatial tasks"
62672433|NCT04716309|ACTIVE_COMPARATOR|CRPP|Closed reduction and percutaenous K-wires/pins
62672434|NCT03660982||FDRs of RBD cases|FDRs of RBD cases. The diagnosis of RBD is based on ICSD-II criteria, as confirmed by v-PSG and with the aid of REM sleep behaviour disorder questionnaire (RBDQ-HK). RBD cases which are secondary to narcolepsy, neurodegenerative diseases or other neurological diseases are excluded.
62672435|NCT03660982||FDRs of non-RBD controls|FDRs of non-RBD controls. Non-RBD control probands are free of narcolepsy, significant clinical RBD symptoms and other neurological diseases.
62672436|NCT02223130|EXPERIMENTAL|Intervention Group|Participants will attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys. After their baseline interview and before their first follow-up interview, participants attend the Intervention Group, which consist of 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who uses Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions, and behaviors in response to stressful/discrimination experiences.
62736034|NCT05369377|ACTIVE_COMPARATOR|Eltrombopag monotherapy|Eltrombopag is given as 50 mg qd for up to 6 weeks.
62736035|NCT02855021|OTHER|Parkinson disease|Patients with a Parkinson disease with clinical diagnosis made for at least 5 years
61916248|NCT03375229|PLACEBO_COMPARATOR|Placebo group|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be 1.5 cm medially from the trigger point. The intervention will be administered one time.
61916249|NCT00089674|EXPERIMENTAL|AMG 162|
61916250|NCT00089674|PLACEBO_COMPARATOR|Placebo|
61916251|NCT03021174|EXPERIMENTAL|Exercise|Exercise for Cancer Patients (EXCAP©®), developed by Dr. Karen Mustian, involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
61916252|NCT03021174|ACTIVE_COMPARATOR|Nutrition Education Control|Nutrition education (control) involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
61916253|NCT03148119|EXPERIMENTAL|Topical QRH Heptapeptide Administration|
61916254|NCT05565417|EXPERIMENTAL|IMT-009 Dose Escalation|Participants will receive an assigned dose level of IMT-009 monotherapy in dose escalation. Up to 64 Participants will be enrolled in the Phase 1 portion of the study.
61916255|NCT05565417|EXPERIMENTAL|IMT-009 Phase 1b|Participants will receive an assigned dose level of IMT-009 in combination with standard of care fruquintinib. Up to 12 Participants will be enrolled in the Phase 1b portion of the study
61916256|NCT05565417|EXPERIMENTAL|IMT-009 Phase 2a Cohort (s)|Each Cohort will evaluate IMT-009 monotherapy in up to 25 Participants
61916257|NCT01511666|EXPERIMENTAL|Hyperinvasive arm|Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
61916258|NCT01511666|ACTIVE_COMPARATOR|Standard arm|Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.
61916259|NCT01011478|PLACEBO_COMPARATOR|Group 1: placebo|Patients receive oral placebo once daily for 5 years.
61916260|NCT01011478|EXPERIMENTAL|Group 2: rosuvastatin|Patients receive oral rosuvastatin once daily for 5 years.
62110965|NCT04299360||MPP BIV|Such modality of left ventricular stimulation requires a dynamic use of the four electrodes located in the proximal segment of the electrocatheter that allows the recruitment of a vast area of the left ventricle. It is limited by the presence of scars on left ventricle surface, or phrenic nerve inadvertent stimulation.
62110966|NCT01960803|EXPERIMENTAL|IOERT arm|Intraoperative electron radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on a mobile self-shielded magnetron-driven X-band linear accelerator specifically developed for use in the operating room. This machine produces megavoltage electron beams of energy ranging between 4 and 12 MeV. The radiation is delivered from the device to the tumor bed through an attached applicator. A single dose of 21 Gy calculated to the 90% depth posterior to the tumor bed will be administered and will last approximately 2.5 minutes.
62110967|NCT04538820|ACTIVE_COMPARATOR|control|patients with BMI=18.5-24.9 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
62110968|NCT04538820|ACTIVE_COMPARATOR|4 mg|patients with BMI\>30 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
62110969|NCT04538820|ACTIVE_COMPARATOR|8 mg|patients with BMI\>30 kg/m2 will be received 8 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
62110970|NCT04302155|EXPERIMENTAL|Nintendo Wii|Balance-specific exer-games focusing on dynamic aspects of center of pressure (COP) on Wii fit system.
62110971|NCT04302155|EXPERIMENTAL|Traditional|Mini trampoline two balance exercises of 6 minutes on mini trampoline for a total duration of 3 min on each leg Inflatable discs 4 balance exercises of 12 minutes on BOSU ball 6 minutes on rounded side and 6 minutes on rigid side.
62110972|NCT00697814|EXPERIMENTAL|Clomiphene|Clomiphene 50 mg/day for 12 weeks
62301152|NCT02945592|NO_INTERVENTION|Control|- unspecific neglect treatment
62301153|NCT00937235|EXPERIMENTAL|Integrated Treatment|Prolonged Exposure + Varenicline + Medication Management Counseling
62736036|NCT00624624||1|"Eugonadal men with Lapband"
62672437|NCT02223130|NO_INTERVENTION|Waitlist Control|"Participants are not given the Intervention Group while they are enrolled in the study. Instead, they only attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys.~After they have completed the study, participants from the first two cohorts are offered the option of attending an intervention group that is identical in content to the intervention group being studied.The third cohort is offered the intervention group after they have completed the first follow-up but before they complete the final follow-up due to timing and budgetary restraints. No data is collected and no incentives are given during these intervention groups."
61916261|NCT04748588|NO_INTERVENTION|Standard of care|
61916262|NCT04748588|EXPERIMENTAL|Anti SARS-CoV-2 monoclonal antibody|Single IV administration of an anti-SARS-CoV-2 Monoclonal antibody
61916263|NCT01981785||Immune deficiencies/Immune disorders|Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
61916264|NCT01981785||No prior immune abnormalities|Patients with no prior immune abnormalities will be enrolled as the control group.
62110973|NCT03707678|EXPERIMENTAL|Subjects receiving GSK2245035|Eligible subjects will be administered 20 nanograms (ng) of GSK2245035 nasal spray solution using a metered Valois VP7 pump (1 spray=10 ng per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol metered dose inhaler (MDI) will be given for symptom relief from screening to the end of the study.
62110974|NCT03707678|PLACEBO_COMPARATOR|Subjects receiving placebo|Eligible subjects will be administered placebo nasal spray solution using a metered Valois VP7 pump (1 spray per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol MDI will be given for symptom relief from screening to the end of the study.
62110975|NCT03319589|EXPERIMENTAL|Supplement Arm|School children (age 6 to 6.5) will receive their supplement 5 days a week in the morning before school starts. They will either receive the supplement at school or at the community health center depending on the preference of the villagers after recruitment. Young children (age 24 to 30 months) will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers.
62110976|NCT03319589|NO_INTERVENTION|Control Arm|Children in the active intervention village will be compared with assessment-only controls in a separate village having comparable demographic characteristics
62110977|NCT01419730|ACTIVE_COMPARATOR|Vitamin D3 50,000 IU|Vitamin D3 50,000 IU: Patients will be assigned to receive a daily multivitamin, calcium supplement and 50,000 IU/week of vitamin D for a period of 24 weeks.
62110978|NCT01419730|ACTIVE_COMPARATOR|Vitamin D3 50,000 IU and Physical Activity|Vitamin D3 50,000 IU and Physical Activity: Patients will be assigned to receive a daily multivitamin, calcium supplement, 50,000 IU/week of vitamin D, and a progressive walking and resistance band exercise prescription for a period of 24 weeks.
62110979|NCT01419730|NO_INTERVENTION|Control|Patients will be assigned to receive a daily multivitamin, calcium supplement, vitamin D placebo, and standard care monitoring.
62301154|NCT00937235|ACTIVE_COMPARATOR|Varenicline|Varenicline + Medication Management Counseling
61916265|NCT01326559|EXPERIMENTAL|Experimental 1|Induction chemotherapy using Docetaxel, Cisplatin and 5-FU for week 1 to week 9 and followed by concurrent chemoradiation plus cetuximab from week 10 to week 16
61916266|NCT01832168|OTHER|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
61916267|NCT01832168|EXPERIMENTAL|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
62301155|NCT01175928|EXPERIMENTAL|Peristaltic Pulse PCD|Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
62301156|NCT01175928|SHAM_COMPARATOR|Sham Device|Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
62301157|NCT00319527||Observation|Living Kidney Donors with controls who have not donated a kidney or had certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
62672438|NCT04105660|EXPERIMENTAL|Intervention arm|EEG monitoring in addition to standard monitoring (clinical parameters and BIS index)
62672439|NCT04105660|ACTIVE_COMPARATOR|Control arm|Standard monitoring including clinical parameters and BIS index
62672440|NCT01429935|ACTIVE_COMPARATOR|Ginger powder|
62110980|NCT02327104|EXPERIMENTAL|Mindfulness Based Relapse Prevention|The Experimental Group (EG) will undergo eight sessions of MBRP after Brazilian Ministry of Health Protocol (BMHP) for Tobacco dependence treatment. MBRP Program: the first three sessions: focus on practicing mindful awareness and integrating mindfulness practices into daily life (body scan, sitting meditation, walking meditation); The next three sessions: emphasize acceptance of present experience and application of mindfulness practices to relapse prevention; The final two sessions: expand to include issues of self-care, support network, and lifestyle balance.
62672441|NCT01429935|ACTIVE_COMPARATOR|Ibuprofen|capsules of Ibuprofen 400 mg
62672442|NCT01429935|PLACEBO_COMPARATOR|placebo|capsules contain starch
62672443|NCT02285244|EXPERIMENTAL|Treatment (sotrastaurin acetate)|Patients receive sotrastaurin acetate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62672444|NCT03473158|ACTIVE_COMPARATOR|Mechanical|fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle
62672445|NCT03473158|ACTIVE_COMPARATOR|Chemical|fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle
62672446|NCT03391323|OTHER|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
62672447|NCT03391323|OTHER|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
62672448|NCT04122495|EXPERIMENTAL|Probiotic|Bifidobacterium lactis M8 at 10 log CFU/day for 4 weeks
62672449|NCT04122495|PLACEBO_COMPARATOR|Placebo|Intervention consists of daily administration of 1g of maltodextrin, administered daily for 4-weeks
62672450|NCT03286075|EXPERIMENTAL|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
62672451|NCT03286075|EXPERIMENTAL|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
62672452|NCT03286075|PLACEBO_COMPARATOR|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).~Subjects will receive a 30-minutes SHAM session of tDCS."
62672453|NCT05633446|EXPERIMENTAL|PepGNP-COVID19 (One vaccination)|One vaccination of PepGNP-COVID19 vaccine candidate administered on Day 0 (50 µl per dose)
62672454|NCT05633446|PLACEBO_COMPARATOR|Placebo (One vaccination)|One vaccination of WFI administered on Day 0 (50 µl per dose)
62672455|NCT05633446|EXPERIMENTAL|PepGNP-COVID19 (Two vaccinations)|Two vaccinations of PepGNP-COVID19 vaccine candidate administered on Day 0 and Day 21 (50 µl per dose)
62672456|NCT05633446|PLACEBO_COMPARATOR|Placebo (Two vaccinations)|Two vaccinations of WFI administered with on Day 0 \& Day 21 (50 µl per dose)
62672457|NCT04317846|ACTIVE_COMPARATOR|Intra-radial group|intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
62672458|NCT04317846|EXPERIMENTAL|Intravenous-post group|intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
62672459|NCT04317846|EXPERIMENTAL|Intravenous-pre group|intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
62672460|NCT06504732|EXPERIMENTAL|Cohort 1|10-20 subjects with HER2-positive advanced/metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction) without systemic treatment will be enrolled in combination with the CAPEOX regimen at a dose of 15 mg/kg of IAH0968 to assess the safety and tolerability of the combination therapy.
62736037|NCT00624624||2|"Hypogonadal men with Lapband"
62736038|NCT00624624||3|Eugonadal men with gastric bypass procedure
62736039|NCT00624624||4|Hypogonadal men with gastric bypass procedure
62736040|NCT04928885|EXPERIMENTAL|WW Treatment Group|Individuals will receive the 12-week Wits Workout Program. Individuals will take the baseline, 3 mos and 6 mos follow-up surveys. They will also take the Wits Workout satisfaction survey and participate in the 6 mos focus-groups.
62736041|NCT04928885|OTHER|WW Control Group|Individuals will be on a waitlist and will take the baseline, 3 mos and 6 mos. assessments. They will receive the Wits Workout workshop after the 6 month study period is completed.
62736042|NCT04345900|EXPERIMENTAL|20 mg/m^2 Plinabulin|75 mg/m\^2 Docetaxel + 20 mg/m\^2 Plinabulin
62736043|NCT04345900|EXPERIMENTAL|10 mg/m^2 Plinabulin|75 mg/m\^2 Docetaxel + 10 mg/m\^2 Plinabulin
62736044|NCT04345900|EXPERIMENTAL|5 mg/m^2 Plinabulin|75 mg/m\^2 Docetaxel + 5 mg/m\^2 Plinabulin
62736045|NCT04345900|ACTIVE_COMPARATOR|6 mg Pegfilgrastim|75 mg/m\^2 Docetaxel + 6 mg Pegfilgrastim
62736046|NCT00562822|ACTIVE_COMPARATOR|Arthroscopic Surgery|Arthroscopic surgery optimized with physical and medical therapy
62736047|NCT00562822|ACTIVE_COMPARATOR|Physical and medical therapy|treatment with physical and medical therapy alone
62736048|NCT04423679||CIN2+|Cases of cervical precancer will include women diagnosed with cervical intraepithelial grades 2 or 3 (CIN2/3) or adenocarcinoma in situ (AIS). If any women are diagnosed with cancer in the study, they will be included in this group.
62736049|NCT04423679||< CIN2|Non-cases will include those with \<CIN2 on colposcopy/biopsy and women who did not have an indication for colposcopy (because of a negative screening test).
62736050|NCT02388165|ACTIVE_COMPARATOR|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
62736051|NCT02388165|PLACEBO_COMPARATOR|Placebo|Diluent (sterile water) for Placebo
62736052|NCT04072952|EXPERIMENTAL|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
62736053|NCT04072952|EXPERIMENTAL|ARV-471 and palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days.
62110981|NCT02327104|OTHER|Brazilian Ministry of Health Protocol|The Control Group (CG) is undergo the protocol of the Brazilian Ministry of Health Protocol (BMHP): clinical evaluation, four sessions of cognitive-behavioral approach and Nicotine Replacement Therapy and/or Bupropion as needed, as the Experimental Group. And during the eight sessions of MBRP (EG) both groups (EG and CG) are subjected to eight maintenance sessions of BMHP.
62110982|NCT05703204|EXPERIMENTAL|QLF32101|single arm with QLF32101 treatment
62110983|NCT02341924|EXPERIMENTAL|Portfolio of functional foods|"A portfolio of functional foods provided as packaged shelf-stable food products (Step One Treatment) which will include foods such as oatmeal, pancakes, cranberry bars, chocolate bars, smoothies, and a sprinkle offering which can be added to almost any food to enhance its nutritional impact.~All products are interchangeable in terms of their nutrients of interest and contain a minimum of 5 g of fibre, 1800 mg of omega-3 fatty acids, 1000 mg of phytosterols and 1800 µmol antioxidants per serving. Calorie counts range from 110-190 kcal per serving."
62110984|NCT02341924|PLACEBO_COMPARATOR|Control foods|Control products will be like-items drawn from the general grocery marketplace. Test and control products will be packaged and coded identically.
62110985|NCT05547191|EXPERIMENTAL|Investigational device|ChloraSolv
62110986|NCT04095403|EXPERIMENTAL|Tarp assisted cooling|Whole body cooling in a small amount of 20'C water.
62110987|NCT04095403|SHAM_COMPARATOR|Passive cooling|Supine lying
62110988|NCT04930393|ACTIVE_COMPARATOR|PECS II Block|This group will receive an interscalene block in addition to a pectoral nerve block under ultrasound guidance with local anesthetic injected in the plane between the pectoralis minor and serratus anterior muscles
62110989|NCT04930393|ACTIVE_COMPARATOR|Axillary Ring Block|This group will receive an interscalene block in addition to a ring block with local anesthetic injected subcutaneously along the axilla from anterior to posterior direction.
62110990|NCT02533206|EXPERIMENTAL|EPIC|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.
62110991|NCT02533206|ACTIVE_COMPARATOR|FESS|The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia
62110992|NCT04107805|EXPERIMENTAL|10 mg BI 1323495 bid EM|
62110993|NCT04107805|EXPERIMENTAL|10 mg BI 1323495 bid PM|
62672461|NCT06504732|EXPERIMENTAL|Cohort 2|10-30 subjects with advanced/metastatic malignant solid tumors with low HER2 expression who have failed standard therapy or have no standard therapy will be enrolled at the 20 mg/kg IAH0968 dose to assess the safety and tolerability of IAH0968 monotherapy. The safety of IAH0968 at 15 mg/kg in combination with the CAPEOX regimen will be evaluated if the starting dose group, i.e., exceeds the MTD.
62110994|NCT04107805|EXPERIMENTAL|30 mg BI 1323495 bid EM|
62110995|NCT04107805|EXPERIMENTAL|30 mg BI 1323495 bid PM|
62110996|NCT04107805|EXPERIMENTAL|70 mg BI 1323495 bid + Midazolam EM|
62110997|NCT04107805|EXPERIMENTAL|120 mg BI 1323495 bid + Midazolam EM|
62110998|NCT04107805|EXPERIMENTAL|120 mg BI 1323495 qd EM|
62110999|NCT04107805|EXPERIMENTAL|150 mg BI 1323495 bid + Midazolam EM|
62111000|NCT04107805|EXPERIMENTAL|Placebo/Placebo+ Midazolam|
62111001|NCT04270734|ACTIVE_COMPARATOR|normal 25-36 gestational week preterm infant|
62111002|NCT04270734|EXPERIMENTAL|25-36 gestational week preterm infant with IVH|25-36 gestational week preterm infant with Intraventricular haemorrhages (IVH)
62111003|NCT00678795|EXPERIMENTAL|Sativex|Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
62672462|NCT06504732|EXPERIMENTAL|Cohort 3|The CAPEOX regimen will be combined at the 20 mg/kg IAH0968 dose to enroll 20-40 unsystematically treated subjects with advanced/metastatic colorectal or gastric cancers with low expression of HER2, including adenocarcinomas of the gastro-esophageal junction, in order to assess the safety and tolerance of the combination therapy. The safety of IAH0968 at 15 mg/kg in combination with the CAPEOX regimen will be evaluated if the starting dose group, i.e., exceeds the MTD.
62672463|NCT01429623|EXPERIMENTAL|ladostigil hemitartrate|10mg ladostigil base
62111004|NCT00678795|PLACEBO_COMPARATOR|Placebo|Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
62111005|NCT02595398|EXPERIMENTAL|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
62111006|NCT02595398|SHAM_COMPARATOR|Sham Procedure|Matching suprachoroidal syringe with sham procedure
62111007|NCT00619645|OTHER|RIST for Heme malignancies|Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy
62111008|NCT05689268|OTHER|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
62111009|NCT04565522||Hemodialysis or peritoneal dialysis patients|Hemodialysis or peritoneal dialysis Covid negative patients
62111010|NCT04565522||dialysis staff healthcare professionals|dialysis staff Covid negative healthcare professionals
62111011|NCT05644080|EXPERIMENTAL|68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
62111012|NCT02967237|EXPERIMENTAL|Insulin glargine (U300)|Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen
62111013|NCT04914936|EXPERIMENTAL|Part 1: ACP-196 and Calcium carbonate|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and a single oral dose of calcium carbonate 1 g tablet coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 2.
62111014|NCT04914936|EXPERIMENTAL|Part 2: ACP-196 and Omeprazole|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of omeprazole 40 mg capsules once daily (QD) for 5 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 5 of Period 2.
62111015|NCT04914936|EXPERIMENTAL|Part 3: ACP-196 and Rifampin|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of rifampin 600 mg capsule QD for 9 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 and Day 9 of Period 2.
62111016|NCT04856228|OTHER|diagnostic single group|Patients diagnosed with lateral epicondylitis with physical examinations will be evaluated with electrophysiology After electrophysiological evaluations, patients' effected extremity evaluated with ultrasonography for lateral epicondylitis and radial tunnel syndrome and compared with uneffected side 30 minutes after posterior interosseous nerve block with 1 cc 2% lidocaine with USG guide, full examination will be repeated for evaluation of NRS score changing to exact diagnose of radial tunnel syndrome 30 minutes after lateral epicondyle 1 cc 2% lidocaine injection with USG guide, full examination will be repeated for evaluation of NRS score changing to final diagnose of lateral epicondylitis
62672464|NCT01429623|PLACEBO_COMPARATOR|Placebo Control|drug product excipients
62672465|NCT04885010|EXPERIMENTAL|Probiotics|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
62672466|NCT04885010|PLACEBO_COMPARATOR|Placebo|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
62672467|NCT06070051|EXPERIMENTAL|Cohort 1a: Low Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost|Participants assigned to Cohort 1a will receive a low dose prime vaccination of AdC7 vector on Day 1. They will receive a low dose boost vaccination of vector AdC6 on Day 91.
62672468|NCT06070051|EXPERIMENTAL|Cohort 1b: Low Dose VRON-0200-AdC6 Prime, No Boost|Participants assigned to Cohort 1b will receive a low dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.
62111017|NCT06417593||group1|Pseudomonas Aeruginosa Isolates
62111018|NCT01711307|EXPERIMENTAL|non-operative|cast applied within 48 hours
62111019|NCT01711307|ACTIVE_COMPARATOR|operative|cast applied within 48 hours and surgery within 14 days
62111020|NCT04586036|EXPERIMENTAL|young healthy adults|Gait measured by Vicon Nexus System
62111021|NCT04586036|EXPERIMENTAL|young adults with chronic ankle joint instability|Gait measured by Vicon Nexus System
62111022|NCT01729819|EXPERIMENTAL|Combination|Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
62111023|NCT01729819|ACTIVE_COMPARATOR|Tolterodine|Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
62111024|NCT04580108||Patients with systemic lupus erythematosus|Patients with systemic lupus erythematosus enrolled in the PLUS cohort between 2007 and 2010
62111025|NCT04689321||Phase 1|Patients recruited for phase 1 will undergo a semi-structured interview to identify issues that may be relevant to include in the revised EORTC QLQ-BN20 questionnaire.
62111026|NCT04689321||Phase 3|Patients recruited for phase 3 will complete the draft questionnaire, and rate each item for relevance, and indicate the 10 most important items. Also, a semi-structured interview will be conducted including debriefing questions to determine if the questionnaire is complete and the questions are acceptable.
62111027|NCT03275077||Controls|Normal Healthy Volunteers
62301158|NCT01244737|EXPERIMENTAL|New diagnosis of brain tumor|In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using \[18F\] FLT.
62301159|NCT01244737|EXPERIMENTAL|Possible recurrent brain tumor|In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using \[18F\] PET.
62672469|NCT06070051|EXPERIMENTAL|Cohort 2a: High Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost|Participants assigned to Cohort 2a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive a high dose boost vaccination of AdC6 vector on Day 91.
62736054|NCT02944721|OTHER|Transversal study|Patients who had surgery for breast cancer for 2 years or less
62736055|NCT02944721|OTHER|Longitudinal study|Patients that must be operated for a breast cancer
62736056|NCT05301621||Arthritis patients|It is not planned any intervention. The patients' group will be invited to 4 visits.
62736057|NCT05301621||Healthy controls|No intervention planned. Only one visit will be conducted.
62736058|NCT03567967|EXPERIMENTAL|San Francisco|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The San Francisco participants will receive and spend these vouchers in an environment which has implemented a sugar-sweetened beverage tax.
62736059|NCT03567967|ACTIVE_COMPARATOR|Los Angeles|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The Los Angeles participants will receive and spend these vouchers in an environment which has NOT implemented a sugar-sweetened beverage tax.
62736060|NCT05887713|EXPERIMENTAL|Group 1: Active CES|Active CES treatment at home 40 minutes daily for 6 weeks
62736061|NCT05887713|SHAM_COMPARATOR|Group 2: Sham CES|Sham CES treatment at home 40 minutes daily for 6 weeks
62736062|NCT03306472|ACTIVE_COMPARATOR|Arm A: Letrozole|Arm A: 15 days of Letrozole 2.5mg daily
62736063|NCT03306472|EXPERIMENTAL|Arm B: Letrozole + Megestrol Acetate (40mg)|Arm B: 15 days of Letrozole 2.5mg daily + Megestrol acetate 40mg daily
62301160|NCT01244737|EXPERIMENTAL|Brain tumor response to chemotherapy|"In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using \[18F\] FLT before the start and after two cycles of chemotherapy.~Despite much effort and working with referring physicians at multiple hospitals, enrollment in this arm remained low, and it seemed unlikely that meaningful enrollment would be accomplished. A revised study plan was submitted to the granting agency and FDA, and this arm was closed to further enrollment."
62301161|NCT06314230||Kidney transplant recipients|"Kidney or kidney-pancreas transplant recipients enrolled into the study prospectively. Risk factors recorded, blood/urine/kidney samples analysed and correlated with outcomes.~Non-interventional, observational in nature."
62301162|NCT01355406|OTHER|PAD|This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at \> 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
62301163|NCT03885284|EXPERIMENTAL|Dose Level 1|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 8-12 of cycle 6"
62301164|NCT03885284|EXPERIMENTAL|Dose Level 2|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 15-19 of cycle 6"
62672470|NCT06070051|EXPERIMENTAL|Cohort 2b: High Dose VRON-0200-AdC6 Prime, No Boost|Participants assigned to Cohort 2b will receive a high dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.
62672471|NCT06070051|EXPERIMENTAL|Cohort 3a: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, VRON-0200-AdC6 Boost|Participants assigned to Cohort 3a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive VIR-2218 and VIR-3434 on Days 28, 56, 84, 112, 140, and 168. They will receive a high dose boost vaccination of AdC6 vector on Day 91.
62672472|NCT06070051|EXPERIMENTAL|Cohort 3b: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, No Boost|Participants assigned to Cohort 3a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive VIR-2218 and VIR-3434 on Days 28, 56, 84, 112, 140, and 168. They will not receive a boost vaccination.
62111028|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
62111029|NCT03012230|EXPERIMENTAL|Treatment (pembrolizumab, ruxolitinib phosphate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62301165|NCT01167608||People with Parkinson's disease|Individuals diagnosed with Parkinson's disease
62301166|NCT01646710|EXPERIMENTAL|Food Based Recommendations|Developing and pretesting tool for FBRs for infants 9 to 11 months old
62301167|NCT00135421|EXPERIMENTAL|A1|
62301168|NCT00135421|ACTIVE_COMPARATOR|A2|
62672473|NCT00857051|EXPERIMENTAL|1|A 22 minute DVD that discusses common stressor in the early postpartum.
62672474|NCT00857051|EXPERIMENTAL|2|A 24 hour hotline available for the first 3 months postpartum.
62672475|NCT00857051|EXPERIMENTAL|3|Both the film and the hotline will be given to this arm.
62672476|NCT00857051|NO_INTERVENTION|4|A CD of children's music will be given to mothers in this arm.
62672477|NCT02526394|ACTIVE_COMPARATOR|1|Repevax + Meningitec
62672478|NCT02526394|ACTIVE_COMPARATOR|2|Repevax + Neis-VacC
62111030|NCT02929511|EXPERIMENTAL|Reciproc Blue|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc Blue single-file system (VDW, Germany). The intervention is root canal treatment with the Reciproc Blue single-file system.
62111031|NCT02929511|EXPERIMENTAL|OneShape|In this group, OneShape rotational single-file system (Micro Mega, France) will be used as single-file system according to the manufacturer's instruction.
62111032|NCT02929511|ACTIVE_COMPARATOR|Protaper|As a control group, Protaper (Dentsply, Mailleffer, Switzerland) will be used according to the manufacturer's instruction.
62111033|NCT04346524||microbiome sampling|pregnant women with type 1 diabetes
62111034|NCT05037032|ACTIVE_COMPARATOR|Study drug naltrexone hydrochloride|50 mg Naltrexone PO
62301169|NCT00135421|PLACEBO_COMPARATOR|A3|
62301170|NCT06235996|EXPERIMENTAL|Music Intervention|A patient is scheduled for an office-based procedure such as a nerve block, epidural steroid injection, etc. Music-of-choice during the office-based procedure intervention is assigned to this group. Music via external speakers played in the procedure room. To ensure acute pain and anxiety control, participants will receive standard analgesic treatment in the beginning of their scheduled interventional procedure. Such treatment includes injection and topical application of lidocaine to induce local anesthesia. Standard of care is applied.
62672479|NCT02526394|ACTIVE_COMPARATOR|3|Repevax + Menitorix
62672480|NCT02526394|ACTIVE_COMPARATOR|4|Boostrix + Meningitec
62672481|NCT02526394|ACTIVE_COMPARATOR|5|Boostrix + NeisVacC
62672482|NCT02526394|ACTIVE_COMPARATOR|6|Boostrix + Menitorix
62672483|NCT02526394|ACTIVE_COMPARATOR|7|Repevax + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
62672484|NCT02526394|ACTIVE_COMPARATOR|8|Boostrix + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
62672485|NCT05268237|EXPERIMENTAL|Part 1: Open Label|Part 1 of the trial will utilise an open label, single ascending dose, repeated treatment design. It will involve 3 subjects, each of whom will receive three single ascending doses of SL liraglutide (3, 12, 30mg and subcutaneous (SC) liraglutide (active comparator) with a mixed meal tolerance test (MMTT), separated by 1 week washout between doses.
62736064|NCT03306472|EXPERIMENTAL|Arm C: Letrozole + Megestrol Acetate (160mg)|Arm C: 15 days of Letrozole 2.5mg daily + Megestrol acetate 160mg daily.
62301171|NCT06235996|OTHER|Control|A patient is scheduled for an office-based procedure such as a nerve block, epidural steroid injection, etc. No music intervention is assigned to this group. No music at any time during the procedure. To ensure acute pain and anxiety control, participants will receive standard analgesic treatment in the beginning of their scheduled interventional procedure. Such treatment includes injection and topical application of lidocaine to induce local anesthesia. Standard of care is applied.
62301172|NCT03267355|EXPERIMENTAL|Gastrointestinal diseases|Endoscopic Ultrasound
62301173|NCT01057121|EXPERIMENTAL|Lenalidomide|Patients receive lenalidomide PO once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62301174|NCT04321343|EXPERIMENTAL|Group 1|PXL065 Dose 1
62301175|NCT04321343|EXPERIMENTAL|Group 2|PXL065 Dose 2
62301176|NCT04321343|EXPERIMENTAL|Group 3|PXL065 Dose 3
62301177|NCT04321343|PLACEBO_COMPARATOR|Group 4|Placebo oral tablet
62301178|NCT01472276|NO_INTERVENTION|Control|
62301179|NCT01472276|ACTIVE_COMPARATOR|Web-based program|
62301180|NCT00262704|NO_INTERVENTION|Group A|Control group
62301181|NCT00262704|ACTIVE_COMPARATOR|Group B|Simulated case-based customized learning
62301182|NCT00262704|ACTIVE_COMPARATOR|Group C|Simulated case based customized learning + leader feedback
62301183|NCT02919306|EXPERIMENTAL|Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 \* 10\^10 viral particles \[vp\]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10\^8 Plaque-forming unit \[pfu\]) at Week 24 and 48.
62301184|NCT02919306|PLACEBO_COMPARATOR|Placebo|0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.
62301185|NCT05459597||Treatment|The use of antiepileptic drugs depends on the clinical practice.
62301186|NCT03384056||Self Pressurized Airway Device with Blocker|
62301187|NCT03384056||Proseal Laryngeal Mask Airway|
62301188|NCT00655720|ACTIVE_COMPARATOR|1|
62301189|NCT00655720|EXPERIMENTAL|2|
62301190|NCT00655720|EXPERIMENTAL|3|
62301191|NCT01595217|EXPERIMENTAL|MRCP and DWI using 3T MRI|MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
62301192|NCT01595217|EXPERIMENTAL|MRCP only using 3T MRI|MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
62301193|NCT01225354|EXPERIMENTAL|Calcium hydroxylapatite|Subject will be treated at baseline and, if needed, at 2 weeks.
62301194|NCT00507715|EXPERIMENTAL|1|Plantago ovata husk
62301195|NCT00507715|PLACEBO_COMPARATOR|2|hemicellulose crystalline
62736065|NCT01794507|EXPERIMENTAL|ABT-199 + BTZ/Dex Dose Escalation Cohorts|Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.
61916268|NCT06132581|EXPERIMENTAL|Delta-beta tACS|The study is investigating the use of transcranial alternating current stimulation (tACS). The stimulation is delivered at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. For the experimental arm, the tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
62301196|NCT02240706|ACTIVE_COMPARATOR|Arm B|Best Supportive Care Alone
62301197|NCT02240706|EXPERIMENTAL|Arm A|BI 836858 plus Best Supportive Care
62301198|NCT02489370|EXPERIMENTAL|Telemonitoring (intervention)|"an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.~Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made."
62301199|NCT02489370|NO_INTERVENTION|Usual care (control)|Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
62301200|NCT03950323|EXPERIMENTAL|patients operated on for parotid tumor|All consecutive patients operated on for parotid tumor.
62301201|NCT06377189|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment as usual (TAU) conducted by PCP; the CL psychiatrist will not be involved in participants' treatment.
62301202|NCT06377189|EXPERIMENTAL|Consultation-Liaison (CL) brief psychiatric intervention|"CL brief psychiatric intervention (2 months) will be conducted in primary care settings.~CL psychiatrists will benefit from regular supervision by experienced CL psychiatrists."
62301203|NCT04305392|EXPERIMENTAL|Normal liver function|Patients will receive single dose of SHR4640
62301204|NCT04305392|EXPERIMENTAL|Mild Hepatic Impairment|Patients will receive single dose of SHR4640
62301205|NCT04305392|EXPERIMENTAL|Moderate Hepatic Impairment|Patients will receive single dose of SHR4640
62301206|NCT04824989|EXPERIMENTAL|Sleep Health|Family receives the Sleep Health In Preschoolers parenting intervention to address toddler sleep problems.
62301207|NCT04824989|EXPERIMENTAL|Behavior Health|Family receives the Family Check-Up parenting intervention to address toddler behavior problems.
62301208|NCT04824989|EXPERIMENTAL|Choice|Family is given the opportunity to select either the Sleep Health in Preschoolers intervention to address toddler sleep problems or the Family Check-Up intervention to address toddler behavior problems.
62301209|NCT04824989|ACTIVE_COMPARATOR|Control|Family receives a safety and hygiene active control intervention.
62301210|NCT00643149|EXPERIMENTAL|1|
62301211|NCT00643149|EXPERIMENTAL|2|
62301212|NCT01877655|EXPERIMENTAL|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
62301213|NCT01877655|PLACEBO_COMPARATOR|Placebo|Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
62301214|NCT03919240|EXPERIMENTAL|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CART-cells
61916269|NCT06132581|ACTIVE_COMPARATOR|Theta-gamma tACS|This arm serves as an active control where tACS will be delivered using the cross-frequency stimulation waveform theta-gamma (5-50Hz).
61916270|NCT06132581|SHAM_COMPARATOR|Active-sham tACS|For active sham stimulation, either delta-beta or theta-gamma stimulation is delivered for 15 seconds only at the beginning and end of the stimulation period. This is intended to mimic the skin sensations (e.g., itching, burning, tingling) that are experienced at the onset and offest of stimulation, assisting with blinding the participant's assignment.
61916271|NCT04168632|EXPERIMENTAL|Intervention|A new 4-week menu plan
61916272|NCT03042026||Acromegaly patients|Acromegaly patients
61916273|NCT03042026||Healthy subjects|Healthy volunteers
61916274|NCT03123185|EXPERIMENTAL|Placebo matching BI 705564 fasted (SRD part)|
61916275|NCT03123185|EXPERIMENTAL|Placebo matching BI 705564 fed (SRD part)|
62111035|NCT05037032|PLACEBO_COMPARATOR|Matching placebo for naltrexone hydrochloride|Matching placebo for Study Drug Naltrexone
62672486|NCT05268237|EXPERIMENTAL|Part 2: Investigator blind|Part 2 of the trial will utilise an investigator-blind, sponsor open, placebo-controlled, randomised, repeated treatment study design. It will involve 12 subjects. Each subjects will receive one of three possible doses of SL-liraglutide (to be decided by the Safety Monitoring Committee following analysis of the results from Part 1), SL-placebo or SC liraglutide in a randomised order with MMTT separated by 1 week washout between doses.
62672487|NCT03476252|EXPERIMENTAL|patients|ST elevation myocardial infarction
62111036|NCT02711826|ACTIVE_COMPARATOR|Maintenance CNI based immunosuppression therapy group|"Standard of care~(N=7 participants in this group)"
62111037|NCT02711826|EXPERIMENTAL|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (550 ± 450 x 10\^6). After receiving at least 300X10\^6 polyTregs infusion, eligible subjects will start mammalian Target of Rapamycin (mTOR) inhibitor.~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued.~(N=7 participants in this group)"
62111038|NCT01912703||Preterm infants with IVH Grades I-II|Preterm infants (post-menstrual age 24-35 weeks) who were diagnosed with IVH Grades 1-2 in the neonatal intensive care unit (NICU).
62672488|NCT06203665|EXPERIMENTAL|Patients enrolled in the protocol|An alveolar recruitment nameuver will be performed after the release of pneumoperitoneum
62111039|NCT01912703||Control Group|Preterm infants (post-menstrual age 24-35 weeks) who had no imaging evidence of IVH in the neonatal intensive care unit (NICU).
62111040|NCT03563391|EXPERIMENTAL|Evaluation of a new infant formula|To evaluate the effects of a new formula on the growth, safety and tolerance of infants with growth failure
62111041|NCT00143689|EXPERIMENTAL|Lopinavir/ritonavir, Zidovudine, Lamivudine|"Participants will be randomly assigned to receive one of the following drug combinations:~* lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;~* Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;~* Combivir and lopinavir/ritonavir twice a day."
62111042|NCT06374667|EXPERIMENTAL|ICO injection group|Y-3 ICO injection (dose was given as 32 ug/kg) once a day for 3 consecutive days, as well as standard treatment and management according to the related guidelines.
62111043|NCT06374667|ACTIVE_COMPARATOR|intravenous injection group|Y-3 intravenous injection(dose was given as 40mg + 250ml normal saline), as well as standard treatment and management according to related guidelines.
62301215|NCT03890055|EXPERIMENTAL|Clinical trial group|（Carboplatin/cisplatin + etoposide）+ （Anlotinib Hydrochloride 12 mg/day ，Each cycle was defined as 2 weeks on-treatment fol- lowed by 1 week off-treatment）, after 4-6 cycles of treatment, the treatment was continued with anlotinib until disease progression.
62672489|NCT03380988|EXPERIMENTAL|Fiber-enriched buckwheat pasta|Acute test meal
62672490|NCT03380988|ACTIVE_COMPARATOR|Corn pasta|Acute test meal
61916276|NCT03123185|EXPERIMENTAL|1 milligram (mg) BI 705564 fasted (SRD part)|
61916277|NCT03123185|EXPERIMENTAL|3 mg BI 705564 fasted (SRD part)|
61916278|NCT03123185|EXPERIMENTAL|10 mg BI 705564 fasted (SRD part)|
61916279|NCT03123185|EXPERIMENTAL|20 mg BI 705564 fasted (SRD part)|
61916280|NCT03123185|EXPERIMENTAL|40 mg BI 705564 fasted (SRD part)|
61916281|NCT03123185|EXPERIMENTAL|80 mg BI 705564 fasted (SRD part)|
61916282|NCT03123185|EXPERIMENTAL|20 mg BI 705564 fed (SRD part)|
61916283|NCT03123185|EXPERIMENTAL|40 mg BI 705564 fed (SRD part)|
61916284|NCT03123185|EXPERIMENTAL|80 mg BI 705564 fed (SRD part)|
61916285|NCT03123185|EXPERIMENTAL|160 mg BI 705564 fed (SRD part)|
61916286|NCT03123185|EXPERIMENTAL|BI 705564 10 mg fasted/ BI 705564 10 mg fed (FE Part)|
61916287|NCT03123185|EXPERIMENTAL|BI 705564 10 mg fed/ BI 705564 10 mg fasted (FE Part)|
61916288|NCT03516903|ACTIVE_COMPARATOR|Methotrexate & Folic acid|ddMTX-LDE 40mg/m2 (100mL total volume) IV and Folic acid 5mg by mouth (the day after ddMTX-LDE) weekly for 6 weeks
61916289|NCT03516903|PLACEBO_COMPARATOR|Placebo & folic acid|Placebo-LDE IV 100mL and Folic acid 5mg by mouth (the day after Placedo-LDE) weekly for 6 weeks
61916290|NCT04783675|EXPERIMENTAL|Intervention/treatment|
62470713|NCT01648582|ACTIVE_COMPARATOR|Insulin Glargine|Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.
61916291|NCT03444987||patients group|"include 35 pre-menopausal women (age ˂ 50 years) enrolled to undergo hysterectomy for symptomatic UF at the women health hospitals, Assiut University.~* The protein expression of the followings markers will be estimated in tumor tissue samples:~  1. Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~ 2. Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~ 3. Phosphorylated protein kinase B (pAKT ) by ELISA (protein level). analysis.~ 4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~ 5. Reduced glutathione, an antioxidant marker by a colorimetric method~     ."
61916292|NCT03444987||Control group|"include 35 normal myometrial tissue samples obtained 1 cm away from the fibroid capsule from the same patients.~* The protein expression followings markers will be estimated in normal myometrial tissue samples~  1. Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~ 2. Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~ 3. Phosphorylated protein kinase B (pAKT) by ELISA (protein level).~ 4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~ 5. Reduced glutathione, an antioxidant marker by a colorimetric method~     ."
62111044|NCT06214221|EXPERIMENTAL|Signos System|For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.
62111045|NCT06214221|ACTIVE_COMPARATOR|Standard Lifestyle Education|"The Active Comparator: Standard Lifestyle Education arm in the clinical trial refers to a control group that receives conventional lifestyle modification advice instead of the experimental Signos System."
62111046|NCT04673851|EXPERIMENTAL|FEP Clients|Participants with first episode psychosis (FEP) recruited from First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) or UNC-affiliated STEP Clinics (Carr Mill Mall, Vilcom Center, Main Wake Clinic) will participate in the online platform Horyzons for 3 months (cohort 1) or 6 months (cohort 2) as a part of their care plan. Participants will be encouraged to use both the therapeutic content and the moderated online community throughout their time in the study.
62301216|NCT03754049|EXPERIMENTAL|TLC599 12 mg|12 mg TLC590 (proprietary lipid formulation that consists of 12 mg DSP \[active ingredient\] with 100 μmol phospholipid) via IA injection in patients with OA of the knee. This 12 mg TLC599 treatment arm consists of six (6) cohorts (G1 to G6), each with different follow-up periods or visit schedules. However, the results will be pooled into a single treatment arm to allow for meaningful analysis across the various synovial fluid (SF) time points, as each subject only has one opportunity to collect an SF sample.
62301217|NCT03754049|EXPERIMENTAL|TLC599 6 mg|6 mg TLC590 (proprietary lipid formulation that consists of 6 mg DSP \[active ingredient\] with 50 μmol phospholipid) via IA injection in patients with OA of the knee. This 6 mg TLC599 treatment arm consists of two (2) cohorts (G7 and G8), each with different follow-up periods or visit schedules. However, the results will be pooled into a single treatment arm to allow for meaningful analysis across the various synovial fluid (SF) time points, as each subject only has one opportunity to collect an SF sample.
62301218|NCT03754049|ACTIVE_COMPARATOR|DSP 4 mg|Dexamethasone Sodium Phosphate (DSP) at a concentration of 4 mg/mL, 1 mL for a total of 4 mg DSP via IA injection in patients with OA of the knee (G9).
62301219|NCT03754049|ACTIVE_COMPARATOR|DSP 10 mg|Dexamethasone Sodium Phosphate (DSP) at a concentration of 4 mg/mL, 2.5 mL for the total of 10 mg DSP via IV injection in healthy subjects (G10).
62470714|NCT03552081|EXPERIMENTAL|fragmented DNA evaluation in blood and semen samples|20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking
62111047|NCT04673851|OTHER|FEP Clinicians|Providers (clinicians and peer support specialists) affiliated with First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in a focus group discussing the implementation and integration of Horyzons into their care routine with clients who participated in the study.
62301220|NCT06066879|EXPERIMENTAL|Ketamine Infusion|ketamine infusion at 0.5 mg/kg over one hour two weeks (14 days) prior to their scheduled surgical date
62470715|NCT05852886|EXPERIMENTAL|Toothbrush|Use of experimental toothbrush for 28 days.
62470716|NCT05333341|ACTIVE_COMPARATOR|TCM|TCM uses clinical pharmacists leading LTOT reassessment and, when indicated for underlying OUD, buprenorphine (BUP) initiation in consultation with a BUP-prescribing physician. Clinical pharmacists will lead LTOT reassessment and, when indicated for underlying OUD, buprenorphine (BUP) initiation in consultation with a BUP-prescribing physician.
62301221|NCT06066879|NO_INTERVENTION|Standard Of Care|No use of ketamine pre, intra, or post-operatively
62470717|NCT05333341|EXPERIMENTAL|TCM plus COPES|Participants in this arm will use TCM plus COPES that will augment the effectiveness of TCM alone.
62111048|NCT02446223|EXPERIMENTAL|Active|
62111049|NCT03755440|EXPERIMENTAL|PD-1 antibody|SHR-1210, 200mg, ivdrip, d1, every two weeks.
62672491|NCT02567292|NO_INTERVENTION|Retrospective Control Group|Approximately 150 patients with congenital gastrointestinal disorders who were treated in the neonatal intensive care unit (NICU) at Children's Healthcare of Atlanta-Egleston and other participating institutions from 2012 to 2015, who had non-human milk (HM) diets will be identified as retrospective controls using the electronic medical records system.
62111050|NCT02960139|EXPERIMENTAL|Test- Treatment with Sylys Surgical Sealant|Standard closure plus treatment with Sylys Surgical Sealant
62111051|NCT02960139|NO_INTERVENTION|Control- Standard of Care|Control group is standard closure of anastomosis.
62111052|NCT01891968|EXPERIMENTAL|Bortezomib|Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
62301222|NCT05505058|EXPERIMENTAL|Audio-visual material|The video for informed consent was developed by a science filmmaker (https://www.lostlikebeesinrain.comhttps://betomation.space/) for the project's purposes.
62301223|NCT05505058|ACTIVE_COMPARATOR|Paper-based conventional material|The written material for informed consent was developed by the Swiss Association of Research Ethic Committees and the booklet was designed by the Clinical Research Center of the Geneva University Hospitals.
62301224|NCT03153852|EXPERIMENTAL|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
62301225|NCT00886938|EXPERIMENTAL|rTMS to DLPF, pilot study|rTMS to the dorsolateral prefrontal cortex for patients with tinnitus
62301226|NCT03643887|EXPERIMENTAL|FMT Capsule DE|FMT Capsule DE
62301227|NCT03643887|PLACEBO_COMPARATOR|Placebo Oral Capsule|Placebo Capsule
62301228|NCT02031679|EXPERIMENTAL|AZD1981|"AZD1981 for oral administration will be available in tablet form. AZD1981 tablets will be provided in 10 mg strengths.~The drug will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
62301229|NCT02031679|PLACEBO_COMPARATOR|Placebo|"The placebo will be available in tablet form. The placebo contains the same ingredients as the AZD1981 with the exception of the active compound.~The placebo will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
62672492|NCT02567292|EXPERIMENTAL|Exclusive Human Milk Diet Group|A minimum of 150 patients with CGD admitted to participating NICUs who meet inclusion criteria and provide informed consent will be enrolled in the prospective arm of the study. These patients will be fed an EHMD comprised of mother's own milk (MOM) or pasteurized donor human milk (DM). Fortification will be provided with human milk derived human milk fortifier, either a human milk-based fortifier (Prolact+ H2MF®) for infants born at less than 37 weeks GA or \<2,200g birth weight or the term-equivalent version (PBCLN-002) formulated for infants \>37 weeks and/or \>2,200g at birth. Infants will receive this EHMD until they have achieved full enteral feedings for 7 days with bowel in continuity
61916293|NCT04577339||Adult patients with acute abdominal conditions|"All adult patients \>=16years of age on all general adult wards (excluding maternity) between 2013 and 2020 with the following inclusion and exclusion criteria:~Inclusion criteria:~* Must have an acute intestinal condition, based on their ICD-10 codes and OPSC-4 codes~* Must be \>= 16 years of age at the time of admission~* Have at least one full set of vital signs recorded on the day of admission~* Have at least one full set of routine blood tests recorded on the day of admission~Exclusion criteria:~* Maternity admissions during/after pregnancy~* Patients admitted or undergoing abdominal surgery for a second time or more"
61916294|NCT04615585|EXPERIMENTAL|Aloe Vera + Scaling and root planing|
62111053|NCT05853224|EXPERIMENTAL|Crosslinked Hyaluronic Acid (CLHA) Hydrogel with Lidocaine|Patients were treated, on one side of the face with crosslinked Hyaluronic Acid Hydrogel with 0.3% lidocaine hydrochloride.
62111054|NCT05853224|EXPERIMENTAL|Crosslinked Hyaluronic Acid (CLHA) Hydrogel without Lidocaine|Patients were treated, on the other side of the face with crosslinked Hyaluronic Acid Hydrogel without lidocaine hydrochloride.
62111055|NCT02076919|EXPERIMENTAL|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
62111056|NCT02076919|PLACEBO_COMPARATOR|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
62470718|NCT04779320|EXPERIMENTAL|Induction Period: 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of 10 to 15 kg will be included in this arm group.
62672493|NCT04612127|EXPERIMENTAL|Experimental group - Spinach|"Consumption for 90 days of spinach extract (1000mg)~Four capsules will be consumed per day, two with breakfast and two with lunch."
62672494|NCT04612127|PLACEBO_COMPARATOR|control group Placebo (sucrose)|Four capsules will be consumed per day, two with breakfast and two with lunch.
62111057|NCT02076919|EXPERIMENTAL|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
62111058|NCT02076919|PLACEBO_COMPARATOR|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
62111059|NCT00518557|EXPERIMENTAL|1|All patients of this arm are treated by TACE together with Andostatin.
62111060|NCT00518557|ACTIVE_COMPARATOR|2|All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.
62111061|NCT00127829|EXPERIMENTAL|1|Gefitinib (IRESSA®)
62111062|NCT05901519|EXPERIMENTAL|Patients treated with Prednisone|Prednisone will be administered for three days before starting RT, and during the first three fractions of RT. Following an interim analysis of the decrease in sTNFR1 level, a decision will be made whether to administer prednisone for seven days prior to RT, and to continue for additional seven days during RT.
62111063|NCT00803933|EXPERIMENTAL|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
62111064|NCT00803933|ACTIVE_COMPARATOR|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
62111065|NCT03591809|EXPERIMENTAL|combined exercise training group|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
62111066|NCT03591809|NO_INTERVENTION|Control group|The patients in the control group will not apply an exercise training.
62111067|NCT05359913|EXPERIMENTAL|African American Women|
62111068|NCT00377455|EXPERIMENTAL|Bosentan|
62111069|NCT00377455|PLACEBO_COMPARATOR|Placebo|
62672495|NCT00819832|EXPERIMENTAL|Phase 1 Group 1 Vertebroplasty|Vertebroplasty
62111070|NCT03724838|ACTIVE_COMPARATOR|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours
62111071|NCT03724838|ACTIVE_COMPARATOR|Esomeprazole alone plus placebo to Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
62111072|NCT03724838|PLACEBO_COMPARATOR|placebo to Esomeprazole plus placebo to Sildenafil Citrate|Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
62111073|NCT00597350||1|Group with diabetes mellitus
62111074|NCT05672446|EXPERIMENTAL|Experimental|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients.
62111075|NCT05672446|NO_INTERVENTION|Control|No attempt was made to the students in the control group.
62111076|NCT05584046|EXPERIMENTAL|CDAM group|Patients receive the CDAM patch and a standard home stretching exercise program
62111077|NCT05584046|NO_INTERVENTION|Untreated group|Patients receive a standard home stretching exercise program
62111078|NCT04977271|EXPERIMENTAL|Treatment Group|"Starting dose of oral venlafaxine immediate release (IR) 37.5 mg BID, to be taken with food. The dosing will be increased at a rate of 75mg per week for 3 weeks, to reach a desired dose of 300mg per day, taken as 150mg BID.~For patients with hepatic impairment, severe renal impairment, or end-stage kidney disease, the starting dose is 37.5 mg once daily, and the dose is increased by increments of 37.5 mg per day, to a maximum of 187.5 mg per day, taken as 93.75 mg BID."
62111079|NCT04977271|NO_INTERVENTION|Control Group|No intervention will be provided for this group
62111080|NCT03525119|OTHER|HAV Vaccine 1.0 ml + Placebo/ Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).
62111081|NCT03525119|EXPERIMENTAL|TDV 0.5 ml + Placebo/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
62672496|NCT00819832|EXPERIMENTAL|Phase 1 Group 2 Kyphoplasty|Kyphoplasty
62672497|NCT00819832|ACTIVE_COMPARATOR|Phase 2 Group 1 Vertebroplasty|Vertebroplasty
61916295|NCT04615585|ACTIVE_COMPARATOR|Scaling and root planing|
62301230|NCT06230796|EXPERIMENTAL|FES-cycling|30 minutes of active leg cycling with FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks
62470719|NCT04779320|EXPERIMENTAL|Induction Period: >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of \>15 to \<30 kg will be included in this arm group.
62111082|NCT03525119|EXPERIMENTAL|TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
62111083|NCT02410538||"families that received the list of FAQ"|"The intervention consists of the delivery to the relatives of ICU patients a list of 21 key issues in intensive care during the first 48h period of ICU stay, only for intubated and mechanically ventilated patients A formal interview is scheduled to relatives of ICU patients on D3 of inclusion"
62111084|NCT02410538||families that received information as usual|A formal interview is scheduled relatives of ICU patients on D3 inclusion
62111085|NCT00837616|ACTIVE_COMPARATOR|Group A|Group A will receive the oral estradiol for 12 months
62111086|NCT00837616|ACTIVE_COMPARATOR|Group B|Group B will receive the transdermal estradiol for 12 months
62111087|NCT00107835|EXPERIMENTAL|S-Caine Peel|
62111088|NCT03425162|ACTIVE_COMPARATOR|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+PCA (morphine)
62111089|NCT03425162|SHAM_COMPARATOR|Group P|Group P:PCA (morphine)
62111090|NCT03994146|EXPERIMENTAL|Remifentanil tapering / Placebo abrupt cessation|Syringe one contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1 and Syringe two contains 40 ml NaCl 9 mg.ml-1 at an identical infusion rate. According to randomisation syringe one will then be tapered towards the end of surgery and syringe two abruptly stopped.
62111091|NCT03994146|PLACEBO_COMPARATOR|Placebo tapering / Remifentanil abrupt cessation.|Syringe one contains 40 ml NaCl 9 mg.ml-1 and Syringe two contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1. According to randomization syringe one will be tapered towards the end of surgery and syringe two abruptly stopped.
62111092|NCT05725889||DIABETES|Visual, finger tapping and auditory tests were performed regularly. The subjects' fasting plasma glucose and HbA1c levels, and the duration of their diabetes were recorded.
62111093|NCT05725889||CONTROL|Visual, finger tapping and auditory tests were performed regularly. The subjects' fasting plasma glucose and HbA1c levels were recorded.
62111094|NCT00684034|OTHER|1|Volunteer healthy
62111095|NCT00684034|OTHER|2|Patient dialysis patient
62301231|NCT06230796|SHAM_COMPARATOR|SHAM-cycling|30 minutes of active leg cycling with Sham FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks
62470720|NCT04779320|EXPERIMENTAL|Induction Period: ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of ≥30 kg will be included in this arm group.
61916296|NCT02439333|ACTIVE_COMPARATOR|Nasal high flow therapy|AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.
62111096|NCT00684034|OTHER|3|Not dialysed chronic renal insufficient patient
62111097|NCT02485626||Anthracycline treated BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.
62111098|NCT02485626||Anthracycline naive BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.
62301232|NCT00155402|EXPERIMENTAL|1|Use of fibrin glue after corneal surgery or transplantation
62301233|NCT01504503|EXPERIMENTAL|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
62111099|NCT06208696|EXPERIMENTAL|Intervention group (TCS)|"Participants with Long-COVID and chronic diseases that agree to participate in the intervention will participate in the Tomando Control de su Salud (TCS) workshops. TCS is an evidenced based intervention in Spanish and a culturally appropriate version similar to the Chronic Disease Self-Management program of the Centers for Disease Control and Prevention (CDC) aimed to improve disease management skills, including decision making, problem solving, and action planning among patients with at least one chronic condition."
62301234|NCT01504503|ACTIVE_COMPARATOR|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
62301235|NCT01568216|EXPERIMENTAL|AMG 747 - Dose 1|
62672498|NCT00819832|ACTIVE_COMPARATOR|Phase 2 Group 2 Vertebroplasty + Cavity SpineWand|Vertebroplasty with Cavity SpineWand
62301236|NCT01568216|EXPERIMENTAL|AMG 747 - Dose 2|
62672499|NCT00819832|ACTIVE_COMPARATOR|Phase 2 Group 3 Kyphoplasty|Kyphoplasty
62672500|NCT00819832|ACTIVE_COMPARATOR|Phase 2 Group 4 Kyphoplasty + Cavity SpineWand|Kyphoplasty with Cavity SpineWand
62672501|NCT03092037||All participants|All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.
62111100|NCT06208696|NO_INTERVENTION|Non-Intervention Group (Regular care)|Those not interested in participating in the intervention will receive general information about chronic disease management available at the CDC website in Spanish, by email or in person.
62111101|NCT03870854|EXPERIMENTAL|PEFA targeted substrate ablation|Use of PEFA strategy to identify and target VT isthmuses.
62111102|NCT02942290|EXPERIMENTAL|Venetoclax + Azacitidine|
62111103|NCT05577611|EXPERIMENTAL|Basic chemotherapy + UCB transplantation|
62301237|NCT01568216|EXPERIMENTAL|AMG 747 - Dose 3|
62301238|NCT01568216|PLACEBO_COMPARATOR|Placebo Comparator|
62301239|NCT02670304|EXPERIMENTAL|letrozole|letrozole for the first day after ovum picked up at least for 5 days.
62470721|NCT04779320|EXPERIMENTAL|Maintenance Period: 10 to 15 kg Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
62672502|NCT03092037||All participants (side-effects)|All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.
62672503|NCT01576393|EXPERIMENTAL|Home-Based family therapy|12 home-based family therapy sessions
62672504|NCT01576393|ACTIVE_COMPARATOR|Office-based family therapy|12 office-based family therapy sessions
62672505|NCT01576393|PLACEBO_COMPARATOR|Women's Health Education|12 womens's health education sessions
62672506|NCT02503865|ACTIVE_COMPARATOR|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
62111104|NCT01196988|EXPERIMENTAL|GSK2321138A 1 Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
62111105|NCT01196988|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
62111106|NCT01196988|ACTIVE_COMPARATOR|GSK2604409A Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
62301240|NCT02670304|ACTIVE_COMPARATOR|aspirin|asprin for the first day after ovum picked up at least for 5 days.
62301241|NCT02678806|EXPERIMENTAL|Postoperative radiotherapy group|Patients hospitalized in Affiliated Tumor Hospital of Guangxi Medical University from 1st November 2017, who were diagnosed as BCLC-A stage hepatocellular carcinoma, accepted hepatocellular carcinoma resection, pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule \< 1cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction were selected and received margin postoperative radiotherapy.
62301242|NCT02678806|ACTIVE_COMPARATOR|Postoperative TACE group|
62301243|NCT06133673||Schools|Prevalence questionnaire data will be collected from 20 schools.
62301244|NCT06133673||Autistic children and young people (CYP)|10 semi-structured qualitative interviews will be conducted with autistics CYP.
62301245|NCT02939521|EXPERIMENTAL|Surgery|Consists of a dorsal flattening of of the bone at the distal phalanx, with a frontal lifting of the distal skin of the toe
62301246|NCT02053688|ACTIVE_COMPARATOR|Astigmatic Correction Lens|Nexis ACCL lenses vs commercial Toric Lenses
62672507|NCT02503865|EXPERIMENTAL|"Analimentary detoxication Weight loss"|Vegetables and salt diet
62672508|NCT02503865|NO_INTERVENTION|Healthy people|64 healthy people
62672509|NCT04062604||Femur fracture|Stabilization of femur fracture according to the AO fundation guidelines
62672510|NCT04062604||Hip alloplasty|Endoprothesis
62672511|NCT04062604||Knee alloplasty|Endoprothesis
62672512|NCT04062604||Knee arthroscopy|Resection of the meniscus lesion or anterior cruciatus ligamentum reconstruction
62672513|NCT05470725|EXPERIMENTAL|Control (normal renal function or mild renal impairment)|Estimated glomerular filtration rate (eGFR) ≥60 mL/min
62672514|NCT05470725|EXPERIMENTAL|Moderate to severe renal impairment|eGFR 15 to 59 mL/min
62470722|NCT04779320|EXPERIMENTAL|Maintenance Period: 10 to 15 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
61916297|NCT02439333|ACTIVE_COMPARATOR|Conventional oxygen therapy|AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.
61916298|NCT04486274|EXPERIMENTAL|non MOSE arm|Three needle passes will be performed for each mass
61916299|NCT04486274|EXPERIMENTAL|MOSE arm|The endoscopist will perform biopsy until a macroscopic visible core (MVC) will be obtained and specimen will be placed in a container (Container A-MOSE). If the needle passes performed are less than 3 (1 or 2 passes) the specimens acquired in the remnant passes to join standard care of 3 passes, according to ESGE guidelines, will be placed in a second container (Container B).
61916300|NCT00306007||English prenatal|English speaking women recruited from the general OB/GYN clinic
62111107|NCT01196988|EXPERIMENTAL|GSK2321138A 2 Group|Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
62111108|NCT04361253|EXPERIMENTAL|Arm A|Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.
62111109|NCT04361253|PLACEBO_COMPARATOR|Arm B|Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)
62111110|NCT02425254|EXPERIMENTAL|Preemptive paracetamol|1000mg intravenous paracetamol given ≥15 minutes before surgical incision and intravenous saline 15 minutes before the end of surgery
61916301|NCT00306007||Spanish prenatal|Spanish speaking (monolingual) women recruited from the general OB/GYN clinic
62111111|NCT02425254|ACTIVE_COMPARATOR|Postincision paracetamol|Intravenous saline ≥15 minutes before surgical incision and 1000mg intravenous paracetamol given 15 minutes before the end of surgery
62111112|NCT06319664||Clivus type|The dural attachment originates from petroclival fissure, and the main portion of lesion is situated on middle-upper clivus, mainly grows toward the median line and even the heterolateral direction, could involve in the whole clivus region from dorsum sellae to foramen magnum.
62470723|NCT04779320|EXPERIMENTAL|Maintenance Period: >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
61916302|NCT00306007||English abortion clinic|English speaking women recruited from the abortion clinic
61916303|NCT00306007||Spanish abortion clinic|Spanish speaking (monolingual) women recruited from the abortion clinic
61916304|NCT05358340|EXPERIMENTAL|Diagnostic (DSC MRI)|
61916305|NCT05365854|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP) then extended sigh|"Patients assigned to this group will receive a CPAP ARM (40cmH2O during 50 seconds), followed by a 10-minute pause corresponding to a period of return to basal state.~Then an ARM by extended sigh (e-sigh) also 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure).~Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
62111113|NCT06319664||Petroclival type|The dural attachment originates likewise from petroclival fissure, but primarily extends toward the homolateral dorsal petrosum region, and the main portion is center on middle-upper clivus and grows toward petrous apex region forward and cerebellopontine angle region backward, leading to the homolateral trigeminus being compressed outwards.
62111114|NCT06319664||Petroclivosphenoidal type|The site of origin lies on petroclival region, while the main part of lesion is located in posterior cranial fossa and extends forward and upward along petroclival fissure, and could spread to posterior clinoid process, dorsum sellae and parasellar area with striding petrous ridge, or expanding into Meckel's cave (MC) and even reaching posterior wall of cavernous sinus (CS) through MC. Overall, the growth pattern direction is basically from posterior cranial fossa to middle cranial fossa and from the infratentorial to supratentorial compartment.
62301247|NCT02053688|ACTIVE_COMPARATOR|Toric Soft Contact Lenses|commercial toric soft contact lenses
62301248|NCT04847986|EXPERIMENTAL|acceptance and commitment therapy (ACT) group|8 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
62301249|NCT04847986|SHAM_COMPARATOR|Control group|care as usual with psychoeducation materials provided
62301250|NCT02719054|EXPERIMENTAL|stimulation|Cognitive behavioral therapy for mother and play stimulation for children aged 6 to 12 months
62301251|NCT02719054|NO_INTERVENTION|Mother child dyad|
61916306|NCT05365854|ACTIVE_COMPARATOR|extended sigh then continuous positive airway pressure (CPAP)|"Patients assigned to this group will receive an ARM by extended sigh (e-sigh) during 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure), followed by a 10-minute pause corresponding to a period of return to basal state.~Then they receive a CPAP ARM (40cmH2O during 50 seconds). Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
61916307|NCT00667446|EXPERIMENTAL|Leuprolide Acetate 3M Depot 11.25 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
61916308|NCT00667446|EXPERIMENTAL|Leuprolide Acetate 3M Depot 30 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
61916309|NCT04909151|EXPERIMENTAL|Robot-assisted gait training with walking speed of 0.5km/h|
61916310|NCT04909151|EXPERIMENTAL|Robot-assisted gait training with walking speed of 0.8km/h|
61916311|NCT04909151|EXPERIMENTAL|Robot-assisted gait training with walking speed of 1.1km/h|
62470724|NCT04779320|EXPERIMENTAL|Maintenance Period: >15 to <30 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
62672515|NCT05470725|EXPERIMENTAL|Kidney failure|"eGFR \<15 mL/min, including:~* Subjects not on dialysis; and~* Subjects on dialysis, with study drug administration on a non-dialysis day"
61916312|NCT06516835|EXPERIMENTAL|Enteral nutrition fluid - ENF|Enteral nutrition will be given continuously with glucose-Na-K Baxter 50 mg/ml solution for infusion (GNAK)-both products to the gastrointestinal tract in the same volume.
62111115|NCT06319664||Sphenopetroclival Subtype I|Sphenopetroclival type (S-PC type): The site of origin saddles the petrous ridge and invades the CS and parasellar region widely. The growth pattern is different from the PC-S type, mainly from the middle cranial fossa to the posterior cranial fossa. This type is then further classified into two subtypes based on the relationship between CS and the lesion site of origin. Subtype I (S-PC I type): The lesion mainly originates from posterior part of CS and posterior clinoid process region, could invade and break though the CS wall, and the main part of lesion expands towards parasellar, middle cranial fossa, and petrous apex, even invades the dorsum sellae and posterior cranial fossa through tentorium. As a result, the CS wall is mostly rough, and the dural space between the lesion and the temporal lobe is not well-defined on MRI.
62301252|NCT05035498|ACTIVE_COMPARATOR|Phenylephrine group|Phenylephrine infusion simultaneous with spinal anesthesia
62301253|NCT05035498|EXPERIMENTAL|Norepinephrine group|Norepinephrine infusion simultaneous with spinal anesthesia
62672516|NCT04383015|OTHER|Carbohydrate (CHO)-only|Carbohydrate dose of 0.3g/kg/hr given every 30 minutes of exercise if blood glucose is in range with usual basal insulin infusion
62672517|NCT04383015|OTHER|50 Percent Basal Rate Reduction (BRR)|A 50 percent basal rate reduction set 90-minutes pre-exercise and throughout exercise
61916313|NCT06516835|EXPERIMENTAL|Intravenous fluid - IVF|Enteral nutrition will be given continuously to the gastrointestinal tract. GNAK will be given continuously intravenously in the same volume.
61916314|NCT02101112|EXPERIMENTAL|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
62301254|NCT04391764|EXPERIMENTAL|Naltrexone|Naltrexone at a dose of 50 mg per day.
62301255|NCT04391764|PLACEBO_COMPARATOR|Placebo|Placebo tablets will be identical in size, colour, shape, and taste and will be given in a similar manner.
61916315|NCT02101112|EXPERIMENTAL|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
62301256|NCT03007277|EXPERIMENTAL|PANJO Intervention|201 nulliparous women will be recruited within the PMI public services. Nurses/Midwives will propose to enroll in the PANJO group, which consist in receiving 6 to 12 home visits by a home visitor trained by the PANJO team The visits will consist on 45 to 90-minutes interventions aiming at supporting the family in the everyday challenges they may encounter, and to support the development of qualitative parent-child relationships.
61916316|NCT02101112|EXPERIMENTAL|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
62301257|NCT03007277|ACTIVE_COMPARATOR|Service as usual|246 nulliparous women will be recruited within several maternity wards. They will recieve the services they may request from (a) the maternities, (b) the maternal and child protection services (PMI, usually 1 or 2 home visit without any standards) or any other service available. They will be provided with the address and telephone of the closest maternity ward.
62301258|NCT01154413|EXPERIMENTAL|Intensive education of the doctor/nursing team on the protocol|
62301259|NCT01154413|NO_INTERVENTION|Without intervention in the team|
62301260|NCT05085210|EXPERIMENTAL|Computer Visual Training with Noninvasive Brain Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of tRNS with visual training on the computer
62301261|NCT05085210|EXPERIMENTAL|Visual Training with Sham Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of sham stimulation with visual training on the computer
61916317|NCT03989739||robotic distal pancreatectomy|
61916318|NCT03989739||laparoscopic distal pancreatectomy|
61916319|NCT02257671|ACTIVE_COMPARATOR|Oral contraceptive|oral dose of ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per day during 11 weeks
61916320|NCT02257671|PLACEBO_COMPARATOR|Placebo|Oral placebo capsule daily during 11 weeks
61916321|NCT02948101|EXPERIMENTAL|Treatment (PD 0360324, cyclophosphamide)|Patients receive anti-CSF1 monoclonal antibody anti-CSF1 monoclonal antibody PD 0360324 IV over 30 minutes on days 1, 8, 15, and 22. Starting on day 43, patients receive cyclophosphamide PO QD. Courses with cyclophosphamide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61916322|NCT02553954|EXPERIMENTAL|Collection of healthy skin tissue|Collection of healthy skin tissue
62301262|NCT05085210|EXPERIMENTAL|Noninvasive Brain Stimulation without visual training|10 daily (Monday-Friday) 20-30 minute sessions of tRNS alone
62301263|NCT05085210|SHAM_COMPARATOR|Sham Stimulation without visual training|Placebo control. Simulation of tRNS without receiving any actual stimulation
62301264|NCT05085210|EXPERIMENTAL|VR Visual Training with Noninvasive Brain Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of tRNS with visual training on the computer
62470725|NCT04779320|EXPERIMENTAL|Maintenance Period: ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
62470726|NCT04779320|EXPERIMENTAL|Maintenance Period: ≥30 kg: Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
62470727|NCT02059070|EXPERIMENTAL|0.125% Bupivacaine|Group 1) Post-operative 0.125% Bupivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
62470728|NCT02059070|EXPERIMENTAL|0.2% Ropivacaine|Group 2) Post-operative 0.2% Ropivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
62672518|NCT04383015|OTHER|Combo|The combination of a 50 percent basal rate reduction and carbohydrate dose of 0.3g/kg/hr (given every 30 minutes) both at exercise onset
62672519|NCT01560988|EXPERIMENTAL|Active Borage and Echium Seed Oils|Borage and echium oil capsules administered daily for six weeks, then a 6 week washout period, followed by ingestion of placebo (corn oil capsules) daily for 6 weeks.
62111116|NCT06319664||Sphenopetroclival Subtype II|The dural attachment of lesion entirely originates within the CS leading to CS region expansile hyperplasia with the virtually intact sinus wall, and part of lesion could spread into the petrous apex and posterior cranial fossa through posterior sinus wall; the large partial lesions may also encroach on the lateral wall of the CS expansion towards the middle cranial fossa. The lateral sinus wall is relatively smooth and maintains the dural space between the lesion and the temporal lobe on MRI.
62672520|NCT01560988|EXPERIMENTAL|Corn oil pills|Corn oil capsules daily for six weeks, then a 6 week washout period, followed by ingestion of Borage and echium oil capsules daily for 6 weeks.
62111117|NCT06319664||Central Skull Base type|The dural attachment originates from the petroclival fissure, but growth pattern is widespread invasion of central skull base region and structures bilaterally and the site of origin extensively involves in dorsum sellae, clivus and bilateral suprasellar, parasellar and CS areas even cerebellopontine angle region.
62111118|NCT05292638|EXPERIMENTAL|CKDB-501A|
62111119|NCT05292638|ACTIVE_COMPARATOR|Botox®|
62111120|NCT00877435|EXPERIMENTAL|1|Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
62301265|NCT01794780|EXPERIMENTAL|Indacaterol|LABA: Indacaterol, once a day, 150μg each time
62672521|NCT06185530|EXPERIMENTAL|Participants undergo the cardiac tests: stress echocardiography with carotid ultrasound|
62111121|NCT00877435|ACTIVE_COMPARATOR|2|Cognitive behavioral therapy (CBT)
62111122|NCT05328076||Surgical group|Patients who undergo thyroid surgery and receive indocyanine green angiography
62111123|NCT05603767|EXPERIMENTAL|RMT+ VR|The patient selects a video with the Oculus Quest headset and music to be played live.
62111124|NCT05603767|NO_INTERVENTION|Control|No intervention
62111125|NCT06189105|EXPERIMENTAL|experimental arm|"Use of facial serum with~niacinamide, plant-based collagen and~peptides on randomized site on forehead"
62111126|NCT06189105|PLACEBO_COMPARATOR|placebo comparator|"No treatment (usual~skincare rutine)"
62111127|NCT03898986|EXPERIMENTAL|MZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62111128|NCT03898986|EXPERIMENTAL|DZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62111129|NCT03745118|OTHER|Monitoring Device|Subjects will be asked to wear up to 4 different noninvasive seizure detection devices including EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv
62301266|NCT01794780|EXPERIMENTAL|Tiotropium Bromide|LAMA: Tiotropium Bromide, once a day, 18 μg
62301267|NCT01794780|EXPERIMENTAL|Salmeterol/Fluticasone|LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg
62672522|NCT06185530|ACTIVE_COMPARATOR|Participants undergo the cardiac test: CT coronary angiography|
62672523|NCT04772430|NO_INTERVENTION|Control group|The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure
62301268|NCT01794780|EXPERIMENTAL|Budesonide/ formoterol|Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg
62301269|NCT01794780|EXPERIMENTAL|Indacaterol +Tiotropium|Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg
62301270|NCT01794780|EXPERIMENTAL|LABA/ICS (Or budesonide/ formoterol)+ Tiotropium|Salmeterol / fluticasone Or budesonide / formoterol
62301271|NCT01794780|EXPERIMENTAL|Oral theophylline|
62301272|NCT01794780|EXPERIMENTAL|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
62301273|NCT02426866||Patient with Efavirenz exposure|Patient with Efavirenz exposure
62301274|NCT02426866||Patient without Efavirenz exposure|Patient without Efavirenz exposure
62301275|NCT00792766|EXPERIMENTAL|RAD001|
62301276|NCT04177030|EXPERIMENTAL|Group A-Morning First|Within the first week of the study, Group A will consume fruits and vegetables within time-restriction morning window (9am-12pm). Following washout week, Group A will consume fruits and vegetables within time-restriction night window (7pm-10pm) for one week.
62672524|NCT04772430|EXPERIMENTAL|Experimental group|The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure.
61916323|NCT01350544|NO_INTERVENTION|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
62111130|NCT04147416|EXPERIMENTAL|HSK3486|HSK3486 for Sedation
62111131|NCT04147416|ACTIVE_COMPARATOR|Propofol|Propofol for Sedation
62111132|NCT02887313|EXPERIMENTAL|Locally advanced rectal cancer|Locally advanced rectal cancer receiveing total neoadjuvant treatment
62111133|NCT01801930|EXPERIMENTAL|Dose level 1|
62111134|NCT01801930|EXPERIMENTAL|Dose level 2|
62111135|NCT01801930|EXPERIMENTAL|Dose level 3|
62111136|NCT01801930|EXPERIMENTAL|Dose level 4|
62111137|NCT04472806|EXPERIMENTAL|chemotherapy+Endostar+Toripalimab(JS001)|
62301277|NCT04177030|EXPERIMENTAL|Group B-Night First|Within the first week of the study, Group B will consume fruits and vegetables within time-restriction night window (7pm-10pm). Following washout week, Group B will consume fruits and vegetables within time-restriction morning window (9am-12pm) for one week.
62301278|NCT03240081|ACTIVE_COMPARATOR|50mcg estradiol cream|Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
62301279|NCT03240081|ACTIVE_COMPARATOR|100mcg estradiol cream|Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
62301280|NCT00661375|EXPERIMENTAL|Arm 1|
62301281|NCT06487403|ACTIVE_COMPARATOR|Arm 1: Integrated Boost Radiotherapy|External beam radiotherapy 70Gy in 35 fractions to head and neck tumour and 56 Gy in 35 fraction to elective nodal regions. This will be given as single integrated boost or two-phase treatment at clinician discretion.
62672525|NCT02722603|EXPERIMENTAL|gabapentin / placebo tramadol|gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.
62111138|NCT06227286|EXPERIMENTAL|EECP Arm|Participants would be assigned for treating with EECP initiated with 0.030 MPa, 30-45 minutes per day, 5 days per week, 7 weeks in total.
62111139|NCT06227286|SHAM_COMPARATOR|Sham-EECP Arm|Participants would be assigned for treating with Sham-EECP initiated with 70 mmHg, 30-45 minutes per day, 5 days per week, 7 weeks in total.
62111140|NCT04314830|ACTIVE_COMPARATOR|Gait training without perturbation|Walking on a treadmill with the same duration as a participants of the experimental arm matched for initial gait speed. Treadmill speed did not change along the training program
62301282|NCT06487403|ACTIVE_COMPARATOR|Arm 2: Two Phase Radiotherapy|Standard of care external beam radiotherapy 70 Gy in 35 fractions to head and neck with delayed 40 Gy in 20 fractions to elective nodal regions. This will be given as reversed two-phase treatment.
62301283|NCT01363050|EXPERIMENTAL|Ketorolac tromethamine|
62301284|NCT01586091|PLACEBO_COMPARATOR|Placebo|Placebo per os at time 0 hours + placebo per os at 12 hours.
62301285|NCT01586091|ACTIVE_COMPARATOR|Levocetirizin|Levocetirizin 5mg at time 0 and placebo per os at 12 hours
62301286|NCT01586091|ACTIVE_COMPARATOR|Fexofenadine|Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours
62301287|NCT01047410|NO_INTERVENTION|Usual care|Patients assigned to the usual care group receive the standard medical care (usual care) during the 15 months lasting study period. Physical training does not form a part of the usual care of renal transplant and dialysis patients. After randomisation, patients assigned to the usual care group receive the advice to meet the 'Nederlandse Norm Gezond Bewegen (NNGB), i.e. the advice to perform 30 minutes of moderately intense physical activity at at least five but preferably all days of the week.
62301288|NCT01047410|EXPERIMENTAL|Exercise intervention|The exercise intervention in this group is identical to the exercise-only group. Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
62470729|NCT04638452|OTHER|Epidemiology|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test Passing self and hetero questionnaires of temotion felt and perceived.
62672526|NCT02722603|ACTIVE_COMPARATOR|tramadol / placebo gabapentin|tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.
62672527|NCT00593645|EXPERIMENTAL|Arm 1: Non-myeloablative conditioning regimen|"* Clofarabine 40mg/m2/day IV over two hours daily x 5 days on Days -6 thru -2~* Cytarabine 1gm/m2/day IV over two hours daily x 5 days on Days -6 thru -2 after the START of Clofarabine.~* Thymoglobulin 1.0mg/kg IV over 6 hours X 1 day on Day -4, then 2.5mg/kg/day x 2 days on Days -3 and -2.~* Stem Cell Transplant - On day 0 a minimum of total CD34+ cell dose of 2 x10E6/kg (actual weight of recipient) will be infused."
62672528|NCT02137356|EXPERIMENTAL|treatment arm|standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
62470730|NCT05069961|ACTIVE_COMPARATOR|ESPB Group|20ml Ropivacaine is injected near the nerves in the back and then continued using an infusion pump.
62672529|NCT04942509|EXPERIMENTAL|Coloring|This group did mindful coloring for at least 5 days or at least 100 minutes in total during a 10-day period
62672530|NCT04942509|NO_INTERVENTION|Wait-list control|This group did not do mindful coloring at all during a 10-day period.
62672531|NCT05925855|EXPERIMENTAL|study Fastum|participant in this group will receive US with fastum gel
62672532|NCT05925855|EXPERIMENTAL|study Reparil|participant in this group will receive US with reparil gel
62672533|NCT05925855|ACTIVE_COMPARATOR|Control plain gel|participant in this group will receive US with gel
62672534|NCT02376335|ACTIVE_COMPARATOR|Rituximab infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
62672535|NCT02376335|PLACEBO_COMPARATOR|Placebo infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
62672536|NCT03831555|ACTIVE_COMPARATOR|PREP-C|The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.
62672537|NCT03831555|NO_INTERVENTION|Standard of care|Participants will receive the standard of care (usual care) for chronic HCV infection.
62672538|NCT04280861|EXPERIMENTAL|Intervention Group|The intervention group will participate in multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
62672539|NCT04280861|NO_INTERVENTION|Control Group|Usual clinical care,
62672540|NCT03569007|ACTIVE_COMPARATOR|Larazotide 0.25 mg|Larazotide 0.25 mg capsules TID
62672541|NCT03569007|ACTIVE_COMPARATOR|Larazotide 0.50 mg|Larazotide 0.50 mg capsules TID
62672542|NCT03569007|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules TID
62672543|NCT01292473|EXPERIMENTAL|Placebo|Placebo subcutaneously (sc) every 4 weeks
62672544|NCT01292473|EXPERIMENTAL|Omalizumab 75 mg|Omalizumab 75 mg sc every 4 weeks
62672545|NCT01292473|EXPERIMENTAL|Omalizumab 150 mg|Omalizumab 150 mg sc every 4 weeks
62672546|NCT01292473|EXPERIMENTAL|Omalizumab 300 mg|Omalizumab 300 mg sc every 4 weeks.
62672547|NCT01426646|EXPERIMENTAL|S-1 treatment|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
62672548|NCT01426646|EXPERIMENTAL|S-1 plus cisplatin treatment|"S-1 plus cisplatin every 3 weeks, A total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1"
62672549|NCT00621322|PLACEBO_COMPARATOR|Control Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the control GSK Biologicals' AS01B adjuvanted system, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
62470731|NCT05069961|ACTIVE_COMPARATOR|TEA Group|5ml Bupivacaine is injected into the space around the spinal cord and then continued using an infusion pump.
62470732|NCT02957318|EXPERIMENTAL|FiberBind|
62470733|NCT02957318|EXPERIMENTAL|RG-I fiber|
62470734|NCT02957318|PLACEBO_COMPARATOR|Placebo|
62672550|NCT00621322|ACTIVE_COMPARATOR|GSK692342_F1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the non-adjuvanted GSK692342 vaccine formulation 1 (F1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
62672551|NCT00621322|EXPERIMENTAL|GSK692342_F2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 2 (F2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
62672552|NCT00621322|EXPERIMENTAL|GSK692342_F3 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 3, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
62672553|NCT00621322|EXPERIMENTAL|GSK692342_F4D1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 1 (F4D1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
62672554|NCT00621322|EXPERIMENTAL|GSK692342_F4D2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 2 (F4D2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
62672555|NCT06064201|EXPERIMENTAL|Short-chain fatty acids (SCFAs)|SCFAs will be delivered directly to the colon using pH-dependent colon delivery capsules (CDCs).
62672556|NCT06064201|PLACEBO_COMPARATOR|Microcrystalline cellulose|Placebo capsules
62672557|NCT03954730|EXPERIMENTAL|Eccentric Training Group|Eccentric training will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
62301289|NCT01047410|EXPERIMENTAL|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
62672558|NCT03954730|ACTIVE_COMPARATOR|Active Release Technique Group|Active release technique will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
62672559|NCT03521336|EXPERIMENTAL|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
62672560|NCT03521336|PLACEBO_COMPARATOR|Control|Placebo: Sham operation, 10ml saline, once a month for 4 months
62111141|NCT04314830|EXPERIMENTAL|Gait training with perturbations|Walking on a treadmill with perturbations produced by changes in the speed of one of the belt of the split-belt treadmill during one gait cycle. Changes in treadmill speed were applied on the paretic or non-paretic side, with and increase or a decrease of the speed of the belt in various magnitude. Perturbations were either repeated with the same characteristics or with different characteristics. Outside of perturbations, treadmill speed did not change along the training program.
62111142|NCT03168191|EXPERIMENTAL|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
62111143|NCT03168191|EXPERIMENTAL|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
62111144|NCT03168191|PLACEBO_COMPARATOR|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
62111145|NCT01450072|SHAM_COMPARATOR|Control arm|Venography and sham angioplasty
62111146|NCT01450072|ACTIVE_COMPARATOR|Active arm|therapeutic balloon angioplasty
62301290|NCT04756544|EXPERIMENTAL|Depressive Disorders + probiotic|
62470735|NCT04899089|EXPERIMENTAL|Video Game Training Condition|Participants complete an 8 week long computerized cognitive training intervention. Participants play the games for 45 minutes, three times per week.
62111147|NCT05578352|ACTIVE_COMPARATOR|Oral hyppoglycemia drug group|Oral hyppoglycemia drugs, including metforemin, acarbose, dipeptidyl peptidase 4 inhibitors, or SGLT2-ihibitors, are added to reduce insulin dose.
62111148|NCT05578352|ACTIVE_COMPARATOR|GLP-1RA group|Add GLP-1 receptor agonists to reduce insulin dose.
62111149|NCT05578352|ACTIVE_COMPARATOR|long-acting insulin group|Change premix insulin to long-acting insulin plus oral hyppoglycemia drugs
62111150|NCT05578352|NO_INTERVENTION|Control group|continue the present premix insulin treatment, adjust insulin dose according to the bloog glucose profile in FGM to improve glycemic control.
62111151|NCT04327063|PLACEBO_COMPARATOR|Placebo|Saline (30 mL maximum)
62111152|NCT04327063|EXPERIMENTAL|Ropivacaïne|Ropivacaïne 5 mg/mL (not to exceed 3 mg/kg and 30 ml of maximal volume)
62111153|NCT00882882|EXPERIMENTAL|1|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
62111154|NCT00882882|EXPERIMENTAL|2|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
62111155|NCT00882882|ACTIVE_COMPARATOR|3|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
62111156|NCT00882882|ACTIVE_COMPARATOR|4|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
62111157|NCT06521892|EXPERIMENTAL|intervention group|Participants in intervention group will receive social supervision and health education interventions.
62111158|NCT06521892|NO_INTERVENTION|control group|Participants in control group will receive routine drug supervision and management measures.
62301291|NCT04756544|PLACEBO_COMPARATOR|Depressive Disorders + placebo|
62301292|NCT04756544|EXPERIMENTAL|Depressive disorder + metabolic syndrome + probiotic|
62301293|NCT04756544|PLACEBO_COMPARATOR|Depressive disorder + metabolic syndrome + placebo|
62470736|NCT04899089|ACTIVE_COMPARATOR|Trivia Training Condition|Participants complete an 8 week long computerized trivia training. Participants complete the trivia training for 45 minutes, three times per week.
62111159|NCT06554431|EXPERIMENTAL|Art Making|Each patient will receive artmaking kits
62111160|NCT03369587|EXPERIMENTAL|Diverging lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
62301294|NCT04751500|EXPERIMENTAL|Outpatient Hysteroscopy|Outpatient hysteroscopic morcellation of retained products of conception
62301295|NCT04751500|ACTIVE_COMPARATOR|Standard Treatment|Standard treatment of retained products of conception in the form of expectant management, medical management, antibiotic therapy and/or surgical management (manual vacuum aspiration/suction curettage/dilatation and curettage)
62470737|NCT03678844|EXPERIMENTAL|Taekwondo practice|
62470738|NCT03678844|PLACEBO_COMPARATOR|CONTROL|
62672561|NCT00676637||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
62301296|NCT05917886|ACTIVE_COMPARATOR|Monaural beat stimulation|20 min sound recording of 8Hz monaural beat
62672562|NCT00977873|ACTIVE_COMPARATOR|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
62111161|NCT03369587|ACTIVE_COMPARATOR|Parallel lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
62111162|NCT04471467||group F|Using tracheal tube fixation method （According to the needs of the surgery, the surgeon who did not participate in the trial）
62111163|NCT04471467||group N|No tracheal tube fixation （According to the needs of the surgery, the surgeon who did not participate in the trial）
62111164|NCT02021760|ACTIVE_COMPARATOR|Remote Ischemic per-postconditioning|Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if \>180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
62111165|NCT02021760|SHAM_COMPARATOR|Sham|"The sham procedures include application of the cuff around the thigh but it is not inflated.~Otheriwize normal primary PCI."
62111166|NCT06114342||HC group|There were 50 healthy control participants in the HC group.
62111167|NCT06114342||MDD group|There were 84 MDD patients in the MDD group. 50 MDD subjects were enrolled at each acupoint for each test.
62111168|NCT00241423|EXPERIMENTAL|Exenatide|Exenatide and the subject's current oral antidiabetic agent regimen
62111169|NCT00241423|PLACEBO_COMPARATOR|Placebo|Placebo and the subject's current oral antidiabetic agent regimen
62111170|NCT03838796|ACTIVE_COMPARATOR|lenvatinib|use lenvatinib after liver resection in HCC patients
62111171|NCT03838796|ACTIVE_COMPARATOR|lenvatinib and TACE|use lenvatinib and TACE after liver resection in HCC patients
62111172|NCT05312866|ACTIVE_COMPARATOR|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
62111173|NCT05312866|ACTIVE_COMPARATOR|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
62111174|NCT02704819|EXPERIMENTAL|Non-specialist doctor +DSS|"Patients allocated to +DSS group will receive the following intervention:~* V1: appointment with a non-specialist doctor with the support of the DSS~* V2: appointment with an overseeing expert~* V3: DSS Customised Vestibular Physiotherapy~* V4: follow-up visit with the overseeing expert"
62111175|NCT02704819|ACTIVE_COMPARATOR|Non-specialist doctor -DSS|"Patients allocated to -DSS group will receive the following intervention:~* V1: appointment with a non-specialist doctor without the support of the DSS~* V2: appointment with an overseeing expert~* V3: Standard Physiotherapy Practice~* V4: follow-up visit with the overseeing expert"
62111176|NCT04364269|EXPERIMENTAL|VIT-2763 Once a day (QD)|"Participants will be assigned to receive VIT-2763 once a day (QD) in a total daily dose of 60 mg or 120 mg depending on their body weight.~The study medication (VIT-2763 and/or matching placebo) will be administered for all participants twice a day to maintain the blind."
62111177|NCT04364269|EXPERIMENTAL|VIT-2763 Twice a day (BID)|Participants will be assigned to receive VIT-2763 Twice a day (BID) in a total daily dose of 60 mg or 120 mg depending on their body weight.
62111178|NCT04364269|PLACEBO_COMPARATOR|Placebo|Participants will be assigned to receive Placebo, Twice a day.
62470739|NCT03290820|ACTIVE_COMPARATOR|Controlled Group|The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
62672563|NCT00977873|PLACEBO_COMPARATOR|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
62111179|NCT02294929|OTHER|Atrial fibrillation ablation|Cryoballoon ablation for pulmonary vein isolation
62111180|NCT02950194||PPAWI|patients with multidisciplinary PPAWI approach
62301297|NCT05917886|SHAM_COMPARATOR|Control|20 min sound recording of 220Hz pure sine wave
62301298|NCT01662999|EXPERIMENTAL|A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)|Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
62470740|NCT03290820|EXPERIMENTAL|Experimental Group|The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
62672564|NCT04725981|EXPERIMENTAL|Arm A (test surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0 and 1 continuous suture with V-Loc 2-0
62672565|NCT04725981|ACTIVE_COMPARATOR|Arm B (control surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0
62672566|NCT00429455||Survey Participants|Female patients who had a hematopoietic stem cell transplantation between January 1987 and September 2004 at M. D. Anderson Cancer Center.
62111181|NCT00580437|EXPERIMENTAL|Arm 1|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
62111182|NCT04878328|EXPERIMENTAL|onsite Point-of-care (o-POC)|CHWs will reach out to participants to schedule O-PoC visits. At O-PoC visits, CHWs will provide: 1. COVID-19 education; 2. PoC Cepheid XpertXpressSARS-CoV-2PCR tests; 3. Needs assessments and facilitated access to masks and hygiene supplies; 4. Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5. Supportive counseling. Due to SCT's emphasis on social influence, external and internal social reinforcement, we propose our O-PoC intervention delivered by CHWs onsite at Fortune locations over a 12-month period will lead to increased uptake of mitigation behaviors.
62301299|NCT01662999|EXPERIMENTAL|A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin|Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
62672567|NCT01104298|ACTIVE_COMPARATOR|Arm A|"Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
62301300|NCT01662999|EXPERIMENTAL|B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
62301301|NCT01662999|EXPERIMENTAL|B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
62470741|NCT01215981|ACTIVE_COMPARATOR|Participants Receiving 1 Dose of Vaccine|"Control group participants (healthy volunteers):~* Age 18 to 50 years~* No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~* No flu vaccine in previous 4 months~and/or HSCT recipients who are greater than 60 days post transplant."
62470742|NCT01215981|ACTIVE_COMPARATOR|Participants Receiving 2 Doses of Vaccine|Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.
62470743|NCT04908007||Professional qualitative group|Qualitative analysis of crisis management by interviewing professionals most involved during the crisis in each university hospital.
62672568|NCT01104298|EXPERIMENTAL|Arm B|"Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.~Route of administration: for intravenous use after reconstitution and further dilution.~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
62672569|NCT03280030|EXPERIMENTAL|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
62672570|NCT03280030|PLACEBO_COMPARATOR|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
62111183|NCT04878328|NO_INTERVENTION|Standard of Care (SOC)|The current standard of care (SoC) for SARS-CoV-2 testing for Fortune clients is referral to offsite community testing sites and informal, unstructured education. In the SoC arm, Fortune staff will provide clients with a list of offsite SARS-CoV-2 testing locations, which are published online and available to all NYC residents. Those without insurance are not subject to a copay. Participants in SoC will continue to receive Fortune's suite of services as they are delivered (remote and/or in-person) at the time of study participation.
62111184|NCT02930590|EXPERIMENTAL|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
62672571|NCT02403778|ACTIVE_COMPARATOR|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
62672572|NCT02403778|EXPERIMENTAL|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
62672573|NCT01346709||In-patient Adult Non-obstetricSurgical|"Consecutive patients admitted to participating centres undergoing surgery Non-obstetric in-hospital surgical procedure, elective or emergent, under general anaesthesia (alone or in combination with regional/neuraxial anaesthesia), neuraxial anaesthesia or plexus block (with and without sedation).~All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible."
62672574|NCT03683901|EXPERIMENTAL|TENS/t-NMES/No stimulation|TENS stimulation parameters were of a symmetric waveform, a frequency of 100 Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #7) applied for 10 seconds. t-NMES parameters were a symmetric waveform with 2 second ramp-up and 2 second ramp-down, a frequency of 35Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #3). The t-NMES current intensity was set by adjusting the amplitude to yield the strongest contraction of the underlying muscles without initiating pain. Device and electrodes remained in place but no stimulation was delivered over the 10 second interval. Exposed to each stimulation 3 times for each shoulder ROM.
62672575|NCT01823887|EXPERIMENTAL|Left Sided Stimulation|Left cervical Vagus Nerve Stimulation (VNS)
62672576|NCT01823887|EXPERIMENTAL|Right Sided Stimulation|Right Cervical Vagus Nerve Stimulation (VNS)
62111185|NCT02930590|EXPERIMENTAL|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
62111186|NCT02930590|ACTIVE_COMPARATOR|Standard mattress|basic foam
62111187|NCT00942058||CA9 level|Serum and urinary CA9 level
62111188|NCT01606995||Group 1|
62111189|NCT01194778|PLACEBO_COMPARATOR|placebo|The participants of the placebo group will receive daily 1 placebo sachet containing only sucrose
62301302|NCT01662999|EXPERIMENTAL|C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
62111190|NCT01194778|ACTIVE_COMPARATOR|vitamin K1|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K1.
62111191|NCT01194778|ACTIVE_COMPARATOR|vitamin K2 - 15 µg|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K2
62111192|NCT01194778|ACTIVE_COMPARATOR|vitamin K2 - 30 µg|The participants of this group will receive daily 1 sachet containing 30 µg vitamin K2
62111193|NCT01194778|ACTIVE_COMPARATOR|vitamin K2 - 45 µg|The participants of this group will receive daily 1 sachet containing 45 µg vitamin K2.
62111194|NCT03107286||Tc-99m MAG3|Children ages 1-6 years old will be eligible to participate. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
62111195|NCT01080131|EXPERIMENTAL|Canakinumab 150 mg|"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to receive open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year, for a total duration of 18 months."
62301303|NCT01662999|EXPERIMENTAL|C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
62470744|NCT04908007||Professional quantitative group|Quantitative analysis of crisis management using the WHO grid adapted sent to the target persons identified within the establishments
62470745|NCT04908007||Patient quantitative group|Quantitative analysis of crisis management using a questionnaire sent to patients hospitalized in the first wave asking them about their perception of crisis and post-crisis management.
62672577|NCT00710957||CHS All Stars|CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n\~1100).
62672578|NCT04941365|EXPERIMENTAL|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
62672579|NCT04933058|EXPERIMENTAL|Opioid-free anesthesia|"1. IV propofol 1-1.5 mg/kg~2. IV acetaminophen 1000mg~3. IV dipyrone 1000mg~4. IV lidocaine 1mg/kg~5. IV dexacort 4mg~6. PR diclofenac 50 mg"
62672580|NCT04933058|ACTIVE_COMPARATOR|Opioid-supplemented anesthesia|"1. IV propofol 1-1.5 mg/kg~2. IV fentanyl 1.5 mcg/kg~3. IV dipyrone 1000mg~4. IV lidocaine 1mg/kg~5. IV dexacort 4mg~6. PR diclofenac 50 mg"
61916324|NCT01350544|EXPERIMENTAL|treatment advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.
61916325|NCT01115582|EXPERIMENTAL|Cholic Acid Capsule|Manufactured cholic acid capsules
62111196|NCT01080131|ACTIVE_COMPARATOR|Triamcinolone acetonide 40 mg|"Participants received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to switch to open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year. Triamcinolone acetonide was not to be administered in the second extension study."
62301304|NCT00003789|EXPERIMENTAL|Arm I|Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.
62672581|NCT02669108|OTHER|PET/MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
62301305|NCT00003789|EXPERIMENTAL|Arm II|Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.
62301306|NCT05004675|EXPERIMENTAL|lerodalcibep|300 mg SC dosed monthly
62301307|NCT05004675|ACTIVE_COMPARATOR|inclisiran|284 mg SC dosed Day 1 and Day 90
62301308|NCT00874380||1|First describe the diet of a cohort of dialysis patients with focus on fiber content.
62301309|NCT06657482|EXPERIMENTAL|Delayed school start times on Mondays and Tuesdays (intervention condition)|Two hour delay in school start time on Mondays and one hour delay on Tuesdays. Ordinary school start time (8:15 ± 15 min) for the rest of the week.
62470746|NCT04908007||Tools development|Development of tools to prepare for situations of uncertainty
62470747|NCT05681130||1 women attending IVF programme|Women attending to IVF programme will be evaluated for pscyhological parameters before and after the precedure
62470748|NCT05681130||2 partners of women attending to IVF programme|Men who are partners of women attending to IVF programme will be evaluated for pscyhological parameters before and after the precedure
62736066|NCT01794507|EXPERIMENTAL|ABT-199 + BTZ/Dex Safety Expansion Cohort|Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.
62736067|NCT01014572|EXPERIMENTAL|Aerobic Exercise Training + Placebo|
62736068|NCT01014572|EXPERIMENTAL|Tai Chi and/or Yoga Training + Placebo|
62111197|NCT06353958||Low|Low dosage of MiSaver cells at 0.5x10\^7 cells/kg
62111198|NCT06353958||Middle|Middle dosage of MiSaver cells at 1.6x10\^7 cells/kg
62111199|NCT01603719|NO_INTERVENTION|Standard Formula|Standard formula with no supplementation
62111200|NCT01603719|EXPERIMENTAL|experimental formula|infant formula with higher beta-palmitate and supplemented GOS
62111201|NCT04027972|EXPERIMENTAL|Primary|6 Subjects will receive all 4 types of medication administration in random sequence
62111202|NCT02215278|EXPERIMENTAL|low phytic acid bean (lpa variety)|
62111203|NCT02215278|EXPERIMENTAL|high iron biofortified bean variety|
62111204|NCT02215278|EXPERIMENTAL|normal iron, normal phytic acid bean|
62111205|NCT04209049|EXPERIMENTAL|Normal renal function|All subjects will receive one dose of NNC0174-0833.
62111206|NCT04209049|EXPERIMENTAL|Mild renal impairment|All subjects will receive one dose of NNC0174-0833.
62111207|NCT04209049|EXPERIMENTAL|Moderate renal impairment|All subjects will receive one dose of NNC0174-0833.
62111208|NCT04209049|EXPERIMENTAL|Severe renal impairment|All subjects will receive one dose of NNC0174-0833.
62672582|NCT02822755|EXPERIMENTAL|Video Recording Group|The experimental group participants will be recorded on their personal smartphone performing their prescribed exercises with individualized instruction from the participating physical therapist. The prescribing therapist will record participants on their own smartphones doing the exercise program in the clinic so that participants can have that video recording of the exercises to help remind them how to do the exercises properly at home. Participants will not be asked to record themselves performing future exercise sessions as documentation of improvement. Intervention: Home Exercise Program and Adherence Logs
62672583|NCT02822755|ACTIVE_COMPARATOR|Conventional Printed Group|The active comparator group will receive individualized instruction from the participating physical therapist on how to perform their home exercise program as well as printed instructions of the exercises. No video recording of the control group participants will be performed. Intervention: Home Exercise Program and Adherence Logs
62672584|NCT02525731||Patient Cohort|The TEACH patient cohort component will establish an observational cohort of HIV-infected patients on chronic opioid therapy.
62672585|NCT03940092||Healthy Volunteers|Healthy volunteers will be scheduled for an 23Na-MR examination
62672586|NCT03940092||Breast cancer patients (primary surgery)|Patients scheduled for primary surgery will undergo a single MR examination, involving 23Na-imaging prior to their planned surgery.
62672587|NCT03940092||Breast cancer patients (neoadjuvant chemotherapy)|Patients undergoing neo-adjuvant therapy will undertake up to two (2) combined PET/MR examinations with FDG. Examinations will be conducted at baseline and after 3-4 cycles of chemotherapy.
62672588|NCT00682435|EXPERIMENTAL|Hydromorphone|1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
62111209|NCT03091712|EXPERIMENTAL|Paper Titration Tool and Glooko MIDS|"Glooko mobile insulin dosing system(MIDS), using the STEP WISE degludec titration algorithm.~The eligible subjects will be started on insulin degludec (Tresiba® U-200 FlexTouch®). Subjects will use MIDS for insulin degludec titration management. The clinician will configure MIDS Prescription Instruction Form(PIF) using pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program. The Clinician can alter this as appropriate based on medical judgment. Subjects will be started on MIDS and trained on use of Glooko MIDS mobile app. Subjects will get dose adjustment check up on the app and also alert to contact physician if subject experiences hyperglycemia or hypoglycemia."
62111210|NCT03091712|NO_INTERVENTION|Paper Titration tool|"Usual care for insulin degludec (Tresiba® U-200 FlexTouch® pens) titration using the STEP WISE degludec titration algorithm.The eligible subjects will be started on insulin degludec(Tresiba® U-200 FlexTouch®).~Subjects in this group will be provided with a one-page description of the pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program and how to follow it. The Clinician can alter this as appropriate based on medical judgment. This document will also include instructions to contact the HCP if the subject experiences hyperglycemia or hypoglycemia."
62111211|NCT00395018|EXPERIMENTAL|entecavir|
62111212|NCT03960619|EXPERIMENTAL|in-person & mHealth coping skills training|hybrid in-person and mHealth coping skills training and activity coaching intervention is to reduce physical disability and decrease pain, fatigue and stress while enhancing patients' abilities to cope with symptoms that interfere with activity.
62111213|NCT02504619|EXPERIMENTAL|CordIn|Transplantation of CordIn
62672589|NCT05865249|NO_INTERVENTION|Control|In participants randomised to the control group, the primary care referrer will receive the spirometry report plus any additional information as per local spirometry pathway. The primary care referrer will not receive an interpretation and quality assessment report generated by ArtiQ.Spiro.
62672590|NCT05865249|OTHER|Intervention|In participants randomised to the intervention group, the primary care referrer will receive the spirometry report plus any additional information as per local spirometry pathway plus an interpretation and quality assessment report generated by ArtiQ.Spiro.
62736069|NCT01014572|EXPERIMENTAL|Aerobic Exercise Training + Alagebrium|
62111214|NCT06237062||adult migraine patients|adult migraine patients across the 4 Gulf Countries (UAE, Qatar, Oman and Kuwait)
62111215|NCT01185522||Tocilizumab|Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months
62470749|NCT03702218|EXPERIMENTAL|Hep C Ab + NAT - Donor to Naïve Recipient|"HCV Ab and HCV NAT testing at 3 days, week 1, week 2 and monthly for 3 months, at 6 months and 1 year. In approximately 16% of the patients, active hepatis C infection will ensue. For these patients, treatment is as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30"
62672591|NCT04595812|ACTIVE_COMPARATOR|Misoprostol group|receive two tablets of 200µg misoprostol (Pfizer Limited, United Kingdom) administered into the posterior fornix of the vagina 1 hour before the onset of surgery
62470750|NCT03702218|EXPERIMENTAL|Hep C Ab+ NAT+ Donor to Naïve Recipient|"HCV RNA levels, liver biochemistries, and renal function will be measured 3 days after transplant. HCV Genotype will be determined after HCV RNA is \>1,000 IU/mL. HCV RNA levels will be measured weekly after transplant until HCV treatment is initiated.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30"
62470751|NCT03702218|ACTIVE_COMPARATOR|Hep C Ab- NAT - Donor to Naïve Recipient|Current standard of care for donor recipient infectious disease matching. No treatment necessary
62470752|NCT03837249|PLACEBO_COMPARATOR|Passive Personal Sleep Monitoring|Wears personal sleep monitor but does not actively self-monitor (will have access to the sleep data and self-monitoring after 4 weeks).
62470753|NCT03837249|ACTIVE_COMPARATOR|Individual Personal Sleep Monitoring|Wears personal sleep monitor and actively self-monitoring sleep and using data to self-manage sleep.
62470754|NCT03837249|ACTIVE_COMPARATOR|Socially Supported Sleep Monitoring|Wears a personal sleep monitor, actively self-monitoring using sleep data to self-manage sleep and shares data for supportive self-management.
62672592|NCT04595812|ACTIVE_COMPARATOR|Oxytocin group|After induction of general anaesthesia and immediately prior to the operation, an infusion of 30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h will be started during myomectomy.
62672593|NCT04595812|EXPERIMENTAL|Carbetocin group|receive 100 μg IV Carbetocin (1ml) \[Pabal, Ferring (UK)\] in 5 ml saline over 1 minute just before skin incision
62672594|NCT04595812|ACTIVE_COMPARATOR|pericervical tourniquet group|pericervical tourniquet using a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision.
62672595|NCT00795405|SHAM_COMPARATOR|1|No exposure to sporting events
62672596|NCT00795405|EXPERIMENTAL|2|Exposure to sporting events
62672597|NCT03028922|OTHER|creos xenogain|Patients in need of bone augmentation prior to implant insertion will undergo GBR procedure using Creos xenogain bone graft substitute
62672598|NCT05264584|OTHER|control arm|This arm is consisted of 60 patients.They will receive IV hydration and N-acetylcysteine (control arm).
62672599|NCT05264584|EXPERIMENTAL|Febuxostat arm|This arm is consisted of 60 patients.They will receive IV hydration, N-acetylcysteine and Febuxostat .
62672600|NCT06539663|EXPERIMENTAL|Treatment of Corneal Perforation|"All patients were prescribed Fortified Vancomycin (50mg %) and Fortified Fortum (50mg %) antibiotic eye drops for initial exposure keratitis with corneal infiltration. Then treatment was modified according to culture and sensitivity results.~Subsequent corneal perforation developed for which OmniLenz® was applied in all patients for 1 week."
62672601|NCT02849223|EXPERIMENTAL|Transcranial Direct Current Stimulation|Participants will receive 24 sessions (3 times a week) of anodal transcranial direct current stimulation concurrent with working memory training. Stimulation will be administered at 2 milliamps (mA) for 20 minutes over the left dorsal lateral prefrontal cortex.
62672602|NCT02849223|SHAM_COMPARATOR|Sham|Participants will receive 24 sessions of working memory training. The experience of transcranial direct current stimulation will be simulated by administering 30 seconds of stimulation at the beginning of the session.
62672603|NCT04033757||Sub-cohort 1|1,469 participants were enrolled in 2015. Three follow-ups have been completed in 2016, 2017, and 2020. They will be asked to participate in follow-up in 2023 and 2026.
62672604|NCT04033757||Sub-cohort 2|1,267 participants were enrolled in 2018. They will be asked to participate in follow-up in 2021, 2024, 2027, and 2030.
62672605|NCT04033757||Sub-cohort 3|1,340 participants were enrolled in 2019. They will be asked to participate in follow-up in 2022, 2025, 2028, and 2031.
62672606|NCT01939275|EXPERIMENTAL|Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)|Patients receive copper Cu 64-DOTA-trastuzumab IV on day 1 and then undergo PET/CT scan on days 2 or 3.
62111216|NCT06182319|EXPERIMENTAL|SBO treated without NG tube|Patients who decline NG intubation will be enrolled in the trial, followed prospectively and have the same outcome measures as are acquired in the other study arms.
62111217|NCT06182319|EXPERIMENTAL|SBO treated with NG tube and Water-Soluble Contrast (WSC)|Patients who select NG tube treatment will be randomized into experimental and control groups. The experimental groups will have 100 cc of WSC administered in the NG tube within 2 hours of NG tube placement.
62111218|NCT06182319|PLACEBO_COMPARATOR|SBO Treated with NG tube and Placebo|The control group will have 100cc of saline administered via the NG tube within 2 hours of NG tube placement.
62111219|NCT03987451|EXPERIMENTAL|Semaglutide|Dose escalation to 2.4 mg of semaglutide once-weekly
62111220|NCT03987451|PLACEBO_COMPARATOR|Placebo|Semaglutide placebo once-weekly
62111221|NCT02945267|EXPERIMENTAL|Nimotuzumab plus S1|Nimotuzumab Injection:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area\<1.5 m2) or 60mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
62111222|NCT02945267|ACTIVE_COMPARATOR|Placebo plus S1|Placebo:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
62672607|NCT03055221|EXPERIMENTAL|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
62672608|NCT06426576|OTHER|Control group|The control group receives instructions on partial weight bearing using the standard method.
62736070|NCT01014572|EXPERIMENTAL|Tai Chi and/or Yoga Training + Alagebrium|
62470755|NCT02909907|EXPERIMENTAL|150 units of abobotulinumtoxinA|150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis \[FCR\] and 75 units in flexor carpi ulnaris \[FCU\]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
62111223|NCT01863004|EXPERIMENTAL|Bortezomib (Velcade®)|"This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.~Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period."
62111224|NCT02286999|EXPERIMENTAL|B.infantis|Infants in the experimental arm will have two doses of the probiotic Bifidobacterium longum subsp. infantis (B. infantis) on Day 7 and Day 14 of life.
62111225|NCT02286999|PLACEBO_COMPARATOR|Placebo|Infants in the experimental arm will have two doses of placebo (powdered maltodextrin) on Day 7 and Day 14 of life.
62111226|NCT03899818|OTHER|new generation DEB|drug-eluting balloon (DEB)
62672609|NCT06426576|EXPERIMENTAL|Intervention group|The intervention group receives instructions on partial weight bearing using a plantar pressure sole inserted into the shoe that measures the force/weight applied to the foot and indicates the applied weight to the patient both visually and acoustically via a smartphone app.
62111227|NCT03899818|OTHER|second generation DES|standard therapy with second generation drug-eluting stent (DES)
62111228|NCT05190913|EXPERIMENTAL|Initiative group I|In the active phase of labor, perineal massage will be performed with the device at an interval of one hour.
62111229|NCT05190913|EXPERIMENTAL|Initiative group II|During the active phase of labor, manual perineal massage will be performed with an interval of one hour.
62301310|NCT06657482|NO_INTERVENTION|Ordinary school start time all weekdays (control condition)|Ordinary school start time (8:15 ± 15 min) all school days
62111230|NCT03736005||General ICU admissions|Non- major trauma ICU admission Exposure to significant period of critical illness
62111231|NCT03736005||Major Trauma admissions|Exposure to Major Trauma Exposure to significant period of critical illness
62301311|NCT06657209|OTHER|Normal weight controls|Control
62672610|NCT00803907|EXPERIMENTAL|nodular BCC of the eyelid|Patients with nodular BCC of the eyelid
62672611|NCT06433011|EXPERIMENTAL|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
62672612|NCT01047397|EXPERIMENTAL|Group 1|Active Drug
62672613|NCT01047397|PLACEBO_COMPARATOR|Group 2|Placebo
62672614|NCT04817579|ACTIVE_COMPARATOR|Conventional visual shade matching|Patients requiring single crown in the esthetic zone treated with Conventional visual shade matching (Ivoclar Classic shade guide)
61916326|NCT06067659|EXPERIMENTAL|Group A: Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
61916327|NCT06067659|EXPERIMENTAL|Group B: Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
61916328|NCT06067659|EXPERIMENTAL|Group C: Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
61916329|NCT01230775|EXPERIMENTAL|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
61916330|NCT01230775|PLACEBO_COMPARATOR|Placebo|"Week 1:~1. x1 tablet/d of Placebo will be administered in week 1.~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
61916331|NCT05634356|EXPERIMENTAL|Experimental|Parents are instructed to say nonsense words in response to infant babbles with a conserved phonological form as infant plays.
61916332|NCT05634356|NO_INTERVENTION|Control|Parents are instructed to say nonsense words at random times with a conserved phonological form as infant plays.
61916333|NCT00672204|EXPERIMENTAL|1|Allogeneic islets of Langerhans
62672615|NCT04817579|EXPERIMENTAL|Spectrophotometer|Patients requiring single crown in the esthetic zone treated with Spectrophotometer (Vita Easy Shade)
62470756|NCT02909907|EXPERIMENTAL|75 units of abobotulinumtoxinA|75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
62470757|NCT03756259|OTHER|Pneumonia perception arm|Caregivers of children under five will be interviewed qualitatively to understand in depth on perception of pneumonia. These will be mothers, fathers and grandmothers of these children. Once the formative research is done, it will inform design of an intervention whereby the caregivers will be recruited to be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject. The LHWs will also be trained on pneumonia case finding which they will manage at their end and refer if required while doing daily field visits.
62672616|NCT04817579|EXPERIMENTAL|Digital photography combined with eLABor_aid shade analyzing software.|Patients requiring single crown in the esthetic zone treated with Digital photography combined with eLABor_aid shade analyzing software.
62672617|NCT05192083|EXPERIMENTAL|Intervention group|The intervention group will receive a smartphone-based self-management support programme, including a 30-min face-to-face or online session at baseline, 3 phone calls (week 2, week 4 and week 6) and 2-month mobile messages in addition to usual care.
62672618|NCT03270241|EXPERIMENTAL|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
62111232|NCT04232592|EXPERIMENTAL|Stem cell preparation solution injection group|The solution of stem cells preparation will be injected.
62111233|NCT04232592|EXPERIMENTAL|Injected stem cell group|The stem cells will injected.
62672619|NCT03384485|OTHER|antiphospholipid syndrome|blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease
62672620|NCT06329297||Open-heart surgery inpatients|Patients having elective open-heart surgery including coronary artery bypass grafting (CABG), aortic valve repair/replacement (AVR), mitral valve repair/replacement (MVR), or any combination of those will have a CGM monitor placed within one hour of admission for up to 7 days or upon discharge.
62672621|NCT06329297||General medical inpatients|Medical inpatients who have a Glucommander order for management of hyperglycemia will have a CGM monitor placed within 24 hours of admission for up to 7 days or upon discharge.
62111234|NCT00094185||General|No intervention
62111235|NCT03545984|EXPERIMENTAL|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
62111236|NCT03545984|ACTIVE_COMPARATOR|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
62470758|NCT02303405|EXPERIMENTAL|Hydroxychloroquine|Treatment with hydroxychloroquine 400 mg (2 x 200 mg tablets) po once daily x 4 months
62111237|NCT02580448|EXPERIMENTAL|Female Triple Negative Breast Cancer Patients|TNBC Patients - Enrollment is complete in this cohort
62111238|NCT02580448|EXPERIMENTAL|Female Estrogen Receptor (+) Breast Cancer Patients|Female ER(+) BC Patients - Enrollment is complete in this cohort
62111239|NCT02580448|EXPERIMENTAL|Male Breast Cancer Patients|Locally advanced or metastatic males with BC
62111240|NCT00408928|EXPERIMENTAL|Bortezomib for Treatment of GHVD|To determine if bortezomib (VELCADE®) will successfully inhibit T-cell responses in clinically acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
62470759|NCT02303405|ACTIVE_COMPARATOR|Pioglitazone|Treatment with pioglitazone 45 mg po (1 tablet) once daily x 4 months
62672622|NCT05099211|EXPERIMENTAL|Patients muscle strengthening|
62672623|NCT05099211|EXPERIMENTAL|Aerobic Training Patients|
62111241|NCT01253226|EXPERIMENTAL|30 milligrams (mg) Tabalumab|30 mg tabalumab every 4 weeks (Q4W) for 20 weeks (6 doses of study drug)
62111242|NCT01253226|EXPERIMENTAL|60 mg Tabalumab|60 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
62111243|NCT01253226|EXPERIMENTAL|120 mg Tabalumab|120 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
62111244|NCT01253226|PLACEBO_COMPARATOR|Placebo Q4W|Q4W for 20 weeks
62672624|NCT05099211|ACTIVE_COMPARATOR|Healthy patients|
62672625|NCT00502515|EXPERIMENTAL|25 mg SSR180575|orally once daily for 24 weeks
62672626|NCT00502515|EXPERIMENTAL|100 mg SSR180575|orally once daily for 24 weeks
62672627|NCT00502515|PLACEBO_COMPARATOR|Placebo|orally once daily for 24 weeks
62672628|NCT00211900|EXPERIMENTAL|vaccine|single dose of StaphVAX in hemodialysis patients
62111245|NCT01253226|EXPERIMENTAL|120 mg once every 2 weeks (Q2W) Tabalumab|Initial loading dose of 240 mg tabalumab followed by 120 mg Q2W for 20 weeks (10 doses of study drug)
62111246|NCT01253226|PLACEBO_COMPARATOR|Placebo Q2W|Q2W for 20 weeks
62111247|NCT04487236|EXPERIMENTAL|ZN-A-1041 50mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
62111248|NCT04487236|EXPERIMENTAL|ZN-A-1041 100mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
62111249|NCT04487236|EXPERIMENTAL|ZN-A-1041 200mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
62111250|NCT04487236|EXPERIMENTAL|ZN-A-1041 400mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
62111251|NCT04487236|EXPERIMENTAL|ZN-A-1041 600mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
62111252|NCT04487236|EXPERIMENTAL|ZN-A-1041 800mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
62111253|NCT04487236|EXPERIMENTAL|ZN-A-1041 1000mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
62111254|NCT04487236|EXPERIMENTAL|ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.~Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
61916334|NCT02646202|ACTIVE_COMPARATOR|Sclerotherapy group|thirty patients treated by sclerotherapy for OV using ethanolamine oleate 5%.
62111255|NCT04487236|EXPERIMENTAL|ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.~Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
62111256|NCT04487236|EXPERIMENTAL|ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
62111257|NCT04487236|EXPERIMENTAL|ZN-A-1041+Capecitabine+Trastuzumab|"Phase 1c:~The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion"
62111258|NCT06052176|PLACEBO_COMPARATOR|Placebo|Saline given at the same volume as the albumin on visits the patients are assigned to it
62111259|NCT06052176|ACTIVE_COMPARATOR|Albumin|IV Albumin at 1.5g/kg ideal body weight
62111260|NCT04963049|EXPERIMENTAL|With Mask|
62111261|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
62111262|NCT02954848|PLACEBO_COMPARATOR|Placebo|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
62301312|NCT06657209|EXPERIMENTAL|Normal weight with diabetes tirzepatide first pioglitazone second|Baseline testing Intervention with tirzepatide for 16 weeks Retesting Washout for 5 weeks Intervention with pioglitazone for 16 weeks Retesting
62301313|NCT06657209|EXPERIMENTAL|Normal weight with diabetes pioglitazone first, tirzepatide second|Baseline testing Intervention with pioglitazone for 16 weeks Retesting Washout for 5 weeks Intervention with tirzepatide for 16 weeks Retesting
62301314|NCT02239406||Metal-on-Metal Revision|Patients who have a failed metal on metal total hip implant and are presenting for revision surgery
62301315|NCT02934854||Observation|Patients with the Creatine Deficiency Syndromes or high-grade suspicion for the Creatine Deficiency Syndromes
62301316|NCT00784758|EXPERIMENTAL|Fenzian Device|Subjects randomized to this arm will receive treatment with the Fenzian Device
62301317|NCT00784758|SHAM_COMPARATOR|Sham Device|Subjects randomized to this arm will receive treatment with the sham device.
62301318|NCT01848314|EXPERIMENTAL|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
62470760|NCT01939756|EXPERIMENTAL|Intravesical baobab oil|Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
62111263|NCT02954848|EXPERIMENTAL|TAK-438 10 mg|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
62111264|NCT02272400|EXPERIMENTAL|IGRT of prone partial breast|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy.
62470761|NCT01173692|PLACEBO_COMPARATOR|Placebo|Twice Daily Orally
62672629|NCT03324958|EXPERIMENTAL|Virtual Reality Helmet|Patients will use a virtual reality helmet during brachytherapy applicator's setting up. The use of virtual reality helmet has already been assessed during oncologic treatments, and seems to reduce pain and anxiety. The use of virtual reality helmet has never been assessed to reduce the pain or anxiety associated with brachytherapy applicators' setting up.
62301319|NCT01574573|EXPERIMENTAL|Obese individuals with weight loss|Self support, group sessions
62301320|NCT01574573|EXPERIMENTAL|Obese individuals without weight loss|self support, group sessions
62301321|NCT01677845|EXPERIMENTAL|Radiation Therapy|Radiation Therapy
62470762|NCT01173692|EXPERIMENTAL|Minocycline|100 mg Twice Daily Orally
62111265|NCT05990517|EXPERIMENTAL|YD01-2022|
62111266|NCT04621682|ACTIVE_COMPARATOR|Non technical skills and check list|10 hours of training in non-technical skills and checklists in high Fidelity simulation
62111267|NCT04621682|ACTIVE_COMPARATOR|check list|Control: 10 hours of standard training with checklists in high Fidelity simulation
62301322|NCT00537719|ACTIVE_COMPARATOR|GSK716155|albiglutide subcutaneous injection
62470763|NCT06456918||patients undergoing elective major gastrointestinal surgery|Patients had a planned elective major gastrointestinal surgery.
62672630|NCT03324958|ACTIVE_COMPARATOR|No Virtual Reality Helmet|Patient wont use virtual reality helmet during brachytherapy applicator setting up, as in current practice.
61916335|NCT02646202|ACTIVE_COMPARATOR|Endoscopic band ligation group|thirty patients treated by endoscopic banding using the Euro-Ligator system.
61916336|NCT02646202|EXPERIMENTAL|Sclero-ligation (SL) group|thirty patients treated by intra variceal endoscopic sclerotherapy combined with band ligation.
62672631|NCT01708837|OTHER|deep anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 30-45
61916337|NCT01221844|EXPERIMENTAL|Lactoferrin treatment in HT pregnacies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
61916338|NCT01221844|ACTIVE_COMPARATOR|Ferrous sulfate in HT pregnancies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
61916339|NCT01461057|EXPERIMENTAL|Pertuzumab 840/420 mg|Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m\^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
61916340|NCT01461057|EXPERIMENTAL|Pertuzumab 840/840 mg|Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m\^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
61916341|NCT00983697|EXPERIMENTAL|FDG PET/CT|Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
61916342|NCT02792621|EXPERIMENTAL|active oral supplement|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for a 14 day period.
61916343|NCT02792621|PLACEBO_COMPARATOR|placebo supplement|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
62111268|NCT01955694|EXPERIMENTAL|BAY94-8862 (2.5 mg)|2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
62301323|NCT00537719|PLACEBO_COMPARATOR|placebo|placebo injection
62111269|NCT01955694|EXPERIMENTAL|BAY94-8862 (5 mg)|5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
62672632|NCT01708837|OTHER|light anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 45-60
62301324|NCT03950986|NO_INTERVENTION|Control|Providers assigned to the control group will receive unmodified vaccine reminders (as they already appear in the VA EHR system). Separate reminders will appear for the different vaccines of interest.
62672633|NCT00686218|EXPERIMENTAL|Treatment (panobinostat, imatinib mesylate)|Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62672634|NCT05001412|EXPERIMENTAL|Cohort one|Extensive SCLC patients who are Peripheral type or tumor vascular invasion grade one or less.
62672635|NCT05001412|EXPERIMENTAL|Cohort two|Extensive SCLC patients who are central type or tumor vascular invasion grade two to three.
62672636|NCT02978768|EXPERIMENTAL|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
62111270|NCT01955694|ACTIVE_COMPARATOR|Eplerenone|25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily \[if not performed at Visit 6 (Day 30)\] or to 50 mg once daily \[if up-titrated to 25 mg once daily at Visit 6 (Day 30)\] at Visit 8 (Day 60), based on the value of blood potassium
62111271|NCT01955694|EXPERIMENTAL|BAY94-8862 (7.5 mg)|7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting).
62111272|NCT01955694|EXPERIMENTAL|BAY94-8862 (10 mg)|10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
62470764|NCT05113693|EXPERIMENTAL|1|"Period 1 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition.~Period 2 - A single dose of 2 tablets(CKD-393 2T) under fed condition."
62470765|NCT05113693|EXPERIMENTAL|2|"Period 1 - A single dose of 2 tablets(CKD-393 2T) under fed condition.~Period 2 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition."
62672637|NCT02978768|EXPERIMENTAL|Cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
62672638|NCT02978768|EXPERIMENTAL|Physico-Mental training|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
62672639|NCT02590510|EXPERIMENTAL|The small dose of group|The dose of methotrexate is 10 mg
62672640|NCT02590510|ACTIVE_COMPARATOR|The high dose of group|The dose of methotrexate is 15 mg
62672641|NCT03446573|EXPERIMENTAL|DTG + 3TC 50 mg/300 mg|Participants will receive a single tablet of a two-drug regimen of DTG 50 mg + 3TC 300 mg once daily from Day 1 through Week 200 (Early and Late Switch Phase).
62672642|NCT03446573|ACTIVE_COMPARATOR|TAF based regimen (TBR)|Participants will continue their TBR from Day 1 to Week 148 (Early Switch Phase), and eligible participants will switch to DTG + 3TC once daily from Week 148 to 200 (Late Switch Phase).
62672643|NCT02065583||GI abdominal surgery patients|Patients recovering from gastrointestinal abdominal surgery.
62672644|NCT06222047|EXPERIMENTAL|Breast milk|Breast Milk Intervention: Wrapping was applied to the baby as a standard approach. 2 minutes before the insertion of the oragastric catheter, 2 ml of breast milk was given to the babys mouth with a syringe. After the baby was given breast milk, video recording started. The steps for inserting an orogastric catheter were followed, and the baby was monitored in an incubator during the application, with pulse and saturation monitored.
62672645|NCT06222047|EXPERIMENTAL|Dextrose|Dextrose Intervention: The baby will receive wrapping as standard treatment. The orogastric catheter is visible to the brim with 2 ml of 20% dextrose syringe 2 minutes before the insertion chamber (Bueno et al., 2013). After the baby is given dextrose, the video recording will start. The steps of the orogastric tube insertion procedure will be followed. The baby will be in an incubator during the application, with pulse and saturation monitored.
62672646|NCT06222047|NO_INTERVENTION|Control group|The control group: Baby will be wrapped as standard treatment. Video recording will start 2 minutes before the baby is inserted into the orogastric catheter. The steps of the orogastric tube insertion procedure will be followed. The baby will be in an incubator during the application, with pulse and saturation monitored. No additional intervention will be applied to the baby.
62672647|NCT03528577|EXPERIMENTAL|Test|Albuterol Sulfate Inhalation Aerosol, eq 90 mcg
62672648|NCT03528577|ACTIVE_COMPARATOR|Reference|PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg
62672649|NCT03528577|PLACEBO_COMPARATOR|Test Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
62672650|NCT03528577|PLACEBO_COMPARATOR|Reference Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
62672651|NCT05737498|EXPERIMENTAL|experimental|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation will applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode will placed over the contralateral supraorbital area with 1.5 ma intensity for 20 min with working memory task on alternate days for two weeks.
62672652|NCT05737498|NO_INTERVENTION|memory task training group|working memory task training for 20 min for two weeks
62736071|NCT06026072|OTHER|CLAD-V|All patient with renal colic will be eligible. The CLAD-V score will fills by the doctor and seven days after the patient will call back to know if he had a surgical intervention or no.
62736072|NCT02264379||normal fractionated irradiation|
62672653|NCT05034354|EXPERIMENTAL|Remote physiological monitoring|"Patients will be recruited from inpatient and outpatient cardiology service at the Stollery Children's Hospital will be purposively selected, with 50% of the patients living at least 100km from the Stollery into one of the following groups:~Group 1: Infants \<12 months of age with single ventricle physiology or biventricular cyanotic congenital heart disease.~Group 2: Patients aged 5-17 with heart failure, listed for transplant, or within 1 year of transplant."
62672654|NCT04124510|EXPERIMENTAL|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
62672655|NCT05075681|EXPERIMENTAL|Ruxolitinib combined with Chidamide|All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid \[p.o.\], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)
62672656|NCT01421134|EXPERIMENTAL|Lurasidone|Lurasidone 20, 40 or 60 mg
62672657|NCT01421134|PLACEBO_COMPARATOR|Placebo|Placebo
62672658|NCT03426488||Västerbotten Intervention Programme|"The cohort is population-based and consists of blood and data from primarily 40, 50 and 60 year olds, taken every year in this age group in connection with the Västerbotten health surveys from 1985 - present.~The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.~The database NSDD (Northern Sweden Diet Database) consists of survey data from VIP concerning nutritional factors.~A large part is fasting samples.~Individuals: 105,700 Individuals with repeated samples: 40,700 Sampling occasions: 156,300"
62672659|NCT03426488||Mammography Screening Project|"Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).~Survey data can be linked to the blood samples.~Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000"
62672660|NCT03426488||The Northern Swedish MONICA Project|"The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.~Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300 (March 2015)"
62672661|NCT00191152|EXPERIMENTAL|Gemcitabine + Docetaxel|
62672662|NCT00191152|ACTIVE_COMPARATOR|Capecitabine + Docetaxel|
62672663|NCT02113046|ACTIVE_COMPARATOR|pancreatico-jejunal anastomosis|patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
62672664|NCT02113046|ACTIVE_COMPARATOR|traditional anastomosis|pancreatic resections with traditional stump closure
62672665|NCT02922660|EXPERIMENTAL|Group TIVA|method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2-4 μg/ml and remifentanil 2-4 ng/ml in target controlled infusion(TCI) during the procedure
62672666|NCT02922660|EXPERIMENTAL|Group Des|method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
62672667|NCT03719937|EXPERIMENTAL|anterior chest wall weight|moderate to severe ARDS patients in whom prone positioning is contraindicated. Patients will have a 100 g/kg weight placed on the anterior chest wall, while in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
62672668|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
62672669|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
62672670|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
62672671|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
62672672|NCT02409901|EXPERIMENTAL|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
62672673|NCT02409901|NO_INTERVENTION|Control|Standard clinical care only
62672674|NCT00950924|EXPERIMENTAL|Bifocal Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
62672675|NCT00950924|PLACEBO_COMPARATOR|Single Vision Soft Contact Lenses|Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.
62301325|NCT03950986|EXPERIMENTAL|Treatment|Providers in the treatment group will receive modified clinical reminders for the vaccines of interest. Reminders for the different vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
62301326|NCT03880812|EXPERIMENTAL|Cost group|These patients reviewed total societal costs associated with carpal tunnel release.
62301327|NCT03880812|NO_INTERVENTION|No cost group|These patients did not review total societal costs associated with carpal tunnel release.
62301328|NCT00364793|EXPERIMENTAL|EFV+ddI+FTC in patients >= 3 months to < 6 months|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m\^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
62301329|NCT00364793|EXPERIMENTAL|EFV+ddI+FTC in patients >=6 months to < 2 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m\^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
62301330|NCT00364793|EXPERIMENTAL|EFV+ddI+FTC in patients >= 2 years to < 3 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m\^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
62301331|NCT00364793|EXPERIMENTAL|EFV+ddI+FTC in patients >= 3 years to <= 6 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m\^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
62301332|NCT06653166||videolaryngocopy with bougie (S Guide)|
62301333|NCT06653166||conventional laryngoscopy with bougie (S Guide)|
62672676|NCT05161156|EXPERIMENTAL|Treatment A: 18 mcg of Test Product (tiotropium bromide inhalation powder)|2 inhalations of test product, followed by 2 inhalations of reference placebo product
62301334|NCT06653166||videolaryngoscopy with introducer|
62301335|NCT06653166||conventional laryngoscopy with introducer|
62301336|NCT01395238|NO_INTERVENTION|Wait-List Group|
62301337|NCT01395238|EXPERIMENTAL|Parenting Group|Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
62301338|NCT06153862|ACTIVE_COMPARATOR|Malaria patients|Malaria patients
62301339|NCT06153862|ACTIVE_COMPARATOR|Non malaria donors|Healthy individuals (donors; controls)
62736073|NCT02264379||hypo fractionated irradiation|
62736074|NCT04317443||Super-Mini Percutaneous Nephrolithotomy|Patients undergo SMP
62736075|NCT04317443||Extracorporeal Shock Wave Lithotripsy|Patients undergo ESWL
62736076|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
62736077|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
62736078|NCT04073511|EXPERIMENTAL|Eungyosan|Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
62736079|NCT04073511|EXPERIMENTAL|Samsoeum|3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
62736080|NCT04073511|PLACEBO_COMPARATOR|Placebo|Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
62736081|NCT00203918||Prostate biopsies|Males undergoing prostate biopsies
62736082|NCT03440463|PLACEBO_COMPARATOR|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
62301340|NCT03185130|ACTIVE_COMPARATOR|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
62301341|NCT03185130|EXPERIMENTAL|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
62301342|NCT04438538||Patients with Dizziness|All trial participants are within this group. All trial participants will either have a diagnosis or a suspected diagnosis of Ménière's Disease in order to take part.
62470766|NCT04046783||Group A included subjects without a history of C-section|Group A consisted of 47 women without a prior a history of C-section: 24 controls and 23 subjects who used patch. These latest 23 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
62470767|NCT04046783||group B subjects who had already undergone previous C-section|Group B consisted of 46 women already undergone previous C-section: 22 controls and 24 subjects who used patch. These latest 24 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
62301343|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 1)|Dose level 1: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Carbohydrate High Calorie (HCHC)
62470768|NCT04815759||Pre pandemic|
62672677|NCT05161156|ACTIVE_COMPARATOR|Treatment B: 18 mcg of Reference Product (Spiriva)|2 inhalations of reference product, followed by 2 inhalations of test placebo product
62301344|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 2)|Dose level 2: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC
62301345|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 3)|Dose level 3: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC
62470769|NCT04815759||Post pandemic|
62470770|NCT02246166|EXPERIMENTAL|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
62470771|NCT02246166|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet
62470772|NCT04074915|PLACEBO_COMPARATOR|Placebo rinse|Normal saline
62470773|NCT04074915|EXPERIMENTAL|Chlorhexidine mouth rinse|Chlorhexidine mouth rinse
62470774|NCT04074915|EXPERIMENTAL|Test group|Chamomile mouth rinse
62470775|NCT05350891|EXPERIMENTAL|endoscopic surgery combined with adjuvant immunotherapy|
62470776|NCT05382377|EXPERIMENTAL|KD-025 cell infusion|Each subject will receive KD-025 cell infusion
62470777|NCT02566239|EXPERIMENTAL|Shared Data|"Share activity data with care team.~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
62672678|NCT05161156|PLACEBO_COMPARATOR|Treatment C: Zero-dose (Placebo)|2 inhalations of reference placebo powder, followed by 2 inhalations of test placebo product
62672679|NCT05196646||(1) 10 preterm infants spontaneously breathing in-room air with no respiratory support|Group 1 will consist of 10 preterm infants spontaneously breathing in room air, with no respiratory support, in whom respiratory acoustic signals from the acoustic sensor will be compared with airflow measurements obtained using a pneumotachometer, i.e. the gold standard. Data will be acquired for 10 minutes.
62672680|NCT05196646||(2) 20 preterm infants spontaneously breathing in-room air with no respiratory support|Group 2 will consist of 20 preterm infants spontaneously breathing in room air, with no respiratory support, in whom respiratory acoustic signals from the acoustic sensor will be compared with airflow measurements obtained using a nasal temperature sensor. In addition, measurements of respiratory efforts will be obtained using the Respiratory Inductance Plethysmography (RIP), an inertial measurement unit (IMU) integrated within the acoustic sensor, and the Transthoracic Impedance (TTI) from the bedside monitor. Data will be continuously recorded for 3 hours.
62672681|NCT05196646||(3) 20 preterm infants on continuous positive airway pressure (CPAP) with cardiorespiratory events|Group 3 will consist of 10 preterm infants on CPAP with established cardiorespiratory events, in whom respiratory acoustic signals from the acoustic sensor will be continuously measured for 3 hours. In addition, measurements of respiratory efforts will be obtained using the Respiratory Inductance Plethysmography (RIP), an inertial measurement unit (IMU) integrated within the acoustic sensor, and the Transthoracic Impedance (TTI). Data will be continuously recorded for 3 hours.
61916344|NCT02755532|ACTIVE_COMPARATOR|Bupivacaine 0,25%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve) In the group bupicavaine 0.25%, 10 ml of 0.25% bupivacaine was injected into each nerve, for a total of 40 ml per patient.
61916345|NCT02755532|ACTIVE_COMPARATOR|Bupivacaine 0,5%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve). In the group bupivacaine 0.5% , 5 ml of 0.5% bupivacaine was injected into each nerve, for a total of 20 ml per patient.
61916346|NCT05344755|EXPERIMENTAL|Plantar Sensorial Training|In addition to hallux valgus mobilization, active thumb abduction, strengthening of the muscles around the feet, hallux valgus taping and hallux valgus night splint, sensory training (using deep plantar massage, brushing, dipping techniques) will be performed.
61916347|NCT05344755|ACTIVE_COMPARATOR|Control Group|Routine hallux valgus physiotherapy approaches such as: hallux valgus mobilization, active thumb abduction, strengthening of the muscles around the feet, hallux valgus taping and hallux valgus night splint.
62301346|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 4)|Dose level 4: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: Standard Diet (SD)
62301347|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 5)|Dose level 5: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
62301348|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 6)|Multiple dose administration of PF-07258669 and placebo over 14 days in Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
62301349|NCT05113940|EXPERIMENTAL|Midazolam with and without PF-07258669 (Cohort 8)|Drug-drug interaction assessment of pharmacokinetics interaction in PF-07258669 and midazolam Dietary allocation: SD
62301350|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 7)|Multiple dose administration of PF-07258669 and placebo over 14 days in older adult participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
62301351|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 9)|Dose level 6: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
62301352|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 10)|Dose level 7: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
62301353|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 11)|Dose level 8: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
62301354|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 12)|Dose Level 9: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)
62301355|NCT05113940|EXPERIMENTAL|PF-07258669 and Placebo (Cohort 13)|Dose Level 10: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)
62301356|NCT02622932|EXPERIMENTAL|Anlotinib and 14C-labeled Anlotinib|each participant will be given a single dose of 14C-labeled gilteritinib.
62301357|NCT03263806|ACTIVE_COMPARATOR|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
62672682|NCT06193629|EXPERIMENTAL|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
61916348|NCT04971330||Known HCV Ab Positive Patients|leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for positive samples.
62301358|NCT03263806|EXPERIMENTAL|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
62301359|NCT04820192||Post-acute concussion (<6 months) or Post-Concussion Syndrome (PCS) (≥ 6 months)|Patients were divided into cohort groupings to compare outcomes of applying CranioSacral Therapy to their unique constellations of persistent symptoms attributed to their concussion injury. Symptoms less than 3-6 months duration may be part of the usually rate of injury resolution through rest along. Symptoms persisting after 6 months are considered PCS. Less than 6 months since injury were considered post-acute concussion stage of recovery.
62301360|NCT04820192||Athletes (A) or Non-athletes (NA)|Reporting of symptoms that exist and/or persist may differ between patients who are/were athletes and concussions were sustained during their sporting events. Non-athletes may report differently. The types of injuries involved in the concussion were also captured.
62301361|NCT04820192||Traditional gender.|Symptoms and response to rest has been reported to have differences between male and female patients. Age under 14 years was considered an exclusion due to immaturity in insight and reporting. Thus, young adult ages and older were included and observations between gender reporting was noted.
62301362|NCT05738863|EXPERIMENTAL|Low Frequency rTMS Protocol|It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.
62301363|NCT05738863|PLACEBO_COMPARATOR|Sham rTMS Protocol|It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.
62470778|NCT02566239|NO_INTERVENTION|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
62470779|NCT00909610|EXPERIMENTAL|Ursodiol (test) First|Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg dosed in second period.
62470780|NCT00909610|ACTIVE_COMPARATOR|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.
62672683|NCT06193629|PLACEBO_COMPARATOR|placebo group|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use。
62672684|NCT02517138|OTHER|Measurements of eye movements and perception|
62672685|NCT05213351|EXPERIMENTAL|Graded Motor İmagery|Graded Motor İmagery (GMI) group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, traditional exercises and home exercises.
62672686|NCT05213351|ACTIVE_COMPARATOR|Exercise|Exercise group will receive training involves mobilizations, stretching, specific exercises for the frozen shoulder.
62672687|NCT06483555|EXPERIMENTAL|PurIST Basal|"Subjects will be screened using the PurIST classifier and basal-like tumors will be assigned combination therapy with GnP and erlotinib."
62672688|NCT06483555|ACTIVE_COMPARATOR|PurIST Classical|Subjects will be screened using the PurIST classifier and with classical tumors will be treated per standard of care on triplet therapy.
62672689|NCT05952193||seniority ≥3 years + POSOS|
62672690|NCT05952193||seniority ≥3 years without POSOS|
62672691|NCT05952193||seniority <3 years with POSOS|
62672692|NCT05952193||seniority <3 years without POSOS|
62672693|NCT00104715|EXPERIMENTAL|Hormonotherapy + chemotherapy|
62672694|NCT00104715|ACTIVE_COMPARATOR|Hormonotherapy alone|
62672695|NCT02623439|EXPERIMENTAL|cyclophosphamide post BMT|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
62672696|NCT01951027|EXPERIMENTAL|Cohort 1|GX-G3 12.5 μg/kg or Placebo
62672697|NCT01951027|EXPERIMENTAL|Cohort 2|GX-G3 25 μg/kg or Placebo
62672698|NCT01951027|EXPERIMENTAL|Cohort 3|GX-G3 50 μg/kg or Placebo
62672699|NCT01951027|EXPERIMENTAL|Cohort 4|GX-G3 100 μg/kg or Placebo
62672700|NCT00449007|ACTIVE_COMPARATOR|1|fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
62672701|NCT00449007|ACTIVE_COMPARATOR|2|bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
62672702|NCT05030701||cancerous patients|
62672703|NCT05030701||non cancerous patients|
62672704|NCT02241915|ACTIVE_COMPARATOR|Microbial Sealant|Integuseal (Kimberly Clark)
62672705|NCT02241915|SHAM_COMPARATOR|Control|No microbial sealant
62672706|NCT06213805|EXPERIMENTAL|Minimally invasive microsclerostomy|
62672707|NCT01386320|ACTIVE_COMPARATOR|Ultrasound guided ankle block|Subjects in this arm will be given an ultrasound guided ankle block prior to foot surgery.
62672708|NCT01386320|ACTIVE_COMPARATOR|Medial forefoot block|Subjects in this arm will be given a nerve-stimulator guided forefoot block prior to anaesthesia and forefoot surgery
62672709|NCT01706380|EXPERIMENTAL|Interactive voice response with personal feedback|Interactive voice response follows the client twice weekly for 3 months with respect to symptoms and substance use, in both arms. This intervention group also receives a personalized and automated feedback describing whether the symptom status of the patient is better, worse or equal, compared to the preceding follow-up.
61916349|NCT04971330||Hospitalized Patients|"leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for hospitalized patient.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
62111273|NCT01955694|EXPERIMENTAL|BAY94-8862 (15 mg)|15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
62111274|NCT00641472|EXPERIMENTAL|1|Budesonide inhalation suspension
62111275|NCT00641472|ACTIVE_COMPARATOR|2|Montelukast sodium
62111276|NCT04174495||Obese patients followed at Nancy University Hospital|
62111277|NCT01457534||liver transplantation|
62111278|NCT06630546|EXPERIMENTAL|phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent)|In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in this group, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
62672710|NCT01706380|ACTIVE_COMPARATOR|Interactive voice response without personal feedback|This control group is also followed with identical interactive voice response follow-up, addressing symptoms and substance use, but without the personal feedback.
62672711|NCT00689286|EXPERIMENTAL|"BION twitch stimulation"|"The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation."
62111279|NCT06630546|ACTIVE_COMPARATOR|phacoemulsification alone group|In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
62111280|NCT01460342|PLACEBO_COMPARATOR|Placebo|Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
62111281|NCT01460342|EXPERIMENTAL|Tadalafil|Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
62111282|NCT06485427|NO_INTERVENTION|Control group|Subjects will receive best medical management (BMM) plus endovascular therapy (EVT) according to the clinical guidelines.
62470781|NCT06407622|EXPERIMENTAL|Patients undergoing appendectomy surgery who received foot reflexology|The study will be carried out with 120 patients hospitalized after appendectomy surgery in the surgical clinic of Bartın State Hospital. In the postoperative period, patients will be divided into experimental (n = 60) and control (n = 60) groups by block randomization with a computer-aided program.
62672712|NCT00689286|EXPERIMENTAL|BION tetanic-frequency stimulation|The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions.
62672713|NCT00689286|NO_INTERVENTION|Standardized program|A third group of experimental subjects will have a standardized program of voluntary exercise.
62111283|NCT06485427|EXPERIMENTAL|IA-SCI group|Subjects randomized to the IA-SCI group will receive selective intra-arterial cooling infusion plus BMM and EVT.
62111284|NCT00789919|NO_INTERVENTION|1|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital for standard inpatient management of their disease.
62301364|NCT03982667|EXPERIMENTAL|PCT group|For patients randomly assigned to the PCT-guided group, measurements of serum PCT concentrations (Day 1, 3, 7, and 9) will be taken and made available to the attending physicians. This means 3 ml of whole blood will be sampled from the arterial line of the patients for each measurement the serum PCT in plain tubes. The samples will be immediately assayed for the PCT measurement using the available device and the results will be ready in next 30 minutes after running the system.
62301365|NCT03982667|NO_INTERVENTION|Standard-of-care group|
62301366|NCT04924322|EXPERIMENTAL|Enoxaparin (Older Children Prophylactic)|Prophylactic dose of enoxaparin for older children 1-17 years old.
62301367|NCT04924322|NO_INTERVENTION|Control (Older Children)|Usual care without placebo for older children 1-17 years old.
62111285|NCT00789919|EXPERIMENTAL|2|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital and their infant is delivered as soon as possible after 34 weeks gestation. As there is no determined optimal time of delivery in these patients, delivery is the intervention.
62111286|NCT00660478|ACTIVE_COMPARATOR|1|Zotarolimus eluting stent
62301368|NCT04924322|EXPERIMENTAL|Enoxaparin (Infants Therapeutic High Anti-Xa Target)|Therapeutic dose of enoxaparin for infants \<1 year old with anti-Xa target of \>0.5-1 IU/mL.
62111287|NCT00660478|ACTIVE_COMPARATOR|2|Sirolimus stent
62111288|NCT01406262|ACTIVE_COMPARATOR|Albiglutide + moxifloxacin placebo|Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
62111289|NCT01406262|ACTIVE_COMPARATOR|Albiglutide matching placebo + moxifloxacin|Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
62301369|NCT04924322|EXPERIMENTAL|Enoxaparin (Infants Therapeutic Low Anti-Xa Target)|Therapeutic dose of enoxaparin for infants \<1 year old with anti-Xa target of 0.2-0.5 IU/mL.
62111290|NCT01282840|OTHER|Bladder wall blood perfusion pattern|
62301370|NCT04924322|NO_INTERVENTION|Control (Infants)|Usual care without placebo for infants \<1 year old.
62301371|NCT01629927||HED-affected males|Male subjects affected by HED
62301372|NCT01629927||Male controls|Male subjects not affected by HED
62301373|NCT05745727|EXPERIMENTAL|PRX-115|Participants will receive a single dose of PRX-115 by IV infusion
62301374|NCT05745727|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo by IV infusion
62301375|NCT03121690|EXPERIMENTAL|prednisone|prednisone 40 mg/day for 7 days
62301376|NCT03121690|EXPERIMENTAL|placebo|5ml saline /day for 7 days
62301377|NCT02689700||HCMV antibody-transfer|Materno-fetal HCMV antibody-Transfer form 24-41 weeks of gestation
62470782|NCT06407622|NO_INTERVENTION|Patients who underwent appendectomy surgery without foot reflexology|The study will be carried out with 120 patients hospitalized after appendectomy surgery in the surgical clinic of Bartın State Hospital. In the postoperative period, patients will be divided into experimental (n = 60) and control (n = 60) groups by block randomization with a computer-aided program.
62111291|NCT01682200|EXPERIMENTAL|ProOxy, Effects and Side Effects in treating acne|Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months.
62111292|NCT06443320|EXPERIMENTAL|Group of young ASD patients receiving videodrama sessions and interviews|Children participating in videodrama sessions, one per week for 9 sessions.
62111293|NCT06443320|NO_INTERVENTION|Cohort of ASD patients not receiving videodrama but receiving care in participating units|Patients included in the cohort will be managed as part of their routine care
62111294|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
62111295|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging \>ypT1-2N0 as poor response.
62111296|NCT05632068|EXPERIMENTAL|Xian-Hua-Cha (XHC) group|Xian-Hua-Cha (XHC) 520 mL, twice a day will be given with diet education/monitoring program for this group for 3 months, followed by one-month wash-out period and a 3-month period with diet education/monitor program alone.
62470783|NCT05321316|EXPERIMENTAL|68Ga-N188|Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-N188 PET/CT scan.
62111297|NCT05632068|NO_INTERVENTION|Control group|Diet education/monitoring program (500 kcal lower than estimated total energy expenditure of each subject) will be given to each subject for 3 months first, followed by one month wash-out period and a 3-month period of Xian-Hua-Cha (XHC) 520 mL, twice a day, intervention course.
62111298|NCT04524832|EXPERIMENTAL|Semaglutide D 50 mg|Participants will receive once daily semaglutide D formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
62111299|NCT04524832|EXPERIMENTAL|Semaglutide C 50 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
62111300|NCT04524832|EXPERIMENTAL|2 x Semaglutide C 25 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 2 x 25 mg (week 13-16)
62111301|NCT04524832|EXPERIMENTAL|Semaglutide E 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 16 weeks: A) Semaglutide C formulation: 2.4 mg (week 1-2), 5.6 mg (week 3-4) and 11.2 mg (week 5-8). B) Semaglutide E formulation: 25 mg (week 9-12) and 50 mg (week 13-16)
62111302|NCT04524832|EXPERIMENTAL|Semaglutide F 50 mg|Participants will receive once daily semaglutide F formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
62301378|NCT02689700||VZV antibody-transfer|Materno-fetal VZV antibody-Transfer form 24-41 weeks of gestation
62301379|NCT05742945|EXPERIMENTAL|ILR|Breast cancer patients receiving axillary lymph node dissection and immediate lymphatic reconstruction
62301380|NCT05742945|NO_INTERVENTION|non-ILR|Breast cancer patients receiving only axillary lymph node dissection
62470784|NCT06107192|EXPERIMENTAL|Apple catechin|A 3-day controlled diet
62470785|NCT06107192|PLACEBO_COMPARATOR|Low catechin|A 3-day controlled diet
62470786|NCT06368869|EXPERIMENTAL|Livento press veneers luted with dual cured resin cement|
62111303|NCT03413319|EXPERIMENTAL|ABBV-8E12|ABBV-8E12 administered by intravenous (IV) infusion.
62111304|NCT01830166|EXPERIMENTAL|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
62111305|NCT02260310|EXPERIMENTAL|Weizhong and Huantiao|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points
62111306|NCT02260310|ACTIVE_COMPARATOR|A-shi point|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in A-shi points, without including Weizhong (BL4) and Huantiao (GB30) Points
62111307|NCT00337818|EXPERIMENTAL|Cervarix New Process|Subjects aged 15 to 25 years received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus \[HPV\]) produced with the new manufacturing process.
62111308|NCT00337818|EXPERIMENTAL|Cervarix Old Process Group|Subjects aged 15 to 25 years who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus \[HPV\]) produced with the old manufacturing process.
62111309|NCT00337818|EXPERIMENTAL|Cervarix Young/Lot 1 Group|Subjects aged 10 to 14 years, who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus \[HPV\]) produced with the new manufacturing process (Lot 1).
62111310|NCT04115436||stroke (+)|Patients experiencing thromboembolic events following a brief discontinuation of anticoagulant or having thrombus on the LAA occlusion device
62111311|NCT04115436||No-stroke|Patients remaining stroke-free months after discontinuation of anticoagulants
62111312|NCT02631499|EXPERIMENTAL|Adjuvant TACE|TACE will be performed 4-6 weeks after hepatectomy in patients with preoperative CTC ≥2 Epirubicin, lipiodol and gelatin sponge articles are used in TACE.
62111313|NCT02631499|NO_INTERVENTION|Control|no interventions were assigned after hepatectomy
62111314|NCT05857306|ACTIVE_COMPARATOR|Olvanil|
62111315|NCT05857306|PLACEBO_COMPARATOR|Placebo|
62111316|NCT02308137|EXPERIMENTAL|Domperidone|Treatment: Oral domperidone four times daily Target dose: 40mg per day Duration: 1 year
62111317|NCT04282980|EXPERIMENTAL|DCC-2618|DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle.
62111318|NCT05864586|ACTIVE_COMPARATOR|Young adult EC users|Young Adult EC users
62111319|NCT05864586|ACTIVE_COMPARATOR|Older adult smokers|Adult smokers
62111320|NCT06026358|EXPERIMENTAL|Tirbanibulin|Treatment
62111321|NCT06026358|PLACEBO_COMPARATOR|Placebo|Placebo
62111322|NCT01492387|NO_INTERVENTION|Local standard of care|Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.
62111323|NCT01492387|EXPERIMENTAL|Individualized arm|Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
62111324|NCT04456920|EXPERIMENTAL|Experimental group 1|PRO (Patient Reported Outcomes) gathered via a phone consultation
61916350|NCT04971330||Unselected Blood Donors|"Leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. les. For blood donors, Abbott PRISM HCV will be used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status."
61916351|NCT03643614|EXPERIMENTAL|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
61916352|NCT04048161|EXPERIMENTAL|Tacrolimus(Group A)|Tacrolimus: 0.5mg and 1mg; Capsule; 0.05-0.10mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
61916353|NCT04048161|ACTIVE_COMPARATOR|Mycophenolate Mofetil(Group B)|Mycophenolate Mofetil: 250mg; Dispersible tablets; 20\~30mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
61916354|NCT06521879|NO_INTERVENTION|IRT-Only|Iron deficiency anemia patients receive iron replacement therapy alone.
61916355|NCT06521879|EXPERIMENTAL|IRT-Pro|Iron deficiency anemia patients receive iron replacement therapy plus L. plantarum 299v probiotic support
61916356|NCT05441306|EXPERIMENTAL|Access to Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL and the standard of care patient portal (Epic®MyChart).
61916357|NCT05441306|ACTIVE_COMPARATOR|Control - MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
61916358|NCT00397943|EXPERIMENTAL|M72/AS01B Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
61916359|NCT00397943|EXPERIMENTAL|M72/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
61916360|NCT00397943|ACTIVE_COMPARATOR|Mtb72F/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
61916361|NCT00397943|ACTIVE_COMPARATOR|Non-adjuvanted Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
61916362|NCT00397943|PLACEBO_COMPARATOR|Control Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
62470787|NCT06368869|ACTIVE_COMPARATOR|Livento press veneers luted with light cured resin cement|
62470788|NCT06368869|EXPERIMENTAL|Celtra duo veneers luted with dual cured resin cement|
62470789|NCT06368869|ACTIVE_COMPARATOR|Celtra duo veneers luted with light cured resin cement|
62470790|NCT01294917|EXPERIMENTAL|Investigational MPS|AMO Investigational MPS.
62470791|NCT01294917|ACTIVE_COMPARATOR|Clear Care|Peroxide-based lens care regimen.
61916363|NCT03188042|EXPERIMENTAL|rtACS Stimulation Group|
62111325|NCT04456920|EXPERIMENTAL|Experimental group 2|e-PRO self-completed via connected objects (tablet/phone)
62470792|NCT01294917|ACTIVE_COMPARATOR|Opti-Free RepleniSH|Multi-purpose disinfecting solution (Alcon).
61916364|NCT03188042|SHAM_COMPARATOR|Sham Intervention Group|Sham stimulation looks like rtACS, but is not active rtACS.
61916365|NCT00928122|EXPERIMENTAL|1 / Presbyopia|Presbyopic patients, slightly hyperopes
61916366|NCT00928122|EXPERIMENTAL|2 / Myopia|Myopic patients without Astigmatism
61916367|NCT00928122|EXPERIMENTAL|3 / Hyperopia|Hyperope patients without Astigmatism
61916368|NCT00928122|EXPERIMENTAL|4 / Myopia with Astigmatism|Myopic patients incl. Astigmatism
61916369|NCT00928122|EXPERIMENTAL|5 / Hyperopia with Astigmatism|Hyperope patients incl. Astigmatism
61916370|NCT04281238|EXPERIMENTAL|yoga group|Participants in this group will be given yoga training 3 days a week for 8 weeks. In addition, patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
61916371|NCT04281238|OTHER|Control group|Patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
62111326|NCT04456920|NO_INTERVENTION|Control group|group without e-PROs (standard care)
62470793|NCT02977260|EXPERIMENTAL|Test Meal 1|Thin/Low Energy
61916372|NCT03876301||Observational Cohort|Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200
61916373|NCT02600754|EXPERIMENTAL|IT-PST|IT-PST refers to problem-solving therapy that will be tele-delivered by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More).
62470794|NCT02977260|EXPERIMENTAL|Test Meal 2|Thin/High Energy
62470795|NCT02977260|EXPERIMENTAL|Test Meal 3|Thick/Low Energy
62470796|NCT02977260|EXPERIMENTAL|Test Meal 4|Thick/High Energy
62470797|NCT04455139|ACTIVE_COMPARATOR|Treatment 1a|IVitC melphalan (randomized) in case of vitreous relapse only
62470798|NCT04455139|EXPERIMENTAL|Treatment 1b|IVitC topotecan (randomized) in case of vitreous relapse only
62470799|NCT04455139|ACTIVE_COMPARATOR|Treatment 2a|IAC melphalan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
62470800|NCT04455139|EXPERIMENTAL|Treatment 2b|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
62470801|NCT04455139|NO_INTERVENTION|Treatment 2c|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with prior intra-arterial treatment
62301381|NCT05957874|EXPERIMENTAL|Experiment|Questionnaires will be applied to the children and their families who agree to participate. A one-week sleep hygiene training will be given for three consecutive days. On the first day of education, children will be given a checklist and tasks that will facilitate the transition to weekly sleep. In addition, within the scope of using technology positively, reminders including sleep hygiene principles will be sent to families every day for four weeks via a social media tool. Total intervention time is planned as 4 weeks. The researchers planned to start the trainings on Monday. At the beginning of each week, face-to-face interviews will be held with the students in the experimental group and it will be evaluated whether the tasks have been fulfilled. At the end of 4 weeks, the final test application of the experimental group will be made. Then, the questionnaires will be applied again after 2 weeks for control measurement.
61916374|NCT02600754|EXPERIMENTAL|IT-SCM|IT-SCM refers to self-care management support that will be tele-delivered by trained lay advisers (TLAs) co-located in an aging-service agency (Meals on Wheels and More).
61916375|NCT02600754|NO_INTERVENTION|Wait-list control (Usual Care or UC)|Participants who will serve as controls with telephone safety calls
61916376|NCT05356728|ACTIVE_COMPARATOR|Thealoz Duo|Thealoz Duo, a combination of trehalose and hyaluronate, will be used on one of the selected eyes of a patient, at least 3 times daily
61916377|NCT05356728|ACTIVE_COMPARATOR|Hyabak|Hyabak, sodium hyaluronate, will be used on the other eye of the patient, at least 3 times daily
61916378|NCT03761771||colonoscopy withdrawal with the ADS monitoring|The ADS automatically initiated once the ileocecal valve was pictured by the colonoscopist or the colonoscopist recorded any image of colon during the insertion. When colonoscopists withdrew the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the ADS, which made it feasible to identify and classify lesions in real time.
62301382|NCT05957874|NO_INTERVENTION|Control|"The children who agreed to participate in the class determined as the control group as a result of drawing lots and the children and their families who agreed to participate will fill in the Sociodemographic Characteristics and Introductory Information Form, the Sleep Deprivation Scale for Children and Adolescents and the mothers will fill in the Child Sleep Habits Questionnaire. At the end of 4 weeks, the post-test application of the control group will be made. After the tests are applied, training will be given to the control group on a suitable day for the class and the training booklet will be distributed."
61916379|NCT06191211|NO_INTERVENTION|Control group|Standard of care - no engagement or communication skills training for first-line providers.
61916380|NCT06191211|ACTIVE_COMPARATOR|Doctors Light Communication|"In facilities randomised to this group, all front-line health workers receiving patients in outpatient consultations over the trial duration will be asked to encourage eligible patients to get vaccinated or receive a booster of the Covid-19 vaccine.~At the start of the intervention period, all facilities will receive a visit from the District office of the Ghana Health Service. The visit will (1) remind them of the importance of covid19 vaccination to all consulting staff; (2) ask all consulting staff to have discussions with patients about Covid19 vaccination during routine consultations and (3) provide a simple tracking sheet to be used by consulting staff to record these consultations."
61916381|NCT06191211|EXPERIMENTAL|Doctors Enhanced Communication|"In addition to facility engagement described in the Doctor light communication group, five front-line health workers from each of the facilities in the treatment group will be invited to take part in a training providing information and developing specific communication skills to encourage patients to get vaccinated. The communication skills are based on principles rooted in Motivational Interviewing (MI) and have been used in Ghana to address vaccine hesitancy."
62301383|NCT05191212|EXPERIMENTAL|Experimental injection|Cervical indocyanine green injections until real-time visualization of the afferent lymphatic channels bilaterally.
62301384|NCT05191212|ACTIVE_COMPARATOR|Standart injection|Cervical indocyanine green injections group
61916382|NCT05785910|EXPERIMENTAL|Normal subjects|
62672714|NCT03274349|ACTIVE_COMPARATOR|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
62301385|NCT04945382|EXPERIMENTAL|Scotchbond universal 3M|Application of dental sealant with Scotchbond universal 3M adhesive.
62301386|NCT04945382|ACTIVE_COMPARATOR|Control (Single bond 3M)|Application of dental sealant with Single Bond 3M adhesive
62301387|NCT04452643|ACTIVE_COMPARATOR|Bacmune (MV130)|Subject included in the active group will receive Bacmune. The dose consists on 2 spray puff every 12 hours for 45 days.
62672715|NCT03274349|EXPERIMENTAL|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
62672716|NCT05961384|EXPERIMENTAL|10 mg [14C]-bexdrostat|single oral dose of 10 mg baxdrostat containing 100 μCi of \[14C\] baxdrostat
62672717|NCT01382407||Cetuximab|All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.
62672718|NCT03996421|EXPERIMENTAL|ferrous fumarate|labelled iron as ferrous fumarate
62672719|NCT03996421|EXPERIMENTAL|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
62672720|NCT00999570||Patients operated by AR trained surgeons|patients who had their total knee replacements performed by surgeons who have completed a fellowship training in adult reconstruction surgery
62672721|NCT00999570||Patients operated by non-AR surgeons|patients who had their total knee replacements performed by orthopaedic surgeons who did not complete an adult reconstruction fellowship training
62672722|NCT06211270|EXPERIMENTAL|Intervention|FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
62672723|NCT06211270|OTHER|Wait-Listed Control|Standard of Care for El Rio Community Health Center persons with type 2 diabetes.
62672724|NCT02687165|ACTIVE_COMPARATOR|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
62672725|NCT02687165|PLACEBO_COMPARATOR|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
62672726|NCT05198310|EXPERIMENTAL|Cohort 1 KPL-404|KPL-404 2mg/kg Subcutaneous (SC) q2wk for 12 weeks
62672727|NCT05198310|PLACEBO_COMPARATOR|Cohort 1 Placebo|Placebo for KPL-404 SC q2wk for 12 weeks
62672728|NCT05198310|EXPERIMENTAL|Cohort 2 KPL-404|KPL-404 5mg/kg SC q2wk for 12 weeks
62672729|NCT05198310|PLACEBO_COMPARATOR|Cohort 2 Placebo|Placebo for KPL-404 SC q2wk for 12 weeks
62672730|NCT05198310|EXPERIMENTAL|Cohort 3 KPL-404|KPL-404 5mg/kg SC qwk for 12 weeks
62672731|NCT05198310|EXPERIMENTAL|Cohort 3 KPL-404 and Placebo|KPL-404 5mg/kg SC q2wk with alternating weekly administrations of KPL-404 or placebo SC for 12 weeks
62672732|NCT05198310|PLACEBO_COMPARATOR|Cohort 3 Placebo|Placebo for KPL-404 SC qwk for 12 weeks
62301388|NCT04452643|PLACEBO_COMPARATOR|Placebo|Subject included in the placebo group will receive placebo. The dose consists on 2 spray puff every 12 hours for 45 days.
62301389|NCT06010667||EBC|cyclophosphamide and bevacizumab in combination with Envafolimab
62301390|NCT06010667||BC|cyclophosphamide in combination with Envafolimab
62672733|NCT05198310|EXPERIMENTAL|Cohort 4 KPL-404|KPL-404 SC q4wk for 12 weeks: 600 mg loading dose at baseline followed by 400 mg at weeks 4 and 8.
62301391|NCT00847613|EXPERIMENTAL|Sequence 1|
62672734|NCT05198310|PLACEBO_COMPARATOR|Cohort 4 Placebo|Placebo for KPL-404 SC q4wk for 12 weeks
62672735|NCT03126734|EXPERIMENTAL|Experimental Group|The parents of this group will receive 5 sessions of infant massage course (1 per week) between two measurements of the variables
62672736|NCT03126734|NO_INTERVENTION|Control Group|The parents of this group will not receive infant massage course (1 per week) between two measurements of the variables. They will receive it after two measurements.
62672737|NCT01356056||Kinesia HomeView Monitoring|Uses Kinesia HomeView at home once per week
62672738|NCT01356056||Control|Assessed in the clinic every 4 weeks using traditional methods
62672739|NCT01533909||Cancer patients|As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
62672740|NCT02919150||Myotonometric and isokinetic measurement|"Myotonometric assessment: into the site of the latent medial myofascial trigger point of the soleus muscle and distal to the lateral medial myofascial trigger point of the soleus muscle but into the same taut band.~Isokinetic assessment: triceps surae muscle tone will be quantified by measuring the passive range of motion for ankle dorsiflexion and the resistance to passive ankle dorsiflexion at slow and fast velocity."
62672741|NCT03286803|EXPERIMENTAL|Arm A|Inactivated Poliovirus vaccine
62672742|NCT03286803|ACTIVE_COMPARATOR|Arm B|fractional dose inactivated poliovirus vaccine
62672743|NCT03286803|EXPERIMENTAL|Arm C|inactivated poliovirus vaccine
62301392|NCT00847613|EXPERIMENTAL|Sequence 2|
62672744|NCT03286803|ACTIVE_COMPARATOR|Arm D|fractional dose inactivated poliovirus vaccine
62672745|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
61916383|NCT04473482|EXPERIMENTAL|MAIN-ART Behavior Tool|The Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Tool (MAIN-ART) behavioral intervention is an online web application with two modules: misconception correction and tailored, preference-sensitive alcohol use disorder (AUD) treatment matching.
62111327|NCT05463354|EXPERIMENTAL|Inactivated COVID-19 vaccines cohort group 1|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
61916384|NCT04473482|NO_INTERVENTION|Routine care|Patients randomized to usual care will receive a pamphlet for alcohol treatment referral to the University of Michigan Addiction Treatment Services, but will receive no further education from the research team.
62111328|NCT05463354|ACTIVE_COMPARATOR|Inactivated COVID-19 vaccines cohort group 2|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
62111329|NCT05463354|EXPERIMENTAL|mRNA COVID-19 vaccines cohort group 1|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
62111330|NCT05463354|ACTIVE_COMPARATOR|mRNA COVID-19 vaccines cohort group 2|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
62111331|NCT05463354|EXPERIMENTAL|Viral Vector COVID-19 vaccines cohort group 1|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
62111332|NCT05463354|ACTIVE_COMPARATOR|Viral Vector COVID-19 vaccines cohort group 2|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
62111333|NCT00608933|ACTIVE_COMPARATOR|Arm I (intervention)|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
62111334|NCT00608933|OTHER|Arm II (wait-list)|Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I (educational intervention) are made available to the wait-list health providers.
62111335|NCT01906060|EXPERIMENTAL|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.
62111336|NCT03780816||Pilot Site: Norris Cotton Cancer Center|Observation and interview protocols will be piloted at this site. The content of these observations and interviews will not be analyzed for content.
62111337|NCT03780816||Karmanos Cancer Institute|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
62111338|NCT03780816||UNC Lineberger Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
62470802|NCT04455139|NO_INTERVENTION|Treatment 3a|sequential administration of IVitC melphalan and IAC melphalan in case of combined vitreous and retinal/diffuse subretinal relapse, if no pretreatment with intra-arterial treatment
62470803|NCT04455139|NO_INTERVENTION|Treatment 3b|sequential administration of IVitC melphalan and IAC melphalan and topotecan, in case of combined vitreous and retinal/diffuse subretinal relapse, if prior pretreatment with intra-arterial treatment
62470804|NCT03223961|EXPERIMENTAL|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
62672746|NCT06503393||Women born in sub-Saharan Africa|Women born in sub-Saharan Africa and diagnosed with breast cancer
62301393|NCT00847613|PLACEBO_COMPARATOR|Sequence 3|
62301394|NCT00847613|PLACEBO_COMPARATOR|Sequence 4|
62301395|NCT02305433|EXPERIMENTAL|Physiotherapy (physical exercise) for frail elderly|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
62301396|NCT02305433|EXPERIMENTAL|Physiotherapy (physical exercise) for operated hip fracture patients|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
62301397|NCT02305433|NO_INTERVENTION|Usual care for frail elderly|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
62672747|NCT06503393||Women born in France|Women born in France and diagnosed with breast cancer
62672748|NCT01404260|EXPERIMENTAL|Gemcitabine +Carboplatin +Gefitinib|Arm A: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, Gefitinib 250mg/d every cycle d15-25, and Gefitinib 250mg/d from d15 of last cycle until disease progression
62672749|NCT01404260|ACTIVE_COMPARATOR|Gemcitabine +Carboplatin|Arm B: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum4 cycles, observation until disease progression
62672750|NCT01297244|EXPERIMENTAL|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
62672751|NCT04590183|EXPERIMENTAL|The experimental group|
62672752|NCT04590183|SHAM_COMPARATOR|The control group|
62672753|NCT01838889|EXPERIMENTAL|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
62672754|NCT01838889|NO_INTERVENTION|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
62111339|NCT03780816||UAB O'Neal Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
62672755|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
62672756|NCT00563212|EXPERIMENTAL|A1|
62111340|NCT03357640|PLACEBO_COMPARATOR|no intervention|The women will receive one package of placebo. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
62672757|NCT02926612||HCT recipients ages ≤21 years|HCT recipients ages ≤21 years for whom lower respiratory secretions are being collected for direct patient care.
62672758|NCT05605080|EXPERIMENTAL|Gelfoam as hemostatic agent after surgery|Use Gelfoam as hemostatic agent after surgery.
62672759|NCT05605080|ACTIVE_COMPARATOR|Gauze with Bosmin as hemostatic agent after anal surgery|Use gauze with Bosmin as hemostatic agent after anal surgery
62672760|NCT03687697|EXPERIMENTAL|Global vs. G-TL Media|Global medium will be compared with G-TL (Time-Lapse) medium.
62672761|NCT03687697|EXPERIMENTAL|Global vs. Cornell's C3 Media|Global medium will be compared with Cornell's C3 single step medium.
62672762|NCT03687697|EXPERIMENTAL|Global vs. Cornell's sequential Media|Global medium will be compared with Cornell's C1/C2 sequential medium.
62672763|NCT01158404|EXPERIMENTAL|LY900009|"Dose escalation phase: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Dose confirmation phase: 30 mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
61916385|NCT03239561|EXPERIMENTAL|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
61916386|NCT00174772|EXPERIMENTAL|B|Concurrent chemoradiotherapy followed by consolidation chemotherapy
61916387|NCT00174772|EXPERIMENTAL|A|Induction chemotherapy followed by concurrent chemoradiotherapy
62111341|NCT03357640|ACTIVE_COMPARATOR|combined oral contraception pills|The women will receive intervention of one package of combined oral contraception pills and will be counseled about how to take oral contraception and informed of possible side effects. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
61916388|NCT05897333||Isolated coronary ectasia|Includes the patients with isolated coronary artery ectasia without coronary stenosis.
62111342|NCT01751724|EXPERIMENTAL|Caffeine Arm|Subjects randomized to this arm will receive blinded Caffeine citrate.
62111343|NCT01751724|PLACEBO_COMPARATOR|Placebo Arm|Subjects randomized to this arm will receive blinded Placebo (equivalent volume of normal saline).
61916389|NCT05897333||Coronary artery disease|Includes the patients with ≥50% stenosis in a vessel ≥2 mm in diameter.
61916390|NCT01837771|ACTIVE_COMPARATOR|Diaphragmatic stimulation|Diaphragmatic stimulation via electrode for 4 weeks
61916391|NCT01837771|NO_INTERVENTION|No intervention|
61916392|NCT02263170||All study participants|Healthy (m/f), normal weighted
61916393|NCT02095314|EXPERIMENTAL|Pentavalen|Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly
61916394|NCT05148520|OTHER|5A's model|The practice guideline emphasizes on the use of '5A's' model that contains five major steps in providing smoking cessation counselling. Specifically, our counsellors will take the following steps to provide telephone counselling for youth smokers who are ready to quit smoking
62111344|NCT00545376|NO_INTERVENTION|1|This group will leave after the first visit without additional instruction and will be asked to return in two weeks for a follow up lung assessment.
62672764|NCT03657407|ACTIVE_COMPARATOR|B&O|29 women randomized to Belladonna \& Opium suppository
61916395|NCT05171829|EXPERIMENTAL|Intervention : Educational tool|self-tracking educational tool (diary)
61916396|NCT05171829|NO_INTERVENTION|Control|
61916397|NCT00600054|EXPERIMENTAL|Single arm|
62470805|NCT03223961|EXPERIMENTAL|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
61916398|NCT00593580|ACTIVE_COMPARATOR|1|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
61916399|NCT00593580|PLACEBO_COMPARATOR|2|
61916400|NCT00921245||Group 1|
61916401|NCT02323360|EXPERIMENTAL|Stereotactic body radiation therapy|HCC after incomplete TAE or TACE treated by SBRT
61916402|NCT02323360|ACTIVE_COMPARATOR|TACE/TAE|HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE
61916403|NCT01302977|EXPERIMENTAL|Fetal intervention|Composed of fetuses that undergo to fetal tracheal occlusion at 26-28 weeks.
62111345|NCT00545376|EXPERIMENTAL|2|This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
62111346|NCT00545376|EXPERIMENTAL|3|This arm is the physicians that I will recruit participants through. They will be exposed to education about the use of OMT for asthma.
62111347|NCT04164563|NO_INTERVENTION|Control|Standard CAM boot treatment without Even-Up device.
62111348|NCT04164563|EXPERIMENTAL|Study|CAM boot treatment with Even-Up for contralateral extremity.
62111349|NCT04319796||Ataxia & HSP|Patients suffering of Ataxia or HSP or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these Rare Neurological Disease (RND).
62111350|NCT04319796||Leukodystrophies|Patients suffering of Leukodystrophies or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
62672765|NCT03657407|SHAM_COMPARATOR|Placebo|27 women randomized to Glycerin suppository
62672766|NCT02249793||Study group|Healthy volunteers
62672767|NCT03184675|EXPERIMENTAL|Functional action observation training|
61916404|NCT01302977|NO_INTERVENTION|Control|Composed of fetuses that do not undergo fetal intervention
61916405|NCT01649843|EXPERIMENTAL|EA|Patients were eligible for enrollment in the study if they had an Eckardt symptom score ≥ 4. The diagnosis of achalasia was made on the basis of the absence of peristalsis and on impaired relaxation of the LES on established methods (barium swallow, manometry, esophagogastroduodenoscopy (EGD)).
61916406|NCT06224751||Near logMAR letter acuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
61916407|NCT06224751||Near logMAR word acuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
61916408|NCT06224751||Letter Contrast Sensitivity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
61916409|NCT06224751||Vanishing Optotype Sloan letters|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
61916410|NCT06224751||Auckland Optotypes/Auckland Vanishing Optotypes|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
61916411|NCT06224751||Low contrast letter acuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
61916412|NCT06224751||Red Green Stereoacuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
61916413|NCT04590248|EXPERIMENTAL|Adavosertib|Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
61916414|NCT00853268|EXPERIMENTAL|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
61916415|NCT00853268|ACTIVE_COMPARATOR|B|OxyContin® 40 mg tablet
61916416|NCT02764190|EXPERIMENTAL|I-ACT with Check Yourself|Adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Check Yourself includes the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive I-ACT and the Check Yourself summary report of health risk behaviors before an adolescent patient's appointment. I-ACT will provide training in adolescent-preferred communication methods and use of Check Yourself as a framework for the provider to use motivational interviewing to consider the patients' change readiness and their personal health goals. I-ACT includes online interactive, case-based learning, with booster sessions and feedback reports to reinforce new skills.
61916417|NCT02764190|NO_INTERVENTION|Usual care|In the usual care group, adolescents are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive I-ACT or the Check Yourself summary report of the adolescent's health risk behaviors.
61916418|NCT02249845||dehydration scales|children aged 1 - 36 months for CDS scale; 1 month - 5 years old for WHO scale and Gorelick scale
62111351|NCT04319796||Frontotemporal Dementia|Patients suffering of Frontotemporal Dementia or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
62111352|NCT04319796||Dystonia, Paroxysmal Disorders and Neurodegeneration with|Patients suffering of Dystonia, Paroxysmal Disorders and Neurodegeneration with Brain Iron Accumulation (NBIA) or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
62111353|NCT04319796||Atypical Parkinsonism|Patients suffering of Atypical Parkinsonism or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
61916419|NCT01931709|EXPERIMENTAL|Diagnostic (FDG PET and DCE-MRI)|Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).
61916420|NCT04309123|EXPERIMENTAL|Treatment|TransAeris stimulation therapy adjunctive to continued mechanical ventilation will begin 24 hours after leaving the operating room, if subject remains on mechanical ventilation. TransAeris stimulator settings (stimulus intensity, stimulus frequency, and burst on/off) will be programmed to optimize diaphragm recruitment without compromising patient comfort.
62111354|NCT04319796||Huntington's Disease & Choreas|Patients suffering of Huntington's Disease or Choreas or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
62111355|NCT00111020|EXPERIMENTAL|Arm 1|
62301398|NCT02305433|NO_INTERVENTION|Usual care for operated hip fracture patients|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
62470806|NCT06370754|EXPERIMENTAL|Cohort1: JS004+JS001+Irinotecan Liposome Injection+5-fluorouracil (5-FU)/leucovorin (LV)|Participants with unresectable locally advanced or metastatic pancreatic cancer who had previously failed at least first line gemcitabine-based system therapy will receive JS004 and JS001 combined with chemotherapy (irinotecan liposome injection+5-FU/LV) until the treatment termination event specified in the protocol occurs.
62672768|NCT03184675|OTHER|General action observation training group|
62672769|NCT04889911|EXPERIMENTAL|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a structured, 20-session group-based treatment called that combines psychoeducation, cognitive restructuring, and elements of narrative psychotherapy. NECT-YA will be modified to meet the needs of people who have experienced an FEP and may have fewer sessions or be provided in individual format or via telehealth for this study. NECT-YA will be offered to participants who are also receiving treatment within Coordinated Specialty Care programs for First Episode Psychosis.
62672770|NCT04889911|ACTIVE_COMPARATOR|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based treatment for FEP that includes multiple treatment components. The FEP programs in at the recruiting site follow the Coordinated Specialty Care model.
62672771|NCT00170755|EXPERIMENTAL|1|Darifenacin
61916421|NCT05770674|ACTIVE_COMPARATOR|1 Month DAPT|Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 1 month following PCI. Following 1 month, clopidogrel 75 mg once daily will be given for 11 months.
62672772|NCT05824676|EXPERIMENTAL|Depuy Synthes LCP Patella Plating System|This group will have 18 randomly selected participants, who will receive the Depuy Synthes LCP Patella Plating System for patella fracture.
62672773|NCT05824676|OTHER|Control/Conventional Fixation|This group will have 18 randomly selected participants, who will receive the conventional treatment for patella fracture.
61916422|NCT05770674|ACTIVE_COMPARATOR|12 Months DAPT|Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 12 months following PCI.
61916423|NCT05121571|EXPERIMENTAL|HAIC of FOLFOX|Retreatment With hepatic arterial infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin
62301399|NCT05589493|EXPERIMENTAL|All-on-4 PEEK routine|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
62672774|NCT02530073|EXPERIMENTAL|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|An un-blinded non-randomized single arm pilot study of FETO in fetuses with congenital diaphragmatic hernia (CDH)
62672775|NCT02931539|EXPERIMENTAL|Maribavir Treatment|Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks.
62672776|NCT02931539|ACTIVE_COMPARATOR|Investigator-Assigned Treatment|Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.
61916424|NCT05121571|ACTIVE_COMPARATOR|Sorafenib|
61916425|NCT03619811|EXPERIMENTAL|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device)
62470807|NCT06370754|EXPERIMENTAL|Cohort2: JS007+JS001+Irinotecan Liposome Injection+5-FU/LV|Participants with unresectable locally advanced or metastatic pancreatic cancer who had previously failed at least first line gemcitabine-based system therapy will receive JS007 and JS001 combined with chemotherapy (irinotecan liposome injection+5-FU/LV) until the treatment termination event specified in the protocol occurs.
62470808|NCT06370754|EXPERIMENTAL|Cohort3: JS015+JS001+Irinotecan Liposome Injection+5-FU/LV|Participants with unresectable locally advanced or metastatic pancreatic cancer who had previously failed at least first line gemcitabine-based system therapy will receive JS015 and JS001 combined with chemotherapy (irinotecan liposome injection+5-FU/LV) until the treatment termination event specified in the protocol occurs.
62672777|NCT02609906|OTHER|PhilosTM with augmentation (Depuy-Synthes)|The intervention group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)
62672778|NCT02609906|OTHER|MultiLoc®-Nail (Depuy-Synthes)|The comparison group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
62672779|NCT03506308|OTHER|LUTONIX 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
62672780|NCT01112267|EXPERIMENTAL|Tramadol Hydrochloride (HCl)/acetaminophen|Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
62672781|NCT01112267|PLACEBO_COMPARATOR|Placebo|Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
62672782|NCT06433544|EXPERIMENTAL|Experimental group will undergo a 6-week online mindfulness course|The experimental group received a 6-week online mindfulness course, once a week for 90 minutes each session. Participants completed questionnaires before the course, at week 3, and at week 6.
62672783|NCT06433544|NO_INTERVENTION|Control group|General routine care
62672784|NCT05569889||control group|The medical staff was using the traditional surgical draping kit and single-packed sterile instruments (SPSI) that have to be opened separately
62672785|NCT05569889||experimental group|The medical staff was using only the single packed CST, and containing all the necessary single-use items like surgical blades, sutures, dressing, surgical drapes, syringes, compresses, surgical gloves, jerseys.
62672786|NCT03275272|OTHER|level of IGF-1 in infant|Measurment of blood level of IGF-1 In infants
62672787|NCT02820103|ACTIVE_COMPARATOR|Information leaflet (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge. The information from two leaflets: 1. 'Using GTN', produced by the hospital and 'Angina' produced by the British Heart Foundation, published 08/04/2014 and available at https://www.bhf.org.uk/publications/heart-conditions/angina . The information explains the symptoms of angina and heart attack and advises what to do in the event of experiencing these symptoms. This information will be presented in written text format on screen.
62672788|NCT02820103|EXPERIMENTAL|Text+Visual BCT-based intervention (Intervention Group 1)|Participants in the visual intervention group will receive the control condition specified above PLUS a specifically developed Text+Visual BCT-based intervention, comprising the 12 BCTs identified earlier in a Systematic Review and expert consensus study. The BCTs are Problem solving; Action planning; Social support (practical); Social support (emotional); Instruction on how to perform the behaviour; Information about health consequences; Salience of health consequences; Prompts/cues; Credible source; Pro's \& Con's; Comparative imagining of future outcomes; Mental rehearsal of successful performance
62672789|NCT02820103|EXPERIMENTAL|Text-only BCT-based intervention (Intervention Group 2)|Information leaflet (usual care) plus text-only BCT-based intervention (Intervention group 2) Participants in the text-only BCT-based intervention group will receive the control condition specified above plus a text-only BCT-based intervention. This was developed in the same way as the text+visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen instead.
62672790|NCT05316051|EXPERIMENTAL|25° inverted angle foot orthoses|
62672791|NCT05316051|EXPERIMENTAL|15° inverted angle foot orthoses|
62672792|NCT05316051|NO_INTERVENTION|Control|
61916426|NCT05260346|PLACEBO_COMPARATOR|Placebo|Cranberry flavored drink, once daily, in a 8fl oz bottle. Identical in appearance and taste compared with the treatment.
61916427|NCT05260346|ACTIVE_COMPARATOR|Cranberry juice|100% cranberry juice, once daily, in a 8fl oz bottle.
61916428|NCT06398405|EXPERIMENTAL|EGCG ARM|Studies investigating EGCG (purity 95% by high-performance liquid chromatography, obtained from Zhejiang Ningbo HEP Biotech Co., Ltd.) utilized a concentration of 4400 umol/L dissolved in 0.9% saline solution, which is administered three times a day for 1 week. Freshly prepared each time, the EGCG was administered 10 minutes before meals. The repeated slow swallowing of 30 ml of the EGCG solution was essential to ensure sustained contact of the drug on the esophageal walls
61916429|NCT05810818|EXPERIMENTAL|Dry needling along stretches and soft tissues therapy|
61916430|NCT05810818|ACTIVE_COMPARATOR|stretching and soft tissue mobilization|
61916431|NCT00450385|EXPERIMENTAL|R-CHOP|"Patients will receive R-CHOP for 6 to 8 cycles:~* Rituximab 375 mg/m2 on day 1~* Cyclophosphamide 750 mg/m2 IV on day 1~* Doxorubicin 50 mg/m2 on day 1~* Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1~* Prednisone 100 mg orally days 1-5, repeated every 21 days."
61916432|NCT02208401|ACTIVE_COMPARATOR|conventional cold snare polypectomy|conventional cold snare polypectomy
61916433|NCT02208401|EXPERIMENTAL|Cold snare polypectomy with suction|Cold snare polypectomy with suction
61916434|NCT05277480|EXPERIMENTAL|Apatinib+IE group|IE: Ifosfamide Plus Etoposide
61916435|NCT05277480|ACTIVE_COMPARATOR|IE group|IE: Ifosfamide Plus Etoposide
61916436|NCT04824716|EXPERIMENTAL|postconditioning|Patients that underwent postconditioning after primary percutaneous coronary intervention.
61916437|NCT04824716|OTHER|control|Patients that underwent primary percutaneous coronary intervention.
61916438|NCT02707159|EXPERIMENTAL|Nab paclitaxel / gemcitabine|Patients will receive 125 mg per m2 nab-paclitaxel and 1000 mg per m2 on days 1, 8 and 15 followed by one week of rest before new treatment cycle.
61916439|NCT00040456|PLACEBO_COMPARATOR|Placebo|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
61916440|NCT00040456|ACTIVE_COMPARATOR|MG Pidolate Administration|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
61916441|NCT05884632|EXPERIMENTAL|Treatment arm|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
62672793|NCT05534607|EXPERIMENTAL|Intervention group|The intervention group will immediately receive the Ola Mau i ka Hula intervention after randomization for 12 months. The intervention program is 8 months with a 4 month self-monitoring period.
62672794|NCT05534607|NO_INTERVENTION|Wait-list control group|"After baseline data collection, participants randomized to the wait-list control arm will not receive the Ola Mau i ka Hula Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not be offered the intervention until after the intervention arm is completed and their 12-month follow-up data collection is completed. They will only receive the educational component of the intervention from us during this 12-month period but they will be instructed to continue with their routine medical care as usual.~Wait-list control group will be offered the opportunity to receive intervention at the conclusion of 12 month assessment period, regardless of whether they were retained for the full 12 months of data collection."
62672795|NCT04557137||NET|"Study A:~A cross-sectional study that investigates 250 patients (Cohort A) with neuroendocrine neoplasia, encompassing both patients with neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC).~Study B:"
62672796|NCT04557137||Newly diagnosed NET|A prospective study that investigates 30 newly diagnosed NET patients over three months (Cohort B) who are offered palliative treatment with somatostatin analogues.
62672797|NCT06066515|EXPERIMENTAL|Survodutide 3.6 mg|
62672798|NCT06066515|EXPERIMENTAL|Survodutide 6.0 mg|
62672799|NCT06066515|PLACEBO_COMPARATOR|Placebo|
62672800|NCT06434779|EXPERIMENTAL|Mechanical Thrombectomy (JETi®)|
62301400|NCT05366829|EXPERIMENTAL|Tislelizumab in conjunction with radiation therapy|"Participants will receive local therapy including TACE+ RT or Ablation (tumors with incomplete ablation) + RT or RT alone (for patients not eligible for TACE or Ablation) and will be screened for eligibility prior to enrollment.~Once eligibility has been confirmed, Tislelizumab will be started before radiation therapy and will continue after radiation therapy.~Participants who do not receive Tislelizumab for a total of two cycles will be replaced and interpreted for only toxicity analysis."
62672801|NCT03358706|EXPERIMENTAL|Crohn's Disease or Ulcerative Colitis Participants: Ustekinumab + Probe Cocktail|Participants will receive a single Intravenous (IV) infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8 and a ustekinumab 90 milligram (mg) maintenance dose via subcutaneous (SC) route on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator. The probe cocktail (2 milligram \[mg\] of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) will be administered orally on Days 1, 22, and 113.
62672802|NCT03358706|EXPERIMENTAL|Healthy Participants: Probe Cocktail|Participants will receive the probe cocktail (2 mg of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) orally on Day 1.
62672803|NCT04201405|EXPERIMENTAL|Haematopoietic stem cell gene therapy for MPS IIIA|Open label
62672804|NCT02021604|EXPERIMENTAL|Pancreatic Imaging with Fluorodopa F 18|
62672805|NCT01520662|EXPERIMENTAL|Wellness Portal Intervention|Wellness Portal Intervention: patients have access to the portal in the course of the study.
62672806|NCT01520662|NO_INTERVENTION|Wellness Portal Control|Control patients don't have access to the Wellness Portal in the course of the study.
62672807|NCT01219075|EXPERIMENTAL|Arm I|Patients receive oral soy isoflavones supplement once daily for 12 months in the absence of disease progression.
62672808|NCT01219075|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily for 12 months in the absence of disease progression.
62672809|NCT03000751|ACTIVE_COMPARATOR|Track A|Simple Audit Report; In-Person Meeting (timed to coincide with the multi-component intervention); Multi-Component Intervention
62672810|NCT03000751|ACTIVE_COMPARATOR|Track B|In-Person Meeting (timed to coincide with the simple audit report); Simple Audit Report; Multi-Component Intervention
62672811|NCT03000751|OTHER|Track C|Simple Audit Report; Multi-Component Intervention
62301401|NCT03883061||mortality of sepsis|the study sample would be extracted from electronic health records in emergence departments. risk factor analysis and mathematical modeling would be performed to evaluate the significant and independent risk factors and predictive models.
62672812|NCT05214950|EXPERIMENTAL|ORI monitoring|SpO2, ECG, NIBP, and oxygen reserve index monitoring
62672813|NCT05214950|NO_INTERVENTION|Standard monitoring|SpO2, ECG, NIBP monitoring
62672814|NCT05890586|EXPERIMENTAL|Arm B - Fluvoxamine|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.
62672815|NCT05890586|PLACEBO_COMPARATOR|Arm B - Placebo|Placebo - appearance and size matched to active study drug. Placebo will be self-administered orally by each participant twice a day for 10 days.
62672816|NCT01801605|ACTIVE_COMPARATOR|on|active session
62672817|NCT01801605|PLACEBO_COMPARATOR|off|fictive session
62672818|NCT04174820||Retrospective Low-Grade Glioma|Inclusion of patients with Low-Grade Glioma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
62672819|NCT04174820||Retrospective Medulloblastoma|Inclusion of patients with Medulloblastoma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
62672820|NCT04174820||Prospective patients|Inclusion of prospective patients with an indication to surgery of a Posterior Fossa Tumor, with evaluation of post-operative mutism and then one year after the end of mutism, an evaluation with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
61916442|NCT06482242|OTHER|Delayed access|The step wedge design ensures that everyone has access to the intervention but data will be collected prior to the intervention being implemented at each site.
61916443|NCT06482242|OTHER|Immediate access|Sites will be randomized to receive intervention and those who receive intervention initially, will then be compared to those who do not at the same time period.
62111356|NCT01286415|EXPERIMENTAL|Group Cognitive Processing Therapy-Cognitive Only|
62672821|NCT04174820||Control patients|Inclusion of patients without Posterior Fossa Tumor, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
62672822|NCT05339061|EXPERIMENTAL|Physician-Modified Endograft|This is a single arm study used to evaluate the safety and effectiveness of fenestrated and branched techniques for the treatment of patients with a complex, juxtarenal, pararenal or thoracoabdominal abdominal aortic aneurysms (Extent I-V).
62672823|NCT01837095|EXPERIMENTAL|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
62672824|NCT00366535|ACTIVE_COMPARATOR|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive Placebo for 12 weeks and then Neurotropin for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
62672825|NCT00366535|ACTIVE_COMPARATOR|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 12 weeks and then Placebo for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others
62672826|NCT04250363|PLACEBO_COMPARATOR|Early liver stage: Pooled Placebo|Participants received single dose of placebo matched to M5717 capsule on Day 1 after 2 hours of Plasmodium falciparum Sporozoite (PfSPZ) (3200 sporozoites per injection) intravenous (IV) inoculation administration on Day 1.
61916444|NCT05384977|EXPERIMENTAL|[14C]-NV-5138|\[14C\]-NV-5138 oral solution
61916445|NCT01089361|PLACEBO_COMPARATOR|Normal saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
62672827|NCT04250363|EXPERIMENTAL|Early liver stage: 30 mg M5717|Participants received single dose of M5717 30 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62111357|NCT01286415|ACTIVE_COMPARATOR|Group Present Centered Therapy|
62111358|NCT00768664|EXPERIMENTAL|A|
62111359|NCT00755781|ACTIVE_COMPARATOR|CIS|CIS in addition to standard immunosuppressive regimen.
62111360|NCT00755781|NO_INTERVENTION|SOC|Standard of care (SOC) therapy for lung transplant recipients
62111361|NCT03310996|EXPERIMENTAL|tDCS Active arm|The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes
62111362|NCT03310996|PLACEBO_COMPARATOR|tDCS Sham arm|The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.
62111363|NCT01792648|ACTIVE_COMPARATOR|Standard Reference Diet|
62111364|NCT01792648|EXPERIMENTAL|Almond Supplemented Diet|
62111365|NCT01792648|ACTIVE_COMPARATOR|Low Carbohydrate Reference Diet|
62111366|NCT01329328|NO_INTERVENTION|CONTROL|NO VIBRATION EXERCISE
62672828|NCT04250363|EXPERIMENTAL|Early liver stage: 60 mg M5717|Participants received single dose of M5717 60 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62672829|NCT04250363|EXPERIMENTAL|Early liver stage: 80 mg M5717|Participants received single dose of M5717 80 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62672830|NCT04250363|EXPERIMENTAL|Early liver stage: 100 mg M5717|Participants received single dose of M5717 100 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62672831|NCT04250363|EXPERIMENTAL|Early liver stage: 200 mg M5717|Participants received single dose of M5717 200 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62672832|NCT04250363|EXPERIMENTAL|Late liver stage: Pooled Placebo|Participants received single dose of placebo matched to M5717 capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62672833|NCT04250363|EXPERIMENTAL|Late liver stage: 60 mg M5717|Participants received single dose of M5717 60 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
61916446|NCT01089361|EXPERIMENTAL|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
61916447|NCT01991639|NO_INTERVENTION|cognitive training|Participants are visited twice a week by buddies, but they do not specifically monitor the nutritional status or perform physical training in the first 10-12 weeks. Instead of that buddies are provided with a portfolio of possible activities, especially cognitive training, which they could perform together with the frail, malnourished subjects.
61916448|NCT01991639|EXPERIMENTAL|nutritional & physical activity|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
62301402|NCT02112448|ACTIVE_COMPARATOR|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
62470809|NCT06370754|EXPERIMENTAL|Cohort4: JS004+JS001+Nab-Paclitaxel+Gemcitabine|Participants with previously untreated systemic pancreatic cancer with unresectable locally advanced or metastatic pancreatic cancer will receive JS004 and JS001 combined with chemotherapy (nab-paclitaxel+gemcitabine) until the treatment termination event specified in the protocol occurs.
62672834|NCT04250363|EXPERIMENTAL|Late liver stage: 100 mg M5717|Participants received single dose of M5717 100 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62672835|NCT04250363|EXPERIMENTAL|Late liver stage: 200 mg M5717|Participants received single dose of M5717 200 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.
62672836|NCT00805220|ACTIVE_COMPARATOR|1|Regular overground walking without poles
62672837|NCT00805220|EXPERIMENTAL|2|Nordic Walking
62672838|NCT02330263|EXPERIMENTAL|carbohydrate group|Randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage in the evening before their surgery and in the morning of the operation day (3 hours before their scheduled operation).
62672839|NCT02330263|NO_INTERVENTION|control group|Patients in the control group consume no food or drink after midnight before surgery.
62672840|NCT02821000|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 2 mg/kg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
62672841|NCT03462563|EXPERIMENTAL|INTERCEED™|patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen).
62672842|NCT03462563|PLACEBO_COMPARATOR|standard of care treatment|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
62672843|NCT03016403|EXPERIMENTAL|Stepped-Care Intervention|Intervention strategies are grounded in evidence-based Cognitive Behavioral Therapy (CBT), that includes stress management and relaxation treatment strategies and coping skills training. Treatment strategies have been adapted from the Transactional Model of Stress and Coping (TMSC), a theoretical model that predicts that individuals who are able to cope and adapt to the stress related to cancer treatment or caregiving will report less psychological distress than those unable to cope.
62672844|NCT03016403|ACTIVE_COMPARATOR|Enhanced Usual Care|Denver Health, St. Mary's and St. Joseph's hospitals provide supportive mental health care for patients such as printed materials, support groups, crisis counseling, and specialized care (e.g., psychiatric medication). Because the amount of usual mental health care that each patient receives varies at each site, the investigators will standardize and monitor the usual care arm across the three sites with an enhanced usual care condition.
62672845|NCT02196909|ACTIVE_COMPARATOR|HIBM patient|motor function, muscle strength, NMR, 24h urine and serum collections at baseline, then annually
62301403|NCT02112448|ACTIVE_COMPARATOR|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
62301404|NCT03114761|EXPERIMENTAL|CTA-IH|
62301405|NCT04203303||Observational|Observational
62672846|NCT02196909|ACTIVE_COMPARATOR|Controls|motor function, muscle strength, 24h urine and serum collections at baseline only
62672847|NCT02245386||Group 1|(40 women after normal vaginal delivery) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
62672848|NCT02245386||Group 2|(40 women after urgent cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
62672849|NCT02245386||Group 3|(40 women after elective cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
62672850|NCT01176994|EXPERIMENTAL|Skin lesions|Individuals with skin lesions whose lesions are not sent for histology by dermatologists
62672851|NCT04708054|EXPERIMENTAL|Treatment (venetoclax, busulfan, fludarabine, cladribine)|Patients receive venetoclax PO QD on days -22 to -3, busulfan IV over 3 hours on days -20, -13, -6, -5, -4, and -3, and fludarabine phosphate IV over 1 hour and cladribine IV over 2 hours on days -6 to -3 in the absence of disease progression or unacceptable toxicity. Patients then undergo stem cell transplantation over 1-2 hours on day 0.
62672852|NCT00290758|EXPERIMENTAL|Arm I (genistein)|Patients receive oral genistein once daily for up to 6 months.
61916449|NCT01138943|ACTIVE_COMPARATOR|Chlorhexidine alcohol-base mouthrinse|
61916450|NCT01138943|EXPERIMENTAL|non alcohol chlorhexidine mouthrinse|
62301406|NCT04976465|EXPERIMENTAL|combined with aPL(+)|the antiphospholipid antibodies appear in blood at least once
62470810|NCT06370754|EXPERIMENTAL|Cohort5: JS007+JS001+Nab-Paclitaxel+Gemcitabine|Participants with previously untreated systemic pancreatic cancer with unresectable locally advanced or metastatic pancreatic cancer will receive JS007 and JS001 combined with chemotherapy (nab-paclitaxel+gemcitabine) until the treatment termination event specified in the protocol occurs.
62672853|NCT00290758|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo once daily for up to 6 months.
61916451|NCT05623488|EXPERIMENTAL|Dose Level 1|3.00 x 10\^7 CAR T cells administered intratumoral
62470811|NCT06370754|EXPERIMENTAL|Cohort6: JS015+JS001+ Nab-Paclitaxel+Gemcitabine|Participants with previously untreated systemic pancreatic cancer with unresectable locally advanced or metastatic pancreatic cancer will receive JS015 and JS001 combined with chemotherapy (nab-paclitaxel+gemcitabine) until the treatment termination event specified in the protocol occurs.
62301407|NCT04976465|EXPERIMENTAL|combined with aPL(-)|the antiphospholipid antibodies never appear in blood
62301408|NCT06001580|EXPERIMENTAL|BR101|
62301409|NCT03572374|EXPERIMENTAL|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
62470812|NCT02252133|OTHER|DT1, then 1DAVTE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
62470813|NCT02252133|OTHER|1DAVTE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
62470814|NCT00512421||A|navigation technique
62470815|NCT00512421||B|conservative surgery
62672854|NCT01727427||Anticoagulants, aspirin|Parenteral or oral anticoagulants: heparin, fondaparinux, vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors; aspirin. Any dosage, frequency and duration
62672855|NCT06476691||study group 1|Cross-sectional study of approx 100 patients undergone alloHCT at the age of 18-29
62672856|NCT06476691||Study group 2|Prospective study of 15 patient before and during a period of 2 years after allo-HCT
62470816|NCT00512421||C|Historical control
62470817|NCT03083886|ACTIVE_COMPARATOR|Usual PCP led care|
62470818|NCT03083886|EXPERIMENTAL|Identify, Coordinated, Enhanced (ICE) Decision Making|
62470819|NCT03083886|EXPERIMENTAL|Individualized Postural Therapy (IPT)|
62470820|NCT05932524|EXPERIMENTAL|Low-dose baricitinib plus high-dose dexamethasone|Oral baricitinib is given at a dose of 2 mg daily for 6 consecutive months. Dexamethasone is administrated at 40 mg per day for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10). Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
62470821|NCT05932524|ACTIVE_COMPARATOR|High-dose dexamethasone|Dexamethasone is administrated at 40 mg per day for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10). Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
62470822|NCT05981989|EXPERIMENTAL|Epidural electrical stimulation (EES)|Subjects will be implanted with 16-electrode epidural array in the C6-T1 area of the spinal cord. After surgery, subjects will undergo a structured program of physical rehabilitation and electrical stimulation.
62470823|NCT04003350|ACTIVE_COMPARATOR|Opioid Regimen|"Weeks 1-4~* Oxycodone 5 mg PRN q4h (30 tablets)~* Tramadol 50 mg PRN q6h (30 tablets)"
62470824|NCT04003350|EXPERIMENTAL|Multimodal pain regimen with PRN opioids|"Weeks 1-4~* Tylenol 1000 mg q8h (standing)~* Meloxicam 15 mg qD (standing).~* Gabapentin 200 mg BID (with morning and evening Tylenol dose)~* Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)~* Esomeprazole 20mg daily if not already on another H2 blocker or PPI~* Oxycodone 5 mg PRN q4h (30 tablets)~* Tramadol 50 mg PRN q6h (30 tablets)"
62470825|NCT04408144|EXPERIMENTAL|StudyGroup|Patients will receive an addition of dydrogesterone (Duphaston) to the standard treatment for luteal phase support
62470826|NCT04408144|NO_INTERVENTION|Control Group|Patients will receive the standard treatment for luteal phase support without Dydrogesterone
62672857|NCT02454582|OTHER|Group 1|15min without CPAP, then 15min with CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
62672858|NCT02454582|OTHER|Group 2|15min with CPAP, then 15min without CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
62672859|NCT04745988|EXPERIMENTAL|Lenvatinib Plus Pembrolizumab|One cycle is 21 days, with Lenvatinib plus Pembrolizumab repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
62672860|NCT04745988|EXPERIMENTAL|Lenvatinib, Pembrolizumab Plus FLOT|One cycle is 21 days, with Lenvatinib, Pembrolizumab plus FLOT repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
62672861|NCT01491932|EXPERIMENTAL|AFQ056|Patients entering the study will be titrated to target dose of AFQ056 twice daily or the highest tolerated dose at weekly intervals.
62470827|NCT04511910||Early surgery Group 1|The surgery is performed within the first 3 days
62301410|NCT03572374|ACTIVE_COMPARATOR|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
62470828|NCT04511910||Early surgery Group 2|Surgery is performed between the fourth and seventh day
62672862|NCT04056637|NO_INTERVENTION|Group 1: Standard of Care|Participants will be asked to complete follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider.
62672863|NCT04056637|EXPERIMENTAL|Group 2: Flexible Follow-Up|Participants will be offered three follow-up options, including: 1) follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider; 2) repeat serum beta-hCG testing; 3) repeat multi-level pregnancy test strategy
62672864|NCT02846454|EXPERIMENTAL|inulin|Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)
62672865|NCT02846454|NO_INTERVENTION|non inulin and arabinoxylan|investigating the satiating effects of a control drink (2.6g/d maltodextrin)
62672866|NCT02846454|EXPERIMENTAL|arabinoxylan|Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)
62672867|NCT05634928||TMA|TMA patients
62672868|NCT06072261|EXPERIMENTAL|Kinesio Tape Group|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
62672869|NCT06072261|NO_INTERVENTION|Control Group|For the control group data, patients who underwent lower extremity surgery at the same institution for similar periods, but were included in the standard rehabilitation program, but did not apply kinesio tape, will be included. Standard rehabilitation practice includes in-bed transfer training, gait training, practice of daily living activities, and therapeutic exercise practices
62672870|NCT03357705|EXPERIMENTAL|synthetic|alveolar ridge preservation with synthetic bone
62672871|NCT03357705|ACTIVE_COMPARATOR|collagen|alveolar ridge preservation with bovine collagen
62672872|NCT04947904|EXPERIMENTAL|Optimised Restrictive Strategy|The volume of non-resuscitative fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in ICU according to a special protocol.
62672873|NCT04947904|NO_INTERVENTION|Control|Resuscitation fluids, maintenance fluids, nutrition and drugs will be administered as usually performed and following most recent guidelines.
62301411|NCT05218213||Healthy young|Healthy young adults
62470829|NCT04511910||Early surgery Group 3|Surgery is performed more than 7 days from the onset of symptoms
62470830|NCT01125137|EXPERIMENTAL|Biopsy|
62470831|NCT03700411|ACTIVE_COMPARATOR|Morphine|Morphine-based perioperative analgesia
62470832|NCT03700411|ACTIVE_COMPARATOR|Piritramid|Piritramid-based perioperative analgesia
62470833|NCT03700411|ACTIVE_COMPARATOR|Epidural|Perioperative epidural analgesia containing an opioid
62672874|NCT00826293|ACTIVE_COMPARATOR|True Stabilization Group|Patients will be randomized to one of the two treatment groups (true stabilization vs. sham stabilization). Patients will be exercising with a belt that is expected to reduce impingement of the rotator cuff tendons.
62672875|NCT00826293|SHAM_COMPARATOR|Sham Stabilization|Patients receive sham stabilization. The sham procedure imitates the treatment without any true effect.
62672876|NCT03053830|EXPERIMENTAL|Intervention Group|Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.
62672877|NCT04220281|ACTIVE_COMPARATOR|propofol group|propofol group will receive propofol infusion
62672878|NCT04220281|ACTIVE_COMPARATOR|nitroglycerin group|will receive nitroglycerin infusion
62672879|NCT03099356|EXPERIMENTAL|Cyclophosphamide and Sirolimus|Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
62672880|NCT03156452|EXPERIMENTAL|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
62672881|NCT03156452|ACTIVE_COMPARATOR|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
62111367|NCT01329328|EXPERIMENTAL|VIBRATION EXERCISE|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIOS, MILAN, ITALY
62301412|NCT05218213||Healthy elderly|Healthy elderly adults
62672882|NCT05378607|EXPERIMENTAL|Externally assigned sub-goals|"Participants will be eligible for prize drawings every three months based on meeting externally chosen subgoals in year 1 and maintaining 90% or more adherence in Year 2 as measured using a Wisepill device. In addition, there will be a larger prize drawing conditional on showing 90% adherence at the end of year 1 and viral suppression at the end of Year 2.~This arm will receive the intervention 'Incentivization based on gradually increasing externally chosen adherence goals ', 'Annual adherence prize drawing', 'SMS motivational messages + reminder of prize drawing', 'Year 2 re-allocation based on year 1 performance' and the intervention 'End of Year 2 viral suppression prize drawing.'"
62672883|NCT05378607|EXPERIMENTAL|Participatory sub-goals|"Participants will be eligible for prize drawings every three months based on meeting self-chosen subgoals in year 1 and maintaining 90% or more adherence in Year 2 as measured using a Wisepill device. In addition, there will be a larger prize drawing at the end of Years 1 and 2 that is conditional on showing 90% adherence and viral suppression, respectively.~This arm will receive the intervention ' Incentivization based on gradually increasing self-chosen adherence goals ', 'Annual adherence prize drawing', 'SMS motivational messages + reminder of prize drawing', 'Year 2 re-allocation based on year 1 performance' and the intervention 'End of Year 2 viral suppression prize drawing.'"
62672884|NCT05378607|EXPERIMENTAL|Fixed goal|"Participants will be eligible for prize drawings every three months based on meeting a fixed adherence goal of 90% in year 1 and maintaining this adherence level in Year 2 as measured using a Wisepill device. In addition, there will be a larger prize drawing at the end of Years 1 and 2 that is conditional on showing 90% adherence and viral suppression, respectively.~This arm will receive the intervention ' Incentivization based on a fixed adherence goal', 'Annual adherence prize drawing', 'SMS motivational messages + reminder of prize drawing', 'Year 2 re-allocation based on year 1 performance' and the intervention 'End of Year 2 viral suppression prize drawing.'"
62672885|NCT05378607|PLACEBO_COMPARATOR|Control|"This arm will be provided with Mildmay's usual standard of care. Participants will not receive a prize drawing incentive based on adherence, but they will also be asked to use the Wisepill device and receive weekly motivational messages.~This arm will receive the intervention ' SMS motivational messages '"
62672886|NCT00324194|EXPERIMENTAL|1|MGCD0103 oral dose 2 times per week.
62672887|NCT04347759|OTHER|System with coaching messages|A telephone-computer interface IVR system to report symtopms and to receive coaching messages based on symptom severity.
62672888|NCT03181009|EXPERIMENTAL|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
62672889|NCT03181009|ACTIVE_COMPARATOR|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
62672890|NCT04432584|EXPERIMENTAL|Arm A (Crovalimab)|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
62672891|NCT04432584|ACTIVE_COMPARATOR|Arm B (Eculizumab)|Participants will receive an approved maintenance dose of eculizumab starting on Day 1 and Q2W (every 2 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of study eculizumab treatment, participants will have the option to switch to crovalimab or to discontinue from the study after completion of 10 weeks of safety follow-up.
62672892|NCT04432584|EXPERIMENTAL|Arm C (Crovalimab) (Exploratory)|Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
62672893|NCT02040220||Group 1|Eylea treatment goup
62672894|NCT01096186|OTHER|Open Label IPX066|Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.
62672895|NCT05280808|EXPERIMENTAL|Experimental phone app|Experimental phone app for self-fitting of hearing aids
62672896|NCT00972257|ACTIVE_COMPARATOR|Drug: Dorzolamide/Timolol|
62111368|NCT01329328|EXPERIMENTAL|VIBRATION EXERCISE PLUS RADIOFREQUENCY ADMINISTRATION|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIO, MILAN, ITALY PLUS LOCAL ADMINISTRATION OF RADIOFREQUENCY
62672897|NCT00972257|ACTIVE_COMPARATOR|Treatment with Brimonidine/Timolol|
62672898|NCT00305279|ACTIVE_COMPARATOR|1|
62672899|NCT00305279|ACTIVE_COMPARATOR|2|
62111369|NCT01738867|PLACEBO_COMPARATOR|Treatment A|Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
62111370|NCT01738867|EXPERIMENTAL|Treatment B|Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
62301413|NCT05218213||Parkinson's disease|Elderly with Parkinson's disease
62301414|NCT01982630|EXPERIMENTAL|Part 1: MK-8521 64/120 μg/day|Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.
62301415|NCT01982630|EXPERIMENTAL|Part 1: MK-8521 34/72 μg/day|T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14.
62301416|NCT01982630|ACTIVE_COMPARATOR|Part 1: Liraglutide 0.6/1.2/1.8 mg/day|T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.
62301417|NCT01982630|PLACEBO_COMPARATOR|Part 1: Placebo for MK-8521|T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.
62672900|NCT00305279|ACTIVE_COMPARATOR|3|
62672901|NCT03926598||Patients/Caretakers Group|Patients with Type II Diabetes and caretakers of patients with Type II Diabetes.
61916452|NCT05623488|EXPERIMENTAL|Dose Level -1|3.00 x 10\^6 CAR T cells administered intratumoral
62111371|NCT01738867|EXPERIMENTAL|Treatment C|Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
62111372|NCT05359224|ACTIVE_COMPARATOR|Clopidogrel|Using a randomization program, the test group (203 patients; Aspirin 100 mg + Prasugrel 5 mg) and control group (203 patients; Aspirin 100 mg + Clopidogrel 75 mg) are classified. Prescribe the above drugs according to the assigned group, and take them 5 days before the procedure.
62111373|NCT05359224|ACTIVE_COMPARATOR|prasugrel|Using a randomization program, the test group (203 patients; Aspirin 100 mg + Prasugrel 5 mg) and control group (203 patients; Aspirin 100 mg + Clopidogrel 75 mg) are classified. Prescribe the above drugs according to the assigned group, and take them 5 days before the procedure.
62111374|NCT05585567|EXPERIMENTAL|V-01/V-01-B5 group|One dose of V-01/V-01-B5
62470834|NCT04189146|OTHER|Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
62672902|NCT03926598||Certified Diabetes Educators Group|Diabetes educators who help patients manage their Type II Diabetes.
62301418|NCT01982630|EXPERIMENTAL|Part 2: MK-8521 64/120/180/240/300 µg/day-T2DM|T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.
62301419|NCT01982630|ACTIVE_COMPARATOR|Part 2: Liraglutide 0.6/1.2/1.8 mg/day-T2DM|T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.
62301420|NCT01982630|PLACEBO_COMPARATOR|Part 2: Placebo for MK-8521-T2DM|T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.
61916453|NCT04344743|EXPERIMENTAL|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
62111375|NCT05585567|EXPERIMENTAL|V-01-351/V-01-B5 group|One dose of V-01-351/V-01-B5
62111376|NCT05585567|EXPERIMENTAL|V-01 group|One dose of V-01
62470835|NCT02079194|EXPERIMENTAL|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
61916454|NCT05578001|EXPERIMENTAL|Pilocarpine|1 drop of Pilocarpine 1% instill in the eye
62470836|NCT02079194|EXPERIMENTAL|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
61916455|NCT02127268|ACTIVE_COMPARATOR|Arm T|Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
61916456|NCT02127268|NO_INTERVENTION|Arm B|With best support according to NCCN Guideline
62111377|NCT03598972||control|teeth of children of non vitamin taking mother
62111378|NCT03598972||intervention|children teeth of vitamin taking mother
62111379|NCT00197236|ACTIVE_COMPARATOR|Havrix Group|Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.
62111380|NCT00197236|EXPERIMENTAL|Infanrix + ActHIB→Havrix Group|Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30 and a second dose of Havrix at Month 7-10.
62111381|NCT00197236|ACTIVE_COMPARATOR|Havrix + Infanrix + ActHIB Group|Subjects received one dose of Havrix co-administered with Infanrix and ActHIB vaccines at Day 0 followed by a second dose of Havrix at Month 6-9.
62672903|NCT03926598||Physician Group|Physicians who help patients manage their Type II Diabetes.
62672904|NCT03926598||Front Desk Staff|Front desk staff who work with physicians that treat Type II Diabetes.
62672905|NCT03926598||Nurses|Nurses who help patients manage their Type II Diabetes.
62672906|NCT05219344|EXPERIMENTAL|One set of muscle flossing|This group will receive one set of muscle flossing around the thigh with low pressure. Pressure will be individualized based on thigh circumferences.
62672907|NCT05219344|ACTIVE_COMPARATOR|Two sets of muscle flossing|This group will receive two sets of muscle flossing around the thigh with low pressure. Pressure will be individualized based on thigh circumferences.
62301421|NCT01982630|EXPERIMENTAL|Part 2: MK-8521 64/120 µg/day-Non-Diabetic Overweight/Obese|Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14.
62301422|NCT00491530|EXPERIMENTAL|ABT-335 + rosuvastatin calcium|
62301423|NCT00491530|EXPERIMENTAL|ABT-335 + simvastatin|
62301424|NCT00491530|EXPERIMENTAL|ABT-335 + atorvastatin calcium|
62672908|NCT01899287|EXPERIMENTAL|education in skin care|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
62672909|NCT01899287|NO_INTERVENTION|no intervention|The control group will not have access to the group education, the profession specific information and the social guidance or the telephone hotline.
62672910|NCT03722030|EXPERIMENTAL|Strength-Training Intervention|Following baseline measures, participants will receive an initial in-person instructional session, instructional material and resistance training equipment, support and feedback via video coaching, mid-point assessment, and an in-person study visit to collect post study measures. Intervention will be 10 weeks, with a 5 week follow up period.
62672911|NCT03722030|PLACEBO_COMPARATOR|Waitlist Control|Following baseline measures, participants will provide mid-point measures, and in-person post-study measures with no 10-week strength training intervention.
62672912|NCT03193307|EXPERIMENTAL|Microgynon® 30 +BI 409306 then BI 409306 alone|Run in period: Microgynon alone Treatment period: Microgynon® 30 +BI 409306 then BI 409306 alone
62672913|NCT03073057|EXPERIMENTAL|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
62672914|NCT03073057|EXPERIMENTAL|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
62672915|NCT03073057|EXPERIMENTAL|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
62672916|NCT03073057|ACTIVE_COMPARATOR|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
62672917|NCT06314035|EXPERIMENTAL|Experimental Group|Participants in experimental group will receive a COPD Decision Support Tool (PDA intervention).
62672918|NCT06314035|PLACEBO_COMPARATOR|Attention Control Placebo Group|Participants in the attention control placebo group will receive a general health coaching intervention. Dose and time similar to experimental group.
62672919|NCT03178942|ACTIVE_COMPARATOR|Reference: Elimite™ Cream|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
62672920|NCT03178942|EXPERIMENTAL|Test: Permethrin Cream, 5%|Test: Permethrin Cream, 5% (Encube Ethicals)
62301425|NCT06540235|EXPERIMENTAL|Off low high|Device order will start with the device turned on but stimulation off, then the low setting and then the high setting
62301426|NCT06540235|EXPERIMENTAL|Off high low|Device order will start with the device turned on but stimulation off, then the high setting and then the low setting
62301427|NCT06540235|PLACEBO_COMPARATOR|Off off off|Device will always be turned on but stimulation off to measure test-retest variability.
62301428|NCT01014884|OTHER|Control Group|The control group will receive usual care as provided by your Health Plan.
62301429|NCT01014884|OTHER|Intervention group|Additional visits will be conducted by a member of the multidisciplinary team (case manager/nurse, social worker and/or pharmacist that will be either face to face or by telephone.
62301430|NCT05651646|EXPERIMENTAL|Interventional Arm|A total of 50 subjects who are undergoing dorsal column stimulator trial will be studied and placed on the SECURE study where their trial leads will be anchored using the StimfixTM system. The trial duration will be for seven days as per standard of care.
62470837|NCT06234722|PLACEBO_COMPARATOR|Rural - Conventional Cigarette|Participants who reside in rural locales of Appalachian KY and receive conventional cigarettes during the sampling period.
62672921|NCT00908687|EXPERIMENTAL|Group 1: 30 µg HA, no LT patch|A/H5N1 Vaccine 30 µg HA i.m. on Day 0
62672922|NCT00908687|EXPERIMENTAL|Group 2: 30 µg HA + 50 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
62672923|NCT00908687|EXPERIMENTAL|Group 3: 30 µg HA + 100 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
62672924|NCT00908687|EXPERIMENTAL|Group 4: 45 µg HA, no LT patch|A/H5N1 Vaccine 45 µg HA i.m. on Day 0
62672925|NCT00908687|EXPERIMENTAL|Group 5: 45 µg HA + 50 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
62672926|NCT00908687|EXPERIMENTAL|Group 6: 45 µg HA + 100 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
62672927|NCT01762462|EXPERIMENTAL|SAR302503|single treatment with oral dose up to 300 mg of SAR302503
62672928|NCT02458495|NO_INTERVENTION|Standard of Care Control Group|"Participants will be granted access to a generic Diabetes website. Participants will complete the same eligibility and baseline self-report as the intervention group. The 1 month and 3 month self-report survey will omit mention of the Diabetes MAP website and will reference the generic diabetes website.~Participants will be provided with access to a generic Diabetes website. Participants will complete the same eligibility, baseline and self-report surveys as the intervention group."
62672929|NCT02458495|EXPERIMENTAL|Diabetes MAP Intervention Group|Participants will be granted access to the Diabetes MAP website. Participants will complete the same eligibility and baseline self-report as the control group. The 1 month and 3 month self-report will refer to the Diabetes MAP website specifically.
62672930|NCT02046187|EXPERIMENTAL|Ketogenic Diet|Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
62672931|NCT00736476|EXPERIMENTAL|1|
62672932|NCT00736476|PLACEBO_COMPARATOR|2|
62672933|NCT04759170|OTHER|Mother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
62672934|NCT04759170|OTHER|Fother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
62672935|NCT04759170|OTHER|Music therapist Recorded Receptive Music therapy intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
62672936|NCT04759170|OTHER|No singing|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
61916457|NCT01610375|OTHER|Telephone Follow-up|Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up. However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up. Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
61916458|NCT02188043|OTHER|Relay Model|"AUDIT score 8+: Brief Motivational Intervention with alcohol therapist. AUDITscore16+:Brief Motivational Intervention and appointment at Alcohol Treatment Clinic~-"
61916459|NCT02188043|NO_INTERVENTION|Usual Referral Procedure|Hospital staff refer patient to Alcohol Treatment Clinic according to usual procedure
61916460|NCT01307020|PLACEBO_COMPARATOR|Placebo|
61916461|NCT01307020|ACTIVE_COMPARATOR|Ibuprofen|
61916462|NCT01307020|ACTIVE_COMPARATOR|TRAM.HCl high dose|
61916463|NCT01307020|ACTIVE_COMPARATOR|TRAM.HCl low dose|
61916464|NCT01307020|ACTIVE_COMPARATOR|DKP-TRIS high dose|
61916465|NCT01307020|ACTIVE_COMPARATOR|DKP-TRIS low dose|
61916466|NCT01307020|EXPERIMENTAL|DKP-TRIS low dose - TRAM.HCl low dose|
61916467|NCT01307020|EXPERIMENTAL|DKP-TRIS low dose - TRAM.HCl high dose|
62672937|NCT01250314|OTHER|With fracture|Patients with fracture
61916468|NCT01307020|EXPERIMENTAL|DKP-TRIS high dose - TRAM.HCl low dose|
61916469|NCT01307020|EXPERIMENTAL|DKP-TRIS high dose - TRAM.HCl high dose|
61916470|NCT00656071||1|Control -- postoperative mechanical ventilation patients without ARDS
62672938|NCT01250314|OTHER|Without fracture|Patients without fracture
62672939|NCT04983498|EXPERIMENTAL|Prospective Experimental Group|For the experimental group, we will recruit 200 participants who will receive the Enhanced Recovery Pathway, which will be ordered as a standing order set by the attending provider and managed by their peri-procedural nurses. The modified ERP for this study includes the following interventions: nursing managed order sets with ERP instructions to receive goal-directed fluid management within anesthesia approved parameters utilizing the NMH Colorectal ERAS protocol for IV fluid administration, PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis, early mobilization up to chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters, and early PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters.
62672940|NCT04983498|NO_INTERVENTION|Retrospective Control Group|The retrospective group will consist of 200 randomly selected medical records of patients who had colonoscopy procedures for a 6 month period prior to study implementation (between 10/1/2019 to 4/1/2020). The retrospective control group will have received the current standard of care including: IV fluids for management of intra-procedural hypotension as indicated/ordered by the physician, PO intake at 30-45 minutes, up to a chair at 60 minutes, and all procedure related complications will have been treated (e.g. PONV) per physician order as is the current standard of practice in the GI Lab recovery area.
61916471|NCT00656071||2|Cases -- postoperative mechanical ventilation patients with ARDS
61916472|NCT01280201|EXPERIMENTAL|Pazopanib|
61916473|NCT06112964||Participants with cancer and cancer associated weight loss/ loss of appetite|Participants with confirmed malignancy, reporting weight loss of \>5% body weight in 6 months, or loss of appetite.
61916474|NCT06112964||Healthy volunteers|No malignancy or weight loss in the past 6 months
61916475|NCT00801307|EXPERIMENTAL|1|He/O2 78:22
61916476|NCT00801307|EXPERIMENTAL|2|He/O2 65:35
61916477|NCT00801307|ACTIVE_COMPARATOR|3|Medical Air
62111382|NCT01014858|EXPERIMENTAL|Donepezil|5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient adjusted to 5mg dose. 10mg does continues for the remainder of the study.
61916478|NCT00923949|EXPERIMENTAL|Pioglitazone|45 mg tablet daily by mouth for six weeks
61916479|NCT01989260|OTHER|Anti-adhesive gel|An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
61916480|NCT02763592|EXPERIMENTAL|Lidocaine|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
61916481|NCT02763592|PLACEBO_COMPARATOR|placebo|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
61916482|NCT05757362|OTHER|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation|Participants will be asked to complete the questionnaire developed.
61916483|NCT01924702|ACTIVE_COMPARATOR|anodal tDCS|Intensive language therapy with anodal transcranial direct current stimulation
61916484|NCT01924702|SHAM_COMPARATOR|sham tDCS|Intensive language therapy with Sham-tDCS
62672941|NCT04725643||Implant Group|Adults who are choosing to get a replacement Nexplanon and agree to track and report their bleeding patterns for one month before replacement and 3 months after.
61916485|NCT02576769||Basal cell carcinoma|Basal cell carcinoma
61916486|NCT04074876||patients with femur fracture|"Group is composed of patients more of 65 years of age with femur fracture undergoing urgent orthopedic surgery.~During normal pre-operative evaluation and classification based on principal scores and laboratory data, patients will be subjected to bedside pulmonary ultrasound.~Pulmonary ultrasound will evaluate the presence of one of four patterns (normal pattern, isolated B lines, coalescent B lines and consolidation) defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient.~These patients will be later subjected to spinal anaesthesia and orthopedic surgery.~They will be follow for evaluation of MACE (major adverse cardiovascular events: atrial fibrillation, flutter, acute heart failure and non-fatal acute myocardial infarction)"
61916487|NCT00950261|EXPERIMENTAL|tri-weekly cisplatin|Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
62111383|NCT01014858|PLACEBO_COMPARATOR|Placebo|Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the remainder of the study.
62672942|NCT02318277|EXPERIMENTAL|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
62672943|NCT03212469|EXPERIMENTAL|Patients with head and neck squamous cell carcinoma|
62672944|NCT03212469|EXPERIMENTAL|Patients lung cancer|
62111384|NCT05280964|EXPERIMENTAL|Intervention|Enrolled into a 6 month coaching program from January 1 2021 to June 30 2021
61916488|NCT05147779|EXPERIMENTAL|Treatment Group (AlloRx)|intravenous and intracavernosal or interstitial delivery (total dose of 100 million cells)
62111385|NCT05280964|NO_INTERVENTION|Control/Wait-list|No intervention from January 1 2021 to July 1 2021 (they were offered the coaching program from July 1 2021-Dec 31 2021)
62111386|NCT05257785|EXPERIMENTAL|Lymfit exercise intervention|Participants randomized to the intervention group will be allocated a pre-registered Fitbit, a personalized exercise prescription designed by the kinesiologist, and 12 weeks of supervision by the kinesiologist.
62672945|NCT03212469|EXPERIMENTAL|Patients with oesophagus cancer|
62672946|NCT03561740|EXPERIMENTAL|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
62672947|NCT03561740|NO_INTERVENTION|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
62672948|NCT05979077|EXPERIMENTAL|MyChart Questionnaire (Intervention Group)|Participants within the intervention group will complete the patient-facing EHR-enabled MyChart® questionnaire.
62672949|NCT05979077|NO_INTERVENTION|Standard Clinical Care (Control Group)|Participants within the control group will undergo standard clinical care with no study intervention.
61916489|NCT05578027|EXPERIMENTAL|Group A: P1M2|19 participants received mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) and the research acupoint (Mingmen) in the first and the second trial phase, respectively. In each trial phase, skin surface temperature at the local stimulated area and the knee area on both sides will be recorded.
62672950|NCT03197935|EXPERIMENTAL|Atezolizumab and Chemotherapy|Participants received atezolizumab (840 milligrams \[mg\]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter \[mg/m\^2\]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m\^2) and cyclophosphamide (600 mg/m\^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
62736083|NCT03440463|EXPERIMENTAL|Intervention plus Norms-only booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use.
62672951|NCT03197935|PLACEBO_COMPARATOR|Placebo and Chemotherapy|Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m\^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m\^2) and cyclophosphamide (600 mg/m\^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
62301431|NCT04392414|EXPERIMENTAL|COVID-19 convalescent hyperimmune plasma|Moderately and severely ill COVID-19 patients treated with convalescent hyperimmune plasma. Patients will be infused with two units of 300 ml
62672952|NCT03167398|EXPERIMENTAL|CRE carriers|Fecal Microbiota Transplantation
62672953|NCT00201773|EXPERIMENTAL|Exemestane & Celecoxib|Patients will receive exemestane 25 mg orally per day for 8 weeks. Starting in the 9th week, patients will receive celecoxib 400 mg orally twice per day for 8 weeks in addition to exemestane.
62672954|NCT01991574|PLACEBO_COMPARATOR|Methylcellulose|On one of the study days: ingest one methylcellulose capsule with a test meal rich in phosphate.
62672955|NCT01991574|ACTIVE_COMPARATOR|Calcium Acetate|On one of the study days: ingest 667 mg calcium acetate, equivalent to 169 mg elemental calcium, with a test meal rich in phosphate.
62672956|NCT01991574|EXPERIMENTAL|Iron Hydroxide Adipate|On one of the study days: ingest 800 mg ferric hydroxide adipate, equivalent to 175 mg elemental iron, with a test meal rich in phosphate.
62672957|NCT06440759|EXPERIMENTAL|oXiris filter|"Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.~The 28-day mortality will be recorded following treatment."
62672958|NCT06440759|ACTIVE_COMPARATOR|M100 filter|"Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.~The 28-day mortality will be recorded following treatment."
62672959|NCT03536065|ACTIVE_COMPARATOR|Pre-Intervention|Current practice (unchanged)
62672960|NCT03536065|EXPERIMENTAL|Post-Intervention|Reduction of opioid prescription based on Pre-Intervention data, implementation of a discharge sheet and nursing education.
62672961|NCT05607758|EXPERIMENTAL|App for Stress management|"Participants will:~* Participate in a physical introduction to the app-based stress management program~* Get access to the app-based program, and a new module every third day (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.~* Receive two phone follow-up calls from study personnel (about 3 and 6 weeks after the physical introduction)"
62470838|NCT06234722|PLACEBO_COMPARATOR|Peri-Urban - Conventional Cigarette|Participants who reside in peri-urban locales of Appalachian KY and receive conventional cigarettes during the sampling period.
62672962|NCT05254210|EXPERIMENTAL|Treatment with RF Device|Subjects may receive up to 3 treatments with the RF device if they are willing to receive treatment for brow lifting and/or present with conditions such as, but not limited to; wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, loose skin on the face, neck and/or body
62672963|NCT06344377|EXPERIMENTAL|Betaine|Betaine supplementation for 8 weeks, daily dose of 3 g/d, taken twice a day in a capsulated form. One capsule will contain 500 mg betaine. Daily number of capsules will be 2 x 3 = 6.
62111387|NCT05257785|OTHER|Waitlist control|Participants will receive the exact same Lymfit exercise intervention 3 months after they consent to participate in the study.
62111388|NCT01363362|EXPERIMENTAL|glaucoma patients|Glaucoma patients undergoing selective laser trabeculoplasty for further IOP reduction
62111389|NCT03227523||subjects with copd|
62470839|NCT06234722|ACTIVE_COMPARATOR|Peri-Urban - Very Low Nicotine Cigarette|Participants who reside in peri-urban locales of Appalachian KY and receive very low nicotine cigarettes during the sampling period.
62672964|NCT06344377|PLACEBO_COMPARATOR|Placebo|Placebo will be inactive substance (maltodextrin) provided in the same-looking capsules as betaine. Placebo will be administered twice a day, daily number of capsules will be 2 x 3 = 6.
62672965|NCT06285695|EXPERIMENTAL|Clareon Toric IOL|Clareon Toric IOL implanted in one or both eyes during cataract surgery
62672966|NCT03167710|EXPERIMENTAL|dry needling, manipulation stretching|
62672967|NCT03167710|ACTIVE_COMPARATOR|manual therapy, exercise, ultrasound|
62672968|NCT04252118|EXPERIMENTAL|MSCs Treatment Group|Conventional treatment plus MSCs Participants will receive conventional treatment plus 3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
62672969|NCT04252118|NO_INTERVENTION|Conventional Control Group|Without MSCs Therapy but conventional treatment should be received.
62672970|NCT05662943||Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy|Patients with type 1 macular neovascularization and polypoidal choroidal vasculopathy who underwent continuous aflibercept injections with tolerating subfoveal retinal fluid more than 6 months
62672971|NCT00520442|EXPERIMENTAL|Ibuprofen|
62672972|NCT00520442|ACTIVE_COMPARATOR|acetamin w codeine|
62672973|NCT06413394||Virtual reality supported environmental education group|virtual reality supported environmental education group
62672974|NCT06413394||The group that will not receive virtual reality-supported environmental education|the group that will not receive virtual reality-supported environmental education
62111390|NCT03227523||subjects without pulmonary disease|
62111391|NCT02537522|EXPERIMENTAL|Test/Control - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 8.5 BC in right eye and Contact Lenses with 9.0 BC in left eye in a contralateral manner.
62111392|NCT02537522|EXPERIMENTAL|Control/Test - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 9.0 BC in right eye and Contact Lenses with 8.5 BC in left eye in a contralateral manner.
62111393|NCT02537522|EXPERIMENTAL|Test/Control - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 9.0 BC at Period 1 and Contact Lenses with 8.5 BC at Period 2 in a bilateral manner.
62111394|NCT02537522|EXPERIMENTAL|Control/Test - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 8.5 BC at Period 1 and Contact Lenses with 9.0 BC at Period 2 in a bilateral manner.
62111395|NCT00202358|PLACEBO_COMPARATOR|placebo|
62111396|NCT00202358|EXPERIMENTAL|atenolol|
62111397|NCT03052361|EXPERIMENTAL|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
62672975|NCT06413394||Control group|control group
62672976|NCT01524458|EXPERIMENTAL|POEM|To perform myotomy using endoscopy through a long submucosal tunnel
62672977|NCT00537082|EXPERIMENTAL|FTY720 0.5 mg|FTY720
62672978|NCT00537082|EXPERIMENTAL|FTY720 1.25 mg|FTY720
62672979|NCT00537082|PLACEBO_COMPARATOR|Placebo|
62672980|NCT03120923|EXPERIMENTAL|Lidocaine 3 cc & Triamcinolone Acetonide|
62672981|NCT03120923|ACTIVE_COMPARATOR|Lidocaine 9cc & Triamcinolone Acetonide|
62672982|NCT02379897|EXPERIMENTAL|LowGI+ModCarb|Low glycemic index + moderate carbohydrate/moderate fat diet
62672983|NCT02379897|EXPERIMENTAL|LowGI+HighCarb|Low glycemic index + high carbohydrate/low fat diet
62301432|NCT04392414|PLACEBO_COMPARATOR|Non-convalescent fresh frozen plasma (Standard plasma)|Moderately and severely ill COVID-19 patients treated with non-convalescent fresh frozen plasma (standard plasma). Patients will be infused with two units of 300 ml
62301433|NCT06332443|ACTIVE_COMPARATOR|SA|SA will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected (32-34)
62470840|NCT06234722|ACTIVE_COMPARATOR|Rural - Very Low Nicotine Cigarette|Participants who reside in rural locales of Appalachian KY and receive very low nicotine cigarettes during the sampling period.
62672984|NCT02379897|EXPERIMENTAL|HighGI+ModCarb|High glycemic index + moderate carbohydrate/moderate fat diet
62672985|NCT02379897|EXPERIMENTAL|HighGI+HighCarb|High glycemic index + high carbohydrate/low fat diet
62672986|NCT03309605|PLACEBO_COMPARATOR|Placebo Comparator Arm|Placebo
62672987|NCT03309605|EXPERIMENTAL|ELX-02|ELX-02
62672988|NCT05342688|EXPERIMENTAL|High contextual interference|The intervention will involve practicing three items from the Wolf motor function test in random order during three sessions. Each item will be repeated 30 times in total.
62672989|NCT05342688|ACTIVE_COMPARATOR|Low contextual interference|The intervention will involve practicing three items from the Wolf motor function test in blocked order during three sessions. Each item will be repeated 30 times in total.
62672990|NCT00726427|EXPERIMENTAL|1|8 increasing oral single doses given to 8 groups (3 on active and 1 on placebo in each group)
62672991|NCT00726427|EXPERIMENTAL|2|2 oral doses of AZD1656 given to 2 groups together with food
61916490|NCT05578027|EXPERIMENTAL|Group B: M1P2|19 participants received mild moxibustion manipulation at the research acupoint (Mingmen) and the control acupoint (the left side Pishu acupoint) in the first and the second trial phase, respectively. In each trial phase, skin surface temperature at the local stimulated area and the knee area on both sides will be recorded.
61916491|NCT05011279|EXPERIMENTAL|Pilot Study|"Participants in the pilot study will participate as members of family-based dyads (n=5 dyads). One member of each dyad will be a breast cancer survivor and one will be a blood relative.~Study involves interviews, questionnaires, Use of Move Together app with Garmin activity tracker watch"
61916492|NCT04823416|ACTIVE_COMPARATOR|Stoma|
62672992|NCT06532071|EXPERIMENTAL|Participants with Pulmonary Fibrosis|Participants with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) will receive \[68Ga\]CBP8 and undergo PET combined with dynamic contrast-enhanced MRI
61916493|NCT04823416|ACTIVE_COMPARATOR|Resection and stoma|
62672993|NCT05763316||Study participants|Neonates admitted to NICU and fulfilling eligibility criteria
61916494|NCT04413227|EXPERIMENTAL|PEG-ENDO+Docetaxel|PEG-ENDO( 1 mg/kg or 2mg/kg or 4mg/kg or 6mg/kg or 8mg/kg）+Docetaxel 75 mg/m2，once every 3 weeks at day 1
61916495|NCT01141777|ACTIVE_COMPARATOR|Spirulina platensis|
61916496|NCT01141777|PLACEBO_COMPARATOR|Soya bean|
61916497|NCT02551952|EXPERIMENTAL|MentalPlus® PILOT-I|This preliminary group will be submitted to the digital game MentalPlus®, also be the submitted to fMRI before and after surgery. The results of standardized tests and the data of the MentalPlus® of patients undergoing surgery will be compared with the results of the same tests and the data of the MentalPlus® of healthy volunteers with similar characteristics regarding the variables age and education.
62672994|NCT04014088|ACTIVE_COMPARATOR|helmet CPAP|helmet CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
62672995|NCT04014088|ACTIVE_COMPARATOR|facemask CPAP|facemask CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
61916498|NCT02551952|EXPERIMENTAL|MentalPlus® PILOT-II|This preliminary group will be of healthy volunteers submitted to the digital game MentalPlus®. The results of standardized tests and the data of the MentalPlus® of volunteers will be compared with the results of tests of patients undergoing surgery and the data of the MentalPlus®.
62672996|NCT03002909|ACTIVE_COMPARATOR|epidural group|an epidural catheter will be inserted under sterile conditions through the T9- 12 interspace using the 'loss-of-resistance' technique. The catheter will be advanced 4 cm cephalad. .
62672997|NCT03002909|ACTIVE_COMPARATOR|preperitoneal group|preperitoneal catheters will be placed in the subfascial (ie, pre-peritoneal) space under direct vision.
61916499|NCT02551952|ACTIVE_COMPARATOR|Group I: MentalPlus®|Evaluated with neuropsychological tests and MentalPlus® before surgery. After surgery, from the 3rd postoperative day a tablet will be use with MentalPlus® in 7 versions for cognitive training during 7 days (7 versions with interfaces adapted for ages up to 20 years and 7 versions for ages over it).
61916500|NCT02551952|SHAM_COMPARATOR|Group II: MentalPlus®|Ratings with neuropsychological testing and evaluation with MentalPlus® before surgery will be realized. After surgery, from the 3rd postoperative day a tablet will be use for entertainment with short films (20 minutes) for use in the placebo effect of digital game MentalPlus® this group also will be submitted to fMRI before and after surgery. (With the intention to respond to the specificity of findings in relation to the control for active placebo effect)
61916501|NCT04142879||Non-Interventional Centers|"Cohort A: Viz Subjects Initially Presenting to a Non-Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a non- interventional center.~Cohort B: Subjects Initially Presenting to a Non-Interventional Center The standard of care group will be comprised of subjects randomized to not have Viz notification and who initially present to a non-interventional center."
62111398|NCT03052361|PLACEBO_COMPARATOR|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
62470841|NCT06144385|EXPERIMENTAL|CAR-GPC3 T cells|The safety and efficacy of JWATM204 will be evaluated in a Bayesian Optimal Interval Design (BOIN) dose escalation approach. 3 CAR-T dose levels will be tested in this study: 1×10\^8, 3×10\^8, 10×10\^8, and 30×10\^8 CAR-T cells will be explored.
62470842|NCT01516996|ACTIVE_COMPARATOR|Neoadjuvant and CCRT|
62470843|NCT01516996|EXPERIMENTAL|Neoadjuvant and CCRT and Nimotuzumab|
62470844|NCT03892863|ACTIVE_COMPARATOR|active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
62470845|NCT03892863|SHAM_COMPARATOR|sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
62470846|NCT02529592|EXPERIMENTAL|Endotoxin|Endotoxin at 2ng/kg of body weight administered intravenously
62672998|NCT01765881|EXPERIMENTAL|Misoprostol|one 25 micrograms capsule all 4 hours by intravaginal route
62672999|NCT01765881|ACTIVE_COMPARATOR|Dinoprostone|one unique intravaginal sustained released of 10 milligrams
62673000|NCT05163535|EXPERIMENTAL|VM-1500A-LAI (1200 mg, 1200 mg, 1200 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 1200 mg, 1200 mg) during daily therapy with 2NRTIs for 12 weeks
62673001|NCT05163535|EXPERIMENTAL|VM-1500A-LAI (1200 mg, 900 mg, 900 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 900 mg, 900 mg) during daily therapy with 2NRTIs for 12 weeks
62470847|NCT02529592|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously
62470848|NCT01268085|EXPERIMENTAL|Radiation Safety Alert|A provider placing an electronic order for a CAT scan will receive a radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part.
62470849|NCT01268085|ACTIVE_COMPARATOR|Control|Parallel control with no intervention
62470850|NCT06144190||Japan|Preterm infants born at 28 to 31 gestational weeks in 2020-2021 in a Level IV NICU in Japan
62470851|NCT06144190||Finland|Preterm infants born at 28 to 31 gestational weeks in 2020-2021 in a Level III NICU in Finland
62470852|NCT05368870||Carlevale implantation|
62470853|NCT03554577|ACTIVE_COMPARATOR|Hearing Aid without NR|Hearing Aid without Noise Reduction (NR) serves as reference condition.
62470854|NCT03554577|EXPERIMENTAL|Hearing Aid with NR_A|NR_A: Noise Reduction principle A
62470855|NCT03554577|EXPERIMENTAL|Hearing Aid with NR_B|NR_B: Noise Reduction principle B.
62673002|NCT05163535|EXPERIMENTAL|VM-1500A-LAI (1200 mg, 600 mg, 600 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 600 mg, 600 mg) during daily therapy with 2NRTIs for 12 weeks
62673003|NCT05163535|OTHER|ELPIDA®|ELPIDA®, 20 mg capsules and 2NRTIs, daily therapy for 12 weeks
62673004|NCT03246594|EXPERIMENTAL|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.~Placement of oesophageal probe for temperature measurement"
62673005|NCT03246594|EXPERIMENTAL|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.~Intervention: Power limitation of RF generator"
62673006|NCT05311462||Weight-loss success with history of weight cycling|High-protein diet for three months
62673007|NCT05311462||Weight-loss failure with history of weight cycling|High-protein diet for three months
62673008|NCT06192212||Jejunostomy group|Intraoperative jejunostomy tube placement received
62470856|NCT03554577|EXPERIMENTAL|Hearing Aid with NR_C|NR_C: Noise Reduction principle C.
61916502|NCT04142879||Interventional Centers|"Cohort C: Viz Subjects Initially Presenting to an Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a interventional center.~Cohort D: Subjects Initially Presenting to a Interventional Center The standard of group will be comprised of subjects randomized to not have Viz notification and who initially present to an interventional center."
61916503|NCT00548405|EXPERIMENTAL|Alemtuzumab 12 mg|Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
61916504|NCT00548405|EXPERIMENTAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
61916505|NCT00548405|ACTIVE_COMPARATOR|Interferon Beta-1a|Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
61916506|NCT02363023||VAP suspects|Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
61916507|NCT05191264||percutaneous osteosynthesis and cementoplasty procedure|"Patient with percutaneous osteosynthesis and cementoplasty procedure will be included.~Patients have assessed for pain and quality of life during consultations as part of an interventional radiology procedure (pre-procedure consultation, and follow-up consultations at 1, 3, 6 and 12 months after the procedure."
61916508|NCT05415384|EXPERIMENTAL|Surgical Stabilization of Rib Fractures plus Multimodal Pain Therapy plus CRYOABLATION|Adding Cryoablation of levels 3-8, in addition to patients that undergo SSRF for multiple rib fractures.
61916509|NCT05415384|ACTIVE_COMPARATOR|Surgical Stabilization of Rib Fractures plus Multimodal Pain Therapy|Standard surgical treatment of patients with multiple rib fractures plus Multimodal Pain Therapy
61916510|NCT02347696|OTHER|Control|The subjects will follow a diet based on INRAN guidelines without doing any physical activity.
61916511|NCT02347696|OTHER|LGIMD|The subjects will follow a Low Glycemic Index Mediterranean Diet without doing any physical activity.
61916512|NCT02347696|OTHER|Endurance Activity (EA)|The subjects will follow a program of endurance (aerobic) activity (EA) without following a specific diet.
62470857|NCT01649011||Scores of the ODI and RMQ for low back pain|
62673009|NCT06192212||Non-jejunostomy group|Intraoperative jejunostomy tube placement not received
61916513|NCT02347696|OTHER|EA+Resistance Training (RT)|The subjects will follow a program of endurance activity (EA) and resistance training (RT) without following a specific diet.
61916514|NCT02347696|OTHER|LGIMD+EA|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA).
61916515|NCT02347696|OTHER|LGIMD+EA/RT|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA) and resistance training (RT).
61916516|NCT01284049|ACTIVE_COMPARATOR|Intralipid 20%®|reference treatment by standard lipid emulsion not enriched in n-3 EFA (Intralipid 20%®)+ vitamin E.
61916517|NCT01284049|EXPERIMENTAL|OMEGAVEN 10%®|Interventional treatment by a lipid emulsion enriched in n-3 EFA (OMEGAVEN 10%®).
62111399|NCT02615912|OTHER|Surfactant Exposure|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5% Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5% Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5% Silwet\* DA-63 (Momentive) 1.5% Sodium lauryl sulfate (Sigma Aldrich) 1.0% Water
62673010|NCT03479346|EXPERIMENTAL|GGT group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
62673011|NCT03479346|PLACEBO_COMPARATOR|Placebo group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
62673012|NCT05162391|OTHER|Contingency management|All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
62111400|NCT04622826|EXPERIMENTAL|sequential immune plasma infused patients|immune covid 19 plasma infusion
62111401|NCT00551226||1|Patients with tuberculosis
62111402|NCT00551226||2|Healthy controls
62111403|NCT00773435|ACTIVE_COMPARATOR|1. Echinacea purpurea|
62111404|NCT00773435|PLACEBO_COMPARATOR|2. placebo|
62470858|NCT00854711|EXPERIMENTAL|nitric oxide|inhaled nitric oxide 80 ppm and oxygen
62470859|NCT00854711|PLACEBO_COMPARATOR|standart of care|no intervention
62470860|NCT05025345|EXPERIMENTAL|Study Lens|Tecnis Eyhance
62470861|NCT05025345|ACTIVE_COMPARATOR|Control Lens|Tecnis 1 piece IOL (Intraocular lens)
62470862|NCT04312165|EXPERIMENTAL|Duramesh Laparotomy Closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
62111405|NCT02276508|EXPERIMENTAL|Probiotic|Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
62111406|NCT02114840|EXPERIMENTAL|Pronator quadratus preservation|Pronator quadratus preservation
62111407|NCT02114840|ACTIVE_COMPARATOR|Pronator quadratus non repair|
62470863|NCT04312165|ACTIVE_COMPARATOR|Control group-Conventional suture closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
62470864|NCT04425928|ACTIVE_COMPARATOR|activity group|Participants received an activity-based home program that was performed for 4 weeks.
62470865|NCT04425928|EXPERIMENTAL|exercise group|Participants received an exercise-based home program was performed that was performed for 4 weeks.
62470866|NCT04425928|NO_INTERVENTION|control group|No intervention
62470867|NCT03384602|ACTIVE_COMPARATOR|Dalcroze Eurhythmics program|music-based multi-task exercise intervention
62470868|NCT03384602|ACTIVE_COMPARATOR|home exercise strength program|simple strength training program to perform individually at home
62470869|NCT03384602|NO_INTERVENTION|Control group|no change in the daily activities, no exercise intervention
62470870|NCT01901783|ACTIVE_COMPARATOR|With primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will be primarily closed.
62470871|NCT01901783|EXPERIMENTAL|Without primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will not be primarily closed.
62111408|NCT02114840|ACTIVE_COMPARATOR|Pronator quadratus repair after disruption|
62111409|NCT03312439|ACTIVE_COMPARATOR|Intervention group|Will be given advice as described above
62111410|NCT03312439|NO_INTERVENTION|Control group|Consisting of subjects from the general Swedish population.
62111411|NCT04878627|EXPERIMENTAL|Cannabidiol (CBD)|"Days 1 to 7: Patients will receive CBD 2.5 mg/kg in divided doses BID for 7 days. Days 8 to 14: Patients will receive an increase dose of 7.5 mg/kg of CBD in divided doses.~Days 15 to 21: Patients will receive an increased dose of 12.5 mg/kg CBD, in divided doses. If patients experience dose limiting side-effects, they ill be maintained on the lowest tolerated dose."
62470872|NCT01590420|EXPERIMENTAL|CPAP treatment|1000 patients with 3-years CPAP treatment after a PSG titration
62470873|NCT01747317|EXPERIMENTAL|Single arm study|Single arm study.The investigators will conduct computed tomography,angiography and FFR measurement during angiography in this single arm.
62470874|NCT03408691|ACTIVE_COMPARATOR|Test product|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks
62470875|NCT03408691|PLACEBO_COMPARATOR|Control product|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks
62111412|NCT04878627|PLACEBO_COMPARATOR|Placebo|Days 1 to 7: Patients will receive placebo in divided doses BID for 7 days. Days 8 to 14: Patients will continue to receive placebo in divided doses. Days 15 to 21: Patients will receive continue to receive placebo in divided doses.
62111413|NCT06457568|EXPERIMENTAL|CONTEC08C and mercury sphygmomanometer|Blood Pressure Measurement with the CONTEC08C Oscillometric Sphygmomanometer (CONTEC08C) and with Mercury Sphygmomanometer
62111414|NCT03629119|EXPERIMENTAL|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet.
62470876|NCT03408691|NO_INTERVENTION|No product|no product
62470877|NCT02508662||Advanced Cancer (Refractory) with Genomic Mutation|Participants with advanced cancer who have exhausted standard treatment option and have no potential clinical trial available, and who have potentially actionable alterations on genomic profiling.
62470878|NCT05667272||Pancreatic fistula group|no intervention(s)
62470879|NCT05667272||non-pancreatic fistula group|no intervention(s)
62470880|NCT01805583|EXPERIMENTAL|ACT|The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
62470881|NCT01805583|EXPERIMENTAL|WPI|"This interventions aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
62673013|NCT02474901|ACTIVE_COMPARATOR|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
62673014|NCT02474901|ACTIVE_COMPARATOR|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
62470882|NCT01805583|EXPERIMENTAL|ACT and WPI|"The study participants receive both ACT and WPI. The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action. WPI aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
62673015|NCT05469061|EXPERIMENTAL|Tislelizumab plus Chemotherapy|In the single experimental arm, patients with locally nonresectable disease were subjected to receive neoadjuvant tislelizumab (200mg) plus chemotherapy (FP regimen) for conversion therapy. If conversion therapy succeeds, patients would proceed to surgery and adjuvant therapy. Otherwise, if patients were still not resectable after the conversion therapy, they will be treated by tislelizumab plus chemotherapy with or without palliative radiotherapy .
62673016|NCT00754039|EXPERIMENTAL|1|Welchol + TriCor
62673017|NCT00754039|PLACEBO_COMPARATOR|2|Welchol + placebo
62673018|NCT02319083||Coronary artery bypass surgery|Patients undergoing coronary artery bypass surgery.
62673019|NCT04447066||Patients hospitalized at the rehabilitation department|
62673020|NCT04389671|EXPERIMENTAL|Lyophilized Lucinactant|Lyophilized Lucinactant reconstituted with sterile water for injection
62673021|NCT03450135||Mid-pubertal girls|Adolescent girls (ages 11-14) who are undergoing a healthy pubertal transition (Tanner developmental stage 3 or 4) will perform Trier Social Stress Test and Emotional go/no-go task.
62673022|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
62673023|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
62673024|NCT01804907|EXPERIMENTAL|CBT|Cognitive Behavioral Therapy
62673025|NCT01804907|SHAM_COMPARATOR|Behavioral Modification|Standard sleep hygiene education/desensitization therapy
62673026|NCT03962816|EXPERIMENTAL|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62673027|NCT03962816|EXPERIMENTAL|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
62673028|NCT03962816|EXPERIMENTAL|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
62673029|NCT03378388||Vedolizumab|Participants diagnosed with UC or CD, who fail or are intolerant to a previous biologic treatment or with contra-indication to anti-tumor necrosis factor alpha (TNF alpha) after failure of conventional treatments without exclusion except participant refusal, and were potentially eligible for a treatment with vedolizumab will be observed from the first prescription during consultation over a period of 24 months.
62673030|NCT06096948|EXPERIMENTAL|NEXPOWDER-ENDOHS|Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
62673031|NCT03033212|EXPERIMENTAL|Early Structured Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 7 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
62673032|NCT03033212|EXPERIMENTAL|Delayed Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 13 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
62673033|NCT03033212|ACTIVE_COMPARATOR|Self Rehabilitation|Patients will begin Self-Guided Rehabilitation at 7 weeks postoperatively in a self-guided fashion. They will be provided with instructions for recommended exercises. They will undergo rehabilitation for a total of 10 weeks.
62673034|NCT04956965|ACTIVE_COMPARATOR|Patient free cardiac amyloidosis|Patient with heart disease (related with rhythm disorders or conduction disorders) but free cardiac amyloidosis.
62673035|NCT04956965|EXPERIMENTAL|Patient with Transthyretin cardiac amyloidosis|Patient with transthyretin cardiac amyloidosis plus heart disease (related with rhythm disorders or conduction disorders).
62673036|NCT02734914|EXPERIMENTAL|SF-URS with automatic control of RPP|Participants in SF-URS with automatic control of renal pelvic pressure (RPP) group undergo ureteroscopy using the intelligent pressure control device (Medical irrigation and suctioning platform with pressure feedback function, and suctioning ureteral access sheath with function of pressure measuring).
62673037|NCT02734914|ACTIVE_COMPARATOR|conventional F-URS|Participants in conventional F-URS group undergo ureteroscopy using the classic flexible ureteroscope.
62673038|NCT06494514|EXPERIMENTAL|NALIRINOX combined with PD-1 synchronous sequential SBRT|Nal-IRI+Oxaliplatin+5-FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, 6-8 cycles. SBRT is performed during the third cycle.
62673039|NCT06494514|EXPERIMENTAL|AG combined with PD-1 synchronous sequential SBRT|Gemcitabine + albumin-paclitaxel +PD-1, these drugs are given on d1, d8, 21 days as one cycle, 6-8 cycles. SBRT is performed during the third cycle.
62673040|NCT00356421|ACTIVE_COMPARATOR|Control|
62673041|NCT00356421|EXPERIMENTAL|Experimental|
62673042|NCT00335192|EXPERIMENTAL|1|"Phase I: 3TC + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv"
62673043|NCT00335192|EXPERIMENTAL|2|"Phase I: ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv"
62673044|NCT00335192|EXPERIMENTAL|3|"Phase I: 3TC + ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv"
62470883|NCT01805583|NO_INTERVENTION|Control group|Treatment as usual (TAU) which means that the participant continues in ordinary health care and does not receive interventions other than the initial assessment.
62111415|NCT04270175|EXPERIMENTAL|daratumumab/pomalidomide/dexamethasone|"Pomalidomide:~(4mg orally) on days 1-21 of a 28-day cycle~Dexamethasone:~* 20mg IV as premedication on days 1, 8, 15, and 22~* 20mg orally the day after daratumumab dosing for cycles 1-2 of induction~* 40mg IV as premedication on days 1 and 15 on daratumumab treatment days~* 40mg orally on non-daratumumab days (8 and 15) for cycles 3-6~* 20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond)~  * If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction.~Daratumumab:~* 1800mg sub-cutaneously weekly x8 weeks~* 1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6)~* 1800mg sub-cutaneously every 4 weeks cycles 7 and beyond"
62111416|NCT04215198|EXPERIMENTAL|Move3™ (NEM + fish oil)|NEM, 500 mg, #0 capsule, + fish oil, 1,500 mg, softgels, once daily orally for 2 weeks
62111417|NCT04215198|PLACEBO_COMPARATOR|Placebo|Placebo, 500 mg, #0 capsule, + placebo oil, 1,500 mg, softgels, once daily orally for 2 weeks
62111418|NCT02644239|ACTIVE_COMPARATOR|Group control|classical ketogenic diet
62111419|NCT02644239|ACTIVE_COMPARATOR|Group case|Group case: modified ketogenic diet to reduce at least 20% saturated fat, up\> 50% of the acid supply monounsaturated, increasing\> 50% polyunsaturated fatty acid content and a lower ratio w6 / w3 at least 50% compared to classic diet used by the control group
62111420|NCT06184451|EXPERIMENTAL|Therapeutic exercise and Transcutaneous electrical nerve stimulation|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets. TENS will be applied with a portable device during the therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.
62111421|NCT06184451|PLACEBO_COMPARATOR|Therapeutic exercise and Placebo Transcutaneous electrical nerve stimulation|Participants in the control group will perform the same therapeutic exercise protocol previously reported in the experimental group, associated with placebo TENS. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this.
62111422|NCT03862833|EXPERIMENTAL|experimental group|"Zoledronic acid and IL-2 Zoledronic acid: 4 mg~Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion"
62111423|NCT03862833|NO_INTERVENTION|control group|no experimental treatment
62111424|NCT03977116|EXPERIMENTAL|heart failure patients with diabetes treated by SGLT2 drugs|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
62111425|NCT03977116|PLACEBO_COMPARATOR|heart failure patients with diabetes treated by placebo|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received placebo therapy.
62111426|NCT02305485|EXPERIMENTAL|NeoVas|"The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA- based polymer scaffold and contains the antiproliferative drug sirolimus.~Intervention: Device: NeoVas BCS"
62111427|NCT02305485|ACTIVE_COMPARATOR|XIENCE PRIME|XIENCE PRIME Everolimus Eluting Coronary Stent System is a balloon expandable metallic platform stent manufactured from a flexible cobalt chromium alloy with a multicellular design and coated with a thin nonadhesive, durable, biocompatible acrylic, and fluorinated everolimus-releasing copolymer. Intervention: Device: XIENCE PRIME EECSS
62111428|NCT01927965|EXPERIMENTAL|Minnelide™ 001|A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
62111429|NCT01539655|EXPERIMENTAL|vandetanib then vandetanib + omeprazole|Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2
62111430|NCT01539655|EXPERIMENTAL|vandetanib + omeprazole then vandetanib|Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2
62111431|NCT01539655|EXPERIMENTAL|vandetanib then vandetanib + ranitidine|Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2
62301434|NCT06332443|ACTIVE_COMPARATOR|SED-EA|EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
62470884|NCT02545803|OTHER|study group|Adult patients (age ≥ 18 years) at the Intensive Care Unit (ICU) who become refractory to conventional mechanical ventilation and are switched to HFPV.
62111432|NCT01539655|EXPERIMENTAL|vandetanib + ranitidine then vandetanib|Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2
62111433|NCT00837499||Mexican Women from Mexico|
62111434|NCT00837499||Mexican-American Women in U.S.|
62470885|NCT02615028|OTHER|Closed eyes double-leg stance|Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
62111435|NCT00837499||African-American Women in U.S.|
62301435|NCT05443022|ACTIVE_COMPARATOR|Photobiomodulation group|Participants in this group will have their larger salivary glands irradiated with diode laser.
62470886|NCT05731674|NO_INTERVENTION|Control|
62470887|NCT05731674|EXPERIMENTAL|Intervention|
62470888|NCT03197883|EXPERIMENTAL|Group 1|Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
62673045|NCT01855568|EXPERIMENTAL|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14."
62673046|NCT01855568|EXPERIMENTAL|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
62673047|NCT05064800|ACTIVE_COMPARATOR|Treatment A|Dabigatran only
62673048|NCT05064800|EXPERIMENTAL|Treatment B|PF-07321332/ritonavir + Dabigatran
62673049|NCT05064800|ACTIVE_COMPARATOR|Treatment C|Ritonavir + Dabigatran
62673050|NCT05803954|EXPERIMENTAL|Group A (SNAGs group)|
62673051|NCT05803954|EXPERIMENTAL|Group B (Neural mobilization group)|
62673052|NCT05803954|ACTIVE_COMPARATOR|Group C (traditional physical therapy)|
62673053|NCT00635180|EXPERIMENTAL|1|1: Healthy subjects
62673054|NCT00632970|EXPERIMENTAL|Raltegravir plus Truvada|Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
62673055|NCT00632970|ACTIVE_COMPARATOR|Lopinavir/Ritonavir plus Truvada|Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
62673056|NCT04233580|ACTIVE_COMPARATOR|Weekly AmnioEXCEL+ group|AmnioEXCEL+ will be applied weekly at study visits
62673057|NCT04233580|ACTIVE_COMPARATOR|PRN AmnioEXCEL+ group|AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)
62673058|NCT01427452||Living Kidney Donor, Transplant Recipient, Healthy Control|Living kidney donors and their transplant recipient will be enrolled. Also, a smaller cohort of healthy controls (potential donors who were medically suitable but not used) will be enrolled.
62673059|NCT00093223|EXPERIMENTAL|1|35mg/m\^2 infusion time is 3.5 minutes
62673060|NCT00093223|EXPERIMENTAL|2|2 doses of 35mg.m\^2 with the second dose given 2 months later
62673061|NCT04464902|OTHER|knee extension constraint rehabilitation group|
62673062|NCT04464902|OTHER|placebo group|
62673063|NCT04464902|OTHER|control group|
62673064|NCT02329275||Azoospermic men|
62673065|NCT02329275||Men with proven fertility|
62673066|NCT06034652||Prospective Analysis of Minimally Invasive Surgical Approach (i.e., laparoscopic or robotic)|Collection of performance data for twenty-one subjects having prior minimally invasive surgical approach for ventral hernia repair (i.e., laparoscopic or robotic) from the previous T-GENVIH-002 study last data collection time-point (1-yr post-op) to present (prospective analysis), not previously reported.
62673067|NCT04309448|EXPERIMENTAL|Perturbation-based balance training with FES|
62673068|NCT06088628||DoC patients|Patients with disorders of consciousness.
62673069|NCT06088628||Healthy controls|Healthy participants matched by gender and age.
62673070|NCT06274437|EXPERIMENTAL|BND-35 Dose Escalation (Sub-Part 1A)|"Accelerated titration followed by standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-35 will be administered at escalating doses of 0.3 mg/kg to 20 mg/kg intravenously (IV), every 2 weeks (Q2W)"
62111436|NCT00597103||1|Prevalent patients who have been receiving more frequent dialysis.
62111437|NCT00597103||2|Incident patients new to more frequent dialysis
62111438|NCT00597103||3|Patients who switch from one more frequent hemodialysis treatment regimen to another more frequent dialysis regimen.
62111439|NCT04875858|ACTIVE_COMPARATOR|healthy old adults aged 70-75 years who received PPSV23|Recruitment of 254 healthy 70-75-year healthy old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
62111440|NCT04875858|EXPERIMENTAL|old adults who have diabetes mellitus aged 70-75 years who rec|Recruitment of 254 healthy 70-75-year diabetic old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
62111441|NCT01281020||Treatment with fixed combination|Patients who receive treatment with latanoprost/timolol fixed combination
61916518|NCT02292784|PLACEBO_COMPARATOR|Placebo (200719 study)|All infants and children born to women who received the placebo (0.9 percent sodium chloride infusion matched for retosiban volume, intravenous \[IV\] loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment) in 200719 study. Current study will not require any medical interventions or study visits to an investigational site.
61916519|NCT02292784|EXPERIMENTAL|Retosiban (200719 and 200721 study)|All infants and children born to women who received retosiban (6 milligram \[mg\] IV loading dose of retosiban over 5 minutes followed by a 6 mg per hour continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg per hour continuous infusion for remainder of 48-hour treatment period) in 200719 study or 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
61916520|NCT02292784|ACTIVE_COMPARATOR|Atosiban (200721 study)|All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter \[mL\] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
61916521|NCT06040242|EXPERIMENTAL|Patients Group|All patients will perform all exercises. Arrhythmogenic activity will compared with that assessed during treadmill walking.
61916522|NCT03282331|EXPERIMENTAL|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
61916523|NCT03282331|OTHER|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
61916524|NCT03282331|OTHER|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
61916525|NCT03636698||Chorioamnionitis Group|preterm infants were born to mothers with chorioamnionitis
62470889|NCT03197883|OTHER|Group 2|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
61916526|NCT03636698||Control Group|preterm infants were born to mothers without chorioamnionitis
61916527|NCT02614469|EXPERIMENTAL|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
61916528|NCT02614469|EXPERIMENTAL|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
61916529|NCT01456377|ACTIVE_COMPARATOR|corticosteroids, analgesics oral pill|Oral Corticosteroids and oral analgesics
61916530|NCT01456377|PLACEBO_COMPARATOR|placebo|oral placebo and oral analgesics
61916531|NCT01274260|ACTIVE_COMPARATOR|Experimental Group|Intervention: Subjects in this study group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
61916532|NCT01274260|PLACEBO_COMPARATOR|Placebo Group|Intervention: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline. The placebo group with receive the masked study drug in infusion rates that mimic the infusions received by the experimental group.
61916533|NCT03324581|EXPERIMENTAL|OPC-64005|During the titration period, participants received OPC-64005 two 10 milligram (mg) tablets, and one OPC-64005-matching placebo tablet along with two atomoxetine-matching placebo capsules, orally, once daily (QD), from Day 1 up to Day 4. During the treatment period, participants received OPC-64005 three 10 mg tablets, and two atomoxetine-matching placebo capsules, orally, QD, from Day 5 up to Day 56. The dose was reduced to 20 mg if the 30 mg dose in the treatment period was not tolerable.
61916534|NCT03324581|ACTIVE_COMPARATOR|Atomoxetine|"During the titration period, participants received atomoxetine one 40 mg capsule and one atomoxetine-matching placebo capsule along with three OPC-64005-matching placebo tablets, orally, QD, from Day 1 up to Day 4.~During the treatment period, participants received two atomoxetine 40 mg capsules and three OPC-64005-matching placebo tablets, orally, QD, from Day 5 up to Day 56. The dose was reduced to 40 mg if the 80 mg dose in the treatment period was not tolerable."
61916535|NCT03324581|PLACEBO_COMPARATOR|Placebo|Participants received three OPC-64005-matching placebo tablets and two atomoxetine-matching placebo capsules, orally, QD, from Day 1 up to Day 56.
62301436|NCT05443022|PLACEBO_COMPARATOR|Placebo group|Participants in this group will be subjected to a simulation, where the application protocol will be repeated, but with the laser turned off.
61916536|NCT03777631|NO_INTERVENTION|Standard medical therapy group|The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
61916537|NCT03777631|ACTIVE_COMPARATOR|Catheter ablation group|Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed \>100 CA annually were participated in the present study in principle.
61916538|NCT04224545|EXPERIMENTAL|Colchicine|Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.)
61916539|NCT04224545|PLACEBO_COMPARATOR|Placebo|Sugar pill
61916540|NCT05480774|ACTIVE_COMPARATOR|KRG hard capsules|Each KRG hard capsule contains 500 mg of red ginseng extract. Dosage of KRG hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
61916541|NCT05480774|PLACEBO_COMPARATOR|Placebo hard capsules|The composition of the Placebo hard capsule contains red ginseng flavor. Dosage of Placebo hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
62301437|NCT02331264||MoM >7ppb|Patients with Metal on Metal hip implants and blood metal ions above the Medicines and Healthcare Products Regulatory Agency (MHRA) threshold of 7 parts per billion
62111442|NCT01281020||Treatment with unfixed therapy|Patients who receive latanoprost and timolol therapy
61916542|NCT00895011|PLACEBO_COMPARATOR|Placebo|
61916543|NCT00895011|EXPERIMENTAL|Avanafil 100 mg|
62111443|NCT04415333|EXPERIMENTAL|Sodium Butyrate [5 mmol] first, then Sodium Butyrate [80 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 mL total). After a 7-days washout period, they will return to testing office to self-administer the other enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 mL total).
62301438|NCT02331264||MoM <7ppb|Patients with Metal on Metal hip implants and blood metal ions below the MHRA threshold of 7 parts per billion
62301439|NCT02331264||Non MoM|Patients with non Metal bearing hip implants such as Ceramic on Ceramic or Plastic
62111444|NCT04415333|EXPERIMENTAL|Sodium Butyrate [80 mmol] first, then Sodium Butyrate [5 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 mL total). After a 7-day washout period, they will return to the testing office to self-administer the other enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 mL total).
62111445|NCT04415333|NO_INTERVENTION|Control|African Americans with normal blood pressure (control group) will not perform self-administration of the enema. They will submit to 1 blood draw and wear the 24-hour ambulatory blood pressure monitor for 1-day.
62301440|NCT06143384||Patients using Home Mechanical Ventilation (HMV)|Patients using Home Mechanical Ventilation (HMV), and registered in the Belgian agreement for HMV at 1/ the Citadelle hospital in Liège, Belgium and 2/HUB-Erasme hospital, Brussels, Belgium.
62673071|NCT06274437|EXPERIMENTAL|BND-35 in Combination with Nivolumab Dose Escalation (Sub-Part 1B)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-35 will be administered at escalating doses of 3 mg/kg to 20 mg/kg intravenously (IV) every 2 weeks (Q2W). Nivolumab will be administered at a dose of 240 mg IV, every 2 weeks (Q2W)."
61916544|NCT00895011|EXPERIMENTAL|Avanafil 200 mg|
61916545|NCT01125787|EXPERIMENTAL|ofatumumab + bendamustine|
61916546|NCT01271790|ACTIVE_COMPARATOR|Arm 1|GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
61916547|NCT01271790|ACTIVE_COMPARATOR|Arm 2|GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
61916548|NCT01271790|PLACEBO_COMPARATOR|Arm 3|Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
61916549|NCT04097743|EXPERIMENTAL|Coping statement|Daily practice of pain coping statements for 7 days
61916550|NCT04097743|NO_INTERVENTION|Control|No instruction about pain coping statement.
61916551|NCT02311101|EXPERIMENTAL|Therapy Group MMC 10/BCG Half|"Intravesical Mitomycin C and intravesical BCG~First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (half dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10\^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The first 3 participants received 10mg of MMC and half dose of BCG. The dose was assigned in order of enrollment."
61916552|NCT02311101|EXPERIMENTAL|Therapy Group MMC 10/BCG Full|First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10\^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The following 3 participants received 10mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
61916553|NCT02311101|EXPERIMENTAL|Therapy Group MMC 20/BCG Full|First intravesical mitomycin C (20 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10\^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The next 3 participants enrolled received 20mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
62111446|NCT05937919|EXPERIMENTAL|68Ga-PMD22 PET/CT dynamic scan|68Ga-PMD22 PET/CT scan Dosimetry study about 6 patients were injected with 2-4 (MBq) per kilogram body weight of 68Ga-PMD22 PET/CT in one dose intravenously and underwent wholebody scan at 5min#15min#30min#60min#90min#120min#180min, then analysis of dosimetric distribution of radiopharmaceuticals in human body by HERMES software.
62111447|NCT05937919|EXPERIMENTAL|68Ga-PMD22 PET/CT scan at one time|After the dynamic scan completed, choose an optimal imaging examination time for PET examination of other patients.
62111448|NCT06533527|ACTIVE_COMPARATOR|Continue medication as normal prior to endoscopic procedure|Does not withhold incretin therapy, maintains dose/frequency/duration of medication.
62111449|NCT06533527|NO_INTERVENTION|Hold dose prior to endoscopic procedure|Withholds prior dose of incretin therapy per ASA guidance recommendations.
62111450|NCT04891887|EXPERIMENTAL|Intervention|Health education program
62111451|NCT04040530||Cryoablation|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with CT-guided cryoablation at Odense University Hospital in the period from 1/6-2019 to 1/6-2021.
62111452|NCT04040530||Partial nephrectomy|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with partial nephrectomy at Odense University Hospital or Zealand University Hospital in the period from 1/6-2019 to 1/6-2021.
62673072|NCT06274437|EXPERIMENTAL|BND-35 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-35 will be administered at escalating doses of 3 mg/kg to 20 mg/kg intravenously (IV) every 2 weeks (Q2W). Cetuximab will be administered intravenously (IV) at a dose of 500 mg/m2, every 2 weeks (Q2W)"
62673073|NCT06274437|EXPERIMENTAL|BND-35 in Combination with Nivolumab Dose Optimization (Sub-Part 2A)|BND-35 dose optimization in combination with nivolumab. The indications for the combination cohorts will be selected following completion of Part 1. Enrollment will start after the recommended dose(s) of BND-35 have been determined based on data from Sub-Parts 1A, 1B, and 1C. Nivolumab will be administered at a dose of 240 mg IV, every 2 weeks (Q2W).
62673074|NCT06274437|EXPERIMENTAL|BND-35 in Combination with Cetuximab Dose Optimization (Sub-Part 2B)|BND-35 dose optimization in combination with cetuximab. The indications for the combination cohorts will be selected following completion of Part 1. Enrollment will start after the recommended dose(s) of BND-35 have been determined based on data from Sub-Parts 1A, 1B, and 1C. Cetuximab will be administered intravenously (IV) at a dose of 500 mg/m2, every 2 weeks (Q2W)
61916554|NCT02311101|EXPERIMENTAL|Therapy Group MMC 40/BCG Full|First intravesical mitomycin C (40 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10\^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The last 3 participants received 40mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
62111453|NCT05334758|EXPERIMENTAL|At least 30 children between 2 - 13 years of age|Subjects less than 14 years of age, where the Parent or legal guardian collects a sample from their child (e.g., ages 2-13) and performs the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.
62111454|NCT05334758|EXPERIMENTAL|Subjects 14 - 90 years of age|The subject will self collect and test using the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.
62111455|NCT04263545|ACTIVE_COMPARATOR|Intervention|
62111456|NCT04263545|PLACEBO_COMPARATOR|Standard Care|
62111457|NCT01499108|EXPERIMENTAL|Liraglutide|single-group study were participants recieve Liraglutide
62111458|NCT05602909|EXPERIMENTAL|Guided biaxial distraction|
62111459|NCT00876837||Adults with pediatric-onset SCI|
61916555|NCT04758000|EXPERIMENTAL|Metformin|"Metformin will be administrated according with patients body mass index (BMI). The study is divided into 2 groups.~* Group 1: Localized osteosarcoma that have presented a response ≤ 60% to the pre-operatory chemotherapy).~* Group 2: Osteosarcoma and Ewing sarcoma patients with complete remission after the first relapse."
61916556|NCT01354054|EXPERIMENTAL|High frrequency TENS|100 Hz TENS, 100 usec
62111460|NCT04842669|EXPERIMENTAL|Low level laser therapy|Low level laser therapy
62111461|NCT04842669|ACTIVE_COMPARATOR|Conservative treatment|Conservative treatment
62301441|NCT04513145|EXPERIMENTAL|Treatment Group (Ropivacaine)|The treatment group will consist of patients undergoing total knee arthroplasty who receive standardized 100 cc periarticularinjection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients will then receive 10cc of ropivacaineinto their adductor canal.This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
62301442|NCT04513145|PLACEBO_COMPARATOR|Control Group (Saline)|The control group will consist of patients undergoing total knee arthroplasty who receive a standardized periarticular injection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients randomized in this group will then receive 10cc of saline into their adductor canal. This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
62301443|NCT02211339|EXPERIMENTAL|Peer-led intervention group|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
62470890|NCT04492553|EXPERIMENTAL|Testogel|All patients will be treated with Testogel. Starting dose is 1 sachet of gel daily applied to the skin of arms, thighs or abdomen. Dose adjustments are made after serum-levels of testosterone. All patients will be treated for a total of 52 weeks, unless they exit the study early because of side-effects or other reasons.
61916557|NCT01354054|EXPERIMENTAL|Low frequency TENS|4 Hz, 100 usec TENS
61916558|NCT01354054|EXPERIMENTAL|Placebo TENS|100 Hz, 100 usec, set at motor minus 10% then ramps to off in 45 sec, 40 minutes
61916559|NCT01354054|NO_INTERVENTION|Control|Age matched controls, no intervention
61916560|NCT01002820|EXPERIMENTAL|participants|all subjects participating in 0602 are receiving ganaxolone for seizure control
61916561|NCT02456103|EXPERIMENTAL|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
62301444|NCT02211339|ACTIVE_COMPARATOR|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
61916562|NCT05604053|EXPERIMENTAL|Within-subjects motivation manipulation|Low or high motivation
61916563|NCT01488474||Diabetes Mellitus (DM)|Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
61916564|NCT01488474||Control (C)|Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
61916565|NCT04948086||TT MTHFR genotype|
61916566|NCT04948086||Non-TT (i.e. CC/CT) MTHFR genotype|
61916567|NCT03279471|EXPERIMENTAL|CBT/BIACA|These participants will receive CBT treatment using Behavioral Interventions for Anxiety in Children with Autism (BIACA). BIACA is an anxiety treatment package designed for children with ASD that includes elements of CBT and social skills training.
62301445|NCT03457298|EXPERIMENTAL|Ossix Volumax|lateral bone augmentation using volume maintaining collagen scaffold (Ossix Volumax)
62470891|NCT04057677|EXPERIMENTAL|Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. We are examining the effects of a recovery exercise program for older adults with pre-diabetes and type 2 diabetes. Following 10 days of bed rest and during the first 4 weeks of recovery, participants will perform a combination of aerobic and resistance exercise training.
61916568|NCT03279471|ACTIVE_COMPARATOR|Sertraline|These participants will receive sertraline
61916569|NCT03279471|PLACEBO_COMPARATOR|Pill Placebo|These individuals will receive a pill placebo.
61916570|NCT01466543|ACTIVE_COMPARATOR|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, once
62111462|NCT03184558|EXPERIMENTAL|Bemcentinib (BGB324) + pembrolizumab|Participants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3. A dose of 200 mg pembrolizumab was given by intravenous infusion over 30 minutes every 3 weeks in all participants. Dosing of both drugs commenced on Day 1. On days when both BGB324 and pembrolizumab were given, pembrolizumab was given first and participants were observed for 1 hour after the end of infusion before BGB324 was administered. From Day 4 onward, participants received a daily maintenance dose of 200 mg along with Pembrolizumab 200 mg intravenous (IV) infusion over 30 minutes every 3 weeks until disease progression, until an unacceptable toxicity occurred that required treatment withdrawal or withdrawal of consent or until 106 weeks had passed.
62111463|NCT04767035|ACTIVE_COMPARATOR|MELT-100 3/25|MELT-100 3mg midazolam / 25 mg ketamine
62111464|NCT04767035|ACTIVE_COMPARATOR|MELT-100 2 x 3/25|MELT-100 2 doses of 3mg midazolam / 25mg ketamine
62111465|NCT04767035|ACTIVE_COMPARATOR|ketamine IV 18mg|
62470892|NCT04057677|EXPERIMENTAL|Non-Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. Participants in the ambulatory recovery group will not receive any exercise intervention or advice on exercise following 10 days of bed rest. Rather these participants will return to their regular daily routine that they engaged in prior to the bed rest intervention.
62470893|NCT05277779||control|non-obese （BMI\<25kg/m2）controls without known endocrine diseases, cardiac disease, or other comorbidities, and with unremarkable imaging results.
62470894|NCT05277779||metabolically healthy obese|obese individuals having no more than one of the metabolic syndrome components (with exception of increased waist circumference) and without impaired glucose tolerance (defined as a 2-hour post loading glucose level of 7.7-11.1mmol/L )
62470895|NCT05277779||metabolically unhealthy obese|obese individuals with more than one metabolic syndrome components or impaired glucose tolerance
61916571|NCT01466543|PLACEBO_COMPARATOR|Placebo|placebo medication
61916572|NCT05203042||prediabetes|
61916573|NCT05203042||diabetes|
61916574|NCT02047318|EXPERIMENTAL|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) administered orally up to twice each day
62111466|NCT04767035|ACTIVE_COMPARATOR|Midazolam IV 3.5mg|
62111467|NCT01845896|EXPERIMENTAL|Combined exercise|12 weeks combined exercise programme (supervised)
62111468|NCT01845896|EXPERIMENTAL|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
62111469|NCT01845896|NO_INTERVENTION|Control|sedentary/habitual lifestyle
62111470|NCT00601848|EXPERIMENTAL|Photodynamic Therapy|PDT
62111471|NCT02178540|OTHER|Open label|one dose (4 capsules) of placebo
62111472|NCT00819819|ACTIVE_COMPARATOR|1 Gluten containing diet|Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
61916575|NCT01133990|ACTIVE_COMPARATOR|FOLFIRI|The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional). The 5-FU IV bolus (400 mg/m2) and CIV infusion (2400 mg/m2) over 46 hours is repeated on Days 15 and 16 of each cycle.
61916576|NCT01133990|EXPERIMENTAL|E7820|E7820 is administered orally in tablet form once daily, every day of each 28-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Phase II portion, the dose will be the MTD recommended Phase IB dose in combination with FOLFIRI, as determined during the Phase Ib portion of the study.
62301446|NCT03457298|ACTIVE_COMPARATOR|FDBA with collagen membrane|lateral bone augmentation using the current gold standard FDBA plus resorbable collagen membrane
62301447|NCT00257127|EXPERIMENTAL|1|Patients will receive PCV, HBV, and MMR at study entry
62301448|NCT00257127|EXPERIMENTAL|2|Patients will receive PPV, HBV, and MMR at study entry
62301449|NCT06337201||Healthcare professionals working in daycare center and residential care.|
62673075|NCT01593111|EXPERIMENTAL|Environmental Intervention|If randomized to this part of the study the patient will receive an individualized homebased program. In addition to general handouts provided to at Visit 3, subjects in this arm will also receive home-based education by Intervention Counselors about how indoor allergens can affect asthma and the importance of strategies for removing allergens. The goal of the intervention is to provide the patient with the knowledge and skills necessary to remove allergens from their home, and to assist them with those clean up measures. Some of the measures implemented will be specifically based on data we have previously collected from them in the clinic and from their previous home visit, while others will be general to reduce all allergen level.
62673076|NCT01593111|NO_INTERVENTION|Control Group|If assigned to this group the patient will receive general health/safety related counseling. At the counselor visit following randomization, the patient will receive handouts related to general health and safety issues. They will also have visits by the Home Evaluators for assessment of the home and collection of dust samples identical to those in the treatment group (week 28 and week 44).
62673077|NCT05538468||Stroke Patients Group|The kinesiophobia scores of the patients were evaluated by (Tampa Kinesiophobia Scale) and (Visual Analog Scale- Kinesiophobia Assessment), depression severity (Beck Depression Inventory), postural control (Postural Assessment Scale), pain severity (Visual Analog Scale).
62673078|NCT02032212|EXPERIMENTAL|Sequence 1|Subjects use the unflavoured EVP on Day 1, the flavoured EVP on Day 2, the nicotine inhalator on Day 3 and the conventional cigarette on Day 4.
62673079|NCT02032212|EXPERIMENTAL|Sequence 2|Subjects use the flavoured EVP on Day 1, the unflavoured EVP on Day 2, the conventional cigarette on Day 3 and the nicotine inhalator on Day 4.
61916577|NCT01133990|EXPERIMENTAL|FOLFIRI plus Bevacizumab|Bevacizumab at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle
61916578|NCT01086280||Patients exposed to Saxagliptin|
61916579|NCT01086280||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
61916580|NCT00420641|EXPERIMENTAL|GSK372475 Arm|GSK372475 1.0- 1.5 mg/day
62301450|NCT04714112|EXPERIMENTAL|preoperative group|Intravenous dexamethasone (5mg) is used when ultrasound guided ISB is performed.
62301451|NCT04714112|ACTIVE_COMPARATOR|postoperative group|Ultasound guided ISB is performed before operation and intravenous dexamethasone (5mg) is used in postoperative care unit ( PACU)
62301452|NCT01172080|NO_INTERVENTION|control|Participants in this group are monitored for adherence to colonoscopy recommendations.
62301453|NCT01172080|EXPERIMENTAL|intervention|Participants to receive a protocol of reminder letters and a phone call regarding due follow up colonoscopy
62301454|NCT02858479|OTHER|patients with pain allodynic peripheral|
62301455|NCT02858479|OTHER|patients with pain allodynic central|
62673080|NCT02032212|EXPERIMENTAL|Sequence 3|Subjects use the nicotine inhalator on Day 1, the conventional cigarette on Day 2, the unflavoured EVP on Day 3 and the flavoured EVP on Day 4.
62673081|NCT02032212|EXPERIMENTAL|Sequence 4|Subjects use the conventional cigarette on Day 1, the nicotine inhalator on Day 2, the flavoured EVP on Day 3 and the unflavoured EVP on Day 4.
62673082|NCT04113486||Renal cancer group|Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
62673083|NCT04113486||Urothiasis group|Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100.
62673084|NCT04113486||Renal cysts group|Patients which imaging studies have found renal cysts (simple or complex) about 100.
62673085|NCT04113486||Liver cancer group|Patients which imaging studies have found hepatic mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
62301456|NCT01972646||Adult patients (≥ 18 years) with uncomplicated cellulitis|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer, or rash) were screened for eligibility by ED staff or trained research assistants and invited to participate in this study once an emergency physician confirmed a cellulitis infection.
62301457|NCT01697332|EXPERIMENTAL|Subjects with and without COPD|All subjects will inhale hyperpolarized 129Xe gas and then have a MRI scan performed to measure lung function.
62301458|NCT01495871|ACTIVE_COMPARATOR|Amino acids|Amino acid supplementation for 6 weeks
62301459|NCT01495871|PLACEBO_COMPARATOR|Placebo|Supplementation of placebo (inert components)for 6 weeks
62301460|NCT01495871|ACTIVE_COMPARATOR|Valine|Valine supplementation for 6 weeks
61916581|NCT00420641|EXPERIMENTAL|Paroxetine Arm|Paroxetine 20-30 mg/day
62301461|NCT02845869|EXPERIMENTAL|Light Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Light Therapy treatment with the THOR laser LX2 system.
62301462|NCT02845869|SHAM_COMPARATOR|Sham Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Sham Therapy.
62301463|NCT04783207|ACTIVE_COMPARATOR|Supplement containing Mitopure|
62301464|NCT04783207|PLACEBO_COMPARATOR|Placebo Supplement|
61916582|NCT00420641|OTHER|Placebo|Placebo to Match
62111473|NCT00819819|ACTIVE_COMPARATOR|2 Gluten free diet|Non gluten containing food starch added to diet from 6-12 months
62673086|NCT02832947|OTHER|Rivaroxaban Arm|
62673087|NCT01576965|EXPERIMENTAL|Mechanical Bowel Prep Group|Half of the subjects will be randomized to a group that does mechanical bowel preparation with sodium phosphate enema. Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
61916583|NCT05313152|EXPERIMENTAL|TAVO103A Low Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
62301465|NCT03429075|EXPERIMENTAL|Psilocybin|Patients receive Psilocybin
62673088|NCT01576965|NO_INTERVENTION|No Bowel Prep Group|Participants randomly assigned to this group will not have the bowel prep treatment before the surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
62673089|NCT06404554||patients with anastomotic stricture|without any intervention, patients diagnose as anastomotic stricture after rectal cancer surgery
62673090|NCT06404554||patients without anastomotic stricture|without any intervention, patients does not diagnose as anastomotic stricture after rectal cancer surgery
62673091|NCT03553888||HS patient|patients with HS
62673092|NCT03553888||no HS patients|patients without HS
62673093|NCT06110182||enteral nutrition|children who received enteral nutritional support during treatment
62673094|NCT06110182||parenteral nutrition|children who received parenteral nutritional support during treatment
62673095|NCT04452838|OTHER|Cohort 1 Sequence 1 (Part A)|Treatment Sequence A,B,C and D
62673096|NCT04452838|OTHER|Cohort 1 Sequence 2 (Part A)|Treatment Sequence B, A,C and D
62673097|NCT04452838|OTHER|Cohort 2 Sequence 1 (Part B)|Treatment Sequence E, F, G, and H
62673098|NCT04452838|OTHER|Cohort 2 Sequence 2 (Part B)|Treatment Sequence E, F, H and G
62673099|NCT04452838|OTHER|Cohort 2 Sequence 3 (Part B)|Treatment Sequence F, E, G, and H
62673100|NCT04452838|OTHER|Cohort 2 Sequence 4 (Part B)|Treatment sequence F, E, H, and G
61916584|NCT05313152|EXPERIMENTAL|TAVO10A Medium Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
61916585|NCT05313152|EXPERIMENTAL|TAVO103A High Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
61916586|NCT05313152|PLACEBO_COMPARATOR|Placebo|Placebo single ascending dose IV infusion.
61916587|NCT01077752|EXPERIMENTAL|1|Patients with continuous ropivacaine preperitoneal infusion
61916588|NCT01077752|ACTIVE_COMPARATOR|2|Patients with intravenous lidocaine infusion
62111474|NCT00562913|EXPERIMENTAL|Arm 1|
61916589|NCT01077752|PLACEBO_COMPARATOR|3|Patients without local anesthetics
62111475|NCT02072226|ACTIVE_COMPARATOR|Alteplase Placebo + Aspirin|Participants will receive single dose of IV alteplase placebo and aspirin orally.
62111476|NCT02072226|EXPERIMENTAL|Alteplase + Aspirin Placebo|Participants will receive single dose of IV alteplase and aspirin placebo orally.
62111477|NCT04730999|EXPERIMENTAL|Single Arm|"Induction phase (6 cycles, 21 days duration): carboplatin, etoposide, bevacizumab and atezolizumab.~Maintenance phase (12 cycles, 21 days duration): bevacizumab and atezolizumab"
62301466|NCT03429075|ACTIVE_COMPARATOR|Escitalopram|Patients receive Escitalopram
62301467|NCT06656741|EXPERIMENTAL|Single group|This is a single group study. All participants belong to this group. Participants will perform resting state task, mindful breathing task, guided breath task, and breath counting task respectively. The task sequence is counter-balanced.
62301468|NCT04242030|OTHER|COPD group|"Participants in the COPD group will receive examination of laser doppler flowmetry(LDF).~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian."
62301469|NCT04242030|OTHER|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
62301470|NCT04242030|EXPERIMENTAL|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
62673101|NCT00567112|EXPERIMENTAL|DFC (fasted)|
62470896|NCT04728763||Cases|"Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of invasive pulmonary aspergillosis (IPA) or Chronic pulmonary aspergillosis (CPA) in current care :~* Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019) or~* Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)"
62111478|NCT01156935|EXPERIMENTAL|Laugh yoga|experimental laugh yoga
62301471|NCT03783156|OTHER|hot snare|polypectomy with hot snare
62301472|NCT03783156|OTHER|cold snare|polypectomy with cold snare
62301473|NCT04616586|EXPERIMENTAL|Arm A|Drug - Siltuximab
62301474|NCT04616586|OTHER|Arm B|Comparator - Normal Saline
62111479|NCT06121596|EXPERIMENTAL|Breathing Exercise with 40 Percent of the Spontaneous Breathing Frequency (A)|Participants are instructed (via visual pacer) to reduce their breathing frequency to 40 percent of their spontaneous breathing frequency for a period of five minutes. In advance, participants are instructed (via pre-recorded video) to breathe nasally (if possible) and abdominally, with a prolonged exhalation (inspiration-to-expiration ratio is 1-to-2 - also instructed via visual pacer) during the breathing exercise.
62111480|NCT06121596|EXPERIMENTAL|Breathing Exercise with 60 Percent of the Spontaneous Breathing Frequency (B)|Participants are instructed (via visual pacer) to reduce their breathing frequency to 60 percent of their spontaneous breathing frequency for a period of five minutes. In advance, participants are instructed (via pre-recorded video) to breathe nasally (if possible) and abdominally, with a prolonged exhalation (inspiration-to-expiration ratio is 1-to-2 - also instructed via visual pacer) during the breathing exercise.
61916590|NCT04153734|EXPERIMENTAL|Immunotherapy plus chemotherapy|Combination of CDDP at 75 mg/m2 (day 1) or CBDCA at Area Under the Curve=6 (AUC=6) (day 1) + PEM at 500 mg/m2 (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, CBDCA at AUC=6 (day 1) + nab-PTX at 100 mg/m2 (days 1, 8, and 15) will be administered at 3-week intervals. If there is no progression after the 4th course of induction therapy, it will be switched to maintenance therapy. For maintenance therapy, the combination of PEM at 500 mg/m2 (day 1) + Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
61916591|NCT01133028|EXPERIMENTAL|Combined|This represents a combination of the tolerance training and behavioral management interventions together.
61916592|NCT01133028|ACTIVE_COMPARATOR|Behavioral management|This represents the behavioral contingency management intervention only.
61916593|NCT01585012|EXPERIMENTAL|Cervical cap|Collection condom with cervical cap inserted
61916594|NCT03195296||Graves' Orbitopathy|Patients with Graves' Orbitopathy subjected to orbital decompression
61916595|NCT03533686|EXPERIMENTAL|Single-Sided Deafness Adult (Aim1) Group|Adult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
61916596|NCT03533686|EXPERIMENTAL|Conductive Hearing Loss Adult (Aim 2) Group|Adult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
62673102|NCT00567112|EXPERIMENTAL|OCT (fasted)|
62673103|NCT00567112|EXPERIMENTAL|OCT (after meal)|
62673104|NCT00567112|ACTIVE_COMPARATOR|OCT (before meal)|
62673105|NCT01032278|EXPERIMENTAL|Cardiac Biomarker Testing|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI), and symptom questionnaires of participants undergoing anthracycline-based chemotherapy.
61916597|NCT03533686|EXPERIMENTAL|Adhear followed by BAHA (Aim 3) Group|Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
61916598|NCT03533686|EXPERIMENTAL|BAHA followed by Adhear (Aim 3) Group|Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
61916599|NCT03533686|EXPERIMENTAL|Pediatric Unilateral Conductive Hearing Loss (Aim 3a) Group|Pediatric participants (aged 2-17 years) and their parents with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
61916600|NCT03533686|EXPERIMENTAL|Pediatric Bilateral Conductive Hearing Loss (Aim 3b) Group|Pediatric participants (aged 2-17 years) and their parents with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
62111481|NCT06121596|EXPERIMENTAL|Breathing Exercise with 80 Percent of the Spontaneous Breathing Frequency (C)|Participants are instructed (via visual pacer) to reduce their breathing frequency to 80 percent of their spontaneous breathing frequency for a period of five minutes. In advance, participants are instructed (via pre-recorded video) to breathe nasally (if possible) and abdominally, with a prolonged exhalation (inspiration-to-expiration ratio is 1-to-2 - also instructed via visual pacer) during the breathing exercise.
62111482|NCT02212535|EXPERIMENTAL|Plerixafor|Adult patients affected by major sickle cell syndrome (SS or Sβ thalassemia)
62301475|NCT06656897|EXPERIMENTAL|FS-D Intervention|All dyads will receive the FS-D intervention
62470897|NCT04728763||Control Group|Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care
62673106|NCT00560404|EXPERIMENTAL|1|
62673107|NCT00560404|ACTIVE_COMPARATOR|2|
62673108|NCT01922414|ACTIVE_COMPARATOR|Laser|Patients will undergo Laser lithotripsy
62673109|NCT01922414|ACTIVE_COMPARATOR|Ultrasonic|Patients will undergo ultrasonic lithotripsy
62673110|NCT06503458||Control Group|"1. Have experienced ≥1 episode(s) of MU VOC requiring documented unplanned medical intervention (eg, clinic, physician's office, emergency room or admission) requiring opioid or IV non-steroidal anti-inflammatory drug treatment within 12 months prior to Screening.~2. Participant has no history of past treatment with HU unless the reason for discontinuation was pregnancy (or pregnancy of a partner).~3. Data available for number of MU VOC(s) during the 12-month interval prior to Screening and a value for %HbF collected subsequent to 1 year of age in the absence of recent transfusion27(see Inclusion Criteria #2 - All Groups)"
62673111|NCT06503458||HU Treatment Group|"1. Have experienced ≥1 episode(s) of MU VOC requiring documented unplanned medical intervention (eg, clinic, physician's office, emergency room or admission) requiring opioid or IV non-steroidal anti-inflammatory drug treatment within12 months prior to initiation of HU.~2. Must be on a stable dose of HU ≥8 weeks prior to Day 1 with the intent of remaining on the same dose throughout the study, unless adjustments are medically necessary due to bone marrow suppression, in accordance with published guidelines.~3. Data available for number of MU VOC(s) during the 12-month interval prior to initiation of HU treatment and a value for %HbF collected subsequent to 1 year of age, prior to initiation of HU treatment and in the absence of recent transfusion27(see Inclusion Criteria #2 - All Groups)."
61916601|NCT01993095|EXPERIMENTAL|Experimental: FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
61916602|NCT01993095|ACTIVE_COMPARATOR|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
61916603|NCT03461354|EXPERIMENTAL|A|Mucolox Arm
61916604|NCT03461354|ACTIVE_COMPARATOR|B|Sodium Bicarb Control Arm
62673112|NCT00585585|EXPERIMENTAL|Arm 1: Betahistine dihydrochloride|Oral betahistine dihydrochloride; daily dose 50-300 mg
61916605|NCT03461679|EXPERIMENTAL|Intervention|Adductor canal block Femoral triangle block
61916606|NCT03461679|ACTIVE_COMPARATOR|Standard|Femoral triangle block
61916607|NCT02574572|EXPERIMENTAL|Single group|Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection
61916608|NCT02373501|EXPERIMENTAL|intra-abdominal repair|intra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
61916609|NCT02373501|EXPERIMENTAL|extra-abdominal repair|extra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
61916610|NCT03020446|EXPERIMENTAL|Sorbion dressing to venous leg ulcer|any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed
61916611|NCT03915860|EXPERIMENTAL|Trifarotene|Participants applied Trifarotene 50 μg/g topically once daily in the evening for 24 weeks.
61916612|NCT05985564||The Bochdalek hernia group|
61916613|NCT05985564||the congenital diaphragmatic eventration group|
61916614|NCT03347578||Lung cancer surgery|All patients undergoing thoracic surgery for lung cancer either with thoracoscopy or thoracotomy will receive diaphragmatic Ultrasonography 2 and 24 hours after surgery
62111483|NCT06555523|EXPERIMENTAL|Ultrasound-guided injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging
62111484|NCT06555523|EXPERIMENTAL|Blinded injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
62111485|NCT02747563|EXPERIMENTAL|Active Surveillance|Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement
62301476|NCT01896232|ACTIVE_COMPARATOR|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
62673113|NCT01356485|EXPERIMENTAL|MP4CO|Escalating doses of MP4CO, administered intravenously
61916615|NCT05371171|EXPERIMENTAL|skin graft|
61916616|NCT05371171|PLACEBO_COMPARATOR|no skin graft|
61916617|NCT01279239||Poly trauma|20 Patients suffering from poly trauma who meet inclusion criteria would be recruited
61916618|NCT01279239||Healthy control|20 healthy volunteers would be recruited to obtain basal metabonomics fingerprinting
62111486|NCT02747563|ACTIVE_COMPARATOR|Controls|Patients without known diagnosis of prostate cancer Intervention - PSA measurement
62673114|NCT01356485|PLACEBO_COMPARATOR|Saline|Normal saline (0.9% sodium chloride solution)
62111487|NCT04709796|EXPERIMENTAL|Intervention group: EmbryoGlue|Embryo transfer with EmbryoGlue®
62111488|NCT04709796|ACTIVE_COMPARATOR|Control group|Conventional embryo transfer
62111489|NCT00961636|EXPERIMENTAL|ERN/LRPT|"One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg~tablets daily (2g/40 mg total) for 28 weeks"
62673115|NCT03548415|PLACEBO_COMPARATOR|Placebo|Participants received placebo by subcutaneous injection (SC) once every 4 weeks for 16 weeks.
61916619|NCT06184620||PACG group|All patients in the experimental group met the diagnostic criteria of primary angle-closure glaucoma in the Chinese Glaucoma Guidelines(2020).
61916620|NCT06184620||control group|The depth of the anterior chamber is normal, and the whole corner of the chamber is open; The cup-to-plate ratio is less than 0.5; No family history of glaucoma
61916621|NCT04976153|EXPERIMENTAL|aSMDC|Autologous skeletal muscle derived cells for the treatment of urge fecal incontinence
61916622|NCT04976153|PLACEBO_COMPARATOR|Placebo|Placebo control is the vehicle solution used for the study product
62301477|NCT01896232|EXPERIMENTAL|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
62301478|NCT06322381|ACTIVE_COMPARATOR|Reinsertion achilles tendon|Reinsertion Achilles tendon by 2-4 anchors.
62301479|NCT06322381|ACTIVE_COMPARATOR|Zadek osteotomy|A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
62301480|NCT05786170|EXPERIMENTAL|magnetic resonance imaging|DW-MRI after ischemic stroke
62301481|NCT05793567||T2MI Patients|Patients with T2MI and no epicardial coronary stenosis \>50% will be prospectively enrolled and undergo a routine standard of care coronary angiogram with coronary reactivity testing (CRT).
62301482|NCT05793567||Controls|Patients with atypical chest pain and no obstructive disease on coronary angiogram who have been referred for investigation of suspected CMD and have a clinical indication for CMD testing will be retrospectively enrolled and data collected from a previous routine standard of care coronary angiogram with coronary reactivity testing (CRT) will be utilized.
62301483|NCT04945655|EXPERIMENTAL|Arm 1: component 1 + component 2 + component 3|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2) + Access to vaccination at school (component 3)
61916623|NCT05837169|EXPERIMENTAL|Intervention group|The MBSR program will be offered through the Zoom platform. It consists of a total of 8 weekly sessions, with an approximate duration of 2 hours per session. During these sessions, patients will be instructed in exercises to promote mindfulness, including body awareness (body scan), gentle yoga exercises, and meditation. Additionally, a digital manual will be delivered with exercises that can be done at home, 8 audios with guided exercises and a video with balance and flexibility postures. Patients will be instructed to practice mindfulness exercises at least twice a day, lasting approximately 20 min per exercise, to cultivate the incorporation of meditation into their daily lives.
61916624|NCT05837169|NO_INTERVENTION|Wait-list control group|
62301484|NCT04945655|EXPERIMENTAL|Arm 2: component 1 + component 2|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2)
62301485|NCT04945655|EXPERIMENTAL|Arm 3: component 1 + component 3|Adolescents and parents' education and motivation at school (component 1) + Access to vaccination at school (component 3)
62301486|NCT04945655|EXPERIMENTAL|Arm 4: component 1|Adolescents and parents' education and motivation at school (component 1)
61916625|NCT00622739|ACTIVE_COMPARATOR|ziprasidone rapid dose|Rapid Dose Titration Group
61916626|NCT00622739|ACTIVE_COMPARATOR|ziprasidone slow dose|Slow Dose Titration Group
61916627|NCT03023670|ACTIVE_COMPARATOR|Group A|This group will include patients with low flow of mixed oxygen / air (1:1L) during the period of cardiopulmonary bypass
62111490|NCT00961636|EXPERIMENTAL|ERN/LRPT then ERN|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.
62111491|NCT00961636|PLACEBO_COMPARATOR|Placebo|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.
62111492|NCT04276987|EXPERIMENTAL|MSCs-derived Exosomes Treatment Group|Conventional treatment and aerosol inhalation of MSCs-derived exosomes treatment participants will receive conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
62111493|NCT02812459|EXPERIMENTAL|Kinesio taping plus exercise|Kinesio taping application for low back plus back exercises.This protocol will be administered three a week for 4 weeks.
62301487|NCT04945655|EXPERIMENTAL|Arm 5: component 2|General practitioners' training (component 2)
62301488|NCT04945655|NO_INTERVENTION|Arm 6: Control|No intervention
62301489|NCT05437796|ACTIVE_COMPARATOR|Hypnotic virtual reality support|Hypnotic virtual reality support using hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
62470898|NCT01174225|ACTIVE_COMPARATOR|I|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Flexi T 380(+) IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
62673116|NCT03548415|EXPERIMENTAL|Cohort A: IONIS GHR-LRx, 60 mg|Participants received IONIS GHR-LRx, 60 milligrams (mg), SC, once every 4 weeks for 16 weeks.
61916628|NCT03023670|ACTIVE_COMPARATOR|Group B|This group will receive low rate (4\\min) with low tidal volume ( 2ml/kg ) during the period of cardiopulmonary bypass.
61916629|NCT02309619|EXPERIMENTAL|trans-substernal group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-substernal path.
61916630|NCT02309619|EXPERIMENTAL|trans-esophageal bed group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-esophageal bed path.
61916631|NCT01233687|EXPERIMENTAL|AMG 102 and erlotinib|Combination of AMG 102 and erlotinib
61916632|NCT02036554|EXPERIMENTAL|Tacrolimus plus Everolimus|Low dose Tacrolimus + Everolimus
61916633|NCT02036554|ACTIVE_COMPARATOR|Tacrolimus plus Mycophenolic acid|standard dose Tacrolimus + Mycophenolic acid
62111494|NCT02812459|ACTIVE_COMPARATOR|Electrical stimulation plus exercise|Electrical stimulation for control pain applied in low back plus exercises.This protocol will be administered three a week for 4 weeks.
62111495|NCT05747313|EXPERIMENTAL|Study group|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
62111496|NCT04768361|EXPERIMENTAL|Behavioral Activation without Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and excludes terms and interventions from Third Generation Therapies.
62111497|NCT04768361|EXPERIMENTAL|Behavioral Activation with Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and include mindfulness practices.
62111498|NCT04283825|EXPERIMENTAL|Humanistic care|In addition to routine therapy, the combinations of different psychological and physical rehabilitation activities will be applied to the patients.
62301490|NCT05437796|SHAM_COMPARATOR|Without hypnotic virtual reality support|
62301491|NCT01420575|EXPERIMENTAL|Visual Decision Making Aid|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower overweight patients with schizophrenia/schizoaffective disorder and help them efficiently arrive at a treatment decision that can be successfully implemented.
62301492|NCT01420575|ACTIVE_COMPARATOR|Usual Care|Usual care reflects the standard of care in psychiatry. Psychiatrists will recommend treatment for overweight patients with schizophrenia on olanzapine who have failed to lose weight despite life style and dietary modifications. They may recommend switching to a comparable antipsychotic with a lower incidence of weight gain.
62301493|NCT04536194|EXPERIMENTAL|norepinephrine|infusion of norepinephrine with a adjusted dose to elevate 10% of mean arterial pressure
62301494|NCT04536194|ACTIVE_COMPARATOR|Dopamine|infusion of dopamine with a adjusted dose to elevate 10% of mean arterial pressure
62301495|NCT04887298|EXPERIMENTAL|Liposomal Annamycin (L-Annamycin)|
62301496|NCT01179529|EXPERIMENTAL|Omalizumab|
62470899|NCT01174225|ACTIVE_COMPARATOR|II|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Nova T IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
62673117|NCT03548415|EXPERIMENTAL|Cohort B: IONIS GHR-LRx, 80 mg|Participants received IONIS GHR-LRx, 80 mg, SC, once every 4 weeks for 16 weeks.
62673118|NCT03548415|EXPERIMENTAL|Cohort C: IONIS GHR-LRx, 120 mg|Participants received IONIS GHR-LRx, 120 mg, SC, once every 4 weeks for 16 weeks.
62111499|NCT04283825|NO_INTERVENTION|Non-humanistic care|Patients only receive routine therapy.
62111500|NCT01740817|EXPERIMENTAL|Intralipid 20%, then saline|Participants first received lipid infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received saline infusion of 30ml/h x48h.
62301497|NCT02986373|EXPERIMENTAL|Risankizumab|Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.
62301498|NCT05178537||AAS users|current og previous use of AAS
62673119|NCT03548415|EXPERIMENTAL|Cohort D: IONIS GHR-LRx, 160 mg|Participants received IONIS GHR-LRx, 160 mg, SC, once every 4 weeks for 16 weeks.
62673120|NCT04201210|EXPERIMENTAL|Experimental Arm|Patients with no matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the experimental arm
62673121|NCT04201210|ACTIVE_COMPARATOR|Control Arm|Patients with a matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the control arm
61916634|NCT01050478|EXPERIMENTAL|Paliperidone ER|Paliperidone ER: recommended dose: 6 mg/day. Can be 9 mg/day for patients with an acute exacerbation of schizophrenia. A benzodiazepine for sedation and/or rescue medication can be added with a maximum of 7.5 mg/day, at the investigators' discretion.
61916635|NCT03018665|EXPERIMENTAL|Exenatide and Metformin|Exenatide in Combination With Metformin
62111501|NCT01740817|EXPERIMENTAL|Saline, then Intralipid|Participants first received saline infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received lipid infusion of 30ml/h x48h.
62111502|NCT05538988|EXPERIMENTAL|Cemiplimab|Study treatment includes administration of cemiplimab 350 mg intravenous every 21 days (+/﹣ 3 days)
62301499|NCT00533000|EXPERIMENTAL|A|Smoking cessation
62111503|NCT05607953|EXPERIMENTAL|SD-101|Two doses of SD-101 given over two cycles via pancreatic retrograde venous infusion (PRVI) using the PEDD method of administration.
62301500|NCT00533000|NO_INTERVENTION|B|
62673122|NCT00723944|ACTIVE_COMPARATOR|Osseotite Certain Prevail|Dental implant with lateralized design
62673123|NCT00723944|PLACEBO_COMPARATOR|Osseotite Certain|Dental implant without the lateralized design
62673124|NCT05139940||Pilot Group to calibrate the operating points for AI algorithms (Estimated Enrollment up to 500)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
62673125|NCT05139940||Main Cross Sectional Group (Estimated Enrollment 1932 minus the volume in pilot)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
62673126|NCT06130137||HIV|Patients with HIV infection
62111504|NCT02652936|EXPERIMENTAL|AF-130 capsule|AF-130 oral capsules administered as a single dose or once daily for 7 days
62673127|NCT06130137||HBV|Patients with HBV infection
62673128|NCT04903509|EXPERIMENTAL|BI 1820237|Part 1 and part 2 of the trial.
62673129|NCT04903509|PLACEBO_COMPARATOR|Placebo|Part 1 and part 2 of the trial.
62673130|NCT04903509|EXPERIMENTAL|BI 1820237 + liraglutide|Part 3 of the trial.
62673131|NCT04903509|PLACEBO_COMPARATOR|Placebo + liraglutide|Part 3 of the trial.
62673132|NCT04757844|EXPERIMENTAL|Young healthy voluntary adults|30 young healthy voluntary adults
62673133|NCT02217553|EXPERIMENTAL|vitamin D (cholecalciferol)|All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
62673134|NCT05733533|EXPERIMENTAL|HRS-2261 oral tablet|
62673135|NCT05733533|PLACEBO_COMPARATOR|Matching placebo to HRS-2261|
62673136|NCT02326246|EXPERIMENTAL|men with low-risk PC|men newly diagnosed with low-risk prostate cancer and put in an active surveillance (AS) program. Eight weeks post TRUS-guided biopsies they are scanned with a multi-parametric magnetic resonans imaging (mMRI). If the scans shows a PIRADS 4 or 5 lesion, MRI-guided biopsies are performed. Otherwise the patients will continue in the AS program as usual. The mMRI will in these cases be repeated after 1 year.
62673137|NCT01658735|ACTIVE_COMPARATOR|H-Wave Device|H-Wave Device with Usual Care
62673138|NCT01658735|ACTIVE_COMPARATOR|TENS|Transcutaneous electrical nerve stimulation (TENS) Device with Usual Care
62673139|NCT01658735|SHAM_COMPARATOR|Sham Electrotherapy|Sham Device plus Usual Care.
62673140|NCT02787798|EXPERIMENTAL|Entresto|"* Stop of all angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor during 2 days.~* valsartan/sacubitril 100 mg tablets (51 and 49 mg) during 2 to 4 weeks twice a day.~* valsartan/sacubitril 200 mg tablets (103 and 97 mg) during 2 to 4 weeks twice a day.~* Microneurography recording of sympathetic activity in muscle destiny (MSNA)"
62673141|NCT02787798|PLACEBO_COMPARATOR|Control|"* Hearth failure treatment as usual (angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor)~* Microneurography recording of sympathetic activity in muscle destiny (MSNA) will be done"
62111505|NCT02652936|PLACEBO_COMPARATOR|AF-130 matching placebo capsule|Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days
62673142|NCT03708770|OTHER|endoAVF|
62673143|NCT05952479||Undernutrition|Undernutrition is defined as weight-for-age z-score (WAZ), height-for-age z-score (HAZ), and weight-for-height z-score (WHZ) of WHO growth chart standards \< -2.00 SD
62673144|NCT05952479||Normal nutrition|Normal nutrition is defined as weight-for-age z-score (WAZ), height-for-age z-score (HAZ), and weight-for-height z-score (WHZ) of WHO growth chart standards in the range of +2 and -2.00 SD
62111506|NCT02888002|EXPERIMENTAL|Internet-based treatment|"Guide to better alcohol habits online. An Internet-based treatment program with online counselor support."
62111507|NCT02888002|EXPERIMENTAL|Face-to-face treatment|"Guide to better alcohol habits F2F: Face-to-face treatment with 5 individual counselor sessions at the clinic."
62111508|NCT01604018||Placebo|Subjects previously randomized to receive placebo in study CP005 and completed CP005A.
62111509|NCT01604018||Cat-PAD Group 1|Subjects previously randomized to receive Cat-PAD dose 1 in study CP005 and completed CP005A.
62111510|NCT01604018||Cat-Pad Group 2|Subjects previously randomized to receive Cat-PAD dose 2 in study CP005 and completed CP005A.
62111511|NCT05582317|ACTIVE_COMPARATOR|Biodentine|20 primary molars were treated by Biodentine
62673145|NCT02175758|EXPERIMENTAL|12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 12 to \< 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
62673146|NCT02175758|EXPERIMENTAL|12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 12 to \< 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
62673147|NCT02175758|EXPERIMENTAL|6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 6 to \< 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
62673148|NCT02175758|EXPERIMENTAL|6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 6 to \< 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
62673149|NCT02175758|EXPERIMENTAL|3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
62673150|NCT02175758|EXPERIMENTAL|3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
62673151|NCT03611465|OTHER|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
62673152|NCT03611465|EXPERIMENTAL|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients scheduled for a cardiac defibrillator implantation in primary prevention.
62673153|NCT03611465|EXPERIMENTAL|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
62673154|NCT00753142|ACTIVE_COMPARATOR|Participants with ketosis-prone diabetes|Obese African Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA) receiving Intralipid 20% and a glucose infusion.
62673155|NCT00753142|ACTIVE_COMPARATOR|Participants with ketosis-resistant diabetes|Obese African American with type 2 diabetes with hyperglycemia without ketosis receiving Intralipid 20% and a glucose infusion.
62673156|NCT00753142|ACTIVE_COMPARATOR|Non-diabetic control group|Obese African Americans without diabetes receiving a glucose infusion.
62673157|NCT03144635|EXPERIMENTAL|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
62673158|NCT06190015|ACTIVE_COMPARATOR|Advanced platelet rich fibrin (APRF) group;|After surgical removal of one of the impacted mandibular third molar, APRF clots will be placed in the alveolus
62673159|NCT06190015|NO_INTERVENTION|Control group 1;|Standard surgical removal of the other impacted mandibular third molar will be performed without placing APRF in the wound
62673160|NCT06190015|ACTIVE_COMPARATOR|Enamel matrix derivative (EMD) group;|After surgical removal of one impacted mandibular third molar, EMD with collagen sponges will be placed in the extraction alveolus
62673161|NCT06190015|NO_INTERVENTION|Control group 2;|Standard surgical removal of the other impacted mandibular third molar will be performed without placing EMD in the wound
62673162|NCT01091532|EXPERIMENTAL|Cohort 1|Subjects will be assigned to receive either UK-396,082 or placebo
62673163|NCT01091532|EXPERIMENTAL|Cohort 2|Subjects will be assigned to receive either UK-396,082 or placebo
62673164|NCT01091532|EXPERIMENTAL|Cohort 3|Subjects will be assigned to receive either UK-396,082 or placebo
62111512|NCT05582317|ACTIVE_COMPARATOR|Simvastatin|20 primary molars were treated by Biodentine
62111513|NCT05582317|ACTIVE_COMPARATOR|combination of Biodentine and Simvastatin|20 primary molars were treated by Biodentine
62111514|NCT02678104|EXPERIMENTAL|Chlorhexidine mouth wash|Tooth extraction. The patients will start using Chlorhexidine mouthwash on 2nd day of extraction twice daily for 7 days.
62111515|NCT02678104|EXPERIMENTAL|Manuka Honey|intra-alveolar application of Manuka Honey after tooth extraction.
62111516|NCT00487578|ACTIVE_COMPARATOR|A|Naratriptan 2.5 mg tablet bid x 30 days
62111517|NCT00487578|PLACEBO_COMPARATOR|B|placebo matching naratriptan 2.5 mg tablet
62111518|NCT03360552|EXPERIMENTAL|the multidimensional score of fragility (RAI CA)|A general practitioner (MG) management strategy guided by a multidimensional evaluation (RAI-CA) on the multidimensional score of fragility (RAI-HC) of patients with mild to moderately severe dementia.
62111519|NCT03360552|PLACEBO_COMPARATOR|Usual care|support for patients without multidimensional evaluation (RAI-CA)
62111520|NCT03800667|EXPERIMENTAL|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1000 mg of vitamin C for one month,
62111521|NCT03800667|NO_INTERVENTION|Women not taking vitamin C|Women who are undergoing elective gynecological surgeries and who are randomized not to take any vitamin C for one month.
62111522|NCT02686554||AD patients|
62111523|NCT02686554||AD patients immunized|
62111524|NCT01544140|EXPERIMENTAL|midazolam then midazolam + vandetanib|Midazolam alone followed by midazolam in combination with vandetanib
62111525|NCT02712411|EXPERIMENTAL|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
62111526|NCT02712411|EXPERIMENTAL|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
62111527|NCT04481906||Women 20 years and older with cystocele|Women 20 years and older with cystocele
62111528|NCT00166192|ACTIVE_COMPARATOR|Chemical Peel|Split face treatment paradigm
62111529|NCT03761966||Pregnant women|"Pregnant women older than 18 years old atended at the Mónica Pretelini Sáenz Maternal-Perinatal Hospital (HMPMPS), Health Institute of the State of Mexico (ISEM)."
62111530|NCT04473638||Arthroscopic|Deltoid Arthroscopic Repair in Ankle Fractures
62111531|NCT02830152|EXPERIMENTAL|Left Atrial Appendage Occlusion (LAAO)|The intervention is implantation of Amplatzer Amulet LAAO device within two months after randomization. Device implantation comprises a catheterization procedure using venous access and a transseptal puncture to obtain access to the left atrium (LA). Procedural imaging guidance is left to the physician's discretion and may include several techniques such as angiography/fluoroscopy, transesophageal echocardiography (TEE) and/or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes ASA therapy for at least 6 months, which may be combined with clopidogrel for the first 45 days after implantation.
62673165|NCT01091532|EXPERIMENTAL|Cohort 4|Subjects will be assigned to receive either UK-396,082 or placebo
62673166|NCT01137721||Pre-Hydroxyurea - subjects with SCD|Patients with a diagnosis of HbSS (sickle cell anemia) or HbS/ß0-thalassemia (beta thalassemia) who will be treated with hydroxyurea therapy.
62673167|NCT01137721||Sibling control|Sibling control with no diagnosis of HbSS or HbS/ß0-thalassemia.
62673168|NCT01137721||Observational - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia.
62673169|NCT01137721||Pre-transfusion - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia who will be treated with transfusion therapy.
62673170|NCT03132259|EXPERIMENTAL|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
62673171|NCT03132259|EXPERIMENTAL|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
62673172|NCT01117350|EXPERIMENTAL|Insulin Glargine|"Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.~The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 \< FPG ≤ 100 mg/dL (3.9 \< FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation."
62673173|NCT01117350|ACTIVE_COMPARATOR|Liraglutide|"Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.~The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment."
62111532|NCT02830152|ACTIVE_COMPARATOR|Medical Therapy|The optimal medical therapy of stroke prevention in non-valvular atrial fibrillation (NVAF) after intracerebral hemorrhage (ICH) is not known. Therefore, it will be left to the discretion of the treating physician to decide if, when, and which pharmacological therapy will be prescribed. Available options include anticoagulation with oral anticoagulation (OAC) or novel oral anticoagulants (NOAC), antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
62111533|NCT00208767|ACTIVE_COMPARATOR|Valsartan|Valsartan titrated up to 320 mg orally daily
62111534|NCT00208767|PLACEBO_COMPARATOR|Placebo|Patients received a placebo instead of Valsartan
62111535|NCT01541358|EXPERIMENTAL|Diagnostic (fluorine F 18 sodium fluoride PET/CT)|Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
62111536|NCT01668212||natural In Vitro Fertilization cycle|Patient doing following natural In Vitro fertilization cycle
62111537|NCT01414231|ACTIVE_COMPARATOR|Cytarabine low dose|This is the golden standard of AML treatment
62111538|NCT01414231|ACTIVE_COMPARATOR|Cytarabine intermediate dose|This is the OSHO internal arm
62111539|NCT02808442|EXPERIMENTAL|UCART19|
62673174|NCT05233540||Locally advanced or synchronous metastatic anal cancer treated with induction chemotherapy|Patients with newly diagnosed anal cancer who by standard of care are eligible for induction chemotherapy prior to definitive CRT or radiotherapy alone (RT) will be screened according to inclusion- and exclusion criteria. Patients eligible for induction chemotherapy will be patients with locally advanced or synchronous metastatic anal cancer.
62673175|NCT03051230||Studied group|Women exposed to ovarian hyperstimulation for In Vitro fertilisation
62111540|NCT04964479|EXPERIMENTAL|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 3 weeks, 1200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
62673176|NCT03518203|EXPERIMENTAL|Eculizumab|All patients will receive eculizumab based on their weight for 24 weeks.
62673177|NCT02222181|EXPERIMENTAL|Pharmacotherapy follow-up|patients with Alzheimer's disease
62111541|NCT04964479|ACTIVE_COMPARATOR|Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules|"Pembrolizumab injection: once every 3 weeks, 200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Placebo of Anlotinib hydrochloride capsules:once a day, 0mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
62470900|NCT01174225|NO_INTERVENTION|III|"Participants who elect for forms of contraception other than a copper IUD will chose which form of contraception they would like to use and be put into one of the groups specified below based on her contraceptive choice. These participants will be observed throughout the study for overall satisfaction and repeat pregnancy rate.~Groups - Participants will be in one of the five following groups Group A - Oral contraceptive pill 28day supply provided after abortion Group B - Medroxyprogesterone acetate (Depo-provera)150mg IM provided after abortion, lasts for 3 months Group C - Ethinyl estradiol and etonogestrel (Nuva ring) provided at time of abortion, lasts for 28 days Group D - Condoms provided at time of abortion Group E - Other"
62470901|NCT04441216|NO_INTERVENTION|Consultation only|Review by Chinese Medicine practitioner only
62673178|NCT04652843|OTHER|Idiopathic REM sleep behavior disorders|Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
62470902|NCT04441216|ACTIVE_COMPARATOR|JinQi JiangTang Fang|JinQi JiangTang Fang (Rhizoma Coptidis, Radix Astragali and Flos Lonicerae)
62673179|NCT04652843|OTHER|Beginning Parkinson's disease|Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy
62673180|NCT04652843|OTHER|Parkinson's disease state Phase|Group of 20 patients with Parkinson's Disease for more than 5 years
62673181|NCT04652843|OTHER|Control|Group of 20 patients undergoing coloscopy for family screening for digestive polyps
62111542|NCT00159796|EXPERIMENTAL|Arm 1|Asenapine
62470903|NCT04441216|ACTIVE_COMPARATOR|JM-ELD|JQJT plus extra low dose Ophiopogonis Radix
62673182|NCT04853537|EXPERIMENTAL|study group|• 126 women will fast 16 consecutive hours per day including sleeping hours. and follow them from 26w till 36w by GTT(glucose tolerance test) and the weight gain and incidence of gestational diabetes
62470904|NCT04441216|ACTIVE_COMPARATOR|JM-LD|JQJT plus low doses Ophiopogonis Radix
62673183|NCT04853537|NO_INTERVENTION|control group|• 126 women will not fasting with the same life style and follow the incidence of gestational diabetes
61916636|NCT03018665|ACTIVE_COMPARATOR|BIAsp30 and Metformin|BIAsp30 in Combination With Metformin
62470905|NCT02458586|PLACEBO_COMPARATOR|MUFA|daily intake of 50 g of olive oil over a period of 8 weeks
62470906|NCT02458586|ACTIVE_COMPARATOR|PUFA|daily intake of 50 g of canola oil (rapeseed oil) over a period of 8 weeks
62111543|NCT00159796|ACTIVE_COMPARATOR|Arm 2|Olanzapine
62111544|NCT00159796|PLACEBO_COMPARATOR|Arm 3|Placebo
62111545|NCT00423254|EXPERIMENTAL|Low Dose Cohort|
62470907|NCT06302686|EXPERIMENTAL|engAGE group|The experimental group will use the technological engAGE system for 6 months.
62470908|NCT06302686|OTHER|control group|To the control group will be given a booklet containing information and activities on well-being to do at home.
62470909|NCT03959683|ACTIVE_COMPARATOR|Trilogy device|Trilogy Lithotrite to fragment urinary tract calculi in the kidney, ureter and bladder
62470910|NCT03959683|ACTIVE_COMPARATOR|ShockPulse-SE|ShockPulse-SE Lithotripsy System to fragment urinary calculi in the kidney, ureter and bladder
62111546|NCT00423254|EXPERIMENTAL|High Dose Cohort|
62111547|NCT03696251||master's nursing program|the graduates of master's nursing program in recent three years in Taiwan
62111548|NCT05095558|EXPERIMENTAL|MST|standard chemotherapy with microtransplantation
62111549|NCT05095558|NO_INTERVENTION|CT|standard chemotherapy only, without microtransplantation
62111550|NCT05192863||Participants with CD|Participants diagnosed with moderately to severely active CD who are initiating vedolizumab intravenous (IV) induction treatment with the option to switch to vedolizumab subcutaneous (SC) treatment, as maintenance therapy in accordance with the current SmPC will be observed prospectively for 18 months.
62111551|NCT03245541|EXPERIMENTAL|Durvalumab + SABR|Durvalumab + Stereotactic Ablative Body Radiotherapy
62111552|NCT01586299|EXPERIMENTAL|ibuprofen|
62111553|NCT01586299|ACTIVE_COMPARATOR|acetaminophen|
62111554|NCT05929911|EXPERIMENTAL|Trauma-focused psychodynamic psychotherapy|Twice-weekly psychotherapy for 24 sessions
62111555|NCT00972504|ACTIVE_COMPARATOR|GSK835726 (10mg)|10mg oral dose
62111556|NCT00972504|ACTIVE_COMPARATOR|GSK1004723 (1000mcg)|1000mcg nasal spray solution
62111557|NCT00972504|ACTIVE_COMPARATOR|Cetirizine 10mg|10mg cetirizine as active comparator
62111558|NCT00972504|PLACEBO_COMPARATOR|placebo|placebo
62673184|NCT05128344|EXPERIMENTAL|AMZ002|
62673185|NCT05128344|ACTIVE_COMPARATOR|Vigabatrin|
62673186|NCT02407015|ACTIVE_COMPARATOR|3D gameplay|Participants will play a game for 30 minutes on the Nintendo 3DS in 3D.
62673187|NCT02407015|ACTIVE_COMPARATOR|2D gameplay|Participants will play a game for 30 minutes on the nintendo 3DS in 2D.
62673188|NCT01400633||001|decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
62673189|NCT04113980|EXPERIMENTAL|music group|The children in the groups were distracted by listening music 2 minutes before venipuncture, until the process was over.
61916637|NCT02752555|NO_INTERVENTION|Antioxidant group|In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).
61916638|NCT02752555|EXPERIMENTAL|Antioxidant+modifiable lifestyle factors|In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.
61916639|NCT03387644|ACTIVE_COMPARATOR|Pregabalin (PG)|Patients received 150 mg pregabalin one hour before the procedure.
61916640|NCT03387644|PLACEBO_COMPARATOR|Control placebo (C)|Patients received placebo tablet one hour before surgery.
61916641|NCT03662243||Acquired brain injury participants|People with acquired alexia and/or agraphia secondary to brain injury who participate in the reading/writing intervention.
61916642|NCT04144218|PLACEBO_COMPARATOR|Control group|
61916643|NCT04144218|EXPERIMENTAL|Experimental group|
61916644|NCT00171054|EXPERIMENTAL|Valsartan 320 mg|
61916645|NCT00171054|EXPERIMENTAL|Amlodipine 10 mg|
61916646|NCT02994888||all patients|All patients will be treated with cetuximab 500mg/m2 every 2 weeks until the time of progression
62111559|NCT05376930|EXPERIMENTAL|DWP16001|DWP16001 Tablets
62111560|NCT04586712|EXPERIMENTAL|Active CBD-extract|Active Dose (2000mg/30mL hemp extract = 67.5mg/day)
61916647|NCT01975831|EXPERIMENTAL|Escalation: 0.3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (0.3 mg/kg every 2 weeks \[Q2W\] for 13 cycles) and tremelimumab (3 mg/kg every 4 weeks \[Q4W\] for 6 cycles, then every 12 weeks \[Q12W\]). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
62111561|NCT04586712|PLACEBO_COMPARATOR|Vehicle-Control (Placebo)|(0mg/30mL hemp extract = no hemp extract)
62111562|NCT00195975||1|Children with FD
62111563|NCT00195975||4|Healthy controls
62111564|NCT03597841||Patients with CRKp BSI:Combination therapy|
62111565|NCT03597841||Patients with CRKp BSI: Monotherapy|
62111566|NCT02918786|ACTIVE_COMPARATOR|Continuous positive airway pressure|After extubation, patients will receive continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System (control) Intervention:Device : CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System for 48 hours
62111567|NCT02918786|ACTIVE_COMPARATOR|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention) Intervention: Device: Nasal high-flow
61916648|NCT01975831|EXPERIMENTAL|Escalation: 1 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (1 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
61916649|NCT01975831|EXPERIMENTAL|Escalation: 3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
61916650|NCT01975831|EXPERIMENTAL|Escalation: 3 mg/kg Durva + 1 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 12 or 13 cycles) and tremelimumab (1 mg/kg Q4W for 6 cycles, then Q12W or Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
61916651|NCT01975831|EXPERIMENTAL|Expansion: Ovarian Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
61916652|NCT01975831|EXPERIMENTAL|Expansion: Colorectal Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
62111568|NCT00434018|OTHER|Wheelchair Skills Training Program|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
62111569|NCT00434018|OTHER|Basic Health Education|Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
62111570|NCT05600946||Patients|Affected individuals that meet inclusion criteria
62111571|NCT01110850||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
62111572|NCT01838824|EXPERIMENTAL|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
62301501|NCT04723030|EXPERIMENTAL|carleilizumab in combination with apathy mesylate and chemoradiotherapy (paclitaxel (albumin-bound)|Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped.
62301502|NCT03265691|EXPERIMENTAL|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
62301503|NCT03265691|NO_INTERVENTION|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
62301504|NCT05952414|EXPERIMENTAL|Intervention group|Experimental: Intervention group Group one (study group, 40 nurses): received self-efficacy-based interventions.
62301505|NCT05952414|NO_INTERVENTION|Control group|Group two(the control group, 40 nurses):act as a control group/ waiting list
62301506|NCT01844076|EXPERIMENTAL|Phase I Level -2|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg once per day (days 1-21) for a 21 day cycle"
62301507|NCT01844076|EXPERIMENTAL|Phase I Level -1|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
62301508|NCT01844076|EXPERIMENTAL|Phase I Level 0|Group 3: capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), quinacrine at a dose of 200 mg twice a day (days 1-21) for a 21 day cycle
62301509|NCT01844076|EXPERIMENTAL|Phase II|"Phase II will use the treatment outlined in phase I, using the recommended phase II dose (RP2D) derived from Phase I.~Patients will receive capecitabine at a dose of 1000 mg/m\^2 twice per day (days 1-14), quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
62301510|NCT03062501|NO_INTERVENTION|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
62301511|NCT03062501|EXPERIMENTAL|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
62301512|NCT04930939|EXPERIMENTAL|Heart rate variability-guided training group|Patients allocated to heart rate variability-guided training group trained 3 days a week for 6 weeks. These patients carried out moderate continuous traininig sessions or high intensity interval training sessions based on their daily heart rate variability assessments follwing a decision schema.
62301513|NCT04930939|ACTIVE_COMPARATOR|Predefined training group|Patients allocated to predefined training group also trained 3 days a week for 6 weeks. Nonetheless, these patients performed a predefined training program regarless of their parasympathetic modulation status.
62301514|NCT02721862|EXPERIMENTAL|Experimental|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
62470911|NCT04093037|EXPERIMENTAL|Patient with dry eye disease|"Patient with dry eye disease will be included. They will have:~* Time #1: LacryDiag examination without dye~* Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score~* Time #3: Standard Break-Up Time (SBUT)~* Time #4: Schirmer test~* Satisfaction questionnaire to the patient"
62470912|NCT01204294|EXPERIMENTAL|Bigu+Lina|biguanide plus linagliptin
62470913|NCT01204294|EXPERIMENTAL|Glin+Lina|glinide plus linagliptin
61916653|NCT01975831|EXPERIMENTAL|Expansion: Non-triple Negative Breast Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
61916654|NCT01975831|EXPERIMENTAL|Expansion: Renal Cell Carcinoma|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
61916655|NCT01975831|EXPERIMENTAL|Expansion: Cervical Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
61916656|NCT05916911|EXPERIMENTAL|Glizigen Group|Patients will receive combined treatment with Glizigen® oral solution and Glizigen® vaginal gel for 2 months.
62673190|NCT04113980|EXPERIMENTAL|kaleidescope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
62470914|NCT01204294|EXPERIMENTAL|Glit+Lina|glitazone plus linagliptin
62111573|NCT01838824|EXPERIMENTAL|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
62111574|NCT04178291|EXPERIMENTAL|Conventional debridement and air polishing|All participants will receive full mouth EPAP as an adjunct to RSD using ultrasonic scalers and Gracey currettes. The EPAP procedure will be performed using the Air-Flow Master R (EMS) equipment. For supragingival biofilm removal, the Air-Flow handpiece will be used, while the Perio-Flow handpiece with a disposable nozzle will be used for subgingival debridement at sites with PPD ≥ 5mm. No time limit is applicable for supragingival air polishing. However, for subgingival debridement, the nozzle will be inserted for 5 seconds into each pocket, and moved vertically up and down. Gracey currettes will be used at sites with PPD ≥ 5mm.
62470915|NCT01204294|EXPERIMENTAL|SU+Lina|sulfonylurea plus linagliptin
62673191|NCT04113980|EXPERIMENTAL|video group|The children in the groups were distracted by watching cartoon 2 minutes before the blood collection, until the process was over.
62673192|NCT04113980|NO_INTERVENTION|control group|No intervention was made to children in the control group
62673193|NCT00372515|EXPERIMENTAL|High dose gefitinib|
62673194|NCT05615961|EXPERIMENTAL|Probiotic Supplementation Arm|This group will receive the probiotic supplement for 4-weeks prior to their ironman race performance.
62470916|NCT01204294|EXPERIMENTAL|A-GI+Lina|alpha-glucosidase inhibitor plus linagliptin
62111575|NCT04178291|ACTIVE_COMPARATOR|Conventional debridement|All participants will receive full mouth RSD using ultrasonic scalers and Gracey currettes. Gracey currettes will be used at sites with PPD ≥ 5mm.
62111576|NCT03639324|EXPERIMENTAL|Dose Combination 1-1|idelalisib + venetoclax
62111577|NCT03639324|EXPERIMENTAL|Dose Combination 1-2|idelalisib + venetoclax
62111578|NCT03639324|EXPERIMENTAL|Dose Combination 1-3|idelalisib + venetoclax
62111579|NCT03639324|EXPERIMENTAL|Dose Combination 1-4|idelalisib + venetoclax
62111580|NCT03639324|EXPERIMENTAL|Sub-Trial Dose Combination 2-1|idelalisib + venetoclax
62111581|NCT03639324|EXPERIMENTAL|Sub-Trial Dose Combination 2-2|idelalisib + venetoclax
62111582|NCT01709266|EXPERIMENTAL|Probiotics|Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
62111583|NCT01709266|PLACEBO_COMPARATOR|Placebo|Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.
61916657|NCT05916911|PLACEBO_COMPARATOR|Placebo Group|Patients will receive combined treatment with Placebo oral solution and Placebo vaginal gel for 2 months.
62111584|NCT01018524|ACTIVE_COMPARATOR|small hernias - suture repair|
62111585|NCT01018524|ACTIVE_COMPARATOR|small hernias - mesh repair|
62111586|NCT01018524|ACTIVE_COMPARATOR|large hernias - sublay mesh|
62111587|NCT01018524|ACTIVE_COMPARATOR|large hernias - onlay mesh|
62111588|NCT00802490|ACTIVE_COMPARATOR|Intervention|20 sessions of EEG biofeedback training
62111589|NCT00802490|PLACEBO_COMPARATOR|Control|Only 1 session of EEG biofeedback training
62301515|NCT02721862|PLACEBO_COMPARATOR|Control|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking a placebo, that is dispensed from the pharmacy and having the same color as the ursodeoxycholic acid 250mg, twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
62301516|NCT05794529||Lung cancer patient|Lung cancer patients diagnosed a non-small cell lung carcinoma requiring resection surgery.
62301517|NCT03344835||Prostate Cancer|Patients diagnosed with prostate cancer
62301518|NCT00468715|EXPERIMENTAL|bicalutamide|This is a multicenter, open-label, phase II study to evaluate the antitumor activity and safety of bicalutamide administered orally daily to patients with ER(-)/PR(-)/AR(+) metastatic breast cancer. Eligible patients who have consented to trial participation will receive bicalutamide at a dose of 150mg PO daily.
62470917|NCT01204294|ACTIVE_COMPARATOR|SU+Met|sulfonylurea plus metformin
62470918|NCT01204294|ACTIVE_COMPARATOR|A-GI+Met|alpha-glucosidase inhibitor plus metformin
62470919|NCT03575403|PLACEBO_COMPARATOR|Placebo|Subjects will receive oral placebo capsules one time daily.
62470920|NCT03575403|EXPERIMENTAL|Low Dose Duloxetine|Subjects will receive 30 mg oral duloxetine one time daily.
62470921|NCT03575403|EXPERIMENTAL|High Dose Duloxetine|Subjects will receive 60 mg oral duloxetine one time daily.
61916658|NCT03504943|ACTIVE_COMPARATOR|Early Intradialytic Exercise|Intradialytic cycling will occur in the first half of hemodialysis treatment
61916659|NCT03504943|EXPERIMENTAL|Late Intradialytic Exercise|Intradialytic cycling will occur in the second half of hemodialysis treatment
61916660|NCT00084773|EXPERIMENTAL|Cetuximab, Fluorouracil, and Pelvic Irradiation|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 and fluorouracil IV continuously on days 1-42. Patients undergo whole-pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Treatment continues in the absence of disease progression or unacceptable toxicity.~Approximately 1-3 weeks after completion of study treatment, patients undergo surgical resection followed by adjuvant chemotherapy off-study.~Patients are followed for up to 5 years."
61916661|NCT04687215||Diabetic patients receiving a spinal cord stimulator|Patients that have been seen in the diabetic foot clinic will be evaluated for participation in the study once they have been referred to one of our pain clinics.
61916662|NCT03963401|EXPERIMENTAL|PF-06700841 60 mg once daily|PF-06700841 60 mg once daily for 52 weeks
61916663|NCT03963401|EXPERIMENTAL|PF-06700841 30 mg once daily|PF-06700841 30 mg once daily for 52 weeks
61916664|NCT03963401|EXPERIMENTAL|PF-06700841 10 mg once daily followed by 60 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
61916665|NCT03963401|EXPERIMENTAL|PF-06700841 10 mg once daily followed by 30 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
61916666|NCT03963401|PLACEBO_COMPARATOR|Placebo once daily followed by 60 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
61916667|NCT03963401|PLACEBO_COMPARATOR|Placebo once daily followed by 30 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
61916668|NCT03688425|EXPERIMENTAL|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far \> intermediate \> near
61916669|NCT03688425|ACTIVE_COMPARATOR|IOL implantation active comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far \> near \> intermediate
61916670|NCT06432868|ACTIVE_COMPARATOR|Solarplast (R)|100mg/day of Solarplast (R) supplementation (28 days).
61916671|NCT06432868|PLACEBO_COMPARATOR|Placebo|100mg/day of Placebo (maltodextrin (98.8%) and medium chain triglycerides (1.2%)).
61916672|NCT04431089|EXPERIMENTAL|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
61916673|NCT01905215|EXPERIMENTAL|Group A|Subjects in this group will receive a single dose of formulation 1 of RSV vaccine
62111590|NCT05305235|EXPERIMENTAL|RISE Guide|"The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)~RISE Guide delivered by smartphone via Qualtrics and is completed in \~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault."
62301519|NCT04012255|EXPERIMENTAL|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
61916674|NCT01905215|EXPERIMENTAL|Group B|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
61916675|NCT01905215|EXPERIMENTAL|Group C|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
61916676|NCT01905215|EXPERIMENTAL|Group D|Subjects in this group will receive a single dose of formulation 4 of RSV vaccine
62301520|NCT04012255|ACTIVE_COMPARATOR|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
62301521|NCT01590329|EXPERIMENTAL|Micrografting|
62470922|NCT03735485|EXPERIMENTAL|Group I|The control group. Participants in this group received only conventional physiotherapy. Number of the participants were 14.
62673195|NCT05615961|PLACEBO_COMPARATOR|Placebo Arm|This group will receive the placebo capsules for 4-weeks prior to their ironman race performance.
62111591|NCT05305235|ACTIVE_COMPARATOR|Relaxation Control|Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.
62111592|NCT04619303|EXPERIMENTAL|Dexamethasone Implant|Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.
62111593|NCT04619303|ACTIVE_COMPARATOR|Bevacizumab|Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.
62673196|NCT01436292|EXPERIMENTAL|Albumin|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
62673197|NCT02307500|EXPERIMENTAL|Regorafenib|Regorafenib 160 mg (40 mg tablets), po, every day for 3 weeks of every 4 week cycle
62673198|NCT00585169|EXPERIMENTAL|memantine|10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.
62111594|NCT06477302||Adherence group|Patients with a confirmed diagnosis of lung cancer who are undergoing respiratory rehabilitation treatment with at least one month of monitoring and follow-up.
62111595|NCT02787694|EXPERIMENTAL|Factor Targeted Walking Training|Individuals undergo 5x 2 week periods of targeted training based upon evaluation of walking factor results
62111596|NCT05505279|ACTIVE_COMPARATOR|30 L - 70 L|Initially, all patients will receive 3L/min of oxygen for 10 minutes. Than, patients in this arm will receive 30L/min of High Flow Nasal Oxygen for 15 minutes and subsequently 70 L/min for another 15 minutes.
62111597|NCT05505279|ACTIVE_COMPARATOR|70 L - 30 L|Initially, all patients will receive 3L/min of oxygen for 10 minutes. Than, patients in this arm will receive 70L/min of High Flow Nasal Oxygen for 15 minutes and subsequently 30 L/min for another 15 minutes.
62111598|NCT03615248|EXPERIMENTAL|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
62111599|NCT04599582|ACTIVE_COMPARATOR|SP-CL|
62111600|NCT04599582|ACTIVE_COMPARATOR|Corail|
62111601|NCT02674750|EXPERIMENTAL|Group A|Group A: MYC translocation+ and/or MYC gene copy number gain by FISH
62111602|NCT02674750|EXPERIMENTAL|Group B|Group B: MYC expression in \> 40% of tumor cells by IHC
62111603|NCT02674750|EXPERIMENTAL|Group C|Group C: MYC translocation- by FISH, and MYC expression in \< 40% of tumor cells, and no MYC gene copy number gain by FISH
62111604|NCT04757103||Above S3|Lesion located above the third sacral vertebra
62111605|NCT04757103||Below S3|Lesion located below the third sacral vertebra
62111606|NCT01123083|EXPERIMENTAL|otelixizumab|otelixizumab
62111607|NCT01123083|PLACEBO_COMPARATOR|placebo|placebo
62111608|NCT06374784|EXPERIMENTAL|Alveolar ridge preservation using demineralized dentin combined with I-PRF + metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft then inserted in the extraction socket and covered then suturing
62111609|NCT06374784|EXPERIMENTAL|Alveolar ridge preservation using demineralized dentin combined with I-PRF|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft. The injectable PRF will be mixed with the particulate demineralized dentin graft then inserted in the extraction socket and covered then suturing
62301522|NCT00586690|EXPERIMENTAL|NK Cell Infusion|Natural Killer (NK) Cell infusion using CD56 monoclonal antibody
62470923|NCT03735485|EXPERIMENTAL|Group II|The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
62470924|NCT03735485|EXPERIMENTAL|Group III|The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises. Number of the participants were 15.
62470925|NCT05852626|EXPERIMENTAL|Intervention|Multimodal intervention in the primary care team that includes: redistribution of diabetes care between nurses and physicians, use of the individualized glycemic target calculator and implementation of minimum care recommendations
62673199|NCT01270867|ACTIVE_COMPARATOR|Merci Retriever|Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
62111610|NCT06374784|ACTIVE_COMPARATOR|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and inserted in the extraction socket and covered then suturing
62111611|NCT04178941|EXPERIMENTAL|Intervention (Single Arm)|The intervention is a combined educational outreach and audit and feedback strategy that includes providing the hospital's own continuous pulse oximetry use data back to them on a weekly basis. The data will be accompanied by staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
62111612|NCT03321539|EXPERIMENTAL|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21days for three cycles
62111613|NCT03321539|ACTIVE_COMPARATOR|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles
62111614|NCT02771938|EXPERIMENTAL|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
62111615|NCT00922675|EXPERIMENTAL|Postconditioning|Active arm:Postconditioning protocol before routine PCI/stenting of an occluded coronary artery
62111616|NCT00922675|OTHER|Control|Control arm: Routine PCI/stenting of an occluded coronary artery without postconditioning
62111617|NCT00877422|NO_INTERVENTION|Group A|Group A is identified as serum vitamin D level more than 16 ng/dl.
62111618|NCT00877422|ACTIVE_COMPARATOR|Group B|Group B is identified as serum vitamin D level less than 16 ng/dl and is supplemented with vitamin D3.
62111619|NCT00877422|NO_INTERVENTION|Group C|Group C is identified as serum vitamin D less than 16 ng/dl and is not supplemented with vitamin D3.
62673200|NCT01270867|EXPERIMENTAL|Trevo Stentriever|Trevo Retriever is a second generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke. The Trevo Retriever is a type of stent, specifically design to allow for clot integration into the device. The clot in the retriever is then removed and blood flow is restored.
62111620|NCT01910636|EXPERIMENTAL|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
62111621|NCT01007344|ACTIVE_COMPARATOR|flaxseed|2 muffins and 1 slice of bread for a total of 30g flaxseed per day
62470926|NCT05852626|ACTIVE_COMPARATOR|Control|Usual follow-up in Primary Health Care (no intervention in the teams)
62470927|NCT05549934|EXPERIMENTAL|PF-06651600 (Ritlecitinib)|200 mg once-daily for 8 weeks and then 100 mg once daily for the remaining 40 weeks
62470928|NCT01559220|EXPERIMENTAL|Open Label|DBS Implant and stimulation
62673201|NCT05003336|EXPERIMENTAL|Xiangshao Granules|dissolve 1 sachet (4 g) of Xiangshao Granules in water to be drank 3 times a day after meal for 8 weeks
61916677|NCT01905215|EXPERIMENTAL|Group E|Subjects in this group will receive a single dose of formulation 5 of RSV vaccine
61916678|NCT01905215|EXPERIMENTAL|Group F|Subjects in this group will receive a single dose of formulation 6 of RSV vaccine
62111622|NCT01007344|PLACEBO_COMPARATOR|whole wheat flour|2 muffins and 1 slice of bread containing whole wheat flour per day
61916679|NCT01905215|PLACEBO_COMPARATOR|Group Placebo 1|Subjects in this group will receive a single dose of placebo
61916680|NCT01905215|PLACEBO_COMPARATOR|Group Placebo 2|Subjects in this group will receive a single dose of placebo
61916681|NCT01949337|EXPERIMENTAL|Arm A: (enzalutamide)|Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.
61916682|NCT01949337|EXPERIMENTAL|Arm B: (enzalutamide, abiraterone, prednisone)|Patients receive enzalutamide 160 mg PO QD, abiraterone 1000 mg PO QD, and prednisone 5 mg PO BID. Treatment will continue until confirmed disease progression or unacceptable toxicity.
61916683|NCT01330017|EXPERIMENTAL|PE 10 mg|
61916684|NCT01330017|EXPERIMENTAL|PE 20 mg|
61916685|NCT01330017|EXPERIMENTAL|PE 30 mg|
62111623|NCT02178917|EXPERIMENTAL|patients with central neuropathic pain|Randomised to 20 neurofeedback therapy sessions
62111624|NCT02178917|OTHER|Control: patients with central neuropathic pain|Randomised to no neurofeedback treatment
62301523|NCT00586690|OTHER|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for \>24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
62301524|NCT04684030|EXPERIMENTAL|CGMS group|Using continuous glucose monitoring system(CGMS) group
62301525|NCT04684030|ACTIVE_COMPARATOR|SMBG group|Self-monitoring of blood glucose group (conventional fingerpricking method)
62673202|NCT05003336|PLACEBO_COMPARATOR|Xiangshao Granules Placebo|dissolve 1 sachet (4 g) of Xiangshao Granules placebo in water to be drank 3 times a day after meal for 8 weeks
61916686|NCT01330017|EXPERIMENTAL|PE 40 mg|
61916687|NCT01330017|PLACEBO_COMPARATOR|Placebo|
61916688|NCT06076278|ACTIVE_COMPARATOR|Group A (Resistant Training)|Patients in this group will recieve Clinic based resistant training . A total of 12 sessions will be conducted over a period of 4 week 3 days a week.
61916689|NCT06076278|EXPERIMENTAL|Group B (Home Based resistant training)|Patients will recieve home based resistant training. A total of 12 sessions will be conducted over a period of 4 week ,3 days a week .
61916690|NCT01695161||mucopolysaccharidosis|mucopolysaccharidosis
61916691|NCT01695161||Fabry disease|Fabry disease
61916692|NCT01695161||healthy controls|healthy controls
61916693|NCT03945175|EXPERIMENTAL|Treatment|After a two-week, single-blinded, placebo lead-in, all patients will receive four weeks of order-fixed treatment with Mydayis.
61916694|NCT02510755|OTHER|PTSD group|PTSD group
61916695|NCT02510755|OTHER|Healthy Volunteers|Healthy Volunteers, age-matched controls.
62111625|NCT02178917|NO_INTERVENTION|patients with no central neuropathic pain|Observed for development of central neuropathic pain
62111626|NCT03329391|EXPERIMENTAL|Intervention Group|The intervention group will receive a 8-week nurse-led psychosocial care group,which involve 90 minutes session every week.
62111627|NCT03329391|NO_INTERVENTION|Control Group|The control group will receive usual care, which refers to the pharmacological therapy provided by psychiatrists in the Psychiatric Department.
62111628|NCT03042520||IFN-based therapy historical controls|Patients who had ever participated the parent studies, GS-US-334-0115 or GS-US-337-0131, will be invited to participate the current study in outpatient clinic. For the patients who have participated study will be invited to participate the current study as matched historical control n our outpatient clinic,
62111629|NCT03042520||Sofosbuvir-based therapy observational group|"1. Patients ≥ 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643)~2. Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies.~Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response:~1. Patients ≥ 20 of years who had received peginterferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response~2. Patients who have ever participated study will be collected as historical control."
62111630|NCT06405867|EXPERIMENTAL|Early cord clamping (< 30 sec)|Regardless of the type of delivery, a stopwatch was started to determine the clamping time by visualizing the baby's shoulder. No intervention was made to the health personnel who gave birth in the ECC group. Routinely, one clamp was clamped close to the baby's umbilicus and the other on the mother's side, with a distance of approximately 5 cm from the first clamp and cut between the two clamps. Cord clamping time was noted on the case report form
62111631|NCT02919176|ACTIVE_COMPARATOR|Mirabegron|Mirabegron 50 mg/day
62111632|NCT02919176|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 30 mg/day
62111633|NCT02919176|EXPERIMENTAL|Mirabegron and Pioglitazone|Combination of Mirabegron 50 mg/day and Pioglitazone 30 mg/day
62111634|NCT00919763|EXPERIMENTAL|CD2027 Ointment 3 mcg/g, twice daily|Participants applied 3 mcg/g CD2027 Ointment (up to 10 gram per application) topically, twice daily (at least 8 hours apart) over 4 weeks on atopic dermatitis lesions.
62111635|NCT00919763|PLACEBO_COMPARATOR|Vehicle Ointment, twice daily|Participants applied Vehicle Ointment (up to 10 gram per application) topically, twice daily (at least 8 hours apart) over 4 weeks on atopic dermatitis lesions.
62111636|NCT00923676|ACTIVE_COMPARATOR|Fenofibrate|Fenofibrate pills
62111637|NCT00923676|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin pills
62111638|NCT00923676|ACTIVE_COMPARATOR|fenofibrate + rosuvastatin|fenofibrate pills + rosuvastatin pills
62301526|NCT02032524|EXPERIMENTAL|Avalglucosidase Alfa|administered intravenously every 2 weeks
62301527|NCT01998607||Round 1|Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
62301528|NCT01998607||Round 2|Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
62301529|NCT00109421|EXPERIMENTAL|Experimental arm|In the experimental condition, the intervention group will receive the half-day Project ÒRÉ intervention. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires. A subset of groups will participate in a process evaluation focus group immediately following the program.
62673203|NCT04795362||patients with Delayed cerebral ischemia|50 adult patients hospitalized in neurological intensive care unit for subarachnoid hemorrhage, in whom the onset of delayed cerebral ischemia is suspected will be included.
62301530|NCT00109421|NO_INTERVENTION|Attention control group|The attention control group will receive a standard health promotion control program which has been used previously with similar populations. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires.
62301531|NCT04831450|EXPERIMENTAL|Cemiplimab After CRT in HNSCC|Participants will receive Cemiplimab for 6 consecutive months (a total of 8 cycles) 14-42 days after completion of standard of care CRT.
62673204|NCT00441740|EXPERIMENTAL|1|VG
62673205|NCT00441740|EXPERIMENTAL|2|DG
62673206|NCT03927755||Sub-xyphoid|Ultrasound views of the heart obtained using the sub-typhoid approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
62673207|NCT03927755||Para-sternal Long|Ultrasound views of the heart obtained using the parasternal long approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
62111639|NCT05338996|EXPERIMENTAL|iENGAGE for PrEP|We will conduct an exploratory pilot of the PrEP intervention, using a quasi-experimental design, among 80 multi-ethnic WOC in Miami-Dade, Broward, and Palm Beach counties to evaluate feasibility, acceptability, and fidelity. PrEP uptake, adherence, and retention in care will be measured over a 4-month period, including biomarkers of adherence.
62111640|NCT01844544||patients after femur neck fracture|
62111641|NCT02364050||Elderly patients with DLBCL|Elderly patients (Age ≥ 65 years) with large B-cell lymphoma classified FIT or UNFIT or FRAIL by Multidimensional Geriatric Assessment (MGA)
62470929|NCT05070052|EXPERIMENTAL|Group CBT|9 group sessions lasting 75-90 minutes each. CBT starts with psychoeducation about emotions, their primary functions, and how our emotions can affect the way we think and behave. They next learn about behavioral strategies that can help them manage or overcome difficult emotions. Group members also complete gradual exposure exercises, which involve engaging with activities that elicit negative emotions. Finally, group members are taught cognitive skills to help them cope with difficult/stressful thoughts.
62673208|NCT04989738|EXPERIMENTAL|THRIVE Condition|Specifically, parents will learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
62111642|NCT04630457|ACTIVE_COMPARATOR|Meridium-RoFT|order of existing prosthesis-Meridium prosthesis-RoFT prosthesis
62111643|NCT04630457|ACTIVE_COMPARATOR|RoFT-Meridium|order of existing prosthesis-RoFT prosthesis-Meridium prosthesis
62111644|NCT01671241|EXPERIMENTAL|Total body polyethylene wrap (body plus head)|The entire body surface (body plus head) is covered by a polyethylene wrap
62301532|NCT01797523|EXPERIMENTAL|Letrozole + Metformin + RAD001|"Patients have a 7-10 day lead in period where they take Metformin alone. The starting dose of Metformin 500 mg by mouth daily for 4 days and then increased to 500 mg by mouth twice a day. Everolimus and Letrozole added and considered the start of Cycle #1.~Everolimus administered by mouth as once daily dose of 10 mg. Letrozole 2.5 mg tablet by mouth once daily. The oral dose of Everolimus should be taken together with the daily dose of Letrozole 2.5mg."
62673209|NCT04989738|ACTIVE_COMPARATOR|Care As Usual - Healthy Steps Model|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
62673210|NCT00729807|EXPERIMENTAL|Pentamidine|
62673211|NCT06109753||Robotically Assisted Laparoscopy|Surgeons perform robot-assisted laparoscopic surgery
61916696|NCT00885001|EXPERIMENTAL|Short Arc Banding Group|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
61916697|NCT01085500|EXPERIMENTAL|Simulation Curriculum|General surgery residents will undergo a simulation-based educational curriculum (Mastery Learning TEP Curriculum) on TEP hernia repair
61916698|NCT01085500|OTHER|Current Practice|General surgery residents will undergo current practice of learning how to perform the TEP repair in the operating room under direct supervision of the staff surgeon without any simulation pre-training.
62673212|NCT06109753||Conventional Laparoscopy|Surgeons perform conventional laparoscopic surgery
61916699|NCT06521450|ACTIVE_COMPARATOR|combined surgery group|
61916700|NCT06521450|ACTIVE_COMPARATOR|prolapse surgery only group|
61916701|NCT05065554|EXPERIMENTAL|ACALABRUTINIB + RITUXIMAB/BIOSIMILAR|"Acalabrutinib and rituximab (or biosimilar) with be contained in the treatment regimen.~Acalabrutinib will be administered twice daily, with 28 consecutive days defined as a treatment cycle. Acalabrutinib will be administered for 48 cycles or until disease progression or unacceptable toxicity.~Rituximab will be administered on Days 1, 8, 15, and 22 of Cycles 1 and 4. Participants will have study visits every cycle for cycles 1-6, then every 3 cycles, with the next visit at Cycle 9, then C12, C15, etc.~Participants will continue acalabrutinib until disease progression or intolerable adverse effect develops. They will be followed for up to 2 years after completion of 48 cycles of treatment or until death"
62470930|NCT05070052|EXPERIMENTAL|Group MBCT|9 group sessions lasting 75-90 minutes each. The focus of sessions 1 through 4 will be learning to bring greater awareness to the present moment, on purpose, and nonjudgmentally. Appropriate responding is the focus of sessions 5 through 8. All skills are reviewed in session 9.
62673213|NCT00514917|EXPERIMENTAL|Docetaxel+Leuprolide+Bicalutamide|Participants received docetaxel 75 milligram per square meter (mg/m\^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
62111645|NCT01671241|ACTIVE_COMPARATOR|Polyethylene wrap (body)|A polyethylene wrap covers the patient's body up to the neck
62673214|NCT00514917|ACTIVE_COMPARATOR|Leuprolide+Bicalutamide|Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
62301533|NCT01173653|PLACEBO_COMPARATOR|Standard EM Smoking Cessation Info|Patients discharged from ER receive pamphlet re: smoking cessation
62470931|NCT02269995||E7040|
62673215|NCT04002427|EXPERIMENTAL|Only one study arm|"\[14C\]AZD7594 Solution for Infusion 5 µg/mL (1.1 kBq/mL)~AZD7594 Inhalation Powder, SD3FL Inhaler"
62673216|NCT06082544|EXPERIMENTAL|Mini-screw implant-supported pontics placed palatally perpendicular to the alveolar ridge|Mini-screw implant-supported pontics placed palatally perpendicular to the alveolar ridge (horizontally placed) using JEIL SCREW 1.6\*8 MM 16-G2-008
62673217|NCT06082544|EXPERIMENTAL|Mini screw implant supported pontics placed at the crest of the ridge|Mini screw implant supported pontics placed at the crest of the ridge (vertically placed) using JEIL SCREW 1.6\* 10 MM 14-G2-f010
62111646|NCT06331871|EXPERIMENTAL|Ultrasound-guided percutaneous nerve stimulation (US-PENS) and physiotherapy protocol.|Ultrasound Guied Percutaneus Electrical Nerve Stimulation on the suprascapular nerve and axillary nerve, along with a manual physical therapy protocol in patients with pain and lack of function after a shoulder surgery.
62301534|NCT01173653|ACTIVE_COMPARATOR|Patients contact 1-800-QUIT-NOW before leaving ED|Prior the patient leaving the ED, the PI will assist the patient with contacting 1-800-QUIT-NOW, who will help patient to quit smoking.
62301535|NCT05268848|EXPERIMENTAL|Termography PRE|Foot thermography before lining test
62470932|NCT03548519|EXPERIMENTAL|Attention Training|OCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
62470933|NCT03548519|ACTIVE_COMPARATOR|Active placebo training|OCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
62470934|NCT03548519|EXPERIMENTAL|PSE and Attention Training|OCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
62470935|NCT00296647|ACTIVE_COMPARATOR|patch|
62673218|NCT06082544|ACTIVE_COMPARATOR|Removable partial denture.|removable partial denture with conventional technique
62111647|NCT06331871|ACTIVE_COMPARATOR|Physiotherapy protocol.|Only a physiotherapy protocol based on available evidence, applied to patients with pain undergoing shoulder surgery.
62111648|NCT03155490|EXPERIMENTAL|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
62111649|NCT03155490|NO_INTERVENTION|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
62111650|NCT01516788|EXPERIMENTAL|Phototesting|
62111651|NCT04857346|EXPERIMENTAL|Controlled Type 2 diabetes mellitus|
62111652|NCT04857346|EXPERIMENTAL|Uncontrolled Type 2 diabetes melltius|
62111653|NCT04857346|ACTIVE_COMPARATOR|Non-diabetic patients|
62111654|NCT02309580|EXPERIMENTAL|Ibrutinib|This will be a standard dose-escalation study to determine the MTD of ibrutinib in relapsed/refractory PTCL or CTCL. At each dose 6 patients with TCL (PTCL or CTCL) will be enrolled. The first 6 patients will be enrolled at dose level 1. Dose escalation to the next dose level will proceed after DLT assessment of all 6 patients at the end of cycle 1 (28-days).
62111655|NCT02866214|EXPERIMENTAL|Group I|This Group of Patients will receive Febuxostat Drug along with their Standard Treatment.
62111656|NCT02866214|PLACEBO_COMPARATOR|Group II|This Group of Patients will receive Placebo along with their standard Treatment.
62111657|NCT05241119|EXPERIMENTAL|SLNB Group|undergo fluorescence SLNB
62301536|NCT05268848|EXPERIMENTAL|Termography POST|Foot thermography after wearing 2 types of liner for three hours (one on each foot)
62111658|NCT05241119|EXPERIMENTAL|pALND Group|undergo low axillary lymph node dissection with ICBN as the boundary
62111659|NCT05241119|EXPERIMENTAL|ALND Group|undergo ALND
62111660|NCT03694678|EXPERIMENTAL|Recovering Together|Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.
62301537|NCT05268848|ACTIVE_COMPARATOR|Thermographic comparations|Thermographic comparations between PRE and POST measurements
62301538|NCT01793987|NO_INTERVENTION|control: shaver|
62470936|NCT00296647|ACTIVE_COMPARATOR|nicotine lozenge|
62470937|NCT00296647|ACTIVE_COMPARATOR|bupropion|
62470938|NCT00296647|ACTIVE_COMPARATOR|patch + lozenge|
62301539|NCT01793987|EXPERIMENTAL|Coblation polypectomy|
62301540|NCT01167127|NO_INTERVENTION|Tablet|OXN tablet, oral BID, flexible dose design
62301541|NCT00509106|EXPERIMENTAL|Ceftaroline fosamil for injection|Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
62301542|NCT00509106|ACTIVE_COMPARATOR|IV Ceftriaxone|Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
62301543|NCT02966457|EXPERIMENTAL|Selective intestinal decolonization|Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days
62301544|NCT02966457|NO_INTERVENTION|"Wait and watch strategy"|Group without decolonization interventions
62301545|NCT00659438|EXPERIMENTAL|1|Bicalutamide 150mg + ZD6474 300mg
62301546|NCT00659438|PLACEBO_COMPARATOR|2|Bicalutamide 150mg + placebo
62301547|NCT02279316|EXPERIMENTAL|Jaques-Dalcroze eurhythmics|Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
62301548|NCT02279316|EXPERIMENTAL|Home exercise program|Home exercise strength program (3x30min/wk) + 800 IU vitamin D
62470939|NCT00296647|ACTIVE_COMPARATOR|buproion + lozenge|
62301549|NCT02279316|OTHER|Vitamin D only|800 IU Vi-De 3
62673219|NCT03043469||Healthy participants|"Day 1: Hospital assessments (\~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
61916702|NCT04325555||Respondents on PrEP|"On PrEP status will be operationalized in multiple ways, and sensitivity analyses will be conducted using multiple definitions as a result of the self-reported nature of the study.~1. Respondents on PrEP are respondents who reported that they are currently on PrEP~2. Respondents on PrEP are respondents who reported to have ever been on PrEP~3. When respondents are used as their own controls, years on PrEP will be those in which they reported to have been on PrEP for at lest 6 months, and PrEP initiation will be the first such year~A comparison group will be constructed by matching on a variety of characteristics, when this method is applied. Most importantly, age, and STD testing frequency among others, which influence the likelihood of being on PrEP and via that avenue sexual practices, as well as the likelihood of detecting STDs (i.e., ascertainment bias). In other models adjustments will be made for these factors."
61916703|NCT04138966||Patients undergoing general anesthesia|Patients are monitored with Nol-Index, skin conductance, and antinociception-index
61916704|NCT06228911|EXPERIMENTAL|insulin treated group|
61916705|NCT06228911|EXPERIMENTAL|non-insulin treated groups|
62111661|NCT03694678|NO_INTERVENTION|Health Education|Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.
62111662|NCT00610688|PLACEBO_COMPARATOR|Prenatal Vitamin D3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a placebo tablet containing 0IU of Vitamin D
62111663|NCT00610688|EXPERIMENTAL|2|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)
62111664|NCT00610688|EXPERIMENTAL|3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3) along with a tablet containing 3600IU of Cholecalciferol (Vitamin D3).
62111665|NCT01133132|PLACEBO_COMPARATOR|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
62301550|NCT02111538||Amyloidosis|Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis
62301551|NCT02179554||cardiopulmonary bypass|Patients undergoing elective surgery requiring cardiopulmonary bypass
62301552|NCT00631462|EXPERIMENTAL|1|
62301553|NCT02032953|EXPERIMENTAL|Insulin, Travasol (35%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
62301554|NCT02032953|EXPERIMENTAL|Insulin, Travasol (20%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
62673220|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (\~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
62301555|NCT02032953|PLACEBO_COMPARATOR|Insulin, no protein after surgery|Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
62301556|NCT05077761|EXPERIMENTAL|High-intensity laser therapy|77 participants will receive active high-intensity laser therapy interventions on hamstring muscle to improve the flexibility of muscle
62301557|NCT05077761|SHAM_COMPARATOR|Sham High-intensity laser therapy|77 participants will receive sham high-intensity laser therapy on hamstring muscle
62301558|NCT06037655|EXPERIMENTAL|Experimental|NeoAdjuvant Therapy with Adebrelimab plus Mecapegfilgrastim and Gemcitabine/cisplatin followed by the operation
62301559|NCT03864276|EXPERIMENTAL|inhalation anesthesia (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
62301560|NCT03864276|EXPERIMENTAL|Total intravenous anesthesia (propofol) group|Anesthesia is induced and maintained with propofol and sufentanil
62673221|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (\~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
62673222|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (\~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
62301561|NCT00318955|EXPERIMENTAL|Dexmedetomidine group|
62301562|NCT00318955|ACTIVE_COMPARATOR|Propofol group|
62301563|NCT01061489|EXPERIMENTAL|sensory-cognitive training|
62673223|NCT00791882|EXPERIMENTAL|1|"Group of behaviors by which someone express feelings, attitudes, wishes,opinions and rights , in an adequate manner regarding situation and context.~Social skills are the substrate for social competence, which is the ability to find and legitimate relevant and personal goals"
62673224|NCT00791882|NO_INTERVENTION|2|Control group will attend the same number of sessions, but without intervention of the therapists
61916706|NCT06089369|EXPERIMENTAL|Sintilimab for six months group (9 cycles)|Patients receive Sintilimab at a dose of 200 mg via intravenous injection, with one cycle every three weeks, for a total of 9 cycles or until disease recurrence or intolerable adverse effects occurred.
61916707|NCT06089369|EXPERIMENTAL|Sintilimab for one year group (18 cycles)|Patients receive Sintilimab at a dose of 200 mg via intravenous injection, with one cycle every three weeks, for a total of 18 cycles or until disease recurrence or intolerable adverse effects occurred.
61916708|NCT06089369|ACTIVE_COMPARATOR|Active surveillance|Patients are closely monitored postoperatively.
61916709|NCT00688207|EXPERIMENTAL|Rosiglitazone|An open-label, single, oral dose of 4mg of rosiglitazone in the morning under fasted conditions
61916710|NCT00510380||growth-restricted Chinese pregnancies|
61916711|NCT00510380||appropriately-grown Chinese pregnancies|
62301564|NCT01061489|EXPERIMENTAL|physical fitness|
62301565|NCT01061489|NO_INTERVENTION|waiting list (control group)|
62301566|NCT01179295|EXPERIMENTAL|Arm 1|
62301567|NCT01179295|EXPERIMENTAL|Arm 2|
62301568|NCT01179295|EXPERIMENTAL|Arm 3|
62301569|NCT01179295|EXPERIMENTAL|Arm 4|
62301570|NCT03280329|NO_INTERVENTION|Control|the patients who belong to this group will not be assigned to a regulated music therapy treatment, thus they will listen to the background sounds (alerts, voices) right in the Intensive Care environment; radio use will be allowed according to medical/ nursing judgements
62301571|NCT03280329|ACTIVE_COMPARATOR|Personalised treatment|A music therapy advice will be performed with each patient (if possible from the neurological point of view) or their caregivers to assess their musical preferences and a list of songs will be generated which will be reproduced for 2 hours per day from admission to discharge with the use of earphones.
62470940|NCT00467896|EXPERIMENTAL|Iloprost|The study enrolled patients who were already using iloprost (10 µg/mL) standard dose (5 µg) delivered by I-neb® Adaptive Aerosol Delivery (AAD) System with Power Disc-6 (PD-6) without any safety or tolerability concerns, thereby facilitating a direct comparison with the Power Disc-15 (PD-15). The single arm design allowed each patient to serve as his/her own control.
62301572|NCT03280329|ACTIVE_COMPARATOR|Generalized treatment|"Music will be broadcasted in each patient room after the creation of a 'weekly playlist' with the following considerations:~1. Daily sound reproduction from 7 am to 11 pm, with 10 minutes break about every 50 minutes of music;~2. Spread through the environment with specifically designated speakers, at a controlled volume (30-50 dB);~3. Choice of playlist of music both classic and modern, with very easy listening, selected according to the daily hours to restore circadian rhythm and following predictable activities of care provided to patients (hygienic care, retail food, administration other therapies, physiotherapy, visit by relatives, ...);~4. Mixing tracks so that there is continuity and fluidity of listening"
62301573|NCT01309516|EXPERIMENTAL|Complex Intervention (LTP-TH)|The 12 sessions of complex intervention (LTP-TH) will be delivered to mothers.
62301574|NCT01309516|NO_INTERVENTION|Control group|Control group will receive standard postnatal follow-up.
62301575|NCT00919659|EXPERIMENTAL|parenteral nutrition|25kcal/kg/bw /day via parenteral support
62301576|NCT02113657|EXPERIMENTAL|Ipilimumab|Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.
62673225|NCT05052307||Fully vaccinated with BNT162b2 COVID-19 vaccine|Defined as 2 doses of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
62111666|NCT01133132|EXPERIMENTAL|Intervention|For those subjects randomized to the Survivorship CHESS condition they will receive a smartphone and access to a web based information system that provides access to clinical information about colon cancer treatment, survivorship, exercise planning and tracking functions to allow these subjects to monitor their self defined exercise goals and objectives.
62111667|NCT03244696|EXPERIMENTAL|Step Tracking|Participants will track their physical activity in steps using an accelerometer for a period of 6 months. Participants will monitor their overall step-count using the accelerometer, and daily and weekly summaries of their progress provided by the experimenters.
62111668|NCT03244696|ACTIVE_COMPARATOR|Water Tracking|Participants will track their water-intake using a smart water bottle for a period of 6 months. Participants will monitor their overall water consumption using a smart water bottle, and daily and weekly summaries of their progress provided by the experimenters.
62111669|NCT04683263|ACTIVE_COMPARATOR|Intervention|Fisiocrem®, a topical cream composed of the natural ingredients Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
62111670|NCT04683263|PLACEBO_COMPARATOR|Placebo|topical cream with similar characteristics and aspect, without active ingredients.
62111671|NCT04860258|EXPERIMENTAL|CVnCoV Vaccine|Participants will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29.
62111672|NCT02467296|ACTIVE_COMPARATOR|A: 1.5 gr of Sodium|Meal Plans with 1.5 gr of Sodium
62111673|NCT02467296|ACTIVE_COMPARATOR|B: 3 gr of Sodium|Meal Plans with 3 gr of Sodium
62111674|NCT05358197|EXPERIMENTAL|Control group|
62111675|NCT04760119|ACTIVE_COMPARATOR|Vein bypass surgery first strategy|
62301577|NCT01183494|EXPERIMENTAL|UGT1A1*1/*1|Participants with UGT1A1\*/\*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
62470941|NCT02695797|EXPERIMENTAL|Immunotherapy|Intravenous immunoglobulin (IVIG) and oral prednisolone. IVIG and oral prednisolone are administered simultaneously: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day).
62470942|NCT02695797|NO_INTERVENTION|Control|No immunotherapy.
62673226|NCT05052307||Ever vaccinated with BNT162b2 COVID-19 vaccine|defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
62111676|NCT04760119|ACTIVE_COMPARATOR|Endovascular treatment first (drug coated balloon angioplasty) strategy|
62111677|NCT06476002|OTHER|women with provoked or mixed vestibulodynia|Completion of translated VPAQscreen, VPAQdesc, VPAQcope and VPAQpartner questionnaires by patients, followed by assessment of comprehension of the various items.
62111678|NCT01507948|EXPERIMENTAL|Immediate Prolonged Exposure Treatment|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
62111679|NCT01507948|NO_INTERVENTION|Wait list, immediately followed by Prolonged Exposure|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
62111680|NCT02867046|EXPERIMENTAL|medial approach group|
62673227|NCT05052307||Partially vaccinated with BNT162b2 COVID-19 vaccine|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
62673228|NCT05052307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines other than the BNT162b2 according to the manufacturer recommendations.
62673229|NCT05052307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
62673230|NCT05052307||Fully vaccinated plus booster dose of BNT162b2 COVID-19 vaccine|Defined as fully vaccinated with available COVID-19 vaccines according to the manufacturer recommendations plus booster dose of BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
62673231|NCT03116087|ACTIVE_COMPARATOR|Testosterone patch|Testosterone patches
62111681|NCT02867046|ACTIVE_COMPARATOR|lateral approach group|
62111682|NCT00243399|EXPERIMENTAL|Oxandrolone|
62111683|NCT01714557|NO_INTERVENTION|No prophylaxis|
62111684|NCT01714557|ACTIVE_COMPARATOR|piperacillin|
62111685|NCT01714557|EXPERIMENTAL|piperacillin/tazobactam|
62673232|NCT03116087|PLACEBO_COMPARATOR|Placebo|Placebo patches
61916712|NCT04649372|OTHER|EndoVE endosCopic Treatment for Oesophageal and Gastric canceR|The patient will be placed under General Anaesthetic or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged. There will be a telephone follow up after 2 days, 7 days, 4 weeks and 8 weeks. The patient will be requested to attend the clinic for a 12-week follow up for clinical review.
62111686|NCT02721225|ACTIVE_COMPARATOR|Fructooligosaccharide|"One kind of prebiotics agent defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
62111687|NCT02721225|PLACEBO_COMPARATOR|Pocari-Sweat|Commercially produced isotonic solution by Otsuka Pharmaceutical Co., Ltd., Tokyo,Japan
62111688|NCT03643042|EXPERIMENTAL|Restrictive group|Transfusion with: Hb \< 80g/L and Hb maintain between 80 and 100g/L
62111689|NCT03643042|EXPERIMENTAL|Liberal group|Transfusion with: Hb \< 100g/L and Hb maintain between 100 and 120g/L
62111690|NCT01191463|EXPERIMENTAL|Mung Bean Meals and Guava fruit|Subject in this group will receive, a lunch meal based on 50g of Mung beans together with a local, Vitamin C rich fruit (Guava)
62111691|NCT01191463|ACTIVE_COMPARATOR|Mung Bean|Subjects in this group will receive a lunch meal based on 50g mung beans but without any vitamin C source.
62111692|NCT01191463|NO_INTERVENTION|School feeding program|Subjects in this arm, will receive the regular school feeding program as provided by the school authorities
62111693|NCT05802602|EXPERIMENTAL|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
62111694|NCT05802602|ACTIVE_COMPARATOR|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
62111695|NCT02619266|EXPERIMENTAL|Acupuncture+Placebo|Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.
62111696|NCT02619266|ACTIVE_COMPARATOR|Megestrol Acetate+Sham acupuncture|Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
62111697|NCT02619266|PLACEBO_COMPARATOR|Placebo+Sham acupuncture|Placebo tablet by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
62111698|NCT05880732|EXPERIMENTAL|Group I|The study group (Group I) was given 50 mg/kg MgSO4 in 250 ml of isotonic 30 minutes before induction,
62111699|NCT05880732|PLACEBO_COMPARATOR|Group II|the control group (Group II) was given only 250 ml of normal saline isotonic solution 30 minutes before induction,
62111700|NCT03807557|EXPERIMENTAL|Robotic mCIMT group|1 hour unilateral robotic therapy, followed by 30 minutes of functional practice of affected UE using shaping technique, 3/week for 8 weeks and restraint of the unaffected limb at home for 2 hrs per day
62301578|NCT01183494|EXPERIMENTAL|UGT1A1*1/*28|Participants with UGT1A1\*1/\*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
61916713|NCT04576338||College Students|The cohort consists of Black and White college students at a university in a southeastern state in America.
61916714|NCT04433143|EXPERIMENTAL|oral medication|just oral minocycline hydrochloride capsules (100mg/ time, once per day),
61916715|NCT04433143|EXPERIMENTAL|Intense Pulsed Light single filter|Intense pulsed Acne filter
61916716|NCT04433143|EXPERIMENTAL|Intense Pulsed Light two filters|Intense pulsed light Acne filter and another filter (560nm, 590nm or 640nm filter)
62111701|NCT03807557|ACTIVE_COMPARATOR|Control group|conventional upper extremity rehabilitation training 1.5 hours per session, 3/week for 8 weeks and home exercise 2 hrs per day
62111702|NCT05307666|EXPERIMENTAL|Medication minimization|"Patients have a dedicated medication minimization visit with their usual primary care provider to which they bring all of their medications (a so-called brown bag medication review)."
62111703|NCT05307666|NO_INTERVENTION|Usual Care|Patients will continue to receive care as appropriate but no dedicated visit to review and minimize medications will be organized as a result of the study. Medications are free to be minimized during the normal course of care should the need arise.
62111704|NCT02486588|NO_INTERVENTION|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
62111705|NCT02486588|EXPERIMENTAL|General Weekly Message|10% cash back, general weekly message, standard monthly message
62111706|NCT02486588|EXPERIMENTAL|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
62111707|NCT02486588|EXPERIMENTAL|25 percent cash back|25% cash back, personal weekly message, standard monthly message
62111708|NCT02486588|EXPERIMENTAL|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
62111709|NCT02486588|EXPERIMENTAL|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
62111710|NCT04666818||Self Monitoring Blood Glucose (SMBG)|Women used self-monitoring of blood glucose= Control group (CG)
62111711|NCT04666818||Flash Glucose Monitoring (FGM)|Women used flash glucose monitoring= FGM group (FG)
62111712|NCT00560014|EXPERIMENTAL|1|Arginine and Canola oil supplemented group
62111713|NCT00560014|EXPERIMENTAL|2|Arginine and Coromega
62111714|NCT00560014|NO_INTERVENTION|3|Control
62111715|NCT04555265|OTHER|Thermal ablation group|Patients with hepatocellular carcinoma treated by thermal ablation
62301579|NCT01814423|EXPERIMENTAL|Chloroquine-base 50 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.
62673233|NCT05645185||Patient with Ma2 antibody|"This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids)."
62673234|NCT00195052||Epilepsy Patients|
62301580|NCT01814423|ACTIVE_COMPARATOR|Chloroquine-base 70 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.
62301581|NCT05290220|EXPERIMENTAL|Arm A: As first-line therapy|HLX07 1500 mg + HLX10 300 mg + HLX04 15mg/kg iv q3w
62301582|NCT05290220|EXPERIMENTAL|Arm B: As second-line therapy|HLX07 1500 mg iv Q3w + Lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW \<60 kg) po qd
62301583|NCT05290220|EXPERIMENTAL|Arm C:As third-line or above therapy|HLX07 1500 mg iv Q3w
62301584|NCT03389672||spinal anesthesia|The anesthesia technique were applied with modified approach and conventional approach
62301585|NCT03389672||epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
62673235|NCT04938674||Standard process for blood collection using Ultrasonic Guided puncture|
62301586|NCT03389672||combined spinal-epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
62301587|NCT06197126||cervical cancer patients with radiotherapy|Radiotherapy is the main treatment strategy with an overall dose of over 75Gy.
62301588|NCT02464631|ACTIVE_COMPARATOR|Sofosbuvir + Ribavirin 1|Sofosbuvir + Ribavirin x 24 weeks
61916717|NCT03332511|EXPERIMENTAL|Investigational arm|Oral nilotinib 300mg twice daily with a 12-hour interval
62301589|NCT02464631|EXPERIMENTAL|Sofosbuvir + Ribavirin 2|Sofosbuvir + Ribavirin x 36 weeks
62301590|NCT02464631|EXPERIMENTAL|Sofosbuvir + Ribavirin 3|Sofosbuvir + Ribavirin x 48 weeks
62301591|NCT03237676|EXPERIMENTAL|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
62301592|NCT03237676|ACTIVE_COMPARATOR|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
62673236|NCT05004298|EXPERIMENTAL|Animal assisted terapy|The Experimental Group, in addition to receiving the usual activities of the rehabilitation device. You will receive the ten weekly sessions of the TAA Program.The program structure will aim to influence the 6 specific factors, described in the Multifactorial Model of Positive Mental Health of Dr. Lluch, which are: F1-Personal Satisfaction, F2-Prosocial Attitude, F3-Self-control, F4-Autonomy, F5- Problem Solving and Self-actualization and F6 Interpersonal Relationship Skills. For this reason, direct contact exercises with the dog will be designed and defined to work on them.
62301593|NCT06655883|EXPERIMENTAL|Suvorexant|Participants receive 10 mg of suvorexant for the first three nights, increased to 20 mg of suvorexant nightly thereafter at the investigator's discretion, for up to approximately 8 weeks.
62301594|NCT06655883|PLACEBO_COMPARATOR|Placebo|Participants receive suvorexant-matching placebo for up to approximately 8 weeks.
62470943|NCT02365454|EXPERIMENTAL|Thoracic Aortic Disease Single Arm Study|Thoracic Aortic Disease treated by Stent Graft Placement
62111716|NCT06080373|EXPERIMENTAL|Formulated-based cognitive behavioral therapy|Participants randomized to the CBT group will receive a minimum of 13 and a maximum of 22 sessions of individual formulation-based CBT. It will be delivered by psychologists trained in CBT, according to a manual that will be available soon. Prior to intervention, a behavioral assessment is conducted to operationalize each case's clinically relevant behaviors, antecedents, and maintenance stimuli. Each case will be formulated and presented to the participant in simple and easy to understand language. To illustrate this, a schematic formulation of the typical case of an adult with ADHD is shown in Figure 2. Specific behavioral goals will then be agreed upon for each participant. To achieve these goals, various treatment strategies will be presented in the following sessions. The choice of strategies, the order in which they are applied, and the duration of each module will be customized for each participant according to the case formulation.
62111717|NCT06080373|ACTIVE_COMPARATOR|PROBECO and social therapeutic establishments|"The Spanish participants assigned to the active control group will receive the PROBECO. It is a group program designed by the Spanish Penitentiary Agency for its application with inmates convicted of different types of violent crimes . Its main goals are to eradicate criminal behavior and reduce recidivism, to modify the relevant dynamic risk factors related to general delinquency, and to introduce new social skills and prosocial values. It consists of four phases: (I) general intervention: aimed at the acquisition of social skills; (II) specific intervention: consists of four specific educational itineraries; (III) relapse prevention; (IV) follow-up.~Similarly, German participants will be assigned to a special type of prison known as a social therapeutic facility, where they will undergo compulsory psychotherapy focused primarily on relapse prevention."
62111718|NCT06080373|NO_INTERVENTION|Waitlist|Participants in waitlist control group will receive no treatment while experimental groups are treated. They will be offered to receive CBT after the study.
62111719|NCT01985906|EXPERIMENTAL|Pararenal aortic aneurysm|"The aneurysm is adjacent to (proximal/distal landing zone \< 15mm) or involving vital branches, including the celiac artery, superior mesenteric artery, or renal artery.~The intervention is endovascular management of the aneurysms with multiple overlapping uncovered stents"
62470944|NCT04042285|ACTIVE_COMPARATOR|Extracorporeal shockwave therapy|The shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second (17). Participants will receive 3 sessions of shockwave therapy in a 7-day period. In addition to standard wound care (dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate).
62301595|NCT04030130|EXPERIMENTAL|NDURE|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system-(care coordination), interpersonal-(social support), and individual- (health belief model \[HBM\]; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, enhance HNSCC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE navigation sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit, time points chosen to facilitate case identification and coordination across key care transitions.
62673237|NCT05004298|NO_INTERVENTION|Control Group|The Control Group will receive the usual activities of the rehabilitation device.
61916718|NCT00258843|EXPERIMENTAL|Group 1|Children at 18 months of age
62111720|NCT04472871||patients with atrial fibrillation and heart failure|Patients with cardiac function ejection fraction less than 35% and underwent Left atrial appendage closure in the period covered by the study
62111721|NCT04472871||patients with atrial fibrillation without heart failure|Patients with cardiac function ejection fraction more than 35% and underwent Left atrial appendage closure in the period covered by the study
62111722|NCT05452980|ACTIVE_COMPARATOR|sleeve gastrectomy|For standard sleeve gastrectomy (SG), a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
62111723|NCT05452980|EXPERIMENTAL|SG with reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak. Three stitches using nonabsorbable 2-0 Prolone were performed to reestablish the acute angle of His: anterior gastric fundus with esophagus, gastric fundus with left crural diaphragm, posterior gastric fundus with left crural diaphragm.
62111724|NCT03775369|ACTIVE_COMPARATOR|Endurance training|"Endurance Training (warm-up; endurance on bike; brisk walking; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
62111725|NCT03775369|ACTIVE_COMPARATOR|Resistance training|"Resistance Training (warm-up; resistance training units; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
62301596|NCT04030130|NO_INTERVENTION|Usual Care|UC consists of discussions about the indications, risks/benefits/alternative, Guidelines, timing, and logistical details of adjuvant therapy. These discussions will be administered according to practice patterns of the involved providers.
62301597|NCT03803215||Theophylline group|Patients who have electrocardiographic documentation of asystolic syncope will be treated with oral theophylline at tailored dosage
62301598|NCT03803215||Control untreated group|A propensity-score matched control group is generated from the large database of patients who had received an implantable loop recorder
62301599|NCT01710761|ACTIVE_COMPARATOR|Nitrate supplement with caffeine|
62301600|NCT01710761|PLACEBO_COMPARATOR|Placebo|
62301601|NCT05698186|EXPERIMENTAL|Part 1: Anti-HER2 targeted therapy containing regimen + Thero2-01S22|Patients will receive Thero2-01S22 at the recommended dose and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
62673238|NCT06059079||Elevated hs-cTnT group|
62673239|NCT02449928|ACTIVE_COMPARATOR|lactate group,|
62301602|NCT05698186|PLACEBO_COMPARATOR|Part 1: Anti-HER2 targeted therapy containing regimen + Placebo|Patients will receive placebo and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
62673240|NCT02449928|ACTIVE_COMPARATOR|control group|
62673241|NCT04607590||Group I (DY)|Patients and their partners attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy.
62673242|NCT04607590||Group II (PY)|Patients attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy. Once data collection is completed, partners will be offered intervention materials, and encouraged to attend yoga classes at the Integrative Medicine Clinic.
62673243|NCT04607590||Group III (WLC)|Patients and their partners receive usual care. Once data collection is completed, couples may participate in the DY or PY program of their choice over 60 minutes each. Partners are also offered intervention materials along with five 60 minute optional yoga sessions.
61916719|NCT00258843|EXPERIMENTAL|Group 2|Infants at 2 months of age
61916720|NCT00672113|EXPERIMENTAL|Arm 1|
61916721|NCT00672113|ACTIVE_COMPARATOR|Arm 2|
62301603|NCT05698186|EXPERIMENTAL|Part 2: Anti-HER2 targeted therapy containing regimen + Thero2-01S22|Patients will receive Thero2-01S22 at the confirmed dose and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
62301604|NCT05698186|PLACEBO_COMPARATOR|Part 2: Anti-HER2 targeted therapy containing regimen + Placebo|Patients will receive placebo and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
62301605|NCT05178901|EXPERIMENTAL|PHV02 2x10^5 pfu|
62301606|NCT05178901|EXPERIMENTAL|PHV02 2x10^6 pfu|
62301607|NCT05178901|EXPERIMENTAL|PHV02 2x10^7 pfu|
62673244|NCT06405425|EXPERIMENTAL|BL-B01D1 + PD-1|Participants receive BL-B01D1 + PD-1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62301608|NCT05178901|PLACEBO_COMPARATOR|Placebo|
62470945|NCT04042285|PLACEBO_COMPARATOR|Standard wound care|Patient with a diabetic foot wound who receive standard wound care, consisting of dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate.
62673245|NCT00051350|PLACEBO_COMPARATOR|CARB|Diet rich in carbohydrate
62301609|NCT05178901|EXPERIMENTAL|PHV02 5x10^8 pfu (Boost)|
62301610|NCT05178901|EXPERIMENTAL|PHV02 5x10^8 pfu (Prime)|
62301611|NCT05931770||Group Child Preference|The children will prefer parents (mother or father) who will accompany them in the preoperative holding area and at induction
62301612|NCT05931770||Group Parent's Preference|Parents will decide among themselves and prefer the parents (mother or father) who will accompany them from the side of the parent, in the pre-operative waiting area and during induction.
62673246|NCT00051350|ACTIVE_COMPARATOR|UNSAT|Diet rich in unsaturated fat
62673247|NCT00051350|ACTIVE_COMPARATOR|PROTEIN|Diet rich in protein
62673248|NCT05456841|EXPERIMENTAL|Oncology Care Providers/OCP-intervention group|Providers participate in Empathic Communication Skills (ECS) training
62301613|NCT03333577|EXPERIMENTAL|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
62301614|NCT05076422|EXPERIMENTAL|BI 3006337 treatment group|BI 3006337
62301615|NCT05076422|PLACEBO_COMPARATOR|Placebo group|Placebo
62301616|NCT06488118|ACTIVE_COMPARATOR|R848 0.1 μg/mL|Inhaled Resiquimod (R848) 0.1 μg/mL
62301617|NCT06488118|ACTIVE_COMPARATOR|R848 1.0 μg/mL|Inhaled Resiquimod (R848) 1.0 μg/mL
62301618|NCT06488118|ACTIVE_COMPARATOR|R848 10 μg/mL|Inhaled Resiquimod (R848) 10 μg/mL
62301619|NCT06488118|ACTIVE_COMPARATOR|R848 100 μg/mL|Inhaled Resiquimod (R848) 100 μg/mL
62301620|NCT06488118|PLACEBO_COMPARATOR|Saline|Inhaled Saline
62301621|NCT06488118|ACTIVE_COMPARATOR|Asthma volunteers inhaled R848|Highest tolerated dose inhaled R848 in healthy volunteers to be given to volunteers with asthma
62301622|NCT06488118|PLACEBO_COMPARATOR|Asthma volunteers inhaled saline|Inhaled saline to be given to volunteers with asthma
62301623|NCT06488118|NO_INTERVENTION|Sample only|Sample only collection from volunteers for protocol optimisation
62301624|NCT04815096|EXPERIMENTAL|[18F]F-AraG|"Radiofluorinated imaging agent, \[18F\]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
62301625|NCT00783640|EXPERIMENTAL|1|Lactic Acid
62301626|NCT00497224|EXPERIMENTAL|Erlotinib|Eligible patients will receive erlotinib 150mg PO daily, with dose escalation occurring as tolerated.
62301627|NCT05809687|ACTIVE_COMPARATOR|Control group|DKP21102_A, DKP21102_C
62301628|NCT05809687|EXPERIMENTAL|Treatment group|DKP21102_A, DKP21102_B
62301629|NCT05352191|ACTIVE_COMPARATOR|Beclomethasone|800 ug inhaled once aday for 8 days
62301630|NCT05352191|PLACEBO_COMPARATOR|Placebo|one pill once aday for 8 days
62301631|NCT00374556|EXPERIMENTAL|Eszopiclone|Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks
62301632|NCT00374556|PLACEBO_COMPARATOR|Placebo|3mg placebo capsule, once daily at bedtime for 12 weeks
62301633|NCT02509962|EXPERIMENTAL|Slow sodium tablets|Increased dietary salt intake
62470946|NCT03137108|EXPERIMENTAL|Incomplete Spinal cord injury|
62470947|NCT02444715|ACTIVE_COMPARATOR|Standard care (SC)|
62470948|NCT02444715|EXPERIMENTAL|Interventional care (IC)|
62470949|NCT02356302|EXPERIMENTAL|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|The vicriviroc (MK-4176) IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
62470950|NCT02356302|EXPERIMENTAL|MK-2048 IVR|The MK-2048 IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
62673249|NCT05456841|ACTIVE_COMPARATOR|Oncology Care Providers/OCP-control group|Providers complete all study measures and are offered ECS training after data collection is completed at their site.
62673250|NCT05456841|EXPERIMENTAL|Participants with Lung Cancer-intervention group|Participants will engage with oncology care providers/OCP who have undergone Empathic Communication Skills (ECS) training
62470951|NCT02356302|EXPERIMENTAL|MK-2048A IVR|The MK-2048A IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
62111726|NCT03775369|ACTIVE_COMPARATOR|Control condition|"Control condition (individualized counselling, but not intended as a bona fide intervention, that is to say: not intended to actively improve participants' well-being):~6 weeks, social support and counseling,1-2 sessions/week; 30 min/session"
62111727|NCT02727764|EXPERIMENTAL|Cohort I|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e12 vg/ MCP joint, 0.6x10e12 vg/ PIP joint or 0.3x10e12 vg/ DIP joint single intra-articular injection
62111728|NCT02727764|EXPERIMENTAL|Cohort II|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint single intra-articular injection
62111729|NCT02727764|EXPERIMENTAL|Cohort III|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint ART-I02 or maximum Tolerated Dose (MTD) as assessed in cohorts I and II: single intra-articular injection
62111730|NCT05907850|ACTIVE_COMPARATOR|Riboflavin Group|Riboflavin 100mg will be self administered by participants, one capsules prior to the long stage of the race followed by a second dose at the completion of the long stage.
62111731|NCT05907850|PLACEBO_COMPARATOR|Placebo/Control Group|Placebo will be self administered by participants, one capsule prior to the long stage of the race followed by a second dose at the completion of the long stage.
62111732|NCT05989412|NO_INTERVENTION|Control arm|a control arm where the investigators will only measure the quality of life using the EQ-5D questionnaire. This measurement will be performed at the same time as both screening arms.
62111733|NCT05989412|EXPERIMENTAL|Standard referral|a screening arm with standard participant referral for diagnosis at the general practitioner's office (after 1 positive test score on the PHQ-9 questionnaire or suicidal ideation).
62111734|NCT05989412|EXPERIMENTAL|Limited referral|a screening arm with limited participant referral for diagnosis at the general practitioner's office (after three consecutive positive test scores on the PHQ-9 questionnaire or suicidal ideation).
62111735|NCT03503630|EXPERIMENTAL|Locally advanced rectal cancer patients|"1. Week 1: D1-5: radiotherapy 25 Gy in 5 fractions~2. mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)~3. Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision"
62111736|NCT02885311|OTHER|At-Risk Drinkers (AR)|AR will receive feedback about their drinking and brief advice along with follow up assessments.
62111737|NCT02885311|OTHER|Problem Drinkers (PD)|PD will be offered a choice of either an evidence-based behavioral intervention(Motivational Enhancement Therapy) or medication (Naltrexone) plus medication management. These participants will also receive follow up assessments.
62301634|NCT03898934|EXPERIMENTAL|Vitamin D group|These patients will receive 6000IU daily for 8 weeks then 2000IU maintenance till pregnancy or end of study
62301635|NCT03898934|PLACEBO_COMPARATOR|Placebo group|These group will receive placebo for the same periods of study group
62301636|NCT06346795|EXPERIMENTAL|G-aenial Universal Injectable|
62301637|NCT06346795|EXPERIMENTAL|Grandio Flow|
62301638|NCT06346795|EXPERIMENTAL|Clearfil Majesty Flow|
62301639|NCT02646475|EXPERIMENTAL|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
62301640|NCT02646475|PLACEBO_COMPARATOR|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
62301641|NCT01907685|EXPERIMENTAL|AVE8062 / Docetaxel|AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria
62301642|NCT06533592|EXPERIMENTAL|Continuous suture technique|Biliary duct-to-duct anastomosis performed with continous suture technique
62301643|NCT06533592|ACTIVE_COMPARATOR|Interrupted suture|Biliary duct-to-duct anastomosis performed with interrupted suture technique - control group
62301644|NCT03243903|EXPERIMENTAL|needle-free insulin injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
62301645|NCT03243903|ACTIVE_COMPARATOR|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
62301646|NCT01153490|PLACEBO_COMPARATOR|Placebo|
62301647|NCT01153490|ACTIVE_COMPARATOR|Quetiapine ER|
62301648|NCT01978561|EXPERIMENTAL|Follow-Up after dosing with NT100 Dose 1|Follow-Up after dosing with NT100 Dose 1
62301649|NCT01978561|EXPERIMENTAL|Follow-Up after dosing with NT100 Dose 2|Follow-Up after dosing with NT100 Dose 2
62301650|NCT01978561|PLACEBO_COMPARATOR|Follow-Up after dosing with Placebo|Follow-Up after dosing with Placebo
62301651|NCT01089855|EXPERIMENTAL|Carbamazepine|
62301652|NCT00608088|ACTIVE_COMPARATOR|1|Usual Care
62301653|NCT00608088|ACTIVE_COMPARATOR|2|Health Nurse/Peer Councelor Intervention
62301654|NCT03734510|ACTIVE_COMPARATOR|hesperidin and flaxseed|
62470952|NCT02356302|PLACEBO_COMPARATOR|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
62470953|NCT06372353|EXPERIMENTAL|intervention Group|The subjects in the intervention group were given 24 sessions of supervised online Baduanjin exercise training
62470954|NCT06372353|NO_INTERVENTION|Control Group|
62470955|NCT01639092|EXPERIMENTAL|Tenofovir monotherapy|Tenofovir 300 mg/day orally
62470956|NCT01639092|ACTIVE_COMPARATOR|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
62673251|NCT05456841|ACTIVE_COMPARATOR|Participants with Lung Cancer-control group|Waitlist control group - WLC
62673252|NCT03008330|EXPERIMENTAL|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62673253|NCT03008330|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62673254|NCT02082093|NO_INTERVENTION|Traditional Care|
62673255|NCT02082093|EXPERIMENTAL|eNephro Application|"Telemedicine system which is a collaborative and expert system, consisting of:~A dynamic shared medical record for the collection of administrative , medical, biological and clinical data for each patient. All health professionals can access the folder and fill in the support. It is the same for patients treated at home.~A secure messaging for communication between health professionals and between patients and health professionals Expert systems analyzing data from each patient A management tool of therapeutic education~These patients have a chronic renal failure moderate to end up being treated by ambulatory dialysis or kidney transplantation. The patients of each population will be randomly assigned in group 1 ie traditional care or in group 2 ie traditional care added by telemedicine system"
62673256|NCT03646188|PLACEBO_COMPARATOR|Placebo-containing MNA|Placebo
62673257|NCT03646188|EXPERIMENTAL|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
62673258|NCT03646188|EXPERIMENTAL|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
62673259|NCT03646188|EXPERIMENTAL|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
62673260|NCT03646188|EXPERIMENTAL|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
62673261|NCT02525432|EXPERIMENTAL|Autologous BMMNC Infusion|Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10\^6 cells/kg body weight) and progressing to the high dose of 9 x 10\^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
62673262|NCT02525432|PLACEBO_COMPARATOR|Placebo Infusion|"Subjects randomized to the placebo control group will undergo a sham bone marrow harvest."
62111738|NCT02885311|OTHER|AD with physiological withdrawal (AD-W)|AD-W will referred to outpatient detoxification as part of standard care, unless medically contraindicated, and will be offered medication (naltrexone) plus medication management as or an evidence-based behavioral intervention (Modified Behavioral Self-Control Therapy \[MBSCT\]) adapted from our two prior protocols. These participants will also receive follow up assessments.
62111739|NCT02885311|OTHER|AD with complex presentation (AD-CMPLX)|AD-CMPLX will receive a referral to specialty substance use disorder treatment and also receive follow up assessments.
62111740|NCT03080038|NO_INTERVENTION|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
62111741|NCT03080038|EXPERIMENTAL|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
62111742|NCT04544761||1-5 Years post|Persons with Spinal Cord Injury occurring between 1-5 years prior
62673263|NCT00567801|ACTIVE_COMPARATOR|1|conventional embolectomy/thrombectomy
62673264|NCT00567801|EXPERIMENTAL|2|embolectomy/thrombectomy with controlled reperfusion
62673265|NCT04967703|EXPERIMENTAL|Ultrasound therapy protocol|Patients in group A received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes).
62673266|NCT04967703|EXPERIMENTAL|Radial shock wave therapy protocol|Patients in group B received radial shock wave therapy protocol with the following parameters: (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz.
62673267|NCT04967703|EXPERIMENTAL|Combined therapy protocol|Patients in group C received a combination of both ultrasound therapy and radial shock wave therapy protocol.
62673268|NCT01084863|EXPERIMENTAL|CT-P6 & Paclitaxel|"CT-P6 was administered at a loading dose of 8 mg/kg body weight by IV infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death, or discontinuation.~Paclitaxel was administered at a dose of 175 mg/m2 BSA as a continuous 3-hour IV infusion on the day following the first dose of study drug (CT-P6). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death, intolerable toxicity, or discontinuation."
62111743|NCT04544761||5-15 Years post|Persons with Spinal Cord Injury occurring between 5-15 years prior
62301655|NCT03734510|PLACEBO_COMPARATOR|control|
62301656|NCT03734510|ACTIVE_COMPARATOR|flaxseed|
62470957|NCT02372266|EXPERIMENTAL|Early Discharge Group|If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.
62470958|NCT02372266|ACTIVE_COMPARATOR|Routine Stay Group|Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.
62470959|NCT02301975|EXPERIMENTAL|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
62470960|NCT02301975|EXPERIMENTAL|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
62470961|NCT02301975|EXPERIMENTAL|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
62470962|NCT04405570|EXPERIMENTAL|Molnupiravir 200 mg|Molnupiravir 200 mg, twice daily (BID) for 5 days
62470963|NCT04405570|EXPERIMENTAL|Molnupiravir 400 mg|Molnupiravir 400 mg, twice daily (BID) for 5 days
62470964|NCT04405570|EXPERIMENTAL|Molnupiravir 800 mg|Molnupiravir 800 mg, twice daily (BID) for 5 days
62111744|NCT04544761||>15 Years post|Persons with Spinal Cord Injury occurring at least 15 years prior
62111745|NCT01935869|EXPERIMENTAL|LEO 90100|
62111746|NCT01935869|PLACEBO_COMPARATOR|Vehicle|
62111747|NCT01935869|OTHER|Petrolatum ointment|
62111748|NCT04983745|EXPERIMENTAL|Experimental|niraparib and dostarlimab
62111749|NCT03324152|EXPERIMENTAL|High-intensity interval training (HIIT) - myositis|12-week, 3d/w, HIIT
62111750|NCT03324152|ACTIVE_COMPARATOR|Standard low-intensity home exercise control (CG)|12-week, 5 d/w, home exercise.
62301657|NCT03734510|ACTIVE_COMPARATOR|hesperidin|
62301658|NCT04100525|ACTIVE_COMPARATOR|Standard Care|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant received a copy of this report in the mail and a call from the psychologist to go over test findings and recommendations.
62470965|NCT04405570|PLACEBO_COMPARATOR|Placebo (PBO) twice daily (BID) for 5 days|
62470966|NCT02959580|EXPERIMENTAL|medical|Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.
62470967|NCT02959580|ACTIVE_COMPARATOR|surgical|lesion extended excision
62736084|NCT03440463|EXPERIMENTAL|Intervention plus Norms-plus-Strategies booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use. It also includes reported harm reduction strategies, and other strategies they might consider.
62111751|NCT03324152|ACTIVE_COMPARATOR|High-intensity interval training (HIIT) - healthy|12-week, 3d/w, HIIT.
62111752|NCT05982613||General|This research is an observational study. There was no control and experimental group.
62111753|NCT00356317|EXPERIMENTAL|1|Participants will receive a 15-week family therapy
62111754|NCT00356317|ACTIVE_COMPARATOR|2|Participants will receive a 3-week family therapy (treatment as usual)
62111755|NCT03804632||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from October to December 2017 with age 18 and above
62111756|NCT02299336|OTHER|PRN (pro re nata)|2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks
62111757|NCT04589780||Posture Assessment|Posture will be assessed with New York Posture Rating Chart (NYPR) originally published in 1958
62301659|NCT04100525|EXPERIMENTAL|Experimental Treatment|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant then receives in-person feedback (and a copy of the report at this visit) and two calls from a care-coordinator research nurse at approximately 1 and 6 months post feedback, who asks participant whether they completed recommendations and assist participant in completing recommendations where possible (i.e., help find a provider, explanation of importance of completing recommendations, etc).
62301660|NCT03216616|EXPERIMENTAL|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
62301661|NCT05695547|NO_INTERVENTION|Standard education|Patients will be educated about the procedure in a standard way by a doctor and a nurse
62301662|NCT05695547|EXPERIMENTAL|VR Education|Patients will be educated with the use of virtual reality
62470968|NCT03892408|EXPERIMENTAL|Optiflow|100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
62470969|NCT03892408|NO_INTERVENTION|Standard|standard anesthesia
62470970|NCT02447874|EXPERIMENTAL|Standard dose|Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
62470971|NCT02447874|EXPERIMENTAL|Loading dose + standard dose|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
62470972|NCT02447874|EXPERIMENTAL|Loading dose + continuous infusion|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first
62111758|NCT04589780||Sagittal spinal alignment and mobility|Sagittal spinal alignment and mobility will be measured using the Spinal Mouse (IdiagAG Mülistrasse 18 CH-8320 Fehraltorf, Switzerland), a computer-aided, non-invasive device.
62111759|NCT04589780||Injury risk assessment|Injury risk will be evaluated with Functional Movement Screen (FMS) test battery. A previous systematic review has demonstrated acceptable reliability for the FMS
62111760|NCT02498769|EXPERIMENTAL|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
62111761|NCT02498769|PLACEBO_COMPARATOR|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
62301663|NCT02675777|EXPERIMENTAL|Quality Improvement Intervention|"Quality improvement intervention: 4 months during which a practice facilitator supports the clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs (see Intervention) as part of behavioral health integration."
62301664|NCT02675777|NO_INTERVENTION|Usual Care|Care received after 2/2016 but before active implementation begins, which includes passive access to tools in the EHR and 2 months of preparation in each clinic (team building and local pretesting by a local implementation team supported by the external practice facilitator).
62301665|NCT06407856|EXPERIMENTAL|conventional therapy|This group will only receive conventional physical therapy.
62301666|NCT06407856|EXPERIMENTAL|Dual Task Training with Conventional Therapy|This group will only receive Dual Task Training along conventional therapy
62111762|NCT02301221|EXPERIMENTAL|Fecal microbiota transplantation (FMT)|Patients included will receive standard FMT, and then will be followed up for 24 weeks.
62111763|NCT05156450|EXPERIMENTAL|Dose Extension|"At the recommended phase II dose of TQB3616 combined with abiraterone acetate (1000 mg, q.d.) plus prednisone (5 mg, b.i.d.), 20-40 patients are planned to be enrolled to evaluate the efficacy and safety of the combination therapy.~Metastatic and genomic tests based on tissue biopsy samples (primary or metastatic) and blood samples will be performed before treatment and after disease progression."
62111764|NCT03398811||"Group I the depot medroxy-progesterone acetate group"|where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,
62111765|NCT03398811||"Group II Implanon group"|where they will have Implanon (etonogestrel implant) 68 mg implant
62111766|NCT03398811||group III (cerazette group)|where they are using Cerazette pills (desogestrel 75 µg l) one pill every day for 28 days without pill-free interval.
62111767|NCT01311180|EXPERIMENTAL|Sensoril®|
62301667|NCT05749588|EXPERIMENTAL|IM/HER2-low|If patients were triple-negative breast cancer with IM subtype and HER2-low-positive
62301668|NCT05749588|EXPERIMENTAL|IM/HER2-0|If patients were triple-negative breast cancer with IM subtype and HER2-zero
62301669|NCT05749588|EXPERIMENTAL|BLIS / HER2-low|If patients were triple-negative breast cancer with BLIS subtype and HER2-low-positive
62111768|NCT01311180|PLACEBO_COMPARATOR|Placebo|
62111769|NCT01549496|EXPERIMENTAL|boceprevir|boceprevir 800 mg tid
62111770|NCT00355914|ACTIVE_COMPARATOR|Group 1 Without Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
62111771|NCT00355914|EXPERIMENTAL|Group 2 With Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
62111772|NCT06424977|EXPERIMENTAL|Treatment|
62111773|NCT01638884|EXPERIMENTAL|Young Healthy Subjects|
62111774|NCT01638884|EXPERIMENTAL|Middle age Healthy Subjects|
62111775|NCT01638884|EXPERIMENTAL|Elderly Healthy Subjects|
62111776|NCT01638884|EXPERIMENTAL|Mild Cognitive Impairment patients|
62111777|NCT01638884|EXPERIMENTAL|Alzheimer Disease patients|
62301670|NCT05749588|EXPERIMENTAL|BLIS /HER2-0|If patients were triple-negative breast cancer with BLIS subtype and HER2-zero
62301671|NCT05749588|EXPERIMENTAL|LAR / HER2-low|If patients were triple-negative breast cancer with LAR subtype and HER2-low-positive
62301672|NCT05749588|EXPERIMENTAL|LAR /HER2-0|If patients were triple-negative breast cancer with LAR subtype and HER2-zero
62301673|NCT05749588|EXPERIMENTAL|MES/ HER2-low|If patients were triple-negative breast cancer with MES subtype and HER2-low-positive
62301674|NCT05749588|EXPERIMENTAL|MES /HER2-0|If patients were triple-negative breast cancer with MES subtype and HER2-zero
62301675|NCT02500550|EXPERIMENTAL|ATIR101|
62301676|NCT03981029||FACT High-dose folic acid treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily high-dose folic acid supplementation during pregnancy.
62301677|NCT03981029||FACT Placebo treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily placebo supplementation during pregnancy.
62470973|NCT02447874|EXPERIMENTAL|Non-Randomized Loading dose 500 mg/kg + standard dose|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 500 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
62470974|NCT02447874|EXPERIMENTAL|Non-Randomized Loading dose 300 mg/kg + standard dose|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 300 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
62673269|NCT01084863|ACTIVE_COMPARATOR|Herceptin & Paclitaxel|"Herceptin was administered at a loading dose of 8 mg/kg body weight by IV infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death, or discontinuation.~Paclitaxel was administered at a dose of 175 mg/m2 BSA as a continuous 3-hour IV infusion on the day following the first dose of study drug (Herceptin). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death, intolerable toxicity, or discontinuation."
62673270|NCT04291833|ACTIVE_COMPARATOR|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
62673271|NCT04291833|ACTIVE_COMPARATOR|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
62673272|NCT04291833|PLACEBO_COMPARATOR|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
62673273|NCT05456893||UC patients|All patients with an established ulcerative colitis
62301678|NCT06082336|EXPERIMENTAL|Single arm|This study is single arm.
62301679|NCT01103739|EXPERIMENTAL|cohort 1|
62301680|NCT01103739|EXPERIMENTAL|cohort 2|
62301681|NCT05011461|EXPERIMENTAL|Almond Oil|Almond Oil Pressed Cold
62301682|NCT05011461|ACTIVE_COMPARATOR|Topical Retinol|Retinol Lotion 0.5%
62301683|NCT03968965|EXPERIMENTAL|3D MvIGS|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 3D MvIGS intraoperative navigation guidance.
62301684|NCT03968965|OTHER|2D Fluoroscopy|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 2D fluoroscopy.
62301685|NCT01605474|ACTIVE_COMPARATOR|Outpatient Cervical Ripening|Patients who are randomized to this arm will be allowed discharged home for 12 hours after fetal status is assessed and noted to be reassuring with the foley bulb in place. They will return sooner if they experience rupture of membranes or enter active labor or if the foley bulb falls out.
62301686|NCT01605474|NO_INTERVENTION|Inpatient Cervical Ripening|In this arm, the fetus will be assessed and a foley bulb placed but these patients will be kept in the hospital.
62470975|NCT02447874|EXPERIMENTAL|Non-Randomized Loading dose 400mg/kg + standard dose|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 400 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
62470976|NCT01517321|EXPERIMENTAL|E|
62470977|NCT01517321|PLACEBO_COMPARATOR|P|
62111778|NCT04866823|EXPERIMENTAL|Medically Tailored Meals|A series of medically tailored meals appropriate for women with gestational diabetes will be developed in partnership with chefs from a local community kitchen and catering company. Meals will create a slight caloric deficit in order to promote gradual weight loss, but with sufficient energy intake and macronutrient balance to allow breastfeeding. These meals will be roughly 40% carbohydrate, 30% protein, and 30% fat in composition. Study Team will plan up to 20 unique lunch and dinner meals for the series. Each meal will be prepared to be between 450-600 kcal and to contain 6 ounces of protein, 4 ounces of vegetable and I cup of whole grain (at a minimum). Participants will receive detailed recipe cards and nutrition information with each meal. In addition to receiving the medically tailored meals, participants will be advised to supplement their own breakfast +/- snacks to reach a total daily calorie goal determined by starting BMI category.
62111779|NCT04866823|NO_INTERVENTION|Usual Care Comparison Group|Participants in this group will receive written materials on self-care, nutrition, and physical activity in the postpartum period and community resources for healthy living.
62111780|NCT01315899|EXPERIMENTAL|ORM-12471 30mg|
62301687|NCT03836144||Cystinuria|10 patients with cystinuria. Experimental. Urine collected before treatment initiation and 3 months after. Treatment: Usual alkalizing treatment using oral potassium citrate. The initial dosage will be 4 g/day divided into 3 to 4 oral daily doses. If the objective of urinary pH is not reached after the first two weeks of treatment, the dose will be increased by 2 grams (6 grams total). If the urinary pH remains below 7.5 after 2 weeks with 6 grams of potassium citrate per day, the alkalizing treatment will then be supplemented with oral sodium bicarbonate in the form of Vichy water or officinal preparation. This treatment is the usual treatment recommended for cystinuria .
62470978|NCT02371486|EXPERIMENTAL|Nich Repair|"Interventions to be administered:~1. Ultrasound Scan~2. Diagnostic Hysteroscopy~3. hysteroscopic repair of cesarean section defect~4. IVF cycle"
62470979|NCT02371486|SHAM_COMPARATOR|No Repair|"Interventions to be administered:~1. Ultrasound Scan~2. Diagnostic Hysteroscopy~3. IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED"
62470980|NCT04461379|EXPERIMENTAL|BCG Vaccine|A single dose BCG vaccine intradermally 0.1 ml.
62470981|NCT04461379|PLACEBO_COMPARATOR|Placebo|A single dose intradermally 0.1 ml of NaCl 0.9% solution
62470982|NCT02158663|ACTIVE_COMPARATOR|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
62673274|NCT02571244|EXPERIMENTAL|Motivational Interview plus text message|Inside the hospital: All participants have received the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended treatment: Participants in this arm have received a telephone counseling session using a motivational interviewing approach and fifteen or eight days of text messages. The timing, duration, and content of the counseling session were consistent with guideline-based recommendations.
62673275|NCT02571244|NO_INTERVENTION|Control Arm|Inside the hospital: All participants have receive the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended care: None
62673276|NCT03849456|EXPERIMENTAL|GWP42006|Oral solution taken twice daily with food for 52 weeks.
62673277|NCT04250675|SHAM_COMPARATOR|Sham|Participants will apply Intermittent Pneumatic Compression (IPC) using a customized version of the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The sham device applies a compression sequence of 30 mmHg to the foot, ankle and calf with inflatable cuffs.
62673278|NCT04250675|ACTIVE_COMPARATOR|Active Comparator - Intermittent Pneumatic Compression|Participants will apply Intermittent Pneumatic Compression (IPC) using the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The Arterial Assist Device® applies a compression sequence of 120 mmHg to the foot, ankle and calf with inflatable cuffs.
62673279|NCT00505362|ACTIVE_COMPARATOR|Rectus muscle closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
62673280|NCT00505362|NO_INTERVENTION|Rectus muscle non-closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.
62673281|NCT04986969|ACTIVE_COMPARATOR|real-time, face-to-face, video-conferenced CBT (vcCBT)|vcCBT is cognitive behavioral therapy that consists of eight face-to-face video-conferencing sessions via tablet computers lasting approximately 45 minutes each.
62111781|NCT01315899|PLACEBO_COMPARATOR|placebo|
62111782|NCT01315899|EXPERIMENTAL|ORM-12471 100mg|
62470983|NCT02158663|ACTIVE_COMPARATOR|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
62470984|NCT01665586|PLACEBO_COMPARATOR|Group C|: Spinal anesthesia with 6mg bupivacaine and intrathecal placebo(normal saline) added
62470985|NCT01665586|ACTIVE_COMPARATOR|Group F|: Spinal anesthesia with 6mg bupivacaine and intrathecal small dose of fentanyl(20micro gram)
62470986|NCT01922765|EXPERIMENTAL|AOC group|AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
62470987|NCT01922765|EXPERIMENTAL|AOM group|AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
62470988|NCT01922765|EXPERIMENTAL|Sequential group|Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
62470989|NCT01922765|EXPERIMENTAL|concomitant group|concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
62470990|NCT02849691||Quartile 1|Quartile 1 of plasma DPP4 activity
62470991|NCT02849691||Quartile 2|Quartile 2 of plasma DPP4 activity
62470992|NCT02849691||Quartile 3|Quartile 3 of plasma DPP4 activity
62470993|NCT02849691||Quartile 4|Quartile 4 of plasma DPP4 activity
62673282|NCT04986969|ACTIVE_COMPARATOR|self-administered internet-based CBT (iCBT)|iCBT is self-directed cognitive behavioral therapy using an interactive internet program, MoodGYM, which does not include direct interactions with a therapist.
62673283|NCT01454063|EXPERIMENTAL|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
62673284|NCT01454063|PLACEBO_COMPARATOR|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
62301688|NCT03836144||Non cystinuria nephrolithiasis|20 patients with a nephrolithiasis not due to cystinuria. Control group. Urine collected once to study biomarkers of inflammation No intervention.
62111783|NCT01335165|EXPERIMENTAL|TT30 (ALXN1102 Formulation)|IV: 0.1, 0.3, and 1.0 mg/kg
62111784|NCT01335165|EXPERIMENTAL|TT30 (ALXN1103 Formulation)|"IV: 3.0, 6.0, and 10.0 mg/kg~SC: 1.0 and 3.0 mg/kg"
62111785|NCT06111937|EXPERIMENTAL|colonoscopy within 2-4 h|"Patients received ultrasound gastric assessment every 15 minutes 2 hours immediately after taking the last dose of MgSO4 solution. During this period, if the gastric ultrasound assessment showed that the patient had an empty stomach, and painless colonoscopy was performed within 2 hours while the gastric is empty."
62111786|NCT06111937|NO_INTERVENTION|colonoscopy within 4-6 h|"The patients received ultrasound gastric assessment every 15min 4h immediately after taking the last dose of MgSO4 solution on the examination day, and colonoscopy was to completed within 4-6h after taking the MgSO4 solution if the gastric ultrasound assessment showed that the patient had an empty stomach."
62301689|NCT03836144||Inflammatory nephropathy|"10 patients with an inflammatory nephropathy of glomerular or tubulo interstitial origin (confirmed by renal biopsy).~Control group. Urine collected once to study biomarkers of inflammation. No intervention."
62301690|NCT01284192|EXPERIMENTAL|ASP3026|Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)
62673285|NCT04844346|EXPERIMENTAL|Plant stanol group|This arm receives 4g of plant stanols per day (delivered as plant stanol esters) by consuming mini drinks (100 mL each).
62111787|NCT06221618||Coronary heart disease cohort|CCTA required for coronary heart disease cohort
62111788|NCT06221618||Stroke cohort|Cranial MRA required for stroke cohort
62111789|NCT06221618||Normal control group|Healthy elderly without coronary heart disease and stroke (≥ 60 years old)
62111790|NCT05571436|EXPERIMENTAL|Intervention group|iCan Diabetes Self-Management and Prevention Program
62111791|NCT04072822|ACTIVE_COMPARATOR|Prednisone|Standard of care plus prednisone 40 mg orally once daily on Days 1-30 and matching placebos for Anakinra (1 syringe s.c. once daily on Days 1-14), and zinc (matched pill once daily on Days 1-90).
62301691|NCT03842137|ACTIVE_COMPARATOR|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
62301692|NCT03842137|SHAM_COMPARATOR|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
62301693|NCT00460928|EXPERIMENTAL|intravenous immune globulin (IVIG)|
62673286|NCT04844346|PLACEBO_COMPARATOR|Placebo group|This arm receives mini drinks without added plant stanols (delivered as plant stanol esters).
62673287|NCT00122187|EXPERIMENTAL|Electronic Consult System|A new consult system designed to automatically send a gastroenterology consult request for patients with positive fecal occult blood testing (FOBT+) results
62673288|NCT00122187|NO_INTERVENTION|Usual Care|The usual and customary procedures for addressing FOBT+ results: primary care physicians continued to be responsible for follow up of FOBT+ results.
62736085|NCT01841021|EXPERIMENTAL|Brentuximab Vedotin Treatment|Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
62736086|NCT05999578|EXPERIMENTAL|Anxious patients with hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
62736087|NCT05999578|NO_INTERVENTION|Anxious patients without hypnosis|Cardiac MRI exam accordingly to usual care
62736088|NCT05999578|NO_INTERVENTION|Non anxious patients|Cardiac MRI exam accordingly to usual care
62736089|NCT05007197|EXPERIMENTAL|Intervention Group|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people.~Group-specific diabetes trainings were completed in two training sessions. Each training session lasted an average of one and a half hours and a fifteen minute break was given.~The auditory group in the intervention group, calling by phone; visual group by SMS and WhatsApp tactile group, reminder alerts were made by phone+SMS+WhatsApp."
62736090|NCT05007197|NO_INTERVENTION|Control Group|The learning modality of the control group were determined and standard group training was provided with the education booklet.
62736091|NCT04789473||Control Normal Glycemic Pregnancy|Cohort of control adults who are currently pregnant or have been pregnant within the last year, but were not diagnosed with gestational diabetes.
62736092|NCT04789473||Gestational Diabetic Cohort|Cohort of adults who are currently pregnant or have been pregnant within the last year, but were diagnosed with gestational diabetes.
62736093|NCT01264692|EXPERIMENTAL|Treatment A|ACT-280778
62736094|NCT01264692|PLACEBO_COMPARATOR|Treatment B|Placebo
62736095|NCT01264692|OTHER|Treatment C|Amlodipine
62736096|NCT04461873|EXPERIMENTAL|Reiki|Reiki was applied to this arm by the researcher who completed her second level education according to the Usui method, for 45 minutes once a week for 6 weeks and by touching the 9 main points in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again. After the 6-week Reiki application, all the caregivers of the intervention group were asked about their experience and opinions regarding the application by the individual in-depth interview method during the home visit.
62673289|NCT03296345|ACTIVE_COMPARATOR|Intervention|"Prior to the second dose of IV opiates, the experiment was to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores were collected using the FACES scale currently in place. In consenting patients, chart review was performed with the following data collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, and whether or not the patient was discharged.~In addition, a survey, which is attached, was given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
62673290|NCT03296345|NO_INTERVENTION|Historical Control|"Patient data from at least one but up three patient encounters within the prior year were compared to their visit in which they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients acted as their own controls in the above manner. Patients were allowed to re-enroll 4 weeks after presentation, which is typically considered a separate vaso-occlusive episode in the literature."
62673291|NCT05651737|ACTIVE_COMPARATOR|Sui App+ (peer guided)|"The active phase of the study is eight weeks per participant with a follow-up online assessment after another eight weeks.~One of the active study groups, the Sui App+ condition, receives the Sui app plus a peer who will guide them online. They receive weekly individual messages from their peer within the chat of the app."
62673292|NCT05651737|ACTIVE_COMPARATOR|Sui App (unguided)|"The active phase of the study is eight weeks per participant with a follow-up online assessment after another eight weeks.~The second active study group receives the app as a standalone intervention. They use whatever content they are interested in and receive weekly push-notifications in case they were not active."
62673293|NCT05651737|NO_INTERVENTION|Waitlist control group|The control arm is a waitlist control group that receives access to the app after eight weeks.
62673294|NCT03923842|EXPERIMENTAL|ARM A: Denosumab Treatment|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
62673295|NCT03923842|ACTIVE_COMPARATOR|ARM B Control Arm|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. At the end of the 6 cycles, if the patient is not progressing, can continue treatment with Gemcitabine alone.for 12 months
62673296|NCT00629213|ACTIVE_COMPARATOR|1|
62301694|NCT04297007|ACTIVE_COMPARATOR|Group P = PECS-II group|In group P, PECS will be performed with patients in the supine position at the end of the surgery before extubation by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions the high frequency linear probe (11-12 MHz) will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. US probe will be placed on the 4th rib. The muscles PMm, Pmm and Sam will be visualized. At the anterior axillary level or mid-axillary level, via the in-plane technique, Pecs II will be applied by injecting 20 mL of 0.25% bupivacaine in a cephalad to caudad direction to the fascia on Sam.
62301695|NCT04297007|ACTIVE_COMPARATOR|Group R = RIB group|In group R, RIB block will be performed with patients in the lateral decubitus position at the end of the surgery before extubation. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injectted into the fascial plane.
62301696|NCT04297007|NO_INTERVENTION|Group C = Control group|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
62673297|NCT00629213|PLACEBO_COMPARATOR|2|
62673298|NCT05474209|ACTIVE_COMPARATOR|exercise patients with multiple sclerosis|"a group that undergoes a tai-chi intervention - a special program for patients with multiple sclerosis - once a week with a Tai Chi instructor lasting 90 minutes. At V0, each patient will receive an accurate instructional video for a separate home exercise tai-chi at an intensity of twice a week."
62301697|NCT04635176|PLACEBO_COMPARATOR|Sham iPACK block|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia+ sham iPACK block with 20 mL of normal saline.
62301698|NCT04635176|ACTIVE_COMPARATOR|Real IPACK block.|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia + real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
62301699|NCT05452382||Partial colectomy|Patients with appendiceal cancer who underwent segmental resection of appendiceal adenocarcinoma
62673299|NCT05474209|NO_INTERVENTION|non-exercising patients with multiple sclerosis|the group will be a control group, patients with multiple sclerosis undergo a whole battery of examinations and scales, they will not undergo exercise.
62301700|NCT05452382||Hemicolectomy|Patients with appendiceal cancer who underwent formal right hemicolectomy of appendiceal adenocarcinoma
62673300|NCT01821053||pregestational type 1 diabetes|It is an observational study. No intervention is made.
62673301|NCT03335566|EXPERIMENTAL|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
62673302|NCT03335566|ACTIVE_COMPARATOR|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
62470994|NCT04058080|EXPERIMENTAL|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6 degrees Celsius, 40% humidity). The class opened with a deep breathing exercise and continued with 50 minutes of standing asanas and 40 minutes of floor-based asanas, including a quick, forceful breathing exercise to finish. All but the last asana (i.e., spine-twisting) were performed twice. Savasana, which is a restorative and relaxation posture, was performed between asanas throughout the floor series and at the end of class. The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
62301701|NCT05343390|EXPERIMENTAL|Enhanced implementation strategy|digitally guided training and continuous quality improvement
62301702|NCT05343390|ACTIVE_COMPARATOR|Standard implementation strategy|standard training and clinical support
62470995|NCT04058080|ACTIVE_COMPARATOR|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Selecting these classes was done in consultation with the general manager of the YMCA, who was familiar with each class type. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration.
62301703|NCT03068559||Study population|"* Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.~* Patient has to be aged ≥ 18~* Patient has to be able to complete questionnaire in French~* Patient must benefit from health insurance~* Patient must sign an informed consent form~* Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
62301704|NCT04375878|ACTIVE_COMPARATOR|MS1819 2240 mg/day vs PERT arm,|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
62673303|NCT04354688|EXPERIMENTAL|T3 Certain Tapered implant with DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
62673304|NCT04354688|ACTIVE_COMPARATOR|T3 Certain Tapered implant without DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
62673305|NCT02269605|PLACEBO_COMPARATOR|Group 1|Patients receiving placebo (sodium chloride) at single dose
62673306|NCT02269605|ACTIVE_COMPARATOR|Group 2|Patients receiving Bryostatin 1 (10ug/m2) at single dose
62673307|NCT02269605|ACTIVE_COMPARATOR|Group 3|Patients receiving Bryostatin 1 (20ug/m2) at single dose
62673308|NCT00417729|ACTIVE_COMPARATOR|acarbose, glibenclamide|acarbose vs. glibenclamide (background metformin therapy)
62673309|NCT05316727||Vaping|At least weekly vape use over the past 3 months of the subjects unspecified product
62673310|NCT05316727||Non vapers|No previous history of vape use and no current history of smoking tobacco for controls
62673311|NCT04236466|EXPERIMENTAL|hyrax group|cleft lip and palate patients with hyrax appliance
62673312|NCT04236466|EXPERIMENTAL|haas group|cleft lip and palate patients with haas appliance
62673313|NCT01759641||Hypotension-prone patients|The study group included all patients treated with standard HD prone to acute intradialytic hypotension.
62673314|NCT04063904|EXPERIMENTAL|Mifepristone and misoprostol|Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
62673315|NCT05648916||Patients with and without HO before Celecoxib clinical pathway|Patients with and without heterotopic ossification (HO) before the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2009-2012.
62301705|NCT04375878|ACTIVE_COMPARATOR|MS1819 4480 mg/day vs PERT arm|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
62301706|NCT03139370|EXPERIMENTAL|KITE-718|"Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A."
62673316|NCT05648916||Patients with and without HO after Celecoxib clinical pathway|Patients with and without heterotopic ossification (HO) after the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2013-2020.
62673317|NCT01266928|ACTIVE_COMPARATOR|vitaminCE|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
62673318|NCT01266928|NO_INTERVENTION|no drug|no drug
62673319|NCT06138080|OTHER|VUR diagnostics|
62673320|NCT00419432|ACTIVE_COMPARATOR|Group A (standard pre-operative analysis)|
62673321|NCT00419432|EXPERIMENTAL|Group B (additional pre-operative analysis)|
62673322|NCT05363085||Mechanically ventilated neurosurgical patients|Observational study in mechanically ventilated neurosurgical patients
62673323|NCT03368560|ACTIVE_COMPARATOR|Sudarshan Kriya Yoga|Thirty participants with treatment-resistant late life depression (TR-LLD) will attend 5 instructional days of Sudarshan Kriya Yoga (SKY), followed by 3 weekly follow-ups, and 8 weeks of bimonthly follow-ups. Participants will also practice SKY for 25 minutes per day at home. These participants will attend 4 mental health assessments at weeks 0, 4, 8, and 12. Thirteen of the recruited TR-LLD will attend an MRI at baseline and post-intervention.
62673324|NCT03368560|NO_INTERVENTION|Control|The seven recruited age-matched controls will complete a screening appointment and an MRI only for comparison. Demographic information will also be collected from the control participants. These individuals will not undergo the study intervention.
62673325|NCT02914223|EXPERIMENTAL|Treatment and observation period|On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected
62673326|NCT02914223|EXPERIMENTAL|Extended observation period|In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected
62673327|NCT05442892|EXPERIMENTAL|Physical exercise|The intervention will consist of a multicomponent exercise training programme, which will be composed of supervised progressive resistance exercise training, balance-training, strength-training and walking for 4 consecutive days. During the training period, patients will be trained in 30 min sessions daily.
62111792|NCT04072822|ACTIVE_COMPARATOR|Anakinra and Zinc|Standard of care plus Anakinra (100 mg s.c.) once daily on Days 1-14 zinc sulfate 220 mg once daily on Days 1-90, and placebo for prednisone (matched pill once daily on Days 1-30).
62111793|NCT05819541|EXPERIMENTAL|High-dose oral montelukast plus standard treatment|Escalating dose-levels of oral montelukast between 2 mg/kg and 3 mg/kg determined by pharmacokinetic-guided dose modeling, added to standard, guideline-based treatment (systemic corticosteroid, inhaled albuterol, and possible treatment adjuncts such as IV magnesium, determined by evidence-based asthma clinical practice guideline).
62111794|NCT05819541|PLACEBO_COMPARATOR|Identical placebo plus standard treatment|Guideline-based treatment (systemic corticosteroid, inhaled albuterol, and possible treatment adjuncts such as IV magnesium, determined by evidence-based asthma clinical practice guideline).
62301707|NCT04856761||Cape Group|In this group, capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
62301708|NCT04856761||S-1 Group|In this group, S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
62673328|NCT05442892|NO_INTERVENTION|Without physical exercise|Participants randomly assigned to the usual care group will receive normal hospital care, which includes physical rehabilitation when needed
62301709|NCT01147783||SimBaby|
62301710|NCT01147783||Infants (1-12 mo)|
62301711|NCT05999305|EXPERIMENTAL|The intervention group|The conventional class and an escape room game will be implemented for the intervention.
62301712|NCT05999305|ACTIVE_COMPARATOR|The comparison group|The conventional class and a case-based learning will be implemented for the comparison
62470996|NCT04058080|NO_INTERVENTION|Waitlist|Waitlisted individuals were not able to access yoga or exercise classes throughout the intervention period but participated in the rest of the study protocol. Following the post-treatment assessment, they received access to the class type of their choosing.
62301713|NCT06143631|EXPERIMENTAL|Letrozole|Oral letrozole 2.5mg/day
62301714|NCT06143631|PLACEBO_COMPARATOR|Placebo and Letrozole|Placebo capsule for 12 weeks; Oral letrozole 2.5mg/day for 12 weeks
62470997|NCT00901745|EXPERIMENTAL|Infusion of apelin|Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
62673329|NCT00710788|EXPERIMENTAL|1|sevelamer as Phosphate-binder treatment
62673330|NCT00710788|ACTIVE_COMPARATOR|2|Calcium carbonate
62301715|NCT05875168|EXPERIMENTAL|Dose Escalation (Part 1)|Participants with locally advanced, metastatic, or unresectable tumors who will receive an intravenous (IV) infusion of DS-3939a.
62111795|NCT05398965|EXPERIMENTAL|Intervention Group|The group will receive standard COVID medication + Eucalyptus oil on external use for 14 days
62111796|NCT05398965|ACTIVE_COMPARATOR|Comparator Group|The group will receive standard COVID medication only
62111797|NCT03107962|EXPERIMENTAL|PD-1 Blocking Antibody|Pembrolizumab
62301716|NCT05875168|EXPERIMENTAL|Dose Expansion (Part 2)|Multiple expansion cohorts targeting various advanced solid tumors.
62301717|NCT00825071|ACTIVE_COMPARATOR|Group D|Dexamethasone group : This group received 8 mg dexamethasone
62301718|NCT00825071|ACTIVE_COMPARATOR|Group O|Ondansetron Group: received 4 mg ondansetron
62301719|NCT00825071|PLACEBO_COMPARATOR|Group P|(Group P) received normal saline (Placebo)
62301720|NCT03431389|ACTIVE_COMPARATOR|Decannulated group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Trial of decannulation was considered successful, if there was no need to reapply tracheostomy within 6 months of decannulation.
62673331|NCT01927289|ACTIVE_COMPARATOR|Proximal Brachial Plexus block|15 mls of 1.5% Mepivacaine injected in the supraclavicular approach and 15 mls of saline injected in the distal forarm nerve blocks
62673332|NCT01927289|ACTIVE_COMPARATOR|Distal Forearm block|15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
62673333|NCT03281720|EXPERIMENTAL|Targeted Axillary Dissection|"After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes.~The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an axillary dissection."
62673334|NCT02307435|EXPERIMENTAL|implantation group|implantation group will receive MSC and HA-CaSo4
62673335|NCT06549764|EXPERIMENTAL|Experimental intervention + school as usual (9th grade curriculum)|The YAM-program consists of a booklet, posters, discussions, lectures, and role-playing games and will be delivered to students aged 15-16 years. During the 3-week of the intervention, 6 educational posters will remain on display in the classroom,
62673336|NCT06549764|NO_INTERVENTION|School as usual (9th grade curriculum) + help seeking information posters|School as usual - 9th grade curriculum + posters
62673337|NCT00552838|NO_INTERVENTION|A|Physicians in this arm did not have any intervention with the AUT. Antimicrobial prescriptions were based on hospital guidelines or on the physician's medical knowledge.
62673338|NCT05702619||Arm 1|Arm 1 - De novo, treatment-naïve metastatic prostate cancer
62673339|NCT05702619||Arm 2|Arm 2 - De novo, treatment- naïve localised prostate cancer planned for radical prostatectomy
62111798|NCT03137966|ACTIVE_COMPARATOR|Deferoxamine|Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
62673340|NCT00908661|ACTIVE_COMPARATOR|Prophylactic mesh|All patients will have a permanent ostomy and a randomisation with prophylactic mesh
62673341|NCT00908661|NO_INTERVENTION|without prophylactic mesh|All patients will have a permanent ostomy and a randomisation without prophylactic mesh
62673342|NCT06137547|EXPERIMENTAL|HPI-guided|The arterial line of patients in HPI-guided arm will be connected to HemoSphere advanced monitoring platform (EV1000), which will provide HPI value calculated with Acumen Hypotension Prediction Index software.
62673343|NCT06137547|NO_INTERVENTION|non-HPI-guided|The arterial line of patients in non-HPI-guided arm will also be connected to HemoSphere advanced monitoring platform (EV1000) and all hemodynamic parameters will be calculated and showed as HPI-guided arm EXCEPT that the HPI value will not be shown on screen.
62673344|NCT04714580|EXPERIMENTAL|Animal Fun Group|Baseline assessment with MABC-2; Animal Fun activity with a certified trainer (physiotherapist) for one month, three times a week, for 30 minutes; one-month follow-up assessment with MABC-2.
62673345|NCT04714580|NO_INTERVENTION|Control Group|Baseline assessment with MABC-2; normal curricular activity at school with the teachers; one-month follow-up assessment with MABC-2.
62673346|NCT03307850|EXPERIMENTAL|Observation of Exercise|Observation During Exercise and Stress
62111799|NCT03137966|PLACEBO_COMPARATOR|Placebo|Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
62111800|NCT00762463|EXPERIMENTAL|Celecoxib 200 mg QD|
62111801|NCT00762463|ACTIVE_COMPARATOR|Diclofenac SR 75 mg QD|
62111802|NCT04680013||Cognitive Control|Participants in this group are cognitively intact.
62111803|NCT04680013||Mild Cognitive Impairment|Participants in this group have mild cognitive impairment.
62111804|NCT04680013||Dementia Group|Participants in this group have dementia.
62111805|NCT00765752||1 Primary Insomnia|Individuals with insomnia not related to another identified cause.
62111806|NCT00765752||3 Healthy comparison subjects|Healthy subjects with no history of insomnia
62111807|NCT00618540|EXPERIMENTAL|Alemtuzumab|Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
62111808|NCT00271700|NO_INTERVENTION|Usual Care|admission to medical team floor to usual care
62111809|NCT00271700|EXPERIMENTAL|Intervention|consists of usual care as well as an admission order set built into BWH's proprietary computer provider order entry (CPOE) system
62111810|NCT04021667|EXPERIMENTAL|INDIVIDUAL BREASTFEEDING TRAINING|"Individual Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates."
62111811|NCT04021667|EXPERIMENTAL|GROUP BREASTFEEDING TRAINING|"Group Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates.The groups were composed of five pairs of parents."
62111812|NCT04021667|NO_INTERVENTION|Control Group|Control Group: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates. Routine procedures were applied to the mother and father candidates.
62111813|NCT04839796||Participants residing in urban areas|Urban residents enjoy convenient transportation, have access to abundant medical resources, have more job opportunities, and are on average younger but are also exposed to more air pollution.
62111814|NCT04839796||Participants residing in rural areas|Rural residents have less access to transportation, medical resources, and job prospects comparatively and are comparatively older. However, Rural residents are exposed to less pollution in general.
62111815|NCT06466070||open (thoracotomy)|Nowadays, pulmonary metastasectomy is performed in RATS, VATS or thoracotomy. A thoracotomy is a surgical procedure during which a surgeon accesses the lungs and other nearby organs through an incision in the chest wall.
62111816|NCT06466070||RATS (robot-assisted thoracoscopic surgery)|RATS is a minimally invasive surgical technique allowing enhanced view, accurate and complex movements, and high ergonomics for the surgeon.
62470998|NCT00901745|ACTIVE_COMPARATOR|Sodium nitroprusside infusion|Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
62673347|NCT05756309|EXPERIMENTAL|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
62673348|NCT00398905|EXPERIMENTAL|Arm 1|
62673349|NCT00398905|EXPERIMENTAL|Arm 2|
62673350|NCT00398905|EXPERIMENTAL|Arm 3|
62673351|NCT00398905|EXPERIMENTAL|Arm 4|
62673352|NCT00398905|EXPERIMENTAL|Arm 5|
62673353|NCT00398905|ACTIVE_COMPARATOR|Arm 6|
62301721|NCT03431389|ACTIVE_COMPARATOR|Failure of decannulation group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Decannulation trail was considered failed if there was a need to reapplication of tracheostomy at the time of decannulation or within six months of decannulation the duration of follow up.
62673354|NCT06310109|EXPERIMENTAL|PICU diary|"The PICU diary arm, will receive a PICU diary at the patient bedside."
62673355|NCT06310109|NO_INTERVENTION|Control arm|The control arm will receive standard care (no PICU diary).
62673356|NCT06377527||Mesonephric-like Adenocarcinoma (MLA)|"Particpants who agree to take part in this research, information such as your demographics (including your name, date of birth, race, etc.), medical history, surgical history, family history, social history, cancer diagnosis, primary treatment, and follow up will be collected.~Participants also have the option to agree to the use of your previously collected tumor tissue samples for future research to better understand MLA."
62673357|NCT03307070|ACTIVE_COMPARATOR|Active Group|Participants who are randomized to begin the Cognitive Behavioral Therapy for individuals with TBI immediately after screening. This treatment is a version of Cognitive Behavioral Therapy (CBT) adapted specifically for patients who have experienced a moderate to severe Traumatic Brain Injury (TBI).
62673358|NCT03307070|OTHER|Waitlist Control|Participants who are randomized to be put on a waitlist after screening. After 12 weeks of being on the waitlist, participants will be offered the Cognitive Behavioral Therapy for individuals with TBI
62673359|NCT01494142||ADEH-Staph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph+ participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
62673360|NCT01494142||ADEH-Staph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph- participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
62673361|NCT01494142||ADEH+|Atopic Dermatitis with previous or current Eczema Herpeticum.We will try to include a minimum of 150 Non-Hispanic Caucasian ADEH+ participants. ADEH+ participants of other racial/ethnic groups will not be excluded
62301722|NCT05110066|ACTIVE_COMPARATOR|BPA group|Balloon pulmonary angioplasty. Typically 4-8 sessions are needed to treat the patient. The specific pre-planning protocol, choice of wires and balloons, the number of vessels treated per session, and the decision that no further BPA sessions are needed is at the discretion of the treating physician.
62470999|NCT02130518|EXPERIMENTAL|Auriclosene (AIS)|Auriclosene Irrigation Solution, 0.2%, 8 treatments over 4 weeks
62471000|NCT02130518|PLACEBO_COMPARATOR|Auriclosene Vehicle Solution|Auriclosene Vehicle Solution, 8 treatments over 4 weeks
62471001|NCT00469417|EXPERIMENTAL|Metvix® PDT|Participants with basal cell carcinoma (BCC) lesions were administered to photodynamic therapy (PDT) with Metvix® cream 160 milligrams per gram (mg/g) applied for three hours, followed by illumination using non-coherent light with a fluency of 75 Joule per centimeter square (J/cm\*2) and fluency rate of 70-200 milliwatt per centimeter square (mW/cm\*2) up to 13 weeks.
62673362|NCT01494142||ADEV+|Atopic Dermatitis with previous or current Eczema Vaccinatum. ADEV+ sub-phenotype is very rare so all eligible participants will be enrolled.
62673363|NCT01494142||Non-atopic|Non-atopic healthy participants. A minimum of 250 non-atopic participants will be enrolled. Non-atopic participants will serve as a control group for the genetic, biomarker, Staph characterization, and microbiome studies.
62673364|NCT00513864|ACTIVE_COMPARATOR|CYP2D6-|This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
62673365|NCT00513864|ACTIVE_COMPARATOR|CYP2D6+|Extensive metabolizers (EM) of codeine
62673366|NCT05689515|EXPERIMENTAL|Mobile Health App group|Mobile health app to increase rates of engagement in care in youths living with HIV
62301723|NCT05110066|ACTIVE_COMPARATOR|PEA group|Patients randomized to PEA will undergo surgery within 4 months after randomization and optional run-in phase. Distality of the dissection plane is at the discretion of the operating physicians.
62673367|NCT05689515|NO_INTERVENTION|Control group|Standard of care for youths living with HIV
62673368|NCT04006457|EXPERIMENTAL|Treatment sequence 1|"Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 tablet or capsule given QD for 59 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 56 visit of the main B7981032 study."
62673369|NCT04006457|EXPERIMENTAL|Treatment sequence 2|"Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 tablet or capsule given QD for 59 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 56 visit of the main B7981032 study."
62673370|NCT05100147|EXPERIMENTAL|Group 1|The uterotomy suture technique is continous, double layer suturing, in which the first layer is continuous and unlocked involving all uterine layers and a second, continuous non-locking imbrictating layer is applied over the first suture.
62301724|NCT04439734|EXPERIMENTAL|Whole-Body Electromyostimulation|WB-EMS once per week for for 16 week (85 Hz, 350 µs, bipolar, duty cycle 4s-4s)
62673371|NCT05100147|EXPERIMENTAL|Group 2|The uterotomy suture technique is continous, double layer suturing, in which the first layer is continuous and unlocked not including decidua and a second, continuous non-locking imbrictating layer is applied over the first suture.
62673372|NCT05100147|EXPERIMENTAL|Group 3|The uterotomy suture technique is continous ,double layer with the first layer unlocked, excluding the decidua and including the deep part of the myometrium, and the second layer unlocked including the remaining part of the myometrium.
62673373|NCT04739774|EXPERIMENTAL|Treatment R|Single dose of CHF6001
62673374|NCT04739774|EXPERIMENTAL|Treatment T|Single dose of CHF6001 administered after repeated doses of oral Itraconazole
62111817|NCT06466070||VATS (video-assisted thoracoscopic surgery)|VATS is minimally invasive thoracic surgery that does not use a formal thoracotomy incision.
62111818|NCT01697319|EXPERIMENTAL|BMN 110 at 2.0 mg/kg/week|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 144 weeks.
62111819|NCT02876471|NO_INTERVENTION|OSA group|100 severe OSA patients without hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS),demographic and anthropometric data The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated
62111820|NCT02876471|OTHER|OSA with hypertension|100 severe OSA patients with hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS), antihypertensive medicine demographic and anthropometric data. The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated.Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood pressure control, the investigators would give one-night CPAP.
62111821|NCT05830604|ACTIVE_COMPARATOR|TMD Wilkes Stage I-II and Subjective Tinnitus|Patients with subjective tinnitus and temporomandibular disorder. It was treated with an occlusal splint.
62111822|NCT05830604|ACTIVE_COMPARATOR|TMD Wilkes Stage I-II, Subjective Tinnitus and Bruxism|Patients with subjective tinnitus and temporomandibular disorder and bruxism. It was treated with an occlusal splint.
62111823|NCT00979056|EXPERIMENTAL|Rifaximin|
62111824|NCT00979056|PLACEBO_COMPARATOR|Lactose|
62111825|NCT02108743|ACTIVE_COMPARATOR|Albuterol|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
62111826|NCT02108743|PLACEBO_COMPARATOR|Placebo|Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
62111827|NCT02482233|EXPERIMENTAL|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)~* the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)~* veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
62111828|NCT02482233|ACTIVE_COMPARATOR|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of \<10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
62111829|NCT01646775|EXPERIMENTAL|Epidural bupivacaine|
62111830|NCT01646775|ACTIVE_COMPARATOR|Epidural bupivacaine and fentanyl|
62301725|NCT04439734|NO_INTERVENTION|Non WB-EMS control|No WB intervention, but maintained physical activity and habitual exercise habits
62301726|NCT00708396|EXPERIMENTAL|Patients|Patients which diagnosed as OCD and schizophrenia
62471002|NCT00469417|ACTIVE_COMPARATOR|Cryotherapy|Cryotherapy was performed with a hand-held liquid nitrogen spray, using a double freeze-thaw cycle. After an initial icefield formation with a 3 millimeter (mm) rim of clinically healthy tissue, the icefield was to be maintained for a minimum of 20 seconds. This procedure was repeated after a thaw of 2-3 times the freeze time up to 12 weeks.
62111831|NCT02247258|ACTIVE_COMPARATOR|Systematic azathioprine group|Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
62111832|NCT02247258|ACTIVE_COMPARATOR|Endoscopy-driven azathioprine group|Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
62111833|NCT03723512|EXPERIMENTAL|Whole group|Whole group
62111834|NCT01400750|ACTIVE_COMPARATOR|Ciproxin-inhaled Colistin|oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months
62111835|NCT01400750|ACTIVE_COMPARATOR|Tobramycine for inhalation (TIS)|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
62111836|NCT03038503|NO_INTERVENTION|A|standard care septic shock according sepsis bundles
62301727|NCT02466256|PLACEBO_COMPARATOR|Autosert Group|Procedure / Surgery : Intraocular lens implantation with Autosert injector
62301728|NCT02466256|PLACEBO_COMPARATOR|Royale Group|Procedure / Surgery : Intraocular lens implantation with Royale Injector
62301729|NCT02466256|PLACEBO_COMPARATOR|Monarch III Injector|Procedure / Surgery : Intraocular lens implantation with Monarch III group
62301730|NCT06229509|EXPERIMENTAL|Effective noninvasive ventilation|Alleviate dyspnea (lower Borg Score by 2 points)
62301731|NCT06229509|SHAM_COMPARATOR|Sham noninvasive ventilation|
62471003|NCT03919630|EXPERIMENTAL|Cervical Thrust Mobilizations|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine.
62111837|NCT03038503|EXPERIMENTAL|B|after defined refractory shock (adequate fluid resuscitation + add NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
62301732|NCT05553132|EXPERIMENTAL|CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects|Subject will receive the combined product of autologous cartilage cells and allogeneic AMSCs in a fibrin glue carrier.
62471004|NCT03919630|ACTIVE_COMPARATOR|Cervical Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
62673375|NCT03394846|EXPERIMENTAL|Test of Existing MI Products|We will test the impact of three widely available MI products (GoNoodle, Take10, ABC for Fitness) on students' physical activity with 60 elementary classroom teachers.
62301733|NCT04177498|EXPERIMENTAL|Treatment (rigosertib sodium)|Patients receive rigosertib sodium either oral or IV over a 52 week period. Patients will take oral rigosertib continuously for a total of three weeks, every four-week cycle (three weeks on, one week off drug). For IV, rigosertib is administered as a 72-hr continuous infusion on Days 1, 2 and 3 of a 2-week cycle for the first eight 2-week cycles, then on Days 1, 2 and 3 of a 4-week cycle thereafter.
61916722|NCT00645788|EXPERIMENTAL|32.50 mg Ciprofloxacin DPI (BAYQ3939)|32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
62111838|NCT03038503|EXPERIMENTAL|C|after defined refractory shock (adequate fluid resuscitation + add NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
62111839|NCT05299333|EXPERIMENTAL|Pulmonary Rehabilitation Group|A total of 24 sessions of breathing exercises and high-repetitive muscle endurance and strengthening exercises will be applied to the pulmonary telerehabilitation group for 8 weeks, two days a week and one day a week unsupervised, via online systems. High-repetition muscle endurance and strengthening exercises will be applied to large muscle groups of the lower and upper extremities by creating resistance with body weight and theraband.
62111840|NCT05299333|ACTIVE_COMPARATOR|Physical Activity Group|Respiratory exercises and physical activity recommendations will be given to the physical activity group. Physical activity recommendations are; It will include information about the importance of physical activity and walking 3-5 days a week for at least 30 minutes of moderate intensity (4-6 on the Modified Borg scale of perceived exertion level).
62111841|NCT04593719|EXPERIMENTAL|Experiment|Lactation management model is applied to the experimental group.
62111842|NCT04593719|NO_INTERVENTION|Control|Lactation management model is not applied to the control group.
62111843|NCT03418324|EXPERIMENTAL|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
62301734|NCT06656936|EXPERIMENTAL|Intervention: PharmFIT|Subjects enrolled in the PharmFIT intervention will receive a referral notice from their primary care facility to pick up a FIT and receive support for screening from their pharmacist. After receiving the FIT and completing the FIT subject will receive their FIT results. Those with positive results will also be provided patient navigation support. This support will be provided by the pharmacist, in collaboration with the subject's PCP, and will include a) Discussing barriers to colonoscopy (e.g., fear, lack of transportation, inability to pay); b) Support for and confirmation of colonoscopy appointment scheduling; c) Review and support prep procedures; e) Post-procedure, discuss results and answer questions.
62301735|NCT06656936|NO_INTERVENTION|Control: Usual Care|Subjects randomized to this arm receive usual care.
62471005|NCT03905005||Pre-flexed reconstruction plate|Patients who undergo mandibular reconstruction using a pre-flexed osseosynthesis reconstruction plate along with free-tissue transfer for reconstruction of a mandibular continuity defect.
62111844|NCT03418324|EXPERIMENTAL|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
62301736|NCT04108767||Health students enrolled in the 3rd year at the University Cla|Health students enrolled in the 3rd year at the University Claude Bernard Lyon 1, aged over 18 years.
62301737|NCT03163342|OTHER|Open label|Licensed seasonal influenza vaccine, intramuscular
62301738|NCT00313430||Dialysis patients|
62301739|NCT00313430||with or wthout glucose added to dialysis fluid|
62301740|NCT04462237|EXPERIMENTAL|collagen matrix + platelet-derived growth factor|Root coverage procedure using collagen matrix + platelet-derived growth factor for the treatment of multiple adjacent gingival recessions
62471006|NCT03905005||Printed reconstruction plate|Patients who undergo mandibular reconstruction using a 3D-printed reconstruction plate made by selective laser melting (SLM), along with free-tissue transfer for reconstruction of a mandibular continuity defect.
62471007|NCT01688934|EXPERIMENTAL|V116517 - 50 mg|V116517 50-mg tablets
62471008|NCT01688934|EXPERIMENTAL|V116517 - 30 mg|V116517 30-mg tablets
62471009|NCT01688934|ACTIVE_COMPARATOR|Naproxen 500 mg|Naproxen 500-mg capsules
62471010|NCT01688934|PLACEBO_COMPARATOR|Placebo|Placebo
62673376|NCT01169337|EXPERIMENTAL|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62673377|NCT01169337|ACTIVE_COMPARATOR|Arm B (observation)|Patients undergo observation until progression to symptomatic myeloma.
62673378|NCT04808895|ACTIVE_COMPARATOR|Acetylsalicylic acid|Tablets of 100 mg acetylsalicylic acid (one 100 mg daily dose. On the first day a loading dose of 300 mg will be administered)
62673379|NCT04808895|PLACEBO_COMPARATOR|Placebo|Tablets of placebo, identical to active comparator (one tablet daily dose. On the first day 3 tablets will be administered)
62471011|NCT05910853||Fanconi Anemia (Non-Specific Genotypes)|"Cohort 1-Fanconi Anemia (Non-Specific Genotypes) (N=4):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A\*Inclusion preference (not required for enrollment into the study): 1)~Participants preferentially have one of the following genotypes:~c3788_3790delTCT, c295 G to T, c3558-3559 insertion of G, or c1115_1118delTTGG~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
62471012|NCT05910853||Fanconi Anemia (c3788_3790delTCT)|"Cohort 2 - Fanconi Anemia (c3788_3790delTCT) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c3788_3790delTCT~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
62471013|NCT05910853||Fanconi Anemia (c295 G to T)|"Cohort 3 - Fanconi Anemia (c295 G to T) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c295 G to T~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
62673380|NCT01734928|EXPERIMENTAL|Pomalidomide, Bortezomib and Low Dose Dexamethasone|4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
62111845|NCT05285514||Brain-damaged patients under anesthesia and requiring the administration of a vasoactive agent|Patients with severe brain injuries over 18 years of age are eligible to participate in this protocol: head trauma, subarachnoid hemorrhage, ischemic or hemorrhagic stroke and requiring the administration of a vasoactive agent as part of routine medical care to restore Cerebral Perfusion pressure (CPP).
62111846|NCT02196818||Mpact Acetabular Shell|Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.
62111847|NCT02215044|EXPERIMENTAL|BI 2536 in combination with gemcitabine|
62111848|NCT02422992||PD|100 PD patients were patients diagnosed with Parkinson's disease
62111849|NCT02422992||Controls|242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
62111850|NCT04090190|OTHER|standard of care anticholinergic treatment|Women presenting to the Urogynecology clinic with urgency urinary incontinence symptoms will receive standard of care anticholinergic treatment and will have their urinary microbiome evaluated before and after treatment
62111851|NCT04629118||Selution SLR™ 018 Drug Eluting Balloon|Subjects will undergo fistuloplasty with the study device - Selution SLR™ 018 Drug Eluting Balloon
62111852|NCT05519969||6-4-2 group|- Cases from centres implementing the rule of a minimum of 6 hours of fasting for solids, 4 hours for breast milk and 2 hours for clear fluids before anesthesia.
62111853|NCT05519969||6-4-1 group|- Cases from centres implementing the 1 hour fasting rule for clear fluids recommended by ESAIC and specified in the guideline Preoperative fasting in children
62111854|NCT05519969||6-4-0 group|"- Cases from centres implementing the zero hour clear fasting rule, which means that children are allowed intake of clear fluids until they are called to the operating room"
62111855|NCT02050724|EXPERIMENTAL|CT guided labelling|CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
62111856|NCT02050724|EXPERIMENTAL|Electromagnetic bronchoscopic labelling|Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
62111857|NCT03457246|EXPERIMENTAL|D-Pigment rich texture|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
62111858|NCT03457246|PLACEBO_COMPARATOR|Hydrance optimale riche|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
62111859|NCT06382558||Chronic stroke patients|Patients who experienced a first unilateral stroke at least 6 months ago
62111860|NCT06382558||Healthy controls|Healthy subjects with no history of any neurological condition and who are in the same age group as the chronic stroke patients
62111861|NCT06069986|ACTIVE_COMPARATOR|on pump CABG|using cardiopulmonary bypass
62111862|NCT06069986|ACTIVE_COMPARATOR|off pump CABG|without cardiopulmonary bypass
62111863|NCT00939042|ACTIVE_COMPARATOR|1|PCI plus BNNC Therapy after acute myocardial infarction
62673381|NCT01734928|ACTIVE_COMPARATOR|Bortezomib and Low Dose Dexamethasone|1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day \[≤ 75 years old\]or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
62673382|NCT04566380|EXPERIMENTAL|ONO-4538 Monotherapy cohort|480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice
62673383|NCT04566380|EXPERIMENTAL|Combination therapy cohort|ONO-4538 at 360 mg IV Q3W or 480 mg IV Q4W, and Combination therapies (S-1 + Oxaliplatin \[SOX\] therapy , Capecitabine + Oxaliplatin \[CapeOX\] therapy , Bevacizumab or Temozolomide) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.
62673384|NCT02213991|EXPERIMENTAL|Intraoperative Radiotherapy|"Intervention:~Intraoperative Radiotherapy~\* Operation day~* Breast conservative surgery + Intraoperative radiotherapy 20 Gy~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity. Purse string suture pulles up tissues and wraps up the applicator. IORT with 20Gy is followed. After IORT, applicator was out of the operative field, and usual wound closure will be done.~\* Postoperative period~* ± Chemotherapy~* WBRT (46 Gy) for 4\~5 weeks~* ± Endocrine therapy or target therapy"
62111864|NCT00939042|ACTIVE_COMPARATOR|2|Percutaneous Coronary Intervention after acute myocardial infarction
62111865|NCT04399525|EXPERIMENTAL|Sequence 1|Desloratadine 5 mg Levocetirizine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
62111866|NCT04399525|EXPERIMENTAL|Sequence 2|Desloratadine 5 mg Levocetirizine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
62111867|NCT04399525|EXPERIMENTAL|Sequence 3|Levocetirizine 5 mg Desloratadine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
62111868|NCT04399525|EXPERIMENTAL|Sequence 4|Levocetirizine 5 mg Desloratadine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
62111869|NCT03861169|EXPERIMENTAL|Viscoeleastic delivery & trabeculotomy|Patients with open angle glaucoma and cataract
62111870|NCT00810225||1|GWI: veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
62111871|NCT00810225||2|HC: healthy veterans of the 1990-1991 Persian Gulf War
62111872|NCT00738075||PD+FOG|Patients with Parkinson's disease prone to freezing
62111873|NCT06416202|OTHER|Open loop insulin delivery|Patients with Type 1 Diabetes (T1D) on OLID, who observe Ramadan fasting.
62111874|NCT06416202|ACTIVE_COMPARATOR|Advanced Hybrid Closed loop system|AHCL system (Medtronic MiniMed 780G or Tandem T-slim x2 pump).
62111875|NCT01693614|EXPERIMENTAL|DLBCL Cohort|Diffuse large B-cell lymphoma cohort
62111876|NCT01693614|EXPERIMENTAL|MCL Cohort|Mantle cell lymphoma cohort
62111877|NCT01693614|EXPERIMENTAL|FL Cohort|Follicular lymphoma cohort
62111878|NCT01981850|EXPERIMENTAL|Stage 1: Cohort 1 Weekly|Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
62111879|NCT01981850|EXPERIMENTAL|Stage 1: Cohort 1 Every 4 Weeks|Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
62111880|NCT01981850|EXPERIMENTAL|Stage 1: Cohort 2 Weekly|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
62111881|NCT01981850|EXPERIMENTAL|Stage 1: Cohort 2 Every 4 Weeks|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
62111882|NCT01981850|EXPERIMENTAL|Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
62111883|NCT01981850|EXPERIMENTAL|Stage 2: Cohort 2 3mg/kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
62111884|NCT01981850|EXPERIMENTAL|Stage 2: Cohort 3 10mg /kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
62111885|NCT03463135|EXPERIMENTAL|SAR439794 [PE SLIT + GLA)]|GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
62673385|NCT00799864|EXPERIMENTAL|Rilpivirine (TMC278)|The patients received rilpivirine with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a background regimen in cohort 1 \[aged greater than or equal to (\> =) 12 to less than (\<) 18 years\] for up to 240 weeks which is already completed and recruitment closed and will receive this treatment in cohort 2 (children aged \> = 6 to \< 12 years) for up to 48 weeks. The NRTIs include zidovudine, abacavir, or tenofovir disoproxil fumarate in combination with lamivudine or emtricitabine.
62301741|NCT04462237|ACTIVE_COMPARATOR|collagen matrix alone|Root coverage procedure using collagen matrix alone (without the use of the platelet-derived growth factor) for the treatment of multiple adjacent gingival recessions
62301742|NCT05772364|EXPERIMENTAL|Low-calcium water first, then high-calcium water|Participants drink 1.5 L of the designated water
62301743|NCT04661813|EXPERIMENTAL|EXTRA-CVD Virtual Care|"An adapted version of a Nurse-led intervention to EXtend the HIV TReatment CascAde for CardioVascular Disease prevention (EXTRA-CVD)."
62673386|NCT01629862|ACTIVE_COMPARATOR|Active CPAP|Therapeutic continuous positive airway pressure (CPAP).
62301744|NCT04630054|EXPERIMENTAL|Mask Intervention|"Communities and individuals randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use.~In the community experiment, every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people.~In the individual experiment, individuals randomized to the intervention arm will not be asked to recommend masks to others, but will also not be discouraged from recommending mask use to others."
62673387|NCT01629862|PLACEBO_COMPARATOR|Sham CPAP|Sham (non-therapeutic) continuous positive airway pressure.
62111886|NCT03463135|EXPERIMENTAL|Placebo for GLA + SLIT PE|Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
62111887|NCT03463135|PLACEBO_COMPARATOR|Placebo for GLA + Placebo for SLIT PE|Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks
62111888|NCT04886180|EXPERIMENTAL|Experimental|
62301745|NCT04630054|NO_INTERVENTION|Control|Control individuals will receive no masks or behavior change communication.
62301746|NCT00606515|EXPERIMENTAL|A|Liposomal paclitaxel
62673388|NCT03043820|ACTIVE_COMPARATOR|Raloxifene|Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.
62673389|NCT03043820|PLACEBO_COMPARATOR|Placebo|Placebo 2 tablets daily for 12 weeks.
62111889|NCT04886180|ACTIVE_COMPARATOR|Control|
62111890|NCT05013606|EXPERIMENTAL|Active Treatment: Hydrogen water|Hydrogen pills mixed in a water glass that is ingested up to five time a day for 30 days.
62111891|NCT05013606|PLACEBO_COMPARATOR|Placebo: Inactive pill|Inactive pills mixed in a water glass that is ingested up to five time a day for 30 days.
62111892|NCT06156319||Group 1|"CHIP group: Patients diagnosed with AMI combined with CKD stage II-IV underwent PCI and were identified as CHIP carriers by gene targeted sequencing.~Non-chip group: Patients diagnosed with AMI combined with CKD stage II-IV underwent PCI and were identified as non-CHIP carriers by gene targeted sequencing."
62111893|NCT06156319||Group 2|CHIP group: Patients diagnosed with AMI combined with ESRD underwent PCI and were identified as CHIP carriers by gene targeted sequencing Non-chip group: Patients diagnosed with AMI combined with ESRD underwent PCI and were identified as non-CHIP carriers by gene targeted sequencing
62111894|NCT02605434|EXPERIMENTAL|AP-CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d and Placebo IR Carbidopa/ levodopa
62111895|NCT02605434|ACTIVE_COMPARATOR|SINEMET®|IR Carbidopa/ levodopa tablets 25/100 mg at least 4 times a day and placebo AP-CD/LD
62111896|NCT02010619|EXPERIMENTAL|Cognitive behavior therapy|
62111897|NCT02010619|ACTIVE_COMPARATOR|Supportive therapy|
62301747|NCT00606515|ACTIVE_COMPARATOR|B|Paclitaxel
62673390|NCT06122051||GROUP A: no significant underlying lung condition|"No significant Underlying lung condition. An Asthma diagnosis requiring short-acting bronchodilators only will be eligible.~For Dynamic Chest - x-ray and simultaneous Spirometry"
62673391|NCT06122051||GROUP B: People with CF|Diagnosis of Cystic Fibrosis For Dynamic Chest x-ray and simultaneous spirometry. Retrospective review of Dynamic Chest-xray metrics and key clinical markers of CF as recorded by the annual review process
62673392|NCT01363830|EXPERIMENTAL|Two-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for two-weeks following discectomy.
62301748|NCT05213169|EXPERIMENTAL|Apomorphine|"Apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: titration phase from 0 to 4 mg/h (5 days), maintenance phase at 4 mg/h, titration-maintenance phase with possible increase up to 6 mg/h depending on tolerance (18 days).~Domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects 2 days before the initiation of apomorphine and maintained at least 7 days before an optional tapering off in the absence side effects."
62301749|NCT05213169|PLACEBO_COMPARATOR|Isotonic saline|Sodium chloride infusion following the administration procedure described for apomorphine
62301750|NCT04722718|EXPERIMENTAL|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Drug:Sintilimab;Drug:Apatinib;Drug:Albumin-Bound Paclitaxel(Nab-Paclitaxel);Drug:Carboplatin
62301751|NCT05928143|ACTIVE_COMPARATOR|Traditional corticotomy|In this group, the acceleration procedure will be performed by elevating flaps and doing the surgical intervention directly using surgical burs.
62301752|NCT05928143|EXPERIMENTAL|Flapless corticotomy|In this group, the acceleration procedure will be performed without elevating flaps, and the surgical intervention will be performed using a special device.
62301753|NCT01288183|SHAM_COMPARATOR|sham tDCS|sham transcranial direct current stimulation The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region
62301754|NCT01288183|ACTIVE_COMPARATOR|active tDCS|active anodal tDCS over the right dorsolateral prefrontal cortex The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region Intensity of the stimulation: 2 mA Duration of the stimulation: 20 min 10 sessions, 2 per day
62301755|NCT06489418|EXPERIMENTAL|Dry and Sensitive Skin|"Wash the face with the gentle cleanser to remove dirt, and oil and pat dry with the towel\| tissue paper. Afterwards take the pea side amount of the test product you finger tips, apply it over the face by small dotes and massage it in circular motion until it absorbed."
62301756|NCT06489418|NO_INTERVENTION|Control|"Wash the application site with warm water and pat dry with towel\| tissue paper."
62673393|NCT01363830|ACTIVE_COMPARATOR|Six-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for six-weeks following discectomy.
62673394|NCT04455295|EXPERIMENTAL|Active Stimulation 0.5|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
62673395|NCT04455295|PLACEBO_COMPARATOR|Lobe Control|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the earlobe. Stimulation 30 second on/30 seconds off for five cycles.
62301757|NCT01029561|ACTIVE_COMPARATOR|CPAP and diet|The patients with severe OSA (AHI\>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
62301758|NCT01029561|ACTIVE_COMPARATOR|Diet|The diet arm wil receive the Conventional diet treatment that usually receive the patients included in the Bariatric Surgery Program
62301759|NCT00454233|EXPERIMENTAL|1|Dose 1
62301760|NCT00454233|EXPERIMENTAL|2|Dose 2
62301761|NCT00454233|EXPERIMENTAL|3|Dose 3
62301762|NCT00454233|EXPERIMENTAL|4|Dose 4
62301763|NCT00454233|ACTIVE_COMPARATOR|5|
62301764|NCT00454233|PLACEBO_COMPARATOR|6|
62301765|NCT02256358|ACTIVE_COMPARATOR|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
62301766|NCT02256358|EXPERIMENTAL|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
62301767|NCT04987203|EXPERIMENTAL|Tivozanib in Combination with Nivolumab|Subjects with advanced RCC will receive 0.89 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment \[for nivolumab\] whichever occurs first.
62301768|NCT04987203|EXPERIMENTAL|Tivozanib|Subjects with advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.
62301769|NCT02957773|EXPERIMENTAL|Qigong and art activities|An integrated group of Qigong and art activities for 90 minutes.
62301770|NCT02957773|EXPERIMENTAL|Art activities|Art activities and daily activities group for 90 minutes.
62301771|NCT02957773|EXPERIMENTAL|Qigong|A Qigong and daily activities group for 90 minutes
62301772|NCT02957773|OTHER|Daily activities|A daily activities group for 90-minutes.
62301773|NCT05712824|EXPERIMENTAL|V-LAP™ System|Heart failure subjects - Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home and will be trained on the use of the device for self-management.
62301774|NCT04036617|EXPERIMENTAL|NaQuinate|Initial SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150 mg
62673396|NCT04455295|PLACEBO_COMPARATOR|Sham Stimulation|0.5mA, 5Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
62673397|NCT04455295|PLACEBO_COMPARATOR|Nonstimulation|Placement of electrode without any stimulation.
62673398|NCT05032105|EXPERIMENTAL|Intervention|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
62673399|NCT01795937|EXPERIMENTAL|Part 1: Faldaprevir + Itraconazole|Interaction of Faldaprevir and Itraconazole
62673400|NCT01795937|EXPERIMENTAL|Part 2:Faldaprevir+Rosuvastatin+Atorvast|Interaction of Faldaprevir, Rosuvastatin and Atorvastatin
62673401|NCT06291207|EXPERIMENTAL|AD-224A|AD-224A+Placebo of AD-224B+Placebo of AD-224C
62673402|NCT06291207|EXPERIMENTAL|AD-224B|Placebo of AD-224A+AD-224B+Placebo of AD-224C
62301775|NCT04036617|EXPERIMENTAL|Placebo|Initial SAD cohorts will receive 1 placebo dose between 10-150 mg . MAD cohorts will receive 7 days placebo dosing between 70-150 mg
62673403|NCT06291207|ACTIVE_COMPARATOR|AD-224C|Placebo of AD-224A+Placebo of AD-224B+AD-224C
62673404|NCT01572688|EXPERIMENTAL|autologous stem cell transplant|
62673405|NCT03318055||Single group study|"The study population will include patients presenting for elective surgery, who fulfil the inclusion criteria of all surgical disciplines undergoing elective surgery period during the period of the study.~Inclusion Criteria:~\> 18 years of age Non-cardiac patients Non-obstetric patients Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
62673406|NCT01829165|EXPERIMENTAL|rTMS Treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own fMRI images. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
62673407|NCT01829165|SHAM_COMPARATOR|Sham Treatment|"rTMS will be delivered for 20 sessions over 4 weeks. Placebo 10Hz rTMS will be delivered through sham stimulation electrodes. The rTMS coil will be positioned using neuro-navigation based on participants' own fMRI images, mimicking active rTMS treatment. Daily treatment regiments will last 36.5minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sham sessions for adverse events and/or side effects.~Upon completing the sham 20 sessions participants are unblinded and offered 20 further treatments of guaranteed open-label treatment. The open-label treatment would follow the active rTMS treatment protocol."
62673408|NCT00003474|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62673409|NCT00709345|EXPERIMENTAL|Group Home|Participants will receive cognitive behavioral sessions.
62673410|NCT00709345|ACTIVE_COMPARATOR|Control|Participants will receive time-matched attention control sessions.
62673411|NCT05901831|EXPERIMENTAL|Finerenone arm|Participants with eGFR ≥25 to \<60 mL/min/1.73 m\^2 at Screening visit will take Finerenone Dose A. Participants with eGFR ≥60 mL/min/1.73 m\^2 at Screening visit will take Dose B. Up-titration and down-titration of study intervention will be based on local potassium and kidney function (eGFR) values. Treatment duration is 6 months.
62673412|NCT05901831|PLACEBO_COMPARATOR|Placebo arm|Participants will take Finerenone matching placebo for 6 months.
62673413|NCT00003501|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62673414|NCT04875273|NO_INTERVENTION|Pre: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
62111898|NCT00696618|EXPERIMENTAL|A|Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home(Stage 2), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
62111899|NCT00696618|EXPERIMENTAL|B|Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
62111900|NCT00696618|EXPERIMENTAL|C|Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Normosol-R enema(iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
62301776|NCT03004560|ACTIVE_COMPARATOR|Standard Laparoscopic Approach|Minimally invasive laparoscopic procedure with 5-10 mm incisions.
62111901|NCT02370563|EXPERIMENTAL|Arm 1|18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
62111902|NCT01559519|ACTIVE_COMPARATOR|albumin|cirrhotic patients who underwent tips placement
62111903|NCT06031194||Observational|Participants undergo blood sample collection and have their medical records reviewed on study.
62111904|NCT05738226|EXPERIMENTAL|EpiCare@Home|Patients with a history or suspicion of focal onset epilepsy admitted to the EMU for routine observation will be able to opt-in to using EpiCare@Home during their admission. Optionally, they will be able to continue using the device at home after EMU discharge.
62301777|NCT03004560|ACTIVE_COMPARATOR|Percutaneous Approach|Minimally invasive laparoscopic procedure with 2-3 mm incisions.
62301778|NCT01408238|EXPERIMENTAL|1|"* Secale cereale allergen extract at 4 different concentrations~* Positive control~* Negative control"
62301779|NCT01242111|EXPERIMENTAL|BMN 110|
62301780|NCT03010189|EXPERIMENTAL|Patient|Cluster headache patients are examined with light reflex pupillometry, two weeks actigraphy and heart-rate variability monitoring both in headache phase and remission phase.
62301781|NCT03010189|ACTIVE_COMPARATOR|Controls|Healthy controls undergo the same examinations once: light reflex pupillometry, actigraphy and heart-rate variability monitoring.
62301782|NCT06143410|ACTIVE_COMPARATOR|Linisol|Patients will receive 1.5 mg/kg of intravenous linisol before propofol sedatation and gastroscope introduction
62301783|NCT06143410|PLACEBO_COMPARATOR|Control|Patients will receive intravenous placebo (saline solution),before propofol sedation and gastroscope introduction
62301784|NCT01616914||delirium group|patients with delirium during ICU stay
62301785|NCT01616914||non-delirium group|patients without delirium during ICU stay
62111905|NCT04183530||SCOPD|Participants with stable COPD diagnosed according to GOLD criteria and hasn't encountered acute exacerbations in the past six months, generally include outpatient clinical patient and community patients.
62111906|NCT04183530||AECOPD|Participants with COPD diagnosed according to GOLD criteria and suffered from acute exacerbations, characterized by worsening clinical symptoms(such as acute worsening of dyspnea, and/or cough and sputum production, and/or increased sputum purulence) and positive laboratory biomarkers suggesting AECOPD (such as serum CRP and serum neutrophilia or eosinophilia) at the time of registering into the group, particularly include inpatient.
62301786|NCT04113629|OTHER|Sofosbuvir/Daclatasvir|standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir
62301787|NCT02085655|EXPERIMENTAL|PEG-ASP+Gemox regimen group|PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21
62301788|NCT02085655|ACTIVE_COMPARATOR|AspaMetDex regimen group|Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD
62301789|NCT03941444|EXPERIMENTAL|Active arm|ANAVEX2-73 liquid oral solution
62301790|NCT03941444|PLACEBO_COMPARATOR|Placebo arm|Placebo liquid oral solution
62301791|NCT01275638|PLACEBO_COMPARATOR|Prednisolone (20 mg/day) for 10 days.|
62301792|NCT00195351|ACTIVE_COMPARATOR|A|
62301793|NCT00195351|ACTIVE_COMPARATOR|B|
62301794|NCT06178640|EXPERIMENTAL|Simvastatin 40 mg, Then ZOCOR 40 mg|Participants first received Simvastatin 40 mg film-coated tablet 1 tablet (Test product) in a fasting state. After a washout period of 1 week, they then recieved ZOCOR 40 mg film-coated tablet (Reference product) in a fasting state
62673415|NCT04875273|NO_INTERVENTION|Pre: pain assessment in the spinous processes of the spine with 2 kg|press on the spinous processes with the algometer perpendicularly.
62673416|NCT04875273|NO_INTERVENTION|Pre: pain assessment in the spinous processes of the spine with 3 kg|press on the spinous processes with the algometer perpendicularly.
62673417|NCT04875273|NO_INTERVENTION|Pre: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
62111907|NCT04183530||Smoking healthy controls|Participants with a smoking history of more than ten years and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
62111908|NCT04183530||Non smoking healthy controls|Participants without a smoking history and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
62111909|NCT02905968|EXPERIMENTAL|TTPLAR|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
62111910|NCT02905968|NO_INTERVENTION|NORLAR|Tranditional low anterior resection without transanual tube placement or ileostomy.
62301795|NCT06178640|ACTIVE_COMPARATOR|ZOCOR 40 mg, Then Simvastatin 40 mg|Participants first received ZOCOR 40 mg film-coated tablet 1 tablet (Reference product) in a fasting state. After a washout period of 1 week, they then recieved Simvastatin 40 mg film-coated tablet (Test product) in a fasting state.
62301796|NCT04287153|EXPERIMENTAL|Croytherapy on abdomen and saddlebags|Six (6) to 10 applicators (application area of 17 cm X 6 cm) are applied on the dorsal side (back, waist, saddlebags) for 45 minutes and then on the ventral side (belly) for 45 minutes, with adjustments according to the size of the participant. The temperature applied with the device is variable (-10°c to -7°C).
62111911|NCT02148133|EXPERIMENTAL|Eltrombopag|Subjects were assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment was done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).
62111912|NCT04355702||Lupus patients treated by hydroxychloroquine|Lupus patients treated by hydroxychloroquine
62111913|NCT04355702||Lupus patients not treated by hydroxychloroquine|Lupus patients not treated by hydroxychloroquine
62111914|NCT00906035|ACTIVE_COMPARATOR|Dipyridamole 200mg and Aspirin 25mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
62111915|NCT00906035|ACTIVE_COMPARATOR|Dipyridamole 200 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
62301797|NCT03545243|OTHER|Pantoprazole 40mg in healthy volunteers|Peroral Pantoprazole 40mg once daily for 4 weeks
62301798|NCT03545243|OTHER|Pantoprazole 40mg in functional dyspepsia|Peroral Pantoprazole 40mg once daily for 4 weeks
62301799|NCT03545243|OTHER|PPI-withdrawal in functional dyspepsia|no PPI for 8 weeks
62301800|NCT03729180|OTHER|Pain Cohort|Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.
62301801|NCT03729180|EXPERIMENTAL|Pharmacogenomic (PGx) Arm [Randomization Arm 1]|All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.
62673418|NCT04875273|EXPERIMENTAL|Post Exp: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
62673419|NCT04875273|EXPERIMENTAL|Post Exp: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
62673420|NCT04875273|EXPERIMENTAL|Post Exp: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
62673421|NCT04875273|EXPERIMENTAL|Post Exp: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
62673422|NCT04875273|PLACEBO_COMPARATOR|Post Pla: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
62673423|NCT04875273|PLACEBO_COMPARATOR|Post Pla: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
62673424|NCT04875273|PLACEBO_COMPARATOR|Post Pla: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
62111916|NCT00906035|ACTIVE_COMPARATOR|Aspirin 25 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.
62111917|NCT02716649||All participants|No intervention
62111918|NCT01260298||MC1 Ultrasonic Device|
62111919|NCT00128193|EXPERIMENTAL|A1-Ramping (MLSA-LAM)|5 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
62111920|NCT00128193|EXPERIMENTAL|C1-Target Population|80 subjects to receive: 1.0 mcg of MLSA-LAM, 1.0 mcg of MLCwA and 2TU Purified Protein Derivative/RT-23.
62111921|NCT00128193|EXPERIMENTAL|C-1b-Target Population (Low Dose)|80 subjects to receive: 0.1 mcg MLSA-LAM, 0.1 mcg MLCwA, 2 TU Purified Protein Derivative/RT-23.
62111922|NCT00128193|EXPERIMENTAL|B2-Full-Scale (MLCwA)|45 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
62111923|NCT00128193|EXPERIMENTAL|B1-Full-Scale (MLSA-LAM)|45 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
62301802|NCT03729180|OTHER|Control Arm [Randomization Arm 2]|All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
62301803|NCT06246682|OTHER|cholesteatoma removal by otoendoscope|removal of the cholesteatoma in atticoantral region by otoendoscope
62301804|NCT02849769||Patients implanted with an MR-conditional Tachy device system|Patients implanted with an MR-conditional Tachy device system in the routine care
62301805|NCT04881539|EXPERIMENTAL|Cannabidiol (CBD)|Each group member will receive one dose of CBD daily for 8 weeks.
62301806|NCT04881539|PLACEBO_COMPARATOR|Placebo|Each group member will receive a calorie matched placebo daily for 8 weeks.
62301807|NCT04034615|EXPERIMENTAL|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
62301808|NCT04034615|EXPERIMENTAL|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
62301809|NCT04034615|PLACEBO_COMPARATOR|Placebo|Placebo without Mesenchyme Stem Cells
62301810|NCT03999970|ACTIVE_COMPARATOR|Phlebotomus papatasi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus papatasi fed on blood twice in the laboratory prior to human exposure.
62471014|NCT05910853||Fanconi Anemia (c3558-3559 insertion of G)|"Cohort 4 - Fanconi Anemia (c3558-3559 insertion of G) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c3558-3559 insertion of G~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
62111924|NCT00128193|EXPERIMENTAL|A2-Ramping (MLCwA)|5 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
62673425|NCT04875273|PLACEBO_COMPARATOR|Post Pla: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
62673426|NCT04875273|NO_INTERVENTION|Pre: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
62673427|NCT04875273|PLACEBO_COMPARATOR|Post Pla: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
62111925|NCT02135172|EXPERIMENTAL|Sitting|During the sitting treatment condition, walking and standing will be restricted. Participants will be in a designated room with access to a computer, books/magazines throughout the day. Participants will have a cannula fitted and the first of the half-hourly blood samples will be taken (time point: -1hr). Participants will then be asked to sit quietly for 60 minutes to achieve a steady state. Following this, participants will have another blood sample taken and then be provided with a standardised mixed meal breakfast (09:00am) (time point: 0h). Blood sampling will continue at 30 minutes intervals for 3 hours following breakfast. A second, lunch meal (12:00pm), will be then be consumed over 15 minutes. Blood sampling will then continue at 30 minute intervals for 3 hours following lunch.
62111926|NCT02135172|EXPERIMENTAL|Standing|This is the same as the sitting condition, but participants will be asked to break their sitting time by standing close to their chair for 5 minutes, after 15 and 45 minutes of each hour following breakfast. The standing protocol will be repeated after lunch. Individuals will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
62111927|NCT02135172|EXPERIMENTAL|Walking|This is identical to the standing condition, but the breaks in sitting time will be punctuated with 5 minute bouts of light-intensity treadmill walking (equivalent to around 4.0km•h-1) rather than standing. In total, individuals will accumulate 12 bouts (60 minutes) of light-intensity activity throughout the test period. The light-intensity walking activity undertaken here replicates the low-grade ambulatory activity associated with everyday life.
62111928|NCT04008394|EXPERIMENTAL|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
62111929|NCT02914522|EXPERIMENTAL|Induction Study (Cohort A): Filgotinib 200 mg|Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.
62111930|NCT02914522|EXPERIMENTAL|Induction Study (Cohort A): Filgotinib 100 mg|Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
62111931|NCT02914522|PLACEBO_COMPARATOR|Induction Study (Cohort A): Placebo|Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
62111932|NCT02914522|EXPERIMENTAL|Induction Study (Cohort B): Filgotinib 200 mg|Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
62111933|NCT02914522|EXPERIMENTAL|Induction Study (Cohort B): Filgotinib 100 mg|Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
62111934|NCT02914522|PLACEBO_COMPARATOR|Induction Study (Cohort B): Placebo|Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
62111935|NCT02914522|EXPERIMENTAL|Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).
62111936|NCT02914522|PLACEBO_COMPARATOR|Maintenance Study: Placebo From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
62673428|NCT04875273|EXPERIMENTAL|Post Exp: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
62673429|NCT04875273|NO_INTERVENTION|Pre: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
61916723|NCT00645788|EXPERIMENTAL|48.75 mg Ciprofloxacin DPI (BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
62111937|NCT02914522|EXPERIMENTAL|Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).
62673430|NCT04875273|PLACEBO_COMPARATOR|Post Pla: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
62673431|NCT04875273|EXPERIMENTAL|Post Exp: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
62673432|NCT04082676|EXPERIMENTAL|Height and weight based group|"Patients in Height and weight based group will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)"
62673433|NCT04082676|ACTIVE_COMPARATOR|Height based group|"Patients in Height based group will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)"
62673434|NCT05062369|EXPERIMENTAL|Participants receiving active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of active transcranial direct current stimulation (tDCS) to dorsolateral prefrontal cortex (DLPFC) while in the Lodging Plus treatment program and then 5 remote sessions of active tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
62673435|NCT05062369|SHAM_COMPARATOR|Participants receiving active and sham active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of sham-tDCS sessions while in the Lodging Plus treatment program and then 5 remote sessions of active-tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
62673436|NCT03587103|EXPERIMENTAL|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
62673437|NCT03587103|EXPERIMENTAL|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
62673438|NCT03587103|EXPERIMENTAL|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
62111938|NCT02914522|PLACEBO_COMPARATOR|Maintenance Study: Placebo From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
62673439|NCT04090749|EXPERIMENTAL|Open Label Group|In this arm, 5 participants will be enrolled in the intervention without blinding or randomization. The intervention and study delivery will be improved based on findings from this arm.
62673440|NCT04090749|OTHER|Waitlist Control|The waitlist control group (n=20) will be provided written materials with community resources for caregivers during the first 16 weeks, then the intervention will begin.
62673441|NCT04090749|EXPERIMENTAL|Immediate Intervention|The immediate intervention group (n=20) will receive the intervention during weeks 0-16. There will be assessment at week 32 to examine maintenance on primary and secondary outcomes.
62673442|NCT00655746|EXPERIMENTAL|1|
62111939|NCT02914522|PLACEBO_COMPARATOR|Maintenance Study: Placebo From Induction Placebo|Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).
62111940|NCT03857334|EXPERIMENTAL|Arm A|
62111941|NCT03857334|ACTIVE_COMPARATOR|Arm B|
62111942|NCT05028712|EXPERIMENTAL|Visual Information Training|
62111943|NCT05028712|EXPERIMENTAL|Multimodal Training|
62111944|NCT05566587|OTHER|Western to Mediteranean to Western Diet|Weeks 2 and 3 = WD Weeks 4 and 5 = MD Weeks 6 and 7 = WD
62111945|NCT05566587|OTHER|Mediteranean to Western to Mediteranean Diet|Weeks 2 and 3 = MD Weeks 4 and 5 = WD Weeks 6 and 7 = MD
62673443|NCT00754559|EXPERIMENTAL|Tocilizumab|
62673444|NCT00720811|EXPERIMENTAL|ACT, antibiotic, paracetamol|CHWs will test children with acute febrile illness for malaria using RDTs, and for pneumonia by counting their respiratory rate with RRTs. Treatment will then be provided on the basis of the test results, in line with national guidelines. Children with a positive RDT will receive artemether-lumefantrine in Burkina Faso and Uganda, and artesunate-amodiaquine in Ghana. Children with a cough and a high respiratory rate will receive amoxicillin in Ghana and Uganda, and cotrimoxazole in Burkina Faso. Additionally, paracetamol (PCT) will be provided to all children with an axillary temperature \> 38.5°C.
62673445|NCT00720811|NO_INTERVENTION|Presumptive fever management|Presumptive treatment of malaria with ACTs. No antibiotic treatment available
62111946|NCT00105794|OTHER|Arm 1|
62111947|NCT00385801|PLACEBO_COMPARATOR|Placebo|Identical placebo tablets and injections
62111948|NCT00385801|ACTIVE_COMPARATOR|risperidone consta|Risperidone 1-2 mg tablets and Risperidone 25 mg injections
62111949|NCT06426303|EXPERIMENTAL|Alcohol Use Disorder (AUD)|"Drug: Naltrexone Half of the study participants with AUD will take an oral tablet of 50 mg naltrexone once daily for one week followed by 11 weeks of 100 mg naltrexone orally, once daily.~Drug: Placebo oral tablet The other half of study participants will receive an identical looking placebo in tablet form and take the medication using an identical schedule as the real drug.~Drug type will be randomized."
61916724|NCT00645788|PLACEBO_COMPARATOR|Matching Placebo for 32.50 mg|Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days
62111950|NCT06426303|NO_INTERVENTION|Healthy Controls|Baseline measures will be taken but controls will not continue to the drug trial.
62111951|NCT00829855||1|Patients with hypertensive (systolic blood pressure ≥160 mmHg) acute pulmonary edema, evaluated within 120 minutes after admittance.
62111952|NCT00829855||2|The same patients from group 1 followed-up at 48 to 96 hours.
62111953|NCT01210157||I Ischemic CMP|Patients with impaired ventricular function caused by coronary artery disease.
62471015|NCT05910853||Fanconi Anemia (c1115_1118delTTGG)|"Cohort 5 - Fanconi Anemia (c1115_1118delTTGG) (N=1):~Inclusion:~1. The participant is willing and able to provide written informed consent~2. The participant is willing and able to provide appropriate photo identification~3. Participants aged 18 to 85~4. Participants have been diagnosed with Fanconi Anemia complementation group A~5. 1 participant must be diagnosed with the following genotype: c1115_1118delTTGG~Exclusion:~1. Participants who are pregnant or are nursing~2. Participants with a known history of HIV, hepatitis, or other infectious diseases~3. Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
62471016|NCT02282189|OTHER|Off/on for 4 weeks followed by on/off for 4 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device or no device for four weeks, then crossover for the following four weeks.
62471017|NCT01136382|EXPERIMENTAL|1|Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
62673446|NCT04419142|EXPERIMENTAL|Total infrapatellar fat pad excision group|Infrapatellar fat pad was totally excised during total knee arthroplasty in patients randomized to this group.
62673447|NCT04419142|EXPERIMENTAL|Partial infrapatellar fat pad excision group|Infrapatellar fat pad was partially excised during total knee arthroplasty in patients randomized to this group.
62673448|NCT05369156|EXPERIMENTAL|Chiropractic care Group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor with at least five years of clinical experience.The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints. Chiropractors use these biomechanical characteristics as clinical indicators of spinal dysfunction and vertebral subluxation.
62111954|NCT01210157||II CMP|Patients with impaired ventricular function which is not caused by coronary artery disease. Subgroups based on etiology (familial cardiomyopathy, toxic cardiomyopathy, etc.)
62111955|NCT05395949|EXPERIMENTAL|Steroid combined with methotrexate|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
62111956|NCT05395949|NO_INTERVENTION|Extensive lesion excision|Patients in the control group underwent wide local excision, make sure the margin is negative. Irrigation and mammoplasty were performed in the same way as in the observation group.
62111957|NCT03646331|EXPERIMENTAL|Tablet A in Session 1 and Tablet B in Session 2|Tablet A = reference product Tablet B = test product
62673449|NCT05369156|PLACEBO_COMPARATOR|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The control intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust. No spinal adjustment will be performed during any control intervention. This control intervention is not intended to act as a sham treatment session
62111958|NCT03646331|EXPERIMENTAL|Tablet B in Session 1 and Tablet A in Session 2|Tablet A = reference product Tablet B = test product
62111959|NCT01336283|ACTIVE_COMPARATOR|COPD with emphysema|Analyze what type of training is more appropriate and beneficial as the patient characteristics that apply to you.
62111960|NCT01336283|ACTIVE_COMPARATOR|COPD non-emphysema|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
62111961|NCT05621811|EXPERIMENTAL|Naronapride 10 mg|
62111962|NCT05621811|EXPERIMENTAL|Naronapride 20 mg|
62111963|NCT05621811|EXPERIMENTAL|Naronapride 40 mg|
62111964|NCT05621811|PLACEBO_COMPARATOR|Placebo|
62673450|NCT01623284|EXPERIMENTAL|PiB and FDG positron emission tomography (PET)|All subjects will receive PiB and FDG PET diagnosis on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
62111965|NCT02411942|EXPERIMENTAL|Adapalene Gel 0.3%|Adapalene Gel 0.3% (Taro Pharmaceuticals Inc.)
62111966|NCT02411942|ACTIVE_COMPARATOR|Differin®|Differin® (adapalene gel 0.3%) (Galderma Laboratories, LP, US)
62471018|NCT01136382|PLACEBO_COMPARATOR|2|Placebo pMDI 2 inhalations bid
62471019|NCT03292328|EXPERIMENTAL|Yoga Arm|After randomization, participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
62673451|NCT02563210|EXPERIMENTAL|airway resistance measurement|interruption and plethysmography techniques airway resistance measurement at each routine visit
62111967|NCT02411942|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
62111968|NCT04392713|ACTIVE_COMPARATOR|Ivermectin arm|Participants will be administered Ivermectin with standard chloroquine regimen
62111969|NCT04392713|NO_INTERVENTION|Control arm|This arm will only receive chloroquine as per existing policy of hospital
62111970|NCT04618458|EXPERIMENTAL|Intervention Arm|Eligible overweight/obese children and their overweight/obese parent (N=20 families) will receive the same telehealth diabetes prevention intervention based on Power to Prevent and delivered by a trained lifestyle coach. Families will meet weekly for 11-weeks (60-min sessions), and then monthly (60-min sessions) for 4 pilot behavioral reinforcement maintenance sessions (15 sessions total). Participants will meet in their respective groups (n=5 families per group) via videoconference using Wi-Fi-enabled tablets with cellular connectivity for the entire intervention. Sessions will consist of nutrition and physical activity behavior change strategies (20 min), problem solving and decision-making skills to circumvent barriers to behavioral change (20 min), and family goal setting and action planning (20 min). Assessment measures will be collected from the child and parent participants at baseline, 12-weeks (post-intervention), and 30-weeks (follow-up).
62111971|NCT02039713||IRIS DeSyne|DeSyne drug eluting stent group
62111972|NCT02709343|EXPERIMENTAL|Bone-marrow derived MSCs|4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks
62111973|NCT02709343|PLACEBO_COMPARATOR|Placebo|Placebo product manufactured to look like MSCs
62301811|NCT03999970|ACTIVE_COMPARATOR|Phlebotomus duboscqi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus duboscqi fed on blood twice in the laboratory prior to human exposure.
62471020|NCT03292328|ACTIVE_COMPARATOR|Wait List Control Arm (WLC)|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these participants will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
62673452|NCT05446155||Patients with a suspected primary melanoma or equivocal pigmented skin tumour|Patients, 18 years or older, in dermatological outpatient routine care in Helsingborg, Lund or Malmö Hospitals. Patients are planned for surgical excision for an equivocal pigmented skin lesion that could be a primary melanoma or a differential diagnosis of melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour/normal skin biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.
62673453|NCT05446155||Patients with secondary melanoma (metastatic disease)|Patients, 18 years or older, in surgical or oncological routine care in Helsingborg, Lund, Malmö or Kristianstad Hospitals. Patients are planned for surgical excision or cytological diagnostics (needle aspiration) of metastatic melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.
62673454|NCT01526746|EXPERIMENTAL|End Stage Renal Disease, dialysis|eGFR \<15 ml/min/1.73m\^2
62111974|NCT04008836|EXPERIMENTAL|Untrained Subjects WITH Diabetes use the T-PLUS BGMS|Untrained subjects WITH Diabetes test capillary fingerstick and palm blood (and study staff test subject fingerstick blood) using the T-PLUS BGMS. All blood glucose results are compared to reference method results. Also, study staff test subject's venous blood and the blood glucose results are compared to the reference method results.
62111975|NCT03659201|EXPERIMENTAL|Neosil complete|"The patient will take the tablets, as follow:~3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and~2 tablets of Neosil Oral, per day - during the last 12 weeks."
62111976|NCT03659201|EXPERIMENTAL|Pantogar|"The patient wil take the tablets, as follow:~3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and~3 tablets of Pantogar, Oral, per day - during the last 12 weeks."
62111977|NCT03659201|EXPERIMENTAL|Neosil|"The patient will take the tablets, as follow:~2 tablets of Neosil Oral, per day - during the 12 weeks."
62111978|NCT04138771|EXPERIMENTAL|Eligible patients for AI test|Device: an artificial intelligence system for postoperative management of cataract patients. These patients are enrolled in primary healthcare units and the AI clinic at Zhongshan Ophthalmic Center.
62111979|NCT01320072||Aspirin-sensitive asthmatics|asthma patients with aspirin allergy
62301812|NCT03368859|EXPERIMENTAL|ABT-165 plus FOLFIRI|ABT-165 plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
62301813|NCT03368859|ACTIVE_COMPARATOR|Bevacizumab plus FOLFIRI|Bevacizumab plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
62301814|NCT04143503||adult critically ill patients|
62301815|NCT01123889|ACTIVE_COMPARATOR|control|corticosteroid injection into subacromial space
62301816|NCT01123889|EXPERIMENTAL|experimental|patients will receive an injection of platelet rich plasma into the subacromial space
62111980|NCT01320072||aspirin-tolerant asthmatics|asthma patients without aspirin allergy
62301817|NCT04515836|EXPERIMENTAL|Treatment Arm|Olaparib will be given orally to patients in 28-day cycles. Patients will attend the clinic on days 1 (first day of treatment) and 15 of the first cycle following the beginning of study treatment and then every 4 weeks (day 1 of every cycle) until discontinuation of treatment.
62301818|NCT02333708||GCA group|
62673455|NCT01526746|EXPERIMENTAL|Severe renal impairment|eGFR \< 29 ml/min/1.73m\^2
62673456|NCT01526746|EXPERIMENTAL|Healthy controls|eGFR \> 80 mL/min/1.73m\^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
62111981|NCT05817318|OTHER|Pre-to-post renal denervation treatment|Pre-to-post treatment comparison
62111982|NCT04137874|EXPERIMENTAL|eSTROKE|
62111983|NCT04137874|ACTIVE_COMPARATOR|Control|Conventional prehospital care
62111984|NCT01591616|OTHER|Oraqix for tooth extraction|
62111985|NCT04867018||Orthopaedic Trauma, Pediatrics and Joint Patients|Patients will have an additional 9ml of blood drawn during their normal course of care for this study up to 4 times. Intraoperatively, we will request a tissue sample of the debrided injured muscle from the area where the surgeon is operating. There will be no additional tissue sample taken during the surgery, but what is removed in the normal course of the operation will be used for analysis in our study.
62301819|NCT02333708||Inflammatory syndrome (without GCA) group|
62301820|NCT02333708||Without inflammatory syndrome and without GCA group|
62301821|NCT03853694|ACTIVE_COMPARATOR|Group 1 (Standard of Care Group)|150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
62301822|NCT03853694|EXPERIMENTAL|Group 2 (Duramorph + EXPAREL TAP)|50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
62301823|NCT03853694|EXPERIMENTAL|Group 3 (EXPAREL TAP)|EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.
62301824|NCT06236217|NO_INTERVENTION|Control group|Patients received standard of care with no intervention before spinal anesthesia.
62301825|NCT06236217|EXPERIMENTAL|Carotid Ultrasound group|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
62301826|NCT06236217|EXPERIMENTAL|Electrical cardiometry group|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
62471021|NCT00449592|EXPERIMENTAL|1|Oral zinc therapy, intervention
62471022|NCT00449592|PLACEBO_COMPARATOR|2|oral placebo
61916725|NCT00645788|PLACEBO_COMPARATOR|Matching Placebo for 48.75 mg|Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days
61916726|NCT01348971|EXPERIMENTAL|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
61916727|NCT01348971|PLACEBO_COMPARATOR|Placebo|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
62111986|NCT04867018||Healthy Volunteer|Blood will be taken from healthy, nonpregnant adults who weigh at least 110 pounds. All volunteers will have a single blood draw of 100ml at the time of consent.
62111987|NCT00038103|ACTIVE_COMPARATOR|1.|
62673457|NCT01745302||TCM plus EGFR-TKIs|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day, six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day ，until progression or unacceptable toxicity;
62673458|NCT01745302||Placebo plus EGFR-TKIs|TCM Placebo:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day ,six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day until progression or unacceptable toxicity;
62301827|NCT04557904|EXPERIMENTAL|Group A: Craniocervical flexion exercises|Exercise protocol were performed over a 4 week duration under the command of a supervisor. Subjects were asked not to obtain any other particular intervention for cervical ache. Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible.
62301828|NCT04557904|EXPERIMENTAL|Group B: Scapular stabilization exercises|Group B performed scapular stabilization workout for 30 minutes per session, three days a week for four weeks. The scapular stabilization exercises were made up of four stages
62301829|NCT05480514|EXPERIMENTAL|TEST/CONTROL|Eligible subjects will be randomized to the wear sequence (TEST/CONTROL) to wear the study lenses during each dispensing period (5 to 7 days) with a wash-out period (2 to 5 days) between wears.
62301830|NCT05480514|EXPERIMENTAL|CONTROL/TEST|Eligible subjects will be randomized to the wear sequence (CONTROL/TEST) to wear the study lenses during each dispensing period (5 to 7 days) with a wash-out period (2 to 5 days) between wears.
62301831|NCT00903084|ACTIVE_COMPARATOR|1|Participants will receive 7 doses per week, then 4 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
62111988|NCT00038103|EXPERIMENTAL|2.|
62111989|NCT05861388|ACTIVE_COMPARATOR|cobalt chrome implant framework|the participants received Co-Cr based screw-retained implant supported prosthesis at one side of the lower jaw
62673459|NCT01132690|EXPERIMENTAL|30 units/kg|
62673460|NCT01132690|EXPERIMENTAL|60 units/kg|
61916728|NCT00918112||Parkinson's Disease|Meets criteria for definite Parkinson's Disease
61916729|NCT00918112||Healthy Controls|- Must be in good health
61916730|NCT03096015|EXPERIMENTAL|Intensive Treatment for Aphasia|
61916731|NCT04009083|OTHER|Standard of Care|
61916732|NCT04009083|EXPERIMENTAL|18F-Fluciclovine PET Scan|
61916733|NCT01586273|EXPERIMENTAL|MR-HIFU treatment|Subjects undergo a MR-HIFU treatment for pain palliation of bone metastases on their most painful metastasis.
61916734|NCT03446261|EXPERIMENTAL|Rosuvamibe® Tab|Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
61916735|NCT03446261|ACTIVE_COMPARATOR|Monorova® Tab|Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks
61916736|NCT04706416|EXPERIMENTAL|N-Acetyl Glucosamine|All patients in the treatment arm of the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
62111990|NCT05861388|EXPERIMENTAL|Bio-Hpp implant framework|The participants received Bio-Hpp based screw-retained implant-supported prosthesis at the other side
62111991|NCT04726813|EXPERIMENTAL|a self-guided Internet delivered intervention|MinADHD: 7 self-help modules.
62301832|NCT00903084|ACTIVE_COMPARATOR|2|Participants will receive 7 doses per week, then 2 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
62301833|NCT00903084|ACTIVE_COMPARATOR|3|Participants will receive 4 doses per week, then 7 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
62301834|NCT00903084|ACTIVE_COMPARATOR|4|Participants will receive 4 doses per week, then 2 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
62301835|NCT00903084|ACTIVE_COMPARATOR|5|Participants will receive 2 doses per week, then 7 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
62301836|NCT00903084|ACTIVE_COMPARATOR|6|Participants will receive 2 doses per week, then 4 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
62301837|NCT05955742|EXPERIMENTAL|Control|Glide path preparation with hand files.
62301838|NCT05955742|EXPERIMENTAL|ProGlider|Glide path preparation using rotational NiTi file.
62301839|NCT05955742|EXPERIMENTAL|WaveOne Gold Glider|Glide path was preparation using reciprocating NiTi file.
62673461|NCT04026516|EXPERIMENTAL|CAVA Dizziness Trial Arm|All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
62673462|NCT04359680|ACTIVE_COMPARATOR|Nitazoxanide|Two NTZ 300 mg tablets orally twice daily for 6 weeks.
62673463|NCT04359680|PLACEBO_COMPARATOR|Placebo|Two placebo tablets orally twice daily for 6 weeks.
62111992|NCT04726813|PLACEBO_COMPARATOR|Psycho-education|One self-guided psychoeducation module
62111993|NCT06321913|EXPERIMENTAL|IBI343|
62111994|NCT04048304|EXPERIMENTAL|short antibiotic therapy|3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
62111995|NCT04048304|ACTIVE_COMPARATOR|long antibiotic therapy|6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
62111996|NCT01219218|EXPERIMENTAL|A|Treatment group. Patients in this group receive actual shockwave therapy.
62111997|NCT00028093|EXPERIMENTAL|Pefinterferon+Ribavirin|Patients with chronic hepatitis C virus (HCV) infection genotype 1 peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
62111998|NCT00028093|ACTIVE_COMPARATOR|Peginterferon|patients with chronic hepatitis C virus (HCV) infection genotype 1 were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
62111999|NCT01620372||Treatment cohort (chemo/radiotherapy)|- those who have survived at least 5 years from the date of diagnosis
62112000|NCT01620372||Self-questionnaire cohort|- those with a complete address, who come of age, are still alive and sent back a signed consent agreement
62112001|NCT01620372||Medical Insurance cohort|- those who come of age and authorize the access to the medical facilities of the French Health Insurance Information System
62112002|NCT02167646|OTHER|Bilaterally innervated flap|Two nerve branches attached with the flap for sensory reconstruction.
62112003|NCT00099619|EXPERIMENTAL|exenatide/insulin glargine|Arm that first receives exenatide, then crosses over to insulin glargine
62301840|NCT03840629||Hypotonic fluid maintenance|exclusive administration of 0.33% saline mixed with potassium and dextrose 5%
62471023|NCT06013293|EXPERIMENTAL|Zinc oxide eugenol based sealer|Root canal treatment will be performed in posterior teeth.In this group the root canal will be dried with paper points and obturated with using gutta-percha cones and zinc oxide eugenol sealer. Coronal access cavities will be restored with direct composite restorations using dentinal adhesives and universal composite resin . Postoperative VAS scores will be recorded after 24 h and 48 h to determine their post-operative pain.
62112004|NCT00099619|EXPERIMENTAL|Insulin glargine/exenatide|Arm that first receives insulin glargine, then crosses over to exenatide
62112005|NCT02303444||MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
62112006|NCT02303444||non-MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
62112007|NCT01444235|ACTIVE_COMPARATOR|Custodiol|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
62112008|NCT01444235|EXPERIMENTAL|Custodiol-N|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
62112009|NCT02613364|EXPERIMENTAL|Arm I (behavioral intervention-yoga)|Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
62112010|NCT02613364|EXPERIMENTAL|Arm II (cognitive intervention-CBT-I)|Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
62301841|NCT03840629||Isotonic fluid maintenance|exclusive administration of 0.9% saline
62673464|NCT02405208||Primary cohort|Primary cohort will receive the PyroTITAN HRA device
62673465|NCT03555097|EXPERIMENTAL|COPD Group|incremental pressure support
62673466|NCT05575427|EXPERIMENTAL|Combination therapy with minocycline|"Minocycline oral 50 mg per capsule~4 capsules oral stat then 2 capsules oral every 12 hours~duration 7-28 days"
62673467|NCT05575427|ACTIVE_COMPARATOR|Monotherapy plus placebo|Patients were treated Stenotrophomonas maltophilia infection with standard monotherapy either levofloxacin or Trimethoprim/sulfamethoxazole plus placebo
62673468|NCT03341221||One group|Diagnosis of ascites in infants and children by history, examination and investigations
62471024|NCT06013293|ACTIVE_COMPARATOR|Resin based sealer|Root canal treatment will be performed in posterior teeth.In this group the root canal will be dried with paper points and obturated with using gutta-percha cones and resin based sealer. Coronal access cavities will be restored with direct composite restorations using dentinal adhesives and universal composite resin . Postoperative VAS scores will be recorded after 24 h and 48 h to determine their post-operative pain.
62301842|NCT00444184|ACTIVE_COMPARATOR|Travoprost/Timolol therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost/timolol drops
62301843|NCT00444184|ACTIVE_COMPARATOR|Travoprost therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost drops
62301844|NCT04490057|EXPERIMENTAL|12 wks NRT+CM / 12 wks NRT+CM|Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.
62301845|NCT04490057|EXPERIMENTAL|12 wks NRT+CM/ 12 wks VAR or bupropion+CM|Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.
62301846|NCT04490057|EXPERIMENTAL|12 wks NRT+CM/12 wks NRT+CM plus|Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.
62301847|NCT04490057|EXPERIMENTAL|12 wks NRT/ 12 wks NRT|Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.
62301848|NCT04490057|EXPERIMENTAL|12 wks NRT/ 12 wks VAR or bupropion|Nicotine replacement therapy alone. Non-responders switch to varenicline or bupropion alone for second 12 weeks.
62301849|NCT04490057|EXPERIMENTAL|12 wks NRT/ 12 wks NRT+CM|Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.
62673469|NCT02725606|ACTIVE_COMPARATOR|Pegylated Recombinant Human G-CSF|100ug/kg 6 subjects (2 subjects per GW003 cohort)
62673470|NCT02725606|EXPERIMENTAL|GW003 300ug/kg|6-8 subjects
62301850|NCT03067220|OTHER|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
62301851|NCT03067220|EXPERIMENTAL|Virtual out patient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
62301852|NCT02152969|OTHER|Part B|Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
62301853|NCT02152969|OTHER|Part A|Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
62301854|NCT02980614|EXPERIMENTAL|Participants to 4D flow imaging|"In addition to the standard clinical MR protocol, 2 added sequences:~4D MR sequence in cine mode 4D velocity mapping sequence"
62301855|NCT02112110|EXPERIMENTAL|BMS-791325 (oral) and [13C]-BMS-791325 (IV)|BMS-791325 single dose tablet orally and \[13C\]-BMS-791325 single dose solution intravenously on specific days
62471025|NCT01134094|ACTIVE_COMPARATOR|Non-Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
62301856|NCT01468519|EXPERIMENTAL|CSII|continuous subcutaneous insulin infusion
62673471|NCT02725606|EXPERIMENTAL|GW003 650ug/kg|6-8 subjects
62673472|NCT02725606|EXPERIMENTAL|GW003 850ug/kg|6-8 subjects
62673473|NCT04953260|NO_INTERVENTION|GTR group|only conventional GTR technique was used to treat periodontal bone defect,
62673474|NCT04953260|ACTIVE_COMPARATOR|APRF+GTR group|GTR technique combined with APRF was used to treat periodontal bone defect
62673475|NCT04953260|ACTIVE_COMPARATOR|CGF+GTR group|GTR technique combined with CGF was used to treat periodontal bone defect
62673476|NCT02410174|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).
62301857|NCT01468519|ACTIVE_COMPARATOR|MDI|multiple daily insulin injections
62301858|NCT01870492||Acute ischemic stroke or TIA|Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
62301859|NCT02835495|EXPERIMENTAL|Lifestyle Weight Loss|"Behavioral: HELP Vets Intervention~Lifestyle intervention consisting of 24 weekly group meetings led by a Veteran community health worker and 3 individual sessions with a nutritionist/diabetes educator"
62301860|NCT02835495|ACTIVE_COMPARATOR|Enhanced Usual Care|"Behavioral: Individual Education Program~Standard care consisting of 2 individual sessions with a nutritionist/diabetes educator and a monthly newsletter"
62673477|NCT06131463|EXPERIMENTAL|ECG function is enabled|Electrocardiogram (ECG) feature on the smartwatch is enabled
62673478|NCT06131463|NO_INTERVENTION|ECG function is not enabled|Electrocardiogram (ECG) feature on the smartwatch is not enabled
62673479|NCT04346238||Patients with Friedriech Ataxia genetically confirmed|Patients with Friedriech Ataxia genetically confirmed
62673480|NCT04541342|EXPERIMENTAL|osteoarthritic with genu varus|initial arthroscopy and high tibial osteotomy to be followed later by a second look arthroscopy with plate removal
62673481|NCT04928404|OTHER|obstructive sleep apnea patients|
62673482|NCT01631929|ACTIVE_COMPARATOR|One bag|IV infusion of fluids, electrolytes and dextrose using one bag
62301861|NCT03709615|NO_INTERVENTION|Wait list|Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.
62301862|NCT03709615|EXPERIMENTAL|Intervention- active treatment|Internet delivered CBT for social anxiety disorder
62301863|NCT03319550|EXPERIMENTAL|Casein|"LPS + 36 hour fast and bedrest + Casein (9% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping."
62301864|NCT03319550|EXPERIMENTAL|Whey|"LPS + 36 hour fast and bedrest + Whey (11% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
62301865|NCT03319550|EXPERIMENTAL|Leucine-enriched whey|"LPS + 36 hour fast and bedrest + Leucine-enriched whey (16% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
62301866|NCT04032366||PEEP 5|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, without inhaled nitric oxide
62301867|NCT04032366||PEEP 10|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, without inhaled nitric oxide
62301868|NCT04032366||PEEP 10 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, with inhaled nitric oxide
62301869|NCT04032366||PEEP 5 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, with inhaled nitric oxide
62301870|NCT01334073|EXPERIMENTAL|Axitinib plus everolimus|
62301871|NCT03397836|EXPERIMENTAL|Health TAPESTRY Intervention|This patient group will begin receiving the TAPESTRY interventions from time zero
62301872|NCT03397836|ACTIVE_COMPARATOR|Usual Care|This patient group will receive the intervention after a 6 month waiting period. In the first 6 months they will receive usual care and they will be used as a comparison group.
62301873|NCT05268380||Household contact study|Investigation of Covid-19 index cases' households for TB infection and disease, HIV seropositivity, Covid-19 active infection and previous infection.
62301874|NCT05268380||Primary healthcare facility study|Investigation of primary healthcare facility attendees for TB infection and disease, HIV seropositivity, Covid-19 active infection and previous infection.
62471026|NCT01134094|ACTIVE_COMPARATOR|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
62471027|NCT00584025|EXPERIMENTAL|1|Keppra IV
61916737|NCT04706416|PLACEBO_COMPARATOR|Control|All patients in the comparator arm were admitted to the same hospital with COVID-19 but did not receive N-Acetyl Glucosamine treatment. All these patients were identified retrospectively.
61916738|NCT04869553|EXPERIMENTAL|ABC's arm|The 3 pain managements are in the ABC's order.
62471028|NCT00584025|PLACEBO_COMPARATOR|2|Placebo
62673483|NCT01631929|EXPERIMENTAL|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
61916739|NCT04869553|EXPERIMENTAL|BCA's arm|The 3 pain managements are in the BCA's order.
61916740|NCT04869553|EXPERIMENTAL|CAB's arm|The 3 pain managements are in the CAB's order.
61916741|NCT02119676|EXPERIMENTAL|Ruxolitinib plus regorafenib|
61916742|NCT02119676|ACTIVE_COMPARATOR|Placebo plus regorafenib|
62112011|NCT02613364|ACTIVE_COMPARATOR|Arm III (educational intervention)|"Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families."
62112012|NCT01557998|OTHER|Control - No intervention|PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
62112013|NCT01557998|EXPERIMENTAL|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
62112014|NCT01557998|OTHER|HCV+PWID|Control and Experimental Confirmed HCV viremic study subject will receive HCV treatment
62112015|NCT01040741||Group 1: 6-23 months|
62112016|NCT01040741||Group 2: 2-8 years|
62112017|NCT01040741||Group 3: 9-17 years|
62112018|NCT01040741||Group 4: 18-44 years|
62112019|NCT01040741||Group 5: 45-60 years|
62301875|NCT02240134|EXPERIMENTAL|Education Intervention (Tx1)|The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies. The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
62301876|NCT02240134|ACTIVE_COMPARATOR|Air Filtration Unit Treatment (Tx2)|"Within each randomly assigned home, a 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove."
62301877|NCT02240134|SHAM_COMPARATOR|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
62301878|NCT01457248|EXPERIMENTAL|endotracheal tube with taper-shaped cuff|
62301879|NCT01457248|ACTIVE_COMPARATOR|Endotracheal tube with cylindrical-shaped cuff|
62673484|NCT05142644||Early / growth restriction|Intrauterine growth restriction with onset before 32 weeks of gestation
62673485|NCT05142644||Late growth restriction|Intrauterine growth restriction with onset after 32 weeks of gestation
61916743|NCT03313908|EXPERIMENTAL|breast surgery|during the breast surgery, detection of the tumor lesion with indocyanine green fluorescence and with radioactive seed localization, in each subject
61916744|NCT03271294|OTHER|Exair transvaginal mesh surgery|This is a prospective study done in 80 consecutive subjects who underwent the Exair transvaginal mesh surgery from June 2013 to August 2015. The subjects were followed at 4 weeks, 6 months and 12 months post-operatively. All eligible subjects underwent a detailed urogynecologic history and examination including a Pelvic Organ Prolapse Quantification system assessment (POP-Q).
61916745|NCT06023576|EXPERIMENTAL|standard-of-care antihypertensive medications|SBP control will consist of treatment with antihypertensive medications titrated every 4 weeks for the first 3 months, and then every 3 months in months 4-12. SBP control will be achieved by titration of antihypertensive medications based upon a standardized algorithm and will be implemented during a 12-month study period. At the time of randomization, no antihypertensive treatments may be initiated or modified if SBP is ≥160 mm Hg. The clinical context may be considered at each visit to inform decision-making regarding treatment initiation or modification, at the discretion of the treating provider.
62112020|NCT01040741||Group: >60 years|
62112021|NCT02176096|EXPERIMENTAL|Glycosade|
62301880|NCT01881555|OTHER|FRACTIONAL FLOW RESERVE|"Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment.~Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8."
62301881|NCT01881555|OTHER|ANGIOGRAPHY|Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
62301882|NCT05647993|PLACEBO_COMPARATOR|Control group (Placebo)|Patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and placebo(0.9% NaCl 100 ml intravenously) before the incision
62471029|NCT05984030|EXPERIMENTAL|STARR NC Intervention Condition|"Intervention arm will receive a multilevel intervention with three components: a PrEP Navigator to facilitate linkage to PrEP services and completion of applications for health insurance/drug assistance; a Digital Health Intervention (DHI) platform (HealthMpowerment); and referral to Telehealth PrEP services as an option for linking to PrEP care.~The Intervention Arm version of the DHI includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center; Interactive skill-building health activities; social support newsfeed/group chat; Ask the Expert anonymous health question and answer; Medication Tracker; Health Behavior Tracker; Gamification features for participant engagement.~Intervention Arm participants will complete baseline and quarterly follow-up assessments.~Intervention Arm participants will complete two Dried Blood Spot self-collection kits at 3 and 6 months."
62673486|NCT03691870|ACTIVE_COMPARATOR|standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment.~The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
62112022|NCT01078246||Raltegravir Cohort Only|Participants with HIV-1 infection who received raltegravir (RAL) on or after 12 October 2007 (the market authorization date in the United States) (Raltegravir Cohort). These participants contributed data to the Raltegravir Cohort only.
62112023|NCT01078246||Historical and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received RAL on or after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Historical and Raltegravir Cohorts only.
62112024|NCT01078246||Historical Cohort Only|Participants with HIV-1 infection who received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort). These participants contributed data to the Historical Cohort only.
62301883|NCT05647993|EXPERIMENTAL|azithromycin|Patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
62112025|NCT01078246||Historical and Concurrent Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Historical and Concurrent Cohorts only.
62112026|NCT01078246||Concurrent Cohort Only|Participants with HIV-1 infection who received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Concurrent Cohort only.
62673487|NCT03691870|EXPERIMENTAL|Trans-Venous Embolization (TVE) (+/- Arterial) strategy|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.~It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion)."
62673488|NCT03563612|ACTIVE_COMPARATOR|cpap first, differential ventilation later|
62673489|NCT03563612|ACTIVE_COMPARATOR|differential ventilation first, cpap late|
62673490|NCT05823883|EXPERIMENTAL|Sequence A|Period 1: Empagliflozin and Metformin Period 2: DW6014
61916746|NCT06023576|EXPERIMENTAL|higher dose antihypertensive medications|Patients randomized to intensive SBP control will be treated to achieve an SBP goal \<120 mm Hg, and patients randomized to standard SBP control will be treated to achieve an SBP goal \<140 mm Hg. Antihypertensive medications will be titrated on the basis of seated blood pressure measurements obtained after a 5-min rest period. All participants will be provided with dietary (e.g., 1500mg/d sodium restriction) and lifestyle recommendations as background therapy for optimizing HTN control.The clinical context may be considered at each visit to inform decision-making regarding treatment initiation or modification, at the discretion of the treating provider.
62112027|NCT01078246||Concurrent and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 2) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Concurrent and Raltegravir Cohorts only.
62112028|NCT01078246||Historical, Concurrent and Raltegravir Cohorts|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), 2) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 3) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to all three cohorts.
62112029|NCT06123585|EXPERIMENTAL|Invisalign® SmileView™|
62112030|NCT06123585|ACTIVE_COMPARATOR|Invisalign aligners|
62301884|NCT03638011|NO_INTERVENTION|Standard of Care|These participant will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They standard neuraxial anesthesia with neuraxial Duramorph for post-operative pain.
62301885|NCT03638011|ACTIVE_COMPARATOR|Bilateral TAP Block|These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.
62301886|NCT04432428|EXPERIMENTAL|sufentanil sublingual tablet|sufentanil sublingual 15µg tablets
62301887|NCT04222985|EXPERIMENTAL|Part A - Group 1|HSV 2 formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62673491|NCT05823883|EXPERIMENTAL|Sequence B|Period 1: DW6014 Period 2: Empagliflozin and Metformin
62673492|NCT04132180|EXPERIMENTAL|Early mobilization|
62673493|NCT04132180|ACTIVE_COMPARATOR|Late mobilization|
62673494|NCT01142687|ACTIVE_COMPARATOR|dihydrocapsiate 3 mg|• Group 1: 1 Dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner
61916747|NCT02420782|EXPERIMENTAL|ASP6282 single ascending dose (fasted)|Part 1
62673495|NCT01142687|ACTIVE_COMPARATOR|dihydrocapsiate 9 mg|• Group 2: 3 Dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
61916748|NCT02420782|PLACEBO_COMPARATOR|Placebo single ascending dose (fasted)|Part 1
61916749|NCT02420782|EXPERIMENTAL|ASP6282 single dose (fed)|Part 1
61916750|NCT02420782|PLACEBO_COMPARATOR|Placebo single dose (fed)|Part 1
62112031|NCT04580199|ACTIVE_COMPARATOR|total thyroidectomy|excision of thyroid gland
62112032|NCT04580199|ACTIVE_COMPARATOR|hemi thyroidectomy|excision half of thyroid gland
62112033|NCT04580199|ACTIVE_COMPARATOR|ethanol ingection|ingection of ethanol into thyroid nodule under guidance of ultrasound
62112034|NCT04580199|ACTIVE_COMPARATOR|monopolar radiofrequency|using radiofrequency for ablation of thyroid nodule
61916751|NCT02420782|EXPERIMENTAL|ASP6282 single dose (fasted)|Part 1 Period 1
61916752|NCT02420782|EXPERIMENTAL|Itraconazole multiple dose and ASP6282 single dose (fasted)|Part 1 Period 2
62301888|NCT04222985|EXPERIMENTAL|Part A - Group 2|HSV 2 formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
61916753|NCT02420782|EXPERIMENTAL|ASP6282 multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
62301889|NCT04222985|EXPERIMENTAL|Part A - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62301890|NCT04222985|EXPERIMENTAL|Part A - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
62471030|NCT05984030|ACTIVE_COMPARATOR|STARR NC Standard-of-Care Control Condition|"Standard-of-Care Control arm will receive the standard PrEP referral services available at the STI clinic setting where they were recruited. They will also receive study staff guided support to install the control arm version of the HealthMPowerment DHI platform.~The Control Arm version of the DHI includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center.~Control Arm participants will complete baseline and quarterly follow-up assessments.~Control Arm participants will complete two Dried Blood Spot self-collection kits at 3 and 6 months."
62673496|NCT01142687|PLACEBO_COMPARATOR|Placebo capsule|• Group 3: 3 placebo capsules three times per day within 30 minutes before breakfast, lunch and dinner
62301891|NCT04222985|EXPERIMENTAL|Part A - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2.
62301892|NCT04222985|PLACEBO_COMPARATOR|Part A - Group 6|Sodium chloride 0.9% (in both arms) at Month 0 and Month 2
62301893|NCT04222985|EXPERIMENTAL|Part B (Stage 1) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62673497|NCT01104337|EXPERIMENTAL|Paracetamol 2g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 2g/d
62673498|NCT01104337|EXPERIMENTAL|Paracetamol 3g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 3g/d
62673499|NCT01104337|PLACEBO_COMPARATOR|Placebo|9 patients on stable warfarin therapy received a 10-day regimen of placebo
62673500|NCT04891861|ACTIVE_COMPARATOR|1 week restart|restart DOAC at 1 week post injury at label dose and frequency
62673501|NCT04891861|ACTIVE_COMPARATOR|4 week restart|restart DOAC at 4 weeks post injury at label dose and frequency
62673502|NCT02322515|EXPERIMENTAL|Intervention Taping|The experimental group will use a rigid patellar taping (G1, n = 22) for the correction of lateralization of the patella and stabilization of the knee. The lateral stabilization will be made with self-adhesive taping positioned in the lateral border of the patella and tensioned in relation to the medial portion of the femur condyle, which allows an edge of the medial board patella and a stretching of lateral structures of the knee. All procedure will follow the recommendation from McConnell studies with regard to the patellar femoral syndrome.
62673503|NCT02322515|PLACEBO_COMPARATOR|Placebo Taping|The placebo group will use a rigid patellar taping (G2, n = 22), but without no correction of lateralization of the patella and/or stabilization of the knee. The taping will be placed incorrectly such as in the vertical position of knee and without any tension or traction around structures and patella.
62673504|NCT01053065|ACTIVE_COMPARATOR|Atorvastatin 10 mg/day|Arm composed of 20 patients, receiving atorvastatin 10 mg/day
62673505|NCT01053065|ACTIVE_COMPARATOR|Atorvastatin 80 mg/day|Arm composed of 20 patients, receiving atorvastatin 80 mg/day
62673506|NCT01053065|ACTIVE_COMPARATOR|Cholestyramine - Sitosterol|Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day
62673507|NCT05888779|EXPERIMENTAL|Beverage One (Milk)|Participants will consume milk prior to completing a novel cognitive assessment on paper.
62673508|NCT05888779|EXPERIMENTAL|Beverage Two (Juice)|Participants will consume a fruit drink prior to completing a novel cognitive assessment on paper.
62301894|NCT04222985|EXPERIMENTAL|Part B (Stage 1) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62673509|NCT03632720|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at 3 months and at 12 to 13 months of age, Bexsero® at 2, 4, and 12 to 13 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.
62673510|NCT03632720|EXPERIMENTAL|Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at 3 months and at 12 to 13 months of age, Bexsero® at 2 and 4 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.
61916754|NCT02420782|PLACEBO_COMPARATOR|Placebo multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing
61916755|NCT02420782|EXPERIMENTAL|ASP6282 and pilocarpine|Part 3
61916756|NCT02420782|OTHER|Placebo and pilocarpine|Part 3
61916757|NCT00893815||1|HIV-Positive and Early HIV infection
61916758|NCT00893815||2|HIV-Positive and Late HIV-infection
61916759|NCT00893815||3|HIV-negative
61916760|NCT05280483|EXPERIMENTAL|Fed states in healthy subjects|A single 25mg dose of ABSK021 administered in a fed state.
61916761|NCT05280483|EXPERIMENTAL|Fasted states in healthy subjects|A single 25mg dose of ABSK021 administered in a fasted state.
61916762|NCT04560244|EXPERIMENTAL|SHR 1701+radiotherapy|SHR-1701 Simultaneously Combined with High Fractionation and Low-dose Radiotherapy
61916763|NCT00661986|EXPERIMENTAL|1|dark chocolate 6 g/day
61916764|NCT00661986|ACTIVE_COMPARATOR|2|dark chocolate 25 g/day
62301895|NCT04222985|EXPERIMENTAL|Part B (Stage 1) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62673511|NCT03632720|ACTIVE_COMPARATOR|Group 3: Bexsero® (2, 4, and 12 to 13 Months)|Participants aged 2 months (at the time of enrollment) received Bexsero® at 2, 4, and 12 to 13 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.
62112035|NCT04580199|ACTIVE_COMPARATOR|laser photocaugulation|using laser for ablation of thyroid nodule
62112036|NCT04025606|ACTIVE_COMPARATOR|Thoracic epidural analgesia|Standard thoracic epidurals preoperatively at the dag of surgery.
62112037|NCT04025606|EXPERIMENTAL|Paravertebral block|Paravertebral block inserted at the end of the operation by the surgeons
62112038|NCT06189391|EXPERIMENTAL|Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in need of systemic therapy
62112039|NCT02459899|PLACEBO_COMPARATOR|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
62112040|NCT02459899|EXPERIMENTAL|Sotagliflozin 75 mg|Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
62112041|NCT02459899|EXPERIMENTAL|Sotagliflozin 200 mg|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
62673512|NCT03391154|ACTIVE_COMPARATOR|levothyroxine|100 pregnant female with TSH of\> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy
62673513|NCT03391154|NO_INTERVENTION|control|100 pregnant female with TSH of\> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will not receive any drug throughout the pregnancy
62673514|NCT05113602|EXPERIMENTAL|Simultaneous acquisition of EEG signals|
62112042|NCT02459899|EXPERIMENTAL|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.
62673515|NCT01442285|EXPERIMENTAL|personalized, motivational messages|A Healthcare Provider Report will be reviewed by oncologist. If mental health functioning scores are elevated or high range,treatment plan is constructed. Subjects receive personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
62673516|NCT01442285|NO_INTERVENTION|Control Group|Control subjects will receive a resource packet upon initial diagnosis consisting of brochures and printed material describing local resources and support groups as part of their routine care. At 12 months, subjects will receive the full assessment with reports and referrals.
62673517|NCT00990379||Controls|Healthy men and women, 18 years of age or older, who have no history of significant medical conditions.
62673518|NCT00990379||HIV positive|Men and women, 18 years of age or older, who have been diagnosed with HIV infection. Patients may be on or off of ARVs.
61916765|NCT03032770||placenta accreta|Having at least one sign suggestive of placenta accreta
61916766|NCT03032770||normal placenta|Never having any of the signs suggestive of placenta accreta
61916767|NCT03460015|EXPERIMENTAL|Sevoflurane group|
62112043|NCT00500500|EXPERIMENTAL|EGb 761® (Tanakan®)|EGb 761® (Tanakan®)
62301896|NCT04222985|EXPERIMENTAL|Part B (Stage 1) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
62112044|NCT00500500|PLACEBO_COMPARATOR|Placebo|Placebo
62112045|NCT06260696||Normal weight|Adults with normal weight, recruited to complete self-administered online service
62112046|NCT06260696||Overweight|Adults with overweight, recruited to complete self-administered online service
62112047|NCT06260696||Obesity Class I|Adults with obesity class I, recruited to complete self-administered online service
62301897|NCT04222985|EXPERIMENTAL|Part B (Stage 1) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
62301898|NCT04222985|PLACEBO_COMPARATOR|Part B (Stage 1) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
62673519|NCT00990379||Parkinson's Disease|Men and women, 18 years of age or older, who have been diagnosed with Parkinson's Disease.
62673520|NCT01531803|EXPERIMENTAL|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g/L human albumin, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin). The duration of treatment is based on the subject's response to treatment until hemodynamic stability is achieved. If hemodynamic stability is not achieved within 72 hours of starting the study treatment, the subject will be withdrawn from the study and will be treated according to standard practice and data collected during the study period will be used for the safety evaluation."
62112048|NCT06260696||Obesity Class II|Adults with obesity class II, recruited to complete self-administered online service
62112049|NCT06260696||Obesity Class III|Adults with obesity class III, recruited to complete self-administered online service
62112050|NCT06421688|EXPERIMENTAL|Ascorbic acid group|Patients received 50 mg/kg of Ascorbic acid after induction of anesthesia
62112051|NCT06421688|PLACEBO_COMPARATOR|Control comparator group|Patients receive 50ml saline after induction of anesthesia
62112052|NCT00771849|EXPERIMENTAL|Menactra® Vaccine Group|Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
62301899|NCT04222985|EXPERIMENTAL|Part B (Stage 1) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62301900|NCT04222985|EXPERIMENTAL|Part B (Stage 2) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62301901|NCT04222985|EXPERIMENTAL|Part B (Stage 2) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62673521|NCT01531803|PLACEBO_COMPARATOR|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
61916768|NCT03460015|ACTIVE_COMPARATOR|Propofol group|
61916769|NCT03721445||CPAP opponent|CPAP opponent: moderate to severe OSA patients who refused CPAP therapy after PSG study and CPAP titration test.
61916770|NCT03721445||CPAP acceptor|CPAP acceptor: moderate to severe OSA patients who accepted CPAP therapy after PSG study and CPAP titration test and had purchased a PAP at home for long term use.
61916771|NCT01535976|PLACEBO_COMPARATOR|Placebo|.9 normal saline infusion
61916772|NCT01535976|ACTIVE_COMPARATOR|Ketamine|Infusion of ketamine
61916773|NCT03660670|EXPERIMENTAL|Interventional Arm|Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs
61916774|NCT03660670|SHAM_COMPARATOR|Standard of care|Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.
61916775|NCT05664698|EXPERIMENTAL|SKILLS-ER|Emotion regulation training
61916776|NCT06391931|EXPERIMENTAL|Cipepofol group|
62112053|NCT00771849|ACTIVE_COMPARATOR|Hiberix® Vaccine Group|Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
62112054|NCT01402271|EXPERIMENTAL|pazopanib in combination with paclitaxel and carboplatin|Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
62301902|NCT04222985|EXPERIMENTAL|Part B (Stage 2) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62301903|NCT04222985|EXPERIMENTAL|Part B (Stage 2) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
62301904|NCT04222985|EXPERIMENTAL|Part B (Stage 2) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
62301905|NCT04222985|PLACEBO_COMPARATOR|Part B (Stage 2) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
62301906|NCT04222985|EXPERIMENTAL|Part B (Stage 2) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
62673522|NCT05540275|EXPERIMENTAL|Cohort 1|Patients with bevacizumab-refractory recurrent glioma with PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.
62673523|NCT05540275|EXPERIMENTAL|Cohort 2|Patients with bevacizumab-refractory recurrent glioma without PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.
62673524|NCT04630730|EXPERIMENTAL|Recombinant intravesical BCG|"The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment.~4 cycles of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine.~After surgery atezolizumab will be administered in the adjuvant setting for 13 cycles."
62673525|NCT03084679|NO_INTERVENTION|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
62673526|NCT03084679|OTHER|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
62673527|NCT03084679|NO_INTERVENTION|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
61916777|NCT06391931|ACTIVE_COMPARATOR|Propofol group|
62112055|NCT01402271|ACTIVE_COMPARATOR|Paclitaxel and carboplatin only|Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
62112056|NCT03531853|EXPERIMENTAL|Imaging patients|Get uveitis patients and ER patients to image their eyes
61916778|NCT04517357|EXPERIMENTAL|Safety Lead-in or Parallel， Fluzoparib+Apatinib|Participants will receive Fluzoparib-Apatinib combination until progression
61916779|NCT04517357|ACTIVE_COMPARATOR|Fluzoparib monotherapy|Participants will receive Fluzoparib monotherapy until progression
61916780|NCT04517357|OTHER|Exploratory cohort: Fluzoparib+Apatinib|Participants who has previously received PARP inhibitor, will receive Fluzoparib-Apatinib combination until progression
61916781|NCT01809977|OTHER|total removal|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
62112057|NCT04148417|EXPERIMENTAL|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
62112058|NCT02599844||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
62112059|NCT02599844||Sepsis without AKI|This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
62301907|NCT01965925|EXPERIMENTAL|Modafinil|Modafinil will be administered at baseline with a single dose of 100 mg/day QAM increased at week 1 to a single dose 200mg/day QAM. Patients will take drug upon waking with no adjustment in sleep schedule. Dosing will be flexible based on side effects with a maximum dose of 200 mg/day. Subjects will be discontinued if 100mg/day is not tolerated.
62301908|NCT01965925|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo upon waking once per day.
62301909|NCT02242279|EXPERIMENTAL|BEA 2180 - low dose|
62301910|NCT02242279|EXPERIMENTAL|BEA 2180 - medium dose|
62301911|NCT02242279|EXPERIMENTAL|BEA 2180 - high dose|
62301912|NCT02242279|ACTIVE_COMPARATOR|Tiotropium|
62301913|NCT02242279|PLACEBO_COMPARATOR|Placebo|
62471031|NCT06451783|EXPERIMENTAL|Combined treatment group|"Traditional Chinese medicine combined with manipulation treatment：the Shengyu Decoction, which consists of the following herbs:~* Shu Di Huang 20 grams~* Bai Shao 15 grams~* Dang Gui 15 grams~* Chuan Xiong 8 grams~* Ren Shen 20 grams~* Huang Qi 18 grams One dose is taken per day, and a course of treatment consists of five weeks."
62673528|NCT03084679|OTHER|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
62673529|NCT05922735||Population living with HIV and PrEP users|Population of people living with HIV and PrEP users followed in the infectious disease departments in Ile de France and in the province.
62673530|NCT00642265|EXPERIMENTAL|1|operative treatment
62673531|NCT00642265|ACTIVE_COMPARATOR|2|conservative treatment
62673532|NCT02366130|EXPERIMENTAL|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
62301914|NCT03146312|EXPERIMENTAL|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
61916782|NCT01809977|OTHER|partial removal|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
62301915|NCT03146312|PLACEBO_COMPARATOR|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
62301916|NCT04025840|NO_INTERVENTION|Control|Patients in this group receive general anesthesia, without epidural block and perioperative dexamethasone. Patient-controlled intravenous analgesia is provided after surgery.
62301917|NCT04025840|EXPERIMENTAL|Epidural block|Patients in this group receive combined epidural-general anesthesia (0.375% ropivacaine for epidural block), without perioperative dexamethasone. Patient-controlled epidural analgesia is provided after surgery.
62301918|NCT04025840|EXPERIMENTAL|Dexamethasone|Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.
62301919|NCT04025840|EXPERIMENTAL|Epidural block+Dexamethasone|Patients this group receive dexamethasone (10 mg) before anesthesia induction and combined epidural-general anesthesia (0.375% ropivacaine for epidural block). Patient-controlled epidural analgesia is provided after surgery.
62301920|NCT04038333||Children|Interviewees are parents or grandparents of children aged between 6 to 59 months.
62301921|NCT04038333||Elderly|Interviewees are the elderly aged 60 years old or above.
62301922|NCT04038333||Chronic disease patients|Interviewees are adult patients with chronic diseases aged below 60 years old.
62301923|NCT04038333||Vaccination and health care personnel|Interviewees are vaccination and health care personnel in each study site.
62301924|NCT05283733|EXPERIMENTAL|group A|the group who was subjected to the reverse conversion technique
62301925|NCT05283733|NO_INTERVENTION|group B|the control group who was completed by open technique
62301926|NCT03257046|EXPERIMENTAL|1 mg ITI-214|Administered once daily for 7 days
62301927|NCT03257046|EXPERIMENTAL|3 mg ITI-214|Administered once daily for 7 days
62301928|NCT03257046|EXPERIMENTAL|10 mg ITI-214|Administered once daily for 7 days
62301929|NCT03257046|EXPERIMENTAL|30 mg ITI-214|Administered once daily for 7 days
62301930|NCT03257046|EXPERIMENTAL|90 mg ITI-214|Administered once daily for 7 days
62301931|NCT03257046|PLACEBO_COMPARATOR|Placebo|Administered once daily for 7 days
62301932|NCT06334679|EXPERIMENTAL|Group-1 (Clinical Routine (liquid vaseline) and Cold Gel Pack applied group)|"Before the first application of the day, the 12-Item Itching Severity Scale will be applied to evaluate the patient's daily itching. Before each application, itching severity will be evaluated with the Visual Analog Scale (VAS) for Itch at minute 0. Vital signs will be measured and recorded. Cold gel packs placed in a sterile cloth sheath will be placed in full contact with the burn areas and applied for 20 minutes. During the application, the skin will be checked every 30 seconds and 5 minutes, and the application will be interrupted in case of new pain, numbness, redness, pallor, chills, cold sensitivity and skin surface temperature ≤13 degrees Celsius. The temperature of the cold gel packs before and during application will be checked with a Digital Infrared Non-Contact Thermometer. Immediately after the application is completed, a 20-minute VAS for itching will be shown and they will be asked to evaluate the severity of the itching they feel instantly."
62301933|NCT06334679|NO_INTERVENTION|Group-2: Clinical routine (liquid petroleum jelly) applied group (control)|"Before the first application of the day, the 12-Item Itching Severity Scale will be applied to evaluate the patient's daily itching. Before each application, the Visual Analog Scale (VAS) for Itch will be shown at minute 0 and they will be asked to evaluate the severity of itching they feel immediately. Vital signs will be measured and recorded. Liquid petroleum jelly, which is the routine practice of the clinic, will be applied by clinic nurses. Immediately after the application is completed, a 20-minute VAS for itching will be shown and they will be asked to evaluate the severity of itching they feel immediately."
62301934|NCT02730806|EXPERIMENTAL|NLP PTSD intervention protocol|Behavioral intervention (NLP) - intervention method will be 5 weekly personal therapy and counseling sessions with a certified therapist specializing in NLP, implementing the NLP PTSD protocol, such as Visual Kinesthetic Dissociation (VKD) behavioral technique for PPPTSD cases
62301935|NCT01471327|EXPERIMENTAL|SB-240563, 10mg|IV, single dose at Day 1
62301936|NCT01471327|EXPERIMENTAL|Placebo|Saline IV, single dose at Day 1
62471032|NCT06451783|ACTIVE_COMPARATOR|Control group|Oral control group medication： Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.
61916783|NCT01963000||CAP|A patient with CAP was identified by encoding pneumonia without severe immunosuppression (HIV infection, solid organ or bone marrow/stem cell transplants, severe neutropenia) as the main diagnosis (ICD 10 GM) of hospital admission.
61916784|NCT04153214|EXPERIMENTAL|Cycling workstation|Participants will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 6 months
61916785|NCT04153214|PLACEBO_COMPARATOR|control|Daily activities unchanged during 3 months. Then they will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 3 months.
62301937|NCT01471327|EXPERIMENTAL|SB-240563, 75mg|IV, single dose at Day 1
62301938|NCT01471327|EXPERIMENTAL|SB-240563, 250mg|IV, single dose at Day 1
62301939|NCT01471327|EXPERIMENTAL|SB-240563, 750mg|IV, single dose at Day 1
62301940|NCT01739595|EXPERIMENTAL|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
62301941|NCT01739595|EXPERIMENTAL|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
62301942|NCT01739595|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules taken one time daily
62301943|NCT06283706|EXPERIMENTAL|Tryptophan in Adults >60y|Tryptophan levels, up to 7 levels, will be tested in a random order in all subjects
62301944|NCT06070363|NO_INTERVENTION|Control|The Patient are cancer patient that experience cancer pain that only receive analgetic drug treatment according to WHO Stepledder of Pain
62301945|NCT06070363|EXPERIMENTAL|Manual acupuncture and standard Therapy|The Patient are cancer patient that experience cancer paint that receive analgetic drug treatement according WHO stepledder of pain and receive manual acupuncture
62471033|NCT03494361||Young normal group|normal participants below 60 years
62471034|NCT03494361||Old normal group|normal participants above 60 years
62301946|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
62301947|NCT02592564|EXPERIMENTAL|Psychological treatment|Psychological treatment during 9 weeks.
62301948|NCT04754087|OTHER|G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners|Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.
62471035|NCT03154645|ACTIVE_COMPARATOR|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
62112060|NCT04132440||Observational (questionnaire, interview)|Patients and physicians complete a questionnaire over 5 minutes and an interview over 30-45 minutes about thoughts on NAFLD, including what they know about NAFLD and its diagnosis, management, and monitoring, and other thoughts on NAFLD.
62112061|NCT04227990|ACTIVE_COMPARATOR|TAC + Pegfilgrastim (6 mg)|
62112062|NCT04227990|EXPERIMENTAL|TAC + Plinabulin 10 mg/m^2|
62112063|NCT04227990|EXPERIMENTAL|TAC + Plinabulin 20 mg/m^2|
62112064|NCT04227990|EXPERIMENTAL|TAC + Plinabulin 30 mg/m^2|
62112065|NCT04227990|EXPERIMENTAL|TAC + Pegfilgrastim (1.5 mg) + Plinabulin (20 mg/m^2)|
62112066|NCT04227990|EXPERIMENTAL|TAC + Pegfilgrastim (3 mg) + Plinabulin (20 mg/m^2)|
62112067|NCT04227990|EXPERIMENTAL|TAC + Pegfilgrastim (6 mg) + Plinabulin (20 mg/m^2)|
62112068|NCT05407142|EXPERIMENTAL|The study group consisted of 3,500 volunteers who received the CoviVac vaccine|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days and revaccinated at 6 months with one dose of the KoviVac vaccine.~Cohort 1 - The first 1000 volunteers of the study group will be used to assess the efficacy + safety + immunogenicity of the vaccine under study.~Cohort 2 - Next 1100 volunteers of the study group will be used to analyze the efficacy + safety of the vaccine under study.~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml.~The data of 1400 volunteers vaccinated three times with an interval of 21 days will be used to assess the effectiveness + safety + immunogenicity of the vaccine under study."
62112069|NCT05407142|OTHER|Control group|The data from volunteers from the control group will be used to evaluate the effectiveness of the investigational vaccine.
62112070|NCT05393336|EXPERIMENTAL|V-sitting posture stabilization|V sitting exercises will be administered where patients will be asked to lift the torso and legs while engaging the core and abdominal muscles.
62112071|NCT05393336|EXPERIMENTAL|modified clamshell exercises|Participants will perform modified clamshell exercises monitored visually and using a stabilizer pressure biofeedback unit.
62112072|NCT02331043|PLACEBO_COMPARATOR|Placebo biscuit|Biscuit without plant stanol ester
62112073|NCT02331043|EXPERIMENTAL|Plant stanol ester biscuit|Biscuit with plant stanol esters
62112074|NCT02869620||Patients with thyroid cancer diagnosis|
62112075|NCT03851237|EXPERIMENTAL|Cohort 1a: Treatment Whipple/Surgical Procedure/Surgery following neoadjuvant therapy|"* Early-staged localized pancreatic cancer~* Standard of care diagnostic biopsy~* 64Cu-DOTA-ECL1i-PET/CT imaging - immediately after the dynamic study~* Receive treatment with upfront surgery such as whipple procedure or surgery following neoadjuvant therapy."
62471036|NCT03154645|ACTIVE_COMPARATOR|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
62471037|NCT03084471|EXPERIMENTAL|Combination therapy|"Combination therapy (durvalumab + tremelimumab) : Patients will receive the combination therapy followed by monotherapy via intravenous (IV) infusion once Q4W:~* Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) and~* Durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab."
62471038|NCT03084471|EXPERIMENTAL|Monotherapy|Monotherapy (Durvalumab 1,500 mg): Patients will receive durvalumab 1,500 mg via IV infusion Q4W on Week 0.
62471039|NCT01336322|ACTIVE_COMPARATOR|Metformin|Metformin 850 mg bid
62471040|NCT01336322|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin 100 mg qd
62471041|NCT01336322|ACTIVE_COMPARATOR|Sitagliptin+Metformin|Sitagliptin 100 mg qd plus Metformin 850 mg bid
62471042|NCT02061891|ACTIVE_COMPARATOR|Deferred invasive evaluation|Deferred invasive coronary evaluation and revascularization (PCI/CABG) within 72 hours from time of clinical diagnosis (CONTROL group)
62112076|NCT03851237|EXPERIMENTAL|Cohort 1b: Standard of Care Treatment Chemotherapy|"* Borderline resectable, locally advanced/metastatic or recurrent pancreatic cancer~* Standard of care diagnostic biopsy (if available tissue to be used for CCR2 expression)~* 64Cu-DOTA-ECL1i-PET/CT imaging pretherapy~* Treatment with any standard of care (SOC) chemotherapy~* Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with positive scan at baseline/early therapy at the time of standard of care follow-up imaging appointment --Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with negative scan at baseline/early therapy at time recurrence is diagnosed by any standard imaging modality"
62112077|NCT03851237|EXPERIMENTAL|Cohort 2: CCR2-Targeted Therapy|"* Locally advanced or borderline resectable pancreatic cancer~* Biopsy per therapeutic protocol (if available tissue to be used for CCR2 expression)~* 64Cu-DOTA-ECL1i-PET/CT imaging pretherapy~* 2 cycles of CCR2-targeted therapy~* Biopsy per therapeutic protocol (tissue to be used for CCR2 expression) --Additional 64Cu-DOTA-ECL1i-PET/CT imaging after 2 cycles of therapy"
62112078|NCT01694628|EXPERIMENTAL|CLIMB (COPD Lifestyle, Mood, and Behavior)|Counseling sessions for COPD and depression
62112079|NCT01694628|NO_INTERVENTION|Control|Usual Care
62112080|NCT05757076||Screening Cohort|"This is a prospective specimen collection cohort study aimed to increase the detection of primary aldosteronism (PA) in patients with hypertension.~Study samples will be obtained longitudinally. One collection of plasma will be obtained. Blood draw may need to be repeated in some subjects after washout period. Study will continue for a period or 1 year, with plan to enroll around 50 subjects."
62301949|NCT04054310|EXPERIMENTAL|Study-gate|Single arm of biopsy naïve participants suspected of having NAFLD or NASH, who have been referred for a liver biopsy as part of routine clinical care
62301950|NCT01071070|ACTIVE_COMPARATOR|Group 1|Initial dosing based on a formula of intact parathyroid hormone value/80 (where intact parathyroid hormone value is the baseline value in pg/mL).
62301951|NCT01071070|ACTIVE_COMPARATOR|Group 2|Dose determined by US paricalcitol injection package insert dosing instructions (starting dose at 0.04 microgram/kg)
62301952|NCT06258278|EXPERIMENTAL|Massive Irreparable Rotator Cuff Tears|Patients scheduled for arthroscopically assisted lower trapezius transfer due to irreparable massive rotator cuff tears
61916786|NCT04941443|EXPERIMENTAL|Oral methadone|Participants will be given a preemptive analgesic in addition to a standard dose of ibuprofen while undergoing early medication abortion with mifepristone and misoprostol (not provided as part of the study). All participants will also be provided with supplementary non- opioid analgesics to be used at their own discretion during the process.
62471043|NCT02061891|EXPERIMENTAL|Very early invasive evaluation|Acute invasive coronary evaluation within 12 hours from time of diagnosis - INTERVENTION group
61916787|NCT02150408|EXPERIMENTAL|assesment by 68Ga-DOTATATE PET-CT|
62301953|NCT01812161|ACTIVE_COMPARATOR|Acupuncture protocol 1|Acupuncture protocol 1：participants will receive treatment (acupuncture protocol 1, real acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
61916788|NCT01216605|ACTIVE_COMPARATOR|Oxytocin|
61916789|NCT01216605|PLACEBO_COMPARATOR|Placebo|
62112081|NCT03813706|ACTIVE_COMPARATOR|LN-prRLN dissection|
62301954|NCT01812161|SHAM_COMPARATOR|Acupuncture protocol 2|Acupuncture protocol 2：participants will receive treatment (acupuncture protocol 2, sham acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
62301955|NCT01305915|NO_INTERVENTION|Control|participant will receive standard print material
62301956|NCT01305915|EXPERIMENTAL|Intervention|patient will receive standard print material and a single session group psychoeducational intervention (GBOT)
62301957|NCT05519696|EXPERIMENTAL|Intervention|This group will receive a 10-week group-based intervention program.
62471044|NCT01262833||Cases|Patients with erectile dysfunction by ILEF questionnaire
62471045|NCT01262833||Controls|Patients without erectile dysfunction by ILEF questionnaire
62471046|NCT02496546|EXPERIMENTAL|LEO 32731 cream|Topical application
61916790|NCT01908738|EXPERIMENTAL|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
61916791|NCT01908738|EXPERIMENTAL|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
61916792|NCT01908738|PLACEBO_COMPARATOR|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
61916793|NCT00625703|EXPERIMENTAL|A|
61916794|NCT00649311|EXPERIMENTAL|Eplerenone group|
61916795|NCT00649311|ACTIVE_COMPARATOR|Losartan group|
61916796|NCT02712814||Hormonally mediated PVD|"* The entire vestibule is tender~* The pain began while taking hormonal contraceptive~* Secondary PVD~* On exam, atrophic vestibular tissue (dry and thin)"
61916797|NCT02712814||Congenital Neuroproliferative PVD|"* The entire vestibule is tender~* Primary PVD~* There may be sensitivity to palpation of the umbilicus~* Normal appearing vestibule"
62112082|NCT03813706|EXPERIMENTAL|no LN-prRLN dissection|
62112083|NCT05735444||Observation group|
62112084|NCT03101618||Allergic LAR|Laboratory animal researchers who experienced allergic symptom during exposure to laboratory or pet animals
62112085|NCT03101618||Non-allergic LAR|Laboratory animal researchers who did not experience allergic symptom during exposure to laboratory or pet animals
62112086|NCT03101618||Allergic PO|Pet owners who experienced allergic symptom during exposure to pet animals
62112087|NCT03101618||Non-allergic PO|Pet owners who did not experience allergic symptom during exposure to pet animals
62301958|NCT05519696|ACTIVE_COMPARATOR|Comparison|The group will receive a 10-week group-based comparison program.
62301959|NCT06172543|EXPERIMENTAL|Creatine Monohydrate Group|25 grams of Whey Protein Isolate + 25 grams of Carbohydrate Powder + 5 grams of Creatine
62471047|NCT02496546|PLACEBO_COMPARATOR|LEO 32731 cream vehicle|Topical application
61916798|NCT02712814||Acquired neuroproliferative PVD|"* The entire vestibule is tender~* Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.~* Normal appearing vestibule"
61916799|NCT02712814||Hypertonic pelvic muscle dysfunction|"* The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule~* Pelvic floor muscles are tight and tender~* Primary or Secondary PVD"
61916800|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~* Primary PVD~* There may be sensitivity to palpation of the umbilicus~* Normal appearing vestibule~* Pelvic floor muscles are tight and tender"
62112088|NCT03101618||Allergic PIW|Allergic pet-related industry workers who experienced allergic symptom during exposure to pet animals
62112089|NCT03101618||Non-allergic PIW|Allergic pet-related industry workers who did not experience allergic symptom during exposure to pet animals
62471048|NCT01320254|EXPERIMENTAL|Cisplatin, Gemcitabine and Panitumumab|Experimental Arm with cisplatin 25mg/sq.m. at day 1 + 8, gemcitabine 1000mg/ sq.m.at day 1 + 8 and panitumumab 9mg/kg BW at day 1. Cycle will be repeated every 3 weeks.
62112090|NCT06460948|EXPERIMENTAL|Arginine-vasopressin deficiency|Norethindrone Acetate-Ethinyl Estradiol will be given to participants with arginine-vasopressin deficiency
62112091|NCT06460948|EXPERIMENTAL|Healthy control|Norethindrone Acetate-Ethinyl Estradiol will be given to the healthy controls.
62112092|NCT02515682|ACTIVE_COMPARATOR|High equol|High equol group will be given natural S-equol supplementation 20mg per day for 24 week.
62471049|NCT01320254|ACTIVE_COMPARATOR|Cisplatin and Gemcitabine|Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
62471050|NCT05244863||One group|Geriatric individuals
62471051|NCT01972165|EXPERIMENTAL|Group I|Mini-incision carpal tunnel release group
62471052|NCT01972165|ACTIVE_COMPARATOR|Group II|Endoscopic carpal tunnel release group
61916801|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~* The pain began while taking hormonal contraceptive~* Secondary PVD~* On exam, atrophic vestibular tissue (dry and thin)~* Pelvic floor muscles are tight and tender"
61916802|NCT02043600|EXPERIMENTAL|Yoga|
61916803|NCT02043600|ACTIVE_COMPARATOR|Self-care|
61916804|NCT05167552|EXPERIMENTAL|Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells|Group 1: Patients with allergic rhinitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
62112093|NCT02515682|ACTIVE_COMPARATOR|Low equol|Low equol group will be given natural S-equol supplementation 10mg/d (+10mg starch) for 24 weeks
62112094|NCT02515682|PLACEBO_COMPARATOR|Placebo|Placebo group will be given placebo control (made from starch) 20 mg per day for 24 weeks.
62112095|NCT02650596|EXPERIMENTAL|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg liraglutide once daily for 1 week, then 1.2 mg liraglutide for another 1 week, and then 1.8 mg liraglutide to the end.
62112096|NCT02650596|PLACEBO_COMPARATOR|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg placebo once daily for 1 week, then 1.2 mg placebo for another 1 week, and then 1.8 mg placebo to the end.
62673533|NCT02559960||Breviscapine Powder-Injection|Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
62673534|NCT04197323|EXPERIMENTAL|Alprostadil liposomes for injection|
62673535|NCT04197323|ACTIVE_COMPARATOR|KAISHI for injection|
62112097|NCT00559949|EXPERIMENTAL|Arm I|Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
62673536|NCT04556097|EXPERIMENTAL|Early Training|Nurse care managers will be randomized to either early or delayed adapted Care Ecosystem training. The Early Training arm will be the first group to receive training and the first to have the opportunity to use the training in a clinical setting. We anticipate that each nurse care manager will manage 10 PWLD and we anticipate a 50% response rate/data availability, yielding 75 patients per arm.
62673537|NCT04556097|ACTIVE_COMPARATOR|Delayed Training|The Delayed Training arm will be the second group of nurse care managers to receive training.
61916805|NCT05167552|EXPERIMENTAL|Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells|Group 2: Patients with chronic polypous rhinosinusitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
61916806|NCT05167552|ACTIVE_COMPARATOR|Patients with allergic rhinitis receiving standard treatment|Group 3: Patients with allergic rhinitis receiving standard treatment
62673538|NCT03202550|PLACEBO_COMPARATOR|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
62673539|NCT03202550|ACTIVE_COMPARATOR|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
61916807|NCT05167552|ACTIVE_COMPARATOR|Patients with chronic polypous rhinosinusitis receiving standard treatment|Group 4: Patients with chronic polypous rhinosinusitis receiving standard treatment
61916808|NCT05224011|EXPERIMENTAL|Experimental|The Boppli device will be applied to the patients' arm or foot on either side of the body and is intended for single use of up to 72 hours and is discarded following use. The device will only be used in patients requiring continuous blood pressure monitoring, through the use of an invasive arterial line (IAL), to compare the data obtained by the Boppli to that obtained by the IAL.
62112098|NCT02485041|EXPERIMENTAL|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
62112099|NCT02485041|EXPERIMENTAL|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
62673540|NCT01060969|ACTIVE_COMPARATOR|Acetazolamide|acetazolamide 125 mg BID
61916809|NCT02538783|NO_INTERVENTION|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
62673541|NCT01060969|EXPERIMENTAL|Acetazolamide and Tadalafil|Intervention arm
62673542|NCT04462250|ACTIVE_COMPARATOR|Control|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points but there will be no reward provided.
61916810|NCT02538783|EXPERIMENTAL|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
61916811|NCT02249247|EXPERIMENTAL|Low dose of BIIL 284 BS|
61916812|NCT02249247|EXPERIMENTAL|Medium dose of BIIL 284 BS|
61916813|NCT02249247|EXPERIMENTAL|High dose of BIIL 284 BS|
61916814|NCT02249247|PLACEBO_COMPARATOR|Placebo|
61916815|NCT00852332|EXPERIMENTAL|Curcumine|With curcumin capsules
61916816|NCT00852332|ACTIVE_COMPARATOR|Drug taxotere only|Without curcumin
62112100|NCT02485041|EXPERIMENTAL|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
62673543|NCT04462250|ACTIVE_COMPARATOR|Contingency Management - Virtual Pet|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which can be used in the care of a virtual pet.
61916817|NCT00907660|ACTIVE_COMPARATOR|Full Dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 2 meals per day of portion-controlled foods (shakes and entrees)
61916818|NCT00907660|EXPERIMENTAL|Half dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 1 meal per day of portion-controlled foods (shakes and entrees)
62112101|NCT02485041|EXPERIMENTAL|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
62112102|NCT02485041|EXPERIMENTAL|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
62673544|NCT04462250|ACTIVE_COMPARATOR|Contingency Management - Monetary|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which will be paid out at the end of the one-week trial in the form of a monetary reward.
62673545|NCT01168479|ACTIVE_COMPARATOR|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
62112103|NCT02485041|EXPERIMENTAL|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
62673546|NCT01168479|EXPERIMENTAL|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
62673547|NCT03209583||Congenital Heart Disease|subjects have CHD and arrhythmias being treated with an implanted pacing device.
62673548|NCT05848375|EXPERIMENTAL|Loco regional anesthesia alone|Arthroscopic rotator cuff repair performed under LRA alone
62112104|NCT02546219||Adults with EoE|Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
62301960|NCT06172543|PLACEBO_COMPARATOR|Non Creatine Group|25 grams of Whey Protein Isolate + 25 grams of Carbohydrate Powder only
61916819|NCT05710380|EXPERIMENTAL|All Participants (Single Arm)|All participants in this trial will be provided with routine instructions and precaution information before starting the magnetic resonance (MRI) scan. After the MRI, participants will undergo an MRI-guided fusion biopsy of the prostate as ordered by their doctor. During this prostate MRI-guided fusion biopsy, the research team will obtain tissue from up to two additional biopsy targets selected by the Risk Map DSS tool. Ultimately, the clinical radiologist will make the final decision on the targets to be biopsied.
61916820|NCT02677324|EXPERIMENTAL|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
62301961|NCT02569515|EXPERIMENTAL|Epoetin Beta|Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
62301962|NCT01363726||2|Jewish and Bedouin children \< 5 years of age in southern Israel
62673549|NCT05848375|ACTIVE_COMPARATOR|Loco regional anesthesia associated to general anesthesia|Arthroscopic rotator cuff repair performed under LRA and GA
62673550|NCT02542579||Subjects for pyrosequencing analysis|Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis
62112105|NCT03537651|EXPERIMENTAL|TEZ/IVA|"Part A: Participants weighing less than (\<)40 kilograms (kg) at Day 1 received tezacaftor (TEZ) 50 milligrams (mg) once daily (qd)/ivacaftor (IVA) 75 mg every 12 hours (q12h) and the participants weighing greater than or equals to (\>=) 40 kg at Day 1 received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 96 weeks. Doses were adjusted upward for changes in body weight and/or age.~Part B: Participants weighing \<30 kg at Day 1 received TEZ 50 mg qd/IVA 75 mg q12h and the participants weighing \>=30 kg at Day 1 received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period up to 192 weeks. Doses were adjusted upward for changes in body weight and/or age."
62673551|NCT04806126||Virtual Mentoring Program Participants|Physicians credentialed at Satellite Healthcare will be eligible to participate along with nephrology fellows from training programs affiliated with credentialed physicians.
62112106|NCT04687085|PLACEBO_COMPARATOR|Neutral Content|Participants will listen to a 10 minute neutral content recording just prior to epidural catheter placement.
62112107|NCT04687085|EXPERIMENTAL|Mindful Meditation|Participants will listen to a 10 minute mindful meditation recording just prior to epidural catheter placement.
62301963|NCT04155879|NO_INTERVENTION|Control Group|Cardioversion without treatment with Colchicine
62301964|NCT04155879|ACTIVE_COMPARATOR|Treatment group|This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months
62673552|NCT05058638|EXPERIMENTAL|Aquamin®|
62673553|NCT05938010||Dailies Total1® contact lenses for astigmatism (T30fA)|Dailies Total1® contact lenses for astigmatism (T30fA)
62673554|NCT01983904|EXPERIMENTAL|Long Pulse Width|deep brain stimulation with short \& long pulse width
62673555|NCT01983904|EXPERIMENTAL|Short Pulse Width|deep brain stimulation with short \& long pulse width
62673556|NCT01368731|NO_INTERVENTION|nil prophylactic coagulation|
62673557|NCT01368731|ACTIVE_COMPARATOR|Prophylactic coagulation|
61916821|NCT03532607|EXPERIMENTAL|Treatment|Participants will be asked to listen to pre-recorded music offered by the research team from an ipod for 30 minutes. After the 30 minutes have elapsed, the research staff will return and ask the patient to turn off the music. The patient then will be escorted to the clinic room to receive the botox injection.
61916822|NCT03532607|NO_INTERVENTION|Control|After completing the consent form, the participants who are assigned to the control group will be asked to remain in the patient waiting area. The patient then will be escorted to the clinic room to receive the botox injection.
61916823|NCT01711060|EXPERIMENTAL|oxytocin|
61916824|NCT01711060|EXPERIMENTAL|balloon catheter|Dufour 1859H18
61916825|NCT02392533||Pre cohort group|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
61916826|NCT02392533||Post cohort group.|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
62673558|NCT05105971|EXPERIMENTAL|BAT6026 0.01mg/kg|BAT6026 0.01mg/kg,intervenous infusion,sample size 1
62673559|NCT05105971|EXPERIMENTAL|BAT6026 0.03mg/kg|BAT6026 0.03mg/kg,intervenous infusion,sample size 1
62673560|NCT05105971|EXPERIMENTAL|BAT6026 0.1mg/kg|BAT6026 0.1mg/kg,intervenous infusion,sample size 3\~6
62673561|NCT05105971|EXPERIMENTAL|BAT6026 0.3mg/kg|BAT6026 0.3mg/kg,intervenous infusion,sample size 3\~6
62673562|NCT05105971|EXPERIMENTAL|BAT6026 1mg/kg|BAT6026 1mg/kg,intervenous infusion,sample size 3\~6
62673563|NCT05105971|EXPERIMENTAL|BAT6026 3mg/kg|BAT6026 3mg/kg,intervenous infusion,sample size 3\~6
62673564|NCT05105971|EXPERIMENTAL|BAT6026 6mg/kg|BAT6026 6mg/kg,intervenous infusion,sample size 3\~6
62673565|NCT05105971|EXPERIMENTAL|Amplification group|BAT6026 10mg/kg,intervenous infusion,sample size 3\~6
62673566|NCT00936039|EXPERIMENTAL|unloading|2 weeks of unloading
61916827|NCT04635670|PLACEBO_COMPARATOR|Placebo|Soluble powder for oral use twice daily
61916828|NCT04635670|ACTIVE_COMPARATOR|Active|The investigational product is soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
62673567|NCT01431547|EXPERIMENTAL|Part 1: Dalotuzumab|
62673568|NCT01431547|EXPERIMENTAL|Parts 2 and 3: Dalotuzumab + ridaforolimus|
62673569|NCT04644757|EXPERIMENTAL|Treatment|
62673570|NCT06286046|EXPERIMENTAL|Mitapivat 100 mg|Participants will receive mitapivat 100 milligrams (mg) tablet, orally, twice daily (BID) for up to 24 months.
62673571|NCT04759092|EXPERIMENTAL|Treatment with tDCS|Home based treatment with tDCS for four months
62673572|NCT02405858|EXPERIMENTAL|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily, concomitantly with oral prednisolone 10 mg per day. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least one hour after the dose of abiraterone acetate is taken. A 28-daily dosing cycle will continue until disease progression or unacceptable toxicity is observed up to 2 years.
62673573|NCT02728726|EXPERIMENTAL|Sugammadex|Subjects will have Sugammadex administered after routine reversal of anesthesia is performed and patient is extubated.
62673574|NCT02728726|PLACEBO_COMPARATOR|Placebo|Subjects will have Placebo administered after routine reversal of anesthesia is performed and patient is extubated.
62673575|NCT02444377|EXPERIMENTAL|High-intensity interval -2min|5 bouts of 2 min cycling at varying intensities of VO2peak (80-100%) with 1 min recovery.
62673576|NCT02444377|EXPERIMENTAL|High-intensity interval -1min|10 bouts of 1 min cycling at 90% of VO2peak with 1 min rest periods
62673577|NCT02444377|NO_INTERVENTION|Control|No exercise
62673578|NCT01038466||CHAT trial participants|CHAT trial participants whose data was used in the final data analysis for the CHAT study
62301965|NCT06488196|EXPERIMENTAL|Motivational Interviewing|Mothers in the MI-arm received up to six weekly MI sessions until the baby was discharged from the NICU. Mothers whose baby was discharged prior to or during week six completed measures at enrollment and NICU discharge. Mothers whose baby was discharged after week six completed questionnaires at enrollment and at the end of week six. Mothers could choose whether to complete MI in English or Spanish. Native Spanish-speaking, ethnically-matched providers conducted Spanish-language sessions. Study team members offered to read questionnaires aloud and record responses; however, all participants chose to independently complete paper-and-pencil measures.
62301966|NCT06488196|ACTIVE_COMPARATOR|Treatment as Usual|In the institution in which the investigators conducted this study, per institutional standards, TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
62301967|NCT05847881|EXPERIMENTAL|Reflective process group|
62301968|NCT06315010|EXPERIMENTAL|Repotrectinib|Repotrectinib 160 mg orally (PO) every day (QD) for 14 days, and 160 mg twice a day (BID) thereafter.
62301969|NCT05041335|EXPERIMENTAL|Heparin and microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue onto the microsieve
62301970|NCT05041335|EXPERIMENTAL|Heparin and no microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue into formalin
62301971|NCT05041335|EXPERIMENTAL|No heparin and microsieve|The needle not be prepped. The provider will expel the tissue onto the microsieve
62673579|NCT03112187|EXPERIMENTAL|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
62673580|NCT02528305|EXPERIMENTAL|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
62673581|NCT02681432|EXPERIMENTAL|HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
62673582|NCT02681432|ACTIVE_COMPARATOR|No HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
62673583|NCT06450704|EXPERIMENTAL|Exercise intervention group (EG)|Major Depressive Disorder patients will receive the exercise intervention for 12 weeks as an add-on to their usual treatment (antidepressant treatment prescribed by the attending specialist). They will gradually increase their levels of physical activity by daily walking and will conduct aerobic and muscle strength activities 2 days per week. The program will be supervised by a physical education and sports professional.
62673584|NCT06450704|NO_INTERVENTION|Control group (CG)|Major Depressive Disorder patients will only receive standard treatment (antidepressant treatment prescribed by the attending specialist) and will be instructed to not change their usual physical activity.
62673585|NCT01842178|EXPERIMENTAL|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.~Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control"
62673586|NCT01842178|PLACEBO_COMPARATOR|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
62673587|NCT01237405||Knee Osteoarthritis|"Unilateral or bilateral knee osteoarthritis on radiograph associated with knee pain on most days of any one-month in the last year in at least one knee.~Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi)."
62673588|NCT01433003|ACTIVE_COMPARATOR|Standard-dose plasma exchange|50-75 ml/kg/day
62673589|NCT01433003|EXPERIMENTAL|High-dose Plasma Exchange|125 ml/kg/day up to 10 L/day
62301972|NCT05041335|ACTIVE_COMPARATOR|No heparina nd no microsieve|The needle not be prepped. The provider will expel the tissue into formalin
62301973|NCT04285528|EXPERIMENTAL|General Anesthesia|The first group which will undergo general anesthesia, will be anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway will be inserted afterwards.
62471053|NCT03657394|ACTIVE_COMPARATOR|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC.
62673590|NCT01014156|EXPERIMENTAL|epoprostenol intraveneously|epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
62112108|NCT02685033|EXPERIMENTAL|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was \< 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.
62112109|NCT02685033|ACTIVE_COMPARATOR|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
62112110|NCT05288348|EXPERIMENTAL|DSUVIA (sufentanil)|Subjects will receive a single dose of 30 micrograms DSUVIA (sufentanil) tablet utilizing a sublingual applicator
62112111|NCT05288348|ACTIVE_COMPARATOR|Standard Care|Subjects will receive standard care pain management
62112112|NCT01981330|EXPERIMENTAL|aMSC with and without hyaluronan gel|autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients
62112113|NCT02852863|EXPERIMENTAL|Ultrasound (case only)|Subjects will fast for a minimum of 8 hours. Ultrasound assessment of gastric volume and content will determine basal conditions. Next, subjects will chew gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
62112114|NCT04658849|EXPERIMENTAL|Pioglitazone Arm|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
62112115|NCT04658849|PLACEBO_COMPARATOR|Placebo Arm|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
62112116|NCT04990219|EXPERIMENTAL|Lu AG06466|Participants will receive Lu AG06466 at a starting dose orally once daily for 4 days (Day 1 to Day 4), followed by Lu AG06466 at a higher titrated dose orally once daily for 4 days (Day 5 to Day 8), followed by Lu AG06466 at a higher titrated treatment dose orally once daily from Day 9 until Day 35/Week 5.
62112117|NCT04990219|PLACEBO_COMPARATOR|Placebo|Participants will receive Lu AG06466-matching placebo orally once daily until Day 35/Week 5.
62301974|NCT04285528|EXPERIMENTAL|PFK group|The second group will undergo intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine will be added, this aims to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water for injection will be added to the mixture.
62301975|NCT04278742|EXPERIMENTAL|Interventional - collaborative education|Collaborative style of communication whereby the clinician and patient co-creates the treatment plan
62471054|NCT03657394|NO_INTERVENTION|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
62673591|NCT01951456|EXPERIMENTAL|Resistance training|Participants will attend two, 45-60-minute progressive, moderate intensity resistance training sessions per week for 12 weeks. The program will maintain a format of a 5-minute warm-up, 35-50 minutes of resistance training and a 5-minute cool-down with flexibility and abdominal exercises.
62301976|NCT04278742|NO_INTERVENTION|Control group|Traditional directive and didactic style of patient information will be provided
62301977|NCT00705900|EXPERIMENTAL|1|LCD Solution: 2 applications / day
62301978|NCT00705900|ACTIVE_COMPARATOR|2|Calcipotriol cream: 2 applications / day
62301979|NCT00391976|EXPERIMENTAL|Tobramycin 300 mg for 28 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
62301980|NCT00391976|EXPERIMENTAL|Tobramycin 300 mg for 56 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
62673592|NCT01951456|ACTIVE_COMPARATOR|Health and Wellness|Participants in this group will be required to attend the exact same number of sessions as those in the Resistance Training group. Each session will last approximately 45-60 minutes. Sessions will include a practical component/demonstration, an informational video, and a handout on a pertinent healthy lifestyle topic for adults.
62112118|NCT04246619|EXPERIMENTAL|Pregabalin Krka Arm|"ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN.~Investigator can choose on V2:~* Total Pregabalin Krka daily dose: 25 mg/day~* Total Pregabalin Krka daily dose: 50 mg/day~* Total Pregabalin Krka daily dose: 75 mg/day~* Total Pregabalin Krka daily dose: 150 mg/day~* Total Pregabalin Krka daily dose: 300 mg/day (from Phone call 1 further on)~V3: daily dose should be achieved: MINIMUM dose 150 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day~V4: Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day"
62112119|NCT04246619|EXPERIMENTAL|Dulsevia® Arm|"• ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:~Investigator can choose on V2:~* Total Dulsevia® daily dose: 30 mg/day~* Total Dulsevia® daily dose: 60 mg/day~V3: daily dose should be achieved: MINIMUM dose 60 mg/day Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day.~V4: Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day."
62112120|NCT04628442||TIP-OB (Office-Based)|Those in TIP-OB will be undergoing regularly scheduled office-based procedures at the otolaryngology clinic at UCSF Mount Zion campus. The investigators will be collecting nasal mucus and blood samples during each of their visits to the clinic, up to 9 times.
62112121|NCT04628442||TIP-OR (Operating Room)|Those in TIP-OR will be undergoing regularly scheduled surgeries in the operating room at UCSF Parnassus or Mount Zion campus. The investigators will be collected nasal polyp tissue, nasal mucus if possible, and blood samples during each of their surgeries, up to 9 times. The investigators will also collect inferior turbinate tissue if consented to.
62112122|NCT06420713|ACTIVE_COMPARATOR|Autogenous bone graft or Leukocyte-and-Platelet-Rich Fibrin (L-PRF)|
62112123|NCT06420713|ACTIVE_COMPARATOR|Groups|
62112124|NCT06420713|ACTIVE_COMPARATOR|Dental Implants|
62112125|NCT01717794|ACTIVE_COMPARATOR|Standard bipolar electrosurgery|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
62112126|NCT01717794|EXPERIMENTAL|Thunderbeat technology|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to coagulate the fallopian tubes, to coagulate and divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to incise the bladder peritoneum, to dissect the bladder, to develop rectovaginal septum, to cut parametria, and to divide the uterosacral ligaments. Thunderbeat is also used to perform the pelvic lymphadenectomy and, if necessary, the para-aortic lymphadenectomy."
62112127|NCT06631976|ACTIVE_COMPARATOR|Rehabilitation|Rehabilitation Treatment - a group of patients will be treated using a standardized rehabilitation protocol.
62112128|NCT06631976|EXPERIMENTAL|Steroid|Rehabilitation treatment combined with a subacromial corticosteroid injection. Patients will receive 1ml of methylprednisolone acetate (40mg/ml) into the subacromial-subdeltoid bursa.
62112129|NCT06631976|EXPERIMENTAL|PRP|Rehabilitation treatment combined with PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
62112130|NCT06631976|EXPERIMENTAL|Nerve Block|Rehabilitation treatment combined with suprascapular nerve block. Patients will receive 4ml of 2% lidocaine around the suprascapular nerve.
62112131|NCT02220491|ACTIVE_COMPARATOR|Whole-brain radiotherapy|"All subjects will have a non-contrast CT scan using a slice thickness of 2.5mm or less.~The Brain contour will be generated using the segmentation wizard and edits as required.~PTV_Brain is an expansion of the Brain by 5mm. 99% of PTV_Brain is to be covered by 95% of 20 Gy in 5 fractions using 6-10 MV photons in a parallel-opposed pair lateral beam arrangement."
62301981|NCT04568499||Suspected and Confirmed COVID-19 cases|Suspected and confirmed COVID-19 cases (age 5 years and above) identified at health facilities or via mobile teams in Juba, South Sudan and in Eastern Democratic Republic of the Congo.
62301982|NCT06657300|EXPERIMENTAL|Group 1 (PRP group)|A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group.
62301983|NCT06657300|EXPERIMENTAL|Group 2 (CS group)|A single dose of 20 mg of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group
62301984|NCT01928979||Group 1|
62301985|NCT02224664|EXPERIMENTAL|Cohort 3|Titration of PF-06649751 up to 5 mg QD
62301986|NCT02224664|EXPERIMENTAL|Cohort 4|Titration of PF-06649751 up to 15 mg QD
62301987|NCT02224664|EXPERIMENTAL|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
62673593|NCT02979158|EXPERIMENTAL|CPB Low Dose|Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s
62673594|NCT02979158|EXPERIMENTAL|CPB High Dose|Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s
62673595|NCT05236127|EXPERIMENTAL|Fasted|Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for the entire 8-day period of the study.
62673596|NCT05236127|EXPERIMENTAL|Pre-heading fasted|Pre-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a 4 hour eating window for a 5-day period prior to the soccer heading.
62673597|NCT05236127|EXPERIMENTAL|Post-heading fasted|Post-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for a 3-day period following the soccer heading.
62471055|NCT06431321|EXPERIMENTAL|Parent training intervention|The Tabudirira Parenting Intervention for Early Childhood Development will be delivered to parents of children aged 4-5 years in Harare, Zimbabwe. Trained facilitators will deliver the programme face to face, and a group of 15 parents will have 3 facilitators. The facilitators comprise of teachers working as guidance and counselling coordinators and psychology graduates. The programme consists of 2 sessions that will be delivered once a week over 2 weeks, with each session lasting 2.5 to 3 hours. The session will have various activities which focus on learning from each other and practising positive parenting behaviours. At the end of each session, parents will receive a home activity which allows them to practise the content taught during the session. At the end of session 2 parents will receive a parent handbook with the summary of the 2 sessions. Schools will be used as venues and the facilitators will receive ongoing mentoring and coaching during programme delivery.
62673598|NCT05236127|EXPERIMENTAL|Control|Control Group: Individuals randomly assigned to eat per usual over the course of the entire 8-day study period.
61916829|NCT01331018|EXPERIMENTAL|Treatment (hematopoietic stem progenitor cells)|"STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim SC BID for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC QD on days 4-6 of mobilization. PBSC count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of \>= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days.~BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells.~REINFUSION: Patients receive methylprednisolone IV or prednisone PO on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0."
61916830|NCT02034136|EXPERIMENTAL|Ginsenoside|"Ginsenoside :~Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group"
61916831|NCT02034136|PLACEBO_COMPARATOR|Dietary fiber fill|Dietary fiber fill manufactured to mimic Ginsenoside tablet
61916832|NCT04421547|EXPERIMENTAL|Letrozole|Letrozole 1 tablet (2,5 mg) orally once a day
61916833|NCT04421547|ACTIVE_COMPARATOR|Standard Chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
61916834|NCT03411837||Dupilumab|Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
61916835|NCT03234881|ACTIVE_COMPARATOR|MOVE!|Weight management delivered as Treatment-as-Usual
62301988|NCT02224664|EXPERIMENTAL|Cohort 6|Titration of PF-0649751 up to 25 mg QD
62301989|NCT02384720||A|Gender: 10 Males, 10 Females
62301990|NCT02384720||B|Gender: 10 Males, 10 Females
61916836|NCT03234881|EXPERIMENTAL|MOVE!+CBT|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
62301991|NCT02384720||C|Gender: 10 Males, 10 Females
18535077|NCT06399965|EXPERIMENTAL|atosiban|
18535078|NCT06399965|PLACEBO_COMPARATOR|normal saline|
62301992|NCT02389881|EXPERIMENTAL|Cohort 1 Non-elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
62301993|NCT02389881|EXPERIMENTAL|Cohort 2 Non-elderly Healthy: TAK-058 75 mg|TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
62301994|NCT02389881|EXPERIMENTAL|Cohort 3 Non-elderly Healthy: TAK-058 150 mg|TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
62301995|NCT02389881|EXPERIMENTAL|Cohort 4 Elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.
62301996|NCT02389881|PLACEBO_COMPARATOR|Cohort 5 Non-elderly Healthy: TAK-058 300 mg|TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.
62301997|NCT02389881|PLACEBO_COMPARATOR|Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.
62301998|NCT02389881|PLACEBO_COMPARATOR|Cohort 4 Elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
62301999|NCT04910217|EXPERIMENTAL|Lokomat intervention|Patients randomized into the Lokomat arm will undergo therapy with Lokomat Pro FreeD for 20-50 minutes 5-times a week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.
62302000|NCT04910217|EXPERIMENTAL|Conventional rehabilitation|Patients in this arm will undergo conventional rehabilitation ((ergotherapy and physiotherapy) for 60 min 5 times a week, a total of 15 times within 3 weeks (a total of 1200 min)
62302001|NCT02172118|EXPERIMENTAL|severely renally impaired patients|
62302002|NCT02172118|EXPERIMENTAL|healthy volunteers|
61916837|NCT04673123|EXPERIMENTAL|Core Stabilization Group|Core stabilization + Multifactorial Education Program (patient-specific upper and lower extremity stretching and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
61916838|NCT04673123|ACTIVE_COMPARATOR|Multifactorial Education Program Group|Multifactorial Education Program (patient-specific upper and lower extremity stretching, relaxation and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
61916839|NCT00061282|PLACEBO_COMPARATOR|1|
61916840|NCT00061282|ACTIVE_COMPARATOR|2|Clotrimazole Therapy
61916841|NCT00061282|ACTIVE_COMPARATOR|3|Clotrimazole Therapy
61916842|NCT01401959|EXPERIMENTAL|Cohort A: Triple-negative breast cancer|Eribulin 1.4 mg/m\^2 intravenously (IV)
62302003|NCT03245814|EXPERIMENTAL|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
62673599|NCT05236127|ACTIVE_COMPARATOR|Subconcussive Head Impact|"All four groups undergo the same soccer heading model as described below.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by 30 second intervals."
61916843|NCT01401959|EXPERIMENTAL|Cohort B: ER/PR+ /HER2- breast cancer|Eribulin 1.4 mg/m\^2 intravenously (IV)
61916844|NCT01401959|EXPERIMENTAL|Cohort C: HER2+ breast cancer|"Eribulin 1.4 mg/m\^2 intravenously (IV)~Trastuzumab 6mg/kg intravenously (IV)"
61916845|NCT02225054|PLACEBO_COMPARATOR|Ropivacaine,Normal Saline,Saline Bolus|Ropivacaine 15 mL 0.5% Normal Saline mL 0.9% Saline Bolus
61916846|NCT02225054|EXPERIMENTAL|Ropivacaine,Dexmedetomidine,Saline Bolus|Ropivacaine15 mL 0.5% Dexmedetomidine0.5 u/kg Saline Bolus
62112132|NCT02220491|EXPERIMENTAL|Single-fraction radiotherapy|Immobilized in the mask, the subject will be imaged for radiotherapy planning with a CT slice thickness of 1.25 mm or less and an axial resolution of \< 0.7 mm (CT field of view \< 35 cm). Subjects that require contrast with GFR 45-59 will have pre-hydration, contrast dose modification and/or Mucomyst administration to preserve renal function, according to standard practice for radiological imaging at the institution.
62302004|NCT03245814|NO_INTERVENTION|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
62302005|NCT04893668||Exposed with COVID 19|The participant with confirmed RT-PCR Covid 19 at the beginning of the study
62112133|NCT03432780|EXPERIMENTAL|Docetaxel, hormone and radiation therapy|Radiation therapy combined with weekly docetaxel (20 mg/m2) and hormone therapy.
62112134|NCT03432780|ACTIVE_COMPARATOR|Hormone and radiation therapy|Radiation therapy and hormone therapy
62302006|NCT04893668||Unexposed with COVID 19|The participant without confirmed RT-PCR Covid 19 at the beginning of the study until 6 month follow up period
62302007|NCT05621863|EXPERIMENTAL|Aim 1 Group 1|"Order of Treatments:~Meal Challenge 1, Meal Challenge 2, Meal Challenge 3"
62673600|NCT03112850|ACTIVE_COMPARATOR|Group A|Participants who will be fitted with hearing aids for the first 3 months of 6 months auditory training program
62302008|NCT05621863|EXPERIMENTAL|Aim 1 Group 2|"Order of Treatments:~Meal Challenge 1, Meal Challenge 3, Meal Challenge 2"
62302009|NCT05621863|EXPERIMENTAL|Aim 1 Group 3|"Order of Treatments:~Meal Challenge 2, Meal Challenge 3, Meal Challenge 1"
61916847|NCT02225054|ACTIVE_COMPARATOR|Ropivacaine,Saline,Dexmedetomidine|Ropivacaine 15 mL 0.5% Normal Saline 1 mL 0.9% Dexmedetomidine single IV bolus 0.5 u/kg over 30 minutes
62112135|NCT03728595||Patients with lung disease having HAST|"Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:~* venepuncture~* spirometry."
62302010|NCT05621863|EXPERIMENTAL|Aim 1 Group 4|"Order of Treatments:~Meal Challenge 2, Meal Challenge 1, Meal Challenge 3"
62302011|NCT05621863|EXPERIMENTAL|Aim 1 Group 5|"Order of Treatments:~Meal Challenge 3, Meal Challenge 1, Meal Challenge 2"
62302012|NCT05621863|EXPERIMENTAL|Aim 1 Group 6|"Order of Treatments:~Meal Challenge 3, Meal Challenge 2, Meal Challenge 1"
62302013|NCT05621863|EXPERIMENTAL|Aim 2 Typical American Diet|
62302014|NCT05621863|EXPERIMENTAL|Aim 2 Typical American Diet Plus Test Foods|
62302015|NCT05621863|EXPERIMENTAL|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|
62302016|NCT03783910|EXPERIMENTAL|GRT9906|"Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).~Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg \[40 mg twice daily\]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks."
62302017|NCT03783910|PLACEBO_COMPARATOR|Placebo|Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks.
62471056|NCT06431321|ACTIVE_COMPARATOR|Control|The control group (8 groups with 15 parents each) will receive a one-hour session on nutrition with facilitators trained by a nutritionist focusing on children aged 4-7 years. The parents will also receive a nutrition handbook. Zimbabwe is faced with the triple burden of malnutrition: underweight, micronutrient deficiencies and overweight. There is an ongoing need to protect and promote diets, services and practices through a multi-systems approach that supports optimal nutrition, growth, and development for all children, using a parent support group can help achieve the goal. The nutrition programme has no components of positive parenting or links to the reduction of violence against children but will serve as a placebo control for the attention received by parents.
62673601|NCT03112850|ACTIVE_COMPARATOR|Group B|Participants who will be fitted with hearing aids for the second 3 months of 6 months auditory training program
62112136|NCT01490580|EXPERIMENTAL|Atropine + Propofol|
62112137|NCT01490580|ACTIVE_COMPARATOR|Atropine + atracurium + sufentanil|
62112138|NCT06435260|EXPERIMENTAL|Hypofractionated radiotherapy+Camrelizumab+chemotherapy|Efficacy evaluation was performed within 2 weeks after the end of neoadjuvant therapy, surgical treatment was performed in patients assessed as operable and in those with a clear intention to undergo surgery, postoperative adjuvant chemotherapy and ICIs were determined according to the patient's tolerance and independent will, and enter the follow-up period.
62112139|NCT00673543||1|Pregnant women with insulin requiring diabetes
62112140|NCT00673543||2|Pregnant women without insulin requiring diabetes
62112141|NCT01198340|ACTIVE_COMPARATOR|With basal local anesthetics|
62112142|NCT01198340|EXPERIMENTAL|Without basal local anesthetics|
62112143|NCT00256243|EXPERIMENTAL|Chemotherapy with GM-CSF|"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6)~This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.~Patients who are her-2 overexpressors by FISH will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination has been found to be synergistic in advanced breast cancer with improved clinical outcome."
62302018|NCT01191593|EXPERIMENTAL|Adductor-Canal-Blockade with ropivacaine|
62302019|NCT01191593|PLACEBO_COMPARATOR|Adductor-Canal-blockade with saline|
62302020|NCT00987415|ACTIVE_COMPARATOR|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
62302021|NCT00987415|PLACEBO_COMPARATOR|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
62112144|NCT02787109|EXPERIMENTAL|CTH522-CAF01|"CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
62112145|NCT02787109|EXPERIMENTAL|CTH522-Al(OH)3|"CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
62112146|NCT02787109|PLACEBO_COMPARATOR|Placebo|Saline for IM and In administrations
62302022|NCT00524303|ACTIVE_COMPARATOR|Arm 1|Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
62673602|NCT05611424|EXPERIMENTAL|FT003 Dose 1|Low dose of FT-003
62673603|NCT05611424|EXPERIMENTAL|FT003 Dose 2|Mid dose of FT-003
62673604|NCT05611424|EXPERIMENTAL|FT003 Dose 3|High dose of FT-003
62673605|NCT05199038|EXPERIMENTAL|2 Days of octreotide infusion|
62673606|NCT05199038|ACTIVE_COMPARATOR|5 Days of octreotide infusion|
62112147|NCT03970590|EXPERIMENTAL|CTC|"An integrated peer narrative-based intervention (VIEW \> SELECT \> GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
62112148|NCT03970590|ACTIVE_COMPARATOR|Control|6-month HTN management assessment text messages without narrative component
62673607|NCT05449873|EXPERIMENTAL|Patients with recurrent hepatocellular carcinoma after locoregional treatment|Patients with chronic liver disease have recurrent hepatocellular carcinoma which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
62673608|NCT04474379|EXPERIMENTAL|Strategy Training|Consists of 8-90 minute sessions over 8 weeks. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the therapist teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based) and instructs in their use before and during the training games. In sessions 3-8, the tester tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. After completing the training games, the therapist and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the therapist helps the participant develop written action plans to do so. Plans and goals are reviewed and modified, if necessary, at each session.
62112149|NCT04436055||All participants|All participants including cannabis users, other drug users, and non-drug users.
62112150|NCT03814395||Exposure group|Group with environmental, nutritional or lifestyle exposures
62112151|NCT03814395||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
62112152|NCT05112354|EXPERIMENTAL|the main group|"Management plan~1. If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2. Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator"
62112153|NCT03150563|NO_INTERVENTION|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
62112154|NCT03150563|EXPERIMENTAL|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
62112155|NCT03150563|EXPERIMENTAL|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
62112156|NCT03150563|EXPERIMENTAL|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
61916848|NCT00799773|EXPERIMENTAL|1|Participants will receive rituximab in addition to plasma exchange and corticosteroids.
61916849|NCT00799773|ACTIVE_COMPARATOR|2|Participants will receive plasma exchange and corticosteroids.
61916850|NCT00865488|NO_INTERVENTION|1|patients who will be treated in accordance with standard of care
61916851|NCT00865488|EXPERIMENTAL|2|patients for which Adhexil will be applied to prevent/reduce adhesions
62112157|NCT03367494|OTHER|Subjects with Cystic Fibrosis|Diagnostic
62112158|NCT03367494|OTHER|Healthy Volunteers|Diagnostic
62112159|NCT04059237|EXPERIMENTAL|Online Decision Aid|web-based psychosocial assessment questionnaires will be administered at baseline (T1; pre-intervention) and at one-month (T2) and three-month (T3) follow-up time points.
62112160|NCT03317535|OTHER|Local anesthesia/conscious sedation|Patients will be injected by propofol (adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
62302023|NCT00524303|EXPERIMENTAL|Arm 2|Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
62302024|NCT00524303|EXPERIMENTAL|Arm 3|Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
62302025|NCT05361512||Patients having an epidural placed for labour analgesia or anesthesia for cesarean delivery|Patients with BMI\>=50 who are having an epidural placed may take part in this study.
62302026|NCT05159193|EXPERIMENTAL|PLD + C + HP followed by THP|pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 followed by docetaxel (T) 90\~100 mg/m\^2, i.v., d1 + trastuzumab (H) 6 mg/kg, i.v., d1 + pertuzumab (P) 420 mg, i.v., d1 q3w, for 4 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
62302027|NCT05159193|ACTIVE_COMPARATOR|TCbHP|docetaxel (T) 75 mg/m\^2, i.v., d1 + carboplatin (Cb) AUC 6, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 q3w, for 6 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
62302028|NCT05623644||TD-PD patients undergoing MRgFUS thalamotomy|The imaging data from patients with tremor dominant PD underwent MRgFUS thalamotomy. Their clinical and imaging data were also collected.
62302029|NCT05623644||MR-ET patients undergoing MRgFUS thalamotomy|The imaging data from patients with medication-resistant ET underwent MRgFUS thalamotomy. Their clinical and imaging data were also collected.
62302030|NCT00594399|EXPERIMENTAL|Arm 1 Physical Activity counseling|Physical activity (PA) counseling program with the following components: baseline in-person counseling session; telephone calls, one physician endorsement of PA in a primary care clinic visit, monthly automated telephone calls from the primary care provider encouraging PA; and quarterly mailed materials providing personalized feedback.
62302031|NCT00594399|NO_INTERVENTION|Arm 2|Usual care from primary, womens or geriatric clinics
62302032|NCT01901744|EXPERIMENTAL|Patients undergoing cataract surgery|
62302033|NCT05635565|ACTIVE_COMPARATOR|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
62302034|NCT05635565|EXPERIMENTAL|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
62302035|NCT01552174||Outpatients attending general ophthalmologic consultation|"* Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation~* Patients informed of the objectives of the survey and agreeing to participate.~* Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up."
62302036|NCT05813470|EXPERIMENTAL|Omalizumab (CinnaGen)|Omalizumab (CinnaGen) was administered every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg/IgE for a duration of 28 weeks
62302037|NCT05813470|ACTIVE_COMPARATOR|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg/IgE for a duration of 28 weeks
62302038|NCT01593982|PLACEBO_COMPARATOR|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
62302039|NCT01593982|ACTIVE_COMPARATOR|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Active rTMS delivered to the left dorsolateral prefrontal cortex.
62302040|NCT05241587|EXPERIMENTAL|The chewing gum group|"Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010). Therefore, this group of patients was allowed to chew xylitol gum for 10 minutes, five times a day for six weeks."
61916852|NCT02176720|NO_INTERVENTION|Standard diagnostics without PET|Standard of care brain imaging modalities, predominantly MRI
62112161|NCT03317535|OTHER|General anesthesia|Patients will be induced with remifentanil (0.2-0.8 μg/kg), propofol (1-2mg/kg) and rocuronium (0.6 mg/kg). Anesthesia will then be maintained keep the BIS between 40 and 60 with propofol and remifentanil. After tracheal intubation, patients will be kept with controlled ventilation.
62302041|NCT05241587|EXPERIMENTAL|The mouth spray group|The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request.
61916853|NCT02176720|EXPERIMENTAL|FDOPA PET-CT|PET-CT with administration of FDOPA as an experimental radiopharmaceutical. This arm includes standard of care imaging plus FDOPA PET-CT
62302042|NCT05157425|EXPERIMENTAL|Experimental|Probiotic multi-strain formulation comprising L. plantarum CECT30292, CECT7484, CECT7585 and P. acidilactici and maltodextrin (E1400, qs) as excipient in hydroxymethylpropyl-cellulose (HPMC) capsules. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
62302043|NCT05157425|PLACEBO_COMPARATOR|Placebo|Maltodextrin (E1400, qs) in HPMC capsules
62302044|NCT04978623||Patient with CIDP|CIDP, is an acquired chronic inflammatory neuropathy characterised by : progressive symmetrical weakness of the proximal and to a lesser extent distal muscles of the lower and/or upper limbs, altered sensitivity and a decrease/abolition of the osteotendinous reflexes. The condition can be relapsing (30% of cases), chronically progressive (60%), or monophasically with total subsequent recovery (10%). Cranial nerve involvement is possible (5-30% of cases). Neuropathic pain as well as respiratory muscle and sub-clinical central nervous system involvement are described.
62302045|NCT04978623||Patient with MMNCB|Patients with MMNCB are at the crossroads between chronic demyelinating neuropathies and motor neuron diseases, the latter for which they constitute a differential diagnosis. The disease usually presents asymmetrically and affects the upper limbs more frequently. The course of the disease is unpredictable, and may be limited to one or two motor nerves or progress to other motor nerves in the contralateral upper limb and possibly the lower limbs. In all cases, the motor deficit is asymmetrical, multi-truncular in distribution, and is usually accompanied by cramps and fasciculations, and eventually by amyotrophy. Osteotendinous reflexes are usually diminished or abolished in the affected areas, but they may also be preserved in the initial attacks. There is no sensory deficit, although some patients occasionally present with paresthesias, and exceptionally with damage to the cranial nerves (especially CN XII).
61916854|NCT01240265|EXPERIMENTAL|Vitamin D 150,000 units once|Single dose of vitamin D3 150,000 IU given orally once
61916855|NCT01240265|EXPERIMENTAL|Vitamin D 5000 units daily|Vitamin D3 5000 IU daily given orally for 28 days
62471057|NCT03141398||High-Risk Group|The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2\* MRI of the pancreas (T2\* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.
62112162|NCT05218408|EXPERIMENTAL|Phase 1Surgical rGBM CYNK-001 infusion ( IV and IC) in combination with IL-2|Phase 1 dose escalation will utilize a 3+3 dose escalation design and will evaluate safety, feasibility, and preliminary efficacy of four cohort dose levels of CYNK-001 administered after a 6M IU subcutaneous dose of rhIL-2 for both IV and IC cycles. Up to 21 patients will be enrolled over 4 dosing cohorts in Phase 1.
62112163|NCT05218408|EXPERIMENTAL|Phase IIa Surgical rGBM CYNK-001 at MPD IV and IC|To evaluate efficacy and safety of CYNK-001 administrations in recurrent GBM at maximum tolerated dose for IV and IC per Phase 1 outcome. No patients staggering will be implemented in phase 2a. DMC will review the phase 2a entirely
62112164|NCT01711047|ACTIVE_COMPARATOR|PVI + Linear ablation|Arm A: patients have PVI and roof and mitral isthmus lines
62112165|NCT01711047|ACTIVE_COMPARATOR|PVI + linear ablation + CFAE|Arm B: patients have PVI + roof and mitral isthmus lines and CFAE ablation
62112166|NCT04874571|EXPERIMENTAL|Muscle Energy Technique group|In the first group, according to Lewit's post-isometric relaxation (Muscle energy technique) method, scalene (anterior / medius / posterior), levator scapula, sternocleidomastoid, trapezius, pectoral muscles, serratus anterior and latismus dorsi muscles are set 3 days a week ( Each set includes three repetitions) The treatment will be applied for 4 weeks. The hypertonic muscle will be taken to the first point that resists movement without straining. The patient will be asked to perform an isometric contraction for 7 seconds, corresponding to 20% of the maximum isometric contraction force where the restriction is felt. After the application, the patient will be asked to exhale and relax completely. 30 seconds will be waited for each stretching and then the neck will be taken back to the barrier point and three repetitions per session will be performed.
62112167|NCT04874571|OTHER|Home Exercise|The individuals in the second group will be asked to do the home exercise program shown to them for 4 weeks, 3 days a week. Individuals included in this group will be given a program that includes stretching and posture exercises for the same muscle groups. Individuals in the control group will be called weekly during the 4-week period. Before, after, and 6 weeks after the study, re-evaluation parameters will be applied to all individuals included in the study.
62112168|NCT04133974|NO_INTERVENTION|Methadone|The subjects take methadone as usual.
61916856|NCT01123434||1|Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
61916857|NCT00540098|EXPERIMENTAL|1|Paroxetine + aerobic exercise
61916858|NCT00540098|ACTIVE_COMPARATOR|2|Paroxetine + relaxation
62673609|NCT04474379|NO_INTERVENTION|Process Training|Consists of 8, 90 minute sessions over 8 weeks. In sessions 1 and 2, the therapist teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3-8, the tester tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the therapist. Feedback on accuracy is provided after each training game. This is typical of a process training approach and expects that practice of the training tasks will improve prospective memory ability per se or that participants will develop effective strategies for completing prospective memory tasks on their own. At the end of each session, the therapist reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Goals are reviewed and modified if necessary.
62673610|NCT04728464||Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Patients will be treated by Periodontally Accelerated Osteogenic Orthodontics using fixed appliances.
62673611|NCT04151641|EXPERIMENTAL|Sequence 1|
62673612|NCT04151641|EXPERIMENTAL|Sequence 2|
62673613|NCT01413646|EXPERIMENTAL|Walnut Supplementation|Eight weeks with walnut supplementation to an ad lib diet
62673614|NCT01413646|PLACEBO_COMPARATOR|2|Eight weeks ad lib diet without walnut supplementation
62673615|NCT04920123|EXPERIMENTAL|Game Intervention|Study participants play Neuro-World 30 minutes per day, twice a week for 12 weeks in your home settings (24 times).
62673616|NCT04920123|NO_INTERVENTION|No Intervention|Study participants do not engage in any cognitive training.
61916859|NCT00540098|ACTIVE_COMPARATOR|3|Placebo + aerobic exercise
61916860|NCT00540098|PLACEBO_COMPARATOR|4|Placebo + relaxation
61916861|NCT04288544|ACTIVE_COMPARATOR|Experimental: Intervention group|The patients get 1x 5,3g per day the microalgae Phaeodactylum tricornutumover for two weeks.
62112169|NCT04133974|EXPERIMENTAL|Methadone-10min-Extinction|The subjects were given extinction training 10 min following methadone administration.
62112170|NCT04133974|SHAM_COMPARATOR|Methadone-6h-Extinction|The subjects were given extinction training 6h following methadone administration.
62112171|NCT02188758||Adults - CFPE Treatment|Other: CF Pulmonary Exacerbation (CFPE) Treatment
62112172|NCT02791750||Observational|Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.
62112173|NCT05127499|EXPERIMENTAL|Experimental:|will do progressive relaxation exercises
62112174|NCT05127499|NO_INTERVENTION|No Intervention|won't do progressive relaxation exercises
62112175|NCT03887546|EXPERIMENTAL|Intervention group|"Intervention is administrated with Inspiratory Muscle Trainer. 20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the second week.~12 weeks, 5 days/week, 15 minutes/day."
62112176|NCT03887546|ACTIVE_COMPARATOR|Control group|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day
62112177|NCT00762606|ACTIVE_COMPARATOR|Phaco|Cataract extraction surgery utilizing Phacoemulsification
62112178|NCT00762606|ACTIVE_COMPARATOR|SICS|Small incision cataract surgery (SICS)
62112179|NCT01242150|EXPERIMENTAL|NCPAP Helmet|Infants with mild Acute Respiratory Failure who need NCPAP
62112180|NCT01242150|ACTIVE_COMPARATOR|NCPAP facial mask|Infants with mild Acute Respiratory failure who need NCPAP
62673617|NCT00744419|EXPERIMENTAL|3 age groups|Assigned to the arm based on age.
62673618|NCT00795795|ACTIVE_COMPARATOR|with PGS|IVF cycles with Preimplantation Genetic Screening (PGS)
62673619|NCT00795795|ACTIVE_COMPARATOR|Without PGS|IVF cycle without Preimplantation Genetic Screening
62673620|NCT05328232|EXPERIMENTAL|Olive oil|
62673621|NCT05328232|NO_INTERVENTION|Routine care|
62471058|NCT04186260|EXPERIMENTAL|NAFLD-specific weight loss intervention|Participants will attend 12 weekly 30-45-minute individual counseling sessions and receive tailored lesson materials focused on behavioral strategies for adopting and maintaining healthy eating and physical activity (PA) behaviors. Participants will self-monitor their body weight, eating, and PA behaviors in a weekly journal. Dietary recommendations will follow nutritional guidelines for the treatment of NAFLD. To facilitate the adoption of the dietary recommendation, participants will be provided culturally-tailored meal plans and grocery lists that allow them to make small, practical dietary changes of \~100 calories. Participants will be prescribed weekly exercise goals with the duration increasing from 15-45 minutes, 5 days/week, over the 12-month program. After the completion of 12 weekly individual counseling sessions, participants will complete a 12-week follow-up including bi-weekly phone calls, followed by a 6-month follow-up period in which no intervention contact is made.
62471059|NCT04186260|OTHER|Wait-list control|The wait-list control group will receive the same intervention strategies described for the NAFLD-specific weight loss intervention after study comparisons have been made.
62471060|NCT05030363|EXPERIMENTAL|Upfront ALDH enzyme supplement|Upfront ALDH enzyme supplement; After randomization, patients will receive ALDH enzyme supplement twice a day for consecutive 14 days during chemotherapy (period 1; day 1 to day 14) until unacceptable toxicity, or consent withdrawal. Patients will visit clinic on day 15, then will be followed on day 29 without ALDH enzyme administration during subsequent chemotherapy (period 2).
61916862|NCT04288544|ACTIVE_COMPARATOR|Omega-3 capsules|The patients get one capsule per day of the Omega-3-fatty acid capsules for 2 weeks.
62112181|NCT05737238|NO_INTERVENTION|Baseline phase (Phase A)|At the start of the study, all participants are assigned to the baseline phase (phase A). During phase A, patients do not receive interventions related to executive function problems. The start of the intervention phase (phase B) is determined randomly for each participant, given the restriction that phase A should last for at least three weeks (21 days) and at most five weeks (30 days). This means that phase B can start on any day between the 21th and the 30th days, resulting in a total of 10 possible assignments. So, in the first three weeks, all participants are in phase A. The duration of phase A will thus be different for each subject. Phase A acts as a control and is therefore compared with phase B.
62112182|NCT05737238|EXPERIMENTAL|Intervention phase (Phase B): Goal Management Training|During the intervention phase (phase B), all included participants will have 6 sessions of Goal Management Training (GMT; twice per week) in which two individual chosen IADL-tasks will be subdivided into multiple steps under guidance of a therapist using the GMT method. In addition participants play the compensatory brain game in which they are challenged to apply the learned GMT strategy in an imaginary and safe environment.
62112183|NCT05737238|NO_INTERVENTION|Follow-up period|A follow-up period of three weeks takes place after phase B. During this follow-up period, patients receive no intervention.
62112184|NCT01215019|ACTIVE_COMPARATOR|Arm 1|20% Mannitol
62112185|NCT01215019|ACTIVE_COMPARATOR|Arm 2|3% sodium chloride
62112186|NCT05987540|EXPERIMENTAL|Investigational Treatment|Investigational treatment mode (stimulation pattern)
62302046|NCT04978623||Patient with Anti-MAG|Anti-MAG is a demyelinating neuropathy characterized clinically by a chronic progressive distal and symmetrical predominantly sensory involvement. This neuropathy belongs to the group of symmetrical acquired demyelinating neuropathies (Distal Acquired Demyelinating Neuropathy (DADS)) which is distinguished from PIDC by: 1. an essentially distal and rather sensitive clinical involvement (unlike PIDC which is proximal and distal with predominantily motor involvement); 2. a strong association with a monoclonal gammopathy of the IgM type (67% of DADS vs 22% of PIDC according to Katz et al, 3. a poor therapeutic response to first line of immunosuppressive drugs (in contrast to PIDC which generally responds well). Certain electrophysiological parameters, such as the demonstration of demyelinating damage with accentuated slowing of distal nerve conduction, make it possible to distinguish anti-MAG neuropathy from CIDP.
62302047|NCT04978623||Patient with L-S|Lewis-Sumner syndrome is an acquired demyelinating polyradiculoneuritis characterised by distal asymmetric upper and lower limb weakness and motor dysfunction that develops in adulthood. It is considered a variant of chronic inflammatory demyelinating polyradiculoneuritis. It has a prevalence of 1-9 per 1,000,000. The diagnosis is made with electroneuromyography (ENMG) which shows marked and persistent conduction blocks, in at least two nerves, having an asymmetric topography, mainly affecting the upper limb, outside the usual areas of compression. Lower limb blocks are much rarer (anterior tibial nerve), and are always located below the fibular neck.
62302048|NCT01955486|EXPERIMENTAL|flight simulation|flight simulation in pressure chamber
62471061|NCT05030363|OTHER|Delayed ALDH enzyme supplement|Delayed ALDH enzyme supplement; patients will not take ALDH enzyme supplement during chemotherapy after randomization on day 1 to day 14 (period 1). On day 15, Patients will visit for subsequent chemotherapy and start ALDH enzyme supplement twice a day for 14 consecutive days during chemotherapy (period 2; day 15 to day 29).
62471062|NCT05596435||Stage I-III pancreatic cancer|Cell-free DNA collected from plasma samples of 260 patients with stage I-III pancreatic cancer will undergo whole-genome sequencing
61916863|NCT04288544|EXPERIMENTAL|sea fish (facultative)|as positive control, one portion of fish is eaten per week for 2 weeks after the Intervention of 8 weeks and 2 wash out (omega 3 must not be eaten).
61916864|NCT01721980|OTHER|50 mg GLPG0974 or placebo|50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
62112187|NCT04602936|ACTIVE_COMPARATOR|Solriamfetol|All medication will be 37.5 mg encapsulated soriamfetol tablets or matching encapsulated placebo tablets supplied in numbered containers for dispensing to patients. The minimum dose of solriamfetol during the trial will be 37.5 mg/day; the maximum dose will be 150 mg/day. At the Baseline Visit (Visit 0), participants will be instructed to take one capsule of solriamfetol 37.5 mg or matching placebo in the morning for the first 7 days. Thereafter, at Visit 1, solriamfetol or placebo will be increased to 75 mg/day, if tolerated. Beginning on day 15 (Visit 2), solriamfetol or placebo will be increased to 150 mg/day, if tolerated. Study medication dosage may be decreased, or a scheduled increase may not be made, because of side effects. Study medication will be administered as a single daily dose in the morning.
61916865|NCT01721980|OTHER|100 mg GLPG0974 or placebo|100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days
61916866|NCT01721980|OTHER|200 mg GLPG0974 or placebo|200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
62112188|NCT04602936|PLACEBO_COMPARATOR|Placebo|Placebo (i.e., inactive compound for comparison)
62112189|NCT02001714|EXPERIMENTAL|Group Behavioral Treatment|Participants will attend a group behavioral treatment class and follow-up visits.
62112190|NCT02001714|NO_INTERVENTION|No Treatment|Subjects will not attend group behavioral treatment class.
62112191|NCT05214235||Metformin|Patients who use metformin to control blood sugar level.
62302049|NCT05911997|EXPERIMENTAL|High Dose MTC 01|High dose MTC 01 is 10 x 11 CFU slurry to be administered via colonoscopy
62302050|NCT05911997|EXPERIMENTAL|Low Dose MTC 01|Low Dose MTC 01 is 10 x 10 CFU slurry to be administered via colonoscopy
62302051|NCT05911997|ACTIVE_COMPARATOR|Low dose Fecal Microbiota Transplantation (FMT)|High dose FMT is 10 x 11 CFU slurry to be administered via colonoscopy
62112192|NCT05214235||Sitagliptin|Patients who use sitagliptin to control blood sugar level.
62302052|NCT05911997|EXPERIMENTAL|High Dose Fecal Microbiota Transplantation (FMT)|Low dose FMT is 10 x 10 CFU slurry to be administered via colonoscopy
62302053|NCT02786641|ACTIVE_COMPARATOR|Group A|low risk NPC treated with concurrent chemoradiotherapy
62302054|NCT02786641|ACTIVE_COMPARATOR|Group B|high risk NPC treated with concurrent chemoradiotherapy
62302055|NCT02786641|EXPERIMENTAL|Group C|high risk NPC treated with induction chemotherapy plus concurrent chemoradiotherapy
62302056|NCT05833880||Atopic dermatitis patients|
62302057|NCT04833036|ACTIVE_COMPARATOR|c-CetuIRI|Irinotecan combined with cetuximab
62302058|NCT04833036|EXPERIMENTAL|s-IRI-CetuIRI|single irinotecan first, then irinotecan plus cetuximab sequentially after PD
62302059|NCT02587494|ACTIVE_COMPARATOR|Early cardiac catheterization|Cardiac catheterization performed as early as possible, within 12h post ROSC following OHCA, with possible PCI during mild therapeutic hypothermia or apyrexia
61916867|NCT01721980|OTHER|400 mg GLPG0974 or placebo|400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
61916868|NCT01585584|EXPERIMENTAL|Boceprevir|
62112193|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
62112194|NCT04612894|EXPERIMENTAL|Neoadjuvant Camrelizumab + Apatinib|Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.
62112195|NCT06202599||Study group|Fruquintinib treatment group
62112196|NCT04302519|EXPERIMENTAL|Pulp mesenchymal stem cells|1. 3, 7 days to increase the injection of mesenchymal stem cells
62112197|NCT02000999||Patients with bile duct strictures|
62112198|NCT04461236|EXPERIMENTAL|Isoleucine|Type 2 Diabetics randomized to isoleucine group
62302060|NCT02587494|NO_INTERVENTION|Medical arm|Initial therapy does not include cardiac catheterization. Cardiac catheterization with possible PCI is allowed after completion of mild therapeutic hypothermia or apyrexia for \>24h post ROSC.
62302061|NCT03338946||CIED subjects|CIED interrogation
62302062|NCT02725788|EXPERIMENTAL|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
62302063|NCT02725788|OTHER|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
62302064|NCT02516930|OTHER|Crowdsourced video|One-minute crowd-sourced video promoting condom use among men who have sex with men and transgender individuals.
62302065|NCT02516930|OTHER|Social marketing video|One-minute social marketing video promoting condom use among men who have sex with men and transgender individuals
62302066|NCT01059812|EXPERIMENTAL|IDegAsp BID|
62302067|NCT01059812|ACTIVE_COMPARATOR|BIAsp 30 BID|
62302068|NCT00049764|EXPERIMENTAL|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
62302069|NCT00049764|PLACEBO_COMPARATOR|2|0.9% sodium chloride
62302070|NCT00786773||1|GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy
62302071|NCT01358110|EXPERIMENTAL|Early palliative care consultation|Early palliative care consultation for ED patients with advanced cancer.
62302072|NCT01358110|OTHER|Care as usual|Care as usual, may or may not receive palliative care consultation
62302073|NCT05274438|EXPERIMENTAL|JS001+Imatinib Mesylate|Imatinib: 400mg qd po. Toripalimab: 240mg q3w ivgtt. The longest cumulative use period of the two drugs was 2 years.
62302074|NCT00542984|ACTIVE_COMPARATOR|A|teriparatide 20 micrograms/day subcutaneous
62302075|NCT00542984|ACTIVE_COMPARATOR|B|salmon calcitonin 100 IU/day subcutaneous
62302076|NCT01328873|EXPERIMENTAL|Laboratory testing|All patients will receive the lab testing on bronchoscopy specimens
62471063|NCT05596435||Pancreatic disease|Cell-free DNA collected from plasma samples of 80 patients with pancreatic benign disease will undergo whole-genome sequencing
62471064|NCT05596435||Healthy controls|Cell-free DNA collected from plasma samples of 100 non-cancer individuals will serve as controls
62471065|NCT00725517|EXPERIMENTAL|1|Icodextrin group
62471066|NCT00725517|NO_INTERVENTION|2|Glucose group
62471067|NCT05222477|ACTIVE_COMPARATOR|Pelvic floor group|pelvic floor exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
62471068|NCT05222477|ACTIVE_COMPARATOR|Abdominal group|Abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
62673622|NCT04744532|EXPERIMENTAL|Drug: Bosutinib (Phase 1 part)|"Phase 1 part:~3 to 6 ALS patients will be enrolled in each of the 4 bosutinib dose lelvels \[100 mg/day (dose level 1), 200 mg/day (dose level 2), 300 mg/day (dose level 3), or 400mg/day (dose level 4)\] to evaluate the safety and tolerability of the investigational drug (bosutinib) under a 3+3 dose escalation study design. The dose will be escalated by 1 dose level at a time; no skipping will be allowed.~Dose escalation and MTD will be determined by the safety assessment committee comprising oncologist, hematologist, ALS Expert based on the incidence of DLT in 4 weeks of treatment among 3 subjects enrolled (6 subjects if additionaly enrolled) in each dose level."
62673623|NCT04744532|EXPERIMENTAL|Drug: Bosutinib (Phase 2 part)|"Phase 2 part:~25 ALS patients will be enrolled; patients will be randomly assigned to the following groups: 13 patients in 300mg/day group and 12 patients in 200mg/day group of the investigational drug (bosutinib). The efficacy and the safety of bosutinib in ALS patients for 24 weeks will be assessed."
62673624|NCT03957057|EXPERIMENTAL|Iron carboxymaltose group|Iron carboxymaltose group. Total dose of intravenous ferric carboxymaltose (Iroprem®) needed to correct anemia and replenish iron stores will be calculated using the Ganzoni formula (28) modified to include adjustment for baseline iron status: prepregnancy weight in kilograms X (15-baseline Hb) X 2.4 + 500. Fifteen is the target Hb in g/dL, 2.4 is a unit less conversion constant and 500 is the target iron stores in mg. The maximal dose administered in a single day will not exceed 15 mg/kg (current weight) or 1000 mg (for participants with body weight \> 67 kg). If total calculated dose will exceed 15 mg/kg or 1000 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
62673625|NCT03957057|EXPERIMENTAL|Iron isomaltoside group|Total dose of intravenous iron isomaltoside (Monofer®) needed to correct anemia and replenish iron stores will be calculated as described above. The maximal dose administered in a single day will not exceed 20 mg/kg (current weight) or 1500 mg (for participants with body weight \> 75 kg). If total calculated dose will exceed 20 mg/kg or 1500 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
62673626|NCT03957057|ACTIVE_COMPARATOR|Iron sulphate group|Iron sulphate group. Participants will receive oral ferrous sulphate (Tardyfer®) 160 mg daily for 6 weeks with instruction to take two tablets by mouth once daily 1 hour before meal. They will receive no additional iron supplementation.
62673627|NCT03376009||Liver transplant assessment patients|"Adult patients admitted to the Scottish Liver Transplant Unit for liver transplant assessment, over a 6 month study period will be considered for recruitment.~Interventions:~Blood sample for serum and plasma biomarkers:~Urine sample for biomarkers Cardiac bio-impedance (Cardioscreen Medis) Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor) Optical Coherence Tomography (Spectralis OCT) Arterial Spin Labelling Magnetic Resonance Imaging"
62673628|NCT01446510||Hospitalized Medical Patients|All hospitalized medical adult patients
62673629|NCT02434614|EXPERIMENTAL|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
62673630|NCT02434614|ACTIVE_COMPARATOR|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
62673631|NCT00821821|EXPERIMENTAL|MCI-186|
62673632|NCT00821821|PLACEBO_COMPARATOR|Placebo Group|
62673633|NCT04119336|EXPERIMENTAL|Nivolumab and Ixazomib|"- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle.~* Oral:~  * Ixazomib given weekly on days 1, 8, 15~ * Dexamethasone given weekly during cycle~* Infused:~  * Nivolumab given once per cycle~ * Cyclophosphamide given on days 1, 8, 15 during cycle"
62673634|NCT02358395|EXPERIMENTAL|BBI608 puls Sorafenib|
62673635|NCT03342859|EXPERIMENTAL|Vilaprisan group|Vilaprisan 2 mg oral daily over 8-12 weeks
61916869|NCT01547780|EXPERIMENTAL|Baseline brain PET in acute TBI patient|Single intravenous injection of \[C-11\]PBR28, \~10-20 mCi, prior to baseline brain positron emission tomography (PET) scan in Acute (\< 5 months post-injury) traumatic brain injury (TBI) patients.
62112199|NCT04461236|PLACEBO_COMPARATOR|Placebo|Type 2 Diabetics randomized to placebo group
62112200|NCT04461236|NO_INTERVENTION|Healthy|gender-, age-, BMI-matched controls for baseline measurements only. No supplementation provided.
62112201|NCT01762072|PLACEBO_COMPARATOR|vitaminB12|VitB12 group (VitB12, n=10) receives 8 weeks of treatment with daily oral doses of 1000 μg of vitamin B12 (one capsule)
62112202|NCT01762072|EXPERIMENTAL|Fish oil|Fish oil group (FO, n=10)receives 8 weeks of treatment with daily oral doses of 2g of fish oil in the form of two capsules of fish oil) .
62471069|NCT00394810|EXPERIMENTAL|1|
62471070|NCT03502161||All subjects|Those receiving a SOT and coming off either 3 months or 6 months of antiviral prophylaxis.
62471071|NCT01745120|EXPERIMENTAL|LentiGlobin BB305 Drug Product|
62302077|NCT06056284|EXPERIMENTAL|Progressive relaxation exercise and sleep hygiene training|It is planned to include 26 patients in the experimental group. Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients and an appointment will be made for the post-test after seven weeks. In the second week, the individuals in the experimental group will be taught progressive relaxation exercise in the hospital environment by the researcher using the compact disc (CD) prepared by the Turkish Psychological Association and after the sleep hygiene training, the progressive relaxation exercise brochure and sleep hygiene training brochure created by the researcher will be distributed. As of the second week, the individuals in the experimental group will be expected to apply the trainings given twice in the hospital environment.
62302078|NCT06056284|NO_INTERVENTION|Control group|It is planned to include 26 patients in the control group. Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the individuals in the control group in the first week of the 7-week research programme. Data will be collected by face-to-face interview with the patients. Individuals in the control group will not be given any training by the researcher. Individuals in the control group will be given an appointment for the post-test after seven weeks. At the end of seven weeks, individuals in the control group will be asked to fill in the Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) again.
62112203|NCT01762072|EXPERIMENTAL|Fish oil+vitaminB12|VitB12+Fish oil group (VitB12+FO, n=10) receives 8 weeks of treatment with daily oral doses of a combination of 1000 μg of vitamin B12 and 2g of fish oil
62112204|NCT02447263|EXPERIMENTAL|HepaSphere|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
62112205|NCT02447263|NO_INTERVENTION|control|liver cancer patients did not receive any interventional therapy
62302079|NCT03820115|EXPERIMENTAL|Elastic abdominal binder|
62302080|NCT03820115|NO_INTERVENTION|No binder|
62302081|NCT04935944||Tube potential difference (FOV)|Using different FOV and mA values of the CBCT machine
62302082|NCT01817010|EXPERIMENTAL|Multi-Component Rehabilitation (CMC)|The CMC group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after THA.
62302083|NCT01817010|ACTIVE_COMPARATOR|Control (CON)|The CON group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same CMC rehabilitation intervention beginning 10 weeks after THA.
62302084|NCT02811926||Ileostomy or colostomy|Patients with a ileostomy or colostomy in the Capital Region of Denmark
62302085|NCT00954785|PLACEBO_COMPARATOR|Placebo drug|
62302086|NCT00954785|EXPERIMENTAL|Etoricoxib|
61916870|NCT01547780|EXPERIMENTAL|Repeat brain PET in acute TBI patient|Single intravenous injection of \[C-11\]PBR28, \~10-20 mCi, prior to repeat brain positron emission tomography (PET) scan in Acute (\< 5 months post-injury) traumatic brain injury (TBI) patients.
62112206|NCT02009735|EXPERIMENTAL|virosensor|virus detection
62112207|NCT06165185|EXPERIMENTAL|Water|"At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 1 L of water (still bottled water) to map the acute water effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 2 L of extra water (i.e. in addition to each subject's habitual food and fluid intake).~Intervention day 2-7: 3 L extra water per day in addition to each subject's habitual food and fluid intake."
62302087|NCT00954785|ACTIVE_COMPARATOR|Diclofenac|
62471072|NCT01774435|EXPERIMENTAL|EN3342|EN3342 (risperidone) subcutaneous implant
62471073|NCT06562023|EXPERIMENTAL|BTA injection|
62471074|NCT06562023|EXPERIMENTAL|Mesotherapy|
62471075|NCT06562023|NO_INTERVENTION|Control|
62471076|NCT02465320|ACTIVE_COMPARATOR|COL-1077|lidocaine bioadhesive gel, 10%
62673636|NCT03342859|ACTIVE_COMPARATOR|Ulipristal group|Ulipristal 5 mg oral daily over 8-12 weeks
61916871|NCT01547780|EXPERIMENTAL|Single brain PET in Chronic TBI patient|Single intravenous injection of \[C-11\]PBR28, \~10-20 mCi, prior to brain positron emission tomography (PET) scan in Chronic (5 months - 5 years post-injury) traumatic brain injury (TBI) patients.
61916872|NCT01547780|EXPERIMENTAL|Single brain PET in healthy subjects|Single intravenous injection of \[C-11\]PBR28, \~10-20 mCi, prior to brain positron emission tomography (PET) scan in Healthy Subjects.
61916873|NCT01692821|EXPERIMENTAL|100% oxygen breathing|
61916874|NCT01692821|EXPERIMENTAL|15% oxygen in N2 breathing|
61916875|NCT01692821|EXPERIMENTAL|12% oxygen in N2 breathing|
61916876|NCT02522871|EXPERIMENTAL|OCS Liver System|OCS Liver System
61916877|NCT02522871|OTHER|Control|Standard of care (ice)
61916878|NCT03706651||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
61916879|NCT03706651||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
61916880|NCT06212687|EXPERIMENTAL|Digital pre-therapy informational intervention (StartHjelp).|Patients gets access to StartHjelp, an app which gradually present treatment relevant information while the patient is on waiting list for mental health outpatient services.
61916881|NCT06212687|ACTIVE_COMPARATOR|Control group|The control group gets sent all the same information as the intervention group in written form, by mail.
61916882|NCT04066764|EXPERIMENTAL|Rivaroxaban|Participants will receive rivaroxaban 15mg oral twice daily for 3 weeks after operation, later rivaroxaban 20mg oral once daily until 3 months after the filter is retrieved.
61916883|NCT04066764|ACTIVE_COMPARATOR|Warfarin/ Nadroparin|Participants will receive Nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 3 months after the filter is retrieved.
61916884|NCT01733797|EXPERIMENTAL|Wooden spatula|
61916885|NCT01733797|EXPERIMENTAL|Therabite|
61916886|NCT02562690||Acute Coronary Syndrome|"Patients with acute chest pain and persistent ST-segment elevation or new left bundle branch block on the 12 lead ECG. This is termed ST-segment Elevation Myocardial Infarction (STEMI).~Patients with acute chest pain but without persistent ST-segment elevation. These patients, based on the measurement of cardiac biomarker values (troponin), will be further classified as Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or unstable angina.~Where possible, all patients will have tests of thrombotic status including thrombin generation assays, TEG and GTT."
61916887|NCT05664854|EXPERIMENTAL|sVNS and EIT of cervical vagus nerve|Selective vagus nerve stimulation (sVNS) with a spatially selective vagal nerve cuff with physiological readouts such as electrocardiogram (ECG), heart rate, end-tidal carbon dioxide (EtCO2), respiratory rate, laryngeal electromyogram (EMG), etc., and electrical impedance tomography (EIT) recordings of the nerve.
61916888|NCT04567732|EXPERIMENTAL|Filtered Autologous Adipose Tissue|based on randomization one of the two knees will be treated with a single injection of Filtered Autologous Adipose Tissue
61916889|NCT04567732|PLACEBO_COMPARATOR|Placebo|based on randomization one of the two knees will be treated with a single injection of Placebo
61916890|NCT05443607||Mother infected/newborn not infected|
62112208|NCT06165185|EXPERIMENTAL|Coffee|"At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 4 dL of coffee to map the acute coffee effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 6dL of extra coffee (i.e. in addition to each subject's habitual food and fluid intake).~Intervention day 2-7: 1 L extra coffee per day in addition to each subject's habitual food and fluid intake."
62112209|NCT06165185|EXPERIMENTAL|Control|"At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest just 10 ml of water to map the acute effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with each subject's habitual food and fluid intake.~Intervention day 2-7: Each subject's habitual food and fluid intake."
61916891|NCT05443607||Mother infected/newborn infected|
61916892|NCT05443607||Mother not infected/newborn not infected|
61916893|NCT05443607||Mother not infected/newborn infected|
61916894|NCT01128036||CHF, cardomyopathy|Patients with signs of poor peripheral perfusion due to cardiomyopathy or congestive heart failure
61916895|NCT03551262|EXPERIMENTAL|OTSC|Use of OTSC to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb, in first-line endoscopic haemostatic treatment.
61916896|NCT03551262|ACTIVE_COMPARATOR|TTS clip|Use of TTS clip to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb in first-line endoscopic haemostatic treatment
61916897|NCT06138223|NO_INTERVENTION|Usual Care|Patients randomized to the control group will receive standard medical care, including nutritional care as provided by the center in usual care. Additionally, they receive an activity tracker (like the intervention group) but without specific instructions. We will provide the control patients with written advice on physical activity and diet according to the current guidelines (in short: to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150 min/week).
61916898|NCT06138223|EXPERIMENTAL|Combined exercise and nutritional intervention.|Intervention: exercise and nutrition program group
61916899|NCT02442401|EXPERIMENTAL|NPWT group|Negative pressure wound therapy was used to prevent donor site seroma formation
61916900|NCT02442401|NO_INTERVENTION|Control group|Conventional method was used to the donor site
61916901|NCT03671590|EXPERIMENTAL|Arm 1: TG-1701 Monotherapy|Participants will receive TG-1701 oral daily dose. As per protocol v6.0, participants from this arm will be transitioned to the long-term extension arm to receive TG-1701 monotherapy.
61916902|NCT03671590|EXPERIMENTAL|Arm 2: TG-1701 + Ublituximab + Umbralisib|Participants will receive TG-1701, oral dose in combination with ublituximab, oral dose and umbralisib, fixed IV infusion on specific Days of Cycles 1 and 2, followed by maintenance infusions in Cycles 3 to 6 (Cycle=28 days). As per protocol v6.0, participants from this arm will be transitioned to the long-term extension arm to receive TG-1701 monotherapy.
61916903|NCT03671590|EXPERIMENTAL|Arm 3: Long Term Safety Extension - TG-1701 Monotherapy|All the ongoing participants from Arm 1 and 2, will be transitioned to TG-1701 monotherapy in long-term extension period, per protocol version 6.0.
61916904|NCT00701623|EXPERIMENTAL|1|patients treated with heparin
61916905|NCT00701623|EXPERIMENTAL|2|Patients treated with heparin
61916906|NCT00701623|ACTIVE_COMPARATOR|3|patients treated with folder water directly on the injured area
61916907|NCT03120455|EXPERIMENTAL|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
61916908|NCT03120455|ACTIVE_COMPARATOR|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
61916909|NCT03120455|PLACEBO_COMPARATOR|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
61916910|NCT05764070|EXPERIMENTAL|Non Invasive Vagus Stimulation|Aerobic exercise + Non Invasive- Vagus Stimulation
62673637|NCT03342859|NO_INTERVENTION|Control group|Patients undergoing surgery without any prior treatment, as control group
61916911|NCT05764070|PLACEBO_COMPARATOR|Placebo Non Invasive Vagus Stimulation|Aerobic exercise + Placebo Non Invasive Vagus Stimulation
62302088|NCT05897424|EXPERIMENTAL|INBRX-101 Q3W|IV every 3-weeks (Q3W)
62673638|NCT01489358|EXPERIMENTAL|Group 1|Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
62673639|NCT01489358|EXPERIMENTAL|Group 2|Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
62673640|NCT01489358|EXPERIMENTAL|Group 3|Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
62673641|NCT05234333||Patients presenting a malaise after the vaccination by any vaccine|
62673642|NCT05234333||Patients presenting any other adverse event after the vaccination by any vaccine|
62673643|NCT01665105|EXPERIMENTAL|Zusanli Group|electroacupuncture at both Zusanli on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
62673644|NCT01665105|ACTIVE_COMPARATOR|Yanlingquan Group|electroacupuncture at both Yanglingquan on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
62673645|NCT01665105|SHAM_COMPARATOR|Sham Group|acupuncture without electrical stimulation at non-acupoint on the leg, and record simultaneously pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
62673646|NCT03322891|EXPERIMENTAL|Educational Supplement|Participants diagnosed with prostate cancer will receive education for treatment options and treatment side effects.
62673647|NCT05560321|EXPERIMENTAL|Intervention|Application of a 24-hour continuously acting quaternary ammonium salt disinfectant: Sani24 (PDI Healthcare Inc.) by study team
62673648|NCT05560321|ACTIVE_COMPARATOR|Control|Routine disinfection completed by hospital staff
62673649|NCT05875077|EXPERIMENTAL|Propofol group|will receive propofol infusion.
62673650|NCT05875077|EXPERIMENTAL|Dexmedetomidine group|will receive dexmedetomidine infusion.
61916912|NCT04872270|ACTIVE_COMPARATOR|Caffeine Group|2 week supply of 100mg caffeine + aspirin 325mg + standard pain regimen (experimental)
61916913|NCT04872270|ACTIVE_COMPARATOR|No Caffeine Group|aspirin 325mg + standard pain (control)
61916914|NCT06436300|NO_INTERVENTION|Control|Usual care arm receives established methods for scheduling colorectal cancer screening with clinic patients.
61916915|NCT06436300|EXPERIMENTAL|Messages only|Receives motivational messages to promote colorectal cancer screening plus usual care.
61916916|NCT06436300|EXPERIMENTAL|Messages plus gift card|Receives motivational messages to promote colorectal cancer screening, plus offer of a $50 gift card for completing screening, plus usual care.
61916917|NCT06436300|EXPERIMENTAL|Messages plus raffle|Receives motivational messages to promote colorectal cancer screening, plus offer of entry into a raffle for a prize worth approximately $200 if they complete screening, plus usual care.
61916918|NCT03487978||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo 3-tesla resting-state functional MRI.
61916919|NCT03487978||Control|Normal controls without headaches will undergo 3-tesla resting-state functional MRI.
61916920|NCT00636987|OTHER|Implanted with Biocor or Biocor Supra Valves|
62112210|NCT01443416|EXPERIMENTAL|13-valent pneumococcal conjugate vaccine|12 month booster dose of Prevenar
62112211|NCT01443416|EXPERIMENTAL|10-valent pneumococcal conjugate vaccine|12 month booster dose of Synflorix
62112212|NCT01192542|OTHER|galyfilcon A prototype lens/enfilcon A lens|galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.
62112213|NCT01192542|OTHER|enfilcon A lens/galyfilcon A prototype lens|enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.
61916921|NCT01546402|EXPERIMENTAL|Phacoemulsification with IOL implant|This group (Group B) includes patients who will undergo phacoemulsification with intraocular lens implantation. The dexamethasone implant will not be injected at the beginning of cataract surgery. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
62471077|NCT02465320|PLACEBO_COMPARATOR|Placebo|placebo bioadhesive gel
62112214|NCT02770430|ACTIVE_COMPARATOR|conventional treatment|"After randomization, patients will be allocated to receive conventional treatment:~1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
62471078|NCT01216150||aspirin|group treated with aspirin alone
62302089|NCT05609526|NO_INTERVENTION|1.Group (Compression Therapy)|"The patient will be placed in the supine position. Short stretch bandages of 6, 8, 10 and 12 cm will be applied to the extremity in a multi-layered and special way. Starting with the finger bandage, the pressure will be reduced as it goes distally. The patient's gait and circulation will be checked after bandaging is finished.~will be."
62673651|NCT02866448|PLACEBO_COMPARATOR|Vehicle control|"Subjects will consume~* 4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~* 1 x 75mg cellulose pill"
62471079|NCT01216150||aspirin clopidogrel|Goup treated with aspirin and clopidogrel
62471080|NCT00410865|EXPERIMENTAL|INGN 201|INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
62471081|NCT02819323|EXPERIMENTAL|BLI800 high dose|BLI800 bowel preparation (high dose)
62471082|NCT02819323|EXPERIMENTAL|BLI800 low dose|BLI800 bowel preparation (low dose)
62673652|NCT02866448|EXPERIMENTAL|Isoquercetin|"Subjects will consume~* 4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~* 1 x 75mg cellulose pill"
62673653|NCT02866448|ACTIVE_COMPARATOR|Aspirin|"Subjects will consume~* 1 x 75mg dispersible aspirin~* 4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid"
62673654|NCT02866448|EXPERIMENTAL|Isoquercetin plus Aspirin|"Subjects will consume~* 4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg folic acid~* 1 x 75mg dispersible aspirin"
62673655|NCT03090035|EXPERIMENTAL|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
62673656|NCT03907423|EXPERIMENTAL|Rosuvastatin|DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients)
62673657|NCT03907423|PLACEBO_COMPARATOR|Placebo Group|DM-type 2 patient who will receive glimepiride-metformin combination (30 patients).
62673658|NCT03153293|EXPERIMENTAL|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10\^10 vg/0.05 mL for test groups.
62673659|NCT00776425|EXPERIMENTAL|Epoetin Beta 150 IU/kg|Participants with solid and lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 150 IU per kg of body weight thrice weekly.
62673660|NCT00776425|EXPERIMENTAL|Epoetin Beta 30000 IU|Participants with lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 30000 IU once weekly.
62673661|NCT06289881|EXPERIMENTAL|Experimental: Sequence 1-Sildenafil test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sildenafil 100 mg tablets test product, treatment 2= Nebivolol tablets 5 mg reference product.
62112215|NCT02770430|EXPERIMENTAL|mesenchymal stem cells|Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg
62112216|NCT02846194|EXPERIMENTAL|brief guided imagery|The study group of our research will go through six Brief Guided Imagery sessions. These sessions will be completed within two months and will last one hour each.
62112217|NCT02846194|NO_INTERVENTION|control group|
62112218|NCT03395353|EXPERIMENTAL|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
62471083|NCT02819323|ACTIVE_COMPARATOR|PEG-ELS|PEG based bowel preparation
62471084|NCT06221319|NO_INTERVENTION|control group|Group K IV to patients paracetamol 1 gr. It will be administered 3x1 + Dexketoprofen 50 mg 2x1. All patients will be administered 1mg/kg tramadol as rescue analgesic when NRS is 3 and above . 4mg IV to all patients with nausea and vomiting Ondansetron will be administered.
62112219|NCT03393117|EXPERIMENTAL|Liposomal Bupivacaine + Bupivacaine|This group will receive a long-acting pain medicine, Liposomal Bupivacaine, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
62673662|NCT06289881|EXPERIMENTAL|Experimental: Sequence 2-Sildenafil reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sildenafil 100 mg tablets test product, treatment 2= Nebivolol tablets 5 mg reference product.
62673663|NCT04097184|ACTIVE_COMPARATOR|"active tDCS group"|Patients will benefit from a series of 10 double-blind effective tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
62471085|NCT06221319|ACTIVE_COMPARATOR|Sacral erektör spinae plane group|sacral erector spinae plane will be applied to patients in Group S
62673664|NCT04097184|SHAM_COMPARATOR|"sham tDCS group"|Patients will benefit from a series of 10 double-blind placebo tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
62112220|NCT03393117|ACTIVE_COMPARATOR|Bupivacaine|This group will receive the same pain medication, Bupivacaine, but in the standard formulation, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
62112221|NCT02975934|EXPERIMENTAL|Rucaparib|Oral rucaparib (monotherapy).
62112222|NCT02975934|ACTIVE_COMPARATOR|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
62112223|NCT00778739|EXPERIMENTAL|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
62112224|NCT00778739|ACTIVE_COMPARATOR|2|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
62302090|NCT05609526|EXPERIMENTAL|2.Group (Inspiratory muscle training)|"Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time 30 minutes per day will be. On the first day, the MIP levels of the participants will be evaluated and the training workload will be determined as 30% of the MIP. For IMT, after a nose clip was inserted from the participants They will be asked to sit on the mouthpiece of the device and close their lips tightly. With the device in this position, the device for four to five breath rests after every 10 breathing cycles.~mouth, and repeat the cycle for 15 minutes."
62471086|NCT06456593|EXPERIMENTAL|Obefazimod 50mg|Obefazimod 50mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
62471087|NCT06456593|EXPERIMENTAL|Obefazimod 25mg|Obefazimod 25mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
62673665|NCT04518423||Elderly people over the age of 65 years|The study group will comprise community dwelling elderly individuals over the age of 65 years who get around by themselves. The subjects will be followed up for 5 years to investigate the frailty and disability development, and survival.
62112225|NCT04674332|EXPERIMENTAL|long acting insulin|
62112226|NCT04674332|ACTIVE_COMPARATOR|multiple dose regimen|
62112227|NCT01312337|EXPERIMENTAL|Iressa for EGFR wild group|salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients
62112228|NCT04639349|EXPERIMENTAL|Exercised group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
62112229|NCT04639349|OTHER|control group|The control group will not be trained
62471088|NCT06456593|EXPERIMENTAL|Obefazimod 12.5mg|Obefazimod 12.5mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
62471089|NCT06456593|PLACEBO_COMPARATOR|Placebo|Placebo given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
61916922|NCT01546402|EXPERIMENTAL|Phacoemulsification with Ozurdex|This group (Group A) includes patients who will undergo phacoemulsification with intraocular lens implantation with intraoperative long acting steroid injection (Ozurdex ®). The dexamethasone implant will be injected at the beginning of cataract surgery, 4mm from the limbus using the specially designed injector. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
62112230|NCT00860717|ACTIVE_COMPARATOR|1|Subjects from the arm number 1 received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
62112231|NCT00860717|EXPERIMENTAL|2|Subjects from the arm number 2 received low level laser therapy 3 times per week for 12 weeks, in addition to the same treatment as patients from the arm number 1.
61916923|NCT03833518|EXPERIMENTAL|Hand impairment due to stroke or spinal cord injury|Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.
61916924|NCT03800472|EXPERIMENTAL|GLPG3312 SAD IR (Part 1)|Single doses of GLPG3312 IR
61916925|NCT03800472|PLACEBO_COMPARATOR|Placebo SAD IR (Part 1)|Single doses of Placebo IR
61916926|NCT03800472|EXPERIMENTAL|GLPG3312 SAD MR (Part 2)|Single doses of GLPG3312 MR
61916927|NCT03800472|PLACEBO_COMPARATOR|Placebo SAD MR (Part 2)|Single doses of Placebo MR
62112232|NCT04479540|EXPERIMENTAL|Hospitalized SARS Cov-2|Hospitalized patients diagnosed with SARS Cov-2 infection
62112233|NCT04680702|EXPERIMENTAL|Metabolic Syndrome and Sims Score|
62112234|NCT04066738|OTHER|Patients with myocardial scar|Patient with previous STEMI resulting in myocardial scar, elected to CRT implant
62112235|NCT03014596|EXPERIMENTAL|Intervention|The Assert-method will be used in the counselling of adolescents with mental health problems
62112236|NCT03014596|NO_INTERVENTION|Control|Treatment as usual, i.e. tha Assert-method will not be used in the counselling
62112237|NCT01944410|EXPERIMENTAL|traumatic bone cyst|Patients with traumatic bone cyst defect are injected with PRP
61916928|NCT03800472|EXPERIMENTAL|GLPG3312 FE MR (Part 3)|Single dose of GLPG3312 MR in fed and fasted state
61916929|NCT03800472|EXPERIMENTAL|GLPG3312 MAD MR (Part 4)|Multiple doses of GLPG3312 MR
61916930|NCT03800472|PLACEBO_COMPARATOR|Placebo MAD MR (Part 4)|Multiple doses of Placebo MR
61916931|NCT03800472|EXPERIMENTAL|GLPG3312 MAD MR optimized (Part 4)|Multiple doses of GLPG3312 MR
62112238|NCT04307043||postnatal age|
62471090|NCT01853566|EXPERIMENTAL|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
61916932|NCT03800472|PLACEBO_COMPARATOR|Placebo MAD MR optimized (Part 4)|Multiple doses of Placebo MR
61916933|NCT00000253|ACTIVE_COMPARATOR|Placebo + 10% N2O|0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
61916934|NCT00000253|ACTIVE_COMPARATOR|Placebo + 20% N2O|Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
61916935|NCT00000253|ACTIVE_COMPARATOR|Placebo + 30% N2O|Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
61916936|NCT00000253|ACTIVE_COMPARATOR|Placebo + 40% N2O|Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
61916937|NCT00393042|EXPERIMENTAL|Focalin XR then Adderall XR|Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.
61916938|NCT00393042|EXPERIMENTAL|Adderall XR then Focalin XR|Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.
62112239|NCT04307043||General information and echocardiographic data|General information:(1)Record the gestational age, birth weight, length, delivery way, Apgar score, maternal pregnancy status, prenatal bleeding or not after admission.(2)PS use, ventilator mode, other illness and complications should be recorded during hospitalization. (3) Record the baby's heart rate, respiratory rate, blood pressure, body surface area on every check.
62112240|NCT00857142|EXPERIMENTAL|1|Oxymorphone hydrochloride 40 mg extended release tablets (Sandoz)
62112241|NCT00857142|ACTIVE_COMPARATOR|2|Opana 40 mg extended release tablets
62112242|NCT03255642|ACTIVE_COMPARATOR|Melatonin 2mg|4 weeks of 2mg of prolonged release Melatonin
62112243|NCT03255642|PLACEBO_COMPARATOR|ClonazePAM 0.5 MG|4 weeks of 0.5mg of rivotril
62112244|NCT00596167|EXPERIMENTAL|Intravenous antibiotics|Intervention: administer intravenous vancomycin, gentamicin and levofloxacin. This study will determine the pharmacokinetics of intravenous vancomycin, gentamicin and levofloxacin in subjects receiving short-daily hemodialysis. There will not be a control arm for this study. The intervention for this arm will be to administer intravenous vancomycin, gentamicin and levofloxacin and draw blood samples at periodic intervals. The blood samples will be tested for these medications and pharmacokinetic analysis will be performed.
62471091|NCT04391933|OTHER|MRI colon cancer|MRI scan of patients with colon cancer
62673666|NCT03164356|NO_INTERVENTION|Arm 1|In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
61916939|NCT01596556|EXPERIMENTAL|smokers|This arm consists of smokers.
61916940|NCT01596556|ACTIVE_COMPARATOR|non-smokers|non-smoking participants in the study
61916941|NCT05608928|EXPERIMENTAL|Vivomixx|Vivomixx also known as VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
61916942|NCT05608928|EXPERIMENTAL|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
61916943|NCT01377285|EXPERIMENTAL|ARB & Pentoxifylline|angiotensin receptor blockers(ARB)and Pentoxifylline 400mg tablet (If CKD3 1# BID(Bi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR\<15ml/min/1.73 m2) 1# QOD(Every other day).
62673667|NCT03164356|EXPERIMENTAL|Arm 2 - Experimental|Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
62112245|NCT05193318|EXPERIMENTAL|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
62673668|NCT03164356|NO_INTERVENTION|Arm 3 - Control|Bioimpedance data will be collected from participants in Arm 3 in parallel with those in Arm 2. However, no data will be provided to the participant's prosthetist.
61916944|NCT01377285|ACTIVE_COMPARATOR|ARB & Placebo|angiotensin receptor blockers(ARB) and Placebo tablet(If CKD3 1# BIDBi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR\<15ml/min/1.73 m2) 1# QOD(Every other day).
61916945|NCT02330328|EXPERIMENTAL|No Telemetry Monitoring|The participants in this arm will be admitted to a bed without telemetry monitoring
61916946|NCT02330328|ACTIVE_COMPARATOR|Telemetry|The participants in this arm will be admitted to a bed with telemetry monitoring
61916947|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 6-48 months who have previously received PCV13
61916948|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
61916949|NCT02551627|EXPERIMENTAL|Test Product|MMN fortified beverage powder \[27 gram (g)\] made up in 150 milliliter (mL) of water, will be administered orally as a single serve, twice daily for 18 weeks.
62302091|NCT05609526|EXPERIMENTAL|3.Group (Calf muscle exercise training)|A strengthening treatment program will be applied to the calf muscles. CMET will consist of static stretching exercise for the dorsiflexors and plantar flexors, isotonic resistance exercise with elastic resistance bands, heel and toe lift in both feet, followed by toe raising and lowering without heel raising. An isotonic exercise (mini squat) will be performed for ankle pumping exercise and knee flexion in sitting position. Patients will begin strength training with elastic resistance bands using red bands (lowest resistance). Green and blue bands by increasing the number of sets and repetitions will start to be used (increased resistance). (31.32)
62302092|NCT05609526|EXPERIMENTAL|4.Group (Inspiratory and calf muscle training)|All applications made in 3 groups will be made in this group.
62302093|NCT03762980|EXPERIMENTAL|Right hemiplegic patients|
62302094|NCT03762980|EXPERIMENTAL|Left hemiplegic patients|
62302095|NCT05180786|OTHER|Group 1|
61916950|NCT02551627|ACTIVE_COMPARATOR|Control|Isocaloric beverage powder without micronutrient fortification (27 g), made up in 150 mL of water will be administered orally as a single serve, twice daily for 18 weeks.
62302096|NCT05180786|OTHER|Group 2|
62302097|NCT01364415|EXPERIMENTAL|Pasireotide LAR|
62673669|NCT03522259|ACTIVE_COMPARATOR|A: Rivaroxaban short arm|7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
62673670|NCT03522259|ACTIVE_COMPARATOR|B: Rivaroxaban long arm|"28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.~Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28"
61916951|NCT00971620|EXPERIMENTAL|BTX-A|BTX-A intralesional injection
61916952|NCT00971620|EXPERIMENTAL|Placebo/Saline|Saline intralesional injection
61916953|NCT03034291|EXPERIMENTAL|Cacao 70%|Consumption for eight weeks of 50 grams of chocolate with 70% cocoa solids equivalent to not less than 430 mg of cocoa polyphenols at each dose.
61916954|NCT03034291|PLACEBO_COMPARATOR|White chocolate|Consumption for eight weeks of 50 grams of chocolate free of cocoa solids as placebo.
61916955|NCT03108781|ACTIVE_COMPARATOR|Lavender Oil|
61916956|NCT03108781|PLACEBO_COMPARATOR|sunflower oil|
62112246|NCT06076434|EXPERIMENTAL|Effect of 10 second Pressure Times on Bruising and Pain|"The patients were randomized according to age and gender and included in the groups.~Patients were injected with heparin subcutaneously in the upper arm by the clinic nurse in accordance with the procedure of the clinic. The area was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected with a 27 gauge needle at a 90° angle to the tissue. The heparin was injected in approximately 10 seconds without aspirating the syringe. After injection, the area was pressurized with dry cotton wool for the specified time. After the injection, pressure was applied to the area with dry cotton for specified periods. Pain level was determined at the time of injection. Using an acetate pen, a circle of approximately 5 cm was marked around the needle insertion site and the bruising level was measured and recorded 48 hours later using a transparent film."
61916957|NCT02824861|EXPERIMENTAL|Text Intervention|Participants receive text messages to a personal cell phone over 8 weeks, wear a fitbit to monitor physical activity, and communicate with a health coach intermittently over 2 weeks
61916958|NCT02824861|ACTIVE_COMPARATOR|Active Control|Participants receive and wear a fitbit only for 8 weeks
62112247|NCT06076434|EXPERIMENTAL|Effect of 35 second Pressure Times on Bruising and Pain|"The patients were randomized according to age and gender and included in the groups.~Patients were injected with heparin subcutaneously in the upper arm by the clinic nurse in accordance with the procedure of the clinic. The area was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected with a 27 gauge needle at a 90° angle to the tissue. The heparin was injected in approximately 10 seconds without aspirating the syringe. After injection, the area was pressurized with dry cotton wool for the specified time. After the injection, pressure was applied to the area with dry cotton for specified periods. Pain level was determined at the time of injection. Using an acetate pen, a circle of approximately 5 cm was marked around the needle insertion site and the bruising level was measured and recorded 48 hours later using a transparent film."
62302098|NCT04609384||Prior to installation of device|Health care workers who perform the surgical rub prior to installation of the device that should increase the time spend on surgical rub.
62302099|NCT04609384||Post device installation|Health care workers who perform the surgical rub following installation of the device that should increase the time spend on surgical rub.
62302100|NCT01220219|EXPERIMENTAL|Pregabalin controlled release, 82.5 mg|
61916959|NCT00704522||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C at sites in Austria.
61916960|NCT03874312||Calibration group|Patients with systolic chronic heart failure who undergo right heart catheterization (RHC) for heart transplant/left ventricular assist device workup.
61916961|NCT03874312||Validation group|Patients with systolic chronic heart failure who undergo RHC for heart transplant/left ventricular assist device workup.
62302101|NCT01220219|EXPERIMENTAL|Pregabalin controlled release, 165 mg|
62673671|NCT02477046|EXPERIMENTAL|tOPV + IPV|tOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive tOPV plus IPV boost
62673672|NCT02477046|EXPERIMENTAL|bOPV + IPV|bOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive bOPV plus 1 IPV boost
62673673|NCT02477046|EXPERIMENTAL|bOPV + 2 IPV|bOPV (6, 10, and 14 weeks) + IPV (14 and 18 weeks) Randomized to receive bOPV plus 2 IPV boost
62673674|NCT05174507|OTHER|Group 1 (anakinra; placebo; empagliflozin)|"Group 1:~study day 1: anakinra; study day2: placebo; study day 3: empagliflozin"
62302102|NCT01220219|OTHER|Pregabalin immediate release, 75mg|Reference Treatment
62302103|NCT00035893|EXPERIMENTAL|Ampligen|Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
62302104|NCT00035893|NO_INTERVENTION|No Ampligen|No Ampligen administered for first 64 weeks
62302105|NCT00201799|EXPERIMENTAL|Infliximab|Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
62471092|NCT03522363|EXPERIMENTAL|Monodose group|1 vial with 4E10 CFU/g Total dose treatment: 4E10 CFU
62673675|NCT05174507|OTHER|Group 2 (placebo; anakinra; empagliflozin)|study day 1: placebo; study day2: anakinra; study day 3: empagliflozin
62673676|NCT05174507|OTHER|Group 3 (empagliflozin; placebo; anakinra)|study day 1: empagliflozin; study day2: placebo; study day 3: anakinra
62673677|NCT05174507|OTHER|Group 4 (empagliflozin; anakinra; placebo)|study day 1: empagliflozin; study day2: anakinra; study day 3: placebo
62673678|NCT05174507|OTHER|Group 5 (placebo; empagliflozin; anakinra)|study day 1: placebo; study day2: empagliflozin; study day 3: anakinra
62673679|NCT05174507|OTHER|Group 6 (anakinra; empagliflozin; placebo)|study day 1:anakinra; study day2: empagliflozin; study day 3: placebo
62673680|NCT02441699||Intervention group|Rural villages in which Gram Vikas has fully implemented its water supply and sanitation (Mantra) intervention. Intervention villages must: 1) be within 3 hours travel to the study office in Brahmapur, 2) have started the intervention by January 2003, and 3) have completed the intervention by January 2013.
61916962|NCT05692973|EXPERIMENTAL|Variable Test|Students will be taught a knowledge base comprised of 18 facts about Egypt. After learning the knowledge base to criterion, students will practice retrieving the knowledge base across four testing sessions spaced 24 hours apart. Students will receive different questions across testing sessions. Next, students will read 6 passages about Egypt and then answer literal and inferential questions about the passages. Immediately after reading the passages, students will get re-tested on their retention of the knowledge base and use of the knowledge base to form inferences. They will also get retested one week and one month later to examine students' long-term retention of the knowledge base and use to make inferences.
61916963|NCT05692973|EXPERIMENTAL|Repeated Test|Students will be taught a knowledge base comprised of 18 facts about Egypt. After learning the knowledge base to criterion, students will practice retrieving the knowledge base across four testing sessions spaced 24 hours apart. Students will receive the same questions repeated across testing sessions. Next, students will read 6 passages about Egypt and then answer literal and inferential questions about the passages. Immediately after reading the passages, students will get re-tested on their retention of the knowledge base and use of the knowledge base to form inferences. They will also get retested one week and one month later to examine students' long-term retention of the knowledge base and use to make inferences.
62302106|NCT03445286|EXPERIMENTAL|Silver Diamine Fluordie Application|This group will receive Silver Diamine Fluoride (SDF) application once every week within three weeks period
62302107|NCT03445286|PLACEBO_COMPARATOR|Normal Saline|This control group will receive normal saline application once a week within a a three-week period
62302108|NCT03022422|OTHER|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
62471093|NCT03522363|EXPERIMENTAL|Multidose group|7 vials with 5,5E09 CFU/g Total dose treatment: 4E10 CFU
62673681|NCT02441699||Control group|Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
62673682|NCT05749185|ACTIVE_COMPARATOR|Group H ( high voltage) radiofrequency|Group H, involved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation).
62673683|NCT05749185|ACTIVE_COMPARATOR|Group S ( standard) radiofrequency|utilized a standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V).
62673684|NCT05206331|EXPERIMENTAL|contrast enhanced mammography|Women who have been recently diagnosed with a suspicious abnormality for which they have scheduled a breast biopsy and meet inclusion criteria will be invited to have a contrast enhanced mammography before their scheduled biopsy procedure.
62673685|NCT05812495|EXPERIMENTAL|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
62673686|NCT05812495|EXPERIMENTAL|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
62673687|NCT02692261|ACTIVE_COMPARATOR|Hyalossᵀᴹ matrix|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution used for maxillary sinus augmentation
62673688|NCT02692261|ACTIVE_COMPARATOR|Apatos alone xenograft|Each sinus was filled with 1 gr xenograft (with or without Hyaluronic Acide) for maxillary sinus augmentation
62673689|NCT02347865||wave 1|postmenopausal women with osteoporosis treated with Prolia
62471094|NCT05378360|PLACEBO_COMPARATOR|Placebo of DWP708|EGF Cream Placebo evenly apply to skin lesion every 12 hr/day
62471095|NCT05378360|EXPERIMENTAL|DWP708 10 ug/g|EGF Cream 10 ug/g evenly apply to skin lesion every 12 hr/day
62471096|NCT05378360|EXPERIMENTAL|DWP708 20 ug/g|EGF Cream 20 ug/g evenly apply to skin lesion every 12 hr/day
62471097|NCT05378360|EXPERIMENTAL|DWP708 40 ug/g|EGF Cream 40 ug/g evenly apply to skin lesion every 12 hr/day
61916964|NCT05692973|PLACEBO_COMPARATOR|Placebo|Students will be taught a knowledge base comprised of 18 facts about Egypt. After learning the knowledge base to criterion, students will re-read the passages. They will not receive any questions. Next, students will read 6 passages about Egypt and then answer literal and inferential questions about the passages. Immediately after reading the passages, students will get re-tested on their retention of the knowledge base and use of the knowledge base to form inferences. They will also get retested one week and one month later to examine students' long-term retention of the knowledge base and use to make inferences.
61916965|NCT06097143|EXPERIMENTAL|Flowable Giomer|Patients with conservative carious class I occlusal cavities will be treated with Shofu™ Beautifil Injectable X, Shofu Dental Corp., Japan flowable composite Novel bio-active flowable resin containing nano S-PRG (Surface Pre-Reacted Glass ionomer).
61916966|NCT06097143|EXPERIMENTAL|Nano-filled Flowable Composite with S-PRG barrier coat|Patients with conservative carious class I occlusal cavities will be treated with Filtek™ Z350 XT 3M ESPE, USA Flowable composite: Conventional resin-based nano-filled flowable composite which will then be coated with Shofu™ PRG Barrier Coat, Shofu Dental Corp., Japan.
61916967|NCT06097143|ACTIVE_COMPARATOR|Nano-Filled Flowable Composite|Patients with conservative carious class I occlusal cavities will be treated with Filtek™ Z350 XT 3M ESPE, USA Flowable composite: Conventional resin-based nano-filled flowable composite.
61916968|NCT04920227|EXPERIMENTAL|CLASS+PHACO|CO2 Laser-Assisted Sclerectomy Surgery combined with phacoemulsification
61916969|NCT04920227|NO_INTERVENTION|CLASS|CO2 Laser-Assisted Sclerectomy Surgery
62112248|NCT06076434|EXPERIMENTAL|Effect of 60 second Pressure Times on Bruising and Pain|"The patients were randomized according to age and gender and included in the groups.~Patients were injected with heparin subcutaneously in the upper arm by the clinic nurse in accordance with the procedure of the clinic. The area was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected with a 27 gauge needle at a 90° angle to the tissue. The heparin was injected in approximately 10 seconds without aspirating the syringe. After injection, the area was pressurized with dry cotton wool for the specified time. After the injection, pressure was applied to the area with dry cotton for specified periods. Pain level was determined at the time of injection. Using an acetate pen, a circle of approximately 5 cm was marked around the needle insertion site and the bruising level was measured and recorded 48 hours later using a transparent film."
62673690|NCT02347865||wave 2|postmenopausal women with osteoporosis treated with Prolia
62112249|NCT05206890||fluzoparib treatment|patients with Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
62112250|NCT00544440|EXPERIMENTAL|Abiraterone acetate plus prednisone|Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
62112251|NCT06479733|ACTIVE_COMPARATOR|Group I (buccal pedicle flap group):|Includes 7 implants that will receive implants with soft tissue augmentation using buccal pedicle flap only.
62112252|NCT06479733|ACTIVE_COMPARATOR|Group II (free CTG group):|Includes 7 implants that will receive implants with soft tissue augmentation using free CTG.
62112253|NCT06479733|ACTIVE_COMPARATOR|Group III (ADM group):|Includes 7 implants that will receive implants with soft tissue augmentation using acellular dermal matrix.
62112254|NCT06479733|SHAM_COMPARATOR|Group IV (control group):|Includes 7 implants that will receive implants without soft tissue augmentation.
62112255|NCT03963128|ACTIVE_COMPARATOR|Supplemented Vitamin D3|
62112256|NCT03963128|PLACEBO_COMPARATOR|Placebo|
62302109|NCT03022422|OTHER|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
62302110|NCT03022422|OTHER|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
62302111|NCT03022422|OTHER|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
62302112|NCT03022422|OTHER|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
62302113|NCT03022422|OTHER|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
62673691|NCT01426659|ACTIVE_COMPARATOR|"Protocol say and do"|reeducation implicit 5 minutes every day at home and 30 minutes of speech therapy every week
62673692|NCT01426659|ACTIVE_COMPARATOR|"no stimulation say and do"|
62471098|NCT04539470|EXPERIMENTAL|Cohort A: Efmarodocokin Alfa Dosage Level 1|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
62673693|NCT03049800||FEP - Treatment as Usual|First Episode Psychosis patients who receive treatment as usual while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
61916970|NCT03785275||Subjects with stable near-normal T1D|"* Mixed-meal tolerance test~* Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
61916971|NCT03785275||Subjects with unstable T1D|"* Mixed-meal tolerance test~* Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
61916972|NCT04535167|EXPERIMENTAL|PF-07304814|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
61916973|NCT04535167|PLACEBO_COMPARATOR|Placebo|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
61916974|NCT01854541||Radiotherapy|All patients receiving radiotherapy
61916975|NCT04615455|EXPERIMENTAL|Adipose tissue-derived mesenchymal stem cells (ASCs)|One transconjunctival injection of allogeneic ASCs into the LG in one eye.
62112257|NCT02561923|EXPERIMENTAL|Rivaroxaban|Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.
62112258|NCT02561923|EXPERIMENTAL|Rivaroxaban plus tranexamic acid (TXA)|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
62112259|NCT02561923|EXPERIMENTAL|Rivaroxaban plus Kcentra|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 \[international units per minute\] IU/min) on Day 4 in Part 2.
62112260|NCT02561923|EXPERIMENTAL|Rivaroxaban plus Saline|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline \[Kcentra saline control or TXA saline control\] on Day 4 in Part 2.
62112261|NCT03505099|EXPERIMENTAL|onasemnogene abeparvovec-xioi|One-time intravenous infusion of onasemnogene abeparvovec-xioi at 1.1 X 10\^14 vg/kg
62112262|NCT04182087||Focal Brain Injury|Patients with focal brain injury (post-stroke or post-cortical resection)
62112263|NCT02703740|EXPERIMENTAL|HA 20 mg/mL|
62112264|NCT02703740|EXPERIMENTAL|HA 24 mg/mL|
62112265|NCT04963569||Albumin|Participants enrolled in the ABC Sepsis trial who have been randomised to 5% Human Albumin Solution as the sole resuscitative fluid in the first 6 hours.
62112266|NCT04963569||Balanced Crystalloid|Participants enrolled in the ABC Sepsis trial who have been randomised to Balanced Crystalloid as the sole resuscitative fluid in the first 6 hours.
62112267|NCT02517411|EXPERIMENTAL|Experimental group|COPD patients with stable disease will be recruited and they will receive physiotherapy added to standard care.
62112268|NCT02517411|OTHER|Control group|COPD patients with stable disease will be recruited and they will receive standard care.
62112269|NCT00690248||1|Bipolar patients admitted to a psychiatric Unit due to an acute mania episode.
62112270|NCT02784327|EXPERIMENTAL|PRF110- oily solution|Post-operative application of new extended release PRF110- oily solution (Ropivacaine)
62112271|NCT01289119|PLACEBO_COMPARATOR|Placebo|Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
62112272|NCT01289119|EXPERIMENTAL|Alogliptin Monotherapy|Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
62112273|NCT01289119|OTHER|Metformin|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
62112274|NCT01289119|EXPERIMENTAL|Metformin + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
62112275|NCT01289119|OTHER|Pioglitazone|Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
62112276|NCT01289119|EXPERIMENTAL|Pioglitazone + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
62112277|NCT01345604|PLACEBO_COMPARATOR|Saline|
62112278|NCT01345604|ACTIVE_COMPARATOR|Ropivicaine|
62112279|NCT05869318|EXPERIMENTAL|Vaping|All participants will undergo two vaping sessions: one using their own device and one using the study device
62302114|NCT03679221||Group 45-54 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
62471099|NCT04539470|EXPERIMENTAL|Cohort B: Efmarodocokin Alfa Dosage Level 2|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
61916976|NCT04615455|PLACEBO_COMPARATOR|Placebo (vehicle, Cryostor CS10)|One transconjunctival injection of Cryostor CS10 into the LG in one eye.
61916977|NCT00947050|ACTIVE_COMPARATOR|rest first|rest first, cfi, exercise, cfi
61916978|NCT00947050|ACTIVE_COMPARATOR|exercise first|ex first
61916979|NCT05776602||Pediatric patients with suspected or confirmed brain tumor|New method och standard MRI in clinical care
62302115|NCT03679221||Group 54-64 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
62302116|NCT03679221||Group 65-74 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
62302117|NCT03679221||Group 75-85 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
62302118|NCT06016712|EXPERIMENTAL|Participant|SENSIMED Triggerfish lenses will be applied on this Arm and Intraocular pressure during active phase of delivery will be measured
62302119|NCT05539430|EXPERIMENTAL|Experimental LB1908|Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells
62302120|NCT04621747|EXPERIMENTAL|Study group|healthy volunteers aged 18-35, balanced sex ratio, all of them undergoing the same battery of psychophysical explorations.
62302121|NCT04516252|EXPERIMENTAL|Intervention|Half of the BodyWorks families will be randomized to the intervention group, and will receive a PAT for the children, the parents, and the dogs at the beginning of the cycle; the children will respond to EMA surveys using a cell phone; the children and the parents will receive the Canine health literacy module in addition to the BW curriculum.
62302122|NCT04516252|ACTIVE_COMPARATOR|Control|Half of the BodyWorks participants will be randomized to the control group and will receive a PAT at the beginning of the cycle for the children, the parents, and the dogs, and the children will respond to EMA surveys using cell phones.
62302123|NCT04397679|EXPERIMENTAL|Treatment (radiation therapy, temozolomide, chloroquine, TTF)|"Patients undergo 30 fractions of 3D CRT or Intensity-modulated radiation therapy (IMRT) and receive temozolomide by mouth (PO) and chloroquine PO daily from day 1 for the duration of radiation therapy up to day 49. Treatment continues in the absence of disease progression or unacceptable toxicity.~ADJUVANT TREATMENT: Beginning 4 weeks after the last day of radiation therapy, patients receive temozolomide PO QD on days 1-5 and chloroquine PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients demonstrating continued benefit may continue to receive temozolomide and chloroquine for up to 12 cycles. Patients also undergo TTF therapy over 18 hours or longer per day."
62302124|NCT02209883||Group normal|The patients which have not clinical diagnosis of chronic obstructive lung disease.
62302125|NCT02209883||Group COPD|The patients which have chronic obstructive lung disease in clinical evaluation
62302126|NCT06123156|ACTIVE_COMPARATOR|Arm I (Sildénafil)|Sildénafil during 10 months (50mg daily), start 30 days after surgery
62302127|NCT06123156|PLACEBO_COMPARATOR|Arm II (Placebo)|Patients receive placebo during 10 month (1 platelet per day)
62302128|NCT01584024|ACTIVE_COMPARATOR|Resin infiltration|Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
62302129|NCT01584024|SHAM_COMPARATOR|Control|Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
62302130|NCT05498298|EXPERIMENTAL|Gtec|
62302131|NCT06509698|EXPERIMENTAL|virtual reality|"Virtual reality used for balance, gait and quality of life the treatment will be given with the frequency of 3 times per week for 6 weeks. Warmup period, Instruct the patient/participants, Gaming time (20 minutes), cool down period (5 minutes).~Treatment sessions will be of 30 minutes with short resting intervals."
62302132|NCT06509698|ACTIVE_COMPARATOR|Frenkel's exercise|"Frenkel's exercise used for balance, gait and quality of life Frenkel's exercise, the treatment will be given with the frequency of 3 times per week for 6 weeks.~Warmup period (5 minutes), frenkel's exercise (20 minutes), cool down period (5 minutes).~Treatment sessions will be of 30 minutes with short resting intervals."
62302133|NCT03217162|EXPERIMENTAL|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
62471100|NCT04539470|EXPERIMENTAL|Cohort C: Efmarodocokin Alfa Dosage Level 3|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
62673694|NCT03049800||FEP - Targeted Cognitive Training|First Episode Psychosis patients who receive targeted cognitive training exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
62673695|NCT03049800||FEP - General Cognitive Exercises|First Episode Psychosis patients who receive general cognitive exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
62673696|NCT03049800||Healthy Controls|Age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
62673697|NCT00908388|EXPERIMENTAL|GORE Conformable TAG® Device Surgical Implant|
62673698|NCT03833843||TGA|
62112280|NCT01547741|ACTIVE_COMPARATOR|Arm 1: Anthracycline-based chemotherapy|"4 anthracycline-based chemotherapy regimens (Regimens A, B, C, or D).~Regimen A (TAC): 75 mg/m2 docetaxel (T) + 50 mg/m2 doxorubicin (A) + 500 mg/m2 cyclophosphamide (C) IV every 3 weeks for 6 cycles.~Regimen B (AC then WP): 60 mg/m2 doxorubicin (A) + 600 mg/m2 cyclophosphamide (C) every 3 weeks for 4 cycles followed by weekly paclitaxel (WP) 80 mg/m2 IV every week for 12 doses.~Regimen C (DD AC then WP): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel 80 mg/m2 IV every week for 12 doses.~Regimen D (DD AC then DD P): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel (P) 175 mg/m2 IV every 2 weeks for 4 cycles."
62112281|NCT01547741|ACTIVE_COMPARATOR|Arm 2: docetaxel + cyclophosphamide|TC: 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide IV every 3 weeks for 6 cycles
62112282|NCT00518726|EXPERIMENTAL|Arm 1|
62112283|NCT02457702|EXPERIMENTAL|Orally administered Labeled Glycerol|Patients will receive an oral mixture of \[U-13C3\]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
62302134|NCT03217162|ACTIVE_COMPARATOR|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
62302135|NCT00631319|EXPERIMENTAL|OROS Hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
62302136|NCT00631319|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
62302137|NCT03829761|EXPERIMENTAL|Cerebellar rTMS|Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
62673699|NCT01794169|EXPERIMENTAL|Azacitidine|Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
62673700|NCT01794169|ACTIVE_COMPARATOR|DA|"Two courses of DA in accordance with the Swedish National treatment program (reduced doses):~In case one induction course was given:~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~In case two induction courses were given:~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5."
62673701|NCT01283425|EXPERIMENTAL|Test|InsuPatch use for 3 months.
62112284|NCT04189900|EXPERIMENTAL|Triptorelin|The subjects in this group receive a single dose treatment. Biologic sample collection (urine) from 48 hours pre-administration to 48 hours post administration.
62112285|NCT05844748|EXPERIMENTAL|diabetes education with motivational interview technique|A face-to-face motivational interview session was applied to each participant in the experimental (intervention) group by the researcher once a week in the 1st month and once in 15 days in the 2nd month. The interviews were held in 6 sessions in total, and each interview was completed in approximately 45-60 minutes.
62112286|NCT05905913|EXPERIMENTAL|Part A: Single Intravenous Ascending Dose of ANT3310|
62112287|NCT05905913|PLACEBO_COMPARATOR|Part A: Single Intravenous Dose of Matching placebo|
62302138|NCT03829761|SHAM_COMPARATOR|Sham TMS|Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
62302139|NCT03018015|EXPERIMENTAL|Ibuprofen 400 mg oral powder|oral fasted administration of 1 sachet of Ibuprofen 400 mg oral powder (Hermes Arzneimittel GmbH, Germany), containing 400 mg ibuprofen
62302140|NCT03018015|ACTIVE_COMPARATOR|Brufen 400 mg film-coated tablets|oral fasted administration of Brufen 400 mg film-coated tablets (Abbott Scandinavia AB, Sweden), containing 400 mg ibuprofen
62471101|NCT04289532|EXPERIMENTAL|99mTc-RWY SPECT/CT|Volunteers and patients were injected intravenously with 11.1 MBq/kg of 99mTc-RWY in one dose and underwent SPECT/CT scan 30-60 min later.
62471102|NCT03680222|NO_INTERVENTION|Standard method|Standard method recommended by the guide
62471103|NCT03680222|EXPERIMENTAL|Reversed Tracking Method|Reversed Tracking Method
62471104|NCT04589247||Patients with cancer treated with definitive-intent radiotherapy|Histologically confirmed loco-regional to advanced primary cancer, including but not limited to lung cancer, esophageal, or gastro-intestinal cancers at risk of developing radiotherapy-related toxicity.
62471105|NCT05645367||premature myocardial infarction|AMI with onset age less than 55 years for men and 65 years for women.
62471106|NCT05645367||control|AMI with onset age not less than 55 years for men and 65 years for women.
62673702|NCT01283425|NO_INTERVENTION|Control|
62673703|NCT00212355|EXPERIMENTAL|NPC-02|zinc acetate
62673704|NCT04418479|ACTIVE_COMPARATOR|Aspirin monotherapy arm|Patients will receive 100 mg of aspirin once daily.
62673705|NCT04418479|EXPERIMENTAL|Clopidogrel monotherapy arm|Patients will receive 75 mg of clopidogrel once daily.
62673706|NCT03075436|EXPERIMENTAL|Enhanced demand-side sanitation, hygiene|The intervention group will receive a package of enhanced, demand-side sanitation and hygiene interventions that are informed by formative research and facilitated by local government and Emory Ethiopia partners.
62673707|NCT03075436|ACTIVE_COMPARATOR|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
62673708|NCT00445120|EXPERIMENTAL|1|
62302141|NCT03018015|ACTIVE_COMPARATOR|Spalt forte 400 mg Weichkapseln|oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen
61916980|NCT06341803|EXPERIMENTAL|Individually neuronavigated intermittent theta burst stimulation (Magpro X100) system for depression|Participants will receive an accelerated intermittent theta burst stimulation (iTBS) treatment delivered with a MagVenture MagPro X100 system (MagVenture A/S, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A/P coil. The treatment course is comprised of 10 treatment sessions daily for 5 consecutive workdays for a total of 50 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.
62112288|NCT05905913|EXPERIMENTAL|Part B: Multiple Intravenous Ascending Doses of ANT3310|
62112289|NCT05905913|PLACEBO_COMPARATOR|Part B: Multiple Intravenous Ascending Doses of Matching Placebo|
62112290|NCT05905913|EXPERIMENTAL|Part C: ANT3310 + Meropenem|Participants will receive a single intravenous dose of ANT3310 or Meropenem in one of the 2 treatment sequences followed by the repeat administrations of ANT3310 + Meropenem.
62112291|NCT05905913|PLACEBO_COMPARATOR|Part C: ANT3310 Placebo + Meropenem Placebo|Participants will receive a single dose of ANT3310-placebo or Meropenem-placebo in one of the 2 treatment sequences followed by repeat administrations of ANT3310-placebo + Meropenem-placebo
62112292|NCT03719391|EXPERIMENTAL|JUUL 5% Virginia Tobacco ENDS|Treatment with JUUL Virginia Tobacco flavored 5.0% ENDS product.
62112293|NCT03719391|EXPERIMENTAL|JUUL 5% Cool Mint ENDS|Treatment with JUUL Cool Mint flavored 5.0% ENDS product.
62112294|NCT03719391|EXPERIMENTAL|JUUL 5% Mango ENDS|Treatment with JUUL Mango flavored 5.0% ENDS product.
62112295|NCT03719391|EXPERIMENTAL|JUUL 5% Creme Brulee ENDS|Treatment with JUUL Creme Brulee flavored 5.0% ENDS product.
62112296|NCT03719391|ACTIVE_COMPARATOR|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine product.
62302142|NCT01157169|EXPERIMENTAL|Investigational Test Product|Buprenorphine 8 mg Sublingual Tablets
62302143|NCT01157169|ACTIVE_COMPARATOR|Reference Listed Drug|Subutex® 8 mg Sublingual Tablets
62112297|NCT03719391|ACTIVE_COMPARATOR|Nicotine Gum|Treatment with nicorette white ice mint 4mg nicotine polacrilex gum product.
62112298|NCT03719391|ACTIVE_COMPARATOR|Usual Brand Combustible Cigarette|Treatment with usual brand combustible cigarette.
62112299|NCT01149681|EXPERIMENTAL|Arm one|
62112300|NCT06563375|EXPERIMENTAL|Dose Escalation|
62112301|NCT06563375|EXPERIMENTAL|Dose Expansion|
62112302|NCT04376385|EXPERIMENTAL|Treatment condition - 9 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
62112303|NCT04376385|EXPERIMENTAL|Treatment condition - 12 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
62112304|NCT04376385|EXPERIMENTAL|Treatment condition - 17 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
62112305|NCT04376385|EXPERIMENTAL|Treatment condition - 19 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
62112306|NCT04376385|EXPERIMENTAL|Treatment condition - 33 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
62302144|NCT03253640||Patients with HAI during hospital stay|Patients who meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
62302145|NCT03253640||Patients without HAI during hospital stay|Patients who do not meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
62471107|NCT02077465|EXPERIMENTAL|Andecaliximab|Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
62471108|NCT02077465|PLACEBO_COMPARATOR|Placebo to match andecaliximab|Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
62471109|NCT00719745|ACTIVE_COMPARATOR|1|
61916981|NCT05530629|EXPERIMENTAL|High intensity of resistance training|"The intensity of 75-80% 1RM is used for high intensity resistance training group. The number of repetitions of each set is relatively few, only 6-8 times. The rest time between sets is relatively long, 2-3 minutes, so that the participants can better adapt to this intensity.~chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
61916982|NCT05530629|EXPERIMENTAL|Moderate intensity of resistance training|"The intensity of 60-65% 1RM is used for moderate intensity resistance training group. The repetition times of each set are relatively moderate, 10-12 times. The rest time between sets is relatively moderate, 1-2 minutes. The relative exercise volume of this group was consistent with that of other experimental groups chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
61916983|NCT05530629|EXPERIMENTAL|Low intensity of resistance training|"The intensity of 40-45% 1RM is used for low intensity resistance training group. The repetition times of each set are relatively more, 16-18 times. The rest time between groups is short, only about 1 minute, so that the participants can still maintain sufficient total exercise load under low intensity.~chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
61916984|NCT05530629|OTHER|Normal P.E. course|Carry out general teaching content according to the college syllabus.
61916985|NCT06332469|EXPERIMENTAL|Treatment group|This group gets immediate access to the program
61916986|NCT06332469|NO_INTERVENTION|Wailtlist group|This group gets access to the same program after a 9 week waiting time
61916987|NCT01879540|EXPERIMENTAL|aTIV|Adult subjects ≥65 years of age received one dose of a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere
61916988|NCT00734760|EXPERIMENTAL|A|a tailored, face-to-face education and counseling intervention with a nurse lasting approximately 45 minutes, followed by a telephonic reinforcement in 30 days
62471110|NCT00719745|EXPERIMENTAL|2|
62471111|NCT02530905|PLACEBO_COMPARATOR|Placebo (double-blind dose titration)|Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.
62471112|NCT02530905|EXPERIMENTAL|SRP-4045 (double-blind dose titration)|Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.
61916989|NCT00734760|NO_INTERVENTION|B|care-as-usual with data collection at the same time points as the experimental group
61916990|NCT01113476|EXPERIMENTAL|Nab-paclitaxel, Gemcitabine + Bevacizumab|Starting doses of Nab-paclitaxel 50 mg/m\^2, Bevacizumab 5 mg/kg + fixed dose of Gemcitabine 1000 mg/m\^2
62302146|NCT05393154||Study Participant|Non-destructive imaging of biopsies using the Aquyre system
62302147|NCT03061708|EXPERIMENTAL|AZD2014 50mg BD continuous schedule of a 28 day cycle|AZD2014 50mg BD continuous schedule of a 28 day cycle
62302148|NCT05957081|EXPERIMENTAL|Phase 1 a: Part A: PMC-309 Monotherapy Dose Escalation|"Phase 1a will enroll participants with advanced or metastatic solid tumors to assess safety, tolerability, PK and clinical efficacy in response to treatment with PMC-309 as a monotherapy~Dosage form and Route of administration: The duration of a treatment cycle is 3 weeks/21 days. Participants will be administered a weekly dose of PMC-309 per cycle as follows:~* Cycle Week 1/Day 1~* Cycle Week 2/Day 8 ± 2 days~* Cycle Week 3/Day 15 ± 2 days PMC-309 will be administered intravenously over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration."
62471113|NCT02530905|EXPERIMENTAL|SRP-4045 (open label extension period)|All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.
62471114|NCT00833157|EXPERIMENTAL|Glucosamine|
62471115|NCT00833157|EXPERIMENTAL|Ibuprofen|
62471116|NCT00833157|PLACEBO_COMPARATOR|Placebo|
62471117|NCT01693263||brachiocephalic fistula placed|Subjects are being asked to participate in this study because they have end-stage renal disease and they are undergoing dialysis, and their doctor has recommended that they will have brachiocephalic fistula placed for their dialysis access.
62673709|NCT00445120|PLACEBO_COMPARATOR|2|
62471118|NCT01693263||Sub-study participants|As part of this study there is an additional sub-study. The researchers would like to collect more information about the vascular access from 50 subjects. For the purposes of this sub-study the following will take place: Intravenous Ultrasound (IVUS) and Hand Held Doppler
62471119|NCT01265056|PLACEBO_COMPARATOR|Sugar Pill|Placebo
62471120|NCT01265056|EXPERIMENTAL|Gabapentin|Gabapentin
62673710|NCT02465047|EXPERIMENTAL|Self-help booklet|The intervention consists of a brief A5 self-help stress management booklet with an audio Compact Disk.
62673711|NCT02465047|NO_INTERVENTION|Delayed Intervention|Participants do not receive the intervention until one month after the initial assessment.
62673712|NCT00684138|EXPERIMENTAL|ReSTOR Aspheric +3.0D|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
62673713|NCT00684138|ACTIVE_COMPARATOR|ReSTOR Aspheric +4.0D|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
62673714|NCT05055336|EXPERIMENTAL|Gastroparesis|Participants in this group are children diagnosed with gastroparesis per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
62673715|NCT05055336|EXPERIMENTAL|Dyspepsia|Participants in this group are children diagnosed with functional dyspepsia per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
62673716|NCT05055336|EXPERIMENTAL|Healthy Controls|Participants in this group are children that do not have gastroparesis, functional dyspepsia, or any other gastroenterology condition. Participants will be getting an ultrasound once.
62673717|NCT01730976|EXPERIMENTAL|Vitamin D 2,000 I.U. daily|Study subjects will take 2,000 I.U. vitamin D daily for three months
62673718|NCT03020888|EXPERIMENTAL|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.~Marker located during surgery using the Sentimag system, and removed with the lesion."
62471121|NCT00794456|EXPERIMENTAL|1|Association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L.
62471122|NCT00794456|ACTIVE_COMPARATOR|2|Valeriana officinalis 50 mg
62673719|NCT00315029|EXPERIMENTAL|1|Receives combined patient centred intervention
62673720|NCT00315029|NO_INTERVENTION|2|Standard treatment
62673721|NCT01033227|NO_INTERVENTION|No drug|No study drug administered
62673722|NCT01033227|EXPERIMENTAL|Sodium nitrite injection, USP|Administration if sodium nitrite injection, USP
62673723|NCT03703986||END group|The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.
62471123|NCT04782765|EXPERIMENTAL|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
62673724|NCT03703986||non-END group|The patients in this group had a slight increase of \< 2 points or a decrease in NIHSS within 7 days of stroke onset.
62673725|NCT01272856|EXPERIMENTAL|Open Label Abatacept|
62673726|NCT03468946|OTHER|high caries risk|children with high caries -identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
62673727|NCT03468946|OTHER|medium caries risk|children with medium caries- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
62673728|NCT03468946|OTHER|low risk|no caries or low risk- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
62471124|NCT01310920||sick sinus syndrome|
62471125|NCT01310920||control|
62673729|NCT01433874|EXPERIMENTAL|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
62673730|NCT01433874|EXPERIMENTAL|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc we will leave the fluid in the abdominal cavity.
62673731|NCT01433874|EXPERIMENTAL|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH20. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
62673732|NCT01433874|PLACEBO_COMPARATOR|Control group|Co2 was removed by passive exsufflation through the port site
62471126|NCT02416726|EXPERIMENTAL|Peripheral blood|The peripheral blood sample will be extrated with DNA and performed NGS using Illumina Nextseq500 sequencer.
62471127|NCT02416726|EXPERIMENTAL|Primary tumor|The gene testing of the primary tumor tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
62673733|NCT03488485|OTHER|DAA arm|"Direct Acting Antivirals therapy An algorithm was developed using DAA (Sofosbuvir-based regimens to treat all patients (RKD).~Non Cirrhotics: Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks~Cirrhotics:~Genotype 3 were treated with SOF+DCV+ ribavirin (RBV) for 24 weeks, Non-Genotype 3 patients were treated with SOF+LDV+RBV for 12-weeks or with SOF+LDV for 24-weeks (in RBV intolerant patients)."
62673734|NCT04743895|ACTIVE_COMPARATOR|Stainless Steel Wire Cerclage|Sternotomy closure using Stainless Steel Wire Cerclage
62673735|NCT04743895|ACTIVE_COMPARATOR|FiberTape Cerclage|Sternotomy closure using FiberTape
62673736|NCT01263028|EXPERIMENTAL|Ergocalciferol supplementation|
62673737|NCT00699166|EXPERIMENTAL|1|
62673738|NCT00699166|EXPERIMENTAL|2|
62471128|NCT02416726|EXPERIMENTAL|Metastatic lymph node|The gene testing of the metastatic lymph node tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
62471129|NCT01854047|EXPERIMENTAL|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
62471130|NCT01854047|EXPERIMENTAL|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
62673739|NCT00699166|PLACEBO_COMPARATOR|3|
62673740|NCT03486639||Patients undergoing urodynamic|All patients older than 18 who are refered for Urodynamics examination
62673741|NCT03346512||Cardiac surgery|Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015
62673742|NCT05303974|EXPERIMENTAL|Novices|Measurement of competence
62673743|NCT05303974|EXPERIMENTAL|Intermediates|Measurement of competence
62673744|NCT05303974|EXPERIMENTAL|Experts|Measurement of competence
62673745|NCT01220154|EXPERIMENTAL|Carboplatin Paclitaxel & Bevacizumab|Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
62673746|NCT05358535|EXPERIMENTAL|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.
62112307|NCT04242732|EXPERIMENTAL|MPFL reconstructed|20 patients with previous recurrent patella dislocation who underwent MPFL reconstruction surgery with fascia lata allograft between 2012 and 2013
62112308|NCT05351372|EXPERIMENTAL|ULD protocol|ultra-low dose protocol in cone-beam computed tomography with a field of view including the cleft area
62112309|NCT05351372|ACTIVE_COMPARATOR|Standard dose protocol|Standard dose protocol in cone-beam computed tomography with a field of view including the cleft area
62112310|NCT06350045|EXPERIMENTAL|subcostal puncture PCNL|puncturing the subcostal region to reach the kidney
62112311|NCT06350045|EXPERIMENTAL|supracostal puncture PCNL|puncturing the supra eleventh rib
62112312|NCT02026219|EXPERIMENTAL|Clopidogrel|Clopidogrel 600mg loading
62112313|NCT02026219|EXPERIMENTAL|Ticagrelor|Ticagrelor 180mg loading
62112314|NCT04463524||Test|They will receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
62673747|NCT05358535|EXPERIMENTAL|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.
62112315|NCT04463524||Control|They will not receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
62112316|NCT04265378|EXPERIMENTAL|Stimulation group|Anodal tDCS + intensive cognitive training
62112317|NCT04265378|SHAM_COMPARATOR|Sham group|Sham tDCS + intensive cognitive training
62112318|NCT01843491|EXPERIMENTAL|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10\^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
62673748|NCT05224648|ACTIVE_COMPARATOR|TOF scan train of four ratio monitoring|recovery of train of four ratio after neostigmine administration
62673749|NCT05224648|EXPERIMENTAL|ITF device tetanus stimulation monitoring|recovery of tetanus 100 Hz and tetanus 50 Hz ratio after neostigmine administration
62112319|NCT02883088||LAD-group|Subjects over 18 years who are undergoing Frequency Domain - Optical Coherence Tomography (FD-OCT) evaluation of the native left anterior descending artery during clinically indicated coronary angiography regardless of the clinical syndrome (silent ischemia, effort angina or acute coronary syndrome).
62112320|NCT04475224|OTHER|Open-label|
62673750|NCT00422461|PLACEBO_COMPARATOR|Placebo|
62673751|NCT00422461|EXPERIMENTAL|PF-00489791 20 mg titrated to 40 mg|
62673752|NCT00422461|EXPERIMENTAL|PF-00489791 4 mg|
62673753|NCT00422461|EXPERIMENTAL|PF-00489791 10 mg|
62673754|NCT06435845|EXPERIMENTAL|RLYB212|RLYB212 Subcutaneous injection
62673755|NCT00395512|EXPERIMENTAL|Alogliptin 25 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
62673756|NCT00395512|ACTIVE_COMPARATOR|Pioglitazone 30 mg QD|Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
62302149|NCT05957081|EXPERIMENTAL|Phase 1a: Part B: PMC-309 Dose Escalation in Combination with Pembrolizumab|"Part B will establish the MTD/preliminary RP2D of PMC-309 when administered in combination with 200 mg pembrolizumab. Part B will be conducted after completion of Part A (PMC-309 monotherapy dose escalation) and before the commencement of Phase 1b.~Dosage form and Route of administration: The duration of a treatment cycle is 3 weeks/21 days. Participants will be administered a weekly dose of PMC-309 plus one dose of pembrolizumab at 200 mg per cycle as follows:~* Cycle Week 1/Day 1: pembrolizumab (administered first), followed by administration of PMC-309.~* Cycle Week 2/Day 8 ± 2 days: PMC-309 only~* Cycle Week 3/Day 15 ± 2 days: PMC-309 only. Both PMC-309 and pembrolizumab will be administered intravenously."
62302150|NCT05957081|EXPERIMENTAL|Phase 1b: Dose Expansion|"Phase 1b will enroll participants after completion of DLT assessments for Phase 1a.~Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts to assess response of monotherapy of PMC-309 and response of PMC-309 in combination with pembrolizumab.~* Cohort A: PMC-309 monotherapy therapy~  - PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~* Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab Participants will be randomly assigned to Cohort A or Cohort B until 20 participants are enrolled in each cohort."
62302151|NCT01052064|EXPERIMENTAL|Transcranial magnetic stimulation|There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
62302152|NCT06231043|EXPERIMENTAL|Drug1|Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.
62471131|NCT01854047|EXPERIMENTAL|Dupilumab 300 mg q4w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
62112321|NCT00272935|EXPERIMENTAL|1|
62112322|NCT00272935|PLACEBO_COMPARATOR|2|
62112323|NCT04844957|OTHER|Clinical Study of Vitamin D in Children With NMS|Correlation between vitamin D and symptoms severity of autonomic nervous mediated syncope child and it 's RAAS
62112324|NCT00893373|EXPERIMENTAL|Sorafenib|Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d
62112325|NCT00893373|PLACEBO_COMPARATOR|Placebo|Induction, Consolidation and Maintenance plus Placebo
62112326|NCT04460573|ACTIVE_COMPARATOR|Smart boot irremovable|Smart boot rendered irremovable with cohesive bandage; no feedback on adherence.
62112327|NCT04460573|ACTIVE_COMPARATOR|Smart boot removable|Smart boot, removable, without feedback on adherence.
62112328|NCT04460573|EXPERIMENTAL|Smart boot removable+reinforcement|Smart boot with, removable, with reinforcement of adherence via smart watch and smart phone as well as remote patient monitoring.
62112329|NCT03355495|NO_INTERVENTION|Left Lateral Decubitus Position|Gold standard positioning for colonoscopy
62112330|NCT03355495|ACTIVE_COMPARATOR|Right Lateral Decubitus Position|Comparing positioning in Right Lateral Decubitus (intervention) for visualization in colonoscopy to the gold standard of Left Lateral Decubitus.
62112331|NCT05506098||Healthy|Subjects without periodontitis
62112332|NCT05506098||Periodontitis|Subjects with periodontitis
62112333|NCT01228448|EXPERIMENTAL|Participants 1-39|PET Scan done right after one radiation treatment is complete and will take 15-20 minutes. After undergoing their first PET scan, participants will have the option to undergo 1-2 additional scans throughout radiation treatment in the same manner as the first scan.
62112334|NCT00092833|EXPERIMENTAL|1|Ezetimibe
62112335|NCT01677104|ACTIVE_COMPARATOR|DPP-IV inhibitor|Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
62112336|NCT01677104|PLACEBO_COMPARATOR|Placebo pill|One placebo tablet before microinjection
62112337|NCT01927835|EXPERIMENTAL|Group 1A: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
62112338|NCT01927835|EXPERIMENTAL|Group 1B: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
62112339|NCT01927835|EXPERIMENTAL|Group 2A: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
62112340|NCT01927835|EXPERIMENTAL|Group 2B: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
62112341|NCT01927835|PLACEBO_COMPARATOR|Group 3A: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
62302153|NCT06231043|ACTIVE_COMPARATOR|Drug2|Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.
62302154|NCT02001740|PLACEBO_COMPARATOR|lidocaine|frequency = once
62673757|NCT00395512|EXPERIMENTAL|Alogliptin 25 mg QD+ Pioglitazone 30 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
62673758|NCT00395512|ACTIVE_COMPARATOR|Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
62673759|NCT03919266|OTHER|Control|usual antibiotic treatment
62673760|NCT03919266|EXPERIMENTAL|Intervention|targeted antibiotic treatment according to the results of PCR multiplex
62112342|NCT01927835|PLACEBO_COMPARATOR|Group 3B: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
62471132|NCT01854047|EXPERIMENTAL|Dupilumab 200 mg q4w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
62673761|NCT01582256||ASD+CNVs|
62673762|NCT01582256||ASD-CNVs|
62673763|NCT01582256||Unaffected siblings of ASD+CNVs|
62112343|NCT03165149|ACTIVE_COMPARATOR|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
62302155|NCT02001740|EXPERIMENTAL|Triamcinalone (steroid) and lidocaine|frequency = once
62302156|NCT00998738|EXPERIMENTAL|Arm I (calcium gluconate, magnesium sulfate)|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after each ixabepilone administration.
62471133|NCT01854047|PLACEBO_COMPARATOR|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
62471134|NCT02096783|ACTIVE_COMPARATOR|Arm I (standard counseling)|Patients receive standard counseling at both the pre-operative and 2-4 week post-operative visit.
62112344|NCT03165149|ACTIVE_COMPARATOR|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
62112345|NCT03165149|ACTIVE_COMPARATOR|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
62112346|NCT02618317|ACTIVE_COMPARATOR|Heparin Lock Solution|Patients on Heparin 1,000 U/ml locking solution, administered at the end of each dialysis session during a 15-week period .
62302157|NCT00998738|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo IV over 30 minutes immediately before and after each ixabepilone administration.
62471135|NCT02096783|EXPERIMENTAL|Arm II (standard counseling, scripted intervention)|Patients receive standard counseling at the pre-operative visit and the scripted sexual health intervention at the 2-4 week post-operative visit.
62471136|NCT02096783|EXPERIMENTAL|Arm III (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at the pre-operative visit and standard counseling at the 2-4 week post-operative visit.
62471137|NCT02096783|EXPERIMENTAL|Arm IV (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at both the pre-operative and 2-4 week post-operative visit.
62112347|NCT02618317|EXPERIMENTAL|Trissodium Citrate 30%|Patients on trissodium citrate 30% locking solution, administered at the end of each dialysis session during a 15-week period .
62302158|NCT02173600|EXPERIMENTAL|Group-level Intensive Dietary Counselling|Active learning through 4-6 60-minute sessions workshop, enrolling 8-12 people each time.
62471138|NCT04772807||Healthy|
62471139|NCT04772807||Patients infected by COVID- 19 with no symptoms|
62112348|NCT02618317|EXPERIMENTAL|Minocycline-EDTA 30 mg/ml - 3 mg/ml|Patients on Minocycline 30 mg/ml/EDTA 3 mg/ml locking solution, administered at the end of each dialysis session during a 15-week period.
62302159|NCT02173600|ACTIVE_COMPARATOR|Individual-level Intensive Dietary Counselling|Individualised dietary counselling delivered at the health-care point
62302160|NCT04346342||Mechanical ventilation|COVID patients receiving invasive mechanical ventilation
62302161|NCT05077514|EXPERIMENTAL|Group A|
62302162|NCT05077514|ACTIVE_COMPARATOR|Group B|
62471140|NCT04772807||Patients infected by COVID- 19 with symptoms|
62471141|NCT04772807||Patients diagnosed with atrial fibrillation|
62471142|NCT04772807||Hypertensive patients|
62673764|NCT01582256||Unaffected siblings of ASD-CNVs|
62673765|NCT01582256||Neurotypicals for ASD+CNVs comparisons|
62673766|NCT01582256||Neurotypicals for ASD-CNVs comparisons|
62673767|NCT04127929|ACTIVE_COMPARATOR|Glass carbomer|
62673768|NCT04127929|ACTIVE_COMPARATOR|Tokuyama Estelite Posterior|
62673769|NCT03556878|EXPERIMENTAL|Fitted TranS-C|Fitted TranS-C involves 4 x 20-30 minute sessions. It involves selected cross-cutting, core and optional modules from Standard TranS-C.
62673770|NCT01570192|EXPERIMENTAL|IV meropenem; parenteral aminoglycoside|"Subjects assigned to this group will receive:~* IV meropenem (2 g infused over 3 hrs q 8 hr);~* a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)~* tobramycin nebulization~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens."
62673771|NCT01570192|ACTIVE_COMPARATOR|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.~\*\*NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion."
62673772|NCT02829957|ACTIVE_COMPARATOR|Rivaroxaban|
62673773|NCT02829957|ACTIVE_COMPARATOR|Apixaban|
62112349|NCT00075491|EXPERIMENTAL|Arm I (fenretinide, surgery)|Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
62112350|NCT00075491|ACTIVE_COMPARATOR|Arm II (surgery)|Patients undergo surgical resection.
62302163|NCT05382481|EXPERIMENTAL|Peak value anti-Xa group (Group A)|The peak value of anti-Xa level of this group should be remain 0.3～0.5IU/mL. This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
62471143|NCT04772807||Heart failure patients, EF < 40%|
62673774|NCT06355687|ACTIVE_COMPARATOR|The Melatonin group|Melatonin group: A total of 30 obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
62673775|NCT06355687|PLACEBO_COMPARATOR|The Control group|Control group: A total of 30 obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia; Control group.
62112351|NCT00132119|EXPERIMENTAL|1|Nalmefene HCl 20 mg
62112352|NCT00132119|EXPERIMENTAL|2|Nalmefene HCl 40 mg
62112353|NCT00132119|PLACEBO_COMPARATOR|3|Placebo
62112354|NCT04056923|EXPERIMENTAL|3D-printed template-guided(3D-G)|Intraoperative 3D-G methylene blue dye marking in the operating room
62112355|NCT04056923|ACTIVE_COMPARATOR|CT-guided(CT-G)|Preoperative localization is performed by CT-G indocyanine green marking in the radiology department
62112356|NCT06239948|PLACEBO_COMPARATOR|control group|without music
62112357|NCT06239948|EXPERIMENTAL|experimental group|with music
62112358|NCT05923008|EXPERIMENTAL|IBI130|IBI130
62112359|NCT02175043|EXPERIMENTAL|the operation to add in CFAE to conventional liner ablation|The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
62112360|NCT02175043|ACTIVE_COMPARATOR|only doing conventional liner ablation|The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
62112361|NCT04890821|EXPERIMENTAL|CI Percutaneous Ring Annuloplasty System|Patients treated with the CI Percutaneous Ring Annuloplasty System
62471144|NCT04772807||Heart failure patients, EF > 40% and < 60%|
61916991|NCT03585127|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
61916992|NCT03585127|EXPERIMENTAL|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
62112362|NCT04371536|ACTIVE_COMPARATOR|Arm A: Oral iron therapy|Arm A is standard oral iron therapy for 3 months.
62112363|NCT04371536|EXPERIMENTAL|Arm B: Oral iron therapy plus IRONCHILD web-based intervention|Oral iron therapy as per Arm A plus the IRONCHILD web-based intervention aimed at promoting oral iron adherence. This web-based intervention was developed specifically for caregivers of young children with nutritional iron deficiency anemia to promote oral iron adherence.
62112364|NCT06165172|EXPERIMENTAL|Intervention|Active treatment with MyoRegulator® device
62112365|NCT01701713|EXPERIMENTAL|TDCS - DKI ED2011|TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues
62112366|NCT01701713|SHAM_COMPARATOR|Sham-TDCS|Sham-TDCS session is followed by a behavioral naming therapy with different cues
62112367|NCT02709174||pregnant with pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
62471145|NCT04772807||Heart failure patients, EF > 60%|
62673776|NCT03701178|ACTIVE_COMPARATOR|zirconia veneered crowns|we will use zirconia veneered single crowns as a control to evaluate the marginal integrity and fracture and patient satisfaction
62673777|NCT03701178|EXPERIMENTAL|milled BioHpp PEEK|we will use milled BioHPP PEEK single crowns as a intervention to evaluate the marginal integrity and fracture and patient satisfaction
62673778|NCT06009497|EXPERIMENTAL|Romiplostim+CsA|"Romiplostim 10 µg/kg, subcutaneous injection, once a week, for at least 3 months. Patients with platelet count ≥50×109/L can stop using, and continue to use with platelet count \< 50×109/L.~Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml. Ciclosporin should be used for at least 6 months to evaluate the efficacy. Effective patients will continue to use ciclosporin for at least 1.5 years, followed by a slow reduction."
62673779|NCT06009497|EXPERIMENTAL|CsA|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml. Ciclosporin should be used for at least 6 months to evaluate the efficacy. Effective patients will continue to use ciclosporin for at least 1.5 years, followed by a slow reduction.
62302164|NCT05382481|EXPERIMENTAL|Trough value anti-Xa group (Group B)|The trough value of anti-Xa level of this group should be remain 0.1～0.2IU/mL. This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
62471146|NCT01171989|EXPERIMENTAL|GSK2202083A + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of GSK2202083A and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of GSK2202083A vaccine at Day 0 and of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
62673780|NCT06244251|EXPERIMENTAL|TU-LESS for myomectomy|Patients complaint of symptoms resulting from uterine fibroids, such as abnormal vaginal bleeding, frequent micturition, lower abdominal pain, constipation, etc or patients with uterine fibroids which were identified accidentally during routine body examination who consulted at our center for surgical removal of the fibroids. In the meantime, the diagnosis of uterine fibroids should be reconfirmed by at least one radiological examination at our center. The patients in the experiment group were those who received transumbilical laparoendoscopic single site surgery (TU-LESS) for myomectomy.
61916993|NCT00477958|EXPERIMENTAL|Geriatric Assessment Tool|
62112368|NCT02709174||pregnant without pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
62112369|NCT02107378|EXPERIMENTAL|DCVAC/OvCa in parallel with chemo (SoC)|Combination therapy with DCVAC/OvCa and Standard of Care (SoC)
62112370|NCT02107378|ACTIVE_COMPARATOR|Standard of Care (Chemotherapy)|Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)
62112371|NCT00261053|OTHER|1|Open-label i.v. administration of 100 U/kg rhC1INH
62112372|NCT01382342|EXPERIMENTAL|rasagiline|Participants in this arm will receive 1 mg of rasagiline daily for the six month duration of the study.
62112373|NCT01382342|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive 1 mg of placebo daily for the six month duration of the study.
62112374|NCT06152484||Normal control group|
62112375|NCT06152484||Subclinical keratoconus|
62112376|NCT06152484||Keratoconus|
62112377|NCT05136443|EXPERIMENTAL|Preventative Treatment|Loteprednol etabonate ophthalmic suspension 0.25% dosed 4 times daily for 2 months, 3 times daily for one month, twice daily for one month, and once daily until the 1 year postop exam.
62112378|NCT00567515|EXPERIMENTAL|LAA Clip|AtriCure LAA Exclusion System
62112379|NCT03721432|EXPERIMENTAL|Pregabalin group (P)|received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
62471147|NCT01171989|ACTIVE_COMPARATOR|INFANRIX HEXA/MENJUGATE GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and 2 doses of Menjugate® vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with Menjugate® vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
62673781|NCT06244251|ACTIVE_COMPARATOR|MPLS for myomectomy|Patients complaint of symptoms resulting from uterine fibroids, such as abnormal vaginal bleeding, frequent micturition, lower abdominal pain, constipation, etc or patients with uterine fibroids which were identified accidentally during routine body examination who consulted at our center for surgical removal of the fibroids. In the meantime, the diagnosis of uterine fibroids should be reconfirmed by at least one radiological examination at our center. The patients in the experiment group were those who received multiport laparoscopic surgery (MPLS) for myomectomy.
62112380|NCT03721432|PLACEBO_COMPARATOR|Control group (C)|received placebo capsules sixty minutes prior to epidural insertion.
62112381|NCT03568799|EXPERIMENTAL|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-\[18F\]Fluoroglutamine IV and 60 minutes after injection, undergo 4-\[18F\]Fluoroglutamine PET/CT before the start of therapy.
62112382|NCT03748433|EXPERIMENTAL|Continuous Glucose Monitoring (CGM)|The RT CGM group will receive a Dexcom G6 transmitter and sensors, as well as a structured education refresher focusing on hypoglycaemia avoidance, recognition, and management.
62112383|NCT03748433|NO_INTERVENTION|Self Monitoring Blood Glucose (SMBG)|The SMBG group will additionally undergo blinded CGM at weeks 1 and 2, weeks 4 to 6 and weeks 9 to 12 using the Dexcom G6 system. Participants in this group will be shown how to insert the Dexcom G6 at the first clinic visit and sensors provided so they can do this at home.
62471148|NCT01171989|ACTIVE_COMPARATOR|INFANRIX HEXA/NEISVAC-C + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with NeisVac-C® vaccine at Day 0 and 1 dose of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
62471149|NCT00183521|EXPERIMENTAL|1|Participants will receive raise-CO2 breathing regulation training
61916994|NCT00476047|EXPERIMENTAL|Treatment (monoclonal antibody therapy)|Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
61916995|NCT05047627|EXPERIMENTAL|Smartphone Digital Intervention Group|The Smartphone Digital Intervention Group is the experimental group. Participants randomized to this group will download the smartphone intervention and be asked to use the intervention four times per week for four weeks ( 16 digital sessions). The smartphone digital intervention will also continuously collect passive sensing data. The smartphone digital intervention will be designed to treat anxiety and depression by providing informational videos to help participants treat these symptoms. These videos include information about physical activity, muscle relaxation, and other proven helpful interventions to help with anxiety and depression.
62302165|NCT05382481|PLACEBO_COMPARATOR|Control group （Group C）|"The control group will not detect the value of anti Xa and not adjust the dose of LMWH.~This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day."
62302166|NCT06079502|EXPERIMENTAL|Neuromuscular Electrical Stimulation group|Thirty patients will receive a supervised program of intradialytic NMES two times per week for 16weeks with medical treatment.
62302167|NCT06079502|EXPERIMENTAL|resistive training group|Thirty patients will receive a supervised program of intradialytic resistive training two times per week for 16weeks with medical treatment.
62302168|NCT02332252|ACTIVE_COMPARATOR|Scalpel|Skin incision performed with a scalpel during cesarean section.
62302169|NCT02332252|EXPERIMENTAL|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
62302170|NCT06657560|EXPERIMENTAL|Cohort A|Healthy volunteer with stable normal renal function defined with an absolute value of eGFR ≥ 90 and \< 130 mL/min based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 25% between the 2 measurements.
62302171|NCT06657560|EXPERIMENTAL|Cohort B|Patient with stable mild renal impairment defined with an absolute value of eGFR ≥ 60 and \<90 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 25% between the 2 measurements.
62302172|NCT06657560|EXPERIMENTAL|Cohort C|Patient with stable moderate renal impairment defined with an absolute value of eGFR between ≥ 30 and \<60 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements.
62302173|NCT06657560|EXPERIMENTAL|Cohort D|Patient with stable severe renal impairment defined with an absolute value of eGFR between ≥ 15 and \<30 mL/min included based on two eGFR assessments done at screening and inclusion, with a maximum tolerance of 15% between the 2 measurements.
62302174|NCT06657560|EXPERIMENTAL|Cohort E|Patient with end-stage renal failure who requires 3 hemodialysis sessions per week and defined with an absolute value of eGFR \<15 mL/min.
62302175|NCT05071339|EXPERIMENTAL|Participants|"Patients treated at the IVF unit at Shamir Medical Center planned for an antagonist cycle will undergo blood test and US exam at day 2-3 of their menstrual cycle. Patients will be recruited if a leading follicle 10-13 is shown in the presence of E2 \> 200-350 pmol/L.~Patients will start GnRH antagonist injections \[Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription\] for 3-5 days intervention."
62302176|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
62302177|NCT05137938|EXPERIMENTAL|Intranasal Ketamine (IN)|Ketamine will be administered intranasally (IN) using an atomizer (MAD300 by Teleflex, North Carolina, USA).
62302178|NCT00658229|EXPERIMENTAL|Strength training group|A four months strength training program during androgen deprivation therapy for prostate cancer patietns.
62302179|NCT00658229|NO_INTERVENTION|Control group|Patients in the control group are not discouraged from performing normal activities. They are however asked not to start a strength training program or increase their activity level in the same period as the experimental group is performing their strength training program. We will offer the control group a modified strength training program after the post-intervention assessment.
62302180|NCT01962142||Exacerbated asthma patients|
62302181|NCT04387279||Inflammatory bowel disease|Patients with inflammatory bowel disease who live in COVID-19 hyperemic area
62302182|NCT03738956|EXPERIMENTAL|Open label clinical trial|NSAID refractory axial spondyloarthritis patients who are eligible after considering inclusion and exclusion crietria will be put on 5 mg tofacitinib BD ,at the end of 1st and 3rd month they will be assessed for safety and efficacy.Those who will not respond will be put on 10 mg tofacitinib BD.All patients will be assessed at the end of 6th month.If any adverse event occur they will be treated accordingly.
62302183|NCT05394844|ACTIVE_COMPARATOR|CGM with DM education|if you are in the intervention group you will received culturally tailored diabetes education and use a Real Time CGM device to see your glucose over 12 weeks. Both group will completed blinded CGM at the beginning of the study and at 24 weeks
62302184|NCT05394844|NO_INTERVENTION|Education only|If you are in the control group your will receive culturally tailored diabetes education and wear a blinded prior to education and after education sessions complete and 24 weeks
61916996|NCT05047627|NO_INTERVENTION|Wait list Control Condition|The wait list control condition will not receive the digital intervention treatment for the duration of the study. They will still provide urine samples during the study. Participants assigned to this condition will be able to access the digital intervention after their participation in the study.
61916997|NCT04425044||AiM Covid|Self Monitoring of symptoms in AiM Covid App
61916998|NCT03754192|OTHER|perfusion computed tomography|Will be realsed before liver surgery
61916999|NCT02386683|ACTIVE_COMPARATOR|Group L|lung-protective ventilation applied in anesthesia
61917000|NCT02386683|NO_INTERVENTION|Group T|traditional ventilation applied in anesthesia
61917001|NCT00753090|EXPERIMENTAL|VG DDRP|This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee.
61917002|NCT00753090|ACTIVE_COMPARATOR|VG CR|This arm utilizes the Vanguard™ Cruciate Retaining Knee.
61917003|NCT04983953||Abnormal|A patient diagnosed with intracranial haemorrhage after a brain CT scan
62471150|NCT00183521|EXPERIMENTAL|2|Participants will receive lower-CO2 breathing regulation training
62471151|NCT00183521|ACTIVE_COMPARATOR|3|Participants will receive no breathing regulation training
62471152|NCT05040880|EXPERIMENTAL|Sequence A|TRTR
62673782|NCT00005596|EXPERIMENTAL|Arm I|Patients receive IT methotrexate on day 1 followed by methotrexate IV over 20 minutes followed by methotrexate continuously over 23.6 hrs on wks 7, 10, 13, 16,19, and 22. At 42 hrs after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium every 6 hrs for a total of 3 doses. Patients also receive oral mercaptopurine daily beginning on wk 5 and continuing until the completion of consolidation therapy; oral dexamethasone twice daily on days 1-7 of wks 8 and 17; and vincristine sulfate IV on day 1 of wks 8, 9, 17, and 18.
62673783|NCT00005596|EXPERIMENTAL|Arm II|Patients receive methotrexate IV over 4 hours on weeks 7, 10, 13, 16, 19, and 22. At 42 hours after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium as in arm I. Patients also receive mercaptopurine, dexamethasone, vincristine sulfate, and IT methotrexate as in arm I.
62302185|NCT06001450||Pregnant people with Crohns disease (Case)|Arm 1 is pregnant people with Crohns disease who enroll with the infant that they are pregnant with at the time.
62302186|NCT06001450||Pregnant people without Crohns disease (Control)|Arm 2 is the control arm of pregnant people without Crohns disease and other inflammatory bowel diseases who enroll with the infant that they are pregnant with at the time.
62471153|NCT05040880|EXPERIMENTAL|Sequence B|RTRT
61917004|NCT04983953||Normal|A normal person or a patient not diagnosed with intracranial haemorrhage after a brain CT scan
61917005|NCT05093790|EXPERIMENTAL|Treatment Arm 1: Ticagrelor + BMS-986141|
61917006|NCT05093790|EXPERIMENTAL|Treatment Arm 2: Aspirin + BMS-986141|
61917007|NCT05093790|EXPERIMENTAL|Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141|
61917008|NCT05093790|EXPERIMENTAL|Treatment Arm 4: BMS-986141|
61917009|NCT05851001|EXPERIMENTAL|Progressive muscle relaxation|"A CD recorded by the Turkish Psychological Association was provided to explain relaxation techniques to Progressive muscle relaxation group (PMR ) participants. The CD contains relaxation exercises instructions and there is relaxing music in the background. This CD consists of two parts. The first part(11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.~PMR exercise consists of four stages: stretching-relaxation (1st stage -approximately 20 minutes), autogenic training - only relaxation (2nd stage approximately 10 minutes), deep breathing training-breathing relaxation (3rd stage approximately 3-4 minutes), rapid relaxation (4th stage--a few seconds)."
62302187|NCT05951582|EXPERIMENTAL|Group A (Plyometrics)|This group will receive 8 weeks of upper and lower body plyometric exercises protocol. The session will last for 60 minutes and 3 time per week. 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set.
62302188|NCT05951582|EXPERIMENTAL|Group B (Conventional)|This group will receive 8 weeks of upper and lower body strength exercises protocol. The session will last for 60 minutes and 3 times per week.
62302189|NCT05086237|EXPERIMENTAL|Reminder|Participants will be sent a text message reminder of their missed well-child visit.
62471154|NCT00287092|EXPERIMENTAL|Group 1|Participants will receive PEDIACEL vaccine
62471155|NCT00287092|ACTIVE_COMPARATOR|Group 2|Participants will receive Infanrix-IPV+Hib vaccines
62471156|NCT00754117||All patients|All patients
62471157|NCT00827047|ACTIVE_COMPARATOR|Total Hemihepatic Vascular Exclusion|Patients with HCC received Total Hemihepatic Vascular Exclusion in hepatectomy.
62471158|NCT00827047|EXPERIMENTAL|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy.
62471159|NCT00827047|EXPERIMENTAL|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
62673784|NCT00005596|EXPERIMENTAL|Arm III|Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
62673785|NCT00005596|EXPERIMENTAL|Arm IV|Patients receive methotrexate IV as in arm II on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; and pegaspargase, mercaptopurine, IT methotrexate, dexamethasone, vincristine sulfate, daunorubicin hydrochloride, cyclophosphamide, cytarabine, and thioguanine as in arm III.
61917010|NCT05851001|SHAM_COMPARATOR|Relaxation music|A CD recorded by the Turkish Psychological Association was provided to RM group participants. It consists of 30 minutes relaxing music only. The participant was asked to just listen to music with without working in a private room.
61917011|NCT05851001|NO_INTERVENTION|Control|In this group, participant were assessed without any other intervention.
61917012|NCT05503927||Participants Exposed to Wegovy|Pregnant participants exposed to Wegovy during the first trimester (T1) (that is, estimated conception date - 35 days through \<14 weeks gestational age \[WGA\]) and their linked infants will be observed in this retrospective observational study.
61917013|NCT05503927||Participants Exposed to Anti-obesity Medication (AOM)|Pregnant participants exposed to other Anti-obesity Medication (AOM) (phentermine, diethylpropion, benzphetamine, phendimetrazine, orlistat, or bupropion/naltrexone) during the first trimester (start of exposure identification window based on five times the half-life of each AOM through \<14 WGA) and their linked infants will be observed in this retrospective observational study.
61917014|NCT05503927||Overweight/Obese Participants|Pregnant participants with obesity or overweight and 1 or more comorbid condition without exposure to Wegovy or other AOM during pregnancy will be observed in this retrospective observational study.
61917015|NCT00860977|PLACEBO_COMPARATOR|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
61917016|NCT00860977|EXPERIMENTAL|Valacyclovir|oral valacyclovir 500mg twice daily
61917017|NCT00251004|EXPERIMENTAL|Low-dose Everolimus Group|"1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
62673786|NCT04432298|EXPERIMENTAL|Pamrevlumab|Pamrevlumab: 35 milligrams/kilogram (mg/kg) on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
62673787|NCT04432298|EXPERIMENTAL|Placebo|Pamrevlumab-matching placebo on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
62673788|NCT00961012|EXPERIMENTAL|Intervention|"Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a settling time of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the randomization/ allocation envelope."
62673789|NCT00961012|NO_INTERVENTION|Control group|"Experimenter A reminds the subject to remain immobile.~For both intervention and control group. After the five-minute period, experimenter A calls experimenter B to return. Experimenter B takes a pressure reading, measures the trunk displacement, obtains spirometry readings, and takes a measure of discomfort."
62673790|NCT06671184||Difficult transoral and submental thyroidectomy|(1) operative time more than 75% of the overall study cases (2) severe intraoperative vascular or recurrent laryngeal nerve injury
62673791|NCT06671184||Normal transoral and submental thyroidectomy|the remaining of the entire study cases excluding the difficult cases
62673792|NCT04846478|EXPERIMENTAL|Dose Escalation Talazoparib + Tazemetostat|"Standard 3+3 dose escalation will be followed, participants will initially receive talazoparib and tazemetostat at a dose of 75% of the starting dose for their FDA-approved indications.~During each 28 day study treatment cycle participants will take:~* Talazoparib once daily.~* Tazemetostat twice daily."
62673793|NCT04846478|EXPERIMENTAL|Dose Expansion Talazoparib + Tazemetostat|"Participants will receive talazoparib and tazemetostat at the safe dose identified in the first part (dose escalation) of the study.~During each 28 day study treatment cycle participants will take:~* Talazoparib once daily.~* Tazemetostat twice daily."
62673794|NCT06119412|OTHER|group 1, starting with standard technique|According to block randomization, the 1st researcher will first apply the standard technique (60 seconds pause between palpation and auscultation), 1 minute break will be given, and the 2nd researcher will apply the alternative new technique (no break between palpation and auscultation) on the same person.
62673795|NCT06119412|OTHER|group 2, starting with alternative new technique|According to block randomization, Investigator 1 will first apply the alternative new technique (no pause between palpation and auscultation) to the people in the second group, and a 1-minute break will be given. The 2nd researcher will apply the standard technique (60 seconds break between palpation and auscultation) on the same person.
62673796|NCT06309797|EXPERIMENTAL|Test (HA group)|the test group were asked to brush their teeth, dip the interdental brush in HA gel, and use the dipped interdental brush.
62673797|NCT06309797|EXPERIMENTAL|Control Group|the control group were asked to brush their teeth and use the interdental brush for oral hygiene.
62673798|NCT06053450|EXPERIMENTAL|Essential Oil Ptach|The nursing staff will wear an essential oil patch for 2 weeks.
62673799|NCT06300905|EXPERIMENTAL|Group I|Brushing twice daily in the morning and evening with 2 minutes each time
62673800|NCT06300905|ACTIVE_COMPARATOR|Group II|Brushing twice daily in the morning and evening with 2 minutes each time
62673801|NCT04656548||HydroPICC|Cohort who received the HydroPICC
62673802|NCT04656548||Standard of Care|Cohort who received something different than HydroPICC
62673803|NCT01783015|EXPERIMENTAL|Group A|Subjects who are mAb ADA positive
62673804|NCT01783015|EXPERIMENTAL|Group B|Subjects who are mAb ADA negative
62673805|NCT01783015|PLACEBO_COMPARATOR|Group C|Subjects who are mAb ADA positive
62673806|NCT01783015|PLACEBO_COMPARATOR|Group D|Subjects who are mAb ADA negative
62673807|NCT04942873||dabigatran group|NVAF patients who taking dabigatran capsule 110mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran.
62112384|NCT03748433|EXPERIMENTAL|Continuous Subcutaneous Insulin Infusion (CSII)|All participants will be re-consented with the choice to continue using RT-CGM for a further 16 weeks or be re-randomised to either receive the Tandem t:slim X2 insulin pump or RT-CGM. Participants randomised to the Tandem t:slim X2 group will be proficiently trained to safely use the Tandem t:slim X2 insulin pump. All participants (Tandem t:slim X2 and RT-CGM) will be provided with Dexcom G6 real time CGM transmitters and sensors for the 16-week second extension phase.
62112385|NCT04189107|EXPERIMENTAL|Experimental|High dose Dexamethasone
62112386|NCT04189107|PLACEBO_COMPARATOR|Control|Standard dexamethasone dosage and placebo
62112387|NCT02937792|NO_INTERVENTION|CONTROL|one with intrathecal 12.5 mg bupivacaine
62112388|NCT02937792|EXPERIMENTAL|experimental|one group with intrathecal 15 mg bupivacaine
62471160|NCT01220362|OTHER|Group 1|Bupivacaine 0.125%
62673808|NCT04942873||Rivaroxaban group|NVAF patients who taking rivaroxaban tablet 15mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and mmas-8 scale were used to evaluate the compliance of patients with dabigatran. PDC value and mmas-8 scale were used to evaluate the compliance of patients with rivaroxaban.
62673809|NCT04942873||wafarin group|NVAF patients who taking wafarin tablet during 2016.2-2021.1，the duration of continuous medication was more than 3 months， the dosage is adjusted according to INR. MMAS-8 scale was used to evaluate the compliance of patients with rivaroxaban.evaluate the compliance of patients with wafarin.
62673810|NCT06304727||enteral feeding group|Infants \< 1 year old with bronchiolitis and exclusive nutritional impairment who underwent short-term enteral feeding and monitoring in the emergency room according to the 2022-2024 seasons protocol
62673811|NCT00320580|EXPERIMENTAL|001|norelgestromin/ethinyl estradiol
62673812|NCT04334811|OTHER|Arm|No arm
62673813|NCT04787120||Individuals with arterial abdominopelvic bleeding|Arterial abdominopelvic bleeding or imminent risk of bleeding
62673814|NCT05819788||FFP|Patients undergoing CPB receiving FFP
62673815|NCT05819788||no FFP|Patients undergoing CPB not receiving FFP
62673816|NCT04986813|ACTIVE_COMPARATOR|Group Tranexamic Acid|50 patients were given 1 gram of Tranexamic acid (TXA) intravenously pre-operatively. Intravenous TXA was administered, at the time of start of surgical incision.
62673817|NCT04986813|PLACEBO_COMPARATOR|Control group|50 patients were kept as a control group and were not given TXA.
62673818|NCT01630811|EXPERIMENTAL|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg), oral, once daily
62673819|NCT01630811|PLACEBO_COMPARATOR|Placebo|Oral, once daily
62673820|NCT00558493|EXPERIMENTAL|1|switching treatment from lamivudine to clevudine
62673821|NCT01964313||ACS cohort|Patients diagnosed with acute coronary syndrome.
62673822|NCT05675696|EXPERIMENTAL|ARDS Patients Intubated on Mechanical Ventilation|ARDS patients in the ICU who are intubated on mechanical ventilation will be included. During ventilation, an esophageal catheter will be used to measure the esophageal pressure, which estimates pleural pressure at the level of the catheter. The esophageal catheter's position will be confirmed by a chest radiograph once inserted. The ventilator settings may be changed to see if these ventilator adjustments can reduce potential lung stress in ARDS patients. There is no set criteria for adjusting the ventilator settings based on the study device, but the goal would be to adjust the volume until the inspiratory effort measured by the catheter disappears so as to protect the patient. A one-to-two-hour study session will be performed for data collection. The esophageal catheter will be removed at the end of the study session or can be left in place for use as a feeding tube if needed for patient care.
62673823|NCT02662465|EXPERIMENTAL|mucositis grade 1, laser 660|Group 1 will include patients with oral mucositis grade 1. Sera used wavelength of 660nm, power 100mW and lluencia of 4 J / cm².
62673824|NCT02662465|EXPERIMENTAL|mucositis grade 2, laser 660|Group 2 included patients with oral mucositis grade 2. Sera used with a wavelength of 660nm, power 100mW and lluencia of 8 J / cm².
61917018|NCT00251004|EXPERIMENTAL|High-dose Everolimus Group|"3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
62112389|NCT05949125|EXPERIMENTAL|Allo-RevCAR01-T-CD123 treatment|Following lymphodepleting therapy, R-TM123 will be administered as continuous infusion from Cycle 1 Day 1 and then will continue for 20 days. After 4 hours (±30 minutes) of R TM123 start on Day 1, a single dose of Allo-RevCAR01-T will be administered as IV infusion
62112390|NCT04985058||Patients with breast cancer randomised in arm A of digital platform|Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm A of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician.
62112391|NCT04985058||Patients with breast cancer randomised in arm B of digital platform|Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm B of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician; additionally they will receive personalised support (as a few word text) for each side-effect reported.
62112392|NCT03782558||Patients with CTS|Surgical transection of transverse ligament
62302190|NCT05086237|NO_INTERVENTION|Treatment as usual|This group will receive treatment as usual, which involves no text messaging follow-up.
62302191|NCT03984409|ACTIVE_COMPARATOR|Group 1|Potassium citrate x 7days Off therapy x 7 days 500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Return to potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
62471161|NCT01220362|OTHER|Group 2|Bupivacaine 0.125%/Fentanyl 2mcg/ml
62471162|NCT02776878|EXPERIMENTAL|Dasatinib|Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.
62302192|NCT03984409|ACTIVE_COMPARATOR|Group 2|500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Off therapy x 7 days Potassium citrate x 7days Continue on potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
62471163|NCT00910663|EXPERIMENTAL|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by Cellcept® 250 mg Capsule dosed in second period.
62471164|NCT00910663|ACTIVE_COMPARATOR|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
62471165|NCT05250843|EXPERIMENTAL|TACE/HAIC and Lenvatinib and PD-1(Sintilimab) before liver resection|For patients staged BCLC B/C,TACE/HAIC combined with Lenvatinib and Sintilimab will be conducted as neoadiuvent therapy before liver resection
62471166|NCT05250843|ACTIVE_COMPARATOR|Direct surgery group|After being diagnosed with hepatocellular carcinoma, surgery will be immediately performed.
62302193|NCT03080987|EXPERIMENTAL|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
62302194|NCT03080987|EXPERIMENTAL|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
62302195|NCT03080987|EXPERIMENTAL|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
62302196|NCT03080987|EXPERIMENTAL|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
62302197|NCT03080987|EXPERIMENTAL|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
62302198|NCT03080987|EXPERIMENTAL|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
62302199|NCT03456492||case|Hyponatremic elderly patients (\>70 years) with hip fractures
62302200|NCT03456492||control|Normonatremic elderly patients(\>70 years) undergoing joint replacement
61917019|NCT00251004|ACTIVE_COMPARATOR|Control Group|"1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
62471167|NCT00772239|EXPERIMENTAL|Rotem|ROTEM: Rotation thromboelastometry
62471168|NCT00772239|ACTIVE_COMPARATOR|S|Standard coagulation managment procedure
62471169|NCT06209320|ACTIVE_COMPARATOR|Experimental group 1|Lower dose atropine sulfate eye drops
62471170|NCT06209320|ACTIVE_COMPARATOR|Experimental group 2|Low dose atropine sulfate eye drops
61917020|NCT01146210||Ancillary-correlative|Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
61917021|NCT05983887|NO_INTERVENTION|Control Group|The participants in this group continue their conventional intervention protocol without using the climbing instructions.
61917022|NCT05983887|EXPERIMENTAL|Climbing Group|The participants in this group continue their conventional intervention protocol plus an in-door climbing intervention protocol.
61917023|NCT00603772|EXPERIMENTAL|1|Safety when exposed to sunlight
62112393|NCT06405555|EXPERIMENTAL|Midodrine treatment|Patients randomized to receive midodrine for up to 5 days in hospital at escalating doses starting at 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days. Patients may be discharged from hospital prior to completion of the full 5 day protocol. All patients in the midodrine treatment arm will receive otherwise usual standard of care treatments.
62471171|NCT06209320|PLACEBO_COMPARATOR|control group|placebo
62471172|NCT02942615|EXPERIMENTAL|Heart safety management|limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity
62471173|NCT02942615|NO_INTERVENTION|Control group|without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity
62471174|NCT02139826|EXPERIMENTAL|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
62471175|NCT02139826|EXPERIMENTAL|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
61917024|NCT01490398|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 10mg qd for 12 months.
61917025|NCT01288976||MitraClip Therapy|Patients treated with the MitraClip System.
61917026|NCT01288976||Medical Management|Patients with MR managed non-surgically based on standard hospital clinical practice.
61917027|NCT01288976||Mitral Valve Surgery|Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
62112394|NCT06405555|NO_INTERVENTION|Control|Patients randomized to the control arm will receive usual standard of care treatments without addition of midodrine.
62112395|NCT04067960|EXPERIMENTAL|Screening (pharmacogenomics testing)|Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients also complete quality of life assessment at baseline and at 3 months after pharmacogenomics testing.
62112396|NCT00956306|EXPERIMENTAL|Child-Pugh A|
62471176|NCT02139826|EXPERIMENTAL|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
62471177|NCT03682159|NO_INTERVENTION|control|
62112397|NCT00956306|EXPERIMENTAL|Child-Pugh B|
62112398|NCT00956306|EXPERIMENTAL|Healthy Volunteers|
62112399|NCT02422121|EXPERIMENTAL|RNS60|RNS60, 4 ml twice daily
62471178|NCT03682159|EXPERIMENTAL|intervention|
62471179|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
62302201|NCT03940885|ACTIVE_COMPARATOR|Erector spinea plane block group|this group is planned for ultrasound-guided Transversus abdominis plane block
62471180|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
62673825|NCT02662465|EXPERIMENTAL|mucositis grade 3, laser 790|Group 3 included patients with oral mucositis grade 3 Sera used laser diode AsGaAl operating in continuous mode, with a wavelength of 790 nm, power of 100mW and fluency of 8 J / cm².
62673826|NCT01412983|EXPERIMENTAL|Bausch & Lomb Test Lens|Bausch + Lomb investigational soft contact lens
62673827|NCT01412983|ACTIVE_COMPARATOR|Ciba Vision soft contact lens|Ciba Vision Air Optix Aqua soft contact lens
62673828|NCT01197898|EXPERIMENTAL|Collagenase Santyl|Ointment applied once daily
62673829|NCT01197898|PLACEBO_COMPARATOR|Vehicle Base|Applied once daily
62673830|NCT00676962|EXPERIMENTAL|Facilitation|Therapists receive assistance with adopting CBT
62673831|NCT03057327|ACTIVE_COMPARATOR|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
62673832|NCT03057327|EXPERIMENTAL|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
62673833|NCT04867070|ACTIVE_COMPARATOR|LLDN with ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
62673834|NCT04867070|NO_INTERVENTION|LLDN without ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
62673835|NCT00732459||1|electro-acupuncture preconditioning group
62673836|NCT00732459||2|control group
62673837|NCT03922971|OTHER|National comparison|Ability to view center's rate compared with all others
62673838|NCT03922971|OTHER|National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1
62673839|NCT00202852|PLACEBO_COMPARATOR|1|
62673840|NCT00202852|EXPERIMENTAL|2|
62112400|NCT02422121|PLACEBO_COMPARATOR|Placebo|Normal Saline, 4 ml twice daily
62112401|NCT04722094||Patients with Psoriasis|All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study
62112402|NCT05163418|EXPERIMENTAL|Flat feet|People with flat feet according to foot posture index (validated by clinical assessment)
62112403|NCT05163418|EXPERIMENTAL|High arches feet|People with high arches feet according to foot posture index (validated by clinical assessment)
62112404|NCT05163418|NO_INTERVENTION|Normal arches feet (control group)|Control group
62112405|NCT01787994|EXPERIMENTAL|Cohort 1|"Cohort 1: HIV-1-positive women and men ≥18 years with a CD4 count \> 350 cells/mm3, HIV-1-RNA levels undetectable by ultrasensitive HIV PCR Abbott assay. Subjects with HIV-1 RNA \< 400 copies/mL are also eligible; however, the HIV-1 RNA must be \< 50 copies/mL within 60 days prior to study entry based on the Abbott assay. Subjects with intermittent isolated episodes of detectable low level viremia (\> 50 but \<1,000 copies RNA/mL; blips) will be eligible.~There should be at least 2 documented HIV-1 RNA assays, one drawn \>3 months before study entry, one drawn \<3 months before study entry. Subjects should be on HAART (no changes to treatment within 4 weeks of study entry) for at least 3 months.~Cohort 1 subjects will receive a single dose of MazF-T cells."
62302202|NCT03940885|ACTIVE_COMPARATOR|Transversus abdominis plane block|this group is planned for ultrasound-guided Transversus abdominis plane block
62302203|NCT03940885|PLACEBO_COMPARATOR|Control group|standard general anesthesia
62302204|NCT05057988|EXPERIMENTAL|Empowered Relief|
62673841|NCT05639712|PLACEBO_COMPARATOR|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo (0.9% NaCl intravenously). This is carried out on the operating table right before anesthesia
62673842|NCT05639712|ACTIVE_COMPARATOR|Morphine 2.5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
62673843|NCT05639712|ACTIVE_COMPARATOR|Morphine 5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously. This is carried out on the operating table right before anesthesia
62302205|NCT00230763|EXPERIMENTAL|Active|
62302206|NCT00230763|OTHER|Procedure|
62302207|NCT05740787||Patient|No intervention
62302208|NCT01261676||Caesarean section|
62673844|NCT05639712|ACTIVE_COMPARATOR|Morphine 10 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously. This is carried out on the operating table right before anesthesia
62673845|NCT05639712|ACTIVE_COMPARATOR|Oxycodone 2.5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
62673846|NCT05639712|ACTIVE_COMPARATOR|Oxycodone 5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously. This is carried out on the operating table right before anesthesia
62673847|NCT05639712|ACTIVE_COMPARATOR|Oxycodone 10 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously. This is carried out on the operating table right before anesthesia
62302209|NCT01261676||Vaginal birth (control)|
62471181|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
62673848|NCT05639712|ACTIVE_COMPARATOR|Fentanyl 0.025 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously. This is carried out on the operating table right before anesthesia
62673849|NCT05639712|ACTIVE_COMPARATOR|Fentanyl 0.05 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously. This is carried out on the operating table right before anesthesia
62673850|NCT05639712|ACTIVE_COMPARATOR|Fentanyl 0.1 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously. This is carried out on the operating table right before anesthesia
62673851|NCT00965094|EXPERIMENTAL|Everolimus|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 \[Month 3 (+1 week) after transplantation\], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.
61917028|NCT02742246|NO_INTERVENTION|Standard treatment as usual (TAU)|This is the regular treatment a participant would normally receive at the clinic and generally includes individual and/or group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as teaching about the treatment program, teaching important ideas about recovery, increasing knowledge about specific problems participants may have with addiction and/or demonstrating new ways of coping with skills designed to fit their lifestyle. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
61917029|NCT02742246|ACTIVE_COMPARATOR|Individual clinician-provided CBT|This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
62471182|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
62673852|NCT00965094|ACTIVE_COMPARATOR|Reference Therapy|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 \[Month 3 (+1 week) after transplantation\], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.
62673853|NCT03914014|ACTIVE_COMPARATOR|intervention|connective tissue manipulation
62673854|NCT03914014|PLACEBO_COMPARATOR|placebo ultrasound|placebo ultrasound
62673855|NCT03914014|NO_INTERVENTION|control|control group
62302210|NCT06031753|EXPERIMENTAL|TRE|Only time restricted eating was carried on by this arm, having the first meal of the day at 12:00hrs and last meal of the day at 18:00hrs. No other medication was allowed during the study for this group.
62302211|NCT06031753|EXPERIMENTAL|TRE-HT|They carried on Time Restricted eating, in combination with the oral contraceptives used for the standard hormonal treatment. First meal of the day at 12:00hrs and last meal of the day at 18:00hrs. Other than oral contraceptives, no medication was allowed during the 3 months of the study.
62471183|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
62471184|NCT01972204|EXPERIMENTAL|Intensive adherence instruction|Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
62673856|NCT03512158|EXPERIMENTAL|High NCPAP|Administration of high NCPAP (\> 8 cmH2O) following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
62673857|NCT03512158|ACTIVE_COMPARATOR|NIPPV|Administration of NIPPV following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
62302212|NCT06031753|NO_INTERVENTION|HT|No time restricted eating was practiced by this group, only oral contraceptives were taken, serving as the control group by having the standard hormonal treatment. No modification to their daily habits and routine was made.
62673858|NCT03377127|ACTIVE_COMPARATOR|Standard of Care (SOC)|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
62673859|NCT03377127|EXPERIMENTAL|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
61917030|NCT02742246|EXPERIMENTAL|CBT4CBT|In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on. The CBT4CBT program will cover the same skills as the individual clinician-provided CBT, only here it will be done by a computer. Participants will be taught how to use the computer program by a staff member and will be asked to spend about 8 hours using the program (approximately one hour per week) at the clinic.Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
62471185|NCT01972204|SHAM_COMPARATOR|Control|The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
62673860|NCT05682469|EXPERIMENTAL|VR group|VR cognitive training receives eight gardening activities. The cognitive elements including attention, working memory, processing speed, and executive function incorporated training.
62673861|NCT05682469|ACTIVE_COMPARATOR|control group|The control group is performing traditional cognitive training program.
61917031|NCT02744937|EXPERIMENTAL|A|continuing LDA
61917032|NCT02744937|NO_INTERVENTION|B|discontinuing LDA
62302213|NCT04191668|OTHER|PSG and NightOwl|Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
62302214|NCT05947019|EXPERIMENTAL|Low-Level Red-Light threapy plus glasses threapy|Myopic amblyopia comprehensive treatment equipment + conventional optometry with glasses for treatment
61917033|NCT02902679|EXPERIMENTAL|End Stage Renal Disease Subjects|Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session
61917034|NCT03745820|EXPERIMENTAL|BIIB104 0.5 mg|Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
61917035|NCT03745820|EXPERIMENTAL|BIIB104 0.15 mg|Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
61917036|NCT03745820|PLACEBO_COMPARATOR|Matching Placebo|Participants will receive matching placebo twice a day, orally, for 12 weeks.
61917037|NCT02704845||Ankylosing Spondylitis|
62302215|NCT05947019|EXPERIMENTAL|glasses threapy|conventional optometry with glasses for treatment
62302216|NCT04203173|EXPERIMENTAL|FINANCE-DM Intervention|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
62471186|NCT03423680|EXPERIMENTAL|Abilify (Tablet)|
61917038|NCT02704845||Chronic non-specific low back pain|
62471187|NCT03423680|PLACEBO_COMPARATOR|Placebo of Abilify (Tablet)|
62471188|NCT00803686|EXPERIMENTAL|Part 1 Double Blind Oral rsCT Tablet|Intervention: Oral rsCT tablet given once 4 hours after evening meal.
62471189|NCT00803686|PLACEBO_COMPARATOR|Part 1, Double-blind Oral Placebo Tablet|Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
62471190|NCT00803686|EXPERIMENTAL|Part 2 Open label, Oral rsCT tablet|Intervention: Oral rsCT tablet given once 2 hours after evening meal.
62471191|NCT00803686|ACTIVE_COMPARATOR|Part 2, Open Label Fortical Nasal Spray|Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
61917039|NCT02836743|EXPERIMENTAL|Circadin 2mg|low-dose (2mg) slow-release melatonin for 1 month.
61917040|NCT02836743|EXPERIMENTAL|Circadin 6mg|high-dose (6mg) slow-release melatonin for 1 month.
62471192|NCT00633256|EXPERIMENTAL|Cycloserine|50 mg cycloserine
62471193|NCT00633256|SHAM_COMPARATOR|Placebo|Matched placebo
62673862|NCT04193527|EXPERIMENTAL|DaTSCAN™ ioflupane (123I) injection|Participants with Parkinsonian Syndrome (PS), Essential Tremor (ET), and Healthy Volunteers (HV) received a single dose of DaTSCAN™ ioflupane (123I) injection. Single photon emission computed tomography (SPECT) imaging was performed between 3 to 6 hours post-injection and lasted approximately 20 minutes to 1 hour.
62673863|NCT01864694|EXPERIMENTAL|TLC-Diet|Participants receive diet intervention through automated telephone system: TLC-Diet
62673864|NCT01864694|EXPERIMENTAL|WEB-Diet|Participants receive diet intervention through web-based system: WEB-Diet
62673865|NCT01864694|EXPERIMENTAL|Control|Assessment-only control group
62471194|NCT00561834|EXPERIMENTAL|Ranibizumab|To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.
61917041|NCT02836743|PLACEBO_COMPARATOR|Placebo|Administer placebo pills with identical morphology
61917042|NCT06242444|EXPERIMENTAL|Experimental Dentifrice|Participants will brush the buccal surfaces of their natural teeth using 1.5+/- 0.1 grams (g) of the experimental dentifrice containing 1150 ppm fluoride and 5 percent (%) potassium nitrate (KNO3) for 25 timed seconds and then swish the resulting dentifrice slurry around the mouth, without further brushing, for a timed period of 95 seconds. Participants will use the dentifrice under supervision of the study staff while the intraoral appliance is in place in Treatment Periods 1 to 3. There will be a washout period of a minimum of 3 days prior to each treatment during which the participants will use their own dentifrice for at least one day, and a 0 ppm fluoride washout dentifrice for two days.
62112406|NCT01787994|EXPERIMENTAL|Cohort 2|"Cohort 2: HIV-1-positive men and women ≥18 years with a CD4 count \> 450 cells/mm3, having well controlled HIV replication on HAART. The subjects should have a CD4 nadir ≥200 cells/mm3. Subjects in Cohort 2 will participate in a 16 week analytical treatment interruption beginning 2 weeks after T cell infusion.~Cohort 2 subjects will receive a single dose of MazF-T cells."
62471195|NCT04561063|NO_INTERVENTION|Arm A: No pharmacological intervention (PPE only)|No intervention
62471196|NCT04561063|ACTIVE_COMPARATOR|Arm B: Nitazoxanide (NTZ)|Nitozoxanide administered
62471197|NCT04561063|ACTIVE_COMPARATOR|Arm C: Sofosbuvir/daclatasvir (SOF/DCV).|Sofosbuvir/daclatasvir administered
62112407|NCT05391724|EXPERIMENTAL|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
62112408|NCT06070324|ACTIVE_COMPARATOR|Prolene|This group of patients will have their periareolar incisions closed with 4-0 Prolene sutures which are non-absorbable (require removal) and require knot-tying.
62471198|NCT02067624|EXPERIMENTAL|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the wrist extensor groups muscle for 9 sessions
62471199|NCT02067624|SHAM_COMPARATOR|Sham Ultrasound therapy|The participants will receive a thirty minutes session of sham ultrasound therapy onto the wrist extensor groups muscle for 9 sessions
62471200|NCT05546138||Type 1 diabetes without known peripheral neuropathy|"People with type 1 diabetes without known peripheral neuropathy with limited diabetes duration"
62471201|NCT01214850|EXPERIMENTAL|rMenB+OMV|Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart
62471202|NCT01214850|EXPERIMENTAL|MenACWY|Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart
62471203|NCT01214850|ACTIVE_COMPARATOR|Control|Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart
62471204|NCT06064331|EXPERIMENTAL|Group Lignocaine|Group Lignocaine will receive an IV bolus dose of 1.5 mg/kg of 2% lignocaine HCL diluted up to 10 ml with normal saline in a 10 ml syringe which will be delivered via a syringe pump over a period of 3 min. This is then followed by an IV infusion at the rate of 1 mg/kg/h of 2% lignocaine HCL in a 20 ml syringe which will be administered by another syringe pump.
62471205|NCT06064331|PLACEBO_COMPARATOR|Group Placebo|Patients in Placebo Group will receive an IV bolus of 10 ml of normal saline over a period of 3 min followed by an IV infusion of an equal volume of normal saline, both of which will be delivered by separate syringe pumps.
62471206|NCT04571658||NEPTUNE Match Participants|"Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas.~NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years."
62471207|NCT05652543|EXPERIMENTAL|Vaccine group|Participants ≥3 years old who have received the recommended dose and immunization procedure of domestically approved COVID-19 vaccine will receive vaccine (SCTV01E).
62471208|NCT05652543|PLACEBO_COMPARATOR|Placebo group|Participants ≥3 years old who have received the recommended dose and immunization procedure of domestically approved COVID-19 vaccine will receive placebo (normal saline)
62471209|NCT04156919|EXPERIMENTAL|Playful condition|Children in the playful and non-playful conditions will receive the fooya! intervention but will be varied in the psychological state of playfulness. Children in the playful condition will play a health game called fooya! Drawing on the playfulness literature, we will manipulate four dimensions of play. First, to manipulate the voluntariness of tasks, children in the playful condition will be asked/invited to participate in the study. Second, to manipulate adult presence, there will be little to no teacher involvement in the playful condition. Third, to manipulate the timing of the activity, children in the playful condition will be given an option to play anytime, including after school hours. Fourth, to manipulate the goal perception, the children in the playful condition will be told that their activity is not graded-i.e., autotelic.
62471210|NCT04156919|EXPERIMENTAL|Non-playful condition|As mentioned earlier, we will manipulate four dimensions of play. First, participation will be mandatory for children in the non-playful condition. Second, teacher presence will be more salient in this condition. Third, children in the non-playful condition will participate during school hours. Fourth, the children in the non-playful condition will be told that their activity is graded.
62471211|NCT04156919|ACTIVE_COMPARATOR|Control condition|Children in the control condition will play a video game unrelated to diet and lifestyle called Wordsearch.
62471212|NCT03503318|PLACEBO_COMPARATOR|Placebo|Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
62112409|NCT06070324|ACTIVE_COMPARATOR|Monocryl|This group of patients will have their periareolar incisions closed with 4-0 Monocryl sutures which are absorbable (do not require removal) and require knot-tying.
62471213|NCT03503318|EXPERIMENTAL|TV-46000 q1m|Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
62673866|NCT05852249||Paper instruction|Participants in this group will use paper instructions to use Neutrocheck.
62673867|NCT05852249||App instruction|Participants in this group will use App instructions to use Neutrocheck.
62673868|NCT06132997|ACTIVE_COMPARATOR|Medical thoracoscopy group|Medical thoracoscopy is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
62673869|NCT06132997|ACTIVE_COMPARATOR|Intercostal tube group|Intercostal chest tube placed without thoracoscopy for patients with confirmed empyema.
62673870|NCT03041480||GROUP I|Estimation of serum lipid levels and Lp-PLA2 in generalized severe chronic periodontitis
62673871|NCT03041480||GROUP II|Estimation of serum lipid levels and Lp-PLA2 in generalized moderate chronic periodontitis
62673872|NCT03041480||GROUP III|Estimation of serum lipid levels and Lp-PLA2 in systemically and periodontally healthy controls
62673873|NCT04576949|PLACEBO_COMPARATOR|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
62673874|NCT04576949|EXPERIMENTAL|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
62673875|NCT04576949|EXPERIMENTAL|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
62673876|NCT05960123|ACTIVE_COMPARATOR|Group with Spongioplasty|patients underwent TIPU with spongioplasty-Dartosoraphy reinforcement
62673877|NCT05960123|ACTIVE_COMPARATOR|Group without Spongioplasty|patients underwent TIPU with dorsal dartos flap interposition without spongioplasty
62673878|NCT02316132|ACTIVE_COMPARATOR|Stress|Injection of corticotropin releasing factor
62673879|NCT02316132|PLACEBO_COMPARATOR|Control|Injection of 0.9% saline 10 ml
62673880|NCT03428269|EXPERIMENTAL|simulation by gaming group|In the simulation by gaming group, the students will individually play with two cases of the LabforGames Warning game (postoperative hemorrhage case and brain trauma in elderly case). After each case, a debriefing to which with all players will participate will be conducted by an instructor.
62673881|NCT03428269|ACTIVE_COMPARATOR|traditional education group|In traditional education group, the students will individually work on the two same cases but the two vignettes and adjoining questions will be presented and answered by the student on a paper sheet. Then a global review of the two cases and the major messages to be retained will be presented by a teacher.
62673882|NCT05504421|ACTIVE_COMPARATOR|Control group|Students will receive theoretical training on sustainability in nursing, given by the narrative technique, and then students will work individually on the subject and share their weekly individual study time with the researcher. When individual work is completed, a simulation application will be performed with the scenario.
62673883|NCT05504421|EXPERIMENTAL|Experimental group|Students will receive theoretical training on sustainability in nursing, given by the narrative technique, and then analyze the some structured cases in groups structured in line with the cooperative learning process. When the case analysis is finished, a simulation application will be performed with the scenario.
62673884|NCT01524705|EXPERIMENTAL|Insulin Glargine, metformin, exenatide|Approximately 60 Type 2 diabetes mellitus (DM) participants will be instructed on an American Heart Association/American Diabetes Association (AHA/ADA) meal plan. Insulin Glargine, metformin and exenatide will used as a combination strategy to control individual glycosylated hemoglobin level (HbA1Cs) between 6.7 and 7.3% throughout the trial. The use of exenatide makes this the intervention arm
62673885|NCT01524705|ACTIVE_COMPARATOR|glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HbA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro). The use of the short acting insulins make this the control arm
62673886|NCT00477217|OTHER|1|
62673887|NCT00388141|EXPERIMENTAL|NIDCAP|In the intervention NIDCAP group the staff has been introduced and trained in the principles of the NIDCAP-care, where main core is to see, organize and conduct the care of the preterm infant on behalf of the childs actually resources and competences
62673888|NCT01161121|EXPERIMENTAL|Adenosine then Regadenoson|Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.
62673889|NCT05553210|EXPERIMENTAL|Intervention group|The intervention group will get a 6-week therapist-guided online stress recovery intervention with an intervention plan.
62112410|NCT06070324|ACTIVE_COMPARATOR|Stratafix|This group of patients will have their periareolar incisions closed with 4-0 Stratafix sutures which are absorbable (do not require removal) and do not require knot-tying.
62112411|NCT04201327|ACTIVE_COMPARATOR|PrEP information only arm|Information to for accessing HIV prevention tools will be provided to participants.
62112412|NCT04201327|EXPERIMENTAL|PrEP counseling arm|Stigma focused counseling (one-session) aimed at addressing barriers to health care access will be provided.
62112413|NCT04201327|EXPERIMENTAL|PrEP counseling plus text messaging arm|Stigma focused counseling (one-session) and interactive text messaging aimed at addressing barriers to health care access will be provided.
62112414|NCT04201327|EXPERIMENTAL|PrEP counseling plus text messaging and on demand counseling|Ongoing stigma focused counseling and interactive text messaging aimed at addressing barriers to health care access will be provided.
62673890|NCT05553210|EXPERIMENTAL|Control group|The control group will get a 6-week therapist-guided online stress recovery intervention without an intervention plan. The control group will participate in the program at the same time as the intervention group.
62673891|NCT02619812|ACTIVE_COMPARATOR|Group A: SBI + Placebo|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
62673892|NCT02619812|ACTIVE_COMPARATOR|Group B: Colesevelam + Placebo|Colesevelam 1.875 g + Placebo twice per day
62673893|NCT02619812|ACTIVE_COMPARATOR|Group C: Colesevelam + SBI|Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
62673894|NCT02619812|PLACEBO_COMPARATOR|Group D: Double Placebo|Double placebo twice per day
61917043|NCT06242444|PLACEBO_COMPARATOR|Placebo Control Dentifrice|Participants will brush the buccal surfaces of their natural teeth using 1.5+/- 0.1 g of the placebo dentifrice containing 0 ppm fluoride and 5% KNO3 for 25 timed seconds and then swish the resulting dentifrice slurry around the mouth, without further brushing, for a timed period of 95 seconds. Participants will use the dentifrice under supervision of the study staff while the intraoral appliance is in place in Treatment Periods 1 to 3. There will be a washout period of a minimum of 3 days prior to each treatment during which the participants will use their own dentifrice for at least one day, and a 0 ppm fluoride washout dentifrice for two days.
62112415|NCT03451435|NO_INTERVENTION|Control|No intervention will be administered in this group as it serves as a control group.
62112416|NCT03451435|EXPERIMENTAL|NAC Treatment|N-Acetyl Cysteine treatment during root canal revascularization
62112417|NCT03419156|EXPERIMENTAL|Text Message Arm|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
62112418|NCT00424762|EXPERIMENTAL|rosiglitazone|4mg titrated to 8mg daily
62112419|NCT00424762|PLACEBO_COMPARATOR|Placebo|blinded matching placebo treatment
62112420|NCT04351646||SARS-CoV-2 negative inpatients|Hospitalised adult patients with SARS-CoV-2 negative tests.
62112421|NCT04351646||SARS-CoV-2 positive inpatients|Hospitalised adult patients with SARS-CoV-2 positive tests.
62112422|NCT04351646||SARS-CoV-2 suspected or confirmed NHS staff|Suspected or proven SARS-CoV-2 positive cases amongst health care professionals and lab staff.
62112423|NCT04852146||Professional|The sample of professionals will be made up of doctors and nurses of the emergency structures (pre and intra-hospital), doctors and nurses of interventional cardiology and ambulance drivers practising in an establishment of the 7 participating SAMU zones
62112424|NCT04852146||Patient|The patient sample will consist of patients included in the REANIM registry during the study period (the entire period of the stepped wedge randomised controlled trial).
62112425|NCT01549730|EXPERIMENTAL|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with cervix cancer
62112426|NCT03702400|ACTIVE_COMPARATOR|Phenylephrine 100 mcg|Phenylephrine will be used at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug to be used whenever systolic blood pressure falls below 10% of baseline.
62112427|NCT03702400|EXPERIMENTAL|Norepinephrine 5 mcg|Norepinephrine will be used at a dose of 5 mcg at a dilution containing 1 mcg / mL to be used whenever systolic blood pressure falls below 10% of baseline.
62112428|NCT03584646|EXPERIMENTAL|Arm 1 - Control Arm|Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
62112429|NCT03584646|EXPERIMENTAL|Arm 2 - Intervention arm|Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls. Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence. Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
62112430|NCT02955069|EXPERIMENTAL|PDR001|Subjects with advanced or metastatic, well-differentiated, NET of pancreatic, GI, or thoracic origin or poorly-differentiated GEP-NEC, that have progressed on prior treatment were treated with 400mg PDR001 administered via intravenous infusion once every 4 weeks.
62112431|NCT01767259|OTHER|Valsartan 160 mg alone|Valsartan alone
62673895|NCT03977610|EXPERIMENTAL|Ga68-PSMA ligand|Glass vial with 4\~20 mCi(148-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), more than 0.33 mCi/mL @ EOS; One time dose of 2-5 mCi (74-185 MBq) for PET Imaging ; i.v. injection
62673896|NCT04212065|ACTIVE_COMPARATOR|Sublingual Suboxone|Women randomized to sublingual dosing will be provided prescription to fill.
62302217|NCT04203173|ACTIVE_COMPARATOR|TIDES Intervention|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change.
62673897|NCT04212065|ACTIVE_COMPARATOR|Subcutaneous Sublocade|Women randomized to subcutaneous administration will have drug administered by nurse during routine prenatal care visits.
62673898|NCT01236807|ACTIVE_COMPARATOR|MR Inform|Management guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
62673899|NCT01236807|ACTIVE_COMPARATOR|FFR Inform|Management guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
62302218|NCT01818349|ACTIVE_COMPARATOR|isokinetic lower-limb training|3 times/week for 6 weeks
62302219|NCT01818349|PLACEBO_COMPARATOR|isokinetic uppe-limb training|3 times/week for 6 weeks
62302220|NCT04696549|EXPERIMENTAL|virtual visual art experience for individuals with dementia and their family care-partners|Individuals with dementia and their family care-partners will participate in three monthly one-hour virtual art sessions in which the facilitator uses Visual Thinking Strategies technique to facilitate participants' viewing and discussion about virtual art images.
62471214|NCT03503318|EXPERIMENTAL|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
62673900|NCT05510973|NO_INTERVENTION|Control|standard of care
62673901|NCT05510973|EXPERIMENTAL|Intervention|Enhanced package of AHD care
62673902|NCT05995418||amnestic mild cognitive impairment(aMCI）|"1. aMCI diagnostic criteria of National Institute of Aging and National Association of Alzheimer's Disease (NIA-AA).~2. The ClinicalDementiaRating scale (CDR) is 0.5.~3. Mini-MentalStateExamination (MMSE): MMSE≥17 for those with 0 years of education, ≥20 for those with less than 7 years, and ≥24 for those with more than 7 years.~4. Memory impairment is prominent, and it may also be accompanied by functional impairment of other cognitive domains.~5. The onset is insidious and the progress is slow.~6. Not up to the level of dementia"
62673903|NCT05995418||mild to moderate AD|Clinical dementia rating (CDR) was used to assess and determine the degree of cognitive impairment of the patients, according to the CDR score, where the mild AD group with a CDR score of 1, and the moderate to severe AD group with a score of 2 to 3.
62673904|NCT05995418||severe AD|Clinical dementia rating (CDR) was used to assess and determine the degree of cognitive impairment of the patients, according to the CDR score, where the mild AD group with a CDR score of 1, and the moderate to severe AD group with a score of 2 to 3.
62673905|NCT01932424|EXPERIMENTAL|Single arm|The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels. The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models). The dose range is usually between a target concentration of 3-8 mcg/ml. However the anaesthetic management is not changed for the study. The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device. The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( \< 3 mcg/ml or \> 10mcg/ml).
61917044|NCT06242444|ACTIVE_COMPARATOR|Reference Dentifrice|Participants will brush the buccal surfaces of their natural teeth using 1.5+/- 0.1 g of the reference dentifrice containing 1100 ppm fluoride as stannous fluoride (SnF2) for 25 timed seconds and then swish the resulting dentifrice slurry around the mouth, without further brushing, for a timed period of 95 seconds. Participants will use the dentifrice under supervision of the study staff while the intraoral appliance is in place in Treatment Periods 1 to 3. There will be a washout period of a minimum of 3 days prior to each treatment during which the participants will use their own dentifrice for at least one day, and a 0 ppm fluoride washout dentifrice for two days.
61917045|NCT04139200|EXPERIMENTAL|Type 1 tele coaching group|Coaching with daily interaction with the coaching application, based on a adaptive physical activity goal
61917046|NCT04139200|SHAM_COMPARATOR|Type 2 tele coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application
62112432|NCT01767259|OTHER|Hydrochlorothiazide 12.5 mg alone|Hydrochlorothiazide alone
62112433|NCT01767259|OTHER|Valsartan160 mg + Hydrochlorothiazide12.5 mg|Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
62112434|NCT01767259|OTHER|Valsartan / Hydrochlorothiazide 160 mg/12.5mg|Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
62112435|NCT03055416|OTHER|Mobile Men App Prototype|Prototype of physical activity mobile app geared for African-American men.
62112436|NCT00623506|ACTIVE_COMPARATOR|1|Pregnenolone
62302221|NCT04903860|ACTIVE_COMPARATOR|Single use reamers|Total hip replacement with the use of disposable reamers
62471215|NCT06560164|ACTIVE_COMPARATOR|Restrictive strategy|The restrictive strategy will consist of a transfusion Hb threshold of 7.0 g/dL, with a target Hb range of 7.1 - 9.0 g/dL. These thresholds are based on previous non-inferior trials in the patient populations in which VV ECMO (comparable to sepsis) and VA ECMO (cardiac surgery, acute myocardial infarction) are often applied.
62112437|NCT00623506|PLACEBO_COMPARATOR|2|Placebo
62112438|NCT05969236|EXPERIMENTAL|Experimental Group|Including 2 single dose groups (Part A) and 2 multiple dose groups (Part B). Participants in experimental groups will receive MDI-1228_mesylate Ophthalmic Solution.
62302222|NCT04903860|ACTIVE_COMPARATOR|conventional ancillary|Total hip replacement with the use of conventional reamers
62302223|NCT05150860|ACTIVE_COMPARATOR|At-home testing + household|At-home COVID-19 testing model with active encouragement of household member participation in regular COVID-19 testing part way through the trial
62302224|NCT05150860|ACTIVE_COMPARATOR|On-site testing + household|On-site COVID-19 testing model with active encouragement of household member participation in regular COVID-19 testing part way through the trial
62302225|NCT05150860|ACTIVE_COMPARATOR|On-site testing|On-site COVID-19 testing model, no active encouragement of household member participation in COVID-19 testing
62471216|NCT06560164|ACTIVE_COMPARATOR|Liberal strategy|The liberal strategy will consist of a transfusion Hb threshold of 9.0 g/dL, with a target Hb range of 9.1 - 11.0 g/dL. These Hb thresholds are based on thresholds that are currently used in ECMO.
62471217|NCT00162474|EXPERIMENTAL|Warfarin|
62471218|NCT03985267|EXPERIMENTAL|Mindfulness Based Swinging Technique (MBST)|Standard guided imagery combined with Mindfulness and breathing technique will be applied. Additionally, the directives will be given to participants to imagine themselves swinging in a green peaceful environment where they will face no harm but healing and full of wellness. Every time they imagine their swing goes up, patient will be asked to physically take a deep breath (taking the breath will be physically (actually) done, not imagining), and when going down patient will be asked to physically release their breath (releasing breath will be physically (actually) done, not imagining).
62471219|NCT03985267|ACTIVE_COMPARATOR|Standard Treatment|Participants will receive a session of standard psycho-social care for anxiety (50 minutes length). The standard psycho-social care interventions involve the most well-known talking therapy approach of Cognitive Behavioural Therapy (CBT).
62471220|NCT02536950|NO_INTERVENTION|Blinded Sensor|Subjects will wear a blinded Dexcom G4P (Generation 4 Platinum) AP (Artificial Pancreas) glucose sensor for a week
62471221|NCT02536950|EXPERIMENTAL|Fixed set point|Subjects will be in a hotel and use a fixed set point for glucose control for two days initialized at 130 mg/dl. The setpoint will be adjusted, if necessary, over the two days in the hotel before they are sent home for 5 days
62471222|NCT02536950|EXPERIMENTAL|Variable Set Point|"Subjects will begin using a variable setpoint which will make adjustments based on their past glucose control over the previous day"
62112439|NCT05969236|PLACEBO_COMPARATOR|Comparator Group|One comparator group will be set for each of the 4 experimental groups, to a total of 4 comparator groups. Participants in comparator groups will receive placebo.
62673906|NCT05356611|EXPERIMENTAL|Engage Treatment|The study is a single-arm study. The single-arm will be implementation of the 9-week protocol of Engage in an older adult population with late-life depression and comorbid executive dysfunction and mild cognitive impairment.
62673907|NCT01654250|EXPERIMENTAL|Active|NWP09
62112440|NCT01934829|EXPERIMENTAL|urea-based cream|Advanced HCC throughout China were treated with 10% urea-based cream 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for up to 12 weeks
61917047|NCT06123182|EXPERIMENTAL|Episodic Future Thinking (EFT) + Positive Affective Imagery (PAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The EFT will always be delivered during warm-up and the PAI will always be delivered during cool-down.
61917048|NCT06123182|EXPERIMENTAL|Episodic Future Thinking (EFT) + Neutral Affective Imagery (NAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The EFT will always be delivered during warm-up and the NAI will always be delivered during cool-down.
62673908|NCT01654250|PLACEBO_COMPARATOR|Placebo|Placebo
62112441|NCT01934829|PLACEBO_COMPARATOR|best supportive care|BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator
62112442|NCT02899585|EXPERIMENTAL|Group A|Elaboration of the questionnaires
62112443|NCT02899585|EXPERIMENTAL|Group B|Patients taken care for more less than 6 days by the health care team palliatives EIVA and they eventual family caregiver. Score
62112444|NCT05922215|EXPERIMENTAL|Experimental Group|
62112445|NCT05922215|ACTIVE_COMPARATOR|Control Group|
62673909|NCT05266950|EXPERIMENTAL|CI-135 CAR-T|chimeric antigen receptor T cell treatment
62673910|NCT00785447|OTHER|1|Twenty healthy subjects between 18 to 59 years of age meeting ASA I-II criteria, undergoing elective surgery, requiring general anesthesia and being able to breathe through both their nose and mouth.
62673911|NCT04038658|EXPERIMENTAL|Intervention Group (MoveIt)|10-minute Qigong exercise session (video demonstration via website) delivered twice a day at set break times during the working day for 12 consecutive weeks
62673912|NCT04038658|NO_INTERVENTION|Wait-list control group|No intervention for 12 weeks. Then received the MoveIt Intervention for 12 weeks.
62673913|NCT03820947|EXPERIMENTAL|VenaSeal™ Closure System|CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping
62673914|NCT03820947|ACTIVE_COMPARATOR|Endothermal Ablation (ETA)|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA
61917049|NCT06123182|EXPERIMENTAL|Episodic Recent Thinking (ERT) + Positive Affective Imagery (PAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The ERT will always be delivered during warm-up and the PAI will always be delivered during cool-down.
61917050|NCT06123182|ACTIVE_COMPARATOR|Episodic Recent Thinking (ERT) + Neutral Affective Imagery (NAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The ERT will always be delivered during warm-up and the NAI will always be delivered during cool-down.
61917051|NCT03737851|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
62112446|NCT01419717|EXPERIMENTAL|Denosumab|Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.
62673915|NCT03820947|ACTIVE_COMPARATOR|Surgical Stripping|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)
62673916|NCT03820947|OTHER|VenaSeal™ Closure System VLU Study|CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System
62673917|NCT06270394|EXPERIMENTAL|68Ga-FAPI PET/MRI scan|"The 68Ge/68Ga generator was eluted with 0.1 M HCL solution to achieve 3.0 ml of liquid, which was mixed thoroughly with 20 µg FAPI precursor and 375 µl of 1.25 M sodium acetate. The mixture was placed in a thermostat at 95°C for 10 min. The finished liquid was passed through an activated Sep-pak 18C column and 0.8 ml of 80% ethanol was passed through the Sep-pak 18C column and a 0.2 µm microporous membrane (Pall Co., Ltd.) before the product was collected in a sterile product vial.~The equipment scan pf PET/MRI is the SIGNA PET/MR manufactured by GE Healthcare. The scan is performed approximately 40 min after injection of 1.85-3.7 MBq 68Ga-FAPI-04 per kg body weight. Breath-gated corrected step-and-shoot (SS) acquisition mode was used. The scan time was 60 ± 10 min (50-70 min). Dedicated T1- and T2-weighted images and diffusion-weighted images (DWI) of the head and neck, chest, abdomen, and pelvis were acquired."
61917052|NCT03737851|EXPERIMENTAL|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
61917053|NCT03737851|EXPERIMENTAL|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
62673918|NCT06499649|PLACEBO_COMPARATOR|Control group|Patients under H. pylori eradication therapy and placebo as treatment
62112447|NCT00984087|EXPERIMENTAL|Active rTMS treatment|
62112448|NCT00414206|ACTIVE_COMPARATOR|1% mecamylamine|
62112449|NCT00414206|ACTIVE_COMPARATOR|0.3% mecamylamine|
62112450|NCT00414206|PLACEBO_COMPARATOR|Placebo|
62112451|NCT06351787|EXPERIMENTAL|Body scan|Participants will follow an audio-guided meditation in the sitting posture, which provides systematic verbal cues to draw their attention to different body parts to cultivate non-judgmental awareness. This will be performed in blocks of 2-minute increments, for up to 10 minutes, interspersed with 30-second periods of rest - where the participant will allow their mind to wander freely.
62112452|NCT06351787|EXPERIMENTAL|Yoga|Participants will follow a video-guided yoga session in the standing posture, which provides verbal and visual cues to draw their attention to their body and breath during upright yoga postures. This practice occurs in 2-minute active intervals for up to 10 minutes, interspersed with 30-second rest to be consistent with the experimental block design.
62112453|NCT06375824|EXPERIMENTAL|Bufei Recipe|Bu Fei Fang: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
62673919|NCT06499649|EXPERIMENTAL|Treated group|Patients under H. pylori eradication therapy and probiotics as treatment
62673920|NCT05610761|EXPERIMENTAL|Core Stabilization Exercises with Kegel Exercises|
62673921|NCT05610761|ACTIVE_COMPARATOR|Kegel Exercises|
61917054|NCT06147375|EXPERIMENTAL|immunosuppressive withdrawal|After enrollment,the recipients will take IS withdrawal follow the protocol of this study.Following enrollment, recipients will be examined at several time periods such as peripheral blood test,liver function , liver biopsy, and other relevant indicators to determine immunosuppressant withdrawal condition and adverse effects.
62673922|NCT03921437|EXPERIMENTAL|decision support intervention|The intervention measures in this study were discussed with the nephrologist and CKD health teachers. Based on theoretical considerations, the experimental group provides decision support. Measures, including CKD Guardian as a decision-maker, and the use of e-book software to develop medical decision-assist tools, and the application and decision-making mode complemented by introduction and selection, including team discussions, option discussions, and decision-making conversations. The control group is introduced with traditional care instructions for routine care. The experimental group and the control group were referred to the CKD health teacher for the introduction of renal replacement therapy by the physician. The experimental group was guided by CKD Health Education to guide the patients to participate in the discussion, discuss the advantages and disadvantages of each treatment and guide patients to explore preferences. And value, supplemented by discussion and final decision.
62673923|NCT03921437|NO_INTERVENTION|routine care|According to the nursing routine provide paper education.
62673924|NCT05560529|EXPERIMENTAL|DBT (Group A)|DBT to be applied over 20 weeks
62673925|NCT05560529|ACTIVE_COMPARATOR|TAU (Group B)|TAU to be applied over 20 weeks
62673926|NCT01217515|EXPERIMENTAL|Diltiazem hydrochloride 4% cream|2.5 cm Diltiazem hydrochloride 4% cream applied peri-anally three times daily for eight weeks.
62673927|NCT01217515|EXPERIMENTAL|Diltiazem hydrochloride 2% cream|2.5 cm of Diltiazem hydrochloride 2% cream applied peri-anally three times daily for eight weeks.
62673928|NCT01217515|PLACEBO_COMPARATOR|Placebo cream|2.5 cm placebo cream applied peri-anally three times daily for eight weeks.
62673929|NCT00274794|OTHER|Rituxan + Etoposide + G-CSF|
62673930|NCT00274794|OTHER|Etoposide + G-CSF|
62673931|NCT03749863|EXPERIMENTAL|Serial PRP injections|This arm will receive experimental intervention of serial monthly platelet-rich plasma (PRP) injections to a unilateral vocal fold mucosa for a total of 4 injections.
62673932|NCT05783050|ACTIVE_COMPARATOR|Wei Nasal Jet Tube Group (Group W)|After induction of anesthesia, the Wei Nasal Jet Tube was placed in the patients.
62673933|NCT05783050|ACTIVE_COMPARATOR|Nasal Cannula Oxygen Support Group (Group N)|After the induction of anesthesia, the Nasal Cannula Oxygen Cannula was placed in the patients.
61917055|NCT02203084||Children with Chronic Medical Conditions|The Social Determinants Questionnaire will be administered to the three groups of children with chronic diseases (cystic fibrosis, diabetes mellitus type I, or chronic renal insufficiency). The questionnaire questions will be asked by a research assistant. Each participant will have the same general and background information questions then will have questions specific to their chronic medical condition.
61917056|NCT05530512|EXPERIMENTAL|Anti-inflammatory EA (AI-EA)|Anti-inflammatory electroacupuncture therapy
61917057|NCT05530512|EXPERIMENTAL|Sympathoinhibitory EA (SI-EA)|sympatho-inhibitory electroacupuncture therapy
61917058|NCT05530512|EXPERIMENTAL|Combined EA (cEA)|combination of SI-EA and AI-EA
61917059|NCT05530512|EXPERIMENTAL|Control EA (Sham-EA)|Sham electroacupuncture
61917060|NCT02050126|EXPERIMENTAL|Scar Revision|Caesarean Scar Revision using Lumenis UltraPulse Encore.
61917061|NCT03080077|ACTIVE_COMPARATOR|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
62673934|NCT04102982|ACTIVE_COMPARATOR|Microwave ablation plus camrelizumab group|Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
62673935|NCT04102982|PLACEBO_COMPARATOR|Camrelizumab group|Patients in the group are treated with camrelizumab alone.
62673936|NCT00841074|EXPERIMENTAL|1|Peridex mouthwash
62673937|NCT00841074|PLACEBO_COMPARATOR|2|Placebo mouthwash
62673938|NCT00851136|EXPERIMENTAL|1|
62673939|NCT04171310|EXPERIMENTAL|SAR442168|Single oral dose of SAR442168 (as a nonsalified compound) containing (NMT) 3.7 MBq of \[14C\]-SAR442168
62673940|NCT06237127|EXPERIMENTAL|Goji berry|For the goji berry arm, participants will consume goji berries.
62471223|NCT05992220|EXPERIMENTAL|Radiotherapy combination|"Atezolizumab+Bevacizumab, combined EBRT to vascular invasion~* Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle.~* Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle.~* The external beam radiotherapy will commence after day 2 of the first cycle of A+B, and will be delivered in accordance with institutional protocol."
62471224|NCT05992220|ACTIVE_COMPARATOR|Atezolizumab+Bevacizumab|"* Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle.~* Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle."
62112454|NCT06375824|PLACEBO_COMPARATOR|Bufei Recipe placebo|The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
62112455|NCT03045419||Patients group|"* with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or \> 20mm) and high-risk group of HCC~* scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
62112456|NCT03045419||Living liver donor candidates|"* living liver donor candidates without history of liver disease~* schedule for gadoxetic acid-enhanced liver MRI as preoperative workup~* only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
62112457|NCT03068611|ACTIVE_COMPARATOR|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
62471225|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
62471226|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
62673941|NCT06237127|ACTIVE_COMPARATOR|Fiber|For the fiber arm, participants will consume fiber supplements that closely matches the fiber type and amount found in the portion of goji berries.
62673942|NCT01185366|EXPERIMENTAL|Everolimus Group 1|Everolimus 10 mg by mouth once a day.
62112458|NCT03068611|EXPERIMENTAL|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
62112459|NCT03329742|PLACEBO_COMPARATOR|Control protein diet arm|20% protein content
62112460|NCT03329742|EXPERIMENTAL|Low protein diet arm|10% protein content
62112461|NCT05102266|EXPERIMENTAL|A(RT)|"Reference drug BR1016D 1 tablet is administered once in fasted state. After having a break of 7 days or more, study drug BR1016C 1 tablet is administered once in fasted state."
62112462|NCT05102266|EXPERIMENTAL|B(TR)|"Study drug BR1016C 1 tablet is administered once in fasted state. After having a break of 7 days or more, reference drug BR1016D 1 tablet is administered once in fasted state."
62112463|NCT04556435||LC Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.
62112464|NCT04556435||Control Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).
62112465|NCT04531488|EXPERIMENTAL|Powered Mobility Training Simulator|Powered mobility simulator- the McGill Immersive Wheelchair Simulator (MiWe) was developed for adults. In a previous study the simulator was found valid for use with children. Participants were provided a laptop, joystick and the software program- MiWe- to practice at home or school
62112466|NCT04531488|ACTIVE_COMPARATOR|Training with Powered Wheel Chair|Participants were provided with a powered wheelchair to practice at home or school
62302226|NCT04915521|ACTIVE_COMPARATOR|erector spinae plane block group|ESPB group received ultrasound-guided bupivacaine and lidocaine injection at T9 vertebral level before anesthesia induction.
62302227|NCT04915521|NO_INTERVENTION|non block control group|Control group received 5 ml 0.5% bupivacaine injection to each trocar site (total of 25 ml) at the beginning of the operation.
62471227|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
62471228|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
62471229|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
62471230|NCT04882150|EXPERIMENTAL|Part A: SAD|SAD = single ascending dose. Each participant will receive a single dose of BMS-986196 or placebo.
62471231|NCT04882150|EXPERIMENTAL|Part B: MAD|MAD = multiple ascending dose. Each participant will receive multiple doses of BMS-986196 or placebo.
62673943|NCT01185366|ACTIVE_COMPARATOR|Sunitinib Group 2|Sunitinib 50 mg by mouth daily for 4 weeks on / 2 weeks off.
62471232|NCT04882150|EXPERIMENTAL|Part C: FE/Formul.|FE/Formul. = food and formulation effects and relative absorption. Participants will receive two formulations of BMS-986196 (solution and suspension), each formulation with and without food.
62471233|NCT05902702|EXPERIMENTAL|Nebulized isotonic saline|5 ml of isotonic saline is administered through a nebulizer with a flow of 10 l oxygen/min
62673944|NCT02131493|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine：1000mg/m2，iv 30min，d1, d8,d15 q4w, 6 cycles
62112467|NCT06087432|ACTIVE_COMPARATOR|Group 1|"Rocabado's 6 x 6 exercise program has been found to be beneficial in reducing pain and increasing masticatory muscle function, as well as improving forward head posture, correcting limited joint mobility, muscle length limitation, and postural and functional limitations.~Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique. Rocabado's 6x6 exercises will be shown to both groups and 6 sets and 6 repetitions will be performed per day for 8 weeks"
62112468|NCT06087432|EXPERIMENTAL|Group 2|"Addition to Rocabado's, Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques.~The patient will be placed supine on the treatment bed and asked to relax. The therapist's hands were placed according to PNF principles, depending on the applied technique and diagonality. Maximum resistance was provided to suit the needs of each individual First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement."
62112469|NCT06553833||Study group 1: PBM only|Participants in study group 1 receive full PBM while they opted not to receive transfusions.
62471234|NCT05902702|EXPERIMENTAL|Nasal irrigation with isotonic saline|0.5-2 ml isotonic saline in each nostril administered as nasal drops
62471235|NCT05902702|NO_INTERVENTION|No treatment with saline|These children will not receive any treatment with isotonic saline, but superficial suctioning of nasal secretions as needed (as part of standard care).
62673945|NCT02131493|EXPERIMENTAL|S-1+ Gemcitabine|S-1：40\~60mg bid，d1\~14; (S-1 dosage：BSA \<1.25m2，40mg bid，1.25m2≤BSA≤1.5m2，50mg bid，BSA\>1.5m2， 60mg bid) Gemcitabine：1000mg/m2，iv 30min，d1, d8 q3w, 8 cycles
62112470|NCT06553833||Study group 2: PBM with transfusions|Participants in study group 2 receive partial PBM while they opted to receive transfusions. Transfusions are given by physicians encouraged to use a restrictive transfusion strategy. PBM is delivered to participants at a convenient time, resorting to a set of standard PBM measures rather than individualized care.
62673946|NCT02272010|EXPERIMENTAL|Experimental diet|Altered n-6 and n-3 fatty acid intake.
62673947|NCT02272010|ACTIVE_COMPARATOR|Comparator Diet|Diet standardized to usual n-6 and n-3 intake.
62673948|NCT03730701|EXPERIMENTAL|Prevention treatment group|Prevention program with 10 week blended intervention utilizing both a digital health app, group-sessions with peers and a interprofessional team of health-care workers chairing 5+1 themed group-sessions as support to change lifestyle habits in to a pattern of activities (behaviors and actions) in everyday life that can promote health and wellbeing and decrease risk for stroke. Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
62673949|NCT03730701|NO_INTERVENTION|Standard treatment group|Usal care in Swedish primary health care. In addition a Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
62673950|NCT06401109|EXPERIMENTAL|AquaPass|"Patients hospitalized with chronic heart failure symptoms and fluid overload will be treated in two phases:~Phase 1: 'In Hospital' Phase: Patients will be enrolled in the study when admitted to the hospital with fluid overload.~Use of the AquaPass system will be performed in the hospital, alongside diuretic therapy.~Phase 2: 'At Home' Phase: Upon the investigator's decision at discharge, the patients will be enrolled in this phase of the study, and will receive AquaPass treatment sessions at their home."
62673951|NCT01567020||Control|Non-blast-exposed and non-TBI, aged younger than 50
62673952|NCT01567020||Blast|Blast-exposed with or without a TBI diagnosis
61917062|NCT03080077|EXPERIMENTAL|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
61917063|NCT01039012|OTHER|Tai Chi plus Standard Care|
62471236|NCT01878344|EXPERIMENTAL|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
62471237|NCT01878344|PLACEBO_COMPARATOR|Saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
62471238|NCT01635322||Lumbar or thoraco-lumbar Adult Deformity|Lumbar or thoraco-lumbar Adult Deformity
62471239|NCT00528905|PLACEBO_COMPARATOR|1|Placebo
62471240|NCT00528905|EXPERIMENTAL|2|AZD3480 oral
62673953|NCT01567020||Non-Blast-Exposed TBI|Non-blast-exposed with TBI diagnosis
62673954|NCT01567020||Older|Non-blast-exposed and non-TBI, aged 50 or older
62673955|NCT04285684|OTHER|Ketamine, lactation|Lactating women--4 subjects, 2 dosage format: ketamine 0;5mg/kg and 1.0mg/kg IM at least 5 days apart.
61917064|NCT01039012|OTHER|Standard Care|
62112471|NCT06553833||Control group: Transfusions only|The control group is treated in an environment where PBM is not implemented and transfusion is the standard therapy for anemia, major bleeding, thrombopenia and coagulopathy beyond the transfusion trigger.
62302228|NCT05432544|EXPERIMENTAL|SAD, SHR-1918|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 injection
62302229|NCT05432544|PLACEBO_COMPARATOR|SAD, SHR-1918 placebo|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 placebo injection
62302230|NCT02191748|ACTIVE_COMPARATOR|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. Saline, which doesn't affect repigmentation in vitiligo, will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of saline injected at each site.
62471241|NCT00528905|EXPERIMENTAL|3|AZD3480 oral dose
62471242|NCT01881854||craniopharyngioma|Patients treated for craniopharyngioma, most of them on pituitary substitution therapy
62471243|NCT01881854||Healthy controls|matched for gender, age and BMI to the patients
61917065|NCT02816164|ACTIVE_COMPARATOR|Neupogen for 5 days|Neupogen injection for 5 days
61917066|NCT02816164|ACTIVE_COMPARATOR|Neupogen for 7 days|Neupogen injection for 7 days
61917067|NCT02816164|ACTIVE_COMPARATOR|Neupogen for 10 days|Neupogen injection for 10 days
62112472|NCT02773160|EXPERIMENTAL|Sensor-based postural feedback|Subjects will receive visual feedback on a computer screen while practicing the motor control task. The feedback is based on information from from motion sensors that mointor the movements of the lumbar spine
62112473|NCT02773160|EXPERIMENTAL|Mirror Feedback|Subjects will receive feedback from a mirror while practicing the motor control task
61917068|NCT03609398|EXPERIMENTAL|RVF Vaccine|1.0 mL dose given SQ in upper arm
62112474|NCT02773160|ACTIVE_COMPARATOR|control group|Subjects will receive no feedback while practicing the motor control task
62112475|NCT03035045|EXPERIMENTAL|Comparator1: Paracetamol 650 mg (325 mg/tablet) oral|Drug: Paracetamol Comparison pain score between paracetamol and placebo
62112476|NCT03035045|PLACEBO_COMPARATOR|Comparator 2: Placebo oral|Drug: placebo Comparison pain score between paracetamol and placebo
62112477|NCT02962674|OTHER|Treatment|
62302231|NCT02191748|EXPERIMENTAL|Needling and Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area. Triamcinolone (concentration: 2.5 mg/cc) will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of triamcinolone injected at each site.
61917069|NCT01501045|EXPERIMENTAL|healthy subjects|healthy subjects
61917070|NCT01501045|EXPERIMENTAL|pain patients|Migraine and muscle headache patients
61917071|NCT03199339|ACTIVE_COMPARATOR|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
62112478|NCT06631872|EXPERIMENTAL|Tele-prehabilitation intervention (Intervention Group)|The Teleprehabilitaiton intervention (also known as Surgery School) is a one-off group based education session delivered online. Video presentations of 8-10 key prehabilitation education areas will be facilitated by a live clinician facilitator who will introduce the educational content and answer any questions. All standardised video presentations during the session will be made available to participants through an online password-protected video repository hosted on a video platform after the session and will be available until their surgery.
62471244|NCT04417933|EXPERIMENTAL|Tumor Electric Fields Treatment System|Patients have a histologically confirmed diagnosis of supratentorial glioblastoma that is recurrent. All patients will receive Tumor Electric Fields Treatment System.
62471245|NCT00184522|EXPERIMENTAL|Aflurax|pectin-containing natural product
62471246|NCT00184522|ACTIVE_COMPARATOR|esomeprazole (Nexium)|esomeprazole (Nexium)
62471247|NCT05115123|ACTIVE_COMPARATOR|Intervention|patients scheduled for elective LC will receive 60 mg duloxetine before surgery
62471248|NCT05115123|PLACEBO_COMPARATOR|Control|patients scheduled for elective LC will receive placebo before surgery
62673956|NCT06334315|EXPERIMENTAL|Combined oral contraceptive pill users|Administered a combined oral contraceptive pill containing desogestrel and ethinyl estradiol (Desogen, 0.15mg desogestrel and 0.03mg ethinyl estradiol per active pill) for at least one cycle (21 days) and up to 13 total cycles (one year)
62673957|NCT02798952|EXPERIMENTAL|HBV Group|Subjects received a single challenge dose of Engerix-B Kinder.
62673958|NCT00160615|EXPERIMENTAL|Levetiracetam|Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).
62471249|NCT05057650|EXPERIMENTAL|Intervention|Vegan food for 5 weeks: approximately 50 participants volunteered for the intervention.
62112479|NCT06631872|ACTIVE_COMPARATOR|Usual care alone (Control Group)|Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling and medical optimisation in preoperative anaesthetic clinic visits. Participants will be asked to maintain their normal daily activities.
62673959|NCT02740582|EXPERIMENTAL|Tolcapone First, then Placebo|Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID
62673960|NCT02740582|PLACEBO_COMPARATOR|Placebo First, then Tolcapone|Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID
61917072|NCT03199339|PLACEBO_COMPARATOR|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
61917073|NCT03199339|ACTIVE_COMPARATOR|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
61917074|NCT03199339|PLACEBO_COMPARATOR|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
61917075|NCT03199339|ACTIVE_COMPARATOR|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
61917076|NCT03199339|PLACEBO_COMPARATOR|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
61917077|NCT03199339|ACTIVE_COMPARATOR|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
61917078|NCT03199339|PLACEBO_COMPARATOR|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
62112480|NCT06631872|EXPERIMENTAL|Sub-study: Tele-prehabilitation and inspiratory muscle training program|"Eligible participants awaiting lung cancer surgery that have been randomised into the intervention arm will be re-randomised to receive either the STTARRS (larger trial) intervention or the STTARRS intervention PLUS an individualised inspiratory muscle training and walking program delivered by a physiotherapist using telehealth in the lead up to their lung cancer surgery.~The inspiratory muscle training program includes an inspiratory muscle training explanatory video and an individually prescribed dosage and resistance for inspiratory muscle training and walking program, delivered via telehealth."
62302232|NCT02191748|NO_INTERVENTION|No treatment|No treatment will be done to these vitiligo patches as a control.
62302233|NCT03785080|EXPERIMENTAL|restart NOAC very early|restart NOAC within 24 hours
62302234|NCT03785080|ACTIVE_COMPARATOR|restart NOAC early|restart NOAC at 72 - 84 hours
62471250|NCT00656305|EXPERIMENTAL|ExAblate Treatment Arm|
62471251|NCT00656305|SHAM_COMPARATOR|ExAblate Sham Arm|
62673961|NCT05540067|EXPERIMENTAL|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered remotely or in-person, depending on preference.
62673962|NCT05540067|OTHER|Treatment-as-Usual (TAU)|Control participants will receive the currently recommended best practices of care at the recruitment site.
62673963|NCT06369051|EXPERIMENTAL|Intervention|A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
62673964|NCT06369051|NO_INTERVENTION|Control|Usual stroke care services
61917079|NCT03199339|ACTIVE_COMPARATOR|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
61917080|NCT03199339|PLACEBO_COMPARATOR|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
61917081|NCT03199339|ACTIVE_COMPARATOR|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
61917082|NCT03199339|PLACEBO_COMPARATOR|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
61917083|NCT03199339|ACTIVE_COMPARATOR|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
61917084|NCT03199339|PLACEBO_COMPARATOR|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
61917085|NCT03199339|ACTIVE_COMPARATOR|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
61917086|NCT03199339|PLACEBO_COMPARATOR|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
61917087|NCT03199339|ACTIVE_COMPARATOR|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
62673965|NCT03292978|EXPERIMENTAL|probiotics intervention|"1. The probiotic is provided in sachets as a 2g powder dried with corn starch.~2. The powder is orally taken once daily for 4 weeks.~3. The powder contains totally 11 log 10 colony forming units(CFU) of probiotics.~4. The types of probiotics are Lactobacillus.rhamnosus, Lactobacillus.acidophilus, Bifidobacteria.animalis and Bifidobacteria.longum."
62673966|NCT03292978|PLACEBO_COMPARATOR|non-probiotic control|The placebo is corn starch alone provided and the shape, color, weight,flavor and taste are same with the powder of probiotics intervention.
62673967|NCT05616780|OTHER|Obtaining lung volume measurements in patients with airflow obstruction|"All patients involved in this study will be attending a pulmonary function test as part of their routine patient treatment pathway, requested by their consultant. Potential participants will be sent a patient information sheet prior to their lung function test.~The pulmonary function test begins routinely, with the pre-test questions. Spirometry will then be performed. If the patient's results are variable and the repeatability criteria are not met, the patient will not be asked to take part in the study, and no additional tests (not requested by the consultant routinely) will be carried out. If the patient has normal or obstructive results (FEV1/FVC \<70%) the patient will sign the consent form and both lung volume tests will be conducted. They must be able to follow the instructions for both nitrogen washout and body plethysmography, and the results must also meet the acceptability and repeatability criteria."
62673968|NCT05250440||(a1)Emmetropia: +0.75 to -0.75 D|age: 12 to 18 years old
62673969|NCT05250440||(a2)Mild myopia: -1.00 to -3.00 D|age: 12 to 18 years old
62471252|NCT03513822|ACTIVE_COMPARATOR|Chronic neuropathic pain and bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
62673970|NCT05250440||(a3)Moderate myopia: -3.25 to -6.00 D|age: 12 to 18 years old
62673971|NCT05250440||(a4)High myopia: >-6.00 D|age: 12 to 18 years old
62673972|NCT05250440||(b1)Emmetropia: +0.75 to -0.75 D|age: 18 to 35 years old
62112481|NCT06631872|ACTIVE_COMPARATOR|Sub-study: Tele-prehabilitation intervention|The Teleprehabilitaiton intervention (also known as Surgery School) is a one-off group based education session delivered online. Video presentations of 8-10 key prehabilitation education areas will be facilitated by a live clinician facilitator who will introduce the educational content and answer any questions. All standardised video presentations during the session will be made available to participants through an online password-protected video repository hosted on a video platform after the session and will be available until their surgery.
62673973|NCT05250440||(b2)Mild myopia: -1.00 to -3.00 D|age: 18 to 35 years old
62112482|NCT02803606||hypothermia|Preterm neonates less than 32 weeks of gestational age admitted at birth to the Neonatal Medicine unit
62112483|NCT06114329|EXPERIMENTAL|AL01211 30 mg, once daily|9 subjects will first be enrolled in this arm, receiving 30 mg AL01211 treatment, once daily
62673974|NCT05250440||(b3)Moderate myopia: -3.25 to -6.00 D|age: 18 to 35 years old
62112484|NCT06114329|EXPERIMENTAL|AL01211 60 mg, once daily|After enrolling into 30 mg arm is completed and preliminary data show good safety, 9 subjects will be enrolled in this arm, receiving 60 mg AL01211 treatment, once daily
61917088|NCT03199339|PLACEBO_COMPARATOR|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
62112485|NCT03841019|EXPERIMENTAL|magnetic seizure therapy|12 treatment sessions of MST, three times per week.
62112486|NCT03841019|ACTIVE_COMPARATOR|electroconvulsive therapy|12 treatment sessions of ECT, three times per week.
62112487|NCT05609448|EXPERIMENTAL|MRI-guided radioembolization|Study patients will receive radioembolization with holmium microspheres in an MRI guided setting.
62471253|NCT03513822|PLACEBO_COMPARATOR|Chronic neuropathic pain and bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
62673975|NCT05250440||(b4)High myopia: >-6.00 D|age: 18 to 35 years old
62112488|NCT05726292|EXPERIMENTAL|Group 1: Participants Who Receive Study Drug (Relacorilant) with Hormone Therapy and Enzalutamide|All participants in this group will have surgery up to 4 weeks after receiving enzalutamide/relacorilant with hormone therapy. A radical prostatectomy (removal of the prostate and any surrounding tissue that the surgeon thinks may be affected by the cancer).
62112489|NCT05726292|EXPERIMENTAL|Group 1: Participants Who Receive Placebo (no study drug) with Hormone Therapy and Enzalutamide|All participants in this group will have surgery up to 4 weeks after receiving enzalutamide/placebo (sugar pill in the form of 2 softgel capsules) with hormone therapy. A radical prostatectomy (removal of the prostate and any surrounding tissue that the surgeon thinks may be affected by the cancer).
62112490|NCT05676736||Study group (S) Obese group|Patients with body mass index (BMI) range from (≥30 kg/m2)
62112491|NCT05676736||Control group (C) Normal weight group|Patients with body mass index (BMI) range from (18.5-24.9 kg/m2)
62112492|NCT01367561|EXPERIMENTAL|Arm 1|
62112493|NCT01367561|EXPERIMENTAL|Arm 2|
62112494|NCT01367561|PLACEBO_COMPARATOR|Arm 3|
62112495|NCT03665298|EXPERIMENTAL|Needle X|Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.
62302235|NCT01053676|EXPERIMENTAL|Arm 1|
62302236|NCT01053676|ACTIVE_COMPARATOR|Arm 2|
62673976|NCT05397405|EXPERIMENTAL|Intervention group|Blood Lipid management with atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
62302237|NCT03421548|EXPERIMENTAL|BKpro I with EyeMate|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
62112496|NCT02023125|EXPERIMENTAL|Group 1: Treatment A first, then Treatment B|Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Each period will be separated by at least 10 days.
62302238|NCT03421548|NO_INTERVENTION|BKpro I|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
62302239|NCT01796132|NO_INTERVENTION|Control|Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
62302240|NCT01796132|EXPERIMENTAL|SSRI/SNRI exposure|Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
62302241|NCT01671410|EXPERIMENTAL|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
62471254|NCT03513822|ACTIVE_COMPARATOR|Chronic neuropathic pain without bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
62471255|NCT03513822|PLACEBO_COMPARATOR|Chronic neuropathic pain without bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
62471256|NCT02587871|EXPERIMENTAL|Treatment (cytarabine, G-CSF mobilized peripheral blood cells)|Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine IV over 1-3 hours BID on days -7 to -2 and G-CSF mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
62673977|NCT05397405|NO_INTERVENTION|Control group|Blood Lipid management with atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg for 6-12 months
62673978|NCT03466164|EXPERIMENTAL|Behavioral: Mindfulness Based Stress Reduction Program|Mindfulness-Based Stress Reduction MZ: identical (monozygotic; MZ) twins are tested in a pre-post manner, with only one twin randomly assigned to MT in between the two testing sessions
62673979|NCT03466164|NO_INTERVENTION|Control MZ|Control MZ twin will complete 2 testing sessions without intervention.
62673980|NCT06281002|ACTIVE_COMPARATOR|conventional physical impressions|"Nine physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs.~The impressions will be scanned to provide a gold standard reference STL files."
61917089|NCT03199339|ACTIVE_COMPARATOR|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
62112497|NCT02023125|EXPERIMENTAL|Group 1: Treatment B first, then Treatment A|Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Each period will be separated by at least 10 days.
61917090|NCT06422754|ACTIVE_COMPARATOR|Conventional Group|The first group will receive 30 sessions of conventional exercises for 1 hour every day. In addition, the patient will be given a home program.
62302242|NCT01671410|ACTIVE_COMPARATOR|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
62302243|NCT03390829||Patients|
62302244|NCT03390829||Doctors|
62302245|NCT01444716|EXPERIMENTAL|Treatment (ofatumumab)|Participants receive ofatumumab IV over 4 hours once a week for 4 weeks, then monthly thereafter. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
62302246|NCT03284450|EXPERIMENTAL|Dance performance fitness test (DPFT)|
62302247|NCT03284450|ACTIVE_COMPARATOR|Sport specific repeated sprints (SSRS)|
62471257|NCT02907047|ACTIVE_COMPARATOR|Tourniquet|These subjects will have their tourniquet inflated during key portions of the total knee arthroplasty procedure
62112498|NCT02023125|EXPERIMENTAL|Group 2: Alectinib Alone, Alectinib + Esomeprazole|Period 1 (Days 1 to 10): Following an overnight fast of at least 10 hours, participants will start a standardized meal and should consume the meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal on Day 1 of Period 1. Period 2 (Days 11 to 20): Participants will receive oral esomeprazole 40 mg once daily for 6 days (Days 11-16) in the morning after an overnight fast of at least 10 hours, and at least 1 hour before a regular breakfast; On Day 16, following an overnight fast of at least 10 hours, a single oral dose of 40 mg esomeprazole will be administered 1.5 hours prior to the start of a standardized meal. Following a standardized meal, a single oral 600 mg dose of alectinib will then be administered.
62302248|NCT05601206|EXPERIMENTAL|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
62302249|NCT05601206|ACTIVE_COMPARATOR|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
62302250|NCT00025038|EXPERIMENTAL|Treatment (tipifarnib, bone marrow/umbilical cord transplant)|See detailed description.
62302251|NCT05233046|EXPERIMENTAL|Impact of Nourish Carolina - Control Group|Group A - nutrition (one time/week) and mental health counseling (biweekly) for 12 weeks
62302252|NCT05233046|EXPERIMENTAL|Impact of Nourish Carolina - Study Group|Group B - nutrition ( one time/week) and mental health counseling (biweekly)with Nourish Carolina for 12 weeks
62302253|NCT03815292|EXPERIMENTAL|MMH-MAP|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatment will be 24 weeks.
62471258|NCT02907047|OTHER|No tourniquet|These subjects will not have their tourniquet inflated during key portions of the total knee arthroplasty procedure
62471259|NCT04684901|NO_INTERVENTION|Standard of Care Group|Standard of Care - No AlloWrap used during surgery
62673981|NCT06281002|EXPERIMENTAL|optical impressions with additional geometric scanning aids coupled with the scan bodies|Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.
62673982|NCT05508594|EXPERIMENTAL|CT001|
62673983|NCT05508594|PLACEBO_COMPARATOR|Placebo|
62673984|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 27 mcg|
62673985|NCT05508594|ACTIVE_COMPARATOR|Ketamine 27 mg|
62673986|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 13 mcg|
62673987|NCT05508594|ACTIVE_COMPARATOR|Ketamine 13 mg|
62673988|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 40 mcg|
62673989|NCT05508594|ACTIVE_COMPARATOR|Ketamine 40 mg|
62673990|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 13 mcg/Ketamine 13 mg|
62673991|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 13 mcg/Ketamine 27 mg|
61917091|NCT06422754|ACTIVE_COMPARATOR|Virtual Reality Group|In the second group, conventional exercises will be applied for 1 hour and 30 sessions every day. In addition to conventional exercise, this group will be enrolled in the balance game group using the Becure Balance System application and Wİ balance board for 45 minutes 5 sessions a week.
62302254|NCT03815292|PLACEBO_COMPARATOR|Placebo|Placebo for 24 weeks, according to the MMH-MAP dosing regimen.
62302255|NCT04744558|EXPERIMENTAL|Ketogenic|Low carb high fat ketogenic diet
62302256|NCT04744558|ACTIVE_COMPARATOR|Non-ketogenic|Low carb high fat non-ketogenic diet
62471260|NCT04684901|EXPERIMENTAL|AlloWrap Group|AlloWrap used in surgery
62112499|NCT02981186|EXPERIMENTAL|IOL Implantation experimental|Implantation of POD F GF in one of the eyes of the study subject
62112500|NCT02981186|ACTIVE_COMPARATOR|IOL Implantation Comparator|Implantation of POD F in the contralateral eye of the study subject
62471261|NCT02011295|OTHER|Microfracture|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT
62471262|NCT02011295|OTHER|microfracture + injection of autologous BMAC|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT plus injection of autologous Bone Marrow Aspirate Concentration
62471263|NCT05974397||AMI|Patients with AMI
62471264|NCT05974397||STEMI|Patients with STEMI
62471265|NCT05974397||NSTEMI|Patients with NSTEMI
62471266|NCT02197260|EXPERIMENTAL|Protocol A|Antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the first, non-surgical phase of periodontal therapy (T1), and placebo during the second, surgical phase (T2)
62673992|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 13 mcg/Ketamine 40 mg|
62673993|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 27 mcg/Ketamine 13 mg|
62673994|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 27 mcg/Ketamine 40 mg|
62673995|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 40 mcg/Ketamine 13 mg|
62673996|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 40 mcg/Ketamine 27 mg|
62673997|NCT05508594|ACTIVE_COMPARATOR|Sufentanil 40 mcg/Ketamine 40 mg|
62673998|NCT05012969|EXPERIMENTAL|intervention|HipStop bandage for 12 weeks to prevent dislocation of the hip
62673999|NCT05012969|NO_INTERVENTION|control|normal procedure after dislocation of hip which is information on movement restrictions
62112501|NCT06186739|EXPERIMENTAL|home-based motor rehabilitation training participated by caregivers|The patients in this group received face-to-face learning of rehabilitation skills when they were discharged from the hospital. The main learning contents of patients are: how to carry out limb rehabilitation training at home? when to carry out rehabilitation training? and how to choose the most appropriate rehabilitation training content? Members of the rehabilitation nursing team should assist patients in setting rehabilitation goals, help patients make weekly rehabilitation plans, and distribute learning manuals and video learning materials to patients for review at home. The rehabilitation nursing team conducts online follow-up of patients every other week to assess whether patients have achieved short-term goals, adjust or add rehabilitation contents for patients, and reconfirm the intensity of home-based training of patients. answer the questions raised by the patient during the rehabilitation process at home and encourage the patient to maintain rehabilitation.
62302257|NCT05412433|ACTIVE_COMPARATOR|Standard of Care|Participants in this arm will receive standard of care
62471267|NCT02197260|ACTIVE_COMPARATOR|Protocol B|Placebo during the first, non-surgical phase of periodontal therapy (T1), and antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the second, surgical phase (T2)
62471268|NCT00485394|EXPERIMENTAL|1|OT-551 0.3% ophthalmic solution
62471269|NCT00485394|EXPERIMENTAL|2|OT-551 0.45% ophthalmic solution
62471270|NCT00485394|PLACEBO_COMPARATOR|3|vehicle placebo
62471271|NCT03558945|EXPERIMENTAL|Personalized neoantigen vaccine|Patients will receive radical resection surgery and at least one circle of post-operative chemotherapy. After chemotherapy, personalized neoantigen vaccines will be administered subcutaneously.
62471272|NCT00857103|NO_INTERVENTION|1|Standard care
62471273|NCT00857103|EXPERIMENTAL|2|Use of Choice intervention to support consultations
62471274|NCT06127797||Questionnaire/Interview|"Participants will take part in this study, before and after your routine breast MRI scan, participants will be asked to answer a series of questions about your experience with this MRI. It may take 10 to 20 minutes to answer. Participants may answer these questions in 1 of 3 ways:~* In-person in the clinic with the study team (either through speaking or writing down your answers on a paper or electronic questionnaire form);~* by phone at a later time; or~* by paper or email at a later time."
62471275|NCT02688023|EXPERIMENTAL|single-arm Irinotecan-Oxaliplatin-5-Fluorouracil/leucovorin|Irinotecan,oxaliplatin and 5-fluorouracil/leucovorin(5-fluorouracil/leucovorin can be substituted with Capecitabine or S-1)
62674000|NCT05703412|EXPERIMENTAL|Transition-FOCUS mHealth Intervention|"All participants will download the tFOCUS app to their mobile phone. tFOCUS uses EMA to assess variables identified as being salient to treatment engagement and illness self-management. The application delivers algorithm-driven micro interventions to address reported problem(s). Data is transmitted to a clinician dashboard, which can be used for remote monitoring."
62302258|NCT05412433|EXPERIMENTAL|Patient Level + Multilevel|Participants in the arm will receive the patient level and multi-level intervention
62471276|NCT03625661|EXPERIMENTAL|Arm with Ferinject|Ferinject will be administered once at inclusion
62471277|NCT03480321|ACTIVE_COMPARATOR|Cilostazol 100 mg|
62674001|NCT05703412|ACTIVE_COMPARATOR|Check-In|Control participants will receive the currently recommended best practices of post-discharge care, including follow-up appointments, instructions, referrals and a follow-up check in.
62674002|NCT01047176||1|Male or female \> 18 year of age with indication to PCI
61917092|NCT00342121||1|Corn farmers enrolled in the Agricultural Health Study who are non-smokers, and who plan to apply specific pesticides.
61917093|NCT00342121||2|Control subjects selected from agricultural extension workers in Iowa who are non-smokers
62471278|NCT03480321|EXPERIMENTAL|PMR 150 mg|
62471279|NCT03480321|EXPERIMENTAL|PMR 200 mg|
62471280|NCT03838276|ACTIVE_COMPARATOR|AL150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
62471281|NCT03838276|EXPERIMENTAL|AL100 BPL150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
62471282|NCT02886247||participants|individuals with a personal or family history of pancreas tumors
62471283|NCT01601145|EXPERIMENTAL|lozenges with Lactobacillus brevis CD2|Randomized group using lozenges for 6 weeks.
62471284|NCT01601145|PLACEBO_COMPARATOR|lozenges|Randomized group using lozenges for 6 weeks.
62471285|NCT01308164|EXPERIMENTAL|MD logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
61917094|NCT05067998||IV Vitamin Therapy Treatments|IV vitamin infusion therapy involves inserting an IV line into a vein in your arm to administer a high concentration of liquid vitamins, antioxidants, amino acids, and minerals into your bloodstream. The therapy may be for only one vitamin or a cocktail of nutrients.
61917095|NCT05067998||Herbal Medicine, Tincture (Liquid Vitamins)|Tinctures are concentrated herbal extracts made by soaking the bark, berries, leaves (dried or fresh), or roots from one or more plants in alcohol or vinegar. The alcohol or vinegar pulls out the active ingredients in the plant parts, concentrating them as a liquid. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort. Herbal Medicine is type of medicine that uses roots, stems, leaves, flowers, or seeds of plants to improve health, prevent disease, and treat illness.
61917096|NCT05067998||Supplements|Dietary supplements are substances you might use to add nutrients to your diet or to lower your risk of health problems such as osteoporosis or arthritis. Dietary supplements come in the form of pills, capsules, powders, gel capsules and tablets, extracts, or liquids. Dietary supplements come in a variety of forms, including tablets, capsules, gummies, and powders, as well as drinks and energy bars. Popular supplements include vitamins D and B12; minerals like calcium and iron; herbs such as echinacea and garlic; and products like glucosamine, probiotics, and fish oils.
61917097|NCT05067998||Vitamins (Orally)|Vitamins are substances that our bodies need to develop and function normally. They include vitamins A, C, D, E, and K, choline, and the B vitamins (thiamin, riboflavin, niacin, pantothenic acid, biotin, vitamin B6, vitamin B12, and folate/folic acid). Vitamins are essential nutrients that enable your body to work properly and to stay healthy. Most vitamins can be found in the food that we eat or from vitamin supplements.
61917098|NCT04357691|OTHER|Healthy individuals (low-high-mod)|Participants will undergo the calibration phase beginning with low intensity training, followed by high, and moderate intensity training. Each training intensity will be performed 3 days a week for 2 weeks
61917099|NCT04357691|OTHER|Healthy individuals (mod-high-low)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by high, and low intensity training. Each training intensity will be performed 3 days a week for 2 weeks
62471286|NCT01308164|NO_INTERVENTION|Control Group|Regular treatment, no change will be made in the insulin pump setting during the study (unless there is a medical need or any safety concern) Only segment 2 of the study, which is conducted as RCT (randomized controlled trial) , will include control group
61917100|NCT04357691|OTHER|Healthy individuals (mod-low-high)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by low, and high intensity training. Each training intensity will be performed 3 days a week for 2 weeks.
61917101|NCT05330078|EXPERIMENTAL|Keloid treatment with botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
61917102|NCT05330078|PLACEBO_COMPARATOR|Keloid treatment with vehicle control (saline)|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
61917103|NCT06506071||Case|Myocardial tissue characterisation using spectral technology and Cardiac Magnetic Resonance (CMR) imaging.
61917104|NCT06506071||Controls|Myocardial tissue characterisation using spectral technology and CMR imaging.
62112502|NCT06186739|ACTIVE_COMPARATOR|routine self-care group|The control group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
62471287|NCT01922180||COPD Exacerbation|COPD patients aged 18 years or more, were included at the time of an exacerbation episode leading to admission in our hospital, which corresponds to a severe episode. There were no exclusion criteria. Patients underwent chest CT scans and PFT. After a minimum of two weeks free of any acute symptom after discharge, CT scans and PFT were redone.
62471288|NCT02046746|EXPERIMENTAL|Oral Nutritional Supplement (ONS)|1-2 serving per day of a renal specific oral nutritional supplement
62471289|NCT01982981|NO_INTERVENTION|control|The control group only be assessed
62302259|NCT05412433|EXPERIMENTAL|Multilevel|Participants in this arm will receive the multi-level intervention
62302260|NCT04674943|NO_INTERVENTION|Control group|No physical therapy intervention was given. Only pharmacological treatment was provided.
62302261|NCT04674943|EXPERIMENTAL|Breathing exercise group|1. Pursed lip breathing 15 reps x 3 sets) 2: Diaphragmatic breathing (15 reps x 3 sets) 3:Lateral costal breathing 15 reps x 3 sets)
61917105|NCT02686281|EXPERIMENTAL|Cohort A (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo"
62471290|NCT01982981|EXPERIMENTAL|water provision|The experimental group get water every 15 days
62302262|NCT00109811|EXPERIMENTAL|Treatment|Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 \[155L\]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.
62302263|NCT04068883|EXPERIMENTAL|Collar group|group of athletes that will wear the collar device
62302264|NCT04068883|NO_INTERVENTION|Non Collar group|group of athletes that will not wear the collar device
62471291|NCT01907334|ACTIVE_COMPARATOR|Advair Diskus100/50 µg and Advair Diskus 100/50 µg|The Advair Diskus 100/50 µg and Advair Diskus 100/50 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
62471292|NCT01907334|ACTIVE_COMPARATOR|Advair Diskus 100/50 µg and Flovent Diskus 100 µg|The Advair Diskus 100/50 µg and Flovent Diskus 100 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair and Flovent a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
62471293|NCT04775745|EXPERIMENTAL|Dose Escalation Phase|Three to six subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-168 on a once or twice daily schedule for 28 days, starting at a dose of 100 mg/day.
62471294|NCT04775745|EXPERIMENTAL|Dose Expansion Phase|Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups.
61917106|NCT02686281|EXPERIMENTAL|Cohort B (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo~The dose administered in Part A (fed) was based on the outcome of Part A (fasted)."
61917107|NCT00401362|EXPERIMENTAL|Arm 1|
61917108|NCT00401362|PLACEBO_COMPARATOR|Arm 3|
61917109|NCT00401362|EXPERIMENTAL|Arm 2|
61917110|NCT05242315|ACTIVE_COMPARATOR|Envarsus|Envarsus tablet Dose 0.11 - 0.13 mg/Kg/day Frequency: once per day
62302265|NCT06477042||Poor prognosis patients|Patients will performed the Quality Of Life Questionnaire (EQ-5D-5L) and the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) at baseline (day of the TAVI procedure) and 2 months post-TAVI. The CAPRI score will be calculated from the data of the pre TAVI assessment at the end of study participation (12 months) and will determine the group of the patient. The higher the score, the worse the prognosis.
62302266|NCT06477042||Intermediate prognosis patients|Patients will performed the Quality Of Life Questionnaire (EQ-5D-5L) and the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) at baseline (day of the TAVI procedure) and 2 months post-TAVI. The CAPRI score will be calculated from the data of the pre TAVI assessment at the end of study participation (12 months) and will determine the group of the patient. The higher the score, the worse the prognosis
62302267|NCT05064241|EXPERIMENTAL|Virtual Advisory Board|Participants have access to a genetic counselor to answer their questions on accessing genetic medicine.
62302268|NCT05064241|NO_INTERVENTION|Virtual Peer-to-Peer Discussion Board|Participants answer each others' questions on the topic of accessing genetic medicine.
62471295|NCT06162169|EXPERIMENTAL|JAB-21822+Itraconazole|
62471296|NCT06162169|EXPERIMENTAL|JAB-21822+ Rifampicin|
62471297|NCT06162169|EXPERIMENTAL|JAB-21822+ Omeprazole|
62471298|NCT06162169|EXPERIMENTAL|Dazolam , Rosuvastatin calcium and digoxin with JAB-21822|
62471299|NCT01278953|EXPERIMENTAL|TactiCath|Catheter ablation to treat paroxysmal AF using the TactiCath catheter with contact force capability
62471300|NCT01278953|ACTIVE_COMPARATOR|Control|Catheter ablation to treat paroxysmal AF using a catheter with no contact force sensing capability
62471301|NCT05008640||Study group (all subjects)|All subjects belonged to the same study group, regardless of symptoms, disease diagnosis or state. Furthermore, there was no stratification of the population by sex, age, race or disease severity.
61917111|NCT05242315|OTHER|Prograf (SOC)|Prograf tablet Dose 0.10 - 0.15mg/Kg daily Frequency: 2 doses per day (dose above split in half for each dose)
61917112|NCT06318962|EXPERIMENTAL|Digital Therapeutic|BCBT Delivery via digital app
61917113|NCT06318962|NO_INTERVENTION|Treatment as Usual|
61917114|NCT03042273|EXPERIMENTAL|High Strength Cranberry|1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months
61917115|NCT03042273|PLACEBO_COMPARATOR|Placebo|1 capsule of Matching Placebo orally daily for 6 months
61917116|NCT05166239|EXPERIMENTAL|HAIC-Cola group|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC. PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
61917117|NCT05166239|ACTIVE_COMPARATOR|Cola group|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily. PD-1 inhibitors injection intravenously or percutaneously every 4 week.
61917118|NCT04231591||ACDH Pregnancy - Study group|Pregnant women with known adult congenital heart disease.
61917119|NCT04231591||Uncomplicated pregnancy - Control group|Healthy women with an uncomplicated pregnancy
61917120|NCT01185431|EXPERIMENTAL|Ficus carica (Fig paste)|
61917121|NCT01185431|PLACEBO_COMPARATOR|Control (Placebo paste)|
61917122|NCT02541383|OTHER|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
61917123|NCT02541383|EXPERIMENTAL|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
61917124|NCT02541383|NO_INTERVENTION|Arm A Part 2|Observation
61917125|NCT02541383|EXPERIMENTAL|Arm B Part 2|daratumumab
61917126|NCT02918981|ACTIVE_COMPARATOR|Whey protein|After resistance exercise, participants aged 50-79 years will consume 14g Whey protein dissolved in 200 mL of water
61917127|NCT02918981|EXPERIMENTAL|Whey + Leucine|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine dissolved in 200 mL of water
61917128|NCT02918981|EXPERIMENTAL|Whey + Leucine + Whey peptides|After resistance exercise, participants aged 50-79 years will consume 4 g Whey protein + 1.25 g Leucine + 2.6 g Whey peptides dissolved in 200 mL of water
61917129|NCT02918981|EXPERIMENTAL|Whey + Leucine + Citrulline|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine + 0.8 g Citrulline dissolved in 200 mL of water
61917130|NCT02918981|SHAM_COMPARATOR|Water|After resistance exercise, participants aged either 20-30 or 50-79 years old will consume 200 mL water
61917131|NCT03175848|EXPERIMENTAL|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
61917132|NCT05413278|OTHER|Training|Patient education, empowerment, and information
61917133|NCT03849027|EXPERIMENTAL|Methoxyflurane|"Inhaled methoxyflurane once-off dose of 3 ml will be administered via the inhaler at each dosing visit .~Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®)."
61917134|NCT03849027|SHAM_COMPARATOR|Sham Methoxyflurane|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test
61917135|NCT05561075|EXPERIMENTAL|Pterostilbene cocrystal|
61917136|NCT05561075|ACTIVE_COMPARATOR|Pterostilbene free form|
61917137|NCT05130944|EXPERIMENTAL|Entre Nosotras (group psychosocial intervention) + stress management intervention|Experimental condition: Women residing in the study community (displaced and host population) will receive both group psychosocial intervention and stress management intervention. Participants will be given the Spanish version of the Doing What Matters in Times of Stress illustrated guide, that is published and made publicly available by the World Health Organization.
61917138|NCT05130944|ACTIVE_COMPARATOR|Entre Nosostras (group psychosocial intervention)|Comparison condition: Women residing in the study community (displaced and host population) will receive group psychosocial intervention only.
61917139|NCT00911378|ACTIVE_COMPARATOR|Pressure support ventilation|Patients in this arm are weaned by gradual reduction of pressure support
62674003|NCT05154929|OTHER|Control arm|Participants in the control group will be provided a smartwatch and home blood pressure monitor. They will also be provided with general instructions on how to download and install a physical activity and diet regulation applications (apps) available to the general public. They will still be asked to perform the blood pressure monitoring at regularly scheduled time periods, but do not receive the intervention components notifications in myBPmyLife app developed for the experimental group.
62674004|NCT05154929|EXPERIMENTAL|Dietary plus physical activity JITAI|Participants in the experimental group will be provided a smarthwatch and home blood pressure monitor. They will then receive the myBPmyLife app that includes push notifications to promote increased physical activity and improve low sodium food choices. The app also provides goal setting for weekly step count and information on low-sodium food choices, as well as feedback on achieving the goals using a dashboard with visualization tools within the mobile application.
62674005|NCT01115010|EXPERIMENTAL|Stiffening wire only if difficulty|Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
62674006|NCT01115010|EXPERIMENTAL|Stiffening wire #1 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
61917140|NCT00911378|ACTIVE_COMPARATOR|Spontaneous breathing trials|Patients in this arm are weaned by T piece trials
62302269|NCT05015712|EXPERIMENTAL|moderate intensity continuous training|
62302270|NCT05015712|NO_INTERVENTION|guideline control|Patients assigned to the guideline control just received 1-time advice on training according to guidelines.
62302271|NCT05465135|EXPERIMENTAL|Dihydroartemisinin Group|The subjects take Dihydroartemisinin, 40mg tid for 12 weeks
62302272|NCT03425383||Test group|Subjects having periapical disease diagnosed clinically and radiographically and free from any other systemic illness. FMD and c-IMT will be determined by ultrasound
62471302|NCT01668602|EXPERIMENTAL|Cohort 1 - FastFES Training|Participants with chronic stroke in Cohort 1 will receive 18 training sessions of FastFES (fast treadmill walking with electrical stimulation).
62471303|NCT01668602|EXPERIMENTAL|Cohort 2 - FastFES and Fast Walking|Participants with chronic stroke in Cohort 2 who complete 3 sessions of FastFES and 3 sessions of fast walking.
62674007|NCT01115010|EXPERIMENTAL|Stiffening wire #2 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.
62674008|NCT05414747|EXPERIMENTAL|Participants randomized to ABV-1701 Ocular Endotamponade|Participants randomized to the interventional device ABV-1701 Ocular Endotamponade undergoing the vitrectomy surgery for uncomplicated retinal detachment
62674009|NCT05414747|ACTIVE_COMPARATOR|Participants randomized to SF6 Gas Ocular Endotamponade|Participants randomized to the control device SF6 Gas Ocular Endotamponade undergoing the vitrectomy surgery for uncomplicated retinal detachment
62674010|NCT01041105||Gastric bypass after previous Nissen|
61917141|NCT04422795|EXPERIMENTAL|External thermomechanical device delivering stimuli|The thermomechanical device is placed on the digit proximally to the injection site with the ice wings frozen and the vibration mechanism switched on.
61917142|NCT04422795|PLACEBO_COMPARATOR|External thermomechanical device without delivering stimuli|The thermomechanical device is placed on the digit proximally to the injection site with the ice wings at room temperature (unfrozen) and the vibration mechanism switched off.
61917143|NCT04422795|ACTIVE_COMPARATOR|Nail injection with ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection immediately before needle insertion
61917144|NCT05384704|EXPERIMENTAL|Internet-based program|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
61917145|NCT03573102|ACTIVE_COMPARATOR|control|ACE inhibitor , aspirin , statins will be given once daily
61917146|NCT03573102|EXPERIMENTAL|cases|SGLT2 inhibitors will be given with classic antiproteinuric drugs
62302273|NCT03425383||Control group|Healthy subject. FMD and c-IMT will be determined by ultrasound
62302274|NCT03099759|ACTIVE_COMPARATOR|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
62302275|NCT03099759|ACTIVE_COMPARATOR|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
62302276|NCT03099759|ACTIVE_COMPARATOR|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
62302277|NCT02277171|EXPERIMENTAL|Nitric oxide impregnated catheter|
62302278|NCT01187225|ACTIVE_COMPARATOR|Fibrinogen concentrate|
62302279|NCT01187225|ACTIVE_COMPARATOR|Cryoprecipitate|
62302280|NCT05293418||ICU mechanically ventilated COVID-19 patients|Patients admitted to Milano Fiera ICU for COVID-19 requiring mechanical ventilation from October 2020 through May 2021
62302281|NCT05621668|EXPERIMENTAL|Part A: Dose Findings (MTD)|The dose of attIL2-T cell therapy the participants will receive will depend on when the participants joined this study. The first group of participants will receive the lowest dose level of attIL2-T cell therapy.
62471304|NCT02296177|NO_INTERVENTION|Control|The control group will receive the standard practice of care related to mammography phone call reminders. If a clinic currently conducts reminders, they will receive that standard call. If no reminders are done, then they will not receive a call during the control period.
62674011|NCT05655572|EXPERIMENTAL|Action Observation therapy|This group will perform exercises in stages. First stage consists of movements to improve balance in sitting position with exercises upright the pelvis, move weight forward, move weight to the left and right and rotate right and left. Second stage consist of sit to stand movements with exercises upright the pelvis in sitting position, move weight forward from a sitting position and stand up from a sitting position. Third stage consist of standing movements to improve balance with exercises move weight right and left, forward weight shift with right foot and left foot (lateral view) and forward weight shift with right foot and left foot (front view). Fourth stage consist of walking side ways to left and then towards right. Therapist will perform these tasks and video will be made which will play in front of patients.
62674012|NCT05655572|ACTIVE_COMPARATOR|Functional Training Group|participants including in this group will perform the tasks including lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor, and stair walking
62674013|NCT05460988|EXPERIMENTAL|Non surgical re-instrumentation|The sites showing remaining pockets (PD\>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
62674014|NCT05460988|ACTIVE_COMPARATOR|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
62674015|NCT03508453|ACTIVE_COMPARATOR|IC14 (monoclonal anti-CD14 antibody)|IC14 4 mg/kg intravenously twice weekly for 12 weeks
62674016|NCT03508453|PLACEBO_COMPARATOR|Placebo|Placebo intravenously twice weekly for 12 weeks
62674017|NCT06293859|PLACEBO_COMPARATOR|Conventional oat flakes-placebo|
62674018|NCT06293859|EXPERIMENTAL|Probiotic oat flakes|
62674019|NCT02303938|EXPERIMENTAL|physical exercise|Patients will exercise three times per week for 6 months home-based exercise intervention. Session duration will vary between 20 minutes and 45 minutes.
62674020|NCT02303938|NO_INTERVENTION|Active control group|Patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl
62674021|NCT06465901|EXPERIMENTAL|Intervention: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower|"Chlorhexidine Gluconate preoperative shower (e.g. hibiscrub)~The participant may prepare themselves by undertaking whole-body disinfection with Chlorhexidine Gluconate.~On two occasions, usually the day before and the day of the operation, the participant, should wash their whole body. Research teams will remind the participant that they must complete the pre-operative washes before they arrive at theatre.~Finally the whole body should be rinsed and dried thoroughly."
62674022|NCT06465901|ACTIVE_COMPARATOR|Comparator: Standard preoperative preparation|Standard of care means whatever pre-operative cleansing is mandated according to local hospital policy.
62674023|NCT06465901|EXPERIMENTAL|Intervention: Intraoperative wound wash (e.g. Granudacyn)|Hypochlorous acid (HOCl) and Sodium hypochlorite (NaOCl) topical wound wash (e.g. Granudacyn)
62674024|NCT06465901|ACTIVE_COMPARATOR|Comparator: Standard intraoperative preparation|Standard of care means whatever irrigation of the wound site is mandated according to local hospital policy.
62674025|NCT06465901|EXPERIMENTAL|Intervention: DACC surgical wound dressing (e.g. Leukomed Sorbact)|Leukomed Sorbact (Essity), is a sterile, single-use, bacteria-binding, adhesive-bordered wound dressing. It is used to prevent SSI in closed surgical wounds that have dry to low exudate.
62674026|NCT06465901|ACTIVE_COMPARATOR|Comparator: Standard post-operative wound care|Standard of care means whatever dressing of the wound site is mandated according to local hospital policy (including no dressing). Centres mandating an active wound dressing will be excluded from the trial.
62674027|NCT00284934|ACTIVE_COMPARATOR|Standard dose EC-MPS|Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
62674028|NCT00284934|EXPERIMENTAL|High EC-MPS|Patients received 1440 mg/day (720 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) tapered to reach a trough blood level target contained between 2 and 4.5 ng/mL within 15 days after randomization at the most. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
62674029|NCT03682393|EXPERIMENTAL|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
62674030|NCT03682393|PLACEBO_COMPARATOR|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
62674031|NCT01128920|EXPERIMENTAL|Skin and Needle Hygiene Intervention|
61917147|NCT02643069|EXPERIMENTAL|Intervention Geriatric Program|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, according to the treating physicians (s) surgeon and the performance of a geriatrician . This management will consist of the therapeutic plan, access to geriatric levels of care, coordination with primary and social care, rehabilitation, and discharge plan.
61917148|NCT02643069|NO_INTERVENTION|Usual clinical practice|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, agreed with the treating physicians (s) surgeon.
61917149|NCT00434239|EXPERIMENTAL|Treatment: Lenalidomide and Ancestim|Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
61917150|NCT05520242|NO_INTERVENTION|Control|No animation
62471305|NCT02296177|ACTIVE_COMPARATOR|Intervention|The intervention group will receive a reminder call about their upcoming appointment that assesses their intent to attend the appointment and counsels them through barriers to attendance. The call is conducted by a trained patient navigator using an adapted NCI RTIP to increase mammography appointment adherence.
62674032|NCT01128920|EXPERIMENTAL|Assessment-Only Condition|
62674033|NCT05538650|EXPERIMENTAL|Mindfulness-based Social Work and Self-care (MBSWSC)|Participants in the experimental group will participate in the 6 session Mindfulness Based Social Work and Self Care (MBSWSC) programme. MBSWSC is facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supported/supplemented with brief homework activities to help embed mindfulness practice.
62674034|NCT05538650|ACTIVE_COMPARATOR|Mindfulness and Self-care (MBSC)|Participants in the active comparator group will participated in the 3 session Mindfulness and Self-care (MBSC) programme. MBSC is facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supported/supplemented with brief homework activities to help embed mindfulness practice.
62471306|NCT01559428|EXPERIMENTAL|Plant sterol-enriched margarine|
61917151|NCT05520242|EXPERIMENTAL|General animation movie|Participants randomized to receive the general animation video
61917152|NCT05520242|EXPERIMENTAL|Men aged 16-24 years|Participants randomized to receive the animation targeted men aged 16-24 years
61917153|NCT05520242|EXPERIMENTAL|Women aged 75 years or older|Participants randomized to receive the animation targeted women aged 75 years or older
62471307|NCT01559428|EXPERIMENTAL|Plant stanol-enriched margarine|
62471308|NCT01559428|PLACEBO_COMPARATOR|Control margarine|
62471309|NCT03466866|EXPERIMENTAL|PREVENT (Preventing and Reducing Emergency Visits in Diabetes through Education and Telehealth)|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
62471310|NCT03466866|ACTIVE_COMPARATOR|EUC (Enhanced Usual Care)|In-home diabetes education with no goal setting or telehealth visits
61917154|NCT05520242|EXPERIMENTAL|Ethnic minorities|Participants randomized to receive the animation targeted ethnic minorities
61917155|NCT04279288|EXPERIMENTAL|participants enrolled with epistaxis and/or nasal fractures|
61917156|NCT04089215|EXPERIMENTAL|JWCAR029 treatment|JWCAR029 be administrated in two dose level
61917157|NCT04420754|EXPERIMENTAL|Cohort -1|AIC100 CAR T Cell Dose Level -1 (Flat Dose): 1 x 10e6 CAR T cells
62302282|NCT05621668|EXPERIMENTAL|Part B: Osteosarcoma Dose Expansion|Participants will receive attIL2-T cell therapy at the recommended dose that was found in Phase 1.
62302283|NCT04802837|EXPERIMENTAL|Ridinilazole|Ridinilazole dosed BID and a comparator placebo dosed QID, to maintain blind, for 40 doses over 10 days.
61917158|NCT04420754|EXPERIMENTAL|Cohort 1|AIC100 CAR T Cell Dose Level 1 (Flat Dose): 1 x 10e7 CAR T cells
61917159|NCT04420754|EXPERIMENTAL|Cohort 2|AIC100 CAR T Cell Dose Level 2 (Flat Dose): 1 x 10e8 CAR T cells
61917160|NCT04420754|EXPERIMENTAL|Cohort 3|AIC100 CAR T Cell Dose Level 3 (Flat Dose): 5 x 10e8 CAR T cells
61917161|NCT04420754|EXPERIMENTAL|Cohort 2.5|AIC100 CAR T Cell Dose Level 2.5 (Flat Dose): 2.5 x 10e8 CAR T cells. The interim step-down dose of Cohort 2.5 may be evaluated, if needed, based on ongoing safety and efficacy data.
61917162|NCT04420754|EXPERIMENTAL|Cohort 4|AIC100 CAR T Cell Dose Level 4 (Flat Dose): 7.5 x 10e8 CAR T cells. The proposed escalation dose of Cohort 4 may be evaluated, if needed, based on ongoing safety and efficacy data.
61917163|NCT04420754|EXPERIMENTAL|Cohort 5|AIC100 CAR T Cell Dose Level 5 (Flat Dose): 1 x 10e9 CAR T cells. The proposed escalation dose of Cohort 5 may be evaluated, if needed, based on ongoing safety and efficacy data.
61917164|NCT02397564|EXPERIMENTAL|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
62302284|NCT04802837|ACTIVE_COMPARATOR|Vancomycin|Vancomycin dosed QID and a Ridinilazole placebo dosed BID, to maintain blind, for 40 doses over 10 days.
62471311|NCT05375604|EXPERIMENTAL|Experimental CDK-004|CDK-004 administered as a single agent intravenously (IV) on Days 1 and 15 of Cycles 1 and 2, on Day 1 of every Cycle.
62471312|NCT01038661|EXPERIMENTAL|First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²|Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
62471313|NCT01038661|EXPERIMENTAL|First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²|Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
62471314|NCT01038661|EXPERIMENTAL|Maintenance treatment: docetaxel (60 mg/m2)|Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
61917165|NCT00358072|EXPERIMENTAL|1|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
62471315|NCT01038661|ACTIVE_COMPARATOR|Maintenance treatment: best supportive care (BSC)|BSC until progressive disease
62471316|NCT02659150|OTHER|Open-Label tocilizumab|tocilizumab will be given to rheumatoid arthritis patients at a dose of 162 mg subcutaneously a week
62471317|NCT02534272||Symptomatic subjects|Subjects with intestinal symptoms
62674035|NCT01554852|ACTIVE_COMPARATOR|Intensive pathway|"The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.~Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):~1. Induction treatment:~   1. CRD regimen - cyclophosphamide, lenalidomide, dexamethasone~  2. CTD regimen - cyclophosphamide, thalidomide, dexamethasone~  3. CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone~2. Consolidation treatment (depending on response to induction treatment):~   1. VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~  2. No consolidation treatment~3. High-dose therapy and stem cell transplant~4. Maintenance treatment:~   1. Lenalidomide maintenance~  2. No maintenance~  3. Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)"
62471318|NCT02534272||Asymptomatic subjects|Subjects without intestinal symptoms
62736097|NCT04461873|PLACEBO_COMPARATOR|Sham Reiki|Four student nurses who did not receive Reiki training and were trained about application by the investigator applied sham by gesturing and mimic imitation through touching 9 points for 45 minutes/week for 6 weeks in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again.
62112503|NCT05829096|EXPERIMENTAL|Intervention arm|"This is a single arm interventional study.~1. A patient-level intervention, which includes:~   * An assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~  * A brief intervention to support health behaviour change with respect to the target behaviours of smoking cessation, increasing physical activity levels and consuming a healthy diet~  * Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring (attached).~   The intervention is to be delivered by physiotherapists, integrated within a routine consultation for people with a RC disorder.~2. A clinician-level implementation toolkit to support the delivery of the clinical intervention, which includes a training package and additional resources e.g. scripts to aid conversations with patients."
62112504|NCT02915055||Patients with pain following knee arthroscopic meniscectomy|
62112505|NCT04680871||Normal, Healthy Subjects|
62112506|NCT04680871||Induced Febrile Subjects|
62471319|NCT04820920|EXPERIMENTAL|LTP+CaCBT|The LTP+CaCBT intervention will consist of 10 (mother-child pairs) participants per sub-group in online group sessions (approx. 60 minutes each) and will deliver one session every fortnight for 12 sessions.
62471320|NCT04820920|ACTIVE_COMPARATOR|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions. The psychoeducation would last approximately 60 minutes each for 12 sessions (10 participants per sub-group). One session would be delivered every fortnight for 12 sessions.
62471321|NCT03251911|EXPERIMENTAL|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
62471322|NCT04062045|EXPERIMENTAL|Group A - Local anesthetic group|Group A will receive a continuous infusion of ropivacaine 0,2% 5ml/h and intermittent boluses of the same local anesthetic 15ml/4h through the erector spinae catheter.
62471323|NCT04062045|PLACEBO_COMPARATOR|Group B - Placebo group|Group B will receive a continuous infusion of 0,9% saline 5ml/h and intermittent boluses of the same fluid 15ml/4h through the erector spinae catheter.
62112507|NCT00939991|EXPERIMENTAL|1|Phase I- Bevacizumab will be administered intravenously every other week. Temozolomide will be administered on a continuous daily dosing schedule. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen.
62112508|NCT00798096|EXPERIMENTAL|1|
62112509|NCT01499654|EXPERIMENTAL|Half-dose radiotracer administration|For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
62302285|NCT05747404||Functional tricuspid regurgitation|Patients with functional tricuspid regurgitation
62471324|NCT00667212|ACTIVE_COMPARATOR|2|Supportive Psychotherapy
62471325|NCT00667212|ACTIVE_COMPARATOR|1|Cognitive Behavioral Therapy (Cognitive Restructuring, Relaxation, and Coping Skills Training: CRCST)
62471326|NCT05609539||AAA patients with a mismatched takeoff of the renal arteries candidated to standard EVAR|Patients suffering to AAA with a mismatched takeoff (\>10mm) of the renal arteries
62471327|NCT02227186|NO_INTERVENTION|Control arm|No school-located influenza vaccination clinic
62471328|NCT02227186|EXPERIMENTAL|School-located influenza vaccination clinics|School-located influenza vaccination clinics
62471329|NCT05514392||Receiving Single Leg Cycling Ergometer Training|First of all, an initial warm-up will be done with 40 watts of exercise intensity for 3 minutes. Exercise will be started with 80 watts of exercise intensity and will be increased by 40 watts every 3 minutes. Cycling cadence will be determined as a pedaling speed of 80 revolutions per minute and patients will be asked to keep their dominant leg on the pedal and keep their non-dominant leg on the ground. The exercise protocol will consist of 2 sets as 15 minutes of exercise + 1 minute of break + 15 minutes of exercise. During the exercise, the heart rate and oxygen saturation of the participants will be monitored by finger pulse oximetry. EMG measurements were taken at the beginning and end of the ergometer training.
62112510|NCT06409949|ACTIVE_COMPARATOR|MitoQ|Participants will be placed on a 24-week regimen of oral dosing with MitoQ. The patients will take two 20 mg caps of MitoQ on empty stomach, each morning
62112511|NCT06409949|PLACEBO_COMPARATOR|Placebo|The patients will take two identical caps of matched placebo on empty stomach, each morning
62112512|NCT04948151|EXPERIMENTAL|Sildenafil Cream, 3.6%|
62112513|NCT04948151|PLACEBO_COMPARATOR|Placebo Cream|
62302286|NCT05747404||Control subjects|Healthy volunteers
62302287|NCT03384043|EXPERIMENTAL|Smartphone Personal Assistant|"Participants will use the personal assistant feature of the smartphone (Cortana) to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state Cortana, I need to remember to... for time--based tasks (...take my medicine at 7pm) and event--based tasks (pick-up milk at the grocery store)."
62302288|NCT03384043|ACTIVE_COMPARATOR|Implementation Intention|"The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a When...then format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks (When it is 7pm, then I will remember to take my medicine), and event--based tasks (When I am at the grocery store, then I will remember to pick--up milk)."
62302289|NCT03946176|EXPERIMENTAL|Symbiotic|HD patients with 7 weeks symbiotic administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
62302290|NCT03946176|PLACEBO_COMPARATOR|Placebo|HD patients with 7 weeks placebo administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
62302291|NCT02843711||Adenocarcinoma|Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
62302292|NCT06137352||Adolescent females who received their first dose of HPV vaccine at 13-14 years|Adolescent females who completed their last dose of domestic bivalent HPV vaccine or imported HPV vaccine and were between 13 and 14 years of age at the time of the first dose. Two follow-up visits were conducted 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of vaccination.
62302293|NCT02596776|ACTIVE_COMPARATOR|Fat biopsy|From each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
62302294|NCT02596776|EXPERIMENTAL|Propranolol and Fat Biopsy|From each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
62112514|NCT01412034|EXPERIMENTAL|CER-001|Open label single arm study of CER-001
62112515|NCT06266858|OTHER|UCG in pre-anaesthetic group|The fasting patients receive UCG in pre-anaesthetic.
62112516|NCT06266858|OTHER|UCG in post-anaesthetic group|The fasting patients receive UCG in post-anaesthetic.
62471330|NCT05514392||Receiving Double Leg Cycling Ergometer Training|First, a 3-minute initial warm-up will be done with an exercise intensity of 40 watts. The workout will begin with an exercise intensity of 80 watts and increase by 40 watts every 3 minutes. Cycling cadence will be determined as a pedaling rate of 80 revolutions per minute and patients will be asked to pedal with both legs. The exercise protocol will consist of 2 sets of 15 minutes of exercise + 1 minute of break + 15 minutes of exercise. During the exercise, the heart rate and oxygen saturation of the participants will be monitored by finger pulse oximetry. EMG measurements were taken at the beginning and end of the ergometer training.
62471331|NCT04438239||Covid-19 discharged|Patients affected by COVID-19 and discharged from hospital wards of the Azienda USL- IRCCS Of Reggio Emilia (Italy).
62471332|NCT01416753|ACTIVE_COMPARATOR|UCR|regulation of ultrafiltration and conductivity
62112517|NCT06266858|OTHER|UCG in post-rehydration group|The fasting patients in anaesthetised receive UCG in post-rehydration.
62112518|NCT06266858|OTHER|cardiac magnetic resonance （CMR） group|The non-fasting patients receive CMR in another time.
62471333|NCT01416753|ACTIVE_COMPARATOR|UTR|regulation of ultrafiltration and temperature
62471334|NCT01416753|NO_INTERVENTION|conventional dialysis|dry weight reduction without BVM
62471335|NCT04413266|ACTIVE_COMPARATOR|Curcumin for CKD|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
62112519|NCT06006091|EXPERIMENTAL|Letrozole-induced endometrial preparation protocol|Starting at D3 of the menstrual cycle, letrozole 2.5 mg po qd was administered for 5 days. After 1 week, ultrasound was performed to dynamically monitor follicular development, and 75-150 IU im qd of human menopausal gonadotrophin (hMG) given to continue ovulation stimulation as needed, and oestradiol valerate 2 mg po qd was given to regulate endometrial thickness until the follicle developed to 16 mm in diameter and 7 mm in endometrial thickness. The follicles developed to ≥16 mm in diameter and ≥7 mm in lining thickness and were dynamically monitored by ultrasound and serum sex hormone levels to determine the day of ovulation. From the day of ovulation, dexamethasone 10 mg po tid was administered, and cleavage-stage embryos were transferred 2 or 3 days later, or blastocysts were transferred 5 days later. Deferiprone 10 mg po tid was continued for 14 days after transfer.
62471336|NCT04413266|PLACEBO_COMPARATOR|Placebo for CKD|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
62471337|NCT05995470|EXPERIMENTAL|DBT-ST group|Participants in the intervention group will receive the DBT-ST by means of a free video-communication app. Over the next 13 weeks from the baseline, the intervention group will receive a weekly 120-minute internet-based DBT-ST focusing on the four modules of DBT-ST.
62674036|NCT01554852|ACTIVE_COMPARATOR|Non-intensive pathway|"The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.~Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:~1. Induction treatment~   1. CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated~  2. CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated~2. Consolidation treatment (depending on participant's response to induction treatment):~   1. VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~  2. No consolidation treatment~3. Maintenance treatment~   1. Lenalidomide maintenance~  2. No maintenance~  3. Lenalidomide plus vorinostat maintenance (\*for participants recruited under Protocol v5.0 only\*)"
62674037|NCT05507216|EXPERIMENTAL|ABX464 50mg|Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks
62674038|NCT05507216|EXPERIMENTAL|ABX464 25mg|Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks
62112520|NCT06006091|NO_INTERVENTION|Natural cycles endometrial preparation protocol|Follicular development was monitored dynamically by ultrasound from D8-D11of the menstrual cycle until the follicles developed to ≥16 mm in diameter and ≥7 mm in endothelial thickness, and the day of ovulation was determined by dynamic ultrasound monitoring and detection of serum sex hormone levels. Deferiprone 10 mg po tid was administered from the day of ovulation, and D2 or D3 cleavage stage embryos were transferred 2 or 3 days later, or blastocysts were transferred 5 days later. Deferiprone 10 mg po tid was continued for a total of 14 days after transfer. Cycles were canceled if endothelial thickness was \<7 mm on the day of ovulation or if serum progesterone levels were 5 nmol/L before ovulation.
62112521|NCT06006091|NO_INTERVENTION|Hormone replacement cycles endometrial preparation protocol|Starting from D1-D5 of the menstrual cycle, estradiol valerate 2 mg po bid was administered for 7 days, followed by ultrasound for dynamic monitoring of endothelial and follicular development, and if the endothelial thickness was \<7 mm, the dosage of estradiol valerate was increased to 3-4 mg po bid as appropriate. The number of days of hormone replacement ranged from 11-20 days, and when the endothelial thickness was 7 mm, luteinizing hormone vaginal slow-release gel 90 mg pv qd was added, as well as dexedrine and progesterone 10 mg po bid to transform the endothelium 2 or 3 days later or 5 days later. Progesterone 10 mg po bid was added to transform the endothelium, and cleavage stage embryos were transferred 2 or 3 days later, or blastocysts were transferred 5 days later. Luteal support as described above was continued for a total of 14 days after transfer.
62302295|NCT02596776|ACTIVE_COMPARATOR|Heavy Water and Fat Biopsy|The investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
62112522|NCT00394381|EXPERIMENTAL|CIK infusion|Infusion of autologous CIK cells in study group. There is only one arm to this study
62112523|NCT00235040|OTHER|1|Intervention
62112524|NCT00235040|NO_INTERVENTION|2|Control
62302296|NCT03195140|EXPERIMENTAL|Intervention Arm|"The intervention arm (use of PLGS feature) will utilize Tandem Diabetes Care's ambulatory insulin infusion pump with integrated Dexcom G5 CGM and predictive low glucose suspend function. This pump is called the t:slim X2 with Basal-IQ Technology and is referred to in the protocol as the Tandem PLGS pump."
62302297|NCT03195140|NO_INTERVENTION|Control Arm|The control arm (SAP only) will utilize an identical pump in functionality as the Tandem PLGS pump except for the lack of the PLGS feature and the associated user interface. This pump is called the t:slim X2 Dexcom G5 Mobile CGM Enabled pump, and is referred to in the protocol as the Tandem SAP pump.
62302298|NCT06519929|EXPERIMENTAL|ESP block with catheter using ropivacaine (bolus followed by continuous infusion)|
62302299|NCT06519929|ACTIVE_COMPARATOR|Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h|
62302300|NCT06519929|NO_INTERVENTION|Standard care with multimodal analgesia and opioids|
62302301|NCT01257971||1|Patients with hypercholesterolaemia
62302302|NCT03359603|EXPERIMENTAL|Group A|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA 3 sessions per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
62302303|NCT03359603|EXPERIMENTAL|Group B|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA once per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
62302304|NCT02286960|ACTIVE_COMPARATOR|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
62302305|NCT02286960|PLACEBO_COMPARATOR|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
62302306|NCT00562419|EXPERIMENTAL|1|CT-322
62302307|NCT00562419|EXPERIMENTAL|2|CT-322 and irinotecan hydrochloride
62302308|NCT01660815|EXPERIMENTAL|Healthy Volunteers|Cognitively normal, healthy volunteers at least 45 years of age.
62112525|NCT03031444|ACTIVE_COMPARATOR|chemotherapy plus cetuximab|Cetuximab plus FOLFIRI/FOLFOX:FOLFIRI plus cetuximab \[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1;Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1;5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.Repeat every 2 weeks.Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks\] or FOLFOX plus Cetuximab \[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1 Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks;Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks\]
62112526|NCT03031444|ACTIVE_COMPARATOR|perioperative chemotherapy alone|FOLFIRI/FOLFOX/CapeOX:routine perioperative chemotherapy including FOLFIRI\[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1 5-FU 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks\] or FOLFOX\[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1;Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks\] or CapeOX\[Oxaliplatin 130 mg/m2 IV over 2 hours, day 1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks\] was adopted in this control arm.
62112527|NCT03119363|EXPERIMENTAL|Experimental Light|The experimental systematic light exposure consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses (AYO) each morning for 4 weeks. The AYO light glasses is a lightweight pair of glasses that emits light from LEDs at a distance of 15 millimeters (15mm, 0.015m) from the eye.
62112528|NCT03119363|ACTIVE_COMPARATOR|Comparison Light|The active comparator condition consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses each morning for 4 weeks.
62112529|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
62112530|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
62112531|NCT06432569|ACTIVE_COMPARATOR|ButirBioma+PeaBioma|Treatment : 3 capsules/day of butyrate (625 mg) + 3 capsules/day PEA (200 mg) at a ratio of dosage of 3/1
62112532|NCT06432569|PLACEBO_COMPARATOR|Placebo|Treatment Placebo :(3+3/day capsules of starch).
62112533|NCT03148990|EXPERIMENTAL|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
62112534|NCT03148990|ACTIVE_COMPARATOR|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
62112535|NCT01552018|ACTIVE_COMPARATOR|Saxagliptin|Saxagliptin 5 mg/day
62302309|NCT01503021|OTHER|SFP/Placebo|Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
62302310|NCT01503021|OTHER|Placebo/SFP|Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
62302311|NCT00467649|EXPERIMENTAL|Group A|
62302312|NCT00467649|ACTIVE_COMPARATOR|Group B|
62302313|NCT01717885||HIV+children on LPV/r|HIV+ children who are stabilized on a LPV/r based ART regimen
62302314|NCT01717885||HIV+ children on nevirapine|HIV+ children who are stabilized on an nevirapine based ART regimen
62302315|NCT01717885||HIV+ children on efavirenz|HIV+ children who are stabilized on an efavirenz based ART regimen
62302316|NCT01717885||HIV+ pregnant women on LPV/r|HIV+ pregnant women who are stabilized on an LPV/r based ART regimen
62302317|NCT01717885||HIV+ pregnant women on NVP|HIV+ pregnant women who are stabilized on an nevirapine based ART regimen
62302318|NCT01717885||HIV+ pregnant women on EFV|HIV+ pregnant women stabilized on an efavirenz based ART regimen
62302319|NCT01717885||HIV negative children|HIV negative children that will serve as a control for HIV positive children on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
62302320|NCT01717885||HIV negative adults|HIV negative adults that will serve as a control for comparing results to HIV negative children and HIV negative pregnant women
62302321|NCT01717885||HIV negative pregnant women|HIV negative pregnant women who will serve as a control for HIV positive pregnant women on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
62302322|NCT03270722|EXPERIMENTAL|patients with scleroderma and trouble swallowing|
62302323|NCT03270722|EXPERIMENTAL|patients with scleroderma but no trouble swallowing|
62302324|NCT03270722|ACTIVE_COMPARATOR|patients without scleroderma undergoing endoscopy|
62302325|NCT02125994|ACTIVE_COMPARATOR|Ropivacaine 0.5%|Ultrasound guided Intercalene nerve block with ropivacaine 0.5 %
62302326|NCT02125994|ACTIVE_COMPARATOR|Ropivacaine 0.375 %|Ultrasound guided Intercalene nerve block with ropivacaine 0.375 %
62471338|NCT05995470|OTHER|TAU group|Participants in the wait list control group will receive a monthly health education for three months that provides general health information and sharing sessions, which is one of the routine care for drinkers during the first 3-4 months after they seek help for drinking problem (waiting period for further intervention).
62471339|NCT00268905|EXPERIMENTAL|1|
62471340|NCT00268905|EXPERIMENTAL|2|
62471341|NCT00268905|EXPERIMENTAL|3|
62302327|NCT00936949|ACTIVE_COMPARATOR|posterolateral approach|The posterolateral approach was described by many authors, but all share a common muscular interval in reference to the gluteus medius tendon. Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
62471342|NCT05729529|ACTIVE_COMPARATOR|Lipoic acid gel|Patients were treated with a topic gel of lipoic acid
62471343|NCT05729529|PLACEBO_COMPARATOR|Placebo|Patients treated with a placebo gel control
62471344|NCT00322439||Etanercept|Participants received etanercept (Enbrel) treatment at the dose and regimen determined by the investigator and were evaluated for up to 5 years at 6-month intervals. During this period, participants may have discontinued etanercept therapy, may have switched to another anti-psoriatic therapy, may have used etanercept in combination with other anti-psoriatic therapies, or may have discontinued any or all antipsoriatic treatments.
62471345|NCT00671320|ACTIVE_COMPARATOR|Arm 1|
62471346|NCT00671320|ACTIVE_COMPARATOR|Arm 2|
62471347|NCT01469650|ACTIVE_COMPARATOR|400 IU/day vitamin D|Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
62471348|NCT01469650|EXPERIMENTAL|800 IU/day vitamin D3|Subjects will receive 800 IU/day vitamin D3
62471349|NCT05241808|NO_INTERVENTION|Control|No-treatment group that only participates in pre- and post-testing.
62471350|NCT05241808|EXPERIMENTAL|Experimental|Experimental group participants will receive the 8-week Girls Can...Move! program.
62471351|NCT05627739||Mycophenolate Mofetil therapy Group|An initial dose of 0.5-1.0g bid MMF was orally administered every day, glucocorticoid was started at a dose of 0.5-0.8 mg/kg/day and no more than 60 mg/day.
62471352|NCT05627739||traditional therapy group|Patients were treated with glucocorticoids alone or glucocorticoids combined with Cyclosporine.
62471353|NCT00882505|EXPERIMENTAL|Vitamin D supplement|Receive vitamin D supplements.
62471354|NCT00882505|PLACEBO_COMPARATOR|Placebo|Receive placebo pills
62471355|NCT00882505|NO_INTERVENTION|Tanning bed user|Regular tanning bed users will be assessed for their vitamin D levels.
62471356|NCT01056666|EXPERIMENTAL|Conveen optima urisheaths|
62471357|NCT01056666|PLACEBO_COMPARATOR|absorbent protections|The patient use their usual absorbent protection as comparator. All brands are allowed.
62471358|NCT03368508|EXPERIMENTAL|Experimental group|the real-object rotatable 3D images were used in demonstrating these three techniques. The photogrammetry technique was used to produce the 3D images.
62112536|NCT01552018|PLACEBO_COMPARATOR|Placebo|Placebo
62471359|NCT03368508|ACTIVE_COMPARATOR|Control group|The control group received similar materials, but the only difference was that all the images were two-dimensional.
62471360|NCT05338047|PLACEBO_COMPARATOR|Generic pegfilgrastim|One 6mg subcutaneous dose of generic pegfilgrastim in day+1 after autotransplant
62471361|NCT05338047|ACTIVE_COMPARATOR|Brand name pegfilgrastim|One 6mg subcutaneous dose of brand name pegfilgrastim in day+1 after autotransplant
62471362|NCT01676974||Travelers|Travelers and their family members
62471363|NCT06311396|EXPERIMENTAL|Neuronal micRoscopy for cEll behaVioural Examination and mAnipuLation|validate the ability of a neuronal microscope to decipher the biomechanism at the origin of liver cancer, especially addressing the problem of biological heterogeneity
62471364|NCT04175366|EXPERIMENTAL|Shared Decision Making|Intervention with Shared Decision Making procedure regarding decision on planning of care and treatment before discharge.
62471365|NCT04175366|NO_INTERVENTION|Care as usual|Discharge planning as usual.
62112537|NCT02158481|ACTIVE_COMPARATOR|Dietary ingredients: polyphenols and carotenoids|Dietary ingredients: polyphenols and carotenoids
62112538|NCT02158481|PLACEBO_COMPARATOR|Placebo product|Placebo product
62112539|NCT03001804||Cohort A|Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr \< 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (\>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
62112540|NCT03001804||Cohort B|Initial treatment (up to 8 cycles): Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr \< 50mg/min) capsule by mouth (PO) on day 1 through 14 of a 21 day cycle, Bortezomib 1.3mg/m2 s.c. on day 1, 4, 8, and 11 of a 21 day cycle, and Dexamethasone 20mg PO on days 1,2,4,5,8,9,11,12 of a 21 day cycle; Successive Treatment: Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr \< 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (\>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
62112541|NCT01835899|EXPERIMENTAL|Placebo to BI 1015550|placebo
62112542|NCT01835899|EXPERIMENTAL|BI 1015550 low dose 1|powder for oral solution
62112543|NCT01835899|EXPERIMENTAL|BI 1015550 low dose 2|powder for oral solution
62112544|NCT01835899|EXPERIMENTAL|BI 1015550 medium dose 1|powder for oral solution
62112545|NCT01835899|EXPERIMENTAL|BI 1015550 medium dose 2|powder for oral solution
62112546|NCT04459988||Patients with MS|Patients with MS who have been newly prescribed Ocrevus
62112547|NCT04459988||Healthy Controls|Healthy Controls
62471366|NCT04848844||Patient transplanted due to ACHD and heart failure|Patients successfully transplanted due to congenital heart failure.
62471367|NCT04848844||ACHD listed due to heart failure for heart or heart and combined organ transplantation|Patients on the actual waiting list for heart or heart and combined organ transplantation. They can have either outcome transplantation or the primary outcome death on the waiting list or delisting due to clinical worsening. The secondary outcome is as well delisting due to clinical improvement.
62471368|NCT04848844||ACHD evaluated for heart transplantation|All patients evaluated for heart or heart and combined organ transplantation at the hospital level
62471369|NCT05198947|ACTIVE_COMPARATOR|Group 1 Permethrin only|Standard regimen of permethrin 5% topical application to be repeated after 1 week.
62471370|NCT05198947|ACTIVE_COMPARATOR|Group 2 Permethrin and Ivermectin|A combination regimen of permethrin 5% topical application with oral ivermectin 200 mcg/kg given on the single day only
62471371|NCT04909190|NO_INTERVENTION|1xIFU|Subjects in this arm are randomized to have a saline flush volume according to the IFU of the used device.
62471372|NCT04909190|EXPERIMENTAL|4xIFU|Subjects in this arm are randomized to have a saline flush volume of 4x of what is stated in the IFU of the used device.
62112548|NCT01952795|ACTIVE_COMPARATOR|Diet and exercise|Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
62112549|NCT01952795|NO_INTERVENTION|No intervention|Usual diet and exercise
62112550|NCT03094767|EXPERIMENTAL|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
62112551|NCT03094767|EXPERIMENTAL|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
62112552|NCT03083405||Opipramol group|Patients diagnosed with SB and opipramol intervention.
62112553|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
62112554|NCT03083405||Healthy controls|Patients without diagnosed SB.
62112555|NCT00954707|PLACEBO_COMPARATOR|12m DAPT Group|
62112556|NCT00954707|ACTIVE_COMPARATOR|30m DAPT Group|
62112557|NCT01204528|ACTIVE_COMPARATOR|Paricalcitol 2 microgram/d|
62112558|NCT01204528|ACTIVE_COMPARATOR|Paricalcitol 1 microgram/d|
62112559|NCT01204528|PLACEBO_COMPARATOR|Placebo|
62112560|NCT05453955|EXPERIMENTAL|Propofol-Remimazolam|General anesthesia was induced and maintained with propofol, then switched to remimazolam after 60 minutes from incision.
62112561|NCT05453955|EXPERIMENTAL|Remimazolam-Propofol|General anesthesia was induced and maintained with remimazolam, then changed to propofol after 60 minutes from incision.
62112562|NCT04604054|EXPERIMENTAL|Group 1|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Granulocyte Colony Stimulating Factor as a treatment.
62112563|NCT04604054|ACTIVE_COMPARATOR|Group 2|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Human Chorionic Gonadotropin as a treatment.
62112564|NCT01377623|PLACEBO_COMPARATOR|Placebo group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
62112565|NCT01377623|EXPERIMENTAL|Dexmedetomidine group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
62112566|NCT06388941|EXPERIMENTAL|Iptacopan|LNP023 administered orally
62112567|NCT06388941|PLACEBO_COMPARATOR|Control|Matching placebo
62112568|NCT00587106||1|One cohort group of patient with PNDS or suspected PNDS
62112569|NCT04009226||Participants with GNE|
62112570|NCT03256812|EXPERIMENTAL|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
62112571|NCT03256812|ACTIVE_COMPARATOR|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
62112572|NCT02864095|EXPERIMENTAL|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
62112573|NCT02864095|EXPERIMENTAL|Topical epinephrine|Topical epinephrine
62112574|NCT02864095|ACTIVE_COMPARATOR|Control|No epinephrine
62112575|NCT05875155||Cryopreservation|Participants will have autologous ovarian tissue cryopreserved for fertility preservation.
62112576|NCT05674370|EXPERIMENTAL|Novel, graphene-based, point-of-care device|Subjects will receive one additional nasal swab at the same time as clinical collection.
62471373|NCT02991404|ACTIVE_COMPARATOR|Continuous adductor canal block|"After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time (Initial bolus) 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.~Multimodal peripheral nerve block injection."
62112577|NCT03749590|EXPERIMENTAL|Magnesium|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate)."
62471374|NCT02991404|SHAM_COMPARATOR|Single injection block with sham cath|Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
62471375|NCT00519194|EXPERIMENTAL|Epicor Cardiac Ablation|
62471376|NCT05926947|EXPERIMENTAL|Verum A|
62471377|NCT05926947|EXPERIMENTAL|Verum B|
62674039|NCT05507216|PLACEBO_COMPARATOR|Placebo|Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks
62674040|NCT02920567|EXPERIMENTAL|octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
62302328|NCT00936949|ACTIVE_COMPARATOR|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
62302329|NCT00942409|EXPERIMENTAL|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10\^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
62302330|NCT00998530||African American HIV+|African American women with HIV and infected with Trichomonas
62302331|NCT00998530||Caucasian HIV-|Caucasian women who are HIV negative and infected with Trichomonas
62302332|NCT00998530||African American HIV-|African American women who are HIV negative and are infected with Trichomonas
62471378|NCT05926947|PLACEBO_COMPARATOR|Placebo|
62674041|NCT02920567|PLACEBO_COMPARATOR|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
62112578|NCT03749590|PLACEBO_COMPARATOR|Placebo (NaCl 0,9%)|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~To each infusion 10 ml NaCl 0.9% (Placebo) will be added ."
62112579|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
62112580|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
62112581|NCT06553989|NO_INTERVENTION|Control group|patients operated for endometriosis without osteopathic visceral mobilization
62112582|NCT06553989|EXPERIMENTAL|Experimental group|patients operated for endometriosis with osteopathic visceral mobilization
62112583|NCT01159249|OTHER|Open Met add-on vildagliptin|
62112584|NCT01159249|OTHER|Open TZD add-on vildagliptin|
62112585|NCT01159249|OTHER|Open α-GI add-on vildagliptin|
62112586|NCT01159249|OTHER|Glinides add-on vildagliptin|
62112587|NCT05127551|ACTIVE_COMPARATOR|iStent Infinite|Subjects implanted with iStent Infinite system
62112588|NCT05127551|ACTIVE_COMPARATOR|Competitor Device|Subject implanted with competitor device
62302333|NCT04146688|ACTIVE_COMPARATOR|Patients with neurodegenerative disease|Patients with neurodegenerative disease (AD or related disease)
62302334|NCT04146688|ACTIVE_COMPARATOR|People with no neuropathological disease|
62302335|NCT01214525||Meatotomy|Toilet trained children scheduled for urethral meatotomy for the treatment of urethral meatal stenosis.
62302336|NCT01656239|EXPERIMENTAL|fedovapagon 1 mg|Once daily oral dose of 1 mg fedovapagon for 12 weeks
62302337|NCT01656239|EXPERIMENTAL|fedovapagon 2 mg|Once daily oral dose of 2 mg fedovapagon for 12 weeks
62302338|NCT01656239|EXPERIMENTAL|fedovapagon 4 mg|Once daily oral dose of 4 mg fedovapagon for 12 weeks
62302339|NCT01656239|PLACEBO_COMPARATOR|sugar pill|Once daily oral dose of placebo for 12 weeks
62302340|NCT04573959|EXPERIMENTAL|SV-3 Capsule Endoscopy|CapsoCam SV-3 Capsule Endoscopy system will perform in a manner consistent with the performance of the CapsoCam SV-3 capsule endoscopy systems.
62302341|NCT05812716|EXPERIMENTAL|Intervention|"Participants in the intervention group will gain access to the 6-week online resilience intervention resiLIR Healthcare Professionals."
62302342|NCT05812716|NO_INTERVENTION|Waitlist control group|Participants will receive the intervention after the first follow up-assessment (3 months post-intervention of the intervention group).
62471379|NCT01513954||IVF population|Long Lupron IVF Population
62302343|NCT02801175||RF|Patients with paroxysmal atrial fibrillation slated for radiofrequency pulmonary vein isolation
62302344|NCT02801175||Cryoballoon|Patients with paroxysmal atrial fibrillation slated for cryoballoon pulmonary vein isolation
62302345|NCT02111811|EXPERIMENTAL|Be Well At Work intervention + IC|CBT based intervention focused on work productivity plus integrated care as usual
62302346|NCT02111811|NO_INTERVENTION|Integrated Care Only|usual care group (Behavioral Health lab care at the PVAMC)
62471380|NCT01513954||IUI patients|Patients undergoing IUI
62471381|NCT02682238|EXPERIMENTAL|BBI-4000, 15%|15% BBI-4000 (sofpironium bromide) topical gel
62471382|NCT02682238|PLACEBO_COMPARATOR|Vehicle|Vehicle (placebo) gel
62471383|NCT05046860|EXPERIMENTAL|Dalbavancine + Rifampicine|
62674042|NCT05414942|NO_INTERVENTION|Treatment As Usual (TAU)|No intervention will be administered.
62674043|NCT05414942|EXPERIMENTAL|Opioid Reduction Program|Participants will engage in a brief, educational intervention pre-surgery and a brief booster session 2 weeks post-surgery.
62674044|NCT02334410|NO_INTERVENTION|Reference|
62674045|NCT02334410|EXPERIMENTAL|Whole body vibration (WBV)|Vibration therapy
62674046|NCT05085405|EXPERIMENTAL|Clinician Notification only|
62674047|NCT05085405|EXPERIMENTAL|Clinician Notification with Nurse Facilitation only|
62674048|NCT05085405|EXPERIMENTAL|Clinician Notification / Patient Activation|
62674049|NCT05085405|EXPERIMENTAL|Clinician Notification with Nurse Facilitation / Patient Activation|
62674050|NCT00378560|PLACEBO_COMPARATOR|1|Placebo
62674051|NCT00378560|EXPERIMENTAL|2|Vaccine
61917166|NCT05176561|EXPERIMENTAL|Treatment: Auditory-Cognitive Training|Behavioral: AR Group will complete sessions in their home or office via internet. Sessions will include independent work using computer software two hours per week and one hour meeting with the clinician each week. One half of the training is devoted to auditory training and one half to auditory cognitive activities. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
62302347|NCT04243759|EXPERIMENTAL|Control App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
62302348|NCT04243759|EXPERIMENTAL|Standard App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
62302349|NCT04243759|EXPERIMENTAL|Experimental, Feedback App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
62471384|NCT04839276|EXPERIMENTAL|Injection Laryngoplasty with PRF and Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is added to 4 mL of PRF and is smoothed by pushing it back and forth 15 times on a 2-tube 10 mL piston tube connected to a three-way connector. 3 mL of the mixture of fat and PRF is injected using a 12 G laryngoplasty syringe until medialization is achieved.
62471385|NCT04839276|ACTIVE_COMPARATOR|Injection Laryngoplasty with Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is mashed by pushing it back and forth 15 times in a container of 2 piston tubes (10 mL) connected to a three-way connector. The crushed fat is injected as much as 3 mL using a 12 G laryngoplasty syringe until medialization is achieved.
62471386|NCT04004676|ACTIVE_COMPARATOR|Placebo|isocaloric carbohydrate - only containing drink will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
61917167|NCT05176561|SHAM_COMPARATOR|Control: Non-auditory Cognitive Training|Behavioral: The CT Group will complete two hours of training in their home or office via internet. Sessions will include independent work using computer software two hours per week. Training exercises will be chosen from: Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Differences. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
61917168|NCT01525173|ACTIVE_COMPARATOR|ALPHAGAN® P and LUMIGAN®|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
62302350|NCT03026803|EXPERIMENTAL|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
62302351|NCT01960686|EXPERIMENTAL|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
62302352|NCT01960686|EXPERIMENTAL|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
62302353|NCT01960686|EXPERIMENTAL|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
62302354|NCT01960686|EXPERIMENTAL|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
62302355|NCT01960686|EXPERIMENTAL|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
62302356|NCT01960686|EXPERIMENTAL|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
62302357|NCT01960686|EXPERIMENTAL|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
62302358|NCT01960686|PLACEBO_COMPARATOR|Placebo|Day 0: Placebo Day 28: Placebo
62302359|NCT03590457|OTHER|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
62302360|NCT04644900|ACTIVE_COMPARATOR|the Mouthwash group|Patients in the mouthwash group received 15 ml of honeysuckle antibacterial mouthwash and vomited it out after 2 minutes
62302361|NCT04644900|ACTIVE_COMPARATOR|the gum group|patients in group gum chewed one piece of herbal sugar-free gum for 2 minutes and then spat it out.
62302362|NCT03473262||EMPA|Empagliflozin 25 mg/day
62302363|NCT03473262||INS|Insulin Glargine dose-titrated
62302364|NCT03304457|ACTIVE_COMPARATOR|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
62302365|NCT03304457|EXPERIMENTAL|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
62302366|NCT04599309||PRE-MERIDIAN|Patients with a histological or cytological diagnosis of LA-HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx (stage III HPV positive or stage III-IV HPV negative). Patients who are candidates for standard definitive treatment such as surgery followed by radiotherapy +/- chemotherapy, or definite radiotherapy, or definite chemoradiotherapy.
62302367|NCT04352829|EXPERIMENTAL|EXPERİMENTAL GROUP|1st day, patients were asked to use an MDI sample that didn't contain an active agent. At the same time, they filled the MDI Skill Evaluation Form, obtaining 'the scores of the 1st measurement'. Next, MDI use was explained through the video twice. After each video and explanation, the patients were asked to use the same MDI sample for 10 min. Simultaneously, the skills were marked by the researcher through observation on the form, obtaining 'the scores of the 2nd measurement'. 2nd day, they were again asked to use the MDI. While using the MDI, the form was marked and 'the scores of the 3rd measurement' were found. Later, a video session was held as on the 1st day, the video was watched twice, and after each repetition, were requested to use the MDI again. While they were using the MDI, the skills were simultaneously marked on the form and 'the scores of the 4th measurement were determined. 3rd day, all steps were repeated.
62471387|NCT04004676|EXPERIMENTAL|Ketone_CHO|Ketone - Carbohydrate supplementation will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
62471388|NCT00428298|EXPERIMENTAL|Active Treatment Valacyclovir|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
62112589|NCT03915613|EXPERIMENTAL|Insulin|"Intranasal insulin will be made prepared from Humulin® R \[insulin injection, human biosynthetic (rDNA Origin) REGULAR; 10 mL/vial, manufactured by Eli Lilly\]. Each mL contains: 100 units of insulin injection, human biosynthetic (rDNA Origin) REGULAR. Nonmedicinal ingredients contain: glycerol, hydrochloric acid, m-cresol, sodium hydroxide and water for injection.~Unopened vials should be stored under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials should be stored at room temperature \<25°C (\<77°F) and discarded after 28 days.~To obtain a dose Humulin R 160 U / placebo~* 16 sprays (0.1 mL/spray) are to be given per dose~* This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.~* The sprays will be administered between alternating nostrils"
62471389|NCT00428298|PLACEBO_COMPARATOR|Placebo Treatment|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
62471390|NCT04394962|NO_INTERVENTION|Control group|Patients who will be randomized to the control group will be waiting for the ET procedure without any intervention and without any deviation from the standard of care
62471391|NCT04394962|EXPERIMENTAL|Study group|Exposure to virtual reality environment exposure
62471392|NCT01349374|EXPERIMENTAL|Group1|healthy volunteers
62471393|NCT01349374|EXPERIMENTAL|group2|Unaffected siblings of MODY patients
62471394|NCT01349374|EXPERIMENTAL|Group3|Type2 Diabetic patients
62471395|NCT01349374|EXPERIMENTAL|Group4|MODY patients
62471396|NCT03804983|ACTIVE_COMPARATOR|Hybrid Closed Loop (HCL)|Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ with Hybrid Closed Loop (HCL) or the Control-IQ with MyTDI. Participants randomized to Control-IQ, participants will continue using their home insulin parameters during the ski admission and then 5 additional days at home.
62471397|NCT03804983|EXPERIMENTAL|Control-IQ with MyTDI|"Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ or the Control-IQ with MyTDI. Participants randomized to Control-IQ with MyTDI, participants will be adjusted as noted below during the ski admission and will then continue these parameters for 5 additional days at home:~* A single basal rate equal to total daily insulin (TDI)/48 will be implemented across the whole day~* A single correction factor (CF) of 1650/TDI will be implemented across the whole day~* Carbohydrate ratios (CR) will be set at:~  * 00:00-04:00 CR=450/TDI~ * 04:00-11:00 CR=360/TDI~ * 11:00-00:00 CR=450/TDI TDI will be set at the internal Control-IQ estimation total daily dose; if not available, total daily dose over the last 5 days will be used."
62674052|NCT04168138|EXPERIMENTAL|Newly diagnosed AML in elderly patient|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when WBC\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
62674053|NCT01166945|PLACEBO_COMPARATOR|Short Course|Short course (5 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination and placebo for next 9 days.
62112590|NCT03915613|PLACEBO_COMPARATOR|Sterile Diluent|"Intranasal placebo will be prepared from Eli Lilly's sterile diluent used with Humulin® R (10 mL/vial, manufactured by Eli Lilly). Nonmedicinal ingredients contain: dibasic sodium phosphate, glycerin, liquefied phenol, metacresol, hydrochloric acid, sodium hydroxide and water for injection.~Unused sterile diluent should be kept at controlled room temperature until the expiration date. The USP defines controlled room temperature as (20° to 25°C \[68° to 77°F\]), with excursions permitted (15° to 30°C \[59° to 86°F\]). Once in-use, the sterile diluent vial should be used within 28 days.~Participants will follow the same dosage, frequency, and administration as Humulin:~* 16 sprays (0.1 mL/spray) are to be given per dose~* This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.~* The sprays will be administered between alternating nostrils"
62112591|NCT02763124|EXPERIMENTAL|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions.
62471398|NCT02190929||Vasculitis Contact Registry Patients|Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC) Patient Contact Registry to participate in an online questionnaire. More than 3000 patients, representing all the different types of idiopathic vasculitis, are currently enrolled into the on-line registry. The different types of vasculitis available for study include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis, granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.
62112592|NCT05069935|EXPERIMENTAL|Dose Escalation|"* Cohort A: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved~* Cohort B: FT538 plus trastuzumab in subjects with advanced documented HER2+ tumors~* Cohort C: FT538 plus cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell carcinoma (HNSCC)"
62471399|NCT04741620|ACTIVE_COMPARATOR|Capsaicin 10microM|10mL capsaicin 10microM solution 3 times/day during 14 consecutive days (2 weeks).
62471400|NCT04741620|ACTIVE_COMPARATOR|Piperine 150microM|10mL Piperine 150microM solution 3 times/day during 14 consecutive days (2 weeks).
62112593|NCT05069935|EXPERIMENTAL|Dose Expansion|"* Cohort A, Arm 1: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved (except urothelial carcinoma (UC))~* Cohort A, Arm 2: FT538 plus an anti-PD-1 antibody (nivolumab or pembrolizumab) in subjects with solid tumor malignancies where anti-PD-1/PD-L1 antibodies are approved (except UC)~* Cohort B, Arm 1: FT538 plus trastuzumab in subjects with HER2+ tumors~* Cohort C, Arm 1: FT538 plus cetuximab in subjects with advanced CRC or HNSCC~Subjects with UC may be enrolled in the randomized expansion cohorts as follows:~* Cohort A, Arm R1: FT538 plus avelumab~* Cohort A, Arm R2: FT538 plus atezolizumab"
62471401|NCT04741620|ACTIVE_COMPARATOR|Cinnamaldehyde 756,6microM + zinc 70microM|10mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
62471402|NCT04741620|ACTIVE_COMPARATOR|Citric acid 457,5microM (pH=3,5)|10mL Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
62471403|NCT04741620|ACTIVE_COMPARATOR|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5)|10mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
62471404|NCT04741620|PLACEBO_COMPARATOR|Placebo|10mL placebo solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
62112594|NCT02275325|EXPERIMENTAL|Preoperative rehabilitation|Patients that have a preoperative vestibular rehabilitation before vestibular schwannoma surgery in addition to the usual postoperative vestibular rehabilitation
62112595|NCT02275325|NO_INTERVENTION|Usual|Group of patients that solely have a postoperative vestibular rehabilitation after vestibular schwannoma surgery
62112596|NCT04168619||Transient elastography (TE)|All patients who had MTX taken
62112597|NCT04168619||Two dimensional shear wave elastography (2D SWE)|For patients who has cumulative more than 3.5g methotrexate
62112598|NCT04168619||Liver biopsy|For patients who has cumulative more than 3.5g methotrexate and had 2D SWE done
62112599|NCT02850055|EXPERIMENTAL|Specific Manual Therapy Group|Conventional Physiotherapy and Specific manual therapy, six one hour treatment sessions. An hour for week.
62112600|NCT02850055|ACTIVE_COMPARATOR|Multimodal Group|Conventional Physiotherapy, six one hour treatment sessions. An hour for week.
62112601|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
62112602|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
62112603|NCT00982033|ACTIVE_COMPARATOR|Aliskiren|50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.
62112604|NCT00982033|PLACEBO_COMPARATOR|Placebo|50% of subjects will be randomized to placebo.
62112605|NCT05899335|EXPERIMENTAL|SmartCP app|The SmartCP app is provided to patients to assist in the management of chronic pancreatitis for 16 weeks
62112606|NCT00853827|PLACEBO_COMPARATOR|1|
62112607|NCT00853827|EXPERIMENTAL|2|Aliskiren 300 mg
62112608|NCT00327665|EXPERIMENTAL|Group A|
62112609|NCT00327665|EXPERIMENTAL|Group B|
62112610|NCT00327665|EXPERIMENTAL|Group C|
62112611|NCT00327665|ACTIVE_COMPARATOR|Group D|
62112612|NCT00327665|ACTIVE_COMPARATOR|Group E|
62112613|NCT00415389|ACTIVE_COMPARATOR|1|interactive educational program
62112614|NCT00415389|ACTIVE_COMPARATOR|2|usual medical care
62471405|NCT02553044|EXPERIMENTAL|50 000IU Vitamin D3|50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
62471406|NCT02553044|EXPERIMENTAL|150 000IU Vitamin D3|150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
62471407|NCT02553044|EXPERIMENTAL|500 000IU Vitamin D3|500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
62471408|NCT02553044|NO_INTERVENTION|Concurrent Control|Control group to receive no intervention.
62471409|NCT05976386|EXPERIMENTAL|New dupilumab product|A single subcutaneous injection on Day 1
62112615|NCT02426320|ACTIVE_COMPARATOR|Sedation Interruption Protocol + standard sedation protocol|Nurse directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
62112616|NCT02426320|ACTIVE_COMPARATOR|Standard sedation protocol|Nurse directed protocol for administering sedation and/or analgesia.
62112617|NCT00541606|EXPERIMENTAL|Intervention|Received collaborative care including a clinical pharmacist practitioner.
62112618|NCT00541606|ACTIVE_COMPARATOR|Control|Patients received usual care directed by their physician.
62112619|NCT03469154|EXPERIMENTAL|Dyad training|The participants in this arm will train in teams of two. Participants will be instructed in paediatric basic life support by instructional videos in a computer programme and train on children resuscitation manikins. Training involves recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management. The training involves series of short video clips and following exercises. Each participant performs the exercise and the other gives feedback. Afterwards roles are changed. The procedure is done for all exercises after a video clip. The duration of the training is maximum 50 minutes
62302368|NCT04352829|NO_INTERVENTION|CONTROL GROUP|20 patients were recruited to the control group. The controls received a routine training on MDI from their clinic nurses including verbal explanation of MDI use. The controls received training about MDI use in line with ethical principles and watched the video once after the 5th measurement. After the study, participants who wished to watch the training video again were provided internet links.
62302369|NCT05910827|EXPERIMENTAL|Arm A|Participants receive HMBD-001 with docetaxel. This treatment arm is closed to recruitment.
62112620|NCT03469154|ACTIVE_COMPARATOR|Instructor led training|"Participants train in courses of up to 6 participants with an instructor. Training content is identical to dyad training content involving: recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management.~Skills are instructed by an instructor using af 4 step approach (1. show skills, 2. show with explanation, 3. participants instruct instructor, 4. participants performs the skills on resuscitation manikins). Training is maximum two hours but course duration is adjusted to number of participants two allow for similar hands-on time per participant as in the experimental arm."
62302370|NCT05910827|EXPERIMENTAL|Arm B|Participants receive HMBD-001 with docetaxel plus cetuximab
62302371|NCT05910827|EXPERIMENTAL|Arm C|Participants receive HMBD-001 with cetuximab
62302372|NCT00339573||National Housing Stock|The target population of this study was the national housing stock (1998-1999) ofapproximately 95 million housing units.
62302373|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
62302374|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
62302375|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
62674054|NCT01166945|ACTIVE_COMPARATOR|Long Course|Long course (14 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination given orally for 14 days.
61917169|NCT01525173|ACTIVE_COMPARATOR|LUMIGAN® Alone|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
62302376|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
62302377|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
62302378|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
62471410|NCT05976386|ACTIVE_COMPARATOR|Current dupilumab product|A single subcutaneous injection on Day 1
62471411|NCT05512442|EXPERIMENTAL|record the centric relation using the gothic tracing method|the vertical dimension of occlusion (VDO) were were determineded through facial appearance observation,thus,the patients were trained to execute bordering protrusive, retrusive and bilateral lateral-protrusive movements wearing the intraoral apparatus and a Gothic Arch Tracing was made, the apex of the Gothic Arch Tracing was defined as the gothic arch position.
62674055|NCT01805570|ACTIVE_COMPARATOR|Prasugrel loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI.
62674056|NCT01805570|ACTIVE_COMPARATOR|Ticagrelor loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI.
62674057|NCT00854854|NO_INTERVENTION|Control|"* Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)~* 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16~* LV infusions (200 mg/m2) on days 1, 2, 15 and 16"
61917170|NCT01209832|EXPERIMENTAL|Drug Interaction arm|
61917171|NCT02782078|OTHER|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
61917172|NCT05543434|EXPERIMENTAL|hyaluronic acid|Application of crosslinked HA gel in pockets after subgingival debridement immediately and one week after.
62112621|NCT02207075||Subjects with SPMS|"Secondary progressive MS Subjects either untreated or on consistent treatment for six months prior to enrollment.~SPMS subjects will have two baseline \[11C\]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months."
62302379|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
62674058|NCT00854854|ACTIVE_COMPARATOR|Active|"Infusion of TKCell(autologous activated lymphocyte) over 2x10\^9 cells, IV route, 7 times~and chemotherapy schedule"
62112622|NCT02207075||Normal Control Subjects|Healthy Controls will have 2 baseline \[C11\]PK-1195 PET scans and 1 MRI.
62302380|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
62674059|NCT00928005|ACTIVE_COMPARATOR|Weight loss diet|Participants will follow a low-calorie, low-fat weight loss diet for 6 months.
62674060|NCT00928005|ACTIVE_COMPARATOR|Weight loss diet plus exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
62471412|NCT05512442|EXPERIMENTAL|record the centric relation using the neuromuscular method|the participant were subjected to a low-frequency transcutaneous electrical nerve stimulation (TENS) using the J5 Myotronics for 45 minutes,With the help of TENS, complete relaxation of the muscles were achieved and the mandibular musculature was induced to guide the mandible in the physiologic position,thus using K7 to track the physical mandibular positon which was defined as the neuromuscular position.
62471413|NCT01395563|EXPERIMENTAL|1|pancreatic cancer patients
62471414|NCT01395563|EXPERIMENTAL|2|pancreatic cancer patients
62471415|NCT00609674|EXPERIMENTAL|fluticasone furoate nasal spray|
62471416|NCT00609674|PLACEBO_COMPARATOR|Placebo|
62471417|NCT03382925|ACTIVE_COMPARATOR|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
62112623|NCT02834182|EXPERIMENTAL|Bipolar Disorder patients and Schizophrenic patients|
62471418|NCT03382925|ACTIVE_COMPARATOR|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
62471419|NCT04471610|NO_INTERVENTION|Control group|Group A: Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. The diagnostic and therapeutic decisions in the control Group and in the Intervention group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.
62674061|NCT03622931|EXPERIMENTAL|the experimental arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
62674062|NCT03622931|PLACEBO_COMPARATOR|the placebo arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + placebo once per week for up to 4 cycles
62674063|NCT02425176|ACTIVE_COMPARATOR|Botulinum toxin A (BoNT-A) 50U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline.~2. Prepare in 1 ml syringe to get 50U/ml :0.1 ml drawn from the mother solution and add 0.9 ml of 0,9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 50U are divided equally into 4 salivary glands, 12.5U each gland"
61917173|NCT05543434|ACTIVE_COMPARATOR|scaling and root planing|scaling and root planing using ultrasonic scaler and hand instruments.
61917174|NCT04500275|EXPERIMENTAL|Vancomycin group|"i. Timing of application: the Vancomycin (China Chemical \& Pharmaceutical Co., Ltd., CCPC, Taiwan R.O.C.) paste will be spread on sternal edge immediately after sternotomy and before sternal closure.~ii. Regimen: The Vancomycin paste will be prepared using 2.5 g of Vancomycin powder mixed with 2 ml normal saline for each time. A total of 5 g of Vancomycin powder will be applied during the cardiac surgery."
61917175|NCT04500275|PLACEBO_COMPARATOR|Placebo group|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure.
62112624|NCT02834182|ACTIVE_COMPARATOR|Healthy Controls|
62112625|NCT02435199|EXPERIMENTAL|EMA401 600mg|2 X 150mg BID
62112626|NCT02435199|PLACEBO_COMPARATOR|Placebo|Placebo to match, 2 capsules BID
62112627|NCT05911750||Male IBD patients|Male patients with a confirmed diagnosis of Inflammatory Bowel Disease (Crohn´s disease or Ulcerative colitis).
62112628|NCT05907720|EXPERIMENTAL|Intervention Arm|The intervention arm will receive a package of behavioral interventions in addition to usual care in health facilities.
62112629|NCT05907720|NO_INTERVENTION|Control Arm|The control arm will not receive any intervention other than usual care.
62112630|NCT04680741|EXPERIMENTAL|Addiction Pilot App|"Patients in this arm will be asked to use an application that works by allowing patients to check in to meetings and tracks patients' location for a period of 90 days.~Patients will be asked to download the application to their smart phone. At each of patients' usual meetings we will ask patients to check in and check out of the meeting via the App. At the conclusion of this study patients may be invited to participate in a focus group."
62112631|NCT01949740||Observational (patient preferences)|Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.
62112632|NCT06432842|ACTIVE_COMPARATOR|Conventional treatment|Within the scope of conventional treatment, individuals were given Transcutaneous Electrical Nerve Stimulation (TENS), infrared, US and exercise therapy.
62112633|NCT06432842|ACTIVE_COMPARATOR|Laser treatment|In the study group, low-dose laser treatment was applied in addition to conventional treatment. Therapeutic Laser device was used for laser treatment. Laser treatment was applied to 8 sensitive points around the knee for 1 minute, for a total of 8 minutes.
62112634|NCT02865733|EXPERIMENTAL|Remodulin Injection|Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
62112635|NCT02865733|PLACEBO_COMPARATOR|Distilled water group|Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours
62112636|NCT03864055||Pediatric Otogenic CSVT|Children with Otogenic Cerebral Sinus Vein Thrombosis (CSVT)
62112637|NCT04296513||High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white-light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.
62112638|NCT04296513||High-definition magnification with digital chromoendoscopy.|The subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
62471420|NCT04471610|EXPERIMENTAL|POC-available group|Group B:Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The blood collection (10 ml of Lithium Heparin blood) for these tests will be done in the morning together with the regularly blood collection. The study team does the the analysis on the study devices. The result of the test will be provided directly to the responsible physician. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.
62471421|NCT04459260|EXPERIMENTAL|Cognitive Behavior Therapy|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on cognitive behavior therapy and includes both cognitive interventions, e.g., cognitive restructuring and behavioral experiments, and behavioral interventions, behavioral activation. The treatment was manualized by Egan et al. (2016) and has been tested in several clinical trials, both via the Internet and face-to-face.
62471422|NCT04459260|ACTIVE_COMPARATOR|Unified Protocol|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on a transdiagnostic approach derived from cognitive behavior therapy called Unified Protocol, focusing on the shared emotional aspects underlying depression and anxiety disorders. The treatment was manualized by Ellard et al. (2010) and has been tested in several clinical trials, but so far not over the Internet.
62471423|NCT02412852|PLACEBO_COMPARATOR|Placebo|One placebo tablet administered twice daily for 12 weeks.
62471424|NCT02412852|ACTIVE_COMPARATOR|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
62471425|NCT02412852|PLACEBO_COMPARATOR|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
62302381|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
62302382|NCT03426046|EXPERIMENTAL|Biodentine|Partial pulpotomy treatment with Biodentine
62302383|NCT03426046|ACTIVE_COMPARATOR|Calcium Hydroxide|Partial pulpotomy treatment with Calcium Hydroxide
62302384|NCT03426046|EXPERIMENTAL|Mineral Trioxide Aggregate|Partial pulpotomy treatment with Mineral Trioxide Aggregate
62302385|NCT05978453||Subject use both BP7 Wrist Automatic Electronic BPM and mercury sphygmomanometers|
62302386|NCT02215681|EXPERIMENTAL|acupuncture|acupuncture treatment
62471426|NCT02412852|ACTIVE_COMPARATOR|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
62471427|NCT04280263|ACTIVE_COMPARATOR|Caffiene|This group will receive 150mg caffeine tablets to be taken twice per day
62471428|NCT04280263|PLACEBO_COMPARATOR|placebo|
62112639|NCT00276250|EXPERIMENTAL|Efalizumab Followed by Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at \< 40 years of age and insulin-dependence for \> 5 years received efalizumab-based immunosuppression regimen after islet-cell transplantation. During the course of the study, efalizumab was withdrawn from the US market due to safety concerns. The protocol was subsequently amended to alter the immunosuppressive regimen to abatacept for these participants.
62112640|NCT00276250|EXPERIMENTAL|Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at \< 40 years of age and insulin-dependence for \> 5 years received abatacept immunosuppresion regimen after islet-cell transplantation.
62302387|NCT02215681|NO_INTERVENTION|standard treament|watchful waiting
62112641|NCT00276250|EXPERIMENTAL|Belatacept Regimen|Participants with Type 1 diabetes with onset of disease at \< 40 years of age and insulin-dependence for \> 5 years received Belatacept immunosuppresion regimen after islet-cell transplantation.
62302388|NCT05483127|OTHER|P1fA, then MDT|Verofilcon A toric soft contact lenses worn first, followed by stenfilcon A toric soft contact lenses, as randomized. Each study lens type will be worn for 8 (-0/+3) days for at least 10 hours per day. Lenses will be removed nightly and disposed of after a single use.
62302389|NCT05483127|OTHER|MDT, then P1fA|Stenfilcon A toric soft contact lenses worn first, followed by verofilcon A toric soft contact lenses, as randomized. Each study lens type will be worn for 8 (-0/+3) days for at least 10 hours per day. Lenses will be removed nightly and disposed of after a single use.
62302390|NCT02167061|EXPERIMENTAL|(Part 1) DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
62302391|NCT02167061|EXPERIMENTAL|(Part 1) E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
62302392|NCT02167061|EXPERIMENTAL|(Part 2) DA-1229_01 fast → fed|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
62302393|NCT02167061|EXPERIMENTAL|DA-1229_01 fed → fast|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
62302394|NCT00761540|EXPERIMENTAL|A1|
62302395|NCT00761540|PLACEBO_COMPARATOR|A2|
62302396|NCT00761540|EXPERIMENTAL|B1|
62302397|NCT00761540|PLACEBO_COMPARATOR|B2|
62471429|NCT02778815|EXPERIMENTAL|Kindness for Mums|An online self-help course designed to promote self-kindness and self-compassion in new mothers
62471430|NCT02778815|NO_INTERVENTION|Wait list control|A waiting list control group, who will receive access to the online self-help intervention once the RCT is complete.
62471431|NCT04907786||Study population|All patients eligible for participation in this registry are aged 18-80 years old and undergoing invasive coronary angiography because of abnormalities found on CCTA in either the left or right coronary artery and no or minimal stenosis (CAD-RADS 0-1; 0-24% stenosis) in the contralateral coronary artery. Patients will be asked for written informed consent to register their clinical data in an anonymized database. The period between CCTA and ICA may not exceed 90 days, in order to prevent possible aggravation of coronary artery disease between both examinations.
62471432|NCT05080322|EXPERIMENTAL|on-demand intranasal corticosteroid (INS) plus antihistamines (AH1)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) plus antihistamines (AH1) for 4 weeks
62302398|NCT00761540|EXPERIMENTAL|C1|
62302399|NCT00761540|PLACEBO_COMPARATOR|C2|
62302400|NCT05502588|ACTIVE_COMPARATOR|Self-Guided Forest Bathing|Forest Bathing intervention without a guide and basic navigational instructions, explanation of forest bathing, and time to return.
62302401|NCT05502588|EXPERIMENTAL|Guided Forest Bathing|Forest Bathing intervention led by a certified Forest Therapy guide.
62302402|NCT03215277|EXPERIMENTAL|Bimekizumab|Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
62302403|NCT03215277|EXPERIMENTAL|Certolizumab pegol|Subjects will receive several certolizumab pegol administrations on pre-defined time points.
62674064|NCT02425176|ACTIVE_COMPARATOR|Botulinum toxin A (BoNT-A) 100U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 100U/ml :0.2 ml drawn from the mother solution and add 0.8 ml of 0.9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 100U are divided equally into 4 salivary glands, 25U each gland"
62674065|NCT02425176|ACTIVE_COMPARATOR|Botulinum toxina A (BoNT-A) 200U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum ToxinA Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 200U/ml :0.4 ml is drawn from the mother solution and 0.6ml of 0.9% saline is added. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 200U are divided equally into 4 salivary glands, 50U each gland"
62302404|NCT03898570||Patients undergoing vascular surgery procedures|Patients will report outcomes via their smartphone.
62471433|NCT05080322|EXPERIMENTAL|on-demand intranasal corticosteroid (INS)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) for 4 weeks
62674066|NCT03335267|EXPERIMENTAL|CPX-351 (Cytarabine:Daunorubicin) Injection|"Dosing for first induction: CPX-351~• CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5~Dosing for second induction:~• CPX-351 at 100 u/m2 will be administered on days 1 and 3~Dosing for consolidation:~• CPX-351 at 65 u/m2 will be administered on days 1 and 3"
62674067|NCT00743262|EXPERIMENTAL|Provox voice prosthesis|
62302405|NCT00800072|EXPERIMENTAL|oxygen therapy|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
62302406|NCT06198257|ACTIVE_COMPARATOR|group A|Spider cage therapy along with strengthening exercises
62471434|NCT05080322|ACTIVE_COMPARATOR|maintenance intranasal corticosteroid (INS)|the patients will be treated with intra-nasal corticosteroid(INS) maintenance therapy for 4 weeks
62471435|NCT00927303||Group 1|Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
62674068|NCT05706402|EXPERIMENTAL|N-acetylcysteine|
62674069|NCT05706402|PLACEBO_COMPARATOR|Placebo|
62674070|NCT02965131|NO_INTERVENTION|Non-temporary portocaval shunt|No temporary portacaval shunt is created. Full mobilization of the liver was followed by dissection of the hilar structure.
62674071|NCT02965131|EXPERIMENTAL|Temporary portocaval shunt|Temporary portocaval shunt is created when inadvertent massive perihepatic bleeding or technical difficulties due to untypical patients' perihepatic anatomy are encountered during total hepatectomy. Hilar dissection preceded the dissection of the retrohepatic vena cava from the native liver. Its creating prolongs the duration of the anhepatic phase.
62471436|NCT00927303||group 2|intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
62674072|NCT04557345||Biological prostheses INC|"Prosthetic valve manufactured in the National Institute of Cardiology Ignacio Chávez."
62674073|NCT04557345||Imported Biological aortic prostheses|St Jude EPIC and Carpentier-Edwards Perimount
62674074|NCT04557345||Mechanical prostheses|St Jude Masters HP, Carbomedics Standart, ON-X Life Technologies, Edwards Mira, Carbomedics Orbis, Medtronic Hall and Medtronic ATS.
62302407|NCT06198257|ACTIVE_COMPARATOR|group B|Modified suits therapy along with strengthening exercise
62302408|NCT01655511|EXPERIMENTAL|Period 1|240 mg tafamidis arm
62302409|NCT01655511|EXPERIMENTAL|Period 2|480 mg arm
62302410|NCT01655511|EXPERIMENTAL|Period 3|TBD dose
62302411|NCT03629509|OTHER|Pre-Intervention|"The BEFORE decision aid will be available for use on the RUBY communication portals (Twitter, Facebook and study portal)~Data will be collected 6 weeks before the implementation of the BEFORE decision aid in RUBY sites to establish a baseline"
62674075|NCT04557345||Control|In subjects who come to donate blood products altruistically, in the blood bank service of the INC, with prior informed consent, the subjects will be matched with PO patients of CVA by age and gender.
62674076|NCT02386579||Diabetics with Charcot foot|
62674077|NCT02039570||haemorrhoids|The cohort contains only patients with symptomatic haemorrhoids - these patients will receive a transvaginal scan to examine their ovarian and internal iliac veins to ascertain whether there is any reflux
62674078|NCT02145611|ACTIVE_COMPARATOR|vildagliptin|Vildagliptin: Dosage: 100 mg/day; Duration: 12 weeks
62471437|NCT00927303||group 3|intervention 2 sequence of observers: 1,2,1,2
62471438|NCT00927303||group 4|intervention 2 sequence of observers: 2,1,2,1
62471439|NCT00927303||group 5|intervention 1 sequence of observers 1,1,2,2
62471440|NCT00927303||group 6|intervention 1 sequence of observers 2,2,1,1
62471441|NCT00927303||group 7|intervention 2 sequence of observers: 1,1,2,2
62471442|NCT00927303||group 8|intervention 2 sequence of observers: 2,2,1,1
62471443|NCT02017119|EXPERIMENTAL|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
62471444|NCT02017119|EXPERIMENTAL|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
62471445|NCT03633474|EXPERIMENTAL|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (\>350 volunteers to date).
62471446|NCT03633474|PLACEBO_COMPARATOR|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
62471447|NCT06135857|EXPERIMENTAL|Intervention group|
62674079|NCT02145611|ACTIVE_COMPARATOR|glibenclamide|Glibenclamide: Dosage: 5 mg to 20 mg; Duration: 12 weeks
62674080|NCT01108796||Patients at cardiovascular risk|
62302412|NCT03629509|EXPERIMENTAL|BEFORE Decision Aid Intervention|"Evaluate more intensive strategies to promote use of the BEFORE decision aid through:~1. We will advertise the availability of the BEFORE decision aid with posters placed in clinic areas at each RUBY site, and will have small handouts available to be distributed in clinic.~2. We will conduct an educational intervention describing and promoting the use of the BEFORE decision aid and general oncofertility information to nurses and support staff at each RUBY site. This will include an optional 1hr informational webinar, direct outreach and training of nurses/support staff on the use of the tool."
62302413|NCT03629509|OTHER|Post-Intervention|Data will be collected after the BEFORE decision aid has been implemented in each RUBY site regarding the recommendation of fertility resources, most useful/least useful tool, and use of the BEFORE decision aid.
62302414|NCT03529487|EXPERIMENTAL|Oxymetazoline applied intra analy|
62302415|NCT00046566|ACTIVE_COMPARATOR|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
62302416|NCT00046566|EXPERIMENTAL|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
62302417|NCT00046566|PLACEBO_COMPARATOR|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
62302418|NCT03395522|EXPERIMENTAL|Device|ITind device implant
62302419|NCT03644576|EXPERIMENTAL|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
62471448|NCT06135857|NO_INTERVENTION|Control group|
62471449|NCT00651586|EXPERIMENTAL|1|Gatifloxacin 0.3% ophthalmic solution
62471450|NCT00651586|ACTIVE_COMPARATOR|2|Ciprofloxacin 0.3% ophthalmic solution
62471451|NCT05457231|EXPERIMENTAL|CST-SF group|The feedback process was as follows. Feedback was given after each interview, including brief feedback and SF. Brief feedback was provided by the clinical instructor based on the Gap-Kalamazoo Communication Skills Assessment Form immediately after each interview. Within two weeks after the first and second interviews, the interns received SF from experts and clinical instructors based on the Communication Skills Measure for Therapist. The SF of the third interview could not be completed because the internship had ended.
62471452|NCT06223893|OTHER|CirrhoCare management system|
62471453|NCT06223893|NO_INTERVENTION|Standard of Care|
62674081|NCT03607136|EXPERIMENTAL|exercise training|Participants in the exercise training group received a 12-week exercise training.
62674082|NCT03607136|NO_INTERVENTION|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
62674083|NCT05357170||Sepsis Survivors|"Feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first feces collection"
62674084|NCT05357170||Healthy Control Population|One time collection of feces and blood upon enrollment used for comparison to identify microbial genes associated with persistent systemic inflammation in sepsis survivors.
62674085|NCT05357170||Trauma Survivor|"Feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first feces collection"
62674086|NCT05357170||Traumatic Brain Injury (TBI)|"Feces collected at admission (day 1(+5)) and between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first and second feces collection."
62674087|NCT06502080|EXPERIMENTAL|Experimental group: consolidative radiotherapy group|patients treated with standard-of-care systemic therapy combined with consolidative radiotherapy
62674088|NCT06502080|OTHER|control group: standard-of-care systemic therapy alone|patients treated with standard-of-care systemic therapy
61917176|NCT02970201|OTHER|Period I EpxDialysis (SMS Messaging)|SMS Messaging arm receives the intervention (EpxDialysis) first, then resumes standard of care at crossover (8 weeks).
62302420|NCT03644576|PLACEBO_COMPARATOR|ozanimod placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
62471454|NCT01805505|EXPERIMENTAL|Transvaginal ultrasound-guided embryo transfer|Transvaginal ultrasound-guided transfer of two day-3 embryos
62674089|NCT02106559|EXPERIMENTAL|Treatment (surgery, porfimer sodium, PDT)|Patients receive porfimer sodium IV over 3-5 minutes. Beginning 24 hours later, patients undergo tumor resection and/or radical pleurectomy followed by intraoperative photodynamic therapy to the pleural space.
61917177|NCT02970201|OTHER|Period II EpxDialysis (Control)|Control arm receives standard of care first, then receives the intervention (EpxDialysis) at crossover.
61917178|NCT04045509|OTHER|Group 'young age'|Group 'young age': 18 - 30 years of age; healthy eyes
61917179|NCT04045509|OTHER|Group 'advanced age'|Group 'advanced age': 50 - 70 years of age; healthy eyes
62471455|NCT01805505|ACTIVE_COMPARATOR|Transabdominal ultrasound-guided embryo transfer|Transabdominal ultrasound-guided transfer of two day-3 embryos
62471456|NCT01172977||HbA1c ≤ 7|Stroke patients with mild diabetes mellitus HbA1c ≤ 7
62471457|NCT01172977||HbA1c ≥ 7,5|Stroke patients with severe diabetes mellitus HbA1c ≥ 7,5
62471458|NCT04449315|EXPERIMENTAL|Peppermint and Lavender Essential Oil|Young Living Essential oil of Peppermint and Lavender will be used to patients who meet the inclusion criteria.
62471459|NCT01240291|EXPERIMENTAL|alanyl-glutamine|Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
62471460|NCT01240291|PLACEBO_COMPARATOR|normal saline|Intravenous placebo (normal saline; 0.9 %)
62471461|NCT04013919||Type 1 Diabetes|
62471462|NCT04013919||Type 2 Diabetes|
62471463|NCT02356354|OTHER|Skin biopsy|On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.
62112642|NCT05230875||Patients participating in the therapeutic education program|Patients participating in an educational program on Inflammatory Bowel Disease (IBD) including a specific discussion on intimacy and sexuality .
62112643|NCT05230875||Patients control (not participating in the therapeutic education program)|A control group (at the rate of two controls for one case) will be made up of IBD patients routinely followed in the gastroenterology department.Those patients will not participate in the therapeutic education program.
62112644|NCT00633854||1|30 volunteer subjects who are age 60 and older
62112645|NCT04889664|EXPERIMENTAL|Ketamine and Written Exposure Therapy|Intravenous Ketamine 0.5 mg/kg and Written Exposure Therapy
62112646|NCT05158361|EXPERIMENTAL|Acupuncture|Participants will receive acupuncture.
62112647|NCT05158361|SHAM_COMPARATOR|Sham acupuncture|Participants will receive sham acupuncture.
62112648|NCT01774994|EXPERIMENTAL|stable isotopes|stable isotope infusion for measurement of metabolism
62112649|NCT01726140|EXPERIMENTAL|TREATMENT|Helmet CPAP
62112650|NCT01726140|ACTIVE_COMPARATOR|CONTROL|Venturi Mask
62112651|NCT03181958|EXPERIMENTAL|NHFOV|"neonates assigned to NHFOV will be started with the following boundaries:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment, similar to what is done in endotracheal high frequency oscillatory ventilation targeting a FiO2≤25-30%. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90%-95%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-12Hz). c)Inspiratory time 50% (1:1).d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2o; amplitude will be titrated according to PaCO2."
62112652|NCT03181958|ACTIVE_COMPARATOR|NCPAP|Neonates assigned to the CPAP group were initiated on a pressure of 5 cmH2O. CPAP can be raised in steps of 1 cmH2O up to 8 cmH2O. If this is not enough to maintain SpO2 between 90% and 95%, FiO2 will be added up to 0.40.
62112653|NCT03181958|EXPERIMENTAL|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of 15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec(according to clinicians' evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at 30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
62112654|NCT02573818||SEDASYS System|
62112655|NCT00600457||A,1|
62112656|NCT05719818||Treatment initiation|patients with a satisfactory oral assessment authorizing the immediate prescription of treatment.
62302421|NCT00833859|EXPERIMENTAL|Chemotherapy followed by Radiation Treatment|GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)
62302422|NCT04642235|EXPERIMENTAL|Nature Nook|Nature Nook builds on our prior work with a standard vacant lot greening intervention involving: removing trash, grading the land, planting new grass and trees, installing a low wooden perimeter fence, and regular maintenance. This greening intervention was designed as a blight removal strategy. People in this arm receive no intervention.
62112657|NCT05719818||Surgical dental care|patients requiring surgical dental care before treatment initaition.
62112658|NCT01921543|EXPERIMENTAL|CI/BNST stimulation on|
62112659|NCT01921543|EXPERIMENTAL|CI/BNST vs stimulation off|randomized, double blind, 1 week crossover
62112660|NCT01921543|EXPERIMENTAL|ITP stimulation on|
62112661|NCT01921543|EXPERIMENTAL|CI/BNST vs ITP vs stimulation off|randomized, double blind, two month crossover
62112662|NCT02332369|EXPERIMENTAL|Device|Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.
62112663|NCT01233050|ACTIVE_COMPARATOR|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
62112664|NCT01233050|ACTIVE_COMPARATOR|Iodine Povacrylex/74% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
62112665|NCT06051500|EXPERIMENTAL|Nostril focus followed by belly focus|Participants will be randomly assigned to concentrate on the nostrils first, then the belly second following a period of rest.
62112666|NCT06051500|EXPERIMENTAL|Belly focus followed by nostril focus|Participants will be randomly assigned to concentrate on the belly first, then the nostrils second following a period of rest.
62112667|NCT04158999||Mother milk|Step 1: Mothers who meet the sample selection criteria will be informed about the scope of the study and their written and verbal consent will be obtained. Data collection form will be applied to mothers who accept to participate in the study by using face to face interview technique. Mothers and newborns will be weighed and 4 ml breast milk sample will be taken from the mother for manual milking.
62112668|NCT00869037|ACTIVE_COMPARATOR|Periarticluar Multimodal Technique|
62112669|NCT00869037|ACTIVE_COMPARATOR|CFNB plus Posterior Capsular Injection|
62112670|NCT05035199||Patients with psychiatric disorders|Patients with psychiatric disorders of the affective spectrum.
62112671|NCT01778712|EXPERIMENTAL|Intervention|Multi-level intervention
62471464|NCT04825535|EXPERIMENTAL|Standard psychiatry and cognitive behavioural online intervention|The online group CBT-M program combines software-based workbooks with phone-based Navigator-Coaching that coordinates software interactions (e.g., secure text messaging, Fitbit tracked walking, food monitoring via photography). Navigation coaching is supplied by students who were pursuing graduate degrees (MSc, MA, PhD) in kinesiology and health science, education, and psychology.
62112672|NCT06113406|ACTIVE_COMPARATOR|Classroom Training|The active control group is given traditional hazmat response training which is already part of their curriculum. For the traditional training group the session is given in the classroom for 45 minutes and the training session is ended.
62471465|NCT04825535|ACTIVE_COMPARATOR|Standard psychiatry and cognitive behavioural in-person intervention|The on-site, usual-care CBT group follows the structure of the Mind Over Mood workbook in reviewing CBT concepts and procedures. A series of work sheets assist participants in differentiating moods, and in differentiating moods from thoughts and situational influences, leading to modifications of thinking, behaviour, emotion and mood. Group leaders are standard leaders in the CAMH group-CBT program who have Masters-level degrees in psychology, social work and occupational therapists.
62471466|NCT02783352|EXPERIMENTAL|treatment group|arthroscopic rotator cuff repair + injection of autologous micro-fragmented adipose tissue (10 mL)
62112673|NCT06113406|EXPERIMENTAL|Virtual Reality Training|After the traditional training has ended, the experimental group will receive the additional VR scenario, online educational content and question and answer session. For the VR training group, the participant is asked to perform the analyze, plan, implement, and evaluation steps individually. After the training is completed the session is closed.
62112674|NCT02935218|OTHER|Parenting Skills for Mothers with BPD|single-arm study
62112675|NCT03617406|OTHER|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
62112676|NCT01833507|ACTIVE_COMPARATOR|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
62112677|NCT01833507|PLACEBO_COMPARATOR|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
62471467|NCT02783352|OTHER|control group|arthroscopic rotator cuff repair only
62471468|NCT06045598||type 2 diabetes group|Participants between the ages of 18-65 who have been diagnosed with Type 2 diabetes according to the criteria of the American Diabetes Association (ADA).
61917180|NCT06057740|EXPERIMENTAL|ACT Bibliotherapy|Participants will read 10 chapters (140 pages) of The Anxious Perfectionist by Clarissa Ong and Michael Twohig over the course of 10 weeks.
61917181|NCT06057740|EXPERIMENTAL|CBT Bibliotherapy|Participants will read 8 chapters (149 pages) of When Perfect Isn't Good Enough by Martin Antony over the course of 10 weeks.
61917182|NCT06057740|NO_INTERVENTION|Waitlist Control|Waitlist condition; assessment only
62302423|NCT04642235|EXPERIMENTAL|Nature Coach|The Nature Coach intervention, developed in a prior study (NCT04146025), will be delivered to people in their homes. Participants will live in the blocks immediately surrounding the study vacant lots randomized to this arm. The lots in this arm receive no intervention.
62302424|NCT04642235|EXPERIMENTAL|Nature Nook + Nature Coach|This is a combined arm: a place-based intervention (Nature Nook) and a person-based intervention (Nature Coach).
62302425|NCT04642235|NO_INTERVENTION|Control|The study lots randomly selected for this arm, as well as the participants living near them, receive no intervention.
61917183|NCT02438358|EXPERIMENTAL|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
62112678|NCT06278025||patients with dysphagia (study)|In the modified barium swallowing study, liquid in the amount of 5 ml was used because it is the optimal amount to monitor physiological events during swallowing . The Penetration Aspiration Scale (PAS) was used to determine the dysphagia severity. The PAS is an 8-point scale describing the degree and nature of laryngeal penetration and aspiration, where a score of 1 refer to 'No penetration or aspiration- No entry of material into the airway', and 8 refer to 'Airway aspiration- Material enters the trachea with no attempt to clear'. According to the MBSS, patients who received a PAS score of 1 were included in the group without dysphagia (control group), and those received a PAS score between 2 and 8 were included in the group with dysphagia (study group).
62302426|NCT04143022|ACTIVE_COMPARATOR|group A (acupuncture press needle)|Group A subjects first receive acupuncture press needle treatment at acupoint of Jin's 3-tongue point and EX-HN25. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
62302427|NCT04143022|ACTIVE_COMPARATOR|group B (acupuncture press needle)|Group B subjects first receive acupuncture press needle treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of Jin's 3-tongue point and EX-HN25. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
62471469|NCT06045598||control group|Healthy participants between the ages of 18-65 who have not been diagnosed with Type 2 diabetes
62674090|NCT05192785|NO_INTERVENTION|Control group|"In the control group, patients who met the sampling criteria filled out the Consent and Information Forms with the researcher, and the breathing and coughing exercises, and early mobilization and pain control practices that were part of the routine clinical procedure were continued.~Arterial and venous oxygen saturation values and vital signs were measured and recorded at the end of the first, second and third postoperative days on the Application Information form. The researchers and clinic nurses were responsible for the execution of applications and the follow-up and monitoring of the pulmonary rehabilitation care throughout the hospitalization of the patient."
61917184|NCT02414503|ACTIVE_COMPARATOR|8IU intranasal oxytocin|8IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
61917185|NCT02414503|ACTIVE_COMPARATOR|24IU intranasal oxytocin|24IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
61917186|NCT02414503|PLACEBO_COMPARATOR|Placebo|Placebo delivered with the OptiNose Breath Powered Bi directional liquid device
62112679|NCT06278025||patients without dysphagia (control)|In the modified barium swallowing study, liquid in the amount of 5 ml was used because it is the optimal amount to monitor physiological events during swallowing . The Penetration Aspiration Scale (PAS) was used to determine the dysphagia severity. The PAS is an 8-point scale describing the degree and nature of laryngeal penetration and aspiration, where a score of 1 refer to 'No penetration or aspiration- No entry of material into the airway', and 8 refer to 'Airway aspiration- Material enters the trachea with no attempt to clear'. According to the MBSS, patients who received a PAS score of 1 were included in the group without dysphagia (control group), and those received a PAS score between 2 and 8 were included in the group with dysphagia (study group).
62471470|NCT02152683|EXPERIMENTAL|long protocol|Renova
61917187|NCT04128787|EXPERIMENTAL|Treatment Sequence ABCD|Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.
61917188|NCT04128787|EXPERIMENTAL|Treatment Sequence BCAD|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 then Treatment A in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
61917189|NCT04128787|EXPERIMENTAL|Treatment Sequence CABD|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 then Treatment B in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
61917190|NCT04281953||People with ototoxicity|People living with and beyond who experience ototoxicity as a result of chemotherapy
62471471|NCT02152683|EXPERIMENTAL|short protocol|Renova
62471472|NCT04017494||Single ventricle|Patients with single ventricle lesions
62471473|NCT03392454||T+LRTI Patients|Patients who received Trapeziectomy with Ligament Reconstruction and Tendon Interposition.
61917191|NCT02153710|EXPERIMENTAL|Phonomotor therapy|Experimental group
62112680|NCT01955668|EXPERIMENTAL|AZD6738|Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached.
62112681|NCT00361517|EXPERIMENTAL|GM test|Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
62112682|NCT00361517|NO_INTERVENTION|no GM monitoring|in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.
62112683|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:~* patients with osteoarthritis of the hip or knee and rehabilitated in the institute~* patients with primary and secondary tumors of the skeleton~* patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(\>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
62112684|NCT02550626||Delirium|occurrence of post-operative delirium
62112685|NCT02550626||No delirium|no presence of post-operative delirium
62112686|NCT01048788|EXPERIMENTAL|OPC|
62112687|NCT01603810||BCC|Adult of any age or gender with capacity to give informed consent who has a basal cell carinoma requiring surgical excision and involving the periocular skin
62112688|NCT00921076|ACTIVE_COMPARATOR|Ankle Arthoplasty|Patients will undergo a Total Ankle Replacement procedure
62674091|NCT05192785|EXPERIMENTAL|Incentive Spirometry Group|"The patients who met the sampling criteria were given consent and information forms in the preoperative period from their admission to the clinic by the researcher and the incentive spirometry (IS) application along with respiratory and cough exercises was explained, demonstrated and performed.~In addition, all postoperative patients underwent a pain assessment using the visual analogue scale (VAS) pain scale every 4-6 hours every day prior to incentive spirometry implementation, and pain control was provided based on the results (with paracetamol and opioids in the clinical routine). The patients whose pain levels were moderate and low continued the incentive spirometry application. Arterial and venous oxygen saturation values and vital signs were measured and recorded at the end of the first, second and third days postoperatively on the Application Information form."
62674092|NCT00147537|EXPERIMENTAL|Phase 2 (Arms A & B)|CP-751,871 + paclitaxel + carboplatin
62674093|NCT00147537|EXPERIMENTAL|Phase 1b|"1. Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin~2. Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib"
62674094|NCT01428973|ACTIVE_COMPARATOR|Arm 1|GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
62674095|NCT01428973|EXPERIMENTAL|Arm 2|GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
62674096|NCT00901095|NO_INTERVENTION|Control|Usual Care
62674097|NCT00901095|EXPERIMENTAL|Lifestyle intervention|The Lifestyle intervention group consists of in-person meetings co-led by an exercise specialist and dietician as well as follow-ups with an interventionist by phone.
62674098|NCT05335265|ACTIVE_COMPARATOR|FIT (face-to-face inhaler training)|"Face-to-face inhaler training.~o The trainers watched the Turkish Thoracic Society (TTS) MDI training video before giving the training.~Training given 3 times on the first day, 2 times on the 2nd day, and once on the 3rd day.~During discharge, inhaler technic was checked according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by TTS.~The trainer and the inhaler technical controller are different."
62674099|NCT05335265|EXPERIMENTAL|VIT (virtual inhaler training)|"Virtual Training was gave 3 times on the first day, 2 times on the 2nd day, and once on the 3rd day (discharge) by the TTS Virtual training video.~During discharge, inhaler technics of the patient's were controlled according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by the TTS.~o The inhaler technique controller and the trainer are different."
62112689|NCT00921076|ACTIVE_COMPARATOR|Ankle fusion|Patients will undergo an Ankle Arthrodesis procedure
62112690|NCT03357549|EXPERIMENTAL|Brief Motivational Intervention|The women of this group will receive a Brief Motivational Intervention during 20 or 30 minutes.
62112691|NCT03357549|ACTIVE_COMPARATOR|Breastfeeding education|The women of this group will receive a standard education about breastfeeding during 20-30 minutes
62471474|NCT03392454||PT+TI Patients|Patients who received the Partial Trapeziectomy and Tendon Interposition
62302428|NCT03551509|NO_INTERVENTION|Control Group|Patients randomly assigned into the control group will undergo open or arthroscopic rotator cuff repair using the surgeon's standard practice. No ECM graft will be used.
62112692|NCT04039971|ACTIVE_COMPARATOR|Tendon-Bone Graft|Participants receive the Quadriceps Tendon Tendon-Bone Graft technique during ACL reconstruction.
62112693|NCT04039971|ACTIVE_COMPARATOR|All-Soft-Tissue Graft|Participants receive the Quadriceps Tendon All-Soft-Tissue Graft technique during ACL reconstruction.
62302429|NCT03551509|ACTIVE_COMPARATOR|Treatment Group|Patients randomly assigned into the treatment group will undergo open or arthroscopic rotator cuff repair and the surgeon will use the ArthroFLEX® ECM graft to augment the repair. ECM scaffold grafts are indicated for the reinforcement of soft tissues repaired by sutures or suture anchors during tendon repair surgery, including rotator cuff.
62302430|NCT03551509|OTHER|Crossover Group|Patients initially randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
62302431|NCT04810052|EXPERIMENTAL|Condition I (contribution)|Patients do 1 nice thing (can be as large or as small as they wish) BIW for 4 weeks for their caregivers while at home.
62302432|NCT04810052|EXPERIMENTAL|Condition II (gratitude)|Patients write a letter or note of gratitude BIW for 4 weeks to their caregivers who have helped with their treatment or recovery.
62302433|NCT04810052|ACTIVE_COMPARATOR|Condition III (daily activities tracking)|Participants keep track of their daily activities.
62471475|NCT06101771||dyslipidemia|"Normal weight children more than 1 month and till age of 18 years that attend Assiut University children Hospital with Clinical manifestation:~1. Non-symptomatic accidentally discovered dyslipidemia.~2. Steatorrhea.~3. Fatty liver."
61917192|NCT02153710|ACTIVE_COMPARATOR|Semantic Feature Analysis therapy|Current standard of care therapy
61917193|NCT06335147|EXPERIMENTAL|Serplulimab, mFOLFOX6|Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
62112694|NCT01544062|EXPERIMENTAL|IV acetaminophen|Study subjects receiving IV acetaminophen
62112695|NCT01544062|PLACEBO_COMPARATOR|Normal saline|Study subjects receiving placebo
62112696|NCT03911245||Patients with age equal or older than 40 years|
62112697|NCT03911245||Patients with age less than 40 years|
62302434|NCT03401749|NO_INTERVENTION|Control Group|Usual preadmission surgery instructions (shower the night before).
62302435|NCT03401749|EXPERIMENTAL|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
62302436|NCT03401749|EXPERIMENTAL|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
62302437|NCT01273818|ACTIVE_COMPARATOR|gentamicin|80 mg gentamicin topical application intraoperatively
62302438|NCT01273818|ACTIVE_COMPARATOR|Cefazolin|Application of 1000 mg cefazolin intra venously 1 hour before surgery
62302439|NCT01273818|ACTIVE_COMPARATOR|gentamicin and cefazolin|1000 mg cefazolin application 1 hour before surgery and topical 80 mg gentamicin intraoperatively
62302440|NCT03847311|PLACEBO_COMPARATOR|Placebos|Subjects will receive sugar pill.
62302441|NCT03847311|ACTIVE_COMPARATOR|Sulfasalazine|Subjects will receive the active drug.
62302442|NCT03853421|EXPERIMENTAL|Dose cohort 3 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
62302443|NCT03853421|EXPERIMENTAL|Dose cohort 6 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
62302444|NCT03853421|EXPERIMENTAL|Dose cohort 9 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
62302445|NCT05006612|ACTIVE_COMPARATOR|Group 1 ((Serratus Anterior Plane Block SAPB)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%.
62471476|NCT06560112|EXPERIMENTAL|Cohort 1|AK104 q3w +Chemo
62471477|NCT06560112|EXPERIMENTAL|Cohort 2|AK112 q3w +Chemo
62471478|NCT06560112|EXPERIMENTAL|Cohort 3|AK112 q3w +AK104 q6w
62471479|NCT06560112|EXPERIMENTAL|Cohort 4|AK112 q3w +AK104 q6w +Chemo
62302446|NCT05006612|ACTIVE_COMPARATOR|Group 2 ((Serratus Anterior Plane Block SAPB combined with Modified Pectoral Nerve Block)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 20 ml levobupivacaine 0.25%and Modified Pectoral Nerve Block with injection of 10 ml levobupivacaine 0.25%between the two pectoralis muscles, after that, the probe was turned toward the axilla, and as the serratus anterior muscle was recognized above the third and fourth ribs, 10 mL of levobupivacaine 0.25% was injected above this muscle
62302447|NCT01917331|EXPERIMENTAL|Beclometasone/Formoterol/Glycopyrrolate|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid
62302448|NCT01917331|ACTIVE_COMPARATOR|Beclometasone/Formoterol|Foster® 100/6 mcg 2 inhalations bid
62302449|NCT03433066|EXPERIMENTAL|group I (Test)|Advanced platelet-rich fibrin mixed with biphasic alloplast
62302450|NCT03433066|ACTIVE_COMPARATOR|Group II (control)|Biphasic alloplast mixed with saline
62302451|NCT01419990|EXPERIMENTAL|GLPG0634 capsules|
62302452|NCT01419990|PLACEBO_COMPARATOR|Placebo capsules|
62302453|NCT00919412||Preterm delivery (< 37 weeks)|
62302454|NCT00919412||Term delivery (>=37 weeks)|
62302455|NCT06269523|ACTIVE_COMPARATOR|Treatment group|18 sessions of functional and proprioceptive re-education, manual lymphatic drainage associated with kinesio taping.
62302456|NCT06269523|ACTIVE_COMPARATOR|Control group|18 sessions of functional and proprioceptive re-education and manual lymphatic drainage.
62302457|NCT01733563|EXPERIMENTAL|fructose sweetened beverage|"Soft drink consumption:~Subjects have to drink a fructose sweetened beverage (3x 200ml per day, 13.3g fructose/100ml) during 7 weeks"
62674100|NCT04799639|EXPERIMENTAL|paclitaxel + cisplantin + Sindilimab|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles paclitaxel 150mg/m2，ivdrip,\>3 hours cisplantin 70mg/m2，ivdrip，\>1 hours Sindilimab 200mg，ivdrip, \>0.5 hours
62302458|NCT01733563|EXPERIMENTAL|glucose sweetened beverage|"Soft drink consumption:~Subjects have to drink a glucose sweetened beverage (3x 200ml per day, 13.3g glucose/100ml) during 7 weeks"
62302459|NCT01733563|EXPERIMENTAL|sucrose sweetened beverage|"Soft drink consumption:~Subjects have to drink a sucrose sweetened beverage (3x 200ml per day, 13.3g sucrose/100ml) during 7 weeks"
62302460|NCT01733563|EXPERIMENTAL|No change of eating habits|"No Soft drink consumption (no soft drink diet):~Subjects do not change their eating habits during 7 weeks"
62302461|NCT01237470|EXPERIMENTAL|Desarda group|Patients with primary inguinal hernia operated using the Desarda technique
62302462|NCT01237470|EXPERIMENTAL|Lichtenstein group|Patients with primary inguinal hernia operated using the Lichtenstein technique.
62302463|NCT03752905|EXPERIMENTAL|PTR-01 0.1 mg/kg|Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.
62302464|NCT03752905|EXPERIMENTAL|PTR-01 0.3 mg/kg|Three intravenous infusions of PTR-01 at 0.3 mg/kg with doses 2 weeks apart.
62302465|NCT03752905|EXPERIMENTAL|PTR-01 1.0 mg/kg|Three intravenous infusions of PTR-01 at 1.0 mg/kg with doses 2 weeks apart.
62302466|NCT03752905|PLACEBO_COMPARATOR|Normal Saline|Saline control to mimic PTR-01.
62302467|NCT03752905|EXPERIMENTAL|PTR-01 3.0 mg/kg|Three intravenous infusions of PTR-01 at 3.0 mg/kg with doses 2 weeks apart.
62302468|NCT00834548||1|WB-MRA standard protocol
62302469|NCT00834548||2|WB-MRA hybrid protocol
62471480|NCT02010190||Cancer Survivors|Participants will be survivors of a childhood cancer.
62674101|NCT05586100|EXPERIMENTAL|cetuximab in combination with toripalimab|"Participants receive toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
62674102|NCT02801227|EXPERIMENTAL|Oxytocin|
62302470|NCT04937023|EXPERIMENTAL|UDCA gel will be injected using a syringe with blunt cannula into the defect site|In the test group, the prepared UDCA gel will be injected using a syringe with blunt cannula into the two or three wall intra-bony defects with probing pocket depth ≥3mm after performing SRP.
62674103|NCT02801227|EXPERIMENTAL|Prostaglandin E2|
62674104|NCT03348397||Contegra patients|
62112698|NCT01771900|EXPERIMENTAL|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
62112699|NCT01771900|EXPERIMENTAL|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
62112700|NCT02560818|ACTIVE_COMPARATOR|Control population : Healthy Volunteers|"20 Healthy Volunteers will be recruited:~* 10 women to recover breast tissue (from surgical waste) : populations A and C~* 10 women to recover ovarian tissue (from surgical waste) : population B"
62112701|NCT02560818|EXPERIMENTAL|Patients|blood samples of 50 patients will be used (use of blood collection in study EXSAL N°ID-RCB 2009-A00833-54)
62112702|NCT01152190|EXPERIMENTAL|5 milligrams (mg) Tadalafil|
62112703|NCT01152190|PLACEBO_COMPARATOR|Placebo|
62112704|NCT04117191|EXPERIMENTAL|Tryptophan loading|All participants are introduced to receive tryptophan loading test.
62112705|NCT04352452||RALS|Surgeons perform robot-assisted laparoscopic surgery
62674105|NCT03348397||Pulmonary homograft patients|
62112706|NCT04352452||CLS|Surgeons perform conventional laparoscopic surgery
62471481|NCT02010190||Control Group|Control participants will consist of age- and gender-matched individuals who are non-first-degree relatives of the survivor group.
62674106|NCT00281580|PLACEBO_COMPARATOR|Placebo|Placebo once daily for eight weeks
62674107|NCT00281580|EXPERIMENTAL|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
62674108|NCT00281580|EXPERIMENTAL|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
62674109|NCT00281580|EXPERIMENTAL|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
62674110|NCT00281580|EXPERIMENTAL|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
62302471|NCT04937023|PLACEBO_COMPARATOR|placebo gel will be injected in to the defect site using a syringe with blunt cannula.|In patients allocated to control group, placebo gel will be injected in to the defect site using a syringe with blunt cannula after scaling and root planing.
62302472|NCT03926403|EXPERIMENTAL|Hypnosis|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
62302473|NCT03926403|ACTIVE_COMPARATOR|conventional management|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
62302474|NCT06380140||patients undergoing Open Tension-free Inguinal Hernia Repair|
62674111|NCT00281580|EXPERIMENTAL|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
62674112|NCT00281580|ACTIVE_COMPARATOR|Amlodipine 10 mg|Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
62674113|NCT00281580|EXPERIMENTAL|Telmisartan 20 / Amlodipine 2.5|Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
62674114|NCT00281580|EXPERIMENTAL|Telmisartan 20 / Amlodipine 5|Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
62674115|NCT00281580|EXPERIMENTAL|Telmisartan 20 / Amlodipine 10|Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
62674116|NCT00281580|EXPERIMENTAL|Telmisartan 40 / Amlodipine 2.5|Telmisartan 40 / Amlodipine 2.5 for eight weeks
62674117|NCT00281580|EXPERIMENTAL|Telmisartan 40 / Amlodipine 5|Telmisartan 40 / Amlodipine 5 for eight weeks
62674118|NCT00281580|EXPERIMENTAL|Telmisartan 40 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
62471482|NCT02753959|EXPERIMENTAL|Acute Intervention|Patients will need to be Clinically stable patients with established neuromuscular disease with clinical secretions or cough PEF \<270 and history of chest infections. Patients are required to be stable for the preceding 4 weeks with no changes to medications or ventilator settings.
62471483|NCT02753959|EXPERIMENTAL|Stable Intervention|Patients with established neuromuscular disease admitted to either the Lane Fox Respiratory Unit or Critical Care at St Thomas' Hospital with acute respiratory deteriorations and with the need for respiratory physiotherapy for secretion management.
62471484|NCT03909620|EXPERIMENTAL|LDCT arm|All eligible participants will undergo screening with LDCT
62674119|NCT00281580|EXPERIMENTAL|Telmisartan 80 / Amlodipine 2.5|Telmisartan 80 / Amlodipine 2.5 for eight weeks
62674120|NCT00281580|EXPERIMENTAL|Telmisartan 80 / Amlodipine 5|Telmisartan 80 / Amlodipine 5 mg for eight weeks
62471485|NCT05824325|EXPERIMENTAL|Experimental: HER2 ADC|Patients diagnosed with HER2 ultra-low or no expression are recruited
62674121|NCT00281580|EXPERIMENTAL|Telmisartan 80 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
62674122|NCT03008577|NO_INTERVENTION|Ambient operating room temperature of 67°F|These patients will have an operating room temperature of 67°F for cesarean delivery, the standard of care at our institution.
62302475|NCT03681717|EXPERIMENTAL|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during laceration repair with sutures.
62302476|NCT03681717|NO_INTERVENTION|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
62302477|NCT05446844|EXPERIMENTAL|A protocol group|A protocol group received a nurse caring behavior protocol by the researcher
62471486|NCT05824325|EXPERIMENTAL|Experimental: TROP2 ADC|Patients diagnosed with HER2 ultra-low or no expression are recruited.
62471487|NCT04057222||Patients included|"Patient with multiple sclerosis and anorectal symptoms, with indication to realize a anorectal manometry, age \> 18~A first record of rectal sensory function will be at strong desire to void. A second record will be after void. Rectal sensory function records consist on an anorectal manometry with 3 measures of external anal sphincter resting pressure, 5 measures of RAIR, 1 measure of perception, constant sensation to need to defecate and maximum tolerable threshold volumes."
62674123|NCT03008577|ACTIVE_COMPARATOR|Ambient operating room temperature of 75°F|Intervention: Ambient operating room temperature of 75°F for cesarean delivery, which is closer to World Health Organization recommendations.
62674124|NCT06354543||CEMFIX1 Knee primary surgery|Patients included for primary knee surgery with CEMFIX 1
62674125|NCT06354543||CEMFIX1 Knee revision surgery|Patients included for revision knee surgery with CEMFIX 1
62674126|NCT06354543||CEMFIX1 Hip primary surgery|Patients included for primary hip surgery with CEMFIX 1
61917194|NCT04473573|OTHER|Lot to Lot Reproducibility|The purpose of this arm is to provide evidence to support that each lot of manufactured reagents for the Spartan Cube CYP2C19 Test produce the same result. Each participant, over the course of the study at the various sites, will be tested using 3 different lots of manufactured Spartan CYP2C19 Test Kits.
62471488|NCT01172145|PLACEBO_COMPARATOR|Cholinesterase inhibitor only|
62471489|NCT01172145|EXPERIMENTAL|Cholinesterase Plus Modafinil|
62471490|NCT02728856|EXPERIMENTAL|Sun Protection Factor (SPF) 50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
62471491|NCT02728856|EXPERIMENTAL|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
62674127|NCT06354543||CEMFIX1 Hip revision surgery|Patients included for revision hip surgery with CEMFIX 1
62674128|NCT06354543||CEMFIX1 Shoulder primary surgery|Patients included for primary shoulder surgery with CEMFIX 1
62674129|NCT06354543||CEMFIX1 Shoulder revision surgery|Patients included for revision shoulder surgery with CEMFIX 1
62674130|NCT06354543||CEMFIX3 Hip primary surgery|Patients included for primary hip surgery with CEMFIX 3
62674131|NCT06354543||CEMFIX3 Hip revision surgery|Patients included for revision hip surgery with CEMFIX 3
62674132|NCT06354543||CEMFIX3 Shoulder primary surgery|Patients included for primary shoulder surgery with CEMFIX 3
62674133|NCT06354543||CEMFIX3 Shoulder revision surgery|Patients included for revision shoulder surgery with CEMFIX 3
62674134|NCT06354543||GENTAFIX1 Knee primary surgery|Patients included for primary knee surgery with GENTAFIX 1
62674135|NCT06354543||GENTAFIX1 Knee revision surgery|Patients included for revision knee surgery with GENTAFIX 1
62674136|NCT06354543||GENTAFIX1 Hip primary surgery|Patients included for primary hip surgery with GENTAFIX 1
62674137|NCT06354543||GENTAFIX1 Shoulder primary surgery|Patients included for primary shoulder surgery with GENTAFIX 1
62674138|NCT06354543||GENTAFIX3MV Hip primary surgery|Patients included for primary hip surgery with GENTAFIX 3MV
62674139|NCT06354543||GENTAFIX3MV Hip revision surgery|Patients included for revision hip surgery with GENTAFIX 3MV
62674140|NCT06354543||GENTAFIX3MV Knee revision surgery|Patients included for revision knee surgery with GENTAFIX 3MV
62674141|NCT06354543||GENTAFIX3 Knee revision surgery|Patients included for revision knee surgery with GENTAFIX 3
62674142|NCT06354543||GENTAFIX3 Hip primary surgery|Patients included for primary hip surgery with GENTAFIX 3
62674143|NCT06354543||GENTAFIX3 Hip revision surgery|Patients included for revision hip surgery with GENTAFIX 3
62471492|NCT02545205|EXPERIMENTAL|Hybrid Assistive Limb (HAL)|
62674144|NCT06354543||CEMSTOP Hip surgery|Patients included for hip surgery with CEMSTOP
62674145|NCT06208163|EXPERIMENTAL|Chiropractic care|6 weeks of chiropractic care
62112707|NCT00707590|EXPERIMENTAL|Part A|"A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days~G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day"
62112708|NCT00707590|EXPERIMENTAL|Part B|"A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days"
62112709|NCT00707590|EXPERIMENTAL|Part C|"A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days~B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days"
62471493|NCT02545205|ACTIVE_COMPARATOR|Conventional gait training|
62471494|NCT04377009|EXPERIMENTAL|Active CBT-I|Internet-guided cognitive behavioral therapy
62471495|NCT04377009|OTHER|Control|Education control program
62674146|NCT06505642|EXPERIMENTAL|nCLE + CBCT-NB|Patients with a suspected malignant peripheral pulmonary nodule(s) referred for cone beam ct navigation bronchoscopy for tissue sampling.
62674147|NCT04874207|EXPERIMENTAL|Patients|Patients
62674148|NCT04822909|EXPERIMENTAL|Apremilast group|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids."
62112710|NCT04178109|ACTIVE_COMPARATOR|Group A|"Group A was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group A was given the oral combination dexketoprofen/tramadole (25mg/75mg) 2h after surgery every 8h for 72h."
62112711|NCT04178109|PLACEBO_COMPARATOR|Group B|"Group B was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group B received postoperative analgesia with intravenous tramadole 75mg and paracetamol 1g every 8h with the first dose beginning 2h after the end of the surgery. For 72h"
62112712|NCT02714127||Cases|"Women (25-64 years old) with abnormal cytology results and/or (high risk) HPV infection refered for colposcopy, and hence possibly diagnosed with an (high risk) HPV infection and/or cervical (pre)cancerous lesions.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
62112713|NCT02714127||Controls|"Healthy women (25-64 years old), falsely diagnosed with abnormal cytology and/or (high risk) HPV infection, but referred for colposcopy, are included as negative controls. Based on a specificity of 76.14% of the HPV type-specific PCR (polymerase chain reaction) used, an estimated 24 out of these 100 participants will be incorrectly scheduled for colposcopy and serve as the control group.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
62471496|NCT00938106|EXPERIMENTAL|(MR BT) in Cervix Cancer|
62471497|NCT04293757|EXPERIMENTAL|Rotational angio|Patients that will undergo 3D rotational angiography before cryoballoon ablation
62471498|NCT04293757|NO_INTERVENTION|No rotational angio|Patients that will receive no preprocedural imaging before cryoballoon ablation
62471499|NCT01299363|NO_INTERVENTION|No dilator use|
62674149|NCT06081465|EXPERIMENTAL|SAD Cohort 1|In SAD Cohort 1, 8 subjects will be randomized to receive a single dose of VG290131 (1 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
62112714|NCT00324506|ACTIVE_COMPARATOR|Cellcept and Avonex|
62112715|NCT04761237|EXPERIMENTAL|Group 1|(H-P) : Pcv-aCO2≥6mmHg between T base and T 0h.;
62112716|NCT04761237|EXPERIMENTAL|Group 2|(L-P) : Pcv-aco2\< 6mmHg at T base and≥6mmHg at T 0h
62112717|NCT03099824|EXPERIMENTAL|GC4419 IV + GC4711 Oral G-101 (82mg)|
62112718|NCT03099824|EXPERIMENTAL|GC4419 IV + GC4711 Oral G-101 (164mg)|
62112719|NCT03099824|EXPERIMENTAL|GC4419 IV + GC4711 Oral G-101 (246mg)|
62112720|NCT03099824|EXPERIMENTAL|GC4419 IV + GC4711 Oral G-111 (175mg)|
62112721|NCT03099824|EXPERIMENTAL|GC4419 IV + GC4711 Oral G-112 (145mg)|
62112722|NCT03099824|EXPERIMENTAL|GC4711 IV + GC4711 Oral G-119 (233mg)|
62112723|NCT03099824|EXPERIMENTAL|GC4711 IV + GC4711 Oral G-125 (233mg)|
62112724|NCT02047851|ACTIVE_COMPARATOR|Acupuncture in active points|Patients in this group will receive real acupuncture
62112725|NCT02047851|SHAM_COMPARATOR|Acupuncture in non-active points|Patients in this group will receive acupuncture, but in non-active points
62471500|NCT01299363|ACTIVE_COMPARATOR|Dilator use|Women randomized to vaginal dilators will be given instructions to perform softening exercises from postoperative weeks 4 to 8
62471501|NCT02892253|EXPERIMENTAL|NIR+ group|"Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND).~Parathyroid identification was done with the use of NIR (intervention group, NIR+ group)"
62471502|NCT02892253|NO_INTERVENTION|NIR- group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only (no intervention group, NIR- group)
62674150|NCT06081465|EXPERIMENTAL|SAD Cohort 2 (FE Study)|SAD Cohort 2 (FE study) is a two-sequence, two-period crossover study. A total of 14 healthy subjects will be randomized to two dosing sequences in a 1:1 ratio. Subjects in sequence 1 will receive a single dose of VG290131 (5 mg) or placebo under fasted condition in Period 1 and under fed condition in Period 2. Subjects in sequence 2 will be administered under fed condition in Period 1 and under fasted condition in Period 2. There will be a 7-day washout between the two dosing periods. Two sentinel subjects will be enrolled in the two dosing sequences of Period 1, respectively: one subject will be randomized to receive VG290131 (5 mg), and the other subject will be randomized to receive placebo. After the investigator reviews safety/tolerability information on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in that sequences will be randomized to receive VG290131 (n=4) and placebo (n=1). No sentinel subjects in Period 2.
62471503|NCT06440694|EXPERIMENTAL|Experimental Arm: Colchicine|Colchicine 0.5 mg po once daily for 180 days. After the Day - 180 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
62674151|NCT06081465|EXPERIMENTAL|SAD Cohort 3|In SAD Cohort 3, 8 subjects will be randomized to receive a single dose of VG290131 (25 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
62112726|NCT02047851|NO_INTERVENTION|No treatment, just observation|Patients in this group will receive no treatment and will only be observed.
62112727|NCT00169780||cohort|patients who require a CT scan prior to kidney stone surgery for diagnostic purposes
62112728|NCT04267250|EXPERIMENTAL|Sequence 1|In sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into period 2 where they will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10.
62112729|NCT04267250|EXPERIMENTAL|Sequence 2|In sequence 2, period 1, participants will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10. After a wash-out period of at least 10 days, participants will continue into period 2 where they will receive an additional single dose of OC.
62112730|NCT01278433|EXPERIMENTAL|Study Group|Participants receiving their first dose of polio vaccine
62112731|NCT02952755|EXPERIMENTAL|Study effect of DWC20162 on DWC20155/DWC20156 PK|To study effect of DWC20162 on DWC20155/DWC20156 PK
62112732|NCT02952755|EXPERIMENTAL|Study effect of DWC20155/DWC20156 on DWC20162 PK|To study effect of DWC20155/DWC20156 on DWC20162 PK
62112733|NCT04346888|EXPERIMENTAL|HBM9161 (680mg and 340 mg)|Subcutaneous injection; Blinded: HBM9161 680mg; Open-label: HBM9161 340mg;
62112734|NCT04346888|EXPERIMENTAL|HBM9161 (340 mg)|Subcutaneous injection; Blinded: HBM9161 340mg; Open-label: HBM9161 340mg;
62112735|NCT04346888|PLACEBO_COMPARATOR|Placebo, HBM9161 (340 mg)|Subcutaneous injection; Blinded: Placebo; Open-label: HBM9161 340mg;
62112736|NCT05073718|EXPERIMENTAL|LDASA (n=200)|
62112737|NCT05073718|PLACEBO_COMPARATOR|Placebo (n=200)|
62112738|NCT05092412|EXPERIMENTAL|Low-dose radiotherapy combined with durvalumab, etoposide, and cisplatin/carboplatin|
62112739|NCT04354610|OTHER|Patients hospitalized for Covid-19 infection|"Patients hospitalized for Covid-19 infection will undergo the following evaluations:~* Clinical examination~* Blood sample retrieved for biological assessment and biobanking~* Telephone interview"
62112740|NCT01138215|EXPERIMENTAL|1|Receive 1 course of VZV vaccine : 2 doses of vaccines with 3 months apart.
62112741|NCT03961152|EXPERIMENTAL|PainCoach-app group|In the PainCoach-app group, in addition to receiving the aforementioned usual care, the PainCoach app was downloaded on each patient's smartphone or tablet. Patients could use this app whenever they wanted until day 14 after surgery. They were not subjected to any different treatment compared to the control group, i.e. advice on pain management was delivered in an extra and different way, but the pain medication itself was exactly the same for both groups.
62112742|NCT03961152|NO_INTERVENTION|Control group|The control group received usual care.
62112743|NCT05851768|ACTIVE_COMPARATOR|Erector spinae plane block with 0.25% bupivacaine|Patients will receive ultrasound guided ESPB with 0.25% bupivacaine
62112744|NCT05851768|EXPERIMENTAL|Erector spinae plane block with 0.25% bupivacaine and Magnesium|Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and magnesium
62112745|NCT05851768|EXPERIMENTAL|Erector spinae plane block with 0.25% bupivacaine and Dexmedetomidine|Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and dexmedetomidine
62112746|NCT00744393|ACTIVE_COMPARATOR|A|Active drug
62112747|NCT00744393|PLACEBO_COMPARATOR|P|Placebo drug
62112748|NCT04136496|ACTIVE_COMPARATOR|Ink placed before chemotherapy (Study A)|In Study A, 0.5 mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy
62112749|NCT04136496|ACTIVE_COMPARATOR|Ink placed after chemotherapy (Study B)|In Study B, 0.5 mL of Black Eye Ink will be placed before neoadjuvant therapy
62112750|NCT04806256|EXPERIMENTAL|CDSS group|Subjects' treatment regimens were influenced by the CDSS, which was the recommended system for Tradictional Chinese Medicine treatment of dry eye.
62471504|NCT06440694|PLACEBO_COMPARATOR|Control Arm : Placebo|Placebo 0.5 mg po once daily for 180 days. After the Day - 180 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
62471505|NCT00053963|EXPERIMENTAL|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62471506|NCT00909662||Patients|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy
62471507|NCT00909662||Participants|Female control subjects will be recruited, consisting predominantly of age-matched (i.e.+/- 10 years of age) friends or family members of the patients.
62471508|NCT06217224|ACTIVE_COMPARATOR|Preventative photobiomodulation therapy arm only in methotrexate weeks.|The application of preventive photobiomodulation therapy (PBMT) will be carried out on the day of methotrexate infusion (D1) and until the patient reaches a serum concentration equal to or less than 0.3 mmol/L.
62471509|NCT06217224|EXPERIMENTAL|Preventive photobiomodulation therapy arm in the weeks of methotrexate, cisplatin and doxorubicin.|The application of preventive photobiomodulation therapy will be performed on the days of doxorubicin infusion and cisplatin and on the day after the doxorubicin infusion; on the day of the methotrexate infusion and until the patient reaches a serum concentration equal to or less than 0.3 mmol /L.
62471510|NCT03730597|ACTIVE_COMPARATOR|glenosphere 42|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 42. reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
62471511|NCT03730597|ACTIVE_COMPARATOR|glenosphere 38 ECC|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 38 ECC reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
61917195|NCT04473573|OTHER|Site to Site Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when tested at different locations, produce the same result.
61917196|NCT04473573|OTHER|Operator Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when collected and tested by different operators, produce the same result.
62112751|NCT04806256|ACTIVE_COMPARATOR|non-CDSS group|The treatment of the subjects was routine and not affected by the CDSS for Tradictional Chinese Medicine.
62112752|NCT06443060|EXPERIMENTAL|Virtual Reality Group|After the scales are filled in, the child will be shown a cartoon film deemed appropriate by the experts by wearing VR glasses and headphones before the Prick test (average 2 minutes). The appropriate cartoon will be shown to the VR glasses group for an average of 15 minutes. After the child starts watching the cartoon, the child will be asked to extend his/her left arm and the prick test process will begin.
61917197|NCT00762424|ACTIVE_COMPARATOR|Tamsulosin|
61917198|NCT00762424|PLACEBO_COMPARATOR|Placebo|
62112753|NCT06443060|EXPERIMENTAL|Buzzy Application Group|The CFS-D scale will be completed only by the child to measure the anxiety level before the procedure. To assess pain and fear, the WB-FACES pain scale and the CFS fear scale will be completed by the child, parent and researcher before the procedure. The buzzy cold and vibration device will be connected to the children in the buzzy experimental group 5-10 seconds before the procedure, at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) and the prick test application will be started.
61917199|NCT01043042||Hospitalized patients|patients hospitalized at VUH between 4/1/2008 to 10/31/2009
62112754|NCT06443060|ACTIVE_COMPARATOR|Control Group|Children in this group will be given routine explanations according to the outpatient clinic procedure and prick test will be applied before the procedure.
62112755|NCT01523249||Scanned and palpated|Healthy, pregnant, term women delivering at BC Women's Hospital and expecting to have neuraxial anesthesia.
62112756|NCT00957658|OTHER|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem Study Device
62112757|NCT00486330|OTHER|Buprenorphine plus Tipranavir/Ritonavir|
62112758|NCT00476060|EXPERIMENTAL|A|
62112759|NCT00476060|PLACEBO_COMPARATOR|B|
62112760|NCT04604873|NO_INTERVENTION|No hospital one day care|No hospital one day care
62112761|NCT04604873|OTHER|Hospital one day care|Hospital one day care
61917200|NCT04841473|ACTIVE_COMPARATOR|Standard Concussion Education|Participants will receive standard concussion education materials (online training) focused on concussion prevention in youth sport.
61917201|NCT04841473|EXPERIMENTAL|TRAIN Concussion Education|After receiving the standard concussion education materials (online training), participants will receive an additional module, the TRAIN concussion education module.
62112762|NCT06333080||Study Cohort|People with dysregulated type 2 diabetes on metformin treatment, which are naïve to second line antidiabetic treatment. These participants will be started on oral semaglutide, as a second line antidiabetic treatment, in addition to their treatment with metformin. The participants will be started on 3mg and the dose increased according to the label. The oral semaglutide will be administered once daily.
62112763|NCT00872417|EXPERIMENTAL|Treatment-naive|To explore the efficiency and safety of generic antiretroviral drugs for 520 treatment-naive HIV/AIDS patients
62112764|NCT00872417|NO_INTERVENTION|TREATMENT-EXPERIENCED|To explore the long term ARV of treatment-experienced patients who have no sign of drug resistance; to explore the long term efficiency and safety and drug sife effects of ARV in HIV/AIDS patients. These patients have taken ARV for approximately 3 years already.
62112765|NCT00872417|EXPERIMENTAL|drug resistance|To explore the second line drugs for those drug resistance patients
62112766|NCT00762099|ACTIVE_COMPARATOR|1|Pregabalin Group
62112767|NCT00762099|PLACEBO_COMPARATOR|2|Placebo group
62302478|NCT05446844|ACTIVE_COMPARATOR|A control group|A control group received routine nursing care by the staff nurse
62302479|NCT04207710|EXPERIMENTAL|Microbial growth on wrist after application of Gebauer's Ethyl Chloride|An area of skin on the wrist will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Ethyl Chloride topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
62302480|NCT04207710|EXPERIMENTAL|Microbial growth on lower back after application of Gebauer's Ethyl Chloride|An area of skin on the lower back will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Ethyl Chloride topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
62302481|NCT04207710|EXPERIMENTAL|Microbial growth on wrist after application of Gebauer's Pain Ease|An area of skin on the wrist will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Pain Ease topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
62302482|NCT04207710|EXPERIMENTAL|Microbial growth on lower back after application of Gebauer's Pain Ease|An area of skin on the lower back will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Pain Ease topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
62302483|NCT05954039|EXPERIMENTAL|Wheat Polar Lipid Complex|Dietary supplement - Wheat Polar Lipid Complex
62302484|NCT05954039|PLACEBO_COMPARATOR|Placebo|Dietary supplement - Placebo
62471512|NCT02119065||Health Services Research (PET/CT scan)|Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.
62471513|NCT05340140||CBCT Images of Maxillary 1st molars|
62471514|NCT01844375|EXPERIMENTAL|Carbohydrate group|The carbohydrate (CHO) group will be given the carbohydrate drink (12.5% carbohydrates, 50 kcal/100 ml, 240 mOsmol/l, pH 5.0) 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except the carbohydrate drink. The pharmacy department is responsible for preparing the carbohydrate drink.
62471515|NCT01844375|ACTIVE_COMPARATOR|Control group|The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
62471516|NCT05445739|OTHER|The effect of an online exercise course on the increase of elders' regular exercise intention|The effect of an online exercise course on the increase of elders' regular exercise intention.
62471517|NCT00594685||Isolated HIT|Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test
61917202|NCT03540043|PLACEBO_COMPARATOR|Placebo|Administration of Placebo
61917203|NCT03540043|EXPERIMENTAL|PUR0110 (Thykamine) 0.05%|Administration of PUR0110 (Thykamine) 0.05%
61917204|NCT03540043|EXPERIMENTAL|PUR0110 (Thykamine) 0.10%|Administration of PUR0110 (Thykamine) 0.10%
61917205|NCT03540043|EXPERIMENTAL|PUR0110 (Thykamine) 0.25%|Administration of PUR0110 (Thykamine) 0.25%
62112768|NCT06414382|EXPERIMENTAL|Koebner induction|Koebner will be induced on area 22mm in diameter on upper bilateral arms and anterior bilateral thighs.
62112769|NCT04241224|EXPERIMENTAL|Excimer Laser Photoablation|"Device: DABRA Laser System~Patients with symptomatic peripheral vascular disease undergoing an endovascular revascularization procedure utilizing the DABRA Laser System."
62112770|NCT06553287|EXPERIMENTAL|LNK01004 ointment 0.3%|Participants will receive LNK01004 ointment 0.3% twice daily
62112771|NCT06553287|EXPERIMENTAL|LNK01004 ointment 1.0%|Participants will receive LNK01004 ointment 1.0% twice daily
61917206|NCT02280083|EXPERIMENTAL|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
61917207|NCT02280083|PLACEBO_COMPARATOR|placebo|excipient
61917208|NCT04358601|EXPERIMENTAL|All-polyethylene tibial components|Triathlon PS Knee System with all-polyethylene tibial components
61917209|NCT04358601|ACTIVE_COMPARATOR|Metal-backed modular components|Triathlon PS Knee System with metal-backed modular components
61917210|NCT06258473|EXPERIMENTAL|Multicomponent decentralized care|mHealth plus decentralized primary care The multi-component intervention aims to increase access to primary care, and to improve care quality and patient retention. The intervention package includes mHealth, decentralization with task sharing, community-based care, and supportive monitoring visits
61917211|NCT06258473|ACTIVE_COMPARATOR|mHealth|In subdistrict with mHealth intervention only, we will provide the same training on hypertension and diabetes care to physicians and nurses at NCD corner in UHC, and training to use Simple App for hypertension and diabetes management. Quarterly supervision by higher-level health administrators and medical professionals to NCD corner helps solve issues with patient management, medication supply, etc. Visits may be informed by a performance summary made available by the Simple App dashboard. Two supportive visits by the study team will be organized to help NCD Corner solve technical issues with Simple App. The healthcare providers at NCD Corner will decide how they react to the information made available by the digital tool, and similarly, the patient component will not be included. Patient pathways remain the same as usual care.
62112772|NCT06553287|EXPERIMENTAL|LNK01004 ointment 1.5%|Participants will receive LNK01004 ointment 1.5% twice daily
62112773|NCT06553287|EXPERIMENTAL|Vehicle|Participants will receive vehicle BID
62471518|NCT04303663|ACTIVE_COMPARATOR|Fibular Plate|Open reduction and internal fixation of the fibular fracture Fixation of the fibular will be performed with a fibular plate +/- lag screws as judged intraoperatively
62471519|NCT04303663|EXPERIMENTAL|Fibular Nail|Percutaneous or mini-open reduction of the fibular fracture and fixation with a fibular nail.
62471520|NCT03380754|EXPERIMENTAL|Carbohydrate Rich Drink|Group A will receive the carbohydrate rich drink, Nutricia preOp. This is the intervention group.
62471521|NCT03380754|PLACEBO_COMPARATOR|Placebo Drink|Group B will receive placebo, Nestle Splash Lemon Flavor Water (Placebo) (similarly flavored and appearing water, however with no calorie, carbohydrate or nutritional content).
62471522|NCT03380754|NO_INTERVENTION|No Drink|Group C will not receive any drink. This group will follow normal protocol.
62674152|NCT06081465|EXPERIMENTAL|SAD Cohort 4|In SAD Cohort 4, 8 subjects will be randomized to receive a single dose of VG290131 (50 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
62674153|NCT06081465|EXPERIMENTAL|SAD Cohort 5|In SAD Cohort 5, 8 subjects will be randomized to receive a single dose of VG290131 (100 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
62674154|NCT06081465|EXPERIMENTAL|SAD Cohort 6|In SAD Cohort 6, 8 subjects will be randomized to receive a single dose of VG290131 (200 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
62674155|NCT06081465|EXPERIMENTAL|MAD Cohort 1|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (1 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
62112774|NCT01092806|ACTIVE_COMPARATOR|Prograf|Patients are treated until steady-state conditions with Prograf and then investigated with clamp
62302485|NCT06257212|ACTIVE_COMPARATOR|BCG vaccine|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
62302486|NCT06257212|ACTIVE_COMPARATOR|MMR vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
62112775|NCT01092806|EXPERIMENTAL|Advagraf|The patients are treated with Advagraf until steady-state conditions and then investigated with clamp
62112776|NCT03546608|EXPERIMENTAL|Healthy Participants (Control)|Participants with normal hepatic function matched to moderate hepatic impairment received single oral dose of 500 milligrams (mg) of tepotinib film-coated tablet on Day 1 after a standard breakfast.
62112777|NCT03546608|EXPERIMENTAL|Mild Hepatic Impairment (Child-Pugh Class A)|Participants with mild hepatic impairment (Child-Pugh Class A, score 5 to 6) received single oral dose of 500 mg tepotinib film-coated tablet on Day 1 after a standard breakfast.
62112778|NCT03546608|EXPERIMENTAL|Moderate Hepatic Impairment (Child-Pugh Class B)|Participants with moderate hepatic impairment (Child-Pugh Class B, score 7 to 9) received single oral dose of 500 mg tepotinib film-coated tablet on Day 1 after a standard breakfast.
62112779|NCT00852618||A|Participants undergoing treatment with raltegravir (RAL) in the main study
62112780|NCT00852618||B|Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
62112781|NCT03769233|EXPERIMENTAL|Mindfulness-based Intervention|5 week, manual-based group MBI treatment for depressive and anxious symptoms
62112782|NCT04761562|ACTIVE_COMPARATOR|Control group|Patients will be treated with a standard surgical procedure - tympanoplasty.
62112783|NCT04761562|EXPERIMENTAL|PVRP group|Patients will be treated with a standard surgical procedure - tympanoplasty combined with PVRP. PVRP will be applied to the reconstructed tympanic membrane.
62112784|NCT04694248|EXPERIMENTAL|Anticoagulant plus antiplatelet therapy|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
62302487|NCT06257212|PLACEBO_COMPARATOR|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
62471523|NCT01565876|EXPERIMENTAL|study|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
62471524|NCT05557747|EXPERIMENTAL|Group A:cervicothoracic junction mobilization|Group A: patients will receive cervicothoracic junction mobilization and conventional physical therapy program for 3 sessions/week over 4 weeks periods
62471525|NCT05557747|EXPERIMENTAL|Group B:autogenic muscle Energy Technique|Group B: will receive autogenic muscle Energy Technique and conventional physical therapy program for 3 sessions/week over 4 weeks periods.
62471526|NCT05557747|ACTIVE_COMPARATOR|Group C:conventional physical therapy|Group C: will receive conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods.
62471527|NCT00610363|PLACEBO_COMPARATOR|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
62674156|NCT06081465|EXPERIMENTAL|MAD Cohort 2|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (5 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
62674157|NCT06081465|EXPERIMENTAL|MAD Cohort 3|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (25 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
62674158|NCT06081465|EXPERIMENTAL|MAD Cohort 4|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (100 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
62674159|NCT06056570|EXPERIMENTAL|dotinurad 2mg|dotinurad 2mg q.d.
62674160|NCT06056570|EXPERIMENTAL|dotinurad 4mg|dotinurad 4mg q.d.
62674161|NCT04674904|EXPERIMENTAL|Group A|Dry Needling
62674162|NCT04674904|ACTIVE_COMPARATOR|Group B|Hot pack , TENS , Stretching
61917212|NCT06258473|NO_INTERVENTION|Usual care|Existing usual care provided by government primary care system including screening, treatment initiating, drug refill, and routine follow-up, at subdistrict NCD corner. Community clinics and CHWs have less involvement in NCD care provision.
61917213|NCT04331197|ACTIVE_COMPARATOR|Clomiphene Citrate-High BMI women|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
62674163|NCT03254147||patients prescribed with Oral Anti-coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
62302488|NCT00588679|EXPERIMENTAL|1|Patients taking part in this study will have one MRI and one MRSI scan acquired in succession during a single MR examination. For those patients who have undergone prostate biopsy it is recommended that this should be done at least eight weeks after the prostate biopsy and should take one hour to one hour and ten minutes total to complete.
62302489|NCT00991900||Healthy subjects|
61917214|NCT04331197|ACTIVE_COMPARATOR|Letrozole-High BMI women|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
62302490|NCT04840667|EXPERIMENTAL|REPLAGAL|Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight of intravenous (IV) infusion Every Other Week (EOW) for 104 weeks.
62674164|NCT02099591|EXPERIMENTAL|Age group: > = 12y to < 18y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
62674165|NCT02099591|EXPERIMENTAL|Age group: > = 12y to < 18y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
62674166|NCT02099591|EXPERIMENTAL|Age group: > = 6y to < 12y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
62674167|NCT02099591|EXPERIMENTAL|Age group: > = 6y to < 12y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
62674168|NCT02099591|EXPERIMENTAL|Age group: > = 6mo to < 6y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
62674169|NCT02099591|EXPERIMENTAL|Age group: > = 6mo to < 6y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
62674170|NCT06484517||The group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope.|Before intubation, Cormack-Lehane score and percentage of glottis opening (POGO) score were recorded by applying direct and indirect laryngoscopy with the Macgreth videolaryngoscope. All tracheal intubations were performed by the same expert with over 10 years of experience in pediatric anesthesia.
62674171|NCT06484517||For the group (Group H, n=20), the Hugemed videolaryngoscope was used.|Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age. After the induction of general anesthesia, patients underwent direct and indirect laryngoscopy with videolaryngoscopes. The Modified Cormack-Lehane score and Percentage of Glottic Opening (POGO) score were recorded, and orotracheal intubation was performed. Number of attempts, need for cricoid pressure, optimization maneuvers, success rate, and hemodynamic parameters of both groups were recorded.
62674172|NCT05029362|OTHER|Beta testing group|
61917215|NCT02776020||Propofol sedated patients|Women undergoing a short trans vaginal ovum retrieval (TVOR) will be sedated with propofol , and monitored non-invasively for changes in blood propofol concentration levels. Propofol dosages will be adapted according to patients vital signs and their reaction to noxious stimuli exerted during the trans vaginal ovum retrieval (TVOR) procedure, irrespective to the proposed study in which these participants undergo.Those changes of administered propofol dosages will be observed by the anesthetic drug monitor (ADM). Propfol is administered by the anesthesiologist in a routine manner and according to anesthesiologist discretion .
62112785|NCT02513238|ACTIVE_COMPARATOR|Stemcells injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10\^6 MSC / Cm\^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10\^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.
62112786|NCT02513238|PLACEBO_COMPARATOR|Saltwater injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%.
62302491|NCT03444337||Catheter Ablation Group|Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI
62302492|NCT02282761|EXPERIMENTAL|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
62302493|NCT02282761|EXPERIMENTAL|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
62302494|NCT02282761|PLACEBO_COMPARATOR|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
62302495|NCT01266096|EXPERIMENTAL|newly diagnosed or recurrent head/neck melanoma|This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.
62302496|NCT06146114||experimental group|"1. Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023;~2. Men aged ≥ 18 years old;~3. The expected survival time is greater than 12 weeks;~4. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points;~5. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up."
62471528|NCT00610363|EXPERIMENTAL|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.
62471529|NCT03236311|PLACEBO_COMPARATOR|Placebo|Matching placebo for 4 weeks.
62471530|NCT03236311|EXPERIMENTAL|SAR407899|SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).
62471531|NCT05584345|ACTIVE_COMPARATOR|CONTROL|Traditional physiotherapy applications will be applied.
62471532|NCT05584345|EXPERIMENTAL|RESPIRATORY EXERCISES GROUP|In addition to traditional physiotherapy and respiratory exercises wiil be applied.
62674173|NCT04329806|EXPERIMENTAL|Moxonidine|Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
61917216|NCT02045303|EXPERIMENTAL|Ambulatory Wound Clinic|Intervention with contact ultrasound therapy and noncontact ultrasound therapy following the study protocol on subjects receiving care at the wound clinic.
62112787|NCT06000618|EXPERIMENTAL|experimental group|The experimental group will undergo intrapulmonary percussive therapy
62302497|NCT05432570|ACTIVE_COMPARATOR|Group A - Muscle Relaxants Used|Muscle Relaxants Used
62302498|NCT05432570|ACTIVE_COMPARATOR|Group B - No Muscle Relaxants|No Muscle Relaxants
62302499|NCT04802746|EXPERIMENTAL|Sequence ABC in Part A|Study participants randomized to this arm will receive Staccato Placebo (A) and two fixed doses of Staccato alprazolam Dose 1 (B) and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
62471533|NCT04309981|EXPERIMENTAL|ARI0002h|Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory region and signal-transduction CD3z that has been humanized
62674174|NCT04329806|ACTIVE_COMPARATOR|Amlodipine|Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
61917217|NCT02702596|EXPERIMENTAL|MBIC + DEF|Measurement-Based Integrated Care with Depression Education Fotonovela
62112788|NCT02947568||CKD|chronic kidney disease
61917218|NCT02702596|EXPERIMENTAL|MBIC + SE|Measurement-Based Integrated Care + Standard Education
61917219|NCT01797172|EXPERIMENTAL|Percutaneous Cervical Nucleoplasty|Percutaneous Cervical Nucleoplasty
61917220|NCT01797172|ACTIVE_COMPARATOR|Pulsed Radio Frequency|Pulsed Radio Frequency treatment
62112789|NCT02947568||DM|diabetes mellitus
62112790|NCT02947568||CKD+DM|chronic kidney disease + diabetes mellitus
62302500|NCT04802746|EXPERIMENTAL|Sequence BCA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato alprazolam Dose 2 (C), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
62302501|NCT04802746|EXPERIMENTAL|Sequence CAB in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato Placebo (A), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
62302502|NCT04802746|EXPERIMENTAL|Sequence ACB in Part A|Study participants randomized to this arm will receive Staccato Placebo (A), Staccato alprazolam Dose 2 (C), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
62302503|NCT04802746|EXPERIMENTAL|Sequence BAC in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato Placebo (A), and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
62471534|NCT04541147|EXPERIMENTAL|Dexamethasone plus analgesics|oral dexamethasone of 0.5mg/kg/day (max of 8mg/day), administered on post-operative days 1,3,5,7 in addition to standardized course of analgesics (opioids/acetaminophen/NSAIDs).
62471535|NCT04541147|ACTIVE_COMPARATOR|analgesics alone|standardized course of analgesics (opioids/acetaminophen/NSAIDs)
62674175|NCT06539377|EXPERIMENTAL|Living donor liver transplantation|"The evaluation tests prior the transplantation will be performed following the standard protocol for the evaluation of a waiting list applicants prior liver transplantation. The aim of this procedure is to rule out any significant co-morbidities (e.g. cardiologic diseases, other malignancies) which would preclude liver transplantation.~After successful evaluation of the recipient and waiting list registration with Eurotransplant, the AB0-compatible donor will be evaluated as well according to a center-specific protocol.~For a local control of the tumor, an additional local-ablative therapy (SIRT) is mandatory."
62674176|NCT03556280|EXPERIMENTAL|Treatment Group|Will use the Active GammaSense Stimulation System.
61917221|NCT01655108|PLACEBO_COMPARATOR|Saline|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
61917222|NCT01655108|ACTIVE_COMPARATOR|Minoxidil 0.5% /2ml|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
62112791|NCT05292599|EXPERIMENTAL|Supervised|All participants in this arm will receive physiotherapy treatment that includes craniocervical flexion exercise (CCFE), isometric flexion exercises (IFE), isometric extension exercises (IEE), self-resistance exercise for neck flexion and extension (RFE), self-resistance exercise for neck rotation (RRE), midscapular exercise (ME) in 2 sessions for week, 60 minutes each, for 8 weeks. CCFE will focus on the recruitment of the deep cervical flexor muscles and will be performed from lower to higher complexity. Each of the exercises will be for 3 sets of 10 repetitions with 10 seconds of isometric contraction during the 8 weeks. IFE and IEE consist of 3 sets of 8 repetitions with 6 seconds of isometric contraction, for 6 weeks. For self-resistance exercises, the patient performs RFE and RRE. These exercises will be performed with 3 sets of 8 repetitions with 6 seconds of isometric contraction during the 8 weeks. The ME will be performed in 3 sets of 8 repetitions during the 5 weeks.
62112792|NCT05292599|ACTIVE_COMPARATOR|No supervised|The participants will perform the same exercises as the supervised group. However, in this arm will be instructed to perform the same exercises as the experimental group at home, without any supervision. These instructions will be given by the physiotherapist through videos and/or photos.
62302504|NCT04802746|EXPERIMENTAL|Sequence CBA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato alprazolam Dose 1 (B), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
62302505|NCT04802746|EXPERIMENTAL|Staccato alprazolam in Part B|Study participants randomized to this arm will receive Staccato alprazolam at pre-specified time points in Part B.
62302506|NCT04802746|PLACEBO_COMPARATOR|Staccato placebo in Part B|Study participants randomized to this arm will receive Staccato placebo at pre-specified time points in Part B.
62302507|NCT03015532|EXPERIMENTAL|Cohort 1, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
62302508|NCT03015532|EXPERIMENTAL|Cohort 1, Group 2: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
62302509|NCT03015532|PLACEBO_COMPARATOR|Cohort 1, Group 3: Saline Placebo|Saline placebo via injection
62471536|NCT01597245|EXPERIMENTAL|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
62674177|NCT03556280|SHAM_COMPARATOR|Control Group|Will use the Sham GammaSense Stimulation System.
62112793|NCT00502372|EXPERIMENTAL|Enriched product, dietary supplement|Subjects receiving enriched product compared to an unenriched product
62302510|NCT03015532|ACTIVE_COMPARATOR|Cohort 1, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
62471537|NCT01597245|EXPERIMENTAL|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
62674178|NCT02173366|EXPERIMENTAL|Change Club Intervention|
62674179|NCT04135443|EXPERIMENTAL|3T Tune in! Turn on! Turn up!|The intervention is a mobile app delivered sexual health promotion program designed specifically for young black men who have sex with men or who are attracted to men. The mobile app includes 36 interactive activities including resource maps, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) content, and an asynchronous communication forum. The app helps participants to become clearer about what they do/don't want to do sexually, to communicate their choices. It also focuses on ways to increase healthy relationships, enhance sexual experience if having sex while reducing HIV/STI risk.
62112794|NCT00502372|ACTIVE_COMPARATOR|1|Subjects not receiving enriched product
62112795|NCT01345838||Dysplasia|Patients with developmental dysplasia of the hip undergoing PAO
62112796|NCT03050788|EXPERIMENTAL|Smartphone confocal microscopy imaging|Subject's skin lesion will be imaged with the smartphone confocal microscopy.
62302511|NCT03015532|EXPERIMENTAL|Cohort 2, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
62302512|NCT03015532|EXPERIMENTAL|Cohort 2, Group 2: HTX-011 + Ropivacaine|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
62302513|NCT03015532|PLACEBO_COMPARATOR|Cohort 2, Group 3: Saline Placebo|Saline placebo via injection
62302514|NCT03015532|ACTIVE_COMPARATOR|Cohort 2, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
62302515|NCT04234438|ACTIVE_COMPARATOR|Before application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa Before subliminal micropulse laser application
62302516|NCT04234438|ACTIVE_COMPARATOR|After application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa After 12 months subliminal micropulse laser application
62302517|NCT02910778|EXPERIMENTAL|Atorvastatin|80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
62302518|NCT02910778|PLACEBO_COMPARATOR|Placebo|Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15
62302519|NCT04264104|EXPERIMENTAL|Low dose neural mobilization|Four series of 10 repetitions of neural mobilization targeting the tibial nerve.
62302520|NCT04264104|ACTIVE_COMPARATOR|High dose neural mobilization|Eight series of 10 repetitions of neural mobilization targeting the tibial nerve.
62302521|NCT04837560|EXPERIMENTAL|Temporarily or permanently wheelchair users which suffer from Venous Edema|Temporarily or permanently wheelchair users which suffer from Venous Edema
62302522|NCT02334709|EXPERIMENTAL|SBRT + fixed dose Tyrosine Kinase Inhibitor|Single arm phase I trial with 3 dose-escalation arms
62112797|NCT05998096|PLACEBO_COMPARATOR|Placebo|Placebo (void of all actives)
62674180|NCT04135443|ACTIVE_COMPARATOR|General Health Website Materials|The control intervention features a website containing seven health promotion materials in online pamphlet or poster formats focusing on mental health (2 pamphlets), nutrition (2 pamphlets), relationships (2 pamphlets) and COVID (1 poster).
61917223|NCT00555139|EXPERIMENTAL|GW876008|The subjects will be randomized to one of the six sequences A/B/D A/D/B B/A/D B/D/A D/A/B D/B/A across three treatment periods where A represents placebo, B represents GW876008 and D represents alprazolam.
61917224|NCT00555139|EXPERIMENTAL|GSK561679|The subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
61917225|NCT01392521|EXPERIMENTAL|Arm 1|
62112798|NCT05998096|ACTIVE_COMPARATOR|Caffeine-Based Energy Drink|Caffeine-based energy drink containing 200 mg caffeine
62112799|NCT05379881|NO_INTERVENTION|Waiting list control (WLC)|Participants who are assigned to the control condition will complete the baseline questionnaires and assessments at weeks 2, 4, and 8. After the last assessment, they will be given access to COMET.
62112800|NCT05379881|EXPERIMENTAL|Common Elements Toolbox (COMET)|"COMET consists of the following modules: cognitive restructuring (labeled flexible thinking), behavioral activation (labeled positive activities), gratitude, and self-compassion. Participants complete these COMET modules by themselves. The format is reading psychoeducational along with completing specific activities."
62112801|NCT03168204|EXPERIMENTAL|Risk of being frail experimental group|
62112802|NCT03168204|NO_INTERVENTION|Risk of being frail control group|
62112803|NCT03168204|NO_INTERVENTION|No/low risk of being frail|
62112804|NCT03168204|NO_INTERVENTION|Risk of being frail care avoiders|
62112805|NCT00732368|EXPERIMENTAL|Mometasone Nasal Spray|Open-label. Two sprays per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
62112806|NCT00366353|OTHER|1|Sedation suring a spontaneous breathing trial.
62302523|NCT00012610|OTHER|Arm 1|
62302524|NCT05434546|EXPERIMENTAL|Sepranolone|Sepranolone 10 mg sc twice weekly for 12 weeks alongside the patient's standard of care Tourette treatment.
62302525|NCT05434546|NO_INTERVENTION|No Intervention|Continuation of the patient's standard of care Tourette treatment for 12 weeks.
62302526|NCT05564130|EXPERIMENTAL|Sodium bicarbonate|50 ml of 1 mmol/ml sodium bicarbonate given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 ml of 1 mmol/ml sodium bicarbonate will be administered after the second dose of adrenaline dose for a maximum of two doses.
62302527|NCT05564130|PLACEBO_COMPARATOR|Placebo|"50 mL of 9 mg/mL NaCl (normal saline) given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 mL of 9 mg/mL NaCl will be administered after the second dose of adrenaline dose for a maximum of two doses."
62112807|NCT00366353|OTHER|2|No sedation during spontaneous breathing trial
62112808|NCT02909751|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv"
62674181|NCT05816473|EXPERIMENTAL|Large Language Model-based Interaction|LLM-powered chatbot with the machine learning dashboard to provide the risk assessment and provide rationale based on interpretability metrics provided by the dashboard in which study participants can directly interact with using natural language. Participants will be provided the Generative Pre-trained Transformer (GPT) chatbot powered machine learning model dashboard.
62302528|NCT00691548|EXPERIMENTAL|1|
62302529|NCT02724033|ACTIVE_COMPARATOR|Group A|Group A - regional nerve block
62302530|NCT02724033|ACTIVE_COMPARATOR|Group B|Group B - antiemetic
62302531|NCT02724033|ACTIVE_COMPARATOR|Group C|Group C - block and antiemetic
62302532|NCT03032744|EXPERIMENTAL|Intervention|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the intervention group will be prescribed the appropriate asthma therapy based on their assessment (i.e. providing 'asthma assessment \& management'), and receive the morning dose of their daily asthma controller medication at school on school days.
62302533|NCT03032744|ACTIVE_COMPARATOR|Usual Care|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the usual care group will be provided with the results of their asthma assessment and be instructed to follow up with their primary care provider. They will continue to receive all of their daily asthma controller medication at home.
62471538|NCT01597245|EXPERIMENTAL|80 mg ixekizumab Dosing Regimen 3|Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
62674182|NCT05816473|NO_INTERVENTION|Machine Learning Dashboard|Machine learning algorithm output with an interactive dashboard that can be used to explain, or interpret the input factors that contribute most towards the generated risk score. Participants will have access to the machine learning dashboard only.
62674183|NCT05948982|EXPERIMENTAL|Human Umbilical Cord Mesenchymal Stem Cells|The trial was divided into three dose groups： Low-dose group: 1000000 cells/kg Medium-dose group: 2000000 cells/kg High-does group: 4000000 cells/kg
62674184|NCT03967665|EXPERIMENTAL|Treatment arm|NAC 400 mg three times per day from -14D pre-HSCT to +2 months
62674185|NCT03967665|NO_INTERVENTION|Control arm|No-NAC concurrent control according to a 2:1 schedule.
62674186|NCT02111356|EXPERIMENTAL|Pinhole glasses|All subjects perform ophthalmic examinations before and after the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
62674187|NCT05629338|EXPERIMENTAL|Cohort 1|Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 1 unit (200 mL) of autologous FrontlineODP.
62674188|NCT05629338|EXPERIMENTAL|Cohort 2|Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection, in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 2 units (400 mL) of autologous FrontlineODP.
62674189|NCT05629338|ACTIVE_COMPARATOR|Cohort 3 Arm 3|Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous FrontlineODP and 4 units of autologous control PF24. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 3 will receive 4 units of FrontlineODP during the first infusion visit, and following a 14 day washout period, they would receive 4 units of PF24 during a second visit.
62112809|NCT02909751|EXPERIMENTAL|Neoadjuvant chemotherapy + tocotrienol|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3"
62112810|NCT05207137|EXPERIMENTAL|Telephone call from family physician|Individuals allocated to the experimental arm will receive a phone call from the their family physician, where they are offered the opportunity to raise questions they might have about the COVID-19 vaccine.
62112811|NCT05207137|NO_INTERVENTION|Usual care|
62112812|NCT01229839|EXPERIMENTAL|infusion group|Infusion of anticancer agent followed by Embolization
62112813|NCT01229839|EXPERIMENTAL|lipiodol chemotherapy group|Infusion of mixture of anticancer agent and lipiodol followed by Embolization
62302534|NCT05888116|EXPERIMENTAL|Hidratante HA|"The investigational product consists of a new vaginal moisturizing gel (class IIb medical device) presented in the form of 5 ml single-dose containers. Each patient will be given 12 single-dose containers inside white boxes identified only with the patient code.~For each participant, the total duration of treatment will be 4 weeks."
62302535|NCT05888116|ACTIVE_COMPARATOR|Cumlaude Hidratante Interno®|"The investigational product is a marketed vaginal moisturizing gel (class IIb medical device) presented in the form of 5 ml single-dose containers. Each patient will be given 12 single-dose containers inside white boxes identified only with the patient code.~For each participant, the total duration of treatment will be 4 weeks."
62471539|NCT01597245|ACTIVE_COMPARATOR|50 mg etanercept|Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
62471540|NCT01597245|PLACEBO_COMPARATOR|Placebo for ixekizumab|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
62302536|NCT01702142||NIATx Only|NIATx (Network for the Improvement of Addiction Treatment) organization change model only
62471541|NCT01181700|EXPERIMENTAL|Treatment A|
62674190|NCT05629338|ACTIVE_COMPARATOR|Cohort 3 Arm 4|Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous control PF24 and 4 units of autologous FrontlineODP. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 4 will receive 4 units of PF24 during the first infusion visit, and following a 14 day washout period, they would receive 4 units of FrontlineODP during the second visit.
62674191|NCT00756444|ACTIVE_COMPARATOR|Panitumumab plus Chemotherapy|Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
62674192|NCT00756444|ACTIVE_COMPARATOR|Chemotherapy Alone|Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
62674193|NCT06265610||group 1|Total intravenous anesthesia with target-controlled infusion (TCI/TIVA) was applied as an anesthesia method to be applied to patients during cardiology angiography procedures.
62112814|NCT02276820|EXPERIMENTAL|Viralym-A|"Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection. Patients will receive 2 x 10\^7 partially HLA-matched Viralym-A/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
62112815|NCT05315336|EXPERIMENTAL|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
62302537|NCT01702142||NIATx and Advancing Recovery|Organizational and system changes
62302538|NCT06483776||COPD|Patients with Chronic Obstructive Pulmonary Disease
62112816|NCT04479254|EXPERIMENTAL|Indirect Calorimetry- Directed Nutrition|Enteral Nutrition (EN) will be the preferred route of nutrition, and will be initiated within the first 24-48 hours of ICU admission. Caloric requirements will be measured by indirect calorimetry IC as soon as possible after recruitment and will be repeated in every 24 hrs. The amount of delivery is gradually increased to avoid the possibility of gastrointestinal intolerance. If EN fails to reach caloric goals or not feasible supplementary Parenteral nutrition(PN) will be initiated after 5-7days
62112817|NCT04479254|ACTIVE_COMPARATOR|Standard weight-based equation- Directed Nutrition|Enteral Nutrition (EN) will be initiated within the first 24-48 hours of ICU. Admission. Enteral nutrient delivery is gradually increased to avoid the possibility of gastrointestinal intolerance so that a few days are required to achieve the caloric target. PN will be started after 5-7 days if EN is not feasible. Energy and protein goals will be calculated by the standard weight-based equation of 25 kcal/kg BW body weight and 1.2-2.5 g/kg body weight, respectively.
62112818|NCT02125825||Parkinson's disease on levodopa|Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms
62302539|NCT05992077|EXPERIMENTAL|Therapeutic phase|Children and adolescents confirmed with active HCV infection (positive HCV RNA) during the screening phase will be referred to a specific consultation in Kantha Bopha hospital and in the National Pediatric Hospital for treatment after evaluation of liver disease. Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks. For all children and adolescents, residual plasma concentrations (trough concentrations) of the drugs will be assessed after 2 weeks of treatment.
62302540|NCT05998343|EXPERIMENTAL|HOW R U? intervention delivered by same-generation peer volunteer|HOW R U?
62302541|NCT05998343|EXPERIMENTAL|HOW R U? intervention delivered by intergenerational volunteer|
62302542|NCT05998343|NO_INTERVENTION|Waitlist control group|After the primary outcome assessment at 12 weeks, control group participants will be offered HOW R U? intervention support outside of the main trial. They will be allowed to choose either intergenerational or same-generation versions.
62302543|NCT05309083|EXPERIMENTAL|Mindfulness Based Walking Therapy (MBWT)|Participants will participate in MBWT.
62302544|NCT02058121|EXPERIMENTAL|Acceptance and Commitment Therapy|
62302545|NCT02058121|ACTIVE_COMPARATOR|Treatment as usual|
62302546|NCT00704106||Group 1|Persistent viremia after 48 weeks or longer.
62302547|NCT00704106||Group 2|\<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
62302548|NCT00704106||Group 3|Patients who responded to adefovir and were switched to entecavir.
62302549|NCT00704106||Group 4|Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.
62302550|NCT06028815|EXPERIMENTAL|Experimental group|Informal carers receive 10 music therapy sessions
62302551|NCT06028815|NO_INTERVENTION|Control group|Informal carers do not receive music therapy sessions
62471542|NCT01181700|EXPERIMENTAL|Treatment B|
62471543|NCT01181700|EXPERIMENTAL|Treatment C|
62471544|NCT01181700|ACTIVE_COMPARATOR|Treatment D|
62471545|NCT01181700|ACTIVE_COMPARATOR|Treatment E|
62471546|NCT01181700|ACTIVE_COMPARATOR|Treatment F|
62471547|NCT01181700|ACTIVE_COMPARATOR|Treatment G|
62471548|NCT03369860|EXPERIMENTAL|Healthy Subjects|Healthy Subjects take part in the experimental manipulation
62674194|NCT06265610||Group 2|In the anesthesia method to be applied to patients during cardiology angiography procedures, inhalation anesthesia was applied.
62302552|NCT03648450||Propeller Smart Inhaler EMD|All enrolled participants will be given the Propeller Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
62302553|NCT06127212|EXPERIMENTAL|Test Dapagliflozin Dexa Medica|Dapagliflozon 10 mg Film-Coated tablet, produced by PT Dexa Medica, Indonesia.
62302554|NCT06127212|ACTIVE_COMPARATOR|Reference Forxiga AstraZeneca|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia.
62302555|NCT03473873||SHIELD|Patients with anterior cruciate ligament injury
62302556|NCT03503123||COPD patients with deventilation dyspnoea|Ten severe COPD patients (age\>18yr) using chronic NIV with severe symptoms of deventilation dyspnoea (Borg Dyspnoea Scale ≥ 5)
62302557|NCT03503123||COPD patients without deventilation dyspnoea|Ten severe COPD patients (age\>18yr) using chronic NIV without symptoms of deventilation dyspnoea, matched with the first cohort/group with regard to the degree of static lung hyperinflation and NIV settings.
62674195|NCT04885712|EXPERIMENTAL|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo
62302558|NCT03149835|EXPERIMENTAL|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
62674196|NCT04885712|EXPERIMENTAL|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo
62674197|NCT04885712|ACTIVE_COMPARATOR|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo
62674198|NCT05994534|ACTIVE_COMPARATOR|cysteamine|Single dose, tablets in current treatment dose
62302559|NCT03149835|EXPERIMENTAL|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
62302560|NCT02863263|OTHER|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
62674199|NCT05994534|EXPERIMENTAL|NPI-001|Single dose, NPI-001 (N-acetylcysteine amide) oral solution at molar equivalent of current cysteamine dose.
62674200|NCT03315689|PLACEBO_COMPARATOR|Vehicle|Vehicle
62674201|NCT03315689|EXPERIMENTAL|Active|ATI-50002 Topical Solution
62674202|NCT00001215||Control|healthy volunteers
62674203|NCT00001215||Family Member|a family member of a documented proband
62674204|NCT00001215||Patient|the participant on initial screening must be found to have or be a carrier of a documented lysosomal storage disorder
62674205|NCT04746183|EXPERIMENTAL|CST-2 EIDD-2801 Phase Ib|EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.
61917226|NCT01873703|EXPERIMENTAL|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
61917227|NCT01873703|PLACEBO_COMPARATOR|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
62302561|NCT02863263|OTHER|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
62302562|NCT00451087|EXPERIMENTAL|1|
62302563|NCT00451087|ACTIVE_COMPARATOR|2|
62674206|NCT04746183|NO_INTERVENTION|CST-2 Control|Phase 1b only (standard of care)
62674207|NCT04746183|PLACEBO_COMPARATOR|CST-2 Placebo|Phase II placebo blinded controlled
62674208|NCT04746183|EXPERIMENTAL|CST-3A Nitazoxanide|Phase Ia Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur
62674209|NCT04746183|EXPERIMENTAL|CST-5 VIR-7832 Phase I|Phase I: Single doses of VIR-7832 will be administered by intravenous (IV) infusion. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated.
62674210|NCT04746183|ACTIVE_COMPARATOR|CST-5 VIR-7831 Phase II|Phase II: 500 mg dose of VIR-7831 will be given by IV infusion.
62674211|NCT04746183|PLACEBO_COMPARATOR|CST-5 Placebo Phase I|Phase I: placebo blinded controlled
62674212|NCT04746183|EXPERIMENTAL|CST3B Nitazoxanide|Phase II experimental arm.
62674213|NCT04746183|NO_INTERVENTION|CST3B Control|Standard of care
62674214|NCT04746183|EXPERIMENTAL|CST6 IV Favipiravir|IV Favipiravir twice daily for 7 days. Starting dose 600 mg twice daily. Dose escalation to 1200 mg twice daily, 1800 twice daily, 2400 twice daily.
62112819|NCT01988233|EXPERIMENTAL|BAILAMOS© Dance Program|BAILAMOS© Dance Program + Maintenance Program: includes a 4-month twice-weekly adoption phase and a 4-month twice-weekly maintenance phase. Each month during adoption a new dance style is introduced by a professional dance instructor. During the 4-month maintenance phase an indigenous dance leader, trained by the professional dance instructor, will lead dance with participants twice per week
62112820|NCT01988233|EXPERIMENTAL|Health Education Control Group|Health Education Control Group: Sedentary older Latinos randomly assigned to the health education control group will participate in classes developed for older adults and offered by the University of Illinois Extension. All classes are conducted in Spanish by extension staff using Spanish-language materials. Classes will meet one day per week for two hours, to provide equitable social contact as the treatment group.
62112821|NCT00817635|EXPERIMENTAL|LCI699 0.25 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.25 mg, capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
62112822|NCT00817635|EXPERIMENTAL|LCI699 1 mg QD|Following a 2-week placebo run-in period, participants received LCI699 1 mg, capsules, orally, once daily (QD), with or without food for up to 8 weeks.
62112823|NCT00817635|EXPERIMENTAL|LCI699 0.5 mg followed by LCI699 1 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.5 mg, capsules, orally, BID, with or without food for up to 4 weeks, followed by LCI699 1 mg, capsules, orally, BID with or without food for up to 4 weeks.
62112824|NCT00817635|ACTIVE_COMPARATOR|Eplerenone 50 mg BID|Following a 2-week placebo run-in period, participants received eplerenone 50 mg, capsules, orally, BID, with or without food for up to 8 weeks.
62112825|NCT00817635|PLACEBO_COMPARATOR|Placebo|For a 2-week placebo run-in period, followed by 8 weeks of the treatment period, participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food.
62112826|NCT03311568|EXPERIMENTAL|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
62112827|NCT03311568|EXPERIMENTAL|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
62112828|NCT03311568|EXPERIMENTAL|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
62112829|NCT03311568|EXPERIMENTAL|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
62112830|NCT00662636|EXPERIMENTAL|Arm I|Patients receive oral dasatinib and lapatinib ditosylate once daily on days 1-28.
62112831|NCT02819336|EXPERIMENTAL|Electroacupuncture (EA) group|"1. Electroacupuncture therapy (10 sessions within 21 days)~2. CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~3. 20 minutes duration with middle frequency (30 Hz) of electrical stimulation~4. Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
62302564|NCT02549950|ACTIVE_COMPARATOR|Conventional OrthodonticTreatment|Conventional orthodontic mechanics: canine and incisor retraction
62302565|NCT02549950|EXPERIMENTAL|Accelerated Tooth Movement|Accelerated orthodontics: Peizo-Corticision Accelerated canine and Incisor retraction
62302566|NCT05953064|EXPERIMENTAL|DHA-NAT|Oral administration with a test meal of 55 kJ/kg bodyweight, with 60% of calories from fat.
62302567|NCT05953064|PLACEBO_COMPARATOR|Placebo|Oral administration with a test meal of 55 kJ/kg bodyweight, with 60% of calories from fat.
62302568|NCT06498037|EXPERIMENTAL|Intervention arm|Patients are given loading doses when dose-increasing fentanyl. The concentrations at 12 and 48 hours after dose increase will be compared
62302569|NCT03306147|EXPERIMENTAL|Chronic pain or long-acting opioid use|Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.
62302570|NCT03944837|EXPERIMENTAL|Severe fetal congenital heart disease (CHD)|Mothers whose fetuses have a diagnosis of CHD will be exposed to 10-15 L/minute of oxygen while undergoing echocardiogaphy and MRI scanning
62302571|NCT02912871|EXPERIMENTAL|MRIgHIFU unilateral subthalamotomy|Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
62674215|NCT04746183|NO_INTERVENTION|CST6 Control|Standard of care
62674216|NCT04746183|EXPERIMENTAL|CST-2 EIDD-2801 Phase II|"EIDD-2801 (also known as MK-4482, molnupiravir).~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
61917228|NCT04178369|EXPERIMENTAL|Experimental-Study Group|In addition to the conservative treatment of the control group, proximal and distal tibiofibular joint manipulations will be applied for 6 weeks.
61917229|NCT04178369|ACTIVE_COMPARATOR|Control Group|All participants were given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept (conservative treatment) for 5 days a week, 45 minutes each.
62302572|NCT00404729|OTHER|Citicoline treatment|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
62302573|NCT01440101|EXPERIMENTAL|Double-blind Natalizumab 300 mg|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
62471549|NCT01839279|EXPERIMENTAL|Tizanidine|Oral dose of 2 and 4 milligram (mg) tablets
62302574|NCT01440101|PLACEBO_COMPARATOR|Double-blind Placebo|IV infusions of placebo over 60 minutes every 4 weeks for 20 weeks
62302575|NCT01440101|EXPERIMENTAL|Open-label Natalizumab|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
62471550|NCT01839279|PLACEBO_COMPARATOR|Placebo|Placebo followed by a single dose 400 mg moxifloxacin tablets.
62471551|NCT01839279|ACTIVE_COMPARATOR|Moxifloxacin|Single dose of 400 mg moxifloxacin followed by placebo.
62471552|NCT06412016|EXPERIMENTAL|Peer Nutritional Counseling + Urban Gardening|Participants in the intervention clinics will receive: 1) nutritional counseling from peer counselors in their clinic (4 sessions administered); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (2 group training workshops and monthly individual follow-up); 3) low-cost tanks for water storage to participants whose communities only have water on certain days; 4) access to community gardens; and 5) two cooking and nutrition workshops.
62302576|NCT05732129|EXPERIMENTAL|Fluzoparib plus Irinotecan|Patients will receive Fluzoparib combined with Irinotecan treatment protocol, which included irinotecan asintravenous infusion at 180mg/m2 (on day 1) and Fluzoparib 150mg capsules given bid (days 1-7) every 2 weeks .
62471553|NCT06412016|NO_INTERVENTION|Usual Care Control|Participants in the control clinics will receive their usual care from the clinic. After 18-month follow-up, they will be offered the opportunity to receive the intervention.
62471554|NCT03797183||Premature Infants|Premature infants \>1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
62471555|NCT03797183||Chronic Respiratory Disease|Participants ages \>1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
62471556|NCT03797183||Neuromuscular Disease|Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
62471557|NCT03797183||Healthy Controls|Age and height matched healthy controls
62471558|NCT03797183||V/Q Scan validation|Adults or children who are having or have recently had a V/Q scan
62471559|NCT03797183||Premature Infants (Longitudinal Cohort)|Premature infants ages 2 weeks to 1 year with diagnosed or suspected bronchopulmonary dysplasia
62674217|NCT04746183|EXPERIMENTAL|CST-8 Phase I Molnupiravir + Paxlovid®|Molnupiravir 800mg Twice a day (BD) in combination with Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required. The dose of Paxlovid® will be fixed for all cohorts.
62112832|NCT02819336|SHAM_COMPARATOR|Park sham (PS) group|"1. Non-penetrating Park sham electroacupuncture treatment (10 sessions within 21 days)~2. CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~3. 20 minutes duration with undelivered electrostimulation of middle frequency (30 Hz)~4. Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
62112833|NCT02993510|ACTIVE_COMPARATOR|microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair
62112834|NCT02993510|EXPERIMENTAL|Microfracture with Chondro-Gide sutured|Microfracture covered with a collagen membrane (Chondro-Gide®) using atraumatic sutures in a one-step mini-arthrotomy procedure
62302577|NCT06513676||Super selective adrenal artery embolization|SAAE for primary aldosteronism
62112835|NCT02993510|EXPERIMENTAL|Microfracture with Chondro-Gide glued|Microfracture covered with a collagen membrane (Chondro-Gide®) using fibrin glue in a one-step mini-arthrotomy procedure
62112836|NCT06252506|EXPERIMENTAL|Placebo first, intervention second|Participants allocated to this arm receive placebo on their first study day and the active drug under investigation on the second study day.
62112837|NCT06252506|EXPERIMENTAL|Intervention first, placebo second|Participants allocated to this arm receive the active drug under investigation on their first study day and placebo on the second study day.
62112838|NCT00739102|EXPERIMENTAL|1|S.M.A.R.T.® Nitinol Self-Expandable Stent System
62112839|NCT01414842|ACTIVE_COMPARATOR|Standard|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
62112840|NCT01414842|EXPERIMENTAL|Automated profiled|Automate sodium profiling in endogenous hemodiafiltration
62302578|NCT06513676||adrenectomy|Surgery to remove part of the adrenal gland
62302579|NCT06513676||Standard drug therapy|Drug treatment of primary aldosteronism
62302580|NCT05936086|EXPERIMENTAL|CTX(Cytoxan) group|
62302581|NCT05936086|ACTIVE_COMPARATOR|Normal treatment group|
62302582|NCT00142506|ACTIVE_COMPARATOR|1|radiotherapy with hormones, questionaire assessments
62302583|NCT00142506|PLACEBO_COMPARATOR|2|radiotherapy without hormones, questionaire assessments
62302584|NCT04763525|EXPERIMENTAL|Intervention group Pythagorean Self-Awareness in patients with type 2 diabetes|N=21 patients with type 2 diabetes
62302585|NCT04763525|EXPERIMENTAL|Intervention group Pythagorean Self-Awareness for healthy individuals|N=27 healthy individuals
62302586|NCT03364218|EXPERIMENTAL|Treatment Group|Subjects will receive N-Acetyl Cysteine (NAC) nebulized 2 mL of 10% NAC solution every 12 hours during their stay in the Pediatric Intensive Care Unit.
62302587|NCT03364218|NO_INTERVENTION|Control Group|Subjects will not receive NAC, but will receive standard care for acute bronchiolitis.
62471560|NCT03797183||Pulmonary Vein/Artery Stenosis|Children age 2 months to 18 years, who will be undergoing cardiac catheterization for pulmonary vein stenosis, pulmonary hypertension and/or pulmonary artery stenosis
62471561|NCT06176326|EXPERIMENTAL|Implementation of the Developed Ethics Education Program|The developed education program will be implemented as a 7 week-2 hour session.
62471562|NCT03429725|EXPERIMENTAL|Individualism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For individualism condition, participant is tasked to write statements relating to his/her differences from the his/her immediate community, circle pronouns that relate to the self, and read passages related to individualism.
61917230|NCT05000112||Patients with mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is seen on surface of the vaginal mucosa, the patient is diagnosed with mesh exposure.
62112841|NCT02093533|EXPERIMENTAL|Eculizumab|Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - \<40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
62112842|NCT06480123|EXPERIMENTAL|Stem Cell Derived Exome|
62112843|NCT01908634|ACTIVE_COMPARATOR|Milk-based Strawberry Beverage no meal|Milk-based Strawberry beverage without meal
62112844|NCT01908634|EXPERIMENTAL|Water-based Strawberry Beverage no meal|Water-based Strawberry beverage without meal
62112845|NCT01908634|ACTIVE_COMPARATOR|Milk-based strawberry Beverage with meal|Milk-based Strawberry beverage with meal
62112846|NCT01908634|EXPERIMENTAL|Water-based strawberry Beverage with meal|Water-based Strawberry beverage with meal
62112847|NCT03037502|EXPERIMENTAL|Intervention: Tailor Made|Intervention Arm: In the pilot intervention, participants will receive: tailored goals/ messages, self-monitoring, weekly small groups to receive health education and community-based information and resources. Participants will also complete two assessment with blood work and anthropometric measurements. These intervention components were selected based on investigator's formative research and experience using them in prior studies. These components will be implemented simultaneously as they complement one another. While all of these components have not been tested together in an intervention for this population, they are variations and enhancements of previous interventions by the investigators.
62112848|NCT03037502|NO_INTERVENTION|Comparison|Comparison Condition: Participants in the attention control group will receive self-help materials on how to improve healthy eating, physical activity and weight loss, self-monitoring, and complete two assessments with blood work and anthropometric measurements. Participants in this condition will receive a copy of their assessment data and the nurses will provide this personalized information as well as answer any questions participants may have about their assessment results.
62112849|NCT01685528|EXPERIMENTAL|CBT|
62112850|NCT05553613|ACTIVE_COMPARATOR|ticagrelor arm|The ticagrelor arm will receive (180 mg loading dose during the first 12 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day)
62112851|NCT05553613|ACTIVE_COMPARATOR|clopidogrel arm|The clopidogrel arm will receive (a 300 mg loading dose during the first 12 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day).
62112852|NCT03652207|PLACEBO_COMPARATOR|Sucrose|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
62112853|NCT03652207|EXPERIMENTAL|Palatinose(TM)|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
62112854|NCT04954040|EXPERIMENTAL|Hydroxychloroquine + Azithromycin|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin. 1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0~Oral intake in all cases. Pills will be taken simultaneously."
62112855|NCT04954040|ACTIVE_COMPARATOR|SOC (Standard of Care)|"SOC for symptoms treatment~Acetaminophen or Metamizole, 1-1-1 Antitussives if needed"
62112856|NCT02002819|EXPERIMENTAL|Levetiracetam-Placebo|This group receives levetiracetam for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives placebo for 4 weeks.
62112857|NCT02002819|EXPERIMENTAL|Placebo-Levetiracetam|This group receives placebo for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives levetiracetam for 4 weeks.
62112858|NCT01194258|EXPERIMENTAL|Lispro-PH20/Insulin lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next, participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (combined: Lispro-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
62112859|NCT01194258|EXPERIMENTAL|Aspart-PH20/Insulin Lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 U/mL insulin glulisine, injected SC, pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 µg/mL rHuPH20 (combined: Aspart-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
62112860|NCT03787706|EXPERIMENTAL|Dry needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
62112861|NCT03787706|ACTIVE_COMPARATOR|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
62302588|NCT01697345|EXPERIMENTAL|Vaginal Testosterone|Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).
62302589|NCT04874740||Kidney transplant recipients|Collection of data from kidney transplant patients at regular outpatient check-ups.
62674218|NCT04746183|NO_INTERVENTION|CST-8 Phase I Molnupiravir + Paxlovid® Control|Standard of care
61917231|NCT05000112||Patients without mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is not seen on surface of the vaginal mucosa, bimanual examination will be performed to confirm no foreign body can be feeled on surface of the vaginal mucosa. Then the patient belong to this group.
62674219|NCT04746183|ACTIVE_COMPARATOR|CST-5 VIR-7832|Phase II: 500 mg dose of VIR-7832 will be given by IV infusion.
62674220|NCT04746183|PLACEBO_COMPARATOR|CST-5 Placebo Phase II|Phase II: placebo blinded controlled
62674221|NCT04746183|EXPERIMENTAL|CST-9a Monotherapy|Phase II: ALG-097558 600 mg twice a day orally for 5 days
62674222|NCT04746183|EXPERIMENTAL|CST-9a Combination|Phase II: ALG-097558 600 mg twice a day orally for 5 days in combination with IV remdesivir for 3 days (200 mg day 1, 100 mg day 2 and 3)
62674223|NCT04746183|ACTIVE_COMPARATOR|CST-9a Control|Phase II : standard of care
62674224|NCT04217057|EXPERIMENTAL|64Cu-DOTA-ECL1i-PET/CT|-64CU-DOTA-ECL1i-PET/CT imaging consisting of a dynamic scan centered at the level of the known tumor followed by a limited body scan of the head/neck and upper chest will be performed
62674225|NCT05358912|ACTIVE_COMPARATOR|Control|"Patients who are diagnosed with septic shock and who have intra-abdominal pressure of less than 8 mmHg.~Target mean arterial pressure is 65 mmHg and above."
62674226|NCT05358912|ACTIVE_COMPARATOR|MAP Group|"Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg.~Target mean arterial pressure is 65 mmHg and above."
62112862|NCT01357044|ACTIVE_COMPARATOR|Plant extracts|
62112863|NCT01357044|PLACEBO_COMPARATOR|Placebo|
62112864|NCT01956669|EXPERIMENTAL|Pazopanib|All subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
62112865|NCT05716373|EXPERIMENTAL|Experimental:|reiki will be aplicated
62112866|NCT05716373|NO_INTERVENTION|control|Routine maintenance will be applied.
62112867|NCT00227032|EXPERIMENTAL|Subjects receiving EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
62112868|NCT00227032|EXPERIMENTAL|Subjects NOT taking EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
62112869|NCT03582618|EXPERIMENTAL|Sorafenib + CVM-1118|"Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)~400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.~Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)~Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
62112870|NCT05997199||Group 1|Patients with vitamin D deficiency and having Vitamin D Replacement
62112871|NCT05997199||Group 2|Control Group. Patients with vitamin D deficiency but not getting Vitamin D replacement
62302590|NCT02650011||ACLF cohort|Patients who have chronic liver disease and admitted for acute deterioration of liver function
62302591|NCT02371629|EXPERIMENTAL|NVA237 Twice daily|Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
62674227|NCT05358912|EXPERIMENTAL|APP Group|"Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg.~Target abdominal perfusion pressure is 65 mmHg and above."
62674228|NCT06547801|EXPERIMENTAL|2'-fucosyllactose|3 g/day of 2'-FL powder orally once daily for 12 weeks
62674229|NCT06547801|PLACEBO_COMPARATOR|Maltodextrin|3 g/day of banana-flavored maltodextrin powder orally once daily for 12 weeks
62112872|NCT00624312|ACTIVE_COMPARATOR|1|Pre-operatively randomized to Procrit
62112873|NCT00624312|PLACEBO_COMPARATOR|2|Pre-operatively randomized to placebo
62112874|NCT01080599|EXPERIMENTAL|conventional pubic approach|
62112875|NCT01080599|EXPERIMENTAL|inguinal approach|
62302592|NCT02371629|EXPERIMENTAL|NVA237 Once daily|Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
62302593|NCT04847271|EXPERIMENTAL|Physical activity on prescription|Physical activity on prescription is a behaviour change intervention comprising 3 components: a person-centred pre-intervention dialogue, a written prescription for individually tailored physical activity, and a structured follow-up.
62302594|NCT05223101|EXPERIMENTAL|Sequence A|TRTR
62302595|NCT05223101|EXPERIMENTAL|Sequence B|RTRT
62302596|NCT01386671|EXPERIMENTAL|Metformin glycinate|Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.
62112876|NCT03758950|PLACEBO_COMPARATOR|Placebo|Once daily inhaled placebo
62302597|NCT01386671|ACTIVE_COMPARATOR|Metformin Hydrochloride|Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.
62674230|NCT04792970|ACTIVE_COMPARATOR|Talc instilled via tunneled pleural catheter combined with standard daily drainage|This arm consists of eligible participants who are randomized to the Talc arm and would receive Talc therapy instilled into the pleural catheter.
62674231|NCT04792970|NO_INTERVENTION|Standard daily drainage|This arm consists of eligible participants who are randomized to control group and would not receive any intervention.
62674232|NCT03843970|EXPERIMENTAL|Levobupivacaine Hydrochloride 0,5%|The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.
62674233|NCT03843970|ACTIVE_COMPARATOR|isobaric bupivacaine 0,5%|The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.
62302598|NCT04934735|ACTIVE_COMPARATOR|The intervention group: received a complex case-management rehabilitation program|The intervention group was followed at 6, 12, 18, 24 months after entering the study. The follow-up was conducted by the case manager for patients in the intervention group, and by a research assistant for patients in the control group. Medical data were retrieved from the computerized medical records in the relevant hospitals.
62302599|NCT04934735|NO_INTERVENTION|The control: group received the standard care|The control group received regular care.
62302600|NCT02875288|EXPERIMENTAL|Liposomal Bupivicaine arm|"Post procedure, infiltrate wounds with liposomal bupivacaine~1. Liposomal Bupivacaine (Brand name Exparel) 266 milligram (mg)/20 mL to be diluted to 30 mL with normal saline~2. 10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
62302601|NCT02875288|ACTIVE_COMPARATOR|Plain Bupivicaine|"1. Post procedure, infiltrate wounds with plain bupivicaine~2. Plain Bupivacaine 0.25%, volume of 30 mL~3. 10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
62302602|NCT01897194||Coma Patients|Observation of EEG patterns in coma patients.
62302603|NCT00499915|EXPERIMENTAL|Secondhand Smoke Reduction and Asthma Education|Parents of children in the experimental group will receive asthma education at NICU discharge as well as a secondhand smoke reduction program.
62302604|NCT00499915|ACTIVE_COMPARATOR|Asthma Education|Parents of children in the active comparator group will receive asthma education at NICU discharge.
62471563|NCT03429725|EXPERIMENTAL|Collectivism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For collectivism condition, participant is tasked to write statements relating to his/her similarities to the his/her immediate community, circle collective pronouns, and read passages related to collectivism.
62674234|NCT04796220|EXPERIMENTAL|Arm A: GEM|
62112877|NCT03758950|ACTIVE_COMPARATOR|Mometasone|Inhaled Mometasone Furoate 220 mcg DPI
62112878|NCT04635488||Trainning group|70% of the whole participants would be randomly divided into the training group to build the predicition model.
62112879|NCT04635488||validation group|30% of the whole participant would be divided into the validation group to validate the model
62112880|NCT02931123|NO_INTERVENTION|standard|
62112881|NCT02931123|EXPERIMENTAL|treatment|rifaximine and lattulose plus low proteine diet
62112882|NCT00608673|EXPERIMENTAL|1|Patients in arm one used twice daily pimecrolimus 1% cream on their facial discoid lupus erythematosus lesions for 8 weeks.
62112883|NCT00608673|ACTIVE_COMPARATOR|2|Twice daily betamethasone valerate 0.1% cream to facial lesions of discoid lupus erythematosus for 8 weeks
62112884|NCT02940561|EXPERIMENTAL|Methotrexate - Amneal|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
62112885|NCT02940561|ACTIVE_COMPARATOR|Methotrexate - DAVA|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
62112886|NCT02655380|EXPERIMENTAL|ketamine 1|Anesthesia induction with ketamine 1 mg followed by remifentanil.
62112887|NCT02655380|EXPERIMENTAL|ketamine 2|Anesthesia induction with ketamine 2 mg followed by remifentanil.
62112888|NCT00357396|EXPERIMENTAL|Chemo followed by DSCT|"* Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.~* Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bone marrow or T-cell depleted peripheral blood stem cell transplantation on day 0.~* Graft-vs-host disease (GVHD) prophylaxis: Patients receive treatment according to institutional guidelines and are given treatment against infection.~After completion of study treatment, patients are followed periodically for at least 3 years."
62112889|NCT03070106|NO_INTERVENTION|Usual Care|usual care delivered by an endocrinologist
62112890|NCT03070106|ACTIVE_COMPARATOR|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
62112891|NCT02375048|ACTIVE_COMPARATOR|Hypofractionated WBI|Patients treated with hypofractionated Whole Breast Irradiation received Simultaneous Integrated Boost irradiation of the whole breast and surgical bed at two different dose levels using external intensity - modulated radiotherapy (VMAT RA).
62112892|NCT02375048|EXPERIMENTAL|Accelerated Partial Breast Irradiation|Patients treated with Accelerated Partial Breast Irradiation received the irradiation on surgical bed using external intensity - modulated radiotherapy (VMAT RA).
62112893|NCT06027112||Male|
62302605|NCT00860470|ACTIVE_COMPARATOR|1|Iron (27 mg) and folic acid (600 ug)
62302606|NCT00860470|EXPERIMENTAL|2|Multiple micronutrient
62302607|NCT05531240|EXPERIMENTAL|PAE|Prostate Artery Embolization (PAE)
62302608|NCT05531240|ACTIVE_COMPARATOR|TURP|Transurethral Prostate Resection (TURP)
62302609|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
62302610|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
62302611|NCT05326919||Acute myeloid Leukemia (AML)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
62112894|NCT06027112||Female|
62112895|NCT02265731|EXPERIMENTAL|Arm A (Phase 1)|Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)
62112896|NCT02265731|EXPERIMENTAL|Arm B (Phase 1)|Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
62112897|NCT02265731|EXPERIMENTAL|Arm C (Phase 1)|Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)
62471564|NCT03244553|EXPERIMENTAL|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
62674235|NCT04796220|EXPERIMENTAL|Arm B: FUS|
62674236|NCT04796220|EXPERIMENTAL|Arm C: GEM/FUS|
62674237|NCT06125379|EXPERIMENTAL|MindCARE|Group A is an experimental group that will receive mindfulness intervention for 4 consecutive weeks. Group A consists of 2-3 cohorts with 10-15 subjects per cohort.
62302612|NCT05326919||Acute lymphoblastic leukemia (ALL)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
62302613|NCT05326919||High-risk myelodysplastic syndrome (MDS)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
62302614|NCT05326919||Myeloproliferative neoplasm -related myelofibrosis|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
62302615|NCT00290472|EXPERIMENTAL|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.
62302616|NCT01006330||Elderly medical inpatients|
62471565|NCT04113265|EXPERIMENTAL|SUNEKOS ® Body|The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated 3 more times with an interval of 1 week (T2i, T3i and T4i).
62302617|NCT01947270||Control group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is not implemented in the medical department. Drug prescriptions are conducted under usual care in the department.
62302618|NCT01947270||Intervention group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is implemented in the medical department.
62302619|NCT01667887||Femur Fractures|Patients with Distal Femur Fractures
62302620|NCT04813744|EXPERIMENTAL|Investigation of atraumatic restorative treatment in adults with a high risk of caries|The study group included a total of 25 healthy individuals with high caries risk who had molar teeth in their mouth with 3-4 mm depth occlusal dentin caries. In the clinical study, the infected and demineralized dentin was cleaned manually with a sterile excavator. The dentin sample was taken from the last removable and affected dentin layer at the cavity floor by one excavation for microbiological assessment. The teeth were restored with a conventional glass ionomer cement. In the 6th month, restorations were removed by using low-speed round steel bur, and the dentin samples were removed with an excavator from the cavity floor to repeat the microbiological assessment. In the first week and 6th month of atraumatic restorative treatment, the impressions were taken from the restored teeth to prepare replicas. The replicas of the twenty teeth out of 25 were randomly selected to evaluate of marginal adaptation under scanning electron microscopy.
62302621|NCT03340350|EXPERIMENTAL|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
62302622|NCT02649036||Emergency call population|Citizens over 18 years old from the Capital Region of Denmark with a first time emergency call within a two-year study period (1/12-2011-30/11-2013)
62302623|NCT02649036||Background population|Citizens over 18 years old from the Capital Region of Denmark with no emergency call within a two-year study period (1/12-2011-30/11-2013)
62302624|NCT04847128|EXPERIMENTAL|Arm I|Participants receive exercise intervention 3 times weekly for 8 weeks.
62302625|NCT04847128|NO_INTERVENTION|Arm II|Participants keep sedentary life without exercise for 8 weeks.
62302626|NCT02743468||Healthy Volunteers|Healthy Volunteers
62302627|NCT06117514|EXPERIMENTAL|Sudapyridine 30 mg single dose|Participants received Sudapyridine 30 mg single dose orally.
62302628|NCT06117514|EXPERIMENTAL|Sudapyridine 100 mg single dose|Participants received Sudapyridine 100 mg single dose orally.
62302629|NCT06117514|EXPERIMENTAL|Sudapyridine 200 mg single dose|Participants received Sudapyridine 200 mg single dose orally.
62471566|NCT06334991|EXPERIMENTAL|CD19 t-haNK with Rituximab|Participants will initially receive a single 3-week cycle of the CD19 thaNK as a single-agent regimen. Following a 1-week safety pause, participants will then receive a single 3-week cycle of CD19 t-haNK in combination with rituximab. Participants will then undergo the first tumor assessment. Participants with no evidence of progressive disease (PD) will be eligible to receive up to 2 additional 3-week cycles of CD19 t-haNK combination with rituximab.
62471567|NCT01541891|EXPERIMENTAL|PRO-148 Ophthalmic Solution|Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
62674238|NCT06125379|NO_INTERVENTION|Wait-list control group|Group B is the wait-list control group which did not receive any intervention for 4 weeks.
62674239|NCT05524909|NO_INTERVENTION|Control Group|The control group will receive a Fitbit device
62302630|NCT06117514|EXPERIMENTAL|Sudapyridine 200 mg multiple doses|Participants received Sudapyridine 200 mg orally for multiple doses.
62302631|NCT06117514|EXPERIMENTAL|Sudapyridine 300 mg multiple doses|Participants received Sudapyridine 300 mg orally for multiple doses.
62302632|NCT06117514|PLACEBO_COMPARATOR|Placebo 100 mg single dose|Participants received Placebo 100 mg single dose orally.
62302633|NCT06117514|PLACEBO_COMPARATOR|Placebo 200 mg single dose|Participants received Placebo 200 mg single dose orally.
62302634|NCT06117514|PLACEBO_COMPARATOR|Placebo 200 mg multiple doses|articipants received Placebo 200 mg orally for multiple doses.
62302635|NCT06117514|PLACEBO_COMPARATOR|Placebo 300mg multiple doses|Participants received Placebo 300 mg orally for multiple doses.
62302636|NCT04919564|EXPERIMENTAL|Furosemide group|Continuous furosemide 2 mg/hour for a period of 12 hours begins since anesthetic induction
62302637|NCT04919564|PLACEBO_COMPARATOR|Placebo group|Continuous NaCl 0.9% 2 cc/hour for a period of 12 hours begins since anesthetic induction
62302638|NCT05816681|EXPERIMENTAL|DWJ1230|
62302639|NCT05816681|EXPERIMENTAL|DWB2001|
62302640|NCT00786240|EXPERIMENTAL|A|
62302641|NCT00786240|EXPERIMENTAL|B|
62302642|NCT00565630|EXPERIMENTAL|1|Vigamox via the experiemntal device
62302643|NCT00565630|ACTIVE_COMPARATOR|2|Vigamox drops from the commercially available bottles
62302644|NCT02085811||Patients|
62302645|NCT00548912|OTHER|1 group - no arms|no arm just error message
62302646|NCT05495607||Patients|We have included 25 neonates and small infants having received CARPEDIEM® machine in France in a multicentric experience
62302647|NCT06392490|OTHER|Peer Group|-The experimental group that will apply the technology-based psychosocial program from peers
62302648|NCT06392490|OTHER|Adult Group|-The group that will apply the technology-based psychosocial program from adult
62302649|NCT06392490|NO_INTERVENTION|Control Group|Control group that will no apply the technology-based psychosocial program
62302650|NCT01199094||Patients with mutation in the Lrp5 gene|Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
62302651|NCT02261740|EXPERIMENTAL|Yoga Therapy Group|Participants will attend twice-weekly group yoga classes and be instructed to practice yoga at home one additional hour a week, using a written manual.
62302652|NCT02605577|EXPERIMENTAL|experimental group|"group of late preterm infants following new systemic nutritional management protocol during hospital stay,which including specific enteral and parenteral nutritional protocol and complication monitor, such as hyperglycemia,hypoglycemia,infection,hyperbilirubinemia and anemia(the intervention refers to thisnew systemic nutritional management protocol )"
62471568|NCT01541891|ACTIVE_COMPARATOR|Arm B. SYSTANE® Ophthalmic Solution|Drug: SYSTANE® Intervention name: SYSTANE® applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
62471569|NCT04935411||nAMD patients|patients diagnosed with Neovascular Age-Related Macular Degeneration
62471570|NCT05279560|EXPERIMENTAL|Autologous intra-ovarian PRP injection|Study group, treated with autologous intra-ovarian PRP injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention
62471571|NCT05279560|PLACEBO_COMPARATOR|intra-ovarian saline solution (NaCL) injection|Control group, treated with intra-ovarian NaCl injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention
62471572|NCT04763746||Sub-protocol 1|"Blood pressure, oxygen saturation and heart rate measured from participants selected because of their blood pressure.~Within each study session, participants will have their blood pressure, oxygen saturation and heart rate measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
62112898|NCT02265731|EXPERIMENTAL|Arm D (Phase 2)|Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
62112899|NCT03958500|EXPERIMENTAL|Comprehensive anastomotic testing|"All patients undergo:~1. Indocyanine green fluorescent angiography intraluminally and intraperitoneally~2. Air leak test~3. Methylene blue test"
62112900|NCT02029664|EXPERIMENTAL|Visual feedback distortion|Visual distortion increment based on the gait pattern
62112901|NCT05458141|EXPERIMENTAL|Group 1: Usual Education + Weekly Exposure to FYA-003|Students in grades assigned to Group 1 play FYA-003 in the classroom for 30 minutes every week for 12 weeks on a day at a time determined by the school \& research team.
62112902|NCT05458141|NO_INTERVENTION|Group 2: Usual Education + Weekly exposure to non-health related educational mobile games|Students in grades assigned to Group 2 play educational games unrelated to health in the classroom for 30 minutes every week for 12 weeks on a day at a time determined by the school \& research team.
62112903|NCT00940992|EXPERIMENTAL|DER 45 EV Gel, 1%|DER 45 EV Gel, 1% topically applied once daily to face for 12 weeks
62112904|NCT00940992|PLACEBO_COMPARATOR|Vehicle|Placebo Gel applied topically once a day for 12 weeks
62302653|NCT02605577|NO_INTERVENTION|control group|group of late preterm infants using current nutritional management protocol during hospital stay
62112905|NCT00940992|EXPERIMENTAL|DER 45 EV Gel, 5%|DER 45 EV Gel, 5% applied topically once a day for 12 weeks
62112906|NCT04118699|EXPERIMENTAL|Rifaximin|Two tablets of the investigational product per dosing (400 mg of rifaximin) are orally administered 3 times daily for 4 weeks.
62112907|NCT04118699|PLACEBO_COMPARATOR|Placebo|Two tablets of the placebo are orally administered 3 times daily for 4 weeks.
62302654|NCT02950506|ACTIVE_COMPARATOR|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
62302655|NCT02950506|SHAM_COMPARATOR|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
62302656|NCT05063370|ACTIVE_COMPARATOR|Levosimendan group|Patients will be admitted to ICU preoperatively and Levosimendan infusion will be started after insertion of an arterial line 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
62302657|NCT05063370|OTHER|Standard group|Patients will not receive Levosimendan perioperatively and will be managed with standard care according to our institutional protocol
62302658|NCT00845429|EXPERIMENTAL|Group 1: Standard-dose Cell-based Influenza Vaccine|Participants will receive a single dose of standard-dose cell-based influenza virus vaccine.
62302659|NCT00845429|EXPERIMENTAL|Group 2: High-dose Cell-based Influenza Vaccine|Participants will receive a single dose of high-dose cell-based influenza virus vaccine.
62471573|NCT04763746||Sub-protocol 2|"Respiratory rate and oxygen saturation measured from any participant.~Within each study session, participants will have their respiratory rate and oxygen saturation measured twice using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
62674240|NCT05524909|EXPERIMENTAL|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk and e-leaflet of type 2 diabetes in addition to the Fitbit .
62112908|NCT00449813|ACTIVE_COMPARATOR|1.|40 mg Pantoprazole
62112909|NCT00435799|ACTIVE_COMPARATOR|A|
62112910|NCT02174562|EXPERIMENTAL|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
62112911|NCT02174562|PLACEBO_COMPARATOR|Enhanced Usual Care|Usual care enhanced with education and controls for attention
62302660|NCT00845429|ACTIVE_COMPARATOR|Group 3: Licensed Fluzone® Influenza Vaccine|Participants will receive a single dose of licensed Fluzone® influenza vaccine.
62302661|NCT03233399|ACTIVE_COMPARATOR|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
62302662|NCT03233399|ACTIVE_COMPARATOR|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
62302663|NCT04519554|OTHER|5FR + 7FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 5FR then 7 FR
62302664|NCT04519554|OTHER|7FR + 5FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 7FR then 5FR
62302665|NCT02327650||RA and OA|Every 2 or 3 months, plain radiograph, blood and urinary tests, and MRI are performed in the painful joints of RA.
62674241|NCT05524909|EXPERIMENTAL|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
62112912|NCT00698191|EXPERIMENTAL|1|
62112913|NCT03671525|EXPERIMENTAL|Nimodipine|One 60mg capsule of nimodipine on first or second study visit
62112914|NCT03671525|PLACEBO_COMPARATOR|Placebo|One placebo capsule on first or second study visit
62112915|NCT00760708||undergoing persantine stress test|
62112916|NCT01199237|ACTIVE_COMPARATOR|Sevoflurane|Patients receive sevoflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
62112917|NCT01199237|ACTIVE_COMPARATOR|Desflurane|Patients receive Desflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
62471574|NCT04763746||Sub-protocol 3|"Oxygen saturation measured from participants expected to have low oxygen saturation.~Within each study session, participants will have their oxygen saturation measured twice using standard-of-care equipment. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
62674242|NCT02091830||Non-surgical treatment|
62112918|NCT06074380|EXPERIMENTAL|Calfactant (Infasurf)|Neonate, 28-35 weeks gestation, less than 48 hours of age, with respiratory distress syndrome on CPAP \> 30% oxygen will be given 3ml/kg of Calfacant
62112919|NCT06074380|EXPERIMENTAL|Poractant alfa (Curosurf)|Neonate, 28-35 weeks gestation, less than 48 hours of age, with respiratory distress syndrome on CPAP \> 30% oxygen will be given 2.5ml/kg of Poractant alfa.
62112920|NCT00927667|EXPERIMENTAL|Arm 1|
62112921|NCT00927667|EXPERIMENTAL|Arm 2|
62112922|NCT00927667|EXPERIMENTAL|Arm 3|
62112923|NCT00927667|EXPERIMENTAL|Arm 4|
62112924|NCT00927667|EXPERIMENTAL|Arm 5|
62112925|NCT03008499|EXPERIMENTAL|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62302666|NCT05614011|EXPERIMENTAL|Subjects 18+ years of age|"A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's (IFU) in one nostril. Mid-turbinate swab samples will be taken from the opposite nostril using Copan FLOQ Swabs and placed into MSwab buffer (Q14-116-P02), for the candidate test. In instances where opposite nostrils cannot be swabbed for both the comparator and the test under investigation, a 15-minute wait period to allow for viral reloading must occur between collecting both the comparator and the test samples on the same nostril.~Comparator RT-PCR samples will be shipped overnight with ice packs and processed for testing within 48 hours of collection. Candidate test samples will tested as soon as possible following collection, however if time is required between specimen collection and testing, the samples must be stored at 2-8 °C for up to 24 hours. Test samples must also be stored at 2-8 °C whilst the Q-POC test is running."
62471575|NCT04763746||Sub-protocol 4|"Blood pressure, heart rate, respiratory rate and oxygen saturation measured from adults lacking capacity.~Within each study session, participants will have their blood pressure, heart rate, respiratory rate and oxygen saturation measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
62471576|NCT06559254|ACTIVE_COMPARATOR|active tdcs with cognitive training|active transcranial direct current stimulation with cognitive training by N-back using computerized programme
62471577|NCT06559254|SHAM_COMPARATOR|Sham tdcs with cognitive training|Sham transcranial direct current stimulation with cognitive training by N-back using computerized programme
62471578|NCT06400355|ACTIVE_COMPARATOR|Group M|in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery.
62471579|NCT06400355|ACTIVE_COMPARATOR|Group C|similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery
62471580|NCT04852380||Patients treated by PRP injection|
62471581|NCT05376319|EXPERIMENTAL|Intravenous dose of obinutuzumab|Subjects who have clinical diagnoses of either granulomatosis with polyangiitis or microscopic polyangiitis will receive two intravenous doses of obinutuzumab
62471582|NCT05376319|ACTIVE_COMPARATOR|Intravenous dose of rituximab|Subjects who have clinical diagnoses of either granulomatosis with polyangiitis or microscopic polyangiitis will receive two intravenous doses of rituximab
61917232|NCT04360655|ACTIVE_COMPARATOR|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
62112926|NCT03008499|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62112927|NCT04952129|EXPERIMENTAL|Selenomethionine|50 micrograms of selenium as Selenomethionine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
62112928|NCT04952129|EXPERIMENTAL|Methylselenocysteine|50 micrograms of selenium as Methylselenocysteine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
62112929|NCT05921526|EXPERIMENTAL|Intervention|Point-of-care lung ultrasound
62112930|NCT05921526|ACTIVE_COMPARATOR|Control|Chest X-ray
62471583|NCT05571189|EXPERIMENTAL|Participants who receive daily activity message|The intervention group will receive instructions for a daily activity sent through SMS text message or email.
62471584|NCT05571189|PLACEBO_COMPARATOR|Participants who receive control message|"The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as I hope you have a good day."
62471585|NCT05514951|EXPERIMENTAL|Blood sampling|Blood sampling
62471586|NCT00878878|EXPERIMENTAL|Arm A|
62112931|NCT02488252|ACTIVE_COMPARATOR|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin at stable dose
62112932|NCT02488252|EXPERIMENTAL|Chinese Medicine on top of standard medical care|"Semi-individualised Chinese Medicine treatment on top of standard medical care The treatment plan consists of 5 different formulas and will be prescribed to patients categorised to 5 subgroups according to clinical manifestation. Patients having multiple manifestations that fit more than 1 subgroup will not be included.~Minor adjustment of the medication will be allowed and determined by the Chinese Medicine practitioner to reflect actual clinical practice. Dosage will follow strictly the China Pharmacopeia.~A: spleen and kidney Qi deficiency, B: spleen and kidney Yang deficiency, C: spleen and kidney Qi and Ying deficiency, D: liver and kidney Ying deficiency, E: Ying and Yang deficiency~Rehmannia-6 decoction: Wolfiporia cocos, Rehmannia glutinosa, Common macrocarpium Fruit, Dioscorea opposita , Paeonia suffruticosa Andr., Oriental waterplantain rhizome~Rehmannia-8 decoction: Radix Aconiti Lateralis preparata, Cinnamomum cassia Presl, Rehmannia-6 decoction"
62471587|NCT00878878|EXPERIMENTAL|Arm B|
62471588|NCT06502262|ACTIVE_COMPARATOR|• control|• Drug: hyperbaric bupivacaine this group will be given 3 ml (15mg) of 0.5% hyperbaric bupivacaine+0.5 ml of normal saline intrathecally.
62471589|NCT06502262|ACTIVE_COMPARATOR|•Fentanyl group|•Drug: Fentanyl this group will be given 3 ml (15 mg) of 0.5% hyperbaric bupivacaine+0.5 ml (25μg) of fentanyl intrathecally.
62302667|NCT01663649|EXPERIMENTAL|Deprexis|Deprexis (Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.)
62302668|NCT01663649|ACTIVE_COMPARATOR|Wait-list|Wait-list group (Subjects receive access to deprexis after six months)
62302669|NCT04544566|EXPERIMENTAL|Test product A new adhesive material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
62302670|NCT04544566|EXPERIMENTAL|Test product B new adhesion material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
62302671|NCT04544566|ACTIVE_COMPARATOR|Comparator|The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
62302672|NCT02054858|EXPERIMENTAL|RIPC|Preconditioning will be performed in the same manner as several previous trials. Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
62302673|NCT02054858|NO_INTERVENTION|Control|Patients randomised to this group will receive routine care associated with undergoing a CT scan.
62302674|NCT03360929|EXPERIMENTAL|experimental group|"Study drug: AZD3759 Strength: 50mg/tablet, 100mg/tablet Dose escalation:A treatment cycle consists of consecutive 21 days of dosing. two dose cohorts are planned for dose escalation, including: 150 and 250 mg twice daily.~RP2D in dose expansion."
62302675|NCT01756157|EXPERIMENTAL|SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2|SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
62302676|NCT01756157|EXPERIMENTAL|SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1|SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.
62302677|NCT01817257|EXPERIMENTAL|A: Continue treatment|Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
62302678|NCT01817257|NO_INTERVENTION|B: Discontinue treatment|Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
62302679|NCT03304808|EXPERIMENTAL|device|
62302680|NCT03304808|ACTIVE_COMPARATOR|behavioral|
62302681|NCT03304808|NO_INTERVENTION|waiting list|
62302682|NCT04026789|ACTIVE_COMPARATOR|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
62471590|NCT06502262|ACTIVE_COMPARATOR|•Dexmedetomidine group|•this group will be given 3 ml (15 mg) of 0.5% hyperbaric bupivacaine+0.5 ml (5μg) of diluted dexmedetomidine intrathecally
62471591|NCT03565133|EXPERIMENTAL|Oral quinine, gastric placebo|Oral sham feeding of quinine and a gastric capsule containing placebo (cellulose)
62302683|NCT04026789|ACTIVE_COMPARATOR|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
62471592|NCT03565133|EXPERIMENTAL|Oral placebo, gastric quinine|Oral sham feeding of placebo (tap water) and a gastric capsule containing quinine
62471593|NCT03565133|EXPERIMENTAL|Oral quinine, gastric quinine|Oral sham feeding of quinine and a gastric capsule containing quinine
62471594|NCT03565133|PLACEBO_COMPARATOR|Oral placebo, gastric placebo|Oral sham feeding of placebo (tap water) and a gastric capsule containing placebo (cellulose)
62302684|NCT05015387|ACTIVE_COMPARATOR|MINST group|Patients with periodontitis received minimally invasive non-surgical therapy .
62302685|NCT05015387|EXPERIMENTAL|MINST+PACNs group|Patients with periodontitis received minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with proanthocyanidins.
62471595|NCT05914454|EXPERIMENTAL|anakinra|anakinra 100 mg/day for 14 consecutive days
62471596|NCT05914454|NO_INTERVENTION|standard of care|
62674243|NCT04134312|EXPERIMENTAL|MVA-BN-Brachyury IV|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
62674244|NCT06355921|EXPERIMENTAL|Desmoid|"Adult patients with desmoid tumors in the soft tissues of the extremities, trunk and paravertebral region of both sexes.In the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated using MRI and CT studies and, if solid components of the tumor are detected, repeated surgical treatment is performed followed by active monitoring after 1 month.~In the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months."
62674245|NCT05476718|ACTIVE_COMPARATOR|kinesio group|"The tape will be applied in the first 24 hours postoperatively and on the 5th, 10th, 15th days of the surgery. The posterior superior iliac spine (PSI) and 12th thoracic vertebra (T12) will be marked while the participant is sitting in a comfortable position. Tape application will be made bilaterally between PSI and T12 with tapes cut in an I shape along the erector spine muscles. The anchor and end parts of the tape will be rounded. The anchor part will be glued without tension. Afterward, individuals are asked to flex and rotate their trunks as much as possible, and the middle part of the band is slightly stretched 10-15%; After the spine is brought to its normal anatomical position, the tip will be glued without tension. After sticking, the tape will be manually activated. This transaction will be carried out by both parties. After the tape adheres, individuals will be asked to keep the tape for five days until the next taping."
62302686|NCT04900701|EXPERIMENTAL|Hypocaloric|Participants placed in energy restriction.
62302687|NCT04900701|EXPERIMENTAL|Energy Balance|Participants placed in energy balance.
62302688|NCT04900701|EXPERIMENTAL|Hypercaloric|Participants placed in energy surplus.
62302689|NCT05689060|EXPERIMENTAL|Group I|received mulligan straight leg raising
62302690|NCT05689060|EXPERIMENTAL|group II|received post facilitation stretch on hamstring muscles
62302691|NCT01874483|EXPERIMENTAL|BI 187004 dose 1|multiple dose given over 14 days
62302692|NCT01874483|EXPERIMENTAL|BI 187004 dose 2|multiple dose given over 14 days
62302693|NCT01874483|EXPERIMENTAL|BI 187004 dose 3|multiple dose given over 14 days
62302694|NCT01874483|EXPERIMENTAL|BI 187004 dose 4|multiple dose given over 14 days
62471597|NCT03767361|ACTIVE_COMPARATOR|Fresh PRBCs|Neonates will receive fresh packed red blood cells transfusion within 7 days of donation
62471598|NCT03767361|ACTIVE_COMPARATOR|Old PRBCs|Neonates will receive fresh packed red blood cells transfusion older than 7 days yet within the standard range accepted universally will be transfused to this group.
62471599|NCT03660020|SHAM_COMPARATOR|local anaesthetic group|
62471600|NCT03660020|ACTIVE_COMPARATOR|hyalorounidase group|
62471601|NCT04370639|EXPERIMENTAL|AccuFlow Sensor|These 50 patients will wear the AccuFlow sensor device during their surgery, and will complete the post-procedural survey. The data will be reviewed after 25 patients, and the pilot study may be stopped at that point if it is felt that the device feasibility and tolerability have been adequately established.
62471602|NCT04457284|EXPERIMENTAL|temozolomide, cisplatin and nivolumab|Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).
62471603|NCT00385346|EXPERIMENTAL|A 1|Expressive writing
62471604|NCT00287963|EXPERIMENTAL|Vinorelbine + topotecan|
62471605|NCT05782634|EXPERIMENTAL|subjected to immediate cortical satellite implants with immediate loading|All patients involved in this study will be subjected to immediate cortical satellite implants with immediate loading
62471606|NCT04366791|EXPERIMENTAL|Supportive care (low-dose radiation therapy)|Patients undergo 1 fraction of low-dose radiation therapy.
62471607|NCT02096991|ACTIVE_COMPARATOR|Glass|consume beverage in glass first and cross over to other interventions
62471608|NCT02096991|EXPERIMENTAL|Can 1|consume one canned beverage and a glass bottled beverage first and cross over to other interventions
62471609|NCT02096991|EXPERIMENTAL|Can 2|Consume two canned beverage first and cross over to other interventions
62471610|NCT04979377||Adult premenopausal women with type 1 diabetes mellitus|One-hundred and fifty women aged from 18 to 45 years old consecutively recruited from a type 1 diabetes clinic at a tertiary hospital of Madrid, Spain
62471611|NCT03792477|EXPERIMENTAL|Part 1: Treatment A|Single 200mg IM testosterone cypionate solution (Test formulation)
62112933|NCT04884737|NO_INTERVENTION|Pre-Intervention|Pre-Intervention Group participants will have 6 visits. During the pre-intervention baseline (3 months) participants will undergo visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, conducted by the research staff: 1.) consent and preoperative, 2.) immediately following surgery in the Post Anesthesia Recovery (PAR) Unit, 3.) on transfer to the floor unit, 4.) post-operative day 1, 5.) post-operative day 3 and 6.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 40 minutes.
62112934|NCT04884737|EXPERIMENTAL|Intervention|Intervention Group participants will have 7 visits. During intervention (3 months) research staff will conduct the visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, and place the MBF dressings to the face (chin, cheeks, forehead), chest and iliac crest: 1.consent and preoperative, 2. MBF dressing placement, 3.) immediately following surgery in the PAR unit with the MBF dressings removed , 4.) on transfer to the floor unit, 5.) post-operative day 1, 6.) post operative day 3 and 7.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 55 minutes.
62112935|NCT00285688||1|Gastroscope positive for H. pylori and resistant to clarithromycin
62302695|NCT01874483|EXPERIMENTAL|BI 187004 dose 5|multiple dose given over 14 days
62674246|NCT05476718|PLACEBO_COMPARATOR|placebo group|The tape will be applied in the first 24 hours postoperatively and on the 5th, 10th, 15th days of the surgery. The placebo-tape application will be applied the lumbar region in a tension-free and horizontal form, while the spine is in a neutral position without positioning the patients. After sticking, the tape will be manually activated. After the tape adheres, individuals will be asked to hold the tape for five days until the next taping.
62674247|NCT05592730||Study Group|Patients with Unexplained İnfertility
62674248|NCT05592730||First Control Group|Healthy Multiparous Women
62674249|NCT05592730||Second Control Group|A: Patients with male infertility B: Patients with tubal factor
62674250|NCT01492803|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo arm.
62674251|NCT01492803|EXPERIMENTAL|Probiotics|The probiotics use in the study contains two strains of Lactobacillus plantarum. Each dose of the active study agent contains contains 1 g maltodextrin plus the probiotic bacteria Lp299v (5 x 109 cfu) and Lp299 (5 x 109 cfu).
62674252|NCT01663805|ACTIVE_COMPARATOR|Everolimus|SCD/ECD: BXB (2x20mg, D1 and D4) + EVL (3.0 -8.0ng/ml) + MYF (1440mg/d)+ Prednisone
62674253|NCT01663805|NO_INTERVENTION|mycophenolate sodium|SCD/ECD: BXB (2x20mg, D1 and D4) + TAC + MYF (1440mg/d)+ Prednisone
62112936|NCT00285688||2|Gastroscope positive for H. pylori and not resistant to clarithromycin
62112937|NCT00876044|EXPERIMENTAL|1|4 mg/kg every 2 weeks
62112938|NCT00876044|PLACEBO_COMPARATOR|2|matching placebo
62112939|NCT04894318|OTHER|Low-fat, low-cholesterol diet|Patients diagnosed with dyslipidemia by the endocrinologist were followed up for 12 weeks with a low-fat, low-cholesterol diet on a monthly basis, provided that they were suitable for each.
62112940|NCT05788146|EXPERIMENTAL|Blended psychological intervention|
62112941|NCT02179281|EXPERIMENTAL|Suspend Before Low feature turned ON|"MiniMed™ 640G system with the Suspend Before Low feature turned ON; continuously set on at 3,6 mmol/L (65 mg/dL). Suspend On Low Alert and Resume Basal Alert for the SmartGuard group should be set OFF.~Administered intervention: Medtronic MiniMed™ 640G system"
62112942|NCT02179281|ACTIVE_COMPARATOR|Suspend Before Low feature turned OFF|"MiniMed™ 640G system with the Suspend Before Low and Suspend On Low features are both turned OFF; Alert On Low is set at 65 mg/dL (3,6 mmol/L). Resume Basal Alert should be set OFF as well.~Administered intervention: Medtronic MiniMed™ 640G system"
62112943|NCT01879371|ACTIVE_COMPARATOR|Ibuprofen (Brufen®)|film-coated tablet
62112944|NCT01879371|ACTIVE_COMPARATOR|Ibuprofen (Nurofen Immedia®)|film-coated tablet
62302696|NCT01874483|EXPERIMENTAL|BI 187004 dose 6|multiple dose given over 14 days
62302697|NCT01874483|PLACEBO_COMPARATOR|Placebo|placebo
62302698|NCT01874483|EXPERIMENTAL|BI 187004 dose 7|multiple dose given over 14 days
62302699|NCT02593370|EXPERIMENTAL|Suprasacral Parallel Shift guided by US/MR image fusion|Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
62302700|NCT02593370|ACTIVE_COMPARATOR|Suprasacral Parallel Shift guided by US|Use of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
62302701|NCT03436264||high sensitivity to pain|
62302702|NCT03436264||low sensitivity to pain|
62302703|NCT04954677|EXPERIMENTAL|Participates being subjected to capsule endoscopy (AI-box assistant)|In this group ,Participates will be subjected to magnet controlled capsule endoscopy with AI-box assistant.
62471612|NCT03792477|ACTIVE_COMPARATOR|Part 1: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
62674254|NCT05477576|EXPERIMENTAL|Phase 1b - RYZ101|Part 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design.
62674255|NCT05477576|ACTIVE_COMPARATOR|Phase 3 - RYZ101|Actinium 225 radiolabeled somatostatin analog (SSA) for injection
62674256|NCT05477576|ACTIVE_COMPARATOR|Phase 3 - Standard of Care|Investigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.
62674257|NCT00884000|ACTIVE_COMPARATOR|1|
62674258|NCT00884000|EXPERIMENTAL|2|
62674259|NCT04245904||proffesional basketball player|
62674260|NCT04245904||sedentary control|
62674261|NCT05174702||Percutaneous surgery|Patient will have a percutaneous hallus valgus surgery
62674262|NCT05174702||conventional surgery|Patient will have a conventional hallus valgus surgery
62674263|NCT01163500|PLACEBO_COMPARATOR|Pill|
62674264|NCT01163500|EXPERIMENTAL|Coenzyme Q10|
62674265|NCT02207179|NO_INTERVENTION|Single Arm|LumaScan Image Guided Surgery
62302704|NCT04954677|NO_INTERVENTION|Participates being subjected to capsule endoscopy|In this group ,Participates will be subjected to magnet controlled capsule endoscopy without AI-box assistant.
62302705|NCT01723306|EXPERIMENTAL|2nd Generation Designer T Cells|All participants will receive gene modified T cells, with concomitant IL2 for 30 days post infusion.
62302706|NCT00755001||with Plasma HA|BiHapro Hip stem with PPS Ti + Plasma HA
62302707|NCT00755001||with BoneMaster HA|BiHapro Hip stem with PPS Ti + BoneMaster HA
62302708|NCT02807077|EXPERIMENTAL|Subjects with mild renal impairment|Group 1, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease \[MDRD\] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
62302709|NCT02807077|EXPERIMENTAL|Subjects with moderate renal impairment|Group 2, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease \[MDRD\] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
62302710|NCT02807077|EXPERIMENTAL|Subjects with severe renal impairment|Group 3, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease \[MDRD\] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
62302711|NCT02807077|EXPERIMENTAL|Subjects with ESRD|Group 4, will consist of patients with ESRD requiring hemodialysis who have been on a stable dialysis regimen for at least 6 months. In this cohort only, patients will participate in 2 treatment periods, Dialysis and Inter-Dialysis, separated by a 14-day period between pacritinib administration. In the Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered 4 hours prior to each patient's normally scheduled hemodialysis. In the Inter-Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered immediately after the end of the patient's normally scheduled hemodialysis session.
62302712|NCT02807077|EXPERIMENTAL|Healthy subjects|Group 5, will consist of 8 healthy subjects enrolled to match the sex-, age-, and weight of the patients with mild, moderate, and severe renal impairment and patients with ESRD enrolled in the study. Healthy subjects will be administered a single 400 mg dose of pacritinib.
62302713|NCT01045070||coronary heart disease|
62471613|NCT03792477|EXPERIMENTAL|Part 2: Treatment A|Single 200 mg IM testosterone cypionate solution (Test formulation)
62471614|NCT03792477|ACTIVE_COMPARATOR|Part 2: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
62471615|NCT02976662|EXPERIMENTAL|Artificial shrinkage|Elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
62471616|NCT02976662|NO_INTERVENTION|Without Artificial shrinkage|Vitrify expanded blastocysts.
62471617|NCT04552418|EXPERIMENTAL|Potato-based dietary starch supplement|Patients undergoing cancer treatment with dual immune checkpoint inhibitors (ICI) will receive potato-based dietary starch supplements.
62471618|NCT04826653|EXPERIMENTAL|Timing suture removal_1 week|
62471619|NCT04826653|EXPERIMENTAL|Timing suture removal_2 weeks|
62471620|NCT04826653|EXPERIMENTAL|Timing suture removal_3 weeks|
62471621|NCT05925621||Lecanemab|Patients with Alzheimer Disease receiving anti-amyloid mAb therapy at the BIDMC
62471622|NCT02443961|EXPERIMENTAL|Mesenchymal Stem Cell (MSC) therapy|There will only be one treatment arm to evaluate the security of the treatment with MSC.
62471623|NCT06122298||Individuals with gambling problems|"This group includes individuals suffering from gambling addiction as defined by the DSM-5, and individuals suffering from problem gambling, just below the DSM-5 diagnostic threshold."
62471624|NCT06122298||Healthy control individuals|Matched healthy individuals
62471625|NCT06394635||Stroke Patients with Genurecurvatum Gait|Stroke patients with genurecurvatum gait will be included.
62471626|NCT00813215|EXPERIMENTAL|1|Relatives to patients with type 2 diabetes.
62674266|NCT06406478|EXPERIMENTAL|Intervention Group|The intervention group will begin working only four days a week as a schedule change.
62674267|NCT06406478|ACTIVE_COMPARATOR|Control Group|The control group will continue to work five days per week, receiving standard practice for the schedule policies at the participating study sites.
62302714|NCT06176703|EXPERIMENTAL|Standard treatment with mobile application in diabetes mellitus patients|
62302715|NCT06176703|NO_INTERVENTION|standard treatment without mobile application in diabetes mellitus patients|
62302716|NCT00861185|EXPERIMENTAL|Senicapoc|
62302717|NCT00861185|PLACEBO_COMPARATOR|Placebo|
62302718|NCT02985346|EXPERIMENTAL|BMSC group|Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment
62302719|NCT02985346|ACTIVE_COMPARATOR|Control group|Patients received standard treatment
62302720|NCT01937312|EXPERIMENTAL|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
62302721|NCT01937312|PLACEBO_COMPARATOR|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
62302722|NCT04391140|EXPERIMENTAL|Experimental|Combination of prone position and HFNC
62302723|NCT04391140|NO_INTERVENTION|Control|Standard care: HFNC set for a SpO2 90-95% if unless indication for intubation is present.
62302724|NCT02511210|ACTIVE_COMPARATOR|regional anesthesia|spinal anesthesia or peripheral nerve block
62302725|NCT02511210|ACTIVE_COMPARATOR|general anesthesia|intubated patients
62471627|NCT00813215|ACTIVE_COMPARATOR|2|Controls with no family history of type 2 diabetes.
62471628|NCT00776048||ABI|Acquired brain injury with lower limb spasticity
62471629|NCT00776048||Healthy Controls|Age matched healthy controls
62674268|NCT05257980|EXPERIMENTAL|Dietary supplement (ONS)|All patients will receive standardised dietary advice in addition to the ONS prescribed daily for 28 days. The ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The ONS prescribed will be the same throughout the 28 days and will be taken orally.
62302726|NCT00579943||premature infants|Inpatient very low birth weight infants who are ventilated and have an umbilical arterial catheter in place
62674269|NCT04289272|EXPERIMENTAL|Dove Confident Me|Dove Confident Me body image intervention to be delivered to students 1 lesson per week for 5 weeks (5 x 45 minute lessons).
62674270|NCT04289272|NO_INTERVENTION|Control|Students receive lessons-as-usual.
61917233|NCT04360655|EXPERIMENTAL|combined with bronchoscopic microwave intervention|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
61917234|NCT01445054|EXPERIMENTAL|1-Arm 1|Subjects with primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
62112945|NCT01879371|EXPERIMENTAL|Ibuprofen+caffeine|fixed-dose-combination (FDC)
62302727|NCT04721873|EXPERIMENTAL|Intervention|
62112946|NCT04561037|ACTIVE_COMPARATOR|Control Group|Control group patients received traditional physical therapy treatment. The traditional physical therapy treatment program consisted of TMJ mobilization techniques include distraction, anterior glide, anterior glide with pre-positioned mouth opening, medial/lateral glides, caudal-anterior-medial (CAM) glide, and CAM glide with pre-positioned mouth opening and isometric exercises against resistance for muscles of mastication.
62112947|NCT04561037|EXPERIMENTAL|Study Group|Study group patients received PEMFT, using EMG 8400 PEMF device (made in Italy, by EME) in addition to physical therapy treatment program.
62674271|NCT05151965||Bankart Repair and Remplissage|Patients will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
62302728|NCT04721873|PLACEBO_COMPARATOR|Placebo|
62302729|NCT04180592|EXPERIMENTAL|CT Fusion Biopsy + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
62302730|NCT04180592|OTHER|Transrectal U/S Guided Prostate Biopsy + CT Fusion Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
62302731|NCT05802329|EXPERIMENTAL|Cohort 1 (Low Dose)|3+3 participants will receive intravitreal injection of OCU200 low dose concentration.
62471630|NCT04146987|ACTIVE_COMPARATOR|Open rotator cuff repair|Patients will be positioned in a beach chair position with the affected limb pending off the table, allowing manipulation and full range of motion range. After asepsis, antisepsis and placement of sterile surgical fields, anterolateral incision will be made in the shoulder in question; the deltoid muscle belly will be gently divided along its fibers until exposure of the subdeltoid / subacromial bursa, which will be partially excised for exposure of the subacromial space and rotator cuff tendons. After mobilization and release of the ruptured tendons and debridement of the rotator cuff footprint, the tendon repair to the bone will be performed using 5.5m metal anchors, according to the preference and technique chosen by the surgeon. In all cases, the release of the coracoacromial ligament and acromioplasty will be performed.
62674272|NCT05151965||Latarjet Coracoid Transfer|Patients will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
62302732|NCT05802329|EXPERIMENTAL|Cohort 2 (Medium Dose)|3+3 participants will receive intravitreal injection of OCU200 medium dose concentration.
62302733|NCT05802329|EXPERIMENTAL|Cohort 3 (High Dose)|3+3 participants will receive intravitreal injection of OCU200 high dose concentration.
62302734|NCT05802329|EXPERIMENTAL|Cohort 4 (High Dose/MTD + Lucentis)|3 + 3 additional participants will be enrolled to receive OCU200 (High Dose or MTD) + Lucentis (in a sequential manner on dosing dates).
62674273|NCT04468009|NO_INTERVENTION|Standard of care|Standard of care for Covid-19
62674274|NCT04468009|EXPERIMENTAL|PCC-19|Treatment with convalescent plasma
62674275|NCT04865978|EXPERIMENTAL|Apixaban|LVAD patients randomized to the experimental arm will be prescribed apixaban 5 mg twice daily.
62302735|NCT01774942|EXPERIMENTAL|Procedure/Surgery (Impants/Overdentures)|One-arm clinical intervention study: All teeth out, full dentures, dental implants, blood draw. The interventions are not experimental in nature, they are standard procedures, namely extraction of all natural teeth followed by suturing to hold soft tissue in place during initial healing; surgical insertion of commercially available dental implants; and fabrication and re-lining (filling in with acrylic the base of the denture as needed during healing and shrinking of underlying tissue) of full dentures, that is full plates in upper and lower jaw to replace all teeth.
62302736|NCT02884635|EXPERIMENTAL|ASP1707|ASP1707 will be orally administered for 12 weeks.
62302737|NCT02884635|PLACEBO_COMPARATOR|Placebo|Placebo will be orally administered for 12 weeks.
62302738|NCT05422079|EXPERIMENTAL|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week for four weeks.
62302739|NCT05422079|EXPERIMENTAL|Group motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program twice a week for four weeks.
62112948|NCT04861610|EXPERIMENTAL|Brief mindfulness based program|A four session program, each last for 2.5 hours. Brief mindfulness exercises promote stress reduction, with an introduction of mindfulness to caregivers and home practice is encouraged with guidance.
62112949|NCT04861610|ACTIVE_COMPARATOR|Psychoeducation|A four session program, each last for 2.5 hours. It promotes the coping and problem solving of caregivers. Brief home application included.
62302740|NCT05422079|EXPERIMENTAL|Group motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
62302741|NCT02975128|EXPERIMENTAL|Patients|
62302742|NCT05048472|EXPERIMENTAL|Intervention|Use of point of care viral load monitoring (Abbott PoC devices)
62471631|NCT04146987|ACTIVE_COMPARATOR|Arthroscopic rotator cuff repair|The patients will be positioned in lateral decubitus position, with the arm to be operated attached to a skin traction device, which trough a traction post and 07 kg, will maintain the shoulder in the following position: abduction of 30 to 60 and flexion of 20 to 30 degrees. After asepsis, antisepsis and placement of impermeable sterile surgical fields, a posterolateral incision will be made in the shoulder for optic introduction, with a 50 mmHg pressure pump and a 0.90 flow, and inspection of the GU joint. After joint inspection, the optic will be introduced into the subacromial space with detachment of the subacromial and subdeltoid. Using shaver blades, partial bursectomy will be performed as well as debridement of the rotator cuff footprint. The tendon will then be reinserted to the bone using metallic 5.5mm anchors. After tendon repair, the coracoacromomial ligament will be released, as well as acromioplasty.
62674276|NCT04865978|ACTIVE_COMPARATOR|Warfarin|LVAD patients randomized to the control arm will be prescribed warfarin which will be dosed to achieve an INR goal of 2-2.5
62302743|NCT05048472|NO_INTERVENTION|Control|Use of the standard of care viral load monitoring (centralized viral load monitoring)
62674277|NCT04724200||Referred from primary care for investigation of suspected heart failure|All patients recruited to the OPERA trial will have been referred from their primary care clinician for investigation of a suspected diagnosis of heart failure.
62674278|NCT06465368|EXPERIMENTAL|Arm A/Experimental/PF-07220060 plus letrozole|PF-07220060 given as tablet by mouth twice a day for 14 days. Letrozole given as tablet by mouth once a day for 14 days.
62302744|NCT01733329|EXPERIMENTAL|Misoprostol|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
62674279|NCT06465368|ACTIVE_COMPARATOR|Arm B/Control/letrozole|Letrozole given by mouth once a day for 14 days.
62674280|NCT03397758|EXPERIMENTAL|Study population|They were treated with AGNES micro-insulated needles with RF applicators in two separate sessions, at intervals of four weeks.
62302745|NCT01733329|PLACEBO_COMPARATOR|Folic Acid|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
62736098|NCT05711160||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~All patients have been undergoing CBCT scans for both jaws. Then, intraoral scanned of the dental arches of each patient have been taken using an intraoral scanner. Then measurements were made on digital images (CBCT \& IOS) and on plaster models."
62302746|NCT00795730|PLACEBO_COMPARATOR|placebo|
62302747|NCT00795730|EXPERIMENTAL|NSA-789|
62302748|NCT02502929|ACTIVE_COMPARATOR|Social Services|Participants in this arm will receive referrals for social services as indicated.
62112950|NCT04861610|NO_INTERVENTION|Treatment-as-usual|
62112951|NCT02857491|EXPERIMENTAL|ranibizumab|Intravitreal Injection of 0.5 mg ranibizumabone week before vitrectomy.
62112952|NCT02857491|SHAM_COMPARATOR|control|Sham intravitreal injection one week before vitrectomy.
62112953|NCT00680472|ACTIVE_COMPARATOR|A,1 HKT-500 Ketoprofen Topical Patch|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain
62112954|NCT00680472|PLACEBO_COMPARATOR|A,2 Placebo Patch|Treatment with placebo patch
62112955|NCT01817036|PLACEBO_COMPARATOR|Placebo|5 placebo pills per day, 16 weeks
62112956|NCT01817036|EXPERIMENTAL|400 IU|(4 placebo pills + 1 vitamin D pill) per day, 16 weeks
62302749|NCT02502929|EXPERIMENTAL|Lifestyle|"Participants in this arm will receive lifestyle modification from community health workers using the manualized lifestyle intervention called Eat, Walk, Sleep. They will receive individual home visits, health activity group sessions, and supportive phone calls."
62302750|NCT02502929|EXPERIMENTAL|Lifestyle plus Medication Therapy Management|Participants in this arm will receive everything in the Lifestyle arm, plus Medication Therapy Management (MTM). Participants will receive MTM from a pharmacist via telemedicine with the assistance of a community health worker.
62471632|NCT06561737|EXPERIMENTAL|Video group|For the students in the experimental group, the application was first demonstrated on a model by the course instructor, after which each student was required to perform the application individually. While the students were performing the application, someone not part of the research team recorded them on their phones. During the application, two researchers independently assessed the student's skills using the application checklist. Afterward, the students were asked to watch their videos and evaluate themselves over a 15-day period. After 15 days, the students were called back and asked to perform the same application again. At this stage, the researchers once again evaluated the students independently.
62471633|NCT06561737|NO_INTERVENTION|Control group|The process of insertion and removal of urinary catheterization was first explained to the students in the control group by the instructor of the course in the research team by demonstrations on the models. Then, each student was allowed to perform the application. Then, all students were invited again 15 days later for the second application. In both applications, the students were evaluated independently by the researchers.
62471634|NCT01751594|ACTIVE_COMPARATOR|H4L Comparison Intervention|
62112957|NCT01817036|EXPERIMENTAL|800 IU|(3 placebo pills + 2 vitamin D pills) per day, 16 weeks
62471635|NCT01751594|EXPERIMENTAL|MOVE Intervention|
62471636|NCT02742935|EXPERIMENTAL|camrelizumab|camrelizumab (SHR-1210) injection, 60,200,400mg/dose, intravenous infusion over 30 minutes, every 2 weeks.
62471637|NCT05499572||Inbrija followed by Cyclops|During an off episode, patients will demonstrate both inhaler user maneuvers. The researcher will observe whether the steps are followed correctly. The handling time will be recorded as well. To see whether the patients prefer a certain inhaler and to see where this preference comes from, they need to fill in a questionnaire. The questionnaire will be filled in during or directly after the off episode. Dummy inhalers are used, so patients will only inhale air (no medication).
62471638|NCT05499572||Cyclops followed by Inbrija|During an off episode, patients will demonstrate both inhaler user maneuvers. The researcher will observe whether the steps are followed correctly. The handling time will be recorded as well. To see whether the patients prefer a certain inhaler and to see where this preference comes from, they need to fill in a questionnaire. The questionnaire will be filled in during or directly after the off episode. Dummy inhalers are used, so patients will only inhale air (no medication).
62471639|NCT02514122|EXPERIMENTAL|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
62471640|NCT02514122|PLACEBO_COMPARATOR|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
62471641|NCT04821908||Group 1|population included in the VIRASTHMA COVID G4 study
62112958|NCT01817036|EXPERIMENTAL|1200 IU|(2 placebo pills + 3 vitamin D pills) per day, 16 weeks
62112959|NCT01817036|EXPERIMENTAL|2000 IU|5 vitamin D pills per day, 16 weeks
62112960|NCT01604447|ACTIVE_COMPARATOR|Incubator removal-torso bag|Use plastic bag covering the torso and lower extremities for temperature regulation with standard bundling practices when removing infant from incubator
62112961|NCT01604447|PLACEBO_COMPARATOR|Incubator removal-no plastic bag|Standard bundling practices when removing the infant from the incubator. No plastic bag used.
62112962|NCT04872829||multifocal IOL group|patients with unilateral and bilateral multifocal IOL
62112963|NCT04872829||monofocal IOL group|patients with unilateral and bilateral monofocal IOL
62302751|NCT01275404|EXPERIMENTAL|(SMRP) + nurse practitioner information phone calls|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
62112964|NCT02496793|EXPERIMENTAL|Peer Facilitator and Support Group|Peer-facilitated community support group is the experimental intervention. The intervention tested in this study involved using trained peer facilitators to create demand for and retention within the ANC/PMTCT program.The peer facilitators were volunteer women from the community, who had recently been through the ANC process themselves and could speak about their experience(s). the support group meetings was to develop skills and generate self-efficacy for the women to be able to take actions such as routine antenatal and postnatal clinic attendance using participatory learning techniques. The peer facilitators were provided with job aids which outlined key points for the various educational sessions.
62112965|NCT02496793|NO_INTERVENTION|Standard Care|ANC/PMTCT activities as per standard of care in Zimbabwe
62112966|NCT04173962|EXPERIMENTAL|Ketamine group|One 0.5mg/kg intravenous dose of ketamine
62112967|NCT04173962|ACTIVE_COMPARATOR|Midazolam group|One 0.045mg/kg intravenous dose of midazolam
62112968|NCT04910932|EXPERIMENTAL|Breathing Exercises group|Breathing exercises will be applied via teleconference by a physiotherapist 1 day a week. Individuals will perform exercises by themselves at their homes on the remaining 6 days of the week. Exercise program will be applied for 4 weeks. Individuals will also be informed about COVID-19 for once at baseline.
62112969|NCT04910932|OTHER|Control group|Individuals will be informed about COVID-19 for once at baseline.
62112970|NCT02765373||steroidal aromatase inhibitors(AIs)|Exemestane 25mg Qd for 5 years
62112971|NCT02765373||non-steroidal aromatase inhibitors(AIs)|Letrozole 2.5mg Qd or Anastrozole 1mg Qd for 5 years
62112972|NCT04042519||Healthy control|age - and sex-matched healthy individuals without lung disease
62112973|NCT04042519||Patients with mild and moderate COPD|Grading according to the GOLD guide standards
62112974|NCT04042519||Patients with severe and very severe COPD|Grading according to the GOLD guide standards
62471642|NCT04821908||Group 2|"population included in the previous studies VIRASTHMA, CHAMPIASTHMA (IRDCB No.: 2019-A03310-57), COBRAPED (NCT02114034), VIRASTHMA 2 (IRDCB No.: 2014 A01687 40, NCT: 03960359), INCOVPED (pediatric emergencies, NCT04336761)."
62674281|NCT05213390|EXPERIMENTAL|Dora follow-up phone call|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards. The entire conversation will be supervised by a clinician. This clinician will be able to interrupt the call at any point if the system fails, the patient struggles to interact with it, or DORA does not collect sufficient information from the patient. The clinician will record a clinical assessment which will be compared to the DORA assessment.
62112975|NCT04042519||The severe and very severe COPD group baseline|Severe and very severe COPD patients were in the baseline time group
62471643|NCT02252120|ACTIVE_COMPARATOR|Supreme|Supreme LMA
61917235|NCT00294281|EXPERIMENTAL|1|Participants will undergo surgical implantation of the VNS system. This will be followed by a 2-week recovery period, then a 2-week period of gradually increasing the electrical output of the VNS system, and finally a 12-week VNS treatment period during which the electrical output level will remain constant. Follow-up will occur until Month 24.
62112976|NCT04042519||The severe and very severe COPD group six months|Patients with severe and very severe COPD were six months from baseline.
62112977|NCT04042519||The severe and very severe COPD group one year|Patients with severe and very severe COPD were one year from baseline.
62112978|NCT03578640|EXPERIMENTAL|Treatment arm|Elbasvir, Grazoprevir 50-100Mg Oral Tablet
62112979|NCT00753168|EXPERIMENTAL|1|OT-730 ophthalmic solution
62112980|NCT00753168|ACTIVE_COMPARATOR|2|timolol maleate ophthalmic solution
62112981|NCT00753168|PLACEBO_COMPARATOR|3|placebo eye drops
62112982|NCT03958513|PLACEBO_COMPARATOR|Placebo|0.9% normal saline, 1.5 ml for 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
62112983|NCT03958513|EXPERIMENTAL|Intervention|0.25% Bupivacaine, 1.5 ml per 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
62112984|NCT05114044|EXPERIMENTAL|Core stability group|Patients were performed therapy 5 times a week for 45 min over a period of 3 weeks. The therapy session takes 45 min; 15 min of the session was core stability training, remaining 30 min were conventional therapy.
62112985|NCT05114044|ACTIVE_COMPARATOR|Conventional therapy group|Patients were performed therapy 5 times a week for 45 min over a period of 3 weeks. The therapy session takes 45 min of conventional therapy.
62112986|NCT05010304|EXPERIMENTAL|Pediatric Patients with a history of penicillin allergy|
62302752|NCT01275404|EXPERIMENTAL|SMRP+ACT-ED|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
62302753|NCT01676961|EXPERIMENTAL|Supportive care (romiplostim)|Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count \> 50 x 10\^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen..
62302754|NCT00513344|EXPERIMENTAL|dark chocolate containing polyphenols|dark chocolate
62302755|NCT00513344|EXPERIMENTAL|Milk chocolate containing polyphenols|Bespoke milk chocolate
62302756|NCT00513344|ACTIVE_COMPARATOR|Control chocolate with no polyphenols|cocoa-free chocolate
62302757|NCT03736044|EXPERIMENTAL|TNF-blockers withdrawal|Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
62302758|NCT03736044|NO_INTERVENTION|DMARDs control group|Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
62302759|NCT04331899|EXPERIMENTAL|Study drug Peginterferon Lambda-1a|Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
62302760|NCT04331899|PLACEBO_COMPARATOR|Placebo injection|Study participants will receive a placebo along with the standard of care treatment.
62302761|NCT05637450|EXPERIMENTAL|Fish protein supplement|Blue Whiting Protein Hydrolysate
62302762|NCT05637450|PLACEBO_COMPARATOR|Placebo|Isocalorific Maltodextrin Citrus Flavoured Powder
62302763|NCT06085157||Ecological momentary assessment (EMA)|a repeated real-time data collection in real-world environment and allows modeling of within-person processes and temporal dynamics.
62302764|NCT02420457||Back pain receiving epidural injection|Patients who have chronic back pain and are scheduled for an epidural injection to treat this pain will be receive a transforaminal epidural steroid injection as determined by routine care provider
62302765|NCT04712175||Patients with SARS-CoV-2 infection|
62302766|NCT04712175||Patients without SARS-CoV-2 infection|
62302767|NCT05021224|OTHER|Engagement strategy groups|We anticipate that approximately 25 patients will receive an engagement strategy (\~5 patients per strategy; only 1 strategy per patient). The exact strategies will be developed during the course of this R21 and cannot yet be specified. This is a non-control, pilot feasibility trial.
62302768|NCT02509546|EXPERIMENTAL|Phase I - 100mg/m^2 1-hour infusion|100mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
62302769|NCT02509546|EXPERIMENTAL|Phase I - 200mg/m^2 1-hour infusion|200mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
62302770|NCT02509546|EXPERIMENTAL|Phase I - 400mg/m^2 1-hour infusion|400mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
62302771|NCT02509546|EXPERIMENTAL|Phase I - 800mg/m^2 1-hour infusion|800mg/m\^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
62302772|NCT02509546|EXPERIMENTAL|Phase I - 400mg/m^2 4-hour infusion|400mg/m\^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
62302773|NCT02509546|EXPERIMENTAL|Phase I - 600mg/m^2 4-hour infusion|600mg/m\^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
62302774|NCT00358163|EXPERIMENTAL|PTK787/ZK 222584|
62302775|NCT02594592||Younger Women|Younger Women (age ≤ 55 years),complete questionaire
62302776|NCT02594592||Younger Men|Younger Men (age ≤ 55 years),complete questionaire
62302777|NCT02594592||Older Men|Older Men (age \> 55 years). complete questionaire
62302778|NCT02594592||Older Women|Older Women (age \> 55 years),complete questionaire
62302779|NCT04460703|SHAM_COMPARATOR|Control|Control message about birdfeeding
62302780|NCT04460703|ACTIVE_COMPARATOR|Baseline message|These participants will be assigned a message about the benefits of vaccination. All other treatment arms include this baseline language.
62302781|NCT04460703|EXPERIMENTAL|Personal freedom|Experimental message arm.
62302782|NCT04460703|EXPERIMENTAL|Economic freedom|Experimental message arm.
62302783|NCT04460703|EXPERIMENTAL|Social benefit, self-interest|Experimental message arm.
62302784|NCT04460703|EXPERIMENTAL|Social benefit, community interest|Experimental message arm.
62302785|NCT04460703|EXPERIMENTAL|Economic benefit|Experimental message arm.
62302786|NCT04460703|EXPERIMENTAL|Social pressure- guilt|Experimental message arm.
62302787|NCT04460703|EXPERIMENTAL|Social pressure- embarrassment|Experimental message arm.
62302788|NCT04460703|EXPERIMENTAL|Social pressure- anger|Experimental message arm.
62302789|NCT04460703|EXPERIMENTAL|Trust in science|Experimental message arm.
62302790|NCT04460703|EXPERIMENTAL|Not bravery arm|Experimental message arm.
62302791|NCT04642144|EXPERIMENTAL|Yerba mate and carbohydrate|Consumption of yerba mate infusion and carbohydrate-based meal.
62302792|NCT04642144|ACTIVE_COMPARATOR|Yerba mate and fasting|Consumption of yerba mate infusion and stay in a fasting state.
62302793|NCT04642144|ACTIVE_COMPARATOR|Carbohydrate and water|Carbohydrate meal consumption and water intake.
62471644|NCT02252120|ACTIVE_COMPARATOR|Laryngeal Tube|Laryngeal tube LTSII
62674282|NCT00004931|EXPERIMENTAL|Arm I|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV (administered after 1 hour of leucovorin calcium) weekly for 6 weeks.
62302794|NCT06380998||petrol station workers|Petrol station workers of 2 years duration and in direct contact with petroleum compounds vapours
62302795|NCT04518371|EXPERIMENTAL|Indirect Restoration|Milled Resin Composite Block, Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments (inorganic pigments such as ferrous oxide or titanium dioxide).
62674283|NCT00004931|EXPERIMENTAL|Arm II|Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and leucovorin calcium and fluorouracil as in arm I.
62674284|NCT00057577|EXPERIMENTAL|Cognitive therapy plus medications|Participants will receive antidepressant medication plus cognitive therapy
62674285|NCT00057577|EXPERIMENTAL|Medications alone|Participants will receive maintenance of antidepressant medication alone
62674286|NCT03364686|EXPERIMENTAL|Biotin-Labeled Red Blood Cells Infusion|Each participant will receive 2 transfusions of biotin labeled red blood cells.
62674287|NCT03943992|EXPERIMENTAL|YYD601 40mg|Esomeprazole magnesium Dihydrate.
62674288|NCT03943992|ACTIVE_COMPARATOR|Nexium 40mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
62674289|NCT06324578||subjects with AT|
62674290|NCT01134614|EXPERIMENTAL|Arm A (ipilimumab and sargramostim)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment with ipilimumab repeats every 12 weeks and treatment with sargramostim repeats every 21 days. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and patients with responsive or stable disease then continue maintenance therapy until disease progression or unacceptable toxicity.
62674291|NCT01134614|ACTIVE_COMPARATOR|Arm B (ipilimumab)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy of ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 12 weeks. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity
62674292|NCT06609148|EXPERIMENTAL|Probiotic Group|
62674293|NCT06609148|PLACEBO_COMPARATOR|Control Group|
62674294|NCT06104306|EXPERIMENTAL|B/F/TAF|Participants will receive a fixed dose combination of B/F/TAF 50/200/25 mg once daily for 24 weeks
62674295|NCT02074137|EXPERIMENTAL|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
62674296|NCT03043937||cardiac patients WHO class 1,2|
62302796|NCT04518371|ACTIVE_COMPARATOR|Direct Restoration|"3M™ Filtek™ One Bulk Fill Restorative is a visible light activated, restorative composite optimized to create fast and easy restorations.~It is composed of fillers which are a combination of a non-agglomerated/non-aggregated 20 nm silica filler, 4 to 11 nm zirconia filler, zirconia/silica cluster filler and ytterbium trifluoride filler consisting of 100nm particles. The inorganic filler loading is about 76.5% by weight (58.5% by volume)."
62302797|NCT05890703|EXPERIMENTAL|IMP2 (lidocaine-23%-tetracaine-7% gel)|
62674297|NCT03043937||cardiac patients WHO class 3,4|
62302798|NCT05890703|ACTIVE_COMPARATOR|IMP1 (EMLA 5% cream)|
62302799|NCT02833311|ACTIVE_COMPARATOR|Computer Tablet Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a computer tablet.
62471645|NCT01499628|NO_INTERVENTION|Group 1-Control|No extra training will be given.
62471646|NCT01499628|ACTIVE_COMPARATOR|Group 2-Control plus supervised reading|The same amount of contact time as Groups 3 and 4 - three 45 minute sessions completed over three weeks.
62471647|NCT01499628|EXPERIMENTAL|Group 3-EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
62471648|NCT01499628|EXPERIMENTAL|Group 4-EVT at the TRL|Eccentric viewing training at the Trained Retinal Locus (TRL), using reading/target cards and microperimeter. Three 45 minute sessions completed over three weeks.
62471649|NCT03579095|EXPERIMENTAL|American ginseng|200mg Cereboost and Maltodextrin
62674298|NCT06375876|EXPERIMENTAL|Single-Session Intervention to Promote Hope|A 30-45 minute self-guided intervention delivered in a web browser.
62674299|NCT02920554|ACTIVE_COMPARATOR|wedge resection|The extent of hepatic resection is wedge resection of gallbladder fossa
62674300|NCT02920554|ACTIVE_COMPARATOR|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy
62674301|NCT03044288|EXPERIMENTAL|Cohort 9|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin.~Standard adhesive strip and a strip with a newly developed adhesive (new adhesive strip)"
62674302|NCT01377311|EXPERIMENTAL|1|Patients suffering from unilateral limbal stem cell insufficiency. Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
62674303|NCT02268487|EXPERIMENTAL|Sertraline|Patients using Sertraline with any dose will be evaluated about Early Improvement
62674304|NCT06288711|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants randomized to TAU will continue to receive standard buprenorphine or methadone maintenance treatment from their current treatment provider and complete follow-up assessments as described above. However, they will not receive posttraumatic stress disorder treatment. Staff will mail participants an emergency naloxone kit containing two naloxone doses with simple instructions, a list of resources and contact information for mental health providers and other relevant resources in their community and assistance contacting any resources of interest.
62112987|NCT05538455|EXPERIMENTAL|Experimental group, use of PC4L solutions|Participants who will use the PC4L solutions for the estabilished period of time, in the selected scenario (home, neurorehabilitation and daycare centers), and will receive recommendations in the PC4L app
62302800|NCT02833311|ACTIVE_COMPARATOR|Paper and Pencil Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a paper-pencil diary.
62112988|NCT05538455|NO_INTERVENTION|Control group, no use of PC4L solutions|Participants who will be monitored for the estabilished period of time, in the selected scenario (home, neurorehabilitation and daycare centers), and will only receive written recommendations
62112989|NCT02250716|EXPERIMENTAL|Arm 1|Immediate treatment with Cryotherapy and 12 month cytology and histology follow-up
62112990|NCT02250716|NO_INTERVENTION|Arm 2|12 month cytology and histology follow-up
62302801|NCT02833311|ACTIVE_COMPARATOR|Contact Control Group|Participants will first meet once with a health education specialist. During this meeting the health education specialist will provide general information about engaging in healthy behaviors. Information will primarily focus on the benefits of engaging in healthy behaviors and safety precautions. Participants will then receive weekly follow-up phone calls to discuss various health topics.
62302802|NCT03003819|ACTIVE_COMPARATOR|Control Collagen Wound Dressing|Bovine collagen sponge used to control bleeding, stabilize blood clots and protect dental wounds
62302803|NCT03003819|ACTIVE_COMPARATOR|Test Collagen Matrix|Bilayer, porcine collagen matrix for soft tissue regeneration used as a socket seal in extraction socket grafting
62302804|NCT04101812|EXPERIMENTAL|Experimental group|Experimental group Pegylated liposomal doxorubicin 40mg/m2 iv every 3 weeks, for 3 cycles; PD-1 every 3 weeks, for 3 cycles.
62302805|NCT04101812|ACTIVE_COMPARATOR|Control group|PD-1 every 3 weeks, for 6 cycles.
62302806|NCT00763893|PLACEBO_COMPARATOR|A: Placebo|placebo
62302807|NCT00763893|ACTIVE_COMPARATOR|B: Losartan|Losartan
62302808|NCT02291159|EXPERIMENTAL|Intervention-DNHS technique|Dry needling of Myofascial Trigger Points
62302809|NCT02291159|SHAM_COMPARATOR|Control-Sham Dry Needling|Sham Dry Needling of Myofascial Trigger Points
62302810|NCT00016315|EXPERIMENTAL|Arm 1|Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
62302811|NCT00016315|EXPERIMENTAL|Arm 2|Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
62112991|NCT03178994|EXPERIMENTAL|2% ketoconazole cream|2% ketoconazole cream apply on face twice daily for 10 weeks.
62112992|NCT03178994|PLACEBO_COMPARATOR|Placebo|Hydrophilic cream (in-house preparation) apply on face twice daily for 10 weeks.
62302812|NCT00016315|EXPERIMENTAL|Arm 3|Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
62302813|NCT00016315|EXPERIMENTAL|Arm 4|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
62302814|NCT00016315|EXPERIMENTAL|Arm 6|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
62674305|NCT06288711|EXPERIMENTAL|Prolonged exposure therapy (PE)|In addition to receiving standard buprenorphine- or methadone-maintenance treatment from their current provider and completing scheduled assessments as described above, PE participants will also receive 12 individual sessions of prolonged exposure therapy scheduled weekly over the 12-week treatment period and delivered via a secure and university-supported telemedicine platform. Beginning in study week 1, PE participants will complete weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by doctoral or master's level therapists trained in prolonged exposure therapy.
62302815|NCT00016315|EXPERIMENTAL|Arm 8|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
62112993|NCT06629675|EXPERIMENTAL|Music Walking Application BeatClearWalker (BCW)|As it is a single-arm feasibility study, all participants will be allocated to one arm, receiving routine personalised walking exercise while listening to music from the smartphone using the music walking application BeatClearWalker during their Pulmonary rehabilitation Programme.
62112994|NCT00315120|OTHER|A (Active OMT and active (UST)|Subjects in this group received active osteopathic manipulation and active ultrasound physical therapy
62112995|NCT00315120|OTHER|B (Sham OMT and active UST)|Subjects in this group received sham osteopathic manipulation and active ultrasound physical therapy
62112996|NCT00315120|OTHER|C (Active OMT and sham UST)|Subjects in this group received active osteopathic manipulation and sham ultrasound physical therapy
62112997|NCT00315120|OTHER|D (Sham OMT and sham UST)|Subjects in this group received sham osteopathic manipulation and sham ultrasound physical therapy
62112998|NCT02490176|EXPERIMENTAL|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
62112999|NCT02490176|PLACEBO_COMPARATOR|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
62113000|NCT03557658|EXPERIMENTAL|Hepatic Impaired|Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9)
62302816|NCT00016315|EXPERIMENTAL|Arm 10|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
62302817|NCT00016315|EXPERIMENTAL|Arm 12|Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
62302818|NCT00016315|EXPERIMENTAL|Arm 14|Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
61917236|NCT06152471|EXPERIMENTAL|Experimental|"Salovum egg powder high in antisecretory factor, 4 g/sachet. Four sachets, ie 16 gr q 8 hours for 6 days before start of abemaciclib~SPC-flakes flat dose 75gr/day in parallel and during first 12 weeks of treatment with abemaciclib"
62113001|NCT03557658|EXPERIMENTAL|Healthy Volunteer|Subjects with normal hepatic function
62113002|NCT02932358|ACTIVE_COMPARATOR|Flexible Family Visitation Model (FFVM)|In the FFVM, two or fewer family members will be allowed to visit the patient for up to 12 consecutive hours each day. In addition to family visitation, patients will be allowed to receive social visits in specific time intervals (according local ICU regulation). To have access to the FFVM, family members of ICU patients will have to attend a structured meeting at ICU in which they will receive orientations about the ICU environment, common ICU treatments, rehabilitation and basic infection control practices, multidisciplinary work at ICU and palliative treatment. Social visitors will not be required to attend the structured meeting.
62113003|NCT02932358|ACTIVE_COMPARATOR|Restrictive Family Visitation Model (RFVM)|In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
62113004|NCT05677178||survival group|Patients who survived 2 months after treatment.
62113005|NCT05677178||death group|Patients who died 2 months after treatment.
62113006|NCT01057758|PLACEBO_COMPARATOR|PLACEBO|Half of the patients will be randomized to the placebo
62113007|NCT01057758|ACTIVE_COMPARATOR|Simvastatin|Half of the subjects will receive the active drug, Simvastatin.
62113008|NCT00208078|NO_INTERVENTION|Usual medical therapy|Usual CF care
62113009|NCT00208078|EXPERIMENTAL|Non-invasive ventilation|Pressure support ventilator (SAIME,AIROX)
62113010|NCT02284308||Patients with any subtype of NSCLC, primary UICC Stage III, age ≥ 75 years|All registered patients will undergo a geriatric assessment to assess vulnerability. Based on this assessment, patients are offered treatment according to the discretion of the physician and patient.
62113011|NCT01876511|EXPERIMENTAL|Cohort A: MSI Positive Colorectal Cancer|
62113012|NCT01876511|EXPERIMENTAL|Cohort B: MSI Negative Colorectal Cancer|
62113013|NCT01876511|EXPERIMENTAL|Cohort C: MSI Positive Non-Colorectal Cancer|
62113014|NCT01115049|EXPERIMENTAL|Experimental mouthwash|The experimental mouthwash (Buccagel®, Curaden Healthcare, Saronno, Italy) was made up of: purified water, dicaprylyl-ether, coco-caprylate caprate, xylitol, glyceryl-stearate, ceteareth-20, ceteareth-12, cetyl-palmitate, cetearyl-alcohol, chlorobutanol, aroma, hexetidine, methylparaben, propylparaben, sodium saccharin, citric acid and colorant C.I. 16255.
62113015|NCT01115049|ACTIVE_COMPARATOR|Chlorexidine-based mouthwash|A conventional commercial mouthwash (Curasept® ADS 0.20%, Curaden Healthcare, Saronno, Italy) made up of: water, xylitol, propylenglycol, Peg-40 of hydrogenated ricin oil, ascorbic acid, chlorhexidine digluconate, aroma, poloxamer 407, sodium metabisulfite, sodium citrate and colorant C.I. 42090.
62113016|NCT04900142|EXPERIMENTAL|1500 mW|1500 mW of Power
62113017|NCT04900142|ACTIVE_COMPARATOR|1000 mW|Standard treatment, 1000 mW
62113018|NCT02305082||Fast-track group|Patients treated according to the enhanced recovery pathway. This group is examined prospectively.
62302819|NCT00016315|EXPERIMENTAL|Arm 5|Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
62302820|NCT00016315|EXPERIMENTAL|Arm 7|Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
62674306|NCT06288711|EXPERIMENTAL|Prolonged exposure therapy + attendance contingent financial incentives (PE+)|Participants assigned to the PE+ condition will receive the procedures noted above for the PE group plus financial incentives delivered contingent upon completion of PE sessions.
61917237|NCT06152471|PLACEBO_COMPARATOR|Placebo Comparator|Placebo, identical to investigational product but without antisecretory factor.
61917238|NCT03249688|OTHER|Control|Regular health advice
62302821|NCT00016315|EXPERIMENTAL|Arm 9|Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
62471650|NCT03579095|PLACEBO_COMPARATOR|Placebo|Placebo
62471651|NCT03763318|EXPERIMENTAL|EQ001 Dose Escalation (Part A)|Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.
61917239|NCT03249688|EXPERIMENTAL|Multidomain 1|Multidomain lifestyle
61917240|NCT03249688|EXPERIMENTAL|Multidomain 2|Multidomain lifestyle + medical food
61917241|NCT01921088|EXPERIMENTAL|Contingent|Contingent RT-fMRI-NF of brain activity in the target region of interest
61917242|NCT01921088|SHAM_COMPARATOR|Non-contingent|Sham RT-fMRI-NF of brain activity of previously recorded subject
61917243|NCT02767544|EXPERIMENTAL|ropivacaine group|Vaginal wound local analgesia by 10ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
62113019|NCT02305082||Control group|Patients treated according to the historic recovery pathway. This group is examined retrospectively.
62113020|NCT06116058|EXPERIMENTAL|Group A: integrated neuromuscular inhibition technique|Group A: patient will receive integrated neuromuscular inhibition technique and conventional physical therapy program for 3 sessions /week over 4 weeks periods
62113021|NCT06116058|EXPERIMENTAL|Group B :Instrument assissted soft tissue mobilization|Group B : patient will receive Instrument assissted soft tissue mobilization technique and conventional physical therapy program for 3 sessions /week over 4 weeks periods
62113022|NCT06116058|ACTIVE_COMPARATOR|Group C:conventional physical therapy|Group C: patient will receive conventional physical therapy only in the form of ( stretch for hamstring ,illiopoaps ,low back muscle and strenghtning for abdominal ,back muscles and side support exercise and quadriped exercise)
62113023|NCT04154137||Patients undergoing digestive endoscopy|"All the patients, age ranged from 18 to 90 years, referred to Digestive Endoscopy Outpatients Clinic of the Department of Gastroenterology of the University Hospital Paolo Giaccone of Palermo, Italy"
62302822|NCT00016315|EXPERIMENTAL|Arm 11|Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT
62302823|NCT00605826|EXPERIMENTAL|Blinded injection of NASHA/Dx gel at randomization.|Blinded injection of NASHA/Dx (Solesta) Gel. For each treatment, a series of 4 equally spaced injections with 1 mL of Solesta into the anal canal. Subjects will be followed for 6 months during the blinded phase. During a subsequent open phase, these subjects will be followed to Month 36 (ie, for an additional 30 months).
62471652|NCT03763318|EXPERIMENTAL|EQ001 (Part B)|EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.
62471653|NCT03763318|PLACEBO_COMPARATOR|EQ001 Placebo (Part B)|Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.
62674307|NCT06479057||PROACT Supportive Care pathways|This is a prospective cohort study including patients participating in institutional supportive care pathways at diagnosis, during treatment and after treatment.
62674308|NCT03517293|EXPERIMENTAL|Aerobic Exercise Intervention|Aerobic Exercise training 50 minutes of moderate intensity exercise, 3 times per week from \~16-40 weeks of pregnancy
61917244|NCT02767544|NO_INTERVENTION|Control group|Vaginal wound no local analgesia by 10 ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
62471654|NCT03521765|EXPERIMENTAL|OT intervention group|The OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic.
62674309|NCT03517293|NO_INTERVENTION|Control|usual daily activities - not exercise, not elevating heart rate
61917245|NCT03295565|ACTIVE_COMPARATOR|A: Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
61917246|NCT03295565|ACTIVE_COMPARATOR|B: Abiraterone OR Enzalutamide|"At physician's discretion:~Abiraterone 1000mg oral, taken daily Prednisone 5mg oral, 2 times a day OR Enzalutamide 160mg oral taken daily"
61917247|NCT03614975|ACTIVE_COMPARATOR|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
61917248|NCT03614975|ACTIVE_COMPARATOR|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
61917249|NCT03036800|EXPERIMENTAL|Targeted Prescribing Pathway (LIRA 3mg + Standard Care)|Standard care plus targeted use of the intervention Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply
61917250|NCT03036800|ACTIVE_COMPARATOR|Standard Care|standard Tier 3 obesity specialist service care
61917251|NCT01113047|EXPERIMENTAL|Non responder Olmesartan/Amlodipine|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
61917252|NCT02873520|EXPERIMENTAL|Precision Cells combined with Chemotherapy treatment:|Precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
61917253|NCT02873520|ACTIVE_COMPARATOR|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
61917254|NCT06246279|EXPERIMENTAL|Experimental group|"In addition to the institution's routine T1DM training, the Adjustment to Adolescence and Transition to Type 1 Diabetes Education Program prepared in line with Meleis's Transition Theory was applied to adolescents online via the Microsoft Teams Program."
61917255|NCT06246279|NO_INTERVENTION|Control group|The institution's routinely planned diabetes education was given by the pediatric diabetes education nurse.
61917256|NCT02235727|EXPERIMENTAL|GBR 900|Test treatment GBR 900
61917257|NCT02235727|PLACEBO_COMPARATOR|Placebo|Placebo Treatment
61917258|NCT02708303||Foregut Surgery|Foregut surgery includes conditions of the esophagus, stomach and proximal small intestine. More specifically foregut surgery includes surgery for gastroesophageal reflux disease, hiatal hernias, and paraesophageal hernias.
61917259|NCT02829944|EXPERIMENTAL|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
61917260|NCT02829944|PLACEBO_COMPARATOR|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
61917261|NCT01376557|EXPERIMENTAL|Treatment A|
61917262|NCT01376557|EXPERIMENTAL|Treatment B|
62471655|NCT03521765|NO_INTERVENTION|non-intervention group|The non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation.
62674310|NCT00775515|EXPERIMENTAL|one|laparoscopic prostatectomy
62674311|NCT05978362|EXPERIMENTAL|With capsular repair|This technique consists of inserting the capsule during the operation according to Latarjet.
62674312|NCT05978362|ACTIVE_COMPARATOR|Without capsular repair|Latarjet technique without capsular repair
61917263|NCT01376557|EXPERIMENTAL|Treatment C|
61917264|NCT01376557|EXPERIMENTAL|Treatment D|
61917265|NCT01376557|PLACEBO_COMPARATOR|Placebo|
61917266|NCT05861180||normal group|no text neck
61917267|NCT05861180||mild text neck|
61917268|NCT05861180||moderate text neck|
61917269|NCT05861180||severe text neck|
62113024|NCT04204720|ACTIVE_COMPARATOR|Group Whitacre|Group whitacre receives the whitacre needle during caudal block
62471656|NCT01133353|EXPERIMENTAL|Tetrabenazine MR|
62471657|NCT01133353|PLACEBO_COMPARATOR|Placebo|
62471658|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
62113025|NCT04204720|EXPERIMENTAL|Group Chiba|Group chiba receives the chiba needle during caudal block
62113026|NCT05667480|EXPERIMENTAL|VR-based script training|
62113027|NCT05667480|ACTIVE_COMPARATOR|Conventional script training|
62113028|NCT02117401|EXPERIMENTAL|group 1|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s
62113029|NCT02117401|EXPERIMENTAL|group 2|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s
62113030|NCT02117401|EXPERIMENTAL|group 3|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
62113031|NCT02117401|EXPERIMENTAL|group 4|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
62113032|NCT02117401|EXPERIMENTAL|group 5|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
62113033|NCT02117401|EXPERIMENTAL|group 6|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
62113034|NCT02117401|EXPERIMENTAL|group 7|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
62113035|NCT02117401|EXPERIMENTAL|group 8|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
62113036|NCT02117401|EXPERIMENTAL|group 9|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
62113037|NCT02117401|EXPERIMENTAL|group 10|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
62113038|NCT02117401|EXPERIMENTAL|group 11|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
62113039|NCT02117401|EXPERIMENTAL|group 12|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
62113040|NCT02117401|EXPERIMENTAL|group 13|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
62113041|NCT02117401|EXPERIMENTAL|group 14|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
62113042|NCT02117401|EXPERIMENTAL|group 15|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
62113043|NCT02117401|EXPERIMENTAL|group 16|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
62113044|NCT01640821|EXPERIMENTAL|Intervention group (CdM?)|This group will be composed of women that are seeking help for weight-related problems that have been referred to the CdM? program.
62113045|NCT01640821|NO_INTERVENTION|Control group|This group will be composed of women that are seeking help for weight-related problems but that are actually on the waiting list for participating to the CdM? program.
62113046|NCT00005840|EXPERIMENTAL|Treatment (paclitaxel, cisplatin, abdominal radiotherapy)|"Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.~Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level."
62113047|NCT04899284|EXPERIMENTAL|Infants eligible for Early Intensive Bimanual Stimulation|Infants between 3 and 12 months of age at the time of inclusion, with unilateral brain injury and clinical signs of underuse of one of the two upper limbs
62113048|NCT04329663|EXPERIMENTAL|training group|Ten children with ADHD who got the 20 sessions training of the Indonesian computer-based game prototype. They we were assessed by CATPRS, BRIEF and fMRI BOLD
62113049|NCT05097469|ACTIVE_COMPARATOR|Laser treatment|Carbon dioxide laser treatment
62113050|NCT05097469|SHAM_COMPARATOR|Sham treatment|Sham laser treatment
62113051|NCT05097781|EXPERIMENTAL|Treatment arm|Local irradiation + immunotherapy
62113052|NCT03014050|EXPERIMENTAL|EH: Stimulation of Head Point|Electrical stimulation of the head point of the hand (EH, experimental stimulation); intervention with e-Tapper TT-R1
62113053|NCT03014050|ACTIVE_COMPARATOR|CS: Control Stimulation|Electrical stimulation of the leg point of the hand (CS, control stimulation); intervention with e-Tapper TT-R1
62113054|NCT06613074|EXPERIMENTAL|Ali Pay intelligent navigation applet group|"Patients in regions with Ali Pay intelligent navigation applet being released would be classified as experimental arm.~In this arm, patients have access to this applet.~The intelligent navigation applet comprises of three function modules:~1. Stroke knowledge public education: information regarding prevention and emergency treatment of stroke would be push to users' mobile phones regularly;~2. Stroke recognition: questionaires, voice interaction, and facial recognition are employed to identify patients with AIS and large vessel occlusion;~3. Hospital recommendation: this module combines real-time traffic and average in-hopital delay of each stroke center nearby, recommending the stroke center in which patients are mostly likely to receive reperfusion therapy"
62113055|NCT06613074|NO_INTERVENTION|Routine pre-hospital triage|"Patients in regions without Ali Pay intelligent navigation applet being released would be classified as control arm.~In this arm, patients do not have access to this applet."
62113056|NCT05773612|OTHER|Rock Steady Boxing classes|The Rock Steady Boxing classes are 60-90 minutes in duration twice a week and include the following 4 components: (1) active warm up (2) functional mobility exercises (3) whole body strengthening exercises and (4) non-contact boxing exercises.
62113057|NCT00057850|EXPERIMENTAL|Arm I|"Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.~Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550."
62674313|NCT05171335|EXPERIMENTAL|Lenvatinib in Combination with TACE Prior to Liver Transplantation|Regimen of six months neoadjuvant lenvatinib in combination with TACE prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria.
62674314|NCT05171335|OTHER|Matched Historical Control Patients|Historical controls will be liver transplant recipients matched on age, etiology of liver disease (viral vs. non-viral), listing tumor size, and number of TACE procedures to cases in the intervention group who receive a transplant.
62674315|NCT01851226|EXPERIMENTAL|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
62674316|NCT01851226|EXPERIMENTAL|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
62113058|NCT05045703|EXPERIMENTAL|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
62113059|NCT06553391||TMR group|The treatment regimen for the tetralogy of medication regimen group (TMR group）commences with the administration of amiodarone during rewarming. In the event of cardiac relapse, a combination of the following drugs may be utilized: aminophylline, ephedrine, and isoproterenol. The selection of these medications is contingent upon the patient's blood pressure and heart rate.
62113060|NCT06553391||Control group|Patients in the control group did not receive treatment with antiarrhythmic drugs.
62113061|NCT03649165|EXPERIMENTAL|Treatment Sequence 1|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
62113062|NCT03649165|EXPERIMENTAL|Treatment Sequence 2|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
62113063|NCT03649165|EXPERIMENTAL|Treatment Sequence 3|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
62113064|NCT03649165|EXPERIMENTAL|Treatment Sequence 4|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
62113065|NCT06040333|EXPERIMENTAL|Dynamic Neuromuscular Stabilisation Exercise|The participants performed DNS exercises addition to standard therapy
62471659|NCT06099340|EXPERIMENTAL|"Experimental  EXC "|eccentric strengthening + conventional rehabilitation
62471660|NCT06099340|ACTIVE_COMPARATOR|"Comparator  CONC "|concentric strengthening + conventional rehabilitation
62471661|NCT04589195|EXPERIMENTAL|Mindfulness Training (MT) Group|Participants will receive four weeks of MT.
62471662|NCT04589195|ACTIVE_COMPARATOR|Wait List MT Group|Participants will receive four weeks of MT training after a five week washout period.
62674317|NCT01851226|EXPERIMENTAL|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
62674318|NCT00712075|EXPERIMENTAL|CBSST+PDA|PDA-Assisted Cognitive-Behavioral Social Skills Training (CBSST+PDA): The CBSST rehabilitation intervention will be combined with the use of a PDA to facilitate homework completion and progress towards recovery goal attainment in consumers.
62674319|NCT00712075|ACTIVE_COMPARATOR|CBSST|Cognitive Behavioral Social Skills Training (CBSST): CBSST is a psychosocial rehabilitation intervention that combines skills from cognitive behavioral therapy and social skills training to assist consumers in improving functioning and recovery goal attainment.
62674320|NCT00712075|ACTIVE_COMPARATOR|PDA-Only|PDA-only: To control of device contact, the PDA-only arm will not receive CBSST and will only carry a PDA with access to the basic features of the device.
62674321|NCT05648357|EXPERIMENTAL|Participants receiving Fluarix tetra vaccine|Participants aged 65 years and above receive 1 dose of Fluarix tetra vaccine.
62674322|NCT03307096|EXPERIMENTAL|Microperc surgery|Patient is turned into prone position and the desired calyx is punctured by 4.8F microperc under fluoroscopic or sonographic guidance. No tract dilation is needed. A 200um holmium laser fiber will be used to break stone into less than 2mm. Pull out microperc without drainage tube left.
61917270|NCT03121339|ACTIVE_COMPARATOR|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
62471663|NCT02118532|EXPERIMENTAL|IN.PACT Admiral|
62674323|NCT03307096|ACTIVE_COMPARATOR|FURS|Patient is placed in the lithotomy position, pull out the pre-inserted double J, and place guidewire into the renal pelvis. A 12/14 Fr ureteral access sheath (UAS) is advanced into the proximal ureter over the guidewire, and flexible ureteroscope is passed through the UAS. The stones are fragmented smeller than 2mm using a 200um holmium laser fiber. Fragments are removed using a stone basket for stone analysis if necessary, a double J stent is placed at the conclusion of the procedure and removed post-operative 4 weeks.
61917271|NCT03121339|ACTIVE_COMPARATOR|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
62113066|NCT06040333|OTHER|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
62113067|NCT04176458|OTHER|MBT in liver disease|Methacetin Breath test (MBT) intervention. We will use the MBT test to measure time from administration of 13C methacetin to obtaining the peak elimination of 13CO2.
62113068|NCT03354169|EXPERIMENTAL|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
62471664|NCT03204539|EXPERIMENTAL|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
62736099|NCT05538949|EXPERIMENTAL|Test group|Participants received 1%, 2%, 4%, 8% of EB-203 eye drops. Group A : EB-203 1% eye drops, Group B : EB-203 2% eye drops, Group C : EB-203 4% eye drops, Group D : EB-203 8% eye drops
61917272|NCT05414227||PSD|Depressed as assessed by the Hamilton Depression Scale 3 months after stroke
61917273|NCT05414227||Non PSD|Nondepressed as assessed by the Hamilton Depression Scale 3 months after stroke
62113069|NCT03354169|EXPERIMENTAL|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
62736100|NCT05538949|PLACEBO_COMPARATOR|Placebo group|Participants received Placebo eye drops. Group A : Placebo eye drops, Group B : Placebo eye drops, Group C : Placebo eye drops, Group D : Placebo eye drops
62113070|NCT04980261|ACTIVE_COMPARATOR|Control Group (ORIF + autograft)|The patients will receive the current gold standard to treat long bone defects.
62113071|NCT04980261|EXPERIMENTAL|Treatment Group (ORIF + FD BHA/Secretome composite)|The patients will receive a novel bone substitute following the ORIF procedure.
62113072|NCT02774538|OTHER|Experimental arm|
62113073|NCT05956600|OTHER|Amisulpride|Amisulpride administered orally. Dose range 50 to 1200 mg daily
62113074|NCT01396291|EXPERIMENTAL|Asenapine|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
62113075|NCT01396291|PLACEBO_COMPARATOR|Placebo|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
62113076|NCT00719017|EXPERIMENTAL|Vaginectomy group|Upper vaginectomy
62471665|NCT03204539|OTHER|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
62471666|NCT03522675|OTHER|NeoMatriX and Two Comparators|NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
61917274|NCT02264873|OTHER|Decitabine|This is a 3+3 design of dose escalation
61917275|NCT03221764|EXPERIMENTAL|Amiodarone with CoSeal administered with CO2 driver|Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
61917276|NCT02329366||Diabetic Foot Ulcer Group|Subjects in this group will have tissue specimens collected from their Diabetic Foot Ulcer during Standard of Care debridement.
61917277|NCT02329366||Control Group|Skin tissue samples will be collected from subjects undergoing routine surgical procedures during which normal skin is removed
62113077|NCT00719017|EXPERIMENTAL|Brachytherapy group|Post-operative brachytherapy
62113078|NCT00719017|ACTIVE_COMPARATOR|Control group|Standard treatment
62113079|NCT02955524|EXPERIMENTAL|Treatment session 1a|"Topical ophthalmic anesthesia to participants (#) on each session (letter) of intra-arterial chemotherapy.~where #1 is the participant identifier and letter-a is the start session with study protocol (most candidates will receive more than 4 sessions in a 6 month period)"
62113080|NCT01645917|EXPERIMENTAL|Ablation|Ablation with Arctic Front Advance Cardiac CryoAblation system
62113081|NCT03910517||E-sport athletes|People aged 15-35 who engage in structured E-sport (e.g. community-based, pro team or educational setting).
62113082|NCT06321809||Intervention group|They were given a calorie-restricted diet and exercise plan by a dietician or physiotherapist at their first visit, and were followed up by telephone calls at weeks 2, 4, 6, 8 and 10 over 12 weeks.
62113083|NCT06321809||Control-1 group|During the initial medical interview, the participants were given a calorie-restricted diet programme by a dietician and an exercise programme by a physiotherapist; they were followed up over 12 weeks with telephone calls at week 4.
62113084|NCT06321809||Control-2 group|During the initial medical interview, the participants were given a calorie-restricted diet programme by a dietician and an exercise programme by a physiotherapist; they were followed up over 12 weeks with telephone calls at week 4.
62471667|NCT04891120|EXPERIMENTAL|With, then without a mask|Participants will first perform a treadmill test with a mask and 48 hours or more later will perform another similar treadmill test without a mask.
62471668|NCT04891120|EXPERIMENTAL|Without, then with a mask|Participants will first perform a treadmill test without a mask and 48 hours or more later will perform another similar treadmill test with a mask.
62471669|NCT04157179|ACTIVE_COMPARATOR|Healthy Controls|
62471670|NCT04157179|ACTIVE_COMPARATOR|Extracorporeal Membrane Oxygenation survivors|
62471671|NCT04157179|ACTIVE_COMPARATOR|Sickle Cell Anemia participants|
62471672|NCT02070822||TACE patients, for HCC|unresectable HCC patients
62471673|NCT03247972||Patients with peripheral artery disease receiving evolocumab + high dose statins|"Adult patients with a history of Peripheral Artery Disease (PAD) defined as one or more of the following:~* Documented history of PAD~* Previous limb or foot amputation for arterial vascular disease (i.e., excludes trauma),~* Carotid artery disease (defined as \>50% stenosis or prior revascularization )"
62471674|NCT04480086|EXPERIMENTAL|Segment A: Mivebresib Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of mivebresib to identify the safe dosing regimen and schedule.
62471675|NCT04480086|EXPERIMENTAL|Segment A: Mivebresib Monotherapy|Participants will receive the identified safe dosing regimen of mivebresib as monotherapy.
62471676|NCT04480086|EXPERIMENTAL|"Segment B: Ruxolitinib + Mivebresib Add-on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and mivebresib as add-on therapy."
62471677|NCT04480086|EXPERIMENTAL|Segment C: Mivebresib + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive mivebresib and navitoclax.
62113085|NCT05507463|EXPERIMENTAL|KBP-7072|Proposed dose levels for Part A: 25, 50, 100, 150 and 200mg KBP-7072. Proposed dose levels for Part B: 50 and 100mg. Administration route is intravenous infusion.
62113086|NCT05507463|PLACEBO_COMPARATOR|Placebo|Placebo for intravenous infusion.
62471678|NCT04480086|EXPERIMENTAL|Segment D: Mivebresib + Ruxolitinib|Participants who have never received JAKi will receive mivebresib and ruxolitinib.
62471679|NCT00974740|PLACEBO_COMPARATOR|atorvastatin matching placebo|atorvastatin matching placebo
62113087|NCT03705299|EXPERIMENTAL|NeuMeDex NICVP (Non-Invasive CVP) vs Standard CVP|Three pressure readings recorded for both NeuMeDex NICVP and central line pressure catheter over a 10 minute period.
62113088|NCT00382135|PLACEBO_COMPARATOR|1|placebo tablet
62113089|NCT00382135|ACTIVE_COMPARATOR|2|20 mg tadalafil tablet
62113090|NCT00662324||1|Trial experienced cancer patients and their primary caregivers.
62113091|NCT00662324||2|Trial naive cancer patients and their caregivers.
62113092|NCT00662324||3|Health care professionals who are involved in running Phase I, II or III clinical trials.
62113093|NCT05100199|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the Glabellar Complex on Day 1.
62113094|NCT05100199|EXPERIMENTAL|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X Dose A will be injected into the Glabellar Complex on Day 1.
62113095|NCT05100199|EXPERIMENTAL|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X Dose B will be injected into the Glabellar Complex on Day 1.
62113096|NCT05100199|EXPERIMENTAL|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X Dose C will be injected into the Glabellar Complex on Day 1.
62113097|NCT04572217|EXPERIMENTAL|Medication Group|"Adolescent patients post vertical sleeve gastrectomy who have had inadequate weight loss, who consented for use of off-label medications prescribed at the discretion (one or both) of physician.~Patients will be followed every 2-12 weeks over one year.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
62113098|NCT04572217|NO_INTERVENTION|Non-Medication Group|"Adolescent patients post vertical sleeve gastrectomy who had inadequate weight loss and did not consent for use of off-label medications.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
62302824|NCT00605826|SHAM_COMPARATOR|Blinded sham inject. at randomization|"Blinded sham injection (needle stick with empty syringes). For each treatment, a series of 4 equally spaced Sham injections (needle sticks) into the anal canal. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
62302825|NCT00605826|OTHER|Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.|"Blinded sham injection at randomization. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
62471680|NCT00974740|EXPERIMENTAL|atorvastatin|40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months
62471681|NCT04643197|EXPERIMENTAL|Experimental arm|Abdominal fascia will be closed with barbed suture.
62471682|NCT04643197|ACTIVE_COMPARATOR|Control|Abdominal fascia will be closed with non-barbed suture.
62471683|NCT03976635|ACTIVE_COMPARATOR|Removable Mandibular Retractor|Patients in this group will be treated by the Removable Mandibular Retractor (RMR) in order to get rid of the anterior cross bite. This appliance is removable.
62113099|NCT03600935|EXPERIMENTAL|Vancouver Clinical Pathway|The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
62113100|NCT06425068|EXPERIMENTAL|Investigation of contact pressure distribution in a novel air mattress|"Exposure of the patient to the novel air mattress. Recording of interface pressure and contact area between the patient and the air mattress for one hour.~Regular measurement of vital signs and comfort and assessment of risk to develop side effects, particularly skin pressure injuries."
62113101|NCT06425068|ACTIVE_COMPARATOR|Investigation of contact pressure distribution in a conventional foam mattress|"Exposure of the patient to the conventional foam mattress. Recording of interface pressure and contact area between the patient and the foam mattress for one hour.~Regular measurement of vital signs and comfort and assessment of risk to develop side effects, particularly skin pressure injuries."
61917278|NCT06061614|EXPERIMENTAL|Dose level 1|Dose level 1 will be administered
62113102|NCT02531568|EXPERIMENTAL|Warfarin and MT-3995|Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.
62113103|NCT01337869|ACTIVE_COMPARATOR|Bascom Cleft Lift Technique|
62113104|NCT01337869|ACTIVE_COMPARATOR|Limberg Flap Technique|
62302826|NCT01857895|EXPERIMENTAL|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
62471684|NCT03976635|EXPERIMENTAL|Bone-anchored intermaxillary Traction|Patients will be treated using bone-anchored intermaxillary traction. Class III elastics will be extended from the Adam's clasps placed in the upper removable appliance towards the heads of mini-implants placed between the permanent canine and lateral incisors on either side of the lower dental arch.
62471685|NCT01668264|EXPERIMENTAL|Magnetic Resonance Imaging (MRI)|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
62471686|NCT01668264|EXPERIMENTAL|Echocardiograph|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
61917279|NCT06061614|EXPERIMENTAL|Dose level 2|Dose level 2 will be administered
61917280|NCT06061614|EXPERIMENTAL|Dose level 3|Dose level 3 will be administered
61917281|NCT01176942|EXPERIMENTAL|Probiotic|
61917282|NCT01176942|PLACEBO_COMPARATOR|Placebo|
61917283|NCT03328182|EXPERIMENTAL|New oral endotracheal tube holder|Single Study Product Arm
61917284|NCT03956797|EXPERIMENTAL|-15 degrees Celsius for 10 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds.
61917285|NCT03956797|EXPERIMENTAL|-15 degrees Celsius for 15 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds.
61917286|NCT00195845|EXPERIMENTAL|Double-Blind Galantamine vs Placebo|Double-Blinded, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction
61917287|NCT00195845|PLACEBO_COMPARATOR|Placebo Control Group|Placebo-Controlled Group
61917288|NCT05911425|OTHER|Prospective Research|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
61917289|NCT00377130|NO_INTERVENTION|Arm I- Usual psychological care|Usual psychological care- no intervention
61917290|NCT00377130|EXPERIMENTAL|Self administered Stress Management|Self-Administered Stress Management Training Plus Usual Psychosocial Care
61917291|NCT05436340|EXPERIMENTAL|EHepIcu|
61917292|NCT05436340|NO_INTERVENTION|Control Grubs|
61917293|NCT04786509||ECG sensor|All subjects performed shuttle run (SR), Cooper 2400 m (C), and 100 m sprint test (S), once wearing the sensor attached to self-adhesive skin electrodes, additionally fixed with self-adhesive tapes, and secondly with the sensor attached to Polar belt and strapped around the chests.
61917294|NCT04112498|EXPERIMENTAL|nivolumab + relatlimab + rHuPH20|
61917295|NCT04856670||Control patients undergoing manual cataract surgery|As above
61917296|NCT04856670||Control patients undergoing FLACS|Femtosecond laser assisted cataract surgery
61917297|NCT04856670||Diabetic patients undergoing manual cataract surgery|As Above
61917298|NCT04856670||diabetic patients undergoing FLACS|As Above
61917299|NCT03630276|OTHER|Neutrophil/lymphocyte ratio|
62113105|NCT04630912|EXPERIMENTAL|Acceptance and Commitment Therapy|12 weekly, 90 minute ACT sessions with person with dementia (with a review at week 6)
62113106|NCT04851561||Cases|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), cases will be defined as such if fulfill for the following criteria: individuals who report on lasting fatigue symptoms which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis and the lasting fatigue symptoms are present for at least six weeks.
62302827|NCT01857895|EXPERIMENTAL|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
62302828|NCT03469310|EXPERIMENTAL|Acetaminophen|Tylenol (also known as acetaminophen) 1000mg every 6 hours for 3 days and tramadol 50 mg every 6 hours as needed for moderate to severe pain
62674324|NCT06565156|EXPERIMENTAL|BR-AM plus Standard Care|"All subjects in the treatment group will receive sponsor-approved standard of care. Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device. Using an appropriate size to cover the entire wound area, BR-AM should be applied directly to the wound surface following sharp debridement. It is recommended that the product be trimmed to fit the area of the wound with sterile scissors before application."
61917300|NCT03630276|OTHER|Platelet/lymphocyte ratio|
61917301|NCT03630276|OTHER|CRP|
61917302|NCT02288377|EXPERIMENTAL|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
61917303|NCT02288377|PLACEBO_COMPARATOR|placebo|In this arm, patients will receive placebo every 28 days until disease progression
61917304|NCT01726660|EXPERIMENTAL|IMT Robotic Arm Therapy: Aim training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for aim training, 3x/week for 12 weeks.
61917305|NCT01726660|EXPERIMENTAL|IMT Robotic Arm Therapy: Smoothness Training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for smoothness training, 3x/week for 12 weeks.
62113107|NCT04851561||Controls|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), did not report fatigue symptoms at any time point following their diagnosis with COVID-19.
62113108|NCT06348849|ACTIVE_COMPARATOR|Low-level laser therapy|These hypersensitive molars with MIH will receive low-level laser therapy.
62113109|NCT06348849|EXPERIMENTAL|Nanosilver fluoride|These hypersensitive molars with MIH will receive nanosilver fluoride treatment.
62113110|NCT05571358|NO_INTERVENTION|Control Group|Following clinical practice guidelines, subjects in the control group will receive multidisciplinary rehabilitation programmes with coordinated delivery of supervised exercise therapy, cognitive behavioural therapy (education on pain), as well as therapeutic massage to relieve low back pain during pregnancy.
62113111|NCT05571358|EXPERIMENTAL|Virtual Reality (Nature Trek)|"* Subjects in the experimental group will receive the same treatment described for the control group.~* Subjects in the experimental group will receive an additional Virtual Reality Intervention (VRi)."
62113112|NCT05561803||Radiodermatitis Case Group|40 patients on palliative care with grade 2 or grade 3 radiodermatitis after radiotherapy for the treatment of cancer submitted to a PBM therapy protocol
62113113|NCT05213715||1/Children with diparetic cerebral palsy|1/Children with diparetic cerebral palsy
62302829|NCT03469310|ACTIVE_COMPARATOR|Codeine Acetaminophen|Tylenol #3 (codeine-acetaminophen) 1 tab every 4 hours or 2 tabs every 6 hours as needed for pain
62113114|NCT05213715||2/Children with hemiparetic cerebral palsy|2/Children with hemiparetic cerebral palsy
62113115|NCT05213715||3/healty peer aged children|3/healty peer aged children
62302830|NCT03492164|OTHER|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
62302831|NCT01627704|OTHER|Fluoroestradiol (18F)|
62302832|NCT00228371|OTHER|1|The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase
62471687|NCT02527382|EXPERIMENTAL|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a distal clamp is placed on the rectal stump.
61917306|NCT01726660|EXPERIMENTAL|IMT Robotic Arm Therapy: Impairment training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole-arm, impairment training, 3x/week for 12 weeks.
61917307|NCT01726660|EXPERIMENTAL|IMT Robotic Arm Therapy: Functional training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole arm, functional training, 3x/week for 12 weeks.
61917308|NCT04932798||High-Risk group|: Montreal Heart Institute biobank participants with a high specific genome-wide polygenic risk scores for atrial fibrillation G
62471688|NCT02527382|NO_INTERVENTION|Open stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while no distal clamp is placed on the rectal stump.
62674325|NCT06565156|ACTIVE_COMPARATOR|Standard Care|"All subjects in the control group will receive sponsor-approved standard of care. Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
62674326|NCT06571032||Consicousness improved group|After receiving neuroelectrial stimulation, the patients with severe TBI have the consciousness improvement (CRS-R score is higher than before).
62674327|NCT06571032||Consicousness unimproved group|After receiving neuroelectrial stimulation, the patients with severe TBI have no consciousness improvement (CRS-R score remains the same as before).
62674328|NCT01578746|ACTIVE_COMPARATOR|Direct lateral approach|Patient operated using direct lateral approach.
62674329|NCT01578746|ACTIVE_COMPARATOR|Anterior approach|Patient operated using anterior approach.
62674330|NCT06299163|EXPERIMENTAL|NM32-2668|
62674331|NCT06410807||Adults with subjective cognitive decline|Five focus groups will be conducted with adults with subjective cognitive decline recruited in the greater Columbus, Ohio area.
62674332|NCT02098538|EXPERIMENTAL|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
62674333|NCT04909411|OTHER|Exposed arm|child infected with chikungunya virus during childbirth
62674334|NCT04909411|OTHER|Non-exposed arm|child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified
61917309|NCT04932798||Low-Risk group|Montreal Heart Institute biobank participants with a low specific genome-wide polygenic risk scores for atrial fibrillation G
61917310|NCT06347679|EXPERIMENTAL|Group 1: single-note sweet orange essential oil|
61917311|NCT06347679|EXPERIMENTAL|Group 2: single-note tea tree essential oil|
61917312|NCT06347679|SHAM_COMPARATOR|Group 3: water|
62674335|NCT03240432|ACTIVE_COMPARATOR|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
62674336|NCT03240432|NO_INTERVENTION|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
61917313|NCT05930366|ACTIVE_COMPARATOR|Gingival depigmentation using microsurgery|Surgical excision of hyper-pigmented gingival tissue using microsurgical blade (keratome 2.2) and magnification loupes under local anaesthesia.
61917314|NCT05930366|ACTIVE_COMPARATOR|Gingival Depigmentation using Diode Laser|Ablation of hyper-pigmented gingival tissue using Diode Laser under local anaesthesia.
61917315|NCT06515028|ACTIVE_COMPARATOR|Group GA: general anesthesia|Group GA
62113116|NCT04235283|EXPERIMENTAL|Group I|Primary total knee replacement by pinless navigation and minimally invasive technique
62113117|NCT04235283|ACTIVE_COMPARATOR|Group II|Primary total knee replacement by traditional jig and minimally invasive technique
62113118|NCT00719823|OTHER|1|
62674337|NCT05705128|ACTIVE_COMPARATOR|dexamethasone group|patients will receive dexamethasone with bupivacaine before general anaesthesia
62674338|NCT05705128|ACTIVE_COMPARATOR|dexmedetomidine group|patients will receive dexemedetomidine with bupivacaine before general anaesthesia
62113119|NCT00199108|EXPERIMENTAL|Only 1 arm|
62113120|NCT00305695|EXPERIMENTAL|Arm I (zoledroic acid)|Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.
62113121|NCT00305695|NO_INTERVENTION|Arm II (clinical observation)|Patients are observed for 18 months after surgery.
62113122|NCT02378116|NO_INTERVENTION|Control|On the control group is done MRI scans of the brain, and patients can be elected for monitoring and/or bicycle stress test to test for neurohormones.
62113123|NCT02378116|ACTIVE_COMPARATOR|Surgical Closure|During open heart surgery, the surgeon closes the left atrial appendage. The research group recommend a double closure with both a ligation and suture, but a single suture is also accepted.
62674339|NCT00784927|EXPERIMENTAL|Treatment|"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:~375 mg/m\^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m\^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22."
61917316|NCT06515028|ACTIVE_COMPARATOR|Group IB : infraclavicular block|Group IB
61917317|NCT02830984|EXPERIMENTAL|EST+LBD+ENBD group|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
61917318|NCT02830984|ACTIVE_COMPARATOR|EST+LBD group|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
62302833|NCT00228371|OTHER|2|The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase
62113124|NCT05363358||Ig-naive (New-to-class) Cohort|Participants who initiate GGL or one of the comparator IVIG products who have no record of previous use of any Ig product (Ig naive) for at least 6 months before study initiation will be include in this cohort.
62302834|NCT05446597|EXPERIMENTAL|Headache Treatment|Participants in the headache arm will be randomized to receive a peripheral, greater occipital nerve block with 0.5% Bupivacaine or the multimodal treatment protocol. Participants will complete a daily headache diary over the 6-week treatment period, following a link on their mobile device. Patients receiving a nerve block will have weekly over-the-phone or virtual check-ins by the study team to evaluate for any side effects, pain, as needed medications, and study compliance. These patients will be given supplemental HA education as needed. Participants receiving the block will be offered a second block at 6 weeks if they meet the following criteria: a. no side effects with the first block, b. participant received relief from the first block and prefers a second, and c. headache is still occurring at least once per week. Participants randomized to the multimodal treatment portion, will have up to 6 weeks of scheduled multimodal treatment sessions.
62302835|NCT05446597|EXPERIMENTAL|Dizziness and/or Neck Pain Treatment|Participants will be randomized to receive cervicovestibular physiotherapy (CV PT) or the multimodal treatment program. The CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings for six weeks. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, and dynamic balance.
62471689|NCT04239872|EXPERIMENTAL|Fluoride mouthwash alone, then Calcium mouthwash before a fluoride mouthwash|Participants with normal to dry mouth will first test a Fluoride mouthwash containing 226 ppm of fluoride, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours. After a washout period of at least 3 days, they will then test a Calcium mouthwash (150 milimolars of calcium) immediately before the Fluoride mouthwash, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours.
62471690|NCT04239872|EXPERIMENTAL|Calcium mouthwash before a fluoride mouthwash, then Fluoride mouthwash alone|Participants with normal to dry mouth will first test a Calcium mouthwash (150 milimolars of calcium) immediately before a Fluoride mouthwash containing 226 ppm of fluoride, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours. After a washout period of at least 3 days, they will then test the Fluoride mouthwash alone, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours.
62471691|NCT04393818|EXPERIMENTAL|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep), work environment, and social support.
62471692|NCT04393818|SHAM_COMPARATOR|Control App|Participants allocated to the control App will receive access to a a fully operational mobile phone App with limited contents about management and prevention of mental health problems. Although this group will also receive psychoeducation, the content will be reduced to general, written recommendations.
62471693|NCT04074655|EXPERIMENTAL|Intervention Arm|Participants of the study will play the driving simulator daily (5 days/week) for 15-20 minutes/day over a period of 2 consecutive weeks.
62471694|NCT01481649||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
61917319|NCT04184258|EXPERIMENTAL|SLE patients MSC treatment|Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols
61917320|NCT04184258|ACTIVE_COMPARATOR|SLE patients standard treatment|Patients with SLE, who receive standard treatment according to the Clinical protocols
61917321|NCT02829541|EXPERIMENTAL|Cohorts 1|6 participants randomized (4:2) to receive a single-ascending dose (SAD) administered orally in tablet
61917322|NCT02829541|EXPERIMENTAL|Cohort 2|6 participants randomized (4:2) to receive a SAD administered orally in tablet(s)
61917323|NCT02829541|EXPERIMENTAL|Cohort 3|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
61917324|NCT02829541|EXPERIMENTAL|Cohort 4|8 participants randomized (6:2) to receive a SAD administered orally in tablet
61917325|NCT02829541|EXPERIMENTAL|Cohort 5|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
61917326|NCT02829541|EXPERIMENTAL|Cohort 6|14 participants (all active) to receive a SAD administered orally in tablet(s)
62113125|NCT05363358||Ig-experienced (New-to-drug) Cohort|Participants who initiate either GGL or a comparator IVIG product with no record of previous use of that specific IVIG product but with previous use of any other Ig product (Ig experienced) in all available study data will be included in this cohort.
62113126|NCT01450124|EXPERIMENTAL|Boswellic acids (BOSWELAN)|Baseline to treatment single arm - 4 months baseline and 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg of BOSWELAN.
61917327|NCT05245396|EXPERIMENTAL|Part A: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of modified release evobrutinib tablet-1 (MR-T1) on Day 1 in treatment period 1, followed by single oral dose of modified release tablet-2 (MR-T2) on Day 1 in treatment period 2, followed by two single oral doses of immediate release (IR) oral tablet \[Ref (TF2)\] on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or multiparticulate system capsules (MUPS-C) formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
61917328|NCT05245396|EXPERIMENTAL|Part A: Evobrutinib: Treatment Sequence 2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MR-T1 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62302836|NCT05446597|EXPERIMENTAL|Multimodal Treatment|The multimodal treatment consists of 6 treatment sessions that will combine basic physiotherapy exercises to address dizziness and balance problems, training in deep breathing, progressive muscle relaxation, visualization to address headache, sleep hygiene education to address insomnia, and cognitive-behavioral intervention and gratitude exercises to promote coping and resilience. The treatment is designed to be implemented by a variety of clinical health care professionals.
62302837|NCT00075881|EXPERIMENTAL|Treatment (bortezomib)|"INDUCTION TREATMENT: Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TREATMENT: Patients who complete induction treatment without progressive disease receive bortezomib IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~REINDUCTION TREATMENT: Patients who progress while on maintenance treatment receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
62302838|NCT01855438|NO_INTERVENTION|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
61917329|NCT05245396|EXPERIMENTAL|Part A: Evobrutinib: Treatment Sequence 3|Participants will receive two single oral doses of Ref (TF2) on Day 1 in treatment period 1, followed by single oral dose of MR-T1 on Day 1 in treatment period 2, followed by single oral dose of MR-T2 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62302839|NCT01855438|EXPERIMENTAL|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
62302840|NCT01855438|EXPERIMENTAL|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
62302841|NCT04223089||Revascularization|This group will include patients whose cutaneous oxygen partial pressure (PO2) around the wound of interest measures less than 40 mmHg and therefore require revascularization.
62302842|NCT04223089||Medical Management|This group will include patients whose cutaneous PO2 around the wound of interest measures greater than 40 mmHg and will be managed conservatively in wound clinic
62302843|NCT05142709||ESCC patients treated with anti-PD-1 immunotherapy as 1st line treatment.|
62302844|NCT01615510|EXPERIMENTAL|Capsaicin (topical)|300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
62302845|NCT01615510|EXPERIMENTAL|Menthol (topical)|1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
62302846|NCT02406664|EXPERIMENTAL|Obese patients|15 Obese patients (BMI\>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI\>35) accepted for bariatric surgery.
62302847|NCT02406664|NO_INTERVENTION|Control patients|15 matched controls receiving Intensive medical therapy
62302848|NCT04400500||Suspected NSTEACS|Patients urgently admitted to the CCU with suspected NSTEACS
62302849|NCT02680067|EXPERIMENTAL|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
62302850|NCT02680067|EXPERIMENTAL|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
62302851|NCT02108457||Proton subjects|
62302852|NCT02108457||IMRT subjects|
62674340|NCT02983942|EXPERIMENTAL|ketogenic diet group|Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
62302853|NCT02366819|EXPERIMENTAL|Treatment (mFOLFIRINOX, surgery)|"PREOPERATIVE THERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo conventional surgery.~POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity."
62302854|NCT03497299|EXPERIMENTAL|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
62302855|NCT03497299|SHAM_COMPARATOR|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
62302856|NCT00356915|EXPERIMENTAL|Itraconazole tablets|Itraconazole 200 mg tablets
62302857|NCT00356915|ACTIVE_COMPARATOR|Itraconazole capsules|Two Itraconazole 100 mg capsules were taken daily.
62302858|NCT00356915|PLACEBO_COMPARATOR|Placebo tablets|The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
62302859|NCT01091129|EXPERIMENTAL|Treatment|Treatment with the miraDry System in both axilla
62302860|NCT04492410|EXPERIMENTAL|Experimental arm|screening using a rapid serological test with a drop of blood from a finger prick.
62302861|NCT00664170|EXPERIMENTAL|1|ANX-514
62302862|NCT00664170|ACTIVE_COMPARATOR|2|Taxotere
62302863|NCT04075643|EXPERIMENTAL|Group 1|"1. Period 1: Reference drug~2. Period 2: Test drug"
62302864|NCT04075643|EXPERIMENTAL|Group 2|"1. Period 1: Test drug~2. Period 2: Reference drug"
62302865|NCT00843986|PLACEBO_COMPARATOR|Placebo|Matching loading dose and continuous intravenous infusion for 48 hours
62302866|NCT00843986|EXPERIMENTAL|Conivaptan|20mg loading dose followed by a 20mg/ day continuous intravenous infusion for 48 hours
62302867|NCT04747145|EXPERIMENTAL|Pulsed reduced dose-rate radiotherapy|Chemoradiation, adjuvant chemotherapy.
62302868|NCT02237027|EXPERIMENTAL|TasP group|HIV positive female sex workers receiving TasP using ART regimen as per Benin guidelines
62302869|NCT02237027|EXPERIMENTAL|PrEP group|HIV negative female sex workers receiving PrEP using Truvada
62302870|NCT03305744||Endurance Athlete with Atrial Fibrillation|These are middle-aged athletes who are diagnosed with paroxysmal Atrial Fibrillation in the last 4 years, but are otherwise free of disease.
62302871|NCT03305744||Endurance Athlete without Atrial Fibrillation|These are middle-aged athletes who will serve as our control group- they have not been diagnosed with AF or any other disease.
62302872|NCT03314168|ACTIVE_COMPARATOR|Control group|Patients who are randomized in control group will receive the usual care in their respective hospital.
62302873|NCT03314168|EXPERIMENTAL|Single-set group|Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
62302874|NCT03314168|EXPERIMENTAL|Multiple-sets group|Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
62302875|NCT02799381|ACTIVE_COMPARATOR|Optimized Medical Treatment (OMT)|Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.
62674341|NCT02983942|ACTIVE_COMPARATOR|routine diet group|Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
62674342|NCT01829503|EXPERIMENTAL|decitabine and cytarabine|
62471695|NCT02314403|EXPERIMENTAL|Combined Bone Marrow and Kidney Transplantation|Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.
61917330|NCT05245396|EXPERIMENTAL|Part A: Evobrutinib: Treatment Sequence 4|Participants will receive single oral dose of modified release evobrutinib tablet-3 (MR-T3) on Day 1 in treatment period 1, followed by single oral dose of modified release tablet-4 (MR-T4) on Day 1 in treatment period 2, followed by two single oral doses of immediate release (IR) oral tablet \[Ref (TF2)\] on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or multiparticulate system capsules (MUPS-C) formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62113127|NCT06419933|NO_INTERVENTION|Control group wait-list|Group without any intervention. Participants in the wait-list group will receive no psychological intervention during the eight-week duration of the SuperKids program. Families will be informed that children in this group will receive the intervention once the follow-up is completed.
62113128|NCT06419933|EXPERIMENTAL|Experimental group|SuperKids Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by SuperKids-trained clinical psychologists. Sessions will take place once a week for eight weeks, with each session lasting approximately forty-five minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
62113129|NCT05355415||Outer retinal disease|Subjects with outer retinal disease affecting the photoreceptor-retinal pigment epithelium complex will be classified by clinical exam by an experienced retina specialist. Outer retinal disease subjects will undergo adaptive optics (AO) imaging of several macular locations.
62113130|NCT05355415||Healthy control|Age-matched healthy control subjects will undergo the same AO imaging procedures as subjects with outer retinal diseases.
62113131|NCT05470894||COVID-19 Vaccination Group|Subjects who have received at lease one dose of approved COVID-19 vaccine
62113132|NCT04143919|EXPERIMENTAL|Subjects with CV risk factors|Subjects with 2 or more CV risk factors will be identified. Cardiovascular risk factors include hypertension, dyslipidemia, obesity, vascular disease, diabetes mellitus, chronic kidney disease, arrhythmia requiring therapy, moderate to severe valvular disease, history of alcohol abuse, smoking, cancer chemotherapy, or thoracic radiotherapy, and abnormal findings in the most recent ECG or thoracic X-ray.
62302876|NCT02799381|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel (LCIG)|The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.
62302877|NCT03864965|EXPERIMENTAL|Intervention Group|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will receive the guided advance care planning conversations with the PI
62302878|NCT03864965|NO_INTERVENTION|Control Patients|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will not receive the guided advance care planning conversations with the PI
62113133|NCT05857319||General Cohort|The General Cohort includes all participants of the study. These are enrolled in the RNPC Program and will provide clinical and biological data usually collected in the RNPC centers, enriched by data from additional clinical and biological examinations as well as by self-questionnaires completed by the participants.
62471696|NCT05404594|EXPERIMENTAL|Very preterm infant|Preterm infant below 33 weeks of GA
62302879|NCT04938648|EXPERIMENTAL|Intervention|"The intervention consists of the following:~1. mailing deprescribing educational materials to care partners and people living with dementia (PLWD);~2. dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;~3. pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
62302880|NCT04938648|ACTIVE_COMPARATOR|Delayed Intervention (wait list control)|"The delayed intervention consists of the following:~1. mailing deprescribing educational materials to care partners and people living with dementia (PLWD);~2. three months after mailing the deprescribing educational materials, dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences.~3. pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
62302881|NCT02682810|ACTIVE_COMPARATOR|DNA PCR HIV diagnostic test|SOC or control arm through existing PMTCT program, with DBS samples sent to an off-site laboratory for DNA PCR testing.
62113134|NCT05857319||Connected Objects Group|"Depending on the RNPC center in which the participant is followed, he/she will be offered to be part of the Connected Objects subgroup, with specific additional examinations on inclusion as well as at certain key times of the intervention:~* Measurement of anthropometric parameters and evaluation of arterial stiffness using the Body Cardio connected scale (Withings).~* Sleep evaluation using the Sleep Analyzer (Withings); Measurements taken at the participant's home."
62113135|NCT05857319||Obstructive Sleep Apnea Syndrome (OSAS) Group|"Depending on the RNPC center in which the participant is followed, he/she will be offered to be part of the OSAS subgroup, with specific additional examinations on inclusion as well as at certain key times of the intervention:~* Sleep assessment and diagnosis of OSAS (if applicable) via the Sunrise device. Measurements taken at the participant's home."
62113136|NCT05857319||Neuropathies Group|"Depending on the RNPC center in which the participant is followed, he/she will be offered to be part of the Neuropathies subgroup, with specific additional examinations at each visit:~* Detection of diabetic neuropathies using SUDOSCAN/EZSCAN technology (Withings). Measurements taken at the center."
62113137|NCT06140745|PLACEBO_COMPARATOR|0 ppm Fluoride Dentifrice 1|
62471697|NCT05404594|ACTIVE_COMPARATOR|Full term neonate|Term neonate from a gestational age of 37 weeks.
62674343|NCT06232421|EXPERIMENTAL|Patients with the neuropathic form. Treatment with Foscelantan|"A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Foscelantan, medicinal plate 4.0×5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarusin adult patients with purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome, phase I-II wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases."
62674344|NCT06232421|ACTIVE_COMPARATOR|Patients with the neuropathic form. Treatment with Povidone-iodine|A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Povidone-iodine produced by BelAseptika JSC, in adult patients with purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome, phase I-II wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
62674345|NCT06232421|EXPERIMENTAL|Patients with chronic venous insufficiency. Treatment with Foscelantan|"A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Foscelantan, medicinal plate 4.0×5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus in adult patients with purulent inflammatory processes of the skin and soft tissues due to chronic venous insufficiency, phase I-II of the wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases."
62113138|NCT06140745|ACTIVE_COMPARATOR|1100 ppm NaF Fluoride Dentifrice|
62113139|NCT06140745|ACTIVE_COMPARATOR|1500 ppm NaMFP Fluoride Dentifrice|
62113140|NCT06140745|SHAM_COMPARATOR|0 ppm Fluoride Dentifrice 2|
62113141|NCT06140745|SHAM_COMPARATOR|0 ppm Fluoride Dentifrice 3|
62113142|NCT02496806|EXPERIMENTAL|Treatment|400mg capsule containing seaweed extract (treatment) Intervention: Dietary Supplement: Treatment capsule containing seaweed extract (treatment)
62113143|NCT05303155||Patient with COVID 19|Pediatric patient infected by COVID 19
62113144|NCT05303155||Pediatric patient without infection of COVID 19|Pediatric patient without infection of COVID 19
62113145|NCT02313090|EXPERIMENTAL|Welltang|patients using Welltang
62302882|NCT02682810|EXPERIMENTAL|Alere Q POC nucleic acid-based platform|POC test to provide same-day diagnosis
62302883|NCT03361501|EXPERIMENTAL|CaPre|
62302884|NCT03361501|PLACEBO_COMPARATOR|Placebo|
62471698|NCT06337721|EXPERIMENTAL|SPEAR|This arm will consist of the SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction) behavioral group intervention to reduce AUDs and alcohol-related harms in Pacific Islander young adults.
62471699|NCT06337721|NO_INTERVENTION|Control|This control group arm will be compared to the SPEAR intervention.
62113146|NCT02313090|NO_INTERVENTION|usual standard care|patients under usual standard of diabetic care
62113147|NCT03261596|EXPERIMENTAL|100 mg solid tablets 2x/day for 3 days|Assess the efficacy (Cure Rate/CR) and safety of 100 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
62113148|NCT03261596|EXPERIMENTAL|Single dose 500 mg solid tablets|Assess the efficacy (Cure Rate/CR) and safety of 500 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
62113149|NCT03991481|EXPERIMENTAL|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
62113150|NCT03991481|ACTIVE_COMPARATOR|Liquid-stored platelets|Platelets that have been liquid stored, with an expiry of 5 days.
62113151|NCT04143555||endoscopic submucosal injection of indocyanine green|
62302885|NCT03542214|EXPERIMENTAL|Calcium electroporation treatment|Experimental treatment with calcium electroporation for inoperabel colorectal cancer
62674346|NCT06232421|ACTIVE_COMPARATOR|Patients with chronic venous insufficiency. Treatment with Povidone-iodine|A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Povidone-iodine produced by BelAseptika JSC, in adult patients with purulent-inflammatory processes of the skin and soft tissues due to chronic venous insufficiency\&#34;, phase I-II of the wound process . All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
62674347|NCT05306574|EXPERIMENTAL|Telitacicept|Telitacicept + Standard of Care (SoC)
62302886|NCT00224016|EXPERIMENTAL|Oxybutynin Transdermal System|Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
62302887|NCT00224016|ACTIVE_COMPARATOR|Oral oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
62302888|NCT02362607|EXPERIMENTAL|Integrated Diabetes Management Protocol|Smartphone apps for food diary, activity monitor, blood glucose will be used for three months.
62302889|NCT02362607|ACTIVE_COMPARATOR|Standard Diabetes Management Protocol|Subjects will receive standard diabetes management protocol with standard education and standard blood glucose measurement devices.
62302890|NCT05041101|EXPERIMENTAL|Treatment (grapiprant, eribulin mesylate)|Patients receive grapiprant PO BID on day 1-21 and eribulin mesylate IV over 5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62674348|NCT05306574|PLACEBO_COMPARATOR|Placebo|Placebo + Standard of Care (SoC)
62674349|NCT06129682|NO_INTERVENTION|Standard of care|
62674350|NCT06129682|EXPERIMENTAL|Self rehabilitation at home|
62674351|NCT05574400|PLACEBO_COMPARATOR|Control|Prepared intravenous piggyback solution of 5 percent dextrose water at multiple postoperative time points over a 30-minute infusion period.
62674352|NCT05574400|EXPERIMENTAL|Low-dose Caffeine|Prepared intravenous low-dose caffeine citrate (1.5 mg/kg) at multiple postoperative time points over a 30-minute infusion period.
62674353|NCT05574400|EXPERIMENTAL|High-dose Caffeine|Prepared intravenous high-dose caffeine citrate (3 mg/kg) at multiple postoperative time points over a 30-minute infusion period.
62674354|NCT05352594||Chronic Low Back Pain|The participants whose low back pain intensity score ≥2 by numeric pain rating scale at 24-week follow-up.
62674355|NCT05352594||Recovered Low Back Pain|The participants whose low back pain intensity score \<1 by numeric pain rating scale at 24-week follow-up.
62113152|NCT02379546|EXPERIMENTAL|BIS<50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values below 50.
62113153|NCT02379546|ACTIVE_COMPARATOR|BIS≥50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values above 50.
62113154|NCT04580303|ACTIVE_COMPARATOR|Uniform 0.1-milliliters (mL) 1-Aliquot Grid Injection Technique (Buttock)|Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area)
62113155|NCT04580303|ACTIVE_COMPARATOR|Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock)|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
62113156|NCT04580303|ACTIVE_COMPARATOR|Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thigh)|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
62113157|NCT04580303|ACTIVE_COMPARATOR|Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thigh)|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
62113158|NCT02909049|ACTIVE_COMPARATOR|CONTROL|Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy
62113159|NCT02909049|EXPERIMENTAL|EXPERIMENTAL|Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.
62113160|NCT04866069|EXPERIMENTAL|Low-Dose Group (Group A)|20 participants will receive 10 µg-3M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
62113161|NCT04866069|EXPERIMENTAL|High-Dose Group (Group B)|20 participants will receive 20 µg-6M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
62113162|NCT04866069|PLACEBO_COMPARATOR|Placebo Group|10 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
62113163|NCT04013646|EXPERIMENTAL|UCB infusion and EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
62113164|NCT04013646|EXPERIMENTAL|UCB infusion and placebo EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
62113165|NCT04013646|PLACEBO_COMPARATOR|Placebo UCB infusion and placebo EPO injection group|Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
62113166|NCT05581654|EXPERIMENTAL|Junior surgeons|The surgeons will be divided into 2 arms based on their surgical experience time: less than 5 years (junior surgeons) and more than 5 years (senior surgeons). The learning curve analysis will include 30 procedures for each surgeon group in each centre. For ethical reasons, all the junior surgeons will first assist the senior surgeons in performing vNOTES salpingectomy, as first assistant in at least 15 procedures, before starting to perform them as operators.
62302891|NCT04194177|EXPERIMENTAL|protective|
62302892|NCT04194177|ACTIVE_COMPARATOR|conventional|
62674356|NCT03182556|PLACEBO_COMPARATOR|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
62674357|NCT03182556|EXPERIMENTAL|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
62674358|NCT03182556|EXPERIMENTAL|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
62113167|NCT05581654|ACTIVE_COMPARATOR|Senior surgeons|The surgeons will be divided into 2 arms based on their surgical experience time: less than 5 years (junior surgeons) and more than 5 years (senior surgeons). The learning curve analysis will include 30 procedures for each surgeon group in each centre.
62113168|NCT04289610|SHAM_COMPARATOR|Control Group|In this group a pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). The device is not going to be activated in the control group. The device will be set at 0 V. TCPRF treatment is going to be applied for one session.
62113169|NCT04289610|ACTIVE_COMPARATOR|Study Group|A pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). It will be activated in the study group. In the study group device will be set at 80 V, every pulse will continue for 10 milliseconds and 5 pulses per second. TCPRF treatment is going to be applied for one session in both groups.
62113170|NCT00521937|EXPERIMENTAL|A|Dermagen®
62113171|NCT00521937|ACTIVE_COMPARATOR|B|Conventional treatment
62302893|NCT01586728|OTHER|Air - oxygen|One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
62113172|NCT03326648|EXPERIMENTAL|Strength training + protein supplement|Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
62113173|NCT03326648|EXPERIMENTAL|Protein supplement|Daily protein supplementation for 10 weeks.
62302894|NCT01586728|OTHER|Oxygen - Air|One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.
62302895|NCT01985321|EXPERIMENTAL|Merlin - ethanol/glycolic acid solution|36 applications over a 96 hour period
62302896|NCT01985321|PLACEBO_COMPARATOR|Placebo/Ethanol|36 applications over a 96 hour period
62302897|NCT00472303|PLACEBO_COMPARATOR|Matching Placebo after Tapentadol in Titration Phase|Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
62302898|NCT00472303|ACTIVE_COMPARATOR|Morphine Controlled Release|Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
62302899|NCT00472303|EXPERIMENTAL|Tapentadol Prolonged Release|Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses.
62302900|NCT02363205|NO_INTERVENTION|control|Weekly check-up
62471700|NCT03676686|EXPERIMENTAL|Nåva Foot Cream|Topical Nåva foot cream administered twice daily.
62113174|NCT06053242|EXPERIMENTAL|Low Dose|Subjects in the low dose arm will receive a single administration of either 6x10\^6 cells (n=8) or a placebo injection (n=2). Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
62302901|NCT02363205|EXPERIMENTAL|internet-delivered CBT|Tailored Internet-administrated CBT-Treatment
62302902|NCT06075056||Chronic spinal cord injuries|Defined as spinal cord injuries secondary to a single traumatic event to the Cervical or thoracic spine, more than 6 months ago.
62302903|NCT01706913|NO_INTERVENTION|No consult|Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
62471701|NCT05332496||Study group: TACE+PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|TACE was performed up to 3 months after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or within 1 month before treatment. The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
62471702|NCT05332496||Control group: TACE|TACE monotherapy
62471703|NCT00066001|PLACEBO_COMPARATOR|1, 2, 3, 4|The 4 arms of the study are based on the treatment groups: 1. scaling and root planing alone (SRP); 2. SRP plus repeated professional supragingival plaque removal; 3. SRP + systemically administered metronidazole; 4. SRP + repeated professional supragingival plaque removal + systemically administered metronidazole.
62471704|NCT02147418||Group 1: HPV-positive Cancer|Oropharyngeal cancer patients testing positive for human papillomavirus (HPV)
62674359|NCT06021223|EXPERIMENTAL|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
62471705|NCT02147418||Group 2: HPV-positive Cancer|Oropharyngeal cancer patients who test positive for human papillomavirus (HPV)
62471706|NCT02147418||Group 3: Healthy Controls|Patients with benign conditions
62471707|NCT01675765|EXPERIMENTAL|Immunotherapy plus chemotherapy|"Weeks 1 and 3: CRS-207 (1 × 10\^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\^2) and cisplatin (75 mg/m\^2)~Weeks 23 and 26: CRS-207~Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression"
62471708|NCT01675765|EXPERIMENTAL|Immunotherapy with cyclophosphamide plus chemotherapy|"Weeks 1 and 3: cyclophosphamide (200 mg/m\^2), CRS-207 (1 × 10\^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\^2) and cisplatin (75 mg/m\^2)~Weeks 23 and 26: cyclophosphamide one day before CRS-207~Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression"
62471709|NCT03281135|OTHER|HPV testing|This is an experimental arm for the primary outcome, 'adherence to the procedures'. In this group self sampling will be done using the Evalyn brush for HPV testing.
62471710|NCT03281135|NO_INTERVENTION|Standard care: VIA screening|Control Arm, in which women's are invited to cervical cancer screening as per standard Ethiopian cervical cancer prevention and control guideline. Uptake of screening in this group will be compared with the HPV testing arm group to test for significant differences in adherence.
62471711|NCT00830700|EXPERIMENTAL|CATMH intervention|Child telemental health service delivery intervention
62113175|NCT06053242|EXPERIMENTAL|Medium Dose|Subjects in the medium dose arm will receive a single administration of either 12x10\^6 cells (n=8) or a placebo injection (n=2). Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
62113176|NCT06053242|EXPERIMENTAL|High Dose|Subjects in the high dose arm will receive a single administration of either 24x10\^6 cells (n=8) or a placebo injection (n=2). Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
62113177|NCT03266302|EXPERIMENTAL|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
62113178|NCT03266302|NO_INTERVENTION|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
62113179|NCT04606069|EXPERIMENTAL|Active Arm|Regadenoson will be given intravenously as 5 ug/kg loading dose (up to 400 mg/patient) over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
62113180|NCT04606069|PLACEBO_COMPARATOR|Control Arm|The same volume of saline will be given intravenously for 30 mins followed by a continuous infusion for 6 hours.
62113181|NCT05622188||Healthy participants|Age of the participants is between 18-40 years, females and males equally distributed
62471712|NCT00830700|NO_INTERVENTION|augmented TAU/PCP|Augmented treatment as usual with primary care physician
62471713|NCT02042781|EXPERIMENTAL|PG545|Once weekly, one hour IV infusion of PG545.
62113182|NCT04055766||Meningitis/Encephalitis|Patients with clinical signs and symptoms suspected of meningitis/encephalitis
62113183|NCT04055766||Stroke|Patients with clinical signs and symptoms suspected of stroke
62113184|NCT04055766||Headache|Patients with clinical signs and symptoms suspected of headache
62113185|NCT04055766||Vertigo|Patients with clinical signs and symptoms suspected of vertigo
62113186|NCT01667354|EXPERIMENTAL|Intervention Clinics|Providers in intervention clinics will receive a training followed by telephone coaching and follow-up visits for six months.
62113187|NCT01667354|NO_INTERVENTION|Control Clinics|Control clinics will receive all intervention materials at the completion of the study.
62471714|NCT02284087||V_PAS|Visuomotor paired associative stimulation protocol
62471715|NCT02284087||Sham V_PAS|Placebo group of Visuomotor paired associative stimulation protocol
62471716|NCT02284087||CER_PAS|cerebellar-motor associative stimulation protocol
62471717|NCT02284087||Sham CER_PAS|Placebo group of cerebellar-motor associative stimulation protocol
62471718|NCT04605861|EXPERIMENTAL|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on abdomen, thigh or upper arm.
62471719|NCT04605861|PLACEBO_COMPARATOR|Placebo|Placebo (Liraglutide Injection simulator), once a day, injected subcutaneously on abdomen, thigh or upper arm.
62471720|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
62113188|NCT06233812|ACTIVE_COMPARATOR|Half A of the FTSG|"A (superior or left relative to the patient, depending on the shape of the wound)"
62113189|NCT06233812|ACTIVE_COMPARATOR|Half B of the FTSG|"B (inferior or right relative to the patient)."
62471721|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
62471722|NCT05084625|EXPERIMENTAL|Arm A- access to digitized support, an app|Patients in Arm A will have access to digitized support-an app for 12 months from baseline in addition to standard follow-up.
62471723|NCT05084625|NO_INTERVENTION|Arm B-standard follow-up|Patients in Arm B-will continue with standard follow-up from baseline and onwards
62471724|NCT01334333|ACTIVE_COMPARATOR|Prograf®|Prograf® is a twice daily formulation of tacrolimus
62113190|NCT01830842|PLACEBO_COMPARATOR|Nicotine, placebo|Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
62471725|NCT01334333|EXPERIMENTAL|Advagraf®|Advagraf® is a once daily formulation of tacrolimus
62471726|NCT01662284||Triple Negative Breast|124I-NM404 in triple negative breast cancer
62471727|NCT01662284||Prostate|124I-NM404 in prostate cancer
62471728|NCT01662284||Colorectal|124I-NM404 in colorectal cancer
62113191|NCT01830842|OTHER|Nicotine withdrawal or satiety|Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
62113192|NCT00915330|ACTIVE_COMPARATOR|TBNA alone|Arm A: TBNA alone.
62113193|NCT00915330|EXPERIMENTAL|TBNA with ROSE|Arm B: TBNA with ROSE.
62113194|NCT01606553|EXPERIMENTAL|High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a dual-vave prototype
62113195|NCT01606553|ACTIVE_COMPARATOR|Sham High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a sham dual-vave prototype
62113196|NCT03556137|EXPERIMENTAL|Pain Patients|Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a \[18F\]FTC-146 PET/MRI scan.
62113197|NCT03556137|EXPERIMENTAL|Healthy Volunteers|Individuals who do not have pain and undergo a \[18F\]FTC-146 PET/MRI scan.
62113198|NCT03752385|NO_INTERVENTION|Control Group|No intervention
62113199|NCT03752385|EXPERIMENTAL|Intervention Group|"Will cut their smartphone screen time in half, sleep without phone in bedroom, and have a bedtime for their phone use."
62113200|NCT04135378|EXPERIMENTAL|student- ascorbic acid|Student that have presentation given ascorbic acid ( 500 mg per day) for one week before presentation .
62113201|NCT04135378|PLACEBO_COMPARATOR|Control- ascorbic acid like|ascorbic acid like placebo for one week before presentation
62302904|NCT01706913|ACTIVE_COMPARATOR|Dermatology Consult|The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
62113202|NCT02041104|EXPERIMENTAL|Bread with added beta-glucans|Experimental food is bread with high amount of barley beta-glucans. Experimental bread contains approximately 3,4 % (w/w) beta-glucans. Participants will consume 6 g of beta-glucans daily (approximately 200 g of bread per day). Beta-glucans are natural polysaccharides found in grain endosperm and are mostly represented in oat and barley. Beta-glucans are linear homopolymers of D- glycopyranosyl residues with mixed linkage (1-4, 1-3)-β-D-glucans. Their molecular structure enable beta-glucans their functional action that mostly depends of their viscosity and solubility (1). Testing bread has integrated flour with high amount of barley beta-glucans (ReducholTM). Beta-glucans are concentrated in flour up to 15 % with dry milling, sieving and air classification of barley flour.
62113203|NCT02041104|PLACEBO_COMPARATOR|Bread without added beta-glucans|Placebo bread without added barley beta-glucans in testing product.
62113204|NCT02400151|OTHER|Non-Obese group|"Non-obese patients will be recruited and frequency matched to obese groups according to sex and level of sexual maturation.~Intervention: Normal control"
62113205|NCT02400151|EXPERIMENTAL|Obese group, Vitamin D|"Subjects randomized to this group will receive vitamin D supplementation. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Vitamin D supplementation"
62302905|NCT05055908|EXPERIMENTAL|Cohort A: Chemotherapy plus Immune Checkpoint Inhibitors|Lung Cancer patients treated with Chemotherapy plus Immune Checkpoint Inhibitors.
62302906|NCT05055908|EXPERIMENTAL|Cohort B: Immune Checkpoint Inhibitors monotherapy|Lung Cancer patients treated with Immune Checkpoint Inhibitors monotherapy.
62471729|NCT01662284||Gastric|124I-NM404 in gastric cancer
62471730|NCT01662284||Ovarian|124I-NM404 in ovarian cancer
62471731|NCT01662284||Pancreatic|124I-NM404 in pancreatic cancer
62471732|NCT01662284||Esophageal|124I-NM404 in esophageal cancer
62471733|NCT01662284||Sarcoma|124I-NM404 in soft tissue sarcoma
62471734|NCT01662284||Head & Neck|124I-NM404 in head and neck cancer
62471735|NCT05195762|EXPERIMENTAL|Patients receiving NFX-179 Gel|NFX-179 Gel 1.50% applied QD for 12 weeks
62471736|NCT02442934|EXPERIMENTAL|Multicomponent program|Multicomponent intervention to reduce perceived discomforts in critically ill patients : the IPREA3 program
62302907|NCT05055908|EXPERIMENTAL|Cohort C: Chemotherapy Group.|Lung Cancer patients treated with Chemotherapy.
62302908|NCT01073943|EXPERIMENTAL|PicoPrep|"Day Before method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy."
62471737|NCT02442934|ACTIVE_COMPARATOR|Standard Care|Standard care
62471738|NCT03186976|EXPERIMENTAL|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
62471739|NCT03186976|ACTIVE_COMPARATOR|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
62471740|NCT02960568|EXPERIMENTAL|Primaquine|Poor and Intermediate Metabolizers will receive 30 mg oral primaquine (PQ) and have peripheral blood draws over a 24-hour period to measure PQ pharmacokinetics
62471741|NCT02960568|NO_INTERVENTION|No primaquine|Extensive and Ultra Metabolizers will not be eligible for the pharmacokinetic portion of the study and participation will be complete after receiving genotype information
62471742|NCT02519491|ACTIVE_COMPARATOR|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
62471743|NCT02519491|ACTIVE_COMPARATOR|Iphone assessment|iPhone assessment of radial and ulnar patency.
62471744|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
62471745|NCT03373162|EXPERIMENTAL|MRI Scans Pre and Post-Botox Injection|Participants will receive MRI scans pre and post-Botox injection, including magnetic resonance spectroscopy, structural, and functional MRI.
62113206|NCT02400151|PLACEBO_COMPARATOR|Obese group, placebo|"Subjects randomized to this group will receive a placebo supplement. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Placebo"
62113207|NCT01785004|ACTIVE_COMPARATOR|Vitamin D + fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
62113208|NCT01785004|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
62113209|NCT01785004|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
62113210|NCT01785004|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
62113211|NCT03433950||Fluctuator|Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
62302909|NCT01073943|ACTIVE_COMPARATOR|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
62471746|NCT01963728|ACTIVE_COMPARATOR|insulin isophane|daily dose will be titrated based on fasting morning glucose values
61917331|NCT05245396|EXPERIMENTAL|Part A: Evobrutinib: Treatment Sequence 5|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MR-T3 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62113212|NCT05216653|EXPERIMENTAL|Preoperative Short-course Radiation followed by Envafolimab plus CAPEOX|"The enrolled patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery).~1. Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~2. After radiotherapy, PD-L1 antibody (150mg/week, subcutaneous injection × 6 weeks) immunotherapy combined with two courses of CAPEOX chemotherapy was performed.~3. Two weeks after the end of the combined treatment plan in step 2), TME surgery is performed."
62471747|NCT01963728|ACTIVE_COMPARATOR|insulin glargine|daily dose will be titrated based on fasting morning glucose values
62302910|NCT04988230|EXPERIMENTAL|Time Restricted Feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
62113213|NCT01254019|EXPERIMENTAL|GSK2402968|6mg/kg
62113214|NCT01254019|EXPERIMENTAL|Placebo|dose-matched
62113215|NCT03206671|EXPERIMENTAL|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
62113216|NCT03206671|EXPERIMENTAL|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
62302911|NCT04988230|ACTIVE_COMPARATOR|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
62302912|NCT02267928|EXPERIMENTAL|Check/Experience|Participants are asked to check the symptoms that they have experienced in the last 6 weeks.
62302913|NCT02267928|EXPERIMENTAL|Un-check/Experience|Participants are asked to un-check the symptoms that they have experienced in the last 6 weeks.
62302914|NCT02267928|EXPERIMENTAL|Check/Not Experienced|Participants are asked to check the symptoms that they have NOT experienced in the last 6 weeks.
62302915|NCT02267928|EXPERIMENTAL|Un-check/Not Experienced|Participants are asked to un-check the symptoms that they have NOT experienced in the last 6 weeks.
62471748|NCT03409133|EXPERIMENTAL|Stimulating nerve electrodes & intramuscular recording electrodes|"Fifteen subjects with lower limb amputation will have multi-contact stimulating nerve cuff electrodes implanted around the nerves in their residual limb. These electrodes will be connected to temporary percutaneous leads.~During experimental testing, a small amount of electrical current will be delivered to the nerves through multi-contact nerve cuff electrodes.~Participants also have the option to have recording electrodes implanted within muscles in their lower limb(s). These muscles are associated with prosthetic movement, and recordings from these muscles will be used to develop a controller for a robotic myoelectric prosthesis."
62302916|NCT05282940|EXPERIMENTAL|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
62302917|NCT05282940|ACTIVE_COMPARATOR|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the test marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
62302918|NCT00996840|EXPERIMENTAL|Cohort 1 - SB-681323 Intravenous 3mg|3mg SB-681323 Intravenous administration, infused over 4 hours
62471749|NCT00207090|EXPERIMENTAL|Ixabepilone + rifampin|
62302919|NCT00996840|EXPERIMENTAL|Cohort 2 - SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
62302920|NCT00996840|EXPERIMENTAL|Cohort 3 - SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
62471750|NCT04236401|OTHER|electrosurgery will be used inanterior abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall electrosurgically.
62113217|NCT03206671|OTHER|R2 stage III standard arm|Standard chemotherapy
61917332|NCT05245396|EXPERIMENTAL|Part A: Evobrutinib: Treatment Sequence 6|Participants will receive two single oral doses of Ref (TF2) on Day 1 in treatment period 1, followed by single oral dose of MR-T3 on Day 1 in treatment period 2, followed by single oral dose of MR-T4 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62113218|NCT03206671|EXPERIMENTAL|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
62113219|NCT03206671|EXPERIMENTAL|R3/R4 standard arm|Rituximab window + standard chemotherapy
62113220|NCT01977612|ACTIVE_COMPARATOR|Stainless Steel Staples|Skin closure with stainless steel staples
62113221|NCT01977612|EXPERIMENTAL|4-0 monofilament Sutures|Skin closure with 4-0 monofilament sutures
62302921|NCT00996840|EXPERIMENTAL|Cohort 4 - SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
62302922|NCT00996840|EXPERIMENTAL|Combined Placebo|Placebo to match intervention
62302923|NCT06657222|EXPERIMENTAL|Phase 1: dose escalation|Drug TUB-030, administered by intravenous (IV) infusion
62113222|NCT00901069|OTHER|Azacitidine|
62113223|NCT03031262|ACTIVE_COMPARATOR|High Dose of Cytarabine|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine.
62302924|NCT06657222|EXPERIMENTAL|Phase 2: dose optimization in NSCLC and HNSCC|Drug TUB-030, administered by intravenous (IV) infusion NSCLC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion HNSCC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion
62113224|NCT03031262|EXPERIMENTAL|HDAC + Chidamide|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine plus chidamide.
62302925|NCT04507815|EXPERIMENTAL|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
62471751|NCT04236401|OTHER|scalpel will be used in abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall sharply.
62113225|NCT02462551|EXPERIMENTAL|FEAST|Patients with treatment-resistant depression will undergo 3 sessions of focal electrically administered seizure therapy for two to six weeks. The complete parameter range of the stimulus delivered (Freq: 20-120 Hz; PW: 0.2-2 ms; Duration: 0.1 to 8 s; Current: 0.5-0.8A; charge: 1-576 mC) is determined by an initial titration session and the PI (as an expert in neuromodulation treatments).
62113226|NCT06116162|ACTIVE_COMPARATOR|CO2 fractional laser treatment|One side face was random to receive CO2 fractional laser. After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage, 300 Hz emission frequency and on the 10 mm spot size without overlap, Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage, 300 Hz emission frequency, 10 mm spot size without overlap.
62302926|NCT04507815|SHAM_COMPARATOR|Sham tDCS|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This ramp up/down method is done at the end of the stimulation period, as well. This method mimics the physical sensation of stimulation typically encountered at the very beginning and end of the intervention period.
62302927|NCT02886715|EXPERIMENTAL|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
62302928|NCT02886715|ACTIVE_COMPARATOR|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
62302929|NCT02886715|PLACEBO_COMPARATOR|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
62302930|NCT03946540||L-FED sample|All young people treated in Maudsley Child and Adolescent Eating Disorder Service between 1/8/2009 and 31/1/2014.
62302931|NCT02288637|EXPERIMENTAL|Conventional Olyset LLIN|High coverage (\>80% access) of conventional Olyset LLIN The arm is the standard of care from the National Malaria Control Program
62471752|NCT06355622|EXPERIMENTAL|Case group|Detection and characterization of pain by clinical evaluations, biochemical analysis and instrumental tests
62302932|NCT02288637|EXPERIMENTAL|Olyset Plus LLIN|High coverage (\>80% access) of Olyset Plus LLIN
61917333|NCT05245396|EXPERIMENTAL|Part B: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of MUPS-C1 evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C2 on Day 1 in treatment period 2, followed by two single oral doses of Ref (TF2) on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
61917334|NCT05245396|EXPERIMENTAL|Part B: Evobrutinib: Treatment Sequence 2|Participants will receive single oral dose of MUPS-C2 evobrutinib on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MUPS-C2 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62113227|NCT06116162|EXPERIMENTAL|SVF-gel preparation and filling|The other side face received SVF-gel filling. The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. The Coleman fat was was islolated by centrifugation. Then, SVF gel further islolated by using cutting and centrifugation. 22G sharp-tip injector was used to inject the SVF-gel into the dermis of acne scars.
62113228|NCT05377346|EXPERIMENTAL|Paratracheal pressure group|After the induction of anesthesia, the i-gel is placed under the application of paratracheal pressure.
62302933|NCT02288637|EXPERIMENTAL|Conventional Olyset LLIN and IRS|High coverage (\>80% access) of conventional Olyset LLIN and high coverage IRS (\>80% of the household sprayed) with pirimiphos methyl CS
62113229|NCT05377346|ACTIVE_COMPARATOR|Cricoid pressure group|After the induction of anesthesia, the i-gel is placed under the application of cricoid pressure.
62674360|NCT06021223|EXPERIMENTAL|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
62674361|NCT06021223|PLACEBO_COMPARATOR|Placebo|140ml of placebo (caesinate) to be consumed daily for 2 weeks
62674362|NCT04249648||Patients with new diagnosis of heart failure with reduced ejection fraction|Patients with new diagnosis of heart failure with reduced ejection fraction who will be started on renin-angiotensin-aldosterone system inhibitors or in whom there is a plan to increase renin-angiotensin-aldosterone system inhibitors (if already taking prior to diagnosis of heart failure).
62674363|NCT04249648||Patients with hyperkalaemia|Hospitalised patients and patients attending emergency department who have at least 1 blood test with a potassium level of ≥5.5 mmol/l.
62113230|NCT03818178|EXPERIMENTAL|Intralipid|
62113231|NCT03818178|EXPERIMENTAL|Palm Oil|
62113232|NCT03818178|PLACEBO_COMPARATOR|Saline|
62113233|NCT04676984|OTHER|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
62113234|NCT00309088|EXPERIMENTAL|1|
62113235|NCT00309088|PLACEBO_COMPARATOR|2|
62113236|NCT03008018|OTHER|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
62113237|NCT02582437|EXPERIMENTAL|Chronic Opioid User|"The patients (ASA class I-III) who receive elective surgery s aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The Patients who use opioid medication daily and regularly immediately before the day of surgery for more than four weeks. The minimum criteria for opioid dose in the intervention goup is oral morphine 20mg per day: Morphine Equivalent Daily Dose(MEDD)"
62113238|NCT02582437|NO_INTERVENTION|Opioid Naive patient|"The patients (ASA class I-III) who receive elective surgery aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The patients who do not use opioid medications immediately before the day of surgery for four weeks."
62113239|NCT00506181|ACTIVE_COMPARATOR|X|receiving probiotics
62113240|NCT00506181|PLACEBO_COMPARATOR|Y|
62113241|NCT00506181|NO_INTERVENTION|Z|
62113242|NCT02918071|EXPERIMENTAL|Arm Benralizumab|Benralizumab administered subcutaneously every 4 weeks
62113243|NCT05639699|EXPERIMENTAL|Experimental group|Motivational interview will be done to the experimental group
62113244|NCT05639699|NO_INTERVENTION|I Control group|No intervention will be applied to the control group
62113245|NCT05639699|NO_INTERVENTION|II Control group|No intervention will be applied to the control group
62302934|NCT02288637|EXPERIMENTAL|Olyset Plus LLIN and IRS|High coverage (\>80% access) of Olyset Plus LLIN and high coverage Indoor Residual Spraying (\>80% of the household sprayed) with pirimiphos methyl CS
62302935|NCT04549012|ACTIVE_COMPARATOR|group A|will receive oxytocin
62302936|NCT04549012|ACTIVE_COMPARATOR|group B|will receive tranexamic acid plus oxytocin
62302937|NCT02039947|EXPERIMENTAL|Cohort A|Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
62302938|NCT02039947|EXPERIMENTAL|Cohort B|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
62302939|NCT02039947|EXPERIMENTAL|Cohort C|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
62302940|NCT02039947|EXPERIMENTAL|Cohort D|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
62302941|NCT02756871|EXPERIMENTAL|Online guided self-help intervention|CBT based online guided self-help intervention. Intervention can be found at www.overcomingperfectionism.co.uk
62302942|NCT02756871|NO_INTERVENTION|Control|No intervention.
62302943|NCT02503891|EXPERIMENTAL|Polymer on Ceramic|MP-1 Polymer on Ceramic articulation system
62302944|NCT01919307|EXPERIMENTAL|Auricular acupuncture|Subjects will then receive auricular acupuncture (NADA Protocol) twice weekly for eight consecutive weeks. Subjects will be evaluated for seizure frequency changes by self-reported diary; adverse events; study feasibility; and mental and physiological symptoms at baseline, 12 weeks (completion of acupuncture), and 16 weeks (1 month after treatment follow up, end of study). A single sham procedure will be tested following treatment completion for use in future studies.
62302945|NCT06656455|ACTIVE_COMPARATOR|Group S|Group S will be given propofol 2 mg/kg and fentanyl 1µg/kg intravenously and anesthesia will be maintained with sevoflurane via LMA
62302946|NCT06656455|EXPERIMENTAL|Group P|Patients randomized to group P will be given propofol 1 mg/kg and fentanyl 1µg/kg intravenously and anesthesia will be maintained with a continuous infusion of propofol 200 µg/kg/min with oxygen 3 L/min via simple mask and oral airway if needed.
62302947|NCT00337051|EXPERIMENTAL|S|General Anesthesia with sevoflurane (inhalation) as hypnotic
62302948|NCT00337051|ACTIVE_COMPARATOR|P|General Anesthesia With Propofol TCI
62302949|NCT06098014|ACTIVE_COMPARATOR|Thalidomide group|Thalidomide group
62302950|NCT06098014|PLACEBO_COMPARATOR|Placebo group|Placebo group
62302951|NCT02957708|EXPERIMENTAL|mCIMT + SR|modified constraint-induced movement therapy plus self regulation
62302952|NCT02957708|ACTIVE_COMPARATOR|Control|conventional occupational therapy
62302953|NCT00203567|ACTIVE_COMPARATOR|Equetro|Equetro
62302954|NCT01671670|EXPERIMENTAL|acupuncture group|use traditional acupuncture to treat functional dyspepsia
62302955|NCT01671670|SHAM_COMPARATOR|sham acupuncture group|use penetrating sham acupuncture to manage functional dyspepsia
62302956|NCT05796661|EXPERIMENTAL|Qb150|"This group will be exposed to continuous venovenous therapy with a blood flow of 150ml/min; already standardized by the institution; for a maximum time of 72 hours or interrupted sooner if the system clots or the filter loses patency.~Both groups will have a wash out of 6 hours before crossing the arms of the work."
62302957|NCT05796661|ACTIVE_COMPARATOR|Qb 250|"This group will be exposed to continuous venovenous therapy with a blood flow of 250ml/min; experimental group to evaluate increased blood flow and filter durability; for a maximum time of 72 hours or interrupted sooner if the system clots or the filter loses patency.~Both groups will have a wash out of 6 hours before crossing the arms of the work."
62302958|NCT01719575|OTHER|Motilitone|take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week
62302959|NCT01719575|OTHER|Placebo|take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week
62302960|NCT00838734||1|Pre-LASIK
62302961|NCT00838734||2|Post-LASIK
62302962|NCT06356740|EXPERIMENTAL|Abacavir 600 mg/lamivudine 300 mg|Patients randomized to this group will take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
62302963|NCT06356740|ACTIVE_COMPARATOR|Control group (standard of care)|Patients randomized to this group will continue their usual treatment for lupus systemic.
62302964|NCT00609609|EXPERIMENTAL|Corticosteroids|Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
62302965|NCT00609609|EXPERIMENTAL|ECP + Corticosteroids|Extracorporeal Photopheresis (ECP) 8-9 treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60 + Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
62302966|NCT02413658|ACTIVE_COMPARATOR|Control|Dressings of best current clinical practice, sugar solution.
62302967|NCT02413658|EXPERIMENTAL|Phenytoin 1|Dressings using phenytoin solution 20mg/ml
62471753|NCT00397787|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62302968|NCT02413658|EXPERIMENTAL|Phenytoin 2|Dressings using phenytoin solution 40mg/ml
62674364|NCT04249648||Healthcare professionals managing patients with hyperkalaemia|Healthcare professionals (doctors, pharmacists, non-medical prescribers) who manage patients with hyperkalaemia and/or heart failure and hyperkalaemia.
62674365|NCT06256874|EXPERIMENTAL|the observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Myofascial Release Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
62674366|NCT06015334|ACTIVE_COMPARATOR|Bilateral implantation of trifocal intraocular lens|Patients will receive bilateral implantation of TECNIS Synergy intraocular lens
62674367|NCT06015334|ACTIVE_COMPARATOR|Bilateral monofocal intraocular lens implantation with monovision|Patients will receive bilateral implantation of TECNIS monofocal intraocular lens
61917335|NCT05245396|EXPERIMENTAL|Part B: Evobrutinib: Treatment Sequence 3|Participants will receive two single oral doses of Ref (TF2) evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C1 on Day 1 in treatment period 2, followed by single oral dose of MUPS-C2 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62113246|NCT04881136|EXPERIMENTAL|Reveal LINQ|The Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present is implanted to the participants who are have experienced non accidental falls. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data.
62113247|NCT00993850|OTHER|Bipolar disorder education|Psychoeducation
62113248|NCT00993850|OTHER|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia
62113249|NCT02378714|PLACEBO_COMPARATOR|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
62113250|NCT02378714|EXPERIMENTAL|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
62113251|NCT02378714|ACTIVE_COMPARATOR|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
62113252|NCT02378714|EXPERIMENTAL|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
62113253|NCT02491749|EXPERIMENTAL|Ultra Fast-Track Anesthesia|Patients who fulfilled the extubation criteria were extubated at the end of surgery and transferred to the ICU for follow up.
62113254|NCT02491749|EXPERIMENTAL|Conventional|patients who did not fulfill extubation criteria were left intubated and sedated and transferred to the ICU for later management
62113255|NCT00364286|EXPERIMENTAL|Dasatinib|Dasatinib 50mg Orally twice daily.
62113256|NCT00456274|OTHER|1|
62113257|NCT02786771|EXPERIMENTAL|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
62113258|NCT02786771|EXPERIMENTAL|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
62471754|NCT04478786||Focus Groups 1-4|An anticipated 3-8 participants who meet the inclusion criteria of being aged 18 or over, a employee of the local ambulance service, are employed as an operational ambulance crew member, irrespective of title and to have had experienced an out of hospital resuscitation where MCCD was used, irrespective of the type of device or their level of involvement, and who also volunteer and agree to take part in the online focus group.
62674368|NCT00617903|EXPERIMENTAL|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
62674369|NCT00617903|PLACEBO_COMPARATOR|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
62674370|NCT04607785|ACTIVE_COMPARATOR|Miswak mouthwash group|Miswak sticks were bought from local markets, Baghdad, Iraq, washed with cold water and dried then crushed into powder. Later,7 grams of the miswak powder weighted and added to 350 ml of distilled water (D.W.) in a conical flask for 24 hours. Finally, the solution then filtered and stored in tightly closed bottles in a cool place.9
62674371|NCT04607785|OTHER|Chlorhexidine mouthwash group|0.12% chlorhexidine gluconate mouthwash for seven days
62674372|NCT04873661|EXPERIMENTAL|Hypnosis|In the hypnosis-based intervention, patients (in groups of approximately 10 participants) will participate in 8 weekly sessions (2 hours each) during which they will benefit from guided hypnosis exercises, and learn how to implement self-hypnosis. They will also receive a CD with hypnosis exercises for home practice. At-home practice is encouraged between sessions.
62674373|NCT04873661|EXPERIMENTAL|Cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
62674374|NCT04873661|EXPERIMENTAL|Meditation|The meditation-based intervention will consist of 8 weekly sessions (2h45 each) in groups of approximately 10 participants, as well as half a day of intensive practice between the fifth and the sixth session. Participants will learn how to implement self-compassion meditation, through practical exercises proposed during the sessions. At-home practice is encouraged between sessions.
62674375|NCT04873661|NO_INTERVENTION|Control group|Participants in the control group will not receive any intervention during the whole duration of the study. They will be assessed at the same times and in the same ways than the 3 experimental groups. After the study, they will have the opportunity to participe in one of the 3 interventions if they want to.
62674376|NCT02388256|EXPERIMENTAL|Acupuncture|Manual and electroacupuncture
62674377|NCT02388256|ACTIVE_COMPARATOR|Enhanced recovery program after surgery|Enhanced recovery program after surgery
62674378|NCT02950974|ACTIVE_COMPARATOR|NSS|NSS 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
62674379|NCT02950974|EXPERIMENTAL|Sterofundin|Sterofundin solution 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
62674380|NCT04933227|EXPERIMENTAL|Atezo + Tira + XELOX|Atezolizumab plus tiragolumab in combination with XELOX (oxaliplatin and capecitabine) will be administered during Cycles 1-4 (each cycle is 21 days). During Cycle 5 and beyond atezolizumab and tiragolumab will be administered on Day 1 of each 21-day cycle. Participants will receive study treatment until disease progression, unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62674381|NCT02083263|EXPERIMENTAL|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
62674382|NCT02083263|ACTIVE_COMPARATOR|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
62674383|NCT00756314|EXPERIMENTAL|Personalized contraceptive counseling|All 123 allocated women for the intervention group received personalized counseling (face-to-face) and the contraceptive method chosen for free by a specialized trained doctor in family planning.
62674384|NCT00756314|NO_INTERVENTION|Control|All 123 women allocated to control group received a standard care available at IMIP.Standard care is comprised of educational group counseling by specialized nursing staff in family planning discussing about contraceptive methods and side effects
62674385|NCT04079764||active surveillance|Patient with Bosniak III or IV lesion that decide to be followed under active surveillance
61917336|NCT05245396|EXPERIMENTAL|Part C: Evobrutinib: Treatment Sequence 4|Participants will receive single oral dose of MUPS-C3 evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C4 on Day 1 in treatment period 2, followed by two single oral doses of Ref (TF2) on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62113259|NCT03987542||Exposed|Patients who had their asparaginase treatment truncated or had no asparaginase enzyme activity.
62113260|NCT03987542||Unexposed|Patients who did not have their asparaginase treatment truncated and had measurable asparaginase enzyme activity
62674386|NCT04079764||Surgery|Patient with Bosniak III or IV lesion that decide to undergo a definitive treatment such as surgery
62674387|NCT05977530|EXPERIMENTAL|self-rescue training|children will receive self-rescue training from a certified instructor
62674388|NCT04123795|EXPERIMENTAL|Cohort A - certolizumab pegol|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent Open-Label Extension Period.
62674389|NCT04123795|PLACEBO_COMPARATOR|Cohort A - placebo|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of placebo from Week 1 to 16 and certolizumab pegol to Week 52 and through the subsequent Open-Label Extension Period.
62113261|NCT00667745|EXPERIMENTAL|1|Participants received lithium plus optimized medication treatment, as needed.
62113262|NCT00667745|ACTIVE_COMPARATOR|2|Participants only received optimized medication treatment, as needed; lithium was not be used.
62471755|NCT00834522|EXPERIMENTAL|Granisetron|Granisetron 2 x 1 mg Tablet (test) dosed in first period followed by Kytril® 2 x 1 mg Tablet (reference) dosed in second period
62674390|NCT04123795|EXPERIMENTAL|Cohort B - certolizumab pegol|Enrolling study participants aged 6 to 11 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent Open-Label Extension Period.
62674391|NCT00576394|ACTIVE_COMPARATOR|1Moderate Glycemic Control|Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl
62674392|NCT00576394|ACTIVE_COMPARATOR|2Aggressive Glycemic Control|Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl
62674393|NCT03886324|EXPERIMENTAL|DCB Treatment|Stricture patients treated by DCB
62674394|NCT02884180|ACTIVE_COMPARATOR|Treatment A|Dexamethasone 24 mg i.v. after start of anaesthesia
62674395|NCT02884180|PLACEBO_COMPARATOR|Treatment B|Saline isotonic i.v. after start of anaesthesia
62674396|NCT05160285|EXPERIMENTAL|Neoadjuvant nivolumab treatment arm|Nivolumab 360mg intravenous adminstration every 3 weeks
62674397|NCT04241718|OTHER|Single-arm|No comparator, placebo, or randomization
62113263|NCT03126656|EXPERIMENTAL|Hypogonadic with chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II), and hypogonadism (plasma testosterone levels \<11.4 nmol / L);
62113264|NCT03126656|EXPERIMENTAL|Hypogonadic|patients just with hypogonadism (testosterone \<11.4 nmol / L) in the absence of documented cardiovascular disease
62113265|NCT03126656|NO_INTERVENTION|chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II) with normal testosterone levels(plasma testosterone levels \> 11.4 nmol / L), in optimized standard therapy for heart failure
62113266|NCT00362726|ACTIVE_COMPARATOR|A|
62113267|NCT00362726|ACTIVE_COMPARATOR|B|
62113268|NCT00362726|ACTIVE_COMPARATOR|C|
62113269|NCT00362726|ACTIVE_COMPARATOR|D|
62113270|NCT00362726|ACTIVE_COMPARATOR|E|
62113271|NCT06464172|EXPERIMENTAL|GABA Start Group|Participants who are randomly assigned to the GABA start group. These participants receive GABA at the first experimental visit and the placebo at the second experimental visit.
62113272|NCT06464172|EXPERIMENTAL|Placebo Start Group|Participants who are randomly assigned to the Placebo start group. These participants will receive a placebo at the first experimental visit and GABA at the second experimental visit.
62113273|NCT06131047|EXPERIMENTAL|High Intensity Traditional Resistance Training Group|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement.
62113274|NCT06131047|EXPERIMENTAL|High Intensity Traditional Resistance Training with Blood Flow Restriction Group|Group B will perform low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment.(
62113275|NCT01850017|EXPERIMENTAL|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
62113276|NCT01850017|NO_INTERVENTION|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
62113277|NCT06554548|EXPERIMENTAL|Sequence AB|fasting, fed
62471756|NCT00834522|ACTIVE_COMPARATOR|Kytril®|Kytril® 2 x 1 mg Tablet (reference) dosed in first period followed by Granisetron 2 x 1 mg Tablet (test) dosed in second period
62113278|NCT06554548|EXPERIMENTAL|Sequence BA|fed, fasting
62113279|NCT02321813|EXPERIMENTAL|intervention group|In the quality of life pathway results of the quality of life (QoL) measure are transferred to a QoL-profile. Three experts with various professional background use the individual patient's QoL-profile and clinical and sociodemographic information in order to generate a QoL-report including therapy recommendation which is sent to the coordinating practitioner. Specific therapeutic options for the treatment of diseased QoL have been identified: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, fitness. To provide continuous medical education, quality circles for each therapy option haven been founded. Coordinating practitioners receive a list with addresses of all quality circle members.
62113280|NCT02321813|PLACEBO_COMPARATOR|control group|In control group QoL is also measured but the coordinating practitioner neither receives a QoL-profile nor a QoL-report.
62113281|NCT05329454|EXPERIMENTAL|Treatment ABC|Receive the investigational product and active comparator in a sequence of treatment A, treatment B and treatment C.
62113282|NCT05329454|EXPERIMENTAL|Treatment ACB|Receive the investigational product and active comparator in a sequence of treatment A, treatment C and treatment B.
62113283|NCT05329454|EXPERIMENTAL|Treatment BAC|Receive the investigational product and active comparator in a sequence of treatment B, treatment A and treatment C.
62113284|NCT05329454|EXPERIMENTAL|Treatment BCA|Receive the investigational product and active comparator in a sequence of treatment B, treatment C and treatment A.
62113285|NCT05329454|EXPERIMENTAL|Treatment CAB|Receive the investigational product and active comparator in a sequence of treatment C, treatment A and treatment B.
62113286|NCT05329454|EXPERIMENTAL|Treatment CBA|Receive the investigational product and active comparator in a sequence of treatment C, treatment B and treatment A.
62113287|NCT02667535|EXPERIMENTAL|Isosorbide Mononitrate 2.0% healthy|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Healthy volunteers
62113288|NCT02667535|EXPERIMENTAL|Isosorbide Mononitrate 0.5% anal fissure|Isosorbide Mononitrate gel 0.5% - 2g Anorectal usage Once daily Participants with anal fissure
62113289|NCT02667535|EXPERIMENTAL|Isosorbide Mononitrate 1.0% anal fissure|Isosorbide Mononitrate gel 1.0% - 2g Anorectal usage Once daily Participants with anal fissure
62113290|NCT02667535|EXPERIMENTAL|Isosorbide Mononitrate 2.0% anal fissure|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Participants with anal fissure
62471757|NCT03235739|EXPERIMENTAL|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
62471758|NCT03235739|PLACEBO_COMPARATOR|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
62471759|NCT03801980|EXPERIMENTAL|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
62471760|NCT03801980|PLACEBO_COMPARATOR|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
62113291|NCT02311907|EXPERIMENTAL|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel\* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
62113292|NCT02311907|PLACEBO_COMPARATOR|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel\* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
62113293|NCT00620217|EXPERIMENTAL|1|intramyocardial injection of bicistronic VEGF-A165/bFGF plasmid
62113294|NCT00620217|PLACEBO_COMPARATOR|2|intramyocardial injection of placebo plasmid
62113295|NCT04633980|EXPERIMENTAL|Experimental group|
62113296|NCT03835390|EXPERIMENTAL|Intervention|Participants who agree to participate in the SIMDiscovery program will be asked if they would like to participate in the research. If they consent, they will fill out pre- and post-questionnaires concerning quality of life, anxiety levels concerning the surgery, and a knowledge assessment.
62113297|NCT05823350|EXPERIMENTAL|Experimental group|"The relatives of the patients were shown the video before the colonoscopy. The video consisted of visual and verbal content about colonoscopy, and the benefits and application steps of abdominal massage in pain management after the procedure.~After the procedure, the relatives of the patients in the experimental group were asked to apply abdominal massage to their patients. During the massage application, when necessary, guidance was given to the patient's relatives about the application of the massage. In this supine position, patient's abdomen was massaged with circular movements and different techniques in the direction of the colon."
62113298|NCT05823350|NO_INTERVENTION|Control Group|After the procedure, the patients who were taken to their beds were asked to evaluate their pain and distension levels after the colonoscopy. The vital signs of the patients who received standard care were monitored after the procedure and were followed up for possible complications.
62113299|NCT03448757|EXPERIMENTAL|Autonomic response|"Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma will be selected and studied.~Group for determination of ideal frequency - 20 patients. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma participants in the group will be selected and studied to determine biofeedback response.~Group for determination of new specific frequencies - 20 individuals. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma not exposed to any specific frequency will be selected."
62302969|NCT02111369|EXPERIMENTAL|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
62302970|NCT01123590||Thymoma|Patients with thymoma
62302971|NCT01123590||Control|Normal controls
62471761|NCT06225622|EXPERIMENTAL|irinotecan liposome injection combined with oxaliplatin +5-FU/LV+ bevacizumab or cetuximab|In dose escalation study, patients will be treated with irinotecan liposome injection combined with oxaliplatin +5-FU/LV+ bevacizumab. In expansion study, patients will be treated with irinotecan liposome injection combined with oxaliplatin +5-FU/LV+ bevacizumab or cetuximab, depending on their baseline mutation status. Oxaliplatin is accepted up to 12 cycles.
61917337|NCT05245396|EXPERIMENTAL|Part C: Evobrutinib: Treatment Sequence 5|Participants will receive single oral dose of MUPS-C4 evobrutinib on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MUPS-C3 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
62113300|NCT02040935|EXPERIMENTAL|Trastuzumab|Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).
62113301|NCT04256876|ACTIVE_COMPARATOR|Active TTNS|Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
62113302|NCT04256876|SHAM_COMPARATOR|TTNS sham intervention|"Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.~Home therapy: Daily stimulation during 60 minutes."
62113303|NCT01844141|EXPERIMENTAL|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
62302972|NCT04884828||one group|patients from the Pulmonology Service of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) who met the following criteria: over 18 years of age, hospital admission for acute chronic respiratory failure, home NIV (single-limb system with intentional leakage) users for more than 6 months with adequate compliance (greater than or equal to 5 hours/night). Patients with underlying psychiatric disease were excluded. The study was conducted during the patient's predischarge phase (the same day or the day before)
62471762|NCT00764777|EXPERIMENTAL|Stenting|
62471763|NCT03233386||Condition 1|Mexico City Cohort
62471764|NCT03233386||Condition 2|Monterrey Cohort
62471765|NCT03233386||Condition 3|Guadalajara Cohort
62471766|NCT03108911|EXPERIMENTAL|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
62113304|NCT01844141|ACTIVE_COMPARATOR|70% alcohol|Ingrown toenail irrigated using 70% alcohol
62113305|NCT03551067|ACTIVE_COMPARATOR|Dexmedetomidine|Patients received Dexmedetomidine (4 µg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
62113306|NCT03551067|ACTIVE_COMPARATOR|Midazolam/Ketamine|Patients received Midazolam (0.5 mg/kg) and Ketamine (1 mg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
62113307|NCT06237868|ACTIVE_COMPARATOR|rTMS Active|the participant will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence over the dlPFC. Participants receive excitatory rTMS with a stimulation frequency of 20 Hz between 100-120% of their resting motor threshold.
62113308|NCT06237868|SHAM_COMPARATOR|rTMS Sham|Sham rTMS will be the same as real rTMS, except a special sham coil will be used, which produces the same sensation on the scalp of the patients as the real coil but delivers no magnetic stimulation to the brain.
62113309|NCT03008915|ACTIVE_COMPARATOR|Aspirin first then placebo|Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
62113310|NCT03008915|PLACEBO_COMPARATOR|Placebo first then aspirin|Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
62113311|NCT05356819|OTHER|Endoscopy|"Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.~Patients were administered 2 mg midazolam as premedication for 5 minutes before the procedure and propofol 1-1.3 mg/kg bolus for sedation, followed by repeated doses (10-30 mg) according to the Ramsey sedation score. All patients were given 2 lt/min oxygen via nasal cannula during the procedure."
62113312|NCT00440973|OTHER|treatment arm|PI relocated, currently data is no longer available
62113313|NCT02854761|EXPERIMENTAL|SC administration|Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
62113314|NCT02854761|EXPERIMENTAL|IM administration|Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
62113315|NCT04710017|OTHER|Tranexamic acid group|will tranexamic acid 500 mg 4 times daily in one group,
62113316|NCT04710017|OTHER|Medroxyprogesterone acetate|will receive 150mg of medroxyprogesterone acetate once intramuscular.
62113317|NCT02131324|ACTIVE_COMPARATOR|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
62302973|NCT05994625|EXPERIMENTAL|Intervention Group|Stream™ Platform will be attached to the abdominal/pelvic drains of the patients enrolled in this group. The platform will conduct continuous pH and electrical conductivity measurements of the abdominal drain fluid. The continuous pH and electrical conductivity measurements will be used to calculate a Risk Score that will be provided to surgeons. Surgeons will employ the Risk Score produced alongside the standard of care for guiding the postoperative care of patients.
62302974|NCT05994625|SHAM_COMPARATOR|Control Group|Stream™ Platform will be attached to the abdominal/pelvic drains of the patients enrolled in this group. The platform will conduct continuous pH and electrical conductivity measurements of the abdominal drain fluid. However, Stream™ Platform will not generate a Risk Score and therefore, will not impact the postoperative care of patients. All procedures will be conducted as per the standard of care or institutional policies. Stream™ Platform will only be used for observation in the Control group.
62113318|NCT02131324|EXPERIMENTAL|DFD06 Cream|applied twice a day for 15 days
62113319|NCT02049697|EXPERIMENTAL|14C-JNJ-39823277|
62113320|NCT02390258|EXPERIMENTAL|Part 1: Single Ascending Dose - Cohort 1|8 subjects (6 receiving 10mg XEN-D0103, 2 receiving placebo)
62113321|NCT02390258|EXPERIMENTAL|Part 1: Single Ascending Dose - Cohort 2|8 subjects (6 receiving 30mg XEN-D0103, 2 receiving placebo)
62113322|NCT02390258|EXPERIMENTAL|Part 1: Single Ascending Dose - Cohort 3|8 subjects (6 receiving 60mg XEN-D0103, 2 receiving placebo)
62113323|NCT02390258|EXPERIMENTAL|Part 1: Single Ascending Dose - Cohort 4|8 subjects (6 receiving 120mg XEN-D0103, 2 receiving placebo)
62113324|NCT02390258|EXPERIMENTAL|Part 1: Single Ascending Dose - Cohort 5|8 subjects (6 receiving 200mg XEN-D0103, 2 receiving placebo)
62113325|NCT02390258|EXPERIMENTAL|Part 2: Fed-Fasted|17 subjects receiving 200mg XEN-D0103 with either a high fat meal or following an overnight fast.
62113326|NCT02390258|EXPERIMENTAL|Part 3: Multiple Ascending Dose - Cohort 1|10 subjects (8 receiving 30mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
62113327|NCT02390258|EXPERIMENTAL|Part 3: Multiple Ascending Dose - Cohort 2|10 subjects (8 receiving 60mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
62113328|NCT02390258|EXPERIMENTAL|Part 3: Multiple Ascending Dose - Cohort 3|10 subjects (8 receiving 150mg XEN-D0103 once daily, 2 receiving placebo once daily)
62113329|NCT04333589|EXPERIMENTAL|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
62113330|NCT04333589|NO_INTERVENTION|Regular treatment group|Treatments other than lopinavir and ritonavir, chloroquine phosphate, hydroxychloroquine sulfate, arbidol, and colomycin can be given.
62113331|NCT05154955|EXPERIMENTAL|10XB-101 Solution for Injection, 2.0%|Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
62113332|NCT05154955|EXPERIMENTAL|10XB-101 Solution for Injection, 3.0%|Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
62113333|NCT05154955|EXPERIMENTAL|10XB-101 Solution for Injection, 4.5%|Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
62113334|NCT05154955|PLACEBO_COMPARATOR|10XB-101 Vehicle Solution for Injection|Participants receive 10XB-101 Vehicle Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
62113335|NCT03750942|EXPERIMENTAL|Adhesix® monofilament polypropylene mesh (Bard Davol) group|The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
62113336|NCT03750942|NO_INTERVENTION|Control group|The control group will not receive a mesh and the stoma will be created according local protocol.
62113337|NCT01913119|EXPERIMENTAL|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
62113338|NCT01738802|EXPERIMENTAL|Anti-oxidant and micronutrient|This group will take the anti-oxidant and micronutrient supplement.
62113339|NCT01738802|PLACEBO_COMPARATOR|Placebo|This group will take the placebo.
62113340|NCT01421654|EXPERIMENTAL|Fixed Mode + Acclimate|S9 Elite flow generator with Acclimate feature activated.
62113341|NCT01421654|ACTIVE_COMPARATOR|Fixed Mode only|S9 Elite Flow Generator with Fixed Mode only
62113342|NCT02813252||JCAR015-treated|Patients who received previous treatment with JCAR015
62113343|NCT00681252|EXPERIMENTAL|A|
62113344|NCT00432458|EXPERIMENTAL|Arm I: Thal/ZLD|Thalidomide (Thal) + Zolendronic acid (ZLD)
62113345|NCT00432458|EXPERIMENTAL|Arm II: ZLD|Zoledronic acid (ZLD)
62302975|NCT04754711|EXPERIMENTAL|Group with oral nutritional supplement|Group 1: receiving an oral nutritional supplement to increase calorie intake by around 20%
62113346|NCT03869918|NO_INTERVENTION|Usual Care|Participant is assigned to undergo standard of care.
62113347|NCT03869918|EXPERIMENTAL|Exercise Group|If the participant is assigned to the exercise group, she will either exercise at home or take a class at the participating facility under the supervision of an instructor.
62113348|NCT03869918|NO_INTERVENTION|Observational Group|If a subject is eligible, but does not want to exercise, she will be in a third group that is an observation group.
62113349|NCT00718406|ACTIVE_COMPARATOR|A|A=metoprolol
62113350|NCT00718406|ACTIVE_COMPARATOR|B|B=metoprolol plus morphine
62113351|NCT03441763|EXPERIMENTAL|Normal participants|Emed foot device 3 times/measure to determine foot pressure in normal participants. .
62113352|NCT03441763|EXPERIMENTAL|Over weight participants|Emed foot device 3 times/measure to determine foot pressure in over weight participants.
62113353|NCT03441763|EXPERIMENTAL|Obese participants|Emed foot device 3 times/measure foot pressure in obese participants.
62113354|NCT02674646|EXPERIMENTAL|Group A: Verum Acupuncture|Group A: Verum Acupuncture (Needle Acupuncture) Needlepoints Bilateral PC 6, S 36, L 8, L 9 Unilateral R4, R 6 Acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
61917338|NCT05245396|EXPERIMENTAL|Part C: Evobrutinib: Treatment Sequence 6|Participants will receive two single oral doses of Ref (TF2) evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C3 on Day 1 in treatment period 2, followed by single oral dose of MUPS-C4 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
61917339|NCT05245396|EXPERIMENTAL|Part D: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of MR-T adapted on Day 1 of treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by 1 sequential period 3. There will be 72 hours washout period between Periods 1 and 2 and 28 days between Period 2 and 3.
62471767|NCT03108911|EXPERIMENTAL|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
62302976|NCT04754711|NO_INTERVENTION|Control group|"Group 2: controls receiving normal calorie intake without oral nutritional supplement"
62471768|NCT00271752|EXPERIMENTAL|PCT guided|Procalcitonin guided treatment of infections in the ICU. Intervention: Intensification of antibiotics, surgery, microbiologic testing and diagnostic imaging, when Procalcitonin levels are increasing
61917340|NCT05245396|EXPERIMENTAL|Part D: Evobrutinib: Treatment Sequence 2|Participants will receive two single oral doses of Ref (TF2) on Day 1 of treatment period 1, followed by single oral dose of MR-T adapted on Day 1 in treatment period 2, followed by 1 sequential period 3. There will be 72 hours washout period between Periods 1 and 2 and 28 days between Period 2 and 3.
62113355|NCT02674646|SHAM_COMPARATOR|Group B: Sham Acupuncture|Group B: Sham Acupuncture (Needle Acupuncture) Needlepoints 8 needles in the medioaxillary line below the 6th rib, bilateral 2 needles unilateral Sham-acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
62113356|NCT02864628|EXPERIMENTAL|Group 1|≥55 year old healthy subjects, receiving either 5x10E7 TCID50 MVA-BN-RSV or Placebo intranasal application
62113357|NCT02864628|EXPERIMENTAL|Group 2|≥55 year old healthy subjects, receiving either 1x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
62113358|NCT02864628|EXPERIMENTAL|Group 3|≥55 year old healthy subjects, receiving either 5x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
62471769|NCT00271752|SHAM_COMPARATOR|Control|"These patients receive Standard of Care which is the recommended treatment in the given ICU"
62471770|NCT06092658||No Intervention|No Intervention
62113359|NCT02864628|EXPERIMENTAL|Group 4|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intranasal and intramuscular application
62471771|NCT05644587|ACTIVE_COMPARATOR|Traditional Induction Arm|In this arm, study participants will wait until they have significant opioid withdrawal (SOWS score \>=17) prior to starting buprenorphine. Participants will then started with 2 mg sublingual and escalate to a maximum of 12 mg on the first day depending on withdrawal symptoms. On day 2, the participant will take same dose as the total dose taken on day 1, and continue that dose daily until reevaluation.
62471772|NCT05644587|ACTIVE_COMPARATOR|Microdosing Induction Arm|In this arm, study participants will not wait until they have significant opioid withdrawal. They will take 0.5 mg buprenorphine on day 1, 2 mg on day 2, 4 mg on day 3, 6 mg on day 4, 8 mg on day 5 and 12 mg starting on day 6.
62471773|NCT04982094|EXPERIMENTAL|Mental Health First Aid and Relationship Building Training (MHFA+RBT)|Mental Health First Aid training in conjunction with Relationship Building Training.
62113360|NCT02864628|EXPERIMENTAL|Group 5|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intramuscular application
62471774|NCT04982094|ACTIVE_COMPARATOR|Mental Health First Aid (MHFA only)|Mental Health First Aid training alone.
62113361|NCT04731051|EXPERIMENTAL|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
62113362|NCT04731051|ACTIVE_COMPARATOR|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
62113363|NCT03068858|EXPERIMENTAL|SYNTAX score category feedback group|A real-time SYNTAX score category feedback from angiographic core lab will be given to the cardiologists rightafter the angiographies.
62113364|NCT03068858|NO_INTERVENTION|Controlled group|Cardiologists' subjective SYNTAX score category judgement will be recorded during the angiography.
62471775|NCT06406491||Subjects|Baseline measurements for all subjects is carried out with their own passive microprocessor-controlled knee prosthesis. After 4 weeks of use of active microprocessor-controlled knee, second measurement is carried out. All subjects follow the same study path.
62471776|NCT05879653|EXPERIMENTAL|MK-3475 and ASG-22CE With Radiation Therapy|
62471777|NCT03192722|EXPERIMENTAL|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
62471778|NCT03192722|OTHER|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
62471779|NCT03192722|OTHER|Immediate exposure to LuxIQ/2|Participants are examined with LuxIQ/2 to determine preferred lighting as determined by device followed by examination with OttLite Cobra
62302977|NCT02591992|ACTIVE_COMPARATOR|Cardiac CT|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo computed tomography angiography (cardiac CT) as the first-choice imaging diagnostics
62302978|NCT02591992|ACTIVE_COMPARATOR|Invasive coronary angiography|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo invasive coronary angiography
62302979|NCT02220881|EXPERIMENTAL|Mold making silicone toe separator|The subject in experimental group will use mold making silicone toe separator everyday
62471780|NCT03192722|OTHER|Immediate exposure to OttLite Cobra|Participants are examined with OttLite Cobra to determine preferred lighting followed by LuxIQ/2
62113365|NCT02187900|EXPERIMENTAL|TWH for the treatment of IgAN|Interventions :The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
62113366|NCT02187900|ACTIVE_COMPARATOR|MMF for IgAN|MMF for the treatment of IgAN for 6 months
62113367|NCT05633368||Discontinuation of C/M-ECT|Participants with major depressive disorder who are unable to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) due to hospital restrictions during Covid-19 or due to personal preference.
62113368|NCT05633368||Continuation of C/M-ECT|Participants with major depressive disorder who are able to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) during Covid-19.
62302980|NCT02220881|OTHER|Observation|This group will follow the physician instruction of care for the hallux valgus
62113369|NCT02734628|EXPERIMENTAL|Dexpanthenol|A squeeze of ointment, approximately 0.5 cm in length corresponding to an amount of about 0.3 g of ointment, which is equal to 15 mg dexpanthenol , twice daily (once in the morning and once in the evening) over a period of 14 days was applied topically under occluded conditions
62113370|NCT02734628|PLACEBO_COMPARATOR|Placebo|Subjects received applications of placebo corresponding to verum
62113371|NCT04643236|EXPERIMENTAL|periodontal health educational group (test)|25 subjects diagnosed with gingivitis received periodontal health education session
62302981|NCT01787071||one group|Patients receiving fluid challebnge
62113372|NCT04643236|ACTIVE_COMPARATOR|oral hygiene motivation group (control)|25 subjects diagnosed with gingivitis received standard oral hygiene motivation session
62113373|NCT03140735|OTHER|Control group of 150 heart disease-free individuals|
62113374|NCT03140735|OTHER|Patients with aortic sclerosis|
62113375|NCT03140735|OTHER|Patients with moderate aortic stenting (RA)|
62113376|NCT03140735|OTHER|Patients with Serious Aortic Retention|
62302982|NCT04937387|EXPERIMENTAL|Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler|
62302983|NCT04937387|EXPERIMENTAL|Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler|
62302984|NCT04937387|EXPERIMENTAL|Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler|
62302985|NCT04937387|EXPERIMENTAL|Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler|
62302986|NCT01687673|EXPERIMENTAL|Treatment|Combination temsirolimus plus sorafenib
62302987|NCT03068962|EXPERIMENTAL|beetroot juice|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of beetroot juice for 5 min,
62302988|NCT03068962|EXPERIMENTAL|low mineral water (Buxton water)|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of low nitrate mineral water in the mouth for 5 min or
62302989|NCT03068962|EXPERIMENTAL|antiseptic mouthwash then beetroot juice|Rinse with antiseptic mouthwash before holding 10 ml of beetroot juice in the mouth for 5 min
62302990|NCT00904254|EXPERIMENTAL|1, diagnostic comparison|EP 1645/Solution For Injection
62302991|NCT02364817||Post-Detox Cohort|"All the patients included should meet Diagnostic and Statistical Manual 4th edition revised (DSM-IV-Tr) criteria for Alcohol Dependance. They are all recruited at the end of an inpatient alcohol detoxification process (see inclusion criteria).~The initial screening is performed just before the end of hospitalization. The subsequent follow-up is 12 weeks-long. There is no drug for abstinence maintenance during the study. The psychosocial intervention is based on the BRENDA model."
62302992|NCT00440323|EXPERIMENTAL|ADBC sequence|In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
62302993|NCT00440323|EXPERIMENTAL|BACD sequence|In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
62471781|NCT04231422||Treatment Group|Monthly intracavernosal platelet-rich plasma injection + daily physical manipulation.
62471782|NCT00485667|ACTIVE_COMPARATOR|Moxifloxacin tablet|
62471783|NCT00485667|EXPERIMENTAL|Placebo tablet|
62471784|NCT00485667|EXPERIMENTAL|SKY0402 300mg|
62471785|NCT00485667|EXPERIMENTAL|SKY0402 450mg|
62302994|NCT00440323|EXPERIMENTAL|CBDA sequence|In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
62302995|NCT00440323|EXPERIMENTAL|DCAB sequence|In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.
62302996|NCT02638181|EXPERIMENTAL|trabeculectomy|
62302997|NCT02224222||Patients undergoing vascular procedures|Including all non-interventional surgical procedures, excluding varix surgery
62471786|NCT00485667|PLACEBO_COMPARATOR|Placebo injection|
62471787|NCT01524718|EXPERIMENTAL|Imaging with two X-ray image intensifiers|There is no change in the procedure except for the imaging technique, while in the first group the X- ray image intensifier serves in the two planes, and being moved from one plane to the other, and in the second group the two devices are static in the same position, one in the AP plane and the other as the axial plane.
62471788|NCT01524718|NO_INTERVENTION|Imaging with one X-ray image intensifier.|The X- ray image intensifier serves in the two planes, and being moved from one plane to the other
62674398|NCT01312077|EXPERIMENTAL|Levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine, and will receive peri- and intraarticular surgical site infiltration during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure and this will be left in situ in the wound. The catheter will be sited under the fascia lata exiting antero-superior to the incision. A bacterial filter will be attached and it will be connected to an elastomeric pump which will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
62674399|NCT01312077|OTHER|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.2 mg).
62674400|NCT03118895|EXPERIMENTAL|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
62674401|NCT04718675|EXPERIMENTAL|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of KB-0742.
62302998|NCT02224222||Patients undergoing cardiac procedures|Including all non-interventional surgical procedures, excluding HTX
62302999|NCT05990439|EXPERIMENTAL|Intervention|"This arm will have full access to the Baby-Feed web application. It was based on the Social Cognitive Theory and the Health Self-Empowerment Theory.~It provides automatic feedback based on the infant FFQ, showing the total amounts of each food group consumed (milk, protein foods, whole and refined grains, fruits, vegetables, juices, sugary beverages, sweets, and salty snacks) with automated feedback of which are consumed adequately or above/below the recommendations.~* Recommendations: this section displays the amount recommended for each food group by age group.~* Tracking: This is a short form that asks participants to evaluate if they gave the recommended amounts of each food group in the past week.~* Weight gain tracker: parents are asked to input the weight and length of their baby and it shows graphically how the baby is progressing."
62303000|NCT05990439|PLACEBO_COMPARATOR|Control group|Participants randomized to the control arm (n=80) will have limited access to certain components of the Baby-Feed web application, such as the online infant FFQ to complete it at the same intervals (before the 4-month, 6-month, and 9-month well-child visits) and infant's weight and length as recorded in the well-child visits, but without any automatic results or feedback. The control group will have a separate user access to the Baby-Feed web application that only allows them to complete the required information without being able to see results, feedback, tracking, recommendations, or resources.
62303001|NCT04358393|EXPERIMENTAL|APG-115 monotherapy|Monotherapy given in part 1
62303002|NCT04358393|EXPERIMENTAL|APG-115 + 5-azacitidine combination|Combination therapy given in part 2
62303003|NCT00488527|EXPERIMENTAL|1|
62303004|NCT03486730|EXPERIMENTAL|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 50-60 patients with advanced solid tumours will be entered in the study.
62471789|NCT01457300||District Rehabilitation Centre (Model 1)|Patients admitted to Primary Health Care Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited continuously at Entrance to the Rehabilitation Centre.
62471790|NCT01457300||Standard PHC Rehabilitation (Model 2)|Patients admitted to Standard Primary Health Care (PHC) Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited Continuously at Entrance to the Short Term Rehabilitation Beds in Nursing Homes or at the Beginning of Rehabilitation in their Own Homes.
62471791|NCT00226317|EXPERIMENTAL|Aripiprazole in depression treatment|
62113377|NCT05739929|ACTIVE_COMPARATOR|Colchicine|0.5 mg colchicine tablets twice daily 72 to 48 hours before planned PCI
62303005|NCT03486730|EXPERIMENTAL|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that up to 70 patients with tumour types known to commonly overexpress MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment (i.e. squamous non-small cell lung cancer) will be entered in the study.
62303006|NCT02574221|EXPERIMENTAL|stannous fluoride toothpaste|brush twice a day for 8 weeks
62303007|NCT02574221|SHAM_COMPARATOR|cavity protection toothpaste|brush twice a day for 8 weeks
62303008|NCT05057728|EXPERIMENTAL|Intervention group (SEP+)|SEP+ is designed as a multi-focused (child, teacher, parent) school-based intervention, which can be employed as either a universal (i.e. targeting all children) or an indicated prevention program (i.e. targeting specifically children at risk for behavior problems). The SEP+ intervention comprises three types of intervention: 1) the classroom-based intervention in the form of a curriculum of 43 activities (2-3 activities/week) delivered over 4-months aimed at developing social-emotional skills; 2) a 6-sessions (2-2.5h/session) teacher training focused on increasing the use of positive discipline strategies and developing coaching skills for supporting children's social-emotional learning; and 3) a 6 sessions parent training (1.5.-2h/session) aiming to teach ways to manage parenting stress, to increase parent-child quality time, support children's emotion regulation and problem-solving, as well as increase positive discipline strategies.
62303009|NCT01491945|EXPERIMENTAL|Ventana Fenestrated Stent Graft System|Ventana Fenestrated Stent Graft System
62303010|NCT00551707|EXPERIMENTAL|CRx-102 (2.7/180)|CRx-102 dose 1 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM titration dose (days 0-13) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM
62303011|NCT00551707|EXPERIMENTAL|CRx-102 (2.7/360)|CRx-102 Dose 2 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 360 mg dipyridamole administered as 1.8 mg prednisolone plus 180 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM
62113378|NCT05739929|PLACEBO_COMPARATOR|Placebo|Matching placebo
62303012|NCT00551707|ACTIVE_COMPARATOR|Prednisolone|treatment dose ( days 0-98) total daily dose of 2.7 mg prednisolone administered as 1.8 mg prednisolone at 8 AM and 0.9 mg prednisolone at 1 PM
62471792|NCT03021018|EXPERIMENTAL|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
62113379|NCT05257798|EXPERIMENTAL|PF-06823859|Participants will receive 900 mg of PF-06823859 via intravaneous (IV).
62113380|NCT05257798|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo via IV.
62113381|NCT04652817|EXPERIMENTAL|MMI-22-04-2019|Sodium hyaluronate at a concentration of 2.5% (25 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent administered once or twice depending on the individual necessity.
62113382|NCT00579189|EXPERIMENTAL|Moxidex|Moxidex otic solution
62113383|NCT00579189|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin otic solution
62113384|NCT02433795|EXPERIMENTAL|Bendamustine plus rituximab(BR)|Intravenous bendamustine plus rituximab intravenously at 1st cycle and subcutaneously from 2nd cycle (to maximum 8th cycle).
62113385|NCT02665130|ACTIVE_COMPARATOR|Tai-Chi group|Tai-Chi exercise plus Indacaterol 150ug/day
62113386|NCT02665130|PLACEBO_COMPARATOR|Pulmonary rehabilitation group|Conventional exercise plus Indacaterol 150ug/day
62113387|NCT01998555|OTHER|CAD-CBT group therapy|CAD receive web-based CBT group therapy
62113388|NCT01998555|OTHER|CAD-CBT group therapy waiting list|CAD waiting list will receive web-based CBT group therapy later
62113389|NCT05037344|EXPERIMENTAL|Internet-based psychotherapy|16 weeks of internet-based cognitive behavioral therapy
62113390|NCT05037344|ACTIVE_COMPARATOR|Internet-based psychotherapy waiting group|16 weeks of internet-based cognitive bahavioral therapy after waiting of 16 weeks
62113391|NCT06002542|EXPERIMENTAL|Information provided|Participants are invited to the chat room and receive messages, which include the stages of their medical care, information about tests and medications, and non-medical information such as directions to pharmacy and parking information.
62113392|NCT06002542|EXPERIMENTAL|Control|Participants are invited to the chat room and they can get information when they request it.
62113393|NCT00296907|EXPERIMENTAL|Psychological Intervention|2-session psychological intervention
62113394|NCT01505101|EXPERIMENTAL|Mindfulness-Oriented Recovery Enhancement|
62113395|NCT01505101|ACTIVE_COMPARATOR|Conventional Support Group (SG)|
62113396|NCT04538755|PLACEBO_COMPARATOR|Placebo|Placebo capsule 4 hours before sleep
62113397|NCT04538755|ACTIVE_COMPARATOR|DAW2020|DAW2020 capsule 4 hours before sleep
62113398|NCT00703625|EXPERIMENTAL|Cohort 1|"Temsirolimus IV 15 mg weekly~Docetaxel 60 mg/m2 IV once every three weeks."
62113399|NCT00703625|EXPERIMENTAL|Cohort 2|"Temsirolimus IV 25 mg weekly~Docetaxel IV 60 mg/m2 once every 3 weeks"
62113400|NCT00703625|EXPERIMENTAL|Cohort 1A|"Temsirolimus IV 15 mg weekly~Docetaxel IV 50 mg/m2 every 3 weeks."
62113401|NCT05427058|ACTIVE_COMPARATOR|group 1: superior hypogastric plexus block group|Device: C-arm fluoroscopic device Drug: lidocaine + alcohol
62471793|NCT03021018|EXPERIMENTAL|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
61917341|NCT03621345|ACTIVE_COMPARATOR|ESP block group|"The bilateral erector spine plane (ESP) block will be performed with ultrasound guided, preoperatively. Following antiseptic preparation of block site with povidone iodine, ultrasound probe will be placed 3 cm lateral to spine at T5 level. After identifying the erector spinae muscle and transverse process, the overlying skin will be infiltrated with local anesthetics and 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL 1% lidocaine) will be injected deep to the erector spinae muscle. The same procedure will be performed on the other side. Also, patients will receive intravenous patient controlled analgesia with morphine, and 1 g acetaminophen for supplemental analgesia if pain score raises over 5/10 on NRS and 50 mg meperidine for rescue analgesic for persistent pain.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
61917342|NCT03621345|SHAM_COMPARATOR|sham block|"A sham block will be performed while looking for intended location for ESP block placement. Skin will be infiltrated with local anesthetics but ESP block will not be performed, instead of ESP block 2 mL subcutaneous saline injection will be applied.~Intervention: Sham block Other: Standard Pain Followup and Monitorization"
62113402|NCT05427058|EXPERIMENTAL|group 2: ganglion impar block group|Device: C-arm fluoroscopic device Drug: lidocaine + alcohol
62113403|NCT05046132|EXPERIMENTAL|Group 1: Setmelanotide 2-7 mg + Placebo for Moxifloxacin|Participants received titrated doses of 2-7 milligrams (mg) setmelanotide once daily by subcutaneous (SC) injection, starting with a dose of 2 mg from Days 1 to 7, 3 mg from Days 8 to 10, 5 mg from Days 11 to 13 and 7 mg from Days 14 to 16. Participants also received single oral dose of placebo matching moxifloxacin on Days 10 and 16.
62113404|NCT05046132|ACTIVE_COMPARATOR|Group 2: Placebo for Setmelanotide + Moxifloxacin 400 mg + Placebo for Moxifloxacin|Participants received placebo matching setmelanotide once daily by SC injection from Days 1 to 16. Participants also received a single oral dose of 400 mg moxifloxacin on Day 10 and a single oral dose of placebo matching moxifloxacin on Day 16.
62113405|NCT05046132|ACTIVE_COMPARATOR|Group 3: Placebo for Setmelanotide + Placebo for Moxifloxacin + Moxifloxacin 400 mg|Participants received placebo matching setmelanotide once daily by SC injection from Days 1 to 16. Participants also received a single oral dose of placebo matching moxifloxacin on Day 10 and a single oral dose of 400 mg moxifloxacin on Day 16.
62113406|NCT03892954||adolescents with CFS ( n= 100)|Participants with CFS who had constant or persisting fatigue lasting 3 months with the severe functional disability to such extent that prevents normal school attendance and also had no drug prescriptions (including hormone contraceptives), any medical or psychiatric disorder that might explain the fatigue were included in this study
62113407|NCT03892954||health control ( n=50).|healthy control subjects with no CFS
62113408|NCT01393119|EXPERIMENTAL|1000mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg|1000mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg
62113409|NCT01393119|EXPERIMENTAL|1000mg Loading DoseGTx-758 BID and Maintenance Dose 2000mg|1000mg Loading Dose GTx-758 BID and Maintenance Dose 2000mg
62113410|NCT01393119|EXPERIMENTAL|1500 mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg|1500 mg Loading Dose GTx-758 BID and Maintenance Dose 1000mg
62113411|NCT01393119|EXPERIMENTAL|1500 mg Loading Dose GTx-758 BID and Maintenance Dose 2000mg|1500 mg Loading Dose GTx-758 BID and Maintenance Dose 2000mg
62113412|NCT04852432|NO_INTERVENTION|Control group|Nasal prong is applied, but sedation is performed without oxygen administration.
62113413|NCT04852432|EXPERIMENTAL|Low flow group|Oxygen administration by nasal cannula
62303013|NCT00551707|ACTIVE_COMPARATOR|Dipyridamole|total daily dose during treatment period (days 14-98) 360 mg dipyridamole administered as 180 mg dipyridamole at 8 AM and and 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 90 mg dipyridamole administered 45 mg dipyridamole at 8 AM and 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 180 mg dipyridamole administered as 90 mg dipyridamole at 8 AM and 90 mg dipyridamole at 1 PM
62303014|NCT00551707|PLACEBO_COMPARATOR|Placebo|placebo administered twice per day at 8 AM and 1 PM
62303015|NCT01613105||Group 1|
62303016|NCT05375292|EXPERIMENTAL|PREHABILITATION GROUP|"Initial visit with the adaptive rehabilitation physician, 6-8 weeks prior to surgery:~* Clinical examination with Wood classification description of impairments, activity limits and participation restrictions.~* Assessment of environmental resources~* Definition with the patient of the extended ambulatory pre-habilitation protocol, identification with the post-operative rehabilitation pathway,~* Provide the patient with a follow-up workbook of the personalized pre-approval protocol and, if the patient's condition requires it, orders for physiotherapy.~Then apply the ambulatory pre-approval protocol defined with the adaptive rehabilitation physician.~- Post-operative follow-up visits with the surgeon (gathering the necessary information for comparative follow-up).~Mail-out of WHODAS 2.0 EQ-5D-5L and DIJON questionnaires at 3 and 6 months post-operative."
62113414|NCT04852432|EXPERIMENTAL|High flow group|Oxygen is administered at a rate of 2L/kg/min using an Optiflow device
62113415|NCT03390569|EXPERIMENTAL|Exercise in GBM|All patients will be assigned a three-month exercise intervention according to their own capabilities and current activity levels
62471794|NCT03021018|ACTIVE_COMPARATOR|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
62674402|NCT04718675|EXPERIMENTAL|Part 2: Cohort Expansion|"Following identification of the contingent recommended Phase 2 dose (RP2D) in Part 1, the following expansion cohorts will be enrolled:~Cohort A: Participants with R/R non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and high grade serous ovarian cancer.~Cohort B: Participants with R/R small cell lung cancer (SCLC), NUT midline carcinomas (NMC), adenoid cystic carcinoma (ACC), chordoma and soft tissue sarcomas associated with transcription factor fusion."
62674403|NCT01862029|EXPERIMENTAL|Roflumilast|
62736101|NCT04315727|OTHER|Study population|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. In addition, healthy parents of volunteers will be recruited if available to facilitate Trio studies.~Study related procedures: Blood sampling, hair collection, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures, organoid cultivation)."
62113416|NCT06015581|EXPERIMENTAL|Implementation Package|Continuous Quality Improvement (CQI)
62113417|NCT06015581|OTHER|Observation|Usual Care
62303017|NCT05375292|NO_INTERVENTION|CONTROL GROUP|"Support without pre-approval with application of other common practices of the service.~Post-operative follow-up visits with the surgeon (gathering the necessary information for comparative follow-up).~Mail-out of WHODAS 2.0 EQ-5D-5L and DIJON questionnaires at 3 and 6 months post-operative."
62303018|NCT01249170|OTHER|First year fellow|
62303019|NCT01249170|OTHER|Second Year Fellow|
62303020|NCT04614792|EXPERIMENTAL|active treatment|open label experimental treatment
62303021|NCT02355340||DXA and pQCT Scan|"* Dual energy x-ray absorptiometry (DXA): Assessment of bone mineral density~* Peripheral quantitative computed tomography (pQCT): Assessment of bone mineral density"
62303022|NCT06388057|EXPERIMENTAL|Patients with Crohn's disease with indication for surgery|
62303023|NCT03306303||Quartile 1 of plasma melatonin|Quartile 1 of plasma melatonin
62303024|NCT03306303||Quartile 2 of plasma melatonin|Quartile 2 of plasma melatonin
62303025|NCT03306303||Quartile 3 of plasma melatonin|Quartile 3 of plasma melatonin
62303026|NCT03306303||Quartile 4 of plasma melatonin|Quartile 4 of plasma melatonin
62303027|NCT04814537|EXPERIMENTAL|Dural Puncture Epidural Technique|Laboring women receiving the Dural Puncture Epidural (DPE) Technique with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS \< 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
62303028|NCT04814537|ACTIVE_COMPARATOR|Epidural Technique|Laboring women receiving the Conventional Epidural Technique (EPL) with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS \< 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
62303029|NCT00315302|ACTIVE_COMPARATOR|Atropine|Atropine 1% once each weekend day in the sound eye
62303030|NCT00315302|ACTIVE_COMPARATOR|Atropine plus plano|Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye
61917343|NCT00740337||COPD|Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).
62113418|NCT06015581|NO_INTERVENTION|EPIS Qualitative|5 providers of 42 sites will participate in Exploration, Preparation, Implementation, Sustainment (EPIS) qualitative interviews (N=210)
62113419|NCT01181375|EXPERIMENTAL|Assays on cervical cancer tissue|
62113420|NCT01802632|EXPERIMENTAL|Daily dose of AZD9291|Daily oral dose of AZD9291
62303031|NCT04335825|ACTIVE_COMPARATOR|phacotrabeculectomy|patients undergoing phacotrabeculectomy
62303032|NCT04335825|ACTIVE_COMPARATOR|ExPress device implantation|patients undergoing ExPress antiglaucoma surgery combined with phacoemulsification
62303033|NCT05700214|EXPERIMENTAL|ESP block|Ultrasound-guided continuous ESP block with opioid PCA A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine
62303034|NCT05700214|ACTIVE_COMPARATOR|lidocaine|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
62303035|NCT04652934|EXPERIMENTAL|Intervention group|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
62674404|NCT03725059|EXPERIMENTAL|Pembrolizumab+Chemotherapy (KX/KA[E]C)|In the neoadjuvant setting, participants receive pembrolizumab (K) 200 mg via intravenous (IV) infusion once every 3 weeks (Q3W) + paclitaxel (X) 80 mg/m\^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by pembrolizumab 200 mg via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m\^2 or 100 mg/m\^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m\^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive pembrolizumab 200 mg via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
62674405|NCT03725059|PLACEBO_COMPARATOR|Placebo+Chemotherapy (PX/PA[E]C)|In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m\^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m\^2 or 100 mg/m\^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m\^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
62674406|NCT06253208||laparoscopic block|laparoscopic transversus abdominis plane block
62674407|NCT06253208||ultrasound guided block|ultrasound guided transversus abdominis plane block
62674408|NCT03020082|EXPERIMENTAL|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
62674409|NCT02202720|EXPERIMENTAL|sevoflurane|
62674410|NCT03568786|EXPERIMENTAL|End-inspiratory pause (EIP) 10%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a of 10% of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 10% of total inspiratory time.
62674411|NCT03568786|EXPERIMENTAL|End-inspiratory pause (EIP) 30%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a 30 % of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 30 % of total inspiratory time.
62674412|NCT06029998|EXPERIMENTAL|Bortezomib|bortezomib starting at a dose of 1.3 mg per square meter of the body-surface area (BSA) subcutaneously on days 1, 4, 8, and 11 in a 21-day cycle.
62674413|NCT03929055|ACTIVE_COMPARATOR|venturi mask|oxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92%
62674414|NCT03929055|ACTIVE_COMPARATOR|HFNC|HFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min
62674415|NCT03929055|ACTIVE_COMPARATOR|CPAP|Helmet CPAP is set to obtain the same esophageal pressure variation during HFNC step
62674416|NCT05420025|EXPERIMENTAL|CHILDREN APPLIED WITH VIRTUAL REALITY GLASSES|Before the first dressing (5 minutes before the dressing) of the children who were accepted to the Organ Transplantation A Service from the intensive care unit after the transplantation, the introductory characteristics form and scales will be applied and the physiological parameters of the child (heart rate, respiratory rate, blood pressure) will be applied by the researcher. , oxygen saturation) will be taken. Then the children will be put on SGG and the glasses will be synchronized. During the dressing, children will be shown a video with SGG, which received expert opinion beforehand. After the dressing, the physiological parameters of the children will be measured again and the scales will be applied again.
62674417|NCT01701635|EXPERIMENTAL|Disclosure intervention|In the disclosure intervention plus usual care arm the adherence and disclosure specialist will meet with caregiver at each clinic visit and provide information, education, disclosure skills, and support till disclosure occurs.
61917344|NCT00740337||Control|Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.
62113421|NCT05014516||Single arm|Those participants who have experienced a documented case (documented by positive COVID19 test and/or clinical history) mild or severe COVID19 infection including those with symptoms and those who were hospitalized with COVID19 infection, all of whom are within 3 months post recovery
62303036|NCT04652934|SHAM_COMPARATOR|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
62303037|NCT03460418||Multiloc nail|Fracture treated with a Multiloc nail (patients treated between 2012 and 2017)
62303038|NCT03460418||Philos plate|Fracture treated with a Philos plate (patients treated between 2012 and 2017)
62303039|NCT03460418||arthroplasty|Fracture treated by arthroplasty (patients treated between 2012 and 2017)
62303040|NCT05972187|EXPERIMENTAL|Temperature and Humidity|32C or 25C and 30%RH or 70%RH
62113422|NCT03590288||TIPS group|Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.
62674418|NCT01701635|ACTIVE_COMPARATOR|Usual care|"In the enhanced usual care (control) arm the disclosure specialist will meet with caregiver at each clinic visit and provide them will general health education and no mention or effort will be made to improve disclosure skills of caregiver."
62113423|NCT01555684|EXPERIMENTAL|venoplasty proceedures|Half of the participants receive treatment and the other half do not
62113424|NCT01555684|PLACEBO_COMPARATOR|Control - no treatment|
62113425|NCT01597154|EXPERIMENTAL|Lifestyle counselling|Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
62113426|NCT01597154|NO_INTERVENTION|Control|Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
62113427|NCT02485236|ACTIVE_COMPARATOR|Low flow oxygen via nasal cannula|In the low flow oxygen via nasal cannula, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of \> 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
62113428|NCT02485236|ACTIVE_COMPARATOR|Humidified Nasal High Flow Therapy|Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
62113429|NCT05596630|EXPERIMENTAL|Stereotactic body radiation therapy|Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
62113430|NCT04069182|OTHER|Behavioral Activation Therapy|Psychological intervention
62113431|NCT00562679||2 groups|The cohort is grouped according to one group with sleep apnea and one group without sleep apnea
62113432|NCT05875350|EXPERIMENTAL|Intraligamental local anesthetic injection|
62113433|NCT05875350|NO_INTERVENTION|Buccal infiltration local anesthetic injection|
62674419|NCT03810794|EXPERIMENTAL|Acupuncture Treatment Group|Participants in this group will be given acupuncture treatment in combination with donepezil for 12 weeks.
62113434|NCT03145246||tooth loss|regeneration treated teeth loss
62113435|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
62113436|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss \< 2 mm
62113437|NCT04672772||Recurrent and/or metastatic SCCHN|Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
62113438|NCT03781206|NO_INTERVENTION|Standard of Care (SOC)|After stoma reversal, patients of SOC group will be treated as for normal clinical practice, using a simple adhesive wound dressing.
62113439|NCT03781206|EXPERIMENTAL|Negative Pressure Wound Therapy (NPWT)|PICO™ 7 will be applied after stoma reversal
62113440|NCT05879588|OTHER|control group-immediate retainer delivery|Retainer will be given to the patients immediately \[Just after debonding\].
62113441|NCT05879588|ACTIVE_COMPARATOR|experimental group-delayed retainer delivery|Retainer will be delivered to the patients 3 days post debonding.
62113442|NCT05924438|EXPERIMENTAL|Treatment Group 1|Delstrigo
62113443|NCT05924438|OTHER|Treatment Group 2|KOCITAF
62113444|NCT03768856|EXPERIMENTAL|Temporally Feathered Radiation Therapy (TFRT)|"Temporally feathered radiation therapy is designed for targets within close proximity to multiple organs at risk. The foundation of this planning technique is the rotation of radiation dose to the nearby organs at risk on a daily basis, and hence the term feathering."
62113445|NCT05135013||Cases|1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
62303041|NCT01416311||Subjects prescribed REVOLADE|Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
62303042|NCT03754153|EXPERIMENTAL|Balanced Binocular Viewing (BBV)|The experimental intervention will be BBV treatment, i.e. viewing movies for one hour or 2x30min/day on a Nintendo 3DSXL console. With this technology, the Investigators will show blurred images to the better-seeing eye and normal images to the amblyopic eye, encouraging the use of the amblyopic eye and improving acuity.
62303043|NCT03754153|ACTIVE_COMPARATOR|Standard Therapy - Occlusion (patching) or blurring (atropine)|The control intervention will be either atropine eyedrops twice a week or daily occlusion (patching) therapy of the better-seeing eye (which are the current standards). As per clinical standard, parents will be offered the choice of occlusion or eyedrop treatment.
62303044|NCT06618313|EXPERIMENTAL|JCXH-213 experimental group|"4 dose groups will be set in this part, following the dose escalation pattern (accelerated titration combined with a 3 + 3)."
62303045|NCT01657123|PLACEBO_COMPARATOR|placebo|
62303046|NCT01657123|EXPERIMENTAL|hydrocortisone stress dosage|
62303047|NCT01587963|ACTIVE_COMPARATOR|Ascorbic Acid|Ascorbic Acid
62471795|NCT05631587|EXPERIMENTAL|Intervention condition (WExercise)|Participants will receive a written information sheet (i.e., PA guide, safety precautions, and goal) same as the control group. In addition, participants in the WExercise group will be provided with 10 weekly technology-based classes delivered in a mobile application aimed at promoting PA. Participants will be given individualised access to the app. The classes aim at developing reflective, regulatory, and reflexive processes of cancer survivors to engage in PA based on the M-PAC framework. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
62674420|NCT03810794|ACTIVE_COMPARATOR|Donepezil Group|Participants in this group will be given only donepezil for 12 weeks.
62113446|NCT05135013||Matched Controls|2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
62674421|NCT00700089|EXPERIMENTAL|A|The concept is to support and guide the person shortly after the in-hospital treatment for self-injury through a recommended follow-up or after treatment based on assertive principles. The intervention is an indicated prevention strategy targeting people with suicide attempts and deliberate self-harm as a high-risk group. They will be offered 8-20 assertive outreach contacts. The outreach contacts will be home visits focusing on providing support and motivating patients to comply with follow-up treatment.
62113447|NCT06674122|ACTIVE_COMPARATOR|400 IU|Participants will receive enteral vitamin D supplementation of 400 IU/day for 28 days
62113448|NCT06674122|EXPERIMENTAL|800 IU|Participants will receive enteral vitamin D supplementation of 800 IU/day for 28 days
62113449|NCT02194933|EXPERIMENTAL|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
62113450|NCT02194933|EXPERIMENTAL|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
62113451|NCT06313125|EXPERIMENTAL|Foot-ankle exercise group|In the foot-ankle exercise group, three-dimensional foot-ankle extension exercises will be applied in the Proprioceptive Neuromuscular Facilitation (PNF) pattern, in diagonal 1 and 2 directions and short-foot exercise.
62113452|NCT06313125|ACTIVE_COMPARATOR|Hip exercise group|Clam exercise will be given to this group as a hip abductor and external rotator strengthening exercise. In addition, short-foot exercise will be applied.
62303048|NCT01587963|PLACEBO_COMPARATOR|Ringers Lactate or Normal Saline|Ringers Lactate or Normal Saline
62303049|NCT05367531|EXPERIMENTAL|Injection Scenario|"For each scenario participants will be asked to administer/inject the medication (likely saline or air) using various methods: 1) standard protocol , 2) Autoinjector 3) Pre-filled syringes. For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding)."
62303050|NCT00087295|EXPERIMENTAL|Treatment|Depsipeptide
62303051|NCT06656351|EXPERIMENTAL|Tafenoquine|Tafenoquine (2 x 100 mg tablets) will be self-administered orally with food on Days 1, 2, 3, 4, then weekly thereafter for a total 12-week treatment period. Weekly treatment will start on Day 11 and end on Day 89.
62303052|NCT04339504|EXPERIMENTAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10\^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
62113453|NCT06313125|ACTIVE_COMPARATOR|Control group|The control group will do only short-foot exercise.
62113454|NCT04126330|EXPERIMENTAL|Probiotics and Omega-3/vitamin D Supplements- Elderly|
62303053|NCT04339504|EXPERIMENTAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10\^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
62303054|NCT04339504|EXPERIMENTAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10\^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
62303055|NCT00215618|EXPERIMENTAL|1|Uterine Balloon Therapy with post procedure curettage
62303056|NCT00215618|EXPERIMENTAL|2|Uterine Balloon Therapy without post-procedure curettage
62303057|NCT01078753|EXPERIMENTAL|Desmopressin|During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of \<75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
62736102|NCT03459469|EXPERIMENTAL|Investigational drug|An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
62113455|NCT04126330|PLACEBO_COMPARATOR|Placebo- Elderly|
62303058|NCT01078753|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets during treatment periods I and II according to the same efficacy criteria as participants in the Desmopressin treatment group.
62303059|NCT00714142|ACTIVE_COMPARATOR|1|Normal volunteers
62303060|NCT00714142|ACTIVE_COMPARATOR|2|Renal failure patients on dialysis
62303061|NCT00714142|ACTIVE_COMPARATOR|3|Renal artery stenosis patients
62303062|NCT05026775|EXPERIMENTAL|Initial Medication Adherence (IMA) intervention|General practitioners (GP) will apply the IMA intervention to all patients receiving a new prescription for treatment of cardiovascular disease or diabetes. Following the IMA intervention, nurses and community pharmacists will offer information support in line with the information provided by the GP.
62303063|NCT05026775|ACTIVE_COMPARATOR|Usual care|Patients will receive the usual care when being prescribed a new prescription for treatment of cardiovascular disease or diabetes. Nurses and community pharmacists will be asked to also provide usual care to those patients.
62303064|NCT03542188|ACTIVE_COMPARATOR|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
62303065|NCT03542188|EXPERIMENTAL|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-trombolysis and early EVT.
62303066|NCT01753492|EXPERIMENTAL|Ologen implantation (single arm)|Ologen implantation as an adjunctive to trabeculectomy
62303067|NCT01020331|EXPERIMENTAL|ACTIVE|
62303068|NCT03165396|EXPERIMENTAL|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0\~2.5μg/ml ）for maintaining
62303069|NCT03165396|EXPERIMENTAL|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
62303070|NCT03165396|EXPERIMENTAL|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
62303071|NCT03165396|EXPERIMENTAL|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
62303072|NCT03808311|EXPERIMENTAL|Intensive BP treatment arm|Participants in the intensive BP treatment arm will be treated to a systolic BP target of \<120 mmHg.
62303073|NCT03808311|OTHER|Standard BP treatment arm|Participants in the standard BP treatment arm will be treated to a systolic BP target of \<140 mmHg.
62303074|NCT06657079|ACTIVE_COMPARATOR|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) and ipratropium bromide (500/2 mL)|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
62303075|NCT06657079|PLACEBO_COMPARATOR|placebo (4 mL normal saline)|placebo (4 mL normal saline)
62303076|NCT03095703|EXPERIMENTAL|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
62303077|NCT01240070|ACTIVE_COMPARATOR|Usual Care|Clinical practice in type 2 diabetes treatment
62303078|NCT01240070|ACTIVE_COMPARATOR|Intensive Care|Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.
62736103|NCT00958360|EXPERIMENTAL|Arm 1|Interdisciplinary Low Vision Rehabilitation: Low vision examination, prescription and dispensing of low vision devices, low vision therapy and homework.
62303079|NCT04410302||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue samples during standard of care tumor biopsy or surgical resection to establish PDXs. Patients may also undergo collection of blood, saliva, and urine samples to compare DNA abnormalities to noncancer cells in order to determine if they were present before the cancer started or developed with it.
62303080|NCT05288465|EXPERIMENTAL|Hair repigmentation during Cerebrolysin treatment for neurological diseases|Patients prescribed for Cerebrolysin treatment due neurological diseases.
62303081|NCT05664633|ACTIVE_COMPARATOR|Sugammadex|Sugammadex dose=4 mg x kg
62303082|NCT05664633|NO_INTERVENTION|Standard of Care|Standard of care= glycopyrrolate and neostigmine (0.01 mg/kg - 50mg/kg)
62303083|NCT06022770|NO_INTERVENTION|Nutritional Counseling|
62303084|NCT06022770|EXPERIMENTAL|Nutrition Support Therapy|
62303085|NCT04665102||No pathology|
62303086|NCT04665102||Pathology|
62303087|NCT05051618|EXPERIMENTAL|POWER-MS|The POWER-MS condition will deliver the Guidelines for Exercise in MS (GEMS) program with a remotely coached/guided, home-based setting using telerehabilitation. GEMS recommends 30 minutes of moderate intensity aerobic activity, 3x/week AND strength training exercises for major muscle groups, 3x/week.
62303088|NCT05051618|ACTIVE_COMPARATOR|FLEX-MS|The FLEX-MS condition will primarily focus on flexibility as the applicable exercise modality. As such, the program will emphasize that flexibility is an important component of fitness. The goal would be for each participant to enhance their flexibility by engaging in a titrated exercise prescription where the number of sets and time to hold per set will increase throughout the 16-week program.
62303089|NCT02375022|EXPERIMENTAL|Endostar and icotinib|Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
62303090|NCT00753636|EXPERIMENTAL|Dynacirc CR (Isradipine)|Dynacirc CR (Isradipine) will start at 5mg dose and increased in increments of 5mg every 2 weeks
62303091|NCT03514147|EXPERIMENTAL|Experimental|Pelvic Floor Muscle Training in group. Exercise Protocol: The exercise group was supervised and met for 1 hour, one time per week, for 12 weeks. Participants were instructed to perform their respective daily exercises.
62736104|NCT00958360|ACTIVE_COMPARATOR|Arm 2|Basic Low Vision Care: Low vision examination, prescription and dispensing of low vision devices without low vision therapy or assigned homework.
62674422|NCT00700089|PLACEBO_COMPARATOR|B|Standard treatment consists of referral to a range of different treatment modalities depending on the diagnosis and clinical and social condition of the patient. In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
62674423|NCT06085209|EXPERIMENTAL|Intervention|Bronchoscopic balloon dilation with radial cuts \& truFreeze spray cryotherapy
62674424|NCT06085209|ACTIVE_COMPARATOR|Standard of care|Bronchoscopic balloon dilation with radial cuts
62674425|NCT03109925|EXPERIMENTAL|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
62113456|NCT04126330|EXPERIMENTAL|Probiotics and Omega-3/vitamin D Supplements- Obese|
62113457|NCT04126330|PLACEBO_COMPARATOR|Placebo- Obese|
62113458|NCT04090762|NO_INTERVENTION|Control|Women in the control arm will complete the baseline and follow up surveys but will not receive any intervention.
62113459|NCT04090762|ACTIVE_COMPARATOR|Risk information only|Women in the risk only arm who exhibit characteristics associated with a greater risk of a poor birth outcome will be informed that they possess these characteristics. Risk characteristics (identified from the medical and epidemiological literature) include age, prior pregnancy and birth history (e.g., previous stillbirth).
62113460|NCT04090762|ACTIVE_COMPARATOR|Conditional Cash Transfer only|Women in this arm will be eligible to receive conditional cash transfers. To receive the transfer, pregnant women must attend prenatal care and give birth in a health facility.
62113461|NCT04090762|ACTIVE_COMPARATOR|Conditional Cash Transfer and risk information|Women in this arm will be provided with risk information at the time of baseline survey administration AND be eligible to receive conditional cash transfers, pending attendance at prenatal care and delivery at a health facility.
62113462|NCT05632731|OTHER|Double Cleavage-stage Embryos transfer|In group A, two embryos at cleavage stage were transplanted on the third day after oocyte retrieval.
62113463|NCT05632731|OTHER|Single Blastocyst Stage Embryos transfer|Group B was graded by Gardner blastocyst grading method, and one blastocyst was transplanted on the 5th or 6th day after oocyte retrieval.
62113464|NCT01927952|ACTIVE_COMPARATOR|Kirschner wire|surgical fixation using a Kirschner wire
62113465|NCT01927952|ACTIVE_COMPARATOR|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
62113466|NCT01927952|ACTIVE_COMPARATOR|Stryker Smart-Toe implant|surgical fixation utilizing the Stryker Smart-Toe implant
62113467|NCT00341523||1|Chinese adults at high risk for esophageal cancer
62113468|NCT01720563|PLACEBO_COMPARATOR|Control|Placebo
62113469|NCT01720563|EXPERIMENTAL|Treatment|Astragalus polysaccharides 500 mg
62113470|NCT00003900|EXPERIMENTAL|irinotecan + docetaxel|Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
62113471|NCT05079269|EXPERIMENTAL|Intervention|The investigators will start a balanced crystalloid solution (in detail we will administer 500ml if the actual body weight is ≤80 kg: the investigators will administer 1000 ml if the actual body weight is \>80 kg:) within 20 to 40 minutes before induction of anesthesia in the pre-operative area or at the ward, as appropriate.
62113472|NCT05079269|NO_INTERVENTION|Control|Patients will receive the balanced crystalloid solution according to the current clinical standard of care.
62113473|NCT01141322|EXPERIMENTAL|UDCA treatment|Patients with drug-induced liver injury will be randomly allocated to UDCA treatment group: oral intake ursodeoxycholic acid (UDCA) 13-15 mg/kg BW/day into 3 divided doses after meal till the endpoint or the 8th week. UDCA is 100 mg per tab.
62113474|NCT01141322|PLACEBO_COMPARATOR|Placebo|Patients with drug-induced liver injury will be randomly allocated to placebo group. The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
62113475|NCT02241668|EXPERIMENTAL|FLT PET Scan + 3'-Deoxy-3'-18f-Fluorothymidine|After a magnetic resonance imaging (MRI) scan of brain performed, an FLT PET scan using 3'-Deoxy-3'-18f-Fluorothymidine solution performed. After solution is injected into a vein, the PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. The entire procedure should last about 60-70 minutes.
62303092|NCT03514147|ACTIVE_COMPARATOR|Control|Pelvic Floor Muscle Training in home Exercise Protocol:The same exercise were performed at home for 12 weeks, without supervision. Participants were instructed to perform their respective daily exercises.
62303093|NCT03427073|EXPERIMENTAL|Solid tumours|"Part 1 - Dose-escalation of ALM201 in patients with advanced solid tumours~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
62303094|NCT03427073|EXPERIMENTAL|Ovarian cancer|"Part 2 - Dose-expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the MTD determined in Part 1"
62736105|NCT04383028|EXPERIMENTAL|MELD-assisted SEEG trajectory planning|Following routine clinical planning, the MELD algorithm will be run on the enrolled patient's scans. Up to 3 extra electrodes may be used to target lesion clusters identified by the algorithm such that the investigators will record from the top 3 clusters, with the aim of improving the rate of identification of a focal seizure onset zone in patients undergoing SEEG.
62674426|NCT04741256|EXPERIMENTAL|Tracheostomy discharge protocol|"All head and neck cancer patients regardless of participation in the study will receive the standard of care: A copy of a tracheostomy education booklet and standardized discharge training for patients and their caregivers by nursing staff during their inpatient stay.~Research personnel will provide protocol training to the inpatient nurses who are to provide training to caregivers.~Pre-implementation phase: Eligible patient participants identified \& healthcare utilization recorded. Nursing staff participants complete nursing survey to capture volume of tracheostomy-related questions received.~Protocol-phase: Caregiver participants will complete a survey prior to patient tracheostomy, on day of patient discharge, and one week following discharge~Post-implementation phase: Nursing staff participants will complete an additional survey similar to the one in the pre-implementation phase. EMR will be reviewed for implementation fidelity."
62674427|NCT02975700|EXPERIMENTAL|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
62674428|NCT03834259|ACTIVE_COMPARATOR|Group 1|12.5 mg 0.5% hyperbaric bupivacaine
62674429|NCT03834259|ACTIVE_COMPARATOR|Group 2|10 mg 0.5% hyperbaric bupivacaine
62674430|NCT03834259|ACTIVE_COMPARATOR|Group 3|12.5 mg 0.5% hyperbaric bupivacaine
62113476|NCT05268042|EXPERIMENTAL|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
62113477|NCT05268042|ACTIVE_COMPARATOR|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
62113478|NCT01405924|EXPERIMENTAL|Fosaprepitant 150 mg|Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy
62113479|NCT03040661|EXPERIMENTAL|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
62113480|NCT03040661|ACTIVE_COMPARATOR|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
62113481|NCT04375449|ACTIVE_COMPARATOR|Pep2dia- dosage 1|700mg of whey protein hydrolysates single dose
62113482|NCT04375449|ACTIVE_COMPARATOR|Pep2Dia - dosage 2|1400mg of whey protein hydrolysates single dose
62113483|NCT04375449|PLACEBO_COMPARATOR|Placebo|maltodextrin single dose
62113484|NCT01456819|EXPERIMENTAL|Mononuclear and mesenchymal stem cells|Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells
62113485|NCT01456819|ACTIVE_COMPARATOR|Mononuclear cells only|Autologous bone marrow-derived mononuclear cells
62113486|NCT02104648|PLACEBO_COMPARATOR|Part A: Placebo|
62113487|NCT02104648|EXPERIMENTAL|Part A: RO4602522|
62113488|NCT02104648|EXPERIMENTAL|Part B: RO4602522 Multiple Doses|
62113489|NCT02104648|EXPERIMENTAL|Part B: RO4602522 Single Dose|
62674431|NCT02852746||Asympt. athletes / scapular dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
62674432|NCT02852746||Symptom. athletes / scapular dyskinesis|Symptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
62674433|NCT00100477|OTHER|Arm 1|
62113490|NCT02104648|EXPERIMENTAL|Part B: moxifloxacin Single Dose|
62113491|NCT05319288|ACTIVE_COMPARATOR|Distal acupoints only group|The DPOG (n=51) will receive acupuncture of distal acupoints only(SI3, EX-UE7) for ALBP.
62113492|NCT05319288|ACTIVE_COMPARATOR|Local acupoints mainly combined with distal acupoints group|LPMG (n=51) will receive acupuncture of local acupoints mainly(BL23, BL25, BL32) combined with distal points(BL40) for ALBP.
62303095|NCT05346302|ACTIVE_COMPARATOR|Pneumococcal (PPSV23) vaccine|PNEUMOVAX 23 is a clear, colorless solution. Each 0.5-mL dose of vaccine contains 25 micrograms of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative under the supervision of a licensed pharmacist.
62303096|NCT05346302|ACTIVE_COMPARATOR|Typhoid (inactivated) vaccine|Typhoid vaccine is a clear, colorless solution. Each dose of 0.5 mL is formulated to contain 25 mcg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7 ± 0.3), 4.150 mg of Sodium Chloride, 0.065 mg of Disodium Phosphate, 0.023 mg of Monosodium Phosphate, and 0.5 mL of Sterile Water for Injection under the supervision of a licensed pharmacist.
62674434|NCT05045963||Observational (medical record review)|Patients' medical charts are reviewed retrospectively.
62674435|NCT04010253|EXPERIMENTAL|SIMEOX|
62674436|NCT04010253|ACTIVE_COMPARATOR|Autogenic Drainage|
62674437|NCT03924076|EXPERIMENTAL|Treatment Group|Received UHT milk + paraprobiotic Lactobacillus plantarum IS-10506 5 x 1010 CFU/day (125 mL) for 90 days
62674438|NCT03924076|PLACEBO_COMPARATOR|Placebo Group|Received UHT milk (125 mL) for 90 days
62113493|NCT00319436|EXPERIMENTAL|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
62303097|NCT05346302|PLACEBO_COMPARATOR|Saline|Saline will be purchased commercially and compounded under the supervision of a licensed pharmacist in sterile syringes for administration of the placebo group.
62303098|NCT04680884|EXPERIMENTAL|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
62303099|NCT04680884|EXPERIMENTAL|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
62113494|NCT00319436|ACTIVE_COMPARATOR|Standard Parent Education for Substance Using Mothers|This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
62113495|NCT02018224|EXPERIMENTAL|End-to-end suturation without augmentation|
62113496|NCT02018224|EXPERIMENTAL|End-to-end suturation with augmentation|
62303100|NCT04680884|EXPERIMENTAL|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
62303101|NCT04680884|OTHER|Best standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
62303102|NCT00584350|EXPERIMENTAL|A: Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
62303103|NCT00584350|ACTIVE_COMPARATOR|B: Standard hydratation|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
62303104|NCT00584350|EXPERIMENTAL|C: Hydratation with sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
62303105|NCT04966221||Adult healthy volunteers|Adult healthy volunteers, age matched to patient volunteers. Will undergo a combination of functional and structural lung MRI scans.
62303106|NCT04966221||Adults with Chronic Obstructive Pulmonary Disease|Will undergo a combination of functional and structural lung MRI scans. Some participants in this cohort will have lung volume reduction (LVR) as part of their normal clinical care. These participants will be given the option to attend two study visits - one before and one after LVR.
62303107|NCT04966221||Adults with alpha-1-antitrypsin deficiency|Will undergo a combination of functional and structural lung MRI scans.
62303108|NCT02888626|EXPERIMENTAL|Treatment with Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
62303109|NCT00607750|PLACEBO_COMPARATOR|1|
62303110|NCT00607750|EXPERIMENTAL|ATG003|
62113497|NCT03937843|EXPERIMENTAL|Arm with 2 cohorts|"Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I:~* Within 7 days after registration, the patients will receive one infusion of carboplatin AUC (Area under the curve) 7 at day 1 of trial treatment, followed 3 weeks later by 12 x 2 Gy involved-node radiation therapy (RT). RT should ideally start on day 22 (range: day 19-25) from the date of carboplatin administration, preferably on a Monday.~Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I:~* Within 7 days after registration, the patients will receive one cycle of etoposide 100 mg/m2/d + cisplatin 20 mg/m2/d at days 1 to 5 of trial treatment, followed 3 weeks later by 15 x 2 Gy involved-node radiation therapy. RT should ideally start on day 22 (range: day 19-25) from the date of chemotherapy start, preferably on a Monday."
62113498|NCT04247204|EXPERIMENTAL|Platelet-rich plasma (PRP) intrauterine infusion|
62471796|NCT05631587|ACTIVE_COMPARATOR|Control condition (Self-directed exercise)|Participants will receive a one-page written information sheet regarding the PA guidelines for cancer survivors and exercise safety precautions extracted from the website of the Centre for Health Protection of the HKSAR Government. Although mixed aerobic and resistance exercise are recommended, participants will be provided with a simple goal of increasing their aerobic exercise levels to 150 minutes of moderate aerobic activity or 75 minutes of vigorous aerobic exercise per week because resistance exercise requires instructions from trained personnel.
62471797|NCT03808805|EXPERIMENTAL|studied group|Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days
62471798|NCT03808805|ACTIVE_COMPARATOR|comparative group|Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days
62113499|NCT05795946|NO_INTERVENTION|Diet Only Group|Diet only: guided diet
62303111|NCT04876339|EXPERIMENTAL|"Gait rehabilitation with sonification"|"The rehabilitation exercises with sonification are supported by the musical component (see Interventions section for details)."
62303112|NCT04876339|ACTIVE_COMPARATOR|Standard gait rehabilitation (without sonification)|The same rehabilitation exercises are performed without musical support.
62471799|NCT02059863|EXPERIMENTAL|SPRING intervention clusters|"SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision~PLUS access to routine maternal and child health services"
61917345|NCT04581460||Patients|Patients entered in the register of the reference Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris, and having reported at least one pregnancy or attempted pregnancy
61917346|NCT01536275|NO_INTERVENTION|Early parenteral nutrition|Parenteral nutrition supplements insufficient enteral nutrition from admission to ICU according to the current standard of care per center
61917347|NCT01536275|EXPERIMENTAL|Late parenteral nutrition|Parenteral nutrition will be withheld during the first 7 days of ICU stay
61917348|NCT01403272|EXPERIMENTAL|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
61917349|NCT03540498|EXPERIMENTAL|Probiotics|The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
62113500|NCT05795946|EXPERIMENTAL|Combination Group|Combination of whole food-based B and D vitamins
62471800|NCT02059863|NO_INTERVENTION|Control clusters|access to routine maternal and child health services
62674439|NCT04900857|ACTIVE_COMPARATOR|Dry needling treatment group|Dry needling treatment group will be treated with acupuncture needles (0.25x25 mm Hua Long Brand).In this group, one active trigger point area in the trapezius muscle was precisely determined and marked with a permanent pen, and dry needling treatment was applied to that area with disposable acupuncture needles in a single session. the trigger point was palpated. From the center, the needle tip was inserted perpendicular to the skin quickly into the subcutaneous tissue and inserted into the muscle with the needle tip until it found the trigger point in the muscle band. Local twitch responses (LTRs) were similar to Hong's rapid entry and exit technique. It was obtained by inserting a large number of rapid needles in and out of. The needle was not removed from that area for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
62674440|NCT04900857|EXPERIMENTAL|Localized vibration treatment group|The tight band in the muscle was determined by palpation, and the location of the most painful points (the middle of the most vertical fibers of the upper part of the trapezius muscle) in the muscle tension band was digitally determined. It was determined with a permanent marker. The skin was cleaned with a suitable antiseptic agent. Localized vibration therapy was applied for 20 minutes with a vibration frequency of 110 Hz and an amplitude of 5.57 mm using a vibrator device. Vibration therapy was applied to our patients by attaching an apparatus with a small area of 1 cm2 to the skin on the trigger point in the trapezius muscle and fixed with medium pressure. We applied a total of 3 sessions every other day in hospital conditions by a single practitioner to all patients.
62674441|NCT05738252||Group A|We expect that some of the eligible patients (Group A) will undergo surgery without NACT. Group A will undergo only one preoperative study visit (baseline) within 45 days prior to their surgery. Group A will complete the study assessments and follow-ups. Some patients of Group A will undergo adjuvant chemotherapy after surgery; this will not affect their study timeline.
62113501|NCT05795946|EXPERIMENTAL|B Only Group|Whole food-based B vitamins
62113502|NCT01510912|EXPERIMENTAL|Diclofenac Capsules 35 mg bid or tid|
62113503|NCT06077019|EXPERIMENTAL|Vilanterol|Participants inhale vilanterol + fluticasone furoat
62113504|NCT06077019|EXPERIMENTAL|Indacaterol|Participants inhale indacaterol + mometasone furoate
62113505|NCT06077019|PLACEBO_COMPARATOR|Placebo|Participants inhale placebo
62303113|NCT05568576||patients with HCC underwent resection|patients with HCC underwent resection
62113506|NCT02577198|EXPERIMENTAL|Intervention|Electronic Health Records with computerised decision support system activated Medilogy Decision Support System (MediDSS)
62471801|NCT01472848|EXPERIMENTAL|Cohort 1|
62471802|NCT01472848|EXPERIMENTAL|Cohort 2|
62471803|NCT01472848|EXPERIMENTAL|Cohort 3|
62471804|NCT01472848|EXPERIMENTAL|Cohort 4|
62471805|NCT01472848|EXPERIMENTAL|Cohort 5|
62471806|NCT01472848|ACTIVE_COMPARATOR|Cohort 6|
62471807|NCT00798954|ACTIVE_COMPARATOR|TAXUS|
61917350|NCT03540498|PLACEBO_COMPARATOR|Control|The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
61917351|NCT06020638|EXPERIMENTAL|Experimental group (Positive Pressure Group)|The nasopharyngeal suction with positive pressure method was employed in the sample group. In this method, the infant's head is turned to the side, to the nostril on the other side 1-2 ml of physiological saline (PS- Mustela trademark), is injected with a 2,5-milliliter syringe (Can Medikal trademark), and then positive pressure is exerted with the help of the end of the oxygen connection hose (CGR Medikal trademark) from the same nostril, with oxygen or air supply at 5-8 lt/min (liter/minute) (if the baby requires oxygen, using an oxygen source) and the nasopharyngeal secretions are removed from the nostril into which physiological saline (PS) has been not injected. The oxygen connection hose is held one centimeter away from the infant's nostril. The researchers prepared a guideline for nasopharyngeal suction with positive pressure based on the literature.
61917352|NCT06020638|ACTIVE_COMPARATOR|Control group (Negative Pressure Group)|The nasopharyngeal suction with negative pressure method was employed in the control group in this study. In this method, the nasal secretions were softened with 1-2 ml of physiological saline (PS- Mustela trademark) like experimental group, and then negative pressure suction was performed using a pine-tipped suction set (Bıcakcılar trademark). The suction pressure was kept between 60 and 80 mmHg, and no suction lasted for more than 15 seconds
62471808|NCT00798954|ACTIVE_COMPARATOR|Cypher|
62471809|NCT04138368|EXPERIMENTAL|dyadic treatment|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
62471810|NCT04138368|ACTIVE_COMPARATOR|supportive treatment|mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
62674442|NCT05738252||Group B|Patients undergoing NACT before their surgery (group B) will have a first baseline study assessment within 45 days prior to their first chemotherapy treatment; in this group, a second preoperative study visit will be repeated after chemotherapy is considered terminated at least 18 days post-chemotherapy cycle and within 45 days prior to surgery. Group B will complete the study assessments and follow-ups. Some patients of Group B will undergo adjuvant chemotherapy after surgery; this will not affect their study timeline.
62674443|NCT05738252||Group C|Post-chemotherapy, a small proportion of patients will not be deemed eligible for surgery by the treating physician (group C). Group C will be included in the evaluation of chemotherapy-related outcomes, and will also be asked to complete a follow-up visit 6 months from the end of their chemotherapy.
62674444|NCT06493383|EXPERIMENTAL|AIR OPTIX COLORS|Lotrafilcon B plano cosmetic contact lenses worn in both eyes at least 5 hours per day, at least 2 days a week, for one year. Lenses will be replaced monthly and cleaned, rinsed, disinfected, and stored in accordance with the package labeling of the lens care products recommended by the eye care professional.
61917353|NCT01403233|EXPERIMENTAL|cogniVida™ 50 mg/day|
61917354|NCT01403233|EXPERIMENTAL|cogniVida™ 100 mg/day|
61917355|NCT01403233|ACTIVE_COMPARATOR|Rebaudioside-A 303.7 mg/day|
62113507|NCT02577198|OTHER|Control|Electronic Health Records with computerised decision support system silenced Medilogy Decision Support System (MediDSS) silenced
62113508|NCT01348191||Elective caesarean section|"Population: ten pregnant women, scheduled for elective caesarean section with a term pregnancy ( \> 37 weeks).~Inclusion criteria~* Elective caesarean section~* Term pregnancy \> 37 weeks~* Age \> 18 years~Exclusion criteria~* Previous caesarean scar~* Gestational age \< 37 weeks~* Maternal temperature \> 37.8 degrees Celsius~* Meconium stained liquor~* Foetal distress~* Maternal diabetes~* Seropositivity~* Use of thyroid medication~* Maternal thyroid disease~* Age \< 18 years"
62113509|NCT01940003|NO_INTERVENTION|Control|Usual care of service Institute of Medicine Professor Fernando Figueira(IMIP) prenatal
62113510|NCT01940003|EXPERIMENTAL|Aquatic exercise|Pool-based exercise classes will be completed in groups of 4 to 6 participants under the instruction of a physiotherapist. The exercise program will be conducted three times per week and each session lasting 45 minute. This will be conducted since GDM diagnosis (26-28th gestational week) to the end of the third trimester (38-39th gestational week). Thus, an average of 30 training sessions will be planned for each pregnant woman.
62113511|NCT03206736|EXPERIMENTAL|Loop DS Patients|Patients who receive a Loop DS procedure
62113512|NCT06549517|ACTIVE_COMPARATOR|Intervention group-MTT24.5|Subjects are assigned to 12 cognitive training in-person sessions of the MTT245 program by a validated trainer. Cognitive evaluations are made initially week 1 and at the end of the intervention at week 12.
61917356|NCT06275490|EXPERIMENTAL|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
61917357|NCT06275490|ACTIVE_COMPARATOR|L- PRF Block|"The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.~Finally, tension free wound closure will be attained after periosteal releasing incision and suturing using 5/0 proline interrupted sutures.~An immediate postoperative CBCT scan will be done following the surgical procedure."
62471811|NCT05700565||Steroid-refractory or dependent immune-related adverse events|Immune-related adverse events (irAE) after immune checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA4 blockade) refractory to therapy with corticosteroids or inability to taper corticosteroids to prednisone equivalent \<= 5mg
62471812|NCT04826718||Cohort|All Health Care Worker (HCW) from Hospital in Santiago and S. Vicente islands, Cabo Verde
62674445|NCT00263562|EXPERIMENTAL|Steroid arm|Receipt of methyprednisolone pulse dose: 15mg/kg to a maximum of 1 gram; following this, the patients also received a steroid taper with oral prednisone:Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
61917358|NCT03447197|ACTIVE_COMPARATOR|On-Pump|Use of extracorporeal circulation
61917359|NCT03447197|NO_INTERVENTION|Off-Pump|
61917360|NCT03723889||PDA|Evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
61917361|NCT03723889||noPDA|No evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
61917362|NCT01302015|EXPERIMENTAL|RNL-Vascostem®|drug name and ingredients : RNL-Vascostem\[Autologous adipose tissue derived mesenchymal stem cells\] dosage : Intramuscular infusion, 5 x 10e6 cells/kg
61917363|NCT02628665|EXPERIMENTAL|24 to 48 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 24 to 48 hours: The injection of photosensitizer(photofrin) 24 to 48 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
61917364|NCT02628665|ACTIVE_COMPARATOR|48 to 72 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 48 to 72 hours: The injection of photosensitizer(photofrin) 48 to 72 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
61917365|NCT06482216||Vaccination group|The last dose of varicella vaccine given 30 days before enrollment was manufacture by Sinovac (Dalian) Vaccine Technology Co. LTD.,(Sinovac).
62113513|NCT06549517|NO_INTERVENTION|Control group|Subjects are assigned to a controlled arm whereas no intervention were done. They should underwent the same cognitive evaluations than active comparator at week 1 and 12.
62113514|NCT03720613||Naldemedine|Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.
62113515|NCT03720613||Lubiprostone|Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.
62113516|NCT03720613||Naloxegol|Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.
62113517|NCT05260502||Autistic children|magnetic resonance imaging brain for autistic children
62113518|NCT05260502||attention deficit hyperactivity disorder children|magnetic resonance imaging brain for attention deficit hyperactivity disorder children
62113519|NCT05260502||Normal children|magnetic resonance imaging brain for Normal children
62471813|NCT04826718||Control|HCW who report no SARS-CoV-2 infection in the period prior to the interview and/or suspected COVID-19 in the period prior to the interview
62113520|NCT03557788|EXPERIMENTAL|Rifaximin|Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
62113521|NCT00573833|EXPERIMENTAL|HDR Brachytherapy|9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
61917366|NCT06482216||Non-vaccination group|Without varicella vaccine history
62113522|NCT04362215||High AA group|Group 1 consisted of those having an AA level of 3.57-4.16 D (high AA group; those who had near clear vision between 24-28 cm). .
62113523|NCT04362215||Low AA group|Group 2 consisted of those having an AA level of 3.44-3.03 D (low AA group; those who had near clear vision between 29-33 cm)
62303114|NCT06644612|EXPERIMENTAL|Intervention Group A (Light Mesh Group)|All the patients will be administered intravenous Antibiotics two hours before induction of anaesthesia. The surgical site will be shaved if needed after scrubbing the patient. Prolene suture material will be used to anchor the light mesh and suture the skin. A negative pressure drain will be placed if needed. The wound will be dressed with gauze dressing. Post-operatively daily dressing will be done by ward dispenser following full aseptic technique.
62303115|NCT06644612|ACTIVE_COMPARATOR|Intervention Group B (Heavy Mesh Group)|"All the patients will be administered intravenous antibiotics two hours before induction of anaesthesia. The surgical site will be shaved if needed after scrubbing the patient.~Prolene suture material will be used for anchoring the Heavy mesh and for suturing the skin. A negative pressure drain will be placed if needed. The wound will be dressed with a gauze dressing. Post-operatively daily dressing will be done by ward dispenser following full aseptic technique."
62303116|NCT02286102|EXPERIMENTAL|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
62303117|NCT02286102|ACTIVE_COMPARATOR|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
62471814|NCT04826718||Cases|HCW who report positive SARS-CoV-2 infection confirmed by performing a positive PCR test and/or positive Rapid Antigen Test in the period prior to the interview
62674446|NCT00263562|PLACEBO_COMPARATOR|Comparison Group|Patients receiving usual care, with receipt of placebo (saline in lieu of intravenous methylprednisolone infusion or a number of placebo pills equivalent in number to what would have been received for the prednisone.
62674447|NCT06445179|ACTIVE_COMPARATOR|without Robotic-Assisted|In the control group, all patients will undergo a Total Laparoscopic Hysterectomy. The number of ports needed for the laparoscope and assistants will be reported.
62674448|NCT06445179|EXPERIMENTAL|Robotic-Assisted|All patients in the experimental group will undergo a Robotic-Assisted Total Laparoscopic Hysterectomy using either the HugoTM Robot-Assisted Surgery system (Medtronic©), the Da Vinci® Xi or X Surgical System, or CMR versus (if available). The number of ports required for the laparoscope, robotic arms, and assistants will be documented.
62113524|NCT04420195|EXPERIMENTAL|Envarsus XR|Envarsus XR to be initiated once patient is tolerating oral medications
62113525|NCT04420195|EXPERIMENTAL|IR tacrolimus (historical control)|Historical cohort of patients maintained on IR tacrolimus following transplant
62113526|NCT03589651|EXPERIMENTAL|Group A|INCMGA00012 with epacadostat.
62113527|NCT03589651|EXPERIMENTAL|Group B|INCMGA00012 with INCB050465.
62113528|NCT01153750|EXPERIMENTAL|Glivec and 5-Fluorouracil/Leucovorin|"All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day 0. Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15."
62113529|NCT03504072|ACTIVE_COMPARATOR|Tofacitinib 5mg|tofacitinib 5 mg 12 hourly daily for 9 months. Evaluation schedule will be baseline, 1st month, 3rd months and 3 monthly for 9 months. relevant investigations will be done at each visit. occurrence of tuberculosis and infections will be recorded at follow up visits.
62113530|NCT03504072|ACTIVE_COMPARATOR|Etanercept 50 mg|Etanercept 50 mg subcutaneously every 7 days interval for 1st month then, Etanercept 50 mg in 15 days interval for 2nd month then 50 mg every 21 days interval for 9 months. Occurrence of tuberculosis and infections will be recorded at follow up visits.
62113531|NCT00952718|NO_INTERVENTION|Control|No intervention.
62113532|NCT00952718|EXPERIMENTAL|Inspiratory muscle training|With intervention.
62113533|NCT05608343|ACTIVE_COMPARATOR|Difamilast Ointment|1% Difamilast Ointment
62303118|NCT06389370||Level 1|
62303119|NCT06389370||Level 2|
62303120|NCT06389370||Level 3|
62303121|NCT06389370||Level 4|
62303122|NCT06389370||Level 5|
62303123|NCT02513381|ACTIVE_COMPARATOR|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
62471815|NCT05898607|ACTIVE_COMPARATOR|Group A|Patients will receive Loading dose of 20 ml 0.25% bupivacaine then continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative
62471816|NCT05898607|ACTIVE_COMPARATOR|Group B|Patients will receive Loading dose of 20 ml 0.25% bupivacaine then continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
62113534|NCT05608343|PLACEBO_COMPARATOR|Vehicle Controlled|Matching placebo
62303124|NCT02513381|PLACEBO_COMPARATOR|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
62471817|NCT04134091|EXPERIMENTAL|Treatment A|LPCN 1144 Formulation A
62113535|NCT02054455|PLACEBO_COMPARATOR|PPI and placebo|Patients will receive PPI and placebo for 3 days/week for 6 months
62113536|NCT02054455|ACTIVE_COMPARATOR|PPI and Lactobacillus paracasei F19|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for 6 months
62303125|NCT02473406|EXPERIMENTAL|Thymosin|Thymosin alpha 1 has been shown to have immunomodulatory properties
62303126|NCT02473406|PLACEBO_COMPARATOR|Placebo|normal saline;
62303127|NCT05779852|EXPERIMENTAL|self-hypnosis and care|
62303128|NCT05779852|OTHER|care|
62303129|NCT03083912||Fortimel Complete|All of the residents included receive ONS
62303130|NCT01812525|ACTIVE_COMPARATOR|NaCl 3% inhalations + standard therapy|"In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.~Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
62303131|NCT01812525|PLACEBO_COMPARATOR|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
62471818|NCT04134091|EXPERIMENTAL|Treatment B|LPCN 1144 Formulation B
62471819|NCT04134091|PLACEBO_COMPARATOR|Treatment C|Placebo
62471820|NCT04953676|OTHER|Control Group|round tunnel
62471821|NCT04953676|EXPERIMENTAL|Experimental group|flat tunnel
62113537|NCT02054455|ACTIVE_COMPARATOR|PPI and Lactobacillus paracasei F19 cross-over 1|Patients will receive placebo 3 days/week for the first three months and Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the following three months
62113538|NCT02054455|ACTIVE_COMPARATOR|PPI and Lactobacillus paracasei F19 cross-over 2|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the first three months and placebo 3 days/week for the following three months
62113539|NCT01420718|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
62113540|NCT01420718|EXPERIMENTAL|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
62303132|NCT05259475|OTHER|Lifestyle advice alone|"The participants in Lifestyle advice alone arm (study control) will receive 1 session of diet advice from the study dietitian at the start of the study only. The dietitian will provide dietary advice on the eating plans and instructions for completion of diet checklist. The lifestyle advice on maintaining a healthy diet and regular exercise (\~180 mins/ week) will be compatible with recommendations by the Health Promotion Board (Singapore)."
62471822|NCT04512092|EXPERIMENTAL|CMT-C group|Compassion Mind Training for Caregivers (CMT-C) is a 12-session structured program to be delivered in a group format, aiming to cultivate a compassionate-self and compassionate care practices in residential youth care.
62471823|NCT04512092|NO_INTERVENTION|Control group|This group did not receive any mind training or group intervention during the study.
62471824|NCT03393208|EXPERIMENTAL|First Test GIR (Fasting), Then Reference GIR (Fasting)|Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
62471825|NCT03393208|EXPERIMENTAL|First Reference GIR (Fasting), Then Test GIR (Fasting)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
62674449|NCT01407978|ACTIVE_COMPARATOR|Vaccination with Fluval AB Novo|"* Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
62674450|NCT01407978|ACTIVE_COMPARATOR|Vaccination with Fluval AB|"* Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
62674451|NCT01407978|EXPERIMENTAL|Vaccination with Fluval P|"* Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
62674452|NCT02157337|EXPERIMENTAL|atrovastatin|
62674453|NCT02157337|PLACEBO_COMPARATOR|placebo|
62674454|NCT04102644||Pregnant Women|Up to 15,000 pregnant women and their fetuses/newborns (including a pilot phase of up to 500 participant pairs)
62674455|NCT01636544|EXPERIMENTAL|contralateral healthy tissue biopsy|
62674456|NCT04086615|EXPERIMENTAL|NMES and exercise supplemented with high BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The High BFR group will have the pressure set at 80% of limb occlusion pressure."
62113541|NCT01750463||Arm A|"Critically ill pediatric patients admitted to PICU requiring hemoglobin monitoring.~Patients admitted to PICU requiring hemoglobin monitoring will have a reading total hemoglobin (SpHb) assessment done with the Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor,prior to standard laboratory blood draw and hemoglobin analysis."
62471826|NCT03393208|EXPERIMENTAL|First Test GIR (Fed), Then Reference GIR (Fed)|Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
62471827|NCT03393208|EXPERIMENTAL|First Reference GIR (Fed), Then Test GIR (Fed)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
62471828|NCT05901090|ACTIVE_COMPARATOR|M-TAPA block|Patients had bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
62113542|NCT04141917|NO_INTERVENTION|Standard influenza surveillance|Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
62113543|NCT04141917|ACTIVE_COMPARATOR|Point-of-care molecular testing and treatment of influenza|Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A \& B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .
62471829|NCT05901090|ACTIVE_COMPARATOR|TAP block|Patients had bilateral TAP block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
62471830|NCT05901090|NO_INTERVENTION|Control|Control group patients were not subjected to any block or local infiltration anesthesia. Their postoperative pain was relieved with tramadol (intravenous) administration.
62471831|NCT02329262|EXPERIMENTAL|Mentoring to be Active|Trained teen mentors will deliver the physical activity curriculum to high school students in a school setting. Physical activity will be measured with accelerometers.
62471832|NCT02329262|ACTIVE_COMPARATOR|Planning to be Active|High school teachers will deliver the physical activity curriculum (usual care) to high school students enrolled in health education courses. Physical activity will be measured with accelerometers.
62471833|NCT01175018|EXPERIMENTAL|Anakinra|Anakinra 100 mg injectable subcutaneously daily
62471834|NCT01175018|PLACEBO_COMPARATOR|Placebo|0.67 ml of sodium chloride (NaCl) 0.9% solution
62471835|NCT01004341|OTHER|Family-based weight control|Group-based family therapy for weight loss in children age 8-12 years.
62471836|NCT01718886||Obalon Gastric Balloon|Patients received 1-3 Obalon Gastric Balloons over a period of 12 weeks
61917367|NCT01112683|EXPERIMENTAL|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
62113544|NCT02243813|EXPERIMENTAL|Delayed Participation|Participants will begin the psilocybin intervention 6 months after study enrollment.
62113545|NCT02243813|EXPERIMENTAL|Immediate Participation|Participants will begin psilocybin intervention immediately after study enrollment.
62471837|NCT05693337||FLIR Imaging|All patients recruited for this study will receive FLIR imaging to monitor the success of a lumbar sympathetic block for CRPS
62471838|NCT06526338|EXPERIMENTAL|IP-001|1.0% IP-001 for injection immediately following local ablation or surgical resection and local ablation
62113546|NCT04991974|NO_INTERVENTION|Usual Care (UC)|The UC Arm will include standard services from the sexual health clinic / city health department \[at the time of the study, no standardized intervention for opioid use disorder treatment linkage\].
62113547|NCT04991974|ACTIVE_COMPARATOR|Patient Navigation (PN)|The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment.
62471839|NCT06526338|ACTIVE_COMPARATOR|Control|Local ablation or surgical resection and local ablation alone
62471840|NCT05016323|EXPERIMENTAL|HR19042 Capsules|
62471841|NCT05016323|PLACEBO_COMPARATOR|Placebo|
62471842|NCT05878483|EXPERIMENTAL|Autonomous blood drawing|"Hospital Sites (outpatients visiting blood drawing department):~In study Phase A1, B1, B2, C1, a subject visiting the outpatient blood drawing department will receive one automated blood draw with the Venipuncture Device. This blood draw is additional to the manual blood draw.~In study Phase C2 the automated blood draw replaces the manual blood draw. In Phase C2, the subject might therefore receive two automated blood draws, in case a redraw is required.~Vitestro Site (volunteers):~In study Phase A, C1 volunteers visit Vitestro Site. Participants receive one to two automated blood draws."
61917368|NCT01112683|PLACEBO_COMPARATOR|Placebo|These are identically-looking pills to the ones in the Memantine Arm
61917369|NCT01551420|ACTIVE_COMPARATOR|Advanced upper limb prosthetic device IMU controlled|Subjects with upper limb amputation who are trained to use a DEKA Arm with IMU controls
61917370|NCT01551420|ACTIVE_COMPARATOR|Advanced upper limb prosthetic EMG-PR controlled|Subjects with TR or TH upper limb amputation who are trained to use a DEKA Arm with EMG-PR Controls
61917371|NCT04294745|EXPERIMENTAL|Group A|Buccal infiltration of 4% Articaine
61917372|NCT04294745|ACTIVE_COMPARATOR|Group B|Inferior alveolar nerve block of 4% Articaine
61917373|NCT05435040|EXPERIMENTAL|self-comparison|"The patient will be fitted with proprioceptive knee brace and with no knee brace.~the patient will perform tests (Y Balance Test, test with Weinstein monofilaments, and Joint Position Sense test) and complete visual analog scales with and without the proprioceptive knee brace in a randomized order.~There is also a satisfaction questionnaire regarding the proprioceptive knee brace to be completed at the end of the study."
61917374|NCT04334109|EXPERIMENTAL|Family-DSME|"Approach~* Family motivational interviewing techniques~* Family goal setting~* Understanding supportive and nonsupportive family behaviors~* Family behavioral changes Mode of Delivery~* Group sessions delivered by a certified diabetes educator (CDE) to patients and their family members Dosage~* 10 hours delivered in one-hour sessions over 10 weeks Participants~* 300 patients with T2D and 300 family members (family members will take part in educational sessions and data collection)"
62113548|NCT04991974|EXPERIMENTAL|Patient Navigation + Buprenorphine Initiation (PN+BUP)|The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community. The standard buprenorphine bridge prescription will be for buprenorphine/naloxone film: 8/2mg, up to 16mg per day, 7 day supply.
62113549|NCT00009646|EXPERIMENTAL|Indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.
62736106|NCT04775355||Observational (biospecimen collection, questionnaire)|Patients undergo collection of stool and urine samples within 2 weeks before hormone therapy or radiation therapy, after hormone therapy but before start of radiation therapy, and after completion of radiation therapy. Patients also complete a series of questionnaires prior to starting radiation therapy, mid-way through radiation therapy, and after completion of radiation therapy (within 1-3 weeks, at 3 months, and then every 6 months until 3 years from radiation completion). Patients' medical records are also reviewed.
61917375|NCT04334109|ACTIVE_COMPARATOR|Standard-DSME|"Approach~* Individual motivational interviewing techniques~* Individual goal setting~* Individual behavioral changes Mode of Delivery~* Group sessions delivered by a CDE to patients Dosage~* 10 hours delivered in one-hour sessions over 10 weeks Participants~* 300 patients with T2D (family members will take part in data collection but not educational sessions)"
61917376|NCT05150444|EXPERIMENTAL|Cognitive and physical exercise training|"This group will perform combined intradialytic cognitive and physical exercise training. First, they will exercise during dialysis (3 times a week; 12 weeks) for \~30 minutes on a customized ergometer. They will start with a 3-min warm-up, then the resistance will be implied to each individual according to the rate of perceived exertion of 4th to 5th grade on a 10-grade Borg scale. After a break, they will be given tablet computers in order to play brain games on a CogniFit platform (\~30 - 45 min)."
61917377|NCT05150444|NO_INTERVENTION|Standard care|This group will receive standard hemodialysis care.
62113550|NCT00009646|PLACEBO_COMPARATOR|Placebo|Saline solution
62113551|NCT00541125|OTHER|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
62113552|NCT02542852|EXPERIMENTAL|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
62113553|NCT05093712||Phase I (survey)|Patients complete surveys over 10 minutes on their background, health literacy level, barriers to cancer care, and knowledge of cervical cancer and its treatment.
62113554|NCT05093712||Phase II (survey, educational video)|Patients watch educational video on cervical cancer. Patients also complete surveys over 5-10 minutes at baseline and after watching educational video.
62113555|NCT01326988||Patients requiring spinal anesthesia for lower limb surgery|Patients of at least 18 years of age undergoing spinal anesthesia for elective lower limb surgery will be recruited. Therefore inclusion and exclusion criteria are the same as for traditionally administered spinal anesthesia as below. Additionally we will exclude those patients who are incapable of providing fully informed consent, patients who are currently enrolled in other studies and patients with communication difficulties
62113556|NCT01885845|EXPERIMENTAL|BRASSS-V drape|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
62471843|NCT01237054|EXPERIMENTAL|Imaging in MGUS, SMM, and MM|Participants will have three imaging studies on separate days: a standard positron emission tomography/computed tomography scan (18-FDG PET/CT), a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT), and magnetic resonance imaging (DCE-MRI).
62471844|NCT05596279|EXPERIMENTAL|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
62736107|NCT04786821|PLACEBO_COMPARATOR|Standard Exercise Training Programme|Participants will receive interventions by an exercise specialist based on the participant's tolerance. These sessions will be delivered by a exercise specialist.
62471845|NCT05596279|EXPERIMENTAL|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
62674457|NCT04086615|SHAM_COMPARATOR|NMES and exercise supplemented with low BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The Low BFR group will have the pressure set at 20 mmHg."
62674458|NCT02255279|EXPERIMENTAL|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
62113557|NCT01885845|EXPERIMENTAL|Indirect weight method|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
62113558|NCT02523391|EXPERIMENTAL|Treatment Period 1|Either 5mg TA-8995 Capsule or Tablet
62113559|NCT02523391|EXPERIMENTAL|Treatment Period 2|Either 5mg TA-8995 Capsule or Tablet
62113560|NCT03565224||Cespace|The patients have been operated with Cespace Titanium Coated PEEK Cage for Degenerative Disc Disease between 2014 and 2017. All patients are invited to the Hospital for Follow-Up. Depending on the date of Initial Intervention the timeframe of follow-up for the individual Patient is 1 to 4 years.
62113561|NCT00612586|EXPERIMENTAL|Enzastaurin + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with enzastaurin
62674459|NCT02255279|ACTIVE_COMPARATOR|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
62113562|NCT00612586|PLACEBO_COMPARATOR|Placebo + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with placebo
62113563|NCT06156306|ACTIVE_COMPARATOR|CBT-I|A total of 6 sessions of face-to-face group CBT-I therapy will be provided. Each session will last 90-120 mins, with each group 8-10 subjects.
62113564|NCT06156306|EXPERIMENTAL|CBT-I combined ACT|A total of 6 sessions of face-to-face group CBT-I+ACT therapy will be provided. Each session will last 90-120 mins, with each group 8-10 subjects.
62303133|NCT05259475|EXPERIMENTAL|Diet Intervention|Participants will be supplied with 2 main meals per day as part of their daily diet, for 6 days a week. This diet is prescribed as a moderate energy restriction (500-1000 kcal/day) to facilitate weight loss. Additional food products are supplied for breakfast and snacks. Participants will receive individual diet consultations with the study dietitian during the study. Participants are told to consume only low-fat dairy products (milk, yoghurt), and avoid ruminant meat (beef, lamb), cheese, butter, butter-containing food products, and sugar-sweetened beverages.
62303134|NCT05259475|EXPERIMENTAL|OCFA Meal-Based Diet-Intervention|"Participants in the OCFA meal-based diet-intervention arm will be provided with OCFA-containing food product, in addition to the lunch and dinner meals (6 days a week) given in the Diet Intervention arm. Participants will receive individual diet consultations with the study dietitian during the study. Participants are told to consume only low-fat dairy products (milk, yoghurt), and avoid ruminant meat (beef, lamb), cheese, butter, butter-containing food products, and sugar-sweetened beverages."
62113565|NCT06367517||Graves' orbitopathy|Patients with active, moderate to severe TED, without disease improvement after methylprednisolone pulse therapy in an intermediate-dose schedule (starting dose of 0.5 g once weekly for 6 weeks, followed by 0.25 g once weekly for 6 weeks) or high-dose regimens (a starting dose of 0.75 g once weekly for 6 weeks, followed by 0.5 g once weekly for 6 weeks) with or without concomitant radiotherapy.
62303135|NCT02122289|EXPERIMENTAL|Application of Smartphone|Weekly questionnaire on Smartphone
62303136|NCT02122289|PLACEBO_COMPARATOR|No application Smartphone|No Weekly questionnaire on Smartphone
62303137|NCT02167269|ACTIVE_COMPARATOR|Baby EAR-JR|The subjects receive Baby EAR circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Jackson-Rees (JR) circuit and the procedure will be repeated.
62471846|NCT02900209||COPD frequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio \<0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
62113566|NCT04577625|ACTIVE_COMPARATOR|L. reuteri Low Dose|L. reuteri will be delivered in a capsule at a low dose including Vitamin D3. Administration twice daily.
62113567|NCT04577625|ACTIVE_COMPARATOR|L. reuteri High Dose|L. reuteri will be delivered in a capsule at a high dose including Vitamin D3. Administration twice daily.
62113568|NCT04577625|PLACEBO_COMPARATOR|Placebo|The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.
62113569|NCT00752817|EXPERIMENTAL|SC|Subjects (surgical trainees) randomised to train under a proficiency-based progression virtual reality simulation curriculum
62674460|NCT03437733|EXPERIMENTAL|Intervention|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
62674461|NCT02892708|ACTIVE_COMPARATOR|Surgery|Surgical resection followed by radiation therapy
62674462|NCT02892708|EXPERIMENTAL|radiotherapy alone|radiotherapy after a brain biopsy
62674463|NCT02369159|EXPERIMENTAL|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.~* Subjects ≥12 years will receive a dose of 600 mg.~* Subjects \<12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).~* Subjects \< 6 months will receive a dose of 8 mg/kg."
62471847|NCT02900209||COPD infrequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio \<0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced no more than 1 course of oral steroids/antibiotics and none exacerbations requiring hospital admission in the previous 12 months.
62471848|NCT02900209||Healthy controls|Aged 65-85 years and do not have any symptoms of lung disease and have normal spirometry.
62674464|NCT02369159|ACTIVE_COMPARATOR|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.~* Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).~* Subjects \< 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
62674465|NCT00195429|EXPERIMENTAL|Sirolimus + Tacrolimus|
62674466|NCT00195429|ACTIVE_COMPARATOR|Sirolimus + Prednisone|
62674467|NCT04375215|ACTIVE_COMPARATOR|Selective caries removal to soft dentin (one step)|In selective caries removal to soft dentine, after caries excavation application of liner will be done on pulpal floor. Teeth will then be filled with composite resin material.
62471849|NCT02322983|EXPERIMENTAL|Cerebral Palsy Subjects|Use of conscious sedation with nitrous oxide in the control of stress during dental treatment in individuals with Cerebral Palsy
62471850|NCT05707507|ACTIVE_COMPARATOR|Outpatient antimicrobial therapy|Included patients will receive outpatient antimicrobial therapy according to their infectious disease.
62471851|NCT05707507|OTHER|Inpatient antimicrobial therapy|Included patients will receive intrahospital antimicrobial therapy according to their infectious disease.
62471852|NCT05803603|EXPERIMENTAL|Intervention Arm|Individuals will receive $500 monthly stipend for the first months of the study and will receive twelve months of social work supports to help individuals find permanent housing.
62471853|NCT04473807|OTHER|DASH-AF|Patients with history of highly symptomatic persistent or paroxysmal AF who are scheduled for sotalol therapy once in sinus rhythm will be enrolled in this study.
62471854|NCT00193804||2|Patients with histologically proven, cervical cancer FIGO Stage IIB eligible will be invited for the study. The patients will recieve either 3D conformal radiation or IMRT external radiation with concomitant cisplatin chemotherapy followed by brachytherapy.
62471855|NCT01013467|ACTIVE_COMPARATOR|color coded bloodpressure booklet|
62471856|NCT01020396|EXPERIMENTAL|1|Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)
62674468|NCT04375215|ACTIVE_COMPARATOR|Stepwise caries removal (two step)|The stepwise caries removal is a two step procedure. The first step is similar to selective caries removal to soft dentin group. In the second step, after 6 months lesion will be re-entered to remove remaining carious tissue till firm dentin is encountered. Once all the caries is removed from floor of cavity a liner followed by final restoration with composite will be performed.
62674469|NCT05352113|EXPERIMENTAL|acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
62113570|NCT00752817|ACTIVE_COMPARATOR|CC|Subjects (surgical trainees) randomised to the current surgical training curriculum
62113571|NCT06326437|EXPERIMENTAL|6-week dyadic intervention|A 6-week psychosocial dyadic programme will comprise 1 weekly 60-90min face-to-face session, followed by 5 weekly internet-based sessions.
62113572|NCT06326437|NO_INTERVENTION|Usual care|The control group to receive the usual care provided by the clinical team in the hospital.
62113573|NCT04050631||L&D team|the first responders on L\&D floor including : anesthesia, nurses and OBGYN
62113574|NCT03215251|EXPERIMENTAL|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
62113575|NCT03215251|NO_INTERVENTION|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
62113576|NCT04379349|EXPERIMENTAL|Active SMS|Weekly interactive SMS text messaging check-ins.
62113577|NCT04379349|SHAM_COMPARATOR|Sham SMS|Weekly minimally interactive SMS text messages.
62113578|NCT06238154|EXPERIMENTAL|Spray group|Spray group consisted of individuals who used flurbiprofen in spray form as a postoperative analgesic
62113579|NCT06238154|ACTIVE_COMPARATOR|Tablet group|Tablet group consisted of individuals who used flurbiprofen in tablet form as a postoperative analgesic
62113580|NCT01546155|EXPERIMENTAL|healthy controls|
62113581|NCT01897233|EXPERIMENTAL|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks."
62113582|NCT00309452|ACTIVE_COMPARATOR|Treatment as usual|Referral to community providers.
62113583|NCT00309452|EXPERIMENTAL|STEP Care|Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.
62113584|NCT02925000|EXPERIMENTAL|TLC178|Liposomal Vinorelbine
62113585|NCT06231277|EXPERIMENTAL|BH002|Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
61917378|NCT02700087|PLACEBO_COMPARATOR|H2 blocker versus placebo|"The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily).~Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo."
61917379|NCT02700087|ACTIVE_COMPARATOR|Treatment arm|Patients who develop severe airway symptoms while they are in the H2 blocker versus placebo arm will then cross over to the treatment arm of the study. These patients will exit randomization and be unblinded. These patients will all be given H2 blockers, and the effects of the H2 blockers will be monitored and studied. Alternatively, patients' families may also elect to undergo surgery to treat laryngomalacia.
61917380|NCT00245583|EXPERIMENTAL|Topiramate|25mg to 300mg daily dose
61917381|NCT00245583|PLACEBO_COMPARATOR|Placebo|placebo equivalent tablets
61917382|NCT03313661|EXPERIMENTAL|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
61917383|NCT03313661|ACTIVE_COMPARATOR|Gliclazide|gliclazide (60-120 mg) once daily
61917384|NCT03313661|NO_INTERVENTION|Placebo|Placebo
61917385|NCT04584307|EXPERIMENTAL|Elotuzumab + Pomalidomide|Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
62674470|NCT05352113|EXPERIMENTAL|acupuncture + placebo group|This group will include 40 patients with MDD who will be treated with acupuncture and a placebo. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
61917386|NCT03597217|EXPERIMENTAL|Cohort A_Active|3 single doses treatment of PF-05221304
61917387|NCT03597217|EXPERIMENTAL|Cohort B_Active|Repeated doses of PF-05221304
61917388|NCT03597217|PLACEBO_COMPARATOR|Cohort B_Placebo|Repeated doses of placebo
62113586|NCT05273242|EXPERIMENTAL|Artesunate|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
62113587|NCT05273242|EXPERIMENTAL|Imatinib|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
62113588|NCT05273242|EXPERIMENTAL|Infliximab|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
62303138|NCT02167269|ACTIVE_COMPARATOR|JR-Baby EAR|The subjects receive Jackson-Rees (JR) circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Baby EAR circuit and the procedure will be repeated.
62674471|NCT05352113|EXPERIMENTAL|sham acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with sham acupuncture and SSRIs antidepressants. The sham acupuncture will be needled on the points 1cm lateral to acupoints. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
62674472|NCT05940636|EXPERIMENTAL|FES+TSCS (combined) neuromodulation group|For the combined neuromodulation with VFT group, the sub-motor threshold, open-loop TSCS will be coupled with closed-loop FES of ankle muscles during VFT. For this purpose, 2 electrical stimulators, one for each leg will stimulate SOL and TA muscles bilaterally while open-loop tonic lumbar TSCS will be applied at an intensity producing paresthesia in most of the lower-limb dermatomes
61917389|NCT01981369|ACTIVE_COMPARATOR|Propofol sedation.|This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
61917390|NCT01981369|EXPERIMENTAL|Dexmedetomidine sedation.|This group will have infraclavicular block and sedation with intravenous Dexmedetomidine. Patients will receive intravenous Dexmedetomidine sedation bolus 0.5mcg/kg in 10 minutes and then 0.2-0.5 mg/kg/hr infusion. The infusion will be stopped 15 minutes before the end of surgery.
62113589|NCT05273242|NO_INTERVENTION|Local Standard of Care|No other Intervention Given except the local standard of care
62113590|NCT05714735||Whole-brain venography|Cerevbral venography
62113591|NCT00831415|EXPERIMENTAL|1|DVS SR
62113592|NCT02064660|EXPERIMENTAL|single arm|A series of acupressure sessions within six months from the baseline
62113593|NCT03312335|EXPERIMENTAL|Low-dose Aldesleukin (Proleukin®)|
62113594|NCT00817830|EXPERIMENTAL|lodenafil carbonate|Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
62113595|NCT01533519|EXPERIMENTAL|NPY/placebo|This arm gets NPY first then placebo (saline). The placebo is 0.9% USP-grade saline without NPY.
62113596|NCT01533519|EXPERIMENTAL|placebo/NPY|This arm gets placebo (saline) first then NPY.
62113597|NCT01795144|ACTIVE_COMPARATOR|Healthy controls|"Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:~* OGTT~* IGI~* IGI with GLP-1 infusion~* OGTT with Exendin 9-39 infusion"
62303139|NCT01880450|EXPERIMENTAL|Project Prepared|
62303140|NCT01880450|ACTIVE_COMPARATOR|TEEN-Teen Education & Employment Network|
61917391|NCT02591329|EXPERIMENTAL|Experimental|The experimental condition (EXP) will receive the targeted intervention material developed and designed by the researchers using focus group discussions with parents. This information will include salient benefits of the consumption of calcium-rich products. In addition, self-regulatory strategies will be provided to encourage purchasing and consumption of calcium-rich products and address any potential barriers to purchase and consumption. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a grocery pad and a recipe book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
61917392|NCT02591329|ACTIVE_COMPARATOR|Standard Care|Individuals in the Control condition (CON) will receive general healthy eating materials including Canada's Food Guide, Healthier Grocery Shopping Guide and Cooking with Kids. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a note pad and an activity book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
62113598|NCT01795144|EXPERIMENTAL|Monogenic diabetes|"Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:~* OGTT~* IGI~* IGI with GLP-1 infusion~* OGTT with Exendin 9-39 infusion"
62113599|NCT06163586|EXPERIMENTAL|Intervention|This group will receive structured neonatal touch or massage therapy from a certified NICU provider. Therapy will given 3 days a week for 5 to 15 minutes for a minimum of 4 weeks. We will also be collecting data to assess pain and stress responses during the period immediately before, during, and shortly after the therapy. This includes assessment of crying/irritability, behavior state, facial expression, extremities tone, and vital signs (heart rate, breathing rate, and oxygen levels).
62113600|NCT06163586|NO_INTERVENTION|Control|This group will receive standard NICU care, no different than if they were not enrolled in the study.
62113601|NCT00405951|EXPERIMENTAL|Obatoclax Mesylate + Docetaxel|Obatoclax Mesylate 250mL in combination with Docetaxel
62113602|NCT00794118||1.0|As per routinary clinical practice
62113603|NCT00563537|EXPERIMENTAL|1|18F-X PET Scan imaging
62674473|NCT05940636|ACTIVE_COMPARATOR|FES group|For the FES with VFT group, participants will receive visual feedback regarding their center of pressure location during four games with varying levels of difficulty and FES will be applied bilaterally to SOL and TA via a closed-loop system.
62113604|NCT03561610|ACTIVE_COMPARATOR|Study group 1|normal Nutrition + sip feed (covers individual energy and nutrient demands)
62113605|NCT03561610|EXPERIMENTAL|Study group 2|normal Nutrition + gumdrops (covers individual energy and nutrient demands)
62113606|NCT04879082||ILD|Patients with ILD, whose file has been discussed in a multidisciplinary meeting since May 2020 at the Louis Pradel Pneumological Hospital, and who have benefited from a professional interview in the Occupational pathology consultation center of the Hospital Center Lyon Sud.
62113607|NCT01764451|EXPERIMENTAL|Simvastatin|20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
62113608|NCT01764451|NO_INTERVENTION|No Treatment|
62113609|NCT04301986|EXPERIMENTAL|TNE Followed by EGD|Subjects will undergo administration of a transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
62303141|NCT00688038|EXPERIMENTAL|Laser Ablation + MRTI|Magnetic resonance thermal imaging = MRTI
62113610|NCT04301986|EXPERIMENTAL|Cytosponge, then TNE, followed by EGD|Subjects will undergo administration of Cytosponge and transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
62303142|NCT01152099|ACTIVE_COMPARATOR|GroupA|"Ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. Multilayer bandage is applied daily during the first four weeks.~The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
62471857|NCT01020396|ACTIVE_COMPARATOR|2|MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)
62674474|NCT03666702|EXPERIMENTAL|Upper limb physiotherapy programme|A progressive, individualised four week upper limb physiotherapy intervention programme delivered via web-based physiotherapy lasting up to 30 minutes/session, five times per week + usual care.
61917393|NCT03766282||Animal study|Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.
61917394|NCT03766282||Clinical study|To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.
61917395|NCT01490827||Argus II Retinal Prosthesis|Patients implanted with an Argus II Retinal Prosthesis
61917396|NCT03534453|EXPERIMENTAL|Olaparib 300mg tablets|Taken orally twice daily
61917397|NCT02220998|EXPERIMENTAL|SOF/VEL|SOF/VEL FDC for 12 weeks
62113611|NCT02491723|EXPERIMENTAL|Azithromycin group|Patients with non-cystic bronchiectasis were treated with azithromycin. The intervention was 500mg daily for three to five days.
62113612|NCT03588845|OTHER|Protocol Treatment|"If a score on the GSS is \> 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
62471858|NCT04383886||Emergency department staff|
61917398|NCT02220998|EXPERIMENTAL|SOF+RBV|SOF+RBV for 12 weeks
62113613|NCT03588845|OTHER|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
62113614|NCT00793286|OTHER|A|Mesh fixation by staples
62113615|NCT00793286|OTHER|B|Mesh fixation by glue
62113616|NCT05576181|EXPERIMENTAL|ThisCART19A cells infusion and HSCT|"In this study, allogeneic anti-CD19 CAR T cell (ThisCART19A) infusion is used to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia.~After patients achieve MRD- remissions through ThisCART19A, they will subsequently receive hematological stem cell transplantations."
62303143|NCT01152099|EXPERIMENTAL|GroupB|"Ambulatory treatment is carried out during one month. Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
62303144|NCT00883753|EXPERIMENTAL|tocilizumab|Participants received tocilizumab 8 mg/kg intravenous (IV), maximum dose not exceeding 800 mg in a single infusion, every 4 weeks for up to 104 weeks or up to 4 weeks after tocilizumab became commercially available in the respective country whichever occurred first.
62303145|NCT02951598||MCI (Amyloid Positive)|Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
62303146|NCT02951598||Mild AD Dementia (Amyloid Positive)|Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
62303147|NCT02951598||MCI (Amyloid Negative)|Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
62303148|NCT02951598||Mild Dementia (Amyloid Negative)|Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
62303149|NCT04943588||HCV Negative|"At initial screen, this population will be HCV negative via the diagnostic testing. They will be eligible if they fulfil the following:~1. over 18 yrs old.~2. willing to participate~3. no previous history of therapy with oral medication for chronic HCV infection"
62303150|NCT04943588||HCV Positive with first-line treatment success|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir plus daclatasvir. After treatment, their blood sample will show that they have achieved a sustained virological response (SVR) defined as HCV RNA undetectable.
62303151|NCT04943588||HCV positive with first-line treatment failure|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir/daclatasvir. After treatment, this proportion of people will NOT achieve an (SVR - defined as HCV RNA undetectable).
62303152|NCT04943588||Cirrhotic Patients|Hepatitis C RNA positive that have cirrhosis
62303153|NCT05011552|EXPERIMENTAL|The intervention group|
62303154|NCT05011552|PLACEBO_COMPARATOR|The control group|
62303155|NCT06279923|EXPERIMENTAL|Administration of CD19-BAFF Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62303156|NCT01163344||Dance Therapy Group|This will group will undergo dance therapy once a week for a series of 8 weeks.
62303157|NCT01163344||Physical Therapy Group|This group will undergo physical therapy sessions once a week for a series of 8 weeks
62303158|NCT01264003|ACTIVE_COMPARATOR|1|Antibiotic prohylaxis / Lichtenstein repair
62303159|NCT02504541|EXPERIMENTAL|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
62303160|NCT03818815|ACTIVE_COMPARATOR|Drug: OP0201 + Antibiotics|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
62471859|NCT02124135|ACTIVE_COMPARATOR|Clinic-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in the clinic setting.
62471860|NCT02124135|EXPERIMENTAL|Restaurant-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in a restaurant, while dining.
62471861|NCT02960594|EXPERIMENTAL|Arm 1|2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62471862|NCT02960594|EXPERIMENTAL|Arm 2|8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62471863|NCT02960594|EXPERIMENTAL|Arm 3|2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
61917399|NCT03331471|ACTIVE_COMPARATOR|alveolar recruitment maneuver|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O and applying alveolar recruitment maneuver (PEEP 10 cmH2O for 3 breath - PEEP 15 cmH2O for 3 breath and PEEP 20 cmH2O for 10 breath) immediate before and after pneumoperitoneum
61917400|NCT03331471|EXPERIMENTAL|conventional ventilation|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O applying during anesthesia
61917401|NCT05573815|EXPERIMENTAL|Positive group|A patient diagnosed with brain metastasis after a brain MR
61917402|NCT05573815|EXPERIMENTAL|Negative group|A normal person or a patient not diagnosed with brain metastasis after a brain MR
61917403|NCT03603067||monophthalmic group|The BCVA of the worse eye is less than 0.05 or CFOV is less than 5°. The better eye need to receive ocular surgery.
61917404|NCT03603067||Normal group|The BCVA of the worse eye is more than 0.3 and CFOV is more than 10°. One of two eyes need to receive ocular surgery.
61917405|NCT04932187|EXPERIMENTAL|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
61917406|NCT00912379||hemoglobin determination|ICU and emergency unit patients
61917407|NCT03682809|EXPERIMENTAL|Systane Complete|Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
61917408|NCT03682809|NO_INTERVENTION|No Treatment|Subjects randomized to this group will not receive a treatment.
62303161|NCT03818815|PLACEBO_COMPARATOR|Placebo Comparator: Placebo +Antibiotics|Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
62303162|NCT03394950|EXPERIMENTAL|rtPA combined with Butyphthalide|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
62471864|NCT02960594|EXPERIMENTAL|Arm 4|2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62471865|NCT02960594|EXPERIMENTAL|Arm 5|8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62471866|NCT02960594|EXPERIMENTAL|Arm 6|8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62471867|NCT02960594|EXPERIMENTAL|Arm 7|2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
61917409|NCT05271279|EXPERIMENTAL|OVV-01 Injection+IBR900 Cell Injection|OVV-01 injection combined with IBR900 cell injection, 2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.
62303163|NCT03394950|ACTIVE_COMPARATOR|rtPA compared with placebo|Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
62303164|NCT03265587||Orientation 1|Nursing staff allocated to a bed space with orientation 1
62303165|NCT03265587||Orientation 2|Nursing staff allocated to a bed space with orientation 2
62471868|NCT02960594|EXPERIMENTAL|Arm 8|8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62674475|NCT03666702|ACTIVE_COMPARATOR|Usual care|An average of 4 to 5 physiotherapy sessions per week, lasting approximately 45 minutes each.
62471869|NCT02960594|EXPERIMENTAL|Arm 9|8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62674476|NCT05059080||Participants Diagnosed with COVID-19|Participants were previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 \[CV43043\]).
61917410|NCT00988767|EXPERIMENTAL|intramuscular injections|Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10
62471870|NCT02960594|EXPERIMENTAL|Arm 10|8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
62471871|NCT04877210|EXPERIMENTAL|Topical Insulin|Insulin (Actrapid) diluted in normal saline
62674477|NCT04325386|EXPERIMENTAL|Education sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
62674478|NCT04325386|PLACEBO_COMPARATOR|No education sessions|
62674479|NCT02688231|EXPERIMENTAL|High intensity group|
62674480|NCT02688231|EXPERIMENTAL|Low intensity group|
62674481|NCT02688231|ACTIVE_COMPARATOR|Control group - conventional treatment|
62471872|NCT04877210|PLACEBO_COMPARATOR|Normal Saline|Normal saline eyedrops
62674482|NCT03847090|EXPERIMENTAL|Reloxaliase|Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule
62303166|NCT03265587||Floater / Control group|Nursing staff not allocated to a bed space with an orientation.
62471873|NCT04877210|ACTIVE_COMPARATOR|Standard Artifical Tear|Gutt systane ultra
62471874|NCT02256722|EXPERIMENTAL|Treatment A|
62471875|NCT02256722|EXPERIMENTAL|Treatment B|
62471876|NCT02256722|EXPERIMENTAL|Treatment C|
62471877|NCT02256722|EXPERIMENTAL|Treatment D|
62674483|NCT03847090|PLACEBO_COMPARATOR|placebo|placebo capsule
62674484|NCT01206270|EXPERIMENTAL|Testosterone|Testosterone undecanoate 1000mg injection at baseline (0-week), 6-week, 18-week, 30-week
62674485|NCT01206270|PLACEBO_COMPARATOR|Placebo|Injection 4 ml of castor oil at baseline (week-0), week-6, week-18, week-30
62674486|NCT02046200|EXPERIMENTAL|Ivermectin|Ivermectin 30 mg single dose
62674487|NCT02046200|PLACEBO_COMPARATOR|Sugar pill|Matched placebo, single dose
62674488|NCT01801969||Rehabilitation service|"* Centralized or Decentralized rehabilitation~* Size of municipality"
61917411|NCT06051708||AKI group|patients who are hospitalized and develop acute kidney injury after 48 hours from admission
62303167|NCT04039139|NO_INTERVENTION|Usual Care|Participants will continue their usual care for 26 weeks
62303168|NCT04039139|EXPERIMENTAL|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Participants will receive a mind body educational-based intervention to learn the techniques comprising intervention 1. Further details are not provided for blinding purposes.
62303169|NCT04039139|ACTIVE_COMPARATOR|Mind Body Intervention 2|Participants will receive a mind-body educational-based intervention to learn the techniques comprising intervention 2. Further details are not provided for blinding purposes.
62471878|NCT02256722|ACTIVE_COMPARATOR|Treatment E|
62471879|NCT02124122|EXPERIMENTAL|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
62674489|NCT04919551|EXPERIMENTAL|KGD|Oral administration after fasting/high-fat meal/low-fat meal
62674490|NCT04919551|EXPERIMENTAL|GDK|Oral administration after high-fat meal/low-fat meal/fasting
62674491|NCT04919551|EXPERIMENTAL|DKG|Oral administration after low-fat meal/fasting/high-fat meal
62471880|NCT02124122|PLACEBO_COMPARATOR|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
62471881|NCT03871361|EXPERIMENTAL|Abatacept 125 MG/ML Prefilled Syringe|"Participants will inject the drug at home on a weekly basis. Participants will receive the syringes on the visit dates, supplying them for the period until the next visit. At baseline, participants will be explained and shown how to inject the drug themselves.~Subject will have to stop all concomitant immunosuppressive drugs at baseline, e.g. Corticosteroids, Methotrexate, Mofetil Mycophenolate, Azathioprine, Tacrolimus, Sirolimus or Cyclosporin. Other drugs can be continued. In case of recurrence in the abatacept group, the study will end for that subject.~Patients treated with abatacept (ORENCIA) may receive concurrent vaccinations, except for live vaccines. Live vaccines should not be given concurrently with abatacept or within 3 months of its discontinuation."
62471882|NCT03946891|EXPERIMENTAL|Arm A|
62471883|NCT03946891|EXPERIMENTAL|Arm B|
62674492|NCT01348490|EXPERIMENTAL|Ruxolitinib 5 mg|Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
62674493|NCT04632030|ACTIVE_COMPARATOR|Control|The tobacco power wall and number of products appears in a typical format: large power wall with a large number of products (defined here as three large cabinets)
62674494|NCT04632030|EXPERIMENTAL|Small|The tobacco power wall and number of tobacco products appear in their smallest format: small power wall with a small number of products displayed (defined here as one large cabinet)
61917412|NCT06051708||no AKI group|patients who are hospitalized and do not develop acute kidney injury after 48 hours from admission till discharge
62303170|NCT05176210|EXPERIMENTAL|SAD portion - Cohort 1 (25mg)|An eligible subject will receive a single dose of 25 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
62471884|NCT02695394||MS / CIS|
62471885|NCT02695394||Healthy controls|
62471886|NCT03851250|EXPERIMENTAL|MRx-4DP0004|"MRx-4DP0004 is a Live Biotherapeutic Product containing 10\^9 to 10\^10 Colony Forming Units.~Participants randomised to this arm will take 2 capsules twice daily at approximately 12 hour intervals for 12 weeks."
62471887|NCT03851250|PLACEBO_COMPARATOR|Placebo|"Participants randomised to this arm will take 2 capsules of placebo twice daily at approximately 12 hour intervals for 12 weeks.~All participants will receive placebo in a single blind manner for two weeks in addition to the 12 weeks of double blind treatment."
62471888|NCT00073307|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.
62674495|NCT04632030|EXPERIMENTAL|Medium|The tobacco power wall and number of tobacco products appear in a format sized between the control and small conditions: a medium sized power wall with a medium number of products displayed (defined here as two large cabinets).
62674496|NCT01803737|ACTIVE_COMPARATOR|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
62674497|NCT01803737|EXPERIMENTAL|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
62674498|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
62674499|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
62674500|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
62471889|NCT00073307|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching in appearance were to be orally administered twice a day.
62471890|NCT02778451|OTHER|Ultrasonography-experienced surgeons|Attending physicians and consultants in head and neck surgery using head and neck Ultrasonography on a daily basis.
62674501|NCT02186171|EXPERIMENTAL|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
62674502|NCT02186171|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections once a month for 12 months.
62674503|NCT02690740|EXPERIMENTAL|open label|"test/retest of a titrated quantitative CPT (TqCPT) with outcomes: CPT-scoring system and correlation with digital photo analysis.~in all patients: 1 Arm = CPT test/re-test, no comparator~No intervention of a new drug (CPT-solution registered (ALK- Abelló, Hørsholm, Denmark));"
62674504|NCT03600727|EXPERIMENTAL|Propofol group|Patients in this arm will be sedated by propofol.
61917413|NCT05793190||Healthy Control|Total number of 20 Healthy Control participants Included in the study
62113617|NCT03182959|EXPERIMENTAL|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
62113618|NCT03182959|EXPERIMENTAL|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
62674505|NCT03600727|EXPERIMENTAL|Dexmedetomidine group|Patients in this arm will be sedated by dexmedetomidine.
61917414|NCT05793190||Alcoholic hepatitis|Total number of 30 Alcoholic hepatitis patients included in the study
61917415|NCT05793190||Alcoholic cirrhosis|Total number of 30 alcoholic cirrhosis patients included in the study
61917416|NCT05793190||Acute-on-Chronic Liver Failure|Total number of 15 alcoholic acute-on-chronic liver failure patients included in the study
61917417|NCT05793190||Alcoholic Hepatocellular carcinoma|Total number of 25 Alcoholic Hepatocellular carcinoma patients included in the study
61917418|NCT03120988|EXPERIMENTAL|Lavage with Platelet Poor Plasma (PPP)|"Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect washing out the joint space."
61917419|NCT01261832|EXPERIMENTAL|Dual antiplatelet therapy for 1 year|Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
61917420|NCT01261832|EXPERIMENTAL|Triple antiplatelet therapy for 1 month|Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
61917421|NCT01261832|EXPERIMENTAL|Triple antiplatelet therapy for 6 months|Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol
62113619|NCT00686023|ACTIVE_COMPARATOR|1|DHS fixation
62113620|NCT00686023|ACTIVE_COMPARATOR|2|IMN fixation
62113621|NCT06301035|EXPERIMENTAL|Asymmetric HFNC|Asymmetric HFNC
62113622|NCT06301035|ACTIVE_COMPARATOR|Standard HFNC|Standard HFNC
62113623|NCT02969954|EXPERIMENTAL|Intervention arm|Study has one arm - who will all receive the intervention
62303171|NCT05176210|EXPERIMENTAL|SAD portion - Cohort 2 (50mg)|An eligible subject will receive a single dose of 50 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
62303172|NCT05176210|EXPERIMENTAL|SAD portion - Cohort 3 (75mg)|An eligible subject will receive a single dose of 75 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
62303173|NCT05176210|EXPERIMENTAL|FE portion - Cohort 4 (50mg)|An eligible subject will receive a single dose of 50 mg PS1 or Placebo tablets in a fasted condition on Day 1 and be followed for 7 days.
62674506|NCT01867554||Intellectual disability|patients with intellectual disability or psycho-motor retardation and their parents and sibs (affected or not)
62674507|NCT06633419|EXPERIMENTAL|Opevesostat Period 1|On Day 1 a single dose of opevesostat will be administered under fasting conditions and a single dose of hormone replacement therapy (HRT) (prednisone and fludrocortisone) will be administered under fed conditions approximately 4.5 hours after opevesostat dosing.
62674508|NCT06633419|EXPERIMENTAL|Opevesostat Period 2|There will be a washout of at least 5 days between opevesostat dosing in Period 1 and the first carbamazepine dosing in Period 2. In Period 2, carbamazepine will be administered twice daily (BID) for 17 consecutive days with a single dose of opevesostat coadministered on the morning of Day 14 under fasting conditions. HRT (prednisone and fludrocortisone) will be administered under fed conditions on Day 14, approximately 4.5 hours after opevesostat and/or carbamazepine dosing.
61917422|NCT00320359|ACTIVE_COMPARATOR|Arm A|Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
61917423|NCT00320359|EXPERIMENTAL|Arm B|Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
61917424|NCT01142089|PLACEBO_COMPARATOR|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours)
61917425|NCT01142089|EXPERIMENTAL|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
61917426|NCT02762851|EXPERIMENTAL|Influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine prior to the influenza season.
62113624|NCT01064804||relative bioavailability|
62674509|NCT01056055||Suture anchor, Bone tunnel|Suture anchor group: patients who underwent the modified Brostrom procedure using suture anchor technique Bone tunnel group: patients who underwent the modified Brostrom procedure using bone tunnel technique
62303174|NCT05176210|EXPERIMENTAL|MAD portion - Cohort 5 (25mg)|An eligible subject will receive 25 mg PS1 or Placebo tablets once daily in a fed condition for 14 days and be followed for additional 7 days.
62674510|NCT04755478||Lung lobectomy via open thoracotomy|participants scheduled for lung lobectomy via open thoracotomy
62674511|NCT04755478||Lung lobectomy via VATS|participants scheduled for lung lobectomy via video-assisted thoracoscopic surgery
62674512|NCT01529112|EXPERIMENTAL|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)
62674513|NCT01529112|PLACEBO_COMPARATOR|Lenvatinib matched placebo|Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC
62674514|NCT02382900|EXPERIMENTAL|Cohort 1|11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
61917427|NCT02762851|PLACEBO_COMPARATOR|Placebo vaccine|Participants at high risk for adverse vascular events will be vaccinated with a 0.5 ml dose of sterile saline prior to the influenza season.
61917428|NCT00251160|ACTIVE_COMPARATOR|ETAC|
61917429|NCT00251160|ACTIVE_COMPARATOR|Open ICS|
62113625|NCT01731665||The Songpa-Kangdong cohort of IBD|Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
62113626|NCT02931383|EXPERIMENTAL|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg once daily (QD) and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
62113627|NCT02931383|PLACEBO_COMPARATOR|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
62303175|NCT05176210|EXPERIMENTAL|MAD portion - Cohort 6 (50mg)|An eligible subject will receive 50 mg PS1 or Placebo tablets once daily in a fed condition for 14 days and be followed for additional 7 days.
62303176|NCT05176210|EXPERIMENTAL|MAD portion - Cohort 7 (25mg)|An eligible subject will receive 25 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 7 days.
62303177|NCT05176210|EXPERIMENTAL|MAD portion - Cohort 8 (50mg)|An eligible subject will receive 50 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 7 days.
62303178|NCT03391869|EXPERIMENTAL|Arm A (ipilimumab, nivolumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients receive nivolumab IV over 60 minutes on days 1, 15, and 29 and ipilimumab IV over 90 minutes on day 1. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
61917430|NCT02099071|EXPERIMENTAL|Group 1|Six subjects will receive a single oral dose of ACT-389949 1 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
61917431|NCT02099071|EXPERIMENTAL|Group 2|Six subjects will receive a single oral dose of ACT-389949 5 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
62303179|NCT03391869|EXPERIMENTAL|Arm B (ipilimumab, nivolumab, LCT)|"INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients receive LCT consisting of surgery and/or radiation 14 days after completion of Induction Phase. Patients then receive nivolumab and ipilimumab as in arm A beginning within 4 weeks after LCT. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
61917432|NCT02099071|EXPERIMENTAL|Group 3|Six subjects will receive a single oral dose of ACT-389949 20 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
61917433|NCT02099071|EXPERIMENTAL|Group 4|"Subjects will participate in two different treatment periods separated by a washout of 7-10 days between the study drug administrations.~In the first treatment period six subjects will receive a single oral dose of ACT-389949 50 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.~In the second treatment period, subjects randomized to ACT-389949 will receive a single oral dose of ACT-389949 50 mg in fed condition, 30 minutes after the start of a high fat and high calorie breakfast."
62471891|NCT02778451|OTHER|Ultrasonography novices|Physicians participating in their one-year internship at other surgical or medical departments with no experience with head and neck US or head and neck surgery.
62674515|NCT02382900|ACTIVE_COMPARATOR|Cohort 2|Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
62113628|NCT03906968|EXPERIMENTAL|SinuSonic Device|SinuSonic Device used twice a day for four to six weeks.
62674516|NCT02382900|ACTIVE_COMPARATOR|Cohort 3|11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
62113629|NCT02816632|EXPERIMENTAL|healthy volunteers|
62674517|NCT02916433|NO_INTERVENTION|Usual care|This group will continue to receive treatments that have already been initiated to manage bronchial secretions.
61917434|NCT02099071|EXPERIMENTAL|Group 5|Six subjects will receive a single oral dose of ACT-389949 100 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
62471892|NCT04107675|EXPERIMENTAL|L-CsA 10 mg plus Standard of Care|"Liposomal Cyclosporine A 10 mg (10 mg/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks.~The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses.~Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication"
62471893|NCT04107675|EXPERIMENTAL|L-CsA 5 mg plus Standard of Care|"Liposomal Cyclosporine A 5 mg (5 mg/1.25 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 5 to 10 minutes for the 5-mg dose.~Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication"
62471894|NCT04107675|PLACEBO_COMPARATOR|Liposomal Placebo plus Standard of Care|"Liposomal Placebo 2.5 mL (0 mg L-CsA/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks.~The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication"
62471895|NCT05137184|EXPERIMENTAL|Methoxyflurane|3 ml inhalation Can be repeated once (3 ml) Maximum total dose of 6 ml
62471896|NCT05137184|EXPERIMENTAL|Fentanyl IN|100 µg IntraNasal, Patients \>70 years: 50 µg IN Can be repeated Maximum total dose 500 µg IN
62471897|NCT05137184|ACTIVE_COMPARATOR|Morphine IV|0.1 mg/kg Intravenous (IV) Patients ≥ 70 years or fragile: 0.05 mg/kg IV Can be repeated Maximum total dose 0.5 mg/kg IV
62471898|NCT01278095|EXPERIMENTAL|GLPG0555 solid dispersion, fasting|50 mg as solid dispersion capsule, in fasting condition
62471899|NCT01278095|EXPERIMENTAL|GLPG0555 solid dispersion, fed|50 mg as solid dispersion capsule, after breakfast
62471900|NCT01278095|EXPERIMENTAL|GLPG0555 nanosuspension, fed|50 mg as nanosuspension, given after breakfast
62471901|NCT05807321|EXPERIMENTAL|Fecobionics|
62674518|NCT02916433|EXPERIMENTAL|Octreotide|This group will continue to receive treatments that have already been initiated to manage bronchial secretions. Additionally, this group will receive parenteral octreotide.
62674519|NCT03425370|EXPERIMENTAL|Wound Side A: buried sutures, Wound Side B: tissue adhesive|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
61917435|NCT02099071|EXPERIMENTAL|Group 6|Six subjects will receive a single oral dose of ACT-389949 200 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
62471902|NCT03655535|EXPERIMENTAL|BTI320|4 g BTI320 administered 10 min before breakfast, lunch, and dinner
62471903|NCT03655535|PLACEBO_COMPARATOR|Placebo|Placebo administered 10 min before breakfast, lunch, and dinner
62471904|NCT02467205|OTHER|Intervention|pedometer supported walking and education A ;pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period Educational component; participants will attend six weekly sessions in small groups of up to six people; the content of the sessions will be based on educational cognitive behavioural programme development, In addition, participants will receive education material in the first education session. The intervention group will receive two booster sessions, after 3 and 6 months.
62471905|NCT02467205|NO_INTERVENTION|Control|participants randomly allocated to the comparison group will receive one education session (visit 2) regarding the importance of exercise and healthy diet and will be given education material similar to intervention group and encouraged to read it.
62471906|NCT03918174|EXPERIMENTAL|Dart Splint orthosis|The Dart-Splint orthosis allows oblique wrist motion along the Dart Throwing Motion (DTM) plane, thus inhibiting movement of the healing structures following surgery around the distal radius. This is a hinged orthosis that permits selective midcarpal mobilization along the plane of the DTM is a novel orthotic device that was developed in order to facilitate protected midcarpal motion.
62471907|NCT03918174|EXPERIMENTAL|The conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions.
61917436|NCT02099071|EXPERIMENTAL|Group 7|Six subjects will receive a single oral dose of ACT-389949 500 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
62113630|NCT06076382|EXPERIMENTAL|the endoscopic ultrasound guided colorectal ESD surgery group|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. Then undergo the colorectal ESD surgery.
62113631|NCT06076382|ACTIVE_COMPARATOR|the traditional colorectal ESD surgery group|the traditional colorectal ESD surgery
62113632|NCT05876130|EXPERIMENTAL|POHIM_EM|adjuvant hypofractionated IMRT for endometrial cancer
62113633|NCT05975983|EXPERIMENTAL|INS018_055|"Group 1: INS018_055 once daily up to 12 weeks, low dose~Group 2: INS018_055 twice daily up to 12 weeks, low dose~Group 3: INS018_055 once daily up to 12 weeks, high dose"
62113634|NCT05975983|PLACEBO_COMPARATOR|Placebo|Group 4: Placebo once or twice daily up to 12 weeks
62113635|NCT02860884||simple fatty liver|patients with fatty liver disease
62113636|NCT02860884||NASH|patients with nonalcoholic steatohepatitis
62113637|NCT06206330|ACTIVE_COMPARATOR|Platelet rich plasma group|In this group we applied Platelet rich plasma after the surgery. The surgery was fistulotomy and curettage.
62113638|NCT06206330|NO_INTERVENTION|Control group|In this group, we did the surgery as fistulotomy and curettage but we did not apply a Platelet rich plasma.
62113639|NCT04664049||NRICM101|Subjects who confirmed, suspected or prevented infected of COVID 19 disease and received dietary supplement NRICM101
62303180|NCT05446675||eTEP|First 30 participants who meet the inclusion criteria and do not exhibit any of the exclusion criteria will be investigated. The option for endoscopic eTEP repair, if feasible, is given preoperatively as a standard for the treatment of symptomatic midline abdominal wall hernias with concomitant rectus abdominis diastasis as an alternative to open Rives-Stoppa mesh repair. The modality of operative treatment is made in cooperation with the participant.
62113640|NCT00676533|EXPERIMENTAL|Arm 1|
62113641|NCT06465498|EXPERIMENTAL|Lung ultrasonography (LUS)|The antero-lateral thorax is examined using an 8-point protocol. Each region is coded positive in presence of ≥3 B-lines simultaneously on a frozen image or in presence of significant pleural effusion (i.e. extending over the costophrenic angle). A 4-level congestion score is defined: absence of congestion (0-1 positive points), mild congestion (2-3 positive points), moderate congestion (4-5 positive points) and severe congestion (6-8 positive points).
62113642|NCT06465498|ACTIVE_COMPARATOR|Physical Examination (PE)|Congestion is clinically assessed by calculating the Everest score. This score, previously used in clinical trials, is composed of 3 congestion symptoms (i.e. dyspnea, orthopnoea and fatigue) and 3 congestion signs (i.e. jugular vein distension, lung rales, oedema), each graded from 0 to 3. From the total score, a sub-score is derived, ranging from absence of congestion to severe congestion.
62113643|NCT05197699||DMT-Treated Participants|MS participants who are receiving DMTs will be enrolled.
62113644|NCT05197699||Untreated Participants|MS participants who are receiving no DMT treatment or receiving only symptomatic treatment will be enrolled.
62113645|NCT00722670|EXPERIMENTAL|Woman-focused (WF)|Woman-focused intervention (Women's CoOp)
62113646|NCT00722670|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU (substance abuse treatment only)
62113647|NCT06183918|ACTIVE_COMPARATOR|1. Group|Gauze soaked with 1000 mg TXA-topical
62113648|NCT06183918|ACTIVE_COMPARATOR|2. Group|Gauze soaked with 500 mg TXA + 5 cc saline -topical
62113649|NCT06183918|ACTIVE_COMPARATOR|3. Group|Gauze soaked with 10 cc of saline-topical.
62113650|NCT06552494|EXPERIMENTAL|The intervention group|"The intervention group will receive the L-mHealth program along with routine care, which includes the L-mHealth APP This app is complemented by an Online Community Support System and the LINE Instant Messaging Software."
62113651|NCT06552494|NO_INTERVENTION|The control group|The control group receiving care as usual alone.
62113652|NCT04344613|EXPERIMENTAL|Blood samples|
62113653|NCT02087644|EXPERIMENTAL|CYT003|Injections of CYT003
62674520|NCT03425370|EXPERIMENTAL|Wound Side A: tissue adhesive, Wound Side B: buried sutures|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
62113654|NCT02087644|PLACEBO_COMPARATOR|Placebo|Injections of placebo
62471908|NCT02352259|EXPERIMENTAL|Electrochemotherapy|
62471909|NCT02821247||Aflibercept|Adult wet Age Related Macular degeneration (AMD) treatment naïve partcipants were treated with intravitreal aflibercept injection
62113655|NCT04176367|EXPERIMENTAL|Test: Nicergoline manufactured in China|
62113656|NCT04176367|ACTIVE_COMPARATOR|Reference: Nicergoline manufactured in Italy|
62113657|NCT05826275|EXPERIMENTAL|Dose Escalation|To determine the MTD in patients with HPV-associated cancers
62471910|NCT04433611|EXPERIMENTAL|'lidocaine flushing' group|intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy
62113658|NCT05826275|EXPERIMENTAL|Dose Expansion|Dose Expansion Phase, in parallel one dose level lower than the highest dose deemed safe in Dose escalation with a PD-1 checkpoint blockade.
62113659|NCT01251354|EXPERIMENTAL|BN83495|
62471911|NCT04433611|PLACEBO_COMPARATOR|Placebo group|intrauterine infusion of 0.9 % normal saline (placebo group) just prior to HyFoSy.
62471912|NCT04810338||All patients received conventional dialysis treatment|All patients received conventional dialysis treatment during an observational period of 3 years
62471913|NCT04849650|EXPERIMENTAL|Renal Impairment Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
62471914|NCT04849650|EXPERIMENTAL|Healthy Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
61917437|NCT02099071|EXPERIMENTAL|Group 8|Six subjects will receive a single oral dose of ACT-389949 1000 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
61917438|NCT03917433|EXPERIMENTAL|Exposure with Tactile Feedback|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
61917439|NCT03917433|EXPERIMENTAL|Exposure with Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. The participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
61917440|NCT03917433|EXPERIMENTAL|Exposure with Tactile Feedback and Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world. Also, the participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
61917441|NCT03917433|OTHER|Virtual Reality Exposure Therapy Alone|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
61917442|NCT02853227||BCS|Photographs og consecutive group of 346 patients operated with breast conserving surgery were used to investigate cosmetic outcomes.
62113660|NCT03302741|ACTIVE_COMPARATOR|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
62113661|NCT03302741|EXPERIMENTAL|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
62113662|NCT06356116|ACTIVE_COMPARATOR|Usual care|Patients will receive the current usual care of the post-operative physical therapy following existing procedure.
62113663|NCT06356116|EXPERIMENTAL|Accelerated rehabilitation|Patients will have pre-operative education and quicker progress rehabilitation program, and combined with telerehabilitation until 4-week post-operation.
61917443|NCT02853227||DIEP|Photographs og consecutive group of 30 patients operated with DIEP-flap were used to assess cosmetic results
61917444|NCT05353140|EXPERIMENTAL|Percutaneous left atrial appendage occlusion (LAAO)|"Device: The WATCHMAN/WATCHMAN FLX device~Drug: Rivaroxaban 15 mg QD + Clopidogrel 75mg QD for 45 days, followed by Aspirin 100mg QD + Clopidogrel 75mg QD for 10.5 months after LAAO"
61917445|NCT05353140|ACTIVE_COMPARATOR|Novel oral anti-coagulation (NOAC)-based anti-thrombotic therapy|Drug: Rivaroxaban 15 mg QD + Clopidogrel 75mg QD for 12 months
61917446|NCT03558412|EXPERIMENTAL|Arm A|Decitabine+CODOX-M/IVAC for patients with relapsed or refractory T-lymphoblastic lymphoma who used Hyper-CVAD or BFM-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B.
62113664|NCT03285191||Subjects participating in the CE interview|Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
62113665|NCT03285191||Subjects participating in interview and real-time data capture|Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
62113666|NCT01792830|NO_INTERVENTION|Control HbA1c < 7%|Subjects not requiring coronary artery bypass graft surgery (CABG), with no history of diabetes with HbA1c \<7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.
62113667|NCT01792830|ACTIVE_COMPARATOR|Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of total daily hospital dose.
62113668|NCT01792830|ACTIVE_COMPARATOR|Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c 7%- 9% will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of total daily hospital dose or with basal bolus regimen at same inpatient total daily insulin dose.
62113669|NCT01792830|ACTIVE_COMPARATOR|No diabetes/ Metformin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c \<7% and persistent hyperglycemia requiring subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.
61917447|NCT02686190|EXPERIMENTAL|Luxtherapy|Luxtherapy exposition
61917448|NCT02686190|NO_INTERVENTION|Not luxtherapy|Not luxtherapy exposition
61917449|NCT04726098|ACTIVE_COMPARATOR|Low dose group|Dexamethasone 6mg/day for 10 days
61917450|NCT04726098|ACTIVE_COMPARATOR|High dose group|Dexamethasone 20mg/day for 5 days + Dexamethasone 10mg/day for 5 days (Total 10 days)
62113670|NCT01792830|ACTIVE_COMPARATOR|Diabetic/antidiabetic regimen|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c \<7% will be discharged on their same outpatient antidiabetic regimen. Subjects will receive one of the three treatment options based on their blood glucose levels: Metformin alone, both metformin and glargine insulin or glargine alone.
62674521|NCT03954938|SHAM_COMPARATOR|Neutral-Look|Subjects will be instructed to look at cocaine associated images and respond naturally.
62674522|NCT03954938|EXPERIMENTAL|Positive|Subjects will be instructed to look at cocaine associated images and anticipate the positive aspects of engaging with the items shown.
62113671|NCT01792830|ACTIVE_COMPARATOR|No diabetes/ Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c \<7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital.
62113672|NCT01792830|ACTIVE_COMPARATOR|Diabetes/Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with an admission HbA1c \>9% and persistent hyperglycemia will be given basal insulin (glargine) once daily, at the same time of the day and rapid-acting insulin (glulisine) before meals.
62113673|NCT04156724|EXPERIMENTAL|HV|6MWT with helmet ventilation
62113674|NCT04156724|NO_INTERVENTION|Control|6MWT alone according to ATS guideline
62113675|NCT01581736|EXPERIMENTAL|Exercise|Proteomics of muscle after a single bout of exercise compared to baseline with U100 Humulin infusion at rate of 80 milliunits(mU)/m\^2 surface area.
62113676|NCT06264648|EXPERIMENTAL|Manual Therapy using group|This group includes physiotherapists that using manual therapy techniques.
62113677|NCT06264648|EXPERIMENTAL|Non Manual Therapy using|This group includes physiotherapists using different techniques during working, not manual therapy
62113678|NCT01984554||Ferric Carboxymaltose (FCM)|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician.
62113679|NCT01984554||Iron Sucrose|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
62113680|NCT01984554||Iron Dextran|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
62113681|NCT01984554||Ferumoxytol|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
62113682|NCT01130558|ACTIVE_COMPARATOR|Ordering template and education|Internal medical residents who were asked to use the insulin order template and received education about basal-bolus insulin ordering.
62113683|NCT01130558|ACTIVE_COMPARATOR|Education|Internal medical residents who received education about basal-bolus insulin ordering.
62113684|NCT02696707|ACTIVE_COMPARATOR|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
62113685|NCT02696707|ACTIVE_COMPARATOR|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
62303181|NCT05446675||Rives-Stoppa, control|Thirty participants will be selected out of all patients who underwent an open Rives-Stoppa (midline repair with sublay mesh) in the investigators' center and who do not meet any of the exclusion criteria. Participant selection will consist of matching to participants in group 1 according to gender and age (e.g. a male participant in group 1 will be matched to a male participant (group 2) out of the investigators' records who underwent an open Rives-Stoppa repair and whose age most closely resembles the age of the matched participant in group 1).
62113686|NCT02614560|EXPERIMENTAL|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
62113687|NCT02614560|EXPERIMENTAL|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
62113688|NCT02698241|OTHER|Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
62113689|NCT02614118|ACTIVE_COMPARATOR|Ketorolac tromethanine|10 mg oral Ketorolac tromethanine 45 minutes before root canal treatment
62303182|NCT00628810|EXPERIMENTAL|FOLFIRI fort plus bevacizumab|Bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.
62113690|NCT02614118|ACTIVE_COMPARATOR|Acetaminphen & Ketorolac tromethamine|1000 mg Acetaminophen and 10 mg Ketorolac tromethamine oral 45 minutes before root canal treatment
62113691|NCT02614118|PLACEBO_COMPARATOR|Placebo|placebo 45 minutes before root canal treatment
62113692|NCT03125382|ACTIVE_COMPARATOR|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
62113693|NCT03125382|ACTIVE_COMPARATOR|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
62113694|NCT03125382|EXPERIMENTAL|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
62303183|NCT03652454|EXPERIMENTAL|micro-osteoperforation|Propel device (ABD) Micro-osteoperforations were performed in the keratinized tissue. Micro-osteoperforations were 1.5 mm in diameter and 3-7 mm in depth.
62303184|NCT03652454|OTHER|conventional treatment|conventional fixed appliance treatment
62303185|NCT02498652|EXPERIMENTAL|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
62674523|NCT03954938|ACTIVE_COMPARATOR|Negative|Subjects will be instructed to look at cocaine associated images and anticipate the negative aspects of engaging with the items shown.
62674524|NCT06500221|EXPERIMENTAL|Type 2 diabetes combined with sarcopenia|incentive spirometry intervention
62674525|NCT06500221|NO_INTERVENTION|Type 2 diabetes combined with sarcopenia control|Routine care.
62674526|NCT02137681|EXPERIMENTAL|2 cycles|2 cycles RTX
62674527|NCT02137681|ACTIVE_COMPARATOR|standard 4 cycles|standard 4 cycles RTX
62674528|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
62674529|NCT03061214|EXPERIMENTAL|Semaglutide 0.5 mg OW + sitagliptin placebo OD|
62674530|NCT03061214|EXPERIMENTAL|Semaglutide 1 mg OW + sitagliptin placebo OD|
62674531|NCT03061214|ACTIVE_COMPARATOR|Sitagliptin OD + semaglutide placebo 0.5 mg OW|
62674532|NCT03061214|ACTIVE_COMPARATOR|Sitagliptin OD + semaglutide placebo 1 mg OW|
62674533|NCT02635789|EXPERIMENTAL|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
62674534|NCT02635789|PLACEBO_COMPARATOR|Placebo gel|Placebo gel is matched ingredient with NPC-12G gel
62674535|NCT06237907||Patients underwent surgery|
62674536|NCT00002836|EXPERIMENTAL|Filgrastim + Chemotherapy|
62674537|NCT00002836|EXPERIMENTAL|Filgrastim|
62674538|NCT06469775|EXPERIMENTAL|LiSWT|men receiving LiSWT
62674539|NCT06469775|ACTIVE_COMPARATOR|Control|Standard of care: phosphodiesterase 5 inhibitor therapy, vacuum erectile device, constriction bands, intracorporal injections, penile implant.
62674540|NCT06035549|EXPERIMENTAL|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Resilience-Building intervention will be provided to East Asian immigrants with cancer and their family caregivers.
62674541|NCT05947955|EXPERIMENTAL|Rhu-pGSN Treatment|Subjects will receive rhu-pGSN 24 mg/kg once, followed by 5 daily doses of 12 mg/kg based on actual body weight in addition to standard care .
62113695|NCT03125382|EXPERIMENTAL|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
62113696|NCT02623868|EXPERIMENTAL|Group 1|A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
62113697|NCT02623868|EXPERIMENTAL|Group 2|B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
62674542|NCT05947955|PLACEBO_COMPARATOR|Normal Saline Placebo|Subjects will receive 6 doses of normal-saline placebo in volumes equivalent to subjects given rhu-pGSN in addition to standard care.
62113698|NCT02623868|EXPERIMENTAL|Group 3|C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
62674543|NCT04951063|EXPERIMENTAL|Split-course adaptive HRT-CHT|"In keeping the same total radiation dose (60Gy), we escalate the fraction dose to find the maximum tolerable fraction dose.~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course.~RT is delivered using the IMRT technique with daily cone-beam CT image guidance. The dose limitation of organ at risk (OAR) are shown in Table 1. Patients receive a weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT. Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT."
62113699|NCT02623868|EXPERIMENTAL|Group 4|A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
62113700|NCT02623868|EXPERIMENTAL|Group 5|B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
62113701|NCT02623868|EXPERIMENTAL|Group 6|C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
62674544|NCT05719597|EXPERIMENTAL|PEP (Positive Expiratory Pressure)|Group A
62674545|NCT05719597|EXPERIMENTAL|IS (Incentive Spirometry)|Group B
62674546|NCT06088446|ACTIVE_COMPARATOR|Supplementary Intrapulpal injection|Supplementary Intrapulpal injections were given using a 30-gauze needle with sufficient back pressure.
62113702|NCT00851240|EXPERIMENTAL|BTT1023|
62113703|NCT00851240|PLACEBO_COMPARATOR|Placebo|
62113704|NCT03259932|OTHER|usual management|
62113705|NCT03259932|EXPERIMENTAL|physical training|
62113706|NCT01351272|EXPERIMENTAL|methylphenidate, non-retard|
62113707|NCT01351272|PLACEBO_COMPARATOR|Placebo|
62113708|NCT02498158||experimental protocol|Functional neural connectivity at rest of 3 groups (heat tolerant, heat intolerant and healthy subjects) will be assessed using the anatomical and functional MRI scans and compared.
62113709|NCT03322332||NonDM-0|Nondiabetics without significant stenoses (\> 50%) in the coronary arteries
62674547|NCT06088446|ACTIVE_COMPARATOR|Intraligamentary injection|Intraligamentary injections were given using an intraligamentary syringe with back-pressure after a failed primary inferior alveolar nerve block.
62674548|NCT02845596|ACTIVE_COMPARATOR|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
62674549|NCT02845596|ACTIVE_COMPARATOR|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
62736108|NCT04786821|ACTIVE_COMPARATOR|Exoskeleton Exercise Programme|The Phoenix Exoskeleton suit will be used in this study. It is a powered Exoskeleton, with a modular design. Participants will receive interventions by an research physiotherapist based on the participant's tolerance.
62736109|NCT01074476|EXPERIMENTAL|1|Glucosamine sulphate tablets
62736110|NCT01074476|PLACEBO_COMPARATOR|2|Placebo tablets
62736111|NCT02679937|EXPERIMENTAL|Fit4Duty|6-week weight gain prevention group
62736112|NCT02679937|ACTIVE_COMPARATOR|Nutrition Education|Two, 50 minute educational videos.
62736113|NCT05606211||Long COVID|Individuals who have been infected with the corona virus and developed Long COVID
62303186|NCT02498652|EXPERIMENTAL|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
62303187|NCT05253521||South Asian Origin|Individuals who identify as having Anglo-Indian, Bangladeshi, Bengali, Bhutanese, Goan, Gujarati, Indian, Jatt, Kashmiri, Maharashtrian, Malayali, Nepali, Pakistani, Punjabi, Sindhi, Sinhalese, Sri Lankan, Tamil, Telugu, or other South Asian origin
62674550|NCT05808127|NO_INTERVENTION|Current Opioid Misuse Measure (COMM)|On a monthly basis, patients will receive the abbreviated Current Opioid Misuse Measure (COMM), a 6-item self-report screener to identify and monitor the risk of aberrant opioid-related behavior in chronic pain patients on opioid therapy. The COMM asks patients to report their behaviors over the past 30 days using a five-point Likert-type rating scale.
62674551|NCT05808127|EXPERIMENTAL|Current Opioid Misuse Measure (COMM) + PainTracker|On a monthly basis, patients will receive both the abbreviated Current Opioid Misuse Measure (COMM) and PainTracker. PainTracker tracks multiple outcomes relevant to the treatment of chronic pain: pain severity, general activity interference, enjoyment of life interference, sleep (initiating and maintaining), depression, and anxiety.
61917451|NCT02655146|EXPERIMENTAL|GnRHa protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 (Progynova) 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2.In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .A single dose of Triptorelin 0.1mg is administrated on the 3rd day after embryo implanted with routine luteal phase support.
62113710|NCT03322332||NonDM-L|Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)
62113711|NCT03322332||NonDM-R|Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
62113712|NCT03322332||NonDM-LR|Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
62113713|NCT03322332||DM-0|Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries
62113714|NCT03322332||DM-L|T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA
62113715|NCT03322332||DM-R|T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
62303188|NCT05253521||White Individuals of European Origin|Individuals who identify as having western European, other northern European, southern European, eastern European or other European origin
62303189|NCT03119649|EXPERIMENTAL|Cohort A: GLPG2222 50 mg once daily (QD)|Participants received a single GLPG2222 50 mg tablet and two matching placebo tablets orally, QD for 29 days.
62471915|NCT01116362|OTHER|secondary repair|secondary closure beyond the first week.the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
62674552|NCT04520451|EXPERIMENTAL|Rilzabrutinib + glucocorticoids|Rilzabrutinib tablets, 400 mg twice daily from Week 0 to Week 12 plus glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 2 weeks on study)
62674553|NCT04520451|ACTIVE_COMPARATOR|Glucocorticoids|Glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 12 weeks on study)
62113716|NCT03322332||DM-LR|T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
62113717|NCT00574743|NO_INTERVENTION|2|
62113718|NCT00574743|ACTIVE_COMPARATOR|1|
62113719|NCT02156609|EXPERIMENTAL|Percutaneous coronary intervention|Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention
62113720|NCT03680391||early postoperative feeding|103 patients will have early postoperative oral fluids and semisolid food after 6 hours of cesarean section irrespective to intestinal sounds ,flatus or stool passage
62113721|NCT03680391||Late postoperative feeding|97 patient will start oral fluids 6 hours with no solid or semi solid until after passage of flatus or stool
62113722|NCT04286529|ACTIVE_COMPARATOR|Men-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
62113723|NCT04286529|ACTIVE_COMPARATOR|Premenopausal Women-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
62113724|NCT04286529|PLACEBO_COMPARATOR|Men-Placebo|0.25mcg capsule daily for eight weeks
62113725|NCT04286529|PLACEBO_COMPARATOR|Premenopausal Women-Placebo|0.25mcg capsule daily for eight weeks
62303190|NCT03119649|EXPERIMENTAL|Cohort A: GLPG2222 100 mg QD|Participants received a single GLPG2222 100 mg tablet and two matching placebo tablets orally, QD for 29 days.
62303191|NCT03119649|EXPERIMENTAL|Cohort B: GLPG2222 200 mg QD|Participants received two GLPG2222 100 mg tablets and one matching placebo tablet orally, QD for 29 days.
62303192|NCT03119649|EXPERIMENTAL|Cohort B: GLPG2222 400 mg QD|Participants received two GLPG2222 150 mg tablets and one GLPG2222 100 mg tablet orally, QD for 29 days.
62303193|NCT03119649|PLACEBO_COMPARATOR|Cohort A Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
62303194|NCT03119649|PLACEBO_COMPARATOR|Cohort B Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
62303195|NCT04421651|EXPERIMENTAL|Treatment group|The participants in the treatment group were offered 20 Dance movement therapy sessions in addition to standard care.
62303196|NCT04421651|NO_INTERVENTION|Control group|Participants in the control group continued treatment as usual in the health services.
62303197|NCT04728945|EXPERIMENTAL|lung recruitment|Standard ventilatory management with lung recruitment every 30 minutes
62303198|NCT04728945|ACTIVE_COMPARATOR|control|Standard ventilatory management
62303199|NCT04954846|EXPERIMENTAL|OMNi-BiOTiC SR-9|Treatment is taken twice a day for 3 months
62471916|NCT01116362|OTHER|primary repair|during first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
62674554|NCT05625971||Myeloma Group|Patients with newly diagnosed and previously treated multiple myeloma will receive bone marrow sampling and functional imaging.
62113726|NCT04696341|EXPERIMENTAL|Matrix Rhythm Therapy|Group I (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound, conventional massage and Matrix Rhythm Therapy were applied. Home-based exercise program and recommendations were also given to patients.
62113727|NCT04696341|EXPERIMENTAL|Control|Group II (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound and conventional massage were applied. Home-based exercise program and recommendations were also given to patients.
62736114|NCT05606211||No Long COVID|Individuals who have been infected with the corona virus and fully recovered.
62113728|NCT02675920||High risk group of HCC|"known high risk group of HCC according to AASLD guideline. And patients whose risk index is equal to or higher than 2.33.~Risk Index = 1.65 (if the prothrombin activity is \<=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is \<=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus \[HCV\] or hepatitis B surface antigen \[HBsAg\] is positive).~Patients undergo ultrasonography and LDCT using non-ionic monomer iodinated CT contrast media biannually and the interval between ultrasound and LDCT is within 30 days."
62113729|NCT02196051|EXPERIMENTAL|Exercise Training|Participants engaged in a single bout of elliptical exercise for 45 minutes (3 times 15 minutes spaced by 5 minutes rest) at baseline. Subjects will be studied before and after this one bout to measure hepatic de novo lipogenesis. Hepatic de novo lipogenesis will be compared pre and post to examine whether acutely improving muscle glucose uptake will decrease hepatic de novo lipogenesis as the glucose is taken up by muscle and not directed to the liver.
62113730|NCT05928364|EXPERIMENTAL|Buccal mucosa graft for ureteral stricture|Patients with inclusion criteria of ureteral stricture will be treated with open ureteroplasty with buccal graft and omental wrapping.
62113731|NCT06537544|ACTIVE_COMPARATOR|Conventional Pelvic Floor Training|This group will receive pelvic floor muscle training exercises in supine, sitting , kneeling and standing position with gradual increase in frequency, dosage and duration of exercises.
62113732|NCT06537544|EXPERIMENTAL|Comprehensive Rehabilitation Program|This group will receive Core Strengthening Exercises, Breathing Exercises and education along with Pelvic Floor Muscle Strengthening Exercises
62113733|NCT05804604||Level of bone intake proteins and muscle atrophy marker in patients after proximal femur fracture|Open reduction of femoral neck or pertrochanteric fracture and preoperative analysis of bone intake proteins and muscle atrophy marker serum concentration
62113734|NCT05804604||Level of bone intake proteins and muscle atrophy marker in patients without proximal femur fracture|Control group without a history of proximal femur fracture. Analysis of the bone intake proteins and muscle atrophy marker serum level
62113735|NCT03259919|EXPERIMENTAL|Metformin|Metformin 850 mg x 2 daily
62113736|NCT03259919|PLACEBO_COMPARATOR|placebo|Placebo 1 tablet x 2 daily
62113737|NCT01983306|EXPERIMENTAL|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
62113738|NCT01983306|EXPERIMENTAL|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
62113739|NCT01983306|EXPERIMENTAL|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
62113740|NCT01983306|PLACEBO_COMPARATOR|Placebo|Placebo orally once daily for 4-week Treatment Period
62113741|NCT03488056|EXPERIMENTAL|Test - ICCMS|"The dentists will perform clinical examination on children following the ICCMS sequence:~The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
62113742|NCT03488056|ACTIVE_COMPARATOR|Control - Standard care SESC|"The clinical sequence in this group will be:~Caries Diagnosis Operative and non-operative treatments Indication of recall interval according to the dentist However, dentists will do that without a schematic guide to follow. They will do as they usually do in their practices."
62303200|NCT04954846|PLACEBO_COMPARATOR|Control|Placebo is taken twice a day for 3 months
62736115|NCT02397915|EXPERIMENTAL|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
62736116|NCT02397915|EXPERIMENTAL|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
62736117|NCT04002583|EXPERIMENTAL|Early-onset Alzheimer's disease (EOAD) subjects|Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
62736118|NCT03685903|EXPERIMENTAL|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
62736119|NCT01811524||Glioma and meningioma patientsl|Glioma and meningioma patients of Tampere University Hospital during the study period
62736120|NCT04234009|EXPERIMENTAL|Healthy lifestyle|Healthy lifestyle intervention, which includes physical activity and dietary advice according to the dutch guidelines.
62736121|NCT04234009|NO_INTERVENTION|Control|Maintenance of habitual physical activity and diet
62736122|NCT04279691||periodontitis and rheumatoid arthritis|group 1: patiernts with periodontitis and rheumatoid arthritis. only
62736123|NCT04279691||periodontitis|group 2: patiernts with periodontitis
62736124|NCT03982108|EXPERIMENTAL|Knotless suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knotless suture-bridge technique.
62674555|NCT02644811|EXPERIMENTAL|Group A - Miniscrews|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal). Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with miniscrews (Spider Screw K1 short neck). Miniscrews are placed buccally between the maxillary second premolar and the first molar after topical anesthesia (buccal) and injection (buccal). Miniscrews are placed when space closure starts. Space closure is performed as en masse retraction. Miniscrew are immediately loaded with 150g Nickel Titanium coil springs."
62674556|NCT02644811|ACTIVE_COMPARATOR|Group B - Molarblock|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal. Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with molarblocks - a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar. Molarblocks are installed from the beginning of leveling and alignment. Space closure is performed as en masse retraction with type one active tie-backs."
62674557|NCT04534725|EXPERIMENTAL|prophylaxis|"This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months.~Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections."
62674558|NCT04534725|EXPERIMENTAL|Post-Exposure Prophylaxis|"This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days~Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections."
62674559|NCT04534725|EXPERIMENTAL|Moderate COVID-19 infection|"This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks~Participants will be followed for 60 days to assess effectiveness and safety."
62674560|NCT04534725|EXPERIMENTAL|Severe COVID-19 infection|"This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.~Participants will be followed for 60 days to assess effectiveness and safety."
62674561|NCT01966497||Core study therapy|"* idarubicin for both induction and consolidation courses~* if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
62674562|NCT05611892||18F-FDS PET/CT|a single intravenous dose of 18F-FDS followed by PET/CT scan.
62674563|NCT03095976|EXPERIMENTAL|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
62674564|NCT04483232||Healthy Subjects|
62674565|NCT04483232||Patients with ear infections|
62674566|NCT05862441|EXPERIMENTAL|AV2-SA|100% AV2 (v/v) - 17% SA (w/v) treatment one drop daily and 10% AV2 (v/v) spray one puff weekly
62674567|NCT05862441|ACTIVE_COMPARATOR|SA|100% d-carvone (v/v) - 17% SA (w/v) treatment one drop daily and 10% d-carvone (v/v) spray one puff weekly
62113743|NCT04575285||Electroencephalogram (EEG)|All participants will undergo EEG recording at baseline and end of treatment for a duration of 10-20 minutes per session.
62113744|NCT00774436|EXPERIMENTAL|Patients scheduled to receive Focal Cryotherapy|After enrollment, patients will undergo a repeat transrectal ultrasound- guided prostate biopsy (minimum of 12 cores) to confirm the low-risk nature of their cancer. For study purposes, patients must meet the original entry crieteria on this repeat biopsy. If the patient meets the repeat-biopsy enrollment criteria, they will be treated with focal cryotherapy, meaning cryoablation of the regions of the prostate containing cancer. Efficacy is defined as all negative biopsy cores at the site of the focal ablation on a repeat transrectal biopsy 6 months after cryoablation. At baseline (prior to the re-staging biopsy), 3 months after focal cryotherapy, and at 6 months after focal cryotherapy (prior to the repeat prostate biopsy used to define efficacy), the patient will complete quality of life questionnaires as standard for all patients in the Urology Service.
62113745|NCT02289625|ACTIVE_COMPARATOR|Attentional performance in OSA|To investigate the attentional performance and muscle sympathetic nerve activity (MSNA) response during Color Word Stroop Test (CWST) in patients with obstructive sleep apnea (OSA) before and after intervention with exercise training.Individuals with no other comorbidities (age=52±1 years, body mass index=29±0.4) were divided in control (n=15) and untreated OSA (n=20) defined by polysomnography.
62303201|NCT01554202|EXPERIMENTAL|Young controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303202|NCT01554202|EXPERIMENTAL|Middle age controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303203|NCT01554202|EXPERIMENTAL|Elderly controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303204|NCT01554202|EXPERIMENTAL|Autosomal dominant forms of early-onset Alzheimer disease|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303205|NCT01554202|EXPERIMENTAL|Subjectif Cognitive Impariment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303206|NCT01554202|EXPERIMENTAL|Mild Cognitive Impairment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303207|NCT01554202|EXPERIMENTAL|Alzheimer Disease patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303208|NCT01554202|EXPERIMENTAL|Non degenerative amnsesic syndrome|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303209|NCT01554202|EXPERIMENTAL|Frontotemporal lobe dementia|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
62303210|NCT05290870||Subjects implanted with hydrophilic acrylic IOLs|Subjects were implanted with a HydroSmart IOL (FEMTIS, LENTIS or VISIOTIS)
62303211|NCT05290870||Subjects implanted with hydrophobic acrylic IOLs|Subjects were implanted with an ACUNEX IOL
62303212|NCT00930410|EXPERIMENTAL|endomicroscopy|Utilisation of an intra-ductal confocal endomicroscopy during the endoscopic Retrograde Cholangio-Pancreatography
62303213|NCT05243771||Rectal resection with diverting stoma|Patients operated for rectal cancer with rectal resection and diverting stoma.
62303214|NCT05243771||Rectal resection without diverting stoma|Patients operated for rectal cancer with rectal resection without diverting stoma.
62303215|NCT05243771||Rectal resection with primary colostomy|Patients operated for rectal cancer with rectal resection with primary colostomy.
62303216|NCT01158183||Group 1|No intervention
62303217|NCT03489213|ACTIVE_COMPARATOR|Arm I (DGA/AICR)|Patients receive DGA/AICR-based dietary intervention for 6 months consisting of 12 education sessions (60 minutes each) every other week. Lectures will take place in an urban garden where fruit, vegetable, and herb harvesting 1-2 times per week is encouraged. All participants will be given a FitBit and regular physical activity will be encouraged. Finally, remote health coaching is offered to all study subjects for the duration of the intervention (12 weeks).
62303218|NCT03489213|EXPERIMENTAL|Arm II (DGA/AICR plus Beef)|Patients receive the same intervention as in Arm I with the addition of 18 ounces of lean beef provided by the study to each subject. Subjects will be encouraged to consume the lean beef and lectures will incorporate healthy beef consumption into each lesson and cooking demonstration.
62113746|NCT02289625|ACTIVE_COMPARATOR|metaboreflex in OSA|"To investigate the metaboreflex control of MSNA before and after intervention with exercise training in patients with obstructive sleep apnea.~Methods: Thirty-five patients underwent conventional polysomnography. The MSNA was assessed by microneurography technique. Beat to beat blood pressure was measured during 4 minutes at rest, 3 minutes of isometric exercise at 30% maximal voluntary contraction, followed by 2 minutes of occlusion of the circulation in previously exercised muscle. The metaboreflex sensitivity was calculated during the first and second minutes of circulatory occlusion when metaboreceptors are evaluated independently of central command and muscle mechanoreceptors."
62113747|NCT00202969|EXPERIMENTAL|1|S-1
62113748|NCT00202969|ACTIVE_COMPARATOR|2|S-1 plus CDDP
62303219|NCT04942639|EXPERIMENTAL|Standard + JOE|Standard Maintenance Treatment plus JOE robot
62303220|NCT04942639|NO_INTERVENTION|Standard|Standard maintenance Treatment
62303221|NCT00921921|EXPERIMENTAL|Extra-fine particle steroid inhaler|
62303222|NCT00921921|PLACEBO_COMPARATOR|Placebo control|
62303223|NCT04278573|EXPERIMENTAL|Vitamin D3 Treatment Group|Subjects will receive a Vitamin D3 injection into their wart
62303224|NCT04278573|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive a placebo injection into their wart
62303225|NCT01272531||lithium|All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
62303226|NCT01272531||valproate|Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
62303227|NCT03166800|PLACEBO_COMPARATOR|Placebo|20 subjects will receive placebo.
62303228|NCT03166800|ACTIVE_COMPARATOR|20mg oral MitoQ|MitoQ is a potent antioxidant supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
62303229|NCT03166800|ACTIVE_COMPARATOR|40mg oral MitoQ|MitoQ is a potent antioxidant supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
62303230|NCT04087499|SHAM_COMPARATOR|regular medication treatment|regular medication treatment
62303231|NCT04087499|EXPERIMENTAL|acupuncture and regular medication treatment|acupuncture and regular medication treatment
62471917|NCT05345665|OTHER|Echography|For the neuronal blockade of the patient, anesthesiologists used an echography.
62113749|NCT00202969|ACTIVE_COMPARATOR|3|5-FU plus CDDP
62113750|NCT06121830|EXPERIMENTAL|DWP14012 20mg|Once daily with water regardless of meals without chewing or crushing for 4 weeks.
62113751|NCT06121830|EXPERIMENTAL|DWP14012 40mg|Once daily with water regardless of meals without chewing or crushing for 4 weeks.
62113752|NCT06121830|PLACEBO_COMPARATOR|Placebo|Once daily with water regardless of meals without chewing or crushing for 4 weeks.
62471918|NCT05345665|OTHER|Neurostimulation|For the neuronal blockade of the patient, anesthesiologists used neurostimulation.
62113753|NCT05161507||Non-palpable breast cancer lesion|Patients with the non-palpable histologically confirmed breast cancer lesion that will undergo breast-conserving surgery and sentinel lymph node detection - the tumor lesion will be labeled with Magseed.
62471919|NCT05345665|OTHER|Active mobilization|For the neuronal blockade of the patient, anesthesiologists used active mobilization.
62471920|NCT04263649||All subjects|patients who require a PICC
62674568|NCT02633631||Women seeking family planning services|Women seeking family planning and gynecological services will be enrolled in our study.
62113754|NCT05161507||Palpable breast cancer lesion|Patients with the palpable histologically confirmed breast cancer lesion that will undergo breast-conserving surgery and sentinel lymph node detection - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag.
62674569|NCT02388958||Women with GDM|
62674570|NCT02388958||Women without GDM|
62674571|NCT02015936|EXPERIMENTAL|Prescriped Physical Activity|Physical fitness evaluation followed by prescribed physical activity and progress reporting.
62674572|NCT05507892|EXPERIMENTAL|Treatment|Participants who will receive 100 mg of canagliflozin daily for six (6) months in addition to standard of care.
62674573|NCT06173843||Firefighters|
62674574|NCT06173843||Non-Firefighters|
62674575|NCT04674800|EXPERIMENTAL|Single, test arm|MYL-1701P- Subjects will receive 3 doses each of 2 mg at 8 weeks interval
62674576|NCT02325453||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
62674577|NCT02325453||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
62674578|NCT02325453||Open Surgery|Patients underwent gastric surgery with open approach.
62113755|NCT05161507||Axillary lymph node metastasis|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy.
62303232|NCT01570010|EXPERIMENTAL|Intervention group|The intervention group (n = 250) receives an intensive dietary intervention lasting for 12 months and a subsequent maintenance intervention for 14 years. Both groups are offered equal general advice of physical activity.
62303233|NCT01570010|OTHER|Control group|The control group (n = 250) receives no dietary intervention other than standard clinical care. Both groups are offered equal general advice of physical activity.
62674579|NCT03142451|EXPERIMENTAL|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
62674580|NCT03142451|PLACEBO_COMPARATOR|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
62113756|NCT06440824|EXPERIMENTAL|Romiplostim N01|
62113757|NCT06440824|ACTIVE_COMPARATOR|Recombinant Human Thrombopoietin|
62113758|NCT00002527|EXPERIMENTAL|Aspirin|325 mg/day PO
62303234|NCT05939284|ACTIVE_COMPARATOR|Group C|
62303235|NCT05939284|ACTIVE_COMPARATOR|Group S|
62303236|NCT05917743|EXPERIMENTAL|Mat Pilates|Mat Pilates exercises targeting core strength, flexibility, and muscle control
62303237|NCT05917743|ACTIVE_COMPARATOR|General Exercises|
62113759|NCT00002527|PLACEBO_COMPARATOR|Placebo|
62303238|NCT03250741|ACTIVE_COMPARATOR|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
62303239|NCT03250741|PLACEBO_COMPARATOR|Placebo|Placebo transdermal patches
62303240|NCT05596981||sorafenib group|FLT3-ITD+ AML patients who receive sorafenib maintenance therapy after Allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
62674581|NCT05199272|EXPERIMENTAL|Part A|Patients will receive escalating doses of 23ME-00610
62674582|NCT05199272|EXPERIMENTAL|Part B|Patients will receive the recommended dose(s) of 23ME-00610
62674583|NCT06253429|ACTIVE_COMPARATOR|Interventional arm|"including pediatric patients with diabetic nephropathy receiving oral alpha-lipoic acid daily.~The capsule of ALA ( Thiotex 300 mg capsule) contains 300 mg of thioctic acid, manufactured bt Marcyrl Pharmaceutical Industries - Egypt.) The patient will receive 1 capsule twice daily for 3 months. Patients' compliance to therapy will be checked by counting pills.~oral angiotensin-converting enzyme inhibitors (ACE-Is) captopril 25 mg tablet provided their blood pressure will be maintained within normal range for age"
62674584|NCT06253429|PLACEBO_COMPARATOR|Control Arm|including pediatric patients with diabetic nephropathy receiving placebo that is similar in appearance to the oral alpha-lipoic acid (Thiotex 300 mg capsule) and oral angiotensin-converting enzyme inhibitors (ACE-Is)(Captopril 25 mg tablet) provided their blood pressure will be maintained within normal range for age
62674585|NCT02537925|ACTIVE_COMPARATOR|concurrent_radiochemotherapy|Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
62674586|NCT02537925|EXPERIMENTAL|celecoxib_radiochemotherapy|Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
62674587|NCT06092580|EXPERIMENTAL|AWT020|Participants receiving intravenous infusion of AWT020
62674588|NCT06218433|EXPERIMENTAL|Screening arm|Invitation to participate in urothelial cancer screening and questionnaires
62674589|NCT04297267|EXPERIMENTAL|GP group|Patients should receive four cycles of GP regimen (cisplatin at 75 mg/m2 iv infusion on day 1 plus gemcitabine at 1250 mg/m2 iv infusion over 30 min on day 1 and 8 every 3 weeks).
62674590|NCT02610257|ACTIVE_COMPARATOR|Vibration Relevant|Vibration applied on the muscle belly after 'motor block' onset
62674591|NCT02610257|ACTIVE_COMPARATOR|Neutral Vibration Relevant|Vibration applied on a bony mark after 'motor block' onset
62113760|NCT05200247|EXPERIMENTAL|Spesolimab|
62113761|NCT04094155|EXPERIMENTAL|Retinal fundoscopy|Retinal vascular analysis by retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
62113762|NCT04106141|OTHER|control group|
62113763|NCT04106141|ACTIVE_COMPARATOR|intervention group|
62303241|NCT05596981||non-sorafenib group|FLT3-ITD+ AML patients who do not receive sorafenib maintenance therapy after Allo-HSCT.
62303242|NCT02869191||blood cultures|Admitted patients in critical care who need blood cultures
62303243|NCT02869191||blood cultures Getafe|Data collection of patients included in study
62674592|NCT02610257|ACTIVE_COMPARATOR|Neutral Vibration Non-Relevant|Vibration applied on a bony mark before 'motor block' onset
62303244|NCT03884634||Dabir Microsurface Overlay Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned ON (in addition to standard operating room table mattress and heating/cooling gel pad).
62471921|NCT04163354|ACTIVE_COMPARATOR|NaF varnish|Application of a 5% NaF varnish (Duraphat, Colgate-Palmolive Ltd, Waltrop, Germany) on the occlusal surfaces of primary second molars and all other teeth, every 3 months during the study period;
62113764|NCT02834871|OTHER|patients with cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients with cervical dystonia
62113765|NCT02834871|OTHER|patients without cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients without cervical dystonia
62113766|NCT00217672|EXPERIMENTAL|Bevacizumab + Docetaxel|"docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.~Bevacizumab: 15 mg/kg IV every 3 weeks. Subjects continue on study until disease progression, unacceptable toxicity, or withdrawal of patient consent."
62113767|NCT00217672|ACTIVE_COMPARATOR|docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
62113768|NCT02200341|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-Based Cognitive Therapy (MBCT) 8-week intervention
62303245|NCT03884634||Control Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned OFF (in addition to standard operating room table mattress and heating/cooling gel pad).
62303246|NCT03645291|ACTIVE_COMPARATOR|Skin test with local extract|Skin prick test and intradermal test with local stinging insect allergen extracts that develop in Immunological division of Siriraj hospital, mahidol University
62471922|NCT04163354|EXPERIMENTAL|GI sealant|Glass ionomer sealant (GC Fuji VII® (pink)) on all primary second molars included in the studies, with no further repair/replacement of the sealant
62471923|NCT00076817|EXPERIMENTAL|1|Participants will receive vaccine injections in the groin area or the upper arm
62471924|NCT00076817|PLACEBO_COMPARATOR|2|Participants will receive vaccine placebo injections in the groin area or the upper arm
62303247|NCT03645291|SHAM_COMPARATOR|Skin test with commercial extract|Skin prick test and intradermal test with commercial stinging insect allergen extracts that order from ALK company
62303248|NCT01486264|ACTIVE_COMPARATOR|Xeomin® Short Flex|short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
62113769|NCT02200341|ACTIVE_COMPARATOR|Progressive Relaxation Training - Psychoeducation|Progressive Relaxation Training and Psychoeducation (PRT-PsyEd) 8-week intervention
62303249|NCT01486264|ACTIVE_COMPARATOR|Xeomin® Long Flex|long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
62303250|NCT05080829|EXPERIMENTAL|Mutation Register|Measure of myeloid mutations after detection of relapse or refractoriness to ITK treatment
62303251|NCT02657239|EXPERIMENTAL|MOVE UP Intervention|Subjects will participate in a healthy lifestyle weight management intervention focused on healthy eating and increasing physical activity
62303252|NCT00077454|EXPERIMENTAL|Treatment (erlotinib hydrochloride, temozolomide)|Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
62471925|NCT04405765|ACTIVE_COMPARATOR|Lyopreserved Stravix|Treated with NPWT and lyopreserved Stravix
62471926|NCT04405765|ACTIVE_COMPARATOR|Cryopreserved Stravix|Treated with NPWT and cryopreserved Stravix
62471927|NCT02468284|EXPERIMENTAL|Degarelix|
62113770|NCT04662840|SHAM_COMPARATOR|Sham procedure|"The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. A script detailing the procedure verbally will be followed by the interventionalists to waste time, but the only actual medical act that will be done is freezing of the skin around the knee (as for nerve ablation procedure) and at the groin (as for embolization procedure). Dressings will be applied at the knee and groin area."
62303253|NCT06657066|EXPERIMENTAL|Intervention arm - Group A|"Standar Therapy- Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.~Along with Probiotics i.e Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii"
62303254|NCT06657066|PLACEBO_COMPARATOR|Control arm- Group B|"Standard therapy only:~Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram"
62303255|NCT03370146||TKA patients - Experimental Group|
62303256|NCT03370146||TKA patients - Control Group 1|
62303257|NCT03370146||Healthy subjects - Control Group 2|
62303258|NCT05888259|EXPERIMENTAL|foot insole, medication and wound care (study group)|"Pressure maps were recorded to calculate peak pressures and pressure-time integrals for (hindfoot, middle foot, hallux, medial forefoot, and lateral forefoot).~The measurements were uploaded to a server of software that uses technology to create a 3D model of the foot insole from multiple images taken by the user."
62303259|NCT05888259|ACTIVE_COMPARATOR|medication and wound care (control group)|participants will receive only medical treatments and wound care for the diabetic foot ulcer
62303260|NCT05460208|EXPERIMENTAL|Enriched spread|Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d)
62303261|NCT05460208|PLACEBO_COMPARATOR|Control spread|Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d)
62303262|NCT03552783|ACTIVE_COMPARATOR|Fathers for a Lifetime (FFL) only|The participants in the comparison arm will receive the standard, 12-week program curriculum of Father For a Lifetime.
62303263|NCT03552783|EXPERIMENTAL|FFL + Cognitive Behavioral Therapy|The participants in the intervention will receive will the standard, 12-week program curriculum of Father For a Lifetime and the Cognitive Behavioral Therapy. The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP). In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program.
62113771|NCT04662840|ACTIVE_COMPARATOR|Geniculate artery embolization|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee (as for the ablation procedure) and at the groin and in this group a geniculate artery embolization will be performed via an intraarterial access and use of embolization microspheres injected into the hypervascular arteries feeding the knee joint. Dressings will be applied at the knee and groin area.
62674593|NCT02610257|ACTIVE_COMPARATOR|Vibration Non-Relevant|Vibration applied on the muscle belly after 'motor block' onset
62674594|NCT02610257|NO_INTERVENTION|No Vibration|
62674595|NCT04559672||Laminoplasty Group|Patients who underwent cervical laminoplasty surgery due to myelopathy.
62674596|NCT04559672||Laminectomy and Fusion Group|Patients who underwent cervical laminectomy and fusion surgery due to myelopathy.
62674597|NCT03724097||Group 1|Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
62674598|NCT03724097||Group 2|Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
62303264|NCT02291341|EXPERIMENTAL|Duloxetine Delayed-Release Capsules, 60 mg|Duloxetine Delayed-Release Capsules, 60 mg of Dr. Reddys Laboratories Limited
62303265|NCT02291341|ACTIVE_COMPARATOR|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
62674599|NCT03724097||Group 3|Patients receiving palliative care
62303266|NCT04537442|EXPERIMENTAL|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
62303267|NCT01855230|EXPERIMENTAL|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
62303268|NCT01855230|PLACEBO_COMPARATOR|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
62303269|NCT00980083|PLACEBO_COMPARATOR|Placebo|
62303270|NCT00980083|ACTIVE_COMPARATOR|Exendin(9-39)|
62303271|NCT06254274|EXPERIMENTAL|RAY1225 (cohort 1)|Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks.
62303272|NCT06254274|PLACEBO_COMPARATOR|Placebo (cohort 1)|Participants received Placebo administered SC once two weeks for 24 weeks.
62303273|NCT06254274|EXPERIMENTAL|RAY1225 (cohort 2)|Escalating doses of RAY1225 administered subcutaneously (SC) once two week
62471928|NCT00772161|EXPERIMENTAL|Sequence 1|First treatment week (day 1 to day 7) 20mg Ritalin LA; second treatment week (day 8 to day 14) 20mg Medikinet retard.
62471929|NCT00772161|EXPERIMENTAL|Sequence 2|First treatment week (day 1 to day 7) 20mg Medikinet retard; second treatment week (day 8 to day 14) 20mg Ritalin LA.
62471930|NCT01900691|EXPERIMENTAL|Evolution® Esophageal Stent|
62471931|NCT00630149|EXPERIMENTAL|1|
62471932|NCT05439447||Patients scheduled for VFSS examination due to dysphagia.|
62471933|NCT01702987|PLACEBO_COMPARATOR|Statin + placebo|9 patients taking statin medications and placebo.
62471934|NCT01702987|ACTIVE_COMPARATOR|Statin + ubiquinol|12 patients on statins and ubiquinol
62471935|NCT04518059||Parkinsonism Group|Participants with Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)
62471936|NCT04518059||Control Group|Participants without parkinsonism
62471937|NCT04416451|EXPERIMENTAL|Rituximab and Venetoclax|Patients will be treated with an Induction phase of rituximab 375 mg/m2 weekly for 4 weeks. Patients will undergo restaging imaging after the last of 4 weekly rituximab doses and before beginning venetoclax. Based on post-rituximab restaging studies, patients will be risk-stratified for risk of Tumor Lysis Syndrome (TLS) and treated in the appropriate setting with TLS prophylaxis per institutional TLS guide lines starting at week 5. Oral venetoclax will follow a ramp-up dosing schedule and will be taken daily after 4 weeks of rituximab therapy. Following the 4-week ramped-up phase of venetoclax, patients will begin their target dose of venetoclax and continue for a maximum of 24 months. In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months. Venetoclax may be continued after this period if patient has not achieved a complete remission
62471938|NCT05063903||Fontan Group|"Fontan Group Inclusion Criteria~be between the ages of 8-50 Having undergone Fontan operation in our hospital or another center Clinical stability of the patients (preserved ventricular function), No change in ongoing drug therapy that adversely affects clinical stability, At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital~Fontan Group Exclusion Criteria:~Inability to access the patient's medical data Neurological and/or genetic musculoskeletal disease Having orthopedic and cognitive problems that prevent testing The patient's and/or family's unwillingness to participate in the study"
62471939|NCT05063903||Control Group|"Control Group Inclusion Criteria:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease Not having orthopedic and cognitive problems that prevent testing The patient's and/or family's willingness to participate in the study"
62471940|NCT00439634|PLACEBO_COMPARATOR|Placebo|
62471941|NCT00439634|EXPERIMENTAL|AVE1625 dose level 1|
62471942|NCT00439634|EXPERIMENTAL|AVE1625 dose level 2|
62471943|NCT00439634|EXPERIMENTAL|AVE1625 dose level 3|
62471944|NCT04150627|ACTIVE_COMPARATOR|deep breathing|
62471945|NCT04150627|NO_INTERVENTION|normal breathing|
62113772|NCT04662840|ACTIVE_COMPARATOR|Geniculate nerve ablation|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee and at the groin (as for the embolization procedure) and in this group a geniculate nerve ablation will be performed by advancing a radiofrequency ablation (RFA) needle at three locations alongside the tibia and femur where the nerves course and ablation performed. Dressings will be applied at the knee and groin area.
62113773|NCT00233519|EXPERIMENTAL|Cohort 1- Two Escalating Doses of Iplex|0.5 and 1.0 mg/kg/day
62674600|NCT00894647|PLACEBO_COMPARATOR|2|placebo cream in 250mg/packet, up to 2 packets applied daily
62113774|NCT00233519|ACTIVE_COMPARATOR|Cohort 2 - Three Escalating Doses of Iplex|0.5, 1.0, and 2.0 mg/kg/day
62113775|NCT02297880|EXPERIMENTAL|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners (flavour)
62471946|NCT01473953|EXPERIMENTAL|Cohort 1a: Lira-depot 2.25 mg|
62471947|NCT01473953|EXPERIMENTAL|Cohort 2a: Lira-depot 6.75 mg|
62471948|NCT01473953|EXPERIMENTAL|Cohort 3a: Lira-depot 15 mg|
62471949|NCT01473953|EXPERIMENTAL|Cohort 4a: Lira-depot 30 mg|
62471950|NCT01473953|PLACEBO_COMPARATOR|Placebo|
62471951|NCT06563011|OTHER|Dependent Sample|Before-after measurements will be made in the dependent sample.
62471952|NCT04658745|EXPERIMENTAL|iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
62674601|NCT00894647|ACTIVE_COMPARATOR|imiquimod cream|Imiquimod 3.75% cream, 250 mg single-use packets, up to 2 packets applied daily
62674602|NCT02417480|ACTIVE_COMPARATOR|Vegan arm|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. Researchers will ask participants on a vegan diet to follow their usual diet and exercise habits consistent for the two week study period.
62113776|NCT02297880|ACTIVE_COMPARATOR|Still water|Still water (no flavour)
62113777|NCT00819442|PLACEBO_COMPARATOR|1|patients without heart failure, with cardiobiopsy
62113778|NCT00819442|EXPERIMENTAL|2|patients with heart failure in NYHA class I, II
62113779|NCT00819442|EXPERIMENTAL|3|Patients with heart failure in NYHA class III, IV
62113780|NCT04012853|EXPERIMENTAL|treatment arm|tDCS treatment group
62113781|NCT04012853|NO_INTERVENTION|control arm|Sham tDCS
62113782|NCT00909363|EXPERIMENTAL|WAS patients receiving Promacta|Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
62113783|NCT00909363|EXPERIMENTAL|WAS patients for blood drawing only|WAS patients not receiving treatment to serve as subjects for platelet parameter studies blood drawing once only
62113784|NCT00909363|PLACEBO_COMPARATOR|healthy children for blood drawing only|healthy children having blood obtained once as controls for platelet parameters study
62113785|NCT05691660|EXPERIMENTAL|Single dose cohort|
62113786|NCT05691660|EXPERIMENTAL|Repeated dose cohort Once daily (QD)|
62113787|NCT05691660|EXPERIMENTAL|Repeated dose cohort Twice daily (BID)|
62113788|NCT04897737|EXPERIMENTAL|Intervention|HIV self-testing kits and counseling on use for participant and partner use + enhanced adherence counseling including urine tenofovir test to provide biofeedback in women using PrEP
62674603|NCT02417480|EXPERIMENTAL|Omnivorous arm|A diet containing all food groups. Researchers will ask participants on an omnivorous diet to follow habitual, usual diet and exercise habits for the first week. During the second week, participants will be asked to switch to a vegan diet for one week and to maintain their usual exercise habits.
62113789|NCT04897737|NO_INTERVENTION|Control|Standard of care intervention including facility based HIV testing, referral for partner to attend facility for testing, and PrEP adherence counseling without biofeedback
62113790|NCT04307316|EXPERIMENTAL|ACBT group|Active cycle breathing technique
62113791|NCT04307316|ACTIVE_COMPARATOR|Conventional treatment group|Conventional treatment group
62674604|NCT02105857|NO_INTERVENTION|Standard care|Patients receiving the standard rehabilitation protocol
62674605|NCT02105857|EXPERIMENTAL|grade A+ knee mobilization|Patients receiving the standard rehabilitation protocol plus grade A+ knee mobilization
62674606|NCT04774354||Abdominal surgery|POSSUM, the P-POSSUM and the Charlson comorbidity index will be calculated and compared to the outcomes obtained in our center.
62113792|NCT06556186|EXPERIMENTAL|Operation group|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
62113793|NCT06556186|ACTIVE_COMPARATOR|Drug group|Bromocriptin 2.5mg, 2-3 times a day
62113794|NCT00156117|EXPERIMENTAL|1|asenapine 5 mg BID and 10 mg BID
62113795|NCT00156117|PLACEBO_COMPARATOR|2|Placebo against olanzapine and asenapine
62113796|NCT00156117|ACTIVE_COMPARATOR|3|olanzapine 15 mgQD
62674607|NCT00949078|EXPERIMENTAL|Open Label Omalizumab Group A|Omalizumab was dosed according to package insert. Patients who have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
62674608|NCT00949078|EXPERIMENTAL|Open Label Omalizumab Group B|Omalizumab was dosed according to package insert. Patients who do not have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
62113797|NCT05442463||women|"Iohexol 5 ml IV push followed 10 ml IV flush of normal saline is administered to establish baseline GFR (glomerular filtration rate). FF (filtration fraction) is calculated as follows: GFR/RPF=FF. Captopril 25 mg is given orally.~Blood will be collected at specific time points, pulse wave velocity testing 3 times throughout morning, Holter monitor and bioelectrical impedance testing."
62113798|NCT05442463||men|"Iohexol 5 ml IV push followed 10 ml IV flush of normal saline is administered to establish baseline GFR (glomerular filtration rate). FF (filtration fraction) is calculated as follows: GFR/RPF=FF. Captopril 25 mg is given orally.~Blood will be collected at specific time points, pulse wave velocity testing 3 times throughout morning, Holter monitor and bioelectrical impedance testing."
62113799|NCT01091298|EXPERIMENTAL|Group 1|
62113800|NCT01091298|PLACEBO_COMPARATOR|Group 2|
62113801|NCT02026258|ACTIVE_COMPARATOR|Orthodontics no piezocision|Subjects will have orthodontic treatment without corticision with piezotome. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
62113802|NCT02026258|EXPERIMENTAL|Orthodontics with piezotome corticision|Subjects receiving orthodontic treatment in conjunction with piezotome-corticision. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
62113803|NCT03806751|EXPERIMENTAL|[O-15]water PET/MRI|Volunteers will have two brain PET/MRI scans; first scan after injection of \[O-15\]water; second scan after injection of 1 gram of acetazolamide followed by injection of \[O-15\]water.
62113804|NCT06409988||Patients with lower gastrointestinal bleeding|Any \>18 years old patient admitted to our hospital due to a lower gastrointestinal bleeding episode.
62736125|NCT03982108|ACTIVE_COMPARATOR|Knot-tying suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knot-tying suture-bridge technique.
62113805|NCT05563246|EXPERIMENTAL|LY3473329 Dose 1|Participants will receive LY3473329 orally.
62113806|NCT05563246|EXPERIMENTAL|LY3473329 Dose 2|Participants will receive LY3473329 orally.
61917452|NCT02655146|OTHER|routine luteal phase protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2. In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .
61917453|NCT02586883|EXPERIMENTAL|Patients with multiple bronchi dilations|
61917454|NCT02586883|ACTIVE_COMPARATOR|Control patients without transport abnormality|
61917455|NCT02586883|ACTIVE_COMPARATOR|Patients with typical cystic fibrosis|
62113807|NCT05563246|EXPERIMENTAL|LY3473329 Dose 3|Participants will receive LY3473329 orally.
62113808|NCT05563246|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally.
62113809|NCT02740530|EXPERIMENTAL|rTMS Active|High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.
61917456|NCT00332371|EXPERIMENTAL|1|
61917457|NCT00332371|NO_INTERVENTION|2|
61917458|NCT03973801|EXPERIMENTAL|Auricular acupressure|
61917459|NCT04485429|EXPERIMENTAL|Methylprednisolone + Standard treatment|Participants will receive the standard treatment and methylprednisolone.
61917460|NCT04485429|EXPERIMENTAL|Full-dose heparin + Standard treatment|Participants will receive the standard treatment and full-dose heparin,
62674609|NCT03907956|EXPERIMENTAL|INTERVENTION|The subjects included in the intervention group will be treated with Dry Needling with Fascial Winding Technique according to the original Four-Pole Carpal Dry Needling approach, which has already been validated recently by means of a first ultrasound study.
61917461|NCT04485429|EXPERIMENTAL|Methylprednisolone + Full-dose heparin + Standard treatment|Participants will receive the standard treatment, methylprednisolone and full-dose heparin
61917462|NCT04485429|NO_INTERVENTION|Standard treatment|Participants will receive the standard treatment
61917463|NCT05279404|EXPERIMENTAL|Group A - electroacupuncture|"electroacupuncture group Insert stainless steel acupuncture needles into Neiguan (cathode) and Jianshi (anode) on both sides and twist the needles.~After that, the electroacupuncture machine was connected and 2 Hz electrical stimulation was administered for 30 minutes.~The stimulation intensity was mainly based on slight muscle contractions and no pain in the subjects. At this time, cardiac function and electrogastrogram were recorded at the same time."
61917464|NCT05279404|SHAM_COMPARATOR|Group B - Sham electroacupuncture|Sham electroacupuncture group The method was the same as that of the electroacupuncture group, but the needles were only acupuncture under the skin of Neiguan and Jianshi without twisting the needles. The electroacupuncture machine was connected but no electrical stimulation was administered.
61917465|NCT05451927|EXPERIMENTAL|Phaseolus Vulgaris|Three oral doses of 1000 mg Phaseolus Vulgaris daily for 3 months
62113810|NCT02740530|PLACEBO_COMPARATOR|rTMS Sham|Sham stimulation will also involve delivering the same stimulus but with angulation of the coil at 45 degrees, which will give similar scalp sensation but unlikely to deliver magnetic stimulation to the cortex
62113811|NCT01692054||Alcohol intoxicated adolescents|Adolescents who were hospitalized due to acute alcohol intoxication
62113812|NCT01692054||Control group|adolescents who were hospitalized due to other medical conditions but not alcohol intoxication
62113813|NCT02016131||none endoleak events|Patients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
62113814|NCT02016131||Endoleak events|Patients who undergo endoleaks related adverse events or persistent endoleaks during follow up.
62113815|NCT02315391|EXPERIMENTAL|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine
62113816|NCT02315391|EXPERIMENTAL|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine
61917466|NCT05451927|PLACEBO_COMPARATOR|Placebo|Three oral doses of Placebo daily for 3 months
61917467|NCT02019901|NO_INTERVENTION|Regular care|"The control-group is treated according to care as usual with visits to physician every 6th month."
61917468|NCT02019901|EXPERIMENTAL|Nurse-led clinic|Nurse-led visits every 6th week, with structured person-centered care and evaluation of disease activity. If disease remission is not reached, pharmacological treatment including both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs and biologics) is modified according to a predefined algorithm.
62674610|NCT03907956|NO_INTERVENTION|CONTROL|The individuals of the control group will remain within the normal course of their waiting list status for CTS surgery, without receiving any extraordinary treatment to what is normally practiced in this situation.
62674611|NCT00400088|EXPERIMENTAL|lithium group|Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
62113817|NCT02315391|EXPERIMENTAL|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline
62113818|NCT04637152|NO_INTERVENTION|Group A: Usual recommended therapy|Antihypertensive regimen based on the usual recommended (optimized) therapy.
62113819|NCT04637152|EXPERIMENTAL|Group B: Sacubitril/Valsartan|Suspension of ACE inhibitors - for at least 36h of the last dose - or ARB. Initial dosage: Sacubitril/valsartan 49mg/51mg, 1 tablet twice daily. Target dose (after two weeks): 97mg/103 mg, 1 tablet twice daily.
62113820|NCT05074615|EXPERIMENTAL|Cranio-Cervical Flexion Training Group|"Participants of this group will receive conventional training along with cranio-cervical flexion training and home plan.~Cranio-cervical flexion training will be given with the help of pressure biofeedback unit. the cuff will be inflated at a specific pressure level and patient will be asked to maintain that pressure and gradually increase it."
62113821|NCT05074615|ACTIVE_COMPARATOR|Conventional Therapy Group|Participants of this group will receive only conventional therapy and home plan will be given which includes; hot pack, TENS, neck isometrics and passive stretching of neck musculature. Home plan will include self-stretches and neck isometrics.
62113822|NCT03073499|EXPERIMENTAL|Intervention|(Partial) Oncological Home Hospitalization
62113823|NCT03073499|NO_INTERVENTION|Control|Standard oncological treatment at the hospital day care unit
62113824|NCT03885596|EXPERIMENTAL|CA-008 Cohort 1|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block."
62113825|NCT03885596|EXPERIMENTAL|CA-008 Cohort 2|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
62113826|NCT03885596|EXPERIMENTAL|CA-008 Cohort 3|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
62113827|NCT03885596|ACTIVE_COMPARATOR|Exparel|"106 mg \[8 mL of the 133 mg/10 mL suspension\] only~All subjects received monitored anesthesia care (MAC) and a Mayo block."
62471953|NCT04658745|SHAM_COMPARATOR|Sham iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere, but with a sham coil (i.e., sham iTBS). After the sham stimulation, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
62674612|NCT00400088|ACTIVE_COMPARATOR|paroxetine group|Start dose at 20 mg po od. If no clinical improvement(\<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
62674613|NCT05667402|EXPERIMENTAL|TBF group|The subjects receive TBF conditioning regimen.
62113828|NCT00576888||Vascular Anomaly with Coagulopathy|All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) or with a vascular anomaly with coagulopathy
62113829|NCT05839938|EXPERIMENTAL|Treatment group|Vitamin D (2000IU/day) for 6 months
62113830|NCT05839938|PLACEBO_COMPARATOR|Control group|placebo
62113831|NCT01425437||Patients with keloid|All patients will have a clinical diagnosis of keloid and will consent to participate in this study.
62113832|NCT06381895||1|Sun Yat-sen Memorial Hospital cohort
62113833|NCT06381895||2|Third Affiliated Hospital of Sun Yat-sen University cohort
62113834|NCT06381895||3|Sun Yat-sen University Cancer Center cohort
62113835|NCT03522519||Assessment of real world performance|
62113836|NCT05587309|EXPERIMENTAL|Healing Phase - BLI5100|During the Healing Phase, patients will take BLI5100 once daily, orally, for up to 8 weeks.
62113837|NCT05587309|ACTIVE_COMPARATOR|Healing Phase - PPI Control|During the Healing Phase, patients will take a PPI control once daily, orally, for up to 8 weeks.
62113838|NCT05587309|EXPERIMENTAL|Maintenance Phase - BLI5100 Low Dose|During the Maintenance Phase, patients will take BLI5100 low dose once daily, orally, for 24 weeks.
62674614|NCT05667402|ACTIVE_COMPARATOR|Modified BuCY2 group|The subjects receive modified BuCY2 conditioning regimen.
62674615|NCT06274476|EXPERIMENTAL|maxillary atrophic ridge|received ridge splitting done by piezo surgery and implant placement in maxillary arch
62674616|NCT06274476|ACTIVE_COMPARATOR|mandibular atrophic ridge|received ridge splitting done by saw technique using ridge expanders and implant placement in maxillary arch
62674617|NCT01289587|EXPERIMENTAL|Alternative frequency variant|An alternative variant of the DIAfit program (progressive increase of the number of administered PA sessions per week, namely one PA session per week during 4 weeks and then twice a week over a period of 16 weeks)
62674618|NCT01289587|ACTIVE_COMPARATOR|Standard frequency program|Standard usual program (3 times per week over a period of 12 weeks)
62674619|NCT02716142|EXPERIMENTAL|Group A|rectal misoprostol 400 microgram
62674620|NCT02716142|ACTIVE_COMPARATOR|Group B|sublingual misoprostol 400 microgram
62113839|NCT05587309|EXPERIMENTAL|Maintenance Phase - BLI5100 High Dose|During the Maintenance Phase, patients will take BLI5100 high dose once daily, orally, for 24 weeks.
62113840|NCT05587309|ACTIVE_COMPARATOR|Maintenance Phase - PPI Control|During the Maintenance Phase, patients will take a PPI control once daily, orally, for 24 weeks.
62113841|NCT01335932|EXPERIMENTAL|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by either IV ganciclovir or oral valganciclovir once daily until hospital discharge
62674621|NCT00370604|EXPERIMENTAL|1|19g needle, 23g catheter
62674622|NCT00370604|ACTIVE_COMPARATOR|2|traditional =\>18g needle
62113842|NCT01335932|PLACEBO_COMPARATOR|Placebo|normal saline IV twice daily for 5 days, then followed by either IV normal saline or oral placebo once daily until hospital discharge
62113843|NCT06555146|OTHER|Randomized to start with Semaglutide intervention in study period 1|Placebo will be given in study period 2
62113844|NCT06555146|OTHER|Randomized to start with Placebo intervention in study period 1|Semaglutide will be given in study period 2
62113845|NCT00775242|EXPERIMENTAL|Estradiol and progesterone injection|Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P
62303274|NCT06254274|PLACEBO_COMPARATOR|Placebo (cohort 2)|Participants received Placebo administered SC once two week
62303275|NCT04813510|EXPERIMENTAL|electroacupuncture treatment|"Participants in the treatment group underwent 30 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment."
62303276|NCT04813510|SHAM_COMPARATOR|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
62303277|NCT05784090||AD|Alzheimer's Disease
62303278|NCT05784090||NON AD|Non Alzheimer's Disease
62674623|NCT02802085||Knee Arthroplasty|Vega Knee Arthroplasty
62674624|NCT04717180|ACTIVE_COMPARATOR|group I|patients who received rehabilitation using the software program for aphasia rehabilitation
62674625|NCT04717180|ACTIVE_COMPARATOR|group II|patients who received rehabilitation using the conventional therapy
62113846|NCT02401919|EXPERIMENTAL|Tell-us Card Intervention|Patients in the experimental arm will receive a Tell-us Card on a daily basis during their stay in the hospital. With this card patients are invited to state what is important to them for that day or before discharge from the ward.
62674626|NCT04202783|EXPERIMENTAL|Treatment of Craniofacial Neuralgia|All patients will receive the same amount (5mL concentrated) of exosomes delivered via ultrasound-guided, regional epineural injection and the same amount (5mL unconcentrated) delivered via IV. Patients will be given 3 mL of the exosome product intravenously, which contains about 45mg of the exosome product containing 15-21 million neonatal stem cell products, and 3 mL of the exosome hyperconcentrate product delivered epineurally using ultrasound guidance, which contains about 15mg of the exosome product carrying 5-7 million neonatal stem cell products.
62113847|NCT02401919|NO_INTERVENTION|Care as usual|In the control arm, patients will receive care as usual.
62303279|NCT05784090||CT|Controls
62303280|NCT03030040|EXPERIMENTAL|MBCT-SH|MBCT-SH will be an unguided, mindfulness-based cognitive therapy, book-based self-help intervention.
62674627|NCT01289535|EXPERIMENTAL|antibody rates|
62303281|NCT03030040|NO_INTERVENTION|Control|A wait list control group who will receive no intervention during the 21 weeks of the study. Control participants will be provided with the self-help book that the MBCT-SH group received after week 21.
62303282|NCT05881993|EXPERIMENTAL|CBP-4888|CBP-4888 administered once as a subcutaneous dose.
62303283|NCT05881993|PLACEBO_COMPARATOR|Placebo|Normal Saline administered once as a subcutaneous dose.
62303284|NCT00686751|EXPERIMENTAL|A|"There is only one arm in this study. Each subject will be studied through 3 phases lasting a total of 4 weeks:~Phase 1: administration of study medication at the end of hemodialysis treatment.~Phase 2: no administration of study medication. Phase 3: administration of study medication at the beginning of hemodialysis."
62674628|NCT04738669|NO_INTERVENTION|Control Arm|No intervention is being conducted in this arm. Routine care is being given to these patients. The patients will be followed up for any readmissions during the intervention period.
61917469|NCT04043390|EXPERIMENTAL|CRP and Xpert ULTRA MTB/RIF|Scheme 1 will screen all patients for HIV using rapid tests routinely used by the clinics and a rapid CRP. Patients with CRP \>10 will be further tested using Xpert ULTRA. Individuals with HIV will undergo an HIV VL using Xpert HIV-1 VL.
61917470|NCT04043390|EXPERIMENTAL|CRP and Molbio Truenat MTB|Scheme 2 will screen individuals for HIV and CRP (as in scheme 1) and patients with CRP \>10 will be tested using Molbio Truenat MTB. Individuals with HIV will undergo an HIV VL using Molbio Truenat HIV-VL and individuals with Truenat MTB-positive samples wil be tested with Truenat MTB RIF.
61917471|NCT04043390|NO_INTERVENTION|standard test Xpert|All patients receiving in scheme 1 and scheme 2 will be tested using the standard tests used in the study context. These are rapid HIV tests, Xpert MTB/RIF and culture.
61917472|NCT02973633|ACTIVE_COMPARATOR|Healthy Volunteers|DTI will be performed in healthy volunteers to characterize normal fiber architecture in the heart and provide a comparison group for the patients imaged in the other arms.
61917473|NCT02973633|ACTIVE_COMPARATOR|Patients with Recent Myocardial Infarction|Patients with recent ST elevation myocardial infarcts will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with remodeling of the left ventricle.
61917474|NCT02973633|ACTIVE_COMPARATOR|Patients with Left Ventricular Hypertrophy|Patients with left ventricular hypertrophy and a history of heart failure will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with the onset and progression of heart failure.
61917475|NCT03103815|EXPERIMENTAL|experimental group|Experimental group will receive Amivita.
61917476|NCT01778179|ACTIVE_COMPARATOR|Group 1|"Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) plus sunscreen for 2 weeks. At week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (From Week 2 up to Week 13)~* Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~* Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~The investigational drug (Tri-Luma® cream) plus sunscreen will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
61917477|NCT01778179|PLACEBO_COMPARATOR|Group 2|"Subjects (group 2) will be treated daily for their solar lentigines with sunscreen alone for 2 weeks. At week 2, all the subjects will have the solar lentigines will treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (Week 2 up to Week 13)~* Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~* Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~Sunscreen alone will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
62113848|NCT03109704|EXPERIMENTAL|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
62113849|NCT03109704|EXPERIMENTAL|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
62113850|NCT03109704|SHAM_COMPARATOR|Sham manipulation|The sham manipulation will be performed two times.
62113851|NCT04018508|EXPERIMENTAL|Massages|During routine clinic visits, subjects will receive a total of six 30-minute massages (one massage per week for 4 weeks, then one massage every two weeks for 4 weeks).
62113852|NCT04018508|NO_INTERVENTION|Control|Subjects randomized to the control arm will also attend routine clinic visits at the same pre-prescribed intervals (one clinic visit per for 4 weeks, then one visit every two weeks for 4 weeks).
62113853|NCT04788433||ROCCO-A (A-symptomatic)|Patients with documented COVID-19 infection and NO symptoms
62113854|NCT04788433||ROCCO-P (Pauci-symptomatic)|Patients with documented COVID-19 infection and mild symptoms but NO oxygen support)
62113855|NCT04788433||ROCCO-L (mild)|Patients with documented COVID-19 infection and mild severity - requiring OXIGEN SUPPORT
62303285|NCT01462513|EXPERIMENTAL|L-BLP25|L-BLP25 treatment
62113856|NCT04788433||ROCCO-M (moderate)|Patients with documented COVID-19 infection and moderate severity - requiring OXIGEN SUPPORT by NON-INVASIVE modalities
62303286|NCT01462513|PLACEBO_COMPARATOR|Placebo|Placebo
62303287|NCT00575679|EXPERIMENTAL|1|Brief motivational interview
62303288|NCT00575679|NO_INTERVENTION|2|No discussion
62303289|NCT05158348|ACTIVE_COMPARATOR|Group A|receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine.
62113857|NCT04788433||ROCCO-S(severe)|Patients with documented COVID-19 infection and severe disease requiring INVASIVE VENTILATION OR EXTRACORPOREAL MEMBRANE OXYGENATION
62113858|NCT02657629|ACTIVE_COMPARATOR|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
62303290|NCT05158348|ACTIVE_COMPARATOR|Group B|receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine
62303291|NCT05158348|ACTIVE_COMPARATOR|Group C|receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
62303292|NCT03328819|EXPERIMENTAL|Acupuncture for Depression/Acupuncture for pain|The computer-generated permuted block randomization was used so that the participating patients were randomly assigned on an exactly 1:1 ratio to either the depression-pain group, in which the depression-specific acupoints were first targeted (12 sessions over six weeks), followed by the pain-specific acupoints (12 sessions over six weeks)
62471954|NCT04658745|SHAM_COMPARATOR|iTBS to the ipsilesional primary motor cortex plus sham mirror therapy|"iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time, but with a covered mirror (e.g., sham mirror therapy).~In the sham mirror therapy condition, the mirror is covered by a cloth and the participant is instructed to move both arms while looking at a cross mark on the covered mirror and imaging the analogous movements of the affected arm. The movement practice will involve 5 table-top tasks (same as mirror therapy) and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes."
62471955|NCT02286739|SHAM_COMPARATOR|Group A TKA without VERASENSE|Patients who undergo primary posterior cruciate ligament (PCL)-retaining or - sacrificing TKA without the use of VERASENSE to guide rotational alignment and balance.
62471956|NCT02286739|ACTIVE_COMPARATOR|Group B TKA with VERASENSE|Patients who undergo primary PCL-retaining or - sacrificing TKA with the use of VERASENSE to guide rotational alignment and balance.
62674629|NCT04738669|EXPERIMENTAL|mHealth Arm|"This arm will receive first receive weekly telephone call followed by the SMS in Urdu regarding medication adherence according to the discharge instructions.~The calls and SMS will be sent on 7, 14, 21 and 30th day post-index discharge. The patients will be followed up for any readmissions during the intervention period."
62674630|NCT04738669|EXPERIMENTAL|Teach back arm|"The trained doctors thoroughly explained the discharge instructions, medication schedule and any other self-care instructions to these participants and asked them to repeat what they have understood from the doctor verbal counselling.~If the instructions were not clearly comprehended by the patients, then the same would be repeated by the consultant doctor.~The patients will be followed up for any readmissions during the intervention period."
62113859|NCT02657629|ACTIVE_COMPARATOR|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
62113860|NCT03631537|EXPERIMENTAL|NST group|Nutrition support team gives the dietary supplement or other nutritional support during the period of chemotherapy
62303293|NCT03328819|EXPERIMENTAL|Acupuncture for pain/Acupuncture for Depression|The computer-generated permuted block randomization was used so that the participating patients were randomly assigned on an exactly 1:1 ratio to either the depression-pain group, in which the pain-specific acupoints (six weeks 12 sessions) were first targeted followed by the depression-specific acupoints (six weeks 12 sessions).
62303294|NCT02760628|EXPERIMENTAL|The First Twenty (TF20)|Participants in TF20 will be provided an online wellness program focused on fitness and nutrition tailored to firefighters. TF20 is interactive and involves health coaching.
62471957|NCT03928691||Study group|pregnant women admitted to Women's Health Hospital , Assiut university during 2019-2020 will be counseled to participate in the study
62674631|NCT01895179|EXPERIMENTAL|Time-Restricted Feeding (early in the day eating)|Participants will consume all meals early in the day and within a 6-hour window.
62674632|NCT01895179|PLACEBO_COMPARATOR|Grazing|Participants will eat meals spread out over the course of the day.
62674633|NCT01296113|EXPERIMENTAL|A|
62113861|NCT03631537|NO_INTERVENTION|routine group|clinicians decide whether to give and how to give the dietary supplement and other nutritional support
62113862|NCT01752465|ACTIVE_COMPARATOR|Standard Care|Patients in the standard care group will receive standard clinical care from their attending psychiatrist, including pharmacotherapy and education. Study assessments will be done at baseline, and once a month thereafter at Months 1, 2, 3, and 6.
62113863|NCT01752465|EXPERIMENTAL|Health Coaching|Patients in the Health Coaching group will receive both Health Coaching, and standard care. In addition to routine clinical appointments, patients receiving Health Coaching will attend Health Coaching sessions twice a month during Months 1, 2, and 3, and once a month during Months 4, 5, and 6. Study assessments will be conducted at baseline, and once a month thereafter during Health Coaching sessions at Months 1, 2, 3, and 6.
62113864|NCT03061474|EXPERIMENTAL|Nicotinamide|1500mg twice daily: 2, 750mg tablets taken orally twice daily
62113865|NCT03061474|PLACEBO_COMPARATOR|Placebo|1500mg twice daily: 2, 750mg tablets taken orally twice daily
61917478|NCT04787081|EXPERIMENTAL|Sleep Care Positioning Training Program GRP1|A sleep care positioning lesson created by a University's postural-care scholars using Camtasia® video creation software with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of interactive videos embedded with learning checkpoints. All videos included narration and closed captioning. The following link contains the videos which were modified post-study to reflect some of the participant's feedback: https://stkatentpc.weebly.com/
62113866|NCT03439124|EXPERIMENTAL|Ceftobiprole medocaril|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
62113867|NCT03439124|ACTIVE_COMPARATOR|IV standard-of-care cephalosporin|"Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
62471958|NCT06358053|EXPERIMENTAL|CRTE7A2-01 TCR-T cell therapy|This study is a single-arm Phase I study, encompassing both dose escalation and dose expansion phases. Patients will undergo lymphocytapheresis, then treatment with TCR-T cell (at escalating doses) + IL-2
62471959|NCT00822822||A|Health History Process
62471960|NCT01746485|EXPERIMENTAL|UT-15C|
62471961|NCT00658762|EXPERIMENTAL|PD 0332334 225 mg BID|
62471962|NCT00658762|EXPERIMENTAL|PD 0332334 300 mg BID|
62471963|NCT00658762|ACTIVE_COMPARATOR|Paroxetine 20 mg q am|
62674634|NCT01558375|PLACEBO_COMPARATOR|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
61917479|NCT04787081|ACTIVE_COMPARATOR|Sleep Care Positioning Training Program GRP2|A sleep care positioning lesson created by a research assistant along with the principal investigator with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of primarily written summary statements and links to freely available web-based information. Most of this lesson's modules included written information that the participant would need to read with the exception of the positioning methods modules. For the positioning module, participants were provided with links to manufacturers' websites which contained video clips on how to place postural supports.
61917480|NCT00976118|PLACEBO_COMPARATOR|placebo|
61917481|NCT00976118|EXPERIMENTAL|oral masitinib (AB1010)|masitinib (AB1010) 3 or 6 mg/kg/day
61917482|NCT05245279|EXPERIMENTAL|Normal placenta-entitle|The 3-DPD indices was measured in the entire placenta volume.
61917483|NCT05245279|EXPERIMENTAL|Normal placenta-sonobyopsy|The 3-DPD indices was measured at cord insertion in placenta by sonobiopsy
61917484|NCT00812487|EXPERIMENTAL|Intravenous insulin|
61917485|NCT00812487|ACTIVE_COMPARATOR|Subcutaneous Insulin|4 injections of insulin/day
61917486|NCT06273683||Complete salpingectomy using a hand-held bipolar energy instrument|
61917487|NCT06273683||Complete salpingectomy using traditional suture ligation|
61917488|NCT00558129|EXPERIMENTAL|Investigational|X-STOP® PEEK IPD
61917489|NCT00558129|ACTIVE_COMPARATOR|Control|Laminectomy
61917490|NCT01036061|EXPERIMENTAL|GSK618334 low Dose|GSK618334 Low Dose
61917491|NCT01036061|EXPERIMENTAL|GSK618334 Medium Dose|GSK618334 medium dose arm
61917492|NCT01036061|EXPERIMENTAL|GSK618334 High Dose|GSK618334 High Dose Arm
61917493|NCT01036061|EXPERIMENTAL|GSK618334 Placebo|Placebo for all 3 dose levels
61917494|NCT06239623|EXPERIMENTAL|Experimental|ERK inhibitor JSI-1187
61917495|NCT04524338|EXPERIMENTAL|At Home tDCS Users|Participants conducting tDCS at home
61917496|NCT04332809|ACTIVE_COMPARATOR|Saline-gentamicin irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline-gentamicin solution
61917497|NCT04332809|ACTIVE_COMPARATOR|Saline irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline solution
61917498|NCT04332809|NO_INTERVENTION|No irrigation|ayer-by-layer irrigation of the appendectomy wound will not be performed
61917499|NCT04738929|EXPERIMENTAL|Normal weight|Normal weight subjects (BMI=18.5-25)
61917500|NCT04738929|EXPERIMENTAL|Obese|Obese subjects (BMI=30-34.99)
61917501|NCT00373061||Pregnant Women Exposed to Xolair®|Women who are exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies.
62113868|NCT05493124|EXPERIMENTAL|Manpixiao treatment group|A traditional Chinese medicine composition (has applied for Chinese patent)，Take 17.15g daily, twice in the morning and evening, for a total of 24 weeks
61917502|NCT00056498|ACTIVE_COMPARATOR|Active|Participants assigned to risperidone
62674635|NCT01558375|EXPERIMENTAL|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
61917503|NCT00056498|PLACEBO_COMPARATOR|Placebo|Participants assigned to placebo
61917504|NCT03188172|EXPERIMENTAL|Trial Treatment|"Induction:~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1\& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11~ASCT stem cell harvest:~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly~Consolidation part 1:~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22~Consolidation part 2:~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1~Maintenance:~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
61917505|NCT04973189|EXPERIMENTAL|A single dose of SHR-1707 by intravenous infusion in healthy young adults.|
61917506|NCT04973189|PLACEBO_COMPARATOR|placebo in healthy young adults.|
61917507|NCT04973189|EXPERIMENTAL|A single dose of SHR-1707 by intravenous infusion in elderly subjects.|
61917508|NCT04973189|PLACEBO_COMPARATOR|placebo in elderly subject|
62113869|NCT05493124|NO_INTERVENTION|Blank treatment group|
62471964|NCT00658762|PLACEBO_COMPARATOR|Placebo BID|
62736126|NCT04644588||Children being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and hand function using postural zone software to assess scapular alignment and pediatric arm function test toassess upper limb function .
61917509|NCT03504137|EXPERIMENTAL|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
62113870|NCT05493124|ACTIVE_COMPARATOR|Active comparator|Including treated with Chinese patent drugs such as Weifuchun and morodan, or treated with antacids, motivational drugs, gastric mucosal protectants, vitamins, folic acid, selenium containing preparations and other drugs. Take it according to the instructions.
62113871|NCT06486987|EXPERIMENTAL|Intervention arm|This is a single arm in an open label pre- post-treatment design to estimate effect size of the intervention
62736127|NCT01790646||patients undergoing general anesthesia|every elective patient undergoing general anesthesia for neurosurgical procedures with endotracheal intubation
62736128|NCT02065843|ACTIVE_COMPARATOR|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
62113872|NCT03987763|EXPERIMENTAL|IDP-122 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 6 to 11 years 11 months) will apply IDP-122 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
62113873|NCT02739035|NO_INTERVENTION|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
62303295|NCT02760628|PLACEBO_COMPARATOR|Life Simple Seven (LS7)|Participants assigned to the LS7 arm will be directed to a website that contains information about health and wellness from the American Heart Association that was developed for the general population. No health coaching is present and the site is not tailored for the fire service.
62736129|NCT02065843|PLACEBO_COMPARATOR|placebo|500 mg of starch (2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
61917510|NCT03504137|NO_INTERVENTION|Standard of Care|Participants will not download the mHealth application. They will continue with their standard of care. Study personnel will send out surveys about general adherence. Participants will take their medications according to the instructions given by their transplant team and without any aid of the mHealth application.
61917511|NCT00711074|EXPERIMENTAL|1|
61917512|NCT06468384||Patients Undergoing Thoracic Erector Spinae Plane Block|The study focuses on a cohort of adult patients who are receiving the thoracic erector spinae plane (ESP) block for pain management. These patients include individuals experiencing pain in the shoulder, arm, or neck, as well as those with complex regional pain syndrome. The patients are generally healthy adults, categorized under ASA I-II (American Society of Anesthesiologists Physical Status Classification System). The primary aim of the study is to observe changes in optic nerve sheath diameter (ONSD) following the ESP block and to investigate the potential impact on the stellate ganglion. Data will be collected through clinical examinations and ultrasound performed before and after the ESP block procedure. The study aims to enhance understanding of the ESP block's safety and potential autonomic effects.
61917513|NCT00437970|ACTIVE_COMPARATOR|A|Arm A- Metformin
62113874|NCT02739035|EXPERIMENTAL|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
62674636|NCT02058407|EXPERIMENTAL|Cohort 1- Part A|This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
62674637|NCT02058407|EXPERIMENTAL|Cohort 2- Part A|This cohort will follow an interlocking design with Cohort 1 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 1 mg, to 10 mg, and 50 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard FDA high fat/high calorie meal.
62736130|NCT02065843|ACTIVE_COMPARATOR|Passiflora incarnata|100 mg Passiflora incarnata (2 capsules of 50 mg) to be administered v.o., one hour before the surgical procedure.
62113875|NCT02987933||Chronic Pain|Adults, \> 6 months duration, daily pain
62113876|NCT02987933||Healthy Normals|Age and gender matched controls
62113877|NCT01025999||RYGB|UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.
62471965|NCT01458561|EXPERIMENTAL|BioFoam Surgical Matrix|Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct
61917514|NCT00437970|ACTIVE_COMPARATOR|B|Arm B- Pioglitazone
62113878|NCT04795050|EXPERIMENTAL|Intervention|
62113879|NCT04795050|NO_INTERVENTION|Control|
62113880|NCT00740155|EXPERIMENTAL|Group 1|
62113881|NCT00740155|EXPERIMENTAL|Group 2|
62113882|NCT00740155|EXPERIMENTAL|Group 3|
62113883|NCT00740155|EXPERIMENTAL|Group 4|
62113884|NCT00740155|ACTIVE_COMPARATOR|Group 5|
62736131|NCT02065843|ACTIVE_COMPARATOR|midazolam|15 mg midazolam (2 capsules of 7.5 mg) to be administered v.o., one hour before the surgical procedure.
62113885|NCT02618239|EXPERIMENTAL|Healthy subjects|Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
62113886|NCT01241292|EXPERIMENTAL|BMS-901608 (Elotuzumab) 10mg|
62113887|NCT01241292|EXPERIMENTAL|BMS-901608 (Elotuzumab) 20mg|
62303296|NCT01771549||Group 1|Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.
62471966|NCT01458561|ACTIVE_COMPARATOR|Gelfoam Plus|Control of bleeding using Gelfoam Plus as a surgical adjunct
62471967|NCT04574102|EXPERIMENTAL|Study Eye|Omega Refractive capsule, model V, with an FDA approved intraocular lens.
62471968|NCT04574102|ACTIVE_COMPARATOR|Control Eye|FDA approved Intraocular Lens
62674638|NCT02058407|EXPERIMENTAL|Cohort 3- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
62674639|NCT02058407|EXPERIMENTAL|Cohort 4- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the higher dose (maximum tolerated or safe dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14. Cohort 4 will commence only after Cohort 3 is completed and data is reviewed. Also there will be no Cohort 4, if only one dose is to be evaluated in Part B.
62674640|NCT03189511|EXPERIMENTAL|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
62674641|NCT01187875|PLACEBO_COMPARATOR|Control|Dextrin Control
62674642|NCT01187875|EXPERIMENTAL|Hi-maize resistant starch 9g|Hi-maize resistant starch 9g
62674643|NCT01187875|EXPERIMENTAL|Novalose 330 resistant starch 9g|Novalose 330 resistant starch 9g
62674644|NCT01187875|EXPERIMENTAL|4.5g Hi-maize and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330
62674645|NCT05431751|EXPERIMENTAL|Experimental Group A|Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where they will consume the active intervention. Following the second clinic day, the participant will consume active intervention for 7 days. The participant will then undergo a washout period of 7 days.
62674646|NCT00655798|PLACEBO_COMPARATOR|1|
62674647|NCT00655798|ACTIVE_COMPARATOR|2|
62471969|NCT01704677|EXPERIMENTAL|Surgery|Replacement of the degenerative intervertebral lumbar disc with an artificial lumbar disc device (degeneration had to be restricted to the two lower levels (L4/L5 and/or L5/S1))
62471970|NCT01704677|ACTIVE_COMPARATOR|Multidiciplinary rehabilitation|
62471971|NCT05293145|EXPERIMENTAL|Building Futures Program Primary Services|Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
62674648|NCT00655798|ACTIVE_COMPARATOR|3|
62674649|NCT00655798|ACTIVE_COMPARATOR|4|
62674650|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
62674651|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
62674652|NCT05792254|EXPERIMENTAL|Huaier granule|Huaier granule is supplied as 20-g granule. Huaier granule will be administered as 20 g orally tid x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. In the absence of intolerable toxicity, a patient may continue to receive treatment with Huaier granule until disease progression, or until 24 months have elapsed.
62674653|NCT03542357|ACTIVE_COMPARATOR|Sumatriptan|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
62113888|NCT05147389||Neoplastic bile duct lesions|This group is confirmed by DSOC videos from patients with DSOC-confirmed neoplastic bile duct lesions, coming from each participating group. Each DSOC video corresponds to a complete DSOC procedure in a single patient. The neoplastic bile duct criteria are in accordance with the two following tools: the Robles-Medranda et al and the Mendoza classification. A further follow will be necessary to confirm neoplastic bile duct lesion and the type: pCCA or dCCA, local extension of iCCA, hepatocarcinoma mixed CCA/hepatocarcinoma, gallbladder cancer, pancreas cancer, or any other neoplastic bile duct lesion. Based on follow-up, videos from patients with confirmed non-neoplastic bile duct lesions will be re-assessed and re-classified or finally excluded by an expert blinded to clinical records and who do not participate in videos classification.
62303297|NCT01771549||Group 2|Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.
62303298|NCT02045199|EXPERIMENTAL|V0111|
62303299|NCT02045199|PLACEBO_COMPARATOR|Placebo|
62471972|NCT01224535|EXPERIMENTAL|Maize porridge with Amaranth|Maize porridge enriched with amaranth grain flour at 70:30 maize/amaranth ratio (80g/day)
62674654|NCT03542357|PLACEBO_COMPARATOR|Placebo|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment
62736132|NCT03115827|EXPERIMENTAL|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
62736133|NCT02096250|EXPERIMENTAL|NaFeEDTA|NaFeEDTA
62736134|NCT02096250|EXPERIMENTAL|Ferrous fumarate|Ferrous fumarate
62736135|NCT02096250|EXPERIMENTAL|NaFeEDTA + ferrous fumarate|NaFeEDTA + ferrous fumarate
62736136|NCT01093248||Heroin-addicted Patients|Heroin-addicted outpatient department (OPD) patients who seek help for methadone maintenance treatment
62674655|NCT01698008|EXPERIMENTAL|Mobile application Diabetes Doctor|The intervention group will send in blood glucoses once a month using the mobile phone app, Diabetes Doctor. All subjects will be evaluated at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After 3 months, a Diabetes Quality of Life (QOL) survey will be completed. A Usability and Satisfaction of Diabetes Doctor (USDD) survey will also be obtained. At the 3 month visit, they will also be given the chance to discontinue the mobile app and switch to standard of care. At 6 months, all mobile app users will complete the USDD and satisfaction and QOL survey. If they are not using the mobile app, then they will complete the QOL survey.
62674656|NCT01698008|NO_INTERVENTION|Standard of Care|The standard of care arm will not use the mobile application Diabetes Doctor to communicate with their physician about their blood sugars. They will attend clinic visits and have evaluations initially, and at 3 and 6 months. They will also receive a HbAIc at each visit. They will do the same QOL survey at 3 months. At 6 months, they will be given the QOL survey.
62674657|NCT06174506||Patients with pacemakers without atrial fibrillation at the beginning or in history|"Patients with pacemakers without atrial fibrillation at the beginning or in history.~Patients are adults over 18 years old."
62674658|NCT02194088|EXPERIMENTAL|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
62674659|NCT02194088|PLACEBO_COMPARATOR|placebo|Placebo capsules will be delivered in same number as the medication
62674660|NCT01760980|EXPERIMENTAL|Test product (B)|B: Subjects receive Exemestane 25 mg tablets under fasting conditions
62674661|NCT01760980|ACTIVE_COMPARATOR|Reference product (A)|A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
62471973|NCT01224535|ACTIVE_COMPARATOR|Maize flour with multiple micronutrients|Maize porridge fortified with a multiple micronutrient powder (MixMe™)
62674662|NCT03675555|ACTIVE_COMPARATOR|M (Mirtazapine) (Merta) group:(n=100)|
62674663|NCT03675555|ACTIVE_COMPARATOR|D (Dexamethasone) (Dex) group: (n=100)|
62674664|NCT03675555|PLACEBO_COMPARATOR|C (Control) group: (n=100)|
62674665|NCT01038895|ACTIVE_COMPARATOR|Ramipril|10 mg/daily
62303300|NCT03795350|EXPERIMENTAL|TRIMBOW|"Experimental: BDP/FF/GB~4 puffs of 99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI"
62471974|NCT01224535|PLACEBO_COMPARATOR|Maize Porridge|Plain maize porridge group
62471975|NCT01508962||Healthy individuals (controls)|
62674666|NCT01038895|EXPERIMENTAL|Aliskiren|300 mg/ daily
62674667|NCT01881295|PLACEBO_COMPARATOR|Placebo control|Subjects will consume tablets containing no potassium in addition to a basal diet containing 2336 mg potassium
62674668|NCT01881295|EXPERIMENTAL|Low dose potassium gluconate|Subjects will consume 720 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
62674669|NCT01881295|EXPERIMENTAL|Medium dose potassium gluconate|Subjects will consume 1440 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
62674670|NCT01881295|EXPERIMENTAL|High dose potassium gluconate|Subjects will consume 2160 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
62674671|NCT01881295|EXPERIMENTAL|Low dose potato|Subjects will consume 720 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
61917515|NCT03109847|EXPERIMENTAL|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
62674672|NCT01881295|EXPERIMENTAL|Medium dose potato|Subjects will consume 1440 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
62674673|NCT01881295|EXPERIMENTAL|High dose potato|Subjects will consume 2160 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
62674674|NCT01881295|EXPERIMENTAL|High dose French fries|Subjects will consume 2160 mg potassium in the form of french fries daily in addition to a basal diet containing 2336 mg potassium
62303301|NCT06656234||Cohort 1|Participants with relapsed or refractory (R/R) DLBCL who have started receiving glofitamab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 4 years).
62471976|NCT01508962||Individuals affected with ALS (sporadic or familial)|
62471977|NCT04599439||High arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass \> 5.15 g will be considered at highest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
62471978|NCT04599439||Low arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass \< 5.15 g will be considered at lowest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
62674675|NCT01881295|EXPERIMENTAL|Basal diet control|Subjects will consume a basal diet containing 2336 mg potassium daily
62674676|NCT06027892|EXPERIMENTAL|Two-fraction stereotactic radiotherapy|Participants receive stereotactic ablative radiotherapy in two treatments to a dose of 27 Gy, with the options to boost a high-grade lesion to 30 Gy
61917516|NCT03109847|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
62674677|NCT06027892|ACTIVE_COMPARATOR|Five-fraction stereotactic radiotherapy|Participants receive stereotactic ablative radiotherapy in five treatments to a dose of 40 Gy, with the options to boost a high-grade lesion to 45 Gy
62674678|NCT01545466|EXPERIMENTAL|Mindfulness Based Stress Reduction|Participants will complete an 8 week course in Mindfulness Based Stress Reduction (MBSR), meeting once/week for 8 weeks and having a 4-6 hour retreat after the 6th class
62674679|NCT01545466|NO_INTERVENTION|Wait-List Control Group|These participants will continue in usual care during the trial and will be offered the intervention of MBSR after the trial is over.
62674680|NCT03876548|EXPERIMENTAL|Cadexomer Iodine Gel|Patients willy apply product to treatment site every other day for the next 28 days and cover with dressing or bandage.
62674681|NCT01522976|EXPERIMENTAL|Arm I (azacitidine and lenalidomide)|Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
62674682|NCT01522976|EXPERIMENTAL|Arm II (azacitidine)|Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
62674683|NCT01522976|EXPERIMENTAL|Arm III (azacitidine and vorinostat)|Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
62674684|NCT03944005|ACTIVE_COMPARATOR|Study Group|Spinal Anesthesia + ACB continuous catheter+ iPACK + Sham LIA
62674685|NCT03944005|SHAM_COMPARATOR|Comparator Group|Spinal Anesthesia + LIA + Sham Blocks
61917517|NCT03671278|OTHER|STarT Back Screening Tool Approach|After baseline consultation, all patients will receive usual care from their medical doctors as well as an educational booklet and weekly videos containing information on the prognosis of back pain and how patients could deal with their problems. Six weeks after baseline consultation all patients will be screened by the STarT Back Screening Tool (SBST) and will receive a stratified care according to their SBST classification.
62471979|NCT00163657|ACTIVE_COMPARATOR|tacrolimus and cyclosporine|immunosuppressant treatment regimens the intervention is antirejection treatment with the above labeled drugs tacrolimus and cyclosporine
62674686|NCT00693732|ACTIVE_COMPARATOR|1, IBS patients|
62674687|NCT00693732|EXPERIMENTAL|2,Healthy controls|
62674688|NCT05726279|NO_INTERVENTION|Observational Cohort|Participants treated with standard guideline-based care for 24 hours. Blood pressure treatment thresholds will be used according to standard practice parameters
62674689|NCT05726279|EXPERIMENTAL|Interventional|Autoregulation-guided blood pressure management for 24 hours. Blood pressure will be measured every four hours by arm cuff; however, in lieu of predetermined blood pressure treatment thresholds, an optimal mean arterial pressure (MAP) range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
62674690|NCT01260415|EXPERIMENTAL|Folfox/Folfiri, Panitumumab|Eligible patients will recieved chemotherapy/panitumumab for 2 months (4 cycles) pre-operatively and 4 months post-operatively, plus a further 6 months of pantimumab post-chemotherapy
62674691|NCT01383824|OTHER|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
62303302|NCT04359966|ACTIVE_COMPARATOR|First line therapy for H pylori infection|Tripple 14 day first line therapy Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID 14 days
62471980|NCT00163657|ACTIVE_COMPARATOR|MMF, tacrolimus and cyclosporine|immunosuppressant treatment regimensthe intervention is antirejection treatment with the above labeled drugs MMF tacrolimus and cyclosporine
62471981|NCT00163657|ACTIVE_COMPARATOR|daclizumub, MMFand tacrolimus|immunosuppressant treatment regimens
62471982|NCT03753230|EXPERIMENTAL|EEG Device 1|Participants are listening to music while their neural activity is recorded with Emotiv Epoc+
62471983|NCT03753230|EXPERIMENTAL|EEG Device 2|Participants are listening to music while their neural activity is recorded with g.tec
62674692|NCT06354842||Control|Healthy control subjects
62674693|NCT06354842||CKDI|Patients with chronic kidney disease G1
62674694|NCT06354842||CKDII|Patients with chronic kidney disease G2
62674695|NCT06354842||CKDIIIa|Patients with chronic kidney disease G3a
62674696|NCT06354842||CKDIIIb|Patients with chronic kidney disease G3b
62674697|NCT06354842||CKDIV|Patients with chronic kidney disease G4
62674698|NCT06354842||CKDV|Patients with chronic kidney disease G5
62674699|NCT06354842||CKDVd|Patients with chronic kidney disease G5 receiving hemodialysis
62674700|NCT04890171|ACTIVE_COMPARATOR|Endoscopic treatment arm|Endoscopic submucosal dissection
62674701|NCT04890171|ACTIVE_COMPARATOR|Surgical treatment group|Gastrectomy with lymph node dissection
62113889|NCT05147389||Non-neoplastic bile duct lesions|This group is confirmed by DSOC videos from patients with DSOC-confirmed non-neoplastic bile duct lesions, coming from each participating group. Each DSOC video corresponds to a complete DSOC procedure in a single patient. The non-neoplastic bile duct criteria are in accordance with the two following tools: the Robles-Medranda et al and the Mendoza classification. A further follow will be necessary to confirm non-neoplastic bile duct lesion and the type, when available: acute or chronic cholangitis secondary to stones or parasite's location, autoimmune cholestatic liver diseases as autoimmune sclerosant cholangitis, and primary biliary cholangitis. Based on follow-up, videos from patients with confirmed neoplastic bile duct lesions will be re-assessed and re-classified or finally excluded by an expert blinded to clinical records and who do not participate in videos classification.
62471984|NCT03753230|ACTIVE_COMPARATOR|High density EEG|Participants are listening to music while their neural activity is recorded with high density 256 electrodes EEG Geodesic
62471985|NCT05648721|EXPERIMENTAL|Mobile health application|Use of GDM application for GDM management
62113890|NCT04340284|EXPERIMENTAL|Patients with nonunion of long bones|A total of 11patients ( november 2012 to august 2018) with atrophic non-union of long bones already treated with percutaneous SVF implantation
62113891|NCT01406028|NO_INTERVENTION|Standard of Care|Standard of care includes discharge instructions from one of our IVF nurses regarding medications and timing of follow-up, at which point patients are told what day they need to return for their pregnancy test. Patients have access to phone numbers for their IVF nurses and physicians, as well as information about how to contact the social workers if additional support is needed. They also are provided the emergency phone numbers for after-hour calls to the fellow on call. However, during the time between the embryo transfer and the pregnancy test, the current standard of care is that contact between the patient and our team is patient-initiated.
62113892|NCT01406028|ACTIVE_COMPARATOR|Intervention phone calls|The intervention consisted of two phone calls from an IVF social worker during the time between embryo transfer and pregnancy test. The first phone call occurred between days 2-4 after transfer and the second phone call occurred between days 5 and 9 after embryo transfer. Standard language for introductions to phone calls and for voice mails was established prior to the start of the study.
62113893|NCT01436838||Group 1|
62113894|NCT05117372|ACTIVE_COMPARATOR|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease|Group 1: Patients treated for cancer with immunotherapy and developing diffuse infiltrative lung disease
62113895|NCT05117372|PLACEBO_COMPARATOR|Patients not treated with immunotherapy and requiring carcinologic lobectomy|Group 2: Patients with lung cancer not treated with immunotherapy and requiring carcinologic lobectomy
62471986|NCT05648721|OTHER|Control|Regular follow-up without the GDM application
62471987|NCT05665686|EXPERIMENTAL|Device Group|Sexual Information and Advice to Individuals Individuals in both groups will be given training on sexuality. Male and female sexual situation, orgasm, male and female anatomical structures will be explained. At the same time, information will be given about the pelvic floor muscles, their function and their importance in sexual life.
62471988|NCT05665686|ACTIVE_COMPARATOR|home exercise|A home exercise program including pelvic floor relaxation exercises in different positions will be created for individuals in both groups and self-myofascial massages will be taught. At the same time, information will be given about the pelvic floor muscles, their function and their importance in sexual life.
62471989|NCT02997150|EXPERIMENTAL|IL-2 low dose|
62471990|NCT01833182|PLACEBO_COMPARATOR|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
62471991|NCT01833182|EXPERIMENTAL|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
62674702|NCT04731662|NO_INTERVENTION|Control Group (8888888)|The Control group will have 8-hours time-in-bed, both weeknights and weekends.
62674703|NCT04731662|EXPERIMENTAL|Stable Short Sleep (8866666)|The short sleep group will have 6-hours time-in-bed on weeknights and 8-hours time-in-bed on weekends.
62471992|NCT02152163|ACTIVE_COMPARATOR|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
62471993|NCT02152163|PLACEBO_COMPARATOR|IV Saline|IV Saline
62471994|NCT05051462|EXPERIMENTAL|Intervention group|Study participants participating in family constellation therapy between assessment 1 and 2.
62471995|NCT05051462|NO_INTERVENTION|Wait-list control group|Study participants participating in family constellation therapy only after all 3 assessment points.
62471996|NCT01467791||Patients|All patients with sarcoidosis associated pulmonary hypertension
62471997|NCT01887548|EXPERIMENTAL|Active CD|Patients whose CDAI score \>150 points would be enrolled in this group.
62471998|NCT01887548|ACTIVE_COMPARATOR|Quiescent CD|Patients whose CDAI score ≤150 points would be enrolled in this group.
62113896|NCT04991233|EXPERIMENTAL|Endoscopic surgery|Endoscopic surgery group
62303303|NCT04359966|EXPERIMENTAL|First line therapy for H pylori infection second arm|"Bismuth quadruple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
62471999|NCT01357863||Patients on second line treatment|Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
62113897|NCT04991233|ACTIVE_COMPARATOR|Suboccipital craniotomy surgery|Suboccipital craniotomy surgery group
62113898|NCT05039723|EXPERIMENTAL|Treatment|Treatment with Xeomin, Radiesse, and/or Belotero
62472000|NCT01357863||Patients on third or more lines treatment|Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
62472001|NCT01863030||Phasix mesh|Mesh being used for approved use. Mesh for ventral and incisional hernias.
62472002|NCT02609256|EXPERIMENTAL|Stereotactic infarct tissue aspiration|Patients receive the stereotactic infarct tissue aspiration 24-48 hours after cerebral infarction beside medical therapy.
62472003|NCT02609256|SHAM_COMPARATOR|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc;
62472004|NCT03112863|EXPERIMENTAL|Bakuchiol|Bakuchiol 0.5% applied to face twice daily
62472005|NCT03112863|ACTIVE_COMPARATOR|Retinol|0.5% retinol applied to face nightly
62472006|NCT03598101|EXPERIMENTAL|Test group|
62472007|NCT05416554|OTHER|Neuropsychological testing|Participants will take neuropsychological testing in-person or via telehealth video
62472008|NCT05183204|EXPERIMENTAL|Arm 1: Newly diagnosed MGMT unmethylated glioblastoma|
62472009|NCT05183204|EXPERIMENTAL|Arm 2: Recurrent glioblastoma, regardless of methylation status|
62113899|NCT03884244|ACTIVE_COMPARATOR|taking chewing gum patients|
62113900|NCT03884244|NO_INTERVENTION|no chewing gum|
62113901|NCT02710149|EXPERIMENTAL|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD20-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62113902|NCT04644185|EXPERIMENTAL|SCTA01 Low Dose+BSC|SCTA01in a lower dose+best supportive care
62113903|NCT04644185|EXPERIMENTAL|SCTA01 High Dose+BSC|SCTA01in a higher dose+best supportive care
62113904|NCT04644185|ACTIVE_COMPARATOR|Placebo+BSC|SCTA01 excipients+best supportive care
62113905|NCT06107738|EXPERIMENTAL|Iberdomide and Daratumumab|
62113906|NCT01121549||Aromasin|All patients included in the study
62113907|NCT01510418||Person with congenital bleeding disorder|Adult men with congenital hemophilia A or B
62303304|NCT04359966|ACTIVE_COMPARATOR|Second line therapy for H pylori infection|"Bismuth quadruple second line therapy for those treated with Tripple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
62303305|NCT04359966|EXPERIMENTAL|Second line therapy for H pylori infection second arm|"Tripple second line therapy~Esomeprazol 40 mg BID Amoxicillin 1000 mg BID, Levofloxacin 500 mg OID, 14 days or"
62472010|NCT05327608|EXPERIMENTAL|Treatment (Intermittent Fasting)|Patients undergo intermittent fasting involving 14 hours of fasting and 10 hours of eating for approximately 4 months while undergoing standard of care neoadjuvant chemotherapy. Acceptable neoadjuvant chemotherapy regimen includes doxorubicin and cytoxan followed by paclitaxel (AC-T). The schedule will be determined by treating physician. Carboplatin and pembrolizumab can also be added to the neoadjuvant chemotherapy regimen if determined to be appropriate by treating physician.
62472011|NCT01980823|EXPERIMENTAL|Metformin-Atorvastatin combination|Patients will receive metformin and atorvastatin for approximately 2 weeks prior to breast surgery.
62472012|NCT00264394|EXPERIMENTAL|Updated CHD risk profiles|Provision of regularly updated CHD risk profiles
62472013|NCT00264394|ACTIVE_COMPARATOR|Guidelines|Physicians received guidelines only
62472014|NCT01263353|EXPERIMENTAL|Functional tumors, pre-treated|
62472015|NCT01263353|EXPERIMENTAL|Functional tumors, treatment naïve|
62472016|NCT01263353|EXPERIMENTAL|Nonfunctional tumors, pretreated 1|
62472017|NCT01263353|EXPERIMENTAL|Nonfunctional tumors, pretreated 2|
62472018|NCT01263353|EXPERIMENTAL|Nonfunctional tumors, treatment-naïve 1|
62472019|NCT01263353|EXPERIMENTAL|Nonfunctional tumors, treatment-naïve 2|
62472020|NCT03071666|EXPERIMENTAL|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
62472021|NCT03071666|PLACEBO_COMPARATOR|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
62472022|NCT01852747|EXPERIMENTAL|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
62674704|NCT04731662|EXPERIMENTAL|Variable short sleep group (8884846)|The short sleep group time in-bed will vary across weeknights but will maintain the same amount of total time-in bed as the stable short sleep (8866666).
62303306|NCT04967690|EXPERIMENTAL|SI-053|Single arm study. Dose escalation will follow a rule-based 3 + 3 design using increasing doses of SI-053. Subjects will receive a single i.c. dose of room-tempered SI-053 gel, which will be applied onto the walls of the cavity formed after tumor resection using a sterile spatula.This will be followed by chemo-radiotherapy commencing at least 21 and no later than 35 days after SI-053 administration. The dose escalation part of the trial will follow a rule-based 3 + 3 design using a total of six dose levels of SI-053 (optional dose of 50 mg will be used to de-escalate in case of DLT at 75 mg) that consist of increasing amounts of TMZ in a constant amount of excipient and sterile WFI. These dose levels are planned to be tested in 21 subjects, including three more subjects at preliminary RP2D.The dose expansion phase will enroll an additional six subjects,to be treated at the RP2D in order to gather additional safety and preliminary efficacy data at that dose.
62303307|NCT01195025|OTHER|A.acetatedRingers, B.colloid & C.colloid+acetatedRingers|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by 150 minutes of equilibration, when blood samples were collected.~Washout \>7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout \> 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
62303308|NCT01195025|OTHER|A.colloid, B.colloid+acetatedRinger & C.acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout \>7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout \> 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
62303309|NCT01195025|OTHER|A.acetatedRingers, B.acetatedRingers+colloid & C.colloid|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout \>7 days~Second intervention: B.Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout \> 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples."
62472023|NCT01852747|NO_INTERVENTION|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
62472024|NCT05379647|EXPERIMENTAL|QN-019a in Combination with Monoclonal Antibodies|QN-019a in Combination with Rituximab in adult subjects with r/r B-cell lymphoma.
62674705|NCT03974490|EXPERIMENTAL|Intervention Group|"2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.~3 Times a week, intervention: Start with global body warming, 15 minutes, following the rhythm marked by the metronome. Central part of the session, 60 minutes, with rhythmic auditory stimulation exercises and music. Closure of the session, 15 minutes, round of impressions."
62674706|NCT03974490|NO_INTERVENTION|Historical control group|2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
62674707|NCT03383133|EXPERIMENTAL|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
62674708|NCT01733888|ACTIVE_COMPARATOR|Office Bleaching|Fluorosed teeth will be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) according to manufactures´ instruction.
62736137|NCT02212366|EXPERIMENTAL|Active TDCS|2-week course of daily (5 days/week) active bilateral anodal TDCS, duration 30 minute each session. Current 2 mA.
62113908|NCT01510418||Spouse/Significant Other|Spouse/significant other of person with congenital bleeding disorder participating in this study.
62113909|NCT04468490||GROUP A: Patients adherent to BTcP European Guidelines|
62113910|NCT04468490||GROUP B: Patients non Adherent to BTcP European Guidelines|
62113911|NCT05059730|ACTIVE_COMPARATOR|Men|Men will belong to one arm
62113912|NCT05059730|ACTIVE_COMPARATOR|Women (follicular phase)|Women will be allocated in this group during the follicular phase of their menstrual cycle.
62113913|NCT05059730|ACTIVE_COMPARATOR|women (luteal phase)|Women will be allocated in this group during the luteal phase of their menstrual cycle.
62113914|NCT01105143|ACTIVE_COMPARATOR|lifestyle intervention|Multimodal lifestyle intervention to reduce body weight
62113915|NCT01105143|PLACEBO_COMPARATOR|placebo|placebo
62113916|NCT00427752|EXPERIMENTAL|Whipple|Patients with pancreatic cancer who will proceed to a Whipple procedure.
62113917|NCT06465563|EXPERIMENTAL|Arm A: SHR-8068, Adebrelimab, Cisplatin and Gemcitabine|
62113918|NCT06465563|EXPERIMENTAL|Arm B: Adebrelimab, Cisplatin and Gemcitabine|
62113919|NCT05535530|NO_INTERVENTION|Control group|Passive PSIO will be used
62113920|NCT05535530|EXPERIMENTAL|Experimental|Active PSIO will be used
62113921|NCT04925739||OSA patients treated with CPAP|"OSA patient, not previously treated with CPAP, are treated with a ResMed Airsense 10 CPAP and an Air Liquide Medical Systems NINA mask during 30 days, monitored by the home care provider AGIRADOM.~After 30 days of CPAP treatment, 4 self-questionnaires are completed by the patient and parameters of the CPAP treatment (compliance, estimated unintentional leakage and therapeutic pressures) are collected."
62113922|NCT03907098|EXPERIMENTAL|endostar + chemotherapy|"Endostar 15 mg per square of BSA, continuous intravenous infusion 24 hours a day, continuous administration for 7 days, every three weeks.~Chemotherapy regimens are selected by physicians based on regular clinical decision."
62113923|NCT04352582||1|Survey respondants
62113924|NCT04424836||H GROUP|patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.
62113925|NCT04424836||C GROUP|patients get the oxygen supply with conventional methods. In group C 6-15 L/min oxygen delivered to patients by conventional methods and targeted to maintain the oxygen saturation %90 or over.
62113926|NCT02927132|EXPERIMENTAL|Alcohol-Guilt Condition|"In this condition, participants are asked to write about an incident in which they drank heavily and experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
62113927|NCT02927132|EXPERIMENTAL|Distress-Guilt Condition|"In this condition, participants are asked to write about an upsetting incident where they experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
62113928|NCT02927132|EXPERIMENTAL|Alcohol-No Guilt Condition|"In this condition, participants are asked to write about a negative drinking incident that they had experienced.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
62113929|NCT02927132|EXPERIMENTAL|Distress-No Guilt Condition|"In this condition, participants are asked to write about an upsetting experience that has affected their life.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
62113930|NCT02927132|NO_INTERVENTION|Neutral Control Condition|"In this condition, participants are asked to write about the laboratory room in which they are seated.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
62113931|NCT02927132|EXPERIMENTAL|Personalized Normative Feedback|Participants in the PNF condition will be given gender-specific personalized feedback regarding their alcohol use. Participants will be presented with the drinking estimates that they previously gave in addition to average gender-specific drinking estimates provided by 1124 students at the University of Houston. Feedback will be provided for drinking frequency (i.e., number of drinking days per week), and drinking quantity (i.e., the number of drinks consumed per week and number of drinks consumed per typical drinking occasion). Participants will also receive a printed a copy of the feedback for their records. PNF participants will receive feedback immediately after the baseline assessment. We also wanted to control for any differences that might be attributed to attention. Thus, participants will be scheduled to come in to the lab for two more sessions, during which time they will write about the laboratory room in which they are seated.
62472025|NCT05379647|EXPERIMENTAL|QN-019a Monotherapy|QN-019a Monotherapy in adult subjects with r/r B-ALL
62674709|NCT01733888|EXPERIMENTAL|Resin Infiltration|"White spots in fluorosed teeth will be infiltrated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
62674710|NCT01733888|EXPERIMENTAL|Resin Infiltration twice|"White spots in fluorosed teeth will be infiltrated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions. Here, the infiltrant Icon is applied twice."
62674711|NCT01733888|EXPERIMENTAL|Office Bleaching + Resin Infiltration|Fluorosed teeth will be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia). After a 20 day wash over period, these teeth will be treated with the resin infiltration intervention (Icon, DMG, Hamburg, Germany).
62674712|NCT02198131|EXPERIMENTAL|Supportive Care (pulsed dye laser)|Patients undergo pulsed dye laser monthly for three months.
62736138|NCT02212366|SHAM_COMPARATOR|Sham TDCS|2-week course of daily (5 days/week) Sham bilateral tDCS. Duration 30 minute each session.
62736139|NCT05894135|EXPERIMENTAL|BG2109 100 mg group|
62736140|NCT05894135|EXPERIMENTAL|BG2109 200 mg +ABT group|
62736141|NCT05894135|PLACEBO_COMPARATOR|Placebo group|
62736142|NCT01350674|EXPERIMENTAL|EBUS|patients undergoing EBUS
62472026|NCT01571245||Veterans with PTSD|Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans who are ages 18 to 60 and currently in or about to start treatment for deployment-related Post-Traumatic Stress Disorder (PTSD) at the Central Arkansas Veterans Healthcare System Mental Health Clinics.
62472027|NCT03677492|EXPERIMENTAL|Handling Medium Supplemented with Cytochalasin D|
62472028|NCT03677492|NO_INTERVENTION|Handling Medium as it is.|
62674713|NCT06209775||Split liver transplantation group|Between January 1, 2015 and December 31, 2022, all recipients who underwent split liver transplantation at the First Affiliated Hospital of the Zhejiang University School of Medicine, Shulan (Hangzhou) Hospital and the Affiliated Hospital of Qingdao University were considered for inclusion. After exluding pediatric cases, multiorgan transplantations, liver cancer patients with macrovascular invasion or distant metastasis and recipients without computed tomography (CT) scan within three months before split liver transplantation, 240 patients were included. The procedures of organ donation and transplantation were strictly implemented under the regulation of the China Organ Donation Committee (CODC), Organ Transplant Committee (OTC) and the Declaration of Helsinki (as revised in 2013). All donor livers came from donation after citizens' death and there was no procurement from prisoners.
62113932|NCT01967654|EXPERIMENTAL|Technical assistance, training, plus clinical reminder system|To assess the contextual factors of the intervention settings (district level policies and organizational level characteristics) that may influence tobacco use treatment in CHCs and to inform additional modifications to the proposed implementation strategies.
62113933|NCT01967654|EXPERIMENTAL|TTC + referral to community health workers|To compare the effectiveness and cost effectiveness of two multi component implementation strategies.
62113934|NCT06410963|NO_INTERVENTION|No treatment waiting period|Participants are randomized to a 7, 14 or 21 day waiting period. Daily measurements are collected throughout this period.
62113935|NCT06410963|EXPERIMENTAL|Reactivate|Reactivate treatment. Daily measurements are collected throughout treatment.
62113936|NCT02724085|ACTIVE_COMPARATOR|Cohort A|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62113937|NCT02724085|ACTIVE_COMPARATOR|Cohort B|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62113938|NCT02724085|ACTIVE_COMPARATOR|Cohort C|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62113939|NCT02724085|ACTIVE_COMPARATOR|Cohort D|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62113940|NCT02724085|ACTIVE_COMPARATOR|Cohort E|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62113941|NCT02724085|ACTIVE_COMPARATOR|Cohort F|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62113942|NCT02724085|ACTIVE_COMPARATOR|Cohort G|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
62113943|NCT01377519|ACTIVE_COMPARATOR|MR Guided Focused Ultrasound|
62113944|NCT01377519|PLACEBO_COMPARATOR|Placebo MR Guided Focused Ultrasound|
62113945|NCT01685788||study participants|
62113946|NCT05058469||Tracheotomy without antiplatelet therapy+technique 1|
62113947|NCT05058469||Tracheotomy under antiplatelet therapy+technique 1|
62113948|NCT05058469||Tracheotomy without antiplatelet therapy+technique 2|
62113949|NCT05058469||Tracheotomy under antiplatelet therapy+technique 2|
62113950|NCT01852019|EXPERIMENTAL|Day 1 - Cangrelor + Prasugrel (60mg) post infusion|Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation
62113951|NCT01852019|EXPERIMENTAL|Day 8 - Prasugrel (10mg) Dosing (5 doses)|Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h)
62113952|NCT01852019|EXPERIMENTAL|Day 1 - Cangrelor + Prasugrel (60mg) at 1.5h|Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time.
62472029|NCT01817985|EXPERIMENTAL|Cohort 1|(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816.
62472030|NCT01817985|EXPERIMENTAL|Cohort 2|(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816.
62472031|NCT01871662|ACTIVE_COMPARATOR|Group C: RIB + Peg-IFN|Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved
62113953|NCT01852019|EXPERIMENTAL|Day 1 - Cangrelor + Prasugrel (60mg) a 1.0h|Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time.
62113954|NCT01852019|EXPERIMENTAL|Day 8 - Prasugrel (10mg) Dosing (6 doses)|Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)
62113955|NCT02747732|EXPERIMENTAL|one arm|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
62113956|NCT06554262||Cardiometabolic risk group|
62113957|NCT01013441|EXPERIMENTAL|Treatment Arm|
62113958|NCT03068468|EXPERIMENTAL|BIIB092|Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
62113959|NCT03068468|PLACEBO_COMPARATOR|Placebo|Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
62113960|NCT02806518||Women scheduled for DIEP|Women scheduled for DIEP breast reconstruction after mastectomy due to breast cancer are examined with DIRT, hand-held Doppler and CTA
62113961|NCT02184325|EXPERIMENTAL|Kiddi® Pharmaton Fizz, effervescent tablets|with reduced amount of minerals
62113962|NCT02184325|ACTIVE_COMPARATOR|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
62303310|NCT01195025|OTHER|A.colloid, B.acetatedRingers & C.colloid+acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout \>7 days~Second intervention: B. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout \> 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
62472032|NCT01871662|EXPERIMENTAL|Group B:Legalon® SIL + RIB + Peg-IFN|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
62472033|NCT01871662|EXPERIMENTAL|Group A: Legalon® SIL + RIB|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
62472034|NCT06068530|ACTIVE_COMPARATOR|MDA + Vaccine|The participants in MVDA villages will receive R21/Matrix M at M0, M1, M2, and a booster M12 plus DHA/piperaquine and a SLD-PQ at M0, M1, and M2
62113963|NCT02184325|ACTIVE_COMPARATOR|Comparator product|in the form of a product that is a market leader
62113964|NCT04514419|EXPERIMENTAL|Trastuzumab + HS627 + Docetaxel|Trastuzumab HS627 Docetaxel
62472035|NCT06068530|ACTIVE_COMPARATOR|MDA only|The participants in MDA only villages will receive DHA/piperaquine and a SLD-PQ at M0, M1, and M2
62736143|NCT03447405|EXPERIMENTAL|Dino Egg Safety and useability|Test the usability of the device (safety for the NICU was confirmed), not the effectiveness of the parents' voice delivery for the infant. Parent and nursing questionnaires about the importance of the device availability and its usability will be collected from parents and RN staff that choose to provide the feedback.
62736144|NCT03447405|NO_INTERVENTION|Standard of Care|
62113965|NCT04514419|EXPERIMENTAL|Trastuzumab + Pertuzumab + Docetaxel|Trastuzumab Pertuzumab Docetaxel
62113966|NCT03795428|EXPERIMENTAL|Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose|Pemziviptadil (PB1046) Injection: Regardless of dose assignment, all subjects will be up-titrated in 0.2 mg/kg weekly increments, beginning with 0.4 mg/kg at Week 1, to the target dose of 1.2 mg/kg or higher depending on safety and tolerability.
62113967|NCT01986686|NO_INTERVENTION|Observational|The observation group will be followed clinically with no further intervention until the primary endpoint is reached.
62113968|NCT01986686|ACTIVE_COMPARATOR|Surgery|The surgery group will be offered colon resection.
62113969|NCT00995150|EXPERIMENTAL|LNG20 (16-35 Year Olds)|LNG20 levonorgestrel-releasing intrauterine system in subjects 16-35 years of age
62113970|NCT00995150|ACTIVE_COMPARATOR|Mirena|Levonorgestrel-releasing intrauterine system for contraception
62113971|NCT00995150|EXPERIMENTAL|LNG20 (36-45 Year Olds)|LNG20 levonorgestrel-releasing intrauterine system in subjects 36-45 years of age
62113972|NCT05473871|EXPERIMENTAL|Standard EBI Condition|Faith in Action as originally implemented
62113973|NCT05473871|EXPERIMENTAL|Enhanced Condition|Standard condition + organizational-level implementation strategies
62113974|NCT05473871|EXPERIMENTAL|Enhanced + Sustainment condition|Enhanced implementation condition + maintenance strategies
62113975|NCT00758602|ACTIVE_COMPARATOR|MMF, Standard Dose Tacrolimus|Participants received mycophenolate mofetil (MMF) 0.75 to (-) 1 gram (g), orally (PO), twice daily (BID) from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 milligrams per kilogram (mg/kg), PO, BID to reach a target trough dose of 8-10 nanograms per milliliter (ng/mL) from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
62472036|NCT06068530|ACTIVE_COMPARATOR|Vaccine only|The participants in vaccine only villages will receive R21/Matrix M at M0, M1, M2, and a booster M12
62472037|NCT06068530|NO_INTERVENTION|Control|The participants in control will receive MVDA at the end of the 24th month assuming that MVDA is found to be safe and effective. During M0 to M24, the comparison villages will receive the standard of care as per national malaria treatment guidelines.
62472038|NCT05497921|OTHER|Test (device arm)|Crossover study. The subject treats 1 hand while the contralateral is the control arm. After 6 weeks the treatment/control hand are swopped.
62472039|NCT02009462|EXPERIMENTAL|Artefill|Four treatment visits using Artefill dermal filler
62472040|NCT01741948||First time users of hormonal contraceptive|
62472041|NCT01631383|PLACEBO_COMPARATOR|Placebo|
62472042|NCT01631383|ACTIVE_COMPARATOR|l-THP|
62472043|NCT06537193|EXPERIMENTAL|AMRI and CT|"Procedure: AMRI examination The study subjects will receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination will be conducted using a 3-Tesla MRI machine, and the MRI protocol will consist of T2-weighted imaging, diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.~Procedure: dynamic CT CT will be performed by obtaining dynamic phases (precontrast phase, arterial phase, portal venous phase, and delayed phase images). Subjects will receive intravenous injection of iodine contrast media. Scan coverage will be from the basal lung to the iliac crest or pelvis."
62472044|NCT04254887|EXPERIMENTAL|EPBD|Small incision of the duodenal nipple + EPBD
62472045|NCT04254887|ACTIVE_COMPARATOR|EST|Large incision of the duodenal nipple
62472046|NCT02053857|ACTIVE_COMPARATOR|RUTF|Standard RUTF at a dose of 175 kcal/kg/d
62472047|NCT02053857|EXPERIMENTAL|RUTF-P|RUTF fortified with polyunsaturated fatty acids (PUFA) at a dose of 175 kcal/kg/d
62472048|NCT00061321|ACTIVE_COMPARATOR|1|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum
62472049|NCT00061321|EXPERIMENTAL|2|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day)by mouth, from week 1 through week 6 post-partum Infants: Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
62674714|NCT06209775||Whole liver transplantation group|2991 patients received deceased donor liver transplantation (DDLT) for liver cancers in the First Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China) between January 2015 and January 2021, Shulan (Hangzhou) Hospital (Hangzhou, China) between July 2017 and January 2021, and the Affiliated Hospital of Qingdao University between January 2015 and January 2022. The subject selection process is shown in Figure 1. After excluding transplants for benign disease (N=1667), pediatric transplants (N=141), re-transplants (N=219), multi-organ transplants (N=23), transplants for neoplasms other than HCC (N=62), patients with macrovascular invasion (N=159), patients who died within 30 days after transplantation (N=55), patients with incomplete clinical data (N=45), and patients without pre-LT CT scans (N=208), 756 patients were studied.
62113976|NCT00758602|EXPERIMENTAL|MMF, Low Dose Tacrolimus|Participants received MMF 0.75-1 g, PO, BID from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 mg/kg, PO, BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to 0.05-0.08 mg/kg, PO, BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
62113977|NCT01118338|EXPERIMENTAL|Redesigned Purevision Contact Lens|Redesigned Bausch \& Lomb PureVision contact lens
62113978|NCT01118338|ACTIVE_COMPARATOR|PureVision Contact Lens|Bausch \& Lomb PureVision contact lens
62472050|NCT00655590|EXPERIMENTAL|Arm 1|
62472051|NCT00655590|ACTIVE_COMPARATOR|Arm 2|
62472052|NCT00655590|PLACEBO_COMPARATOR|Arm 3|
62472053|NCT00919230|NO_INTERVENTION|no treatment|no iron given
62472054|NCT00919230|EXPERIMENTAL|ferrous sulphate|iron given
62472055|NCT01373593|EXPERIMENTAL|lidocaine|lidocaine block
62113979|NCT05116839|PLACEBO_COMPARATOR|the first 15 minutes with PSV|"All patients will breath at the first 15 minutes with PSV:triggered by minute volume \<3 Liter,with with no frequency .~Monitoring: (basal\&every 3minutes)~1. Tidal volume (inspiratory \& expiratory).~2. End tidal co2.~3. Mean air way pressure.~4. Leakage %.~5. Respiratory rate .~6. Spo2.~7. Heart rate.~8. Blood pressure (mean arterial pressure"
62113980|NCT05116839|ACTIVE_COMPARATOR|the following 15 minutes ventilation will be changed to CPAP mode|"then the following 15 minutes ventilation will be changed to CPAP mode at 10 cm H2o .~Monitoring: (basal\&every 3minutes)~1. Tidal volume (inspiratory \& expiratory).~2. End tidal co2.~3. Mean air way pressure.~4. Leakage %.~5. Respiratory rate .~6. Spo2.~7. Heart rate.~8. Blood pressure (mean arterial pressure)."
62113981|NCT06343896||PEDIATRIC PATIENTS BETWEEN 2-18 YEARS OF AGE|monitorization reliability evaluation of the use of the integral pulmonary index in the child patient group
62472056|NCT01373593|PLACEBO_COMPARATOR|Placebo|
62472057|NCT05967715|EXPERIMENTAL|Exercise training|high intensity interval training: thrice a week
62472058|NCT05967715|ACTIVE_COMPARATOR|Probiotics|VSL#3# probiotic: twice daily
62472059|NCT05967715|PLACEBO_COMPARATOR|Placebo|Comparator of the Probiotics arm
62113982|NCT04285762||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA by a single surgeon from March 2016 to October 2018.
62472060|NCT03379467|EXPERIMENTAL|SMS Reminder|"Single SMS at each of the following times:~* 3 days before immunization~* 1 day before immunization~* Day of immunization"
62472061|NCT03379467|EXPERIMENTAL|Interactive Reminder|"Single SMS at each of the following times:~* 3 days before immunization~* 1 day before immunization~* Day of immunization On the day of immunization, study participants are required to respond back through SMS notifying us that child got vaccinated or if not, the reason for delay in immunization. In case of no response, 2 additional reminders will be sent at:~* 1 day after scheduled immunization date~* 1 week after scheduled immunization date"
62472062|NCT03379467|NO_INTERVENTION|Control|Subjects in this arm will not receive any intervention
62674715|NCT06209125|OTHER|study group|use new device for treatment of class II malocclusion
62674716|NCT05736146||Case: GWI|This group includes participants who served in the Gulf War during 1990 -1991 and have Gulf War Illness based on either the Kansas or CDC symptom criteria.
61917518|NCT01933815|EXPERIMENTAL|TPI 287 + bevacizumab|"All subjects in phase 1 \& subjects randomized to the TPI 287 + bevacizumab arm in phase 2 will be administered a 1-hour IV infusion of TPI 287 once every 3 weeks (Days 1 \& 22 of 42-day cycle) \& a 30-90 minute IV infusion of bevacizumab once every 2 weeks (Days 1, 15, \& 29).~In phase 1, the dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6, while the dose of bevacizumab remains constant (10 mg/kg). The first 5 dose levels will be 140, 150, 160, 170, \& 180 mg/m2. Dose levels beyond 180 mg/m2 will be increased in increments of 20 mg/m2. Three subjects will be treated at a dose level halfway between the dose level that exceeds the MTD and the dose level immediately prior to further refine the MTD.~In phase 2, the dose of TPI 287 will be the MTD determined in phase 1, \& the dose of bevacizumab will be the same as phase 1 (10 mg/kg).~Subjects may continue on treatment unless they meet one or more of the protocol discontinuation criteria."
62113983|NCT03833102||Colonized patients' group (CPG)|all adult patients hospitalized in or consulting the Rennes University Hospital, known as S. aureus colonized could be included. In our institution, S. aureus colonization in the nostrils is screened in all patients supposed to undergo neurosurgical or orthopedic surgery.
62674717|NCT05736146||Control|This group includes participants who served in the Gulf War during 1990 -1991 and have no symptoms of Gulf War Illness based on both the Kansas and CDC symptom criteria.
62674718|NCT05001555|EXPERIMENTAL|Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)|"Group A:~Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days."
62674719|NCT05001555|ACTIVE_COMPARATOR|Group B: Dexketoprofen|Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.
62472063|NCT01203332||Alternative Venue Testing (AVT)|Participants recruited for testing through the AVT recruitment method.
62472064|NCT01203332||SSNIT - Index Recruiter|Participants recruited for HIV testing and to bring members of their social and sexual network to the study.
62674720|NCT02872688|EXPERIMENTAL|GanedenBC30|
62674721|NCT05511480|EXPERIMENTAL|Interference on sequence 1|The interference intervention (session six) will be applied to one of the two previously learned sequences (temporal).
62674722|NCT05511480|EXPERIMENTAL|Interference on sequence 2|The interference intervention (session six) will be applied to one of the two previously learned sequences (spatial).
62113984|NCT03833102||SAB patients' group (SAB)|"all adult patients with SAB could be included. S. aureus colonization in the nostrils will be systematically screened immediately after the first result of positive S. aureus blood culture. Two subgroups will be individualized depending on the SOFA Score:~* Severe patients~* Non-severe patients"
62472065|NCT01203332||SSNIT - Network Member|Participants recruited by someone in their social or sexual network to participate in the study, including HIV testing.
62674723|NCT05511480|EXPERIMENTAL|Interference on sequences 1 and 2|The interference intervention (session six) will be applied to both of the two previously learned sequences (temporal and spatial).
62674724|NCT05511480|SHAM_COMPARATOR|No interference|The interference intervention (session six) will be applied.
62674725|NCT01367756|EXPERIMENTAL|1|
62674726|NCT01367756|PLACEBO_COMPARATOR|2|
62674727|NCT00882765|EXPERIMENTAL|Arm I|Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity.
62674728|NCT00882765|NO_INTERVENTION|No intervention|Patients receive no specific neoadjuvant therapy.
62674729|NCT05414253|EXPERIMENTAL|Test group 1|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: 0.2% chlorhexidine + anti-discoloration system + hyaluronic acid mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
62472066|NCT02996591|ACTIVE_COMPARATOR|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
62674730|NCT05414253|EXPERIMENTAL|Test group 2|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: 0.2% chlorhexidine + anti-discoloration system mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
62674731|NCT05414253|PLACEBO_COMPARATOR|Control Group|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: placebo mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
62674732|NCT01449994|PLACEBO_COMPARATOR|Placebo-Activator|Treatment with Placebo Activator IV
62674733|NCT01449994|ACTIVE_COMPARATOR|Activator|Treatment with Activator IV adjusting instrument
62674734|NCT01714388|EXPERIMENTAL|Remifentanil, Vagotonic response|1 microgram/kg remifentanil given iv over at least 30 sec. at the beginning of induction of general anaesthesia
62674735|NCT05386836|EXPERIMENTAL|Healthy adult volunteers|All subjects within this single arm of the study will undergo the validation experiment as described in the description
62472067|NCT02996591|ACTIVE_COMPARATOR|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
62472068|NCT01783561|ACTIVE_COMPARATOR|early caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 15 minutes within the first 2 hours of life. If the infant is in the early caffeine group, the blinded drug will be IV caffeine citrate 20mg/kg in the first 2 hours and placebo at 12 hours of life.
62472069|NCT01783561|PLACEBO_COMPARATOR|Routine caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. If the infant is in the routine caffeine group, the blinded drug will be placebo in the DR and IV caffeine citrate 20mg/kg at 12 hours of life.
62472070|NCT06381141|EXPERIMENTAL|Part 1 Dose Escalation|Cohorts of patients with R/R MM will be treated at ascending doses of CLN-619 using a standard 3+3 dose escalation design.
62472071|NCT04534790|NO_INTERVENTION|Not radiotherapy|control group
62472072|NCT04534790|EXPERIMENTAL|Radiotherapy|patientis with treatment with radiotherapy 1 Gy to Whole lung.
61917519|NCT01933815|ACTIVE_COMPARATOR|Bevacizumab|"All subjects randomized to the bevacizumab alone arm in phase 2 will be administered bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of a 42-day cycle). The dose of bevacizumab will be 10 mg/kg.~Subjects will be withdrawn from the study if they meet one or more of the discontinuation criteria outlined in the protocol; however, treatment with bevacizumab may continue under the FDA approved labeling for bevacizumab at the discretion of the subject's doctor.~All subjects in phase 1 will be administered TPI 287 in combination with bevacizumab (i.e., there will be no bevacizumab alone arm during phase 1)."
61917520|NCT01221454|ACTIVE_COMPARATOR|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
62113985|NCT04267744|OTHER|Remote patient monitoring|"After consenting to the study, the Myia in-home suite of devices, and mobile phone application if the patient owns a smart phone, will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Patients enrolled will transmit daily vital sign data to the Myia Health remote patient monitoring platforms for clinical review.~Enrolled patients will complete medication change/compliance survey monthly to assess for medication changes.~Enrolled patients will complete symptomatic assessments (KCCQ-12) at 0, 3, and 6 months.~Enrolled patients will complete a Check-In survey to assess utility and usability of the intervention at the 2, 4, and 6 month timepoints"
62472073|NCT01415232|EXPERIMENTAL|Ultrasound measurement|Ultrasound using the Sonosite S-Nerve® US system (SonoSite, Bothell,WA) to measure depth to epidural space in morbidly obese parturients.
62113986|NCT01390402|EXPERIMENTAL|NK Infusion + Chemotherapy|Fludarabine 40 mg/m2 intravenous (IV) daily for 4 days, immediately followed by Busulfan 130 mg/ m2 IV every 24 hours and NK cell infusion IV.
62113987|NCT00836797||1 Case with scaffold|This group of patients will be having a placement of PLGA bioscaffold in the alveolar socket after teeth extraction
62113988|NCT00836797||2 Control without scaffold|The Alveolar socket will be left to heal and no treatment/scaffold placement will be done
62113989|NCT06549933|EXPERIMENTAL|Cryostimulation|Cryostimulation performed in a cryosauna for five consecutive days.
62113990|NCT00202865|EXPERIMENTAL|1|
62472074|NCT02074020|EXPERIMENTAL|Blisibimod|
62472075|NCT02074020|PLACEBO_COMPARATOR|Placebo|
62472076|NCT03215693|EXPERIMENTAL|X-396 capsule|225mg once daily
61917521|NCT01221454|EXPERIMENTAL|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
61917522|NCT01343225|ACTIVE_COMPARATOR|atripla|comparator
61917523|NCT01343225|EXPERIMENTAL|darunavir ritonavir raltegravir|experimental
61917524|NCT03046277||Patients undergoing LTx|Retrospective analysis of clinical data
62113991|NCT00202865|PLACEBO_COMPARATOR|2|
62113992|NCT01460290|EXPERIMENTAL|Asenapine|12-weeks of open-label asenapine treatment
62113993|NCT05499637|EXPERIMENTAL|acute cellular cardiac allograft rejection|\[68Ga\]Ga-PentixaFor PET/CT
62113994|NCT05499637|EXPERIMENTAL|cardiac sarcoidosis|\[68Ga\]Ga-PentixaFor PET/CT
62113995|NCT05499637|EXPERIMENTAL|immune checkpoint inhibitor induced myocarditis|\[68Ga\]Ga-PentixaFor PET/CT
62113996|NCT01306513|EXPERIMENTAL|cells|
62113997|NCT01063686|NO_INTERVENTION|Insemination cervical cap|
62113998|NCT01783977|EXPERIMENTAL|Part A: Group 1: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
62113999|NCT01783977|EXPERIMENTAL|Part B: Group 2: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
62114000|NCT01783977|PLACEBO_COMPARATOR|Part B: Group 2: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
62114001|NCT01783977|EXPERIMENTAL|Part B: Group 3: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
62472077|NCT02728674|OTHER|Man+Breathlessness|Person in the case is a male. Symptom in the case is breathlessness.
62472078|NCT02728674|OTHER|Man+Pain|Person in the case is a male. Symptom in the case is pain.
62472079|NCT02728674|OTHER|Woman+Breathlessness|Person in the case is a female. Symptom in the case is breathlessness.
62472080|NCT02728674|OTHER|Woman+Pain|Person in the case is a female.Symptom in the case is pain.
62472081|NCT05220657||Low active subjects|No intervention
62472082|NCT05220657||Moderately active subjects|No intervention
62472083|NCT05220657||Elite soccer players|No intervention
62472084|NCT05220657||Elite cyclists|No intervention
62472085|NCT03203876|EXPERIMENTAL|Part One Combination Therapy|Lirilumab and Nivolumab
62472086|NCT03203876|EXPERIMENTAL|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
62472087|NCT00905346|EXPERIMENTAL|Test First|Topiramate Capsules 25 mg
61917525|NCT03046277||Patients with pretransplant renal functional reserve testing|Prospective analysis of clinical data
61917526|NCT04494022|NO_INTERVENTION|Cross-sectional image only|Image set which consists of a Cross-sectional image only.
62303311|NCT01195025|OTHER|A.colloid+acetatedRingers, B.colloid & C.acetated Ringers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout \>7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout \> 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
62303312|NCT06264453|EXPERIMENTAL|Group A|KH001 0.2mg/mL
62674736|NCT04928638|EXPERIMENTAL|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
62674737|NCT04928638|EXPERIMENTAL|Written educational intervention|Educacional intervention about the disease, the use of medication and the context of pandemic
62674738|NCT04928638|NO_INTERVENTION|Control intervention|Control intervention
62674739|NCT02786511||Subjects with multiple myeloma|Subjects treated with ex vivo gene therapy in a bluebird bio sponsored trial who agree to participate in this study.
62674740|NCT00441935||Interstim Neuromodulation|Subjects undergoing implantation of an Interstim device for neuromodulation.
62674741|NCT01496703||renal transplantation with MMF from day 1|
62674742|NCT05287100|EXPERIMENTAL|Midodrine|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
61917527|NCT04494022|ACTIVE_COMPARATOR|Cross-sectional image with CEUS|The same participants with Arm1. But image set will consist of a Cross-sectional image and CEUS.
61917528|NCT05465720|ACTIVE_COMPARATOR|motor|
61917529|NCT05465720|EXPERIMENTAL|sensory|
61917530|NCT05465720|EXPERIMENTAL|cognitive|
62114002|NCT01783977|PLACEBO_COMPARATOR|Part B: Group 3: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
62114003|NCT01783977|EXPERIMENTAL|Part B: Group 4: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 140.
62114004|NCT01783977|PLACEBO_COMPARATOR|Part B: Group 4: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 140.
62114005|NCT02057692|EXPERIMENTAL|LUM001|LUM001 for oral administration
62114006|NCT02057692|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once each day
61917531|NCT04268849|ACTIVE_COMPARATOR|Oral Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
61917532|NCT04268849|ACTIVE_COMPARATOR|IV Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
61917533|NCT04253509||Lung cancer|
61917534|NCT04253509||Benign pulmonary disease|
62114007|NCT04181307|NO_INTERVENTION|standard EPIC instantiation|As per standard procedure at NewYorkUniversity Langone Health
62472088|NCT00905346|ACTIVE_COMPARATOR|Reference First|Topamax® 25 mg Capsule
62472089|NCT05917925|EXPERIMENTAL|COLLAGEN (COL)|Subjects in this group will intake 10 g/day of a hydrolyzed collagen-based supplement.
62472090|NCT05917925|PLACEBO_COMPARATOR|PLACEBO (PLA)|Subjects in this group will intake 10 g/day of placebo (maltodextrin).
62472091|NCT00801164|EXPERIMENTAL|Frio Oral Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
62472092|NCT00801164|EXPERIMENTAL|Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
62472093|NCT04135235||TAF group|take propofol fumarate for Maternal and child blockade treatment
62472094|NCT04135235||TDF group|take difenofurate fumarate for Maternal and child blockade treatment
62472095|NCT05333809|EXPERIMENTAL|1|Pembrolizumab plus Disitamab vedotin
62674743|NCT05287100|ACTIVE_COMPARATOR|Standard medical therapy|Standard medical therapy as per departmental protocol
62114008|NCT04181307|EXPERIMENTAL|standard EPIC instantiation plus the BE-EHR module.|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
62114009|NCT06010888|EXPERIMENTAL|Fruquintinib+mFOLFOX6/FOLFIRI|
62114010|NCT06248359||Arginine Use|At least one dose of L-arginie was administered in the early postoperative stage
62114011|NCT06248359||Without Arginine|No L-arginie was administered
61917535|NCT00004229|EXPERIMENTAL|Arm I|Patients undergo a biopsy during prestudy and after the second course of treatment. Patients receive endostatin IV daily for 4 weeks. Patients on dose level 1-6 receive endostatin over 20 minutes. Patients on dose level 7 receive endostatin over 40 minutes, with no treatment on day 2 of the first course only. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of endostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
61917536|NCT01000038|EXPERIMENTAL|Wii-Fit Intervention|Intervention: Subjects in this arm participate in Wii-Fit exercises
61917537|NCT01000038|ACTIVE_COMPARATOR|Walking Intervention|Intervention: Subjects in this arm participate in walking
61917538|NCT00206076|EXPERIMENTAL|1|mycophenolate mofetil monotherapy
61917539|NCT00206076|ACTIVE_COMPARATOR|2|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
62303313|NCT06264453|EXPERIMENTAL|Group B|KH001 0.4mg/mL
62303314|NCT06264453|PLACEBO_COMPARATOR|Group C|Water for Injection
62674744|NCT02620111|EXPERIMENTAL|Whey protein high leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein high in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
62674745|NCT02620111|ACTIVE_COMPARATOR|Whey protein normal leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein normal in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
62674746|NCT06013085|EXPERIMENTAL|cognitive behavioral therapy|6 weeks cognitive-behavioral therapy for insomnia
62674747|NCT06013085|NO_INTERVENTION|treat as usual|provide usual care
62674748|NCT01633112|EXPERIMENTAL|fingolimod 0.5 mg|orally once daily
62674749|NCT01633112|EXPERIMENTAL|fingolimod 0.25mg|orally once daily
62674750|NCT01633112|ACTIVE_COMPARATOR|glatiramer acetate 20 mg|subcutaneous once daily
62674751|NCT02813824|ACTIVE_COMPARATOR|Aspirin300|Acetylsalicylic acid 300 mg tablet by mouth, daily dose during 4 years
62674752|NCT02813824|PLACEBO_COMPARATOR|Placebo300|Placebo (like Acetylsalicylic acid 300 mg) tablet by mouth, daily dose during 4 years
62674753|NCT02813824|ACTIVE_COMPARATOR|Aspirin100|Acetylsalicylic acid 100 mg tablet by mouth, daily dose during 4 years
62674754|NCT02813824|PLACEBO_COMPARATOR|Placebo100|Placebo (like Acetylsalicylic acid 100 mg) tablet by mouth, daily dose during 4 years
62674755|NCT01356888|ACTIVE_COMPARATOR|Abbott Laboratories - Xience Prime DES|
62674756|NCT01356888|EXPERIMENTAL|Biotronik - Orsiro DES|
62674757|NCT03306290|OTHER|Bariatric surgery candidate|"Patients included in this study belong to this arm and put up with intervention Serum dosage of antibiotic prophylaxis CEFOXITIN"
62674758|NCT01173926|EXPERIMENTAL|IAsp|
62674759|NCT01173926|EXPERIMENTAL|IDeg|
62674760|NCT01173926|EXPERIMENTAL|IDegAsp|
62674761|NCT04858529|EXPERIMENTAL|THP|
61917540|NCT00873470|EXPERIMENTAL|Stimulation|All patients included have the stimulation
61917541|NCT06325332||Cohort 1: Nirsevimab-Exposed Cohort|Full-term (born ≥ 37 weeks gestational age) infants born on or after 01 April 2023, without a high-risk condition, who receive nirsevimab before or during their first RSV season per recommendations, ie, before or during the 2023-2024 RSV season.
61917542|NCT06325332||Cohort 2: Comparator Cohort|Full-term (born ≥ 37 weeks gestational age) infants born on or after 01 April 2023, without a high-risk condition, who do not receive nirsevimab before or during the 2023-2024 RSV season.
62303315|NCT04112914|NO_INTERVENTION|Education as usual|Participants receive education/healthcare provider communication as usual during their visit to the ED for concussion care.
62303316|NCT04112914|EXPERIMENTAL|New education|Participants receive the newly developed educational intervention.
62472096|NCT06386887|EXPERIMENTAL|Intermittent Fasting|Participants will receive 16 hours of fasting, 8 hour regular feeding for 5 days a week starting 2 days prior to chemotherapy.
62674762|NCT04858529|ACTIVE_COMPARATOR|TCHP|
62674763|NCT00933166|EXPERIMENTAL|Lotrafilcon A|Investigational contact lens worn in both eyes for three months
62674764|NCT06009926|EXPERIMENTAL|Group I (BSSE-placebo)|Participants receive BSSE PO QD for 7-10 days then undergo the first flashover training between day 7-10 of agent intervention. Participants then receive placebo PO QD for 7-10 days then undergo second flashover training after a washout period of 2 weeks to 3 months. Participants also undergo urine sample collection throughout the study.
62674765|NCT06009926|EXPERIMENTAL|Group II (placebo-BSSE)|Participants receive placebo PO QD for 7-10 days then undergo the first flashover training between day 7-10 of agent intervention. Participants then receive BSSE for 7-10 days then undergo second flashover training after a washout period of 2 weeks to 3 months. Participants also undergo urine sample collection throughout the study.
62674766|NCT03128086|EXPERIMENTAL|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation: performing a spontaneous breathing trial through a T-tube and after that to assess the patient's capacity to maintain airway. In case of reach a score the patient will extubated.
62674767|NCT03128086|NO_INTERVENTION|Conventional weaning|A control group of weaning from mechanical ventilation according to the usual procedure: performing a spontaneous breathing trial through a T-tube and then extubation if the patient success this trial.
62114012|NCT03709628|EXPERIMENTAL|Patients with active Crohn's disease|EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.
62303317|NCT05498272|EXPERIMENTAL|Investigational Group|"300 mg of olaparib taken orally twice a day for 6 cycles (approximately 6 months). There are 30 days in a cycle.~Olaparib will be taken with an LHRH agonist (leuprolide, triptorelin, or goserlin). This choice of therapy will be taken for a total of 180 days per institutional standards.~After 6 cycles of neoadjuvant therapy, patients will undergo a radical prostatectomy (RP). After RP, patients will be followed for testosterone recovery and PSA progression."
62303318|NCT05750914|EXPERIMENTAL|Treatment Arm|Broadband light treatment using in-motion protocol
62303319|NCT03661385|ACTIVE_COMPARATOR|Intervention arm|• Intervention arm will receive nitric oxide 20 parts per million (ppm) into the oxygenator of a cardio-pulmonary bypass circuit
62303320|NCT03661385|NO_INTERVENTION|Control arm|Control arm will not receive nitric oxide, they will receive standard bypass as per local policy
62303321|NCT04646395|EXPERIMENTAL|Tafasitamab and Acalabrutinib|"Acalabrutinib will be administered continuously at the dose of 100 mg BID (equivalent to a total daily dose of 200 mg), from day 1 to day 28 of each cycle for 24 cycles.~Tafasitamab will be administered 12 mg/kg iv on days 1, 8, 15 and 22 for the first 3 cycles. Then patients will continue treatment until cycle 24 with tafasitamab 12mg/kg iv on day 1"
62303322|NCT04248777|OTHER|left main PCI guided by OCT|The LM PCI strategy is guided by 3 OCT runs, according to a pre-defined standardized protocol.
62303323|NCT05932433|EXPERIMENTAL|Exercise|Exercise during 6 weeks, twice a week.
62303324|NCT05932433|NO_INTERVENTION|Control|There is no intervention
62303325|NCT02484261|NO_INTERVENTION|Monitoring phase|Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
62303326|NCT02484261|EXPERIMENTAL|Treatment phase|Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
62303327|NCT03465956|OTHER|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy for patients with morbid obesity using the gastro-intestinal anastomosis stapler.
62303328|NCT05164523||Patients with type 2 diabetes treated with SGLT2 inhibitors|metformin using patients with type 2 diabetes who were recently prescribed an SGLT2 inhibitor
62303329|NCT05164523||Patients with type 2 diabetes treated with other oral agents|metformin using patients with type 2 diabetes who were recently prescribed a pre-defined antidiabetic medication other than SGLT2 inhibitors
62303330|NCT04655625|EXPERIMENTAL|Group A (AG-0302-COVID19)|
62303331|NCT04655625|PLACEBO_COMPARATOR|Group A (Placebo)|
62303332|NCT04655625|EXPERIMENTAL|Group B (AG-0302-COVID19)|
62303333|NCT04655625|PLACEBO_COMPARATOR|Group B (Placebo)|
62303334|NCT00815308|EXPERIMENTAL|cetuximab, concurrent chemo-radiotherapy|Cetuximab, injection, loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m\^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m\^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction daily, Days 1-5 every week for Weeks 2-7, and Days 1-3 for Week 8
62303335|NCT02195830|OTHER|Single arm - Ultrasound|All participants will have an Ultrasound measurement of their inferior vena cava at enrolment as described in the intervention
62303336|NCT00957372|EXPERIMENTAL|ESL 800 mg daily (Part I)|ESL 800mg daily
62303337|NCT00957372|EXPERIMENTAL|ESL 1200 mg daily (Part I)|ESL 1200mg daily
62303338|NCT00957372|PLACEBO_COMPARATOR|placebo (Part I)|placebo
62303339|NCT00957372|EXPERIMENTAL|ESL - Open-label Extension (Part II)|All patients were treated with only ESL during Part II.
62303340|NCT01936337|ACTIVE_COMPARATOR|DLX105 Hydrogel|
62303341|NCT01936337|PLACEBO_COMPARATOR|Placebo Hydrogel|
62303342|NCT04673838|EXPERIMENTAL|Lower Extremity Sensory Training + Bobath Therapy|Intervention Group will have Lower extremity sensory training and Bobath Therapy.
62303343|NCT04673838|ACTIVE_COMPARATOR|Bobath Therapy|Control Group will have only Bobath Therapy. Bobath approach will be applied for 4 weeks, 3 days a week and 12 sessions in total.
62303344|NCT04252378|EXPERIMENTAL|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and external intercostal muscle near 5th rib.
62303345|NCT04252378|ACTIVE_COMPARATOR|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
62303346|NCT06477718||Successful Conversion Therapy Group (SCTG)|All cases were categorized into a successful conversion therapy group
62303347|NCT06477718||Failed Conversion Therapy Group (FCTG)|if they achieved no evidence of disease (NED) status through surgery after conversion therapy, and a failed conversion therapy group
62303348|NCT00117767|EXPERIMENTAL|1|Terbinafine
62303349|NCT00117767|ACTIVE_COMPARATOR|2|Griseofulvin
62303350|NCT00644579|ACTIVE_COMPARATOR|1|bLAC high dose
62303351|NCT00644579|ACTIVE_COMPARATOR|2|bLAC low dose
62303352|NCT00644579|PLACEBO_COMPARATOR|3|
62303353|NCT06166771|EXPERIMENTAL|Woman who developed PPH after vaginal birth and first line therapies have been attempted and failed|Group which Alma treatment was applied
62303354|NCT05671900|EXPERIMENTAL|All patients|All patients receive same intervention throughout the trial.
62303355|NCT02362373|OTHER|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
62674768|NCT02192697|EXPERIMENTAL|Phase I dose-escalation group|Oral administration
62472097|NCT06386887|ACTIVE_COMPARATOR|Standard of Care|Participants will receive standard of care dietary recommendations and will provide a 3-day diet diary at study enrollment and during cycles 2 and 3.
62472098|NCT02017262|EXPERIMENTAL|Self-management group|8 weekly sessions of group self-management
62472099|NCT02017262|ACTIVE_COMPARATOR|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
62114013|NCT03899480|EXPERIMENTAL|Haploidentical Natural Killer Cells|Day -7 the subject will undergo inguinal lymph node biopsy \& colonoscopy to obtain ileal \& rectal biopsies. Blood samples will be obtained. PBMCs will be obtained to sort into CD4 subsets \& measure frequencies of HIV RNA \& DNA. On Day -1, the donor will undergo apheresis \& donor cells will be obtained \& incubated overnight. On Day 0 subjects will be infused with N-803 activated NK cells. Subjects will receive 1st dose of N-803 4 hrs after the infusion. Plasma will be obtained at 2, 4 \& 12 hrs after. Subjects will return on Days 2, 4, 7, 10, \& 14 for blood draw. Subjects will return Days 21 \& 42 for blood work \& to receive 2 additional doses of N-803, for a total of 3 doses. Subjects will be monitored for toxicity assessment by targeted physical exam \& laboratory evaluations on Days 2, 4, 7, 10, 21, \& 42. On day 49, we will perform lymph node biopsy \& colonoscopy to obtain ileal \& rectal tissues. The patient will then be followed until day 100 post infusion.
62303356|NCT04291157|EXPERIMENTAL|Proactive CVD prevention|Proactive invitation to total CVD risk estimation incorporating the PRS and provision of guideline based preventive interventions.
62303357|NCT04291157|ACTIVE_COMPARATOR|Usual care|Usual GP care (opportunistic CVD risk estimation and prevention upon usual GP contacts).
62303358|NCT04819828|EXPERIMENTAL|Tamsulosin|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed plus oral tamsulosin (0.4 mg/day) for eight weeks.
62303359|NCT04819828|ACTIVE_COMPARATOR|Control|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed
62303360|NCT05427630|EXPERIMENTAL|THC ~2.5%|Inhalation of cannabis flower containing THC \~2.5%
62472100|NCT04230525||Bioimpedence|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia.
62472101|NCT04486339|EXPERIMENTAL|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.
62114014|NCT05232630|EXPERIMENTAL|- Group 1A.|Patients with genetic testing showing a pathogenic or likely pathogenic variant in main synaptopathy genes (SYNGAP1 and STXBP1)
62114015|NCT05232630|EXPERIMENTAL|Group 1B.|Patients with genetic testing showing a pathogenic or likely pathogenic inverted duplication of chromosome 15 \[inv-dup (15)\].
62114016|NCT05232630|EXPERIMENTAL|Group 1C.|Patients with neuroimaging showing multifocal or bilateral malformations of cortical development.
62114017|NCT05232630|EXPERIMENTAL|Group 2.|Electroclinical diagnosis of Continuous Spikes and Waves during Sleep (CSWS) syndrome, with baseline video-EEG monitoring showing epileptiform activity occupying at least 50% of slow sleep tracing, after failing at least 3 antiseizure medications
62674769|NCT02192697|EXPERIMENTAL|Phase I EGFR-T790M mutation group|Oral administration
62114018|NCT02887768|EXPERIMENTAL|Treatment|Epicardial Infarct Repair with CorMatrix-ECM in addition to coronary artery bypass grafting
62114019|NCT02524288|EXPERIMENTAL|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62114020|NCT03728816||SCAP groups|all the SCAP patients who meet the inclusion criteria
62114021|NCT03709693||SternaLock Blu|All patients will receive SternaLock Blu for closure of full mid-line sternotomy.
62303361|NCT05427630|EXPERIMENTAL|THC ~5%|Inhalation of cannabis flower containing THC \~5%
62303362|NCT05427630|EXPERIMENTAL|THC ~10%|Inhalation of cannabis flower containing THC \~10%
62303363|NCT05427630|SHAM_COMPARATOR|Sham Cannabis|Inhalation of cannabis flower from which the THC and CBD have been extracted
62303364|NCT05289661|EXPERIMENTAL|UT-DSAEK plus topical ripasudil|This arm will receive UT-DSAEK plus topical ripasudil 0.4%
62303365|NCT05289661|PLACEBO_COMPARATOR|UT-DSAEK plus topical placebo|This arm will receive UT-DSAEK plus topical placebo
62303366|NCT05289661|EXPERIMENTAL|DMEK plus topical ripasudil|This arm will receive DMEK plus topical ripasudil 0.4%
62303367|NCT05289661|PLACEBO_COMPARATOR|DMEK plus topical placebo|This arm will receive DMEK plus topical placebo
62472102|NCT03675269|EXPERIMENTAL|Treatment|HBOT
62472103|NCT03675269|ACTIVE_COMPARATOR|Control|Standard wound care
62472104|NCT02554032|ACTIVE_COMPARATOR|Axillary artery cannulation|Axillary artery cannulation for antegrade cerebral perfusion
62472105|NCT02554032|ACTIVE_COMPARATOR|Innominate artery cannulation|Innominate artery cannulation for antegrade cerebral perfusion
62472106|NCT00949585|OTHER|Dietary potassium intake: 100 mmol/day|Participants will be given one of two diets: one contains 100 mmol of potassium per day, and the other contains 40 mmol of potassium per day
62472107|NCT00949585|OTHER|Dietary potassium intake: 40 mmol/day|Diet containing 40 mmol/day of potassium
62472108|NCT00858845|EXPERIMENTAL|Clonidine patch|Participants assigned to wear a clonidine patch.
62472109|NCT00858845|PLACEBO_COMPARATOR|Placebo|Participants assigned to wear a matching placebo patch.
62472110|NCT04468867|EXPERIMENTAL|Patient group|
62472111|NCT06333457||VR group|50 patients with diagnosed alcohol dependence (in-patients, patients in the outpatient department or day clinics) receiving VR Cue-Exposure Therapy (VR-CET) additional to the standard treatment.
62472112|NCT06333457||control group|50 patients with diagnosed alcohol dependence (in-patients, patients in the outpatient department or day clinics) receiving standard treatment.
62472113|NCT04518631|EXPERIMENTAL|8-week mindfulness program|8-week .b Foundations course
62472114|NCT04518631|NO_INTERVENTION|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
62674770|NCT02192697|EXPERIMENTAL|Phase II group|Oral administration
62472115|NCT05114447||Clinical sample|a) clinical cases of severe/uncontrolled asthma attending hospital specialist centres already included in the online RItA Registry and b) new clinical cases of severe/uncontrolled asthma attending the clinical centres and not yet included in the online RItA Registry, with the following characteristics: adult subjects with a diagnosis of asthma since at least one year with a) uncontrolled asthma, despite regular treatment with GINA (Global Initiative for Asthma) step 4 level, in the last three months or b) controlled asthma with a step 5 level treatment according to GINA (Global Initiative for Asthma).
62114022|NCT05574530|EXPERIMENTAL|Colon-delivered multivitamin supplement|Colon-delivered multivitamin mix with vitamin B2, B3, B6, B9, vitamin C and D3. These vitamins are delivered as capsules coated by a eudragit S100 coating layer, in order to prevent systemic absorption of the vitamins in the small intestine.
62472116|NCT05114447||Epidemiological sample|a) epidemiological cases of severe/uncontrolled asthma from a general population Pisa cohort already inserted in the online RItA Registry and b) new epidemiological cases of severe/uncontrolled asthma from pre-existing Pisa cohort not yet included in the online RItA Registry, with the following characteristics: adult subjects with at least one asthma attack in the last 12 months or wheezing and/or asthma therapy in the last 12months.
62114023|NCT05574530|PLACEBO_COMPARATOR|Placebo supplement|Placebo supplement containing microcrystalline cellulose, coated in the same way as the experimental product in order to prevent systemic absorption in the small intestine.
62114024|NCT02882230||exposition to the drugs|patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine
62114025|NCT02882230||patients non exposed to the drugs|
62114026|NCT00947596|EXPERIMENTAL|Atropine Dry Powder Inhaler|
62114027|NCT00947596|ACTIVE_COMPARATOR|Atropen Autoinjector|
62114028|NCT04151550|OTHER|AVG LSM Procedure|Ace Vision Group LSM procedure performed on both eyes.
62114029|NCT02008253||INTRASTROMAL CORNEAL RING SEGMENT|Forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series.
62114030|NCT02156687|ACTIVE_COMPARATOR|Cololast, Inc. Restorell Y mesh|Y mesh
62114031|NCT02156687|ACTIVE_COMPARATOR|Coloplast, Inc. Restorelle Dual flat mesh|Dual flat mesh
62114032|NCT04994054|EXPERIMENTAL|silkworms (Bombyx mori L.) pupae extracts group|This group takes silkworms (Bombyx mori L.) pupae extracts for 12 weeks.
62114033|NCT04994054|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks.
62114034|NCT04972591||CHB Group|Patients with CHB
62114035|NCT04972591||Compared Group|Healthy people
62114036|NCT04120051|EXPERIMENTAL|Fermented canola-seaweed supplement|Ingredients: Canola meal, seaweed, wheat, glucose, Vitamin D and lactic acid bacteria
62114037|NCT04120051|PLACEBO_COMPARATOR|Placebo|Ingredients: Rye flour, water, iodized salt, brown sugar
62114038|NCT04670835||Case Group (unic)|"1. Group/Cohort Label :~   Users of Emergency Call Centers Users of French territory 'Region Pays de la Loire'~2. Group/Cohort Description:~All Users calling through the five Emergency Medical Centers of the French Pays de la Loire region (5 areas of the region are : Loire-Atlantique, Maine-et-Loire, Mayenne, Sarthe, Vendée).~In each Emergency Medical Center, an advanced telephone system automatically keeps track of all inbound calls.~Average annual number of incoming calls for the 5 Emergency Medical Center of Pays de la Loire region is 1,6 million."
62114039|NCT01717677|EXPERIMENTAL|radical prostatectomy|Procedure/Surgery: radical prostatectomy
62114040|NCT01717677|EXPERIMENTAL|percutaneous radiation therapy|Radiation: percutaneous radiation therapy
62303368|NCT05839132|EXPERIMENTAL|acupuncture treatment group|"Disposable acupuncture needles will be inserted into acupoints for a depth of 20-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.~Acupuncture points: Baihui(DU20), Sishencong(EM1), Hegu(LI4), Taichong(LR3)"
62303369|NCT05839132|PLACEBO_COMPARATOR|sham acupuncture treatment group|"Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.~Acupuncture points: Baihui(DU20), Sishencong(EM1), Hegu(LI4), Taichong(LR3)"
62303370|NCT05260411|EXPERIMENTAL|AK102 regimen 1|
62303371|NCT05260411|EXPERIMENTAL|AK102 regimen 2|
62303372|NCT05260411|PLACEBO_COMPARATOR|Placebo|
62303373|NCT04626713|EXPERIMENTAL|Intervention|Participants will undergo a brief interactive psychoeducation session four times a week for two weeks. For each session, participants will wear a commercially available Electroencephalography (EEG) headset and play a downloaded online game for a total of 30 minutes. Participants can feel free to play the game for more than the instructed frequency during their 2-week intervention participation.
62303374|NCT04626713|NO_INTERVENTION|Waitlist control|Participants in Waitlist Control will receive no intervention in the first four weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
62472117|NCT00752297|ACTIVE_COMPARATOR|1|Mentor Purified Toxin Botulinum Toxin Type A
62114041|NCT01717677|EXPERIMENTAL|permanent seed implantation|Radiation: permanent seed implantation
62114042|NCT01717677|EXPERIMENTAL|Active Surveillance|Procedure/Surgery: Active Surveillance
62114043|NCT01081340|EXPERIMENTAL|Social network building intervention|Healthy lifestyle intervention focused on building reciprocal social ties between the intervention group members
62114044|NCT01081340|ACTIVE_COMPARATOR|Home visit|Home visits focused on preventable infant injuries
62114045|NCT04615299|ACTIVE_COMPARATOR|Auricular acupuncture|Auricular (Battlefield) acupuncture needles will be utilized in the test arm, location of needles and stickers will be placed according to 5 VA approved BFA auricular acupuncture points associated with PONV, pain, and anxiety respectively
62114046|NCT04615299|SHAM_COMPARATOR|Sham acupuncture|The control arm will receive sham or placebo acupuncture via pressing of a blunt needle on the specified BFA locations and then application of adhesive stickers. In the control group simulating acupuncture, the needles will never enter the patients' skin and will give the impression to the patient that the procedure has taken place.
62114047|NCT02533713|EXPERIMENTAL|Immediate gait training|Participants assigned to this arm will begin Exoskeleton assisted gait training right away and will continue training for the first 6 months of the study.
62303375|NCT01106638|EXPERIMENTAL|Intensive behavioral intervention|Eight session, behavioral intervention targeting HIV-infected smokers
62303376|NCT01106638|ACTIVE_COMPARATOR|Standard care|Advice to quit, smoking cessation brochure, offer of nicotine patch
62303377|NCT05958420||Group 1|Patients with liver failure
62303378|NCT05958420||Group 2|Healthy donors
62303379|NCT06657261|ACTIVE_COMPARATOR|The patient group receiving deep and superficial serratus anterior plane block|In this group, the ultrasound probe will be placed on the 5th rib in the mid-axillary line. After visualizing the muscle structures down to the rib (latissimus dorsi, teres major, and serratus anterior), the needle will be advanced using the in-plane technique to two separate areas on the 5th rib: the superficial and deep fascial planes of the serratus anterior muscle. A total of 20 ml of 0.25% bupivacaine will be injected into both areas. The procedure will be performed bilaterally.
62303380|NCT06657261|ACTIVE_COMPARATOR|The patient group receiving a combination of deep serratus anterior plane block and transverse thora|In this group, for the TTMP block, the ultrasound probe will be placed on the midclavicular line at the 3rd or 4th intercostal space, where the pleura, pectoralis major, and intercostal muscles will be visualized. A lateral-to-medial scan will be performed to visualize the hypoechoic TTMP located deep to the intercostal muscle and above the pleura. The needle target will be the plane between the internal intercostal muscle and the TTMP. In this area, 10 ml of 0.25% bupivacaine will be injected. The procedure will be performed bilaterally. For the deep SAPB, the ultrasound probe will be placed on the 5th rib in the mid-axillary line. After visualizing the muscle structures down to the rib (latissimus dorsi, teres major, and serratus anterior), the needle will be advanced using the in-plane technique to the fascial plane deep to the serratus anterior muscle on the 5th rib. In this area, 10 ml of 0.25% bupivacaine will be injected. The procedure will be performed bilaterally.
62303381|NCT02631161|EXPERIMENTAL|EQUIA forte|Dental non-carious cervical restorations are being restored with a glass hybrid restorative system (Medical product: EQUIA forte).
62303382|NCT02631161|ACTIVE_COMPARATOR|Filtek Supreme XT/Clearfil SE Bond|Dental non-carious cervical restorations are being restored with a composite resin based material/Adhesive combination (Medical product: Filtek Supreme XT/Clearfil SE Bond).
62303383|NCT06221930|EXPERIMENTAL|attexis + TAU|"Participants allocated to the intervention group will receive access to attexis in addition to treatment as usual (TAU).~attexis is a digital health application designed for individuals with adult attention deficit hyperactivity disorder (ADHD), accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by attexis are attention, self-image, impulsivity and physical exercise, problem-solving strategies, and resources.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
62303384|NCT06221930|NO_INTERVENTION|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
62303385|NCT02495363||PECS block in additions to general anesthesia|"As standard analgesic protocol participants undergoing mastectomy surgeries under general anesthesia will have an addition of Pectoral Block regional anesthesia.~Following obtaining written informed consent, ultrasound guided PECS Block will be performed by identifying the thoracic muscles, in addition to general anesthesia Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% ."
62303386|NCT01316484||No Treatment|Adult subjects with diabetes mellitus and a diagnosis of gastroparesis
62303387|NCT01412242|EXPERIMENTAL|Extensive search for isolated calf DVT|As this is a prospective cohort study, for definition there is only 1 arm
62303388|NCT01329757|ACTIVE_COMPARATOR|GH|Administration of a daily dose of GH (0.4mg)for 1 year
62303389|NCT01329757|PLACEBO_COMPARATOR|Placebo|Administration of a daily dose of placebo for 1 year
62303390|NCT03240640|EXPERIMENTAL|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
62303391|NCT03240640|SHAM_COMPARATOR|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
62303392|NCT01158898|ACTIVE_COMPARATOR|TPI ASM8 low dose|
62674771|NCT05281640|EXPERIMENTAL|Affect Dysregulation intervention|"The AD module focuses on skills training in relation to identifying and labelling feelings, emotion management, distress tolerance, and acceptance of feelings and experiencing positive emotions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
62114048|NCT02533713|OTHER|Delayed gait training|Participants assigned to this arm will not gait train for 6 months. They will engage in Exoskeleton assisted gait training for the last 6 months of the study.
62303393|NCT01158898|ACTIVE_COMPARATOR|TPI ASM8 high dose|
62303394|NCT01158898|PLACEBO_COMPARATOR|Placebo|
62114049|NCT02780245|EXPERIMENTAL|Group (X) Prophylactic Tranexamic Acid|Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).
62303395|NCT04824261|ACTIVE_COMPARATOR|group 1|randomized 50 otomycosis patients will receive Clotrimazol solution 1%
62303396|NCT04824261|ACTIVE_COMPARATOR|group 2|randomized 50 otomycosis patients will receive 4%boric acid in distilled water
62303397|NCT02070432|EXPERIMENTAL|LUZ11 PDT|"Study consists of two phases, in each participant:~1. Dose-finding phase with sequential periods in which single-ascending doses of LUZ11 will be titrated up to a dose that shows to be effective following photoirradiation of small spots of tumor surface.~2. Final PDT session with the previously identified individual effective dose."
62303398|NCT03016234|ACTIVE_COMPARATOR|Desflurane|inhalation anesthesia administration for maintenance of anesthesia
62114050|NCT02780245|EXPERIMENTAL|Group (Y) Intraoperative Uterine Cooling|Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly \[Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen\].
62114051|NCT04407325|EXPERIMENTAL|AeoNose|the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
62114052|NCT05460936|ACTIVE_COMPARATOR|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
62303399|NCT03016234|ACTIVE_COMPARATOR|Propofol|intravenous anesthesia administration for maintenance of anesthesia
62114053|NCT05460936|EXPERIMENTAL|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
62472118|NCT00752297|PLACEBO_COMPARATOR|2|Preservative-free Saline
62114054|NCT03586596|EXPERIMENTAL|The Decídetext program|Participants will receive a tablet-based interactive educational session, 6 months of text-messaging based counseling, which includes prompts to access free pharmacotherapy.
62303400|NCT04112758|EXPERIMENTAL|Exercise group|The group will receive twice a week for 5 week
62303401|NCT04112758|NO_INTERVENTION|Control group|The group will be maintained their normal after school activities
62472119|NCT02258347|EXPERIMENTAL|Single arm|
62472120|NCT01835860|OTHER|Embolization|Prostate artery embolization
62472121|NCT03951363|NO_INTERVENTION|Qualitative Interview|Interviews: The investigators will enroll at least 10 adults 18 years or older with CKD (self-report).
62472122|NCT03951363|OTHER|Pilot Testing|Pilot Study: The investigators will enroll 30 adults at least 18 years old with mild to moderate CKD (documented estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2) who also have diabetes and/or hypertension.
62472123|NCT00834340|EXPERIMENTAL|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
62472124|NCT00834340|ACTIVE_COMPARATOR|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
62472125|NCT02431494|ACTIVE_COMPARATOR|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
62674772|NCT05281640|NO_INTERVENTION|Treatment as usual (1)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
62303402|NCT03992300|EXPERIMENTAL|Intraoral scanning|An intraoral scanning is taken. An auxiliary device is used to achieve better accuracy. A zirconia framework is produced
62736145|NCT06340724|ACTIVE_COMPARATOR|Vonoprazan-amoxicillin dual therapy|Participants received Vonoprazan 20 mg tablet orally twice daily and Amoxicillin 1 g tablet orally three times daily for 2 weeks.
62674773|NCT05281640|EXPERIMENTAL|Negative Self Concept intervention|"The NSC module focus on the impact of trauma on one's self concept, how to stay in the present moment and combat dissociation, introduce self - compassion and mindfulness skills, challenge thinking patterns including tackling negative thoughts rules and assumptions that relate to ones-self, how to be more nurturing towards one's self, explore personal qualities and develop a balanced view of self.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
62674774|NCT05281640|NO_INTERVENTION|Treatment as usual (2)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
62674775|NCT05281640|EXPERIMENTAL|Disturbed Relationships intervention|"The DR module will focus on exploration and revision of maladaptive schemas, effective assertiveness, awareness of social context, and flexibility in interpersonal expectations and behaviours that are displayed in social interactions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
62674776|NCT05281640|NO_INTERVENTION|Treatment as usual (3)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
62472126|NCT02431494|ACTIVE_COMPARATOR|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
62674777|NCT01512537|ACTIVE_COMPARATOR|UVB|UVB exposed group
62674778|NCT01512537|ACTIVE_COMPARATOR|Oral vitamin D tablet|Vitamin D supplementation
62114055|NCT03586596|ACTIVE_COMPARATOR|Standard Care Control|Participants will receive an adapted version of standard printed smoking cessation educational materials from the American Cancer Society and, the National Cancer Institute, which include information about the health risks of smoking, benefits \& strategies for quitting and access to free pharmacotherapy by calling a free number.
62114056|NCT05619107|ACTIVE_COMPARATOR|Active transauricular nerve stimulation|Using a training device, two conductive clips are placed securely on both the left and right tragus areas of the outer ear. Using parameters we have identified through systematic review, electrical stimulation (pulse width:200μs; frequency:30Hz) is initiated at 10mA, until the participant feels a 'tingling' sensation within 20s of commencing. At this point the current is reduced to a level just below this perceptible threshold (20-60 mA), which is defined as the 'prescription dose'. The participant then receives another active device set at the 'prescription dose'.
62303403|NCT03992300|ACTIVE_COMPARATOR|Conventional scanning|A conventional elastomeric impression is taken and a zirconia framework is produced
62674779|NCT06251830||Pediatric patients|Pediatric patients referred to the participating imaging centre for a standard MRI procedure.
62674780|NCT06251830||Adult Patients|Adult patients referred to the participating imaging centre for a standard MRI procedure, with neurological signs and symptoms.
62674781|NCT06251830||Healthy Controls|Adult healthy controls
62674782|NCT04341662|EXPERIMENTAL|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
62674783|NCT04341662|ACTIVE_COMPARATOR|Usual care|Usual care with dissemination of the current guidelines
62674784|NCT03133780|ACTIVE_COMPARATOR|Ketamine|Patients will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
62674785|NCT03133780|ACTIVE_COMPARATOR|Midazolam|Patients will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
62303404|NCT04024696|EXPERIMENTAL|Dosing Cohorts|Three (3) dose cohorts are pre-set to include 40 mg BID, 60 mg BID and 80 mg BID,respectively.The pre-set dose group is subject to change during the study and the actual dosage increment is determined by the Data safety Monitoring Committee (DSMC).
62674786|NCT02560415|EXPERIMENTAL|1: Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
61917543|NCT06325332||Cohort 3: Historical Control Cohort|Full-term (born ≥ 37 weeks gestational age) infants without a high-risk condition from previous RSV seasons 2016-2017, 2017-2018, 2018-2019, 2019-2020, and 2022-2023. The 2020-2021 and 2021-2022 seasons are excluded due to low circulation of RSV during the COVID-19 pandemic. Historical seasons' data are intended for descriptive purpose only, to contextualize the impact of the treatment during the 2023-2024 season.
62114057|NCT05619107|SHAM_COMPARATOR|Sham transauricular nerve stimulation|Using a training device, two conductive clips are placed securely on both the left and right tragus areas of the outer ear. Using parameters we have identified through systematic review, electrical stimulation (pulse width:200μs; frequency:30Hz) is initiated at 10mA, until the participant feels a 'tingling' sensation within 20s of commencing (Figure 2). At this point the current is reduced to a level just below this perceptible threshold (20-60 mA), which is defined as the 'prescription dose'. The participant then receives another device set at the 'prescription dose' but this sham device is disabled from delivering any current .
62114058|NCT04047966||Fetal growth restriction|63 fetuses with defects in fetal growth qith an estimated fetal weight below 10th percentile
62114059|NCT04047966||Control group|63 control fetuses with an estimated fetal weight about the 10th percentile
62114060|NCT00511160|ACTIVE_COMPARATOR|S|Study arm: Cardiac surgery group
62114061|NCT00511160|ACTIVE_COMPARATOR|C|Routine cardiology group
62114062|NCT01931813||Infants likely to present febrile convulsions|
62114063|NCT03566186|EXPERIMENTAL|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
62114064|NCT03566186|PLACEBO_COMPARATOR|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
62114065|NCT03566186|OTHER|non-treatment control group|(n=13) Phase 2 training + control group
62114066|NCT00578656|EXPERIMENTAL|1|Baked milk and at least 4 oral food challenges as clinically indicated
62114067|NCT03334019||subjects|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
62674787|NCT02560415|ACTIVE_COMPARATOR|2: Comparator|Treatment as usual
62674788|NCT03782103|EXPERIMENTAL|ZuraPrep (70% IPA)|Isopropyl alcohol (IPA) 70%
62674789|NCT03782103|ACTIVE_COMPARATOR|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
62114068|NCT00174434|EXPERIMENTAL|A|
62114069|NCT01967186|EXPERIMENTAL|Intraportal islet transplantation|Subject randomized to the protocol with intraportal islet transplantation and kidney transplantation
62114070|NCT01967186|EXPERIMENTAL|Intramuscular islet transplantation|Subject randomized to the protocol with intramuscular islet transplantation and kidney transplantation
62114071|NCT01967186|EXPERIMENTAL|Intramuscular transpl with stemcells|Subject randomized to the protocol with intramuscular islet transplantation and where islets have been incubated autologous mesenchymal stemcells. Will also receive kidney transplant
62114072|NCT01967186|ACTIVE_COMPARATOR|Kidney transplantation only|Subject that only undergoes kidney transplantation
62114073|NCT04048018||Active Tuberculosis Patient|
62674790|NCT03782103|PLACEBO_COMPARATOR|ZuraPrep Vehicle|Zurex Prep without IPA
62674791|NCT05403515|NO_INTERVENTION|Control group|Routine nursing interventions were performed on the patients.
62674792|NCT05403515|EXPERIMENTAL|Foot massage group:|For the patients in this group, sociodemographic form, happiness questionnaire, and PSQI was applied as pretest in preliminary examination. The final examination was performed 1 month later (posttest) by using the same scale. For the patients in foot massage group, 30-min foot massage sessions (15 min for each foot, 3 sessions per week for 1 month) were performed in a special room of rehabilitation center, in a quiet atmosphere at suitable temperature and without environmental stimulants.
62674793|NCT05403515|EXPERIMENTAL|Foot massage +Aromatherapy group:|For the patients in this group, sociodemographic form, happiness questionnaire, and PSQI was applied as pretest in preliminary examination. The final examination was performed 1 month later (posttest) by using the same scale. During the foot massage + aromatherapy lavender inhalation intervention, the patients were given lavender oil for 30 minutes by using a censer. The intervention protocol was developed reviewing the literature about lavender oil inhalation
62674794|NCT01922661|EXPERIMENTAL|Cohort 1|Dose 1 of REGN1908-1909 or placebo
62674795|NCT01922661|EXPERIMENTAL|Cohort 2|Dose 2 of REGN1908-1909 or placebo
62674796|NCT01922661|EXPERIMENTAL|Cohort 3|Dose 3 of REGN1908-1909 or placebo
62674797|NCT01655212|EXPERIMENTAL|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
62674798|NCT01655212|NO_INTERVENTION|Control|Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.
62674799|NCT03588000|EXPERIMENTAL|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
62674800|NCT03588000|NO_INTERVENTION|Control group|Voluntary self-monitoring of blood glucose
62674801|NCT00098293|EXPERIMENTAL|1|
62674802|NCT00098293|ACTIVE_COMPARATOR|3|
62674803|NCT00098293|EXPERIMENTAL|2|Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
62674804|NCT01229670|EXPERIMENTAL|aerobic intermittent group|aerobic intermittent group
62674805|NCT01229670|EXPERIMENTAL|aerobic continuous group|aerobic continuous group
62674806|NCT01229670|NO_INTERVENTION|control|home exercise group
62674807|NCT03033693|OTHER|The deep anesthesia group|
62674808|NCT03033693|OTHER|The light anesthesia group|
62674809|NCT01712074|EXPERIMENTAL|30 mg QD of PF-05212377|
62674810|NCT01712074|PLACEBO_COMPARATOR|Placebo|
62674811|NCT06092983|EXPERIMENTAL|HS-10383 (Multiple doses)|Escalating doses of HS-10383 administered orally once daily for a week in healthy participants.
62674812|NCT06092983|PLACEBO_COMPARATOR|HS-10383 Placebo (Multiple doses)|Escalating doses of HS-10383 Placebo administered orally daily for a week in healthy participants.
62674813|NCT03079583|PLACEBO_COMPARATOR|Control-group|Control Rice used for meal, normal zinc level
62674814|NCT03079583|ACTIVE_COMPARATOR|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
62674815|NCT04116697|EXPERIMENTAL|Acupuncture with Anti-Emetics|
62674816|NCT04116697|EXPERIMENTAL|Aromatherapy with Anti-Emetics|
62674817|NCT04116697|NO_INTERVENTION|Control Group|
62674818|NCT06535321|PLACEBO_COMPARATOR|Control|After modelling, when the vibration platform is closed, all participants of the control group completed the same action as vibration training.
62674819|NCT06535321|EXPERIMENTAL|Vibration group|For the vibration group, vibration training was performed immediately after DOMS modelling.
62674820|NCT06535321|EXPERIMENTAL|Kinesio group|For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.
62674821|NCT06535321|EXPERIMENTAL|Combined group|For the combined group, the vibration group and kinesio group interventions were performed simultaneously.
62674822|NCT01713140|EXPERIMENTAL|1 strength training set performed until contraction failure|Knee extensions until contraction failure will be performed, using a relative loading of 10 repetition maximum (RM).
62674823|NCT02898441|ACTIVE_COMPARATOR|Screening Arm|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
62674824|NCT02898441|NO_INTERVENTION|Passive Arm|Eligible subjects were randomized to follow up in usual care
62674825|NCT02077712|ACTIVE_COMPARATOR|Dexmedetomidine 1 ug/kg|1 ug/kg of intranasal dexmedetomidine
62674826|NCT02077712|ACTIVE_COMPARATOR|Dexmedetomidine 2 ug/kg|2 ug/kg of intranasal dexmedetomidine
62674827|NCT03822819|EXPERIMENTAL|probiotic cocktail capsules uptake|Participants take two capsules of probiotic cocktail everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
62114074|NCT04048018||High risk for LTBI Participant|
62114075|NCT04048018||Low risk for prior TB infection Participant|
62114076|NCT04048018||NTM patient|
62114077|NCT04048018||Precision patient|
62114078|NCT04128423|EXPERIMENTAL|AMV564|
62114079|NCT04946045|EXPERIMENTAL|İntervention (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking) Group|"1. Tactile/Kinesthetic Stimulation (15 min): It was applied 3 times a day, once every 3 hours for 10 days.~2. Nonnutritive Sucking: It was applied 8 times a day for 10 days with Orogastric (OG) feeding throughout the feeding."
62114080|NCT04946045|NO_INTERVENTION|Control (Nonnutritive Sucking) Group|1) Nonnutritive Sucking: Administered during feeding with Orogastric (OG) 8 times a day for 10 days.
62114081|NCT01125761|EXPERIMENTAL|dexamethasone 0.5 mg and 1.0 mg clemastine cream|
62114082|NCT01125761|ACTIVE_COMPARATOR|dexamethasone 0,5 mg cream|
62114083|NCT01713530|EXPERIMENTAL|IDegAsp BID+/-OADs|
62114084|NCT01713530|EXPERIMENTAL|IDeg OD plus IAsp +/-OADs|
62114085|NCT01157182|EXPERIMENTAL|Investigational Test Product|Estradiol/Norethindrone acetate 1/0.5 mg Tablets
62114086|NCT01157182|ACTIVE_COMPARATOR|Reference Listed Drug|Activella® 1/0.5 mg Tablets
62114087|NCT04670419||HEV gt 3 clade abchijklm|patients infected with HEV gt 3 clade abchijklm
62114088|NCT04670419||HEV gt 3 clade efg|patients infected with HEV gt 3 clade efg
62114089|NCT06320119|EXPERIMENTAL|Personal approach on asthma control (PDO group)|
62114090|NCT06320119|NO_INTERVENTION|Non-personalized approach (UC group)|
62114091|NCT05982353|SHAM_COMPARATOR|PTFE application with immediate implantation|this group received PTFE membranes during immediate implantation as the gold standard
62114092|NCT05982353|EXPERIMENTAL|Gelatin Sponge application with immediate implantation|this group received gelatin sponges during immediate implant placement
62114093|NCT06438406|ACTIVE_COMPARATOR|Orthotic devices and therapeutic exercise (Group A)|Group A consisting of patients who were prescribed orthoses, to use gradually, and a 20-session rehabilitation programme, based on the Back School method
62114094|NCT06438406|ACTIVE_COMPARATOR|Orthotic devices (Group B)|Group B consisting of patients who were only prescribed orthoses for the lower limbs
62114095|NCT04210765|ACTIVE_COMPARATOR|Clomiphene citrate group 1|Clomiphene citrate dose 50mg/day for 5 days starting on cycle day (2-4).
62472127|NCT02431494|ACTIVE_COMPARATOR|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
62114096|NCT04210765|ACTIVE_COMPARATOR|Clomiphene citrate group 2|Non-responsive to ovulation induction with Clomiphene Citrate with dose:50mg/day; and treated with dose:100mg/day in the succeeding cycle for 5 days, starting on cycle day (2-4).
62114097|NCT05262803|NO_INTERVENTION|Standard-of-care DAPT|Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and prasugrel or ticagrelor for 6 months followed by ASA monotherapy.
62114098|NCT05262803|EXPERIMENTAL|Genotype-guided DAPT|DAPT according to CYP2C19\*2/\*3-genotyping for 6 months followed by ASA monotherapy.
62114099|NCT05262803|EXPERIMENTAL|Shorter genotype-guided DAPT|DAPT according to CYP2C19\*2/\*3-genotyping for 3 months followed by ASA monotherapy.
62114100|NCT02278848|EXPERIMENTAL|Diagnosis of ICAH|"One arm: patients with chronic adult hydrocephalus.~All patients have: Computerised gait analysis, Ultrasound measurement of cerebral pulsatility, MRI flow, Urinary incontinence scale"
62303405|NCT04062812|EXPERIMENTAL|Diluted citrate|"Initial citrate dose 3.5 mmol/L Initial calcium programmed 100% (compensation dose) only dialysis and ratio 1:10 (blood/dialysis) No fluids in the repositioning scale"
62303406|NCT04062812|ACTIVE_COMPARATOR|Concentrated citrate|Initial citrate dose: 3.5 mmol/L Initial calcium dose: 1.9 mmol/L and 1:20 ratio (blood/dialysis) No convection programmed
62303407|NCT05232955||GTS patient group|Cohort of adult GTS patients, males and females, age range 18 to 50 years
62674828|NCT03822819|PLACEBO_COMPARATOR|placebo capsules uptake|Participants take two capsules of placebo everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
62674829|NCT04584554|EXPERIMENTAL|Intervention|
61917544|NCT06325332||Cohort 4: Infant Cohort with High-Risk Conditions|Infants born \< 37 weeks gestational age and those diagnosed with a high-risk condition between birth and the end of the observation period (regardless of gestational age at birth), will be considered infants with high-risk conditions. Infants with high-risk conditions will be excluded from Cohort 1, Cohort 2, and Cohort 3. Descriptive statistics will be separately assessed for this high-risk cohort.
61917545|NCT00695890||1|Healthy volunteers
62674830|NCT01217138|OTHER|Original epinephrine autoinjector group|Participants were given original epinephrine autoinjector trainer wrapped by a gray sticky paper.
61917546|NCT02985970||ČSARIM - questionnaire|Members of Czech society of anesthesiology, resuscitation and intensive care will obtain the questionnaire
61917547|NCT00789074|EXPERIMENTAL|Varenicline pre-treatmemt|Participants will use varenicline (1mg BD) 4-weeks prior to quitting
61917548|NCT00789074|PLACEBO_COMPARATOR|Placebo|Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
61917549|NCT01165736|ACTIVE_COMPARATOR|Intravenous: PF-05186462|
61917550|NCT01165736|ACTIVE_COMPARATOR|Oral: PF-05186462|
61917551|NCT01165736|ACTIVE_COMPARATOR|Intravenous: PF-05089771|
61917552|NCT01165736|ACTIVE_COMPARATOR|Oral: PF-05089771|
61917553|NCT01165736|ACTIVE_COMPARATOR|Intravenous: PF-05150122|
61917554|NCT01165736|ACTIVE_COMPARATOR|Oral: PF-05150122|
62303408|NCT05232955||Control group|Cohort of healthy control subjects, males and females, age range 18 to 50 years
62674831|NCT01217138|ACTIVE_COMPARATOR|Modified epinephrine autoinjector group|Participants were given the same epinephrine autoinjector trainer wrapped by a gray sticky paper which was modified by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.
62674832|NCT04560114|EXPERIMENTAL|Essential oils|Inhalation will be carried out via an inhaler stick containing essential oils (Mentha x Piperita; Citrus Limon; Zingiber Officinale)
62674833|NCT06477510|EXPERIMENTAL|Test group|self perception of esthetics and clinical periodontal parameters will be evaluated in patients with stage I/II/III periodontitis at baseline and post non surgical periodontal therapy.
62674834|NCT03774472|EXPERIMENTAL|Treatment (hydroxychloroquine, palbociclib, letrozole)|"PHASE I: Patients with advanced, metastatic (stage IV) breast cancer receive hydroxychloroquine PO QD, palbociclib PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients with early stage (stage I-III) breast cancer receive hydroxychloroquine PO QD on days 15-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive palbociclib PO QD, and letrozole PO QD on days 1-28, followed by standard of care surgery at week 5. If there is a proliferative benefit with CCCA by biopsy at 4 weeks, cycles may repeat every 28 days for up to 20-24 weeks in the absence of disease progression or unacceptable toxicity, followed by standard of care surgery during weeks 20-24."
62674835|NCT06150014|PLACEBO_COMPARATOR|Placebo +Nucleoside (acid) analogs (NAs) combination therapy 24 weeks|Placebo and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
62674836|NCT06150014|ACTIVE_COMPARATOR|50 mg of TQA3605 tablets +NAs combination therapy 24 weeks|50 mg of TQA3605 tablets and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
62674837|NCT06150014|ACTIVE_COMPARATOR|100 mg of TQA3605 tablets +NAs combination therapy 48 weeks|TQA3605 is taken orally 100mg once daily; Nucleoside (acid) analogues were used once daily for 48 weeks.
62674838|NCT06150014|ACTIVE_COMPARATOR|200 mg of TQA3605 tablets +NAs combination therapy 48 weeks|TQA3605 is taken orally 200mg once daily; Nucleoside (acid) analogues were used once daily for 48 weeks.
62674839|NCT06150014|PLACEBO_COMPARATOR|Placebo +Nucleoside (acid) analogs (NAs) combination therapy|Placebo taken orally once daily, continue for 12 weeks. Placebo was then combined with nucleoside (acid) analogues (once daily) for 36 weeks
62674840|NCT06150014|ACTIVE_COMPARATOR|100 mg of TQA3605 tablets +NAs combination therapy|TQA3605 was taken orally 100mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.
62674841|NCT06150014|ACTIVE_COMPARATOR|200 mg of TQA3605 tablets +NAs combination therapy|TQA3605 was taken orally 200mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.
62674842|NCT06150014|ACTIVE_COMPARATOR|300 mg of TQA3605 tablets+NAs combination therapy|TQA3605 was taken orally 300mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.
62674843|NCT06519175||Children and adolescent with lower limb deformities|
62736146|NCT06340724|EXPERIMENTAL|Banxiaxiexin decoction combined with vonoprazan-amoxicillin dual therapy|Participants received Vonoprazan 20 mg tablet orally twice daily,Amoxicillin 1 g tablet and Banxiaxiexin decoction 100 ml liquid-medicine orally three times daily for 2 weeks.
62736147|NCT05027347||100 healthy people|10 ml blood and tissue biopsy were collected from each patient
61917555|NCT01165736|ACTIVE_COMPARATOR|Intravenous: PF-05241328|
61917556|NCT01165736|ACTIVE_COMPARATOR|Oral: PF-05241328|
61917557|NCT04836715||Parkinson's Disease|Individuals with idiopathic Parkinson's Disease and no other neurological disease
61917558|NCT04836715||Other Neurological Disorders|Individuals with one neurological disorder other than Parkinson's Disease (e.g. Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Parkinsonism)
61917559|NCT04836715||Healthy|Individuals without any neurological disorder
61917560|NCT01528423||Men 16 - 18yrs|
61917561|NCT01528423||Men 30 - 32 yrs|
61917562|NCT01528423||Men 70 yrs +|
61917563|NCT01528423||Women 16 - 18 yrs|
61917564|NCT01528423||Women 30 - 32 yrs|
61917565|NCT01528423||Women 70 yrs +|
62736148|NCT05027347||100 gastric cancer patients|10 ml blood and tissue biopsy were collected from each patient
62736149|NCT02853396|EXPERIMENTAL|Cognitive behavioural therapy|Cognitive behaviour therapy
62736150|NCT02853396|ACTIVE_COMPARATOR|Psychoeducation|psychoeducation
62736151|NCT01084291|EXPERIMENTAL|DEN1 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
62674844|NCT02400736|EXPERIMENTAL|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) competitive employment: IPS assists participants to enter into competitive jobs; 2) eligibility based on client choice, i.e. zero exclusion; 3) integration of IPS and treatment team, i.e. the PACT; 4) patient-centered job match for competitive employment; 5) personalized benefits counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) rapid job search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) job development: IPS specialists build an employer network based on Veterans' interests; 8) time-unlimited and individualized support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
62736152|NCT01084291|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo vaccine.
62472128|NCT03197285|ACTIVE_COMPARATOR|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
61917566|NCT02814331||symptomatic partial epilepsy|whose brain MRI is abnormal multimodal high-resolution EEG-NIRS
61917567|NCT02814331||not symptomatic partial epilepsy|whose brain MRI is normal multimodal high-resolution EEG-NIRS
61917568|NCT06553859||Test Group|"Fifty subjects are to be enrolled prospectively. Breast cancer patients who are willing to undergo breast reconstruction surgery based on inserting breast implants with ADM will be selected as the test group, with SC Derm(Acellular Dermal Matrix processed by CO2 supercritical fluid technology.)"
62303409|NCT00336362|ACTIVE_COMPARATOR|1|Participants will receive hydroxyurea pretreatment.
61917569|NCT06553859||Control Group|Fifty subjects are to be enrolled retrospectively from the medical records of breast cancer patients who have undergone breast reconstruction surgery based on inserting breast implants with ADM made by other companies. All breast reconstruction surgeries have operated from 1, June 2021 to 9, November 2021 at Asan medical center at Seoul, South Korea.
61917570|NCT04613401||VAD-patients with Telemonitoring|
61917571|NCT05990621|EXPERIMENTAL|Anti-CD70 CAR-T cells|Anti-CD70 CAR-T cells are autologous genetically modified T cells.
61917572|NCT01568801|NO_INTERVENTION|Control Group|Individuals randomized into the control arm will receive usual community care services referred by the social worker from SGH and AH.
61917573|NCT01568801|EXPERIMENTAL|Intervention Group|Individuals in the intervention group will go through an integrated program of community based health and social care based on intake and ongoing evaluation by the SingaPACE team.
62303410|NCT00336362|NO_INTERVENTION|2|Participants will not receive hydroxyurea pretreatment.
61917574|NCT06392945|EXPERIMENTAL|Cognitive Treadmill Walking Training with Rhythmic Auditory Cueing (CTW+RAC) group|The CTW+RAC group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing (i.e., 110% of baseline cadence).
61917575|NCT06392945|ACTIVE_COMPARATOR|Cognitive Treadmill Walking Training (CTW)|The CTW group will receive cognitive training while walking at a progressive speed on the treadmill.
61917576|NCT06392945|ACTIVE_COMPARATOR|Treadmill Walking Training (TW)|The TW group will train only in treadmill walking with progressive speed adjusted weekly.
61917577|NCT04493840|EXPERIMENTAL|Shenfu Injection|
61917578|NCT04493840|PLACEBO_COMPARATOR|5% Glucose Injection|
62114101|NCT06427252|EXPERIMENTAL|HIPEC plus PD-1 plus SOX therapy|HIPEC treatment (paclitaxel, at 43°C for 60 min) was performed on the 1st day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ). Systemic therapy was started 3 weeks after HIPEC. Systemic therapy including: Tirilizumab: 200 mg, Q3W; oxaliplatin: 130mg/m2, Q3W; Herceptin: loading dose of 8 mg/kg followed by 6 mg/kg Q3W. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle Q3W; After 2-6 weeks, laparoscopic exploration was performed, PCI score was calculated, and radical surgery was performed in patients who were eligible for radical surgery. Postoperative HIPEC was performed twice.
62303411|NCT01826214|EXPERIMENTAL|LDE225-400|Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
62303412|NCT01826214|EXPERIMENTAL|LDE225-800|Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
62114102|NCT00143936|ACTIVE_COMPARATOR|Low Carb|Low Cabohydrate Diet: 20 week of weekly group behavior modification, 20 weekly bi-weekly, bi-monthly to finish
62114103|NCT00143936|ACTIVE_COMPARATOR|Low Calorie|Low Calorie Diet: 20 weeks of weekly behavior modification, 20 weekly of bi-weekly, bimonthly to finish 2 years
62114104|NCT06097429||study group|COVID-19 confirmed cases with positive PCR test in the first week of diagnosis
62114105|NCT06097429||control group|healthy volunteers, persons with no history nor symptoms suggestive of COVID-19 with negative COVID -19 PCR test and no CT Chest changes suggestive of COVID-19 infection.
62114106|NCT02823548|EXPERIMENTAL|Droglican|Patients take one sacchet of Droglican (Chondroitin Sulfate 1,500mg + Glucosamine Hydrochloride 1,200mg) Once a day during 6 months.
62303413|NCT06214728|PLACEBO_COMPARATOR|MINST|Minimally invasive non-surgical treatment (MINST): Using mini five curettes and ultrasonic devices with precise tips , the root surfaces were cleaned reaching to the base of the pocket, avoiding excessive root surface smoothing and gingival curettage.
62303414|NCT06214728|ACTIVE_COMPARATOR|MINST+HA|Minimally invasive non-surgical technique (MINST) with application of Hyaluronıc Acid gel: Using mini five curettes and ultrasonic devices with precise tips , the root surfaces were cleaned reaching to the base of the pocket, avoiding excessive root surface smoothing and gingival curettage. HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus.
62114107|NCT02823548|PLACEBO_COMPARATOR|Placebo|Patients take one sacchet of Placebo once a day during 6 months.
62114108|NCT06406972||Lund 2010-09-15-2015-09-14|Lund, before implementation of Brief Admission by self-referral
62303415|NCT02302911||Early intensive behavioral intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive behavioral Intervention at one of the participating centres.
62303416|NCT02302911||Early intensive eclectic intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive eclectic Intervention at the participating centre.
61917579|NCT04149275|EXPERIMENTAL|Cabozantinib + Nivolumab + Ipilimumab|All recurrent carcinosarcomas
61917580|NCT04038632|EXPERIMENTAL|District Hospital focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be implemented at the DH level. PHCs in this district, will only conduct systematic TB screening.
62736153|NCT03280199|OTHER|Type of simulator - 1|"VR simulator with physical mannequin and probe.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
62736154|NCT03280199|OTHER|Type of simulator - 2|"VR simulator with virtual mannequin / abdomen~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
62303417|NCT02302911||Control group|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving treatment as usual or no treatment at all.
61917581|NCT04038632|EXPERIMENTAL|Primary Health Center focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be done at the PHC.
61917582|NCT00877097|EXPERIMENTAL|1|Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
61917583|NCT00877097|PLACEBO_COMPARATOR|2|Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
61917584|NCT00877097|ACTIVE_COMPARATOR|3|Clodronate 800 mg / day for five years.
61917585|NCT00919841||Postpartum women|Women who deliver a singleton vaginally
61917586|NCT02034344||Group 1: Healthy participants|20 healthy participants will be enrolled.
61917587|NCT02034344||Group 2: DLE/SCLE without SLE|30 participants with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE) will be enrolled.
61917588|NCT02034344||Group 3: DLE/SCLE with SLE|30 participants with DLE/SCLE with SLE will be enrolled.
61917589|NCT04759183|EXPERIMENTAL|Arm I (Angry Birds, TRIPP)|Patients participate in a VR intervention (Angry Birds) over 15 minutes before standard of care surgery and then participate in a VR intervention (TRIPP) over 15 minutes after surgery.
61917590|NCT04759183|EXPERIMENTAL|Arm II (TRIPP, Angry Birds)|Patients participate in a VR intervention (TRIPP) over 15 minutes before standard of care surgery and then participate in a VR intervention (Angry Birds) over 15 minutes after surgery.
62303418|NCT03397186|OTHER|Basic science (trabectedin, biopsy)|Patients undergo a biopsy at baseline and then receive trabectedin for up to 4 cycles. Beginning 1 week after completion of cycle 2 and prior to cycle 3, patients undergo a second biopsy. Patients who achieve clinical benefit (CR, PR, SD) after the first post-treatment scan and who continue trabectedin for 4 cycles undergo a third biopsy after cycle 4.
62674845|NCT02400736|ACTIVE_COMPARATOR|Treatment as Usual Vocational Rehabilitation/Transitional Work (TAU-VR)|Treatment as Usual Vocational Rehabilitation includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW) which involves 1) time-limited set-aside work experiences: short-term transitional work experiences in a brokered or set-aside work setting; 2) no strict entrance criteria other than general medical clearance; 3) limited integration of TW and clinical Services; 4) not patient-centered: TW jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) personalized benefits counseling; 6) limited job search: TW specialists provide variable and limited guidance for competitive job search; 7) no job development: TW specialists do not engage in community based job development; 8) time limited: The TW specialist does not provide long-term follow-up after the first job is obtained.
62736155|NCT03280199|OTHER|Type of image acquisition - 3|"US images are acquired through real US volumes from patients~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
61917591|NCT05648656|ACTIVE_COMPARATOR|TXA|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days.
61917592|NCT05648656|PLACEBO_COMPARATOR|Control|Nebulization with 0.9%normal saline 5mL 8 hourly for 2 days
62303419|NCT04752787|EXPERIMENTAL|Experimental|Experimental group 1: Breastfeeding training for successful breastfeeding in twin babies will be given to the online training group. The training will be carried out by the researchers (DM) and (SYC) using visual training tools (power point presentation, simultaneous breastfeeding animations in twin babies and breastfeeding guide). Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. In the first session, about 45 minutes of online slide-assisted training on successful breastfeeding in twin babies and the importance of breast milk will be conducted and questions of pregnant women will be answered. Total training will take approximately one and a half hours.
62308360|NCT05475691||Type 1 SMA (with and without use of disease-modifying treatment (DMTs))|"* Participants of both sexes who presented signs and symptoms of Spinal Muscular Atrophy before six months of age and have a genetic report confirming 5q SMA.~* No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~* Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~* The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
62736156|NCT03280199|OTHER|Type of image acquisition - 4|"US images are acquired through computer-generated images.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
61917593|NCT02940002|EXPERIMENTAL|BAY1003803 0.1% lipophilic cream|BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)
61917594|NCT02940002|EXPERIMENTAL|BAY1003803 0.1% ointment|BAY1003803 0.1% ointment (on plaque and healthy skin)
61917595|NCT02940002|EXPERIMENTAL|BAY1003803 0.01% lipophilic cream|BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)
61917596|NCT02940002|EXPERIMENTAL|BAY1003803 0.01% ointment|BAY1003803 0.01% ointment (on plaque and healthy skin)
61917597|NCT02940002|ACTIVE_COMPARATOR|Clobetasol propionate|Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)
62303420|NCT04752787|ACTIVE_COMPARATOR|Active comparator|"Experimental group 2: Breastfeeding training for successful breastfeeding in twin babies will be given to the QR supported online training group. Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. Total training will take approximately one and a half hours.~In the guideline, there will be 4 vieos ralted to Breastfeeding and Feeding with Breast Milk in Twin Babies, Breastfeeding Techniques and Positions in Twin Babies, Expressing Breastfeeding, Storing and Feeding it to Babies and Problems Encountered in Breastfeeding and its Solutions, and simultaneous breastfeeding used in breastfeeding twin babies and also there will be a total of 7 QR codes, 3 of which are related to the animations (Animation 1-2-3) of the positions (double cradle grip, double football grip, combination of armpit and cradle grip-parallel grip)."
62303421|NCT04752787|NO_INTERVENTION|Control Groups|Pregnant women in the control group will be followed up in line with the routine health monitoring and information of the hospital.
62472129|NCT03197285|EXPERIMENTAL|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
62472130|NCT03368287|EXPERIMENTAL|activity tracker|In this study, Fitbit One, the activity tracker, will be used for every participants to evaluate the daily steps before and after surgery for one year
62472131|NCT01419093|NO_INTERVENTION|5A Communication|Behavioral: 5 A intervention for physical activity
62472132|NCT02384876|EXPERIMENTAL|Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|Dose escalation: 6 successive cohorts with a maximal increasing dose
62472133|NCT02384876|ACTIVE_COMPARATOR|Ephedrine, dose : 0.1 mg/kG, reference dose|Reference dose
62472134|NCT01027923|EXPERIMENTAL|Dose Level 1|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
62472135|NCT01027923|EXPERIMENTAL|Dose Level 2|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
62472136|NCT01027923|EXPERIMENTAL|Dose Level 3|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
62472137|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
62472138|NCT01244022||Colorectal cancer patients|Patients with pathohistologically verified colorectal cancer or adenoma with epithelial dysplasia
62674846|NCT04802785|EXPERIMENTAL|The study Group|"1. Before the flight in the conditions of the clinic's medical treatment room: Citicoline 500 mg(Vitaae®) and Cytochrome10 mg (Cytochrome C®) per os.~2. 30 minutes before the flight: dilute 1 sachet of ORS® (Sodium Chloride 2.6 g+Potassium Chloride 1.5 g+Sodium Citrate 2.90 g+Dextrose 13.5 g) in 1 liter of water. Drink half of the solution (0.5 l) 30 minutes before the flight (at the airport). Also, 0.5 L of the solution will be provided on the plane during landing. If the flight lasts more than 1.5 hours, then dilute the second sachet of ORS® with 0.5-1 liters of water.~3. 30 minutes before the flight (per os): Domperidone (Motilium ®) (1 tablet), Simethicone (Gas-X®) (3-4 capsules), Acetylsalicylic acid 150 mg and magnesium hydroxide 30,39 mg (Cardiomagnyl®)(1 tablet), probiotic (Bactistatin®) (1 capsule) per os."
62674847|NCT04802785|ACTIVE_COMPARATOR|Control group|Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
62674848|NCT04802785|NO_INTERVENTION|Explanatory group:|12 participants without any intervention.
62674849|NCT04476485||experimental group|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy.
62674850|NCT03547232|EXPERIMENTAL|Indomethacin group|Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
62674851|NCT03547232|SHAM_COMPARATOR|Standard group|Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
62674852|NCT05945758|EXPERIMENTAL|Spacing in the maxillary anterior teeth area treated with injectable resin composite technique.|"The injectable composite resin technique is an indirect/direct method that uses a transparent silicone index for accurate and predictable translation of diagnostic wax-up into composite restorations without the need for tooth preparation.~The Spaces will be restored with injectable resin composite."
61917598|NCT02940002|ACTIVE_COMPARATOR|Betamethasone/calcipotriene|Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)
62472139|NCT03165994|EXPERIMENTAL|APX005M With Standard of Care Chemoradiation|"Participants will receive standard of care chemoradiation, consisting of:~* External beam radiation in daily fractions (28 fractions) from Weeks 1-6, administered once per day up to 5 days/week.~* Carboplatin (area under the carboplatin plasma concentration versus time curve = 2) and paclitaxel (50 mg/m\^2) chemotherapy intravenously (IV) over 1 hour, once weekly, from Weeks 1-5.~The participants also will receive concurrent 0.3 mg/kg APX005M IV over 1 hour, once weekly, on Weeks 1, 2, 4, and 6 (2-3 days after chemoradiation).~Surgical resection of the tumor will be planned from Week 10 up to approximately Week 17, as indicated in the protocol amendment under which each participant is enrolled."
62472140|NCT04371133||Endometrioma|Endometrioma (n=23)
62472141|NCT04371133||Healthy controls|Healthy controls Healthy volunteers n=25
62472142|NCT03535896|EXPERIMENTAL|HSR and injection|HSR and corticosteroid injection
62674853|NCT05945758|ACTIVE_COMPARATOR|Spacing in the maxillary anterior teeth area treated with conventional layering composite technique.|shade mapping of enamel and dentin, then isolation the teeth with rubber dam. Palatal index will be done on waxing up and applied against the palatal surface to check the adaptation of the index. Then, the enamel shade adapted on the index in the spacing area. index will be placed back on the anterior teeth to build the palatal wall. A brush will be used to adapt the composite to the margin. After removing excess material, light curing will be carried out for 20 seconds. The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
62674854|NCT01389284|EXPERIMENTAL|Naproxen Sodium ER (BAYH6689)|1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
62674855|NCT01389284|ACTIVE_COMPARATOR|Naproxen Sodium IR (Aleve, BAYH6689)|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
62674856|NCT01389284|PLACEBO_COMPARATOR|Placebo|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
62114109|NCT06406972||Lund 2015-09-15-2020-09-14|Lund, after implementation of Brief Admission by self-referral in Lund, before implementation of Brief Admission by self-referral in Linköping
62114110|NCT06406972||Lund 2020-09-15-2025-09-14|Lund, after implementation of Brief Admission by self-referral in Lund and in Linköping
62114111|NCT06406972||Linköping 2010-09-15-2015-09-14|Linköping before implementation of Brief Admission by self-referral
62472143|NCT01223105|EXPERIMENTAL|Slow Freezing|oocytes will be frozen by slow freeze/ rapid thaw
62472144|NCT01223105|EXPERIMENTAL|Vitrification|oocytes will be frozen using rapid freezing/rapid thaw
62472145|NCT06293872|EXPERIMENTAL|12*2 mm length miniscrew|"The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots."
62472146|NCT06293872|ACTIVE_COMPARATOR|14*2 mm length miniscrew|"The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots."
62674857|NCT03938415|EXPERIMENTAL|Acupuncture|Acupuncture
62114112|NCT06406972||Linköping 2015-09-15-2020-09-14|Linköping after implementation of Brief Admission by self-referral in Lund, before implementation of Brief Admission by self-referral in Linköping
62114113|NCT06406972||Linköping 2020-09-15-2025-09-14|Linköping after implementation of Brief Admission by self-referral in Lund and in Linköping
62114114|NCT06406972||Helsingborg 2014-02-15-2017-02-14|Helsingborg before implementation of Brief Admission by self-referral
62114115|NCT06406972||Helsingborg 2017-02-15-2020-02-14|Helsingborg after implementation of Brief Admission by self-referral in Helsingborg, before implementation of Brief Admission by self-referral in Norrköping
62114116|NCT06406972||Helsingborg 2020-02-15-2023-02-14|Helsingborg after implementation of Brief Admission by self-referral in Helsingborg and in Norrköping
62472147|NCT04470115|ACTIVE_COMPARATOR|General anesthesia|Patients will receive general endotracheal anesthesia with propofol, fentanyl, sevoflurane and rocuronium.
62114117|NCT06406972||Norrköping 2014-02-15-2017-02-14|Norrköping before implementation of Brief Admission by self-referral
62114118|NCT06406972||Norrköping 2017-02-15-2020-02-14|Norrköping after implementation of Brief Admission by self-referral in Helsingborg, before implementation of Brief Admission by self-referral in Norrköping
62114119|NCT06406972||Norrköping 2020-02-15-2023-02-14|Norrköping after implementation of Brief Admission by self-referral in Helsingborg and in Norrköping
62114120|NCT04300816|EXPERIMENTAL|CBT-UT|Seven telephone-based sessions of cognitive behavioral therapy for uncertainty tolerance (CBT-UT) delivered over seven weeks.
61917599|NCT05676593|ACTIVE_COMPARATOR|People living with diabete standard TPE|HBA1c at 3 and 6 months Therapeutic education Auto questionnary on Aviitam plateform at 3 and 6 months
62114121|NCT04300816|ACTIVE_COMPARATOR|tCBT|Seven telephone-based sessions of traditional cognitive behavioral therapy (tCBT) delivered over seven weeks.
62114122|NCT04300816|NO_INTERVENTION|TAU|Participant continues with their lives as they normally would.
62674858|NCT03938415|ACTIVE_COMPARATOR|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone
62114123|NCT02248480|EXPERIMENTAL|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
62114124|NCT02248480|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once a day for 15 weeks.
62114125|NCT05647044|ACTIVE_COMPARATOR|active iTBS|Subjects receiving active iTBS treatment
62114126|NCT05647044|PLACEBO_COMPARATOR|placebo iTBS|Subjects receiving placebo (sham) iTBS treatment
62114127|NCT04224181||Women with HIV|Individuals with female nascent sex who have been diagnosed with HIV.
62114128|NCT04224181||Women without HIV|Individuals with female nascent sex who do not have HIV.
62114129|NCT02268630||Group A|Patients treated with Warfarin for VTE
62303422|NCT02734563||Multiple hernia group|Males undergoing at least three repairs of abdominal wall hernias at three different anatomic locations. Collagen turnover is analysed.
62303423|NCT02734563||Control group|Males without any history or presence of hernias
62674859|NCT01057940||PEJ placement|Patients who have failed conventional DPEJ placement and would otherwise require surgical intervention.
62114130|NCT02268630||Grup B|Patients treated with Rivaroxaban for VTE
62114131|NCT01144182|NO_INTERVENTION|Current Best Practice (CBP)|CBP received no intervention and only current best practices for inpatient HF care.
62114132|NCT01144182|ACTIVE_COMPARATOR|Quality improvement program (QIP)|Comprehensive quality improvement program (QIP) intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
62114133|NCT06245200|EXPERIMENTAL|Guided Internet Based Intervention|Participants in this group will use the UNIPDES intervention with guidance support.
62674860|NCT04472208|EXPERIMENTAL|Ambulatory Monitoring Solution|The evaluable device is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
62674861|NCT01893762|EXPERIMENTAL|16 rowers|Adult rowers, aged between 18 and 25, training \>6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
62114134|NCT06245200|EXPERIMENTAL|Unguided Internet Based Intervention|Participants in this group will use the UNIPDES intervention without guidance
62114135|NCT06245200|NO_INTERVENTION|Waitlist|Participants in this group will not receive any intervention. However, if they wish, they will be able to access the UNIPDES unguided version when the trial ends.
62303424|NCT04676243|EXPERIMENTAL|Quizartinib plus standard of care (SOC)|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Quizartinib
62303425|NCT04676243|ACTIVE_COMPARATOR|Physician's choice|Physician's choice (usually Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Midostaurin)
62472148|NCT04470115|EXPERIMENTAL|Regional anesthesia|Patients will receive femoral and lateral femoral cutaneous nerves block under ultrasonographical guidance before operation.During surgical procedure they will receive deep sedation with propofol.
62472149|NCT03592953|EXPERIMENTAL|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
62303426|NCT03364998|EXPERIMENTAL|BAY94-9027 and Elocta|Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
62303427|NCT03364998|EXPERIMENTAL|Elocta and BAY94-9027|Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment
62303428|NCT01733355|EXPERIMENTAL|Tau diagnostic|\[F18\] T807
62303429|NCT02610283|ACTIVE_COMPARATOR|QPI-1002|QPI-1002 Injection, single dose
62303430|NCT02610283|PLACEBO_COMPARATOR|Placebo|isotonic saline
62674862|NCT00145327|EXPERIMENTAL|Zoledronic Acid 6|Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
61917600|NCT05676593|EXPERIMENTAL|People living with diabete standard TPE + FSL 28 days|"Continuous mesure of glucose (FSL2) during 28 days at enrollment Therapeutic education HBA1c at 3 and 6 months Auto questionnary on Aviitam plateform at 3 and 6 months~Auto questionnary on Aviitam plateform at 3 and 6 months"
61917601|NCT03865576||Thomas Jefferson University|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
62114136|NCT02873754|EXPERIMENTAL|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
62114137|NCT05061342||Cancer Patients|Those with cancer.
62114138|NCT05061342||Normal (non cancer) controls|Those without cancer.
62114139|NCT05318573|EXPERIMENTAL|Safety Run-in Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
61917602|NCT03865576||Honor Health in Phoenix|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
61917603|NCT03865576||Emory University Hospital in Atlanta|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors"
61917604|NCT03865576||University of Washington|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device. .~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors and lumbar puncture"
61917605|NCT01520831|EXPERIMENTAL|BIAsp 30|
61917606|NCT01520831|EXPERIMENTAL|BIAsp 50|
61917607|NCT01520831|EXPERIMENTAL|BIAsp 70|
61917608|NCT01520831|ACTIVE_COMPARATOR|Insulin aspart|
61917609|NCT02719873||control group|the group with normal BMI
61917610|NCT02719873||study group|The group with the BMI more than 24.9 kg per meter square to study the impact of maternal obesity in pregnancy outcome
62114140|NCT05318573|EXPERIMENTAL|Urothelial Monotherapy - FF-10832 Expansion Phase|FF-10832 will be dosed at 40 mg/m2
62114141|NCT05318573|EXPERIMENTAL|Urothelial Combination - FF-10832 + pembrolizumab Expansion Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
62114142|NCT05318573|EXPERIMENTAL|NSCLC Monotherapy - FF-10832 Expansion Phase|FF-10832 will be dosed at 40 mg/m2
62114143|NCT05318573|EXPERIMENTAL|NSCLC Combination - FF-10832 + pembrolizumab Expansion Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
62114144|NCT02824159||Patient with haematologic malignancies|"Interventions to be administrated are :~* Clinical examinations~* Biological statement~* Blood samples for pharmacokinetics exploration~* Imagery with positron emission tomography scan or resonance magnetic imagery~* Saliva samples for genetics analyses~* Blood samples for treatment mutation resistance search~* Quality of life scale questionary~* Detection of adverse events"
62114145|NCT03278028|EXPERIMENTAL|Active|A-101 Topical Solutions
62303431|NCT01612910|EXPERIMENTAL|microencapsulated diindolylmethane, lab. biomarker analysis|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
62303432|NCT00827489|EXPERIMENTAL|HTC-867|
62674863|NCT00145327|PLACEBO_COMPARATOR|Zoledronic Acid 3 Placebo 3|Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
61917611|NCT01193751||asphyxiated newborns > 37 weeks of gestation|
62114146|NCT03278028|PLACEBO_COMPARATOR|Vehicle|Vehicle
62114147|NCT03829917|EXPERIMENTAL|Paromomycin and Miltefosine|Paromomycin-Aquaphilic cream applied topically once daily for 28 days plus oral miltefosine pills 2.5 mg/day \[50 mg tid\] for 28 days.
62114148|NCT03829917|ACTIVE_COMPARATOR|Miltefosine|Miltefosine pills alone \[2.5 mg/day \[50 mg tid\] for 28 days. This group will also receive Aquaphilic-vehicle cream for 28 days
62114149|NCT03829917|ACTIVE_COMPARATOR|Paromomycin|Paromomycin-Aquaphilic cream applied topically once daily for 28 days.
62114150|NCT05404893||Fibromyalgia without gastrointestinal symptoms|Patients diagnosed as having Fibromyalgia according to american college of rheumatology 2016 classification criteria, with no abdominal pain, constipation, diarrhea, tenesmus, abdominal cramps
62114151|NCT05404893||Fibromyalgia with gastrointestinal symptoms|Patients diagnosed as having Fibromyalgia according to american college of rheumatology 2016 classification criteria, with abdominal pain and constipation and/or diarrhea and/or tenesmus and/or abdominal cramps
62114152|NCT05404893||Healthy controls|Healthy controls, no gastrointestinal symptoms
62114153|NCT05387837|EXPERIMENTAL|Stage 1 wAMD|"* Cohort A1 - 0.18 mg/kg of D-4517.2~* Cohort B1 - 0.36 mg/kg of D-4517.2~* Cohort C1 - 0.71 mg/kg of D-4517.2~* Cohort D1 - 1.5 mg/kg of D-4517.2"
62114154|NCT05387837|EXPERIMENTAL|Stage 1 DME|"* Cohort B2 - 0.36 mg/kg of D-4517.2~* Cohort C2 - 0.71 mg/kg of D-4517.2~* Cohort D2 - 1.5 mg/kg of D-4517.2"
62114155|NCT05387837|EXPERIMENTAL|Stage 1A wAMD|"* Cohort E1 - 2.0 mg/kg of D-4517.2 every 2 weeks~* Cohort F1 - 2.0 mg/kg of D-4517.2 every 4 weeks"
62114156|NCT05387837|EXPERIMENTAL|Stage 1A DME|"* Cohort E2 - 2.0 mg/kg of D-4517.2 every 2 weeks~* Cohort F2 - 2.0 mg/kg of D-4517.2 every 4 weeks"
62114157|NCT02452242|EXPERIMENTAL|ABX464|
62114158|NCT02452242|PLACEBO_COMPARATOR|Placebo|
62114159|NCT01463046|EXPERIMENTAL|Panobinostat|
62114160|NCT03003988|EXPERIMENTAL|Creatine monohydrate|Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
62114161|NCT03003988|ACTIVE_COMPARATOR|Creatine nitrate|Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
62114162|NCT03003988|PLACEBO_COMPARATOR|Placebo|6.5 g. dextrose
61917612|NCT03616171|EXPERIMENTAL|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:~1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
62114163|NCT05679830|EXPERIMENTAL|160mg Cannabidiol Isolate|320mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
62114164|NCT05679830|EXPERIMENTAL|320mg Cannabidiol Isolate|160mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
62114165|NCT05262270|EXPERIMENTAL|Drug intervention (XR-NTX+XR-BUP)|"The study intervention is three doses of 380mg XR-NTX (Weeks 0, 3 and 6) and two doses of 300mg XR-BUP (Weeks 0, 4).~Drug: XR-NTX XR-NTX: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Extended Release Injectable Naltrexone Arm: Experimental~Drug: XR-BUP XR-BUP: 2 subcutaneous injections administered Week 0, 4. Other Names: Extended Release Injectable Buprenorphine Arm: Experimental"
62114166|NCT05262270|PLACEBO_COMPARATOR|Placebo|"Matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).~Drug: Placebo (PLB) Injectable Placebo: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Injectable matching (to XR-NTX) placebo Arm: Placebo Comparator - matched Placebo (PLB)~Drug: Placebo (PLB) Injectable Placebo: 2 subcutaneous injections administered Week 0, 4. Other Names: Injectable matching (to XR-BUP) placebo Arm: Placebo Comparator - matched Placebo (PLB)"
62114167|NCT03896841||PCOS|premenopausal patients with PCOS
62114168|NCT03896841||control subjects|non-pregnant healthy control subjects
62303433|NCT00827489|PLACEBO_COMPARATOR|Placebo|
62472150|NCT03592953|EXPERIMENTAL|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
62674864|NCT00145327|EXPERIMENTAL|Placebo 3 Zoledronic Acid 3|Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.
62472151|NCT03592953|NO_INTERVENTION|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
62472152|NCT01757392|EXPERIMENTAL|Candin® 0.3 mL|Monthly intralesional injections of Candin® 0.3 ml until lesion resolves or up to 6 injections.
62303434|NCT06006078|ACTIVE_COMPARATOR|Endoscopic Facemask|Patients undergoing endoscopy with the use of an endoscopic facemask
62303435|NCT06006078|NO_INTERVENTION|No Endoscopic Facemask|Patients undergoing endoscopy without an endoscopic facemask
62114169|NCT02052648|EXPERIMENTAL|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.~Temozolomide will also be given by mouth at 150 mg/m\^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
62303436|NCT04439578|EXPERIMENTAL|Treatment|subjects receiving a single oral dose of SHR6390 tablets, then rifampicin capsules 600 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
62303437|NCT02635230||Patients with chronic oral anticoagulation and P2Y12 inhibitor|Patients with chronic indication for chronic oral anticoagulation (OAC) because of a heart valve prosthesis and/or atrial fibrillation undergoing coronary revascularisation (by PCI or CABG) and requiring concomitant treatment with P2Y12 inhibitors.
62472153|NCT03820310|EXPERIMENTAL|Experimental group|traditional therapy plus autologous Tcm cellular immunotherapy.
62472154|NCT03820310|NO_INTERVENTION|control group|traditional therapy alone, such as radiotherapy or chemotherapy.
62114170|NCT02052648|EXPERIMENTAL|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
62308361|NCT05475691||Type 2 SMA (with and without disease-modifying treatment (DMTs))|"* Participants of both sexes who presented signs and symptoms of Spinal Muscular Atrophy starting between six and eighteen months of age and have a genetic report confirming 5q SMA.~* No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~* Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~* The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
62472155|NCT01065610|EXPERIMENTAL|Oxytocin|Intranasal Oxytocin, 24 IU
62472156|NCT01065610|PLACEBO_COMPARATOR|Placebo|
62472157|NCT04129346|EXPERIMENTAL|Fit2ThriveMB|Participants assigned to the Fit2ThriveMB will receive the Fit2ThriveMB smartphone app, Fitbit, and coaching calls.
62472158|NCT04129346|ACTIVE_COMPARATOR|Healthy Living Control|Participants in the healthy living group will receive the American Society of Cancer Oncologists smartphone app, cancer.net. They will also receive calls during the intervention period and the Fitbit following completion of 12 week assessments
62472159|NCT01762579|ACTIVE_COMPARATOR|wheat flour|wheat flour is administered blindly versus placebo for 15 days
62472160|NCT01762579|PLACEBO_COMPARATOR|Xylose|placebo will be administered blindly versus wheat flour for 15 days
62472161|NCT00834756|EXPERIMENTAL|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
62472162|NCT00834756|ACTIVE_COMPARATOR|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
62674865|NCT04286503|EXPERIMENTAL|Carrimycin|basic treatment + Carrimycin
62674866|NCT04286503|ACTIVE_COMPARATOR|lopinavir/ritonavir or Arbidol or chloroquine phosphate|any of basic treatment + lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
62472163|NCT05296304|EXPERIMENTAL|Bexarotene Combined With Radiotherapy|Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.
62472164|NCT03491579|EXPERIMENTAL|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with standard chemotherapy (Cladribine and Cytarabine)
62472165|NCT00252720|EXPERIMENTAL|candesartan|candesartan cilexetil 32 mg once daily
62472166|NCT00252720|NO_INTERVENTION|placebo|control
62472167|NCT03331289|PLACEBO_COMPARATOR|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
62472168|NCT03331289|ACTIVE_COMPARATOR|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
62472169|NCT03331289|ACTIVE_COMPARATOR|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
61917613|NCT03616171|OTHER|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
61917614|NCT05918081||Adolescent Basketball Players|Adolescent male basketball players registered in a local basketball academy will form the universe of the research.
61917615|NCT05011448|OTHER|Single arm study with two interventions|Single arm where each participant will undergo two interventions in the following order: Verbal Interaction and Music Therapeutic Interaction. Both interactions will be conducted by the same music therapist.
62472170|NCT03331289|ACTIVE_COMPARATOR|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
62472171|NCT02298647||Observation|Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis
62472172|NCT01691456|EXPERIMENTAL|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
62472173|NCT01691456|ACTIVE_COMPARATOR|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp \& Dohme Ltd., USA
62472174|NCT03289845|OTHER|BHX implant|All patients implanted with BHX implant
62472175|NCT02489526|EXPERIMENTAL|VVZ-149 Injections|
62472176|NCT02489526|PLACEBO_COMPARATOR|Placebo|
62472177|NCT01074879|EXPERIMENTAL|Whey protein|20 g whey protein + 20 g carbohydrates
61917616|NCT04705740||September 2013 to August 2015|5 endoscopists
61917617|NCT04705740||September 2015 to December 2017|4 endoscopists
61917618|NCT04705740||January 2018 to June 2020|3 endoscopists
61917619|NCT02318108|EXPERIMENTAL|Intervention|Mentored organizational change and feedback.
61917620|NCT02318108|OTHER|Education only|Education and feedback.
61917621|NCT01466777|ACTIVE_COMPARATOR|traditional laparoscopic surgery type|
61917622|NCT01466777|EXPERIMENTAL|Robotic assisted operation type|
62114171|NCT02052648|EXPERIMENTAL|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
62114172|NCT02052648|EXPERIMENTAL|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
62114173|NCT02767219|OTHER|Dexamethasone and 5-fluorouracil|The control arm consists of current standard therapy of subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of 5-fluorouracil as required for 4 consecutive weeks after entry into the trial.
62114174|NCT02767219|ACTIVE_COMPARATOR|Dexamethasone and Avastin|Subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of bevacizumab will be given for 4 consecutive weeks from time of entry into trial
62114175|NCT00515450|EXPERIMENTAL|1|
62114176|NCT00515450|ACTIVE_COMPARATOR|2|
62114177|NCT00966017||DS|Those with Down syndrome
62114178|NCT00966017||Non-DS|Healthy controls
62114179|NCT02961127||group 1|no drugs were used in our study
62114180|NCT02961127||group 2|
62114181|NCT02375581|EXPERIMENTAL|Icotinib & Radiotherapy|Icotinib, 125mg, Po, Tid, during the course of radiotherapy; Thoracic radiotherapy, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
62114182|NCT02375581|ACTIVE_COMPARATOR|Radiotherapy alone|Thoracic radiotherapy alone, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
62114183|NCT03890263|EXPERIMENTAL|Opioid deprescribing and self-management|
62114184|NCT02397317|EXPERIMENTAL|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
62114185|NCT03192319|EXPERIMENTAL|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
61917623|NCT04730414||Age, Male, Female, ethnicity,|"The aim of the study is to be inclusive of all groups as to avoid bias. Furthermore, the study aims to determine if its formulation will encompass all skin types, genders and age groups.~Full-spectrum hemp dosage is determined to begin with 40mg - 2-3X/day = topical application; for a period of 2-3 months.~Drug: Full Spectrum hemp (0.018% THC), Topical Application Placebo = cream without hemp (Double blinded) One cream will be placed on one side of the face (R/L) and the other cream on the other side of the face."
62674867|NCT02583009|EXPERIMENTAL|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
61917624|NCT04763876|ACTIVE_COMPARATOR|15 mg ketorolac intramuscular|Patients who received a single 15 mg dose of ketorolac administered intramuscularly
61917625|NCT04763876|ACTIVE_COMPARATOR|60 mg ketorolac intramuscular|Patients who received a single 60 mg dose of ketorolac administered intramuscularly
61917626|NCT01876433|ACTIVE_COMPARATOR|Beta-3-agonist|Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
62114186|NCT03192319|ACTIVE_COMPARATOR|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
62114187|NCT03192319|ACTIVE_COMPARATOR|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
62114188|NCT03192319|ACTIVE_COMPARATOR|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
62114189|NCT04770935|EXPERIMENTAL|efanesoctocog alfa (BIVV001)|A single IV dose of BIVV001 will be administered to each patient
62114190|NCT03946813|EXPERIMENTAL|Poor ovarian reserve|Infertile women with poor ovarian reserve
62114191|NCT06354738|EXPERIMENTAL|All women older than 18 newly diagnosed with endometrial cancer of all stages and histotypes|All patients must undergo total hysterectomy and bilateral salpingo-oophorectomy or bilateral salpingectomy if premenopausal status and the lymph-node assessment according to European guidelines and local protocol. A comprehensive surgical peritoneal staging is required, which includes omentectomy/omental biopsies and six peritoneal biopsies.
62114192|NCT02087358||Stress and craving|This 3 weeks study examines the correlation between stress and alcohol using an ecological, prospective design. Participants will be given phone calls 4 times a day for 3 weeks, assessing perceived stress and alcohol related craving.
62114193|NCT06025019|EXPERIMENTAL|Electronic Health (eHealth)|Participants allocated to the eHealth intervention group will be delivered the evidence-based information and interactive components via social media (i.e., WeChat, similar to WhatsApp; and TikTok/Douyin, similar to YouTube). The interactive components include game, push notification, social rapport, influence agent, goal setting and personalized feedback.
62114194|NCT06025019|NO_INTERVENTION|Control group|Participants allocated to the control group will be delivered printed evidence-based educational materials on standard recommendations for PA, diet, and sleep, without interactive components.
62114195|NCT04965467||Screening population|Screening for Fabry disease with early symptoms
62472178|NCT01074879|EXPERIMENTAL|Milk protein|20 g milk protein + 20 g carbohydrates
62674868|NCT02583009|EXPERIMENTAL|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
62674869|NCT02583009|EXPERIMENTAL|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
62674870|NCT02583009|PLACEBO_COMPARATOR|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
62674871|NCT00573820|OTHER|1|
62674872|NCT02030639|EXPERIMENTAL|[14C]-rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
62674873|NCT05514899|EXPERIMENTAL|THC first, then CBD|THC 10mg daily for 2 weeks, followed by washout for 2 weeks, followed by CBD 600mg daily for 2 weeks
62303438|NCT04556864||Description Group|"* For each patient included in the study, the secondary variables will be noted in the patient's data collection logbook.~* This is followed by radial artery cannulation (if absent), and connection to the HemoSphere/EV1000 platform~* After the daily visit, the PI/collaborating investigators (CI) will measure the clinical, treatment, and mechanical ventilation parameters of the patient during the last 24 hours.~* Daily arterial analysis will be requested~* This information collection process will be followed for 5 days. At the end of the information collection period, the IP will perform two downloads, the engineering download, and the standard download in which the values are monitored every 20 seconds.~* These will be noted in the secondary variables of the data collection logbook, along with the patients' ICU discharge date.~* In-hospital mortality will be monitored during admission to a conventional hospital ward.~* Records will be closed upon discharge of the patient."
62303439|NCT03905772|EXPERIMENTAL|Voluntary exercise|The participants will perform 36 voluntary contractions of 20% of maximal voluntary isometrical contraction, 3 times per week for 8 weeks.
62303440|NCT03905772|EXPERIMENTAL|Wide pulse responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in responder in the acute fase."
62472179|NCT01074879|ACTIVE_COMPARATOR|Carbohydrates|40 g carbohydrates
62114196|NCT06461637|EXPERIMENTAL|Stepped Care Mental Health for Foreign Domestic Helpers (SCMH-FDH)|Participants in the SCMH-FDH group will receive a 4-step intervention, i.e., Step 1: Self-Help Intervention and Online Peer-Support, Step 2: Group-Based Intervention, Step 3: Guided Self-Help CBT, and Step 4: Referral to mental health professionals.
62114197|NCT06461637|NO_INTERVENTION|Care-As-Usual (CAU)|Participants in CAU group will not receive the stepped care intervention but will have access to care based on their needs and preferences.
62472180|NCT05394935|EXPERIMENTAL|Polycystic Ovary Syndrome|Women with PCOS
62472181|NCT05394935|ACTIVE_COMPARATOR|Controls|Healthy, age and BMI matched controls
62114198|NCT05066113|EXPERIMENTAL|Healthy Participants|Electrothermolysis treatment using varying levels of RF energies
62472182|NCT01689311|EXPERIMENTAL|Treatment|All samples will undergo dose response treatment (increasing concentrations) of one of the four uterotonic drugs: oxytocin, ergonovine, prostaglandin F2alpha, or misoprostol.
62472183|NCT04138186|EXPERIMENTAL|2.0g G-PUR® capsules|
62472184|NCT04138186|PLACEBO_COMPARATOR|Placebo capsules|
62472185|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
61917627|NCT01876433|PLACEBO_COMPARATOR|Placebo|Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
62303441|NCT03905772|EXPERIMENTAL|Wide pulse non responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in non responder in the acute fase."
62303442|NCT03905772|EXPERIMENTAL|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
62303443|NCT02203682|EXPERIMENTAL|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
62303444|NCT02203682|PLACEBO_COMPARATOR|Placebo|Tablet placebo for 12 weeks
62303445|NCT04987593|EXPERIMENTAL|Intervention|Four probiotic strains to be consumed once daily
62303446|NCT06301854|EXPERIMENTAL|TPN171H group|10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
62303447|NCT04698187|EXPERIMENTAL|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
62303448|NCT04884243|PLACEBO_COMPARATOR|CBT-006|Vehicle
62303449|NCT04884243|EXPERIMENTAL|CBT-006 lower concentration|lower concentration dose
62303450|NCT04884243|EXPERIMENTAL|CBT-006 higher concentration|higher concentration dose
62674874|NCT05514899|ACTIVE_COMPARATOR|CBD first, then THC|CBD 600mg daily for 2 weeks, followed by washout for 2 weeks, followed by THC 10mg daily for 2 weeks
62674875|NCT05714228||Surgical repair|
61917628|NCT03737071|EXPERIMENTAL|Low Carbohydrate Diet|Low Carbohydrate Diet
61917629|NCT03737071|ACTIVE_COMPARATOR|Simple Calorie Restriction Diet|Simple Calorie Restriction Diet
61917630|NCT02591771|EXPERIMENTAL|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
61917631|NCT05447221||Whole slide images of gastric biopsy specimens|Whole slide images of gastric biopsy specimens
62303451|NCT06468579|EXPERIMENTAL|Experimental: GT20029|
62303452|NCT06468579|PLACEBO_COMPARATOR|Placebo Comparator: GT20029 Placebo|
62303453|NCT01810887|EXPERIMENTAL|Ritonavir and darunavir|Ritonavir will be administered orally twice daily at a dose of 100 milligram (mg) from Day 1-5. Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 mg on Day 3.
62303454|NCT02626338|EXPERIMENTAL|Arm A|"* Mitoxantrone~* Cytarabine~* Crenolanib"
62303455|NCT02626338|EXPERIMENTAL|Arm B|"* Fludarabine~* Cytarabine~* G-CSF~* Idarubicin~* Crenolanib"
62303456|NCT02626338|EXPERIMENTAL|Arm C|"* Mitoxantrone~* Etoposide~* Cytarabine~* Crenolanib"
62303457|NCT03319628|EXPERIMENTAL|Dose Escalation|"XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.~This cohort is closed to enrollment."
62674876|NCT05714228||Transcatheter repair|
62674877|NCT05950126||Group 1|low pain catastrophizing score in mother
62114199|NCT04027426|ACTIVE_COMPARATOR|FBT (family-based behavioral treatment)|This condition will be prescribed the Traffic Light Diet (1000-1500 kcal/day, \< 2 servings/day of RED \[non-nutrient-dense, energy-dense\] foods) and a \> 60 min/day of MVPA prescription for children and \> 30 min/day of MVPA for adults at least 5 days/week. FBT will receive a family-based, behavioral intervention to assist the targeted child and a participating adult caregiver with making changes in energy balance behaviors.
62303458|NCT03319628|EXPERIMENTAL|Dose Expansion - Ovarian Cancer|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
62303459|NCT03319628|EXPERIMENTAL|Dose Expansion - NSCLC adenocarcinoma|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
61917632|NCT05977478|EXPERIMENTAL|SPECTRA IMDx™.|During endoscopy, the endoscopist will first locate the precancerous/cancerous gastric lesions using HD-WLE. Upon location of the lesion, the endoscopist will use the SPECTRA IMDx™ probe to capture the Raman spectra from the lesion and its adjacent normal mucosa.
61917633|NCT01245361|EXPERIMENTAL|Infliximab|Group I: Infliximab 3 mg/kg wk 0,2,6
62303460|NCT03319628|EXPERIMENTAL|Pivotal Cohort (UPLIFT)|"Patients with platinum-resistant ovarian cancer will receive XMT-1536 (upifitamab rilsodotin) to further confirm the efficacy.~This cohort is closed to enrollment."
62303461|NCT03319628|EXPERIMENTAL|QTc Sub-Study|"For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536.~This cohort is closed to enrollment."
62303462|NCT01759303|EXPERIMENTAL|pazopanib|"For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
62472186|NCT04499963|EXPERIMENTAL|Open Label Arm|The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
61917634|NCT01245361|PLACEBO_COMPARATOR|sodium chloride|RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride
61917635|NCT01042782|EXPERIMENTAL|RAD-MitC|RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
61917636|NCT02392832|EXPERIMENTAL|Intervention arm|Fourstar® granule formulation, 90day and 180 day briquettes Bti/Bs in larval habitats of malaria vectors.
61917637|NCT02392832|NO_INTERVENTION|Control arm|No larvicide application.
61917638|NCT04678206|EXPERIMENTAL|BLU-5937 Dose A|BLU-5937 oral dose A twice a day.
61917639|NCT04678206|EXPERIMENTAL|BLU-5937 Dose B|BLU-5937 oral dose B twice a day.
61917640|NCT04678206|EXPERIMENTAL|BLU-5937 Dose C|BLU-5937 oral dose C twice a day.
62114200|NCT04027426|EXPERIMENTAL|FBT+Variety|The FBT+Variety condition will receive FBT along with a limited variety prescription. In this prescription families will identify two RED foods, a dinner entree and snack food, and develop meal plans that reduce variety of RED foods by regularly consuming these foods and limiting consumption of other RED entrees and snack foods.
62114201|NCT04589130|EXPERIMENTAL|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets.
62114202|NCT04589130|PLACEBO_COMPARATOR|Placebo|Group given placebo
62114203|NCT06358066|EXPERIMENTAL|curodont repair fluoride plus|Group I (study group): Teeth will be treated with self-assembling peptide (P11-4) fluoride plus varnish.
62114204|NCT06358066|ACTIVE_COMPARATOR|fluoride varnish|Group II (control group): Teeth will be treated with fluoride varnish.
62303463|NCT06631287|EXPERIMENTAL|Baricitinib|Janus kinase inhibitor
62303464|NCT06631287|PLACEBO_COMPARATOR|Placebo|Placebo
61917641|NCT04678206|PLACEBO_COMPARATOR|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
61917642|NCT04678206|EXPERIMENTAL|BLU-5937 Dose A (Population with baseline cough < 25 coughs/hour)|BLU-5937 oral dose A twice a day.
62114205|NCT06084117|EXPERIMENTAL|High Flow Nasal Oxygen (HFNO)|Patients will start at a flow of 50 L/min and a temperature of 37°C, FiO2¬ will start at 25%, and titrated to target SpO2 (88-92%, as in usual care).
62303465|NCT01310738|ACTIVE_COMPARATOR|Meglumine antimoniate|Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
62303466|NCT01310738|EXPERIMENTAL|Liposomal Amphotericin B|Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
62303467|NCT01310738|EXPERIMENTAL|Amphotericin B|Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
62114206|NCT06084117|ACTIVE_COMPARATOR|Non-Invasive Ventilation (NIV)|"Patients will be started at~* Using the facemask interface: EPAP/PEEP set at 5-7 cmH2O and PS of 5-7 cmH2O (equal to IPAP of 10-14 cmH2O).~* Using the helmet interface; EPAP/PEEP set at least 10 cmH2O and PS of 10 cmH2O (equal to IPAP of 20 cmH2O).~* PEEP/EPAP and IPAP/PS can be titrated to effectiveness, tolerance and comfort~* FiO2 should be set to achieve a SpO2 of 88-92%"
62674878|NCT05950126||Group 2|high pain catastrophizing score in mother
62674879|NCT03979989|EXPERIMENTAL|Tapentadol IR|A single oral dose of tapentadol IR was administered in a fasted state (Treatment A).
62472187|NCT04499963|NO_INTERVENTION|Healthy Control Arm|We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
62114207|NCT03103971|EXPERIMENTAL|Treatment (leukapheresis, chemotherapy, huJCAR014)|Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
62114208|NCT00510601|EXPERIMENTAL|1|
62114209|NCT05762419|EXPERIMENTAL|Focused ultrasound using oral etoposide|All patients enrolled in the study will be treated with oral etoposide after receiving focused ultrasound (FUS) treatment with microbubbles and neuro-navigator-controlled sonication.
62114210|NCT04678830|PLACEBO_COMPARATOR|Placebo|Syringes containing normal saline for injection were prepared by an unblinded pharmacist at the clinical sites for use as the placebo.
62114211|NCT04678830|EXPERIMENTAL|700mg Leronlimab|Each vial of active contains 350mg of leronlimab at a concentration of 175mg/ml (nominal 2mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections
62114212|NCT05593146|EXPERIMENTAL|modified anteversion angle placement (( α-15°)±10°) of the acetabular component|α refers to the anatomical preoperative anteversion angle of the affected hip. α equals to the anteversion angle of the contralateral limb if it cannot be accurately measured on the affected limb. A standard error within 10° is accepted
62114213|NCT05593146|PLACEBO_COMPARATOR|conventional anteversion angle placement ( α±10°) of the acetabular component|α refers to the anatomical preoperative anteversion angle of the affected hip. α equals to the anteversion angle of the contralateral limb if it cannot be accurately measured on the affected limb. A standard error within 10° is accepted
62114214|NCT05165888|EXPERIMENTAL|Communication and Bias Mitigation Training|This is a communication training session based on a culturally-based program developed with rural, southern Black patients and families and modified for an urban, northern population. A strategy of bias mitigation successfully used with medical students will be adapted for practicing clinicians using results of phase 1. This strategy is based on transformational learning theory and incorporates critical reflection, guided dialogue, perspective taking exercises, role plays and strategy development. If specific communication behaviors are found related to bias and stereotyping in phase 1, these will be discussed and targeted using these techniques. Otherwise, these techniques will be used to address racial bias generally. The intervention will be incorporated within the communication training session.
62114215|NCT05165888|ACTIVE_COMPARATOR|Communication Training Only|This is a communication training session based on standard palliative care techniques to listen empathically, share prognostic information and treatment options, elicit patient and family goals and values related to their treatment, and facilitate shared decision-making regarding end-of-life treatment.
62114216|NCT03684213|ACTIVE_COMPARATOR|Control (Norepinephrine)|Subjects will be administered norepinephrine at varying concentrations (10\^-2 to 10\^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
62114217|NCT03684213|EXPERIMENTAL|Norepinephrine + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
62114218|NCT03684213|EXPERIMENTAL|Norepinephrine + L-NAME|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) at the same rate and for the same time as the control arm.
62674880|NCT03979989|EXPERIMENTAL|Omeprazole, Tapentadol IR|Oral doses of omeprazole were administered once daily in a fasted state on 4 consecutive days (Days -3 to 1), plus 1 capsule of CG5503 IR administered 2 hours after the administration of omeprazole on Day 1 (Treatment B).
62674881|NCT00858052|EXPERIMENTAL|breast augmentation|breast implant
62674882|NCT01300520|NO_INTERVENTION|Target Tape|Including target tape in the procedure
62674883|NCT01300520|OTHER|Control|Without target tape in the procedure
62674884|NCT04626531|EXPERIMENTAL|Intervention Group|After the pre-tests (Self-Care Activities, Self-Efficacy, Quality of Life) , the patients were given web based education and containing information and recommendations on self-management strategies for three months.
62674885|NCT04626531|EXPERIMENTAL|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
62736157|NCT01341535|EXPERIMENTAL|adaptive DPBN|"This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
61917643|NCT04678206|PLACEBO_COMPARATOR|Placebo (Population with baseline cough < 25 coughs/hour)|Matching Placebo for BLU-5937 oral dose twice a day.
61917644|NCT03560739|OTHER|OMB 20mg PFS abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on abdomen
62472188|NCT03464240|ACTIVE_COMPARATOR|Glucose|50 grams glucose in 50 ml water
62472189|NCT03464240|PLACEBO_COMPARATOR|Water|50 ml water
62472190|NCT04671368|EXPERIMENTAL|Artificial Intelligence|A deep learning based artificial intelligence diagnostic system(DOI:10.1093/neuonc/noaa163)
62472191|NCT04671368|ACTIVE_COMPARATOR|Practicing Pathologists|One pathologist who has at least 5 years of experience
62472192|NCT04671368|OTHER|Gold Standard|A committee composed of two expert pathologists who has at least 10 years of experience and one expert pathologist who has at least 15 years of experience
62472193|NCT01279902|EXPERIMENTAL|Rituximab plus CHOP Immunochemotherapy|"Interventions: conventional R-CHOP every 3 weeks for 3 cycles~* Rituximab 375 mg/M2 IV day 1~* Cyclophosphamide 750 mg/M2 IV day1~* Vincristine 1.5 mg/M2 (max. 2 mg) IV day1~* Prednisolone 50 mg bid day 1-5, every 3 weeks"
62472194|NCT01173211|EXPERIMENTAL|Arm 1: Fluarix®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluarix®.
62472195|NCT01173211|EXPERIMENTAL|Arm 3: Fluzone®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluzone®.
62472196|NCT01173211|EXPERIMENTAL|Arm 2: Agriflu®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Agriflu®.
62472197|NCT01680380||At-Home|Overnight sleep at home
62472198|NCT04415515|EXPERIMENTAL|Treatment 1|RN Standard care coordination and disease management + RN Case Management
62472199|NCT04415515|EXPERIMENTAL|Control|RN Standard care coordination and disease management
62472200|NCT04415515|EXPERIMENTAL|Treatment 2|RN Standard care coordination and disease management + Community Health Worker Case Management
62472201|NCT05004116|EXPERIMENTAL|Phase I portion|"Phase 1:~Part A : TPX-0005 (Repotrectinib) will be given orally (without regard to food) once daily for 14 days, then increased to twice daily for remainder of cycles and concurrently administered with chemotherapy backbone described below. For patients less than 12 years old or less than 50kg, adult equivalent dosing (AED) will be used. Approximately 4-24 pediatric subjects will be enrolled into 2-4 dose levels (pending if DL-1 or DL-1b are utilized), with maximum of 6 subjects per dose level according to the 'rolling 6' design. Starting dose of TPX-0005 (Repotrectinib) will begin at dose level (DL) 1. Part B (combination therapy; patients less than 12 years old or ≤ 50kg): For 6 additional patients, a safety run-in will be conducted with TPX-0005 (Repotrectinib) and chemotherapy."
62472202|NCT05004116|EXPERIMENTAL|Phase II, ALK-mutated neuroblastoma Cohort|Phase II, ALK-mutated neuroblastoma Cohort. Participants will be treated with the recommended phase 2 dose of TPX-0005 (Repotrectinib) + chemotherapy determined in Phase 1
62114219|NCT03684213|EXPERIMENTAL|Norepinephrine + L-NAME + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and combined L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
62114220|NCT02519699|EXPERIMENTAL|Norepinephrine|Noradrenaline continuous infusion IV
62114221|NCT03199235|EXPERIMENTAL|LIF + Citrus|Parents of subjects \> 1 year and \< 5 years with anemia (Hemoglobin \< 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
62114222|NCT03199235|ACTIVE_COMPARATOR|enhanced standard of care|Parents of subjects \> 1 year and \< 5 years with anemia (Hemoglobin \< 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
62114223|NCT02736799|SHAM_COMPARATOR|Sham vibrating capsule|Sham vibrating capsule
62114224|NCT02736799|ACTIVE_COMPARATOR|Vibrant Capsule (1 vibration)|1 vibration/min
62114225|NCT02736799|ACTIVE_COMPARATOR|Vibrant Capsule (3 vibration)|3 vibrations/min
62114226|NCT02736799|ACTIVE_COMPARATOR|Vibrant Capsule (5 vibration)|5 vibrations/min
62114227|NCT01624168|PLACEBO_COMPARATOR|Anxiety Management Education|
62114228|NCT01624168|EXPERIMENTAL|10 week tai chi intervention|10 week course in Evidence Based Tai Chi meeting 2 times per week
62114229|NCT01624168|EXPERIMENTAL|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
62303468|NCT01310738|EXPERIMENTAL|Combination therapy|Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.
62114230|NCT03890016||snakebite victims|Victims of snakebite presenting to the Emergency Department of Jubilee Mission Medical College and Research Institute
62472203|NCT05004116|EXPERIMENTAL|Phase II, Molecularly defined DSRCT Cohort|Phase II, Molecularly defined DSRCT Cohort. Participants will be treated with the recommended phase 2 dose of TPX-0005 (Repotrectinib) + chemotherapy determined in Phase 1
62472204|NCT05004116|EXPERIMENTAL|Phase II, Exploratory Cohort|Phase II, Exploratory Cohort. Participants will be treated with the recommended phase 2 dose of TPX-0005 (Repotrectinib) + chemotherapy determined in Phase 1
62114231|NCT01301196|EXPERIMENTAL|Behaviour change|Attendance at 3-h workshop
62114232|NCT01810263|EXPERIMENTAL|high protein supplement|high protein supplement given
62114233|NCT01810263|NO_INTERVENTION|Control|no intervention
62114234|NCT02523651|EXPERIMENTAL|DPSC injection|20 patients will receive DPSC injection（1000000 cells/ 0.5ml） at the local periodontal defects immediately after periodontal scaling and root planing.
62114235|NCT02523651|PLACEBO_COMPARATOR|Placebo control|20 patients will receive saline injection at the local periodontal defects immediately after periodontal scaling and root planing.
62114236|NCT03773120|EXPERIMENTAL|Using Neuromonitoring to find EBSLN|With Neuromonitoring of the EBSLN using nerve monitoring system
62114237|NCT03773120|NO_INTERVENTION|No Using Neuromonitoring to find EBSLN|Without Neuromonitoring of the EBSLN using nerve monitoring system
62303469|NCT03206658|PLACEBO_COMPARATOR|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
62674886|NCT03087123|ACTIVE_COMPARATOR|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
62114238|NCT02667249||check list|clinical pathway using a paper based check-list
62114239|NCT02667249||integrated clinical pathway|clinical pathway in form of a clinical pathway integrated into the paper based medical treatment and nursing documentation
62674887|NCT03087123|ACTIVE_COMPARATOR|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
62114240|NCT04410055|ACTIVE_COMPARATOR|Sitting|Three hours of sitting condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
62114241|NCT04410055|ACTIVE_COMPARATOR|Static standing|Four hours of static standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
62114242|NCT04410055|ACTIVE_COMPARATOR|Dynamic standing|Four hours of dynamic standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
62114243|NCT01256034|ACTIVE_COMPARATOR|Group A|preoperative immunonutrition
62114244|NCT01256034|NO_INTERVENTION|Group B|ordinary diet
62114245|NCT01568749|ACTIVE_COMPARATOR|Standard paracetamol|Marketed formulation
62114246|NCT01568749|EXPERIMENTAL|Formulation 1|Paracetamol formulation 1
62114247|NCT01568749|EXPERIMENTAL|Formulation 2|Paracetamol formulation 2
62114248|NCT01568749|EXPERIMENTAL|Formulation 3|Paracetamol formulation 3
62114249|NCT01568749|EXPERIMENTAL|Formulation 4|Paracetamol formulation 4
62114250|NCT04184804|EXPERIMENTAL|Behavioral Intervention|School-based intervention
62114251|NCT04184804|NO_INTERVENTION|Control|Control. No intervention (usual education). The school does not receive any material and gets the information that they are part of a study on eating habits of primary school children.
62114252|NCT05218837||First vaginal birth|The first vaginal birth in nulliparous women
62114253|NCT05218837||Vaginal birth after cesarean section (VBAC)|The first vaginal birth after one or more prior cesarean sections (VBAC)
62114254|NCT05218837||Second vaginal delivery|The second vaginal delivery
62114255|NCT03097016|EXPERIMENTAL|Single oral dose of 3 mg CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
62114256|NCT03571191|EXPERIMENTAL|1|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
62114257|NCT04411446|EXPERIMENTAL|Vitamin D|5 capsules containing 100.000 UI of vitamin D each. The intervention will be 5 capsules given in one-time oral intake.
62114258|NCT04411446|PLACEBO_COMPARATOR|Placebo|5 capsules containing placebo. The intervention will be 5 capsules given in one-time oral intake.
62114259|NCT03498170|OTHER|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - itraconazole 200mg on Day 1 to 14 and BCT197 14mg on Day 7"
62114260|NCT05179837|EXPERIMENTAL|Optical coherence tomography (OCT) probe|After consent, the endoscopist will perform a standard of care colonoscopy. If a polyp is found, then OCT will be used to image that polyp. Patients with polyps, regardless of number found, will have either one tubular adenoma (NICE type 2) imaged OR one hyperplastic polyp (NICE type 1) imaged. If no polyps are found, then one area of normal mucosa will be imaged. If on the rare chance a malignant appearing colonic tumor (NICE type 3) is found, this and no other polyps will be imaged with OCT.
62114261|NCT01376336|EXPERIMENTAL|Safe storage device|This arm will be assigned a safe water storage device.
62114262|NCT01376336|NO_INTERVENTION|Control|This arm of the trial will receive nothing until the end of the trial.
62114263|NCT04261855|EXPERIMENTAL|Arm A|Avelumab plus External Beam Radiation Therapy (EBRT)
62303470|NCT03206658|EXPERIMENTAL|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
62303471|NCT01617486|EXPERIMENTAL|BALANCE|
62114264|NCT04261855|EXPERIMENTAL|Arm B|Avelumab plus Lutetium-177 (177Lu)-DOTATATE
62114265|NCT03014830|ACTIVE_COMPARATOR|Alirocumab|Subjects will receive alirocumab for 6 weeks.
62114266|NCT03014830|PLACEBO_COMPARATOR|Placebos|Subjects will receive placebo for 6 weeks.
62114267|NCT06070207|ACTIVE_COMPARATOR|TEP Group|In 20 patients; Bilateral inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
62303472|NCT02234037|EXPERIMENTAL|Decitabine and Exercise|8-week program of physical conditioning and decitabine treatment in newly diagnosed AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy.
62303473|NCT02051101|OTHER|Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
62114268|NCT06070207|EXPERIMENTAL|eTEP Group|In 20 patients; Bilateral inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
62114269|NCT01499134|EXPERIMENTAL|nebivolol|nebivolol 1 to 4 capsules daily
62303474|NCT02014948|EXPERIMENTAL|Exercises|This group will consist of 20 individuals, 10 with lumbar disc herniation and 10 with chronic low back pain who underwent treatment with exerxises.
62114270|NCT01499134|ACTIVE_COMPARATOR|metoprolol succinate|metoprolol 1 to 4 capsules daily
62303475|NCT03386240|EXPERIMENTAL|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
62303476|NCT03386240|PLACEBO_COMPARATOR|Vicryl, monocryl, PDS (not coated with triclosan)|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
62303477|NCT04046302|EXPERIMENTAL|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
62303478|NCT04046302|PLACEBO_COMPARATOR|placebo|one tablet of placebo self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
61917645|NCT03560739|OTHER|OMB 20mg AI abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on abdomen
62114271|NCT00184925|ACTIVE_COMPARATOR|subglottic drainage|suctioning of subglottis with cannula
62114272|NCT01526642|NO_INTERVENTION|Long Term Oxygen Therapy|
62114273|NCT01526642|ACTIVE_COMPARATOR|Non Invasive Ventilation|
62114274|NCT02499419||Healthy|Individuals without any known heart/ respiratory/ metabolic problems that might limit their exercise capacity
62114275|NCT02499419||Mild MVP|0 or 1 of the following secondary risk factors: Mild MR Flail leaflet Left atrial diameter \> 40 mm Atrial fibrillation Age ≥ 50
62303479|NCT03968146|ACTIVE_COMPARATOR|Group E|patients will receive Erector Spinae plane block in addition to intravenous fentanyl
62303480|NCT03968146|OTHER|Group C|Control group will receive only intravenous fentanyl.
61917646|NCT03560739|OTHER|OMB 20mg PFS thigh|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on thigh
61917647|NCT03560739|OTHER|OMB 20mg AI thigh|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on thigh
61917648|NCT01153464|NO_INTERVENTION|Treatment As Usual|In this arm, participants are not provided any intervention through the study, they are just followed for research purposes at 3m, 6m, 9m, and 12m post baseline as the comparison group.
61917649|NCT01153464|EXPERIMENTAL|Recovery Support Counseling|This group is eligible to receive the telephone based recovery support counseling from paraprofessionals based out of the City of Philadelphia's Department of Behavioral Health.
62303481|NCT00159484|EXPERIMENTAL|A|EPO906, celecoxib
61917650|NCT01891526||Hepatic patients|patients with hepatic insufficiency
61917651|NCT01891526||Healthy Controls|Healthy adults
61917652|NCT00849888|EXPERIMENTAL|Atypical Complete DiGeorge|Thymus Transplantation with Immunosuppression
61917653|NCT00849888|EXPERIMENTAL|Typical Complete DiGeorge|Thymus Transplantation without Immunosuppression
62114276|NCT02499419||Moderate MVP|2 or more of the above secondary risk factors.
62114277|NCT02499419||Severe MVP|1 or more of the following primary risk factors: EF \< 50% MR ≥ moderate
62114278|NCT01953757|EXPERIMENTAL|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
62114279|NCT01953757|ACTIVE_COMPARATOR|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
61917654|NCT05185011|EXPERIMENTAL|mild hepatic impairment|Subjects with mild hepatic impairment
61917655|NCT05185011|EXPERIMENTAL|moderate hepatic impairment|Subjects with mild moderate impairment
61917656|NCT05185011|EXPERIMENTAL|healthy volunteers|Subjects with normal hepatic function
61917657|NCT02486627|EXPERIMENTAL|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
61917658|NCT02486627|ACTIVE_COMPARATOR|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
61917659|NCT02873585|EXPERIMENTAL|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
61917660|NCT04612023|ACTIVE_COMPARATOR|1 mL NyDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 1 mL NyDYN injection.
61917661|NCT04612023|ACTIVE_COMPARATOR|2 mL NuDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL NyDYN injection.
61917662|NCT04612023|PLACEBO_COMPARATOR|Placebo of Sterile Saline|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL dose of sterile saline.
61917663|NCT04578080|EXPERIMENTAL|Anodal-tDCS & PT|"Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere.~Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
61917664|NCT04578080|ACTIVE_COMPARATOR|Sham-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area of affected hemisphere, Cathodal on the supraorbital area of affected hemisphere. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity.
61917665|NCT06155864||1|To study the reproducibility of anatomical measurements of the superficial temporal artery using X-ray angio-modensitometry.
61917666|NCT06155864||2|Investigate different CT techniques for studying the superficial temporal artery.
61917667|NCT06155864||3|Study the anatomy of the superficial temporal artery on CT.
61917668|NCT06155864||4|Study the anatomy of the superficial temporal artery on MRI.
61917669|NCT01651689||Scalp biopsy|Subjects are on scadule list for hair transplantation in Siriraj hospital. Scalp biopsy with punch biopsy No.4 Scalp biopsy by punch biopsy No.4 at occipital area was done in subjects who have hair transplantaion.
61917670|NCT02048293|ACTIVE_COMPARATOR|Group O|Remifentanyl innovative molecule = Ultiva®
62114280|NCT05032937|EXPERIMENTAL|ECMR|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.
62736158|NCT01341535|ACTIVE_COMPARATOR|standard IMRT|"This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
61917671|NCT02048293|ACTIVE_COMPARATOR|Group A|Remifentanyl comparator A = Remifentanil Laboratorios Chalver de Colombia S.A.
61917672|NCT02048293|ACTIVE_COMPARATOR|Group B|Remifentanyl comparator B = Fada Remifentanilo
61917673|NCT04330326|EXPERIMENTAL|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
61917674|NCT04330326|PLACEBO_COMPARATOR|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
61917675|NCT02604121|EXPERIMENTAL|transepithelial brushing|transepithelial brushing in liquid-based technology + biopsy
61917676|NCT05340647||Group 1 Preserflo microshunt|
61917677|NCT05340647||Group 2 Trabeculectomy|
61917678|NCT05340647||Group 3 Other MIGS|Other micro-invasive glaucoma surgery (MIGS) than Preserflo microshunt (e.g., Xen gel stent, iStent inject)
61917679|NCT01974765|EXPERIMENTAL|Enzalutamide|"After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.~All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting."
61917680|NCT05377073|EXPERIMENTAL|Hatha Yoga|Participants performed 1 hour supervised Yoga sessions once a week for a total of eight weeks.
61917681|NCT05377073|EXPERIMENTAL|Stretching|Participants performed 1 hour supervised Stretching sessions once a week for a total of eight weeks.
61917682|NCT03291301|EXPERIMENTAL|CBT Group|Cognitive Behavioral Therapy for Insomnia
62736159|NCT02808325|EXPERIMENTAL|balanced gelatine solution|isotonic colloidal volume substitute
61917683|NCT03291301|EXPERIMENTAL|Combined Group|Cognitive Behavioral Therapy for Insomnia plus Acupressure
61917684|NCT03291301|NO_INTERVENTION|Wait-list Control Group|
61917685|NCT01322581||observational cohort|This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal
61917686|NCT06283927||Re-resection|Resection of the recurrent tumor
62114281|NCT02668263|ACTIVE_COMPARATOR|Surgery and Drain|Group 1 will be allocated to receive a drain intra-operatively.
62114282|NCT02668263|OTHER|Surgery alone|Group 2 will not receive a drain and no further intervention.
62114283|NCT02668263|EXPERIMENTAL|Surgery and quilting sutures|Group 3 will not receive a drain but will receive quilting sutures
62114284|NCT05380869|OTHER|Point-of-care test Procalcitonin for LRTI|Diagnostic study, a POCT-PCT is done in all included patients
62303482|NCT06454968|EXPERIMENTAL|OGL|Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
62303483|NCT04348903|EXPERIMENTAL|Virtual Reality Distraction|Virtual reality refers to a human-computer interface that completely immerse the child in a simulated environment. It integrates multiple perceptual senses including; the visual, auditory and kinaesthetic stimulation modalities. Virtual reality diverts children's attention away from the negative feelings associated with unpleasant experience.
61917687|NCT06283927||Best oncological treatment|Best oncological treatment consisting of re-challenge temozolomide, re-irradiation, experimental therapy, or best supportive care
61917688|NCT01609478|EXPERIMENTAL|indacaterol acetate 75 µg|"indacaterol acetate 75 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
61917689|NCT01609478|EXPERIMENTAL|indacaterol acetate 150 µg|"indacaterol acetate 150 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
61917690|NCT01609478|PLACEBO_COMPARATOR|placebo|"placebo delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
61917691|NCT04569071|EXPERIMENTAL|Sinovation Laser Ablation System treatment|Sinovation Laser Ablation System treatment
61917692|NCT05869084|EXPERIMENTAL|pulmonary function tests|
61917693|NCT01721785||Primary staging group I|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME.~Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI."
61917694|NCT01721785||Restaging group II|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group II are patients that will be stratified for a long course of chemoradiotherapy.~Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI."
62114285|NCT04800016|EXPERIMENTAL|Vivity IOL|AcrySof IQ Vivity Extended Vision IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery
62303484|NCT04348903|EXPERIMENTAL|Positive Pre-Visit Imagery Intervention|Positive pre-visit imagery is one of the superior cognitive- behavioral interventions. It is kind of psychological preparation that is designed to provide children with a step-by-step explanation of the dental local anaesthesia injection in an attractive approach
61917695|NCT01931631|EXPERIMENTAL|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
62303485|NCT04720144||bIMI cases|"Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for:~i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD).~AND~iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days."
61917696|NCT01931631|ACTIVE_COMPARATOR|ADA diet|American Diabetes Association diet
61917697|NCT03808103|PLACEBO_COMPARATOR|Placebo|Dose is 1mL of placebo given orally twice a day for 15 days
61917698|NCT03808103|EXPERIMENTAL|Phage|Dose is 1mL of bacteriophage preparation given orally twice a day for 15 days
61917699|NCT02102373|ACTIVE_COMPARATOR|low-fiber diet|Patients received low-fiber diet for 24 hours before colonoscopy
61917700|NCT02102373|ACTIVE_COMPARATOR|clear liquid diet|Patients received clear liquid diet for 24 hours before colonoscopy
61917701|NCT06116240|EXPERIMENTAL|Subjects with advanced hepatocellular carcinoma|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
61917702|NCT06116240|EXPERIMENTAL|Advanced gastric adenocarcinoma / gastroesophageal junction adenocarcinoma subjects|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
61917703|NCT06116240|EXPERIMENTAL|Advanced non-small cell lung cancer|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
62114286|NCT01810250||Abdominal Aortic Aneurysm (Challenging anatomy)|Endovascular aneurysm repair
62114287|NCT02487316|EXPERIMENTAL|crizotinib combined with chemotherapy|crizotinib 250mg, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
62114288|NCT02900326|PLACEBO_COMPARATOR|Control patients with no intervention|group without intervention
62114289|NCT02900326|EXPERIMENTAL|Endurance training program (8 weeks) group|only physical training group
62114290|NCT02900326|EXPERIMENTAL|MBSR group (mindfulness-based-stress-reduction)|only mental training group (8 weeks)
62114291|NCT02900326|EXPERIMENTAL|Endurance training program combined with MBSR sessions|Endurance training program combined with MBSR sessions, during 8 weeks (mindfulness-based-stress-reduction)
62114292|NCT02106442||Sodium Risedronate 75 mg|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking. Participants receive sodium risedronate 75 mg as part of routine medical care.
62114293|NCT05022147|EXPERIMENTAL|Alternating-Frequency DBS|In this single-arm study, all participants will receive all interventions in a crossover fashion.
62114294|NCT01838200|EXPERIMENTAL|Cohort 1, Group 1 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration \<10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
62114295|NCT01838200|EXPERIMENTAL|Cohort 1, Group 2 (BCG 0.8-3.2 × 10^6 CFU)|Patients with an induration \<10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
62736160|NCT02808325|ACTIVE_COMPARATOR|non-balanced gelatine solution|colloidal volume substitute
62736161|NCT04737356|EXPERIMENTAL|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
62114296|NCT01838200|EXPERIMENTAL|Cohort 1, Group 3 (BCG 4.0-16.0 × 10^6 CFU)|Patients with an induration \<10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
62114297|NCT01838200|EXPERIMENTAL|Cohort 2 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration ≥10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
62472205|NCT05004116|EXPERIMENTAL|Phase II, DIPG Cohort|Patients with DIPG will enroll in cohort 4 and receive TPX-0005 (Repotrectinib) monotherapy at the pediatric recommended phase 2 dose
62114298|NCT01231113|ACTIVE_COMPARATOR|artesunate-amodiaquine arm|A co-blistered pack of amodiaquine and artesunate.The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
62114299|NCT01231113|EXPERIMENTAL|Dihydroartemisinin-piperaquine arm|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
62114300|NCT06037187||Immune-mediated condition|Participants with an immune-mediated condition
62114301|NCT06037187||Without immune-mediated dermatologic condition|Participants without an immune-mediated dermatologic condition
62114302|NCT02355158|EXPERIMENTAL|Active|Clonidine hydrochloride topical gel, 0.1%
62114303|NCT03510949|OTHER|Group N|Patients' nasal mucosa will be anaesthetized and vasoconstricted. K-Y gel will be applied to the tip of nasopharyngeal airway (NPA) of appropriate size. The NPA will then be advanced into the dominant nostril along the septum horizontally.
62114304|NCT03510949|OTHER|Group L|K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt.
62114305|NCT04498754|EXPERIMENTAL|Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants assigned to this arm will receive eight sessions of a well-established, evidence-based therapy called cognitive behavior therapy for insomnia (CBT-I).
62114306|NCT04498754|OTHER|Minimal Contact Control Condition|Participants assigned to this condition will be contacted every week for eight weeks and monitored regarding their insomnia symptoms.
62114307|NCT01437358||intensive care unit|
62114308|NCT05347199|PLACEBO_COMPARATOR|Healthy Volunteers Placebo|placebo pill at two time points
62114309|NCT05347199|ACTIVE_COMPARATOR|Healthy Volunteers Amisulpride|amisulpride pill at two time points
62472206|NCT00851877|EXPERIMENTAL|arm one|Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
62472207|NCT00988663|ACTIVE_COMPARATOR|Memantine arm|Patient receiving ECT and Memantine
62303486|NCT04720144||Controls|"For each bIMI case, we will include 2 control cases fulfilling the following criteria:~i) Receiving continuous posaconazole prophylaxis for at least 7 days~ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay"
62303487|NCT05417321|EXPERIMENTAL|HB0036|HB0036 IV every 3 weeks (q3w)
62736162|NCT04737356|NO_INTERVENTION|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
61917704|NCT06116240|EXPERIMENTAL|Locally advanced or metastatic urothelial cancer|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
62114310|NCT05347199|ACTIVE_COMPARATOR|MDD Patients Placebo|placebo pill at two time points
62114311|NCT05347199|EXPERIMENTAL|MDD Patients Amisulpride|amisulpride pill at two time points
62114312|NCT05165849|EXPERIMENTAL|GFS101A+Toripalimab|Patient will be administrated with GFS101A IV in combination with Toripalimab IV. The duration of the treatment cycle is defined as 21 days.
62114313|NCT02493933|ACTIVE_COMPARATOR|Phytoestrogen|Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
62114314|NCT02493933|ACTIVE_COMPARATOR|Isosorbid mononitrate|Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
62114315|NCT02493933|ACTIVE_COMPARATOR|N-Acetyl cysteine|Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
62114316|NCT03009513|EXPERIMENTAL|single arm|
62114317|NCT01270633|OTHER|Treatment|PriMatrix applied to appropriately debrided wound bed and covered with a non-adherent dressing. Dressings applied to maintain moist wound therapy.
62303488|NCT01712360|EXPERIMENTAL|NAFT500 (pediatric)|Topical once a day for two weeks
62303489|NCT01712360|EXPERIMENTAL|NAFT600 (pediatric)|Topical once a day for two weeks
62114318|NCT01270633|ACTIVE_COMPARATOR|Standard of Care|Non adherent dressing applied to appropriately debrided wound bed and moist wound therapy maintained.
62114319|NCT05344300||Lung-healthy group|
62114320|NCT05344300||Bronchiectasis group|
62114321|NCT03368833||Caudal block|Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
62114322|NCT03368833||Control|Patients who do not receive a caudal block.
62114323|NCT04602052|ACTIVE_COMPARATOR|Medical arm|Those who choose medical abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48 hours later for admission and misoprostol administration.
62303490|NCT01712360|EXPERIMENTAL|NAFT500 (adult)|Topical once a day for two weeks
62303491|NCT01712360|EXPERIMENTAL|NAFT600 (adult)|Topical once a day for two weeks
62303492|NCT02450357||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
61917705|NCT06116240|EXPERIMENTAL|Advanced esophageal squamous cell carcinoma|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
61917706|NCT06116240|EXPERIMENTAL|Non-scaly and non-small cells lung cancer|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle. Pemetrexed disodium for injection, 21 days as a treatment cycle. Cisplatin injection, 21 days as a treatment cycle.
61917707|NCT05440773|EXPERIMENTAL|Treatment group 1 (TG 1)|Group of 8 persons receiving A. afra infusions of 5g/1liter of water, 3drinks a day, daily for 1week (7 days) (current recommendation)
62114324|NCT04602052|EXPERIMENTAL|Surgical arm|Those who chose surgical abortion are given mifepristone 200 mg with or without laminaria and appointed to return the next day for surgical abortion.
62114325|NCT00517933|ACTIVE_COMPARATOR|Sildenafil|20 mg of sildenafil 3 times a day (TID) for 12 weeks followed by 20 mg of sildenafil TID for an additional 12 weeks
62303493|NCT02450357||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
62303494|NCT02450357||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
62736163|NCT02284815|ACTIVE_COMPARATOR|Glutenfree diet|Self-chosen glutenfree diet
62736164|NCT02284815|PLACEBO_COMPARATOR|Normal diet|Those not following the glutenfree diet
61917708|NCT05440773|EXPERIMENTAL|Treatment group 2 (TG 2)|Group of 8 persons receiving A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
62472208|NCT00988663|PLACEBO_COMPARATOR|placebo|25 patients receiving ECT will will receive placebo
62114326|NCT00517933|PLACEBO_COMPARATOR|Placebo / Sildanafil|20 mg of placebo TID for 12 weeks followed by 20 mg of sildenafil citrate TID for an additional 12 weeks
62114327|NCT01980641|NO_INTERVENTION|Control group|Assessment of each participant's home and his or her performance of ADL.
62114328|NCT01980641|EXPERIMENTAL|Experimental group|Educational intervention: Assessment of each participant's home and his or her performance of ADL and the therapist will provide to the participants of the experimental group a list of advice related to the HTAS items that are evaluated negatively.
61917709|NCT05440773|EXPERIMENTAL|Treatment group 3 (TG 3)|Group of 8 persons receiving A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
61917710|NCT05440773|EXPERIMENTAL|Treatment group 4 (TG 4)|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
61917711|NCT05440773|EXPERIMENTAL|Treatment group 5 (TG 5)|Group of 8 persons flavored A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
62114329|NCT01980641|EXPERIMENTAL|Application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
62472209|NCT04645914|NO_INTERVENTION|No smokers|Healthy subjects who do not consume any nicotine products
62472210|NCT04645914|EXPERIMENTAL|Smokers/Vapers|Healthy subjects who consume nicotine products
62736165|NCT06268184|ACTIVE_COMPARATOR|omega 3|D3LAB syrup each 5 ml contain :EPA 825 mg and DHA 550 mg each child receive 3.6 ml every day for 6 months
62736166|NCT06268184|PLACEBO_COMPARATOR|placebo|Placebo capsules contain only the standard ingredients of soft gelatin capsules (gelatin, water, glycerin, and vitamin E in minute amounts as preservatives).
62472211|NCT01646554|ACTIVE_COMPARATOR|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
61917712|NCT05440773|EXPERIMENTAL|Treatment group 6 (TG 6)|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
61917713|NCT05440773|PLACEBO_COMPARATOR|Treatment group 7|Group of 4 persons receiving flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
61917714|NCT05440773|PLACEBO_COMPARATOR|Treatment group 8|Group of 4 participants receiving regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
61917715|NCT04369820|EXPERIMENTAL|COVID-19 PATIENTS|"Two blood samples (40mL) at 2 different points in time:~1. Within the first 72 hours of medical care in resuscitation unit or department.~2. Between the 5th and the 10th day of medical care (ideally at the end of the first week) or on the day of discharge of patient if it is earlier, or of death if it takes place earlier."
62114330|NCT01980641|NO_INTERVENTION|Non Application smartphone-based group|Non Smartphone-based application group (NSG) sample won't have a reminder
62114331|NCT04552886|EXPERIMENTAL|Dendritic cell vaccine: Starting dose|This arm will evaluate the safety of administering a total dendritic cell dose of 3.5 x 10\^6. A total of 3-6 patients will be enrolled with this dose. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
62114332|NCT04552886|EXPERIMENTAL|Dendritic cell vaccine dose de-escalation|If unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10\^6, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 1.75 X 10\^6.
62472212|NCT01646554|EXPERIMENTAL|Arm B: modified FOLFOX6 + Aflibercept and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Aflibercept 4 mg/kg intravenous infusion 1-h~Hour 1: Oxaliplatin 85 mg/m2 2-h infusion~Hour 1: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 3: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~Day 1 of a 14 day cycle~Aflibercept should be given in all cycles, except cycle 6 of pre-operative treatment."
62472213|NCT03175718|EXPERIMENTAL|VAC Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 7 days of Incisional Negative pressure wound therapy.
62472214|NCT03175718|ACTIVE_COMPARATOR|Control Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive standard gauze dressing with no negative pressure application.
61917716|NCT05278637|ACTIVE_COMPARATOR|Aspirin 81mg/day, Aspirin 325mg/day, Aspirin washout, Ticagrelor 90mg BID|
62303495|NCT02450357||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
62736167|NCT03978741|EXPERIMENTAL|Test Device|Yōni.Fit Test Device
61917717|NCT05278637|ACTIVE_COMPARATOR|Aspirin 325mg/day, Aspirin 81mg/day, Aspirin washout, Ticagrelor 90mg BID|
61917718|NCT05278637|ACTIVE_COMPARATOR|Ticagrelor 90mg BID|
61917719|NCT01629771||Lymphatic Filariasis|
61917720|NCT01629771||Patients without Lymphatic Filariasis|
62303496|NCT03707717|EXPERIMENTAL|Bimekizumab-SS|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.
61917721|NCT03490981|OTHER|Treatment as usual (TAU) only|Primary care treatment as usual
61917722|NCT03490981|EXPERIMENTAL|Treatment as usual (TAU) plus Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Primary care treatment as usual and Brief CBT-CP
61917723|NCT06408155|EXPERIMENTAL|Task with verbal encouragement|Endurance isometric exercise performed with verbal encouragement
62303497|NCT03707717|EXPERIMENTAL|Bimekizumab-AI|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.
61917724|NCT06408155|ACTIVE_COMPARATOR|Task 1 without motivational feedback|Task without motivational feedback
61917725|NCT06408155|EXPERIMENTAL|Task with music|Endurance isometric exercise performed with music
61917726|NCT06408155|ACTIVE_COMPARATOR|Task 2 without motivational feedback|Task without motivational feedback
61917727|NCT04604691|EXPERIMENTAL|Blinatumomab Treatment|
61917728|NCT00858819||AS|Patients with AS attending three different rheumatology clinics in Western Sweden have been invited to participate.
62114333|NCT04552886|EXPERIMENTAL|Dendritic cell vaccine dose escalation one|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10\^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 7.0 X 10\^6.
62114334|NCT04552886|EXPERIMENTAL|Dendritic cell vaccine dose escalation two|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 7.0 x 10\^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1.4 X 10\^7.
62114335|NCT04781218||Participants enrolled in the registry|Participants enrolled in the registry will include school community members including students, parents, staff, etc.
62114336|NCT03316794|EXPERIMENTAL|SC-005|SC-005 intravenous (IV) (various doses and dose regimens)
62114337|NCT02779608|EXPERIMENTAL|intraperitoneal docetaxel and oral S-1|"Docetaxel is diluted in 1litre normal saline and administered intraperitoneal（IP）at a dose of 60 mg/m2 over 1 hour on day 1. S-1 was administered orally twice daily at a dose of 40mg/m2 per day for 14 consecutive days, followed by 7 days of rest.~Intervention: Drug: Intraperitoneal docetaxel Intervention：Drug：Oral S-1"
62114338|NCT04922658|EXPERIMENTAL|Surufatinib|
62114339|NCT04922658|EXPERIMENTAL|Surufatinib plus Vinorelbine|
62114340|NCT02328352|EXPERIMENTAL|BP selfstanding felt|"laparotomy intervention with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.~V-Loc 180 (ref VLOCL0024, lot. A1D0899)"
62114341|NCT02328352|ACTIVE_COMPARATOR|PP mesh|"intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PP mesh was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia.~Other names: V-Loc 180 (ref VLOCL0024, lot. A1D0899) PR Parietene mesh Tyco (ref. PP3030, lot. SIK00587)"
62114342|NCT02328352|EXPERIMENTAL|BP intraperitoneal mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply for entering into the abdominal cavity. In five rabbits (BPR21-BPR25). A 2x2cm2 BP intraperitoneal mesh was then be inserted with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut.
61917729|NCT04461041|ACTIVE_COMPARATOR|Empagliflozin|Single 10 mg tablet, administered orally once daily for 6 months
61917730|NCT04461041|PLACEBO_COMPARATOR|Placebo|Single 10 mg tablet, administered orally once daily for 6 months
61917731|NCT03211806|EXPERIMENTAL|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
61917732|NCT03211806|ACTIVE_COMPARATOR|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
61917733|NCT01171833|EXPERIMENTAL|Group A(Sevoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
61917734|NCT01171833|EXPERIMENTAL|Group B(Desflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
62114343|NCT02328352|ACTIVE_COMPARATOR|control group|Five rabbits (R26-R30) will be used as control group.
62114344|NCT05714358|EXPERIMENTAL|INTERVENTION GROUP|Face to face education programme and mobile app were used.
62114345|NCT05714358|NO_INTERVENTION|CONTROL GROUPS|Only face to face education was used.
62303498|NCT03707717|EXPERIMENTAL|Bimekizumab-TN|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.
61917735|NCT01171833|EXPERIMENTAL|Group C(Isoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
61917736|NCT01074047|EXPERIMENTAL|Azacitidine|Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
61917737|NCT01074047|ACTIVE_COMPARATOR|Conventional Care Regimen|Conventional Care Regimen
62114346|NCT04789798|EXPERIMENTAL|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~1. Electronic transmission of capillary blood glucose measurement results~2. Electronic transmission of blood pressure measurements~3. Synchronized video-conferencing, secure messaging~4. Access to clinical data from patient files when necessary~5. Reminding of routine follow-up tests and examinations~6. Providing web-based educational materials to patients."
62303499|NCT06365359||Lupus patients who consult the Martinique University Hospital|
62472215|NCT04140318|EXPERIMENTAL|treatment|combination therapy of PD-1 and chemotherapy including: sintilimab 200mg iv, 30-60min, q3w; nab-paclitaxel 125mg/m2, iv, d1,d8, q3w
62472216|NCT00858793|EXPERIMENTAL|A|
61917738|NCT04554004|EXPERIMENTAL|Study group|All consecutive patients undergoing outine CT angiography and dynamic CT-myocardial perfusion imaging(MPI) will be potentially eligible for inclusion in the trial. Assessment of coronary stenosis severity using invasive fractional flow reserve (FFR) and the status of myocardial microcirculation perfusion including coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be performed as part of invasive coronary angiography(CAG).
61917739|NCT03112590|EXPERIMENTAL|Combination Therapy|"Phase 1: Participants with HER-2 positive metastatic breast cancer enrolled in groups of 3-6 or more; each group participant to be given the same dose and schedule of Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. If group participants do not have bad side effects, the next group will be given a higher dose of Interferon-gamma. This will continue until the highest safe dose of Interferon-gamma is found. Once highest safe dose of Interferon-gamma is found, participants may be enrolled in Phase II.~Phase 2: Approximately 31 participants with Stage 2-3 HER2 positive early stage breast cancer enrolled to receive therapy with Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. Interferon-gamma given at dose found in the Phase 1.~Phase 2: Post therapy surgery."
61917740|NCT02910128|EXPERIMENTAL|School intervention|chiquichefs education innovation
61917741|NCT02910128|NO_INTERVENTION|control school|A primary schools will function as control schools.
61917742|NCT06393959|ACTIVE_COMPARATOR|pulsed radiofrequency group|Caudal epidural pulsed radiofrequency for lumbar spinal stenosis
61917743|NCT06393959|ACTIVE_COMPARATOR|steroid enjection grroup|Caudal epidural steroid enjection for lumbar spinal stenosis
62472217|NCT01549353|EXPERIMENTAL|chewing gum|
62472218|NCT00263588|EXPERIMENTAL|single arm|750 mg lapatinib administered orally twice daily
61917744|NCT00868179|EXPERIMENTAL|Pradax|This is the only arm in the study and all will follow the same protocol for the study which is taking the pradax after total knee replacement
61917745|NCT04983303|EXPERIMENTAL|TICK-B group as intervention group|TICK-B group: The children will receive a picture as they want. They will be asked to trace and color the pictures that need coloring. After the procedure, the child will take his or her picture which he colored during the procedure.
61917746|NCT04983303|EXPERIMENTAL|Coughing trick|Coughing trick: Children in this group will be taught how to cough during the procedure. coughs with start moderate force and then coughs again which coincides with a needle procedure, such as venipuncture for example.
62472219|NCT04606628|EXPERIMENTAL|Intervention|Participants will consume 2 capsules containing eggshell membrane(ESM) with breakfast every day in 4 weeks.
62114347|NCT04789798|ACTIVE_COMPARATOR|Usual Care|usual diabetes care, as provided by primary care providers in the hospital
62114348|NCT01919697|EXPERIMENTAL|Plecanatide 3.0 mg|Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
62472220|NCT04606628|EXPERIMENTAL|Placebo|Participants will consume 2 capsules with no bioactive substance (placebo) with breakfast every day in 4 weeks.
62472221|NCT04926805|EXPERIMENTAL|Mask A|Overnight CPAP using the participant's usual pressure settings and using Mask A. One night only.
62472222|NCT04926805|ACTIVE_COMPARATOR|Mask B|Overnight CPAP using the participant's usual pressure settings and using Mask B. One night only.
62736168|NCT03978741|ACTIVE_COMPARATOR|Comparator Device|Yōni.Fit Comparator Device
62736169|NCT00293813|PLACEBO_COMPARATOR|3|Placebo for denosumab and placebo for alendronate
62736170|NCT00293813|EXPERIMENTAL|1|denosumab and placebo for alendronate
62736171|NCT00293813|ACTIVE_COMPARATOR|2|Placebo for denosumab and alendronate
62674888|NCT03087123|ACTIVE_COMPARATOR|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
61917747|NCT04983303|EXPERIMENTAL|Balloon inflation group as intervention group|Balloon inflation group: In this group, the children will receive a balloon colored as their favorite, and they will be asked to inflate the balloon before starting the venipuncture procedure.
61917748|NCT04983303|NO_INTERVENTION|Standard care provided group as control group|Standard care provided group as the control group
62114349|NCT01919697|EXPERIMENTAL|Plecanatide 6.0 mg|Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks
62114350|NCT06391619||Huntington's disease gene carriers|Individuals with a positive test for the HD gene who were more than 20 years from expected symptom onset at baseline assessment.
62114351|NCT06391619||Controls|Healthy controls matched to the gene carrier group for age, sex and education
62114352|NCT05586113|EXPERIMENTAL|10-day treatment group|10-day Tegoprazan bismuth-containing quadruple therapy Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
62114353|NCT05586113|ACTIVE_COMPARATOR|14-day treatment group|14-day Tegoprazan bismuth-containing quadruple therapy Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
62114354|NCT04286256|EXPERIMENTAL|Treatment Group|The treatment group received motivational interviewing.
62114355|NCT04286256|NO_INTERVENTION|Control Group|The control group received standard information only.
62114356|NCT00811057|ACTIVE_COMPARATOR|1 Magnesium Sulfate|
62114357|NCT00811057|ACTIVE_COMPARATOR|2 Nifedipine|Participants randomized to this group will receive the medication nifedipine orally.
62114358|NCT00811057|ACTIVE_COMPARATOR|3 Indomethacin|Participants randomized to this arm will receive the medication indomethacin per rectum and orally.
62114359|NCT02892968|EXPERIMENTAL|U/S Guided Regional Anesthesia|"Fascia-Iliaca Block(FIB) Femoral Nerve Block(FNB)~All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. EPs will then be trained to use two approaches to ultrasound (U/S) guided regional anesthesia, the fascia iliaca and femoral nerve blocks. Which block that will be used will be randomly determined at the individual patient level"
62114360|NCT02892968|NO_INTERVENTION|Current Local Standard Analgesia|"All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. Physicians who are in the control group will provide current local standard of analgesic care for hip fracture patients such as the use of IV opiods with supplemental acetaminophen and non-steroidal anti-inflammatory agents until they receive training."
62114361|NCT04915885|OTHER|Control arm|routine contraceptive counseling and care and a range of family planning methods that are routinely available at field level
62114362|NCT04915885|EXPERIMENTAL|Intervention package|contraceptive counseling package but still with a range of family planning methods that are routinely available at field level
61917749|NCT03046914|EXPERIMENTAL|HLA-B*5801 screen test|An arm in which a participant takes HLA-B\*5801 test before administration of allopurinol
62114363|NCT04915885|EXPERIMENTAL|Intervention package & expanded methods|contraceptive counseling package but with an expanded range of family planning methods that are recommended by national guidance
62114364|NCT02861937|NO_INTERVENTION|healthy|"Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)"
62114365|NCT02861937|ACTIVE_COMPARATOR|chronic gingivitis|"Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm and more than to 25% sites with the gingival bleeding present (BOP)~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
62114366|NCT02861937|ACTIVE_COMPARATOR|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
62114367|NCT04351113|EXPERIMENTAL|MITO-AO|Healthy older adult subjects ages 65-75 will take the supplement MITO-AO during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (31P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
62114368|NCT04351113|EXPERIMENTAL|PB-125|Healthy older adult subjects ages 65-75 will take the supplement PB-125 during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
62114369|NCT04351113|PLACEBO_COMPARATOR|Placebo|Healthy older adult subjects ages 65-75 will take placebo during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
62114370|NCT02045719|EXPERIMENTAL|cat's claw|100 mg dose of a dry extract of U. tomentosa three times per day
62114371|NCT00878462|EXPERIMENTAL|Sequence 1|Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
62114372|NCT00878462|EXPERIMENTAL|Sequence 2|Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
62114373|NCT00878462|EXPERIMENTAL|Sequence 3|Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
62114374|NCT00878462|EXPERIMENTAL|Sequence 4|Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
62114375|NCT00878462|EXPERIMENTAL|Sequence 5|Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
62114376|NCT00878462|EXPERIMENTAL|Sequence 6|Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
62114377|NCT04083833|EXPERIMENTAL|Treatment Arm|(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)
62303500|NCT06210126|ACTIVE_COMPARATOR|Pectointercostal Fascial Plane Block Group|In addition to routine standard perioperative and postoperative analgesia protocol patients will receive bilateral local anesthetic injections at the Pectointercostal Fascial Plane Block
62303501|NCT06210126|OTHER|Control|Patients will receive standard perioperative and postoperative analgesia protocol
62303502|NCT06411444|ACTIVE_COMPARATOR|Kidney Shaped Nasal Stent|Conventional NAM with kidney shaped nasal stent added to it.
62303503|NCT06411444|EXPERIMENTAL|Grape Design Nasal Stent|Conventional NAM with grape shaped nasal stent added to it.
62303504|NCT02589431||Patients with severe sepsis|
62303505|NCT02589431||Controls|Healthy subjects
62303506|NCT03846947|EXPERIMENTAL|All participants|All participants will receive the investigational MR Fingerprinting sequence.
62303507|NCT00736229|EXPERIMENTAL|Exenatide|0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
62303508|NCT02258412|ACTIVE_COMPARATOR|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
62303509|NCT02258412|ACTIVE_COMPARATOR|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
62674889|NCT00375310|EXPERIMENTAL|Gemcitabine + Sorafenib & radiotherapy|"Induction: Gemcitabine with Sorafenib for 4 weeks (1 cycle). Chemo-radiotherapy: Gemcitabine with Sorafenib and Radiotherapy for 5 weeks. Sorafenib will be given in escalating dose cohorts.~Sorafenib only: Sorafenib alone for 4 weeks. Consolidation: Gemcitabine with Sorafenib for 16 weeks (4 cycles). Maintenance: Sorafenib alone until disease progression."
61917750|NCT00936429|EXPERIMENTAL|10 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
61917751|NCT00936429|EXPERIMENTAL|50 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
61917752|NCT00936429|PLACEBO_COMPARATOR|Placebo|Administration of placebo vaccine at Weeks 0, 4, and 8.
62303510|NCT03445676|NO_INTERVENTION|Usual Care|Study personnel silently observe and record what the healthcare worker does at each hand hygiene opportunity without direction to the healthcare worker
61917753|NCT02392715|EXPERIMENTAL|Intervention cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' inspiratory muscle training with Threshold by Respironics~Inspiratory muscle training intensity: 15% of maximal inspiratory pressure (PiMax) during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
62303511|NCT03445676|EXPERIMENTAL|ABHR directly on gloves|Healthcare worker will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
61917754|NCT02392715|SHAM_COMPARATOR|Control cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' sham inspiratory muscle training with Threshold by Respironics~Sham inspiratory muscle training intensity : 5 centimeters of water (cmH20)"
62303512|NCT03445676|PLACEBO_COMPARATOR|Ideal Standard|Healthcare worker will be directed by study personnel to remove gloves, perform hand hygiene and replace gloves at each hand hygiene opportunity
62303513|NCT02049567|EXPERIMENTAL|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
62303514|NCT02354001|EXPERIMENTAL|Raloxifene Hydrochloride|120 mg per capsule (1 tablet daily)
62114378|NCT04083833|PLACEBO_COMPARATOR|Control|"Treatment D:~(Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo~Treatment E:~(Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment F:~(Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment G:~(Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment H:~(Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment I:~(Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin"
62303515|NCT02354001|PLACEBO_COMPARATOR|placebo tablet|1 tablet daily for 12 weeks
62472223|NCT03998605|EXPERIMENTAL|Abuse Prevention Program Condition|"The abuse prevention program will address: (1) BEFORE -- (a) Learning about problem of abuse and what abuse is; (b) Knowing about types of abuse, who the abusers are and where abuse happens; (c) Planning ahead and identifying safe people; (2) DURING -- (a) Rejecting abuse by saying no; (b) Getting away if possible/staying safe and paying attention, (c) Staying calm and getting home; and (3) AFTER -- (a) Telling your safe person, (b) Knowing what to do and what not to do, and (c) Reporting the abuse and getting help to cope with the event."
62674890|NCT01740427|EXPERIMENTAL|PD-0332991 + Letrozole|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
62674891|NCT01740427|ACTIVE_COMPARATOR|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
62674892|NCT01259882|EXPERIMENTAL|Cohort 1: Experimental intervention: PF-05089771 or placebo|Cohort 1
62674893|NCT01259882|EXPERIMENTAL|Cohort 2: Experimental intervention: PF-05089771 or placebo|Cohort 2
62114379|NCT05033509||ECMO and AKI|
62114380|NCT06261450|EXPERIMENTAL|CBD first|A single dose of CBD dose administered followed by a dose of placebo 3 weeks later.
62114381|NCT06261450|EXPERIMENTAL|Placebo first|A single dose of placebo dose administered followed by a dose of CBD 3 weeks later.
62114382|NCT05649878|ACTIVE_COMPARATOR|Intravenously MEP|"Single dose of MEP sodium succinate intravenously administered. MEP (equivalent to 62.5 mg of Methylprednisolone).~Samples were obtained at 0.333, 0.50, 0.667, 0.833, 1, 1.0, 2, 3, 4, 6, 8, 10, 12 and 24 h after MEP administration."
62674894|NCT01259882|EXPERIMENTAL|Cohort 3: Experimental intervention: PF-05089771 or placebo|Cohort 3
62674895|NCT01259882|EXPERIMENTAL|Cohort 4: Experimental intervention: PF-05089771 or placebo|Cohort 4
61917755|NCT06188273||Myosteatotic Group|The group of patients was diagnosed with myosteatosis through CT imaging assessment before transplantation.
61917756|NCT06188273||Non-myosteatotic Group|The group of patients was diagnosed without myosteatosis through CT imaging assessment before transplantation.
61917757|NCT06188273||The Group with Severe Muscle Loss|The group of patients, through the comparison of CT images before and after transplantation, was diagnosed with significant muscle loss.
61917758|NCT06188273||The Group without Severe Muscle Loss|The group of patients, through the comparison of CT images before and after transplantation, was diagnosed without significant muscle loss.
62114383|NCT05649878|ACTIVE_COMPARATOR|Intranasally MEP|Volunteers were randomly assigned to receive a single dose of MEP intranasally administered (equivalent to 62.5 mg of Methylprednisolone), using a Mucosal Atomization Device (MAD Nasal). Samples were obtained at 0.333, 0.50, 0.667, 0.833, 1, 1.0, 2, 3, 4, 6, 8, 10, 12 and 24 h after MEP administration.
62114384|NCT02592954|EXPERIMENTAL|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
62674896|NCT01259882|EXPERIMENTAL|Cohort 5: Experimental intervention: PF-05089771 or placebo|Cohort 5
62674897|NCT01259882|EXPERIMENTAL|Cohort 6: Experimental intervention: PF-05089771 or placebo|Cohort 6
62674898|NCT03044912|EXPERIMENTAL|treatment group|Mirabegron 50 mg for comparison
62303516|NCT05453799|EXPERIMENTAL|Treatment (vudalimab)|Patients receive vudalimab IV over 1 hour on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62303517|NCT05428371||Thyroid carcinoma|Patients with indeterminate thyroid nodule and pathological diagnosis of thyroid carcinoma
62303518|NCT05428371||Follicular adenoma|Patients with indeterminate thyroid nodule and pathological diagnosis of follicular adenoma
62114385|NCT02592954|PLACEBO_COMPARATOR|Jojoba oil|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
62303519|NCT04837612||Subjects with dilated cardiomyopathy|Subjects diagnosed with dilated cardiomyopathy by medical history, physical examination and echocardiography.
62114386|NCT05429424|EXPERIMENTAL|Verum acupuncture group|The study uses manual acupuncture as verum intervention.
62114387|NCT05429424|SHAM_COMPARATOR|Sham control group I|The study used specific made needle with a blunt tip, Streitberger device, as sham intervention.
62114388|NCT05429424|SHAM_COMPARATOR|Sham control group II|Manual acupuncture at the points unrelated to the dysphagia is another sham intervention in this study.
62114389|NCT01832506|EXPERIMENTAL|MSC2156119J|
62303520|NCT01661647|EXPERIMENTAL|3D knee kinematic assessment|3D knee kinematic assessment under local anesthesia
62303521|NCT02940964|EXPERIMENTAL|COMSCPR first|Group A will proceed to perform one cycle (two minutes) of COMSCPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
62303522|NCT02940964|ACTIVE_COMPARATOR|Standard CPR first|Group A will proceed to perform one cycle (two minutes) of Standard CPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
62674899|NCT03044912|ACTIVE_COMPARATOR|Comparative group|Patient take Mirabegron 25 mg
62674900|NCT01141790|PLACEBO_COMPARATOR|Silence|"The control group listened silence and was evaluated the same things."
62303523|NCT04543448|OTHER|Traditional Rehabilitation|Traditional Rehabilitation program was included strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs in all individuals. Indıvıduals participated in 2 training sessions per week for 4 weeks. Each training session consisted of a 5-minute non-balance coordination exercise, a 30-minute balance and coordination exercise, a 10-minute stretching and strengthing.
62114390|NCT02114749|EXPERIMENTAL|volunteers in daily life activities|a set of wearable respiration and cardiac monitoring devices
62114391|NCT04441593|EXPERIMENTAL|Intervention|Videoconferencing Intervention for Heavy Drinking and Chronic Pain
62114392|NCT04441593|ACTIVE_COMPARATOR|Control|Treatment as Usual
62303524|NCT04543448|EXPERIMENTAL|Cervical Mobilization|Cervical Mobilization program, cervical mobilization techniques were applied to the patients for 30 minutes in addition to the traditional program. Cervical mobilization includes suboccipital relaxing techniques, myofascial muscle relaxing techniques for Levator scapula, trapezius, scalenes muscles. These techniques were applied bilaterally.
62303525|NCT04438421|EXPERIMENTAL|BMG0703|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
62303526|NCT04438421|ACTIVE_COMPARATOR|Chlorhexidine 0.2%|Subjects will then be given a 0.2% Chlorhexidine product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
62303527|NCT04438421|PLACEBO_COMPARATOR|Placebo Product|Subjects will then be given a placebo product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
62472224|NCT03998605|ACTIVE_COMPARATOR|Control condition|During the study the control group will receive 12 activity sheets from the ESCAPE-NOW curriculum. Six activity sheets will be given at the initial meeting and half way through the study the remaining activity sheets will be mailed to the dyads. We chose these activity sheets because they provide abuse information that was designed for individuals with ID.
62472225|NCT02225314|EXPERIMENTAL|Brain Fitness|Brain Fitness is a computer-based cognitive training programs designed to augment auditory processing speed and accuracy over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
62472226|NCT02225314|EXPERIMENTAL|InSight|InSight is a computer-based cognitive training programs designed to augment visual processing and working memory over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
62472227|NCT02225314|ACTIVE_COMPARATOR|Active Control|An active control arm is necessary to model practice effects in an untreated group. Participants in this group will view and complete quizzes on a computerized learning program designed to improve knowledge about literature, art, and history.
62472228|NCT00387686|EXPERIMENTAL|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
62472229|NCT00387686|EXPERIMENTAL|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
62472230|NCT00387686|ACTIVE_COMPARATOR|C|Buffer/CPM + surgical fixation Intervention
62472231|NCT00387686|OTHER|D|Standard of Care: Surgical fixation intervention
62472232|NCT01779544|ACTIVE_COMPARATOR|Brief intervention only|Brief intervention, an educational model, consists of information
62472233|NCT01779544|ACTIVE_COMPARATOR|Exercise group|Brief educational intervention combined with exercise therapy
62674901|NCT00700232||1|Normal multiparous pregnant women without intrahepatic cholestasis of pregnancy (control group)
62114393|NCT02558218|ACTIVE_COMPARATOR|Systane ultra group|Participants in this group were administered systane ultra quid (Alcon, Fort Worth) for two months postoperatively), additionally to tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.
62114394|NCT02558218|ACTIVE_COMPARATOR|Control group|Participants in this group were administered the standard postoperative medication \[tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.\]
62114395|NCT04416971||mature AVF|Patients initiate HD with mature AVF.
62114396|NCT04416971||immature AVF|Patients initiate HD with immature AVF.
62114397|NCT06343103|OTHER|Workers exposed|Workers exposed to cytotoxic agents
62114398|NCT06343103|OTHER|Workers not exposed|Workers not exposed to cytotoxic agents
62114399|NCT04402320||Control group|extubated and weaning from the ventilator and followed our routine protocol of management post extubation without mechanical ventilation or BIPAP machine
62674902|NCT01062295|EXPERIMENTAL|Siesta-System|Use of Siesta-System
61917759|NCT06136988|EXPERIMENTAL|HB1801 and SG001 in combination with cisplatin and simultaneous radiotherapy|SG001 360 mg, Intravenous infusion, D1, Q3W, up to approximately 2 years ; Docetaxel for Injection (Albumin-bound) (HB1801), Intravenous infusion, D1, Q3W, 60 or 75 mg/m\^2, up to 2 cycles; cisplatin for injection 25 mg/m\^2, D1-D3, Q3W, up to 2 cycles; radiotherapy (28×1.8Gy).All treatments will be administered until disease progression or intolerable toxicity.
61917760|NCT06136988|ACTIVE_COMPARATOR|Paclitaxel in combination with cisplatin and simultaneous radiotherapy|Paclitaxel 135 mg/m\^2, Intravenous infusion, D1, Q3W; cisplatin for injection 25 mg/m\^2, D1-D3, Q3W, radiotherapy (28×1.8Gy). No other systemic antineoplastic therapy is allowed until disease progression, optimal supportive care and local palliative care are allowed.
61917761|NCT05860374|EXPERIMENTAL|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors
61917762|NCT06181045|EXPERIMENTAL|Cohort 1 (Treatment A): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule formulation.
61917763|NCT06181045|PLACEBO_COMPARATOR|Cohort 2 (Treatment B): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule formulation.
61917764|NCT06181045|EXPERIMENTAL|Cohort 3 (Treatment C): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
62472234|NCT04106193|EXPERIMENTAL|Toolkit + Implementation as Usual|Participating clinics assigned to this arm will receive a guiding toolkit and implementation as usual regarding IPV screening practices.
62472235|NCT04106193|EXPERIMENTAL|Toolkit + Blended Facilitation|Participating clinics assigned to this arm will receive a guiding toolkit and blended facilitation to support IPV screening practices.
62472236|NCT00747565|EXPERIMENTAL|Tecnis Multifocal IOL group|Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
62674903|NCT01062295|ACTIVE_COMPARATOR|Standard headrest|Use of standard headrest
62674904|NCT04772924|EXPERIMENTAL|fasting group|those preferred to take long time fasting
62674905|NCT04772924|ACTIVE_COMPARATOR|non fasting|those preferred not to take fasting
62674906|NCT00086125|EXPERIMENTAL|1|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
62674907|NCT04887038|ACTIVE_COMPARATOR|Drug :SRT-015|Experimental, Single and Multiple Oral escalating dose and Food Effect Cohort
62674908|NCT04887038|PLACEBO_COMPARATOR|Matching Placebo for SRT-015|
62674909|NCT01707550||Cohort|
62674910|NCT02650349|EXPERIMENTAL|spinal cord stimulation|The Vectris® SureScan® MRI lead will be connected to a RestoreSensor® SureScan® MRI neurostimulator.
62674911|NCT05897502|EXPERIMENTAL|the theoretical model nutritional education|instruction with multimedia
62674912|NCT05897502|PLACEBO_COMPARATOR|control|instruction with traditional paper
61917765|NCT06181045|EXPERIMENTAL|Cohort 4 (Treatment D): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
61917766|NCT06181045|EXPERIMENTAL|Cohort 5 (Treatment E): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
61917767|NCT06181045|EXPERIMENTAL|Cohort 6 (Treatment F): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
62472237|NCT00747565|ACTIVE_COMPARATOR|CeeOn 911A monofocal control IOL group|Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
62472238|NCT03781739|EXPERIMENTAL|MANP|subjects receiving MANP (2.5 micrograms/kg, single subcutaneous injection)
62472239|NCT03781739|PLACEBO_COMPARATOR|Placebo|subjects receiving placebo (saline solution, single subcutaneous injection)
62674913|NCT04163770|EXPERIMENTAL|performance of pacemaker at time of implantation|
62674914|NCT04163770|EXPERIMENTAL|performance of pacemaker 6 months after implantation|
62674915|NCT05545488|EXPERIMENTAL|Experimental group|Before preparing for pelvic training, information was given about virtual training applications, 1-2 minutes of practical information about both virtual glasses and pelvic training. Afterwards, the woman was taken to the gynecological examination table and, as the doctor began the examination, virtual glasses were put on the woman and a virtual reality application containing both sound and image was performed for 5-15 minutes. In the meantime, the pelvic examination was performed by the physician, the researcher accompanied the woman at all stages of the pelvic examination process and provided care based on ethical principles, which cared for the woman, respected, protected privacy.
62674916|NCT05545488|NO_INTERVENTION|Control group|The control group was accompanied by the woman at all stages of the pelvic examination process, and the care service that cared for the woman, was respectful, privacy was protected and based on ethical principles was given in the same way, but the virtual glasses initiative was not applied.
62472240|NCT01114893|ACTIVE_COMPARATOR|TRAVATAN|TRAVATAN 0.004% once daily
61917768|NCT06181045|EXPERIMENTAL|Cohort 7 (Treatment G): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
61917769|NCT00159562|EXPERIMENTAL|group education|Bipolar 1 and 2 patients in a stable euthymic phase will receive group education in 10 weekly sessions and then a session every third month for two years. Symptoms, admittances to hospital and function will be followed for two years.
61917770|NCT00159562|ACTIVE_COMPARATOR|individual education|Bipolar 1 and 2 patients in a stable euthymic phase will receive three individual sessions of education.
61917771|NCT03965273|EXPERIMENTAL|Full TP|Full TP intervention including emphasized social norms change
62472241|NCT01114893|PLACEBO_COMPARATOR|Travoprost Vehicle|Travoprost Vehicle
62674917|NCT05847335||University students' forms|A socio-demographic data form will be given to the participants and the childhood trauma scale, Bar-On emotional intelligence scale and Personality Beliefs scale will be administered.
62472242|NCT01114893|EXPERIMENTAL|Travoprost Group A|Travoprost Group A
62674918|NCT05708235|NO_INTERVENTION|Arm A: Control Arm|Patients must continue the same standard ET,prescribed as per standard practice, used in the surveillance phase. Changes in ET are not allowed.
62674919|NCT05708235|EXPERIMENTAL|Arm B: Experimental Arm with giredestrant|Giredestrant: 30 mg will be taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).
61917772|NCT03965273|EXPERIMENTAL|Light TP|Light TP intervention without emphasized social norms change
61917773|NCT03965273|NO_INTERVENTION|Pure control|Pure control
61917774|NCT06282887|EXPERIMENTAL|Music Therapy Group|Participants in the Music Therapy Group will receive standard care and approximately 15 minutes of music therapy before the MRI scan and will have music played through their headphones during the scanning process.
61917775|NCT06282887|NO_INTERVENTION|Control Group|Participants in the Control Group will receive standard care throughout the awaiting period and the scanning process.
62472243|NCT01114893|EXPERIMENTAL|Travoprost Group B|Travoprost Group B
62472244|NCT01114893|EXPERIMENTAL|Travoprost Group C|Travoprost Group C
62472245|NCT04807439||SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
61917776|NCT03665857|EXPERIMENTAL|multicomponent intervention|"Schools in the intervention arm will receive a multicomponent intervention at the school-, parent- and student-level, with a mobile application to promote the collaboration between investigators, school teachers, parents and students.~The school-level intervention elements will include school policies and health education for teachers.~The parent-level intervention elements will include health education for parents and promoting students' physical activity at home.~The student-level intervention elements will include health education for students, promoting students' physical activity in school and monthly monitoring of weight and height."
62674920|NCT05708235|EXPERIMENTAL|Arm C: Experimental Arm with giredestrant + abemaciclib|"* Giredestrant: 30 mg will be taken PO QD on Days 1to 28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).~* Abemaciclib 150mg will be taken PO twice daily (BID) (two intakes for a total daily dose of 300 mg) during each 28-day cycle up to two years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first)."
62674921|NCT05708235|EXPERIMENTAL|Arm D: Experimental Arm with giredestrant + inavolisib|"* Giredestrant: 30 mg will be administered PO QD on Days 1-28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).~* Inavolisib: 9 mg will be administered PO QD on Days 1-28 of each 28-day cycle up to two years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first)."
61917777|NCT03665857|NO_INTERVENTION|usual-care control|Schools assigned to the control group will have usual education provision throughout their participation in the trial, and after finishing the study they will be offered the health education package, policy suggestion and materials as the schools in the multicomponent intervention group.
62114400|NCT04402320||Invasive ventilation group|reconnected to mechanical ventilator before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use of NIV.
62674922|NCT06172049||CRC cases|
62674923|NCT04954443|EXPERIMENTAL|Removing urinary catheter at 24 hours after surgery|The participants will removing urinary catheters at 24 hour after vaginal surgery of pelvic organ prolapse.
61917778|NCT02218177||Non-responders receiving aflibercept therapy|Non-responders to ranibizumab who are now receiving aflibercept therapy
61917779|NCT02218177||Non-responders receiving PDT combo therapy|patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
62114401|NCT04402320||non invasive ventilation group|following the same previous protocol done after extubation with immediate connection to NIV with BIPAP mode for 1 hour and repeated every 12hours for 48 hours, BIPAP adjusted in our study by FIO2 40%, PEEP 8 cmH2O, Pressure support of 15 cmH2O.
62114402|NCT05826951|EXPERIMENTAL|Alcohol-alcohol|Both conversation partners receive alcohol
62114403|NCT05826951|PLACEBO_COMPARATOR|placebo-placebo|Both conversation partners receive placebo
62114404|NCT05826951|EXPERIMENTAL|alcohol-placebo|participant receives alcohol and conversation partner receives placebo
62114405|NCT05826951|EXPERIMENTAL|placebo-alcohol|participant receives placebo and conversation partner receives alcohol
62114406|NCT04089488||Observational (respond to surveys, medical record review)|Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
62114407|NCT04551781|EXPERIMENTAL|steroid|20 mg prednisolone for 14 days
62114408|NCT04551781|PLACEBO_COMPARATOR|control|controll
62114409|NCT02072213|EXPERIMENTAL|GL2702 GLARS-NF1 , fasted|Tamsulsoin 0.4mg
62114410|NCT02072213|ACTIVE_COMPARATOR|Omix Ocas® , fasted|Tamsulsoin 0.4mg
62114411|NCT02072213|EXPERIMENTAL|GL2702 GLARS-NF1, after meal|Tamsulsoin 0.4mg
62303528|NCT00815789|EXPERIMENTAL|Intervention|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
62674924|NCT04954443|PLACEBO_COMPARATOR|Removing urinary catheter at 48 hours after surgery|The participants will removing urinary catheters at 48 hour after vaginal surgery of pelvic organ prolapse.
62674925|NCT02622594|ACTIVE_COMPARATOR|1|Treatment 1 will include microneedling performed prior to ALA application to their right face and ALA application only to the left face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
62674926|NCT02622594|ACTIVE_COMPARATOR|2|Treatment 2 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
62114412|NCT02072213|ACTIVE_COMPARATOR|Omix Ocas®, after meal|Tamsulsoin 0.4mg
61917780|NCT02218177||Responders to ranibizumab|Patients who are responders to ranibizumab and are continuing monthly injections.
61917781|NCT02277834||pancreatic adenocarcinoma|15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).
62303529|NCT00815789|NO_INTERVENTION|Control|Receive educational material about CVD reduction at baseline
62674927|NCT02622594|ACTIVE_COMPARATOR|3|Treatment 3 will include microneedling performed prior to ALA application to their right face and ALA application only to the left side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
62674928|NCT02622594|ACTIVE_COMPARATOR|4|Treatment 4 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
62674929|NCT01769118||Caffeine|caffeine will be given according to clinical judgment
62674930|NCT05224908|EXPERIMENTAL|pregnant women with a breech fetus|pregnant women with a breech fetus performing standing and sitting EOS pelvimetry
62674931|NCT06397066||the white light endoscopy group|The characteristics of white light endoscopic extraction include degree of atrophy (Kimura-Takemoto classification), congestion and edema, yellow white nodules, mucus turbidity, the arrangement of the collecting veins is regular (RAC)/irregular/disappearing, goose flesh, map-like redness, blood scabs, gastric fundus gland polyps, and scratch syndrome, and are judged according to the Kyoto Classification of Gastritis.
62674932|NCT06397066||the Magnifying endoscopy group|Magnifying endoscopy(ME) uses Narrow Band Imaging (NBI)+ME to observe the non atrophic area of the gastric fundus gland. According to the proportion of the opening of the gastric fundus gland duct in one magnified field of view, it is classified as grade 1 ≤ 25%, indicating Hp current infection, 25%\<grade 2\<50%, Hp uncertain state, indicating Hp current infection or after recent sterilization, grade 3 ≥ 50%, indicating Hp non-infection or past H. pylori infection.
62674933|NCT05280158|ACTIVE_COMPARATOR|Standard-dose|mRNA-1273 (Moderna COVID-19 vaccine) 50 ug
62674934|NCT05280158|EXPERIMENTAL|Mid-Dose|mRNA-1273 (Moderna COVID-19 vaccine) 100 ug
62674935|NCT05280158|EXPERIMENTAL|High-Dose|mRNA-1273 (Moderna COVID-19 vaccine) 200 ug
62674936|NCT06153459|ACTIVE_COMPARATOR|Delayed Cord Clamping at 30 Seconds (DCC-30)|The umbilical cord will be clamped between 1 - \<60 seconds following delivery, with a goal of around 30 seconds.
62674937|NCT06153459|ACTIVE_COMPARATOR|Delayed Cord Clamping at 120 Seconds (DCC-120)|"The umbilical cord will be clamped at 60 - 180- seconds following delivery, with a goal of around 120 seconds.~In the DCC-120 group, if there is concern for pregnant individual or baby and their doctor is not able to wait until at least 60 seconds, the doctor may do cord milking, which is four gentle squeezes of the umbilical cord pushing blood from the placenta to baby."
62674938|NCT01032343|ACTIVE_COMPARATOR|Omega-3 PUFA capsule|
62674939|NCT01032343|PLACEBO_COMPARATOR|Gelatine capsule|
61917782|NCT02277834||chronic pancreatitis|15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .
61917783|NCT02277834||non-pancreatic, non-neoplastic disorders|15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.
62303530|NCT01927458|EXPERIMENTAL|anodal tDCS with treadmill training|Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min
62674940|NCT02551809|EXPERIMENTAL|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
62674941|NCT02551809|EXPERIMENTAL|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
62674942|NCT02551809|PLACEBO_COMPARATOR|Placebo|Subjects will receive 7 doses of placebo.
62303531|NCT04935736|EXPERIMENTAL|CORTISOMOL SP|Zinc oxide/Eugenol-type sealer containing 1% Prednisolone Acetate. The sealer is used in combination with gutta percha points for the permanent obturation of root canals.
62303532|NCT04935736|ACTIVE_COMPARATOR|SEALITE REGULAR|The Zinc oxide/Eugenol-type sealer is used in combination with gutta percha points for the permanent obturation of root canals.
62303533|NCT04248010|ACTIVE_COMPARATOR|standard tDCS|20 min of standard 2-electrode transcranial direct current stimulation (2 mA) at a previously reported scalp location.
62303534|NCT04248010|ACTIVE_COMPARATOR|HD-tDCS - anterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to anterior language areas of the brain.
62303535|NCT04248010|ACTIVE_COMPARATOR|HD-tDCS - posterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to posterior language areas of the brain.
62303536|NCT04248010|SHAM_COMPARATOR|sham tDCS|sham transcranial direct current stimulation using a brief pulse at the beginning and end of the 20 min intervention.
62303537|NCT04632849|EXPERIMENTAL|GEM + CGM|A self-directed lifestyle intervention for controlling Type 2 Diabetes
62303538|NCT06109909|EXPERIMENTAL|Neurofeedback|Half of the participants will be blindly assigned to receive 12 sessions of LIP-tES intervention over 6 weeks. A subset of these participants will also complete a resting-state MRI scan during the initial session (prior to LIP-tES intervention) and after their final LIP-tES intervention.
62674943|NCT05119907|EXPERIMENTAL|Cohort A: Esophageal Squamous Cell Carcinoma (ESCC)|Participants will receive Sacituzumab Govitecan-hziy (SG) 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
62472246|NCT01097577|EXPERIMENTAL|pregabalin|Oral Pregabalin 75 mg capsule twice daily administered prior to PRK and continued for 5 days
62472247|NCT01097577|PLACEBO_COMPARATOR|Placebo|Oral placebo capsule (Lactose) twice daily administered prior to PRK and continued for 5 days
62472248|NCT05091645||Hip fracture_GFI|Greek patients with hip fracture assessed for frailty syndrome with the adapted for the greek population GFI questionnaire
62472249|NCT02514876|EXPERIMENTAL|Single arm- Foresight ICE System|This open label feasibility study will evaluate the Foresight ICE system for imaging chambers of the heart and guiding transseptal puncture during an atrial fibrillation (AF) ablation procedure.
62472250|NCT02419898||Feasibility Study|Nulliparous women of reproductive age (18-40 years), who are not pregnant but could have a planned or unplanned pregnancy during the duration of the study.
62472251|NCT03388853|EXPERIMENTAL|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
62303539|NCT06109909|SHAM_COMPARATOR|Sham Treatment|Half of the participants will be blindly assigned to receive 12 sessions of a sham intervention that will mirror all aspects of the LIP-tES intervention except that no neurofeedback pulses will be delivered. A subset of these participants will also complete a resting-state MRI scan at the beginning of the initial session and at the end of the 12th session.
62303540|NCT01773473|EXPERIMENTAL|Insulin Lispro Mix25|Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
62472252|NCT03388853|PLACEBO_COMPARATOR|Placebo|Placebo once daily for four weeks
62472253|NCT04093505|EXPERIMENTAL|GO147_G|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_G: Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27"
62472254|NCT04093505|PLACEBO_COMPARATOR|GO147_P|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_P: Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27"
62472255|NCT04093505|EXPERIMENTAL|GO1_G|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_G: Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27"
62114413|NCT03394027|EXPERIMENTAL|Arm 1-ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: estrogen receptor (ER) + breast cancer, triple negative breast cancer, and endometrial cancer
62303541|NCT01773473|EXPERIMENTAL|Insulin Lispro Mix50|Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.
62303542|NCT02638246|EXPERIMENTAL|Contingent|Participants in this group received incentives contingent on meeting pre-specified daily blood-glucose testing adherence goals.
62303543|NCT02638246|ACTIVE_COMPARATOR|Noncontingent|Participants in this group received incentives independent of meeting pre-specified daily blood glucose testing adherence goals.
62303544|NCT00775567|ACTIVE_COMPARATOR|1|30g fructose dissolved in water twice a day
62303545|NCT00775567|NO_INTERVENTION|No Intervention|
62303546|NCT02183389|EXPERIMENTAL|Treatment B: BI 1356 and Warfarin|BI 1356 for 12 days combined with a single dose of warfarin on day 6
62472256|NCT04093505|PLACEBO_COMPARATOR|GO1_P|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_P: Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27"
62303547|NCT02183389|ACTIVE_COMPARATOR|Treatment A: Warfarin|Warfarin as single dose
62303548|NCT00104104|EXPERIMENTAL|15 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks
62303549|NCT00104104|EXPERIMENTAL|30 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.
62303550|NCT03142607|ACTIVE_COMPARATOR|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
62303551|NCT03142607|ACTIVE_COMPARATOR|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
62472257|NCT02161445||AHF group|patients with AHF diagnosed based on clinical, biological and echocardiographic findings. Two sub-groups of patients were identified within HF group: Patients with reduced (\<45%) LVEF (HFrEF) and those with preserved (≥45%) LVEF (HFpEF).
62472258|NCT02161445||non AHF group|we included patients with acute dyspnea and for whom acute heart failure was excluded
62472259|NCT02235935||diabetic patients, hyperbaric chamber, diabetic retinopathy|
62472260|NCT05435391||Group 1|Patients with chest pain or who are clinically suspected as acute myocardial infarction with equivalent symptoms.
62472261|NCT03733730|EXPERIMENTAL|Cohort 1|ACRYSOF IQ RESTOR Multifocal Toric IOL (+3.0 D or +2.5 D) implanted in at least one eye during cataract surgery, with implantation occurring from November 2018 through July 2020.
62472262|NCT03733730|EXPERIMENTAL|Cohort 2|ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL or ACRYSOF IQ RESTOR +2.5 D Multifocal IOL implanted in at least one eye during cataract surgery, with implantation occurring after July 2020.
62114414|NCT06553014||Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome|Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
62114415|NCT01597752|EXPERIMENTAL|1|"Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)~Positive control~Negative control"
62114416|NCT00820079|EXPERIMENTAL|ADX10059 120 mg|Twice-daily
62674944|NCT05119907|EXPERIMENTAL|Cohort B: Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJC)|Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
62114417|NCT00820079|PLACEBO_COMPARATOR|ADX10059 Matching Placebo|twice-daily
62114418|NCT03398837|EXPERIMENTAL|Cohort 1|Lenabasum 5 mg BID
62114419|NCT03398837|EXPERIMENTAL|Cohort 2|Lenabasum 20 mg BID
62114420|NCT03398837|PLACEBO_COMPARATOR|Cohort 3|Placebo BID
62114421|NCT05456386|EXPERIMENTAL|The Circadian Rhythm Approach to Weight Loss (CRAWL) Intervention Arm|The Circadian Rhythm Approach to Weight Loss (CRAWL) intervention subjects will continuously wear their Fitbit Versa 2 (aside from periodic charging periods) and participate in the pre-scheduled CRAWL sessions. Every week, subjects will complete a sleep diary, which assesses subject's time in bed, sleep latency, awakenings, wake after sleep onset, awakening time, overall sleep quality, overall refreshed rating, naps, exercise, energy level and mood. Subjects are to ensure their Fitbit is sufficiently charged every night before bed and they are to wear their Fitbit continuously throughout the night. Subjects will weigh themselves using their home scale each week prior to exercise, taking a shower or eating breakfast. They will record their weight in their provided weight tracking sheet
62114422|NCT05456386|NO_INTERVENTION|Waitlist Control Arm|Waitlist control subjects will follow the same protocol outlined above for 16 weeks minus the scheduled CRAWL sessions. When the initial treatment arm has completed their 16 weeks of group sessions, the waitlist control group will begin their CRAWL sessions.
62114423|NCT03949335|EXPERIMENTAL|Investigational|Bilateral implantation with investigational IOL Model ZFR00V
62114424|NCT03949335|ACTIVE_COMPARATOR|Control|Bilateral implantation with control IOL Model ZCB00
62114425|NCT01456078|EXPERIMENTAL|177Lu-DOTA-TATE|
62114426|NCT00786942|ACTIVE_COMPARATOR|1|autologous bone graft
62114427|NCT00786942|EXPERIMENTAL|2|without bone graft
62114428|NCT01958099|OTHER|Injury Prevention Specialist|
62114429|NCT01958099|EXPERIMENTAL|Kiosk Intervention|
62114430|NCT00432029|OTHER|1|IDDM
62114431|NCT00432029|OTHER|2|Hypercholesterolemia and/or Hypertension
62114432|NCT00432029|OTHER|3|age/sex matched healthy control subjects
62114433|NCT04911439|ACTIVE_COMPARATOR|Low Arousal|This group will see 25 affective images of the International Affective Picture System with low arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
62114434|NCT04911439|ACTIVE_COMPARATOR|Medium Arousal|This group will see 25 affective images of the International Affective Picture System with medium arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
62303552|NCT03142607|ACTIVE_COMPARATOR|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
62303553|NCT06453694|ACTIVE_COMPARATOR|Efgartigmod alfa|"10 patients will receive efgartigimod alfa~All participants will receive standard of care high dose corticosteroids for 3 days with a prednisone taper over 3 weeks."
62303554|NCT06453694|PLACEBO_COMPARATOR|Placebo|"10 patients will receive placebo.~All participants will receive standard of care high dose corticosteroids for 3 days with a prednisone taper over 3 weeks."
62674945|NCT05119907|EXPERIMENTAL|Cohort C: Cervical Cancer (CC)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
62114435|NCT04911439|ACTIVE_COMPARATOR|High Arousal|This group will see 25 affective images of the International Affective Picture System with high arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
62114436|NCT01301469|EXPERIMENTAL|1|6% HES 130/0.42 in plasma adapted Ringer's solution (balanced solution)
62114437|NCT01301469|ACTIVE_COMPARATOR|2|HES 130/0.4 in a saline solution
62114438|NCT00817817|EXPERIMENTAL|Group 1|
62114439|NCT00817817|EXPERIMENTAL|Group 2|
62114440|NCT06401174|EXPERIMENTAL|Patient navigation|Patient navigation will be rolled out at the clinic level (15 clinics). Referral orders will become available to participating clinics, with education and audit and feedback for providers. The study team will tailor patient navigation supports by clinic site for specifics on how the intervention is delivered.
62114441|NCT06401174|NO_INTERVENTION|Usual care|
62114442|NCT01319435|OTHER|Pharmacokinetics of ciprofloxacin|Patients receiving ciprofloxacin following clinical decision by attending physician
62114443|NCT03419208|EXPERIMENTAL|SPIN-HAND Program|Offered the SPIN-HAND program
62114444|NCT03419208|NO_INTERVENTION|Treatment as usual|Not offered SPIN-HAND program, treatment as usual
62114445|NCT02205086|OTHER|Diagnosis|Test diagnostic decision support software
62114446|NCT04671641|EXPERIMENTAL|Endovenous Radiofrequency Ablation Closure System|
62114447|NCT04671641|ACTIVE_COMPARATOR|ClosureFast™ Radiofrequency Ablation System|
62114448|NCT02692742|EXPERIMENTAL|Myelo001|Myelo001 100 mg QD
62114449|NCT02692742|PLACEBO_COMPARATOR|Placebo|Matching Placebo QD
62303555|NCT06273904|EXPERIMENTAL|Group Receiving Active Stimulation and Sham Stimulation on Separate Days (All Participants)|All participants will receive active stimulation and non-active (sham) stimulation on different days. Before the stimulation sessions, all participants will complete experimental tasks during functional magnetic resonance imaging. On the next two study days, all participants will complete tasks before and after receiving active transcranial focused ultrasound (tFUS) on one day and sham (non-active) tFUS on another day. Stimulation (active or sham) is conducted briefly (\< 10 minutes) in between tasks, not during tasks.
62303556|NCT02975323|EXPERIMENTAL|Single|To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form
62303557|NCT01301326|EXPERIMENTAL|subthreshold laser treatment|
62114450|NCT05236491|ACTIVE_COMPARATOR|Trajectory A|"Participants who have received 3 doses of an mRNA vaccine, will be offered a choice between a fourth dose of an mRNA vaccine and a dose of a protein subunit vaccine (PSV) (Novavax NUVAXOVID)~For the Moderna SPIKEVAX Bivalent Original/Omicron BA.4/5: participants will receive one (1) intramuscular injection of 0.5 mL (50 mcg).~For the Novavax Nuvaxovid vaccine: participants will receive one (1) intramuscular injection of 0.5 mL (5 mcg) of Novavax Nuvaxovid."
62114451|NCT05236491|NO_INTERVENTION|Trajectory B|Participants who have already received a 4 doses or more of COVID-19 vaccine in the community at inclusion and do not wish to receive a 5th dose of vaccine in the study.
62114452|NCT05236491|ACTIVE_COMPARATOR|Trajectory B5|"Participants who have received 4 doses of an mRNA vaccine at inclusion and wish to receive a dose of a protein subunit vaccine (PSV) (Novavax NUVAXOVID) as a fifth dose.~For the Novavax Nuvaxovid vaccine: participants will receive one (1) intramuscular injection of 0.5 mL (5 mcg) of Novavax Nuvaxovid."
62114453|NCT04840862|EXPERIMENTAL|rifabutin|Rifabutin PO \[two 150mg capsules\] ; Trikafta PO \[one orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg\]
62114454|NCT01726530|ACTIVE_COMPARATOR|Transdermal fentanyl patch|Transdermal fentanyl patch, 50 mcg/hour, was attached to the patient's chest wall at 10 pm the day before surgery
62674946|NCT05119907|EXPERIMENTAL|Cohort D: Biliary Tract Cancer (BTC)|Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
61917784|NCT00572221|OTHER|CQI Program Only|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. (The SAVE+ intervention, the CQI system with facility responsible for identifying or designing care protocols for the identified problem condition.)
61917785|NCT00572221|OTHER|CQI Program and Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions. (The SAVE+ intervention, a CQI system plus best-practice protocols designed by study team to address identified problem condition.)
61917786|NCT01176357||1|CABG
62303558|NCT01301326|ACTIVE_COMPARATOR|threshold laser treatment|
62303559|NCT02860793|EXPERIMENTAL|AML patients at diagnosis|
62303560|NCT06319911||Primary Anatomic|Those subjects who have the AETOS implanted in the Primary Anatomic configuration
62303561|NCT06319911||Primary reverse|Those subjects who have AETOS implanted in the Reverse configuration
62303562|NCT05085002|OTHER|Lerociclib + letrozole or fulvestrant|
62674947|NCT05119907|EXPERIMENTAL|Cohort E: Lung Adenocarcinoma (LAC)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
62674948|NCT02571855|EXPERIMENTAL|Part A: ACT-541468 multiple ascending doses|Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
62674949|NCT02571855|PLACEBO_COMPARATOR|Part A: Placebo|For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
62114455|NCT01726530|PLACEBO_COMPARATOR|Placebo|Placebo patch was attached to the patient's chest wall at 10 pm the day before surgery
61917787|NCT01176357||2|Valve surgery
61917788|NCT04898621|EXPERIMENTAL|Group A|Subjects in Group A will drink 75g fructose solution daily for 4 weeks.
61917789|NCT04898621|EXPERIMENTAL|Group B|Subjects in Group B will drink 150g fructose solution daily for 4 weeks.
61917790|NCT01830777|EXPERIMENTAL|Experimental Arm|Brentuximab Vedotin + MEC
61917791|NCT04999254|EXPERIMENTAL|Osteopathic treatment / Usual care|osteopathic treatment will be applied in this intervention group.
61917792|NCT04999254|ACTIVE_COMPARATOR|Usual care|Classic medical treatment
61917793|NCT03085277|ACTIVE_COMPARATOR|Preterm Formula|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
61917794|NCT03085277|EXPERIMENTAL|Bovine Colostrum|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive Bovine Colostrum (BC), as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
62114456|NCT06256211|OTHER|Group has treated by Intravenous Paracetamol|"* Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).~* After the 3-day follow up echocardiogram will be done."
62114457|NCT06256211|OTHER|Group has treated by Rectal Paracetamol|"* Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.~* The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total)."
62114458|NCT01413594|EXPERIMENTAL|HABIT|Hand-Arm Bimanual Intensive Therapy (HABIT)
62114459|NCT01413594|NO_INTERVENTION|Ongoing usual and customary rehabilitation care|Subjects are tested over 6 months while receiving their ongoing usual and customary care schedule of physical and occupational therapy or following constraint-induced movement therapy received as usual and customary care independent of the study, and then are crossed-over to receive HABIT.
62114460|NCT06212167|EXPERIMENTAL|Nursing Interventions for Stroke Patient Care|"Within the scope of nursing interventions for caregivers;~* Oral or enteral nutrition application steps and the use of necessary materials will be explained,~* Oral or enteral drug administration, in-bed exercises, suctioning, simple ROM exercises, in-bed bathing, pressure sore care, position change, oral care, and whole body care will be taught,~* Videos regarding the use of all medical devices and materials to be taken home with the patient will be shown and demonstration methods will be used,~* Information about the storage conditions of drugs, side effects and nutrition will be explained, supported by powerpoint presentations,~* Motivational interviews will be held regarding communication with the stroke patient and the emotional state of the caregivers."
62114461|NCT00031512|PLACEBO_COMPARATOR|Placebo|Placebo.
62114462|NCT00031512|EXPERIMENTAL|Pleconaril (VP63843)|The first dosing cohort received 5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation. Subsequent dosing cohorts are receiving 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
62114463|NCT01021865||With type 2 Diabetes|
62114464|NCT01021865||Without type 2 diabetes|
62114465|NCT03119636|EXPERIMENTAL|NPC transplantation|The patients will receive Levodopa combined with a regular neural precursor cell (NPC) transplantation
62114466|NCT03119636|EXPERIMENTAL|HLA-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-matched neural precursor cell (NPC) transplantation
62303563|NCT00608140|EXPERIMENTAL|1|Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
62303564|NCT00608140|ACTIVE_COMPARATOR|2|Participants will receive optimal medical therapy alone
62303565|NCT00608140|EXPERIMENTAL|3|Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement
62674950|NCT02571855|EXPERIMENTAL|Part B: ACT-541468 single ascending doses|Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
62674951|NCT02571855|PLACEBO_COMPARATOR|Part B: Placebo|For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
62674952|NCT02571855|EXPERIMENTAL|Part C: repeated dose of ACT-541468|Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
61917795|NCT03473457|EXPERIMENTAL|CART therapy in Acute myeloid leukemia|In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10\^6-10\^7/Kg transduced CAR T cells at one time.
61917796|NCT00072527|EXPERIMENTAL|Induction and consolidation chemotherapy|"Induction chemotherapy (Cycles 1 and 2): Patients receive cisplatin 30 mg/m\^2 on days 1, 8, 22 and 29 and irinotecan 65 mg/m\^2 on days 1, 8, 22 and 29 for cycles 1 and 2.~Consolidation chemotherapy (Cycles 3, 4 and 5 beginning on day 43, week 7): Patients receive carboplatin on days 43, 64 and 85, etoposide 100 mg/m\^2 IV on days 43-45, 64-66 and 85-87 and XRT 5 fractions/week starting on day 43"
61917797|NCT05969327|NO_INTERVENTION|with out vitamin D|neonates without supplementation
61917798|NCT05969327|EXPERIMENTAL|Vitamin D 400 IU|neonates with 400 IU supplementation
61917799|NCT05969327|EXPERIMENTAL|Vitamin D 800 IU|neonates with 800 IU supplementation
61917800|NCT02592187|EXPERIMENTAL|Experimental intervention|ReMemory-MCI training
62674953|NCT02571855|PLACEBO_COMPARATOR|Part C: Placebo|Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
62674954|NCT06121219|EXPERIMENTAL|Experimental: Cortically Blind (CB) Subjects|Cortically Blind subjects will be enrolled to perform a daily home visual training task.
62674955|NCT06121219|NO_INTERVENTION|Normative Comparator: Control Subjects|Healthy control subjects will be recruited to collect normative data by which to compare test results from CB subjects. No home training will be asked.
62674956|NCT06582771|EXPERIMENTAL|Sotorasib|All patients will start at sotorasib 960 mg (8 pills) daily within 7 days of completion of the pretreatment tumor biopsy.
62674957|NCT01124266|EXPERIMENTAL|endoscopist only|
62674958|NCT01124266|EXPERIMENTAL|nurse participation|
62674959|NCT05380570||Korean radiation workers|The study population is Korean radiation workers exposed to ionizing radiation in workplaces. Diagnostic medical radiation workers were not included in the study population.
62674960|NCT01514435|EXPERIMENTAL|ECT verum group|Patients with treatment refractory depression treated with ECT
62674961|NCT00657501|EXPERIMENTAL|testosterone gel|1% testosterone transdermal gel
61917801|NCT02592187|ACTIVE_COMPARATOR|Control intervention|Control intervention
62114467|NCT03119636|EXPERIMENTAL|HLA-non-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-non-matched neural precursor cell (NPC) transplantation
62114468|NCT00800163|EXPERIMENTAL|ED Physician Activation/Immediate Transfer|
62674962|NCT00657501|PLACEBO_COMPARATOR|Placebo gel|placebo transdermal gel
62674963|NCT01151631|ACTIVE_COMPARATOR|100% occipital nerve stimulation|Stimulation frequency and pulse width will be uniformly held constant at 60 Hz and pulse width at 450 ms. The perception and discomfort amplitude will be defined by increasing the stimulation amplitude in steps of 0.1 V. The amplitude at which the patient starts feeling paraesthesis is called the perception threshold. The threshold at which the patient does not want the voltage to be increased any further because of painful sensations is designated the discomfort threshold. 100% stimulation is defined as stimulation at 90% of the range between perception and discomfort thresholds.
62674964|NCT01151631|SHAM_COMPARATOR|30% occipital nerve stimulation|30% stimulation means a stimulation level at 30% of the range between perception threshold and 100% stimulation level
62674965|NCT02256800|EXPERIMENTAL|UGT1A1 genotyping (6,6)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2
62674966|NCT02256800|EXPERIMENTAL|UGTA1T1 genotyping (6,7)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2
62674967|NCT02256800|EXPERIMENTAL|UGTA1T1 genotyping (7,7)|The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2
62303566|NCT02677584|ACTIVE_COMPARATOR|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
62303567|NCT02677584|ACTIVE_COMPARATOR|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
62674968|NCT02256800|EXPERIMENTAL|UGT1A1 non-genotyping|The investigators will maintain the dosage of irinotecan by 180mg/m2
62674969|NCT05376306|EXPERIMENTAL|MBSR - STEM|STEM MAJOR in COLLEGE randomized to receive Mindfulness-based Stress Reduction intervention
62674970|NCT05376306|EXPERIMENTAL|MBSR - non-STEM|Non-STEM MAJOR in COLLEGE randomized to receive Mindfulness-based Stress Reduction intervention
62674971|NCT05376306|EXPERIMENTAL|PMR - STEM|STEM MAJOR in COLLEGE randomized to receive Progressive Muscle Relaxation intervention
62674972|NCT05376306|EXPERIMENTAL|PMR - Non-STEM|Non-STEM MAJOR in COLLEGE randomized to receive Progressive Muscle Relaxation intervention
62674973|NCT02563431|ACTIVE_COMPARATOR|SP-ED|Classic use
61917802|NCT04175509|ACTIVE_COMPARATOR|Rectal acetaminophen|Patients will receive two 650mg suppositories rectally of acetaminophen for a total dose of 1300mg at the end of surgery.
61917803|NCT04175509|ACTIVE_COMPARATOR|Intravenous acetaminophen|Patients will receive one dose of 1000mg of acetaminophen, administered intravenously, at the end of surgery.
61917804|NCT03464565||Patients with acute ischemic stroke secondary to LVO|
62114469|NCT05482854|EXPERIMENTAL|Patients treated early and carrying the MHC B35/53Bw4TTC2 Genotype|Patients included in the ANRS CO6 PRIMO cohort, treated early and carrying the MHC B35/53Bw4TTC2 Genotype
62114470|NCT03479736||Cohort 1: Participants with Achilles Tendon Rupture (ATR)|Participants will be defined as having ATR if they receive a diagnosis for ATR as well as one of the following procedures: tenotomy or primary ruptured Achilles Tendon (AT) repair (with or without graft) within 7 days of diagnosis. Index will be based on the earlier date of diagnosis or procedure. Participants with ATR, and exposures to Fluoroquinolone (FQ) or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
62303568|NCT04427085|EXPERIMENTAL|Obese group|body mass index≥ 30 kg/m2
62303569|NCT04427085|ACTIVE_COMPARATOR|Non-obese group|BMI \< 30 kg/m2
62303570|NCT01773824|OTHER|No feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial).
62674974|NCT02563431|EXPERIMENTAL|4P-ED|Literature update
62674975|NCT01843504|ACTIVE_COMPARATOR|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
62674976|NCT01843504|PLACEBO_COMPARATOR|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
62674977|NCT03545581|OTHER|Experimental diet Fru rich diet|Enriched fructose diet from day 1 to day 7.
62674978|NCT03545581|OTHER|Experimental low Fru diet|Low fructose diet from day 1 to day 7.
62674979|NCT00917982|OTHER|Vision therapy|
61917805|NCT03584373|EXPERIMENTAL|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).~Acetaminophen - Oral; patient directed as needed. Not prescribed.~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
61917806|NCT03584373|ACTIVE_COMPARATOR|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
62114471|NCT03479736||Cohort 2: Participants with Retinal Detachment (RD)|Participants will be defined as having a RD if they received a diagnosis of RD and a procedure for RD, e.g.: sclera buckle, vitrectomy, retinopexy, retinal cryotherapy, silicone oil fill, air gas fluid exchange or pneumatic retinopexy, within 14 days of index. Index will be defined as the earlier date of diagnosis or procedure. Participants with RD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
62114472|NCT03479736||Cohort 3: Participants with Aortic Aneurysm & Dissection (AAD)|Participants will be defined as having AAD if they received a primary diagnosis for aortic aneurysm, aortic rupture or dissection and have also received an aortic repair surgical procedure concurrently to the AAD diagnosis, in an inpatient or emergency department (ED) setting. Index will be defined as the earlier date of diagnosis or procedure. Participants with AAD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
62114473|NCT02067026|EXPERIMENTAL|Aleurone supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
62114474|NCT02067026|PLACEBO_COMPARATOR|Hemicellulose supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Hemicellulose/day. One bread bun (35 g) contains 4.8 g Hemicellulose; one biscuit (15 g) contains 4 g Hemicellulose; 36 g of RTE cereals contain 9 g Hemicellulose. Placebo products contain the same levels of cellulose in place of aleurone's dietary fiber content.
62114475|NCT04742842|EXPERIMENTAL|Part A: Arm1 (COVIGEN (C19) 0.8 mg ID or Placebo ID)|Participants will be randomized to receive either COVIGEN C19 (0.8 mg) given by ID (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
62114476|NCT04742842|EXPERIMENTAL|Part A: Arm2 (COVIGEN (C19) 2.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN C19 (2 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
62114477|NCT04742842|EXPERIMENTAL|Part A; Arm 3 (COVIGEN (C19) 4.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN C19 (4 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart
62114478|NCT04742842|EXPERIMENTAL|Part B: Arm 1 (COVIGEN (C20) 1.0 mg ID) in BNT162b2 primed participants|Participants in Part B who have received a 2 dose primary course of Pfizer BNT162b2 vaccine will receive COVIGEN C20 (1mg) vaccine given by ID (n=25)
62114479|NCT04742842|EXPERIMENTAL|Part B: Arm 2 (COVIGEN (C20) 1.0 mg ID) in ChAdOx1-S primed participants|Participants in Part B who have received a 2 dose primary course of Astra Zeneca ChAdOx1-S vaccine will receive COVIGEN C20 (1mg) vaccine given by ID (n=25)
62114480|NCT04704037|ACTIVE_COMPARATOR|Arm 1: Minimally enhanced usual care|See intervention/treatment description
62114481|NCT04704037|EXPERIMENTAL|Arm 2: Guideline implementation tool|See intervention/treatment description
62114482|NCT02221219|PLACEBO_COMPARATOR|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
62114483|NCT02221219|EXPERIMENTAL|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
62114484|NCT02221219|ACTIVE_COMPARATOR|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
62303571|NCT01773824|EXPERIMENTAL|Antibiotic prescription feedback|Physicians receive quarterly electronic feedback on their antibiotic prescriptions
62303572|NCT00938548|PLACEBO_COMPARATOR|Placebo|Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
61917807|NCT00454831|ACTIVE_COMPARATOR|HEP 400mg TID|HEP-40 400 mg three times a day
62303573|NCT00938548|EXPERIMENTAL|Pregabalin|Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later
62303574|NCT02748369|NO_INTERVENTION|Control Group|No somatostatin and glucagon infusions
62303575|NCT02748369|ACTIVE_COMPARATOR|Intervention Group|Somatostatin and glucagon infusions
62303576|NCT03405103|EXPERIMENTAL|Striving|Striving vs Boning-up \& Personal Choice
62303577|NCT03405103|ACTIVE_COMPARATOR|Boning-up Standard Education|Boning-up vs Striving and Personal Choice
62303578|NCT03405103|SHAM_COMPARATOR|Personal Choice|Personal Choice vs Striving \& Boning-up
62303579|NCT02053974|ACTIVE_COMPARATOR|Spironolactone|patients who randomized to spironolactone administered arm
62303580|NCT02053974|PLACEBO_COMPARATOR|Placebo|Patients who randomized to placebo administered arm
62303581|NCT02421874|EXPERIMENTAL|Use of electronic health record / outcomes monitoring|Use of electronic health record / outcomes monitoring via a specified electronic behavioral health information system
62303582|NCT02421874|ACTIVE_COMPARATOR|education about outcomes monitoring|Care coordination as usual with education about fidelity and outcomes monitoring but no use of EBHIS
61917808|NCT00454831|ACTIVE_COMPARATOR|HEP 800mg BID|HEP-40 800 mg twice a day
61917809|NCT00454831|ACTIVE_COMPARATOR|HEP 800mg TID|HEP-40 800 mg three times a day
62472263|NCT03944447|EXPERIMENTAL|Cannabis users|"Most patients will have used cannabis before their initial physician visit, and many current patients will be returning for an in-person follow-up. Patients will be given the survey shortly after the physician encounter to assess baseline parameters with current cannabis use. Any patient who is cannabis-naïve, defined as no use within the past year or longer, will be placed into a separate data analysis arm. The investigators will follow up with patients again at 3, 6, 9, and 12 months with the online survey. Patients returning for their annual physician encounter will continue on the 3-month survey schedule until the end of the study, or if lost to follow-up. There may be slight variations in the interval based on state law, for example in Florida the in-person follow-up with the physician is required every 210 days, and some states allow for 2 year in-person visits. Every attempt will be made to adhere to a 3-month interval survey distribution."
62472264|NCT03944447|EXPERIMENTAL|Cancer prevention|Non-cancer patient medical cannabis users with extensive or life-long cannabis use will be compared to the general population for incidence and prevalence of development of cancer. The hypothesis is that cannabis use acts as a cancer preventive substance.
62674980|NCT04403126|EXPERIMENTAL|Forgiveness curriculum for 5th grade|"Classrooms randomly assigned to the experimental group will receive the forgiveness intervention. The forgiveness intervention will follow the curriculum - The Journey Toward Forgiveness -A Guided Curriculum for Children Ages 10-12 (Grade 5 in the US). The Forgiveness Curriculum Guide consists 14 lessons over 12 weeks. Each class meets weekly for 40 to 60 minutes to complete one lesson (in two of the weeks, there will be two lessons)."
61917810|NCT00454831|ACTIVE_COMPARATOR|HEP 2400mg QD|HEP-40 2400 mg once a day
62114485|NCT02221219|EXPERIMENTAL|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
62114486|NCT04128436|OTHER|Progesterone levels|Patients will be divided into groups according to quartiles (25/50/75) of progesterone levels. Optimal range of progesterone levels for ongoing pregnancy rate will be calculated.
62114487|NCT02251613|EXPERIMENTAL|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
62114488|NCT02251613|ACTIVE_COMPARATOR|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
62674981|NCT04403126|NO_INTERVENTION|Regular school instruction|Classrooms randomly assigned to the control group will have instruction as usual.
62674982|NCT03299335|OTHER|Early-stage sIMB patients|
62674983|NCT03299335|OTHER|Late-stage sIMB patients|
62114489|NCT06044545|EXPERIMENTAL|Web Based Pregnancy Preparation Education Group|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors
62674984|NCT03299335|OTHER|Control subjects|
62114490|NCT06044545|NO_INTERVENTION|Control Group|No action will be taken.
62114491|NCT04960176|ACTIVE_COMPARATOR|Acupuncture Group|Acupuncture will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
62114492|NCT04960176|SHAM_COMPARATOR|Non-Invasive Sham Acupuncture Group|Non-invasive sham acupuncture using a blunted needle will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
62114493|NCT05692947|EXPERIMENTAL|Hot/Dry|Core body temperature, skin temperature, heart rate, and heat perceptions will be collected from elite athletes while running or cycling for 45 minutes in the heat at low humidity (38 degrees Celsius with 10-20% relative humidity).
62114494|NCT05692947|EXPERIMENTAL|Hot/Humid|Core body temperature, skin temperature, heart rate, and heat perceptions will be collected from elite athletes while running or cycling for 45 minutes in the heat at high humidity (28 degrees Celsius with 80-100% relative humidity).
62114495|NCT02770196|EXPERIMENTAL|Group One (Two-year Intervention, 2016 Enrollment)|Group one intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2016 and 2017. During the 2016 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
62674985|NCT05914259||Diagnosed cohort - CKD Stage 1|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 1.
62674986|NCT05914259||Diagnosed cohort - CKD Stage 2|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 2.
62674987|NCT05914259||Diagnosed cohort - CKD Stage 3|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 3.
61917811|NCT00454831|PLACEBO_COMPARATOR|Placebo|Placebo, three times a day
62674988|NCT05914259||Diagnosed cohort - CKD Stage 4|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 4.
62674989|NCT05914259||Diagnosed cohort - CKD Stage 5|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 5.
62674990|NCT05914259||Diagnosed cohort - CKD Stage Unspecified|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage Unspecified.
61917812|NCT05116072|EXPERIMENTAL|Experimental group|Patients benefited from total pancreatectomy for resectable adenocarcinoma of the cephalic region at high risk of postoperative pancreatic fistula, with intaportal/intramuscular islet autotransplantation
62114496|NCT02770196|EXPERIMENTAL|Group Two (Delayed Two-year Intervention, 2016 Enrollment)|Group two intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2017 and 2018. During the 2017 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
62114497|NCT02770196|EXPERIMENTAL|Group Three (One-year Intervention, 2017 Enrollment)|Group three intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2017 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
62114498|NCT02770196|EXPERIMENTAL|Group Four (Delayed One-year Intervention, 2017 Enrollment)|Group four delayed intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2018 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
62114499|NCT06378528|EXPERIMENTAL|Adolescents with Severe PTSD|
62114500|NCT01957319|ACTIVE_COMPARATOR|Silybin - vitamin E - phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
62114501|NCT01957319|PLACEBO_COMPARATOR|placebo|sugar pill
62114502|NCT03665701|EXPERIMENTAL|Inhibitory effects of Fevipiprant|in vitro experiments: The reaction of the innate lymphoid cells by cytokine secretion in response to the stimulation by Prostagalandin D2 metabolites and the measurement of a potential suppressive effect of Fevipiprant will be assessed.
62114503|NCT06281431|EXPERIMENTAL|Echogenic nerve block needle|Using a echogenic nerve block needle.
62114504|NCT06281431|OTHER|Non-echogenic nerve block needle|Using a common nerve block needle.
62114505|NCT01777893|EXPERIMENTAL|HP-HI|High protein/ high intensity physical activity
62114506|NCT01777893|EXPERIMENTAL|HP-MI|High protein/ moderate intensity physical activity
62674991|NCT05914259||Lab based cohort - CKD Stage 1|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using Logical Observation Identifiers Names and Codes (LOINC) codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 1.
62674992|NCT05914259||Lab based cohort - CKD Stage 2|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 2.
62114507|NCT01777893|EXPERIMENTAL|MP-HI|Moderate protein/ high intensity physical activity
62114508|NCT01777893|EXPERIMENTAL|MP-MI|Moderate protein/ moderate intensity physical activity
62114509|NCT05672797|NO_INTERVENTION|Control|Participants in the control group will not receive additional adherence reminders or financial incentives during the 9-month study.
62114510|NCT05672797|EXPERIMENTAL|Wellth|Participants will be eligible to receive $30 at the end of three consecutive 30-day periods ($90 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 4-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 4-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
62674993|NCT05914259||Lab based cohort - CKD Stage 3 overall|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 3 overall.
62674994|NCT05914259||Lab based cohort - CKD Stage 3a|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 3a.
62674995|NCT05914259||Lab based cohort - CKD Stage 3b|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 3b.
62674996|NCT05914259||Lab based cohort - CKD Stage 4|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 4.
62674997|NCT05914259||Lab based cohort - CKD Stage 5|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 5.
62674998|NCT05914259||Lab based cohort - CKD Stage unspecified|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage unspecified.
62674999|NCT03426852||Study group|Individuals with lumbar back pain plus sacroiliac disc herniation
62675000|NCT03426852||Control Group|Individuals with lumbar back pain
62675001|NCT03125356|EXPERIMENTAL|Diet Soda|Subjects will be asked to consume a diet soda three times daily for eight weeks.
62675002|NCT00176254|EXPERIMENTAL|Induction chemotherapy and radiation|Induction chemotherapy with low dose radiation
62675003|NCT03526432|EXPERIMENTAL|Bevacizumab + Atezolizumab|
62675004|NCT05612607|OTHER|IGRT discontinuation|Participants will be tested to determine Switched memory B cells (SMB) levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
61917813|NCT01007253|OTHER|FF/PL, PL/OLO, FF/OLO, PL/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and~* placebo (PL) nasal spray and PL eye drops (PL/PL)."
61917814|NCT01007253|OTHER|PL/OLO, FF/OLO, PL/PL, FF/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~* placebo (PL) nasal spray and PL eye drops (PL/PL), and~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)."
61917815|NCT01007253|OTHER|FF/OLO, PL/PL, FF/PL, PL/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~* placebo (PL) nasal spray and PL eye drops (PL/PL),~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO)."
62303583|NCT03157544|EXPERIMENTAL|Pain Relief Kit|Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.
62675005|NCT01630603||mother infants pairs|
62675006|NCT04865458|EXPERIMENTAL|HEC89736 treatment|HEC89736 tablets,25 mg, 50 mg, 100 mg, 150 mg, 200 mg, QD, 28 days for each cycle
62675007|NCT01539889|EXPERIMENTAL|DFH-12 PulmoBind|DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
62675008|NCT03969758|ACTIVE_COMPARATOR|Ciprofloxacin plus Metronidazole therapy|Will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks. Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
61917816|NCT01007253|OTHER|PL/PL, FF/PL, PL/OLO, FF/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~* placebo (PL) nasal spray and PL eye drops (PL/PL),~* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),~* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and~* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO)."
61917817|NCT02755792|EXPERIMENTAL|Calligraphy Training|This group receives a Chinese calligraphy training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
61917818|NCT02755792|ACTIVE_COMPARATOR|iPad Training|This group receives an iPad training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
62675009|NCT03969758|ACTIVE_COMPARATOR|Cefixime plus Metronidazole Therapy|Will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks.Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
62675010|NCT00810186||Newborns needing respiratory monitoring|Premature and term newborn infants (male/female)
62675011|NCT02151604|EXPERIMENTAL|129 Xenon MR Imaging|Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
62675012|NCT05598307|ACTIVE_COMPARATOR|magnesium bolus|A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, normal saline will be administered at a rate of 20 mL/h
62675013|NCT05598307|ACTIVE_COMPARATOR|magnesium bolus and magnesium infusion|A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
62675014|NCT05598307|PLACEBO_COMPARATOR|placebo|100 mL of normal saline will be administered within 10 minutes preoperatively. Followingly, normal saline will be administered at a rate of 20 mL/h
62675015|NCT01783873|PLACEBO_COMPARATOR|Placebo|
62675016|NCT01783873|ACTIVE_COMPARATOR|flour allergen extract or quaternary ammonium compound|
62675017|NCT02576366|EXPERIMENTAL|Voriconazole|Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.
62675018|NCT02576366|EXPERIMENTAL|Rifampin|Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.
62675019|NCT06386042||Chronic heart failure|Patients with chronic HF at least 6 months after the initial HF diagnosis with are in stable condition, treated with HF medication (not necessarily all GDMT) and evaluated for an intrinsic cardiac defibrillator device if applicable.
62675020|NCT06386042||Worsening heart failure|"Patient with established chronic heart failure which after a period of stable HF have experienced an hospital admission with necessity of iv. diuretics or urgent visit needing iv. diuretics. Patients can be included in inpatient / admitted setting or outpatient setting where drug changes during admission (GDMT uptitration) can be recorded. The index event of hospitalisation must be within 6 months prior to inclusion in the registry (retrospective)."
62675021|NCT06386042||de novo heart failure|Patients with heart failure with reduced ejection fraction (ejection fraction \<40% with diagnosis within 3 months of inclusion (de novo heart failure or newly-diagnosed HF) with no previous diagnosis of HF.
62675022|NCT04619030|EXPERIMENTAL|Augmented Reality Leaflet|Patient Leaflet with Augmented reality component
62675023|NCT04619030|ACTIVE_COMPARATOR|Traditional Leaflet|Traditional leaflet without Augmented Reality component
62472265|NCT03944447|EXPERIMENTAL|Life-Threatening Conditions|"Opioids are a class of drugs naturally found in the opium poppy plant. Opioids are often used as medicines because they contain chemicals that relax the body and can relieve pain. Prescription opioids are used mostly to treat moderate to severe pain. Opioids can also make people feel very relaxed and high - which is why they are sometimes used for non-medical reasons. This can be dangerous because opioids can be highly addictive, and overdoses and death are common.~From 1999 to 2017, more than 700,000 people have died from a drug overdose. Around 68% of the more than 70,200 drug overdose deaths in 2017 involved an opioid.~In 2017, the number of overdose deaths involving opioids was 6 times higher than in 1999.~On average, 130 Americans die every day from an opioid overdose.~This study will focus on examining outcomes of patients that have been treated with cannabis as a replacement or alternative to life-threatening opioids or other prescription drugs."
62472266|NCT03944447|EXPERIMENTAL|COVID-19 / SARS-CoV-2|Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted through respiratory droplets, with potential for aerosol and contact spread. It uses receptor-mediated entry into the human host via angiotensin-converting enzyme II (ACE2) that is expressed in lung tissue, as well as oral and nasal mucosa. Modulation of ACE2 levels in these gateway tissues may prove a plausible strategy for decreasing disease susceptibility. Cannabis sativa, especially one high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been proposed to modulate gene expression and inflammation and possess anti-cancer and anti-inflammatory properties. Covid-19 infection rates in cannabis users will be compared to rates in the general population. Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population.
62472267|NCT05288881|EXPERIMENTAL|ANX105|
61917819|NCT03914846|EXPERIMENTAL|Cohort I (ultrasound)|Patients with skin lesions undergo at least 1 ultrasound during the consultation. Patients may undergo at most 2 additional scans after the standard of care approach for non-malignant lesions at the discretion of the radiation oncologist and/or dermatologist.
61917820|NCT03914846|EXPERIMENTAL|Cohort II (ultrasound)|Skin cancer patients who undergo surgery or radiation undergo 2-5 ultrasounds over a 1 year period (a baseline ultrasound scan may be performed prior to treatment, followed by 1 scan during and/or after radiation, and additional ultrasounds may be conducted \[at the discretion of the treating physician\] upon completion of radiation and/or surgery, at approximately 1, 6, and 12 month follow-up examinations).
61917821|NCT03914846|EXPERIMENTAL|Cohort III (ultrasound)|Participants with inflammatory skin disorders (psoriasis, eczema, alopecia, acne) undergo ultrasound at baseline and follow-up visits.
61917822|NCT02176824|EXPERIMENTAL|Triple Chronotherapy|Total Sleep Deprivation, Sleep phase advance, and Bright Light Therapy. Carex Health Brands Day-Light Classic 10,000 Lux
61917823|NCT02176824|SHAM_COMPARATOR|Sham Triple Chronotherapy|Total sleep deprivation, Three day fixed wake schedule, and sham light therapy.
61917824|NCT02176824|ACTIVE_COMPARATOR|Treatment As Usual|Normal inpatient care including pharmacotherapy, psychotherapy, milieu therapy, and social work interventions.
61917825|NCT03935399|OTHER|Oxytocin first, then saline placebo|Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day
61917826|NCT03935399|PLACEBO_COMPARATOR|Saline placebo first, then oxytocin|Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day
62114511|NCT05672797|EXPERIMENTAL|Wellth + Habit Training|Participants will also be eligible for $30 at the end of three consecutive 30-day periods ($90 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Similar to T1, participants will lose $2 (from their $30 total) for every day they miss a check-in with the Wellth app within a 4-hour window around the time of day of their choosing at the start of each 30-day period. Participants will not have to pay money, i.e. they lose $2 per missed check-in from the $30 of incentives until their incentives equal $0. Thus, participants will be ineligible for any financial incentives if they miss more than 15 days in a 30-day period, where this group's check-in includes one photo of pill-taking and one photo of their contextual cue.
62114512|NCT05924074|EXPERIMENTAL|SF3B1 mutant Myelodysplastic syndromes patients (MDS)|Patients diagnosed with MDS carrying the SF3B1 somatic mutation associated myelodysplastic neoplasm with ring sideroblasts
62114513|NCT05924074|ACTIVE_COMPARATOR|Monoclonal Gammapathy of Unknown Significance patients (MGUS)|MGUS patients, referred to as normal bone marrow controls
62114514|NCT00005786|EXPERIMENTAL|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Treatment repeats every 21 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding or stable disease may receive 6 additional courses.
62114515|NCT06553521|OTHER|Intervention arm|"In the MyHEARTSMAP intervention group, research assistants (RAs) help with the self-administered screening using a device. Validated for ages 10-17, both self-reporting and proxy-reporting are allowed.~After self- and/or parent-reports, a MyHEARTSMAP report is auto-submitted to REDCap, with one printed copy for the patient chart. if there are any mental health concerns identified in MyHEARTSMAP report, they will be addressed by the treating teams. Respondents can receive reports via email, ensuring privacy and separate reports for parents and youth. Discussions with the treating team are encouraged. Severe safety concerns during ED screening prompt immediate contact with the treating team. The admitting service manages concerns in the care plan."
62114516|NCT06553521|NO_INTERVENTION|Standard of care (delayed MyHEARTSMAP arm):|"Participants receiving standard care will complete an initial data collection form for demographic and medical information. After hospital discharge, they'll get a link to complete MyHEARTSMAP. Reminder email will be sent if MyHEARTSMAP is not completed by days 3 and 7.~Severe or acute safety concerns from MyHEARTSMAP trigger alerts, directing participants to crisis lines or EDs. RAs review daily for such concerns, contacting the research team for follow-up, led by a pediatric emergency physician."
62114517|NCT05744206|EXPERIMENTAL|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
62114518|NCT04651244||Patients with suspected acute pyelonephritis|Patients admitted in the ED with suspected infection, where the initial medical assessment raises suspicion of APN.
62114519|NCT06182917||ctDNA alternation during the treatment of Ovarian cancer|Tumor samples of included patients were detected by WES, and 16 major clonal mutation sites were screened for the personalized monitoring panel. All patients received blood ctDNA detection to monitor the major clonal alternation after 3 cycels treatment or 3 months after therapy, at the same time, the detection of serum tumor markers (CA125) and imaging examination were carried out, in order to evaluate the MRD detection efficiency.
62114520|NCT02008084|SHAM_COMPARATOR|TRIA-662 single-blind baseline|Baseline, 6 to 8-week, dietary lead-in period
62114521|NCT02008084|EXPERIMENTAL|TRIA-662|Following successful completion of the Baseline randomized to active drug
62114522|NCT02008084|PLACEBO_COMPARATOR|Placebo|Following successful completion of the Baseline randomized to placebo drug
62114523|NCT02188199||Knee Replacement|Patients undergoing knee replacement surgery
62472268|NCT05288881|PLACEBO_COMPARATOR|Placebo|
62472269|NCT03134222|EXPERIMENTAL|Lanraplenib 30 mg|Lanraplenib + filgotinib placebo for 48 weeks
62472270|NCT03134222|EXPERIMENTAL|Filgotinib 200 mg|Filgotinib + lanraplenib placebo for 48 weeks
62114524|NCT02188199||Hip Replacement|Patients undergoing hip replacement
62114525|NCT02378155|OTHER|electrical cardioversion|Hemodynamic unstable patients with atrial fibrillation who are scheduled to undergo electrical reconversion to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
62114526|NCT02378155|OTHER|pharmacological cardioversion|Patients who develop atrial fibrillation after cardiac surgery. Pharmacological treatment with amiodarone is started in order to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
62114527|NCT05923762||18-85 years of age|
62114528|NCT02168751|ACTIVE_COMPARATOR|propofol|propofol doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
62114529|NCT02168751|EXPERIMENTAL|sevoflurane|Sevoflurane doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
62114530|NCT01787266||1|pregnant women
62114531|NCT02423135|EXPERIMENTAL|Blood bags without DEHP|Intervention : Autologous blood transfusion
62114532|NCT02423135|EXPERIMENTAL|Blood bags with DEHP|Intervention : Autologous blood transfusion
61917827|NCT01722227|ACTIVE_COMPARATOR|Liraglutide 0.6mg|Daily Injection
61917828|NCT01722227|PLACEBO_COMPARATOR|Placebo|Daily Injection
62114533|NCT05582057|EXPERIMENTAL|Experimental Group|Behavioral: Strengths to Grow Program In an online, self-directed format, the Strengths to Grow: Preteen program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
62114534|NCT05582057|NO_INTERVENTION|Waitlist Control Group|
62114535|NCT03342872|EXPERIMENTAL|Core Training|
62114536|NCT03342872|EXPERIMENTAL|Core Training & Facilitation|
62114537|NCT03342872|NO_INTERVENTION|Control|
62114538|NCT00402155||1|Normal subjects
62114539|NCT00402155||2|Reading discomfort subjects
62114540|NCT02964780||Gastric Bypass Surgery|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
62114541|NCT02964780||Conservative weight loss|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
62114542|NCT06039852|EXPERIMENTAL|Novel Postural Management Night-time Intervention Components|Intervention Arm
62114543|NCT04484402|EXPERIMENTAL|mesenchymal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived mesenchymal stem cells
62114544|NCT04484402|EXPERIMENTAL|limbal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived limbal stem cells
62114545|NCT04484402|ACTIVE_COMPARATOR|control|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment
62114546|NCT00602264||1|Treatment-naïve patients with a recent diagnosis of anorexia nervosa
62114547|NCT00602264||2|The weight recovered subgroup of group 1
62114548|NCT00602264||3|Recovered patients with a previous history of anorexia nervosa but normal menstrual cycles and body weight at the present time
62114549|NCT00602264||4|Control group
62114550|NCT01606163|EXPERIMENTAL|group 1|"1. Drug:GC1102~2. Amount:3ml (30,000IU)"
62114551|NCT01606163|EXPERIMENTAL|group 2|"1. Drug: GC1102~2. Amount: 5ml(50,000IU)"
62114552|NCT01606163|EXPERIMENTAL|group 3|"1. Drug: GC1102~2. Amount: 8ml (80,000IU)"
62114553|NCT01606163|PLACEBO_COMPARATOR|group 4|drug: JW normal saline
62472271|NCT03134222|PLACEBO_COMPARATOR|Placebo|Filgotinib placebo + lanraplenib placebo for 12 weeks
62675024|NCT03753503|EXPERIMENTAL|PD-TR|"Intervention:~exercise, dose: 8-week HIIT program (three times a week) \& conventional physical therapy"
62114554|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
62675025|NCT03753503|ACTIVE_COMPARATOR|PD-NTR|conventional physical therapy
62675026|NCT03753503|NO_INTERVENTION|Healthy controls|healthy controls without any kind of therapy
62675027|NCT05757700|EXPERIMENTAL|Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma|Participants have histologically confirmed DLBCL and large B cell lymphoma. Participants will be treated with escalating doses of modified T cells.
62675028|NCT06407778|EXPERIMENTAL|High Intensity Strength Training|Group of TKR patients are given high intensity strength training.
62675029|NCT06407778|ACTIVE_COMPARATOR|Muscle Energy Technique Exercises|patients are given muscle energy technique exercise.
62675030|NCT05366842|EXPERIMENTAL|Stravix|Direct placement of LPT over the spared neurovascular bundles during bilateral nerve sparing radical prostatectomy for prostate cancer.
62675031|NCT05366842|SHAM_COMPARATOR|Standard of Care|Standard care (no placement of tissue) bilateral nerve sparing radical prostatectomy for prostate cancer.
62675032|NCT00063999|ACTIVE_COMPARATOR|Arm I (doxorubicin hydrochloride, cisplatin, paclitaxel)|Patients receive doxorubicin hydrochloride IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
62114555|NCT05647967||the consolidation perfusion/the consolidation size|Patients with respiratory failure and lung consolidation proved by chest imaging underwent lung ultrasound to evaluate the regional perfusion and the size of consolidation.
62114556|NCT01819493|ACTIVE_COMPARATOR|Standard Family-Based intervention|"Families randomized to the Standard Family-based Intervention will receive three-month family YMCA memberships, one orientation training session, access to available equipment and programming at the YMCA, and receive diabetes educational materials from the Power to Prevent curriculum via email. Based on our previous experience with AA adults, the investigators anticipate that all families will have access to email either at home or at work. Educational materials will be mailed to families without access to email. The study will also maintain contact with participants by sending holiday and birthday cards, as well as postcard reminders of scheduled data collection visits."
62472272|NCT03134222|EXPERIMENTAL|Placebo to Lanraplenib 30 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.
62675033|NCT00063999|EXPERIMENTAL|Arm II (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
62675034|NCT00638079|EXPERIMENTAL|A|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal
62675035|NCT00638079|ACTIVE_COMPARATOR|B|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast
62675036|NCT02560792|EXPERIMENTAL|Positive Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to positive affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to positive feelings.
62472273|NCT03134222|EXPERIMENTAL|Placebo to Filgotinib 200 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.
62472274|NCT01493466||Normal|normal person under physical examination
62675037|NCT02560792|EXPERIMENTAL|Negative Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to negative affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to negative feelings.
62675038|NCT02560792|EXPERIMENTAL|Control Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise - affect was not mentioned.
62472275|NCT01493466||SIRS|"1. temperature \>38 ℃ or \<36℃;~2. pulse rate\>90 beats/min;~3. ventilatory rate\>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)\<32mmHg;~4. white blood cell count\>12,000μL-1 or \<4000μL-1 or \>10% immature cells"
62472276|NCT01493466||spesis|sepsis is defined as SIRS plus confirmed infection.
62472277|NCT01493466||severe sepsis|"1. severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~2. septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
62472278|NCT01493466||death|sepsis patients within 48 hours before death
62114557|NCT01819493|EXPERIMENTAL|Lifestyle Intervention|"The lifestyle intervention for adults will involve a dietary weight loss program and an increase in caloric expenditure through moderate PA. Parents will be encouraged to decrease caloric intake in a sound manner to produce a total weight loss of 5%. The PA component will be to promote an increase in family home-based activity.~Children. The study will promote healthy eating behaviors, rather than restrictive eating plans with caloric restrictions."
62114558|NCT03408925|EXPERIMENTAL|Intervention|The intervention consists of an exercise program developed by the medical team of the National Federation of Orienteering. Specifically, it consists of four exercises targeting strength, flexibility and coordination of the lower extremity. The orienteerers are asked to perform the exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function (online supplement). Each second week the exercises' difficulty level is increased.
62114559|NCT03408925|NO_INTERVENTION|Control|Normal training, no intervention
62114560|NCT03502278|ACTIVE_COMPARATOR|PTSD lay-led group treatment program|This group will go through the Islamic Trauma Healing Program
62114561|NCT03502278|NO_INTERVENTION|Waitlist|Waitlist
62114562|NCT05300399|EXPERIMENTAL|With mHealth app|
62114563|NCT05300399|NO_INTERVENTION|Without mHealth app|
62114564|NCT05081310|EXPERIMENTAL|SVC arm|Patients who will receive SVC isolation by the means of cryoballoon after the PVI procedure
62114565|NCT05081310|ACTIVE_COMPARATOR|PVI arm|Patients who will receive convectional cryoballoon PVI procedure
62114566|NCT01596504|EXPERIMENTAL|Lixisenatide 20 μg|Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
62114567|NCT01596504|ACTIVE_COMPARATOR|Liraglutide 1.2 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
62114568|NCT01596504|ACTIVE_COMPARATOR|Liraglutide 1.8 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
62114569|NCT03484585|EXPERIMENTAL|Rogaratinib (BAY1163877)|Healthy male subjects
62114570|NCT06073158|OTHER|Anastomosis group|Esophageal biopsies collected during the anastomosis for the patient with esophageal atresia
62114571|NCT06073158|NO_INTERVENTION|Control group|Esophageal biopsies collected during a standard care endoscopy for patient with esophageal atresia during the first year of life
62114572|NCT03020108||Group 1|The group 1 will comprise of 30 patients with benign ovarian cysts such as mature teratoma or simple serous cysts on ultrasound examination.
62114573|NCT03020108||Group 2|The group 2 will comprise of 30 patients with diagnosis of stage 1-2 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
62114574|NCT03020108||Group 3|The group 3 will comprise of 30 patients with diagnosis of stage 3-4 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
62114575|NCT02053363|EXPERIMENTAL|High Dose/Study Group|Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
62114576|NCT02053363|ACTIVE_COMPARATOR|Standard of Care/Control|Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
62114577|NCT02469467|EXPERIMENTAL|VS-505|750 mg capsule
62114578|NCT02939469|EXPERIMENTAL|Experimental: Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
62114579|NCT03425630|EXPERIMENTAL|Argicolina (cross-over vs Normolip)|Argicolina is a dietary supplement containing monacolin (sachets)
62114580|NCT03425630|ACTIVE_COMPARATOR|Normolip (cross-over vs Argicolina)|Normolip is a dietary supplement containing monacolin (tablets)
62114581|NCT00702806|EXPERIMENTAL|Org 36286 120 μg + Puregon® 150 IU|On Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 120 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of \>= 14 mm.
62472279|NCT03327545|EXPERIMENTAL|Experimental Group 1|Neural mobilization for a total of 12 minutes
62472280|NCT03327545|EXPERIMENTAL|Experimental Group 2|Soft tissue techniques and Stretching right side of the craniocervical for a total of 12 minutes
62472281|NCT03327545|PLACEBO_COMPARATOR|Control group|Control group
62472282|NCT02593357|EXPERIMENTAL|COPD patients|measure of endothelial function with EndoPAT® in COPD patients
62472283|NCT01423994|ACTIVE_COMPARATOR|implantable loop recorder|
62472284|NCT01423994|ACTIVE_COMPARATOR|pacemaker|
62472285|NCT03965286||Patients with chronic HCV will be on direct antiviral drugs|is defined as the presence of detectable viral replication for at least six months diagnosed by quantitative HCV RNA polymerase chain reaction (PCR)
62472286|NCT01139047|ACTIVE_COMPARATOR|metronidazole 1% gel|
62472287|NCT01139047|ACTIVE_COMPARATOR|azelaic acid 15% gel|
62472288|NCT03421834|EXPERIMENTAL|Prophylactic VT ablation prior to ICD implantation|
62675039|NCT04784871|EXPERIMENTAL|5waysA Intervention|The intervention, 5WaysA, is a 10 week modified web-based version of the original Five Ways to Wellbeing course. The intervention consists of a two-hour main webinar with live lecturing from a facilitator introducing the Five Ways to Wellbeing framework and teaching the participants how to implement the five health promotive activities in life, a booster session webinar four weeks later, as well as an SMS message twice a week in the six following weeks. Each SMS encourages participants to engage in one of the five activities, register activities/goals and queries about the degree of participation in the activity introduced in the previous SMS.
62675040|NCT04784871|OTHER|5waysA Active wait-list control|The active wait-list control group will get the same intervention as the interventions group, five months later. The active wait-list control group will be encouraged (in SMS messages) to write down an activity log once a week in ten weeks, while waiting. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
62472289|NCT03421834|ACTIVE_COMPARATOR|ICD implantation and optimal medical treatment|ICD implantation and optimal medical care until at least 2 appropriate ICD shock occurs or an arrhythmic storm and catheter ablation thereafter.
62472290|NCT03936556|EXPERIMENTAL|Marketed Stannous Fluoride Paste|Brush twice daily
62472291|NCT03936556|PLACEBO_COMPARATOR|Marketed Cavity Protection Toothpaste|Brush twice daily
62675041|NCT04784871|OTHER|5waysA Inactive wait-list control|The inactive wait-list control group will get the same intervention as the interventions group, five months later. The inactive wait-list control group will not do anything specific while waiting for the intervention. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
62675042|NCT02238327||HIV positive normal pulmonary function|HIV positive DLCO percent predicted \>=.80 FEV1/FVC percent predicted \>=0.70
62675043|NCT02238327||HIV positive with pulmonary dysfuntion|HIV positive DLco percent predicted \<=0.80% FEV1/FVC percent predicted\<=0.70%
62114582|NCT00702806|EXPERIMENTAL|Org 36286 180 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 180 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of \>= 14 mm.
62114583|NCT00702806|EXPERIMENTAL|Org 36286 240 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 240 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of \>= 14 mm.
62114584|NCT00702806|ACTIVE_COMPARATOR|Puregon® 150 IU|On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of \>= 14 mm.
62114585|NCT00109785|EXPERIMENTAL|PET Scans|The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
62114586|NCT06491212|EXPERIMENTAL|People with pes planus|Individuals with pes planus that we identified according to the inclusion criteria will be evaluated in this group.
62472292|NCT05084677|EXPERIMENTAL|PD-1 arm|PD-1 concurrent with and subsequent after concurrent chemoradiotherapy
62472293|NCT01242774|EXPERIMENTAL|Panobinostat|
62472294|NCT02713425|EXPERIMENTAL|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game. Parents will observe and provide their own feedback about the game.
62472295|NCT03212339|EXPERIMENTAL|Mothers with children <3 years of age|Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
62472296|NCT03212339|EXPERIMENTAL|Mothers with children 3-5 years of age|Dyads of mothers with children between the ages of 3 and 5 years will be attending Brief Dyadic Intervention (BDI) sessions at Child Witness to Violence and/or the SPARK Center with their child and an individual therapist. Dyads will be offered the 10 session therapeutic intervention.
62472297|NCT00738049|ACTIVE_COMPARATOR|Group 1|Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
62675044|NCT01856660|EXPERIMENTAL|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
62675045|NCT01856660|EXPERIMENTAL|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
62675046|NCT04457778|EXPERIMENTAL|Part 1A: M6223 Monotherapy|
62675047|NCT04457778|EXPERIMENTAL|Part1B: M6223 + Bintrafusp alfa|
62114587|NCT06491212|ACTIVE_COMPARATOR|Healthy People|Volunteer individuals without pes planus who meet the inclusion criteria will be evaluated for comparison in this group
62114588|NCT01036113|EXPERIMENTAL|Experimental: EZN-2208|Experimental: EZN-2208 EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
62114589|NCT03349736|OTHER|Pelvic Floor Muscle Training|"Women visiting antenatal (up to16 weeks of gestation) will be enrolled for the study. The women will be follow up 4 times during the antenatal visit until 37 weeks of gestation. Questionnaire data and clinical measurements(strength of PFM by Electromyograph biofeedback) will be registered at baseline and and follow-up at week 37 of pregnancy.~The treatment program will include~1) Information, educational material (leaflets, posters, and video) and individual/group exercise on PFM exercise on the 1st day of the visit. Counseling about the importance of performing PFM exercise will be provided. Women are advised to perform home PFM exercise and record in the exercise diary."
62114590|NCT04521192|EXPERIMENTAL|TR sequence group|
62114591|NCT04521192|EXPERIMENTAL|RT sequence group|
62114592|NCT00924534|PLACEBO_COMPARATOR|1|
62114593|NCT00924534|EXPERIMENTAL|2|
62114594|NCT00924534|EXPERIMENTAL|3|
62114595|NCT00924534|EXPERIMENTAL|4|
62114596|NCT04935489|EXPERIMENTAL|Patients receiving accelerated rTMS|
62114597|NCT00588419||1|Patients who have undergone mastectomy Patients who have undergone immediate, twostage expander/implant breast reconstruction; Patients who have undergone immediate, autogenous tissue flap reconstruction including: pedicled and/or free TRAM flap or DIEP flap reconstruction
62114598|NCT02371746|EXPERIMENTAL|Cohort 1|ENV515-1 and ENV515-3 implants in Study Eye for 28 days
62114599|NCT02371746|EXPERIMENTAL|Cohort 2|Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
62114600|NCT02371746|EXPERIMENTAL|Cohort 3|One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)
62114601|NCT04842604|EXPERIMENTAL|Participants from B1371019 and B1371012|"Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed.~The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study.~Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study."
62114602|NCT01556958||Active Wheezing - age 5-12|
62114603|NCT01556958||Active Wheezing - under age 5|
62675048|NCT04661332||Endoscopic retrograde cholangio-pancreatography|Endoscopic retrograde cholangio-pancreatography procedure
62675049|NCT00449969|EXPERIMENTAL|1. Extended feedback|
62675050|NCT00449969|ACTIVE_COMPARATOR|2. Limited feedback|
62675051|NCT00894725|EXPERIMENTAL|LPS|laparoscopic left colonic resection
62114604|NCT01556958||No Wheezing|
62114605|NCT05998525|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg orally every 24 hours for 12 months
62114606|NCT05998525|PLACEBO_COMPARATOR|Placebo|Placebo orally every 24 hours for 12 months
62114607|NCT00887835|EXPERIMENTAL|PERPOS™ PLS|Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
62114608|NCT03574844|EXPERIMENTAL|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
62114609|NCT03574844|EXPERIMENTAL|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
62114610|NCT03574844|PLACEBO_COMPARATOR|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
62114611|NCT00711919|ACTIVE_COMPARATOR|1|Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
62114612|NCT00711919|ACTIVE_COMPARATOR|2|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
62114613|NCT03467555|EXPERIMENTAL|distalization group|Class II correction using zygomatic miniplates
62114614|NCT06055114||study group|Age 20-49 years old; Premenopausal; Clinical diagnosis of uterine myoma; Cervical liquid-based cytology and human papillomavirus typing test are negative.
62114615|NCT06055114||Healthy control group|Age 20-49 years old; Premenopausal; Uterine B-ultrasonography is normal; Cervical liquid-based cytology and human papillomavirus typing test are negative; No vaginal infection.
62114616|NCT05307614|EXPERIMENTAL|Moksi® 400mg Tablet of Abbott|Healthy subjects were orally administered a single dose of Moksi® 400mg Tablet (Moxifloxacin) under fasting condition
62114617|NCT05307614|ACTIVE_COMPARATOR|Avelox® 400mg Tablet of Bayer|Healthy subjects were orally administered a single dose of Avelox® 400mg Tablet (Moxifloxacin) under fasting condition.
62114618|NCT00810680|EXPERIMENTAL|Valproic acid|
62114619|NCT01789489|ACTIVE_COMPARATOR|3 dimensional sonohysterography|3 dimensional sonohysterography
62114620|NCT01789489|ACTIVE_COMPARATOR|Standard hysteroscopy|Standard hysteroscopy
62114621|NCT04505813|EXPERIMENTAL|Safety Evaluation Phase|Treatment with NEXI-002 T cells, derived from PBMCs of the patient
62114622|NCT04505813|EXPERIMENTAL|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI- 002 T cell product at the dose established from the Safety Evaluation Phase.
62114623|NCT01768676|EXPERIMENTAL|avanafil|100 mg
62114624|NCT01768676|PLACEBO_COMPARATOR|Placebo|placebo
62472298|NCT00738049|ACTIVE_COMPARATOR|Group 2|Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
62675052|NCT00894725|ACTIVE_COMPARATOR|Open|open left colonic resection
62675053|NCT00986583|OTHER|Statin use group|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
62675054|NCT00986583|OTHER|non statin use|Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
62472299|NCT01512823|EXPERIMENTAL|Interactive educational intervention|Two education sessions (four-hours and two-hours respectively), emailed notes and reminders
62472300|NCT01512823|EXPERIMENTAL|Didactic educational intervention|Education alone
62472301|NCT04737486|EXPERIMENTAL|Single Ascending Dose Cohort 1-4|Intervention: AV-001, 6 subjects per cohort will receive single doses of 1.4 µg/kg up to 56 µg/kg of AV-001 by intravenous bolus injection.
62675055|NCT00743080|EXPERIMENTAL|1|Laparoscopic myomectomy and supracervical hysterectomy using GYNECARE MORCELLEX
62472302|NCT04737486|PLACEBO_COMPARATOR|Single Ascending Dose Cohort 1-4, Placebo|Intervention: Placebo, 2 subjects per cohort will receive single doses of D-PBS placebo by intravenous bolus injection.
62472303|NCT04737486|EXPERIMENTAL|Multiple Ascending Dose Cohort 1-2|Intervention: AV-001, 6 subjects per cohort will receive multiple doses of 1.4 µg/kg/day up to 56 µg/kg/day of AV-001 daily for 7 consecutive days by intravenous bolus injection.
62472304|NCT04737486|PLACEBO_COMPARATOR|Multiple Ascending Dose Cohort 1-2, Placebo|Intervention: Placebo, 2 subjects per cohort will receive multiple doses of D-PBS placebo daily for 7 consecutive days by intravenous bolus injection.
62114625|NCT04292054|ACTIVE_COMPARATOR|active group|"The antibiotic prophylaxis will be cefazolin 2 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump, in case of absence of colonization to Pseudomonas aeruginosa prior to the surgical procedure.~The dose administer is 2g.~Antibiotic prophylaxis will be piperacilline-tazobactam 4 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe driver in patients with burn wound colonized to Pseudomonas aeruginosa.~The dose administer is 4g."
62472305|NCT00789230|ACTIVE_COMPARATOR|primary suture|
62472306|NCT00789230|ACTIVE_COMPARATOR|mesh enforced closure|
62675056|NCT00743080|ACTIVE_COMPARATOR|2|Laparoscopic myomectomy and supracervical hysterectomy using ROTOCUT G1
62675057|NCT03160807|EXPERIMENTAL|Levofloxacin 5 days|Levolet 500 mg given for 5 days
62675058|NCT03160807|ACTIVE_COMPARATOR|Levofloxacin 10 days|Levolet 500 mg given for 10 days
62675059|NCT02362932|EXPERIMENTAL|Intervention|Sanitation
62114626|NCT04292054|PLACEBO_COMPARATOR|Placebo group|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
62114627|NCT00987961|NO_INTERVENTION|Treatment as usual|Participants in this arm will receive the standard detox treatment for individuals hospitalized with opioid dependence.
62472307|NCT03427944|ACTIVE_COMPARATOR|Calcium Dobesilate group|Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
62472308|NCT03427944|PLACEBO_COMPARATOR|Conventional Treatment group|conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
62472309|NCT05641961|EXPERIMENTAL|Survivorship Mobile Application|Participants are seen in the survivorship clinic and receive education about potential late effects and the survivorship application on study. Participants enrolled in this study will be asked to complete two self-administered questionnaires at 4 time points. Questionnaires will be designed and made available electronically, to be completed on the participant's personal mobile device (e.g., mobile phone).
62472310|NCT01313780|EXPERIMENTAL|'Oxycodone/Naloxone'|Trade name is Targin(fixed combination drug).
62675060|NCT02362932|NO_INTERVENTION|Control|No sanitation
62675061|NCT05098236|EXPERIMENTAL|Cortically Blind Subjects|
62675062|NCT05098236|PLACEBO_COMPARATOR|Control|
62114628|NCT00987961|EXPERIMENTAL|Linkage|Participants in this arm will receive a maintenance schedule of Suboxone during their hospital stay, and an appointment with an outpatient Suboxone provider for after their discharge.
62675063|NCT02978508|EXPERIMENTAL|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
62675064|NCT02978508|ACTIVE_COMPARATOR|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
62675065|NCT05014542|EXPERIMENTAL|Acupuncture Group|Participants in Acupuncture group will get acupuncture treatments to their symptomatic knee/knees according to the study protocol. Acupuncture will be provided to participants in three cycles, each three weeks duration, with frequency three times weekly. Period between the cycles is three weeks long. Participants will get acupuncture as adjunctive therapy to conventional medical treatment (analgesic therapy) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
62675066|NCT05014542|ACTIVE_COMPARATOR|Control Group|Participants in Control group will get their standard conventional treatment (analgesics) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
61917829|NCT04789018||Observational (survey, virtual genetic board, interview)|Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
61917830|NCT04817852|EXPERIMENTAL|CBCT data of C-shaped canal in mandibular second molar will Be assessed for age.|Detection of variation in root canal morphology by using CBCT.
62675067|NCT03383081|EXPERIMENTAL|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
61917831|NCT05879510|EXPERIMENTAL|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
61917832|NCT02112955|EXPERIMENTAL|Stroke self-management program|The program is aimed at enhancing community-dwelling stroke survivors' post-stroke recovery.
62675068|NCT03383081|EXPERIMENTAL|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
62303584|NCT05008887|EXPERIMENTAL|Fractional CO2 laser and topical methotrexate solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of methotrexate solution (2.5% concentration vial 50mg/2ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
62303585|NCT05008887|ACTIVE_COMPARATOR|Fractional CO2 laser and topical 5-fluorouracil solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of 5-fluorouracil solution 5% concentration vial 250mg/5ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
62303586|NCT05466435|EXPERIMENTAL|Heavy Slow Resistance group|Heavy slow resistance exercise will be given along with traditional physical therapy program
62303587|NCT05466435|PLACEBO_COMPARATOR|Control group|Traditional physical therapy program will be given to the control group
62303588|NCT05835401|EXPERIMENTAL|Experimental (Beetroot juice NO3)|Acute ingestion of beetroot juice rich in NO3 (800mg).
62303589|NCT05835401|PLACEBO_COMPARATOR|Placebo (Beetroot juice without NO3)|Acute ingestion of beetroot juice rich depleted in NO3.
62303590|NCT03037216|EXPERIMENTAL|Experimental Exercise-Training Intervention|Subjects will undergo a 10-week aerobic exercise protocol.
62472311|NCT01313780|ACTIVE_COMPARATOR|Oxycodone|Trade name is Oxycontin(single compound).
62472312|NCT01074541|ACTIVE_COMPARATOR|Group 1|UV intensity 10 MIN
62675069|NCT03383081|NO_INTERVENTION|Control groups|No intervention
62675070|NCT02087878||Group 1|To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL.
62675071|NCT04443777|ACTIVE_COMPARATOR|Sulphonylurea Group|Gliclazide 60 mg (Diamicron® MR) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
61917833|NCT02112955|ACTIVE_COMPARATOR|Usual care|Usual care provided to stroke survivors discharged to their home.
61917834|NCT01443767||Partial liver resection|Adult patients scheduled for elective partial liver resection
62472313|NCT01074541|ACTIVE_COMPARATOR|Group 2|UV intensity 5 MIN
62472314|NCT01074541|ACTIVE_COMPARATOR|Group 3|UV intensity 1 MIN
62675072|NCT04443777|PLACEBO_COMPARATOR|Placebo Group|Placebo (starch, sodium lauryl sulfate and Aerosil) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
62675073|NCT04169412||Resuscitation Failure, High PCO Level, High RIPK3 Level|"1. Resuscitation failure was defined as lactate level ≥2 mmol/L or lactate reduction \<20% hour-4 after initial sepsis recognition.~2. High PCO level was defined as PCO level ≥ cut off point.~3. High RIPK3 level was defined as PCO level ≥ cut off point."
62472315|NCT01074541|ACTIVE_COMPARATOR|Group 4|UV intensity 20 MIN
62472316|NCT03467399|EXPERIMENTAL|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
62472317|NCT01771939|EXPERIMENTAL|idiopathic epiretinal membranes|Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)
61917835|NCT04696497|OTHER|Muscular Assessment|All the patients will received the muscular assessments
61917836|NCT06107179||Crohns Disease|Patients with Crohns Disease
61917837|NCT06107179||Ulcerative Colitis|Patients with Ulcerative Colitis
62675074|NCT04169412||Resuscitation Success, Low PCO Level, Low RIPK3 Level|"1. Resuscitation success was defined as lactate level \<2 mmol/L or lactate reduction ≥20% hour-4 after initial sepsis recognition.~2. Low PCO level was defined as PCO level \< cut off point.~3. Low RIPK3 level was defined as PCO level \< cut off point."
62675075|NCT00553475|PLACEBO_COMPARATOR|Placebo|
61917838|NCT05080231||COVID-19 Vaccinated Individuals|Males and females, 13years old and above, vaccinated for COVID-19
61917839|NCT05080231||Previously positive for COVID-19 and unvaccinated individuals|Males and females, 13years old and above, unvaccinated for COVID-19 and previously tested positive for COVID-19.
61917840|NCT05080231||No previous COVID infection or vaccination|Males and females, 13years old and above, unvaccinated for COVID-19 and previously not tested positive for COVID-19.
62675076|NCT00553475|EXPERIMENTAL|Pregabalin 300 mg/day|
62675077|NCT00553475|EXPERIMENTAL|Pregabalin 600 mg/day|
62675078|NCT06134895|EXPERIMENTAL|Tramadol with Ketamine|Tramadol 0.25mg/Kg with Ketamine 0.25 mg/Kg
62675079|NCT06134895|ACTIVE_COMPARATOR|Tramadol|Tramadol 0.5mg/kg
62675080|NCT00991003|EXPERIMENTAL|Colon capsule endoscopy and colonoscopy|Patients underwent CCE on day 1 and conventional colonoscopy on day 2
62675081|NCT00620802|EXPERIMENTAL|A|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg)
62675082|NCT00620802|ACTIVE_COMPARATOR|B|Plavix (clopidogrel 75 mg)
62675083|NCT02096497||Vascular pattern 1|
62675084|NCT02096497||Vascular pattern 2|
62675085|NCT02096497||Vascular pattern 3|
62675086|NCT02096497||Vascular pattern 4|
62114629|NCT03298919|EXPERIMENTAL|Exercise Videogames|Exercise videogames 3 times weekly for 12 weeks followed by 6 months of home practice
62114630|NCT03298919|ACTIVE_COMPARATOR|Standard Exercise|Exercise using aerobic equipment such as stationary bikes and treadmills 3 times weekly for 12 weeks followed by home practice
62114631|NCT03298919|NO_INTERVENTION|Wellness Control|Weekly mailings on general health and wellness topics for 12 weeks followed by monthly mailings for 6 months.
62675087|NCT02096497||Vascular pattern 5|
62675088|NCT02096497||Vascular pattern 6|
62675089|NCT02096497||Vascular pattern 7|
62675090|NCT02096497||Vascular pattern 8|
62675091|NCT02096497||Vascular pattern 9|
62675092|NCT02096497||Vascular pattern 10|
62675093|NCT02096497||Vascular pattern 11|
62675094|NCT01502072|EXPERIMENTAL|Inhaled Ribavirin|Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.
62675095|NCT01502072|EXPERIMENTAL|Oral Ribavirin|Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.
62675096|NCT01502072|NO_INTERVENTION|No Ribavirin|Group 3: No Ribavirin treatment.
62675097|NCT00602641|ACTIVE_COMPARATOR|Arm I (thalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and thalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive thalidomide PO QD and continue in the absence of disease progression."
62472318|NCT01771939|ACTIVE_COMPARATOR|idiopathic epiretinal membrane|Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only
61917841|NCT01874990|EXPERIMENTAL|women with a history of severe preeclampsia|women with a history of severe preeclampsia(\< 34 weeks gestation) between 5 and 10 years ago
62114632|NCT04154241|EXPERIMENTAL|neuroendocrine tumor Patients|A cohort of patients that were diagnosed with NET using biopsy.
62114633|NCT01712113|EXPERIMENTAL|irbesartan|300 mg tablet
62472319|NCT04430985|EXPERIMENTAL|FOLFOX + Immunotherapy|"8 cycles of FOLFOX every 2 weeks with intrahepatic administration of oxaliplatin in cycles 1-4, thereafter (cycles 5-8) oxaliplatin i given i.v.; starting from cycle 3 this is combined with i.v. administration of nivolumab (cycle 3-8) and ipilimumab (cycle 3 + 6)~Immunotherapy:~Starting from cycle 3: Nivolumab 3 mg/kg i.v. on day 3 (every 2nd week, total of 6 administrations), Ipilimumab 1 mg/kg i.v. on day 3 (every 6th week, total of 2 administrations)"
62472320|NCT03133533|ACTIVE_COMPARATOR|laparoscopic|laparoscopic inguinal hernia repair
61917842|NCT01874990|EXPERIMENTAL|control|women with no history of pregnancy-related hypertensive complications
61917843|NCT05767801||RA patients in sustained clinical and ultrasound remission not changing treatment|
61917844|NCT05767801||RA patients in sustained clinical and ultrasound remission changing treatment|
61917845|NCT03473938||Spatz3 AIGB|Patients with implanted Spatz3 AIGB balloon.
61917846|NCT02632838|EXPERIMENTAL|the mHealth Group|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor on a daily basis at HOME and also will be asked to visit community health center once a week to receive the regular hypertension care for the 6-month period as usual.
62114634|NCT01712113|ACTIVE_COMPARATOR|Avapro|300 mg tablet
62114635|NCT04700930|EXPERIMENTAL|CBD|Patients receive CBD cigarettes additionally to standard psychiatric care including neuroleptic medication
62114636|NCT04700930|NO_INTERVENTION|Non-CBD|Patients recieve standard psychiatric care including neuroleptic medication
62472321|NCT03133533|ACTIVE_COMPARATOR|robot-assisted|robot-assisted inguinal hernia repair
62472322|NCT05451069||Multiple sclerosis patients|MS patients according to 2017 Macdonald criteria
62472323|NCT05451069||Non Multiple sclerosis persons|Control persons
62114637|NCT04266080|EXPERIMENTAL|childhood cancer survivors & and one parent/legal guardian|The study plans to recruit 30 childhood cancer survivors and a parent/legal guardian for each survivor. Participants will be provided with a Fitbit Inspire HR wearable device to record their step counts for two weeks pre-intervention, and over the six-month follow-up period (3-month intervention and 3month follow-up).
62114638|NCT04379713|EXPERIMENTAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
62114639|NCT04379713|ACTIVE_COMPARATOR|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
62114640|NCT02777099|EXPERIMENTAL|RIPostC|Receiving RIPostC with pressure set at 200 mmHg. Intervention:Procedure:Remote Ischemic Postconditioning
62114641|NCT02777099|SHAM_COMPARATOR|sham RIPostC|"Receiving sham RIPostC with pressure set at the patient's diastolic blood pressure.~Intervention:Procedure:Sham Remote Ischemic Postconditioning"
62114642|NCT05126004|NO_INTERVENTION|Control group|receive supportive care
62675098|NCT00602641|EXPERIMENTAL|Arm II (lenalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression."
62675099|NCT03442465||Regenerative Osseous Surgery|Participants undergoing osseous reconstructive surgery (RegOS) for bone neoplasm. Study visits for post-op assessments will be annually after month-36.
62675100|NCT03442465||Other Reconstructive Surgery|Participants undergoing other reconstructive surgery for bone neoplasm. Study visits for post-op assessments will be annually after month-36.
62675101|NCT04296682|NO_INTERVENTION|Atraumatic Extraction Without Gingival Graft|Alveolar closure with elevation of total flaps and simple suture (Silk thread 4.0, Ethicon, Johnson \& Johnson, SJC).
62675102|NCT04296682|EXPERIMENTAL|Atraumatic Extraction With Gingival Graft|Closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual palate.
62675103|NCT03407911||Peri-implant microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
62675104|NCT03407911||Periodontal pocket microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
62675105|NCT03407911||healthy teeth|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
62675106|NCT04955093|EXPERIMENTAL|Intervention|
62675107|NCT04955093|NO_INTERVENTION|Control|
62675108|NCT06114550|EXPERIMENTAL|High-intensity resistance training group (HIRT)|All subjects were instructed to conduct HIRT consisted of 4-5 sets of 12 repetitions at 80%1RM, with 1-2 minutes rests between each set.
62675109|NCT06114550|EXPERIMENTAL|low-intensity resistance training group (LIRT)|All subjects were instructed to conduct LIRT consisted of 4-5 sets of 24 repetitions at 40%1RM, with same period) in random order.
62675110|NCT06232031|EXPERIMENTAL|The observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Active Breathing Exercises, with weekends off and training conducted only on weekdays. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors.
62675111|NCT02993432|ACTIVE_COMPARATOR|Prostaglandin|Administration of the prostaglandin for cervical ripening of the clinician's choice, ie Prostin (Prostin E2 Vaginal Gel 1mg intravaginally) or Cervidil (dinoprostone, 10 mg vaginal insert)
62675112|NCT02993432|EXPERIMENTAL|Foley catheter filled to 80cc|Insertion of a Foley catheter through the cervix and filling to 80cc
62675113|NCT05916287|EXPERIMENTAL|Healthy volonteer|
62675114|NCT05198362|PLACEBO_COMPARATOR|Placebo|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated Tesomet dose from the double-blind period
62675115|NCT05198362|EXPERIMENTAL|Tesomet Low Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
62675116|NCT05198362|EXPERIMENTAL|Tesomet Medium Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
62675117|NCT05198362|EXPERIMENTAL|Tesomet High Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
62675118|NCT03439878|EXPERIMENTAL|Galactose|Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
62675119|NCT03439878|ACTIVE_COMPARATOR|Glucose|Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
62675120|NCT05063383||PCOS|"1. Oligomenorrhea/amenorrhea~2. Clinical androgen excess or biochemical androgen excess~3. Polycystic ovary showed by gynecological ultrasound"
62675121|NCT05063383||NOPCOS|not meet Rotterdam standards
62675122|NCT05129202||Chemotherapy alone or chemotherapy combined with anti-angiogenesis|patients with Chemotherapy
62675123|NCT05129202||immuntherapy|patients treated with immune checkpoint inhibitor monotherapy or combination therapy.
62675124|NCT01986322|EXPERIMENTAL|DTP/HB/Hib vaccine|"Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.~DTP/HB/Hib component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
62675125|NCT01986322|ACTIVE_COMPARATOR|DTP/HB and Hib vaccine|"Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age~DTP/HB component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal~Hib component:~Purified Haemophilus influenzae type b polysaccharide 10 mcg"
62675126|NCT02320825|EXPERIMENTAL|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
62675127|NCT02320825|EXPERIMENTAL|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
62675128|NCT06217900||Case arm|Participants with newly diagnosed cancer of lung, breast, digestive tract, urinary tract and etc.
62675129|NCT06217900||Control arm|Participants without a cancer diagnosis after routine cancer screening tests.
62675130|NCT00052715|EXPERIMENTAL|poly-ICLC Newly diagnosed GBM|"Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy~Intramuscular injection~Drug Poly-ICLC"
62675131|NCT05040464|EXPERIMENTAL|AZA group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg(W0)-80mg(W2)-40mg(W6) and then 40mg EOW and oral AZA capsules at a daily dose of 2.5 mg/kg
62114643|NCT05126004|EXPERIMENTAL|AZA+NAC group|AZA 50mg Subcutaneous daily d1-d5 + NAC 600mg oral bid d1-28， 28 days for one cycle
62675132|NCT05040464|EXPERIMENTAL|MTX group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg (week (W) 0)-80mg(W2)-40mg(W6) and then 40mg EOW and sub-cutaneous MTX 25mg once a week
62675133|NCT01004393|EXPERIMENTAL|Methylnaltrexone bromide|A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.
62114644|NCT01623349|EXPERIMENTAL|Arm BKM|BKM120 and Olaparib
62114645|NCT01623349|EXPERIMENTAL|Arm BYL|BYL719 and Olaparib
62675134|NCT04682964|EXPERIMENTAL|Nebulizer inhalation bacteriophage therapy|To study the effects of bacteriophage therapy on acute tonsillitis in children and adolescents in an outpatient setting.
62675135|NCT06323720||Episodic tension-type headache|Patients with 1 - 14 days of TTH/month.
62675136|NCT06323720||Chronic tension-type headache|Patients with more than 14 days TTH/month
62675137|NCT06323720||Healthy controls|Participants without tension-type headache
62675138|NCT06453876|ACTIVE_COMPARATOR|Unfractionated Heparin / Low molecular heparin and thrombolysis if needed|Standard medical Therapy for intermediate-high risk pulmonary embolism
62675139|NCT06453876|ACTIVE_COMPARATOR|Ultrasound assisted Thrombolysis|Ultrasound assisted Thrombolysis using teh EKOS system. 10 mg af alteplase over 6 hours total and heparin
62675140|NCT06453876|ACTIVE_COMPARATOR|Percutaneous Thrombectomy|Percutaneous Embolectomy using the Inari (R) Flowtriever thrombectomy system (R) and heparin
62675141|NCT05487495|EXPERIMENTAL|CD5 CAR T (CT125B)|All patients who receive CD5 CAR T (CT125B) cell infusion.
62675142|NCT03464448||1|Patients with RRMS who have been newly prescribed Teriflunomide.
62675143|NCT03464448||2|Healthy Controls
62675144|NCT04032327|ACTIVE_COMPARATOR|Plain Bupivacaine|20 mL of 0.25% plain bupivacaine
62675145|NCT04032327|ACTIVE_COMPARATOR|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed
62675146|NCT04256031||Excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are higher than 30
62675147|NCT04256031||Non-excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are 30 or less
62675148|NCT04313439|EXPERIMENTAL|Treatment|Online Cognitive Therapy (I-CT)
62675149|NCT00804557||Uro-Ease Spirus Catheter|10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
62675150|NCT00804557||Standard Urinary Catheter|10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.
62675151|NCT04197505|EXPERIMENTAL|Acute fracture specific|The FLIR E95 camera will be used for the study. The injured extremity will be scanned with the thermal camera and a second scan will be performed on the non-injured extremity to provide an internal control for any differences in room temperature and humidity. Prior to scanning, both the injured and non-injured extremity will remain uncovered for 10 minutes, about the length of an average office visit, and the areas to be scanned will remain free from contact by the patient or interviewer during this time period. The camera will be held 2 feet away from the extremity at a 90º angle to limit reading contamination from objects other than the patient.
62675152|NCT04495478|EXPERIMENTAL|Placebo - Intravenous (IV)|Participants received single dose of placebo administered IV.
62675153|NCT04495478|PLACEBO_COMPARATOR|350 mg Ramucirumab IV|Participants received single 350 milligram (mg) ramucirumab administered as a 60-minute intravenous infusion at a concentration of 10 milligram per millilitre (mg/mL) as one 35 mL infusion.
62675154|NCT04495478|EXPERIMENTAL|Placebo - Subcutaneous (SC)|Participants received single dose of placebo administered SC.
62675155|NCT04495478|PLACEBO_COMPARATOR|350 mg Ramucirumab SC (1x2 mL)|Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as one 2 mL injection.
62675156|NCT04495478|EXPERIMENTAL|350 mg Ramucirumab SC (2x2 mL)|Participants received single 350 mg ramucirumab SC administered at a concentration of 87.5 mg/mL as two 2 mL injections.
61917847|NCT02632838|NO_INTERVENTION|the Standard Follow-up Group|The standard follow-up group will receive regular hypertension care as usual which consists: nursing assessment, medication management, patient education, follow up and continuing care in the community health center
62472324|NCT05669781|ACTIVE_COMPARATOR|Gum-Metoclopramide|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and to chew one a stick of sugar free gum (to be chewed over 15minutes) 8 hourly till either first flatus or feces was passed
62472325|NCT05669781|ACTIVE_COMPARATOR|Gum-only|Chew one stick of sugar free gum (to be chewed over 15minutes) 8 hourly till either first flatus or feces was passed
62675157|NCT04495478|EXPERIMENTAL|350 mg Ramucirumab SC (2x1 mL)|Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 1 mL injections.
62675158|NCT04495478|EXPERIMENTAL|700 mg Ramucirumab SC (2x2 mL)|Participants received single 700 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 2 mL injections.
62675159|NCT04416685|OTHER|Level 1|Those tumors located superior to the portal confluence were classified as Level I,
62675160|NCT04416685|OTHER|Level II|those tumors located on the confluence (involving the confluence) located on the portal confluence
62675161|NCT04416685|OTHER|Level III|those tumors located inferior to the portal confluence
62675162|NCT01829607|ACTIVE_COMPARATOR|Functional electrical stimulation|Functional electrical stimulation of lower limbs
62675163|NCT01829607|PLACEBO_COMPARATOR|Placebo|
62675164|NCT03305211|OTHER|Biological sample|biological sampling will be performed on patients requiring renal biopsy and well-phenotyped patients (diagnosis of renal disease)
62675165|NCT02473263|NO_INTERVENTION|Conventional|No antibiotic administration and no hemodynamic target are required
62675166|NCT02473263|ACTIVE_COMPARATOR|Aggressive|Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient
62675167|NCT00512044|ACTIVE_COMPARATOR|A: general|general anesthesia: spinal and general
62675168|NCT00512044|EXPERIMENTAL|B: pudendal|local anesthesia: pudendal block
62675169|NCT05892874||Parents|
62675170|NCT04356001|EXPERIMENTAL|Socket preservation group|"Extraction sockets filled with a one-piece dual tissue graft harvested from the tuberosity using an adjusted trephine."
62675171|NCT05071833|PLACEBO_COMPARATOR|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
62675172|NCT05071833|EXPERIMENTAL|Peppermint oil|50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
62675173|NCT03066557|ACTIVE_COMPARATOR|study group|TACE and Apatinib
62675174|NCT03066557|EXPERIMENTAL|control group|TACE alone
62675175|NCT05544955|EXPERIMENTAL|Protein ingestion immediately prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
62675176|NCT05544955|EXPERIMENTAL|Protein ingestion 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
62675177|NCT04605588|ACTIVE_COMPARATOR|Active Study Drug|5 day dosing of Nitazoxanide, Ribavirin \& Hydroxychloroquine sulfate
62675178|NCT04605588|PLACEBO_COMPARATOR|Placebo|5 day dosing of placebo
62675179|NCT04807868||Biopsy Group|Adults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason
62675180|NCT04807868||Non-Biopsy Group|Adults without any history of NAFLD
62675181|NCT01391871||PRO-Kinetic DES|Patients receiving PRO-Kinetic drug-eluting stent
62675182|NCT01391871||Endeavor Resolute DES|Patient receiving Endeavor Resolute zotarolimus-eluting stent
62114646|NCT05129124|EXPERIMENTAL|T01: +6.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62472326|NCT05669781|ACTIVE_COMPARATOR|Metoclopramide-only|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
62675183|NCT02916771|EXPERIMENTAL|Ixazomib|"* Cycles 1-9~  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~ * Lenalidomide is administered orally on days 1-21 on a 28 days cycle~ * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle~* Cycle 10-24~  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~ * Lenalidomide is administered orally on days 1-21 on a 28 days cycle~* Supportive measures consistent with optimal patient care may be given throughout the study"
62675184|NCT05463666||Population controls|Participants between 55 and 85 years of age without a diagnosis of RA, or other inflammatory RMD (osteoarthritis allowed). Controls \> 80 years who are physically unable to complete the whole study procedure, are allowed to undergo only part of the study measurements.
62675185|NCT05463666||RA patients|Participants between 55 and 85 years of age with a diagnosis of RA by the treating rheumatologist. Patients \> 80 years who are physically unable to complete the whole study procedure, are allowed to undergo only part of the study measurements.
62675186|NCT05180773|ACTIVE_COMPARATOR|Bromocriptine Treatment Arm|100 Women in the Treatment Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of bromocriptine administered orally as 2.5 mg twice daily for 2 weeks then 2.5mg once daily for 6 weeks. Women not on clinical anticoagulation will also receive prophylactic anticoagulation with rivaroxaban 10 mg once daily for 8 weeks while on bromocriptine.
62472327|NCT05669781|PLACEBO_COMPARATOR|Control|10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
62114647|NCT05129124|EXPERIMENTAL|T02: +6.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62114648|NCT05129124|EXPERIMENTAL|T03: -3.00-2.75 x180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62114649|NCT05129124|EXPERIMENTAL|T04: -3.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62114650|NCT05129124|EXPERIMENTAL|T05: -9.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62114651|NCT05129124|EXPERIMENTAL|T06: -9.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62114652|NCT05129124|EXPERIMENTAL|T07: -12.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62114653|NCT05129124|EXPERIMENTAL|T08: -12.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
62114654|NCT05129124|ACTIVE_COMPARATOR|C01: +6.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
62472328|NCT06197009|PLACEBO_COMPARATOR|Placebo Group /Group1|Induction: Placebo s.c. every 2 weeks. Maintenance: 160mg SCT650C s.c. every 4 weeks
62675187|NCT05180773|PLACEBO_COMPARATOR|Placebo Arm|100 Women in the Placebo Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of a placebo administered orally twice daily for 2 weeks then once daily for 6 weeks. Women not on clinical anticoagulation will not receive rivaroxaban but will instead receive a second placebo for 8 weeks.
62675188|NCT05180773|OTHER|Breastfeeding Observational Cohort|Up to 50 women meeting all other criteria but excluded from REBIRTH due to an intent to continue to breastfeed will be enrolled in an observational cohort. They will receive guideline directed medical therapy with no additional interventions and will have the same follow up and assessment of myocardial recovery by echocardiogram at 6 and 12 months post entry as women in the randomized trial.
62675189|NCT03598764|OTHER|Classic head extraction group|
62675190|NCT03598764|OTHER|External Pop out group|
62675191|NCT06090721|EXPERIMENTAL|DMT310 Topical Powder|DMT310 Powder mixed with Hydrogen Peroxide
62114655|NCT05129124|ACTIVE_COMPARATOR|C02: +6.00-2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
62114656|NCT05129124|ACTIVE_COMPARATOR|C03: -3.00-2.75 x180|Commercially available Ultra for Astigmatism Contact Lenses
62675192|NCT06090721|EXPERIMENTAL|Placebo Topical Powder|Placebo powder mixed with Hydrogen Peroxide
62472329|NCT06197009|ACTIVE_COMPARATOR|SCT650C low dose Group /Group 2|Induction: 160mg SCT650C s.c. every 2 weeks. Maintenance: 160mg SCT650C s.c. every 4 weeks
62114657|NCT05129124|ACTIVE_COMPARATOR|C04: -3.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
62114658|NCT05129124|ACTIVE_COMPARATOR|C05: -9.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
62303591|NCT06513702|EXPERIMENTAL|Recruitment maneuver group|Participant received TELUS guided lung reinflation during CPB weaning and TELUS guided recruitment maneuver during sternal wiring
62472330|NCT06197009|ACTIVE_COMPARATOR|SCT650C medium dose Group /Group3|Induction: 320mg SCT650C s.c. every 2 weeks. Maintenance: 320mg SCT650C s.c. every 4 weeks
62472331|NCT06197009|ACTIVE_COMPARATOR|SCT650C high dose Group /Group 4|Induction: 320mg SCT650C s.c. every 2 weeks. Maintenance: 160mg SCT650C s.c. every 4 weeks
62472332|NCT02409355|EXPERIMENTAL|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
62472333|NCT02409355|ACTIVE_COMPARATOR|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
62472334|NCT04316884||COVID-19|Patients with suspected or verified COVID-19 admitted to intensive care at Uppsala University Hospital
62472335|NCT02813018|EXPERIMENTAL|preemptive group|Group who will be received ropivacaine bolus and continous infusion 5 minutes before skin incision.
62675193|NCT04924452|EXPERIMENTAL|Er:YAG laser therapy|Er:YAG laser will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment.
62675194|NCT04924452|ACTIVE_COMPARATOR|Conventional therapy|Conventional rotary instruments will be used for caries treatment.
62472336|NCT02813018|PLACEBO_COMPARATOR|saline group|Group who will be received saline bolus and continous infusion 5 minutes before skin incision
62472337|NCT04970420|EXPERIMENTAL|HeRFAPIW|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).
62472338|NCT04970420|ACTIVE_COMPARATOR|Control group|
62472339|NCT05369884|EXPERIMENTAL|Experimental group|Oral administration of WPQW granule with warm water，2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
62472340|NCT05369884|PLACEBO_COMPARATOR|Control group|Oral administration of WPQW granule simulant，which containing 5% WPQW granule，with warm water，2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
62472341|NCT04362020|EXPERIMENTAL|Group-1|No anticoagulation
62472342|NCT04362020|ACTIVE_COMPARATOR|Group-2|ACT-guided anticoagulation
62472343|NCT06416826|NO_INTERVENTION|control|"healthy controls~n = 10"
62472344|NCT06416826|ACTIVE_COMPARATOR|patients|"patients with fibromyalgia~n =20"
62472345|NCT01684774||I. USG|Patients receiving Ultrasound-guided Ankle Block
62472346|NCT01684774||II. ALG|Patients receiving Anatomic Landmark-guided Ankle Block
62472347|NCT02538523|ACTIVE_COMPARATOR|Erchonia FX-635|The Erchonia FX-635 is made up of 3 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
62472348|NCT02538523|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia FX-635 but does not emit any therapeutic light.
62675195|NCT04460794|EXPERIMENTAL|Ballet-inspired workout programme (Group A)|Participants will continue their usual activities and exercises, and in addition, receive an 8-week home-based programme delivered by trained volunteers via hybrid on-site and virtual contacts, and supported by volunteer healthcare professionals. A self-directed resource package will be developed.
62114659|NCT05129124|ACTIVE_COMPARATOR|C06: -9.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
62114660|NCT03502317|EXPERIMENTAL|Prehabilitation Study Arm|Patients will participate in a two-pronged prehabilitation strategy - physical prehabilitation and psychological prehabilitation. Prehabilitation will last from a minimum of 21 days to a maximum of 42 days before a patient's clinically indicated surgery.
62303592|NCT06513702|ACTIVE_COMPARATOR|Control group|Participant received manual bag lung inflation during CPB weaning
62472349|NCT05318365|ACTIVE_COMPARATOR|Treatment of constipation and/or faecal incontinence|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition
62472350|NCT05318365|ACTIVE_COMPARATOR|Treatment of constipation and/or faecal incontinence combined with urotherapy|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition combined with standard urotherapy in accordance with International Children's Continence Society (ICCS)
62472351|NCT04024007||Dialysis patients|Intensive care dialysis patients (Continuous Venous Hemofiltration with citrate). Dialysis performed according to the standard indications of the service. Patients are dialysed with the prismaflex system on AN69ST membranes.
62472352|NCT02375685|EXPERIMENTAL|gevokizumab|
62472353|NCT00520923|EXPERIMENTAL|1|160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.
62675196|NCT04460794|OTHER|Usual care (Group B)|Control participants will continue their usual activities and exercises during the study period. In addition, they will be provided with an information sheet about recommendations with pictorial demonstrations on basic stretching and leg exercises for stroke survivors.
62675197|NCT05610839|EXPERIMENTAL|AEBT website with check-ins|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT) and will receive weekly check-ins. Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
62675198|NCT05610839|ACTIVE_COMPARATOR|AEBT website without check-ins|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT) but will not receive weekly check-ins. Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
62675199|NCT02883933||melanoma|Patients with melanoma.
62303593|NCT01498991|EXPERIMENTAL|AMES Treatment|The subject will receive 30 treatment sessions, conducted 3-4 times per week on the AMES device. Each session will consist of testing followed by 40 minutes of treatment time (20 minutes per each leg) using the AMES device.
62303594|NCT02075164|EXPERIMENTAL|Fructose|Volunteers will be challenged with oral 150g Fructose per day for 56 days.
62303595|NCT02075164|EXPERIMENTAL|Glucose|Volunteers will be challenged with oral 167g Fructose per day for 56 days.
62303596|NCT02075164|NO_INTERVENTION|NAFLD|Patients with confirmed simple fatty liver will be compared at baseline with other arms.
62303597|NCT02075164|NO_INTERVENTION|NASH|Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.
62303598|NCT02452359|EXPERIMENTAL|Treatment Group|Group receiving treatment with Venus Versa IPL energy
62303599|NCT02904226|EXPERIMENTAL|Part A (JTX-2011)|Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
62303600|NCT02904226|EXPERIMENTAL|Part B (JTX-2011 + nivolumab)|Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
62303601|NCT02904226|EXPERIMENTAL|Part C (JTX-2011)|Phase 2 expansion of JTX-2011 by IV infusion
62472354|NCT00520923|EXPERIMENTAL|2|80mg of LY2140023, taken orally as 40mg twice daily, for up to 4 weeks.
62472355|NCT00520923|EXPERIMENTAL|3|40mg of LY2140023, taken orally as 20mg twice daily, for up to 4 weeks.
62675200|NCT06238700|EXPERIMENTAL|pregnenolone|Participants will take 250mg of pregnenolone twice per day (daily total=500mg) for four weeks
62675201|NCT06238700|PLACEBO_COMPARATOR|placebo|Participants will take placebo twice per day for four weeks
62303602|NCT02904226|EXPERIMENTAL|Part D (JTX-2011 + nivolumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
62303603|NCT02904226|EXPERIMENTAL|Part E (JTX-2011 + ipilimumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
62303604|NCT02904226|EXPERIMENTAL|Part F (JTX-2011 + ipilimumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
62675202|NCT03896932|EXPERIMENTAL|minipooled- Intravenous immunoglobulin(MP-IVIG)|• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
62303605|NCT02904226|EXPERIMENTAL|Part G (JTX-2011 + pembrolizumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
62675203|NCT00825175|ACTIVE_COMPARATOR|1|Treadmill Training in infants with Down syndrome only
62675204|NCT00825175|EXPERIMENTAL|2|Treadmill Training and supramalleolar orthoses use for infants with Down syndrome
62303606|NCT02904226|EXPERIMENTAL|Part H (JTX-2011 + pembrolizumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
62675205|NCT01817452|EXPERIMENTAL|Arm A|Trastuzumab + Pertuzumab
62675206|NCT01817452|ACTIVE_COMPARATOR|Arm B|Trastuzumab + Pertuzumab + Paclitaxel
62675207|NCT04886037||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
62675208|NCT04886037||control|It consists of healty women between the ages of 18-45
62303607|NCT05981950||Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
62472356|NCT00520923|EXPERIMENTAL|4|10mg of LY2140023, taken orally as 5mg twice daily, for up to 4 weeks.
62472357|NCT00520923|PLACEBO_COMPARATOR|5|Placebo of LY2140023, taken orally twice daily, for up to 4 weeks.
62472358|NCT00520923|ACTIVE_COMPARATOR|6|Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.
62472359|NCT03059615|EXPERIMENTAL|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
62472360|NCT03059615|EXPERIMENTAL|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
62472361|NCT03059615|EXPERIMENTAL|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
62472362|NCT03059615|EXPERIMENTAL|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
62303608|NCT03222271|ACTIVE_COMPARATOR|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:~* Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).~* Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.~* Respiratory rate (RR): 10-12 breath/minute."
62472363|NCT04906863||Mild Cognitive Impairment|Individuals with mild cognitive impairment that began before age 70
62114661|NCT03502317|NO_INTERVENTION|Usual Care Study Arm|No specific exercises or stress reduction techniques are prescribed and the patient will be counseled to continue their current level of activity, and will be given the information on exercise as outlined in the Cancer Care Ontario guidelines. Patients in the Usual Care arm will also be given the same Fitbit activity tracker as patients in the Prehabilitation arm in order to eliminate the activity tracker as an intervention itself and to be able to track the activity (steps) for comparison. Patients in the Usual Care arm will be required to wear their Fitbit activity tracker from the day of randomization to 90 days post-surgery. Patients will record their steps in the diary provided.
62114662|NCT00770965|EXPERIMENTAL|AIN457 0.3 mg/kg|Participants received AIN457 0.3 mg/kg IV on Day 1.
62303609|NCT03222271|EXPERIMENTAL|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:~* Patient's height in cm..~* Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).~* Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O~* Minimum and maximum Pressure Support (PS) :8-16~* Respiratory rate :10-12 breath/min."
62303610|NCT05422300|EXPERIMENTAL|Mid-Follicular Phase|7-10 days after the onset of menses, determined by self-reports and confirmed with ovulation test kits.
62114663|NCT00770965|EXPERIMENTAL|AIN457 1.0 mg/kg|Participants received AIN457 1.0 mg/kg IV on Day 1.
62303611|NCT05422300|EXPERIMENTAL|Mid-Luteal Phase|5-7 days after ovulation, determined by self-reports and confirmed with ovulation test kits.
62303612|NCT01866631||No treatment|
62303613|NCT06282380|OTHER|FibriCheck Mobile Application measurements|Participants will perform one measurement using the FibriCheck Mobile Application and the result will be compared with the ground truth.
62303614|NCT04554368||IA-CEFDCT group|95 patients who underwent IA-CEFDCT and MT for acute anterior stroke.
62303615|NCT05969210|EXPERIMENTAL|Group A|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
62303616|NCT05969210|EXPERIMENTAL|Group B|12 participants will be in control group they will do only there running training.
62303617|NCT05861583||Lipohypertrophy|Active Comparator Tissue from healthy patients with lipohypertrophy,
62303618|NCT05861583||Lipoedema mild stage|Experimental Tissue from lipoedema patients with mild stage (stage 1)
62303619|NCT05861583||Lipoedema moderate stage|Experimental Tissue from lipoedema patients with moderate stage (stage 2)
62303620|NCT05861583||Lipoedema severe stage|Experimental Tissue from lipoedema patients with severe stage (stage 3)
62303621|NCT03816605||control|Cells were cultured in the basic medium containing 2× penicillin and streptomycin antibody.
62472364|NCT04906863||Dementia/Alzheimer's Disease|Individuals with Alzheimer's Disease or other dementia that began before age 70
62675209|NCT02929121|ACTIVE_COMPARATOR|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg).
62114664|NCT00770965|EXPERIMENTAL|AIN457 3.0 mg/kg|Participants received AIN457 3.0 mg/kg IV on Day 1.
62303622|NCT03816605||Recombinant FGF19|Cells were cultured in the basic medium with recombinant FGF19 at concentration of 100ng/ml.
62303623|NCT03816605||High-glucose|Cells were cultured in the high-glucose medium at concentration of 25mM.
62303624|NCT03816605||FGF19 and HG|Cells were cultured in the medium with both recombinant FGF19 and high-glucose.
62675210|NCT02929121|PLACEBO_COMPARATOR|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
62303625|NCT05060042|EXPERIMENTAL|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week.
62303626|NCT05060042|ACTIVE_COMPARATOR|Bilateral proprioceptive training Group|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
62303627|NCT01538615|EXPERIMENTAL|HOME Plus Intervention|described below
62303628|NCT01538615|NO_INTERVENTION|Control|Control participants receive a monthly newsletter for the 10 months of the study with tips on healthy eating. The topics do not overlap the intervention content.
62303629|NCT01519726|EXPERIMENTAL|Morbidly obese patients|
62472365|NCT04906863||Cognitively Healthy|Cognitively healthy individuals over the age of 30 years
62303630|NCT03770143||Group 1|Infants feeding predominantly with palm olein free formula if presence in addition to breast milk for 8 weeks of life
62303631|NCT03770143||Group 2|Infants feeding with other formulas including palm olein if presence in addition to breast milk for 8 weeks of life
62303632|NCT03770143||Group 3|Having similar demographical properties with infants feeding with breast milk (gender, age, weight, height)
62303633|NCT01106781||1|Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.
62303634|NCT00662155|EXPERIMENTAL|Continuous 1 (QHS-10)|continued nightly use with 10mg zolpidem
62472366|NCT06265298|EXPERIMENTAL|Reconstruction conjonctival|Patients undergoing conjunctival reconstruction using oral mucosa
62675211|NCT00781664|EXPERIMENTAL|A|AN2718 Cream SF Vehicle
62675212|NCT00781664|EXPERIMENTAL|B|AN2718 Cream SF, 0.3%
62675213|NCT00781664|EXPERIMENTAL|C|AN2718 Cream SF, 1%
62675214|NCT00781664|EXPERIMENTAL|D|AN2718 Gel Vehicle
62675215|NCT00781664|EXPERIMENTAL|E|AN2718 Gel, 1.5%
62675216|NCT00781664|EXPERIMENTAL|F|AN2718 Gel, 2.5%
62675217|NCT00781664|EXPERIMENTAL|G|AN2718 Gel, 5%
62675218|NCT00781664|EXPERIMENTAL|H|AN2718 Gel, 7.5%
62675219|NCT00781664|ACTIVE_COMPARATOR|I|Sodium Lauryl Sulfate, 0.5%
62114665|NCT00770965|PLACEBO_COMPARATOR|Placebo|Participants received placebo to AIN457A IV on day 1.
62675220|NCT01319461|PLACEBO_COMPARATOR|sterile normal saline injection|
62114666|NCT03411239|OTHER|Interventional arm|Patients recruited will have OBC inserted under general anaesthesia and various pressure measured
62114667|NCT00937846|EXPERIMENTAL|GSK1034702|Single oral 5 mg dose in liquid formulation
62114668|NCT01586780|EXPERIMENTAL|Reference meal|
62114669|NCT01586780|EXPERIMENTAL|Whey protein|
62114670|NCT01586780|EXPERIMENTAL|Whey + 5 amino acids|
62114671|NCT01586780|EXPERIMENTAL|Whey + 6 amino acids|
62114672|NCT01586780|EXPERIMENTAL|Soy protein drink|
62114673|NCT01586780|EXPERIMENTAL|Soy + 5 amino acids|
62114674|NCT01586780|EXPERIMENTAL|Soy + 6 amino acids|
62114675|NCT00234091|ACTIVE_COMPARATOR|1|Immediate treatment; individuals receive HAART on Day 1 of the study
62114676|NCT00234091|ACTIVE_COMPARATOR|2|Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness
62114677|NCT05907551||Patients with Digestive System Cancer|
62675221|NCT01319461|EXPERIMENTAL|Hyalgan injection|
62675222|NCT03845868||Egang hospital physical examination center|
62675223|NCT03845868||Ezhou CDC physical examination center|
62675224|NCT05459610||group for training the algorithm|This group of images is used for training the algorithm of the artificial intelligence
62675225|NCT05459610||group for testing the algorithm|This group of images is used for testing the algorithm of the artificial intelligence
62114678|NCT05907551||Patients with Head and Neck Cancer|
62114679|NCT05907551||Patients with Breast Cancer|
62114680|NCT05907551||Patients with Nervous System Tumors|
62114681|NCT05907551||Patients with Urological Cancer|
62114682|NCT05907551||Patients with Lung Cancer|
62114683|NCT05907551||Patients with Gynecologic Cancer|
62114684|NCT01784146|PLACEBO_COMPARATOR|Oxygen|
62114685|NCT01784146|EXPERIMENTAL|PEEP + Heliox|
62114686|NCT01784146|EXPERIMENTAL|Oxygen + PEEP|
62114687|NCT01784146|ACTIVE_COMPARATOR|Heliox|
62114688|NCT01184235||Autism Spectrum Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Autism Spectrum Disorder
62114689|NCT01184235||Attention Deficit Hyperactivity Disorder|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Attention Deficit Hyperactivity Disorder.
62114690|NCT01184235||Unaffected 1st Degree Relatives|This group will include unaffected, non treated first degree relatives of this study's subjects receiving or anticipating receiving pharmacological intervention.
62114691|NCT01184235||Mood Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is mood disorder.
62114692|NCT05235789|EXPERIMENTAL|Intervention group|The social workers in each center of primary care held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
62114693|NCT05235789|ACTIVE_COMPARATOR|Control group|The control group (GC) in each center of primary care will take the usual medical care for depression, according with up-dated national and international guidelines.
62114694|NCT02808039||DAPT patients|Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation.
62114695|NCT01990937|ACTIVE_COMPARATOR|Oral midazolam|Oral midazolam (5 mg) in 15 mL of apple juice was drunk 30 minutes before EGD
62114696|NCT01990937|PLACEBO_COMPARATOR|Apple juice|15 mL of apple juice was drunk 30 minutes before EGD
62114697|NCT01537133|EXPERIMENTAL|Inhaled corticosteroid|Fluticasone (250 mcg/puff, one puff, twice a day)
62114698|NCT01537133|PLACEBO_COMPARATOR|Placebo|Placebo fluticasone (one puff, twice a day)
62114699|NCT01537133|NO_INTERVENTION|Healthy Control|
62114700|NCT01537133|NO_INTERVENTION|Atopic Non-asthmatics|
62114701|NCT05113355|EXPERIMENTAL|Chidamide + Sintilimab|Experimental arm will be treated by chidamide combined with sintilimab for up to 24 months.
62114702|NCT03772379|EXPERIMENTAL|tooth borne hyrax expander group|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars .
62114703|NCT03772379|EXPERIMENTAL|tooth borne hyrax expander with microosteoperforation|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars and microosteoperforation .
62114704|NCT05434650||Treatment group|Single arm group to receive ablation
62114705|NCT03245593||Shared Decision making for care|
62114706|NCT03245593||Standard decision making for care|
62114707|NCT04010448|EXPERIMENTAL|TV P2-VP8|
62114708|NCT04010448|ACTIVE_COMPARATOR|Rotarix®|
62114709|NCT02892162|EXPERIMENTAL|With additional LAAW linear ablation|Patients who undergo CPVI+LA roof linear ablation+/ MI linear ablation, and additional LAAW linear ablation using ThermoCool SmartTouch catheter.
62114710|NCT02892162|ACTIVE_COMPARATOR|Without additional LAAW linear ablation|Patients who undergo CPVI+LA roof +/ MI linear ablation using ThermoCool SmartTouch catheter, without LAAW linear ablation.
62114711|NCT03889678||Peripheral IV|Patients with peripheral intravenous line in place undergoing elective surgery
62114712|NCT01230619|EXPERIMENTAL|RV568 treatment group|
62114713|NCT01230619|PLACEBO_COMPARATOR|Placebo treatment group|
62303635|NCT00662155|EXPERIMENTAL|Partial Reinforcement (PRS-10)|partial reinforcement with 10mg zolpidem (PRS-10 \[nightly pill use with 50% active meds and 50% placebos\])
62472367|NCT04857008|EXPERIMENTAL|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
62675226|NCT02676622|EXPERIMENTAL|Stem-cell mobilization and Leukapheresis|"Stem-cell mobilisation will be achieved using Cyclophosphamide (CY) 4g/m² (2g/m2 on 2 consecutive days) followed 5 days later by filgrastim (G-CSF) 10 mg/kg injection. This will be done daily until the day before the last day of leukapheresis. The PBSCs will be harvested usually between day +9 and +11 of completing CY.~Leukapheresis will be performed to a target cell dose of 3-8 x106 CD34+ cells/kg Approximately 1 month later patients will undergo HSCT"
62114714|NCT01194154|EXPERIMENTAL|Mircera|
62114715|NCT01194154|PLACEBO_COMPARATOR|Placebo|
62114716|NCT01123928|EXPERIMENTAL|Counseling|Subjects will be asked to watch a 5-10 min video and participate in a 10-15 min pre-operative counseling session with a trained nurse. Subjects will also participate in a 5 min post-operative counseling session.
62114717|NCT01123928|NO_INTERVENTION|Non-counseling|
62114718|NCT04652076|OTHER|Arm A: Standard Chemotherapy alone (Paclitaxel + Carboplatin)|Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
62114719|NCT04652076|OTHER|Arm B: Experimental double combination [Standard Chemotherapy +NP137]|Experimental double combination \[Standard Chemotherapy +NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
62114720|NCT04652076|OTHER|Arm C: Experimental double combination [Pembrolizumab +NP137]|Experimental double combination \[Pembrolizumab +NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
62114721|NCT04652076|OTHER|Arm D: Experimental triple therapeutical combination [Pembrolizumab+ Standard Chemotherapy + NP137]|Experimental triple combination \[Pembrolizumab+ Standard Chemotherapy + NP137\] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
62114722|NCT00135135|OTHER|1|
62114723|NCT00549536|NO_INTERVENTION|2|
62114724|NCT00549536|ACTIVE_COMPARATOR|1|Patients on calcium supplementation
62114725|NCT00796068|EXPERIMENTAL|Arm I (low risk for graft failure)|"Patients receive a conditioning regimen comprising fludarabine phosphate IV over 1 hour QD on days -6 to -2 and treosulfan IV over 120 minutes on days - 6 to -4. Patients undergo TBI on day -1. Patients then undergo donor UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour or PO 2-3 times daily on days -3 to 100, followed by a taper in the absence of GVHD. Patients also receive mycophenolate mofetil IV 3 times daily on days 0 to 40, followed by a taper in the absence of GVHD."
62114726|NCT00796068|EXPERIMENTAL|Arm II (high risk for graft failure)|Patients receive a conditioning regimen, TBI, donor UCBT, GVHD prophylaxis, and mycophenolate mofetil as in Arm I.
62114727|NCT05227066|EXPERIMENTAL|traditional physical therapy group|received traditional physical therapy protocol
62114728|NCT05227066|EXPERIMENTAL|lower extremity weights group|received the same traditional physical therapy in addition to lower extremity weights
62114729|NCT05496816||Sepsis|
62114730|NCT05496816||Septic shock|
62303636|NCT00662155|EXPERIMENTAL|Intermittent (IDS-10)|intermittent dosing with 10mg zolpidem
62303637|NCT00662155|EXPERIMENTAL|Continuous 2 (QHS-5)|continued nightly use with 5mg zolpidem
62303638|NCT02139189|EXPERIMENTAL|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
62303639|NCT01189773|EXPERIMENTAL|1|Ibuprofen given orally (10 mg/kg, max = 600 mg) and codeine given orally (1 mg/kg, max = 60 mg).
62303640|NCT01189773|PLACEBO_COMPARATOR|2|Ibuprofen given orally (10 mg/kg, max = 600 mg) and placebo given orally ( identical in taste color to codeine preparation).
62303641|NCT06448156||0-19 years age group|
62472368|NCT03173547|ACTIVE_COMPARATOR|146-9251 cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
62472369|NCT03173547|PLACEBO_COMPARATOR|Vehicle cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
62472370|NCT05181566|EXPERIMENTAL|Modular dual mobility group|A group of patients who underwent total hip replacement arthroplasty using a modular dual mobility cup
62114731|NCT02404233|EXPERIMENTAL|Darunavir/ cobicistat and Rilpivirine|"Single arm study:~Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food Rilpivirine tablet 25 mg once daily taken with food"
62114732|NCT03018041|EXPERIMENTAL|Marine n-3 PUFAs|3 capsules of Omacor 1000 mg daily, corresponding to a dose of 2.5 g / day of marine n-3 PUFAs (EPA plus DHA).
62114733|NCT03018041|PLACEBO_COMPARATOR|Placebo|Corresponding placebo oral capsules with olive oil, three capsules daily.
62114734|NCT01976910|EXPERIMENTAL|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~* At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~* The MTD will be where 2 DLTs are noted and the study is discontinued."
62114735|NCT01299974|OTHER|Parents and Residents in Session|Parents and Residents in Session
62114736|NCT00652301|EXPERIMENTAL|1|ezetimibe 10 mg tablet plus simvastatin 20 mg tablet
62114737|NCT00652301|ACTIVE_COMPARATOR|2|ezetimibe 10 mg tablet
62114738|NCT00652301|ACTIVE_COMPARATOR|3|simvastatin 20 mg tablet
62114739|NCT00652301|PLACEBO_COMPARATOR|4|matching placebo
62114740|NCT00680342|PLACEBO_COMPARATOR|1|Placebo (lactose pill)
62114741|NCT00680342|EXPERIMENTAL|2|700mg of Legalon (silymarin) three times daily
62114742|NCT00680342|EXPERIMENTAL|3|420mg Legalon (silymarin) three times daily
62114743|NCT00839540|ACTIVE_COMPARATOR|micafungin 100|Patients receive Micafungin 100 mg qd
62114744|NCT00839540|ACTIVE_COMPARATOR|micafungin 200|Patients receive 200 mg Micafungin qd
62114745|NCT00839540|ACTIVE_COMPARATOR|Caspofungin|Patients receive caspofungin 70 mg LD followed by 50 mg qd
62114746|NCT00913913|EXPERIMENTAL|bevacizumab,IL-2, IFN, DC vaccine|Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
62303642|NCT06448156||20-29 years age group|
62114747|NCT00039455|EXPERIMENTAL|Treatment (trastuzumab and alvocidib)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62114748|NCT01595321|EXPERIMENTAL|Cohort 1: SBRT and FOLFIRINOX|The initial 3 patients were treated with SBRT and full dose FOLFIRINOX and observed for the first 2 cycles (8 weeks) for dose limiting toxicities (DLTs). If 2-3 patients are observed with uncontrolled grade 3-4 diarrhea, 2-3 patients are observed with grade 3-4 thrombocytopenia, or if 3 patients are observed with grade 3-4 neutropenia within the first 2 cycles of FOLFIRINOX administration (8 weeks) then the dose level will be deemed unacceptable.
62114749|NCT01595321|EXPERIMENTAL|Cohort 2: SBRT and modified FOLFIRINOX|The next 4 patients were treated with SBRT and modified FOLFIRINOX and observed for the first 2 cycles (8 weeks) for dose limiting toxicities (DLTs). If no patients are observed with grade 3-4 diarrhea, thrombocytopenia, or neutropenia, then the next cohort of patients will receive SBRT, modified FOLFIRINOX, and GVAX (with Cy).
62114750|NCT01595321|EXPERIMENTAL|Cohort 3: CY, GVAX, SBRT, and modified FOLFIRINOX|The last 12 patients will receive Cy, GVAX, SBRT, and modified FOLFIRINOX.
62114751|NCT05272046|ACTIVE_COMPARATOR|Monopolar Electrocautery tool|Patients randomized into this group will receive the standard of care monopolar tool for their POEM procedure.
62114752|NCT05272046|EXPERIMENTAL|Bipolar Electrocautery tool|Patients randomized into this group will receive the standard of care bipolar tool for their POEM procedure.
62114753|NCT05566418|NO_INTERVENTION|Group A|Group A will get standard therapy and the Mulligan mobilization technique for 12 sessions. A Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide. The patient will be instructed to constantly extend their wrists while the therapist applies manual resistance to their attempts, and the therapist will continue to work on the patient. When the user can fully extend their wrist without discomfort, the lateral glide will be abolished. Three repeats will be performed, each separated by a fifteen-to twenty-second interval.
62114754|NCT05566418|EXPERIMENTAL|Group B|In addition to the standard treatment, Group B participants will receive 12 sessions of myofascial release technique and Mulligan mobilization. Participants will be instructed to lie supine on the plinth with the afflicted arm internally rotated, elbow slightly flexed and pronated, and palm of hand on the plinth. While standing on the side of the body affected by the ailment being treated, the therapist turned their body to face the affected hand. Myofascial release will be performed on the patient The therapeutic session will last five minutes and will be repeated twice.
62114755|NCT02925195|EXPERIMENTAL|Active Treatment|
62114756|NCT02925195|PLACEBO_COMPARATOR|Placebo|Placebo
62114757|NCT05061953||EDSS 0-2.0|Confirmed diagnosis of MS with an EDSS score between 0 and 2.0.
62114758|NCT05061953||EDSS 2.5-4.0|Confirmed diagnosis of MS with an EDSS score between 2.5 and 4.0.
62114759|NCT05061953||EDSS 4.5-6.0|Confirmed diagnosis of MS with an EDSS score between 4.5 and 6.0.
62114760|NCT05061953||EDSS 6.5-8.0|Confirmed diagnosis of MS with an EDSS score between 6.5 and 8.0.
62114761|NCT05061953||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
62114762|NCT06028451||Survivors|Critically ill patients with invasive aspergillus infection who survived
62114763|NCT06028451||Nonsurvivors|Critically ill patients with invasive aspergillus infection who not survived
62303643|NCT06448156||30-39 years age group|
62303644|NCT06448156||40 to 49 age group|
62303645|NCT06448156||50 to 59 age group|
62303646|NCT06448156||60 to 69 age group|
62303647|NCT06448156||70 to 79 age group|
62303648|NCT06448156||80+age group|Age group greater than or equal to 80 years
62303649|NCT06114043|OTHER|Operation|60 participants will be operated for mild to moderate hallux valgus deformity
62303650|NCT06114043|OTHER|Conservative|60 participants will be treated conservatively with a wide shoe
62303651|NCT05218629|EXPERIMENTAL|Anlotinib， PD-1inhibitor|Anlotinib 8-14 mg, oral, once a day for 14 days every 3 weeks. PD-1 inhibitor (Pembrolizumab) 200mg iv day1, every 3 weeks
62675227|NCT05595395|PLACEBO_COMPARATOR|Intravenous Fluid Arm|"In Group 1 (Standard of practice/intravenous fluid group) no enteral administration of fluid other than enteral nutrition is going to be allowed. Intravenous fluid administration is going to be administered at the discretion of the physician in charge and Elomel isoton is going to be the fluid of choice."
62675228|NCT05595395|ACTIVE_COMPARATOR|Enteral Fluid Arm|"In Group 2 (Test practice/enteral fluid group) enteral fluid administration is going to be the primary mode of administration. Intravenous fluid administration can be performed by physicians at their own discretion. Primary enteral fluid administered is going to be tap water, intravenous fluid of choice is going to be Elomel isoton."
62114764|NCT01286155||with gastroesophageal reflux disease(GERD)|Subjects with gastroesophageal reflux disease (GERD)
62114765|NCT01286155||Non-GERD|Subjects with no history of gastroesophageal reflux disease (GERD)
62114766|NCT01286155||Barrett's esophagus|Subjects with confirmed barrett's esophagus in Olmsted county
62114767|NCT04109534|PLACEBO_COMPARATOR|Placebo|Placebo comparator 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Placebo Comparator
62114768|NCT04109534|ACTIVE_COMPARATOR|Verum|PUFAS: 2640 mg of middle-chain and polyunsaturated fatty acids 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Active Comparator
62114769|NCT01291563|EXPERIMENTAL|001|TMC207 8 tablets of TMC207 (100 mg/tablet) on Day 1
62114770|NCT01291563|PLACEBO_COMPARATOR|002|TMC207 placebo 8 tablets of TMC207 placebo on Day 1
62114771|NCT01291563|ACTIVE_COMPARATOR|003|Moxifloxacin 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
62114772|NCT01291563|PLACEBO_COMPARATOR|004|Moxifloxacin placebo 1 capsule of moxifloxacin placebo on Day 2
62114773|NCT05796440|EXPERIMENTAL|LUM-201 (1.6 mg/kg/day)|
62114774|NCT04801329||Adults diagnosed with transthyretin-mediated amyloidosis (ATTR-CM)|
62114775|NCT04304859||Cases referred from GP|BASIC (Brief Assessment of Impaired Cognition) MMSE (Mini Mental State Examination) Extensive diagnostic work-up including clinical interview, neurological and physical examination, laboratory screening tests, structural neuroimaging
62114776|NCT04304859||Healthy controls|"Test performed:~BASIC MMSE GDS-15 (Geriatric Depression Scale)"
62114777|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
62114778|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
62114779|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
62114780|NCT01148719|ACTIVE_COMPARATOR|Index group|Patients in the index group receive the diagnostic triage instrument. This includes echocardiographic, electrocardiographic and spirometric measurements and blood testing.
62303652|NCT06375850|EXPERIMENTAL|Intervention|This arm will be administered 2 drops of sesame oil daily along the channeled vein, about 3 centimeters from the insertion point.
62303653|NCT06375850|PLACEBO_COMPARATOR|Control|This arm will be administered 2 drops of physiological saline daily along the channeled vein, about 3 centimeters from the insertion point.
62303654|NCT03576027|EXPERIMENTAL|Hyperbaric oxygen therapy|
62303655|NCT00101361|ACTIVE_COMPARATOR|1|oxandrolone
62303656|NCT00101361|PLACEBO_COMPARATOR|2|placebo
62675229|NCT04492293|EXPERIMENTAL|ICP-192|ICP-192
62675230|NCT02408770|EXPERIMENTAL|treatment|ulipristal acetate 5mg daily for 3 months
62675231|NCT02583477|EXPERIMENTAL|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
62675232|NCT02583477|EXPERIMENTAL|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
62675233|NCT04264195|EXPERIMENTAL|Constraint-induced movement therapy|Constraint-induced movement therapy (PEPS-MIT)
62675234|NCT04264195|ACTIVE_COMPARATOR|Bimanual manipulation|Bimanual manipulation (PEPS-Bimanual)
62114781|NCT01148719|NO_INTERVENTION|Control|Participants receive care as usual.
62303657|NCT03972371|EXPERIMENTAL|Treatment Group|The ProVee Urethral Expander is implanted into the prostatic urethra to treat BPH symptoms
62303658|NCT01981187|EXPERIMENTAL|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
62303659|NCT04627545|EXPERIMENTAL|IVF: 2h exposure|Half of a patients' oocytes will be subjected to 2h exposure to sperm
62303660|NCT04627545|ACTIVE_COMPARATOR|IVF: overnight exposure|Half of a patients' oocytes will be subjected to overnight incubation with sperm (=usual practice).
62303661|NCT02048514|EXPERIMENTAL|Nellix Aneurysm Sealing|The Nellix® EndoVascular Aneurysm Sealing System
62675235|NCT03357445|OTHER|Subgroup 1|Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD
62675236|NCT03357445|OTHER|Subgroup 2|Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner
62114782|NCT01358136||Hemithyroidectomy|Patients with benign nontoxic goiter who have an indication for hemithyroidectomy
62114783|NCT05964231|EXPERIMENTAL|Heat-treated PS23|Lactobacillus paracasei PS23 heat-treated
62675237|NCT03387774|EXPERIMENTAL|Concurrent chemoradiotherapy and ulinastatin|"Concurrent chemoradiotherapy (CCRT) and intravenous drip of ulinastatin, the details are as follows:~1. Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT;~2. Ulinastatin through intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline, 3 times every radiation day, until the end of radiotherapy."
62675238|NCT03387774|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|"Concurrent chemoradiotherapy (CCRT) alone:~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT."
62675239|NCT05377671|EXPERIMENTAL|Cognitive deficit group|All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
62675240|NCT05377671|EXPERIMENTAL|Without cognitive group|All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
62303662|NCT01068470||patients with melanoma or kidney cancer|
62303663|NCT00404443|SHAM_COMPARATOR|1|arm 1: placebo needle
62303664|NCT04184648||There was no adverse systems outcome after PMA36 weeks|Premature infants at PMA36 weeks did not show the following conditions (1) before follow-up tracheotomy; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
61917848|NCT00495079|EXPERIMENTAL|Marqibo|Eligible subjects received study drug at 2.25 mg/m\^2 intravenously via peripheral or central venous access over 60 minutes (± 10 minutes).
62114784|NCT05964231|PLACEBO_COMPARATOR|Placebo|microcrystalline cellulose
62114785|NCT05323682|EXPERIMENTAL|Experimental|Individualized physical exercise program
62114786|NCT05323682|ACTIVE_COMPARATOR|Control|No individualized physical exercise program
62114787|NCT02065050|NO_INTERVENTION|Usual Care|Individuals in the usual care arm will not receive frequent contact by the study team. Individuals will be seen by a study team clinician 1 year after discharge to review diabetes management and obtain pertinent study related data.
62114788|NCT02065050|EXPERIMENTAL|Continued care|team-based care: Individuals in the continued care arm will be frequently contacted by the study team (consisting of endocrinologists, nurse practitioners, and health coaches) over the course of one year post-discharge. The team will monitor blood sugars and other health data, altering management as needed.
62114789|NCT00436644|EXPERIMENTAL|Lapatinib + Topotecan|Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.
62114790|NCT03273348|OTHER|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
62114791|NCT02618278|EXPERIMENTAL|Intervention|Patients randomised to the intervention arm will receive a individual, goal -orientated physiotherapy management package within 2 weeks G.P referral for physiotherapy.
62472371|NCT05181566|ACTIVE_COMPARATOR|Conventional group|A group of patients who underwent total hip replacement arthroplasty using a conventional acetabular cup
62472372|NCT06151691||Case-Cancer arm|Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
62675241|NCT05854264|ACTIVE_COMPARATOR|microbiota and specialized nutrition|microbiota analysis in lower lavage (Bronco Alveolar Lavage: BAL) samples in patietns treated with specialized nutrition
62675242|NCT05854264|SHAM_COMPARATOR|microbiota and standard nutrition|microbiota analysis in lower lavage (Bronco Alveolar Lavage: BAL) samples in patients treated with standard nutrition
62675243|NCT02298569|NO_INTERVENTION|Phase 1 (before multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of a French perinatal network consecutively, whatever the duration of their hospital stay
62303665|NCT04184648||Death or adverse respiratory outcome after 36 weeks of pma|Premature infants at PMA36 weeks presented the following conditions (1) before tracheotomy during follow-up; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
62303666|NCT02381158|EXPERIMENTAL|Nebulized Beclomethasone dipropionate|Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).
62303667|NCT03572634|EXPERIMENTAL|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
62303668|NCT03572634|EXPERIMENTAL|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
62303669|NCT01575912||schizophrenia SC|subjects with a diagnosis of schizophrenia (SC) according to the DSM-IV-TR, submitted to experimental pain tests
62303670|NCT01575912||major depression MD|subjects with a diagnosis of major depression (MD) according to the DSM-IV-TR, submitted to experimental pain tests
62303671|NCT01575912||controls C|subjects without any diagnosis of psychiatric disorder (C) submitted to experimental pain tests
62303672|NCT06035718|EXPERIMENTAL|Active tDCS over the dorsolateral prefrontal cortex (DLPFC)|In this group, participants will receive active 2 milliampere (mA) tdcs over the DLPFC (anode on F3 and cathode onF4) for 20 minutes.
62303673|NCT06035718|ACTIVE_COMPARATOR|Active tDCS over the ventromedial prefrontal cortex (VMPFC)|In this group, participants will receive active 2 mA tdcs over the VMPFC (anode on Fpz and cathode on Cz) for 20 minutes.
62303674|NCT06035718|SHAM_COMPARATOR|Sham tDCS Stimulation|In this group, participants will receive sham tDCS which will ramp up for 30 s at the beginning of the session and then ramp down and be switched off during the 20-minute stimulation session.
62303675|NCT06035718|ACTIVE_COMPARATOR|Probiotic supplementation|In this group, participants will consume 2 probiotic supplements (The synbiotics family) daily, for one month.
62303676|NCT03669393|EXPERIMENTAL|THR-317|
62303677|NCT03554239|OTHER|Voriconazole treatment|Patients who start voriconazole treatment and receive benefits of genotyping
62303678|NCT05598086|EXPERIMENTAL|TXA group|Postoperative 1g TXA was infiltrated locally around the incision immediately for patients in TXA group.
62303679|NCT05598086|PLACEBO_COMPARATOR|Normal saline group|1 g 0.9% saline was infiltrated locally around the incision immediately after surgery for patients in normal saline group.
62303680|NCT04544267|EXPERIMENTAL|QIV-HD|One injection of QIV-HD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
62303681|NCT04544267|ACTIVE_COMPARATOR|QIV-SD|One injection of QIV-SD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
62303682|NCT03348514|EXPERIMENTAL|CPX-POM - 30 mg/m^2|
62303683|NCT03348514|EXPERIMENTAL|CPX-POM - 60 mg/m^2|
62303684|NCT03348514|EXPERIMENTAL|CPX-POM - 120 mg/m^2|
62303685|NCT03348514|EXPERIMENTAL|CPX-POM - 240 mg/m^2|
62303686|NCT03348514|EXPERIMENTAL|CPX-POM - 360 mg/m^2|
62303687|NCT03348514|EXPERIMENTAL|CPX-POM - 600 mg/m^2|
62303688|NCT03348514|EXPERIMENTAL|CPX-POM - 900 mg/m^2|
62303689|NCT03348514|EXPERIMENTAL|CPX-POM - 1200 mg/m^2|
62303690|NCT01086111||PMSF|type 2 diabetes patient receiving a protein sparing diet
62303691|NCT01086111||sleeve gastrectomy|type 2 diabetes patient receiving a gastric bypass
62303692|NCT01086111||RYGBP|type 2 diabetes patient receiving a gastric bypass
62472373|NCT00934050|EXPERIMENTAL|ELND005|
62675244|NCT02298569|EXPERIMENTAL|Phase 2 (after multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of the same French perinatal network 3 months after the intervention (introduction of the multi-pronged program) consecutively, whatever the duration of their hospital stay
62675245|NCT03435315|ACTIVE_COMPARATOR|Treadmill exercise|
62675246|NCT03435315|EXPERIMENTAL|Treadmill exercise with behavioral techniques|
62675247|NCT05874011||Patients|Patients with right stroke consecutively recruited according to inclusion and non-inclusion criteria
62675248|NCT05874011||Healthy volunteers|Healthy volunteers with no known history of stroke
62675249|NCT00268398|ACTIVE_COMPARATOR|FOLFOX4|
62675250|NCT00268398|EXPERIMENTAL|FOLFOX7 followed by FOLFIRI|
62675251|NCT05153187||Patients with HR+/HER2- advanced breast cancer|
62675252|NCT01300065|EXPERIMENTAL|Experimental- Soflens|Bausch \& Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.
62675253|NCT01300065|ACTIVE_COMPARATOR|Marketed - Soflens|Bausch \& Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.
62675254|NCT00562107|EXPERIMENTAL|1|AAIsafeR /SafeR Patient randomized with the SafeR switched ON
62675255|NCT00562107|EXPERIMENTAL|2|DDD(R) mode. Patients randomized with the SafeR mode switched OFF
62675256|NCT01602666|EXPERIMENTAL|Treatment (combination chemotherapy, radiation therapy)|See Detailed Description
62675257|NCT02455089|EXPERIMENTAL|Test group|"250 SLE patients : All SLE patients included in the study. Intervention : Blood analysis including GADD34 RNA level measurement every 3 months up to 1 year.~They will provided a blood sample every 3 months during a year. The result of GADD34 RNA level in mononuclear blood cells will be correlated to the clinical assessment of a SLE flare during the next 3 months.~A flare occurence will the group"
62472374|NCT03782779|EXPERIMENTAL|Breathing program and regular exercise|Diaphragmatic Breathing Program plus regular upper and lower limb exercises
62472375|NCT03782779|ACTIVE_COMPARATOR|Regular Exercise|Regular upper and lower limb exercises
62472376|NCT04553146|EXPERIMENTAL|Interventional arm|immediate implant placement in posterior sites using a custom-made sealing socket abutment combined to alveolar ridge preservation
62472377|NCT03670017|OTHER|Time In Range during OptiScanner Connection|Participants will be connected to the OptiScanner 5000 for up to 72 hours.
62675258|NCT00355550|ACTIVE_COMPARATOR|AC-1202|Tricaprilin formulation, once daily. Administered orally
62675259|NCT00355550|PLACEBO_COMPARATOR|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
62675260|NCT03385486|EXPERIMENTAL|TBX-3400|TBX-3400 by intravenous infusion
62675261|NCT02605694|EXPERIMENTAL|Arm 1|Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
62675262|NCT02605694|ACTIVE_COMPARATOR|Arm 2|"R-CHOP will be administered as follows:~IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)~* Prednisone (100 mg) will be administered."
62675263|NCT02176525|EXPERIMENTAL|BI 207127 in patients with cirrhosis|multiple rising doses
62675264|NCT02176525|EXPERIMENTAL|BI 207127 in patients without cirrhosis|multiple rising doses
62675265|NCT02176525|PLACEBO_COMPARATOR|Placebo in patients without cirrhosis|
62114792|NCT02618278|ACTIVE_COMPARATOR|Usual care|Patients randomised to usual care will receive the same individual, goal-orientated physiotherapy management as the intervention arm but at 6 weeks post G.P referral, as is usual care.
62114793|NCT05263960|EXPERIMENTAL|Part A, Dose escalation|There are 10 dose groups in dose escalation part.
62114794|NCT05263960|EXPERIMENTAL|Part B, Dose expansion|Based on the data of part A, one (MTD or the dose of one level less than MTD) or two (MTD and the dose of one level less than MTD) dose levels will be discussed for further evaluation in part B.
62114795|NCT00373269||Diabetic subject|Subjects with acute stroke, hyperglycemia and history of diabetes.
62675266|NCT01064284|ACTIVE_COMPARATOR|PLASMA DERIVED Factor VIII|Plasma-derived vWF/FVIII
62114796|NCT00373269||Normoglycemic Control|Subjects with acute stroke and normal blood glucose.
62303693|NCT06511752|EXPERIMENTAL|Treatment Condition|Support group meetings and strategy practice
62472378|NCT05217472|EXPERIMENTAL|Ravagalimab|Participants will receive a loading dose of intravenous (IV) ravagalimab dose A at Week 0 followed by subcutaneous (SC) ravagalimab dose A every other week (eow)
62472379|NCT05217472|PLACEBO_COMPARATOR|Placebo|Participants will receive a loading dose of intravenous (IV) placebo at Week 0 followed by subcutaneous (SC) placebo every other week (eow)
62675267|NCT01064284|ACTIVE_COMPARATOR|rFVIII|Recombinant FVIII
62675268|NCT02903381|EXPERIMENTAL|Nivolumab, Lenalidomide, Dexamethasone|"* A treatment cycle is defined as 28 consecutive days.~* Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
62675269|NCT06532422||cohort of outpatients|Adult patients diagnosed with localised kidney cancer, undergoing scheduled surgery for partial or total laparoscopic nephrectomy on an outpatient basis.
62675270|NCT01579305|EXPERIMENTAL|Juvéderm® Volbella with Lidocaine|Subjects injected with Juvéderm® Volbella with Lidocaine in their lips
62675271|NCT01579305|ACTIVE_COMPARATOR|Restylane-L®|Subjects injected with Restylane-L® in their lips
62675272|NCT02314247|EXPERIMENTAL|Selinexor|60 mg dose (equivalent to \~35 mg/m²)
62114797|NCT00628719|EXPERIMENTAL|1|a single dose of 10 mg/kg of liposomal amphotericin B
62114798|NCT00628719|ACTIVE_COMPARATOR|2|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
62114799|NCT03601351||TT|Tumor Tissue. Colon or rectum neoplasia stage II and III tumor tissue.
62114800|NCT03601351||NTT|Nontumorous Tissue. Colon or rectum neoplasia stage II and III adjacent nontumorous tissue.
62303694|NCT04885738||Chronic Cough|cough as a sole presenting lasted more than 8 weeks; with an age of 18-70years; with a normal chest X-ray; without steroids treatment in the last 4 weeks.
62303695|NCT04885738||Asthma|classic asthma
62303696|NCT04885738||COPD|patients with COPD in stable stage or acute exacerbation
62472380|NCT00731978|NO_INTERVENTION|Standard|Standard intraoperative fluid management
62472381|NCT00731978|EXPERIMENTAL|Restricted|Restricted intraoperative fluid management
62472382|NCT02827071||Retina abnormalities|Subjects with various retina vascular disorders
62472383|NCT06110377|ACTIVE_COMPARATOR|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
62472384|NCT06110377|EXPERIMENTAL|MMP (INJECTIONS WITH TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
62472385|NCT06498700|EXPERIMENTAL|Ketamine(K)|0.5 mg/kg/h ketamine infusion
62472386|NCT06498700|EXPERIMENTAL|dexmedetomidine(D)|0.1 ug/kg/h dexmedetomidine infusion
62114801|NCT02582710|EXPERIMENTAL|VASCAZEN|Patients treated with Vascazen
62114802|NCT02582710|PLACEBO_COMPARATOR|Placebo|Patients treated with a placebo
62303697|NCT06251687|EXPERIMENTAL|Transbronchial Cryobiopsy (TBLC)|Transbronchial lung cryobiopsy (TBLC) has been increasingly utilised to diagnose diffuse parenchymal lung diseases
62303698|NCT06251687|ACTIVE_COMPARATOR|Transbronchial Lung Biopsy (TBLB)|Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
62114803|NCT04292093|EXPERIMENTAL|Home rehabilitation training|Home rehabilitation training
62114804|NCT04292093|ACTIVE_COMPARATOR|Home control activity|Home control activity
62114805|NCT01250548|ACTIVE_COMPARATOR|2|
62114806|NCT01250548|PLACEBO_COMPARATOR|Apremilast|Placebo Compared to apremilast arm
62114807|NCT03853655|NO_INTERVENTION|Control arm|Patients in this arm will be observed and kept under active follow-up after surgery for the primary.
62114808|NCT03853655|EXPERIMENTAL|Study arm|Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.
62114809|NCT05214287|EXPERIMENTAL|Intermittent with 5x5-minutes, FiO2 0.163|Delivered intermittently, with FiO2 0.163 and room-air, each 5 minutes, for 5 cycles/session
62114810|NCT05214287|EXPERIMENTAL|Intermittent with 5x5-minutes, FiO2 0.127 or 0.133|Delivered intermittently, with FiO2 0.127 or 0.133 (depending on SaO2 during screening procedure at FiO2 0.127, see study procedures) and room-air, each 5 minutes, for 5 cycles/session
62114811|NCT05214287|EXPERIMENTAL|Continuous for 45 minutes, FiO2 0.163|Delivered via the hypoxicator
62114812|NCT05214287|EXPERIMENTAL|Continuous for 45 minutes, FiO2 0.127 or 0.133|FiO2 0.127 or 0.133 (depending on SaO2 during screening procedure at FiO2 0.127, see study procedures)
62114813|NCT05214287|PLACEBO_COMPARATOR|Continuous for 45 minutes, FiO2 0.209|Delivered via an open three-way valve in the circuitry from hypoxicator to the participant
62114814|NCT01247337|EXPERIMENTAL|Single arm chemotherapy treatment|
62114815|NCT03058991|EXPERIMENTAL|Distress Tolerance Intervention|For the Distress Tolerance Intervention, the investigators will use a Mindfulness Based Stress Reduction (MBSR) program that has been adapted for use with adolescents. This version of MBSR follows closely the original conceptualization developed by Kabat-Zinn. The focus is on formal and informal mindfulness practices, which encourage participants to foster intention, attention and attitude. The investigators will make slight modifications to the delivery of the MBSR intervention to take into account the developmental period of their participants (e.g., attention span) to encourage retention and increase relevancy. These changes will also allow the investigators to match the duration with their Working Memory Intervention.
62303699|NCT05203627|EXPERIMENTAL|Arm I (telehealth session, guidebook)|Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.
62303700|NCT05203627|ACTIVE_COMPARATOR|Arm II (standard nutritional support)|Patients receive standard nutritional support.
62675273|NCT06126380|EXPERIMENTAL|AT-1501|AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg per os (orally) (PO) twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
62114816|NCT03058991|EXPERIMENTAL|Working Memory Intervention|"For the working memory training, the investigators will use the Cogmed RM program. Participants will be asked to use the program, while supervised twice a week, each time for an hour, for 8 weeks. Participants will also be asked to use the program on the other days for 25-35 minutes. The program resembles a video game, and comprises several different games that require visuo-spatial working memory (remembering the position of objects) and a combination of verbal and visual working memory (remembering phonemes, letters, and digits). The program adapts to the user's performance, such that trainees are able to perform at the limit of their ability, stimulating WM capacity adaptation."
62114817|NCT03058991|ACTIVE_COMPARATOR|Control Informational Intervention|This Control Informational Intervention has been used in the investigators' and other's previous studies. In the current application, it will match the session time of the Distress Tolerance and Working Memory interventions and will omit a focus on smoking (which is specific to the SPII intervention provided across all interventions), and will consist of discussions of a variety of healthy lifestyle topics, such as healthy eating, stress/time management, and recommended health screenings.
62114818|NCT05774717|EXPERIMENTAL|Tranexamic Acid|Patients receive 1 gram IV tranexamic acid in the operating room prior to surgical incision.
62114819|NCT05774717|NO_INTERVENTION|Control|Routine care, no tranexamic acid given.
62303701|NCT05290467|NO_INTERVENTION|control group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the control group. Participants will be scheduled for 12 routine ANC visits.
62303702|NCT05290467|EXPERIMENTAL|experimental group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the experimental group. Participants will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Message, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
62303703|NCT03244098|EXPERIMENTAL|Transition Assistance Program (TAP)|
62303704|NCT03244098|NO_INTERVENTION|Standard of Care|
62472387|NCT03751345|NO_INTERVENTION|Treatment As Usual (TAU)|The TAU condition consists of the standard treatment elements offered to all Gateway (study site) patients, and will be received by patients in both the PW and the TAU-only condition. TAU services during the adolescent's treatment are typically eclectic and mainly entail meeting with the adolescent alone to provide support and psychoeducation, with occasional family therapy sessions. Medication management is offered as needed.
62675274|NCT06126380|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
62303705|NCT00080327|ACTIVE_COMPARATOR|1|
62303706|NCT00080327|ACTIVE_COMPARATOR|2|
62303707|NCT00080327|ACTIVE_COMPARATOR|3|
62303708|NCT00080327|PLACEBO_COMPARATOR|4|
62303709|NCT04914338|EXPERIMENTAL|Supportive care (MDT-intervention)|Patients participate in the MDT-intervention including access to a HCT physician, a geriatrician, physical or occupational therapist, dietician, and a social worker for three months before HCT and up to 100 days after HCT.
62303710|NCT05858008|EXPERIMENTAL|Time-restricted eating|Participants will have baseline and post-study data collected, including activity/sleep data, metabolic parameters (fasting labs and anthropometric measurements), and cognitive testing. In addition, food timing will be collected throughout the study. Subjects will be educated about the potential health benefits of time-restricted eating and will self-select a 10-hr window, during which all daily calories will be consumed for 8 weeks.
62303711|NCT03261869|EXPERIMENTAL|Cold application|Cold applied after extraction of third molar tooth.
62303712|NCT03261869|NO_INTERVENTION|No Cold application|Cold application is not advised after extraction of third molar tooth
62472388|NCT03751345|EXPERIMENTAL|Parenting Wisely (PW)|In addition to TAU services, the PW arm includes in-person sessions where parents complete computer-administered PW sessions, in-person session including therapist coaching to reinforce PW material and personalize treatment by applying PW skills to individual issues, and access to PW material remotely so parents can access information and skills from home as needed.
62675275|NCT06501261|EXPERIMENTAL|CALM arm|patients receiving CALM sessions
62114820|NCT03954015|OTHER|patients over age 30 with suspicious BIRADS 4/5 Lesions|Patients who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with CEDM, CEMR and CEUS.
62114821|NCT02540551|EXPERIMENTAL|Sentinel node procedure.|Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.
62114822|NCT02655367|EXPERIMENTAL|Milled followed by flaked oats|Participant consumes test meal consisting of porridge made from milled oats on study day 1, followed by porridge made from flaked oats on study day 2
62303713|NCT01811030|EXPERIMENTAL|755nm Alexandrite Laser|755nm Alexandrite Laser
62303714|NCT04689308|EXPERIMENTAL|Part A: Dose Escalation and Determination of RP2D|Part A: Dose Escalation and determination of RP2D, multiple dose levels of MH048 to be evaluated
62303715|NCT04689308|EXPERIMENTAL|Part B: Dose Expansion in Selected Relapsed/Refractory B-cell Malignancies|Part B: Selected relapsed/refractory B-NHL subjects with at least 1 prior systemic OR standard-of-care therapy.
62472389|NCT05093491||Stroke patients|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio of stroke patients. Spirometry evaluation was performed by another investigator. Diagnostic Test: Bilaterally diaphragm and abdominal muscle thickness and thickening ratio with ultrasonography
62472390|NCT05093491||Healthy individuals|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio. Spirometry evaluation was performed by another investigator. Diagnostic Test: Dominant side diaphragm and abdominal muscle thickness and thickening ratio with ultrasonography
62675276|NCT03152890|EXPERIMENTAL|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
62675277|NCT02834442|EXPERIMENTAL|Single ascending dose, MT-7117 or Placebo|
62675278|NCT02834442|EXPERIMENTAL|Multiple ascending dose, MT-7117 or Placebo|
62675279|NCT04461535|EXPERIMENTAL|AVS with ACTH stimulation|Patients divided into AVS with ACTH stimulation group need to undergo stimulation with a continuous cosyntropin infusion.
62675280|NCT04461535|NO_INTERVENTION|AVS without ACTH stimulation|Patients divided into AVS without ACTH stimulation group take the same procedure of AVS with a continuous saline infusion.
62675281|NCT05688423|EXPERIMENTAL|SIRI Team|"The study intervention (SIRI Team) consists of a hospital-based multidisciplinary (ID/SUD consult) team that will provide intensive, integrated care for participants' ID and SUD both during the hospital stay and post-discharge for up to four months post-randomization. The SIRI Team will provide low barrier access to medications and harm reduction services for SUD; streamline ID/SUD treatment; provide longitudinal care with familiar providers; leverage different areas of expertise between physicians, advance practice providers, and patient navigators; and create patient-centered treatment plans, tailored to the individual, and informed by each patient's social circumstances, substance use, and personal goals/desires."
62675282|NCT05688423|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual (TAU) will consist of the current healthcare landscape at each participating hospital site.
62114823|NCT02655367|EXPERIMENTAL|Flaked followed by milled oats|Participant consumes test meal consisting of porridge made from flaked oats on study day 1, followed by porridge made from milled oats on study day 2
62114824|NCT04298606|EXPERIMENTAL|Prevention (recombinant human EGF-rP64K/montanide ISA 51)|"LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity."
62303716|NCT03920605|ACTIVE_COMPARATOR|Peginterferon alfa group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
62303717|NCT03920605|ACTIVE_COMPARATOR|Combination group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week and meanwhile oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive treatment of oral TDF 300 mg once per day from 49 to 144 weeks.
62303718|NCT04894383|EXPERIMENTAL|Prefabricated Orthotics in shoes & indoor comfort sandals with built-in arch support|Participants from Group A will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420\&search-button=\&lang=en_US) and an Aetrex comfort sandal with built-in arch support (https://www.aetrex.com/aetrex-flips-black-L3000M.html?lang=en_US or https://www.aetrex.com/fiji-flips-women-watermelon-L7009W.html?lang=en_US) according to participants shoe size. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the orthotic/comfort sandal wherever possible.
61917849|NCT02599805|EXPERIMENTAL|Natrox treatment group|In this group, all subjects will have the Natrox™ ODS will be applied to the ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. Dressings according to the standard practice guidelines will be used. Patients in this group will continue to receive treatment as described by the diabetic foot ulcer standard of care. The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software.
61917850|NCT02599805|NO_INTERVENTION|Control group|"All subjects in this group will receive the Diabetic foot ulcer standards of care which include:~* Full medical assessment in all cases.~* Surgical operation/Intervention where indicated.~* Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software."
61917851|NCT03141645|EXPERIMENTAL|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
61917852|NCT03141645|ACTIVE_COMPARATOR|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
61917853|NCT03141645|NO_INTERVENTION|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
61917854|NCT04859114|ACTIVE_COMPARATOR|Text-only outcome data, 30% survival|Participants in this arm are provided a repeat of the outcome data in a text-only format, displaying a 30% chance of survival.
62303719|NCT04894383|ACTIVE_COMPARATOR|Prefabricated Orthotics in shoes only|Group B will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420\&search-button=\&lang=en_US) alone. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the Orthotic wherever possible.
62303720|NCT04859946|EXPERIMENTAL|Supportive care (itacitinib)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3.~STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients also receive itacitinib PO QD on days 5-60 in the absence of disease progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby patients then receive tacrolimus PO BID."
62303721|NCT01475201|EXPERIMENTAL|Step Count Prescription Arm|The active trial arm intervention consists of usual care plus step count prescription delivered by the treating doctor, over a one-year period.
62675283|NCT04023474|EXPERIMENTAL|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft in clinic at the time any pertinent post-operative complication is identified.
61917855|NCT04859114|ACTIVE_COMPARATOR|Text-only outcome data, 60% survival|Participants in this arm view a repeat of the outcome data in a text-only format, displaying a 60% chance of survival.
61917856|NCT04859114|EXPERIMENTAL|Static pictograph outcome data, 30% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 30% chance of survival.
62114825|NCT04477538||Participants with prepectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
62114826|NCT04477538||Participants with postpectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
62114827|NCT02710929||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
62114828|NCT02710929||TD group|Typically development controls without lifetime diagnosis with ADHD
62114829|NCT03936348|EXPERIMENTAL|FB group|Participants who performed an exercise training program for 8 weeks using a nasal restriction device for inspiratory muscle training, called Feelbreathe®
62114830|NCT03936348|EXPERIMENTAL|ONB group|Participants who performed an exercise training program for 8 weeks with oronasal breathing without FB
62114831|NCT03936348|NO_INTERVENTION|control group (CG)|Participants who received the standard medical recommendations for patients with COPD, but not participated in the exercise intervention program
62114832|NCT05131386|EXPERIMENTAL|Multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas|"Premedication~4 mg oral dexamethasone 24h and 12h before trabectedin administration, 20 mg IV dexamethasone 30 minutes before treatment. Ondansetron or analogue will also be given prior to trabectedin.~Medication~Trabectedin at 1.5 mg/m2 24-h IV CI along with radiation therapy (30 Gy, 3 Gy/day for 10 days for non-extremity location and 45 Gy, 1.8 Gy/day for 25 days for extremity location of target lesion(s)), starting within 1 hour after the first trabectedin infusion withdrawal (day 2)) will be given every 3 weeks up to progression or intolerance."
61917857|NCT04859114|EXPERIMENTAL|Static pictograph outcome data, 60% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 60% chance of survival.
61917858|NCT04859114|EXPERIMENTAL|Iterative pictograph outcome data, 30% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 30% chance of survival.
62114833|NCT03815396|EXPERIMENTAL|Part 1 Single Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
62114834|NCT03815396|EXPERIMENTAL|Part 2 Multiple Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
62114835|NCT02928757|EXPERIMENTAL|Intervention Group|In addition to standard medical care, participants will be enrolled to be seen as soon as possible in a complex care clinic as part of the CCKO initiative.
62114836|NCT02928757|NO_INTERVENTION|Wait-list Group|The control group will receive usual care, but will be wait-listed for 1 year to be seen in a complex care clinic as part of the CCKO initiative.
62114837|NCT03814668|EXPERIMENTAL|Probiotic powder|One sachet of Probiotic powderwill be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
62303722|NCT01475201|ACTIVE_COMPARATOR|Usual care arm|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week). Consistent with clinical practice guidelines, our collaborating doctors have indicated that the usual care of the target population requires clinic visits at roughly three-month intervals to ensure vascular risk factor monitoring and management.
62303723|NCT00567931|EXPERIMENTAL|Treatment (Immunomodulating therapy)|Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62303724|NCT05600010||Study group|Detection of microplastics/nanoplastics in heart tissue and the blood of patients undergoing cardiac surgery
62472391|NCT03405454|ACTIVE_COMPARATOR|standard chemotherapy|Patients on physician's choice of chemotherapy are allowed to receive any systemic chemotherapy either as a single agent or in combination. However, biologics( including bevacizumab) and oral tyrosine kinase inhibitors will not be allowed for patients on this arm
62114838|NCT03814668|ACTIVE_COMPARATOR|Lactase|One sachet of Lactase powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
62114839|NCT03814668|PLACEBO_COMPARATOR|Placebo|One sachet of placebo powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
62114840|NCT03301454|EXPERIMENTAL|Arm A|Pursuit of chemotherapy.
62114841|NCT03301454|NO_INTERVENTION|Arm B|Interruption of chemotherapy, best supportive care
62114842|NCT00932022|EXPERIMENTAL|trospium chloride XR 60 mg|Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
62114843|NCT00932022|PLACEBO_COMPARATOR|placebo|Placebo capsule taken orally once daily for 14 weeks.
62114844|NCT03279718|EXPERIMENTAL|periodontal treatment|
61917859|NCT04859114|EXPERIMENTAL|Iterative pictograph outcome data, 60% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 60% chance of survival.
62114845|NCT03279718|NO_INTERVENTION|only oral hygiene instruction, no treatment|
62114846|NCT02525510|ACTIVE_COMPARATOR|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.
62303725|NCT04006769|EXPERIMENTAL|Entacapone & Imatinib mesylate|"Entacapone 200mg tablet (Orion pharma,Switzerland) by mouth, three times a day and then escalated to final dose of 1.0 grams three times per day within one week, until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.~And Imatinib mesylate 400mg tablet by mouth, once a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first."
62472392|NCT03405454|EXPERIMENTAL|durvalumab|Patients on durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months
62472393|NCT01507337|EXPERIMENTAL|Elderly|
62114847|NCT02525510|ACTIVE_COMPARATOR|Pump Eligible - Hypothermia and Pump Right Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
62114848|NCT02525510|ACTIVE_COMPARATOR|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
62114849|NCT02525510|ACTIVE_COMPARATOR|Not Pump Eligible - Normothermia|Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.
62114850|NCT02525510|ACTIVE_COMPARATOR|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
62114851|NCT03496649|EXPERIMENTAL|Dysport|"Dysport administration by intramuscular injection Each patient will receive one dose of Dysport at Visit 1.~At least 2 of the 4 muscles below will be injected, depending on which muscles are affected:~250 IU for the gracilis muscle 200 IU for the pectineus muscle 300 IU for the adductor longus muscle 200 IU for the adductor brevis muscle~These injections will be uni or bilateral, it will depend on clinical diagnosis.~If necessary, the 4 muscles will be injected with a maximum of 1500U Dysport. The total dose cannot exceed 1500 units."
62114852|NCT06454734|EXPERIMENTAL|DLT + ESWT|To DLT + ESWT group, decongestive lymphatic therapy (DLT) plus radial extracorporeal wave treatment (ESWT) will be applied, at a dose and intensity probed to be useful to diminish volume in upper limb lymphedema.
62472394|NCT01507337|EXPERIMENTAL|Young|
62303726|NCT02803502|EXPERIMENTAL|hemophilia|Patients with severe hemophilia (or moderate hemophilia if presence of hemorrhages) under prophylaxy and subjected to a pharmacokinetic profile of factor VIII
62303727|NCT00060892|ACTIVE_COMPARATOR|1|0.4 mg AMG0001 on days 0, 14, and 28
62472395|NCT06562777||Observational|Patients complete surveys and have their medical records reviewed on study.
62472396|NCT02081612|ACTIVE_COMPARATOR|Nutrition Education|Educational weight management group sessions alone
62472397|NCT02081612|ACTIVE_COMPARATOR|Nutrition Education Plus Acupuncture|Educational weight management group sessions in addition to weight loss acupuncture
62472398|NCT00993122|ACTIVE_COMPARATOR|ribavirin pre-treatment|patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
61917860|NCT04958512|OTHER|blank control group|
61917861|NCT04958512|EXPERIMENTAL|treatment group(Yangxue Qingnao pill)|
61917862|NCT04958512|ACTIVE_COMPARATOR|control group(hidezhen)|
62472399|NCT00993122|ACTIVE_COMPARATOR|combined stardard therapy|patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
62472400|NCT03547622|ACTIVE_COMPARATOR|MAT taper with galantamine|Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
62303728|NCT00060892|ACTIVE_COMPARATOR|2|4.0 mg AMG0001 on days 0, 14, and 28
62303729|NCT00060892|ACTIVE_COMPARATOR|3|4.0 mg AMG0001 on days 0 and 28; placebo on day 14
62303730|NCT00060892|PLACEBO_COMPARATOR|4|Placebo (saline) on days 0, 14, and 28
62303731|NCT03731715|EXPERIMENTAL|Cohort I|Subjects ≥18 years of age. Carisbamate, 200 mg, will be administered on Day 1 and 2 of the single-dose period. Carisbamate will be administered at 100 mg twice daily (BID) during the multiple-dose period.
62303732|NCT03731715|EXPERIMENTAL|Cohort II|Subjects 12 to \<18 years of age. Carisbamate, 140 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 70 mg twice daily (BID) during the multiple-dose period.
62303733|NCT03731715|EXPERIMENTAL|Cohort III|Subjects 6 to \<12 years of age. Carisbamate, 60 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 30 mg twice daily (BID) during the multiple-dose period.
62303734|NCT03731715|EXPERIMENTAL|Cohort IV|Subjects 2 to \<6 years of age. The starting doses for the single dose and multiple-dose periods will be based on the PK and safety results of the first 3 cohorts.
62303735|NCT01645163|EXPERIMENTAL|Mobile phone counselling|
62303736|NCT05856864|EXPERIMENTAL|Cadonilimab in Combination With Ramucirumab|Cadonilimab Injection 10mg/kg, intravenous drip ,q2w,
62472401|NCT03547622|PLACEBO_COMPARATOR|MAT taper with placebo|Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
62472402|NCT01067963|EXPERIMENTAL|Behavioral-education/counseling|"Computer assisted education and telephone counseling using motivational interviewing.~Computer assisted education and motivational interviewing"
62303737|NCT02366962|EXPERIMENTAL|ASP7374 group|
62303738|NCT00467883|EXPERIMENTAL|amphotericin B|Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks
62303739|NCT01390168|EXPERIMENTAL|tailored internet-administrated CBT|Behavioral: tailored internet-administrated CBT
62303740|NCT01390168|ACTIVE_COMPARATOR|waitlist|waitlist
62303741|NCT04402489|PLACEBO_COMPARATOR|Placebo Comparator|Oral tablet of placebo once a day.
62303742|NCT04402489|EXPERIMENTAL|MT-7117 Low Dose|Oral tablet of MT-7117 Low Dose once a day.
62303743|NCT04402489|EXPERIMENTAL|MT-7117 High Dose|Oral tablet of MT-7117 High Dose once a day.
62303744|NCT02259231|EXPERIMENTAL|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
62303745|NCT02259231|EXPERIMENTAL|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
62303746|NCT02259231|EXPERIMENTAL|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
62303747|NCT02259231|EXPERIMENTAL|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
62303748|NCT02259231|EXPERIMENTAL|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
62303749|NCT02259231|EXPERIMENTAL|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
62472403|NCT01067963|PLACEBO_COMPARATOR|Group talks/social chat|Group session talks on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
62472404|NCT01274039||Patient with a trabeculectomy planed|
62472405|NCT01424761|EXPERIMENTAL|Placebo|Placebo:starch
62114853|NCT06454734|SHAM_COMPARATOR|DLT + Sham ESWT|To DLT + Sham ESWT group, decongestive lymphatic therapy plus sham radial extracorporeal wave treatment will be applied, at a placebo dose and intensity.
62114854|NCT00339989||Women undergoing colposcopy|women attending the University of Oklahoma Colposcopy Clinic
62114855|NCT01946035|PLACEBO_COMPARATOR|Placebo|Participants will take 1 capsule placebo each evening
62114856|NCT01946035|EXPERIMENTAL|Doxazosin XL|Participants will take 1 capsule Doxazosin 4mg XL each evening
62114857|NCT02508896|EXPERIMENTAL|AFFITOPE® AT04A+adjuvant|3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
62114858|NCT02508896|EXPERIMENTAL|AFFITOPE® AT06A+adjuvant|3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
62114859|NCT02508896|PLACEBO_COMPARATOR|Adjuvant without active component|3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization
62114860|NCT01362920||Sepsis or Septic shock cohort|
62114861|NCT01362920||Non-sepsis or non-Septic shock cohort|
62114862|NCT05647980|EXPERIMENTAL|TACTIC|"Participants in the TACTIC intervention will be provided a 3-step approach, i.e.~1. an online information video to inform patients about the cardiovascular risks of antipsychotic use and the procedures of the multidisciplinary meeting~2. a multidisciplinary meeting with their general practitioner, the primary care nurse, a psychiatrist, and an experience expert to discuss cardiovascular risk and side effect and to provide personalised treatment options~3. a consultation with their general practitioner to translate treatment options into an individualised treatment plan including lifestyle and medication treatment and monitoring frequency, based on shared-decision making"
62472406|NCT01424761|EXPERIMENTAL|Coenzyme Q10|
62472407|NCT04808648|EXPERIMENTAL|Itraconazole and SH-1028|In the itraconazole study, patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.
62303750|NCT02259231|EXPERIMENTAL|Omaveloxolone 150 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
62675284|NCT04023474|NO_INTERVENTION|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
62675285|NCT05706675|EXPERIMENTAL|Experimental|Periodontitis patients that will be treatyed with Non surgical Periodontal Therapy
62675286|NCT05706675|NO_INTERVENTION|Control|Periodontally healthy patients
62114863|NCT05647980|NO_INTERVENTION|Care as usual|Care as usual, i.e. renewal of prescriptions for antipsychotics by the general practitioner without multidisciplinary treatment advice and without the use of scheduled and structured monitoring visits.
62303751|NCT06495710|EXPERIMENTAL|Intensive BP targets|\<120 mmHg systolic)
62303752|NCT06495710|ACTIVE_COMPARATOR|Standard blood pressure targets|\<140 mmHg systolic
62303753|NCT03560440||Plasma exposure vancomycin|Pediatric patients treated with vancomycin
62114864|NCT04333329|EXPERIMENTAL|AD Patients|"All patients were treated with the TPS device (new name: NEUROLITH (Storz Medical AG))~- 6 sessions within 2 weeks, each sessions consisting of 6000 TPS pulses of 0.2 mJ/mm²"
62675287|NCT00689052|EXPERIMENTAL|Pramipexole ER|0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
62114865|NCT05206630|EXPERIMENTAL|Embedded ED Physical Therapy|An ED physical therapist will be embedded with the primary treatment team to evaluate patients presenting with low back pain at the beginning of the overall treatment course. The physical therapist will utilize a clinical protocol that matches the patient's history and exam findings to an appropriate treatment classification consisting of directional preference exercises, manual traction, stabilization exercises, non-thrust manipulation/mobilization, and/or psychologically informed rehabilitation. The embedded PT intervention will supplement any usual care performed by the treating physician.
62114866|NCT05206630|NO_INTERVENTION|Usual Care|Usual care consists of any ED testing or treatment not involving an ED physical therapist in accordance with the treating physician's usual and customary practice. This could include diagnostic imaging, patient education and reassurance, and administration and/or prescribing of analgesic medications.
62114867|NCT04238000|ACTIVE_COMPARATOR|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
62303754|NCT01895686||Open angle glaucoma|patients diagnosed with open angle glaucoma
62303755|NCT01895686||Narrow angle|patients diagnosed with narrow angles
62303756|NCT01895686||Angle Closure Glaucoma|patients diagnosed with angle closure glaucoma
62303757|NCT02303587|EXPERIMENTAL|low dose group|methylprednisolone 2mg-4mg/Kg
62675288|NCT00689052|PLACEBO_COMPARATOR|Placebo|Placebo tablets, once daily in the evening
62675289|NCT01819480|EXPERIMENTAL|Transoral robotic surgery|Transoral robotic surgery
62675290|NCT03987607||Patients scheduled for elective surgery|Patients scheduled for elective surgery requiring neuromuscular blockade
62675291|NCT03302936|EXPERIMENTAL|Pyridium arm|Phenazopyridine 200mg tablet, once prior to surgery
62675292|NCT03302936|NO_INTERVENTION|Control arm|No intervention in this group. Routine perioperative care.
62675293|NCT03779854|EXPERIMENTAL|Arm I (chemotherapy, naive T-cell depleted PBSC)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.~TRANSPLANT: Patients receive naive T-cell depleted PBSCs on day 0.~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11.~Additionally, patients undergo ECHO and CSF collection at baseline as well as blood sample collection and bone marrow aspiration with or without biopsy throughout the trial."
62675294|NCT03779854|ACTIVE_COMPARATOR|Arm II (chemotherapy, unmanipulated T cell replete BM)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.~TRANSPLANT: Patients receive unmanipulated T cell-replete BM on day 0.~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11.~Additionally, patients undergo ECHO and CSF collection at baseline as well as blood sample collection and bone marrow aspiration with or without biopsy throughout the trial."
62675295|NCT03237312|OTHER|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
62303758|NCT02303587|EXPERIMENTAL|high dose group|methylprednisolone 10mg/Kg
62303759|NCT03501576||Inactivated Influenza Vaccine|Patients will be vaccinated with an FDA approved seasonal inactivated influenza vaccine
62303760|NCT03501576||Qualifying subjects to receive a SARS-CoV2 vaccine.|Patients receive a SARS-CoV2 vaccine.
62303761|NCT03501576||Clinical Group Receiving SARS-CoV2 Booster Vaccines|Patients receive a SARS-CoV2 vaccine.
62303762|NCT00484354|ACTIVE_COMPARATOR|1|Bicarbonate administration
62303763|NCT00484354|PLACEBO_COMPARATOR|2|Normal saline administration
62303764|NCT03864354||Participants|Participants were adults with a diagnosis of asthma, treated using a standardized Osteopathic Manipulative Treatment protocol.
62303765|NCT02463942|ACTIVE_COMPARATOR|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
62472408|NCT04808648|EXPERIMENTAL|Rifampicin and SH-1028|In the rifampicin study, patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16
62472409|NCT03134586|OTHER|trial participant|All participants undergoes the same diagnostic imaging
62675296|NCT03237312|OTHER|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
62675297|NCT05777278|EXPERIMENTAL|Savolitinib Plus Docetaxel|Single Arm
62675298|NCT01081938|EXPERIMENTAL|1|Insulin Glargine + Insulin Glulisine
62303766|NCT02463942|OTHER|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
62472410|NCT04203147|EXPERIMENTAL|Home DM-BAT Intervention|A trained nurse educator will deliver the manualized Home DM-BAT intervention. Subjects will receive 8-weekly sessions of behavioral activation and monthly booster sessions from months 3-12 via telephone.
62472411|NCT04203147|ACTIVE_COMPARATOR|Control Group (GHE+ST)|Patients randomized to the control group will receive in-home 8-weekly sessions of combined general health education (GHE) and supportive therapy (ST) and monthly booster sessions from months 3-12 via telephone.
62472412|NCT02255708|OTHER|Healthy group.|Group formed by healthy patients.
62472413|NCT02255708|OTHER|Group with demyelinating polyneuropathy|Group formed by patients with demyelinating polyneuropathy.
62675299|NCT01081938|ACTIVE_COMPARATOR|2|Insulin Glulisine
62472414|NCT05281341|EXPERIMENTAL|Poseidon Group 4A & 3A|80 eligible infertile women fulfilling the criteria of Poseidon Group 4 (35 years or more and AMH \<1.2ng/ml) will be randomized into Group 4A will receive controlled ovarian stimulation (COS) and growth hormone (GH) and Group 4B will receive COS only. Similarly, 80 eligible infertile women fulfilling the criteria of Poseidon Group 3 (less than 35 years and AMH \<1.2ng/ml) will be randomized into Group 3A will receive COS and GH and Group 3B will receive COS only.
62675300|NCT00721890|EXPERIMENTAL|1|
62675301|NCT01624207|EXPERIMENTAL|Atorva|generic formulation (Atorva®) of atorvastatin 20mg once daily
62675302|NCT01624207|ACTIVE_COMPARATOR|Lipitor|branded formulation (Lipitor®) of atorvastatin 20mg once daily
62675303|NCT02203760|EXPERIMENTAL|Pazopanib plus Gemcitabine|Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
62675304|NCT02203760|ACTIVE_COMPARATOR|Pazopanib|Pazopanib 800 mg orally once daily
62675305|NCT06016790||the cancer group|200 cases of early breast cancer (stage I-IIa breast cancer, and breast carcinoma in situ) and 80 cases of middle and advanced breast cancer (stage IIb, IIc, III, IV)
62675306|NCT06016790||the benign control group|200 cases of control group (100 cases of breast hyperplasia, 100 cases of breast fibroma)
62472415|NCT05281341|NO_INTERVENTION|poseidon Group 4B & 3B|80 eligible infertile women fulfilling the criteria of Poseidon Group 4 (35 years or more and AMH \<1.2ng/ml) will be randomized into Group 4A will receive controlled ovarian stimulation (COS) and growth hormone (GH) and Group 4B will receive COS only. Similarly, 80 eligible infertile women fulfilling the criteria of Poseidon Group 3 (less than 35 years and AMH \<1.2ng/ml) will be randomized into Group 3A will receive COS and GH and Group 3B will receive COS only.
62114868|NCT04238000|PLACEBO_COMPARATOR|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
62114869|NCT04353830|EXPERIMENTAL|Phase Ia Dose-Escalation Stage:IBI939|Participants will be treated with escalating doses of IBI939 to determine the MTD.
62114870|NCT04353830|EXPERIMENTAL|Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab|Participants will be treated with escalating doses of IBI939 in combination with a fixed dose of Sintilimab to determine the MTD.
62114871|NCT04353830|EXPERIMENTAL|Phase Ib Expansion Stage:IBI939+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI939 in combination with Sintilimab in different cancer types.
62114872|NCT00547118|EXPERIMENTAL|1|Rimonabant
62114873|NCT00547118|PLACEBO_COMPARATOR|2|Placebo
62114874|NCT02203630|ACTIVE_COMPARATOR|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
62114875|NCT02203630|ACTIVE_COMPARATOR|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
62114876|NCT02311972|ACTIVE_COMPARATOR|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
62114877|NCT02311972|ACTIVE_COMPARATOR|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
62114878|NCT01486550|ACTIVE_COMPARATOR|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
62114879|NCT01486550|PLACEBO_COMPARATOR|Sodium Chloride 9mg/ml|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
62114880|NCT03856541|EXPERIMENTAL|SHR-A1403 Dose Escalation|SHR-A1403 given intravenously (IV).
62114881|NCT00873691||1|ICD shocks programmed to Tuned Waveform
62114882|NCT00873691||2|ICD shocks programmed to 50% Tilt waveform
62114883|NCT05721612|EXPERIMENTAL|Study group|
62114884|NCT05721612|ACTIVE_COMPARATOR|Control gorup|
62114885|NCT04584450||1|COVID-19 survivors.
62114886|NCT02833272|EXPERIMENTAL|EMPOWER Educational Brochure|This is the only arm of the study. All participants will undergo the intervention, which is an educational brochure (EMPOWER educational brochure) to explain the possible harms of benzodiazepine and non-benzodiazepine sedative drugs.
62114887|NCT04028336|EXPERIMENTAL|TITRATION|"All patients hospitalized in intensive care and meeting inclusion criteria and without criteria for non-inclusion will be included in this study. All patients will benefit from Lung ultrasound (LUS) and esophageal pressure measurement (Peso) according to the habits of the service. A PEP titration pulmonary opening (PEP-OP) test using a recruitment maneuver was then performed in all patients followed by a new LUS and Peso measurement."
62114888|NCT00630188|EXPERIMENTAL|1|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with physician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
62675307|NCT06696027||Giant Cell Arteritis (GCA)|Patients with GCA (cross sectional, newly diagnosed with follow-up after twelve months).
62675308|NCT06696027||Polymyalgia Rheumatica (PMR)|Patients with PMR (cross sectional, newly diagnosed with follow-up after twelve months).
62114889|NCT00630188|ACTIVE_COMPARATOR|2|Highway Safety video
62472416|NCT04018482|EXPERIMENTAL|Open label test arm|Subjects will have their right eye treated with 5% Povidone Iodine per standard institutional protocol prior to receiving their intravitreal injection (2 drops of PI followed by application of 3.5% non-preserved lidocaine gel for 10 minutes, followed by 1 drop of PI for 30 seconds prior to injection). Subjects will have their left eye treated with Avenova per the same application protocol as PI prior to receiving their intravitreal injection. Prior to and following disinfecting both eyes but before the injection, a physician will gently swab the inferior conjunctival fornix (white part of each eye below the lower eye lid) with an ocular brush. Swabs will be cultured to compare bacterial counts. Subjects will be asked to complete a questionnaire regarding comfort of the disinfectant and injection procedure in general immediately following the injection and 1-2 hours post-injection.
62472417|NCT03760939|EXPERIMENTAL|Ambulatory care|Colorectal surgery in ambulatory care
62472418|NCT03760939|OTHER|Standard hospitalization|Colorectal surgery with standard hospitalization for retrospective patients who benefit from the ERAS program, selected by statistical matching.
62472419|NCT03977272|ACTIVE_COMPARATOR|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
62675309|NCT06696027||ANCA Associated Vasculitis (AAV)|Patients with AAV (cross sectional, newly diagnosed with follow-up after twelve months).
62114890|NCT05250895|EXPERIMENTAL|Diagnostic (18F-fluoromisonidazole, PET, DCE MRI)|Patients receive 18F-fluoromisonidazole IV and undergo PET and DCE MRI within 30 days before beginning Y90 SIRT. Patients undergo Y90 SIRT per standard of care.
62114891|NCT00814346|ACTIVE_COMPARATOR|EGb 120 mg|
62114892|NCT00814346|PLACEBO_COMPARATOR|Placebo|
62114893|NCT04589000|EXPERIMENTAL|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
62114894|NCT04589000|NO_INTERVENTION|control|No accupressure will be applied. Milk will be expressed for a total of 15 minutes, 1 time on the post-op 0th day, 2 times on the post-op 1st day and once on the post-op 2nd day for a total of 15 minutes and will be recorded in the milk measurement table.
62114895|NCT05566145||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
62114896|NCT05566145||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
62114897|NCT05786456|EXPERIMENTAL|Supportive Care (DBD)|Patients receive DBD intervention consisting of group and web-based self-study sessions and check-in calls on study. Patients also watch videos and receive handouts to reinforce the group sessions.
62114898|NCT05773326|EXPERIMENTAL|Single infusion of Temsirolimus|Single infusion of Temsirolimus via super-selective intra-arterial infusion or IV
62114899|NCT04926571||Dexamethasone versus non-users of corticosteroids|
62114900|NCT04926571||Dexamethasone versus non-users of dexamethasone|
62114901|NCT04926571||Dexamethasone versus methylprednisolone active comparator|
62114902|NCT00829348|NO_INTERVENTION|Statins, counseling|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
62114903|NCT00829348|EXPERIMENTAL|Statins, Counselling, SMS|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
62114904|NCT04357236||Experimental Group|The experimental group received 18F-FDG PET examination
62114905|NCT04357236||Control Group|The control group received 18F-FDG PET examination
62114906|NCT02219919|EXPERIMENTAL|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
62114907|NCT02219919|ACTIVE_COMPARATOR|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
62114908|NCT04645069|EXPERIMENTAL|ADG126 mono dose escalation|ADG126 monotherapy dose escalation will be traditional 3+3 cohort design.
62303767|NCT02463942|OTHER|Healthy controls|"Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.~Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia."
62114909|NCT04645069|EXPERIMENTAL|ADG126 mono dose expansion|Monotherapy dose expansion is designed to evaluate the preliminary antitumor activity of ADG126 at RP2D or the doses approved by the SRC.
62114910|NCT04645069|EXPERIMENTAL|ADG126-anti PD1 drug dose escalation|Combination therapy will commence at a dose level lower than the cleared dose from the monotherapy dose escalation arms and approved by the SRC.
62114911|NCT04645069|EXPERIMENTAL|ADG126-anti PD1 drug dose expansion|Combination therapy expansion will commence at RP2D or the dose approved by the SRC.
62114912|NCT04645069|EXPERIMENTAL|ADG126-ADG106 dose escalation|Combination therapy will commence at a dose level lower than the cleared dose from the monotherapy dose escalation arms and approved by the SRC.
62114913|NCT04645069|EXPERIMENTAL|ADG126-ADG106 dose expansion|Combination therapy expansion will commence at RP2D or the dose approved by the SRC.
62114914|NCT04009642||Type 2 Diabetes|
62114915|NCT04009642||Non Diabetic|
62114916|NCT03895034|EXPERIMENTAL|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
62303768|NCT00440401|ACTIVE_COMPARATOR|TachoSil®|
62303769|NCT00440401|ACTIVE_COMPARATOR|Standard Treatment|Standard Treatment of haemorrhage in cardiovascular surgery
62303770|NCT02542995|NO_INTERVENTION|Non-intervention|Usual clinical conditions
62114917|NCT04076202|EXPERIMENTAL|Cementless Vanguard DD RP|Patients receiving a total knee prosthesis
62114918|NCT03709719|EXPERIMENTAL|blinatumomab|
62114919|NCT00422019|EXPERIMENTAL|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
62114920|NCT00422019|EXPERIMENTAL|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.
62114921|NCT00015990|EXPERIMENTAL|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.
62114922|NCT05047341|EXPERIMENTAL|Single arm|
62303771|NCT02542995|OTHER|Intevention|"QI interventions and got to see their own survey data - examples include:~Workflow redesign:~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms~Communication improvement:~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders~Chronic disease QI projects:~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
62303772|NCT04269408|EXPERIMENTAL|NicaPlant®|"10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.~In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines."
62303773|NCT04269408|OTHER|Control|Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.
62303774|NCT06433115|EXPERIMENTAL|Lean (93%) Grass-Fed Beef|The quantity of beef will be adjusted or normalized based on their individual energy requirements. The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal. Participants will consume meals for six weeks.
62303775|NCT06433115|EXPERIMENTAL|Lean (93%) Grain-Fed Beef|The quantity of beef will be adjusted or normalized based on their individual energy requirements. The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal. Participants will consume meals for six weeks.
62303776|NCT06433115|ACTIVE_COMPARATOR|Plant-Based Meat|Plant-based meat (beyond meat product) would be macronutrient matched to the same quantities of meat prescribed for a given energy level. Participants will consume meals for six weeks.
62303777|NCT03646019||Normal coronary arteries|
62303778|NCT03646019||Non significant coronary artery disease|
62303779|NCT03646019||Significant coronary artery disease|
62303780|NCT01925521|EXPERIMENTAL|Part1 : OPS-2071|Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
62303781|NCT01925521|PLACEBO_COMPARATOR|Part1 : Placebo of OPS-2071|Single dose, Placebo
62303782|NCT01925521|EXPERIMENTAL|Part2 : OPS-2071|Multiple dose
62303783|NCT01925521|PLACEBO_COMPARATOR|Part2 : Placebo of OPS-2071|Multiple doses, Placebo
62303784|NCT01860170|ACTIVE_COMPARATOR|Cohort 1-Bortezomib (Velcade®)|Bortezomib (Velcade®) 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
62472420|NCT03977272|EXPERIMENTAL|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2, Anti-PD-1 antibody 200mg.
62114923|NCT04306354|EXPERIMENTAL|Conventional oxytocin treatment (T + OC)|32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
62114924|NCT04306354|PLACEBO_COMPARATOR|Conventional treatment with placebo administration (T + PBO)|32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
62114925|NCT04306354|NO_INTERVENTION|Conventional treatment (T)|32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization.
62114926|NCT06056908||Patients with SDS/SDS-Like conditions and their families|
62303785|NCT01860170|ACTIVE_COMPARATOR|Cohort 2-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
62303786|NCT01860170|ACTIVE_COMPARATOR|Cohort 3-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
62303787|NCT00885469||1|Patients with known Barrett's Esophagus or chronic GERD
62303788|NCT02140463||metastatic cancer|metastatic gastrointestinal cancer metastatic genitourinary cancer other rare cancer lung cancer
62303789|NCT03554512|NO_INTERVENTION|Standard of Care|No Intervention
62303790|NCT03554512|EXPERIMENTAL|Telehealth|Telehealth virtual appointment
62303791|NCT00815971||NSCLC|Patients with non-small cell lung cancer carcinoma treated with erlotinib
62303792|NCT01090557||RSV positive subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are positive for RSV by Direct Fluorescent Antibody technique and/or viral culture
62303793|NCT01090557||RSV negative subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are negative for RSV by Direct Fluorescent Antibody technique and/or viral culture (usually positive for influenza A \& B, parainfluenza, human metapneumovirus or adenovirus)
62303794|NCT01090557||Control group|Children with same age range, ethnic background, and gender distribution as the study group coming for evaluation in the outpatient setting without evidence of viral infection
62303795|NCT01099345||Group 1 - OAB with DO+|Subjects that DO+ nocturia
62303796|NCT01099345||Group 2- OAB with DO-|Subjects that DO- nocturia
62303797|NCT00837538||Back pain|Persons with back pain and supposed instability of lumbar spine
62303798|NCT02711371||Cannabis Dependence|Cannabis dependent individuals according to DSM 4 criteria, aged 18-40 years
62472421|NCT00849030|ACTIVE_COMPARATOR|1|Arimidex 1mg + Nolvadex placebo
62472422|NCT00849030|ACTIVE_COMPARATOR|2|Arimidex placebo + Nolvadex 20mg
62472423|NCT00849030|ACTIVE_COMPARATOR|3|Arimidex 1mg + Nolvadex 20mg
62472424|NCT01183910|PLACEBO_COMPARATOR|Calcium carbonate placebo pill|Placebo medication to treat the appearance of the skin in patients with senile purpura
62472425|NCT01183910|ACTIVE_COMPARATOR|Nutraceutical|Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
62472426|NCT00185458|EXPERIMENTAL|LNG IUS|Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
62472427|NCT01370733|EXPERIMENTAL|Active sTMS|Treatment with the NEST-1 Device
62472428|NCT01370733|SHAM_COMPARATOR|Sham|Treatment with a sham (inactive) device, identical in sound and appearance to the NEST-1 Device
62472429|NCT01274988|EXPERIMENTAL|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
62472430|NCT01274988|ACTIVE_COMPARATOR|Standard Control|methadone maintenance treatment
62114927|NCT05266599|ACTIVE_COMPARATOR|MTA Fillapex group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. MTA Fillapex sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
62472431|NCT03282162|EXPERIMENTAL|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
62675310|NCT06696027||IgG4 Related Diseases|Patients with IgG4 Related Diseases (cross sectional, newly diagnosed with follow-up after twelve months).
62675311|NCT06696027||Idiopathic Inflammatory Myopathies (IIM)|Patients with IIM (cross sectional, newly diagnosed with follow-up after twelve months).
62675312|NCT06696027||Rheumatoid Arthritis (RA)|Patients with RA (cross sectional, newly diagnosed with follow-up after twelve months).
62675313|NCT06696027||Psoriatic Arthritis (PsA)|Patients with PsA (cross sectional, newly diagnosed with follow-up after twelve months).
62675314|NCT06696027||Connective Tissue Diseases (CTD)|Patients with CTD (cross sectional, newly diagnosed with follow-up after twelve months).
62675315|NCT06696027||Sarcoidosis|Patients with sarcoidosis (cross sectional, newly diagnosed with follow-up after twelve months).
62114928|NCT05266599|ACTIVE_COMPARATOR|AH Plus group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. AH Plus sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
62114929|NCT05022251||Lumbar radiculopathy|Lumbar radiculopathy patients (n=122), classified as ASA I to II without any symptoms of spinal cord compression (i.e. bilateral leg pain), who are scheduled for a first-time, single-level, unilateral lumbar discectomy.
62114930|NCT05022251||Healthy controls|Sex, age, and BMI-matched healthy, pain-free control subjects (n=122) will be recruited for study participation.
62114931|NCT00978237|ACTIVE_COMPARATOR|EFV and Fixed combinations of analogues|EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
62114932|NCT00978237|EXPERIMENTAL|LPV/r and combination of analogues.|
62114933|NCT01830010|EXPERIMENTAL|Study Part 1: KRP203|All patients to receive KRP203 for 111days
62114934|NCT01830010|EXPERIMENTAL|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
62114935|NCT01830010|EXPERIMENTAL|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
62303799|NCT02711371||Healthy|Healthy controls, socio-demographically matched
62303800|NCT04914897|EXPERIMENTAL|Cohort A1: Non-small cell lung cancer 1rst line therapy with Tumor proportion score > 50%|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
62303801|NCT04914897|EXPERIMENTAL|Cohort A2: Non-small cell lung cancer 1rst line therapy with Tumor proportion score 1-49%|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
62303802|NCT04914897|EXPERIMENTAL|Cohort B1: Non-small cell lung cancer 2/3rd line therapy|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
62472432|NCT03282162|EXPERIMENTAL|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
62472433|NCT03239314|ACTIVE_COMPARATOR|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
62472434|NCT03239314|ACTIVE_COMPARATOR|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
62472435|NCT01051765|EXPERIMENTAL|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin: 30mg/m2, d1,d2 every three weeks
62303803|NCT04914897|EXPERIMENTAL|Cohort C1: :Mesotheloma 2/3rd line therapy|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
62114936|NCT04438668|ACTIVE_COMPARATOR|Standard Care|Standard care (SC) for screening for FGR is a healthcare provider auscultating the foetal heart rate with a standard stethoscope, palpation of foetal size by hand, and measuring the size of the woman's uterus with a tape measure, and comparing the measurement to the expected measurement for the gestational age of the foetus.
62114937|NCT04438668|EXPERIMENTAL|Standard Care and Centaflow|Centaflow uses sound-derived maternal intra-arterial turbulence as a marker of foetal growth restriction (FGR) and provides information on the foetal heart rate. Indication for use is as a screening device for FGR in women beyond 27 weeks of pregnancy with a singleton pregnancy.
62114938|NCT01569919|EXPERIMENTAL|TroVax®|In this single-arm study, all participants will receive 9 injections of the TroVax® vaccine, plus standard cisplatin and pemetrexed chemotherapy.
62114939|NCT01671124||Soline capsule|Salvia divinorum, Lycium, Chenpi and Dihuang
62114940|NCT01623336|ACTIVE_COMPARATOR|Pegasys ®|Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
62114941|NCT01623336|EXPERIMENTAL|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
62303804|NCT06340711|EXPERIMENTAL|OBP-301 Plus Pembrolizumab|All participants will receive 4 intratumoral injections of OBP-301 with each injection occurring approximately 2 weeks apart. All participants will also receive infusions of pembrolizumab every 6 weeks until disease progression or for a maximum of 2 years.
62303805|NCT01673061|ACTIVE_COMPARATOR|Lidocaine|Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
62114942|NCT06383546||Atrial septal defect|
62114943|NCT06383546||Pulmonary hypertension|
62114944|NCT06383546||Control|
62303806|NCT01673061|ACTIVE_COMPARATOR|Vapocoolant|Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.
62303807|NCT03135093||Stroke subjects|
62303808|NCT03135093||Healthy subjects|
62303809|NCT04936932|ACTIVE_COMPARATOR|Standard|1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
62114945|NCT04875130||confirmed pulmonary embolism|"* Patients with intermediate high and high risk of an acute pulmonary embolism with clinical symptoms.~* On image based procedures confirmed pulmonary embolism (TTE, contrast CT-angiography).~* Age under 18.~* Written agreement to the examination."
62114946|NCT05983107|EXPERIMENTAL|cohort 1 PIK3CA Mutant|Everolimus combined with endocrine therapy
62303810|NCT04936932|ACTIVE_COMPARATOR|Slow|1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
62303811|NCT03958201|OTHER|Protocol|Patients will have perioperative neuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed objectively at adductor pollicis with quantitative neuromuscular monitoring.
62303812|NCT02621333|EXPERIMENTAL|CIK combined chemotherapy group|autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.
62114947|NCT05983107|EXPERIMENTAL|cohort 2 PIK3CA wild type|chidamide combined with endocrine therapy
62303813|NCT02621333|ACTIVE_COMPARATOR|chemotherapy group|platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.
62303814|NCT05928741|EXPERIMENTAL|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast after a 12-hour fast. Two hours later they were given 50 g of available carbohydrates from the two preloads (enriched orange juice or control orange juice) in a random order, and 3 hours after the preload they were offered an ad libitum lunch. Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. There was a washout period of at least one week between the two visits. Fingertip capillary blood glucose samples were collected at baseline and at several time points after food intake. Visual analog scales (VAS) of 100 mm were collected to assess subjective appetite. Blood pressure was measured at several time-points.
62303815|NCT05928741|EXPERIMENTAL|Control orange juice without vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast after a 12-hour fast. Two hours later they were given 50 g of available carbohydrates from the two preloads (enriched orange juice or control orange juice) in a random order, and 3 hours after the preload they were offered an ad libitum lunch. Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. There was a washout period of at least one week between the two visits. Fingertip capillary blood glucose samples were collected at baseline and at several time points after food intake. Visual analog scales (VAS) of 100 mm were collected to assess subjective appetite. Blood pressure was measured at several time-points.
62303816|NCT04632979|EXPERIMENTAL|Backward runners|Training protocol patients
62303817|NCT00929292|EXPERIMENTAL|Modilac Dahlia 1|Formula enriched with alpha-lactalbumin and containing a probiotic
62303818|NCT00929292|PLACEBO_COMPARATOR|Modilac 1|Regular milk
62303819|NCT02913807|PLACEBO_COMPARATOR|Traditional Reconstruction|This cohort will be reconstructed using hand contoured osteotomies and reconstruction bars
62303820|NCT02913807|EXPERIMENTAL|Computerized Custom|This cohort will be reconstructed using customized computer-modeled titanium locking customized jigs and plates for the osteotomies.
62303821|NCT03014648|EXPERIMENTAL|Atezolizumab|"Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV over 60 (plus or minus 15) minutes for first infusion; can be decreased to 30 (plus or minus 10) minutes for subsequent cycles.~Atezolizumab will be given as long as the patient continues to experience clinical benefit in the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration attributed to disease progression.~There will be no dose reduction for Atezolizumab. Patients may temporarily suspend study treatment for up to 84 days beyond the scheduled date of delayed infusion if study drug-related toxicity requiring dose suspension is experienced. If Atezolizumab is held because of adverse events for greater than 84 days beyond the scheduled date of infusion, the patient will be discontinued from Atezolizumab and will be followed for safety and efficacy."
62303822|NCT00117312|EXPERIMENTAL|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
62472436|NCT04263467|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive a 6-weeks exercise-based intervention with supervised and group-based exercise training three times a week at the hospital setting. Each training session will consist of intermediate and high intensity interval training. The exercise-based intervention will be combined with standard oncological treatments; checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
62675316|NCT06696027||Interstitial Lung Diseases (ILD)|Patients with ILD (cross sectional, newly diagnosed with follow-up after twelve months).
62114948|NCT01230840|PLACEBO_COMPARATOR|placebo|Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
62114949|NCT01230840|EXPERIMENTAL|wheat dextrin|wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
62114950|NCT03614611|EXPERIMENTAL|Contiform pessary|Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
62114951|NCT02310295|ACTIVE_COMPARATOR|IVB-Laser|Intravitreal Bevacizumab combined with focal laser therapy
62114952|NCT02310295|ACTIVE_COMPARATOR|IVTA-Laser|Intravitreal Triamcinolone combined with focal laser therapy
62114953|NCT02310295|ACTIVE_COMPARATOR|Laser|focal laser therapy
62114954|NCT02624219|EXPERIMENTAL|Group 1|N = 55 receive 7.5 mcg A/H5N8 + AS03 on Day 1, 22
62114955|NCT02624219|EXPERIMENTAL|Group 2|N = 55 receive 7.5 mcg A/H5N8 + MF59 on Day 1, 22
62114956|NCT02624219|EXPERIMENTAL|Group 3|N = 55 receive 15 mcg A/H5N8 unadjuvanted on Day 1, 22
62114957|NCT02624219|EXPERIMENTAL|Group 4|N = 55 receive 15 mcg A/H5N8 + AS03 on Day 1, 22
62114958|NCT02624219|EXPERIMENTAL|Group 5|N = 55 receive 15 mcg A/H5N8 + MF59 on Day 1, 22
62114959|NCT00542113|EXPERIMENTAL|1|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 1
62472437|NCT04263467|EXPERIMENTAL|Control group|Participants in the control group will receive standard oncological treatments; immune checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
62472438|NCT02432976|EXPERIMENTAL|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
62675317|NCT06696027||Chronic Obstructive Pulmonary Disease (COPD)|Patients with COPD (cross sectional, newly diagnosed with follow-up after twelve months).
61917863|NCT01434316|EXPERIMENTAL|Treatment (veliparib and dinaciclib)|"PART 1A: Patients receive veliparib PO BID on days 1-28 and dinaciclib IV over 2 hours on days 8 and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART 1B: Patients receive veliparib and dinaciclib as patients in Part 1A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART 1C: Patients receive veliparib PO BID on days 1-7 of cycle 0. Patients then receive veliparib PO BID on days 1-21 and dinaciclib IV over 2 hours on days 1, 4, 8, and 11 or days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62114960|NCT00542113|EXPERIMENTAL|2|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 2
62114961|NCT00542113|SHAM_COMPARATOR|3|Parents of elementary school children in grades 2-6 participating in Program ENERGY matched to the intervention groups
62114962|NCT04882449|EXPERIMENTAL|Bodyport Scale|All subjects will be given the Bodyport scale to use
62303823|NCT00117312|EXPERIMENTAL|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
62303824|NCT00117312|EXPERIMENTAL|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
62303825|NCT00117312|EXPERIMENTAL|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
62303826|NCT02629705|OTHER|Group A|"1. Placebo intervention~2. Assessment block (3 days)~3. Washout-phase of 21-35 days~4. Carrageenan intervention~5. Assessment block (3 days)"
62303827|NCT02629705|OTHER|Group B|"1. Carrageenan intervention~2. Assessment block (3 days)~3. Washout-phase of 21-35 days~4. Placebo intervention~5. Assessment block (3 days)"
62303828|NCT02832271|ACTIVE_COMPARATOR|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
62303829|NCT02832271|PLACEBO_COMPARATOR|placebo group|placebo fro women with ultrasound confirmed endometriosis
62303830|NCT05959499|ACTIVE_COMPARATOR|BR6002A+BR6002B|
62303831|NCT05959499|EXPERIMENTAL|BR6002|
62472439|NCT02432976|ACTIVE_COMPARATOR|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
62472440|NCT02970994||Preterm neonates <34 wks|Haemodynamicaly stable preterm neonates \<34 weeks with in 48 hours of admission
62675318|NCT06696027||Asthma Bronchiale|Patients with asthma bronchiale (cross sectional, newly diagnosed with follow-up after twelve months).
62675319|NCT06696027||Healthy Control Group|Age-/ gender matched healthy controls
62675320|NCT00362609|ACTIVE_COMPARATOR|Low dose|
62675321|NCT00362609|ACTIVE_COMPARATOR|High dose|
62303832|NCT04696094||Healthy volunteers|"Health volunteers' inclusion criteria:~Age between 4-60; Male or female;~Exclusion criteria:~Exclude the volunteers with history of cerebrovascular disease."
62675322|NCT04633876|ACTIVE_COMPARATOR|Control group|The subjects allocated to this group receive some results from baseline measurements (as do subjects in the intervention) but do not receive lifestyle counselling
62675323|NCT04633876|EXPERIMENTAL|Individual coaching|These subjects receive individual counselling during the study.
62114963|NCT01607372|EXPERIMENTAL|GSK2245035 - 40 ng or placebo|Subjects will receive GSK2245035 - 40 nanogram (ng) or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
62114964|NCT01607372|EXPERIMENTAL|GSK2245035 - 80 ng or placebo|Subjects will receive GSK2245035 - 80 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
62114965|NCT01607372|EXPERIMENTAL|GSK2245035 - 120 ng or placebo|Subjects will receive GSK2245035 - 120 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
62675324|NCT04633876|EXPERIMENTAL|Group coaching|These subjects receive individual counselling during the study.
62114966|NCT01607372|EXPERIMENTAL|GSK2245035 - 160 ng or placebo|Subjects will receive GSK2245035 - 160 ng or placebo once per week, for four treatment weeks. There will be washout period of 7 days between treatment periods.
62303833|NCT04696094||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:~1.written informed consent had been obtained; 2. more than 4 years old and less than 60 years old; 3. cerebral digital subtraction contrast angiography (DSA) revealed severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'; 4. received surgical revascularization;~Exclusion Criteria:~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
62303834|NCT00003323|EXPERIMENTAL|Hormone Therapy|Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
62303835|NCT03845283|EXPERIMENTAL|Physical Activity|Participants will receive the core 6-month weight loss program and the tailored intervention to promote structured physical activity.
62303836|NCT03845283|EXPERIMENTAL|Core Program|Participants will receive the core 6-month weight loss program alone. This program includes weekly lessons for the first 12 weeks and monthly lessons for the remaining 12 weeks. Participants will track their intake, physical activity, and weight, input these data into the system, and received tailored feedback.
62303837|NCT03845283|EXPERIMENTAL|Physical Activity & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the virtual meetings to support weight loss.
62303838|NCT03845283|EXPERIMENTAL|Virtual Meetings|Participants will receive the core 6-month weight loss program and the virtual meetings to support weight loss.
62303839|NCT03845283|EXPERIMENTAL|Physical Activity & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and access to the virtual reality platform for behavioral weight loss skills training.
62303840|NCT03845283|EXPERIMENTAL|Virtual Reality|Participants will receive the core 6-month weight loss program and access to the virtual reality platform for behavioral weight loss skills training.
61917864|NCT03316183|EXPERIMENTAL|Intervention Group|"* Maintain rSO2 values at or above 75% of the baseline~* Midline position~* Target CO2 of ≥40 mmHg, target MAP \>60 mm Hg~* Maintain cerebral perfusion pressure \>50 mm Hg~* Target pump flow 2.5 L/m2/min~* If rSO2 persistently below treatment threshold:~  * FiO2 is increased~ * or propofol 50-100 mg bolus is administered~* If Hct below 20% packed red blood cells will be transfused~timeline: before induction, after time-out has been performed, and will continue until 24 hours post surgery."
62114967|NCT02692105|ACTIVE_COMPARATOR|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
62114968|NCT02692105|EXPERIMENTAL|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
62114969|NCT01725854|EXPERIMENTAL|Relaxation Response Training|The Military tailored RR training program will consist of six weekly small group sessions which involve group presentations, in-group skill building exercises, and at-home assignments. Groups will contain 5-8 participants who are active-duty Soldiers enrolled in either Respect-MIL or the Interdisciplinary Pain Management Center (IPMC).
62114970|NCT01725854|NO_INTERVENTION|Standard of Care|Participants randomized to the control group will receive standard care through their providers at Respect-MIL or at the IPMC. Participants randomized to the control group will remain on the wait list for further standard care. After the collection of the final data point, these participants will also have the option to participate in an abbreviated, two-hour version of the RR training.
62114971|NCT04645394|PLACEBO_COMPARATOR|Placebo|The participants are receiving 1 dose of each in the stated order.
62114972|NCT04645394|ACTIVE_COMPARATOR|Fermented aronia high dose|The participants are receiving 1 dose of each in the stated order.
62114973|NCT04645394|ACTIVE_COMPARATOR|Fermented aronia low dose|The participants are receiving 1 dose of each in the stated order.
62114974|NCT04645394|ACTIVE_COMPARATOR|Aronia|The participants are receiving 1 dose of each in the stated order.
62114975|NCT06465680|EXPERIMENTAL|Within-participant micro-randomization|"Each day in the study, with probability .5 for each, a participant is randomized to receive a notification that day or no notification that day.~If a participant is assigned to receive a notification that day, 1 message set will be randomly selected from a pool of 358 core message sets. Each core message set will be comprised of 4 messages containing comparable content, however they will be tailored based on the participant's wearable (steps, sleep) or mood data for the specified time interval (7 days, 30 days, since the start of internship) as follows: 1) no data, 2) low, 3) moderate, or 4) high."
62114976|NCT02845050|EXPERIMENTAL|Vinflunine+Cisplatin+radical cystectomy|neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
62114977|NCT04838210|EXPERIMENTAL|Group Prenatal Care|Group prenatal care model
62114978|NCT04838210|ACTIVE_COMPARATOR|Individual Prenatal Care|Individual prenatal care
62114979|NCT02318381|NO_INTERVENTION|Control|Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically without release of the superior transverse scapular ligament.
62472441|NCT03614845|ACTIVE_COMPARATOR|VCV-Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography. after induction of anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode.
62472442|NCT03614845|ACTIVE_COMPARATOR|PCV-VG- Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography.after induction of anesthesia patients will be supported by mechanical ventilation on pressure controlled volume guaranteed mode
62472443|NCT05729594|EXPERIMENTAL|T4032|
62472444|NCT05729594|ACTIVE_COMPARATOR|Lumigan|
62114980|NCT02318381|OTHER|Ligament Release|"Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically with release of the suprascapular nerve.~Arthroscopic dissection of the superior transverse scapular ligament"
62114981|NCT02278393|ACTIVE_COMPARATOR|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 3 bottles of test product/day with 1,6g of phytosterols each
62472445|NCT01879345|EXPERIMENTAL|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093 600 mg
62472446|NCT01879345|EXPERIMENTAL|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
62472447|NCT01879345|PLACEBO_COMPARATOR|Placebo|placebo tablets
62472448|NCT06376656|EXPERIMENTAL|Cognitive stimulation|Participants will take part in psychoeducation, videogaming, book club and technology training workshops.
62472449|NCT06376656|EXPERIMENTAL|Physical activity|Participants will take part in walking, Zumba, resistance exercise and aerobics sessions.
62472450|NCT06376656|EXPERIMENTAL|Combined intervention|Participants will take part in both cognitive stimulation and physical activity intervention sessions.
62114982|NCT02278393|PLACEBO_COMPARATOR|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 3 bottles test productl/day with no Phytosterols
62114983|NCT05270551|ACTIVE_COMPARATOR|Group 1|Without augmentation
62114984|NCT05270551|ACTIVE_COMPARATOR|Group 2|With augmentation
62114985|NCT00664911|OTHER|Chemotherapy|chemotherapy regimen
62472451|NCT06376656|NO_INTERVENTION|Non-intervention control|Participants will not take part in any intervention.
62114986|NCT04876573|EXPERIMENTAL|Cyproheptadine|
62114987|NCT05004272|ACTIVE_COMPARATOR|Massage|
62114988|NCT05004272|ACTIVE_COMPARATOR|Gymnastics|
62114989|NCT05004272|PLACEBO_COMPARATOR|Lecture|
62114990|NCT00878722|EXPERIMENTAL|Arm A|"PXD101 administered as a 30-minute intravenous (IV) infusion of 1000 mg/m²/d for five consecutive days every 3 weeks.~Idarubicin administered on day 5 (first steps) or days 4 and 5 (later steps). Patients will be treated in a 21-day cycle for a minimum of 2 cycles and a maximum of 6 cycles (depending on cumulated idarubicin dose)."
62114991|NCT00878722|EXPERIMENTAL|Arm B|PXD101 administered by continuous intravenous infusion over 24-48 hours and idarubicin (in the later steps) added after the first 24 hours. The second cycle will start on day 15 but under observation of possible toxicity. Further cycles will be administered q 14 d for up to 6 cycles. The first dose steps will be carried out with PXD101 alone for safety reasons.
62472452|NCT05732363||1|"The population will consist of patients, who have participated in the MUSCLE study and have received bariatric surgery at the CON / MCL. A potential subject who meets any of the following criteria will be excluded from participation in this study:~* Inability to communicate in either Dutch or English~* Weight over 204 kilograms (due to limitations of the DXA)~* Pregnancy~* Pacemaker"
62472453|NCT02700776||COHORT I-BIRADS 1 or 2,|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0 and 6-12.
62472454|NCT02700776||COHORT II -BIRADS 3|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0, 3-6, and 6-12.
62472455|NCT02700776||COHORT III-BIRADS 4-6|SOC Tissue Biopsy. Occurs at months 0, 3-6, and 6-12.
62472456|NCT05833425||Scoliosis group|In this study, an evaluation form including demographic and clinical characteristics, respiratory muscle strength measurement, quadriceps muscle strength measurement with electronic hand dynamometer, hand grip strength with dynamometer and postural stability assessment with Biodex Balance System® will be applied to all scoliosis adolescent.
62472457|NCT05833425||Healthy group|In this study, an evaluation form including demographic and clinical characteristics, respiratory muscle strength measurement, quadriceps muscle strength measurement with electronic hand dynamometer, hand grip strength with dynamometer and postural stability assessment with Biodex Balance System® will be applied to all healthy adolescent.
62472458|NCT06017713|EXPERIMENTAL|tDCS + symptoms provocation|
62472459|NCT02980822||Sweden, Denmark, Norway|"Group: Degenerative lumbar disc disease patients treated in Sweden and included in the Swespine register~Group: Degenerative lumbar disc disease patients treated in Norway and included in the NORspine register~Group: Degenerative lumbar disc disease patients treated in Denmark and included in the DaneSpine register"
62472460|NCT06093386|EXPERIMENTAL|Intervention|
62472461|NCT06093386|NO_INTERVENTION|Control/ Usual Care|Standard of care in the control group will involve the utilization of existing tools within clinical programs which may include preparation for transitions, but there will be no systematic follow-up by a paediatric provider beyond age 18. Care will be transferred to adult providers (primary care and specialists) via a transition guide that will be offered to participants and their referring providers. This is the current model of care for virtually all CMC in Ontario.
62303841|NCT03845283|EXPERIMENTAL|Physical Activity, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the virtual meetings to support weight loss, and access to the virtual reality platform for behavioral weight loss skills training.
62303842|NCT03845283|EXPERIMENTAL|Virtual Reality & Virtual Meetings|Participants will receive the core 6-month weight loss program, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
62303843|NCT03845283|EXPERIMENTAL|Physical Activity & Bite Counter|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the Bite Counter device to reduce dietary intake.
62303844|NCT03845283|EXPERIMENTAL|Bite Counter|Participants will receive the core 6-month weight loss program and the Bite Counter device to reduce dietary intake.
62303845|NCT03845283|EXPERIMENTAL|Physical Activity, Bite Counter, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
62472462|NCT00953498|ACTIVE_COMPARATOR|pioglitazone|treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)
62675325|NCT01570582|EXPERIMENTAL|drug effect|"Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.~Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.~Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.~Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is"
61917865|NCT03316183|NO_INTERVENTION|Control Group|Patients in the control group will be managed under the attending physician's discretion. Cerebral oximetry data will be collected in the same fashion as in the intervention group, but the measurements will be blinded to the physician. Blood samples will be collected for metabolomic profiling in the same fashion and at identical time points as the intervention group for later analysis.
62114992|NCT03906942|EXPERIMENTAL|Fun For Wellness (FFW)|Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks of 24 hr access to the FFW online intervention during data collection for this study. Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being and/or physical activity.
62114993|NCT03906942|NO_INTERVENTION|Usual Care (UC)|Participants assigned to the UC group (i.e., UC participants) will proceed through the pre-operative weight management program provided by the center.
62114994|NCT01979393|EXPERIMENTAL|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
62114995|NCT01979393|EXPERIMENTAL|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
62114996|NCT02675348|EXPERIMENTAL|Dietary Supplement: Beef Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of beef protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
62114997|NCT02675348|EXPERIMENTAL|Dietary Supplement: Whey Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of whey protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
62303846|NCT03845283|EXPERIMENTAL|Bite Counter & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
62303847|NCT03845283|EXPERIMENTAL|Physical Activity, Bite Counter, & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
62303848|NCT03845283|EXPERIMENTAL|Bite Counter & Virtual Reality|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
62303849|NCT03845283|EXPERIMENTAL|Physical Activity, Bite Counter, Virtual Reality & Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
62472463|NCT00953498|ACTIVE_COMPARATOR|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
62472464|NCT06042335|EXPERIMENTAL|DAISe EZ|Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.
62472465|NCT05757908|OTHER|Long-Acting Beta Agonist|Standard of care LABA
62472466|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
62472467|NCT03332745||Severe aortic stenosis|Patients with severe aortic stenosis who are scheduled to undergo aortic valve replacement surgery
62472468|NCT03332745||Control group|Patients scheduled to undergo non-aortic valve cardiac or elective ascending aortic surgery
62675326|NCT01935154|PLACEBO_COMPARATOR|Placebo|Placebo will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
62114998|NCT02675348|ACTIVE_COMPARATOR|Dietary Supplement: CHO|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of maltodextrin powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
62675327|NCT01935154|EXPERIMENTAL|Vx-001|Vx-001 will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
62675328|NCT02872142|EXPERIMENTAL|Albutein 5%|Plasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant.
62114999|NCT04783610|EXPERIMENTAL|Study subjects for vHIT- and VOG-measurements|Each study subject is his/hers own comparator at different phases of ethanol consumption.
62675329|NCT02333968|EXPERIMENTAL|Intervention group|Self-management support
62675330|NCT02333968|NO_INTERVENTION|Control group|Care as usual
62115000|NCT01312441|EXPERIMENTAL|Ergocalciferol|Ergocalciferol 50,000 IU by mouth once weekly for 6 months
62675331|NCT00677378||EXPERIMENTAL|Children undergoing an endoscopy for retrosternal chest pain, epigastric pain, regurgitation, heart burn or dyspepsia.
62675332|NCT00677378||CONTROL|Children undergoing an endoscopy for reasons not stated in the experimental group condition (i.e. celiac disease, rectal bleeding, polyps, weight loss, malabsorption).
62675333|NCT02384343|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine 4 mcg/ml, 30 mcg (7,5 ml), single intravenous bolus
62675334|NCT02384343|PLACEBO_COMPARATOR|Normal saline|NaCl 0,9% 7,5 ml, single intravenous bolus
62675335|NCT00997191|ACTIVE_COMPARATOR|Laser Group|Focal / grid Laser photocoagulation in diabetic macular edema
62675336|NCT00997191|EXPERIMENTAL|Triamcinolone group|Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
62675337|NCT00997191|EXPERIMENTAL|Bevacizumab group|Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
62675338|NCT02197104|EXPERIMENTAL|Citocoline|The intervention will be 1000mg of citicoline in capsule form once daily.
62675339|NCT06479083|OTHER|Interventional group|New intervention form
62675340|NCT06479083|OTHER|control group.|Standard treatment for Parkinson Disease
62115001|NCT01312441|PLACEBO_COMPARATOR|Placebo|Placebo by mouth once weekly for 6 months
62115002|NCT05543837|EXPERIMENTAL|Capsaicin .66μMol/ml|Group receiving .66μMol/ml
62115003|NCT05543837|EXPERIMENTAL|Capsaicin .99μMol/ml|Group receiving .99μMol/ml
62115004|NCT02485379|OTHER|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
62115005|NCT03487042|EXPERIMENTAL|Generalized vitiligo patients|"Each patient with generalized vitiligo will be subjected to the following:~One side will be treated by narrow band ultraviolet rays sessions twice weekly for 3 months + topical bimatoprost 0.03% ophthalmic solution solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% ophthalmic solution twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months."
62115006|NCT02884544|EXPERIMENTAL|HLD100 10mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)
62115007|NCT02884544|EXPERIMENTAL|HLD100 20mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)
62472469|NCT05673317|EXPERIMENTAL|Experiment Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the breastfeeding application at admission to labor and delivery or in the immediate postpartum period. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
62675341|NCT04425278|ACTIVE_COMPARATOR|Real Stimulation|The Real Stimulation of tDCS lasted 20 mins.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
62675342|NCT04425278|SHAM_COMPARATOR|Sham Stimulation|The Sham Stimulation of tDCS lasted 20 minutes with no current. In particular, the current went up for the first 30 seconds and went down for the last 30 seconds.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
62675343|NCT04425278|NO_INTERVENTION|Control|Behavior and ERPs dataset should be acquired before and after 14 days.
62675344|NCT02417337|ACTIVE_COMPARATOR|Group I|paracetamol 1000mg
62675345|NCT02417337|EXPERIMENTAL|Group II|ibuprofen 600mg + paracetamol 1000mg,
62675346|NCT02417337|EXPERIMENTAL|Group III|Mefenamic acid 500mg + Paracetamol 1000mg
62675347|NCT02417337|EXPERIMENTAL|Group IV|Diclofenac K 50mg + paracetamol 1000 mg
62675348|NCT02417337|PLACEBO_COMPARATOR|Group V|No medication
62675349|NCT01494857|EXPERIMENTAL|Adalimumab|Adalimumab 40 mg
62675350|NCT02292680||NICU Tooth Study Cohort|All study subjects will have been cared for in the Mount Sinai NICU and have had the same hospital environment exposure.
62675351|NCT06195774||Observational cohort|Measure regional electric impedance of the lung for before and after insertion of an epidural analgesia catheter
62675352|NCT00667589|EXPERIMENTAL|urea 40% cream|
62675353|NCT00667589|EXPERIMENTAL|fluocinonide 0.05% cream|
62675354|NCT00667589|EXPERIMENTAL|tazarotene 0.1% cream|
62675355|NCT00667589|EXPERIMENTAL|bland emollient cream|
62675356|NCT02459925|ACTIVE_COMPARATOR|CBT- Mental Health Program|Cognitive Behavioral Therapy. Manualized Stress Management class; brief individual behavioral counseling.
62303850|NCT03845283|EXPERIMENTAL|Bite Counter, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
62303851|NCT02632825|EXPERIMENTAL|Nasal High Flow|NHF will be applied at 8 L/min (AIRVO 2) through (OPT 316) Optiflow nasal cannula interface without supplemental oxygen
62303852|NCT02632825|NO_INTERVENTION|Control|Control is no NHF intervention
62303853|NCT01548638|EXPERIMENTAL|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
62303854|NCT00811226||Patients|Patients with arterial hypertension Stade I or Stade II
62303855|NCT04807491|ACTIVE_COMPARATOR|Kabat Technique's|Kabat exercises on Upper fulcrum, Intermediate fulcrum and lower fulcrum
62303856|NCT04807491|EXPERIMENTAL|Neuromuscular Re-Education:|For initiation, Facilitation, Movement control and movement control
62303857|NCT04673994||Chronic Stroke|Individuals 40-80 years old who have had a stroke 6 months to 5 years ago.
62303858|NCT04673994||CON|Control group (CON) comprised of age- and sex-matched healthy adults.
62303859|NCT04673994||CONyoung|Healthy, young adult control group (CONyoung) who are age 18-30 years old.
62303860|NCT00702624||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular \[IM\] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
62303861|NCT00702624||recFSH 150 IU|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
62303862|NCT04837391||Urologic oncology surgery in elderly|Elective urologic oncology surgeries such as radical nephrectomy, radical cystectomy, radical prostatectomy in older than 65 years
62303863|NCT02493907||heart failure|heart failure patients with CRT
62303864|NCT00520026|ACTIVE_COMPARATOR|1|Lithium treatment
62303865|NCT00520026|PLACEBO_COMPARATOR|2|Placebo treatment
62472470|NCT05673317|NO_INTERVENTION|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
62472471|NCT06503601||Responders to empagliflozin|Heart failure patients who showed response to empagliflozin
62472472|NCT06503601||Non responders to empagliflozin|Heart failure patients who showed no response to empagliflozin
62472473|NCT05419661|EXPERIMENTAL|PPO +|Operational Pre-Planning + intracranial aneurysm embolization treatment
62472474|NCT05419661|NO_INTERVENTION|PPO -|Only intracranial aneurysm embolization treatment
62472475|NCT02533973|ACTIVE_COMPARATOR|Xamiol® gel|calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks
62472476|NCT02533973|ACTIVE_COMPARATOR|. Daivonex® scalp solution|calcipotriol 50mcg/g twice daily as required, for up to 28 weeks
62472477|NCT05234502|EXPERIMENTAL|Group-1 (Ketogenic diet)|Group-1 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with an anthracycline. And simultaneously with standard neoadjuvant therapy containing taxane (12 weeks), KD will be planned for Group-1
62472478|NCT05234502|OTHER|Group-2 (Adequate and balanced healthy diet)|Group-2 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with anthracycline and taxane (12 weeks).
62303866|NCT06430541|EXPERIMENTAL|Psilocybin Assisted Psychotherapy|25mg cGMP Psilocybin in combination with manualized therapy
62303867|NCT05068804|EXPERIMENTAL|cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
62303868|NCT05068804|PLACEBO_COMPARATOR|Control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
62303869|NCT01025336|OTHER|23vPS Naive|Group 1.1 13vPnC/13vPnC Group 1.2 13vPnC/23vPS Group 2 23vPS/13vPNC
62303870|NCT01025336|OTHER|Prior 23vPS>/= 5 years|Group 1 13vPnC/13vPnC Group 2 23vPS/13vPnC
62472479|NCT03620591|ACTIVE_COMPARATOR|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
62472480|NCT03620591|PLACEBO_COMPARATOR|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
62472481|NCT05732207|EXPERIMENTAL|Cathodal cerebellar transcranial direct current stimulation (ctDCS)|For ctDCS, the cathodal (-) electrode will be positioned over the right cerebellum 1 cm below and 3 cm lateral to the inion, and the anodal (+) electrode will be placed on the contralateral supraorbital area (FP2 EEG location).
62472482|NCT05732207|EXPERIMENTAL|Anodal cerebellar transcranial direct current stimulation (atDCS)|For atDCS, anode/cathode locations are reversed from those of ctDCS..
62115008|NCT02884544|EXPERIMENTAL|HLD100 30mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)
62115009|NCT02884544|EXPERIMENTAL|HLD100 40mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)
62115010|NCT02533635|EXPERIMENTAL|A-first intervention|Subjects in Arm A receive Ganoderma tea (30g) daily for 8 weeks initially, followed by 8 weeks no intervention.
62303871|NCT06312306|EXPERIMENTAL|Transcranial direct current stimulation (tDCS) group|Anodal tDCS applied using a DC stimulator
62303872|NCT06312306|EXPERIMENTAL|pilates based core training group|The Pilates training program will last 30 min per session. The selected exercises will be given to all patients and progressed week-wise
62303873|NCT06312306|ACTIVE_COMPARATOR|control group|Will receive conventional physiotherapy program
62303874|NCT03597906|EXPERIMENTAL|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
62303875|NCT03597906|EXPERIMENTAL|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
62115011|NCT02533635|EXPERIMENTAL|B-second intervention|Subjects in Arm B receive no intervention for 8 weeks initially, followed by receiving Ganoderma tea (30g) daily for 8 weeks .
62115012|NCT04650048|ACTIVE_COMPARATOR|Active tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
62115013|NCT04650048|PLACEBO_COMPARATOR|Sham tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
62115014|NCT03510091|EXPERIMENTAL|Video-Assisted Counseling|Patients receiving video-assisted counseling
62303876|NCT03597906|EXPERIMENTAL|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
62303877|NCT04477122|EXPERIMENTAL|Blue|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes (2000 shots approximately) of extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles at 2 bars and 10 Hertzs. Participants will wear splint 23 hours/day
62303878|NCT04477122|PLACEBO_COMPARATOR|Red|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes of placebo extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles. Participants will wear splint 23 hours/day
62303879|NCT00693186|EXPERIMENTAL|1|
62303880|NCT00693186|EXPERIMENTAL|2|
62472483|NCT05732207|SHAM_COMPARATOR|Sham cerebellar transcranial direct current stimulation (stDCS)|For stDCS, the electrodes will be configured randomly as atDCS 50% of the time, and as ctDCS 50% of the time.
62115015|NCT00647530|EXPERIMENTAL|Pre&Post Op Chemo|12 weeks of OxFP neuoadjuvantly followed by surgery and 18 weeks of OxFP
62115016|NCT00647530|EXPERIMENTAL|Pre&Post Op Chemo with P-mab|12 weeks of OxFP and panitumumab neuoadjuvantly followed by surgery and 18 weeks of OxFP alone.
62115017|NCT00647530|ACTIVE_COMPARATOR|Post Op Chemo|surgery followed by 24 weeks of OxFP.
62115018|NCT04670159|EXPERIMENTAL|Online Education Group|
62115019|NCT04670159|EXPERIMENTAL|Brochure Group|
62115020|NCT06513234|EXPERIMENTAL|OG|6 cycles of OG regimen. Patients with CR/PR after 6 cycles of OG treatment will be treated with 18 cycles of single-agent orelabrutinib regimen. Orelabrutinib 150mg QD
62115021|NCT04988048|ACTIVE_COMPARATOR|Gam-COVID-Vac C1/ ChAdOx1 nCoV-19|Heterologous: Gam-COVID-Vac C1/ ChAdOx1 nCoV-19
62303881|NCT00288340|ACTIVE_COMPARATOR|1,2|
62303882|NCT03133715|ACTIVE_COMPARATOR|laparoscopic ventral hernia|laparoscopic ventral hernia repair
62303883|NCT03133715|ACTIVE_COMPARATOR|robot-assisted ventral hernia|robot-assisted ventral hernia repair
62472484|NCT02045472|EXPERIMENTAL|VIS410|VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
62472485|NCT02045472|PLACEBO_COMPARATOR|Placebo|Placebo administered as a single infusion
62472486|NCT04786353||COVID positive kids|Children with at least one positive SARS-CoV-2 test.
62472487|NCT04786353||Controls|Children with no positive SARS-CoV-2 test.
62472488|NCT04207983|EXPERIMENTAL|Treatment Arm A (Re-administration)|Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.
62115022|NCT04988048|ACTIVE_COMPARATOR|ChAdOx1 nCoV-19 / Gam-COVID-Vac C1|Heterologous: ChAdOx1 nCoV-19 / Gam-COVID-Vac C1
62115023|NCT04988048|ACTIVE_COMPARATOR|Gam-COVID-Vac C1/ BBIBP-CorV|Heterologous: Gam-COVID-Vac C1/ BBIBP-CorV
62115024|NCT04988048|ACTIVE_COMPARATOR|BBIBP-CorV / Gam-COVID-Vac C1|Heterologous: BBIBP-CorV / Gam-COVID-Vac C1
62115025|NCT04988048|ACTIVE_COMPARATOR|ChAdOx1 nCoV-19 / BBIBP-CorV|Heterologous: ChAdOx1 nCoV-19 / BBIBP-CorV
62115026|NCT04988048|ACTIVE_COMPARATOR|BBIBP-CorV / ChAdOx1 nCoV-19|Heterologous: BBIBP-CorV / ChAdOx1 nCoV-19
62115027|NCT04988048|ACTIVE_COMPARATOR|Gam-COVID-Vac C1/ mRNA-1273|Heterologous: Gam-COVID-Vac C1/ mRNA-1273
62115028|NCT04988048|ACTIVE_COMPARATOR|ChAdOx1 nCoV-19 / mRNA-1273|Heterologous: ChAdOx1 nCoV-19 / mRNA-1273
62115029|NCT04988048|ACTIVE_COMPARATOR|BBIBP-CorV / mRNA-1273|Heterologous BBIBP-CorV / mRNA-1273
62115030|NCT04988048|ACTIVE_COMPARATOR|Gam-COVID-Vac C1/ Gam-COVID-Vac C2|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C2
62472489|NCT04207983|EXPERIMENTAL|Treatment Arm B (Single administration)|One administration of EYS606 (135μg pEYS606/90 μL) at the baseline visit (V1).
62472490|NCT01377779|EXPERIMENTAL|Intercoat treatment|women treated by Intercoat gel following hysteroscopy for retained products of conception
62472491|NCT01377779|PLACEBO_COMPARATOR|Control group|No additional treatment following hysteroscopy was performed
62472492|NCT00549718|EXPERIMENTAL|Lurasidone 40mg|
62472493|NCT00549718|EXPERIMENTAL|Lurasidone 80mg|
62472494|NCT00549718|EXPERIMENTAL|Lurasidone 120mg|
62472495|NCT00549718|PLACEBO_COMPARATOR|Sugar Pill|
62472496|NCT02368639|EXPERIMENTAL|Positive airway pressure (PAP) device|Fisher \& Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
62472497|NCT01633645|EXPERIMENTAL|Velcade/GEM/CDDP|Bortezomib / Gemcitabine / Cisplatin
62472498|NCT03708458|ACTIVE_COMPARATOR|Control group|Control group - patients receiving 100 mg indomethacin suppository immediately post ERCP
62675357|NCT02459925|ACTIVE_COMPARATOR|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
62115031|NCT04988048|ACTIVE_COMPARATOR|ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19|Homologous: ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19
62115032|NCT04988048|ACTIVE_COMPARATOR|BBIBP-CorV / BBIBP-CorV|Homologous: BBIBP-CorV / BBIBP-CorV
62115033|NCT04988048|ACTIVE_COMPARATOR|mRNA-1273 / mRNA-1273|Homologous: mRNA-1273 / mRNA-1273
62115034|NCT04988048|ACTIVE_COMPARATOR|Gam-COVID-Vac C1/ Gam-COVID-Vac C1|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C1
62115035|NCT02888249|EXPERIMENTAL|Cigarette W|"Altered composition cigarettes~moisture = 12.20 %, tar = 10.40 mg/cigarette, total particulate matter = 12.0 mg/cigarette, high sugar content"
62115036|NCT02888249|EXPERIMENTAL|Cigarette X|"Altered composition cigarettes~moisture = 12.10 %, tar = 8.60 mg/cigarette, total particulate matter = 9.60 mg/cigarette, low sugar content"
62115037|NCT02888249|EXPERIMENTAL|Cigarette Y|"Altered composition cigarettes~moisture = 13.20 %, tar = 9.10 mg/cigarette, total particulate matter = 10.10 mg/cigarette, low sugar content"
62115038|NCT02888249|EXPERIMENTAL|Cigarette Z|"Altered composition cigarettes~moisture = 13.60 %, tar = 8.10 mg/cigarette, total particulate matter = 9.10 mg/cigarette, low sugar content"
62303884|NCT04287530|EXPERIMENTAL|Tachidino + PUFA supplementation|Group 1 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform). The program will be delivered during four weeks, starting two months after the pre-testing session. Additionally, the children will receive daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
62303885|NCT04287530|ACTIVE_COMPARATOR|Tachidino + Placebo|Group 2 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session, exactly as Group 1. Additionally, the children will receive daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
62303886|NCT04287530|EXPERIMENTAL|PUFA supplementation|Groups 3 will receive only daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
62303887|NCT04287530|PLACEBO_COMPARATOR|Placebo|Groups 4 will receive only daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
62303888|NCT04287530|NO_INTERVENTION|Control group|Typically Developing participants, as a comparison group for experimental tasks and for PUFA levels in the blood
62303889|NCT01609283|EXPERIMENTAL|Autologous Mesenchymal Stem Cells|
62303890|NCT04304677||Pre PCI state|The current study will analyze the pre-PCI pullback recording and amount of FFR step-up. The association of the amount of FFR step-up with post-PCI percent FFR increase, post-PCI FFR, and clinical outcome at 2 years will be analyzed
62303891|NCT01480986|EXPERIMENTAL|Treatment arm|This is a single arm trial. The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
62303892|NCT02826057|ACTIVE_COMPARATOR|24 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
62303893|NCT02826057|EXPERIMENTAL|48 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
62472499|NCT03708458|ACTIVE_COMPARATOR|Group A|Group A - patients receiving N-acetylcysteine (NAC) 600 mg before performing ERCP and indomethacin suppository 50 mg before and after performing ERCP
62472500|NCT03708458|ACTIVE_COMPARATOR|Group B|Group B - patients receiving indomethacin suppository 50 mg before and 50 mg after ERCP
62472501|NCT04280120|EXPERIMENTAL|Neural Mobilisation Group|"1. Massage therapy.~2. Faradic electrical stimulation.~3. Exercises in front of the mirror.~4. Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest."
62675358|NCT06254690|EXPERIMENTAL|Pyrotinib dose escalation group|Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd)
62115039|NCT05286762|ACTIVE_COMPARATOR|18.75 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (18.75 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to their assigned dose of 18.75 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
62115040|NCT05286762|ACTIVE_COMPARATOR|25 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (25 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to their assigned dose of 25 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
62115041|NCT05286762|ACTIVE_COMPARATOR|37.5 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (37.5 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to 25 mg; at week 3 they will be increased to their assigned dose of 37.5 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
62675359|NCT06254690|ACTIVE_COMPARATOR|Pyrotinib dose normal group|Pyrotinib: 400mg per week, by mouth(po),once a day(qd)
62115042|NCT05286762|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will be on placebo for the full 5 weeks of the study.
62115043|NCT02091336|ACTIVE_COMPARATOR|Glyburide|Glyburide 2,5 mg
61917866|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
61917867|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
62115044|NCT02091336|ACTIVE_COMPARATOR|Metformin|Metformin 500mg bid
62115045|NCT04569318|EXPERIMENTAL|Treatment Arm|Treatment with treatment beam.
62115046|NCT01669148|ACTIVE_COMPARATOR|Conventional + Tomosynthesis|conventional (2D) imaging plus tomosynthesis (3D) imaging first then tomosynthesis alone 1 month later.
62115047|NCT01669148|ACTIVE_COMPARATOR|Tomosynthesis alone|tomosynthesis (3D) imaging alone first then conventional (2D) imaging plus tomosyntheis 1 month later.
62115048|NCT03967886|EXPERIMENTAL|YYD601 20mg|Esomeprazole magnesium Dihydrate.
62115049|NCT03967886|ACTIVE_COMPARATOR|Nexium 20mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
62115050|NCT03812354|ACTIVE_COMPARATOR|THRIVE 2L/kg/min using OptiFlow|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
62115051|NCT03812354|EXPERIMENTAL|THRIVE 4L/kg/min using OptiFlow|"After apnea sets in and mask ventilation is successfully established, randomization envelopes are opened and according to group allocation, the following oxygen delivery system is applied.~High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand."
62115052|NCT02633423|EXPERIMENTAL|PEEP and CPAP|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
62115053|NCT02633423|EXPERIMENTAL|ZEEP and CPAP|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
62115054|NCT02633423|EXPERIMENTAL|PEEP and NO VM|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
62115055|NCT02633423|PLACEBO_COMPARATOR|ZEEP and NO VM|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
62115056|NCT04801836|EXPERIMENTAL|Treatment Arm|Subjects will receive 15 mg E4 orally once daily for 21 consecutive days
62115057|NCT04801836|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive matching placebo orally once daily for 21 consecutive days.
62115058|NCT01975311|EXPERIMENTAL|Lumbopelvic Manipulation|Participants in this group will receive lumboplevic manipulation twice within a week.
62115059|NCT01975311|PLACEBO_COMPARATOR|Passive lumbar spine flexion and extension|Participants in this group will receive passive lumbar spine flexion and extension for 1 min twice within a week.
62115060|NCT01215695|ACTIVE_COMPARATOR|Control|Patients will be randomly assigned to having their ETT placed with use of a pre-formed stylet provided by the manufacturer of the GVL (control group)
62115061|NCT01215695|EXPERIMENTAL|Intervention|Patients will be randomly assigned to either having their ETT placed with use of flexible, disposable tracheoscope (aScope, Ambu, Denmark) (intervention group).
62115062|NCT05237258|EXPERIMENTAL|Specialty Palliative Care|- Participants will complete baseline self-report assessments at the time of informed consent
62115063|NCT05237258|EXPERIMENTAL|Primary Palliative Care|- Participants will complete baseline self-report assessments at the time of informed consent
61917868|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
62675360|NCT01477411|EXPERIMENTAL|PA21 and Digoxin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
62675361|NCT01477411|EXPERIMENTAL|No PA21; Digoxin with food|The maximum dosage of Digoxin will be 0.5 mg/day
62115064|NCT02770599||IBD multidisciplinary team model (MDT)|IBD multidisciplinary team model including IBD nurse
62115065|NCT02770599||IBD conventionally follow up model (CF)|IBD patient treated by doctors with specialist qualifications, assistant doctors, general practitioner or scarcity of follow-up-service.
62115066|NCT00854906||Keratometric Tear Breakup Time|These are the study participants whose tear break up times were measured with a keratometer.
62115067|NCT00854906||Fluorescein Break Up Time|These are the study participants whose tear break up times were measured with with fluorescein dye.
62115068|NCT02867566|EXPERIMENTAL|IBI301|IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
62115069|NCT02867566|ACTIVE_COMPARATOR|Rituximab|Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
62115070|NCT00552552|EXPERIMENTAL|1|
62115071|NCT00552552|OTHER|2|waiting control group
62675362|NCT01477411|EXPERIMENTAL|PA21 with food and Digoxin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
62303894|NCT05434910|EXPERIMENTAL|Intervention|"Changes in mean arterial pressure (MAP).~In all subjects MAP is temporally adjusted using noradrenaline to the following three levels:~* MAP 65 mmHg.~* MAP 80 mmHg.~* MAP 95 mmHg. When MAP has been stable at the given level for 20 min, measurements are conducted over 5 min. When the measurements are done, the study is finished. The study will last approximately 2 hours.~Measurements include internal carotid and vertebral artery blood flow, mean arterial pressure, heart rate, peripheral O2 saturation, cardiac output, left ventricle ejection fraction, frontal lobe and muscle oxygenation, blood velocity in the middle cerebral artery, pupillometry, and arterial, central venous, and internal jugular venous gas variables and blood samples for analysis of metabolomics."
62472502|NCT04280120|ACTIVE_COMPARATOR|Conservative group|"1. Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.~2. Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.~3. Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes."
62472503|NCT01952522|EXPERIMENTAL|Weighted brace|
62472504|NCT01952522|PLACEBO_COMPARATOR|non weighted brace|
62472505|NCT05442021|EXPERIMENTAL|Neubie Direct Current Electrical Stimulation|The experimental group subjects follow with 12 sessions of physical therapy over a 6-week period which include: a 30-min foot bath session using the Neubie and 15-min of various physical therapy exercises.
62472506|NCT05442021|OTHER|Transcutaneous Electrical Nerve Stimulation|The control group subjects follow with 12 sessions of physical therapy over a 6-week period which include: a 30-min footbath with TENS and 15-min of various physical therapy exercises.
62472507|NCT02594358|ACTIVE_COMPARATOR|Caffeine 20 mg|Patching plus once daily caffeine for 12 weeks
62472508|NCT02594358|ACTIVE_COMPARATOR|Caffeine 40 mg|Patching plus once daily caffeine for 12 weeks
62675363|NCT06535776|ACTIVE_COMPARATOR|Control group|Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
62115072|NCT01299753|PLACEBO_COMPARATOR|Control|
62115073|NCT01299753|EXPERIMENTAL|Beta blockade|
62115074|NCT02298140|EXPERIMENTAL|SMS reminders|This arm will receive automated mobile phone text message reminders for health workers in outpatient departments of public and private health facilities on issues related to care of malaria patients and suspected patients.
62115075|NCT05242653|EXPERIMENTAL|cotton swab|
62115076|NCT05242653|ACTIVE_COMPARATOR|balanced salt solution (BSS)|
62115077|NCT01114945|EXPERIMENTAL|Video-Mac|Video-Mac device used during intubation procedure
62115078|NCT01114945|EXPERIMENTAL|GlideScope|GlideScope device used during intubation procedure
62115079|NCT01114945|EXPERIMENTAL|McGrath|McGrath device used during intubation procedure
62115080|NCT01114945|ACTIVE_COMPARATOR|Direct Macintosh Laryngoscopy|Direct Macintosh Laryngoscopy (DL) used during intubation procedure
62115081|NCT06677411||University students|
62115082|NCT01145248|EXPERIMENTAL|Malignant biliary disease|
62115083|NCT01145248|EXPERIMENTAL|Benign biliary disease|
62115084|NCT02894749|NO_INTERVENTION|2D Angiography (2DA)|Standard of care - Patients benefit from a 2D completion angiogram at the end of the procedure, and from a angioCT-scan before discharge. If any technical issues is depicted on the CT-scan, a new intervention needs to be scheduled.
62115085|NCT02894749|EXPERIMENTAL|3D rotational angiography (3DRA)|New strategy - Patients benefit from a 3D rotational acquisition at the end of procedure, which offers CT-like reconstructions. If any technical issues is depicted on the 3DRA, it can be treated during the same operating time. A contrast-enhanced ultrasound is performed for each patient before discharge to confirm that no technical issue was missed by the 3DRA.
62675364|NCT06535776|EXPERIMENTAL|Study group|Individuals in this group will be taught home exercises face-to-face in a single session as in the home-based exercise group and will be asked to perform the exercises themselves at home for 3 non-consecutive days a week for 6 weeks. In this group, home exercises will be monitored by phone and recorded with an exercise tracking chart. In addition to home-based exercises, a total of 12 sessions of face-to-face matrix rhythm therapy will be performed, 2 non-consecutive days a week for 6 weeks. Matrix rhythm therapy applications will be applied by a specialist physiotherapist who has received training with the matrix rhythm therapy vibromassage device.
62675365|NCT04307355|ACTIVE_COMPARATOR|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
62303895|NCT04328662||Cohort 1: Participants with RRMM|Participants diagnosed with relapsed or refractory multiple myeloma (RRMM) who have received at least one dose of ixazomib plus lenalidomide - low dose dexamethasone (IRd) treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
62675366|NCT04307355|NO_INTERVENTION|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
62303896|NCT04328662||Cohort 2: Participants with NDMM, RRMM, and Non-myeloma|Participants diagnosed with NDMM who have received at least one dose of ixazomib-based regimen treatment, diagnosed with RRMM who have received at least one dose non-IRd ixazomib-based regimens treatment, and diagnosed with non-myeloma who have received at least one dose of ixazomib-based regimens treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
62303897|NCT03291327|ACTIVE_COMPARATOR|Investigational product (Lactobacillus A)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (A) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
62115086|NCT00307463|ACTIVE_COMPARATOR|strict volume control policy|strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
62736172|NCT02137447|EXPERIMENTAL|Negative Pressure Wound Therapy|"After the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg.~For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7"
62736173|NCT04469023|EXPERIMENTAL|TS-142 2.5 mg|Period in which participants received multiple-dose of 2.5 mg TS-142 prior to bedtime
62736174|NCT04469023|EXPERIMENTAL|TS-142 5 mg|Period in which participants received multiple-dose of 5 mg TS-142 prior to bedtime
61917869|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
61917870|NCT01398878|NO_INTERVENTION|Traditional work schedule|Residents in the intensive care unit perform overnight shifts in excess of 24 hrs every fourth night
61917871|NCT01398878|ACTIVE_COMPARATOR|Intervention work schedule|Residents in the Intensive Care Unit perform shifts less than 16 hours in length and have at least 8 hours off between shifts
61917872|NCT03528395|EXPERIMENTAL|Semi-immersive virtual reality|8 week protocol with semi-immersive virtual reality provided with the XBOX 360º video game console and its Kinect device. The commercial video games used will be: Kinect Sports I ®, Kinect Sport II ®, Kinect Joy Ride ® and Kinect Adventures ®.
61917873|NCT03528395|ACTIVE_COMPARATOR|Conventional Rehabilitation|Physical therapy and Occupational Therapy based on a task-oriented approach
61917874|NCT04914039||CTA examination|CTA examination group for suspected brain death
61917875|NCT04914039||Confirmed|Confirmed group for brain death
61917876|NCT00993044|EXPERIMENTAL|Single Arm|
62115087|NCT00307463|OTHER|antihypertensive drugs administration|antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.
62115088|NCT04573803|EXPERIMENTAL|MAST DURATION - <3 months|TBI patients with early seizures (within first 7 days following trauma) will receive a short course of up to 3 months of either Phenytoin Sodium or Levetiracetam.
62115089|NCT04573803|EXPERIMENTAL|MAST DURATION - >6 months|TBI patients with early seizures (within first 7 days following trauma) will receive a longer course of at least 6 months of either Phenytoin Sodium or Levetiracetam.
62115090|NCT04573803|EXPERIMENTAL|MAST PROPHYLAXIS - Phenytoin Sodium|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Phenytoin Sodium as seizure prophylaxis.
62115091|NCT04573803|EXPERIMENTAL|MAST PROPHYLAXIS - Levetiracetam|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Levetiracetam as seizure prophylaxis. Dosing will be as prescribed clinically by the treating physician.
61917877|NCT02012673|EXPERIMENTAL|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system
62736175|NCT04469023|EXPERIMENTAL|TS-142 10 mg|Period in which participants received multiple-dose of 10 mg TS-142 prior to bedtime
62115092|NCT04573803|NO_INTERVENTION|MAST PROPHYLAXIS - no treatment|TBI patients, without an acute symptomatic seizure, will not receive any anti-epileptic drug.
62115093|NCT03610958|EXPERIMENTAL|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
62115094|NCT02079155|ACTIVE_COMPARATOR|Arm I (RALP)|Patients undergo standard RALP.
62115095|NCT02079155|EXPERIMENTAL|Arm II (R-LESS RP)|Patients undergo R-LESS RP.
62115096|NCT05392179|EXPERIMENTAL|ADX-2191 Three Injections|
62115097|NCT05392179|EXPERIMENTAL|ADX-2191 Six Injections|
62115098|NCT03465345|EXPERIMENTAL|Metformin + OPC dose escalation|
62115099|NCT01930045|EXPERIMENTAL|Ralt→MAL4Ralt→Ralt4MAL→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Raltegravir (Ralt) alone in Period 1, MAALOX (MAL) followed 4 hrs later by Ralt in Period 2, Ralt followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
62115100|NCT01930045|EXPERIMENTAL|MAL4Ralt→Ralt4MAL→Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt followed 4 hrs later by MAL in Period 2, Ralt alone in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
62115101|NCT01930045|EXPERIMENTAL|Ralt4MAL→Ralt→MAL4Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, Ralt alone in Period 2, MAL followed 4 hrs later by Ralt in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
62115102|NCT01930045|EXPERIMENTAL|Ralt→Ralt4MAL→MAL4Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt alone in Period 1, Ralt followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Ralt in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
62115103|NCT01930045|EXPERIMENTAL|MAL4Ralt→Ralt→Ralt4MAL→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt alone in Period 2, Ralt followed 4 hrs later by MAL in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
62115104|NCT01930045|EXPERIMENTAL|Ralt4MAL→MAL4Ralt→Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Ralt in Period 2, Ralt alone in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
62115105|NCT01517542|EXPERIMENTAL|Nutritional counseling|It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.
62115106|NCT01517542|NO_INTERVENTION|Usual diet|It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits
62115107|NCT01672619||children with craniosynostosis|children with craniosynostosis aged 6 months to 13
62115108|NCT03575819|EXPERIMENTAL|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
62736176|NCT04469023|EXPERIMENTAL|Placebo|Period in which participants received single placebo prior to bedtime
62115109|NCT03575819|EXPERIMENTAL|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
62303898|NCT03291327|ACTIVE_COMPARATOR|Investigational product (Lactobacillus B)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (B) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
62303899|NCT03291327|PLACEBO_COMPARATOR|Placebo Product (P)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Placebo (P) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The placebo will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
62303900|NCT04598438|EXPERIMENTAL|Music intervention treatment group|Participants attending the music behavioral early intervention program
62303901|NCT04598438|ACTIVE_COMPARATOR|Arts and crafts active control group|Participants attending the arts and crafts developmental enhancement program
62303902|NCT00215150|OTHER|Open Label Treatment|8 weeks of open label treatment with sertraline
62303903|NCT00215150|OTHER|Randomization Ziprasidone|8 weeks of treatment with sertraline augmented with ziprasidone
62303904|NCT00215150|OTHER|Randomization Placebo|8 weeks of treatment with sertraline augmented by placebo
62303905|NCT02750410|EXPERIMENTAL|Dulaglutide|Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
62303906|NCT02750410|PLACEBO_COMPARATOR|Placebo|Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.
62303907|NCT00581607|ACTIVE_COMPARATOR|Bosentan for 16 weeks|Active drug
62303908|NCT00581607|PLACEBO_COMPARATOR|Placebo|Placebo for 16 weeks
62303909|NCT02278978|EXPERIMENTAL|FGFR3 mutated|BIBF 1120 in patients with advanced FGFR3 mutated
62303910|NCT02278978|EXPERIMENTAL|FGFR3 overexpressed|BIBF 1120 in patients with advanced FGFR3 overexpressed
62303911|NCT02278978|EXPERIMENTAL|FGFR3 wild type|BIBF 1120 in patients with advanced FGFR3 wild type
62303912|NCT01771302|ACTIVE_COMPARATOR|Bio-Oss|the xenograft is of bovine origin where the organic phase has been eliminated.
62303913|NCT01771302|EXPERIMENTAL|calcium phosphate ceramic|is a calcium phosphate biomaterial
62303914|NCT02446782|EXPERIMENTAL|Cefazolin|A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
62303915|NCT02446782|PLACEBO_COMPARATOR|saline|100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
62303916|NCT05478915|EXPERIMENTAL|patients with TMJ anterior disc displacement|patients had clinically limited mouth opening and by MRI we found anterior disc displacement
62303917|NCT02271490|ACTIVE_COMPARATOR|micoinjection according to classical protocole|incubation of sperm in incubation medium
62303918|NCT02271490|EXPERIMENTAL|incubation in follicular fluid|incubation of sperm in follicular fluid prior to microinjection
62303919|NCT05681728|EXPERIMENTAL|Pembrolizumab combined with chemotherapy|
62303920|NCT03103399|EXPERIMENTAL|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
62303921|NCT03103399|EXPERIMENTAL|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
62736177|NCT05858476|EXPERIMENTAL|Chef V's 21-Day Starter Challenge Detox & Green Drink Supplement|"The detox program provides the three primary macronutrients alongside antioxidants to promote detoxification. The 21-Day Detox schedule is below:~Days 1-7: Healthy Routine- The Healthy Routine involves drinking a 16oz Green Drink and Protein Shake for breakfast and then choosing their lunch, snack, and dinner from the Meal Planner that will be provided.~Days 8-10: 3-Day Cleanse- Each day during the three-day cleanse, participants will consume 4 16oz Green Drinks, 2 Protein Shakes, and a Soup designed explicitly to detox the body.~Days 11-21: Healthy Routine- The last period of the 21 days will mimic the Healthy Routine from Days 1-7.~Days 21-28 Participants will follow up this program by using the Green Drink supplement provided for an additional 7 days."
62303922|NCT03103399|EXPERIMENTAL|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
62115110|NCT06630338||Observational|Patients undergo shear wave elastography ultrasound over 10-15 minutes during their standard of care surgery on study.
62303923|NCT03103399|ACTIVE_COMPARATOR|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
62303924|NCT03103399|PLACEBO_COMPARATOR|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
62303925|NCT05000320||Vigabatrin-naive|Adults 18 - 80 years of age suffering from post anoxic status epilepticus (PASE) who have not received vigabatrin.
62303926|NCT06421324|NO_INTERVENTION|Healthy controls|"Subjects will be recruited prospectively from the Digestive Medicine/Endoscopy Departments of the centres involved. Patients will be treated according to the medical and patient decisions according to the clinical practice protocols of each site. Sample collection will be performed during a gastroscopy for pathological and molecular characterisation. This gastroscopy will be always indicated within usual clinical practice, so no additional risk is planned for the subjects included.~Inclusion criteria: Subjects ≥18 years old to whom an endoscopy is performed due to gastric symptoms, without previous history of gastric chronic inflammation or Helicobacter pylori infection"
62303927|NCT06421324|NO_INTERVENTION|Gastric cancer controls|"Subjects will be recruited prospectively from the Digestive Medicine/Endoscopy Departments of the centres involved. Patients will be treated according to the medical and patient decisions according to the clinical practice protocols of each site. Sample collection will be performed during a gastroscopy for pathological and molecular characterisation. This gastroscopy will be always indicated within usual clinical practice, so no additional risk is planned for the subjects included.~Inclusion criteria: Subjects ≥18 years old with a diagnosis of Gastric Cancer, to whom a gastroscopy is indicated within clinical care naive for chemotherapy."
62472509|NCT06280183|ACTIVE_COMPARATOR|Aerobic and Resistive Exercise Training|"The exercise program will start with a 5-10 minute warm-up and end with a 5-10 minute cool down. Aerobic exercise is planned at 60-85% of Maximum Heart Rate on the bike for 30-40 minutes.~Resistive exercise program, covering all major major muscle groups; The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body muscles, abdominal muscles and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1 maximum repetition (1RM)."
62472510|NCT06280183|EXPERIMENTAL|Functional Inspiratory Muscle Training Group in obese individuals:|Inspiratory muscle training will be applied simultaneously with aerobic exercise. This program will create the functional IMT. The exercise program will start with a 5-10 minute warm-up and cool down. Aerobic exercise is planned at 60-85% of MHR on the bike for 30-40 minutes, progress will be achieved. Participants will first work with bicycle ergometry and then continue with IMT in the same session for the first three weeks. The intensity of IMT exercise will be set at 40-60% of MIP. After 10 consecutive breathing cycles, participants will be asked to perform 3-4 breath checks. Resistive exercise program, covering all major muscle groups; The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body muscles, abdominal muscles and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1RM.
62472511|NCT06280183|NO_INTERVENTION|Control Group:|Patient education will be given and no intervention will be made.
62472512|NCT04364126|ACTIVE_COMPARATOR|Standard of care|Clinical blood pressure measured at regular visits
62472513|NCT04364126|EXPERIMENTAL|Home blood pressure monitoring|Home blood pressure measured daily for 1 week before regular clinical visits
62472514|NCT00854659|ACTIVE_COMPARATOR|1|ABT-102 Tablets, 4 mg BID
62472515|NCT00854659|ACTIVE_COMPARATOR|2|ABT-102 Tablets BID, escalating dose
62472516|NCT00854659|ACTIVE_COMPARATOR|3|ABT-102 Tablets BID, escalating dose
62736178|NCT05965583|EXPERIMENTAL|BI 1815368 (Reference, R) then BI 1815368 + Itraconazole (Test, T)|
62115111|NCT00696280||Group 1|"All patients will be given the Functional Living Index - Emesis (FLIE) standardized questionnaire during their scheduled clinic visit prior to receiving chemotherapy.~This is a self-administered questionnaire. Patients will complete the questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours, 72 hours, and 96 hours) of their first and third cycles of chemotherapy.~Patients will also be interviewed by a trained CRA or research nurse over the telephone 24-48 hours following carboplatin administration in order to assess the severity of the delayed nausea and vomiting."
62115112|NCT05787964||Healthy participants|Healthy adults aged \> 18 years
62115113|NCT05787964||Participants with haematological malignancies|Multiple myeloma patients receiving lenalidomide and smoldering multiple myeloma patients under observation.
62115114|NCT05787964||Participants with solid tumours|Stage IV non-small cell lung cancer patients treated with checkpoint inhibitor therapy +/- chemotherapy.
62472517|NCT00854659|PLACEBO_COMPARATOR|4|Placebo Tablets, BID
62472518|NCT01971060|EXPERIMENTAL|V-Loc suture|Laparoscopic surgery utilizing V-Loc suture
62472519|NCT01498003|PLACEBO_COMPARATOR|Control group|normal saline was applied to those randomized to control group, with same use as tirofiban
62472520|NCT01498003|EXPERIMENTAL|Tirofiban group|after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion
62472521|NCT00645762|ACTIVE_COMPARATOR|Balloon Dilation|Balloon dilation with FinESS device
62736179|NCT01921556|ACTIVE_COMPARATOR|QualiCCare education|"QualiCCareeducation is a training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
62115115|NCT03730428||pneumonitis group|Patients who developed drug-related pneumonitis after treated with everolims
62303928|NCT06421324|EXPERIMENTAL|GIM cases|"Subjects will be recruited prospectively from the Digestive Medicine/Endoscopy Departments of the centres involved. Patients will be treated according to the medical and patient decisions according to the clinical practice protocols of each site. Sample collection will be performed during a gastroscopy for pathological and molecular characterisation. This gastroscopy will be always indicated within usual clinical practice, so no additional risk is planned for the subjects included.~Inclusion criteria: Subjects ≥18 years old with a diagnosis of GIM or previous or current H. pylori infection, to whom a gastroscopy is indicated within clinical care"
62303929|NCT03528681|EXPERIMENTAL|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the open label initial phase.
62303930|NCT03528681|EXPERIMENTAL|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the open label initial phase.
62303931|NCT03528681|PLACEBO_COMPARATOR|Matching Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase.
62303932|NCT04093219|EXPERIMENTAL|IV Acetaminophen|1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
62303933|NCT04093219|PLACEBO_COMPARATOR|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
62303934|NCT02631187|EXPERIMENTAL|Balloon Eustachian Tuboplasty|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
62303935|NCT01351662|EXPERIMENTAL|Self management program|"The Arthritis Self-Management Program (ASMP) will be administered to 15 African American lupus patients participating in an ongoing SLE Clinic Database Project at the Medical University of South Carolina (MUSC). Fifteen other patients will serve as controls and receive usual care."
62303936|NCT02418494||Observational (ANCHOR HRQoL interview, cognitive interview)|Participants complete the ANCHOR HSIL HRQoL interview over 45-60 minutes, comparing the list of symptoms, concerns, or HRQOL impacts related to HSIL diagnosis and treatment. Some patients also undergo a cognitive interview for up to 3 sessions.
62303937|NCT06512402|ACTIVE_COMPARATOR|Norepinephrine group|After subarachnoid block, mothers will be placed in supine position with left-lateral tilt and will receive norepinephrine infusion until 5 min after delivery
62472522|NCT03666026|NO_INTERVENTION|Standard of care control|Participants in this group will not receive any MyChart influenza vaccination reminders
62736180|NCT01921556|NO_INTERVENTION|usual care|The practices randomized to the control group apply care as usual
62115116|NCT03730428||non-pneumonitis group|Patients who didn't develop drug-related pneumonitis after treated with everolims
62115117|NCT00383513|EXPERIMENTAL|Epratuzumab|
62115118|NCT06677515|EXPERIMENTAL|Virtual reality (VR) training|"Participants randomized to the intervention arm will attend VR sessions twice a week in 5 weeks, or 10 sessions in total. They will be placed into different virtual environments with increasing complexity, where they will be confronted with normal everyday situations in city environments.~In the first session, participants will receive instructions on using the head mounted display and navigating the scenarios. In three scenarios, participants are only observers, while in the remaining they can choose between several response options. These responses will be displayed on the screen, and participants can select their preferred response by pointing their finger to the chosen response alternative. The response alternatives are also provided verbally."
62303938|NCT06512402|ACTIVE_COMPARATOR|Epinephrine group|After subarachnoid block, mothers will be placed in supine position with left-lateral tilt and will receive epinephrine infusion until 5 min after delivery
62303939|NCT04666883||Splenic flexure cancer patients|Splenic flexure cancer patients
62303940|NCT05977543|NO_INTERVENTION|Control wheat crackers|Volunteers consumed 80g of white bread, 30g of full fat butter and 55g of wheat flour crackers.
62303941|NCT05977543|OTHER|Grape seed flour crackers|Volunteers consumed 80g of white bread, 30g of full fat butter and 55g of wheat flour crackers, enriched with 10% grape seed flour crackers.
62303942|NCT05977543|OTHER|Barley flour and β-glucan crackers|Volunteers consumed 80g of white bread, 30g of full fat butter and 55g of 60% wheat flour and 40% barley flour crackers, enriched with β-glucan
62303943|NCT00577590|PLACEBO_COMPARATOR|Metformin Alone|Participants assigned to take Metformin alone.
62303944|NCT00577590|EXPERIMENTAL|Metformin and Rosiglitazone|Participants assigned to take Metformin and Rosiglitazone
62303945|NCT00577590|EXPERIMENTAL|Metformin and Lovaza|Participants assigned to take Metformin and Lovaza
62472523|NCT03666026|EXPERIMENTAL|1 MyChart R/R|Participants in this group will receive up to 1 influenza reminder recall notice via their MyChart account
62472524|NCT03666026|EXPERIMENTAL|2 MyChart R/R|Participants in this group will receive up to 2 influenza reminder recall notices via their MyChart account
62472525|NCT03666026|EXPERIMENTAL|3 MyChart R/R|Participants in this group will receive up to 3 influenza reminder recall notices via their MyChart account
62675367|NCT04319276|EXPERIMENTAL|Dose-escalation Phase (500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
62675368|NCT04319276|EXPERIMENTAL|Dose-escalation Phase (1,000 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
62736181|NCT00000428|EXPERIMENTAL|1|Patients received each intervention multiple times in random-order crossover design.
62472526|NCT04032782|EXPERIMENTAL|HM15136|
62472527|NCT04032782|PLACEBO_COMPARATOR|Placebo of HM15136|
62115119|NCT06677515|NO_INTERVENTION|Treatment as usual|Treatment of substance use disorders (SUD) is delivered by personnel with medical, psychological, and social expertise, meeting specialist-level healthcare standards. SUD treatment clinics offer patient-centred, interdisciplinary, holistic treatment focusing on physical, mental and social problems. Treatment often consists of both individual and group therapies and include activities (e.g., physical exercise, social activities) in the clinic as well as in external settings. Since treatment approaches and facilities may vary across clinics, patients' preferences or choice of clinic are emphasized. According to national guidelines, persons with SUD and co-occurring severe mental illness (i.e., schizophrenia or severe bipolar disorder) can receive treatment in SUD treatment clinics as long as their mental condition is stable. Otherwise, persons with SUD and severe mental illness receive treatment for both conditions within mental health services.
62736182|NCT03780621|EXPERIMENTAL|Andrographis and Withania|Active ingredient: 550 mg of Andrographis paniculata (standardized to 40 mg andrographolides) and Withania somnifera (standardized to 10 mg withanolides) taken twice daily, once in the morning and once in the evening
62115120|NCT05676190|EXPERIMENTAL|CIK combined with chemotherapy group|Combination of CIK cells and chemotherapy
62303946|NCT05248997|ACTIVE_COMPARATOR|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
62472528|NCT01383486|EXPERIMENTAL|Naproxen Sodium ER (BAYH6689) or Advil IR|Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
62472529|NCT05041361|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH)|Participants receive up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions. Each WBH session (including preparation and cool down) is up to approximately 3.5-4 hours, and each CBT session is approximately 50 minutes.
62472530|NCT02516839|EXPERIMENTAL|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning.
61917878|NCT05329571|EXPERIMENTAL|Low-FODMAP Diet|Participants will be instructed to maintain their usual diet, while eliminating FODMAPs (A subgroup of carbohydrates are considered fermentable, given the lack of suitable hydrolase enzymes in the colon, required for their digestion and absorption, thus making them available for fermentation).
61917879|NCT05329571|EXPERIMENTAL|Gluten-Free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
62115121|NCT05676190|EXPERIMENTAL|CIK combined immunotherapy group|Combination of CIK cells and immunotherapy
62115122|NCT05676190|EXPERIMENTAL|CIK combined targeted therapy group|Combination of CIK cells and targeted therapy
62303947|NCT05248997|ACTIVE_COMPARATOR|Matching Placebo|One dose of matching placebo
61917880|NCT05329571|OTHER|Control|Patients of this group will be asked to adhere to their regular, daily diet.
62115123|NCT05676190|EXPERIMENTAL|CIK in combination with other therapies|CIK in combination with any two or three of these (i.e., chemotherapy, immunotherapy, and targeted therapy) treatments
62303948|NCT06075940|EXPERIMENTAL|MAGNITUDE BRS|
62472531|NCT02516839|EXPERIMENTAL|Behavioral Weight Loss (BWL)|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
62472532|NCT02516839|EXPERIMENTAL|BWL+ ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments.
62472533|NCT02516839|ACTIVE_COMPARATOR|Nutrition Education, Stress Management Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
62472534|NCT04236856|OTHER|Robotic Endovascular Procedure|Subjects with a clinical indication for endovascular coil and/or stent assisted coiling embolization of cerebral aneurysms will be treated using the CorPath GRX System.
62472535|NCT02773134|ACTIVE_COMPARATOR|Brace Group|Patients in the brace group will be fitted by an orthotist postoperatively and will be instructed to wear a rigid molded Lumbosacral Orthosis (LSO) full time for 8 weeks except during hygiene and wound care followed by daytime wear for another 4 weeks. All patients will start wearing the brace 48 hours after the surgery following removal of the wound drain. All braces will be molded and fitted by the same experienced orthotist affiliated with the hospital. Self-compliance to brace wear will be noted every day for 3 months by each patient on a specific form.
62472536|NCT02773134|EXPERIMENTAL|Control Group|No brace prescription postoperatively. Patients in this group will be observed and results will be compared to the brace group.
61917881|NCT05045378|ACTIVE_COMPARATOR|1. Two 0.045mg/kg midazolam infusions|Two 0.045mg/kg midazolam infusions as active placebo
61917882|NCT05045378|EXPERIMENTAL|2. First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion|Single ketamine infusion + Single midazolam placebo infusion
62472537|NCT04233385|EXPERIMENTAL|Myofascial Massage|Participants randomized to this group will receive 30 minutes of myofascial massage to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed 8 week protocol developed with a massage therapy consultant and the study team.
62472538|NCT04233385|ACTIVE_COMPARATOR|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months.
62472539|NCT06147622|EXPERIMENTAL|KT110|Subjects will be randomized to receive KT110 on period 1 or period 2
62472540|NCT06147622|EXPERIMENTAL|Prazosin + cyproheptadine|Subjects will be randomized to receive prazosin + cyproheptadine on period 1 or period 2
61917883|NCT05045378|EXPERIMENTAL|3. Two 0.5mg/kg ketamine infusions|Repeated (Two) ketamine infusions: Two 0.5mg/kg ketamine infusions
62115124|NCT05664100|EXPERIMENTAL|FX-345 Cohort 1|Patients in the first cohort receiving FX-345 intratympanic injection
62472541|NCT02406560|EXPERIMENTAL|4 tablets of 12.2 mg tafamdis free acid|
62472542|NCT02406560|EXPERIMENTAL|4 tablets of 12.2 mg tafamidis free acid|
62472543|NCT02406560|EXPERIMENTAL|5 tablets of 12.2 mg tafamidis free acid|
62472544|NCT06310655|EXPERIMENTAL|Proton Stereotactic Body Radiotherapy (SBRT)|All patients will receive standard of care proton SBRT either daily or every other day for a total of 5 fractions. At the time of each treatment, the initial pre-plan will be generated on the patient and assessed for coverage and safety. An adaptive plan based on the patient's anatomy that day will also be generated and then compared to the initial pre-plan. The optimal treatment plan will be chosen and administered to the patient on that day. This process will be repeated for each fraction for every patient.
62472545|NCT01049997||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
62472546|NCT05349435|EXPERIMENTAL|Cohort 1 Dose Level 1|Drug: Fezagepras and sodium PBA
62472547|NCT05349435|EXPERIMENTAL|Cohort 2 Dose Level 2|Drug: Fezagepras and sodium PBA
62472548|NCT04681534|ACTIVE_COMPARATOR|conventional DBS|
62472549|NCT04681534|EXPERIMENTAL|adaptive DBS|
62472550|NCT04208724|EXPERIMENTAL|Training program|Community-based organizations participate in the support program, consisting of 2 half-day training workshops over 2 weeks, and 30-minute bi-weekly consultations in order to adapt and implement the cancer screening intervention for community members.
62472551|NCT05310591|EXPERIMENTAL|Patients with MRD negative disease status: Time to Event Continual Reassessment Method (TITE-CRM)|
62472552|NCT05310591|EXPERIMENTAL|For relapsed patients|
62472553|NCT03755947|EXPERIMENTAL|IGV|"Cytoreduction 3 cycles (I) Ibrutinib, \[Imbruvica, Janssen\]~Induction 6 cycles (G) Obinutuzumab, \[Gazyva, Roche\]~Consolidation 12 cycles (V) Venetoclax, \[Venclexta, Abbvie\]."
62736183|NCT03780621|PLACEBO_COMPARATOR|Placebo|550 mg capsule visually identical to the active dietary supplement, containing brown sugar, microcrystalline cellulose, corn starch, and magnesium stearate
62115125|NCT05664100|PLACEBO_COMPARATOR|Placebo Cohort 1|Patients in the first cohort receiving placebo intratympanic injection
62115126|NCT05664100|EXPERIMENTAL|FX-345 Cohort 2|Patients in the second cohort receiving FX-345 intratympanic injection
62736184|NCT05319808|EXPERIMENTAL|Group A|Telehealth using NeckCare equipment
61917884|NCT03277833|EXPERIMENTAL|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
61917885|NCT03277833|PLACEBO_COMPARATOR|Placebo|Placebo
62115127|NCT05664100|PLACEBO_COMPARATOR|Placebo Cohort 2|Patients in the second cohort receiving placebo intratympanic injection
62115128|NCT04157530|SHAM_COMPARATOR|sham group|15 subjects with seeds of wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
62115129|NCT04157530|EXPERIMENTAL|acupuncture group|15 subjects with acupuncture applied to Qingming and Qiuhou with Der-qi
62115130|NCT04157530|EXPERIMENTAL|Electroacupuncture group|15 subjects wth acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi
62303949|NCT02107664||Radiation therapy for bone cancer pain|The group includes all cancer diagnoses, and different fractions of RT planned.
62675369|NCT04319276|EXPERIMENTAL|Dose-escalation Phase (1,500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
62736185|NCT05319808|ACTIVE_COMPARATOR|Group B|Exercises without telehealth intervention
62736186|NCT05319808|NO_INTERVENTION|Group C|No intervention provided by the researchers
62115131|NCT02674451|ACTIVE_COMPARATOR|RIPC|Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
62115132|NCT02674451|SHAM_COMPARATOR|Controls|Participants will have routine blood pressure measurements will be obtained.
62115133|NCT05737095||Premature infants|premature infants born between 32 and 36 weeks of amenorrhea + 6 days hospitalized for respiratory distress
62115134|NCT02263508|EXPERIMENTAL|Phase 1b: Talimogene Laherparepvec + Pembrolizumab|Participants received talimogene laherparepvec at an initial dose of up to 4 mL 10⁶ plaque-forming units (PFU)/mL by intralesional injection. Subsequent doses of talimogene laherparepvec at up to 4 mL of 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until disappearance of injectable lesions, complete response (CR), confirmed disease progression (PD) per modified Immune-related Response Criteria (irRC), intolerance of study treatment, 24 months from the date of the first dose of pembrolizumab, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 2 weeks starting at the time of the third dose of talimogene laherparepvec (week 6) until confirmed PD per modified irRC, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
62115135|NCT02263508|PLACEBO_COMPARATOR|Phase 3 : Placebo + Pembrolizumab|Participants received up to 4 mL placebo to talimogene laherparepvec by intralesional injection on day 1 of week 0. Subsequent doses of placebo (up to 4 mL) began 3 weeks after the first dose and were administered every 2 weeks until the fifth injection (week 9), and then synchronously with pembrolizumab thereafter every 3 weeks until disappearance of injectable lesions, complete response per modified Immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST) (iCR), confirmed iPD per modified irRC-RECIST, intolerance of study treatment, 24 months from the date of the first dose of placebo, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 3 weeks starting on day 1 of week 0, until confirmed iPD per modified irRC-RECIST, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
62115136|NCT02263508|EXPERIMENTAL|Phase 3: Talimogene Laherparepvec + Pembrolizumab|Participants received talimogene laherparepvec at an initial dose of up to 4 mL 10⁶ PFU/mL by intralesional injection on day 1. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL (up to 4 mL) began 3 weeks after the first dose and were administered every 2 weeks until the fifth injection of talimogene laherparepvec (week 9), and then synchronously with pembrolizumab thereafter every 3 weeks until disappearance of injectable lesions, iCR, confirmed iPD per modified irRC-RECIST, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 3 weeks starting on day 1 of week 0, until confirmed iPD per modified irRC-RECIST, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
62115137|NCT00868192|EXPERIMENTAL|Pemetrexed and bevacizumab|"Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle~Bevacizumab 15 mg/kg IV on Day 1 of each 21 day cycle"
62115138|NCT01113333|EXPERIMENTAL|SAR113945|SAR113945, single dose according to dose escalation design
62115139|NCT01113333|PLACEBO_COMPARATOR|Placebo|0.9% saline solution, single dose
62115140|NCT05785494|EXPERIMENTAL|Intervention|Access to web-site
62115141|NCT05785494|NO_INTERVENTION|Control|Standard care
62115142|NCT03996746||Non-dialysis Group|non-dialysis patients with CKD 2-5
61917886|NCT06110975|EXPERIMENTAL|Intervention group|"The primary care clinics in the intervention group will contact and evaluate all patients receiving one or more of the following drugs:~G04BD04 Oxybutynin G04BD07 Tolterodine G04BD08 Solifenacin G04BD09 Trospium G04BD10 Darifenacine G04BD11 Fesoterodine G04BD12 Mirabegron The patients will be asked to discontinue the treatment and eventually be deprescribed"
62115143|NCT03996746||Hemodialysis Group|patients with CKD 5 under hemodialysis for more than 3 months
62115144|NCT05544578|EXPERIMENTAL|Nurses Taking On Readiness Measures (N-TORM) Intervention Group|This is a phase 1 feasibility study via a cluster randomized controlled trial.
62115145|NCT05544578|NO_INTERVENTION|Disaster and Emergency Preparation Pocket Guide Control Group|The control group will receive the Korean version of the 2-page Prepared New York: Disaster and Emergency Preparation pocket guide (NYC Emergency Management, n.d.) after data collection has been completed.
62115146|NCT02200159||dexmedetomidine|
62115147|NCT04956146|EXPERIMENTAL|Fruquintinib Combined With Sintilimab and Chemotherapy|
62115148|NCT01601223||Surgical mechanically-ventilated|Surgical patients undergoing invasive mechanical ventilation for general anesthesia
62115149|NCT04128839|EXPERIMENTAL|Aronia juice (ARO)|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day for duration of intervention period (28-30 days)
62115150|NCT04128839|SHAM_COMPARATOR|Placebo juice (PLA)|The placebo juice was flavor, color, and carbohydrate-matched to experimental Aronia juice. PLA consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day for duration of intervention period (28-30 days)
62472554|NCT06561867|ACTIVE_COMPARATOR|Ticagrelor arm|The ticagrelor arm will receive (a 180mg loading dose during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd to the 90th day)
62115151|NCT03698708|EXPERIMENTAL|CARES Intervention- 12 sessions|Participants in the intervention will participate in 12 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
62675370|NCT04319276|EXPERIMENTAL|Dose-escalation Phase (2,000 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
62736187|NCT04277481||Group 1 (10 minute cold pack)|10 min, s package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
62736188|NCT04277481||Group 2 (12 minute cold pack)|12 min, s package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
62736189|NCT04277481||Group 3 (15 minute cold pack)|15 min, s package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
62736190|NCT04277481||Group 4 (20 minute cold pack)|20 min, s package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
62115152|NCT03698708|EXPERIMENTAL|CARES Intervention- 8 sessions|Participants in the intervention will participate in 8 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
62115153|NCT02032719|EXPERIMENTAL|smartphone assisted lifestyle coaching|6 months of smartphone assisted lifestyle coaching
62115154|NCT02032719|ACTIVE_COMPARATOR|Lifestyle health coaching|6 months of lifestyle health coaching
62115155|NCT00978406||Healthy volunteers|Healthy volunteers
62115156|NCT00726999|ACTIVE_COMPARATOR|1|Gabapentin
62115157|NCT00726999|PLACEBO_COMPARATOR|2|Placebo Comparator -- pill matched in appearance to gabapentin
62115158|NCT04635358|EXPERIMENTAL|Intervention|Setting up hypnosis sessions, psychological and nutritional assistance.
62303950|NCT03851601||ECP|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
62472555|NCT06561867|ACTIVE_COMPARATOR|cilostazol arm|The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day)
62472556|NCT06219577|OTHER|Systane Complete Multi-Dose PF|
62472557|NCT06219577|OTHER|Walgreen's Lubricant Balance|
61917887|NCT06110975|NO_INTERVENTION|Control group|The primary care clinics in the control group will not contact and evaluate patients and are not informed about the study. Data will be extracted from registries
62115159|NCT01065636|EXPERIMENTAL|Diet + Resistance Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised resistance exercise training three times a week
62115160|NCT01065636|EXPERIMENTAL|Diet + Aerobic Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised aerobic exercise training three times a week
62115161|NCT01065636|EXPERIMENTAL|Diet + Combined Aerobic/Resistance Exercise|Weekly behavioral/diet-induced weight loss plus combined supervised resistance exercise training and aerobic exercise training three times a week
62303951|NCT03668132||Left damage|Have the ischemic brain damage and the location of the damage ,and in the left brain
62303952|NCT03668132||Right damage|Have the ischemic brain damage and the location of the damage ,and in the right brain
62303953|NCT03668132||Normal control|Not have the ischemic brain damage
62303954|NCT05731739||RESPONDERS|The investigators will define responders as patients achieving Numerical Rating Score (NRS) reductions of 30% or greater based on literature defined criteria for meaningful reductions in pain scores
62303955|NCT05731739||NON RESPONDERS|When a patient failed to respond to the lidocaine infusion, they were given the option to have repeat infusion after four weeks. If no response was obtained, despite two infusions, this was considered as a failure of treatment and no further lidocaine infusions were conducted. Patient will be labelled as a non responder
61917888|NCT04665193|EXPERIMENTAL|Abbott Panbio test device|WestJet passengers departing from YVR screened for COVID-19 using Abbott Panbio test device
62115162|NCT01065636|NO_INTERVENTION|Control Group (No Diet/No Exercise)|No diet No exercise training
62115163|NCT03499236|EXPERIMENTAL|Treatment|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
62115164|NCT03499236|OTHER|Control|Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
62115165|NCT03499236|EXPERIMENTAL|Roll in|Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
62303956|NCT04321863||Adults with Crohn's disease in remission|All patients recruited will submit two samples to facilitate faecal zinc and qFIT in addition to FC which is standard of care. All patients recruited will have an additional tube of blood taken to measure serum zinc at the same time as they have their routine (standard of care) monitoring bloods taken - no additional venepuncture will be required.
62303957|NCT06208176|ACTIVE_COMPARATOR|active stimulation group|23 patients will receive 20 sessions of active HD-tDCS
62303958|NCT06208176|PLACEBO_COMPARATOR|placebo stimulation group|High-definition transcranial direct current (HD-tDCS), sham condition
62303959|NCT05611138|EXPERIMENTAL|Isolated pea protein|Dietary supplementation with isolated pea protein powder. Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
62472558|NCT06561750|EXPERIMENTAL|Rooibos|Participants in the AG will consume the test drink (12 g per 1200 ml of pure green rooibos tea). Participants will be asked to return after 24, 48 and 72 hours of the exercise. During each visit, the baseline measurements, perceived muscle soreness and muscle recovery will be repeated.
62472559|NCT06561750|PLACEBO_COMPARATOR|Control|Participants in the control group will be asked to drink 1200 ml of water since rooibos has a very unique taste
62675371|NCT04319276|EXPERIMENTAL|Dose-escalation Phase (2,500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
62675372|NCT04319276|EXPERIMENTAL|Dose-expansion Phase|A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
62675373|NCT06378255|EXPERIMENTAL|Polycation-based new dentinal desensitizer|Use a cotton ball or brush to apply a small amount of desensitizing agent to the sensitive tooth surface for about 1 minute and wait for 2 minutes. Excess gel is then wiped off the surface.
62303960|NCT05611138|EXPERIMENTAL|Isolated whey protein|Dietary supplementation with isolated whey protein. Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
62303961|NCT05611138|EXPERIMENTAL|Concentrated pea protein|Dietary supplementation with concentrated pea protein Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
62303962|NCT04884087|EXPERIMENTAL|EMA, 3x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
62303963|NCT04884087|EXPERIMENTAL|EMA, 6x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
62303964|NCT04884087|EXPERIMENTAL|EMA, 3x/day, prize-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
62472560|NCT06558669|NO_INTERVENTION|Control Group|There are 100 participants in this arm and will only consume their prescribed medicines.
62472561|NCT06558669|EXPERIMENTAL|Treatment 1|There are 100 participants in this arm who will consume 170mL of fresh sugarcane juice and take their prescribed medicines.
62472562|NCT06558669|EXPERIMENTAL|Treatment 2|There are 100 participants in this arm who will consume 230mL of fresh sugarcane juice and take their prescribed medicines.
62472563|NCT06558669|EXPERIMENTAL|Treatment 3|There are 100 participants in this arm who will consume 300mL of fresh sugarcane juice and take their prescribed medicines.
62675374|NCT06378255|PLACEBO_COMPARATOR|GLUMA desensitizer|Use according to instructions
62675375|NCT01943825|EXPERIMENTAL|CYD Dengue Vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
61917889|NCT04449029|EXPERIMENTAL|Cohort 1: GSK3228836 300 mg + LD|Eligible participants on stable nucleos(t)ide treatment will receive 300 milligrams (mg) GSK3228836 once weekly for 24 weeks along with loading dose (LD) of 300 mg GSK3228836 on Day 4 and Day 11.
62675376|NCT01943825|EXPERIMENTAL|CYD Dengue Vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
62303965|NCT04884087|EXPERIMENTAL|EMA, 6x/day, prized-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
62303966|NCT05069779|EXPERIMENTAL|Diazepam|Oral
62303967|NCT05069779|PLACEBO_COMPARATOR|Placebo|Oral
62303968|NCT05182164|EXPERIMENTAL|Stratum 1: advanced undifferentiated pleomorphic sarcoma|Patients with advanced undifferentiated pleomorphic sarcoma will be treated by the combination of pembrolizumab + cabozantinib
62303969|NCT05182164|EXPERIMENTAL|Stratum 2: advanced osteosarcoma|Patients with advanced osteosarcoma will be treated by the combination of pembrolizumab + cabozantinib
62115166|NCT00843193|EXPERIMENTAL|GSK679586|Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
62303970|NCT05182164|EXPERIMENTAL|Stratum 3: advanced Ewing sarcoma|Patients with advanced Ewing sarcoma will be treated by the combination of pembrolizumab + cabozantinib
62472564|NCT01342263|NO_INTERVENTION|Usual Care|Does not get to participate in the interactive chronic disease website.
62675377|NCT01943825|EXPERIMENTAL|CYD Dengue and JE Vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
62675378|NCT01943825|EXPERIMENTAL|CYD Dengue and JE Vaccine: Group 4|Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
62675379|NCT05945732||Trastuzumab deruxtecan (T-DXd)|Participants with HER2-low expressing unresectable and/or metastatic breast cancer who will be treated with trastuzumab deruxtecan and part of the enrolled participants will receive conventional chemotherapy. The participants on conventional chemotherapy will be analyzed exploratory only.
62115167|NCT00843193|PLACEBO_COMPARATOR|PLACEBO|Subjects will receive three, once monthly intravenous administration of saline, according to randomization
62115168|NCT05862454||Adult chronic pain patients|Cohort of adult chronic pain patients, undergoing interventional injection therapy for pain management at a Canadian pain clinic
62115169|NCT05132686|EXPERIMENTAL|Intermittent energy restriction (IER) + Mediterranean diet (MED) or IER+MED|The IER+MED group intervention will be to restrict 70% energy (25%, 45% and 30% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow a MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. This would be equivalent to an over-all 20% daily energy restriction. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
62115170|NCT05132686|EXPERIMENTAL|Mediterranean diet (MED) + daily energy restriction (DER) or MED/DER|The MED/DER group intervention will restrict 20% energy (25%, 45% and 30% distribution of protein, carbohydrate, and fat, respectively) continuously. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
62115171|NCT01137799|EXPERIMENTAL|001|JNJ-39393406 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
62115172|NCT01137799|EXPERIMENTAL|002|JNJ-39393406 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
62115173|NCT01137799|EXPERIMENTAL|003|JNJ-39393406 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
62115174|NCT01137799|EXPERIMENTAL|004|JNJ-39393406 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
62115175|NCT01137799|EXPERIMENTAL|005|JNJ-39393406 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
62115176|NCT01137799|PLACEBO_COMPARATOR|006|placebo Once daily (single dose)
62115177|NCT04126239||Participant suffering from obesity|Patient, male or female, over 18 and under 70 years old Patient group with a Body Mass Index (BMI) greater than or equal to 30 kg / m2
62115178|NCT04126239||healthy volunteer|
62115179|NCT00649935|EXPERIMENTAL|1|Azithromycin Tablets 600 mg
62115180|NCT00649935|ACTIVE_COMPARATOR|2|Zithromax® Tablets 600 mg
62115181|NCT02881944|EXPERIMENTAL|Low FODMAP (modified healthy) Diet|Low FODMAP diet for 3 weeks. Veterans will be provided a diet containing foods low in FODMAP.
62115182|NCT02881944|EXPERIMENTAL|High FODMAP (typical healthy) Diet|High FODMAP diet for 3 weeks. Veterans will be provided a typically healthy diet following US Dietary Guidelines, containing foods high in FODMAPs
62115183|NCT05837390||High risk singleton pregnancy for preterm birth|
62115184|NCT04955119|EXPERIMENTAL|Fusion imaging contrast-enhanced ultrasound LI-RADS|"Fusion imaging contrast-enhanced ultrasound will be performed in patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
62303971|NCT04918693||Participant|All 15 participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.
61917890|NCT04449029|EXPERIMENTAL|Cohort 1: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
61917891|NCT04449029|EXPERIMENTAL|Cohort 1: GSK3228836 300 mg + LD/ Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
61917892|NCT04449029|EXPERIMENTAL|Cohort 1: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants on stable nucleos(t)ide treatment will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
62303972|NCT04918693||Trainee|All 15 trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner
62303973|NCT02472483|EXPERIMENTAL|bipolar disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
62303974|NCT02472483|EXPERIMENTAL|anxious disorders|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
62303975|NCT02472483|EXPERIMENTAL|alcohol disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
62303976|NCT01715025|EXPERIMENTAL|E2/Nomac|Women with demonstrated HMB at baseline will be assigned to 3 cycles of a E2/Nomac combined pill 1 daily for 24 days followed by 1 placebo pill daily for 4 days per cycle.
62303977|NCT03009747||sphincter-preserving surgery|Patients meet the inclusion criteria will be enrolled into this observing group
62303978|NCT00302640|ACTIVE_COMPARATOR|Nitazoxanide|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
62303979|NCT00302640|PLACEBO_COMPARATOR|Placebo|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
61917893|NCT04449029|EXPERIMENTAL|Cohort 2: GSK3228836 300 mg + LD|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 24 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11.
61917894|NCT04449029|EXPERIMENTAL|Cohort 2: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
61917895|NCT04449029|EXPERIMENTAL|Cohort 2: GSK3228836 300 mg + LD/ Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
62303980|NCT02404506|EXPERIMENTAL|Arm: Eribulin mesilate|
61917896|NCT04449029|EXPERIMENTAL|Cohort 2: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants not currently on nucleos(t)ide therapy will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
61917897|NCT02601807|ACTIVE_COMPARATOR|Active|Subjects given active ActiPatch device before or after crossover (randomised)
62303981|NCT04366765||COVID-19 suspects|Patients presenting with suspected COVID-19 to the emergency department of the University Hospital Basel.
62303982|NCT03308630|EXPERIMENTAL|Energy Alignment and Mantra|
62303983|NCT05012696|EXPERIMENTAL|Sequence A: Non-invasive ventilation - High flow nasal cannula|Once participants are extubated they will receive one hour of Non-invasive ventilation followed by one hour of high-flow nasal cannula.
62303984|NCT05012696|EXPERIMENTAL|Sequence B: High flow nasal cannula - Non-invasive ventilation|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of Non-invasive ventilation
62303985|NCT05042245|EXPERIMENTAL|ornithine aspartate granule group|Patients in this group will be given aspartate ornithine granules (3 g po tid, after three meals) and silymarin capsule simulant (140 mg po bid, before breakfast and dinner).
62303986|NCT05042245|ACTIVE_COMPARATOR|silymarin capsule group|Patients in this group will be given silymarin capsule (140 mg po bid, before breakfast and dinner) and aspartate ornithine granules simulant (3 g po tid, after three meals) .
62303987|NCT03730389|EXPERIMENTAL|EPVL Group|In treatment group, patients were given one to three sessions of External Physical Vibration Lithecbole therapy in two weeks. These patients were also instructed to drink a minimum of 2500 ml water daily and take more exercise.
62303988|NCT03730389|NO_INTERVENTION|Traditional Group|patients with 4-10mm ureteral stone, were treated by traditional treatment methods, including drinking a minimum of 2500 ml water daily and taking more exercise.
62303989|NCT02651610|ACTIVE_COMPARATOR|Taxane|Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
62303990|NCT02651610|EXPERIMENTAL|Bavituximab plus taxane|Bavituximab 3 mg/kg weekly PLUS Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
62303991|NCT04740242||Cohort of exposed patients (Group 1)|All patients admitted for decompensated HF and presenting MA at the time of admission
62303992|NCT04740242||Cohort of unexposed patients (Group 2)|All patients admitted for decompensated HF and who do NOT present MA at the time of admission
62675380|NCT02441816|OTHER|Eylea Treatment|The intravitreal dose of Eylea will be 2mg (in 0.05ml) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks in the first year of treatment before applying a treat and extend paradigm to patient visits in year 2. This is an open-label study.
62675381|NCT01594372|ACTIVE_COMPARATOR|Laparoscopic Repair|Laparoscopic supracervical hysterectomy with sacropexy
61917898|NCT02601807|PLACEBO_COMPARATOR|Placebo|Subjects given placebo ActiPatch device before or after crossover (randomised)
62675382|NCT01594372|ACTIVE_COMPARATOR|Vaginal Repair|Vaginal hysterectomy with uterosacral colposuspension
62675383|NCT03686722|ACTIVE_COMPARATOR|Metformin|Subjects administered Metformin 500mg(Glucophage tablets) twice daily till day(4) then Metformin 1000mg twice daily till day(7)
61917899|NCT04531631|OTHER|Group 1|receive a single oral dose of dorzagliatin 75mg tablet on visit 2 and receive one placebo tablet on visit 3
61917900|NCT04531631|OTHER|Group 2|receive a single oral dose of one placebo tablet on visit 2 and receive dorzagliatin 75mg tablet on visit 3
61917901|NCT06247397|EXPERIMENTAL|High-flow oxygen therapy|Intervention arm
61917902|NCT06247397|ACTIVE_COMPARATOR|Low-flow oxygen therapy|Comparison arm
61917903|NCT02254239|EXPERIMENTAL|Treatment (everolimus, brentuximab vedotin)|"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or QOD on days 1-21. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity. Patients then receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or every other day on days 1-84 for 1 course.~MAINTENANCE THERAPY: Beginning on course 17, patients receive everolimus PO QD, QOD, twice weekly, or thrice weekly on days 1-84. Courses repeat every 84 days in the absence of disease progression and unacceptable toxicity."
61917904|NCT05517460|EXPERIMENTAL|experimental group I(auricular acupressure and usual care)|Experimental group I receives 8 weeks of auricular acupressure first, then interventions are stopped for two month as residual effect wash-out period. And after that Experimental group I receives 8 weeks of routine health care of constipation.
61917905|NCT05517460|EXPERIMENTAL|experimental group II(usual care and auricular acupressure)|Experimental group II receives 8 weeks of routine health care of constipation first, then interventions are stopped for two month as residual effect wash-out period. And after that Experimental group II receives 8 weeks of auricular acupressure .
62115185|NCT03884855|ACTIVE_COMPARATOR|Classical Cardiac Rehabilitation|Patients benefit from a classic cardiac rehabilitation cycle during 3 months.
62115186|NCT03884855|EXPERIMENTAL|Karate Rehabilitation|Patients benefit from cardiac rehabilitation cycle with traditional karate during 3 months.
62675384|NCT03686722|EXPERIMENTAL|Metformin and Daclatasvir|Subjects Coadministered Metformin 500mg(Glucophage tablets) twice daily and Daclatasvir 60mg tablets once daily till day (4) then Metformin 1000mg twice daily and Daclatasvir 60mg tablets once daily till Day(7)
62115187|NCT03305003|ACTIVE_COMPARATOR|Communication modality: spiral notebook|
62115188|NCT03305003|EXPERIMENTAL|Communication modality: mobile application|
62675385|NCT06016660|EXPERIMENTAL|Resistance exercise|Resistance exercise
62675386|NCT06016660|EXPERIMENTAL|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
62675387|NCT06016660|EXPERIMENTAL|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation
62675388|NCT06016660|NO_INTERVENTION|Control|No intervention
62675389|NCT05229367|EXPERIMENTAL|Eccentric isokinetic group|In this group, eccentric isokinetic training of hamstring muscle was performed.
62115189|NCT03969472|EXPERIMENTAL|probiotic group|apply probiotic after surgery
62115190|NCT03969472|EXPERIMENTAL|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery without probiotic
62115191|NCT03969472|NO_INTERVENTION|control|without electrophysiologic therapy and probiotic after surgery
62115192|NCT01180153|EXPERIMENTAL|SOX: advanced BTC or ampullary carcinoma|unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen
62115193|NCT05426863|EXPERIMENTAL|Psychosocial Counselling|A multi-component intervention counseling package to prevent the reoccurrence of IPV and address psychological distress among women experiencing violence. The DeVI intervention is structured into five weekly sessions.
62115194|NCT05426863|NO_INTERVENTION|Standard Usual Care|Provide standard usual care and information booklet similar to that of the intervention group that contains updated contact information for the referral services.
62115195|NCT03284411|EXPERIMENTAL|Spinal Cord Stimulation|Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude
62115196|NCT02771171||Age groups|The cohort is divided into on the basis of age
62115197|NCT05928819||Gastric lesion diagnostic|Every patient referred to our center for upper gastrointestinal endoscopy for investigation and/or resection of gastric neoplastic lesion can join the cohort of this study and will benefit from diagnosis and treatment by experienced endoscopists.
62115198|NCT06498895||post operative living liver transplant recipient|lung ultrasound score will be done in first 24 hours in intensive care unit for living liver transplant recipient patient
62675390|NCT05229367|ACTIVE_COMPARATOR|Concentric isokinetic group|In this group, concentric isokinetic training of hamstring muscle was performed.
62303993|NCT06278259|EXPERIMENTAL|experimental group|The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
62303994|NCT06278259|ACTIVE_COMPARATOR|control group|The control group will receive the same aerobic exercises only
62303995|NCT00840463|ACTIVE_COMPARATOR|1|
62303996|NCT00840463|PLACEBO_COMPARATOR|2|
62303997|NCT04527757||Paediatric patients with inhalation induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
62303998|NCT04527757||Paediatric patients with intravenous induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O). For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
62303999|NCT04153630|EXPERIMENTAL|Haploidentical MSCs derived from bone marrow|Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
62304000|NCT01878565|EXPERIMENTAL|Drug treatment|Drug: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20μg of HBV vaccine subcutaneously at day 6.
62304001|NCT01878565|OTHER|GM-CSF control|GM-CSF was given four times as control in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with GM-CSF intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
62304002|NCT01013727|EXPERIMENTAL|Postural Reconstruction|
62304003|NCT01013727|ACTIVE_COMPARATOR|muscular stretching|
62304004|NCT03332888|EXPERIMENTAL|Interventional Group|For this trial, HMA-CD20 will be given as an intravenous infusion of 1000 mg I.V twice in a month separating them by fourteen days starting at the baseline visit. The dose for both HMA-CD20 dosages willbe identical at the screening visit after the participant's eligibility has been established, and it will remain thesame for both infusions. The standard dose for HMA-CD20 is 1,000 mg per intravenous infusion on day 1 and day 15.
62304005|NCT02158533|EXPERIMENTAL|High Dose|
62304006|NCT02158533|EXPERIMENTAL|Low Dose|
62304007|NCT02158533|PLACEBO_COMPARATOR|Placebo|
62304008|NCT05511922|EXPERIMENTAL|KVD900 600 mg|
62304009|NCT02388776|EXPERIMENTAL|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
62304010|NCT03896425|EXPERIMENTAL|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
61917906|NCT05415709|ACTIVE_COMPARATOR|Arm I (carboplatin, paclitaxel, CRS)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM I: No chemotherapy immediately before, during or after surgery. Carboplatin/paclitaxel is given 3-4 weeks prior to surgery and again 2-4 weeks after surgery."
62304011|NCT03896425|EXPERIMENTAL|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
62304012|NCT03896425|SHAM_COMPARATOR|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
62304013|NCT04734873|EXPERIMENTAL|CPI-006 (2 mg/kg) Plus Standard of Care|Participants will receive a single dose of CPI-006 at 2 mg/kg up to a maximum dose of 200 mg intravenously on Day 1 plus standard of care.
62675391|NCT03114644|OTHER|Babies born prematurely between 27 and 37 SA|
62675392|NCT02642276|ACTIVE_COMPARATOR|Maximal walking group|Patients to be randomized to the 'maximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to the point of pain-free walking distance.
62675393|NCT02642276|ACTIVE_COMPARATOR|Submaximal walking group|Patients to be randomized to the 'submaximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to 2/3 of pain-free walking distance.
62304014|NCT04734873|EXPERIMENTAL|CPI-006 (1 mg/kg) Plus Standard of Care|Participants will receive a single dose of CPI-006 at 1 mg/kg up to a maximum dose of 100 mg intravenously on Day 1 plus standard of care.
62304015|NCT04734873|PLACEBO_COMPARATOR|Placebo Plus Standard of Care|Participants will receive a single dose of placebo intravenously on Day 1 plus standard of care.
62304016|NCT01850810|EXPERIMENTAL|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
62304017|NCT01850810|PLACEBO_COMPARATOR|Control Study Product|1 serving of control beverage.
62675394|NCT02642276|NO_INTERVENTION|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
62675395|NCT01215162|EXPERIMENTAL|Single arm study|Patients with stage T1/T2No breast cancer receiving breast conserving treatment
61917907|NCT05415709|EXPERIMENTAL|Arm II (carboplatin, paclitaxel, CRS, HIPEC, cisplatin)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM II: Patients undergo HIPEC and receive cisplatin IV over 90 minutes at the time of interval debulking surgery"
61917908|NCT05415709|EXPERIMENTAL|Arm III (carboplatin, paclitaxel, CRS, cisplatin)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM III: Patients receive cisplatin IV the day prior to interval debulking surgery"
61917909|NCT05655806|ACTIVE_COMPARATOR|group A|will receive aminophylline loading dose 5mg/kg on a 50 cm syringe using syringe pump over 5 minutes and maintenance dose 1.5 mg/kg/hr as a continuous infusion half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5 cm syringe of saline will be given over 5 minutes
61917910|NCT05655806|ACTIVE_COMPARATOR|group B|will receive a 50 cm syringe of saline using syringe pump over 5 minutes and maintenance continuous infusion of saline half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5cm syringe of aminophylline bolus 5mg\\kg will be given over 5 minutes
61917911|NCT05655806|PLACEBO_COMPARATOR|group C|will receive a 50 cm syringe of saline using syringe pump over 5 minutes and maintenance continuous infusion of saline half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5 cm syringe of saline will be given
62675396|NCT02285959|EXPERIMENTAL|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
62675397|NCT01687205|ACTIVE_COMPARATOR|Group 1|Single Dose/1 hour before and 1 hour after sex (BAT) Cohort
62675398|NCT01687205|ACTIVE_COMPARATOR|Group 2|Multiple Dose Cohort
62675399|NCT05632900|EXPERIMENTAL|NAGI BI-FLANGED METAL STENT WITH CO-AXIAL PLASTIC STENT FOR DRAINAGE OF WOPN.|Endoscopic ultrasound guided drainage -Nagi Bi Flanged metal stent--16mm diameter 2cm long with co Axial double pig tail stent used for drainage of walled of necrosis. Intra and post prodecural complications will be noted, a plane CT screening abdomen will be performed with in 48 to 72 hours to document the size of collection.
62675400|NCT05632900|ACTIVE_COMPARATOR|NAGI BI-FLANGED METAL STENT ALONE FOR DRAINAGE OF WOPN.|Endoscopic ultrasound guided drainage -Nagi Bi Flanged metal stent--16mm diameter 2cm long used for drainage of walled of necrosis. Intra and post prodecural complications will be noted, a plane CT screening abdomen will be performed with in 48 to 72 hours to document the size of collection.
61917912|NCT05167110|EXPERIMENTAL|Treatment group|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
62472565|NCT01342263|EXPERIMENTAL|iCDM|The iCDM will support patient self-management through collaborative planning and goal setting, education and skill development, support for behaviour change, and regular patient monitoring with follow-up. For each chronic condition, we have outlined sample patient signs and symptoms to be monitored, frequency of patient provider contact and frequency of patient prompt questions on their condition. The main premise of the iCDM is that only those patients who generate 'alerts' will be contacted by the iCDM nurse allowing for the potential to manage more patients than through traditional means of required patient follow-up regardless of patient condition . Across these five diseases are the following cross-cutting features: nutrition therapy, exercise therapy, psychological support, medication adherence and smoking cessation.
62472566|NCT03081403|OTHER|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
62675401|NCT04878926|ACTIVE_COMPARATOR|Group A (n=30)|IV Sedation + TAP block
62675402|NCT04878926|ACTIVE_COMPARATOR|Group B (n=30)|IV Sedation + LA infiltration
61917913|NCT05167110|PLACEBO_COMPARATOR|Placebo group|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
62675403|NCT03409146||Term Patients|"Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton \>37 week pregnancy.~Subjects will be recruited for the study in the following groups :~At least 10 patients with Body Mass Index (BMI) \< 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2"
62472567|NCT03081403|OTHER|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
62675404|NCT03238157|NO_INTERVENTION|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of \>40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
62675405|NCT03238157|ACTIVE_COMPARATOR|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of \>40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
62675406|NCT01018056|EXPERIMENTAL|D-serine (glutamate agonist)|24 subjects age 8-17 years with moderate to severe TS (TTS \> 22) will be enrolled in this treatment arm. They will receive D-serine for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
62675407|NCT01018056|EXPERIMENTAL|Riluzole (glutamate antagonist)|24 subjects age 8-17 years with moderate to severe TS (TTS \> 22) will be enrolled in this treatment arm. They will receive riluzole for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
61917914|NCT02484625|EXPERIMENTAL|Potato chips|Commercial potato chips, 180 kcal
62115199|NCT03824080|EXPERIMENTAL|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles without a treatment-free period in between.~Responding patients (as per criteria of European LeukaemiaNet and International MDS working Group (2006)) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
62472568|NCT01721681|EXPERIMENTAL|FACTOR X|"At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X. After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 6 months (26 weeks).~A dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory. Each dose of FACTOR X must not exceed 60 IU/kg."
62675408|NCT01018056|PLACEBO_COMPARATOR|Placebo|12 subjects age 8-17 years with moderate to severe TS (TTS \> 22) will be enrolled in this treatment arm. They will receive placebo for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
62675409|NCT01426555|ACTIVE_COMPARATOR|FES Rowing|Group 1 - FES-Rowing Exercise for entire study period
62675410|NCT01426555|EXPERIMENTAL|FES Rowing + Zoledronic acid|Group 2 - FES-Rowing Exercise for entire study period plus Zoledronic Acid 5mg administered by i.v. infusion one-time at the end of observation period
62675411|NCT05676567||Hip Arthroplasty|Patients undergoing total hip replacement, hip resurfacing or revision hip replacement
62675412|NCT05676567||Knee Arthroplasty|Patients undergoing total knee replacement, partial knee replacement or revision knee replacement
62675413|NCT05676567||Shoulder Arthroplasty|Patients undergoing total shoulder replacement, reverse shoulder replacement or partial shoulder replacement (hemiarthroplasty).
62675414|NCT05301231||NAFLD group without fibrosis|Group diagnosed to have NAFLD without fibrosis according to the recommendation of EASL; AASLD (13) and ESPGHAN Hepatology Committee (14), (75 adults aged 30-60 years, 75 children aged 12-18 years) ,
62675415|NCT05301231||NAFLD group with fibrosis (potential NASH)|Group diagnosed to have NAFLD with fibrosis according to the recommendation of EASL; AASLD (13) and ESPGHAN Hepatology Committee (14), (75 adults aged 30-60 years, 75 children aged 12-18 years),
62472569|NCT03820427||bronchial asthma|Patients with known or suspected asthma.
62675416|NCT05301231||Healthy group|Healthy control group age and sex-matched with the previous group (75 adults aged 30-60 years, 75 children aged 12-18 years),
62675417|NCT03780712||Sepsis Risk Group|419 infants born from mothers at risk to deliver babies with neonatal infections in Cotonou hospitals (Benin) 166 infants without sepsis born from mothers enrolled in a study to monitor pregnancy-associated malaria and Intrauterine growth restriction in Benin
62675418|NCT01213771|NO_INTERVENTION|Preoperative care 2009|Patients are receiving the usual care
62675419|NCT01450267|PLACEBO_COMPARATOR|Physiological solution|
62675420|NCT01450267|EXPERIMENTAL|Reduced Inhaled Glutathione|
62675421|NCT01200134|EXPERIMENTAL|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
62675422|NCT01407133|EXPERIMENTAL|Active rTMS|"48 subjects will receive active temporal rTMS, applied with the following combined parameters:~* intensity: 100% of resting motor threshold~* stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz)~* number of stimulations per session: 300, 900 or 1800 per session~* number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week)~* total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions)."
62675423|NCT01407133|SHAM_COMPARATOR|Sham rTMS|16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)
62675424|NCT04868903|ACTIVE_COMPARATOR|Low Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 400 IU/day) for 9 continuous months.
62675425|NCT04868903|ACTIVE_COMPARATOR|Medium Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 4,000 IU/day) for 9 continuous months.
62675426|NCT04868903|ACTIVE_COMPARATOR|High Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 10,000 IU/day) for 9 continuous months.
62675427|NCT04875845||6-hours fasting gastric volume|gastric volume measured after 6-hours fasting
62675428|NCT04875845||8-hours fasting gastric volume|gastric volume measured after 8-hours fasting
62472570|NCT03820427||pulmonary healthy controls|Patients without known or suspected pulmonary disease
62472571|NCT01072890|EXPERIMENTAL|Temsirolimus and Pazopanib|
62675429|NCT05263245|NO_INTERVENTION|Standard regimen|Patients will continue to use cabozantinib in fasted state, as part of standard of care, in the recommended dose as prior to enrollment in the study.
61917915|NCT02484625|EXPERIMENTAL|Greek yogurt|Greek yogurt, 180 kcal
62675430|NCT05263245|EXPERIMENTAL|Experimental regimen|Patients will take the prior recommended dose cabozantinib with a light breakfast.
62675431|NCT03221296|EXPERIMENTAL|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
61917916|NCT02484625|EXPERIMENTAL|Cookies|Sandwich-type cookies, 180 kcal
61917917|NCT02484625|EXPERIMENTAL|Cheese|Mozzarella cheese, 180 kcal
61917918|NCT02484625|EXPERIMENTAL|Milk (fluid)|Milk, 2% m.f., 180 kcal
61917919|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
61917920|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
62115200|NCT01183871|ACTIVE_COMPARATOR|good pulmonary functions (group 1)|FVC and/or FEV1 of 80% of predicted or more
62115201|NCT01183871|ACTIVE_COMPARATOR|mild pulmonary dysfunction (group 2)|FVC and/or FEV1 of 70%-79% of predicted
62115202|NCT01183871|ACTIVE_COMPARATOR|moderate pulmonary dysfunction (group 3)|FVC and/or FEV1 of 60%-69% of predicted
62115203|NCT01183871|ACTIVE_COMPARATOR|severe pulmonary dysfunction (group 4)|FVC and/or FEV1 of 50%-59% of predicted
62115204|NCT01941277|EXPERIMENTAL|Intensive Exercise Group|Behavioral
62115205|NCT01941277|EXPERIMENTAL|Current Recommendations Exercise Group|Behavioral
62115206|NCT03662048|ACTIVE_COMPARATOR|intervention at 1 month + usual care|Parents will send the study team photographs of their infant sleeping during the night at ages 1 and 2 months.
62115207|NCT03662048|PLACEBO_COMPARATOR|usual care|Parents will send the study team photographs of their infant sleeping during the night only at at age 2 months.
62675432|NCT03221296|NO_INTERVENTION|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
62675433|NCT04652882|EXPERIMENTAL|Tasimelteon|
62675434|NCT04652882|PLACEBO_COMPARATOR|Placebo|
62675435|NCT04287556||Population in risk of MH|Patient with hypermetabolic response of skeletal musculature by causes related with Malignant Hyperthermia in the literature.
62675436|NCT05811975|EXPERIMENTAL|TCR-T cells|Drug: KSX01 injection individualization TCR-T cell injection
62675437|NCT05320757|EXPERIMENTAL|Olaparib|Olaparib: 300mg BID orally for 10 - 28 days (stop 3 - 4 days before definitive treatment)
62675438|NCT05496699|EXPERIMENTAL|mckenzie group|Mckenzie exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
62115208|NCT01989910|ACTIVE_COMPARATOR|Raltegravir|Raltegravir 400mg oral twice daily
62115209|NCT01989910|ACTIVE_COMPARATOR|Efavirenz|Efavirenz 600mg oral at bedtime
62115210|NCT00299741|EXPERIMENTAL|1|Sunitinib
62472572|NCT02935517|EXPERIMENTAL|Group 1: 4.0 x 10^10 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 4.0 x 10\^10 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
62472573|NCT02935517|EXPERIMENTAL|Group 2: 1.2 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.2 x 10\^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
62472574|NCT02935517|EXPERIMENTAL|Group 3: 3.6 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.6 x 10\^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
62472575|NCT02935517|EXPERIMENTAL|Group 3a: 3.6 x 10^11 vg/mL of AGTC-402|Subjects 6 to 17 y/o treated with 3.6 x 10\^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
62675439|NCT05496699|EXPERIMENTAL|mullgian group|Mulligan exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
62675440|NCT03012945|EXPERIMENTAL|Combined epidural-general anesthesia|Patients assigned to this group (experimental group) receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
62675441|NCT03012945|ACTIVE_COMPARATOR|General anesthesia|Patients assigned to this group (control group) receive general anesthesia and postoperative patient-controlled intravenous analgesia.
62675442|NCT03981393||'Less severe hypoxaemia'|PaO2/FiO2 ratio \> 68 mmHg (9.1kPa) at decision-to-cannulate
62115211|NCT02794350||Cohort|
62115212|NCT00748410|EXPERIMENTAL|7 Days Repeat Dose|
62115213|NCT04911842||TPU|Thermoplastic polyurethane
62115214|NCT04911842||HBM|Hydrophilic BioMaterial
62115215|NCT04047784|EXPERIMENTAL|Critically Ill Patients|"Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
62115216|NCT04047784|EXPERIMENTAL|Patients undergoing standard of care clinical bronchoscopy|"Patients undergoing clinical bronchoscopy as a part of their standard of care.~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
62115217|NCT04047784|NO_INTERVENTION|Previously recorded patient media from standard of care clinical bronchoscopy with EBUS|"Patients who underwent a standard of care clinical bronchoscopy with EBUS previously.~Information and media including images and videos that were previously recorded for patients who underwent a standard of care clinical bronchoscopy with EBUS will be available to the study team."
62115218|NCT02457507|EXPERIMENTAL|Vitamin B12|Vitamin B12, 1mg, daily, 27 months
62115219|NCT02457507|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62115220|NCT06423742|SHAM_COMPARATOR|control|The subjects in control group were received two consecutive sessions of sham stimulation twice a week for 4 weeks (8 sessions in total).
62115221|NCT06423742|ACTIVE_COMPARATOR|single-session|Patients enrolled to the single-session group received tDCS on one random session out of two consecutive sessions.
62115222|NCT06423742|EXPERIMENTAL|dual-session|In the dual-session group, the patients underwent two consecutives tDCS.
62115223|NCT04537065||preterm infants without ROP|
62115224|NCT04537065||preterm infants with regressed ROP|
62115225|NCT04537065||preterm infants with threshold ROP|
62115226|NCT04537065||full-term infants|
62115227|NCT02403219|EXPERIMENTAL|Botulinum toxin type A injection|An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
62115228|NCT02403219|SHAM_COMPARATOR|Sham injection|An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
62115229|NCT04021381|EXPERIMENTAL|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate
62115230|NCT04021381|PLACEBO_COMPARATOR|Placebo|Patients are treated with placebo
62115231|NCT01273844|EXPERIMENTAL|Bortezomib|Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
62115232|NCT04476745|EXPERIMENTAL|Experimental: VD3 group|Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,
62115233|NCT04476745|NO_INTERVENTION|Control group|Control group No intervention was given
62304018|NCT04506424|EXPERIMENTAL|CT-Based Program for First Year of CI Use|"The Flat Panel CT scan will take place after a CI has been implanted and prior to the CI device activation.~The CI device will be activated using a CT-based program. The participant may continue to use this program for 1 year. Speech and music perception abilities will be monitored at regular intervals (approx. at 1, 3, 6, and 12 months post-activation).~After the 1 year of experimental program use, the participant may be switched over to a program that uses only the clinical default settings for 1 month; after which the participant will again complete the speech and music test battery.~At the end of the 13 month study the participant may choose whether to use the CT-based program or the clinical default program moving forward."
62304019|NCT05449353|EXPERIMENTAL|Trauma-infomed Cognitive Behavioural Therapy|Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
62304020|NCT04479761|EXPERIMENTAL|Virtual Reality|Participants will be wearing a virtual reality headset and observing 2 types of scenes: abstract (a display of stars) or contextual (a subway station).
62304021|NCT01491958|EXPERIMENTAL|Donor|Related donors will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines. Peripheral blood stem cells will not be manipulated or T-depleted prior to administration.
62304022|NCT01491958|EXPERIMENTAL|Patient|Patients will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first. Standard post transplant care will be administered.
62304023|NCT00986336|EXPERIMENTAL|001|
62304024|NCT00986336|EXPERIMENTAL|002|
62304025|NCT00986336|EXPERIMENTAL|003|
62304026|NCT00986336|EXPERIMENTAL|004|
62304027|NCT05782296||Cohort|Women in active labor following rupture of membranes and placement of an IUPC and/or FSE for obstetric indications
62304028|NCT02001012|ACTIVE_COMPARATOR|Artemether-lumefantrine|"Artemether-lumefantrine.~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; \>35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, \>10-15kg = 1 tablet."
62304029|NCT02001012|ACTIVE_COMPARATOR|Chloroquine|"Chloroquine.~1 tablet contains 155mg chloroquine base. Adult dose (\>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (\>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours."
62304030|NCT05476796|EXPERIMENTAL|Trifluridine/Tipiracil + Oxaliplatin ± nivolumab|"Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² twice-daily \[BID\] for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.~Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.~± nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years."
62304031|NCT05476796|ACTIVE_COMPARATOR|FOLFOX ± nivolumab|"Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.~± nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years."
62304032|NCT00522860|EXPERIMENTAL|Vicryl Suture|Vicryl sutures, 5/0, 3/8 curved cutting needle
62304033|NCT00522860|ACTIVE_COMPARATOR|Silk Suture|Silk suture, 4/0, 3/8 curved cutting needle
62304034|NCT03767569|EXPERIMENTAL|Myo-inositol|Pretreatment with Gynositol (Myo-Inositol 4mg + Folic Acid 0.4mg) daily during 12 weeks before start of ART (Assisted Reproductive Technology)
62304035|NCT03767569|OTHER|Folic acid|Folic acid 0.4 mg daily during 12 weeks before start of ART
62304036|NCT01828827|EXPERIMENTAL|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
62304037|NCT01828827|EXPERIMENTAL|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
62304038|NCT02782715|EXPERIMENTAL|Radiotherapy & Microwave Ablation|"3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:~1. Dose level I: 6 Gy x 5 fractions~2. Dose level II: 8 Gy x 5 fractions~3. Dose level III: 10 Gy x 5 fractions~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration)."
62472576|NCT02935517|EXPERIMENTAL|Group 4: 1.1 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.1 x 10\^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
62472577|NCT02935517|EXPERIMENTAL|Group 4a: 1.1 x 10^12 vg/mL of AGTC-402|Subjects 4 to 8 y/o treated with 1.1 x 10\^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
62472578|NCT02935517|EXPERIMENTAL|Group 5: 3.2 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.2 x 10\^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
61917921|NCT02518503||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (high doses of rosuvastatin, high doses of atorvastatin, and high doses of simvastatin) between 1 January 1997 and 31 March 2011, or 1 year after the beginning of data availability.
62304039|NCT02141061|EXPERIMENTAL|Telapristone Acetate, Proellex Formulation A (Treatment A)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
62115234|NCT05149313|EXPERIMENTAL|Lebrikizumab|Lebrikizumab administered subcutaneously (SC), participants will receive 2 injections of lebrikizumab 250 mg at Baseline and Week 2, followed by 1 injection of lebrikizumab 250 milligram (mg) once every two weeks (Q2W) in the induction period up to week 16. Participants who received lebrikizumab 250 mg Q2W during the Induction Period will continue to receive lebrikizumab 250 mg Q2W during the Maintenance Period. In order to maintain the double blind, participants from the lebrikizumab 250 mg Q2W arm will be administered a second injection of blinded placebo during Week 16 and Week 18. From Week 20 up to Week 52, all participants will receive 1 injection of lebrikizumab 250 mg Q2W in Open-label maintenance period.
62304040|NCT02141061|EXPERIMENTAL|Telapristone Acetate, Proellex Formulation B (Treatment B)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
61917922|NCT02518503||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 31 of March 2011, or 1 year after the beginning of data availability.
62472579|NCT02935517|EXPERIMENTAL|Group 6: MTD of AGTC-402|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGA3 study drug determined by Groups 1-5.
62472580|NCT02146105|EXPERIMENTAL|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
62472581|NCT00214097|EXPERIMENTAL|Level 1|64.7 Gy/22 fractions of 2.94 Gy
62472582|NCT00214097|EXPERIMENTAL|Level 2|58.08 Gy/16 fractions of 3.63 Gy
62472583|NCT00214097|EXPERIMENTAL|Level 3|51.6 Gy/12 fractions of 4.3 Gy
62472584|NCT03472105|OTHER|Habitual diet|18 participants were on a habitual diet for 7 days
61917923|NCT00924781|EXPERIMENTAL|MK2578 1 mcg for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment every week (QW).
61917924|NCT00924781|EXPERIMENTAL|1 mcg of MK2578 for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
62472585|NCT03472105|ACTIVE_COMPARATOR|New Nordic Renal Diet|18 participants were given a New Nordic Renal Diet for 7 days
61917925|NCT00924781|EXPERIMENTAL|MK2578 1 mcg for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
61917926|NCT00924781|EXPERIMENTAL|1 mcg of MK2578 for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
61917927|NCT00924781|EXPERIMENTAL|MK2578 1 mcg for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
61917928|NCT00924781|EXPERIMENTAL|1 mcg of MK2578 for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
62304041|NCT02900092|EXPERIMENTAL|Ganaxolone|Participants received ganaxolone
62304042|NCT00920543|ACTIVE_COMPARATOR|Fluticasone propionate|
62304043|NCT00920543|ACTIVE_COMPARATOR|Fluticasone propionate/salmeterol combination|
62304044|NCT03658889||Patients under treatment(s) for GCA|Patients at least 50 years old with Giant Cell Arteritis (GCA) and under treatment(s) for GCA
62472586|NCT03682653|ACTIVE_COMPARATOR|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
62472587|NCT03682653|PLACEBO_COMPARATOR|Placebo|a single dose of placebo will be administered to infants between their 8-27th days of life
61917929|NCT02454231|EXPERIMENTAL|peripheral blood EPC injection|
61917930|NCT02454231|ACTIVE_COMPARATOR|bone marrow MNC injection|
61917931|NCT04472754||A(healthy control group)|patients who did not have ischemic stroke and whose TCM constitution was dialectically peaceful;
61917932|NCT04472754||B|Patients with no ischemic stroke and whose TCM constitution was dialectical with damp phlegm constitution
61917933|NCT04472754||C|patients with ischemic stroke diagnosed with phlegm dampness syndrome
61917934|NCT04472754||D|patients with ischemic stroke diagnosed as non-phlegm dampness syndrome
61917935|NCT00868517|EXPERIMENTAL|True Group Auricular Acupuncture|Received true group auricular acupuncture twice weekly for a period of two months.
62472588|NCT06029686|EXPERIMENTAL|Stimulation|Patients will be asked to stimulate using a non invasive vibrotactile device.
62472589|NCT03670485|EXPERIMENTAL|Revised sequential activation protocol|"Apply 4 channel electrical stimulation device with a revised sequential activation protocol.~It sequentially activates Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device."
62472590|NCT03670485|NO_INTERVENTION|control subject|Apply 4 channel electrical stimulation device without any stimulation
62472591|NCT02834663|EXPERIMENTAL|Lucentis|Patients were administered 0.5-mg IVR injections monthly for 6 months.
62472592|NCT04893291|ACTIVE_COMPARATOR|Everolimus Eluting Stent|
62472593|NCT04893291|EXPERIMENTAL|Magic Touch Sirolimus Coated Balloon|
62472594|NCT05428020|EXPERIMENTAL|Indwelling foley catheter|Short-term indwelling foley catheter
61917936|NCT00868517|SHAM_COMPARATOR|Sham Group Auricular Acupuncture|Received sham group auricular acupuncture twice weekly for a period of two months.
62472595|NCT05428020|PLACEBO_COMPARATOR|No Foley catheter|No foley catheter
62472596|NCT02889848|SHAM_COMPARATOR|Saline only|Injection of saline to assess the injection procedure
62472597|NCT02889848|EXPERIMENTAL|1.16 mg EN3835|Injection of maximum marketed dose of EN3835 regardless of fibroid size
62472598|NCT02889848|EXPERIMENTAL|Dose 1|Injection of 0.05 mg EN3835 per cm3 fibroid
61917937|NCT00868517|OTHER|Wait-List Control Group|Served as wait list control. Did not receive any acupuncture during the study period.
62115235|NCT05149313|PLACEBO_COMPARATOR|Lebrikizumab-matching Placebo|Lebrikizumab-matching Placebo administered SC, 250 mg dose, Q2W in the induction period for 16 weeks. Participants will receive 2 injections of lebrikizumab 250 mg at Week 16 and Week 18 followed by 1 injection of lebrikizumab 250 mg Q2W from Week 20 up to Week 52 in Open-label maintenance period.
62115236|NCT06268262||Obesity|Non-intervention
62115237|NCT06268262||Healthy control|Non-intervention
62115238|NCT03579368|OTHER|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
62115239|NCT01687452|EXPERIMENTAL|Groupe A|Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load \> 1000 copies / ml
62115240|NCT01687452|EXPERIMENTAL|group B|Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load \> 40 copies / ml
62115241|NCT01687452|PLACEBO_COMPARATOR|group C|Healthy volunteers
62115242|NCT02082158|ACTIVE_COMPARATOR|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
62115243|NCT02082158|ACTIVE_COMPARATOR|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
62115244|NCT02082158|EXPERIMENTAL|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
62115245|NCT02082158|EXPERIMENTAL|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
62115246|NCT02082158|EXPERIMENTAL|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
62472599|NCT02889848|EXPERIMENTAL|Dose 2|Injection of 0.1 mg EN3835 per cm3 fibroid
62472600|NCT02889848|EXPERIMENTAL|Dose 3|Injection of 0.2 mg EN3835 per cm3 fibroid
62472601|NCT01136174|EXPERIMENTAL|BIBF 1120 50 mg|Low dose for cohort 1
62472602|NCT01136174|EXPERIMENTAL|BIBF 1120 100 mg|Middle dose for cohort 2
61917938|NCT05125185|ACTIVE_COMPARATOR|Standard Counseling|Trained diabetic educators educate patients using flip charts produced based on Malaysian Diabetes educators' manuals, insulin pen models and handouts. All patients were given SMBG diaries and encouraged to titrate their insulin dose based on SMBG
62115247|NCT02082158|EXPERIMENTAL|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
62115248|NCT02881749|EXPERIMENTAL|TSEBT & mechlorethamine gel 0.016%|All subjects enrolled in the study will receive two weeks of low dose total skin electron beam therapy (TSEBT) (12 Gy total divided into 6 fractions delivered over two weeks) followed by a weekly maintenance mechlorethamine gel 0.016% regimen for one year. The initiation of the mechlorethamine gel regimen is dependent on their disease stage downgrading to IA and IB following low dose TSEBT.
62115249|NCT06312943||Patients with various bone and joint diseases|Patients with various bone and joint diseases
62115250|NCT04932707|EXPERIMENTAL|Study group 1|sub-occipital muscle inhibition.
62115251|NCT04932707|EXPERIMENTAL|Study group 2|Received neurodynamic mobilization.
62115252|NCT04932707|ACTIVE_COMPARATOR|control group|Received passive stretch of the hamstring muscle.
62115253|NCT05967338||Group Direct|glottis visualization in direct lifting
62115254|NCT05967338||Group Indirect|glottis visualization in indirect lifting
62115255|NCT04714502||Infants enrolled in AAMBI1|
62115256|NCT00130780|ACTIVE_COMPARATOR|A|Pre-surgical Treatment with Bevacizumab plus Chemotherapy
62115257|NCT00130780|ACTIVE_COMPARATOR|B|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
62115258|NCT02845856|EXPERIMENTAL|Cetuximab and NK immunotherapy|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62115259|NCT02845856|ACTIVE_COMPARATOR|Cetuximab|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62115260|NCT02589002|EXPERIMENTAL|Sucralose|Ingestion of 15% of the ADI of sucralose daily during two weeks
62472603|NCT01136174|EXPERIMENTAL|BIBF 1120 150 mg|High dose for cohort 3
62472604|NCT01136174|PLACEBO_COMPARATOR|Placebo|Placebo for cohort 1,2,3
62472605|NCT03950089||Patients with Central Serous Chorioretinopathy|
62472606|NCT03950089||Healthy patients|
62472607|NCT00747162|EXPERIMENTAL|1|We will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
61917939|NCT05125185|EXPERIMENTAL|USM-IAM- based counseling|Trained diabetes educators counselled patients using the USM Insulin adherence module. Each patient was given the module so that they could freely refer to it when necessary. The module contains all information from standard counseling, with additional info on the definition of insulin non-adherence, causes of non-adherence, measures to overcome non-adherence and fasting safely with insulin. All patients were given SMBG diaries and encouraged to titrate their insulin dose based on SMBG
62115261|NCT02589002|NO_INTERVENTION|Control|Absence of sucralose ingestion
62115262|NCT04002973|EXPERIMENTAL|INVSENSOR00037|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.
62115263|NCT01966055|EXPERIMENTAL|Solithromycin|
62115264|NCT03808883|EXPERIMENTAL|TGNC Cohort|The Translate Study developed a cohort of transgender and gender non-conforming individuals (referred to here as TGNC cohort) and held three facilitated dialogue sessions with healthcare providers and staff (referred to here as healthcare participants). The overall goal of the Translate Study was to improve quality of life by reducing health disparities suffered by transgender and gender nonconforming (TGNC) individuals and by increasing their access to and use of primary health care.
62115265|NCT03808883|EXPERIMENTAL|Healthcare Participants|The Translate Study held three facilitated dialogue sessions between the TGNC Cohort and a group of healthcare participants, identified as physicians, nurse practitioners, registered nurses, students, physician assistants, and non-provider staff positions. Non-providers included healthcare administrative positions, rehabilitation, and vocational services.
62472608|NCT01599728|OTHER|Patients with heart failure|Assessing the response to infusion of intra-arterial Urocortin 2, 3 and Substance P in patients with heart failure
62675443|NCT03981393||'Very severe hypoxaemia'|PaO2/FiO2 ratio ≤ 68 mmHg (9.1kPa) at decision-to-cannulate
62675444|NCT02501785||patient and caregivers|This is a prospective cohort study. Four questionnaires will be used to collect data from caregivers: demographic and socioeconomic data will be collected from the caregiver before the patient's surgery, and caregiver burden information will be collected 15 (+/- 3) days after surgery.
62675445|NCT02470767||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fribilation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
62115266|NCT03624140|EXPERIMENTAL|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
62115267|NCT03200587|EXPERIMENTAL|Avelumab and cabozantinib, all patients|
62115268|NCT06512649|EXPERIMENTAL|Early Intervention Group|ASD and typical siblings with Signs of concern
62115269|NCT06512649|NO_INTERVENTION|Clinical Monitoring Group|Typical siblings with no signs of concern Children allocated to this arm will undergo to re-assessment at T1 and T2
62115270|NCT06512649|EXPERIMENTAL|Active monitoring Group|ASD siblings, no signs of concern
62115271|NCT04956224|EXPERIMENTAL|VLA2001|
62115272|NCT06555198|EXPERIMENTAL|Intervention group|Foot(at)Work intervention will be offered to participant sin the intervention group. The Foot(at)Work intervention lasts for 5 weeks. The intervention is constructed on electronic learning environment consisting of 5 themes illustrating self-care activities for common foot problems among nursing professionals. The idea of self-directed learning is to support nurses competence to self-care their lower extremities and thus, promote their work wellbeing in clinical nursing environments.
62115273|NCT06555198|NO_INTERVENTION|Control group|The control group will work and live as usual.
62115274|NCT05605834|EXPERIMENTAL|Hydrogen peroxide 9.5% bleaching using a tray with reservoir.|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir.
62115275|NCT05605834|ACTIVE_COMPARATOR|Hydrogen peroxide 9.5% bleaching using a tray without reservoir.|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.
62675446|NCT05450120|ACTIVE_COMPARATOR|Functional Rehabilitation|Functional rehabilitation protocol
62675447|NCT05450120|EXPERIMENTAL|NMES + Functional Rehabilitation|Functional rehabilitation protocol associated with neuromuscular electrical stimulation
62675448|NCT06633406||Prenatal Anaesthesia Exposure|Children exposed in utero to maternal general anaesthesia to allow laparoscopy or laparotomy for appendicectomy, adnexal pathology, cholecystectomy or for diagnostic procedures to rule out intra-abdominal pathology
62675449|NCT06633406||No Prenatal Anaesthesia Exposure|Children not exposed to general anaesthesia for non-obstetric or obstetric (e.g. cesarean section) surgery in utero
62304045|NCT02850796|EXPERIMENTAL|Kg-Free|Kg-free is a manualized acceptance, mindfulness \& compassionate-based group intervention for women struggling with their weight. It comprises 10 weekly group sessions plus 2 booster fortnightly sessions (31/2months) 2h30 hours each, run in small groups (ranging from 10 to 12 participants).
62304046|NCT02850796|OTHER|Treatment as Usual (TAU)|nutritional treatment for weight loss in primary care units and Hospitals from Coimbra's district that includes dietary and physical activity support
62304047|NCT03540823|EXPERIMENTAL|Patients with rheumatic diseases|Patients with diagnosis of adult and juvenile systemic lupus erythematosus (SLE and JSLE) and Sjogren syndrome (SSp)
62304048|NCT03540823|OTHER|Healthy controls|Healthy children and adults
62304049|NCT01259466|EXPERIMENTAL|Cognitive Behavioral + Nicotine Patch|Cognitive Behavioral Therapy + Nicotine Replacement Patch
61917940|NCT02820714|EXPERIMENTAL|BLI801 Laxative|BLI801 oral laxative
62472609|NCT01599728|OTHER|Healthy controls|Assessing response to intra-arterial infusions of Urocortin 2, 3 and Substance P in age and sex-matched healthy volunteers as controls.
62675450|NCT06427174|ACTIVE_COMPARATOR|Fascia iliaca group|For the group who will receive the fascia iliaca block .... After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position after sterilization of skin over the groin area at the side from which split thickness graft will be taken, high frequency ultrasound probe
61917941|NCT04841200|EXPERIMENTAL|Chinese medicine compound combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound based on TCM syndrome differentiation in addition to symptomatic treatments.
61917942|NCT04841200|PLACEBO_COMPARATOR|Chinese medicine compound placebod combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound placebo based on TCM syndrome differentiation in addition to symptomatic treatments.
61917943|NCT01432210|OTHER|Tomato Meal|A tomato meal will be fed with and without avocado.
61917944|NCT01432210|OTHER|Carrot Meal|A carrot meal will be fed with and without avocado.
62115276|NCT01948804|EXPERIMENTAL|IVF patients|patients that has applied to Yeditepe University Hospital assisted reproduction center
62115277|NCT04397198||HIBRIDH-SG 01|Study subjects with documented ST segment Elevation Myocardial Infarction
62115278|NCT01669382|ACTIVE_COMPARATOR|Exo Seal system|Percutaneous coronary intervention
62115279|NCT01669382|ACTIVE_COMPARATOR|AngioSeal system|percutaneous coronary intervention
62115280|NCT01641913|EXPERIMENTAL|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
61917945|NCT04666077|EXPERIMENTAL|Home-based MT through Supervised, Supported Singing (H3S)|Treatment arm 1
62304050|NCT01259466|ACTIVE_COMPARATOR|Health Education + Nicotine Patch|Health Education + Nicotine Replacement Patch
62304051|NCT02795234|OTHER|Participants with Vitamin D deficiency|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
62304052|NCT02795234|OTHER|Participants with sufficient Vitamin D Level|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
62304053|NCT04902885|ACTIVE_COMPARATOR|Part I ( Safety run-in and PK Evaluation); Trilaciclib Group|12 patients( 6 patients are first line, 6 patients are second or third line) recieved Trilaciclib(240mg/m\^2) plus chemotherapy.
62304054|NCT04902885|ACTIVE_COMPARATOR|Part II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib Group|41 patients received trilaciclib(240mg/m\^2) plus chemotherapy
62304055|NCT04902885|PLACEBO_COMPARATOR|Part II ( Randomized Double-blind, Placebo-controlled ), Placebo Group|42 patients received placebo plus chemotherapy
62304056|NCT04292600||BRH|Cohort recruited at Brandon Regional Hospital by Bay Area Consulting Telemedicine
62304057|NCT03420677|ACTIVE_COMPARATOR|Application of tones|During non-rapid eye movement (NREM) sleep short tones will be played
61917946|NCT04666077|EXPERIMENTAL|H3S and IMT|Treatment arm 2 received both Home-based Supervised, Supported Singing (H3S) and Individualized Music Therapy (IMT)
61917947|NCT04666077|PLACEBO_COMPARATOR|Attention Control (AtCon)|Comparison condition with comparable attention
61917948|NCT01066676|EXPERIMENTAL|Dexibuprofen|Dexibuprofen 400 mg powder for oral suspension
61917949|NCT01066676|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 400 mg powder for oral suspension
62115281|NCT03915769|EXPERIMENTAL|0.46 mg ozanimod oral capsule once daily (QD)|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.46 mg ozanimod.
62115282|NCT03915769|EXPERIMENTAL|0.92 mg ozanimod oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.92 mg ozanimod.
62115283|NCT03915769|PLACEBO_COMPARATOR|Placebo oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with a placebo capsule, followed by 3 days of treatment with two placebo capsules, followed by two placebo capsules.
62304058|NCT03420677|SHAM_COMPARATOR|No application of tones|During NREM sleep no short tones will be played
62304059|NCT03289715|EXPERIMENTAL|arm 1|on demand humidification
62304060|NCT00583739|ACTIVE_COMPARATOR|1|Yoga intervention
62304061|NCT00583739|NO_INTERVENTION|2|Control. No Yoga for 8 weeks.
62304062|NCT05176678|ACTIVE_COMPARATOR|Escalating dose of natural protein hydrolysate - sequence A|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 4 gram/day.
62304063|NCT05176678|ACTIVE_COMPARATOR|Escalating dose of natural protein hydrolysate - sequence B|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 8 gram/day.
62304064|NCT00679107|EXPERIMENTAL|1|autogenous bone graft with the addition of OP-1 Putty
62304065|NCT00679107|ACTIVE_COMPARATOR|2|autogenous bone graft alone
62304066|NCT01186653|EXPERIMENTAL|Symbicort|Symbicort® (budesonide / formoterol, 400 micrograms/9 micrograms one puff bd, dose as per NICE guidelines
61917950|NCT01902771|EXPERIMENTAL|DC Vaccine + Lysate|"* Leukapheresis: Baseline, post-surgery;~* Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered intradermally once weekly via intradermal injection, for 4 weeks for a total of four vaccinations;~* Tumor Lysate (Lysate): Post-DC Vaccine therapy. Administered intradermally during weeks 8, 12, 16, and 28;~* Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
62115284|NCT05416450|ACTIVE_COMPARATOR|Antimuscarinic Naive (AM-N)|None of the women had previously taken anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) in this group.
62115285|NCT05416450|ACTIVE_COMPARATOR|Antimuscarinic Refractory (AM-R)|Women with idiopathic OAB refractory to anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) when 2 or more were administered for at least 6 weeks each and failure was due to lack of efficacy with or without side effects were included in this group.
62115286|NCT03414736|EXPERIMENTAL|Cohort 1|Daily dose escalation (click-by-click): Starting at dose 1 in the morning with daily increments to dose 2. During the escalation phase, the dose will only be increased if the patient is feeling fine.
62115287|NCT03414736|EXPERIMENTAL|Cohort 2|Weekly dose escalation in 6 escalation steps (7 dose levels): Starting at dose 1 injected in the morning with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
62115288|NCT03414736|EXPERIMENTAL|Cohort 3|Weekly dose escalation in 4 escalation steps (5 dose levels): Starting at dose 3 with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
62115289|NCT00967512|EXPERIMENTAL|cenersen, idarubicin, cytarabine|cenersen, idarubicin, cytarabine
62115290|NCT00967512|PLACEBO_COMPARATOR|placebo, idarubicin, cytarabine|placebo, idarubicin, cytarabine
62115291|NCT00918957|EXPERIMENTAL|TIP (Tobramycin Inhalation Powder)|Tobramycin 28 mg powder. The TIP dose of 112 mg twice a day (bis in diem = b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment.
62115292|NCT00918957|PLACEBO_COMPARATOR|Placebo|Placebo 20 mg powder capsules. The dose regimen for the reference product was inhaling the contents of four capsules twice a day (bis in diem = b.i.d.), in the morning and in the evening for 28 days (on treatment), followed by 28 days of no study treatment (off treatment).
62115293|NCT05503212||AIS and isolated VAO|Patients with acute ischemic stroke (AIS) and concomitant isolated intracranial and/or extracranial vertebral artery occlusion (VAO)
62115294|NCT01305434|OTHER|Placebo then mulberry leaf|These patients receive placebo for two weeks, then 1 week washout, then two weeks of mulberry leaf extract.
62115295|NCT01305434|OTHER|Mulberry leaf then placebo|These patients receive mulberry leaf extract for two weeks, then 1 week washout, then two weeks of placebo.
62115296|NCT05134025|EXPERIMENTAL|SMART A1|A full dose of meal-time insulin with announced exercise immediately prior to commencement
62115297|NCT05134025|EXPERIMENTAL|SMART A2|a 25% dose reduction in meal-time insulin with exercise announcement 90-minutes prior to commencement
62115298|NCT05134025|EXPERIMENTAL|SMART A3|a 25% dose reduction in meal-time insulin with exercise announcement 45-minutes prior to commencement
62115299|NCT02713048||Acute coronary syndrome culprit coronary lesion|
62115300|NCT02713048||Stable obstructive coronary artery disease|
62115301|NCT02713048||Non-obstructive coronary artery disease|
62115302|NCT04291586|EXPERIMENTAL|Virtual Reality|The Virtual Reality group will perform personalized activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
62115303|NCT04291586|ACTIVE_COMPARATOR|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalized to their deficits and generated automatically through a Task Generator.
62115304|NCT06467253|ACTIVE_COMPARATOR|1. rTMS + CS|Repetitive Transcranial Magnetic Stimulation (rTMS) + Cognitive Stimulation (CS)
62115305|NCT06467253|SHAM_COMPARATOR|2. rTMS Sham + CS|Repetitive Transcranial Magnetic Stimulation Sham (rTMS Sham) + Cognitive Stimulation (CS)
62115306|NCT06467253|ACTIVE_COMPARATOR|3. tDCS + CS|Transcranial Direct Current Stimulation (tDCS) + Cognitive Stimulation (CS)
62115307|NCT06467253|SHAM_COMPARATOR|4. tDCS Sham + CS|Transcranial Direct Current Stimulation Sham (tDCS Sham) + Cognitive Stimulation (CS)
62115308|NCT05345561||Pregnant women|Women with higher risk of FNAIT
62115309|NCT04680260|ACTIVE_COMPARATOR|A: Standard of care|Standard decision making regarding adjuvant chemotherapy with fluoropyrimidine and oxaliplatin as per institutional standards.
62115310|NCT04680260|EXPERIMENTAL|B: ctDNA guided therapy approach|Post ablation ctDNA results will be used for treatment decision.
62115311|NCT02823106|EXPERIMENTAL|Verapamil and Citicoline|10mg of verapamil in 10 cc of normal saline and 1000mg of citicoline in 10cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
62115312|NCT02823106|PLACEBO_COMPARATOR|Placebo|The control group will receive saline only.
62115313|NCT02707913|EXPERIMENTAL|BF-Amlodipine Tablet 10mg|During the study session, healthy subjects will be administered a single dose of BF-Amlodipine Tablet 10mg after an overnight fast of approximately 10 hours
62115314|NCT02707913|ACTIVE_COMPARATOR|Norvasc Tablet 10mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablet 10mg after an overnight fast of approximately 10 hours
62115315|NCT02806869|EXPERIMENTAL|Arm #1 - Fasting State, 2 study visits|"1. Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~2. Washout period of at least 7 days~3. Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
62472610|NCT03872596|EXPERIMENTAL|Part A: Sequence 1|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.~Treatment Period:~Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15."
62472611|NCT03872596|EXPERIMENTAL|Part A: Sequence 2|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15."
62472612|NCT03872596|EXPERIMENTAL|Part A: Sequence 3|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15."
62472613|NCT03872596|EXPERIMENTAL|Part B: Sequence 1|Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
62115316|NCT02806869|EXPERIMENTAL|Arm #2 - Fed State, 2 study visits|"1. Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~2. Washout period of at least 7 days~3. Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
62472614|NCT03872596|EXPERIMENTAL|Part B: Sequence 2|Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
62472615|NCT04195360||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilization
62472616|NCT04195360||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilization
62472617|NCT05458635|NO_INTERVENTION|HP without Pulmonary hypertion|HRCT chest , pulmonary functions and echocardiography
62472618|NCT05458635|ACTIVE_COMPARATOR|HP with Pulmonary hypertion|HRCT chest , pulmonary functions ,echocardiography and RT heart catheter in high echocardiographic probability of PH
62472619|NCT02152397|ACTIVE_COMPARATOR|Therapist-led brief intervention (TBI)|"Participants will receive therapist-led, computer-assisted intervention sessions with a therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
62472620|NCT02152397|NO_INTERVENTION|Enhanced usual care|Participants will receive therapist-led, computer-assisted control sessions with a therapist.
62472621|NCT02356978|EXPERIMENTAL|Arm 1|"Each patient will be treated before using the active usual homemade device, and after using the experimental new DRAP device.~This new sheet was designed by weaving optical fibers connected to LEDs ( BROCHIER Technology). The LIGHTEX technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)"
62472622|NCT03714685|EXPERIMENTAL|Firibastat prototype tablet formulations|Firibastat (QGC001) 500 mg modified release prototype tablet formulations or immediate release capsule formulation - 1 tablet or 1 capsule administered per period
62472623|NCT00420303|EXPERIMENTAL|A|
62472624|NCT00420303|PLACEBO_COMPARATOR|B|
62472625|NCT06322420|EXPERIMENTAL|Treatment|Active treatment provided to all participants in the study.
62472626|NCT04069286|EXPERIMENTAL|Treated Group|Active Group with 237 participants undergoing treatment with oral mastic (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks
62472627|NCT04069286|ACTIVE_COMPARATOR|Control Group|Comparator Group with 237 participants undergoing treatment with omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.
62115317|NCT05923567||CA19-9<385 & FE-1>100|
62115318|NCT05923567||CA19-9<385 and FE-1>100|
62115319|NCT05923567||CA19-9>385 & FE-1>100|
62304067|NCT01186653|ACTIVE_COMPARATOR|Seretide|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
62304068|NCT01357239|EXPERIMENTAL|25 mg bid|
62304069|NCT01357239|EXPERIMENTAL|50 mg bid|
62304070|NCT01357239|EXPERIMENTAL|100 mg bid|
62304071|NCT01357239|PLACEBO_COMPARATOR|Placebo|
62304072|NCT03980093|EXPERIMENTAL|Education plus Values|
62304073|NCT03980093|ACTIVE_COMPARATOR|Education|
62304074|NCT04632199|EXPERIMENTAL|111In-IPN01087 Low dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a low mass dose of IPN01087
62304075|NCT04632199|EXPERIMENTAL|111In-IPN01087 High dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a high mass dose of IPN01087
62304076|NCT06009614|PLACEBO_COMPARATOR|Placebo Control 1|GI Health Product Form 1 - control
62304077|NCT06009614|EXPERIMENTAL|Active Product 1.1|GI Health Product Form 1 - active product 1
62304078|NCT06009614|PLACEBO_COMPARATOR|Placebo Control 2|GI Health Product Form 2 - control
62675451|NCT06427174|ACTIVE_COMPARATOR|Caudal block|"And the second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.~With the patient in the left lateral decubitus position and the hips and knees flexed, the sacral hiatus can be identified .First of all, the posterior superior iliac spines are palpated via anatomical landmarks, the line between both spines (Tuffier's line) representing the base of an equilateral triangle the tip of which indicates the position of the sacral hiatus. The sacrococcygeal ligament can be palpated between the two sacral cornua, which is where the needle should penetrate the skin at an approximate 45° angle. Once the ligament has been passed, a flatter angle is adjusted by descending the needle before it can be advanced to the correct final position."
62675452|NCT06284837|ACTIVE_COMPARATOR|Radial secondary access|
62675453|NCT06284837|ACTIVE_COMPARATOR|Femoral secondary access|
62675454|NCT00496327|EXPERIMENTAL|1|Open label
62115320|NCT05923567||CA19-9>385 & FE-1<100|
62304079|NCT06009614|EXPERIMENTAL|Active Product 2.1|GI Health Product Form 2 - active product 1
62675455|NCT03418207|OTHER|TTMB for patients|give trans-perineal template-guided mapping biopsy for participants suspected prostate cancer
62115321|NCT04989725|ACTIVE_COMPARATOR|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
62115322|NCT04989725|EXPERIMENTAL|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
62115323|NCT01101152|EXPERIMENTAL|Female|
62115324|NCT01101152|EXPERIMENTAL|Male|
62115325|NCT04418323|ACTIVE_COMPARATOR|Video-assisted anal fistula treatment (VAAFT|Video-assisted anal fistula treatment (VAAFT) in the Management of anal fistula
62304080|NCT06009614|EXPERIMENTAL|Active Product 2.2|GI Health Product Form 2 - active product 2
62304081|NCT06009614|PLACEBO_COMPARATOR|Placebo Control 3|GI Health Product Form 3 - control
62304082|NCT06009614|EXPERIMENTAL|Active Product 3.1|GI Health Product Form 3 - active product 1
62304083|NCT05651087|EXPERIMENTAL|Experimental|Breast cancer patient who treated with LACUD
62115326|NCT04418323|ACTIVE_COMPARATOR|Fistula-tract Laser Closure (filac)|Fistula-tract Laser Closure (filac)in the Management of anal fistula
62115327|NCT04418323|ACTIVE_COMPARATOR|Conventional seton|Conventional seton in the Management of anal fistula
62115328|NCT05125133|EXPERIMENTAL|ITENs + ITWS|Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m² are coated in ITENs and ITWS nets that will be installed to cover opened eaves and windows. This was manufactured by Moon Netting FZCO, United Arab Emirates.
62115329|NCT05125133|NO_INTERVENTION|Negative arm|The houses allocated NOT to receive ITENs and ITWS.
62115330|NCT03197337|EXPERIMENTAL|Control manipulation first|Patients in this group will first undergo the control manipulation while the study manipulation will follow.
62304084|NCT05651087|NO_INTERVENTION|Observation|Breast cancer patient who does not treated with LACUD
62304085|NCT01882725|EXPERIMENTAL|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
62304086|NCT04090164||Study group|The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
62304087|NCT04090164||Control group|A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.
62304088|NCT03501212|ACTIVE_COMPARATOR|Interventional|EMLA group layer of 2.5 gr EMLA cream (standard adult dose) was applied to both wrists
62304089|NCT03501212|PLACEBO_COMPARATOR|Placebo|Placebo cream was applied to both wrists
62304090|NCT03744689|ACTIVE_COMPARATOR|Erector Spinae Plane Block|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks"
62304091|NCT03744689|SHAM_COMPARATOR|Control Group|Sham block will be done with serum physiologic.
62304092|NCT04246047|EXPERIMENTAL|Belantamab mafodotin and Bortezomib plus Dexamethasone (Arm A)|
62304093|NCT04246047|ACTIVE_COMPARATOR|Daratumumab and Bortezomib plus Dexamethasone (Arm B)|
62304094|NCT01111071||STEMI|patients with discharge diagnosis of ST elevation myocardial infarction
62304095|NCT01111071||nSTEMI|patients with discharge diagnosis of non ST elevation myocardial infarction
62304096|NCT01111071||unstable angina|patients with discharge diagnosis of unstable angina
62675456|NCT04315142|EXPERIMENTAL|Transcutaneous tibial nerve stimulation (TTNS)|
62675457|NCT04315142|SHAM_COMPARATOR|TTNS sham stimulation|
62304097|NCT01362322|EXPERIMENTAL|BOOSTRIX NEW GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a new syringe presentation (prefilled syringes from a different manufacturer) in the deltoid of the non-dominant arm, at Day 0.
62304098|NCT01362322|ACTIVE_COMPARATOR|BOOSTRIX PREV GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a previous syringe presentation (single dose vial or a prefilled disposable syringe without a needle) in the deltoid of the non-dominant arm, at Day 0.
62304099|NCT05355012|EXPERIMENTAL|5A-QUIT-N intervention|"The 5A-QUIT-N intervention can be defined as multilevel, i.e., it is based on a territorial organization with expected results at the level of professional practice (structuring of practices around the 5A method) and therefore of the care of pregnant women who smoke tobacco.~This project is based on three strategic axes:~* A gradation of the care offer~* Personalized care by developing specific treatment paths~* Coordination of territorial resources to support pregnant women in quitting smoking.~These elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
62304100|NCT05355012|NO_INTERVENTION|5A-QUIT-N control|Usual care in the care of pregnant women who smoke tobacco.
62304101|NCT02261623||Palliation|Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery
62304102|NCT02261623||Curative intent surgery|Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy
62304103|NCT02261623||Benign biliary strictures|Treatment of benign biliary strictures
62304104|NCT02261623||Other indication|Other indication
62304105|NCT03883893|ACTIVE_COMPARATOR|IV Tylenol|Participants will receive IV acetaminophen 15mg/kg in the OR.
62304106|NCT03883893|PLACEBO_COMPARATOR|Normal Saline|Participants will receive 0.9% normal saline in the OR. The amount received will be equivalent of what would be given if they were receiving IV acetaminophen.
62304107|NCT04612088|EXPERIMENTAL|Bariatric Multivitamin|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
62472628|NCT05420896|ACTIVE_COMPARATOR|Manual therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
62472629|NCT05420896|NO_INTERVENTION|Control group|Patients assigned to the control group randomly will be re-evaluated 4 weeks after their initial evaluation. No intervention will be applied during this period. After 4 weeks, when the patients are re-evaluated, they will be directed to the appropriate treatment.
62472630|NCT03059186|EXPERIMENTAL|Intervention|Online daily gratitude journal.
62472631|NCT03059186|NO_INTERVENTION|Control|
62115331|NCT03197337|EXPERIMENTAL|Study manipulation First|Patients in this group will first undergo the study manipulation while the control manipulation will follow.
62115332|NCT02572141|EXPERIMENTAL|Perioperative chemotherapy|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
62115333|NCT02572141|ACTIVE_COMPARATOR|Postoperative chemotherapy|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
62115334|NCT05903833|EXPERIMENTAL|Treatment allocation|Administration of pembrolizumab 400 mg Q6W in combination with lenvatinib 20 mg QD
62115335|NCT04405713|ACTIVE_COMPARATOR|from the onset of symptoms within the first 3 days (group 1)|ELC for ACC from the onset of symptoms within the first 3 days (group 1)
62115336|NCT04405713|ACTIVE_COMPARATOR|from the onset of symptoms within the 4-7 days|ELC for ACC from the onset of symptoms within the4-7 days (group II)
62115337|NCT04405713|ACTIVE_COMPARATOR|from the onset of symptoms beyond 7 days|ELC for ACC from the onset of symptoms beyond 7 days (group III)
62115338|NCT01943799|EXPERIMENTAL|OAV Alone|Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.
62115339|NCT01943799|EXPERIMENTAL|OAV + GS-4774 2 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.
62115340|NCT01943799|EXPERIMENTAL|OAV + GS-4774 10 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.
62115341|NCT01943799|EXPERIMENTAL|OAV + GS-4774 40 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.
62115342|NCT00442117|EXPERIMENTAL|MF-DPI|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day)
62115343|NCT00442117|ACTIVE_COMPARATOR|BUD-DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day)
62115344|NCT06296056|EXPERIMENTAL|Combi|Dendritic cell+NK cell+Cytotoxic T cell
62115345|NCT01794936|EXPERIMENTAL|VTI Probe|During robotic-assisted laparoscopic prostatectomy, the VTI Doppler probe (test) will utilized to measure blood blow within the neurovascular bundles. This is to be completed after the bladder neck and seminal vesicles are identified and dissected. To use the probe, the assistant surgeon will place the Doppler probe within the abdomen and systematically move it cephalad along the lateral prostate pedicles to identify NVB vessels. The Doppler flow in these regions will be quantified as arterial (strong) flow, venous (minimal) flow or no flow. The procedures will proceed by dissecting the lateral margin of prostate step by step up to the gland's apex. Blood loss and the time required to identify and dissect the NVB will be recorded.
62304108|NCT04612088|NO_INTERVENTION|Waitlist|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
62304109|NCT00650585|NO_INTERVENTION|Control group|Did not receive Project ALERT
62304110|NCT00650585|EXPERIMENTAL|Treatment group|Received Project ALERT
61917951|NCT02282345|EXPERIMENTAL|Treatment (talazoparib)|"Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice.~This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib."
62115346|NCT01794936|NO_INTERVENTION|Non-Probe|Patients randomized to not receive probe evaluation.
62115347|NCT05576844|EXPERIMENTAL|Interpersonal and social rhythm intervention|
62115348|NCT05576844|ACTIVE_COMPARATOR|Controlled group|
62115349|NCT05112861|EXPERIMENTAL|Biological: bevacizumab|
62115350|NCT04776993|EXPERIMENTAL|Methimazole|Antithyroid drugs (at individualized dosage) for 72 weeks and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
62115351|NCT04776993|ACTIVE_COMPARATOR|Thyroid ablation|Radioiodine therapy or total thyroidectomy (according to ultrasound thyroid volume) and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
62115352|NCT03825133|EXPERIMENTAL|Bone Marrow Aspirate Concentrate|Patients treated with single injection of BMAC in the knee
62115353|NCT03825133|EXPERIMENTAL|Leukocyte Rich Platelet Rich Plasma|Patients treated with single injection of LR-PRP in the knee
62115354|NCT03825133|EXPERIMENTAL|Hyaluronic Acid|Patients treated with 3 single injection of high molecular HA in the knee ( one injection weekly)
62115355|NCT01941563|EXPERIMENTAL|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
62115356|NCT01941563|SHAM_COMPARATOR|Control|Sham injection
62115357|NCT03608618|EXPERIMENTAL|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
62115358|NCT03608618|EXPERIMENTAL|Cohort 2 and 2i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)
62115359|NCT03608618|EXPERIMENTAL|Cohort 3 and 3i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)
62115360|NCT03608618|EXPERIMENTAL|Cohort 4 and 4i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)
62115361|NCT01566708|EXPERIMENTAL|treatment group|
62115362|NCT01566708|ACTIVE_COMPARATOR|waiting list group|
62115363|NCT01566708|ACTIVE_COMPARATOR|control group|
62115364|NCT06386562|ACTIVE_COMPARATOR|Internet-based parenting program|Internet-based parenting program with weekly parental support from a family guide (psychologist) via a chat function integrated into the program. The program consists of a brief introducing module and 5 modules conducted over 5-7 weeks. Parents work independently with material online and receive support from the family guide through chat/text messages in the program.
62115365|NCT06386562|EXPERIMENTAL|Internet-based parenting program with additional parental support through digital/phone meetings|The same internet-based parenting program with weekly parental support from a family guide (psychologist) via a chat function integrated into the program. The addition is three 10-15 minutes long digital/phone meetings between the family guide and the parent.
62115366|NCT04616053|EXPERIMENTAL|Intervention group|IMPACT intervention
62115367|NCT04616053|NO_INTERVENTION|Control group|Usual care
62115368|NCT04628026|EXPERIMENTAL|1|standard chemotherapy in combination with venetoclax
62115369|NCT04628026|PLACEBO_COMPARATOR|2|standard chemotherapy in combination with placebo
62115370|NCT05417893|ACTIVE_COMPARATOR|Cohort-1: MeRes 100 BRS|1248 subjects will be delivered with MeRes 100 BRS
62115371|NCT05417893|ACTIVE_COMPARATOR|Cohort- 2: Contemporary DES platforms|624 subjects will be delivered with Contemporary DES
62115372|NCT06345560|EXPERIMENTAL|Drospirenone|Participants received Drospirenone 4 mg tablet orally once daily for 21-28 days
62472632|NCT04729881|EXPERIMENTAL|Conventional Rehabiliation Group|"Participants 5 days a week for 4 weeks; TENS, US and neck specific exercise program will be applied.~Conventional TENS will be applied to the participants with the CefarCompex rehab400 (New Chattanooga Compex Rehab, USA) muscle rehabilitation device. It will be applied with electrodes coated with a special adhesive material for each participant for 20 minutes at a frequency of 60-120 Hz. In the study; 4 channels and 8 electrodes will be used. Electrodes will be placed paravertebrally in the cervicothoracic space, covering the painful area. The dose of the current will be increased as the patients become accustomed to the current intensity.~Continuous Ultrasound will be applied to the participants due to chronic neck pain. It will be applied at a frequency of 1MHz and a dose of 1.5 W / cm2 for 5 minutes."
62675458|NCT05520450||Intervention group|Recruitment will be based on consecutive patients receiving regular home care in the ATDOM Programme by the Primary Care Team, with prior informed consent.
62675459|NCT02691377|EXPERIMENTAL|Acupuncture group|Participants will receive acupuncture for 8 weeks. In particular, acupuncture will be performed three times a week in earlier 4 weeks and twice a week in later 4 weeks.
61917952|NCT01191879||acute MI group|Patients presenting with acute ST elevation myocardial infarction, admitted to the intensive cardiac care unit and that are planned for emergency primary PCI
61917953|NCT01191879||Controls|Patients undergoing a non-invasive evaluation of possible myocardial ischemia.
62115373|NCT03967795|OTHER|All patients|"Citrulline genration test before starting enteral nutrition~At ICU admission, a blood sample is collected (i) before and (ii) 90 minutes after N2-L-Alanyl-L-Glutamine administration"
62115374|NCT00816049|ACTIVE_COMPARATOR|6MPfixed|Fixed dose 6-mercaptopurine days 30-85
62115375|NCT00816049|EXPERIMENTAL|6MPindividualized|Individualized dose increments of 6-mercaptopurine days 30-85
62115376|NCT00269516|EXPERIMENTAL|1|
62115377|NCT00269516|EXPERIMENTAL|2|
62115378|NCT00269516|EXPERIMENTAL|3|
62115379|NCT00269516|PLACEBO_COMPARATOR|4|
62115380|NCT05831917|EXPERIMENTAL|Treatment Group|
62115381|NCT05664880|EXPERIMENTAL|Paricalcitol|Participants receive Paricalcitol 2mcg capsule once daily for 12 months.
62115382|NCT05664880|PLACEBO_COMPARATOR|Placebo|Participants receive Paricalcitol Placebo capsule matching Paricalcitol once daily for 12 months.
62115383|NCT03419325|EXPERIMENTAL|HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:~An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
62115384|NCT03419325|EXPERIMENTAL|HTPR/no-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of HTPR, but no CYP2C19 LOF allele found:~An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
62115385|NCT03419325|EXPERIMENTAL|no-HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of a CYP2C19 LOF allele, but no HTPR:~An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
62115386|NCT03419325|EXPERIMENTAL|No-HTPR/No-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Absence of both HTPR and CYP2C19 LOF alleles:~Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
62115387|NCT02783755|EXPERIMENTAL|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
62115388|NCT06553794|EXPERIMENTAL|Non-therapeutic intervention|"Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 loading day, 1 maintenance day) and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed."
62115389|NCT04465734|EXPERIMENTAL|A (treatment group)|HLX10 in combination with HLX04
62115390|NCT04465734|SHAM_COMPARATOR|B (control group)|sorafenib
62115391|NCT00839046|ACTIVE_COMPARATOR|1 Community Health Worker Intervention|This is the active control group, which all 150 participants will receive. It consists of visits from trained community health workers, who will provide asthma education, as well as provision of equipment and supplies to reduce indoor environmental exposures for asthma. These will include: vacuum cleaners, mattress and pillow covers, cleaning supplies.
62115392|NCT00839046|EXPERIMENTAL|2 Air Filter|The 50 families in the Air Filter Arm will receive an air filter in addition to the standard community health worker intervention. The Air Filter will be installed right after baseline measurements in the home.
62115393|NCT00839046|EXPERIMENTAL|3 Air Filter and Air Conditioner|"Fifty families will be assigned to the Air Filter and Air Conditioner Arm. In addition to the standard community health worker intervention, they will receive an air filter and an air conditioner (for the warmer months)."
62115394|NCT00332644|EXPERIMENTAL|1|nicotine patch alone treatment
62115395|NCT00332644|EXPERIMENTAL|2|nicotine lozenge alone treatment
62115396|NCT00332644|EXPERIMENTAL|3|nicotine patch + lozenge combination treatment
62115397|NCT00332644|EXPERIMENTAL|4|bupropion alone treatment
62115398|NCT00332644|EXPERIMENTAL|5|bupropion + nicotine lozenge combination treatment
62115399|NCT00332644|PLACEBO_COMPARATOR|6|placebo control (no active medication) treatment
62115400|NCT01377259||1Tissue oxygenation change|Spinal anesthesia may result different changes of tissue oxygenation in blocked area ( upper extrimities ) and non-blocked area ( lower extrimities). The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for orthopedic surgery
62115401|NCT01377259||2Tissue oxygenation change|The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for cesarean section
61917954|NCT04388371|EXPERIMENTAL|Prior to subject taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
62115402|NCT02469337|ACTIVE_COMPARATOR|Preoperative carbohydrate drinks|Patients who were randomised to carbohydrate group ingested 800ml PreOp (Nutricia Clinical Care, 12.5g CHO/100 ml) the night before and 400ml in the morning of surgery, about 2-3 hours before the induction of anaesthesia.
62115403|NCT02469337|ACTIVE_COMPARATOR|Dichloroacetate infusion|The patients in the dichloroacetate group received the CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 min, one- two hours before the induction of anaesthesia.
62115404|NCT02469337|ACTIVE_COMPARATOR|Moderate intensity exercise|Patients randomised to exercise group, will perform a 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate(determined by the formula: (220-Age)\*0.7 under close supervision and monitoring of their vital parameters.
62304111|NCT05713955|ACTIVE_COMPARATOR|study group|For the study group, a unit of autologous BioMatrix OBSiDiAN will be produced. Blood sample (120ml) will be taken after randomization at the ending of the abdominal phase of the surgery. The surgeon will create an esophagogastric anastomosis, after ruling out tension or torsion. Around 1-2ml of autologous BioMatrix OBSiDiAN will be applied on the distal/or proximal resection stump before the stapled anastomose will be created. After firing the standard circular device and creation of a functional anastomosis, a further 2.5-3ml OBSiDiAN must be applied circumferentially on the outside on the anastomosis. Once application is completed, a 30 seconds waiting period is required before putting the esophagus back into the surgical field (study specific). A methylene blue leakage test or other leakage test is performed (standard of care). If there is a leak, the anastomosis will be corrected or the completed procedure has to be done again.
62304112|NCT05713955|NO_INTERVENTION|standard group|The surgeon will create an esophagogastric anastomosis, after ruling out tension or torsion. A methylene blue leakage test or other leakage test is performed (standard of care). If there is a leak, the anastomosis will be corrected.
62304113|NCT00148239|EXPERIMENTAL|Caregiver Only|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
62304114|NCT00148239|EXPERIMENTAL|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
61917955|NCT04388371|EXPERIMENTAL|subjects taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
62115405|NCT02469337|NO_INTERVENTION|Control|Patients in this group will have surgery as standard practice with none of the above interventions
62115406|NCT06372912||Patients undergoing bariatric surgery|
62115407|NCT00755118|EXPERIMENTAL|1|LoHP/AIO/Avastin-\>CPT-11/AIO/Erbitux
62115408|NCT06070415|EXPERIMENTAL|Experimental|Home exercise assisted with a chatbot
62115409|NCT06070415|ACTIVE_COMPARATOR|Control|Home exercise, usual care
62115410|NCT04533464|EXPERIMENTAL|MultiStem|
62115411|NCT04533464|PLACEBO_COMPARATOR|Placebo|
62115412|NCT02785718|EXPERIMENTAL|Patients with FXI or FXII deficiency|12 patients with FXI deficiency and 6 patients with FXII deficiency
62115413|NCT01831791|EXPERIMENTAL|Dutasteride Arm|Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months).
62304115|NCT00148239|ACTIVE_COMPARATOR|Control|Participants are provided with written materials at beginning of study; nothing thereafter
62304116|NCT00653315|EXPERIMENTAL|A|Subjects received kali product under fasting conditions
62304117|NCT00653315|ACTIVE_COMPARATOR|B|Subjects received Ortho-Mcneil product under fasting conditions
62304118|NCT01035151|ACTIVE_COMPARATOR|Delayed Control|Women in the delayed control condition received culturally sensitive smoking cessation written materials at week 1, and mailed materials at week 6, 12, and 18. At the end of the study (i.e., after the 12 month data collection), participants were offered counseling, nicotine patches, and community health worker contacts.
62304119|NCT01035151|EXPERIMENTAL|Experimental|Women in neighborhoods randomized to the S2S received 24-week bundled multi-level intervention. Individual-led strategies were led by paid community health workers (CHWs). The CHWs provided 1:1 contact to reinforce social support, and enhanced self-efficacy with cessation attempts. A certified smoking cessation counselor led behavioral group sessions using the S2S handbook based on the PHS Guidelines. The weekly group sessions were initiated during the 1st week of the intervention, with a total of 6 group sessions over a 6-week period. Transdermal nicotine patches were offered to participants who set a quit date. Within the 24-week study period, the neighborhood tenant association, in partnership with study staff, implemented at least two neighborhood level anti-smoking activities
62304120|NCT02132221|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|cognitive therapy (10 weekly sessions)
62304121|NCT02132221|NO_INTERVENTION|no CBT- wait list|no cognitive therapy
62304122|NCT01565525|NO_INTERVENTION|Bright Futures|This represents 'usual care' in the pediatric office. The anticipatory guidance regarding nutrition is based on the Bright Futures Pocket Guide.
62304123|NCT01565525|EXPERIMENTAL|Maternal focused intervention|Childhood obesity prevention was approached in this arm via anticipatory guidance aimed at maternal eating habits.
62304124|NCT01565525|ACTIVE_COMPARATOR|Ounce of Prevention|This is a program of anticipatory guidance given to mothers of infants ages 2 weeks to one year which focuses on serving size per age and tips for introducing new foods for the infant.
62304125|NCT04219371||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
62304126|NCT06118879|EXPERIMENTAL|Sensory level stimulation with exercise|
62304127|NCT06118879|SHAM_COMPARATOR|Sham stimulation with exercise|
62675460|NCT02691377|SHAM_COMPARATOR|Sham Acupuncture group|Participants will receive sham acupuncture for 8 weeks. The procedure is the same as the acupuncture arm.
61917956|NCT02699788|EXPERIMENTAL|Multifunction Cardiogram|non-invasive computerized, multiphase, resting electrocardiogram analysis device
62304128|NCT06118879|ACTIVE_COMPARATOR|Exercsie alone|
61917957|NCT06100328||Cardiac myxoma group|patients who are diagnosed as cardiac myxoma
62115414|NCT03939819|EXPERIMENTAL|ViSiGi® 3D suction calibration device|"The ViSiGi® 3D is the first calibration system specifically intended for use during sleeve gastrectomy.ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.~Advantages of ViSiGi® 3D device include simplification of sleeve calibration in addition to suctioning the stomach and performing leak tests all with one device making operative steps simpler for both the anesthesiology team and surgeons. Since it is single patient use it does not require reprocessing."
62115415|NCT03939819|ACTIVE_COMPARATOR|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope, similar to The ViSiGi device, have suction, calibration, and leak testing capabilities.
62304129|NCT04718090|ACTIVE_COMPARATOR|interscalene block|
62304130|NCT04718090|ACTIVE_COMPARATOR|PENG block|
62304131|NCT01466751|ACTIVE_COMPARATOR|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
62304132|NCT01466751|EXPERIMENTAL|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
62304133|NCT01217749|EXPERIMENTAL|Group 1|In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
62304134|NCT01217749|EXPERIMENTAL|Group 2|In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
62115416|NCT03321344|EXPERIMENTAL|Test Arm|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
62304135|NCT01217749|EXPERIMENTAL|Group 3|In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily
62304136|NCT01006356|EXPERIMENTAL|Hydromorphone hydrochloride (HCl) oral osmotic system (OROS)|Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.
62304137|NCT03455946|EXPERIMENTAL|Interventional|DASH Cloud with Alexa
62304138|NCT06052462|EXPERIMENTAL|[14C]-LY3556050|Single dose of \[¹⁴C\]-LY3556050 administered orally
62304139|NCT05797766|EXPERIMENTAL|Treatment|The fluid distribution timetable as defined by Mina et al. (2019) is a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
62304140|NCT05797766|NO_INTERVENTION|Control|Standard care that consists of 10 to 15 minutes of face-to-face health teaching of their treatment regimen including management of medication, vascular access, dietary and fluid, and hemodialysis schedule.
62304141|NCT06046560|ACTIVE_COMPARATOR|Medication & Education-First|Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
62304142|NCT06046560|EXPERIMENTAL|Education-First|Patient will first receive curated patient education, an alert to providers, and provider education, and then after 2 months begin participation in the remote clinic.
62675461|NCT06307444|NO_INTERVENTION|medical treatment only|All patients will receive oral medication for antiviral therapy (800mg of acyclovir 5 times daily) at the time of diagnosis and supportive treatments, including acetaminophen (1gm 3times daily), and gabapentin (starting at 100mg three times daily) to be incrementally up titrated over time as needed by 100 to 300 mg every 3 to 5 days, to as high a dosage as 1800 to 3600 mg/day in 3 or 4 divided doses
62304143|NCT03592862|EXPERIMENTAL|HTL0018318 high dose|oral capsule, once daily
62304144|NCT03592862|EXPERIMENTAL|HTL0018318 mid dose|oral capsule, once daily
62304145|NCT03592862|EXPERIMENTAL|HTL0018318 low dose|oral capsule, once daily
62304146|NCT03592862|PLACEBO_COMPARATOR|Placebo|oral capsule, once daily
62304147|NCT04579861||High human development|Countries classified as very high and high human development as per the United Nations development programme.
62304148|NCT04579861||Low and medium human development|Countries classified as low and medium human development as per the United Nations development programme.
62304149|NCT04066621|EXPERIMENTAL|CRO-SBT|Ceftriaxone Sodium and Sulbactam Sodium for Injection(2:1)
62304150|NCT00467844|EXPERIMENTAL|1|1 mg GTx-024
62304151|NCT00467844|EXPERIMENTAL|2|3 mg GTx-024
62304152|NCT00467844|PLACEBO_COMPARATOR|3|Placebo
62675462|NCT06307444|EXPERIMENTAL|Ultrasound-Guided Stellate Ganglion Block|Ten milliliters of a local anesthetic solution (bupivacaine (0.25%)+ 8 mg dexamethasone) is injected until the fluid spreads along the paravertebral fascia to the stellate ganglion.
62675463|NCT06307444|EXPERIMENTAL|Group III T2 T3 (High Thorathic) ErectroSpinae Plan Block|ocal anesthetic drugs(0.2-0.3ml/kg of bupivacaine 0.25% 8mg Dexamethazone) will be administered as standard in all patients aiming to distribute within the plane between the anterior fascia of the erector spinae muscle and the transverse process.
62675464|NCT01457456||Observation|Patients with Morquio disease
62304153|NCT00691574|ACTIVE_COMPARATOR|2|Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
62304154|NCT00691574|EXPERIMENTAL|1|Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.
62115417|NCT02319122|OTHER|Progressive Resistance Training|"The key for the PRT is the timely progression of load, based on the child's individual level of strength, which ensures progressive overload.~Every training session will consist of a warm up, progressive resistance exercises and a cool down period. During warm up and cool down periods.These exercises will be the same for both training groups.~The strength training exercises have been chosen to strengthen the main lower extremity muscle groups which are important for the gait: sit-to-stand, lateral step-ups, the half knee rise, heel-rises and bridging.~All these exercises are performed loaded according to the individual level. Three sets of 8 to 10 repetitions of each exercise will be practiced on 3 non-consecutive days with moderate velocity."
62115418|NCT02319122|OTHER|High Intensity Interval Training|The High Intensity Circuit Training is a sub form of High Intensity Interval Training. The key feature is the very little rest between the exercises which causes a consistent elevation of the participant's heart rate and a short duration of the whole exercise session. Every training session consists of a warm-up, a circuit of 5 exercises (the same as these in the PRT group) and a cool-down period. The children will be asked to train 3 times a week on non-consecutive days and to perform 3 sets. Exercise workload is controlled by determination of time intervals (30 seconds). The children will be instructed to perform as many repetitions as possible during the exercise interval and to keep the rest between the exercises short (it must not exceed 30 seconds).
62115419|NCT04658212|EXPERIMENTAL|3D LCBDE group|
62304155|NCT02128568|ACTIVE_COMPARATOR|Waitlist + YRI only|Participants will complete the assessment and collection of biomarkers and be placed on a waitlist. Once the trial of the first arm has been concluded, participants complete another round of assessments and are offered the YRI sessions. The epigenetic biomarkers collected will be compared with the experimental arm.
62304156|NCT02128568|EXPERIMENTAL|YRI only|Immediately following assessment and collection of biomarkers, participants will be offered the YRI sessions.
62304157|NCT01442584|EXPERIMENTAL|fertility restoration by transplantation|fertility restoration by transplantation of ovarian cortex slivers that were cryopreserved prior to chemotherapy
62304158|NCT00883324||1|fetal fibronectin specimens collected with a speculum
62675465|NCT00005922|EXPERIMENTAL|A|Participants will receive 100% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
61917958|NCT06100328||Cardiac fibroma group|patients who are diagnosed as cardiac fibroma
61917959|NCT06100328||Cardiac lipoma group|patients who are diagnosed as cardiac lipoma
61917960|NCT06100328||Cardiac hemangioma group|patients who are diagnosed as cardiac hemangioma
62115420|NCT04658212|ACTIVE_COMPARATOR|ERCP group|
62115421|NCT04330950||Surgical Cohort|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
62115422|NCT05696977|ACTIVE_COMPARATOR|Obese nephrotic patients with BMI>25 kg/m2|"Nephrotic obese patients receive Cyclosporine capsule initially according to weight-based dose then modifying the dose according to targeted therapeutic level.~To determine the best weight can be used to get the targeted therapeutic level. Correlate with the lipid profile, fat percentage and other anthropometric measures."
62115423|NCT05696977|OTHER|Non obese nephrotic patients with BMI<25 kg/m2|Nephrotic non-obese patients receive Cyclosporine capsule initially according to weight-based dose then modified dose according to targeted therapeutic level.
62304159|NCT00883324||2|fetal fibronectin specimens collected without a speculum
62304160|NCT03361670||Specimens that meet inclusion criteria|
62304161|NCT03426969|EXPERIMENTAL|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on days -5, fludarabine phosphate IV over 1 hour on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously for approximately 2 weeks, then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 100, and filgrastim SC daily from day 7 until continued until ANC \> 1,500/mm\^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
62304162|NCT01945892||Irvine Gass Syndrome|"Patients older than 18 years who develop macula edema secondary to cataract surgery.~Group may receive intravitreal Ozurdex medication in case of persistent macular edema."
62304163|NCT00674531|OTHER|1|Enterovirus RNA analysis
62304164|NCT00800761|ACTIVE_COMPARATOR|Deferoxamine alone|comparison of deferoxamine subcutaneous 40mg/kg/die alone versus combined therapy deferoxamine-deferiprone
62304165|NCT00800761|ACTIVE_COMPARATOR|Deferoxamine plus Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
62304166|NCT04176510|EXPERIMENTAL|Patient Centered Medical Home (PCMH) plus Health Coach|A health coaching intervention that employs a positive affect/self-affirmation intervention to help motivate patients to succeed at implementing self-management by setting life goals, in addition to the usual care provided for patients with multiple chronic diseases by the The Patient-Centered Medical Home (PCMH).
62675466|NCT00005922|EXPERIMENTAL|B|Participants will receive 100% of the dose of the medication on a partial reinforcement schedule (25% or 50%) as received during the baseline (maintenance) period
62675467|NCT00005922|EXPERIMENTAL|C|Participants will receive 25% or 50% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
62675468|NCT01287429||acute dyspnea|
62675469|NCT05215847|EXPERIMENTAL|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
62675470|NCT03499665|EXPERIMENTAL|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|This group of patients received patients with bruxism. It was applied proprioceptive neuromuscular facilitation (PNF), myofascial releasing maneuvers and home exercises.
62472633|NCT04729881|ACTIVE_COMPARATOR|Spesific Exercise Group|Participants will be given a home exercise program consisting of exercises specifically applied to the neck. Participants will be asked to practice the exercises 5 days a week. The application status of the participants' home exercise program will be followed by the researcher over the phone. Participants who do not practice the home exercise program will be excluded from the study. The exercise program to be applied to the participants in the exercise group is listed below.Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise.
62472634|NCT04729881|OTHER|Control Group|
62472635|NCT02632344|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
62675471|NCT03499665|ACTIVE_COMPARATOR|Myofascial Releasing Maneuvers and Home Exercises Group|This group of patients received patient with bruxism. It was applied myofascial releasing maneuvers and home exercises.
62675472|NCT03499665|ACTIVE_COMPARATOR|Control Group|This group of patients received patient with bruxism. It was applied conventional treatment and no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
62675473|NCT02608346|OTHER|Blood sampling|
62675474|NCT03555045|ACTIVE_COMPARATOR|conducting the slanted recession technique|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
61917961|NCT06100328||Cardiac malignant tumor group|patients who are diagnosed as cardiac malignant tumor
62675475|NCT03555045|ACTIVE_COMPARATOR|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
62115424|NCT05288868|EXPERIMENTAL|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
62115425|NCT05288868|NO_INTERVENTION|Caregiver Satisfaction|Caregivers who accompany their children with autism to the clinic will be surveyed for their comfort scores before and after the study participants' educational intervention
62304167|NCT04176510|NO_INTERVENTION|Patient Centered Medical Home (PCMH)|Usual care provided for patients with multiple chronic diseases by the Patient-Centered Medical Home (PCMH).
62675476|NCT01749566|ACTIVE_COMPARATOR|Group A (standard maraviroc dosing)|maraviroc 300mg po bid x 7 days
62675477|NCT01749566|ACTIVE_COMPARATOR|Group B (reduced maraviroc dosing)|maraviroc 300mg po daily x 7 days
62675478|NCT01749566|NO_INTERVENTION|Group C (no drug)|No additional drug
62675479|NCT00930332|ACTIVE_COMPARATOR|Arm A: Methadone|"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
62675480|NCT00930332|ACTIVE_COMPARATOR|Arm B: Methadone|"Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
61917962|NCT01906879|ACTIVE_COMPARATOR|Triple therapy (A)|lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po
61917963|NCT01906879|EXPERIMENTAL|non-bismuth quadruple therapy|Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid
62472636|NCT03575234|EXPERIMENTAL|Treatment (nivolumab, cyclophosphamide, IRX-2, surgery)|Participants receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, participants undergo surgery.
62675481|NCT00137280|EXPERIMENTAL|Collaborative Chronic Illness Care Model|Collaborative Chronic Illness Care Model: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
62675482|NCT00137280|NO_INTERVENTION|Usual Care|Usual Care
62675483|NCT03947021|EXPERIMENTAL|BSPM-only group|Participants will only receive body-surface potential mapping (BSPM) with an extensive electrode set (256 electrodes).
62472637|NCT04897321|OTHER|Treatment Phase|During the treatment phase, the participant receives an infusion of the B7-H3-CAR T cells that were made in the Collection and Manufacturing Phase. Chemotherapy is given for several days prior to the cellular infusion. Patients are then monitored for possible side effects, as well as effects of the treatment on their cancer.
62472638|NCT02766881||Patients with DCIS|Whether patients with DCIS receive radiotherapy based on Oncotype DX DCIS score, radiation oncologist treatment recommendation and patient's decision.
62472639|NCT06074289|EXPERIMENTAL|Family connections program|In each centre, caregivers are consecutively assigned to a group intervention including from 10 to 12 participants.
62115426|NCT03009006|EXPERIMENTAL|Calcium Hydroxide Mixed With Chlorhexidin|efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria.
62115427|NCT03009006|EXPERIMENTAL|Calcium Hydroxide|The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
62472640|NCT05269901||Seizures group|20 newly diagnosed untreated school-aged children from Jan 20, 2021 to Jan 1, 2022 in affiliated Hospital of Jiangnan University, department of pediatrics.
62675484|NCT03947021|EXPERIMENTAL|CT+BSPM group|Participants will receive body-surface potential measurements (BSPM) and a CT scan. These data will allow for non-invasive reconstruction of electrical potentials at the heart surface.
62675485|NCT03997838|EXPERIMENTAL|VVZ-149 Injections|
62675486|NCT03997838|PLACEBO_COMPARATOR|Placebo|
62675487|NCT04579419|EXPERIMENTAL|Sodium Bicarbonate|
62675488|NCT04579419|PLACEBO_COMPARATOR|Normal Saline|
62675489|NCT05459714|EXPERIMENTAL|MCE for obese patients|After a standardized gastrointestinal preparation, the patient will undergo MCE examination. After completing the MCE procedure, the patient is evaluated for examination comfort and can then leave the hospital on his or her own and watch for capsule excretion.
62675490|NCT03041337||Healthy subjects|Cohort of patients referred to our echocardiography laboratory to work assessment procedures and without any cardiovascular risk factor. They will underwent stress echocardiography.
62115428|NCT03009006|PLACEBO_COMPARATOR|Placebo|Mechanical preparation without intracanal medications.
62304168|NCT02438930|EXPERIMENTAL|Motivational interviewing counseling|"The brief intervention is adapted from the OPTIONS project, which is a brief client-centered risk reduction intervention for HIV-positive patients in clinical care. The OPTIONS intervention content is based upon the IMB model of health behavior change, and uses motivational interviewing techniques to create client-centered discussions in which HIV counselors and patients collaborate to identify patients' HIV transmission risk behaviors and to mutually identify strategies and goals for reducing the patient's risky behavior.~The brief intervention will be facilitated by health care providers (nurses, lab technicians) specifically trained in the intervention protocol and will consist of 2 brief counseling sessions occurring during the same-day rapid HIV-testing procedure"
62304169|NCT02438930|ACTIVE_COMPARATOR|Standard of care counseling|Participants in this study condition will receive standard-of-care counseling that is usually implemented during HIV testing.
62304170|NCT05946252|EXPERIMENTAL|Motor Imagery Group|"Risky pregnant women who have completed the 12th week of pregnancy, received inpatient treatment and have any of the following risk factors will be included in the study:~* Pregnant women who are at risk for obstetric outcomes such as cervical insufficiency, multiple pregnancy and uncontrolled gestational diabetes, and physical activity restriction is recommended due to these conditions, and exercise is contraindicated,~* Pregnant women with a maternal body mass index above 30, which causes them to be physically inactive"
62675491|NCT03041337||cardio-respiratory diseases|patients with any possible cardiovascular and respiratory condition. They will underwent stress echocardiography.
62675492|NCT06436521|EXPERIMENTAL|Positive CBT (P-CBT)|Participants received P-CBT intervention after a standard protocol. The intervention used Solution-focused questioning.
62675493|NCT06436521|EXPERIMENTAL|Traditional CBT (T-CBT)|Participants received T-CBT intervention after a standard protocol. The intervention used Problem-solving questioning.
62675494|NCT03848351|NO_INTERVENTION|Control Group|70 patients not receiving oral hygiene instructions or devices and continuing with their routine oral hygiene habits
62675495|NCT03848351|ACTIVE_COMPARATOR|Test Group|"70 patients receiving intense oral hygiene instructions assisted by specific software or devices as well as oral hygiene (OH) tools (electric toothbrush, interdental floss, toothpaste) Thus, interventions will consist of.~* Oral Hygiene Instruction (OHI)~* Professional supragingival scaling and polishing"
62675496|NCT00888082|NO_INTERVENTION|A|Patients receiving only adjuvant chemotherapy
62675497|NCT00888082|EXPERIMENTAL|B|Patient receiving goserelin acetate along with adjuvant chemotherapy
62675498|NCT00002835|EXPERIMENTAL|Arm I|"3 courses of early intensification:~First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.~Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.~Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity."
62675499|NCT00002835|EXPERIMENTAL|Arm II|IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.
62675500|NCT00711204|PLACEBO_COMPARATOR|1|
62115429|NCT02773017|EXPERIMENTAL|Youth female group|patients in the Youth female group, aged 20\~35, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
62115430|NCT02773017|EXPERIMENTAL|Middle-aged female group|patients in the Middle-aged female group, aged 40\~60, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
62304171|NCT05946252|ACTIVE_COMPARATOR|Control Group|"Risky pregnant women who have completed the 12th week of pregnancy, received inpatient treatment and have any of the following risk factors will be included in the study:~* Pregnant women who are at risk for obstetric outcomes such as cervical insufficiency, multiple pregnancy and uncontrolled gestational diabetes, and physical activity restriction is recommended due to these conditions, and exercise is contraindicated,~* Pregnant women with a maternal body mass index above 30, which causes them to be physically inactive"
62675501|NCT00711204|ACTIVE_COMPARATOR|2|
62675502|NCT03148782|EXPERIMENTAL|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
62304172|NCT01634243|EXPERIMENTAL|SPM 962|SPM 962 transdermal patch
62304173|NCT05619926|EXPERIMENTAL|Consecutive doses of low-dose of STSP-0601|
62675503|NCT05013086|EXPERIMENTAL|1.48 GBq of 177Lu-AB-3PRGD2|The patients were intravenously injected with the dose about 1.48GBq (40 mCi) of 177Lu-AB-3PRGD2 and underwent 68Ga-RGD PET/CT scans before and after the treatment.
62675504|NCT03412890|EXPERIMENTAL|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 28 weeks.
62115431|NCT02773017|EXPERIMENTAL|Elderly female group|Patient in the elderly female group, aged 65\~79, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
62304174|NCT05619926|EXPERIMENTAL|Consecutive doses of high-dose of STSP-0601|
62472641|NCT05269901||Healthy control group|20 age-matched healthy school-aged children from Jan 20, 2021 to Jan 1, 2022 in affiliated Hospital of Jiangnan University, department of pediatrics.
62675505|NCT03706352|EXPERIMENTAL|tunneling group|Epidural Catheter Insertion and fixation by subcutaneous tunneling procedure.
62675506|NCT03706352|ACTIVE_COMPARATOR|taping group|Epidural Catheter Insertion and fixation by use of adhesive tape without tunneling.
62675507|NCT01571609|EXPERIMENTAL|Carriers|
62675508|NCT01571609|EXPERIMENTAL|Non-carriers|
62675509|NCT00624078|EXPERIMENTAL|1|Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
62115432|NCT01799148||Particulate air pollutants|Cohort of consecutive patients admitted with diagnosis of acute coronary syndrome in the cardiology unit of a tertiary hospital, which will quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to admission.
62675510|NCT01515111||Internal Medicine Staff|All interns, residents and attendings training (or working) at an Internal Medicine department of a Guatemalan teaching hospital.
62675511|NCT01471574|EXPERIMENTAL|Daclatsvir + Ribavirin + PEG-Interferon alfa-2a|
62675512|NCT02382263|EXPERIMENTAL|Arm B|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
62675513|NCT02382263|EXPERIMENTAL|Arm C|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
62675514|NCT02382263|EXPERIMENTAL|Arm D|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
62675515|NCT02382263|EXPERIMENTAL|Arm E|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
62115433|NCT02854319|EXPERIMENTAL|LOTUS Edge Valve System|Transcatheter aortic valve implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
62115434|NCT06158048|EXPERIMENTAL|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62115435|NCT06158048|EXPERIMENTAL|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62115436|NCT02101190|EXPERIMENTAL|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
62115437|NCT02101190|EXPERIMENTAL|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
62472642|NCT04813081|ACTIVE_COMPARATOR|Free gingival graft around dental implant patients|Test Group (TG) consists of patients have free gingival graft around dental implant patients
62675516|NCT04378088||Group 1 - experts|"Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
62675517|NCT04378088||Group 2 - mix experts/trainee|"If intra and interobserver rates in group 1 are \>0.7 proceed to group 2 evaluation with the same intervention.~Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
62675518|NCT02656342|EXPERIMENTAL|250 mg DCS|64 patients receive 250 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
62675519|NCT02656342|EXPERIMENTAL|100 mg D-Cycloserine|64 patients receive 100 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
62675520|NCT02656342|ACTIVE_COMPARATOR|Placebo|32 patients receive placebo two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
62675521|NCT00635583|EXPERIMENTAL|Increased Dairy Consumption|Increased Dairy Consumption - Each subject in this arm will receive three additional servings of dairy to consume each day for 18 months.
62675522|NCT00635583|NO_INTERVENTION|Control|This group will not receive the intervention but will continue their normal diet; they will act as the control.
62115438|NCT00545077|ACTIVE_COMPARATOR|Arm A: Endocrine Therapy (ET)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
62115439|NCT00545077|EXPERIMENTAL|Arm B: ET with Bevacizumab (ET-B)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
62115440|NCT03816124|EXPERIMENTAL|Genicular RF|Patients who will receive genicular radiofrequency ablation
62115441|NCT03570827|EXPERIMENTAL|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
62115442|NCT03570827|EXPERIMENTAL|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
62115443|NCT03570827|EXPERIMENTAL|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
62115444|NCT02217644|EXPERIMENTAL|BI 653048 H3PO4 solution|single rising doses
62115445|NCT02217644|EXPERIMENTAL|BI 653048 H3PO4 low dose capsule|
62115446|NCT02217644|EXPERIMENTAL|BI 653048 H3PO4 high dose capsule|
62115447|NCT02217644|PLACEBO_COMPARATOR|Placebo|
62115448|NCT05383313|EXPERIMENTAL|Psilocybin|25 mg, orally (capsule), single administration
62115449|NCT05383313|ACTIVE_COMPARATOR|Ketamine|250 mg, orally (capsule), single administration
62304175|NCT02339714|EXPERIMENTAL|Acupuncture combined moxibustion|Acupuncture at Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14). Needle warming moxibustion at Dazhui(Du14). Patients will be treated once per day for 30 min, 3 times in a weeks for 4 weeks.
62304176|NCT02339714|ACTIVE_COMPARATOR|loratadine|Loratadine taken orally, 10mg/day in the morning
61917964|NCT01906879|EXPERIMENTAL|bismuth quadruple therapy for 10 days|Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid
62115450|NCT05383313|PLACEBO_COMPARATOR|Midazolam|5 mg, orally (capsule), single administration
62304177|NCT02571413|OTHER|oral presentation|"Scoring the correct use of INC before, immediate after and 3 months after oral presentation without demonstration how to use INCS"
62115451|NCT05185830|EXPERIMENTAL|Interactive robot|Children in the interactive robot will be mobilized for the first time with interactive robots.
62115452|NCT05185830|NO_INTERVENTION|Control group|Children in the control group will be mobilized with nurses
62115453|NCT03145337|ACTIVE_COMPARATOR|Cohort A|FlexHD ADM
62115454|NCT03145337|ACTIVE_COMPARATOR|Cohort B|AlloDerm RTU ADM
62115455|NCT05372380|EXPERIMENTAL|Sequence F/AE/F+AE|A total of 32 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(F, AE, F+AE) assigned to on sequence group in Period 1, Period 2, and Period 3.
62304178|NCT02571413|OTHER|animated cartoon-aided VDO|"Scoring the correct use of INC before, immediate after and 3 months after animated cartoon-aided teaching how to use INCS"
62304179|NCT03086850|EXPERIMENTAL|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
62304180|NCT03086850|ACTIVE_COMPARATOR|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
62304181|NCT05817201|EXPERIMENTAL|Toripalimab & Radiotherapy|Toripalimab, 240mg/d, radiotherapy D7, D28; Thoracic radiotherapy, 54Gy/25F, IMRT; Maintenance Toripalimab therapy after completed radiotherapy, 240mg/Q3W, until progression or 1 years or intolerant
62675523|NCT01599676|SHAM_COMPARATOR|Not essential amino acid|"Non essential amino acid:~The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive 1 unit of an equivalent quantity of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity) isonitrogenous to 10 g of citrulline, once in the morning for 12 weeks."
62675524|NCT01599676|EXPERIMENTAL|Citrulline|The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive citrulline 10 g/day orally in the morning for 12 weeks.
62675525|NCT03695601||HeartCare|Diagnostic Test: Heart Care 2300 patients managed with HeartCare (AlloMap® and AlloSure-Heart® )
62675526|NCT03695601||Control|A historical control group will be matched to the estimated 1150 HeartCare group patients who complete at least two years of HeartCare surveillance use and inclusive of year 3 post-transplant clinical follow-up for outcome. The criteria for the matched controls will be based on allograft donor type, age, gender, ethnicity/race, and other clinical factors. Propensity scores will be used to perform the matching.
62675527|NCT01398475|EXPERIMENTAL|LY3009104 Reference Formulation|8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
62675528|NCT01398475|EXPERIMENTAL|LY3009104 Test Formulation 1|8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
62675529|NCT01398475|EXPERIMENTAL|LY3009104 Test Formulation 2|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
62675530|NCT01398475|EXPERIMENTAL|LY3009104 Test Formulation 2 + Meal|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.
62675531|NCT06694038|ACTIVE_COMPARATOR|Standard Cannulation|Standard Biliary Cannulation
62115456|NCT05641363|ACTIVE_COMPARATOR|Standard dose group A|IV ketorolac 0.5 mg/kg/dose up to a maximum dose of 30 mg plus IV normal saline placebo given at 0.25 mg/kg to a maximum of 30 mg plus IV normal saline placebo given at 0.5 mg/kg to a maximum of 10 mg
62675532|NCT06694038|EXPERIMENTAL|NKF Cannulation|Biliary Cannulation using NKF technique
62675533|NCT01766843|ACTIVE_COMPARATOR|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
62675534|NCT01766843|ACTIVE_COMPARATOR|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
62675535|NCT01766843|EXPERIMENTAL|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
62675536|NCT01766843|EXPERIMENTAL|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
62675537|NCT04640987|EXPERIMENTAL|Cohort 1|The participant will undergo a alpha-beta depleted stem cell transplant using donor cells. The participant's cells will then be manipulated via a T-allo10 cell addback to reach a dose level of 1 X 10\^5/kg
62115457|NCT05641363|EXPERIMENTAL|Low dose group B1|IV ketorolac 0.5 mg/kg to a maximum of 10 mg plus IV normal saline placebo given at 0.25 mg/kg to a maximum of 30 mg plus IV normal saline placebo given at 0.5 mg/kg to a maximum of 30 mg
62675538|NCT04640987|EXPERIMENTAL|Cohort 2|The participant will undergo a alpha-beta depleted stem cell transplant using donor cells. The participant's cells will then be manipulated via a T-allo10 cell addback to reach a dose level of 3 X 10\^5/kg
62115458|NCT05641363|EXPERIMENTAL|Low dose group B2|IV ketorolac 0.25 mg/kg to a maximum of 30 mg plus IV normal saline placebo given at 0.5 mg/kg to a maximum of 30 mg plus IV normal saline placebo 0.5 mg/kg to a maximum of 10 mg
62115459|NCT04195516|EXPERIMENTAL|Health Promotion Group|Experimental group will be applied Health Promotion Model Basic Health Promotion Program. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.
62304182|NCT05817201|ACTIVE_COMPARATOR|Chemotherapy & Radiotherapy|Tegafur, 70mg/m2/d, radiotherapy D1-14, D29-42; Thoracic radiotherapy, 54Gy/25F, IMRT.
62304183|NCT05252312||Healthy adult population aged 18 to 80 years|"After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?)."
62304184|NCT06217406|EXPERIMENTAL|ACYCLOVIR|Intravenous acyclovir (ACYCLOVIR )
61917965|NCT03230201|NO_INTERVENTION|Blank control|do not receive Lymph node dissection during surgery.
61917966|NCT03230201|EXPERIMENTAL|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
61917967|NCT01618812||Pes plano valgus|Children with painful flatfeet
61917968|NCT00388427|OTHER|Advanced Solid Malignancies|
62115460|NCT04195516|NO_INTERVENTION|Control Group|The control group will be given educational brochures to develop healthy eating and physical activity behaviors.
62115461|NCT02967588|EXPERIMENTAL|Intervention|
62304185|NCT06217406|PLACEBO_COMPARATOR|PLACEBO|saline bags
62304186|NCT01923610|EXPERIMENTAL|Main|MVA HIV-B
62115462|NCT05638620|EXPERIMENTAL|Active|This is a non-randomized, non-blinded study. Participants eligible for this study will receive active treatment. Dual Sympathetic Blocks of the stellate ganglion are minimally- invasive outpatient procedures performed under monitored care anesthesia (light sedation). Under ultrasound visualization, a small needle is guided into the neck region that contains the stellate ganglion nerve cluster at C6-C7. Once the needle position is confirmed, a local anesthetic (7 cc of 0.5% bupivacaine/Marcaine) is injected around the stellate ganglion by the Principal Investigator. This procedure is repeated at the C3-C4 level to block the superior cervical ganglion nerve cluster (3 cc of 0.5% bupivacaine/Marcaine).
62115463|NCT04277299|EXPERIMENTAL|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Solution which is the surgical pathway currently practiced in the study hospital. The ICory-Solution has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
62472643|NCT04813081|ACTIVE_COMPARATOR|Free gingival graft around the teeth|Control Group (CG) consists of patients have free gingival graft around the teeth.
62472644|NCT04195230|EXPERIMENTAL|Computerized Cognitive Training (Breakfast Game)|"Participants will undergo a pilot training protocol where they will have to perform two tasks concomitantly, in a multi-tasking fashion. The tasks are related to everyday activities as cooking and setting tables."
62472645|NCT01456221|EXPERIMENTAL|omega 3 and an hypocaloric diet|Participants will receive a supplement containing omega 3: Docosahexaenoic acid (DHA) and EPA fatty acids together with an hypocaloric diet.
62472646|NCT01456221|PLACEBO_COMPARATOR|Placebo|Participants will receive a supplement containing sunflower oil with an hypocaloric diet.
62472647|NCT06279286|EXPERIMENTAL|HS-10506, 10 milligram (mg) and placebo|Phase Ib part: Participants will receive either 10mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 10mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
62675539|NCT04640987|EXPERIMENTAL|Cohort 3|The participant will undergo a alpha-beta depleted stem cell transplant using donor cells. The participant's cells will then be manipulated via a T-allo10 cell addback to reach a dose level of 1 X 10\^6/kg
62675540|NCT02178189|ACTIVE_COMPARATOR|Standard-calorie infant formula|Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.
62675541|NCT02178189|EXPERIMENTAL|High-calorie infant formula|Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.
62675542|NCT03156621|EXPERIMENTAL|Alirocumab SC Q2W|"Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
62115464|NCT04277299|NO_INTERVENTION|Control group|Children in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care. Parents in this group will receive BuddyCare mobile app which is supposed to be as a normal routine in this hospital.
62115465|NCT05005065|EXPERIMENTAL|Treatment AB|Participants will be randomized to receive IN-C005 Y mg (Treatment A) and IN-A001 Y mg (Treatment B) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
62304187|NCT02171715|EXPERIMENTAL|BIBW 2992 MA2, final formulation|
62675543|NCT03156621|EXPERIMENTAL|Placebo SC Q2W|"Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
62675544|NCT02239484|EXPERIMENTAL|Sequence 1|Tadalafil→Tamsulosin→Tadalafil+Tamsulosin
62675545|NCT02239484|EXPERIMENTAL|Sequence 2|Tadalafil+Tamsulosin→Tadalafil→Tamsulosin
62675546|NCT02239484|EXPERIMENTAL|Sequence 3|Tamsulosin→Tadalafil+Tamsulosin→Tadalafil
62304188|NCT02171715|EXPERIMENTAL|BIBW 2992 MA2, trial formulation II|
61917969|NCT00677430||Questionnaire + Digital Imaging|A brief questionnaire packet will be completed. Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
61917970|NCT06329115|EXPERIMENTAL|Exercise Group|This group will get aerobic exercise programme and respiratory exercise
62472648|NCT06279286|EXPERIMENTAL|HS-10506, 20 milligram (mg) and placebo|Phase Ib part: Participants will receive either 20mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 20mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
62472649|NCT06279286|EXPERIMENTAL|HS-10506, 40 milligram (mg) and placebo|Phase Ib part: Participants will receive either 40mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 40mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
62472650|NCT06279286|EXPERIMENTAL|HS-10506, 80 milligram (mg) and placebo|Phase Ib part: Participants will receive either 80mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 80mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
62675547|NCT00676689|EXPERIMENTAL|SAPIEN THV|
62675548|NCT02116062|OTHER|Amniotic membrane transplantation|
62115466|NCT05005065|EXPERIMENTAL|Treatment BA|Participants will be randomized to receive IN-A001 Y mg and IN-C005 Y mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
62675549|NCT02116062|OTHER|Pterygium surgery|
61917971|NCT03110939|EXPERIMENTAL|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
62115467|NCT05005065|EXPERIMENTAL|Treatment CD|Participants will be randomized to receive IN-C005 Z mg (Treatment C) and IN-C005 X mg (Treatment D) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
62115468|NCT05005065|EXPERIMENTAL|Treatment DC|Participants will be randomized to receive IN-C005 X mg and IN-C005 Z mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
62115469|NCT05719038||Healthy control group|
62115470|NCT05719038||Pulmonary fibrosis after COVID-19 Pneumonia|
62304189|NCT02171715|ACTIVE_COMPARATOR|BIBW 2992 MA 2 drinking solution|
62675550|NCT02116062|OTHER|Penetrating keratoplasty|
62675551|NCT00609973|ACTIVE_COMPARATOR|A|Ciprofloxacin 500 mg bid
62675552|NCT00609973|PLACEBO_COMPARATOR|B|Placebo bid
62675553|NCT05417386|EXPERIMENTAL|Safety Run-In|Following a 3 + 3 dose escalation design 6-18 participants will receive NIS793 and FOLFIRINOX on day 1 of each 14 day cycle for 3+ cycles until recommended phase 2 dose is determined.
61917972|NCT03110939|NO_INTERVENTION|control group|standard surgery of advanced lung cancer/esophageal cancer
62115471|NCT05719038||No pulmonary fibrosis after COVID-19 Pneumonia|
62115472|NCT05729724||Change treatment|Deprescribing (patients on hypotensive medications): withdrawal or reduction of one or more medications among cardiovascular and psychoactive drugs with known hypotensive effects (Table) Prescription of vasoactive medications (patients with constitutional hypotension): prescription of Fludrocortisone or other drugs that actively increase blood pressure.
62115473|NCT06533878|OTHER|Part A Dose Level 1|HY209 10 mg (1 tablet; 10 mg qd) fed, morning
62115474|NCT06533878|OTHER|Part A Dose Level 2|HY209 50 mg (1 tablet; 50 mg qd) fed, morning
62115475|NCT06533878|OTHER|Part A Dose Level 3|"1. HY209 100 mg (1 tablet; 100 mg qd) fed, morning~2. HY209 100 mg (2 tablets; 50 mg bid) fed, morning, evening"
62115476|NCT06533878|OTHER|Part A Dose Level 4|"1. HY209 200 mg (2 tablets; 200 mg qd) fasting, morning~2. HY209 200 mg (2 tablets; 200 mg qd) fed, morning"
62304190|NCT00968734|EXPERIMENTAL|Low fat meal|
62304191|NCT00968734|EXPERIMENTAL|Hight fat meal|
62304192|NCT04453644|EXPERIMENTAL|Group A (Hamstrings)|Hamstring stretching would be done then isometric strength would be measured.
62304193|NCT04453644|EXPERIMENTAL|Group B (Calf)|Calf stretching would be done then isometric strength would be measured.
62304194|NCT02062086|OTHER|Population 1|"(Community-dwelling older adults) will participate in the study for approximately 65 days.~Population 1 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~The estimation of muscle mass will be made on 2 separate occasions in the community-dwelling elderly population in order to assess reproducibility of the method when tested approximately 60 days apart."
62675554|NCT05417386|EXPERIMENTAL|FOLFIRINOX|"Participants will be randomly assigned to receive:~* FOLFIRINOX on day 1 of each 14 day cycle for cycles 1-8~* Cycles 9+: Chemoradiation (CRT) and surgery"
62115477|NCT06533878|OTHER|Part A Dose Level 5|"1. HY209 300 mg (3 tablets; 300 mg qd) fasting, morning~2. HY209 300 mg (3 tablets; 300 mg qd) fed, morning"
62115478|NCT06533878|OTHER|Part A Dose Level 6|"1. HY209 400 mg (4 tablets; 400 mg qd) fasting, morning~2. HY209 400 mg (4 tablets; 400 mg qd) fed, morning"
62115479|NCT06533878|PLACEBO_COMPARATOR|Part B Dose Level 1|"1. HY209 150 mg (3 tablets; 50 mg tid) fed, morning, afternoon, evening~2. HY209 placebo fed, morning, afternoon, evening"
62115480|NCT06533878|PLACEBO_COMPARATOR|Part B Dose Level 2|"1. HY209 200 mg (2 tablets; 200 mg qd) fed, morning~2. HY209 placebo fed, morning"
62115481|NCT06533878|PLACEBO_COMPARATOR|Part B Dose Level 3|"1. HY209 200 mg (2 tablets; 100 mg bid) fed, morning, evening~2. HY209 placebo fed, morning, evening"
62115482|NCT06533878|PLACEBO_COMPARATOR|Part B Dose Level 4|"1. HY209 300 mg (3 tablets; 100 mg tid) fed, morning, afternoon, evening~2. HY209 placebo fed, morning, afternoon, evening"
62115483|NCT01027299|ACTIVE_COMPARATOR|Standard pacing|Standard pacing settings prescribed by the cardiac surgeon or intensivist after revascularisation.
62115484|NCT01027299|ACTIVE_COMPARATOR|BiVentricular pacing (BiV).|The group of patients receiving biventricular pacing after cardiac surgery.
62115485|NCT06552884|EXPERIMENTAL|experimental group|As a nursing approach, a 4-session motherhood identity development training was given to the experimental group based on the Maternal Role Attainment Theory
62115486|NCT06552884|NO_INTERVENTION|control group|Not intervention
62115487|NCT01505946||LOW RESPONDERS|Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre \>0.6 and \< 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre \>0.6 and \< 5 BU/ml and no increase in the INH titer \> 5 BU over treatment with FVIII)
62115488|NCT01505946||HIGH RESPONDERS|Patients who documented high response after FVIII exposure (FVIII inhibitors titre \> 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI
62115489|NCT03368378|EXPERIMENTAL|Group 1|During robot-assisted radical prostatectomy after the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
62115490|NCT03368378|ACTIVE_COMPARATOR|Group 2|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
62115491|NCT06109831|EXPERIMENTAL|SHR-1918|
62115492|NCT06109831|PLACEBO_COMPARATOR|SHR-1918 placebo|
62115493|NCT01788930|ACTIVE_COMPARATOR|CPAP|"This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.~Other Name: positive airway pressure"
62115494|NCT01788930|PLACEBO_COMPARATOR|Sham-CPAP|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
62115495|NCT01736098|EXPERIMENTAL|High Energy Flux|Energy Flux Exercise Intervention: 7kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
62115496|NCT01736098|EXPERIMENTAL|Medium Energy Flux|Energy Flux Exercise Intervention: 3.5kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
62115497|NCT01736098|NO_INTERVENTION|Low Energy Flux|No Intervention: maintain normal lifestyle
62115498|NCT04385355|OTHER|Control Group|Control group will receive an intermediate transmucosal abutment with conventional diameter and 3mm height, once the implants are placed.
62472651|NCT02656368|EXPERIMENTAL|Interventional, open label, Safety/Efficacy Study|SEBORRHEAMEDIS Face Cream Interventional 30
62472652|NCT06314022|NO_INTERVENTION|Control group|which receives the standard information given in writing,
62472653|NCT06314022|EXPERIMENTAL|APP group|Group which receives the standard information together with the mobile application individually adapted to the scheduled colonoscopy appointment and the type of laxative.
62675555|NCT05417386|EXPERIMENTAL|FOLFIRINOX + NIS793|"Participants will be randomly assigned to receive:~* FOLFIRINOX FOLFIRINOX + NIS793 on day 1 of each 14 day cycle for cycles 1-8~* Cycles 9+: Chemoradiation (CRT) with NIS793, Surgery, NIS793"
62675556|NCT01691807|EXPERIMENTAL|Arm A|bendamustine and ofatumumab treatment of NHL
62304195|NCT02062086|OTHER|Population 2|"(Hip-fracture patients) will participate in the study for approximately 35 days during their in-hospital period, followed by 30 during their post-discharge period, so for a total period of at least 65 days.~Population 2 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~In the hip fracture population, estimation of muscle mass by the D3 creatine method will be performed on up to 3 separate occasions to assess whether the method is sensitive enough to detect decreases in muscle mass that may occur during the recovery period after hip fracture."
62472654|NCT04298918|EXPERIMENTAL|Dose Escalation Phase|Participants received venetoclax in combination with a fixed dose of trastuzumab emtansine.
62675557|NCT01691807|EXPERIMENTAL|Arm B|ofatumumab only treatment of NHL
61917973|NCT01767831||Group A: CGM monitoring (1) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
62115499|NCT04385355|EXPERIMENTAL|Test Group|Test group will receive an intermediate transmucosal abutment with a TCP design, narrower than the conventional one, of 3mm height, once the implants are placed
62115500|NCT04998903||Stem cell transplant with Graft versus host disease|Patients who following hematopoietic stem cell transplant suffered from graft versus host disease and presented with pulmonary infiltrates.
62115501|NCT06374732|EXPERIMENTAL|High-intensity interval training group|The experimental group, which will perform high-intensity interval training (HIIT), 5 time per week for 12 weeks.
62115502|NCT06374732|ACTIVE_COMPARATOR|Control group|Control group, which will continue their normal physical activity, including their usual physical education classes.
62115503|NCT02015741||Aged patients|EEG monitoring with Bispectral Index and NeuroSENSE
62115504|NCT02511197|EXPERIMENTAL|68Ga-NOTA-PRGD2 injection & PET/CT scan|The patients were intravenously injected with 68Ga-NOTA-PRGD2 in one dose in nearly 111 MBq and then underwent PET/CT scan 0.5 h later.
62472655|NCT04298918|EXPERIMENTAL|Dose Expansion Phase|Participants were to receive venetoclax at the Phase II Recommended Dose (RP2D) in combination with trastuzumab emtansine.
62472656|NCT04298918|EXPERIMENTAL|Randomized Phase II Arm 1|Participants were to receive trastuzumab emtansine + placebo.
62472657|NCT04298918|EXPERIMENTAL|Randomized Phase II Arm 2|Participants were to receive trastuzumab emtansine + venetoclax.
62472658|NCT04094103|EXPERIMENTAL|Active strawberry powder|Participants will consume a 39g freeze-dried active strawberry powder beverage once per day for 4-weeks.
62472659|NCT04094103|PLACEBO_COMPARATOR|Placebo strawberry powder|Participants will consume a 39g freeze-dried strawberry powder placebo beverage once per day for 4-weeks.
62675558|NCT04738162|EXPERIMENTAL|5-Aminolevulinic Acid (5-ALA)|Application of 5-ALA oral solution followed by fluorescence-guided brain tumor resection
62675559|NCT04826614|EXPERIMENTAL|optimized treatment|early adjust dose or change drug
62675560|NCT04826614|ACTIVE_COMPARATOR|routine treatment|slowly adjust dose or change drug
61917974|NCT01767831||Group B: CGM monitoring (2) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
61917975|NCT06305871|EXPERIMENTAL|Ablation group|Patients with hyperthyroidism undergoing ultrasound-guided ablation
61917976|NCT04996472|EXPERIMENTAL|Sensitivity to phonological rules: Adults|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern
61917977|NCT04996472|EXPERIMENTAL|Sensitivity to semantic category cues: Adults|Arm 1. Referential cue during OR learning.
61917978|NCT02478398|EXPERIMENTAL|Short ragweed pollen allergen extract|Participants receive one sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
62472660|NCT04094103|ACTIVE_COMPARATOR|Mixed active/placebo strawberry powder|Participants will consume a 39g mixed active/placebo strawberry powder beverage once per day for 4-weeks.
62472661|NCT02193061|ACTIVE_COMPARATOR|ROTA 1|two doses of monovalent vaccine Rotarix followed by one dose of sterile water
62472662|NCT02193061|ACTIVE_COMPARATOR|ROTA 2|three doses of pentavalent vaccine RotaTeq
62472663|NCT02193061|ACTIVE_COMPARATOR|ROTA 3|one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
62472664|NCT02193061|ACTIVE_COMPARATOR|ROTA 4|one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
62675561|NCT04295265|EXPERIMENTAL|Smartphone|Receive daily whatsapp/ SMS message remind the drug intake.
62115505|NCT01293604|EXPERIMENTAL|Whole Grain Barley Diet|A controlled diet containing at least 4 daily servings of whole grain barley.
62472665|NCT02193061|ACTIVE_COMPARATOR|ROTA 5|two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
62472666|NCT02193061|ACTIVE_COMPARATOR|ROTA 6|one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
62675562|NCT04295265|NO_INTERVENTION|Control|receive instruction to take the medication at recruitment
62675563|NCT05236465|EXPERIMENTAL|A 3-day course|The course consists of teaching in basic psychology, stress physiology and practice of a specific technique with self-instructions and visualization in a group setting by non-health personnel
62115506|NCT01293604|ACTIVE_COMPARATOR|Whole Grain Oats Diet|A diet containing at least 4 servings of whole grain oats.
62115507|NCT01293604|OTHER|Low Whole Grain Diet|A control diet containing 0.7 daily servings of whole grain.
62115508|NCT03391635|EXPERIMENTAL|Electroacupuncture|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand needles (0.30×50mm or 0.30×70mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.After acupuncture，the needle handle will be connected with the electrode in the electroacupuncture instrument.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 0.1mA-1.0mA."
62115509|NCT03391635|ACTIVE_COMPARATOR|TranscutaneousElectricNerveStimulation|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 2mA-5mA."
62472667|NCT02193061|ACTIVE_COMPARATOR|ROTA 7|a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix
62472668|NCT04977739||those with a condition|
62675564|NCT05236465|ACTIVE_COMPARATOR|Waiting list|Treatment as usual (TAU)
62675565|NCT03861507|OTHER|Patient|Patient undergoing standard care prostate high dose rate brachytherapy.
62675566|NCT05509673|EXPERIMENTAL|Intervention group|The intervention group received a fat grafting under the wound bed and into the wound edges.
62304196|NCT01789879|ACTIVE_COMPARATOR|Control group (no current ART)|Levonorgestrel subdermal implant in subjects not yet receiving ART (control group)
62304197|NCT01789879|ACTIVE_COMPARATOR|NVP-based ART group|Levonorgestrel subdermal implant in subjects receiving nevirapine-based ART
61917979|NCT02478398|PLACEBO_COMPARATOR|Placebo|Participants receive one placebo sublingual tablet, QD for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
61917980|NCT03872011|EXPERIMENTAL|Vitamin C,thiamine,hydrocortisone|"The combination of vitamin C, thiamine, hydrocortisone :~Vitamin C 2g every 6 hours x 5-days Thiamine 200mg every 12 hours x 5-days Hydrocortisone 200mg as a continuous infusion x 5-days"
61917981|NCT03872011|PLACEBO_COMPARATOR|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
61917982|NCT06454266|EXPERIMENTAL|ORM regimen(Orelabrutinib, Rituximab and Methotrexate)|The subjects received ORM regimen treatment every 21 days for a total of 6 cycles.
62472669|NCT04977739||those without a condition|
62472670|NCT00668915||A|Primary arthroplasty
62472671|NCT05313217|EXPERIMENTAL|neural tension testing|All participants in this arm will undergo four tests: KEA, SLR, Slump, and Extended Slump
62472672|NCT02252250|ACTIVE_COMPARATOR|conventional laparoscopic|conventional laparoscopic total mesentery excision surgery for rectal cancer.
62675567|NCT05509673|NO_INTERVENTION|Control group|The control group received an injection of saline solution (0.9%) under the wound bed and into the wound edges.
62675568|NCT02306785|EXPERIMENTAL|Formulation D|TP05 Coating D
61917983|NCT01467245|EXPERIMENTAL|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
62304198|NCT01789879|ACTIVE_COMPARATOR|EFV-based ART group|Levonorgestrel subdermal implant in subjects receiving efavirenz-based ART
62304199|NCT03908632||Step 1|Subjects 14 years or older diagnosed with Community Acquired Pneumonia (CAP) and positive serology for primary pulmonary coccidioidomycosis (PPC) will enroll in Step 1 within 14 days of symptom onset, n=750
62304200|NCT03908632||Step 2|Subjects with a diagnosis of primary pulmonary coccidioidomycosis (PPC) confirmed by positive serologic testing during Step 1 will enter Step 2 within 21 days of their test collection date, n=200
62304201|NCT05647213|EXPERIMENTAL|Treated|Subjects in Treated arm will receive one dose of Investigational Product. Within this arm are three dose levels. Dose level selection will be determined by product availability subjects have available product and when they can be treated. Dose levels will escalate in order of treatment date.
62304202|NCT05647213|NO_INTERVENTION|Control|Subjects who enroll but do not receive Investigational Product will be placed in the control arm.
62304203|NCT02417623|EXPERIMENTAL|Smartphone intervention group|The experimental group will receive the standard diet intervention for weight loss plus free Smartphone app plus a wearable device.
62472673|NCT02252250|EXPERIMENTAL|Transanal hybrid-laparoscopic|Transanal hybrid-laparoscopic total mesentery excision surgery for rectal cancer.
62675569|NCT02306785|EXPERIMENTAL|Formulation E|TP05 Coating E
62675570|NCT02306785|EXPERIMENTAL|Formulation H|TP05 Coating H
62675571|NCT01777529|EXPERIMENTAL|Multidose|Multidose from MMR Vaccine produced by Bio-Manguinhos/Fiocruz
62675572|NCT01777529|ACTIVE_COMPARATOR|Singledose|Singledose from MMR (GSK-TV), produced by GlaxoSmithKline
62675573|NCT06471166||Conservative management|
62675574|NCT06471166||Medical treatment|
62675575|NCT06471166||Surgical treatment (Open or laparoscopic salpingectomy)|
62675576|NCT06471166||Surgical treatment after failed medical treatment (Open or laparoscopic salpingectomy)|
62675577|NCT06471166||Conservative surgical treatment (salpingotomy, salpingostomy, tubal milking)|
62675578|NCT06471166||Conservative surgical treatment after failed medical treatment|
62675579|NCT01052428|ACTIVE_COMPARATOR|Toprol XL|beta 1 receptor blockade; generic name metoprolol succinate
62675580|NCT01052428|PLACEBO_COMPARATOR|Placebo|Pill that looks like Toprol XL but does not have the active ingredients
62675581|NCT03854981|PLACEBO_COMPARATOR|Standard Care|If subjects are assigned to this group they will not be provided materials to increase exercise participation. Subjects will however be asked to participate in the standard education sessions that are provided to all bariatric surgery patients. This standard care includes meetings with a nutritionist, psychologist, and bariatric surgeon.
62115510|NCT06676111|EXPERIMENTAL|Probiotic group|Probiotic pectin gummies(500 million CFU)/2 pellets/day BC99; Storage: Store in a cool, dry place without sun exposure.
61917984|NCT01467245|EXPERIMENTAL|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
61917985|NCT01275547|EXPERIMENTAL|S-ketamine & midazolam spray|all 20 minutes as a patient controlled analgesia alternating s-ketamine / midazolam
62304204|NCT02417623|NO_INTERVENTION|Control group|Control group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline
62304205|NCT02615301|EXPERIMENTAL|Salmon (HD+HK)|Tailor-made salmon with high levels of vitamin D3 and K1
62304206|NCT02615301|EXPERIMENTAL|Salmon (LD+HK)|Tailor-made salmon with low levels of vitamin D3 and high K1
62304207|NCT02615301|EXPERIMENTAL|Salmon (HD+LK)|Tailor-made salmon with high levels of vitamin D3 and low K1
62304208|NCT02615301|EXPERIMENTAL|Supplement (vitamin D + Calcium)|Supplement with vitamin D and Calcium
62304209|NCT00564928|EXPERIMENTAL|IPI-504: Group A|No Prior treatment for prostate cancer with cytotoxic chemotherapy (adjuvant or neoadjuvant chemotherapy is acceptable if completed \>2 years prior to study)
62472674|NCT00272597|OTHER|Risperidone LAI|"Subjects treated with any antipsychotic can be switched to Risperidone LAI.~* If the subject is currently treated with an antipsychotic other than risperidone, the dosage will be tapered gradually and discontinued. Simultaneously, oral risperidone will be started at 2 mg/day and increased to no more than 6 mg/day. The subject will be treated with risperidone monotherapy for at least five days prior to entering the stabilization phase of the study.~* On the other hand, if the patient has already been treated for more than 5 days with risperidone monotherapy then he/she may enter the stabilization phase of the study immediately."
62675582|NCT03854981|ACTIVE_COMPARATOR|Exercise + Standard Care|Subjects will be asked to exercise 5 days/week for 30 min/day at an intensity of 65-85% of their measured HRmax. Walking will be the main type of exercise. In addition to this training program, subject's will participate in the standard education sessions that are provided to all bariatric surgery patients.
62675583|NCT03256656|EXPERIMENTAL|Healthy subjects|
62304210|NCT00564928|EXPERIMENTAL|IPI-504: Group B|"* Must have evidence of radiographic metastatic disease~* Must have been treated with a docetaxel-based chemotherapy regimen for HRPC with a minimum of 2 cycles with either PSA or RECIST defined radiographic progression during or witin 60 days of completeing docetaxel based chemotheraph or be intolerant of docetaxel-based chemotherapy~* No more than three prior chemotherapies regimens for HRPC"
62304211|NCT04002687|EXPERIMENTAL|ATV-PG 1000-400 mg + AQ 612 mg|T1 (n=16) - Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.
62304212|NCT04002687|ACTIVE_COMPARATOR|ATV-PG 1000-400 mg + AQ unmatched placebo|T 2 (n=12) - Atovaquone (ATV)-Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) unmatched placebo on days 1,2, 3.
62304213|NCT04002687|ACTIVE_COMPARATOR|ATV-PG unmatched placebo + AQ 612 mg|T 3 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + Amodiaquine (AQ) 612 mg on days 1,2, 3.
62304214|NCT04002687|PLACEBO_COMPARATOR|ATV-PG unmatched placebo + AQ unmatched placebo|T 4 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + AQ unmatched placebo on days 1,2, 3.
62472675|NCT05176015|EXPERIMENTAL|Frenzel Lens with Diagnostic Algorithm|"Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and if present describe its main characteristic.~Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging"
62675584|NCT03256656|ACTIVE_COMPARATOR|Patients with SCI|
62675585|NCT03666793|NO_INTERVENTION|Control|Standard healthcare procedures
61917986|NCT01275547|ACTIVE_COMPARATOR|morphine, patient controlled analgesia|morphine as an active comparator as a patient controlled analgesia system
62115511|NCT06676111|PLACEBO_COMPARATOR|Placebo group|No probiotic pectin gummies/2 pellets/day; Storage: Store in a cool, dry place without sun exposure.
62115512|NCT06070688|EXPERIMENTAL|MeMed BV® biomarker test and standard of care|In addition to the standard of care for acute respiratory infections, the experimental arm shall reveal the results of the 'BV' test to the clinician co-investigators. The BV test reports a clinical score from 1-100 that as an adjunct to usual care, may help the clinician better direct appropriate resources towards the patient.
62304215|NCT06150209|OTHER|Treatment with Vendaje|application of Vendaje
62304216|NCT00824421|EXPERIMENTAL|UK- 453,061 Dose One|UK 453,061 Dose One plus Truvada
62304217|NCT00824421|EXPERIMENTAL|UK-453,061 Dose Two|UK 453,061 Dose Two plus Truvada
62304218|NCT00824421|ACTIVE_COMPARATOR|Efavirenz + Truvada|Efavirenz + Truvada
62304219|NCT02007837|EXPERIMENTAL|Combined aspirin and multinutrient supplement|In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12
62304220|NCT02007837|PLACEBO_COMPARATOR|Placebo|5mg folic acid, cellulose filler
62304221|NCT01217281|NO_INTERVENTION|Control|"Full mouth supra-gingival debridement using hand instruments and ultrasonic scalers, in one session. Patient motivation and oral hygiene instructions Review and prophylaxis at 1 month, 3 months and 6 months after initial treatment session.~Full mouth periodontal therapy provided at the end of the 6month period (supra and sub- gingival full mouth scaling)"
62304222|NCT01217281|ACTIVE_COMPARATOR|Test/ Non-surgical Periodontal Therapy|"Full mouth periodontal therapy (sub and supra- gingival debridement) provided under local anaesthesia in two half-mouth sessions.~Review and prophylaxis 1 month, 3 months and 6 months after the end of the initial therapy."
62304223|NCT03826914|EXPERIMENTAL|Experimental group|Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
62472676|NCT05176015|EXPERIMENTAL|Frenzel Lens without Diagnostic Algorithm|Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and describe its main characteristics. No diagnostic algorithm will be used to interpret nystagmus.
62675586|NCT03666793|EXPERIMENTAL|experimental: Reconciliation group|medical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital
62675587|NCT05990738|EXPERIMENTAL|Part A: BI 764532 low dose + topotecan|
62675588|NCT05990738|EXPERIMENTAL|Part A: BI 764532 medium dose + single agent chemotherapy|
62675589|NCT05990738|EXPERIMENTAL|Part A: BI 764532 high dose + single agent chemotherapy|
62115513|NCT06070688|ACTIVE_COMPARATOR|Usual Care|The co-investigators shall evaluate, diagnose and manage the acute respiratory infection presenting to the ED using the standard practice known in the community. This may include hospital sepsis practice protocols, clinical judgement, and national or local practice standards.
62675590|NCT05990738|EXPERIMENTAL|Part B: BI 764532 + topotecan|
62675591|NCT02636036|EXPERIMENTAL|enadenotucirev and nivolumab|
62115514|NCT02839369||children|post Traumatic Brain Injury With Cerebral Palsy Typically developed
62115515|NCT03946241||Pre-reform study populations|Children from 1st to 9th grade (n \~ 2,600) from four different school-based studies collecting objective physical activity data. The four studies are 1) The European Youth Heart Study (EYHS) conducted in 1997-98, 2003-04 and 2009-10, 2) When Cities Move Children (WCMC) conducted in 2010 and 2012, 3) Childhood Health, Activity, and Motor Performance School Study Denmark (CHAMPS-DK) conducted in 2009, 2010 and 2012, and 4) School site, Play Spot, Active transport, Club fitness and Environment (SPACE) conducted in 2010 and 2012. A total of 44 schools where included in the studies.
62304224|NCT03826914|PLACEBO_COMPARATOR|Control Group|Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.
62304225|NCT03665597|EXPERIMENTAL|Pembrolizumab Sequence 1|Participants receive a single dose of pembrolizumab (pembro) in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A subcutaneously (SC); Cycle 2 Day 1: pembro Dose B intravenously (IV); Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
62675592|NCT04835428|EXPERIMENTAL|Treatment with AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
62675593|NCT04835428|ACTIVE_COMPARATOR|Treatment with PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
62675594|NCT00850187|EXPERIMENTAL|Bone marrow mesenchymal stem cells|
62675595|NCT06069271|NO_INTERVENTION|Rest|Subjects in the control group were instructed to complete the general warm up followed by a 10-minute rest period.
62675596|NCT06069271|EXPERIMENTAL|Exercise|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
62675597|NCT03728231||Fifty patients with RA.|"-CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~* Functional Performance Tests:(12)~* Fatigue severity scale (13).~* Short-Form Health Survey 36 (SF-36) (14).~* the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~* frequency intensity time (FIT) index of kasari (16). :\* Disease activity Score(DAS)(17)"
62675598|NCT03728231||Fifty patients with SLE.|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~* Functional Performance Tests:(12)~* Fatigue severity scale (13).~* Short-Form Health Survey 36 (SF-36) (14).~* the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~* frequency intensity time (FIT) index of kasari (16). :\* SLE Disease activity Index(SLEDAI)(18)"
62675599|NCT03728231||Fifty apparently healthy controls|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~* Functional Performance Tests:(12)~* Fatigue severity scale (13).~* Short-Form Health Survey 36 (SF-36) (14).~* the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~* frequency intensity time (FIT) index of kasari (16)."
62675600|NCT00490412|EXPERIMENTAL|A: tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group A (who are already taking Tenofovir) once every four weeks during study visits.
62675601|NCT00490412|PLACEBO_COMPARATOR|B: tenofovir/placebo|A placebo will be administered orally to subjects in Group B (who are already taking Tenofovir).
62675602|NCT00490412|EXPERIMENTAL|C: no tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group C (who are not taking Tenofovir) once every four weeks during study visits.
62675603|NCT00490412|PLACEBO_COMPARATOR|D: no tenofovir/placebo|A placebo will be administered orally to subjects in Group D (who are not taking Tenofovir).
62675604|NCT01423890|OTHER|Early Stage Breast Cancer|Women and men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
62675605|NCT04169659|EXPERIMENTAL|Kyphoplasty with Titanium spheres|Patients treated with kyphoplasty with baloons and insertion of titanium microspheres inside the body vertebra.
62675606|NCT04169659|ACTIVE_COMPARATOR|Kyphoplasty with Polymethylmethacrilate|Patients treated with Kyphoplasty with baloons and insertion of Polymethylmetacrylate inside the body vertebra.
62675607|NCT00983957|EXPERIMENTAL|BMS-790052 plus Ortho Tri-Cyclen®|
62304226|NCT03665597|EXPERIMENTAL|Pembrolizumab Sequence 2|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A SC; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
62304227|NCT03665597|EXPERIMENTAL|Pembrolizumab Sequence 3|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
62675608|NCT05023889|OTHER|open label|single open arm label
62304228|NCT03665597|EXPERIMENTAL|Pembrolizumab Sequence 4|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose B IV; Cycle 3 Day 1: pembro Dose A SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
62472677|NCT05176015|EXPERIMENTAL|No Frenzel Lens with Diagnostic Algorithm|"Nystagmus assessment in different manoeuvres is performed without the use of Frenzel lens.~Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging"
62472678|NCT05176015|NO_INTERVENTION|No Frenzel Lens and No Diagnostic Algorithm|The emergency physician is performing the assessment of nystagmus and its interpretation as usual. The Frenzel lens and the diagnostic algorithm are not used.
62472679|NCT04550013|ACTIVE_COMPARATOR|Heavy-Slow Resistance training|Heavy-Slow Resistance training. Three times weekly for 12 weeks.
62675609|NCT03313765|EXPERIMENTAL|Intervention|
62675610|NCT03313765|ACTIVE_COMPARATOR|Standard-of-care|
62472680|NCT04550013|EXPERIMENTAL|Low-Load Blood Flow Restriction training|Low-Load Blood Flow Restriction training. Three times weekly for 12 weeks
62472681|NCT05166148|EXPERIMENTAL|eccentric cycling compared to concentric cycling|Every participant will perform the same protocol and will participated to the 3 experimental sessions (a, b and c) of the assigned intervention.
62472682|NCT00058955|EXPERIMENTAL|1|Sodium oxybate
62115516|NCT03946241||Post-reform study population|Children from 1st to 9th grade in 2017-18 from the same schools as included in the pre-reform research studies (n \~ 2,600). Two of the pre-reform research studies (CHAMPS-DK and SPACE) introduced PA promoting initiatives as part of the study. To minimize any influence from participation in these interventions we chose only to include and recruit participants from control schools from these studies. A total of 36 schools where invited and 31 subsequently accepted to participate. Parents and teachers of the children were included as well.
62115517|NCT00981630|EXPERIMENTAL|ChimeriVax™-JE Dose Level 1|Participants received ChimeriVax™-JE (Japanese Encephalitis) a dose of 3.0 log10 Plaque-forming units (PFU) on Day 0.
62472683|NCT00058955|ACTIVE_COMPARATOR|2|triazolam
62115518|NCT00981630|EXPERIMENTAL|ChimeriVax™-JE Dose Level 2|Participants received ChimeriVax™-JE a dose of 4.0 log10 PFU on Day 0.
62115519|NCT00981630|EXPERIMENTAL|ChimeriVax™-JE Dose Level 3|Participants received ChimeriVax™-JE a dose of 5.0 log10 PFU on Day 0.
62115520|NCT00981630|PLACEBO_COMPARATOR|Placebo|Participants received ChimeriVax diluent, 0.5 mL on Day 0.
62115521|NCT02035735|EXPERIMENTAL|Videoendoscopy with WL and NBI|The day before the laryngoscopy under general anesthesia (LGA), two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light (WL) and the second one with NBI (NBI).
62115522|NCT02723929|EXPERIMENTAL|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
62115523|NCT02723929|SHAM_COMPARATOR|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
62115524|NCT03945942|OTHER|Pediatric liver transplant patients|Using somatic and cerebral Near infrared spectroscopy devices
62472684|NCT00058955|ACTIVE_COMPARATOR|3|pentobarbital
62472685|NCT00058955|PLACEBO_COMPARATOR|4|Placebo
62472686|NCT01346735||ICU infections|Infections acquired during the ICU stay
62472687|NCT04457674|OTHER|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.
62304229|NCT03665597|EXPERIMENTAL|Pembrolizumab Sequence 5|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose A SC: Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
62304230|NCT03665597|EXPERIMENTAL|Pembrolizumab Sequence 6|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
62304231|NCT03665597|EXPERIMENTAL|Pembrolizumab Dose D|Participants receive a single dose of pembro Dose D IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).
62304232|NCT03560076||Group 1|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 1 implementation
62304233|NCT03560076||Group 2|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 2 (delayed) implementation
62304234|NCT03792958|EXPERIMENTAL|CM082|CM082 tablet
62304235|NCT05631028|EXPERIMENTAL|Group A|Dexmedetomidine pretreatment dose was 0. The effective dose of remimazolam tosilate inhibiting cardiovascular response during double-lumen tracheal intubation in elderly patients (age \> 65 years) and young patients (18 \< age \<65 years) was explored respectively, without the use of dexmedetomidine. The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.25 mg / kg, and the adjusted unit dose was 0.01mg.
62304236|NCT05631028|EXPERIMENTAL|Group B|Dexmedetomidine hydrochloride injection (200ug per bottle, HengRui medicine, China) was diluted to 50ml and the pretreatment dose was 0.5μg/kg at first 10 mins.The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.15 mg / kg, and the adjusted unit dose was 0.01mg.
61917987|NCT02195687|EXPERIMENTAL|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
61917988|NCT02195687|PLACEBO_COMPARATOR|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
61917989|NCT00590837|EXPERIMENTAL|1|Patients will be treated by adding lomustine to chemotherapy
62304237|NCT05631028|EXPERIMENTAL|Group C|Dexmedetomidine hydrochloride injection (200ug per bottle, HengRui medicine, China) was diluted to 50ml and the pretreatment dose was 1μg/kg at first 10 mins.The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.1 mg / kg, and the adjusted unit dose was 0.01mg.
62304238|NCT03671044|EXPERIMENTAL|Nanosomal Docetaxel Lipid Suspension - 75 mg/m2|Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
62304239|NCT03671044|EXPERIMENTAL|T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
62304240|NCT03671044|ACTIVE_COMPARATOR|R, Taxotere® (100 mg/m2)|Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
62304241|NCT06076044|EXPERIMENTAL|healthy subjects|healthy male subjects aged 20-30 years
62304242|NCT04151602||PWUD with active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with active TB disease
62304243|NCT04151602||PWUD with no active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with no active TB disease
62304244|NCT04151602||non-PWUD with active TB|People who do not use meth/mandrax who have active TB disease
62472688|NCT04457674|OTHER|Sleep Hygiene Education (SHE)|SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.
62472689|NCT05642286|EXPERIMENTAL|Robot assisted surgery group|robotic-assisted PCI
62472690|NCT04396015|PLACEBO_COMPARATOR|medium chain triglyceride (MCT) vs placebo|MCT or placebo (olive oil) for 4 months. Crossover at 4 months
61917990|NCT00590837|NO_INTERVENTION|2|Patients will be treated without adding lomustine to chemotherapy
61917991|NCT04319822|EXPERIMENTAL|blood samples, muscular biopsy, and quality of life|quality of life, blood samples, quadriceps biopsy in intensive care unit (before and after the ICU hospitalization and one at M6
61917992|NCT01967368|EXPERIMENTAL|Intanza|intradermal injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Intanza, single dose injection
61917993|NCT01967368|ACTIVE_COMPARATOR|Vaxigrip|intramuscular injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Vaxigrip, single dose injection
61917994|NCT00184873|ACTIVE_COMPARATOR|Lifestyle counseling|Patients receiving lifestyle counseling
61917995|NCT00184873|NO_INTERVENTION|Regular care|Patients receiving regular care
61917996|NCT02121132||No treatment|
61917997|NCT00531687|OTHER|GCT|cisplatin Paclitaxel gemcitabine
61917998|NCT05820737|PLACEBO_COMPARATOR|Placebo|1 capsule to be consumed once a day
61917999|NCT05820737|ACTIVE_COMPARATOR|EF2001|1 capsule to be consumed once a day
61918000|NCT05820737|ACTIVE_COMPARATOR|beLP1|1 capsule to be consumed once a day
61918001|NCT04173793|EXPERIMENTAL|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
61918002|NCT04173793|EXPERIMENTAL|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
62115525|NCT05590650|EXPERIMENTAL|SZKJT group|Patients who meet the inclusion criteria and agree to receive concomitant treatment with SZKJT.
62304245|NCT04562363||Low risk of herniation.|Use of any method of suturing, including modified.
62304246|NCT04562363||The average risk of hernia formation|The application of modified methods of closure of laparotomy wound.
62675611|NCT06663293|PLACEBO_COMPARATOR|Conventional Nasal Cannula Oxygen group|Participants received low flow oxygen therapy through a conventional nasal cannula. The initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min.
62675612|NCT06663293|ACTIVE_COMPARATOR|High-flow Nasal Cannula Oxygen Group|Participants received nasal high flow therapy delivered by AIRVO™ 2 (Fisher and Paykel Healthcare Systems, New Zealand) along with single-use nasal oxygen cannulas.
62675613|NCT02321150|ACTIVE_COMPARATOR|Sutures|After pterygium removal the conjunctival graft to cover bare sclera will be secured with interrupted 8.0 polyglactin sutures.
61918003|NCT04173793|EXPERIMENTAL|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
62115526|NCT04036630|EXPERIMENTAL|2kHz tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62675614|NCT02321150|EXPERIMENTAL|Cautery|After pterygium removal the conjunctival graft to cover bare sclera will be secured with bipolar electrocautery, power set at 25 until whitening of tissue observed.
62675615|NCT05371223|EXPERIMENTAL|Interventional|"Eligible patients affected by pancreatic cancer PM will be enrolled according to in-/exclusion criteria.~Each patient will be scheduled for three treatment combined courses for a total of six cycles of endovenous Nabpaclitaxel-Gemcitabine chemotherapy and three of Nabpaclitaxel-PIPAC."
62115527|NCT04036630|SHAM_COMPARATOR|sham tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62115528|NCT04036630|EXPERIMENTAL|2kHz tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62115529|NCT04036630|SHAM_COMPARATOR|sham tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62115530|NCT04036630|EXPERIMENTAL|2kHz tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62304247|NCT04562363||high risk of herniation|The use of alloplastic methods of closure of laparotomy wound.
61918004|NCT04173793|PLACEBO_COMPARATOR|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
62304248|NCT04562363||The presence of eventrations|The use of alloplastic methods of suturing a laparotomic wound in the absence of suppuration.
62304249|NCT02573116|EXPERIMENTAL|Obstructive sleep apnea with chronic parodontis|patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment
61918005|NCT04173793|PLACEBO_COMPARATOR|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
61918006|NCT00721903|ACTIVE_COMPARATOR|Healthy Subjects|Ultrasound scan
61918007|NCT00721903|ACTIVE_COMPARATOR|Cancer|120 women diagnosed by biopsy to have breast cancer will have an ultrasound scan
61918008|NCT01095094|EXPERIMENTAL|Arm I|Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.
61918009|NCT04260243|SHAM_COMPARATOR|Sham Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + sham Myofascial Release
62472691|NCT04396015|OTHER|open label extension|6 months of MCT oil.
62472692|NCT04915495|EXPERIMENTAL|Singe-arm Study|Experimental device being evaluated for sensitivity and specificity.
61918010|NCT04260243|EXPERIMENTAL|Experimental-Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + Myofascial Release
61918011|NCT03444077|ACTIVE_COMPARATOR|Control group|The patients allocated in the control group will be managed as recommended in the local guidelines and protocols. As the trial involves participating centers with different prehospital and hospital realities and local practices, the control group will reflect a wide panel of levels of care and will not be limited to a unique approach.
61918012|NCT03444077|EXPERIMENTAL|Intervention group|"Patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS \< 10 will be classified as not in need for DCR.~TICCS \< 10 This subgroup will be considered without a need for DCR and without coagulopathy. There will not be any activation of the DCR components (no phone contact to the blood bank, to the surgical team, no prehospital transfusion). There will be any prehospital treatment/prevention of the hyperfibrinolysis using Tranexamic acid (TXA). Crystalloids infusion will be allowed.~TICCS ≥ 10 This subgroup will be considered with a need for DCR and with coagulopathy. They will be treated using the STTTOPPP the bleeding protocol."
62304250|NCT02573116|NO_INTERVENTION|Obstructive sleep apnea without chronic parodontis|patients with severe OSA treated by CPAP
62472693|NCT02071108|EXPERIMENTAL|Lithoplasty Treatment|Shockwave Lithoplasty System
62472694|NCT04138745||Control|Historical control patients that are matched to the surgery type
62472695|NCT04138745||Experimental|After the practice change of TTP was initiated, the future pediatric patients were put into a database.
61918013|NCT04322201|EXPERIMENTAL|Intervention group - Continuous passive paracentesis|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care.
62304251|NCT04146558|EXPERIMENTAL|Internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
62675616|NCT01720602|EXPERIMENTAL|Treatment (vorinostat, AI therapy)|Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
62675617|NCT03951415|EXPERIMENTAL|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
62675618|NCT01167712|EXPERIMENTAL|Arm I (adjuvant chemotherapy suboptimally debulked)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
62115531|NCT04036630|SHAM_COMPARATOR|sham tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62115532|NCT04036630|EXPERIMENTAL|env tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
61918014|NCT04322201|ACTIVE_COMPARATOR|Control group - Large volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter performed and repeated during ICU stay according to standard-of-care clinical practice.
61918015|NCT00800462|ACTIVE_COMPARATOR|Oxybutynin Cl|
61918016|NCT00800462|ACTIVE_COMPARATOR|Trospium Cl|
61918017|NCT00800462|ACTIVE_COMPARATOR|Darifenacin Hydrogren Bromide (HBr)|
61918018|NCT05729802|EXPERIMENTAL|Group A: HoloSIM (intervention)|Training by Mixed Reality Simulation
62115533|NCT04036630|ACTIVE_COMPARATOR|time-reversed env-tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62115534|NCT04036630|SHAM_COMPARATOR|sham tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
62115535|NCT04566042|EXPERIMENTAL|ACT video game|
62304252|NCT04146558|ACTIVE_COMPARATOR|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
62115536|NCT03110458|EXPERIMENTAL|SENS-111 100mg|SENS-111 100mg: 2 Oral Dispersible Tablets (1 SENS-111 100 mg and 1 placebo)
62304253|NCT01104831|PLACEBO_COMPARATOR|21 degree Cooling|Room temperature water circulated through cryotherapy sleeve.
62304254|NCT01104831|ACTIVE_COMPARATOR|10 degree cooling|Cooled water circulated through a cryotherapy sleeve.
62304255|NCT04615871|EXPERIMENTAL|semaglutide|Eligible subjects randomized to this arm will receive semaglutide 0.25 mg s.c. after randomization (Day 0), then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21 in addition to standard of care.
62472696|NCT03323008|EXPERIMENTAL|Training Prototype|Testing of 3 modules
62675619|NCT01167712|EXPERIMENTAL|Arm II (neoadjuvant chemotherapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
62675620|NCT02763748|EXPERIMENTAL|Laparoscopic surgery|Laparoscopic endoscopy combined surgery. This is a kind of traditional surgical method.
62675621|NCT02763748|EXPERIMENTAL|laparoscopic and endoscopic|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
62675622|NCT02763748|EXPERIMENTAL|Single-arch laparoscopic and endoscopic|Single-arch LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
62675623|NCT05409612|ACTIVE_COMPARATOR|Supemtek® arm|"Patients recieving a quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
62675624|NCT05409612|ACTIVE_COMPARATOR|Vaxigriptetra® arm|Patients receiving a quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
61918019|NCT05729802|ACTIVE_COMPARATOR|Group B: Mannequin (control)|Training by Mannequin Based Simulation
62675625|NCT06139796|EXPERIMENTAL|Cohort A Twice daily|DRV/r twice daily (BID): 30 children with 1 or 2 DRV RAM\* weighing 10 to \<25 kg (10 per weight band: 10-13.9kg, 14-19.9kg, 20-24.9kg)
61918020|NCT02550769|EXPERIMENTAL|TRANSANAL TOTAL MESORECTAL EXCISION|Transanal approach of total mesorectal excision.
61918021|NCT02550769|ACTIVE_COMPARATOR|Laparoscopic-LAR|Type of surgical intervention as control group: Laparoscopic low anterior resection with total mesorectal excision for rectal cancer
62115537|NCT03110458|EXPERIMENTAL|SENS-111 200mg|SENS-111 200mg: 2 Oral Dispersible Tablets (SENS-111 100 mg)
62115538|NCT03110458|PLACEBO_COMPARATOR|Placebo|Placebo: 2 placebo Oral Dispersible Tablets
62675626|NCT06139796|EXPERIMENTAL|Cohort B Once daily|"DRV/r once daily (OD): 20 children with no DRV RAM\* weighing 10 to \<20 kg (10 per weight band: 10-13.9kg, 14-19.9kg)~\*DRV RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V"
62675627|NCT02256878|EXPERIMENTAL|BIRT 2584 XX + Amitriptyline|"BIRT 2584 XX:~Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)~Amitriptyline:~Single dose on day -8, day 1, and day 15"
62675628|NCT04662632|EXPERIMENTAL|Experimental|Local antibiotic irrigation via the VT-X7 (Vancomycin and Tobramycin Exchanged over 7 Days) Treatment System adjuvant to two-stage exchange arthroplasty per standard of care.
62675629|NCT04662632|ACTIVE_COMPARATOR|Control|Standard of care for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer.
62675630|NCT04213339|EXPERIMENTAL|Kegal Exercises|
62675631|NCT04213339|NO_INTERVENTION|Control|
62675632|NCT04530695|EXPERIMENTAL|Arm A: Deep Cleaning|participants with periodontitis will undergo treatment by scaling and root planing (SRP)
62675633|NCT04530695|NO_INTERVENTION|Arm B: No cleaning|participants with periodontitis will undergo no periodontal treatment
62675634|NCT02282033|EXPERIMENTAL|Treatment|"This is an unblinded, treatment only study in which each patient serves as his or her own control.~All patients who meet entry criteria will undergo implantation of the Moderato System. During the first month the pacemaker Performance will be evaluated and an additional 3 month period of treatment for studying the Moderato-HTN therapy effect."
62675635|NCT02816970|EXPERIMENTAL|A Test|Test drug (Gliptus) 1 tablet contains 50 mg vildagliptin
62675636|NCT02816970|ACTIVE_COMPARATOR|B Reference|Reference drug (Galvus) 1 tablet contains 50 mg vildagliptin
62675637|NCT05343507|EXPERIMENTAL|Ketalar arm|Patients will receive ketamine (sold in the form of Ketalar) intravenously, up to 0.75 µg/ml concentration, for a maximum of 90' minutes. Ketalar concentration will be increased slowly in a step-wise manner unless new signs of consciousness are evident.
62675638|NCT05343507|PLACEBO_COMPARATOR|Placebo arm|Patients will receive placebo (saline solution)
62115539|NCT02497092|ACTIVE_COMPARATOR|Slow angled injection|Slow and angled insertion of the needle through the sclera
62115540|NCT02497092|ACTIVE_COMPARATOR|Slow straight injection|Slow and straight insertion of the needle through the sclera
62675639|NCT04918628|EXPERIMENTAL|Arm A|Neoadjuvant Chemotherapy Combined With CCRT Followed by Adjuvant Chemotherapy and Anti-PD-1 Antibody(Sintilimab 200mg intravenous drip every three weeks until PD or 2 years).
62675640|NCT03686111||infertile patientes with medical assistance to procreation|
62675641|NCT03686111||Infertile patientes with induction of ovulation to give their|
62675642|NCT06493071|EXPERIMENTAL|Active taVNS|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany).
62115541|NCT02497092|ACTIVE_COMPARATOR|Fast angled injection|fast and angled insertion of the needle through the sclera
62115542|NCT02497092|ACTIVE_COMPARATOR|Fast straight injection|fast and straight insertion of the needle through the sclera
62304256|NCT04615871|NO_INTERVENTION|control|Eligible subjects randomized to the control arm will receive no active treatment, only standard of care.
62304257|NCT01106261|EXPERIMENTAL|Pulmonary metastasectomy|Pulmonary metastasectomy
62304258|NCT01106261|ACTIVE_COMPARATOR|Active monitoring|Active monitoring
62304259|NCT02215629|EXPERIMENTAL|Experimental VS4718|Oral VS-4718 administered BID during a 28 day cycle.
62675643|NCT06493071|SHAM_COMPARATOR|Sham taVNS|Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
62675644|NCT04583826|EXPERIMENTAL|CAVA|20 participants will wear the CAVA device, and a consumer-grade sleep monitoring device, and undergo polysomnography, for one night. 40 participants will wear the CAVA device and undergo polysomnography for two nights
62675645|NCT00106535|EXPERIMENTAL|Tocilizumab 4 mg/kg + Methotrexate|Tocilizumab 4 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with \< 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a \>70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
62472697|NCT00743964|EXPERIMENTAL|ECX|Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
62472698|NCT00743964|ACTIVE_COMPARATOR|CX|Cisplatin and capecitabine combination chemotherapy will be administered.
62472699|NCT05081960||Stone Formers|Individuals who have experienced at least one incidence of calcium-based kidney stones in the last 12 months
62472700|NCT05081960||Controls|Individuals who have never had a kidney stone in their lifetime.
62472701|NCT05548647|ACTIVE_COMPARATOR|Behavioral Treatment + Placebo|Behavioral treatment (lifestyle modification counseling for weight loss) plus placebo
62472702|NCT05548647|ACTIVE_COMPARATOR|Behavioral Treatment + Medication|Behavioral treatment (lifestyle modification counseling for weight loss) plus semaglutide
62472703|NCT01958450|EXPERIMENTAL|Er:YAG laser|acne scar treatment using Er:YAG laser
62472704|NCT01958450|ACTIVE_COMPARATOR|Bipolar radiofrequency with diode laser|Bipolar radiofrequency with diode laser
62472705|NCT04374487|EXPERIMENTAL|Test Arm|50 subjects will be randomized in this arm. Patients in the test group will receive convalescent plasma.
62472706|NCT04374487|OTHER|Control Arm|50 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health and Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity. For the management of ARDS or sepsis, the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented.
62472707|NCT04318821|EXPERIMENTAL|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), PC6 (Neiguan, B3), ST25 (Tianshu, B3), ST36 (Zusanli, B2), CV4 (Guanyuan), CV12 (Zhongwan, B3).
62472708|NCT04318821|SHAM_COMPARATOR|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
62115543|NCT04340362|EXPERIMENTAL|VX-147|All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks. Part A was enrolled in 2 cohorts: Cohort 1 and Cohort 2. Cohort 1 included participants with urine protein to creatinine ratio (UPCR) approximately greater than or equal to (≥) 3 g/g (± 10%) and less than (\<) 10 g/g and estimated glomerular filtration rate (eGFR) approximately ≥30 mL/min/1.73 m2 (± 10%). Cohort 2 included participants with UPCR approximately ≥0.8 g/g (± 10%) and \<2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.
62115544|NCT01219699|EXPERIMENTAL|BYL719|In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
62472709|NCT04131621|EXPERIMENTAL|Nivolumab/Ipilimumab|
62472710|NCT05271786||Tracheostomized patients|Patients who underwent percutaneous tracheostomy performed for any reason
62304260|NCT00189826|ACTIVE_COMPARATOR|1|
62304261|NCT00189826|EXPERIMENTAL|2|
62472711|NCT01802320|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62472712|NCT02503293|OTHER|Chrono Super PID then Generic Syringe - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Chrono Super PID then Generic Syringe-Gammanorm"
62472713|NCT02503293|OTHER|Generic Syringe then Chrono Super PID - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Generic Syringe then Chrono Super PID-Gammanorm"
62472714|NCT03982030|EXPERIMENTAL|Dalbavancin|Participants with susceptible gram-positive infections requiring prolonged parenteral antibiotic therapy will be treated with dalbavancin.
62472715|NCT03094598|NO_INTERVENTION|Control|No intervention
62472716|NCT03094598|EXPERIMENTAL|Leaflet|The leaflet is based on information and journalism theories, paying attention primarily to reader appeal and readability.
62472717|NCT03094598|EXPERIMENTAL|Brochure|The brochure is based on practical communication experience, focusing primarily on logical composition and presentation of condensed information.
62472718|NCT03094598|EXPERIMENTAL|Booklet|The booklet is also based on practical communication experience, but give more elaborate explanations.
62472719|NCT03726892|ACTIVE_COMPARATOR|The SYNERGY stent|
62472720|NCT03726892|ACTIVE_COMPARATOR|Xience|
62472721|NCT00056667|EXPERIMENTAL|CBT plus relaxation response|Participants will receive cognitive behavioral therapy plus relaxation response training
62304262|NCT06604325|ACTIVE_COMPARATOR|Group A|All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
62115545|NCT01219699|EXPERIMENTAL|BYL719 + fulvestrant|In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
62115546|NCT01987154|ACTIVE_COMPARATOR|Marketed cow milk-based premature infant formula|
62115547|NCT01987154|EXPERIMENTAL|Marketed extensively hydrolyzed casein infant formula|
62115548|NCT02516644|EXPERIMENTAL|Virtual reality|Xbox Kinect + treadmill training
62115549|NCT02516644|ACTIVE_COMPARATOR|Conventional Therapy|Specific conventional training for Parkinson's Disease
62115550|NCT04483063|EXPERIMENTAL|Extended shoulder group|2% chlorhexidine gluconate skin cleanser over the not only the operative shoulder and axilla but also the chest, back, neck, and face
62115551|NCT04483063|EXPERIMENTAL|Shoulder group|2% chlorhexidine gluconate skin cleanser over the operative shoulder and axilla
62115552|NCT04483063|NO_INTERVENTION|Control group|Skin prepare with soap as usual
62115553|NCT05948358||Females|18 Years to 45 Years (Adult )
62115554|NCT01693419|EXPERIMENTAL|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14"
62115555|NCT05455424|EXPERIMENTAL|Niraparib + ASC|"Patients will receive 200/300 mg of niraparib daily for study period of up to 24 weeks. Patients will be treated until disease progression, withdrawal, death or development of significant treatment limiting toxicity. Niraparib will be supplied in oral formulation as 100 mg capsules. The starting dose of Niraparib will be based upon the patient's baseline body weight and/or platelet count:~Participants with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 109/L will be administered niraparib 300 mg daily.~Participants with a baseline body weight \<77 kg or baseline platelet count \<150 x 109/L will be administered niraparib 200 mg daily.~The dose of Niraparib can be reduced in 100 mg increments, to a minimum of 100 mg, per protocol. Dose escalations are not permitted."
62115556|NCT05455424|ACTIVE_COMPARATOR|Active Symptom Control|Patients in this arm will be managed symptomatically and will be treated as per the standard of care at each participating site. ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
62115557|NCT06167265|OTHER|Treatment RTRT (R: Cilostazol, T: PMR)|"Treatment R: One Cilostazol Tablet 100 mg in the morning and another at an interval of 12 hours of the morning dose~Treatment T: Two PMR Tablet 145 mg in the morning~Four-period dosing following the sequence of Treatment RTRT"
62304263|NCT06604325|PLACEBO_COMPARATOR|Group B|All women recruited to Group A will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision, as placebo.
62304264|NCT04691661|PLACEBO_COMPARATOR|Placebo: Dose escalation|Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
62304265|NCT04691661|EXPERIMENTAL|Radotinib HCl: Dose escalation|"Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.~The inclusion of subjects in the next dose level will be decided by the sponsor in consultation with a Data Monitoring Committee (DMC)."
62115558|NCT06167265|OTHER|Treatment TRTR (T: PMR, R: Cilostazol)|"Treatment R: One Cilostazol Tablet 100 mg in the morning and another at an interval of 12 hours of the morning dose~Treatment T: Two PMR Tablet 145 mg in the morning~Four-period dosing following the sequence of Treatment TRTR"
62115559|NCT04155151|EXPERIMENTAL|Single Arm|6 Minute Walking Test
62115560|NCT01771666|EXPERIMENTAL|ISB and ICG|"The dose of Isosulfan blue (ISB) dye and Indocyanine green (ICG) solution will be started.~(IC-GREEN) SPY Elite Imaging willbe used to capture the images of axillary cavity."
62115561|NCT06400446|OTHER|Control group (standard care)|The babies in this group will receive the standard care of the unit.
62115562|NCT06400446|EXPERIMENTAL|Experimental group (Kangaroo care)|Kangaroo care will be applied to the experimental group for seven days.
62304266|NCT03788473||Control.|Healthy Pregnant
62115563|NCT05620303|EXPERIMENTAL|Exercise group|
62115564|NCT05620303|NO_INTERVENTION|Control group|
62115565|NCT04323358|ACTIVE_COMPARATOR|IOL Master® 700|Biometry will be performed three times consecutively.
62115566|NCT04323358|ACTIVE_COMPARATOR|Pentacam®|Keratometry will be performed three times consecutively.
62115567|NCT04323358|ACTIVE_COMPARATOR|Casia II®|Keratometry will be performed three times consecutively.
62304267|NCT03788473||Case.|Pregnant with Periodontal Disease
62472722|NCT00056667|ACTIVE_COMPARATOR|Relaxation Response|Participants will receive relaxation response training
62472723|NCT00056667|PLACEBO_COMPARATOR|Education|Participants will receive rheumatoid arthritis education
62472724|NCT04043377|EXPERIMENTAL|All patients|
62472725|NCT02335658|EXPERIMENTAL|DSP-5423P|Percutaneous
62304268|NCT02998502|EXPERIMENTAL|Device Group|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with PD. FBS has now received FDA clearance for the treatment of PD adults and is currently commercially available and more than 150 therapist have provided the service nationally. However, FBS has not yet been tested for efficacy in a pediatric populations. Due to its portability, FBS may pose an advantage for use in younger age groups, compared to multiple therapy sessions required for CBT or lower acceptability for long-term medication use for adolescent PD. In this pilot intervention study, the efficacy of the FBS system in youth will be tested.
62675646|NCT00106535|EXPERIMENTAL|Tocilizumab 8 mg/kg + Methotrexate|Tocilizumab 8 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with \< 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a \>70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
62675647|NCT00106535|PLACEBO_COMPARATOR|Placebo + Methotrexate|Placebo intravenously (IV) every 4 weeks plus methotrexate (MTX) 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with \< 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a \>70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
62115568|NCT04323358|ACTIVE_COMPARATOR|Spectralis Anterion®|Biometry will be performed three times consecutively.
62115569|NCT04347954|EXPERIMENTAL|Povidone-Iodine 2%|"Participants will administer PVP-I 2% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
62115570|NCT04347954|EXPERIMENTAL|Povidone-Iodine 0.5%|"Participants will administer PVP-I 0.5% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5"
62115571|NCT04347954|PLACEBO_COMPARATOR|Isotonic saline 0.9%|"Participants will administer two sprays of isotonic saline nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
62115572|NCT01696578|EXPERIMENTAL|BF-CBT and group physiotherapy|Multivitamin+10 sessions of biofeedback supported cognitive behavioral therapy (BF-CBT) and 10 sessions of group physiotherapy
62115573|NCT01696578|ACTIVE_COMPARATOR|Waiting list|The waiting list group receives only multivitamin pills while being waiting and will receive the same intervention 3 months later
62115574|NCT03514251|NO_INTERVENTION|Control group|Routine thyroidectomy and central lymph node dissection
62115575|NCT03514251|EXPERIMENTAL|Parathyroid marker group|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker.
62472726|NCT05388123|EXPERIMENTAL|Low dose Vemurafenib and Rituximab|Eligible patients will receive vemurafenib at a dose of 240 mg orally twice daily (b.i.d.) continuously for 8 weeks. Rituximab 375 mg/m2 will be administered every 2 weeks for a total of 16 weeks. The entire duration of treatment will be 16 weeks.
62472727|NCT01636661|EXPERIMENTAL|Transcranial Direct Current Stimulation|Receiving active tDCS
62675648|NCT00610038|EXPERIMENTAL|1|Glibenclamide
62115576|NCT00130819|EXPERIMENTAL|1|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
62115577|NCT00130819|ACTIVE_COMPARATOR|2|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
62115578|NCT01126307|ACTIVE_COMPARATOR|verapamil|verapamil 80mg tid
62115579|NCT01126307|PLACEBO_COMPARATOR|placebo sugar pill|placebo tid
62115580|NCT00338858|ACTIVE_COMPARATOR|1|TD
62115581|NCT00338858|EXPERIMENTAL|2|TBI
62304269|NCT02998502|NO_INTERVENTION|Control Group|The device will be given to those in the control group after 8-week baseline period.
62472728|NCT01636661|SHAM_COMPARATOR|Sham tDCS|tDCS equipment set to placebo setting.
62472729|NCT02737046|EXPERIMENTAL|Belinostat + Zidovudine|Belinostat + Zidovudine (AZT) in combination as consolidation therapy, followed by standard zidovudine (AZT)-based maintenance therapy with optional Interferon-Alfa-2b (IFNalfa-2b) or Pegylated Interferon-Alfa-2b (PEG-IFN-alfa-2b)
62675649|NCT01401205||shoulder arthroscopic surgery group|the patients who undergo the elective shoulder arthroscopic surgery of rotator cuff repair
62115582|NCT00338858|EXPERIMENTAL|a|Cerebral palsy
62472730|NCT00613522||case|Fist ischaemic hemispheric stroke or TIA
62472731|NCT00613522||control|No ischaemic hemispheric stroke or TIA
62472732|NCT02608177|EXPERIMENTAL|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
62115583|NCT00873899||Remote Arm|The patients in Remote arm will receive a Medtronic CareLink Monitor to perform remote interrogation and transmission of ICD data. The remote arm ICD will be programmed to transmit over the CareLink Network.
62115584|NCT00873899||Implantable defibrillator patients|Heart failure patients implanted with a wireless-transmission-enabled ICD.
62115585|NCT01034943|ACTIVE_COMPARATOR|External fixation|Operation with external fixation and optional addition of k-wire
62115586|NCT01034943|ACTIVE_COMPARATOR|Volar plate|Operation with Synthes volar two column plate (TCP)
62472733|NCT02608177|EXPERIMENTAL|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
62115587|NCT04608955|EXPERIMENTAL|Arm A: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.
62115588|NCT04608955|EXPERIMENTAL|Arm B: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.
62472734|NCT03360305|NO_INTERVENTION|Usual care|The ED clinician will perform a standard medical evaluation. This evaluation includes a focused history and exam to identify injuries. Laboratory tests and radiologic imaging may be ordered. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics). The research assistant (RA) will read the CDC STEADI brochure to the patient and provide them with a printed copy at the conclusion of their visit. The RA will solicit feedback from the clinician and the patient at the conclusion of the visit using the post-visit survey.
62675650|NCT03080714||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
62675651|NCT03080714||Subjects presenting with Retinal Disease|Subjects with Retinal diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
62675652|NCT03080714||Subjects presenting with Glaucoma|Subjects with Glaucoma will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
62675653|NCT01466231|EXPERIMENTAL|everolimus 10 mg po daily|everolimus 10 mg po daily
62115589|NCT04608955|EXPERIMENTAL|Arm C: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.
62675654|NCT05265637||Implantation of the Visian ICL|Visian implantable collamer lens (ICL)
62675655|NCT02102386||CerOx|Patients will be monitored using the CerOx monitor. Probes will be attached bi-laterally in the OR to the forehead.
62675656|NCT02884960|EXPERIMENTAL|Embozene Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
62675657|NCT02884960|ACTIVE_COMPARATOR|Embosphere Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
62675658|NCT03765021|EXPERIMENTAL|Tranexamic acid injection (Kapron)|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
62675659|NCT03765021|ACTIVE_COMPARATOR|Fractional CO2 laser resurfacing|The other side of the face will be randomly assigned to do low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
62675660|NCT06108336|EXPERIMENTAL|Cerebellar Stimulation|TMS will be administered to the cerebellum on half the trials of a sequence-demanding task, and on half the trials of a non-sequence-demanding task. Task order will be counterbalanced.
62675661|NCT06108336|ACTIVE_COMPARATOR|Occipital Stimulation|TMS will be administered to an occipital control region on half the trials of a sequence-demanding task, and on half the trials of a non-sequence-demanding task. Task order will be counterbalanced.
62115590|NCT04608955|ACTIVE_COMPARATOR|Arm D: Standard treatment|Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.
62115591|NCT04608955|EXPERIMENTAL|Arm E: WX-081+MBT|Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.
62115592|NCT04608955|ACTIVE_COMPARATOR|Arm F: Bedaquiline+MBT|Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.
62304270|NCT01772134|EXPERIMENTAL|Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
62675662|NCT05812599|EXPERIMENTAL|COVID Test Learning Module|In the experimental condition, participants will respond to survey questions (pre-exposure) before being presented with four narrative scenarios, questions, and accompanying messages about COVID testing (exposure), followed by post-test survey questions about COVID testing behaviors (post-exposure).
62304271|NCT01772134|ACTIVE_COMPARATOR|Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
62304272|NCT01772134|PLACEBO_COMPARATOR|Placebo + Fluticasone propionate/Salmeterol|Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
62304273|NCT02343328|ACTIVE_COMPARATOR|Fecal Microbiota Transplant Capsules|Fecal microbiota transplant capsules
62304274|NCT02343328|PLACEBO_COMPARATOR|Placebo Capsules|Placebo capsules made from a mixture of natural cocoa powder and gelatin
62304275|NCT03379350|EXPERIMENTAL|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
62304276|NCT03379350|NO_INTERVENTION|control group|Patients in control group are managed with gravity drainage (water seal only, without suction) all the time after operation.
62304277|NCT03880396||hypofractionated Rth with weekly cisplatin 40mg/m2|hypofractionated radioyherapy with weekly cisplatin 40mg/m2
62472735|NCT03360305|EXPERIMENTAL|Intervention|"1. ED clinician will perform standard medical evaluation, including focused history and exam to identify injuries. RA will solicit feedback from clinician and patient via post-visit survey at conclusion of visit.~2. PT will perform services, including integrative mobility training and lower extremity strength training and recommending outpatient services/referrals. Specific assessments and treatments will be tailored to patient.~3. Pharmacist will perform a medication review using the updated BEERS criteria and CDC's STEADI instrument and recommend changes to potential fall risk increasing medication. Recommendations will be communicated to ED treatment team.~4. Seniors will return home with standardized checklist containing details of their assessment and action plan. The checklist addresses patient's personal risk factors for the fall and required further actions."
62675663|NCT05812599|NO_INTERVENTION|Control|In the control condition, participants will respond to survey questions (pre-exposure) and post-test survey questions about COVID testing behaviors (post-exposure) only.
62675664|NCT01353885||Anterior Approach THA|500 Patients will be included who have received a total hip arthroplasty using the Anterior Approach. The anterior approach to total hip arthroplasty refers to an internervous approach to the hip, where the incision is made from the middle of the iliac crest, then curved distally and laterally to the anterior superior iliac spine (Kelmanovich et al., 2003). To optimize feasibility and applicability of our results, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size. Surgeons will use the manufacturer specific guides for insertion of the total hip arthroplasty.
62472736|NCT00614250|EXPERIMENTAL|Dose Level 1|
62472737|NCT00614250|EXPERIMENTAL|Dose Level 2|
62472738|NCT00614250|EXPERIMENTAL|Dose Level 3|
62472739|NCT00614250|EXPERIMENTAL|Dose Level 4|
62675665|NCT01353885||Posterior Approach THA|100 patients will be enrolled who have received a total hip arthroplasty using the posterior approach. The posterior approach is performed by making a curved incision posteriorly on the greater trochanter (Jolles \& Bogoch, 2004). The fascia lata is then incised and the fibers of the gluteus maximus split using dissection (Jolles \& Bogoch, 2004). To ensure the feasibility and applicability of our findings, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size used in the posterior approach.
62675666|NCT01353885||Anterolateral Approach THA|100 patients will be enrolled who have had a total hip arthroplasty using the anterolateral approach. An anterolateral approach to THA utilizes an intermuscular approach by incising the patient posteriorly and distally to the anterior superior iliac spine, extending distally to the greater trochanter along the shaft of the femur (Kelmanovich et al., 2003). To optimize the feasibility and applicability of our results, the implant manufacturer, femoral head size or the use of cemented components will not be standardized in this study.
62675667|NCT05683080||Achilles Tendon Rupture|Individuals who have experienced an Achilles tendon rupture and presented to the Achilles tendon rupture clinic.
62675668|NCT02294019|EXPERIMENTAL|Ibuprofen caplet arm|
62675669|NCT05358782||Implant with peri-implantitis|Implant with progressive marginal bone loss
62675670|NCT05358782||Healthy implant|Implant without any sign of marginal bone loss
62675671|NCT06384703||coronary ectasia cohort|Patients with coronary ectasia detected on coronary angiography and without any exclusion criteria were included.
61918022|NCT05081102|EXPERIMENTAL|Group 1: FDC oxycodone 5 mg/ibuprofen 400 mg from Eurofarma Laboratórios SA (experimental drug)|Participants randomized to this group will receive one (01) tablet of the experimental drug + one (01) tablet of Tylex® placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS). Participants will be instructed to, from then on, use this same treatment whenever needed for pain relief, observing a minimum interval of six (06) hours between two intakes, for up to 3 days (72 hours after the initial dose).
62472740|NCT00614250|PLACEBO_COMPARATOR|Placebo|12 subjects: 3 subjects per dose level
62115593|NCT06125106|EXPERIMENTAL|Blinatumomab Group|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
62472741|NCT03359356|EXPERIMENTAL|Dupilumab|An initial dupilumab dose of 600 mg (two 300 mg subcutaneous injections), followed by dupilumab 300 mg given every week
62472742|NCT03359356|PLACEBO_COMPARATOR|Placebo|Matching placebo in prefilled syringes identical to the dupilumab syringes
62675672|NCT06384703||normal coronary cohort|Patients who underwent coronary angiography and did not have any of the exclusion criteria
62115594|NCT05304546|EXPERIMENTAL|Single Arm MK3475, encorafenib and binimetinib|Intravenous pembrolizumab 400 mg Q6W + oral encorafenib 450 mg QD + oral binimetinib 45mg BID, for the first 4 weeks of the study. Starting week 5, monotherapy pembrolizumab 400 mg Q6W.
62115595|NCT00158054|EXPERIMENTAL|Intervention Condition (INT)|Enhanced depression care: Participants assigned to INT condition will be given an information brochure describing the intervention. This description will include an overview of the two elements of treatment (Problem Solving Therapy (PST), pharmacotherapy), the choice that the participant has for which element of treatment they will receive, and the stepped care aspect of treatment.
62675673|NCT06092957|ACTIVE_COMPARATOR|Induction chemotherapy plus conventional concurrent chemoradiotherapy|
62675674|NCT06092957|EXPERIMENTAL|Induction chemotherapy plus reduced-dose radiotherapy and concurrent chemotherapy|
62675675|NCT06092957|EXPERIMENTAL|Induction chemotherapy plus reduced-dose radiotherapy alone|
62675676|NCT02697929|ACTIVE_COMPARATOR|sugammadex|at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
61918023|NCT05081102|ACTIVE_COMPARATOR|Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg)|Participants randomized to this group will receive one (01) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (01) tablet of FCD placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS). Participants will be instructed to, from then on, use this same treatment whenever needed for pain relief, observing a minimum interval of six (06) hours between two intakes, for up to 3 days (72 hours after the initial dose).
62472743|NCT01111461|EXPERIMENTAL|Lenvatinib 24 mg|Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.
62472744|NCT05832411|EXPERIMENTAL|AI group|In the AI group, except for the original videos, there is additional information presented to endoscopists:（1）the virtual stomach model monitoring;（2）time;（3）scoring. Endoscopists will complete EGD examination without blind spots.
62472745|NCT05832411|NO_INTERVENTION|Routine group|In the Routine group, only the original videos and there is no additional information, and inspection time will be no less than 7 minutes.
62472746|NCT01461421|ACTIVE_COMPARATOR|Standard Behavioral Treatment|Nutrition education, behavioral weight loss techniques, and standard cognitive strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
62675677|NCT02697929|ACTIVE_COMPARATOR|neostigmine|at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation
62675678|NCT03318419|EXPERIMENTAL|Cladribine group|Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm
62675679|NCT03204747||Patients enrolled|"Patient with multiple sclerosis and lower urinary tract symptoms, age \> 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes.~A first record of gait will be at strong desire to void. A second record will be after void Gait records consist on : 3 10meter walk test and 1 Timed up and Go test."
62675680|NCT06249477|OTHER|Control group|Patients receive a wrist activity monitor and a scale. They are also followed with monthly calls ensuring adequate functioning of devices and receiving case-specific nutritional guidance.
62675681|NCT06249477|EXPERIMENTAL|Group intervention group|In addition to receiving a wrist activity monitor, scale, and being followed with monthly calls, patients in this arm received every other month nutritional coaching group sessions on topics related to nutrition and physical activity to promote education and lifestyle changes
62675682|NCT03932383|EXPERIMENTAL|Modified CPAP|Single arm cohort study of modified mask
62472747|NCT01461421|EXPERIMENTAL|Acceptance Based Behavioral Intervention|Nutrition education, behavioral weight loss techniques, and acceptance based strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
62675683|NCT04250974|EXPERIMENTAL|electroacupuncture|electroacupuncture at points after surgery
62675684|NCT04250974|SHAM_COMPARATOR|electroacupuncture non-point|electroacupuncture at non-points after surgery
62675685|NCT04250974|NO_INTERVENTION|Control group|only oral or injection painkiller were used after surgery
62675686|NCT00974233|EXPERIMENTAL|Induction/Maintenance chemotherapy|Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy
62675687|NCT04926493||BIOPAVIR Cohort|Critically ill patient \> 18 years of age with mechanical ventilation for \>2 calendar days, at increased risk for the development of Ventilator-Associated Pneumonia in the Intensive Care Unit during COVID-19 pandemic.
62675688|NCT05296655||Laryngopharegeal reflux symptoms patients|patients with symptoms of laryngopharyngeal reflux detected at an outpatient appointment with an ENT doctor
62675689|NCT05296655||Asymptomatic laryngopharegeal reflux patients|patients without symptoms of laryngopharyngeal reflux who applied for an appointment with an otorhinolaryngologist
62675690|NCT05359757|EXPERIMENTAL|Naturalistic therapeutic techniques and PECS therapy.|
62115596|NCT00158054|OTHER|Usual Cardiologic Care Condition (UCC)|Referred depression care: Participants assigned to the usual cardiologic care condition (UCC) condition will be scheduled for their next follow-up visit and thanked for their time.
62115597|NCT02026778|EXPERIMENTAL|ondansetron-betahistine|ondansetron-betahistine group
62115598|NCT02026778|PLACEBO_COMPARATOR|ondansetron|ondansetron group
62675691|NCT05359757|ACTIVE_COMPARATOR|PECS therapy Only.|
62675692|NCT04997421|ACTIVE_COMPARATOR|CVVHDF with Oxiris®-AN69 membrane|Control arm
62115599|NCT05661162|OTHER|CR500 single-dose gel|Interventional study on CR500 1.5 mL will be topically administered twice a week for four weeks
62115600|NCT04653935|EXPERIMENTAL|Full app with all app components|Users receive app that contains all intervention components including: Symptom and Lifestyle information, Energy management, Goal Setting, Managing Difficult Times, Assertiveness and Communication Skills.
62115601|NCT04653935|ACTIVE_COMPARATOR|Control minimal app with information component only|Users receive app that contains only Symptom and Lifestyle information, and cannot see other intervention components.
62115602|NCT06357819||Mock Result Interpretation|Testing with non-functional devices (Mock-ups) that are modified to display contrived results to assess the ability of previously untrained users to correctly interpret one of the possible results as defined by each device manufacturer (e.g., Negative/Non-Reactive, Positive/Reactive, Invalid etc.)
62115603|NCT00270803|PLACEBO_COMPARATOR|A|Low nicotine cigarettes without THC
62472748|NCT01820793|EXPERIMENTAL|cefoxitin|this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.
62675693|NCT04997421|ACTIVE_COMPARATOR|CVVHDF with Oxiris®-AN69 membrane + Hemoadsorption using HA380|Intervention arm
62675694|NCT04555733|EXPERIMENTAL|Cohort 1: Lemborexant 5 mg|Participants will receive a single dose of lemborexant 5 milligram (mg) tablet, orally on Day 1.
62675695|NCT04555733|EXPERIMENTAL|Cohort 2: Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1 followed by a washout period of approximately 14 days further followed by multiple doses of lemborexant 10 mg tablets, orally, once daily from Day 15 through Day 28.
62675696|NCT04555733|EXPERIMENTAL|Cohort 3: Lemborexant 25 mg|Participants will receive a single dose of lemborexant 25 mg (1\*5 mg tablet and 2\*10 mg tablet), orally on Day 1.
62675697|NCT01242046|EXPERIMENTAL|Caffeine|Participants will ingest a tablet with 400 mg caffeine
62675698|NCT01242046|PLACEBO_COMPARATOR|Placebo|Participants will ingest an inert placebo tablet
62675699|NCT02111980|EXPERIMENTAL|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
62675700|NCT01857115|EXPERIMENTAL|CCyd|"Treatment schedule for 9 cycles of induction:~1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.~2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
62675701|NCT05362136|ACTIVE_COMPARATOR|Control|standard sinus floor elevation
62675702|NCT05362136|EXPERIMENTAL|Test|standard sinus floor elevation with additional perforation of the sinus floor
62675703|NCT03683498|EXPERIMENTAL|Regulatory T-cell enriched infusion|"Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:~Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg"
62472749|NCT01044485|OTHER|lapatinib + docetaxel|"dose level Lapatinib (OD) Docetaxel (q3wks) Systematic Growth factor Minus 0 1250 mg 75 mg/m2 + systematic growth factor support~0, 1250mg 75 mg/m2 No~+1 1500mg 75mg/m2 No~Minus +1\* 1500mg 75mg/m2 + systematic growth factor support~+2 1250mg 100mg/m2 No~Minus +2\* + systematic growth factor support~+3 1500mg 100mg/m2 No~Minus +3\* + systematic growth factor support~Apart within the minus dose levels, G-CSF support should be added only as rescue strategy if severe neutropenia occurred during the first cycle of studied dose.Patients will receive 4 cycles of the association. In case of benefit of the treatment, they should continue the treatment with lapatinib until progression.\* patients will be included at level minus X only if 2 DLT out of 6 patients based on febrile neutropenia occurred at level X"
62472750|NCT04542356|EXPERIMENTAL|experimental group|patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy
62675704|NCT01881633|EXPERIMENTAL|ISU302|15 U/kg I.V. injection
61918024|NCT00768469|EXPERIMENTAL|Nera 160 + Pac|Neratinib 160 mg + Paclitaxel 80 mg/m\^2
62472751|NCT04542356|PLACEBO_COMPARATOR|control group|patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC\<1✕109/L
62472752|NCT05589363|ACTIVE_COMPARATOR|ABC block with bupivacaine and liposomal bupivacaine|The study solution used in the active arm will comprise 20 mL of liposomal bupivacaine (266 mg) admixed with 40 mL of 0.25% bupivacaine HCl. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).
62472753|NCT05589363|SHAM_COMPARATOR|ABC block with saline|The study solution used in the active arm will comprise 60 mL of 0.9% saline. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).
62472754|NCT03377894|ACTIVE_COMPARATOR|• Group (A) blunt incision|"100 primigravidas at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy.~undergoing blunt uterine incision expansion"
62675705|NCT01881633|EXPERIMENTAL|ISU302 30 U/kg|Drug ISU302 I.V. injection
62675706|NCT01881633|EXPERIMENTAL|ISU302 60 U/kg|Drug ISU302 I.V. injection
62675707|NCT01881633|PLACEBO_COMPARATOR|Placebo|ISU302 Placebo I.V. injection
62675708|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
62675709|NCT01558414|EXPERIMENTAL|SILS|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
62675710|NCT01558414|EXPERIMENTAL|FSIS|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
62675711|NCT01558414|ACTIVE_COMPARATOR|Conventional laparoscopy|Cholecystectomy performed by a conventional laparoscopic approach
62675712|NCT02923622||Traditional Chinese and Western medicine combined group|
62675713|NCT02923622||Traditional Chinese medicine group|
62675714|NCT02923622||Western medicine group|
62675715|NCT02187081|EXPERIMENTAL|Sorafenib+RFA|We give radiofrequency ablation plus Sorafenib for the treatment of HCC
62675716|NCT02187081|ACTIVE_COMPARATOR|RFA alone|We give Radiofrequency ablation alone for the treatment of HCC
61918025|NCT00768469|EXPERIMENTAL|Nera 240 + Pac|Neratinib 240 mg + Paclitaxel 80 mg/m\^2
62115604|NCT01205620|EXPERIMENTAL|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
62675717|NCT04773977|EXPERIMENTAL|IBI362 liquid formulation|Participants received single subcutaneous injection of IBI362 liquid formulation
62675718|NCT04773977|EXPERIMENTAL|IBI362 lyophilized powder|Participants received single subcutaneous injection of IBI362 lyophilized powder
62675719|NCT01336972|EXPERIMENTAL|Group A - eGFR > 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM \[8 hours later\]) to the maximally tolerated dose.
62675720|NCT01336972|EXPERIMENTAL|Group B - eGFR 30 to 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM \[8 hours later\]) to the maximally tolerated dose.
62675721|NCT01336972|EXPERIMENTAL|Group C - eGFR < 30 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM \[8 hours later\]) to the maximally tolerated dose.
62115605|NCT01205620|NO_INTERVENTION|No intervention|No intervention will be performed in this control group
62115606|NCT01637662|EXPERIMENTAL|Healthy subjects|
62115607|NCT02361437|PLACEBO_COMPARATOR|placebo|placebo
62675722|NCT00693108|EXPERIMENTAL|1|Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles
62675723|NCT00693108|NO_INTERVENTION|2|
62675724|NCT06309329|EXPERIMENTAL|Strength at Home Parents|
62675725|NCT06309329|ACTIVE_COMPARATOR|VA treatment as usual|
62675726|NCT05553288||active group|Every study participant will actively receive daily text messages asking about their change in health and concomitant medication.
62675727|NCT01708746||Enrolled subjects|
62675728|NCT01708746||Historic control|
62304278|NCT03394495|EXPERIMENTAL|BCE Combination group|"16-week BCE programme with exercise training.~Six 1-hour sessions of BCE programme and a weekly 45-60 minute centre-based exercise programme from week 4 to week 16."
62472755|NCT03377894|ACTIVE_COMPARATOR|• Group (B) sharp incision|100 primigravidas, at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy undergoing sharp uterine incision expansion
62472756|NCT03125135|EXPERIMENTAL|Test Subject|All subjects are enrolled into the test group and all subjects receive the MightySat RX Pulse Oximeter Sensor.
62304279|NCT03394495|NO_INTERVENTION|Exercise group|"16-week programme with health talks and exercise training.~Six 1-hour sessions of health talks and a weekly 45-60 minutes centre-based exercise programme from week 4 to week 16."
62304280|NCT03394495|NO_INTERVENTION|Control group|Six sessions of centre-based health talks on the management of different health issues with the exception of fatigue.
62472757|NCT03663179|EXPERIMENTAL|Active TMS|Participants will receive 20 sessions of active TMS targeting the left DLPFC.
62115608|NCT02361437|EXPERIMENTAL|Vasculera|diosmin
62115609|NCT05636852|EXPERIMENTAL|Altropane (123I) Injection|
62115610|NCT02211898|EXPERIMENTAL|BNS003|
62472758|NCT03663179|SHAM_COMPARATOR|Sham TMS|Participants will receive 20 sessions of sham TMS over the left DLPFC.
62115611|NCT04010955||Edoxaban Monotherapy|"edoxaban monotherapy without additional antiplatelet therapy in long term stroke prevention.~However, transient additional antiplatelet therapy will be allowed at the discretion of duty physicians."
62115612|NCT04010955||Edoxaban and antiplatelet combination|edoxaban plus additional antiplatelet therapy in long term stroke prevention. However, transient cessation of antiplatelet therapy will be allowed at the discretion of duty physicians.
62304281|NCT02924844||Observation period before presence of clinical pharmacist|The group of patients was observed between Janary 2013 and December 2013
62472759|NCT01623791||Group 1|Group 1: mild pre-eclamptic group Mild and severe pre-eclampsia were defined American College of Obstetrics and Gynecology criteria (ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia. January 2002.)
62472760|NCT01623791||Group 2|Group 2: severe pre-eclamptic group
62472761|NCT03170323|EXPERIMENTAL|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
62472762|NCT03170323|ACTIVE_COMPARATOR|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
62472763|NCT05253950||Observational Group|A sample of 120 people was collected from all over Greece, more specifically 7.6% belong to the region of Attica, 7.6% belong to the region of Western Greece, 0.8% belong to the region of Thessaly, 32.8% belong to the region of Central Macedonia and 51.3% belong to the region of Crete .
62472764|NCT02627235|EXPERIMENTAL|DIAL Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes daily IVR-system call feedback and monthly graphic-based feedback delivered in the mail. In addition, social support, outcome expectations and perceived physical activity enjoyment variables will be assessed at baseline, 30, 60, and 90 days. Responses will be used to select appropriate tailored feedback modules.
62472765|NCT02627235|ACTIVE_COMPARATOR|Wait List Control|Access to the intervention 12 weeks following baseline assessment.
62472766|NCT03816072|ACTIVE_COMPARATOR|Propofol|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with intravenous anaesthesia (propofol).
62472767|NCT03816072|ACTIVE_COMPARATOR|Sevoflurane|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with inhalational anaesthesia (sevoflurane).
62472768|NCT02563561|EXPERIMENTAL|1 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
62115613|NCT01252316|ACTIVE_COMPARATOR|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
62115614|NCT01252316|ACTIVE_COMPARATOR|Recruitment with Volunteers|UPHS volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
62115615|NCT01252316|ACTIVE_COMPARATOR|Recruitment with Nurses|UPHS Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
62115616|NCT01252316|ACTIVE_COMPARATOR|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
62472769|NCT02563561|EXPERIMENTAL|2 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of 4 mg of apaziquone by intravesical administration via an indwelling catheter on Day 15 (±5 days).
62115617|NCT04201249|ACTIVE_COMPARATOR|Mesotherapy with piroxicam and lidocaine|
62115618|NCT04201249|SHAM_COMPARATOR|Mesotherapy without piroxicam and lidocaine|
62304282|NCT02924844||Period with presence of clinical pharmacist|The group of patients was observed between January 2014 and June 2015.
62304283|NCT05766735|ACTIVE_COMPARATOR|Routine Care (RC)|Participants will be actively working with their primary care provider during the study and will attend appointments with their provider as needed. The study team will monitor their progress at the scheduled Assessment Visits. The participants should discuss any concerns they have, including side effects or cost, in order to adjust the medication regime with their primary care team. Their physician/clinician may recommend additional things, like weight loss, exercise programs and/or diabetes education programs.
62472770|NCT02563561|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive first dose of matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of matching placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
62472771|NCT05137821|EXPERIMENTAL|non tested comparative group|two sealed new implants as a control
62675729|NCT04642066|EXPERIMENTAL|Active Group|Healthy volunteers were followed during the 5-month CWI exposition under standard conditions (three times per week 7-10 min). Neoprene equipment was not allowed; volunteers with followed weight or muscle mass changes over 5% were excluded
62675730|NCT04642066|SHAM_COMPARATOR|Sham control|Control without CWI exposition
61918026|NCT02566408|EXPERIMENTAL|Supportive Care (interview about KAPs towards PA)|"Participants undergo a 2-hour one-on-one interview and answer survey questions about their beliefs, attitudes, and preferences (KAPs) towards physical activity (PA). Ten topics will be used to explore older women's attitudes toward PA. Six topics will also be used to explore ethnic-specific and culture-specific contexts that surround older women's participation in PA.~REFINEMENT OF THE PA INTERVENTION: Approximately 1-2 months after the conclusion of interviews, participants are invited to a joint session and presented with results of analyzed data. Participants are asked to review results and themes identified from interviews, and to concur whether conclusions capture their KAPs. Through this process a set of preferences that is agreed upon by all as most critical for enhancing PA participation, adherence, and retention will be identified."
61918027|NCT02718300|EXPERIMENTAL|Part 1: Ruxolitinib + Parsaclisib|Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
61918028|NCT02718300|EXPERIMENTAL|Part 2: Ruxolitinib + Parsaclisib|Part 2 will compare 2 doses of parsaclisib .
62115619|NCT06556251|EXPERIMENTAL|Experimental Group|Experimental group (EG) will have access to the PIPPEP platform in addition to treatment in the Early Psychosis Programme.
62115620|NCT06556251|ACTIVE_COMPARATOR|Treatment as Usual|The control group (CG) will receive treatment as usual (TAU) without using the platform.
62115621|NCT05026086|EXPERIMENTAL|biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
62472772|NCT05137821|EXPERIMENTAL|Er: YSGG laser tested group|24 infected implants divided into four subgroups that will be decontaminated by Er: YSGG laser in various peri-implant defects
62472773|NCT05952986|EXPERIMENTAL|cohort 1|FB825 300 mg or placebo with single SC administration in 3:1 ratio
62472774|NCT05952986|EXPERIMENTAL|cohort 2|FB825 450 mg or placebo with single SC administration in 3:1 ratio
62675731|NCT00930176|EXPERIMENTAL|Human Coagulation FACTOR X|
62675732|NCT02182453|EXPERIMENTAL|BI 10773 - single rising dose|
62675733|NCT02182453|PLACEBO_COMPARATOR|Placebo|
62115622|NCT05026086|ACTIVE_COMPARATOR|isometric exercises|10 patients will be treated with isometric exercises without pressure biofeedback.
62675734|NCT03272165|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intravenous (IV) infusion of placebo matched to MEDI1341 and will be followed up for 13 weeks.
62675735|NCT03272165|EXPERIMENTAL|Cohort 1: MEDI1341 Dose 1|Participants will receive a single IV infusion of MEDI1341 Dose 1 and will be followed up for 13 weeks.
62675736|NCT03272165|EXPERIMENTAL|Cohort 2: MEDI1341 Dose 2|Participants will receive a single IV infusion of MEDI1341 Dose 2 and will be followed up for 13 weeks.
62675737|NCT03272165|EXPERIMENTAL|Cohort 3: MEDI1341 Dose 3|Participants will receive a single IV infusion of MEDI1341 Dose 3 and will be followed up for 13 weeks.
62675738|NCT03272165|EXPERIMENTAL|Cohort 4: MEDI1341 Dose 4|Participants will receive a single IV infusion of MEDI1341 Dose 4 and will be followed up for 13 weeks.
62115623|NCT00745446|EXPERIMENTAL|1|1 hour exposure to filtered air
62115624|NCT00745446|EXPERIMENTAL|2|1 hour exposure to diesel exhaust (300mcg/m3)
62115625|NCT00745446|EXPERIMENTAL|3|1 hour exposure to filtered diesel exhaust
62115626|NCT06100705|EXPERIMENTAL|Testosterone Cypionate + Sipuleucel-T|Participants will start with testosterone injection every 4 weeks. The first dose of standard of care Sipuleucel-T will be prepared and infused after two doses of testosterone and will continue every 2 weeks for a total of 3 infusions at a standard schedule. The testosterone injection will continue once every 4 weeks until treatment discontinuation criteria are met.
62675739|NCT03272165|EXPERIMENTAL|Cohort 5: MEDI1341 Dose 5|Participants will receive a single IV infusion of MEDI1341 Dose 5 and will be followed up for 13 weeks.
62675740|NCT03272165|EXPERIMENTAL|Cohort 6: MEDI1341 Dose 6|Participants will receive a single IV infusion of MEDI1341 Dose 6 and will be followed up for 13 weeks.
62115627|NCT05189340|NO_INTERVENTION|Standard of Care|Patients in the Standard of Care arm will receive pharmacist discharge education via fully in-person education as is currently being done.
62115628|NCT05189340|EXPERIMENTAL|Intervention|Patients in the Intervention arm will have access to pre-recorded educational videos covering key educational points. Patients will also have in-person interaction with pharmacists to address additional questions not covered in the videos.
62115629|NCT05380791||IEM in patients with GERD with normal MRS contraction|Esophageal motility determined by high resolution esophageal manometry and multiple rapid swallow (MRS) tests
62472775|NCT05952986|EXPERIMENTAL|cohort 3|300 mg single IV administration
62472776|NCT01003054|EXPERIMENTAL|Autologous Transplantation|Busulfan 130 mg/m\^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
62472777|NCT04435353|ACTIVE_COMPARATOR|Time-day of respiratory fail|Objective data
62472778|NCT04435353|ACTIVE_COMPARATOR|Oxygen status|Facultative data
62472779|NCT04435353|ACTIVE_COMPARATOR|Oxugen support|FiO2
62472780|NCT04435353|ACTIVE_COMPARATOR|Adverse outcomes|Complication
62675741|NCT01807104|ACTIVE_COMPARATOR|Anterior Approach Total Hip|Total hip arthroplasty performed through an anterior surgical approach. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach
62675742|NCT01807104|ACTIVE_COMPARATOR|Posterior Approach Total Hip|The additional arm is the posterior approach total hip, which the Anterior Approach is being compared too. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach.
62675743|NCT00083109|EXPERIMENTAL|Treatment (suramin and fluorouracil)|"PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.~PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.~In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62115630|NCT05380791||IEM in patients with GERD with abnormal MRS contraction|Esophageal motility determined by high resolution esophageal manometry and multiple rapid swallow (MRS) tests
62115631|NCT00431431|EXPERIMENTAL|1|tibolone
62304284|NCT05766735|EXPERIMENTAL|Routine Care + Glucose Excursion Minimization (RC+GEM)|Participants will actively work with their primary care provider and receive personalized routine care (RC). In addition, participants will receive GEM, an individualized, person-centered, empowerment program, not a behavior modification program. GEM provides individuals with personally relevant information to make choices that will help them achieve their diabetes goals. It focuses on techniques - eating low glycemic load foods, increasing moderate and vigorous exercise, and monitoring blood glucose (BG) to educate individuals about the impact of high glycemic load nutrients and vigorous exercise. The emphasis is on minimizing glucose excursions by any practical means, e.g., nutrient selection, timing and combinations of nutrient intake, time restricted eating, eating carbohydrates after protein and fat, post prandial physical activity, whatever is personally affirmed by BG feedback.
62304285|NCT04408456|ACTIVE_COMPARATOR|Post Exposure Prophylaxis (PEP) Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene Plus Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
62115632|NCT00431431|ACTIVE_COMPARATOR|2|raloxifene
62115633|NCT03646123|EXPERIMENTAL|Part A: A+AVD|Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
62115634|NCT03646123|EXPERIMENTAL|Part B: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
62115635|NCT03646123|EXPERIMENTAL|Part C: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
62115636|NCT00078533|EXPERIMENTAL|CMV CTL infusion|Subjects are assigned a dose level at the time of enrollment.
62115637|NCT06532435|OTHER|DHA & ARA Candy|Sibot DHA algal oil ARA gelainzed Candy, each containing DHA 100 mg + ARA 100 mg
62115638|NCT03684265|EXPERIMENTAL|Test to Reference|
62115639|NCT03684265|EXPERIMENTAL|Reference to Test|
62115640|NCT01291290|NO_INTERVENTION|Control treatment|Usual transfusion regime to patients with rAAA
62115641|NCT01291290|EXPERIMENTAL|Thrombocyte|Early thrombocyte administration to patients with rAAA
62115642|NCT01224054||Bypass gastric|The mixed surgery which combine the gastric reduction with some degree of disabsorption
62115643|NCT01224054||Biliopancreatic diversion|The mal-absorptive surgery which reduce the intestinal absorption of food
62115644|NCT01224054||Duodenal exclusion|This surgery provides disabsortion by duodenal derivation maintaining an intact stomach
62304286|NCT04408456|OTHER|Control Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
62115645|NCT04102371|EXPERIMENTAL|Balanced fluids (BF)|Balanced fluids (BF), including Lactated Ringer's and Plasma-Lyte (PL), will be administered to patients randomized to the experimental arm. BF will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
62115646|NCT04102371|ACTIVE_COMPARATOR|"0.9% Normal Saline Fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
62675744|NCT03636269|ACTIVE_COMPARATOR|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
62675745|NCT03636269|PLACEBO_COMPARATOR|Placebo|IV Placebo administered after each dialysis session (3 times/week)
62675746|NCT03255590|EXPERIMENTAL|Finger Dexterity Training|"Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved.~Participants trained for 5 consecutive days, 3 to 4 h/d, on a multi-finger piano-chord-like task that cannot be performed by compensatory actions of other body parts (e.g., arm). Participants had to learn to simultaneously coordinate and synchronize multiple fingers to break unwanted flexor synergies."
62675747|NCT02968875|ACTIVE_COMPARATOR|Endurance Training|The first group of 40 people will do endurance training; 20 of them will perform a continuous exercise on cycle ergometer at a power equivalent to 70% of the maximal heart rate, twice a week. The other group will do Interval Training, with a four minute long base and one minute long peak, twice a week. The base workload will be equivalent to an intensity of 60% of the maximal heart rate and the peak will be equivalent to 80% of the maximal heart rate.
62472781|NCT01188681|EXPERIMENTAL|Phase 1: 15 mg/kg TRU-016 + Bendamustine|TRU-016 (15 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
62472782|NCT01188681|EXPERIMENTAL|Phase 1: 20 mg/kg TRU-016 + Bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
62115647|NCT01196429|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, temsirolimus, docetaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV on days 1 and 8. Treatment repeats every 3 weeks for 6 courses. Patients then receive consolidation therapy comprising temsirolimus IV on days 1, 8, and 15. Treatment repeats every 3 weeks for 11 courses in the absence of disease progression or unacceptable toxicity.~NOTE: \* For circumstances in which docetaxel should be substituted for paclitaxel, docetaxel is given IV over 1 hour."
62115648|NCT05815342|EXPERIMENTAL|Treatment|All subjects wearing the Omnipod 5 Automated Glucose Monitoring System
62115649|NCT00845832|EXPERIMENTAL|1|
62115650|NCT00845832|ACTIVE_COMPARATOR|2|
61918029|NCT02718300|EXPERIMENTAL|Part 3: Ruxolitinib + Parsaclisib|Part 3 will compare 2 different long term dosing strategies.
62304287|NCT00652587|EXPERIMENTAL|A, LRTACE|hepatectomy with adjuvant transcatheter arterial chemoembolization
62304288|NCT00652587|ACTIVE_COMPARATOR|B, LR|hepatectomy alone
62304289|NCT03037905|EXPERIMENTAL|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
62304290|NCT03037905|NO_INTERVENTION|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
62304291|NCT00618956|EXPERIMENTAL|1|
62304292|NCT00618956|PLACEBO_COMPARATOR|2|
62304293|NCT06439043|EXPERIMENTAL|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The face-to-face Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered by the psychotherapist at their clinic. The treatment will consist of a total of 12 to 13 sessions, with one session conducted per week.
62472783|NCT01188681|EXPERIMENTAL|Phase 2: TRU-016 and bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 32 patients
62472784|NCT01188681|ACTIVE_COMPARATOR|Phase 2: Bendamustine|Bendamustine (70 mg/m2), n = 33 patients
62472785|NCT00546988|NO_INTERVENTION|Standard risk IFN|Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
62472786|NCT00546988|NO_INTERVENTION|Standard risk PEGIFN|Maintenance treatment with pegylated interferon following autologous stem cell transplantation
62472787|NCT00546988|EXPERIMENTAL|High risk allo|Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
62472788|NCT00546988|NO_INTERVENTION|High risk auto|Second cycle of high-dose melphalan in subjects without an HLA-identical donor
62472789|NCT02068820|ACTIVE_COMPARATOR|ISB dye, standard white light|SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
61918030|NCT02718300|EXPERIMENTAL|Part 4: Ruxolitinib + Parsaclisib|Part 4 will compare 2 different daily dosing strategies.
62115651|NCT04710225|ACTIVE_COMPARATOR|Group 1 (General anesthesia group)|"Upper limb fracture surgery will be performed with the aid of pneumatic tourniquet. General anesthesia will be induced with intravenous (IV) thiopental sodium and fentanyl.~Rocuronium will be used as the neuromuscular blocking agent. Endotracheal tube will be placed and anesthesia will be maintained with sevoflurane and IV fentanyl while the lungs were ventilated with O2-N2O (50-50%) to achieve an EtCO2 at 30-35 mm Hg."
61918031|NCT03989726|EXPERIMENTAL|High density voltage and fractionation map guided group|"* Complex fractionated atrial electrogram (CFAE), voltage and fractionation map will be performed with a multielectrode mapping catheter.~* The mapping should be performed in AF.~* First, low-voltage zone is defined as an area with bipolar peak-to-peak voltage amplitudes \< 0.5mV.~* A voltage-map guided segmental PV isolation is performed. Radiofrequency energy is applied in the antral regions of the PVs. High voltage zone over 0.5mV in the antral region is targeted. IF PV isolation in not achieved by voltage-guided segmental ablation, additional Lasso catheter guided segmental antral ablation is performed.~* Radiofrequency energy is delivered at target sites for 15-30 sec guided by contact force, lesion size index (LSI) and local electrogram elimination.~* If the patient is still in AF after PV isolation, additional fractionation map guided ablation is performed. The fractionation area within low voltage area (\<0.5mV) should be targeted."
61918032|NCT03989726|ACTIVE_COMPARATOR|Circumferential PV isolation|A control group will be chosen from database of patients who underwent AF ablation between 2018-2019. A control group includes the same number of consecutive patients who underwent anatomy-based circumferential PV isolation.
62304294|NCT06439043|ACTIVE_COMPARATOR|Online Eye Movement Desensitization and Reprocessing therapy|The online Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered by the psychotherapist using BilateralBase software. The treatment will consist of 12 to 13 online sessions, with one session conducted per week.
61918033|NCT04529187|ACTIVE_COMPARATOR|DEX group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a dexmedetomidine infusion in a rate of of 0.7 ug.kg-1.hr-1will be initiated. After 5 minutes of dexmedetomidine therapy a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
61918034|NCT04529187|ACTIVE_COMPARATOR|MID group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a single dose of midazolam (2 mg intravenously) will be given to each participant in this arm. After 5 minutes of midazolam administration a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
61918035|NCT00353028|EXPERIMENTAL|F|
61918036|NCT00353028|PLACEBO_COMPARATOR|P|
61918037|NCT01640093|EXPERIMENTAL|Treatment B|Abiraterone acetate (500 mg), 2 coated, reformulated tablets.
61918038|NCT01640093|EXPERIMENTAL|Treatment C|Abiraterone acetate (250 mg), 4 coated, reformulated tablets.
61918039|NCT01640093|EXPERIMENTAL|Treatment D|Abiraterone acetate (500 mg), 2 coated, reformulated tablets, showing slower in vitro dissolution.
62472790|NCT02068820|EXPERIMENTAL|ICG dye, FireFly fluorescence imaging|SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
62472791|NCT01239017|EXPERIMENTAL|Dose 1|SC REGN475 Dose 1 and IV Placebo
61918040|NCT01640093|ACTIVE_COMPARATOR|Treatment A|Abiraterone acetate (250 mg), 4 uncoated, current commercial tablets.
61918041|NCT00769483|EXPERIMENTAL|Phase I, Arm A|MK-0646 + Gemcitabine
61918042|NCT00769483|EXPERIMENTAL|Phase I, Arm B|MK-0646 + Gemcitabine + Erlotinib
61918043|NCT00769483|EXPERIMENTAL|Phase II, Arm A|Gemcitabine + Erlotinib
61918044|NCT00769483|EXPERIMENTAL|Phase II, Arm B|MK-0646 + Gemcitabine + Erlotinib
61918045|NCT00769483|EXPERIMENTAL|Phase II, Arm C|Gemcitabine + Erlotinib
62304295|NCT05435430||women with previously SARS-COV2 infection.|"2 group from 2 IVF CENTER with egual criteria :~INCLUSION CRITERIA:~* Women 24-43 years of age~* Previous history of COVID-19 infection~* INFERTILITY DIAGNOSIS~ESCLUSION CRITERIA:~* women with current symptoms of COVID-19 infection~* Positive for HIV or the presence of active viral hepatitis~* Previosuly ovarian cancer, removal of ovaries or gonadotoxic treatments"
62472792|NCT01239017|EXPERIMENTAL|Dose 2|SC REGN475 Dose 2 and IV Placebo
62472793|NCT01239017|EXPERIMENTAL|Dose 3|SC REGN475 Dose 3 and IV Placebo
62472794|NCT01239017|EXPERIMENTAL|Dose 4|SC Placebo and IV REGN475 Dose 4
62472795|NCT01239017|PLACEBO_COMPARATOR|Dose 5|SC Placebo and IV Placebo
62472796|NCT01472341||All Participants|Participants receiving routine care under a diabetologist.
62304296|NCT03318367|EXPERIMENTAL|Supportive care (virtual reality education module)|After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.
62304297|NCT01228773|EXPERIMENTAL|A|"Providing tailored web-based care program(Health Navigation®), which provides various information related to the CRF.~Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue etc."
62472797|NCT04908098|EXPERIMENTAL|Laser group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling. Laser application was then applied to the areas where root planning was applied. Laser was applied in continuous phase at 0.80W power, 940 nm wavelength and 0.80 J / s energy level.
62675748|NCT02968875|ACTIVE_COMPARATOR|Control group|20 persons will be in the control group and they will not perform the endurance training. However, they will have 9 therapeutic education meetings.
62675749|NCT01852214|ACTIVE_COMPARATOR|Prasugrel first, then ticagrelor|Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
62675750|NCT01852214|ACTIVE_COMPARATOR|Ticagrelor first, then prasugrel|Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.
62675751|NCT05004168|EXPERIMENTAL|SPF evaluation|Healthy male or female subjects with Fitzpatrick Skin Type of II-IV were included in the SPF study
62675752|NCT01148420|EXPERIMENTAL|DMPA & MPA|150 mg intramuscularly received DMPA and two 10 mg tablets of MPA every 8 hours for 3 days
62675753|NCT02454764|EXPERIMENTAL|Tenofovir + Interferon alpha 2 b|
62675754|NCT02454764|ACTIVE_COMPARATOR|Tenofovir|
62115652|NCT04710225|ACTIVE_COMPARATOR|Group 2 (Multiple injection axillary block group)|Multiple injection axillary block will be performed with the aid of a nerve stimulator. When the slight twitching of the motor response from the relevant muscles is achieved (at 0.4 mA, 2Hz, 0.1 ms) % 18-20 ml of Bupivacaine 0.5 (90-100 mg) will be injected.
62115653|NCT01492218||NovoLet®|
62115654|NCT00665379|ACTIVE_COMPARATOR|1|Regular compression therapy with non elastic trico bandaging
62115655|NCT00665379|ACTIVE_COMPARATOR|2|New two layer compression bandage coban 2
62115656|NCT04931446||Gastroenteropancreatic neuroendocrine neoplasms|
62115657|NCT02888080|EXPERIMENTAL|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
62115658|NCT02888080|PLACEBO_COMPARATOR|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
62115659|NCT03219645|ACTIVE_COMPARATOR|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
62115660|NCT03219645|PLACEBO_COMPARATOR|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
62115661|NCT06550102||Hematological malignancy|Patients witha diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma
62115662|NCT01441453|OTHER|Preoperative FibroScan|
62115663|NCT03636867||data and specimen collection|consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia
62472798|NCT04908098|ACTIVE_COMPARATOR|Control group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling.
62675755|NCT02609451|EXPERIMENTAL|2 weeks|Ileostomy closure after 2 weeks
62115664|NCT03092713|ACTIVE_COMPARATOR|Cognitive Intervention and Supported Employment (CCI-SE)|Combined cognitive and vocational rehabilitation in a mixed design.
62675756|NCT02609451|EXPERIMENTAL|12 weeks|Ileostomy closure after 12 weeks
62675757|NCT01905267|EXPERIMENTAL|Treatment|Participants randomized to the experimental condition will receive 8 weeks of individual treatment with Rumination-Focused Cognitive Behavior Therapy
62675758|NCT01905267|NO_INTERVENTION|Control|Participants randomized to the control arm will complete questionnaires and receive mood monitoring for the duration of the study
62675759|NCT05936853|ACTIVE_COMPARATOR|Total intravenous anaesthesia (TIVA)|This arm will receive maintenance of anaesthesia through a total intravenous anaesthesia approach (TIVA)
62675760|NCT05936853|ACTIVE_COMPARATOR|Inhalational anaesthesia|This arm will receive maintenance of anaesthesia through an inhalational anaesthesia approach
62675761|NCT03093870|EXPERIMENTAL|Varlitinib and Capecitabine|
62115665|NCT03092713|ACTIVE_COMPARATOR|Control group|Usual follow-up assessment and treatment provided by the multidisciplinary TBI rehabilitation team.
62115666|NCT02984319|ACTIVE_COMPARATOR|Cherry|Cherry concentrate
61918046|NCT02065362|EXPERIMENTAL|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f
62115667|NCT02984319|PLACEBO_COMPARATOR|Placebo|Placebo concentrate
62115668|NCT04983537|ACTIVE_COMPARATOR|Gam-COVID-Vac / Gam-COVID-Vac|
62304298|NCT01228773|OTHER|B|Attention control arm: Providing usual care for CRF. Three months later, as attention control, they will be provided tailored web-based care program(Health Navigation®), which provides various information related to the CRF.
62304299|NCT03486236|EXPERIMENTAL|Cohort C1|
62115669|NCT04983537|ACTIVE_COMPARATOR|Gam-COVID-Vac / ChAdOx1 nCoV-19|
62115670|NCT04983537|ACTIVE_COMPARATOR|Gam-COVID-Vac / BBIBP-CorV|
62115671|NCT00641654|ACTIVE_COMPARATOR|A|Patients having previously received 24 weeks of therapy with pegylated interferon and ribavirin will be treated with pegylated interferon alfa-2a kD (PEGASYS) plus ribavirin, (Copegus) for a treatment period of 48 weeks, with a follow-up period of 24 weeks irrespective of the level of HCV-RNA measured in plasma on treatment day 27.
62115672|NCT00641654|ACTIVE_COMPARATOR|B|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having detectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 48 weeks, with a follow-up period of 24 weeks.
62115673|NCT00641654|ACTIVE_COMPARATOR|C|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having undetectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 24 weeks, with a follow-up period of 24 weeks.
62115674|NCT02412774|EXPERIMENTAL|Diet Beverages (DBs)|Diet beverages after the main meal+ Diet
62115675|NCT02412774|EXPERIMENTAL|Water|Water after the main meal+ Diet
62115676|NCT01080950||fever zinc vit. d|patients with fever but without sepsis
62115677|NCT01080950||sepsis zinc vit. d|patients with sepsis
62304300|NCT03486236|PLACEBO_COMPARATOR|Cohort C1: Triple Placebo|
62304301|NCT03486236|EXPERIMENTAL|Cohort C2|
62675762|NCT03093870|PLACEBO_COMPARATOR|Placebo and Capecitabine|
62675763|NCT06466772|SHAM_COMPARATOR|Adaptation arm|Hyper-personalized feedback-based motor rehabilitation with sham targeted auditory stimulation during sleep (HPF intervention, TASS sham intervention)
62115678|NCT03181464|EXPERIMENTAL|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
62115679|NCT03181464|PLACEBO_COMPARATOR|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
62115680|NCT05300919|EXPERIMENTAL|MBC for depressive and manic symptoms|"Measurement-based care (MBC) is a clinical strategy involving consistent assessment of clinical status and using those findings to drive clinical decision making. MBC involves clinic staff providing the measure to the patient at each visit which the patient completes and returns, staff enters results into the electronic medical record, clinician reviews current results and compares to past results, and discusses with the patient.~The experimental condition patients will receive MBC for manic and depressive symptoms."
62115681|NCT05300919|ACTIVE_COMPARATOR|MBC for depressive symptoms only|The active comparator arm patients will receive MBC for depressive symptoms.
62115682|NCT04190342|OTHER|control group|standard care (intervention provided after the completion of the trial)
62115683|NCT04190342|EXPERIMENTAL|tai chi group|Tai chi intervention + standard care
62304302|NCT03486236|PLACEBO_COMPARATOR|Cohort C2: Triple Placebo|
62304303|NCT03490344|EXPERIMENTAL|Participants with Multiple Myeloma|Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
62304304|NCT03662321||sexual behavior on the internet|this group of teenagers use internet for sexuality
62304305|NCT03662321||not sexual behavior on the internet|this group of teenagers doesn't use internet for sexuality
62304306|NCT02585544|OTHER|Genital prolapse|Single arm: i.e., all patients
62304307|NCT00663130|EXPERIMENTAL|Arm 1|
62304308|NCT00663130|ACTIVE_COMPARATOR|Arm 2|
62304309|NCT03715543|EXPERIMENTAL|Surgical Resection Arm|Surgical Resection of the Greater Splanchnic Nerve
62304310|NCT01999829|EXPERIMENTAL|citrate of caffeine|
62304311|NCT01999829|PLACEBO_COMPARATOR|placebo|
62304312|NCT00608465|ACTIVE_COMPARATOR|Treatment A|Eplerenone (study drug)
62304313|NCT00608465|ACTIVE_COMPARATOR|Treatment B|Ramipril
62304314|NCT02039154|EXPERIMENTAL|Aerobic and strength training group|
62304315|NCT02039154|ACTIVE_COMPARATOR|Balance and flexibility group|
62304316|NCT01946009|EXPERIMENTAL|Cidofovir 1%|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
62675764|NCT06466772|EXPERIMENTAL|Consolidation arm|Hyper-personalized feedback-based motor rehabilitation with targeted auditory stimulation during sleep (HPF intervention, TASS verum intervention)
62675765|NCT04088357|ACTIVE_COMPARATOR|5 Percent TolaSure Topical Gel|5%(w/w) TolaSure Gel
62304317|NCT05255757|NO_INTERVENTION|No intervention|This group will only complete study survey and refer members of their family and social network for participation in a web survey.
62675766|NCT04088357|PLACEBO_COMPARATOR|Topical Vehicle Gel|Vehicle Gel
61918047|NCT06206343|EXPERIMENTAL|TENS application treatment program|"Conventional TENS will be performed for 3 weeks and 15 sessions. In this application, two electrodes will be placed on each side of the spinous processes of the patient's cervical region.~Two of them will be placed right and left, just below the skull, where the scalp ends, and the other two will follow them, about 5 cm away.~Care will be taken not to place the electrodes directly on your spine."
62472799|NCT03498794|ACTIVE_COMPARATOR|Ureteral stent|"Technique of ureteral stent insertion:~All patients will be in lithotomy position, and an endoscopy operating table with fluoroscopic imaging capability will be used. Before the procedures, all patients will have retrograde ureteropyelography. Then, a 0.035-inch hydrophilic guide wire will be placed into the renal pelvis under the guidance of flexible cystoscope.~The ureteral stent will be inserted retrograde by using flexible cystoscope, under mild sedation or local anesthesia by instilling 2% xylocain gel per urethra. Patients will be covered by specific antimicrobial therapy according to urine and/or blood culture. This treatment will be continued until there was no fever and any evidence of infection disappeared. A Foley's catheter will be left in the bladder for 2 hours in all patients. In each case the type of stent will be that of 5 or 6 F, with side-holes and remain in place until definitive treatment of stone."
62675767|NCT03808909|EXPERIMENTAL|Doula|Participants will be assigned a doula.
62675768|NCT03808909|NO_INTERVENTION|Control|Participants will not be assigned a doula.
61918048|NCT06206343|EXPERIMENTAL|Tele-rehabilitation application treatment program:|"Patients who accept the treatment will be evaluated before treatment. The treatment program will be done online for 3 weeks, 3 times a week. In the first session, neck anatomy and things to be considered in neck pain will be explained to the patient. In the following sessions, neck exercises will be performed with the participation of the patients.~Neck exercises: 1.Head rotation movements 2.Chin tuck 3.Neck isometric exercises 4.Shoulder shrug 5.Scapula approach 6.Isometric strengthening 7.Exercises against gravity 8.Stretching exercises etc. will be done."
61918049|NCT06206343|NO_INTERVENTION|Control group|"Control group patients will not receive any treatment. The first evaluation was done.~After 3 weeks, the second evaluation will be done again."
62304318|NCT05255757|EXPERIMENTAL|Script Intervention|This group will complete the survey, refer members of their family and social network for participation in a web survey, and review a set of suggested talking points and an example script to guide discussion of potential living donation with members of their network.
62675769|NCT00713180|NO_INTERVENTION|1|Pterygium free participants
62304319|NCT05255757|EXPERIMENTAL|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
62675770|NCT00713180|EXPERIMENTAL|2|Pterygium participants
62675771|NCT04920825|ACTIVE_COMPARATOR|Sacha Inchi Oil softgel|Oral Sacha Inchi oil softgel supplement
62675772|NCT04920825|PLACEBO_COMPARATOR|Corn oil softgel|Oral corn oil softgel
62675773|NCT02334254|EXPERIMENTAL|Dual antithrombotic therapy (DAT)|Dual Antithrombotic Therapy (DAT) regimen of rivaroxaban 2.5mg/5mg b.i.d. plus ticagrelor 90mg b.i.d.
62675774|NCT02334254|ACTIVE_COMPARATOR|Triple antithrombotic therapy (TAT)|Triple antithrombotic therapy (TAT) regimen of aspirin 100mg q.d., clopidogrel 75mg q.d. plus warfarin (INR 1.8-2.5).
62675775|NCT00797901|EXPERIMENTAL|Collaborative Care, Treatment as Usual|
62675776|NCT04242654|EXPERIMENTAL|Doppler ultrasound|Placement of Doppler US on chest to obtain newborn's heart rate.
62675777|NCT04242654|NO_INTERVENTION|Stethoscope|Placement of stethoscope on chest to obtain newborn's heart rate.
62675778|NCT03780322|EXPERIMENTAL|Armeo Spring Pediatric|This group will receive training with Armeo Spring Pediatric in 45 minute sessions, 3 times a week, for a total of 15 sessions
61918050|NCT05447741||Patients with fibromyalgia|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
61918051|NCT05447741||Patients with psoriasis arthritis|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
61918052|NCT05447741||Asymptomatic controls|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
61918053|NCT03149627||Individuals from selected households|Individuals residing in selected households in Lusaka Province, Zambia.
61918054|NCT03603509|ACTIVE_COMPARATOR|Fluad vaccine|Subjects receive a single dose of the Fluad influenza vaccine.
61918055|NCT03603509|ACTIVE_COMPARATOR|Fluzone vaccine|Subjects receive a single dose of the Fluzone High-Dose influenza vaccine.
61918056|NCT01499862|EXPERIMENTAL|Tibion Arm|Arm of the study in which enrolled post-stroke subjects undergo rehabilitative therapy with the Tibion Bionic Leg.
61918057|NCT02577471||During pregnancy|Pregnant ladies filled bowel function questionnaires
61918058|NCT02577471||After delivery|ladies within three weeks of delivery filled bowel function questionnaires
61918059|NCT02577471||Controls|Non pregnant ladies filled bowel function questionnaires
62304320|NCT05255757|EXPERIMENTAL|Both Search and Script Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation, and review a set of suggested talking points and an example script to guide discussion of potential living donation with members of their network.
62304321|NCT05813821|EXPERIMENTAL|Patients with antibiotic treatment in surgical departments|All patients admitted for antibiotic treatment in the surgical departments of the participating centres were included.
61918060|NCT00965328|ACTIVE_COMPARATOR|hemofiltration at 4L/h|Hemofiltration was started at 4L/h and crossed over to 2L/h after 60 minutes of hemofiltration
61918061|NCT00965328|ACTIVE_COMPARATOR|hemofiltration at 2L/h|hemofiltration was started at 2L/h and crossed over to 4L/h after 60 min
61918062|NCT01501084|ACTIVE_COMPARATOR|Exenatide|Exenatide injection 10 mcg subcutaneous
61918063|NCT01501084|PLACEBO_COMPARATOR|Saline|.2cc SC injection of sterile normal saline
61918064|NCT02477137|EXPERIMENTAL|Intervention group|In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
62675779|NCT03780322|ACTIVE_COMPARATOR|Conventional physical and occupational therapy|This group will receive combined physical and occupational therapy in 45 minute sessions, 3 times a week, for a total of 15 sessions.
61918065|NCT02477137|NO_INTERVENTION|Control group|Usual care according to the routines at the clinic.
61918066|NCT05934188||Young Healthy Subjects (N = 40)|"* 20-50 years old~* Cognitively healthy (Mini-Mental State examination ≥ 26)~* Absence of significant neurological disorders"
61918067|NCT05934188||Old Healthy Subjects (N = 40)|"* 60-90 years old~* Cognitively healthy (Mini-Mental State examination ≥ 26)~* Absence of significant neurological disorders"
61918068|NCT05934188||Patients with prodromal Alzheimer's Disease (N = 40)|"* Subjective cognitive complaint (corroborated by the informant)~* Episodic memory deficit on neuropsychological testing~* Clinical Dementia Rating = 0.5~* Mini-Mental State Examination (MMSE) \> 23~* Independently functioning in activities of daily living"
62304322|NCT03175523|ACTIVE_COMPARATOR|Imaging guided Bioresorbable scaffold|
62304323|NCT03175523|EXPERIMENTAL|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
62304324|NCT01480180|EXPERIMENTAL|Prophylaxis|
62304325|NCT01480180|EXPERIMENTAL|On-demand|
62304326|NCT04599426|EXPERIMENTAL|Test Group|10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.
62675780|NCT05112068||Control group|
61918069|NCT05934188||Patients with Parkinson's Disease (N = 40)|"* Recent diagnosis of Parkinson's Disease~* Mild-moderate score at the Unified Parkinson's Disease Rating Scale (UPDRS)~* Cognitively healthy (Mini-Mental State examination ≥ 26)~* In case of taking medications for Parkinson's Disease: stable dosage for at least 6 months"
61918070|NCT05934188||Patients with Multiple Sclerosis (N = 40)|"* Recent diagnosis of relapsing-remitting Multiple Sclerosis~* Expanded Disability Status Scale score ≤ 4.0~* Cognitively healthy (Mini-Mental State examination ≥ 26)~* In case of taking medications for Multiple Sclerosis: stable dosage for at least 6 months"
62675781|NCT05112068||Experimental group|
62675782|NCT02232321|OTHER|PsA MDA|
62304327|NCT05308147|OTHER|Arm 1 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62304328|NCT05308147|OTHER|Arm 2 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
61918071|NCT02103543|ACTIVE_COMPARATOR|Physical Therapy first|patients will undergo physical therapy 3-4 sessions followed by lumbar interlaminar epidural steroid injection
62304329|NCT05308147|OTHER|Arm 3 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62304330|NCT05308147|OTHER|Arm 4 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62304331|NCT05308147|OTHER|Arm 5 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62675783|NCT01362530|EXPERIMENTAL|Aprepitant Regimen|"Cycle 1:~Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to \<12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg).~Optional Cycles 2-6:~Open-label aprepitant administered in the same manner as in Cycle 1."
61918072|NCT02103543|ACTIVE_COMPARATOR|lumbar epidural steroid first|lumbar interlaminar epidural steroid injection followed by patients will undergo physical therapy 3-4 sessions
61918073|NCT01764802|ACTIVE_COMPARATOR|Arm I (enhanced standard care)|Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.
62304332|NCT05308147|OTHER|Arm 6 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62304333|NCT01983865|OTHER|Exposure to birch pollen|
62472800|NCT03498794|ACTIVE_COMPARATOR|Percutaneous nephrostomy tube|"Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively. The patients will be placed on the ultrasound table with fluoroscopic imaging capability in prone position and a pillow placed under the abdomen on the affected side to support the kidney. Then the initial puncture site will be chosen, cleaned and draped. Local anesthesia was injected and a stab incision was given at the puncture site. The 18-gauge Chiba needle will be inserted at the renal angle or at the posterior axillary line under ultrasound guidance into dilated pelvicalyceal system. Urine or pus drained out spontaneously or will be sucked with a disposable syringe and sample was sent to the laboratory for culture and sensitively."
62304334|NCT03215914|EXPERIMENTAL|Subjects with type 1 diabetes using MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
62472801|NCT04079088|PLACEBO_COMPARATOR|Placebo|Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
62304335|NCT04909567|EXPERIMENTAL|Intervention arm|"Optimisation:~Diet, organised exercise, psychosocial support"
62304336|NCT04909567|NO_INTERVENTION|Control arm|Current standard preparation before surgery
61918074|NCT01764802|EXPERIMENTAL|Arm II (psychological intervention)|Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.
61918075|NCT02153476|EXPERIMENTAL|2.0mg of ALG-1001|2.0mg of ALG-1001
61918076|NCT02153476|PLACEBO_COMPARATOR|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
61918077|NCT06046157|EXPERIMENTAL|Breast milk-scented PIOMI|During PIOMI application, the baby will be smelled his/her own breast milk.
61918078|NCT06046157|EXPERIMENTAL|Breast milk-tasting PIOMI|During PIOMI application, the baby will be able to taste his own breast milk. The finger on which PIOMI was applied will be immersed in breast milk.
61918079|NCT06046157|NO_INTERVENTION|Control|Only PIOMI application will be made.
61918080|NCT02022176|ACTIVE_COMPARATOR|Sodium nitrate|0.1 mmol NaNO3 / kg bodyweight / day for three days.
61918081|NCT02022176|PLACEBO_COMPARATOR|Sodium Chloride|0.1 mmol NaCl / kg bodyweight / day for three days.
61918082|NCT02022176|ACTIVE_COMPARATOR|Sodium nitrite infusion|Sodium nitrite (NaNO2) at a rate of 1, 10 and 100 nmol kg-1 min-1 (10 minutes per dose) was infused intravenously.
61918083|NCT02022176|PLACEBO_COMPARATOR|Saline infusion|Saline at a rate corresponding to 1, 10 and 100 nmol NaCl kg-1 min-1 (10 minutes per dose) was infused intravenously.
62304337|NCT05954754|EXPERIMENTAL|Diaphragmatic breathing exercise|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
62472802|NCT04079088|EXPERIMENTAL|BIIB061 Dose 1|Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
62472803|NCT04079088|EXPERIMENTAL|BIIB061 Dose 2|Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
62675784|NCT01362530|PLACEBO_COMPARATOR|Control Regimen|Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to \<12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
61918084|NCT02800876||asymptomatic not ruptured aneurysm|Patients with asymptomatic not ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
61918085|NCT02800876||symptomatic not ruptured aneurysm|Patients with symptomatic aortic aneurysms greater than 3 cm who received a clinical indicated CT
61918086|NCT02800876||symptomatic ruptured aneurysm|Patients with symptomatic ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
61918087|NCT02800876||patients with small aneurysms|Patients with small aortic aneurysms approximately 5.5 cm, ruptured and not ruptured, who received a clinical indicated CT
61918088|NCT05650554|EXPERIMENTAL|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose|participants will receive a single dose of QIV mRNA vaccine (low dose)
62472804|NCT04079088|EXPERIMENTAL|BIIB061 Dose 3|Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
62472805|NCT03218137|OTHER|Adenosine/ Verapamil Arm|"Adenosine: 0.84 mg/kg IV (140 mcg/kg/minute IV for 6 minutes) Verapamil: 0.15 mg/kg IV~Adenosine is known to terminate ventricular arrhythmias that are due to triggered activity (ref Lerman). To study the effects of adenosine on PVC, the investigators will administer Verapamil to slow down the heart initially and adenosine after catheters are introduced to patients who are being treated for symptomatic PVC and have consented to treatment with an invasive electrophysiology study and catheter ablation."
62675785|NCT03733483|EXPERIMENTAL|Sleep Deprivation|
62675786|NCT05922098|EXPERIMENTAL|experimental group|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
62675787|NCT05922098|NO_INTERVENTION|control group|Traditional Soft Food Care Manual
62675788|NCT01009242|EXPERIMENTAL|0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV|Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.
61918089|NCT05650554|EXPERIMENTAL|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5413 medium dose|participants will receive a single dose of QIV mRNA vaccine (medium dose)
61918090|NCT05650554|EXPERIMENTAL|Group 3: Quadrivalent Influenza mRNA Vaccine MRT5413 high dose|participants will receive a single dose of QIV mRNA vaccine (high dose)
61918091|NCT05650554|ACTIVE_COMPARATOR|Group 4: RIV4|participants will receive a single dose of RIV4 vaccine
61918092|NCT05650554|ACTIVE_COMPARATOR|Group 5: QIV-SD|participants will receive a single dose of QIV-SD vaccine
61918093|NCT05650554|ACTIVE_COMPARATOR|Group 6: QIV-HD|participants will receive a single dose of QIV -HD vaccine (for elderly only)
61918094|NCT02162576|OTHER|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
61918095|NCT04501562||Subject|
61918096|NCT01931176|EXPERIMENTAL|rDEN2Δ30-7169 vaccine|Participants will receive a single injection of the rDEN2Δ30-7169 vaccine at study entry.
62115684|NCT02071979|EXPERIMENTAL|Autologous PRP Gel|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. The application of topical PRP gel may be used in chronic wounds possessing an open, moist wound bed according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical application) data.
62115685|NCT02071979|EXPERIMENTAL|Autologous PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Autologous PRP Injections may be used where chronic wounds possess a raised, hyperproliferative wound margin and/or plaque, according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare Autologous PRP for injections. For data analysis, the data from these patients will be classified as PRP Treatment Group (Direct Injection) data.
62115686|NCT02071979|EXPERIMENTAL|Autologous PRP Gel plus PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Some wounds may be suitable for both Autologous PRP Gel plus PRP Injections. Autologous PRP injections into, or to the periphery of, a moist wound bed in which no scarification or raised wound margin is apparent (where autologous PRP Gel can also be used) may further augment wound healing by addressing wound healing in multiple areas, following the treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical and Direct) data.
62115687|NCT02071979|NO_INTERVENTION|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices. For data analysis, the data from these patients will be classified as Control (Standard of Care) Group data
62115688|NCT03986424|EXPERIMENTAL|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg once daily
62115689|NCT03986424|ACTIVE_COMPARATOR|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg twice daily
62304338|NCT05954754|NO_INTERVENTION|Control|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(Personal Information Form,Revised-Prenatal Coping Inventory (NuPCI), Fetal Health Anxiety Inventory (FHAI)) were re-administered 2 weeks later to women who did not receive any intervention.
62304339|NCT01953315|EXPERIMENTAL|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
62304340|NCT06584279||prostate biopsy|
62304341|NCT01870635|EXPERIMENTAL|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
62675789|NCT01009242|EXPERIMENTAL|1 mg/kg CDP6038 SC and Placebo SC|Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.
62675790|NCT01009242|EXPERIMENTAL|Optimized CDP6038 SC|Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.
62675791|NCT04980794|EXPERIMENTAL|Parent-Child Intervention|This is a four-dose intervention that includes psychoeducational modules and communication coaching administered through community organizations over the course of four weeks. Both participating adults and the participating child receive materials to review each week, paired with weekly contact from a family coach.
62675792|NCT04980794|ACTIVE_COMPARATOR|Self-study intervention|This is a four-dose intervention that include written self-study materials to review, paired with weekly contact with a family coach. Both participating adults receive self-study materials; the participating child does not receive separate materials.
62675793|NCT04348578|NO_INTERVENTION|control group|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL NaOCl and 5mL sterile saline in the control group.The root canals were dried with sterile paper points and were filled with gutta-percha and AH Plus sealer with the cold lateral condensation method and the entry cavity was restored with composite. All treatments were performed following a standardized procedure by one operator. After completion of the root canal treatment, periapical radiographs were taken using the paralleling technique. All the patients were called for follow-up examination at 12 months, and were examined radiographically.
62675794|NCT04348578|EXPERIMENTAL|QMix 2in1|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL Mix 2in1 and 5mL sterile saline in the experimental group.
62675795|NCT04167436|EXPERIMENTAL|Prehabilitation|Patients receive multi-modal prehabilitation with exercise three times weekly, protein supplements, vitamin supplements, dietitian consultation and medical optimization prior to surgery. A minimum of four weeks.
62675796|NCT04167436|NO_INTERVENTION|Standard of Care|Receives standard of care
62675797|NCT02452658|EXPERIMENTAL|Changed menu|All participants will be exposed to the same changed menu after making their hypothetical choice. Changes will include reduced calorie labels, reduced prices, and changes to item descriptions.
62675798|NCT01894360|EXPERIMENTAL|Belimumab 200 mg/mL, prefilled syringe|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe on Day 0.
62675799|NCT01894360|EXPERIMENTAL|Belimumab 200 mg/mL, Autoinjector|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe contained within an autoinjector device on Day 0.
62675800|NCT02541201|EXPERIMENTAL|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
62675801|NCT02541201|PLACEBO_COMPARATOR|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
62675802|NCT01439334|EXPERIMENTAL|Online Program Brief|Online Program Brief
62675803|NCT01439334|EXPERIMENTAL|Online Program Extended Length|Online Program Extended Length
62675804|NCT01439334|ACTIVE_COMPARATOR|Control|Control
62115690|NCT04028635|EXPERIMENTAL|Cognitive-behavioral therapy plus VR-based body exposure|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, six sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which the they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions, until a healthy BMI value is reached.
62304342|NCT01870635|PLACEBO_COMPARATOR|Placebo (sugar pill)|
62304343|NCT05034679||Vaciinated|First group patients who vaccinated and measure the AMH before and up to 9 months after vaccination.
62675805|NCT04727827|EXPERIMENTAL|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
62675806|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
62675807|NCT04359706||Covid-19 group|Critically ill patients with SARS-CoV-2 infection
62675808|NCT04359706||control group|Historical critically ill patients with no SARS-CoV-2 infection
62675809|NCT03401580|EXPERIMENTAL|Viena II - 160/10|Fixed-dose, 160mg +10 mg, orally, once daily.
62675810|NCT03401580|EXPERIMENTAL|Viena II - 190/10|Fixed-dose, 190mg + 10 mg, orally, once daily.
62675811|NCT03401580|EXPERIMENTAL|Viena II - 160/12|Fixed-dose, 160mg + 12 mg, orally, once daily.
61918097|NCT01931176|PLACEBO_COMPARATOR|Placebo|Participants will receive a single injection of placebo at study entry.
62304344|NCT05034679||Infected patients by covid-19 and not vacinated|Second group patients who were infected by Covid-19 ant therefor were not vaccinated
62304345|NCT05034679||Not infected nor vacinated|Ptients who who were not infected nor vacinated by Covid-19.
62304346|NCT00677950|EXPERIMENTAL|1|OP-1 Putty
62304347|NCT00677950|ACTIVE_COMPARATOR|2|Autograft
62472806|NCT02880761|EXPERIMENTAL|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
62675812|NCT03401580|EXPERIMENTAL|Viena II - 190/12|Fixed-dose, 190mg + 12 mg, orally, once daily.
62304348|NCT02981290|EXPERIMENTAL|Renodapt Then Mycept Then Cellmune Then CellCept|Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
62304349|NCT02981290|EXPERIMENTAL|Mycept Then CellCept Then Renodapt Then Cellmune|Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.
62304350|NCT02981290|EXPERIMENTAL|Cellmune Then Renodapt Then CellCept Then Mycept|Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
62472807|NCT02880761|NO_INTERVENTION|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
62675813|NCT05051358||Subjects undergoing Therapeutic Endoscopic Ultrasound|"Procedures that will be captured include:~EUS- ERCP, Endoscopic Hepatology - EUS, EUS-Coils placement, EUS Glue injection, EUS-Fiducial placement, EUS-Neurolysis, EUS-Stent placement, EUS-alcohol injection, EUS-guided Ablation, EUS-guided anastomosis, EUS Guided ERCP for gallbladder, pancreatic duct or biliary duct drainage, EUS guided - Hemostasis, EUS guided- Therapy for cancer or premalignant lesion (Injection, neurolysis, fiducial, aspiration, RFA ), EUS - Fluid Collection, abscess or cavity drainage, EUS - Guided Ductal Drainage, EUS - Guided Anastomosis"
62472808|NCT04039334|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 week. All exercise sessions will be performed at home.
61918098|NCT06043284||HBO Treatment Group|Children diagnosed with autism spectrum disorder received applied behavior therapy and hyperbaric oxygen therapy
61918099|NCT06043284||Control Group|Children diagnosed with autism spectrum disorder received applied behavioral therapy
62472809|NCT04039334|EXPERIMENTAL|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive creative dance based exercise training for 60 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised in a clinic per week.
62472810|NCT00144014|EXPERIMENTAL|V10153, 1.0 mg/kg|Single acute intravenous bolus dose
62675814|NCT03368521|OTHER|Back pain screening group|Includes the Group of patients where the care giver has used the back pain screening tests studied in order to judge how to proceed with rehabilitation, which level of rehabilitation is appropriate.
62115691|NCT04028635|ACTIVE_COMPARATOR|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the centre in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
62472811|NCT00144014|EXPERIMENTAL|V10153, 2.5 mg/kg|Single acute intravenous bolus dose
62472812|NCT00144014|EXPERIMENTAL|V10153, 5.0 mg/kg|Single acute intravenous bolus dose
62115692|NCT04476095|EXPERIMENTAL|Active PBMT|Active PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
62115693|NCT04476095|PLACEBO_COMPARATOR|Placebo PBMT|Placebo PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
62115694|NCT01367548|EXPERIMENTAL|Arm 1|
62115695|NCT01367548|PLACEBO_COMPARATOR|Arm 2|
62115696|NCT00587925|EXPERIMENTAL|1|Bone Mineral Density
62304351|NCT02981290|EXPERIMENTAL|CellCept Then Cellmune Then Mycept Then Renodapt|Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.
62472813|NCT00144014|EXPERIMENTAL|V10153, 7.5 mg/kg|Single acute intravenous bolus dose
62472814|NCT00144014|EXPERIMENTAL|V10153, 10 mg/kg|Single acute intravenous bolus dose
62472815|NCT00859430|EXPERIMENTAL|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
62472816|NCT00859430|ACTIVE_COMPARATOR|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
62472817|NCT00440518|PLACEBO_COMPARATOR|Placebo|Placebo
62115697|NCT05917249|EXPERIMENTAL|interventional|
62115698|NCT03023280||Patients undergoing radio frequency ablation|Patients undergoing radio frequency for large symptomatic heterotypic gastric mucosa
62115699|NCT00457691|EXPERIMENTAL|1|
62115700|NCT00457691|PLACEBO_COMPARATOR|2|
62115701|NCT04502511||Adult critically ill patients in the ICU|Acutely admitted to the ICU
62115702|NCT02127333||CAD patients with COPD|
62304352|NCT06411626||Participants with PNH|Participants with PNH
62304353|NCT02493751|EXPERIMENTAL|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
62472818|NCT00440518|EXPERIMENTAL|Lacosamide 100mg|100mg lacosamide
62472819|NCT00440518|EXPERIMENTAL|Lacosamide 300mg|300mg lacosamide
62472820|NCT00633451|EXPERIMENTAL|1|Manual Therapy + Exercise
62472821|NCT00633451|ACTIVE_COMPARATOR|2|Exercise Only
61918100|NCT04401527|ACTIVE_COMPARATOR|Sodium Nitrite|Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.
62115703|NCT02127333||CAD patients without COPD|
62115704|NCT02127333||healthy volunteers|
62472822|NCT02450682|ACTIVE_COMPARATOR|Apixaban|30 participants prescribed Apixaban 3-14 days before and 28 days after CIED procedure.
62675815|NCT03368521|NO_INTERVENTION|treatment as usual|The Group get treatment as usual, where the care giver base the rehabilitation plan without taking the scorings from the screening tool into consideration.
62675816|NCT06262997|ACTIVE_COMPARATOR|Pilates|Participants will receive an average of 1 hour of pilates training accompanied by a physiotherapist for 8 weeks, 2 days a week in groups of 2-3 people.
62675817|NCT06262997|EXPERIMENTAL|Pilates and Kinesiotape|They will receive exactly the same Pilates training as the patients in the Pilates group and in addition kinesio tape will be applied.
61918101|NCT04401527|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.
61918102|NCT03920072|OTHER|Open label|All subjects will be administered subcutaneously burosumab every 4 weeks at the dosage defined in study UX023-CL303 or UX023-CL304 until December 2021 or when the drug becomes commercially available.
61918103|NCT01985854|ACTIVE_COMPARATOR|Propofol|Propofol target-controlled infusion will be kept 2-4μg /ml plasma concentration throughout procedure.
62115705|NCT02401633|EXPERIMENTAL|CO-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions only
62304354|NCT00167622|ACTIVE_COMPARATOR|1|Physiotherapy, oxygen as needed
61918104|NCT01985854|EXPERIMENTAL|Desflurane|After taking off the electrophysiological monitoring from the patients, discontinue propofol and start desflurane from 6% (dialed concentration) at flow rate of 4L/min for 2 minutes in desflurane group. When achieve end tidal concentration of 4-5%, decrease the flow rate to 2L/min.
61918105|NCT05089071|EXPERIMENTAL|CADe group|Endoscopists perform colonoscopy with CADe system
61918106|NCT05089071|NO_INTERVENTION|Control|Endoscopists perform colonoscopy without CADe system
61918107|NCT00546221|EXPERIMENTAL|Psychosocial support|Comprising 22 participants engaging in the experimental exercise programme, exercising with psychosocial support.
61918108|NCT00546221|ACTIVE_COMPARATOR|Prescribed exercise|Comprising 21 participants engaging in a programme of typical prescribed exercise.
61918109|NCT03794960|EXPERIMENTAL|TOL-3021|
61918110|NCT03794960|PLACEBO_COMPARATOR|TOL-3021 Placebo|
61918111|NCT03838783|NO_INTERVENTION|Usual CSII|Continue to use the established CSII insulin therapy
61918112|NCT03838783|EXPERIMENTAL|Untethered CSII|Basal dosing - total CSII basal dose will be delivered by 50% through continuing CSII therapy used prior to study enrollment and 50% through the addition of once daily insulin degludec injected in the morning; Bolus dosing - continue the established bolus insulin dose
62115706|NCT02401633|ACTIVE_COMPARATOR|S-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions and rescue breaths in a 30:2 ratio
62115707|NCT04152616|EXPERIMENTAL|Optitrack®|Instrumental evaluation of posture
62115708|NCT02135341|EXPERIMENTAL|Group A: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
62115709|NCT02135341|EXPERIMENTAL|Group B: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
62115710|NCT04074577|ACTIVE_COMPARATOR|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. The first colonoscopy will be performed without automated polyp detection software (standard technique) followed immediately by another colonoscopy with automated polyp detection software (combination technique).
62304355|NCT00167622|EXPERIMENTAL|2|Mechanical ventilation
62304356|NCT02988648|EXPERIMENTAL|radioiodide (I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
62304357|NCT04240743|ACTIVE_COMPARATOR|cephalomedullary nail|Cephalomedullary nails was inserted and fixed to the femoral head. In this study, all patients were treated with short nails (Profin®, TST).
62675818|NCT03279068||Without Pattern Interpretation|All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
62675819|NCT03279068||With Pattern Interpretation|"All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM."
62304358|NCT04240743|ACTIVE_COMPARATOR|sliding hip screw|Sliding hip screws was inserted and fixed to the femoral head. In this study, all patients were treated with a side plate with three holes (DHS plate, TST).
62304359|NCT01887912|EXPERIMENTAL|C. difficile Vaccine Group|Participants received 1 injection of 0.5 mL C. difficile toxoid vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
62675820|NCT00625729|EXPERIMENTAL|Treated Patients|Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.
62675821|NCT04456270||Primary care patients with current asthma|Male and female primary care patients aged ≥18 years of age with clinically diagnosed asthma.
62675822|NCT03342794|OTHER|preexisting posterior capsule defects|congenital cataracts with a preexisting posterior capsule defect
62675823|NCT04459637||Asymptomatic group|Definition of asymptomatic disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
62675824|NCT04459637||Mild group|Definition of mild disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
62675825|NCT04459637||general-type group|Definition of general-type disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
62304360|NCT01887912|PLACEBO_COMPARATOR|Placebo Group|Participants received 1 injection of 0.5 mL placebo matched to vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
62675826|NCT04459637||severe group|Definition of severe disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
62304361|NCT01538771|PLACEBO_COMPARATOR|Control group|Received same volume of saline
62304362|NCT01538771|ACTIVE_COMPARATOR|Darbepoetin group|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning \& conventional treatment
62304363|NCT03446924|PLACEBO_COMPARATOR|Control|The control group will be given a single dose of 1.5 g rice flour in capsule form (250 mg / capsule). The gelatine capsules (MyProtein, Northwich, UK) used are identical to those used in the treatment group. Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
62304364|NCT03446924|ACTIVE_COMPARATOR|Treatment|"The treatment group will be given a single dose of 1.5g phosphatidic acid in capsule form (250 mg / capsule). Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).~PA is considered a dietary supplement ingredient according to the US FDA. The source of PA will be a commercial available soy-derived PA (Mediator®, Chemi Nutra, White Bear Lake, MN). The safety of Mediator® Soy-PA has been thoroughly demonstrated in humans. Mediator® Soy-PA does not contain any compounds with narcotic, psychotropic or pharmaceutical effects and is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Mediator® Soy-PA is not a medicinal product."
62675827|NCT04459637||critical group|Definition of critical disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
62675828|NCT00618566|EXPERIMENTAL|Oregon|
62304365|NCT04049825|EXPERIMENTAL|Dose Escalation Stage|The dose of OPB-111077 in the first cohort will be 200 mg/day, increasing as appropriate to 400 mg/day in the second cohort and then to 600 mg/day in the third cohort.
62115711|NCT04074577|ACTIVE_COMPARATOR|Combination +followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. In this arm, the first colonoscopy with be performed with automated polyp detection software (combination technique) followed immediately by another colonoscopy without automated polyp detection software (standard technique)
62115712|NCT05635604|ACTIVE_COMPARATOR|Eptinezumab and PACAP-38|The participants will receive an intravenous infusion of eptinezumab (300 mg) over 30 minutes followed (2 hours later) by an intravenous infusion of PACAP-38 (10 pmol/kg/min) over 20 minutes.
62115713|NCT05635604|PLACEBO_COMPARATOR|Placebo and PACAP-38|The participants will receive an intravenous infusion of placebo (saline) over 30 minutes followed (2 hours later) by an intravenous infusion of PACAP-38 (10 pmol/kg/min) over 20 minutes.
62304366|NCT04049825|EXPERIMENTAL|Dose Expansion Stage|4 days on and 3days off of 21-day cycles of OPB-111077 Day 1 of 21-days cycles of rituximab Day 2 and 3 of 21-day cycles of bendamustine
62472823|NCT02450682|OTHER|Warfarin|30 participants will take stable dose of warfarin and go through the procedure without drug interrupt. The dose is adjusted by INR level. Length of treatment is 42 days, 14 days before and 28 days after the procedure.
62472824|NCT04710862|ACTIVE_COMPARATOR|Breathing training with a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will perform exhalation exercises through a breathing device. Homework activities will be assigned. Post-training testing sessions will also be conducted.
62472825|NCT04710862|ACTIVE_COMPARATOR|Breathing training without a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will receive training on the use of breathing techniques without a device, but with visual feedback throughout training. Homework activities will be assigned. Post-training testing sessions will also be conducted.
62675829|NCT04617938|EXPERIMENTAL|TACUNA|Randomized participants will attend 3 virtual TACUNA workshops, focused on behavioral, physical, and spiritual domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use. They will also attend a Wellness Circle, focused on healthy social networks and engaging in traditional practices.
62115714|NCT04421391|EXPERIMENTAL|Treatment Arm|Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks
62115715|NCT01043263|EXPERIMENTAL|EN3324 (axomadol)|
62115716|NCT01043263|PLACEBO_COMPARATOR|Placebo|
62115717|NCT02522000||Patients with functional dyspepsia|
62304367|NCT02515669|ACTIVE_COMPARATOR|RO7239361|RO7239361 subcutaneous injections on specified days
62304368|NCT02515669|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injections on specified days
62304369|NCT01069848|EXPERIMENTAL|Vedera KXS|
62675830|NCT04617938|ACTIVE_COMPARATOR|Opioid education|Randomized participants will attend 1 virtual opioid education workshop, focused on behavioral and physical domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use.
62115718|NCT02522000||Healthy controls|
62115719|NCT03429062||personal training|Individuals with a diagnosis of MS and any level of function will be recruited to participate in exercise two times per week with trained personal trainers. Exercise consists of strengthening, stretching, balance, endurance and gait when able. Equipment to be used include treadmill, stationary bike, weight equipment.
62115720|NCT03429062||Whole Body Platform|Individuals with a diagnosis of MS and able to walk with or without an assistive device will be recruited to participate in whole body platform training two times per week with a physical therapist. The exercise on the whole body platform includes strengthening, balance, stretching, and endurance for 30 second bouts. The whole body platform is on for 30 seconds then off. Each exercise will use the 30 seconds to complete.
62304370|NCT05780866|OTHER|Video and Activity Tracker|
62304371|NCT01649492|NO_INTERVENTION|diclofenac without pineapple juice|single dose of diclofenac 25 mg without pre-exposure to pineapple juice
62304372|NCT01649492|ACTIVE_COMPARATOR|diclofenac with pineapple juice|single dose of diclofenac 25 mg with pre-exposure to pineapple juice
62304373|NCT01923064|ACTIVE_COMPARATOR|NBCA-lipiodol|Patients will receive injection of a mixture of cyanoacrylate and lipiodol to treat gastric varices
62472826|NCT04598828|EXPERIMENTAL|Treatment 1|Participants will receive Experimental treatment 1 stimulation for a duration of 12 weeks, twice daily for 19 minutes
62675831|NCT03511066|EXPERIMENTAL|CT-P27 90 mg/kg|CT-P27 will be administrated once in IV infusion.
62675832|NCT03511066|EXPERIMENTAL|CT-P27 45mg/kg|CT-P27 will be administrated once in IV infusion.
62675833|NCT03511066|PLACEBO_COMPARATOR|Placebo|Placebo will be administrated once in IV infusion.
62472827|NCT04598828|EXPERIMENTAL|Treatment 2|Participants will receive Experimental treatment 2 stimulation for a duration of 12 weeks, twice daily for 19 minutes
62675834|NCT06480812|ACTIVE_COMPARATOR|Synbiotic arm|Synbiotic mixure (10g prebiotic fibre + 170ml kefir) will be randomly allocated to eligible participants in order to test specific effects of the synbiotic mixture on gut microbiome composition and metabolic markers.
62675835|NCT06480812|PLACEBO_COMPARATOR|Control|Individuals in the control arm will not be provided with the test supplement and asked to carry on with their usual diet and lifestyle.
62675836|NCT04678960|NO_INTERVENTION|Standard Reentry Practice|Youth/safe adult participants only receive assessments (baseline assessment while youth are at the facility; 3, 6, 12, 18 months follow-up assessments after youth are released from the facility).
62675837|NCT04678960|EXPERIMENTAL|TBRI Training only|"Youth/safe adult dyads participate in 9 TBRI caregiver modules (caregivers only), 9 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After the youth's release, they would receive phone support (only when requested by the caregiver or youth)."
62115721|NCT04736849|EXPERIMENTAL|Percutaneous ES and DRS|Epidural Stimulation (ES) and Dorsal Root Stimulation (DRS) will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of ES and DRS will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
62115722|NCT02939378|EXPERIMENTAL|ketogenic diet group|Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
62115723|NCT02939378|OTHER|Standard diet group|Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
62115724|NCT00708032|OTHER|spectacles|habitual spectacles worn daily for 12 months
62115725|NCT00708032|EXPERIMENTAL|narafilcon A soft contact lenses|narafilcon A soft contact lenses worn as daily disposable for 12 months
62115726|NCT02214693|EXPERIMENTAL|Group 1(Severe decrease in GFR)|Severe decrease in GFR
62115727|NCT02214693|EXPERIMENTAL|Group 2(Moderate decrease in GFR)|Moderate decrease in GFR
62115728|NCT02214693|EXPERIMENTAL|Group 3(Mild decrease in GFR)|Mild decrease in GFR
62115729|NCT02214693|EXPERIMENTAL|Group 4(Normal GFR)|Normal GFR
62115730|NCT03382080|EXPERIMENTAL|Dream School Program (DSP)|The Dream School Program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
62115731|NCT03382080|EXPERIMENTAL|DSP and Mental Health Support Team|"A combination of the universal Dream Schoop Program (see description above) and the selective/indicative intervention Mental Health Support Team which is aimed at specific students at risk of dropping out of upper secondary school. It is a systematization of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school"
62115732|NCT03382080|NO_INTERVENTION|Control|The control group are upper secondary schools who run classes and the school as usual, and do not introduce new programs similar to the Dream School or Mental Health Support Team during the project period.
62115733|NCT00740415|EXPERIMENTAL|ARM RiBVD|"RiBVD 6 cycles every 28 days day 1 :~* Rituximab /Mabthera®, 375 mg/m2 en IV~* Bendamustine, 90 mg/m2 en IVD~* Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD~* Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD"
62115734|NCT00155558|EXPERIMENTAL|A|
62115735|NCT06229717||Children with sensorineural hearing loss|Children in the age of 3-10 years with either unilateral or bilateral sensorineural hearing loss is recruited at The Audiologic Clinic at Viborg Regional Hospital, Denmark
62304374|NCT01923064|EXPERIMENTAL|NBCA-lauromacrogol|Patients will receive injection of the mixture of cyanoacrylate and lauromacrogol to treat gastric varices
62304375|NCT00986960|ACTIVE_COMPARATOR|Adrenocorticotropin hormone|Patients receive the hormone
62304376|NCT00986960|PLACEBO_COMPARATOR|Placebo|Patients receive placebo only
62304377|NCT02522377|EXPERIMENTAL|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
62304378|NCT02522377|ACTIVE_COMPARATOR|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
62472828|NCT03974035|NO_INTERVENTION|Control Group|Patients undergoing elective bimaxillary osteotomy who receive a preincisional infiltration of lidocaine and adrenaline.
62304379|NCT01609933|EXPERIMENTAL|2-DAA + PegIFN/RBV|2-direct-acting antiviral (2-DAA: ABT-450 \[paritaprevir\] 200 mg once daily \[QD\], ritonavir 100 mg QD, ABT-267 \[ombitasvir\] 25 mg QD) plus pegylated interferon alpha-2a (pegIFN) 180 mcg once weekly and Ribavirin (RBV) weight-based dosing, 1000 to 1200 mg divided twice daily (BID) for 24 weeks (Substudy 1) and followed by pegIFN and RBV alone for an additional 24 weeks (Substudy 2).
62304380|NCT03645187|ACTIVE_COMPARATOR|FOLFERI|FOLFERI regien
62304381|NCT03645187|ACTIVE_COMPARATOR|FOLFERI and celecoxib|FOLFERI and celecoxib
62304382|NCT02296346|ACTIVE_COMPARATOR|Corticosteroid arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
62304383|NCT02296346|EXPERIMENTAL|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:~ECP will be administered according to the following schedule:~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
62115736|NCT01395225||All Patients|There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
62115737|NCT00481390||HIV-1 infected adults|HIV-1 infected adults
62304384|NCT00327444|PLACEBO_COMPARATOR|Placebo|"Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study."
62304385|NCT00327444|EXPERIMENTAL|Aflibercept|"Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study."
62304386|NCT02783781||Cardiac surgery|All patients (planned and urgent) needed cardiac surgery, and agreed to participate
62304387|NCT04377529|EXPERIMENTAL|Back Skills Training Champion|In additional to access to the online provider Back Skills Training course, participants in clusters randomised to this arm will receive additional support from a local champion. The local champion will have received additional training and support on the implementation of the Back Skills Training intervention from the study team.
62115738|NCT02001623|EXPERIMENTAL|Tisotumab Vedotin (HuMax-TF-ADC)|All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
62115739|NCT01466881|EXPERIMENTAL|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
62115740|NCT05039606|EXPERIMENTAL|the treatment group|Nedplatin combined with intensive radiotherapy group
62115741|NCT05039606|ACTIVE_COMPARATOR|the control group|Cisplatin was combined with the IMRT group
62115742|NCT01563991|ACTIVE_COMPARATOR|Standard fluid volume|Subject receives normal fluid volume during peri-operative period
62304388|NCT04377529|ACTIVE_COMPARATOR|No Champion|Participants in clusters randomised to this arm will not receive any additional training or support beyond access to the online provider Back Skills Training course.
62304389|NCT03545516|PLACEBO_COMPARATOR|Placebo|Wound infiltration with a placebo
62304390|NCT03545516|EXPERIMENTAL|Bupivacaine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL
62304391|NCT03545516|EXPERIMENTAL|Bupivacaine and Dexmedetomidine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .
62115743|NCT01563991|EXPERIMENTAL|Reduced Fluid Volume|Subject receives a reduced fluid volume during the peri-operative period
62115744|NCT02005094||Healthy group|patients without MAC/MAB lung disease and colonization
62304392|NCT02865369||Daclatasvir plus Asunaprevir treatment|Among patients taking Daclatasvir and Asunaprevir combined treatment and having advanced liver fibrosis assessed by transient elastography
62675838|NCT04678960|EXPERIMENTAL|TBRI Training + TBRI In-Home Structured Coaching|"Youth/safe adult dyads participate in 9 TBRI caregiver modules (caregivers only), 9 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads in which they meet 4 times (once monthly) over the first 4 months following release."
61918113|NCT02296879|EXPERIMENTAL|SAIT301|"For Stage 1, subjects will be sequentially assigned to 1 of approximately 8 cohorts comprised of 3 to 6 subjects each. SAIT301 will be administered according to a modified Fibonacci sequence and following a 3 + 3 design.~For Stage 2, the MTD or (RP2D) determined in the Stage 1 will be administered to additional subjects with selected diagnoses, 15 subjects per selected diagnosis. After completion of Stage 1 the SRC may elect to increase the interval between doses (i.e., increase cycle length to 28 days) based on the emerging PK data from the lower SAIT301 dose levels."
61918114|NCT04946227|EXPERIMENTAL|Single Arm|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor.
62115745|NCT02005094||MAC/MAB colonization group|patients with pulmonary MAC/MAB colonization
62115746|NCT02005094||MAC/MAB lung disease group|Patient with MAC/MAB lung disease
62115747|NCT06339489||POI Group|The patients with premature ovarian insufficiency
62115748|NCT01909778|EXPERIMENTAL|BI 201335|BI 201335 two single oral doses, separated by 14 days washout period
62115749|NCT01806454|ACTIVE_COMPARATOR|calcium A|tablets, 600mg per day,till birth
62115750|NCT01806454|ACTIVE_COMPARATOR|calcium B|tablets,1200mg per day,till birth
62115751|NCT01597258||Crizotinib (Xalkori)|
62115752|NCT04590287||Patients after ischemic stroke|The analysis included the presence of CVD risk factors in patients after ischemic stroke durning in the early rehabilitation.
62472829|NCT03974035|EXPERIMENTAL|Study Group|Patients undergoing elective bimaxillary osteotomy who receive two infiltrations (firstly pre-incision with lidocaine and adrenaline, secondly pre-extubation with ropivacaine).
62472830|NCT02198391||3 x 1 tablet per day|Echinaforce Junior tablets (low dose)
62115753|NCT04590287||Patients after hemorrhagic stroke|The analysis included the presence of CVD risk factors in patients after hemorrhagic stroke durning in the early rehabilitation.
62115754|NCT05774119|EXPERIMENTAL|breakfast with coffee|250 mL of water with 6 mg/caffeine/kg
62115755|NCT05774119|PLACEBO_COMPARATOR|breakfast with water|250 mL of water
62115756|NCT01521624|ACTIVE_COMPARATOR|Case|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
62115757|NCT01521624|NO_INTERVENTION|Control|Subjects provided only advice for lifestyle modification with no drug intervention
62115758|NCT03959241|ACTIVE_COMPARATOR|Tacrolimus/Methotrexate|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
62115759|NCT03959241|EXPERIMENTAL|Tacrolimus/MMF/PTCY|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
62115760|NCT04941924|EXPERIMENTAL|Intervention|Biliary stenting plus radio-frequency ablation of the bile duct
62115761|NCT04941924|ACTIVE_COMPARATOR|Control|Biliary stenting alone
62115762|NCT01174199|EXPERIMENTAL|Arm I|Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62115763|NCT00571818|ACTIVE_COMPARATOR|Euglycemic pancreas transplant recipients|Participants receiving a pancreas transplant who have blood glucose level is within the normal range
62115764|NCT00571818|ACTIVE_COMPARATOR|Hyperglycemic pancreas transplant recipients|Participants receiving a pancreas transplant who have high blood glucose (blood sugar)
62472831|NCT02198391||5 x 1 tablet per day|Echinaforce Junior tablets (high dose)
62472832|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
62472833|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
62472834|NCT05381688||ET VIM DBS patients|Essential tremor patients scheduled for VIM DBS
62472835|NCT05381688||DT VIM DBS patients|Dystonic tremor patients scheduled for VIM DBS
62675839|NCT04678960|EXPERIMENTAL|TBRI Training + TBRI In-Home Responsive Coaching|"Youth/safe adult dyads participate in 9 TBRI caregiver modules (caregivers only), 9 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads. They meet a minimum of 2 times during the first 2 months after release. Starting from Month 3, TBRI Practitioners would provide additional coaching when requested or when a research assistant (RA) identifies a need for additional coaching sessions."
62675840|NCT04626596|EXPERIMENTAL|ENG implant|Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
62675841|NCT01205737|EXPERIMENTAL|TL011|
61918115|NCT02218632|ACTIVE_COMPARATOR|lactose-free diet|lactose-free diet (standard therapy) vs. lactose-free diet plus temporary oral galactose supplements
62115765|NCT00571818|ACTIVE_COMPARATOR|Euglycemic Kidney Transplant Recipients|Participants receiving a kidney transplant who have blood glucose level is within the normal range
62115766|NCT00571818|ACTIVE_COMPARATOR|Euglycemic Healthy Control Participants|Participants who do not receive either a pancreas or kidney transplant who have blood glucose level is within the normal range
62675842|NCT01205737|ACTIVE_COMPARATOR|MabThera®|
62115767|NCT02422095||Pancreatic fluid collections|Patients with pancreatic fluid collections undergoing endoscopy-based (EUS-guided) interventions
62115768|NCT02422095||Pancreatic cysts|Patients with pancreatic cysts undergoing EUS examination and possible EUS-guided sampling of cystic fluid.
62115769|NCT03801551|EXPERIMENTAL|Patient|
62115770|NCT02066441|EXPERIMENTAL|Bio-D-Mulsion Forte®|Bio-D-Mulsion Forte® at a dosage level of 2 drops (4,000 IU) once daily for the 6-month treatment period.
62115771|NCT02066441|PLACEBO_COMPARATOR|Placebo|Placebo a dosage level of 2 drops once daily for the 6-month treatment period.
62115772|NCT06060002|ACTIVE_COMPARATOR|Group A - Patients will undergo stent removal and cholangiogram at 3 months of follow up|In group A, patients will undergo stent removal and cholangiogram at 3 months of follow up. If we detect recurrent stone/s on cholangiogram, clearance will be done accordingly. If the patient is dated for cholecystectomy beyond 3 months then stent exchange will be done and patient will be followed up till they undergo cholecystectomy. During this waiting period in the later group, patients will undergo monthly follow up for development of any new onset symptoms that are suggestive of biliary pain, pancreatitis, cholangitis and cholecystitis.
62115773|NCT06060002|SHAM_COMPARATOR|Group B - Patients will undergo endoscopic ultrasound (EUS) at 3 months of follow up.|"In group B, patients will undergo endoscopic ultrasound (EUS) at 3 months of follow up. If we detect recurrent stone/s in EUS then ERC and clearance will be done accordingly. Those who are dated for cholecystectomy beyond 3 months will undergo monthly follow up clinically (biliary pain, pancreatitis, cholangitis and cholecystitis) till they undergo cholecystectomy.~Those patient in group B who are unwilling for EUS will be requested to get an magnetic resonance cholangiopancreatography (MRCP) while those unwilling for both EUS/MRCP will be followed up with ultrasound abdomen and liver function test (LFT)."
62675843|NCT03983070|ACTIVE_COMPARATOR|Control Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 80% maximal Watts, and deadlifts at 60% of one-repetition maximum.
62472836|NCT03270462|OTHER|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
61918116|NCT02218632|ACTIVE_COMPARATOR|lactose free diet|lactose-free diet (standard therapy)
61918117|NCT04010539|EXPERIMENTAL|Participants receiving Gepotidacin|Participants will receive Gepotidacin orally at the study site during the Baseline (Day 1) visit followed by self-administration of a second oral dose as an outpatient 10 to 12 hours after the first dose.
61918118|NCT04010539|ACTIVE_COMPARATOR|Participants receiving Ceftriaxone plus Azithromycin|Participants will receive a single IM dose of Ceftriaxone plus a single oral dose of Azithromycin at the study site during the Baseline (Day 1) visit.
62472837|NCT01075893||Adenomatous polyp|Patients who have begun the polyp-cancer sequence (ie. are in polyp surveillance after excision of a prior adenomatous polyp) will be used to test those patients at higher risk of colorectal.
62472838|NCT01075893||Patients at normal risk of cancer|Patients found to have endoscopically and histological normal mucosa.
61918119|NCT03657966|EXPERIMENTAL|Standard of care chemotherapy + DCVAC/Ov|Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa
62304393|NCT05741021|EXPERIMENTAL|F520+Chemotherapy|"Cohort 1:~Treatment period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg), pemetrexed and carboplatin were administered sequentially by intravenous infusion (at least 30 min between doses).~Maintenance period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg) and pemetrexed were administered sequentially by intravenous infusion (at least 30 min between doses).~Cohort 2:~Treatment period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg), paclitaxel and carboplatin were administered sequentially by intravenous infusion (at least 30 min between doses).~Maintenance period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg) was administered sequentially by intravenous infusion (at least 30 min between doses)."
62304394|NCT06443086||Duodenal carcinoma patients|The patients included in this study were drawn from a hospital-based cohort and included cases diagnosed and treated at the facility. Inclusion criteria were histologically confirmed non-ampulla DA, including all stages of disease at diagnosis. Patients were excluded if they had ampulla cancer or other forms of gastrointestinal cancer, had incomplete medical records, or lost follow-up shortly after diagnosis. This rigorous selection process ensured the homogeneity of the study population and the relevance of the findings to non-ampulla DA.
62304395|NCT02109029|EXPERIMENTAL|Insulin Peglispro (LY2605541)|Part A Cohort 1: (low dose) priming dose (PD) of 2.00 units (U), 0.92 U/hour (U/h) constant infusion of insulin peglispro Part A Cohort 1: (high dose) PD of 8.00 U, 4.50 U/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 1) PD of 4.00 U, 1.84/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 2) PD of 6.0 U, 2.76 U/h constant IV infusion of insulin peglispro Part B Insulin Peglispro: PD of 6.00 U, 2.76 constant IV infusion of insulin peglispro and a constant infusion of 6 pico moles per kilogram per minute (pmol/kg/min). IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
62304396|NCT02109029|ACTIVE_COMPARATOR|Human Insulin|Constant IV infusion ( 6 pico moles per kilogram perminute \[pmol/kg/min\]) of human insulin for up to 36 hours. IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
62304397|NCT02624648|PLACEBO_COMPARATOR|Placebo Group|"The effects of Placebo on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
62304398|NCT02624648|EXPERIMENTAL|Maca (Lepidium Meyenii Walp) Group|"The effects of Lepidium Meyenii Walp on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
62472839|NCT01075893||Ulcerative colitis|Patients who are under surveillance for known ulcerative colitis will be used to test those patients at higher risk of colorectal.
62472840|NCT04171583||mucoid S. aureus|CF patients with mucoid S. aureus
62472841|NCT04171583||non-mucoid S. aureus|CF patients with non-mucoid S. aureus
62472842|NCT03006705|EXPERIMENTAL|Nivolumab group|"Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
62675844|NCT03983070|EXPERIMENTAL|Blood Flow Restriction and Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include the application of blood flow restriction during two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 40% maximal Watts, and deadlifts at 30% of one-repetition maximum. Blow flow restriction will be applied at 80% occlusion during both exercise modalities.
62675845|NCT03193385||Closed reduction|
62675846|NCT00538265|ACTIVE_COMPARATOR|A|tacrolimus + steroids
62675847|NCT00538265|EXPERIMENTAL|B|ATG+ tacrolimus without steroids in maintenance therapy
62675848|NCT00538265|EXPERIMENTAL|C|ATG+ Mycophenolate Mofetil + tacrolimus a reduced dosage without steroids in maintenance therapy
61918120|NCT03857373||Renal Cancer|Patients identified with RCC
61918121|NCT05058495|EXPERIMENTAL|mobile programme users|Patients will receive and use Mobile Lymphedema Self-Care Support Program application and will receive standart lymphedema education.
61918122|NCT05058495|ACTIVE_COMPARATOR|control group|Patients who will receive standart lymphedema education
61918123|NCT00137839|EXPERIMENTAL|Erlotinib|Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.
62304399|NCT05467085|EXPERIMENTAL|LIFU in OCD group|"Each subject will receive 3 LIFU sessions epr week for two weeks (6 total image-guided treatments).~A total of 20 sonications will be administered to one side of the head, with a derated (based on FDA standard of 0.3 dB/cm-MHz) spatial-peak temporal-average intensity (i.e., Ispta) of approximately 720mW/cm2, each lasting 30 s, separated by 30 s pause intervals. Thus, total duration of sonication will be 10 minutes, the same as used in our study of VS LIFU in healthy subjects. Sonication will be administered within a 3T Siemens Prisma scanner. During sonication, we will use the 20-channel head coil as the 32-or 64-channel coil does not allow enough space to fit the transducer.~In summary, the entire sequence of 20 sonications, each lasting 30s, separated by 30s pause intervals, will be administered over 20 minutes for a total duration of sonication equal to 10 minutes."
62472843|NCT03006705|PLACEBO_COMPARATOR|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
62675849|NCT06260839|EXPERIMENTAL|MRN guided minimally invasive surgery group|The intervention measures of the experimental group were to analyze the relationship between the shape of the contracture band, the distance between the sciatic nerve and the contracture band, and the external rotation angle according to the preoperative MRN manifestations of the patients, and to design the individualized surgical approach according to the imaging manifestations and perform MRN-assisted minimally invasive release.
62675850|NCT06260839|ACTIVE_COMPARATOR|Minimally invasive surgery group|In the control group, preoperative magnetic resonance imaging was only used to assist in the diagnosis and evaluation of gluteal muscle contracture, and the results of magnetic resonance imaging were not used to assist in the design of surgical approach. In the control group, non-MRN-assisted minimally invasive release was performed
62675851|NCT05877664|EXPERIMENTAL|Part1：Dose Escalation|"During the dose-escalation stage, an accelerated titration design (ATD) will be utilized for the first three lower dose groups (0.06, 0.12 and 0.18 mg/m\^2). The conventional 3+3 dose escalation method will be used for the subsequent dose groups. The entire duration of 21 days after the first dose of ZG0895.HCl is defined as the dose-limiting toxicity (DLT) observation period."
62304400|NCT05036785|ACTIVE_COMPARATOR|Suture removal at 7 days|Suture removal at 7 days post skin surgery
62304401|NCT05036785|ACTIVE_COMPARATOR|Suture removal at 10 days|Suture removal at 10 days post skin surgery
62304402|NCT01043640|EXPERIMENTAL|Transplant Patients|Includes patients who received allogeneic stem cell transplantation following treatment plan of Campath-1H, cyclophosphamide, cyclosporine A, mycophenolate mofetil, and busulfan.
62304403|NCT01748760|EXPERIMENTAL|CLASP-A intervention|Adolescent participants and parents will receive adjunctive psychosocial intervention.
62304404|NCT01748760|ACTIVE_COMPARATOR|Treatment as Usual|Adolescent participants and parents will not receive study intervention
62304405|NCT05282212||Dental Implant Surgery|Subjects scheduled for a revision surgery after developing infection after implant surgery
62304406|NCT04680923|EXPERIMENTAL|CPPLAI|Group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline in patients scheduled for laparoscopic sleeve gastrectomy.
62675852|NCT00465283|ACTIVE_COMPARATOR|Donepezil|
62115774|NCT04536441|EXPERIMENTAL|Treatment|Ultra Brief Online Mindfulness-based Intervention
62304407|NCT04680923|PLACEBO_COMPARATOR|Placebo|Group 2 (placebo) (n= 58) will receive intraoperative combined periportal and preperitoneal sterile water 40 ml in patients scheduled for laparoscopic sleeve gastrectomy.
62304408|NCT05330520|EXPERIMENTAL|Patients Who Completed 12 Months of Follow-Up Post Butterfly Implantation|Continuation study for Study BM-011-IL
62304409|NCT04063943|EXPERIMENTAL|Sidus Stem-Free Total Shoulder|This arm will include all subjects who are implanted with the Sidus Stem-Free Total Shoulder Arthroplasty System
62304410|NCT06656468||Leadless pacemaker patients|Consecutive patients undergoing leadless pacemaker patients
62472844|NCT01433497|EXPERIMENTAL|Experimental Arm A|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
62472845|NCT01433497|EXPERIMENTAL|Experimental Arm B|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
62675853|NCT00465283|PLACEBO_COMPARATOR|placebo|
62675854|NCT00250575|EXPERIMENTAL|1|
62675855|NCT05562635|EXPERIMENTAL|5 % polymers with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
62115775|NCT04536441|PLACEBO_COMPARATOR|Control|This arm requires participants to answer questions about themselves.
62115776|NCT02798718|ACTIVE_COMPARATOR|lactose digesters|Participants in arm 1 are grouped as lactose digesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is less than 20 ppm.
62115777|NCT02798718|ACTIVE_COMPARATOR|lactose maldigesters|Participants in arm 2 are also grouped as lactose maldigesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is not less than 20 ppm.
62304411|NCT00117962|EXPERIMENTAL|Std Tx + Pemetrexed|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on days 1, 22, 43, and 64. Patients also undergo thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
62472846|NCT01433497|PLACEBO_COMPARATOR|Placebo Comparator A|Participants receive placebo given orally twice daily.
62675856|NCT05562635|EXPERIMENTAL|10 % polymers with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
62675857|NCT05562635|PLACEBO_COMPARATOR|Placebo group|Application of polymers without CBD on the masseter muscles, bilaterally
62675858|NCT04210245|EXPERIMENTAL|Daily 0.3 mg dose|Administered by subcutaneous injection
62472847|NCT01433497|PLACEBO_COMPARATOR|Placebo Comparator B|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.
62675859|NCT04210245|EXPERIMENTAL|Daily 1 mg dose|Administered by subcutaneous injection
62675860|NCT04210245|EXPERIMENTAL|Daily 3 mg dose|Administered by subcutaneous injection
62675861|NCT04210245|PLACEBO_COMPARATOR|Placebo|Administered by subcutaneous injection
62115778|NCT05307991||Index PrEP participants|This group includes persons 15 years and older who are started on PrEP at the STI clinic. Participants in this group will be followed for 6 months, with follow-up visits at 1, 3, and 6 months, and will be asked to refer sexual partners from the preceding 6 months as well as any new sexual partners throughout the study period. They will also receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
62115779|NCT05307991||Non-PrEP participants|This group includes persons who are eligible to receive PrEP but who decline initiation at their index visit to the STI clinic. These participants will be followed for 6 months, with follow-up visits at 3 and 6 months, and receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. However, at any time during the follow-up period these persons can choose to initiate PrEP. This would not change their follow-up frequency nor their assigned group, and they would continue to be followed for 6 months from the date of initial enrollment. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
62115780|NCT05307991||Partner participants|This group is made up of named/referred partners from the Group 1 (Index PrEP participant) who are eligible for and agree to start PrEP. They will receive identical intervention to that of the Group 1, specifically: this group will be followed for 6 months, with follow-up visits at 1, 3, and 6 months, and will be asked to refer sexual partners from the preceding 6 months as well as any new sexual partners throughout the study period. They will also receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
62115781|NCT05307991||Providers|This group is made up providers involved in the provision of PrEP or other related services including STI management, HIV testing or counseling, or assisted partner notification (aPN). Examples include: clinicians, nurses, HIV testing/aPN counselors, registration staff, community tracers, and clinic management who provide clinical or aPN services. These participants will be asked to complete a survey responding to acceptability, feasibility, and appropriateness of the enhanced PrEP implementation strategy as an integrated strategy within the STI clinic. They will also participate in in-depth interviews. These activities will be completed at baseline and approximately 6 months thereafter.
62115782|NCT06545994||PCOS group|"Pregnant women between 18 and 40 years old who were diagnosed as polycystic ovary syndrome before pregnancy, registered in the OB \& GYN Hospital of Fudan University for prenatal check during the first trimester. The diagnostic criteria for PCOS are based on the 2003 Rotterdam diagnostic criteria.~Exclude healthy women with all other diseases that may have ovulation disorders or hyperandrogenism; There are other serious illnesses or complications present; Other endocrine disorders exist: thyroid diseases such as hyperthyroidism or hypothyroidism; During pregnancy, medication that may affect Kisspeptin or insulin levels, such as metformin or insulin therapy, is being used;"
62115783|NCT06545994||Control group|"Healthy pregnant women between 18 and 40 years old women without a history of PCOS.~Exclude healthy women with all other diseases that may have ovulation disorders or hyperandrogenism; There are other serious illnesses or complications present; Other endocrine disorders exist: thyroid diseases such as hyperthyroidism or hypothyroidism; During pregnancy, medication that may affect Kisspeptin or insulin levels, such as metformin or insulin therapy, is being used;"
62115784|NCT02519452|EXPERIMENTAL|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase \[rHuPH20\] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
62472848|NCT03531294|EXPERIMENTAL|Group 1|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based on OPTOS funds photos.
62472849|NCT03531294|EXPERIMENTAL|Group 2|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based leakage index of OPTOS wide field fluorescein angiography.
62675862|NCT03066375|EXPERIMENTAL|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
62675863|NCT05285163|EXPERIMENTAL|palliative care education|The patients in the intervention group were presented palliative care training in addition to their usual care. The training period lasts at least 45 minutes. After the training, patients were given the book 'Palliative Care in Heart Failure'. In this training, patients were informed about heart failure and pharmacological and non-pharmacological methods for symptoms such as dyspnea, pain, constipation, depression, edema, tiredness, nausea. The patients were followed up by telephone at the first, third, and sixth months after discharge. The patient's symptoms and quality of life were re-evaluated in telephone follow-up. During the follow-up period, the patient's training related to symptoms was repeated. The patients were referred to the physician for the symptoms and problems which they experienced in the house.
61918124|NCT03841305|ACTIVE_COMPARATOR|portal vein embolization|Liver preparation before major hepatectomy : portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.
62304412|NCT00117962|EXPERIMENTAL|Std Tx + Pemetrexed and Cetuximab|Patients receive pemetrexed disodium, carboplatin, and thoracic radiotherapy as in arm I. Patients also receive cetuximab IV over 2 hours on day 1 and then IV over 1 hour on days 8, 15, 22, 29, 36, and 43.
62304413|NCT03233048|EXPERIMENTAL|ORBERA™ Intragastric Balloon|Participants will have the ORBERA™ Intragastric Balloon inserted for 6 months. In addition, participants will have ongoing visits with a physician, dietitian, and psychologist before the balloon is inserted, while its in place, and for 6 months after the balloon is removed, for a total of approximately 1 year.
62115785|NCT02519452|EXPERIMENTAL|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase \[rHuPH20\] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
62304414|NCT01508676|ACTIVE_COMPARATOR|Pennsaid Phase I|Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
62304415|NCT01508676|PLACEBO_COMPARATOR|Placebo Phase I|Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
62304416|NCT00754390|EXPERIMENTAL|Overall Study|Participants consumed 4 experimental diets for 4 weeks each in randomized order
62304417|NCT06085066|ACTIVE_COMPARATOR|Conventional Ultrafiltration alone on Cardiopulmonary bypass|Conventional ultrafiltration was used on a cardiopulmonary bypass procedure for patients who underwent open heart surgery
62304418|NCT06085066|ACTIVE_COMPARATOR|Conventional Ultrafiltration followed by Modified Ultrafitration on Cardiopulmonary bypass|Modified ultrafiltration was used following the conventional ultrafiltration on cardiopulmonary bypass procedure for patients who underwent open heart surgery
62304419|NCT06447792||Group 1|immediately placed implants with a delayed loading protocol. Loading was performed after 3 months.
62304420|NCT06447792||Group 2|immediately placed implants with a progressive loading protocol. Loading was performed after 5 weeks.
62304421|NCT06447792||Group 3|immediately placed implants with an immediate loading protocol. The day of the surgery was also the day of loading.
62304422|NCT06656026|EXPERIMENTAL|ZSP1273(Arm a)|"* ≥2 ，\<6 year old，dose 1 QD；5day~* ≥6 ，\<12 year old，dose 2 QD；5day~* ≥12，≤17 year old，dose 3 QD；5day"
62304423|NCT06656026|EXPERIMENTAL|ZSP1273(Arm b)|"* ≥2 ，\<6 year old，dose 4 QD；5day~* ≥6 ，\<12 year old，dose 5 QD；5day~* ≥12，≤17 year old，dose 6 QD；5day"
62675864|NCT05285163|NO_INTERVENTION|usual care|Firstly, the usual care provided to patients was described. It was determined that patients were not given regular and comprehensive training on heart failure, and no training was given on palliative care. Written educational material was not given to the patients. Patients were not followed up after discharge. Palliative care was not discussed with patients and their relatives. Also, they were not asked about their preferences. In usual care, Heart failure patients received medical treatment for their symptoms during hospitalization.
62675865|NCT01512173|EXPERIMENTAL|propranolol gel|
62675866|NCT01512173|PLACEBO_COMPARATOR|Placebo|
62675867|NCT03570138|EXPERIMENTAL|Flash continuous glucose monitoring system|Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
62115786|NCT02519452|EXPERIMENTAL|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
62304424|NCT01813487|OTHER|HBsAg vaccine with Entecavir|
62304425|NCT02065778|EXPERIMENTAL|Stem Cells|autologous bone marrow mononuclear cell transplantation
62304426|NCT01585649|EXPERIMENTAL|XM22, 100 μg/kg BW|
62304427|NCT00677261|EXPERIMENTAL|1|
62304428|NCT00677261|EXPERIMENTAL|2|
62304429|NCT00677261|SHAM_COMPARATOR|3|
62304430|NCT03426059||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
62304431|NCT00553787|EXPERIMENTAL|VI-0521 Top|high dose experimental treatment
62304432|NCT00553787|EXPERIMENTAL|VI-0521 Mid|mid dose experimental treatment
62304433|NCT00553787|PLACEBO_COMPARATOR|Placebo|Placebo
62304434|NCT05394298|EXPERIMENTAL|Short-treatment of any active antibiotic regimen|7 days from the initiation of an appropriate antimicrobial therapy and documented resolution of bacteremia (negative control blood cultures performed on day 2 or 3)
62304435|NCT05394298|ACTIVE_COMPARATOR|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment from the date of the last positive blood culture and documented resolution of bacteremia (negative control blood cultures performed on day 2 or 3)
62304436|NCT01658800|EXPERIMENTAL|VAX161C vaccine|Subjects will be injected into the arm on 2 occasions during the study, once on Day 0 and then again on Day 21 with the vaccine VAX161C
62304437|NCT05117801|EXPERIMENTAL|children at the general practitioner or pediatrician|Children between 9 months and 3 years-old coming to their doctor for any consultation
62304438|NCT01381107|EXPERIMENTAL|ALKS 5461 (ALKS 33 and buprenorphine)|
62304439|NCT01381107|PLACEBO_COMPARATOR|Placebo|
62304440|NCT02579603|EXPERIMENTAL|Nintedanib|Nintedanib 150 mg bid
62304441|NCT02579603|EXPERIMENTAL|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
62304442|NCT01175512|ACTIVE_COMPARATOR|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
62304443|NCT01175512|PLACEBO_COMPARATOR|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
62304444|NCT01571271|EXPERIMENTAL|Electrohydraulic lithotripsy|Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method
62304445|NCT01571271|EXPERIMENTAL|Laser Lithotripsy|Laser Lithotripsy: Lithotripsy will be performed using laser method
62472850|NCT01746615|EXPERIMENTAL|30 Patients with BRVO in one eye|
62472851|NCT01746615|EXPERIMENTAL|30 healthy age and sex matched controls|
62675868|NCT03570138|ACTIVE_COMPARATOR|Standard self monitoring blood glucose system|Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
62304446|NCT02334267|ACTIVE_COMPARATOR|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
62304447|NCT02334267|ACTIVE_COMPARATOR|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
62304448|NCT05088317||Obese group|Volunteer female and male individuals aged 20-65 years, followed in an Internal Diseases unit of a state hospital in Turkey, diagnosed with obesity (BMI\> 30 kg/m\^2), who met the inclusion criteria of the study.
62304449|NCT05088317||Healthy group|Healthy male and female individuals between the ages of 20-65 who were not diagnosed with obesity and volunteered to participate in the study.
62304450|NCT01368068|EXPERIMENTAL|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
62675869|NCT01204281|EXPERIMENTAL|High assistance PAV+|Ventilatory support performed by PAV at 80% assistance (PB 840-plus) FiO2 and PEEP according to routine practice
62675870|NCT01204281|ACTIVE_COMPARATOR|Assist-control ventilation|Tidal volume, FiO2 and PEEP set according to routine practice
62675871|NCT04849000|EXPERIMENTAL|SHR-1209|
62675872|NCT04849000|PLACEBO_COMPARATOR|SHR-1209 Placebo|
62675873|NCT01126398||Ankle / dist. tibia fracture fixation|
62675874|NCT04428593|EXPERIMENTAL|Treamid 5 mg|Cohort 1 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 5 mg (4 subjects) or placebo (1 subject, see placebo arm).
62675875|NCT04428593|EXPERIMENTAL|Treamid 15 mg|Cohort 2 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 15 mg (4 subjects) or placebo (1 subject, see placebo arm).
62675876|NCT04428593|EXPERIMENTAL|Treamid 50 mg|Cohort 3 - 5 subjects were randomized in a 8:2 ratio to be treated either Treamid 50 mg (8 subjects) or placebo (2 subjects, see placebo arm).
62675877|NCT04428593|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm consists of 4 subjects (1 subject from Сohorts 1 and 2, 2 subjects from Cohort 3).
62675878|NCT03473301|EXPERIMENTAL|Allogeneic Umbilical Cord Blood|Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
62675879|NCT03473301|EXPERIMENTAL|Cord Tissue Mesenchymal Stromal Cells|Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
62115787|NCT02519452|EXPERIMENTAL|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
62675880|NCT03473301|ACTIVE_COMPARATOR|Natural History|Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.
62675881|NCT01078740||Non-CF subjects|Rectal tissue obtained from study subjects without cystic fibrosis (CF) as part of scheduled colonoscopy/biopsies performed for clinical care
62675882|NCT01078740||CF subjects|"Rectal tissue obtained from study subjects with cystic fibrosis (CF) in one of three ways:~* Rectal biopsy as part of scheduled colonoscopy/biopsies performed for clinical care~* Sigmoidoscopy/biopsy added onto a scheduled, unrelated procedure or surgery performed under general anesthesia~* Sigmoidoscopy/biopsy performed for the sole purpose of obtaining rectal tissue for the current study"
62675883|NCT04950907|EXPERIMENTAL|treatment|Uniportal VATS biopsy
62675884|NCT04950907|ACTIVE_COMPARATOR|control|CT-guided fine needle biopsy
62675885|NCT06042660||newly diagnosed CML patients|
62675886|NCT02302326|EXPERIMENTAL|Metformin|PCOS women began treatment with ER 500 mg metformin per day, and the dose was increased to 1000 mg after 2 weeks, and to 1700 mg/d after a further 2 weeks, and was maintained at this dose for a total of 12 weeks.
62675887|NCT02302326|EXPERIMENTAL|Myo-inositol + folic acid|PCOS women received a dietary supplement (Ovusitol® : 4 g myo-inositol plus 400 micrograms of folic acid) for 12 weeks
62675888|NCT02302326|NO_INTERVENTION|Healthy women|Healthy untreated women adjusted for age and body mass index
62115788|NCT02519452|EXPERIMENTAL|Part 3: Dara-CF 1800 mg|Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
62115789|NCT06429852|EXPERIMENTAL|DeST-ACT Intervention Group|Participants in the intervention group will undergo the DeST-ACT psychosocial intervention. This program includes a 4-session online intervention supplemented with self-help materials. These materials comprise concise texts designed to reinforce the skills covered in each session.
62115790|NCT06429852|NO_INTERVENTION|Waitlist Group|The other group will consist of participants on the wait-list. Similar to those in the intervention group, participants in the waitlist group will undergo research assessments at baseline, post-therapy, and 1 month after therapy. Subsequently, they will be included in the 4-session intervention program. No measurements will be taken after the intervention.
62115791|NCT04332666|PLACEBO_COMPARATOR|Placebo|Standard of care treatment
62675889|NCT02491060|EXPERIMENTAL|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
62304451|NCT01368068|ACTIVE_COMPARATOR|Escitalopram|10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
62675890|NCT02491060|PLACEBO_COMPARATOR|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
62115792|NCT04332666|EXPERIMENTAL|Study drug|Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h
62115793|NCT03799380|ACTIVE_COMPARATOR|Control - Standard of Care|Standard of care nutritional support
62115794|NCT03799380|EXPERIMENTAL|Experimental - Gatorade|Standard of care nutritional support with the addition of daily Gatorade G2
62675891|NCT02472951|ACTIVE_COMPARATOR|Type 2 diabetic subjects|
62115795|NCT01926002|EXPERIMENTAL|Low-Dose MK-8351|Low-dose MK-8351 administered as single inhaled dose.
62115796|NCT01926002|EXPERIMENTAL|High-Dose MK-8351|High-dose MK-8351 administered as a single inhaled dose.
62115797|NCT01926002|PLACEBO_COMPARATOR|Placebo to MK-8351|Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose.
62115798|NCT01779999||PICC-carrying patients|All patients carrying a peripherally inserted central catheter in our service
62115799|NCT03404583|EXPERIMENTAL|Person-centred care at distance|Person-centred care at distance through an eHealth platform
62115800|NCT03404583|NO_INTERVENTION|Usual Care|Evidence-based care
62115801|NCT02049866|EXPERIMENTAL|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.
62115802|NCT06002360|EXPERIMENTAL|Reach Out and Read|Families assigned to this group will receive Reach Out and Read education every two weeks between enrollment and when their infant reaches 36 weeks gestation.
62675892|NCT02472951|ACTIVE_COMPARATOR|Prediabetic subjects|
62675893|NCT02472951|ACTIVE_COMPARATOR|Healthy subjects|
62675894|NCT01810107||Children Examined with the OCT Probe|Children undergoing surgery will also have the Optical Coherence Tomography probe.
62675895|NCT01810107||Adults|Adults undergoing surgery will also have the Optical Coherence Tomography probe.
62115803|NCT06002360|NO_INTERVENTION|Control|Standard neonatal care
62115804|NCT06122896|EXPERIMENTAL|Pancreatic Cancer High-Risk Participants|"Study procedures will be conducted as follows:~* Baseline visit with questionnaires, blood tests, and pancreas screening procedure (EUS or MRI/MRCP).~* Pancreas screening procedures (Endoscopic ultrasound (EUS), or Magnetic Resonance (MRI)/Magnetic Resonance Cholangiopancreatography (MRCP), and collection of blood, stool, and saliva samples) every 12 months.~* Blood tests and questionnaires every 6 months.~* Follow up visits."
62115805|NCT04628572||Cohort 1|Eligible adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice
62115806|NCT00974025|EXPERIMENTAL|Vitamin C|High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks
62115807|NCT00974025|PLACEBO_COMPARATOR|Placebo|Placebo will be given in two-daily doses for four weeks
62115808|NCT03483662|EXPERIMENTAL|Multicomponent Intervention|Protocol-based treatment using the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification
62115809|NCT03483662|ACTIVE_COMPARATOR|Enhanced Usual Care|Webinar education session for providers on the new ACC/AHA hypertensive clinical guideline and the SPRINT study findings
62115810|NCT05712018|EXPERIMENTAL|0 ml/kg Hydroxyethyl starch coload group|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia
62115811|NCT05712018|EXPERIMENTAL|5 ml/kg Hydroxyethyl starch coload group|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
62115812|NCT05712018|EXPERIMENTAL|10 ml/kg Hydroxyethyl starch coload group|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
62115813|NCT03400462|EXPERIMENTAL|dry needling + oral appliance|Three visits are needed in this therapy method. Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd) Equipment: acupuncture needle 0,6\*13 e.g. Dragon Medical Device, solution for skin disinfection, sterile gauze. Exposition time : 30 minutes once a week
62115814|NCT03400462|EXPERIMENTAL|antiinflammatory drugs + splint therapy|"Patient's instruction for NSAID use:~Nimesulide 2\*100 mg/ 24 h- twice a day one pill of the 100 mg Nimesulide during 14 days"
62115815|NCT03400462|ACTIVE_COMPARATOR|splint therapy|"Splint therapy is an useful treatment method for several group of patients e.g TMD patients, patients with retrodiscitis, patients with muscle pain disorders like local muscle soreness or chronic myalgia.~The patients have been instructed to use the appliance during nighttime. After 7 days the patient had to came back for a control visit."
62115816|NCT03002246||Average for Gestational Age|This cohort will include a sample size of 90 subjects. Fetuses will have an estimated fetal weight greater than 10th percentile and less than 90th percentile based on clinical ultrasound assessment. This cohort will receive an ultrasound examination 4-7 days before their delivery.
62675896|NCT02626351|EXPERIMENTAL|Receiving/ received QI intervention|A clinic which is presently receiving the Intensive Phase of the QI intervention, or is in the Maintenance Phase
62675897|NCT02626351|ACTIVE_COMPARATOR|Not yet received QI intervention|A clinic which has not yet received the QI intervention
62675898|NCT05298969|EXPERIMENTAL|Flap survival|Harvesting temporalis myofascial flap for cranio-maxillofacial defects
62675899|NCT05238103|EXPERIMENTAL|Corrie Hybrid Cardiac Rehabilitation Program (Intervention Group)|Receives Corrie Virtual Cardiac Rehabilitation Program along with option to continue traditional, center-based cardiac rehabilitation.
62675900|NCT05238103|NO_INTERVENTION|Facilitated Center-Based Cardiac Rehabilitation Program (Control Group)|Receives traditional, center-based cardiac rehabilitation. The study team will help facilitate the logistics of receiving center-based cardiac rehabilitation, including proper referrals.
62675901|NCT06298864|EXPERIMENTAL|Internet-based Cognitive Behavioral Therapy (Internet-CBT)|Internet-CBT following ACS is exposure-based, centering on exposure to cardiac related symptoms and situations. The CBT is therapist-guided and lasts for 8 weeks.
62675902|NCT06298864|ACTIVE_COMPARATOR|Internet-based Cardiac Lifestyle intervention (Internet-CL)|Internet-CL is based on strategies for behavioral change and guidelines on health promoting lifestyle modifications following ACS. The Internet-CL is therapist-guided and lasts for 8 weeks.
62675903|NCT04448080|EXPERIMENTAL|Topical Anesthesia|topical tetracaine eye drops (3 times, given in 1 minute intervals) followed by topical Xylocaine 2% Gel (alcohol-free formulation), given in 1 minute intervals for a total of 5 minutes
62675904|NCT04448080|ACTIVE_COMPARATOR|Analgosedation|Remifentanil 1mg i.v., and, Thiopental i.v., adapted to patients' weight, age, and hepatic and renal function; usually, a bolus of 150-250mg
62675905|NCT04044287|ACTIVE_COMPARATOR|Intervention|200 micrograms of Misoprostol applied sublingually together with standard parenteral oxytocic therapy
62675906|NCT04044287|PLACEBO_COMPARATOR|Placebo|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy micrograms of misoprostol
62115817|NCT03002246||Large for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight greater than 90th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
62115818|NCT03002246||Small for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight less than 10th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
62115819|NCT02142348||osteoprosis research|
62675907|NCT01875276||Persistent Patients|Defined as those with ≥1 treatment for allergic rhinitis in the six months preceding the IPD (defined as the first script of the hay fever season - May to August)
62675908|NCT01875276||Seasonal Rhinitis|No treatment for allergic rhinitis in the six months preceding the IPD
62675909|NCT03380481||SECRETS-TCM|Stroke patients who treated by western medicine and/or traditional Chinese medicine in southern China
62304452|NCT01368068|PLACEBO_COMPARATOR|Placebo|Placebo arm containing sweetener has been approved and will be used as placebo arm.
62304453|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
62675910|NCT05364346||Pregnant women|Pregnant women in the area of South-East Brabant, The Netherlands
62675911|NCT03595722|EXPERIMENTAL|Early rectal cancer|Patients with early rectal cancer undergoing a treat and resect pathway - patients will be treated with high intensity focused ultrasound 7-10 days prior to the surgical resection of their rectal cancer
62675912|NCT03595722|EXPERIMENTAL|Late pelvic cancer|Patients with late pelvic (rectal, endometrial, cervical) cancer will undergo a treat and observe pathway - patients will be treated with high intensity focused ultrasound and their response will be observed
62675913|NCT05597891|EXPERIMENTAL|Investigational Device|The study design includes two cohorts: a Pre-Pivotal Cohort of up to 50 subjects (25 Feasibility and up to 25 Roll-Ins), and a Pivotal Cohort enrolling up to 131 subjects, to yield 100 evaluable subjects at 48 hours post procedure.
62675914|NCT03751748|SHAM_COMPARATOR|Control arm|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
62304454|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
62675915|NCT03751748|EXPERIMENTAL|AFR arm|Implantation of Occlutech atrial flow regulator (AFR) device
62304455|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
62304456|NCT01333189|EXPERIMENTAL|RELOAD: Weight-bearing biofeedback exercise|RELOAD participants participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games. These biofeedback training sessions were provided in addition to the standard of care rehabilitation that the CONTROL group received. Total dose of exercise across groups was matched.
62675916|NCT01528852|EXPERIMENTAL|CHX Cord application|Chlorhexidine cord application for 10 days
62675917|NCT01528852|ACTIVE_COMPARATOR|Control|Same liquid as intervention without the chlorhexidine used for cord cleaning for 10 days once daily
62675918|NCT01528852|NO_INTERVENTION|Dry Cord care|Use current recommended keep cord dry
62675919|NCT02035228|EXPERIMENTAL|Seated|"Patients breathing will be compared across a series of 9 trials in which unassisted breathing is compared to abdominal stimulation (SecondBreath) assisted breathing at various intensities. Each breathing trial will last for 2 minutes and will be conducted while the patient is seated. The following abdominal stimulation trials were included:~Abdominal Stimulation - low / early Abdominal stimulation - low/late Abdominal Stimulation - low/full Abdominal stimulation - med/early Abdominal stimulation - med/late Abdominal Stimulation - med/full Abdominal Stimulation - high/early Abdominal Stimulation - high/late Abdominal Stimulation - high/full"
62675920|NCT02035228|EXPERIMENTAL|6 minute step test|"Patients will complete a 6 minute step test with and without abdominal stimulation (SecondBreath).~Abdominal Stimulation - high/full"
62675921|NCT02209909|EXPERIMENTAL|aspirin continuation|Intervention : Low-dose aspirin (\< 100mg/day) is used before OPCAB surgery in the aspirin continuation group.
62304457|NCT01333189|ACTIVE_COMPARATOR|CONTROL: Standard of care exercise|CONTROL participants were provided two weeks of home rehabilitation (6 visits) by a physical therapist. Patients then progressed to outpatient rehabilitation, consisting of 4 weeks of treatment for a total of 6 weeks of standard of care rehabilitation. Total dose of exercise across groups was matched.
62675922|NCT02209909|EXPERIMENTAL|aspirin discontinuation|Intervention: Low-dose aspirin is stopped more than 4 days before OPCAB surgery in the aspirin discontinuation group.
62472852|NCT03224494|OTHER|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
62675923|NCT00186992|OTHER|Treatment|Eligible patients will be accessioned at the time of irradiation and undergo a pre-radiotherapy evaluation, treatment planning, image-guided radiotherapy delivery and intra-and post-irradiation evaluations.
62675924|NCT06154447|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-828.
62675925|NCT06154447|PLACEBO_COMPARATOR|Part A: Placebo|Participants will be randomized to receive placebo matched to VX-828.
62675926|NCT06154447|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-828. The dose levels will be determined based on the data from Part A.
62675927|NCT06154447|PLACEBO_COMPARATOR|Part B: Placebo|Participants will be randomized to receive placebo matched to VX-828.
62675928|NCT06154447|EXPERIMENTAL|Part C: Drug Drug Interaction|"Participants will receive a single dose of VX-828, followed by a washout period, Itraconazole administration, and concomitant administration of itraconazole and VX-828; or participants will receive Midazolam followed by VX-828 administration, and concomitant administration of VX-828 and Midazolam.~Part C will be an open-label optional cohort."
62675929|NCT00107289|EXPERIMENTAL|Radiation|
62675930|NCT05932680|EXPERIMENTAL|Off Drug Surveillance|Participants will stop receiving teclistamab and will be monitored closely for growth of their multiple myeloma. Participants will restart teclistamab if their multiple myeloma starts to grow.
62675931|NCT05573737|EXPERIMENTAL|Group Receiving Umbilical Cord Training|Oral umbilical care training will be given to the primiparous mothers who gave birth on odd days of the week and met the research criteria, and the training brochure will be printed out and given to the mothers. The training will be given face-to-face during the postpartum period when the mother is stabilized. In order to increase the effectiveness of the training, the content of the training will be reinforced by making mutual questions and answers.
62115820|NCT06462963|EXPERIMENTAL|single-fraction SBRT|"All lesions to be treated with radical radiotherapy will be treated with single-fraction SBRT, delivered using a dose ranging from 16 Gy to 34 Gy, depending on metastasis location. Acceptable ablative doses are developed in the protocol (see Section 6.4).~Radiotherapy treatment will last from one single visit to a few weeks, depending on the number of treated metastases."
62115821|NCT06462963|ACTIVE_COMPARATOR|multiple-fraction SBRT|All lesions to be treated with radical radiotherapy will be treated with multiple-fraction SBRT.
62472853|NCT03224494|OTHER|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
62675932|NCT05573737|NO_INTERVENTION|Group Without Umbilical Cord Training|The routine operation of the clinic will be carried out without any intervention for primiparous mothers who gave birth on even days of the week and met the research criteria.
62115822|NCT02020824|ACTIVE_COMPARATOR|Exposure without control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments without control.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
62115823|NCT02020824|EXPERIMENTAL|Exposure with control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments with the ability to control and secure these.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
62115824|NCT02020824|OTHER|Healthy volunteers|"20 healthy volunteers will be submitted to the same initial measurements in order to explore potential differences between them and the patients.~Imagery with functional MRI initial. Imagery with PET-scanner initial."
62115825|NCT04060537||Research|Patients with Renal Cell Carcinoma who have had previous systemic treatment, with adequate tissue samples and radiological data
62115826|NCT05922124|EXPERIMENTAL|Cefiderocol + ampicillin-sulbactam|Cefiderocol 2 gram intravenous (IV) q8 hours and ampicillin-sulbactam 3 gram IV q6 hours for patients with normal creatinine clearance, both administered as extended infusion of 3 hours. Dosing adjusted according to reduced and augmented renal clearance and to renal replacement therapies.
62115827|NCT05922124|ACTIVE_COMPARATOR|Colistin or colistin + meropenem|Colistin 9 million units (MIU) intravenous (IV) loading dose followed by 4.5 MIU for patients with normal creatinine clearance +/- meropenem 2 gram IV administered as extended infusion of 3 hours. Dosing adjusted according to reduced and augmented renal clearance and to renal replacement therapies.
62115828|NCT02534350|EXPERIMENTAL|Presatovir|Presatovir 200 mg (4 x 50 mg) on Day 1, followed by 100 mg (2 x 50 mg) from Day 2 to Day 14
62115829|NCT02534350|PLACEBO_COMPARATOR|Placebo|Placebo tablets for a total of 14 days
62115830|NCT02837497|NO_INTERVENTION|Control|Standard ICU resuscitation practices
62115831|NCT02837497|EXPERIMENTAL|ICU-RESUS CPR Improvement Bundle|ICU-RESUS bundle implementation: 1) point-of-care bedside CPR training; and 2) post-cardiac arrest debriefings.
62472854|NCT05536739|EXPERIMENTAL|Powered Hip Exoskeleton for Stroke Assistance|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
62472855|NCT02975622|ACTIVE_COMPARATOR|Subclavian|Subclavian vein will be individualized and approached by longitudinal incidence, according to previous studies. Skin puncture will be made next to the transducer, lateral to the first rib, maintaining constant visualization of the needle tip.
62675933|NCT05159011|NO_INTERVENTION|Usual Care|Virtual Genetic Counseling
62115832|NCT03185819|PLACEBO_COMPARATOR|Oral Midazolam + Intranasal Placebo|Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
62115833|NCT03185819|EXPERIMENTAL|Oral Placebo + Esketamine 84 mg|Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
62472856|NCT02975622|ACTIVE_COMPARATOR|Jugular|Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
62472857|NCT05017480|EXPERIMENTAL|CBP-201 Dose|CBP-201 Dose subcutaneous (SC) injection
62472858|NCT05017480|PLACEBO_COMPARATOR|Placebo|subcutaneous (SC) injection
62472859|NCT00820586|EXPERIMENTAL|Mononuclear bone marrow derived cells|Intramyocardial injection of total mononuclear bone marrow derived cells
62472860|NCT00820586|EXPERIMENTAL|Selected CD34+ bone marrow derived cells|Intramyocardial injection of selected CD34+ bone marrow derived cells
62472861|NCT00612287|EXPERIMENTAL|A|
62115834|NCT03185819|EXPERIMENTAL|Oral Placebo + Esketamine 56 mg|Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
62115835|NCT03185819|EXPERIMENTAL|Oral Placebo + Esketamine 28 mg|Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
62675934|NCT05159011|OTHER|Chatbot|computer program that that uses machine learning to provide tailored counseling to patients
62115836|NCT06232629|ACTIVE_COMPARATOR|Active Low-Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4-channel transducer Stimulation target = GPi Stimulation parameters = 5Hz and 10 Hz protocols at ISPPA=30 W/cm2
62115837|NCT06232629|SHAM_COMPARATOR|Sham Low-Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4-channel transducer Stimulation target = GPi and occipital cortex Stimulation parameters = for the passive sham protocol: GPi target (5Hz and 10 Hz protocols at 0 ISPPA) and for the active sham protocol: occipital target (5Hz and 10 Hz protocol at 30 ISPPA)
62115838|NCT01760837|OTHER|baked milk products, cow's milk allergy|to offer baked milk products to cow's milk allergic patients and to follow them for tolerance and if this intervention may have any impact on the natural history of milk allergy
62472862|NCT04057872|EXPERIMENTAL|TPE in Septic Shock|The patients will undergo a dosing trial to determine safety and the most effective dose
62472863|NCT03145493|EXPERIMENTAL|Usage of suction drains|Usage of suction drains
62115839|NCT01370694|EXPERIMENTAL|MK-8808 Combination Therapy|Participants received MK-8808 375 mg/m\^2 intravenously (IV) + cyclophosphamide 750 mg/m\^2 IV + vincristine 1.4 mg/m\^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m\^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m\^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.
62115840|NCT03774914||Lemtrada|Pregnant women exposed to LEMTRADA which is administered by IV infusion for 5 consecutive days, then for 3 consecutive days, 12 months after the first/previous treatment course
62115841|NCT03043638|EXPERIMENTAL|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
62115842|NCT03043638|ACTIVE_COMPARATOR|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
62115843|NCT05899179|EXPERIMENTAL|Left arm injection EC group|The Recombinant Mycobacterium tuberculosis fusion protein(EC) was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.
62115844|NCT05899179|ACTIVE_COMPARATOR|Right arm injection EC group|The Recombinant Mycobacterium tuberculosis fusion protein(EC) was injected intradermally into the volar side of the right forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the left forearm.
62115845|NCT05969665|EXPERIMENTAL|Wearing a smartwatch and glucose measuring device|The intervention will be wearing a smart watch as well as continuous glucose monitoring with direct feedback via an application. Participants will wear these devices for 3 months.
62472864|NCT03145493|NO_INTERVENTION|No usage of suction drains|No usage of suction drains
62472865|NCT01921894|EXPERIMENTAL|Cholecalciferol 4000 IU|Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
62115846|NCT05969665|NO_INTERVENTION|Standard care|The control group will be given the standard recommendations that all patients completing cardiac rehabilitation receive.
62115847|NCT00780663|EXPERIMENTAL|Quarfloxin|Single arm study - open label.
62115848|NCT04423328|EXPERIMENTAL|acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Shenmen→Neiguan→Hegu acupoints.
62472866|NCT01921894|EXPERIMENTAL|Cholecalciferol 2000 IU|Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
62472867|NCT01921894|ACTIVE_COMPARATOR|Cholecalciferol 200 IU|Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
62472868|NCT02235155||Pregnant women of 13-22 weeks gestation|Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.
62675935|NCT03607786|ACTIVE_COMPARATOR|RIVP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(28-30℃). The combination of selective antegrade cerebral perfusion and retrograde inferior vena caval perfusion is performed. The antegrade perfusion flow rate was is maintained at 6-12 mL/min/kg.Pump pressure of retrograde perfusion was is maintained at 20-30 mmHg, and blood flow was is maintained at 8-12 mL/min/kg.
62675936|NCT03607786|ACTIVE_COMPARATOR|ACP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(26-28℃). Only select antegrade cerebral perfusion is performed by maintaining the flow rate at 6-12 mL/min/kg.
62115849|NCT04423328|SHAM_COMPARATOR|sham acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Waiguan→Liangqiu→Tiaokou→ Chengshan acupoints
62115850|NCT03336450|EXPERIMENTAL|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram \[mg/kg\] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
62115851|NCT06600425|EXPERIMENTAL|PCD Participants|RCT1100 mRNA therapy supplied to eligible participants with with Primary Ciliary Dyskinesia caused by disease-causing mutations in the DNAI1 gene
62115852|NCT00980135|EXPERIMENTAL|Arm 1|
62675937|NCT04521166|EXPERIMENTAL|Setting 1|Hearing aid features presented in this arm include omnidirectional microphone settings and fast-acting compression
62675938|NCT04521166|EXPERIMENTAL|Setting 2|Hearing aid features presented in this arm include omnidirectional microphone settings and slow-acting compression
62115853|NCT00980135|EXPERIMENTAL|Arm 2|
62115854|NCT00980135|OTHER|Arm 3|
62675939|NCT04521166|EXPERIMENTAL|Setting 3|Hearing aid features presented in this arm include directional microphone settings and fast-acting compression
62675940|NCT04521166|EXPERIMENTAL|Setting 4|Hearing aid features presented in this arm include directional microphone settings and slow-acting compression
62675941|NCT03294655|NO_INTERVENTION|No contact control|the no contact control group will do nothing
62675942|NCT03294655|EXPERIMENTAL|Intervention|the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks
62675943|NCT04985656|EXPERIMENTAL|Pevonedistat 20 mg/m^2 + Decitabine 35 mg + Cedazuridine 100 mg|Pevonedistat 20 mg/m\^2, 60-minute intravenous (IV) infusion, once daily, on Days 1, 3, and 5 in each 28-day cycle in combination with decitabine 35 mg and cedazuridine 100 mg tablets, orally, once daily on Days 1 through 5 in each 28-day cycle up to 30 months.
62675944|NCT00563563|EXPERIMENTAL|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg daily subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
62675945|NCT03892915|EXPERIMENTAL|Depression Care|Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.
62675946|NCT03892915|NO_INTERVENTION|Usual care|Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).
62675947|NCT00018798||Bi-weekly telephone calls|34 participants received bi-weekly telephone calls in addition to the annual reviews
62115855|NCT05818904||Healthy|Healthy group is recruited. They would not receive any intervention. The ultrasound imaging data will be collected to serve as the comparison for no fibrosis joint.
62115856|NCT05818904||Arthrosis of knee|People with arthrosis of the knee joint will be treated using the traditional intervention, which includes physical therapy. The ultrasound imaging will be collected before the intervention and at 3-month. The imaging data will be used to build a imaging model using the machine learning method.
62115857|NCT05818904||arthrosis of shoulder|People with arthrosis of the shoulder joint will be treated using the traditional intervention, which includes physical therapy. The ultrasound imaging will be collected before the intervention and at 3-month. The imaging data will be used to build a imaging model using the machine learning method.
62115858|NCT05733936|EXPERIMENTAL|criterion-based rehabilitation protocol|It's a three phases rehabilitation protocol with a goal-based progression which include a three criterion based postoperative phases: (1) impairment phase, (2) sport-specific training phase and (3) return to play phase. Patients can start with the next phase only if specific goals of the previous phase are achieved
62115859|NCT05733936|ACTIVE_COMPARATOR|accelerated rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
62115860|NCT03356444|EXPERIMENTAL|Abiraterone group|Abiraterone acetate is administered in this arm.
62115861|NCT03356444|ACTIVE_COMPARATOR|Docetaxel group|Docetaxel is administered in this arm.
62115862|NCT00754936|EXPERIMENTAL|Escitalopram|12 week open label with 2 week placebo period (14 weeks total)
62115863|NCT03426683|EXPERIMENTAL|Standardized IMT|The patients will receive Standardized Intestinal Microbiota Transplantation(Standardized IMT). The IMT was given to mid-gut by nose-jejunum nutrition tube or capsules. It was given three times a week.
62115864|NCT03426683|NO_INTERVENTION|traditional drugs|The patients will receive traditional medicine treatment as usual.
62115865|NCT04455399|OTHER|Intravitreal injection guide|Single use, combination ocular surface caliper to determine point of intravitreal injection and set-depth injection guide to limit injection needle entry into the eye
62115866|NCT04455399|OTHER|Dual blade eyelid speculum|Dual blade eyelid speculum to open eyelids followed by Castroviejo surgical caliper to measure injection point 3.5 mm from limbus
62115867|NCT01134354||TEFTOM|Patient outcome measure
62115868|NCT01287052|EXPERIMENTAL|Nitrous Oxide|
62472869|NCT04776330|EXPERIMENTAL|BCMA targeted prime CAR-T cells treat|Patients will be be treated with BCMA targeted prime CAR-T cells
62675948|NCT00018798||Annual review only|23 participants received annual reviews only
62675949|NCT01509209|PLACEBO_COMPARATOR|Placebo|placebo
62675950|NCT01509209|EXPERIMENTAL|Cossac L|Pseudoephedrine 120mg + Levocetirizine 2.5mg
62675951|NCT01179620|EXPERIMENTAL|Certoparin|
62115869|NCT02787161|ACTIVE_COMPARATOR|Hemodialysis|Patients who are treated with high flux hemodialysis will continue the same treatment with high flux hemodialysis.
62115870|NCT02787161|EXPERIMENTAL|Hemodiafiltration|Patients who are treated with high flux hemodialysis will be switched to hemodiafiltration for 6 months.
62115871|NCT04628286|PLACEBO_COMPARATOR|Sham Laser|Placebo laser application in plantar fascia
62675952|NCT02614066|EXPERIMENTAL|Phase 1: 2 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with relapsed or refractory B-precursor acute lymphoblastic leukemia (r/r B-ALL) will receive conditioning chemotherapy (fludarabine 25 mg/m\^2 intravenously \[IV\] over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel (KTE-X19) chimeric antigen receptor (CAR) transduced autologous T cells at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 2 x 10\^8 anti-CD19 CAR T cells/kg of body weight will be administered.
62675953|NCT02614066|EXPERIMENTAL|Phase 1: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight will be administered.
62115872|NCT04628286|EXPERIMENTAL|Experimental group Myofascial Induction|Myofascial Induction technique application in plantar fascia
62675954|NCT02614066|EXPERIMENTAL|Phase 1: 0.5 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 0.5 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 0.5 x 10\^8 anti-CD19 CAR T cells/kg of body weight will be administered.
62675955|NCT02614066|EXPERIMENTAL|Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 1 x 10\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \> 100 kg, a maximum flat dose of 1 x 10\^8 anti-CD19 CAR T cells/kg of body weight will be administered.
62675956|NCT06106295|EXPERIMENTAL|Mild Autonomous Cortisol Secretion (MACS) Open Label Phase and Optional Extension Phase|Subjects diagnosed with Mild Autonomous Cortisol Secretion (MACS) will receive metyrapone for a 6 month treatment period (Open Label Phase) with the option to continue for an additional 30 months of metyrapone therapy. If a patient chooses to participate in the Optional Extension Phase they will continue to receive metyrapone therapy until Month 36. This is an additional 30 months of therapy after completion of the Open Label Phase.
62115873|NCT05489406|ACTIVE_COMPARATOR|Single-dose DTG 30 mg|Healthy volunteers receiving a single-dose DTG 30 mg as 6X5 mg dispersible tablets (DT) as a dispersed suspension in a fasted state. Samples will be taken pre-dose (t=0) and 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, and 48 hours post ingestion.
62115874|NCT05489406|ACTIVE_COMPARATOR|Single-dose F/TAF 180/22.5 mg|Healthy volunteers receiving a single-dose F/TAF 180/22.5 mg as 3X60/7.5 mg TOS as a dispersed suspension in a fasted state. Samples will be taken pre-dose (t=0) and 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, and 48 hours post ingestion.
62115875|NCT05489406|EXPERIMENTAL|Single-dose DTG 30 mg and F/TAF 180/22.5 mg|Healthy volunteers receiving a single-dose F/TAF 180/22.5 mg as 3X60/7.5 mg TOS + DTG 30 mg as 6X5 mg DT as a co-dispersed suspension in a fasted state. Samples will be taken pre-dose (t=0) and 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, and 48 hours post ingestion.
62115876|NCT03444506|PLACEBO_COMPARATOR|Placebo nasal spray|Placebo nasal spray - 2 sprays per nostril, BID
62115877|NCT03444506|EXPERIMENTAL|Molo 1 (also referred as GSP 301-2 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID
62115878|NCT03444506|EXPERIMENTAL|Molo 2 (also referred as GSP 301-1 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD
62115879|NCT03444506|ACTIVE_COMPARATOR|DYMISTA nasal spray|Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID
62115880|NCT03444506|ACTIVE_COMPARATOR|PATANASE nasal spray|Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID
62115881|NCT02690090||enoxaparin|enoxaparin prophylaxis as directed by treating Intensivist
62115882|NCT04874415|EXPERIMENTAL|Condition 1|1RLD=One text per day, ramped goal, loss incentive, daily goal time period.
62115883|NCT04874415|EXPERIMENTAL|Condition 2|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
62115884|NCT04874415|EXPERIMENTAL|Condition 3|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
62115885|NCT04874415|EXPERIMENTAL|Condition 4|1RGW=One text per day, ramped goal, gain incentive, weekly goal time period.
62115886|NCT04874415|EXPERIMENTAL|Condition 5|2RLD=Two texts per day, ramped goal, loss incentive, daily goal time period.
62115887|NCT04874415|EXPERIMENTAL|Condition 6|2RLW=Two texts per day, ramped goal, loss incentive, weekly goal time period.
62115888|NCT04874415|EXPERIMENTAL|Condition 7|2RGD=Two texts per day, ramped goal, gain incentive, daily goal time period.
62115889|NCT04874415|EXPERIMENTAL|Condition 8|2RGW=Two texts per day, ramped goal, gain incentive, weekly goal time period.
62115890|NCT04874415|EXPERIMENTAL|Condition 9|1FLD=One text per day, fixed goal, loss incentive, daily goal time period.
62115891|NCT04874415|EXPERIMENTAL|Condition 10|1FLW=One text per day, fixed goal, loss incentive, weekly goal time period.
62115892|NCT04874415|EXPERIMENTAL|Condition 11|1FGD=One text per day, fixed goal, gain incentive, daily goal time period.
62115893|NCT04874415|EXPERIMENTAL|Condition 12|1FGW=One text per day, fixed goal, gain incentive, weekly goal time period.
61918125|NCT03841305|EXPERIMENTAL|liver venous deprivation|Liver preparation before major hepatectomy : Patients with the liver venous deprivation (LVD) technique that combines both PVE and hepatic vein embolization (HVE) during the same procedure.
62115894|NCT04874415|EXPERIMENTAL|Condition 13|2FLD=Two texts per day, fixed goal, loss incentive, daily goal time period.
62115895|NCT04874415|EXPERIMENTAL|Condition 14|2FLW=Two texts per day, fixed goal, loss incentive, weekly goal time period.
62115896|NCT04874415|EXPERIMENTAL|Condition 15|2FGD=Two texts per day, fixed goal, gain incentive, daily goal time period.
62115897|NCT04874415|EXPERIMENTAL|Condition 16|2FGW=Two texts per day, fixed goal, gain incentive, weekly goal time period.
62115898|NCT06316206|NO_INTERVENTION|Control|Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
61918126|NCT02859818|OTHER|adolescents with type 1 diabetes|adolescents with type 1 diabetes following their participation in therapeutic education program
61918127|NCT04390555||CV involvement|Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).
61918128|NCT04390555||Control|Patients with COVID-19 without preexisting cardiac involvement.
62115899|NCT06316206|EXPERIMENTAL|Treatment|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
62115900|NCT03123172|OTHER|co2 gap|arterial and central venous blood gases to measure Co2 gap
62115901|NCT01374893|ACTIVE_COMPARATOR|Exercise|
62115902|NCT01374893|PLACEBO_COMPARATOR|Control group|Usual care
62115903|NCT04282304|OTHER|Usual Care|The patients in this arm will have usual care during preoperative period, bariatric surgery and follow-up.
62115904|NCT04282304|EXPERIMENTAL|UGECAM|During the preoperative period, the patients in this arm will have usual care and a 4 weeks intensive, comprehensive behavioral lifestyle intervention. They will then have usual bariatric surgery and follow-up.
62115905|NCT00831935||Depressed|Depressed individuals, as identified by their referring physician.
62115906|NCT00831935||Non-depressed|Non-depressed individuals, confirmed to be non-depressed by the Centers for Epidemiological Studies Depression Scale (CES-D).
62115907|NCT02940704|EXPERIMENTAL|Reciproc|"* Reciproc (VDW, Munich, Germany) is a single file reciprocating system for mechanical instrumentation of root canals.~* Size: R40 (40/0.06)"
62115908|NCT02940704|ACTIVE_COMPARATOR|One Shape|"* One Shape (MicroMega, Besançon Cedex, France) is a single file system that works by continuous rotation for mechanical instrumentation of root canals.~* Size: 25/0.06"
62115909|NCT06552676||Percutaneous tracheostomy|Patients receiving percutaneous tracheostomy for any reason during their ICU stay
62115910|NCT02682537||Female, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 Years
62115911|NCT02682537||Female, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
62115912|NCT02682537||Female, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
62115913|NCT02682537||Female, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
62115914|NCT02682537||Female, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
62115915|NCT02682537||Female, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
62115916|NCT02682537||Female, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
62115917|NCT02682537||Female, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
62115918|NCT02682537||Female, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
62115919|NCT02682537||Male, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 years
62115920|NCT02682537||Male, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
62115921|NCT02682537||Male, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
62115922|NCT02682537||Male, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
62115923|NCT02682537||Male, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
62115924|NCT02682537||Male, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
62115925|NCT02682537||Male, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
62115926|NCT02682537||Male, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
62115927|NCT02682537||Male, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
62115928|NCT05617586||DCD Parents|An in-depth interview will be conducted of parents of a child with DCD. Parents will be asked to complete a Developmental Coordination Disorder Questionnaire (DCD-Q).
62115929|NCT04747392|OTHER|Sequence A|The test drug (SAL001) is administrated once by subcutaneous injection in the first period, and the reference drug (FORSTEO) is administrated once by subcutaneous injection in the second period.
62115930|NCT04747392|OTHER|Sequence B|The reference drug (FORSTEO) is administrated once by subcutaneous injection in the first period, and the test drug (SAL001) is administrated once by subcutaneous injection in the second period.
62115931|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
62115932|NCT02079324|EXPERIMENTAL|GX-051|GX-051 intratumoral injection
62115933|NCT04039984|EXPERIMENTAL|Prime Cup|The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm CoCr femoral head, articulating on a highly crosslinked acetabular liner.
62115934|NCT01069341|OTHER|Treatment|All subjects enrolled received treatment with identical dosage of Ranibizumab
62115935|NCT04273412|EXPERIMENTAL|lifestyle intervention (LI)|moderate-intensity lifestyle intervention (Individualised counseling on diet, physical activity, and target weight gain) by license dietitian
62115936|NCT04273412|NO_INTERVENTION|usual standard care group (UC)|standard antenatal care as per usual clinic protocol
62115937|NCT00354640|EXPERIMENTAL|Anastrozole and Simvastatin|This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.
62115938|NCT01018212|EXPERIMENTAL|A|Cicatrix cream
62115939|NCT01610479|EXPERIMENTAL|TAS-114/S-1|TAS-114 plus S-1
62115940|NCT04892290||Group C|Postdural puncture headache patients treated with Conservative treatment
62115941|NCT04892290||Group SGB|Postdural puncture headache patients treated with Sphenopalatine Ganglion Block and conservative treatment
62115942|NCT05790616|EXPERIMENTAL|NI(Fast-Sitting)|"Subgroup Non-Invasive (Fast-Sitting): sitting volunteers undergo an ambient oxygen decrease from 21% to 10% (SpO2 \<73% for 1 minute) followed by a fast increase of ambient oxygen concentration.~Fast: if the study is completed for a volunteer reaching SpO2 ≤73%, the subject leaves the room and breaths 21% oxygen. The hypoxia inducing device is stopped after all subjects left the hypoxia room and the door of the hypoxia room is opened, allowing air with 21% O2 to enter the room. Airco fan stays running."
62115943|NCT05790616|EXPERIMENTAL|NI(Slow-Sitting)|"Volunteers of subgroup Non-Invasive (Slow-Sitting) follow the NI (Rapid-Sitting) protocol, but after hypoxia at FiO2=0,10 oxygen normalization is programmed to increase at the same speed as the hypoxia creation.~Slow: after target hypoxia has been reached, air with 21% of oxygen is allowed to enter the room in such a way that the speed of increase of O2 to 21% is approximately equal to the decrease of the room's oxygen to 10%"
62115944|NCT05790616|EXPERIMENTAL|NI(Fast-Lying)|Volunteers included in the Non-Invasive (Fast-Lying) group follow the NI (Rapid-sitting) protocol although in lying position.
62115945|NCT05790616|EXPERIMENTAL|IN(Fast-Sitting)|After full completion of the Non-Invasive (NI) studies, and a defined algorithm to compute SpO2 by TDw1 is achieved, the study is repeated as described for the NI (Rapid-Sitting) protocol, but arterial blood oxygen saturation (SaO2) will be determined during 5 stable ambient oxygen plateaus (the Invasive (Fast-Sitting) study). These results are used as benchmark to define the final accuracy of TDw1 for SpO2 reproduction. In this part of the study, according to the minimal requirements of the regulatory agencies, 12 volunteers that successfully completed the study will be included.
62115946|NCT01918163|NO_INTERVENTION|No Pills|Patients in this group will not receive Pomegranate pills.
62115947|NCT01918163|ACTIVE_COMPARATOR|Pomegranate pills|The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
62115948|NCT04024631|OTHER|Phenotyping|"All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.~They will also undergo a whole body DXA (intervention) during the study day."
62115949|NCT02953080|ACTIVE_COMPARATOR|Call for Life Mobile phone support|"The intervention is Call for life mHealth adherence support tool  through basic mobile phone-based interactive voice response."
62115950|NCT02953080|NO_INTERVENTION|Standard of Care|No call for life Uganda: Patients are randomized to standard of Care
62675957|NCT00985192|EXPERIMENTAL|Everolimus|Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity
62675958|NCT04017975|NO_INTERVENTION|Non-imaging cohort|There will be no intervention for the non-imaging group. Subjects will receive standard of care for cardiac surgery.
61918129|NCT01802970|EXPERIMENTAL|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle), or capecitabine (1000mg/m\^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle), or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
61918130|NCT06514651|EXPERIMENTAL|Cohort 1|1mg/kg of MAQ-001 administered intravenously every 3 weeks
61918131|NCT06514651|EXPERIMENTAL|Cohort 2|3 mg/kg of MAQ-001 administered intravenously every 3 weeks
61918132|NCT06514651|EXPERIMENTAL|Cohort 3|10 mg/kg of MAQ-001 administered intravenously every 3 weeks
61918133|NCT06514651|EXPERIMENTAL|Regimen 1|MAQ-001 at 1 mg/kg in combination with ipilimumab at 3 mg/kg administered intravenously every 3 weeks for the first 4 doses, followed by the maintenance phase of MAQ-001 monotherapy administered intravenously at a dose of 3 mg/kg every 3 weeks (q3W)
61918134|NCT06514651|EXPERIMENTAL|Regimen 2|MAQ-001 at 3 mg/kg in combination with ipilimumab at 1 mg/kg administered intravenously every 3 weeks for the first 4 doses, followed by the maintenance phase of MAQ-001 monotherapy administered intravenously at a dose of 3 mg/kg every 3 weeks (q3W)
61918135|NCT02981459|EXPERIMENTAL|Mirabegron 25 mg or 50 mg|
61918136|NCT05969171|EXPERIMENTAL|Sofantinib in combination with abraxane and gemcitabine|Abraxane: 125mg/m2 intravenously, d1, 8; Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks for a treatment cycle. Sofantinib capsules, 250mg orally, taken within 1 hour after breakfast, once a day for continuous administration, d1-d21, every 3 weeks for a treatment cycle. AG chemotherapy did not exceed a maximum of 6 treatment cycles, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (while the patient was on treatment) or toxicity became intolerant or other criteria for discontinuation of study therapy were met in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
61918137|NCT05969171|ACTIVE_COMPARATOR|Abraxane combined with gemcitabine|Abraxane: 125mg/m2 intravenously, d1, 8; Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks as a treatment cycle, treatment until toxicity intolerance or disease progression, death, or other criteria for termination of study therapy as specified in the protocol. AG chemotherapy should not exceed a maximum of 6 treatment cycles. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
61918138|NCT02874768|EXPERIMENTAL|dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
61918139|NCT02874768|ACTIVE_COMPARATOR|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
61918140|NCT00735059|EXPERIMENTAL|1|treatment with dialyzer ELISIO 170H
61918141|NCT00735059|ACTIVE_COMPARATOR|2|treatment with dialyzer PES-170DS
61918142|NCT06404346|EXPERIMENTAL|High Velocity Thrust|
62304458|NCT04782739||Description of PMTCT service provision and uptake at healthcare facilities|Aggregated data will be collected from all 1560 public healthcare facilities in Zimbabwe on key indicators including antenatal testing and treatment of HIV and syphilis, and management of HIV-exposed and HIV-positive infants. Data will be collected from March 2015 (5 years prior to the pandemic) to the end of the study, to explore trends over time.
62675959|NCT04017975|EXPERIMENTAL|Imaging cohort|Up to 5mL of 1:1000 dilute fluorescite will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes. The system will be used to assist the investigator with the operative course.
62675960|NCT03767231|EXPERIMENTAL|HCV POC VL Group|This group will receive the POC HCV viral load testing via fingerstick using the novel Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
62675961|NCT03767231|NO_INTERVENTION|Reference Group|This group will receive the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing only. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
62115951|NCT02717299|EXPERIMENTAL|Sensor Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The surgeon will use this data to intraoperatively align the knee according to the indications of the data.
62115952|NCT02717299|PLACEBO_COMPARATOR|Surgeon Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The computer displaying the data will be turned away from the surgeon, so that he is not able to use the sensor data, and must balance the knee with feel and visual estimation of balance.
62115953|NCT05237921|EXPERIMENTAL|Combined Exercise and Dietary Intervention|Behavioral Intervention
62115954|NCT05237921|OTHER|Control|Standard Care
62115955|NCT04033432|EXPERIMENTAL|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on day 1. Treatment repeats every 14 days for cycles 1-6 and then every 21 days for subsequent cycles. Patients may continue to receive sEphB4-HSA treatment until no longer clinically benefiting (PCWG3), unacceptable toxicity, treatment delay \>= 4 weeks, or prohibitive illness/change in patient?s condition, or patient decides to withdraw from study.
62115956|NCT04807322||Elective cases|Patients, who received a RTSA for degenerative reasons like cuff arthropathy or osteoarthritis
62115957|NCT04807322||Fracture cases|Patients, who received a RTSA for a proximal humerus fracture
62115958|NCT02768272|EXPERIMENTAL|Epidural analgesia|Randomized allocation to receive patient controlled epidural analgesia or programed intermittent epidural boluses
62115959|NCT02768272|EXPERIMENTAL|Epidural technique|Randomized allocation to be punctioned a conventional epidural or a combined spinal-epidural technique
62115960|NCT02060019|EXPERIMENTAL|exforge 10/160mg(amlodipine 10mg, valsartan160mg)|1 tablet daily for 10days
62115961|NCT02060019|EXPERIMENTAL|crestor 20mg(rosuvastatin 20mg)|1 tablet daily for 7days
62115962|NCT02391207||patients having at least one CLM|Hepatic vein-sparing hepatectomy guided by intraoperative ultrasonography
62115963|NCT04665661|EXPERIMENTAL|High-intensity aerobic training (HIAT)|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
62115964|NCT04665661|ACTIVE_COMPARATOR|Wait-list control (WLC)|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
62304459|NCT04782739||Neonatal admissions at Harare Children's Hospital|Individual-level patient data will be collected on all neonates admitted for care at Harare Children's Hospital, including on patient characteristics, clinical status at presentation and outcomes. Data will be collected from February 2019 to the end of the study, to explore trends over time.
62304460|NCT04782739||Qualitative study|Qualitative study of 20 pregnant/lactating women accessing routine PMTCT services and 10 community healthcare workers from the Mabvuku and Kuwadzana Polyclinics. The estimated enrolment of 30 participants given in the study design section above refers to participants from this group only.
62304461|NCT03792711|EXPERIMENTAL|HMB group|2 servings (440 mL)/day Ensure® Plus Advance for use as a supplement with or between meals
61918143|NCT06404346|OTHER|Bowen therapy|
62115965|NCT04825184|EXPERIMENTAL|Body image chatbot|The artificial intelligence chatbot, Topity, is designed to target sociocultural risk and protective factors for body image using eight therapeutic techniques derived from several evidence-based theories, including media literacy, cognitive behaviour theory and positive body image. The intervention aims to engage users in techniques that teaches users how to 1) Critically analyse and evaluate media content to reduce vulnerability to negative media influences (i.e., media literacy theory; 10); 2) Identify and challenge unhelpful thinking styles and behaviours that perpetuate body image distress (i.e., cognitive behaviour theory; 11); and 3) Appreciating the features, functions and health of the body, beyond it's appearance (i.e., positive body image theory; 12). Users will be assessed on state body satisfaction and affect before and after engaging with a technique to assess the immediate impact of the micro-intervention.
62115966|NCT04825184|NO_INTERVENTION|Assessment only|The comparison control condition will be assessment only. This is informed by a care as usual framework; whereby, Brazilian adolescents are not currently offered online body image prevention or intervention resources at school or within the community.
62115967|NCT04505943|EXPERIMENTAL|isonicotinic acid hydrazide|2vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
61918144|NCT00749554|ACTIVE_COMPARATOR|Disc biacuplasty|
62304462|NCT03792711|NO_INTERVENTION|Control group|Standard of care includes mainly dietary consultation for healthy aging by dietitians to reach sufficient dietary protein intake.
62304463|NCT02454114|ACTIVE_COMPARATOR|Standard Hospital Care (SHC)|All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
61918145|NCT00749554|PLACEBO_COMPARATOR|Sham treatment.|
61918146|NCT03490318||Patients with DMO and/or PDR|
61918147|NCT02145702|EXPERIMENTAL|Exercise Group|Subjects randomized to this group will start 12 weeks of supervised aerobic exercise after baseline testing.
61918148|NCT02145702|EXPERIMENTAL|Control Group|Subjects randomized to this group will continue with 12 weeks of Standard Care. After 12 weeks, the subjects will cross over to the exercise arm and undergo baseline testing again and then start 12 weeks of exercise intervention.
61918149|NCT02259075|EXPERIMENTAL|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards both the right and left sphenopalatine ganglion, a total of 50 IU.
61918150|NCT06290245|EXPERIMENTAL|study group|the participants will receive combined PEP Buddy plus the same exercise protocol as in the control group three times per week for eight weeks
62675962|NCT05521282|EXPERIMENTAL|Treatment group|"Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.~Qianglidingxuan Tablets:~Specifications: 60 tablets per bottle; Storage: airtight, moisture-proof; Active ingredients:Gastrodia elata, Eucommia ulmoides, wild chrysanthemum, Eucommia ulmoides leaves, Chuanxiong; Manufacturer: Shaanxi Hanwang Pharmaceutical Co., LTD."
61918151|NCT06290245|ACTIVE_COMPARATOR|control group|the participants will perform an aerobic exercise in the form of cycling three times per week for eight weeks
62115968|NCT04505943|ACTIVE_COMPARATOR|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 12 hours before IUD insertion.
61918152|NCT01964456|ACTIVE_COMPARATOR|Patients|Patients suffering of anorexia
61918153|NCT01964456|PLACEBO_COMPARATOR|Control|Subjects controls (not suffering of anorexia)
61918154|NCT04551339|ACTIVE_COMPARATOR|High dose Zinc (PreserVision AREDS formulation soft gels or tablets)|Subjects will have a high dose Zinc supplementation in combination with Copper, Vitamin C/E and beta-carotene
61918155|NCT04551339|ACTIVE_COMPARATOR|Multivitamin with 11mg of zinc|Subjects in this arm will have a multivitamin supplement with 11mg of zinc
61918156|NCT04879979|EXPERIMENTAL|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) designed for the treatment of Cancer-Related Cognitive Impairment (CRCI)
61918157|NCT03203343|ACTIVE_COMPARATOR|PIRS group|Patients operated laparoscopically - PIRS technique
61918158|NCT03203343|ACTIVE_COMPARATOR|Marcy group|Patients operated by open modified Marcy technique
61918159|NCT02954042|EXPERIMENTAL|Pelvital probe|Probe to use for incontinence-Pevital is company name of product
61918160|NCT02954042|PLACEBO_COMPARATOR|Placebo Probe|Placebo probe
61918161|NCT02270437|EXPERIMENTAL|cocktail analgesia|The local infiltration mixture of ropivacaine, fentanyl, adrenaline is used intra-articularly during operation. The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
62115969|NCT04505943|ACTIVE_COMPARATOR|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 12hours before IUD insertion.
61918162|NCT02270437|NO_INTERVENTION|no cocktail injection|The patients in the no cocktail injection group received PCIA morphine postoperatively.
61918163|NCT02088515|EXPERIMENTAL|experimental group|experimental group: Nedaplatin(（80 mg/m2, i.v Day1）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total.
61918164|NCT02088515|ACTIVE_COMPARATOR|comparative group|comparative group:Cisplatin (（75 mg/m2, i.v Day1 or 25 mg/m2 Day1-3）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total
61918165|NCT03095768|EXPERIMENTAL|Intervention|Lifestyle Education and Cooking Demonstration
62115970|NCT00920881||Diabetes|
62115971|NCT05599256|EXPERIMENTAL|The group of daGOAT model prevention|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
62115972|NCT01165658|EXPERIMENTAL|Proton Therapy|The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.
62115973|NCT02266641|ACTIVE_COMPARATOR|healthy pregnant women|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
62115974|NCT02266641|EXPERIMENTAL|healthy pregnant women's lineal relative with cancer|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
62675963|NCT05521282|PLACEBO_COMPARATOR|Control group|"Based on basic treatment, Qianglidingxuan Tablets mimetics were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.~Qianglidingxuan Tablets mimetics:~Specifications: 60 tablets per bottle; Storage: airtight, moisture-proof; Active ingredients:NA; Manufacturer: Shaanxi Hanwang Pharmaceutical Co., LTD."
62675964|NCT01063673||Active runners|Observational follow-up study on 39 runners
62304464|NCT02454114|ACTIVE_COMPARATOR|HOMEFIRST|"Patients randomised to HOMEFIRST care will initially receive up to twice daily visits for the first 48 hours. After this, the frequency and duration of visits will depend on clinical need but not exceed 5 days. The study nurse will establish the need for the involvement of other MDT members. Laboratory tests will be performed as clinically indicated. Venepuncture will be performed for clinical purposes as needed.~Patients will be discussed at a weekly case-note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.~Patients are either discharged from HOMEFIRST, readmitted or handed over to their community care team at the end of the intervention."
62304465|NCT03392233|EXPERIMENTAL|Phase II open lable Study|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.
62304466|NCT02764879|EXPERIMENTAL|omega 3 group|scaling and root planing omega3 received 2 times daily-for 6 months
62304467|NCT02764879|PLACEBO_COMPARATOR|control group|scaling and root planing placebo soft gelatin capsules 2 times daily-for 6 months
62304468|NCT00291343|EXPERIMENTAL|TRITANRIX™-HEPB/HIB-MENAC +MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses of Tritanrix™-HepB/Hib-MenAC vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one booster dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
62304469|NCT00291343|ACTIVE_COMPARATOR|TRITANRIX™-HEPB/HIBERIX™+MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses Tritanrix™-HepB/Hiberix™ vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
62304470|NCT03876587|EXPERIMENTAL|Pyrotinib Maleate combine with Docetaxel|"Pyrotinib Maleate combine with Docetaxel should be administrate to all subjects.~Initial dose: Pyrotinib Maleate 400mg oral administration everyday plus Docetaxel 75mg per square of BSA every three weeks intravenous injection."
62675965|NCT02531711|EXPERIMENTAL|Diet A|Dietary intervention: Dietary fats are adjusted. Key study foods and oils are provided for 12 weeks. Participants learn which foods to eat and which to avoid.
62115975|NCT02266641|EXPERIMENTAL|pregnant women or lineal relative with overweight/obesity|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
62115976|NCT02266641|NO_INTERVENTION|healthy pregnant women's lineal relative with diabetes|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
62115977|NCT03766711|EXPERIMENTAL|Actual - Augmented|Reaching task as a physical therapy intervention. First with 1:1 visual feedback, then with augmented forward symmetry.
62304471|NCT01794390||Turbuhaler and MDI patients (Arm 1)|Patients (Diskus naive) will be randomised to receive training on the PulmoJet© device followed by Diskus, or vice versa
62304472|NCT01794390||Diskus patients (Arm 2)|Patients (Turbuhaler naive) will be randomised to receive training on the PulmoJet© device followed by Turbohaler, or vice versa
62304473|NCT00907738|EXPERIMENTAL|Vorinostat|
62675966|NCT02531711|ACTIVE_COMPARATOR|Diet B|Dietary intervention: This diet also adjusts dietary fats, and provides key study foods and oils for 12 weeks.
62675967|NCT04634175|EXPERIMENTAL|Mind-body group|The mind-body group will practice mind-body intervention.
61918166|NCT01423604|EXPERIMENTAL|Capecitabine and ruxolitinib|
62115978|NCT03766711|EXPERIMENTAL|Augmented - Actual|Reaching task as a physical therapy intervention. First with augmented forward symmetry, then with 1:1 visual feedback.
62304474|NCT04610307|PLACEBO_COMPARATOR|control group|patients receiving 1 % plain xylocaine
62304475|NCT04610307|EXPERIMENTAL|intervention group|patients receiving buffered 1 % xylocaine
62304476|NCT01233726|EXPERIMENTAL|T-DIET PLUS DIABET IR|Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
62675968|NCT04634175|ACTIVE_COMPARATOR|Sham group|The sham group will practice sham intervention.
62115979|NCT03320096|EXPERIMENTAL|Microfocused ultrasound with visualization|
62115980|NCT01640678|EXPERIMENTAL|ReCell epidermal cell suspension grafting|CO2 laser abrasion + ReCell epidermal cell suspension + UV-therapy
62472870|NCT04035395|EXPERIMENTAL|Intervention|Participants randomized to the intervention group will receive the SyV 2.0 program, which in addition to standard diabetes management services of SyV 1.0 services, could include MTM services, care coordination by a team of behavioral health care providers, and/or referrals to community-based lifestyle programs, as determined by their tailored care plan. The participant will be seen by evaluation staff to complete baseline assessment for the study. Then, an individualized care plan will be developed by SyV 1.0 interdisciplinary staff and reviewed by the chronic care case management team. The care plan will include information on additional services provided by UTHealth such as, but not limited to, behavioral health services, or pharmacy services. Each participant will receive an individualized care plan and when applicable, referrals to community-based programs. Evaluation staff and CHWs will make follow-up appointments for the participant depending on their care plan.
62472871|NCT04035395|NO_INTERVENTION|Control|Participants randomized to the usual care group will receive the SyV 1.0 program which includes community based program referrals (excluding intervention programs) and home-based visits from CHWs. These participants will also receive the standard follow-up from UTHealth staff such as a phone call, an information session as per their treatment plan, and /or a onetime mailing of information about the importance of following their treatment plan. Before implementation begins, additional details about standard care will be ascertained from partner organizations to better understand how these differ from the treatment conditions of the intervention group. Once the participant completes 12 months in the study, 2.0 services will be initiated.
62304477|NCT01233726|ACTIVE_COMPARATOR|ISOSOURCE PROTEIN FIBRE|Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
62472872|NCT05213156|ACTIVE_COMPARATOR|Patients without Dry Eye Disease|Control Group
62115981|NCT01640678|ACTIVE_COMPARATOR|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
62115982|NCT01640678|NO_INTERVENTION|No treatment + UV-therapy|
62304478|NCT01233726|ACTIVE_COMPARATOR|GLUCERNA SELECT|Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
62304479|NCT00262405|EXPERIMENTAL|zileuton|Zileuton
62304480|NCT00262405|ACTIVE_COMPARATOR|azathioprine/prednisone|azathioprine/prednisone
62115983|NCT03795558|EXPERIMENTAL|Etelcalcetide 2.5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
62115984|NCT03795558|EXPERIMENTAL|Etelcalcetide 5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
62115985|NCT03795558|EXPERIMENTAL|Etelcalcetide 7,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
62115986|NCT03795558|EXPERIMENTAL|Etelcalcetide 10 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
62115987|NCT03795558|EXPERIMENTAL|Etelcalcetide 12,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
62115988|NCT03795558|EXPERIMENTAL|Etelcalcetide 15 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
62115989|NCT02508844|EXPERIMENTAL|Vivomixx®|Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus
62472873|NCT05213156|EXPERIMENTAL|Patients with Dry Eye Disease, except the severe Dry Eye Disease|non severe Dry Eye Disease
62472874|NCT05213156|EXPERIMENTAL|Patients with severe Dry Eye Disease|severe Dry Eye Disease
62472875|NCT02664103|EXPERIMENTAL|SAR439281(Cohort 1)|Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
62472876|NCT02664103|EXPERIMENTAL|SAR439281(Cohort 2)|Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
62472877|NCT02664103|EXPERIMENTAL|SAR439281(Cohort 3)|Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
62472878|NCT00731783|ACTIVE_COMPARATOR|Index patient only|Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
62115990|NCT02508844|PLACEBO_COMPARATOR|Placebo|microcrytalline cellulose, magnesium stearate and silicon dioxide.
62304481|NCT04015765|EXPERIMENTAL|Group treatment h-APC and EMR|Standard endoscopic mucosal resection (EMR) technique will be used for primary removal of all polyps. Submucosal injection will be used to lift the polyp from the muscularis propria. Injection is used as per the current standard of care using a contrast agent and a lifting agent (e.g. NaCl 0.9% or Voluven). Snare electrocautery resection will be facilitated until complete visible removal of the complete polyp. Electrocautery snare technique is facilitated using standard microprocessor controlled electrocautery (e.g. ERBE VIO Endocut 3-1-6). Ablation of the margin after visibly complete removal of the polyp is routinely applied. For thermal ablation hybrid APC (Erbe Hybrid APC) will be applied using standard settings on the margin and resection base. Once resection and thermal ablation is considered complete the mucosal defect can be closed with clips or another preventative measure applied to reduce the risk for post-polypectomy bleeding.
62304482|NCT05325112||FFR-CT Group|Sites who have CCTA and FFR-CT analysis incorporated into their standard evaluation of chest pain in the ED/observation unit.
62304483|NCT05325112||Control Group|Sites who have CCTA but not FFR-CT incorporated into the ED/observation unit.
62115991|NCT05752136|EXPERIMENTAL|Neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Name: KN053~Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient."
62304484|NCT02894073|NO_INTERVENTION|control group|PVC placement performed in the usual manner: visual inspection of the patient's anatomy
62304485|NCT02894073|EXPERIMENTAL|visualisation group|a skin transilluminator (such as the VeinViewer®Vision) is used to guide PVC placement
62304486|NCT03013595|EXPERIMENTAL|TRAM feedback|"1. The completion of the Transition Readiness and Appropriateness Measure (TRAM, a standardized structured assessment ) prior to the transition boundary by the child and adolescent mental health service (CAMHS) clinician, young person and parent/carer.~2. Feedback of TRAM findings to the CAMHS clinician to support decisions made regarding transition, communication with stakeholders and the transition process. Clinicians will be expected to communicate the findings to the young person and parent/carer, and, if a referral is made, to send the TRAM feedback to the adult clinician along with the referral letter.~3. The clinicians will also receive information prior to recruitment begin on the use of TRAM and the way in which it fits in with optimal transition."
62304487|NCT03013595|NO_INTERVENTION|Usual care|Patients, parent/carers and clinicians in the control arm will complete the TRAM prior to the transition boundary, but the clinicians won't receive any feedback from it nor any information on the benefits of using the decision support tool.
62472879|NCT00731783|ACTIVE_COMPARATOR|Household|All members of the household (over the age of 6 months) will be asked to follow the study protocol.
62675969|NCT04140344|EXPERIMENTAL|ARM 1: Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
62472880|NCT05742971|EXPERIMENTAL|VR group|The intervention group can choose for an immersive guided relaxation VR experience or an interactive VR experience during the external version Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
62472881|NCT05742971|NO_INTERVENTION|Standard care group|The participants randomised to the standard care group receive the usual standard care given during external version.Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score.
62472882|NCT05820893|EXPERIMENTAL|Prebiotic arm|Subjects will consume the RS prebiotic daily for 4 weeks. A dose escalation will be used with subjects taking 4g of the prebiotic for the first 4 days, 7g the next 3 days and the full dose of 10g on day 8.
62115992|NCT05752136|NO_INTERVENTION|Neoadjuvant chemoradiotherapy and total mesorectal excision|"Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient."
62115993|NCT01026064|EXPERIMENTAL|Part C- Azithromycin|2 x 250 mg once daily over 3 days
62115994|NCT01026064|PLACEBO_COMPARATOR|Part C- Placebo|Once daily over 3 days
62115995|NCT06089954|OTHER|ROR Arm 1|Disclosure of results with a Genetic Counselor.
62115996|NCT06089954|EXPERIMENTAL|ROR Arm 2|eHealth disclosure of results by private web-portal (with option to speak with a GC).
62115997|NCT05247034|EXPERIMENTAL|Intervention group|Diet for patients with diabetes + 4 capsules of cocoa powder, 500 mg each, daily for 12 weeks.
62115998|NCT05247034|PLACEBO_COMPARATOR|Control group|Diet for patients with diabetes + 4 capsules of methylcellulose 500 mg each, daily for 12 weeks.
62472883|NCT05820893|NO_INTERVENTION|Standard diet|Subjects randomized to this arm will be asked to maintain their usual diet.
62472884|NCT00454025||Glaucoma|Patients with Glaucoma
62472885|NCT00454025||Healthy Patients|Patients without glaucoma
61918167|NCT01423604|PLACEBO_COMPARATOR|Capecitabine and placebo|
62304488|NCT05357183||PEG-IFN optimized treatment group|Patients received optimized treatment of NAs (ETV + TDF or ETV + TAF) combined with PEG-IFN ETV 0.5 mg, TDF 300 mg or TAF 25 mg, oral once a day, PEG-IFN 180 or 135 micrograms, subcutaneous injection once a week, with a personalized course of treatment of 24 weeks.
62304489|NCT05357183||NAs optimized treatment group|Patients received NAS (ETV + TDF or ETV + TAF) combination therapy and continued NAs maintenance therapy.
62304490|NCT06495151||Endometriosis group (Study group)|"* The study group included 32 women with endometriosis.~* The study group consisted of women diagnosed with endometriosis who consecutively underwent laparoscopic endometriosis surgery."
62304491|NCT06495151||Healthy women (Control group)|"* Control group consisted of 26 healthy women.~* The control group consisted of women who consecutively visited the outpatient clinic for routine gynecologic examinations and had no known diseases."
62304492|NCT04746521||Severe COVID-19 hospitalized patients|A total of 50 severe COVID-19 patients admitted to the Sub-Intensive Care Unit of A.O.R.N. Ospedali dei Colli, Cotugno Hospital, Naples (Italy) will be recruited, of which N=50 with thromboembolic complications (PE+) and N=50 without thromboembolic complications (PE-) balanced for age and sex of individuals.
62304493|NCT04746521||Healthy controls (comparator group)|"As control group (CTRL), we will recruit a total of N=50 healthy subjects (never diagnosed with Sars-Cov2 infection) among the volunteer blood donors attending the U.O.C. Divisione di Immunologia Clinica, Immunoematologia, Medicina Trasfusionale e Immunologia dei Trapianti, Dipartimento di Medicina Interna e Specialistica, AOU, L. Vanvitelli University of Campania (Naples, Italy)."
62304494|NCT04746521||COVID-19 patients compared with vaccinated subjects|"1. Patients with previous Sars-CoV-2 infection who did not undergo vaccination;~2. Patients with previous Sars-CoV-2 infection who undergone vaccination~3. Subjects without previous Sars-CoV-2 infection who undergone vaccination"
62304495|NCT04541069|EXPERIMENTAL|Social Communication and Emotional Skill Development (SCESD)|This arm will get the intervention which is the Early Childhood Development (ECD) training.
62304496|NCT04541069|NO_INTERVENTION|Control|This arm will not get any intervention.
62304497|NCT06656286|EXPERIMENTAL|Women undergoing laparoscopic hysterectomy|Women undergoing laparoscopic hysterectomy for benign indication with no evidence or suspicious for malignancy.
62675970|NCT04140344|NO_INTERVENTION|ARM 2: Control group|The control group will be given the standard post-op packet that includes detailed instructions on proper wound care and signs and symptoms of infection. They will not receive text messages. The same outcomes will be assessed in both groups through a 30-day post-operative phone call.
62675971|NCT03938324|EXPERIMENTAL|PiCASO Intervention Group|Peer coaching intervention delivered by young adults with a childhood onset chronic condition and trained in coaching curriculum that includes motivational interviewing techniques and the benefits of peer relationships over a shared experience such as a chronic condition. The peer coach supports the AYA to identify their goals and feel a sense of success in making change towards goals within a supportive environment. This process involves goal-setting, development of self-discovery and accountability for changes in health behavior. The peer coach elicits the AYA's vision of optimal health and identifies the AYAs values. As the AYAs identify a vision of wellness and develop goals and action steps to progress towards that vision, the peer coach elicits the AYA's intrinsic motivation and activates skill development in self-advocacy and communication and empowers the AYA to take leadership in managing their condition.
62304498|NCT02991612|EXPERIMENTAL|Rifaximin Treatment Group|Rifaximin 400mg bid for 2 months,
62304499|NCT02991612|NO_INTERVENTION|Control Group|Receive routine endoscopic treatment without having rifaximin for 2 months
62304500|NCT05996744|EXPERIMENTAL|Obeldesivir (ODV)|"Participants will receive ODV for 5 days. The ODV dose to be administered in each cohort based on age and weight as follows:~* Cohort 1: ODV, tablets, 350 mg twice daily (BID)~* Cohort 2: ODV, tablets, 175 mg BID~* Cohorts 3-7: ODV doses will be determined based on available PK data."
62304501|NCT02997514|ACTIVE_COMPARATOR|Intensive Solution Focused Coaching|Participants will engage in 5 solution focused coaching sessions, each up to 60 minutes in duration
62304502|NCT02997514|ACTIVE_COMPARATOR|Solution Focused Coaching|Participants will engage in 1 solution focused coaching session up to 60 minutes in duration
62304503|NCT06346275|ACTIVE_COMPARATOR|Control group|Cognitive rehabilitation therapy: The cognitive training system (JZ-RZ-1020, Extreme Medical Technology, Hangzhou, China) will be used to help develop personalized rehabilitation plans for one-on-one training based on the cognitive function of each patient. The trainings include memory, hand eye reinforcement, attention, reaction. Patients are treated for 30 minutes each time and 5 times a week for 8 weeks.
62304504|NCT06346275|EXPERIMENTAL|Acupuncture group|Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
62304505|NCT02427581|EXPERIMENTAL|Arm 1 - personlized synthetic long peptide vaccine|"* Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.~* The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.~* The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
62304506|NCT01939262|EXPERIMENTAL|Vegan Diet|Limitation of Animal Fat and Protein in the Diet. Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
62304507|NCT01939262|PLACEBO_COMPARATOR|Control|Subjects maintained their existing diet without modification.
62472886|NCT05900934|ACTIVE_COMPARATOR|Myofascial Releasing Group|The intensity of application is important for foam rollers. For intensity, the intensity of the pressure will be determined by a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort) and applied at the end of each session.
62304508|NCT04109079|EXPERIMENTAL|No axillary treatment|Patients in this arm will not receive axillary treatment (axillary lymph node dissection or axillary radiotherapy). Supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
62304509|NCT04109079|ACTIVE_COMPARATOR|Axillary treatment|Patients in this arm will receive axillary treatment. Axillary treatment can be axillary lymph node dissection or axillary radiotherapy.
62304510|NCT05170191||Sleep deprivation|Participant data will be acquired before and after 24 hours of sleep deprivation.
62304511|NCT00666315||Harmonic|Group operated with Harmonic device
62472887|NCT05900934|SHAM_COMPARATOR|Sham Myofascial Releasing Group|In the sham group, similar to the literature, the intensity will be applied with foam rollers in accordance with the 0/10 numerical rating scale, to the same application areas, for the same duration and with the same rest intervals.
62472888|NCT02731534|EXPERIMENTAL|Z-213|
62675972|NCT03938324|SHAM_COMPARATOR|Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
61918168|NCT01915628||BioMatrix Flex|percutaneous coronary intervention
61918169|NCT03480633||Control|Defined as patients without a history of heart failure
61918170|NCT03480633||Heart Failure w/NormalEjectionFraction|Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 50%.
62115999|NCT01426750|EXPERIMENTAL|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
62116000|NCT04630080|EXPERIMENTAL|Scalp Cooling|
62304512|NCT00666315||Conventional|Group operated with Electrocauery and Clip/Suture
62472889|NCT02731534|ACTIVE_COMPARATOR|Saccharated Ferric Oxide|
62472890|NCT01135446|EXPERIMENTAL|dapagliflozin (0.001 mg)|Cohort 1
62472891|NCT01135446|EXPERIMENTAL|dapagliflozin (0.01 mg)|Cohort 2
62472892|NCT01135446|EXPERIMENTAL|dapagliflozin (0.1 mg)|Cohort 3
62472893|NCT01135446|EXPERIMENTAL|dapagliflozin (0.3 mg)|Cohort 4
62472894|NCT01135446|EXPERIMENTAL|dapagliflozin (1 mg)|Cohort 5
62472895|NCT01135446|EXPERIMENTAL|dapagliflozin (2.5 mg)|Cohort 6
61918171|NCT03480633||HeartFailure w/ReducedEjectionFraction|Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 50%.
62116001|NCT03920215|ACTIVE_COMPARATOR|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, 0.12 mg/mL
62116002|NCT03920215|ACTIVE_COMPARATOR|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.60 mg/mL
62116003|NCT03920215|ACTIVE_COMPARATOR|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
62116004|NCT03920215|PLACEBO_COMPARATOR|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
62472896|NCT05524701|EXPERIMENTAL|Sleep Restriction Condition|Participants will be asked to restrict their sleep duration to a maximum of four hours per night (3 am to 7 am) for the two nights prior to the measurement day.
61918172|NCT01634178|EXPERIMENTAL|Sequence 1: Apremilast Fasted / Fed|In Period 1 participants will receive a single 30 mg apremilast tablet administered under fasted conditions and in Period 2 participants will receive a single 30 mg apremilast tablet administered after a high fat meal.
62116005|NCT03897348|EXPERIMENTAL|Crossover Sequence A: Placebo, then Lacosamide 200 mg, then Lacosamide 100 mg|Participants receive a single dose of Placebo in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
62304513|NCT06644183|EXPERIMENTAL|Phase 1b Arm A: Venetoclax + Roginolisib + Rituximab Dose Level -1|"3+3 design to establish a Recommended Phase 2 Dose (RP2D) for Roginolisib, starting at Dose Level -1.~* Baseline visit, imaging, bone marrow biopsy~* CT scan every 2 cycles~* Cycle 1 (5 weeks): Predetermined dose of Venetoclax 1x daily~* Cycle 2: Days 1 through 28 of 28 day cycle: Predetermined dose of Venetoclax 1x daily and predetermined dose of Roginolisib 1 x daily~  --If 0 of 3 participants do not experience a dose-limiting toxicity (DLT), the study will proceed. If 1 of 3 participants experience a DLT, 3 more participants will be enrolled, and if 1 of those 6 participants experience a DLT, this is the RP2D for phase 2. If a DLT is observed in 2 of 3 or 2 of 6, the study will be stopped.~* Cycles 3 through Cycle 8: Day 1 of 28 day cycle: Predetermined dose of Rituximab once~* Cycles 3 through 13: Days 1 through 28 of 28 day cycle: Predetermined dose of Venetoclax 1x daily and predetermined dose of Roginolisib 1 x daily~* End of treatment visit~* Follow up visits for up to 5 years"
62304514|NCT06644183|EXPERIMENTAL|Phase 1b Arm B: Venetoclax + Roginolisib + Rituximab Dose Level 1|"* Baseline visit, imaging, bone marrow biopsy~* CT scan every 2 cycles~* Cycle 1 (5 weeks): Predetermined dose of Venetoclax 1x daily~* Cycle 2: Days 1 through 28 of 28 day cycle: Predetermined dose of Venetoclax 1x daily and predetermined dose of Roginolisib 1 x daily~  --If 0 of 3 participants do not experience a DLT, Phase 2 will start at this dose level. If 1 of 3 participants experience a DLT, 3 more participants will be enrolled, and if 1 of those 6 participants experience a DLT, this dose level will be used for Phase 2. If a DLT is observed in 2 of those 6, de-escalate to Dose Level -1.~* Cycles 3 through Cycle 8: Day 1 of 28 day cycle: Predetermined dose of Rituximab once~* Cycles 3 through 13: Days 1 through 28 of 28 day cycle: Predetermined dose of Venetoclax 1x daily and predetermined dose of Roginolisib 1 x daily~* End of treatment visit~* Follow up visits for up to 5 years"
62304515|NCT06644183|EXPERIMENTAL|Phase 2 Arm A: Venetoclax + Roginolisib + Rituximab|"Participants will be randomized 1:1 and stratified by TP53 aberrant disease and by the number of prior therapies.~* Baseline visit, imaging, bone marrow biopsy.~* CT scan every 2 cycles.~* Cycle 1 (5 weeks): Predetermined dose of Venetoclax 1x daily~* Cycles 2 through 13:~  * Days 1 through 28 of 28 day cycle: Predetermined dose of Venetoclax 1x daily.~ * Days 1 through 28 of 28 day cycle: Predetermined dose of Roginolisib 1 x daily.~* Cycles 3 through Cycle 8:~  --Day 1 of 28 day cycle: Predetermined dose of Rituximab once.~* End of treatment visit~* Follow up visits for up to 5 years"
62304516|NCT06644183|ACTIVE_COMPARATOR|Phase 2 Arm B: Venetoclax + Rituximab|"Participants will be randomized 1:1 and stratified by TP53 aberrant disease and by the number of prior therapies.~* Baseline visit, imaging, bone marrow biopsy.~* CT scan every 2 cycles.~* Cycle 1 (5 weeks): Predetermined dose of Venetoclax 1x daily~* Cycles 2 through 13:~  --Days 1 through 28 of 28 day cycle: Predetermined dose of Venetoclax 1x daily.~* Cycle 3 through 8:~  --Day 1 of 28 day cycle: Predetermined dose of Rituximab once.~* End of treatment visit~* Follow up visits for up to 5 years"
62304517|NCT02712450||Control group|"* Patients included from January 2016 to August 2016~* Before regulating doctors training course"
62304518|NCT02712450||Experimental group|"* Patients included from January 2017 to August 2017~* After regulating doctors training course"
62304519|NCT02696083|EXPERIMENTAL|Active Treatment|
62304520|NCT05461729||Coronary Artery Disease|Patients with Coronary Artery Disease
62304521|NCT06657534|EXPERIMENTAL|Intervention|Push-pull technique
62116006|NCT03897348|EXPERIMENTAL|Crossover Sequence B: Lacosamide 200 mg, then Lacosamide 100 mg, then Placebo|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 100 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
62116007|NCT03897348|EXPERIMENTAL|Crossover Sequence C: Lacosamide 200 mg, then Placebo, then Lacosamide 100 mg|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Placebo. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
62116008|NCT03897348|EXPERIMENTAL|Crossover Sequence D: Lacosamide 100 mg, then Lacosamide 200 mg, then Placebo|Participants receives a single dose of Lacosamide 100 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
62116009|NCT03899675|EXPERIMENTAL|Caffeine|Volunteers will ingest 300mg caffeine one hour before strength training.
62304522|NCT06657534|ACTIVE_COMPARATOR|Control|Standard of care blood sampling method with waste blood
62304523|NCT03271489|EXPERIMENTAL|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
62304524|NCT03271489|PLACEBO_COMPARATOR|Placebo|Placebo
62472897|NCT05524701|EXPERIMENTAL|Normal Sleep Condition|Participants will be asked to sleep for at least eight hours per night (11 pm to 7 am) for two nights prior to the measurement day.
62472898|NCT02906293||Healthy Participants|Potential participants will self-refer.
62472899|NCT02458625|ACTIVE_COMPARATOR|Iron sucrose 500 mg|One treatment arm will receive a single dose of I.V iron sucrose 500 mg.
62472900|NCT02458625|ACTIVE_COMPARATOR|Iron sucrose 500 mg+60 mg Iron bisglycinate|Second treatment arm will receive a single dose of I.V iron sucrose 500 mg and oral treatment with 60 mg Iron bisglycinate for 6 weeks after giving birth.
62116010|NCT03899675|PLACEBO_COMPARATOR|Placebo|Volunteers will ingest 300mg placebo one hour before strength training.
62472901|NCT04277390||Controls|145 systemically and periodontally healthy pregnant women Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
62472902|NCT04277390||Group A|"Group A-100 Systemically healthy pregnant women with chronic periodontitis.~Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155."
62472903|NCT04277390||Group B|Group B- 100 Preeclamptic pregnant women with chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
62472904|NCT04277390||Group C|Group C-100 Preeclamptic pregnant women without chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
62472905|NCT05492279|EXPERIMENTAL|intervention|10 gr Sheep ghee
62472906|NCT05492279|ACTIVE_COMPARATOR|control group|10 gr sunflower oil
62116011|NCT04805073|EXPERIMENTAL|Promethazine|The treatment will consist of a blinded syringe of 1cc clear liquid 25mg/ml Promethazine
62472907|NCT01483950||Patients with hypercholesterolaemia|
62472908|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age \>=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
62472909|NCT06263959|EXPERIMENTAL|Cohort 1|Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 1) or placebo for 28 days.
62472910|NCT06263959|EXPERIMENTAL|Cohort 2|Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 2) or placebo for 28 days.
62472911|NCT06263959|EXPERIMENTAL|Cohort 3|Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 1 or 2) or placebo for 12 weeks.
62472912|NCT04819594|EXPERIMENTAL|Study Group|Nurses will wear the Elequil aromatabs ® (100% pure essential oil) over a four-hour period
62472913|NCT06241963|ACTIVE_COMPARATOR|Unilateral real High definition transcranial direct current stimulation|"The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10 .~In the unilateral treatment group, HD-tDCS treatment based on Epileptic discharge is placed on either the left or right side of the brain.Ten 2-mA sessions were applied for 30 minutes,once a day over 10 consecutive workdays."
62472914|NCT06241963|ACTIVE_COMPARATOR|Bilateral real High definition transcranial direct current stimulation|"The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10 .~In the bilateral treatment group, HD-tDCS treatment was placed on the left and right sides of the brain, at least eight hours apart.. Twenty 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 30 minutes,twice a day over 10 consecutive workdays."
62116012|NCT04805073|PLACEBO_COMPARATOR|Placebo|The treatment will consist of a blinded syringe of 1cc 0.9% Sodium Chloride
62116013|NCT06544161|OTHER|CPMX2 Arm|"This study is a single-center, single arm, prospective, exploratory proof of concept study.~Cirrhotic patients with an indication for intravenous albumin will undergo a venous compression technique of the external jugular vein plus an ultrasound examination before/after passive leg raise as well as before/after intravenous albumin infusion in order to study the dynamics of the intravascular volume status and to rule out volume overload."
62116014|NCT03272113|NO_INTERVENTION|Control|"Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support.~Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week."
62116015|NCT03272113|EXPERIMENTAL|Intervention|Women will receive usual care as described above plus the SKIP-IT intervention
62116016|NCT06121310||Survey grup|No intervention is to be administered. Just a survey study
62116017|NCT02994654|EXPERIMENTAL|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
62116018|NCT02994654|EXPERIMENTAL|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
62116019|NCT04017169||No reflow phenomenon|"Those that during procedure experience no reflow phenomenon~To define no reflow requires:~• Angiographic evidence of reopening of occluded coronary artery and successful stent placement with no evidence of flow-limiting residual stenosis (\<50%), dissection, vessel spasm, or thrombus burden~and~* Angiographic documentation of a TIMI flow grade ≤II, or~* A TIMI flow grade III with a myocardial perfusion grade 0 or I, at least 10 min after the end of PCI procedure."
62116020|NCT04017169||No NRP|Normal angiographic coronary flow/blush post patent culprit vessel.
62472915|NCT06241963|SHAM_COMPARATOR|Sham High definition transcranial direct current stimulation|"The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10.~The 30 subjects were randomly divided into two groups, 15 receiving bilateral Sham HD-tDCS and 15 receiving unilateral Sham HD-tDCS.~Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds."
62304525|NCT05594524|EXPERIMENTAL|Body Confident Athletes|Participants in the intervention condition will take part in an in-person program consisting of three sessions over three weeks.
62472916|NCT06056817|EXPERIMENTAL|Treatment|Chronic implantation of the Calyan pacemaker device
62472917|NCT05230563|NO_INTERVENTION|Control Group|Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images
62472918|NCT05230563|EXPERIMENTAL|"Experimental Group - with the aid of Taihao lung CT decision support system"|"Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images with the aid of Taihao lung CT decision support system"
62116021|NCT03224299|EXPERIMENTAL|Investigational Product #1 (IP1)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
62116022|NCT03224299|EXPERIMENTAL|Investigational Product #2 (IP2)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
62116023|NCT03224299|ACTIVE_COMPARATOR|Active Control|ChloraPrep® - Hi-Lite Orange® applicator
62116024|NCT03224299|PLACEBO_COMPARATOR|Negative Control|sterile 0.9% saline applied with single use applicator
62116025|NCT00391755|ACTIVE_COMPARATOR|1|ramelteon 8 mg po qhs with sleep and migraine journal
62116026|NCT00391755|PLACEBO_COMPARATOR|2|Placebo po qhs with sleep and migraine journal
62116027|NCT04668742|EXPERIMENTAL|Arm 1: DYNAtraq - tracheostomy fixation device|Use of DYNatraq installed in chest with skin adhesive and fixed to tracheostomy tube
62116028|NCT04668742|NO_INTERVENTION|Arm 2: Usual management of tracheostomy|No interventions will be used additional to usual management
62116029|NCT04714450|NO_INTERVENTION|MMST control|
62116030|NCT04714450|EXPERIMENTAL|MMST+|
62116031|NCT05938387|EXPERIMENTAL|Dose escalation: CVGBM Dose Level -1|Dose Level -1 represents a dose that may be evaluated if dose level 1 is poorly tolerated. No dose de-escalation below this level is planned for this study. If the dose level -1 is poorly tolerated, the study will be terminated.
62116032|NCT05938387|EXPERIMENTAL|Dose escalation: CVGBM Dose Level 1|
62116033|NCT05938387|EXPERIMENTAL|Dose escalation: CVGBM Dose Level 2|
62116034|NCT05938387|EXPERIMENTAL|Dose escalation: CVGBM Dose Level 3|
62116035|NCT05938387|EXPERIMENTAL|Dose escalation: CVGBM Dose Level 4|
62116036|NCT05938387|EXPERIMENTAL|Dose expansion|After completion of the dose-escalation part and safety data review by the DSMB, approximately 20 patients will be enrolled at the selected Recommended Dose for Expansion (RDE) to generate more data on safety, tolerability and immunogenicity.
62116037|NCT03794180|EXPERIMENTAL|TJ003234|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion
62116038|NCT03794180|PLACEBO_COMPARATOR|Placebo|0 mg/kg via single IV infusion
62116039|NCT03812003|EXPERIMENTAL|remifentanil|After emergence and extubation of endotracheal tube, remifentanil 1mcg/kg were diluted with 0.9% saline to 50 ml, added in IV bag, and drip for 30 minutes.
62116040|NCT03812003|NO_INTERVENTION|no intervention|After emergence and extubation of endotracheal tube, 0.9% saline 50ml were added in IV bag and drip for 30 minutes.
62116041|NCT04330768|EXPERIMENTAL|PRF|
62116042|NCT04330768|ACTIVE_COMPARATOR|MTA|
62116043|NCT06496958|EXPERIMENTAL|CO2 insufflation colonoscopy with an abdominal compression device|Colonoscopic insertion will be performed with CO2 insufflation with assistance by an abdominal compression device.
62116044|NCT06496958|SHAM_COMPARATOR|CO2 insufflation colonoscopy with a sham abdominal compression device|Colonoscopic insertion will be performed with CO2 insufflation in standard method. A sham abdominal compression device will be used as a sham comparator.
62116045|NCT06496958|ACTIVE_COMPARATOR|Water exchange colonoscopy|Colonoscopic insertion will be performed with water exchange method.
62116046|NCT01221142|EXPERIMENTAL|Hypothermia|Device: Cincinnati Sub-Zero Hyper-Hypothermia to core temperature of 34C for 24 hours, rewarming rate 0,5/2h until the patient reaches 36,5C
62116047|NCT06345417||PBM only|"Participants in study group 1 receive full PBM while they opted not to receive transfusions.~Full PBM included an individualized, structured approach to detection and management of anemia, bleeding and coagulopathy. PBM is provided in a timely manner."
62304526|NCT05594524|NO_INTERVENTION|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they will receive access to the intervention after the first survey (intervention group) or after follow-up assessments (waitlist control group). Following completion of follow-up assessments, the control condition will get access to the intervention, but they will not be monitored or assessed.
62116048|NCT06345417||PBM with transfusion|Participants in the study group 2 receive partial PBM together with transfusions when deemed necessary. Transfusions are given by physicians encouraged to use a restrictive transfusion strategy. PBM is delivered to patients at a convenient time, resorting to a set of standard PBM measures rather than individualized care.
62116049|NCT06345417||Transfusion only|The control group is treated in an environment where PBM is not implemented and transfusion is the standard therapy for severe anemia.
62116050|NCT05358119||Prospective cohort|Patients with long COVID and new-onset musculoskeletal pain
62116051|NCT05951218|EXPERIMENTAL|inhibition technique|In the first group, patients will receive inhibition treatment of the TP.
62116052|NCT05951218|SHAM_COMPARATOR|placebo|The second group will receive a placebo treatment.
62304527|NCT00147771|EXPERIMENTAL|1|
62472919|NCT04024553||bipolar disorder family|Screening priori BD-I/BD-II patients， their relatives with mental illness (including but not limited to BD) and their healthy families.
62472920|NCT04024553||health control|Group-matched non-psychiatric family history health subjects were enrolled, DSM-IV-TR is used for demographic assessment.
62675973|NCT06350513|EXPERIMENTAL|Animation movie, story book|"Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused."
62675974|NCT06350513|OTHER|control group|No applications will be made.
62675975|NCT04076579|EXPERIMENTAL|Olaparib + Trabectedin|"There are 2 cohorts. Both cohorts receive the same treatment:~* Cohort 1: Leiomyosarcoma and liposarcoma~* Cohort 2: Other bone or soft tissue sarcoma histologies~Treatment consists of 21-day cycles for a maximum of 18 months."
62675976|NCT06019819|ACTIVE_COMPARATOR|General training group A|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed.
62675977|NCT06019819|EXPERIMENTAL|Postural correction exercises group B|"Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch~."
62675978|NCT00773110|EXPERIMENTAL|1 Albumin|Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
62675979|NCT00773110|PLACEBO_COMPARATOR|2 Gelofusin|Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery
62675980|NCT04455750|EXPERIMENTAL|Arm I (enzalutamide, rucaparib)|Patients receive enzalutamide PO QD and rucaparib PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62116053|NCT06129370|EXPERIMENTAL|Software, then Standard|Participants will use the medication dosage software to calculate and prepare intravenous medications during the initial run through of pediatric case scenarios. Then, they will use standard clinical practice (Lexicomp and manual calculator) during the second run through of pediatric case scenarios.
62116054|NCT06129370|EXPERIMENTAL|Standard, then Software|Participants will use standard clinical practice (Lexicomp and manual calculator) to calculate and prepare intravenous medications during the initial run through of pediatric case scenarios. Then, they will use the medication dosage software during the second run through of pediatric case scenarios.
62116055|NCT03993613|EXPERIMENTAL|human apotransferrin|Patients will receive an intravenous dose of human apotransferrin every two weeks for 14-18 weeks.
62116056|NCT05121506|EXPERIMENTAL|CBD and THC with GT4 technology|
62116057|NCT02984124|EXPERIMENTAL|Intervention|Participants (n= approximately 100 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
62116058|NCT02984124|PLACEBO_COMPARATOR|Usual Care with Attention Control|Participants (n= approximately 100 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
62116059|NCT06677268|EXPERIMENTAL|interventional|Patient in this arm will perform a 2-months respiratory rehabilitation program
62116060|NCT06677268|NO_INTERVENTION|control|patient in the control group will have standard care without respiratory rehabilitation program
62116061|NCT04467788|ACTIVE_COMPARATOR|Computer-aided session|Training on ergonomic principles in dentistry will be given to the participants through Computer-Aided sessions, including explaining videos on proper postures in dental practice .
62116062|NCT04467788|ACTIVE_COMPARATOR|Clinical Simulation Session|Training on ergonomic principles in dentistry will be given to the participants through clinical simulation sessions showing the proper postures in dental practice.
62116063|NCT06134466|EXPERIMENTAL|Liquid Formula|Liquid Formula (Extensively hydrolyzed cow's milk protein infant formula) - 2.8 g protein/100 kcal
62116064|NCT02916836||With TDC sheet|Use of therapeutic drug conciliation sheet (TDC) by the hospital and transmitted to the family practitioner with other usual documentation
62116065|NCT02916836||Without TDC Sheet|transmission of usual documentation only to the family practitioner
62116066|NCT00506727|EXPERIMENTAL|Adderall XR|
62116067|NCT00506727|ACTIVE_COMPARATOR|Atomoxetine hydrochloride|
62116068|NCT01630564|EXPERIMENTAL|Treatment (T-cell infusion)|Patients undergo ex vivo-expanded umbilical cord blood progenitor cell donor T cell infusion with aldesleukin 11-14 days after T-cell co-stimulation begins.
62116069|NCT01071993|ACTIVE_COMPARATOR|atorvastatin|
62116070|NCT01071993|PLACEBO_COMPARATOR|placebo|
62116071|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
62116072|NCT01026636|EXPERIMENTAL|Ceftobiprole|Ceftobiprole 7mg/kg - 15mg/kg per day as 2h infusion
62472921|NCT02020915||Patients with chronic anal fissure|Patients are included who had previous treatment with diltiazem or glycerol-nitrate and botox injections
62472922|NCT02658045||Normal healthy volunteers|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in healthy volunteers during 6 min walking test
62675981|NCT04455750|ACTIVE_COMPARATOR|Arm II (enzalutamide, placebo)|Patients receive enzalutamide PO QD and placebo PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62116073|NCT02570191|EXPERIMENTAL|Peginterferon alfa-2a|Participants received 180 micrograms (uG) of Pegasys (0.5 milliliter \[mL\] solution) once a week subcutaneously for 48 weeks.
62116074|NCT01321606|EXPERIMENTAL|Arm 1: Probiotic|subjects will be given a capsule formulation of a 1x10\^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
62116075|NCT01321606|PLACEBO_COMPARATOR|Arm 2: Placebo|Placebo identical to the active product will be given
62116076|NCT00540202|EXPERIMENTAL|1.Oral quinine|Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days
62116077|NCT00540202|ACTIVE_COMPARATOR|2. Coartem|Tablets
62116078|NCT03229707|ACTIVE_COMPARATOR|group 1 Color matching using Vita 3D master|"Outcome Name: Color Matching measured by :~Modified (USPHS) criteria"
62116079|NCT03229707|EXPERIMENTAL|group 2 Color matching using digital photography|"Outcome Name: Color Matching measured by Digital Photography using (Photoshop)~Software:~* 0 to 1: no difference in perception~* 1 to 2: only perceptible to a trained observer~* 2 to 3.5: perceptible difference~* 3.5 to 5: marked difference"
62116080|NCT04136912|EXPERIMENTAL|Breast Imaging Cohort|A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy
62116081|NCT04136912|EXPERIMENTAL|Thyroid Imaging Cohort|A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy
62116082|NCT04136912|EXPERIMENTAL|Healthy Volunteers Cohort|A total of 15 participants will be included to optimize imaging parameters.
62116083|NCT02897622|OTHER|Case management|Case management
62116084|NCT00005772|EXPERIMENTAL|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
62116085|NCT00005772|PLACEBO_COMPARATOR|Normothermic|Placebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
62116086|NCT01637506||Study group|"* Age \> 19~* Radiological evidence indicating presence of a current renal or ureteric stone"
62116087|NCT01637506||Control group|"* Age \> 19.~* No history of kidney stone disease"
62116088|NCT01269736|EXPERIMENTAL|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
62116089|NCT01269736|NO_INTERVENTION|Control|Usual in-service education for nurses
62116090|NCT01365637|EXPERIMENTAL|Cohort 1 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
62116091|NCT01365637|EXPERIMENTAL|Cohort 2 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
62116092|NCT01365637|EXPERIMENTAL|Cohort 3 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
62116093|NCT01365637|EXPERIMENTAL|Cohort 4 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
62116094|NCT06028282||Radioiodine I-131 (RAI)|oral administration of radioiodine I-131 (RAI) to patients with well-differentiated thyroid cancer
62116095|NCT03993392|EXPERIMENTAL|TM buprenorphine followed by SUBLOCADE 300 mg|Participants with a diagnosis of OUD stopped use of their current opioid prior to coming to the clinic to be assessed for withdrawal symptoms. If confirmed to be in withdrawal, participants were administered 4 mg transmucosal (TM) buprenorphine. If tolerated without sensitivity, clinical signs of sedation, or precipitated withdrawal, 300 mg SUBLOCADE was administered. Following SUBLOCADE administration, participants remained in the clinic for approximately 48 hours and were assessed for safety and tolerability, as well as for any signs of precipitated withdrawal. Participants returned to the clinic weekly, until the end-of-treatment (EOT) visit (28 days after SUBLOCADE administration).
62116096|NCT03122704|EXPERIMENTAL|Group B Streptococcus (GBS) screening|Vaginal and anal swab of patients will be screened for GBS screening
62116097|NCT04565691|EXPERIMENTAL|Bacteremia inducing arm|As mentioned the participants will be their own controls at the different time-points.
62116098|NCT04704739|EXPERIMENTAL|GLPG1205 oral and [14C]-GLPG1205 IV|Single oral dose of GLPG1205 followed by \[14C\]-GLPG1205 solution for infusion
62116099|NCT04704739|EXPERIMENTAL|[14C]-GLPG1205 capsule|Single oral dose of GLPG1205 as solid formulation
62116100|NCT05146817|ACTIVE_COMPARATOR|Traditional oral care in long-term mechanical ventilation ICU patients|Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
62116101|NCT05146817|EXPERIMENTAL|Original oral care protocol in long-term mechanical ventilation ICU patients|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine .
62116102|NCT05607108|EXPERIMENTAL|ZEN003694|All patients enrolled on the study will undergo treatment with ZEN003694 60mg po qd on a 5 days on/2 days off schedule in an every 21-day cycle. All assessments, including drug dosing, have a window of +/- 7 days unless otherwise noted.
62116103|NCT02044523||Hepatis C, Hepatitis B, NAFLD|"All patients enrolled will undergo:~* Transient Elastography (Fibroscan)~* Acoustic Radiation Force Impulse (ARFI)~* Magnetic Resonance Elastography (MRE)"
62116104|NCT02616861|EXPERIMENTAL|IW-1973|1973 Escalating Doses
62116105|NCT02616861|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62116106|NCT02061228|NO_INTERVENTION|Control arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle.
61918173|NCT01634178|EXPERIMENTAL|Sequence 2: Apremilast Fed / Fasted|In Period 1 participants will receive a single 30 mg apremilast tablet administered after a high fat meal and in Period 2 participants will receive a single 30 mg apremilast tablet administered under fasted conditions.
62472923|NCT02658045||COPD patients|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in COPD patients during 6 min walking test
62675982|NCT01793909|OTHER|Single Leg Exercise|Supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
62116107|NCT02061228|EXPERIMENTAL|Induced endometrial injury arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).
62116108|NCT03657017|OTHER|PET/MR|Patients are examined with PET/MR.
62116109|NCT00962117||Obese/Non-obese|
62472924|NCT02849093||Dry Eye Syndrome Patients|Patients who have been diagnosed clinically with Sjögren's will have an OCT image of their lacrimal glands and buccal mucosa taken. Imaging from patients found to have Sjögren's clinically diagnosed following examination of buccal mucosa under the microscope will be compared with images from patients without dry eye syndrome to see of any obvious differences can be identified.
62472925|NCT02849093||Epiphora Patients|Pre and post-operative OCT images of patients undergoing punctoplasty or conjunctivoplasty will be compared to images of the same structures in people without watery eyes.
62675983|NCT01530997|EXPERIMENTAL|De-escalated Radiation and Chemotherapy|Patients will receive 54 to 60 Gy of Intensity Modulated Radiotherapy (IMRT) with concurrent weekly intravenous cisplatin (30 mg/m2). Diagnostic imaging (CT and/or MRI) will be obtained 4 to 8 weeks after completion of CRT to assess response. All patients will have surgical resection of any clinically apparent residual primary tumor or biopsy of the primary site if there is no evidence of residual tumor and will undergo a limited neck dissection to encompass at least those nodal level(s) that were positive pre-treatment, 4 to 14 weeks after CRT.
61918174|NCT04516837|EXPERIMENTAL|eltrombopag plus rhTPO|Combination of eltrombopag and rhTPO
61918175|NCT04516837|ACTIVE_COMPARATOR|eltrombopag|Eltrombopag monotherapy
61918176|NCT04924803|EXPERIMENTAL|No video condition|Participants in the no video condition will receive weekly text messages designed to increase vaccination among our sample.
62116110|NCT01698255|EXPERIMENTAL|ENGAGE|"ENGAGE is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression. The steps of ENGAGE are:~1. basic social and physical engagement, which has been found to be a very effective depression strategy for most older adults;~2. the addition of strategies to address clinical features of depression interfering with treatment engagement, namely affect regulation, pessimism, and disorganization."
62116111|NCT01698255|ACTIVE_COMPARATOR|Standard of Care Psychotherapy|The comparison group for this study will be the current standard of care psychotherapy offered by Westchester Jewish Community Services (WJCS) therapists. This type of psychotherapy is often supportive or eclectic in nature. Therapists will focus on helping the subject to express feelings and focus on strengths and abilities in working through current difficulties and transitions. Therapists assigned to provide standard psychotherapy to eligible participants will receive training and supervision from WJCS staff consistent with agency practice.
62116112|NCT01510041|EXPERIMENTAL|Inspiratory muscle training group|
62116113|NCT01510041|EXPERIMENTAL|Respiratory exercise group|
62116114|NCT04558112|EXPERIMENTAL|100 mg L-DOPA|Complete a \~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for \~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return \~24 hours later for Day 2 fMRI, in which they will complete a single \~40-minute fMRI scan while listening to either their trauma or neutral narrative.
62472926|NCT02849093||Asymptomatic Patients|OCT images will be captured of the cornea, conjunctiva, lacrimal gland and buccal mucosa to establish normal appearance in asymptomatic patients.
62675984|NCT05181631|EXPERIMENTAL|Biobanking|"If the patient consents, two tubes of blood will be collected for biobanking, at the same time as routine tubes will be collected.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in the biological resources center of Avicenne hospital ."
62116115|NCT04558112|PLACEBO_COMPARATOR|Placebo|Complete a \~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for \~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return \~24 hours later for Day 2 fMRI, in which they will complete a single \~40-minute fMRI scan while listening to either their trauma or neutral narrative.
62116116|NCT01290224|EXPERIMENTAL|Supportive Care|See Detailed Description
61918177|NCT04924803|EXPERIMENTAL|Video text condition|Participants in the video text condition will receive the text messages designed to increase vaccination among our sample, along with links to iteratively developed intervention videos
62116117|NCT02796092|ACTIVE_COMPARATOR|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
62116118|NCT02796092|EXPERIMENTAL|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
62116119|NCT05110391||NOA_Treated|Hypogonadal patients with non-obstructive azoospermia who received gonadotropin therapy before sperm retrieval
62116120|NCT05110391||NOA_Untreated|Hypogonadal patients with non-obstructive azoospermia who did not receive gonadotropin therapy before sperm retrieval
62116121|NCT02866435|EXPERIMENTAL|Euglycemia pre-conditioning|Participants will undergo two euglycemia (normal blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where the target glucose during the clamp will be 95 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
62116122|NCT02866435|EXPERIMENTAL|Hypoglycemia pre-conditioning|Participants will undergo two hypoglycemia (low blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where target glucose during the clamp will be 50 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
62116123|NCT05802264|EXPERIMENTAL|Part A Healthy Volunteer|Subjects will be assigned to one of six planned dose cohorts and receive single doses of ABCI (0.5mg, 1.0mg, 2.0mg, 4.0mg, 6.0mg, 10.0mg). In each cohort, six subjects will receive ABCI and 2 will receive placebo
62116124|NCT05802264|EXPERIMENTAL|Part B Healthy Volunteer|Subjects will be assigned to one of three planned dose cohorts and receive a loading dose and multiple ascending doses of ABCI (loading dose 1.5mg/0.5mg daily, loading dose 6.0mg/2.0 daily, loading dose 10.0mg/4.0mg daily). In each cohort, six subjects will receive ABCI and 2 will receive placebo.
62116125|NCT05802264|EXPERIMENTAL|Part C People with Cystic Fibrosis|Subjects will be assigned to one of two planned dose cohorts of ABCI (loading dose 6.0mg/2.0mg daily, loading dose 10.0mg/4.0mg daily) for a total of 28 days of open-label study drug administration. Up to 20 subjects with CF, including 2 sentinels subjects not on cystic fibrosis transmembrane conductance regulator (CFTR) modulators will be enrolled. The 2 sentinel subjects will receive the medium dose/regimen. If the medium dose/regimen is tolerated, the remaining subjects with CF will receive the high dose/regimen of ABCI and may be either on CFTR modulators or not on CFTR modulators.
62116126|NCT00886145|OTHER|Vibration and No Vibration|Vibration: Right Leg and No Vibration: Left Leg.
62116127|NCT02999048|NO_INTERVENTION|control group|Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
62116128|NCT02999048|OTHER|intervention group|Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
62116129|NCT02013830|EXPERIMENTAL|Avastin + Xeloda|
62304528|NCT02179398|EXPERIMENTAL|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.~(WBC and band counts blinded to the physician in charge of the patient)"
62304529|NCT02179398|ACTIVE_COMPARATOR|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
62675985|NCT04367935|ACTIVE_COMPARATOR|Intervention|Pentoxifylline tablets 400mg three times daily for 2 months
62675986|NCT04367935|NO_INTERVENTION|Control|Control Group receiving placebo tablets three times daily for 2 months
62472927|NCT02104908|EXPERIMENTAL|paravertebral nerve|Injection with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1)
62472928|NCT02104908|OTHER|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
62472929|NCT06504056||Left ventricle group|The patients mainly had thickened myocardial wall with a thin, compacted epicardial layer and a thicker endocardial layer, and were diagnosed with LVNC.
62472930|NCT06504056||Right ventricle group|The patients mainly had thickened myocardial wall with a thin, compacted epicardial layer and a thicker endocardial layer, and were diagnosed with right NVM.
62472931|NCT06504056||Two sided ventricle group|The patients mainly had thickened myocardial wall with a thin, compacted epicardial layer and a thicker endocardial layer, and were diagnosed with right and left ventricle NVM.
62116130|NCT02050308|EXPERIMENTAL|Internet-All Nations Breath of Life (I-ANBL)|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to quitting smoking (like: preparing to quit, dealing with cravings, and support systems, etc.) and topics relevant to American Indian culture (like traditional use of tobacco).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
62675987|NCT05507229|EXPERIMENTAL|Arm 1|Hillchol®(BBV131) vaccine - (Lot-I ) administered to 450 subjects on day 0 and 14.
62675988|NCT05507229|EXPERIMENTAL|Arm 2|Hillchol®(BBV131) vaccine - (Lot-II) administered to 450 subjects on day 0 and 14.
62675989|NCT05507229|EXPERIMENTAL|Arm 3|Hillchol®(BBV131) vaccine - (Lot-III ) administered to 450 subjects on day 0 and 14 .
62116131|NCT02050308|ACTIVE_COMPARATOR|Honoring the Gift of Heart Health|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to heart health (like: Assessing risk for heart disease, increasing fruit and vegetable consumption, physical activity, etc.).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
62116132|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
62116133|NCT03804086|EXPERIMENTAL|Test Group|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement (OFD).
62116134|NCT03804086|ACTIVE_COMPARATOR|Control Group|Open flap debridement alone.
62675990|NCT05507229|ACTIVE_COMPARATOR|Arm 4|Shanchol Vaccine administered to 450 subjects on day 0 and 14
61918178|NCT03778775||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and liver stiffness measurement by FibroTouch.
62116135|NCT05831007|EXPERIMENTAL|LX102-C01 Injection|"Potential doses:~3E10 vg, 0.06 mL/eye/dose~1E11 vg, 0.06 mL/eye/dose"
62116136|NCT01465724|EXPERIMENTAL|Renal denervation|
62116137|NCT00688519|EXPERIMENTAL|U0267 Foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
62116138|NCT00688519|PLACEBO_COMPARATOR|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
62116139|NCT06346769|EXPERIMENTAL|'O' shape polyethylene fiber|
62116140|NCT06346769|EXPERIMENTAL|mesiodistal I shape polyethylene fiber|
62116141|NCT06346769|EXPERIMENTAL|buccolingual I shape polyethylene fiber|
62116142|NCT00043082|EXPERIMENTAL|carboplatin and doxorubicin|carboplatin and liposomal doxorubicin given q 4 weeks
62116143|NCT00043082|ACTIVE_COMPARATOR|carboplatin|carboplatin alone
62116144|NCT04456348||positive|Subjects have gait disorder according to intelligent gait assessment at baseline.
62116145|NCT04456348||negative|Subjects don't have gait disorder according to intelligent gait assessment at baseline.
62116146|NCT01320280|EXPERIMENTAL|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
62472932|NCT03829891|EXPERIMENTAL|Beinaglutide|"1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
62472933|NCT03829891|ACTIVE_COMPARATOR|glargine|"1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
62675991|NCT02927314|PLACEBO_COMPARATOR|Placebo|Placebo tablets orally q12h
62675992|NCT02927314|ACTIVE_COMPARATOR|CF102 12.5mg|CF102 tablets orally q12h
62675993|NCT02927314|ACTIVE_COMPARATOR|CF102 25mg|CF102 tablets orally q12h
62116147|NCT06304636|EXPERIMENTAL|Part 1 Descartes-15 with lymphodepletion|Intra-patient dose escalation arm with three dose levels over the course of six infusions of cell product. Patients will receive lymphodepletion prior to initiating cell therapy.
62116148|NCT06304636|EXPERIMENTAL|Part 2 Arm 1 Descartes-15 with lymphodepletion|Descartes-15 infusions at the maximum tolerated dose level from Part 1. Patients will receive lymphodepletion prior to initiating cell therapy.
62116149|NCT06304636|EXPERIMENTAL|Part 2 Arm 2 Descartes-15 without lymphodepletion|Descartes-15 infusions at the maximum tolerated dose level from Part 1. Patients will not receive lymphodepletion prior to initiating cell therapy.
62116150|NCT03870191|ACTIVE_COMPARATOR|Twin Block Group|This group will receive twin block injections.
62116151|NCT03870191|ACTIVE_COMPARATOR|Trigger Point Injection Group|This group will receive trigger point injections.
62116152|NCT04365400|EXPERIMENTAL|DS102 2000mg|Participants in this group received 1000mg DS102 capsules twice daily.
62675994|NCT04761588|EXPERIMENTAL|Tyr sphere|All patients to receive Tyr sphere as part of their dietary management for tyrosinaemia or alkaptonuria (AKU).
62675995|NCT06450470|ACTIVE_COMPARATOR|Therapeutic lens alone|
62675996|NCT06450470|EXPERIMENTAL|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|
62116153|NCT04365400|EXPERIMENTAL|DS102 4000mg|Participants in this group received 2000mg DS102 capsules twice daily.
62116154|NCT04365400|PLACEBO_COMPARATOR|Placebo|Participants in this group received placebo capsules twice daily.
62304530|NCT00942682|EXPERIMENTAL|Sorafenib and RAD001|"* Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have neuroendocrine tumors, not everyone who participates in this research study will receive the same dose of the study drug. The dose the participant will be given will depend on the number of participants who have been enrolled in the study.~* Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in the morning. Participants will take sorafenib orally twice daily.~* Participants will remain on this research study as long as they continue to benefit from the study medications."
62304531|NCT03619785|EXPERIMENTAL|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
62116155|NCT02052219|EXPERIMENTAL|Blisibimod|
62116156|NCT02052219|PLACEBO_COMPARATOR|Placebo|
62304532|NCT03619785|ACTIVE_COMPARATOR|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
62304533|NCT02730247|EXPERIMENTAL|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
62304534|NCT04757337|ACTIVE_COMPARATOR|Doxorubicin|Intravenous Doxorubicin 60 mg/m² Cycle 1 then 75 mg/m² Cycle 2 to Cycle 6 D1-D21 with granulocyte-colony stimulating factor (G-CSF) and dexrazoxane.
62304535|NCT04757337|EXPERIMENTAL|Cyclophosphamide|Cyclophosphamide per os 100 mg twice a day, 1 week on, 1 week off until 2 years, or unacceptable toxicity, disease progression, withdrawn of consent or death.
62472934|NCT05570981||Chronic Refractory Cough (CRC)|Individuals with a diagnosis of chronic refractory cough
62472935|NCT05570981||Healthy controls|Healthy control subjects matched to the CRC group by age and gender
62675997|NCT06695949|EXPERIMENTAL|Percutaneous neuromodulation|"Patients assigned to this group (n=50) will receive three weekly sessions of percutaneous neuromodulation for a total of 6 weeks, with each session lasting 30 minutes. For the treatment application, the patient will be positioned in a prone decubitus position, leaving the dorsal-cervical area exposed, and we will apply skin disinfectant (chlorhexidine). Subsequently, and under ultrasound guidance, we will perform the technique using a 30 x 40 mm acupuncture needle, which will be inserted at three vertebral levels and bilaterally; the greater occipital nerve and the posterior root of the C3 and C7 levels. Once the needles are correctly positioned, we will connect alligator clip electrodes segmentally, connecting them to an electrotherapy device (TensMed S82-Enraf Nonius) applying a TENS current. The parameters used will be set to low-frequency (2 Hz) symmetric biphasic pulsed current with a pulse width of 120 μs and an intensity described by the patient as mild to moderate."
62675998|NCT06695949|ACTIVE_COMPARATOR|Therapeutic Exercise|These participants (n=50) will engage in resistance training for the cervical flexor muscles, following a progressive exercise program in a supine position with the head comfortably supported, as described by Falla et al. (2008). Participants will perform these exercises with a frequency of 3 days a week for 6 weeks, with each session lasting 30 minutes.
62116157|NCT01221779|PLACEBO_COMPARATOR|sham tDCS|
62304536|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
62472936|NCT03055637|ACTIVE_COMPARATOR|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
62472937|NCT03055637|ACTIVE_COMPARATOR|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
62116158|NCT01221779|EXPERIMENTAL|anodal tDCS|
62116159|NCT03156712|EXPERIMENTAL|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
62304537|NCT00473694|EXPERIMENTAL|rocuronium+sugammadex|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 post-tetanic counts (PTC) and after the last dose of rocuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
62304538|NCT00473694|ACTIVE_COMPARATOR|rocuronium+neostigmine|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 PTC and after the last dose of rocuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
62304539|NCT00473694|EXPERIMENTAL|vecuronium+sugammadex|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
62304540|NCT00473694|ACTIVE_COMPARATOR|vecuronium+neostigmine|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
62304541|NCT06656559|EXPERIMENTAL|Envafolimab and Surufatinib|
62304542|NCT01561131|ACTIVE_COMPARATOR|Whey protein supplement|Whey protein
62304543|NCT01561131|ACTIVE_COMPARATOR|Whey protein enriched with calcium supplement|Whey protein enriched with calcium
62304544|NCT01561131|ACTIVE_COMPARATOR|Soy protein supplement|Soy protein
62116160|NCT03156712|EXPERIMENTAL|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
62304545|NCT01561131|PLACEBO_COMPARATOR|Control supplement|Maltodextrin
62304546|NCT00951795||Adults|Adult men and women over age of 18
62116161|NCT03156712|EXPERIMENTAL|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
62116162|NCT04986683|EXPERIMENTAL|Patients with drug-resistant epilepsy|All patients who undergo two-stage epilepsy surgery will receive two longitudinal evaluations of brain MRI and neuropsychology test: a month before surgery and 1.5 years after surgery.
62116163|NCT05685095|EXPERIMENTAL|Treadmill walking|The training program will last 12 weeks and consist of treadmill walking. The duration of the walking bouts (and pauses), and the speed of the belt will be adjusted as needed following the patients' progress. Music will be added as suited to boost motivation and support regular cadence. All training sessions will be supervised.
62304547|NCT00951795||Pediatrics|Pediatric boys and girls ages 12-18
62304548|NCT05509244|ACTIVE_COMPARATOR|control group|acetaminophen 1g iv dripping
62304549|NCT05509244|EXPERIMENTAL|experimental group|the combination of acetaminophen 1g and ibuprofen 300mg iv dripping
62304550|NCT02765893|NO_INTERVENTION|Foley|Patients will have Foley in place overnight after completion of surgery, which is currently standard of care at our institution.
62304551|NCT02765893|ACTIVE_COMPARATOR|No Foley|Patients will have Foley catheter removed 6 hours post-op.
62675999|NCT00976300|EXPERIMENTAL|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
62472938|NCT01959672|EXPERIMENTAL|Treatment (chemotherapy, oregovomab, SBRT, surgery)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV, leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses.~IMMUNOTHERAPY: Patients with CA125 level \>= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate PO BID for 5 weeks beginning on day 15 of week 9.~STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18."
62676000|NCT00976300|ACTIVE_COMPARATOR|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).
62676001|NCT05999552|NO_INTERVENTION|Control Group|any exercise program will not be applied and will only be followed.
62676002|NCT05999552|EXPERIMENTAL|Experimental Group|eye exercise program will be applied.
61918179|NCT04703101|EXPERIMENTAL|Treatment (IMRT, mFOLFOX6, CapeOX, TME)|Patients undergo SCRT in the form of IMRT over 5 fractions daily for 5 consecutive days. Beginning 11-18 days after the last day of radiation therapy, patients receive either oxaliplatin IV and leucovorin IV on day 1 and fluorouracil IV on days 1-3 (mFOLFOX6) or oxaliplatin IV on day 1 and capecitabine PO BID on days 1-14 (CapeOX). Treatment with mFOLFOX6 repeats every 2 weeks for up to 8 cycles, and treatment with CapeOX repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. At 8-12 weeks after completion of all therapy, patients with residual tumor undergo TME. Patients with cCR undergo NOM.
62676003|NCT05800015|EXPERIMENTAL|Phase 2 - Arm A|Randomized 1:1:1 fianlimab (higher dose) + cemiplimab + platinum-doublet chemotherapy
62676004|NCT05800015|EXPERIMENTAL|Phase 2 - Arm B|Randomized 1:1:1 fianlimab (lower dose) + cemiplimab + platinum-doublet chemotherapy
62676005|NCT05800015|EXPERIMENTAL|Phase 2 - Arm C|Randomized 1:1:1 cemiplimab + platinum-doublet chemotherapy + placebo
62676006|NCT05800015|EXPERIMENTAL|Phase 3 - Arm A or B|Randomized 1:1 fianlimab (chosen dose) + cemiplimab + platinum-doublet chemotherapy
61918180|NCT06127537|NO_INTERVENTION|Control Group|Health Education Programme in cardiac rehabilitation without a Therapeutic Intervention Group
61918181|NCT06127537|EXPERIMENTAL|Experimental Group|Health Education Programme in cardiac rehabilitation with a Therapeutic Intervention Group
62116164|NCT05685095|EXPERIMENTAL|Nordic walking|The training program will last 12 weeks and consist of Nordic walking, taught and supervised by an adapted physical activity teacher. The session will be carried out outside, weather permitting. When possible, training will gather 2 to 4 patients for group emulation. The duration of the walking bouts (and pauses) will be adjusted to follow the patients' progress.
62116165|NCT00637234|EXPERIMENTAL|1|
62116166|NCT00637234|PLACEBO_COMPARATOR|2|
62116167|NCT02083991|EXPERIMENTAL|Steroid-free low TAC-arm|"Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.~Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o."
62116168|NCT02083991|ACTIVE_COMPARATOR|Standard low-TAC arm|"Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.~Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months)."
62304552|NCT05811195|ACTIVE_COMPARATOR|Intraoral photobiomodulation (PBMI)|"Intraoral application: A low-power laser (Diode Semiconductor, Duo, MMOptics Ltda, São Carlos, SP, Brazil) with a wavelength of 660 nm (red). Four anatomical areas will be irradiated perpendicularly in oral mucosa through several anatomical points with a distance of 1 cm approximately between them in order to cover the largest area per cm² in each region.~Application points:~* Jugal mucosa: 4 points for each side: upper and lower internal buccal vestibule, (8 points).~* Jugal mucosa for younger children 2 points internal buccal vestibule in the center - each side (4 points)~* Tongue: 2 points on right and left lateral border and 1 point on right and left belly (6 points)~* Oral floor: (2 points).~* Upper and lower lips: 2 points on upper inner labial mucosa, 2 points on lower inner labial mucosa (4 points).~* Soft palate: right and left sides (2 points)"
62304553|NCT05811195|ACTIVE_COMPARATOR|Extraoral photobiomodulation (PBME)|"A gallium-aluminum arsenide diode laser (Gemini® manufactured by Azena Medical, LLC, distributed by Ultradent Products, Inc.) with double wavelength 810 + 980 nm. The equipment will be programmed with 1 W of power.~* 4 points - on each side of the face (2 on the right 2 on the left);~* 2 points - on each side of the face: for younger children 1 point will be performed on each side of the face (1 on the right, 1 on the left)~* 1 point on the lip; patients with sealed lips being able to cover both the upper and lower lip;~* 5 points in the neck region (2 in right submandibular space and 2 in left submandibular space and submental space in the midline).~* 3 points in the neck region for younger children (1 in right submandibular space and 1 in left submandibular space and submental space in the midline)"
62472939|NCT04595279|EXPERIMENTAL|Smoking sessions|This is the single arm that will go through cigarette smoking sessions
62676007|NCT05800015|EXPERIMENTAL|Phase 3 - Arm C|Randomized 1:1 cemiplimab + platinum-doublet chemotherapy + placebo
62676008|NCT02743754|PLACEBO_COMPARATOR|Standard Therapy|Standard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.
61918182|NCT04386915|EXPERIMENTAL|Single-dose experimental group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2 and Day4. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
62116169|NCT01391130|EXPERIMENTAL|LY2510924 + Sunitinib|LY2510924: 20 milligram administered subcutaneously once daily, given every day of the 6 week cycle. Sunitinib: 50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
62472940|NCT03414593|EXPERIMENTAL|preoperative blocked leg: group preB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml Before surgical incision
62472941|NCT03414593|ACTIVE_COMPARATOR|postoperative blocked leg: group postB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml After surgical incision
62676009|NCT02743754|ACTIVE_COMPARATOR|Standard Therapy and hyperbaric oxygen|Standard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).
62116170|NCT01391130|ACTIVE_COMPARATOR|Sunitinib|50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
62116171|NCT05859971|EXPERIMENTAL|Sentinel Lymph Node (SLN) mapping|SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging.
62116172|NCT05262478||Alpha-D cervical disc prosthesis|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
62116173|NCT01335542|ACTIVE_COMPARATOR|Epidural Pathway (PCEA+FNB)|
62116174|NCT01335542|ACTIVE_COMPARATOR|Peri-Articular Injection|
62116175|NCT00758433|ACTIVE_COMPARATOR|1|Civamide patch 0.0075%
62116176|NCT00758433|ACTIVE_COMPARATOR|2|Civamide patch 0.0150%
62676010|NCT01189227|EXPERIMENTAL|Arm 1: Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
62676011|NCT01189227|EXPERIMENTAL|Arm 2: Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
62676012|NCT04784780|EXPERIMENTAL|Elobixibat|AJG533 (elobixibat) 10 mg orally once a day before meals for 12 weeks
62676013|NCT04784780|PLACEBO_COMPARATOR|Placebo|AJG533 placebo orally once a day before meals for 12 weeks
62116177|NCT00758433|PLACEBO_COMPARATOR|3|Placebo patch
62116178|NCT00959413||A|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1,000 copies/ml
62116179|NCT00959413||B|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1,000 copies/ml or less
62116180|NCT00959413||C|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1,000 copies/ml
62676014|NCT05511844|EXPERIMENTAL|Part 1 Dose Escalation|All participants receive ORM-5029 in escalating dose cohorts in Part 1 Dose Escalation and at the Expansion Dose Level (EDL) in Part 2 Dose Expansion.
62676015|NCT05511844|EXPERIMENTAL|Part 2 Dose Expansion|All participants receive ORM-5029 at dose levels with pharmacodynamic activity or efficacy signals (Expansion Cohort A) or at the Expansion Dose Level (EDL) (Expansion Cohorts B and C).
62304554|NCT05098288|EXPERIMENTAL|App + Unified Protocol Arm|"Participants at this condition will be daily monitored by the app (Multicentre Pain Monitor) while they are administered a self-applied online transdiagnostic intervention (Unified protocol) for their emotional disorders. Alarms will be generated in the face of certain pre-set undesired events.~Therapists will receive pre-set clinical alarms in real time in the presence of relevant clinical events previously determined by the clinical staff (e.g., clinical worsening or no improvement of functionality, mood or psychological mechanisms worked in therapy). This information will be used to make clinical decisions in a short period of time (e.g., call the patient, or send additional therapeutic material by mail or through the app (momentary ecological intervention), or for its implementation during the course of psychological therapy in order to make the therapy more efficient, safe, personalized and adapted to the needs of the patient"
62676016|NCT04841876||Group-1|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-1, participants will be asked to play three consecutive rugby matches, with 40 min for each match. The total duration will be 2 hours. There is no additional intervention on this group.
62676017|NCT04841876||Group 2|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-2, participants will be asked to only watch the rugby matches. They will not received any intervention.
62116181|NCT00959413||D|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1,000 copies/ml or less
62116182|NCT05023512|EXPERIMENTAL|Message 1|Participants will be randomized to receive version #1 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
62116183|NCT05023512|EXPERIMENTAL|Message 2|Participants will be randomized to receive version #2 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
62116184|NCT03253913|EXPERIMENTAL|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
62116185|NCT01802866|EXPERIMENTAL|ACU-4429 2.5 mg|2.5 mg tablet
62116186|NCT01802866|EXPERIMENTAL|ACU-4429 5 mg|5 mg tablet
62116187|NCT01802866|EXPERIMENTAL|ACU-4429 10 mg|10 mg tablet
62116188|NCT01802866|PLACEBO_COMPARATOR|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
62304555|NCT03842709|PLACEBO_COMPARATOR|Standard Treatment + Placebo|Patients reporting sub-optimal results of pain therapy, assigned to placebo in addition to routine care.
62304556|NCT03842709|EXPERIMENTAL|Standard Treatment + Pramipexole|Patients reporting sub-optimal results of pain therapy, assigned to receive pramipexole in addition to routine care.
62676018|NCT04029038|EXPERIMENTAL|Treatment (CD19-CD22 CAR T cells)|Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
62676019|NCT06052397||Sleep and Circadian Rhythms biomarker cohort|Cohort will complete a series of blood sample donations (both intraoperatively and postoperatively) as well as complete daily neurocognitive assessments at baseline and on PODs 1 - 3.
62676020|NCT06553820|EXPERIMENTAL|Intervention group I, yoga 20 minutes x2 pr week|
62676021|NCT06553820|EXPERIMENTAL|Intervention Group II, yoga 40 minutes pr week|
62676022|NCT06553820|OTHER|Control group, no intervention|standard of care
61918183|NCT04386915|PLACEBO_COMPARATOR|Single-dose control group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
62116189|NCT05826678|ACTIVE_COMPARATOR|Participants on CGM|Participants in this group will be offered a CGM device for glucose monitoring, with training and educational materials provided in either English or Chinese, according to the participant's preference.
62116190|NCT05826678|PLACEBO_COMPARATOR|Participants on Finger-stick only|Participants in this group continue standard fingerstick self-monitoring of blood glucose (FSGM) as per standard care protocol. They will also receive educational materials provided in either English or Chinese, according to the participant's preference.
62116191|NCT04640064||Patient with type 1 diabetes|Children younger than 17 years with a diagnosis of type 1 diabetes prior to 2018 will be included.
62116192|NCT00739518|EXPERIMENTAL|MRI scan - new technology|The patient's clinical MRI scan will also utilize some new technology, such as a change in software or additional MRI sequences
62116193|NCT01727128|EXPERIMENTAL|Mild Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - mildly hepatically impaired
62116194|NCT01727128|EXPERIMENTAL|Moderate Hepatic Impaired group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - moderately hepatically impaired
62116195|NCT01727128|EXPERIMENTAL|Severe Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - Severely hepatically impaired
62116196|NCT01727128|EXPERIMENTAL|Control Group|Matching healthy control subjects who do not have hepatic impairment and are matched to the hepatic impaired subjects by sex, age, gender and BMI
62116197|NCT00761930|PLACEBO_COMPARATOR|A|commercially available Fluoride toothpaste
62116198|NCT00761930|ACTIVE_COMPARATOR|B|fluoride/triclosan/copolymer toothpaste
62116199|NCT00761930|EXPERIMENTAL|C|fluoride/herbal toothpaste
62676023|NCT01638299|EXPERIMENTAL|Hypo-Hyper Minimizer (HHM) System|
62676024|NCT04619082|EXPERIMENTAL|TAF prophylaxis|Using TAF to prevent HBV reactivation for HBsAg-positive cancer patients
62676025|NCT02405637|EXPERIMENTAL|SAFE group|simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
62116200|NCT04035291|ACTIVE_COMPARATOR|Interventional|The first group (n = 25) will be asked to apply the physiotherapy program by the family at home that includes the principles of therapeutic handling-holding-positioning of NDT principles, starting at the third month for 8 weeks. And It will last for at least 45 minutes, 3 days a week. Family education will be evaluated after 4 weeks and improvements will be made in accordance with the motor development of the infant. The program will be implemented by families for 8 weeks.
62676026|NCT02405637|PLACEBO_COMPARATOR|placebo|distilled water 2.5 ml/kg every 3 hours enterally
62116201|NCT04035291|EXPERIMENTAL|Experimental|In the second study group (n = 25), family collaborative physiotherapy program will be applied by the family. This program will start from the postterm third month, and will include family trainings based on the goal-oriented active motor learning model of the baby in an 8-week in enriched environment and to include holding-carrying-positioning trainings in daily routines. Also it will last for at least 45 minutes, 7 days a week. All members of the family will be included in the family trainings and home visits will be made at 2-week intervals. Families will be encouraged to apply the physiotherapy processes of their babies in their natural environment at every moment of their daily routines (feeding, carrying on lap, gas extraction, changing the bed, sleeping, waking time, shopping moment, playing games etc.).
62304557|NCT04135781|EXPERIMENTAL|AS|Arm A：nab paclitaxel （120mg/m2；iv；d1，8）+S-1 （\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）Q3W；up to eight cycles
62304558|NCT04135781|ACTIVE_COMPARATOR|XELOX|Arm B：Capetabine（1000 mg/m2 po, d1-14 bid ）+ Oxaliplatin（130mg/m2 , iv, d1）Q3W；up to eight cycles
62304559|NCT00749086|EXPERIMENTAL|2|balloon kyphoplasty
62304560|NCT00749086|ACTIVE_COMPARATOR|1|vertebroplasty
62304561|NCT01561638|ACTIVE_COMPARATOR|group p|pulse radiofrequency lesioning
62304562|NCT01561638|PLACEBO_COMPARATOR|sham group|Controlled, conventional
62116202|NCT04035291|NO_INTERVENTION|control|In the third study group, families who are out of town or who cannot participate in the treatment program for other reasons will be included in the evaluations.
62116203|NCT00564967|EXPERIMENTAL|1|CBT via the Internet
62116204|NCT00564967|EXPERIMENTAL|2|15 weeks, CBT group therapy, 1 session/week (2.5 hours).
62116205|NCT04246762|EXPERIMENTAL|Olokizumab 128 mg +Cocktail drugs|"All subjects have received the following treatment:~Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered with 240 mL of water on Day 1, single subcutaneous injection of Olokizumab 128 mg administered on Day 8 and second dose of Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered on Day 22"
62116206|NCT02662530|ACTIVE_COMPARATOR|Botulinum toxin type A clinical|Initial and optimization of BoNT-A injection parameters will be conducted by clinical visual assessment
62116207|NCT02662530|ACTIVE_COMPARATOR|Botulinum toxin type A kinematic|Initial and optimization of BoNT-A injection parameters will be conducted by kinematic assessment
62116208|NCT01424332|EXPERIMENTAL|Treatment arm 1|darexaban, wash-out, ASA, wash-out, darexaban plus ASA
62116209|NCT01424332|EXPERIMENTAL|Treatment arm 2|darexaban, wash-out, darexaban plus ASA, wash-out, ASA
62304563|NCT01561638|ACTIVE_COMPARATOR|group C|Pulse dose radiofrequency
62116210|NCT01424332|EXPERIMENTAL|Treatment arm 3|ASA, wash-out, darexaban, wash-out, darexaban plus ASA
62116211|NCT01424332|EXPERIMENTAL|Treatment arm 4|ASA, wash-out, darexaban plus ASA, wash-out, darexaban
62304564|NCT01969656|PLACEBO_COMPARATOR|Placebo|
62304565|NCT01969656|ACTIVE_COMPARATOR|Calcitriol|
62304566|NCT01969656|EXPERIMENTAL|50 ng 2MD|
62304567|NCT01969656|EXPERIMENTAL|110 ng 2MD|
62304568|NCT01969656|EXPERIMENTAL|170 ng 2MD|
62304569|NCT01969656|EXPERIMENTAL|220 ng 2MD|
62304570|NCT01969656|EXPERIMENTAL|440 ng 2MD|
62304571|NCT03918993||Group T|31 Patients with ED who receiving 5 mg/day of Tadalafil for 8 weeks.
62304572|NCT03918993||Group C|Thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up
62304573|NCT03823729|EXPERIMENTAL|Elosan Cabin|Treatment with Elosan cabin
62304574|NCT03823729|NO_INTERVENTION|No Treatment|Continuation of taking pain medication as prescribed before study start.
62304575|NCT01432639|EXPERIMENTAL|Experimental group|Patients undergoing the exercise-based cardiac rehabilitation program (intervention)
62304576|NCT01432639|NO_INTERVENTION|Control group|Usual medical care
62304577|NCT02936440||critical patients with AKI|Critical patients with AKI will be followed up to 12 weeks after diagnosis
62304578|NCT05381961||Stable hemodialysis regimen|Up to 50 patients on hemodialysis \>6 months, with stable target/dry weight, and have not been hospitalized recently
62304579|NCT05381961||Unstable hemodialysis regimen|Up to 20 patients who have been on hemodialysis \<6 months, or have unintended weight loss/gain, or have recently been hospitalized
62304580|NCT03702933||Placebo|starch
62304581|NCT03702933||High Dose|3.5 g/d D-serine adjuvant treatment
62304582|NCT03702933||Low Dose|2.1 g/d D-serine adjuvant treatment
62304583|NCT05230043||Suicide Attempters using Violent Means|A violent suicidal act is any suicidal act conducted with any means except for medication overdose or superficial wrist cutting.
62304584|NCT05230043||Patient Control|
62304585|NCT05230043||Healthy Controls|
62304586|NCT05230043||Suicide Attempters not using Violent Means|
62304587|NCT04073615|EXPERIMENTAL|Rivoceranib|Participants will receive an oral dose of rivoceranib once per day on Days 1 through 28 of each 28-day cycle.
62304588|NCT04073615|ACTIVE_COMPARATOR|Trifluridine/tipiracil|Participants will receive an oral dose of Trifluridine/tipiracil twice per day with food, on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.
62304589|NCT04073615|EXPERIMENTAL|Rivoceranib and trifluridine/tipiracil|Participants will receive a daily oral dose of rivoceranib on Days 1 through 28 and the recommended phase 2 dose (RP2D) of trifluridine/tipiracil twice per day between Days 1 to 5 and 8 to 12 of each 28-day cycle.
62304590|NCT03435900|EXPERIMENTAL|Intervention group|
62304591|NCT03435900|ACTIVE_COMPARATOR|Control group|
62472942|NCT05228626|PLACEBO_COMPARATOR|Standard of care plus placebo arm|Will contain standard of care plus placebo
62676027|NCT01260324||NAION cases|From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
62304592|NCT01930071|EXPERIMENTAL|PQ Bypass Guide Wire Delivery System|PQ Bypass Guide Wire Delivery System to complete percutaneous Fem-pop bypass
62472943|NCT05228626|EXPERIMENTAL|Stanadard of care plus COVIDEX arm|Will contain the standard of care plus the intervention given for 3 times daily for seven days
62116212|NCT01424332|EXPERIMENTAL|Treatment arm 5|darexaban plus ASA, wash-out, darexaban, wash-out, ASA
62116213|NCT01424332|EXPERIMENTAL|Treatment arm 6|darexaban plus ASA, wash-out, ASA, wash-out, darexaban
62116214|NCT06620406|EXPERIMENTAL|Synbiotic Therapy|A mixture of the prebiotic potato resistant starch (RS, Bobs Red Mill) and the probiotic IVS-1 (Bifidobacterium adolescentis).
62116215|NCT06620406|PLACEBO_COMPARATOR|Placebo|The placebo we will use is Maltodextrin, a carbohydrate packaged similarly to the study intervention.
62116216|NCT04619914|EXPERIMENTAL|Group A (clomiphene citrate & estradiol group)|included 35 anovulatory PCO patients who received clomiphene citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14
62116217|NCT04619914|EXPERIMENTAL|Group B (Letrozole group)|included 35 anovulatory PCO patients who received letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 5 mg daily from cycle day 3 to day 7.
62116218|NCT00860353|EXPERIMENTAL|1|
62116219|NCT00860353|PLACEBO_COMPARATOR|2|
62116220|NCT05717114|PLACEBO_COMPARATOR|Group I|received plan bupivacaine1ml/Kg
62116221|NCT05717114|ACTIVE_COMPARATOR|Group II|received plain bupivacaine 1ml/Kg plus dexmetomedine0.5 µg/Kg
62116222|NCT05717114|ACTIVE_COMPARATOR|GroupIII|received plain bupivacaine 1ml/Kg plus dexmetomedine1µg/Kg
62116223|NCT01807858|ACTIVE_COMPARATOR|Bifidobacterium lactis|5 billion Bifidobacterium lactis
62116224|NCT01807858|ACTIVE_COMPARATOR|İnulin|900 mg İnulin per day will be given
62116225|NCT01807858|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin
62304593|NCT02449330|EXPERIMENTAL|Teneligliptin in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as Teneligliptin treatment by randomization
62472944|NCT02110953|EXPERIMENTAL|Treatment (irinotecan-eluting beads)|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for a total of 2 treatments in the absence of disease progression or unacceptable toxicity. Patients with bi-lobular disease and no evidence of progression in the treated lobe may repeat treatment at the discretion of the treating physician.
62472945|NCT02436447|EXPERIMENTAL|Normal renal function|
62472946|NCT02436447|EXPERIMENTAL|Mild renal impairment|
62116226|NCT01807858|ACTIVE_COMPARATOR|Bifidobacterium lactis plus İnülin|5 billion active Bifidobacterium lactis plus 900 mg İnülin per day
62116227|NCT02201173|EXPERIMENTAL|Locomotor Training|
62116228|NCT04123132||Patients with metabolic syndrome|
62116229|NCT04123132||Healthy controls|
62116230|NCT05103748|ACTIVE_COMPARATOR|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
62116231|NCT05103748|EXPERIMENTAL|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
62116232|NCT02182414|ACTIVE_COMPARATOR|BI 207127 NA (TF-I)|trial part 1: 800 mg BI 207127 NA Trial formulation I (TF-I)
62116233|NCT02182414|EXPERIMENTAL|BI 207127 NA (TF-II)|trial part 1: 800 mg BI 207127 NA Trial formulation II (TF-II)
62116234|NCT02182414|EXPERIMENTAL|BI 207127 NA delayed release|trial part 1: 800 mg BI 207127 NA TF-II, delayed release
62304594|NCT02449330|NO_INTERVENTION|Other agents in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
62472947|NCT02436447|EXPERIMENTAL|Moderate renal impairment|
62472948|NCT02436447|EXPERIMENTAL|Severe renal impairment|
62676028|NCT01260324||Controls|From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
62472949|NCT00365846|EXPERIMENTAL|Campath 1H induction w/ Sirolimus immunosuppression|Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,
62304595|NCT02449330|EXPERIMENTAL|Teneligliptin in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as Teneligliptin treatment by randomization
62472950|NCT02955641|ACTIVE_COMPARATOR|NSAIDs-Placebo|Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
62472951|NCT02955641|ACTIVE_COMPARATOR|Placebo-NSAIDs|Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye
62472952|NCT02955641|ACTIVE_COMPARATOR|Steroid-Placebo|Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
62676029|NCT06067971|EXPERIMENTAL|Laparoscopic surgery with the augmented reality device|
62676030|NCT02742974|NO_INTERVENTION|FloTrac™ and EV1000™ pre and post-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the pre and post-operative period in the control arm.
62304596|NCT02449330|NO_INTERVENTION|Other agents in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
62472953|NCT02955641|ACTIVE_COMPARATOR|Placebo-Steroids|Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye
62472954|NCT00840606|EXPERIMENTAL|1|
62304597|NCT03414359|ACTIVE_COMPARATOR|2% Lidocaine|Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts \[0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl
62304598|NCT03414359|EXPERIMENTAL|3% Chloroprocaine|20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride
62304599|NCT06293092|EXPERIMENTAL|control group C|receive hemodialysis sessions
62304600|NCT06293092|EXPERIMENTAL|study group A aerobic exercise|receive hemodialysis sessions and intradialytic aerobic exercise
62472955|NCT00840606|ACTIVE_COMPARATOR|2|
62472956|NCT00707161|EXPERIMENTAL|All participants|
62472957|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
62472958|NCT03144505|NO_INTERVENTION|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
62472959|NCT03144505|EXPERIMENTAL|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
62676031|NCT02742974|EXPERIMENTAL|FloTrac™ and EV1000™ peri-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the perioperative period for the intervention arm
62676032|NCT05993325|EXPERIMENTAL|1 dose of AdCLD-CoV19-1 OMI|Test group will receive 1 dose of AdCLD-CoV19-1 OMI
62676033|NCT05993325|ACTIVE_COMPARATOR|1 dose of Comirnaty Bivalent|Control group will receive 1 dose of Comirnaty Bivalent
62304601|NCT06293092|EXPERIMENTAL|study group B resistive exercise|receive hemodialysis sessions and intradialytic resistive exercise
62676034|NCT00147797||Pravastatin group|Patients in the pravastatin group were consecutively recruited in four department of infectious diseases if they fulfilled the following criteria : (1) HIV-infected treated with HAART for \> 12 months 2) with dyslipidemia, defined as fasting serum LDL cholesterol \> 160 mg/dL before initiation of pravastatin, (3) treated with pravastatin \> 12 months and one more coronary risk factor.
62676035|NCT00147797||COotrol group|The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART \> 12 months 2) fasting serum LDL cholesterol \> 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
62676036|NCT01990352|EXPERIMENTAL|Pegylated liposomal doxorubicin|The enrolled patients will be treated with pegylated liposomal doxorubicin at 30mg/m2 every 21 days.
62676037|NCT00893581|ACTIVE_COMPARATOR|1--Quetiapine & Placebo|Quetiapine \& Placebo in the place of Lithium
62676038|NCT00893581|ACTIVE_COMPARATOR|2-- Lithium & Placebo|Lithium \& Placebo in the place of Quetiapine
62676039|NCT00893581|PLACEBO_COMPARATOR|Placebo|Sugar Pill (Placebo) given to mimic drug
62116235|NCT02182414|EXPERIMENTAL|BI 207127 NA extended release (10% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (10% Hydroxypropyl methyl cellulose (HPMC))
62116236|NCT02182414|EXPERIMENTAL|BI 207127 NA extended release (15% PEO)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (15% Polyethylene oxide (PEO))
62116237|NCT02182414|EXPERIMENTAL|BI 207127 NA extended release (20% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (20% HPMC)
62116238|NCT02182414|EXPERIMENTAL|BI 207127 (TF-II), fed|trial part 2
62116239|NCT02182414|EXPERIMENTAL|BI 207127 (TF-II), fasted|trial part 2
62116240|NCT03727854|EXPERIMENTAL|Premeal protein group|Premeal protein enriched bar with dietary modification
62116241|NCT03727854|OTHER|Dietary modofication only group|Dietary modification only
62116242|NCT06555354||Retrospective|Identification in a retrospective cohort of a miRNA panel associated with the development of distant metastases.The retrospective cohort consists of tumor and normal tissue obtained from breast cancer patients, stored at -80°C at the Laboratory of Oncology. Of these samples, 360 met the inclusion criteria.
62116243|NCT06555354||Prospective|The association between miRNA expression and the clinical course of the disease identified in the retrospective cohort, is being confirmed in an independent prospective cohort. Both normal and tumor tissues of the patients, as well as plasma collected before surgery and at each follow-up time point, is being analyzed. Based on the annual number of surgeries performed at the Breast Surgery Unit, we initially estimated that the prospective cohort would consist of about 500 patients recruited over three years. Since the project was extended for additional two years the actual number of subject recruited was 972. In addition plasma sample for 100 breast benign condition was also collected as controls.
62116244|NCT00947986|EXPERIMENTAL|Johnson's Baby Shampoo|1% diluted solution
62116245|NCT02960542|EXPERIMENTAL|Lifestyle Weight Loss|The Behavioral: HELP Prevent Cancer Intervention is a lifestyle intervention consisting of 24-weekly group meetings led by a community health worker and 3 individual sessions with a nutritionist/diabetes educator
62116246|NCT00538213|EXPERIMENTAL|Adjuvanted influenza vaccine GSK576389A Group|Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A.
62116247|NCT00538213|ACTIVE_COMPARATOR|Fluarix young Group|Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
62116248|NCT00538213|ACTIVE_COMPARATOR|Fluarix elderly Group|Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
62116249|NCT02162420|EXPERIMENTAL|Treatment Plan for Dyskeratosis Congenita|Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.
62116250|NCT02162420|EXPERIMENTAL|Treatment for Severe Aplastic Anemia|Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
62116251|NCT02616835|EXPERIMENTAL|theta-burst TMS|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
62116252|NCT02616835|SHAM_COMPARATOR|sham theta-burst TMS|Sham protocol for theta-burst transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
62116253|NCT05632432|ACTIVE_COMPARATOR|CABG + collaged-based patch arm (control)|In total, 25 patients are recruited to form the CABG group. During CABG, RAA tissue is removed as detailed for the AAMs-patch group. However, the tissue is collected as a cryostored sample for later analyses rather than processed to AAMs (Method 4). CABG is performed without epicardial transplantation of AAMs, yet the collagen-based patch material is transplanted onto the epicardium of the scarred myocardium according the same principles as in the AAMs-patch intervention arm.
62116254|NCT05632432|EXPERIMENTAL|CABG + collagen based patch + AAMs arm (intervention)|In total, 25 patients are recruited to the AAMs-patch group. Here, the AAMs are prepared from the RAA tissue sample by mechanical processing in the operating room during the CABG surgery. The RAA tissue piece is removed during right atrial cannulation, a part of the routine setup of cardiopulmonary bypass and mechanically processed to AAMs, which is allowed to gel with fibrinogen and thrombin in cold, covered, and sterile metallic dish until the last stages of CABG surgery. After all the coronary anastomoses are done, to form an AAMs-patch, the AAMs in a fibrin matrix gel are placed onto a collagen based matrix sheet and then epicardially transplanted onto the scar border area identified by preoperative LGE-CMRI to have most suffered from ischemia.
62116255|NCT01334320|EXPERIMENTAL|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
62304602|NCT05091346|EXPERIMENTAL|Phase 1b and 2: E7386 + Pembrolizumab|Participants will receive E7386 twice daily (BID) along with pembrolizumab 200 mg intravenous (IV) infusion once every 3 weeks (Q3W) in 21-day treatment cycle until RP2D is determined in Phase 1b. The recommended dose for Phase 2 part of the study will be based on Phase 1b result. Participants will continue to receive study treatment in Phase 2 part until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study.
62304603|NCT05091346|EXPERIMENTAL|Phase 2: E7386 + Pembrolizumab + Lenvatinib|Participants will be randomized to receive E7386 Dose 1 (Cohort 1) or Dose 2 (Cohort 2) tablet, BID, orally in combination with pembrolizumab 200 mg Q3W IV infusion plus lenvatinib 8 mg capsule, orally, once daily (QD) continuously in 21-days treatment cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study. The dose of treatment depends on tolerability data of both Cohorts.
62304604|NCT00760175|ACTIVE_COMPARATOR|intradermal|
62304605|NCT00760175|ACTIVE_COMPARATOR|intramuscular|
62304606|NCT05179395|EXPERIMENTAL|Brasthesis|All five participants will wear Brasthesis for 4-weeks
62304607|NCT06329388|EXPERIMENTAL|Treatment - Oral Protein Supplement|Participants in this arm will receive the TruHeight Growth Protein Shake. Each serving consists of two scoops of the supplement powder mixed with 12-16 fluid ounces of water. The regimen is once daily, five times per week, for a duration of six months.
62304608|NCT06329388|NO_INTERVENTION|Control - No Supplement|Participants in this arm will not receive the oral protein supplement but will continue their regular diet. They serve as a comparison group to evaluate the effects of the TruHeight Growth Protein Shake administered to the treatment group.
62304609|NCT05128617||Epirubicin-cyclophosphamide|Woman with early breast cancer receiving a first cycle of epirubicin-cyclphosphamide
62304610|NCT05128617||Paclitaxel|Woman with early breast cancer receiving a first cycle of paclitaxel
62304611|NCT04327648|ACTIVE_COMPARATOR|Social interaction treatment|During the treatment days, children in social interaction treatment group will have 30min social interaction each day for 3 months. ASD children are followed up closely.
62304612|NCT04327648|SHAM_COMPARATOR|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. ASD children are followed up closely.
62116256|NCT01334320|NO_INTERVENTION|wait and see|patient underwent primary tumor excision transorally as initial treatment, and without a cervical intervention
62116257|NCT05723510|EXPERIMENTAL|Edoxaban 60mg|Multiple dosing of edoxaban alone once daily for 5 days
62116258|NCT05723510|EXPERIMENTAL|Edoxaban 60mg + Tegoprazan 50mg|Multiple dosing of edoxaban once daily in combination with tegoprazan once daily for 5 days
62116259|NCT05723510|EXPERIMENTAL|Apixaban 5mg|Multiple dosing of apixaban alone twice daily for 5 days
62304613|NCT04327648|OTHER|Routine treatment|Children in routine treatment group will keep the same initial treatment. ASD children are followed up closely.
62304614|NCT00793923|EXPERIMENTAL|Combination Therapy|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
62116260|NCT05723510|EXPERIMENTAL|Apixaban 5mg + Tegoprazan 50mg|Multiple dosing of apixaban twice daily in combination with tegoprazan once daily for 5 days
62304615|NCT00793923|ACTIVE_COMPARATOR|Monotherapy|intravitreal injection of 0.5 mg ranibizumab
62116261|NCT05723510|EXPERIMENTAL|Rivaroxaban 20mg|Multiple dosing of rivaroxaban alone once daily for 5 days
62116262|NCT05723510|EXPERIMENTAL|Rivaroxaban 20mg + Tegoprazan 50mg|Multiple dosing of rivaroxaban once daily in combination with tegoprazan once daily for 5 days
62304616|NCT02242396||Hypertensive patients|
62304617|NCT03977077|EXPERIMENTAL|Albumin binding taxol|
62304618|NCT04258618|ACTIVE_COMPARATOR|CBT-I (Cognitive Behavioral Therapy for Insomnia) with TMS|
62304619|NCT04258618|OTHER|rTMS (repetitive Transcranial Magnetic Stimulation)|Subjects will be getting Transcranial Magnetic Stimulation as part of their standard of care.
62116263|NCT04679519|ACTIVE_COMPARATOR|Control|Control group that was not given a supplement.
62304620|NCT03899740||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
62304621|NCT04649385|EXPERIMENTAL|Phase 1a: Dose Escalation|"Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses~Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy )"
62304622|NCT04649385|EXPERIMENTAL|Phase 1b: Dose Expansion|Phase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a
62304623|NCT06657339||Endoscopic sleeve gastroplasty|Therapeutic endoscopy using a gastric suturing device (OverStitch™/Endomina™) according to the practices of the investigating center
62304624|NCT06133543|EXPERIMENTAL|Negative sentinel lymph node|Patients with negative sentinel lymph node biopsy are enrolled to active surveillance after surgery
62304625|NCT06133543|EXPERIMENTAL|Positive sentinel lymph node|Patients with positive lymph node biopsy undergo a template retroperitoneal lymph node dissection in the same procedure
62304626|NCT01600781|ACTIVE_COMPARATOR|NutriniDrink/Fortini group|this group will receive 2 bottles of NutriniDrink/Fortini MF unflavoured daily (200 ml each) and standard dietary counselling for a period of 6 weeks.
62304627|NCT01600781|NO_INTERVENTION|control group|this control group will only receive standard dietary counselling
62304628|NCT02942498|EXPERIMENTAL|Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg|Vitamin C and Vitamin E supplementation 10 mg/kg/ day
62116264|NCT04679519|EXPERIMENTAL|BCAA|Supplement group that was given Branched Chain Amino Acids (BCAA).
62304629|NCT02942498|PLACEBO_COMPARATOR|Placebo|Placebo solution
62116265|NCT04679519|EXPERIMENTAL|Leucine|Supplement group that was given Leucine.
62116266|NCT04679519|EXPERIMENTAL|HMB|Supplement group that was given β-Hydroxy β-methylbutyric acid (HMB)
62116267|NCT06530264|OTHER|External DCR|Different techniques in posterior flap management
62116268|NCT02576340|ACTIVE_COMPARATOR|study|drug was administered
62116269|NCT02576340|NO_INTERVENTION|control|no drug administered
62116270|NCT03375255|EXPERIMENTAL|SRP-5051|"Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051 on Day 1.~Patients who complete the study and continue to meet safety eligibility criteria will have the opportunity to enroll in an open-label extension study to continue to receive SRP-5051."
62116271|NCT05304663|EXPERIMENTAL|ARM 1: Fractionating Lomustine|"Patients will be treated in escalating cohorts of 6 patients with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and lomustine at different doses on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~* Cohort 1: 10 µg/kg L19TNF and 60 mg/m2 lomustine~* Cohort 2: 10 µg/kg L19TNF and 75 mg/m2 lomustine"
62304630|NCT02688569|EXPERIMENTAL|CBT-CWP|Participants in this condition will receive Cognitive Behavioral Therapy for Chronic Widespread Pain (CBT-CWP)
62676040|NCT01277731|EXPERIMENTAL|Methylprednisolone replacement|"This study will enroll the patients who were previously experienced dexamethasone-induced hiccup. Patients who experienced dexamethasone-induced hiccup during chemotherapy will enroll to study arm.~Run-in period \* Dexamethasone 10mg-20mg q day iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Treatment period \* Methylprednisolone 60mg-125mg iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Response will be evaluated by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and NRS to hiccup at 24hrs after start methylprednisolone.~Nausea and vomiting will be assessed as CTCAE 4.0"
62304631|NCT02688569|NO_INTERVENTION|Control|Participants in the Control condition will not receive CBT-CWP. They will however, continue completing the weekly assessments.
62304632|NCT05240937|EXPERIMENTAL|mindfulness-based self-compassion will be applied|The group in which mindfulness-based self-compassion program will be implemented.
62304633|NCT05240937|NO_INTERVENTION|Control Group|The group in which mindfulness-based self-compassion program will not be implemented
62304634|NCT03466554|EXPERIMENTAL|hyperbaric oxygen therapy (HBOT) active treatment|60 daily HBOT sessions will be administrated 5 days per week. Comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
62116272|NCT05304663|EXPERIMENTAL|ARM 2: Priming with L19TNF|"Patients will be treated in escalating cohorts of 6 patients with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and lomustine at different doses on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles.~* Cohort 1: 10 µg/kg L19TNF and 90 mg/m2 lomustine~* Cohort 2: 10 µg/kg L19TNF and 110 mg/m2 lomustine In each arm, patients will be enrolled sequentially and no more than 2 patients will be treated in Cycle 1 in the same arm in parallel.~Recruitment to an arm will be stopped should ≥ 2 DLTs occur in a cohort."
62116273|NCT01818401|OTHER|Control group|The control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
62116274|NCT01818401|OTHER|Matched patient|The treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
62116275|NCT00157014|EXPERIMENTAL|Tacrolimus - Adult|Adults: 0.05 - 0.10 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
62116276|NCT00157014|ACTIVE_COMPARATOR|Cyclosporine - Adult|Adults: 3-5 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
62116277|NCT00157014|EXPERIMENTAL|Tacrolimus - Pediatric|Pediatrics: 0.05 - 0.30 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
62116278|NCT00157014|ACTIVE_COMPARATOR|Cyclosporine - Pediatric|Pediatrics: 6 - 10 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
62116279|NCT02551055|EXPERIMENTAL|MLN1117 300 mg + Alisertib|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
62116280|NCT02551055|EXPERIMENTAL|MLN1117 600 mg + Alisertib|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
62304635|NCT03466554|NO_INTERVENTION|Control-follow up|"The standard of care of psychological and mediational support .~After 3 months of follow up, participants will be re-evaluated. The individuals in the control group will then be offered to receive the treatment and to be re-reevaluated after the treatment is over (3 months)."
62304636|NCT06448377||Airway Team Group|In this group, the intervention time and methods used by the airway team will be evaluated in patients who have been called for airway assistance.
62304637|NCT06448377||Control Group|In this group, anesthesiologists' feedback on difficult airway cases will be received.
62304638|NCT06077799||supraventricular tachycardia treated with intra-venous adenosine|supraventricular tachycardia treated with intra-venous adenosine
62304639|NCT06077799||supraventricular tachycardia treated with electrical synchronised cardioversion|supraventricular tachycardia treated with electrical synchronised cardioversion
62304640|NCT02654925||Young Men|men 21-40 years of age
62304641|NCT02654925||Young Women|women 21-40 years of age; young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy.
62472960|NCT03144505|EXPERIMENTAL|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
62472961|NCT01095315|NO_INTERVENTION|standard|parturients were placed back to the supine position immediately after spinal injection following standard protocol of spinal anesthesia
62472962|NCT01095315|EXPERIMENTAL|lateral|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
62676041|NCT03796975|EXPERIMENTAL|Combination of Pioglitazone and Metformin Tablets|dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
62116281|NCT02551055|EXPERIMENTAL|MLN1117 300 mg + Paclitaxel|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m\^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
62116282|NCT02551055|EXPERIMENTAL|MLN1117 600 mg + Paclitaxel|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m\^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
62116283|NCT02551055|EXPERIMENTAL|MLN1117 300 mg + TAK-659|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 \[NCT02000934\]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
62116284|NCT02551055|EXPERIMENTAL|MLN1117 200 mg + Docetaxel|MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m\^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
62116285|NCT02551055|EXPERIMENTAL|MLN1117 300 mg + Docetaxel|MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m\^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
62116286|NCT00822055|ACTIVE_COMPARATOR|1|brimonidine/timolol Fixed-combination monotherapy
62116287|NCT00822055|ACTIVE_COMPARATOR|2|dorzolamide/timolol fixed-combination monotherapy
62116288|NCT00822055|ACTIVE_COMPARATOR|3|prostaglandin analogue + brimonidine/timolol fixed combination
62116289|NCT00822055|ACTIVE_COMPARATOR|4|prostaglandin analogue + dorzolamide/timolol fixed combination
62116290|NCT01866566|PLACEBO_COMPARATOR|HBV-3|one dose HBV
62116291|NCT01866566|PLACEBO_COMPARATOR|HBV-6|one dose HBV
62116292|NCT01866566|EXPERIMENTAL|varicella-3|2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time
62116293|NCT01866566|EXPERIMENTAL|varicella-6|2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time
62116294|NCT00410124|EXPERIMENTAL|RAD001 +BSC|The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
62116295|NCT00410124|PLACEBO_COMPARATOR|Placebo (plus BSC)|Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
62116296|NCT04962074|EXPERIMENTAL|Density gradient method|Sperm prepared by density gradient method
62116297|NCT04962074|EXPERIMENTAL|Microfluidic chip|Sperm prepared by microfluidic chip method
62304642|NCT02654925||Older Men|men 55-100 years of age
62304643|NCT02654925||Older Women|women 55-100 years of age; older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP).
62304644|NCT04029337|EXPERIMENTAL|Transcatheter Mitral Valve Replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools.
62116298|NCT01883492|EXPERIMENTAL|BIOLOX delta head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
62116299|NCT01883492|ACTIVE_COMPARATOR|CoCr head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
62116300|NCT01278888|ACTIVE_COMPARATOR|PLEACE 1|Anterolateral vs. posterolateral thoracotomy
62116301|NCT01278888|ACTIVE_COMPARATOR|PLEACE 2|Video assisted thoracic surgery (VATS) vs. anterolateral thoracotomy
62116302|NCT02878915|ACTIVE_COMPARATOR|Ultrasound guided femoral puncture|Ultrasound guided femoral puncture
62116303|NCT02878915|NO_INTERVENTION|Palpation guided femoral puncture|Palpation guided femoral puncture
62116304|NCT02607384|EXPERIMENTAL|Vision problems|Children with refractive error will be prescribed eyeglass wearing, and children with convergence insufficiency will be given orthoptic exercises. Children with any other vision problem will be given a specialist referral to a pediatric eye specialist.
62116305|NCT04951518||Van Positive|Large Vessel Occlusion Positive
62472963|NCT06185322|ACTIVE_COMPARATOR|Neck strengthening exercises group|10 sessions of physical therapy over two weeks.Each session will consist of 20 minutes of hotpack and transcutaneous electrical nerve stimulation and 10minutes of therapeutic ultrasound. Exercise sessions lasting 20minutes will consist of conventional neck isometric strengthening exercises under the supervision of a single physiotherapist. These exercises will be repeated 5 times each, twice daily. A brochure depicting each exercise,accompanied by a description,will be given to the patient.The patient will continue with the exercise program for 3 months and be reminded once a week via telephone.
62116306|NCT04951518||Van Negative|Large Vessel Occlusion Negative
62116307|NCT05340244|EXPERIMENTAL|Arm 1: Experimental|
62116308|NCT04853017|EXPERIMENTAL|ELI-002 2P Cohort 1|ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
62116309|NCT04853017|EXPERIMENTAL|ELI-002 2P Cohort 2|ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
61918184|NCT04386915|EXPERIMENTAL|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
61918185|NCT04386915|PLACEBO_COMPARATOR|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
61918186|NCT04386915|EXPERIMENTAL|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
61918187|NCT04386915|EXPERIMENTAL|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
61918188|NCT02964923||Olanzapine group|Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
62116310|NCT04853017|EXPERIMENTAL|ELI-002 2P Cohort 3|ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
62116311|NCT04853017|EXPERIMENTAL|ELI-002 2P Cohort 4|ELI-002 2P Amph-CpG-7909 (5.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
62116312|NCT04853017|EXPERIMENTAL|ELI-002 2P Cohort 5|ELI-002 2P Amph-CpG-7909 (10.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
62116313|NCT00354406|EXPERIMENTAL|A|Patients in Arm A (Early abciximab arm) will receive abciximab at time of STEMI diagnosis, before transfer to the Cath Lab to undergo primary angioplasty.
62116314|NCT00354406|ACTIVE_COMPARATOR|B|Patients in Arm B (Late abciximab arm) will receive abciximab at time of primary angioplasty, directly in the Cath Lab.
62116315|NCT00189202|EXPERIMENTAL|Sirolimus, steroid avoidance arm|Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
62116316|NCT01233713|ACTIVE_COMPARATOR|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering ileostomy, followed by a stoma reversal operation.
62116317|NCT01233713|ACTIVE_COMPARATOR|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
62116318|NCT06261775|OTHER|Control|Lacto-ovo-vegetarian meal
62116319|NCT06261775|EXPERIMENTAL|Test|Red meat-based meal
62116320|NCT04570631|EXPERIMENTAL|Safety Lead-in|Participants will receive escalating doses of eftozanermin alfa in combination with bortezomib and dexamethasone to determine recommended phase 2 dose (RP2D).
62116321|NCT04570631|EXPERIMENTAL|Dose Expansion|Participants will receive eftozanermin alfa at RP2D determined in Safety Lead-in part in combination with bortezomib and dexamethasone.
62676042|NCT03796975|ACTIVE_COMPARATOR|Metformin Hydrochloride Tablets|dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
62304645|NCT06090474|EXPERIMENTAL|NDC-002|"In Period 1, Two tablets of NDC-002C are repeatedly administered once a day for seven days to reach a steady state of NDC-002C. There is a seven-day washout period between Period 1 and Period 2.~In Period 2, after repeated administration of one tablet of NDC-002A once a day for seven days, one tablet of NDC-002B is administered repeatedly once a day for eight days to reach a steady state of NDC-002B.~In Period 3, after the completion of Period 2 administration and without a washout period, one tablet of NDC-002B and two tablets of NDC-002C administered repeatedly in combination once a day for seven days."
62304646|NCT02035943|ACTIVE_COMPARATOR|Insulin separated|Seprated infusion of insulin
62116322|NCT00042198|EXPERIMENTAL|1|Cognitive Behavior Therapy. The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist. Treatment consisted of up to 12 weekly, hour-long sessions.
62116323|NCT00042198|ACTIVE_COMPARATOR|2|Supportive Stress Management. The treatment modality was individual, face-to-face therapy with an experienced psychotherapist. Treatment consisted of up to 12 weekly, hour-long sessions.
62116324|NCT00042198|NO_INTERVENTION|3|Usual Care, minimally enhanced. Participants in all three arms were given information about depression. There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed. Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
62116325|NCT04609618|EXPERIMENTAL|Obstructive Sleep Apnea patients|Appscent device will discharge odor during the in lab night sleep
62116326|NCT01842724|ACTIVE_COMPARATOR|Motec total wrist arthroplasty|
62116327|NCT01842724|ACTIVE_COMPARATOR|Remotion total wrist arthroplasty|
62116328|NCT00940537||NAFLD|Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)
62116329|NCT00940537||Non-NAFLD|Non-diabetic, obese with no previous diagnosis of NAFLD
62116330|NCT06427486|EXPERIMENTAL|Parent Telecoaching Intervention|The telecoaching intervention will consist of eight weekly sessions, lasting between 40 minutes to one hour each, conducted through Zoom. Before the sessions begin, an initial assessment meeting will take place with each parent. The sessions will follow the occupational performance coaching (OPC) processes, which aim to enhance parents' problem-solving skills and promote children's participation. These processes include the Connect, Structure, and Share stages, focusing on active listening, goal-setting, and information exchange between the provider and the parent. A Casenote template will be used to organize these sessions.
62116331|NCT06427486|NO_INTERVENTION|Access to a web-based (sanadmed).|"The Waitlist Control Group Intervention will have access to a web-based Autism resources called Sanad Al-Haya. This resource provides general information and videos on Autism and how to manage specific needs such as sensory issues, social interaction, and activities of daily living. The resources are developed by the trial author in Arabic language. All participants are required to register on the Sanad platform and create an account in their child's name. If they wish, the waitlist control group will have the option to take parent telecoaching sessions after the intervention group has completed all sessions."
62116332|NCT02886754|ACTIVE_COMPARATOR|National e-learning programme only (HSE)|National e-learning programme only Recent successful completion the National e-learning programme by certificate will be displayed. Students then complete a student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
62116333|NCT02886754|ACTIVE_COMPARATOR|Simulation (S)|Simulation Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to standard simulation using the same series of paper cases as PBP which prompt simulated phone calls but no requirement to meet a proficiency benchmark. 4 hours will be allotted to this training. Following training participants will complete the student satisfaction survey and will then proceed directly for performance assessment to the high-fidelity simulation suite.
62116334|NCT02886754|EXPERIMENTAL|Proficiency-Based Progression (PBP)|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to PBP simulation using the same series of paper cases as S which prompt simulated phone calls. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks. Following training participants will complete the student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
62116335|NCT03775551|NO_INTERVENTION|Control|The participants belonging to the hospitals assigned to the control group the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC following usual practice.
62116336|NCT03775551|EXPERIMENTAL|Improvement cycle|In participants belonging to the hospitals assigned to the intervention group,the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC using innovative intervention to assure continuity of care and assistant level approach. This innovations will be crafted from the rapid improvement cycles considering the environment and key aspects of the every day care at the participating centers.
62116337|NCT04023916|EXPERIMENTAL|Sintilimab-R-CHOP|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and Sintilimab, rituximab, and CHOP during Cycles 2-6 (21-day cycle) ,Sintilimab and rituximab during Cycles 6-8 (21-day cycle) , followed by Sintilimab from Cycles 9-14 (8-week cycle) during consolidation treatment.
62116338|NCT06501586|EXPERIMENTAL|SGB-3908|
61918189|NCT02964923||Risperidone group|Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4\~6ml/d within 1 week.
61918190|NCT02964923||Ziprasidone group|Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80\~160mg/d within 10 days.
61918191|NCT05404360|EXPERIMENTAL|Treatment Group|During the acute treatment phase, subjects will receive daily prefrontal Deep TMS treatment, 5 days a week for 6 consecutive weeks. Following the acute phase, patients will receive semi-weekly Deep TMS stimulation for an additional seven weeks. Treatment will include a total of 44 treatments over 13 weeks.
61918192|NCT05404360|SHAM_COMPARATOR|Sham Control Group|During the acute treatment phase, subjects will receive daily prefrontal sham treatment, 5 days a week for 6 consecutive weeks. Following the acute phase, patients will receive semi-weekly sham stimulation for an additional seven weeks. Treatment will include a total of 44 treatments over 13 weeks.
62116339|NCT06501586|PLACEBO_COMPARATOR|SGB-3908-Matching placebo|
62116340|NCT01826695|PLACEBO_COMPARATOR|Placebo group|35 women are recruited in order to the inclusion criteria for the study. Placebo controlled. They received only standard treatment without neurodynamic intervention. They are diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and end.
62116341|NCT01826695|ACTIVE_COMPARATOR|Neurodynamic technique group|35 women are recruited, diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and at the end.
62116342|NCT03547752|ACTIVE_COMPARATOR|Effective movement group|Observation of a video of neck movement at 100% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
62116343|NCT03547752|EXPERIMENTAL|Ineffective movement group|Observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
62116344|NCT05001750|EXPERIMENTAL|continuous antibiotic use until the EVD is removed|continuous antibiotic use until the EVD is removed. Nafcillin 1-2 grams every 6 hours (depending on weight) until the EVD is removed. If penicillin allergic Doxycycline 100mg every 12 hours until the EVD is removed.
62116345|NCT05001750|NO_INTERVENTION|antibiotics for a total of twenty-four hours|antibiotics for a total of twenty-four hours Nafcillin 1-2 grams every 6 hours (depending on weight) for a total of 24 hours. If penicillin allergic Doxycycline 100mg every 12 hours for a total of 24 hours.
62116346|NCT02732314|EXPERIMENTAL|Investigational OTC Cream|Investigational OTC Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
62116347|NCT02732314|PLACEBO_COMPARATOR|Placebo Cream|Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
62116348|NCT02732314|ACTIVE_COMPARATOR|Cosmetic Eczema Cream|Cosmetic Eczema Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
62116349|NCT02732314|ACTIVE_COMPARATOR|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 4 weeks to atopic dermatitis lesions and then on any new lesions that appear for 4 weeks and as directed by the study doctor.~Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, anywhere the patient would apply their ordinary body moisturizer except atopic dermatitis lesions."
62116350|NCT02886793|EXPERIMENTAL|FDG|all patients will undergo a PET scan and will receive 18F fludeoxyglucose
62116351|NCT06069726|EXPERIMENTAL|Pre-Surgery Atezolizumab|80 patients with rGBM who are eligible for surgical debulking will be treated with one dose of atezolizumab prior to resection. Resected tissue will be used to pathologically confirm recurrence, and tumor tissue will be analyzed by whole exome sequencing (WES). Anticipating that40 patients with low TMB and 40 with high TMB will be treated. All treated subjects will receive post-operative atezolizumab until progression, unacceptable toxicity, death or withdrawal of consent. Post-atezolizumab survival will be compared between low vs high TMB arms to determine if low TMB associates with longer survival after atezolizumab
62304647|NCT02035943|ACTIVE_COMPARATOR|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
62304648|NCT00949338|ACTIVE_COMPARATOR|Arm I|Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
61918193|NCT06109922|EXPERIMENTAL|Experimental|"Bioactive whey protein concentrate containing phospholipids.~40g pre weighed powder to be mixed with 350ml of water. Consumed once daily for 12 weeks alongside their fattiest meal of the day."
61918194|NCT06109922|PLACEBO_COMPARATOR|Placebo|"Placebo~Placebo powder matched for macronutrient and caloric content containing pea protein around 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside fattiest meal of the day."
61918195|NCT01840644||all participants|Walking on treadmill, different velocities and incline
62676043|NCT04679025||Diabetes with postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c \> 6.5%) who had postoperative hyperglycemia (point of care test \> 10.0 mmol/L).
61918196|NCT00669760||Observation|CF-patients with persistent culture of Staphylococcus aureus in their respiratory specimens
61918197|NCT01099709|EXPERIMENTAL|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
62116352|NCT03441360|EXPERIMENTAL|Eribulin mesylate 1.4 mg/m^2: RMS|Pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS) will receive eribulin mesylate administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 milligrams per meters squared (mg/m\^2). Participants will continue study therapy until progression of disease (per Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1), intolerable toxicity, or withdrawal of consent.
62116353|NCT03441360|EXPERIMENTAL|Eribulin mesylate 1.4 mg/m^2: NRSTS|Pediatric participants with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
62116354|NCT03441360|EXPERIMENTAL|Eribulin mesylate 1.4 mg/m^2: EWS|Pediatric participants with Ewing sarcoma (EWS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m\^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
62116355|NCT00950404|ACTIVE_COMPARATOR|Viagra 50 mg tablet, administered with water.|
62116356|NCT00950404|EXPERIMENTAL|Formulation B ODT tablet 50 mg, administered without water.|
62116357|NCT00950404|EXPERIMENTAL|Formulation C ODT tablet 50 mg, administered without water.|
62116358|NCT00950404|EXPERIMENTAL|Formulation D ODT tablet 50 mg, administered without water.|
62116359|NCT02171663|EXPERIMENTAL|BIBW 2992|
62116360|NCT05061615||acne vulgaris patients|
62116361|NCT03183999|EXPERIMENTAL|GINST group|Experimental group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Fermented ginseng (GINST) was supplied.
61918198|NCT01099709|ACTIVE_COMPARATOR|Original OxyContin® (OXY) 10 mg|Original OxyContin® (OXY) 10 mg x 1 dose
61918199|NCT03227341|OTHER|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
61918200|NCT03227341|OTHER|patients with partially controlled asthma|8 week pulmonary rehabilitation program
62116362|NCT03183999|PLACEBO_COMPARATOR|Control group|Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
62116363|NCT03630939|EXPERIMENTAL|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
62116364|NCT03630939|EXPERIMENTAL|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
61918201|NCT03539224|EXPERIMENTAL|Dolutegravir (DTG) + Lamivudine (3TC)|Eligible subjects will receive one 50 mg tablet of DTG plus 300 mg 3TC tablet orally once daily upto 48 weeks
61918202|NCT00542451|EXPERIMENTAL|Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer|80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab, the dosing of Trastuzumab could be continued on a weekly basis, or the regimen could be changed to 6 mg per kilogram every 3 weeks for 40 weeks to complete a full year of intravenous treatment with trastuzumab.
62116365|NCT03630939|PLACEBO_COMPARATOR|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
62116366|NCT03611530|EXPERIMENTAL|CoQun®|Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
62116367|NCT03611530|PLACEBO_COMPARATOR|Placebo|Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.
62116368|NCT03710564|EXPERIMENTAL|Brolucizumab|Brolucizumab 6 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
62116369|NCT03710564|ACTIVE_COMPARATOR|Aflibercept|Aflibercept 2 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
62116370|NCT03786263||Prospective Treatments for NS|"Observation of children (between the ages of 1 and 17) who are diagnosed with Nephrotic Syndrome at their initial presentation, first or second relapse.~Observation of children who receive Glucocorticoids to treat Nephrotic Syndrome.~Observation of children who receive other drugs (Second Line Agents) for Nephrotic Syndrome."
62304649|NCT00949338|EXPERIMENTAL|Arm II|Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
62304650|NCT05994651|EXPERIMENTAL|Tidal Model improvement model|In order to provide individualized care to the individuals in the experimental group, initiatives will be implemented by starting individual interviews and in line with the goals of the individuals and the research objectives.
62304651|NCT05994651|NO_INTERVENTION|Tidal Model Control Group|Individuals in the control group will continue their lives.
62304652|NCT00101088|EXPERIMENTAL|Treatment (imatinib mesylate, temsirolimus)|Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
62304653|NCT05854134|EXPERIMENTAL|Closed Chain|
62304654|NCT05854134|OTHER|Aerobic Exercise|
62304655|NCT01163422|ACTIVE_COMPARATOR|Immediate RVRT|RVRT switched on immediately after pacemaker implant
62116371|NCT05148780|OTHER|Participants with Acute Respiratory Infections (ARI) in Outpatient Setting|Participants presenting with ARIs in an outpatient setting who are at high risk of progressing to severe disease will be screened for viral respiratory pathogens (respiratory syncytial virus \[RSV\], Influenza, severe acute respiratory syndrome coronavirus 2 \[SARS-COV-2\]) by collecting a nasal swab. If a participant is positive for RSV and/or influenza virus and/or SARS-CoV-2 based on a study test or standard-of-care (SOC) polymerase chain reaction (PCR)-based test, the participant will be eligible for enrollment in the study in the home-based short-term and long-term follow-up phases.
62116372|NCT03637634||NPC survivors|Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
62116373|NCT03637634||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.
62116374|NCT05646745|EXPERIMENTAL|Autologous Fascia lata TOT|"Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
62116375|NCT05401227|EXPERIMENTAL|High Ketamine, TS-134|Two administrations of ketamine 0.23 mg/kg pre post 4 days of TS-134 20 mg
62116376|NCT05401227|PLACEBO_COMPARATOR|High ketamine, placebo|Two administrations of ketamine 0.23 mg/kg pre post 4 days of placebo
62116377|NCT05401227|EXPERIMENTAL|Medium Ketamine, TS-134|Two administrations of ketamine 0.125 mg/kg pre post 4 days of TS-134 20 mg
62116378|NCT05401227|PLACEBO_COMPARATOR|Medium Ketamine, placebo|Two administrations of ketamine 0.125 mg/kg pre post 4 days of placebo
62116379|NCT05401227|EXPERIMENTAL|Low Ketamine, TS-134|Two administrations of ketamine 0.06 mg/kg pre post 4 days of TS-134 20 mg
62116380|NCT05401227|PLACEBO_COMPARATOR|Low Ketamine, placebo|Two administrations of ketamine 0.06 mg/kg pre post 4 days of placebo
62116381|NCT02414204|ACTIVE_COMPARATOR|Sildenafil|20 mg twice a day orally
62116382|NCT02414204|PLACEBO_COMPARATOR|Placebo|Placebo twice a day orally
62116383|NCT06009120|EXPERIMENTAL|Intervention|"Intervention (education) group:~In addition to the standard discharge education, mothers in this group received breastfeeding education."
62304656|NCT01163422|PLACEBO_COMPARATOR|Delayed RVRT|RVRT switched on 4 weeks after pacemaker implant
62304657|NCT01435512|EXPERIMENTAL|Group|PTSD-Focused Cognitive Behavioral Therapy for Partner Violence
62304658|NCT01435512|NO_INTERVENTION|Waitlist|Control group - no intervention
62304659|NCT00506389|EXPERIMENTAL|Esmirtazapine 3.0 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 3.0 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
62304660|NCT00506389|EXPERIMENTAL|Esmirtazapine 4.5 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 4.5 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
62304661|NCT00506389|PLACEBO_COMPARATOR|Placebo|Participants took placebo tablets on Days -7 and -6, placebo tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
62304662|NCT01557725||THR/TKR patients|Any patients receiving fast-track THR or TKR in departments participating in the Lundbeck Foundation Centre for fast-track THR and TKR
62304663|NCT01691118|ACTIVE_COMPARATOR|Fimasartan|Fimasartan 60mg qd added on conventional antihypertensive treatment for 10 months.
62304664|NCT01691118|PLACEBO_COMPARATOR|Placebo|Conventional antihypetensive treatment
62116384|NCT06009120|NO_INTERVENTION|Control|"Control group: In this group, first of all, mothers were informed about the study within the first day after birth, and informed consent forms were signed by those who voluntarily agreed to participate. In addition, Personal Information Form, IOWA Infant Feeding Attitude Scale and Psychosexual Theory and Breastfeeding Information Scale were applied to these mothers on the first day. Then, as the routine care of the institution, the standard discharge education program on the third day was applied by the institution nurse. After this education, IOWA Infant Feeding Attitude Scale and Psychosexual Theory and Breastfeeding Knowledge Form were re-administered to mothers as a post-test. No additional intervention was applied other than standard care education. During the 5 days following discharge, mothers were interviewed by phone and Breastfeeding Form'' applied."
62116385|NCT02792374||Dental patients group|Psychological measurement is done when they refer to a dental clinic.
62116386|NCT02792374||Control group|Psychological measurement is done when they refer to a dental clinic.
62304665|NCT04295187||Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
62304666|NCT04295187||Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
62304667|NCT04595955|EXPERIMENTAL|Intervention group|This arm uses the CMyLife platform for at least 6 months
62304668|NCT04595955|NO_INTERVENTION|Control group|This arm does not use the CMyLife platform
62304669|NCT03455387||sampling of serum marker Flt1 and PIGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
62116387|NCT02959658|ACTIVE_COMPARATOR|Active drug|Dimethyl fumarate, 240mg twice daily for 48 weeks
62116388|NCT02959658|PLACEBO_COMPARATOR|Placebo|Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
62116389|NCT00878618|EXPERIMENTAL|HAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with heavy breakfast
62116390|NCT00878618|EXPERIMENTAL|HBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with heavy breakfast
62116391|NCT00878618|EXPERIMENTAL|LAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with light breakfast
62116392|NCT00878618|EXPERIMENTAL|LBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with light breakfast
62116393|NCT01609517||Obese group|patients with BMI \>= 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
62116394|NCT01609517||Non-obese group|patients with BMI \< 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
62116395|NCT03668249||All Participants|Participants diagnosed with CD from approximately 12 to 15 investigational sites will be observed retrospectively for previous 5 years.
62304670|NCT03520049|EXPERIMENTAL|Oseltamivir|Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
62304671|NCT03520049|PLACEBO_COMPARATOR|Placebo|Placebo capsule administered orally twice daily for five consecutive days.
62304672|NCT01588080|PLACEBO_COMPARATOR|SiPAP|
62304673|NCT01588080|EXPERIMENTAL|Neurally Adjusted Ventilatory Assist|
62116396|NCT01924884||Prospective|Patients newly referred to the Principal Investigator for intra-abdominal surgery and for whom the Principal Investigator anticipates using Negative-Pressure Wound Therapy.
62116397|NCT01924884||Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 will be identified through patient medical records. Living patients will be contacted via letter from the Principal Investigator introducing the study along with the study's consent form for the patients' review. Interested patients will be consented either in person at the patient's next clinic visit or via telephone by a member of the study staff.
62116398|NCT01924884||Historical Controls|Patients who underwent intra-abdominal surgery without Negative-Pressure Wound Therapy by the Principal Investigator prior to January 1, 2011 will be enrolled as Historical Controls.
62116399|NCT01924884||De-Identified Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 and are deceased or do not consent to be in the study will be enrolled in the De-Identified Retrospective Case Cohort.
62304674|NCT04387474|EXPERIMENTAL|Experimental group|brain-computer interface rehabilitation training and traditional rehabilitation training.
62304675|NCT04387474|OTHER|Control group|traditional rehabilitation training.
62304676|NCT02455115|EXPERIMENTAL|60 mmHg|Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine
62304677|NCT02455115|EXPERIMENTAL|75 mmHg|Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine
62304678|NCT02455115|EXPERIMENTAL|90 mmHg|Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine
62304679|NCT03414125|ACTIVE_COMPARATOR|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
62676044|NCT04679025||Diabetes without postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c \> 6.5%) who did not have postoperative hyperglycemia (point of care test \> 10.0 mmol/L).
62676045|NCT04679025||No diabetes with postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c \> 6.5%) who had postoperative hyperglycemia (point of care test \> 10.0 mmol/L).
62304680|NCT03414125|EXPERIMENTAL|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences.~Choice Strategy outreach invitation includes: 1) invitation letter, 2) option grid comparing FIT and colonoscopy 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
62304681|NCT02936895|EXPERIMENTAL|Vitamin D3 (Low dose)|vitamin D at a dose of 50,000 IU per day for 2 days
62304682|NCT02936895|PLACEBO_COMPARATOR|Placebo|Placebo (same size and shape) for 2 days
62676046|NCT04679025||No diabetes and no postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c \> 6.5%) who did not have postoperative hyperglycemia (point of care test \> 10.0 mmol/L).
62676047|NCT04576221|EXPERIMENTAL|stacked breathing group|experimental group received staked breathing exercise for 7 days , 3 sessions per day, 7-8 times per session
62676048|NCT04576221|EXPERIMENTAL|CPAP group|experimental group received NIV with CPAP mask
62676049|NCT04851015|EXPERIMENTAL|Reduced dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 10mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as a dose of 10mg/kg/day open label with additional placebo tablets or intravenous placebo solution given to simulate 15mg/kg/day. All doses will be adjusted for obesity and renal function.
62676050|NCT04851015|ACTIVE_COMPARATOR|Standard dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 15mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as 10mg/kg/day open label plus an extra masked 5mg/kg/day of tablets or intravenous solution. All doses will be adjusted for obesity and renal function.
62676051|NCT05847543||Non-weaned Children|Children who have not started weaning food
62116400|NCT01045655|EXPERIMENTAL|MOMCare intervention|Depression care treatment with study depression care specialist (brief interpersonal psychotherapy or pharmacotherapy)
62116401|NCT01045655|NO_INTERVENTION|Care Plus|Usual care group; referral to community mental health treatment
62116402|NCT05390099|EXPERIMENTAL|moringa plant toothpaste|
62676052|NCT05847543||Weaned Children (Non-Caucasian)|Non-Caucasian children who have started weaning food
62116403|NCT05390099|ACTIVE_COMPARATOR|Fluoride toothpaste|
62116404|NCT04623658||Sacrococcygeal teratoma|Fetuses and infants diagnosed with sacrococcygeal teratoma and cared for between 2007 and 2017 in the main Parisian fetal medicine and pediatric surgery units: Necker-Enfants Malades Hospital, Antoine Béclère Hospital, Armand Trousseau Hospital, Robert Debré Hospital and Le Kremlin-Bicêtre Hospital.
62116405|NCT04430426|EXPERIMENTAL|Controlled Dietary Study|Participants will consume the controlled diet for five days and be administered an intravenous (IV) load of glycolate. Participants will provide urine and blood samples both before the glycolate load to establish baseline levels and after the glycolate load to measure oxalate levels afterwards.
62116406|NCT04812951|NO_INTERVENTION|young control|25 patients \< 65 years old without any prophylactic anti-inflammatory preoperative treatment
62676053|NCT05847543||Weaned Children (Caucasian)|Caucasian children who have started weaning food
62676054|NCT06380530|EXPERIMENTAL|Pediatric patients with musculoskeletal diseases|Children, adolescents, and young adults suffering from musculoskeletal disorders (MMD) who exhibit complex conditions characterized by rare and severe anomalies in skeletal development. These abnormalities may affect bones, joints, and musculotendinous structures.
62676055|NCT05986058|EXPERIMENTAL|Hybrid PA intervention|The PA intervention implemented 1-hour sessions for 12 weeks focusing on improving (1) body muscle, (2) body flexibility, (3) muscle endurance, and (4) body balance. The 12-week hybrid PA intervention was concurrently deployed in-person at a senior center and at-home through a web-based modality.
62676056|NCT06568536||Patients with acute disorders of consciousness receiving TMS-EEG|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post-injury.
62116407|NCT04812951|NO_INTERVENTION|control|25 patients \> 75 years old without any prophylactic anti-inflammatory preoperative treatment
62116408|NCT04812951|EXPERIMENTAL|Study group|25 patients \> 75 years old with prophylactic anti-inflammatory preoperative treatment
62116409|NCT04812951|ACTIVE_COMPARATOR|Vehicle group|25 patients \> 75 years old with vehicle preoperative treatment
62116410|NCT00877513|EXPERIMENTAL|Smokers|Cigarette smokers wishing to quit
62304683|NCT04880317|EXPERIMENTAL|Single arm|
62676057|NCT01266083|EXPERIMENTAL|Galinpepimut-S + Montanide + GM-CSF|Galinpepimut-S (GPS) and Montanide (in a 1 mL emulsion) are administered subcutaneously (s.c.) Q2W on weeks 0, 2, 4, 6, 8, and 10. GM-CSF (70 μg) are administered s.c. one to two days before and on the day of GPS/Montanide administration. Participants with no recurrence after Week 12 and who are clinically stable may be eligible to receive up to 6 additional monthly vaccinations.
62116411|NCT01534910|PLACEBO_COMPARATOR|Sugar pill|placebo
62116412|NCT01534910|ACTIVE_COMPARATOR|Aged Garlic Extract|2400 mg of aged garlic extract
62304684|NCT03797287|EXPERIMENTAL|Tensor Tunnler|The Tensor Tunneler (Chattanooga, TN) will be used to create the bone tunnels during the arthroscopic procedure. This is an FDA approved device and is used currently in routine clinical practice.
62676058|NCT02936271|ACTIVE_COMPARATOR|Active Vasculera (diosmiplex)|Active Vasculera will be prescribed as one (1) tablet (630 mg) twice a day.
61918203|NCT00945854|ACTIVE_COMPARATOR|Wholegrain cereal diet|Treatment with a diet based on wholegrain cereals and foods with low glycemic index
62116413|NCT01828320|EXPERIMENTAL|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
62116414|NCT01828320|ACTIVE_COMPARATOR|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
61918204|NCT00945854|ACTIVE_COMPARATOR|Refined cereal diet|Treatment with a diet based on refined cereals and foods with high glycemic index
62304685|NCT03797287|ACTIVE_COMPARATOR|Smith and Nephew PEEK Helicoil Anchor|The anchors used in this trial are FDA approved and are used currently in routine clinical practice (Anchor Rotator Cuff Repair).
62472964|NCT06185322|EXPERIMENTAL|Upper Cross Syndrome exercises group|10sessions of physical therapy over two weeks.Each session will consist of 20minutes of hotpack and transcutaneous electrical nerve stimulation and 10minutes of therapeutic ultrasound.Exercise sessions lasting 20minutes will consist of stretching and strengthening exercises under the supervision of a single physiotherapist.Strengthening exercises for the deep neck flexors,upper and middle trapezius,serratus anterior will be performed by the patient.Ten repetitions of each exercise,three times daily will be recommended.Stretching exercises will include those for the upper trapezius,pectoralis majör,levator scapula,suboccipital and sternocleidemastoid muscles and izometric neck flexion-extension exercises.These will be repeated 5times each,twice daily.A brochure depicting each exercise,accompanied by a description,will be given to the patient.The patient will continue with the exercise program for 3 months and be reminded once a week via telephone.
61918205|NCT01633437|PLACEBO_COMPARATOR|Sugar pill|
61918206|NCT01633437|EXPERIMENTAL|CX157|CX157 is a reversible monoamine oxidase inhibitor (RIMA) in Phase II development for the treatment of depression.
62116415|NCT00781196|EXPERIMENTAL|1|Oral folic acid
62116416|NCT00781196|PLACEBO_COMPARATOR|2|placebo
62116417|NCT05781555|EXPERIMENTAL|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62116418|NCT00609700||1|Historical group: patients treated with Ringer's Lactate solution after severe burn injury
62116419|NCT00609700||2|Actual group: patients treated with Ringer's Acetate solution after severe burn injury
62116420|NCT02559518|EXPERIMENTAL|anodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
62116421|NCT02559518|EXPERIMENTAL|cathodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
62116422|NCT02559518|SHAM_COMPARATOR|sham ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
62116423|NCT02559518|EXPERIMENTAL|high frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
62116424|NCT02559518|EXPERIMENTAL|low frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
62116425|NCT02559518|SHAM_COMPARATOR|sham c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
62304686|NCT01576471|PLACEBO_COMPARATOR|Placebo|
62304687|NCT01576471|EXPERIMENTAL|TSO 7500|
62304688|NCT04701411|EXPERIMENTAL|Darvadstrocel|Darvadstrocel (Cx601), 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
62304689|NCT00730093|OTHER|A|
62676059|NCT02936271|PLACEBO_COMPARATOR|Vasculera Placebo|Vasculera Placebo will be prescribed as one (1) tablet twice a day.
61918207|NCT01456910|EXPERIMENTAL|Working group|G1 intervention group of 20 participants aged 14-36 years old and mild to severe intellectual disability of both gender.
61918208|NCT01456910|ACTIVE_COMPARATOR|Daily Living|G2 control group continue usual routine
61918209|NCT04063527|ACTIVE_COMPARATOR|Standard therapy|combination of paclitaxel and carboplatin
61918210|NCT04063527|NO_INTERVENTION|Observation|Observation
61918211|NCT04250311|EXPERIMENTAL|MMH-407|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
62116426|NCT00764920||Skin Imaging|non-invasive imaging modalities for assessment of skin
62116427|NCT03990272|EXPERIMENTAL|artemisia annua allergen extract drops|
62116428|NCT03990272|PLACEBO_COMPARATOR|Placebo drops|
62116429|NCT01513135|EXPERIMENTAL|Group A, Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin; administered intradermally 3 times at weeks 0, 4 \& 8
62116430|NCT01513135|PLACEBO_COMPARATOR|group B, Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin, administered intradermally 3 times at weeks 0, 4 \& 8
62116431|NCT01185899||Suspected ACS patients|Patients presenting with chest pain to the Emergency Department, who are suspected of having ACS, will be asked to participate in the study.
62304690|NCT00278824|EXPERIMENTAL|50 mcg/hr matrix fentanyl patch|active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
62304691|NCT00278824|PLACEBO_COMPARATOR|Placebo Patch|placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
62304692|NCT02704429|EXPERIMENTAL|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 weeks follow-up; Part B: Open-label PRN1008, 24 weeks; 4 weeks follow-up
62472965|NCT04492774|EXPERIMENTAL|GOLDIC serum|Epidural ultrasound guided injections
62472966|NCT04492774|ACTIVE_COMPARATOR|Steroid|Epidural ultrasound guided injections
62472967|NCT04492774|ACTIVE_COMPARATOR|Manual therapy|veno-lymphatic spinal drainage
62676060|NCT00888966||Out of hospital cardiac arrest|Out of hospital cardiac patients successfully resuscitated and admitted to ICU
62472968|NCT04819243|EXPERIMENTAL|Atezolizumab+Talazoparib|"1. st line treatment~   * Palbociclib 125mg po D1-21~  * AI : Prescribed as per local guideline~  * GnRH agonist: Prescribed as per local guideline~2. nd line treatment~   * Talazoparib 1mg po~  * Atezolizumab 1200mg IV (3week)"
62472969|NCT04819243|EXPERIMENTAL|Talazoparib|"1. st line treatment~   * Palbociclib 125mg po D1-21~  * AI : Prescribed as per local guideline~  * GnRH agonist: Prescribed as per local guideline~2. nd line treatment - Talazoparib 1mg po"
62472970|NCT03520517|EXPERIMENTAL|BHV-0223|riluzole 40 mg sublingual tablet
62472971|NCT03206008|PLACEBO_COMPARATOR|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
62472972|NCT03206008|ACTIVE_COMPARATOR|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
62472973|NCT05488834|OTHER|Intensive care units|The unit will be subject to the intervention. Data will be collected from all 8 units in the control phase of this study. Units will then be randomised in blocks to the intervention.
61918212|NCT04250311|PLACEBO_COMPARATOR|Placebo|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
61918213|NCT05976984||Medicaid enrollees|Medicaid enrollees age15 years or older 2016-2020
61918214|NCT03016676|EXPERIMENTAL|Spinal manipulation|Spinal manipulation -High velocity low amplitude thrust (HVLA), Dosages : 2 repetition at the same time, Duration-10-20 minutes. total 2 weeks.
62116432|NCT06553560|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2 cm lateral to the sternal border to visualize the T2-T4 intercostal space and to identify the pectoralis major muscle, intercostal muscle, and pleura. 10 ml of 0.25% bupivacaine local anesthetic is administered between the pectoralis major and intercostal muscle using an in-plane approach with a 100 mm needle. In addition, a Recto-Intercostal Fascial Plane Block is performed with a high-frequency linear USG probe. The probe is placed 2-3 cm lateral to the xiphoid so that the rectus abdominis muscle and 6-7th cartilages are visualized. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique and 1-2 ml of saline is injected. After observing the spread to the target plane, 20 ml of 0.25% bupivacaine is applied. The same process is repeated bilaterally.
62472974|NCT05935631|EXPERIMENTAL|Salt with folic acid and iodine|Intervention is intake of double fortified salt with folic acid and iodine (DFS). We will ask the participants to substitute their current salt with the study saltshaker and use it when preparing food or when eating out. We estimate minimum daily intake from salt consumption by participants will be 200 micrograms (µg) of folic acid per serving. Serving is 2g of salt. Participants will be given portion suggestions: 1/2 teaspoon or 2-3 pinches or 8-10 shakes/5 times a day. Containers (125g) will be weighted at the beginning and end of 1 month. We will ask each day if woman cooked/used the salt for herself only or to list number of people each day. Participants will also agree to complete either daily paper salt log. A commercially available salt that is fortified with folic acid has been provided by AlpenJodSalz produced by Sudwestdeutsche Salzwerk. For 30 participants, we will need 30 containers.
61918215|NCT03016676|EXPERIMENTAL|Exercise therapy|Exercise Therapy(ET): Exercise therapy (ET) 3 program: self education, supervised exercise visits, and home exercise. Duration-45 minutes,Total number of visits 12 for 2 weeks.
61918216|NCT01362595|OTHER|Leucine|No alternative treatment arm
62116433|NCT03751150|NO_INTERVENTION|Control|Normal training, no intervention
62116434|NCT03751150|EXPERIMENTAL|Intervention INT|The intervention consists of an exercise program developed by a team specialised in orthopaedics, physiotherapy and biomechanics, based on the results from a recent prospective study in Gothenburg, Sweden. The exercises included cover muscle control training for the core, abductors, quadriceps and foot pronators, as well as foamrolling for the abductors, quadriceps, hamstrings, calf muscles and gluteal muscles. The runners will be instructed to perform the training program twice a week for the entire intervention period.
62116435|NCT04672590||Cases|Patients admitted to a study hospital meeting criteria for confirmed or probable acute new-onset neurological disease and confirmed or probable COVID-19.
62116436|NCT04672590||Controls|Patients admitted to a study hospital meeting criteria for confirmed or probable COVID-19, without confirmed or probable acute new-onset neurological disease.
62304693|NCT06114654||Participants|Physiotherapy students of the Rovira i Virgili University aged between 18 and 35 years enrolled during the academic year 2022-2023. All participants were allowed three practice trials for each test. Consistent feedback was provided throughout to ensure proper technique. Electrodes were placed to assess muscle activity according to SENIAM recommendations in gluteus medius, gluteus maximus, tibialis anterior and peroneus longus. After electrode placement, a maximal isometric strength test (MVIC) was performed for each muscle to normalize the electromyographic data. During this MVIC test, the maximum isometric force was measured using the Chronojump Boscosystem force gauge. Following this, ankle stability evaluation tests were performed. The Single Leg Stance Test, the Hurdle Step test and finally the Single leg vertical jump will be performed.
62304694|NCT05144022|EXPERIMENTAL|Interventions group: High stress condition (bungee jump)|25-30 healthy male volunteers participating in a bungee jump
62304695|NCT05144022|PLACEBO_COMPARATOR|Control group: No stress condition|10-15 healthy males serving as a control group without undergoing a stress event/intervention
62304696|NCT02201823|EXPERIMENTAL|ABTL0812|ABTL0812 oral
62304697|NCT06233292|EXPERIMENTAL|Part 1: Dose Escalation|The study will begin with open-label dose escalation in ZG005 monotherapy treatment to determine the Maximum tolerated dose (MTD).
62472975|NCT01860521|ACTIVE_COMPARATOR|Programmed Intermittent Epidural Bolus|
62472976|NCT01860521|ACTIVE_COMPARATOR|Continuous Epidural Infusion|
62676061|NCT06290024||Patients with neuropathic pain|With prospective and longitudinal research design, patients with neuropathic pain that meet the entry/displacement standards will be included in the group and receive the routine diagnosis and treatment of the pain department. At the same time, the patients admitted to the group will be clinical observation and studied. After the diagnosis and treatment, follow-up will be carried out until 3 months after joining the group.
62676062|NCT02831036|EXPERIMENTAL|trial group|subjects in trial group will be following the experimental protocol (VO2max tests and spatial orientation tests) while performing a training program during the trial (3 months).
62676063|NCT02831036|OTHER|control group|following the experimental protocol (VO2max tests and spatial orientation tests)without performing additional exercise.
62676064|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral~Pharmacokinetics"
62676065|NCT02226783|EXPERIMENTAL|Treatment A AZD1722 salt tablet (fasted)|Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner
62676066|NCT02226783|EXPERIMENTAL|Treatment B AZD1722 salt tablet (fed)|Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner
62676067|NCT02226783|EXPERIMENTAL|Treatment C AZD1722 salt tablet (fasted)|Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption
62676068|NCT02226783|EXPERIMENTAL|Treat D AZD1722 free-base tablet (fast)|Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner
62676069|NCT02226783|EXPERIMENTAL|Treat E AZD1722 free-base+Omeprazole|Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
62116437|NCT02616237|EXPERIMENTAL|Intervention Group|"Lifestyle Intervention: The interventions include participation in a private research group on Facebook for health education, self monitoring and social support. Participants will receive 12 weekly lessons related to nutrition, physical activity, Chinese food therapy, acupressure, weight loss. A registered nutritionist and a registered Chinese medicine practitioner will join the Facebook group as health partners. Both of them are also registered nurses.~Besides the Facebook contents, the participants will also receive government printed health information on healthy eating, physical activity, obesity and cancers."
62116438|NCT02616237|NO_INTERVENTION|Control Group|The participants randomized into the Control Group will only receive government printed health information on healthy eating, physical activity, obesity and cancers.
62116439|NCT03230396|PLACEBO_COMPARATOR|Placebo|"Commercially-available chewing gum not supplemented with vitamins. Contains: Sugar; Dextrose; Gum Base; Corn Syrup; Natural and artificial flavors; artificial colors; carnauba wax; resinous glaze; neotame; butylated hydroxytoluene.~For saliva collection phase: No placebo is used. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
62116440|NCT03230396|EXPERIMENTAL|Vitamingum Sport|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (1250 IU); ascorbic acid (15 mg); cholecalciferol (100 IU); dl-tocopherol acetate (7.5 IU); thiamine mononitrate (375 microg); riboflavin (425 microg); niacinamide (5 mg); calcium d-panothenate (2.5 mg); pyroxidine HCl (500 microg); cyanocobalamin (1.5 microg); folic acid (100 microg); biotin (11.25 microg).~For saliva collection phase: Subjects will chew 2 pieces for 30 min. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
62116441|NCT03230396|EXPERIMENTAL|Vitamingum Immunity|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (2000 IU); ascorbic acid (62.5 mg); cholecalciferol (200 IU); dl-tocopherol acetate (20 IU); niacinamide (10 mg); calcium d-panothenate (10 mg); pyroxidine HCl (1 mg); cyanocobalamin (5 microg); folic acid (200 microg); biotin (75 microg); zinc sulfate (2.5 mg); sodium selenite (17.5 microg); chromium picolinate (60 microg); and potassium iodide (40 microg).~For saliva collection phase: Subjects will chew 1 pieces for 30 min. For blood collection phase: Subjects will chew 1 piece at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
62116442|NCT01494246|EXPERIMENTAL|electronic mail|
62116443|NCT01494246|NO_INTERVENTION|brief advise|
62116444|NCT00346151|EXPERIMENTAL|Belatacept|Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.
62116445|NCT01456936|PLACEBO_COMPARATOR|placebo|Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
62116446|NCT01456936|ACTIVE_COMPARATOR|varenicline|
62116447|NCT01456936|ACTIVE_COMPARATOR|bupropion|
62116448|NCT01456936|ACTIVE_COMPARATOR|Nicotine Replacement Therapy Patch|
62116449|NCT02177318||Patients with COPD|
62116450|NCT06184854|ACTIVE_COMPARATOR|Standard 3D LapPass Training Models|Participants in the standard 3D group practised laparoscopic skills using the standard 3D LapPass training models for polo manipulation and intracorporeal suturing
62116451|NCT06184854|EXPERIMENTAL|3D-Enhanced Training Models|Participants in the 3D-enhanced group practised laparoscopic skills using the 3D-enhanced training models for polo manipulation and intracorporeal suturing
62116452|NCT02709863|ACTIVE_COMPARATOR|Sevoflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
62116453|NCT02709863|ACTIVE_COMPARATOR|Desflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
62116454|NCT02709863|ACTIVE_COMPARATOR|Propofol|6-10 mg/kg/h, iv infusion, during operation
62304698|NCT06233292|EXPERIMENTAL|Part 2: Dose Expansion: Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy|The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.Single drug dose expansion was performed in different tumors, such as :Non-small cell lung cancer, small cell lung cancer, Esophageal squamous cell carcinoma, Alveolar soft part sarcoma
62676070|NCT04972175|ACTIVE_COMPARATOR|Rapid Insulin lispro - Conventional bolus|Participants will use subcutaneously-delivered rapid insulin (lispro) through pump therapy.
62676071|NCT04972175|EXPERIMENTAL|BC LisPram - Conventional bolus|Participants will use subcutaneously-delivered BC LisPram through pump therapy.
62116455|NCT05767099||Patient undergoing general anesthesia with videolaryngoscopy intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway.
62116456|NCT04827654|EXPERIMENTAL|Intervention group|Families in the intervention arm will receive a program of 4 weeks of access to fruit and vegetables through direct access (produce box) and a gift card to the grocery store for purchase of preferred produce.
62116457|NCT04827654|NO_INTERVENTION|Control Group|Families in the control group will not receive any produce boxes or gift cards during the study period. At the end of the study period they will receive gift cards of equivalent amount.
62116458|NCT03720990|EXPERIMENTAL|Cholic acid|Participants will be treated with cholic acid 10 mg/kg body weight.
62116459|NCT02306343|EXPERIMENTAL|Test (with the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, the InsuPad device was placed on the abdomen of the subject. The InsuPad device was activated and insulin bolus (0.2 units/kg body weight) was injected right before study start. The injection was given to the subject's abdomen through the injection window of the InsuPad device. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months with the device (test). Subjects were asked to perform at least 3 blood glucose measurements during the day."
62116460|NCT02306343|NO_INTERVENTION|Control (without the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, insulin bolus (0.2 units/kg body weight) was injected to the abdomen right before study start. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months without the device (control). Subjects were asked to perform at least 3 blood glucose measurements during the day."
62116461|NCT00929721|OTHER|Subjects with Community-Acquired Pneumonia|Subjects with Community-Acquired Pneumonia
62116462|NCT04347499|EXPERIMENTAL|Intervention|This group will receive CaCBT based guided selfhelp using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
62116463|NCT04347499|NO_INTERVENTION|Control|This group will receive treatment as usual
62116464|NCT01576133|EXPERIMENTAL|CAPABLE|Experimental group participants received up to 10 sessions; up to 6 with an OT, and up to 4 sessions with an RN, and ≤ $1200 of safety and functional modifications from a licensed handyman. These sessions happened in coordinated fashion over the course of 4 months.
62116465|NCT01576133|ACTIVE_COMPARATOR|Attention visits|Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
62304699|NCT02732951|EXPERIMENTAL|BI 1026706|
62304700|NCT02732951|ACTIVE_COMPARATOR|Placebo|
62304701|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
62304702|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c \>7.5% \& \<10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
62304703|NCT02212418|EXPERIMENTAL|Abdominal hypopressive technique|
62304704|NCT05741203||children with LRTI|
62304705|NCT02515695|EXPERIMENTAL|0.5 MIU i.v. and 1.5 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
62304706|NCT02515695|EXPERIMENTAL|1 MIU i.v. and 3 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
62676072|NCT04972175|EXPERIMENTAL|BC LisPram - Dual wave bolus|Participants will use subcutaneously-delivered BC LisPram through pump therapy. During dual wave bolusing, 50% of the prandial bolus is delivered immediately, and the other 50% delivered over the next 30 minutes.
62676073|NCT02557165||COPD patients|Patients with mild to moderate COPD having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery
62676074|NCT02557165||Patients with normal lung function|Patients with normal lung function having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery.
62676075|NCT01420003|EXPERIMENTAL|Allergen Challenge|
62116466|NCT02863380|EXPERIMENTAL|Individualized rTMS (transcranial magnetic stimulation)|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks."
62676076|NCT04491383|EXPERIMENTAL|Tocovid Suprabio (HOV-12020)|200mg, twice 1 day, 12 months
62676077|NCT04491383|PLACEBO_COMPARATOR|Placebo|200mg, twice 1 day, 12 months
62116467|NCT02863380|ACTIVE_COMPARATOR|Classical rTMS (transcranial magnetic stimulation)|rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
62116468|NCT02863380|ACTIVE_COMPARATOR|Classical tDCS (transcranial direct current stimulation)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
62116469|NCT00414648|EXPERIMENTAL|Active Agent (Sirolimus)|Participants receive sirolimus daily for 1 year and are followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.
62116470|NCT00414648|PLACEBO_COMPARATOR|Placebo Arm|Participants receive placebo daily for 1 year and followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.
62116471|NCT04870060|NO_INTERVENTION|Control|Patients in this arm received only standard supportive care
62116472|NCT04870060|EXPERIMENTAL|Curcumin|Patients in this arm received curcumin lozenges (4 lozenges BD) along with standard supportive care
62116473|NCT06043128||Group with High Body Control|This group consists of stroke patients who received 23 or close to 23 points on the trunk impairment scale. In these patients, muscle stiffness, awareness of the sense of balance and position, quality of life will be evaluated and their relationships will be examined.
62116474|NCT06043128||Group with Low Body Control|This group consists of stroke patients who received 0 points or close to 0 points from the trunk impairment scale. In these patients, muscle stiffness, awareness of the sense of balance and position, quality of life will be evaluated and their relationships will be examined.
62116475|NCT04405063|EXPERIMENTAL|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
62116476|NCT04405063|ACTIVE_COMPARATOR|SeQuent® Please|Paclitaxel Coated PTCA Balloon Catheter
62116477|NCT06015750|EXPERIMENTAL|Pediatric participants with HPP|Pediatric participants who have been receiving asfotase alfa treatment for their HPP, and who demonstrate immune-mediated LoE.
62116478|NCT00042224|EXPERIMENTAL|1 ECT plus clozapine|Electroconvulsive therapy ECT plus clozapine for 8 weeks
62116479|NCT00042224|ACTIVE_COMPARATOR|2 Clozapine|Clozapine for 8 weeks
62116480|NCT04136639|EXPERIMENTAL|Miswak|Miswak sticks used twice daily, every 12 hours, for three months.
62116481|NCT04136639|EXPERIMENTAL|Grape Seed Extract|Grape seed extract 6.5% mouthwash used twice daily, every 12 hours, for three months.
62116482|NCT04136639|ACTIVE_COMPARATOR|Fluoride Mouthwash|0.05% fluoride mouthwash used twice daily, every 12 hours, for three months.
62472977|NCT03227497|ACTIVE_COMPARATOR|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).~Treatment arm includes 56 g of whole walnuts daily."
62676078|NCT05663593|EXPERIMENTAL|HSK31858|Single or multiple oral doses of HSK31858 Tablet, orally once daily
62676079|NCT05663593|PLACEBO_COMPARATOR|Placebo|Matching placebo Tablet, orally once daily
62676080|NCT05783323|EXPERIMENTAL|Larotrectinib monotherapy with 131I therapy|"Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.~Patients will receive 131I therapy after 6 months of larotrectinib. Larotrectinib will be continued for 5 days after RAI therapy and then patients will enter a wait and see period off treatment.~Patients who experience disease progression at any point while on larotrectinib will proceed to 131I therapy and discontinue larotrectinib."
62676081|NCT06686719|EXPERIMENTAL|Post Facilitation group|"subjects are asked to isometrically contract the hamstring and calf using 30 % of the strength for 15 seconds by attempting to push the leg back toward the therapist and relax. The therapist then passively stretched the muscle until a mild stretch sensation was reported. The stretch was held for another 10 seconds. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantarflexor muscles. Functional training includes bridging, kneeling, sit to stand"
62676082|NCT06686719|ACTIVE_COMPARATOR|Post Isometric Relaxation|"Subjects are asked to isometrically contract the hamstring and calf using 25 % of the strength for 7-10 seconds by attempting to push the leg back toward the therapist and relax. After relaxation, the therapist further extends the knee for 3 to 5 seconds. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantarflexor muscles. Functional training includes bridging, kneeling, sit to stand."
62676083|NCT06686719|ACTIVE_COMPARATOR|Myofascial Release|MFR for Hamstring muscle will be given with patient in prone position with 120 second hold. For giving the MFR, the thumb of the therapist will be allowed to sink in to the central portion of the hamstring. It will held for 120 seconds to allow the tissue to soften and then myofascial structures will spread in a lateral direction until feeling of first fascial barrier. MFR will be performed for 15 mins.
62676084|NCT06074523|EXPERIMENTAL|Attention and Working Memory Tests|All participants will complete a series of behavioral tasks, including cued visual search with positive (target color), negative (distractor color) and neutral (baseline) cues, learned visual search with a repeated salient distractor color, a visual working memory capacity task, and a daily life inattentive traits questionnaire (self-report). Single Arm.
62676085|NCT06469580|EXPERIMENTAL|NPLUS group|In the NPLUS group (intervention group) lung ultrasound is performed at time point T0 (prior to extubation), T1 (2-4 hours post extubation) and time point T2 (16-24 h) post extubation.
62304707|NCT02515695|EXPERIMENTAL|2 MIU i.v. and 6 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
62304708|NCT02515695|EXPERIMENTAL|4 MIU i.v. and 12 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
62304709|NCT01086683|EXPERIMENTAL|Intervention group|
62304710|NCT01086683|NO_INTERVENTION|Control group|Wait list control group: The control group received usual care including clinical control visits but no systematic rehabilitation activities.
62304711|NCT05580289|NO_INTERVENTION|control group|Routine care of the patient will be done and the level of pain will be determined with McGill pain scale questionnaire short form
62472978|NCT03227497|NO_INTERVENTION|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
62676086|NCT06469580|NO_INTERVENTION|control group|Includes routine care in the control group in case of clinical (respiratory) deterioration which is optional chest x-ray or NPLUS at any time point after extubation indicated by the clinician in charge. There are no study-specific measures in the control group.
62676087|NCT06319287|ACTIVE_COMPARATOR|PEP-TISSEEL+SOC|"Treatment for the PEP-TISSEEL+SOC arm is:~* PEP-TISSEEL~* Mepitel dressing followed by Tegaderm® (Mepilex can be used if subjects are allergic to Tegaderm)~* 3M Cavilon® (may be used on the borders prior to placing the Tegaderm or Mepilex)~* Padded 3-layer secondary outer layer dressing (Profore (Smith and Nephew (Memphis, TN)); and~* Offloaded with an offloading Controlled Ankle Movement (CAM) Boot (Foot Defender (Miami, FL) or Total Contact Cast (TCC)) Use of an alternate offloading device (e.g., Charcot Restraint Orthotic Walker (CROW) boot, custom shoe, etc.) may be approved on a case-by-case basis"
62472979|NCT02132494|EXPERIMENTAL|Physical activity|60 minutes of daily physical activity during one school year
62472980|NCT02132494|NO_INTERVENTION|Control|
62472981|NCT01199718|EXPERIMENTAL|CX-4945|CX-4945 oral formulation
61918217|NCT00003854|EXPERIMENTAL|Surgery + radiotherapy + adjuvant therapy|"Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.~Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H\&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.~All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.~Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery."
61918218|NCT02750215|EXPERIMENTAL|Capmatinib (INC280)|"Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib.~After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles"
61918219|NCT03361176|ACTIVE_COMPARATOR|Control|Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
61918220|NCT03361176|EXPERIMENTAL|w/ Triamcinolone|Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
61918221|NCT01871103|OTHER|Surgical flap|The dorsal homodigital island flap is a perforator type flap based on the DB, which uses the dorsal skin of the injured finger to provide soft tissue coverage for a volar defect.
61918222|NCT03869827||IUGR|All birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea with isolated intrauterine growth restriction at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2016.
61918223|NCT03869827||Control|To each of these children with intrauterine growth restriction is matched a control child: the child without intrauterine growth restriction of the same gestational age whose date of birth is consecutive to that of the case.
62304712|NCT05580289|EXPERIMENTAL|detrimental group|Warm half shower + dry hot application will be applied to the experimental group in the early postoperative period.mplementation Phase: After mobilizing the patients in the experimental group, who have regained their muscle strength and can be mobilized, their legs will be washed with 40-45oC warm tap water for 5 minutes (down from the hip level) until their legs are up to the femur acetabulum level, and then the patient will be taken to the bed for 20 minutes. Dry hot application will be done over the bladder. Palpation and bladder examination will be performed every hour to understand bladder filling in patients who will be expected to urinate within 6-8 hours after surgery.
62304713|NCT05707130|EXPERIMENTAL|gaze stabilization exercises group|Experimental group will receive Vestibulo ocular reflex VOR / gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
61918224|NCT01867073||Advanced solid tumours|
61918225|NCT05505994|EXPERIMENTAL|Study group|DWP16001 A mg, Dapagliflozin placebo
61918226|NCT05505994|ACTIVE_COMPARATOR|Control group|DWP16001 A mg placebo, Dapagliflozin
62304714|NCT05707130|ACTIVE_COMPARATOR|control group|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
62304715|NCT03619122|EXPERIMENTAL|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
62304716|NCT03619122|NO_INTERVENTION|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
61918227|NCT05669001|EXPERIMENTAL|TCD601 (siplizumab)|TCD601 administered in combination with belatacept, mycophenolic Acid (MPA), and corticosteroids
61918228|NCT05669001|ACTIVE_COMPARATOR|ATG|Antithymocyte globulin (ATG), tacrolimus (TAC), mycophenolic acid (MPA), and corticosteroids
61918229|NCT06134531|EXPERIMENTAL|MR001|The investigational product is MR001 which will be supplied in glass vials containing 50 mg of Freeze-dried powder. MR001 could be diluted in saline for intravenous (IV) administration.
62676088|NCT06319287|SHAM_COMPARATOR|Standard of Care|"* Fibracol~* Mepitel dressing followed by Tegaderm (Mepilex can be used if subjects are allergic to Tegaderm)~* 3M Cavilon (may be used on the borders prior to placing the Tegaderm or Mepilex )~* Padded 3-layer secondary outer layer dressing (Profore (Smith and Nephew (Memphis, TN)) or equivalent); and~* Offloaded with an offloading CAM Boot (Foot Defender (Miami, FL) or TCC)~* Use of an alternate offloading device (e.g., Charcot Restraint Orthotic Walker (CROW) boot, custom shoe, etc.) may be approved on a case-by-case basis"
62676089|NCT05524532|EXPERIMENTAL|Immulina TM 800 mg/day|Immulina Dietary supplementation (200 mg per capsule) 2-200 mg capsules given by mouth in the morning and 2-200 mg capsules given by mouth in the evening for 8 weeks duration
62676090|NCT05524532|PLACEBO_COMPARATOR|Placebo|inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 8 weeks duration
62676091|NCT06565078||Immune Globulin Subcutaneous (Human), 20% Solution|Participants with primary immunodeficiency disease who received Immune Globulin Subcutaneous (Human) 20% infusion in accordance with package insert.
62676092|NCT04483219|EXPERIMENTAL|TKI ± anti-PD-1 antibody|According to response to TKI, the combination of anti-PD-1 treatment would be determined.
62116483|NCT03942341||Adult subjects with Down syndrome and Alzheimer Disease|"Patients will be included from the 6 centers of the Horizon 21 european consortium. Horizon 21 consortium consists of DS cohorts from Spain (the Down Alzheimer Barcelona Neuroimaging Initiative -DABNI). France (the TriAl 21 at Jérôme Lejeune Institute in Paris), the UK (The LonDowns consortium and Dementia in Down's Syndrome (DiDS) in Cambridge), the Netherlands (the Rotterdam DS cohort) and Germany (AD21 in Munich), with a combined total of more than 1,000 older participants with DS to pool data and bioresources to address current gaps in knowledge about AD in DS.~All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity."
62116484|NCT03731936||Model establishment and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to establish the facial based diagnostic model of coronary artery diseases, and to prospectively validate the diagnostic effectiveness of the model.
62116485|NCT03630224|EXPERIMENTAL|Plasmalyte Viaflo|Intervention type: drug (Plasmalyte Viaflo) Intervention name: plasmalyte Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
62116486|NCT03630224|ACTIVE_COMPARATOR|NaCl 0.9%|Intervention type: drug (NaCl 0.9%) Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
62116487|NCT06089694||All Enrolled Subjects|In-clinic Testing Visit: All enrolled subjects will have a Holter recorder, capnography monitor and SpO2 sensor applied and will undergo various breathing/exercise activities. Subjects will go home connected to the Holter recorder for 24 hours for collection of ambulatory data.
62116488|NCT00491517|EXPERIMENTAL|Sirolimus|
62304717|NCT04721314|EXPERIMENTAL|Lower rate set to a higher, personalized backup heart rate (myPACE)|Patients randomized to this group will have their pacemaker lower heart rate setting programmed to a personalized lower rate based on a resting heart rate algorithm.
62304718|NCT04721314|ACTIVE_COMPARATOR|Lower rate left at 60 beats-per-minute|Patients randomized to this group will have their pacemaker lower heart rate setting left at or programmed to the conventional pacemaker lower rate setting of 60bpm.
62304719|NCT04939818||Group 1: Cognitive Disorders|"Alzheimer's Disease (AD) Meet National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Dementia with Lewy bodies (DLB) Diagnosis of possible or probable DLB based on the criteria defined by The Dementia with Lewy Bodies Consortium (2015)~Non-AD non-DLB MCI Diagnosis of 'probable' and 'possible' behavioral variant frontotemporal dementia (bvFTD) according to the International Behavioral Variant FTD Criteria Consortium OR semantic variant or nonfluent-agrammatic variant primary progressive aphasia (PPA) FTD according to Mesulam's criteria OR Vascular Dementia according to NINDS-AIREN International Workshop~AND~Date of diagnosis not more than five years prior to consent Subjects must have MMSE scores of 23-30 (inclusive); or TICS40 score of 20-40 (inclusive) based on a test not older than 1 month at the time of consent.~Age of 50-85 years (inclusive)"
62304720|NCT04939818||Group 2: Motor disorders|"Parkinson's Disease (PD)~* Diagnosis of idiopathic Parkinson's Disease based on the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria~* Date of diagnosis not more than five years prior to consent~* Hoehn and Yahr stage 2 or less~* Age of 30-85 years (inclusive)~Motor neuron Disease (MND)~* Diagnosis of Amyotrophic Lateral Sclerosis based on gold-standard clinical criteria~* Stage 3 or less on the King's ALS Staging system~* Age of 18-85 years (inclusive)"
62472982|NCT00852462|EXPERIMENTAL|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
62676093|NCT04813874||neuraxial analgesia only|Receiving neuraxial analgesia only for labor
62676094|NCT04813874||NO2 and neuraxial analgesia|Receiving nitrous oxide and neuraxial analgesia for labor
62676095|NCT03784300|ACTIVE_COMPARATOR|50 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.
62116489|NCT00491517|ACTIVE_COMPARATOR|conventional therapy|
62116490|NCT03162978|EXPERIMENTAL|HIIT + POE|High-intensity interval training (HIIT) plus positive outcome expectations (POE) from participating in the exercise program.
62116491|NCT03162978|EXPERIMENTAL|HIIT only|High-intensity interval training (HIIT) only.
62676096|NCT03784300|PLACEBO_COMPARATOR|50 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.
62676097|NCT03784300|ACTIVE_COMPARATOR|100 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.
62676098|NCT03784300|PLACEBO_COMPARATOR|100 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.
61918230|NCT05169827||PD-OFF|"Patients with PD who have previously been included in the Personalized Parkinson Project return for fMRI measurements in an off-medicated state (12h withdrawal). N = 60.~The PD-OFF group undergoes a single testing session."
62116492|NCT01979354|ACTIVE_COMPARATOR|Spinal morphine|0.15 mg spinal morphine
62472983|NCT00852462|NO_INTERVENTION|Usual Care|Symptom assessment and management follows customary procedures in each study site.
62472984|NCT04533295|EXPERIMENTAL|Acupuncture and IVF|Acupuncture and IVF
62472985|NCT04533295|SHAM_COMPARATOR|Sham acupuncture and IVF|Sham acupuncture and IVF
62676099|NCT03784300|ACTIVE_COMPARATOR|200 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.
62676100|NCT03784300|PLACEBO_COMPARATOR|200 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.
62676101|NCT06375772|ACTIVE_COMPARATOR|Study Drug|Each subject receives a multiple dose of a 3.5% 2-Deoxyglucose as nasal spray solution. The maximum daily dose is 56 mg/day if applied 4 times/day, over 7 days.
62676102|NCT06375772|PLACEBO_COMPARATOR|Placebo|Each subject receives a multiple dose of placebo as nasal spray solution. The dose is corresponding to the amount of solution needed in the serum group.
62676103|NCT02944825|ACTIVE_COMPARATOR|Antibiotic|Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal
62676104|NCT02944825|ACTIVE_COMPARATOR|No Antibiotic|Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal
62676105|NCT01652274||Mother|study objectives to Mother only
62676106|NCT01652274||Father|study objectives to Father only
61918231|NCT05169827||Healthy controls|"Healthy individuals who are matched on age and sex with respect to the PD-OFF group. N = 60.~The healthy group undergoes baseline and two year follow-up testing sessions."
62116493|NCT01979354|NO_INTERVENTION|Control|No spinal morphine
62116494|NCT03121131|OTHER|Accurate Clinical Exam Findings|Radiologists will be provided with accurate clinical exam data.
62472986|NCT05799313|EXPERIMENTAL|At home removal|
62472987|NCT05799313|ACTIVE_COMPARATOR|In office removal|
62676107|NCT04140929|EXPERIMENTAL|Intervention group|In the intervention group, a range of clinical parameters are recorded and the dentists prepares an individual oral hygiene and care recommendation, based on the Oral Health Tool Box. The Box is also used for instructing the dental assistants and the nursing staff for each patient individually. It is then determined when and how the dental assistants re-evaluates the oral hygiene and care process and reinstructs and remotivates the nursing staff. If the examination reveals a need for dental treatment (possibly requiring referral and transport), this will be communicated to the nursing staff. The dental assistant will further receive a training in communication, enabling them in reinstruction and remotivation. Dentists and dental assistants will further receive a training in geriatric dentistry by the State Commissioner of the German Society for Geriatric Dentistry.
62676108|NCT04140929|NO_INTERVENTION|Control group|In the control group, the residents receive care as usual. This includes the recording of the same parameters are recorded as in intervention group, a standardized form is filled out and handed over to the nursing staff. As in the case of Intervention group, the nursing staff is informed in the event of a need for treatment. No further measures are applied.
62116495|NCT03121131|OTHER|Inaccurate Clinical Exam Findings|Radiologists will be provided with purposefully incorrect clinical exam data
62116496|NCT03121131|OTHER|No Clinical Exam Findings|Radiologists will be not be provided with any clinical exam data
62472988|NCT03065374|EXPERIMENTAL|Treatment arm A|IMM-529, 1000 mg three times daily, orally
62472989|NCT03065374|PLACEBO_COMPARATOR|Treatment arm B|Matching Placebo, three times daily, orally
62472990|NCT06562569|EXPERIMENTAL|Group 1|Vagal nerve stimulation at an intensity under 10 units. Participants will self-administered at this intensity for 2 minutes each day over 4 weeks.
62472991|NCT06562569|EXPERIMENTAL|Group 2|Vagal nerve stimulation at the highest intensity tolerated by the participant. Participants will self-administered at this intensity for 12 minutes each day over 4 weeks.
62472992|NCT06562569|NO_INTERVENTION|Group 3|This group will not receive any stimulation. Participants will receive their treatment as usual.
62472993|NCT01403194|EXPERIMENTAL|CPAP/Bi-PAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
62472994|NCT00673647|EXPERIMENTAL|1|Individual psychotherapy including cognitive behavioral components, motivational interviewing techniques and case management
62472995|NCT00673647|NO_INTERVENTION|2|Delayed treatment control group
62472996|NCT02807545|EXPERIMENTAL|Physical Therapy Exercise Group|"Each patient assigned to the SSE group will attend at least 8 hours of supervised exercise training led by a Schroth-based certified physical therapist over the course of 6 months. Ideally, patients will be seen for 7 sessions.~Patients will perform a home exercise program for 15 minutes a day, 5 days a week, when they can independently execute their prescribed exercises. An exercise log initialed by the guardian will help families keep track of their exercise adherence and serve as a way to monitor exercise adherence for patients who may not have a smartphone, tablet, or computer.~Patients will also be able to meet with the therapists at their return-to-clinic visits and every 2-3 months thereafter until their 1 year follow-up to assess performance quality, maintain motivation, and progress intensity. Patients will be withdrawn if they do not achieve 80% exercise adherence within 6 months."
62472997|NCT02807545|NO_INTERVENTION|Control Group|Patients randomized to this group will continue receiving standard-of-care treatment from their orthopaedic physician which includes regularly scheduled clinic visits and observation. Observation consists of no treatment of the scoliosis, only routine clinical assessment by the orthopaedic surgeon to detect curve progression every 3 to 6 months.
62472998|NCT06554405|ACTIVE_COMPARATOR|Unilateral Intervention|Patients will be treated for 4 weeks (2 days in a week, 8 sessions). The treatment plan involves massage therapy, neuromobilization exercises and cold application. In this arm, treatment plan will be applied only for the symptomatic side. The rest of the treatment will be the same as the other group.
62472999|NCT06554405|EXPERIMENTAL|Bilateral Intervention|Patients will be treated for 4 weeks (2 days in a week, 8 sessions). The treatment plan involves massage therapy, neuromobilization exercises and cold application. In this arm, treatment plan will be applied only for both symptomatic and nonsymptomatic sides. The rest of the treatment will be the same as the other group.
62473000|NCT01208077||Acute CHF|"1. Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint~2. Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF~3. Known history of physician diagnosed CHF~4. Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up"
62473001|NCT01208077||Acute Stroke Syndrome|"1. Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint~2. Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome~3. Non contrast head CT will be ordered by the treating physician as part of the patient's work up"
62473002|NCT01208077||Acute Systemic Infection|"1. Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection~2. Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up"
62473003|NCT01458002|NO_INTERVENTION|Control|Assessment only
62473004|NCT01458002|OTHER|Tailored Internet Communications|TTM expert system only
62116497|NCT04821336||Thyroid tissue samples|from 30 patients, tissue samples , frozen and embedded paraffin have been collected and preserved for research. For this study, tumoral tissue and healthy tissue will be used;
62116498|NCT03329144|EXPERIMENTAL|Cognitive Behavioural Therapy|The women in this arm will receive a 9-week CBT-based curriculum delivered by Public Health Nurses to help build resilience and optimize mood, anxiety, and emotion regulation while attending a supported school program in Niagara Region.
62116499|NCT05417542|EXPERIMENTAL|Exposition I|preterm neonates between 28 and 30 wGA Exposition to music during the NICU period
62116500|NCT05417542|EXPERIMENTAL|Exposition II|preterm neonates between 32 and 34 wGA Exposition to music during the NICU period
62116501|NCT05417542|ACTIVE_COMPARATOR|Control I|preterm neonates between 28 and 30 wGA
62116502|NCT05417542|ACTIVE_COMPARATOR|Control II|preterm neonates between 32 and 34 wGA
62116503|NCT05417542|ACTIVE_COMPARATOR|Control III|preterm neonates between 36 and 40 wGA
62116504|NCT01537003|EXPERIMENTAL|Promogran and Low EPA|Patients with low EPA will be treated with PROMOGRAN and standard of care for vlu compression
62304721|NCT04939818||Group 3: Affective disorders|"Major Depressive Disorder (MDD)~* Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a current major depressive episode (MDE) as assessed by the MINI~* Current episode of at least moderate severity as assessed by the Clinical Global Impression (CGI) scale.~* Date of diagnosis (using MINI assessment) and severity (CGI) maximum of two months prior to consent.~* Age of 18-85 years (inclusive).~Bipolar Disorder (BD)~* Meet DSM-5 criteria for BD as assessed by the MINI (type 1 or type 2)~* Current depressive episode as assessed by the MINI~* Current episode of at least moderate severity as assessed by the Clinical Global Impression (CGI) scale.~* Date of diagnosis (using MINI assessment) and severity (CGI) maximum of two months prior to consent.~Age of 18-85 years (inclusive)."
62304722|NCT04939818||Group 4: Unaffected Controls|"Group 4 specific recruitment criteria matched for the 'Group 1: Cognitive Disorders' cohort:~* Age of 50-85 years (inclusive)~* Approximately age, gender and education matched to AD subjects on a group level.~* In otherwise good health condition.~Group 4 specific recruitment criteria matched for the 'Group 2: Motor Disorders' cohort:~* Age of 30-85 years (inclusive)~* Approximately age, gender and education matched to PD subjects on a group level.~* In otherwise good health condition.~Group 4 specific recruitment criteria matched for the 'Group 3: Affective Disorders' cohort:~* Age of 30-85 years (inclusive).~* Approximately age, gender and education matched to MDD/BD subjects on a group level.~* In otherwise good health condition."
62304723|NCT05299892|EXPERIMENTAL|Children with Hearing Loss|Participants age 5-12 with hearing loss who will be fit with study hearing aids and tested on speech perception in unaided and aided condition.
62304724|NCT02519231|ACTIVE_COMPARATOR|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
62304725|NCT02519231|PLACEBO_COMPARATOR|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
62304726|NCT04648371|ACTIVE_COMPARATOR|Cognitive Remediation and Active Transcranial Direct Current Stimulation|Cognitive Remediation (CR) is a form of group psychosocial intervention that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. Transcranial Direct Current Stimulation (tDCS): tDCS will be administered for 30 min/day, at the beginning of each group session. tDCS montage will be frontal with anode placed over Fz and the cathode over Iz. The direct current will be of 2 mA (current density = 0.57 A/m2). CR + tDCS is administered in groups consisting of 2-10 participants and one or two therapists. The groups meet 5 times per week for two hours per session over eight weeks, for a total of 40 sessions in induction phase. Afterwards 3 to 5 sessions per week on monthly boosters.
62304727|NCT04648371|SHAM_COMPARATOR|Cognitive Remediation and Sham Transcranial Direct Current Stimulation|CR is identical to the one described under the Active Comparator Arm. However, sham tDCS will consist of active stimulation for only 1 min/day, at the beginning of each group session. tDCS montage and the frequency of the sessions and the boosters will be the same as for the Active Arm.
62304728|NCT03369847|EXPERIMENTAL|Inhaled Corticosteroids|"* Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer x 28 days.~* Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer x 28 days"
62304729|NCT03369847|NO_INTERVENTION|Standard Care|Patients allocated to this group will not receive an asthma controller medication from the emergency department. The intervention group will receive prescriptions for inhaled albuterol and oral corticosteroids as per standard treatment.
62304730|NCT04911153||Aim 1: Physical Activity|250 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of physical activity on cardiometabolic health among veterans with and without PTSD.
62304731|NCT04911153||Aim 2: Diet Quality|200 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of diet quality on cardiometabolic health among veterans with and without PTSD.
62473005|NCT01458002|EXPERIMENTAL|Tailored Internet Communication with Relational Agent|TTM expert system plus relational agent
62473006|NCT02347722||Retrospective|Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
62473007|NCT02347722||Prospective|This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
62473008|NCT02347722||Healthy volunteers|Age matched healthy volunteers for comparison with heart failure patients
62116505|NCT01537003|ACTIVE_COMPARATOR|Low EPA and compression|Patients with Low EPA will only get standard of care for VLU which is compression.
62304732|NCT04911153||Supplemental Aim: Instrument Validation|100 participants will be recruited to examine the validity of a self-report clinical measure of physical activity against objectively measured physical activity obtained via accelerometry.
62304733|NCT02638012|EXPERIMENTAL|HHT - Floseal|"Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity.~If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care)."
62304734|NCT03547050||Patients diagnosed with RE|People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.
62304735|NCT03547050||Controls|People without a lifetime history of seizures.
62304736|NCT03400293||Subjects living with HIV|Subjects living with HIV will be recruited via digital advertising. These subjects will participate in completing various PRO instruments and targeted questions.
62304737|NCT03716791|PLACEBO_COMPARATOR|Placebo Control Group|pill capsules containing white rice flour
62304738|NCT03716791|ACTIVE_COMPARATOR|Methylsulfonylmethane Group|pill capsules containing MSM
62304739|NCT04939493|EXPERIMENTAL|Rhythmic Auditory Cueing|Group (B): Patients in this group will receive the same designed physical therapy program given to the control group in addition to auditory cueing during bilateral arm training using the metronome.
62304740|NCT04939493|ACTIVE_COMPARATOR|Bilateral arm training|Patients in this group will receive a standard physical therapy program in addition to Bilateral arm training.
62304741|NCT01987544|ACTIVE_COMPARATOR|Self-Control|3 months of ergometer training under self control at home without any interventional motivation.
62304742|NCT01987544|EXPERIMENTAL|Motivation|3 months of ergometer training at home with telemonitoring and motivation phone calls once a week when training sessions drop below 20 minutes per day.
62304743|NCT00756002|EXPERIMENTAL|Ramelteon 4 mg QD|
62304744|NCT00756002|PLACEBO_COMPARATOR|Placebo QD|
62473009|NCT01887652|ACTIVE_COMPARATOR|conventional ovarian stimulation|women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment
62473010|NCT01887652|ACTIVE_COMPARATOR|individualized ovarian stimulation|women whose protocol of ovarian stimulation was based on anti-mullerian hormone
62116506|NCT01537003|ACTIVE_COMPARATOR|High EPA and compression|Patients with high EPA will get standard of care for VLU which is compression.
62116507|NCT01537003|EXPERIMENTAL|Promogran High EPA|patients with HIGH EPA will then be treated with PROMOGRAN and standard of care for VLU compression
62116508|NCT03900637|EXPERIMENTAL|Arm I|"1. MammaPrint high risk :~   * Neoadjuvant chemotherapy : Adriamycin/Cyclophosphamide #4 followed by Docetaxel #4~2. MammaPrint low risk :~   * Premenopausal women : Letrozole 2.5mg PO QD + leuprorelin acetate 3.6mg SQ every 4weeks during 16 weeks (if needed, maximum for 24 weeks)~  * Postmenopausal women : Letrozole 2.5mg PO QD during 16 weeks (if needed, maximum for 24 weeks)"
62304745|NCT04494165|EXPERIMENTAL|Aromatherapy Group|In addition to the standard physical therapy session, 30 patients in this group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
62473011|NCT03149874|ACTIVE_COMPARATOR|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
62473012|NCT03149874|ACTIVE_COMPARATOR|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
62473013|NCT05223322|ACTIVE_COMPARATOR|Taking Charge during Treatment (TCT) Intervention|"Taking Charge during Treatment (TCT) Intervention. TCT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Participants will receive Take Charge program binder, 2-4 x weekly text messaging, activity tracker and resistance bands."
62116509|NCT03289611|NO_INTERVENTION|Control|Usual management
62116510|NCT03289611|EXPERIMENTAL|Experimental|Ambulatory management if sFlt-1 / PlGF ratio is below 38 Usual management if sFlt-1/PlGF is between 38 and 85. If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued
62304746|NCT04494165|PLACEBO_COMPARATOR|placebo group|In addition to the standard physical therapy session, 31 patients in this group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
62304747|NCT04494165|NO_INTERVENTION|control group|30 patients in this group received standard physical therapy sessions, and no massage was applied.
62304748|NCT05593432|EXPERIMENTAL|Ruxolitinib cream|Ruxolitinib 1.5% cream BID for 16 weeks, followed by ruxolitinib cream BID 16-week open-label extension.
62304749|NCT05593432|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream BID for 16 weeks, followed by ruxolitinib 1.5% cream BID in a 16-week open-label extension.
62304750|NCT05088148||Group 1: FGR group|Estimated fetal weight \<10th percentile
62304751|NCT05088148||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
62304752|NCT05315440|ACTIVE_COMPARATOR|control group|"The treatment of control group will be organized according to the classic protocol currently in use in our Institute which consists of:~30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation."
62304753|NCT05315440|EXPERIMENTAL|experimental group|30 minutes of passive and active assisted mobilization guided by the therapist associated with instrument assisted soft tissue mobilization, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
62473014|NCT05223322|NO_INTERVENTION|Control Group|"To ensure scientific rigor allowing us to test causal pathways associated with exercise, women will be randomized to the TCT intervention or control group arm. The control group will not receive the TCT intervention The investigators experience teaches us that to increase the likelihood of retaining control group participants, the investigators must offer some resources. Thus, the investigators will provide the control group with a one-page summary of the American College of Sports Medicine exercise recommendations, and the Take Charge program binder at the completion of the study. Participants will also receive resistance bands and activity tracker at the end of the study. 95 The investigators will also send weekly text messages with supportive content not related to exercise or lifestyle (i.e., a riddle, take a moment to smile today, a picture of a baby animal)."
62473015|NCT02373397|EXPERIMENTAL|Cacicol20|Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
62473016|NCT02373397|PLACEBO_COMPARATOR|Placebo|Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
61918232|NCT05169827||PD-ON|"Patients with PD who are included in the Personalized Parkinson Project. N = 360.~Available data will be used. There will be no further data collection in this group."
61918233|NCT01732653|EXPERIMENTAL|TT+VR|The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
61918234|NCT01732653|ACTIVE_COMPARATOR|TT alone|The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
61918235|NCT04148729|ACTIVE_COMPARATOR|bupivacaine+lidocaine|15 ml bupivacaine+ 5 ml lidocaine will use for USG guided ESP block under general anaesthesia with Sevuflurane and remifentanil. This block will perform at the T10 level bilaterally after induction of anaesthesia at the prone position. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with VAS score. The rescue analgesic 0.4 mg/kg meperidine will be apply intravenously whenever the patient requested to the analgesic.
62473017|NCT04992507|EXPERIMENTAL|Arm I (surgical resection with TIVA)|Patients undergo surgical resection with TIVA.
62473018|NCT04992507|ACTIVE_COMPARATOR|Arm II (surgical resection with inhaled volatile anesthetics)|Patients undergo surgical resection with inhaled volatile anesthetics.
61918236|NCT04148729|SHAM_COMPARATOR|saline|"In this group, the same volume saline will apply to the block region. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with VAS score.~The rescue analgesic 0.4 mg/kg meperidine will be apply intravenously whenever the patient requested to the analgesic."
61918237|NCT05977725||Healthy Volunteers|Lack of upper limb arterial disease.
61918238|NCT05977725||Patients with Chronic Upper Limb Ischemia|Known diagnosis of chronic upper limb ischemia.
61918239|NCT04369924|EXPERIMENTAL|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
61918240|NCT04369924|EXPERIMENTAL|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
61918241|NCT00755911|EXPERIMENTAL|Tissue Repair Cells (TRC)|Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier
61918242|NCT00755911|SHAM_COMPARATOR|Control|Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy.
61918243|NCT05261451|EXPERIMENTAL|Head Start Teachers|Participants will engage in three 1- hour workshops and optional consultations with an occupational therapist
61918244|NCT04540939|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT is a mindfulness-based intervention group intervention involving in session and at home practicve of mindfulness meditation and other mindfulness practices. There are8 sessions each with a specific theme and and these are \~2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
62473019|NCT02655679|EXPERIMENTAL|VTP-38543 0.05%|VTP-38543 0.05% administered topically every 12 hours for 28 days.
62473020|NCT02655679|EXPERIMENTAL|VTP-38543 0.15%|VTP-38543 0.15% administered topically every 12 hours for 28 days.
62676109|NCT05376553|EXPERIMENTAL|Cohort A|"* 3 cycles of Cemiplimab-TP induction chemotherapy will be delivered in cohort A.~* Cemiplimab-TP chemotherapy will be given every 21 days starting on days 1, 22 and 43, etc. (+ 2 days) with TP given on days 1, 22, and 43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).~* Patients in cohort A will get 3 doses of Cemiplimab during induction therapy."
62676110|NCT05376553|EXPERIMENTAL|Cohort B|"* In cohort B first dose of Cemiplimab will be given 7 days prior to TP followed by TP given on days 1,22,43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).~* Patient in cohort B will get 4 doses of Cemiplimab during induction therapy."
62676111|NCT04606966|EXPERIMENTAL|Therapeutic Horseback Riding|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual, . Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table before class, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for one minute while watching a 1-minute timer. Participants will then don their riding helmets and enter the riding arena. Each week after conclusion of the THR intervention, participants will again sit with their group at an art table for 5 minutes followed by doing another saliva sample.
62473021|NCT02655679|PLACEBO_COMPARATOR|Vehicle without Transcutol®P|Vehicle without Transcutol®P administered topically every 12 hours for 28 days.
62473022|NCT02655679|EXPERIMENTAL|VTP-38543 1%|VTP-38543 1% administered topically every 12 hours for 28 days.
62473023|NCT02655679|PLACEBO_COMPARATOR|Vehicle with Transcutol®P|Vehicle with Transcutol®P administered topically every 12 hours for 28 days.
62473024|NCT03375047|EXPERIMENTAL|Low Dose|8 mg MRT5005
62473025|NCT03375047|EXPERIMENTAL|Low/Mid Dose|12 mg MRT5005
62473026|NCT03375047|EXPERIMENTAL|Mid Dose|16 mg MRT5005
62473027|NCT03375047|EXPERIMENTAL|Mid/High Dose|20 mg MRT5005
61918245|NCT04540939|ACTIVE_COMPARATOR|Muscle Relaxation Therapy|"PMR is a relaxation-based group intervention similar to other relaxation interventions commonly used for anxiety and PTSD. It involves in session and at home practicve of relaxation techniques including tensing and relaxing muscle groups, but no specifici mindfulness or meta-cogntive awaremess instructions. This PMR group has been designed as an active comparator with similar stucture to MBCT, but without mindfulness instruction. There are 8 sessions each with a specific theme and these are \~2 hours long. Over the 8-weeks participants will learn several relaxation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
61918246|NCT03956355|EXPERIMENTAL|Tapinarof (DMVT-505)|Tapinarof (DMVT-505) Cream Group
61918247|NCT03956355|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Cream Group
61918248|NCT03425422|EXPERIMENTAL|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
61918249|NCT03425422|NO_INTERVENTION|Control|Stable guideline-directed medical therapy
61918250|NCT01780896||Study Group|
62116511|NCT02140138|EXPERIMENTAL|Arm A (i.d. vaccinations with needle free injection device)|"Duration: Patients in Arm A will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
62116512|NCT02140138|EXPERIMENTAL|Arm B (i.d. vaccination by conventional injection)|"Duration: Patients in Arm B will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the medial part of the upper arms and thigh~Dose: 2 x 160 μg mRNA per injection (2 x 200 μL), equals 320 μg mRNA per RNActive® drug product component"
62473028|NCT03375047|EXPERIMENTAL|High Dose|24 mg MRT5005
62473029|NCT03375047|PLACEBO_COMPARATOR|Placebo Comparator|Normal Saline 0.9% USP
62473030|NCT03375047|EXPERIMENTAL|Daily Dose|20 mg MRT5005 delivered in 5 consecutive daily doses of 4mg
62473031|NCT03129022|ACTIVE_COMPARATOR|Successful epidural anaesthesia|It is defined as VAS score \<5, 30 min after a loading dose, given after the last attempt.
62473032|NCT03129022|ACTIVE_COMPARATOR|Failed epidural anaesthesia|It is defined as VAS score ≥5, 30 min after a loading dose, given after the last attempt.
61918251|NCT04220853|EXPERIMENTAL|Septoplasty|The patients indicated for septoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
61918252|NCT04220853|EXPERIMENTAL|Turbinoplasty|The patients indicated for turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
62676112|NCT04606966|ACTIVE_COMPARATOR|Barn Activity|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor and co-led by a mental health or Occupational therapy provider. Participants will have one assigned volunteer and will have no physical contact with horses at the riding center, just view horses from a distance. There will be a life-sized stuffed toy horse for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table before class, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for one minute while watching a 1-minute timer. Each week after conclusion of the BA intervention, participants will again sit with their group at an art table for 5 minutes followed by doing another saliva sample.
62116513|NCT02140138|OTHER|Arm C (i.d. vaccination with needle free injection device)|"Duration: Patients in Arm C will receive no vaccination before radical prostatectomy. After surgery high risk or very high risk patients will be offered to receive 6 vaccinations with CV9104 at week 8, 9, 10, 12, 14 and 16 after surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
62116514|NCT01846754||Hemodialysis patients|
62116515|NCT02545751|EXPERIMENTAL|SBRT and Thymalfasin arm|SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
62116516|NCT02104765|EXPERIMENTAL|5 mg LY2951742 Single Dose|5 mg LY2951742 given subcutaneously once
62473033|NCT02598089|EXPERIMENTAL|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:~* NYMC BX-51B reassortant of B/Massachusetts/2/2012~* NYMC X-179A reassortant of A/California/7/2009 (H1N1)~* NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
62116517|NCT02104765|EXPERIMENTAL|50 mg LY2951742 Single Dose|50 mg LY2951742 given subcutaneously once
62473034|NCT02598089|PLACEBO_COMPARATOR|Placebo|This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline
62473035|NCT04956198||Patients with newly diagnosed as well as relapsed/refractory sarcomas.|The investigators intend to enroll newly diagnosed or refractory/relapsed pediatric patients with all types of sarcomas where tumor tissue would be available for ex vivo drug screening and genomic profiling. This observational study will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas
62473036|NCT04073394|ACTIVE_COMPARATOR|Standard Lifestyle Intervention|Participants in this group will be instructed to follow a standard low calorie diet, recommended to have 30 minutes of physical activity 3-5 days per week, and will be followed by a wellness couch weekly.
62676113|NCT04606966|NO_INTERVENTION|Waitlist|Those assigned to the waitlist group will not have any horse-related intervention during a 10-week waiting period. Following this waiting period and the completion of post assessments, participants in this condition will begin a Hybrid group (see Hybrid Arm)
62116518|NCT02104765|EXPERIMENTAL|120 mg LY2951742 Single Dose|120 mg LY2951742 given subcutaneously once
62116519|NCT02104765|EXPERIMENTAL|300 mg LY2951742 Single Dose|300 mg LY2951742 given subcutaneously once
62116520|NCT02104765|EXPERIMENTAL|300 mg LY2951742 Multiple Dose|300 mg LY2951742 given subcutaneously once every 4 weeks (Q4W)
62116521|NCT02104765|PLACEBO_COMPARATOR|Placebo Single Dose|Placebo given subcutaneously once
62116522|NCT02104765|PLACEBO_COMPARATOR|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks (Q4W)
62116523|NCT01392872|OTHER|sclerosis|
62116524|NCT00707135|EXPERIMENTAL|1|
62116525|NCT06017167|ACTIVE_COMPARATOR|Dexmedetomidine Group|will receive ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline to complete 10 ml. volume IV infusion over 10 minutes.
62116526|NCT06017167|ACTIVE_COMPARATOR|Dexamethasone Group|will receive Ondansetron 4mg + dexamethasone 8mg + normal saline to complete 10 ml. volume IV infusion over 10 minutes.
62116527|NCT06127888||Unit of headache and neurological pain of the Hospital Vall d'Hebron (VHIR) - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116528|NCT06127888||Unit of headaches and neuralgias of the Hospital de Sant Pau - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116529|NCT06127888||Unit of headache of the Hospital Sant Joan de Déu - Althaia - Manresa|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116530|NCT06127888||Unit of headache of the Hospital Universitari Arnau de Vilanova - Lleida|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116531|NCT06127888||Group of work on headaches of the Hospital Clínic de Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116532|NCT06127888||Headache Unit of Hospital de Bellvitge - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116533|NCT06127888||Headache Unit of Hospital del Mar - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116534|NCT06127888||Headache Unit of Hospital de Germans Tries i Pujol - Can Ruti - Badalona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116535|NCT06127888||Headache Unit of Hospital Josep Trueta - Girona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
62116536|NCT01564199|EXPERIMENTAL|Treatment A|Salmeterol/fluticasone propionate with concomitant charcoal
62116537|NCT01564199|EXPERIMENTAL|Treatment B|Salmeterol/fluticasone propionate without concomitant charcoal
62116538|NCT05535491|EXPERIMENTAL|GROUP 1|BREATHING EXERCISE GROUP
62116539|NCT05535491|NO_INTERVENTION|GROUP 2|CONTROL GROUP
62116540|NCT02032329|EXPERIMENTAL|FastFES|Single Group Study - see Intervention Description
62116541|NCT05685173|EXPERIMENTAL|Odronextamab and REGN5837|Odronextamab and REGN5837 will be administered by IV infusion using a step-up dosing schedule.
61918253|NCT04220853|EXPERIMENTAL|Septoplasty and turbinoplasty|The patients indicated for septoplasty and turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
62116542|NCT01050569|ACTIVE_COMPARATOR|VLNC Cigarette|Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
62116543|NCT01050569|ACTIVE_COMPARATOR|Nicotine Patch|21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
62116544|NCT01050569|EXPERIMENTAL|VLNC Cigarette plus Nicotine Patch|Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
62116545|NCT01140048||All Enrolled Participants|All participants who completed Protocol 272 and were enrolled in Protocol 374
61918254|NCT05161039|OTHER|Serranator|
62116546|NCT06513559|EXPERIMENTAL|Anatomic total shoulder replacement|Anatomic replacement replaces the humeral head with a metal ball and the glenoid socket with a polyethylene glenoid component.
62116547|NCT06513559|EXPERIMENTAL|Reverse total shoulder replacement|Reverse shoulder replacement reverses these implants with the polyethylene socket on the humeral side and the glenosphere going on the glenoid side.
62116548|NCT00227682|EXPERIMENTAL|Arsenic Trioxide|Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid
62116549|NCT06005220|ACTIVE_COMPARATOR|SBD121 Medical Food|Two capsules administered twice daily with food
62116550|NCT06005220|PLACEBO_COMPARATOR|Placebo|Two capsules administered twice daily with food
62116551|NCT02698891|EXPERIMENTAL|Paclitaxel|"After the screening procedures confirm participation in the research study:~175 mg/m\^2 Paclitaxel via IV, once every 2 weeks x 4 cycles. (1 cycle = 2 weeks)~-- Neulasta™ (Pegfilgrastim) 6 mg SQ x1 is administered on day 2 of each treatment cycle, approximately 24 hours after the chemotherapy treatment, if:~* The patient experiences a prior episode of fever and neutropenia.~* If the patient has an active infection this decision will be at provider discretion.~* If Neulasta™(Pegfilgrastim) is administered in any Paclitaxel cycle for a given patient, it will be then administered for all future cycles."
62116552|NCT01239563|EXPERIMENTAL|Thymoglobulin|Thymoglobulin induction group
61918255|NCT05161039|OTHER|POBA|
61918256|NCT00827580|EXPERIMENTAL|Eniluracil|
62116553|NCT01239563|ACTIVE_COMPARATOR|Basiliximab|Basiliximab induction - 20 mg, day 0 and day 4
62116554|NCT06535958|EXPERIMENTAL|Test group (OHI)|
62116555|NCT06535958|EXPERIMENTAL|Control Group (OHI+PMPR)|
62116556|NCT05027178|EXPERIMENTAL|Chiropractic care for Ischemic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
62116557|NCT05027178|EXPERIMENTAL|Chiropractic care for Hemorrhagic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
62304754|NCT04289883|EXPERIMENTAL|High molecular weight whey protein-alginate/Calcium alginate|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
62304755|NCT04289883|EXPERIMENTAL|Nano-particulated whey protein/Non-particulated whey protein|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
62304756|NCT00142103|EXPERIMENTAL|CPG10101|
62304757|NCT00142103|EXPERIMENTAL|CPG10101 + pegylated interferon|
62304758|NCT00142103|EXPERIMENTAL|CPG10101 + ribavirin|
62116558|NCT02899286|EXPERIMENTAL|PEG-BCT-100|PEG-BCT-100 (PEGylated recombinant human arginase)
62116559|NCT05272124|EXPERIMENTAL|Hip Abductor Strengthening|This group received quadriceps and hip abductor strengthening along with patellar mobilization and stretching exercises.
62116560|NCT05272124|ACTIVE_COMPARATOR|Traditional Physical Therapy|This group received quadriceps strengthening along with patellar mobilization and stretching exercises.
62304759|NCT00142103|EXPERIMENTAL|CPG10101 + pegylated interferon + ribavirin|
62116561|NCT05209880|EXPERIMENTAL|Intervention Arm|The intervention will take place in the emergency department or days after an emergency department visit at home/hospital virtually using zoom or phone by our trained clinicians. At the time of follow-up assessments, participants may also receive additional counseling by our trained clinicians as needed.
62116562|NCT05209880|NO_INTERVENTION|Control Arm|No intervention will be conducted (standard of care).
62116563|NCT00325013|EXPERIMENTAL|II|
62116564|NCT01500395||Stent Graft and open surgery|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.
62116565|NCT05675956|EXPERIMENTAL|High Intensity|The device will be set to 100% intensity for this group.
62116566|NCT05675956|ACTIVE_COMPARATOR|Low Intensity|The device will be set to 10% intensity in this group
62304760|NCT00142103|ACTIVE_COMPARATOR|Pegylated inteferon + ribavirin|
62473037|NCT04073394|EXPERIMENTAL|Modified Lifestyle Intervention|Participants in this group will have a tailored diet, exercise, and behavioral plan according to their obesity phenotype.
62473038|NCT01022463|ACTIVE_COMPARATOR|Ivabradine|Crossover study to compare ivabradine and atenolol
62116567|NCT03101436|EXPERIMENTAL|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
62116568|NCT03101436|EXPERIMENTAL|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
62116569|NCT01326130|ACTIVE_COMPARATOR|Chronic care management 1|Content of chronic care model implemented in territory 1 and level of implementation
62304761|NCT00142103|EXPERIMENTAL|CPG10101 + pegylated interferon + ribavirin (rollover)|
62304762|NCT06482879||High flow nasal canula|Patient undergoing upper GI endoscopic procedure under deep sedation will receive high flow nasal canula.
62304763|NCT06482879||Simple nasal canula|Patient undergoing upper GI endoscopic procedure under deep sedation will receive simple nasal canula.
62304764|NCT01836315||Obese|Defined by a BMI \>35 kg/M2
62304765|NCT01836315||Non-Obese|Defined by a BMI \<35 kg/M2
62304766|NCT04866472|OTHER|Video Laryngoscope and GlideRite Ridgid Stylet|
62304767|NCT04866472|EXPERIMENTAL|Video Laryngoscope and TCI Articulating Introducer|
62304768|NCT04889677|EXPERIMENTAL|Group 1: 200 mg|All participants (fasted) received either 200 mg of danicopan as a single oral dose or dose-matched placebo.
62304769|NCT04889677|EXPERIMENTAL|Group 2: 600 mg|All participants (fasted) received either 600 mg of danicopan as a single oral dose or dose-matched placebo.
62304770|NCT04889677|EXPERIMENTAL|Group 3: 1200 mg|All participants (fasted) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
62304771|NCT04889677|EXPERIMENTAL|Group 4: 2400 mg|All participants (fasted) received either 2400 mg of danicopan administered as 2 single doses of 1200 mg each, 12 hours apart, or dose-matched placebo.
62304772|NCT04889677|EXPERIMENTAL|Group 5: 1200 mg|All participants (fed) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
62473039|NCT01022463|PLACEBO_COMPARATOR|Atenolol|
62304773|NCT02981212|EXPERIMENTAL|Mycophenolate Mofetil|MYREPT® capsule(CKDpharm, KOREA) and corticosteroid
62304774|NCT02981212|ACTIVE_COMPARATOR|Conservative treatment|maintain conservative treatment (ACE inhibitor or ARB)
62676114|NCT04606966|EXPERIMENTAL|Hybrid|Participants completing the Wait list Arm and post assessments, will begin a Hybrid group between 1:00-5:00 PM. The group consists of a 5- week 1 -hour BA small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor or OT. Participants will have one assigned volunteer and have no physical contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse for hands-on learning weekly topics per BA study manual. Group. Then, participants will complete 5-weeks of Therapeutic Horseback Riding small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills followed by a 15-minute unmounted horse grooming and tacking activity per THR manual. Participants will have an assigned horse and volunteer(s).
62116570|NCT01326130|ACTIVE_COMPARATOR|Chronic care management 2|Content of chronic care model implemented in territory 2 and level of implementation
62676115|NCT05537857|EXPERIMENTAL|High dietary salt|High salt diet will be tested in random order by all participants.
62116571|NCT01326130|ACTIVE_COMPARATOR|Chronic care management 3|Content of chronic care model implemented in territory 3 and level of implementation
62116572|NCT01326130|ACTIVE_COMPARATOR|Chronic care management 4|Content of chronic care model implemented in territory 4 and level of implementation
62116573|NCT01326130|ACTIVE_COMPARATOR|Chronic care management 5|Content of chronic care model implemented in territory 5 and level of implementation
62304775|NCT02691273|EXPERIMENTAL|breathing technique|this arm includes learning breathing technique using the patient's smartphone.
62304776|NCT00658333|EXPERIMENTAL|Enteric-coated Mycophenolate Acid|Equimolar dose of enteric-coated mycophenolate acid with mycophenolate mofetil placebo. 1000 mg mycophenolate mofetil = 720 mg enteric-coated mycophenolate acid (MPA equivalent dose). The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
62116574|NCT01326130|ACTIVE_COMPARATOR|Chronic care management 6|Content of chronic care model implemented in territory 6 and level of implementation
62116575|NCT00842257|EXPERIMENTAL|Panitumumab|Panitumumab administered by a central line infusion on days 1 and 15 of each 4 week cycle.
62116576|NCT06251193|EXPERIMENTAL|E-CBSST|E-CBSST is the experimental arm in this study.
62304777|NCT00658333|ACTIVE_COMPARATOR|Mycophenolate Mofetil|Mycophenolate mofetil therapy with placebo enteric-coated mycophenolate acid. The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
62304778|NCT02058381|EXPERIMENTAL|Group 1 (alpelisib)|Alpelisib plus Tamoxifen and Goserelin (Group 1)
62304779|NCT02058381|EXPERIMENTAL|Group 2 (buparlisib)|Buparlisib plus Tamoxifen and Goserelin (Group 2)
62304780|NCT02299934|OTHER|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
62116577|NCT04382365|OTHER|Internet-Based Insomnia Intervention|"2 weeks of online sleep diaries. Participants will also wear an Actiwatch at night, which records measurements of movements of a limb, providing an estimation of sleep duration, sleep pattern and disturbed sleep.~9 week interveition period, subjects complete the internet based CBT-I program, consisting of six Cores (Getting Ready, Sleep Scheduling, Sleep Practices, Thinking Differently, Sleep Hygiene, and Moving On).Each Core takes approximately 45-60 minutes to review online, and most participants spend an additional 30-45 minutes per week on recommended exercises.~Participant will then be instructed to complete a post-Assessment, consisting of one online questionnaire and two weeks of Daily Sleep Diaries. The Actiwatch is worn as before during this two week period."
62116578|NCT02336776|EXPERIMENTAL|Functional electrical stimulation group|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20s time off, intensity as patient tolerance, total session time ranged from 20 to 34 minutes.
62304781|NCT04707872||Heart transplant protocol and for cause biopsies|The study population includes patients with a functioning heart transplant undergoing a biopsy for clinical indications as standard of care, or protocol biopsies of heart in high-risk patients, or follow-up after treatment.
62304782|NCT02189382|EXPERIMENTAL|Potassium Oxalate Gel|Self Applied
61918257|NCT02746003|OTHER|Managed Aquifer Recharge water|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control at different times.
61918258|NCT02746003|OTHER|Control|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control arms at different times.
62304783|NCT02189382|OTHER|Water|Self Applied
62304784|NCT00648310|ACTIVE_COMPARATOR|1|arm 1: Tolterodine 4 mg once daily for 12 weeks
61918259|NCT05111275|EXPERIMENTAL|Group MEMO|Patients will perform cognitive exercises on the MEMO site at least 4 times per week for a month. During this month, patients will be contacted by phone on a weekly basis in order to maintain their motivation and ensure their treatment compliance. The time spent on the site during the month of evaluation will be quantified by the study investigator, via the professional profile created on the MEMO site, allowing to see the patient's activity on this same site.
62676116|NCT05537857|EXPERIMENTAL|Low Dietary salt|Low salt diet will be tested in random order by all participants.
61918260|NCT05111275|NO_INTERVENTION|Control Group|Patients will not change their habits or perform cognitive exercises during the same assessment period.
62116579|NCT02336776|NO_INTERVENTION|Control group|The patients in this group were evaluated at baseline and reassessed after eight weeks of follow-up.
62304785|NCT00648310|EXPERIMENTAL|2|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
62304786|NCT01707875||fetal ventricle brain asymmetry|
62304787|NCT04411238||Patients|
62304788|NCT04411238||Caregivers|
62676117|NCT00944021|EXPERIMENTAL|PA-824 50 mg/qd|
62676118|NCT00944021|EXPERIMENTAL|PA-824 100mg/qd|
62676119|NCT00944021|EXPERIMENTAL|PA-824 150mg/qd|
62676120|NCT00944021|EXPERIMENTAL|PA-824 200mg/qd|
61918261|NCT02925793|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
61918262|NCT02925793|EXPERIMENTAL|1% DS107 Cream|1% DS107 cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
61918263|NCT02925793|EXPERIMENTAL|5% DS107 Cream|5% DS107 cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
62116580|NCT01257074|EXPERIMENTAL|Drug 1|Penciclovir 10mg/g
62116581|NCT01257074|ACTIVE_COMPARATOR|Drug 2|Acyclovir 50mg/g
62116582|NCT06368089|EXPERIMENTAL|IMT group|Inspiratory muscle training group
62116583|NCT06368089|ACTIVE_COMPARATOR|EM group|Early mobilization group
62304789|NCT04411238||Home help|
62304790|NCT03409302|EXPERIMENTAL|The ALGEapp (Brief i-ACT intervention)|The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla \& Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
62304791|NCT03409302|ACTIVE_COMPARATOR|Active Control group|The Active control group will have access only to limited component of the ALGEApp intervention, namely the Bonus section, which contains limited psycho-educational information regarding pain management.
62676121|NCT00944021|ACTIVE_COMPARATOR|Rifafour e-275mg|
62676122|NCT05697003|EXPERIMENTAL|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|Test
62676123|NCT05697003|ACTIVE_COMPARATOR|ADVAIR DISKUS® 100/50|Reference
62676124|NCT02802865|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7
62676125|NCT02802865|EXPERIMENTAL|Letrozole + Clomiphene|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7
62676126|NCT02080130|EXPERIMENTAL|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
62116584|NCT00612391|EXPERIMENTAL|Lateral, Minimally Invasive Approach|Lateral, Minimally Invasive Approach in GT fractures treated operatively (plates and screws)
62116585|NCT00612391|ACTIVE_COMPARATOR|Deltopectoral approach:|Deltopectoral approach for GT fracture treated operatively
62304792|NCT03008551|EXPERIMENTAL|Empagliflozin group|Each participant will receive empagliflozin 25mg daily for 3 months
62304793|NCT03008551|ACTIVE_COMPARATOR|Metformin group|Each participant will receive metformin 1500mg daily for 3 months
62304794|NCT04653662|EXPERIMENTAL|Treatment group|Treatment group arm. Open label. Only 1 arm study
62304795|NCT05952830|ACTIVE_COMPARATOR|ESWT Group|ESWT Group: external corporeal shockwave therapy subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii
62304796|NCT05952830|EXPERIMENTAL|DN Group|DN Group: dry needling Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
62304797|NCT04605627||Chronic coronary syndrome|50 patients with chronic coronary disease
62304798|NCT04605627||Non ST segment-elevation myocardial infarction|75 patients with non ST-elevation myocardial infarction
62304799|NCT04605627||ST-elevation myocardial infarction|75 patients with ST segment-elevation myocardial infarction
62304800|NCT06345040|EXPERIMENTAL|Virtual-reality assisted therapy + treatment as usual|Seven sessions
62304801|NCT06345040|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Seven sessions
62304802|NCT04913805|ACTIVE_COMPARATOR|Potassium Nitrate|Potassium Nitrate (KNO3) 6 mmol three times daily
62304803|NCT04913805|ACTIVE_COMPARATOR|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate (KNO3) 6 mmol three times daily + Propionyl-L-Carnitine (PLC) 1000 mg twice daily + Nicotinamide Riboside (NR) 300 mg three times daily
62304804|NCT04913805|PLACEBO_COMPARATOR|Potassium Chloride|Potassium Chloride (KCl) 6 mmol three times daily
62304805|NCT04745442|EXPERIMENTAL|Best available treatment + Antithrombin|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
62304806|NCT04745442|ACTIVE_COMPARATOR|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
62304807|NCT06069063|EXPERIMENTAL|Zafirlukast cross-over to Placebo|This group will receive the Zafirlukast pre-treatment nasally (400 mcg in 150 mcl in each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril) in the first study visit. In the second study visit, they will receive a placebo pre-treatment nasally (150 mcl each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril).
62304808|NCT06069063|EXPERIMENTAL|Placebo cross-over to Zafirlukast|This group will receive a placebo pre-treatment nasally (150 mcl each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril) in the first study visit. In the second study visit, they will receive the Zafirlukast pre-treatment nasally (400 mcg in 150 mcl in each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril).
62304809|NCT05762341|EXPERIMENTAL|EXPERIMENT GROUP|BOTH GROUPS WILL RECEIVE PRESSURE INJURY PREVENTION TRAINING. ONLY EXPERIMENTAL GROUP WILL USE THE MOBILE LEARNING TOOL
62304810|NCT05762341|EXPERIMENTAL|CONTROL GROUP|BOTH GROUPS WILL RECEIVE PRESSURE INJURY PREVENTION TRAINING. ONLY EXPERIMENTAL GROUP WILL USE THE MOBILE LEARNING TOOL
62473040|NCT02430272|EXPERIMENTAL|Anticholinergic premedication|Premedication with 0.005mg/Kg of glycopyrrolate
62676127|NCT02080130|EXPERIMENTAL|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
61918264|NCT04633408|EXPERIMENTAL|Intervention|The investigators will recruit 15 Latino caregivers for each study arm (total sample size of 30). The sample size was based on a rule of thumb of 12 to 15 participants per group for pilot studies. This group will have access to the app.
62116586|NCT00968448|ACTIVE_COMPARATOR|Training|respiratory muscle training (pressure threshold loading)
62116587|NCT00968448|SHAM_COMPARATOR|sham training|training with low resistance
62116588|NCT05452681|EXPERIMENTAL|Y-AMBIENT|"Y-AMBIENT is a four-month, telephone-based intervention that includes three themed education sessions with three follow-up sessions, written materials, and videos. All themed education and follow-up sessions are conducted according to the respective Y-AMBIENT session outlines and audio-recorded. Session 1, titled My Self, My Soul, covers topics related to spiritual growth and finding meaning in illness. Session 2, titled My Body, covers topics related to breast changes, aches/pains, fatigue, and weight changes. Session 3, titled My Mind and My Relationships, covers topics related to anxiety, fear, and relationships with others. The sessions will take approximately one hour, with follow-ups lasting about 20 minutes. Participants will receive both printed and electronic PDF versions of written materials, in addition to video links, to reinforce content delivered during Sessions."
62676128|NCT02080130|PLACEBO_COMPARATOR|Placebo|Placebo sachet. One sachet orally, BID, for 5 days.
61918265|NCT04633408|NO_INTERVENTION|Control|12 to 15 participants, will not have access to the app.
61918266|NCT01486810|EXPERIMENTAL|Lisdexamfetamine and medication management|Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
62304811|NCT05361096|EXPERIMENTAL|Educational approach (Flipped learning) group|The teaching of the patient safety subject was performed with the flipped learning to the intervention group (n=45).
62676129|NCT05295290|OTHER|myocarditis/pericarditis following COMIRNATY|myocarditis/pericarditis following COMIRNATY within 28 days of dose
62304812|NCT05361096|NO_INTERVENTION|Traditional education group|The teaching of the patient safety subject was performed with the traditional educational to the control group (n=44).
62304813|NCT00784407|ACTIVE_COMPARATOR|FOCUS (group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
62304814|NCT00784407|ACTIVE_COMPARATOR|HARMONIC ACE (group B)|Patients submitted to total thyroidectomy with the use of the HARMONIC ACE harmonic scalpel device
62473041|NCT02430272|NO_INTERVENTION|Control group|Same volume of normal saline
62473042|NCT04783051|ACTIVE_COMPARATOR|IPTp-SP|The IPTp-SP group will be pregnant women who will receive the standard regimen recommended by the Malaria National Control Program (MNCP) at week 16, 28, 32 and 36 of their pregnancy
62473043|NCT04783051|EXPERIMENTAL|ISTp-US-Py|The ISTp-US-Py group will comprise pregnant women who will be screened monthly from the beginning of the 2nd trimester with ultra-sensitive -RDT and who will be treated with Pyramax® if the test is positive
62676130|NCT05295290|OTHER|myocarditis/pericarditis following COVID-19 or MIS-C|myocarditis/pericarditis following COVID-19 or MIS-C without exposure to COMIRNATY
62676131|NCT03077308||Rett Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 60 individuals with Rett syndrome.
62676132|NCT03077308||MECP2 Duplication Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with MECP2 Duplication syndrome.
62676133|NCT03077308||Rett-related disorders|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with CDKL5 syndrome and 14 individuals with FOXG1 syndrome.
62676134|NCT03077308||Controls|Auditory and Visual event-related potentials (ERP) and EEG in 60 Control individuals (30 males and 30 females).
62676135|NCT05232305|EXPERIMENTAL|People with type 2 diabetes who eat bread with pomegranate crust - Experimental Group|"Individuals with type 2 diabetes who met the inclusion criteria and participated in the study will divided into two groups by Specialist Akkız Zuhal ÖZTAŞ and Specialist Doctor Emel ŞENOL, and they will be asked to consume the breads produced (in the preliminary study) produced as a standard (n=15) and with the addition of pomegranate peel (n=15) for eight weeks.~The individuals participating in the study will be asked not to change their eating habits, physical activity habits, and drug treatments during the study period. Each individual participating in the study will be provided with the required amount of bread during the study and will be contacted weekly by Zeynep ÇAMLIK, a specialist dietitian, to verify whether they consume bread regularly."
62116589|NCT05452681|ACTIVE_COMPARATOR|Attention Control|"The control condition will consist of receiving a culturally-targeted cookbook applied by an adapted Food for Thought cookbook, a guide to grocery shopping smart, and telephone socialization calls. We opted to use the cookbook and guide as conversation pieces given cultural practices associated with food and avert financial constraints with shopping tips. During three, one-hour socialization calls, we will use scripted questions to encourage discussion about the participant, cookbook and guide, and obtain information about survivorship concerns without providing coaching. The follow-up calls will last about 20 minutes."
62676136|NCT05232305|NO_INTERVENTION|No intervention - Control Group|Individuals with type 2 diabetes will not eat pomegranate crust bread
62116590|NCT04925492|EXPERIMENTAL|Finding Optimal Scan Timing|Group A will receive two PET scans after the radiotracer injection to learn the best timing of the scan for the rest of the people in the study during participant's baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
62116591|NCT04925492|EXPERIMENTAL|Scan at Determined Optimal Timepoint|Group B participants will receive an injection of the radiotracer and undergo only one PET scan during a baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
62304815|NCT05277012|EXPERIMENTAL|Treatment sequence ABC|Participants will be sequentially administered with Treatment A, B then C (Treatment A: etrumadenant capsule in fasted state; Treatment B: etrumadenant tablet in fasted state; Treatment C: etrumadenant tablet in fed state). Each treatment will be separated by a washout period of 7 days.
62304816|NCT05277012|EXPERIMENTAL|Treatment sequence BCA|Participants will be sequentially administered with Treatment B, C then A. Each treatment will be separated by a washout period of 7 days.
62473044|NCT05707676|EXPERIMENTAL|Dose Escalation|"Up to 9 dose cohorts will be sequentially enrolled in the dose escalation part using an accelerated titration combined with the standard BOIN dose escalation algorithm approach."
62116592|NCT04258358|EXPERIMENTAL|People living with dementia intervention group|"Long term care and support are provided in a dementia care friendly environment with emphasis on 'the person's home'. Each resident's home carries a registered address to symbolise the person's home. Based on needs and strengths, people living with dementia and their families are supported to choose the technology to enable the person's independence plus developing new and maintaining existing skills. Examples of supportive and assistive technology include mobile devices, memory clocks, gas and flood detectors, sensor mats and global positioning system trackers or safe return ornaments. Routine care follows a holistic integrated health and social care plan tailored to the needs of the person living with dementia.~Respite care provided in guesthouse facilities embody a similar approach only for a shorter period of time without assigning registered home addresses."
62473045|NCT05707676|EXPERIMENTAL|Single Drug Expansion|To further evaluate the safety, tolerance and preliminary clinical efficacy of LB4330 single drug in specific tumor species, the planned expanded cohort and number of subjects are as follows: Cohort A: LB4330 single drug therapy, 10 patients with advanced gastric and gastroesophageal junction adenocarcinoma with Claudin 18.2 expression;Cohort B: LB4330 single drug therapy, 5 patients with advanced pancreatic ductal adenocarcinoma with Claudin 18.2 expression; Cohort C: LB4330 single drug therapy, other advanced solid tumor patients with Claudin 18.2 expression, a total of 8-15 cases.
62473046|NCT01190865|OTHER|HP802-247|Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
62473047|NCT02259972|EXPERIMENTAL|BI 113823 solution|single rising doses, dose group 5 twice (fed and fasted)
62116593|NCT04258358|NO_INTERVENTION|People living with dementia control group|"People living with dementia in need of long-term rehabilitation or recovery for at least eight months; and people living with dementia in need of respite care for up to 14 days~People living with dementia will continue to use standard care. Standard care in this respect constitutes usual health and social care or any other nationally acceptable form of therapy that people living with dementia would seek to use."
62116594|NCT04519671|EXPERIMENTAL|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
62116595|NCT04519671|PLACEBO_COMPARATOR|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)
62116596|NCT04928053|EXPERIMENTAL|phenotypic data and a blood prelevment|
62116597|NCT01229358|EXPERIMENTAL|Silver Eluting Dressing|Acticoat Absorbant™ applied as post-operative dressing
62304817|NCT05277012|EXPERIMENTAL|Treatment sequence CAB|Participants will be sequentially administered with Treatment C, A then B. Each treatment will be separated by a washout period of 7 days.
62304818|NCT00501319||1|Patients with Non-Small Cell Lung Cancer.
62473048|NCT02259972|EXPERIMENTAL|BI 113823 tablet|dose group 5 only
62473049|NCT02259972|PLACEBO_COMPARATOR|Placebo|
62473050|NCT00979043|ACTIVE_COMPARATOR|Dietary weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
62304819|NCT04215094||infected group|Intracranial infection were diagnosed according to the Centers for Disease Control (CDC) definitions
62304820|NCT04215094||non-infected group|the postoperative recovery was uneventful with no infection
62304821|NCT06020469||Numeric Rating Scale (NRS) score after surgery <4|
62304822|NCT06020469||Numeric Rating Scale (NRS) score after surgery ≥ 4|
62304823|NCT05056714||patients with Nasosinus Polyposis|patients with Nasosinus Polyposis included in the study
62304824|NCT00474253|EXPERIMENTAL|Rocuronium + Sugammadex|Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
62304825|NCT00474253|ACTIVE_COMPARATOR|Succinylcholine|Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
62676137|NCT03508570|EXPERIMENTAL|Group I (nivolumab)|Patients receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62676138|NCT03508570|EXPERIMENTAL|Group II (nivolumab and ipilimumab)|Patients receive nivolumab as in group I and ipilimumab i.p. on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62676139|NCT05669066|NO_INTERVENTION|Control|This group will undergo a standardized conventional intra-operative and postoperative analgesia regimen. Anesthetic type and postoperative analgesia will be standardized.
62676140|NCT05669066|EXPERIMENTAL|Mindful meditation|Start the MM program 2 weeks preoperatively and continue for 30 days post operatively. Study subjects will meet with the meditation instructor for 30 minutes once, 2 weeks prior to surgery, and daily during hospital admission following total joint replacement (TJR). Throughout the intervention period, subjects will be asked to practice daily 15 minutes twice a day, and record their daily meditation experience. Upon discharge from hospital, subjects will receive telephone follow up sessions with the research assistant weekly until 30 days have elapsed. Subjects will be required to show compliance by recording their daily meditation experience in the Daily Meditation Diary (Post-op). At the end of the meditation intervention period, subjects will be asked to provide their feedback in the Patient Satisfaction Survey. Will undergo a standardized, conventional intra-operative postoperative analgesia regimen in addition to the meditation intervention. Anesthetic type will be standardized
62676141|NCT02827370|EXPERIMENTAL|Precision Nutrition (dietary intervention)|During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing. Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
62676142|NCT01141543||cohort 1|Patients in Cohort 1 will be followed with daily Flowcytometric studies to quantify CXCR4 positive cells.The samples will be obtained before the following doses of FLUDARABINE and BUSULFAN. Eighteen hrs (range 18 -20 hrs) after start of the last dose of FUDARABINE andBUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR
62676143|NCT01141543||Cohort 2|Patients in Cohort 2 will receive the second dose of PLERIXAFOR 24 hrs after the first dose. A PB sample for a CBS and Flowcytometry will be drawn prior to the dose. Nine hrs later a further study sample for Flowcytometry will be obtained prior to administration of the second dose of FLUARABINE and BUSULFAN. Flowcytometric studies will be repeated on day 3 and 4. Eighteen hrs (range 18 - 20 hrs) after start of the last dose of FLUDARABINE and BUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR.
62676144|NCT01141543||cohort 3|Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN
62676145|NCT01141543||Cohort 4|Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
62116598|NCT01229358|ACTIVE_COMPARATOR|Standard Guaze|Standard dry gauze applied as post-operative dressing
62116599|NCT03330418|EXPERIMENTAL|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
62116600|NCT03330418|EXPERIMENTAL|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
62116601|NCT01025843|EXPERIMENTAL|Pbo → 5 mg → Candesartan → 24 mg → 38 mg|Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
62116602|NCT01025843|EXPERIMENTAL|1 mg → 5 mg → 12 mg → Candesartan → Pbo|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
62676146|NCT05020119|EXPERIMENTAL|Low dose of neoantigen-based cell therapy (N=3+3)|(1±20%) × 109cells/200 mL every 14 days for 10 doses
62676147|NCT05020119|EXPERIMENTAL|Medium dose of neoantigen-based cell therapy (N=3+3)|(3±20%) × 109cells/200 mL every 14 days for 10 doses
61918267|NCT04016584|EXPERIMENTAL|Latino adults with type 2 diabetes|"Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -~1. hemoglobin A1c \> 8% at or prior to enrollment, or~2. hemoglobin A1c \< 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):~   * Fasting plasma glucose \> 130 mg/dL~  * 2-hour post-prandial or random blood glucose \> 180 mg/dL~  * \> 1 hypoglycemic event (blood glucose \< 70 mg/dL) , or~3. adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider."
61918268|NCT01724320|EXPERIMENTAL|OTX008|Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
61918269|NCT01251627|EXPERIMENTAL|Decitabine|Eligible patients will recieve Dacogen 20mg/m2 in 1 hour iv infusion for 5 days every 28 days (1 cycle)plus Best Supportive Care.A total of 6 courses is planned.
61918270|NCT01554631|EXPERIMENTAL|Arm 1|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken without water
62116603|NCT01025843|EXPERIMENTAL|1 mg → Candesartan → Pbo → 24 mg → 38 mg|1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
62116604|NCT01025843|EXPERIMENTAL|1 mg → 5 mg → 12 mg → Pbo → Candesartan|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
62116605|NCT01025843|EXPERIMENTAL|Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan|Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
62116606|NCT01025843|EXPERIMENTAL|2 mg→Pbo → Candesartan → Pbo fed→38 mg|2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
62304826|NCT02870673|ACTIVE_COMPARATOR|Injection of Shincort 0.5 ml and Xylocaine 0.5ml mixture|"In the first week of recruitment, this group will receive the local injection around the distal wrist crease with mixture of Shincort Inj(10mg/ml) 0.5 ml and xylocaine(20mg/ml) 0.5 ml only one time.~The ultrasound-guided procedure is performed by the orthopedic physician."
61918271|NCT01554631|EXPERIMENTAL|Arm 2|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken with water
61918272|NCT01554631|ACTIVE_COMPARATOR|Arm 3|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet 100 mg; Day 1: oral sucrose load plus Glucobay standard tablet 100 mg taken with water
61918273|NCT04033523|EXPERIMENTAL|High intensity-interval training (HIIT)|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
62116607|NCT01025843|EXPERIMENTAL|2 mg→Candesartan→Pbo→Candesartan fed→38 mg|2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
62116608|NCT01025843|EXPERIMENTAL|2 mg → 8 mg → 18 mg → 2 mg fed → Pbo|2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
62473051|NCT00979043|ACTIVE_COMPARATOR|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
61918274|NCT04033523|NO_INTERVENTION|normal counterparts|gender-matched normal counterparts (NC) did not receive any form of intervention
61918275|NCT03456609|EXPERIMENTAL|shenqifuzheng|
61918276|NCT03456609|PLACEBO_COMPARATOR|0.9%sodium chloride|
61918277|NCT00150644|EXPERIMENTAL|1|
62473052|NCT00979043|ACTIVE_COMPARATOR|Dietary weight-loss & exercise|Participants received both the dietary weight-loss and exercise interventions for 18-months
62473053|NCT00979043|NO_INTERVENTION|Health lifestyle control|The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
62116609|NCT01025843|EXPERIMENTAL|Candesartan→8 mg→ 18 mg →2 mg fed→38 mg|Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
62116610|NCT01025843|EXPERIMENTAL|Candesartan→Pbo → 12 mg → 24 mg→38 mg|Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
62116611|NCT02021799|NO_INTERVENTION|Undernourished Pregnant Women|Pregnant women who are classified as undernourished
62473054|NCT03406494|EXPERIMENTAL|intervention group|Early multicomponent physical therapy program plus sepsis standard therapy
62473055|NCT03406494|NO_INTERVENTION|control group|Sepsis standard therapy, including early initiation of intravenous antibiotics, infection source debriding, appropriate fluid therapy, minimum sedation, protocolized weaning procedure, blood glucose control and early enteral feeding, etc.
62473056|NCT00115960|EXPERIMENTAL|1|Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.
61918278|NCT00150644|EXPERIMENTAL|2|
62116612|NCT02021799|NO_INTERVENTION|Nourished Pregnant Women|Pregnant women who are classified as healthy
62116613|NCT02021799|NO_INTERVENTION|Overweight/obese Pregnant women|Pregnant women who are classified as obese or overweight
62116614|NCT02021799|EXPERIMENTAL|Undernourished + Yogurt Pregnant Women|Pregnant women who are undernourished and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10\^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
62116615|NCT02021799|EXPERIMENTAL|Nourished + Yogurt Pregnant Women|Pregnant women who are healthy and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10\^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
62116616|NCT01418391|EXPERIMENTAL|morphine consumption|
62116617|NCT00732381|EXPERIMENTAL|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
62116618|NCT00732381|PLACEBO_COMPARATOR|Arm 2|Matching placebo nasal spray
62676148|NCT05020119|EXPERIMENTAL|High dose of neoantigen-based cell therapy (N=3+3)|(9±20%) ×109cells/400 mL every 14 days for 10 doses
62676149|NCT01210911|EXPERIMENTAL|Gemcitabine, erlotinib and metformin|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
62676150|NCT01210911|PLACEBO_COMPARATOR|Gemcitabine, erlotinib and placebo|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. PLacebo will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
62676151|NCT01439295||Preterm less than 33 weeks|This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
62116619|NCT03353116|ACTIVE_COMPARATOR|maxilla first group|the maxillary osteotomy is going to be done and fixed first
62116620|NCT03353116|EXPERIMENTAL|mandible first group|the mandibular osteotomy is going to be done and fixed first
62116621|NCT02874430|EXPERIMENTAL|Treatment (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62676152|NCT06694103|EXPERIMENTAL|Reverse Kangaroo Care Position Group|The advantages of kangaroo care will be utilised in the ROP examination. By reversing the position of the baby's face to the mother's breast, a change in the traditional kangaroo care posture will be applied, called the reverse kangaroo care position. Premature infants will be placed on the examination table for ROP examination and the infants' clothes other than diapers will be removed. Mothers will lie on the examination table by removing their upper clothes and their infants will be positioned in the inverted kangaroo care position, with the infant's back resting between the mother's bare chest. The privacy of the mother and the infant will be ensured and the infant will be able to smell the mother's scent with a piece of clothing taken off by the mother.
62116622|NCT02639013|EXPERIMENTAL|ttransducer technique|the nurses will measure intraabdominal pressure at each shift during the day by using transducer technique
62116623|NCT06676644|EXPERIMENTAL|adjuvanted|adjuvanted (aIIV4) influenza vaccine
62116624|NCT06676644|ACTIVE_COMPARATOR|non-adjuvanted|non-adjuvanted (IIV4) influenza vaccine
62116625|NCT00929617|EXPERIMENTAL|1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
62116626|NCT00929617|OTHER|2. Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
62116627|NCT03747354|ACTIVE_COMPARATOR|complete blood count|blood samples will be taken from patient and complete blood count is done early morning
62116628|NCT03747354|ACTIVE_COMPARATOR|erythrocyte sedimentation rate|blood samples will be taken from patient and erythrocyte sedimentation rate is done
62116629|NCT00636064|PLACEBO_COMPARATOR|A|
62116630|NCT00636064|EXPERIMENTAL|B|
62116631|NCT00636064|EXPERIMENTAL|C|
62116632|NCT01521013|ACTIVE_COMPARATOR|Supported self-care|
62116633|NCT01521013|ACTIVE_COMPARATOR|Unsupported self-care|
61918279|NCT00150644|PLACEBO_COMPARATOR|3|
61918280|NCT06478628||Unicare Helsefort|Patients taking part in rehabilitation due to pain at Unicare Helsefort
62116634|NCT02813486|EXPERIMENTAL|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
62116635|NCT02813486|ACTIVE_COMPARATOR|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
62116636|NCT05245825|EXPERIMENTAL|Flaxseed and dietary plan|30 g of ground flaxseed daily and a dietary plan
62116637|NCT05245825|OTHER|Control|Dietary plan controlled in alpha-linolenic acid consumption
62116638|NCT03922412|ACTIVE_COMPARATOR|plantar block|Short lasting sciatic nerve block (mepivacaine 1% 200mg) and long lasting plantar block (ropivacaine 0,5% 25mg + 2mg dexamethasone) with distal deep peroneal block (ropivacaine 0,5% 2ml).
62116639|NCT03922412|ACTIVE_COMPARATOR|Sciatic popliteal block|Long lasting sciatic nerve block (ropivacaine 0,5% 100mg + 2mg dexamethasone)
62116640|NCT02572219|ACTIVE_COMPARATOR|Nutraceutical|Treated with nutraceutical compound
62116641|NCT02572219|PLACEBO_COMPARATOR|Placebo|Treated with placebo
62116642|NCT02734056|EXPERIMENTAL|Music|The intervention to be administered is music
62116643|NCT02734056|EXPERIMENTAL|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
62116644|NCT06289348||groupe 1|60 parents of children screened for PKU. Each of them will be assessed using a socio-psychological questionnaire (7 days after the announcement) and the revised event impact scale (7 days, 4 and a half months).
62116645|NCT06289348||groupe 2|25 parents from group 1. This smaller sample of 25 parents will be subjected to non-directive interviews (1 month after the announcement) and to the Stern interview (4 and a half months after the announcement).
62116646|NCT06289348||groupe 3|15 doctors : interview
62116647|NCT06289348||groupe 4|5 midwifes : short interview
62116648|NCT00842049|EXPERIMENTAL|Study|Insertion of lumbar drain
62116649|NCT00842049|OTHER|Control|Normal clinical management without lumbar drain
62116650|NCT03091010|EXPERIMENTAL|Fecal Microbiota Transplantation|
62116651|NCT03091010|ACTIVE_COMPARATOR|Steroid|
62116652|NCT05502458|ACTIVE_COMPARATOR|propofol|propofol（50ml,1g）,Intravenous propofol infusion was slowly pushed until loss of consciousness, and anesthesia was maintained at 4-8 mg/kg/h
62116653|NCT05502458|ACTIVE_COMPARATOR|desflurane|In the general anesthesia group with desflurane( 240ml), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane
62116654|NCT05936671|EXPERIMENTAL|EEG-and-ANI-guided group|During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
62116655|NCT05936671|ACTIVE_COMPARATOR|Usual care group|During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
62116656|NCT05250141|EXPERIMENTAL|Levodopa and Carbidopa Test Product|Participants will receive one tablet of the test formulation containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
62116657|NCT05250141|EXPERIMENTAL|Levodopa and Carbidopa Referent Product|Participants will receive one tablet of the marketed reference containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
62116658|NCT01872403|EXPERIMENTAL|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung
62116659|NCT00920257|EXPERIMENTAL|GSK2141795|Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified.
62116660|NCT02997280|EXPERIMENTAL|Ruxolitinib treatment|Ruxolitinib 10 mg bid for adults and children with body weight \> 40 kg, 0.15 mg/kg bid for children with body weight \< 40 kg.
62116661|NCT01918644|EXPERIMENTAL|Treatment (SBRT, capecitabine, and surgery)|Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
62116662|NCT00535977|EXPERIMENTAL|1|Dietary intervention of ITC-enriched broccoli
62116663|NCT00535977|EXPERIMENTAL|2|Dietary intervention of frozen peas
62116664|NCT02110056|EXPERIMENTAL|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
62116665|NCT02110056|SHAM_COMPARATOR|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
62116666|NCT05657041|EXPERIMENTAL|Group 1: body weight <60kg|Treatment with clopidogrel 50mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with clopidogrel 25mg once daily (max 14 days).
62116667|NCT05657041|NO_INTERVENTION|Group 2: body weight 60-100kg|Treatment with clopidogrel 75mg once daily
62116668|NCT05657041|EXPERIMENTAL|Group 3: body weight >100kg|Treatment with clopidogrel 150mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with prasugrel 10mg once daily (max 14 days).
62116669|NCT06431516||Patients with significant LMCA disease|
62116670|NCT06431516||normal patient|
62116671|NCT06325761|EXPERIMENTAL|Fasted dosing followed by fed dosing|A single oral dose in the fasted state at Period 1 followed by fed dosing at Period 2
62116672|NCT06325761|EXPERIMENTAL|Fed dosing followed by fasted dosing|A single oral dose in the fed state at Period 1 followed by fasted dosing at Period 2
62116673|NCT04091152||old patients|"Patient will freely use Ardoiz during their hospitalisation for a maximum of 9 days.~After this use, a survey concerning the usability of Ardoiz will be administered to the patient, before their discharge from hospital."
62116674|NCT04091152||relatives / unformal caregivers|"Unformal caregivers will freely use Ardoiz during the hospitalization of their relatives and a maximum of 9 days.~After this use, a survey concerning the usability of Ardoiz will be administered to the unformal caregivers, before the discharge of their hospitalized relatives from hospital."
62116675|NCT04091152||profesionnal caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Ardoiz will be administered to professional caregivers."
62304827|NCT02870673|EXPERIMENTAL|sham electroacupuncture|"In this group, the participants receive acupuncture treatment and only 2 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant. After 2 minutes, the stimulator will turn off spontaneously and the participant will not be informed.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
62304828|NCT02870673|EXPERIMENTAL|electroacupuncture|"In this group, the participants receive acupuncture treatment and 20 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
62304829|NCT02655861||Ichthyosis|
62304830|NCT02928419|EXPERIMENTAL|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
62304831|NCT02928419|PLACEBO_COMPARATOR|Arm 2 (Placebo)|Arm 2 is the control arm
62473057|NCT00115960|EXPERIMENTAL|2|Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
62473058|NCT00115960|EXPERIMENTAL|3|Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
62676153|NCT06694103|EXPERIMENTAL|ROP Position Group|The position is given while the premature infant is in the supine position with the presence of two people (mother and nurse). It is performed in two stages by positioning the lower and upper extremities of the premature infant. The feet and legs are in the lower extremities, and the arms and head are in the upper extremities. During the examination, the premature infant's head is in slight hyperextension so that the retinal maneuvers applied by the ophthalmologist can be easily performed. The nurse places the infant's own palms on the temporal region and supports the head by holding it with her hands, while the mother supports the infant by bringing the infant's legs together and pushing it towards her abdomen.
62676154|NCT05047887|EXPERIMENTAL|Study group (in one side)|Modified socket shield technique with autogenous dentin graft
62676155|NCT05047887|ACTIVE_COMPARATOR|Control group (in contrlateral side)|Modified socket shield technique with alloplast
62676156|NCT05811637|ACTIVE_COMPARATOR|Supervised Rehabilitation|The supervised rehabilitation focused mainly on strengthening the hip-knee muscles and flexibility exercises for the gastrocnemius and hamstring muscles. Hip and knee targeted strengthening and stretching exercises will be applied for 6 weeks, two sessions a week 12 sessions of all exercises, 3 sets, and 10-15 repetitions of each set.
61918281|NCT06478628||Unicare Hokksund|Patients taking part in rehabilitation due to pain at Unicare Hokksund
61918282|NCT06478628||Unicare Coperio|Patients taking part in rehabilitation due to pain at Unicare Coperio
62116676|NCT01392313|EXPERIMENTAL|Carnitine|Participants will be given Creatinine supplements
62116677|NCT01392313|PLACEBO_COMPARATOR|Placebo|participants will be given creatinine placebo
62116678|NCT04577014|EXPERIMENTAL|Phase I: Safety Run-In / Dose Level 0|A safety run-in (dose level 0 in Table 1, below) will be performed and enroll 6 patients with advanced high-grade sarcoma who are treatment naïve. Cycle one will consist of gemcitabine plus docetaxel at the institution's standard dose and schedule: 900 mg/m2 of gemcitabine on days 1 and 8, and 75 mg/m2 of docetaxel on day 8. Intravenous Retifanlimab at a flat dose of 210 mg will be administered every 3 weeks starting on C2D1 for a total of two cycles (cycles 2 and 3). All visits are to be done +/-3 days of the scheduled timepoints.
62116679|NCT04577014|EXPERIMENTAL|Phase I: Dose De-escalation Level 1|"If ≤ 1 patient out of 6 at dose level 0 has a dose-limiting toxicity during this safety run-in, then the dose de-escalation portion of the protocol will commence.~Dose Level 1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 900 mg/m2 Docetaxel (Day 8) - 75 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
62116680|NCT04577014|EXPERIMENTAL|Phase I: Dose De-escalation Level -1|"Dose Level -1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 750 mg/m2 Docetaxel (Day 8) - 60 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
62304832|NCT00630032|ACTIVE_COMPARATOR|Docetaxel|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
62304833|NCT00630032|EXPERIMENTAL|Ixabepilone|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
62473059|NCT00115960|EXPERIMENTAL|4|Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
62473060|NCT00115960|EXPERIMENTAL|5|In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
62473061|NCT00115960|EXPERIMENTAL|7|In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.
62473062|NCT04481919|ACTIVE_COMPARATOR|Protocolized spot urine sodium guided diuretic therapy|Patients will have a spot urine sodium and urine creatinine obtained. The urine and creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance. Performed 3 times per day, diuretic dosing will be individualized based on the proportion of 24-hour diuresis achieved since the prior IV diuretic dose. Every 24 hours new goals for urine output and net negative fluid balance are established based on the study and treatment team's assessment of residual congestion until protocol completion.
61918283|NCT06478628||Unicare Jeløy|Patients taking part in rehabilitation due to pain at Unicare Jeløy
62676157|NCT05811637|ACTIVE_COMPARATOR|Pilates Exercise|The principles of Pilates exercises will be taught to the patients in the first session, and the evaluation will be made. The exercises, including basic training exercises in the first week, will be performed for 6 weeks, each session lasting 45 minutes, two days a week, each exercise for 8-12 repetitions. The Pilates exercises, consisting of gradually increasing strengthening will be applied under the supervision of a physiotherapist.
62676158|NCT01310114|EXPERIMENTAL|Cohort 1|1 unit PDA001 \[approximately 2 x 108 cells\] in 240 mL per infusion on Day 1.
61918284|NCT06478628||Unicare Friskvern|Patients taking part in rehabilitation due to pain at Unicare Friskvern
61918285|NCT01799382|EXPERIMENTAL|EBUS-TBNA + Rapid on-site evaluation|Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA
61918286|NCT01799382|ACTIVE_COMPARATOR|EBUS-TBNA|Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation
62676159|NCT01310114|EXPERIMENTAL|Cohort 2A - Experimental|1 unit PDA001 \[approximately 2 x 108 cells\] or placebo in 240 mL per infusion on Day 1
62676160|NCT01310114|EXPERIMENTAL|Cohort 2B - Experimental|4 units PDA001 \[approximately 8 x 108 cells\] or placebo in 240 mL per infusion on Day 1
61918287|NCT03355443|ACTIVE_COMPARATOR|Re-examination Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined in the same fashion. After that, the rest of the colon is examined in routine method.
62116681|NCT04577014|EXPERIMENTAL|Phase I: Dose De-escalation Level -2|"Dose Level -2:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 675 mg/m2 Docetaxel (Day 8) - 50 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
62676161|NCT00414609|EXPERIMENTAL|Aliskiren|"Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.~Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.~Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study."
62676162|NCT00414609|PLACEBO_COMPARATOR|placebo|Core study: placebo for 36 weeks once daily in the morning
62676163|NCT00276380|EXPERIMENTAL|EGb761®|"EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).~The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
62676164|NCT00276380|PLACEBO_COMPARATOR|Placebo|"6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).~The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
62676165|NCT01506336|EXPERIMENTAL|masitinib|masitinib 12 mg/kg/day
62676166|NCT01506336|ACTIVE_COMPARATOR|sunitinib|sunitinib 50 mg/day
62676167|NCT03656575|ACTIVE_COMPARATOR|intra-articular alpha-2-macroglobulin|intra-articular injection of 1 mL of the 40 mg/ml strength (1 vial)
61918288|NCT03355443|EXPERIMENTAL|Retroflexion Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined with the colonoscope tip in reverse direction (retroflexion fashion). After that, the rest of the colon is examined in routine method.
61918289|NCT04079673|ACTIVE_COMPARATOR|Patient controlled epidural analgesia|Use of patient controlled epidural analgesia (PCEA) for postoperative pain control
62116682|NCT04577014|EXPERIMENTAL|Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma|"(UPS/MFS)~After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints."
62116683|NCT04577014|EXPERIMENTAL|Liposarcoma/LPS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
62116684|NCT04577014|EXPERIMENTAL|Leiomyosarcoma/LMS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
62116685|NCT04577014|EXPERIMENTAL|Vascular Sarcoma|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
62116686|NCT04577014|EXPERIMENTAL|Other Soft tissue sarcoma/STS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
62116687|NCT00662480|EXPERIMENTAL|1|Invited to screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
62116688|NCT00662480|NO_INTERVENTION|2|Participants which are not offered vascular screening
62116689|NCT01325142||ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
62116690|NCT01325142||No ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
62116691|NCT03417492|EXPERIMENTAL|Sildenafil Citrate|Open label treatment with forced titration of sildenafil citrate.
62116692|NCT01288326||A|
62116693|NCT03047083||IC eligible AML patients with FLT3 mutation|Newly diagnosed AML patients
62116694|NCT03047083||IC ineligible patients with FLT3 mutation|Newly diagnosed AML patients
62676168|NCT03656575|ACTIVE_COMPARATOR|intra-articular Platelet-rich Plasma (PRP) injection|Standard of care PRP treatment
62676169|NCT03656575|ACTIVE_COMPARATOR|Intra-articular corticosteroid|Standard of Care steroid treatment
62676170|NCT02080728|EXPERIMENTAL|TAP-Bloc|
62676171|NCT02080728|PLACEBO_COMPARATOR|Control|
61918290|NCT04079673|SHAM_COMPARATOR|Intravenous patient controlled analgesia|Use of intravenous patient controlled analgesia(IVPCA) for postoperative pain control
62676172|NCT01716559||Cohort|
62676173|NCT00664677|EXPERIMENTAL|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off).
62676174|NCT05422222|EXPERIMENTAL|Part A: VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
62676175|NCT05422222|EXPERIMENTAL|Part B: VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning with the dose(s) to be based on the outcome of Part A.
62676176|NCT03931512|EXPERIMENTAL|transcranial direct current stimulation|"20 minutes of transcranial direct current stimulation~1 mA on bi-hemispheric colocation with cathode on the left M1 and anode on the right M1"
62676177|NCT03931512|SHAM_COMPARATOR|sham transcrial direct current stimulation|20 minutes positioning the electrodes on the scalp. Whith an initial increasing of the current intensity by 10 seconds, until 1mA and a ramp down from 20 seconds to reach zero.
62116695|NCT03047083||AML patients after R/R with FLT3 mutation|R/R are relapse/refractory patients
62116696|NCT03047083||IC eligible patients without FLT3 mutation|Newly diagnosed AML patients
62116697|NCT03047083||IC ineligible patients without FLT3 mutation|Newly diagnosed AML patients
62676178|NCT01146444|EXPERIMENTAL|sunscreens with a low, medium, high SPF|sunscreens with a low, medium, and high SPF. UVA and UVB irradiation
62116698|NCT03047083||AML patients after R/R without FLT3 mutation|R/R are relapse/refractory patients
62676179|NCT01146444|EXPERIMENTAL|vehicle|Intra-individual application of vehicle in random order; UVA and UVB irradiation
62676180|NCT05539911|ACTIVE_COMPARATOR|group f|patient received 50 mic fentanyl as an adjuvant to the local anesthetic mixture applied during peribulbar block in the operative eye
62676181|NCT05539911|PLACEBO_COMPARATOR|group C|received the traditional mixture used
62116699|NCT06636929||Study group|Participants with problematic smartphone use were identified with the Smartphone Addiction Scale Short Form. Participants with a score above 31 for women and 33 for men were defined as individuals with problematic smartphone use.
62116700|NCT06636929||Control group|Participants with problematic smartphone use were identified with the Smartphone Addiction Scale Short Form. Participants with a score below 31 for women and 33 for men were defined as the control group.
62116701|NCT06469684|EXPERIMENTAL|Intervention|This arm receive health promotion intervention on breast cancer and mammogram including Mammobus deployment.
62116702|NCT06469684|PLACEBO_COMPARATOR|Control|This arm receive health promotion intervention on healthy lifestyle.
62304834|NCT04295902|EXPERIMENTAL|VL-group|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Germany) with blades Miller nr 0 and Miller nr 1.
62676182|NCT05121922|EXPERIMENTAL|Intervention|All patients recieve active treatment
62676183|NCT05791149|EXPERIMENTAL|OSCC patients|
62676184|NCT05791149|ACTIVE_COMPARATOR|controls|
62676185|NCT03118271|ACTIVE_COMPARATOR|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
62116703|NCT02307565|EXPERIMENTAL|Midodrine|Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
62116704|NCT02307565|PLACEBO_COMPARATOR|Placebo|Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.
62116705|NCT03083119|EXPERIMENTAL|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
62116706|NCT03083119|PLACEBO_COMPARATOR|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
62116707|NCT06175572||NCF cohort|Normanl coronary-flow patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
62116708|NCT06175572||CSF cohort|Coronary slow-flow patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
62116709|NCT06175572||ANOCA cohort|Angina with nonobstructive coronary artery patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
62116710|NCT06175572||INOCA cohort|Ischemia with nonobstructive coronary artery patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
62116711|NCT04153435|EXPERIMENTAL|Calcium|The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
62116712|NCT04153435|PLACEBO_COMPARATOR|Placebo|"The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, normal saline) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline."
62116713|NCT03420209|EXPERIMENTAL|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
62116714|NCT03420209|NO_INTERVENTION|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
62116715|NCT04415086|SHAM_COMPARATOR|Group A|Participants will receive the standard of care treatment
62116716|NCT04415086|ACTIVE_COMPARATOR|Group B|Participants will receive the standard treatment and convalescent plasma in a volume of 200ml (150-300ml)
62116717|NCT04415086|ACTIVE_COMPARATOR|Group C|Participants will receive the standard treatment and convalescent plasma in a volume of 400ml (300-600ml)
62116718|NCT01353963||1|
62116719|NCT00910754|EXPERIMENTAL|Abiraterone acetate|Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.
62116720|NCT02000817|EXPERIMENTAL|Otelixizumab 9 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
62116721|NCT02000817|EXPERIMENTAL|Otelixizumab 18 mg|Each subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
62116722|NCT02000817|EXPERIMENTAL|Otelixizumab 27 mg|Each subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
62116723|NCT02000817|EXPERIMENTAL|Otelixizumab 36 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
62116724|NCT02000817|PLACEBO_COMPARATOR|Placebo|Each subject will receive otelixizumab matching placebo diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days
62116725|NCT02331004|ACTIVE_COMPARATOR|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
62116726|NCT02331004|PLACEBO_COMPARATOR|Support to activities of daily living|Performing of general activities planned in the centres where the participants are included
62116727|NCT04014933||open-angle glaucoma|patients with a diagnosis of open-angle glaucoma, i.e. untreated IOP \>21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
62116728|NCT04014933||normal tension glaucoma|patients with a diagnosis of normal tension glaucoma, i.e. untreated IOP \</=21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
62116729|NCT04014933||healthy controls|individuals with normal optic disc and IOP \</21mmHg and normal visual fields
62116730|NCT01750307|EXPERIMENTAL|Fatty acid supplementation|4 capsules to be taken daily
62116731|NCT01750307|PLACEBO_COMPARATOR|Medium Chain Triglyceride (MCT) oil softgel|4 capsules to be taken daily
62116732|NCT03087084|EXPERIMENTAL|Cardiac Pacing and Impedance Measurement system|
62116733|NCT06454721|EXPERIMENTAL|[89Zr]Zr-DFO-BIIB080 + BIIB080|Participants will receive a single injection of a small dose of radiolabeled BIIB080 (\[89Zr\]Zr-DFO-BIIB080) along with a dose of BIIB080 together via an intrathecal (IT) injection.
62116734|NCT05671263||cases women LSc|women with LSc- vulvar lesional skin (including mons pubis, labia minora and labia majora) in women with genital LSc
62116735|NCT05671263||cases men LSc|men with LSc -penile lesional skin (including glans penis and coronal sulcus) in men with genital LSc
62116736|NCT05671263||control women|women without genital disease
62473063|NCT04481919|NO_INTERVENTION|Guideline-based care|Patients will be placed on guideline-based diuretic dosing consistent with usual practice. The initial dose will be two times their home dose and will be subsequently adjusted by the treating team based on renal function and symptom severity. The treating team can increase or decrease the frequency and dose of diuretic based on urine output and clinical assessment. Patients in this arm also have urine collected 3 times per day by the bedside nurse to mirror the intervention arm.
62473064|NCT03863002|NO_INTERVENTION|Standard Medical Treatment|Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin \<30 g/L), fresh frozen plasma (200-400 mL/day until the INR was \<1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome \[HRS\]).
62473065|NCT03863002|EXPERIMENTAL|Mesenchymal Stem Cell|Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10\^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.
62473066|NCT01583127|EXPERIMENTAL|School-Wide (SW)-PBIS intervention|SW-PBIS intervention
62473067|NCT01583127|NO_INTERVENTION|Control|Practice as usual
62676186|NCT03118271|ACTIVE_COMPARATOR|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
62304835|NCT04295902|ACTIVE_COMPARATOR|DL-group|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
62304836|NCT02857712|EXPERIMENTAL|Axitinib|Axitinib will be administered at 5 mg BID (starting dose); in case of no adverse events above CTCAE version 4.0 Grade 2 for a consecutive 2-week periods, the dose may be increased to 7 mg BID and further to 10 mg BID using the same criteria until tumor progression, unacceptable toxicity or other criteria for discontinuation is met.
62304837|NCT03381040|ACTIVE_COMPARATOR|Group A|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with adequate skin envelope (normal or thick skin). Treated with Restylane Lyft.
62304838|NCT03381040|ACTIVE_COMPARATOR|Group B|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with poor skin envelope (thin skin). Treated with Restylane Volyme.
62304839|NCT05337124||Lupkynis Treatment Group|
62304840|NCT03322137|ACTIVE_COMPARATOR|SNA-120 (0.05% )|Pegcantratinib Ointment
62116737|NCT05671263||control men|men without genital disease
62116738|NCT01801449|EXPERIMENTAL|Rilonacept Treatment|Rilonacept loading dose of 4.4 mg/kg/week followed by maintenance dose of 2.2 mg/kg/week. Total duration of the study 24 months. Maintenance dose could be escalated to 4.4 mg/kg/week or further to 6.6 mg/kg/week for 3 months only.
62473068|NCT03065062|EXPERIMENTAL|Combination Of Palbociclib and Gedatolisib|"* Palbociclib will be administered orally once daily on Days 1-21 for each of the 4-week cycles at a pre-determined dose.~* Gedatolisib will be administered intravenously once weekly on the first day for each of the four weeks during the 4-week cycles at a pre-determined dose."
62473069|NCT03023150|EXPERIMENTAL|Ischemic Preconditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
62473070|NCT03023150|SHAM_COMPARATOR|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
62473071|NCT04032977|EXPERIMENTAL|PN40082|Test device: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w
62116739|NCT03257813|OTHER|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
62116740|NCT03257813|OTHER|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
62304841|NCT03322137|ACTIVE_COMPARATOR|SNA-120 (0.5%)|Pegcantratinib Ointment
62304842|NCT03322137|PLACEBO_COMPARATOR|Vehicle|
62304843|NCT03378687||status epileptius|Cases were patients 29 days to 18 years who were diagnosed with status epileptius in 35 hospitals in China between January 1， 2013 and December 31，2015.
62304844|NCT01802944|EXPERIMENTAL|10 IU BID|10 IU BID Intranasal Insulin
62304845|NCT01802944|EXPERIMENTAL|20 IU BID|20 IU BID Intranasal Insulin
62304846|NCT01802944|EXPERIMENTAL|PLACEBOS|Saline nasal solution used as placebo
62304847|NCT04371510|OTHER|Covid-19 patients with moderate symptoms|Whole blood, culture supernatant, serum
62304848|NCT01598181|EXPERIMENTAL|active tDCS|
62304849|NCT01598181|SHAM_COMPARATOR|sham tDCS|tDCS fades out after 20 sec. administered double blind by coded program.
62304850|NCT06221111|EXPERIMENTAL|rimegepant|"* Rimegepant 75mg oral dissolving tablet (ODT)~* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days"
62304851|NCT06221111|PLACEBO_COMPARATOR|placebo|Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
62473072|NCT04032977|ACTIVE_COMPARATOR|Restylane Silk|Restylane Silk (manufactured by Q-Med AB for Medicis - A Division of Valeant Pharmaceuticals Corporation North America, LLC ) is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
62473073|NCT06118047|EXPERIMENTAL|Intervention group|crisaborole ointment
62473074|NCT02887339|EXPERIMENTAL|Intervention Group|Tissue requesters from participating OPOs are randomly assigned to complete additional informed consent training through an interactive online training website.
62473075|NCT02887339|EXPERIMENTAL|Control Group|The control group of tissue requesters receive the standard training offered by their OPO and GTEx partners.
62473076|NCT03848286|EXPERIMENTAL|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
62473077|NCT03199547|EXPERIMENTAL|AZITHROMYCIN|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
62473078|NCT03199547|PLACEBO_COMPARATOR|Placebo oral tablet|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
62473079|NCT05703932|NO_INTERVENTION|Group One|AS patients diagnosed according to ASAS criteria under pharmacological treatment using NSAID ,anti-tnf and DMARD
62473080|NCT05703932|ACTIVE_COMPARATOR|Group Two|AS patients diagnosed according to ASAS criteria under pharmacological treatment using NSAID ,anti-tnf and DMARD ;and will take exercise program including; joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises . Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
62473081|NCT03238781|PLACEBO_COMPARATOR|Placebo|Participants randomized to Placebo were administered 6 subcutaneous (SC) injections on day 1 and weeks 2, 4, 6, 8 and 10 during the 12 week double-blind treatment period.
62473082|NCT03238781|EXPERIMENTAL|AMG 301 210 mg Q4W|Participants randomized to AMG 301 210 mg every fourth week (Q4W) received a total of 3 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) plus 3 matching placebo injections on day 1 and weeks 4 and 8. Participants also received 6 SC placebo injections on weeks 2, 6, and 10 during the 12 week double-blind treatment period.
62473083|NCT03238781|EXPERIMENTAL|AMG 301 420 mg Q2W|Participants randomized to AMG 301 420 mg every second week (Q2W) received a total of 6 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) on day 1 and weeks 2, 4, 6, 8, and 10 during the 12 week double-blind treatment period.
62473084|NCT00766168|ACTIVE_COMPARATOR|Control|FluoroPerm 30 RGP lens daily wear
62473085|NCT00766168|EXPERIMENTAL|HDS HI 1.54|New rigid gas permeable contact lens material material
62473086|NCT05508659|EXPERIMENTAL|Combined therapy (cohort A)|Duvelisib combine with SG001 injection regimen in patients who had failed with prior PD-1/PD-L1 therapy
62473087|NCT05508659|EXPERIMENTAL|Combined therapy (cohort C)|Duvelisib combine with SG001 injection regimen in patients who had failed with prior systemic therapy but naïve with prior PD-1/PD-L1.
62116741|NCT06491888|EXPERIMENTAL|Group Accepting Photoelectric Detection|The subjects in this group need to undergo the detection of fluorescence photoelectric cervical lesion image detector before colposcopy, and then undergo routine colposcopy and biopsy after the detection.
62116742|NCT06491888|NO_INTERVENTION|Routine colposcopy group|Subjects who entered this group underwent colposcopy and biopsy according to the routine gynecological examination procedure.
62116743|NCT04835870|EXPERIMENTAL|R-CHOP + Zanubrutinib|Zanubrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
62116744|NCT02510534|ACTIVE_COMPARATOR|Control|This arm receives Menopur 150 international units x 1 dose
62116745|NCT02510534|ACTIVE_COMPARATOR|Treatment|This arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
62116746|NCT03698396|EXPERIMENTAL|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cell will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
62116747|NCT02529696||Medical device, accelerometer|A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.
62473088|NCT05508659|ACTIVE_COMPARATOR|SG001 injection monotherapy (cohort B)|SG001 monotherapy in patients who had failed with prior systemic therapy but naïve with prior PD-1/PD-L1
62473089|NCT00000261|EXPERIMENTAL|Moderate drinking adults|
62473090|NCT05217524||Pennington and Univ. of Hawaii cohorts|Same protocol but two different sites.
62473091|NCT05217524||Pennington|Primarily non-Hispanic (NH) White and NH Black at PBRC and more Asian and Native Hawaii or Pacific Islander (NHOPI) at Hawaii.
62473092|NCT01173263|ACTIVE_COMPARATOR|BIS 70|BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
62473093|NCT01173263|ACTIVE_COMPARATOR|BIS 50|BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)
62473094|NCT01173263|ACTIVE_COMPARATOR|BIS 35|BIS levels of 35 will be targeted (low frequency EEG activity)
62473095|NCT05945030||With Xanthelasma|T2DM with Xanthelasma
62473096|NCT05945030||Without Xanthelasma|T2DM without Xanthelasma
61918291|NCT02628769|EXPERIMENTAL|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
62116748|NCT02095899|EXPERIMENTAL|Rufinamide|- oral Rufinamide administration as ad-on to Oxycodone
62116749|NCT02095899|PLACEBO_COMPARATOR|Manitol|- oral Placebo administration - as ad-on to Oxycodone
62116750|NCT05862363|ACTIVE_COMPARATOR|Normal BMI women|A total of 30 women with functional dyspepsia will be recruited as a control arm of AIM 1A. The women will be recruited who will present with GI symptoms. A total of 100 women will undergo EGD, out of which 30 women will be enrolled based on their diagnosis of functional dyspepsia and willingness to participate in the study.
62304852|NCT03666767||Oesophageal atresia (OA) +/- tracheo-oesophageal fistula (TOF)|
62304853|NCT03666767||Congenital diaphragmatic hernia (CDH)|
62304854|NCT03666767||Intestinal atresia (IA)|
62473097|NCT00574327||A- Barrett's Esophagus subjects|Patients with documented Barrett's Esophagus with or without dysplasia (LGD or HGD) that will undergo surveillance endoscopies dictated by the grade of dysplasia.
62676187|NCT03118271|ACTIVE_COMPARATOR|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
62676188|NCT04776252|EXPERIMENTAL|MK-8591A|Fixed dose combination (FDC) tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks.
62116751|NCT05862363|ACTIVE_COMPARATOR|Low- BMI women|A total of 60 women from low-socioeconomic status (SES) and with low BMI will be included in the intervention arm of aim A1. They will be recruited based on their willingness to participate and through meeting the inclusion criteria. They will under EGD, including collection of duodenal aspirates and 6-8 biopsy samples. After EGD, 30 participants will receive MD-BEP and 30 will receive RUSF-BEP upon randomization.
62473098|NCT00574327||B- gastroesophageal reflux subjects|Patients undergoing endoscopy for evaluation of GERD symptoms.
62676189|NCT06278298|EXPERIMENTAL|Group A|Shockwave
62676190|NCT06278298|EXPERIMENTAL|Group B|Shockwave
62676191|NCT06278298|PLACEBO_COMPARATOR|Group C|CDT
62676192|NCT06548347|EXPERIMENTAL|Linperlisib80mg+CHOP|
62676193|NCT06548347|EXPERIMENTAL|Linperlisib60mg+CHOP|
62676194|NCT06548347|ACTIVE_COMPARATOR|CHOP|
62676195|NCT03702374|EXPERIMENTAL|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
62676196|NCT03702374|PLACEBO_COMPARATOR|Placebo group|This arm will be administered with placebo, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
62676197|NCT05835557|EXPERIMENTAL|Blood flow restriction with short interval training (BFR-ST)|9 sessions of high intensity short interval training with blood flow restriction.
61918292|NCT02628769|PLACEBO_COMPARATOR|Placebo|28 day treatment with placebo taken once per day.
61918293|NCT00874614|EXPERIMENTAL|Ultratrace® Iobenguane I 131 Treatment|
62473099|NCT00574327||C-subjects without BE or GERD|The control group would include patients undergoing upper endoscopy for reasons other than stated above, such as evaluation of iron deficiency anemia, weight loss, positive fecal occult blood, etc.
62473100|NCT04829981|EXPERIMENTAL|Intervention community|Two communities in rural Colombia
62473101|NCT04829981|NO_INTERVENTION|Control community|One community in rural Colombia
62676198|NCT05835557|SHAM_COMPARATOR|Sham altitude with short interval training (ST)|9 sessions of high intensity short interval training in an altitude chamber.
62676199|NCT00180700|EXPERIMENTAL|Self-hypnosis|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 13 participants with diagnosed HIV
62676200|NCT00180700|EXPERIMENTAL|Johrei healing method|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 9 participants with diagnosed HIV
62676201|NCT02617212|EXPERIMENTAL|Definitive abutment|Implant surgery. No abutment dis-/reconnections.
62676202|NCT02617212|ACTIVE_COMPARATOR|Conventional treatment|Implant surgery. Three abutment dis-/reconnections.
62116752|NCT05862363|ACTIVE_COMPARATOR|Low-BMI pregnant women|We will recruit 60 pregnant women with low-BMI before 14 weeks of gestation. 30 participants will receive MD-BEP and 30 will receive RUSF-BEP upon randomization. They will be followed to note changes in weight gain, BMI, changes in EED biomarkers, gut microbial community repair, and pregnancy related outcomes.
62116753|NCT05862363|ACTIVE_COMPARATOR|Normal BMI pregnant women|We will recruit 30 pregnant women with normal-BMI before 14 weeks of gestation. They will be provided with standard antenatal care. They will be followed to note changes in weight gain, BMI, changes in EED biomarkers, gut microbial community repair, and pregnancy related outcomes.
62304855|NCT03666767||Gastroschisis|
62304856|NCT03666767||Exomphalos|
62473102|NCT05168150|NO_INTERVENTION|Control Group No-expert mediated post hoc benchmark group|"30 participants. Individuals receive identical introductory information,same time, to perform, same scenarios as other groups.~Students receive their scores on 5 performance metrics compared to expert performance benchmarks. Scores are presented in the 5 minute breaks between tasks. Student goal is to be within the benchmark in all five metrics."
62473103|NCT05168150|EXPERIMENTAL|Experimental Group - Intelligent Continuous Expertise Monitoring System group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task, participants receive no feedback. For the subsequent 4 practice tasks participants will receive real-time auditory feedback instruction by the intelligent system. After each of the 5 attempts, a student takes a 5-minute break. During each of the 5 breaks the participants will be shown the errors they made during the task by the intelligent system regarding five performance metrics monitored. After seeing each error outline, the participant will be shown a video demonstration to learn how to expertly perform on each performance metric. On their 6th attempt they will perform on the realistic scenario without any feedback given."
62473104|NCT05168150|EXPERIMENTAL|Experimental Group In-person expert-mediated instruction group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task participants receive no feedback. For the subsequent 4 practice tasks participants receive real-time auditory feedback instruction by in-person expert during the task. After each of the 5 tasks, students takes a 5-minute break. During each of the 5 breaks the in-person expert provides feedback to the participant based on their OSATS score assessment during the previous trial. If the expert feels it is appropriate the expert will demonstrate how to do the specific procedure which has been found to be a concern on the simulator themselves so the participant can understand how to improve their performance. On their 6th attempt they will perform on the realistic scenario without any feedback given."
62473105|NCT02193165|ACTIVE_COMPARATOR|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
62116754|NCT05388565|EXPERIMENTAL|The DOVE in China Intervention Group|Our intervention consists of four major components: a) information about IPV and effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
62116755|NCT05388565|PLACEBO_COMPARATOR|The Control Group|The control group will be provided with a standard of care including usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV, and mental health resources).
62116756|NCT02393716|OTHER|Endovascular repair|Endurant Evo AAA Stent Graft System
62116757|NCT03329066|EXPERIMENTAL|MAST - Managing Asthma & Sleep in Teens|This is an eight week intervention consisting of 4 group and 4 individual tailored coaching sessions that focuses on both asthma and sleep. In this behavioral medicine intervention, teenagers learn ways to better care for their asthma and sleep hygiene. Teen sessions are delivered in school. Their caregivers will receive four educational booklets that correspond to each group session; topics mirror the objectives of each group and the booklets are sent at the time of each group.
62116758|NCT03329066|ACTIVE_COMPARATOR|ASMA - Asthma Self-Management for Adol|ASMA is an evidence-based intervention for students, caregiver education, and education for students' medical providers. The student intervention consists of 3 group sessions \& 5 individual tailored coaching sessions. All sessions are held at school. The caregiver intervention includes 3 educational booklets that correspond to the timing of the student group and 4 brief telephone-counseling sessions to review the booklets, answer questions, and provide strategies to support adolescents' steps to care for their asthma. With caregiver permission, we mail students' healthcare providers a toolkit consisting of (1) a letter informing them their patient is participating in ASMA and is being directed to them for clinical evaluation and (2) summaries of key NHLBI guidelines for treating asthma.
62116759|NCT03329066|PLACEBO_COMPARATOR|Information & Referral Control Group|The information-and-referral control intervention is a student-only intervention that consists of 3 group sessions and 5 individual sessions. Sessions are held once a week at school, where students will receive guideline-based information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
62304857|NCT03666767||Anorectal malformation (ARM)|
62304858|NCT03666767||Hirschsprung's disease|
62304859|NCT00735358|ACTIVE_COMPARATOR|A|Single dose cyanoacrylate in one shot
62304860|NCT00735358|EXPERIMENTAL|B|Double doses cyanoacrylate in one shot
62304861|NCT00895492||Sotero del Rio|Emergency Room and Hospital based surveillance
62304862|NCT00895492||Van Buren|Emergency Room and Hospital based surveillance
62304863|NCT00893607|EXPERIMENTAL|Intra-anal|The first 12 subjects were administered 10mg NRL001 as a slow release suppository into the anal canal.
62304864|NCT00893607|EXPERIMENTAL|Rectal|The second 12 subjects were administered 10mg NRL001 as a slow release rectal suppository.
62304865|NCT06163235|EXPERIMENTAL|Semi-attendance.|This group will follow a semi-attendance program after bariatric surgery.
62304866|NCT06163235|NO_INTERVENTION|Control group.|This group will follow the conventional controls after bariatric surgery.
62304867|NCT01144637|EXPERIMENTAL|Group 1|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
62304868|NCT01144637|EXPERIMENTAL|Group 2|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
62304869|NCT01144637|EXPERIMENTAL|Group 3|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
62304870|NCT01144637|PLACEBO_COMPARATOR|Group 4|Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
62304871|NCT00716521|PLACEBO_COMPARATOR|Placebo|groups of 3-4 subjects for overnight polysomnography assessments
62304872|NCT00716521|EXPERIMENTAL|Low dose Zolpidem|
62304873|NCT00716521|EXPERIMENTAL|High dose zolpidem|
62304874|NCT05926206|EXPERIMENTAL|TiTE-CRM Dose Escalation|Devimistat at Dose Level IV 2 hrs + modified FOLFIRINOX
62304875|NCT05926206|EXPERIMENTAL|Expansion Cohort A|Devimistat 500 mg/m2 IV 2 hrs + modified FOLFIRINOX
62304876|NCT05926206|EXPERIMENTAL|Expansion Cohort B|Devimistat at MTD IV 4 hrs + modified FOLFIRINOX
62304877|NCT00731029|EXPERIMENTAL|Group A|The subjects in this group will be 18-60 years.
62304878|NCT00731029|EXPERIMENTAL|Group B|The subjects in this group will be \> 60 years.
62304879|NCT00731029|ACTIVE_COMPARATOR|Group C|The subjects in this group will be 18-60 years.
62304880|NCT00731029|ACTIVE_COMPARATOR|Group D|The subjects in this group will be \> 60 years.
62304881|NCT01024244|PLACEBO_COMPARATOR|0 milligrams (mg) Placebo|Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
62676203|NCT06038032|EXPERIMENTAL|Intervention group|"Participants will receive the intervention for 24 weeks. The first 16 weeks will involve an intensive behavioral program (digital wellness platform plus online healthcare professional support), followed by an 8-week maintenance period (digital wellness platform alone).~At baseline, participants will receive handouts with publicly available health information; they will also wear an activity monitor and receive support telephone calls for the 24 weeks."
62676204|NCT06038032|NO_INTERVENTION|Control group|At baseline, participants will receive handouts with publicly available health information; they will also wear an activity monitor and receive support telephone calls for the 24 weeks.
61918294|NCT02526329|EXPERIMENTAL|Treatment (donor regulatory T lymphocytes)|Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.
62116760|NCT04755530|ACTIVE_COMPARATOR|Regular whole milk|Substitution of a part of the habitual diet with 400 g/day of regular whole milk
62116761|NCT04755530|EXPERIMENTAL|Yogurt with live bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with life bacteria
62116762|NCT04755530|EXPERIMENTAL|Yogurt with inactivated bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with inactivated bacteria
62116763|NCT04755530|EXPERIMENTAL|Acidified whole milk|Substitution of a part of the habitual diet with 400 g/day of acidified whole milk
62116764|NCT03413748|ACTIVE_COMPARATOR|Peritoneal irrigation|Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
62116765|NCT03413748|ACTIVE_COMPARATOR|Non peritoneal irrigation|No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
62116766|NCT02356549|ACTIVE_COMPARATOR|GROUP 1: (EMR) Tailoring Alone|Patients will be randomized to receive tailored messages based on demographic and disease information extracted from Massey Cancer Center (MCC) electronic medical records (EMR) that will include a) demographic information: age, income, education and health insurance status, b) disease variables: cancer type and severity and c) trial variables: phase of trial being offered and prior trial participation.
62116767|NCT02356549|ACTIVE_COMPARATOR|GROUP 2:EMR Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
62116768|NCT02356549|ACTIVE_COMPARATOR|GROUP 3:EMR+Survey Tailoring alone|Patients will be randomized to receive tailored messages based on EMR data as in Group 1. Patients will complete a survey that will be used to provide a deeper level of tailored messages
62304882|NCT01024244|EXPERIMENTAL|100 mg LY2599506|Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
62304883|NCT01024244|EXPERIMENTAL|200 mg LY2599506|Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
62304884|NCT01024244|EXPERIMENTAL|400 mg LY2599506|Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
62304885|NCT01024244|EXPERIMENTAL|200 mg LY2599506 once daily|Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
62304886|NCT03540017|EXPERIMENTAL|HIPEC|Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
62304887|NCT05449392|EXPERIMENTAL|Neosporin|Neosporin will be distributed by the Yale Investigational Pharmacy. Subjects are to use Neosporin twice a day for 7 days.
62304888|NCT05449392|PLACEBO_COMPARATOR|Vaseline or equivalent|Vaseline or equivalent will be distributed by the Yale Investigational Pharmacy. Subjects are to use Vaseline twice a day for 7 days.
61918295|NCT04785521||BM patients|Adult patients carrying new diagnosed BM confirmed by MRI
62304889|NCT03045146||Multimodal brain imaging|Consecutive patients experiencing an acute ischemic stroke treated by thrombectomy according to the current recommendations. Clinical outcome will be compared according to the baseline imaging profile processed after patient treatment.
62304890|NCT05136391|EXPERIMENTAL|XTR003|Administration and investigation of myocardial fatty acid radiotracer
62304891|NCT06187818||experience group 1|Take 4 total glucosides of crocin tablets (Ruiyang Pharmaceutical Co., Ltd.) 3 times a day for 8 days (the day before chemotherapy) during each chemotherapy.Previous history of heart disease.
61918296|NCT04785521||No BM patients|Adult patients carrying extracranial tumor without BM as confirmed by MRI
62676205|NCT06149013|EXPERIMENTAL|MindAhead + TAU Group|The intervention group receives the digital health app MindAhead Active for 3 months as well as treatment-as-usual (TAU, see Control intervention).
62676206|NCT06149013|ACTIVE_COMPARATOR|TAU Group|The control group receives TAU which may include antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins depending on clinical findings.
62676207|NCT02639559|EXPERIMENTAL|Arm 1: Donors|-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10\^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10\^6 CD34+ cells/kg and at least ≥ 2 x 10\^6 CD34+ cells/kg from the combined collections.
62116769|NCT02356549|ACTIVE_COMPARATOR|GROUP 4:EMR+Survey Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from their EMR as in Group I. Patients will complete a survey that will be used to provide a deeper level of tailored messages as in Group 3. Physicians also receive a summary of tailored messages provided to patients as in Group 2.
62304892|NCT06187818||experience group 2|Take 4 total glucosides of crocin tablets (Ruiyang Pharmaceutical Co., Ltd.) 3 times a day for 8 days (the day before chemotherapy) during each chemotherapy.No previous heart disease.
62304893|NCT06187818||Control group 1|Did not take crocine tablets during chemotherapy.Previous history of heart disease.
62304894|NCT06187818||Control group 2|Did not take crocine tablets during chemotherapy.No previous heart disease.
62304895|NCT05631951|ACTIVE_COMPARATOR|bone transport through induced membrane|"First stage~1. antibiotic impregnated cement spacer was applied to the bone defect~2. external fixator was applied for 6-8 weeks ϖ Second stage~1.removal of cement spacer done 2.metaphyseal osteotomy done"
62304896|NCT05631951|ACTIVE_COMPARATOR|bone transport|"1. removal of all hardware~2. resection of infected bone segments~3. external fixator was applied~4. metaphyseal osteotomy done"
62304897|NCT04674163|EXPERIMENTAL|Patients with clinical signs that suggest Multiple Sclerosis (MS) or Guillain Barré Syndrome (GBS)|
62304898|NCT02717702||ACS Patients|Subjects will be patients presenting to the Emergency Department for evaluation of ACS.
62304899|NCT02429505||Miltefosine|Miltefosine : target of 2.5 mg/kg/day for 28 days. Patients 45 kg or greater were to receive one 50 mg capsule 3 times daily for 28 consecutive days. This prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine in the United States who weighed \>75 kg could volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
62676208|NCT02639559|EXPERIMENTAL|Arm 2: Recipients|-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0
62676209|NCT00158431|ACTIVE_COMPARATOR|Arthroscopy plus Medical Management|Arthroscopic Surgery of the Knee plus the optimized medical management including physiotherapy, education, medication, etc
62676210|NCT00158431|NO_INTERVENTION|Medical Management|Optimized Medical management including physiotherapy, education, medication, etc
61918297|NCT04785521||Benign lesion patients|Adult patients carrying intracranial extra-axial tumor as as confirmed by MRI
61918298|NCT00112398|ACTIVE_COMPARATOR|Standard (paramedic) prehospital care|
61918299|NCT00112398|EXPERIMENTAL|Physician prehospital care|
62116770|NCT06182462|EXPERIMENTAL|Virtual Reality Distraction|Use of virtual reality (VR) during dental procedure.
62116771|NCT06182462|ACTIVE_COMPARATOR|Standard Treatment|Dental Clinic's standard treatment during dental procedure.
62116772|NCT00328393|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 45 mg, 8 weeks
62116773|NCT00328393|PLACEBO_COMPARATOR|Placebo|Placebo
62116774|NCT04225780|EXPERIMENTAL|Treatment of low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group and low-dose IL-2 is defined as 1 million IU per day subcutaneously.
62116775|NCT04225780|PLACEBO_COMPARATOR|Treatment of ganciclovir|If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in ganciclovir treatment group.
62116776|NCT02670525|EXPERIMENTAL|Relapsed/Refractory Leukemia|"Cohort 1: Relapsed/Refractory Leukemia~* Acute lymphoblastic leukemia (ALL), first or greater relapse~* Acute myeloid leukemia (AML), first or greater relapse~* Leukemia refractory to induction chemotherapy~* Other recurrent leukemia~* Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy~After the screening procedures confirms patient eligibility:~* Leukemia Profiling will be performed~* Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
62116777|NCT02670525|EXPERIMENTAL|New Diagnosis|"Cohort 2: New Diagnosis~* Acute myeloid leukemia (AML), new diagnosis (excluding acute promyelocytic leukemia (APL))~* New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (\<40 chromosomes) ALL~* Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage~* Secondary leukemia~* Myelodysplastic syndrome (MDS) not eligible for stem cell transplant~After the screening procedures confirms eligibility:~* Leukemia Profiling will be performed~* Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
62116778|NCT00521833|EXPERIMENTAL|1|Temporal (right eye)
62116779|NCT00521833|EXPERIMENTAL|2|Nasal (Left eye)
62116780|NCT03738111|EXPERIMENTAL|TG02 Citrate|TG02 citrate capsules given orally.
62676211|NCT05038826||trial 1|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
62676212|NCT05038826||trial 2|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
62676213|NCT05038826||trial 3|RNA-polymerase-II inhibitor
62676214|NCT05038826||trial 4|Tyrosine kinases inhibitor
62676215|NCT05038826||trial 5|Tyrosine kinases inhibitor
61918300|NCT02220127|EXPERIMENTAL|8 mm collimator|GKR with a single shot of the 8 mm collimator
61918301|NCT02220127|EXPERIMENTAL|4 mm collimator|GKR with a single shot of the 4 mm collimator
61918302|NCT02596282|ACTIVE_COMPARATOR|Clinical Officer (CO),|COs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
62473106|NCT02193165|ACTIVE_COMPARATOR|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
62304900|NCT05387161||Observational group|"A nutritional assessment will be held with the detection of anthropometric parameters. Each participant will be asked to fill in the SF36, the VAS scales, the KESS questionnaire, the SFFI questionnaire, the Questionnaire PUF and O'Leary/Santn, the BDI and the TAS for an assessment of the psychological component.~In addition, patients will be asked to fill in a FFQ of food consumption and a 7 days food diary. Finally, routine blood chemistry tests will also be performed, to which will be added those for measuring the inflammatory state and stool examination for the evaluation of fecal Calprotectin for the measurement of intestinal inflammatory markers.~The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative daily diet plan, which must be followed for 6 months.~At the end of the 6 months, all anthropometric assessments, blood chemistry and stool tests will be repeated, together with the questionnaires."
62304901|NCT02298244|ACTIVE_COMPARATOR|PV isolation + GP Ablation|
62304902|NCT02298244|ACTIVE_COMPARATOR|PV isolation + GP ablation + Pulmonary GP ablation|
62473107|NCT02193165|PLACEBO_COMPARATOR|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
62304903|NCT05742620|EXPERIMENTAL|anlotinib+CAPEOX/SOX|Adjuvant treatment of locally advanced gastric cancer and colorectal cancer
62304904|NCT04560127|EXPERIMENTAL|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
62304905|NCT05575518|NO_INTERVENTION|No intervention|Standard of care according to the National TB Programmes which is a weight-banded rifampicin, isoniazid, pyrazinamide, and ethambutol for weeks 0-8 followed by rifampicin and isoniazid for weeks 9-26.
62304906|NCT05575518|EXPERIMENTAL|Experimental Arm 1|Optimised dose of rifampicin. The rifampicin 35mg/kg alongside standard weight-banded doses of isoniazid, pyrazinamide, and ethambutol, once daily
62304907|NCT05575518|EXPERIMENTAL|Experimental Arm 2|Optimised dose of rifampicin and moxifloxacin. The rifampicin 35mg/kg and moxifloxacin 400mg alongside standard weight-banded doses of isoniazid and pyrazinamide, once daily.
62304908|NCT02512796||Transplant patients, MRI with Gadolinium contrast dye|Patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents.
62304909|NCT02512796||Non-transplant patients, MRI with Gadolinium contrast dye|Non-transplant patients exposed to gadolinium contrast.
62304910|NCT02512796||Healthy controls, no transplant no Gadolinium contrast dye|Age- and sex-matched healthy controls not exposed to gadolinium contrast.
62473108|NCT02834026|EXPERIMENTAL|Intervention|The intervention group held two months of training in hemodialysis a physical therapy protocol with cycle ergometer
62473109|NCT02834026|EXPERIMENTAL|Control|The control group was reassessed after two months of the initial evaluation
62473110|NCT01723397|ACTIVE_COMPARATOR|Nasaleze spray|"Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
62473111|NCT01723397|PLACEBO_COMPARATOR|Placebo spray|"Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
62473112|NCT04009486|EXPERIMENTAL|Obstructive Sleep Apnea|Subjects will undergo 6 weeks of whole body vibration.
62473113|NCT00505622|EXPERIMENTAL|E2007|E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).
62676216|NCT05038826||trial 6|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
62676217|NCT02048813|EXPERIMENTAL|Arm A (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28. Beginning cycle 2, patients also receive rituximab IV over 4 hours on days 1 and 2 of cycle 2, and day 1 of cycles 3-7. Treatment repeats every 28 days for 7 cycles in the absence of unacceptable toxicity. In the absence of disease progression, patients may continue ibrutinib PO QD.
61918303|NCT02596282|EXPERIMENTAL|Nurse Midwife (NMW)|NMWs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
62304911|NCT02534337|EXPERIMENTAL|GEMOX|gemcitabine 1000 mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2.
62304912|NCT02534337|ACTIVE_COMPARATOR|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.
62304913|NCT05523492|EXPERIMENTAL|Culturally Enhanced Wellbeing Course|For this study, the ICBT program, called the Wellbeing Course was culturally enhanced by simplifying language for individuals with limited command of English, acknowledging cultural differences and increase representation in imagery. Audiovisual components were included to provide a brief summary of each lesson. Furthermore, additional client stories were added to the intervention to diversify narratives and be more representative of the clients seeking this intervention.
62304914|NCT04283877|EXPERIMENTAL|Methylphenidate|30 mg methylphenidate, 60 minutes before testing
62304915|NCT04283877|PLACEBO_COMPARATOR|Control|30 mg of lactose pill, 60 minutes before testing
62473114|NCT05345990|EXPERIMENTAL|Hepatitis B immunoglobulins|"20 patients treated in two cohorts for 12 weeks with hepatitis B Immunoglobulins (HBIG, Hepatect®CP/ Zutectra®).~Cohort A:~10 HBsAg positive, HBeAg-negative patients being treated with anti-HBV nucleotide or nucleoside analogous (NAs) for at least 12 months before screening. HBV-DNA should be below the lower limit of detection at screening. HBsAg should be positive and below 100 IU/ml.~Cohort B:~10 HBsAg positive, HBeAg-negative patients untreated with NAs for at least 12 months before screening. Patients with HBV-DNA levels below 2000 IU/ml and ALT \< 1.5 times upper the limit of normal. HBsAg should be positive and below 100 IU/ml.~Trial duration: A recruiting period of approximately 6 months is planned. The total time per patient to complete all study visits is approximately 40 weeks including:~* an 28 day screening period~* an 12 week treatment period~* an 24 week follow-up period"
62473115|NCT00088829|EXPERIMENTAL|Paclitaxel|Paclitaxel given before surgery
62473116|NCT02900443|EXPERIMENTAL|Mycophenolate mofetil|The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
62473117|NCT02900443|ACTIVE_COMPARATOR|Azathioprine|. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
62304916|NCT02599012|EXPERIMENTAL|Subjects|
62304917|NCT05079438|EXPERIMENTAL|CRT with Dendrobium huoshanense Suppository|"Dendrobium huoshanense Suppository: 1.7g rectal administration per day for 5 weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2 (UGT1A1\*28 and \*6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1\*28 and \*6 ：7/7+GG or 6/6+AA or 6/7+GA）."
62304918|NCT05079438|NO_INTERVENTION|CRT with Placebo|"Placebo: 1.7g rectal administration per day for 5 weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2 (UGT1A1\*28 and \*6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1\*28 and \*6 ：7/7+GG or 6/6+AA or 6/7+GA）."
62304919|NCT05442385||cardiac patients admitted to PICU|To describe the clinical patterns of infants and children with cardiac disease admitted to PICU and their outcome.
62304920|NCT01910506|EXPERIMENTAL|RDEA3170|
62304921|NCT03554590|EXPERIMENTAL|carbo-counters|carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy
62304922|NCT03554590|ACTIVE_COMPARATOR|control group|insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy
62304923|NCT05940337||Elderly|
62304924|NCT05940337||Young adults|
62116781|NCT03071848||Bevacizumab|Participants with advanced cervical cancer (metastatic, recurrent or persistent) who have received treatment with bevacizumab from 01 January 2015 to 01 January 2016 (retrospective and independent from this study) combined with standard chemotherapy (cisplatin/carboplatin or topotecan and paclitaxel) will be observed.
62304925|NCT03982225|EXPERIMENTAL|2.5% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 2.5% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62116782|NCT04516564|EXPERIMENTAL|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects.
62116783|NCT04516564|EXPERIMENTAL|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects.
62116784|NCT00903019|EXPERIMENTAL|1|Participants will receive problem-solving therapy (PST) delivered via teleconferencing (tele-PST).
62304926|NCT03982225|EXPERIMENTAL|5.0% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62304927|NCT03982225|EXPERIMENTAL|5.0% Polyene Phosphatidylcholine Injection 0.4 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.4 mL injections, 1.0 cm apart, up to 20.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62304928|NCT03982225|PLACEBO_COMPARATOR|Placebo 0.2 mL/1.0 cm|Participants receive placebo administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62304929|NCT02262130|EXPERIMENTAL|Omalizumab|Omalizumab 300 mg W0, W4 and W8
62304930|NCT00509886|EXPERIMENTAL|1|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
62304931|NCT00509886|EXPERIMENTAL|2|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
62304932|NCT03563248|ACTIVE_COMPARATOR|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~* SBRT should be administered 2-6 weeks after completing chemotherapy~* All participants will undergo an attempt at definitive surgical resection following SBRT"
62304933|NCT03563248|EXPERIMENTAL|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~* Losartan will be administered orally as a tablet to be taken by the patient at home every day~* SBRT should be administered 2-6 weeks after completing chemotherapy~* All participants will undergo an attempt at definitive surgical resection following SBRT"
62304934|NCT03563248|EXPERIMENTAL|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~* Losartan will be administered orally as a tablet to be taken by the patient at home every day~* SBRT should be administered 2-6 weeks after completing chemotherapy~* Participants will receive nivolumab during SBRT~* All participants will undergo an attempt at definitive surgical resection following SBRT"
62304935|NCT03563248|EXPERIMENTAL|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"* The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~* SBRT should be administered 2-6 weeks after completing chemotherapy~* Participants will receive nivolumab during SBRT~* All participants will undergo an attempt at definitive surgical resection following SBRT"
62304936|NCT01341912|EXPERIMENTAL|Human-cl rhFVIII|Recombinant FVIII derived from a human cell line.
62304937|NCT06435715|EXPERIMENTAL|Intervention Group|The group that carries out the intervention of the treatment being studied
62304938|NCT06435715|ACTIVE_COMPARATOR|Control Group|The group that did usual care
62304939|NCT05691062|EXPERIMENTAL|PEEK|Medtronic Capstone
62304940|NCT05691062|EXPERIMENTAL|Titanium|Medtronic Adaptix
62304941|NCT01519843|ACTIVE_COMPARATOR|Real|Real tDCS
62116785|NCT00903019|ACTIVE_COMPARATOR|2|Participants will receive problem-solving therapy (PST) delivered in-person.
62116786|NCT00903019|PLACEBO_COMPARATOR|3|Participants will receive monitoring phone calls.
62304942|NCT01519843|PLACEBO_COMPARATOR|sham|Sham tDCS
62304943|NCT03746197|EXPERIMENTAL|Project EVO Multi- Treatment|Treatment group receives video game device treatment. Participant plays the game for 30 minutes a day, at least five days a week for four weeks.
61918304|NCT00136604|EXPERIMENTAL|ACAC GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccines at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
62116787|NCT04132024|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
62116788|NCT03768843|OTHER|traumatic odontoid fracture|C1 C2 fusion screws
62116789|NCT00801983|EXPERIMENTAL|A|Subject receives typical keyboard first for 6 months and alternative keyboard second for 6 months
62116790|NCT00801983|EXPERIMENTAL|B|Subject receives alternative keyboard first for 6 months and typical keyboard second for 6 months
62116791|NCT01596751|EXPERIMENTAL|Phase Ib: 600 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~* PLX3397 at a dose of 600 mg/day taken by mouth in the form of 100-200 mg gelcaps~* Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8."
62116792|NCT01596751|EXPERIMENTAL|Phase Ib: 800 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~* PLX3397 at a dose of 800 mg/day taken by mouth in the form of 100-200 mg gelcaps~* Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
62116793|NCT01596751|EXPERIMENTAL|Phase Ib: 1000 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~* PLX3397 at a dose of 1000 mg/day taken by mouth in the form of 100-200 mg gelcaps~* Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
62116794|NCT01596751|EXPERIMENTAL|Phase II: 800 mg/Day PLX3397 Lead in +Combined with Eribulin|"Treatment begins with a 7 day Lead-in phase of PLX3397 alone, followed by 21 day cycles of PLX3397 in combination with eribulin.~Lead-in phase treatment:~* PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest.~Treatment given in each 21 day cycle:~* PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest, repeated weekly~* Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
62116795|NCT06237751|OTHER|calcium tablet|calcium tablet
62116796|NCT02239796|EXPERIMENTAL|TPTNS|"12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.~Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps."
62116797|NCT02239796|SHAM_COMPARATOR|Sham TPTNS|"The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.~The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.~The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided."
62116798|NCT04378062|ACTIVE_COMPARATOR|Traction Neurectomy|Traction neurectomy - of digital sensory nerves at the time of amputation.
62116799|NCT04378062|EXPERIMENTAL|Targeted Muscle Reinnervation|Targeted Muscle Reinnervation - of digital sensory nerves at the time of amputation
62116800|NCT04378062|EXPERIMENTAL|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface - of digital sensory nerves at the time of amputation
62116801|NCT02715258|ACTIVE_COMPARATOR|Bexagliflozin tablets, 20 mg|Each subject will self-administer bexagliflozin tablets once daily for 24 weeks.
62116802|NCT02715258|PLACEBO_COMPARATOR|Placebo tablets|Each subject will self-administer placebo (inactive tablet) once daily for 24 weeks.
62116803|NCT01116180|ACTIVE_COMPARATOR|Candesartan|
62473118|NCT01929863|EXPERIMENTAL|Arm A|Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
61918305|NCT00136604|EXPERIMENTAL|ACHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
62116804|NCT01116180|PLACEBO_COMPARATOR|Placebo|
62116805|NCT00212784|EXPERIMENTAL|Arm 1|
62116806|NCT00212784|ACTIVE_COMPARATOR|Arm 2|
62116807|NCT00478335|EXPERIMENTAL|Active Therapy|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, calcitonin, sildenafil
62116808|NCT00478335|PLACEBO_COMPARATOR|Placebo Control|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, placebo for calcitonin, placebo for sildenafil
62304944|NCT03746197|NO_INTERVENTION|Control|No contact control
62304945|NCT01773031||Autoimmune pancreatitis|Patients with autoimmune pancreatitis based on clinical and CT findings
62473119|NCT01929863|EXPERIMENTAL|Arm B|Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
62473120|NCT05314647|EXPERIMENTAL|Lutein|5 mg lutein gummy taken daily for 180 days
62473121|NCT05314647|PLACEBO_COMPARATOR|Placebo|0 mg lutein gummy taken daily for 180 days
62116809|NCT01807546|EXPERIMENTAL|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
62304946|NCT06489964|OTHER|Community Pharmacy Sites (Step 1)|A pharmacy site in Nova Scotia and Ontario will be assigned to pilot Step 1 of the transitional co-payment model for the duration of the pilot study.
62304947|NCT06489964|OTHER|Community Pharmacy Sites (Step 2)|A pharmacy site in Nova Scotia and Ontario will be assigned to pilot Step 2 of the transitional co-payment model for the duration of the pilot study.
62304948|NCT06489964|OTHER|Community Pharmacy Sites (Step 3)|A pharmacy site in Nova Scotia and Ontario will be assigned to pilot Step 3 of the transitional co-payment model for the duration of the pilot study.
62304949|NCT06489964|OTHER|Community Pharmacy Sites (Step 4)|A pharmacy site in Nova Scotia and Ontario will be assigned to pilot Step 4 of the transitional co-payment model for the duration of the pilot study.
62304950|NCT01158612|EXPERIMENTAL|Growth hormone|The effect of Growth hormone on the collagen synthesis rate
62304951|NCT01158612|PLACEBO_COMPARATOR|Saline|
62304952|NCT01438983||breastfeeding infants|
62473122|NCT01880632|EXPERIMENTAL|XELOX|Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
62676218|NCT02048813|ACTIVE_COMPARATOR|Arm B (rituximab, fludarabine phosphate, cyclophosphamide)|Patients receive rituximab IV over 4 hours on days 1 and 2 of cycle 1, and day 1 of cycles 2-6. Patients also receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 30 minutes on days 1-3. Treatment repeats every 28 days for 6 cycles in the absence of unacceptable toxicity.
62676219|NCT05858151|ACTIVE_COMPARATOR|Intervention|
62116810|NCT01265134||Experimental Group|the healthy elders
62304953|NCT01438983||bottle feeding infants|
62304954|NCT03067311|EXPERIMENTAL|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
62304955|NCT03067311|ACTIVE_COMPARATOR|Treatment as Usual|Usual treatment provided at the University of North Carolina at Chapel Hill (UNC) Outreach and Support Intervention Services (OASIS) Clinic by trained clinicians.
62473123|NCT04030286||Control|Healthy patients
62473124|NCT04030286||Periodontitis|Patients with periodontal disease
62473125|NCT04030286||Cardiovascular|Patients with cardiovascular disease
62473126|NCT04030286||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
62116811|NCT01265134||Control Group|the elders who have fallen once
62116812|NCT00922207|EXPERIMENTAL|1|
62116813|NCT00922207|EXPERIMENTAL|2|
62676220|NCT05858151|NO_INTERVENTION|Control/No Intervention|
62116814|NCT00922207|PLACEBO_COMPARATOR|3|
62116815|NCT05254171|EXPERIMENTAL|Experimental Arm|SBP-101 + Nab-paclitaxel and Gemcitabine
62116816|NCT05254171|PLACEBO_COMPARATOR|Control Arm|Placebo + Nab-Paclitaxel and Gemcitabine
62116817|NCT03346018||uveitis of tuberculous etiology|Analysis of aqueous humor and plasma samples: The patients with diagnosis of uveitis of tuberculous etiology, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
62304956|NCT01417260||Nocebo|Told breastfeeding may worsen pain
62304957|NCT01417260||No treatment|Told nothing
62304958|NCT01417260||Placebo|Told will improve pain
62304959|NCT05475873|SHAM_COMPARATOR|Control group|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
62304960|NCT05475873|EXPERIMENTAL|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
62304961|NCT05475873|EXPERIMENTAL|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
62304962|NCT04901507|EXPERIMENTAL|The Voutia System|The Voutia System oral irrigation device
62304963|NCT03848520||Total Knee Arthroplasty|Internal Registry of Patients having a TKA and with a high (\>=9) activity-scale score at anytime between preoperatively and now.
62304964|NCT02270177|NO_INTERVENTION|Regular consultation|Regular headache consultations
62304965|NCT02270177|OTHER|Videoconsultation|Headache consultations through telemedicine technology
62304966|NCT02837172||Parkinson's disease from UAB|MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, Diffusion Weighted Imaging (DWI), and neurological examination.
62304967|NCT02837172||Parkinson's disease from PPMI dataset|Obtain retrospective and prospective de-identified data from the The Parkinson's Progression Markers Initiative (PPMI) dataset on Parkinson's disease (PD) subjects that have the following characteristics: within 2 years of diagnosis, positive DaTscan, and not (at study entry) on any PD related medication.
62304968|NCT02837172||Controls from PPMI dataset|Obtain retrospective and prospective de-identified DTI imaging and data from the PPMI dataset
62304969|NCT02429648|ACTIVE_COMPARATOR|PVI performed in Normal Sinus Rhythm|DCC first then PVI
62473127|NCT06250309|ACTIVE_COMPARATOR|Mediterranean Diet (MD)|The Mediterranean Diet (MD) includes similar food patterns to those described in the Healthy Mediterranean-Style Dietary Pattern in the Dietary Guidelines for Americans, 2020-2025. The daily caloric needs of participants will be calculated to ensure weight stability. For a daily 2,000 kcal diet, participants will consume 2.5 cup equivalents of vegetables, 2.5 cup equivalents of fruits, 3 ounce equivalents of whole grains, 2 cup equivalents of dairy, 6 ounces equivalent of protein foods (with 32% from seafood, and 11% from nuts, seeds and soy products), and 27 grams of canola or olive oil, per day. No more than 12% of calories per day will come from discretionary foods (I.e., added sugar, saturated fat).
62676221|NCT05783765|EXPERIMENTAL|Heightened Drive to Eat|"* Eating rate~* Eating in the absence of hunger~* Relative reinforcing value of food"
62676222|NCT06517316|OTHER|Nelfilcon A plano cosmetic contact lenses|Nelfilcon A plano cosmetic contact lenses worn in both eyes at least 5 hours per day, at least 2 days a week, for one year. The lenses will be worn in a daily wear, daily disposable modality.
61918306|NCT00136604|EXPERIMENTAL|HibACPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
62116818|NCT03346018||uveitis of suspect sarcoidosis|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of suspect sarcoidosis, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
62304970|NCT02429648|ACTIVE_COMPARATOR|PVI performed in Atrial Fibrillation|PVI then DCC after if patient remains in Atrial Fibrillation
62116819|NCT03346018||uveitis of undifferentiated origin|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of undifferentiated origin (tuberculosis/sarcoidosis), undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
62116820|NCT04215471|EXPERIMENTAL|NeoAdjuvant Therapy With PD-L1 Antibody SHR-1316 group|Patients will receive the neoadjuvant therapy with SHR-1316 followed by the operation.
62116821|NCT04116203|OTHER|Fish Oil|Fish oil capsules 1200mg 6 tablets/day 12 weeks
62304971|NCT03291379|EXPERIMENTAL|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
62116822|NCT04116203|OTHER|Metformin|Metformin tablets (500 mg) 2/day 12 weeks
62116823|NCT04116203|OTHER|Fish Oil and Metformin|Combo of other 2 arms
62116824|NCT01990924|EXPERIMENTAL|7.5 FPS|Low rate fluoroscopy at 7.5 frames per second (FPS)
62116825|NCT01990924|ACTIVE_COMPARATOR|15 FPS|Conventional rate fluoroscopy at 15 FPS
62116826|NCT00212056|ACTIVE_COMPARATOR|ANP|
62116827|NCT00212056|PLACEBO_COMPARATOR|Control|
62116828|NCT01884636|EXPERIMENTAL|isavuconazole and methotrexate|Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 - 9
62304972|NCT03951987|EXPERIMENTAL|Treatment A: 4 ml CG5503|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) was administered as a 2 minutes infusion.
62304973|NCT03951987|EXPERIMENTAL|Treatment B: 4 ml CG5503; 5 g charcoal powder|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) with oral co-administration of charcoal (5 g charcoal were co-administered orally at 1, 0.5 hours and 10 minutes before the start of CG5503 infusion and 0.5, 1, 1.5, 2 and 4 hours thereafter)
62304974|NCT05755789|EXPERIMENTAL|Intervention group (innovative administration scheme)|Continuous infusion of cefoxitin + Intermittent placebo
62116829|NCT02281318|EXPERIMENTAL|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
62473128|NCT06250309|ACTIVE_COMPARATOR|Western Diet (WD)|The Western Diet (WD) includes similar food patterns to those described in the Data Tables of What We Eat in America, NHANES (13) . We will match intake according to gender and age group in years (I.e., 20-29; 30-39; 40-49; 50-59; 60-69; 70 and over). On average, participants will consume 1.6 cup equivalent of vegetables, 0.9 cup equivalents of fruits, 0.8 ounce equivalents of whole grains,1.4 cup equivalents of dairy, 6.3 ounces equivalent of protein foods (with 10% from seafood, and 14% from nuts, seeds and soy products). The diet will contain 12% of calories per day from saturated fat, and 12.7% of calories from added sugars.
62473129|NCT06124014|EXPERIMENTAL|Cranial Electrotherapy Stimulation (CES)|Alpha-Stim AID ® is an FDA-cleared device for the treatment of anxiety that delivers CES through two earclip electrodes.
61918307|NCT00136604|EXPERIMENTAL|HibHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
61918308|NCT00136604|EXPERIMENTAL|CC GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix + Meningitec vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
62116830|NCT02281318|PLACEBO_COMPARATOR|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
62116831|NCT05471414|EXPERIMENTAL|Whole-food, Plant-based Diet (WFPBD)|Home-delivered WFPBD meals will be provided to participants, along with nutritional coaching and education. 12 meals a week will be delivered for the first 4 weeks, followed by 6 meals a week for the next 4 weeks. Finally, for the last 18 weeks they will not receive pre-packed meals, but will continue to receive WFPBD coaching. 30 participants are anticipated to be accrued in this arm.
62116832|NCT05471414|ACTIVE_COMPARATOR|General Nutrition Counseling|Participants will receive general nutritional counseling weekly for the first 4 weeks, followed by monthly nutritional counseling for the following 18 weeks. 30 participants are anticipated to be accrued in this arm.
62116833|NCT04689425|EXPERIMENTAL|MNC+PRP|The combination of PRP and MNC
62116834|NCT04689425|ACTIVE_COMPARATOR|PRP|PRP alone.
62116835|NCT06466902||Patients undergoing minimally invasive gastrectomy|Patients undergoing minimally invasive gastrectomy with D2 lymphadenectomy for gastric cancer
62116836|NCT01585558|EXPERIMENTAL|Treatment Group 1|
62116837|NCT01585558|EXPERIMENTAL|Treatment Group 2|
62116838|NCT01585558|PLACEBO_COMPARATOR|Treatment Group 3|
62116839|NCT04807725||Peri-implant health|Includes patients with peri implant mucosa without inflammatory signs and absence of peri-implant bone loss.
62116840|NCT04807725||Peri-implantitis|Includes patients with bleeding and / or suppuration on probing, probing depth equal or greater than 6mm and bone loss equal to or greater than 3mm.
62116841|NCT04978935|NO_INTERVENTION|Control group|In the control group (n=40), interventions for the position, mobilization and spirometry of the patient are applied to all patients in the clinic where the study was conducted. However, these applications are not made in accordance with a certain order and protocol. Shoulder exercises are not routinely taught to patients. In the study, no additional application will be made to the control group other than the routine treatment and care practice of the clinic.
62304975|NCT05755789|ACTIVE_COMPARATOR|Control group (recommended administration scheme)|Intermittent cefoxitin + Continuous infusion of placebo
62304976|NCT01046318|EXPERIMENTAL|OPC-262 5 mg|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
62304977|NCT02616653|ACTIVE_COMPARATOR|Sitting followed by lateral position|First half of participants will be assigned to have their L3-L4 intervertebral space located first in the sitting position followed by the lateral position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
62473130|NCT06124014|SHAM_COMPARATOR|Sham Cranial Electrotherapy Stimulation (CES)|The device for sham stimulation is physically identical and delivers a non-therapeutic dose of stimulation to replicate salient features of device usage.
62473131|NCT04873518||Cohort 1|These are the eldest children who entered kindergarten in September 2016.
62473132|NCT04873518||Cohort 2|These children entered kindergarten in September 2017.
62473133|NCT04873518||Cohort 3|These are the youngest children who entered kindergarten in September 2018
62473134|NCT06278844|EXPERIMENTAL|Conduction system pacing|In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing.
62473135|NCT06278844|ACTIVE_COMPARATOR|Right ventricular apical pacing|Control group, in this group patients will receive a pacemaker with the ventricular lead in the right ventricle apex.
62473136|NCT04032119|EXPERIMENTAL|Epinephrine|0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection
62473137|NCT04032119|ACTIVE_COMPARATOR|Non-epinephrine|No epinephrine would be added into the solution
62473138|NCT04927091|NO_INTERVENTION|Specialty Addiction Clinic|
62473139|NCT04927091|EXPERIMENTAL|ECHO-IC/QI-enhanced primary care clinic|
62473140|NCT04927091|ACTIVE_COMPARATOR|ECHO-IC/QI-enhanced primary care clinic with Pay for Performance|
62473141|NCT01594203||Advanced Soft Tissue Sarcoma|patients with advanced Soft Tissue Sarcoma
62304978|NCT02616653|ACTIVE_COMPARATOR|Lateral followed by sitting position|Second half of participants will be assigned to have their L3-L4 intervertebral space located first in the lateral position followed by the sitting position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
62304979|NCT05162235|EXPERIMENTAL|AR-localization|
62304980|NCT05139524||Health facility based cohort|Cohort of individuals with acute or reported fever enrolled at health facilities and followed up for upto 24 months.
62304981|NCT05139524||Community survey|Individuals enrolled in study as part of a cross sectional survey in the community.
62304982|NCT03724708|EXPERIMENTAL|Hang up technique|"where the enrolled patients will have the IUD applied in the middle of the uterine cavity and then attached to the fundus of the uterus by an absorbable suture Hang up technique"
62304983|NCT03724708|ACTIVE_COMPARATOR|Postpartum insertion|will include patients where IUD will be inserted after 6 weeks post-partum.
62304984|NCT03724708|ACTIVE_COMPARATOR|Control|will serve as our control group where the enrolled patients will have the IUD just applied into the middle of the uterine cavity at the level of the fundus without attachment
62304985|NCT05990530|EXPERIMENTAL|YD02-2022|
62304986|NCT00735423||No groups|IDE used for outcome measurement not intervention
62473142|NCT04280107||Temporomandibular Dysfunction|For this study, 154 patient files who were admitted to the radiology department of the faculty of dentistry between 2013 and 2019 with complaints such as TMJ pain, mouth opening restriction, joint sound, joint function disorder were scanned retrospectively. Inclusion criteria: TMD patients with MR and CBCT images recorded in the digital archive. Exclusion criteria: Patients who have been operated or treated from TMJ, patients with head and neck trauma, patients with orthodontic treatment.
62473143|NCT02561520|EXPERIMENTAL|PRP and PPP|PRP eye drops and PPP eye drops will be prepared from patient's own blood by Magellan technology. Patients will receive eye drops in sterile amber glass droppers. Patients will be instructed to keep refrigerated each bottle after opening for 7 days and keep frozen the unopened bottles up to 30 days.
62473144|NCT01979861|EXPERIMENTAL|vapor endometrial ablation|endometrial ablation using the AEGEA Vapor System
62473145|NCT05519800|ACTIVE_COMPARATOR|High Glycaemic Index|A diet comprising of High Glycaemic Carbohydrate. Supplemented with a maltodextrin containing beverage.
62473146|NCT05519800|EXPERIMENTAL|Low Glycaemic Index|A diet comprising of Low Glycaemic Carbohydrate. Supplemented with an Isomaltulose containing beverage.
62304987|NCT00844883|EXPERIMENTAL|sorafenib and drug eluting beads|single arm
62473147|NCT02411903|ACTIVE_COMPARATOR|atorvastatin and Clopidogrel|80 patients will be taking atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months。
62473148|NCT02411903|EXPERIMENTAL|rosuvastatin and Clopidogrel|80 patients will be taking rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months。
62473149|NCT01796730|EXPERIMENTAL|sequence I|10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)
62304988|NCT05751408||Stiff knee gait|Subjects referred to clinical 3D gait analysis because of a clinical question related to stiff knee gait
62473150|NCT01796730|EXPERIMENTAL|sequence II|bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)
62304989|NCT05751408||Foot surgery|Subjects referred to clinical 3D gait analysis because of a clinical question related to foot surgery
62304990|NCT01421368|EXPERIMENTAL|DMPA and tenofovir 1% gel|
62304991|NCT01421368|EXPERIMENTAL|Oral contraceptive and tenofovir 1% gel|
62304992|NCT03062917|OTHER|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
62304993|NCT03062917|OTHER|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
62473151|NCT01796730|EXPERIMENTAL|sequence III|placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout (7 days) - bambuterol 5mg (21 days)
62473152|NCT05941065|EXPERIMENTAL|Balancing gel cream|"Product will be used twice daily in the morning and in the evening for 6 weeks. 1-2 pumps (dime size) of product will be applied on the face.~In addition to the study product, a Cetaphil cleanser will be used as well. Cleanser will be applied twice daily in the morning and in the evening for 6 weeks. Cleanser will be used on wet face and gently pat dry."
62473153|NCT04579770|PLACEBO_COMPARATOR|Placebo|Only carbohydrates will be provided
62473154|NCT04579770|EXPERIMENTAL|Ketone ester|Ketone ester with carbohydrates will be provided
62473155|NCT04579770|EXPERIMENTAL|Ketone ester + bicarbonate|Ketone ester with bicarbonate and carbohydrates will be provided
62473156|NCT04579770|EXPERIMENTAL|Bicarbonate|Bicarbonate and carbohydrates will be provided
62473157|NCT02503527|OTHER|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
62473158|NCT02503527|OTHER|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
62304994|NCT03062917|OTHER|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
62304995|NCT03062917|OTHER|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
62473159|NCT01354860|EXPERIMENTAL|Moxibustion treatment plus usual care|
62473160|NCT01354860|NO_INTERVENTION|usual care alone|
62473161|NCT05241691||Pediatric patients treated with GGPSP for the correction of femur and/or tibia deformities|
62473162|NCT03171545|EXPERIMENTAL|Patient Activation|This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling.
62473163|NCT03171545|EXPERIMENTAL|Provider Education|This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
62116842|NCT04978935|EXPERIMENTAL|Intervention|Care protocol will be applied to the study group (n=40), starting from the first day spent in the intensive care unit.Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises. The bed head of the patient will be raised 30°-45° in line with the application steps. In the study, the patient's in-bed and out-of-bed mobilization will be provided by considering the mobilization application steps, and the patient will be asked to stay out of bed for two hours on the 0 th day after surgery. The patient will be asked to stay out of bed for six hours from the first postoperative day until discharge. After the thoracotomy, the conditions that the doctor considers as complications will be recorded.The time of chest tube removal and the day of discharge will be recorded. In the study, the use of spirometry and shoulder exercises will be carried out by taking into account the implementation steps of the care protocol.
62304996|NCT03062917|OTHER|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
62473164|NCT03171545|NO_INTERVENTION|No Intervention|Patients in clinic receive usual care.
62473165|NCT03171545|EXPERIMENTAL|Patient and Provider|This arm includes both Patient Activation and Provider Education interventions
62304997|NCT04074993|EXPERIMENTAL|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
62304998|NCT01695629||None to Mild|Subjects with Diabetes with none to mild peripheral neuropathy
62304999|NCT01695629||Severe|Subjects with diabetes with severe neuropathy
62305000|NCT04300725|NO_INTERVENTION|Verbal Counseling|Patients in one study arm receive only verbal counseling prior to their induction of labor.
62473166|NCT06366581||IH group|Patients who underwent incisional hernia repair were defined as the experimental group (labelled as the IH group)
62473167|NCT06366581||NC group|patients who underwent laparoscopic cholecystectomy were defined as the control group (labelled as the NC group)
62473168|NCT05099198||Sitagliptin|Reference group
62473169|NCT05099198||Glimepiride|Exposure group
62305001|NCT04300725|EXPERIMENTAL|Video Counseling|Patients in other study arm will receive verbal + video counseling prior to their induction of labor.
62305002|NCT03490786|EXPERIMENTAL|Dose escalation|Single arm dose escalation.
62305003|NCT04285034||Ribavirin only|"Patients will receive ribavirin in accordance with Nigerian treatment guidelines. Patients will either receive the McCormick regimen or the Irrua regimen.~PK blood tests will be done on Day 1,2,5,6,10,11,12,13, discharge; Paxgene RNA blood test on day 1, 3, 5, discharge Haematocrit finger prick test on day 1,2, 5, 6, 10, discharge"
62305004|NCT04285034||Cardiocascular study only|Cardiac tests (NICAS (daily), ECG (Day 1, 5, 10, discharge), Echocardiogram (Day 1, 5, discharge), Ultrasound (Day 1, 3, 5, 7, 10), Endopat (Day 1 and discharge)) will be done throughout; Haematocrit finger prick test daily PAXgene RNA blood test on day 1, 5, discharge
62305005|NCT02171169||Transsacral lumbar interbody fusion|
62305006|NCT02171169||Transforaminal lumbar interbody fusion|
62305007|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
62305008|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
62305009|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
62473170|NCT02584439|OTHER|ivabradine-placebo|Volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
62473171|NCT02584439|OTHER|placebo-ivabradine|Volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
62473172|NCT00813787||A. glioma|A. glioma population
62473173|NCT00813787||B. Normal brain|B. Normal brain
62116843|NCT06024369|EXPERIMENTAL|Using wearable CPM Device daily|The patients will be using the wearable device once daily at home for 6 months.
62116844|NCT03522467|EXPERIMENTAL|MRCP001|MRCP001 administered per protocol dose titration regimen (beginning at 1 capsule daily, titrated to a maximum of 3 capsules BID)
62116845|NCT04327180||patients suspected of infection with COVID-19.|Patients included with positive PCR and patients with negative PCR included
62116846|NCT02312336|PLACEBO_COMPARATOR|Cohort A|Cohort A - Room temperature coronary perfusate
62116847|NCT02312336|ACTIVE_COMPARATOR|Cohort B|Cohort B - Cooled coronary perfusate
62116848|NCT04162119|EXPERIMENTAL|multiple myeloma|This study is to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with Relapsed/Refractory Multiple Myeloma.
62116849|NCT04779333|EXPERIMENTAL|LEAP Group|In addition to the components of the BMT group, the LEAP program includes an emphasis on supporting optimal physical activity, limiting screen time, and encouraging adequate sleep. The child and caregiver are also given a wrist-worn activity tracker and caregivers participate in a motivational Facebook group.
62305010|NCT04121910|EXPERIMENTAL|Savolitinib and/or Itraconazole|Treatment Period 1: Single administration of savolitinib (200 mg) will occur on Study Day 1 after a high-fat, high-calorie breakfast followed by PK sampling for 48 hours Treatment Period 2: Itraconazole will be administered (200 mg BID) on Study Day 15, and (200 mg QD) on Study Days 16 and 17, 1 hour before breakfast (and before dinner, when applicable) Treatment Period 3: A single combination of itraconazole (200 mg) 1 hour before breakfast + savolitinib (200 mg) after a high-fat, high-calorie breakfast on Study Day 18, and a single dose of itraconazole (200 mg) on Study Day 19, 1 hour before breakfast
62305011|NCT05914363|EXPERIMENTAL|Intervention (improved floor)|"* Replacement of rudimentary floors with an improved floor,~* Support for behaviour change through 'floor clubs'.~* Annual mass treatment for STH infections (400 mg albendazole)~* Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county DoH recommendations"
62305012|NCT05914363|ACTIVE_COMPARATOR|Control (rudimental floor)|"* Annual mass treatment for STH infections (400 mg albendazole)~* Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county DoH recommendations"
62305013|NCT05726695||Heart failure with reduced ejection fraction.|"Patients indicated for biochemical analysis due to a suspected heart disease, with HFrEF diagnosed on echocardiography with left-ventricular ejection fraction lower than 35%.~Diagnostic Test: MicroRNA test. Laboratory analysis for the detection of microRNA in blood samples.~Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination."
62305014|NCT05726695||Control group|"Patients with no known heart disease (hypertrophy or dilatation), which has been confirmed on echocardiography.~Diagnostic Test: microRNA test. Laboratory analysis for the detection of microRNA in blood samples.~Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination."
62305015|NCT03682796|EXPERIMENTAL|Escalation|Estimated to be \<31 subjects across multiple centers
62305016|NCT03682796|EXPERIMENTAL|Expansion|Estimated to be \<121 subjects across multiple centers
62305017|NCT02764619|ACTIVE_COMPARATOR|Aldo group|Fixed dose of spironolactone, Spirix (Takeda Pharma A/S), 25 mg once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
62305018|NCT02764619|PLACEBO_COMPARATOR|Control group|Matched placebo, 1 pill once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
62305019|NCT03219125||Group 1 (cases)|occurence of incident major osteoporotic fracture less than 12 weeks
62305020|NCT03219125||Group 2 (controls)|no history of fragility fracture
62305021|NCT02456623|EXPERIMENTAL|Intervention|Behavioral intervention that targets the parent of a preschool age child who is overweight. The intervention is 8 sessions in length. Each session is expected to last 1-1.5 hours and will be carried out in the participant's home over 4 months. The sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to these factors. Intervention content for the parent will be based on Motivational Interviewing principles.
62305022|NCT02456623|ACTIVE_COMPARATOR|Attention Control|The attention control condition includes 1 initial Motivational Interviewing (MI) session conducted in the home. The content of the MI session will be the same as for the intervention participants. Following this session, parents will receive bi-monthly newsletters that will include content similar to what intervention participants receive. AC participants will receive a total of 7 newsletters; 2 on nutrition, 2 on physical activity, 2 on parenting behavior and 1 on community resources. AC participants will also receive a monthly 20-min phone call designed to review newsletter content and answer parent questions.
62473174|NCT04353063|NO_INTERVENTION|control group|"The patients in the control group will not receive any walking exercise education until the 4-week intervention ends. They will then receive the same education material (How walking is beneficial to your health) and will be told about the benefits of walking."
62116850|NCT04779333|ACTIVE_COMPARATOR|BMT Group|The BMT Group will take part in a family-based intervention within the context of evidence-based behavioral management training (BMT) for caregivers. Standard BMT represents the current standard of care for childhood ADHD.
62116851|NCT03967717||Patients with edematous states|Patients with edematous states receive standard of care diuretic.
62116852|NCT00468910|EXPERIMENTAL|Arm I|Patients receive oral acetylsalicylic acid (aspirin) once daily.
62116853|NCT00468910|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily.
62116854|NCT04970810|NO_INTERVENTION|Attention Control|Subjects monthly calls similar in structure to the intervention arms, but without support. (attention placebo control)
62116855|NCT04970810|ACTIVE_COMPARATOR|My Diabetes Goal|My Diabetes Goal protocol
62116856|NCT04970810|ACTIVE_COMPARATOR|My Diabetes Goal + Community Rx|My Diabetes Goal protocol + Community Rx protocol
62116857|NCT04402957|PLACEBO_COMPARATOR|Placebo|100 mL drug-free IV saline infusion over 2 hours daily
62116858|NCT04402957|EXPERIMENTAL|LSALT|100 mL of 5 mg IV LSALT peptide infusion over 2 hours daily
62116859|NCT01070888|EXPERIMENTAL|Budesonide/Formoterol first|This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.
62116860|NCT01070888|ACTIVE_COMPARATOR|Budesonide first|This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.
62116861|NCT02621424|EXPERIMENTAL|RTMS|repetitive transcranial magnetic stimulation
62305023|NCT02085577|EXPERIMENTAL|Ketamine|"* (S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/h terminated at last suture to the skin.~* Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~* Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~* Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~* Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~* Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~* Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~* The patients usual daily opioids"
62305024|NCT02085577|PLACEBO_COMPARATOR|Placebo|"* Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/h terminated at last suture to the skin.~* Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~* Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~* Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~* Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~* Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~* Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~* The patients usual daily opioids"
62116862|NCT02621424|SHAM_COMPARATOR|sham|sham noise to block the sound of treatment
62305025|NCT00410891|EXPERIMENTAL|topical antibiotic|topical gatifloxacin 4 times per day
62305026|NCT03251690|EXPERIMENTAL|Switching TDF/FTC/EFV to TDF/FTC/RPV|Switching from Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day (once daily) to Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Rilpivirine 25 mg/day (once daily) Intervention: Tenofovir/Emtricitabine/Rilpivirine
62305027|NCT03251690|ACTIVE_COMPARATOR|Continuing TDF/FTC/EFV|Continuing Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day Intervention: Tenofovir/Emtricitabine/Efavirenz
62305028|NCT01938170|EXPERIMENTAL|FluMist|Subjects receiving vaccine at home
62305029|NCT02046135|EXPERIMENTAL|Sodium bicarbonate|At the start of the surgery, the patient will receive NaHCO3 as a continuous infusion of D5% 1/3NS + 100 meq/L NaHCO3 + 20 meq/L KCl at maintenance IVF (solution contains \~154 meq of sodium which is equivalent to normal saline). The NaHCO3 infusion will continue for the first 24 hours after the discontinuation of CPB. After 24 hours of receiving the NaHCO3 infusion, the IVF administered to the patient will be the standard solutions used in the PICU at CCMC.
62473175|NCT04353063|EXPERIMENTAL|experimental group|"Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days. The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials How walking is beneficial to muscle mass and your health. And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4."
62473176|NCT02769494|EXPERIMENTAL|Mesalazine Group|Mesalazine Sustained-Release Tablets and 0.02L glycerol mixed, 2.5% mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. Daily treatment time of the drug is 8 am,12 pm and 4 pm.
62473177|NCT02769494|ACTIVE_COMPARATOR|Riboflavin Sodium Phosphate Group|wipe the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. Daily treatment time of the drug is am,12 pm and 4 pm.
62473178|NCT02294786|EXPERIMENTAL|Octreotide treatment|Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m\^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
62473179|NCT02294786|EXPERIMENTAL|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m\^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
62473180|NCT05056974|EXPERIMENTAL|UB-421 + chidamide|UB-421 + chidamide combination therapy
62116863|NCT00746330|EXPERIMENTAL|F12M - PL - F12D - MFF|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
61918309|NCT03042702|EXPERIMENTAL|Kevetrin 250 mg/m2 IV Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
62676223|NCT03531567|EXPERIMENTAL|Virtual Reality Mystic Isle Game|"Subjects in the treatment arm will complete a prescribed 2-month treatment using the virtual reality program Mystic Isle. The OT will follow the Treatment Arm Intervention Protocol, which provides standardized guidelines for grading the intensity, level of challenge, and types of games/activities of the intervention up or down. The OT will complete weekly phone calls with participant to discuss progress, answer any questions, and remotely make updates to the game as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the intervention will be 7 hours/week. The minimum amount of time spent on the intervention will be 3.5 hours/week."
62116864|NCT00746330|EXPERIMENTAL|F12D - F12M - MFF - PL|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
62305030|NCT02046135|ACTIVE_COMPARATOR|Sodium Chloride|At the start of surgery, patients in the control arm will receive D5% Normal Saline + 20 meq/L KCl at maintenance IVF. After 24 hours, standard IVF, not containing NaHCO3 or Na acetate will be administered for the duration of the PICU stay as required, determined by the clinicians primarily caring for the patient postoperatively.
62676224|NCT03531567|ACTIVE_COMPARATOR|Standard Home Exercise Program|"Subjects assigned to the control arm will complete the prescribed 2-month treatment. The OT will follow the Control Arm Intervention Protocol to design and prescribe the home exercise program. The OT will complete weekly phone calls with the participant to check on progress, adherence, and update the exercises as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the control intervention will be 7 hours/week. The minimum amount of time spent on the control intervention will be 3.5 hours/week."
62116865|NCT00746330|EXPERIMENTAL|MFF - F12D - PL - F12M|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
62305031|NCT01581190|EXPERIMENTAL|Bananas versus 6% carbohydrate beverage|
62305032|NCT04481100|EXPERIMENTAL|Experimental Group|Itraconazole capsule 100mg twice daily for 6 weeks concurrent with chemoradation.
62305033|NCT05115318||Adult Tourette syndrome patients|Patients will be assessed before (baseline), 4 (visit 2) and 12 weeks (visit 3) after use of Medical cannabis via inhaled dried buds or sublingual oil extract. The percentage of THC and CBD were pre-set to 10% and 2%, respectively. All patients received the same general instructions for treatment titration, which was to start with 1 drop or puff a day and increase by 1 drop or puff as needed. There was no fixed schedule for the incremental increases, thus each patient freely raised the dose as well as number of daily consumptions until clinical benefit was achieved or SE emerged over a follow-up period of 12 weeks.
62305034|NCT00582231||1|Participants that are starting penile injections therapy.
62305035|NCT06334133|EXPERIMENTAL|Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg QD|The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.
62305036|NCT06334133|EXPERIMENTAL|Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg BID|The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.
62305037|NCT06334133|PLACEBO_COMPARATOR|Placebo: 52 Week Double Blind Treatment Period|The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.
62305038|NCT00469508|ACTIVE_COMPARATOR|Modafinil|Modafinil 400mg oral dose taken daily for 12 weeks
62305039|NCT00469508|PLACEBO_COMPARATOR|Placebo|Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks
62305040|NCT01225406||third line naive|Children on second line or other regimen who switch or start third line regimen
62305041|NCT01225406||third line experienced|children who are on third line regimen
62305042|NCT00765583|EXPERIMENTAL|restylane|Restylane arm with different re-treatment schedules
62305043|NCT01647763|EXPERIMENTAL|HAL/RAR|hemorrhoidal artery ligation with rectoanal repair
62305044|NCT01647763|ACTIVE_COMPARATOR|Stapled hemorrhoidopexy|"procedure for prolapse and hemorrhoids (PPH)~Resection using a circular stapler"
62305045|NCT03669133|ACTIVE_COMPARATOR|Group A|Vitamin E 800 IU/daily for 24 weeks
62305046|NCT03669133|PLACEBO_COMPARATOR|Group B|Matching placebo for 24 weeks
62305047|NCT04382261|PLACEBO_COMPARATOR|Periodontitis quadrant|Patients undergo non surgical quadrant scaling and root planing
62473181|NCT00476281|OTHER|abnormal glucose tolerance|abnormal glucose tolerance
62473182|NCT01639534||Biomarkers, Carotid Stenting, Blood sample|Subjects requiring Carotid Stenting Procedure at Virginia Commonwealth University/Medical College of Virginia Health Systems
62305048|NCT04382261|ACTIVE_COMPARATOR|Periodontitis full mouth|Patients undergo non surgical full mouth scaling and root planing
62473183|NCT01538888|EXPERIMENTAL|WHOLE BODY VIBRATION|SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY
62473184|NCT03649477|PLACEBO_COMPARATOR|Placebo|matched placebo during first 8-weeks; prospectively randomized 1:1 to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods
62116866|NCT00746330|EXPERIMENTAL|PL - MFF - F12M - F12D|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
62116867|NCT00246012|EXPERIMENTAL|Intetumumab 3 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
62116868|NCT00246012|EXPERIMENTAL|Intetumumab 5 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs. If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
62116869|NCT00246012|EXPERIMENTAL|Intetumumab 10 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs.
62116870|NCT00246012|EXPERIMENTAL|Dacarbazine + intetumumab 5 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with stable disease (SD) or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 milligram per meter-square (mg/m\^2) intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
62116871|NCT00246012|EXPERIMENTAL|Dacarbazine + intetumumab 10 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m\^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
62116872|NCT00246012|EXPERIMENTAL|Dacarbazine + placebo [Phase 2]|Placebo will be administered intravenously over a period of 2 hr (±15 minutes). Commercially available dacarbazine will be administered at the dose of 1000 mg/m\^2 intravenously over a period of 60 minutes (± 30 minutes) prior to placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue with 10 mg/kg intetumumab alone.
62116873|NCT00246012|EXPERIMENTAL|Intetumumab 5 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
62305049|NCT01725763|OTHER|suspected PH|60 minute Cardiac MRI
62305050|NCT04974307|EXPERIMENTAL|Children with CLN3 disease|Children with CLN3 use the OrCam MyEye 2, a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs for text reading, facial recognition, and product identification. The study participants and parents/guardians were trained on how to use the device.
62473185|NCT03649477|EXPERIMENTAL|3.2 mg of LV-101|3.2 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
62473186|NCT03649477|EXPERIMENTAL|9.6 mg of LV-101|9.6 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
62473187|NCT04551976|EXPERIMENTAL|Mindful Video Game Then Laundry Group|Receive mindfulness prompt and play their video game first and fold laundry second.
62473188|NCT04551976|EXPERIMENTAL|Mindful Laundry Then Video Game Group|Receive mindfulness prompt and fold laundry first, play their video game second.
62473189|NCT04551976|NO_INTERVENTION|Control Video Game Then Laundry Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will play their video game first and fold laundry second.
62676225|NCT02645162|EXPERIMENTAL|Preschool|"* This arm will receive the community-based preschool intervention.~* The preschool sessions will include 2 groups per day (3 years 6months to 4 years 6 months in the morning session and 4 years 7 months to 5 year 6 months in the afternoon session at the time of enrolment)~* Each session will last 3 hours for 5 days per week.~* The expected CYL-to-child ratio will be 1:15; however, given the expected high level of local demand it may exceed to a maximum of 1:20 ratio."
62676226|NCT02645162|NO_INTERVENTION|Control|The control group will receive standard services available in the community.
61918310|NCT03042702|EXPERIMENTAL|Kevetrin 350 mg/m2 IV Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
62676227|NCT05304962|EXPERIMENTAL|Arm A|RGT-419B given alone as monotherapy
62676228|NCT05304962|EXPERIMENTAL|Arm B|RGT-419B in combination with Hormonal Therapy
61918311|NCT01035450|EXPERIMENTAL|Everolimus-eluting stent|
62473190|NCT04551976|NO_INTERVENTION|Control Laundry Then Video Game Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will fold laundry first and will play their video game second.
62305051|NCT04974307|EXPERIMENTAL|Children with Low vision without CLN3|Children with low vision not related to CLN3 use the OrCam MyEye 2, a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs for text reading, facial recognition, and product identification. The study participants and parents/guardians were trained on how to use the device.
62305052|NCT01318616|EXPERIMENTAL|Training group|
62473191|NCT00850174|EXPERIMENTAL|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
62473192|NCT00850174|ACTIVE_COMPARATOR|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
62473193|NCT05839834||Cancer|Patients with new diagnosis of cancers
62473194|NCT05839834||Non-cancer|Healthy participants
62473195|NCT00678717|ACTIVE_COMPARATOR|Healthy|Healthy volunteers
62473196|NCT00678717|EXPERIMENTAL|Chronic Visceral Pain|Chronic Visceral Pain patients. Participants will be tested before and after implantation of a Spinal Cord Stimulator (implantation of the Spinal Cord Stimulator is done as usual care and is not a study procedure)
62473197|NCT01098786||Healthy|
62676229|NCT04165486|EXPERIMENTAL|Part 1: ION464|ION464 will be administered at multiple-ascending doses by IT injection at regular intervals over 12 weeks.
62676230|NCT04165486|PLACEBO_COMPARATOR|Part 1: Placebo|ION464-matching placebo will be administered by IT injection at regular intervals over 12 weeks.
62116874|NCT00246012|EXPERIMENTAL|Intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
62305053|NCT03517436|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR)|
62305054|NCT01962662|EXPERIMENTAL|variable practice|EMG biofeedback training on force control muscle the goal of force level control training is 25%, 50%, 75%, and 100% of maximal strength.
62473198|NCT04957953||Pregnant Women Vaccinated against Covid-19|Woman over 18 years of age who has received at least one Covid-19 vaccine during her pregnancy, regardless of the trimester of pregnancy.
62473199|NCT05643911|EXPERIMENTAL|HFNC (Hight-flow oxygen therapy)|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes. Oxygen will be passed through a heated humidifier and continuously delivered through medium or large nasal cannulas (OptiflowTM, Fisher and Paykel Healthcare) depending on patient anatomy, with a gas flow of 50 litres per minute and the FiO2 will be adjusted to maintain a SpO2 between 95% and 98%.
62473200|NCT05643911|ACTIVE_COMPARATOR|Non-invasive ventilation (NIV)|In the NIV Group, patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance. The pressure-support level will be adjusted with the aim of an expired tidal volume of 6 to 8 ml per kilogram of predicted body weight, with a positive end-expiratory pressure (PEEP) of 5 cmH2O. The FiO2 will be adjusted to maintain a SpO2 between 95% and 98%.
62473201|NCT03593512|EXPERIMENTAL|PPN DBS|All patients will undergo bilateral PPN DBS
62473202|NCT04127656|EXPERIMENTAL|Amino Acid-Based Experimental Study Formula|Single-Arm Study
62116875|NCT00246012|EXPERIMENTAL|Dacarbazine + intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m\^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
62116876|NCT06676826|EXPERIMENTAL|Test Group (VCMX)|The periodontal infrabony defect will be opened by a papilla preservation flap, the root surface will be thoroughly cleaned with hand instruments and ultrasonic scalers, then the bony defect will be filled with a volume-stable collagen matrix (VCMX) only.
62473203|NCT04926480|EXPERIMENTAL|low flow Anesthesia group|Antioxidant parameters are measured in the low flow anesthesia group.
62305055|NCT01962662|EXPERIMENTAL|constant practice group|EMG biofeedback training on force control muscle the goal of force level control training is 100% of maximal strength.
62473204|NCT04926480|ACTIVE_COMPARATOR|high flow Anesthesia gruop|Antioxidant parameters are measured in the high flow anesthesia group.
62473205|NCT04438187|OTHER|Aggressive Arm|If an intubated patient is suspected of having an ICU-acquired HAP/VAP during the aggressive period, antimicrobials should be initiated immediately after quantitative or semi-quantitative endobronchial cultures are sent regardless of clinical status. This will include patients who, as determined by the attending intensivist, are in sepsis or septic shock. If, after 72 hours, cultures and other clinical data do not point to a pneumonia, the antimicrobials should be stopped in the absence of another source of infection.
61918312|NCT01035450|ACTIVE_COMPARATOR|Sirolimus-eluting stent|
61918313|NCT06142227|NO_INTERVENTION|Control Group|Routine dental treatment will be applied to the control group. No action will be taken.
62305056|NCT01962662|OTHER|control group|U/E exercise
62305057|NCT03019549|EXPERIMENTAL|Rosuvastatin|Period 1: 20 mg rosuvastatin administered once orally (PO)
62676231|NCT04165486|EXPERIMENTAL|Part 2: ION464|ION464 will be administered at the same doses as Part 1 by IT injection, at regular intervals, for 72 weeks.
62676232|NCT04165486|PLACEBO_COMPARATOR|Part 2: Placebo|ION464-matching placebo will be administered by IT injection, at regular intervals, for 72 weeks.
62676233|NCT01401075|ACTIVE_COMPARATOR|doxifluridine|oral chemotherapy with the 5-FU prodrug doxifluridine
62676234|NCT01401075|EXPERIMENTAL|doxifluridine + mistletoe extract|oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
62676235|NCT02845180|EXPERIMENTAL|3 Mo. Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 3 months.
62676236|NCT02845180|EXPERIMENTAL|6 Month Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 6 months.
62473206|NCT04438187|OTHER|Conservative Arm|If a patient is suspected of having an ICU-acquired HAP/VAP during the conservative period, quantitative or semi-quantitative endobronchial cultures should be sent. If the patient is in septic shock persistent hypotension requiring vasoactive medications to maintain mean arterial pressure (MAP) ≥65 mm HG or persistent lactic acidosis (\>2 mmol/L) despite adequate resuscitation) antimicrobials will be initiated immediately. If the patient has new onset organ dysfunction that is presumed to be due to infection (sepsis) then antimicrobials will be initiated at the discretion of the attending intensivist. In the absence of septic shock or sepsis (intensivist discretion), antimicrobials will not be initiated unless objective evidence of pneumonia is present or another documented source of infection is identified mandating treatment with antimicrobials.
62473207|NCT05088577|EXPERIMENTAL|Whole egg|Two whole eggs (50g each) to be eaten daily during 8 weeks
62473208|NCT05088577|EXPERIMENTAL|Annatto-enriched egg|Two whole eggs (50g each) enriched with annatto (Bixa orellana L.) to be eaten daily during 8 weeks. Dose of annatto: 1,2 mg bixin/kg of body weight.
62676237|NCT04204642||Cerebral amyloid angiopathy (CAA)|Cerebral amyloid angiopathy (CAA) patients
62676238|NCT06389695|EXPERIMENTAL|68Ga-NYM032 injection|
62116877|NCT06676826|ACTIVE_COMPARATOR|Control Group (Deproteinized bovine bone mineral)|The periodontal infrabony defect will be opened by a flap, the root surface will be thoroughly cleaned with hand instruments and ultrasonic scalers, then the bony defect will be filled with deproteinized bovine bone mineral with 10% collagen.
62116878|NCT03308461|EXPERIMENTAL|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
62116879|NCT02337569|EXPERIMENTAL|NPC-02|Oral dose
62116880|NCT02337569|PLACEBO_COMPARATOR|Placebo|Oral dose
62116881|NCT02783235|OTHER|cervical cancer|cervical cancer screening and training for ANMs/ASHAs/PHWs To develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
62116882|NCT01026233|EXPERIMENTAL|1|brentuximab vedotin
62116883|NCT04676568|ACTIVE_COMPARATOR|extravesical VVF repair|
62116884|NCT04676568|ACTIVE_COMPARATOR|Transvesical VVF repair|
62116885|NCT05695833|EXPERIMENTAL|Radiofrequency|Device
62116886|NCT05695833|ACTIVE_COMPARATOR|Nd Yag Laser|Device
62305058|NCT03019549|EXPERIMENTAL|Lanabecestat + Rosuvastatin|Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8
62305059|NCT01252966|EXPERIMENTAL|Cognitive Training|Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
62305060|NCT01252966|PLACEBO_COMPARATOR|Control Training|Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
62305061|NCT05325164|EXPERIMENTAL|Methadone|"DESCRIPTION:~Blinded methadone 1mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 0.5mg Q4H x 4 doses + 1.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.0 mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Second increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Third increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Fourth increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 1.0mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Second increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Third increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.5mg Q2H PRN (max 4 doses)~Fourth increase: 3.0mg Q4H x 4 doses + 6.0mg QHS + 1.5mg Q2H PRN (max 4 doses)"
62305062|NCT05325164|ACTIVE_COMPARATOR|Morphine|"DESCRIPTION:~Blinded morphine 5mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 2.5mg Q4H x 4 doses + 5.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 5.0 mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Second increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Third increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Fourth increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 5.0mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Second increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Third increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 12.5mg Q2H PRN (max 4 doses)~Fourth increase: 15.0mg Q4H x 4 doses + 30.0mg QHS + 12.5mg Q2H PRN (max 4 doses)"
62305063|NCT03322683|EXPERIMENTAL|EXPERIMENTAL GROUP|The intervention for this group consisted of 5 massage sessions with the PHYSIUM device for a month.
62305064|NCT03322683|EXPERIMENTAL|CONTROL GROUP|"The multimodal physical therapy program includes 10 sessions of:~* ultrasound pulsatil therapy (US) for 10 minutes.~* transcutaneous electric nerve stimulation (TENS) for 20 minutes.~* massage for 20 minutes."
62473209|NCT05088577|PLACEBO_COMPARATOR|Egg whites - Control|Two egg whites to be eaten daily during 8 weeks
62473210|NCT02476994|EXPERIMENTAL|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
62116887|NCT01649180|EXPERIMENTAL|Axitinib|Axitinib will be given orally and will continue until progression of disease.
62116888|NCT01793441|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to RG7314 in each stage (Stage I, II, III and IV) for 12 weeks.
62116889|NCT01793441|EXPERIMENTAL|RG7314|Participants will receive RG7314 orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
62473211|NCT02476994|ACTIVE_COMPARATOR|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
62473212|NCT00202722|ACTIVE_COMPARATOR|Remifentanil IVPCA|Bolus dose steps of 0.15 microgr/kg, with a 2-min lock-out time
62473213|NCT00628654||Volunteers|Serum samples will be obtained from volunteers, but no tissue specimens. Volunteers will complete a questionnaire.
62473214|NCT00628654||Patients with cancer|Ascites from patients with ovarian, peritoneal, and fallopian tube cancers for basic science studies
62473215|NCT03647254|EXPERIMENTAL|Patient Education Group|A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls
62116890|NCT01015404|EXPERIMENTAL|Experimental H|high volume (0.6mL、0.3% Trafermin)
62116891|NCT01015404|EXPERIMENTAL|Experimental L|low volume (0.2mL、0.3% Trafermin)
62116892|NCT01212991|EXPERIMENTAL|Enzalutamide|
62305065|NCT05646550|EXPERIMENTAL|Dose Escalation Part|In the dose escalation part, up to 7 dose cohorts will be included depending on occurrence of dose-limiting toxicity (DLT). Each dose cohort has a predefined day 3 dose level (DL): cohort 1, 78µg; cohort 2, 110µg; cohort 3, 150µg; cohort 4, 210µg; cohort 5, 300µg; cohort 6, 400µg; cohort 7, 600µg. Each dose cohort will consist of at least three patients evaluable for DLT. Maximum tolerated dose (MTD) is defined on at least six patients
62305066|NCT05646550|EXPERIMENTAL|Dose Expansion Part|CC-1 is administered as a 3-hour short-term intravenous infusion started at the MTD dose level identified in the dose escalation part of the study or based on the discretion of the sponsors delegate and DSMB recommendation supported by preliminary safety and efficacy data to constitute a modified MTD, e.g. to be one or more dose levels lower than the MTD determined. Patients can be treated simultaneously during the dose expansion phase. Patients must be hospitalized during step dosing, i.e. from day 1-4 (last dosing on day 3) of the first cycle. Thereafter inpatient treatment (overnight stay) depends on the discretion of the investigator, an outpatient treatment is preferred.
62305067|NCT01861197|EXPERIMENTAL|Dovitinib monotherapy|
62305068|NCT03946267|EXPERIMENTAL|IFCG = Infracyanine Green stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 ml of low-concentration (0.5 mg/mL, 0.05%) IFCG injected over the macular area with the infusion line closed.
62305069|NCT03946267|EXPERIMENTAL|BBG = Brilliant Peel stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 mL BBG at a concentration of 0.25 mg/mL (0.025%) injected over the macular area with the infusion line closed.
62305070|NCT05190575|EXPERIMENTAL|TST001|Drug: TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
62305071|NCT04415138||Robotic-assisted Group|
62305072|NCT04415138||Video-assisted Group|
62473216|NCT03647254|NO_INTERVENTION|Control group|Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate.
62116893|NCT01212991|PLACEBO_COMPARATOR|Placebo|
62116894|NCT04275817||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking: unintentional weight loss of ≥ 5% between two assessments, 2) Weakness: a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy: answer of no to the question Do you feel full of energy? from the 15-item Geriatric Depression Scale; 4) Slowness: average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level: PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
62305073|NCT05097911|EXPERIMENTAL|Advanced HCC patients|Patients will receive treatment as outlined until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. If scheduled dosing and study assessments are precluded because of a holiday, weekend, or other event, then dosing may be postponed to the soonest following date, with subsequent dosing continuing on a 21-day schedule. If treatment was postponed for fewer than 3 days, the patient can resume the original schedule.
62305074|NCT01495026|EXPERIMENTAL|Fixed dose combination product|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg
62305075|NCT01495026|EXPERIMENTAL|Dutasteride|Commercial formulation of Dutasteride 0.5mg
62305076|NCT01495026|EXPERIMENTAL|Harnal-D Tablets|Commercial formulation of Harna--D Tablets comprising 0.2mg Tamsulosin Hydrochloride
62473217|NCT02360761|ACTIVE_COMPARATOR|Lobectomy|Patients undergo lobectomy by thoracotomy or thoracoscopy/Video assisted thoracoscopic surgery(VATS).
62473218|NCT02360761|EXPERIMENTAL|Sublobar resection|Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.
62473219|NCT00814034||1:Tamoxifen|
62473220|NCT00814034||2:Steroidal Aromatase Inhibitor|
62473221|NCT00814034||3:Non-steroidal Aromatase Inhibitor|
62676239|NCT06395636|NO_INTERVENTION|Aim 1 - Validation|"1a. Development and Internal validation~* analyze Fitbit data (PA, HR, sleep) by applying ML methods to create an infection algorithm indicating onset of infection.~  1b. External Validation~* Once the ML classifier has been internally validated (using Lurie Children's data only) for its ability to detect the presence or absence of postoperative infection using LOSO cross-validation, where each subject is iteratively held out from the training data and used as a test set. External validation will involve applying this classifier to a newer cohort at LCH and cohorts at Loyola University Hospital and CDH and evaluating its performance."
62305077|NCT05778318||Control group|Patients without Lianhua Qingwen treatment.
62305078|NCT05778318||Observation Group|Patients with Lianhua Qingwen treatment.
62305079|NCT01823562|ACTIVE_COMPARATOR|Arm I (regular diet)|Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
62305080|NCT01823562|ACTIVE_COMPARATOR|Arm II (low polyphenol diet)|Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
62305081|NCT01823562|ACTIVE_COMPARATOR|Arm III (low ellagitannin diet)|Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
62305082|NCT01823562|EXPERIMENTAL|Arm IV (lower-dose lyophilized black raspberry gummy)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
62116895|NCT04275817||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.~In this study, an individual will be considered a CHI if they meet the following criteria: no history of dementia, no use of anti-dementia drugs, normal cognitive performance on cognitive tests and normal scores of ADL and IADL scales. Different participant subgroups will be identified: 1) Individuals will be classified as MCI if they meet the following criteria: Objective cognitive impairment (i.e., performance between 1.5 and 1.9 SDs below the age-appropriate mean) in one or two cognitive domains (i.e., episodic memory and/or executive function) and normal scores of ADL and IADL scales; 2) Individuals will be considered older adults with mild-stage major neurocognitive disorders"
62116896|NCT04275817||Individuals with MCR|"The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.~Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?)."
62305083|NCT01823562|EXPERIMENTAL|Arm V (higher-dose black raspberry gummy)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
62305084|NCT01823562|EXPERIMENTAL|Arm VI (lower-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
62305085|NCT01823562|EXPERIMENTAL|Arm VII (higher-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
62116897|NCT04408898|EXPERIMENTAL|ADP-A2M4 T cells in combination with pembrolizumab|
62305086|NCT02320331|EXPERIMENTAL|PILI Lifestyle Program|
62305087|NCT03751202|EXPERIMENTAL|Test product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
62305088|NCT03751202|ACTIVE_COMPARATOR|Reference product|ADVAIR DISKUS® 500/50
62305089|NCT01079715|EXPERIMENTAL|Propranolol|Oral Propranolol administration is the experimental arm of this study
62305090|NCT01079715|NO_INTERVENTION|Control|Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group
62305091|NCT04285723||alpelisib|Patients treated with alpelisib
62305092|NCT04510259|EXPERIMENTAL|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthesize the whole upper limb.
62305093|NCT04454814|ACTIVE_COMPARATOR|Rotary Engine-driven Instruments|The instrumentation protocol with Protaper Universal rotary files was began with an S1 file with a brushing movement to the two thirds of the working length and then an SX file was introduced to the two thirds of the working length with a brushing movement Afterwards, S1, S2, F1, F2 files in mesial roots and F4 files in distal roots were used to the working length, respectively. Protaper F2 instrument was then used to complete the canal preparation in mesial roots and Protaper F4 instrument was used to complete the canal preparation in distal roots.
62305094|NCT04454814|ACTIVE_COMPARATOR|Reciprocal Engine-driven Instruments|The instrumentation of the root canal in the Reciproc Blue group began with a R25 instrument with a slow in-and-out pecking movement.According to the manufacturer instructions, a #10 K-file was inserted to the canal to check the canal is free to 1 mm beyond the prepared canal section. After each 3 pecks or when a resistance was encountered the instrument was pulled out of the canal. Afterward, the R25 instrument was inserted in to root canal until approximately two thirds of the working length.RB R25 instrument was then used to complete the canal preparation in mesial roots and RB R40 instrument was used to complete the canal preparation in distal roots.
61918314|NCT06142227|EXPERIMENTAL|Experimental Group|Before dental treatment, the child will be read a story book with pictures of the dental clinic.
61918315|NCT02064075|ACTIVE_COMPARATOR|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day.
61918316|NCT02064075|ACTIVE_COMPARATOR|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day.
61918317|NCT02326545|EXPERIMENTAL|MindLight|MindLight is the video game being tested for effectiveness to reduce child anxiety
62116898|NCT06173258|ACTIVE_COMPARATOR|Water exchange alone|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
62116899|NCT06173258|EXPERIMENTAL|Water exchange plus Artificial intelligence (AI)|During colonoscopic insertion, residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion. Either a commercially available AI system (CAD-EYE, Fujifilm used in Evergreen General Hospital, Taiwan; Endo-AID, Olympus used in CTO Hospital, Italy) or a self-developed AI system with confirmed efficacy (Dalin Tzu-Chi Hospital, Taiwan) will be employed. During AI-assisted procedures, the AI will be activated during the withdrawal phase of the procedure, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device.
62116900|NCT06265636|EXPERIMENTAL|Experimental Group|Manual Therapy, exercise and percutaneous electrical nerve stimulation.
62305095|NCT03196713|OTHER|Tailored supervision|
61918318|NCT02326545|ACTIVE_COMPARATOR|Online CBT|Online CBT program for children
62116901|NCT06265636|ACTIVE_COMPARATOR|Control Group|Manual Therapy, exercise.
62305096|NCT03196713|OTHER|Regular supervision|
62305097|NCT06128837|EXPERIMENTAL|LY01610|Patients will consecutively receive LY01610 on Day 1 q2wk (every two weeks = one treatment cycle)
62676240|NCT06395636|EXPERIMENTAL|Aim 2 - Implementation of Algorithm|"2a. Exploratory \& Inductive analysis~* one transcript will be coded to generate initial themes, using qualitative analytic software 2b. Time to first contact with the healthcare system \& Healthcare use~* Cox regression model will be used to model the time to first contact, adjusted for covariates~* All comparisons between the two groups will be tested using a chi-square test. Cost will be modeled as a continuous variable and is expected to be skewed, as is typical of cost data. We will use a general linear model (GLM) to model cost outcomes."
61918319|NCT04230720|EXPERIMENTAL|Artificial Tears|One eye of each participant is randomized to receive Systane Complete artificial tears 4 times a day for 14 days
61918320|NCT04230720|NO_INTERVENTION|No Artificial Tears|One eye of each participant is randomized to receive no artificial tears for 14 days
61918321|NCT02944422||Males|Primary school Egyptian boys from 7-10 years.
62305098|NCT06128837|ACTIVE_COMPARATOR|Topotecan|Patients will consecutively receive Topotecan on Days 1-5 q3wk(every three weeks = one treatment cycle)
62305099|NCT02729129|EXPERIMENTAL|Commercially available highly-efficient facemask|
61918322|NCT02944422||Females|Primary school Egyptian girls from 7-10 years.
61918323|NCT05683184|OTHER|Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
61918324|NCT05683184|OTHER|Opioid Use Disorder|Patients diagnosed with opioid use disorder
62116902|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
62116903|NCT03587168||Healthy Controls|Healthy People
62305100|NCT02729129|SHAM_COMPARATOR|Sham facemask|
62305101|NCT05032508|EXPERIMENTAL|xylocaine|
62305102|NCT05032508|PLACEBO_COMPARATOR|Placebo|
62305103|NCT04037085|EXPERIMENTAL|Ketamine|Ketamine - IV after cord clamping; IV infusion for 12 hours OR in the weaning population IV Ketamine infusion for 12 hours in the Montefiore CTRC
62305104|NCT02306278|PLACEBO_COMPARATOR|vitamin capsules|vitamin capsules orally at the night before operation and 2 hours before surgery,respectively
62305105|NCT02306278|EXPERIMENTAL|gabapentin|gabapentin 600mg orally at the night before operation and 2 hours before surgery,respectively
62305106|NCT03455543|EXPERIMENTAL|Active Group|Treatment with active Provant Therapy System
62305107|NCT03455543|SHAM_COMPARATOR|Sham Group|Treatment with in-active (sham) Provant Therapy System
62676241|NCT02739828||Patients with Hidradenitis Suppurativa|Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.
61918325|NCT03721679|EXPERIMENTAL|Poly-ICLC treatment combination aPD-1or aPD-1L1|"Weeks 1 and 2: Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM ONLY twice a week with a 48-72 hour interval between the two injections~Weeks 3-25:~1. Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND~2. ONLY 1 of the following regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows:~   * Nivolumab (Opdivo), OR~  * Pembrolizumab (Keytruda), OR~  * Cemiplimab (Libtayo) OR~  * Atezolizumab (Tecentriq) OR~  * Durvalumab (Imfinzi) Follow up: After completion of treatment subjects may be contacted by telephone at least twice over 12 months, or longer with patient consent, in order to inquire on their health status (e.g., in remission, progressive disease, on new cancer treatment)."
61918326|NCT01500343|EXPERIMENTAL|Saccharomyces boulardii|
61918327|NCT01500343|PLACEBO_COMPARATOR|Placebo|
61918328|NCT04174950|ACTIVE_COMPARATOR|control group|Routine perioperative nursing intervention
61918329|NCT04174950|EXPERIMENTAL|experimental group|Perioperative ERAS Based Nursing Model
61918330|NCT04809077|OTHER|Reverse total shoulder replacement|Patients who underwent a total shoulder replacement using a reverse type implant (Delta Xtend or Zimmer TM)
61918331|NCT06050603|EXPERIMENTAL|Experimental_Aim1: Healthy Volunteers|All participants will receive all conditions and the order of all conditions will be counterbalanced across participants. Statistical comparisons will be within-subjects.
61918332|NCT06050603|EXPERIMENTAL|Experimental_Aim2: Amnestic Mild Cognitive Impairment|All participants will receive all conditions and the order of all conditions will be counterbalanced across participants. Statistical comparisons will be within-subjects.
62116904|NCT05355116|EXPERIMENTAL|Group A: Physiolab S1|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert an intermittent pressure of 25-50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will be 8℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
62305108|NCT04643041|EXPERIMENTAL|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3W) therapy and start watch and wait.
62305109|NCT02220374|EXPERIMENTAL|Supportive Finger Tape|Participants will be randomised to either placebo or supportive taping
62305110|NCT06004661|EXPERIMENTAL|AAA617|Participants will receive a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for 3 to 6 cycles according to eGFR calculation at screening and radiation absorbed dose results from Cycle1 Day1.
61918333|NCT01990144|EXPERIMENTAL|Bendamustine|Bendamustine is a novel chemotherapeutic agent, a hybrid of a purine analogue and an alkylator. It shows only partial in vitro cross-resistance with other alkylating agents and it is clinically well tolerated. In fact it has shown to be active in vitro against cell lines which are resistant to other alkylating agents. Preclinical data demonstrate that bendamustine acts in two distinct ways to kill cancer cells: it damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect may be attributable to its unique chemical structure.Bendamustine has demonstrated clinical activity in patients with chronic lymphocytic leukaemia, patients with relapsed indolent NHL, mantle cell lymphoma, multiple myeloma and several solid tumors.
61918334|NCT00951782|ACTIVE_COMPARATOR|High frequency TMS + smoking cue|
61918335|NCT00951782|SHAM_COMPARATOR|Sham TMS + smoking cue|
62473222|NCT05996926|EXPERIMENTAL|Three-Dimensional Transvaginal Ultrasound (3D TVS)|"In this study, Three-Dimensional Transvaginal Ultrasound will be employed as one of the interventions to evaluate Cesarean Scar Defects (CSD) and associated complications in symptomatic patients with a history of cesarean section.~A specialized ultrasound machine (Samsung WS80A) equipped with a transvaginal 2-11 MHz probe will be used for the Three-Dimensional Transvaginal Ultrasound examination. The examination will be conducted in the 1st half of the menstrual cycle. The ultrasound probe will be introduced into the posterior fornix of the vagina to capture three-dimensional images of the uterus and scar area. The examiner will identify and measure the characteristics of the Cesarean Scar Defects (CSD), including length, depth, width, volume, residual myometrial thickness, adjacent myometrial thickness, and presence of any branches."
62676242|NCT03142334|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).
62676243|NCT03142334|PLACEBO_COMPARATOR|Placebo|Participants receive placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).
61918336|NCT00951782|ACTIVE_COMPARATOR|Low frequency TMS +smoking cue|
61918337|NCT00951782|SHAM_COMPARATOR|Sham TMS - no cue|
62473223|NCT05996926|EXPERIMENTAL|Saline-Infused Sonography (Sonohystrography)|The Sonohystrography will be performed using a Toshiba ECCO CEE SSA-340A ultrasound equipment with a 7.5 MHz transvaginal probe. A sterile vaginal speculum will be inserted, the cervix cleansed with an antiseptic solution, and a thin Foley's catheter inserted into the cervical os. Sterile saline solution will be infused into the uterus through the catheter to distend the uterine cavity. The examiner will use the ultrasound probe to visualize and assess the uterine cavity, focusing on identifying and measuring Cesarean Scar Defects (CSD) characteristics, including depth, width, volume, and myometrial thickness.
61918338|NCT00951782|ACTIVE_COMPARATOR|High frequency TMS - no cue|
61918339|NCT00951782|ACTIVE_COMPARATOR|Low frequency - no cue|
61918340|NCT00790257|EXPERIMENTAL|Monolayer Cellular Device|Encapsulated human islets allotransplantation transplanted in subcutaneous tissue in Type 1 diabetes patient
61918341|NCT03633760|EXPERIMENTAL|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
61918342|NCT03633760|EXPERIMENTAL|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
61918343|NCT01063777|ACTIVE_COMPARATOR|1|
62473224|NCT00836758|EXPERIMENTAL|CPAP Device|Breathing event detection (AED) by the CPAP device will be compared to breathing event detection by a simultaneous PSG (manual PSG scoring).
61918344|NCT01063777|ACTIVE_COMPARATOR|2|
61918345|NCT05999539||Faller transtibial prosthetic users|Transtibial prosthetic users who fell at least once in the last year.
61918346|NCT05999539||Non-faller transtibial prosthetic users|Transtibial prosthetic users who have no fall history.
61918347|NCT02577276|EXPERIMENTAL|Tele-motion rehabilitation system|Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
61918348|NCT00146107|NO_INTERVENTION|1|
61918349|NCT00146107|EXPERIMENTAL|2|Weight loss
61918350|NCT00146107|EXPERIMENTAL|3|Exercise
61918351|NCT00146107|EXPERIMENTAL|4|Weight loss and exercise
62305111|NCT05004467|EXPERIMENTAL|Mobilization with movement technique|"The therapist applies supported pressure on right and left side and articular planes. Meanwhile, the patient executes active movements and the therapist is trying to find the specifies cervical joint to get partial or total painful relief or movements with restrictions.~If the therapist couldn´t relief or remove pain or restriction with the pressure permorfem, he will readjust pressure and slide in differents planes of motion. It is necessary achieve that aim.~After that, the patient stay in sit down raised position on a stool, with his back in contact with the wall.~Hip, knee and ankle of the patient suppor a certain position: 90º of flexion which will be checked with a conventional goniometer. His hands are on the thighs. The treatment lasts 5 minutes."
62305112|NCT05004467|SHAM_COMPARATOR|Placebo technique|Placebo manual technique is performed similar to experimental group technique but no slides are performed. The therapist simply embraces cervical region with boths hands, avoiding any pressure or any painfully caoture.
62473225|NCT02957994|EXPERIMENTAL|TAF Arm|Tenofovir alafenamide fumarate 25mg, 1 tablet once daily for 24 weeks
62676244|NCT02564770||Rheumatoid arthritis (RA) participants|Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.
62473226|NCT02624050|ACTIVE_COMPARATOR|Methohexital|Methohexital will be administered intravenously as a general anesthetic at a dosage of 1.5mg per kg of patient body weight.
62473227|NCT02624050|ACTIVE_COMPARATOR|Propofol|Propofol will be administered intravenously as a general anesthetic at a dosage of 2.5mg per kg of patient body weight.
62676245|NCT04414202||1 GROUP|"Patient with an Invasive breast cancer with a good prognosis that is accessible to breast-conserving surgery.~The treatment combines extended tumorectomy with axillary dissection (sentinel lymph node) in addition to 20 Gy of per-operative partial irradiation at the tumor Follow up after this treatment will scheduled 10 years"
61918352|NCT01440790|PLACEBO_COMPARATOR|Glucose bolus alone|50g glucose dissolved in water and consumed within 5 minutes.
61918353|NCT01440790|EXPERIMENTAL|Glucose sipping alone|50g glucose dissolved in water and consumed gradually over 3 hours.
62305113|NCT03331211||Chmotherapy combined with TKIs|Patients with ALL were treated by chmotherapy and TKIs(PDT-NFH-2016)
62305114|NCT03194425|EXPERIMENTAL|OAB|Patients with overactive bladder on sacral neuromodulation.
62305115|NCT03194425|EXPERIMENTAL|NOUR|Patients with non-obstructive urinary retention on sacral neuromodulation.
62305116|NCT05190835|OTHER|Hallux surgery|These are patients operated on for hallux without change of strategy compared to current care
62305117|NCT05190835|OTHER|Metatarsal paddle surgery|These are patients operated on for metatarsal paddle without change of strategy compared to current care
62676246|NCT02719860|EXPERIMENTAL|Green tea|
62676247|NCT02719860|EXPERIMENTAL|Black tea|
62676248|NCT02719860|PLACEBO_COMPARATOR|Placebo tea|
62676249|NCT02261532|EXPERIMENTAL|TAS-102|
62676250|NCT01115621|ACTIVE_COMPARATOR|Glutenfree diet|Glutenfree diet during the first year of life
62676251|NCT01115621|NO_INTERVENTION|Control - normal diet|
62676252|NCT05138822|EXPERIMENTAL|GSK3882347 + Placebo|Participants will be administered GSK3882347 plus placebo.
62676253|NCT05138822|ACTIVE_COMPARATOR|Nitrofurantoin+ Placebo|Participants will be administered nitrofurantoin plus placebo.
62676254|NCT03323476|EXPERIMENTAL|Discontinuation of maintenance treatment|
62676255|NCT03323476|ACTIVE_COMPARATOR|Maintenance of immunosuppressive treatment|
62676256|NCT03710733|ACTIVE_COMPARATOR|Sequential boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus sequential boost 10 Gy/4 fx (2.5 Gy/fx) to lumpectomy cavity
62676257|NCT03710733|EXPERIMENTAL|Concomitant boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus concomitant boost 8 Gy/15 fx (0.53 Gy/fx) to lumpectomy cavity
62676258|NCT06335979|EXPERIMENTAL|Cohort 1|Dose level 1
62676259|NCT06335979|EXPERIMENTAL|Cohort 2|Dose level 2
62473228|NCT00522262|EXPERIMENTAL|Exercise|Women randomized to the exercise intervention arm completed a one year aerobic exercise intervention of 225 minutes/week.
62676260|NCT06335979|EXPERIMENTAL|Cohort 3|Dose level 3
62676261|NCT06335979|EXPERIMENTAL|Cohort 4|Dose level 4
62676262|NCT06335979|EXPERIMENTAL|Cohort 5|Dose level 5
61918354|NCT01440790|ACTIVE_COMPARATOR|Glucose bolus plus 1g vitamin C|50g glucose dissolved in water and consumed in 5 minutes with 1g vitamin C
61918355|NCT01440790|EXPERIMENTAL|Glucose sipping plus 1g vitamin C|50g glucose dissolved in water and consumed gradually of 3 hours. In addition 1g vitamin C will be taken with the first mouthful of glucose solution.
62116905|NCT05355116|EXPERIMENTAL|Group B: Breg Vpulse|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a dynamic peak pressure of 50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will not be lower than 5.5℃. The selected pressure and temperature represents the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
61918356|NCT04652596|ACTIVE_COMPARATOR|Fresh Connect Produce Prescription Program|Investigators will partner with a community organization, About Fresh, that administers a produce prescription program (PPR) and operates mobile fresh foods markets. Participants randomized to this comparator will receive a stipend to Fresh Connect PPR to purchase fresh food items available at mobile markets and at independent farmers markets throughout Boston.
62116906|NCT05355116|EXPERIMENTAL|Group C: Cryo/Cuff|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The pressure and temperature that the device applies to the treatment area is non-modifiable and undefined. The device will be used according to the manufacturer's recommendations, which will represent the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
62473229|NCT00522262|NO_INTERVENTION|Control|Women randomized to the control arm were asked to maintain their regular lifestyle which meant no changes to their exercise or dietary intake. Women eligible for this trial were inactive and hence were expected not to increase their levels of physical activity in the control arm.
62676263|NCT06335979|EXPERIMENTAL|Cohort 6|Dose level 6
62676264|NCT06335979|EXPERIMENTAL|Cohort 7|Dose level 7
62676265|NCT06335979|EXPERIMENTAL|Cohort 8|Dose level 8
62676266|NCT03502772|EXPERIMENTAL|Pilates exercises group|
62676267|NCT03502772|ACTIVE_COMPARATOR|Home exercise program group|
62676268|NCT04633720|EXPERIMENTAL|Evaluation of intratidal compliance|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~1. Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg~2. Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg~3. Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg~4. Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
62676269|NCT03302611|EXPERIMENTAL|Surf Therapy|Participants receive a physical activity-based intervention, which in this arm is surf therapy. Each service member is paired with a surf instructor who typically works with them each week for the length of the program.
62676270|NCT03302611|ACTIVE_COMPARATOR|Hike Therapy|Participants receive a physical activity-based intervention, which in this arm is hike therapy. During hike therapy, service members may hike together or at a self-selected pace.
62676271|NCT03382860||Ventriculoperitoneal dysfunction|Patients with suspected ventriculo-peritoneal (VP) shunt dysfunction are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The patients are approached within this time frame.
62676272|NCT03382860||Normal Pressure Hydrocephalus (NPH)|Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
62676273|NCT05922033|EXPERIMENTAL|Patient-led self-titration of insulin|Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
62676274|NCT05922033|ACTIVE_COMPARATOR|Standard of care|Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
62473230|NCT01931007|EXPERIMENTAL|Autologous bone marrow concentrate|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.
62676275|NCT05610150|ACTIVE_COMPARATOR|Myobrace functional Appliance|Thirteen patients with developing skeletal Class II malocclusion will be treated with Myobrace functional appliance for six months.
62676276|NCT05610150|ACTIVE_COMPARATOR|Twin Block Functional appliance|Thirteen patients with developing skeletal Class II malocclusion will be treated with Twinblock functional appliance for six months.
62305118|NCT05190835|OTHER|Hallux and metatarsal pallet surgery|These are patients operated on for hallux and metatarsal paddle without change of strategy compared to current care
62305119|NCT01409889|ACTIVE_COMPARATOR|Diabetes Prevetion Program|Individuals in this group will receive the Diabetes Prevention Program
62305120|NCT01409889|ACTIVE_COMPARATOR|Healthy Living Program|Individuals in this group will receive the Healthy Living Program
62305121|NCT01776268|EXPERIMENTAL|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
62473231|NCT01931007|PLACEBO_COMPARATOR|Placebo|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo.
62473232|NCT00539110|EXPERIMENTAL|zolpidem|zolpidem or ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
62473233|NCT00539110|ACTIVE_COMPARATOR|ramelteon|ramelteon or zolpidem dosed at 2200 and 0200 per the feeding tube depending on randomization
62676277|NCT01210599|EXPERIMENTAL|IV infusion of pamidronate vs placebo|
62676278|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
62676279|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
62676280|NCT02545166||Dynamic controls|10 aortic aneurysm repair patients, 10 critical leg ischaemia patients, 10 endovascular aneurysm repair patients, 10 kidney transplant patients, and 10 free flap surgery patients.
62676281|NCT02545166||Local sampling patients|10 Patients undergoing revascularisation, 10 patients undergoing lower limb surgery with a tourniquet and 5 patients diagnosed with acute compartment syndrome.
62676282|NCT03014388|EXPERIMENTAL|Autogenous bone graft (Gold Standard).|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and to be used for bone augmentation with sinus lift.
62305122|NCT01776268|NO_INTERVENTION|No oral priming|No oral priming
62305123|NCT01568411|ACTIVE_COMPARATOR|TD-1211|
62305124|NCT01568411|ACTIVE_COMPARATOR|TD-1211+ itraconazole|
62305125|NCT00847561|EXPERIMENTAL|Family-based CBT|Family-based CBT. Participants will receive family-based cognitive behavioral therapy. Families in this group will learn about how to identify the signs and symptoms of anxiety, ways to cope with anxiety, relaxation techniques, and problem-solving skills. They will participate in 8, one-hour sessions, once/week with trained clinicians and 3 monthly booster sessions to reinforce what they learned.
62305126|NCT00847561|PLACEBO_COMPARATOR|Information Monitoring|Information Monitoring. Participants will receive a packet of information about anxiety. Participants in this group will be called monthly to monitor symptoms of anxiety.
62305127|NCT06057571|EXPERIMENTAL|TT-00420 (tinengotinib) Tablet Monotherapy|TT-00420 (tinengotinib) tablets will be administered once daily in 21-day cycles with initial dosage of 10 mg QD.
62305128|NCT05324215|ACTIVE_COMPARATOR|Transversalis Fascia Plane Block and Rectus Sheath Block Group|Transversalis Fascia Plane Block and Rectus Sheath Block will be administered to this group.
62305129|NCT05324215|SHAM_COMPARATOR|Control Group|No regional anesthesia technique will be applied to the control group.
62305130|NCT05962307||Hepatis Delta|Bulevirtide (BLV) at a dose of 2 mg/day subcutaneously
62305131|NCT03858582|EXPERIMENTAL|Arm A|Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles.
62305132|NCT03858582|EXPERIMENTAL|Arm B|Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles.
62305133|NCT03858582|EXPERIMENTAL|Arm C|Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles.
62305134|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
62305135|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
62305136|NCT01091350|ACTIVE_COMPARATOR|Diprifusor group|Propofol was infused via Diprifusor TCI (Target-controlled infusion)
62305137|NCT01091350|EXPERIMENTAL|Orchestra group|Propofol was infused via Orchestra TCI
62473234|NCT05118412|EXPERIMENTAL|Lucerne protein concentrate|Lucerne protein concentrate powder presented in the form of a shake.
62473235|NCT05118412|EXPERIMENTAL|Whey protein concentrate|Whey protein concentrate powder presented in the form of a shake.
62473236|NCT02182817||GA-Exposed Group|Exposure to general anaesthesia below 15 months of age
62473237|NCT02182817||Unexposed Group|Children not exposed to general anaesthesia or surgery from GUSTO cohort. (GUSTO: Growing Up Towards Healthy Outcomes in Singapore: a prospective longitudinal study providing normative data from the local population)
62473238|NCT01149473|EXPERIMENTAL|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
62305138|NCT00728338|EXPERIMENTAL|1|Martek Biosciences Corporation Neuromins Capsules 7.5 g DHA oil/day
62305139|NCT00728338|PLACEBO_COMPARATOR|2|7.5 g/ day olive oil
62305140|NCT01815398|ACTIVE_COMPARATOR|Computer skills training|26 sessions conducted 2-3 times a week to train in computer skills related to the workforce.
62305141|NCT01815398|EXPERIMENTAL|Cognitive Remediation|26 sessions conducted 2-3 times a week of cognitive remediation
62305142|NCT05006443|OTHER|Moderate or severe tricuspid regurgitation|40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.
62305143|NCT01389128|ACTIVE_COMPARATOR|Control Group|Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
62305144|NCT01389128|EXPERIMENTAL|Intervention Group|Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: pelvic mobility , lumbosacral massage and warm shower.
62473239|NCT01149473|ACTIVE_COMPARATOR|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
62473240|NCT03075761|EXPERIMENTAL|Intervention|Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
62473241|NCT03075761|ACTIVE_COMPARATOR|Control|Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
62473242|NCT02001441||No treatment|
62473243|NCT01720147|EXPERIMENTAL|Quercetin - Dietary Supplement|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required) for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
62473244|NCT04608188|EXPERIMENTAL|Summer Program|Children in the intervention will attend a summer day camp operated at their school.
62305145|NCT05508425|ACTIVE_COMPARATOR|water at room temperature|
62305146|NCT05508425|EXPERIMENTAL|hot water|
62305147|NCT05508425|EXPERIMENTAL|cold water|
62305148|NCT05508425|EXPERIMENTAL|hot water with tea bag|
62305149|NCT05508425|EXPERIMENTAL|room temperature water with tea bag|
62305150|NCT05508425|EXPERIMENTAL|cold water with tea bag|
62473245|NCT04608188|NO_INTERVENTION|No Program|The control children will not receive an intervention of any kind and will be asked to go about their summer as they typically would.
62473246|NCT03453476|EXPERIMENTAL|SRP and Fotosan 630|Scaling and root planing, photodynamic therapy using Fotosan 630
62473247|NCT03453476|NO_INTERVENTION|Control|Scaling and root planing only
62473248|NCT04391621|EXPERIMENTAL|Adipose Derived Stem Cell(ADSC) arm|In this arm, the participant selected keloid will receive a single dose intra-lesional Adipose derived Stem cells infiltration. This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6).
62473249|NCT04391621|ACTIVE_COMPARATOR|Triamcinolone Acetanoide (TAC) arm|"This arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid.~This will be a single dose infiltration of 40mg/cubic centimetres."
62473250|NCT05402553|ACTIVE_COMPARATOR|Intervention|
62473251|NCT05402553|PLACEBO_COMPARATOR|Control|
62473252|NCT05672264|EXPERIMENTAL|WB-EMS group|WB-EMS application
62473253|NCT05672264|ACTIVE_COMPARATOR|Control|Standardised physiotherapy (six sessions)
62305151|NCT05508425|EXPERIMENTAL|bubble water at room temperature|
62305152|NCT05508425|EXPERIMENTAL|cold bubble water|
62305153|NCT00759577|OTHER|Home titration|Patients were given drug to self titrate
62305154|NCT01506791|EXPERIMENTAL|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
62305155|NCT01506791|ACTIVE_COMPARATOR|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
62305156|NCT05087056|EXPERIMENTAL|ABCWY-24 Group|Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441.
62473254|NCT03491072|EXPERIMENTAL|Transcutaneous electrical nerve stimulation (TENS)|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
62473255|NCT03491072|ACTIVE_COMPARATOR|Fentanyl|Patients will receive IV fentanyl 1µg /Kg. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
62473256|NCT04395586||Culture-proven infected patients|
62473257|NCT05854186|EXPERIMENTAL|Telehealth solution|Telehealth solution offered.
62473258|NCT05854186|NO_INTERVENTION|Control|Usual care.
62473259|NCT03974685|EXPERIMENTAL|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single
62676283|NCT03014388|EXPERIMENTAL|Mineralized Plasmatic Matrix (MPM)|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will receive bone graft using Mineralized plasmatic matrix.
62676284|NCT05987137||Households|Interviews conducted with the parent or guardian of a child or children under age 13.
62676285|NCT05987137||Home-based providers|Interviews conducted with individuals who provide care in a home-based setting to children under age 13 who are not their own for five or more hours a week.
62676286|NCT05987137||Center-based Providers|Interviews conducted with directors of early care and educations programs that provide care to children not yet in kindergarten.
62676287|NCT05987137||Workforce (Classroom Staff)|Interviews conducted with classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
62305157|NCT05087056|EXPERIMENTAL|ABCWY-48 Group|Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721.
62305158|NCT06374810|EXPERIMENTAL|Breathwork Group|This group participated in 6 weeks of 90-minute Conscious Connected Breathwork groups conducted via Zoom. Participants attended 1 workshop per week
62305159|NCT06374810|PLACEBO_COMPARATOR|Waitlist control group|This group were told the 1st cohort of the study was full and they would be permitted to join cohort 2 in 6 weeks time. At the end of this waitlist period participants were invited to join the second cohort so long as they still met the inclusion criteria.
62305160|NCT03616743|EXPERIMENTAL|Brief pain and smoking arm|The experimental arm incorporated a novel psychoeducational component that addressed associations between cigarette smoking and chronic pain
62305161|NCT03616743|ACTIVE_COMPARATOR|Brief smoking control arm|"The brief smoking control arm was comprised of the 5A's of smoking cessation."
62305162|NCT00542698|NO_INTERVENTION|Control|Control group uses 90 minutes of standard diabetes education/ 7 days using the International Diabetes Center curriculum \& update phone call at 4 weeks.
62305163|NCT00542698|EXPERIMENTAL|Intervention|Interventional group received standard diabetes education, CGMS monitor, and extra educational topics including CGMS counceling.
62305164|NCT04407507|EXPERIMENTAL|Ivermectin|Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
62305165|NCT04407507|PLACEBO_COMPARATOR|Placebo|Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
62473260|NCT05963035|EXPERIMENTAL|18F-PFPN PET|A positron probe for the targeted melanin
62676288|NCT05954988|EXPERIMENTAL|2.5 mg LTI-03 BID|2.5 mg LTI-03 BID x 14 days
62676289|NCT05954988|EXPERIMENTAL|5 mg LTI-03 BID|5 mg LTI-03 BID x 14 days
62676290|NCT05954988|PLACEBO_COMPARATOR|Placebo|Matching placebo BID x 14 days
62305166|NCT02772380|EXPERIMENTAL|VT/ VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and termination through use of a defibrillator, will be carried out as the intervention in all subjects undergoing study procedures.
62305167|NCT00542815|EXPERIMENTAL|1|
62305168|NCT00542815|ACTIVE_COMPARATOR|2|
62305169|NCT03929042|EXPERIMENTAL|Posture Correction Girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
62305170|NCT00033735|EXPERIMENTAL|fluorouracil|
62305171|NCT00033735|EXPERIMENTAL|Irofulven|
62473261|NCT05506007|EXPERIMENTAL|[Part A] DA-5216|
62473262|NCT05506007|EXPERIMENTAL|[Part A] DA-5216-R|
62473263|NCT05506007|EXPERIMENTAL|[Part B] DA-5216(Fasting)|
62473264|NCT05506007|EXPERIMENTAL|[Part B] DA-5216(Fed)|
62473265|NCT02827266|EXPERIMENTAL|Epoetin beta|Participants will receive epoetin beta over an 8-week correction phase and a 4-week extension or continuation phase, for a total exposure of up to 12 weeks.
62473266|NCT03248635||Focus group|Male and female adults age 40-75
62473267|NCT01494532|EXPERIMENTAL|ropinirole|active treatment 4, 8, 12, 16, or 24mg/day
62473268|NCT01494532|PLACEBO_COMPARATOR|placebo|placebo comparator 4, 8, 12, 16, or 24mg/day
62676291|NCT02037880||MPS IIIA/B Subjects|Cohort will be followed for one year to assess natural history of the disease.
62676292|NCT04630886|EXPERIMENTAL|Tranexamic acid|The TXA group will receive 2% lidocaine with 1:100,000 epinephrine mixed 50/50 with 50mg/ml TXA (with 50% dilution, this will yield 1% lidocaine with 1:200,000 epi).
62676293|NCT04630886|ACTIVE_COMPARATOR|Control|The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
62676294|NCT05552495|EXPERIMENTAL|Reference-Test1-Test2|
62676295|NCT05552495|EXPERIMENTAL|Reference-Test2-Test1|
62473269|NCT01305681|ACTIVE_COMPARATOR|LoFric® catheters|LoFric® catheters during clean intermittent catheterization will be compared to non-LoFric® catheters during clean intermittent catheterization
62676296|NCT05552495|EXPERIMENTAL|Test1-Reference-Test2|
62116907|NCT05355116|EXPERIMENTAL|Group D: GameReady|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert an intermittent pressure of 5-50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will be 1℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
62116908|NCT05355116|EXPERIMENTAL|Group E: Physiolab Gel Therapy Wrap|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The pressure and temperature that the device applies to the treatment area is non-modifiable and undefined. The device will be used according to the manufacturer's recommendations, which will represent the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
62116909|NCT06513806|ACTIVE_COMPARATOR|granisetron group|will receive granisetron 3 mg iv bolus
62116910|NCT06513806|ACTIVE_COMPARATOR|pethidine group|will receive pethidine 25 mg iv bolus
62305172|NCT01607021||Chinese children with HCV RNA positive|"A sample of 200 children with a recent confirmation of anti-HCV-antibody positive and HCV RNA positive. All the children were treated with antiviral therapy, and the course of treatment depend on HCV Viral genotyping(ie, genotype 1,2,3,4 subtypes).~Primary Outcome Measures:~Virologic response \[ Time Frame: Weeks 2, 4, 6, 8, 10, and 12 \] Sustained virologic response (SVR, defined as plasma HCV RNA \< lower limit of quantification \[LLoQ\] at 24 weeks after treatment cessation) following antiviral treatment.~Secondary Outcome Measures: Safety and tolerability of therapy. \[ Time Frame: Up to 48 weeks \] measured by frequency of laboratory abnormalities , reported adverse events and discontinuations due to adverse events"
62305173|NCT04862416|EXPERIMENTAL|1A 30μg R0.6C Alhydrogel|3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
62473270|NCT02950987|EXPERIMENTAL|Whole Body MRI|"* Magnetic resonance imaging will be performed on participants~* Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
62473271|NCT01543217|ACTIVE_COMPARATOR|Control|Ususal care.
62473272|NCT01543217|ACTIVE_COMPARATOR|Intervention|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
62473273|NCT00007605|ACTIVE_COMPARATOR|1|Amiodarone or Sotalol
62473274|NCT00007605|ACTIVE_COMPARATOR|2|Sotalol
62473275|NCT02857322|OTHER|subjects with documented psychiatric pathology|
62473276|NCT05236764|EXPERIMENTAL|Alpha beta+ T cell depleted CD34+ stem cells|The patient will be receiving a donor stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The investigators will be specially treating the donor's blood cells used for the stem cell transplant.
62473277|NCT00068991|EXPERIMENTAL|1|Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session. After training, participants complete a post-training evaluation of the training sessions. Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
62116911|NCT02847312|ACTIVE_COMPARATOR|High avenanthramide, phenolic acid|66.8g Pepsico Oatmeal + 60g Oat cake
62116912|NCT02847312|ACTIVE_COMPARATOR|Low avenanthramide, medium phenolic acid|17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast
62116913|NCT02847312|PLACEBO_COMPARATOR|Control|69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast
62473278|NCT00068991|EXPERIMENTAL|2|Participants will be villagers considered influential members of their community. In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Participants will also attend additional support meetings monthly, from Months 2 to 15. They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
62676297|NCT05552495|EXPERIMENTAL|Test1-Test2-Reference|
62676298|NCT05552495|EXPERIMENTAL|Test2-Reference-Test1|
62676299|NCT05552495|EXPERIMENTAL|Test2-Test1-Reference|
62676300|NCT05542901|OTHER|Diabetic Group (DG)|Examine the effect of joint position sense on compliance with the prosthesis, balance and functional performance in individuals with lower extremity amputation due to diabetic polyneuropathy.
62676301|NCT05542901|OTHER|Traumatic Group (TG)|Examine the effect of joint position sense on compliance with the prosthesis, balance and functional performance in individuals with lower extremity amputation due to traumatic causes.
62676302|NCT02403037|EXPERIMENTAL|True Auricular Acupressure Group|Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
62676303|NCT02403037|SHAM_COMPARATOR|Sham Auricular Acupressure Group|Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
62676304|NCT02403037|OTHER|Standard Care Group|Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
62305174|NCT04862416|EXPERIMENTAL|1B 30μg R0.6C Alhydrogel + Matrix M1|3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
62305175|NCT04862416|EXPERIMENTAL|2A 30μg R0.6C Alhydrogel|5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
62305176|NCT04862416|EXPERIMENTAL|2B 30μg R0.6C Alhydrogel + Matrix M1|5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
62305177|NCT04862416|EXPERIMENTAL|3A 100μg R0.6C Alhydrogel|3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
62305178|NCT04862416|EXPERIMENTAL|3B 100μg R0.6C Alhydrogel + Matrix M1|3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
62305179|NCT04862416|EXPERIMENTAL|4A 100μg R0.6C Alhydrogel|5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
62676305|NCT02455323|EXPERIMENTAL|Suboccipital inhibitory|Suboccipital inhibitory pressure technique. According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues.
62116914|NCT05495334||All participants|Eligible and enrolled subjects with knee OA pain who require treatment on the target knee as a part of pain management.
62116915|NCT03236064|EXPERIMENTAL|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
62116916|NCT00868569|EXPERIMENTAL|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.
62305180|NCT04862416|EXPERIMENTAL|4B 100μg R0.6C Alhydrogel + Matrix M1|5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
61918357|NCT04652596|ACTIVE_COMPARATOR|Grocery store gift cards|Participants randomized to this comparator will receive grocery gift cards redeemable at conventional grocery stores.
62116917|NCT00868569|ACTIVE_COMPARATOR|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
62305181|NCT04575129||Study Group|No intervention will be applied
62305182|NCT01444391|EXPERIMENTAL|Tympanostomy Tube Placement|
62305183|NCT03976232|EXPERIMENTAL|tDCS-Group|Participants of this arm will receive tDCS and Conventional therapy for 2 weeks.
62116918|NCT05001945|PLACEBO_COMPARATOR|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
62116919|NCT05001945|EXPERIMENTAL|Dose 1 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
62116920|NCT05001945|EXPERIMENTAL|Dose 2 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
61918358|NCT01018446|EXPERIMENTAL|Busulfan, Pharmacokinetic|To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.
62305184|NCT03976232|EXPERIMENTAL|CST- Group|Participants of this arm will receive CST and Conventional therapy for 2 weeks.
62305185|NCT03976232|ACTIVE_COMPARATOR|combination of tDCS and CST|Participants of this arm will receive CST+ tDCS and Conventional therapy for 2 weeks.
62305186|NCT04463030|ACTIVE_COMPARATOR|Liposomal vitamin C, 1 gram|Participants will consume 1 gram on study day
62305187|NCT04463030|ACTIVE_COMPARATOR|Liposomal vitamin C, 2 grams|Participants will consume 2 grams on study day
62305188|NCT04463030|ACTIVE_COMPARATOR|Liposomal vitamin C, 5 grams|Participants will consume 5 grams on study day
62305189|NCT04463030|PLACEBO_COMPARATOR|Placebo|Participants will consume placebo on study day
62116921|NCT05001945|EXPERIMENTAL|Dose 3 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
62116922|NCT05001945|PLACEBO_COMPARATOR|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
62116923|NCT05001945|EXPERIMENTAL|Dose (Part II)|MLS-101 tablet(s) by mouth once daily.
62305190|NCT01633060|EXPERIMENTAL|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
62305191|NCT01633060|PLACEBO_COMPARATOR|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
62676306|NCT02455323|EXPERIMENTAL|Spinal Manipulative|Suboccipital inhibitory pressure technique. This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility.
62676307|NCT02455323|EXPERIMENTAL|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
62676308|NCT02455323|PLACEBO_COMPARATOR|Control group|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
62676309|NCT01067911|ACTIVE_COMPARATOR|1|In this study subjects will consume test meals containing vegetable oils (soy) and butter
62676310|NCT01067911|ACTIVE_COMPARATOR|2|In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
61918359|NCT02387255||Normal Volunteers|60 normal volunteers will be recruited. Each volunteer will undergo a single MRE scan (with Resoundant driver System ) of their abdominal aorta.
62116924|NCT01263730|ACTIVE_COMPARATOR|Tai Chi Training|The active group will be given 12 weeks of tai chi training
62116925|NCT01263730|NO_INTERVENTION|Waitlist control group|There is a waitlist control group that will receive the training following a 12 week no treatment period of time
62116926|NCT06288932|EXPERIMENTAL|Mycophenolate Mofetil (MMF) Treatment|"Patients in this arm will receive Mycophenolate Mofetil (MMF) at a starting dose of 500mg twice daily along with Prednisolone.~The pediatric dose of MMF will be calculated by 30mg/kg/day. Dose adjustment will be based on treatment response, with potential increases to 750mg twice daily or 1g twice daily.~MMF will be administered for a specific duration, as determined by the study design."
62116927|NCT06288932|NO_INTERVENTION|Standard Treatment Control|Patients in this arm will receive the standard treatment for ITP, which may include corticosteroids (prednisolone) commonly used for ITP management.The treatment regimen will be determined based on current standard guidelines and clinical practice.
62116928|NCT03887624|EXPERIMENTAL|Experimental group|Ethosuximide(2 weeks) + Escitalopram (4 weeks)
62305192|NCT04663620|ACTIVE_COMPARATOR|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
62116929|NCT03887624|PLACEBO_COMPARATOR|Control group|Placebo(2 weeks)+Escitalopram(4 weeks)
62305193|NCT04663620|PLACEBO_COMPARATOR|No Saving Babies Lives Programme|Control arm
62305194|NCT01336101|OTHER|SFA stenting|
62116930|NCT01023490|PLACEBO_COMPARATOR|Placebo|
62116931|NCT01023490|ACTIVE_COMPARATOR|Vitamin D|34,500 IU vitamin D per week
62116932|NCT05570994|EXPERIMENTAL|177Lu HTK03170 Phase I/II|"Phase I, the administered activity will be 1.1 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes. Initial Activity (IA) escalation will only occur on the initial dosimetry IA, with an increase of 30% over the initial IA (used for dosimetry) at each subsequent level ( 1.65 GBq, 2.5 GBq, 3.7 GBq) in up to 12 participants. Personalized dosimetry will be calculated for each subject.~Phase II, subjects will be treated with an initial IA of 177Lu-HTK03170 at the MTIA as determined during Phase I or 13.7 GBq whichever is lower. Treatment is administered as an intravenous infusion over a time of 10 - 30 minutes. Personalized dosimetry will be calculated for each subject so that subsequent treatments will be estimated to remain within the absorbed cumulative dose limits of 28Gy and 35Gy for kidneys and salivary glands, adjusted iteratively over the 4 remaining treatment cycles separated by 8 weeks. Up to 32 subjects will be enrolled to continue efficacy evaluation."
62116933|NCT02427698|ACTIVE_COMPARATOR|cyrolipolysis|
62116934|NCT02427698|ACTIVE_COMPARATOR|cryolipolysis plus subcision|
62116935|NCT00855465|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521)_individual dose titration|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
62116936|NCT00855465|PLACEBO_COMPARATOR|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks
62305195|NCT04566536||Surgery|Patients ≥ 18 years old scheduled for robotic surgery (all specialties except ENT)
62305196|NCT01023529||Prostate cancer|Patients with incurable prostate cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
62305197|NCT01023529||Rectal Cancer|Patients with incurable rectal cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
62305198|NCT01370070|EXPERIMENTAL|MK-2206|
62305199|NCT00231478|EXPERIMENTAL|1|
62305200|NCT00231478|EXPERIMENTAL|2|
62305201|NCT02180386|EXPERIMENTAL|Experimental group|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
62676311|NCT01067911|ACTIVE_COMPARATOR|3|In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
62676312|NCT01067911|ACTIVE_COMPARATOR|4|In this study subjects will consume test meals containing vegetable oils (canola) and butter
62676313|NCT01282138|EXPERIMENTAL|Patanol|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
62676314|NCT01282138|PLACEBO_COMPARATOR|Tears Naturale II|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
62676315|NCT06247215|EXPERIMENTAL|Experimental|Participants will evaluate the culturally-tailored resilience-building intervention prototype
62676316|NCT02441257|EXPERIMENTAL|control ventilation|patients are scheduled to receive control or spontaneous ventilation
62676317|NCT00433511|ACTIVE_COMPARATOR|Arm I (chemotherapy, placebo)|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV over 20-30 minutes, and placebo IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo IV over 30-90 minutes on day 1. Treatment with paclitaxel and placebo repeats every 3 weeks for 4 courses.
62676318|NCT00433511|EXPERIMENTAL|Arm II (chemotherapy, bevacizumab)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses.
62676319|NCT00433511|EXPERIMENTAL|Arm III (chemotherapy, bevacizumab monotherapy)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab as in arm II. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab as in arm II. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses. Beginning 2 months later, patients then receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab alone repeats every 3 weeks for 10 courses.
62116937|NCT03760627|EXPERIMENTAL|Refugees Mindfulness Resiliency Training|The Collateral Repair Project (CRP) will conduct a Mindfulness Resiliency Training Program (MRTP) for refugees residing in Amman, Jordan. A small support group will demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
62676320|NCT04817800|EXPERIMENTAL|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|
62676321|NCT04817800|EXPERIMENTAL|100 μg Beclomethasone dipropionate, Nasal Spray|
62676322|NCT04817800|ACTIVE_COMPARATOR|RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)|
62676323|NCT06235905|OTHER|SPN-820 6 x 400 mg capsules|
62676324|NCT03727061|EXPERIMENTAL|Arm A(porfimer sodium, I-PDT|Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later.
62676325|NCT05306015|EXPERIMENTAL|test group|Patients undergoing brain-computer interface-based mindfulness meditation training during the perioperative period of radiofrequency ablation.
62676326|NCT05306015|ACTIVE_COMPARATOR|control group|Patients receiving routine care for radiofrequency ablation.
62116938|NCT03760627|PLACEBO_COMPARATOR|Control arm|The control group will receive the training after the study group at 2 months and the control group will then become the study group for the new session. A new group of 20 participants will be recruited who will act as a control for that session. The surveys from the control group will be compared with the study group at 0 and 2 months. Each session will last for two months. The control group will receive the training at the end of the two months. This process will be repeated for a total of nine sessions over a total period of 12 months.
62116939|NCT02427633|NO_INTERVENTION|Control|Randomized to standard care (control group) - observations only
62305202|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
62676327|NCT06012695|EXPERIMENTAL|monotherapy in advanced solid tumors|Subjects with advanced solid tumors will be treated with NBM-BMX monotherapy at different dose levels depending on the order of their enrollment.
62676328|NCT06012695|EXPERIMENTAL|combination therapy in newly diagnosed glioblastoma|Subjects with newly diagnosed glioblastoma will be treated with NBM-BMX at different dose levels in combination with the standard of care treatment (concomitant RT/TMZ followed by adjuvant TMZ). In the expansion study, Subjects will be treated with NBM-BMX at the recommended Phase 2 dose (RP2D) in combination with RT/TMZ.
62676329|NCT05549453|EXPERIMENTAL|SNBT device use|SNBT device is used for motor cortex localization, motor threshold determination and for targeting the intracranial electric field induced by the device to the intarcranial location required for the use of the device for its intended use
62473279|NCT00068991|EXPERIMENTAL|3|Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
62116940|NCT02427633|EXPERIMENTAL|UKRC 1997|Randomized to modified UKRC 1997 - Intervention and Observations
62116941|NCT02427633|EXPERIMENTAL|UKRC 2010|Randomized to modified UKRC 2010 - Intervention and Observations
62676330|NCT05275244||Osteoarthritis Group|The patients diagnosed with single or preferential symptomatic osteoarthritis of the shoulder or hip treated with KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%), and ankle or base of the thumb treated with KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%). Each patient will be administrated three injections, one per week.
62676331|NCT05243316|ACTIVE_COMPARATOR|Patients with clamping of the chest tube|Patients with 6hour clamping prior to removal
62676332|NCT05243316|SHAM_COMPARATOR|Patients without clamping of the chest tube|Patients will have chest tube removed immediately
62676333|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
62676334|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
62676335|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
62116942|NCT05572801|NO_INTERVENTION|ARM A: HPV positive standard of care follow-up|The national follow-up program + collection of blood samples for retrospective translational research
62116943|NCT05572801|EXPERIMENTAL|ARM B: HPV positive ctDNA guided imaging in follow-up|The national follow-up program + ctDNA guided additional imaging + collection of blood samples for retrospective translational research
62116944|NCT05572801|NO_INTERVENTION|ARM O: HPV negative observational arm|"Patients with HPV negative disease will be included in an observational arm (ARM O)~ARM O: The national follow-up program + collection of blood samples for retrospective translational research"
62116945|NCT02838342|EXPERIMENTAL|Metronomic cyclophosphamide and interferon-alpha|
62305203|NCT04664491|EXPERIMENTAL|Standardized management|Patients will be managed according to recommendations in GOLD guideline and China's guidelines for COPD care.
62676336|NCT04707183|PLACEBO_COMPARATOR|Control Arm|1.0mg/kg/hr IV lidocaine infusion
62676337|NCT04707183|EXPERIMENTAL|Treatment Arm|10 mL of 2% lidocaine via ESPB
62676338|NCT02061956||HCC received TACE|Patients with HCC in cancer center, Sun Yat-sen University received TACE between 2011.01-2011.12
62116946|NCT02669524|ACTIVE_COMPARATOR|T2D + OGTT + LY2409021|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
62116947|NCT02669524|PLACEBO_COMPARATOR|T2D + OGTT + placebo|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor.
62305204|NCT04664491|OTHER|Usual care|Patients will undergo usual care according to current clinical practice in study sites.
62305205|NCT02680288|PLACEBO_COMPARATOR|Oral Placebo|Oral inert treatment
62305206|NCT02680288|EXPERIMENTAL|Active Treatment, Low-Dose|Lorcaserin 10 mg, single dose
62305207|NCT02680288|EXPERIMENTAL|Active Treatment, High-Dose|Lorcaserin 20 mg, single dose
62305208|NCT03429647|OTHER|Sigmoid perfusion|Measured by visible light spectroscopy
62676339|NCT05800847|PLACEBO_COMPARATOR|Control|Patients in this arm will be receiving 100 mg placebo q8h for 2 days followed by 300 mg placebo q8h for 12 days. Patients will also receive 30 pills of hydrocodone-acetaminophen 5-325 mg q4-6h as needed.
62676340|NCT05800847|EXPERIMENTAL|Gabapentin|Patients in this arm will be receiving 100 mg gabapentin q8h for 2 days followed by 300 mg gabapentin q8h for 12 days. Patients will also receive 30 pills of hydrocodone-acetaminophen 5-325 mg q4-6h as needed.
62676341|NCT03685435||Non-fasting patients|We will examine non-fasting patients using bedside ultrasound. First we examine the gaster in a supine position. Then we repeat the procedure in a right lateral position.
62676342|NCT06126744|EXPERIMENTAL|MVR-C5252|Open label single arm infusion of MVR-C5252, genetically engineered type 1 oHSV (oncolytic herpes simplex viruses) into the tumor via Convection-enhanced delivery (CED) a modality that can bypass the BBB (Blood Brain Barrier), allowing the intracranial delivery through the BBB and avoiding systemic toxicities.
62676343|NCT03915054|ACTIVE_COMPARATOR|AREG-TRIGGER|"Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media."
62116948|NCT02669524|ACTIVE_COMPARATOR|T2D + IIGI + LY2409021|Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
62116949|NCT02669524|PLACEBO_COMPARATOR|T2D + IIGI + placebo|Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor.
62305209|NCT03028493|EXPERIMENTAL|Adapted SAFE Intervention|Adapted version of the SAFE Health Behavior and Exercise intervention.
62305210|NCT03028493|ACTIVE_COMPARATOR|Original SAFE Intervention|Original version of the SAFE intervention.
62676344|NCT03915054|ACTIVE_COMPARATOR|CONTROL-TRIGGER|Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
62676345|NCT01192477|EXPERIMENTAL|Ozone 0.1 ppm|
62676346|NCT01192477|EXPERIMENTAL|Ozone 0.2 ppm|
62676347|NCT01192477|SHAM_COMPARATOR|Filtered air|
62305211|NCT00003018|EXPERIMENTAL|Chemotherapy|dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
62676348|NCT00948207|EXPERIMENTAL|My Living Story|"My Living Story elicits a dignity-enhancing life story via a telephone interview, and delivers the edited transcript on the patient's personal miLivingStory social network. miLivingStory also provides a direct link to miStory, a life review education website with links to high quality websites that provide cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.~miLivingStory and miStory are both password protected."
62676349|NCT00948207|ACTIVE_COMPARATOR|My Own Resources|"My Own Resources offers usual care access to high quality websites that provide cancer information, databases to do your own research, social support, and interactive planning tools. Participants will receive access to the website miOwnResources."
62676350|NCT04983511|EXPERIMENTAL|Electrical Epidural Stimulation Test (EST)|Postpartum women are given EST to predict epidural catheter reactivation for their subsequent procedures (i.e. tubal ligation).
62676351|NCT02443077|EXPERIMENTAL|Arm I (ibrutinib, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen.~BEAMi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1.~CBVi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2.~TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
62676352|NCT02443077|PLACEBO_COMPARATOR|Arm II (placebo, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.~TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I."
62676353|NCT00629642|EXPERIMENTAL|I.Solifenacin succinate 10mg (2x5mg 1/day)|Oral
62676354|NCT00629642|EXPERIMENTAL|II.Solifenacin succinate 5mg (5mg 1/day)|Oral
62676355|NCT00629642|ACTIVE_COMPARATOR|III.Oxybutynin hydrochloride 15mg (5mg 3/day)|Oral
62676356|NCT00629642|PLACEBO_COMPARATOR|IV. Placebo|Oral
62676357|NCT05694208|EXPERIMENTAL|Experimental group|The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
62676358|NCT05694208|NO_INTERVENTION|Control Group|It is the group in which no intervention will be made other than data collection.
62676359|NCT05340660|EXPERIMENTAL|ALS Patient|
61918360|NCT02387255||Patients with AAA|Fifty to sixty five patients with AAA will be recruited. These patients will undergo MRE (with Resoundant driver system) of their AAA every six months for three years, or until the study ends or until the time of surgical repair or death due to rupture of AAA or other causes.
62676360|NCT01515527|EXPERIMENTAL|Cladribine + Cytarabine Alt. with Decitabine|"Induction cycle: Cladribine intravenous (IV) over approximately 1 to 2 hours, daily on days 1-5 combined with Cytarabine subcutaneous (SQ) twice daily on days 1-10. Cytarabine should be administered approximately 3-6 hours following the start of the cladribine infusion.~Consolidation cycle: Cladribine IV over 1 to 2 hours, daily on days 1-3 combined with Cytarabine SQ twice daily on days 1-10. Cytarabine should be administered 3-6 hours following the start of the cladribine infusion.~Alternating with: Decitabine IV over 1 to 2 hours, daily on days 1-5."
62676361|NCT02544087|NO_INTERVENTION|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
62676362|NCT02544087|OTHER|Clearing heat|Treat with KDZ injection on the basis of basic treatment
62676363|NCT02544087|OTHER|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
62676364|NCT02544087|EXPERIMENTAL|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
62676365|NCT03099863|PLACEBO_COMPARATOR|Standard Care|Standard cystoscopy with normal saline solution.
62676366|NCT03099863|ACTIVE_COMPARATOR|Neosporin G. U. Irrigant|Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
62676367|NCT05299970|EXPERIMENTAL|fermented porridge|this study arm participant will consume fermented millet porridge, daily
62676368|NCT05299970|ACTIVE_COMPARATOR|Non-fermented porridge|this study arm participants will consume non-fermented millet porridge, daily
62676369|NCT05415527|OTHER|patients with inoperable high-grade ovarian carcinoma|Evaluation of sarcopenia in patients with inoperable high-grade ovarian carcinoma as part of optimised management
62676370|NCT04874779||Acute kidney injury (AKI) group|Acute kidney injury (AKI) group met the guidelines of Kidney Disease, Improving Global Outcomes (KDIGO)
62676371|NCT04874779||NON-Acute kidney injury (non-AKI) group|NON-Acute kidney injury (non-AKI) group not met the guidelines of Kidney Disease Improving Global Outcomes (KDIGO)
62676372|NCT06662422|EXPERIMENTAL|Electrostimulation|Device will be turned on to send electrostimulation.
62676373|NCT06662422|SHAM_COMPARATOR|Sham - no electrostimulation|Device will be toggled to Sham so no electrostimulation will be given.
62676374|NCT00049309|NO_INTERVENTION|Control|Usual diet
61918361|NCT02387255||Open Surgical Repair Patients|Fifty to sixty five patients patients undergoing open surgical repair will be recruited and undergo MRE (with Resoundant driver system) prior to surgery
61918362|NCT05524298||Elderly Patients With Low Grade Non-Hodgkin Lymphoma|"Elderly Patients With Low Grade Non-Hodgkin Lymphoma Treated With Immunotherapy Or Immunochemotherapy And/Or Radiotherapy.~Assess QoL (quality of life) at baseline, at the end of treatment and after 1 year from the start of the therapy."
61918363|NCT03230669|NO_INTERVENTION|Control|this arm receives treatment as usual and no intervention.
61918364|NCT03230669|EXPERIMENTAL|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
61918365|NCT05287542|EXPERIMENTAL|Hypnotic suggestion|During the first phase of the study, two groups will receive identical hypnotic inductions followed by targeted suggestion for one group and non-targeted suggestion for the other. The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
61918366|NCT05287542|ACTIVE_COMPARATOR|Mindfulness|The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
61918367|NCT05287542|NO_INTERVENTION|No treatment|The passive control group receives no intervention
61918368|NCT04720261|OTHER|Caplacizumab|All patients in the study are aTTP and needs to be treated by caplacizumab. The duration of this treatment will be evaluated through the ADAMTS 13 activity.
62676375|NCT00049309|EXPERIMENTAL|Flaxseed diet|30 gram flaxseed dietary modification
62305212|NCT00649961|EXPERIMENTAL|Melatonin Open Label Single Arm|Infants born less than 31 weeks gestation who are less than 7 days old
61918369|NCT02155946|EXPERIMENTAL|active tDCS + mnemonic strategy training|Group receives active brain stimulation plus memory rehabilitation
61918370|NCT02155946|ACTIVE_COMPARATOR|sham tDCS + mnemonic strategy training|Group receives sham brain stimulation plus memory rehabilitation
61918371|NCT02155946|ACTIVE_COMPARATOR|active tDCS + autobiographical memory recall|Group receives active brain stimulation plus reminiscence training
61918372|NCT02155946|ACTIVE_COMPARATOR|sham tDCS + autobiographical memory recall|Group receives sham brain stimulation plus reminiscence training
61918373|NCT04561999||Patients with Superficial Lymphadenopathy|
61918374|NCT04235010|EXPERIMENTAL|Manual toothbrush|Patients used manual orthodontic toothbrush (Oral B Ortho, Procter \& Gamble, USA) for four months
61918375|NCT04235010|EXPERIMENTAL|Genius toothbrush|Patients used genius orthodontic toothbrush (Oral B Genius 8900, Procter \& Gamble, USA) for four months
61918376|NCT00327470|EXPERIMENTAL|Open Label|
61918377|NCT05930704|EXPERIMENTAL|SHR-2017 injection|
61918378|NCT05930704|PLACEBO_COMPARATOR|Placebo|
61918379|NCT02052856||ACL Surgery|All English speaking patients 16 years and older having anterior cruciate ligament (ACL) surgery without any other surgery to knee or contralateral knee.
61918380|NCT01895361|EXPERIMENTAL|High-dose SelG1 (Selg1 5.0 mg/kg)|IV Infusion, once every 4 weeks through Week 50
62305213|NCT06656949|ACTIVE_COMPARATOR|sentinel lymph node mapping with One injection site (cervix) group|injecting indocyanine green (ICG) dye Intraoperative in cervix
62305214|NCT06656949|EXPERIMENTAL|sentinel lymph node mapping with two injection site (cervix-uterus) group|injecting indocyanine green (ICG) dye Intraoperative in cervix and uterus
62305215|NCT02567695|EXPERIMENTAL|Treatment Sequence 1|Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 1 followed by Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 2.
62305216|NCT02567695|EXPERIMENTAL|Treatment Sequence 2|Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 1 followed by Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 2.
62305217|NCT02990338|ACTIVE_COMPARATOR|Pd (pomalidomide + dexamethasone)|Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (\>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 241.6 weeks).
62676376|NCT00049309|EXPERIMENTAL|Low fat diet|Low fat dietary modification
62676377|NCT00049309|EXPERIMENTAL|Low fat + Flaxseed diet|Low fat and 30 gram flaxseed dietary modification
61918381|NCT01895361|EXPERIMENTAL|Low-dose SelG1 (Selg1 2.5 mg/kg)|IV Infusion, once every 4 weeks through Week 50
62116950|NCT02669524|ACTIVE_COMPARATOR|T2D + MEAL + LY2409021|Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor.
62116951|NCT02669524|PLACEBO_COMPARATOR|T2D + MEAL + placebo|Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor.
61918382|NCT01895361|PLACEBO_COMPARATOR|Placebo|IV Infusion, once every 4 weeks through Week 50
62116952|NCT02669524|ACTIVE_COMPARATOR|CTRL + OGTT + LY2409021|Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
62116953|NCT02669524|PLACEBO_COMPARATOR|CTRL + OGTT + placebo|Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor.
62116954|NCT02669524|ACTIVE_COMPARATOR|CTRL + IIGI + LY2409021|Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
62116955|NCT02669524|PLACEBO_COMPARATOR|CTRL + IIGI + placebo|Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor.
61918383|NCT04344288|EXPERIMENTAL|Prednisone group|Prednisone during 10 days after randomization
61918384|NCT04344288|OTHER|Control group|
61918385|NCT01198171||Basic science (DNA analysis)|DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
61918386|NCT03433027|EXPERIMENTAL|BB-401|BB-401 Intratumoral injection
62116956|NCT02669524|ACTIVE_COMPARATOR|CTRL + MEAL + LY2409021|Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor.
62116957|NCT02669524|PLACEBO_COMPARATOR|CTRL + MEAL + placebo|Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor.
62116958|NCT05506943|EXPERIMENTAL|CTX-009 plus Paclitaxel|
62116959|NCT05506943|ACTIVE_COMPARATOR|Paclitaxel|Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.
62116960|NCT04880694|EXPERIMENTAL|Cohort 1: STC3141 58.3mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72 hours) N=10
62116961|NCT04880694|EXPERIMENTAL|Cohort 2: STC3141 87.5mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72 hours) N=10
62116962|NCT04880694|NO_INTERVENTION|Cohort 3: Comparator|Only to receive appropriate standard of care N=5
61918387|NCT01418560|EXPERIMENTAL|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with chronic renal failure.
61918388|NCT01418560|NO_INTERVENTION|Absolute medicine therapy|Maintenance of anti-renal failure medications only
61918389|NCT00739271|ACTIVE_COMPARATOR|Study arm|Early enteral feed 48 hours after abdominal surgery
61918390|NCT00739271|ACTIVE_COMPARATOR|Control arm|Traditional treatment where patient is kept on a nasogastric drainage for a few days after abdominal surgery, wait for bowel sounds to appear and then start enteral feeds.
61918391|NCT02374047|EXPERIMENTAL|Cohort A1, Dose Level 1: CAT-2054 or placebo fasting|Single dose
61918392|NCT02374047|EXPERIMENTAL|Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed|Single dose
61918393|NCT02374047|EXPERIMENTAL|Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed|Single dose
62676378|NCT06695286||People with Parkinson's Disease consecutively referred to the outpatient rehabilitation facility|Single center historical cohort study of people with PD consecutively referred to the outpatient rehabilitation facility of a Center for Diagnosis and Treatment of Movement Disorders, based in a university hospital in Italy.
61918394|NCT02374047|EXPERIMENTAL|Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed|Single dose
61918395|NCT02374047|EXPERIMENTAL|Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed|Single dose
61918396|NCT02374047|EXPERIMENTAL|Cohort B1, Dose Level 1: CAT-2054 or placebo|Multiple dose for 14 days
61918397|NCT02374047|EXPERIMENTAL|Cohort B2, Dose Level 2: CAT-2054 or placebo|Multiple dose for 14 days
62305218|NCT02990338|EXPERIMENTAL|IPd (isatuximab + pomalidomide + dexamethasone)|Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 245.6 weeks).
62676379|NCT00666341|PLACEBO_COMPARATOR|Placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
61918398|NCT02374047|EXPERIMENTAL|Cohort B3, Dose Level 3: CAT-2054 or placebo|Multiple dose for 14 days
61918399|NCT02374047|EXPERIMENTAL|Cohort B4, Dose Level 4: CAT-2054 or placebo|Multiple dose for 14 days
61918400|NCT02374047|EXPERIMENTAL|Cohort B5, Dose Level 5: CAT-2054 or placebo|Multiple dose for 14 days
61918401|NCT02374047|EXPERIMENTAL|Cohort B6, Dose Level 6: CAT-2054 with atorvastatin|Multiple dose for 14 days
61918402|NCT02374047|EXPERIMENTAL|Cohort B7, Dose Level 7: CAT-2054 or placebo|Multiple dose for 14 days
61918403|NCT02101814|OTHER|Bariatric surgery|Roux-en-Y gastric bypass procedure is being performed by surgery in all patients in this study.
61918404|NCT04036643|EXPERIMENTAL|patient with rectal cancer|Patient with rectal cancer treated by neoadjuvant chemo-radiation therapy with clinical complete response
61918405|NCT03559426|ACTIVE_COMPARATOR|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
61918406|NCT03559426|EXPERIMENTAL|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
61918407|NCT02408432|EXPERIMENTAL|Arm I (hMSCs)|Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.
61918408|NCT02408432|ACTIVE_COMPARATOR|Arm II (standard of care drugs)|Patients receive only standard of care drugs for heart failure.
61918409|NCT00827671|OTHER|Pre-operative chemotherapy|
61918410|NCT05688826|EXPERIMENTAL|Sugar load|Sugar dissolved in water will be ingested during 5 minutes
61918411|NCT01329835|EXPERIMENTAL|Written information via brochure|Written information by a brochure
61918412|NCT01329835|NO_INTERVENTION|standard care|standard prenatal care
61918413|NCT01329835|EXPERIMENTAL|Lifestyle counseling|Psycho-education based on principles of motivational interviewing and positive reinforcement
61918414|NCT03784924||Initial prostate biopsy|Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.
61918415|NCT05530876|EXPERIMENTAL|Experimental Group|Women with breast cancer who will undergo the intervention with virtual game.
61918416|NCT05530876|ACTIVE_COMPARATOR|Control Group|Healthy women who will undergo the intervention with virtual game.
61918417|NCT05829187|EXPERIMENTAL|Dihydro artemisinin Piperakuin (Fixed Dose Combination) and Primaquine|Fixed Dose Combination content in the form of 40 mg dihydroartemisinin and 320 mg piperaquine administered for 3 days with a dose of dihydroartemisinin 2-4 mg/Kg body weight, piperaquine at a dose of 16-32 mg/Kg body weight in the form of a combination set out in the table based on body weight and age. Primaquine dose of 0.25 mg/Kg body weight is given only on the first day. Dihydroartemisinin-piperaquine was local product by PT Mersi Pharmaceuticals, batch No 220610, produced on Jun/22 and expiring on Jun/24. primaquine was local product by PT Phapros Indonesia, Batch No 56386001, produced on Jan/22 and expiring date jan/25.
61918418|NCT05829187|EXPERIMENTAL|Extract Capsul Momordica Charantia|Momordica Charantia 325 mg in 500 mg capsules is given to patients with uncomplicated plasmodium falsiparum malaria as one capsule per day for three days for body weight less than 60 kg. Patients with a body weight of more than 60 kg are given two capsules per day for three days.
61918419|NCT04173208|EXPERIMENTAL|Fecal microbial transplant|The participants of the experimental arm will receive an oral fecal microbial transplant after delivery
62305219|NCT02453841|ACTIVE_COMPARATOR|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
61918420|NCT04173208|PLACEBO_COMPARATOR|Placebo group|The participants of the placebo arm will receive an oral placebo after delivery
62116963|NCT06675539||AUD participant|"Subject evaluation included during 3 days.~Day 1: Collection of consent and clinical data, DSM-5 criterion for alcohol use disorders, AUDIT, PRSAC scale (twice by two investigators), and CIWA-AR scale every 8 hours.~Day 2 and Day 3: administration of CIWA-AR scale every 8 hours."
62305220|NCT02453841|ACTIVE_COMPARATOR|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
62116964|NCT00861458|EXPERIMENTAL|PF-00868554|
61918421|NCT06517108|EXPERIMENTAL|Chuna therapy|15 patients with chuna therapy
62116965|NCT05561036|EXPERIMENTAL|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) with a treatment cycle of once every 28 days
62116966|NCT05561036|PLACEBO_COMPARATOR|intravenous placebo|saline solution
62116967|NCT02950558|ACTIVE_COMPARATOR|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
62116968|NCT02950558|EXPERIMENTAL|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
62116969|NCT02982993||WTC responders participating in HCV infection study|Members of the World Trade Center Health Program cohort born from 1945 to 1965 who choose to participate in this research study on hepatitis C infection
62305221|NCT02453841|ACTIVE_COMPARATOR|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
62305222|NCT02624700|EXPERIMENTAL|A: Pemetrexed + Sorafenib|Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle
62305223|NCT02624700|EXPERIMENTAL|B: Pemetrexed + Sorafenib|Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.
62676380|NCT00666341|EXPERIMENTAL|20 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
62676381|NCT00666341|EXPERIMENTAL|40 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
62676382|NCT00666341|EXPERIMENTAL|80 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
62676383|NCT00666341|EXPERIMENTAL|120 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
62676384|NCT06089798||PIFB Group|The patients in this group will be applied pecto-intercostal fascial block before surgical incision additional to general anesthesia.
62676385|NCT06089798||Nonblock Group|The patients in this group will be given only standard general anesthesia.
62676386|NCT03903770|EXPERIMENTAL|Intervention|Upper extremity rehabilitation
62676387|NCT02250573|EXPERIMENTAL|Replenine®-VF|
62676388|NCT02191397|EXPERIMENTAL|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
62676389|NCT02191397|ACTIVE_COMPARATOR|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
62676390|NCT02096965|EXPERIMENTAL|Tolvaptan first, then Placebo|Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)
62676391|NCT02096965|EXPERIMENTAL|Placebo first, then Tolvaptan|Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)
62676392|NCT05738291|EXPERIMENTAL|MRD part: BI 1839100 dose group 1|Multiple rising dose (MRD)
62676393|NCT05738291|EXPERIMENTAL|MRD part: BI 1839100 dose group 2|Multiple rising dose (MRD)
62305224|NCT02026388||Primary Hyperoxaluria|Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
62676394|NCT05738291|EXPERIMENTAL|MRD part: BI 1839100 dose group 3|Multiple rising dose (MRD)
62305225|NCT02026388||Dent Disease|Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
62305226|NCT02026388||Cystinuria|Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
62305227|NCT02026388||APRT deficiency|Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
62676395|NCT05738291|EXPERIMENTAL|MRD part: BI 1839100 dose group 4|Multiple rising dose (MRD)
62676396|NCT05738291|EXPERIMENTAL|MRD part: BI 1839100 dose group 5|Multiple rising dose (MRD)
62676397|NCT05738291|PLACEBO_COMPARATOR|MRD part: Placebo matching BI 1839100|
62676398|NCT05738291|EXPERIMENTAL|DDI part|Drug-Drug Interaction (DDI)
62676399|NCT01946100|OTHER|Multifocal Lung Adenocarcinoma|
62676400|NCT03765918|EXPERIMENTAL|Pembro Neoadjuvant+Pembro SOC Adjuvant|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles as a neoadjuvant prior to surgery. Following surgical resection, high risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 every 3 weeks (Q3W) for fifteen 21-day cycles plus standard of care radiotherapy plus cisplatin 100 mg/m\^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 Q3W for fifteen 21-day cycles plus standard of care radiotherapy as adjuvant therapy.
62116970|NCT06489899|EXPERIMENTAL|PEGISUS|PEGISUS is based on two existing evidence-based interventions: Reducing Alcohol and Drug use and other Problem behavior in Adolescent Learners (RAD-PAL) and Manhood 2.0. RAD-PAL was developed to target primary substance use and other challenging behaviors. Manhood 2.0 was developed to reduce traditional gender beliefs. These interventions have been adapted based on formative work with the target user group. PEGISUS will be embedded into existing vocational training programs and delivered by existing staff at these institutions.
62116971|NCT06489899|NO_INTERVENTION|Standard of Care|Standard of care is receiving the vocational training program that is offered through the partner organization and a healthcare referral for substance use. The vocational training programs are SOZO Foundation (South Africa), Build It International (Zambia), and Masvingo Polytechnic (Zimbabwe). SOZO Foundation offers training in six different vocational areas, including hairstyling, coding, and nutrition. They also teach life skills. Build It International offers construction programs and support beyond initial training through connection to employment and mentorship. Masvingo Polytechnic offers many programs, including electrical engineering, welding, guidance counseling, motor mechanics, and catering.
62116972|NCT00509639|EXPERIMENTAL|Metronidazole 10% ointment|Metronidazole 10% ointment
62116973|NCT00509639|PLACEBO_COMPARATOR|Placebo ointment|Placebo ointment
62116974|NCT04486222|EXPERIMENTAL|Experimental Group|The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.
62116975|NCT04486222|ACTIVE_COMPARATOR|Standard Treatment Group|The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.
62305228|NCT03085069|EXPERIMENTAL|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
62116976|NCT02507336|EXPERIMENTAL|Group A - CR+Thalidomide|Patients who achieved complete response (CR) in 20030165 and continue to receive maintenance Thalidomide. Patients in Group A will receive daily oral thalidomide (THALOMID®) as per standard of care and THALOMID® REMS™ guidelines. Patients will continue with thalidomide (THALOMID®) as per standard of care guidelines, until progression of disease, discontinuation due to toxicity, death or study withdrawal. Patients will receive annual clinical/laboratory evaluations.
62116977|NCT02507336|NO_INTERVENTION|Group B - CR+No Thalidomide|Patients who achieved complete response (CR) in 20030165, but are not receiving maintenance Thalidomide. Patients will receive annual clinical/laboratory evaluations.
62116978|NCT02507336|NO_INTERVENTION|Group C - PD or Expired|All other patients enrolled in 20030165 who expired or experienced disease progression (PD). Patients will be followed annually for survival.
62116979|NCT01748318|EXPERIMENTAL|NM Regional Honey|15 ml of NM Honey applied directly to wound
62116980|NCT01748318|ACTIVE_COMPARATOR|Bactrim DS|Standard of Care Oral Antibiotic
62116981|NCT06556199|EXPERIMENTAL|selinexor-based treatment|
62305229|NCT03085069|EXPERIMENTAL|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
61918422|NCT06517108|ACTIVE_COMPARATOR|Physical therapy|15 patients with physical therapy
62116982|NCT06219187||Male breast cancer|
62116983|NCT04557488|EXPERIMENTAL|Music therapy|The treatment group will receive social skill intervention using music therapy in groups of eight. A certified music therapist with prior experience with children with ASD and ID will be the trainer for the treatment group. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to facilitate the group activities, manage unexpected situations, and ensure the safety of the participants.
62116984|NCT04557488|EXPERIMENTAL|Behavioral-based social skill training|The control group will receive behavioral-based social skill training in groups of eight. The trainer will be a registered social worker with experience in providing social skill training for children with ASD and ID. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to provide support.
62305230|NCT03085069|EXPERIMENTAL|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
62305231|NCT03085069|EXPERIMENTAL|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
61918423|NCT05366673|EXPERIMENTAL|Massage therapy|Patients will receive massage therapy for 10 minutes, once per day from the first day to the seventh day of admission to the intensive care unit.
62116985|NCT05181254|EXPERIMENTAL|Health dialogue|Patients \> 18 years old seeking primary care for mental illness (depression, anxiety, sleep disorders or stress related problems) will be followed at 12 and 24 months from baseline in a first assessment, and after 5 and 10 years with follow-up in national registers in a later phase. The patient will fill out a web-based questionnaire about lifestyle habits before the visit to the health center and will be called for blood sampling and measurement of blood pressure and BMI. A nurse with special training in the Health Dialogue then meets the patient and provides individually tailored advice based on the patient's unique conditions and the risk profile on the Health Dialogue, such as help with smoking cessation, physical activity on prescription (PaR-S), contact with a dietitian, physiotherapist. A continued contact with a psychologist or physician will be planned if necessary
62305232|NCT06040177|EXPERIMENTAL|SBRT+cardonilizumab+lenvastinib Group|Renvatinib: 8mg (weight \<60kg) or 12mg (weight ≥60kg) once a day until disease progression, intolerable toxicity Radiation therapy: Stereotactic radiotherapy (5-8Gy\*5F) for portal vein thrombus within 21 days after entry Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
62676401|NCT03765918|ACTIVE_COMPARATOR|No Neoadjuvant+SOC Adjuvant|Participants receive no neoadjuvant prior to surgery. Following surgical resection, high risk participants receive standard of care radiotherapy plus cisplatin 100 mg/m\^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive standard of care radiotherapy as adjuvant therapy.
62116986|NCT03504644|EXPERIMENTAL|Phase Ib (venetoclax, vincristine liposomal)|Patients receive venetoclax PO QD on days 1-42 of cycle 1 and days 43-70 of cycle 2. Patients also receive vincristine liposomal IV over 1 hour weekly for 4 weeks starting on day 15 of cycle 1. Patients who achieve at least a stable disease response may continue treating at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the trial. Patients may also undergo CT and/or PET scan as well as a lumbar puncture as clinically indicated.
62116987|NCT03504644|EXPERIMENTAL|Phase II (venetoclax, vincristine liposomal/sulfate)|Patients receive venetoclax PO QD on days 1-28 of each cycle. Patients also receive vincristine liposomal IV over 1 hour weekly for 4 weeks on day 1 of each cycle or vincristine sulfate IV weekly on days 1, 8, 15, and 22 of cycle 1 and once every 4 weeks on day 1 of each subsequent cycle. Cycles repeat every 28 days. Patients who achieve at least a stable disease response may continue treating at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the trial. Patients may also undergo CT and/or PET scan as well as a lumbar puncture as clinically indicated.
62305233|NCT03614390|OTHER|MBCT group|"There is only 1 arm in the study.~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
62305234|NCT06270225|EXPERIMENTAL|SSGJ-613 100 mg|Subjects will receive 100mg SSGJ-613 on Day 1.
62305235|NCT06270225|EXPERIMENTAL|SSGJ-613 200 mg|Subjects will receive 200mg SSGJ-613 on Day 1.
62305236|NCT06270225|ACTIVE_COMPARATOR|Colchicine 0.5mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
62676402|NCT06644417|PLACEBO_COMPARATOR|TQA3605 Placebo plus NAs|TQA3605 placebo plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks
62676403|NCT06644417|EXPERIMENTAL|100mg TQA3605 tablets plus NAs|100mg TQA3605 tablets plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks
61918424|NCT05366673|NO_INTERVENTION|Control group|Patients will maintain usual care.
61918425|NCT01541202|PLACEBO_COMPARATOR|Placebo|placebo in addition to standard therapy
61918426|NCT01541202|EXPERIMENTAL|rhNRG-1|rhNRG-1 in addition to standard therapy
61918427|NCT03218683|EXPERIMENTAL|Monotherapy AZD5991|Dose escalation - multiple dose levels
62473280|NCT05261945|EXPERIMENTAL|Routine Physical Therapy|"1. Electrotherapy~2. Exercises.~   * Electrotherapy Hot pack Patients will be in prone position and for relaxation pillow will place beneath the abdomen. Then to reduce muscle spasm and to induce vasodilation hot pack will use for 15 minutes. Treatment with hot pack helps in improving and relaxing the muscle spasm and soft tissue elasticity.~TENS TENS will be of 50 Hz, duration of pulse will be\<150 microseconds, for 15 minutes to reduce pain.~TENS and Hot Pack will use at the same time for 15 minutes.~Ultrasound Ultrasound's gel will be applied on outer surface of skin with 2-3 mm thickness. Then ultrasound which frequency will be 1MHz applied for 5 min.~• Exercises Passive Range of Motion exercises for 10 minutes~1. Neck Flexion~2. Neck Side bending~3. Neck Rotation~4. Isometric neck flexion~5. Isometric neck extension~6. Isometric neck side bending~These exercises will repeat 3 times within the treatment program."
62116988|NCT00420316|EXPERIMENTAL|Rotarix Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
62116989|NCT00420316|PLACEBO_COMPARATOR|Placebo Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
62116990|NCT01839903|ACTIVE_COMPARATOR|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
62116991|NCT01839903|ACTIVE_COMPARATOR|Care as usual|Care as usual in the ED will be tracked
62116992|NCT05323838||Control Healthy Women|Aged-matched control group of healthy women.
62116993|NCT05323838||Only Fibromyalgia|Patients diagnosed only with fibromyalgia.
62116994|NCT05323838||Fibromyalgia and Chronic Fatigue Syndrome|Patients diagnosed with fibromyalgia and chronic fatigue syndrome.
62116995|NCT04473586|OTHER|Sample tested in less than one-hour|Buccal samples will be collected and analyzed on the Spartan Cube CYP2C19 System immediately (\<1hr). The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
62116996|NCT04473586|OTHER|Samples tested greater than 24 hours|Buccal samples will be collected, stored and then analyzed on the Spartan Cube CYP2C19 System greater than 24 hours after collection. The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
62116997|NCT03178110|EXPERIMENTAL|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week.
62116998|NCT03161990||Transgluteal approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a transgluteal approach.
62473281|NCT05261945|EXPERIMENTAL|Manual Therapy And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 mins, TENS and hot pack for 15 mins, ultrasound for 5 mins.~Manual therapy~Natural Apophyseal Glides The natural apophyseal glides, which will be applied between C2 and C7, will be the Manual Muscle Testings first action. Patients may request to sit and lean on a chair. The oscillatory motions will reapply the mobilization.~Sustained Natural Apophyseal Glides Sustained Natural Apophyseal Glides will be a mixture of mobilization and active gestures/movements.~5 repetitions for 10 minutes of each."
62473282|NCT05261945|EXPERIMENTAL|Stretching Exercises And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 minutes, TENS and hot pack is applied for 15 minutes at the same time, then ultrasound will applied for 5 minutes.~Stretching exercises will be done in the following order;~For trapezius: Stretching into lateral flexion for the upper part, For scalene: rotation and ipsilateral flexion For the extensor muscles: flexion will be performed.~Performing each action for 30 seconds with 5 repetitions for 10 minutes Finally, by retruding the jaw, a neck straightening exercise can be performed."
62116999|NCT03161990||Posterior approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a posterior approach.
62117000|NCT03547804|EXPERIMENTAL|experimental arm|apatinib 500 mg qd;The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events.Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
62117001|NCT01971788|EXPERIMENTAL|Prolonged bivalirudin infusion|Bivalirudin infusion is prolonged after the end of primary PCI
62473283|NCT06445192|EXPERIMENTAL|Group I (exercise intervention)|Participants receive the supervised aerobic and resistance exercise intervention over 1 hour via telehealth BIW in weeks 1-8 and QW in weeks 9-12 and then continue with unsupervised exercise sessions BIW in weeks 13-52. Participants also attend group counseling sessions over 1 hour QW in weeks 1-8 and bi-weekly in weeks 9-12. Participants also wear a Fitbit throughout the trial and undergo collection of blood samples at baseline and follow up.
62117002|NCT01971788|ACTIVE_COMPARATOR|Intra-procedural bivalirudin infusion|Bivalirudin infusion is stopped at the end of primary PCI
62117003|NCT02129049|EXPERIMENTAL|Supportive care (Enhancing Connections Telephone Program)|See Detailed Description.
62305237|NCT00201201|EXPERIMENTAL|Education|PEP-NG targeted and tailored education intervention
62676404|NCT06644417|EXPERIMENTAL|200mg TQA3605 tablets plus NAs|200mg TQA3605 tablets plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks
62676405|NCT02957123|EXPERIMENTAL|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.~30 patients with organic brain syndrome will receive auto-M2-BFs with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days."
62676406|NCT05373836||brain tumor surgery|adult patients undergoing brain tumor surgery
62117004|NCT02554240|EXPERIMENTAL|DA-5202 High dose|- DA-5202 20mg
62117005|NCT02554240|EXPERIMENTAL|DA-5202 Low dose|- DA-5202 10mg
62117006|NCT02554240|ACTIVE_COMPARATOR|Na Hyaluronate 20mg|Na Hyaluronate 20mg
62117007|NCT02929485|EXPERIMENTAL|Experimental: Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
62117008|NCT02929485|PLACEBO_COMPARATOR|Comparator: Placebo|Drug: Placebo for tolcapone administered at study visit
62117009|NCT02929485|EXPERIMENTAL|Experimental: Bromocriptine|Drug: Bromocriptine 1.25mg (single dose) administered at study visit
62676407|NCT05249855|OTHER|Longitudinal Study|A longitudinal study of anxiety over the balneological treatment.
62676408|NCT01129284|EXPERIMENTAL|Acthar gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
62117010|NCT03988569|EXPERIMENTAL|Intervention Group|Will view audiovisual decision aid (AVDA) and then have opportunity for questions with physician before signing consent forms
62117011|NCT03988569|NO_INTERVENTION|Control Group|Will undergo standard verbal informed consent with physician before signing consent forms
62117012|NCT03299816|ACTIVE_COMPARATOR|Self-Shopping DASH group (S-DASH)|The Self-Shopping DASH group will receive printed patient-centered materials on the DASH diet and chronic kidney disease. Participants will also receive $30/week allowance for the purchase of food and drinks of their choosing from a local grocer (Klein's ShopRite stores of Maryland) during the first four months. During the remainder of the study (months 5-12), the participants in this group will be asked to continue to follow the dietary advice provided but will not receive the food allowance.
62117013|NCT03299816|EXPERIMENTAL|Coaching DASH group (C-DASH)|The C-DASH group intervention will be a patient-tailored program, delivered by a study coach that is trained by a dietitian, which emphasizes key self-management behaviors - diet and self-monitoring. This group will receive advice from the study coach and purchase $30 worth of fresh fruits, vegetables, nuts and beans that are high in potassium on a weekly basis for the first four months.
62117014|NCT04426045|EXPERIMENTAL|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
62117015|NCT04426045|ACTIVE_COMPARATOR|Supra-inguinal fascia iliaca compartment block|Participants receiving supra-inguinal fascia iliaca compartment block
62676409|NCT04007874|EXPERIMENTAL|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
62676410|NCT04007874|ACTIVE_COMPARATOR|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
62676411|NCT06672575|EXPERIMENTAL|Treatment with Ivonescimab|Participants will be enrolled in either Phase 1 or Phase 2 depending on when they join the study.
62117016|NCT00982618|EXPERIMENTAL|LIDOCAINE group|LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
62117017|NCT00982618|EXPERIMENTAL|Epidural Group|Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
62117018|NCT00982618|ACTIVE_COMPARATOR|PCA group|Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.
62117019|NCT00457769|EXPERIMENTAL|Aricept- A|Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.
62117020|NCT00457769|EXPERIMENTAL|A2-12-week waiting period|The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks
62117021|NCT01638039|ACTIVE_COMPARATOR|Diarrheal disease|
62305238|NCT00201201|OTHER|Control|Control, intervention is care as usual.
62305239|NCT00367809|EXPERIMENTAL|1|
62473284|NCT06445192|ACTIVE_COMPARATOR|Group II (usual care)|Participants receive usual care consisting of education on standard recommendations for physical activity, the benefits of exercise, and an example of a light walking program. Participants also wear a Fitbit throughout the trial and undergo collection of blood samples at baseline and follow up.
62676412|NCT00026403|EXPERIMENTAL|radiotherapy + gemcitabine + cisplatin|"Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy.~Patients are followed every 3 months for 2 years and then every 6 months for 1 year."
62676413|NCT03865498|EXPERIMENTAL|Hispanic dementia caregivers|De-identified followers of our Hispanic dementia caregiver Twitter network will receive messages from the network (Twitter for Hispanic caregivers' intervention).
62305240|NCT00367809|ACTIVE_COMPARATOR|2|
62305241|NCT00367809|NO_INTERVENTION|3|
62117022|NCT01638039|ACTIVE_COMPARATOR|Control|Samples of stool, blood, urine saliva
62305242|NCT06049316|EXPERIMENTAL|Scapular stabilization exercises|Scapular stabilization exercises
62305243|NCT06049316|ACTIVE_COMPARATOR|Scapular functional exercises|Scapular functional exercises
62305244|NCT03271710|EXPERIMENTAL|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
62305245|NCT05736315|EXPERIMENTAL|Fermented dairy beverage|Concumption of 3 servings of the fermented dairy beverage a day, during oncological treatment.
62305246|NCT05736315|PLACEBO_COMPARATOR|Placebo|Consumption of 3 servings of the placebo dairy beverage a day, during oncological treatment.
62473285|NCT00939718|ACTIVE_COMPARATOR|Vitamin B12 with antidepressants|Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
62473286|NCT00939718|PLACEBO_COMPARATOR|Placebo injections dextrose water|Subjects in this arm will receive placebo injections which will contain only dextrose water. They will also receive 6 injections on a weekly basis and the injection vials will be covered with foil to ensure masking.
62473287|NCT02319590||heart failure, no CAD, QRS < 150ms|no CAD, QRS \< 150ms
62676414|NCT03865498|EXPERIMENTAL|African American dementia caregivers|De-identified followers of our African American dementia caregiver Twitter network will receive messages from the network (Twitter for African American caregivers' intervention).
62676415|NCT04643431|EXPERIMENTAL|Carotid SHAPE estimation|The ultrasound contrast agent is infused (4-10 mL/min). An area within the plaque demonstrating internal flow is selected and a software based calibration algorithm is executed. After selecting the optimal acoustic output power 3D SHAPE volumes of the entire plaque (including the carotid artery) are acquired. Infusion is stopped and after microbubble clearance a second set of 3D SHAPE volumes (without contrast) are obtained.
62305247|NCT05766956|EXPERIMENTAL|Advanced Care at Home (ACH)|Patients will receive inpatient hospitalization at home.
62473288|NCT02319590||heart failure, CAD QRS < 150ms|CAD, QRS \< 150ms
62473289|NCT02319590||heart failure, CAD > 150ms|CAD, QRS \> 150ms
62473290|NCT02319590||heart failure, no CAD, > 150ms|no CAD, QRS \> 150ms
62473291|NCT03036085|ACTIVE_COMPARATOR|Bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
62117023|NCT02842424|EXPERIMENTAL|Ramipril Treatment|6 months treatment with the medication Ramipril
62117024|NCT01002768|EXPERIMENTAL|IDeg|
62117025|NCT01002768|EXPERIMENTAL|IGlar|
62117026|NCT05244486|EXPERIMENTAL|Treatment Arm|Men will begin utilizing PTT 30-60 minutes daily for 5-7 days weekly beginning 1 month post-prostatectomy until 6 months. After 6 months, they will have the option to continue to use the therapy for 3 additional months or discontinue at their discretion.
62305248|NCT05766956|ACTIVE_COMPARATOR|Traditional Inpatient (Brick-and-Mortar) Hospital Care|Patients will receive inpatient hospitalization at the hospital.
62305249|NCT01912118|EXPERIMENTAL|PROPOFOL ONLY GROUP|In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated. This will be done without additional administration of muscle relaxant.
62676416|NCT06057428||Patients with lumbar spinal stenosis|Patients diagnosed with lumbar spinal stenosis and referred to operation. Measurements of activity levels will be undertaken before operation, and compared to after operation.
62676417|NCT03457597|EXPERIMENTAL|Period 1|Period 1 (Study Days 1 to 4): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 1. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 2
62676418|NCT03457597|EXPERIMENTAL|Period 2|Period 2 (Study Days 5 to 13): Relacorilant will be given daily from Day 5 to Day 13.
62676419|NCT03457597|EXPERIMENTAL|Period 3|Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
62676420|NCT04501445|EXPERIMENTAL|Rounding Summary|Surrogates who were assigned to the intervention group received a written rounding summary every day or every other day that the patient is in the ICU.
62676421|NCT04501445|NO_INTERVENTION|Usual Care|
62676422|NCT03055078|EXPERIMENTAL|mesenchymal stem cells|According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion.
62676423|NCT05881330|EXPERIMENTAL|ArtiAid® group|Each pre-filled syringe contains 10 mg/ml (1.0%) sodium hyaluronate, subjects received one injection per week for five weeks.
62676424|NCT03502590|EXPERIMENTAL|IGEL arm|Placement of a physician decided IGEl airway device in patients with prior radiotherapy to the neck to assess adequacy of ventilation
62676425|NCT06686667|EXPERIMENTAL|Time Restricted Eating|Participants will follow a time-restricted eating diet during day and night shifts over 2 weeks
61918428|NCT03218683|EXPERIMENTAL|Monotherapy AZD5991 expansion|Dose expansion
62117027|NCT05244486|ACTIVE_COMPARATOR|Control|Men will not utilize PTT for the first 6 months post-prostatectomy. Beginning at 6 months, they may utilize PTT if they desire (open label) until 9 months post-prostatectomy.
62473292|NCT03036085|EXPERIMENTAL|Liposomal bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.
62676426|NCT06686667|NO_INTERVENTION|Control Arm|Participants will follow their usual eating patterns without restrictions during day and night shifts over 2 weeks
62676427|NCT06024161||Weight gainers|Weight gain 11-15 months after arthroplasty
62676428|NCT06024161||Weight losers|Weight loss11-15 months after arthroplasty
61918429|NCT03218683|EXPERIMENTAL|AZD5991 + venetoclax|Dose escalation - multiple dose levels
62473293|NCT03387072||Patients affected with CIQTP|Patients affected with catecholamine-induced QT prolongation (CIQTP)
62473294|NCT03387072||Healthy relatives of patients affected with CIQTP|Healthy relatives of patients affected with CIQTP identified during the familial screening
62676429|NCT06024161||Weight unchanged|Weight unchanged 11-15 months after arthroplasty
62676430|NCT05062772||Glioblastoma|
62676431|NCT02618395|EXPERIMENTAL|Treatment A|
62676432|NCT02618395|EXPERIMENTAL|Treatment B|
62676433|NCT02618395|EXPERIMENTAL|Treatment C|
62676434|NCT05450718|EXPERIMENTAL|Low-dose initiation|"Participants randomized to low-dose buprenorphine initiation will start low-dose buprenorphine-naloxone (bup-nx) according to an at-home, 8-day protocol (below). Participants in the low-dose buprenorphine initiation arm will be allowed to continue taking the full opioid agonist that they were taking at the time of enrollment until they reach a therapeutic dose of buprenorphine-naloxone.~Day 1: 0.5 mg once; Day 2: 0.5 mg every 12 hours; Day 3: 1 mg every 12 hours; Day 4: 2 mg every 12 hours; Day 5: 3mg every 12 hours; Day 6: 4 mg every 12 hours; Day 7: 6 mg every 12 hours; Day 8: 8 mg every 12 hours"
62676435|NCT05450718|ACTIVE_COMPARATOR|Treatment as usual|Participants randomized to treatment as usual will start buprenorphine-naloxone (bup-nx) following standard clinical guidelines for two-day, at-home initiation.
62676436|NCT06027463||xi'an/Tangdu hospital|
61918430|NCT04618887||Meige sydrome patients|
61918431|NCT05680259|EXPERIMENTAL|Maela connected follow-up|patient will benefit of the Maela connected follow-up
61918432|NCT05680259|ACTIVE_COMPARATOR|control group|control group with a traditional follow-up
62676437|NCT02213107|EXPERIMENTAL|Enzalutamide and dutasteride or finasteride|Use of either 1. Enzalutamide and dutasteride or 2. Enzalutamide and finasteride.
62676438|NCT02427672|EXPERIMENTAL|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
61918433|NCT04482985|ACTIVE_COMPARATOR|Meclizine responders|
62676439|NCT02427672|SHAM_COMPARATOR|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
62676440|NCT02577380|EXPERIMENTAL|IPV/GBV HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to IPV/GBV HTC HIV testing.
62676441|NCT02577380|NO_INTERVENTION|Standard HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to Standard HIV testing and counseling.
62676442|NCT00070499|EXPERIMENTAL|Arm I (QD imatinib mesylate)|Patients receive imatinib mesylate PO QD. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
62676443|NCT00070499|EXPERIMENTAL|Arm II (BID imatinib mesylate)|Patients receive imatinib mesylate PO BID. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
62676444|NCT00070499|EXPERIMENTAL|Arm III (dasatinib)|Patients receive dasatinib PO BID. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
62676445|NCT01279187|EXPERIMENTAL|Teriparatide|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
62676446|NCT01279187|PLACEBO_COMPARATOR|Control|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
62676447|NCT06349473|EXPERIMENTAL|Part A: Cohort 1A (SR604 Dose 1)|Participants will receive single subcutaneous (SC) dose of SR604 dose 1 or matching placebo to SR604 on Day 1.
62676448|NCT06349473|EXPERIMENTAL|Part A: Cohort 2A (SR604 Dose 2)|Participants will receive single SC dose of SR604 dose 2 or matching placebo to SR604 on Day 1.
62676449|NCT06349473|EXPERIMENTAL|Part A: Cohort 3A (SR604 Dose 3)|Participants will receive single SC dose of SR604 dose 3 or matching placebo to SR604 on Day 1.
62676450|NCT06349473|EXPERIMENTAL|Part A: Cohort 4A (SR604 Dose 4)|Participants will receive single SC dose of SR604 dose 4 or matching placebo to SR604 on Day 1.
62676451|NCT06349473|EXPERIMENTAL|Part B: Cohort 1B (SR604 Dose 5)|Participants with Hemophilia A or Hemophilia B will receive SR604 dose 5 as SC injection.
62676452|NCT06349473|EXPERIMENTAL|Part B: Cohort 2B (SR604 Dose 6)|Participants with Hemophilia A or Hemophilia B will receive SR604 dose 6 as SC injection.
62676453|NCT06349473|EXPERIMENTAL|Part B: Cohort 3B (SR604 Dose 7)|Participants with Hemophilia A or Hemophilia B will receive SR604 dose 7 as SC injection.
62676454|NCT06349473|EXPERIMENTAL|Part B: Cohort 4B (SR604 Dose 8)|Participants with Hemophilia A or Hemophilia B will receive SR604 dose 8 as SC injection.
62676455|NCT03114397|ACTIVE_COMPARATOR|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
62676456|NCT03114397|PLACEBO_COMPARATOR|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
62676457|NCT06118281|EXPERIMENTAL|Ziltivekimab|Participants will receive an initial loading dose of ziltivekimab Dose 1 subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for ST-elevation myocardial infarction (STEMI) and within 48 hours of hospitalisation for non-ST-elevation myocardial infarction (NSTEMI), followed by ziltivekimab Dose 2 s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.
62676458|NCT06118281|EXPERIMENTAL|Placebo ziltivekimab|Participants will receive placebo matched to ziltivekimab at an initial loading dose subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for STEMI and latest within 48 hours of hospitalisation for NSTEMI, followed by placebo matched to ziltivekimab s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.
62117028|NCT00269880|PLACEBO_COMPARATOR|Placebo and Standard Dose of Heparin|Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
62676459|NCT05899816|EXPERIMENTAL|Rocatinlimab|Rocatinlimab every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
62676460|NCT05899816|PLACEBO_COMPARATOR|Placebo|Placebo every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
62305250|NCT01912118|EXPERIMENTAL|PROPOFOL + REMIFENTANIL TARGET A|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.
62117029|NCT00269880|ACTIVE_COMPARATOR|Abciximab and Low Dose of Heparin|Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
62117030|NCT00269880|ACTIVE_COMPARATOR|Abciximab and Standard Dose Heparin|Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.
61918434|NCT04482985|ACTIVE_COMPARATOR|Meclizine non responders|
61918435|NCT03374618|EXPERIMENTAL|systemic lupus erythematosus|adult with systemic lupus erythematosus
61918436|NCT03374618|EXPERIMENTAL|systemic sclerosis|adult with systemic sclerosis
61918437|NCT03374618|OTHER|healthy volunteers|healthy volunteer (adult)
62676461|NCT05399134|EXPERIMENTAL|Modified Functional Foods (Treatment)|Anthocyanin black rice extract powder (ABREP)-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice for breakfast, lunch, and dinner respectively served in a mixed meal.
62676462|NCT05399134|PLACEBO_COMPARATOR|Control Functional Foods (Control)|White bread, beehoon noodles, and jasmine white rice for breakfast, lunch, and dinner respectively served in a mixed meal.
62676463|NCT02070380|EXPERIMENTAL|MultiHance 0.1 then Dotarem 0.1 mmol/kg|MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg
62676464|NCT02070380|EXPERIMENTAL|MultiHance 0.05 then Dotarem 0.1 mmol/kg|MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg
61918438|NCT02086279|NO_INTERVENTION|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for surgery are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients enrolled will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between 1 and 4 days of the menstrual cycle will be measured at study entry and at 1, 3 and 6 months after the administration of the first vial of GnRH-a"
61918439|NCT03276520|EXPERIMENTAL|ethyl glucuronide|subjects being screened with ethyl glucuronide
62117031|NCT06552962|EXPERIMENTAL|Intervention Group|The experimental group will have the same lumbar stabilization exercises performed on the whole body vibration device twice a week for 6 weeks. The frequency of the device will be set to 30 Hz. Exercise duration, frequency, number and variety will be kept equal for the experimental and control groups. Demographic information of the patients, viscoelastic properties of the lumbar region, pain, function, quality of life, lower extremity muscle strength, endurance, balance and proprioception will be evaluated. Measurements will be made before treatment and at the end of 6 weeks of treatment.
62676465|NCT02070380|ACTIVE_COMPARATOR|Dotarem 0.1 then MultiHance 0.1 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg
62676466|NCT02070380|ACTIVE_COMPARATOR|Dotarem 0.1 then MultiHance 0.05 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg
62117032|NCT06552962|ACTIVE_COMPARATOR|Control Group|Within the scope of the research, individuals with chronic non-specific low back pain will be randomized and divided into two separate groups. Lumbar stabilization exercises will be applied to the control group twice a week for 6 weeks. Exercise duration, frequency, number and variety will be kept equal for the experimental and control groups. Demographic information of the patients, viscoelastic properties of the lumbar region, pain, function, quality of life, lower extremity muscle strength, endurance, balance and proprioception will be evaluated. Measurements will be made before treatment and at the end of 6 weeks of treatment.
62117033|NCT02824939|EXPERIMENTAL|Transversus Abdominis Plane group|
62305251|NCT01912118|EXPERIMENTAL|PROPOFOL + REMIFENTANIL TARGET B|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil
62676467|NCT02565186|EXPERIMENTAL|Lasmiditan 100mg|Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
62676468|NCT02565186|EXPERIMENTAL|Lasmiditan 200mg|Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
62676469|NCT06454812|NO_INTERVENTION|Control|The control group will receive routine Hepatitis B vaccination.
62676470|NCT06454812|EXPERIMENTAL|Mechanical vibration|Mechanical vibration will be used during routine Hepatitis B vaccination of infants in this group.
62117034|NCT02824939|EXPERIMENTAL|Quadratus Lumborum group|
62117035|NCT02824939|NO_INTERVENTION|Control group|
62305252|NCT01912118|EXPERIMENTAL|PROPOFOL + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.
62676471|NCT06454812|EXPERIMENTAL|Helfer skin tap technique|Helfer skin tap technique will be used during routine Hepatitis B vaccination of infants in this group.
62676472|NCT05869825|ACTIVE_COMPARATOR|The high-flow nasal cannula (HFNC)|The high flow nasal cannula (HFNC) is a unique mode of respiratory support that delivers warmed, humidified oxygen with a wide range of fractions of inspired oxygen (FiO2) and flow rate (liters/min) without an invasive device such as an endotracheal tube (breathing tube).
62676473|NCT05869825|ACTIVE_COMPARATOR|Non-invasive positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation (NPPV or NIPPV) is a unique mode of respiratory support that delivers pressurized, oxygen-enriched gas to the airway via the nose and/or oropharynx without a more invasive device such as an endotracheal tube (breathing tube).
61918440|NCT03276520|ACTIVE_COMPARATOR|ethanol|subjects being screened with ethanol
61918441|NCT00815724|EXPERIMENTAL|1|Participants will take part in a distance learning group.
61918442|NCT00815724|NO_INTERVENTION|2|Participants in the control group will not receive any study materials or take part in any study activities.
61918443|NCT05236595||Rare genetic disease individualized drug development screening candidate|Patients with targetable disease-causing genetic alterations will be evaluated on a case by case basis. The research study will utilize biospecimens to determine if an individualized therapeutic may be developed as a possible treatment option. If an individualized therapeutic drug can be developed, a future IND FDA application (n=1) will be filed.
61918444|NCT05441332|EXPERIMENTAL|Patellofemoral pain syndrome|Kinematic and neuromuscular assessment
61918445|NCT00887744|OTHER|Aperius Treatment Arm|Single Arm
61918446|NCT02890628||pregnant/post-natal adolescents (<20 years)|12-24 individual with pregnant or postnatal adolescent girls (\<20 years) will be interviewed.
61918447|NCT02890628||non-pregnant female adolescents (<20 years)|1 Focus group discussion of 6-10 non-pregnant female adolescents (\<20 years)
62676474|NCT05879172|ACTIVE_COMPARATOR|traditional anastomotic device|
62676475|NCT05879172|EXPERIMENTAL|electric tubular anastomotic device|
61918448|NCT02890628||male adolescents (<20 year)|1 Focus group discussion of 6-10 adolescent men (\<20 years)
61918449|NCT02890628||SMRU health staff of antenatal clinics (ANC)|1 Focus group discussion of 6-10 Shoklo Malaria Research Unit antenatal clinic staff
62305253|NCT01912118|EXPERIMENTAL|PROPOFOL + REMIFENTANIL TARGET D|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
62676476|NCT04097912||Low-dose aspirin users|Patients who receive low-dose aspirin (75-100mg) for either the primary or secondary prevention of cardiovascular disease (CVD).
62676477|NCT02540434|ACTIVE_COMPARATOR|RiaSTAP Arm|Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
62676478|NCT02540434|ACTIVE_COMPARATOR|Cryopreciptiate Arm|Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
62676479|NCT06358703||Cases|
61918450|NCT06430827|EXPERIMENTAL|Experimental|Patients will receive irinotecan hydrochloride liposome injection combined with Capecitabine therapy in a 2-week treatment cycle.
62676480|NCT06358703||Controls|
62676481|NCT04774146||triple air fluid exchange|those undergoing triple air fluid exchange
61918451|NCT06520579|EXPERIMENTAL|Proactive Behavioral Intervention coupled with protein supplementation|Patients will receive the behavioral intervention program comprised of hydration counseling, protein supplementation, and daily pharyngeal/laryngeal exercise for a total of 7 weeks.
61918452|NCT06520579|NO_INTERVENTION|Historical Control Group|Historical control data from subjects who underwent Anterior Cervical Discectomy and Fusion (ACDF) surgery but did not receive any behavioral intervention.
62117036|NCT02804516|EXPERIMENTAL|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
62117037|NCT02804516|EXPERIMENTAL|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
62117038|NCT03922867|NO_INTERVENTION|Control Group|Subjects with receive standard of care for management of insomnia in subjects with fibromyalgia
62117039|NCT03922867|ACTIVE_COMPARATOR|Intervention Group|Subjects will receive standard of care and additionally complete the online cognitive behavior therapy program
62117040|NCT06242899|EXPERIMENTAL|8-minutes short exercise group|Participants performed an intervention for 3 sessions/week, over 3 weeks and a cycle ergometer was used. The workout regimen consisted of a structured warm-up lasting 2 minutes. The main exercise phase comprised an 8-minute cycling session performed at 75% of HRmax. Finally, a cool down phase lasting 2 minutes.
62117041|NCT06242899|EXPERIMENTAL|10-minutes short exercise group|Participants performed an intervention for 3 sessions/week, over 3 weeks and a cycle ergometer was used. The workout regimen consisted of a structured warm-up lasting 2 minutes. The main exercise phase comprised an 10-minute cycling session performed at 75% of HRmax. Finally, a cool down phase lasting 2 minutes.
62117042|NCT06242899|EXPERIMENTAL|15-minutes short exercise group|Participants performed an intervention for 3 sessions/week, over 3 weeks and a cycle ergometer was used. The workout regimen consisted of a structured warm-up lasting 2 minutes. The main exercise phase comprised an 15-minute cycling session performed at 75% of HRmax. Finally, a cool down phase lasting 2 minutes.
62117043|NCT06677528||Patients undergoing TAVR or SAVR|
62117044|NCT05722106|EXPERIMENTAL|Control - Info only|"Participants read a flyer containing the following message:~The virus spreads mainly between people who are in close contact with one another. You can help prevent the spread of COVID-19. We can all do our part:~* Avoid social gatherings.~* Wear a mask when you go out.~* Stay at least six feet away from people outside your household.~* Wash your hands often with soap and water. These actions prevent the spread of COVID-19."
62676482|NCT04774146||irrigation|those undergoing vitreous chamber irrigation with comparable volume of BSS
62676483|NCT05465876|EXPERIMENTAL|EVUSHELD|
62676484|NCT03270163|EXPERIMENTAL|Experimental|Magnetic and Transcutaneous electrical stimulation of quadriceps
62305254|NCT01912118|EXPERIMENTAL|PROPOFOL + REMIFENTANIL TARGET E|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.
62305255|NCT01912118|EXPERIMENTAL|PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
61918453|NCT04046588|OTHER|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
61918454|NCT04046588|OTHER|Healthy control group|This group will include 40 healthy volunteers.
61918455|NCT04046588|EXPERIMENTAL|Healthy intervention group|This study will include 40 healthy adults. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively.
62676485|NCT04202211|PLACEBO_COMPARATOR|Placebo oral & enema|twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema
62676486|NCT04202211|ACTIVE_COMPARATOR|LYO-FMT oral + placebo enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema
62676487|NCT04202211|ACTIVE_COMPARATOR|LYO-FMT oral + LYO-FMT enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema
62305256|NCT01912118|EXPERIMENTAL|PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.
62305257|NCT04603378|OTHER|KB195|
62676488|NCT03614585|EXPERIMENTAL|High-intensity interval training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= \[max HR - resting HR\] x \[% training\] + \[resting HR\]) and ratings of perceived exertion (RPE). The protocol will involve 10 60-second intervals of high intensity interspersed with 9 60-second low-intensity intervals. The initial high intensity intervals will start at 80% of the HRR (RPE=14-17) and progress by 10% every 4 weeks. Low intensity intervals will be performed at 30% of HRR (RPE=9-11). Three-minute warm-up and 2-minute cool-down periods will be performed at 30% of HRR. Total HIIT time including warm-up and cool-down is 24 minutes.
62305258|NCT04603378|OTHER|Polydextrose|
62676489|NCT03614585|EXPERIMENTAL|Moderate-intensity continuous training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= \[max HR - resting HR\] x \[% training\] + \[resting HR\]) and ratings of perceived exertion (RPE). The MICT protocol will be increased using a progression schedule previously used (initial intensity at 40% HRR (RPE=9-11), and progressed by 10% HRR every 4 weeks up to 60% HRR (RPE=13-14) will be maintained until the end of the intervention). A 3-minute warm-up and 2-minute cool-down will be performed at 30% HRR (RPE=9-11). The total duration of MICT, including warm-up and cool-down, will be 35 minutes.
61918456|NCT03859830|EXPERIMENTAL|Artis Dialysis System|One midweek HDF session for a duration of 4 hours.
61918457|NCT03859830|ACTIVE_COMPARATOR|AK200 Ultra S|One midweek HDF session for a duration of 4 hours.
62305259|NCT04603378|OTHER|Pullulan|
62305260|NCT04603378|OTHER|Maltodextrin|
62305261|NCT04767880|EXPERIMENTAL|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast in the women's own environment.
62473295|NCT04036539|PLACEBO_COMPARATOR|Control (placebo)|Patients in Control will receive the photobiomodulation placebo,application, but with the laser off. Procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described: Simulations will be performed with the same laser.This will require 10 seconds of application simulation per point. As 10 points will be simulated, it will take 100 seconds for this simulation.5 points lingual and 5 points at vestibular
62473296|NCT04036539|EXPERIMENTAL|Experimental:|Experimental: Molar verticalization + PBM (n = 17 + 3) - patients will receive laser treatment (photobiomodulation) in order to modulate orthodontic movement and act on inflammation and pain. The procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described:The irradiations will be performed with the red diode laser ( = 660 nm) with 100 milliwatts output power The power of the device will be 100miliWatts and the wavelength used will be 808 nanometers (± 10nm). The optical fiber diameter of the device is 600 micrometer, therefore a spot (area) of 0.002826 centimeter2. The energy delivered per point will be 1Joule. This will require 10 seconds of application per point. As 10 points will be irradiated, the total application time will be 100 seconds and the total energy delivered will be 10Joule. The energy density will be 25 Joule / cm2 and the power density will be 35.38 Watt / cm2
62473297|NCT06017635||Case|1. Age 1-18 years old, male or female. 2. Diagnosed with cerebral contusion/cerebral hemorrhage/intracranial tumor postoperative / intracranial infection/septic encephalopathy/metabolic encephalopathy. 3. The research purpose, significance, risks, benefits, and informed consent of patients and their families to the study.
62676490|NCT02539394|EXPERIMENTAL|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
62117045|NCT05722106|EXPERIMENTAL|Deontological|"Participants read a flyer containing the following message:~The virus spreads mainly between people who are in close contact with one another. You can help prevent the spread of COVID-19. We can all do our part:~* Avoid social gatherings.~* Wear a mask when you go out.~* Stay at least six feet away from people outside your household.~* Wash your hands often with soap and water. We all need to do this, however difficult, because it is the right thing to do: it is our duty and responsibility to protect our families, friends, and fellow citizens."
62117046|NCT05722106|EXPERIMENTAL|Empathy|"Participants read a flyer containing the following message:~The sick, elderly, and immunocompromised need our help. We all have a choice. If we don't take the right actions, we risk the lives of others. But we can protect those most likely to be harmed. We can protect those who are vulnerable by taking simple steps:~* Avoid social gatherings.~* Wear a mask when you go out.~* Stay at least six feet away from people outside your household.~* Wash your hands often with soap and water. Take action to protect those who are vulnerable!"
62117047|NCT05722106|EXPERIMENTAL|Identifiable victim|"Participants read a flyer containing the following message:~A few weeks ago, Sam was a healthy 26-year-old with no medical complications. The he suddenly came down with a bad cough and a feeling like he could not breath. He tested positive for COVID-19, and is now hospitalized, receiving oxygen from a ventilator, and fighting for his life. This could be any of us. Reduce the risk to yourself and other:~* Avoid social gatherings.~* Wear a mask when you go out.~* Stay at least six feet away from people outside your household.~* Wash your hands often with soap and water. If we take these actions, we can prevent more people from suffering the way Sam has."
62117048|NCT05722106|EXPERIMENTAL|Goal proximity|"Participants read a flyer containing the following message:~The recent development of safe and effective vaccines gives us great hope. We see the light at the end of the tunnel, but we are not quite there yet. Until a large proportion of the population is immunized, we must remain vigilant and double our efforts to prevent the spread of COVID-19.~* Avoid social gatherings.~* Wear a mask when you go out.~* Stay at least six feet away from people outside your household.~* Wash your hands often with soap and water. These actions prevent the spread of COVID-19."
62117049|NCT05722106|EXPERIMENTAL|Reciprocity|"Participants read a flyer containing the following message:~Doctors, nurses, and other healthcare workers are working around the clock, often risking their lives to care for patients with the coronavirus. Working long hours in highly infectious environments, many of them are falling ill. As our healthcare workers put their lives on the line, we can do our part:~* Avoid social gatherings.~* Wear a mask when you go out.~* Stay at least six feet away from people outside your household.~* Wash your hands often with soap and water. Our brave healthcare workers have sacrificed to help others. We should take action too."
62117050|NCT04574635||Cohort 1 (surgery patients)|Patients undergo collection of blood samples at baseline prior to surgery, at 6 weeks, 3, 6, and 12 months post-surgery, every 6 months during year 2, and at the time of recurrence (if applicable).
62117051|NCT04574635||Cohort 2 (post-operative radiation +/- chemotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, at 6 weeks, 3, 6, and 12 months post-radiotherapy, every 6 months during year 2, and at the time of recurrence (if applicable).
62305262|NCT04767880|PLACEBO_COMPARATOR|Placebo|The placebo will be ingested 30 min. prior to an OGTT (3 hours). The placebo will also be ingested 30 min prior to breakfast in the women's own environment.
62305263|NCT00802477|EXPERIMENTAL|1|Application of Autologous Blood Products to surgical site during mastectomy.
62305264|NCT00802477|ACTIVE_COMPARATOR|2|Standard Modified Radical Mastectomy
62305265|NCT03227926|EXPERIMENTAL|Screening Phase|"Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the molecular eligibility of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared molecularly eligible for the Trial Phase."
62305266|NCT03227926|EXPERIMENTAL|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
62305267|NCT02123329|ACTIVE_COMPARATOR|Control arm|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
62473298|NCT06017635||Contral|1. Age 1-18 years old, male or female. 2. Non-cranial organic injury diseases. 3. Physical condition allows them to participate in the study. 4. The research purpose, significance, risks, benefits, and informed consent of patients and their families to the study.
62305268|NCT02123329|EXPERIMENTAL|Intervention arm|Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy. The sessions will be set at a date and time that is convenient for both the pharmacist and the participant. The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
62305269|NCT01450540|ACTIVE_COMPARATOR|Group 1|REMStar auto A-Flex
62305270|NCT01450540|EXPERIMENTAL|Group 2|modified REMstar Auto A-Flex with AGPAP
62305271|NCT01300221||Group 1|Subjects who are healthy normal children.
62305272|NCT01300221||Group 2|Subjects who have congenital heart disease.
62305273|NCT01300221||Group 3|Subjects who have sickle cell disease
62305274|NCT01300221||Group 4|Subjects who have Duchenne muscular dystrophy
62305275|NCT01300221||Group 5|Patients who have Marfan syndrome and other aortic disease
62305276|NCT04323501|EXPERIMENTAL|Experimental treatment group|"This group will undergo an intensive-rehabilitation treatment of post-stroke sensorimotor disability based on a guided self-rehabilitation contract. This approach is based on the fact that the patient must complete a diary of his self-rehabilitation activity in order to verify its correct and full execution. The treatment protocol will be defined on the basis of the clinical picture (patterns) manifested by the patient (the intensity and frequency of the exercises will be adapted according to the characteristics of each patient). The duration of treatment will be the same for all patients. The exercises will be performed every day throughout the study period (12 months).~Before undertaking the intensive self-management treatment, each patient will undergo 10 sessions of neurorehabilitation treatment at the UOC Neurorehabilitation of the Integrated University Hospital according to normal clinical practice, during which the patient will be provided with infographic support material."
62305277|NCT04323501|ACTIVE_COMPARATOR|Control group|The patients allocated to the control group, during the study period they will undergo conventional outpatient rehabilitation treatment (usual care) at the Neurorehabilitation Unit of the AOUI according to the clinical practice through the procedures provided for by the Health System National.
62305278|NCT05286294|EXPERIMENTAL|Treatment|Fecal Microbiota Transplant (FMT)
62305279|NCT03873597|EXPERIMENTAL|Tele-coaching + Usual Care|This group will undergo a 12 week physical activity tele-coaching intervention consisting of a step-counter and smartphone application, in addition to usual care. Usual care will also include sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
62305280|NCT03873597|NO_INTERVENTION|Usual Care|This group will receive sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
62473299|NCT05593991|EXPERIMENTAL|Healthy adults|Subjects with elevated heels
62473300|NCT02045563||Patients with type-1 diabetes|
61918458|NCT01887093|EXPERIMENTAL|Morning walking|Participants were requested to walk in the morning at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
62305281|NCT00368368|EXPERIMENTAL|1|
62305282|NCT00368368|EXPERIMENTAL|2|
62305283|NCT00368368|EXPERIMENTAL|3|
62305284|NCT04519528||Patients|Minors who required veno-venous or veno-arterial ECMO, in pediatric intensive care unit at Necker Enfants Malades hospital between 2014 and 2019.
62305285|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
62305286|NCT05221190|EXPERIMENTAL|Single buccal infiltration of articaine anesthesia|The local anesthetic solution will be administered using single buccal infiltration with articaine anesthesia.
62305287|NCT05221190|ACTIVE_COMPARATOR|Inferior alveolar nerve block of lidocaine anesthesia|The anesthetic solution will be administered using inferior alveolar nerve block with lidocaine anesthesia.
62305288|NCT02803216|EXPERIMENTAL|standard triple region|The patients in this group were given 10-day standard triple therapy.
62305289|NCT02803216|ACTIVE_COMPARATOR|standard triple region +2-week TCM|The patients in this group were given 10 days of standard triple therapy + 2-week Xiang-sha-liu-jun decoction.
62473301|NCT02045563||Patients with type-2 diabetes|
62473302|NCT02045563||Volontaires sains|
62473303|NCT01650350|EXPERIMENTAL|Low Dose Naltrexone|LDN, 5 mg/day-(1 cycle = 28 days).
62473304|NCT03409367|EXPERIMENTAL|Daily Emollient|Parents assigned to the intervention arm will receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until their infant is 24 months old. Parents will select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
62676491|NCT02539394|PLACEBO_COMPARATOR|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
62676492|NCT05704829|EXPERIMENTAL|T-DXd: HER2+ and low-intermediate risk for recurrence|12 weeks T-DXd i.v. in neoadjuvant treatment; pCR dependent T-DXd for 1 year in total in postneoadjuvant treatment
62676493|NCT05704829|EXPERIMENTAL|T-DXd: HER2+ and intermediate-high risk for recurrence|18 weeks T-DXd i.v. in neoadjuvant treatment; pCR dependent T-DXd for 1 year in total in postneoadjuvant treatment
62676494|NCT05704829|OTHER|Control: HER2+ and low-intermediate risk for recurrence|Standard-of-Care-Treatment: 12 weeks PAC+T+P (standard-of-care) in neoadjuvant treatment; pCR dependent SOC chemotherapy +T+/-P or SOC T+/-P for 1 year in total in postneoadjuvant treatment
62117052|NCT04574635||Cohort 3 (definitive chemoradiotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, on the day of the final fraction of radiotherapy, at 3 months post-radiotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
62117053|NCT04574635||Cohort 4 (systemic treatment patients)|Patients undergo collection of blood samples at baseline prior to initiation of chemotherapy or immunotherapy, at 4 weeks and 8 weeks after initiation of chemotherapy or immunotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
62117054|NCT06554080||Platform-matched|UK Armed Forces patients who had platform-switched implants (Nobel Brånemark or NobelSpeedy Groovy) placed at DCRD between the period of 01 Jan 2017 and 31 Dec 2023.
62117055|NCT06554080||Platform-switched|UK Armed Forces patients who had platform-switched implants (NobelParallel or NobelActive) placed at DCRD between the period of 01 Jan 2017 and 31 Dec 2023.
62117056|NCT05686421|EXPERIMENTAL|Device C (OD-OS), then Device N (OD-OS)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device C, a standard conventional device with no attachment; and device N, the standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device.~Participants will first be imaged using device C starting with the right eye (OD), then left eye (OS). They will then be imaged using device N, starting with OD, then OS."
62117057|NCT05686421|EXPERIMENTAL|Device C (OS-OD), then Device N (OS-OD)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device C, a standard conventional device with no attachment; and device N, the standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device.~Participants will first be imaged using device C starting with the left eye (OS), then right eye (OD). They will then be imaged using device N, starting with OS, then OD."
62117058|NCT05686421|EXPERIMENTAL|Device N (OD-OS), then Device C (OD-OS)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device N, a standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device; and device C, the standard conventional device with no attachment.~Participants will first be imaged using device N starting with the right eye (OD), then left eye (OS). They will then be imaged using device C, starting with OD, then OS."
62117059|NCT05686421|EXPERIMENTAL|Device N (OS-OD), then Device C (OS-OD)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device N, a standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device; and device C, the standard conventional device with no attachment.~Participants will first be imaged using device N starting with the left eye (OS), then right eye (OD). They will then be imaged using device C, starting with OS, then OD."
62117060|NCT00509769|EXPERIMENTAL|Trastuzumab emtansine 3.6 mg/kg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
62117061|NCT04143126|EXPERIMENTAL|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
62305290|NCT02803216|ACTIVE_COMPARATOR|standard triple region +4-week TCM|The patients in this group were given 10days of standard triple therapy + 4-week Xiang-sha-liu-jun decoction.
62305291|NCT03448835|EXPERIMENTAL|atezolizumab and chemotherapy|1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel
61918459|NCT01887093|EXPERIMENTAL|Evening walking|Participants were requested to walk in the evening at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
61918460|NCT01887093|NO_INTERVENTION|No walking|The control group was requested to maintain their usual level of physical activity.
62305292|NCT02985801|EXPERIMENTAL|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
62305293|NCT02985801|EXPERIMENTAL|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
62305294|NCT03304951|EXPERIMENTAL|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
61918461|NCT04227054|EXPERIMENTAL|Intervention|
61918462|NCT03088462|ACTIVE_COMPARATOR|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
62305295|NCT01827501|EXPERIMENTAL|Group GDT|Goal-directed Management according to pulse contour analysis (PulsioflexTM Monitoring)
62676495|NCT05704829|OTHER|Control: HER2+ and intermediate-high risk for recurrence|Standard-of-Care-Treatment: 18 weeks PAC/DOC+Carbo+T+P (standard-of-care) in neoadjuvant treatment; pCR dependent SOC chemotherapy +T+/-P or SOC T+/-P for 1 year in total in postneoadjuvant treatment
61918463|NCT03088462|EXPERIMENTAL|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
61918464|NCT04221243|EXPERIMENTAL|Group 1: Children with 3D printed space maintainer|
61918465|NCT04221243|ACTIVE_COMPARATOR|Group 2: Children with conventional band and loop|
61918466|NCT06332638|EXPERIMENTAL|Group A|Tegoprazan 12.5mg
61918467|NCT06332638|ACTIVE_COMPARATOR|Group B|Tegoprazan 25mg
61918468|NCT06332638|ACTIVE_COMPARATOR|Group C|Famotidine 20mg
61918469|NCT00972647|NO_INTERVENTION|Unguided|Fluoroscopy images taken without laser beam guidance
62117062|NCT04143126|ACTIVE_COMPARATOR|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 2 hours per week; Location: Pittsburgh, PA only"
62117063|NCT01134562|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo intravenous (IV) injection after hemodialysis.
62117064|NCT01134562|EXPERIMENTAL|Etelcalcetide|Participants received a single dose of etelcalcetide by intravenous (IV) injection after hemodialysis.
62117065|NCT00597519|EXPERIMENTAL|Treatment|Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
62117066|NCT01418118|EXPERIMENTAL|Pressors|Epinephrine, Norepinephrine, Dobutamine, Dopexamine
62305296|NCT01827501|NO_INTERVENTION|Group Co|Conventional fluid management
62117067|NCT06369922|EXPERIMENTAL|Active TENS|In the active treatment group, the TENS unit will remain on up to 30 minutes (10 minutes pre-procedure, during the procedure and during the questionnaires).
61918470|NCT00972647|EXPERIMENTAL|Laser guided|Fluoroscopy images taken with laser beam guidance
62117068|NCT06369922|SHAM_COMPARATOR|Control TENS|The sham stimulation group will undergo the same procedure; however, the TENS stimulation current will be reduced to a minimal detectable level and turned off after 20 seconds.
62117069|NCT02520856||Hypertrophic cardiomyopathy|"All patients with newly diagnosed unexplained HCM will be prospectively included.~All patients will undergo both classical genetic analysis and WES technology."
62117070|NCT03587363|EXPERIMENTAL|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
62676496|NCT06200207|ACTIVE_COMPARATOR|Ziltivekimab|Participants will receive ziltivekimab administered subcutaneously (s.c.) once-monthly and added to standard of care for 12 months.
62676497|NCT06200207|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to ziltivekimab administered s.c. once-monthly and added to standard of care for 12 months.
62676498|NCT01197105|EXPERIMENTAL|Aroeira|
62676499|NCT00576407|EXPERIMENTAL|Cultured Thymus Tissue Implantation in Complete DiGeorge|"Participants with Complete DiGeorge Syndrome, who were eligible, received cultured thymus tissue implantation (CTTI).~No specific dose was assigned. There was a one time administration of the cultured thymus tissue."
62676500|NCT06445166|EXPERIMENTAL|Propranolol|"Begin at 1/2 the target dose for 2 days (4 doses), followed by a tolerability assessment. Patients who tolerate the 1/2 dose will begin the target dose on Day 3 for 2 days (4 doses), after which tolerability will be assessed. Patients who do not tolerate the target dose will decrease to a 1/2 dose for 2 days and then discontinue treatment; these patients will be withdrawn from the study and replaced. Those who continue will take the target dose for 12 weeks. At 12-week time point, one of the following paths will be taken:~* Complete response: continue taking propranolol at the target dose for another 6 weeks, followed by a reduced dose (1/2 the target) for 7 days, then discontinue treatment~* Partial response: continue taking propranolol at the target dose for another 12 weeks, followed by a reduced dose (1/2 the target) for 7 days, then discontinue treatment~* No response (stable disease/disease progression):reduced dose (1/2 the target) for 7 days, then discontinue treatment"
61918471|NCT01283854|EXPERIMENTAL|Exercise group|Each participant randomised to the exercise group will receive routine, regular antenatal care. In addition, these women will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist.
61918472|NCT01283854|NO_INTERVENTION|Control group|Women allocated to the control group will not participate in the home-based exercise program, and will continue their normal physical activity throughout pregnancy. This group will receive routine, regular antenatal care, together with the additional outcome assessments at baseline (14 weeks gestation) and cessation of the study (28 weeks gestation).
62117071|NCT03587363|EXPERIMENTAL|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
62117072|NCT03587363|EXPERIMENTAL|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
61918473|NCT06506305|EXPERIMENTAL|SAD Cohort 1|Participants in this cohort will receive SAD dose 1 of FB1001
62117073|NCT03587363|EXPERIMENTAL|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.
62117074|NCT01801293|EXPERIMENTAL|Intervention Arm|One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning.
62117075|NCT00588666|EXPERIMENTAL|Bevacizumab, Carboplatin, Gemcitabine|Patients will initially receive bevacizumab 10 mg/kg followed by a 2 week treatment-free interval. Treatment will then begin with combination therapy. Gemcitabine 1000 mg/m2 will be administered intravenously on day 1 and 8 and carboplatin AUC 4.5 on day 1 with treatment recycled every 21 days. Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of each 21-day cycle. Restaging evaluations will be performed after every 3 cycles of treatment (approximately 9 weeks). Patients will receive a total of 6 cycles of chemotherapy unless disease progression or unacceptable toxicity occurs. Patients who achieve stable disease, a partial response, or a complete response after completion of 6 cycles, will be eligible to continue bevacizumab at the same dose and schedule until disease progression for a maximum of 18 additional doses.
62117076|NCT04541901|EXPERIMENTAL|Massage|12 minutes of effleurage and petrissage on the upper limbs administered after fatiguing exercise in the swimming pool
62473305|NCT03409367|NO_INTERVENTION|Natural Skin|Parents assigned to the control arm will receive educational materials promoting general infant skin care guidelines only and will be asked to refrain from emollient use unless dry skin develops (current standard of care guidelines).
62473306|NCT03681080|NO_INTERVENTION|lying|cognitive tests are performed during lying in all groups (SFN, AAN, EDS, POTS and controls)
62305297|NCT05815953|EXPERIMENTAL|Polarstem|Polarstem uncemented femoral stem
62473307|NCT03681080|NO_INTERVENTION|standing|cognitive tests are performed during active Standing in all groups (SFN, AAN, EDS, POTS and controls)
62473308|NCT03681080|EXPERIMENTAL|crossed legs|cognitive tests are performed during leg crossing in all groups (SFN, AAN, EDS, POTS and controls)
62305298|NCT05815953|ACTIVE_COMPARATOR|Corail|Corail uncemented femoral stem
62473309|NCT01498172|EXPERIMENTAL|NMIBC at intermediate risk of progression|
62473310|NCT01498172|EXPERIMENTAL|NMIBC at high risk of progression|
62473311|NCT01498172|EXPERIMENTAL|NMIBC at low risk of progression|
62473312|NCT04889586|EXPERIMENTAL|Experimental Group|The subjects were clinically assessed with a define clinical protocol. After that, the subjects executed the device test with EMG-biofeedback wearable armband.
62473313|NCT02810886|EXPERIMENTAL|Single, arm exploratory|Patients will undergo a 68Ga-PSMA PET/CT within 1 month after routine imaging diagnostic work-up.
62676501|NCT03517969|ACTIVE_COMPARATOR|Arm A (docetaxel, carboplatin)|Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.
62676502|NCT03517969|EXPERIMENTAL|Arm B (carboplatin, berzosertib)|Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62676503|NCT01694771|EXPERIMENTAL|Olodaterol and Tiotropium|2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
62676504|NCT01694771|OTHER|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
62676505|NCT04281771|EXPERIMENTAL|Patients who undergo cardiac MRI|"Patients undergo cardiac MRI within 30 days after TAVI to assess the amount of paravalvular leakage~Patients with anemia pre-TAVI are asked to undergo videocapsule endoscopy before and 6 months after the TAVI procedure."
62305299|NCT01815684|EXPERIMENTAL|ASP3652 Group 1|Dosed according to the following scheme: placebo, low dose, medium dose, high dose
62305300|NCT01815684|EXPERIMENTAL|ASP3652 Group 2|Dosed according to the following scheme: low dose, placebo, medium dose, high dose
62305301|NCT01815684|EXPERIMENTAL|ASP3652 Group 3|Dosed according to the following scheme: low dose, medium dose, placebo, high dose
62676506|NCT05554003|EXPERIMENTAL|Metronomic Temozolomide|Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs) Dosage and schedule: 60 mg/die continuosly
62305302|NCT01815684|EXPERIMENTAL|ASP3652 Group 4|Dosed according to the following scheme: low dose, medium dose, high dose, placebo
62676507|NCT04139499||Adults with OSA|Adults with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
62676508|NCT04139499||Children with OSA|Children with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
62305303|NCT01880346|ACTIVE_COMPARATOR|100,000 IU D-50 powder|Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period
62305304|NCT01880346|ACTIVE_COMPARATOR|100,000 IU Maximum D3 in oil|Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period
62305305|NCT00308620|EXPERIMENTAL|Chloroquine|Chloroquine 205mg or 500mg orally once daily (Results pooled)
62305306|NCT00308620|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 8 weeks
62305307|NCT04332549|ACTIVE_COMPARATOR|Reconstitution Method 1|
62473314|NCT05087745|EXPERIMENTAL|Tumor Infiltrating Lymphocytes|1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62473315|NCT04530656|EXPERIMENTAL|Middle-dose vaccine (18-55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
62473316|NCT04530656|EXPERIMENTAL|Middle-dose vaccine (> 55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
62473317|NCT04530656|EXPERIMENTAL|High-dose vaccine (18-55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
62473318|NCT04530656|EXPERIMENTAL|High-dose vaccine (> 55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
62473319|NCT04530656|EXPERIMENTAL|High-dose vaccine (18-55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
62473320|NCT04530656|EXPERIMENTAL|High-dose vaccine (> 55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
62473321|NCT04530656|PLACEBO_COMPARATOR|Middle-dose placebo (18-55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
62473322|NCT04530656|PLACEBO_COMPARATOR|Middle-dose placebo (> 55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
62473323|NCT04530656|PLACEBO_COMPARATOR|High-dose placebo (18-55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
62473324|NCT04530656|PLACEBO_COMPARATOR|High-dose placebo (> 55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
62473325|NCT04530656|PLACEBO_COMPARATOR|High-dose placebo (18-55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
62473326|NCT04530656|PLACEBO_COMPARATOR|High-dose placebo (> 55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
62473327|NCT01504763|EXPERIMENTAL|Massage|Chair massage for 15 minutes once a week for 10 weeks.
62305308|NCT04332549|ACTIVE_COMPARATOR|Reconstitution Method 2|
62305309|NCT05076708|OTHER|IQOS|
62305310|NCT00005037|EXPERIMENTAL|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
62305311|NCT04231981|EXPERIMENTAL|Interventional arm|Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.
62676509|NCT04139499||Adult control|Adult without any obstruction at four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent a control.
62305312|NCT03540095|EXPERIMENTAL|Erector Spinae Plane Block|The patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
62676510|NCT04139499||Children control|Children exam will be done for all the participants. Subject without obstruction represent a control.
62676511|NCT05129384|ACTIVE_COMPARATOR|Treatment|B. infantis EVC001 infant probiotic
62676512|NCT05129384|PLACEBO_COMPARATOR|Placebo|Lactose
62676513|NCT02557893|EXPERIMENTAL|Resistance exercise|Resistance exercise involved 12 weeks of weight lifting exercise
62676514|NCT02557893|SHAM_COMPARATOR|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
61918474|NCT06506305|EXPERIMENTAL|SAD Cohort 2|Participants in this cohort will receive SAD dose 2 of FB1001
62305313|NCT03540095|EXPERIMENTAL|Paravertebral Nerve Block|The patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
62676515|NCT02557893|PLACEBO_COMPARATOR|Pregnancy education|Maternity nurses taught six bimonthly pregnancy education classes (\~20 per class) which covered several topics including information about what to expect during normal labor and delivery, common interventions during delivery (medications, induction, Cesarean delivery), parenting skills needed for baby care, breastfeeding, baby and child cardiopulmonary resuscitation, typical child development and communicating with infants. No physical activity education was included in the curriculum. The pregnancy education participants formed an attention control group.
62676516|NCT06581666||All patients who have undergone or will seek fertility preservation services|All patients who have undergone or will seek fertility preservation services, but they will be asked to complete the same set of questionnaires.
62676517|NCT06581666||General public|The general public will also be asked to complete the sane set of questionnaires.
62676518|NCT03480516|EXPERIMENTAL|SDF arm|SDF arm is application of 38% silver diamine fluoride solution (SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained.
62676519|NCT03480516|EXPERIMENTAL|Fluoride varnish arm|Fluoride varnish arm is application of 5% sodium fluoride varnish on all surface of every tooth.
62676520|NCT03480516|EXPERIMENTAL|Combination arm|Combination arm is application of 38% silver diamine fluoride solution(SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained and then apply of 5% sodium fluoride varnish on all surface of every tooth.
62676521|NCT03952520|ACTIVE_COMPARATOR|Standard Approach (SA)|The Standard Approach is a one-size-fits-all multifaceted implementation strategy that was systematically developed using Intervention Mapping.
62676522|NCT03952520|EXPERIMENTAL|Tailored Approach (TA)|The Tailored Approach includes an implementation strategy that will be tailored to match site-specific barriers to implementation of SNaP at that site.
62676523|NCT04630626|EXPERIMENTAL|Simplify Disc|Extended follow-up of IDE Subjects treated with the Simplify Cervical Artificial Disc during IDE G140154
62676524|NCT04630626|OTHER|Historical ACDF Control|Historical ACDF Data from similar protocol used as control.
62676525|NCT06695377||Patients with a PCR-confirmed COVID-19 diagnosis who were followed up on an outpatient basis|
61918475|NCT06506305|EXPERIMENTAL|SAD Cohort 3|Participants in this cohort will receive SAD dose 3 of FB1001
61918476|NCT06506305|EXPERIMENTAL|Experimental: SAD Cohort 4|Participants in this cohort will receive SAD dose 4 of FB1001
62305314|NCT04970680|ACTIVE_COMPARATOR|blind glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block with the blind technique
62305315|NCT04970680|ACTIVE_COMPARATOR|ultrasonic glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block using the ultrasonic technique
62473328|NCT00652288|ACTIVE_COMPARATOR|Catheter day 4|Adolescents with type 1 diabetes with catheters day #4
62676526|NCT06426888|EXPERIMENTAL|Experimental interventional group 1(scapular stabilization exercise therapy)|1. Ball stabilization exercise, 2.Wall push up 3. Wall push up Patients will be treated 3 times per week for 4 consecutive weeks
62676527|NCT06426888|EXPERIMENTAL|Experimental :interventional group II (scapular mobilizations)|scapular mobilization in elevation, depression, protraction and retraction. Patients will be treated 3 times per week for 4 consecutive weeks
62676528|NCT05193149|EXPERIMENTAL|4 wk IMT + 12 wk exercise|4 weeks of IMT, 3/week, 3 sets of 15 repetitions, intensity up to 70% of MIP using a pressure threshold device PLUS 12 weeks of aerobic exercise training including cycling, walking, elliptical, starting in week 5, 3/week, up to 50min per session, moderate intensity
62676529|NCT05193149|SHAM_COMPARATOR|4 wk SHAM + 12 wk exercise|4 weeks of SHAM training, 3/week, 3 sets of 15 repetitions, intensity up of 10% of MIP using a pressure threshold device PLUS 12 weeks of aerobic exercise training including cycling, walking, elliptical, starting in week 5, 3/week, up to 50min per session, moderate intensity
62676530|NCT01284088|EXPERIMENTAL|PrePex™|Adult male circumcision by the PrePex™ Device
61918477|NCT06506305|EXPERIMENTAL|Experimental: SAD Cohort 5|Participants in this cohort will receive SAD dose 5 of FB1001
61918478|NCT06506305|EXPERIMENTAL|Experimental: MAD Cohort 1|Participants in this cohort will receive MAD dose 1 of FB1001
62676531|NCT01284088|ACTIVE_COMPARATOR|Surgical|Adult male surgical circumcision
62676532|NCT01459731||Age 18-29|
62676533|NCT01459731||Age 30-39|
62676534|NCT01459731||Age 40-49|
62676535|NCT01459731||Age 50-59|
62676536|NCT01459731||Age 60-69|
62676537|NCT01459731||Age 70+|
62305316|NCT04219306|EXPERIMENTAL|Machine alert|These cardiac suspected cardiac arrest will have had an alert generated by the machine learning model in addition to standard Emergency Medical Services response.
62676538|NCT03965299|EXPERIMENTAL|VERUM transcutaneous tibial nerve stimulation (TTNS)|
62676539|NCT03965299|SHAM_COMPARATOR|SHAM transcutaneous tibial nerve stimulation (TTNS)|
62676540|NCT05525715|EXPERIMENTAL|Phase Ib Cohort 1（2mg QY201 tablets or 2mg QY201 placebo）|8 subjects use 2mg QY201 tablets，2 subject uses 2mg QY201 placebo ，BID，29 days
62676541|NCT05525715|EXPERIMENTAL|Phase Ib Cohort 2（5mg QY201 tablets or 5mg QY201 placebo）|8 subjects use 5mg QY201 tablets，2 subject uses 5mg QY201 placebo ，BID，29 days
62676542|NCT05525715|EXPERIMENTAL|Phase Ib Cohort 3（10mg QY201 tablets or 10mg QY201 placebo）|8 subjects use 10mg QY201 tablets，2 subject uses 10mg QY201 placebo，QD，29 days
62676543|NCT05525715|EXPERIMENTAL|Phase Ib Cohort 4（10mg QY201 tablets or 10mg QY201 placebo）|8 subjects use 10mg QY201 tablets，2 subject uses 10mg QY201 placebo，BID，29 days
62676544|NCT05525715|EXPERIMENTAL|Phase Ib Cohort 5（15mg QY201 tablets or 15mg QY201 placebo）|8 subjects use 15mg QY201 tablets，2 subject uses 15mg QY201 placebo，BID，29 days
62676545|NCT05525715|EXPERIMENTAL|Phase Ib Cohort 6（20mg QY201 tablets or 20mg QY201 placebo）|8 subjects use 20mg QY201 tablets，2 subject uses 20mg QY201 placebo，BID，29 days
62676546|NCT05525715|EXPERIMENTAL|Phase II Cohort1 (5mg QY201 tablets)|50 subjects use 5mg QY201 tablets twice daily for 12 weeks
62676547|NCT05525715|EXPERIMENTAL|Phase II Cohort2 (10mg QY201 tablets)|50 subjects use 10mg QY201 tablets twice daily for 12 weeks
62676548|NCT05525715|EXPERIMENTAL|Phase II Cohort3 (20mg QY201 tablets)|50 subjects use 20mg QY201 tablets twice daily for 12 weeks
62676549|NCT05525715|EXPERIMENTAL|Phase II Cohort4 (QY201 placebo)|50 subjects use QY201 placebo twice daily for 12 weeks
62676550|NCT01853085||Patients with POAG or OHT|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
62676551|NCT05061355|EXPERIMENTAL|Surgery plus medical therapy|Heart valve surgery will be performed as soon as possible and preferably within 48 hours of randomization in addition to standard medical care for IE.
61918479|NCT06506305|EXPERIMENTAL|Experimental: MAD Cohort 2|Participants in this cohort will receive MAD dose 2 of FB1001
62117077|NCT04541901|EXPERIMENTAL|Cold-water immersion|12 minutes of cold-water immersion at the shoulder level with water temperature between 11 to 15°C
62117078|NCT04541901|NO_INTERVENTION|Control|12 minutes of rest. The athletes are free to sit or walk around the place but are advised to refrain from exercise in and out of the pool.
62117079|NCT04213599||Anterior infarction|Patients with anterior ST-elevation myocardial infarction
62117080|NCT04213599||Inferior infarction|Patients with inferior ST-elevation myocardial infarction
62117081|NCT04213599||Lateral infarction|Patients with lateral ST-elevation myocardial infarction
62117082|NCT03635294|EXPERIMENTAL|Blood sample|Blood sample for analyses
62117083|NCT04610008||APON|Retrospective review of routine clinical images from patients with an acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
62117084|NCT04610008||No APON control|Retrospective review of routine clinical images from patients with NO acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
62117085|NCT05379491|ACTIVE_COMPARATOR|3 L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 3 L polyethylene glycol solution combined with 2-day linaclotide.
62117086|NCT05379491|PLACEBO_COMPARATOR|3 L PEG + Placebo|Bowel preparation for colonoscopy was performed with 3 L polyethylene glycol solution combined with 2-day placebo.
62117087|NCT04183959|ACTIVE_COMPARATOR|Group- video stylet intubation (VS)|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
62117088|NCT04183959|ACTIVE_COMPARATOR|Group- fiberoptic intubation (FO)|: intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
62117089|NCT06041919|EXPERIMENTAL|1 (Active)|Inhaled RESP301 6ml via nebulisation three times daily
62117090|NCT06041919|ACTIVE_COMPARATOR|2 (Control)|HRZE taken orally once daily
62117091|NCT06041919|EXPERIMENTAL|3 (Active)|Inhaled RESP301 6 ml via nebulisation once daily
62117092|NCT06041919|EXPERIMENTAL|4 (Active)|Inhaled RESP301 6 ml via nebulisation twice daily
62117093|NCT06041919|EXPERIMENTAL|5 (Active)|Inhaled RESP301 6 ml via nebulisation three times daily plus HRZE taken orally once dialy
62305317|NCT04219306|NO_INTERVENTION|Usual care|These suspected cardiac arrests will receive standard Emergency Medical Services response.
62473329|NCT00652288|ACTIVE_COMPARATOR|Catheter day 1|Adolescents with type 1 diabetes with catheter day #1
62676552|NCT05061355|NO_INTERVENTION|Medical therapy|Only standard medical care for IE.
62676553|NCT03834662|EXPERIMENTAL|Dose Level 1: 180 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
62676554|NCT03834662|EXPERIMENTAL|Dose Level 2: 550 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks.
62676555|NCT03834662|EXPERIMENTAL|Dose Level 3: 1100 mg/m2|Intravenous infusion of AVID200 over 1.5 hours administered every three weeks.
62676556|NCT00926705|ACTIVE_COMPARATOR|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
62676557|NCT00926705|EXPERIMENTAL|Dexmedetomidine and Fentanyl|This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
62676558|NCT03995511|EXPERIMENTAL|Bilateral sagittal split|
62676559|NCT02533674|EXPERIMENTAL|gemcitabine plus PM060184|
62676560|NCT06009354|EXPERIMENTAL|Intervention Group|The study group will receive multi-component training in addition to the usual practices. In the multi-component training content, self-massage applications performed by the patient's relatives, joint range of motion applications for the extremities, respiratory training, issues to be considered in activities of daily living, training on the use of assistive devices and training on methods of coping with pain kinesiophobia will be given to the patient's relatives through a video.
62676561|NCT06009354|ACTIVE_COMPARATOR|Control Group|The control group will receive the usual post-operative applications (elevation, rest, cold application, stretching).
61918480|NCT06506305|EXPERIMENTAL|Experimental: MAD Cohort 3|Participants in this cohort will receive MAD dose 3 of FB1001
61918481|NCT06157216|EXPERIMENTAL|MRD-guided treatment|Patients post-surgery will receive MRD tests and receive MRD-guided adjuvant therapies. After that, MRD status will be continuously monitored for three years to guide the following therapies.
61918482|NCT02761837|ACTIVE_COMPARATOR|IVR call/text|Identify gaps in care and contact patients by IVR phone call or text
62676562|NCT04153032|EXPERIMENTAL|DTZ arm|The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.
62676563|NCT04153032|EXPERIMENTAL|MEBO arm|The second group of patients will apply topical DTZ ointment peri-anally 3 times daily for 6 weeks.
61918483|NCT02761837|ACTIVE_COMPARATOR|Email|Identify gaps in care and contact patients by email
61918484|NCT03667300|ACTIVE_COMPARATOR|Evogliptin Group|Intervention group will take daily evogliptin 5mg per oral, not linagliptin 5mg per oral
61918485|NCT03667300|ACTIVE_COMPARATOR|Linagliptin Group|Control group will take daily linagliptin 5mg per oral, not evogliptin 5mg per oral
61918486|NCT01275339|ACTIVE_COMPARATOR|Tadalafil in Diabetic Cohort|
61918487|NCT01275339|PLACEBO_COMPARATOR|Placebo in Diabetic Cohort|
61918488|NCT01275339|ACTIVE_COMPARATOR|Tadalafil in Non-Diabetic Cohort|
61918489|NCT01275339|PLACEBO_COMPARATOR|Placebo in Non-Diabetic Cohort|
61918490|NCT06146998|EXPERIMENTAL|3D model group|Received a explanation combined with 3D medical education model
62117094|NCT04442919|EXPERIMENTAL|Ticagrelor followed with methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
61918491|NCT06146998|ACTIVE_COMPARATOR|traditional explanation group|Received a regular explanation
62117095|NCT04442919|ACTIVE_COMPARATOR|Ticagrelor followed with morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
62117096|NCT04442919|ACTIVE_COMPARATOR|Ticagrelor|patients who received ticagrelor without any analgesia due to unstable angina
62676564|NCT04153032|EXPERIMENTAL|MEBO and DTZ arm|The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
62676565|NCT06686095|ACTIVE_COMPARATOR|Group Adductor canal block|Patients who underwent adductor canal block
62676566|NCT06686095|ACTIVE_COMPARATOR|Group IPACK Block|Patients who underwent Infiltration between Popliteal Artery and Capsule of the Knee block
62676567|NCT06686095|ACTIVE_COMPARATOR|Group Genicular Nerve Block|Patients who underwent Genicular nerve block
62676568|NCT02926196|EXPERIMENTAL|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
62305318|NCT03411070|EXPERIMENTAL|Treatment (SCOUT reflector surgery)|Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
62305319|NCT00707577|EXPERIMENTAL|Internet-based maintenance program|9-month Internet based self-monitoring maintenance program to track weight, exercise, and food logs
62305320|NCT00707577|NO_INTERVENTION|Control|No maintenance program provided
62305321|NCT01037712|EXPERIMENTAL|ZELITREX|ZELITREX
62305322|NCT01037712|PLACEBO_COMPARATOR|Placebo|placebo
62305323|NCT06428773|ACTIVE_COMPARATOR|Exercise Group|The exercise group performed moderate-intensity aerobic exercise on a stationary bicycle ergometer for 30 minutes during hemodialysis sessions, three days a week over 12 weeks. Additionally, the exercise group engaged in walking exercise for 30 minutes, three days a week outside of hemodialysis sessions, maintaining the heart rate between 50-60%. The exercise group also performed isolated exercises to expand wrist vessels, including wrist and elbow flexion, extension, and rotation, repeated 10 times, 2-3 days a week outside of hemodialysis sessions.
62305324|NCT06428773|EXPERIMENTAL|control group|The control group did not engage in any exercise.
62305325|NCT02528695|ACTIVE_COMPARATOR|Healthy euglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during an euglycemic clamp
62305326|NCT02528695|ACTIVE_COMPARATOR|healthy hypoglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
62305327|NCT02528695|EXPERIMENTAL|Type 2 diabetes hypoglycemic clamp|In 5 type 2 diabetes patients, an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
62305328|NCT02047552|ACTIVE_COMPARATOR|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
62305329|NCT02047552|ACTIVE_COMPARATOR|Oxandrolone|Oxandrolone 10 mg PO q12 hours will be dosed for seven days.
62305330|NCT02047552|EXPERIMENTAL|Iron sucrose + oxandrolone|Combination goal-directed iron sucrose (as described in the iron sucrose only arm) and oxandrolone (as described in the oxandrolone only arm) for seven days.
62305331|NCT02047552|PLACEBO_COMPARATOR|IV iron placebo and Oxandrolone placebo|100 mL normal saline in place of iron and similar color and size sugar pill for Oxandrolone placebo
62305332|NCT02604966|EXPERIMENTAL|Artesunate (AS) group|P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
62305333|NCT02604966|ACTIVE_COMPARATOR|DHA - PPQ group|P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
62305334|NCT04844190|EXPERIMENTAL|Addition of ADM and EndoFLIP to pre-G-POEM evaluation|During the preoperative upper endoscopy, the EndoFLIP catheter is inserted through the mouth with endoscopic guidance and placed through the gastric pylorus. Once deployed, water is sequentially added at set volumes to a balloon that can be used to measure pyloric diameter, cross-sectional area, pressure, and distensibility at set volumes of 30, 40, and 50 mL for at least five seconds. We will record this data for each patient. The EndoFLIP catheter will then be removed. Subsequently, a high resolution ADM catheter will be inserted through the nose and placed through the pylorus to measure baseline intragastric, transpyloric, and intraduodenal pressures. The patient will be observed for up to four hours to assess a migrating motor complex (MMC). After the MMC is observed, the patient will be given a meal and observed for meal response with the manometry catheter. The meal will be water and two pieces of toast/bread. Following the meal, the catheter will be removed.
62305335|NCT01914133|NO_INTERVENTION|No Postprandial Hypotension (PPH)|Screening Meal Test performed and subject does not meet criteria for Postprandial Hypotension (PPH).
62305336|NCT01914133|PLACEBO_COMPARATOR|Placebo|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension (PPH). At second Meal Test subject will receive a placebo and will take a placebo with the first bite of the next 3 meals.
62305337|NCT01914133|ACTIVE_COMPARATOR|Acarbose|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
62676569|NCT02926196|NO_INTERVENTION|Arm Observation|Observation as per guidelines
61918492|NCT02314143|EXPERIMENTAL|Dabrafenib followed by combination therapy|Eligible subjects will receive dabrafenib 150 milligrams (mg) twice a day (BID) continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
62117097|NCT03280017|EXPERIMENTAL|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
62117098|NCT03280017|PLACEBO_COMPARATOR|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
62676570|NCT02203786|ACTIVE_COMPARATOR|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
62676571|NCT02203786|ACTIVE_COMPARATOR|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
62676572|NCT05259176|EXPERIMENTAL|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) on the left posterior parietal cortex and rehabilitative treatment with Smania's training
62676573|NCT05259176|SHAM_COMPARATOR|Placebo stimulation (sham-tDCS)|Placebo stimulation and rehabilitative treatment with Smania's training
62676574|NCT05627986||chronic shoulder impingement syndrome|Subjects with shoulder impingement more than 6 months will be included to assess pain threshold, neurophysiological measurements of scapular muscles.
62676575|NCT05627986||control group|Healthy controls without any shoulder and neck problems will be included to compare the differences in pain threshold, neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with chronic or acute shoulder impingement syndrome.
62676576|NCT03574779|EXPERIMENTAL|Cohort A: 1-2 prior lines of therapy (TSR-042, Bevacizumab, and Niraparib)|PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered 500 milligrams (mg) on Day 1 every 3 weeks (Q3W) for 4 cycles (each cycle is 21 days), followed by 1000 mg every 6 weeks (Q6W) beginning on Cycle 5 Day 1 until progressive disease (PD) or toxicity. Bevacizumab administered 15 milligram per kilogram (mg/kg) every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day until PD or toxicity.
62676577|NCT03574779|ACTIVE_COMPARATOR|Cohort C: Arm 1: Participants receiving platinum plus taxane|Participants are expected to receive 1 run-in cycle (up to 5 weeks) of carboplatin-paclitaxel during pre-screening. After confirmation that the tumor is homologous recombination-deficient (HRd). Participants will then be randomized to three 21-day cycles of platinum-taxane doublet chemotherapy (carboplatin plus paclitaxane). After interval debulking surgery (IDS), all participants will receive up to three 21-day cycles of adjuvant platinum-taxane doublet chemotherapy (and optional bevacizumab for participants deemed high-risk; third cycle is optional) followed by niraparib (and optional bevacizumab or bevacizumab biosimilar for participants deemed high- risk) maintenance treatment.
62117099|NCT03542630||fertile, without periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
62117100|NCT03542630||fertile, with periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do have periodontitis.~Interventions:~salivary MMP8 test;periodontal examination;blood tests"
62117101|NCT03542630||infertile, without periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination;blood tests"
62117102|NCT03542630||infertile, with periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
62305338|NCT05059197|EXPERIMENTAL|AP collagen peptide|Each subject takes one active bottle per day for 12 weeks. Each bottle contains AP collagen 1000 mg
62305339|NCT05059197|PLACEBO_COMPARATOR|Placebo|Each subject takes one active bottle per day for 12 weeks.
62305340|NCT02236624|EXPERIMENTAL|Aerobic Exercise|
62473330|NCT00652288|ACTIVE_COMPARATOR|Aspart and Detemir|Adolescents with type 1 diabetes
62473331|NCT00652288|ACTIVE_COMPARATOR|Lispro and Glargine|Adolescents with type 1 diabetes
61918493|NCT02314143|EXPERIMENTAL|Trametinib followed by combination therapy|Eligible subjects will receive trametinib 2 mg per day continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
62117103|NCT04782635|EXPERIMENTAL|AI group|"* Care givers will be selected through permuted block.~* They will be explained the procedure of intervention and written consent will be asked.~* Mobile application will be installed in their mobile.~* They will be explained the working of mobile application~* Application will make a standard diet plan for the child according to the requirements of the child~* Then the child will use the application for one month.~* After one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application.~* Nutritional status of the patient will be monitored including weight, height, clinical signs, dietary history and will be updated in application.~* Then patient will follow the application for one month~* After another one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application and nutritional status will be measured"
62305341|NCT02197962|EXPERIMENTAL|Extracorporeal radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwave per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
62305342|NCT02197962|PLACEBO_COMPARATOR|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
62676578|NCT03574779|EXPERIMENTAL|Cohort C: Arm 2: Participants receiving neoadjuvant Niraparib|Participants are expected to receive 1 run-in cycle (up to 5 weeks) of carboplatin-paclitaxel during pre-screening. After confirmation that the tumor is HRd, participants will be randomized to three 21-day cycles of neoadjuvant niraparib therapy. After IDS, all participants will receive up to three 21-day cycles of adjuvant platinum-taxane doublet chemotherapy (and optional bevacizumab for participants deemed high-risk; third cycle is optional) followed by niraparib (and optional bevacizumab or bevacizumab biosimilar for participants deemed high- risk) maintenance treatment.
61918494|NCT02314143|EXPERIMENTAL|Combination therapy|Eligible subjects will receive trametinib 2 mg per day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
62305343|NCT04020432||pregnant women|"Pregnant women are coming to their monthly consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Pregnant women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
62305344|NCT04020432||childbearing age women|"Women of childbearing age, who are coming for a gynecological consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Childbearing age women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
62305345|NCT05412329|EXPERIMENTAL|GC012F treatment|R/R multiple myeloma patients be treated with a single dose of GC012F cells.
62305346|NCT01499576|EXPERIMENTAL|Acetic acid spraying|
62473332|NCT01082926|EXPERIMENTAL|Arm I|Patients receive intratumoral GRm13Z40-2 therapeutic allogeneic lymphocytes over 10 minutes on days 1 and 3 and intratumoral aldesleukin over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity.
62676579|NCT05373966||Delphi Panel|A team of experts in the field of robotic RNU will be invited to participate in the current survey. These experts are identified according to surgical experience, research and academic interest, expertise in running training courses, and participation in live-surgery cases.
62676580|NCT06623266|PLACEBO_COMPARATOR|Experimental arm|The patients in the experimental arm will receive radical resection of the primary lesion only, with neck observation, the safety margins of the primary lesion are 1.0-1.5cm far away from the palpable margins of the lesion. Ultrasonography, CT scan, and/or MRI examination will be used to detect lesions.
62676581|NCT06623266|ACTIVE_COMPARATOR|Control arm|The patients in the control arm will receive radical resection of the primary lesion with the safety margins of the primary lesion are 1.0-1.5cm far away from the palpable margins of the lesion, they will also receive simultaneous elective neck dissection. Ultrasonography, CT scan, and/or MRI examination will be used to detect lesions.
62676582|NCT04299425|EXPERIMENTAL|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo parathyroidectomy (PTx).
61918495|NCT00321893|EXPERIMENTAL|Arm I: Budesonide|Inhaled Budesonide 800 ug twice daily for 1 year
61918496|NCT00321893|PLACEBO_COMPARATOR|Arm II: Placebo|Inhaled placebo twice daily for 1 year
61918497|NCT03206957|OTHER|Study group|Down Syndrome children
61918498|NCT03206957|OTHER|Control group n°1|Down Syndrome children's mothers
61918499|NCT03206957|OTHER|Control group n°2|Age and sex matched healthy children
61918500|NCT03206957|OTHER|Control group n°3|Down syndrome children's healthy siblings
61918501|NCT00521911|ACTIVE_COMPARATOR|1|Cognitive Behavioural Therapy
61918502|NCT00521911|NO_INTERVENTION|2|Treatment as Usual
62676583|NCT04299425|NO_INTERVENTION|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo parathyroidectomy (PTx).
62305347|NCT05343195|ACTIVE_COMPARATOR|Control group|"Conventional physiotherapy was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program:~* 1-2 week: 20 min. of active exercise in lying position (e.g.: hip flexion, extension, abduction) with the goal to improve hip range of motions, strengthen muscles. Various equipment was used (slippery base, elastic bands, foam roller, gymnastic ball etc.). + gait training exercise within the bars (10 min);~* 3 week: 20 min. of active exercise in lying position + stationary bicycle / treadmill (10 min)."
62305348|NCT05343195|EXPERIMENTAL|Task oriented exercise group|"Task oriented exercise program was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program included:~* 1 week: active exercise in lying position (15 min) + task-oriented exercise (15 min);~* 2 week: active exercise in lying position (10 min) + task-oriented exercise (20 min);~* 3 week: stationary bicycle / treadmill (10 min) + task-oriented exercise (20 min).~Task oriented exercise included:~* walking backwards, sideways, high kneels (on the instable bases);~* walking with alternate speed (physiotherapist give the instruction when to walk faster / slower);~* Sit and stand from the chair (standing up to reach for the ball held by the physiotherapist);~* step onto the step (after stepping to reach the ball held by the physiotherapist);~* walk with the obstacles (obstacle course);~* Catch and throw the ball while standing on an unstable base."
62305349|NCT04837040|EXPERIMENTAL|Paltusotine|
62305350|NCT04837040|PLACEBO_COMPARATOR|Placebo|
62305351|NCT02646904|EXPERIMENTAL|Beclometasone Dipropionate (BDP)|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of Nasal Beclomethasone Dipropionate for 21 days.
62305352|NCT02646904|ACTIVE_COMPARATOR|CERCHIO 10 mg/ml OS|For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
62305353|NCT02386423|EXPERIMENTAL|RESTIFFIC|RESTIFFIC™ Brand Pressure Application System
62305354|NCT04107220|OTHER|one arm|One arm study patients where NT-proBNP and BNP tests will be monitored.
62305355|NCT01137435|EXPERIMENTAL|Study Group|
62305356|NCT04754373|EXPERIMENTAL|GFA-918|Participants will be instructed to take one GFA-918 capsule twice per day with their morning and evening meals for 12 weeks.
62305357|NCT04754373|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
62305358|NCT06231108||Case Group|"In the Single Group, three different taping applications will be performed."
62305359|NCT04219267|EXPERIMENTAL|The intervention group|Character strengths-based intervention, 3 sessions every week for three weeks. 30 minutes each session.
62305360|NCT04219267|PLACEBO_COMPARATOR|The control group|Early memories for placebo control, 3 sessions every week for three weeks. 30 minutes each session.
62676584|NCT06544148||All Study Participants|
62117104|NCT04782635|OTHER|usual care group|"* Caregivers (Mothers/fathers/guardians) will be selected through permuted block.~* Patient weight, height, clinical signs will be noted.~* Caregivers will be handed over pamphlet regarding dietary instructions on discharge.~* After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted including weight, height, clinical signs and dietary history.~* Patient will leave hospital with no added dietary instruction.~* After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted weight, height, clinical sign, and dietary history."
62305361|NCT00463437|EXPERIMENTAL|GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
62305362|NCT00463437|EXPERIMENTAL|GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany \& Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
62305363|NCT00463437|EXPERIMENTAL|GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
62305364|NCT00463437|ACTIVE_COMPARATOR|Prevenar™ + Menitorix™|Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany \& Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
62117105|NCT02999581|EXPERIMENTAL|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 10 mg Bitter Orange (Citrus Aurantium) fruit standardized for 30% synephrine (Advantra Z), 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
62117106|NCT02999581|ACTIVE_COMPARATOR|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
62117107|NCT02999581|PLACEBO_COMPARATOR|Placebo|One dose of flavored placebo (powder mixed with water)
62117108|NCT00835380|EXPERIMENTAL|1|VAQTA™
62117109|NCT01343342|EXPERIMENTAL|capsules omega-3|Omega-3 supplementation (3g EPA+DHA/d)
62117110|NCT05861050|EXPERIMENTAL|Treatment (venetoclax, glofitamab, lenalidomide)|Patients receive venetoclax PO, obinutuzumab IV, glofitamab IV, and lenalidomide IV on study. Patients undergo bone marrow biopsy, blood sample collection, and CT scan and/or PET scan throughout the study. Patients may undergo tumor biopsy throughout the study.
62117111|NCT03445598|EXPERIMENTAL|Interactive CCBT group|This group receives Interactive and Personalized CCBT
62117112|NCT03445598|ACTIVE_COMPARATOR|Limited CCBT control group|This group receives Feature-limited CCBT
62305365|NCT01050777|EXPERIMENTAL|Liposomal Paromomycin|Liposomes containing 10% Paromomycin
62305366|NCT01050777|EXPERIMENTAL|Liposomal meglumine antimoniate|Liposomes containing meglumine antimonate
62305367|NCT01050777|PLACEBO_COMPARATOR|Placebo|
62305368|NCT04252417|ACTIVE_COMPARATOR|Patients with hepatic impaired function|8 patients with hepatic impairment of moderate Child Pugh category
61918503|NCT06517797|EXPERIMENTAL|S1B-509|Simultaneous oral dosing once daily with two to four extended-release tablets or capsules of S1B-509, for 48 weeks
62305369|NCT04252417|ACTIVE_COMPARATOR|Healthy subjects|Healthy volunteers will be matched with impaired hepatic function patients
62117113|NCT03445598|OTHER|Waitlist control group|This group receives waitlist control
62117114|NCT02576821|OTHER|Patients with Hippocampal sclerosis non AD|Patients with Hippocampal sclerosis non AD (n=40)
62117115|NCT02576821|OTHER|Patients with Alhzeimer's Disase|Patients with Alhzeimer's Disase (n=40)
62117116|NCT02576821|OTHER|Patients with DLFT|Patients with DLFT (n=20)
62117117|NCT02576821|OTHER|Patients with CBD/PSP|Patients with CBD/PSP (n=20)
62117118|NCT02576821|OTHER|Normal controls|Normal controls (n=20)
61918504|NCT06517797|PLACEBO_COMPARATOR|Placebo|Simultaneous oral dosing once daily with two to four placebos, for 48 weeks
61918505|NCT04467996|ACTIVE_COMPARATOR|6 hour IUBT placement|
61918506|NCT04467996|ACTIVE_COMPARATOR|18 hour IUBT placement|
62117119|NCT06552702||Community sample|Black Americans (8 high SEP, 8 low SEP) and White Americans (8 high SEP, 8 low SEP) between the ages of 35 and 70
62117120|NCT05006092|EXPERIMENTAL|surveillance endoscopy with CADe support|Endoscopy perfomed with CADe support.
62117121|NCT05006092|NO_INTERVENTION|conventional surveillance endoscopy|Endoscopy perfomed without CADe support.
62305370|NCT02471963|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin, 25 mg/day, oral administration, 6 weeks
62305371|NCT02471963|PLACEBO_COMPARATOR|Placebo|Placebo, oral administration, 6 weeks
62305372|NCT06481358||AI group|Participants read CT images with AI.
62305373|NCT06481358||Manual group|Participants read CT images without AI
62473333|NCT06220097|EXPERIMENTAL|Effective of MHL injection-containing bridging regimens with CD19 CAR-T|After enrollment, all subjects will receive a combination regimen of mitoxantrone hydrochloride liposomal injection within 28 days to 7 days before CAR-T infusions will be included, including but not limited to the R-MINE regimen (mitoxantrone hydrochloride liposomal injection combined with rituximab, mesna, ifosfamide and etoposide), G-MINE regimen (mitoxantrone hydrochloride liposomal injection combined with obinutuzumab, mesna, ifosfamide and etoposide), MAE scheme (mitoxantrone hydrochloride liposomal injection combined with cytarabine, etoposide), etc.
62473334|NCT01177020||Placentas after delivery or abortion|
62473335|NCT01933360|ACTIVE_COMPARATOR|Misoprostol sublingual,1h|Administration of misoprostol sublingually 1h prior to surgery
62473336|NCT01933360|ACTIVE_COMPARATOR|Misoprostol sublingual. 3h|Administration of misoprostol sublingually 3h prior to surgery
61918507|NCT04638504||11-14 weeks of normal pregnancy.|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
62305374|NCT02715648|NO_INTERVENTION|No Phenazopyridine before cystoscopy|This group will not receive phenazopyridine prior to cystoscopy
62305375|NCT02715648|EXPERIMENTAL|Phenazopyridine before cystoscopy|This group will receive 200mg of phenazopyridine prior to cystoscopy
62305376|NCT03228186|EXPERIMENTAL|Pevonedistat plus Docetaxel|Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle
62305377|NCT06394622|EXPERIMENTAL|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|"Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC729 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2;"
62305378|NCT01277575|EXPERIMENTAL|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
62305379|NCT01277575|SHAM_COMPARATOR|Placebo stimulation|Sham stimulation (placebo condition) no intervention
62305380|NCT01933984|EXPERIMENTAL|Individualized dosing|"* Ventilator support~* Determining personal target airway resistance~* Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~* Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~* Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~* Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)"
62305381|NCT01933984|ACTIVE_COMPARATOR|Fixed dosing|"* Ventilator support~* Determining personal target airway resistance~* Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~* Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~* Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~* No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met"
62305382|NCT04353947||Healthy older adults|Healthy older adults with 65 years or older
62305383|NCT04353947||Older adults with Alzheimer's disease|Older adults with Alzheimer's disease with 65 years or older
62473337|NCT01933360|ACTIVE_COMPARATOR|Misoprostol vaginal,1h|Administration of misoprostol vaginally 1h prior to surgery
62473338|NCT01933360|ACTIVE_COMPARATOR|Misoprostol vaginal,3h|Administration of misoprostol vaginally 3h prior to surgery
62473339|NCT02613754|EXPERIMENTAL|Contingency Management|Contingency Management (CM+): This procedure is designed to reinforce treatment attendance, non-gambling behaviour, and study completion. Participants will earn points that will be recorded on vouchers that could be subsequently redeemed for gift cards at a variety of local businesses. Submission of evidence of gambling behaviour or non-attendance re-sets the point value for future vouchers to the starting level. This intervention is in addition to Treatment as Usual.
62473340|NCT02613754|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual (TAU): This is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling.
62305384|NCT04353947||Older adults with Parkinson's disease|Older adults with Alzheimer's disease with 65 years or older
62305385|NCT05924477|ACTIVE_COMPARATOR|Sulcus tube placement|Glaucoma drainage device (GDD) implantation with tube placement in the ciliary sulcus
62305386|NCT05924477|ACTIVE_COMPARATOR|Anterior chamber (AC) tube placement|Glaucoma drainage device (GDD) implantation with tube placement in the anterior chamber
62305387|NCT00666185|EXPERIMENTAL|1|
62305388|NCT00666185|ACTIVE_COMPARATOR|2|
62305389|NCT02823912|EXPERIMENTAL|Capsaicin|75 mg capsaicin every 12 hours for 90 days
62305390|NCT02823912|PLACEBO_COMPARATOR|Control|75 mg magnesia calcinada every 12 hours for 90 days
62473341|NCT00002601|EXPERIMENTAL|Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT|"Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.~Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused"
62473342|NCT05212363|EXPERIMENTAL|Calf Compression|Subjects will wear calf compression garments while video gaming for 2 hours. All subjects will undergo blood flow assessments before and after wearing lower leg graduated compression gear during their gaming session (i.e. compression during uninterrupted sitting).
62473343|NCT05212363|EXPERIMENTAL|6- minute Walk|Subjects will game for 2 hours sitting and take a 6 minute walking break at the one hour period before resuming game play. All subjects will undergo blood flow assessments before and after taking an active break (i.e. 6-minute walk) during their gaming session.
62473344|NCT05212363|NO_INTERVENTION|Continuous video game play|Subjects will game for 2 hours sitting with no break. All subjects will undergo blood flow assessments without wearing lower leg graduated compression gear or taking an active break during their gaming session (i.e. during uninterrupted sitting).
62473345|NCT02135263|EXPERIMENTAL|Methylphenidate|
62473346|NCT02135263|EXPERIMENTAL|Enalapril|
62676585|NCT03568071|EXPERIMENTAL|Cohort A - dose regimen A|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen A) will be administered on Day 1.
62473347|NCT05401734||Cohort 1|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
62117122|NCT06037824|EXPERIMENTAL|Experimental Group|"This group received classic rehabilitation\* + compressive cryotherapy~\* classic rehabilitation include passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
62473348|NCT05401734||Cohort 2|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
62473349|NCT05401734||Cohort 3|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
62473350|NCT03205774|SHAM_COMPARATOR|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
62676586|NCT03568071|EXPERIMENTAL|Cohort B - dose regimen B|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen B) will be administered on Day 1.
62305391|NCT04732377|PLACEBO_COMPARATOR|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
62305392|NCT04732377|ACTIVE_COMPARATOR|Group (D)|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
62473351|NCT03205774|SHAM_COMPARATOR|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
62676587|NCT03568071|EXPERIMENTAL|Cohort C - dose regimen C|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen C) will be administered on Day 1.
62117123|NCT06037824|ACTIVE_COMPARATOR|Control Group|"This group received classic rehabilitation\* + classic cryotherapy~\*classic rehabilitation include passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
62117124|NCT00586586|EXPERIMENTAL|Group CBT|The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered in groups of 4 to 8. 10 weekly sessions plus 2 booster sessions.
62117125|NCT00586586|EXPERIMENTAL|Individual CBT|"The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered individually.~10 weekly sessions plus 2 booster sessions."
62117126|NCT00586586|NO_INTERVENTION|Wait-list control|Wait-list control condition for 5 weeks after last child has been included.
62117127|NCT06072105|ACTIVE_COMPARATOR|Group 1|Personalized best medical care.
62117128|NCT06072105|EXPERIMENTAL|Group 2|Personalized best medical care PLUS telemedicine
62117129|NCT04108754||Diagnosis of AIT|Patients in the neurovascular unit of the Neurological Hospital of Lyon between 01/01/2016 and 30/12/2017 with a probable diagnosis of AIT and having an MRI within 7 days of TIA.
62117130|NCT04551794|EXPERIMENTAL|Online self-help program with additional peer support|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
62117131|NCT04551794|NO_INTERVENTION|No intervention: waitlist-control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 9 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
62676588|NCT03568071|EXPERIMENTAL|Cohort D - dose regimen D|MOR106 will be administered as IV infusion. Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen D) will be administered on Day 1.
62676589|NCT03568071|EXPERIMENTAL|Cohort E - dose regimen E|MOR106 will be administered as IV infusion.Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen E) will be administered on Day 1.
62676590|NCT03568071|PLACEBO_COMPARATOR|Placebo|Subjects will receive repeated doses of placebo over a 12-week treatment period.
62676591|NCT06557577||Healthy athletes|Competitive athletes without any groin injury.
62676592|NCT05874297|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients receive standard of care consisting of symptom monitoring, scheduled nurse visits, and access to current Cook for Your Life website.
62676593|NCT05874297|EXPERIMENTAL|Arm II (enhanced Cook for Your Life)|Patients receive standard of care as in Arm I and access to enhanced Cook for Your Life information on symptom management.
62676594|NCT02668315|EXPERIMENTAL|Cohort 1|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 1.0-4.9 x 10E5/kg and TNC superior or equal to 2.0 x 10E7/kg
62305393|NCT02037945|EXPERIMENTAL|pts with brain mets going for surgery|"This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal hot spots (a focus of lesion/normal white matter ratio \>1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue."
62305394|NCT05426343|EXPERIMENTAL|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62305395|NCT05426343|ACTIVE_COMPARATOR|AZD1222|n=ChAdOx1 nCoV-19 vaccine
62305396|NCT05004012|OTHER|Control|No diagnosis of gastroparesis, functional dyspepsia, or prior G-POEM
62117132|NCT04551794|EXPERIMENTAL|Online self-help program with therapeutic guidance|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences and difficulties concerning the program on a weekly basis with a therapeutic guide on the phone.
62117133|NCT01829386||Non heme iron levels on MRI|"Intervention: MRI scans To develop a reliable MR based measurement of Non-heme iron in brain tissue of patients with hemorrhagic stroke : on day 1, 14 and 30 after stroke to assess the non heme iron levels on MRI.~To evaluate the role of iron chelators following a hemorrhagic stroke/parenchymal hemorrhage."
62117134|NCT03688659|OTHER|vancomycin,gentamycin in endocarditis|patients with infective endocarditis will recieve intravenous infusion Vancomycin 30 mg/kg/day for 4:6 weeks and intravenous Gentamycin 3mg/kg/day for 2 weeks
62305397|NCT05004012|OTHER|Gastroparesis|Patients with a diagnosis of gastroparesis meeting the inclusion criteria
62676595|NCT02668315|EXPERIMENTAL|Cohort 2|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.5-4.9 x 10E5/kg and TNC superior or equal to 1.5 x 10E7/kg
62117135|NCT06178822||Patients with infection|Patients with an (suspected) infection and a MEWS score 2 or higher
62117136|NCT03699293|ACTIVE_COMPARATOR|ASA and Celecoxib|Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
62117137|NCT03699293|ACTIVE_COMPARATOR|ASA and Naproxen|Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)
62305398|NCT05004012|OTHER|Functional Dyspepsia|Patients with a diagnosis of functional dyspepsia meeting the inclusion criteria
62117138|NCT05746247|EXPERIMENTAL|Patients without a primary care physician within the UPHS health system|Patients without a primary care physician within the UPHS health system will receive direct outreach from the study team to invite them to schedule a visit with a lipid specialist for a formal evaluation of FH.
62305399|NCT05004012|OTHER|G-POEM|Patients who received a G-POEM procedure meeting the inclusion criteria
62676596|NCT02668315|EXPERIMENTAL|Cohort 3|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.25-4.9 x 10E5/kg and TNC superior or equal to 1.25 x 10E7/kg
61918508|NCT04638504||11-14 week obese pregnant|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
62676597|NCT06081114|PLACEBO_COMPARATOR|MNs - Placebo|Placebo powder, daily in the form of a powdered flavored drink. Plus, a daily fortified balanced energy and protein food supplement containing 400 kcals and 14 g of protein and 1 recommended daily allowance (RDA) of 18 micronutrients will be given daily including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of copper and 500 mg of calcium
62676598|NCT06081114|ACTIVE_COMPARATOR|MNs - Level 1|"Dose 1 of micronutrients (MNs) listed provided daily in the form of a powdered drink.~Micronutrients:~Vitamin A -0.355 mg Vitamin D - 0.02 mg Vitamin E - 34 mg Vitamin B1 - 1.4 mg Vitamin B2 - 1.4 mg Vitamin B3 - 17 mg Vitamin B6 - 2.1 mg Vitamin B12 - 0.0034 mg Vitamin C - 20 mg Selenium - 0.035 mg Choline - 550 mg Pantothenic acid - 7mg Biotin - 0.035 mg Potassium - 1000 mg Manganese - 2.6 mg Magnesium - 145 mg Plus, a daily fortified balanced energy and protein supplement containing 400 kcals and 14 g of protein and 1 RDA of 18 micronutrients will be given simultaneously including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of Copper and 500 mg of calcium"
61918509|NCT04638504||24-28 week normal pregnant|24-28. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery, and maternal uterine artery dopes will be examined ultrasonographically.
62117139|NCT05746247|EXPERIMENTAL|Patients with a primary care physician within the UPHS health system|For patients with a primary care physician within the UPHS health system, their primary care physicians will be asked to review and sign physician referrals to a lipid specialist and invite patients to schedule a visit with a lipid specialist for a formal evaluation of FH.
62117140|NCT03567798|EXPERIMENTAL|A|"UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
62117141|NCT03567798|PLACEBO_COMPARATOR|B|"Placebo~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
62117142|NCT05404906|EXPERIMENTAL|Treatment (azacytidine+venetoclax)|Participants will receive azacytidine QD, on Days 1-5 and venetoclax QD, on Days 1-14 of each 28-day cycle for 8 cycles.
62305400|NCT00831051|EXPERIMENTAL|Q8003 12mg/8mg|Combination
62305401|NCT00831051|ACTIVE_COMPARATOR|Morphine sulfate 12 mg|Single component
62305402|NCT00831051|ACTIVE_COMPARATOR|Oxycodone HCl 8mg|Single component
62305403|NCT00831051|EXPERIMENTAL|Q8003 6mg/4mg|Combination
62305404|NCT00831051|ACTIVE_COMPARATOR|Morphine sulfate 6mg|Single component
62305405|NCT00831051|ACTIVE_COMPARATOR|Oxycodone HCl 4mg|Single component
62305406|NCT04373122|EXPERIMENTAL|REBOA|Insertion of the ER-REBOA Catheter during ongoing CPR
62305407|NCT05510986|ACTIVE_COMPARATOR|Fentanyl group|Drugs
62305408|NCT05510986|EXPERIMENTAL|Oxycodone Hydrochloride group|Drugs
62305409|NCT04047030||Injured Cohort|Approximately 300 participants treated for a fracture of the tibial plateau, pilon, ankle or calcaneus will be enrolled from METRC civilian trauma centers and military treatment facilities over an 18 month period. Participating centers treat large numbers of severe orthopaedic injuries and have a proven track record for successfully recruiting and retaining participants in prospective studies in orthopaedic trauma. Participants will be enrolled following definitive treatment of their injury.
62305410|NCT04047030||Non-Injured Volunteers|Non-injured adults of similar age and gender distribution will be enrolled at two participating centers (Carolinas Medical Center and Womack Military Medical Center). The sample of non-injured volunteers will exclude individuals with history of lower extremity injury, vascular disease, or who require use of ambulatory aides to walk.
62305411|NCT01211691|EXPERIMENTAL|Phase 1 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects with heme malignancies will be assigned to one of 11 planned KB004 (dose levels (20mg, 40mg, 70mg, 100mg, 140mg, 190mg, 250mg, 330mg)"
62305412|NCT01211691|EXPERIMENTAL|Phase 2 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects will be assigned to the recommended Phase 2 dose of 250 mg"
62305413|NCT03442803|EXPERIMENTAL|Propofol TCI|Delivery of Propofol via a Target-controlled infusion pump for procedural sedation.
62305414|NCT05164328||Athletes|"1. Males and females aged 14-23 years old~2. Athletes competing in endurance sports at national or international level for at least 2 years. Sports include:~   1. Triathlon~  2. Cycling~  3. Distance running (≥ 1500 meters)~  4. Rowing~  5. Swimming"
62305415|NCT05164328||Non-athletes|"1. Males and females aged 14-23 years old~2. Non athletes engaged in \< 3 hours per week of physical activity"
62305416|NCT00982605||non small cell lung cancer|cancer patients
62117143|NCT05404906|EXPERIMENTAL|Comparator ( best supportive care)|Participants will receive observation and supportive care during remission.
62117144|NCT06673602|ACTIVE_COMPARATOR|Conventional treatment group|Conventional treatment: blood pressure control and care as according to the current guidelines
62117145|NCT06673602|EXPERIMENTAL|FCYC group|Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment
62117146|NCT03856099|EXPERIMENTAL|TTAC-0001|TTAC-0001 with dose assigned to each dose group will be administered
62117147|NCT05175248|EXPERIMENTAL|Plant-based Intervention Group|Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.
62305417|NCT05782088|EXPERIMENTAL|Single Piezocision|
62305418|NCT05782088|EXPERIMENTAL|Repeated Piezocision|
62473352|NCT03205774|SHAM_COMPARATOR|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
62473353|NCT03205774|SHAM_COMPARATOR|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
62473354|NCT06139588||POST QUART NATIVE|Native adm used in the setting of mastectomy and implant reconstruction after QUART
62305419|NCT05597566||Elderly depression patients with suicidal ideation|Conformity: Age 60-85 years old; meet DSM-5 diagnostic criteria for major depressive disorder; currently in acute phase, HDRS-17 ≥ 24; history of suicide attempt in this depressive episode; current suicidal ideation, SIOSS ≥ 12.Exclusions: Patients with unstable physical diseases; patients currently suffering from acute inflammatory infection or chronic inflammatory disease; participated in another interventional clinical study within the past 1 month; previous or current diagnosis of other psychiatric diseases by DSM-IV ; abuse of alcohol and active drugs within 12 months, except for nicotine; severe aphasia, visual and hearing impairment, etc. unable to complete the scale evaluation; MECT treatment contraindications; pregnant, lactating women or planning pregnancy; allergic to propofol and succinylcholine chloride.
62305420|NCT03317587|EXPERIMENTAL|INSPIRE|
62305421|NCT02363400|EXPERIMENTAL|Adjuvant Chemotherapy|MEP followed by oral Tegafur-uracil
62305422|NCT02363400|NO_INTERVENTION|control arm|closely followed with frequency similar to the experiemental arm
62305423|NCT06070610|EXPERIMENTAL|Pirfenidone + nintedanib (R) then BI 1015550 + pirfenidone+ nintedanib (T)|Reference Treatment (R) Test Treatment (T)
62305424|NCT00500071|EXPERIMENTAL|1|
62473355|NCT06139588||POST QUART VERITAS|Veritas adm used in the setting of mastectomy and implant reconstruction after QUART
62473356|NCT06139588||POST EXPANDER NATIVE|Native adm used in the setting of expander removal and implant positioning after mastectomy + RT
62473357|NCT06139588||POST EXPANDER VERITAS|Veritas adm used in the setting of expander removal and implant positioning after mastectomy + RT
62473358|NCT06139588||IMPLANT EXCHANGE NATIVE|Native adm used in the setting of implant exchange after mastectomy + RT
61918510|NCT04638504||24w-28w obese normal pregnant|24w-28w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
62117148|NCT05175248|NO_INTERVENTION|Control Group|Control group participants will be asked to maintain their usual diet for the duration of the 12-week study period. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant. At the conclusion of the 12 weeks, control group participants will be offered instruction in the plant-based diet.
62117149|NCT05206773|EXPERIMENTAL|Venglustat|Participant will receive venglustat dose once daily up to 12 months
62676599|NCT06081114|ACTIVE_COMPARATOR|MNs - Level 2|"Dose 2 of micronutrients listed below provided daily in the form of a powdered flavored drink.~Micronutrients:~Vitamin A -0.93 mg Vitamin D - 0.04 mg Vitamin E - 109 mg Vitamin B1 - 2.8 mg Vitamin B2 - 2.8 mg Vitamin B3 - 47 mg Vitamin B6 - 4.1 mg Vitamin B12 - 0.0094 mg Vitamin C - 20 mg Iron - 10 mg Zinc - 5 mg Selenium - 0.135 mg Choline - 750 mg Pantothenic acid - 7mg Biotin - 0.035 mg Potassium - 1000 mg Manganese - 2.6 mg Magnesium - 145 mg Plus, a daily fortified balanced energy and protein food supplement containing 400 kcals and 14 g of protein and 1 RDA of 18 micronutrients will be given daily including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of copper and 500 mg of calcium"
62676600|NCT06081114|ACTIVE_COMPARATOR|MNs - Level 3|"Dose 3 of micronutrients listed below provided daily in the form of a powdered drink.~Micronutrients:~Vitamin A - 1.48 mg Vitamin D - 0.06 mg Vitamin E - 184 mg Vitamin B1 - 4.2 mg Vitamin B2 - 4.2 mg Vitamin B3 - 82 mg Vitamin B6 - 8.1 mg Vitamin B12 - 0.0154 mg Vitamin C - 20 mg Iron - 10 mg Zinc - 5 mg Selenium - 0.235 mg Choline - 900 mg Pantothenic acid - 7mg Biotin - 0.035 mg Potassium - 1000 mg Manganese - 2.6 mg Magnesium - 145 mg Plus, a daily fortified balanced energy and protein food supplement containing 400 kcals and 14 g of protein and 1 RDA of 18 micronutrients will be given daily including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of copper and 500 mg of calcium"
62676601|NCT04302168|ACTIVE_COMPARATOR|Choline Supplement Group|Choline Supplement 470 mg twice daily for total of 8 weeks.
62676602|NCT04302168|PLACEBO_COMPARATOR|Placebo Group|Placebo pill twice daily for total of 8 weeks.
62117150|NCT05206773|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once daily up to 12 months
62117151|NCT02631343|EXPERIMENTAL|Intervention KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
62117152|NCT02631343|OTHER|Control|Routine visits by government health workers
62117153|NCT00411996|OTHER|1|IDV/r 600/100 mg + rifampicin
62305425|NCT06255886|ACTIVE_COMPARATOR|Proton pump inhibitor|Omeprazole 1 mg/ kg and continuing nutrition containing cow's milk protein
62305426|NCT06255886|ACTIVE_COMPARATOR|Mother or infant diet|Mother on cow milk-protein-free diet if breastfeeding and infant on a hypoallergenic formula if bottle-fed.
62305427|NCT06255886|PLACEBO_COMPARATOR|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/kg and continuing nutrition containing cow's milk protein
62305428|NCT06082778|EXPERIMENTAL|Increased fermented food intake|Participants take part in a n-of-1 design. They are first required to consume their habitual diet, for one week, followed by a period of dietary advice, for two weeks.
62305429|NCT00863187|EXPERIMENTAL|rituximab|b cell depletion drug
62305430|NCT01057264|EXPERIMENTAL|HAI Abraxane + Gemcitabine + Bevacizumab|HAI (hepatic arterial infusions) Abraxane with Gemcitabine + Bevacizumab
62305431|NCT01513018|ACTIVE_COMPARATOR|high (10 ml/kg) tidal volumes|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
62305432|NCT01513018|ACTIVE_COMPARATOR|low tidal volume (5 ml/kg)|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
62473359|NCT06139588||IMPLANT EXCHANGE VERITAS|Veritas adm used in the setting of implant exchange after mastectomy + RT
62473360|NCT06139588||IMPANT EXCHANGE AFTER QUART NATIVE|Native adm used in the setting of implant exchange after QUART+ Mastectomy and implant reconstruction
62473361|NCT06139588||IMPLANT EXCHANGE AFTER QUART VERITAS|Veritas adm used in the setting of implant exchange after QUART+ Mastectomy and implant reconstruction
62676603|NCT05754775|EXPERIMENTAL|Low-calorie diet|Korean low-calorie diet for type 2 diabetes
62676604|NCT03091491|EXPERIMENTAL|Nivolumab|
62676605|NCT03091491|EXPERIMENTAL|Nivolumab and Ipilimumab|
62117154|NCT03384069|EXPERIMENTAL|Group-based Cognitive Behavioral Therapy (CBT)|The Group-based CBT will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
62117155|NCT03384069|EXPERIMENTAL|Phone-based Cognitive Behavioral Therapy (CBT)|This intervention will follow the same protocol as the group-based CBT, but without the opportunity for group-interaction. It will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
62117156|NCT03384069|NO_INTERVENTION|Standard of care|Participants will continue to receive care and follow up from their primary care providers, that incorporates general education regarding lifestyle activities and AD prevention.
62473362|NCT03999684|EXPERIMENTAL|Tretinoin|-Participants will receive Tretinoin orally divided over two daily doses for days 1 through 14 of a 28-day cycle
62117157|NCT00666094|ACTIVE_COMPARATOR|endurance training|supervised endurance training
62117158|NCT00666094|EXPERIMENTAL|strength training|Supervised strength training
62117159|NCT02631148|EXPERIMENTAL|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 6 weeks
62117160|NCT02631148|PLACEBO_COMPARATOR|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 6 weeks
62117161|NCT05650268|EXPERIMENTAL|Vitamin D3|The experimental group will receive 576000 IU in single oral dose of liquid vitamin D3\~7 days prior to the surgery.
62117162|NCT05650268|PLACEBO_COMPARATOR|Control group|The control group will receive 95% MCT D3\~7 days prior to the surgery.
62117163|NCT00558363|EXPERIMENTAL|Avodart|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
62117164|NCT00558363|PLACEBO_COMPARATOR|Placebo Arm|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
62117165|NCT01245452|EXPERIMENTAL|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
62473363|NCT06099795|EXPERIMENTAL|Patients likely to be affected by COVID-19|The study population consists of adult people who are likely to be affected by COVID-19 (symptomatic or close contacts) consulting for RT-PCR screening.
62117166|NCT01245452|ACTIVE_COMPARATOR|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
62117167|NCT01495936|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|"After 20 minutes ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-ventilated lung at a pressure of 5cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
62117168|NCT01495936|ACTIVE_COMPARATOR|RM + Positive End Expiratory Pressure|"After 20 minutes of ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm RM + Positive End Expiratory pressure which is a Recruitment Maneuver (RM) followed by Positive End Expiratory Pressure (RM-PEEP) which will be applied to the ventilating lung at a pressure of 5cmH2O."
62676606|NCT06066931|OTHER|Group 1 of a simple method (Plastic surgery with local tissues) n=50|In group 1 patients (plastic surgery with local tissues), a simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
62676607|NCT06066931|OTHER|Group 2 is plastic surgery with a mesh endoprosthesis n=50|In group 2 patients, a mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
62676608|NCT06066931|EXPERIMENTAL|Group 3 is a new method of plastic surgery n=50|In group 3 the plastic stage is performed: on one side of the perineal wound, a cutaneous-subcutaneous-fascial flap on the leg is cut out and deepithelized, along the entire length of the wound, thereby forming a diamond-shaped perineal wound, plunging it into the pelvic aperture, fixing it with single sutures to the remnants of the muscle lifting the anus of the opposite side, and the flap width is 3-4 cm to fill the pelvic aperture. On the opposite side of the wound, a triangular skin-subcutaneous fascial flap is cut out on a leg equal to the width of the previously formed diamond-shaped wound at an angle of 60-80 degrees from the middle of the wound edge, and the sides of the triangular flap should be equal to half the length of the edge of the diamond-shaped wound, then it is moved and additionally fill the wound cavity with it, in condition of displacement of the apex of the triangle flap with the top of the rhombus-wounds. The flap is fixed with separate skin nodular sutures.
62676609|NCT02551107|EXPERIMENTAL|Congenital heart disease|"Inclusion criteria: All participants, less than one year of age, with CHD will be eligible for this study with the exception of those patients with only patent foramen ovale (PFO) and patent ductus arteriosus (PDA). The diagnosis of CHD will be confirmed by echocardiography.~Exclusion criteria: Participants with only PDA or PFO, without written informed consent, patients older than one year of age or any subject on oxygen at the time of nNO assessment."
62676610|NCT02551107|ACTIVE_COMPARATOR|Controls|The control group will consist of age matched infants, less than one year of age, without CHD or acute respiratory illness. The participants will also require written informed consent and will have to be breathing room air at the time of the nNO test.
62305433|NCT05667519|EXPERIMENTAL|Transesophageal echocardiography + fluoroscopy guided lead implantation|TEE will be done in addition to fluoroscopy to guide lead implantation.
62305434|NCT05667519|NO_INTERVENTION|Fluoroscopy guided lead implantation|Fluoroscopy only will be used to guide lead implantation.
62305435|NCT05946330|EXPERIMENTAL|Patients will be followed up for one year by nutritionist intervention, on individual goals|Patients allocated in the study will be randomized 1:1 and followed up for one (1) year, intervention group (IG) with nutritionist consultations, nutritional diagnosis and educational intervention with agreement on individual goals.
62676611|NCT05449262|EXPERIMENTAL|functional resistance training GROUP A|Session of 45-60 min starting with Warm Up Exercise and stretching prior to therapy and cool-down and stretching after the training sessions
61918511|NCT04638504||37w -40w normal pregant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
62305436|NCT05946330|ACTIVE_COMPARATOR|Control Group (CG) will maintain the usual outpatient care.|Patients in the Control Group (CG) will maintain the usual outpatient care.
62305437|NCT04133324||Main group|One groupe in the study
62305438|NCT02164565|EXPERIMENTAL|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
62305439|NCT02164565|EXPERIMENTAL|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
62305440|NCT03895138|ACTIVE_COMPARATOR|Standard Glucommander Protocol (SGP)|CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations
62676612|NCT05449262|EXPERIMENTAL|functional resistance training GROUP B|Session of 45-60 min starting with Warm Up Exercise and stretching prior to therapy and cool-down and stretching after the training sessions
62305441|NCT03895138|EXPERIMENTAL|Optimized Glucommander (OGM)|CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol
62305442|NCT01302275|EXPERIMENTAL|oxcarbazepine|Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
62305443|NCT01302275|PLACEBO_COMPARATOR|placebo|
62305444|NCT04952727|EXPERIMENTAL|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3\~6 months.
62305445|NCT04952727|ACTIVE_COMPARATOR|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3\~6 months.
62305446|NCT04952727|EXPERIMENTAL|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1\~3 months
62305447|NCT04952727|ACTIVE_COMPARATOR|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1\~3 months.
62305448|NCT01574781||Women with abnormal fetus|Women carrying fetus that is identified as chromosomally abnormal by CVS/Amniocentesis
62305449|NCT01574781||Women experiencing miscarriage|Women identified as miscarrying, prior to any D\&C or D\&E procedure
62305450|NCT01574781||Born children|The children born from women participating in other cohorts of the study.
62305451|NCT01574781||Male relatives|The male partners (and presumed biological father of any fetuses/children) of women participating in other cohorts of the study or the biological father's brother and/or father.
62305452|NCT01574781||Non-pregnant women|Healthy women who are not pregnant
62305453|NCT01574781||Pregnant women|
62305454|NCT04284644|EXPERIMENTAL|Group P|Patient received a dose of 1.5 mg/kg of Propofol slowly over 2 minutes for induction.
62305455|NCT04284644|EXPERIMENTAL|Group S|Patient received 8% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen.
62305456|NCT04284644|EXPERIMENTAL|Group C|Patient received 4% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
62305457|NCT06510426|EXPERIMENTAL|Active Treatment|Patients enrolled to participate in the Active Treatment arm will receive 3 subcutaneous injections of 44mcg Interferon b-1a (Rebif), given 48h hours apart.
62305458|NCT06510426|PLACEBO_COMPARATOR|Placebo|Patients enrolled to participate in the placebo arm will receive 3 subcutaneous injections of normal saline, given 48h hours apart.
62305459|NCT04119908|EXPERIMENTAL|Patients with haemorrhagic disease|Patients with von Willebrand disease or Patients with Glanzmann Thrombasthenia
62305460|NCT04119908|OTHER|Control group|Patients with moderate or severe hemophilia A or women carrying the hemophilia gene
62676613|NCT05035693|EXPERIMENTAL|PMCF MOVE-C|PMCF MOVE®_C is a single arm observational study with 170 patients.
62676614|NCT00421733|ACTIVE_COMPARATOR|Paricalcitol 1 mcg|One paricalcitol 1 mcg capsule and one matching placebo capsule per dose
62676615|NCT00421733|ACTIVE_COMPARATOR|Paricalcitol 2 mcg|Two paricalcitol 1 mcg capsules per dose
62305461|NCT03719573|EXPERIMENTAL|Geriatric intervention|A comprehensive geriatric assessment and intervention, including exercise program.
62305462|NCT03719573|NO_INTERVENTION|control.|Usual treatment and care.
62305463|NCT01400646|EXPERIMENTAL|Rivaroxaban + Warfarin Concomitant Therapy Phase|Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for \>= 2 to \<= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
62305464|NCT01400646|EXPERIMENTAL|Warfarin Monotherapy Phase|Warfarin monotherapy 10 mg/day for \>=2 to \<=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.
62473364|NCT03531021|EXPERIMENTAL|Heart healthy intervention|The intervention group will receive 2 modules (one in in person and one by video conference) and will receive follow-up phone calls/emails by study staff 3 weeks following each visit to review education and strategies for and barriers to reaching goals. Intervention sessions must include teen; parents may attend if they wish. Participants will be placed on teams and encouraged to complete behavioral challenges to earn points towards a cash reward.
62676616|NCT00421733|PLACEBO_COMPARATOR|Placebo|Two placebo capsules per dose
62676617|NCT06291961|EXPERIMENTAL|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
62305465|NCT02032628|EXPERIMENTAL|High Intensity/Longer Duration|Exercise at higher intensity (\~75% of VO2max) for 40 minute bouts 4 times per week
62305466|NCT02032628|EXPERIMENTAL|High Intensity/Lower Duration|Exercise at high intensity (\~75% of VO2max) for 20 minute bouts 4 times per week
62305467|NCT02032628|EXPERIMENTAL|Lower Intensity/Higher Duration|Exercise at lower intensity (\~55% of VO2max) for 40 minute bouts 4 times per week
62305468|NCT02032628|EXPERIMENTAL|Low Intensity/Low Duration|Exercise at lower intensity (\~55% of VO2max) for 20 minute bouts 4 times per week
62305469|NCT04902248|EXPERIMENTAL|Over-the-scope clips|"The OTSC® System Set is an instrument for flexible endoscopy~The OTSC® System Set consists of an applicator cap with a mounted OTSC® clip, thread, thread retriever and a hand wheel for clip release.~The OTSC® clip is delivered by means of an applicator cap mounted to the tip of gastroscopes or colonoscopes. The clip is released by tightening the thread with the hand wheel.~The OTSC® clip for flexible endoscopy is a superelastic Nitinol device for compression and approximation of tissue in the digestive tract"
62305470|NCT04902248|EXPERIMENTAL|angiographic embolization|"The procedure was performed in the angiographic suite and under local anaesthetics to the patient's groin. The celiac and then gastroduodenal artery or the left gastric artery was selectively cannulated depending on ulcer location.~Coils were deposited distal to the bleeding point. Gel foam particles were then packed into the artery and its collaterals. This was followed by further coils deposited in its proximal portion until complete cessation of arterial flow. Our protocol requested empiric embolisation of the artery even in the absence of active contrast extravasation or a pseudoaneurysm."
62676618|NCT04091438|EXPERIMENTAL|TAK-925 Dose A + Placebo|TAK-925 112 milligram (mg), 9-hour intravenous infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by TAK-925 placebo-matching 9-hour intravenous infusion once on Day 3, Treatment Period 2.
62676619|NCT04091438|PLACEBO_COMPARATOR|Placebo + TAK-925 Dose A|TAK-925 placebo-matching 9-hour intravenous infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by, TAK-925 112 mg, 9-hour intravenous infusion once on Day 3, Treatment Period 2.
62676620|NCT02286791|EXPERIMENTAL|Mindful Awareness Program|18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
62676621|NCT02286791|ACTIVE_COMPARATOR|Health Education Program|18 sessions of health education program focusing on healthy living topics
61918512|NCT04638504||37-40 w obese normal pregnant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
62117169|NCT06048991|EXPERIMENTAL|Knees termographic evaluation|All 30 patients will undergo thermographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
62117170|NCT02563613|EXPERIMENTAL|Physical Exercise (PE)|Physical exercise will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will comprise of a core intervention session on physical exercise, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on healthy diet. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
62676622|NCT05615350|EXPERIMENTAL|Meals served during breakfast|Twice a week for six weeks (in total twelve times) participants will consume meals ad libitum during breakfast.
62676623|NCT05615350|EXPERIMENTAL|Meals served during lunch|Twice a week for six weeks (in total twelve times) participants will consume meals ad libitum during lunch. They will receive a standardized breakfast meal.
62676624|NCT03947827|ACTIVE_COMPARATOR|Active|Minocycline will start at an oral dose of 100mg daily and will be increased after one week to 100mg twice daily.
62676625|NCT03947827|PLACEBO_COMPARATOR|Placebo|Placebo capsules will start at one capsule daily, and will be increased after one week to one capsule twice daily
62676626|NCT06007248||Case Group|IR-CAD patients (from the IR-CAD cohort study)
62676627|NCT06007248||Control Group|AS-CAD patients
62676628|NCT05156125|EXPERIMENTAL|VTX002 Dose A|VTX002 Dose A tablet administered orally once daily
61918513|NCT05498701|EXPERIMENTAL|Test tablet (fasted) followed by Reference capsule (fasted) followed by Test tablet (fed)|On Day 1 of each period, participants will receive a single dose of one of the tafamidis formulations under fasted or fed conditions. Each period is separated by a washout of at least 16 days between administration of study drug.
61918514|NCT05498701|EXPERIMENTAL|Reference capsule (fasted) followed by Test tablet (fasted) followed by Test tablet (fed)|On Day 1 of each period, participants will receive a single dose of one of the tafamidis formulations under fasted or fed conditions. Each period is separated by a washout of at least 16 days between administration of study drug.
62676629|NCT05156125|EXPERIMENTAL|VTX002 Dose B|VTX002 Dose B tablet administered orally once daily
61918515|NCT02856893|EXPERIMENTAL|Osimertinib till progression|Osimertinib until PD according to RECIST 1.1
61918516|NCT02856893|EXPERIMENTAL|Gefitinib till + blood test/progression than Osimertinib|"Gefitinib until emergence of positive T790M status (cfDNA T790M positive progression) followed by Osimertinib until second PD according to RECIST 1.1"
61918517|NCT02856893|ACTIVE_COMPARATOR|Gefitinib till progression than Osimertinib|Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
62676630|NCT05156125|PLACEBO_COMPARATOR|Placebo|Placebo tablet administered orally once daily
62676631|NCT03216291|ACTIVE_COMPARATOR|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
62676632|NCT03216291|ACTIVE_COMPARATOR|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
62676633|NCT04803903||HPI + GDHT treatment|HPI + GDHT treatment using the FlowTraQ sensor and EV1000 monitor with the HPI algorithm incorporated following our protocol for hemodynamic treatment (fluids, vasopressors and inotropes) administered
62676634|NCT04803903||Control|Conventional treatment with invasive blood pressure monitoring. Administration of fluids and/or vasopressors are guided by standard hemodynamic parameters at the discretion of the attending physician.
62676635|NCT05528666||Overall cohort|Included all patients
62473365|NCT03531021|NO_INTERVENTION|Attention Control|There will be a delayed intervention for the control group with study handouts after 3 months. The control group will meet with the RAs for demographic and survey completion and receive reminder phone calls/emails in order to match for attention.
62676636|NCT05528666||Previous Non-HET|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
62676637|NCT05528666||Previous HET|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
62676638|NCT05358938|EXPERIMENTAL|Adjuvant Arm with Exercise|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting. Adjuvant participants will receive 1 year \[currently 9-18 cycles\] of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab or relatlimab, or currently approved standard of care treatment, either alone or in combination. Participants also will complete 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles. Blood samples will be collected at 1) baseline (upon arrival to clinic), 2) post-exercise, and 3) post-infusion. Blood samples will be obtained on the first, third, midpoint, and final infusion dates.
62676639|NCT05358938|ACTIVE_COMPARATOR|Adjuvant Arm without Exercise|Participants will receive clinical care following Moffitt standards for the patients disease type and therapeutic setting. Adjuvant participants will receive one year \[currently 9-18 cycles\] of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab, relatlimab, or currently approved standard of care treatment, either alone or in combination. Blood samples will be collected at 1) baseline (upon arrival to clinic) and 2) post-infusion. Blood samples will be obtained on the first, third, midpoint, and final infusion dates.
62676640|NCT05358938|EXPERIMENTAL|Neoadjuvant Arm with Exercise|Participants will complete 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles. Neoadjuvant participants will receive up to 4 cycles of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab, or relatlimab, or currently approved standard of care treatment, either alone or in combination. Blood samples will be collected at 1) baseline (upon arrival to clinic), 2) post-exercise, and 3) post-infusion. Blood samples will be obtained on the first and third infusion dates.
62676641|NCT05358938|ACTIVE_COMPARATOR|Neoadjuvant Arm without Exercise|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting. Neoadjuvant participants will receive up to 4 cycles of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab, or relatlimab, or currently approved standard of care treatment, either alone or in combination. Participants also will complete 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles. Blood samples will be collected at 1) baseline (upon arrival to clinic), 2) post-exercise, and 3) post-infusion. Blood samples will be obtained on the first and third infusion dates.
62676642|NCT04293965|EXPERIMENTAL|Single Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in a single dose to assess the safety, tolerability, PK and PD profile of X842.
62676643|NCT04293965|EXPERIMENTAL|Multiple Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in multiple doses to assess the safety, tolerability, PK and PD profile of X842. The dose ascending at this stage will be based on the results of the single dose tolerability study.
62305471|NCT05316363|EXPERIMENTAL|OMT Intervention Arm|Patients treated with 4 techniques for 8 minutes in the supine position. OMT systematically administered to address the 4 body regions - cervical spine, thoracic spine, ribs and diaphragm. The techniques utilized for this study include: suboccipital release, diaphragmatic release, rib raising and paraspinal inhibition of the thoracic spine. Each technique administered for approximately 2 minutes.
62676644|NCT04293965|EXPERIMENTAL|Food Effect Study|A randomized, open label, single-dose, self-controlled, double-cycle, two-way crossover clinical trial.
62676645|NCT05508165|NO_INTERVENTION|Cohort 1a: in-person clinical assessment of LUTS/BPH|COHORT 1a: Subjects randomized to undergo in-person initial clinical workup of Lower Urinary Tract Symptoms (LUTS) / Benign Prostatic Hyperplasia (BPH) and in-person clinical follow-up after 3 months of clinical intervention. In-person clinical workup at both the initial and Month 3 follow-up timepoint includes International Prostate Symptom Score (IPSS), and standard of care uroflowmetry, post void residual (PVR), and urinalysis (UA) assessments.
62676646|NCT05508165|EXPERIMENTAL|Cohort 1b: virtual (telehealth) clinical assessment of LUTS/BPH|COHORT 1b: Subjects randomized to undergo virtual initial clinical workup of Lower Urinary Tract Symptoms (LUTS) / Benign Prostatic Hyperplasia (BPH) and virtual clinical follow-up after 3 months of clinical intervention. Virtual clinical workup at both the initial and Month 3 follow-up timepoint includes at home completion of International Prostate Symptom Score (IPSS), at home uroflowmetry assessment through use of the Stream Dx device, at home assessment of post void residual (PVR) through use of the DFree device, and at home urinalysis (UA) through use of the TestCard device.
62676647|NCT05508165|OTHER|Cohort 2: Validation Cohort|COHORT 2: Non-randomized subjects who will attend a single, clinically scheduled, in-person follow-up appointment to directly compare the standard of care assessments/devices to the experimental assessments/devices. Prior to the in-person appointment, patients will complete at home uroflowmetry assessment through use of the Stream Dx device. At the in-person appointment, the clinic staff will perform standard of care uroflowmetry, post void residual (PVR), and urinalysis (UA). At this visit, clinic staff will also obtain PVR measurements through use of the DFree device and urinalysis through the TestCard device.
62676648|NCT03485209|EXPERIMENTAL|Part A: Tisotumab Vedotin - Q3W Schedule|Tisotumab Vedotin on Day 1 of every 21-day cycle in participants with various solid tumors in 2L+
62676649|NCT03485209|EXPERIMENTAL|Part B: Tisotumab Vedotin - 3Q4W Schedule|Tisotumab Vedotin on Days 1, 8, and 15 of 28-day cycle in participants with various solid tumors in 2L+
62676650|NCT03485209|EXPERIMENTAL|Part C: Tisotumab Vedotin - 2Q4W Schedule|Tisotumab Vedotin on Days 1 and 15 of every 28-day cycle in participants with HNSCC or sqNSCLC in 2L+
62676651|NCT03485209|EXPERIMENTAL|Part D: Tisotumab Vedotin Combination Therapy - Q3W Schedule|Tisotumab Vedotin + pembrolizumab + (carboplatin or cisplatin). Given on Day 1 of every 21-day cycle in participants with various solid tumors in 1L HNSCC or sqNSCLC
62676652|NCT03485209|EXPERIMENTAL|Part E: Tisotumab Vedotin - 2Q4W Schedule|Tisotumab Vedotin on Days 1 and 15 of every 28-day cycle in participants with HNSCC in the second- or third-line setting
62117171|NCT02563613|EXPERIMENTAL|Healthy Diet (HD)|Healthy diet will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will include a core intervention session on healthy diet, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on physical exercise. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
62117172|NCT02563613|PLACEBO_COMPARATOR|Wait-list Control (C)|The control group will consist of a tea gathering session at the beginning and 1 month later, followed by a follow-up session at 3 months on physical exercise or healthy diet. The tea gathering sessions will cover topics unrelated to the intervention, such as arts and crafts workshops. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
62305472|NCT05316363|NO_INTERVENTION|Control|Patients lie supine on the treatment table and rested quietly for a total of 8 minutes.
62676653|NCT03485209|EXPERIMENTAL|Part F: Tisotumab Vedotin Combination Therapy - Q2W Schedule|Tisotumab Vedotin + pembrolizumab. Tisotumab Vedotin given on Days 1, 15, and 29 of every 6-week cycle. Pembrolizumab given on Day 1 of every 6-week cycle in participants with HNSCC in the first line setting
62676654|NCT03485209|EXPERIMENTAL|Part G: Tisotumab Vedotin Combination Therapy - Q2W Schedule|Tisotumab Vedotin + pembrolizumab + carboplatin. Tisotumab Vedotin and carboplatin given on Days 1, 15, and 29 of every 6-week cycle. Pembrolizumab given on Day 1 of every 6-week cycle in participants with HNSCC in the first line setting
62676655|NCT03438656|EXPERIMENTAL|Behavioral Activation Arm|See treatment description for information on Behavioral Activation. Participants will receive 12 weekly sessions of Behavioral Activation.
62676656|NCT02916914|OTHER|Q2 feeding|feeding intervals: 2 hours
62676657|NCT02916914|NO_INTERVENTION|Q3feeding|feeding intervals: 3 hours
62676658|NCT06480110|EXPERIMENTAL|Intervention|Standard docetaxel (10 cycles) plus ebastine daily
62676659|NCT06480110|ACTIVE_COMPARATOR|Comparator|Standard docetaxel (10 cycles) without ebastine
62676660|NCT00401830|PLACEBO_COMPARATOR|Placebo|
62676661|NCT00401830|EXPERIMENTAL|Lacosamide|Lacosamide Tablet 400mg daily
62676662|NCT03015779|EXPERIMENTAL|experimental group|cultured autologous oral mucosal epithelial cell sheet
61918518|NCT05244642|EXPERIMENTAL|Group A (Penpulimab)|Participants receive Penpulimab 200mg intravenously (IV) on Day 1, Q2W for 24 months.
62305473|NCT04773769|EXPERIMENTAL|Overall Statistical design|We will treat 9 patients of each tumor type with a tea made of Graviola Leaves. If no responses are observed then the trial will be closed for that particular histological type. Should a response occur, then the trial will continue to the second stage for that cell type until 24 patients are accrued. If 3 or more responses are observed out of 24 cases, then the result will be considered promising.
61918519|NCT05244642|ACTIVE_COMPARATOR|Group B (Chemotherapy)|Participants receive investigator's choice of chemotherapy Q2W or Q3W for up to 4 or 6 cycles.
61918520|NCT05463627||BMI<24 kg/m2|women diagnosed with PCOS with BMI\<24 kg/m2
61918521|NCT05463627||BMI24-28 kg/m2|women diagnosed with PCOS with BMI24-28 kg/m2
61918522|NCT05463627||BMI>28 kg/m2|women diagnosed with PCOS with BMI\>28kg/m2
61918523|NCT04426903|EXPERIMENTAL|LLM Care|LLM Care training Participants use the webFitForAll exergaming computer platform as the physical training component (PT); Participants use the language adapted version of the BrainHQ Program as the cognitive training component (CT)
62676663|NCT06557369|EXPERIMENTAL|Combination Therapy - Treated Eye|Enrolled eye which will receive the light combined treatment.
61918524|NCT04426903|EXPERIMENTAL|Physical Training (PT)|Physical training only. Participants use the webFitForAll exergaming computer platform as the physical training component (PT).
61918525|NCT04426903|EXPERIMENTAL|Cognitive Training (CT)|Cognitive training only. Participants use the language adapted Version of the BrainHQ Program as the cognitive training component (CT).
61918526|NCT04949919|EXPERIMENTAL|ESRD patients with supervised training|The participants will receive in-hospital supervised exercise training prior to HD
61918527|NCT03631797|EXPERIMENTAL|Microvascular reactivity evaluation|"Patients referred for a preoperative arterial palmar arches assessment before cardiac valvular or coronary surgery.~Intervention is measurement of microvascular reactivity with a laser speckle contrast imaging before surgery."
62676664|NCT06557369|NO_INTERVENTION|Intra-patient Control Eye|Contralateral eye used as control to relatively evaluate safety profile and performance
62676665|NCT05667493|EXPERIMENTAL|Eplontersen|Eplontersen will be administered once every month by sub-cutaneous (SC) injection for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first.
62676666|NCT06239480|EXPERIMENTAL|Active|
61918528|NCT02974101|EXPERIMENTAL|spinal cord stimulation(RestoreSensor)|
61918529|NCT01252303|EXPERIMENTAL|Nutrisystem|Group will receive Nutrisystem meals in addition to the behavioral weight loss program.
61918530|NCT01252303|ACTIVE_COMPARATOR|Control|Group will receive a behavioral weight loss program only.
61918531|NCT04537221||No transfusions|Patients receiving no perioperative blood transfusions (PBT)
62676667|NCT04704921|EXPERIMENTAL|RGX-314 Dose 1|RGX-314 Dose 1 administered via subretinal delivery one time.
62676668|NCT04704921|EXPERIMENTAL|RGX-314 Dose 2|RGX-314 Dose 2 administered via subretinal delivery one time.
62676669|NCT04704921|ACTIVE_COMPARATOR|Control Arm|Ranibizumab administered via intravitreal injection approximately every 28 days
62117173|NCT03255096|EXPERIMENTAL|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
62117174|NCT03255096|EXPERIMENTAL|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
62305474|NCT04757363|EXPERIMENTAL|Nivolumab Combined With FOLFOX and Regorafenib|Each treatment cycle consists of 28 days. Patients will initially receive induction therapy with regorafenib (80 mg on days 1-21 of the 28-day cycle) and nivolumab (240 mg on days 1 and 15 of the 28-day cycle). Starting on cycle 2, day 1, patients will also receive FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h). If the patient is not a good candidate for induction regorafenib and nivolumab (i.e. symptomatic from a large burden of disease), 5-FU and oxaliplatin can be added during cycle 1 at the treating physician's discretion. 39 Patients will continue with this regimen until disease progression, unacceptable toxicity, or development of serious intercurrent illness. Treatment will be performed on the scheduled day (±7-day treatment window).
62305475|NCT02088034|EXPERIMENTAL|Promotora-led Intervention|The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
62305476|NCT02088034|ACTIVE_COMPARATOR|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
62305477|NCT02088034|ACTIVE_COMPARATOR|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
62305478|NCT05978869|EXPERIMENTAL|physical fitness training|The training group received physical fitness training for 12 weeks
61918532|NCT04537221||Transfusions|Patients receiving perioperative blood transfusions (PBT)
62305479|NCT05978869|NO_INTERVENTION|No training group|The no training group did not receive any training program
61918533|NCT03363425|ACTIVE_COMPARATOR|Lidocaine|
62676670|NCT04595578|ACTIVE_COMPARATOR|Cerebellar rTMS + Physical therapy|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
62305480|NCT03129438|EXPERIMENTAL|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
62305481|NCT03129438|ACTIVE_COMPARATOR|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
62305482|NCT05415280|EXPERIMENTAL|Mindfulness based stress reduction|mindfulness based stress reduction intervention was used to treat psychological and addiction problems of the individuals
62305483|NCT05415280|OTHER|Relaxation Exercise|the control group was provided with the relaxation technique.
61918534|NCT03363425|ACTIVE_COMPARATOR|Dexmedetomidine|
61918535|NCT03363425|PLACEBO_COMPARATOR|Normal Saline 0,9%|
61918536|NCT04396054|ACTIVE_COMPARATOR|Lag Screws|Group 1: underwent open reduction and internal fixation using two lag screws.
61918537|NCT04396054|ACTIVE_COMPARATOR|Double Y-shaped plates|Group 2: underwent open reduction and internal fixation using double Y-shaped plates.
61918538|NCT04150406|ACTIVE_COMPARATOR|Flexofytol|2 capsules containing 42mg of curcumin will be administered twice a day for a duration of 4 months.
61918539|NCT04150406|PLACEBO_COMPARATOR|Placebo|2 capsules of the placebo, identical in appearance to Flexofytol, will be administeres twice a day for a duration of 4 months.
61918540|NCT00829283|ACTIVE_COMPARATOR|1|Standard Care
61918541|NCT00829283|EXPERIMENTAL|2|Stepped-care
61918542|NCT02951676||EA - Extraction with antibiotics|"Patients undergoing third molar extraction with antibiotic treatment.~Amoxicillin 250 mg , three times daily for five days."
61918543|NCT02951676||E - Extraction without antibiotics|Patients undergoing third molar extraction with antibiotic treatment.
61918544|NCT02951676||Control|Age and sex matched controls who are not undergoing extractions or antibiotic treatment
61918545|NCT06484205|EXPERIMENTAL|WHO QualityRights e-training|"Participants assigned to the intervention group (n 40) will participate in the WHO QualityRights (QR) online training course on Mental Health, Recovery and Community Inclusion. The QR training aims to increase knowledge of the rights of people with psychosocial disabilities and to change negative attitudes towards them and their role as rights holders."
61918546|NCT06484205|ACTIVE_COMPARATOR|Emotional intelligence e-training|"Participants assigned to the control group (n 40) will receive the online Emotional Intelligence Training for Informal Caregivers offered by PeerCare."
61918547|NCT02789579|EXPERIMENTAL|levofloxacin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 3 days before Minimally invasive upper tract lithotomy.
61918548|NCT02789579|EXPERIMENTAL|nitrofurantoin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 3 days before Minimally invasive upper tract lithotomy.
62676671|NCT04595578|SHAM_COMPARATOR|Sham stimulation + Physical therapy|Sham stimulation was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator. Sham stimulation was delivered to the cerebellum for 5 seconds at 55 second intervals in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
62117175|NCT01629186|EXPERIMENTAL|outcome|"Cardiopulmonary parameters were measured and recorded at baseline, just before and at every minute during NC-AC, and at the end of the FB session. In infants who already had an arterial line, arterial blood gas (ABG) analyses were taken for study. Data was represented as mean ± SD. The results obtained from the baseline and different stages. The values were considered statistically significant only when p \< 0.05.~Technique failure was defined as: any vital signs of hypoxia did not return to accepted levels(HR\>100 beat/min, SpO2\>90%, mean BP\>50 mmHg)within 2 minutes of the experimental CPR technique. Then traditional CPR procedures involving bag-mask ventilation, endotracheal intubation, Ambu bag ventilation or even chest compressions were substituted."
62305484|NCT05485103|EXPERIMENTAL|Modified bowel preparation method group|One day before the colonoscopy, only asol (or other intestinal nutrient solution) was taken. On the examination day (4 hours before), 1 bag of polyethylene glycol solution + (2 hours before) glycerin enema 110ml was taken
62676672|NCT03990844|PLACEBO_COMPARATOR|0% Okra seed noodle|In this arm, subjects will consume noodles made with 0% okra seed. This serves as a control arm for the study.
62676673|NCT03990844|EXPERIMENTAL|10% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
62117176|NCT04727424|ACTIVE_COMPARATOR|Fluvoxamine Maleate + Budesonide Inhalation powder|"Fluvoxamine 100 mg oral tablets:~One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days PLUS~Budesonide Inhalation powder 400 mcg capsule:~One 400 mcg capsule (inhalation) after randomization (Day 0) followed by one puff of 400 mcg BID for the following 09 days"
62117177|NCT04727424|ACTIVE_COMPARATOR|Spirulin Platensis|Spirulin Platensis 500mg oral tablets Two tablets right after randomization (day 0) followed by 1.000mg (two tablets) BID for the following 10 days.
61918549|NCT02789579|EXPERIMENTAL|cefuroxime group|There are 150 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and does not receive oral antibiotics 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
62305485|NCT05485103|ACTIVE_COMPARATOR|Traditional bowel preparation method group|Low residue diet 2 days before the colonoscopy, take 2 bags of polyethylene glycol solution the night before the examination and 1 bag of which on the examination day (4 hours before)
62305486|NCT02586207|EXPERIMENTAL|Single Arm|Pembrolizumab + Cisplatin + Radiation
62305487|NCT01283620|OTHER|Usual Care|
62305488|NCT01283620|EXPERIMENTAL|modified CIMT (mCIMT)|
62305489|NCT01486238|EXPERIMENTAL|IVMac q6 Arm|Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
62305490|NCT01486238|EXPERIMENTAL|IVMac q4 Arm|Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.
62305491|NCT03157557|EXPERIMENTAL|Lifestyle treatment|Lifestyle treatment
62305492|NCT03157557|NO_INTERVENTION|Treatment as Usual|Treatment as Usual
62305493|NCT06388369|EXPERIMENTAL|Neoadjuvant Combination Therapy|4 cycles of Ipilimumab 3mg/kg + 2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617
62305494|NCT06388369|ACTIVE_COMPARATOR|Neoadjuvant Mono Therapy|2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617
62305495|NCT03615027|EXPERIMENTAL|Intervention|see detailed description
62305496|NCT05934760|EXPERIMENTAL|High intensity interval training (HIIT)|"Older participants (over 60) will be randomized to perform home-based unsupervised exercise, the HIIT group will perform the HIIT intervention 3 times a week, at home, unsupervised for 4 weeks. This will be supported by regular contact from a member of the research team to provide support and to encourage adherance.~Our research group has conducted many similar exercise regimes of this intensity to subjects in the anticipated age-range without incident. Participants will be adviced to terminate exercise training immediately if experiencing:~* Chest pain or tightness~* Faintness~* Sudden pallor~* Loss of co-ordination~* Confusion~* Dizziness~* Palpitations~* Sudden breathlessness~Should any participant experience these effects during any session, they will be advised to seek urgent medical attention and will be withdrawn from the exercise arm of the study for safety purposes."
62676674|NCT03990844|EXPERIMENTAL|20% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
62676675|NCT05933876||OC-SABR|Patients diagnosed with Oligometastatic Cancer (OC) that will receive Stereotactic ABlative Radiotherapy (SABR) that has been prescribed per clinical protocol.
62676676|NCT05933876||Controls|Individuals who have never been diagnosed with cancer or oligometastasis.
62676677|NCT05034887|EXPERIMENTAL|Trastuzumab Deruxtecan (T-DXd) monotherapy|One cycle is 21 days, with T-DXd repeated 3 cycles before surgery as the neo adjuvant treatment.
62676678|NCT05034887|EXPERIMENTAL|Combination cohort|T-DXd 5.4 mg/kg and Durvalumab 1500 mg were infused intravenously once 3 weeks, and Capecitabine 750 mg/m2 was administered orally twice daily for 14 days with a 7-day rest period. T-DXd, Capecitabine, and Durvalumab were repeated 3 cycles preoperatively and 3 cycles postoperatively, followed by 10 cycles of Durvalumab monotherapy every 4 weeks.
62676679|NCT05970406|EXPERIMENTAL|Active Participants in high intensity dysphagia therapy|Participants with acute dysphagia who will receive high intensity dysphagia therapy during stay in inpatient rehab facility
62676680|NCT01121354|EXPERIMENTAL|Cefazolin 2g (Test)|
61918550|NCT02789579|EXPERIMENTAL|levofloxacin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 7 days before Minimally invasive upper tract lithotomy.
62117178|NCT04727424|ACTIVE_COMPARATOR|Fluoxetine + Budesonide Inhalation powder|"Fluoxetine 20 mg oral tablets:~Two tablets right after randomization (Day 0) followed by 40 mg MID for the following 06 days PLUS~Budesonide Inhalation powder 400 mcg capsule:~One 400 mcg capsule (inhalation) right after randomization (Day 0) followed by one puff of 400 mcg BID for the following 06 days"
62117179|NCT04727424|PLACEBO_COMPARATOR|Placebo|"Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)"
62117180|NCT05573035|EXPERIMENTAL|Experimental LYL845|Epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy
62117181|NCT03582410|ACTIVE_COMPARATOR|Absorbable suture|laparoscopic sacral colpopexy with absorbable suture
62117182|NCT03582410|ACTIVE_COMPARATOR|Non absorbable suture|laparoscopic sacral colpopexy with non absorbable suture
62117183|NCT01911169|EXPERIMENTAL|Vitamin D 5000|5,000 IU vitamin D (cholecalciferol) given orally daily
62676681|NCT01121354|ACTIVE_COMPARATOR|Cefazolin 1.5g (Control)|
62676682|NCT03123562|EXPERIMENTAL|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
62676683|NCT00144508|EXPERIMENTAL|1|
62676684|NCT00144508|OTHER|2|continue current treatment
62676685|NCT06241482|EXPERIMENTAL|Enhanced recovery after surgery|The technologies, processes and measures of enhanced recovery after surgery were applied.
62676686|NCT06241482|ACTIVE_COMPARATOR|Conventional therapy|Conventional therapy were applied.
62676687|NCT06165653|EXPERIMENTAL|Guided Meditation Intervention|
62117184|NCT01911169|ACTIVE_COMPARATOR|Vitamin D 400|cholecalciferol 400 IU daily by mouth
62117185|NCT02825225|EXPERIMENTAL|20 core-biopsy fragments|Patients submitted to experimental intervention (extended sextant biopsy with 20 cores) compared to current standard biopsy protocol (extended sextant biopsy with 12 cores) guided by transrectal ultrasound.
62117186|NCT02825225|EXPERIMENTAL|Base and apex local anesthesia|Patients submitted to experimental intervention in prostate-biopsy anesthetic protocol (prostate base and prostate apex bilateral local anesthetic injection) compared to participants submitted to current standard anesthetic protocol in institution (prostate base bilateral local anesthesia) guided by transrectal ultrasound. guided by transrectal ultrasound.
62676688|NCT06165653|NO_INTERVENTION|Standard of Care|
62676689|NCT02327247|EXPERIMENTAL|Test|Felodipine Extended Release Tablets USP 10 mg
62676690|NCT02327247|ACTIVE_COMPARATOR|Reference|Plendil® Extended release tablets 10 mg
62676691|NCT01218256|ACTIVE_COMPARATOR|Hypertrophy resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
62676692|NCT01218256|ACTIVE_COMPARATOR|Endurance resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
62676693|NCT01733693|EXPERIMENTAL|Buprenorphine|Oral sublingual tablet, 8-32 mg per day, administered daily for duration of 4 months
62676694|NCT01733693|ACTIVE_COMPARATOR|Methadone|Oral sublingual tablet, 60-100 mg per day, administered daily for duration of 4 months
62676695|NCT05123105|EXPERIMENTAL|Experimental|Each person participated in three tests with an interval of approximately one week between them.
62676696|NCT06362642|EXPERIMENTAL|PC14586 and Itraconazole|Healthy participants will receive a single, oral dose of PC14586 on day 1. On day 20, participants will receive BID oral doses of itraconazole. On days 21-22, participants will receive a single, oral dose of itraconazole. On day 23, participants will receive a single, oral dose of PC14586 and a single oral dose of itraconazole. On days 24-27, participants will receive a single, oral dose of itraconazole.
62117187|NCT01692730|EXPERIMENTAL|Enhanced Web Assisted Intervention|Enhanced Web Assisted Tobacco Intervention. An enhanced and highly interactive website for cessation.
62305497|NCT05934760|EXPERIMENTAL|Resistance exercise training (RET)|"Older participants (over 60) will be randomized to perform home-based unsupervised exercise, the RET group will perform the RET intervention at home, 3 times a week unsupervised for 4 weeks.This will be supported by regular contact from a member of the research team to provide support and to encourage adherance.~Our research group has conducted many similar exercise regimes of this intensity to subjects in the anticipated age-range without incident. Participants will be adviced to terminate exercise training immediately if experiencing:~* Chest pain or tightness~* Faintness~* Sudden pallor~* Loss of co-ordination~* Confusion~* Dizziness~* Palpitations~* Sudden breathlessness~Should any participant experience these effects during any session, they will be advised to seek urgent medical attention and will be withdrawn from the exercise arm of the study for safety purposes."
62305498|NCT01565486|OTHER|Ultrasonic coagulation device|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
62305499|NCT01565486|OTHER|Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
62305500|NCT00248677|NO_INTERVENTION|No Contact Control|
62305501|NCT00248677|EXPERIMENTAL|Behavior Family Intervention|
62305502|NCT00248677|EXPERIMENTAL|Behavioral Parent-Only Intervention|
62676697|NCT01034657|EXPERIMENTAL|LBH589|During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
62117188|NCT01692730|ACTIVE_COMPARATOR|Basic Web Assisted Intervention.|Basic Web Assisted Tobacco Intervention. A basic website for cessation comparable to those for general adult populations, including established evidence-based cessation information and features.
62117189|NCT06376357|EXPERIMENTAL|Study|
62117190|NCT06376357|NO_INTERVENTION|Control|
62117191|NCT00316316|ACTIVE_COMPARATOR|1|Participants will receive motivational interviewing plus exposure and response prevention
62305503|NCT03237208|ACTIVE_COMPARATOR|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
62305504|NCT03237208|SHAM_COMPARATOR|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
62305505|NCT02330991|EXPERIMENTAL|Arm1 ,one-week on/one-week off regimen|One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
62305506|NCT02330991|EXPERIMENTAL|Arm 2,continuous dose-intense regimen|Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
62676698|NCT01034657|EXPERIMENTAL|LBH589 + Epoetin Alfa|During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.
62117192|NCT00316316|ACTIVE_COMPARATOR|2|Participants will receive exposure and response prevention only
62117193|NCT02695290|EXPERIMENTAL|Afatinib|
62117194|NCT00753012|EXPERIMENTAL|Lisdexamfetamine|"Adults who meet DSM-IV-TR criteria for ADHD.~Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of \<135/85."
62305507|NCT04896177|EXPERIMENTAL|Sirolimus drug-eluting coronary balloon catheter|Manufacturer: Shenzhen Salubris Pharmaceuticals Co., Ltd. This product is a sirolimus drug eluting balloon catheter for coronary artery therapy. It is a rapidly exchangeable PTCA balloon catheter (RX), effective length is 140cm, and compatible with 0.014 in. (0.36mm) guide wire. The balloon at the distal end of the catheter was coated with sirolimus, an anti-proliferative and anti-inflammatory drug.
62305508|NCT04896177|ACTIVE_COMPARATOR|Drug-eluting balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd Coated with paclitaxel.
62305509|NCT04956484|EXPERIMENTAL|Belimumab 10 mg/kg plus standard of care|Standard of care and Belimumab: 10 mg per kilogram of body weight，days 1 (baseline), 15, and 29 and every 28 days thereafter to week 24
62117195|NCT00903266|EXPERIMENTAL|MIT|Melodic Intonation Therapy
62117196|NCT00903266|ACTIVE_COMPARATOR|SRT|Speech-Repetition-Therapy
62117197|NCT00903266|NO_INTERVENTION|NTC|No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
62117198|NCT06676748|EXPERIMENTAL|Study group|Study group will receive Difflam spray by delivering 4 sprays to the posterior pharynx. Patients will be asked to swallow after each spray. Questionnaires will then be administered to the patients 10 minutes after administration of the intervention, and then 4 hours after for their pain scores and side effects, if any.
62676699|NCT04103970|NO_INTERVENTION|Control group|"Usual care:~Before surgery all patients are invited to participate in a pre-surgery seminar, where they receive information and advice about the time before, during and after the LSF. The seminar will be guided by nurses, surgeons, anesthesiologist, occupational therapists and physiotherapist.~After the surgery the patient will be hospitalized on an average of 3-4 days. During hospitalization a physiotherapist consults the patients on a daily basis to provide information, guidance on mobilization and instructions in gradually progressing movement. The patients will have no restrictions on movement after surgery and should gradually return to normal activity level.~Three months post-operatively all patients will receive physical rehabilitation delivered by physiotherapists in a community care center."
62676700|NCT04103970|EXPERIMENTAL|Intervention group: Graded Activity and Pain Education (GAPE)|"Patients in the intervention-group will receive usual care and 9 sessions of GAPE, 4 sessions at the hospital, 2 sessions in the patient's home and 3 sessions by telephone.~Pain education in GAPE is viewed as an approach which target cognitive attitudes and beliefs about pain. The pain education will target 3 overall questions: 1. What is pain and is my pain normal? 2. What can affect my pain? 3. What can I do to relieve my pain? The education will be individually adjusted to each patient, so the patient's context and concerns regarding pain and movement are included.~The aim of Graded activity is to improve the patient's functional ability by positive reinforcement of health behaviors and activity levels. Graded activity will be based on which short-term activity-goals the patient evaluates as the most important for the treatment outcome. In close collaboration with the patient the physiotherapist will set quotas for the selected exercises/activities."
62676701|NCT05670340|EXPERIMENTAL|Swithed-platform|In this group the implants will be rehabilitated with a narrower emergence profile for the prosthetic rehabilitation.
62676702|NCT05670340|ACTIVE_COMPARATOR|Matched-platform|This the conventional approach in wich the prosthetic rehabilitation is matched with the implant-platform dimensions
62676703|NCT06101862|ACTIVE_COMPARATOR|Coronary computed tomography angiography + team-based interventional triage|
62117199|NCT06676748|NO_INTERVENTION|Control group|Patients will be asked to fill in questionnaires for their pain scores and side effects, if any.
62117200|NCT02329613|ACTIVE_COMPARATOR|Standard evening meal|"Patients randomized to this arm will receive standard evening meals.~Intervention: Standard evening meals."
62117201|NCT02329613|EXPERIMENTAL|Improved evening meal|"Patients randomized to this arm will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.~Intervention: Improved evening meal"
62305510|NCT05567328|EXPERIMENTAL|Adult patient (age >= 18 y.o) followed for a liver disease, all etiologies combined|Adult patients followed in the Hepatology or Endocrinology department for a liver disease, all etiologies combined.
62305511|NCT05066815|EXPERIMENTAL|Hybrid superstructure|screw retained hybrid ceramic crowns
62676704|NCT06101862|OTHER|Conventional invasive coronary angiography|
62676705|NCT05013229|EXPERIMENTAL|IcoSema|Participants will receive once weekly subcutaneous (s.c) injections of IcoSema during the 52-week treatment period.
62117202|NCT05105646||Patients|"• All patients undergoing primary total knee arthroplasty for osteoarthritis of the knee reported in the Dutch Arthroplasty Register.~and~• Patients who filled out the EQ-5D-3L anxiety/depression score."
62117203|NCT01370707|ACTIVE_COMPARATOR|Metformin|
62117204|NCT01370707|EXPERIMENTAL|CJ-30001/CJ-30002|
62117205|NCT00413595||Observation|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease
62117206|NCT00117663|NO_INTERVENTION|No Hormone Suspension|No hormone suspension prior to screening mammogram
62117207|NCT00117663|ACTIVE_COMPARATOR|1 month hormone suspension|discontinuation of hormone therapy for 1 month prior to screening mammogram.
62117208|NCT00117663|ACTIVE_COMPARATOR|2 month hormone suspension|discontinuation of hormone therapy for 2 months prior to screening mammogram.
62117209|NCT04222959|EXPERIMENTAL|Girls Invest Intervention|Girls Invest intervention participants receive the app trainings and savings account with $100 deposited.
62117210|NCT04222959|NO_INTERVENTION|Wait-List Control Condition Participants|Control condition participants will be provided the Girls Invest intervention after the 6 month follow-up.
62305512|NCT05066815|ACTIVE_COMPARATOR|Ceramic superstructure|screw retained lithium disilicate based ceramic crowns
62305513|NCT01039168|ACTIVE_COMPARATOR|Workplace dialogue|Clinical examination and dialogue with supervisor to find solutions to reduce job-person mismatch and facilitate return to work
62305514|NCT01039168|SHAM_COMPARATOR|Care as usual|No intervention besides of the care as usual being available for the patient
62305515|NCT00555945|ACTIVE_COMPARATOR|1|Gamma3 intramedullary nail
62117211|NCT02828423|ACTIVE_COMPARATOR|Control group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) alone
62117212|NCT02828423|EXPERIMENTAL|Test group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) and Biphasic Calcium phosphate (BC)
62117213|NCT02485444|ACTIVE_COMPARATOR|Oxytocin|
62305516|NCT00555945|ACTIVE_COMPARATOR|2|Sliding hip screw
62305517|NCT00982722|EXPERIMENTAL|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
62305518|NCT00982722|ACTIVE_COMPARATOR|calciumcarbonate|calcium carbonate 500 mg x 2
62305519|NCT06117592||Pre-Intervention|Retrospective data collection for pre-education intervention period: 1st April 2023- 1st June 2023
62305520|NCT06117592||Post-Intervention|Retrospective data collection for post-education intervention period: 1st October 2023- 31st December 2023
62676706|NCT05013229|ACTIVE_COMPARATOR|Insuling glargine/insulin aspart|Participants will receive subcutaneous (s.c) injections of insulin glargine once daily combined with 2-4 times daily injections of insulin aspart.
62676707|NCT05348915|EXPERIMENTAL|Inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
61918551|NCT02789579|EXPERIMENTAL|nitrofurantoin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 7 days before Minimally invasive upper tract lithotomy.
62676708|NCT03225989|EXPERIMENTAL|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
62676709|NCT06688669||Patients with complete denture|Patients with total edentulism who require complete dentures.
62676710|NCT06688669||Patients with removable partial dentures|Patients with partial edentulism who require removable-partial dentures.
62676711|NCT05569954|EXPERIMENTAL|V116|Participants will receive a single intramuscular (IM) vaccination of 0.5 mL of V116 on Day 1.
62676712|NCT05569954|ACTIVE_COMPARATOR|PPSV23|Participants will receive a single IM vaccination of 0.5 mL of PPSV23 on Day 1.
62676713|NCT06254326|EXPERIMENTAL|Adoptive Cellular Therapy|All participants will receive 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment), a single i.v. infusion of ex vivo expanded tumor-reactive T cells, and a i.v. single infusion of autologous HSCs.
61918552|NCT01744145|ACTIVE_COMPARATOR|Interventional 40-60|Interventional group aged 40-60
61918553|NCT01744145|NO_INTERVENTION|Control 40-60|Control group aged 40-60
62676714|NCT01596244|EXPERIMENTAL|Microclinics training|Diabetic, pre-diabetic, or those with family members who are diabetic/pre-diabetic who participated in a 4 month long intervention with a focus on disease management, health behavior change, and social network supports in order to improve chronic disease risk factors.
62676715|NCT05362175||Cross sectional area of umbilical cord and Hadlock's formula|Ultrasound measurement of cross sectional area of umbilical cord within 1 cm from the umbilical cord insertion into the fetal abdomen And Fetal biometry using the standard Hadlock's formula
62676716|NCT00231465|EXPERIMENTAL|Taxotere® (Docetaxel) + ZD1839 (IRESSA®)|"Patients will receive Taxotere at 75 mg/m2 given IV over 60 minutes on day 1 of a three week cycle.~ZD1839 will be administered orally at 250mg daily starting on day one, concurrently with the Taxotere."
62676717|NCT05441696||Adult CHF subjects with initial high CVP|Adult subjects with congestive heart failure diagnosis who have an indicated high non-invasive estimated central venous pressure on first measurement after clinical unit admission.
62676718|NCT05441696||Adult CHF subjects with initial low CVP|Adult subjects with congestive heart failure diagnosis who have an indicated low non-invasive estimated central venous pressure on first measurement after clinical unit admission.
62676719|NCT01399099|EXPERIMENTAL|embrace Dressing|Investigational Dressing
62676720|NCT01399099|NO_INTERVENTION|Standard of Care|Standard of care comparator
62736191|NCT05210088|EXPERIMENTAL|PHASE 1- Dose escalation protocol|"4-step dose-escalation protocol with increasing doses of intermittent hypoxia and continuous reassessment of safety criteria (primary endpoint).~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored: 90% for stage 1 (n=1 patient), 85% for stage 2 (n=3 patients), 80% for stage 3 (n=3 patients), 75% for stage 4 (n=3 patients)."
61918554|NCT01744145|ACTIVE_COMPARATOR|Interventional 60 and above|Interventional group aged 60 and above
61918555|NCT01744145|NO_INTERVENTION|Control 60 and above|Control group aged 60 and above
61918556|NCT04144491|EXPERIMENTAL|Yoghurt|Yoghurt, containing Lactobacillus rhamnosus yoba 2012, Streptococcus thermophilus C104, whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence.
61918557|NCT04144491|PLACEBO_COMPARATOR|Custard|Custard, containing whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence, 4% modified corn starch.
61918558|NCT03336710||Primary sample|Community sample of adults (18-65) from the greater Buffalo, NY region, oversampling people who are seeking mental health treatment.
62117214|NCT02485444|NO_INTERVENTION|Observation|
62117215|NCT03105505|ACTIVE_COMPARATOR|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
62117216|NCT03105505|ACTIVE_COMPARATOR|Synthomycine 5%,|Contains chloramphenicol 5%.
62117217|NCT03105505|ACTIVE_COMPARATOR|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
62117218|NCT00092014|EXPERIMENTAL|Alendronate 70 mg|Alendronate sodium, 70 mg, orally once weekly for up to 24 months
62117219|NCT00092014|ACTIVE_COMPARATOR|Risendronate 35 mg|Risendronate, 35 mg, orally once weekly for up to 24 months
62117220|NCT04300426|EXPERIMENTAL|ACHIM by gastroduodenoscopy|"Intestinal microbiota (acronym ACHIM - anaerobically cultured human intestinal microbiota) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml, containing approximately 10\^9 bacteria / ml.~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
62117221|NCT04300426|PLACEBO_COMPARATOR|Placebo by gastroduodenoscopy|"ACHIM culture media (no bacteria) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml.~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
62117222|NCT02613871|EXPERIMENTAL|LDV/SOF|LDV/SOF FDC for 12 weeks
62117223|NCT03007836|EXPERIMENTAL|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62117224|NCT03007836|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62117225|NCT04091425|EXPERIMENTAL|TAK-925 Dose A|TAK-925 dose A intravenous (IV) infusion in each treatment sequence (crossover design).
62117226|NCT04091425|EXPERIMENTAL|TAK-925 Dose B|TAK-925 dose B IV infusion in each treatment sequence (cross over design).
62117227|NCT04091425|PLACEBO_COMPARATOR|Placebo|TAK-925 placebo-matching IV infusion in each treatment sequence (crossover design).
61918559|NCT01190787|EXPERIMENTAL|VMP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
61918560|NCT01190787|EXPERIMENTAL|VCP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
61918561|NCT01190787|EXPERIMENTAL|VP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
61918562|NCT05160987|EXPERIMENTAL|Remimazolam Group|The patients are administered with sedation of remimazolam and analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drug before enrollment, patient would be administered with a bolus of remimazolam with 0.1-0.3mg/kg intravenously in 1 minute for the first time. And maintenance dose is 0.25-0.1mg/kg/h, meanwhile the dose of remimazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
61918563|NCT05160987|PLACEBO_COMPARATOR|Midazolam Group|The patients are administered with sedation of midazolam analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drugs before enrollment, patients would be administered with a bolus of midazolam with 0.01-0.05mg/kg intravenously in 1 minute for the first time. And the maintenance dose is 0.02-0.1mg/kg/h, meanwhile the dose of midazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
61918564|NCT00998764|EXPERIMENTAL|Bapineuzumab 0.5 mg/kg|
62117228|NCT02666742|EXPERIMENTAL|DOAC (Direct Oral Anticoagulant)|Participants will be asked to take standard dose approved for stroke prophylaxis
62117229|NCT02666742|ACTIVE_COMPARATOR|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
62117230|NCT05162144|EXPERIMENTAL|Proximal Medial Gastrocnemius Recession Surgery|All patients included in the Cohort Study will recieve this PMGR-surgery
62117231|NCT04104698||Study Group (MDD with SIs)|25 Egyptian patients diagnosed with major depression (with suicidal ideations)
62305521|NCT05965570|EXPERIMENTAL|Brensocatib + Clarithromycin|Participants will receive a single oral dose of brensocatib in the morning on Days 1 and 13 after an overnight fast, and oral doses of clarithromycin, twice daily (BID), with food on Days 8 to 19. On Day 13, brensocatib will be coadministered with the morning dose of clarithromycin. Clarithromycin can be taken with food, with the exception of the morning dose on the day of coadministration with brensocatib (Day 13), which will be taken after an overnight fast.
62305522|NCT02997930|EXPERIMENTAL|Elderly Hip Fracture|Postoperative assess cognitive function in elderly subjects after fracture hip surgery. Measure function connectivity and DTI (diffusion tensor imaging) via: fMRI. Subjective measures will include: Montreal Cognitive Assessment (MoCA), Digital Clock Drawing Test Command and Copy, Wide Range Achievement Test reading subtest, Hopkins Verbal Learning Test (HVLT), General Depression Scale (GDS)
62305523|NCT04713319|PLACEBO_COMPARATOR|Placebo|"Ten participants were randomly selected to the placebo group.~Calcium chloride (E509) dissolved into water. Extremely small equimolar calcium dose with the test item."
62473366|NCT04531605|EXPERIMENTAL|Intervention|"12-week program of combined life-skills training and financial incentives (YBank program) described in more detail below.~1. Life-skills training: Every 4 weeks through the 12 week program, life-skills training sessions will be delivered during peer-group sessions at the clinic. Topics include economic empowerment, financial literacy, healthy relationships, and anti-retroviral therapy (ART) adherence.~2. Financial incentives: The incentives program combines an immediate financial reward with a long-term savings opportunity. For clinic attendance, 500 RWF (\~$0.50) will be deposited into participants' mobile money short-term account, where funds will be immediately accessible, and 1500 RWF (\~$1.50) will be deposited into their savings account upon completing the program. If participants demonstrate a suppressed viral load at a clinic appointment, an additional 1000 RWF (\~$1) will be deposited to their short-term account and 3000 RWF (\~$3) into their saving account."
62473367|NCT00568672|ACTIVE_COMPARATOR|1|Olanzapine 5 mg / day
62117232|NCT04104698||Control group (MDD without SIs)|25 Egyptian patients diagnosed with major depression (without suicidal ideations)
62305524|NCT04713319|ACTIVE_COMPARATOR|RH013001 (DGA)|D-glyceric acid (DGA) calcium salt dehydrate (RH013001) dissolved into 1.8 dl of water. Effective dose of DGA was 3.33 mg / kg body weigh for the first 4 days. Thereafter the dose was reduced to half for the 14 days follow up period. Frequency: 2 times a day.
62305525|NCT04937257|ACTIVE_COMPARATOR|Virtual Reality|"Participants randomized to the immersive virtual reality study arm, considered the intervention group received training on donning and doffing PPE using a program developed by Axon Park Inc. (California, USA)"
62305526|NCT04937257|PLACEBO_COMPARATOR|E-module|"Participants randomized to the e-module study arm, considered the control group received training on donning and doffing PPE using an e-module containing a video and slide show."
62473368|NCT00568672|PLACEBO_COMPARATOR|2|Placebo
62473369|NCT05658783|EXPERIMENTAL|Intervention Group|Participants in this study group will be asked to keep their feet in 42oC (42 Degrees Celsius) hot water for 20 minutes on the night of the day of surgery.
62473370|NCT05658783|NO_INTERVENTION|Control Group|Participants in this study group will take the standard service clinical procedure and hot water foot bath will not be applied.
62305527|NCT02316444|OTHER|HAART exposed|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
62473371|NCT03600467|EXPERIMENTAL|Adrogen Postive Solid Tumours|
62676721|NCT05343650|EXPERIMENTAL|Study arm|"Stage 1 After shellfish allergy is confirmed through the skin prick test and IgE analysis, Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm. Participants will then be monitored for 1 hour, and any- reaction will be documented. In case of any symptoms of an allergic reaction, their study participation will be terminated.~Stage 2 If no allergic symptoms are observed in stage 1, the patient's nose will be anesthetized with topical lidocaine. A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes. After removal, the participant will be monitored in the clinic for an hour. Any allergic reaction will be documented, including increased nasal congestion, rhinorrhea, or pruritis."
61918565|NCT01946906|NO_INTERVENTION|No treatment|patient receive no active treatment
61918566|NCT01946906|EXPERIMENTAL|Rifaximin|Patient takes Rifaximin 550mg twice daily for 14 days
62305528|NCT02316444|OTHER|HAART naive|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
62305529|NCT02428140|EXPERIMENTAL|Implanted Loop Recorder|long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
62305530|NCT02428140|EXPERIMENTAL|External Loop Recorder|external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days
61918567|NCT05204407|ACTIVE_COMPARATOR|Luteolin|
61918568|NCT05204407|PLACEBO_COMPARATOR|Placebo|
62305531|NCT05207462|EXPERIMENTAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
62473372|NCT04487691|EXPERIMENTAL|Platelet Lysate|Inhaled nebulized platelet lysate (PL), 2-ml 1x per day for 8 weeks.
62473373|NCT04487691|ACTIVE_COMPARATOR|Saline|Inhaled nebulized normal sterile saline, 2-ml 1x per day for 8-weeks.
62473374|NCT04741893|EXPERIMENTAL|faecally incontinent patients|faecally incontinent patients are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
62473375|NCT04741893|EXPERIMENTAL|Asymptomatic individuals|asymptomatic individuals are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
61918569|NCT05457894|EXPERIMENTAL|Flu-M, II trimester of pregnancy|Subjects during their II trimester of pregnancy (gestational age: 14-26 weeks), immunized once with the Flu-M vaccine.
62305532|NCT05661383|EXPERIMENTAL|iTBS active combined with an olfactory stimulation|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.
62305533|NCT05661383|ACTIVE_COMPARATOR|iTBS active alone|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.
62305534|NCT04590612|ACTIVE_COMPARATOR|Carbidopa-Levodopa|Patients will be randomized to any of the 2 arms. In Levodopa/carbidopa arm, patients will be taking Carbidopa-Levodopa (25-100mg) three times a day for the duration of the study.
61918570|NCT05457894|ACTIVE_COMPARATOR|Ultrix®, II trimester of pregnancy|Subjects during their II trimester of pregnancy (gestational age: 14-26 weeks), immunized once with Ultrix®.
61918571|NCT05457894|EXPERIMENTAL|Flu-M, III trimester of pregnancy|Subjects during their III trimester of pregnancy (gestational age: 27-32 weeks), will be immunized once with the Flu-M vaccine.
61918572|NCT05457894|ACTIVE_COMPARATOR|Ultrix®, III trimester of pregnancy|Subjects during their III trimester of pregnancy (gestational age: 27-32 weeks), immunized once with Ultrix®.
61918573|NCT01314846||Control Group|sequential culture system
61918574|NCT01314846||Co-culture system|
61918575|NCT03269552|EXPERIMENTAL|Treatment (carfilzomib, rituximab)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.
62117233|NCT03359460|EXPERIMENTAL|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
62117234|NCT00846066|EXPERIMENTAL|Hands on Training|Hands on Training by a pediatric dentist
62117235|NCT00846066|ACTIVE_COMPARATOR|Web Based Training|Web Based Training for all residents before randomization
61918576|NCT01736657|EXPERIMENTAL|Red cell exchange in sickle cell|Open arm; Red cell blood exchange for patients with sickle cell disease
62117236|NCT01035658|EXPERIMENTAL|Dose Level 1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
62117237|NCT01035658|EXPERIMENTAL|Dose Level -1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
62117238|NCT01035658|EXPERIMENTAL|Dose Level 1 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
62305535|NCT04590612|EXPERIMENTAL|Citalopram|Patients will be randomized to any of the 2 arms. In Citalopram arm, patients will be taking Citalopram (20mg) daily for the duration of the study.
62117239|NCT01035658|EXPERIMENTAL|Dose Level 2 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
62117240|NCT02630719|ACTIVE_COMPARATOR|Timolol eye drops|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
62117241|NCT02630719|PLACEBO_COMPARATOR|Artificial tears|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
62117242|NCT01443117|EXPERIMENTAL|Step 1: PPV-23 Vaccine (Arm 1a)|Participants will receive one intramuscular (IM) injection of 0.5 mL of the PPV-23 vaccine at baseline.
62117243|NCT01443117|EXPERIMENTAL|Step 1: PCV-13 Vaccine (Arm 1b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine at baseline.
62117244|NCT01443117|PLACEBO_COMPARATOR|Step 1: Placebo Vaccine (Arm 1c)|Participants will receive one IM injection of 0.5 mL of the placebo vaccine at baseline.
62305536|NCT04045912|EXPERIMENTAL|HIVST + AGYW-Friendly Services|"Drug shops in Arm 1 will implement AGYW-friendly services, including a sexual and reproductive health (SRH) product display, a tablet with SRH videos, and a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. They will also provide HIV self-test (HIVST) kits to AGYW customers for free."
62305537|NCT04045912|ACTIVE_COMPARATOR|HIVST Only|Drug shops in Arm 2 will provide HIVST kits to AGYW customers for free.
62305538|NCT01684826|EXPERIMENTAL|ClarityIQ|Angiographic run with new algorithm and low dose (50% dose)
62305539|NCT01684826|EXPERIMENTAL|AlluraXper|Angiographic run with predecessor algorithm and dose (100% dose)
62305540|NCT01496014||severe open fractures of the tibia bone|
62305541|NCT03025581|ACTIVE_COMPARATOR|Intervention group|Nipple stimulation.
62305542|NCT03025581|NO_INTERVENTION|Control group|No intervention (expectant management only).
62305543|NCT02728934||Golimumab Intravenous (IV)|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Golimumab IV.
62305544|NCT02728934||Infliximab|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Infliximab.
62305545|NCT03880643||Study Group|Patients with primary membranous nephropathy who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to at least one set of prior therapies including corticosteroids, alkylating agents or calcineurin inhibitors.
62676722|NCT04250389||Patients with VS receiving methylene blue infusion|The studied population will be all patients receiving methylene blue for refractory vasoplegic shock (VS) after Cardiopulmonary Bypass (CPB). Refractory VS is defined as follow: a dose of norepinephrine \> 0.5µg/kg/min to obtain a mean arterial pressure of 65-75 mmHg with a normal or increase cardiac (\> 2 L.min-1.m-2). Patients will be included in the investigator's 20-bed adult cardiothoracic intensive care unit (ICU) in a tertiary teaching hospital (Hopital Cardiologique Louis Pradel, Hospices Civils de Lyon).
62676723|NCT05130957|EXPERIMENTAL|Experimental Group|The pregnant women in the experimental group are given a massage with clove oil.
62117245|NCT01443117|EXPERIMENTAL|Step 2: PPV-23 Vaccine (Arm 2a)|Participants will receive one IM injection of 0.5 mL of the PPV-23 vaccine 6 months after delivery.
62117246|NCT01443117|EXPERIMENTAL|Step 2: PCV-13 Vaccine (Arm 2b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine 6 months after delivery.
62117247|NCT04172246|EXPERIMENTAL|Zanubrutinib|
62117248|NCT03208101|EXPERIMENTAL|Test group|DTP-HepB-IPV-Hib vaccine
62117249|NCT03208101|ACTIVE_COMPARATOR|Control group|DTP-HepB-Hib vaccine \& IPV
62117250|NCT02500654|EXPERIMENTAL|Surgery and Emdogain®|access peri-implant surgery with Emdogain® applied after cleaning of implant surface with saline
62117251|NCT02500654|PLACEBO_COMPARATOR|Surgery alone|access peri-implant surgery and cleaning of implant surface with saline
62305546|NCT05696340||JIA patients|Children diagnosed with JIA between 4 and 24 months before the start of the study, treated and followed in a pediatric rheumatology center (old enough to answer the questions)
62117252|NCT05739903|EXPERIMENTAL|Sequence A(Before→ After)|
62117253|NCT05739903|EXPERIMENTAL|Sequence B(After→ Before)|
62117254|NCT00552942|EXPERIMENTAL|1|surgery plus omentectomy
62117255|NCT00552942|NO_INTERVENTION|2|standard gastric bypass
62117256|NCT01970358|EXPERIMENTAL|Personalized NeoAntigen Cancer Vaccine|"- NeoVax (peptides + poly-ICLC)~Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 162~Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 162"
62117257|NCT04155177||begining of curriculum|trainees in obstetrics and gynecology who have achieved less than 2 years of their hole curriculum
62117258|NCT04155177||mid curriculum|trainees in obstetrics and gynecology who have achieved at least 2 years and less than 4 years of their hole curriculum
62676724|NCT05130957|OTHER|Control Group|The pregnant women in the control group are given a massage without any oil as standard midwifery care
62676725|NCT05196724|EXPERIMENTAL|Mentalization Based Therapy (MBT)|MBT for foster carers is a 12 session therapeutic intervention that will be offered to foster families by municipal foster care consultants
62676726|NCT05196724|ACTIVE_COMPARATOR|Usual care|the control group will receive the usual care offered to foster families such as supervision
61918577|NCT01966692|ACTIVE_COMPARATOR|Fluticasone Propionate Formulation Sequence 1233*|"Patients first received Fluticasone Propionate Drug formulation 1, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 2, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 3, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 3\*.~All Fluticasone Propionate Drug formulations were administered via Plastiape Monodose Dry Powder Inhaler, 500mcg single dose.~Mass Median Aerodynamic Diameter (MMAD) for formulation 1 is 4.5 µm. MMAD for formulation 2 is 3.8 µm MMAD for formulation 3 is 3.7 µm. MMAD for formulation 3\* is 3.7 µm. See Formulation Development in Detailed Description for details regarding differences in formulations"
62117259|NCT04155177||Advanced|trainees in obstetrics and gynecology who have achieved at least 4 years of their hole curriculm
62676727|NCT06260618|ACTIVE_COMPARATOR|Gelfoam Arm|"The current standard of care in middle ear packing material has been Gelfoam, Gelfoam is an absorbable gelatin sponge manufactured from denatured porcine skin. Generally, Gelfoam resides within the middle ear for 2 to 9 weeks prior to being degraded via phagocytosis.~A single Gelfoam sponge is divided into small pieces and used within the ear. One piece of Gelfoam can typically be cut into over 200 smaller pieces. The surgeon uses approximately 10 to 20 of these smaller pieces per surgery. Approx a third of the product is applied into the middle ear, as a support material for the graft. After graft suturing is complete, the remaining two thirds are applied into the external ear canal as a packing agent.~The surgeon administers the foam during the surgery as they would with the standard TMP repair surgery. The product comes in a sterile package to be opened and cut up by Scrub Nurse."
61918578|NCT01966692|ACTIVE_COMPARATOR|Fluticasone Propionate Formulation Sequence 23*13|"Patients first received Fluticasone Propionate Drug formulation 2, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 3\*, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 1, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 3.~All Fluticasone Propionate Drug formulations were administered via Plastiape Monodose Dry powder Inhaler, 500mcg single dose.~MMAD for formulation 1 is 4.5 µm. MMAD for formulation 2 is 3.8 µm. MMAD for formulation 3 is 3.7 µm. MMAD for formulation 3\* is 3.7 µm. See Formulation Development in Detailed Description for details regarding differences in formulations"
62117260|NCT06174662|EXPERIMENTAL|Music|Music through noise cancelling headphones.
62117261|NCT06174662|NO_INTERVENTION|No music|Control group receiving regular care. No music will be offered to the patient.
62117262|NCT03731312||Study group|We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
62117263|NCT02698007|NO_INTERVENTION|without lma|standard fiberoptic bronchoscopy without lma
62117264|NCT02698007|EXPERIMENTAL|with lma|fiberoptic bronchoscopy with the use of lma
62117265|NCT03833804|EXPERIMENTAL|NLP (natural language processing) pre-screen|Automated processing of clinical notes collected during routine care in first 24 hours of hospital admission to identify individuals at-risk for substance misuse to receive standard-of-care full screening and assessment, brief intervention, or referral to treatment (SBIRT) intervention.
62117266|NCT02342119|EXPERIMENTAL|KTFT+TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are receiving the Talking About Living Kidney Donation intervention
62117267|NCT02342119|ACTIVE_COMPARATOR|KTFT+No TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are not receiving the Talking About Living Kidney Donation intervention
62117268|NCT00361283|OTHER|atorvastatin|80mg of atorvastatin given once daily for 16 weeks
62305547|NCT05696340||Parents of JIA patients|Parents of a child diagnosed with JIA between 4 and 24 months prior to the start of the study (treated and followed in a pediatric rheumatology center)
62117269|NCT06167525|OTHER|Neck posture monitoring device without feedback option|Real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for \>1 minute.
62305548|NCT05696340||Health care professionals|Physician with experience in the initial management of JIA patients (between symptom onset and first visit with a pediatric rheumatologist)
62117270|NCT04675944|EXPERIMENTAL|BIA 5-1058 / treprostinil|Three treatment periods separated by a washout period of at least 10 days
62676728|NCT06260618|EXPERIMENTAL|Chitodex Arm|"Chitosan-dextran gel is packaged within a syringe and has a cannula attached, much like the Gelfoam syringe system. Approx 3-5mL of product is applied during the surgery. Approx 2mL into the middle ear, as a support material for the graft. After graft suturing is complete, another 3mL (approx) is applied into the external ear canal as a packing agent. This is the same procedure as Gelfoam is currently used for this purpose.~The surgeon will administer the gel during the surgery as they would with the standard of care Gelfoam. The product comes in a sterile kit to be opened by Scrub Nurse."
62676729|NCT06361810|EXPERIMENTAL|177Lu-PNT2002 3.4 GBq|177Lu-PNT2002 administered at 3.4 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 megabecquerel (MBq) (9 mCi) at screening, week 12 and week 24.
62676730|NCT06361810|EXPERIMENTAL|177Lu-PNT2002 5.1 GBq|177Lu-PNT2002 administered at 5.1 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
62117271|NCT04425408|EXPERIMENTAL|Positional pillow followed by vibrating belt|26 patients with positional sleep apnea will be randomized to spend 3 nights using a positional pillow followed by a vibrating belt. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
62117272|NCT04425408|EXPERIMENTAL|Vibrating belt followed by positional pillow|26 patients with positional sleep apnea will be randomized to spend 3 nights using a vibrating belt followed by a positional pillow. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
62117273|NCT04364789|ACTIVE_COMPARATOR|Pilot dose Cohort|A pilot dose of 20 mg will be evaluated in 2 subjects (all receiving TT-00920) for safety, tolerability, and PK profile before the initiation of dose escalation.
62117274|NCT04364789|ACTIVE_COMPARATOR|SAD Dose 1|
62117275|NCT04364789|ACTIVE_COMPARATOR|SAD Dose 2|
62117276|NCT04364789|ACTIVE_COMPARATOR|SAD Dose 3|
62117277|NCT04364789|ACTIVE_COMPARATOR|SAD Dose 4|
62117278|NCT04364789|ACTIVE_COMPARATOR|Food Effect Cohort|
62117279|NCT04364789|PLACEBO_COMPARATOR|Placebo|
62117280|NCT02399696|EXPERIMENTAL|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum.
62676731|NCT06361810|EXPERIMENTAL|177Lu-PNT2002 6.8 GBq|177Lu-PNT2002 administered at 6.8 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
62676732|NCT06361810|EXPERIMENTAL|Dose Expansion|177Lu-PNT2002 administered at the maximum tolerated dose (determined by the 3 dose levels in the dose escalation phase of the study) intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
62117281|NCT02399696|ACTIVE_COMPARATOR|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
62117282|NCT00360451|EXPERIMENTAL|1|Adolescent only Penn Resiliency Program
62676733|NCT01544075|EXPERIMENTAL|PNE+PI|The interventional group who will receive the experimental PNE+PI treatment.
62117283|NCT00360451|EXPERIMENTAL|2|Adolescent plus parent Penn Resiliency Program
62117284|NCT00360451|NO_INTERVENTION|3|Control
62117285|NCT05562050||Control|
62117286|NCT05562050||COVID-19 related anosmia|
62117287|NCT05562050||Head-trauma related anosmia|
62117288|NCT02181660|EXPERIMENTAL|Dose Escalation Cohort|ASP2215
62117289|NCT02599142|ACTIVE_COMPARATOR|Group A: Closed-face shells|Cranial radiotherapy using the control closed-face immobilisation shell.
62117290|NCT02599142|EXPERIMENTAL|Group B: open-face shell|Cranial radiotherapy using the experimental open-face immobilisation shell
62117291|NCT04120597|EXPERIMENTAL|Therapy group|
62117292|NCT04120597|PLACEBO_COMPARATOR|Control group|
62117293|NCT02871999|ACTIVE_COMPARATOR|Control group|This group receives normal treatment after surgery,with no acupuncture.
62117294|NCT02871999|EXPERIMENTAL|Experimental group|This group receives acupuncture therapy besides normal treatment after surgery. The acupuncture therapy starts after 24 hours of surgery, 1 time a day, 30 minutes every time, until the fifth day.
62117295|NCT03749044|EXPERIMENTAL|Patient Educational Tool|At the baseline visit, after having responded to the questionnaire, participants in the education arm will be given the patient educational tool.
62117296|NCT03749044|NO_INTERVENTION|Standard of Care|Subjects in the standard of care arm will not receive the patient educational tool. If participants ask specific questions on pregnancy complications and/or preeclampsia, the clinicians will provide relevant information as they judge appropriate, but without handing out the patient educational tool.
62117297|NCT05705700|EXPERIMENTAL|1245c positive (1245c+) patients with dutasteride|Continue on abiraterone 1000 mg PO daily with dutasteride 3.5 mg PO daily as an add-on therapy until radiographic progression is documented
62117298|NCT05705700|EXPERIMENTAL|1245c positive (1245c+) patients|Continue on abiraterone 1000 mg PO daily (the standard of care for PSA only progression) until radiographic progression is documented
62473376|NCT01827163|EXPERIMENTAL|Paclitaxel With Trastuzumab and Lapatinib|Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase \& continued for the remaining year during the HL phase for about a year.
62676734|NCT01544075|ACTIVE_COMPARATOR|NS|The control group who will receive the neck school treatment.
62676735|NCT03460964|EXPERIMENTAL|Patients with Diabetes|All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.
62117299|NCT05705700|EXPERIMENTAL|1245c negative (1245c-) patients|abiraterone 1000 mg PO daily (the standard of care for PSA only progression) until radiographic progression is documented
62117300|NCT02874326|EXPERIMENTAL|Active comparator: Octreotide LAR|Sandostatin LAR Sandostatin LAR 20 mg will be administered once every 4 weeks as a intramuscular injection
62117301|NCT04460612|PLACEBO_COMPARATOR|Placebo Sock|Placebo Socks will be placed on participants feet either first or second for 60 minutes
62117302|NCT04460612|ACTIVE_COMPARATOR|Active IR Sock|Active IR socks will be placed on participants feet either first or second
62473377|NCT02009163|EXPERIMENTAL|Lisdexamfetamine dimesylate|Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
62676736|NCT06197711|EXPERIMENTAL|Intervention group|The intervention, PRISMA, addresses the issue of poor mental health of inmates during pretrial detention and after release. PRISMA has been adapted for the context of the model trial from Problem Management Plus (PM+). PRISMA has a total of four sessions provided during the first two weeks after entry such that most inmates can benefit from it before their potential release. The four sessions involve stress management, problem solving, meaningful activities (behavioral activation, and strengthening social support) and relapse prevention (staying well, looking forward). Additionally, participants will receive 2 booster sessions, 4 and 9 weeks after the final session, when most inmates will already have been released from jail.
62676737|NCT06197711|NO_INTERVENTION|Control group|REGULAR PRETRIAL: participants in this group experience the same pretrial system, conditions, and services that they would have experienced if the RCT did not exist. They will not be offered PRISMA or extended social services, but they can still access social services upon request as well as medical support through the jails' health services.
62676738|NCT06549127|EXPERIMENTAL|Experimental Group|This group is evaluated on three conditions.
62676739|NCT05540600|EXPERIMENTAL|Digoxin group|Patients will receive digoxin 0.25 mg once daily for a duration of 4 weeks
62117303|NCT04808505|EXPERIMENTAL|Cohort 1: Cipaglucosidase Alfa/Miglustat in ERT-experienced pediatric IOPD subjects|Pediatric IOPD subjects 6 months to \<18 years experiencing clinical decline
62117304|NCT04808505|EXPERIMENTAL|Cohort 2: Cipaglucosidase Alfa/Miglustat in ERT-naïve pediatric IOPD subjects|Pediatric IOPD subjects \<6 months
62473378|NCT02009163|PLACEBO_COMPARATOR|Placebo|Administer one capsule orally daily at approximately 7:00 AM.
62473379|NCT06288035|EXPERIMENTAL|At-night oral dexamethasone|Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.
62473380|NCT06288035|ACTIVE_COMPARATOR|At-induction dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.
62473381|NCT04660747||CVT cohort|
62473382|NCT01868945|EXPERIMENTAL|5 µg/day Hy.D Calcifediol|
62473383|NCT01868945|EXPERIMENTAL|10 µg/day Hy.D Calcifediol|
62117305|NCT02954016|EXPERIMENTAL|ePass|Subjects implanted with the investigational ValenTx Endo Bypass System
62117306|NCT03016455||DSA positive patients without cAMR|Presence of DSA w/o cAMR
62117307|NCT03016455||DSA positive patients with cAMR|Presence of DSA w/ cAMR
62117308|NCT03016455||Stable patients|No DSA No cAMR
62473384|NCT01868945|EXPERIMENTAL|15 µg/day Hy.D Calcifediol|
62473385|NCT01868945|ACTIVE_COMPARATOR|20 µg/day vitamin D3|
62305549|NCT04350203||Intracorporeal Anatomosis (IA)|Laparoscopic Right colectomy with intracorporeal (IA) side-to-side isoperistaltic anastomosis
62305550|NCT04350203||Extracorporeal Anastomosis (EA)|Patients submitted to a Laparoscopic Right Colectomy with extracorporeal anastomosis (EA)
62305551|NCT02862795|OTHER|HPV detection in anal canal samples|
62305552|NCT02260011|EXPERIMENTAL|Ipratropium bromide HFA-134a low|
62305553|NCT02260011|EXPERIMENTAL|Ipratropium bromide HFA-134a high|
62305554|NCT02260011|ACTIVE_COMPARATOR|Atrovent® CFC low|
62305555|NCT02260011|ACTIVE_COMPARATOR|Atrovent® CFC high|
62305556|NCT02260011|PLACEBO_COMPARATOR|Placebo|
62305557|NCT03065530|PLACEBO_COMPARATOR|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
62305558|NCT03065530|EXPERIMENTAL|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
62305559|NCT03065530|EXPERIMENTAL|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
62305560|NCT03065530|EXPERIMENTAL|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
62305561|NCT01441154||Group 1|Adults with clinical indication for withdrawal from thyroid hormone replacement therapy in preparation for nuclear medicine imaging or therapeutic procedures with radioactive iodine
62305562|NCT05124938||Group 1|Healthy individuals
62305563|NCT05124938||Group 2|patients with localized thyroid malignancy
62305564|NCT05124938||Group 3|patients with metastatic thyroid malignancy
62305565|NCT02916446|EXPERIMENTAL|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, daily administration
62305566|NCT02916446|PLACEBO_COMPARATOR|Placebo|Placebo patch, daily administration
62117309|NCT01567683|EXPERIMENTAL|Limtop solution (imiquimod), Vehicle solution for topical use|
61919953|NCT01525121|EXPERIMENTAL|Expiratory Rib Cage Compression|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
62117310|NCT03471611|EXPERIMENTAL|Subjects with Endothelial Dysfunction|Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
62117311|NCT02785380|EXPERIMENTAL|laparoscopic surgery(LS)|For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
62117312|NCT02785380|ACTIVE_COMPARATOR|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA).
62117313|NCT04063826|OTHER|PET MRI Scan|Imaging scan of the liver
62117314|NCT00765973|EXPERIMENTAL|A|Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
62117315|NCT00765973|EXPERIMENTAL|B|Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
62117316|NCT05119023|EXPERIMENTAL|Characterization of learning|All participants are assigned to complete behavioral (computer-based) learning tasks that measure their ability to learn observationally (observational learning ability) and via rules (rule-based learning ability).
62117317|NCT03121586|EXPERIMENTAL|Drug - Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, + background antipsychotic, taken once daily by mouth
62117318|NCT02105064|ACTIVE_COMPARATOR|Active rTMS|rTMS over Supplementary Motor Area, 1hz, no pauses, 20 minutes per sessions. Total: 20 sessions.
62117319|NCT02105064|SHAM_COMPARATOR|Sham|Sham stimulation, 20 minutes per session, total 20 sessions
62117320|NCT01550666|EXPERIMENTAL|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
62117321|NCT01550666|NO_INTERVENTION|Treatment As Usual|Participants of this group will continue to receive medication follow up at the Center for Health Care Services. They will not be required to do anything additional except to complete assessment visits.
62117322|NCT05654012|OTHER|Family History of Migraine|This group has a first degree relative diagnosed with migraine.
62117323|NCT05654012|OTHER|No Family History of Migraine|This group does not have a first or second degree relative diagnosed with migraine.
62117324|NCT00566904|EXPERIMENTAL|1|Participants will receive one of three different topical treatments on Days 8, 15, or 22.
62305567|NCT02851446||DS|
62305568|NCT02851446||no DS|
62305569|NCT01558687|EXPERIMENTAL|Group A = Cilengitide Group|Cilengitide + SoC (Temolozomide + Radiotherapy)
62305570|NCT01558687|ACTIVE_COMPARATOR|Group B = Control Group|SoC (Temolozomide + Radiotherapy)
62305571|NCT01784471|EXPERIMENTAL|Magic foot shoe|Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
62305572|NCT01613612|SHAM_COMPARATOR|control group:core decompression|single core decompression
62117325|NCT05399394|EXPERIMENTAL|LAPC patients|Patients treated with induction FOLFIRINOX; for patients without disease progression as detected through restaging exams, chemotherapy was followed by chemoradiation which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
62305573|NCT01613612|ACTIVE_COMPARATOR|Treatment group: BMCs+core decompression|Enriched bone marrow cells combined with core decompression
62305574|NCT00834119|EXPERIMENTAL|Mometasone furoate|
62117326|NCT04949607|EXPERIMENTAL|Chronic Traumatic Brain Injury|Subjects aged 18-70 years with chronic traumatic brain injury receiving Inulin treatment.
62117327|NCT04949607|EXPERIMENTAL|Healthy Controls|Healthy subjects aged 18-70 years receiving Inulin treatment.
62305575|NCT00834119|EXPERIMENTAL|Mometasone furoate plus an oral antihistamine|
62305576|NCT02375776|EXPERIMENTAL|Intervention|Download and use mobile health application - CORA- Device:smartphones for 12 weeks.
62117328|NCT03180450|EXPERIMENTAL|Treatment group|conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.
62117329|NCT03180450|PLACEBO_COMPARATOR|Control group|Conventional treatment
62117330|NCT04753099|EXPERIMENTAL|Intervention|Receives occupation-based coaching via telehealth
62117331|NCT04753099|NO_INTERVENTION|Control|No intervention Will receive the occupation-based coaching via telehealth after the 12-weeks
62117332|NCT00361946||lean subjects|BMI \<85th for age, normal glucose tolerance
62117333|NCT00361946||obese subjects|BMI\> 95th for age normal glucose tolerance
62117334|NCT00361946||Type diabetes|BMI \> 85th for age , history of Type 2 diabetes as per ADA criteria
62117335|NCT04164680||Patients with disorders of consciousness|
62305577|NCT02375776|NO_INTERVENTION|Control|Usual Care - The control group will not use the study's mobile health application during the study.
62305578|NCT03983941|ACTIVE_COMPARATOR|FNB-AC + Sciatic nerve block|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.
62117336|NCT04133740|ACTIVE_COMPARATOR|Standard regime|Supplementary oxygen is given according to the standard regime with a fraction of inspired oxygen (FiO2) of at least 0.60 during mechanical ventilation and 3 liter/minute or more after weaning from the ventilator in the intensive care unit (ICU).
62117337|NCT04133740|ACTIVE_COMPARATOR|Oxygenation targeting|Supplementary oxygen is given to achieve a partial pressure of arterial oxygen (PaO2) within the normal range defined as 10-12 kPa (75-120 mmHg) during surgery and in the ICU.
62117338|NCT05981534|EXPERIMENTAL|Intervention group|The intervention group will receive vitamin D supplement for 6 months
62305579|NCT03983941|EXPERIMENTAL|FNB-AC + IPACK|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)
62305580|NCT01783405||Cases|FH heterozygous
62305581|NCT01783405||Controls|Parents of FH heterozygotes with FH
62305582|NCT02189265||Full cohort|All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.
62305583|NCT06498908|EXPERIMENTAL|Nitrous Oxide|Patients in the intervention arm will receive an inhalant of 50% nitrous/50% oxygen intended to target pain relief for the duration of their foley ballon placement.
62305584|NCT06498908|PLACEBO_COMPARATOR|Oxygen|Patients in the control arm will receive an inhalant of 100% oxygen for the duration of their foley balloon placement.
62305585|NCT06507020|EXPERIMENTAL|Fall prevention knowledge education & Exercise education & Home hazard reduction education|"Fall Prevention Education:~Form a health education group for the intervention subjects to learn about fall prevention. The project team will teach through talks, discussions, and shared experiences to boost their understanding and concepts on preventing falls.~Exercise Education:~In group settings, the project team will instruct participants on exercises to prevent falls, focusing on balance, leg strength, and endurance, and demonstrate the use of assistive tools.~Home Hazard Reduction:~Staff will visit homes to assess and guide on reducing fall risks, teaching participants to identify and suggest changes to home environment hazards."
62473386|NCT06180460|EXPERIMENTAL|Managing Cancer and Living Meaningfully (CALM)|CALM optimally consists of six individual sessions of 45 to 60 minutes, delivered over a three- to six-month period. CALM sessions address four broad and interrelated domains found to be important and relevant in this population: (1) symptom management and communication with healthcare providers, (2) changes in personal relationships, (3) sense of meaning and purpose, and (4) the future, hope and mortality.
62473387|NCT06180460|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|Treatment as usual (TAU) for managing distress in brain cancer involves being provided a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.
62473388|NCT05718284|EXPERIMENTAL|HFNC|Administration of high flow nasal oxygen after extubation for 48 hours
62117339|NCT05981534|PLACEBO_COMPARATOR|Control group|The control group will receive placebo for 6 months
62676740|NCT05540600|EXPERIMENTAL|beta blocker group|Patients will receive bisoprolol 2.5 mg or 5 m twice a day for a duration of 4 weeks. The choice of dose will depend on blood pressure (BP): If systolic BP ≥ 150 mmHG, the patient will have bisoprolol 5 mg x 2 per day, If systolic BP \< 150 mmHG, the patient will have bisoprolol 2.5 mg x 2 per day
62117340|NCT01188499|EXPERIMENTAL|Carboplatin/Paclitaxel + Birinapant|Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
62117341|NCT01188499|EXPERIMENTAL|Irinotecan + Birinapant|Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
62117342|NCT01188499|EXPERIMENTAL|Docetaxel + Birinapant|Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
62117343|NCT01188499|EXPERIMENTAL|Gemcitabine + Birinapant|Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).
62117344|NCT01188499|EXPERIMENTAL|Liposomal Doxorubicin + Birinapant|Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).
62117345|NCT01052454|NO_INTERVENTION|Wait list|Women assigned to the waitlist have the opportunity of taking the MBSR program at no cost following final study assessment
62117346|NCT01052454|EXPERIMENTAL|Mindfulness-based stress reduction|Women in the MBSR arm attend eight weekly MBSR classes
62117347|NCT00867191|PLACEBO_COMPARATOR|1|Placebo, 1 tablet daily, per os
62117348|NCT00867191|ACTIVE_COMPARATOR|2|Desloratadine, one 5 mg tablet daily, per os
62117349|NCT05193188|EXPERIMENTAL|Anlotinib combined with PD-1 monoclonal antibody|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off; PD-1 monoclonal antibody，PD-1 inhibitor，Intravenous injection，once 3 week.
62117350|NCT05193188|ACTIVE_COMPARATOR|Anlotinib monotherapy|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off.
62117351|NCT03861741|EXPERIMENTAL|Participants|All participants will be screened through complete clinical evaluations, genetic tests and imaging modalities (TTE and MRI) for the presence of newly Non Syndromic-Thoracic Aortic Diseases. Demographic and clinical data from all participants will be collected using case report forms, and by accessing their medical records. Data on imaging investigations will be obtained from TTE and MRI. Blood samples will be used for the purpose of isolation of genetic material and subsequent whole exome sequencing along with the analysis of selected loci. Additional citrated blood samples and plasma will be collected and stored for the potential analysis of circulating microvesicles and miRNA.
62117352|NCT02061930||single crowns supported by implants|single crowns supported by implants placed in the anterior maxilla region, periodontally healthy
62117353|NCT03909477||Cannabis Smoker|Participants in this group will be current or former cannabis smokers
62117354|NCT02547922|EXPERIMENTAL|Anifrolumab - Lower Dose|Anifrolumab - Lower Dose
62117355|NCT02547922|EXPERIMENTAL|Anifrolumab - Higher Dose|Anifrolumab - Higher Dose
62117356|NCT02547922|PLACEBO_COMPARATOR|Placebo|Placebo IV Q4W plus SOC
62117357|NCT05987969|EXPERIMENTAL|Intervention|"Access to the Alena CBT-based mobile application intervention for 8 weeks. Instructed to complete one of the 4 main modules every 2 weeks. Also asked to complete one additional short exercise per week and engage with one forum post per week."
62117358|NCT05987969|NO_INTERVENTION|No intervention|Wait list control - Given access to the intervention at the end of the 10-week trial period.
62117359|NCT01595906|EXPERIMENTAL|The experiment subjects|"The subjects will undergo:~1. 6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, during which the subjects walk on a treadmill at 5km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH). Core (rectal) and skin temperatures and heart rate will be monitored continuously.~2. Three consecutive days including 3 scenarios:~   1. Without a helmet b.With a helmet c.With a ventilated helmet During the experiment days the subjects will be exposed to the following protocol : A 5 minute sitting, performing cognitive tests on a computer for 15 min, 120 min walking on a treadmill at 5km/h on a 2% incline, at the end of the effort the same cognitive tests will be repeated for extra 15 min, 155 min in total."
62117360|NCT00790790|PLACEBO_COMPARATOR|Placebo|Participants randomized to LY545694 placebo were given LY545694 placebo twice daily (BID) oral (po) for 5 weeks.
62117361|NCT00790790|EXPERIMENTAL|LY545694 49 mg|Participants randomized to LY545694 49 milligrams (mg) BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. Participants who were intolerant of this dose were titrated back down to 21 mg BID po for the remainder of study treatment.
62473389|NCT05718284|OTHER|STANDARD OXYGEN|Administration of oxygen through standard devices (nasal cannulae, venturi mask, none)
62473390|NCT01915186|EXPERIMENTAL|Dihydroepiandrosterone (DHEA)|DHEA 25mg 3 times a day for 12 weeks
62676741|NCT06088563|ACTIVE_COMPARATOR|Morning injection|EFLUELDA influenza vaccine injection between 07:00 am and 09:00 am.
62676742|NCT06088563|ACTIVE_COMPARATOR|Evening injection|EFLUELDA influenza vaccine injection between 07:00 pm and 09:00 pm.
62676743|NCT03928704|EXPERIMENTAL|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
62676744|NCT03928704|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
62676745|NCT06549114|EXPERIMENTAL|Leniolisib|All subjects participating will receive Leniolisib film-coated tablets (FCTs) at a starting dose of 10 mg BID for 4 weeks, followed by 30 mg BID for 4 weeks, and then 70 mg BID for 12 weeks.
62676746|NCT04063137|ACTIVE_COMPARATOR|Anthocyanin fortified bread|White bread is fortified with a 25% (w/w) black rice anthocyanin extract. Extract fortification is 4% w/w of bread flour.
62676747|NCT04063137|PLACEBO_COMPARATOR|White bread|
62676748|NCT05086172|EXPERIMENTAL|UBA Arm|All subjects in this arm will receive ultrabrief behavioral activation therapy via a single, 90-minute session.
62117362|NCT00790790|EXPERIMENTAL|LY545694 105 mg|Participants randomized to LY545694 105 mg BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. At Visit 5, participants were titrated to the final dose of LY545694 105 mg BID po. Participants who were intolerant of this dose were titrated back down to LY545694 49 mg BID po for the remainder of study treatment.
62117363|NCT01199705|EXPERIMENTAL|IgPro20|
62305586|NCT06507020|EXPERIMENTAL|Fall prevention knowledge education & Exercise education|"The intervention in this arm consists of the following two components： Component 1: Fall prevention knowledge education To organise the study subjects in the intervention group to set up a falls prevention health education activity group, in which the project team will disseminate the knowledge and concepts of falls prevention through lectures, discussions, questions and answers, and sharing, so as to enhance the knowledge base required by the study subjects to prevent falls as well as to cultivate the relevant concepts.~Component 2: Exercise education Using the group activities of the intervention group, through lectures, demonstrations, on-site exercises and practices, the project team taught the intervention group participants fall prevention exercise skills such as improvement of balance function, enhancement of lower limb muscle strength, endurance exercise, etc., and the use of fall prevention related assistive tools."
62305587|NCT06507020|EXPERIMENTAL|Fall prevention knowledge education & Home hazard reduction education|"The intervention in this arm consists of the following two components： Component 1: Fall prevention knowledge education To organise the study subjects in the intervention group to set up a falls prevention health education activity group, in which the project team will disseminate the knowledge and concepts of falls prevention through lectures, discussions, questions and answers, and sharing, so as to enhance the knowledge base required by the study subjects to prevent falls as well as to cultivate the relevant concepts.~Component 2: Home hazard reduction education Through the staff's in-home assessment and guidance, the project team instructed the study participants to assess the fall-related home environment risk factors and make recommendations for modifications."
62305588|NCT06507020|EXPERIMENTAL|Exercise education & Home hazard reduction education|"The intervention in this arm consists of the following two components： Component 1: Exercise education Using the group activities of the intervention group, through lectures, demonstrations, on-site exercises and practices, the project team taught the intervention group participants fall prevention exercise skills such as improvement of balance function, enhancement of lower limb muscle strength, endurance exercise, etc., and the use of fall prevention related assistive tools.~Component 2: Home hazard reduction education Through the staff's in-home assessment and guidance, the project team instructed the study participants to assess the fall-related home environment risk factors and make recommendations for modifications."
62473391|NCT01915186|PLACEBO_COMPARATOR|Placebo|Matched placebo capsules are given 3 times a day for 12 weeks
62473392|NCT01110109||Continuous Suctioning|Anesthesia staff will suction secretions continuously at 20 mmHg with a safety stop of 5 seconds every 30 minutes.
62117364|NCT00158028|EXPERIMENTAL|Risperidone|starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
62117365|NCT00158028|PLACEBO_COMPARATOR|Placebo|placebo match in identical tablets
62676749|NCT05086172|NO_INTERVENTION|Control Arm|All subjects in this arm will complete all study assessment instruments collected in the interventional arm but will not receive an intervention.
62676750|NCT04673695|EXPERIMENTAL|Group A|"1. Period 1: Reference drug(Lixiana 60 mg)~2. Period 2: Test drug(CKD-344 60 mg)"
62676751|NCT04673695|EXPERIMENTAL|Group B|"1. Period 1: Test drug(CKD-344 60 mg)~2. Period 2: Reference drug(Lixiana 60 mg)"
62676752|NCT04146909|ACTIVE_COMPARATOR|Breast Feeding|This group will consist of women who exclusively or mostly breast-fed for at least 4-6 months (\< 6 ounces of formula/24 hours at 6-9 weeks of delivery)1 and who delivered within the past 18 months.
62676753|NCT04146909|ACTIVE_COMPARATOR|Formula Feeding|This group will consist of women who exclusively or mostly formula-fed (no breastfeeding or \< 3 weeks of breastfeeding)1 and who delivered within the past 18 months.
62117366|NCT01356758||Psoriasis topical treatment|Psoriasis topical treatment. No systemic drugs.
62117367|NCT01356758||Psoriasis biological treatment|Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
62117368|NCT01356758||Severe atopic dermatitis|Severe atopic dermatitis
62117369|NCT01356758||Control|No intervention. No inflammatory skin disease.
62117370|NCT05813899|EXPERIMENTAL|Heat-treated PS23|PS23 heat-treated, 2 caps daily use
62117371|NCT05813899|PLACEBO_COMPARATOR|Placebo|The placebo , 2 caps daily use
62117372|NCT00475319|PLACEBO_COMPARATOR|Placebo|0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
62117373|NCT00475319|EXPERIMENTAL|1% OPC-12759 ophthalmic suspension|1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
62676754|NCT05503732|EXPERIMENTAL|Energy drink first, then placebo drink|Subjects will consume two 16-oz energy drinks before sleep for the first study visit, then consume two 16-oz identical looking placebo drink before sleep at the second study visit.
62117374|NCT00475319|EXPERIMENTAL|2% OPC-12759 ophthalmic suspension|2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
62117375|NCT00920725|ACTIVE_COMPARATOR|Subcutaneous Insulin|Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
62676755|NCT05503732|EXPERIMENTAL|Placebo drink first, than energy drink|Subjects will consume two 16-oz identical looking placebo drink before sleep at the fist study visit, then consume two 16-oz energy drinks before sleep for the second study visit.
62117376|NCT00920725|ACTIVE_COMPARATOR|IV Regular Insulin|Intravenous Regular Insulin 0.1 units/kg/hour
62117377|NCT00920725|ACTIVE_COMPARATOR|Intravenous Novolog Insulin|Intravenous Novolog Insulin 0.1 units/kg/hour
62117378|NCT01556971|ACTIVE_COMPARATOR|Botox|The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
62117379|NCT01556971|PLACEBO_COMPARATOR|Saline Solution|A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
62117380|NCT02399358||High-dose Cyclophosphamide|Patients requiring infusion of high-dose cyclophosphamide in the period 2015-2017 will be included. After informed consent, patients will de follow up from the infusion of cyclophosphamide to 30 days after hospital discharge.
62676756|NCT05599581|EXPERIMENTAL|Tu'Washindi intervention plus usual HIV prevention services|Participants in the intervention wards will receive the Tu'Washindi intervention plus access to evidence-based HIV prevention services offered throughout the county. These include PrEP delivery through ministry of health, which is accessible to all AGYW.
62676757|NCT05599581|NO_INTERVENTION|Standard of care HIV (Usual) prevention services only|Participants in the non-intervention (control) wards will have access to evidence-based standard of care HIV prevention services offered throughout the county. These include PrEP delivery through Ministry of Health facilities, which is accessible to all AGYW.
62676758|NCT02793414||Malaria patients|
62117381|NCT02905812|ACTIVE_COMPARATOR|RGI & Massage|"1. relaxation and guided imagery with background music (RGI) (40 min, headphones)~2. a brief moderate pressure massage session (massage: 15 min)"
62117382|NCT02905812|NO_INTERVENTION|Control|Sham intervention: Silent headphones to mask the audio component, and presence of an intervention nurse at the bedside with drawn curtains.
62676759|NCT02793414||Febrile controls|
62676760|NCT01290354|EXPERIMENTAL|lapatinib|unlabelled, administered orally
62676761|NCT05257161|ACTIVE_COMPARATOR|Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))|183 Carotid stenting (Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))
62676762|NCT05257161|EXPERIMENTAL|MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS)|183 Carotid stenting (MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS))
62676763|NCT04798924|EXPERIMENTAL|Training in the blind field|Training in the blind field using specialized software
62676764|NCT04798924|EXPERIMENTAL|Training in the intact field|Training in the intact field using specialized software
62676765|NCT05099588||Infants treated for ROP|
62117383|NCT02980718|EXPERIMENTAL|intensive olfactory training|90 participants will undergo intensive olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 4 minutes) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
62117384|NCT02980718|EXPERIMENTAL|ordinary olfactory training|90 participants will undergo ordinary olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 40 seconds) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
62117385|NCT02980718|NO_INTERVENTION|controls|20 participants represent a control group with no olfactory training
62117386|NCT04661150|EXPERIMENTAL|Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)|Participants will receive atezolizumab + trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, patrticipants will receive 5 further cycles of this regimen.
62117387|NCT04661150|ACTIVE_COMPARATOR|Arm B: Trastuzumab with XELOX (Capecitabine + Oxaliplatin)|Participants will receive trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, participants will receive 5 further cycles of this regimen.
62117388|NCT06181318||Study group|Participants will be recruited after they have been diagnosed and their treatment has been planned by a multidisciplinary tumor board. Patients indicated to undergo major liver resection (\> 3 segments based on Brisbane classification \[23\]) will be eligible for participation.
62117389|NCT06226636|EXPERIMENTAL|intervention|intervention given
62117390|NCT03127995|EXPERIMENTAL|HYPOFRACTIONATED|"40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~* sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions~* or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions"
62117391|NCT03127995|OTHER|NORMOFRACTIONATED|"50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~* sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions~* or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions"
62117392|NCT06054867|EXPERIMENTAL|Aquablation|
62117393|NCT00864786|EXPERIMENTAL|Cohort 1|200 mcg
62117394|NCT00864786|EXPERIMENTAL|Cohort 2|600 mcg
62117395|NCT00864786|EXPERIMENTAL|Cohort 3|1000 mcg
62676766|NCT04619173|EXPERIMENTAL|Thoracic manipulation|additional thoracic manipulation along with hotpack, transcutaneous electrical nerve stimulation ,serratus anterior,pectoralis major,minor, posterior capsular stretches..
62676767|NCT04619173|ACTIVE_COMPARATOR|Conventional Physical Therapy Program|hot pack transcutaneous electrical nerve stimulation, serratus,anterior,pectoralis major, minor, posterior capsular stretches.
62676768|NCT00649571|EXPERIMENTAL|1|Doxycycline Monohydrate Tablets 100 mg
62117396|NCT00864786|EXPERIMENTAL|Cohort 4|Dose to be decided
62117397|NCT00864786|EXPERIMENTAL|Cohort 5|Dose to be decided
62117398|NCT00419094|EXPERIMENTAL|Keppra XR 1000 mg/day|1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
62117399|NCT00419094|EXPERIMENTAL|Keppra XR 2000 mg/day|2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
62117400|NCT03280836|NO_INTERVENTION|Control|We ask that participants in the control arm do not start an exercise program.
62117401|NCT03280836|EXPERIMENTAL|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
62117402|NCT00367991|ACTIVE_COMPARATOR|A|recombinant human erythropoietin 200 U/kg IV daily for 3 days
62676769|NCT00649571|ACTIVE_COMPARATOR|2|Adoxa Tablets 100 mg
62676770|NCT05315583|OTHER|Group with collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
62676771|NCT04948333|EXPERIMENTAL|ABL001|Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
62676772|NCT04594083|EXPERIMENTAL|Palm Stimulator|The Palm Stimulator was placed in the palm of the child's active hand 20 seconds before the injection. It ensured by researcher that the apparatus was held tightly in the child's palm throughout the procedure. The apparatus was taken back from the child after completing the injection process.
61918579|NCT01966692|ACTIVE_COMPARATOR|Fluticasone Propionate Formulation Sequence 313*2|"Patients first received Fluticasone Propionate Drug formulation 3, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 1, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 3\*, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 2.~All Fluticasone Propionate Drug formulations were administered via Plastiape Monodose Dry Powder Inhaler, 500mcg single dose.~MMAD for formulation 1 is 4.5 µm. MMAD for formulation 2 is 3.8 µm MMAD for formulation 3 is 3.7 µm. MMAD for formulation 3\* is 3.7 µm. See Formulation Development in Detailed Description for details regarding differences in formulations"
62117403|NCT00367991|PLACEBO_COMPARATOR|B|Normal saline volume to match active treatment IV daily for 3 days
62117404|NCT06185114||Young (ages 21-50) requiring multiple extractions|Subjects aged 21-50 requiring multiple extractions will be consented. These subjects will undergo soft tissue, GCF, venous blood sampling and CBCT analysis to determine age-related factors associated with post-extraction wound healing.
62117405|NCT06185114||Old (ages 65-80) requiring multiple extractions|Subjects aged 65-80 requiring multiple extractions will be consented. The older subjects (compared to other group) will undergo soft tissue, GCF, venous blood sampling and CBCT analysis to determine age-related factors associated with post-extraction wound healing.
62117406|NCT05826457||RBD group|Clinical observation involving annual visits to a study site for up to 5 years.
62117407|NCT05826457||control group|Clinical observation involving annual visits to a study site for up to 5 years.
62117408|NCT01326715|ACTIVE_COMPARATOR|mangafodipir|see protocol
62117409|NCT05310136|EXPERIMENTAL|Nurse-guided BBTi intervention group|Participants will experience 4-week treatment period (2 in person and 2 via telephone).
62117410|NCT05310136|NO_INTERVENTION|Control group|Participants will received sleep hygiene at the enrollment of the study and be required to maintain their usual lifestyle and medical treatment for 4 weeks.
62117411|NCT04242264|EXPERIMENTAL|Arm 1|Vaccine: 1 ml of saline containing10\^6 or 5X10\^5 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 1 and Day 29. Challenge: 1 ml of S. sonnei 53G challenge in 30 ml of sterile saline administered orally on Day 57. N=40
62117412|NCT04242264|EXPERIMENTAL|Arm 2|Placebo + Vaccine: 30 ml of sterile normal saline placebo administered orally on Day 1 and 1 ml of saline containing 10\^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 29. Challenge: 1 ml of S. sonnei 53G challenge in 30ml of sterile saline administered orally on Day 57. N=40
62117413|NCT04242264|PLACEBO_COMPARATOR|Arm 3|Placebo: 31 ml of sterile normal saline placebo administered orally on Day 1 and Day 29. Challenge: 1 ml of S. sonnei 53G challenge in 30 ml of sterile saline administered orally on Day 57. N=40
62117414|NCT03512756|EXPERIMENTAL|Part 1 and Part 2 SM-88 Arm|"(Part 1 enrollment complete) SM-88 used with MPS (methoxsalen, phenytoin and sirolimus)~(Part 2 actively enrolling) SM-88 (920 mg per day) used with MPS (methoxsalen, phenytoin and sirolimus) will be administered to 125 evaluable participants until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met."
62117415|NCT03512756|EXPERIMENTAL|Physician's Choice|Physician's Choice therapy will be administered for a total of 125 evaluable participants until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met.
62117416|NCT03192046|EXPERIMENTAL|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
62117417|NCT03192046|ACTIVE_COMPARATOR|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
62117418|NCT02129582|EXPERIMENTAL|Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)|"CONDITIONING: Patients undergo TMI BID on days -10 to -7. Patients also receive fludarabine phosphate IV over 1 hour on days -6 to -2 and busulfan IV or PO on days -5 and -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11."
61919954|NCT01525121|NO_INTERVENTION|Control|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
62117419|NCT06513455|EXPERIMENTAL|Cohort A|Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w，gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w，irinotecan Liposome was administered 40mg/m2, D1，iv. q2w
62117420|NCT06513455|EXPERIMENTAL|Cohort B|Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w，gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w，irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
62676773|NCT04594083|EXPERIMENTAL|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
62117421|NCT04353037|EXPERIMENTAL|Sub Study 1 Patients|Patients tested for COVID-19 who meet symptomology and age requirements for eligibility
62117422|NCT04353037|EXPERIMENTAL|Sub Study 2 Health Care Workers|Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months
62676774|NCT04594083|NO_INTERVENTION|Control|The routine IM injection was applied to the children in the control group.
62676775|NCT03103308|EXPERIMENTAL|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
62117423|NCT02298751|EXPERIMENTAL|CET via smartphone|Cue Exposure Treatment
62117424|NCT02298751|EXPERIMENTAL|CET via group sessions|Cue Exposure Treatment
62117425|NCT02298751|NO_INTERVENTION|Aftercare as usual|
62117426|NCT01145170|EXPERIMENTAL|Nimotuzumab|The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
62117427|NCT01328418|OTHER|Achondroplasia lengthening|
62117428|NCT03318406||BTVA treated patients|Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment
62117429|NCT02707224|EXPERIMENTAL|Group A|combination dose of Candesartan cilexetil and Rosuvastatin and DP-R208 in order
62117430|NCT02707224|EXPERIMENTAL|Group B|DP-R208 and combination dose of Candesartan cilexetil and Rosuvastatin in order
62117431|NCT05486260|EXPERIMENTAL|Group A|Pills with 300 mg of DMB equivalent to 5,5 mg of the miraculin glycoprotein
62117432|NCT05486260|EXPERIMENTAL|Group B|Pills with 150 mg of DMB equivalent to 2,8 mg of miraculin glycoprotein + 150g of freeze-dried strawberry
62117433|NCT05486260|PLACEBO_COMPARATOR|Group C|Pills with 300 mg of strawberry lyophilisate
62117434|NCT04493242|PLACEBO_COMPARATOR|Placebo|Normal saline 100 mL
62117435|NCT04493242|EXPERIMENTAL|Experimental Dose 1|Normal saline 90 mL and ExoFlo 10 mL
62117436|NCT04493242|EXPERIMENTAL|Experimental Dose 2|Normal saline 85 mL and ExoFlo 15 mL
62676776|NCT03103308|EXPERIMENTAL|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
62676777|NCT03309111|EXPERIMENTAL|ISB 1342|Part 1: Cohorts of multiple ISB 1342 dose levels; Part 2: One dose regimen until disease progression or other discontinuation criterion is met
62676778|NCT04901052|EXPERIMENTAL|n-3 supplementation group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus Omega 3 supplementation, the dosage was 2 capsules per day, containing 1.5 g of omega 3, of which 1000 mg were EPA and 500mg DHA. The omega 3 capsules were obtained from the same batch.
62117437|NCT04942249||Symptomatic|167 symptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
62117438|NCT04942249||Asymptomatic|167 asymptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
62117439|NCT04942249||No evidence of infection|167 Swiss army recruits with no evidence of infection (who also were tested for SARS-CoV-2 in 2020)
62117440|NCT03131206|EXPERIMENTAL|Phase 1 RP2D of alectinib|"The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NSCLC, not everyone who participates in this research study will receive the same dose of the study drug. The dosage will depend on the number of participants who have been enrolled in the study and how well the dosage has been tolerated.~* Alectinib~* Oral, BID~* A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days."
62676779|NCT04901052|PLACEBO_COMPARATOR|Placebo group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus placebo capsules (2 capsules per day made from sunflower oil)
62676780|NCT04376632|NO_INTERVENTION|Control|Participants in this group avoid all nuts for 8 weeks.
62676781|NCT04376632|EXPERIMENTAL|Pecan ADD|Participants in this group consume 68 g of pecans/d with no additional dietary instructions and avoid all other nuts.
62117441|NCT03131206|EXPERIMENTAL|Cohort A|"Participants with RET-rearranged NSCLC with no previous history of RET-TKI therapy.~* Alectinib~* Oral, BID, participants will receive the RP2D identified during Phase 1.~* Each treatment cycle will be defined as 28 consecutive days."
62117442|NCT03131206|EXPERIMENTAL|Cohort B|"Participants with RET-rearranged NSCLC with previous history of RET-TKI therapy.~* Alectinib~* Oral, BID, participants will receive the RP2D identified during Phase 1.~* Each treatment cycle will be defined as 28 consecutive days."
62117443|NCT03131206|EXPERIMENTAL|Cohort C|"Participants with RET-rearranged thyroid cancer~* Alectinib~* Oral, BID, participants will receive the RP2D identified during Phase 1.~* Each treatment cycle will be defined as 28 consecutive days."
62117444|NCT01544270|ACTIVE_COMPARATOR|Study product containing milk proteins|Yoghurt-like milk-based product
62117445|NCT01544270|ACTIVE_COMPARATOR|Study product containing probiotics|Yoghurt-like milk-based product
62117446|NCT01544270|PLACEBO_COMPARATOR|Control product|Yoghurt-like milk-based product without supplemented nutrients
62117447|NCT05968833|EXPERIMENTAL|iParent2Parent Program|
62676782|NCT04376632|EXPERIMENTAL|Pecan SUB|Participants in this group consume 68 g of pecans/d with instructions to substitute pecans with isocaloric foods in the habitual diet. They are also instructed to avoid all other nuts.
62676783|NCT03309475|EXPERIMENTAL|SocialMIND|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
62676784|NCT03309475|ACTIVE_COMPARATOR|Psychoeducational Multicomponent Intervention|The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
62676785|NCT03098407|OTHER|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
62676786|NCT03098407|OTHER|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
62676787|NCT05984667||C-SMART|C-SMART intervention will be provided via telehealth. Participants will complete in-person neurocognitive testing (baseline, post-intervention) as well as surveys (baseline, post-session, post-intervention) via secure email link. Exit interviews will be conducted by Zoom.
61919955|NCT01172275|EXPERIMENTAL|N-Acetylcysteine|N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
62676788|NCT03850431|EXPERIMENTAL|Social Norms + Behavioral Instructions|Clinics assigned a letter with two types of nudges (Social Norms + Behavioral Instructions)
62676789|NCT03850431|EXPERIMENTAL|Caring + Consequences for Others + Behavioral Instructions|Clinics assigned a letter with three types of nudges (Caring + Consequences for Others + Behavioral Instructions)
62676790|NCT03850431|EXPERIMENTAL|Caring + Consequences for Self + Behavioral Instructions|Clinics assigned a letter with three types of nudges (Caring + Consequences for Self + Behavioral Instructions)
62676791|NCT03850431|EXPERIMENTAL|Combination of all Nudges|Clinics assigned a letter with a combination of all types of nudges (Behavioral: Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions)
61919956|NCT01172275|PLACEBO_COMPARATOR|Placebo|Placebo effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
61919957|NCT01227148|EXPERIMENTAL|Tightly glucose conntrol|
62117448|NCT06447987|EXPERIMENTAL|Treatment (huCD19-CAR T)|Patients undergo leukapheresis then receive lymphodepletion chemotherapy with fludarabine IV and cyclophosphamide IV on days -5, -4 and -3 and huCD19-CAR T IV cells over 10-15 minutes on day 0. Patients may optionally receive cetuximab IV over 60-120 minutes at least 28 days post T cell infusion and undergo alloHCT. Additionally, patients undergo ECHO or MUGA, CT or PET/CT and optional MRI on study and bone marrow biopsy and aspiration and blood sample collection throughout the study.
62117449|NCT04116515|ACTIVE_COMPARATOR|Care Only|A third of the participants will have standard clinical care only.
62117450|NCT04116515|EXPERIMENTAL|Care + AVG|A third of the participants will have the same standard clinical care plus an Xbox and active games.
61919958|NCT01227148|ACTIVE_COMPARATOR|Conventional glucose control|
61919959|NCT05882721|EXPERIMENTAL|Cellulite|
62676792|NCT03850431|NO_INTERVENTION|Usual Care|Clinics assigned to usual care. Usual care consisted of a letter with basic appointment information on date, location, and phone number(s) for scheduling changes
62676793|NCT01221480||Beta Blocker Use|
62117451|NCT04116515|EXPERIMENTAL|Care + AVG + Narratives|A third of the participants will have the same standard clinical care, an Xbox and active games, plus the stories delivered to their Xbox consoles.
62676794|NCT01221480||No beta blocker use|
62117452|NCT03444701|EXPERIMENTAL|E7130 (2-Week Regimen)|Part 1 (Cycle 1; 28 days): The first cohort of 3 participants will receive 25 micrograms per meters squared (μg/m\^2) of E7130, on Day 1 and Day 15 as an intravenous infusion. If a drug-related Grade 2 or higher toxicity excluding clinically insignificant events is not observed in the initial cohort, dose-limiting toxicities (DLTs) will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the maximum tolerated dose (MTD) will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 2-week or in a 3-week regimen based on the evaluations in Part 1.
62117453|NCT03444701|EXPERIMENTAL|E7130 (3-Week Regimen)|Part 1 (Cycle 1; 21 days): On Day 1, participants will receive E7130 at (-1) a lower dose than the dose at which the first DLT was observed in the 2-week regimen. Once the MTD will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 3-week or in a 2-week regimen based on the evaluations in Part 1.
62676795|NCT05939609|ACTIVE_COMPARATOR|Ballistic Stretching Exercise|Athletes will be asked to reach the floor by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes will be requested to make small rebounding motion at degrees between 3°-5° for half a minute.
62676796|NCT05939609|ACTIVE_COMPARATOR|Extender Exercise|Athletes will lie on his back. Then, athletes will be asked to do 90 degrees of knee and hip flexion at the same time. Finally, the athletes is expected to perform slow repetitive knee extension to the point of maximal possible extension. According to Askling et al. and Aspetar protocol, it will be applied 12 repetitions and 3 sets.
62676797|NCT05939609|ACTIVE_COMPARATOR|Kinesiotaping|Kinesio taping will be applied to the hamstring muscle in the direction of inhibition with a Y-shaped and 25% tension force.
62676798|NCT03978156|EXPERIMENTAL|Dronabinol, Then Placebo|Participants will take 2.5 mg of Dronabinol for 2 weeks, 1 week washout and then take 2 weeks of placebo (microcrystalline cellulos). Subjects will take up to 8 capsules daily of the treatment daily during each phase.
62676799|NCT03978156|EXPERIMENTAL|Placebo, Then Dronabinol|Participants will take placebo (microcrystalline cellulos) for 2 weeks, 1 week washout and then take 2.5 mg of Dronabinol for 2 weeks. Subjects will take up to 8 capsules daily of the treatment daily during each phase.
62676800|NCT04364971|EXPERIMENTAL|singleradius|Single Radius(SR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Single Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
62676801|NCT04364971|EXPERIMENTAL|Multiradius|Multi Radius(MR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Multi Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
62676802|NCT01163565|ACTIVE_COMPARATOR|Ligasure device|
62676803|NCT01163565|NO_INTERVENTION|Hand ties|
62117454|NCT03653013|ACTIVE_COMPARATOR|Control Group|Usual standard of care from their diabetes care team
62117455|NCT03653013|EXPERIMENTAL|Neuropsychological Consultation Group|Children will be administered a number of neuropsychological tests. Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL, Generic Scale and Diabetes Module), diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
62117456|NCT06301841|NO_INTERVENTION|control|"Conventional microbiological investigations are performed as soon as possible after ICU admission including blood cultures, non-invasive or invasive respiratory tract sample, urine antigen assays and viral PCR.~Antibiotics have to be started as soon as possible after ICU admission and during at less 3 days"
62117457|NCT06301841|EXPERIMENTAL|Intervention|"In addition to conventional microbiological investigations, a non-invasive or invasive respiratory tract sample is collected as soon as possible and tested with the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux). This test detects 18 bacteria, 9 viruses and 7 antibiotic resistance markers. In addition a procalcitonin assay is performed on day-3 of ICU admission.~Antibiotics have to be started as soon as possible after ICU admission and during at less 3 days.~At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation."
62305589|NCT06507020|EXPERIMENTAL|Fall prevention knowledge education only|"Fall prevention knowledge education:~To organise the study subjects in the intervention group to set up a falls prevention health education activity group, in which the project team will disseminate the knowledge and concepts of falls prevention through lectures, discussions, questions and answers, and sharing, so as to enhance the knowledge base required by the study subjects to prevent falls as well as to cultivate the relevant concepts."
62305590|NCT06507020|EXPERIMENTAL|Exercise education only|"Exercise education:~Using the group activities of the intervention group, through lectures, demonstrations, on-site exercises and practices, the project team taught the intervention group participants fall prevention exercise skills such as improvement of balance function, enhancement of lower limb muscle strength, endurance exercise, etc., and the use of fall prevention related assistive tools."
62305591|NCT06507020|EXPERIMENTAL|Home hazard reduction education only|"Home hazard reduction education:~Through the staff's in-home assessment and guidance, the project team instructed the study participants to assess the fall-related home environment risk factors and make recommendations for modifications."
62305592|NCT06507020|NO_INTERVENTION|Care as usual|
62117458|NCT04867291|EXPERIMENTAL|Pizza|Consumption of a portion of Eat Balanced pizza equivalent to 200 µg of iodine (half a pizza) consumed with 450 mL water. Collection of urine for 36 hours following pizza ingestion. Collection of one fecal sample up to 24 hours following pizza ingestion.
62305593|NCT04403438||patients with behçet's or fmf|
62305594|NCT01400828|EXPERIMENTAL|Bilastine|Intervention: Drug: Bilastine
62117459|NCT04867291|EXPERIMENTAL|Seaweed Sheets|Consumption of a portion of Itsu Crispy Seaweed Thins equivalent to 200 µg of iodine (10g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
62117460|NCT04867291|EXPERIMENTAL|Seaweed Powder|Consumption of a portion of seaweed powder in a capsule equivalent to 200 µg of iodine (0.25g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
62117461|NCT04867291|EXPERIMENTAL|Potassium Iodide Supplement|Consumption of a portion of Piping Rock Potassium Iodide supplements equivalent to 200 µg of iodine (1.3 tablets) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
62117462|NCT00532220|ACTIVE_COMPARATOR|A|
62117463|NCT00532220|PLACEBO_COMPARATOR|B|
62117464|NCT04431388||SIPB (block)|Patients undergone nephectomy and who received SIPB as analgesia
62117465|NCT04431388||QL block|Patients undergone nephectomy and who received QL as analgesia
62117466|NCT04431388||control|Patients undergone nephrectomy who didn´t receive regional anesthesia
62305595|NCT01400828|ACTIVE_COMPARATOR|Desloratadine|Intervention: Drug: Desloratadine
62117467|NCT04396730|PLACEBO_COMPARATOR|Placebo followed by cannabidiol|Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily for cycle 1. During cycle 3, cannabidiol will be taken once daily along with OCPs.
62305596|NCT01400828|PLACEBO_COMPARATOR|Placebo|Intervention: Drug: Placebo
62305597|NCT04471220|ACTIVE_COMPARATOR|Low FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 10 L/min).
62305598|NCT04471220|ACTIVE_COMPARATOR|Low FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 40-50 L/min).
62305599|NCT04471220|ACTIVE_COMPARATOR|High FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 10 L/min).
62305600|NCT04471220|ACTIVE_COMPARATOR|High FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 40-50 L/min).
62305601|NCT04098380|ACTIVE_COMPARATOR|Small bite|The needle bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
62305602|NCT04098380|ACTIVE_COMPARATOR|Large bite|The needle bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
62305603|NCT06266637|EXPERIMENTAL|Study group|The experimental group will receive the same standard treatment in addition to Physiotherapeutic Scoliosis-Specific Exercise
62305604|NCT06266637|ACTIVE_COMPARATOR|Control group|The control group will receive the standard care composed of trunk muscles strengthening exercises, trunk proprioception exercises .
62305605|NCT02634515|EXPERIMENTAL|Julphar Insulin R|Julphar Insulin R, soluble human insulin, biosimilar, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
62305606|NCT02634515|ACTIVE_COMPARATOR|Huminsulin® Normal|Huminsulin® Normal, soluble human insulin, reference, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
62305607|NCT03497689|EXPERIMENTAL|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Subjects began Remodulin at 2 ng/kg/min subcutaneously (SC) or intravenously (IV) and were optimized to their maximum tolerated dose (MTD) of Remodulin. Subjects were then transitioned to Orenitram XR tablets (oral) based upon their Remodulin dose. Subjects were optimized on Orenitram therapy to a MTD. There were no maximum Remodulin or Orenitram doses specified during the study.
62305608|NCT04761185|EXPERIMENTAL|HIPEC using Raltitrexed|
62676804|NCT03954873|EXPERIMENTAL|Hyperglycaemia + GLP-2|Glucose + GLP-2
62676805|NCT03954873|ACTIVE_COMPARATOR|Hyperglycaemia + Placebo|Glucose + saline
62473393|NCT01110109||Intermittent Suctioning|Anesthesia staff will suction secretions intermittently using an intermittent suction regulator. The regulator will be set to suction at 100-150 mmHg. The regulator has a preset cycle of intermittent suctioning for 15 seconds with an 8 second pause.
62473394|NCT00681798|ACTIVE_COMPARATOR|Dose level 1|Vandetanib 100mg/day plus Gemcitabine
62473395|NCT00681798|ACTIVE_COMPARATOR|Dose level 2|Vandetanib 300mg/day plus Gemcitabine
62473396|NCT00681798|ACTIVE_COMPARATOR|Dose level 3|Vandetanib 100mg/day plus Gemcitabine plus CapecitabineDose
62473397|NCT00681798|ACTIVE_COMPARATOR|Dose level 4|Vandetanib 300mg/day plus Gemcitabine plus CapectiabineDose
62473398|NCT01481363|ACTIVE_COMPARATOR|Treatment as usual|Half of participants recruited will be randomly assigned to the control group to receive treatment as usual. This is will be based on a single one hour consultation which will include communication advice and information.
62473399|NCT01481363|EXPERIMENTAL|The Talking Sense treatment|Half of carer participants recruited will be randomly assigned to receive the Talking Sense treatment. This will be conducted one to one and individualised over 3 sessions and no more than 4.5 hours during no more than 8 weeks.
62473400|NCT00059306|ACTIVE_COMPARATOR|Antiplatelet|Participants receive aspirin + placebo OR aspirin + clopidogrel
62473401|NCT00059306|ACTIVE_COMPARATOR|Blood pressure|The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
62676806|NCT03954873|EXPERIMENTAL|Hypoglycaemia + GLP-2|Insulin + glucose + GLP-2
62117468|NCT04396730|EXPERIMENTAL|Cannabidiol follow Placebo|Oral contraceptives will be taken daily for 24 days along with Cannabidiol 400mg once daily for cycle 1. During cycle 3. placebo will be taken once daily along with OCPs.
62117469|NCT06392633|ACTIVE_COMPARATOR|Group I|Patients who meet the inclusion criteria and who will be treated with botulinum toxin (1 injection/4months).
62117470|NCT06392633|EXPERIMENTAL|Group II|Patients who meet the inclusion criteria and who will be treated by surgery.
62473402|NCT04414891|EXPERIMENTAL|NAVA arm|"Delivery of NIV-NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~Subjects randomised to this arm will undergo placement of Edi catheter and will be initiated on NIV. Appropriate NAVA level will be selected based on the scalars corresponding to stable ventilation in pressure support mode. During NAVA, the NAVA level would be increased in multiples of 0.2 cm H2O/µV to attain favourable response (tidal volume 6-8mL/kg RR ≤25). Once the patient's clinical condition stabilises, and the Edi maximum starts declining or remains unchanged with stable tidal volumes, NAVA level will be decreased in steps of 0.2 cm H2O/μV every 2 hours. If response to new settings is not favourable earlier settings will be restored. If favourable response is attained the weaning is continued until peak pressure is \<12cm H20 and PEEP requirement is \<5cm H2O. NIV will be replaced by a venture mask to titrate SpO2 between 88-92%"
62473403|NCT04414891|ACTIVE_COMPARATOR|ASV arm|Patients randomised to the ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland). The patients will be ventilated with an initial setting of 100%-minute volume (MV%). Increments of 10% will be made every 15 minutes to achieve clinical response (relief of dyspnea, RR\<30, and tidal volume 6-8mL/kg). The expiratory trigger sensitivity will be set at 35% and adjusted accordingly. PEEP will be commenced at 3-4 cm H2O and increased by 1 cm of H2O to achieve SpO2 between 89-92% and maximum PEEP of 10 cm of H2O. Weaning would be performed by reducing the MV% gradually in decrements of 10%/hour to a MV% of 60% after the peak inspiratory pressure decreases to \<8 cm of H2O, and the respiratory rate is \< 28 breaths per minute and patient is able to maintain SpO2 \> 90% at FiO2\< 30%. Once the patient is comfortable on these settings, NIV will be replaced with oxygen supplementation using a venturi mask to maintain SpO2 between 89 and 92%.
62473404|NCT01551498|PLACEBO_COMPARATOR|Placebo|subject takes one oral placebo lozenge, three times per day
62473405|NCT01551498|ACTIVE_COMPARATOR|Anatabloc Supplement|subject takes one oral Supplement lozenge, three time per day
62676807|NCT03954873|ACTIVE_COMPARATOR|Hypoglycaemia + Saline|Insulin + glucose
62676808|NCT03954873|EXPERIMENTAL|Euglycaemia + GLP-2|GLP-2
62676809|NCT03954873|ACTIVE_COMPARATOR|Euglycaemia + Placebo|
62676810|NCT03365908|EXPERIMENTAL|Adductor Canal Nerve Block|Participant will receive an adductor canal nerve block via 15 mL 0.5% ropivacaine injection prior to OR for ACL reconstruction. Participant will receive pre-op oral medications.
62117471|NCT02314117|EXPERIMENTAL|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m\^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m\^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m\^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
62117472|NCT02314117|ACTIVE_COMPARATOR|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m\^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m\^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m\^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
62117473|NCT02507752||Rituximab|Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
62676811|NCT03365908|NO_INTERVENTION|No Nerve Block|Participant will receive pre-op oral medications but no nerve block prior to OR for ACL reconstruction.
62676812|NCT06670521|EXPERIMENTAL|Corticosteroid Intervention|50 mg Methylprednisolone IV every 6 hours for 4 doses (total dose 200mg)
62676813|NCT06670521|PLACEBO_COMPARATOR|Placebo Control|Normal Saline placebo dose IV every 6 hours for 4 doses
62676814|NCT04579211||Adults with a diagnosis of CF with history of negative NTM sputum cultures|Male or female participants age 18 or greater at time of enrollment with diagnosis of CF consistent with the 2017 CFF Guidelines and NTM culture status of negative, as defined by a review of at least 3 year or more years of culture data and at least 3 NTM negative cultures with one of those negative cultures being within the last 3 years and no known history of previous positive cultures for pathogenic NTM by chart review.
62117474|NCT00401323|EXPERIMENTAL|docetaxel plus cisplatin|Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
62117475|NCT00401323|ACTIVE_COMPARATOR|cisplatin plus 5-FU|Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
62117476|NCT00401323|EXPERIMENTAL|docetaxel plus 5-FU|"Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5~Arm only in the phase II part of the study"
62117477|NCT04021615|EXPERIMENTAL|Group A (study group)|Twenty five patients will receive comprehensive rehabilitation program combined with inspiratory muscle training.
62117478|NCT04021615|ACTIVE_COMPARATOR|Group B (Control group)|Twenty five patients will receive traditional chest physical therapy combined with inspiratory muscle training.
62117479|NCT01834248|EXPERIMENTAL|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62117480|NCT03122574|EXPERIMENTAL|Treatment|Pure (100%) lavender aromatherapy
62117481|NCT03122574|PLACEBO_COMPARATOR|Placebo Control|Pure (100%) jojoba aromatherapy
62117482|NCT03122574|NO_INTERVENTION|Standard of care Control|No aromatherapy control group
62117483|NCT05766189|EXPERIMENTAL|Intervention arm|Receives communications on level of SARS-CoV-2 as identified in the wastewater
62117484|NCT05766189|NO_INTERVENTION|Comparison arm|
62117485|NCT01140113|NO_INTERVENTION|Placebo|this group had undergone to routine coronary artery bypass graft surgery
62117486|NCT01140113|EXPERIMENTAL|Modified Ultrafiltration|patients after weaning from bypass were submitted to ultrafiltration
62117487|NCT00597038|EXPERIMENTAL|Phase I Dose Escalation|Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established.
62117488|NCT00597038|EXPERIMENTAL|Phase II Dose Treatment|Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm\^2.
62117489|NCT05758727|EXPERIMENTAL|Home-based exercise group|This group will be asked to practise the 'exercise snacking and Tai-chi snacking' exercises once each and record the exercise bouts in a log book.
62117490|NCT05758727|NO_INTERVENTION|Control group|Usual care control group
62117491|NCT06676514||IBS-D (diarrhea-predominant)|This group received probiotic treatment for IBS-D as three tablets daily for 8-weeks
62117492|NCT03196167|EXPERIMENTAL|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
62117493|NCT03196167|PLACEBO_COMPARATOR|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
62117494|NCT01839578|EXPERIMENTAL|RCA Group|SHF-CVVHD with regional citrate anticoagulation
62117495|NCT01839578|EXPERIMENTAL|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
62117496|NCT03614546|OTHER|A（surgery） group|Hepatectomy
62117497|NCT03614546|EXPERIMENTAL|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
62117498|NCT03614546|EXPERIMENTAL|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
62117499|NCT03614546|EXPERIMENTAL|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
62117500|NCT03614546|EXPERIMENTAL|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
62117501|NCT03614546|EXPERIMENTAL|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
62117502|NCT03614546|EXPERIMENTAL|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
62117503|NCT04567888|ACTIVE_COMPARATOR|Happify Teens|Happify Teens is a digital well-being intervention that can be accessed via mobile application or web browser
62117504|NCT04567888|NO_INTERVENTION|Waitlist Control|Waitlist Control Condition
62117505|NCT05992311|EXPERIMENTAL|Montelukast Group|Montelukast two capsules of 20 mg (40 mg total) taken by mouth once daily for ten weeks
62117506|NCT05992311|PLACEBO_COMPARATOR|Placebo Group|Microcrystalline cellulose two capsules taken by mouth once daily for ten weeks
62117507|NCT01039142|ACTIVE_COMPARATOR|25 mg acitretin|capsule acitretin 25 mg/day will be administered to each patient for a period of 12 weeks
62305609|NCT00760292||1|Type 2 Diabetic Patients
62117508|NCT01039142|ACTIVE_COMPARATOR|35 mg acitretin|capsule acitretin 35 mg/day will be administered to each patient for a period of 12 weeks
62117509|NCT01039142|ACTIVE_COMPARATOR|50 mg acitretin|capsule acitretin 50 mg/day will be administered to each patient for a period of 12 weeks
62676815|NCT05669599|EXPERIMENTAL|Cohort A: Maridebart Cafraglutide|Part 1: Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 7 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.
62305610|NCT00760292||2|Non-diabetic individuals
62473406|NCT05829733|EXPERIMENTAL|SYNOLIS VA 80/160|Single guided intra-articular injection of SYNOLIS VA 80/160
62676816|NCT05669599|PLACEBO_COMPARATOR|Cohort A: Placebo|Part 1: Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 7 dose cohorts . Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.
62676817|NCT05669599|EXPERIMENTAL|Cohort B: Maridebart Cafraglutide|Part 1: Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 4 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.
61919960|NCT05526209||1 with using longitudinal relaxing incision|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
62117510|NCT02675309|EXPERIMENTAL|MT-8554, rosuvastatin and simvastatin|Subjects will be administered a single dose of rosuvastatin followed on Day 4 by a single dose of simvastatin. MT-8554 will be administered from Days 6 to 12 with co-administration of rosuvastatin and simvastatin on Days 9 and 12, respectively.
62117511|NCT03498651|EXPERIMENTAL|CBM-I, low attrition|Computer- or phone-based Cognitive Bias Modification - Interpretation training
62117512|NCT03498651|EXPERIMENTAL|CBM-I, high attrition, coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training + Coaching
62117513|NCT03498651|EXPERIMENTAL|CBM-I, high attrition, no coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training
62117514|NCT03498651|ACTIVE_COMPARATOR|Psychoeducation|Online psychoeducation about anxiety
62117515|NCT03689699|EXPERIMENTAL|Arm A: Nivolumab alone|Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
62117516|NCT03689699|EXPERIMENTAL|Arm B: Nivolumab plus BMS-986253|Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
62305611|NCT03187379|EXPERIMENTAL|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
62473407|NCT06083259|ACTIVE_COMPARATOR|gelatin sponge + cyanoacrylate + suspending sutures|After administration of local anesthesia (2% articaine hydrochloride with epinephrine 1:100,000), palatal thickness will be measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area. Epithelialized gingival graft will be harvested. After a rectangular-shaped initial incision, a graft with 1-1.5 mm thickness will be harvested approximately 1.5 to 3 mm away from the gingival margins of the upper teeth. The donor site will be closed with a gelatin sponge + cyanoacrylate + suspending sutures.
62117517|NCT02918032||NLSD / TGCV|Patients who are diagnosed with NLSD / TGCV
62117518|NCT00971906|EXPERIMENTAL|low dose of antigen + low dose of adjuvant|
62117519|NCT00971906|EXPERIMENTAL|high dose of antigen + high dose of adjuvant|
62117520|NCT00971906|EXPERIMENTAL|high dose of antigen|
62117521|NCT04881318|EXPERIMENTAL|Waist-High Compression Tights and Medications|Participants will wear the waist-high compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of waist-high compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
62117522|NCT04881318|EXPERIMENTAL|Waist-High Compression Tights and No Medications|Participants will wear the waist-high compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of waist-high compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
62305612|NCT03187379|ACTIVE_COMPARATOR|Control|Subjects in this arm will receive 0.25% bupivacaine alone
62117523|NCT04881318|EXPERIMENTAL|Abdominal Compression Garments and Medications|Participants will wear the abdominal compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of abdominal compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
62305613|NCT04267237|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab on Day 1 of each 28-day cycle (Q4W) for 12 cycles.
62305614|NCT04267237|EXPERIMENTAL|Atezolizumab + RO7198457|Participants will receive atezolizumab Q4W along with RO7198457 for 12 cycles.
62305615|NCT04758793|OTHER|patients without liver disease,|taking blood samples and biopsy of muscular wall
62305616|NCT04758793|OTHER|patient with chronic liver disease without cirrhosis,|taking blood samples and biopsy of muscular wall
62305617|NCT04758793|OTHER|patients with compensated cirrhosis,|taking blood samples and biopsy of muscular wall
62305618|NCT04758793|OTHER|patient with severe cirrhosis|taking blood samples and biopsy of muscular wall
62305619|NCT02179632|EXPERIMENTAL|Disclosure intervention zero|Treatment Group 1: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. A. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. A, according to manufacturer, in 2012. Dr. A will be a physician the researchers have chosen who does not appear on the website and therefore did not receive any payments in 2012. Participants should report $0/not listed as the response. Following this stage, participants will be told that Dr. A does not appear on the website and therefore did not receive any payments.
62305620|NCT02179632|EXPERIMENTAL|Disclosure intervention low|"Treatment Group 2: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. B. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. B, according to manufacturer, in 2012. Dr. B will be a physician the researchers have chosen who received an aggregate amount that is a low payment (below $100) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. B in 2012."
62305621|NCT02179632|EXPERIMENTAL|Disclosure intervention high|"Treatment Group 3: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. C. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. C, according to manufacturer, in 2012. Dr. C will be a physician the researchers have chosen who received an aggregate amount that is a high payment (above $250) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. C in 2012."
62305622|NCT02179632|NO_INTERVENTION|Control group|Control Group: The control group will not be exposed to the disclosure website, but will participate in another online information-seeking task. These participants will visit the Farmer's Almanac website and be asked to search for temperature reports.
62473408|NCT06083259|ACTIVE_COMPARATOR|gelatin sponge + cyanoacrylate|After local anesthesia (2% articaine hydrochloride with epinephrine 1:100,000) administration, palatal thickness will be measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and the mean value will be recorded as palatal tissue thickness. The epithelialized gingival graft will be harvested using 15 knives. After a rectangular-shaped initial incision, a graft with 1-1.5 mm thickness will be harvested approximately 1.5 to 3 mm away from the gingival margins of the upper teeth. The donor site will be closed with a gelatin sponge and cyanoacrylate without sutures.
62473409|NCT01808794|ACTIVE_COMPARATOR|Mucograft|Placement of randomized membrane on half of subjects Mucograft
62676818|NCT05669599|PLACEBO_COMPARATOR|Cohort B: Placebo|Part 1: Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive maridebart cafraglutide or placebo in 1 of 4 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive maridebart cafraglutide or Placebo in 1 of 4 dose cohorts.
62676819|NCT02296359||Asthma Discordant Monozygotic Twins|This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic. Influenza Vaccination will be performed for both cohorts.
62676820|NCT02296359||Non-Asthma Concordant Monozygotic Twins|This is a group where both of the monozygotic twins are non-asthmatic. Influenza Vaccination will be performed for both cohorts.
62676821|NCT04995003|EXPERIMENTAL|Arm A|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody pembrolizumab
62676822|NCT04995003|EXPERIMENTAL|Arm 2|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody nivolumab
62676823|NCT06031051|OTHER|Pillcam Crohn's Capsule Endoscopy and colonoscopy|All patients will be submitted to a Pillcam Crohn's Capsule Endoscopy (Medtronic) previous their colonoscopy
62676824|NCT03430570|EXPERIMENTAL|Tablet TRAC Emotion Regulation Intervention|
62117524|NCT04881318|EXPERIMENTAL|Abdominal Compression Garments and No Medications|Participants will wear the abdominal compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of abdominal compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
62473410|NCT01808794|ACTIVE_COMPARATOR|Dynamatrix|Placement of randomized membrane on half of subjects Dynamatrix Membrane Placement
62473411|NCT00367861|EXPERIMENTAL|interruption of Glivec®|
62676825|NCT03430570|NO_INTERVENTION|Waitlist Control|Control participants are assessed on the same schedule as the treatment condition and offered the intervention after the 3-month follow-up
62676826|NCT06451926|EXPERIMENTAL|Experimental|escape room game (play group):The experimental group will play the educational escape room game. The experimental group will play the game once in total.
62117525|NCT03371966|ACTIVE_COMPARATOR|High Nitrate Beetroot Juice|Beetroot juice high in nitrate will contain approximately 10.0 mmole nitrate per 120 ml.
62117526|NCT03371966|PLACEBO_COMPARATOR|Low Nitrate Beetroot Juice|Beetroot juice low in nitrate will contain approximately 0.5 mmole nitrate per 120 ml.
62117527|NCT05475106|EXPERIMENTAL|Treatment|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks and once every month after that for 5 months.
62117528|NCT01209546|ACTIVE_COMPARATOR|Flutter group|In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
62473412|NCT00447577|EXPERIMENTAL|Zylet|Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
62473413|NCT00447577|ACTIVE_COMPARATOR|Tobradex|Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
62473414|NCT05057702|EXPERIMENTAL|Individualized Treatment Recommendation|Participants will receive an individualized treatment recommendation including a combination of up to four FDA-approved drugs within 21 business days of tissue acquisition using the results of real-time high-throughput drug screening, whole exome sequencing (WES), and RNA sequencing.
62473415|NCT02075463|EXPERIMENTAL|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
62473416|NCT02004197|EXPERIMENTAL|Pylorex plus|Pylorex plus consisting of medicinal plants.
62473417|NCT02004197|ACTIVE_COMPARATOR|Quadruple therapy|Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
62473418|NCT01364493|EXPERIMENTAL|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
62473419|NCT06450145|EXPERIMENTAL|interferon α-2b|Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax
62305623|NCT03701503|EXPERIMENTAL|Obese|"Women age 20-40, with BMI ≥ 25-35 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
62305624|NCT03701503|ACTIVE_COMPARATOR|Non Obese|"Women age 20-40, with BMI 18,5-23 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
62473420|NCT00871247|EXPERIMENTAL|A|Finasteride 5 mg single dose tablet, single dose
62473421|NCT00871247|ACTIVE_COMPARATOR|B|Proscar® 5 mg Tablet, single dose
62473422|NCT02431000||Male Chemo/Radiotherapy Candidates|"Adult and post-pubertal males, 13 years of age or older, presenting to clinic because diagnosed with cancer, who wish to preserve their future fertility. Sperm and blood collected for analysis. If minors, parents or guardians have to give consent to the procedure while the boys give their assent.~This is a prospective observational cohort study."
62473423|NCT02136290|OTHER|Usual Care|Weight loss counseling
61919961|NCT05526209||2 without using longitudinal relaxing incision|without using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
62305625|NCT03443024|EXPERIMENTAL|125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W)|"125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.~Baseline: Loading dose 250 mg Lebrikizumab SC (two injections SC 1-milliliter (mL) of 125 mg/mL Lebrikizumab and 1-mL placebo).~Week 2: Four 1-mL SC injections placebo.~Weeks 4, 8, 12: 125 mg SC Lebrikizumab and 1-mL SC placebo.~Weeks 6, 10, 14: Two 1-mL SC placebo."
62305626|NCT03443024|EXPERIMENTAL|250 mg Lebrikizumab - Q4W|"250 mg Lebrikizumab administered SC once Q4W.~Baseline: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 2: Four 1-mL SC injections of placebo.~Weeks 4, 8, 12: 250 mg (two 1-mL injections of 125 mg/mL Lebrikizumab).~Weeks 6, 10, 14: Two 1-mL injections of placebo."
62473424|NCT02136290|EXPERIMENTAL|Prepackaged meal|Prepackaged meals
62473425|NCT04609917||trainee group|Patients with native papilla who underwent selective biliary cannulation with trainee involvement
62473426|NCT04609917||non-trainee group|Patients with native papilla who underwent selective biliary cannulation without trainee involvement
62473427|NCT06023433|ACTIVE_COMPARATOR|Canines to be distalized|The canines need distalization after orthodontic upper first premolar asymmetrical extractions.
62473428|NCT06023433|NO_INTERVENTION|Controlateral canines|The controlateral canines don't need distalization since the adjacent first premolars are not extracted.
62473429|NCT03408665|EXPERIMENTAL|SBRT|Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.
62473430|NCT03194217|EXPERIMENTAL|BEN-2001, 0.5mg|Experimental treatment
62473431|NCT03194217|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62473432|NCT03194217|EXPERIMENTAL|BEN-2001, 1.0mg|Experimental treatment
62473433|NCT03194217|EXPERIMENTAL|BEN-2001, 3.0mg|Experimental treatment
62473434|NCT00840411|EXPERIMENTAL|Clarithromycin (test) First|
62473435|NCT00840411|ACTIVE_COMPARATOR|Biaxin® XL (reference) First|
62473436|NCT00327379|EXPERIMENTAL|Arm 1|
62473437|NCT00327379|PLACEBO_COMPARATOR|Arm 2|
62473438|NCT03498391|EXPERIMENTAL|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
62473439|NCT03498391|EXPERIMENTAL|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
62473440|NCT03018717|OTHER|Tele-monitoring Constant|To analyze the efficacy and cost-efficacy of incorporating tele-monitoring of bio-parameters into the shared comprehensive clinical care plan. Patients will receive in their home a kit consisting of a briefcase containing all equipment (scale, pulse-oximeter ... etc) and a logo access to devices (Tablet) through mobile communications m2m between patient and platform Management for Chronic Patients.
62473441|NCT03018717|OTHER|Standard clinical care|Standard clinical care plan shared between plan of attention to the patient with Pluri-pathological process and the care plan for patients with chronic diseases, based on a comprehensive clinical assistance shared between Primary Care and Hospital Care
62473442|NCT06330142|OTHER|entire study population|
62473443|NCT02761512|EXPERIMENTAL|CJ-12420 50 mg QD|CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks
62473444|NCT02761512|EXPERIMENTAL|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
62473445|NCT02761512|ACTIVE_COMPARATOR|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks
62473446|NCT00153530|ACTIVE_COMPARATOR|1|1 chemotherapy with radiotherapy
62473447|NCT00153530|EXPERIMENTAL|2|chemotherapy without radiotherapy
62473448|NCT04067635||Conservative Arm|Participants are followed by the research team conservatively. Participants in this arm may choose to undergo any valvular intervention at the discretion of their treating clinical team.
62473449|NCT04067635||Surgical Arm|Participants have already elected upfront to undergo surgical repair (at least, mitral annuloplasty) with their treating clinical team, just prior to enrollment into this study.
62473450|NCT03225547|EXPERIMENTAL|Cohort 1|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with hormone receptor positive, hormone refractory advanced breast cancer will be enrolled in cohort 1. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
62473451|NCT03225547|EXPERIMENTAL|Cohort 2|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with triple-negative advanced breast cancer will be enrolled in cohort 2. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
62473452|NCT03818581|ACTIVE_COMPARATOR|Treatment Group|
62473453|NCT03818581|PLACEBO_COMPARATOR|Placebo Responders|
62473454|NCT03818581|ACTIVE_COMPARATOR|Placebo Non-responders Re-randomized to Treatment|
62473455|NCT03818581|PLACEBO_COMPARATOR|Placebo Non-responders Re-randomized to Placebo|
62473456|NCT00804960|EXPERIMENTAL|Letrozole|1) Letrozole/ Recombinant FSH
62676827|NCT06451926|NO_INTERVENTION|Control|The control group will not receive any intervention.
62676828|NCT01253356|NO_INTERVENTION|No IABP|Standard of care and no IABP
62676829|NCT01253356|ACTIVE_COMPARATOR|Intra-Aortic Balloon Pump (IABP)|Standard of care, IABP inserted \< or = 3 hours before noncardiac surgery, maintained for \> or = 12-24 hours after surgery
62676830|NCT01239745||1|
62676831|NCT02449577|EXPERIMENTAL|Beverage sequence ABCD|Each participant randomized to this arm is exposed to 4 test meals in the order ABCD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62117529|NCT01209546|ACTIVE_COMPARATOR|PEP group|In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
62473457|NCT00804960|ACTIVE_COMPARATOR|Standard IVF|luteal phase GnRHa suppression/gonadotropin
62473458|NCT02061917|EXPERIMENTAL|Tobacco-Heating Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette
62473459|NCT02061917|EXPERIMENTAL|Snus (Smokeless Tobacco)|A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)
62676832|NCT02449577|EXPERIMENTAL|Beverage sequence CADB|Each participant randomized to this arm is exposed to 4 test meals in the order CADB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62117530|NCT01209546|PLACEBO_COMPARATOR|control group|In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
62117531|NCT01209546|SHAM_COMPARATOR|Group Sham|Exercise with Flutter®VRP1 without the ball inside
62117532|NCT06068699|EXPERIMENTAL|Postcards|Participants who received a postcard.
62117533|NCT06068699|NO_INTERVENTION|Controls|Participants did not receive a postcard (usual care).
62117534|NCT04918849||Community Sample|We plan to recruit a community sample of 1000 from the Indian Population.
62473460|NCT02061917|EXPERIMENTAL|Tobacco-Burning Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette
62473461|NCT02938962|ACTIVE_COMPARATOR|Intravenous TXA|The IV administration group will receive a single 20mg/kg dose of TXA prior to the skin incision.
62473462|NCT02938962|ACTIVE_COMPARATOR|Topical TXA|The topical administration group will have a 100mL solution (3g TXA in 100cc of normal saline) instilled into the surgical field throughout the operative procedure; 50mL of the solution will be instilled after bony preparation of the acetabulum and/or femur and 50mL of the solution will be instilled prior to closure. The topical TXA solution will be allowed to bathe the wound for 5 minutes at each administration.
62473463|NCT02082392|PLACEBO_COMPARATOR|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
62473464|NCT02082392|PLACEBO_COMPARATOR|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
62473465|NCT02082392|ACTIVE_COMPARATOR|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
62117535|NCT03312309|EXPERIMENTAL|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
62305627|NCT03443024|EXPERIMENTAL|250 mg Lebrikizumab - Every 2 Weeks (Q2W)|"250 mg Lebrikizumab administered SC once Q2W.~Baseline and Week 2: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 4, 6, 8, 10, 12, 14: 250 mg (two 1-mL SC injections of 125 mg/mL Lebrikizumab)."
62305628|NCT03443024|PLACEBO_COMPARATOR|Group 4 - Placebo|"Placebo administered SC once Q2W.~Baseline and Week 2: Four 1-mL SC injections of placebo.~Week 4, 6, 8, 10, 12, 14: Two 1-mL SC injections of placebo."
62305629|NCT05366608||RA patients|188 patients with RA he RA activity parameters were evaluated in RA patients. BMD was measured. Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
62305630|NCT05366608||Control|192 matched controls were enrolled. T
62305631|NCT05782855|SHAM_COMPARATOR|Control group|Participants in the control group will receive usual individualized training with a physiotherapist and passive sham training of lower extremities with the rehabilitation robot twice a day until day of discharge. The physiotherapist will be blinded to allocation. Sham training consists of 3 sets of 8 passive repetitions with each leg twice a day.
62305632|NCT05782855|ACTIVE_COMPARATOR|Intervention group|The intervention group will receive usual individualized training with a physiotherapist and active strength training of lower extremities by the robot twice a day until day of discharge. The physiotherapist will be blinded to allocation. Training will focus on the muscle groups in the lower extremities, which are used to get up from a chair and walk around (thigh- and calf muscles). Active training consists of 3 sets of maximum repetitions with a minimum of 65% (65-80%) intensity of 1 RM with each leg twice a day.
62305633|NCT03154138|EXPERIMENTAL|Prismatic adaptation (PA) group|Patients in the experimental group will benefit from 10 sessions of adaptation prismatic (PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy ...) according to the needs of the patients.
62305634|NCT03154138|PLACEBO_COMPARATOR|Sham group|Patients in the sham group will benefit from 10 sessions of sham adaptation prismatic (S-PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy ...) according to the needs of the patients.
62305635|NCT04668378|EXPERIMENTAL|Time restricted eating (TRE) - two month|partecipants underwent 2 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
62305636|NCT04668378|ACTIVE_COMPARATOR|Normal Diet (ND) - two month|partecipants underwent 2 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
62305637|NCT04668378|EXPERIMENTAL|Time restricted eating (TRE) - twelve month|partecipants underwent 12 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
62305638|NCT04668378|ACTIVE_COMPARATOR|Normal Diet (ND) - twelve month|partecipants underwent 12 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
62305639|NCT03366714|EXPERIMENTAL|RAM cannula|nasal CPAP support with RAM cannula
62473466|NCT02082392|ACTIVE_COMPARATOR|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
62473467|NCT05728541|EXPERIMENTAL|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
62473468|NCT03265522|EXPERIMENTAL|"Group 1: ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=20)"
62117536|NCT02230358|OTHER|Regional anesthesia (RA)|Regional anesthesia (RA) for a carotid endarterectomy Interventions: Regional anesthesia (RA), blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, Near-infrared spectroscopy (NIRS) monitoring, oxygen supply (not invasive 'Vigileo')
62117537|NCT02230358|OTHER|General anesthesia (GA)|General anesthesia (GA) for a carotid endarterectomy Interventions: General anesthesia, blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, NIRS monitoring, oxygen supply (not invasive 'Vigileo')
62305640|NCT03366714|ACTIVE_COMPARATOR|Hudson cannula (short binasal cannula)|nasal CPAP support with Hudson cannula
62473469|NCT03265522|EXPERIMENTAL|"Group 2: ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=20)"
62473470|NCT03265522|PLACEBO_COMPARATOR|Group 3: Standard Care (control) group|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention) (n=20)"
62473471|NCT03559491||Macular Edema Patients|Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.
62473472|NCT01424124|EXPERIMENTAL|YHD001 dose level 1|
62473473|NCT01424124|EXPERIMENTAL|YHD001 dose level 2|
61918580|NCT01966692|ACTIVE_COMPARATOR|Fluticasone Propionate Formulation Sequenct 3*321|"Patients first received Fluticasone Propionate Drug formulation 3\*, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 3, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 2, after a washout period of at least 5 days, they then received Fluticasone Propionate Drug formulation 1.~All Fluticasone Propionate Drug formulations were administered via Plastiape Monodose Dry powder Inhaler, 500mcg single dose. \* (The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation.~MMAD for formulation 1 is 4.5 µm. MMAD for formulation 2 is 3.8 µm MMAD for formulation 3 is 3.7 µm. MMAD for formulation 3\* is 3.7 µm."
62117538|NCT01740063|EXPERIMENTAL|DAS181-F02 formulation|DAS181 10 mg dose for three days of the F02 formulation
62117539|NCT01740063|EXPERIMENTAL|DAS181-F04 formulation|DAS181 20 mg dose group for three days of the F04 formulation,
62117540|NCT01740063|PLACEBO_COMPARATOR|Placebo|placebo group
62676833|NCT02449577|EXPERIMENTAL|Beverage sequence DACB|Each participant randomized to this arm is exposed to 4 test meals in the order DACB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62473474|NCT01424124|ACTIVE_COMPARATOR|Singulair|
62676834|NCT02449577|EXPERIMENTAL|Beverage sequence CBAD|Each participant randomized to this arm is exposed to 4 test meals in the order CBAD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62305641|NCT02131701|ACTIVE_COMPARATOR|Training group|The training group received individualized information about moderate training and was also offered training in group twice a week during 12 months. The training included both endurance training (nordic walking, water gymnastics) and training in gym.
62305642|NCT02131701|ACTIVE_COMPARATOR|Prescription of exercise|Individualized sessions for exercise prescription aiming at moderate exercise of 30 minutes at least 5 days a week
62676835|NCT02449577|EXPERIMENTAL|Beverage sequence ABDC|Each participant randomized to this arm is exposed to 4 test meals in the order ABDC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62676836|NCT02449577|EXPERIMENTAL|Beverage sequence DABC|Each participant randomized to this arm is exposed to 4 test meals in the order DABC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62676837|NCT02449577|EXPERIMENTAL|Beverage sequence DCAB|Each participant randomized to this arm is exposed to 4 test meals in the order DCAB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62676838|NCT02449577|EXPERIMENTAL|Beverage sequence DBCA|Each participant randomized to this arm is exposed to 4 test meals in the order DBCA with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62117541|NCT05228691||Long COVID|"Participants will self-complete some questionnaires, while the rest of the variables will be evaluated by the evaluating physiotherapist.~After the consultation, the evaluator himself will provide the participants with some recommendations that he should make. As support, a diptych has been made with different general activities to be developed by the participant. With the purpose of track this activity, they will be informed that they will be contacted once 6 months have passed since the evaluation (via phone call or SMS)."
62117542|NCT03221569|EXPERIMENTAL|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
62117543|NCT03221569|ACTIVE_COMPARATOR|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
62117544|NCT02801071|EXPERIMENTAL|L-citrulline|15 g L-citrulline p.o. per day (3x 5g) for 24 weeks
62473475|NCT01424124|PLACEBO_COMPARATOR|Placebo|
62473476|NCT00204373|EXPERIMENTAL|single group|This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
62305643|NCT02462161|EXPERIMENTAL|Insulin Aspart|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.
62676839|NCT02449577|EXPERIMENTAL|Beverage sequence ADCB|Each participant randomized to this arm is exposed to 4 test meals in the order ADCB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
61918581|NCT06163820|EXPERIMENTAL|Intervention|"Patients will receive the following:~1. Bevacizumab 7.5 mg/kg every 3 weeks for 4 cycles~2. Nivolumab 1 mg /kg + ipilimumab 3 mg/kg every 3 weeks for 4 cycles (induction phase) followed by nivolumab monotherapy at 480mg every 4 weeks (maintenance phase)~3. hSRT (24-27Gy/3# or 25-30Gy/5#)"
61918582|NCT02920853|EXPERIMENTAL|BT-CPR|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback training to provide pain relief when relaxation is achieved.
62117545|NCT02801071|PLACEBO_COMPARATOR|Placebo|L-citrulline Placebo 3 times daily p.o. for 24 weeks
62117546|NCT05601466|EXPERIMENTAL|QN-023a|QN-023a in adult subjects with r/r AML
62117547|NCT00281424|NO_INTERVENTION|control|no pedometer
62117548|NCT00281424|EXPERIMENTAL|pedometer|given pedometer
62117549|NCT03823911|ACTIVE_COMPARATOR|HIV Mono-Infected|Patients infected with HIV only, and not currently or previously infected with hepatitis C.
62117550|NCT03823911|EXPERIMENTAL|Hepatitis C Mono-Infected|Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
62117551|NCT03823911|EXPERIMENTAL|HIV and Hepatitis C Co-Infected|Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.
62117552|NCT06676579|ACTIVE_COMPARATOR|Avacopan and Low Doses Glucocorticoid|"* Methylprednisolone 1g intravenous on day +1~* Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)~* Avacopan 30 mg oral twice a day (1-0-1) for 12 months"
62117553|NCT06676579|ACTIVE_COMPARATOR|High Doses Glucocorticoid|"* Methylprednisolone 1g intravenous on day +1~* Prednisone 0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months)"
62117554|NCT03762213|EXPERIMENTAL|Oculus GO VR HMD, application Happy Place (© Mimerse)|"Oculus GO is a stand-alone, consumer-grade, virtual reality head-mounted display (HMD). The HMD is placed on the head of the user blocking off the surrounding environment. The visuals and audio are relayed through the HMD in a virtual space.Happy Place (© Mimerse) is a publicly available application with an explicit intent to be used for chronic pain patients. It has the critical elements of VR, namely immersion and interactivity.~Immersion: The scene is a serene lakeside campground with guided relaxation and soothing music. The application intends to promote positive effects such as calmness and feeling of wonder.~Interactivity: Happy Place uses an innovative 'gaze-based interaction' with the virtual world. Around 50 'gaze objects' are placed around the scene and gazing at them would trigger an event.~The entire duration of the experience will be kept at 10 minutes."
62117555|NCT03762213|PLACEBO_COMPARATOR|iPad, application Happy Place (© Mimerse)|An iPad with earphones (Apple Inc. Cupertino CA) will be used for controls. The participants in control group will watch the same content for the same duration on an iPad screen (flat version of Happy Place). This experience will be different from the intervention group in two ways: first, lack of an immersive environment, and second, lack of interactivity with the environment.
62305644|NCT02462161|PLACEBO_COMPARATOR|Placebo|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.
62305645|NCT02243566||Essential hypertension|
62305646|NCT00983775|EXPERIMENTAL|healthy low dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.
62305647|NCT00983775|EXPERIMENTAL|healthy high dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
62117556|NCT02910635|EXPERIMENTAL|Volanesorsen, Intravenous (IV)|300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose
62117557|NCT02910635|EXPERIMENTAL|Volanesorsen, Subcutaneous (SQ)|300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose
62117558|NCT02910635|ACTIVE_COMPARATOR|Moxifloxacin Hydrochloride|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
62117559|NCT02910635|PLACEBO_COMPARATOR|Placebo Intravenous (IV) single dose|Administered as normal saline (0.9% Sodium Chloride)
62117560|NCT02910635|PLACEBO_COMPARATOR|Placebo Subcutaneous (SC) single dose|Administered as normal saline (0.9% Sodium Chloride)
62305648|NCT00983775|EXPERIMENTAL|type 1 diabetes mellitus|16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
62305649|NCT02788539|NO_INTERVENTION|Science Cafe|One time event, Group discussion for 30 participants who are chronic pain stakeholders on pain in their community.
62305650|NCT02788539|EXPERIMENTAL|Cohort 1- Pilot OWL Study|Participants will pilot test a website- Our Whole Lives website for nine weeks in order to determine if it will help with their chronic pain management.
62305651|NCT04538950|OTHER|Checkpoint Inhibitor (ICI)|Subjects diagnosed with cancer and will be receiving immune checkpoint inhibitors as treatment standard of care will have a PET/CT scan before and after therapy. PET/CT scan is done for study purposes only.
62305652|NCT01613092|EXPERIMENTAL|Conventional|Preoperative Antibiotics
62305653|NCT01613092|ACTIVE_COMPARATOR|Aggressive (Incremental)|Preoperative antibiotics, antibiotic wash and post operative antibiotics
62305654|NCT03744234|EXPERIMENTAL|Platelet-Rich Plasma Injection|Autologous injection of platelet-rich plasma (PRP) in the sacroiliac joint
62305655|NCT03744234|ACTIVE_COMPARATOR|Steroid Injection|Steroid injection in the sacroiliac joint
62305656|NCT05339516||Healthy group|
62305657|NCT05339516||Women with low back pain|
62473477|NCT03411148|EXPERIMENTAL|Exercise Group A|Weekly exercise sessions with physical therapist and psychologist
62473478|NCT03411148|PLACEBO_COMPARATOR|Exercise Group B|Home-based exercises
62676840|NCT02449577|EXPERIMENTAL|Beverage sequence BADC|Each participant randomized to this arm is exposed to 4 test meals in the order BADC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
61918583|NCT02920853|ACTIVE_COMPARATOR|Biofeedback-Only|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback.
62305658|NCT02435628||Satisfaction Questionnaires|"After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale.~Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap."
61919962|NCT03790631||imipenem TDM|Adult patients receiving imipenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
62473479|NCT02078791|EXPERIMENTAL|Botox infiltration|Botox infiltration in cervical region
62473480|NCT02078791|EXPERIMENTAL|Psychology therapy|Problem solving group therapy
62473481|NCT02078791|EXPERIMENTAL|Botox infiltration & psychology therapy|Botox infiltration in cervical region and problem solving group therapy.
61918584|NCT03195842|NO_INTERVENTION|Usual discharge care|Standard discharge instructions, meaning conversation with physician, usually via interpreter, along with written instructions compiled by the nurse. Written instructions include pre-translated handouts for common languages, and untranslated (English) patient-specific instructions.
62473482|NCT03222557|EXPERIMENTAL|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
62117561|NCT06677099|EXPERIMENTAL|Control group|Two sessions of CPT (morning and afternoon, 20 minutes each) were conducted. The CPT session consisted of modified postural drainage, assisted cough technique, positive expiratory pressure and chest percussion, vibration. The appointed therapist performed pulmonary auscultation and thoracic palpation to assess the status of pulmonary ventilation and secretion retention, and whether the patient's cough ability can complete effective airway clearance. Individualized program was formed according to the assessment, internal guidelines, the patient's tolerance, education level, and patient's preference prior to the randomization. All CPT sessions were performed by the same physiotherapist to avoid potential bias.
62117562|NCT06677099|EXPERIMENTAL|EIT-guided group|EIT-guided group: Similar to the patients in the Control group, the CPT techniques were predefined for the patients according to the assessment prior to the randomization. For each CPT session, EIT measurement was conducted and the images were used to guide the CPT treatments. The uses of EIT to guide individual treatments are briefly described as follows.
62117563|NCT06677216||Patients with TMD-related myalgia treated with BTX-A at the department of OMS|Participants for this study were adults with TMD-related myalgia according to the DC/TMD treated with a BTX-A injection. All participants were recruited at the department of Oral and Maxillofacial Surgery (OMS) of the Diakonessenhuis, Utrecht, The Netherlands.
62117564|NCT01126112|EXPERIMENTAL|Panitumumab|Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.
62305659|NCT03942614|EXPERIMENTAL|Nordic pole walking|walking with a pair of poles customized to an individual's height and stride length
62305660|NCT03942614|NO_INTERVENTION|Control|usual daily routine and activities of daily living
62305661|NCT03694522|EXPERIMENTAL|Bemarituzumab + mFOLFOX6|Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
62473483|NCT03222557|SHAM_COMPARATOR|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
62473484|NCT01498120|EXPERIMENTAL|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)"
62473485|NCT03161717|EXPERIMENTAL|Epidural electrical stimulation (EES)|n=20
62473486|NCT03161717|ACTIVE_COMPARATOR|Loss of resistance (LOR)|n=20
62473487|NCT03448107|EXPERIMENTAL|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
62473488|NCT03448107|ACTIVE_COMPARATOR|Complex Prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
62473489|NCT04343001|NO_INTERVENTION|Standard care|Usual standard of care at the study hospital
62473490|NCT04343001|EXPERIMENTAL|Aspirin|Aspirin 150mg once daily
62473491|NCT04343001|EXPERIMENTAL|Losartan|Losartan 100mg once daily. Dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
62473492|NCT04343001|EXPERIMENTAL|Simvastatin|Simvastatin 80mg once daily
62473493|NCT04343001|EXPERIMENTAL|Aspirin and Losartan|Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
62676841|NCT02449577|EXPERIMENTAL|Beverage sequence ACDB|Each participant randomized to this arm is exposed to 4 test meals in the order ACDB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (\<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
62473494|NCT04343001|EXPERIMENTAL|Aspirin and Simvastatin|Aspirin 150mg once daily and Simvastatin 80mg once daily
61918585|NCT03195842|EXPERIMENTAL|Recordable card|Usual care, as above, plus patient-specific and standard instructions recorded in the patient's preferred language for care and given to them on a card to take home.
61918586|NCT03520244|EXPERIMENTAL|Exercise + Holistic Education|A 12-week exercise program with 6 bi-weekly education sessions.
61918587|NCT03520244|NO_INTERVENTION|Wait list control|Participants in the control group will be offered the exercise + education sessions after the study is complete.
61918588|NCT01235871|EXPERIMENTAL|SB1578|
62473495|NCT04343001|EXPERIMENTAL|Losartan and Simvastatin|Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
62676842|NCT04065256|EXPERIMENTAL|Personalized music intervention group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. A total treatment dosage of 560 minutes is required.
62676843|NCT04065256|EXPERIMENTAL|Personalized music plus earplug group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. In addition, using earplug during night time sleep. The music intervention total treatment dosage of 560 minutes is required.
62676844|NCT04065256|NO_INTERVENTION|Control group|The control group involves neither music intervention nor using earplug at night.
62676845|NCT05861453|EXPERIMENTAL|Epeleuton 4g/day|
62676846|NCT06225531|EXPERIMENTAL|Autobiographical Memory Based Intervention|"All participants will be placed into the intervention arm, in which the participants will receive 6 autobiographical memory based intervention sessions, lasting approximately one hour.~Baseline lengths will vary from 3 - 5 sessions, with the initial session lasting approximately one hour, and follow up sessions lasting approximately 30 minutes. This randomisation is 1) to enable the effects of treatment to be separated from the effects of time seen clinically and 2) in order to control for the therapeutic value of contact."
62676847|NCT00067873|ACTIVE_COMPARATOR|Diet only|
62676848|NCT00067873|EXPERIMENTAL|Diet plus aerobic exercise|
62676849|NCT00067873|EXPERIMENTAL|Diet plus resistance exercise|
62676850|NCT02123511|EXPERIMENTAL|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
62676851|NCT02123511|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
62676852|NCT00004163|EXPERIMENTAL|Trastuzumab|"* Trastuzumab is administered intravenously weekly~* CAT or MRI scans will be performed every 2 cycles"
62676853|NCT00050427|EXPERIMENTAL|001|ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
61918589|NCT01235871|PLACEBO_COMPARATOR|Placebo|
62117565|NCT04530513|EXPERIMENTAL|Dose Level 1|
62305662|NCT03694522|PLACEBO_COMPARATOR|Placebo + mFOLFOX6|Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
61918590|NCT05587465|EXPERIMENTAL|Treatment|Lobster device implantation
62117566|NCT04530513|EXPERIMENTAL|Dose Level 2|
62117567|NCT04530513|EXPERIMENTAL|Dose Level 3|
62117568|NCT04530513|EXPERIMENTAL|Dose Level 4|
62117569|NCT04530513|EXPERIMENTAL|De-escalation Level|
62305663|NCT01994577||Adults (18+) presenting to the ED with symptoms of ACS|
62305664|NCT03933501|EXPERIMENTAL|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
62305665|NCT03933501|PLACEBO_COMPARATOR|FMUD|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
62676854|NCT00050427|EXPERIMENTAL|002|ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
62676855|NCT01061710||varenicline (Champix®)|Subjects who have been retreated with varenicline within 52 weeks and have been enrolled to varenicline protocol A3051109.
62676856|NCT04315207|ACTIVE_COMPARATOR|In-person visit|"In-person meeting with the patient in the out-patient department. The patient is free to bring up to four\* relatives or other persons of their own choice to the in-person meeting.~(\* Restriction due to space limitation)."
62117570|NCT06375291||1: Steroid injected|The pregnant women with steroid injection
62117571|NCT06375291||2: splint|The pregnant women with splinting
62117572|NCT06375291||3:both|The pregnant women with steroid injection and splinting
62117573|NCT01181180|EXPERIMENTAL|water consumation treatment|
62117574|NCT01181180|PLACEBO_COMPARATOR|no water consumption treatment|
62117575|NCT01132794|PLACEBO_COMPARATOR|Placebo|Intranasal nasal saline
62117576|NCT01132794|ACTIVE_COMPARATOR|Dexmedetomidine|Intranasal dexmedetomidine
62676857|NCT04315207|EXPERIMENTAL|Telephone call|Telephone call with the patient. The patient is free to turn on loudspeaker to include relatives or other persons in the telephone conversation, alternatively to ask the physician to call and inform one relative or other person after the patient-doctor telephone call
62676858|NCT00507507|EXPERIMENTAL|Tenofovir DF|Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
62676859|NCT00507507|EXPERIMENTAL|FTC+Tenofovir DF|Participants were randomized to receive FTC plus tenofovir DF once daily.
62676860|NCT03206385||CK Boost pelvis|
62676861|NCT05863364|NO_INTERVENTION|control group|Group A: Patients in the control group were administered only conventional therapy
62473496|NCT04343001|EXPERIMENTAL|Aspirin, Losartan and Simvastatin|Aspirin 150mg once daily, Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
62305666|NCT03933501|EXPERIMENTAL|SRP + AM|Four sessions (1/week) of scaling and root planning, plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the last session of treatment and taken every 8 hours for 7 days.
62305667|NCT03933501|PLACEBO_COMPARATOR|SRP|Four sessions (1/week) of scaling and root planning, plus two distinct placebo pills prescribed on the last session of treatment and taken every 8 hours for 7 days.
62305668|NCT03485612||change of the optic nerve sheath diameter|The test group will be male and female patients, aged over 18 and below 90 years of age. Each patient will be operated for urological reasons in the position for lithotomy.
62117577|NCT00244855|OTHER|No previous treatment|Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
62117578|NCT00244855|OTHER|Previous treatment|Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
62117579|NCT06676306||Observational|Patients and their caregivers participate in interviews on study. Patients also have their medical records reviewed on study.
62117580|NCT04744402|EXPERIMENTAL|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
62117581|NCT05315180|EXPERIMENTAL|dose exploration|Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 1-6 subjects treated at the lowest planned dose level. If no DLT is observed, dose escalation will continue to the next planned dose cohort
62117582|NCT05315180|EXPERIMENTAL|dose expansion|dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 2 groups may be done concurrently
62117583|NCT01117584|EXPERIMENTAL|ASP1941 lowest dose|oral tablet
62117584|NCT01117584|EXPERIMENTAL|ASP1941 low dose|oral tablet
62117585|NCT01117584|EXPERIMENTAL|ASP1941 high dose|oral tablet
62305669|NCT01904175||Reduced Intensity Allogeneic Transplant|Subjects undergoing a reduced intensity allogeneic stem cell transplant
62305670|NCT04429932|EXPERIMENTAL|Product use sequence ABDC|Subjects use MybluTM e-cigarette product variant A (2.4% nicotine) ad libitum for 2 days, then switch to use variant B (2.4% nicotine) for 2 days, then D (2.4% nicotine) for 2 days and then C (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
62117586|NCT01117584|EXPERIMENTAL|ASP1941 highest dose|oral tablet
62117587|NCT01117584|PLACEBO_COMPARATOR|Placebo|oral tablet
62117588|NCT03968666||Gynecological surgery with ERAS protocol|Patients scheduled for benign gynecological surgery under ERAS protocol
62117589|NCT01815450|EXPERIMENTAL|BLI1100|BLI1100 topical cream
62117590|NCT01815450|EXPERIMENTAL|BLI1100 - modified formulation|BLI1100 topical cream
62117591|NCT01815450|PLACEBO_COMPARATOR|Placebo|Topical cream
62117592|NCT05239299||Adolescents with chronic pain|
62117593|NCT05239299||Parents of adolescents with chronic pain|
62117594|NCT05239299||Health care professionals who work with adolescents with chronic pain|
62117595|NCT01656096|EXPERIMENTAL|Renal sympathetic denervation|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
62117596|NCT01656096|SHAM_COMPARATOR|Sham procedure|Sham procedure mimicking the renal sympathetic denervation procedure in the experimental arm
62117597|NCT01112644|EXPERIMENTAL|OXN PR|Different daily doses; intake every 12 hours
62305671|NCT04429932|EXPERIMENTAL|Product use sequence BCAD|Same as previous arm, but in a different randomization order.
62305672|NCT04429932|EXPERIMENTAL|Product use sequence CDBA|Same as previous arm, but in a different randomization order.
62473497|NCT02404701|EXPERIMENTAL|Aloe vera with cactus|1 capsule (500 mg), 2 times/day
62473498|NCT02404701|EXPERIMENTAL|Cranberry|3 capsules (810 mg), 2 times/day
62473499|NCT02404701|EXPERIMENTAL|Green tea extract|2 capsules (630 mg), 2 times/day
62117598|NCT01112644|PLACEBO_COMPARATOR|PLA|Different daily doses; intake every 12 hours
62117599|NCT00861549|EXPERIMENTAL|cohort 1|1mg / 0.5 tablet
62117600|NCT00861549|EXPERIMENTAL|cohort 2|2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China
62117601|NCT00861549|EXPERIMENTAL|cohort 3|4mg / 2 tablets
62473500|NCT02404701|EXPERIMENTAL|Bilberry|1 softgel (1000 mg), 2 times/day
62473501|NCT02404701|EXPERIMENTAL|Cinnamon|1 capsule (500 mg), 2 times/day
62473502|NCT02404701|EXPERIMENTAL|Milk thistle|1 capsule (250 mg), 3 times/day
62305673|NCT04429932|EXPERIMENTAL|Product use sequence DACB|Same as previous arm, but in a different randomization order.
62473503|NCT02404701|EXPERIMENTAL|Turmeric|1 capsule (450 mg turmeric + 50 mg turmeric extract), 1 time/day
62676862|NCT05863364|EXPERIMENTAL|the low-dose rifaximin treatment group|Group B
62676863|NCT05863364|EXPERIMENTAL|the conventional dose rifaximin treatment group|Group C
62676864|NCT02298504|EXPERIMENTAL|Indirect pulp cap|IDP will be performed for this group
62676865|NCT02298504|EXPERIMENTAL|MTA pulpotomy|MTA pulpotomy will be performed for this group
62676866|NCT02298504|EXPERIMENTAL|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
62676867|NCT03495440|EXPERIMENTAL|Center Sessions|Treatment condition in which participants receive psychoeducation and communication coaching.
62676868|NCT03495440|ACTIVE_COMPARATOR|At-home|Active, self-study control condition in which participants receive regular communication with study personnel and self-study materials to review on their own.
62676869|NCT04895280|OTHER|Group 1 (marcaine)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine
62676870|NCT04895280|EXPERIMENTAL|Group 2 (ketorolac)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
62676871|NCT04895280|OTHER|Group 3 (kenalog)|4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1. Group 3 is standard of care
62676872|NCT00562861|ACTIVE_COMPARATOR|citalopram + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to citalopram.
62676873|NCT00562861|PLACEBO_COMPARATOR|placebo + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to placebo
62676874|NCT06545955|EXPERIMENTAL|Nadofaragene firadenovec|Intravesical treatment with nadofaragene firadenovec only
62676875|NCT06545955|EXPERIMENTAL|Nadofaragene firadenovec + gemcitabine & docetaxel|Nadofaragene firadenovec (intravesical), and gemcitabine and docetaxel (intravesical)
62676876|NCT06545955|EXPERIMENTAL|Nadofaragene firadenovec + pembrolizumab|Nadofaragene firadenovec (intravesical), and pembrolizumab (IV infusion)
62676877|NCT04998149|NO_INTERVENTION|standard care|The control group subjects will receive standard of care during labor using pillows and wedges as positional devices.
62473504|NCT02404701|EXPERIMENTAL|Aloe vera|1 capsule (470 mg), 2 times/day
62676878|NCT04998149|EXPERIMENTAL|Peanut ball intervention|The experimental group will receive peanut ball as positioning device during labor
62676879|NCT02598999|EXPERIMENTAL|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
62473505|NCT04862572|EXPERIMENTAL|People with tinnitus|People with tinnitus will undergo all interventions (audiology test, MRI scans, tinnitus-related questionnaires).
62117602|NCT03506373|EXPERIMENTAL|Treatment (ixazomib citrate, ibrutinib)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62117603|NCT00316836||Group 1|Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
62473506|NCT04862572|EXPERIMENTAL|People without tinnitus|People with tinnitus will undergo most of all interventions (audiology test, MRI scans) except filling up the tinnitus-related questionnaires.
62473507|NCT00947076|EXPERIMENTAL|1|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
62473508|NCT00947076|ACTIVE_COMPARATOR|2|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
62676880|NCT02598999|EXPERIMENTAL|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
62676881|NCT02598999|EXPERIMENTAL|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in CF patients in healthy volunteers
62676882|NCT02598999|EXPERIMENTAL|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in healthy volunteers and in patients (CF and NCFBE)
62676883|NCT05825131||Retrospective and prospective observational study of patients living with MPS IIIC|Cohort 1: These participants will be a part of the retrospective and prospective Natural History Study, including the C-RARE video assessments. In clinic visits will include: neurocognitive, developmental and behavioral clinical outcome assessments as well as biochemical sample analysis, imaging measures and retrospective medical record review. Participants will record daily living activities through the C-RARE app on their mobile device.
62676884|NCT05825131||Remote video recording study and retrospective medical chart review of patients living with MPS IIIC|Cohort 2: These participants will not attend in clinic visits. They will be a part of the C-RARE and retrospective medical chart review analysis. 35 patients with a confirmed diagnosis of MPS IIIC from English, Spanish and Portuguese speaking households will be recruited for this portion of the study.
62676885|NCT05825131||Retrospective medical chart review of MPS IIIC patients either living or deceased|Cohort 3: Deceased or living medical record analysis only of patients with MPS IIIC. Living patients will not be participating in cohort 1 clinical study or cohort 2 C-RARE study.
62676886|NCT01306994||Syndrome Group|Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3
62676887|NCT01306994||Control Group|Healthy individuals
62676888|NCT04548050||mothers informed by untrained nurse|
62676889|NCT04548050||mothers informed by trained nurse|
62676890|NCT04548050||mothers informed by nurses trained 6 months ago|
62473509|NCT06326697|EXPERIMENTAL|Test Product: Azacitidine 300 mg Film coated tablets|Single oral dose of Azacitidine 300 mg Film coated tablets
62473510|NCT06326697|ACTIVE_COMPARATOR|Reference Product: Onureg® 300 mg Film Coated Tablets|Single oral dose of Onureg® 300 mg Film Coated Tablets
62473511|NCT03026374|EXPERIMENTAL|intervention group|The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
62473512|NCT03026374|NO_INTERVENTION|control group|patients from both groups were provided medical, social, or psychological care if necessary, as assessed by primary oncologists. Additionally, all patients received an educational brochure about breast cancer every 1 to 2 months, and relaxation therapy was provided to both groups to prevent demoralization from random assignment.
62473513|NCT04344106|EXPERIMENTAL|Prone positioning|"Participants are all turned to prone position for an optimal minimum duration of 3 hours .~Tolerance, oxygen saturation, heart rate and position are monitoring during all procedure. Arterial blood gases are realized before, 1 to 2 hours after the beginning of the prone position, and 6 to 12 hours after resupination."
62473514|NCT00693290|ACTIVE_COMPARATOR|1|Fleet plus low residue diet sheet.
62473515|NCT00693290|NO_INTERVENTION|2|No intervention, usual care, Fleet plus liquid only diet
62473516|NCT04052503|EXPERIMENTAL|Fully Supported Group|Meetings with knowledge broker 6 times over 10 months to design and implement knowledge translation intervention. Intervention consisted of audit and feedback, goal setting, education, reminders, documentation changes, and KB support.
62473517|NCT04052503|ACTIVE_COMPARATOR|Partially Supported Group|Meetings with knowledge broker 4 times over 10 months to design and partially implement knowledge translation intervention. Group meets 2 additional times without knowledge broker to self implement intervention. Intervention consisted of audit and feedback, goal setting and documentation changes. Group self implemented education and reminders.
62473518|NCT04351425|EXPERIMENTAL|study group|study group will be shifted from incubator to an unheated open cot a weight of 1400 grams
62676891|NCT02959892|EXPERIMENTAL|TAK-041 20 mg|\[11C\] PHNO 180 megabecquerel (MBq), injection, intravenously, prior to positron emission tomography (PET) scan on Day 1, followed by amphetamine (AMPH) 0.5 milligram per kilogram (mg/kg), tablet, orally, once and \[11C\] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 20 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and \[11C\] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
62676892|NCT02959892|EXPERIMENTAL|TAK-041 40 mg|\[11C\] PHNO 180 MBq, injection, intravenously, prior to PET scan on Day 1, followed by AMPH 0.5 mg/kg, tablet, orally, once and \[11C\] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 40 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and \[11C\] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
62676893|NCT06322862|OTHER|single arm|
62676894|NCT04658147|EXPERIMENTAL|Arm A - Nivolumab|Participants receive Nivolumab only.
62305674|NCT04429932|EXPERIMENTAL|Product use sequence EFHG|Subjects use MybluTM e-cigarette product variant E (1.2% nicotine) ad libitum for 2 days, then switch to use variant F (1.2% nicotine) for 2 days, then H (2.4% nicotine) for 2 days and then G (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
62305675|NCT04429932|EXPERIMENTAL|Product use sequence FGEH|Same as previous arm, but in a different randomization order.
62305676|NCT04429932|EXPERIMENTAL|Product use sequence GHFE|Same as previous arm, but in a different randomization order.
62676895|NCT04658147|EXPERIMENTAL|Arm B - Nivolumab and Relatlimab|Participants receive Nivolumab and Relatlimab.
62305677|NCT04429932|EXPERIMENTAL|Product use sequence HEGF|Same as previous arm, but in a different randomization order.
62676896|NCT05145439|EXPERIMENTAL|VibratoSleeve TUS|In this single arm study, there is only one group/arm, all of whom will be given 3 levels of treatment with the VibratoSleeve TUS device.
62676897|NCT02234986|EXPERIMENTAL|ENMD-2076|ENMD-2076, oral capsule Once daily dose 250 mg/day
62676898|NCT05753969|EXPERIMENTAL|MPH / AMPH Treatment|
62676899|NCT05753969|PLACEBO_COMPARATOR|Placebo|
62676900|NCT06695559|ACTIVE_COMPARATOR|Labrida Bioclean|The implant pockets will be debrided with the Labrida BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline. The treatment will be repeated every three months. Debridement is performed with local anaesthesia as needed.
61918591|NCT05262231|EXPERIMENTAL|Experimental|Study group intervention consists 1-session. A session takes approximately 1 hour. The pre-test will be applied just before the intervention. The final test will be administered immediately after the intervention.
62473519|NCT04351425|ACTIVE_COMPARATOR|control group|control group will be shifted from incubator to an unheated open cot at a weight of 1600 grams
62473520|NCT00276848|ACTIVE_COMPARATOR|Fludarabine plus Cyclophosphamide|
62473521|NCT00276848|ACTIVE_COMPARATOR|Fludarabine|
62676901|NCT06695559|EXPERIMENTAL|Labrida Bioclean and tetracycline slurry|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated two minutes with tetracycline-hydrochloride (Arco Interpharma AS, Hokksund, Norway) in sterile saline with a concentration of 150 mg/ml, as chemical detergent adjunct to the chitosan brush. The treatment will be repeated every three months. Debridement is performed with local anaesthesia as needed.
62676902|NCT01327781|EXPERIMENTAL|Treatment (Z-endoxifen hydrochloride)|Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61918592|NCT05262231|NO_INTERVENTION|No Intervention|No intervention is applied to the control group.
61918593|NCT03729362|EXPERIMENTAL|Cipaglucosidase Alfa/Miglustat|Participants received cipaglucosidase alfa co-administered with miglustat every 2 weeks (Q2W).
61918594|NCT03729362|ACTIVE_COMPARATOR|Alglucosidase Alfa/Placebo|Participants received alglucosidase alfa co-administered with placebo Q2W.
61918595|NCT05666115|EXPERIMENTAL|Probiotic group|Participants in the probiotics group will receive probiotic supplementation for 12 weeks.
61918596|NCT05666115|ACTIVE_COMPARATOR|Exercise group|The control group will undergo a 12-week online-delivered Tabata program, as a form of high-intensity interval training.
61918597|NCT03774095|NO_INTERVENTION|No oil|6-hour oral glucose tolerance test
61918598|NCT03774095|ACTIVE_COMPARATOR|Hydrolyzed pine nut oil|6g hydrolyzed pine nut oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
61918599|NCT03774095|ACTIVE_COMPARATOR|Hydrolyzed pine nut oil and olive oil|3g hydrolyzed pine nut oil and 3g olive oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
61918600|NCT02785289|EXPERIMENTAL|Flocked|Patients will perform vaginal cell collection beginning with the flocked swab, followed by the coton swab.
61918601|NCT02785289|EXPERIMENTAL|Coton|Patients will perform vaginal cell collection beginning with the coton swab, followed by the flocked swab.
61918602|NCT00981773|EXPERIMENTAL|Immediate switch|"* Continue current boosted protease inhibitor~* Switch NRTI backbone to maraviroc 150 mg bid"
61918603|NCT00981773|ACTIVE_COMPARATOR|Continue current antiretroviral therapy|* Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.
61918604|NCT03063671|ACTIVE_COMPARATOR|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
61919963|NCT03790631||meropenem TDM|Adult patients receiving meropenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
62117604|NCT06249295|EXPERIMENTAL|Intervention group|The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth).
62117605|NCT06249295|NO_INTERVENTION|control group|The control group received general routine care.
62117606|NCT05609032|EXPERIMENTAL|Intervention (App Arm)|Participants randomized to the intervention arm will receive access to the Sense2Quit App (A multi-component intervention that links a smartphone app to a smartwatch to provide real-time quit reminders to curtail relapses and avoid potential triggers), standard smoking cessation counseling, and nicotine replacement therapy.
62117607|NCT05609032|NO_INTERVENTION|Control|Participants randomized to the control arm will receive standard smoking cessation counseling and referral to quitline.
62117608|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
62117609|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
62117610|NCT04191434|EXPERIMENTAL|FLAMBOYANT 125/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 125/12 capsule~1 Budesonide/formoterol 200/6 Placebo capsule."
62117611|NCT04191434|ACTIVE_COMPARATOR|Budesonide/formoterol 200/6|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 200/6 capsule~1 Flamboyant 125/12 Placebo capsule."
62117612|NCT02891278|EXPERIMENTAL|Sertraline with cytosine arabinoside|"All subjects will receive the following:~Induction phase~* Sertraline, twice daily at one of the pre-defined dose levels~* Cytosine arabinoside, on days 1 and 10~Consolidation phase~Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:~* Allogeneic SCT and off study~* Repeat cycle of oral sertraline and cytosine arabinoside IV infusion~* Maintenance phase with sertraline for cycles of 28 days in length"
62117613|NCT04689568|ACTIVE_COMPARATOR|Moodkit|MoodKit is a cognitive behavioral therapy (CBT)-based app designed to provide tools for managing depressed mood, anxiety and stress.
62117614|NCT04689568|ACTIVE_COMPARATOR|Moodgym|Moodgym is an online cognitive behavioral therapy (CBT)-based program designed to prevent or reduce symptoms of depression and anxiety by helping users identify and overcome problem emotions and to develop good coping skills.
62117615|NCT04689568|ACTIVE_COMPARATOR|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey. The Toolkit offers help to people who are experiencing problems with a mood disorder as well as with stress and anxiety.
62117616|NCT02620410|OTHER|Axonics SNM System|Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
62117617|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
62117618|NCT06676631|EXPERIMENTAL|NK 010 or NK 042 infusion|Subjects with refractory SLE or LN will receive rituximab followed by NK010 or NK042.
62676903|NCT01783145||Patients|Patients with disseminated TC who have finished their chemotherapy, if needed followed by surgery, and who are in complete remission and currently in active follow-up.
62305678|NCT01495819|ACTIVE_COMPARATOR|Nicotine|subjects will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg). At the beginning of each experimental session, subjects will first sample the assigned nicotine dose and placebo (saline) condition that are randomly labeled as A or B. which may be nicotine or saline. This procedure will allow subjects to sample the nicotine and saline that will be available during that session. In addition, subjective and physiological responses to the sample nicotine dose and saline will be assessed.
61918605|NCT03063671|ACTIVE_COMPARATOR|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
62305679|NCT01495819|PLACEBO_COMPARATOR|Saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
62473522|NCT04691895||Patients admitted to hospital for COVID19 disease (case group)|"The study cohort will be composed by consecutively enrolled COVID19 confirmed inpatients (case group)~Inclusion criteria:~* Signed informed consent~* Age ≥18 years and ≤85 years~* Consecutive COVID19 confirmed patients (COVID +ve)~* Ability to conform to study protocol~Exclusion criteria:~* Patients under mechanical ventilation~* Patients unable to report required data~* Current diagnosis of cancer"
62117619|NCT02660645||Blue Light Cystoscopy with Cysview®|Bladder cancer patients who have undergone Blue light cystoscopy with Hexaminolevulinate hydrochloride (Cysview®) 100mg in 50 milliliters (mL) reconstituted solution instilled intravesically into bladder prior to cystoscopy in operating room (OR). Retention time: 1-3 hours. The Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is used for the cystoscopy procedure at the OR examination.
62117620|NCT04548830|EXPERIMENTAL|Transbronchial cryobiopsy|All study participants will undergo transbronchial biopsies via our proposed standardized cryo-biopsy protocol in place of the traditional forceps transbronchial biopsy that is typically used at MSK.
62117621|NCT04531137|EXPERIMENTAL|CLA-fortified milk powder|Respondents will receive CLA-fortified milk powder containing 3.4 gram for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
62117622|NCT04531137|OTHER|Placebo|Respondents will receive a placebo milk powder for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
62117623|NCT06488625|EXPERIMENTAL|Low-Dose (2 g/d CICR-NAM (blinded))|To maintain blinding for patients and investigators in the induction and maintenance treatment, all patients self-administer 6 tablets per day. In the low-dose arm, subjects receive 4 tablets of verum CICR-NAM and 2 tablets of placebo CICR-NAM per day, resulting in a total daily intake of 2 g/d CICR-NAM
62305680|NCT00392873|EXPERIMENTAL|EAMD+Calories|This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy expenditure.
62305681|NCT00392873|NO_INTERVENTION|EAMD Control|This group contains women with exercise-associated menstrual disturbances (EAMD) and undergoes the same procedures as the EAMD+Calories group. However, this group is instructed to maintain exercise and eating habits.
62305682|NCT00392873|NO_INTERVENTION|Heathy Control|This group contains exercising women with regular, ovulatory menstrual cycles. this group is instructed to maintain body weight and exercise and eating habits.
62305683|NCT03419702|NO_INTERVENTION|Control|No almonds
62305684|NCT03419702|EXPERIMENTAL|Experimental|Almonds
62305685|NCT00841724|ACTIVE_COMPARATOR|Busilvex, Fludara, Thymoglobuline|D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion
62117624|NCT06488625|EXPERIMENTAL|High-Dose (3 g/d CICR-NAM (blinded))|To maintain blinding for patients and investigators in the induction and maintenance treatment, all patients self-administer 6 tablets per day. In the high-dose arm, subjects receive 6 tablets of verum CICR-NAM and 0 tablets of placebo CICR-NAM per day, resulting in a total daily intake of 3 g/d CICR-NAM
62117625|NCT06488625|PLACEBO_COMPARATOR|Placebo (0 g/d CICR-NAM (blinded))|To maintain blinding for patients and investigators in the induction and maintenance treatment, all patients self-administer 6 tablets per day. For the placebo arm, subjects receive 0 tablets of verum CICR-NAM and 6 tablets of placebo CICR-NAM per day, resulting in a total daily intake of 0 g/d CICR-NAM
62117626|NCT06488625|EXPERIMENTAL|Open-Label (3 g/d CICR-NAM (blinded))|Patients that have completed the induction period and show worsening of disease activity at the end of the induction period will be allowed to switch to the open-label arm to receive 6 tablets of verum CICR-NAM of 0 tablets of placebo CICR-NAM per day, resulting in a total daily intake of 3 g/d CICR-NAM
62305686|NCT02822365||Diagnostic (PET/CT)|Patients undergo a PET/CT scan as part of their standard clinical care. While still positioned for the clinical scan, patients undergo additional research PET/CT scans in a smaller region over 10 minutes with the pocket phantom placed nearby and a low-dose single bed position CTAC.
62305687|NCT00378729|ACTIVE_COMPARATOR|A|
62305688|NCT00378729|ACTIVE_COMPARATOR|B|
62676904|NCT05922280|EXPERIMENTAL|experimental group|Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory foot mobilizations. Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, wash and properly wear shoes and perform ankle ROMs
62676905|NCT05922280|ACTIVE_COMPARATOR|control group|Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, wash and properly wear shoes and perform ankle ROMs.
62676906|NCT04952688|EXPERIMENTAL|Experimental|"Inclusion~Before Anti-VEGF treatment: opht"
62676907|NCT01120444|ACTIVE_COMPARATOR|Subcutaneous delivery of insulin|A bolus dose of insulin will be given subcutaneously just prior to a standardized meal.
62676908|NCT01120444|EXPERIMENTAL|Intradermal delivery of insulin|A bolus dose of insulin will be given intradermally just prior to a standardized meal
62676909|NCT02882893|EXPERIMENTAL|DWP450|Single-dose
62676910|NCT02882893|ACTIVE_COMPARATOR|Botox|Single-dose
62676911|NCT05655169|EXPERIMENTAL|Piezosurgery and low-level laser therapy|Piezocision will be applied in this group of patients using a piezosurgery knife and after six weeks of initial retraction, low-level laser therapy will be applied in this group of patients using a diode laser device.
62676912|NCT05655169|EXPERIMENTAL|Piezosurgery only|Piezocision will be applied in this group of patients using a piezosurgery knife
62676913|NCT05655169|ACTIVE_COMPARATOR|Traditional treatment without acceleration|In this group of patients, the en masse retraction will be conventional without any acceleration intervention.
62676914|NCT02244528|EXPERIMENTAL|Treatment|sildenafil treatment
62676915|NCT04539431||Retrospective|The cases with glioma will be identified in the databases of hospital, the material will be preliminarily evaluated in order to see if there is sufficient tissue left for analysis.
62676916|NCT04539431||Prospective|A blood sample for molecular analyses will be collected in all the cases, CSF samples will be taken only if recommended by the normal surgical routine.
62676917|NCT05916482||OPT OBESE|Vietnamese patients with obesity present at outpatient clinics of University Medical Center Ho Chi Minh City and My Duc General Hospital
62676918|NCT02562040|ACTIVE_COMPARATOR|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
62676919|NCT02562040|EXPERIMENTAL|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
62676920|NCT05759364|ACTIVE_COMPARATOR|Intervention group- IV PAPAVERINE 80 mg|Administration of IV PAPAVERINE 80 mg in 100 ml of saline, once within half an hour before inserting a single-balloon balloon catheter
62676921|NCT05759364|PLACEBO_COMPARATOR|Conrol group- Placebo group.|Administration of 100 ml of saline within half an hour before the insertion of a single-balloon catheter
62676922|NCT03456297|EXPERIMENTAL|Experimental cluster|The Web-based clinical pedagogy program (WCP) will be provided to the participants in the experimental cluster.
62676923|NCT03456297|NO_INTERVENTION|Control cluster|The participants in the control cluster will receive the current face-to-face preceptorship course.
62676924|NCT05111964|EXPERIMENTAL|HIFU Treatment of STS or Intra-abdominal Desmoid Tumour|All participants receive HIFU to their target tumour, hence this is a single arm study with 4 recruitment pathways.
62676925|NCT04143438|EXPERIMENTAL|Undergoing EOS 3D imaging|Patients with patello-femoral instability will undergo EOS 3D Imaging protocol before and after undergoing corrective surgery
62676926|NCT05144581||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County 2013-2017, identified by ICD-code K.58.
62676927|NCT02718482|EXPERIMENTAL|Gemcitabine and Docetaxel|Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
62676928|NCT02718482|EXPERIMENTAL|Ifosfamide|Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks
62676929|NCT06236009|EXPERIMENTAL|Part 1: TAK-004 or Placebo (Single Ascending Dose Cohorts)|Participants will receive TAK-004 or matching-placebo subcutaneous injection on Day 1 in Cohort S1 using a sentinel dosing scheme in a double-blind manner. After dosing the first two participants in Cohort S1, the investigator will review all available safety and tolerability data up to 24 hours post-dose before dosing the remaining participants in the Cohort S2-S10. Single ascending doses are nominal and may be modified based on emerging safety and available PK data during the study but will have a corresponding dose that does not exceed the maximal defined exposure.
62676930|NCT06236009|EXPERIMENTAL|Part 2: TAK-004 or Placebo (Multiple Ascending Dose Cohorts)|Participants will receive TAK-004 (dose to be decided \[TBD\]) or matching-placebo subcutaneous injection, once daily for 5 days (i.e., Day 1 to 5) in each 5 multi-ascending dose cohorts (M1-M5). The dose in Part 2 will be determined at the dose escalation meeting based upon emerging safety, tolerability, and available PK data from Part 1.
62676931|NCT06236009|EXPERIMENTAL|Part 3: TAK-004 or Placebo (Expansion Cohorts)|Participants will receive TAK-004 (TBD) or matching-placebo subcutaneous injection on Day 1 in each single ascending dose expansion cohorts (E1 and E2). Doses will be determined at the dose escalation meeting based on safety, tolerability and available PK data from Parts 1 and 2. Expansion cohort 2 (optional) may be conducted at the sponsor's discretion after reviewing expansion cohort 1 data.
62676932|NCT05623085|EXPERIMENTAL|Aerobic Exercise|Aerobic exercise group with 8 weeks of individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
62676933|NCT05623085|ACTIVE_COMPARATOR|Yoga Exercise|Yoga exercise group with 8 weeks of individualized exercise program. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
62676934|NCT01229111|EXPERIMENTAL|Treatment (cediranib maleate and modified FOLFOX)|Patients receive cediranib maleate PO QD on days 1-14 and modified FOLFOX6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.
62676935|NCT05971888|ACTIVE_COMPARATOR|Intervention|
62676936|NCT05971888|NO_INTERVENTION|Control|In Amhara, an equal number of districts outside the program coverage area with characteristics similar to the intervention districts will serve as the control.
62117627|NCT04613024|EXPERIMENTAL|Experiment|Topamax randomized group
62117628|NCT04613024|ACTIVE_COMPARATOR|Control|Gabapentin randomized group
62117629|NCT06153641||Biopsy arm|Post-transplant patients undergoing standard of care liver biopsy (Biopsy arm).
62117630|NCT06153641||Stable post-liver transplant arm|Stable post-liver transplantation patients without rejection (Stable post-liver transplant arm).
62117631|NCT06153641||Healthy arm|Healthy non-transplant control patients without liver disease (Healthy arm).
62117632|NCT01518829||Patients with hepatocellular carcinoma|Patients with hepatocellular carcinoma who will undergo locoregional therapy
62117633|NCT01518829||patients with chronic liver disease|patients with chronic liver disease, as a control group
62117634|NCT01970748|PLACEBO_COMPARATOR|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
62117635|NCT01970748|ACTIVE_COMPARATOR|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
62117636|NCT01645098|EXPERIMENTAL|Dexmedetomidine 1 mcg/kg|Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
62117637|NCT01645098|EXPERIMENTAL|Dexmedetomidine 0.5 mcg/kg|Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
62117638|NCT00078572|ACTIVE_COMPARATOR|capecitabine alone|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2. Randomization is 1:1.
62117639|NCT00078572|EXPERIMENTAL|Combination|Lapatinib 1250 mg once daily plus capecitbine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the combination arm was 2000 mg/m2.
62117640|NCT03484611|ACTIVE_COMPARATOR|AMH < 0.3 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH \< 0,3 ng/ml
62117641|NCT03484611|ACTIVE_COMPARATOR|AMH 0.3 to 0.7 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml
62117642|NCT03484611|ACTIVE_COMPARATOR|AMH > 0.7 to 1 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml
62117643|NCT00761436|EXPERIMENTAL|Arm 1|
62117644|NCT05790408|OTHER|AS-OCT and iOCT|This prospective study will include approximately 25 patients with open-angle glaucoma who will undergo TCNR of trabeculectomy bleb by a glaucoma specialist at Northwestern Medicine. These patients will have a history of glaucoma and failed trabeculectomy bleb (as evidenced by clinical features and elevated IOP). During routine clinic visit, the patient will undergo lit lamp grading of bleb by Indiana Bleb Appearance Grading Score (IBAGS). Subjects who agree to participate and provide written informed consent will undergo AS-OCT imaging (Spectralis OCT, Heidelberg) of the bleb. During their operation, the Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), a commercially available device will be utilized to visualize and evaluate the morphology of the trabeculectomy bleb at the start and conclusion of the case.
62117645|NCT04058990|EXPERIMENTAL|Agent Paclitaxel-Coated PTCA Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (Agent Paclitaxel-Coated PTCA Balloon Catheter with paclitaxel 2.0 μg/mm²)
62117646|NCT04058990|ACTIVE_COMPARATOR|SeQuent Please Drug Eluting Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (SeQuent Please Drug Eluting Balloon Catheter with paclitaxel 3.0 μg/mm²)
62117647|NCT02835768|EXPERIMENTAL|Intervention|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Participants will be given an additional leaflet about the domestic safety website with address link and brief introductory information.
62117648|NCT02835768|NO_INTERVENTION|Control|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Only this booklet serves as the anticipatory guidance to mothers about domestic safety.
62117649|NCT05434611||Kawasaki disease|All children with Kawasaki disease met the diagnostic criteria for Kawasaki disease revised by the American Heart Association in 2017.
62117650|NCT05434611||Healthy controls|Healthy control group were healthy children who underwent outpatient physical examination.
62117651|NCT00590369|ACTIVE_COMPARATOR|1|KCI VAC type negative pressure wound therapy device
62117652|NCT00590369|EXPERIMENTAL|2|Versatile One (EZCare) negative wound therapy device
62117653|NCT04177316||hypermethylation|The hypermethylation group was defined as differential methylation status of tumor- normal ≥ 5%.
62117654|NCT04177316||hypomethylation/no change|The hypomethylation were defined as differential methylation status of tumor- normal \<5%
62117655|NCT05651399|ACTIVE_COMPARATOR|Remimazolam|A maintenance dose of remimazolam is administered for sedation
62117656|NCT05651399|ACTIVE_COMPARATOR|Propofol|A maintenance dose of propofol is administered for sedation
62117657|NCT00573339||Normal Controls|
62117658|NCT01131494|EXPERIMENTAL|Swallowing exercises|
62117659|NCT00326924|EXPERIMENTAL|Biological|PRBCs that are less than 7 days old are considered 'fresh'.
62117660|NCT00326924|EXPERIMENTAL|Standard PRBCs|PRBCs 'stored' as per hospital policy.
62305689|NCT04735029|EXPERIMENTAL|Thermal Gun group|"The thermal gun applied on acupressure points in TCM. The thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
62676937|NCT03815019|EXPERIMENTAL|Megestrol|"Megestrol is a steroid and progestational drug FDA approved for treating anorexia or weight loss in patients with acquired immunodeficiency syndrome. Its use in the current protocol is off label to stimulate appetite in tube-fed infants and toddlers who are weaning from tube feedings and learning to eat. The precise mechanism of action that leads to increased appetite and weight gain is unknown, but is probably related to megestrol's glucocorticoid effect.~The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable."
62676938|NCT03815019|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo protocol will receive a placebo syrup identical in taste and smell to megestrol at the same intervals as those in the megestrol group but the syrup will contain no active ingredients.
62676939|NCT03283995||cardiogenic shock without SCA|
62676940|NCT03283995||cardiogenic shock with SCA|
62676941|NCT03283995||SCA,|
62676942|NCT03283995||acute left heart failure with severe alteration of LVEF|
62676943|NCT03932409|EXPERIMENTAL|Pembrolizumab + Radiation Therapy + Pembrolizumab/Chemotherapy|Pembrolizumab given 7 days prior to radiation therapy (e.g., vaginal cuff brachytherapy) followed by three cycles pembrolizumab combined with Carboplatin/Paclitaxel chemotherapy
62676944|NCT05835687|EXPERIMENTAL|Arm A (relapsed/refractory CNS tumors)|Patients with B7-H3-positive relapsed/refractory non-brainstem primary CNS tumors.
62676945|NCT05835687|EXPERIMENTAL|Arm B (diffuse midline gliomas [DMG])|Patients with DMG.
62676946|NCT04381377|EXPERIMENTAL|Polyoxidonium|Polyoxidonium will be administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
62117661|NCT03546634|ACTIVE_COMPARATOR|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
62117662|NCT03546634|EXPERIMENTAL|Two-dose schedule for Sabin IPV|Subjects first dose IPV vaccinate at 4 months of age, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
62117663|NCT01033058|ACTIVE_COMPARATOR|usual care|
62117664|NCT01033058|EXPERIMENTAL|intensive statin treatment|
62117665|NCT01442935|ACTIVE_COMPARATOR|Arm A1 : Folfiri + targeted therapy|"Every 2 weeks :~* irinotecan 180 mg/m² D1~* Folinic acid 400 mg/m² D1~* 5FU 400 mg/m² bolus~* 5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~* For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~* For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
62305690|NCT04735029|ACTIVE_COMPARATOR|Heat Pack group|A hydrocollator heat pack used to simulate traditional thermal therapy. The application of the heat pack was wrapped with six layers of terry towels to bring the temperature down to around 43°C.
62305691|NCT01064089|EXPERIMENTAL|HSP990|dose escalation
62305692|NCT04243044|EXPERIMENTAL|Intensity 1 (0.8x reflex threshold, continuous, 30 minute duration)|Transcutaneous spinal stimulation will be applied continuously at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
62473523|NCT04691895||Patients admitted to hospital in absence of COVID19 disease (control group)|"The study cohort will be composed by consecutively enrolled COVID19 negative patients hospitalized for other reasons (controls group)~Inclusion criteria:~* Signed informed consent~* Age ≥18 years and ≤85 years~* Consecutive hospitalized COVID19 negative patients (COVID -ve)~* Ability to conform to study protocol~Exclusion criteria:~* Patients under mechanical ventilation~* Patients unable to report required data~* Current diagnosis of cancer"
62676947|NCT04381377|PLACEBO_COMPARATOR|Placebo|Placebo will be administered (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
62676948|NCT03197272|EXPERIMENTAL|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
62676949|NCT03197272|ACTIVE_COMPARATOR|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
62676950|NCT05253833|ACTIVE_COMPARATOR|Group 1|Allopurinol once daily for 24 weeks
62676951|NCT05253833|EXPERIMENTAL|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 22 weeks
62117666|NCT01442935|ACTIVE_COMPARATOR|Arm A2 : Folfox 4 + targeted therapy|"Every 2 weeks :~* oxaliplatin 85 mg/m² D1~* Folinic acid 400 mg/m² D1~* 5FU 400 mg/m² bolus~* 5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~* For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~* For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
62117667|NCT01442935|EXPERIMENTAL|Arm B : Folfirinox + targeted therapy|"Every 2 weeks :~* oxaliplatin 85 mg/m² D1~* irinotecan 150 mg/m² D1~* Folinic acid 400 mg/m² D1~* 5FU 400 mg/m² bolus~* 5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.~And targeted therapy in function of Kras:~* For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~* For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
62117668|NCT03978468|ACTIVE_COMPARATOR|Usual Care Group|Children will receive usual care.
62117669|NCT03978468|EXPERIMENTAL|Interagency Collaboration (ICollab Group)|Subjects of this arm will receive ICollab intervention in addition to usual care which consists of communication with Home Health Nurse (HHN) , Collaborative meetings, and communication with Primary Care Physician (PCP)
62117670|NCT05356572|ACTIVE_COMPARATOR|Investigational Skin Preparation Device versus Disposable Dermal Curette|
62117671|NCT05356572|ACTIVE_COMPARATOR|Investigational Skin Preparation Device versus Abrasive Pad for Skin Preparation|
62676952|NCT05253833|EXPERIMENTAL|Group 3|AR882 Dose 1 + Allopurinol for 24 weeks
62117672|NCT02590042|EXPERIMENTAL|ADSC-SVF-002|Cells will be administered at 1x10\^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10\^6 cells/mL of defect.
62117673|NCT04913779|ACTIVE_COMPARATOR|Anti-SARS-CoV-2|Administration of 10 ml of a concentrated equine hyperimmune serum solution with neutralizing activity of SARS-CoV-2 not less than1/5120, administered in slow intravenous infusion (10 ml diluted in100 ml of physiological solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
62117674|NCT04913779|PLACEBO_COMPARATOR|Placebo|Administration of 10 ml of a control-solution with no-neutralizing activity of SARS-CoV-2, administered in slow intravenous infusion (10ml diluted in 100 ml of physiological solution, administered over 50 to60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0when incorporated into the study -initial dose- and at 48 hours -second dose-).
62117675|NCT04439799|ACTIVE_COMPARATOR|Testosterone Cypionate Group|Participants in this group will receive the intramuscular Testosterone Cypionate intervention for four months
62117676|NCT04439799|ACTIVE_COMPARATOR|Natesto Group|Participants in this group will receive the intranasal testosterone (Natesto) intervention for four months.
62117677|NCT00190216|EXPERIMENTAL|A|
62117678|NCT02808585|EXPERIMENTAL|PB1046 Injection, 0.2 mg/kg|Four weekly doses of PB1046 Injection, 0.2 mg/kg
62117679|NCT02808585|EXPERIMENTAL|PB1046 Injection, 0.4 mg/kg|Four weekly doses of PB1046 Injection, 0.4 mg/kg
62676953|NCT06243926||Density gradient centrifugation (DGC)|DGC is a protocol to select sperm based on their density and isopycnic points. It is a conventional protocol commonly used in IVF laboratories.
62473524|NCT02649621|EXPERIMENTAL|Amniotic Membrane Extract Eye Drop recipient|patients with limbal stem cell Deficiency who receive amniotic membrane transplantation and amniotic membrane extract eye drop as eye drop.
62473525|NCT00312039|EXPERIMENTAL|A|
62676954|NCT06243926||In-Situ rheotaxis handmade microfluidics (isM)|The isM is a novel protocol to select sperm for ICSI based on microfluidics and sperm guidance responses to rheotaxis and thermotaxis. The isM protocol proved its efficacy and effectivity for ICSI in previous proof of concept and non-inferiority studies, respectively.
62676955|NCT05371028||Participants With SBS-IF|Participants with SBS-IF who as part of standard or routine clinical practice, must have received teduglutide (Revestive®) treatment and were dependent on parenteral support prior to teduglutide treatment initiation will be observed in this retrospective observational study for up to 48 months.
62676956|NCT05684614||Healthy individuals|Adult individuals recruited from the community through announcements at the university and social media
62676957|NCT06360341|EXPERIMENTAL|Intervention Group|The intervention group will receive Emergency Department Digital Pain Self-Management Intervention (EDPSI) + routine discharge care (RC).
62676958|NCT06360341|ACTIVE_COMPARATOR|Control Group|The control group will receive routine discharge care (RC).
62676959|NCT04367454|EXPERIMENTAL|Personal Protective Equipment|"Wearing: Tyvek pro-tech® C gear (Bonetti, Milano, Italy), a full visor SGE 400 mask (EN 136:98 CL3) connected to an A2B2E2K2-P3 R filter (Spasciani, Milano, Italy), and well-fitting, non-sterile Mapa Ultranitril 480 gloves (Mapa SAS, Colombes, France)."
62676960|NCT04367454|NO_INTERVENTION|NO-Personal Protective Equipment|only wearing well-fitting, medical examination nitrile gloves.
62473526|NCT00312039|ACTIVE_COMPARATOR|B|
62676961|NCT04765072|EXPERIMENTAL|Survivorship care|Participants in rural areas will receive a telehealth (providing health-related services through electronic communication technologies) survivorship care plan in combination with assistance from a patient navigator.
62676962|NCT04869124|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin tablet (10mg/tablet), orally, once daily for 12 weeks.
62676963|NCT04869124|PLACEBO_COMPARATOR|Placebo|Placebo tablet, matching Dapglilflozin, orally, once daily for 12 weeks.
62676964|NCT01663142||Patients who receive surgical resection for intestinal in CD|
62676965|NCT05810116|ACTIVE_COMPARATOR|Levagen+|PEA in capsule form - 1 capsule with water upon pain onset, followed by another capsule with water after 2 hours if pain persists.
62676966|NCT05810116|PLACEBO_COMPARATOR|Microcrystalline cellulose|PEA in capsule form - 1 capsule with water upon pain onset, followed by another capsule with water after 2 hours if pain persists.
62676967|NCT06424535|EXPERIMENTAL|intervention group|"1. Traditional Chinese medicine for internal or external use~2. Acupuncture or laser acupuncture treatment~3. Acupoint massage~4. Traditional Chinese Medicine Cake Acupoint Application:~5. Nursing and health education and guidance~6. Dietary hygiene education"
62676968|NCT06424535|ACTIVE_COMPARATOR|control group|Routine Western medicine burn and scald care prescribed by department doctor
62676969|NCT02944461|EXPERIMENTAL|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
62117680|NCT02808585|EXPERIMENTAL|PB1046 Injection, 0.6 mg/kg|Four weekly doses of PB1046 Injection, 0.6 mg/kg
62117681|NCT02808585|EXPERIMENTAL|PB1046 Injection, 1.2 mg/kg|Four weekly doses of PB1046 Injection, 1.2 mg/kg
62117682|NCT02808585|PLACEBO_COMPARATOR|Placebo Comparator|Four weekly doses of Placebo (0.9% NaCl) Injection
62117683|NCT05247749|EXPERIMENTAL|Convivo Imaging|The brain area that the operating surgeon plans to resect will be scanned using the CONVIVO device
62117684|NCT02886741|OTHER|Quality Improvement Campaign|"IHI designed and encouraged implementation of a five-component enhanced surgical site infection (SSI) prevention bundle with three relatively new evidence-based practices and two Surgical Care Improvement Program (SCIP) practices.~The campaign recruited state organizations to share information about evidence-based practices and publicize IHI activities and intervention materials (a How-to Guide, evidence reviews, a summary of the business case for interventions, and tip sheets for surgeons, other providers, patients and families). A project website and email listserv offered learning opportunities including webinar calls, faculty-led office hours, and town hall meetings."
62473527|NCT01417663|PLACEBO_COMPARATOR|Alagebrium|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
62473528|NCT01417663|OTHER|Exercise training|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
62676970|NCT00906750|EXPERIMENTAL|1|
62676971|NCT00906750|ACTIVE_COMPARATOR|2|
62676972|NCT05317455|PLACEBO_COMPARATOR|Placebo|oral solution with flavoring agent, no active drug.
62676973|NCT05317455|ACTIVE_COMPARATOR|Dichloroacetate|oral solution of dichloroacetate with flavoring agent
62676974|NCT04331171||Web-application users|questionnaire of comorbidity and symptomes completed by the user on his smartphone
62676975|NCT03920020|OTHER|the concentric isokinetic exercise group|the concentric isokinetic exercise group will perform quadriceps and hamstring concentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
62676976|NCT03920020|OTHER|the eccentric isokinetic exercise group|the eccentric isokinetic exercise group will perform quadriceps and hamstring eccentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
62473529|NCT00794547|EXPERIMENTAL|1|In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.
62676977|NCT03920020|OTHER|the control group|the control group will perform the standard exercise program predetermined by us consisting of stretching exercises and isometric strengthening (these exercises will be done at home, too) and the conventional physiotherapy program will be applied 3 times a week during 6 weeks.
62676978|NCT02532946|EXPERIMENTAL|Bedsider counseling group|Women exposed to: Bedsider.org counseling will be offered a computer or tablet at check-in to clinic. The outcome measure is measured at the patient's surgical abortion procedure appointment, or at medical abortion follow-up, which can range up to 10 days after enrollment
62676979|NCT02532946|NO_INTERVENTION|Routine counseling group|Women were given counseling in the providers' usual practice style. They were given a card with Bedsider.org's web address along with the counseling.
62676980|NCT01152385|EXPERIMENTAL|high|AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
62676981|NCT01152385|EXPERIMENTAL|Middle|AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
62676982|NCT01152385|EXPERIMENTAL|low|AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
62676983|NCT01152385|PLACEBO_COMPARATOR|4|
62676984|NCT03709095|ACTIVE_COMPARATOR|Moderate Intensity Continuous Training|Training was performed three times a week for five weeks. Each session began with a 2 minute warm up, and concluded with a 3 minute cool down. Following the warm-up, participants performed 20 minutes of arm cycling at a self-selected cadence at 45-65% of their peak power output. Total training duration was 25 mins.
62676985|NCT03709095|EXPERIMENTAL|Sprint Interval Training|"The SIT protocol was adopted from Gillen and colleagues (See Ref), and consisted of 3 x 20 second all-out efforts at ≥ 100% of an individuals peak power output. Each sprint was interspersed by 120 seconds of active recovery at 10% of an individuals peak power output. Total training duration was 10 mins."
62676986|NCT06063083|EXPERIMENTAL|"Tell Me More (Dime Mas) group"|"Participants will get the Tell Me More (Dime Mas) program within up to 6 months."
62676987|NCT06063083|EXPERIMENTAL|"Peer Ambassador Stories [Listen Miami (Oye Miami)] group"|"Participants will get the Peer Ambassador Stories \[Listen Miami (Oye Miami)\] within up to 6 months."
62676988|NCT06063083|ACTIVE_COMPARATOR|Standard Community Outreach group|Participants will receive standard community outreach within up to 6 months.
62676989|NCT05608668|EXPERIMENTAL|Active inspiratory muscle rehabilitation (IMR) group|"Each participant will be provided a PrO2™ device and trained on its use and its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal).~The research team will implement biofeedback signals at a specific inspiratory resistance to provide a precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP."
62676990|NCT05608668|ACTIVE_COMPARATOR|SHAM|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition.
62473530|NCT00794547|EXPERIMENTAL|2|In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.
61918606|NCT03063671|ACTIVE_COMPARATOR|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
62117685|NCT02886741|NO_INTERVENTION|Comparison|Matched state pairs received no campaign intervention and experienced usual care
62676991|NCT01775709|EXPERIMENTAL|PE tube with Duckbill Valve|PE tube with Duckbill Valve
62676992|NCT06567327|EXPERIMENTAL|Cohort 1|Participants will receive a single dose of atorvastatin and multiple oral doses of danuglipron with and without atorvastatin
62676993|NCT06567327|EXPERIMENTAL|Cohort 2|Participants will receive a single dose of rosuvastatin and multiple oral doses of danuglipron with and without rosuvastatin
62676994|NCT06567327|EXPERIMENTAL|Cohort 3|Participants will receive a single dose of atorvastatin and multiple oral doses of danuglipron with and without atorvastatin
62676995|NCT06567327|EXPERIMENTAL|Cohort 4|Participants will receive a single dose of rosuvastatin and multiple oral doses of danuglipron with and without rosuvastatin
62676996|NCT02681042|EXPERIMENTAL|SentreHeart Lariat|Left atrial appendage closure with SentreHeart Lariat device
62117686|NCT05843136|EXPERIMENTAL|Intervenction|"We used the SONOPULSE II device from the manufacturer IBRAMED, the electrodes measuring nine centimeters in length and five centimeters in width, from the manufacturer ARKTUS, of the adhesive plate type.~According to the IBRAMED manual (2011, p. 47), the application is produced by two medium frequency currents through four electrodes, quadripolar method. The current type is tetrapolar interferential and the stimulation mode is automatic vector; the carrier frequency of 4000HZ, AMF modulation frequency of 50HZ, and the sweep frequency of SWEEP will be 20HZ. SWEEP sweep modes with 6 seconds of rise from the modulation frequency to the threshold the sweep frequency upon reaching the threshold immediately decays over the next 6 seconds. The positioning of the four-leaf clover type electrodes and the intensity of the strong current, however comfortable, according to the patient's report."
62117687|NCT05843136|ACTIVE_COMPARATOR|Control Group 01|he treatment is based on non-invasive methods, highlighting manual therapy techniques, especially joint manipulation therapy. Manual therapy techniques are adjustments in lumbar rotation. Joint adjustment is a controlled lever-like force with direction, amplitude, and speed that is applied to specific, tissue-adjacent joints. While joint mobilization is manual therapy without the impulse, the joint remains within the physiological range of motion (SILVA et al., 2012). Therefore, a high-velocity, low-amplitude (HVA) manual maneuver was applied. The thrust (impulse) is carried out in the para-physiological environment, between the physiological and anatomical barriers. preload phase before the manipulation, thrust phase where the maneuver is performed with high speed and low amplitude and the resolution phase where the manipulation ends. The maneuver is detailed by the authors Bergmann \& Peterson (2010).
62117688|NCT05843136|ACTIVE_COMPARATOR|Control Group 02|The procedure adopted in this group was based on the guidelines and recommendations for non-pharmacological treatment of the Associação Médica Brasileira AMB (RACHED, R.D.V.A. et al, 2013) use of 1 MHZ Ultrasound with a power of 1W/cm2, continuous IBRAMED device for 10 minutes, Wave Diathermy Short for 15 minutes/day, HTM brand, TENS 50 HZ and 50 ms intensity phase according to the patient's threshold, 30 minutes, IBRAMED brand
62117689|NCT05469802|EXPERIMENTAL|PIZV 0.5 mL|Participants will receive PIZV 0.5 mL injection, IM, once on Day 1 (first dose) and Day 29 (second dose).
62117690|NCT05469802|PLACEBO_COMPARATOR|Placebo 0.5 mL|Participants will receive a placebo injection, IM, once on Day 1 (first dose) and Day 29 (second dose).
62117691|NCT02261467|EXPERIMENTAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
62117692|NCT02261467|PLACEBO_COMPARATOR|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
62305693|NCT04243044|EXPERIMENTAL|Intensity 2 (0.8x reflex threshold, dual-site, 30 minute duration)|Transcutaneous spinal stimulation will be applied continuously at two sites at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
62473531|NCT00395694|EXPERIMENTAL|lamictal|
62473532|NCT03181594|EXPERIMENTAL|Treatment with the ClariFix Device|Bilateral ablation of nasal tissue for treatment of chronic rhinitis
62676997|NCT00017186|EXPERIMENTAL|gemcitabine + epirubicin|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and epirubicin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.~Quality of life is assessed at baseline, prior to course 3, at 3 months, and then at 1 year.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
62676998|NCT01125644|EXPERIMENTAL|Single Arm|"Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam (patients with definite diagnosis), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology (patients with clinical diagnosis)."
62676999|NCT05150886||Patients at low risk of intubation|Patients with a ROX index of 4.88 and above measured at the 12th hour of hospitalization in the intensive care unit.
62677000|NCT05150886||Patients at hihg risk of intubation|Patients with a ROX index of less than 4.88, measured at the 12th hour of admission to the intensive care unit.
62677001|NCT04323566|EXPERIMENTAL|Treatment-first arm|Participants receive i.v. infusions with 500 mg Rituximab at 0 and 4 months, followed by placebo infusions (NaCl) at 8 and at 12 months, Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
61918607|NCT03063671|ACTIVE_COMPARATOR|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
61918608|NCT03695874||Phase 1: statistical purification|"400 Hereditary Haemorrhagic Telangiectasia patients:~* over 18 years~* able to read French~* with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~* who received the information and did not object to participate in the study"
61918609|NCT03695874||Phase 2: statistical validation|"200 Hereditary Haemorrhagic Telangiectasia patients:~* over 18 years~* able to read French~* with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~* who received the information and did not object to participate in the study"
61918610|NCT05847712|EXPERIMENTAL|Younger adults|Adults aged 18-30 years with no pre-existing health conditions
61918611|NCT05847712|EXPERIMENTAL|Older adults|Adults aged 50-69 with no pre-existing health conditions
61918612|NCT05089201|EXPERIMENTAL|Animal-assisted interaction (AAI)|Dogs and handlers will visit with patients for 20 minutes and discuss semi-scripted topics.
61918613|NCT05089201|ACTIVE_COMPARATOR|Conversational interaction|Handlers will have a 20 minute semi-scripted conversation with patients.
61918614|NCT05089201|NO_INTERVENTION|Treatment as usual|Patients will receive treatment as usual.
61918615|NCT05475782|ACTIVE_COMPARATOR|Spyglass group|lithotripsy through Spyglass and ERCP
61918616|NCT05475782|EXPERIMENTAL|ESWL group|Lithotripsy through ESWL and ERCP
61918617|NCT04903379|OTHER|Pain science education and self management strategies|The intervention will be educational in the form of the provision of contemporary pain science education and supportive advice from people with a history of persistent pain. The duration of the webinar will be 90 minutes.
62117693|NCT06360016|EXPERIMENTAL|Protocol-RP|"The sample size was determined using the G-Power 3.01 program (G\*Power 3.1 Manual, 2017), based on a Type I error of 0.05, a power of 0.95, and an effect size of f=0.55. According to these calculations, the sample size was set to a minimum of 10 individuals. Since the study was a pre-test post-test control group design and to prevent the reduction of internal validity due to any data loss, it was decided that each group (experimental and control) should have 20 participants.~The school that formed the experimental group had only one preschool class, comprising 21 students."
62117694|NCT06360016|NO_INTERVENTION|Control|The control group's school also had one preschool class, with 19 students making up the control group.
62117695|NCT03996083|EXPERIMENTAL|Multicomponent exercise intervention|The multicomponent exercise program consisted of strength and balance exercises performed on two non-consecutive days per week and lasting approximately an hour per session. Strength exercises were mainly focused on lower limb strengthening. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. As for balance exercises, the first weeks consisted of mainly less complex static balance exercises and progressed to more complex and dynamic balance exercises. These exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.
62305694|NCT04243044|EXPERIMENTAL|Intensity 3 (0.8x reflex threshold, burst, 30 minute duration)|Transcutaneous spinal stimulation will be applied in bursts at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
62677002|NCT04323566|EXPERIMENTAL|Placebo-first arm|Participants receive placebo (NaCl) i.v. infusions at 0 and 4 months, followed by 500-mg-Rituximab infusions at 8 and 12 months. Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
61918618|NCT02496507|EXPERIMENTAL|Intervention|Provision of a sit-stand workstation for use at work.
61918619|NCT02496507|NO_INTERVENTION|Control|Participants were asked to maintain their normal work practices and received no intervention. Participants were offered the opportunity to have a sit-stand workstation installed for 8 weeks after all data collection.
61918620|NCT03433729|EXPERIMENTAL|Patient Agenda Form|Patient Agenda form: Patients receive an agenda form to use before their consultation.
61918621|NCT03433729|NO_INTERVENTION|Usual care|Patients' appointment continues as usual.
61918622|NCT03513523|EXPERIMENTAL|Group 1: 1X dose of NRPT|250 mg of NR and 50 mg of PT
61918623|NCT03513523|EXPERIMENTAL|Group 2: 2X dose of NRPT|500 mg of NR and 100 mg of PT
62677003|NCT04359693||SARS-CoV2 group|Patients receiving invasive mechanical ventilation for more than 48h with SARS-CoV-2 infection
62677004|NCT04359693||Flu group|Patients receiving invasive mechanical ventilation for more than 48h with influenza infection
62117696|NCT03996083|EXPERIMENTAL|Walking intervention|Participants assigned to the walking group walked with the research staff two days per week; additionally, they walked partially supervised by LTNH staff, family members or caregivers the rest of the week. Daily walking goals were set follows: walking between 5 to 10 minutes on the first month, up to 15 minutes on the second, and finally 20 minutes per day on the third month. The final goal was to get as close as possible to the recommendations of engaging in 150 minutes of aerobic exercise per week from the World Health Organization (WHO). Participants were asked to walk as fast as they could and rest was allowed whenever needed. Walking goals were achieved in one or multiple sessions, depending on each participant´s capacities. Those participants that met the walking goals without any rest were encouraged to walk at a faster pace.
62117697|NCT05516004|EXPERIMENTAL|PXL 330|Participants will receive riboflavin 0.25% solution (Peschke TE), one drop every minute for 25 minutes to the eye, followed by UVA light 9mW/cm2 continuous mode for 10 minutes
62117698|NCT01435395|EXPERIMENTAL|Therapy|Therapy with temozolomide, bevacizumab and bortezomib
62473533|NCT03823924||Psoriatic arthritis|
62117699|NCT05727397|EXPERIMENTAL|RC28-E|RC28-E 2 mg will be initially injected 3 times at 4 week intervals, then each subject will be injected every 12 weeks unless there is disease activity. If disease activity is identified, the subject will be reassigned to receive injections every 8 weeks thereafter, up to study exit.
62117700|NCT05727397|ACTIVE_COMPARATOR|Aflibercept|Aflibercept 2 mg will be injected 3 times at 4 week intervals, followed by injections every 8 weeks.
62117701|NCT02245334|EXPERIMENTAL|Povidone-iodine|povidone iodine pill
62473534|NCT03823924||Healthy volunteers|
62473535|NCT03284476||ICU patients|Collection of medical data of Patients with peritonitis (nosocomial or community-acquired) or Patients with post-operative peritonitis
62473536|NCT05289674|EXPERIMENTAL|Interventional study with a pre-, post-test design|"After the subject are diagnosed with infection (tuberculosis/TB or urinary tract infection/ UTI), they will receive 400 kcal/day (96 g/day divided 4 times consumption) of high calorie formula prescribed by the researcher (A pediatrician) for 90 days consumption ( 8640 g). the subject will be monitored every 30 days for acceptance, tolerance, weight increment, length increment evaluation.~The blood are withdrawn at day 0 (before invention) and day 90 (after intervention) to measure the IL-6 and IL-10 levels"
62473537|NCT06161623|EXPERIMENTAL|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions
62473538|NCT06161623|NO_INTERVENTION|Control group|The participants in the control group also filled in the data collection tools without undergoing any intervention.
62473539|NCT06627725|EXPERIMENTAL|intervention|The voice message prepared by a patient's relative, decided by the patient's family members, was recorded using a voice recorder. Before the voice message was recorded, the researcher met with the patient's relative and gave preliminary information about the message content (Table 1) in order to prevent the message from negatively affecting the patient. In the study, care was taken to ensure that the messages to be played to the patient were between 3-5 minutes and simple terms that could be understood by individuals with low educational level were used. The patient's relatives recorded the messages they wanted to convey to the patient with a voice recorder. The voice message was played to the patient by the researcher using a music pillow in the CICU . After the condition of the patient in the intervention group stabilized, a pretest (IIF, HADS, VAS-A, FS-ICU) was administered to the patient's relative, then a voice recording was prepared and the patient's relative's voice recording
62473540|NCT06627725|NO_INTERVENTION|Control|After the condition of the patients in the control group stabilized, a pretest (IIF, HADS, VAS-A, FS-ICU) was administered to the relatives. Afterwards, the relatives were routinely informed about the patient's general condition, treatment process, and needs.
62473541|NCT04666116|NO_INTERVENTION|COVID-19 patients no dietary administration|Only medication agreed by the hospital committee
62473542|NCT04666116|EXPERIMENTAL|COVID-19 patients with dietary administration|Medication agreed by the hospital committee and nutritional supplement.
62473543|NCT06000449|EXPERIMENTAL|Center M|This intervention will include digital PD screening as well as four weekly one-hour group telehealth Mindfulness Cognitive Behavioral Therapy sessions and digitally delivered home practice materials for skill building between online group sessions.
62473544|NCT06000449|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|This arm will receive the current standard of care, which includes a paper-based PD screening and a PD educational handout.
62473545|NCT03133637||Ceftriaxone Arm|
62473546|NCT01692717|ACTIVE_COMPARATOR|Atorvastatin|Citalor (Atorvastatin) - Pfizer
62473547|NCT01692717|ACTIVE_COMPARATOR|Hydrochlorothiazide + Losartan|Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp \& Dohme
62473548|NCT01692717|EXPERIMENTAL|Atorvastatin + Hydrochlorothiazide + Losartan|Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas
62473549|NCT05601674|PLACEBO_COMPARATOR|Conventional group|Anesthesia induction will be performed with 2 mg/kg propofol, 1 µg/kg fentanyl and 0.6 mg/kg rocuronium as standard.After intubation, anesthesia will maintained with %40 O2 and sevoflurane at 2% volume. When the sevoflurane concentration reached 1 MAC, the fresh gas flow rate will be brought to 2 L/min. Inhalation anesthetics will be turned off 10 minutes before the end of the operation. The fresh gas flow will be increased to 6 l/min to be 100% O2. At the end of the surgery, the neuromuscular block will be antagonized with neostigmine-atropine. Sedation and agitation will be assessed immediately after extubation.
62677005|NCT04359693||No viral infection group|Patients receiving invasive mechanical ventilation for more than 48h with no viral infection at ICU admission
62677006|NCT01435980|NO_INTERVENTION|basal treatment|basal treatment
62117702|NCT02245334|NO_INTERVENTION|no intervention|no intervention
62117703|NCT02590952|EXPERIMENTAL|Epitinib|Epitinib is a capsule in the form of 5mg,20 mg, and 40 mg. Route: oral (daily)
62117704|NCT05552508|EXPERIMENTAL|Benralizumab|Participants will receive 3 doses of benralizumab having a strength of 30 mg subcutaneously once every 4 weeks (Week 0, Week 4, and Week 8).
62117705|NCT05777317|EXPERIMENTAL|10 kHz SCS plus CMM|Treatment with high frequency, 10 kHz spinal cord stimulation (SCS) in addition to conventional medical management (CMM)
62117706|NCT05777317|ACTIVE_COMPARATOR|CMM alone|Treatment with conventional medical management (CMM) alone
61918624|NCT03513523|PLACEBO_COMPARATOR|Group 3: Placebo|Placebo capsules contain microcrystalline cellulose, silicon dioxide and magnesium stearate
62117707|NCT03505619|EXPERIMENTAL|ASSIST 1.0|A ten-week intervention program using a person-centred approach to support the older person to set up goals to perform daily activities that he/she wants or needs to do. The activity goals will target improvements in quality of life, physical health, mental well-being, and conditions for social community. The focus will be on supporting the older person's activities in everyday life that are considered meaningful for the individual. During the intervention, a specially designed application will send reminders and feedback related to the older adults' activity goals of doing their prioritized everyday activities both to the older adults and to the home care providers via mobile phones, tablet etc. The home care providers will participate in coaching sessions supporting the intervention held by the team of researchers.
62305695|NCT01259739|EXPERIMENTAL|Flavanol rich cocoa|(596 mg), dissolved in water, twice daily intervention
62305696|NCT01259739|EXPERIMENTAL|flavanol poor cocoa drink|( 13mg) dissolved in water, twice daily intervention
62305697|NCT05399693||Patients with Platelet Transfusion Refractoriness|
62305698|NCT05399693||Patients without Platelet Transfusion Refractoriness|
62473550|NCT05601674|ACTIVE_COMPARATOR|Low Flow Group|anesthesia induction will be performed with 2 mg/kg propofol, 1 µg/kg fentanyl and 0.6 mg/kg rocuronium as standard.After intubation, anesthesia will maintained with %40 O2 and sevoflurane at 2% volume. When the sevoflurane concentration reached 1 MAC, the fresh gas flow rate will be brought to 0.5 L/min. Inhalation anesthetics will be turned off 10 minutes before the end of the operation. The fresh gas flow will be increased to 6 l/min to be 100% O2. At the end of the surgery, the neuromuscular block will be antagonized with neostigmine-atropine. Sedation and agitation will be assessed immediately after extubation.
62473551|NCT00082147|EXPERIMENTAL|Biopsy|Biopsy
62473552|NCT06560125||WOUNDCHEK Bacterial Status positive|Wounds testing positive for bacterial protease activity
62473553|NCT06560125||WOUNDCHEK Bacterial Status negative|Wounds testing negative for bacterial protease activity
62117708|NCT03505619|NO_INTERVENTION|Ordinary home care services|The home care providers in the control group (CG) will provide services as usual to older adults participating in the control group. They will however, identify potential older persons to participate in the control group according to the same procedure and criteria as the intervention group.
62117709|NCT03573258|EXPERIMENTAL|Fiber|"300 ml of orange juice plus Intervention~* 6 g of oat beta glucan = FIBER (study A) or~* 25 g inulin/FOS = FIBER (study B)"
62305699|NCT02054832||Glycosade|A prospective cohort design will be used to assess the impact on sleep and continue to monitor safety of Glycosade.
62305700|NCT04677270|EXPERIMENTAL|Traditional interface|Digital problem solving tool with a simple textbased graphical interface
62305701|NCT04677270|EXPERIMENTAL|Advanced interface|Digital problem solving tool with an advanced graphical interface and automatic functions
62305702|NCT00986778|ACTIVE_COMPARATOR|Lamivudine plus Adefovir|
62473554|NCT02851771|EXPERIMENTAL|Pneumonia Patients|Patient admitted at hospital with pneumonia, who need a microbiological diagnosis
62473555|NCT06559722|EXPERIMENTAL|Insulin Degludec/liraglutide injection|Subcutaneously (s.c., under the skin) administration once daily in combination with metformin. Dose was individually adjusted.
62473556|NCT06559722|ACTIVE_COMPARATOR|XULTOPHY®|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
62473557|NCT03378492|ACTIVE_COMPARATOR|Standard Epidural|Participants in this group will have epidurals placed using standard practice.
62473558|NCT03378492|EXPERIMENTAL|Ultrasound Guided Epidural|Participants in this group will have epidurals placed using standard practice with the assistance of ultrasound.
62473559|NCT01010555|ACTIVE_COMPARATOR|lotrafilcon B|Lotrafilcon B contact lens randomly assigned to one eye, with balafilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
61918625|NCT04157556|EXPERIMENTAL|Group of athletes|Age: 18-35 Gender: Male Basketball, volleyball, handball players who have been training regularly for at least last 3 months.
61918626|NCT04157556|EXPERIMENTAL|Group of sedentary people|Age: 18-35 Gender: Male Individuals with similar physical characteristics to the group of athletes and who have not exercise regularly for at least last 3 months.
61919964|NCT03790631||piperacillin TDM|Adult patients receiving piperacillin (with or without tazobactam) for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
62117710|NCT03573258|PLACEBO_COMPARATOR|Placebo|"300 ml of orange juice plus Placebo:~* 13.5 g maltodextrin = PLACEBO (study A) or~* 15.5 g maltodextrin = PLACEBO (study B)"
62305703|NCT00986778|ACTIVE_COMPARATOR|Entecavir|
62305704|NCT00986778|EXPERIMENTAL|Entecavir plus Adefovir|
62305705|NCT04332419|EXPERIMENTAL|PET/CT & PET/MR|One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
62305706|NCT05937711|EXPERIMENTAL|PTNS+Duloxetine|Posterior tibial nerve stimulation (PTNS), twice weekly, 3-4 days apart + Duloxetine 30 mg 1X1 p.o PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes
62305707|NCT05937711|ACTIVE_COMPARATOR|Duloxetine|Duloxetine 30 mg 1X1 p.o
62305708|NCT05450068|ACTIVE_COMPARATOR|Group A-Combined Group|Participants in this group will receive both Mulligan's mobilization with movement and Spencer's muscle energy technique along with conventional therapy and home exercise plan. 3 sessions per week will be given for 4 weeks.
62677007|NCT01435980|EXPERIMENTAL|Gastric Bypass|basal treatment and Gastric Bypass
62677008|NCT01435980|EXPERIMENTAL|Exenatide|basal treatment and Exenatide
62305709|NCT05450068|ACTIVE_COMPARATOR|Group B-Mulligan Group|Participants in this group will receive Mulligan's mobilization with movement along with conventional therapy and home exercise plan. 3 sessions per week will be given for 4 weeks.
62305710|NCT05450068|ACTIVE_COMPARATOR|Group C-Spencer Group|Participants in this group will receive Spencer's muscle energy technique along with conventional therapy and home exercise plan. 3 sessions per week will be given for 4 weeks.
62305711|NCT05450068|ACTIVE_COMPARATOR|Group D-Conventional Group|Participants in this group will receive conventional therapy alone in hospital with home exercise plan. 3 sessions per week will be given for 4 weeks.
62305712|NCT00515125|OTHER|Dietary Advice|Dietary Advice
62305713|NCT00515125|OTHER|Oral Nutritional Supplements|Oral Nutritional Supplements
62305714|NCT03913910||Lipogems|Lipogems injection in the internal orifice, mucosal, submucosal and muscular layer, in the fistula tract and external orifice.
62473560|NCT01010555|ACTIVE_COMPARATOR|balafilcon A|Balafilcon A contact lens randomly assigned to one eye, with lotrafilcon B contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
62305715|NCT05109390|EXPERIMENTAL|Part 1: Danicopan plus Cyclosporine|"Participants (N=14) received danicopan and cyclosporine in a fixed sequence over 2 periods:~Treatment A (Period 1): 300 milligrams (mg) cyclosporine administered on Day 1.~Treatment B (Period 2): 200 mg danicopan administered 3 times daily (TID) on Days 1-7 with 300 mg cyclosporine coadministered on Day 5.~There was a washout period of 3 days between the dose of cyclosporine in Period 1 and the first dose of danicopan in Period 2."
61919965|NCT03790631||flucloxacillin TDM|Adult patients receiving flucloxacillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
62305716|NCT05109390|EXPERIMENTAL|Part 2: Danicopan plus Tacrolimus|"Participants (N=28) received danicopan and tacrolimus in a fixed sequence over 2 periods:~Treatment C (Period 1): 2 mg tacrolimus administered on Day 1.~Treatment D (Period 2): 200 mg danicopan administered TID on Days 1-10 with 2 mg tacrolimus coadministered on Day 5.~There was a washout period of 7 days between the dose of tacrolimus in Period 1 and the first dose of danicopan in Period 2."
61918627|NCT03518671|EXPERIMENTAL|CBT (face to face)|"Self-limited cognitive behavioral therapy (CBT) delivered via 6 weekly sessions, face-face~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score \> 5 will undergo time-limited CBT consisting of 6 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last \~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT."
61919966|NCT03790631||amoxicillin TDM|Adult patients receiving amoxicillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
61919967|NCT03790631||ceftazidime TDM|Adult patients receiving ceftazidime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
61919968|NCT03790631||cefepime TDM|Adult patients receiving cefepime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
62117711|NCT00036933|EXPERIMENTAL|vaccine|"Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50.~Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression."
62117712|NCT03745001|EXPERIMENTAL|Single dose study part|there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
62117713|NCT03745001|EXPERIMENTAL|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
62473561|NCT01010555|ACTIVE_COMPARATOR|senofilcon A|Senofilcon A contact lens randomly assigned to one eye, with enfilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
62473562|NCT01010555|ACTIVE_COMPARATOR|enfilcon A|Enfilcon A contact lens randomly assigned to one eye, with senofilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
62473563|NCT06515054|EXPERIMENTAL|isometric exercise|wall squat exercise. Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
62677009|NCT00225758|EXPERIMENTAL|1|Subjects will continue on their prior endocrine therapy with the addition of lapatinib at 1500 mg once daily for 26 weeks or longer.
62677010|NCT05813834|ACTIVE_COMPARATOR|genicular nerve block group|patients will receive genicular nerves block
62677011|NCT05813834|NO_INTERVENTION|control group|patients will not receive genicular nerves block
62677012|NCT05187624|EXPERIMENTAL|Part I: Dose Escalation|Participants with newly diagnosed GBM will receive RO7428731, intravenously (IV), up to one year or until disease progression, withdrawal of consent, unacceptable toxicity, or death, whichever occurs first.
62677013|NCT05187624|EXPERIMENTAL|Part II: Dose-Expansion(s)|Participants with newly diagnosed GBM will receive RO7428731, IV, in maximum of two dose expansion cohorts at a dose(s) not exceeding the maximum tolerated dose (MTD) established in Part I.
62473564|NCT06515054|ACTIVE_COMPARATOR|passive stretching|A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
62677014|NCT05187624|EXPERIMENTAL|Part III: Safety Run-in|Participants with recurrent GBM will receive RO7428731, IV in a dosing schedule determined in Part I. At the end of the Safety Run-in period, a decision will be made as to whether to open the Dose-Expansion Cohort Part IVA or open a second Safety Run-in Cohort at a lower dose.
61918628|NCT03518671|EXPERIMENTAL|CBT (telemedicine)|"Self-limited cognitive behavioral therapy (CBT) delivered via 6 weekly sessions, via tablet-based telemedicine platform~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score \> 5 will undergo time-limited CBT consisting of 6 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last \~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT. To overcome the expected travel distance-related barrier to receipt of CBT, patients will receive the intervention via tablet-based telemedicine delivery platform"
62117714|NCT02277288|NO_INTERVENTION|Emptied bladder arm|No instillation of fluid into bladder.
62677015|NCT05187624|EXPERIMENTAL|Part IV A: Dose-Expansions Cohort|Participants with recurrent GBM will receive RO7428731, IV at specified doses and dosing schedules.
62677016|NCT06501235|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT)|This group will receive a 9-week CBT intervention.
62677017|NCT06501235|EXPERIMENTAL|Virtue-Based Intervention (VBI)|This group will receive a 9-week VBI intervention.
62117715|NCT02277288|EXPERIMENTAL|Filled bladder arm|Instilled bladder with fluid.
61918629|NCT03355664|ACTIVE_COMPARATOR|ACT|Artemether-lumefantrine for 3 days plus primaquine at hour 24
62117716|NCT00102063|ACTIVE_COMPARATOR|Aripiprazole 10 mg/day Group|Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
62117717|NCT00102063|ACTIVE_COMPARATOR|Aripiprazole 30 mg/day Group|Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
62117718|NCT00102063|PLACEBO_COMPARATOR|Placebo Group|Participants were given a single pill administered once daily
62117719|NCT05394779|EXPERIMENTAL|DTXO APP|"Patients randomized to Group A (experimental group) will be administered the Mediterranean based dietary program by means of App DTXO. The dietary program will be administered through the DTXO application. Each patient will select the assigned daily menu or the proposed alternatives; The dietary program is personalized according to the patients caloric intake needs and to their nutritional restrictions.~Patients randomized to Group A (experimental group) will be administered the Physical activity program by means of App DTXO. The activity program will be administered through the DTXO application based on the individual's background fitness level.~Patients randomized to Group A (experimental group) will be invited to follow a psycho-behavioral program to increase awareness of the behaviors and habits related to obesity, consisting of multimedia and educational content, self-assessment and dynamic exercises."
62677018|NCT04396860|ACTIVE_COMPARATOR|Arm I (radiation therapy, temozolomide)|Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial.
62677019|NCT04396860|EXPERIMENTAL|Arm II (radiation therapy, ipilimumab, nivolumab)|Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
62677020|NCT03416933|EXPERIMENTAL|Biological|
62677021|NCT03760068|ACTIVE_COMPARATOR|MYL-1601D Product (100 U/mL)|
62677022|NCT03760068|ACTIVE_COMPARATOR|FlexPen NovoLog® (100 U/mL)|
62677023|NCT04031768|OTHER|0-2-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~0 minutes 2 minutes 5 minutes 5 minutes"
61918630|NCT03355664|EXPERIMENTAL|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24
61918631|NCT04545203|EXPERIMENTAL|Slow-Stroke Back Massage Group|
61918632|NCT04545203|NO_INTERVENTION|Control group|
61918633|NCT01680510|EXPERIMENTAL|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|50 patients will receive first the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder and after 24 weeks of washout period will receive capsule containing placebo (Starch).
62117720|NCT05394779|PLACEBO_COMPARATOR|PLACEBO APP-Control group|"Patients randomized in Group B (control group) will be delivered a dietary program, according to the current standard of care and will be printed on paper with the information on the Mediterranean diet and general educational content related to food. The control arm will also be equipped with a placebo App to ensure the patient's blindness to treatment allocation and there will be asked to the patient to complete weekly the Diet Adherence questionnaire.~Patients randomized in Group B (control group) will be advised to perform regular physical activity and provided with educational material and some tips on physical activity; no formal plan will be provided, as currently done in standard clinical practice.~Patients randomized in Group B (control group) will receive printed educational material with generic content and advice for self-help support and followed as per standard clinical practice. The placebo App will be used as a data entry tool for questionnaires."
62117721|NCT01063036|EXPERIMENTAL|Entecavir + Tenofovir|
62677024|NCT04031768|OTHER|0-5-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~0 minutes 5 minutes 2 minutes 5 minutes"
62677025|NCT04031768|OTHER|2-0-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~2 minutes 0 minutes 5 minutes 5 minutes"
62677026|NCT04031768|OTHER|5-0-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~5 minutes 0 minutes 2 minutes 5 minutes"
62677027|NCT04031768|OTHER|2-5-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~2 minutes 5 minutes 0 minutes 5 minutes"
62677028|NCT04031768|OTHER|5-2-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~5 minutes 2 minutes 0 minutes 5 minutes"
61918634|NCT01680510|PLACEBO_COMPARATOR|Placebo (Starch)|The other 50 Patients will receive first the placebo (Starch) capsules and after 24 weeks of washout period will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
62473565|NCT06248827||Lumbar Spine MRI exams|"An information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not.~1. MRI Data from exams (DICOM format)~   * Sagittal T1~  * Sagittal T2~  * Sagittal DIXON~  * Sagittal STIR~  * Sagittal FLAIR~  * Axial T2~2. Clinical Data from questionnaires~   * biometric data (height, weight),~  * age~  * gender,~  * smoking status,~  * comorbidities,~  * basic clinical examination,~  * medical history."
61918635|NCT03239691|EXPERIMENTAL|ACT-709478 - Single dose administration|Up to 16 subjects with photosensitive epilepsy will be studied across a maximum of 4 dose levels. Each dose level will initially be investigated in cohorts of 4 subjects undergoing a fixed sequence of study treatment administration in fed condition
61918636|NCT03239691|PLACEBO_COMPARATOR|Placebo|Placebo will be administered on two study days
62117722|NCT03618134|EXPERIMENTAL|Cohort I (SBRT, durvalumab, TORS, neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62473566|NCT05703022|EXPERIMENTAL|Early exercise training|Supervised aerobic interval training (uphill treadmill walking or cycling on an exercise bike 4x4 min at 65-85% of peak heart rate) 3 times weekly.
62117723|NCT03618134|EXPERIMENTAL|Cohort II (SBRT, durvalumab,tremelimumab,TORS,neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive tremelimumab IV and durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62473567|NCT00039286|EXPERIMENTAL|Positron Emission Tomography|Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
62473568|NCT00787254|EXPERIMENTAL|Lansoprazole 15 mg QD|
62473569|NCT00787254|ACTIVE_COMPARATOR|Gefarnate 50 mg BID|
62473570|NCT04630431|EXPERIMENTAL|Part I (questionnaire, medical record review)|Patients complete a questionnaire about their preferences, understanding, and attitudes regarding clinical trials. Patients also have their medical records reviewed.
62473571|NCT04630431|ACTIVE_COMPARATOR|Part II: Arm A (clinical trial education, standard of care)|Patients undergo clinical trial education via a video and educational booklet and then standard of care follow-up on study.
61918637|NCT04211233|ACTIVE_COMPARATOR|Invasive subdural arm|Implantation of invasive subdural electrode in patients after surgical treatment of acute subdural hematoma
61918638|NCT04211233|SHAM_COMPARATOR|Standard treatment arm|Patients with acute subdural hematoma who underwent surgical Treatment and receive Standard medical treatment
62305717|NCT05109390|EXPERIMENTAL|Part 3: Danicopan plus Antacids and Omeprazole|"Participants (N=30) received danicopan, calcium carbonate, aluminum/magnesium hydroxide/simethicone, and omeprazole in fixed sequences over 2 periods:~Treatment E1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment E2 (Period 1): 200 mg danicopan coadministered with 1 gram calcium carbonate on Day 5.~Treatment F1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment F2 (Period 1): 200 mg danicopan coadministered with 200 mg aluminum hydroxide/200 magnesium hydroxide/25 mg simethicone on Day 5.~Note: Participants were randomized in a 1:1 ratio to receive either Treatment E2 or F2 coadministered with danicopan on Day 5.~Treatment G1 (Period 2): 40 mg omeprazole administered once daily (QD) on Days 1-4.~Treatment G2 (Period 2): 40 mg omeprazole administered QD with 200 mg danicopan administered orally TID on Days 5-8.~There was a washout period of 2 days between the last dose of danicopan in Period 1 and the first dose of omeprazole in Period 2."
61918639|NCT00736177|ACTIVE_COMPARATOR|Control|Patients in the control group will undergo conventional IVF cycles with fresh blastocyst transfer.
62473572|NCT04630431|EXPERIMENTAL|Part II: Arm B (clinical trial education, navigation)|Patients undergo clinical trial education via a video and educational booklet and then undergo patient navigation with active clinical trial matching and receive clinical trial information through the electronic medical record portal on study.
62473573|NCT00652977|ACTIVE_COMPARATOR|I|The delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head.
62473574|NCT00652977|OTHER|II|Standard care at delivery: Manual support of the perineum
62473575|NCT00834405|EXPERIMENTAL|Leflunomide|Leflunomide 20 mg Tablet
62473576|NCT00834405|ACTIVE_COMPARATOR|Arava®|Arava® 20 mg Tablet
62677029|NCT03159442|EXPERIMENTAL|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
61918640|NCT00736177|EXPERIMENTAL|Test group|Patients in the Test group will have their embryos cryopreserved for transfer in a second cycle.
61918641|NCT04985643||Participants With MM|Participants diagnosed with MM (complete response \[CR\], very good partial response \[VGPR\] and partial response \[PR\]) and who have received one prior first line treatment within 3 months preceding the enrollment, will be observed retrospectively and medical data will be monitored and collected prospectively every 3 months until the second biochemical and symptomatic relapse is identified.
61918642|NCT01768247|EXPERIMENTAL|HCG priming|Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
61918643|NCT05506137|EXPERIMENTAL|Treatment|
61918644|NCT05506137|PLACEBO_COMPARATOR|Placebo|
61918645|NCT05321056|EXPERIMENTAL|Intervention group: Mask on model face|"The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
61918646|NCT05321056|NO_INTERVENTION|Control group: No mask on model face|"No mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
62473577|NCT04818892||IBD and Non-Immunosuppressive Group|Clinical diagnosis of IBD, non-systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
62473578|NCT04818892||IBD and Immunosuppressive Group|Clinical diagnosis of IBD, treated with systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
61918647|NCT02094404||Children at the ED<18yr|
61918648|NCT00249288|EXPERIMENTAL|Folate|Participants will receive a 2 mg/ day dose of folate, for 12 weeks
61918649|NCT00249288|PLACEBO_COMPARATOR|Placebo|Participants will receive a 2 mg/ day dose of placebo, for 12 weeks
61918650|NCT03442400|EXPERIMENTAL|FFR/iFR arm|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
61918651|NCT01380938|NO_INTERVENTION|Arm C. Standard duration|"Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment."
61918652|NCT01380938|EXPERIMENTAL|Arm A|"Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight \< 75 kg or 1200 mg/day for those with a body weight \> 75 kg.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)"
61919969|NCT03872414|EXPERIMENTAL|Healthy Younger Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
61919970|NCT03872414|EXPERIMENTAL|Healthy Older Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
62473579|NCT04613258|ACTIVE_COMPARATOR|SCAR Porridge Group|There were 22 subjects in the intervention group (I) who received 50 g of SCAR porridge once per day, along with dietary counseling.
62117724|NCT00687622|EXPERIMENTAL|GSK1120212|Part 1 will identify the maximum tolerated dose using a dose-escalation procedure. Part 2 will explore further the safety, tolerability, and clinical activity of GSK1120212 in subjects with pancreatic, melanoma, non-small cell lung, and KRAS or BRAF mutation-positive colorectal cancer. Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic markers in tumor tissue
62305718|NCT05446246||Superobese patients|Patients with preoperative BMI \> 50
62305719|NCT05446246||Morbidobese patients|Patients with preoperative BMI \> 35 and \<50
62473580|NCT04613258|ACTIVE_COMPARATOR|Counseling Group|21 subjects in the control group (C) who only received dietary counseling
62473581|NCT05358405|OTHER|Müller maneuver|Open Label with intervention Müller maneuver
62473582|NCT03429712|EXPERIMENTAL|Dose Split CT|
62473583|NCT05180877||Intermittent& mild persistent asthma|According to asthma severity assessment, this group included asthmatic pregnant females patients with intermittent asthma and mild persistent asthma
62117725|NCT02350842|EXPERIMENTAL|Triple-site biventricular pacing|Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
62473584|NCT05180877||Moderate& severe persistent asthma|According to asthma severity assessment, this group included asthmatic pregnant females patients with Moderate\& severe persistent asthma
62473585|NCT03191474|NO_INTERVENTION|Standard of Care Arm|Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.
62473586|NCT03191474|EXPERIMENTAL|T-POWr Intervention Arm|Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.
62117726|NCT02350842|ACTIVE_COMPARATOR|Standard biventricular pacing|Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
62117727|NCT05056753|ACTIVE_COMPARATOR|Investigational Device|The HWBV chair consists of a custom-made saddle-seat type of chair. The vibration actuators are embedded into the underside design of the chair. The base contains two vibrators, one for each side of the chair, and the chair is split in half vertically so that the vibrating actuators are able to send a harmonic vibration at alternating frequencies, upwards through each side of the chair. The HWBV system is considered a non-significant and non-substantial risk device.
62117728|NCT05056753|SHAM_COMPARATOR|Control Device|The Control device is identical in construction to the Active device. The vibration mode, however, is a significantly different setting than that used by the Active version, so that the mechanoreceptors in the cervical spine are not effectively stimulated.
62117729|NCT05003570|EXPERIMENTAL|Remifentanil|Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml) + 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase).
62117730|NCT05003570|ACTIVE_COMPARATOR|Fentanyl|Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase).
62117731|NCT03930823|OTHER|Interview|One to one interviews with older people from Turkish origin in Belgium
62117732|NCT05150613|OTHER|Group A|No Mask
62117733|NCT05150613|OTHER|Group B|Surgical Mask
62117734|NCT05150613|OTHER|Group C|N95 Mask
62117735|NCT05949749||Case|
62117736|NCT05949749||Control|
62117737|NCT06258031|EXPERIMENTAL|All participants|Up to 10mg of psilocybin on two separate dosing days (separated by 4 weeks)
62117738|NCT01385436||HPV HSIL cervical carcinoma|
62117739|NCT03477149|EXPERIMENTAL|Embolization with Easyx|Patients requiring embolization of varicocele, portal vein before ablation, type 2 endoleak, angiomyolipoma or active bleeding will be treated with the liquid embolic agent Easyx during index procedure.
62117740|NCT04139538|EXPERIMENTAL|Invisalign treatment|Aligner patients will be treated with Invisalign® aligners to correct malocclusion
62117741|NCT04139538|ACTIVE_COMPARATOR|selfligating bracket treatment|Multibracket patients will be treated with self ligating orthodontic brackets
62473587|NCT06448104|EXPERIMENTAL|Dry needling and immersive virtual reality|"Participants assigned to Dry needling and immersive virtual reality group will carry out a first session in which the dry needling technique will be performed together with immersive virtual reality and the results will be recorded. Likewise, after two weeks, these participants will repeat the dry needling session (with virtual reality) and evaluation, adding a previous exercise session."
62473588|NCT06448104|ACTIVE_COMPARATOR|Standard dry needling|"Participants assigned to Standard dry needling group will undergo a first session in which the dry needling technique will be performed and the results will be recorded. After two weeks, these participants will repeat the dry needling and evaluation session, in this case adding a previous exercise session."
62473589|NCT03818841|EXPERIMENTAL|High-flow nasal cannula group|Patients randomised in this group will receive oxygen therapy via a high-flow nasal cannula device with a 60 L/min flow and a 100% fraction of inspired oxygen
62117742|NCT02749578|OTHER|Treatment|Atorvastatin followed by MGL-3196 daily followed by separate co-administration of atorvastatin
62117743|NCT02205307|EXPERIMENTAL|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
62117744|NCT02205307|NO_INTERVENTION|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
62117745|NCT05799963|EXPERIMENTAL|BioMatrix Alpha|All patients will receive the BioMatrix Alpha as per treatment.
62117746|NCT02562352|EXPERIMENTAL|TAPER program|"The intervention arm is comprised of:~1. Identification of medications that are appropriate for discontinuation/dose reduction.~2. Linked pharmacist/family physician consultations with patient to discuss medication discontinuation/dose reduction."
62117747|NCT02562352|NO_INTERVENTION|Control|Standard of Care as wait list control
62117748|NCT03615924|EXPERIMENTAL|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day."
62677030|NCT03159442|EXPERIMENTAL|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
62117749|NCT03615924|PLACEBO_COMPARATOR|Placebo|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
62117750|NCT05715151|EXPERIMENTAL|CQI intervention|The proposed CQI cohort consists of three activities carried out iteratively until the improvement objectives are achieved.
62117751|NCT05715151|ACTIVE_COMPARATOR|Audit and feedback|Clinics in the control group will receive feedback on six key AA indicators, patients reported experience about access and selected AA processes.
62305720|NCT04150458|EXPERIMENTAL|Fluorocholine PET/CT|The sole study-specific procedure is a single 18F-fluorocholine positron emission tomography / computed tomography (PET/CT). Subjects will receive 9 mCi 18F-fluorocholine IV, 5 to 120 minutes prior to PET/CT. 18F-fluorocholine PET/CT studies will be performed on hybrid PET/CT scanners which combine a dedicated, full-ring PET scanner with a multi-slice spiral CT scanner.
62305721|NCT01701700|EXPERIMENTAL|portable electronic magnifier|Use of a prescribed electronic magnifier plus existing optical aids for a period of 2 months
62305722|NCT01701700|ACTIVE_COMPARATOR|optical aids|Use of existing optical aids for 2 months
62305723|NCT03623750|EXPERIMENTAL|EGFR-TK Inhibitor plus EGF-PTI|Elegile patients will receive a single pre-treatment low dose of intravenous cyclophosphamide 200mg/m2 before experimental treatment starts. Daily oral therapy with afatinib according to the SmPC of the product in nominal treatment cycles of 21 days followed by immunisation with EGF-PTI.
62305724|NCT05012566|EXPERIMENTAL|Hyaluronic Acid filler and Botulinum Toxin group|"1. Hyaluronic Acid filler:~   * Juvederm Volbella: it will be used in the softer soft tissue, beacuse its reology is the softest~  * Juvederm Volift: it will be used in malar area, because its reology is intermediate between the three products~  * Juvederm Voluma: il will be used unstructured area bacause it has the best rheologic characteristics in the reintegration of loss of tissue.~   The differents products are going to use in different areas, depending on the area of the paralysis.~2. Botulinum Toxin:~   * Vistabex (50U/vial): it is going to be used in the controlateral area of the paralysed face, in order to relax muscle hyper-tonicity.~Dosage and administration steps will be selected according to the clinical situation."
62305725|NCT05012566|NO_INTERVENTION|Control group|The control group will undergo at the same examinations of the treated group but it will not be subjected to any treatment.
62305726|NCT02117089|EXPERIMENTAL|Device-assisted rehabilitation|
62305727|NCT03910699|ACTIVE_COMPARATOR|Two-row anastomosis|Colorectal anastomosis is created with a two-row circular surgical stapler
61918653|NCT01380938|EXPERIMENTAL|Arm B|"Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)"
61918654|NCT01261468|ACTIVE_COMPARATOR|Active SCS|
61918655|NCT01261468|SHAM_COMPARATOR|Inactive SCS|
62305728|NCT03910699|EXPERIMENTAL|Three-row anastomosis|Colorectal anastomosis is created with a three-row circular surgical stapler
62305729|NCT01293435||1|
62473590|NCT03818841|OTHER|Non-rebreathing oxygen mask group|In this group patients will be treated with standard oxygen therapy delivered through a non-rebreathing face mask with a 15 L/min flow
61918656|NCT00539097|EXPERIMENTAL|A, treated|treated with Juven po supplement x 3 weeks postop
61918657|NCT00539097|NO_INTERVENTION|B, control|Usual nutrition therapy received postop
61918658|NCT03225157||1|adult patients with head and neck squamous cell carcinoma of the upper aerodigestive tract who will undergo cisplatin chemotherapy with concurrent radiation.
61918659|NCT02048579|NO_INTERVENTION|Treatment as Usual|
62117752|NCT01482013|EXPERIMENTAL|HPP854|Oral HPP854 once a day for 28 days.
62117753|NCT01482013|PLACEBO_COMPARATOR|Placebo|Oral, placebo once a day for 28 days.
62117754|NCT05400707||patients admitted to emergency ward of the University Hospital Basel.|
62305730|NCT05957562|ACTIVE_COMPARATOR|EA/TOF primary repair with Azygos vein preservation|primary esophagoesophagostomy with azygous vein preservation technique and will be done for 32 neonates with EA/TOF amenable for primary repair
62677031|NCT03159442|EXPERIMENTAL|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
61918660|NCT02048579|EXPERIMENTAL|Behavior Therap + Motivational Interviewing|Supporting Teens' Academic Needs Daily Therapy program delivered to parents and teens
62305731|NCT05957562|ACTIVE_COMPARATOR|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary esophagoesophagostomy with azygous vein disconnection ordinary technique and will be done for 32 neonates with EA/TOF suitable for primary repair
62305732|NCT03335124|EXPERIMENTAL|Active substances|"Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.~Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.~Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge."
62305733|NCT03335124|PLACEBO_COMPARATOR|Control|Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.
62305734|NCT00718133|EXPERIMENTAL|1|Children at school age from Haifa bay region
62677032|NCT04057638|EXPERIMENTAL|Treatment group|There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
62677033|NCT06356597|EXPERIMENTAL|Tislelizumab with Fruquintinib, Metronidazole|
62677034|NCT04274465||Control|Negative high risk (HR)-HPV, cytology co-test
62677035|NCT04274465||CIN 1|Biopsy with low grade dysplasia
62677036|NCT04274465||CIN 2-3|Biopsy with high grade dysplasia
62677037|NCT05694637|ACTIVE_COMPARATOR|SBIRT|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
62677038|NCT05694637|NO_INTERVENTION|Standard of Care|Trained LHWs will provide a brief motivation counseling and a brochure about smoking cessation.
62677039|NCT05432960|EXPERIMENTAL|RPH-104|The investigational product RPH-104 as SC injections at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W).
62677040|NCT05432960|PLACEBO_COMPARATOR|Placebo|placebo SC Q2W (equivalent to investigational product volume)
62677041|NCT04401631||Interventions|"* A minimum of 20 subjects with targeted levels of total IgE are needed to participate in the Operator-to-Operator whole blood study.~* A minimum of 20 subjects with targeted levels of allergen-specific and total IgE are needed to participate in the capillary whole blood between-run imprecision study in the POL environment.~* A minimum of 40 subjects with targeted levels of Fel d 1-specific IgE and total IgE are needed to participate in the sample type comparison study. These subjects will be recruited, and their samples analyzed at 1 POL.~* A minimum of 300 subjects (approximately 100 subjects enrolled and evaluated at each of three sites) and with targeted levels of total IgE are needed to participate in the method comparison study."
62677042|NCT03269786||cirrhotic patients with esophagel varisces|Endoscopic band ligation or injection scelerotheraby will be done for all patients
62677043|NCT00271570|ACTIVE_COMPARATOR|Second Dose of IVIG (2g/kg)|Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg)
62677044|NCT00271570|EXPERIMENTAL|Infliximab (5mg/kg)|Remicade (5mg/kg) single dose
62677045|NCT05166928|ACTIVE_COMPARATOR|group 1: control group|will be treated using carriere motion appliance for distalization of upper buccal segment in the presence of upper third molar
62677046|NCT05166928|ACTIVE_COMPARATOR|group2: teste group|will be treated with using carriere motion appliance for distalization of upper buccal segment with upper third molar extraction or have congenital missing upper third molar
62677047|NCT05416632|EXPERIMENTAL|Arthrometer|
61918661|NCT06024733|SHAM_COMPARATOR|inhalational|
61918662|NCT06024733|ACTIVE_COMPARATOR|Target Controlled Infusion|
61918663|NCT06024733|ACTIVE_COMPARATOR|Target Controlled Infusion and lidocaine|
62305735|NCT04861038|EXPERIMENTAL|aerSleep II|Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP
62305736|NCT00227461|OTHER|Wait control|Levitiracetam is started after a delay, with dosage and administration as described below.
62305737|NCT00227461|EXPERIMENTAL|Treatment first|Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
62305738|NCT00624338|EXPERIMENTAL|Atacicept 75 mg|
62677048|NCT05227430|EXPERIMENTAL|Surgical trainees|Surgical trainees that would be given educational video tutorials before entering gynecological laparoscopic surgeries
62677049|NCT05227430|NO_INTERVENTION|Control|Surgical trainees that would not be given educational video tutorials before entering gynecological laparoscopic surgeries
62677050|NCT05383950|EXPERIMENTAL|smartphone application based 12-week pulmonary or cardiac rehabilitation|
62677051|NCT04318886|NO_INTERVENTION|Usual Care|
62677052|NCT04318886|EXPERIMENTAL|Project ENABLE Cornerstone|
62305739|NCT00624338|EXPERIMENTAL|Atacicept 150 mg|
62305740|NCT00624338|PLACEBO_COMPARATOR|Placebo|
62305741|NCT01901328|EXPERIMENTAL|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period
62305742|NCT01901328|PLACEBO_COMPARATOR|Placebo|Placebo administered orally BID for a 12-week treatment period
62305743|NCT01682915||Group 1: ADHD+DAT1, Probands|30 ADHD probands with DAT1 variants
62305744|NCT01682915||Group 2: ADHD+DAT1, Unaffected sibling|30 same-sex unaffected siblings of Group 1
62305745|NCT01682915||Group 3: ADHD Drug-naïve, Probands|30 ADHD probands without DAT1 gene variants, who were age-, sex-, and IQ-matched to Group 1
62305746|NCT01682915||Group 4: ADHD Drug-naïve, unaffected sibling|30 same-sex unaffected siblings of Group 3
61918664|NCT04515862|EXPERIMENTAL|intervention|Intervention group: Mothers in the intervention group were included in the breastfeeding training program with the group training method. The training program was developed by the researchers, and the content of the program was evaluated with the expert opinion of academicians, obstetricians, nurses and breastfeeding counselor midwives working on breastfeeding.
62117755|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).
62117756|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen \[PSA\] despite testosterone less than \[\<\]50 nanogram per deciliter \[ng/dL\] \[\<1.7 nano moles per liter{nmol/L}\]), the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.
62305747|NCT01682915||Matched controls|30 age-, sex- and IQ-matched TD controls for each of 4 groups
62305748|NCT01523444|NO_INTERVENTION|Treatment as Usual|
62305749|NCT01523444|ACTIVE_COMPARATOR|computer Screening & Brief Advice|All participants receiving care at the site assigned to the computer-facilitated screening and brief advice (cSBA) condition will receive the cSBA intervention as part of their care at that clinic.
62473591|NCT02679703|EXPERIMENTAL|High voltage|The applied parameters of high voltage electrical stimulation are medium voltage of 100 volts, an increase in the course of the session, frequency of 10 Hz, with application in the donor areas of thigh or scalp for 40 minutes, 25% above of level engine daily until complete epithelialization, and removal of the dressing type rayon.
62473592|NCT02679703|EXPERIMENTAL|Neuromuscular transcutaneous electrical stimulation (TENS)|10 Hz, 40 min, 200 μs and 25% above of motor level
62473593|NCT02679703|EXPERIMENTAL|Control Group|There will be no intervention
62473594|NCT02023177||Phase angle|Phase angle obtained from bioelectrical impedance
62677053|NCT05453357||iGlucose Remote Glucose Monitoring|Patients will be provided with the iGlucose monitor at baseline data collection.
61919971|NCT03872414|EXPERIMENTAL|Parkinson Disease Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
62305750|NCT01523444|EXPERIMENTAL|computer Screening & Brief Advice Plus|All participants receiving care at the site assigned to the cSBA+ condition will receive the cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider as part of care at that clinic.
62305751|NCT06513468|ACTIVE_COMPARATOR|The standard health education of primary care .|The first group will receive a standard health education for self-care practices done by attending two appointments in our clinics with the health education and dietitian in a personal session. The HA1C blood test together with completing a brief questionnaire form measuring the Diabetes Self-Care Activities during the past three months will be done after 3 and, 6 months will be done.
62305752|NCT06513468|EXPERIMENTAL|The standard group health education (DESMOND) session|The second group will attend a group health education using a standard DESMOND method (10-12 patients for each session lasting for 6 hours over one day by certified DESMOND educator in the conference room of the health center). The HA1C blood test together with completing a brief questionnaire form measuring the Diabetes Self-Care Activities during the past three months will be done after 3 and, 6 months will be done.
62305753|NCT05089565||Sarcoidosis, not on treatment|Sarcoidosis patients, 18 years of age or older, not currently being treated with immunosuppressive medications
62305754|NCT05089565||Sarcoidosis, on treatment|Sarcoidosis patients, 18 years of age or older, currently being treated with immunosuppressive medications
62305755|NCT05089565||Healthy controls|Healthy individuals, matched for age and sex with those in the two sarcoidosis cohorts
62473595|NCT02570009|ACTIVE_COMPARATOR|TEAMS|
62473596|NCT02570009|ACTIVE_COMPARATOR|TEAMS+|
62473597|NCT04761861|EXPERIMENTAL|Vildagliptin|Vildagliptin 50 mg tablet daily
62473598|NCT04761861|PLACEBO_COMPARATOR|Placebo|Placebo tablet daily
62473599|NCT01024166||Patient|Patient computer system use questionnaire
62473600|NCT01024166||Caregiver|Caregiver computer system use questionnaire
62473601|NCT01024166||Healthcare Provider|Physician and Nurse computer system use questionnaire
62473602|NCT01074203|EXPERIMENTAL|Nitazoxanide arm|All patients will receive nitazoxanide
62473603|NCT03265574|EXPERIMENTAL|Intervention|
62677054|NCT01848223||late menopause|
62305756|NCT03591822|OTHER|Arm AB : Intervention under study x Control intervention|Subjects receive intervention A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by intervention B during which patients will benefit from a systemic pain assessment without the PARO robot.
61918665|NCT04515862|NO_INTERVENTION|control|Control Group:Routine obstetric care and treatment procedures were applied to the mothers in the control group. In the hospital where the study was conducted, all mothers are routinely evaluated for breastfeeding by an infant nurse.
61918666|NCT00872625|EXPERIMENTAL|Cyberknife|
61918667|NCT03607643|PLACEBO_COMPARATOR|Colon: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
61918668|NCT03607643|EXPERIMENTAL|Colon: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
61918669|NCT03607643|PLACEBO_COMPARATOR|Rectal: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
62473604|NCT03265574|NO_INTERVENTION|Standard care|
62473605|NCT01727180||Chronic kidney disease|
62473606|NCT05332535|EXPERIMENTAL|Serious game web aplication|Nursing students played the serious game for two weeks.
62473607|NCT05332535|NO_INTERVENTION|Control grup|
62473608|NCT01194648|OTHER|High Intensity Focused Ultrasound|HIFU, the Intervention
61918670|NCT03607643|EXPERIMENTAL|Rectal: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
61918671|NCT03607643|PLACEBO_COMPARATOR|Multiple myeloma: Chemo + Placebo|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.
61918672|NCT03607643|EXPERIMENTAL|Multiple myeloma: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.
61918673|NCT03607643|PLACEBO_COMPARATOR|Pancreatic: Chemo + Placebo|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
61918674|NCT03607643|EXPERIMENTAL|Pancreatic: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
62305757|NCT03591822|OTHER|Arm BA: Control intervention x Intervention under study|Subjects receive intervention B during which they will benefit from a systemic pain assessment without the PARO robot, followed by intervention A during which patients will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator.
62305758|NCT02329925|EXPERIMENTAL|Tongue Stabilizing Device Treatment|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
62473609|NCT02203058|EXPERIMENTAL|Pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) with pursed-lips breathing.
62473610|NCT02203058|PLACEBO_COMPARATOR|No pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) without pursed-lips breathing.
62305759|NCT00575796|EXPERIMENTAL|1|"Children will be treated with Vinblastine Sulphate chemotherapy via intravenous administration once a week over a period of 26 weeks. MRI disease evaluation should be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 \> stable (i.e. stable disease, objective or partial or complete response compared to the baseline MRI exam), continue weekly Vinblastine to the total duration of treatment (i.e. 70 weeks).~All children will be followed until they demonstrate clear signs tumour progression."
62305760|NCT03968510||parathyroidectomy cases|patients who will be operated for primary hyperparathyroidism
62305761|NCT03600116||Study Visit|After consent and enrollment, subjects with type 1 diabetes will arrive to the study visit having fasted the night before. Subjects will be given a meal, and will be given an insulin injection for this meal, calculated based on their prescribed meal to carbohydrate ratio as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL based on their prescribed insulin sensitivity factor. Following the insulin injection, subjects will eat breakfast and be observed in the clinic setting. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
62305762|NCT06499571||Cohort 1|Geographic Atrophy (GA ) : GA (both eyes with GA)
62305763|NCT06499571||Cohort 2|GA : nAMD (1 eye with GA; the other eye with nAMD, including MNV)
62305764|NCT06499571||Cohort 3|"GA : early/intermediate AMD (1 eye with GA; the other eye with early/intermediate AMD)~o Other subgroups (GA : drusen, GA : reticular pseudodrusen) will be consider if the sample size allows AMD: Age -Related Macular Degeneration MNV: Macular Neovascularization nAMD: Neovascular Age -Related Macular Degeneration"
62305765|NCT04630314||Consecutive patients treated with covered stents post PCI CAP|
62305766|NCT03118843|EXPERIMENTAL|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
62305767|NCT00857610||1|Subjects using 0.1% retinol one day per week
62305768|NCT00857610||2|Subjects using 0.1% retinol three days per week
62305769|NCT00857610||3|Subjects using 0.1% retinol seven days per week
62305770|NCT00857610||4|Subjects using 0.5% retinol one day per week
62305771|NCT00857610||5|Subjects using 0.5% retinol three days per week
62305772|NCT00857610||6|Subjects using 0.5% retinol seven times per week
62305773|NCT04775043||Control population|First part of the study for the HFRDIS Questionnaire French validation
62305774|NCT04775043||Patients on hormone therapy for breast cancer|Second par of the study for the HFRDIS questionnaire use on patients on hormone therapy for breast cancer
62473611|NCT03214276|ACTIVE_COMPARATOR|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
62473612|NCT03214276|PLACEBO_COMPARATOR|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
62473613|NCT02131363|EXPERIMENTAL|Ingrowing Toenail Treatment Kit|"Ingrowing Toenail Treatment Kit consists of 3 components:~1. Toe nail clip: one clip to be applied each week, for 6 weeks.~2. Aerosol spray: to be applied up to 5 times a day, no more than one spray per hour.~3. Nail adhesive: used to attach the clip to the nail."
62305775|NCT03376828|ACTIVE_COMPARATOR|Hypertensive T group|Hypertensive T group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure \<180 mmHg and diastolic blood pressure \<100 mmHg) Macintosh laryngoscopy using intubated
62473614|NCT03987191|ACTIVE_COMPARATOR|Standard of Care Transition|Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections
62305776|NCT03376828|ACTIVE_COMPARATOR|Hypertensive VL group|Hypertensive VL group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure \<180 mmHg and diastolic blood pressure \<100 mmHg) C-Mac Videolaryngoscope using intubated
62473615|NCT03987191|EXPERIMENTAL|Inverstigational Transition|Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition
62305777|NCT03376828|SHAM_COMPARATOR|Non-hypertensive T group|Non-hypertensive T group: (Preoperative systolic blood pressure \< 140 mmHg and diastolic blood pressure \< 100 mmHg) Macintosh laryngoscopy using intubated
62305778|NCT03376828|SHAM_COMPARATOR|Non-hypertensive VL group|Non-hypertensive VL group: Preoperative systolic blood pressure \< 140 mmHg and diastolic blood pressure \< 100 mmHg C-Mac Videolaryngoscope using intubated
62305779|NCT05691725||Patients with antisynthetase syndrome|
62305780|NCT03617393||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection.
62305781|NCT03617393||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
62473616|NCT06395194|ACTIVE_COMPARATOR|Valsartan|Treatment based on the ARB valsartan
62677055|NCT06213636|EXPERIMENTAL|Experimental: Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients will be administered fludarabine phosphate intravenously (IV) over a 30-minute period on days -4 to -2. Additionally, cyclophosphamide will be administered intravenously (IV) over 60 minutes on day -2. Subsequently, patients will receive CD19/CD22-CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0. Patients who exhibit positive responses to the initial dose of CD19/CD22-CAR T cells, do not experience unacceptable side effects, and have a sufficient quantity of cells available may be eligible to receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
62677056|NCT06694844|EXPERIMENTAL|M1 - permamem + bone grafting|M1: In the group M1, the grafted site was covered with a d-PTFE membrane (Permamem®, botiss biomaterials GmbH, Zossen, Germany)
62677057|NCT06694844|ACTIVE_COMPARATOR|M2 - Cytoplast + bonegrafting|• M2: In the group M2 the site was covered with an alternative d-PTFE membrane (Cytoplast™, Osteogenics Biomedical, Texas, USA)
62117757|NCT03501173||NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)|Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone \<50 ng/dL \[\<1.7 nmol/L\]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.
62305782|NCT03617393||DM group|Patients without pulmonary infection while the fasting blood-glucose \> 8 mmol/L.
62473617|NCT06395194|ACTIVE_COMPARATOR|Amlodipine|Treatment based on the CCB amlodipine
62677058|NCT05485350|EXPERIMENTAL|Anlotinib combined with SBRT and penpulimab|
62677059|NCT04006756|EXPERIMENTAL|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
62677060|NCT04006756|ACTIVE_COMPARATOR|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
62677061|NCT04570423|EXPERIMENTAL|Cohort 1: ≥12 to <17 years|Participants will receive a SC injection of eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
62677062|NCT04570423|EXPERIMENTAL|Cohort 2: ≥6 to <12 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
62117758|NCT03501173||mCRPC (Treatment-experienced in the nmCRPC or mCSPC Setting)|Participants will be defined as having mCRPC (treatment-experienced in the nmCRPC or mCSPC setting) if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone \<50 ng/dL \[\<1.7nmol/L\]), the first treatment for mCRPC clinical state was started in the past 6months or is scheduled to begin, disease progression occurred while receiving active treatment (ARAT or chemotherapy) in the prior nmCRPC or mCSPC clinical state.
62117759|NCT01377129|ACTIVE_COMPARATOR|Single Bundle|These patients are operated using a single bundle technique.
62117760|NCT01377129|EXPERIMENTAL|Double bundle|These patients are operated using a double bundle technique.
62117761|NCT04747756|OTHER|Study participants|No participants will be randomized. All participants will have an opportunity to participate in the study procedures.
62117762|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
62117763|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
62117764|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
62117765|NCT00411138|ACTIVE_COMPARATOR|Radiation Therapy|Pelvic Radiotherapy alone
62117766|NCT00411138|EXPERIMENTAL|Radiation Therapy and Chemotherapy|Pelvic Radiation plus 2 concurrent cycles cisplatin followed by 4 adjuvant cycles carboplatin and paclitaxel
62117767|NCT02212054|EXPERIMENTAL|conservative & operative treatment|anal dilation; colon lavage; probiotics
62117768|NCT02212054|ACTIVE_COMPARATOR|operative treatment|one stage pull- through radical colectomy
62117769|NCT02957539|NO_INTERVENTION|No Reward|At enrollment, participants randomized to usual care will be given the MOVE! workbook that serves both as an information resource on diet and exercise, a resource for tools to achieve weight loss goals, and a log of participants' goals, motivations, and outcomes. Each participant will be given a chart with a personalized target weight for a loss of 1lb. per week for 16 weeks. Participants will be given a digital scale or wireless scale and counseled to weigh themselves daily. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
62117770|NCT02957539|EXPERIMENTAL|Financial Reward Arm|Same as usual care, plus financial rewards that are earned in two ways: an assured and random. For the assured reward, they will receive compensation at the end of each month that they are at or below their target weight on the last day of that period. For the random portion, each week that a participant is at or below their target weight, the patient is entered in random drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning.Over the 17-32 week period, Veterans in this group will receive token rewards for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters his/her weight into the portal, he will have a 1-in-8 chance to earn the token reward, such as a t-shirt or movie tickets. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
62117771|NCT02957539|EXPERIMENTAL|Non-financial Reward Arm|Procedures for the non-financial rewards arm is identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each week a random drawing will be for 20 points, each monthly weigh in is worth 5 points. Veterans will be given non-financial rewards associated with the number of points they earn.
62117772|NCT06676189|ACTIVE_COMPARATOR|medial pivot polyethylene|Total knee replacement with medial pivot polyethylene
62117773|NCT06676189|ACTIVE_COMPARATOR|ultra-congruent polyethylene|Total knee replacement with ultra-congruent polyethylene
62117774|NCT04669925||Users of Lombardy Emergency System 2018-2020|Adults (affected or not affected by Covid-19) who asked for assistance to the Lombardy region's emergency system during the pandemic period and the previous two years
62117775|NCT06049732||Nursing home residents with moderate to severe dementia|Simultaneous pain assessments using PainChek® and the Abbey Pain Scale undertaken by two independent pain assessors, blinded to each others results
62117776|NCT03616639|EXPERIMENTAL|Oxycodone|Continuous subcutaneous infusion (CSCI) of oxycodone.
62117777|NCT03616639|ACTIVE_COMPARATOR|Morphine|Continuous subcutaneous infusion (CSCI) of morphine.
62117778|NCT05256641|EXPERIMENTAL|Group I (acalabrutinib)|Beginning day 90, patients receive acalabrutinib PO QD and then PO BID once no longer on prophylactic antifungal (CYP34A inhibitors) until day 365 in the absence of disease progression or unacceptable toxicity.
62117779|NCT05256641|EXPERIMENTAL|Group II (acalabrutinib)|Beginning day 60, patients receive acalabrutinib PO QD and then PO BID from day 74 if there are no dose reductions until day 365 in the absence of disease progression or unacceptable toxicity.
62117780|NCT05256641|EXPERIMENTAL|Group III (acalabrutinib)|Beginning anytime between days 28-104, patients receive acalabrutinib PO BID until day 365 in the absence of disease progression or unacceptable toxicity.
62473618|NCT03992118|EXPERIMENTAL|Feeding Challenges|Parents will be coached to implement strategies to address factors contributing to feeding challenges based on a multidisciplinary assessment using the medico-oral-behaviour-sensory-environment (MOBSE) approach.
62117781|NCT06677333|EXPERIMENTAL|Whey protein supplement|This group of participants will consume 50 g of whey protein supplement daily.
62117782|NCT06677333|EXPERIMENTAL|Pea protein supplement|This group of participants will consume 50 g of pea protein supplement daily.
62117783|NCT03691428|EXPERIMENTAL|Intervention|
62117784|NCT03691428|OTHER|Wait-list|Participants will get the WOOP training after the last outcome assessment.
62117785|NCT05153551|EXPERIMENTAL|PEARS assessment|
62117786|NCT06632379|ACTIVE_COMPARATOR|10 mg Atorvastatin|Atorvastatin 10 mg daily for 3 months
62117787|NCT06632379|PLACEBO_COMPARATOR|Placebo|Identical appearing placebo for 3 months
62305783|NCT03617393||Control group: normal people|Patients without pulmonary infection while the fasting blood-glucose in the normal range.
62117788|NCT06556160|EXPERIMENTAL|hearing impaired patients|have a sensorineural hearing loss defined by hearing thresholds of 20 dB HL or better from 0.25 to 2 kHz and from 20 dB HL excluded to 55 dB HL at frequencies above 2 kHz.
62305784|NCT03004846|EXPERIMENTAL|Part A: GSK2981278 4%|Subjects will receive topical application of GSK2981278 4% ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
62305785|NCT03004846|EXPERIMENTAL|Part B: GSK2981278 4% and vehicle|In Part B, subjects will receive topical application of GSK2981278 4 % ointment or vehicle ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
62305786|NCT01845077|ACTIVE_COMPARATOR|5 mg Linagliptin/1000 mg Metformin, fed|3 single tablets under fed conditions
62305787|NCT01845077|EXPERIMENTAL|5 mg Linagliptin/1500 mg Metformin FDC|2 FDC tablets under fasted conditions
62305788|NCT01845077|ACTIVE_COMPARATOR|5 mg Linagliptin/1500 mg Metformin|4 single tablets under fasted conditions
62305789|NCT01845077|EXPERIMENTAL|5 mg Linagliptin/1000 mg Metformin FDC|1 fixed dose combination(FDC) tablet under fasted conditions
62117789|NCT06556160|ACTIVE_COMPARATOR|normal hearing patients|free of neuro-sensory deafness, defined by mean hearing thresholds of less than or equal to 20 dB HL in pure tone audiometry in air conduction bilaterally on the side of the ear operated on and on the non-operated side from 0.25 to 8 kHz
62117790|NCT03572023|ACTIVE_COMPARATOR|MINOCA|"This group will include patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).~Integrative characterization of MINOCA patients:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
62117791|NCT03572023|ACTIVE_COMPARATOR|MI with coronary obstruction|"This group will include patients with myocardial infarction and obstructive coronary arteries.~Characterization of MI patients with coronary obstruction:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
62117792|NCT05573854|SHAM_COMPARATOR|Overnight Fast|After an overnight fast period of eight hours, the 6 participants will attend the Radiology Service of the Hospital de Câncer, Cuiaba, Brazil to perform MRI images of the upper abdomen with the objective of measuring the fasting GRV. GRV will be evaluated by tracking the region of interest (ROI) in each slice, forming a volume by the sum of all ROIs (phase 1).
62305790|NCT01845077|ACTIVE_COMPARATOR|5 mg Linagliptin/1000 mg Metformin|3 single tablets under fasted conditions
62305791|NCT01845077|EXPERIMENTAL|5mg Linagliptin/1000mg Metformin, FDCfed|1 FDC tablet under fed conditions
62305792|NCT02950129|OTHER|measurements of gait|all subjects will undergo 6 tests to assess gait before and after SIJ; SIJ pain diagnostic tests
62305793|NCT03071432|ACTIVE_COMPARATOR|Non-diabetic patients|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
62473619|NCT02355886|EXPERIMENTAL|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
62473620|NCT02355886|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
61918675|NCT03607643|PLACEBO_COMPARATOR|GBM: Chemo + Placebo|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
62117793|NCT05573854|ACTIVE_COMPARATOR|Oral Supplement|Each of the 6 participants while still inside the MRI exam room just after the MRI in fast condition, will ingest 200mL of the study oral supplement (OS). The individual will be immediately positioned in the supine position and another MRI scan will be carried out. In this second phase, GRV will be evaluated again as in phase 1 (phase 2).
62117794|NCT05573854|ACTIVE_COMPARATOR|3h after ingestion|Finally, phase 3 will be performed after a 3-hour pause. All volunteers, while still in the Radiology Service and fasted after the ingestion of the OS described in phase 2, will be submitted to a third MRI scan of the upper abdomen to measure again the GRV as previously described.
62117795|NCT01883908|EXPERIMENTAL|Acupuncture with Seirin® needles|Participants will be randomized to receive acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
62305794|NCT03071432|ACTIVE_COMPARATOR|Diabetic patients with cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
62305795|NCT03071432|ACTIVE_COMPARATOR|Diabetic patients without cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
62305796|NCT03984526|PLACEBO_COMPARATOR|Control group|intravenous normal saline pretreatment
62305797|NCT03984526|EXPERIMENTAL|Atropine group|intravenous atropine 0.5mg pretreatment
62305798|NCT03984526|EXPERIMENTAL|Ephedrine group|intravenous ephedrine 8mg pretreatment
62117796|NCT01883908|ACTIVE_COMPARATOR|Usual medical care|Participants will be randomized to receive usual medical care for 8 weeks coinciding with their chemoradiation treatments. Patients will receive usual medical care such as viscous Lidocaine for relief of pain.
62305799|NCT00576914|ACTIVE_COMPARATOR|A|vinorelbine plus cisplatin plus recombinant human endostatin
62305800|NCT00576914|NO_INTERVENTION|B|vinorelbine plus cisplatin
62305801|NCT02657642||Cohort 1 (exposed)|cohort 1: patients who will receive the OMAGE-P transitional care in geriatric or internal medicine departement of the Eaubonne Hospital
62117797|NCT02571816|EXPERIMENTAL|ASP2215: Subjects with mild hepatic impairment|Subjects with Child Pugh classification score of 5-6 (mild)
62117798|NCT02571816|EXPERIMENTAL|ASP2215: Subjects with moderate hepatic impairment|Subjects with Child Pugh classification score of 7-9 (moderate)
62117799|NCT02571816|EXPERIMENTAL|ASP2215: Subjects with normal hepatic function|Healthy subjects that match with respect to age, sex and body mass index (BMI)
61919972|NCT03872414|ACTIVE_COMPARATOR|Control Group|Participants will receive rt-fMRI training to increase primary auditory cortex activation.
62117800|NCT05761834||Partecipants with Fabry Desease (FD)|"For each patient, at the time of enrollment, a blood sample will be collected and plasma levels of markers of inflammation, oxidative stress and cardiac remodeling will be determined (C-reactive protein, interleukin \[IL\]-6, IL-1β, IL-2, soluble vascular cell adhesion molecule, tumor necrosis factor \[TNF\], TNF receptor 1 and 2, Myeloperoxidase, calprotectin, uric acid, asymmetric dimethyl arginine, symmetric dimethyl arginine, matrix metalloprotease \[MMP\]-2, MMP-8 and MMP-9, galectin-1, galectin-3, B-type natriuretic peptide, midregional pro-atrial natriuretic peptide, monocyte chemoattractant protein-1).~Serum proteomic analysis and transcriptomic analysis on peripheral blood mononuclear cells, investigating molecular mediators involved in inflammatory pathways will be also performed.~Patients enrolled will also undergo a comprehensive 2D-echocardiography with Doppler, Tissue Doppler (TD) and speckle tracking analysis and 12-leads electrocardiogram."
62305802|NCT02657642||Cohort 2 (non exposed)|Cohort 2: : patients included in the usual care arm of the OMAGE RCT study in 2007-2008
62473621|NCT01188135|EXPERIMENTAL|Interactive Voice messaging|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed"
62473622|NCT01188135|NO_INTERVENTION|Usual care arm|usual care treatment with no interactive phone reminder calls phone
62677063|NCT04570423|EXPERIMENTAL|Cohort 3: ≥2 to <6 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
62677064|NCT04570423|EXPERIMENTAL|Cohort 4: ≥1 month to <2 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
62677065|NCT01534403|EXPERIMENTAL|Epratuzumab 4x600 mg every 12 weeks Group|
62677066|NCT00135161|EXPERIMENTAL|Intensity modulated radiation therapy (IMRT).|
62677067|NCT06447688|PLACEBO_COMPARATOR|Plasebo|No other vasodilating drug such as nitrate will be given intravenously
62677068|NCT06447688|ACTIVE_COMPARATOR|Verapamil|Verapamil will be given orally at least 2 hours before angiography
62677069|NCT04597333|ACTIVE_COMPARATOR|2nd Dinoprostone.|Women induced with a second dinoprostone insert.
62677070|NCT04597333|ACTIVE_COMPARATOR|Cervical ripening balloon.|Women induced with a cervical ripening balloon.
62677071|NCT02037984|EXPERIMENTAL|Adult V114: 1x:1x:1x|Adults receive a single vaccination on Day 1.
62677072|NCT02037984|EXPERIMENTAL|Adult V114: 2x:2x:2x|Adults receive a single vaccination on Day 1.
62677073|NCT02037984|EXPERIMENTAL|Infant V114: 1x:1x:1x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
62677074|NCT02037984|EXPERIMENTAL|Infant V114: 2x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
62677075|NCT02037984|EXPERIMENTAL|Infant V114: 2x:2x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
62677076|NCT02037984|EXPERIMENTAL|Infant V114: 0.5x:0.5x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
62677077|NCT02037984|EXPERIMENTAL|Infant V114: 1x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
62677078|NCT02037984|ACTIVE_COMPARATOR|Infant Prevnar 13®|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
62305803|NCT00337532|ACTIVE_COMPARATOR|paclitaxel-cisplatin combination regimen|
62305804|NCT02660697|ACTIVE_COMPARATOR|Test - Extraction site development group|In the test group 29 healthy patients presenting 33 single rooted teeth scheduled for extraction with Extraction Defect Sounding (EDS) Class 3-4 type buccal bony dehiscences were included. 29 maxillary single rooted teeth and 4 single rooted teeth in the mandible (27 incisors, 2 canines and 4 premolars) were removed and treated by the novel extraction site development method. Pre- and postoperative ConeBeam Computer Tomography (CBCT) data were collected for further analysis.
62305805|NCT02660697|NO_INTERVENTION|Control - Spontaneous healing group|In the control group. pre- and postextraction CBCT data sets of 14 patients with 21 extracted teeth were collected. 11 maxillary single rooted teeth and 10 single rooted teeth in the mandible (13 incisors, 2 canines and 6 premolars) were extracted and left for spontaneous healing.
62305806|NCT05717322|EXPERIMENTAL|TENS arm|
62305807|NCT05717322|ACTIVE_COMPARATOR|non TENS arm|
62305808|NCT01573468|EXPERIMENTAL|Capecitabine-tesetaxel|21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
62305809|NCT01573468|ACTIVE_COMPARATOR|Capecitabine-placebo|21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
62305810|NCT05873530|EXPERIMENTAL|Time|Morning or evening
62305811|NCT05873530|EXPERIMENTAL|Treatment|Grape or Placebo
62305812|NCT00206518|EXPERIMENTAL|A: Taxotere/Docetaxel|Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity.
62677079|NCT03837535||Patients undergoing surgery|Swedish patients, \>18 years undergoing surgery 2007-2014
62677080|NCT04269187|EXPERIMENTAL|With theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU and before administration of theophylline; 200 mg/d orally for 12 days then reassessment of diaphragm by ultrasound.
62677081|NCT04269187|NO_INTERVENTION|No theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU then reassessment of diaphragm by ultrasound before discharge
62677082|NCT05467228|EXPERIMENTAL|Low dose / continuous VTS|Low dose refers to receiving VTS 5 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
62120031|NCT04586686|OTHER|Group 1: right ovarian biopsy|Patients in group 1 will undergo a laparoscopy for an ovarian biopsy from the right ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels \<2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
62305813|NCT00206518|EXPERIMENTAL|B: AC Adriamycin/Cytoxan|In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks.
62305814|NCT03035812|EXPERIMENTAL|Alkali|Patients in whom an oral alkalinization whatever the formulation
62305815|NCT00820638|EXPERIMENTAL|1|observational
62473623|NCT01188135|EXPERIMENTAL|IVR messaging w/ Psycho-ed. materials|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed. In addition, participants will receive educational material about antidepressant medication."
62473624|NCT01973088||non-urate calculus|
62473625|NCT01973088||non-calculus|
62677083|NCT05467228|EXPERIMENTAL|Low dose / speech activated VTS|Low dose refers to receiving VTS 5 times/week for 20 minutes each; VTS during connected speech
61919973|NCT05563480|EXPERIMENTAL|TQB2618+Pempulimab+Chemotherapy|Induction therapy: TQB2618 injection + Penpulimab injection + Gemcitabine hydrochloride injection + cisplatin injection; Maintenance treatment: TQB2618 injection +Penpulimab injection; 21 days as a treatment cycle.
62473626|NCT01973088||urate calculus|
62677084|NCT05467228|EXPERIMENTAL|High dose / continuous VTS|High dose refers to receiving VTS 7 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
62677085|NCT05467228|EXPERIMENTAL|High dose / speech activated VTS|High dose refers to receiving VTS 7 times/week for 20 minutes each; VTS during connected speech
62677086|NCT03931785|EXPERIMENTAL|MD-7246 300 μg|1 MD-7246 300-μg oral tablet and 3 matching placebo oral tablets
62677087|NCT03931785|EXPERIMENTAL|MD-7246 600 μg|2 MD-7246 300-μg oral tablets and 2 matching placebo oral tablets
62677088|NCT03931785|EXPERIMENTAL|MD-7246 1200 μg|4 MD-7246 300-μg oral tablets
62677089|NCT03931785|PLACEBO_COMPARATOR|Placebo|4 matching placebo oral tablets
62677090|NCT02003209|ACTIVE_COMPARATOR|Arm I (combination chemotherapy, surgery, radiation)|"NEOADJUVANT: Patients receive docetaxel IV over 60 minutes, carboplatin IV over 30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
62677091|NCT02003209|EXPERIMENTAL|Arm II (chemo, estrogen deprivation, surgery, radiation)|"NEOADJUVANT: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I. Premenopausal patients also receive goserelin acetate SC every 28 days until surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Postmenopausal patients receive aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
62473627|NCT01393431||EBC pH|Observational study
62473628|NCT04817904|EXPERIMENTAL|Statin-Treated|"This arm will be receiving:~* Cisplatin along with conventional nephroprotective interventions (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)~* Rosuvastatin 10 mg/day"
62305816|NCT04484129||Close contacts of MDR-TB patients|"Close contacts of MDR-TB who met the inclusion and exclusion criteria were enrolled. Routine follow-up is scheduled at week 8, 20, 32, and 80. During the visit, participants with suspected tuberculosis symptoms will have detailed clincial assessent, weight measurement, sputum smear, sputum culture and drug sensitivity examination, imaging examinations, etc. For patients diagnosed with TB, the trial ends. Proper treatment will be started. For all paricipants who are not diagnosed with tuebrculosis in previous follow-up, the last follow-up of this study is all face-to-face visits. Sputum smear, sputum culture and chest imaging screening will be performed when necessary to exclude the possibility of tuberculosis infection. In addition, If the participants has suspected TB symptoms or is diagnosed with TB in another hospital, the researchers can be contacted for follow-up at any time."
62305817|NCT03250520|EXPERIMENTAL|glioma brain stem|
62305818|NCT03250520|EXPERIMENTAL|high grade recurrent brain tumor in the central nervous system|
62305819|NCT05704530|OTHER|1. primary resection then follow-up|Scenario 1: primary resection then follow-up - Study-specific liquid biopsies will be collected in 98 patients, at the time of routine labs. Samples will be acquired before resection, at 6-8 weeks, 6 and 12 months after resection.
62305820|NCT05704530|OTHER|2. chemoradiation followed by resection and follow-up|Scenario 2: chemoradiation followed by resection and follow-up - Study-specific liquid biopsies will be collected in 50 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks, 6 and 12 months after surgery. A subgroup of patients will undertake adjuvant immunotherapy and will constitute Group 3. Timing of sampling will be adjusted accordingly as per study flowcharts.
62305821|NCT05704530|OTHER|3. chemoradiation followed by resection followed by adjuvant immunotherapy|chemoradiation followed by resection followed by adjuvant immunotherapy - Study-specific liquid biopsies will be collected in 100 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks after surgery and during adjuvant immunotherapy every 3 months including a sample at the end of treatment.
62305822|NCT02190591|NO_INTERVENTION|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
62305823|NCT02190591|EXPERIMENTAL|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
62305824|NCT02506777|EXPERIMENTAL|FDC x 6 cycles with metformin|32 patients will receive 5 - Fluoruracil 500 mg/m\^2, doxorubicin 50 mg/m\^2, cyclophosphamide 500 mg/m\^2 once every 21 days with metformin 850 mg BID
62305825|NCT02506777|EXPERIMENTAL|FDC x 6 cycles with melatonin|32 patients will receive 5 - Fluoruracil 500 mg/m\^2, doxorubicin 50 mg/m\^2, cyclophosphamide 500 mg/m\^2 once every 21 days with melatonin 3 mg before sleep daily
62305826|NCT02506777|ACTIVE_COMPARATOR|FDC x 6 cycles|32 patients will receive 5 - Fluoruracil 500 mg/m\^2, doxorubicin 50 mg/m\^2, cyclophosphamide 500 mg/m\^2 once every 21 days
62305827|NCT05272514||Healthy individuals|10 healthy individuals will be recruited.
62305828|NCT05076968||Complete dentures fabricated by undergraduate students|
62305829|NCT05076968||Complete dentures fabricated by prosthodontists|
62305830|NCT04711421|EXPERIMENTAL|Experimental: Feedback|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve feedback regrding the number of steps taken by them at the end of each day
62305831|NCT04711421|NO_INTERVENTION|No Intervention: Control|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve no feedback regrding the number of steps taken by them.
62305832|NCT05784389|EXPERIMENTAL|Low PRAL diet|Experimental: Low PRAL diet Crossover design: 1 arm consisting of three consecutive periods of two weeks (control, intervention and follow up).
62305833|NCT02283944|EXPERIMENTAL|TMS electrochemotherapy|Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
62305834|NCT01666132|EXPERIMENTAL|Intramyocardial injection of BM cells|
62305835|NCT01666132|EXPERIMENTAL|Intramyocardial / intracoronary injection of BM cells|
62305836|NCT01666132|OTHER|control|
62677092|NCT01341548|ACTIVE_COMPARATOR|Civamide Nasal Solution 0.01%|
62305837|NCT03877744|EXPERIMENTAL|Interactive virtual presence|Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
62305838|NCT03877744|ACTIVE_COMPARATOR|Live technician|Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.
62305839|NCT00196937|EXPERIMENTAL|Cervarix (15-25 Years) Group|Women aged 15 to 25 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
62305840|NCT00196937|EXPERIMENTAL|Cervarix (26-45 Years) Group|Women aged 26 to 45 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
62677093|NCT01341548|PLACEBO_COMPARATOR|Vehicle Solution|
62677094|NCT01758471|EXPERIMENTAL|Acarbose|The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month. With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)\<7.0,PBG(postprandial blood glucose)\<10.0
62473629|NCT04817904|NO_INTERVENTION|Statin-Free|"This arm will be receiving:~-Cisplatin along with conventional nephroprotective interventions only (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)"
62473630|NCT02167620|PLACEBO_COMPARATOR|Metformin|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
61918676|NCT03607643|EXPERIMENTAL|GBM: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
61918677|NCT01646294|EXPERIMENTAL|OCAS-F|YM178 OCAS tablet (OCAS-Fast) taken orally under fasted and fed condition
61918678|NCT01646294|EXPERIMENTAL|OCAS-S|YM178 OCAS tablet (OCAS-Slow) taken orally under fasted and fed condition
61918679|NCT01646294|EXPERIMENTAL|OCAS-M|YM178 OCAS tablet (OCAS-Medium) taken orally under fasted and fed condition
62305841|NCT00196937|EXPERIMENTAL|Cervarix (46-55 Years) Group|Women aged 46 to 55 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
62305842|NCT01655407|EXPERIMENTAL|Treatment|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
62305843|NCT01655407|ACTIVE_COMPARATOR|Control|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
62473631|NCT02167620|PLACEBO_COMPARATOR|Placebo|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
62473632|NCT01887691|EXPERIMENTAL|eszopiclone|We will evaluate the impact of pharmacologic enhancement of effective sleep with nightly eszopiclone (taken before bedtime for 1 week, home environment) on glycemic profiles (continuous glucose monitoring, 72 hrs) in prediabetics and diabetics compared to pretreatment baseline. The dose of eszopiclone will be the lowest tolerated dose (1-3 mg) via dose escalation and side effect profile assessment.
62473633|NCT01010932|EXPERIMENTAL|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
62473634|NCT04804605|EXPERIMENTAL|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
62677095|NCT01758471|ACTIVE_COMPARATOR|glipizide|There is no fixed dosage of glipizide to control hyperglycemia for patients in this group. As long as the targeted blood glucose concentration is reached, FBG\< 7.0, PBG\< 10.0, patients will have the least dosage of glipizide according to their glucose level.
62677096|NCT03763266|EXPERIMENTAL|1 day low residue diet|Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
62677097|NCT03763266|ACTIVE_COMPARATOR|3 days low residue diet|Patients are instructed to complete a low residue diet three days prior the colonoscopy.
61918680|NCT02607566|EXPERIMENTAL|Iyengar Yoga|Iyengar Yoga Intervention twice weekly for 60 minutes for 12 weeks.
61918681|NCT02607566|ACTIVE_COMPARATOR|Standard Exercise Program|professionally supervised program of aerobic exercise including use of an indoor walking track, treadmills, stationary bicycles and elliptical machines, held for 60 minutes twice weekly for 12 weeks
61918682|NCT01987401||Iraq and Afghanistan Era Veterans|Veterans who served during the Iraq and Afghanistan Era
62305844|NCT03663244|EXPERIMENTAL|MindfulnessBasedStressReduction(MBSR)|Standardised, curriculum-based MBSR-programme: 2.5-hour weekly group sessions over 8 weeks; one 6-hour silence retreat day; and 45 minutes daily homework 6 days a week.
62305845|NCT03663244|EXPERIMENTAL|Local Stress Reduction (LSR)|Local stress reduction programme ; developed and delivered by two local psychologists. This programme is delivered in groups of 12 participants, in 2.5-hour weekly sessions over 8 weeks and includes approximately 10 minutes daily homework between the sessions.
62305846|NCT03663244|NO_INTERVENTION|Wait-list|Usual practice
62305847|NCT05087186|EXPERIMENTAL|Intervention|Group sessions with psychological therapists
62305848|NCT06670482|EXPERIMENTAL|Arm 1|NIV using Mask A, with mouth-open
62305849|NCT06670482|EXPERIMENTAL|Arm 2|NIV using Mask A, with mouth-closed
62473635|NCT04412811||Patients with hematological disease|Adult and children allogenic Hematopoietic stem cell transplantation recipients
62473636|NCT04760704||Experimental group|Persons aged 65 and over, residing in an institution for dependant elderly or in a long-term care unit
62473637|NCT04760704||control group|Health and medico-social professionals between 40 and 65 years of age
62473638|NCT05265520|ACTIVE_COMPARATOR|His-CRT implantation|His-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an endocardial His-bundle pacing leads directly pacing the intrinsic conduction system.
62117801|NCT05761834||Partecipants with hypertrophic cardiomyopathy (HCM) systemic inflammation|"For each patient, at the time of enrollment, a blood sample will be collected and plasma levels of markers of inflammation, oxidative stress and cardiac remodeling will be determined (C-reactive protein, interleukin \[IL\]-6, IL-1β, IL-2, soluble vascular cell adhesion molecule, tumor necrosis factor \[TNF\], TNF receptor 1 and 2, Myeloperoxidase, calprotectin, uric acid, asymmetric dimethyl arginine, symmetric dimethyl arginine, matrix metalloprotease \[MMP\]-2, MMP-8 and MMP-9, galectin-1, galectin-3, B-type natriuretic peptide, midregional pro-atrial natriuretic peptide, monocyte chemoattractant protein-1). Serum proteomic analysis and transcriptomic analysis on peripheral blood mononuclear cells, investigating molecular mediators involved in inflammatory pathways will be also performed.~Patients enrolled will also undergo a comprehensive 2D-echocardiography with Doppler, Tissue Doppler (TD) and speckle tracking analysis and 12-leads electrocardiogram."
62473639|NCT05265520|ACTIVE_COMPARATOR|BIV-CRT implantation|BIV-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
62473640|NCT05792072|ACTIVE_COMPARATOR|active rTMS|The patient will receive one daily rTMS session for 5 days of HF-rTMS, delivered through an H-coil applied to the primary motor area of the leg. Each session will last 20 minutes during which 30 consecutive trains of 50 stimuli will be delivered at 20 Hz at 100% of resting motor threshold (RMT), with an intertrain interval of 30s
62473641|NCT05792072|SHAM_COMPARATOR|Sham rTMS|Sham stimulation will be delivered using a sham coil.
62677098|NCT06032975||Cohort 1:|Patients undergoing their first medical treatment for OC (including adjuvant and neo-adjuvant chemotherapy and first-line treatment for advanced in patients not previously treated with adjuvant chemotherapy)
62677099|NCT06032975||Cohort 2|Patients undergoing their second medical treatment for OC (including the second-line treatment for advanced disease and the first-line treatment for advanced disease in patients previously treated with adjuvant CT)
62305850|NCT06670482|ACTIVE_COMPARATOR|Arm 3|NIV using Mask B, with mouth-open
62305851|NCT06670482|ACTIVE_COMPARATOR|Arm 4|NIV using Mask B, with mouth-closed
62473642|NCT04261894|EXPERIMENTAL|OPTIMIZE|This arm includes implementation of the OPTIMIZE perinatal care checklist with patient navigation support.
62473643|NCT04261894|NO_INTERVENTION|Standard Care|This arm includes provision of standard perinatal care.
62117802|NCT04097418|EXPERIMENTAL|Aerobic training in healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
62305852|NCT03927040|EXPERIMENTAL|TEMT Administration|Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.
62473644|NCT02023229|EXPERIMENTAL|Diet plus branched chain aminoacids|High-fiber high-protein diet Oral supplement : branched chain aminoacids
62305853|NCT02424487||Intracuff pressure during one-lung ventilation|Measurement of changes in intracuff pressure with one-lung ventilation during thoracic surgery.
62305854|NCT06197607|OTHER|control group|The control group will receive thera putty hand exercises.
62473645|NCT02023229|ACTIVE_COMPARATOR|Diet|High-fiber high-protein diet
62473646|NCT02991378|EXPERIMENTAL|Intervention group|"Subjects in this group will receive the Children's emotional and stress coping program which train the children the emotional self-regulation skills and stress coping skill with a standardized protocol."
62473647|NCT02991378|NO_INTERVENTION|Control group|"Subjects in this group will not receive the Children's emotional and stress coping program."
62473648|NCT01724372|EXPERIMENTAL|Antidepressant|Fluoxetine
62473649|NCT01724372|ACTIVE_COMPARATOR|Antipsychotic|Aripiprazole
62473650|NCT00664014|EXPERIMENTAL|Tolvaptan|
62677100|NCT06032975||Cohort 3|Patients undergoing their third medical treatment for OC (including the third-line treatment for advanced disease and the second-line treatment for advanced disease in patients previously treated with adjuvant CT)
62677101|NCT06032975||Cohort 4|Patients undergoing their fourth medical treatment for OC (including the fourth- treatment for advanced disease and the third-line treatment for advanced disease in patients previously treated with adjuvant CT)
62677102|NCT04465305|EXPERIMENTAL|enraped group|patients with a new treatment of tarlov cysts
62305855|NCT06197607|ACTIVE_COMPARATOR|experimental group|The experimental group will receive sensory stimulation along with theraputty hand exercises.
62305856|NCT00889356|EXPERIMENTAL|Clindamycin 100mg and Ketoconazole 400mg|
62305857|NCT00889356|ACTIVE_COMPARATOR|Tetracycline 100mg and Amphotericin B 50mg|
62305858|NCT02981472|EXPERIMENTAL|Apixaban|
62473651|NCT00664014|PLACEBO_COMPARATOR|Placebo|
62473652|NCT01577381|EXPERIMENTAL|PF-04382923|
62473653|NCT01577381|PLACEBO_COMPARATOR|Placebo|
62677103|NCT04465305|ACTIVE_COMPARATOR|plasty group|patients with traditional treatment of tarlov cysts
62677104|NCT00614341|ACTIVE_COMPARATOR|1, 2|"1. Pulse MedRelief SE 55~2. Continuous MedRelief SE 55"
62677105|NCT03600103|NO_INTERVENTION|Control|Participants will receive standard of care.
62677106|NCT03600103|EXPERIMENTAL|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
62677107|NCT02201628|EXPERIMENTAL|Nasopharyngeal and oesophageal temperatures|An oesophageal and nasopharyngeal temperature probe will be placed and temperature will be measured at these site
62305859|NCT02981472|ACTIVE_COMPARATOR|LMWH/VKA|
62117803|NCT04097418|ACTIVE_COMPARATOR|Conventional motor training of healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
62305860|NCT04503980|EXPERIMENTAL|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
62305861|NCT03690791|ACTIVE_COMPARATOR|MediCabilis CBD Oil|
62305862|NCT03690791|PLACEBO_COMPARATOR|Placebo Oil|
62305863|NCT06374641|EXPERIMENTAL|Mitochondrial Substrate Supplement then Placebo|"Administered as a drink, participants receive mitochondrial substrate supplement to be taken in the morning in a fasted state in a dose of 65 mL/day twice daily for 16 days. After a washout period of 28 (or 46 for young females) days they then receive the placebo matching the mitochondrial substrate supplement to be taken in the same way, for 16 days.~Each 65 mL dose of the supplement provides a dose of 481.66 mg choline, 273.01 mg succinic acid, and 15 mg nicotinamide. 65 mL of placebo consists of Aspartame (15.3 mg), Acesulfame-K (10.3 mg), Potassium Sorbate (9.1 mg), Sodium Benzoate (9.8 mg), Cellulose Gum (6.5 mg), Gluconic acid (1105.0 mg), Ginger Natural Flavouring (130.0 mg), Orange Natural Flavouring (130.0 mg), Bitter Sensation Natural Flavouring (65.0 mg), Natural Colour (colouring food) (26.0 mg), Water (63493.0 mg)."
62305864|NCT06374641|PLACEBO_COMPARATOR|Placebo then Mitochondrial Substrate Supplement|"Administered as a drink, participants receive placebo supplement matching the mitochondrial substrate supplement in taste and appearance, to be taken in a dose of 65 mL twice daily for 16 days. After a washout period of 28 (or 46 for young females) days they then receive the mitochondrial substrate supplement, to be taken in the same way, for 16 days.~Each 65 mL dose of the placebo supplement provides 481.66 mg choline, 273.01 mg succinic acid, and 15 mg nicotinamide. 65 mL of placebo consists of Aspartame (15.3 mg), Acesulfame-K (10.3 mg), Potassium Sorbate (9.1 mg), Sodium Benzoate (9.8 mg), Cellulose Gum (6.5 mg), Gluconic acid (1105.0 mg), Ginger Natural Flavouring (130.0 mg), Orange Natural Flavouring (130.0 mg), Bitter Sensation Natural Flavouring (65.0 mg), Natural Colour (colouring food) (26.0 mg), Water (63493.0 mg)."
62305865|NCT03530163|EXPERIMENTAL|Respiratory Muscle Training|
62305866|NCT03530163|SHAM_COMPARATOR|Sham Breathing Training|
62305867|NCT00377962|EXPERIMENTAL|Everolimus + CNI reduction|Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level \< 75 ng/mL or a tacrolimus trough level \< 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.
62305868|NCT00377962|ACTIVE_COMPARATOR|Control|CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.
62117804|NCT04097418|EXPERIMENTAL|Aerobic training in MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
62117805|NCT04097418|ACTIVE_COMPARATOR|Conventional motor training of MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
62117806|NCT06677112|EXPERIMENTAL|Selective Surgical Staging with side-specific lymphadenectomy (LAD)|Pathologist and surgeon jointly perform the Intraoperative Consultation (IOC).
62117807|NCT06677112|ACTIVE_COMPARATOR|REFLEX side-specific LAD|Sentinel node procedure
62117808|NCT03309579|EXPERIMENTAL|Liberal RBC Transfusion Strategy|Hemoglobin value of ≤100g/L
62305869|NCT06244927||Only 20 patients undergo replantation following penile amputation were investigate, only 1group|Patients undergo surgery.
62305870|NCT06232915||Mechanical ventilation|Children requiring mechanical ventilation during a surgical procedure.
62305871|NCT00850512|EXPERIMENTAL|CHOP21|4 cycles CHOP21-R plus Zevalin
62473654|NCT05428943|OTHER|OPT101 1.1 mg/kg and Placebo|9 subjects (6 investigational product:3 placebo)
62677108|NCT01795131|ACTIVE_COMPARATOR|Vitamin B12|Supplementation group (N=60) that will receive 250 µg of vitamin B12 in addition to 60 mg of Fe and 400µg of folate.
62677109|NCT01795131|PLACEBO_COMPARATOR|Placebo|Placebo group (N=60) that will receive placebo tablets and 60 mg of Fe and 400µg of folate daily.
62117809|NCT03309579|ACTIVE_COMPARATOR|Restrictive RBC Transfusion Strategy|Hemoglobin value of ≤80g/L
62117810|NCT05875285|EXPERIMENTAL|Methotreaxate iontophoresis|Thirty patients of both sexes of primary palmar hyperhidrosis are selected to participate in this group from EL KASR EL- AINI
62117811|NCT05875285|EXPERIMENTAL|Coal tar ointment|Thirty patients of both sexes of primary palmar hyperhidrosis are selected to participate in this group from EL KASR EL- AINI
62117812|NCT03951207|EXPERIMENTAL|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
62117813|NCT03951207|EXPERIMENTAL|Rosuampin 20/5mg|Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
62117814|NCT03951207|ACTIVE_COMPARATOR|Amlodipine/Atorvastatin 5/20mg|Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks
62117815|NCT06245746|EXPERIMENTAL|UCMSC-Exo intervention|UCMSC-Exo will be preset with 3 escalation dose levels in single time infusion.
62117816|NCT03385967|ACTIVE_COMPARATOR|ropivacaine only|0.5% ropivacaine
62117817|NCT03385967|ACTIVE_COMPARATOR|ropivacaine with dexmedetomidine|25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine
62305872|NCT03580057|EXPERIMENTAL|Breastfeeding promotion intervention (BPI)|
62473655|NCT05428943|OTHER|OPT101 2.8 mg/kg and Placebo|9 subjects (6 investigational product:3 placebo)
62117818|NCT06677138|EXPERIMENTAL|gefurulimab|Participants will receive a single SC dose of gefurulimab in the abdomen on Day 1.
62117819|NCT03941912|EXPERIMENTAL|Erchonia EVRL|635 nanometers (nm) and 405 nm dual-diode laser application
62117820|NCT04520880||Critically ill SARS-Cov2 patients|Critically ill patients with acute hypoxemic respiratory failure defined as those admitted to ICU and receiving mechanical ventilation (invasive or non-invasive) or high-level supplemental oxygen (via a high-flow nasal cannula or non-rebreathing face mask at a flow rate of 15 L per min or greater), at or during hospitalization
62117821|NCT04520880||Hospitalized non-critically ill SARS-Cov2 symptomatic patients|Hospitalized non-critically ill SARS-Cov2 symptomatic patients
62117822|NCT02279017|OTHER|Weight Loss|We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.
62117823|NCT03597100|EXPERIMENTAL|Cala TWO|Two 40-minute stimulation sessions daily, separated by at least two hours
62117824|NCT04988841|EXPERIMENTAL|Fecal microbiotherapy (MaaT013) associated to ipilimumab and nivolumab|Fecal microbiotherapy MaaT013 (actif arm) enemas will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
62117825|NCT04988841|PLACEBO_COMPARATOR|fecal microbiotherapy Placebo associated to ipilimumab and nivolumab|Placebo fecal microbiotherapy will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
62117826|NCT03445130|ACTIVE_COMPARATOR|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
62117827|NCT03445130|ACTIVE_COMPARATOR|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
62305873|NCT03580057|EXPERIMENTAL|Diet- and weight loss intervention (D)|
62305874|NCT03580057|EXPERIMENTAL|BPI and D|Both interventions.
62305875|NCT03580057|NO_INTERVENTION|Control|
62677110|NCT03158779|EXPERIMENTAL|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.~The SBRT schedule will be \[6 x 9 Gy = 54 Gy\] delivered in consecutive days."
62677111|NCT02526316|OTHER|P16_37-63 Vaccination|Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
62677112|NCT02813512|EXPERIMENTAL|GXNPC1|Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment.
62677113|NCT02301429|EXPERIMENTAL|Model 20105|Receiving the model 20105 Lead
61918683|NCT03554265|EXPERIMENTAL|mTBI subjects|"mTBI subjects will receive recombinant human growth hormone replacement therapy daily for 6 months.~Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin~Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 6 will be dosed at 0.6 mg / day"
62117828|NCT03445130|ACTIVE_COMPARATOR|Almond oil (AO)|2 Drops in Oxygen Mask
62117829|NCT03445130|ACTIVE_COMPARATOR|Water|2 Drops in Oxygen Mask
62117830|NCT03656094|EXPERIMENTAL|Pembrolizumab plus chemotherapy|Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
62117831|NCT03656094|ACTIVE_COMPARATOR|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
62117832|NCT06676696|ACTIVE_COMPARATOR|Control Arm|
62117833|NCT06676696|ACTIVE_COMPARATOR|Investigational arm|
62117834|NCT05295134|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62117835|NCT05295134|ACTIVE_COMPARATOR|Lipase: Low-Dose|Candida cylindracea lipase (75,000 FIP per serving)
62117836|NCT05295134|ACTIVE_COMPARATOR|Lipase: Medium-Dose|Candida cylindracea lipase (150,000 FIP per serving)
62117837|NCT05295134|ACTIVE_COMPARATOR|Lipase: High-Dose|Candida cylindracea lipase (225,000 FIP per serving)
62117838|NCT05128019|EXPERIMENTAL|Intervention|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will offer the patients a session of unspecified length or number of consultations, to follow the conversation tool ICIT
62305876|NCT02124798|EXPERIMENTAL|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
62677114|NCT01155310|EXPERIMENTAL|Helium/Oxygen|Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
62305877|NCT02024256|ACTIVE_COMPARATOR|Magnesium sulfate|Pads soaked in cold magnesium sulfate solution
62677115|NCT01155310|ACTIVE_COMPARATOR|Air/Oxygen|Air/Oxygen will be administered for a maximum of 72 hours.
62677116|NCT01655069|EXPERIMENTAL|Children Treated with Placebo in 905-CL-076|Male and female children aged 5 to less than 12 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
62677117|NCT01655069|EXPERIMENTAL|Children Treated with Solifenacin in 905-CL-076|Male and female children aged 5 to less than 12 years old who received solifenacin in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
61918684|NCT03554265|NO_INTERVENTION|Household Control Subjects|household control subjects will not receive any intervention.
62117839|NCT05128019|NO_INTERVENTION|Control|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will however, only receive standard routine care and follow-up by their GP.
62117840|NCT00778362||Splenectomy|all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.
62117841|NCT04962906|ACTIVE_COMPARATOR|Gam-COVID-Vac / Gam-COVID-Vac|
62117842|NCT04962906|ACTIVE_COMPARATOR|Gam-COVID-Vac / ChAdOx1 nCoV-19|
62117843|NCT04962906|ACTIVE_COMPARATOR|Gam-COVID-Vac / BBIBP-CorV|
62117844|NCT06677541|ACTIVE_COMPARATOR|Control arm|
62117845|NCT06677541|EXPERIMENTAL|Intervention arm|
62305878|NCT02024256|SHAM_COMPARATOR|Water|Pads soaked with cold water
62305879|NCT00581503||diagnostic|oct imaging
62305880|NCT04238845|ACTIVE_COMPARATOR|SMC + Vitamin A alone|Children under SMC Coverage, receiving AQSP and Vitamin A supplementation alone
62305881|NCT04238845|EXPERIMENTAL|SMC+ Vitamin A + Plumpy'Doz|Children under SMC Coverage, receiving AQSP + Vitamin A plus Plumpy'Doz supplementation
62305882|NCT04238845|EXPERIMENTAL|SMC+ Vitamin A + Zinc|Children under SMC Coverage, receiving AQSP + Vitamin A plus Zinc supplementation
61918685|NCT03554265|EXPERIMENTAL|PASC subjects|"PASC subjects will receive recombinant human growth hormone replacement therapy daily for 9 months.~Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin~Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 9 will be dosed at 0.6 mg / day"
61918686|NCT05200494|NO_INTERVENTION|Flexible Bronchoscopy without Recruiting Maneuver|At the end of the bronchoscopy, no further interventions or ventilator maneuvers will be done.
61918687|NCT05200494|EXPERIMENTAL|Flexible Bronchoscopy with Recruiting Maneuver|At the end of the bronchoscopy, a recruiting maneuver will be applied to the patients. Recruiting Maneuver consists in the application of an airway pressure of 30 cmH2O for a period of 30 seconds.
61918688|NCT04050917|EXPERIMENTAL|Real stimulation|The smartwatch produces vibration stimulation.
61918689|NCT04050917|SHAM_COMPARATOR|No stimulation|The smartwatch produces no vibration.
61918690|NCT02127060|EXPERIMENTAL|Vitamin C|in postoperative time, vitamin C administered orally with other pain analgesics.
61918691|NCT02127060|PLACEBO_COMPARATOR|Placebo drug|in postoperative time, vitamin C do not administered.
62117846|NCT05286632|EXPERIMENTAL|KidneYou APP|"In patients randomized in Group A (intervention group) the NP program will be administered by means of App KidneYou. Each patient will select the assigned daily menu or the proposed alternatives, following instructions reported for breakfast, mid-morning snack, lunch, afternoon snack, and dinner.~Patients randomized to Group A (intervention group) will be administered the PA program by means of App KidneYou. Each patient will follow the assigned exercise program (i.e., recommended type of PA, minutes of exercise/day, number of days/week, level of intensity).~Only patients randomized to Group A (KidneYou users) will be invited by the investigator to follow stress-reducing activities. This difference between the two groups is based on the nature of the mindfulness program, consisting solely of multimedia contents."
62117847|NCT05286632|NO_INTERVENTION|Standard of care control group|"In patients randomized in Group B (control group) the NP program will be administered by means of a paper diary containing the entire range of daily menu and related alternatives needed to terminate the 3-month study period.~Patients randomized to Group B (control group) will be administered the PA program by means of a paper diary containing the entire range of exercises needed to terminate the 3-month study period.~The stress reduction program is not a standard of care currently used within the treatment strategy of CKD patients, neither through face-to-face visits with a specialist, nor through multimedia content.~Patients provided with paper diary and randomized in Group B (KidneYou non-users) represent the population followed by the current standard of care and will not be provided with any multimedia content in the context of their participation in the present study."
62117848|NCT02620618|EXPERIMENTAL|Intravitreal Infliximab|Patients with refractory behcets uveitis.
62117849|NCT04707313|PLACEBO_COMPARATOR|Placebo (Cohorts 1 and 2)|
62117850|NCT04707313|EXPERIMENTAL|PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID.
62305883|NCT02458976|EXPERIMENTAL|PDL|Pre-treatment of surgical area with PDL
62677118|NCT01655069|EXPERIMENTAL|Adolescents Treated with Placebo in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
61918692|NCT05974501|ACTIVE_COMPARATOR|Preoperative Adductor Canal Block Group|Participants in this group will receive the standard of care treatment for pain management for TKA including a preoperative adductor canal block. Participants will be in this group for up to 24 hours after surgery.
61918693|NCT05974501|EXPERIMENTAL|Postoperative Adductor Canal Block Group|Participants in this group will receive the standard of care treatment for pain management after TKA, however, the adductor canal block will be placed postoperatively. Participants will be in this group for up to 24 hours
61918694|NCT02882074|OTHER|Human albumin|Human albumin 5% during surgery.
61918695|NCT02882074|OTHER|Hydroxyethyl starch|Hydroxyethyl starch 6% (130/0.4) solution during surgery
61918696|NCT01865071|EXPERIMENTAL|loop ileostomi|Compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer
61918697|NCT05200741|EXPERIMENTAL|Test Product|DelNS1-2019-nCoV-RBD-OPT1 virus titre at not less than 6.3 lg CCID50/dose, 2 doses 3 weeks apart, intranasal administration
61918698|NCT05200741|PLACEBO_COMPARATOR|Reference Product|Matching placebo, 2 doses 3 weeks apart, intranasal administration
61919974|NCT05563480|ACTIVE_COMPARATOR|Penpulimab + Chemotherapy|Induction therapy: Penpulimab injection + Gemcitabine hydrochloride injection + cisplatin injection; Maintenance treatment: Penpulimab injection; 21 days as a treatment cycle.
61919975|NCT05563480|EXPERIMENTAL|TQB2618+Pempulimab|TQB2618 injection combined with Penpulimab injection, 21 days as a treatment cycle.
62305884|NCT01532453|ACTIVE_COMPARATOR|Standard Sun Protection Measures|Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
62473656|NCT05365932|EXPERIMENTAL|TMD Pain group|Arm included patients with TMD Pain intensity \>3 on a VAS scale and with diagnosis of myofascial pain, either alone or in combination with arthralgia, headache attributable to TMD or with disc displacement with reduction. Participants had to be 18 years of age or older. All subjects had to wear the device for 6 months and it should not be used for more than 23 hours in a 24-hour period
62677119|NCT01655069|EXPERIMENTAL|Adolescents Treated with Solifenacin in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received solifenacin in Study 905- CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
62677120|NCT04656028|ACTIVE_COMPARATOR|Group 1 - without genetic testing; subgroup without motivational counseling|Group 1 - without genetic testing; subgroup without motivational counseling
62677121|NCT04656028|EXPERIMENTAL|Group 1 - without genetic testing; subgroup with motivational counseling|Group 1 - without genetic testing; subgroup with motivational counseling
62677122|NCT04656028|EXPERIMENTAL|Group 2 - with genetic testing; subgroup without motivational counseling|Group 2 - genetic testing has been performed; subgroup without motivational counseling.
61919976|NCT00931346|EXPERIMENTAL|FTC/TDF Daily|Daily dosing
61919977|NCT00931346|EXPERIMENTAL|FTC/TDF Intermittent|Dosed intermittently
61919978|NCT00931346|PLACEBO_COMPARATOR|Placebo Daily|Placebo dosed daily
62117851|NCT04707313|EXPERIMENTAL|PF-06882961 80 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID.
62117852|NCT04707313|EXPERIMENTAL|PF-06882961 120 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID.
62117853|NCT04707313|EXPERIMENTAL|PF-06882961 160 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID.
62117854|NCT04707313|EXPERIMENTAL|PF-06882961 200 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID.
62117855|NCT04707313|EXPERIMENTAL|PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2)|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID.
62117856|NCT04707313|EXPERIMENTAL|PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2)|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID.
62305885|NCT01532453|EXPERIMENTAL|MD-3511356|Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
62677123|NCT04656028|EXPERIMENTAL|Group 2 - with genetic testing; subgroup with motivational counseling|Group 2 - genetic testing has been performed; subgroup with motivational counseling.
62677124|NCT06512155|EXPERIMENTAL|Pregabalin Group|The Pregabalin group started taking Pregabalin 75mg bid two days before surgery and Pregabalin 150mg bid from the day before surgery to three days after surgery
62677125|NCT06512155|EXPERIMENTAL|Zolpidem Group|Patients in the zolpidem group took zolpidem 10mg every night from two days before surgery to three days after surgery
62677126|NCT06512155|NO_INTERVENTION|Control group|Control group patients do not take any additional medication that affects sleep
62677127|NCT00240773|EXPERIMENTAL|001|acetaminophen 4 grams daily for 12 months
62677128|NCT00240773|ACTIVE_COMPARATOR|002|naproxen 750 mg daily for 12 months
62677129|NCT00240773|EXPERIMENTAL|003|acetaminophen 4 grams daily for six months
62677130|NCT00240773|ACTIVE_COMPARATOR|004|naproxen 750 mg daily for six months
62677131|NCT05439837|ACTIVE_COMPARATOR|Infraclavicular and subomohoid block|
62677132|NCT05439837|ACTIVE_COMPARATOR|Paracoracoid subscapularis plane block|
62117857|NCT04707313|EXPERIMENTAL|PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2)|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID.
62473657|NCT03968172|EXPERIMENTAL|EBBC programme|Participants in the intervention group will receive access to evidence-based patient information (EBPI) about lifestyle factors in MS combined with a complex behaviour change programme (EBBC programme), an online tool that was developed in line with principles of patient empowerment and cognitive behavioural therapy (CBT) approaches, including acceptance and mindfulness oriented techniques.
62473658|NCT03968172|ACTIVE_COMPARATOR|Control group programme|Participants randomized to the active control group will receive access to an information platform with optimized standard care consisting of information compiled from the German Multiple Sclerosis Society (DMSG) information material to reflect current practice.
62473659|NCT02478047|ACTIVE_COMPARATOR|only antiemetic|The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.
62117858|NCT04707313|PLACEBO_COMPARATOR|Placebo (Cohort 3)|
62305886|NCT03563534|ACTIVE_COMPARATOR|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
62305887|NCT03563534|ACTIVE_COMPARATOR|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
62305888|NCT02466529||type 1 spinal muscular atrophy|The age of onset of patients with type 1 SMA is below 6 months of age.
62305889|NCT03792009|EXPERIMENTAL|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
62305890|NCT03792009|PLACEBO_COMPARATOR|Paracervical block with normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
62305891|NCT00707226||1|15 patients with primary open angle glaucoma
62305892|NCT00707226||2|15 age matched healthy subjects
62473660|NCT02478047|EXPERIMENTAL|Matching points ST36+CV12|
62473661|NCT02478047|EXPERIMENTAL|Matching points PC6+CV12|
62677133|NCT04970576|EXPERIMENTAL|Treatment group|Patients in the intervention group will receive Rivaroxaban 20 mg once a day (OD) for three months
62677134|NCT04970576|ACTIVE_COMPARATOR|Control group|Patients in the control group will receive usual warfarin therapy dose adjusted as per the target INR of 2 to 3
62677135|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
62677136|NCT03073304|ACTIVE_COMPARATOR|Control|Erythrocyte based prime solution
62677137|NCT03073304|EXPERIMENTAL|Intervention|Crystalloid based prime solution
62677138|NCT03823885|EXPERIMENTAL|E-cig|One time exposure to e-cig
62677139|NCT03823885|EXPERIMENTAL|sham|One time exposure to empty e-cig
62305893|NCT06235346||Control Group|Eyes of subjects with no history of use of any substance
62305894|NCT06235346||Seronegative Synthetic Cannabinoids Group|Eyes of patients declaring no present use of any substance and as verified by three consecutive negative urine toxicology tests performed two weeks apart
62305895|NCT06235346||Seropositive Synthetic Cannabinoids Group|Eyes of patients with positive urine toxicology tests proving present use of synthetic cannabinoids
62305896|NCT06067477|ACTIVE_COMPARATOR|Vitamin D Supplement 400 IU|400 IU (10 µg) of Vitamin D3
62305897|NCT06067477|ACTIVE_COMPARATOR|Vitamin D Supplement 1000 IU|1000 IU (25 µg) of Vitamin D3
62305898|NCT06067477|ACTIVE_COMPARATOR|Vitamin D Supplement 2000 IU|2000 IU (50 µg) of Vitamin D3
62473662|NCT02478047|EXPERIMENTAL|Matching points CV3+CV12|
62677140|NCT05606614|EXPERIMENTAL|Cohort 1|Dose Level 1
62305899|NCT04707248|EXPERIMENTAL|Dose Escalation|Participants with ovarian cancer (OVC) or renal cell carcinoma (RCC) will receive an intravenous infusion of R-DXd (starting dose 1.6 mg/kg).
62677141|NCT05606614|EXPERIMENTAL|Cohort 2|Dose Level 2
62117859|NCT04707313|EXPERIMENTAL|PF-06882961 80 mg BID, 4-week titration (Cohort 3)|The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 80 mg BID.
62117860|NCT04707313|EXPERIMENTAL|PF-06882961 140 mg BID, 4-week titration (Cohort 3)|The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 140 mg BID.
62117861|NCT04707313|EXPERIMENTAL|PF-06882961 200 mg BID, 4-week titration (Cohort 3)|The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 200 mg BID.
62117862|NCT02765438|EXPERIMENTAL|BOBO|"Playing with the BOBO system."
62473663|NCT00982397|EXPERIMENTAL|Single-chamber detetction|Patients implanted with a Protecta VR-ICD.
62473664|NCT00982397|EXPERIMENTAL|Dual-chamber detection|Patients implanted with a Protecta DR-ICD or CRT-D.
62677142|NCT04394559|NO_INTERVENTION|Usual care|inpatient pharmacists as available; standard discharge orders; standard follow up visit.
62677143|NCT04394559|EXPERIMENTAL|Intervention|Discharge counseling; discharge opioid order set; post-discharge pain management follow up; patient pain management app.
61918699|NCT02982278|EXPERIMENTAL|CINGS Intervention|CINGS is a 12-week nurse coordinated, Community Health Worker (CHW) intervention structure. Registered Nurse (RN) developed After hospital care plan with home visits sessions will be conducted by the CHW and intermittent televideo RN interactions. After baseline assessment, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly during months two and three. follow up assessments at 3, 6, and 12-month intervals.
62677144|NCT02500342|EXPERIMENTAL|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
61918700|NCT02982278|EXPERIMENTAL|Control|Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
61918701|NCT02325791|EXPERIMENTAL|Part A: Suptavumab 30 mg/kg|
62117863|NCT01591928||Infants with heterotaxy syndrome|
62117864|NCT01685606|EXPERIMENTAL|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.
62473665|NCT03994172|EXPERIMENTAL|teriparatide (TPTD) + the calcimimetic cinacalcet|Combination arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide \[PTH (1-34)\] (20 mcg per day) and at the same time swallow a 30-mg tablet of cinacalcet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
62677145|NCT02500342|PLACEBO_COMPARATOR|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
62677146|NCT05172310|EXPERIMENTAL|Cancer patients|"* Adults with suspected cancer of either pancreas, bile ducts or stomach~* Adults with primary and recurrent epithelial ovarian cancer (EOC)"
62677147|NCT05172310|ACTIVE_COMPARATOR|Non cancer patients|Non cancer patients operated for non-malignant diseases in pancreas during the same period of time will be investigated with the same procedure.
62117865|NCT02348658|OTHER|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
61918702|NCT02325791|EXPERIMENTAL|Part B: Placebo Matched to Suptavumab|
61918703|NCT02325791|EXPERIMENTAL|Part B: Suptavumab 30 mg/kg- 1 Dose|
61918704|NCT02325791|EXPERIMENTAL|Part B: Suptavumab 30 mg/kg - 2 Doses|
61918705|NCT01604109|ACTIVE_COMPARATOR|Tooth Mousse|10% w/v Calcium Phosphopeptide Amorphous Calcium Phosphate paste
61918706|NCT01604109|PLACEBO_COMPARATOR|placebo control paste|the paste without Calcium phosphopeptide - Amorphous Calcium Phosphate
61918707|NCT06251479|EXPERIMENTAL|A group behavioral 1|The first group will perform perceptual and verbal and non-verbal motor execution tasks, while behavioral measurement techniques will be used.
61918708|NCT06251479|EXPERIMENTAL|B group behavioral 2|The second group will perform the same tasks as group A and will be subjected to the same measurements as group A. Differently from group A, the members of group B will perform the experimental tasks together with another participant.
61918709|NCT06251479|EXPERIMENTAL|C group neuromoulation 1|The third group is identical to group A except that neurophysiological measurement techniques will also be applied.
61918710|NCT06251479|EXPERIMENTAL|D group neuromodulation 2|The fourth group is identical to group B except that neurophysiological measurement techniques will also be applied.
61919979|NCT00931346|PLACEBO_COMPARATOR|Placebo Intermittent|Placebo dosed intermittently, orally.
62117866|NCT02348658|OTHER|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
62117867|NCT04025359|ACTIVE_COMPARATOR|Dronabinol 2.5mg|Dronabinol 2.5mg
62117868|NCT04025359|ACTIVE_COMPARATOR|Dronabinol 5mg|Dronabinol 5mg
62117869|NCT04025359|PLACEBO_COMPARATOR|Placebo|Placebo
62117870|NCT01750333||Lean children|
62117871|NCT01750333||Overweight Children (OW)|
62117872|NCT01750333||Obese children (Ob)|
62117873|NCT05925686|EXPERIMENTAL|Tramadol.|
62117874|NCT03874299||Kidney Transplant Receipients|
62117875|NCT01901276|EXPERIMENTAL|Omeprazole 40 mg bid x 4-8 weeks|See study description for further details.
62117876|NCT05985356|EXPERIMENTAL|iTBS|intermittent Theta Burst Stimulation (a form of transcranial magnetic stimulation) targeting the left dorsolateral prefrontal cortex
62117877|NCT03774459|EXPERIMENTAL|High dose ANAVEX2-73|High dose ANAVEX2-73
62473666|NCT03994172|PLACEBO_COMPARATOR|teriparatide (TPTD) + placebo|Monotherapy arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide \[PTH (1-34)\] (20 mcg per day) and at the same time swallow a placebo tablet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
62473667|NCT03572777|ACTIVE_COMPARATOR|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
62473668|NCT03572777|ACTIVE_COMPARATOR|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.
62677148|NCT03737032|EXPERIMENTAL|Intermittent, Continuous, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Continuous theta burst stimulation, 3) Sham theta burst stimulation.
62677149|NCT03737032|EXPERIMENTAL|Intermittent, Sham, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Sham theta burst stimulation, 3) Continuous theta burst stimulation.
62677150|NCT03737032|EXPERIMENTAL|Continuous, Intermittent, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Sham theta burst stimulation.
62677151|NCT03737032|EXPERIMENTAL|Continuous, Sham, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Sham theta burst stimulation, 3) Intermittent theta burst stimulation.
62677152|NCT03737032|EXPERIMENTAL|Sham, Intermittent, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Continuous theta burst stimulation.
62677153|NCT03737032|EXPERIMENTAL|Sham, Continuous, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Continuous theta burst stimulation, 3) Intermittent theta burst stimulation.
62677154|NCT00559117|EXPERIMENTAL|Cohort|
62677155|NCT01065766||All participants|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin
62677156|NCT01406054|EXPERIMENTAL|neuromuscular training|subjects in this arm will undergo neuromuscular warm-up exercises before practices and games
62677157|NCT01406054|NO_INTERVENTION|control|subjects in the control arm will proceed to practice and games without additional neuromuscular warm-up exercises.
62117878|NCT03774459|EXPERIMENTAL|Mid dose ANAVEX2-73|Mid dose ANAVEX2-73
62117879|NCT03774459|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo oral capsule
62117880|NCT03776890|EXPERIMENTAL|DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=30) will be recruited to participate.
62117881|NCT06271304|EXPERIMENTAL|Blue blocking glasses (BB)|Eyewear with orange-tinted lenses that block 99% of short wavelength visible light \< 500 nm
62305900|NCT04707248|EXPERIMENTAL|Dose Expansion: Cohort B-1|Participants with RCC will receive an intravenous infusion of R-DXd at the RDE. Enrollment has ended for this cohort.
62305901|NCT04707248|EXPERIMENTAL|Dose Expansion: Cohort B-2|Participants with OVC will receive an intravenous infusion of R-DXd at the RDE.
62305902|NCT01405079|EXPERIMENTAL|Gefitinib|Gefitinib 250 mg/day oral daily
62117882|NCT06271304|SHAM_COMPARATOR|Low filtration glasses (LF)|Eyewear with clear lenses that block 15% of short wavelength light \< 500 nm
62117883|NCT03802266|EXPERIMENTAL|Electromagnetic Navigation group|Electromagnetic Navigation Guided Transthoracic Needle Aspiration
62117884|NCT03802266|ACTIVE_COMPARATOR|CT group|CT-guided Transthoracic Needle Aspiration
62117885|NCT05204615||Prospective Long COVID cases|The target population will be 10 patients diagnosed during 2021 with long COVID, who will then be followed-up for one month.
62117886|NCT00172185|EXPERIMENTAL|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d teduglutide subcutaneous injection
62117887|NCT00172185|EXPERIMENTAL|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d teduglutide subcutaneous injection
62117888|NCT01321411||1. ARDS/COPD|Critically ill patients with either ARDS or COPD weaning from mechanical ventilation.
62117889|NCT01321411||2. Healthy Volunteers|
62305903|NCT01405079|ACTIVE_COMPARATOR|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
62305904|NCT01258439|ACTIVE_COMPARATOR|1.Raltegravir plus truvada|Raltegravir 400mg twice daily plus truvada 300mg/200mg once daily for 24 weeks
62677158|NCT03352180|ACTIVE_COMPARATOR|subscapularis tendon repair|arthroscopic reapir of subscapularis tendon
62305905|NCT01258439|ACTIVE_COMPARATOR|2. ritonavir boosted darunavir plus truvada|Darunavir 800mg with ritonavir 100mg plus truvada 300mg/200mg once daily for 24 weeks
62677159|NCT03352180|ACTIVE_COMPARATOR|subscapularis tendon debridement|arthroscopic debredement of subscapularis tendon
62677160|NCT01818310|EXPERIMENTAL|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
62677161|NCT01818310|EXPERIMENTAL|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
62677162|NCT01818310|EXPERIMENTAL|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
62677163|NCT01818310|OTHER|Group D: Control-standard treatment|Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
62677164|NCT02059642|PLACEBO_COMPARATOR|Placebo|Placebo tablet identical in appearance to study investigational product Route, frequency: Administered orally once daily
61918711|NCT04972747|EXPERIMENTAL|Suggest skin care with sunflower oil for preterm babies|"* Before each application, preterm babies will be given skin care in the service routine and sunflower oil will be applied twice a day for 14 days.~* Absorption of sunflower oil for preterm babies will be provided by using a baby massage application.~* Before the massage, 3-4 ml of sunflower oil will be applied to the whole body surface except the genital area and scalp..~* 12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
62305906|NCT00671151|ACTIVE_COMPARATOR|1|Low-dose theophylline on top of standard therapy for COPD exacerbation
62305907|NCT00671151|NO_INTERVENTION|2|Standard therapy for COPD exacerbation
62305908|NCT00863954|ACTIVE_COMPARATOR|Output A|
62305909|NCT00863954|ACTIVE_COMPARATOR|Output B|
62305910|NCT00863954|ACTIVE_COMPARATOR|Output C|
62305911|NCT00863954|ACTIVE_COMPARATOR|Output D|
62677165|NCT02059642|EXPERIMENTAL|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) Dose, route, and frequency: 1400 mg administered orally once daily
62677166|NCT04129333|EXPERIMENTAL|Hypnosis group|A hypnosis group with standard care during the invasive procedure according to the usual practice of the care team and setting up a hypnotic accompaniment by an nurse trained beforehand and dedicated throughout the gesture. The hypnosis session will end at the same time as the invasive procedure.
62677167|NCT04129333|PLACEBO_COMPARATOR|Control group|A control group with standard care during the invasive procedure according to the usual practice of the care team.
61918712|NCT04972747|EXPERIMENTAL|Suggest skin care with cocunut oil for preterm babies|"* Before each application, preterm babies will be given skin care in the service routine and coconut oil will be applied twice a day for 14 days.~* Absorption of coconut oil for preterm babies will be provided by using a baby massage application.~* Before the massage, 3-4 ml of coconut oil will be applied to the whole body surface except the genital area and scalp.~* 12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
61918713|NCT00657826|EXPERIMENTAL|19mm arotic valve implant|Single arm study for patients who require a smaller valve size of the ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm.
61918714|NCT02096575|EXPERIMENTAL|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
62117890|NCT05966779||modified CDT physical therapy protocol, based on Godoy's Method|"A complete physical therapy assessment was done. All sociodemographic data were recruited as well as body mass index (BMI), the month of intervention, kind of surgery, extracted liters, psychological treatment, physical therapy sessions, pain, mobility, complications (seroma, wound infection, chafing or risk of ulcer, pain, fibrosis, genital edema), compression, smoking, satisfaction with the treatment received.~A modified CDT physical therapy protocol, based on Godoy's Method, was applied to all study participants. This protocol comprised of~1. Cervical Stimuli 15min~2. MLD based on Godoy~3. Mechanical lymphatic drainage with RA Godoy® device~4. Compression therapy with multilayer and multicomponent bandages during the mechanical lymphatic drainage.~5. Skin care - before and after the bandages- and therapeutic education.~6. Put on compression garments~7. Active movement if possible."
62305912|NCT00863954|ACTIVE_COMPARATOR|Output E|
62677168|NCT06059001|EXPERIMENTAL|Nab-Paclitaxel+Gemcitabine+OMO-103|SoC Gemcitabine/Nab-Paclitaxel plus experimental OMO-103
62117891|NCT00943735||Fesoterodine arm|subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy
62305913|NCT00863954|ACTIVE_COMPARATOR|Output F|
62305914|NCT05614947|EXPERIMENTAL|tart cherry|two capsules daily for 60 days
62305915|NCT05614947|PLACEBO_COMPARATOR|placebo|two capsules daily for 60 days
62305916|NCT04943211|OTHER|R1 low intervention arm|Children of both sexes who meet all inclusion criteria and do not meet any exclusion criteria will be eligible for the study.
62305917|NCT00629824|ACTIVE_COMPARATOR|A|110 naïve CHC patients who are 65 to 80 years of age
62305918|NCT00629824|ACTIVE_COMPARATOR|B|140 naïve CHC patients who are 50 to 64 years of age
62305919|NCT00629824|ACTIVE_COMPARATOR|C|40 HCV-1 infected patients with an RVR who are 65-80 years of age will receive 24 weeks of treatment
62305920|NCT00863668|ACTIVE_COMPARATOR|Efavirenz|
62305921|NCT00863668|EXPERIMENTAL|Raltegravir|
62305922|NCT02952716|EXPERIMENTAL|intervention group|Human Cord Blood Mononuclear Cell will be slowly infusion three times,at one days, 30 days,at 60days.
62305923|NCT02952716|PLACEBO_COMPARATOR|control group|hyperbaric oxygen
62305924|NCT03879590|EXPERIMENTAL|Budesonide and Doxophylline|Budesonide at the same dose in which the subject is currently treated (GINA step 3 or 4) plus doxophylline at a dose of 18 mg / kg per day
62305925|NCT03879590|ACTIVE_COMPARATOR|Low budesonide and Doxophylline|Reduced dose of inhaled budesonide (GINA step down) plus doxophylline to a dose of 18 mg / kg per day, maximum of 800 mg / day (Group B)
62305926|NCT05267028||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
62473669|NCT03465761|EXPERIMENTAL|ExAblate 4000 System|ExAblate treatment of Bilateral Essential Tremor
62677169|NCT04810858|OTHER|HIV+ marijuana user|Participants with HIV who report marijuana use
62677170|NCT04810858|OTHER|HIV+ non-drug user|Participants with HIV who report no drug use
62677171|NCT04810858|OTHER|HIV- marijuana user|Participants without HIV who report marijuana use
62677172|NCT04810858|OTHER|HIV- non-drug user|Participants without HIV who report no drug use
62677173|NCT00183391|ACTIVE_COMPARATOR|Atomoxetine|Participants will receive treatment for ADHD with the non-stimulant atomoxetine
62677174|NCT00183391|ACTIVE_COMPARATOR|Methylphenidate|Participants will receive treatment for ADHD with the stimulant methylphenidate
62677175|NCT04209803|ACTIVE_COMPARATOR|Minoxidil group|The first group will receive Minoxidil 5% topically twice daily for 4 months.
61918715|NCT02096575|NO_INTERVENTION|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
61918716|NCT02573701|EXPERIMENTAL|1 Guideline treatment|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
61918717|NCT02573701|ACTIVE_COMPARATOR|2 Treatment as Usual|Participants will receive the Treatment as Usual (atypical antipsychotic) plus psychosocial treatment decided by clinician
61918718|NCT01117792|EXPERIMENTAL|S-ICD System|
61918719|NCT00814879|ACTIVE_COMPARATOR|a.|N(t)RTI(s) based backbone \& PI/r
61918720|NCT00814879|EXPERIMENTAL|b.|Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
62117892|NCT04957225|EXPERIMENTAL|Direct intervention|Goal level 60 hours of intensive treatment during 6 weeks. Intensive treatment of aphasia and AOS in ICAP-format (MIRAA).
62117893|NCT04957225|NO_INTERVENTION|Waiting group|No intervention during 6 weeks, testing directly before and after the waiting period. After the waiting period the participants receives the same intervention as the direct intervention arm.
62305927|NCT05267028||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
62305928|NCT01926886|EXPERIMENTAL|Trastuzumab|Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).
61918721|NCT00910247|EXPERIMENTAL|eslicarbazepine acetate|Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD
61918722|NCT04397887|EXPERIMENTAL|Men with Azoospermia and varicocele|In this single arm study, TEX 101 is measured in the seminal fluid of all participants, and it will be used as a predictor for appearance of sperms in the ejaculate in 3 and 6 moths follow-up periods
61918723|NCT01594437|EXPERIMENTAL|TCN-202|
61918724|NCT01594437|PLACEBO_COMPARATOR|Placebo|
61918725|NCT05475340|EXPERIMENTAL|Experimental|Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
62117894|NCT00309595|EXPERIMENTAL|1|Cordis SMART™ nitinol self expandable stent
62117895|NCT00309595|ACTIVE_COMPARATOR|2|balloon
62305929|NCT01926886|NO_INTERVENTION|Health Care Professionals|Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.
62305930|NCT01707147||Patients with Type 2 Diabetes Mellitus|
62305931|NCT01011686|EXPERIMENTAL|ANT-SM|autologous adipose-derived stem cell
61919980|NCT06278233|EXPERIMENTAL|Transcranial direct current stimulation study arm|For bi-hemispheric stimulation, the anode will be placed at the intersection of F7 and FC5 and the cathode will be placed at the intersection of F8 and FC6. For all stimulations, the stimulation will be increased for 15 seconds at a dosage of 1 mA (milliampere) for the entire 20 minute session duration and decreased for 15 seconds at the end of the stimulation.
62117896|NCT01340079|EXPERIMENTAL|Virtual world|Virtual world delivery method
62117897|NCT01340079|ACTIVE_COMPARATOR|face to face|face to face method of health education
62117898|NCT00661648|NO_INTERVENTION|1|glucose levels were controlled using sliding scale
62117899|NCT00661648|EXPERIMENTAL|2|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
62117900|NCT03302546|ACTIVE_COMPARATOR|Incremental Hemodialysis|Subjects on this arm will be treated with 2 hemodialysis sessions of at least 4 hour per week.
62305932|NCT02739139|PLACEBO_COMPARATOR|Placebo|Placebo
62305933|NCT02739139|EXPERIMENTAL|AlphaBrain|AlphaBrain(TM)
62117901|NCT03302546|ACTIVE_COMPARATOR|Conventional hemodialysis|Subjects on this arms will be treated with 3 hemodialysis sessions of at least 3.5 hour per week.
62117902|NCT04033042|EXPERIMENTAL|Protocol 1|RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.
62117903|NCT04033042|EXPERIMENTAL|Protocol 2|"RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.~One group of subjects will receive training in the use of the device the other will not. Both groups will receive the instructions for use."
62305934|NCT00787007|EXPERIMENTAL|1|10 mg
62305935|NCT00787007|EXPERIMENTAL|2|20 mg, fasted and fed
62305936|NCT00787007|EXPERIMENTAL|3|40 mg
62305937|NCT00787007|EXPERIMENTAL|4|80 mg
62305938|NCT00787007|EXPERIMENTAL|5|160 mg
62305939|NCT00787007|EXPERIMENTAL|6|320 mg
62305940|NCT00787007|PLACEBO_COMPARATOR|7|placebo capsule
62305941|NCT04442529|NO_INTERVENTION|Control|Pregnant women will receive prenatal care as usual.
61918726|NCT03924466|EXPERIMENTAL|Cancer patients|"Cohort 1: locally advanced or metastatic breast cancer patients~Cohort 2: Patients with locally advanced, unresectable, or metastatic cancer disease of breast with low, intermediate or high HER2-expression, salivary gland; gastric body or gastro-esophageal junction; endometrium; uterus; lung; biliary tract; gallbladder; pacreas; colorectum; urothelium; prostate; other solid with intermediate or high HER2-expression~Cohort 3: Patients with local or locally advanced HER2-+ breast carcinoma, who are planned for neo-adjuvant treatment prior to surgery, and who are suspected for axillary lymph node invasion."
61918727|NCT05661201|EXPERIMENTAL|Dose Level 1: NEROFE with doxorubicin|weekly doses of NEROFE at 96 mg/m2, intravenously over 60 minutes
61918728|NCT05661201|EXPERIMENTAL|Dose level -1: Nerofe with doxorubicin|weekly doses of NEROFE at 48 mg/m2, intravenously over 60 minutes
61918729|NCT05661201|EXPERIMENTAL|Dose level 2: Nerofe with doxorubicin|weekly doses of NEROFE at 192 mg/m2, intravenously over 60 minutes
61918730|NCT05661201|EXPERIMENTAL|Dose Level 3: Nerofe with doxorubicin|weekly doses of NEROFE at 288 mg/m2, intravenously over 60 minutes
62305942|NCT04442529|EXPERIMENTAL|Intervention|Pregnant women will receive the 12-session Mothers and Babies intervention
62305943|NCT01809366|EXPERIMENTAL|seminal plasma insemination|seminal plasma insemination
62305944|NCT01809366|PLACEBO_COMPARATOR|culture medium insemination|culture medium insemination
62305945|NCT02655198|EXPERIMENTAL|fenfluramine|"Experimental : one armed open label study :~Add-on fenfluramine in refractory Lennox Gastaut patients. Starting dose 0.2mg/kg/day. In non-responders (\<50% seizure frequency decrease), dose will be uptitrated every 4 weeks from 0,2 to 0,4 and max 0,8 mg/kg/day (max 30 mg). Total duration study and max exposure to the drug 20 weeks"
62305946|NCT04722978|ACTIVE_COMPARATOR|Experimental group|Gemcitabine combined with carboplatin plus moxifloxacin
62473670|NCT04360161|EXPERIMENTAL|Healthy participants|Swept-source optical coherence tomography A device testing TM/SC and Lens morphology
61918731|NCT00769665||Systane Ultra|Systane Ultra
61918732|NCT00769665||Sensitive Eyes|Sensitive Eyes
61918733|NCT04024384|EXPERIMENTAL|Daratumumab|Daratumumab as maintenance after peripheral blood stem cell transplantation from HLA-identical or haploidentical family donor in the treatment of refractory or relapsed multiple myeloma
62305947|NCT04722978|PLACEBO_COMPARATOR|Control group|Gemcitabine combined with carboplatin plus placebo
62305948|NCT04788563|EXPERIMENTAL|Heat-sensitive moxibustion group A|In this group, patients are compulsively randomized to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
62305949|NCT04788563|ACTIVE_COMPARATOR|Control group A|In this group, patients are compulsively randomized to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
62305950|NCT04788563|EXPERIMENTAL|Heat-sensitive moxibustion group B|Patients who voluntarily choose to receive randomization and are randomly assigned to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
62305951|NCT04788563|ACTIVE_COMPARATOR|Control group B|Patients who voluntarily choose to receive randomization and are randomly assigned to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
62473671|NCT05951192|EXPERIMENTAL|Commercial daprodustat|Prescription of oral daprodustat in accordance with the FDA approved package label.
62473672|NCT05621694|EXPERIMENTAL|Qigong/Tai Chi Intervention|"Tai chi and Qigong combined into a simplified, standard practice, Tai Chi Easy"
62473673|NCT01644058|EXPERIMENTAL|Immediate loading|Immediate loading of 2 endo-osseous mandibular implants
62473674|NCT03465163|NO_INTERVENTION|Recovery|Two months recovery (no stimulation) following bilateral implantation of Medtronic PC+S devices into the anterior nucleus of the thalamus and the hippocampus. Thirty second EEG snapshots will be recorded every 15 minutes
62473675|NCT03465163|NO_INTERVENTION|Baseline|No stimulation, 30 second EEG snapshots recorded every 15 minutes We require a minimum of 5 seizures to occur during this phase.
62473676|NCT03465163|EXPERIMENTAL|Probing|"Deep Brain Stimulation Electrically stimulate the thalamus continuously at a low frequency (2Hz). Thirty second EEG snapshots recorded every 15 minutes.~We require a minimum of 5 seizures to occur during this phase."
62473677|NCT03465163|EXPERIMENTAL|Probe Calibrated Deep Brain Stimulation|Deep Brain Stimulation In this phase we explore 18 deep brain stimulation parameter configurations (three stimulus intensities; 3,4,5 Volts, six different frequencies; 125 130, 135, 140,145, 150 Hz) during two of the clinic visits. Each deep brain stimulation parameter configuration will be tested for 1 minute with 4 minutes between each configuration test. The probing responses will be used to optimise the deep brain stimulation parameters for each participant. This phase of the study continues for 2 months.
62473678|NCT03465163|EXPERIMENTAL|Open Deep Brain Stimulation|Deep Brain Stimulation During this phase the deep brain stimulation parameters may be altered from the probing optimised parameters according to patient needs.
62677176|NCT04209803|ACTIVE_COMPARATOR|NAC group|The second group will receive NAC orally 600 mg 3 times a day for 4 months.
62117904|NCT02031471|EXPERIMENTAL|Tocilizumab|Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
62117905|NCT05838495|EXPERIMENTAL|Enteral tube fed children|Children being fed an enteral formula with a feeding tube
62117906|NCT01523405||1|
62117907|NCT01622075|EXPERIMENTAL|SeQuent® Please|Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
62117908|NCT01622075|ACTIVE_COMPARATOR|Taxus Liberte|Paclitaxel Drug-eluting Coronary Stent and Conveying System
62117909|NCT01131624|ACTIVE_COMPARATOR|Ferric carboxymaltose|"Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.~subjects with bw \<66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening"
62117910|NCT01131624|ACTIVE_COMPARATOR|Oral Iron|Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
62117911|NCT02662855|ACTIVE_COMPARATOR|Control|WHO-recommended therapies, mainly symptomatic and supportive treatments. Briefly: body fluid management (intravenous or oral, depending on patient status), balanced nutrition (including glucose, electrolytes, vitamin, et al.), preventing intravascular volume depletion, correcting profound electrolyte abnormalities, avoiding the complications of shock, defervesce, anti-diarrheal, acesodyne, anti-anxiety. For patients with positive Plasmodium detection or bacterial infection, apply artemether-lumefantrine or antibiotics respectively. Details refer to 'Manual for the care and management of patients in Ebola Care Units/Community Care Centres, Interim emergency guidance' and 'Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker' by WHO.
62677177|NCT04209803|ACTIVE_COMPARATOR|Minoxidil + NAC group|The third group will receive combined treatment of Minoxidil 5% twice daily and oral NAC 600 mg 3 times a day for 4 months.
62677178|NCT04209803|NO_INTERVENTION|Control group|The fourth group will be the patients who are refusing the treatment and will be followed-up over 4 months.
62677179|NCT00422929||chronic otitis media with effusion (OME)|history of chronic effusion (3 months if both ears, 6 months if one ear, or 3 episodes of effusion each lasting for 2 months or longer)
62677180|NCT00422929||recurrent AOM|recurrent acute otitis media (3 episodes in 6 months or 4 episodes in 1 year)
62677181|NCT00422929||no OM|no history of significant otitis media (i.e., does not meet criteria for chronic OME or recurrent AOM)
61918734|NCT05369390|EXPERIMENTAL|Part A: Single ascending dose (SAD)|Participants will receive a single dose of any of the six different dose levels (1, 3, 6, 12, 25 and 50 milligrams (mg)) of NNC0487-0111 A or matching placebo in a sequential manner with the dose increasing between cohorts.
62117912|NCT02662855|EXPERIMENTAL|Treatment|WHO-recommended therapies plus oral administration of Favipiravir
62117913|NCT00027820|EXPERIMENTAL|Treatment (PBSCT)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -4, -3, and -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO every 8 hours on days 0-40 with taper to day 96."
62117914|NCT03961633|EXPERIMENTAL|AWARE intervention|"This arm is the treatment group, which receives the intervention, and is the only arm in the study. See the intervention column for more descriptions."
62117915|NCT02682446||Negative H. pylori group|The participants revealed negative findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
62117916|NCT02682446||Previous H. pylori infection group|The participants revealed positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
62473679|NCT04044261|EXPERIMENTAL|Study Arm|Single open-label study arm. All participants are enrolled into this arm.
62473680|NCT04665063|EXPERIMENTAL|Auto CAR-T|Patients will be treated with Auto CAR-T cells
62473681|NCT02405481|NO_INTERVENTION|Wait List Control|
62677182|NCT04653064|EXPERIMENTAL|Placebo Cream first|"Each participant will undergo thermal pain tasks after being administered a treatment cream to one of eight body sites."
62677183|NCT04653064|EXPERIMENTAL|Control Cream first|"Each participant will undergo thermal pain tasks after being administered a control cream to one of eight body sites."
62677184|NCT05803499|EXPERIMENTAL|Targeted Intervention for Sleep and Bereavement (Targeted CBT-I)|This intervention consists of 6, 50-60-minute online individual sessions delivered via video conference. Content will include a CBT-I based program adapted to the specific needs of spousally bereaved individuals.
62677185|NCT05803499|PLACEBO_COMPARATOR|Information-Only Control|The information-only control consists of 1, 50-60-minute online individual session delivered via video conference. Content will provide basic psychoeducation about sleep and aging.
62677186|NCT06695520|EXPERIMENTAL|Group (A)|patients will receive General Anesthesia and Caudal Epidural Anesthesia
62117917|NCT02682446||Eradicated H. pylori group|The participants revealed to success for H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
62305952|NCT04788563|EXPERIMENTAL|Heat-sensitive moxibustion group C|Patients who voluntarily choose to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
62305953|NCT04788563|ACTIVE_COMPARATOR|Control group C|Patients who voluntarily choose to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
62305954|NCT00066781|EXPERIMENTAL|Cohort I (closed to accrual 11/17/05)|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62473682|NCT02405481|EXPERIMENTAL|SEPA III Intervention|SEPA brings together two important theoretical perspectives that will be effective and sustainable for HIV/AIDS prevention among Hispanic women in an inner city environment. The content and learning strategies of SEPA are based on the social cognitive theory and of HIV/AIDS prevention that prior research has shown to be the most effective in increasing HIV/AIDS prevention behaviors, modified to take into account the special needs of Hispanic women related to gender inequality and cultural values and practices. SEPA's conceptual framework integrates the Social Cognitive Model of behavioral change with Freire's Pedagogy of the Oppressed that guides the delivery and contextual tailoring.
62473683|NCT00244764|EXPERIMENTAL|Pazopanib|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
62473684|NCT00244764|PLACEBO_COMPARATOR|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
62473685|NCT02674880|EXPERIMENTAL|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
62117918|NCT02682446||Persistent H. pylori group|The participants revealed to fail in H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
62117919|NCT01688089|EXPERIMENTAL|ODM-103|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
62117920|NCT01688089|PLACEBO_COMPARATOR|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
62117921|NCT01688089|ACTIVE_COMPARATOR|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
62117922|NCT06027372||IPF patients with acute exacerbation during test period|"IPF patients completing pulmonary function, overnight SpO2 monitor and LARGAN ECG Holter reqire hospitalization during test period."
62117923|NCT06027372||IPF patients without acute exacerbation during test period|"IPF patients completing pulmonary function, overnight SpO2 monitor and LARGAN ECG Holter remain stable during test period."
62117924|NCT01606631||Arm 1 : experimental (case)|Patients included in the study and admitted to the ICU either directly from UAA or after a hospitalization in a specialty, for a severe sepsis or septic shock on their infectious disease community.
62305955|NCT00066781|EXPERIMENTAL|Cohort II|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62305956|NCT03771872|EXPERIMENTAL|Virtual Prism Adaptation Therapy|This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
62473686|NCT02674880|PLACEBO_COMPARATOR|Placebo|5 ml of saline via nebulizer b.i.d.
62677187|NCT06695520|NO_INTERVENTION|GROUP (B)|patients will receive General Anesthesia only
62677188|NCT05259540|EXPERIMENTAL|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days
62677189|NCT02246036|EXPERIMENTAL|APD probe|Placement of a duodenal probe during 24 hours.
62677190|NCT04506775|EXPERIMENTAL|Wrist one|Wrist one will have both the ViTrack wrist cuff on one wrist
62677191|NCT04506775|ACTIVE_COMPARATOR|Wrist Two|Wrist two and the radial artery catheter in the opposite wrist.
62677192|NCT03047213|EXPERIMENTAL|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62677193|NCT04298112||relapse after radical treatment for prostate cancer|prostate cancer patients with biochemical relapse following radical treatment, or patients with persistently elevated PSA levels after radical prostatectomy, that have been (or will be) referred to PSMA PET/CT and PSMA PET/MRI at one of the participating hospitals.
62677194|NCT01063881|EXPERIMENTAL|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity may be increased after 4 weeks to 60mg taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
62305957|NCT03771872|SHAM_COMPARATOR|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
62473687|NCT06030583||Study Group|The research group comprises children aged 8 to 11 diagnosed with Attention Deficit Hyperactivity Disorder.
62473688|NCT06030583||Control Group|The control group consists of children aged 8 to 11 who do not have a diagnosis of ADHD, matched in terms of age and gender with the research group.
62473689|NCT01038817|ACTIVE_COMPARATOR|fluoride varnish|"Duraphat:~Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)"
62473690|NCT01038817|NO_INTERVENTION|control|no application on the other side
62473691|NCT01997047||Tachypneic children|All tachypneic children under 5 yrs age presenting to study centres. No exclusions.
61918735|NCT05369390|EXPERIMENTAL|Part B: Multiple ascending dose (MAD)|Participants will receive NNC0487-0111 once daily for 10 days at any of the five different dose levels (3, 6, 12, 25 and 50 milligrams (mg)) of NNC0487-0111 A or matching placebo in a sequential manner with the dose increasing between cohorts.
62305958|NCT06430255|EXPERIMENTAL|Global Postural Re-education|is a physical therapy method developed in France by Philippe-Emmanuel Souchard. This therapy method is founded on an integrated concept of the muscular system, which is composed of muscle chains. These muscle chains are susceptible to shortening as a result of constitutional, behavioral, and psychological factors, Patients allocated to this group will be having a GPR method course of 8 sessions, two sessions per week for a four-week period. Each session will consist of 3 therapeutic postures, lying, sitting, or standing, to be held for 15-20 minutes each. The postures used are considered the most effective in lengthening the posterior chain, which is usually shortened in patients with LBP.
62305959|NCT06430255|EXPERIMENTAL|Laser-guided Supervised Exercise|Patients allocated to this group will be having a LGSE method course of 8 sessions, two sessions per week for a four-week period. Each session will consist of lumbar movement control exercises. The physiotherapist responsible for the intervention corrected each participant individually as required when performing the movement control exercises to ensure the correct technique. The exercises is progress from the supine position through to standing, 4-point kneeling. The program consists of 8 exercises first starting with abdominal-diaphragmatic breathing and isolated contraction of the transversus abdominis contractions of 10 seconds' duration 5 repetition, Abdominal preparation, Pelvic elevation with previous transversus abdominis contraction and neutral pelvis,
62305960|NCT02448550|EXPERIMENTAL|bivalirudin|Bivalirudin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
62473692|NCT02625558|ACTIVE_COMPARATOR|Riociguat|Active drug
62473693|NCT02625558|PLACEBO_COMPARATOR|Placebo|placebo
62473694|NCT04841317|EXPERIMENTAL|Single-arm: Blood pressure intervention|Participants will use a mobile technology system comprising of a remote home blood pressure monitoring cuff and a mobile application integrated with a clinician-facing component to view and manage remote blood pressures. Participants will use this for 12 weeks, with assessment of blood pressure outcomes and anonymous surveys regarding the technology at 12 weeks.
61918736|NCT05369390|EXPERIMENTAL|Part C|Participants will receive NNC0487-0111 A or matching placebo once-daily for 12 weeks: 3 or 6 mg for weeks 1-2, 6 or 12 mg for weeks 3-4, 12 or 25 mg for weeks 5-6, 25 or 50 mg for weeks 7-8, 25 or 50 mg for weeks 9-10 and 50 or 2\*50 mg for weeks 11-12.
62117925|NCT01606631||Arm 2 : control|Patients included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before hospital discharge.
62117926|NCT04846491|EXPERIMENTAL|Nucleot(s)ide-treated patients-Experimental Group 1|
62117927|NCT04846491|EXPERIMENTAL|Nucleot(s)ide-treated patients-Experimental Group 2|
62117928|NCT04846491|ACTIVE_COMPARATOR|Nucleot(s)ide-treated patients-Control Group|
62305961|NCT02448550|ACTIVE_COMPARATOR|unfractionated heparin|Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
62473695|NCT05099380|EXPERIMENTAL|TEST lens|Eligible subjects that are habitual wearers of silicone hydrogel spherical contact lenses will be randomized to the TEST Lens for the duration of the study.
62473696|NCT05099380|ACTIVE_COMPARATOR|CONTROL lens|Eligible subjects that are habitual wearers of silicone hydrogel spherical contact lenses will be randomized to the CONTROL Lens for the duration of the study.
62473697|NCT04297891||ARSACS|Participants with genetically confirmed ARSACS (ORPHA:98) will be recruited. Target sample size for the ARSACS cohort is 120.
62473698|NCT04297891||SPG7|Participants with genetically confirmed SPG7 (ORPHA:99013) will be recruited. Target sample size for the SPG7 cohort is 72.
62473699|NCT04297891||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as the ARSACS and SPG7 cohort. Target sample size for the control cohort is 50.
62473700|NCT02727088|ACTIVE_COMPARATOR|Pulpectomy : root canal treatment|Pulpectomy : ablation of the whole dental pulp, preparation and filling of the whole root canal system
62473701|NCT02727088|EXPERIMENTAL|Pulpotomy : Conservative pulp management|Pulpotomy : ablation of the coronal part of the pulp
62473702|NCT02399917|EXPERIMENTAL|Phase 1b Lead-in Cohort 1|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m\^2 Lirilumab 1.0 mg/kg"
62117929|NCT04846491|OTHER|Treatment Naive Group|
62117930|NCT00970307|EXPERIMENTAL|GSK2202083A + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
62473703|NCT02399917|EXPERIMENTAL|Phase 1b Lead-in Cohort 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m\^2 Lirilumab 3.0 mg/kg"
62473704|NCT02399917|EXPERIMENTAL|Phase 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m\^2 Lirilumab 3.0 mg/kg"
61918737|NCT05369390|EXPERIMENTAL|Part D|Participants will receive NNC0487-0111 B or matching placebo once-daily for 12 weeks: 3 or 6 mg for weeks 1-2, 6 or 12 mg for weeks 3-4, 12 or 25 mg for weeks 5-6, 25 or 50 mg for weeks 7-8, 25 or 50 mg for weeks 9-10 and 50 or 2\*50 mg for weeks 11-12.
61918738|NCT03829800|EXPERIMENTAL|Ensure® Abbott Nutrition|A standard nutritional formula not specific for diabetics
61918739|NCT03829800|EXPERIMENTAL|Glucerna® Abbott Nutrition|A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
62305962|NCT00337636|EXPERIMENTAL|HuCNS-SC|human central nervous system stem cells
62305963|NCT01777633|EXPERIMENTAL|re-irradiation|re-irradiation for progressive DIPG in children
62305964|NCT01940718|EXPERIMENTAL|Transdermal Testosterone|Transdermal Androgel 1.62% (20.25 mg testosterone = 1 pump actuations) to be applied once daily for 3.5 months. Initial dose will be at lowest level, 20.25 mg testosterone with dosing adjustments given in 20.25 mg testosterone increments.
62473705|NCT02882945||Group A|150 healthy blood donors without a family history of diabetes mellitus
62473706|NCT02882945||Group B|200 cases of type 2 DM without complications (group B), there were 62 males and 108 females, aged 29-53, with an average age of 42 ± 9 years
62473707|NCT02882945||Group C|120 cases of type 2 DM with macroangiopathy complication (group C), there were 70 males and 50 females, aged 40-53, with an average age of 47 ± 6 years. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD
62473708|NCT00904423|EXPERIMENTAL|Vitamin D|
62473709|NCT04437706||Participants|Participants completing COVID-19 testing
61918740|NCT03829800|EXPERIMENTAL|Diasip® Nutricia Advanced|A formula whose composition has isomaltulose and resistant starch
61918741|NCT03829800|ACTIVE_COMPARATOR|Glicolab®|Glucose solution
62117931|NCT00970307|ACTIVE_COMPARATOR|INFANRIX HEXA + MENJUGATE GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 3 and 4 months of age, 2 doses of Menjugate® vaccine at 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Menjugate® vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
62117932|NCT00970307|ACTIVE_COMPARATOR|INFANRIX HEXA + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
62117933|NCT00282971|EXPERIMENTAL|Inhaled Insulin|Inhaled insulin plus oral therapy
62117934|NCT00282971|OTHER|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
62117935|NCT04263480|EXPERIMENTAL|Arm A: Carfilzomib + Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated. Patients will receive in addition Carfilzomib for two years.
62117936|NCT04263480|ACTIVE_COMPARATOR|Arm B: Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated.
62117937|NCT05746325|EXPERIMENTAL|Treatment (TTFields, digital photos)|Patients have transducer arrays applied and digital photographs taken of placement on study. Patients wear the NovoTTF-200T portable system on study. Patients also undergo MRI and may undergo LP during screening and on study.
62117938|NCT01845532|EXPERIMENTAL|TPI group|
62117939|NCT01845532|ACTIVE_COMPARATOR|ELMA group|
62117940|NCT01845532|NO_INTERVENTION|None group|
62117941|NCT06281704|EXPERIMENTAL|Part 1 : AK101 IV|Subjects will be enrolled in sequential cohorts treated with successively higher doses of AK101 via intravenous injection on Day1.
62117942|NCT06281704|EXPERIMENTAL|Part 1 : AK101 SC|Subjects will be enrolled in sequential cohorts treated with successively higher doses of AK101 via subcutaneous injection on Day1.
62117943|NCT06281704|PLACEBO_COMPARATOR|Part 1 :Placebo|Subjects will be received matching placebo intravenously or subcutaneously on Day1.
62473710|NCT04212234|EXPERIMENTAL|free ultrasound propagation velocity|ultrasound exams will be performed using several ultrasound propagation velocities
62473711|NCT04212234|NO_INTERVENTION|conventional ultrasound propagation velocity|ultrasound exams will be performed using the 1540m/s conventional celerity
62473712|NCT02803450|EXPERIMENTAL|High Volume, Low Concentration via Epidural Needle|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via epidural needle followed by catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
62305965|NCT00249561|EXPERIMENTAL|Recovery by Choice|A modified Therapeutic Community program.
62305966|NCT00249561|ACTIVE_COMPARATOR|Intensive Outpatient Program|Designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism.
62305967|NCT01576081|EXPERIMENTAL|Unilateral orthotic intervention|The HEPHAISTOS orthotic was worn unilaterally for 56days by 11 healthy male subjects.
62473713|NCT02803450|EXPERIMENTAL|High Volume, Low Concentration via Epidural Catheter|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via the epidural catheter administration following catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
61918742|NCT03742440|OTHER|GrafixPL PRIME|Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
61918743|NCT01580371|EXPERIMENTAL|Treatment|CKD-581
62677195|NCT04179162|EXPERIMENTAL|Bacillus Calmette-Guérin (BCG) and Gemcitabine|Eligible patients will receive combination intravesical chemoimmunotherapy. Treatment is sequential, with twice-weekly intravesical gemcitabine given at weeks 1, 4, 7, and 10, for a total of 8 doses, administered in a standard fashion. In phase I, the dose of gemcitabine will depend on the dose level being assessed for the determination of the MTD. phase II, 1 dose level will be given (the MTD from phase I). Fixed doses of once-weekly intravesical BCG therapy (TICE strain, 50 mg) will be given at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6 (+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days), for a total of 6 doses, also administered in a standard fashion. All intravesical therapy will be administered in the chemotherapy suite on an outpatient basis, in accordance with standard clinical practice. Intravesical therapies will be retained in the bladder for up to 2 h (BCG) or 1 h (gemcitabine), or as tolerated.
61918744|NCT02394145|EXPERIMENTAL|Ticagrelor 180mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
61918745|NCT02394145|ACTIVE_COMPARATOR|Clopidogrel 75mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
61918746|NCT02394145|ACTIVE_COMPARATOR|Clopidogrel 150mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
61918747|NCT02394145|ACTIVE_COMPARATOR|Ticagrelor 180mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed
61918748|NCT02394145|ACTIVE_COMPARATOR|Clopidogrel 75mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
61918749|NCT00536861|EXPERIMENTAL|1|
61918750|NCT02500576|EXPERIMENTAL|Arm I (pembrolizumab, high-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide IV over 2 hours on days -7 and -6 followed by fludarabine phosphate IVPB over 15-30 minutes on days -5 to -1. Patients also receive therapeutic tumor infiltrating lymphocytes IV over 15-60 minutes on day 0 followed by high-dose aldesleukin IV over 15 minutes every 8-16 hours for up to 15 doses on days 1-5. Beginning between 21-28 days after TIL infusion, patients receive maintenance therapy comprising pembrolizumab IV over 30 minutes every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62305968|NCT01701791|EXPERIMENTAL|Computerized Decision Support System (CDSS)|GPs will use a CDSS with treatment algorithms, supervision from a consultant psychiatrist, and despatch to patients of reminders via mobile texting or automatic mobile (or landline) phone calls to improve adherence to the treatment prescribed.
61918751|NCT02500576|EXPERIMENTAL|Arm II (pembrolizumab, low-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide and fludarabine phosphate and therapeutic tumor infiltrating lymphocytes as in Arm I, followed approximately 6 hours later by low-dose aldesleukin SC for 14 days. Patients also receive pembrolizumab as in Arm I.
61918752|NCT04322539|EXPERIMENTAL|Fruquintinib Plus Best Supportive Care (BSC) Group|Participants will be orally administered Fruquintinib 5 mg in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break (with each cycle length of 28 days).
61918753|NCT04322539|PLACEBO_COMPARATOR|Placebo Plus BSC Group|Participants will be orally administered Placebo 5 mg in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break (with each cycle length of 28 days).
62117944|NCT06281704|EXPERIMENTAL|Part 2:AK101-AK101 low-dose SC every 8 weeks|Subjects received single IV infusion of AK101 on Day1 will be randomized to receive low-dose AK101 subcutaneously every 8 weeks along with matching placebo subcutaneously (to maintain the blind).
62117945|NCT06281704|EXPERIMENTAL|Part 2: AK101-AK101 high-dose SC every 8 weeks|Subjects received single IV infusion of AK101 on Day1 will be randomized at Week8 to receive high-dose AK101 subcutaneously every 8 weeks.
62117946|NCT06281704|EXPERIMENTAL|Part 2: Placebo-AK101 low-dose SC every 8 weeks|Subjects received placebo on Day1 will receive a single IV infusion of AK101 at Week8 along with matching subcutaneous placebo (to maintain the blind). And subjects will be randomized at Week8 to receive low-dose AK101 subcutaneously every 8 weeks along with matching placebo subcutaneously (to maintain the blind).
61918754|NCT02837484|OTHER|NuTech Affinity™ Membrane|Sharp dissection of the defect will be performed being careful not to violate the subchondral bone sparing the calcified cartilage layer. After hemostasis is reached, the defect will be treated with an Affinity™ patch stabilized with fibrin glue.
62305969|NCT01701791|NO_INTERVENTION|Treatment as usual|GPs will provide TAU, will make their own decisions and will therefore not use the CDSS. Patients will not receive any reminders.
62305970|NCT00332657|EXPERIMENTAL|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
62305971|NCT00332657|EXPERIMENTAL|Anecortave Acetate, 30 mg|One 0.5 mL injection of 60 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
62305972|NCT00332657|SHAM_COMPARATOR|Anecortave Acetate Vehicle|One sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
61918755|NCT00280670|EXPERIMENTAL|Cognitive Behavioral Therapy|
61918756|NCT00280670|NO_INTERVENTION|Waitlist|
61918757|NCT02587247|EXPERIMENTAL|TF2 antibody/68Ga-IMP-288|TF2 antibody/68Ga-IMP-288
61918758|NCT04862195|ACTIVE_COMPARATOR|Attune™|Attune™ is a completely digital, 10-session, cognitive behavioral therapeutic intervention.
62305973|NCT04728854||Adult bullous pemphigoid patients|Patients with diagnosis of bullous pemphigoid will participate in monitoring with face to face assessment and remote telehealth visits with store and forward images captured.
62473714|NCT02803450|ACTIVE_COMPARATOR|Low Volume, High Concentration via Epidural Catheter|"Standard of Care Epidural Administration Epidural loading: Participants will receive 10ml of 0.125% bupivacaine with fentanyl 2mcg/ml in 5 ml increments 5 minutes apart via the epidural catheter following epidural catheter placement, per standard of care.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.0625% bupivacaine with 2mcg/ml fentanyl. The infusion rate will be set at 10ml/hr basal rate and 4ml every 15 minutes on demand with lockout of 26ml/hr.~For inadequate analgesia: One additional 5ml boluses of the standard 0.125% bupivacaine with 2mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
62473715|NCT02532621|EXPERIMENTAL|Venous InterGraft Connector (VIG)|This is a nonrandomized, single-arm study: All enrolled patients are assigned to the same treatment: AVG implantation using a VIG (study device) to create the venous anastomosis and standard suturing to create the arterial anastomosis of the implanted AVG.
62677196|NCT05522972|EXPERIMENTAL|Video Games|Participants will be required to play video games for a period of time: 1-2 hrs per session, 4-5 sessions/week for \~1-6 months
62677197|NCT05522972|EXPERIMENTAL|Perceptual learning|Participants will be required to practice a visual discrimination task (e.g. visual acuity, position acuity, contrast sensitivity, \& stereoacuity) for a period of time: 1-2 hrs per session, 4-5 sessions/week for \~1-6 months
62473716|NCT01197248|ACTIVE_COMPARATOR|Cystocele Plication|Placement of sutures over the pubocervical fascia during cystocele repair.
62473717|NCT01197248|EXPERIMENTAL|No Plication|Avoid sutures over pubocervical fascia during cystocele repair
62473718|NCT05886920|EXPERIMENTAL|D3S-002|Dose Escalation, D3S-002 administered orally.
62473719|NCT06102434|EXPERIMENTAL|Psilocybin|25 mg psilocybin
62473720|NCT04270721|EXPERIMENTAL|After intervention (sequence 1)|'After intervention' group receives the training immediately and data are only collected after the intervention.
62677198|NCT05522972|ACTIVE_COMPARATOR|Occlusion therapy|Participants will be required to cover the dominant eye during the day in order to push the brain to use the fellow amblyopic eye: 1-2 hrs per session, 4-5 sessions/week for \~1-6 months
62677199|NCT06305858|EXPERIMENTAL|Partial denture surgical procedure|
62677200|NCT06305858|ACTIVE_COMPARATOR|Total denture surgical procedure with patellar resurfacing|
62677201|NCT01775410|EXPERIMENTAL|Wolverine System|Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries
62473721|NCT04270721|EXPERIMENTAL|Before and after intervention (sequence 2)|For the 'Before and after intervention' group, data are collected both before and after the training.
62473722|NCT04270721|NO_INTERVENTION|Before intervention (sequence 3)|"The 'before intervention' group collects data only before the training.~\*This arm will receive the educational intervention after data collection is completed."
62677202|NCT01820104|PLACEBO_COMPARATOR|Placebo|oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
62677203|NCT01820104|EXPERIMENTAL|Combination of lansoprazole and sitagliptin|oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
62677204|NCT06415344|EXPERIMENTAL|GTX-102|Participants will receive GTX-102 via intrathecal lumbar puncture (IT LP) on a intrapatient flexible dosing schedule.
62677205|NCT06272929||45 patients with behcet disease|
62677206|NCT06272929||45 healthy participants|
62677207|NCT03699995|EXPERIMENTAL|Screening (imaging, biopsy)|Participants undergo imaging of suspicious moles via smartphone app MoleMapper/Sklip app/native smartphone camera app, digital dermoscopy, and confocal microscopy. Participants then receive lidocaine SC and undergo shave or punch biopsy of suspected melanomas.
62677208|NCT03838328|EXPERIMENTAL|Dose group 1|The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.
62677209|NCT03838328|EXPERIMENTAL|Dose group 2|The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.
62677210|NCT03838328|ACTIVE_COMPARATOR|Dose group 3|The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.
62677211|NCT05302518|EXPERIMENTAL|Cognitive behavioral therapy with exposure in virtual reality|This arm of the study will receive cognitive behavioral therapy with exposure in virtual reality. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
62677212|NCT05302518|ACTIVE_COMPARATOR|Cognitive behavioral therapy with exposure in vivo|This arm of the study will receive cognitive behavioral therapy with exposure in vivo. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
62677213|NCT04286386||Arm Ia (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy.
62677214|NCT04286386||Arm Ib (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy and at a second time 3-4 weeks after.
62677215|NCT04286386||Arm II (MRSI, surgery)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy, followed by standard of care surgery within 6 months after.
62677216|NCT05492682|EXPERIMENTAL|Cohort 1|Patients in Cohort 1 are treated with PeptiCRAd-1 administered i.t.
62677217|NCT05492682|EXPERIMENTAL|Cohort 2|Patients in Cohort 2 are treated with PeptiCRAd-1 administered i.t. and s.c.
62473723|NCT00828698||Acute Myocardial Infarction patients|
62473724|NCT00573417|EXPERIMENTAL|modafinil|modafinil 100mg, 200mg, or 300mg (dose escalation)
62473725|NCT00573417|PLACEBO_COMPARATOR|placebo|placebo
62473726|NCT03916861|EXPERIMENTAL|Bioelectrical Impedance|The first group will be monitored by Inbody S20 analysis to measure fluid status. The Bioimpedance will be measured each time prior to hemodialysis session . The value of BIA measurement of more than 0.4 will be considered as edema.
62473727|NCT03916861|ACTIVE_COMPARATOR|Physicain-guided group|The fluid monitoring will be managed by physician-adjustment by physical examination and fluid balance record . The fluid balance (FB) is the total fluid administered minus the total fluids eliminated over a period of time.
62677218|NCT05541471|EXPERIMENTAL|Arm 1|Participants will receive a single dose of midazolam and digoxin on Day 1 in dosing period 1 followed by VX-548 every 12 hours (q12h) on Days 6 through 23 in dosing period 2. On Day 19, single doses of midazolam and digoxin will be administered with the morning dose of VX-548.
62677219|NCT03531502|ACTIVE_COMPARATOR|Standard medical therapy|Patients who have a positive NIPS study and are randomized to the medical therapy arm will either be initiated on antiarrhythmic therapy or will have their antiarrhythmic therapy intensified. All medication therapy is considered usual standard therapy.
62677220|NCT03531502|EXPERIMENTAL|Ventricular Tachycardia Ablation|Patients who have a positive NIPS study and are randomized to the ablation arm will undergo ventricular tachycardia ablation procedure guided by CardioInsight.
62677221|NCT03531502|OTHER|Negative NIPS/Non-intervention|Patients who had a negative NIPS study will not be assigned to a treatment group and will be followed according to standard of care.
62677222|NCT05718518|EXPERIMENTAL|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
62677223|NCT05718518|EXPERIMENTAL|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
62305974|NCT05850377||Participants with known or suspected High-Grade Gliomas|Patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy
62677224|NCT05718518|PLACEBO_COMPARATOR|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo
62677225|NCT00931320||3000 patients|Who have at least made 1 visit to the outpatient clinic within previous 6 months .
62677226|NCT03255499|EXPERIMENTAL|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
61918759|NCT04862195|ACTIVE_COMPARATOR|Cerena™|Cerena™ is a completely digital, 10-session, health education and wellness intervention.
61918760|NCT04059367|EXPERIMENTAL|NNC9204-1177 and cocktail of approved drugs|
62305975|NCT03940105|NO_INTERVENTION|Control|For 3 days during the control snack pattern, the participants will be asked to complete dietary recalls concerning their afternoon and evening snacking behavior. The participants will use the Automated Self-Administered 24-hour Recall (ASA24) system which was developed by the National Cancer Institute.
62305976|NCT03940105|ACTIVE_COMPARATOR|Standard Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch.
62305977|NCT03940105|ACTIVE_COMPARATOR|Large Package Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that the package sizes of all the foods are larger (though food amount remains the same).
62305978|NCT03940105|ACTIVE_COMPARATOR|Variety Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that there is about twice as much snack variety (though food amount remains the same).
62305979|NCT01905735|PLACEBO_COMPARATOR|placebo|1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .
62305980|NCT01905735|ACTIVE_COMPARATOR|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
62305981|NCT01631162|NO_INTERVENTION|lung disease|
62677227|NCT03255499|EXPERIMENTAL|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
61918761|NCT04403269|EXPERIMENTAL|IgIV|The experimental arm is human immunoglobulins. 2 infusion at D1 and D2. (0.8 g / kg by IV infusion)
61918762|NCT05920083|EXPERIMENTAL|CPAP withdrawal|CPAP withdrawal for 2 weeks
61918763|NCT02882373|EXPERIMENTAL|Group I (arginine)|Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
61918764|NCT02882373|PLACEBO_COMPARATOR|Group II (placebo)|Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
61919981|NCT06278233|NO_INTERVENTION|Sham stimulation study arm|In the sham condition, the same electrode placement will be used, during which the current will be increased for 15 seconds, kept at 1 mA for 15 seconds, decreased for 15 seconds and terminated, and the 20 minute session duration will be performed with 45 seconds of real stimulation accompanied by speech with a metronome.
62305982|NCT01243931|EXPERIMENTAL|Surgery|OCT is assisting in surgery guidance.
62305983|NCT02108730||non-focal congenital hyperinsulinism|13 children and one adult with non-focal congenital hyperinsulinism
62473728|NCT00564408|EXPERIMENTAL|I|
62473729|NCT02974595||Affected Participants|Individuals with undifferentiated autoinflammatory diseases or genetically defined conditions, such as NOMID/CAPS, DIRA, CANDLE, SAVI, and NLRC4 MAS.
62473730|NCT02974595||Healthy Volunteer|Volunteers without known autoinflammatory disease who consent to providing blood specimen for genetic testing.
62473731|NCT02974595||Unaffected Relatives|Blood relatives of the affected patients without known autoinflammatory disease who consent to providing specimen for genetic testing.
62677228|NCT03255499|EXPERIMENTAL|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
62677229|NCT03255499|ACTIVE_COMPARATOR|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
61918765|NCT03160196|EXPERIMENTAL|Experimental practices|The decision support tool is a Web-based software program accessed via a GP computer desktop icon. Clicking the icon opens a single page of tick boxes asking for relevant aspects of the presenting illness. Most fields for relevant medical history and patient demographics are automatically populated from data in the electronic health record. Depending on diagnosis and risk estimation, the tool recommends a guideline-based management strategy. Override options exist but require a justification from the GP. The tool also provides relevant prescriptions, radiology access, and referral forms, and a variety of patient information leaflets. GPs in practices randomized to the intervention group will have to initiate the tool but will not have to follow the tool's advice.
61918766|NCT03160196|ACTIVE_COMPARATOR|Control practices|Control practices will be aware of the tool but will be unable to access it and managed patients by usual care, which could include care aligned with the Guidelines. Prior to randomization, GPs from all participating practices (control and intervention) will attend a 1-hour face-to-face didactic education session on diabetes mellitus 2 management and the Colombia diabetes mellitus 2 Guidelines. The intervention pertains to the cluster level.
61918767|NCT01812980|EXPERIMENTAL|Trivalent Inactivated Influenza Vaccine|"Single dose, intramuscular injection from a pre-filled syringe~WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
61918768|NCT01444677|EXPERIMENTAL|MB12066 300mg|single dose
61918769|NCT01444677|ACTIVE_COMPARATOR|MB12066 400mg|single dose
61918770|NCT01444677|ACTIVE_COMPARATOR|MB12066 100mg|multiple dose
61918771|NCT01444677|ACTIVE_COMPARATOR|MB12066 200mg|multiple dose
62677230|NCT00890097|EXPERIMENTAL|AL-8309B 1.0%|AL-8309B 1.0% Ophthalmic Solution, 1 drop in each eye twice daily for 30 months, up to a maximum of 36 months
62677231|NCT00890097|EXPERIMENTAL|AL-8309B 1.75%|AL-8309B 1.75% Ophthalmic Solution, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
61918772|NCT01444677|PLACEBO_COMPARATOR|Placebo|Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
61918773|NCT00564720|EXPERIMENTAL|1|GEM/TAR
62305984|NCT04429750|ACTIVE_COMPARATOR|Immediate umbilical cord clamping|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH management procedure as described in the French national CDH management guidelines (Programme National de Soins).The resuscitation maneuvers are started after the umbilical cord is clamped."
62305985|NCT04429750|EXPERIMENTAL|Intact cord resuscitation|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH resuscitation maneuvers as described in the French national CDH management guidelines (Programme National de Soins) before the umbilical cord is clamped. The resuscitation maneuvers are started at birth while the umbilical cord still bridges mother and child."
62473732|NCT03128723|EXPERIMENTAL|Acne Mask|The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
62473733|NCT04282954|EXPERIMENTAL|Group 1|JP-1366 A mg
62677232|NCT00890097|PLACEBO_COMPARATOR|Vehicle|AL-8309B Vehicle, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
62677233|NCT06491576|EXPERIMENTAL|Test Group|
62677234|NCT06491576|PLACEBO_COMPARATOR|Placebo Group|
62677235|NCT03990337|NO_INTERVENTION|Control group (CPG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage using finger palpation without ultrasonography
62677236|NCT03990337|ACTIVE_COMPARATOR|Ultrasound group (USG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage after localization with ultrasonography
62677237|NCT02809781|EXPERIMENTAL|Intravenous infusion of MSCs|Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
62677238|NCT02809781|ACTIVE_COMPARATOR|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
62677239|NCT02144818|ACTIVE_COMPARATOR|GnRH agonist|
62677240|NCT02144818|ACTIVE_COMPARATOR|hCG|
62677241|NCT02144818|ACTIVE_COMPARATOR|dual triggering: GnRH agonist and hCG|
62305986|NCT03767738|EXPERIMENTAL|Intravitreal Aflibercept Injection (IAI)|Cohort 1 - Initial patients Cohort 2 - Additional patients
62473734|NCT04282954|EXPERIMENTAL|Group 2|JP-1366 B mg
62677242|NCT01282554|EXPERIMENTAL|stimulated group|stimulated group
62677243|NCT01282554|NO_INTERVENTION|control group|Control group : non stimulated group.
62473735|NCT04282954|EXPERIMENTAL|Group 3|JP-1366 C mg
62473736|NCT04282954|ACTIVE_COMPARATOR|Goup 4|Esomeprazole 40 mg
62473737|NCT00313794|EXPERIMENTAL|1|single arm
62677244|NCT02245893|ACTIVE_COMPARATOR|Screw|"In the SCREW Group (standard surgery technique), surgical treatment will be by closed reduction utilizing intraoperative fluoroscopy to visualize the reduction and percutaneous syndesmosis screw insertion. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
62677245|NCT02245893|ACTIVE_COMPARATOR|Anatomic repair technique (ART)|"In the ART group (study group) surgical treatment will be by open reduction and internal fixation. In order to stabilize the syndesmosis, direct visual anatomic alignment will be conducted and a syndesmotic screw inserted. In addition, fixation of the anterior ligament will be performed with use of a 2.7 to 4.0 mm suture anchor. Repair of the intact portion of the ligament will be made using a modified Mason -Allen repair. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
62473738|NCT03949426|EXPERIMENTAL|KPG-818|Dose escalation
62473739|NCT03949426|NO_INTERVENTION|Placebo|Matching placebo
62473740|NCT03428386|EXPERIMENTAL|Gastric plication ileal bypass|single-anastomosis plication ileal bypass
62473741|NCT00739947||1|Standard of Care
62677246|NCT03517020|EXPERIMENTAL|Test|Torrent's Nebivolol Tablets 20 mg
62677247|NCT03517020|ACTIVE_COMPARATOR|Reference|Forest Pharmaceuticals Inc.'s Bystolic® Tablets 20 mg
62677248|NCT04476680|ACTIVE_COMPARATOR|Military recruits|Vitamin D supplementation (1000 IU/day D3 for 4 weeks, and 400 IU/d D3 as a maintenance dose)
61918774|NCT00564720|EXPERIMENTAL|2|GEM/OX/TAR
62677249|NCT04476680|NO_INTERVENTION|No intervention|
62677250|NCT05084885|EXPERIMENTAL|Online treatment|The participants will receive counseling over the internet.
62677251|NCT05084885|NO_INTERVENTION|Non-treatment|Participants who did not participant in the group were asked to complete the 12ve month followup questionnaire (but not the post treatment questionnaire).
62305987|NCT06396481|EXPERIMENTAL|To evaluate the safety and feasibility of allogeneic Vγ9Vδ2 T cell therapy.|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
61918775|NCT01718912|OTHER|Metronidazole-nystatin oral rinse, regular oral hygiene|Week 1: daily brushing with suction brush. Week two: daily brushing with a mixture of metronidazole-nystatin suspension.
62117947|NCT06281704|EXPERIMENTAL|Part 2:Placebo-AK101 high-dose SC every 8 weeks|Subjects received placebo on Day1 will receive a single IV infusion of AK101 at Week8 along with matching subcutaneous placebo (to maintain the blind). And subjects will be randomized at Week8 to receive high-dose AK101 subcutaneously every 8 weeks.
62117948|NCT02981706|ACTIVE_COMPARATOR|Arteriovenous Fistula (AVF) Group|Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
62117949|NCT02981706|ACTIVE_COMPARATOR|Arteriovenous Graft (AVG) Group|Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
62117950|NCT04013555|EXPERIMENTAL|N-acetylcysteine & Tryptophan|N-acetylcysteine 140 mg/kg up to a maximum of 15 g. Thirty minutes after N-acetylcysteine administration participants will receive Tryptophan, 6 grams.
62117951|NCT04013555|PLACEBO_COMPARATOR|Placebo & Tryptophan|Placebo 140 mg/kg up to a maximum of 15 g. Thirty minutes after placebo administration participants will receive Tryptophan, 6 grams.
62473742|NCT03859102|NO_INTERVENTION|ERAS Control/non-ERAS group|Standard usual care after cardiac surgery.
62473743|NCT03859102|EXPERIMENTAL|ERAS group|"Enhanced Recovery After Cardiac Surgery. Pre-op carbohydrate drink, Lansoprazole and Gabapentin.~Intra-operative: IV Paracetamol, Dexamethasone, Ondansetron, Local Anaesthetic to wounds.~Post-op: Gabapentin PO, Paracetamol IV then PO, Ondansetron IV for 24hrs. Opiate sparing. Early extubation, early mobilisation, early removal of invasive devices. Early discharge."
62677252|NCT05051657|EXPERIMENTAL|express pus range (PKU, MSUD, HCU, TYR and GA)|express plus to be transitioned onto over a maximum of 6 weeks and then incorporated into each participants usual diet for 28 days. Amount taken and frequency to be determined by dietitian.
62677253|NCT04394000||Before or control group|All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
62677254|NCT04394000||After or intervention group|On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
61918776|NCT01179997|ACTIVE_COMPARATOR|Tissue Doppler Imaging (TDI) optimization|Interventricular pacing delay optimized according to Tissue-Doppler echocardiography
61918777|NCT01179997|ACTIVE_COMPARATOR|Electrocardiographic optimization|Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram
61918778|NCT02708082||Glaucoma|Early, moderate or advanced glaucoma, glaucoma suspects or pre-perimetric glaucoma will perform OCT scanning and HFA perimetry
62117952|NCT02163954|ACTIVE_COMPARATOR|Clopidogrel|Patients treated with clopidogrel for 14 days
62117953|NCT02163954|EXPERIMENTAL|Ticagrelor|Patients treated with ticagrelor for 14 days
62117954|NCT03516604|EXPERIMENTAL|PF-04995274|"PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days~+ 1 placebo capsule, once daily for 7-9 days"
62677255|NCT02758080|EXPERIMENTAL|Matched|A molecular profile is identified using next generation sequencing. A participant in this arm is assigned to early clinical trial studying targeted agent, which is anticipated to have the best response rate.
62677256|NCT02758080|OTHER|Not matched|A participants in this arm is assigned to a clinical trial at physician's choice.
62677257|NCT06631092|EXPERIMENTAL|NECVAX-NEO1|Personalised neoantigen-targeting oral DNA cancer vaccine
62677258|NCT04191733|EXPERIMENTAL|Anterior Approach with KINCISE|Anterior Approach THA using KINCISE(TM) Surgical Automated System
62677259|NCT04191733|ACTIVE_COMPARATOR|Anterior Approach without KINCISE|Anterior Approach THA with a mallet (without KINCISE)
62677260|NCT03898609|EXPERIMENTAL|Low-fat diet|20% fat 20% protein 60% carbohydrate
62677261|NCT03898609|EXPERIMENTAL|Low-carbohydrate diet|45% fat 20% protein 35% carbohydrate
62677262|NCT05517785||Medicated|Assessment of motor function will be performed 1 hour after taking the usual stimulant ADHD medication.
62677263|NCT05517785||Unmedicated|Participants will remain unmedicated for the duration of the assessment, and will delay taking their usual stimulant ADHD medication until all the motor function assessments are completed.
62677264|NCT06450444|EXPERIMENTAL|Treatment Group|Active Stimulation
62677265|NCT06450444|OTHER|Control Group|Sham stimulation
62677266|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
62677267|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
62677268|NCT03363464||patients with T2DM initiating a GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist treated patients
62677269|NCT05292183|EXPERIMENTAL|Stimulation|This part will include 24 randomly chosen images from each of four categories (total of 96 images varying in valence and arousal) and will be presented block-randomized amygdala stimulation.
62677270|NCT05292183|NO_INTERVENTION|No stimulation|This part will include 24 randomly chosen images from each of four categories (total of 96 images varying in valence and arousal) and will be presented without amygdala stimulation.
62677271|NCT03593408||Pediatric Patients on ECMO Support|
62677272|NCT02079285||EUS-FNA|Any patients who will undergo EUS-FNA for pancreas lesion during the study period
62677273|NCT01856829|PLACEBO_COMPARATOR|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
62677274|NCT01856829|EXPERIMENTAL|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
62677275|NCT05977491|NO_INTERVENTION|Standard treatment|Patients are treated by the health care practitioner according to local protocol. This protocol corresponds to the syndromic approach without laboratory or microscopic testing. This may or may not include inspection and examination of the vulva, vagina, cervix and lower abdomen.
62677276|NCT05977491|ACTIVE_COMPARATOR|POCT based treatment|"The health care practitioner is informed about the POCT results for CT and NG (positive or negative). In addition, if the pH is within the normal level (4.5 and below). If it is higher, he will receive the outcome of the whiff test (positive or negative). For the second half of enrolled participants: if pH is \> 4.5 and whiff test is negative, the OSOM test for TV will be performed an self collected vaginal discharge. The Health care practitioner is informed if the TV test is positive or negative.~Examination of the patient is performed according to the discretion of the health care practitioner."
62677277|NCT05977491|ACTIVE_COMPARATOR|POCT based treatment PLUS|"Same as in POCT based treatment PLUS in addition:~1. All women complete a questionnaire prior to examination, including a screening tool for anxiety and depression and domestic violence. If they screen positive, they are offered psychological counseling. All women are informed about referral possibilities to a crisis management center.~2. Patients are given a short educational leaflet and 10 min audio-recording about physiological and abnormal vaginal discharge and about problems associated with unnecessary use of antibiotics."
62677278|NCT04165902|EXPERIMENTAL|steroid plus hyaluronic acid|steroid plus hyaluronic acid injection, one time per week, for 3 weeks
62677279|NCT04165902|ACTIVE_COMPARATOR|dextrose plus hyaluronic acid|dextrose plus hyaluronic acid injection, one time per week, for 3 weeks
62677280|NCT05274035||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
62677281|NCT04140903|EXPERIMENTAL|Oral antibiotics|Patients will be randomised to oral antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
62677282|NCT04140903|ACTIVE_COMPARATOR|Standard treatment|Patients will be randomised to continuation of standard intravenous antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
62677283|NCT05879432|EXPERIMENTAL|LSALT Peptide|LSALT peptide 10 mg IV administered over 1 hour twice daily, every 12 ± 1 hour, for 5 days
62677284|NCT05879432|PLACEBO_COMPARATOR|Placebo|Placebo IV administered over 1 hour twice daily, every 12 ± 1 hour, for 5 days
62677285|NCT05572216|NO_INTERVENTION|conventional group|Robot-Assisted Partial Nephrectomy without 3D navigation
62473744|NCT06161350||Group 1|"Infants who consulted between January 1st 2000 and December 31st 2009 (this is before the implementation of the pre-convention).~Inclusion criteria:~* Children consulting a pediatric gastroenterologist for feeding problems in UZB between the 1st of January 2000 and the 31st of December 2009 and receiving the label feeding difficulties.~* The infants have a pediatric feeding disorder that prevent them from feeding normally by oral means.~* The infants need or have needed (enteral or parenteral) artificial nutrition.~* The infants are aged between 0 and 12 years at their first presentation.~* The infants are capable of developing normal feeding behavior.~Infants will be excluded from this study if they:~* Have no 6-months follow-up available.~* Parents refusal to enter a multi-disciplinary approach for the feeding problems of their children."
62117955|NCT03516604|ACTIVE_COMPARATOR|Citalopram|"Citalopram, one x 20mg capsule, once daily for 7-9 days~+ 3 placebo tablets, once daily for 7-9 days"
62305988|NCT06396481|EXPERIMENTAL|To evaluate the therapeutic effect of allogeneic Vγ9Vδ2 T cells on brain malignant glioma|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
62305989|NCT06396481|EXPERIMENTAL|To investigate the expansion, infiltration and persistence of Vγ9Vδ2 T cells after reinfusion.|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
62305990|NCT00813475|EXPERIMENTAL|tight control|
62677286|NCT05572216|EXPERIMENTAL|3D IGRAPN GROUP|Robot-Assisted Partial Nephrectomy with 3D navigation
62677287|NCT04154488|EXPERIMENTAL|Mavorixafor|"Part 1: Adult participants and adolescent participants who weigh more than 50 kilograms (kg) will receive mavorixafor 400 milligrams (mg) (4 capsules of 100 mg each), orally once on Day 1. Adolescents weighing less than or equal to 50 kg will receive mavorixafor 200 mg (2 capsules of 100 mg each), orally once on Day 1.~Part 2: Eligible participants from Part 1 will receive once daily dosing of mavorixafor for 6 months."
62117956|NCT03516604|PLACEBO_COMPARATOR|Placebo|3 placebo tablets and 1 placebo capsule, once daily for 7-9 days
62305991|NCT00813475|EXPERIMENTAL|standard control|basal bolus insulin regimen
62677288|NCT05080543|ACTIVE_COMPARATOR|Group AT|will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)
62677289|NCT05080543|PLACEBO_COMPARATOR|Controlled|will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).
62677290|NCT03586232|PLACEBO_COMPARATOR|Control|Participants will take two placebo pills q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
62117957|NCT05274217|EXPERIMENTAL|Immediate group|Study participants in the immediate group will be randomly assigned to start the intervention immediately at the beginning of the fall trimester.
62117958|NCT05274217|EXPERIMENTAL|Waitlist group|Study participants in the waitlist group will be randomly assigned to start the intervention at the beginning of the winter trimester.
62117959|NCT00670020|EXPERIMENTAL|1|supplemental perioperative oxygen
62117960|NCT00670020|NO_INTERVENTION|2|Normal
62117961|NCT01942707|ACTIVE_COMPARATOR|Abdominoplasty without Scarpa´s Facia|Anchor-line abdominoplasty where the Scarpa's Fascia will be removed.
62117962|NCT01942707|EXPERIMENTAL|abdominoplasty with Scarpa's Fascia|Anchor-line abdominoplasty where the Scarpa's Fascia will be preserved.
62117963|NCT06211907|ACTIVE_COMPARATOR|Gas tamponade|Intravitreal gas tamponade
62117964|NCT06211907|EXPERIMENTAL|Air tamponade|Intravitreal Air tamponade
62117965|NCT03988036|EXPERIMENTAL|HER2-enriched|"Trial treatment is defined as neoadjuvant therapy only. The Investigational Medicinal Products (IMPs) are pembrolizumab, trastuzumab biosimilar and pertuzumab.~* Trastuzumab Biosimilar (Trazimera®) - Investigational Medicinal Product~  * Loading dose: 8 mg/kg bodyweight at initial administration infusion over 90 min; monitor patient for at least 6 h afterwards.~ * Maintenance dose: 6 mg/kg bodyweight, over 30-90 min; monitor patient for 2 h afterwards.~ * Route: Intravenous infusion.~ * Schedule: Every 3 weeks during the neoadjuvant phase.~* Pertuzumab (Perjeta®) - Investigational Medicinal Product~  * Loading dose: 840 mg, initial administration.~ * Maintenance dose: 420 mg.~ * Route: Intravenous infusion.~ * Schedule: Every 3 weeks during the neoadjuvant phase.~* Pembrolizumab (Keytruda®) - Investigational Medicinal Product~  * Dose: 200 mg.~ * Route: Intravenous infusion.~ * Schedule: Every 3 weeks during the neoadjuvant phase."
62305992|NCT04901338||Veno-arterial ECMO patients|Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption.
62305993|NCT04901338||Veno-venous ECMO patients|Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption.
62305994|NCT03038724|OTHER|Targeted testing|Patients complete a questionnaire on risk factors for HIV acquisition and are offered rapid (fingerprick) HIV testing if their questionnaire responses indicate they have HIV risk factors
62117966|NCT01628237|ACTIVE_COMPARATOR|Monocolumn spinal cord stimulation|Specify 5-6-5 Lead (only one column)
62305995|NCT03038724|OTHER|Non-targeted screening|Patients offered a brief information on HIV and HIV testing and are then offered rapid (fingerprick) HIV testing without completing an HIV risk factor assessment
62305996|NCT04685148|EXPERIMENTAL|Intervention|Estradiol patches (200 μg per day) 0-3 weeks postpartum.
62305997|NCT04685148|PLACEBO_COMPARATOR|Placebo|Placebo patches (Coloplast Comfeel) for 0-3 weeks postpartum
62305998|NCT04880174|OTHER|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
62305999|NCT00133744|ACTIVE_COMPARATOR|A, 1|
62473745|NCT06161350||Group 2|"Infants who consulted after the implementation of the pre-convention, who consulted between January 1st 2010 and December 31st 2021.~Inclusion criteria:~* Children consulting a pediatric gastroenterologist for feeding problems in UZB between the 1st of January 2010 and the 31st of December 2021 and receiving the label feeding difficulties.~* The infants have a pediatric feeding disorder that prevent them from feeding normally by oral means.~* The infants need or have needed (enteral or parenteral) artificial nutrition.~* The infants are aged between 0 and 12 years at their first presentation.~* The infants are capable of developing normal feeding behavior.~Infants will be excluded from this study if they:~* Have no 6-months follow-up available.~* Parents refusal to enter a multi-disciplinary approach for the feeding problems of their children."
62473746|NCT03084250|EXPERIMENTAL|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
62473747|NCT03084250|ACTIVE_COMPARATOR|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
62473748|NCT02648074|EXPERIMENTAL|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation.
62117967|NCT01628237|EXPERIMENTAL|Multicolumn spinal cord stimulation|Specify 5-6-5 Lead
62473749|NCT02648074|ACTIVE_COMPARATOR|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation."
62473750|NCT04730466|EXPERIMENTAL|Neuropsychological rehabilitation|In the experimental group, patients will receive a 12-session neuropsychological rehabilitation protocol that will be carried out over four weeks (3 weekly sessions). The protocol and the number of sessions has been designed by neuropsychologists following the Díez-Cirarda et al. recommendations
62117968|NCT04803630|EXPERIMENTAL|Treatment of depression (thermal therapy)|Patients undergo thermal therapy over 2.5 hours.
62117969|NCT02744521|EXPERIMENTAL|Symptom based screening intervention|
62306000|NCT00133744|EXPERIMENTAL|A, 2|
62473751|NCT04730466|NO_INTERVENTION|Control|The control group will not receive any therapy. The participants will be simply evaluated at the same time as the experimental group
62473752|NCT01017926|ACTIVE_COMPARATOR|Triazolam Reference Arm|There will be a clearance period of at least 3 days between the two phases of the study.
62473753|NCT01017926|EXPERIMENTAL|Triazolam Trial Arm|
62473754|NCT00507572||Observational (medical chart review)|Patients' medical records are reviewed prospectively and retrospectively.
62677291|NCT03586232|EXPERIMENTAL|Arnica Montana|Participants will take Arnica Montana, 30C oral, pill and a placebo pill q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
62677292|NCT03586232|EXPERIMENTAL|Arnica Montana and Bromelain|Participants will take Bromelain, 500mg oral pill + Arnica Montana, 30C oral, q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
62117970|NCT02744521|NO_INTERVENTION|control|
62117971|NCT05921708||X Generation|Generation X refers to those born between 1965 and 1979 (1).
62117972|NCT05921708||Y Generation|Generation Y is a population, also known as the Millennials, who was born between 1980 and 1994 (1).
62117973|NCT05921708||Z Generation|Generation Z are individuals born between 1995 and 2015 (1).
62117974|NCT01434134|EXPERIMENTAL|Metoprolol|Tablet, target dose 100 mg once daily
62117975|NCT01434134|PLACEBO_COMPARATOR|Placebo for Metoprolol|Tablet, target dose 100 mg once daily
62117976|NCT01434134|EXPERIMENTAL|Candesartan|Tablet, target dose 32 mg once daily
62117977|NCT01434134|PLACEBO_COMPARATOR|Placebo for Candesartan|Tablet, target dose 32 mg once daily
62306001|NCT00133744|EXPERIMENTAL|A, 3|Multiple micronutrient supplement
62306002|NCT06097806||Low-flow anesthesia group|In this group, ventilation parameters is adjusted to have fresh gas flow/minute ventilation ratio below 0.5
62306003|NCT06097806||High-flow anesthesia group|In this group, ventilation parameters is adjusted to have fresh gas flow/minute ventilation ratio above 1.0
62306004|NCT04516902|EXPERIMENTAL|100 μg LSD + MDMA placebo|100 μg LSD + MDMA placebo
62306005|NCT04516902|EXPERIMENTAL|LSD placebo +100 mg MDMA|LSD placebo +100 mg MDMA
62306006|NCT04516902|EXPERIMENTAL|100 μg LSD + 100 mg MDMA|100 μg LSD + 100 mg MDMA
62306007|NCT04516902|PLACEBO_COMPARATOR|LSD placebo+ MDMA placebo|LSD placebo+ MDMA placebo
61918779|NCT05680740|EXPERIMENTAL|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
61918780|NCT04590742|PLACEBO_COMPARATOR|Group 1|Placebo Tablet
61918781|NCT04590742|ACTIVE_COMPARATOR|Group 2|Melatonin (6mg)
61918782|NCT03882931|EXPERIMENTAL|TMS to left DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the left DLPFC and complete a visuomotor rotation task.
61918783|NCT03882931|EXPERIMENTAL|TMS to right DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the right DLPFC and complete a visuomotor rotation task.
61918784|NCT03882931|SHAM_COMPARATOR|TMS Control|A Sham Theta Burst Transcranial Magnetic Stimulation will be delivered to the right/left DLPFC and complete a visuomotor rotation task.
62117978|NCT02846480|EXPERIMENTAL|surgical treatment+behavior therapy+physical therapy|Including POP surgical treatment, and pre- post physical therapy to aim the posture, PFM awareness and the strengthening. They will be also informed and instructed on hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
62473755|NCT03957447||patients exhibiting skin wounds|Within the framework of Taabo HDSS Cross-sectional community and health services surveys are performed before wound management intervention (main study and substudy 1) is implemented (baseline) and are continued at 6 monthly intervals thereafter. Surveys are done door-to-door. All patients with skin lesions (broken skin barrier) are enrolled, lesions are documented with help of a questionnaire and photographic documentation.
62473756|NCT03957447||patients identified in the survey and willing to participate|Each patient with a wound will be enrolled. Presumptive clinical diagnosis and empirical treatment, as well wound assessment, will be recorded at enrollment and at each follow-up visit. Additional laboratory testing done within the framework of the local health system will also be recorded.
62677293|NCT00831896|EXPERIMENTAL|1|TAK-701
62677294|NCT06580925|SHAM_COMPARATOR|sham tape|
62677295|NCT06580925|ACTIVE_COMPARATOR|kinesio tape|
61918785|NCT03882931|EXPERIMENTAL|FUS to right/left DLPFC|Low intensity Focused Ultrasound stimulation will be delivered to either the left or right DLPFC depending on the subject's DLPFC response during their functional MRI flanker task.
61918786|NCT00719797|EXPERIMENTAL|Arm I (FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
61918787|NCT00719797|EXPERIMENTAL|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
61918788|NCT04049227|EXPERIMENTAL|Treatment (letrozole, abemaciclib)|Patients receive letrozole PO QD and abemaciclib PO BID on days 1-14. Patients then undergo standard of care hysterectomy on day 15.
61918789|NCT03993093||HIV with OIs|Treatment naive HIV patients with OIs
61918790|NCT02598570|EXPERIMENTAL|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
61918791|NCT04665882|EXPERIMENTAL|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
61918792|NCT04665882|NO_INTERVENTION|Standard axillary lymph node dissection|Standard axillary lymph node dissection was performed with complete resection of Berg's levels I and II.
61918793|NCT01258270|ACTIVE_COMPARATOR|(AQUACEL® Ag Surgical Dressing|
61918794|NCT01258270|ACTIVE_COMPARATOR|Standard island gauze and tape dressing|A standard island dressing consists of adhesive tape and gauze.
61918795|NCT06370078|EXPERIMENTAL|Human Albumin Group|About 23 patients will be objected for resuscitation with 60 gm (300 ml) human albumin 20% (HA 20%) over 2-3 hours combined usual practice with 30 ml/kg crystalloid.
61918796|NCT06370078|ACTIVE_COMPARATOR|Control Group|About 23 patients will be objected for resuscitation with 30 ml/kg crystalloid.
62117979|NCT02846480|EXPERIMENTAL|surgical treatment+behavior therapy|Including POP surgical treatment, and information and instruction about hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
62306008|NCT04526587||Basic science (medical chart review, biospecimen collection)|Patients electronic medical records are reviewed to capture clinical information, and patients undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples for diagnosis/treatment decision, biomarker assessments, and description of mechanisms of resistance/response related to ciclib-therapy.
62306009|NCT00793585|EXPERIMENTAL|Allopurinol|Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr \< 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
62306010|NCT00793585|OTHER|Control group|Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
62117980|NCT02130128|EXPERIMENTAL|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System
62117981|NCT01763892||Children admitted to hospital with a TBI|non-intervention study
62117982|NCT03624166|ACTIVE_COMPARATOR|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
62117983|NCT03624166|PLACEBO_COMPARATOR|isotonic saline|isotonic saline 3 ml volume will be given
62306011|NCT06313216|EXPERIMENTAL|Immediate Implant Placement Using duoteck membrane|after insertion of immediate implant, the dehisced bone defect will be grafted Using duoteck membrane
62306012|NCT06313216|EXPERIMENTAL|Immediate Implant Placement autogenous demineralized tooth graft|after insertion of immediate implant, the dehisced bone defect will be grafted Using autogenous demineralized tooth graft
62677296|NCT06580925|EXPERIMENTAL|dynamic tape|
62117984|NCT04206215|EXPERIMENTAL|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
61918797|NCT03705624|NO_INTERVENTION|Standard of Care|Standard of care with passively monitored malaria incidence at health centers that receive appropriate diagnostic and clinical supplies and Seasonal Malaria Chemoprevention (SMC) for children less than 5 years of age
61919982|NCT01040078|EXPERIMENTAL|7.5ug H1N1 vaccine|360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.
61919983|NCT01040078|EXPERIMENTAL|15ug H1N1 vaccine|360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.
62117985|NCT04206215|SHAM_COMPARATOR|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
62117986|NCT06028984|EXPERIMENTAL|Intervention app|Digitally-delivered self-guided intervention for depression accessed via mobile app
62117987|NCT06028984|ACTIVE_COMPARATOR|Control app|An app based control condition
62117988|NCT01101685|ACTIVE_COMPARATOR|Escitalopram|7 days dosing at 10mg per day
62117989|NCT01101685|PLACEBO_COMPARATOR|Placebo|7 days dosing at 10mg daily
62117990|NCT05271188|ACTIVE_COMPARATOR|Group 1 who will receive IPACK block|This group of patients will receive IPACK block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
62677297|NCT03451305|EXPERIMENTAL|Pillow group|Before surgery, with the patient lying in the supine position, a soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position. 12 hours duration suggested from 11:00 pm 1 night before the surgery till next day.
62677298|NCT03451305|NO_INTERVENTION|No pillow group|No intervention was given in this group before surgery.
62677299|NCT05349773||endoscopic left radial artery harvesting|single group of 32 patients listed for coronary artery bypass surgery with endoscopic radial artery harvesting.
62677300|NCT03681093|EXPERIMENTAL|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily orally
62677301|NCT03681093|EXPERIMENTAL|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily orally
62677302|NCT03681093|PLACEBO_COMPARATOR|Placebo|Placebo once daily orally
62677303|NCT06383052|EXPERIMENTAL|177Lu-NYM032 injection|
62677304|NCT01628809|ACTIVE_COMPARATOR|Rest and Relaxation|three-day relaxation retreat without mindfulness components
62677305|NCT01628809|EXPERIMENTAL|Mindfulness-Based Meditation|three-day mindfulness-based meditation retreat
62677306|NCT06403267|ACTIVE_COMPARATOR|NoNO-42|Randomized participants will be given a single, 2.6 mg/kg 20-minute intravenous dose of NoNO-42 with a target start time of less than 10 minutes from randomization.
62473757|NCT03957447||patients exhibiting Buruli ulcers < 2cm|Buruli ulcer patients fulfilling inclusion criteria will be offered thermotherapy instead of standard antibiotic treatment. Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
62677307|NCT06403267|PLACEBO_COMPARATOR|Placebo|Randomized participants will be given a single 20-minute intravenous dose of placebo (comprising normal saline infusion only) with a target start time of less than 10 minutes from randomization.
62677308|NCT03612895|EXPERIMENTAL|Internal Care Coordination|The smoker will be connected to a Tobacco Care Coordinator who is based centrally within the health care system but has ready access via EHR, email, and telephone with staff in each primary care practice.
62677309|NCT03612895|EXPERIMENTAL|External Community Referral|"This intervention will connect the smoker directly via warm transfer to a the Massachusetts Smokers Helpline operated by National Jewish Health, which will provide its standard services to smokers."
62677310|NCT03612895|OTHER|Usual Care|Passive referral to quitline and referral to primary care physician.
62677311|NCT06312813|EXPERIMENTAL|Imipramine and Vehicle|4% imipramine and vehicle are applied on a 2x2cm2 area of the subject's cheek. The imipramine is applied on one side of the subject's face (cheek) and vehicle is applied on the other side.
62677312|NCT06312813|EXPERIMENTAL|Amitriptyline and Vehicle|4% amitriptyline and vehicle are applied on a 2x2cm2 area of the subject's cheek. The amitriptyline is applied on side of the subject's face (cheek) and vehicle is applied on the other side.
62677313|NCT01230814|EXPERIMENTAL|Arm 1|Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
62677314|NCT01230814|PLACEBO_COMPARATOR|Arm 2|Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.
62677315|NCT05317871||Lewy Body Spectrum Diseases|
62117991|NCT05271188|ACTIVE_COMPARATOR|Group 2 who will receive adductor canal block|This group of patients will receive adductor canal block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
62473758|NCT03184389|OTHER|Within-participant micro-randomization|Each minute when participant is available is randomly assigned to either intervention (to practice a stress management exercise) vs. no intervention prompt. When intervention occurs, participant's smartphone vibrates and relaxation app opens, prompting performance of a relaxation exercise.
62117992|NCT03103295|EXPERIMENTAL|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
62117993|NCT05016713|ACTIVE_COMPARATOR|Intervention group 1|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
62473759|NCT01771263|OTHER|iControl-RP|iControl-RP is a system which performs controlled delivery of both remifentanil and propofol infusions.
62677316|NCT05317871||Progressive Supranuclear Palsy|
62677317|NCT05317871||Corticobasal Syndrome|
62677318|NCT05317871||Frontotemporal Degeneration|
62677319|NCT00440739|PLACEBO_COMPARATOR|1|1=placebo
62677320|NCT00440739|ACTIVE_COMPARATOR|2|2= etoricoxib
61919984|NCT01040078|PLACEBO_COMPARATOR|seasonal influenza vaccine|180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.
62677321|NCT00440739|ACTIVE_COMPARATOR|3|3=falvoxate
62677322|NCT00440739|ACTIVE_COMPARATOR|4|etoricoxib and flavoxate
62677323|NCT05807750|ACTIVE_COMPARATOR|Control|Enhanced care planning only (plus $15 as compensation for participation)
62677324|NCT05807750|EXPERIMENTAL|Intervention|Enhanced care planning plus a one-time $300 post-discharge income supplement
62677325|NCT03723525|EXPERIMENTAL|Package of HIV care|Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI), Rapid antiretroviral therapy (ART) initiation and Enhanced adherence support.
62677326|NCT03723525|EXPERIMENTAL|Standard HIV care|Screening and management of common OIs, basic health assessment (CD4, viral load and other tests), ARV drugs and follow up.
62677327|NCT06492720|EXPERIMENTAL|Low dose group FUS treatment|"FUS treatment will be conducted with following exposure parameters:~intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals."
62677328|NCT06492720|EXPERIMENTAL|High dose group FUS treatment|"FUS treatment will be conducted with following exposure parameters:~intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: three consecutive 10-minute FUS exposures with two 5-minute intermission intervals."
62677329|NCT02731768|ACTIVE_COMPARATOR|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively. They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
62677330|NCT02731768|EXPERIMENTAL|Social support-enhanced|Participants will receive the same intervention components as the Standard group, as well as two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
61918798|NCT03705624|EXPERIMENTAL|CCM|Standard of care supplemented with enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with artemether-lumefantrine (AL) according to national guidelines
61918799|NCT03705624|EXPERIMENTAL|CCM+MSAT|Standard of Care supplemented with CCM and Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
62117994|NCT05016713|ACTIVE_COMPARATOR|Intervention group 2|Chlorhexidine mouthwash is added to the previous oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.
62117995|NCT05016713|PLACEBO_COMPARATOR|Control group|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
62117996|NCT02805439|EXPERIMENTAL|S47445 15mg|
62117997|NCT02805439|EXPERIMENTAL|S47445 50mg|
62117998|NCT02805439|PLACEBO_COMPARATOR|Placebo|
62117999|NCT06113692||Moderna vaccination targeting SARS-CoV-2-exposed Case Cohort|All participants with myocarditis are selected among the participants who received at least 1 dose of Moderna vaccination targeting SARS-CoV-2. Cases are those participants who develop myocarditis or pericarditis any time during the follow-up after Moderna vaccination targeting SARS-CoV-2 vaccination.
62118000|NCT06113692||Myocarditis/Pericarditis Cohort|All participants with myocarditis and/or pericarditis with or without prior Moderna vaccination targeting SARS-CoV-2 exposure will be selected from the available databases.
62118001|NCT05345119||Sirolimus|Treatment with sirolimus for 12 weeks, given as a second-line treatment
62118002|NCT05345119||Methylprednisolone|Treatment with methylprednisolone for 12 weeks, given as a second-line treatment
62118003|NCT01287286|EXPERIMENTAL|AC-Can|Antrodia cinnamomea and concomitant chemotherapy
62118004|NCT01287286|PLACEBO_COMPARATOR|control|Placebo and concomitant chemotherapy
62118005|NCT04480827|EXPERIMENTAL|Part 1: Mild Hepatic Impairment (Cohort A)|8 mild hepatic impaired subjects
62118006|NCT04480827|EXPERIMENTAL|Part 1: Moderate Hepatic Impairment (Cohort B)|8 moderate hepatic impaired subjects
62118007|NCT04480827|EXPERIMENTAL|Part 1: Severe Hepatic Impairment (Cohort C)|8 severe hepatic impaired subjects
62118008|NCT04480827|EXPERIMENTAL|Part 1: Healthy Volunteers (Cohort D)|15 matched healthy volunteers
62118009|NCT04480827|EXPERIMENTAL|Part 2: Mild Hepatic Impairment Cohort|4 mild hepatic impaired subjects
62118010|NCT04480827|EXPERIMENTAL|Part 2: Moderate Hepatic Impairment Cohort|7 moderate hepatic impaired subjects
62118011|NCT04480827|EXPERIMENTAL|Part 2: Healthy Volunteers Cohort|7 matched healthy volunteers
62118012|NCT01944319|ACTIVE_COMPARATOR|Control group|The participants in control group will accept routine meropenem therapy
62118013|NCT01944319|EXPERIMENTAL|Study group|The participants in study group will accept meropenem therapy based on a PPK and PD model.
62118014|NCT01097343|ACTIVE_COMPARATOR|75 mg clopidogrel|
62118015|NCT01097343|ACTIVE_COMPARATOR|150 mg clopidogrel|
62118016|NCT01071733||ultrasound wrist|
62118017|NCT01071733||ultrasound finger|
62118018|NCT01071733||ultrasound ankle|
62118019|NCT02116543|EXPERIMENTAL|TD-6450|TD-6450 capsules
62118020|NCT02116543|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62118021|NCT00687388|ACTIVE_COMPARATOR|Alpha-blocker|Alpha-blocker only
62118022|NCT00687388|ACTIVE_COMPARATOR|NSAID|NSAID only
62118023|NCT00687388|EXPERIMENTAL|alpha-blocker and NSAID|Combination treatment of alpha-blocker and NSAID
62118024|NCT00568542|ACTIVE_COMPARATOR|1|35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
62118025|NCT00568542|PLACEBO_COMPARATOR|2|Placebo to erythropoetin beta.
62118026|NCT02441036|ACTIVE_COMPARATOR|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
62118027|NCT02441036|ACTIVE_COMPARATOR|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
62118028|NCT02441036|ACTIVE_COMPARATOR|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
62118029|NCT02441036|ACTIVE_COMPARATOR|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
62118030|NCT02441036|ACTIVE_COMPARATOR|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
62118031|NCT03903900|EXPERIMENTAL|Intervention group|Adults with chronic pain (n=48) matching the inclusion and exclusion criteria will be included.
61918800|NCT03615365||Patients with moderate-to-severe COPD.|"Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria.~Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry."
61918801|NCT03906227|ACTIVE_COMPARATOR|low CD5+ /on maintenance|Subjects in remission with Cluster of Differentiation (CD)19+CD5+ lower than 43% will continue on maintenance immunosuppression (Maintenance Therapy Group)- no randomization.
61918802|NCT03906227|ACTIVE_COMPARATOR|high CD5/ on maintenance|Subjects in remission with CD19+CD5+ 43% or greater, randomized to continue on maintenance immunosuppression (Maintenance Therapy Group)
61918803|NCT03906227|EXPERIMENTAL|high CD5 / NO maintenance|Subjects in remission with CD19+CD5+ 43% or greater , randomized to NO maintenance immunosuppression (NO Maintenance Therapy Group)
61918804|NCT06243744|OTHER|Procedure with the Renuvion APR System in lower facelift area|Subjects will receive a lower facelift surgery per the Investigator's standard clinical practice and treatment with the Renuvion APR System.
62118032|NCT03629730|EXPERIMENTAL|High dose|Will receive the greatest duration of coordination intervention training.
61918805|NCT06325930|EXPERIMENTAL|single dose of [14C]-HU6|
62473760|NCT06558851|EXPERIMENTAL|Exercise|The exercise intervention group perform three sessions of HIIT per week for 12 weeks. HIIT involves 4 times 4-minutes intervals at 85-95% of maximal heart rate (HRmax) with 3-minutes active breaks (\~60% HRmax) between the intervals. Two HIIT sessions are supervised at the NextMove core facility, and performed on treadmills or spinning bikes, while the last session of HIIT is unsupervised. In this unsupervised session, HIIT in a pool will be recommended based on the potential benefits gained from compression. The criteria for adequate compliance to the exercise intervention program will be set to ≥80%.
62473761|NCT06558851|NO_INTERVENTION|Control|In the control period, the participants will live as normal.
61918806|NCT06409455|ACTIVE_COMPARATOR|Intervention|Caregiver training
61918807|NCT06409455|OTHER|Waitlist control|Waitlist control
61918808|NCT05449483|EXPERIMENTAL|tislelizumab+ Paclitaxel+Cisplatin|Paclitaxel 135mg/m2 , D1; Cisplatin 80mg/m2, D1; tislelizumab 200mg D2 ; totally 2-4 cycles
61918809|NCT02891616|EXPERIMENTAL|FDG-PET/CT + FLT-PET/CT + PET/MR|"-Baseline, Week 3 (between days 14-20), Week 6 (between days 35-41)~* FDG-PET/CT - Patients required to fast for at least 4 hours prior to FDG administration. Roughly 60 minutes prior to PET/CT imaging, FDG will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~* FLT-PET/CT - Patients required to fast for at least 4 hours prior to FLT administration. Roughly 80 minutes prior to PET/CT imaging, FLT will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~* PET/MR - A limited whole body scan performed immediately following PET/CT imaging when possible. Should be performed at least once at each time-point. This scan will be of a more limited area and be performed for no more than 30 minutes."
61918810|NCT04609475|EXPERIMENTAL|Osseodensification technique|
61918811|NCT04609475|ACTIVE_COMPARATOR|Motor driven expanders' technique|
61918812|NCT01419821|ACTIVE_COMPARATOR|Vit D supplementation|Group 2-Infants with 25(OH)D below 15ng/ml receiving continued vitamin D supplementation of 800IU (4gtt/d) for one year.
61918813|NCT01419821|PLACEBO_COMPARATOR|Placebo group|Group 3- Infants with 25(OH)D below 15ng/ml those receiving the placebo.
61918814|NCT01419821|NO_INTERVENTION|Normal group|Group 1- infants with 25(OH)D above 15ng/ml (normal levels) will receive no intervention.
61918815|NCT03860935|EXPERIMENTAL|acoramidis HCl 800 mg|Subjects will receive acoramidis HCl 800 mg twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.
61918816|NCT03860935|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo to match twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.
62118033|NCT03629730|EXPERIMENTAL|Intermediate dose|Will receive a moderate duration of coordination intervention training.
62118034|NCT03629730|EXPERIMENTAL|Low dose|Will receive a short duration of coordination intervention training.
62473762|NCT04258917|EXPERIMENTAL|Total Knee Arthroplasty|
62473763|NCT04258917|EXPERIMENTAL|Anterior Cruciate Ligament Reconstruction|
62473764|NCT00486863|PLACEBO_COMPARATOR|Control|Placebo at 12-16 weeks gestation.
62473765|NCT00486863|EXPERIMENTAL|Praziquantel|Praziquantel at 12-16 weeks gestation.
62473766|NCT01997372|EXPERIMENTAL|high dose ATG,low dose ATG|
62677331|NCT03963622|ACTIVE_COMPARATOR|Control|Standard ventilation strategy.
62677332|NCT03963622|EXPERIMENTAL|Respiratory Mechanics|The goal of this arm is to individualize tidal volume (VT) and PEEP according to respiratory mechanics.
62677333|NCT06218784|EXPERIMENTAL|iN1011-N17 HCl Suspension (Part 1)|"Oral, Preformulation Suspension, b.i.d, Multiple Ascending Dose (Day 1\~ Day7)~Part 1:~Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning."
62677334|NCT06218784|EXPERIMENTAL|iN1011-N17 HCl Capsule (Part 1)|"Oral, Nano Suspension Powder Capsule, b.i.d, Multiple Ascending Dose (Day 1\~ Day7)~Part 1:~Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning."
62677335|NCT06218784|PLACEBO_COMPARATOR|Placebo Capsule (Part 1)|"Oral, Placebo capsule, b.i.d, Multiple Ascending Dose (Day 1\~ Day7)~Part 1:~Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning."
62677336|NCT06218784|EXPERIMENTAL|iN1011-N17 HCl Capsule (Part 2)|"Oral, Nano Suspension Powder Capsule, Single dose~Part 2:~2-period, randomized, open-label, crossover bioavailability part. Participants will receive a single oral dose of each study treatment (HCl salt and Mesylate salt), one during each of the 2 inpatient periods, in a randomized sequence of administration. There will be a minimum washout period of 5 days between each dose of study treatment."
62677337|NCT06218784|ACTIVE_COMPARATOR|iN1011-N17 Mesylate Capsule (Part 2)|"Oral, AA10 Capsule, Single dose~Part 2:~2-period, randomized, open-label, crossover bioavailability part. Participants will receive a single oral dose of each study treatment (HCl salt and Mesylate salt), one during each of the 2 inpatient periods, in a randomized sequence of administration. There will be a minimum washout period of 5 days between each dose of study treatment."
62677338|NCT06218784|EXPERIMENTAL|iN1011-N17 HCl Capsule (Part 3)|"Oral, Nano Suspension Powder Capsule, b.i.d, Multiple dose (Day 1\~ Day7)~Part 3:~2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.~Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning."
62677339|NCT06218784|PLACEBO_COMPARATOR|iN1011-N17 Mesylate Capsule (Part 3)|"Oral, AA10 Capsule, b.i.d, Multiple dose (Day 1\~ Day14)~Part 3:~2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.~Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning."
62677340|NCT06218784|EXPERIMENTAL|Placebo Capsule (Part 3)|"Oral, Placebo capsule, b.i.d, Multiple dose (Day 1\~ Day14)~Part 3:~2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.~Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning."
62677341|NCT06471517|EXPERIMENTAL|Somatosensory feedback|Somatotopic sensory feedback elicited by transcutaneous electrical stimulation (TENS) will be provided to the patients using electrodes integrated into the garment sock. The closed loop system provides stimulation parameter change based on the data recorded with sensorized insoles.
62677342|NCT04262427|EXPERIMENTAL|Single Group Assignment|Cyclophosphamide 50mg PO OD for 3 weeks as monotherapy followed by cyclophosphamide 50mg PO OD with pembrolizumab 200mg IV every 3 weeks
62677343|NCT01728961|ACTIVE_COMPARATOR|ARM A: AL + NVP -based ARV treatment|AL given to children who test positive for malaria and are already taking NVP as prescribed by their healthcare provider
62677344|NCT01728961|ACTIVE_COMPARATOR|ARM B: AL with No ARV treatment|AL given to children who do not meet national guidelines for beginning ARV treatment
62677345|NCT05180656|EXPERIMENTAL|Yoga Intervention Group|All participants will be assigned to the yoga intervention group (single arm).
62118035|NCT03629730|ACTIVE_COMPARATOR|Active control|Will perform the same number and duration of physical exercises as the High Dose group, but while moving one body segment at a time.
62473767|NCT00188539|EXPERIMENTAL|Pre-treatment tumour oxygen measurements (under anesthesia)|
62473768|NCT03695692|EXPERIMENTAL|Connective tissue massage group|Pelvic floor exercises and connective tissue massage have been applied
62677346|NCT04463914|OTHER|Group A- Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
62118036|NCT02950896||intraoperative FHR monitoring|Intraoperative fetal heart rate (FHR) monitoring
62118037|NCT04978571|EXPERIMENTAL|Active Neurostim Device|Patients in this group will receive the active devices for the initial 4 study weeks.
62118038|NCT04978571|SHAM_COMPARATOR|Sham Neurostim Device|Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.
62473769|NCT03695692|EXPERIMENTAL|Control group|Pelvic floor exercises alone have been applied
62473770|NCT02765724|EXPERIMENTAL|Group 1|Patients with mild hepatic impairment
62473771|NCT02765724|EXPERIMENTAL|Group 2|Patients with moderate hepatic impairment
62473772|NCT02765724|EXPERIMENTAL|Group 3|Patients with severe hepatic impairment
62473773|NCT02765724|EXPERIMENTAL|Group 4|Healthy subjects
62473774|NCT06562049||cases|rheumatoid arthriris patients
61918817|NCT04101201|OTHER|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
62306013|NCT06313216|EXPERIMENTAL|Immediate Implant Placement with autogenous demineralized tooth graft and tooth plate|after insertion of immediate implant, the dehisced bone defect will be grafted Using autogenous demineralized tooth graft and autogenous demineralized tooth plate
62306014|NCT04803812|EXPERIMENTAL|Receive weekly SMS containing wellness stories shared by other Ontario physicians|
62306015|NCT04803812|EXPERIMENTAL|Receive weekly SMS containing aim wellness resources/strategies.|
62306016|NCT04803812|EXPERIMENTAL|Receive weekly SMS combining wellness stories & resources/strategies|
62306017|NCT02119130|NO_INTERVENTION|TST only|Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
62306018|NCT02119130|EXPERIMENTAL|QGIT|QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
62677347|NCT04463914|EXPERIMENTAL|Group B- Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
62677348|NCT04463914|EXPERIMENTAL|Group C- Moodivate + EHR|Participants randomized to the Moodivate + EHR condition will receive similar instructions as those randomized to Moodivate, but will also be instructed that their PCP will have access to metrics related to their app utilization and may choose to follow-up with them regarding treatment utilization and response. The PCP for each participant randomized to this condition will be provided EHR access to Moodivate metrics which will include metrics related to change in mood, frequency of app utilization, and frequency of activity completion. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
62677349|NCT02143778|EXPERIMENTAL|Compensated cirrhotic patients|A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
62306019|NCT04020874|NO_INTERVENTION|Baseline|Year 1, no intervention to generate baseline, comparative data for subsequent years
62306020|NCT04020874|EXPERIMENTAL|HuTT-2x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 2 times each week throughout the regular season.
62473775|NCT06562049||control|systemic lupus patients
62473776|NCT06562049||controls|healthy controls
62473777|NCT05381220|EXPERIMENTAL|early mobilization in stroke patients|The first day is to elevate the head of the bed and sit for 5 minutes The second day is to elevate the head of the bed for 10 minutes and sit on the edge of the bed for 5 minutes.On the third day, sit on the edge of the bed for 10 minutes, get out of bed and stand for 10 minutes, and stand still for 5 to 15 minutes. The exercise duration will be adjusted according to the patient's condition, with each session lasting at least 25 minutes. The frequency of activities will be twice daily, for a duration of three days.
62677350|NCT02775851|EXPERIMENTAL|Cohort A (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab. Patients undergo CT scan and may undergo PET and MRI throughout the study. Patients also undergo blood sample collection at screening and tumor biopsy throughout the study.
61918818|NCT04101201|PLACEBO_COMPARATOR|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
62473778|NCT05381220|NO_INTERVENTION|usual care in stroke patients|Participants will receive routine rehabilitation once daily, consisting of 20 minutes of bed exercises, including both active and passive joint movements.
61918819|NCT06265480|EXPERIMENTAL|FallFitness intervention group|FallFitness 8-weeks exercise program, pre-and post assessment.
62473779|NCT04019951|EXPERIMENTAL|Propionate (1 g)|Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by \> 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
62473780|NCT04019951|EXPERIMENTAL|Propionate (3 g)|Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by \> 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
62677351|NCT02775851|EXPERIMENTAL|Cohort B (pembrolizumab)|Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity. Patients undergo CT scan and may undergo PET and MRI throughout the study. Patients also undergo blood sample collection at screening and tumor biopsy throughout the study.
62473781|NCT04019951|PLACEBO_COMPARATOR|Placebo|Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by \> 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
62677352|NCT03847805|EXPERIMENTAL|Experimental|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
62677353|NCT03847805|ACTIVE_COMPARATOR|Control|The control group followed a program of glenohumeral stabilization exercises,
61918820|NCT06265480|NO_INTERVENTION|Control group|No treatment, standard information about fall prevention, pre-and post assessment.
61918821|NCT02012582|EXPERIMENTAL|VAS203 15 mg/kg|Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
62677354|NCT06140238|EXPERIMENTAL|Experimental group|Groups of patients who have Parecoxib drug administration before start surgery
62677355|NCT06140238|PLACEBO_COMPARATOR|Control group|Group of patients who have normal saline (Placebo) administration before start surgery
62677356|NCT05848232|EXPERIMENTAL|coraFlex, coraForce, and/or coraCross Catheters|Single arm
61918822|NCT02012582|EXPERIMENTAL|VAS203 20 mg/kg|10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
61918823|NCT02012582|EXPERIMENTAL|VAS203 30 mg/kg|10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
61918824|NCT02012582|PLACEBO_COMPARATOR|Saline|0.9 % Sodium chloride infusion
61918825|NCT02054481|EXPERIMENTAL|Arm 1|BI 655066 s.c.
62306021|NCT04020874|EXPERIMENTAL|HuTT-4x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 4 times each week throughout the regular season.
62306022|NCT03148028||PID IBD patients|patients with an immunodeficiency and inflammatory bowel disease phenotype
62677357|NCT02605538|ACTIVE_COMPARATOR|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
61918826|NCT02054481|EXPERIMENTAL|Arm 2|BI 655066 s.c.
62677358|NCT02605538|ACTIVE_COMPARATOR|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
62677359|NCT05574244|EXPERIMENTAL|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
62677360|NCT05574244|EXPERIMENTAL|Partial surgery preserving the prostatic apex|Patients randomised to the partial endoscopic resection group will undergo surgical treatment that preserves the apex area of the prostate (tissue located 1 cm around the veru montanum).
62677361|NCT06087510|ACTIVE_COMPARATOR|Low-dose group|Patient-controlled analgesia is established with esketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
62677362|NCT06087510|EXPERIMENTAL|medium-dose group|Patient-controlled analgesia is established with esketamine 100 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
61918827|NCT02054481|EXPERIMENTAL|Arm 3|BI 655066 s.c.
61918828|NCT02054481|ACTIVE_COMPARATOR|Arm 4|Ustekinumab s.c.
61918829|NCT03178695|EXPERIMENTAL|Treatment Group|PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
61918830|NCT03178695|NO_INTERVENTION|Comparison Group|Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
62118039|NCT04978571|EXPERIMENTAL|COVID Active Neurostim Device|Patients in this group will receive the active devices for the 6 study weeks.
62118040|NCT05865379|EXPERIMENTAL|BUFY01|0.18% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.3 mL
62118041|NCT05865379|ACTIVE_COMPARATOR|SVS20|0.18% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.3 mL
62118042|NCT03175913|EXPERIMENTAL|Vapocoolant spray group|vapocoolant spray was applied for 10 second
62118043|NCT03175913|ACTIVE_COMPARATOR|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
62118044|NCT00779545|PLACEBO_COMPARATOR|Placebo|The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID
62118045|NCT00779545|EXPERIMENTAL|Mometasone furoate nasal spray 100 mcg QD|
62118046|NCT00779545|EXPERIMENTAL|Mometasone furoate nasal spray 200 mcg QD|
62118047|NCT00779545|EXPERIMENTAL|Mometasone furoate nasal spray 400 mcg QD|
62118048|NCT00779545|EXPERIMENTAL|Mometasone furoate nasal spray 100 mcg BID|
62118049|NCT00779545|EXPERIMENTAL|Mometasone furoate nasal spray 200 mcg BID|
62118050|NCT03761108|EXPERIMENTAL|Linvoseltamab - Phase 1|"Phase 1 has two parts. Part 1, consists of REGN5458/linvoseltamab intravenous (IV) dose escalation and Part 2, consists of subcutaneous (SC) administration.~Note: subcutaneous (SC) administration is not applicable for US."
62118051|NCT03761108|EXPERIMENTAL|Linvoseltamab - Phase 2 - Cohort 1|Low Dose of REGN5458/linvoseltamab IV monotherapy.
62118052|NCT03761108|EXPERIMENTAL|Linvoseltamab - Phase 2 - Cohort 2|High Dose of REGN5458/linvoseltamab IV monotherapy.
62306023|NCT05401071|EXPERIMENTAL|Short Regimen with Rifapentine 10mg/kg|Intervention: Short Regimen with Rifapentine 10mg/kg consists of two periods of 17- 26 weeks. The first is an intensive phase of 8 weeks, and included rifapentine, isoniazid, pyrazinamide, and moxifloxacin. This is followed by a continuation phase of 9 weeks with the following agents: rifapentine, isoniazid and moxifloxacin (extended up a maximum of 18 weeks if no smear conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of 17 weeks).
62473782|NCT05278507|EXPERIMENTAL|Arrow PICC With Arrowga+rd Blue Advanced Protection|"The Arrow PICC with Arrowga+rd Blue Advanced protection (Teleflex Medical Incorporated, Morrisville, NC, USA; hereafter referred to as AGBA) is an FDA-cleared pressure injectable device that offers both antimicrobial and anti-thrombogenic protection for at least 30 days. The application of Arrowga+rd Blue Advanced protection uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body. The device is cleared for marketing in the United States of America by the Food and Drug Administration, and has obtained the CE mark for marketing in the European Union. The French size and length selected for use will be documented."
62473783|NCT05278507|SHAM_COMPARATOR|Standard of Care PICC|The standard, unprotected PICC currently in use at the institution will be used in this study (here after referred to as Standard). The details of the PICC selected will be recorded including brand, French size, and length.
62473784|NCT01471886|ACTIVE_COMPARATOR|Naproxen|Every 8 hours for 4 days.
62473785|NCT01471886|EXPERIMENTAL|Ketorolac Tromethamine|Every 8 hours for 4 days
62473786|NCT05636020|EXPERIMENTAL|Treatment (ICARE)|ICARE treatment consisting of 12 sessions that train affect recognition and empathic behaviors.
62473787|NCT04811794||Group A (largest part of the cohort)|Children, adolescents, and adults who are still in follow-up care (data are collected retrospectively until 2016 at the most)
62473788|NCT04811794||Group B (very small part of the cohort)|Children, adolescents, and adults who left follow-up care (data are collected retrospectively until 2016 at the most)
62473789|NCT02986386|EXPERIMENTAL|Intervention 1|Dental occlusion restoration by placement of dental implants and prosthesis on missing teeth.
62473790|NCT02986386|OTHER|Wait list control 1|Group of patients that will be evaluated until they receive the dental occlusion restoration procedure.
62473791|NCT02986386|EXPERIMENTAL|Intervention 2|Orthodontic treatment of malocclusion.
62473792|NCT02986386|OTHER|Wait list control 2|Group of patients that will be evaluated until they receive the orthodontic treatment of malocclusion.
62473793|NCT03309774|EXPERIMENTAL|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
62473794|NCT03965169|EXPERIMENTAL|Patients undergoing prone spinal surgery|Patients undergoing elective spinal surgery in prone position under general anesthesia, which is performed by neurosurgeons in Seoul National University Hospital
62473795|NCT04414228|ACTIVE_COMPARATOR|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
62473796|NCT04414228|ACTIVE_COMPARATOR|ProAQT in guiding goal-directed hemodynamic therapy|Subjects randomized to the GDT group will be managed according to the ERAS algorithm utilizing ProAQT variables (mean arterial pressure, stroke volume variation and cardiac index) If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If mean arterial pressure is \< 70 mmHg and/or cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of \< 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
62473797|NCT01681745|EXPERIMENTAL|Cryo-Touch Treatment|Initial treatment with Cryo-Touch III and three optional re-treatments (up to 4 treatments) performed 68 days to 1 day prior to abdominoplasty.
62473798|NCT04685486|EXPERIMENTAL|Virtual Reality|Virtual reality-enhanced distraction using a portable head mounted display during panful events (such as wound dressing changes or physical therapy sessions) in addition to standard of care.
62473799|NCT04685486|NO_INTERVENTION|Treatment as Usual|Standard of care during painful event (such as wound dressing changes or physical therapy sessions).
62306024|NCT05401071|EXPERIMENTAL|Short Regimen with Rifapentine 15mg/kg|Intervention: Short Regimen with Rifapentine 15mg/kg consists of two periods of 17- 26 weeks. The first is an intensive phase of 8 weeks, and included rifapentine, isoniazid, pyrazinamide, and moxifloxacin. This is followed by a continuation phase of 9 weeks with the following agents: rifapentine, isoniazid and moxifloxacin (extended up a maximum of 18 weeks if no smear conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of 17 weeks).
62306025|NCT05401071|ACTIVE_COMPARATOR|Standardized Regimen|Intervention：World Health Organization (WHO) Standardized Regimen group consists of 26 weeks with two phases of treatment. The first is an intensive phase of 8 weeks, and included rifampicin, isoniazid, pyrazinamide, and ethambutol. This is followed by a continuation phase of 18 weeks with the following agents: rifampicin and isoniazid.
62473800|NCT02598063|ACTIVE_COMPARATOR|ADV + Lamivudine|Participants will receive ADV and lamivudine tablets at a dose of 10 mg orally QD for first 12 weeks followed by ADV for 60 weeks.
62473801|NCT02598063|EXPERIMENTAL|Peginterferon alfa-2a + Lamivudine|Participants will receive peginterferon alfa-2a injection at a dose of 180 micrograms (mcg) once weekly (QW) and 100 milligrams (mg) lamivudine tablets orally once daily (QD) for first 12 weeks followed by peginterferon alfa-2a for 36 weeks.
62473802|NCT03916393|EXPERIMENTAL|PF-06651600 Treatment A|Active pharmaceutical ingredient (API)solution in water
62473803|NCT03916393|EXPERIMENTAL|PF-06651600 Treatment B|API in sweetened solution
62677363|NCT06087510|EXPERIMENTAL|High-dose group|Patient-controlled analgesia is established with esketamine 150 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
62473804|NCT03916393|EXPERIMENTAL|PF-06651600 Treatment C|API blend suspension in water
62473805|NCT03916393|EXPERIMENTAL|PF-06651600 Treatment D|API blend suspension in apple sauce
62677364|NCT04558853|EXPERIMENTAL|Autologous NK cells|"The investigation product is a cell suspension based on ex vivo expanded NK cells from patients with MM. The treatment is strictly autologous. The IP is given as three infusions with escalating doses.~Mode of administration Intravenous infusions. Dose levels~* First infusion; 5x10\^6 cells/kg body weight~* Second infusion; 50x10\^6 cells/kg body weight~* Third infusion; 100x10\^6 cells/kg body weight"
62677365|NCT00520572|ACTIVE_COMPARATOR|1|Etanercept 50mg, subcutaneous, once weekly
61918831|NCT02981355|ACTIVE_COMPARATOR|Microfracture treatment|Microfracture surgery of the femoral condyle
62306026|NCT05401071|EXPERIMENTAL|Short Regimen with Rifapentine 20mg/kg|Intervention: Short Regimen with Rifapentine 20mg/kg consists of two periods of 17- 26 weeks. The first is an intensive phase of 8 weeks, and included rifapentine, isoniazid, pyrazinamide, and moxifloxacin. This is followed by a continuation phase of 9 weeks with the following agents: rifapentine, isoniazid and moxifloxacin (extended up a maximum of 18 weeks if no smear conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of 17 weeks).
62306027|NCT03707093|EXPERIMENTAL|ADG106 Dose escalation|
62306028|NCT02350543|ACTIVE_COMPARATOR|Aspirin continuation|Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
62306029|NCT02350543|NO_INTERVENTION|Aspirin discontinuation|Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.
62306030|NCT04847115|ACTIVE_COMPARATOR|Operative|The patients in this arm will be treated operatively with intramedullar screw osteosynthesis. In addition to this, they will weight bear as tolareted in a walking boot orthosis for six weeks.
62306031|NCT04847115|ACTIVE_COMPARATOR|Non-operative|The patients in this arm will have non-operative treatment with a walking boot orthosis for six weeks. They will weight bear as tolerated
62306032|NCT01232725|EXPERIMENTAL|Donor Human Milk|VLBW infants randomized to be fed donor human milk, fortified as appropriate, for all feedings for which maternal milk is not available, including infants who receive no maternal milk
62306033|NCT01232725|EXPERIMENTAL|Preterm Formula|VLBW infants randomized to receive preterm infant formula for any feedings for which maternal milk is unavailable, including infants receiving no maternal milk
62306034|NCT02608164|ACTIVE_COMPARATOR|Vitamin D oral spray solution|An oral spray solution containing 3000IU (75micrograms) vitamin D3 per spray
62306035|NCT02608164|ACTIVE_COMPARATOR|Vitamin D capsules|A capsule containing 3000IU (75micrograms) vitamin D3 per capsule
62306036|NCT05753111|PLACEBO_COMPARATOR|Placebo|Participants receive placebo supplements on two separate occasions in a randomized order. The placebo supplements contain 350 mg of maltodextrine. Placebo supplements are packaged in non-see-through hard capsules to assure that there are no differences in appearance or taste. Participants are instructed to ingest their supplement twice a day (in the morning and one hour before bedtime) for 6 consecutive days starting after collection of baseline measures.
62306037|NCT05753111|EXPERIMENTAL|Palmitoylethanolamide (PEA) supplementation|Participants receive PEA supplements on two separate occasions in a randomized order. The PEA supplements contain 350 mg of Levagen+ (315 mg of PEA and 35 mg of excipients). Levagen+ consists for 90% of palmitoylethanolamide and for 10% of a mixture of coconut oil (fractionated), polyglycerol polyricinoleate, citrus oil, olive oil, lecithin, dl-alpha tocopheryl acetate, and silicon dioxide to improve the bioavailability of PEA. Both PEA supplements are packaged in non-see-through hard capsules to assure that there are no differences in appearance or taste. Participants are instructed to ingest their supplement twice a day (in the morning and one hour before bedtime) for 6 consecutive days starting after collection of baseline measures.
62677366|NCT00520572|EXPERIMENTAL|2|50mg oral, once daily
62677367|NCT00520572|EXPERIMENTAL|3|100 mg oral, once daily
62306038|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
62306039|NCT04055649|EXPERIMENTAL|Treatment - ONC201 & Paclitaxel|Patients receive ONC201 PO on days 1, 8, 15, and 22 and paclitaxel IV over 1 hour on days 2, 9, and 16. Cycles repeat every 28 days in the absence disease progression or unacceptable toxicity. If paclitaxel must be stopped for any reason, patients may continue on ONC201 alone.
62473806|NCT03916393|OTHER|Bitrex (Registered) Treatment E|Positive control for bitterness
61918832|NCT02981355|EXPERIMENTAL|BST-CarGel plus microfracture treatment|BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
62473807|NCT05119946|EXPERIMENTAL|Suicide prevention video|In this group, in addition to receiving the standard of care for their suicidality, the participants will also view a suicide prevention video.
62473808|NCT05119946|ACTIVE_COMPARATOR|Standard suicide treatment|In this group, participants will only receive the standard of care for their suicidality, which can include medications and/or therapy. The care will be determine by their attending physician.
61918833|NCT04152980|EXPERIMENTAL|Pentoxifylline therapy 2,5 mg/kg/h for 3 hours.|This is a dose optimization study, different dosages will be tested, the lowest dosage that will be tested is 2,5 mg/kg/h for 3 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
62473809|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
62473810|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
62473811|NCT02130856|EXPERIMENTAL|Neonatal Kit|The neonatal kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Lady Health Workers will be equipped with a hand held electric scale to identify low birth weight newborns.
62677368|NCT00520572|EXPERIMENTAL|4|200 mg oral, once daily
62677369|NCT00520572|EXPERIMENTAL|5|400mg once, daily
62677370|NCT00520572|PLACEBO_COMPARATOR|6|oral, once daily
62677371|NCT05882331|EXPERIMENTAL|Extracorporeal photopheresis arm|Patients will receive extracorporeal photopheresis on this arm, in conjucntion to standard COVID-19 treatments (remdesivir, dexamethasone, IL-6- and/or JAK-inhibition).
62677372|NCT01133977|EXPERIMENTAL|Lenvatinib + Dacarbazine (Phase 1b)|Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine
62118053|NCT03761108|EXPERIMENTAL|Linvoseltamab - Phase 2 - Cohort 3|"Anti-interleukin (IL)-6 receptor (R) prophylactic therapy followed by high dose of IV dose of REGN5458 monotherapy.~Note: Cohort 3 is not applicable for US."
62306040|NCT03348202||Focus Group Participants|Approximately 24 groups (6 per country; Finland, Norway, Spain, Italy) consisting participants aged 80+ recruited from: senior community centres, adult day care centres, nursing homes. Each focus group will comprise from 4 to 8 people. Attempts would be made to create gender-balanced groups.
62118054|NCT01183780|EXPERIMENTAL|FOLFIRI + Ramucirumab|
62118055|NCT01183780|PLACEBO_COMPARATOR|FOLFIRI + Placebo|
62118056|NCT05612048|EXPERIMENTAL|Patients diagnosed with esophagogastric cancer|Patients have completed the intervention once completing the survey, undergoing dental imaging and future patients will also provide an optional saliva sample.
62118057|NCT05612048|EXPERIMENTAL|Patients diagnosed with colorectal, pancreatic, breast, head and neck, or non-small cell lung cancer|Patients undergo consenting and dental imaging during their routine visits at MSK.
62118058|NCT05612048|EXPERIMENTAL|Healthy volunteers who have not been diagnosed with cancer|Healthy controls will be defined as those without a known or suspected invasive cancer history and excluding those undergoing a procedure for symptomatic reflux.
62118059|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
62118060|NCT03060642||Controls|Non-BE endoscopic controls
62677373|NCT01133977|EXPERIMENTAL|Lenvatinib + Dacarbazine (Phase 2)|Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine
62677374|NCT01133977|ACTIVE_COMPARATOR|Dacarbazine (Phase 2)|Participants received dacarbazine
62677375|NCT05826158|OTHER|Children with Neuroblastoma|
62677376|NCT00597792|ACTIVE_COMPARATOR|A|Active Plicator Treatment
62677377|NCT04391816||Study Participants|Participants that were previously enrolled in the NIAAA Screening Protocol.
62118061|NCT05757310|EXPERIMENTAL|Treatment (conditioning, haploHCT)|Patients receive cyclophosphamide PO and IV, pentostatin IV, anti-thymocyte globulin IV and undergo CD4+ T-cell depleted haploHCT on study. Patients also undergo bone marrow aspirate, bone marrow biopsy, and collection of blood samples at screening and follow-up.
62118062|NCT01382030|EXPERIMENTAL|Treatment Arm|All patients receive 4 cycles of EIA chemotherapy pre- and postoperatively. There is no further observation arm. The study is non-randomized.
62118063|NCT02083029|EXPERIMENTAL|Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
62118064|NCT02083029|EXPERIMENTAL|Non Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
62118065|NCT02083029|EXPERIMENTAL|Normal Volunteers|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
62118066|NCT01039688|EXPERIMENTAL|5 mg BID CP-690,550|
62118067|NCT01039688|EXPERIMENTAL|10 mg BID CP-690,550|
62118068|NCT01039688|ACTIVE_COMPARATOR|methotrexate|
62118069|NCT00880048|EXPERIMENTAL|orvepitant 30 mg|orvepitant 30 mg (low dose)
62118070|NCT00880048|EXPERIMENTAL|orvepitant 60 mg|orvepitant 60 mg (high dose)
62118071|NCT00880048|PLACEBO_COMPARATOR|Placebo|inactive placebo to match orvepitant 30 mg and 60 mg dosage forms
62118072|NCT04219137||Localized Esophagogastric Adenocarcinoma|Patients diagnosed with gastroesophageal adenocarcinoma who will undergo surgical resection for curative intent, with or without neo-adjuvant chemotherapy or chemoradiotherapy.
62118073|NCT04219137||Metastatic Esophagogastric Adenocarcinoma|Patients diagnosed with de novo metastatic gastroesophageal adenocarcinoma who will undergo platinum based first line chemotherapy.
62118074|NCT06357910|EXPERIMENTAL|Arm 1|"* Period1 : RLD2302 + RLD2102~* Period2 : HCP2303"
62118075|NCT06357910|EXPERIMENTAL|Arm 2|"* Period1 : HCP2303~* Period2 : RLD2302 + RLD2102"
62118076|NCT05393180|OTHER|Hybrid Convergent|"Once the procedure intra-op exclusion conditions have been evaluated, the Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.~Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®- Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation."
62118077|NCT05565859|EXPERIMENTAL|Planetary Health Plate Signage|A Planetary Health Plate intervention phase where signage was posted in the dining hall promoting the planetary health diet
62118078|NCT05565859|NO_INTERVENTION|Control|Control phase with dining hall signage as usual.
62118079|NCT00617812|EXPERIMENTAL|Shan5|
62306041|NCT00233571|EXPERIMENTAL|Adalimumab 40mg subcutaneous (SC) every other week (EOW)|Adalimumab 40mg subcutaneous (SC) every other week (EOW)
62306042|NCT02357992|EXPERIMENTAL|Stereotactic Radiotherapy (SRT)|"Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.~50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor."
62677378|NCT02149797|ACTIVE_COMPARATOR|Four port laparoscopic cholecystectomy|This group of patients undergone classical four port laparoscopic cholecystectomy
62473812|NCT02130856|NO_INTERVENTION|Control (Standard care)|"In the control arm, Lady Health Workers will visit the home according to the regular schedule (same as in the intervention clusters) and will deliver the standard post-natal care consisting of:~1. be present at delivery (though not conduct the delivery) and thorough examination of newborn and mother post delivery~2. check mother for vaginal bleeding and abnormal blood pressure and make referral to nearest health facility as appropriate~3. refer any newborn with congenital anomaly or evidence of asphyxia~4. if unable to attend delivery for any reason, visit within first 24 hours post delivery~5. assess newborn in first month of life during visits and provide basic treatment for acute respiratory infections, pneumonia, and diarrhea in the home~6. encourage breastfeeding"
62473813|NCT05167981|EXPERIMENTAL|RETAIN Programming|The experimental group receives the full set of RETAINWORKS intervention activities.
62118080|NCT05977634|EXPERIMENTAL|Transcutaneous tibial nerve stimulation plus bladder training|Patients will receive transcutaneous tibial nerve stimulation for 30 minutes, twice a week, for 6 weeks. Application will be done in an outpatient setting, using disposable surface electrodes.
62473814|NCT05167981|NO_INTERVENTION|Control|The control group receives information and referral to partner services.
62473815|NCT04985019|EXPERIMENTAL|I (Prepectoral)|VR treatment group Participants received the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for panic disorder.
62473816|NCT04985019|NO_INTERVENTION|II (Subpectoral)|Waiting list Participants in a waiting list.
62473817|NCT00461786|EXPERIMENTAL|Pemetrexed|
62473818|NCT06317454||Subjects with T1DM|
62473819|NCT06317454||Control subjects|
62677379|NCT02149797|ACTIVE_COMPARATOR|SILC-Pick'n roll-Beginning (group I)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's beginning arm."
62677380|NCT02149797|ACTIVE_COMPARATOR|SILC-Pick'n roll-Experienced (group II)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's experienced arm."
62677381|NCT06056024|EXPERIMENTAL|Part A (Phase Ia): Dose escalation|
62677382|NCT06056024|EXPERIMENTAL|Part B (Phase Ib): Dose confirmation|
62677383|NCT06056024|EXPERIMENTAL|Part C (Phase Ib): Dose expansion|
62677384|NCT06010108|ACTIVE_COMPARATOR|Heroes for Her|Market outreach intervention- Community entry to engage major stakeholders. Awareness of the project will be made in the community through a public market crier who makes public announcements in the market daily using an audio recording. Lead/Mentor mothers who are mothers from the neighbourhood will be recruited to go door-to-door to reach out to the community. Before the screening and vaccination exercise, the woman will be counselled properly and taught about the HPV self-screening procedure. Mothers are expected to come to the hospital when returning their samples with their daughter so their daughter receive the vaccine
62677385|NCT06010108|ACTIVE_COMPARATOR|The Reach Initiative|"School based intervention-The Reach Initiative involves the Mother-Daughter Day (MDD) to create awareness and provide screening and vaccination to women and girls. This will adopt the following components. MDD which is a campaign that includes educative activities and participants will be given souvenir packs containing key-cards. On-site vaccination and sample collection kits education to be provided by healthcare providers.~To foster community engagement and promote sustainability, mothers and daughters will be encouraged to volunteer to be on the Mother-Daughter Planning Committee and participate in creating awareness."
62118081|NCT05977634|OTHER|Bladder training|patients will receive only the routine education program that is given to every patient with idiopathic overactive bladder syndrome. This includes education about the anatomy of the urinary system, patient motivation, and frequent bathroom visits in order to avoid incontinence with gradual increase between each visit to the bathroom.
62118082|NCT04743765|EXPERIMENTAL|Accelerated medical clearance and surgery|Accelerated medical clearance and targeted arrival to the operating room within 6 hours of eligibility criteria met.
62118083|NCT04743765|NO_INTERVENTION|Standard surgical care|Hip fracture repair and surgical care according to treating institution guidelines.
62118084|NCT02737878|EXPERIMENTAL|Aerobic Training and Resistance Training (A&RT)|The A\&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
62118085|NCT02737878|EXPERIMENTAL|Aerobic Training (AT)|The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
62473820|NCT01839344|EXPERIMENTAL|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
62473821|NCT01839344|ACTIVE_COMPARATOR|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
62473822|NCT01839344|PLACEBO_COMPARATOR|Placebo|An oral single dose of a solid, colored empty capsule.
62473823|NCT03121443||Patient position|Perfusion index
62473824|NCT02376777||Patient receiving NOAC|Follow up of patients receiving new oral anticoagulants (NOAC) medication
62306043|NCT03665155|EXPERIMENTAL|89Zr-daratumumab|"Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.~Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II."
61918834|NCT04152980|EXPERIMENTAL|Pentoxifylline therapy 2,5 mg/kg/h for 6 hours|The second lowest dosage that will be tested is 2,5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
62306044|NCT01472237|ACTIVE_COMPARATOR|Nutritional intervention|It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
62306045|NCT01472237|PLACEBO_COMPARATOR|Care as usual|The patients are referred to their cardiologyst and primary care physicians
62306046|NCT02838030|EXPERIMENTAL|acetylsalicylic acid and L-arginine|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
61918835|NCT04152980|EXPERIMENTAL|Pentoxifylline therapy 5 mg/kg/h for 6 hours.|The third lowest dosage, is the start dosage and the dosage that is already used in other clinical studies: 5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
61918836|NCT04152980|EXPERIMENTAL|Pentoxifylline therapy 5 mg/kg/h for 12 hours.|The fourth dosage that is tested is 5 mg/kg/h for 12 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease..
62306047|NCT02838030|PLACEBO_COMPARATOR|acetylsalicylic acid and placebo|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
62306048|NCT00725738|EXPERIMENTAL|A|"Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA over-the-wire catheter."
62306049|NCT02750566|EXPERIMENTAL|Osteopathic Manipulative Treatment|A board certified NMM/OMM or FP/OMM physician will perform an osteopathic structural exam and osteopathic treatment for a 30 minute session. The investigators will follow a generalized protocol for diagnosis and treatment of the head, neck, spine, rib cage, and pelvis. The following techniques will be included in the treatment protocol, OA (Occipitoatlantal) decompression, V-Spread, venous sinus drainage, balanced membranous tension (BMT), cranial lifts, CV4, and a mix of balanced ligamentous tension (BLT), muscle energy techniques, facilitated positional release, articulatory techniques (ART), high-velocity low-amplitude, and counterstrain to address any somatic dysfunctions.
62473825|NCT02376777||Patient receiving VKA|Follow up of patients receiving vitamin K antagonist (VKA) medication
62473826|NCT05439148|EXPERIMENTAL|OPC-61815|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day
62473827|NCT05572723|ACTIVE_COMPARATOR|Group Remifentanil|Remifentanil group was initially to receive remifentanil (group R), 0.01-0.2 g/kg/min without intraoperative loading.
62473828|NCT05572723|ACTIVE_COMPARATOR|Group Dexmedetomidine|Dexmedetomidine group, dexmedetomidine (group D) was initiated with a bolus of 1 mg/kg and received 0.2-0.7 g/kg per hour as an infusion during surgery.
62473829|NCT01703975|NO_INTERVENTION|Single training|Students training alone on the simulator
62677386|NCT06010108|ACTIVE_COMPARATOR|W.H.I.T.E Project|"Community based intervention- Community engagement by consulting with stakeholders in the community, and seeking their support for the W.H.I.T.E Project through advocacy visits. Study participants will be recruited through community based outreaches and will be educated on Human Papilloma virus and cervical cancer. This will be carried out through inter-personal communication, and use of Information, Education and Communication (IEC) materials designed for the purpose of this intervention.~Vaccination of girls age 9-14years recruited for the study will be through referral to the service point (health facility) and vaccination at outreach site.~The W.H.I.T.E self-sample kit, will be distributed to women age 30 to 65 years through referral to the service point and distribution at outreach site."
62677387|NCT06010108|ACTIVE_COMPARATOR|Project Shield|Distribution of branded self-sampling kits for HPV screening and vaccination through community based structures- Participants will be recruited through fliers, posters and community volunteers. The branded kit will include the Evalyn brush, sanitary pad/panty liner, a user manual which will be translated in local languages. Mothers who purchase the self-sampling kit will receive a free vaccination voucher for their daughters. The kits will be sold at a discounted rate. The voucher will enable the daughters to receive the HPV vaccine for free. To create awareness about cervical cancer, banners will be displayed at pharmacies and the community health facilities. The Community Development Association (CDA) will participate in awareness campaigns utilizing local languages and culturally appropriate messages. Community hospitals and pharmacies will serve as points of access for the self-sampling kits and vaccines.
62677388|NCT06010108|ACTIVE_COMPARATOR|Project SHADE|"Community based intervention using a uniquely designed bag Eno Iban to package and distribute the self collection kit and use of a simple app (d-SHADE) to collect participants data- Community outreaches will be carried out in several areas within the community such as markets to create awareness on cervical cancer prevention and to recruit women and girls. Female healthcare providers will be actively involved in these outreaches. Interested participants will be given uniquely branded kits containing a self-sampling brush from the mothers and a vaccination voucher for daughters. Mothers will be required to collect their samples either at the community facility or at home. When returning the Samples to the community facility, mothers will be expected to come with their daughters who then receive the HPV vaccination. All collected samples will be returned to the reference laboratory for analysis"
62736302|NCT03370419|EXPERIMENTAL|The Pick Two to Stick To|Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
62736303|NCT03370419|OTHER|Usual Care|Participants receive usual care only.
62473830|NCT01703975|EXPERIMENTAL|Training in pairs (Dyad Training)|Students training in pairs on the simulator
62473831|NCT04852393||Block|Patients undergoing ultrasound-guided cervical medial branch blocks as part of their usual care
62473832|NCT06165367|NO_INTERVENTION|Blastocysts exposed to normal media (NEG)|Blastocysts exposed to routine-in use medium No intervention
62473833|NCT06165367|ACTIVE_COMPARATOR|Blastocysts exposed to EmbryoGlue (EG)|Blastocysts exposed to EmbryoGlue
62473834|NCT04881435|EXPERIMENTAL|Hydrogen gas inhalation therapy accompanied with standard steroid treatment|
62306050|NCT02750566|ACTIVE_COMPARATOR|Counseling|"For the control group, an investigator will complete a 30-minute counseling session with the subject. The focus of discussion will be from the CDC's What to expect after a concussion article. Other resources that will also be used come from the American Academy of Family Physicians (AAFP), FamilyDoctor.org, and the Brain Care Center. Each counseling session will follow the same protocol. The counseling session will provide subject with similar face-to-face time with the OMT arm."
62306051|NCT04837911|OTHER|Patients using the Spirobank Smart|Use of a portable spirometry
62306052|NCT04063761|EXPERIMENTAL|Esophageal Cooling|Single arm study: Patients receive the Attune Medical Esophageal Heat Transfer Device
62118086|NCT02737878|EXPERIMENTAL|Resistance Training (RT)|The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
62118087|NCT02737878|ACTIVE_COMPARATOR|Balance and Tone Program (CON)|The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
62306053|NCT03931837|EXPERIMENTAL|Tourniquet: Systolic blood pressure + 75 mmHg|Before skin incision
62306054|NCT03931837|EXPERIMENTAL|Tourniquet: Systolic blood pressure + 100 mmHg|Before skin incision
62118088|NCT04440046|EXPERIMENTAL|Real manual therapy|Real manual therapy directed to the thoracic spine and glenohumeral joint added to a therapeutic exercise program
62118089|NCT04440046|SHAM_COMPARATOR|Sham thoracic manual therapy|Sham manual therapy directed to the thoracic spine with real manual therapy directed to the glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
62306055|NCT03931837|EXPERIMENTAL|Tourniquet: Systolic blood pressure + 150 mmHg|Before skin incision
62736304|NCT03689049|EXPERIMENTAL|SPIDER|QI Learning Collaboratives.
62736305|NCT03689049|PLACEBO_COMPARATOR|Usual Care|Standard primary care.
62118090|NCT04440046|SHAM_COMPARATOR|Sham manual therapy|Sham manual therapy directed to the thoracic spine and glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
62118091|NCT01692938||No Retinal Disease|
62118092|NCT01692938||Retinal Disease|
62118093|NCT00317226|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
62306056|NCT02919293|EXPERIMENTAL|Adjuvant-Free MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.
62306057|NCT02919293|ACTIVE_COMPARATOR|Adjuvant MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.
62306058|NCT03844438|EXPERIMENTAL|LPM3480226|LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.
62736306|NCT04396548|ACTIVE_COMPARATOR|Group A (midodrine group)|Midodrine will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
62736307|NCT04396548|PLACEBO_COMPARATOR|Group B (placebo group):|Inert tablet containing sugar (placebo) will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
62306059|NCT05558345|EXPERIMENTAL|Contingency Management for Methamphetamine Reduction|8 weeks of contingency management, twice weekly visits, with escalating rewards from $10 to $40 for negative urine tests
62306060|NCT05558345|NO_INTERVENTION|Non-substance-using Control|Observational visits (no intervention) at baseline, Week 4, Week 8, and Week 12 for those who do not use methamphetamine.
62473835|NCT04881435|ACTIVE_COMPARATOR|Standard steroid treatment|
62473836|NCT01196572|EXPERIMENTAL|Laser IU|Urethral stricture incised by Holmium laser
62473837|NCT01196572|ACTIVE_COMPARATOR|Cold knife IU|Urethral stricture incised by knife
62473838|NCT01704222||Child in nursery|Children older than 3 months and less than 6 years kept in nurseries retained, regardless of the duration of custody of the child in the manger concerned.
62473839|NCT06453980|SHAM_COMPARATOR|HC sham tDCS|Sham (placebo) dose of HD-tDCS treatment for 20 minutes, for 1 session.
62473840|NCT06453980|EXPERIMENTAL|HC active tDCS|3 milliAmp dose of HD-tDCS treatment for 20 minutes, for 1 session.
62473841|NCT06453980|SHAM_COMPARATOR|MCI sham tDCS|Sham (placebo) dose of HD-tDCS treatment for 20 minutes, for 1 session.
62473842|NCT06453980|EXPERIMENTAL|MCI active tDCS|3 milliAmp dose of HD-tDCS treatment for 20 minutes, for 1 session.
62473843|NCT06262269|EXPERIMENTAL|TELE-APA|The TELE-APA group will benefit from an individual, specific HIIT type program, adapted to the scoliosis of each patient, by tele-rehabilitation, supervised by a teacher in adapted physical activities during 12 weeks. Then he will benefit from an adapted physical activity program at home, based on a booklet of specific exercises identical to that of the CONTROL group, of HIIT type, adapted to the scoliosis of adapted to the scoliosis of each patient for 12 weeks.
62306061|NCT01458769|ACTIVE_COMPARATOR|Part A1|"Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz.~C-10276 200 mg -\> C-10276 400 mg -\> Reyataz 400 mg~C-10276 200 mg -\> Reyataz 400 mg -\> C-10276 400 mg"
62306062|NCT01458769|ACTIVE_COMPARATOR|Part A2|"Part A2 will evaluate the single agent C-10276, co-administration of CTP-518 and C-10276, and a dose of Reyataz.~C-10276 300 mg -\> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)-\> C-10276 400 mg~C-10276 300 mg -\> C-10276 400 mg -\> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)"
62473844|NCT06262269|ACTIVE_COMPARATOR|CONTROL|The CONTROL group will benefit from an adapted physical activity program at home, based on a booklet of specific HIIT-type exercises, adapted to the scoliosis of each patient for 2 times 12 weeks. A new exercise booklet is given at the end of the first 12 weeks.
62473845|NCT03692182||Study group|Participants enrolled in PACE who received an antipsychotic medication.
62473846|NCT06323096||Polytrauma with SIRS|No intervention(s) to be administered.
62473847|NCT06323096||Polytrauma with Bloodloss|No intervention(s) to be administered.
62473848|NCT06323096||Polytrauma with ATC|No intervention(s) to be administered.
62306063|NCT01458769|ACTIVE_COMPARATOR|Part B Group 1|"Group B1 will evaluate single doses of an ATV isotopolog, C-10297.~C-10297 200 mg"
62306064|NCT01458769|ACTIVE_COMPARATOR|Part B Group 2|"Group B2 will evaluate single doses of an ATV isotopolog, C-10299.~C-10299 200 mg"
62306065|NCT01458769|ACTIVE_COMPARATOR|Part B Group 3|"Group B3 will evaluate two single ascending doses of isotopologs C-10297 and 400 mg dose of Reyataz in a 3-way crossover design.~C-10297 400 mg -\> Reyataz 400 mg -\> C-10297 600 mg"
62306066|NCT01458769|ACTIVE_COMPARATOR|Part B Group 4|"Group B4 will evaluate two single ascending doses of isotopolog C-10299 and a 400 mg dose of Reyataz in a 3-way crossover design.~C-10299 400 mg -\> Reyataz 400 mg -\> C-10299 600 mg"
62473849|NCT06323096||Polytrauma with Pneumonia|No intervention(s) to be administered.
62306067|NCT01458769|ACTIVE_COMPARATOR|Part B Group 5|"Group B5 will evaluate a single dose of C-10276 and a 400 and 600 mg dose of Reyataz in a 3-way crossover design.~C-10276 600 mg -\> Reyataz 400 mg -\> Reyataz 600 mg"
62306068|NCT06123416||Control Caregivers|Control participants will write about their daily and future tasks three times.
62306069|NCT06123416||Expressive Writing Caregivers|Experimental participants will write about their thoughts and feelings about an emotionally difficult event three times.
62306070|NCT05370157|EXPERIMENTAL|TeamTRACS (Team Training in Roles, Awareness, Communication, and Support)|CACs randomized to the intervention condition (n = 4) will participate in TeamTRACS. CACs will receive an implementation guide to assist in preparing for and maximizing the impact of training.
62306071|NCT05370157|NO_INTERVENTION|Waitlist Comparison|CACs randomized to the waitlist comparison (n = 2) will participate in TeamTRACS approximately 4 months after CACs in the intervention condition.
62306072|NCT01979744|EXPERIMENTAL|Resolute Integrity - IVUS|Resolute Integrity - IVUS arm
62473850|NCT00796341|EXPERIMENTAL|1|
62473851|NCT00796341|NO_INTERVENTION|2|
62473852|NCT05377931||Normal subjects users of battle ground games (Group 1)|Subjects with no history of any medical diseases that are using mobile battle ground games for average 2 hours per day.
62473853|NCT05377931||Post COVID-19 users of battle ground games (Group 2)|Adults with a recent history of COVID-19 (average of 6 months after onset of the disease) that returned to their normal life style and are using mobile battle ground games.
62473854|NCT05377931||Normal subjects not playing mobile games (Groups 3)|Normal subjects that are not using any action mobile games.
62473855|NCT02664961|EXPERIMENTAL|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
62736308|NCT06129591|EXPERIMENTAL|Split-scar randomized trial arm with CBD oil|The study targets the vertical forehead scar, treating half with CBD oil and a silicone patch (experimental).
62736309|NCT06129591|PLACEBO_COMPARATOR|Split-scar randomized trial arm without CBD oil|The study targets the vertical forehead scar, treating half with a silicone patch (control).
62736310|NCT02429193|EXPERIMENTAL|Abiraterone / enzalutamide|Abiraterone + prednisone; Enzalutamide
62736311|NCT00612378|EXPERIMENTAL|1|
61918837|NCT04152980|EXPERIMENTAL|Pentoxifylline therapy 5 mg/kg/h for 18 hours.|The fifth dosage that is tested is 5 mg/kg/h for 18 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
61918838|NCT04152980|EXPERIMENTAL|Pentoxifylline therapy 5 mg/kg/h for 24 hours.|The sixth dosage that is tested is 5 mg/kg/h for 24 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
62306073|NCT01979744|ACTIVE_COMPARATOR|Resolute Integrity - Angio|Resolute Integrity - Angio arm
62306074|NCT01979744|ACTIVE_COMPARATOR|Promus - Angio|Promus - Angio arm
62677389|NCT06010108|ACTIVE_COMPARATOR|Operation Reach Her (ORH)|"Faith-based intervention- Reaching women and girls through places of religious worship and religious leaders. Awareness programs would be conducted in the chosen religious centres to educate women and girls about their health, cervical cancer, its prevention. This would be achieved by organizing a  Health Day  for free health check-ups for all members of the congregation. HPV screening and vaccination would be a part of these check-ups. Announcements would be carried out in worship centres to enrol women and girls. HPV vaccination to girls will be provided by health care providers stationed at the religious centres in the area. The self-sampling kit would be distributed to women in mobile tents stationed in churches and mosques. Girls who have been successfully vaccinated would receive a vaccination card and wristband to show that they have been vaccinated. The self-sampling kits would be collected from the women on the same day and transported to the reference laboratory"
61918839|NCT00967928|EXPERIMENTAL|Single arm|All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
62306075|NCT01979744|ACTIVE_COMPARATOR|Promus - IVUS|Promus - IVUS arm
62306076|NCT02232438|EXPERIMENTAL|Behavioral activation therapy|Patients treated with Behavioral activation therapy will improve in mood and anxiety symptoms and psychosocial functioning at the end of the 6 weeks of treatment.
62306077|NCT05817721||PPI-group|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necroses (WON) upon acute pancreatitis (AP) and were prescribed proton pump inhibitors (PPI) concomitantly
62306078|NCT05817721||Non-PPI-group|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necroses (WON) upon acute pancreatitis (AP) and were not prescribed proton pump inhibitors (PPI) concomitantly
62306079|NCT04036760||Standard of Care transitional care coordination|
61918840|NCT03751306|ACTIVE_COMPARATOR|Control-Cardiorespiratory Rehabilitation|These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
61918841|NCT03751306|PLACEBO_COMPARATOR|Transcranial Photobiomodulation Placebo|In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
61918842|NCT03751306|EXPERIMENTAL|Transcranial Photobiomodulation|In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
61918843|NCT03095547|EXPERIMENTAL|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
61918844|NCT03095547|EXPERIMENTAL|F901318 & posaconazole|Interaction between posaconazole and F901318
62306080|NCT04036760||Research transitional care coordination|
62306081|NCT05465681|EXPERIMENTAL|HR20013 for injection+dexamethasone|
62306082|NCT06203808||COACH GROUP|The COACH group consists of newly diagnosed head and neck cancer patients seen in consultation for treatment information at Oncologic University Hospital during the first two months of the study. These patients receive coaching support from a specialized nurse, facilitating appointment scheduling, treatment coordination, and access to various rehabilitation services
62306083|NCT06203808||CONTROL GROUP|The control group includes patients who received the treatment information during the third and fourth months of the study, without receiving specific coaching support.
62306084|NCT01722006||Pairing group|Paired, high reward, oral methamphetamine (20 mg) vs placebo Paired, low reward, oral methamphetamine (20 mg) vs placebo Paired, no reward, oral methamphetamine (20 mg) vs placebo Unpaired, oral methamphetamine (20 mg) vs placebo
62306085|NCT05265351|EXPERIMENTAL|Patients with confirmed or suspected diaphragm dysfunction|"Diaphragm function will be assess. Surface electromyography of the diaphragm will be performed in parallel. The abdominals displacement will be recorded using strain gauge. The intra-thoracic and intra-abdominal pressure will be measured using esophageal and gastric catheter-balloon.~Ultrafast ultrasound imaging will be performed during Cervical and bi-lateral anterior magnetic stimulation, and during phrenic electrical stimulation."
61918845|NCT03095547|EXPERIMENTAL|F901318 & pantoprazole|Interaction between pantoprazole and F901318
62306086|NCT03477916|OTHER|Control (Placebo FMT and cellulose)|
62306087|NCT03477916|EXPERIMENTAL|FMT only (FMT followed by cellulose)|
62306088|NCT03477916|OTHER|Prebiotic only (Placebo FMT and prebiotic fiber)|
62306089|NCT03477916|EXPERIMENTAL|FMT + prebiotic fiber|
62473856|NCT04306783|EXPERIMENTAL|Arm A: In-Home Sensor Monitoring|Older adults with cancer undergoing systemic cancer treatment will undergo passive monitoring with motion sensors and bed sensor. Passive infrared (PIR) motion sensors will be installed in their homes to detect presence in a particular room (e.g., bathroom or kitchen) as well as for specific activities. There will also be a bed sensor, which is a pneumatic strip installed under the bed linens, which measures displacement of the resident's upper torso as he or she lies on the bed. Participants will complete a baseline primarily self-administered survey, an abbreviated assessment with each follow up clinic visit (at least once per month) for 6 months of follow up and a final end of study assessment.
62473857|NCT04306783|NO_INTERVENTION|Arm B: Survey Only|Patients that choose to not proceed with in-home sensor monitoring will be asked to complete a brief survey that explores attitudes regarding in-home sensor monitoring
62473858|NCT05710783|EXPERIMENTAL|Phase II - Experimental|AVX-COVID/12 Dose: 10\^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response, Cellular response
62473859|NCT05710783|ACTIVE_COMPARATOR|Phase II - Active Control|ChAdOx-1-S\[recombinant\]) intramuscular Study parameters: Safety, Serological response, Cellular response
61918846|NCT03095547|EXPERIMENTAL|F901318|F901318 alone
61918847|NCT02155803|EXPERIMENTAL|Sarcoidosis related Calcium Dysregulation|Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.
61918848|NCT02023073||Healthy volunteers|
61918849|NCT04032574|EXPERIMENTAL|Herbal medicinal product|three times daily two film coated tablets containing: extracts of restharrow root (Ononidis radix) 80mg,Java tea (Orthosiphonis folium) 90mg, goldenrod herb (Solidaginis herba) 180mg
62306090|NCT01642537|OTHER|Rhythmia Mapping System & Catheter|This is a single arm diagnostic feasibility study with the Rhythmia Mapping System and the Rhythmia Mapping Catheter
62306091|NCT00730743|EXPERIMENTAL|1|Intermittent clamp group
62306092|NCT00730743|NO_INTERVENTION|2|No clamp group
62306093|NCT02363647|EXPERIMENTAL|Tumor Genomic Analysis|Personalized Therapy Plan Patients with Metastatic Medullary or Colon Cancer being treated with the Personalized Treatment Plan developed during the different tumor genomic analysis study.
61918850|NCT04032574|PLACEBO_COMPARATOR|Placebo|three times daily two film coated tablets
61918851|NCT05832476||Matured|It is defined as the target HDAVF can be used
61918852|NCT05832476||Non-matured|RC-AVF underwent additional intervention after 90 days of observation
61918853|NCT04532424|EXPERIMENTAL|Targeting insistence on sameness|
61918854|NCT04532424|EXPERIMENTAL|Targeting stereotyped motor behaviors|
61918855|NCT06516445|EXPERIMENTAL|SCRT followed by camrelizumab combined with fluzoparib and chemotherapy|
61918856|NCT04781660|EXPERIMENTAL|Implantable Alginate Hydrogel|All patients will be treated with Implantable Alginate Hydrogel
61918857|NCT01284985||METIS|Patient who has an indication of : Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis and for which surgeon has recommended that a METIS® prosthesis be implanted.
61918858|NCT01347580|EXPERIMENTAL|Ticagrelor|Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
61918859|NCT01347580|EXPERIMENTAL|Placebo|Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
61918860|NCT01357200||critically ill obese adults|Age ≥ 18 years, body mass index (BMI) ≥ 30, in intensive care unit (ICU) requiring tube feeding ≥ 3 days
61918861|NCT06298604|ACTIVE_COMPARATOR|Standard EUS-guided FNB|Patients scheduled for EUS-guided liver or pancreas biopsy will undergo the procedure using a standard 19-gauge needle
62473860|NCT05710783|EXPERIMENTAL|Phase III - Experimental|AVX-COVID/12 Intramuscular Dose: 10\^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response
62473861|NCT05710783|ACTIVE_COMPARATOR|Phase III - Active Control|ChAdOx-1-S\[recombinant\]) intramuscular Study parameters: Safety, Serological response
62473862|NCT05710783|EXPERIMENTAL|Phase III - Security|AVX-COVID/12 Intramuscular Dose: 10\^8.0 EID50/ intramuscular dose Study parameters: Safety.
62473863|NCT05710783|EXPERIMENTAL|Phase II- Experimental|AVX-COVID/12 Dose: 10\^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response.
62473864|NCT05710783|ACTIVE_COMPARATOR|Phase II- Active Control|ChAdOx-1-S\[recombinant\]) intramuscular Study parameters: Safety, Serological response.
61918862|NCT06298604|EXPERIMENTAL|Motorized EUS-guided FNB|Patients scheduled for EUS-guided liver or pancreas biopsy will undergo the procedure using a motorized 20-gauge needle.
61918863|NCT05404984|EXPERIMENTAL|Dry cupping with core stabilization exercises|On 12 patients, dry cupping will be performed by using a disposable manual cupping set including a hand suction pump and plastic cups of different sizes. These cups will be placed over the points GB 30, Huantiao, BL-28 Pangguangshu, BL-54 ZHIBIAN and EM-Yaoyan. After dry cupping session core stabilization exercises will be added.
61918864|NCT05404984|ACTIVE_COMPARATOR|Core stabilization exercises|12 patients will be asked to perform core stabilization exercises where the local stabilizers of the lumbopelvic region will be targeted to ensure segmental control in different positions such as supine, crook-lying, side-lying, prone, four-point kneeling, sitting, and standing.
61918865|NCT00182702|EXPERIMENTAL|Treatment|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62473865|NCT00283608||Anastrozole|Blood draws for baseline and six to twelve weeks.
61918866|NCT00335231|EXPERIMENTAL|gatifloxacin|one group will receive topical application of gatifloxacin prior to surgery,
62118094|NCT01471392|EXPERIMENTAL|Identigene STD Test Kit Arm|Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
62118095|NCT01086917|EXPERIMENTAL|Group 1|to receive a dose of 2,500 PfSPZ Challenge
62306094|NCT04237883|PLACEBO_COMPARATOR|Arm 1: Standard Communication Arm|Monthly email communication: Monthly standard communication via email informing physicians of their health maintenance completion rate over the prior three-month period. The email will also include a link to the performance dashboard, a link to a FAQ page that outlines their incentive plan, a link to helpful resources such as care guidelines, key tips from top performers, the quality measure on which they are performing the best, and the two quality measures that they could improve on the most.
62473866|NCT00283608||Exemestane|Blood draws for baseline and six to twelve weeks
62118096|NCT01086917|EXPERIMENTAL|Group 2|to receive a dose of 10,000 PfSPZ Challenge
62118097|NCT01086917|EXPERIMENTAL|Group 3|to receive a dose of 25,000 PfSPZ Challenge
62118098|NCT00487305|EXPERIMENTAL|Biological/Vaccine|"Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.~--------------------------------------------------------------------------------"
62473867|NCT01642277|EXPERIMENTAL|Women using Solifenacin for OAB treatment|Solifenacin treated women: Women with OAB who are prescribed solifenacin
62473868|NCT01642277|NO_INTERVENTION|Control: Women without OAB|Women without OAB who are not prescribed solifenacin.
62473869|NCT06561789|EXPERIMENTAL|Functionalized Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by investigator at Nano Gate institute (Egypt,cairo,elmokatm)
62473870|NCT06561789|EXPERIMENTAL|Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by investigator at Nano Gate institute(Egypt,cairo,elmokatm)
61918867|NCT00335231|NO_INTERVENTION|no eye drops|this group will receive no eye drops.
61918868|NCT03900962|EXPERIMENTAL|Slow-speed strength training|The slow-speed strength training group performed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds.
62118099|NCT03861767|EXPERIMENTAL|SPRY: Metformin LD-SC (low-dose, short course)|"LD-SC (low-dose, short course)~Participants take Metformin ER 500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118100|NCT03861767|EXPERIMENTAL|SPRY: Metformin LD-IC (low-dose, intermediate course)|"LD-IC (low-dose, intermediate course)~Participants take Metformin ER 500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118101|NCT03861767|EXPERIMENTAL|SPRY: Metformin LD-LC (low-dose, long course)|"LD-LC (low-dose, long course)~Participants take Metformin ER 500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
61918869|NCT03900962|EXPERIMENTAL|High-speed power training|During the first three weeks of training, the high-speed power training group completed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds. Thereafter, this group completed the concentric phase of five resistance exercises (squat, press-up, incline chest press, seated row and push-press) as fast as possible whilst still taking two seconds to complete the eccentric phase.
62473871|NCT06561789|EXPERIMENTAL|sodium fluoride mouth wash|The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
62473872|NCT06561789|NO_INTERVENTION|artifacial saliva|it is an artificial solution that is mimic to human saliva prepared by investigator at faculty of pharmacy Tanta university
62473873|NCT03232619|EXPERIMENTAL|CD19-CART with a murine scFv|All enrolled patients in this arm will receive CD19-CART with a murine scFv.
61918870|NCT01541345|ACTIVE_COMPARATOR|Control Group (A)|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland). These course of action is well documented in the literature and standard procedures.
61918871|NCT01541345|EXPERIMENTAL|Test group (B)|The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group. In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
61918872|NCT04144465|ACTIVE_COMPARATOR|NORADRENALIN|NORADRENALINE INFUSION
62473874|NCT03232619|EXPERIMENTAL|humanized CD19-CART|All enrolled patients in this arm will receive humanized CD19-CART.
62473875|NCT06560437|EXPERIMENTAL|the CNP group|The CNP group received Chinese Jingjin manual therapy which is divided into three major parts: fascia manipulation, bone setting manipulation, and finishing techniques. The operation takes about 30 minutes, and there is one treatment every other day, three treatments per week, and five consecutive weeks of treatment.
62473876|NCT06560437|NO_INTERVENTION|the HC groups|The healthy control group without intervention
62473877|NCT06558721|ACTIVE_COMPARATOR|Conventional Rehabilitation|Lower extremity conventional rehabilitation in stroke patients
62473878|NCT06558721|ACTIVE_COMPARATOR|Conventional Rehabilitation + Mirror Therapy|Mirror therapy in addition to conventional rehabilitation of the lower extremity in stroke patients
62118102|NCT03861767|EXPERIMENTAL|SPRY: Metformin ID-SC (intermediate-dose, short course)|"ID-SC (intermediate-dose, short course)~Participants take Metformin ER 1000 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118103|NCT03861767|EXPERIMENTAL|SPRY: Metformin ID-IC (intermediate-dose, intermediate course)|"ID-IC (intermediate-dose, intermediate course)~Participants take Metformin ER 1000 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118104|NCT03861767|EXPERIMENTAL|SPRY: Metformin ID-LC (intermediate-dose, long course)|"ID-LC (intermediate-dose, long course)~Participants take Metformin ER 1000 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118105|NCT03861767|EXPERIMENTAL|SPRY: Metformin HD-SC (high-dose, short course)|"HD-SC (high-dose, short course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118106|NCT03861767|EXPERIMENTAL|SPRY: Metformin HD-IC (high-dose, intermediate course)|"HD-IC (high-dose, intermediate course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118107|NCT03861767|EXPERIMENTAL|SPRY: Metformin HD-LC (high-dose, long course)|"HD-LC (high-dose, long course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
62118108|NCT03861767|PLACEBO_COMPARATOR|SPRY: Placebo|Participants are randomized to receive dose matched placebo to take daily for either short-, intermediate-, or long-course.
62118109|NCT05062577|EXPERIMENTAL|ASP8062 in combination with buprenorphine/naloxone|Participants will receive ASP8062 once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
62118110|NCT05062577|PLACEBO_COMPARATOR|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants will receive matching placebo once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
62118111|NCT05871346|EXPERIMENTAL|Complementary Feeding Counseling|Complementary feeding counseling to the mother-child pairs, in the intervention clusters, will be given by trained women development army (WDA) team leaders. The intervention process will have two components; training of WDA leaders, and counseling of mothers. Counselors' training will be given centrally by the principal investigator. During counseling, WDA leaders will use a counseling guide, which is prepared in Amharic, the local and the national language. The counseling guide contains seven key messages; complementary feeding: at 6 months, from 6-8 months, from 9-11 months, from 12-23 months, hygiene, breast feeding a sick child greater than 6 months, and signs that require mothers' special care of their children. Starting the children's 6 months of age, participants in the intervention group will receive in group counseling at convenient places, and individual counseling at each mother-child pair's home every month for 9 consecutive months (a total of 9 months follow up).
62118112|NCT05871346|EXPERIMENTAL|Routine Complementary Feeding Counseling|Participants in the control clusters will receive the routine complementary feeding counseling, which is offered by heath extension workers and other health professionals.
62118113|NCT06643507|ACTIVE_COMPARATOR|patients with gingival recession control group|patients with gingival recessions of miller class III /RT2 the control group will be treated with modified vista technique using connective tissue graft
62118114|NCT06643507|EXPERIMENTAL|patients with gingival recession interventional group|patients with gingival recessions of miller class III /RT2 the interventional group will be treated with modified vista technique using albumin PRF
62118115|NCT03213249|ACTIVE_COMPARATOR|Arm 1: Intraoperative pocket irrigation with NS|"* 1 gram cefazolin intravenous before surgical incision~* Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~* Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~* Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
62118116|NCT03213249|ACTIVE_COMPARATOR|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"* 1 gram cefazolin intravenous before surgical incision~* Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~* Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~* Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
62118117|NCT06656715||SingleArm|Symptom Assessment and Comparison
61918873|NCT04144465|ACTIVE_COMPARATOR|PHENYLEPHRINE|PHENYLEPHRINE INFUSION
62118118|NCT04940117|EXPERIMENTAL|blood test data before and after taking|Checking eGRF value before and after taking Eefooton oral solution
61918874|NCT02514954|EXPERIMENTAL|BioChaperone® Combo|1 single dose 400 U/mL
61918875|NCT02514954|ACTIVE_COMPARATOR|Humalog® Mix25|1 single dose 100 U/mL
62473879|NCT06558721|ACTIVE_COMPARATOR|Conventional Rehabilitation + Bicycle Ergometer with Functional Electric Stimulation|Bicycle Ergometer with Functional Electric Stimulation Therapy in addition to conventional rehabilitation of the lower extremity in stroke patients
62473880|NCT01259791|EXPERIMENTAL|Statin|Individual-specific statin causing myopathy - i.e., Patients will receive the specific statin previously associated with myopathic symptoms in them (can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously).
62473881|NCT01259791|PLACEBO_COMPARATOR|Placebo|Identical placebo to patient-specific statin
62118119|NCT05702996|EXPERIMENTAL|Patient with Thrombotic microangiopathies induced by gemcitabine|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
62473882|NCT01948414|OTHER|obese women with eating disorders|Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8
62677390|NCT06010108|ACTIVE_COMPARATOR|Project Care|Use of community pharmacies to promote awareness and serve as service points for self-collection and vaccination-Trained pharmacists and healthcare workers, student pharmacists, and students in other fields of study will serve as ambassadors to recruit, provide education and provide guidance on the use of the self- sample kit when needed. Participants will be recruited through community outreach programs, awareness campaigns in hair saloons, workplaces, social media and collaboration with local healthcare facilities. In addition, pharmacies will display promotional materials and provide information to potential participants. Dedicated areas within the local pharmacies will be set up for screening and vaccinations. The mothers and daughters on participation will be given hair accessories as incentives. The screening and HPV vaccination will also be provided at discounted prices.
62118120|NCT06629155||People with multiple sclerosis|"This study will include 50 people with MS (see in/exclusion criteria under Eligibility)."
62118121|NCT01948999|ACTIVE_COMPARATOR|ECT|Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis
62118122|NCT01948999|SHAM_COMPARATOR|SHAM ECT|Anesthesia and concomitant muscular paralysis
62118123|NCT02537769|EXPERIMENTAL|LVAD+TVR|In addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
62677391|NCT06580769|EXPERIMENTAL|Experimental|They will develop the physics activity program through immersive virtual reality
62677392|NCT06580769|EXPERIMENTAL|Experimental 2|They will develop a physical activity program through HIIT
62473883|NCT01948414|OTHER|Obese women without eating desorders|Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8
62473884|NCT01948414|OTHER|Lean women|Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8
62677393|NCT06580769|NO_INTERVENTION|Control|They do not perform physical activity
62677394|NCT05978414|EXPERIMENTAL|2 subgroups with wisceral therapy|A group of women with endometriosis and reproductive organ prolapse will be randomly assigned to the intervention will have visceral therapy performed, and the group without the intervention will have a placebo.
62473885|NCT04781517||Short-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments less than 3 was divided into Short-segment group(200).
62473886|NCT04781517||Long-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments no less than 3 was divided into Long-segment group(200).
62677395|NCT05978414|PLACEBO_COMPARATOR|2 subgroups with placebo (without intervention)|The group of women with endometriosis and reproduvtive organ prolapse without the intervention will have a placebo only hands held on the pelvis by a physiotherapist.
62677396|NCT05623605|EXPERIMENTAL|Moringa mouthwash|5 ml Moringa mouthwash two times per day for 1 week
62677397|NCT05623605|EXPERIMENTAL|Star Anis mouthwash|5 ml Star Anis mouthwash two times per day for 1 week
62677398|NCT05623605|EXPERIMENTAL|Indian Costus mouthwash|5 ml Indian Costus mouthwash two times per day for 1 week
62677399|NCT06687512|EXPERIMENTAL|SaaTwae Bio-Natural Moisturizing Cream|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
62677400|NCT06687512|PLACEBO_COMPARATOR|Placebo|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
61918876|NCT03722043|EXPERIMENTAL|Parenting Program|"All study participants will receive our parenting program curriculum. There will not be a control group.~The parenting program will include the topics of mindful parenting strategies, emotional regulation, positive discipline, and positive parenting/attachment. Participants will be provided skills to develop strategies for each of the modules. Each session will contain elements of group troubleshooting and practice in-session. Practice at home will be assigned so that participants can continue to practice and implement these skills and strategies in their homes.~The program is taken from a published, empirically based program called Everyday Parenting: A Professional's Guide to Building Family Management Skills written by Thomas Dishion, Elizabeth Stormshak, and Kathryn Kavanagh."
61918877|NCT05606146|EXPERIMENTAL|Treatment|IUB SEAD procedure
62118124|NCT02537769|ACTIVE_COMPARATOR|LVAD only|LVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
62473887|NCT04011410|EXPERIMENTAL|Hydroxychloroquine|"Hydroxychloroquine (HCQ)~DOSAGE FORM: 200 mg tablet, oral route~DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg~FREQUENCY: HCQ is taken twice daily (morning and night) with food.~DURACTION OF HCQ: 90-days"
61919985|NCT02480907|ACTIVE_COMPARATOR|Workshop Group|Parents of \~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the workshop support group for parents for a period of three months, including a written manual, a DVD (Digital Video Disc) with additional information and weekly workshops. Over the course of three months, parents will participate at the 8 workshop sessions and get the manual to read and the DVDs to use at home to illustrate workshop contents with examples and video clips.
62118125|NCT02346006|EXPERIMENTAL|Physical activity|Subject from schools with more physical activity.
62677401|NCT03076164|EXPERIMENTAL|Trametinib 1.5mg + Erlotinib 75mg|Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
62677402|NCT03978208|ACTIVE_COMPARATOR|Placebo Comparator|ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days
62677403|NCT03978208|ACTIVE_COMPARATOR|ATB-346 mid-dose|ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days
62677404|NCT03978208|ACTIVE_COMPARATOR|ATB-346 standard dose|ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days
62677405|NCT03978208|PLACEBO_COMPARATOR|Active Comparator|Overencapsulated placebo tablet taken by mouth once daily for 14 days
62677406|NCT03522246|EXPERIMENTAL|Arm A|oral rucaparib + intravenous (IV) nivolumab
62677407|NCT03522246|EXPERIMENTAL|Arm B|oral rucaparib+IV placebo
62677408|NCT03522246|EXPERIMENTAL|Arm C|oral placebo+ IV nivolumab
62677409|NCT03522246|PLACEBO_COMPARATOR|Arm D|Oral placebo + IV placebo
62677410|NCT06050512|EXPERIMENTAL|Phase l: Mezigdomide + Ixazomib + Dexamethasone|Dose level -2: Mezigdomide: 0.3 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 2.3 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level -1: Mezigdomide: 0.6 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 2.3 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level 0 (Starting dose): Mezigdomide: 0.6 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 3.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level +1: Mezigdomide: 1.0 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 3.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level +2: Mezigdomide: 1.0 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 4.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22
62677411|NCT06050512|EXPERIMENTAL|Phase ll (RP2D): Mezigdomide + Ixazomib + Dexamethasone|Mezigdomide: RP2D daily on days 1-21 of a 28-day schedule Ixazomib: RP2D PO weekly on days 1, 8 and 15 of a 28-day schedule Dexamethasone: RP2D on days 1, 8, 15 and 22
62118126|NCT03760419|EXPERIMENTAL|Intervention Arm|The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive usual care and all treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
62118127|NCT03760419|NO_INTERVENTION|Control Arm|No experimental decision support will be provided to those randomized to the control arm. All children will receive usual care and treatment will not be restricted or altered in any way by the study.
62118128|NCT05847842|ACTIVE_COMPARATOR|Group Q|Anterior quadratus lumborum block
62118129|NCT05847842|ACTIVE_COMPARATOR|Group T|Transversus abdominis plane block
62118130|NCT05847842|ACTIVE_COMPARATOR|Group L|Local infiltration
62118131|NCT01491399|EXPERIMENTAL|INFUSE™ Bone Graft/CORNERSTONE-SR™|
62118132|NCT01491399|ACTIVE_COMPARATOR|Autogenous bone/CORNERSTONE-SR™|
62118133|NCT00793754|NO_INTERVENTION|1|
62118134|NCT00793754|EXPERIMENTAL|2|Aspirin 100 mg / day
62118135|NCT00793754|EXPERIMENTAL|3|Atorvastatin 40 mg / day
62118136|NCT00793754|EXPERIMENTAL|4|Aspirin 100 mg / day + Atorvastatin 40 mg / day
62118137|NCT03580798|EXPERIMENTAL|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
62118138|NCT03580798|ACTIVE_COMPARATOR|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
62118139|NCT04433429||RYR plus CoQ|333 mg of red yeast rice (RYR, equivalent to 10 mg of Monacolin K) plus 30 mg of Coenzyme Q10 (CoQ10) in a single pill once daily
62118140|NCT06676423|EXPERIMENTAL|Groups/Cohorts|"In the first-stage dose, a 1:1 mixture of autologous CSF and HypoThermosol® FRS (HTS-FRS) is used as a suspension, and in the second-stage dose, only HypoThermosol® FRS (HTS-FRS) is used as a suspension without cerebrospinal fluid.~Mix 1.0 ⅹ 10\^6 cells per kg of body weight with the suspension at the dose level below~1. First stage dose: HTS-FRS 0.5mL/10kg + cerebrospinal fluid 0.5mL/10kg~2. Second stage dose: HTS-FRS 1.0mL/10kg"
62118141|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
62118142|NCT02008019|NO_INTERVENTION|No treatment|No Everolimus treatment before surgery
62118143|NCT02008019|EXPERIMENTAL|Everolimus 2,5 mg/day|Everolimus treatment at 2,5 mg/day for 30 days
62473888|NCT05514431||Dural puncture epidural (DPE)|Subjects that received neuraxial labor analgesia of dural puncture epidural for intrapartum cesarean delivery
62473889|NCT05514431||Combined spinal epidural (CSE)|Subjects that received neuraxial labor analgesia of combined spinal epidural for intrapartum cesarean delivery
62677412|NCT05633667|EXPERIMENTAL|Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM)|Participants will receive ZIM, SG and DOM until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met.
62677413|NCT05633667|EXPERIMENTAL|Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA)|Participants will receive ZIM, DOM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
62677414|NCT05633667|EXPERIMENTAL|Substudy 01: ZIM + ETRUMA|Participants will receive ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
62118144|NCT02008019|EXPERIMENTAL|Everolimus 10 mg/day|Everolimus treatment at 10 mg/day for 30 days
62118145|NCT02052375|EXPERIMENTAL|ASP2408 low dosing frequency|
62118146|NCT02052375|EXPERIMENTAL|ASP2408 high dosing frequency|
62118147|NCT02052375|EXPERIMENTAL|Placebo low dosing frequency|
62118148|NCT02052375|EXPERIMENTAL|Placebo high dosing frequency|
62118149|NCT05739474|EXPERIMENTAL|Flu-M Tetra vaccine, children aged 10 to 17 years old|Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly
62118150|NCT05739474|ACTIVE_COMPARATOR|VaxigripTetra vaccine, children aged 10 to 17 years old|Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly
62118151|NCT05739474|EXPERIMENTAL|Flu-M Tetra vaccine, children aged 3 to 9 years old|Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
62118152|NCT05739474|ACTIVE_COMPARATOR|VaxigripTetra vaccine, children aged 3 to 9 years old|Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
62118153|NCT05739474|EXPERIMENTAL|Flu-M Tetra vaccine, children aged 6 to 35 months old|Сhildren will be vaccinated twice 0.25 mL dose of the Flu-M Tetra vaccine intramuscularly
62118154|NCT05739474|ACTIVE_COMPARATOR|VaxigripTetra vaccine, children aged 6 to 35 months old|Сhildren will be vaccinated twice 0.25 mL dose of the VaxigripTetra vaccine intramuscularly
62118155|NCT01393353|SHAM_COMPARATOR|Computer game|Nintendo Wii
62118156|NCT01393353|EXPERIMENTAL|Cognitive Training with Cogniplus|CogniPlus
62118157|NCT05211544|ACTIVE_COMPARATOR|intervention group 1|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
62118158|NCT05211544|ACTIVE_COMPARATOR|intervention group 2|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
62118159|NCT05211544|ACTIVE_COMPARATOR|control group|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
62118160|NCT06466564|EXPERIMENTAL|Experimental group|Bioabsorbable/Nufairy coil embolization system
62118161|NCT06466564|ACTIVE_COMPARATOR|Control group|Numen coil embolization system
62118162|NCT01056835|NO_INTERVENTION|control|
62118163|NCT03949348|ACTIVE_COMPARATOR|autologous fascia|Patients who underwent a transobturator sling placement using autologous rectus fascia
62118164|NCT03949348|ACTIVE_COMPARATOR|synthetic mesh|Patients who underwent a transobturator sling placement using synthetic mesh
62118165|NCT06554093|EXPERIMENTAL|Medical Device- PathKeeper System (PKS)|"One to ten-level posterior, open, instrumented spine surgery using unilateral or bilateral pedicle screw instrumentation under PKS intraoperative navigation guidance.~Intervention: Medical Device - PKS. The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels."
62118166|NCT06554093|ACTIVE_COMPARATOR|2D Fluoroscopy|Control arm: Standard of care - free-hand technique guided by intra-operative 2D Fluoroscopy One to ten-level posterior, open, instrumented spine surgery using unilateral or bilateral pedicle screw instrumentation under free-hand technique guided by intra-operative 2D fluoroscopy
62118167|NCT06243588||Patients|patients treated at Rizzoli Institute from 1991 to 2021.
62118168|NCT05831202|OTHER|Single arm (The SEAL™ Saccular Endovascular Aneurysm Lattice System)|Prospective, US and OUS single-arm, multicenter, interventional study.
62118169|NCT02914951|EXPERIMENTAL|Cognitive-Behavioral Therapy|CBT is a behavioral intervention where children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger-provoking for their child.
62118170|NCT05221736|EXPERIMENTAL|Warthin tumor in parotid tumor|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.
62118171|NCT04275778|ACTIVE_COMPARATOR|Hydroxychloroquine|"Hydroxychloroquine will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.~Treatment will be continueted during the pregnancy and will be stopped at delivery."
62306095|NCT04237883|EXPERIMENTAL|Arm 2: Arm 1 Message + Social Comparison Intervention|"Monthly email communication as in Arm 1~Social comparison: In addition to the information given in Arm 1 email messaging, physicians in this arm will receive a list of the names of the top 25 performers from the prior month, and a high performer benchmark. Each physician in this group will receive a personalized message and subject line based on where in the performance distribution they fall (categories: top 25 performers, high performers, nearly high performers, and low performers). Message content will incorporate language utilizing principles of social comparison theory."
62118172|NCT04275778|PLACEBO_COMPARATOR|Placebo group|"Placebo will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.~Treatment will be continueted during the pregnancy and will be stopped at delivery."
62306096|NCT04237883|EXPERIMENTAL|Arm 3: Arm 2 Interventions + Leadership training|"Monthly email communication as in Arm 1 and Arm 2.~Social comparison as in Arm 2.~Quality improvement leadership training: Physician leads and clinic managers within clinics randomized to Group 3 will receive an in-person quality improvement and primary care clinic performance training, using the principles of quality improvement, self-determination theory and social comparison. Clinic leaders will be trained on how to guide these conversations, formulate their own performance/quality improvement goals, design effective strategies to reach these goals, and track their clinic's progress. Check-in emails and calls will be provided on a monthly basis to follow up on clinic-based quality improvement efforts and share key take-aways from the new Primary Care Clinical Excellence Recognition Program. This program aims to support a positive and collaborative culture of clinical excellence by recognizing and sharing best practices from high performing physicians and clinical teams."
62306097|NCT02146846||Imatinib, CML|Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
62306098|NCT05914779|EXPERIMENTAL|Subject with antibiotics treatment|"Individuals with low risk of infection after OHCA will be randomized to either 1) early antibiotics, or 2) no antibiotics.~Experimental arm received antibiotics as per local hospital clinical care pathways and physician choice."
62306099|NCT05914779|ACTIVE_COMPARATOR|Subjects with no antibiotics treatment|"Individuals with low risk of infection after OHCA will be randomized to either 1) early antibiotics, or 2) no antibiotics.~Active comparator arm will receive no antibiotics,"
62306100|NCT02198144|OTHER|barbershop-based BP measurement|BP monitoring by barbershop based Barbers and BP lowering medication(s)
62306101|NCT04457921|EXPERIMENTAL|Deep tissue massage|deep tissue massage applied group
62306102|NCT04457921|NO_INTERVENTION|Standard of care|group without deep tissue massage
62306103|NCT03921372|EXPERIMENTAL|Normal Tension Glaucoma (NTG)|Patients with diagnosed NTG
62306104|NCT03921372|EXPERIMENTAL|Healthy Control Subjects|Subjects with no sign of glaucoma, Age and sex matched
62306105|NCT04255134|EXPERIMENTAL|Abatacept|Drug administered to participants with active rheumatoid arthritis
62306106|NCT04255134|ACTIVE_COMPARATOR|Adalimumab|Comparator drug administered to participants with active rheumatoid arthritis
62306107|NCT02330029|ACTIVE_COMPARATOR|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (\~10-15g), Paeonia Lactiflora (\~15-30g), Tangerine Peel (\~10g), Ledebouriella Root (\~10g), Radix codonopsitis (\~10-15g), Radix curcumae (\~10g), Fingered citron (\~10g), Tuckahoe (\~15g), etc.
62306108|NCT02330029|ACTIVE_COMPARATOR|Pinaverium|
62306109|NCT02330029|PLACEBO_COMPARATOR|Placebo|Placebo is blindly given to patients
62306110|NCT02818634|ACTIVE_COMPARATOR|Muscle-sparing|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were passed with blunt dissection. Muscle fibers were dissected parallel to their positioning.
62306111|NCT02818634|ACTIVE_COMPARATOR|Muscle-cutting|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were cut with Monopolar electrocautery at (25 watts).
62306112|NCT02450253|ACTIVE_COMPARATOR|Active Treatment|Tadalafil 20mg Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
62306113|NCT02450253|PLACEBO_COMPARATOR|Control|Matched placebo Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
62306114|NCT01307150||Before and after treatment|SCORAD of each patient before and after treatment.
62306115|NCT00405041|EXPERIMENTAL|A|
62306116|NCT01519115|ACTIVE_COMPARATOR|Usual care|usual care of one physical therapy visit in hospital after ACF surgery
62118173|NCT04877834|EXPERIMENTAL|DelanzoTMDR group|Subjects will take DelanzoTMDR 60 mg Capsule, manufactured by SAMI Pharmaceuticals (Pvt.) Ltd. after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
62118174|NCT04877834|ACTIVE_COMPARATOR|Dexilant® Group|Subjects will take Dexilant® 60 mg Capsule, manufactured by Takeda Pharmaceutical Company Limited after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
62306117|NCT01519115|EXPERIMENTAL|Early physical therapy intervention|early physical therapy program instructed and followed at home for 6 weeks
62306118|NCT04511299|EXPERIMENTAL|Fish oil-enriched intravenous lipid emulsion|SMOFlipid 20%, given for 3 consecutive days with 1-4 g/kg/day.
62306119|NCT04511299|ACTIVE_COMPARATOR|Standard intavenous lipid emulsion|Lipofundin 20%, given for 3 consecutive days with 1-4 g/kg/day.
62306120|NCT01047787||CHF Patients|Congestive Heart Failure Patients
62118175|NCT01738308|EXPERIMENTAL|Healing Touch Treatment|"Healing Touch Treatment~When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
62473890|NCT05514431||Traditional Epidural|Subjects that received neuraxial labor analgesia of epidural for intrapartum cesarean delivery
62473891|NCT00113386|OTHER|Induction chemotherapy, surgery, consolidation chemotherapy|Induction/surgery/consolidation
62473892|NCT00113386|OTHER|Chemotherapy and radiation, surgery, consolidation ch|Induction/radiation/surgery/cosolidation
62473893|NCT02894593|OTHER|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62473894|NCT02894593|ACTIVE_COMPARATOR|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62473895|NCT02894593|PLACEBO_COMPARATOR|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62677415|NCT05633667|EXPERIMENTAL|Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG)|Participants will receive ZIM and SG until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met.
62677416|NCT05633667|ACTIVE_COMPARATOR|Substudy 01: ZIM + Platinum Based Chemotherapy|"Expansion Stage Only: Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be cisplatin or carboplatin and pemetrexed (non-squamous histology) or carboplatin, paclitaxel and nabpaclitaxel (squamous histology)."
62118176|NCT01738308|SHAM_COMPARATOR|Sham Healing Touch Treatment|Usual standard of post operative care plus a sham Heal Touch treatment upon entering the post anesthesia care unit. Treatment done by untrained study staff using same hand locations.
62118177|NCT01738308|NO_INTERVENTION|Control- No treatment done|Usual standard of post operative care with no additional intervention
62118178|NCT03292315|EXPERIMENTAL|Semaglutide 1MG Injection [Ozempic]|20 subjects will be randomized to receive once weekly injection of Semaglutide (Ozempic1mg) for 26 weeks.
62118179|NCT03292315|OTHER|No Intervention|10 subjects will be randomized to receive no intervention for 26 weeks.
62118180|NCT01182116|EXPERIMENTAL|J Pouch side to end|Colorectal surgery Function Quality of Life
62118181|NCT01811108||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
62118182|NCT00717626|EXPERIMENTAL|Daily administration of low dose FVIII|Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)
62118183|NCT02890368|EXPERIMENTAL|TTI-621 Monotherapy Escalation|TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).
62118184|NCT02890368|EXPERIMENTAL|TTI-621 Monotherapy (Single Lesion)|TTI-621 Single Lesion Injection Expansion Cohort
62118185|NCT02890368|EXPERIMENTAL|TTI-621 Monotherapy (Multiple Lesions)|TTI-621 Multiple Lesion Injections Expansion Cohort
62118186|NCT02890368|EXPERIMENTAL|TTI-621 + PD-1/PD-L1 Inhibitor|Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor
62118187|NCT02890368|EXPERIMENTAL|TTI-621 + Pegylated Interferon-α2a|Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a
62306121|NCT01820910|EXPERIMENTAL|Doxycycline|
62306122|NCT03578406|EXPERIMENTAL|HPV TCR-T|HPV E6-specific TCR-T cell
62118188|NCT02890368|EXPERIMENTAL|TTI-621 + T-Vec|Combination Therapy Expansion Cohort of TTI-621 plus T-Vec
62118189|NCT02890368|EXPERIMENTAL|TTI-621 + Radiation|Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy
62118190|NCT00891176|EXPERIMENTAL|Synflorix-Meningitec Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age. 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
62306123|NCT03578406|EXPERIMENTAL|HPV TCR-T with anti-PD1|HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element
62306124|NCT03832231|EXPERIMENTAL|Ventilator liberating trial|The diaphragmatic function of patients undergoing a ventilator liberating trial will be determined with transient shear wave elastography.
62473896|NCT02894593|EXPERIMENTAL|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
62677417|NCT05633667|EXPERIMENTAL|Substudy 02: SG + ZIM + ETRUMA|Participants will receive SG, ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
61918878|NCT02093026|EXPERIMENTAL|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (\>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first \[Day 1\] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints \>=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
61918879|NCT06361992|EXPERIMENTAL|Blue cap Foam|Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
62306125|NCT03603132|ACTIVE_COMPARATOR|Hetrombopag Olamine A|health subjects received 7.5 mg Hetrombopag Olamine while fasting.
62306126|NCT03603132|ACTIVE_COMPARATOR|Hetrombopag Olamine B|health subjects received a high-fat meal one hour after taking7.5 mg Hetrombopag Olamine
62306127|NCT03603132|ACTIVE_COMPARATOR|Hetrombopag Olamine C|health subjects received a high-fat meal two hours after taking7.5 mg Hetrombopag Olamine
62306128|NCT05584826|EXPERIMENTAL|MDMA-Assisted Therapy|Participants will receive two doses of MDMA, administered during the Treatment Period with manualized therapy. This 8-week Treatment Period includes two Preparatory Sessions and four Integrative Sessions of non-drug therapy.
62306129|NCT02856737|EXPERIMENTAL|Earplugs and eye masks (to be used concurrently)|Group will include patients consented to the use of earplugs and eye masks. Patients will participate in the intervention nightly
62306130|NCT04893850|EXPERIMENTAL|BRIDGE-KIDTHINK Condition|Caregivers in this group will participate in 16 sessions of online therapy delivered through a combination of asynchronous material and virtual support groups. These sessions will include Dialectical Behaviour Therapy (DBT) and parenting training. This group will be asked to evaluate the program with surveys completed pre-program, immediately post-program, and three months post-program. This group will also be invited to complete weekly surveys expected to take 5 minutes.
62306131|NCT04893850|EXPERIMENTAL|Services as Usual Condition|Caregivers in this group will not participate in Dialectical Behaviour Therapy (DBT) and parenting training. Rather, this group will be asked to refer to a list of community mental health and family support services as part of the BRIDGE therapy program. This group will be asked to complete weekly surveys expected to take 5 minutes.
61918880|NCT06346808|EXPERIMENTAL|Oncolytic virus Plus Anti-PD1 and Chemotherapy|Oncolytic virus d1 ;Camrelizumab 200mg, d2+AG(Gemcitabine d2/9+Capecitabine d2-d15),q3w；up to 4 cycles;
62306132|NCT01521845|ACTIVE_COMPARATOR|omega 3|receive omega 3 in addition to standard treatment
62306133|NCT01521845|NO_INTERVENTION|control|This group is without omega 3 : just receives standard treatment
62306134|NCT01169545||Cancer patients over the age of 18|Cancer patients over the age of 18 who are receiving active treatment.
62306135|NCT01220778|EXPERIMENTAL|Exercise|
62677418|NCT05633667|ACTIVE_COMPARATOR|Substudy 02: Either Docetaxel or SG (Monotherapy Only)|Participants will receive either Docetaxel or SG until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
62677419|NCT05633667|EXPERIMENTAL|Substudy 03 - ZIM + DOM + Platinum-based Chemotherapy|"Participants will receive ZIM plus DOM and any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology)."
62306136|NCT01220778|NO_INTERVENTION|Control|
62306137|NCT02764840|EXPERIMENTAL|experimental group isokinetic dynamometer (GEDI)|Isokinetic Biodex System Pro 4
62677420|NCT05633667|EXPERIMENTAL|Substudy 03 - ZIM + Platinum-based Chemotherapy|"Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology)."
62306138|NCT02764840|EXPERIMENTAL|experimental group elastic tube (GETE)|elastic tube brand LEMGRUBER 203
62306139|NCT01096667|PLACEBO_COMPARATOR|Placebo|Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
62306140|NCT01096667|EXPERIMENTAL|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
62306141|NCT01096667|EXPERIMENTAL|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
62306142|NCT01096667|EXPERIMENTAL|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
62473897|NCT03435835|EXPERIMENTAL|Sham, then heat therapy|Participants were fitted with liquid-circulating trousers. In the sham-treatment session, water at 33℃ was circulated through the trousers for 90 min using a water pump (HTP-1500, Adroit Medical, Louden, Tennessee, United States). At least 72 hrs after completion of the sham treatment session, participants returned to the laboratory and received the heat therapy (HT) treatment. In the HT session, water at 43℃ was circulated through the tube-lined trousers using a heated bath circulator (HT; Aqua Relief Systems, Akron, Ohio, United States) with the goal of increasing leg skin temperature to 37-38ºC.
62473898|NCT03435835|EXPERIMENTAL|Heat therapy, then sham|Participants were fitted with liquid-circulating trousers. In the HT session, water at 43℃ was circulated through the tube-lined trousers using a heated bath circulator (HT; Aqua Relief Systems, Akron, Ohio, United States) with the goal of increasing leg skin temperature to 37-38ºC. At least 72 hrs after completion of the sham treatment session, participants returned to the laboratory and received the sham treatment. In the sham-treatment session, water at 33℃ was circulated through the trousers for 90 min using a water pump (HTP-1500, Adroit Medical, Louden, Tennessee, United States).
62473899|NCT05624034||Healthy group|Subjects with no previous medical history (healthy volunteers) will be assessed for eligibility criteria.
62473900|NCT05624034||Idiopathic Gastroparesis|Patients with symptoms of Gastroparesis based on ROME IV criteria and not having a known cause of gastroparesis like endocrine, neurological, rheumatological disorder.
62677421|NCT05633667|ACTIVE_COMPARATOR|Substudy 03: Nivolumab + Platinum-based Chemotherapy|"Participants will receive nivolumab plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology)."
62677422|NCT01553500|EXPERIMENTAL|glucomannan|
62677423|NCT01553500|PLACEBO_COMPARATOR|placebo|
62677424|NCT05092503|EXPERIMENTAL|JINZHEN low dose arm|Patients will take 0.375 gram of JINZHEN Granules twice a day for 14 days.
62677425|NCT05092503|EXPERIMENTAL|JINZHEN middle dose arm|Patients will take 0.75 gram of JINZHEN Granules twice a day for 14 days.
62677426|NCT05092503|EXPERIMENTAL|JINZHEN high dose arm|Patients will take 1.5 gram of JINZHEN Granules twice a day for 14 days.
62677427|NCT05092503|PLACEBO_COMPARATOR|Placebo arm|Patients will take placebo granules twice a day for 14 days.
62677428|NCT05676944|EXPERIMENTAL|vestibular implant|Up to 15 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
62677429|NCT01704560|EXPERIMENTAL|Coversheet to Informed Consent|Coversheet attached to Informed Consent.
62677430|NCT01704560|NO_INTERVENTION|No Coversheet|Standard, full permission form, without the coversheet.
62677431|NCT05414812|EXPERIMENTAL|Multi-component oncofertility care intervention|After the intervention implementation, all breast cancer patients presenting to oncology clinical visits that meet eligibility criteria will receive the multi-component oncofertility care intervention.
62677432|NCT05414812|NO_INTERVENTION|Usual Care|Prior to the intervention implementation, all breast cancer patients presenting to oncology clinical visits that meet eligibility criteria will receive usual care.
62677433|NCT06687954||Control|Players of basketball team without CAI: this players have no history of ankle sprain
62677434|NCT06687954||Case|Players of basketball team with CAI: scored ≥ 11 on the functional ankle instability identification questionnaire.
62677435|NCT06686004|ACTIVE_COMPARATOR|High dose (300g) carrot with 2 slices of bread and 10g butter|"Test Session 2:~The participants will consume the 300g carrots with bread and butter. This is considered a reasonable high enough dose that detection of the compounds must occur. This dose would be compared with the normal dose (100g) to see if there is more absorption of the compound when eaten a hiher dose."
62677436|NCT06686004|ACTIVE_COMPARATOR|Experimental: Normal dose (100g) carrot with 2 slices of bread and 10g butter|"Test session 1: This is a normal dose (100g) which would be compared with the high dose to see if there dose-dependent effect in the magnitude of absorption.~Test Session 2: All the process as in the test session 1 will be repeated for the 300g dose carrot."
62306143|NCT01096667|ACTIVE_COMPARATOR|HCTZ 12.5mg|HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days
62306144|NCT04866836|EXPERIMENTAL|tislelizumab combined with radiotherapy|To observe and evaluate the effectiveness and safety of tislelizumab combined with radiotherapy in the treatment of patients with advanced biliary malignancies.
62473901|NCT05624034||Diabetic Gastroparesis|Patients with symptoms of Gastroparesis based on ROME IV criteria and Diabetes mellitus of any duration.
62473902|NCT05010018|EXPERIMENTAL|Intervention|We will pilot the BUD app in 19 intervention corner stores over an 8-month period in East Baltimore. During this time, we will collect data from corner store owners, producers, whole salers, and consumers.
62677437|NCT01341938|ACTIVE_COMPARATOR|Lozenge Self Help: self help materials & lozenge NRT.|Self-help materials + Commit® nicotine lozenges (4 mg)
61918881|NCT03638843|EXPERIMENTAL|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
61918882|NCT04385927|EXPERIMENTAL|Immediate e-NET Group|Parents of neurodiverse children with PTSI will receive e-NET immediately after the baseline survey
61918883|NCT04385927|EXPERIMENTAL|Wait List Control Group|Parents of neurodiverse children with PTSI will receive e-NET 3 months after the baseline survey
61918884|NCT00366340|EXPERIMENTAL|1|13-valent pneumococcal conjugate vaccine
61918885|NCT00366340|ACTIVE_COMPARATOR|2|7-valent pneumococcal conjugate vaccine
62677438|NCT01341938|EXPERIMENTAL|Lozenge Assisted Self-help: lozenge NRT, phone counseling, & self help materials|Self-help materials + Commit® nicotine lozenges (4 mg) + Phone counseling
61918886|NCT06064162|ACTIVE_COMPARATOR|Ketamine (active treatment)|dose of 0.5 mg/kg intravenously over 40 minutes on day 1
62118191|NCT00891176|EXPERIMENTAL|Synflorix-NeisVac-C Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
62118192|NCT00891176|EXPERIMENTAL|Synflorix-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
62677439|NCT01341938|EXPERIMENTAL|Assisted Self-Help: self-help materials & phone counseling without lozenges|Self-help materials + Phone counseling
62677440|NCT01392495|EXPERIMENTAL|QTI571|Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
62677441|NCT06446362|EXPERIMENTAL|IMCHB-Based Support Program|"Participants in this arm will receive a structured breastfeeding support program based on the Interaction Model of Client Health Behavior (IMCHB). This program includes:~Educational Sessions: Conducted during the last trimester of pregnancy. Motivational Interviews: Conducted face-to-face postpartum at 1-3 days, 15 days, 30 days, 45 days, and 60 days.~Follow-Up Support: Two additional follow-up sessions via WhatsApp video calls at 4 and 5 months postpartum."
62677442|NCT06446362|ACTIVE_COMPARATOR|Standard Care|Participants in this arm will receive the standard care provided at Family Health Centers, which includes routine breastfeeding education and support. This standard care does not include the structured and additional support interventions provided to the experimental group.
62677443|NCT02631694|EXPERIMENTAL|Fear reactivation with propranolol|
62677444|NCT02631694|PLACEBO_COMPARATOR|Fear reactivation with placebo|
62677445|NCT02631694|PLACEBO_COMPARATOR|No fear reactivation with propranolol|
62677446|NCT06362200|EXPERIMENTAL|40 Hz tACS group|40 Hz tACS group participants will receive tACS intervention stimulation (40Hz, 2.0mA, 20 minutes per session, three times a day, 21 times in total) for 1 week.
61918887|NCT06064162|PLACEBO_COMPARATOR|Saline (placebo treatment)|Placebo (saline solution) over 40 minutes on day 1
61918888|NCT03249389|EXPERIMENTAL|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
61918889|NCT00873860|PLACEBO_COMPARATOR|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
61918890|NCT00873860|EXPERIMENTAL|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
62118193|NCT00891176|ACTIVE_COMPARATOR|Prevenar-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
62677447|NCT06362200|PLACEBO_COMPARATOR|control group|the control group will be given the same frequency of pseudo-stimulation (0mA, 20 minutes per session, three times a day, 21 times in total) for 1 week.
62677448|NCT05280314|EXPERIMENTAL|Cohort A - Melanoma|"Cutaneous resectable Stage III melanoma.~Neoadjuvant Treatment (3 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W.~Post-surgery Treatment (15 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W."
61918891|NCT00873860|EXPERIMENTAL|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
61918892|NCT00873860|EXPERIMENTAL|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
61918893|NCT02091674|EXPERIMENTAL|Hyaluronic acid|All subjects administered hyaluronic acid
61918894|NCT01850602|EXPERIMENTAL|PA21|
61918895|NCT01850602|ACTIVE_COMPARATOR|Sevelamer hydrochloride|
61918896|NCT02850081|NO_INTERVENTION|Observational - Maximal Dose - ARM 1|Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for \~2 weeks before their CEA.
62677449|NCT05280314|EXPERIMENTAL|Cohort B - SCCHN|"Stage III or IVA resectable locoregionally advanced Squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx (HPV-negative), hypopharynx, or larynx~Neoadjuvant Treatment (2-3 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W Post-surgery Treatment (15 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W."
62677450|NCT05280314|EXPERIMENTAL|Cohort C|Cutaneous resectable Stage III melanoma. Neoadjuvant Treatment (3 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W (Arm A) versus intravenous Pembrolizumab KEYTRUDA® 200mg Q3W alone (Arm B) Post-surgery Treatment (15 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W (Arm A) versus Pembrolizumab KEYTRUDA® 200mg Q3W alone (Arm B)
62677451|NCT02469961|EXPERIMENTAL|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
62677452|NCT02469961|ACTIVE_COMPARATOR|Propofol|Participants will receive an interscalene block and be sedated with propofol
62677453|NCT05765344|EXPERIMENTAL|Group A: Bulevirtide (BLV), Moderate Hepatic Impairment|Participants with moderate hepatic impairment and their matched control group participants with normal hepatic function will receive BLV 2 mg injection once daily for 6 days starting on Day 1.
62677454|NCT05765344|EXPERIMENTAL|Group B: BLV, Severe Hepatic Impairment|Participants with severe hepatic impairment and their matched control group participants with normal hepatic function will receive BLV 2 mg injection once daily for 6 days starting on Day 1.
62677455|NCT05765344|EXPERIMENTAL|Group C: Bulevirtide (BLV), Moderate Hepatic Impairment|Participants from Group A, whose safety and phamacokinetic (PK) data had been reviewed and their matched control group participants with normal hepatic function, will receive BLV 10 mg injection once daily for 6 days.
62306145|NCT02255838|EXPERIMENTAL|Disposable bronchoscope first (aScope IV), then Reusable bronchoscope (Storz 8402 2x)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
62677456|NCT05765344|EXPERIMENTAL|Group D: BLV, Severe Hepatic Impairment|Participants from Group B, whose safety and PK data had been reviewed and their matched control group participants with normal hepatic function, will receive BLV 10 mg injection once daily for 6 days.
62118194|NCT02296619|EXPERIMENTAL|TAP Block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
62118195|NCT02296619|SHAM_COMPARATOR|Control|A sham band-aid will be applied to the abdomen of subjects who are randomized to the no intervention group.
62118196|NCT04998318|ACTIVE_COMPARATOR|Standard of Care|"Visual Inspection with Acetic Acid (VIA): First, the cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied to the cervix using a spray bottle or fox swab. After approximately 1-minute, any changes to the cervix using the naked eye will be noted. Acetic acid may be reapplied if acetowhitening diminishes during visual inspection.~Visual Inspection with Lugol's Iodine (VILI): After imaging with Acetic acid, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Lesion location(s) will be noted on a clock-face diagram and used to direct biopsy if a lesion is present or random biopsies will be obtained from two quadrants in the absence of a visible lesion."
62118197|NCT04998318|EXPERIMENTAL|Pocket Colposcope|"Pocket-Assisted Visual Inspection with Acetic Acid (PA-VIA): The cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied using a spray bottle or fox swab. After approximately 1-minute, using the Pocket Colposcope any changes to the cervix will be noted. Using the Calla Health image acquisition software, both white and green images of the cervix will be captured at low-resolution. High-resolution green light images will be obtained at the provider's discretion. Acetic acid may be reapplied between white and green imaging at the provider's discretion if acetowhitening diminishes.~Pocket-Assisted Visual Inspection with Lugol's Iodine (PA-VILI): After imaging with AA, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Images will be acquired. A biopsy will be obtained using the pocket. Random biopsies will be obtained from 2 quadrants in the absence of a visible lesion."
62118198|NCT01932450|EXPERIMENTAL|renal sympathetic denervation|One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
62677457|NCT00480311||1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
62677458|NCT05799950||AcrySof single-piece IOL|Pseudophakic subjects previously implanted with an AcrySof single-piece IOL
62677459|NCT05799950||AcrySof multi-piece IOL|Pseudophakic subjects previously implanted with an AcrySof multi-piece IOL
62118199|NCT01932450|ACTIVE_COMPARATOR|antihypertensive drugs|Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)
62118200|NCT00644709|EXPERIMENTAL|Arm A|
62118201|NCT02251080||Internet-based Survey|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF); and responses to a weekly Internet-based questionnaire of adherence and disease severity.
62473903|NCT05010018|NO_INTERVENTION|Control|We will collect data from 19 control corner stores over the same 8-month period. They will not receive any form of intervention or delay intervention.
62677460|NCT05344274|EXPERIMENTAL|Isocapnic Oxygen|Investigators will evaluate retinal blood flow in response to oxygen supplementation.
62677461|NCT03180138|NO_INTERVENTION|Controls|
62677462|NCT03180138|ACTIVE_COMPARATOR|Reminders alone|
62677463|NCT03180138|ACTIVE_COMPARATOR|Reminders + compliance-linked incentives|
61918897|NCT02850081|EXPERIMENTAL|Less Than Maximal Dose - ARM 2|Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin \<40mg without amlodipine and \<20mg with amlodipine; Atorvastatin (\<80mg) or Rosuvastatin (\<20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for \~2 weeks before their CEA.
61918898|NCT02850081|EXPERIMENTAL|Statin Naive - ARM 3|Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for \~2 weeks before their CEA
61918899|NCT05965271||Fabulous Thoracic Aortic Stent System|
61918900|NCT05461807||Cancer patients with venous thromboembolism (VTE)|Adults diagnosed with active (primary or metastatic) cancer excluding oesophageal, gastric, unresected colorectal, bladder, central nervous system cancers (except brain) and leukaemia (a cohort of CAT (Cancer-associated thrombosis) patients at a low risk for bleeding, which is defined as per the ISTH (International Society on Thrombosis and Haemostasis) guidelines), admitted to the hospital, emergency department or observation unit for acute DVT (Deep vein thrombosis) and/or PE (Pulmonary embolism) on or after January 1, 2013 (to correspond with the US availability of rivaroxaban for VTE treatment), being treated with a therapeutic VTE dose of rivaroxaban or apixaban on day 7 post-acute VTE diagnosis (index date).
61918901|NCT01459939|PLACEBO_COMPARATOR|Placebo|Daily treatment with placebo
61918902|NCT01459939|ACTIVE_COMPARATOR|Rose-hip powder|Daily treatment with Rose-hip powder
61918903|NCT01490723|EXPERIMENTAL|Yttrium-90 Ibritumomab + Chemo|Day -22 and -14, Rituximab 250 mg/m2 preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14, (90Y) ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.
62473904|NCT02043132|ACTIVE_COMPARATOR|Tranexamic acid|Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
62677464|NCT01029197|EXPERIMENTAL|CBT Intervention|The CBT intervention includes psychoeducation and coping and social skills delivered in a group format, and exposure therapy delivered in individual sessions
62677465|NCT01029197|ACTIVE_COMPARATOR|Treatment as Usual|The TAU Condition will receive usual services at the community clinic, which may include medications, individual or group therapy
62677466|NCT06249672||Organ preservation without local excision|
62677467|NCT06249672||Organ preservation after local excision|
62677468|NCT04187690|EXPERIMENTAL|Jin-shui Huan-xian granule|Participants in this arm will be given Jin-shui Huan-xian granule.
62677469|NCT04187690|PLACEBO_COMPARATOR|Jin-shui Huan-xian granule placebo|Participants in this arm will be given Jin-shui Huan-xian granule placebo.
62677470|NCT06353932|NO_INTERVENTION|control group|The endotracheal tubes of the control group were placed and inflated by the caregiver. A seperate blinded researcher measured cuff pressures by manometer but did not inform the team and no intervention was made.
62677471|NCT06353932|ACTIVE_COMPARATOR|study group|The endotracheal tube cuff pressures of the study group patients were constantly monitored and kept within the range of 20-25 cm H2O.
62677472|NCT01642849|EXPERIMENTAL|high protein diet|12 subjects will be place on a high protein diet
62473905|NCT02043132|PLACEBO_COMPARATOR|Normal Saline|Infusion of placebo on study subjects. They will be randomized to receive an infusion of placebo (an equivalent volume of normal saline). One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
62473906|NCT00139113|EXPERIMENTAL|HAVRIX 6 and 12 mos; mother antibody pos|HAVRIX administered to infants born to anti-HAV positive mothers at ages 6 and 12 months
62306146|NCT02255838|ACTIVE_COMPARATOR|Reusable bronchoscope first (Storz 8402 2x), then Disposable bronchoscope (aScope IV)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
62306147|NCT01791530||MV>48h|10-20 consecutive admissions with a predictive duration of intubation and mechanical ventilation \> 48h.
62473907|NCT00139113|ACTIVE_COMPARATOR|HAVRIX age 6, 12 mos; mom antibody neg|HAVRIX administered to infants born to anti-HAV negative mothers at ages 6 and 12 months
62473908|NCT00139113|EXPERIMENTAL|HAVRIX ages 12, 15 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 12 and 15 months
62473909|NCT00139113|ACTIVE_COMPARATOR|HAVRIX ages 12, 15 mos; mom antibody-|HAVRIX administered to infants born to anti-HAV negative mothers at ages 12 and 15 months
62473910|NCT00139113|EXPERIMENTAL|HAVRIX ages 15,21 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 15 and 21 months
62473911|NCT00139113|ACTIVE_COMPARATOR|HAVRIX ages 15,21 mos; mom antibody -|HAVRIX administered to infants born to anti-HAV negative mothers at ages 15 and 21 months
62473912|NCT03621163|EXPERIMENTAL|bleaching agent|intervention : bleaching agent ( Boost 40%)
62473913|NCT03621163|ACTIVE_COMPARATOR|laminate veneers|laminate veneers ( monolithic lithium - silicate)
62473914|NCT02100761||invasive pulmonary aspergillosis|Patients with invasive pulmonary aspergillosis and will be treated with voriconazole according to their physician decision in five hospital, Jinan, China
62473915|NCT00252967|PLACEBO_COMPARATOR|Placebo|Placebo taken daily
62306148|NCT00681681||1|Men and women with 1 or more cardiovascular risk factors
62306149|NCT02650310|NO_INTERVENTION|Conventional transfer|This arm is the control group (conventional embryo transfer protocol) where there is no intervention.
62306150|NCT02650310|EXPERIMENTAL|Thermostable device transfer|This arm is the study group: embryo transfer protocol using a new thermostable device.
62306151|NCT03580447|EXPERIMENTAL|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
62306152|NCT03580447|PLACEBO_COMPARATOR|Placebo|During this period participants receive daily maltodextrin supplements for four week
62306153|NCT04439669|ACTIVE_COMPARATOR|Starts with active stimulation|"Active nrTMS is given to S2 at the right side (10 sessions in a three week period). Thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to M1 contralateral to the side of pain. After 5 stimulation sessions the response is evaluated. If pain is still ≥510, the investigators change the target to the S2 on the left side for five sessions. If there is response with pain relief, a maintenance therapy with this target is offered for 6 months with gradually reducing stimulation sessions."
62473916|NCT00252967|EXPERIMENTAL|Atorvastatin|Atorvastatin at a dose of 80 mg daily
62473917|NCT05545098||JIA patients|"* Assessment of Survivin and Lubricin in the serum and in the Synovial fluid if available in JIA patients~* Assessment of activity using Juvenile arthritis disease activity score in 27 joints (JADAS 27) in the studied JIA patients.~* Identifying the prevalence of functional disability in JIA children and adolescents using the childhood health assessment questionnaire (CHAQ).~* performing MSUS on the involved joints."
62473918|NCT05545098||control group|Assessment of Survivin and Lubricin in the serum
62473919|NCT01208727|NO_INTERVENTION|Control|22 controls patients without post conditionment
62473920|NCT01208727|EXPERIMENTAL|Intervention|22 posconditioned patients
62473921|NCT04086186|ACTIVE_COMPARATOR|Adductor Canal Block Group|Standard method for peri-operative pain control. Adductor canal block is performed by anesthesiologist prior to surgery.
62473922|NCT04086186|EXPERIMENTAL|Liposomal Bupivacaine Group|Experimental method for peri-operative pain control. Liposomal bupivacaine peri-articular injection is performed by surgeon during surgery.
62473923|NCT04757220|EXPERIMENTAL|Patients with schizophrenia|"* 5 subjective questionnaires~* 4 cognitive tasks with EEG recordings"
62473924|NCT04757220|EXPERIMENTAL|Patients with depression|"* 5 subjective questionnaires~* 4 cognitive tasks with EEG recordings"
61918904|NCT03351985||Delirium Group|The cardiac surgery patients with delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
62473925|NCT04757220|ACTIVE_COMPARATOR|Healthy controls|"* 5 subjective questionnaires~* 4 cognitive tasks with EEG recordings"
62473926|NCT03084991||OCT group|1500 AMI patients with OCT imaging guidance during PCI
62473927|NCT03084991||CAG group|3000 AMI patients without OCT imaging guidance during PPCI
62473928|NCT04119986|EXPERIMENTAL|drug coated balloon|A total of 110 patients with ISR are assigned to drug coated balloon treated group after randomization schedule.
62473929|NCT04119986|OTHER|drug eluted stent implantation|A total of 110 patients with ISR are assigned to drug eluted stent treated group after randomization schedule.
62473930|NCT05468879|EXPERIMENTAL|Glimepiride 3 mg Tablet|Participants received Glimepiride 3 mg Tablet with 240 mL of 20% glucose solution
62118202|NCT02251080||Standard-of-Care|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF);
62118203|NCT05211063|EXPERIMENTAL|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
62118204|NCT05211063|PLACEBO_COMPARATOR|Placebo|Daily intake of one tablet for 42 days. This tablet is organoleptically indistinguishable from the experimental tablet.
62306154|NCT04439669|PLACEBO_COMPARATOR|Starts with sham stimulation|"Sham nrTMS will be targeted to the S2 on the right side, but using a sham box/coil. Stimulation period is similar than for the active comparator. Similarly, thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to S2 at the right side. After 5 stimulation sessions the response is evaluated. If pain is still ≥5/10, the investigators change the target to M1 on the contralateral side of the pain and furthermore to S2 at the left side after 5 stimulation sessions, if pain is still ≥5/10."
62306155|NCT04292938|ACTIVE_COMPARATOR|Ketogenic diet|patients will follow a low carbohydrate high lipid personalized diet causing blood BOHB level to be between 1.5-4 mmol/l for six months
62306156|NCT04292938|NO_INTERVENTION|control group|Patients will be asked to maintain their usual dietary regimen
62306157|NCT03843580|NO_INTERVENTION|Standard Allocation|apnea without oxygenation like usual traitement
62306158|NCT03843580|EXPERIMENTAL|oxygenation optiflow|optiflow oxygenation during apnea
62306159|NCT03047005|EXPERIMENTAL|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
62306160|NCT03047005|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
62306161|NCT02707757|ACTIVE_COMPARATOR|Iron sucrose|Iron sucrose 200mg for 5 doses
62306162|NCT02707757|ACTIVE_COMPARATOR|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
62306163|NCT02215265|NO_INTERVENTION|A: No adjuvant treatment|Group A Patients with tumours which exhibit no adverse histological features. Patients in this group will not receive any adjuvant treatment as per standard of care.
62306164|NCT02215265|ACTIVE_COMPARATOR|B1: Postoperative radiotherapy 60 Gray|"Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes \<61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
62306165|NCT02215265|EXPERIMENTAL|B2: Postoperative radiotherapy 50 Gray|"Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes \<61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
62306166|NCT02215265|ACTIVE_COMPARATOR|C1: Postoperative radiotherapy 60 Gray with Cisplatin|"Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of \<1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
62473931|NCT05468879|ACTIVE_COMPARATOR|Amaryl® 3 mg tablet|Participants received Amaryl® 3 mg tablet (Glimepiride 3 mg) with 240 mL of 20% glucose solution
62473932|NCT02054117||Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
62677473|NCT01642849|EXPERIMENTAL|high carbohydrate diet|12 subjects will be put on a high carbohydrate diet for 6 months
62118205|NCT03493269|EXPERIMENTAL|BAY1834845|"Part 1 in healthy male subjects:~Dose Groups 1-4 : orally administered multiple ascending doses. The treatment will last 10 consecutive days (treatment period1) and 1 day (treatment period 2) Dose Group 5: The treatment will last 1 day (treatment period 1) and 10 consecutive days (treatment period 2)"
62118206|NCT03493269|PLACEBO_COMPARATOR|Matching Placebo|Part 1: Matching placebo in healthy male subjects.
62118207|NCT03493269|EXPERIMENTAL|Chosen dose of BAY1834845|Part 2: This dose level will be adminstered in female and male patients with psoriasis
62118208|NCT03493269|PLACEBO_COMPARATOR|Placebo|Part 2: The placebo will be adminstered in female and male patients with psoriasis
62473933|NCT01643135|ACTIVE_COMPARATOR|tranexamic acid|Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.
62473934|NCT01643135|PLACEBO_COMPARATOR|0.9% NaCl|0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose
62677474|NCT00432991|PLACEBO_COMPARATOR|Saline Placebo|Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
61918905|NCT03351985||Non-delirium Group|The cardiac surgery patients without delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
61918906|NCT04356170|ACTIVE_COMPARATOR|TPF (docetaxel, cisplatine, 5-FU)|Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
61918907|NCT04356170|EXPERIMENTAL|TPFm (docetaxel, cisplatine, 5-FU) modifié|Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
61918908|NCT04663919|ACTIVE_COMPARATOR|Anorexia Nervosa|Patients diagnosed with Anorexia Nervosa, having a BMI of \<18, being followed up and treated in the Psychiatry Eating Disorders Polyclinic and endocrinology outpatient clinics, and who have approximately 10% weight gain during the treatment process
62118209|NCT00003292|EXPERIMENTAL|ifosfamide|ifosfamide
62118210|NCT06226714|EXPERIMENTAL|ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)|Intramuscular injection, 0.5ml
62306167|NCT02215265|EXPERIMENTAL|C2: Postoperative radiotherapy 60 Gray without chemotherapy|"Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of \<1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
62473935|NCT04866524||ICSI technique|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
62473936|NCT04866524||Conventional IVF|In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
62473937|NCT04229121||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation positive.
62473938|NCT04229121||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation negative.
62118211|NCT06226714|ACTIVE_COMPARATOR|ACYW135 Group Meningococcal Polysaccharide Vaccine (MPSV4)|Subcutaneous iniection, 0.5ml
62118212|NCT00958386|EXPERIMENTAL|1|Panitumumab+irinotecan
62473939|NCT03827356|EXPERIMENTAL|"High intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
62473940|NCT03827356|ACTIVE_COMPARATOR|"Low intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
61918909|NCT04663919|ACTIVE_COMPARATOR|Morbidly Obese|Patients with a BMI\> 40 diagnosed with Morbid Obesity and who lost approximately 10% of their weight by performing obesity surgery (gastric bypass or sleeve gastrectomy)
61918910|NCT04663919|NO_INTERVENTION|Healthy Volunteer|Volunteers with normal BMI and without any additional chronic disease
61918911|NCT00378079|EXPERIMENTAL|3|
61918912|NCT00378079|ACTIVE_COMPARATOR|1|
61918913|NCT00378079|EXPERIMENTAL|2|
61918914|NCT00752596|EXPERIMENTAL|1|1 tablet of 125 mg/day of azimilide 2HCl, oral
62118213|NCT05785988||Patients with migraine treated with a second anti-CGRP|Patients with migraine treated with a second anti-CGRP monoclonal antibody as per responsible physician criteria in routine clinical practice.
62118214|NCT01424969||PRFM Group|Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
62306168|NCT05632172||maxillary group|implant insertion
61918915|NCT01150331|EXPERIMENTAL|Clonazepam + levetiracetam|Clonazepam IV 1 mg+ levetiracetam IV 2500 mg
61918916|NCT01150331|ACTIVE_COMPARATOR|Clonazepam + placebo|Clonazepam IV 1 mg + placebo levetiracetam IV
61918917|NCT03566836||AF Detection|Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure.
61918918|NCT04869020|OTHER|Otoband efficacy versus Sham A|Participants in Arm 1 will receive, in random order, an OtoBand or Sham Device A to use for two weeks each. Sham Device A is an OtoBand in which the transducer is modified so that the vibrations do not target the vestibular system. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham or effective).
62118215|NCT01424969||Control Group|The control group were recruited retrospectively. Patients who have undergone arthroscopic repair of rotator cuff tears with similar size characteristics without PRFM augmentation will be encouraged to participate by letter initially, and then by telephone invitation. The same inclusion and exclusion criteria applied. MRI, pain, and functional scores will be collected in the same manner as the PRFM group at one time point at least one year post operatively.
62118216|NCT01511172|EXPERIMENTAL|NNC 90-1170 + Met|
62118217|NCT01511172|EXPERIMENTAL|NNC 90-1170 + Met placebo|
62473941|NCT00852020|EXPERIMENTAL|1|oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants
62473942|NCT00852020|PLACEBO_COMPARATOR|2|oral nutritional supplement (isocaloric, isonitrogenous)
62677475|NCT00432991|EXPERIMENTAL|IM Ephedrine|Drug: Ephedrine \[Synonyms: Ephedra, Ephedrinum\] 25 mg, IM (in the muscle), one time
62677476|NCT02385487||Critical illness and type 2 MI|Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
62677477|NCT02385487||Critical illness without type 2 MI|Critically ill adults without an elevation in troponin I complicating critical illness.
62306169|NCT03389334|EXPERIMENTAL|massage group|Subjects will complete the SF-36, ODI, demographics surveys and then will receive pre-treatment range of motion, muscle strength and visual analogue pain scale prior to massage. Then will have a 45-minute myofascial release massage. Then they will fill out the visual analogue pain scale again. (Approximately 90-minutes) The second and third visits: visual analogue scale prior to the treatment; 45-minute massage, by the same therapist who treated them during the initial visit, and will fill out a second visual analog pain scale following the treatment. (Approximately 60-minutes) The fourth visit: visual analogue pain scale and 45-minute massage; post-treatment SF-36, ODI surveys, visual analogue pain scale, post-treatment range of motion and muscle strength.
62677478|NCT02168439|EXPERIMENTAL|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
62677479|NCT02168439|EXPERIMENTAL|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
62677480|NCT04525183|EXPERIMENTAL|Run In|"Recruit up to 5 patients who meet eligibility criteria to participate in the run-in period of the study~* Participants will receive a 6-week Acceptance and Commitment Therapy (ACT) intervention (REVITALIZE)."
62118218|NCT01511172|PLACEBO_COMPARATOR|Met + NNC 90-1170 placebo|
62118219|NCT01511172|ACTIVE_COMPARATOR|Met + Glim|
62118220|NCT04683718|EXPERIMENTAL|BIOTRONIK Prosper SCS (Spinal Cord Stimulation) System|Eligible participants will be permanently implanted with a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management.
62118221|NCT02961179|EXPERIMENTAL|Increased dairy product|Subjects will be asked to consume a total of 3 to 5 servings per day.They will be instructed on options and variations for incorporating the dairy foods into their routine dietary pattern.
62118222|NCT02961179|PLACEBO_COMPARATOR|Dietary counselling|Subjects will review the standard dietary recommendation(http://www.diabetes.ca/diabetes-and-you/nutrition/meal-planning-guide/) by a registered dietitian.
62118223|NCT00711958|EXPERIMENTAL|HX575 epoetin alfa Hexal AG|HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
62118224|NCT00711958|ACTIVE_COMPARATOR|ERYPO® Janssen-Cilag|ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
62118225|NCT03837028||HPV 16/18 (+), cytology normal|"Women who have HPV 16/18 positivity and normal cytology results in their cervical cancer screening test (co-test) results.~The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later."
62118226|NCT03837028||HPV 16/18 (+), cytology abnormal|Women who have HPV 16/18 positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
62118227|NCT03837028||non-16/18 HPV (+), cytology abnormal|Women who have non- 16/18 high-risk HPV positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
62118228|NCT03837028||non-16/18 HPV (+), cytology normal|Women who have non- 16/18 high-risk HPV positivity and normal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
62118229|NCT05790928||AONDA DW|Lotrafilcon A contact lenses worn in a daily wear (DW) modality (lenses removed nightly for cleaning) for at least 1 year with monthly replacement.
62118230|NCT05790928||AONDA CW|Lotrafilcon A contact lenses worn in a continuous wear (CW) modality (lenses worn continuously including overnight) for at least 1 year with monthly replacement.
62118231|NCT06257693|EXPERIMENTAL|Enolen (tm)|Enolen (tm) implants containing enzalutamide
62306170|NCT06114082|EXPERIMENTAL|IDA-TACE|Patients treated by conventional TACE using idarubicin chemoemulsion
62677481|NCT04525183|EXPERIMENTAL|Enhanced Usual Care (EUC)|Participants randomized to EUC will receive educational materials developed by the National Comprehensive Cancer Network (NCCN) about fatigue and exercise during cancer treatment.
62677482|NCT04525183|EXPERIMENTAL|REVITALIZE ACT Intervention|Participants randomized to the REVITALIZE acceptance and commitment therapy (ACT) will receive 6 weekly sessions lasting approximately 60-75-minutes over a 6-8 week period, delivered face-to-face using iPads, computers or tablets, and a HIPAA-compliant platform (Zoom for Healthcare). If participants have difficulty connecting to the platform, telephone sessions are permitted.
62118232|NCT00057837|EXPERIMENTAL|PET (Topotecan/Etoposide/Cisplatin/G-CSF)|Patients receive topotecan intravenously (IV) over 30 minutes on days 1-3; etoposide IV over 60 minutes immediately followed by cisplatin IV over 60 minutes on days 8-10; and filgrastim (G-CSF) subcutaneously daily beginning on day 11 and continuing until blood counts recover.
62118233|NCT00057837|EXPERIMENTAL|PIE (Irinotecan/Cisplatin/Etoposide)|Patients receive irinotecan IV over 90 minutes and cisplatin IV over 60 minutes on days 1 and 8 and oral etoposide twice daily on days 3 and 10 of each cycle.
62118234|NCT06518798|EXPERIMENTAL|Fasting Mimicking Diet (FMD)|The fasting-mimicking diet (FMD) group will be instructed on the benefits and use of the FMD kit. Participants will be given one 5-day FMD kit at their baseline visit. They will be instructed to follow the kit, and only eat its items, for five consecutive days and to report back for a follow-up visit and measurements at the end of their 5 days before returning to their normal diet.
62306171|NCT06114082|ACTIVE_COMPARATOR|DOX-TACE|Patients treated by conventional TACE using doxorubicin chemoemulsion
62677483|NCT06000904|EXPERIMENTAL|Exergame-based balance training group|
62677484|NCT06000904|ACTIVE_COMPARATOR|Upper limb and trunk training group|
62677485|NCT04713046|EXPERIMENTAL|Allogeneic bone marrow transplant|non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
62473943|NCT01233622|EXPERIMENTAL|Vildagliptin (metformin + glimepiride)|
62473944|NCT01233622|PLACEBO_COMPARATOR|Placebo (metformin + glimepiride)|
62677486|NCT04713046|EXPERIMENTAL|CD8-depleted donor lymphocyte infusion (DLI) per dose escalation scheme|CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
62677487|NCT00969085|EXPERIMENTAL|Curcumin|
62118235|NCT01595854|EXPERIMENTAL|Test 2 (part 3)|low dose dabigatran + high dose ticagrelor
62677488|NCT00452530|EXPERIMENTAL|Apixaban, 2.5 mg BID + Placebo|Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
62677489|NCT00452530|ACTIVE_COMPARATOR|Enoxaparin, 40 mg QD + Placebo|Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
62677490|NCT05460000|EXPERIMENTAL|Arm A (3 cycles of chemotherapy + maintenance therapy with niraparib)|3 cycles carboplatin + paclitaxel maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
62677491|NCT05460000|ACTIVE_COMPARATOR|Arm B (6 cycles of chemotherapy + maintenance therapy with niraparib)|6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
62677492|NCT06438107||Renal transplantation recipients|Living donor and deceased donor renal transplant recipients. There is no intervention to be administered.
62677493|NCT01091415|EXPERIMENTAL|calcium phosphate bone cement|one arm; volar locking plate alone the other arm; calcium phosphate bone cement as well as volar locking plate
62677494|NCT02573441|EXPERIMENTAL|Math + Liaison Service|To help with mathematics, participants will be assigned to a workbook based version of the JUMP Math program which will be completed at home with a parent. This intervention focuses on mental math skills. In addition all participants will receive the liaison service program.
61918919|NCT04869020|OTHER|Otoband efficacy versus Sham B|Participants in Arm 2 will receive, in random order, a OtoBand or Sham Device B. Sham Device B is an OtoBand that operates at settings found to be non-therapeutic in motion sickness studies. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham, or effective).
61918920|NCT02383225|EXPERIMENTAL|Condition A|Substance use resistance skills; no Lakota language enhancement, no FaceBook supplement
62118236|NCT01595854|ACTIVE_COMPARATOR|Test 1 (part 1 + 2)|high dose ticagrelor
62677495|NCT02573441|EXPERIMENTAL|Working Memory + Liaison Service|To help with working memory, participants will be assigned to Cogmed, a game-like computer exercise focusing on improving working memory. In addition all participants will receive the liaison service program.
62118237|NCT01595854|EXPERIMENTAL|Reference 1 (part 1 + 2)|medium dose dabigatran
62118238|NCT01595854|EXPERIMENTAL|Reference 2 (part 3)|low dose dabigatran
62306172|NCT05880914||Bone-targeted management - prospective cohort|Participants diagnosed with a bone disorder related to chronic kidney disease (CKD) and undergoing a clinically indicated treatment for bone disease. Participants will have some questionnaires, research blood draws, bone scans and a bone biopsy. There will be a total of 4 visits over six months for data collection.
62473945|NCT02984696|EXPERIMENTAL|Hormonal Replace Therapy|1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months
62677496|NCT02573441|OTHER|Liaison Services|Participants in this group will only receive the liaison service program for 12 weeks before being assigned to one of the intervention groups.
62677497|NCT01431573|EXPERIMENTAL|Wake Therapy + light box +/- lithium|"* Bipolar patients must take lithium; others do not take lithium~* all patients are hospitalized for a week during which they do not sleep on alternating nights~* for six weeks, including the week in the hospital all patients sit in front of bright lights at specified times and for specified durations"
62677498|NCT01899378|EXPERIMENTAL|daily probiotic|10\^8 CFU Lactobacillus reuteri DSM 17938 and 10\^9 Bifidobacterium longum infantis daily for one month
62118239|NCT01811407|OTHER|Private/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Participants will be required to set a forward-looking commitment each week as to how many days during the following week they will meet their step count target. Commitment and results will be private.
62118240|NCT01811407|EXPERIMENTAL|Public/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments are made as in the Private/Private condition. In addition, one Facebook announcement will be posted at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week. An email will also be sent directly to 3 friends the participant chose with the same announcements.
62118241|NCT01811407|EXPERIMENTAL|Public/public|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments will be made as in the Private/Private condition. In addition, one message will be posted to Facebook at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week, and how they did on their previous weekly commitment. An email will also be sent directly to 3 friends the participant chose with the same announcements.
62118242|NCT04320186|ACTIVE_COMPARATOR|Treatment|Participants viewed informational video content plus entertainment content
62306173|NCT01416181|EXPERIMENTAL|natalizumab|In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
62677499|NCT01899378|EXPERIMENTAL|weekly probiotic|10\^8 CFU Lactobacillus reuteri DSM 17938 and 10\^9 Bifidobacterium longum infantis weekly for one month
62677500|NCT01899378|EXPERIMENTAL|bi-weekly probiotic|10\^8 CFU Lactobacillus reuteri DSM 17938 and 10\^9 Bifidobacterium longum infantis bi-weekly for one month
62118243|NCT04320186|PLACEBO_COMPARATOR|Control|Participants viewed entertainment content only
62118244|NCT00074568||1|Patients with scleroderma and their family members (parents, brothers, and sisters)
62118245|NCT00074568||2|Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
62118246|NCT06223113|OTHER|EyenableTM PA60AS1 IOL implanation|IOL implantation
62118247|NCT01490086|EXPERIMENTAL|15mg RP5063 daily|
62118248|NCT01490086|EXPERIMENTAL|30mg RP5063 daily|
62118249|NCT01490086|EXPERIMENTAL|50mg RP5063 daily|
62306174|NCT01416181|EXPERIMENTAL|Placebo|In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
62306175|NCT05545397||The propofol group|Patients undergoing painless gastroenteroscopy under general anesthesia
62306176|NCT00503971|EXPERIMENTAL|Vorinostat plus erlotinib|Vorinostat plus erlotinib
62306177|NCT03014869|EXPERIMENTAL|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37 degree centigrade.
62306178|NCT03014869|NO_INTERVENTION|Noninvasive positive ventilation|Parameters are set according to NPPV protocols
62306179|NCT03887572||Pre-intervention/control|20 older adult patients (age 65 or older) will be recruited over 3 months prior to implementation of the unit-based MOVIN intervention.
62677501|NCT01899378|NO_INTERVENTION|control|
61918921|NCT02383225|EXPERIMENTAL|Condition B|FaceBook supplement; no Lakota language enhancement; no Substance Use resistance skills
61918922|NCT02383225|EXPERIMENTAL|Condition C|Lakota language enhancement; no FaceBook supplement; no Substance Use resistance skills
61918923|NCT02383225|EXPERIMENTAL|Condition D|Lakota language enhancement; FaceBook supplement; Substance Use resistance skills
62677502|NCT06100172|ACTIVE_COMPARATOR|Active tAN + standard of care (SOC) for post-operative pain management for lumbar fusion patients.|"Subjects will be randomized to receive the active device on the day of surgery.~Subjects will receive treatment according to the following time points:~* Pre-operative: 30 minutes in the hour prior to surgery~* Intra-operative: 30 minutes before the end of surgery~* Post-operative: 30 minutes at 3 and 6 hours after surgery~* Inpatient: Four 30-minute sessions on Day 2"
61918924|NCT02753244|EXPERIMENTAL|Intendu FBT inpatient|Other: Motion Based Cognitive Video Games Software
61918925|NCT02753244|ACTIVE_COMPARATOR|iPad games|Other: iPad apps
61918926|NCT02753244|EXPERIMENTAL|Intendu FBT community|Other: Motion Based Cognitive Video Games Software
62118250|NCT01490086|PLACEBO_COMPARATOR|Placebo|
62118251|NCT01490086|ACTIVE_COMPARATOR|aripiprazole|aripiprazole 15 mg daily
62118252|NCT04260750|EXPERIMENTAL|Expert-chosen content, regular guidance|Content chosen by the therapist, weekly guidance by a therapist.
62118253|NCT04260750|EXPERIMENTAL|Expert-chosen content, on-demand guidance|Content chosen by the therapist, guidance upon request from the health care team.
62118254|NCT04260750|EXPERIMENTAL|Participant-chosen content, regular guidance|Content chosen by participants themselves, weekly guidance by a therapist.
62118255|NCT04260750|EXPERIMENTAL|Participant-chosen content, on-demand guidance|Content chosen by participants themselves, guidance upon request from the health care team.
62118256|NCT03902236||Cystic fibrosis group|Children diagnosed with cystic fibrosis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
62118257|NCT03902236||Bronchiectasis group|Children diagnosed with bronchiectasis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
62118258|NCT03902236||Healthy group|Healthy children more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
62118259|NCT04288219|ACTIVE_COMPARATOR|Standard of Care Treatment|Continuous supplemental oxygen and nifedipine 30mg will be administered to patients.
61918927|NCT00718081|EXPERIMENTAL|1|Oral Sufentanil
61918928|NCT00718081|EXPERIMENTAL|2|Oral sufentanil
61918929|NCT00718081|PLACEBO_COMPARATOR|3|Oral dosage of placebo
61918930|NCT01007682|NO_INTERVENTION|Screening for working memory capacity|
62118260|NCT04288219|EXPERIMENTAL|Non-Invasive Positive Pressure Ventilation Management|CPAP at 10mmHg with supplemental oxygen, as well as nifedipine 30mg will be administered to patients.
62118261|NCT03726268|ACTIVE_COMPARATOR|IV methadone|Intraoperative and post-operative IV methadone
62118262|NCT03726268|ACTIVE_COMPARATOR|IV fentanyl, sufentanil, morphine or hydromorphone|Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion
62118263|NCT04771234|EXPERIMENTAL|Treatment group|The intervention consists of a self-guided digital tool to guide participants with chronic insomnia through sleep restriction and stimulus control procedures.
62118264|NCT06677320||Rotator cuff patients|Patients with rotator cuff disease who will receive conservative treatment.
62118265|NCT04372394|EXPERIMENTAL|Fed/Fasted|surufatinib with food on Day 1 and surufatinib without food on Day 8
62118266|NCT04372394|EXPERIMENTAL|Fasted/Fed|surufatinib without food on Day 1 and surufatinib with food on Day 8
62118267|NCT01500954||squamous cell carcinoma|
62118268|NCT01500954||non-lesional skin|
62677503|NCT06100172|PLACEBO_COMPARATOR|Sham tAN + standard of care (SOC) for post-operative pain management for lumbar fusion patients.|"Subjects will be randomized to receive the sham device on the day of surgery.~Subjects will receive treatment according to the following time points:~* Pre-operative: 30 minutes in the hour prior to surgery~* Intra-operative: 30 minutes before the end of surgery~* Post-operative: 30 minutes at 3 and 6 hours after surgery~* Inpatient: Four 30-minute sessions on Day 2"
62306180|NCT03887572||Post-intervention|20 older adult patients (age 65 or older) will be recruited over 3 months after MOVIN has been implemented on the unit for a period of 12-14 weeks.
62306181|NCT06272214|EXPERIMENTAL|Adjuvant radiotherapy|Following surgery, patients start adjuvant radiotherapy 4-6 weeks after the operation, with a radiation dose of 45Gy/25F/5W, completed no later than 8 weeks post-surgery. Two weeks after completing radiotherapy, patients continue with immunotherapy maintenance therapy for up to 1 year (17 cycles Q3W) or until tumor progression.
62118269|NCT02965248|ACTIVE_COMPARATOR|Arm A|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.
62118270|NCT02965248|EXPERIMENTAL|Arm B|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.
62306182|NCT06272214|ACTIVE_COMPARATOR|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year (17 cycles Q3W) or until tumor progression.
62306183|NCT01887444|EXPERIMENTAL|Lactobacillus reteuri|Dietary Supplement: Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days
62306184|NCT01887444|PLACEBO_COMPARATOR|Placebo|Other: Placebo
62306185|NCT03095105|EXPERIMENTAL|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
62306186|NCT03095105|EXPERIMENTAL|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
62306187|NCT00174941|EXPERIMENTAL|1|
62306188|NCT00174941|EXPERIMENTAL|2|
62306189|NCT00174941|EXPERIMENTAL|3|
62677504|NCT05656976|EXPERIMENTAL|A Self sampling device (SSD) provided by the general practitioner (GP)|A self sampling device will be provided by the GP.
62118271|NCT02965248|EXPERIMENTAL|Arm C|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)
62306190|NCT03949777|EXPERIMENTAL|Study Cohort|61 subjects will undergo colonoscopy
62306191|NCT01873950|EXPERIMENTAL|Ranolazine 1500mg|Ranolazine
62306192|NCT01873950|EXPERIMENTAL|Dofetilide 500mcg|Dofetilide
62306193|NCT01873950|EXPERIMENTAL|Verapamil HCl 120 mg|Verapamil
62306194|NCT01873950|EXPERIMENTAL|Quinidine sulfate 400mg|Quinidine sulfate
62306195|NCT01873950|PLACEBO_COMPARATOR|Placebo|Placebo
62306196|NCT01718717|ACTIVE_COMPARATOR|6 days TEA|Postoperative analgesia for the first six postoperative days with TEA and daily monitoring for arrhythmia
62306197|NCT01718717|ACTIVE_COMPARATOR|3 days TEA and 3 days intravenous morphine|Postoperative analgesia for the first three postoperative days with TEA followed for the next three days with intravenous morphine, and daily monitoring for arrhythmia
62306198|NCT02818010||exposed = patient practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire)~A patient is defined as practicing physical activity (exposed) when he meets one of the conditions following:~* At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~* At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~* At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
62677505|NCT05656976|EXPERIMENTAL|B Self sampling device provided by letter|A self sampling device will be provided by letter.
62677506|NCT05656976|NO_INTERVENTION|C (control arm) Recommendation letter|"Following the usual care procedure, a random sample of 1125 Flemish women who meet the same inclusion criteria as in arm A and B and are not included in one of the latter arms is drawn by Centrum voor Kankeropsporing (CvKO) from Heracles, the database of the Flemish screening program."
62306199|NCT02818010||unexposed = patient not practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire(Global Physical Activity Questionnaire)~A patient is defined as unexposed if he does not fulfill any of these conditions :~* At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~* At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~* At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
62306200|NCT03527043|EXPERIMENTAL|Escitalopram|10mg by mouth daily for 6 weeks
61918931|NCT01007682|EXPERIMENTAL|Distressing movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
62118272|NCT04244604|EXPERIMENTAL|High Sodium Meal (2500 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a high sodium meal (2500 mg sodium).
62306201|NCT03527043|PLACEBO_COMPARATOR|Placebo|Matched placebo control by mouth for 6 weeks.
62306202|NCT05347056||Vertebral Body Tethering Group|Vertebral Body Tethering applied to the lumbar region, with or without fusion to the thoracic region
62306203|NCT05347056||Selective Thoracic Fusion Group|selective thoracic fusion was applied, no intervention was applied to the lumbar region
62306204|NCT02542345|EXPERIMENTAL|magnetic resonance imaging|
62118273|NCT04244604|PLACEBO_COMPARATOR|Low Sodium Meal (140 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a low sodium meal (140 mg sodium) which will serve as the control condition to demonstrate whether or not observed changes are due to high sodium or occur irrespective of sodium in the postprandial state.
62118274|NCT06201819|EXPERIMENTAL|Patients with morbid obesity in bariatric surgery preparation protocol|All patients with body mass index \>48 kg/m2 in preoperative protocol for bariatric surgery using liraglutide for preoperative weight loss
62118275|NCT00572078|EXPERIMENTAL|Sorafenib, Bevacizumab & Paclitaxel|Paclitaxel is given as i.v infusion over 60 min on days 1, 8, 15 every 28 days. Sorafenib is given orally starting with cycle 1 day 2. Bevacizumab is given as i.v infusion on days 1 and 15 every 28 days.
62118276|NCT04485156|ACTIVE_COMPARATOR|Arm 1 (Conventional treatment group)|"Will be treated as recommended by Korean Guidelines For Tuberculosis as well as WHO guidelines (e.g. isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months followed by isoniazid, rifampicin, (and ethambutol)) Duration of the treatment~- 6 months in total"
62118277|NCT04485156|EXPERIMENTAL|Arm 2 (High-dose rifampicin group)|"High-dose rifampicin, isoniazid, and pyrazinamide~* Rifampicin: 30mg/kg~* Isoniazid: 300mg/day~* Pyrazinamide: 1000mg/day (\<50kg), 1500mg/day (50-70kg), 2000mg /day (\>70kg), till culture conversion Duration of the treatment~* Till 12 weeks after culture conversion on liquid media"
62306205|NCT06023914|EXPERIMENTAL|Isometric strength evaluation with a device of electro-stimulation|"The measurement of rotator cuff strength (medial and lateral rotation) and shoulder elevation will be performed with a Medeor® manual dynamometer. To measure the strength of the medial and lateral rotators, the subject will be positioned in dorsal decubitus, with the shoulder abducted at 45º and in 30º of horizontal adduction (scapular plane), elbow flexed at 90º and neutral rotation, with the dynamometer positioned, respectively, over the distal radio-ulnar joint on the volar or dorsal surface. In all these strength assessments, individuals will be required to perform a maximum isometric contraction for 5 seconds.~According to the order of randomization, one of the two evaluations will be carried out initially. We will call the evaluation with electrostimulation experimental here. The device to be used will be a GLOBUS® brand equipment, the equipment presents several types of pre-programmed currents, parameters have also been used in similar studies."
62306206|NCT06023914|ACTIVE_COMPARATOR|Isometric strength evaluation|"The measurement of rotator cuff strength (medial and lateral rotation) and shoulder elevation will be performed with a Medeor® manual dynamometer. To measure the strength of the medial and lateral rotators, the subject will be positioned in dorsal decubitus, with the shoulder abducted at 45º and in 30º of horizontal adduction (scapular plane), elbow flexed at 90º and neutral rotation, with the dynamometer positioned, respectively, over the distal radio-ulnar joint on the volar or dorsal surface. In all these strength assessments, individuals will be required to perform a maximum isometric contraction for 5 seconds.~We will call this intervention active comparator, as both groups of patients will undergo this evaluation, which will be performed without electrostimulation."
62306207|NCT05780281|EXPERIMENTAL|VIR-7831 plus SOC|"* VIR-7831 500 mg solution (2 vials of 250 mg); administered as a single IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62306208|NCT05780281|PLACEBO_COMPARATOR|Placebo plus SOC|"* Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62306209|NCT02346448|ACTIVE_COMPARATOR|endoscopic sphincterotomy|performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome
62306210|NCT02346448|ACTIVE_COMPARATOR|balloon dilatation for 3 minutes|Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)
62677507|NCT02842281|ACTIVE_COMPARATOR|Fructan|Fructans will be provided for 72 hours.
62677508|NCT02842281|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin will be provided for 72 hours.
61918932|NCT02835352|EXPERIMENTAL|Essential oils then oil massages|Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days
61918933|NCT02835352|EXPERIMENTAL|Oil then essential oils massages|Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days
62118278|NCT03983889|EXPERIMENTAL|F|Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance
62677509|NCT00965991|ACTIVE_COMPARATOR|Metformin|
62677510|NCT00965991|ACTIVE_COMPARATOR|Glyburide|
62677511|NCT04172064||377patients evaluated by MPS and DSE|
61918934|NCT00624702|ACTIVE_COMPARATOR|1|Active Comparator 1 different salt formulation of Indacaterol.
62118279|NCT03983889|EXPERIMENTAL|DR|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
62118280|NCT03983889|EXPERIMENTAL|DF|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance
62118281|NCT03983889|EXPERIMENTAL|PR|Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
62118282|NCT02171104|EXPERIMENTAL|IMD - Except Haplo-identical|"Inherited Metabolic Disease (IMD) - Except Haplo-Identical~See intervention descriptions."
62118283|NCT02171104|EXPERIMENTAL|OP - Except Haplo-Identical|"Severe Osteoperosis (OP) - Except Haplo-Identical~See intervention descriptions."
62118284|NCT02171104|EXPERIMENTAL|OP and IMD -Haplo-Identical Only|"Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)~-Haplo-Identical Only~See intervention descriptions."
62118285|NCT02171104|EXPERIMENTAL|cALD SR-A (Standard-Risk, Regimen A)|See intervention descriptions.
62118286|NCT02171104|EXPERIMENTAL|cALD SR-B (Standard-Risk, Regimen B)|See intervention descriptions.
62118287|NCT02171104|EXPERIMENTAL|cALD HR-C (High-Risk, Regimen C)|See intervention descriptions.
62118288|NCT02171104|EXPERIMENTAL|cALD HR-D (High-Risk, Regimen D)|See intervention descriptions.
62118289|NCT02253719||HIV positive women|500 HIV women will be recruited from the hospital's current patient base as well as the community
62118290|NCT02253719||HIV negative women|500 HIV women will be recruited from the hospital's current patient base as well as the community
62118291|NCT01830946|EXPERIMENTAL|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
62118292|NCT01830946|PLACEBO_COMPARATOR|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
62118293|NCT01830946|EXPERIMENTAL|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
62118294|NCT06249204|ACTIVE_COMPARATOR|Coaching Group|The intervention group will be exposed to six coaching sessions (one a month for 6 months) as well as a nine month touch point to complete the 3-month post survey. This group will have access to a care community coach, resources and use these supports to create action steps towards adopting and implementing person-centered best practices based on an initial self-assessment of their current practices.
62118295|NCT06249204|NO_INTERVENTION|Training Group|This group will complete the same pre, immediate post and 3-month post surveys as the intervention group but will receive no intervention during the six month period.
62118296|NCT03476070||AYA cancer patients|Patients (aged between 15-39) diagnosed with breast cancer, lymphoma or germ cell tumor
62677512|NCT06558279|EXPERIMENTAL|Efgartigimod PH20 SC in part A+B|Participants receiving efgartigimod PH20 SC during part A and part B
62118297|NCT03476070||Healthy controls|Healthy controls
62118298|NCT06676605|EXPERIMENTAL|Intervention Group|The intervention group consisted of 17 participants who were administered a dietary supplement of Withania somnifera, classified as such and subject to FDA regulations comparable to pharmaceutical medications. Over a period of 40 days, participants in this group consumed 500 mg capsules of W. somnifera daily, in accordance with the manufacturer's instructions and within the recommended dose range of 240-600 mg. Prior to the supplementation period, comprehensive anthropometric and biochemical analyses were carried out to establish baseline measurements. Members of this group also received personalized meal plans to ensure that any observed changes were a direct result of the supplementation. Additionally, participants were closely monitored via email and/or text messages to remind them of study guidelines, address any questions or concerns, and watch for potential adverse effects.
62118299|NCT06676605|PLACEBO_COMPARATOR|Placebo Group|The placebo group also comprised 17 participants who were given a capsule/tablet of starch rice daily for the same 40-day period. Like the intervention group, participants in the placebo group underwent initial anthropometric and biochemical analyses to set baseline measurements before starting the supplementation period. This group similarly received personalized meal plans to ensure that any observed changes could be accurately attributed to the placebo effect. The placebo group participants were monitored via email and/or text messages to reinforce study guidelines, answer any questions or concerns about their meal plans or supplements, and monitor for any potential adverse effects.
62677513|NCT06558279|EXPERIMENTAL|Placebo PH20 SC in Part A + Efgartigimod PH20 SC in Part B|Participants receiving placebo PH20 SC in Part A and Efgartigimod PH20 SC in Part B
62677514|NCT05042466|EXPERIMENTAL|Plant Medicine On Boarding|The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every M/W/F with a tailored dose of plant medicine psilocybin in the enhanced micro dose levels or 0.15g. to 0.33g with a monthly dose of 1 gram to 1.5 grams. Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
62118300|NCT02847117|OTHER|Mastiha|
62677515|NCT05042466|EXPERIMENTAL|Participant|0.15g. thru 0.33g. tailored to participant, then Monthly a 1 time dose of 1gram to 1.5 grams dose of non-synthesized plant medicine psilocybin.
62677516|NCT05042466|EXPERIMENTAL|Psychiatrist|Psychiatrist QC scaling back SSRI's replacing with psilocybin.
62677517|NCT05042466|EXPERIMENTAL|On-Boarding Plant Medicine Specialist|The On-Boarding Provider will control dosage of the plant medicine via Telehealth.
62677518|NCT03479684|EXPERIMENTAL|Gene-directed group|the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
62677519|NCT03479684|ACTIVE_COMPARATOR|Standard care group|the first day given 4.5mg; adjusted dose based on INR from the second day
62677520|NCT05813483|EXPERIMENTAL|Test group|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
62677521|NCT05813483|OTHER|Control group|fraxel laser therapy combined with routine moisturizing and sun protection
62677522|NCT06390371|EXPERIMENTAL|Intervention (Spotlight AQ)|Spotlight AQ is an Artificial Intelligence (AI) powered adaptive survey which identifies the main concerns and gaps in patients tailored to their specific needs in preparation for clinic visits
62677523|NCT06390371|NO_INTERVENTION|Standard of Care|The pre-clinic survey typically given to patients before clinic visits at each institution
62677524|NCT03638271|OTHER|nonischemic cardiomyopathic patient|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging.
62677525|NCT03199365|EXPERIMENTAL|Prevention (TSSC intervention)|Participants undergo two TSSC intervention sessions delivered at participants' homes by trained CHWs over 1.5 hours.
62677526|NCT03056430|EXPERIMENTAL|Training Group 1|Slackline training
62677527|NCT03056430|EXPERIMENTAL|Training Group 2|Slackline training
62677528|NCT01950390|ACTIVE_COMPARATOR|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning cycle 8, patients receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
62677529|NCT01950390|EXPERIMENTAL|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning cycle 8, patients also receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
62118301|NCT01511471|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
62118302|NCT04920032|EXPERIMENTAL|TASIRI|"Patients randomized to the experimental arm (TASIRI) will be treated with TAS-102 25mg/m2 p.o. on days 1-5 and irinotecan 180mg/m2 i.v. on day 1 every 14 days. If ANC \<1500/uL on day 1 of a cycle, then G-CSF will be added on day 6 for three days."
62118303|NCT02947217|EXPERIMENTAL|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
62118304|NCT02947217|PLACEBO_COMPARATOR|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
62677530|NCT06148285|EXPERIMENTAL|100% oxygen under 2.0ATA|The first intervention arm consists of ischemic stroke patients who would undergo HBOT at 2.0 ATA with 100% oxygenation for 60 minutes x10 treatments (Monday-Friday of two sequential weeks).
62677531|NCT06148285|ACTIVE_COMPARATOR|21% oxygen under 2.0ATA|The second intervention arm would consist of ischemic stroke patients undergoing HBOT at 2.0 ATA with 21% oxygen (room air) for 60 minutes x10 treatments (Monday-Friday of two sequential weeks).
62677532|NCT06148285|SHAM_COMPARATOR|21% oxygen under 1.14ATA|For sham-control; ischemic stroke patients will undergo placement in the hyperbaric oxygen chamber for the same duration of time (60 minutes x10 treatments, Monday-Friday of two sequential weeks) and pressure maintained at 1.14 ATA with 21% oxygen (room air), a non-therapeutic dose of HBOT that sufficiently increases pressure to simulate ear popping, hence maintaining participants blinded to the intervention / sham.
62677533|NCT05380596|NO_INTERVENTION|Control|Patients in the control group will remain out of contact with the research group and will receive usual care, which consists of receiving medications without additional information. After completion of the project, the control group will receive educational materials related to the care of people with diabetes and, if the effectiveness of the Pharmaceutical Telecare service is proven, this possibility of care will be offered to users.
62677534|NCT05380596|ACTIVE_COMPARATOR|Intervention|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3), via cell phone. Each consultation will address an aspect of health education for DM2.
62677535|NCT03845673|EXPERIMENTAL|Psyllium|This group of patients was given psyllium for 6 weeks
62677536|NCT03845673|EXPERIMENTAL|Bowel recipe|This group was administered a specialized bowel recipe for 6 weeks
62677537|NCT02370693|ACTIVE_COMPARATOR|bortezomib plus mycophenolate mofetil|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
61918935|NCT00624702|ACTIVE_COMPARATOR|2|Active Comparator 2 different salt formulation of Indacaterol.
61918936|NCT00624702|ACTIVE_COMPARATOR|3|Active Comparator 3 different salt formulation of Indacaterol.
62118305|NCT00988637|OTHER|1) Vectical™ Ointment and Clobex® Spray|Vectical™ Ointment weekdays \& Clobex® Spray weekends regimen
62118306|NCT00988637|OTHER|2) Clobex® Spray and Vectical™ Ointment|Clobex® Spray morning and Vectical™ Ointment evening regimen
62677538|NCT02370693|PLACEBO_COMPARATOR|Placebo plus mycophenolate mofetil|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
61918937|NCT00624702|PLACEBO_COMPARATOR|4|
61918938|NCT03673735|EXPERIMENTAL|Experimental Arm|Patients will receive 1 infusion of 1500 mg Durvalumab within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with Durvalumab will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
62118307|NCT06227468||Greek population|The enrolled subjects will be managed as a single group.
62118308|NCT01641172|ACTIVE_COMPARATOR|Patients|Patients with disseminated testicular cancer
62118309|NCT01641172|PLACEBO_COMPARATOR|Healthy volunteers|Healthy men, age 18-50 years old
62118310|NCT03393377|EXPERIMENTAL|intervention group|received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
62118311|NCT03393377|PLACEBO_COMPARATOR|control group|received placebo for 30 days
62118312|NCT00475501|EXPERIMENTAL|Arm 1|testosterone enanthate
62118313|NCT00475501|EXPERIMENTAL|Arm 2|finasteride
62118314|NCT00475501|EXPERIMENTAL|Arm 3|testosterone enanthate + finasteride
62118315|NCT00475501|PLACEBO_COMPARATOR|Arm 4|placebo
62118316|NCT01063517|EXPERIMENTAL|1|Olaparib + paclitaxel
62118317|NCT01063517|ACTIVE_COMPARATOR|2|paclitaxel + placebo
62118318|NCT01965119|EXPERIMENTAL|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
62306211|NCT02346448|ACTIVE_COMPARATOR|balloon dilatation for 6 minutes|Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)
62306212|NCT03020511|OTHER|Ancient wheat flours|"We prospectively will survey 30 nuns from the Congregazione delle Suore Collegine della Santa Famiglia, Palermo, Italy. The subjects will be recruited between January 2017 and June 2017 and will be examined before and after the diet period (30 days) with ancient grains, undergoing clinical evaluation and blood and feces samples collection. Ancient wheat flours will be administered in open label for 30 days"
62306213|NCT00858832|EXPERIMENTAL|Methergine|Methergine group received Methergine 0.2mg po every 6 hours for two days, plus routine postpartum care.
62306214|NCT00858832|NO_INTERVENTION|No treatment|No treatment group received only routine postpartum care.
62306215|NCT04379583||Subjects|Female subjects providing DNA saliva sample
62306216|NCT04163783|EXPERIMENTAL|Arm A|Subjects will be administered a single oral dose of 320 mg of \[14C\]-BGB-3111
62306217|NCT00670111|EXPERIMENTAL|RAP On then Off at 1 month visit|"1. Rate Adaptive Pacing (RAP) On for first cardiopulmonary exercise test (CPX) at one month.~2. Rate Adaptive Pacing (RAP) Off for second cardiopulmonary exercise test (CPX) at one month."
62306218|NCT00670111|EXPERIMENTAL|RAP Off then On at 1 month visit|"1. Rate Adaptive Pacing (RAP) Off for first cardiopulmonary exercise test (CPX) at one month.~2. Rate Adaptive Pacing (RAP) On for second cardiopulmonary exercise test (CPX) at one month."
62306219|NCT01134510|EXPERIMENTAL|C1 esterase inhibitor|10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
62306220|NCT01134510|PLACEBO_COMPARATOR|Placebo|10 subjects placebo \[normal saline\] in addition to standard of care immunosuppressive therapy.
62118319|NCT06404710|NO_INTERVENTION|Control|Scales will be filled in for the control group without any progressive relaxation exercise.
62118320|NCT06404710|EXPERIMENTAL|Exercise|Scales will be filled in by the intervention group by performing a progressive relaxation exercise.
62118321|NCT06510348|NO_INTERVENTION|EN group|enteral nutrition intake will progressively be increased according to the gastrointestinal tolerance (evaluated based on ultrasound guided gastric residual volume measurement) until the target of 100% is attained following admission to the ICU.
62118322|NCT06510348|EXPERIMENTAL|Supplemental parenteral nutrition (SPN) group|gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
62118323|NCT04703920|EXPERIMENTAL|Talozoparib in combination with Belinostat|Patients will receive Talozoparib in combination with Belinostat
62118324|NCT01441934|ACTIVE_COMPARATOR|Sildenafil citrate|20 mg t.i.d.
62118325|NCT01441934|PLACEBO_COMPARATOR|Sugar pill|
62306221|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
62306222|NCT02902809|EXPERIMENTAL|Open-label study to evaluate safety|A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting β2-agonist.
62306223|NCT03037294|NO_INTERVENTION|Control group|Subjects in the control group will receive no intervention.
62306224|NCT03037294|EXPERIMENTAL|Protein group|Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
62306225|NCT05914883|EXPERIMENTAL|ECG screening|ECG247 is used for continuous screening for 3-7 days
62677539|NCT04928066|EXPERIMENTAL|Tofacitinib (TF)+Iguratimod (IGU)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
62118326|NCT04490369||Group 1- short interval|Less than or equal to six minutes between receiving sedation and the start of the procedure
62118327|NCT04490369||Group 2- long interval|Greater than or equal to seven minutes between receiving sedation and the start of the procedure
62118328|NCT06554886|EXPERIMENTAL|Active treatment|Cryoneurolysis
62118329|NCT03624413|EXPERIMENTAL|Social Media Intervention|Adolescent HIV-positive participants receiving the social media intervention.
62118330|NCT03624413|ACTIVE_COMPARATOR|Standard of Care|Adolescent HIV-positive participants receiving the standard of care.
62118331|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
62118332|NCT02421081|ACTIVE_COMPARATOR|having arteriel cut|30 patients who refer to Erciyes University emergency department because of wrist laceration with radial and/or ulnar artery incision,will be presenting to the study.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery,under a microscope using microsurgical techniques and polyamide suture will be held vascular repair.Patients will be assessed by Doppler ultrasonography again 4 weeks after surgery;flow velocity and vessel diameter will be measured at the anastomoses line and patient will be divided to 4 groups. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; The relationship between the anastomosis opening will be evaluated statistically.
62118333|NCT02421081|ACTIVE_COMPARATOR|having tendon cut|10 patients having similar age and sex with first group, who refer to Erciyes University emergency department because of wrist laceration without radial or ulnar artery cutting,will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery to repair tendons and/or nerves. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; and will compare with first group.
62118334|NCT02421081|NO_INTERVENTION|healthy control|10 healty having similar age and sex with first group,controls who accept to give blood to determine normal range of serum CD34,CD133 and CD 309 will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.
62118335|NCT00570219|EXPERIMENTAL|B|Gradual benzodiazepine discontinuation and valproate treatment
62118336|NCT00570219|NO_INTERVENTION|A|Gradual benzodiazepine discontinuation
62118337|NCT04243304|EXPERIMENTAL|PD patients|At baseline and 2-year follow-up
62118338|NCT04243304|ACTIVE_COMPARATOR|Healthy controls|At baseline and 2-year follow-up
62118339|NCT01807663|EXPERIMENTAL|healthy volunteers|Free breath monitoring. Correlation between two device for recording parameters of ventilation.
62118340|NCT01807663|EXPERIMENTAL|Chronic patient|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
62118341|NCT01807663|EXPERIMENTAL|ACUTE PATIENT|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
62677540|NCT04928066|OTHER|Tofacitinib (TF)|"Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
62677541|NCT04634903|ACTIVE_COMPARATOR|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
62306226|NCT05914883|NO_INTERVENTION|No ECG screening|Standard of care
62677542|NCT04634903|EXPERIMENTAL|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
62306227|NCT05822869|EXPERIMENTAL|EIT guided group|During prone ventilation, the PEEP level is adjusted based on EIT monitoring.
62118342|NCT05799261|ACTIVE_COMPARATOR|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
62118343|NCT05799261|EXPERIMENTAL|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~1. Staining of all tooth surfaces to detect soft and hard deposits.~2. Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~3. If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~4. Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
62677543|NCT04634903|EXPERIMENTAL|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
62677544|NCT06478940|ACTIVE_COMPARATOR|MTA pulpotomy|pulpotomy with MTA applied in the vital pulp therapy
62118344|NCT06675968|EXPERIMENTAL|Direct suture|
62677545|NCT06478940|EXPERIMENTAL|3 Mixtatin pulpotomy|pulpotomy with 3 mixtatin (triple antibiotic paste of (Metronidazole, cefixime, and Ciprofloxacin mixed with simvastatin ) applied in the vital pulp therapy
62677546|NCT01275937|OTHER|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days followed by40mg once daily orally for two months.
62473946|NCT05684276|EXPERIMENTAL|Experimental: Neodjuvant treatment + Adjuvant maintenance treatment|"Neodjuvant treatment:~Nivolumab: 360 mg intravenous Q3W Paclitaxel: 200mg/m2 infusion over 3 hours Carboplatin: AUC6 at the end of the Paclitaxel infusion~Neoadjuvant treatment will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)~Depending on surgery results the patient will receive:~* Patients with degree of resection 'R0': Adjuvant treatment for 6 months with Nivolumab 480mg QW4~* Patients with degree of resection 'R1' or 'R2': standard treatment according to local guidelines"
62677547|NCT01275937|ACTIVE_COMPARATOR|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days followed by 40mg once daily orally for two months.
62677548|NCT03566550||CF|people with cystic fibrosis
62677549|NCT03566550||Control|people without cystic fibrosis
62677550|NCT06406816|EXPERIMENTAL|Neoantigen Vaccine plus Capecitabine|Neoantigen Vaccine plus Capecitabine for the treatment of high-risk recurrent intrahepatic cholangiocarcinoma
62677551|NCT03849612|EXPERIMENTAL|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
62677552|NCT02628067|EXPERIMENTAL|Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment).
62118345|NCT06675968|EXPERIMENTAL|Transsosseus suture|
62677553|NCT02628067|EXPERIMENTAL|Pembrolizumab 400 mg|Participants with any advanced solid tumor that has failed at least one line of therapy and is Tumor- Mutational Burden-High (TMB-H), excluding participants with mismatch repair deficient (dMMR/MSI-H) tumors. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment).
62677554|NCT01216085|EXPERIMENTAL|imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
62677555|NCT04314180||Slit-lamp image quality assessment|Device: an artificial intelligence system for quality assessment of slit-lamp images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center
62118346|NCT02249988|EXPERIMENTAL|Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm|ABX203 therapeutic vaccine in addition to NUCs background therapy
62118347|NCT02249988|NO_INTERVENTION|Group 2 - Control arm|NUCs background therapy only
62118348|NCT01241435|EXPERIMENTAL|LY2216684|LY2216684: A single dose of 18 milligrams (mg) administered orally in participants with normal hepatic function, mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C)
62473947|NCT03072433|ACTIVE_COMPARATOR|Standard of Care|Comparison group will receive the current standard of care. Nurses are instructed to tell mothers about nutrition and water, sanitation and hygiene at any point prior to discharge from hospital. In addition, nurses will tell primary caregivers to play with their children even while they are receiving treatment in a play area with toys available.
62473948|NCT03072433|EXPERIMENTAL|Counseling Intervention Package|Primary caregivers in the intervention group receive group education sessions involving psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene components during a total of four days.
62473949|NCT03708991||IVF combined with PGT-A|5000-10000 motile sperm will be added to the oocyte
62473950|NCT03708991||ICSI combined with PGT-A|1 motile sperm will be injected into the oocyte
62118349|NCT04305574||Community sample|We plan to recruit a representative sample of the Singapore population.
62118350|NCT03276104|ACTIVE_COMPARATOR|IOL repositioning group|
62118351|NCT03276104|ACTIVE_COMPARATOR|IOL exchange group|
62473951|NCT02778321|OTHER|Uses of SpiderFlash monitor|"The intervention corresponds to the use of Spiderflash as Holter monitor. Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist."
62473952|NCT05667649|EXPERIMENTAL|RB-ADSC low dose|Participants will receive one dose of 2x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir
62473953|NCT05667649|EXPERIMENTAL|RB-ADSC medium dose|Participants will receive one dose of 5x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir
62473954|NCT05667649|EXPERIMENTAL|RB-ADSC high dose|Participants will receive one dose of 10x10\^6 RB-ADSC infused in the previously implanted Ommaya reservoir
62473955|NCT01319383|EXPERIMENTAL|Open Label, Translational Research|Vorinostat will be administered to all eligible participants in each step of each phase (period) of the study
62736312|NCT05153603||Olaparib mono-maintenance therapy group|Olaparib monotherapy in clinical practice and will be conducted in patients with tBRCAwt newly diagnosed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy following the standard of care from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required) at tertiary-referral university hospitals and main cancer centers in China.
62118352|NCT02009839|EXPERIMENTAL|Meeky Mouse program|"14-week Meeky Mouse program consists of 8 training sessions (psychoeducation and anxiety management) followed by 6 practice sessions (exposure using social skills training)"
62118353|NCT02009839|PLACEBO_COMPARATOR|Computer Games|14 weeks of interactive session with the therapist while playing computer games
62118354|NCT05857267|EXPERIMENTAL|Dorzolamide+Timolol PF|Glaucotensil TD LC, Laboratorios Poen
62118355|NCT05857267|EXPERIMENTAL|Dorzolamide + Timolol BAK|Glaucotensil TD, Laboratorios Poen
62306228|NCT05822869|OTHER|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
62306229|NCT04373083|EXPERIMENTAL|Concomitant treatment|Treatment Group A
62306230|NCT04373083|EXPERIMENTAL|Sequential treatment|Treatment Group B
62306231|NCT04394169|EXPERIMENTAL|Intervention arm|The intervention is a program that includes early patient care, therapeutic education, and psychological intervention. It will be performed through three medical visits and a psychological intervention that requires seven face-to-face sessions.
62306232|NCT04394169|NO_INTERVENTION|Standard care arm|Standard medical practice: patient follow-up is carried out by their referring physicians (primary care physicians or specialists) who are outside the study.
62306233|NCT01509027|ACTIVE_COMPARATOR|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
62306234|NCT01509027|ACTIVE_COMPARATOR|Education by unpersonalised DVD|Information on detrimental consequences of hyperphosphatemia is presented on DVD
62306235|NCT01509027|PLACEBO_COMPARATOR|Standard Care|standard care
62306236|NCT05499195||ESD group|ESD was performed by a highly experienced endoscopist who underwent systemic training. First, the endoscopist carried out chromoendoscopy by spraying 1.25% Lugol's iodine solution to identify the lesion and made dots with a dual-knife outside the margin of the lesion. Next, a forward-viewing endoscope was introduced with a transparent cap attachment on its tip. A saline solution with methylene blue and epinephrine was injected into the submucosa with an injection needle to create a liquid cushion separating the lesion and the muscle layer. Then, a mucosal incision at the periphery of the marking dots was performed with a dual-knife. After that, the submucosal connective tissue beneath the lesion was dissected using the same dual-knife, and the lesion was totally removed through dissection.
62306237|NCT05499195||ESD+adjuvant radiotherapy group|The process of ESD was the same as that of ESD group. A total dose of 41.4-60.0 Gy in common fractionation based on three-dimensional conformal radiotherapy or intensity modulated radiotherapy technology was prescribed.
62473956|NCT04230330|EXPERIMENTAL|Nivolumab|After 4 doses of nivolumab, if the patient has complete responses (CR) or good partial response (PR), the patient will continue on nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment. During PET4-directed treatment with single agent nivolumab, if patient has PD, they will proceed to the Nivo+GDP/L-aspa arm.
62473957|NCT04230330|EXPERIMENTAL|Nivolumab + GDP/ L-asparaginase|After 4 doses of nivolumab, if the patient has PR, stable disease (SD), or progressive disease (PD), the patient will switch to nivolumab-GDP/L-aspa treatment. After 6 cycles of treatment, if CR is achieved, the patient will continue on single agent nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment.
62677556|NCT05864716|EXPERIMENTAL|probiotics-spray (PS) group|In the PS group, 1 vial of multi-strain probiotics powder via colonoscopic spray is performed once, followed by five-days of two oral placebo capsules daily. After the five-day treatment, the 2nd fecal sample will be collected. Both groups will receive a 23-day course of oral probiotics (two capsules twice daily) subsequently. The patients were asked to keep a diary to record bowel habits and register any adverse events. The 3rd fecal sample will be collected 28 days after the colonoscopy. The questionnaires will be completed 28 days and 84 days after the colonoscopy to assess responses of treatment. Polyethylene glycol and loperamide were allowed during the intervention as the rescue medication.
62677557|NCT05864716|ACTIVE_COMPARATOR|probiotics-oral (PO) group|In the PO group, 1 vial of placebo powder via colonoscopic spray is performed once, followed by five-days of two oral probiotics capsules daily. After the five-day treatment, the 2nd fecal sample will be collected. Both groups will receive a 23-day course of oral probiotics (two capsules twice daily) subsequently. The patients were asked to keep a diary to record bowel habits and register any adverse events. The 3rd fecal sample will be collected 28 days after the colonoscopy. The questionnaires will be completed 28 days and 84 days after the colonoscopy to assess responses of treatment. Polyethylene glycol and loperamide were allowed during the intervention as the rescue medication.
62677558|NCT04284436|EXPERIMENTAL|High Intensity Exercise|Treadmill exercise 4x per week at 80-85% HRmax.
62677559|NCT04284436|ACTIVE_COMPARATOR|Moderate Intensity Exercise|Treadmill exercise 4x per week at 60-65% HRmax.
62677560|NCT03516708|EXPERIMENTAL|Dose Escalation Cohort (Phase I): Epacadostat + SCRT + Chemotherapy + Surgery|"* Epacadostat at the designated dose level starting on the 1st day of radiation therapy and continuing throughout chemotherapy until the day of surgery.~* Standard of care preoperative therapy will consist of a total of approximately 20-24 weeks of short-course pelvic radiation and chemotherapy:~  * Cycle 0 Days 1-7(Week 1): Short-course pelvic radiation therapy (SCRT), 5 fractions over 1 week~ * Cycle 0 Days 8-21 or 8-28 (Weeks 2-4): Treatment break for 2 to 3 weeks; for patients enrolled at Washington University and Dana Farber only, tumor biopsy will be obtained between the end of RT and prior to chemotherapy (target Days 14-28)~ * Cycles 1-6: (6) 21-day cycles of CAPOX for a total of 18 weeks. CAPOX is typically capecitabine at 1000 mg/m\^2 PO BID (days 1-14 of each cycle) and oxaliplatin 130 mg/m\^2 IV Q3W.~ * Surgery will follow approximately 4 to 6 weeks after completion of CAPOX"
62677561|NCT03516708|EXPERIMENTAL|Phase II Treatment Cohort: Epacadostat + SCRT + Chemotherapy + Surgery|"* Epacadostat 400 mg BID 1st day of radiation therapy and continuing for \~28 days, until biopsy (with the exception of patients enrolling to dose expansion and starting on epacadostat with neoadjuvant chemotherapy prior to approval of post-sIRB A2)~* Preoperative therapy approximately 20-24 weeks of chemoradiation:~  * Week 1: SCRT, typically 5 Gy x 5 fractions over 1 week, with epacadostat 400 mg BID starting on D1 of SCRT~ * Weeks 2-4: Epacadostat monotherapy 400 mg BID \& continued for a minimum of 21 days, until the day prior to chemotherapy~ * For patients enrolled at Washington University and Dana Farber Cancer Institute ONLY, tumor biopsy between the end of RT and prior to initiation of chemotherapy. Tumor biopsy target of between Days 15-28~ * Weeks 3-6: 4-5 weeks after completion of SCRT \& after completion of approximately 21-35 days of epacadostat, SOC neoadjuvant chemotherapy of CAPOX or FOLFOX will be initiated~ * Surgery will occur approximately 4-6 weeks after chemotherapy"
62736313|NCT04300205|EXPERIMENTAL|High intensity LED light treatment|Participants treated with high intensity LED phototherapy
62306238|NCT02532842||Participants with Schizophrenia|This is a retrospective, non-interventional, multicenter study to retrospectively evaluate hospitalization and medical resource use, patterns of paliperidone palmitate use, and clinical outcomes documented within the medical records of young, adult, newly diagnosed schizophrenia participants for the first 12 months of continuous treatment with paliperidone palmitate. Only retrospective data available from clinical routine practice and documented in a participant's medical record will be collected.
62306239|NCT05714371||Immunotherapy (IO)|Patients receiving IO
62473958|NCT02612298|EXPERIMENTAL|arotinolol|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks
62473959|NCT02612298|ACTIVE_COMPARATOR|Metoprolol|Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
62306240|NCT05714371||Targeted therapy (TT)|Patients receiving TT
62306241|NCT03185676|EXPERIMENTAL|Billberry|A bilberry-based probiotic beverage
62306242|NCT03185676|ACTIVE_COMPARATOR|Control|A control beverage without bilberries or probiotics
62306243|NCT00479466|EXPERIMENTAL|MK0893 80 mg|MK0893 tablets totaling 80 mg once daily.
62306244|NCT00479466|EXPERIMENTAL|MK0893 60 mg|MK0893 tablets totaling 60 mg once daily.
62306245|NCT00479466|EXPERIMENTAL|MK0893 40 mg|MK0893 40 mg tablet once daily.
62306246|NCT00479466|EXPERIMENTAL|MK0893 20 mg|MK0893 20 mg tablet once daily.
62306247|NCT00479466|ACTIVE_COMPARATOR|Metformin|Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
62677562|NCT03516708|ACTIVE_COMPARATOR|Phase II Biomarker Cohort: SCRT + Chemotherapy + Surgery|Washington University and Dana Farber only: Patients enrolled to this cohort will not receive epacadostat. Patients will undergo standard of care preoperative therapy consisting of approximately 20 to 24 weeks of chemoradiation. All treatment will be administered in this cohort as per institutional standard. The expected schedule for these patients will consist of 1 week of short-course pelvic radiation therapy, followed by a treatment break, followed by neoadjuvant chemotherapy. Approximately 4 to 6 weeks after completion of neoadjuvant chemotherapy, patients may undergo surgery. Tumor biopsy may occur at screening and after completion of RT, prior to starting neoadjuvant chemotherapy.
61918939|NCT03673735|PLACEBO_COMPARATOR|Control arm|Patients will receive 1 infusion of placebo within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with placebo will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
62677563|NCT03852693||Retrospective Group|
61918940|NCT03049293|NO_INTERVENTION|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
61918941|NCT03049293|EXPERIMENTAL|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
61918942|NCT04192227|EXPERIMENTAL|Wellness Group 1|Administered by wellness facilitator and co-facilitator.
61918943|NCT04192227|ACTIVE_COMPARATOR|Wellness Group 2|Administered by wellness facilitator and co-facilitator.
62118356|NCT02834884||RP-1828 IMMUcan (CLOSED for recruitment since August 2024)|"The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions.~Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary"
62118357|NCT02834884||RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)|"The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials.~Tumor type: CNS"
62118358|NCT02834884||RP-1843 Arcagen (CLOSED for recruitment since November 2022)|"This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population.~Tumor types: all 10 EURACAN domains"
62118359|NCT02834884||RP-1920 BioRadon|"The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon).~Tumor type: Thorax"
62118360|NCT01430858|OTHER|Strain Gauge|We wish to determine the relationship between tibial bone strain (recorded from implanted tibial strain gauges) and measured displacements of the limb and pelvis (using video motion analysis) during vibration exercise and a range of habitual locomotor activities. Only healthy volunteers will be recruited to this one arm.
62118361|NCT03521037|EXPERIMENTAL|no name|Group 1: patients with normal hepatic function Group 2: patients who have moderate hepatic impairment
62118362|NCT01787240|PLACEBO_COMPARATOR|Placebo|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
62118363|NCT01787240|EXPERIMENTAL|Escitalopram 10mg|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
61918944|NCT01056380|ACTIVE_COMPARATOR|Nitazoxanide|
62306248|NCT00479466|PLACEBO_COMPARATOR|Placebo|PLA tablets. 12 week treatment period.
61918945|NCT01056380|PLACEBO_COMPARATOR|Placebo|
61918946|NCT03931668|EXPERIMENTAL|0.125mg single dose|single dose of TPN-672 0.125mg, 2 subjects
61918947|NCT03931668|EXPERIMENTAL|0.25mg single dose|single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)
61918948|NCT03931668|EXPERIMENTAL|0.5mg single dose|single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)
61918949|NCT03931668|EXPERIMENTAL|1mg single dose|single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)
61918950|NCT03931668|EXPERIMENTAL|2mg single dose|single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)
62306249|NCT04603248|EXPERIMENTAL|Single Arm|
62306250|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
62306251|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
62306252|NCT03450772|EXPERIMENTAL|Creon® 25000 then Creon® 10000|Pancreatic enzyme
62306253|NCT03450772|ACTIVE_COMPARATOR|Creon® 10000 then Creon® 25000|Pancreatic enzyme
62306254|NCT02365077||Control|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week without the symptom of femur head necrosis after 1 year.
62677564|NCT03852693||Prospective Group|
62677565|NCT05708599|EXPERIMENTAL|Patients with early-stage and advanced-stage disease per indication|Indications: Pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and non-small cell lung cancer (NSCLC)
62306255|NCT02365077||Necrosis|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week with the diagnosis of femur head necrosis.
62473960|NCT00131391|PLACEBO_COMPARATOR|Phase A/B; Arm 1|Phase A: Arm 1: MK0364 Pbo capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.
62473961|NCT00131391|EXPERIMENTAL|Phase A/B: Arm 2|Phase A: Arm 2: MK0364 4 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 2: MK0364 4 mg capsule once daily.
62473962|NCT00131391|EXPERIMENTAL|Phase A/B: Arm 3|Phase A: Arm 3: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 3: MK0364 Pbo capsule once daily.
62473963|NCT00131391|EXPERIMENTAL|Phase A/B: Arm 4|Phase A: Arm 4: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 4: MK0364 2 mg capsule once daily.
62473964|NCT00131391|EXPERIMENTAL|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 5: MK0364 4 mg capsule once daily.
62306256|NCT02436239|EXPERIMENTAL|Vilazodone|
62473965|NCT00131391|EXPERIMENTAL|Phase A/B: Arm 6|Phase A: Arm 6: MK0364 6 mg once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 6: MK0364 6 mg capsule once daily.
62306257|NCT04352660|ACTIVE_COMPARATOR|Injection group|MMC delivered by preoperative subconjunctival injection
62306258|NCT04352660|ACTIVE_COMPARATOR|Sponge group|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
62306259|NCT03255278|EXPERIMENTAL|Safety and portable study group|"12 persons who have got a single decreased dose (0.25 of the planned dose for regular administration) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: single GamTBvac vaccination (0.25 dose)."
62306260|NCT03255278|PLACEBO_COMPARATOR|Placebo safety study group|12 persons who have got a single dose of placebo (0.5 ml). The intervention for the Arm: Placebo administration (0.5 ml)
62306261|NCT03255278|EXPERIMENTAL|Immunogenicity study group #1|"12 persons who will get a double sequential administration of the decreased dose (0.25 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.25 dose)."
62677566|NCT01232361||Methylphenidate|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)\* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~\*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
62677567|NCT01232361||Amphetamine / dextroamphetamine|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)\* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~\*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
62118364|NCT05076435|EXPERIMENTAL|Restrictive fluid administration|"No IV fluids unless one of the extenuating circumstances occur;~1. In case of severe hypoperfusion or severe circulatory impairment defined by either: 1) Lactate≥4 mmol/L, 2) Hypotension (systolic BP \< 90 mmHg), 3) Mottling beyond the kneecap (mottling score \>2) OR 4) Urinary output\<0.1 mL/kg bodyweight/h (only in the first 4hrs after randomization) then a bolus of 250 ml of IV crystalloid solution may be given followed by re-evaluation~2. In case of overt fluid losses (e.g. vomiting, large aspirates,) IV fluid may be given to correct for the loss, but not above the volume lost.~3. In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~   Correct dehydration or electrolyte deficiencies Ensure a total fluid input of 1 L in 24hrs~4. IV fluids may be given as carrier for medication, but with lowest possible volume"
62306262|NCT03255278|EXPERIMENTAL|Immunogenicity study group #2|"12 persons who will get a double sequential administration of the mean dose (0.5 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.5 dose)."
62306263|NCT03255278|EXPERIMENTAL|Immunogenicity study group #3|"12 persons who will get a double sequential administration of the maximum (regular) dose of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (1.0 dose)."
62306264|NCT00806117|ACTIVE_COMPARATOR|Radiotherapy (RT)|Radiotherapy
62306265|NCT00806117|EXPERIMENTAL|Concurrent chemoirradiation (CCRT)|"Concurrent chemoirradiation:~External beam radiation with concurrent weekly platinum chemotherapy"
62306266|NCT00806117|EXPERIMENTAL|Sequence chemo and radiation (SCRT)|"Sequence chemotherapy and radiotherapy:~2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation"
62306267|NCT01050660|ACTIVE_COMPARATOR|3 gm/kg/day intravenous lipid emulsion|
62306268|NCT01050660|EXPERIMENTAL|Intravenous Fat Emulsion-restricted|
62306269|NCT05987670|EXPERIMENTAL|Intervention|"Receive 3-6 AI-stethoscopes (Eko DUO, Eko Health Inc, CA, USA) including artificial intelligence software for detection of:~1. Reduced left ventricular ejection fraction \<40%~2. Atrial fibrillation~3. Cardiac murmurs"
62306270|NCT05987670|NO_INTERVENTION|Control|Usual care
62306271|NCT00548314|EXPERIMENTAL|1|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
62306272|NCT00548314|EXPERIMENTAL|2|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5.
62473966|NCT00698256|EXPERIMENTAL|1|
62473967|NCT00698256|PLACEBO_COMPARATOR|2|
62473968|NCT03004118|ACTIVE_COMPARATOR|Ursochol|About 10.5mg/kg/day of ursochol (calculated before start study for each participant individually) (combination of ursochol 150 and 300) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
61918951|NCT03931668|EXPERIMENTAL|3mg single dose|single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)
61918952|NCT03931668|EXPERIMENTAL|4mg single dose|single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)
62306273|NCT00548314|EXPERIMENTAL|3|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
62306274|NCT00548314|ACTIVE_COMPARATOR|4|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5.
62473969|NCT03004118|PLACEBO_COMPARATOR|Placebo|Same amount of pills as ursochol (calculated before start study for each participant individually) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
62473970|NCT02158572|EXPERIMENTAL|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
62473971|NCT01149590|EXPERIMENTAL|CT Calcium Score & Coronary Angiography|CT Scan
62473972|NCT01149590|NO_INTERVENTION|No CT Scan|No CT Scan
62677568|NCT04431778|EXPERIMENTAL|Ethosuximide|Patients with chronic peripheral neuropathic pain
62677569|NCT04431778|PLACEBO_COMPARATOR|Placebo|Patients with chronic peripheral neuropathic pain
62677570|NCT02841631||Post-Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
62473973|NCT00579345|EXPERIMENTAL|cTIV|Cell culture derived seasonal trivalent influenza vaccine (cTIV)
61918953|NCT04161300|ACTIVE_COMPARATOR|Foam Rolling Group (FR)|
62677571|NCT04423367|EXPERIMENTAL|bortezomib/dexamethasone|Enrolled patients will receive the combination therapy of bortezomib and dexamethasone.
62677572|NCT03486106|PLACEBO_COMPARATOR|Headphones without music|Participants in the control group will receive noise-cancelling wireless headphones that will not play any noise throughout the procedure. They will also receive propofol for sedation as needed.
62677573|NCT03486106|EXPERIMENTAL|Headphones with music|Participants in the experimental group will receive the same noise-cancelling wireless headphones but will be permitted to listen to the music of their choice while in the operating room. They will also receive propofol for sedation as needed.
62677574|NCT02913859|EXPERIMENTAL|pelvic radiotherapy|long-term hormonal therapy (LHRH agonist and/or antiandrogens) plus radiotherapy to the pelvis and prostate
62677575|NCT02913859|ACTIVE_COMPARATOR|No pelvic radiotherapy|long-term hormonal therapy ( LHRH agonist and/or antiandrogens) alone
62677576|NCT03268161||Patients with anti-MAG neuropathy|Mutational analysis of clonal B cells
62306275|NCT02396147|EXPERIMENTAL|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
62473974|NCT00579345|ACTIVE_COMPARATOR|eTIV_a|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
62473975|NCT00579345|EXPERIMENTAL|FLU (cTIV or eTIV_a)|Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
62677577|NCT00758043|EXPERIMENTAL|T12PR24 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
61918954|NCT04161300|ACTIVE_COMPARATOR|Orthopaedic Manual Physical Therapy Group (OMPT)|
61918955|NCT04161300|OTHER|Control Group (CG)|
61918956|NCT02642939|EXPERIMENTAL|mifepristone|mifepristone 300 mg capsule per day, orally in 28-day cycles
61918957|NCT03277079|ACTIVE_COMPARATOR|statin + ezetimibe|Low dose statin associated with ezetimibe
61918958|NCT03277079|ACTIVE_COMPARATOR|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
62677578|NCT00758043|EXPERIMENTAL|T12PR48 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
62677579|NCT00758043|EXPERIMENTAL|T12PR48 (eRVR-)|Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
62677580|NCT00758043|EXPERIMENTAL|Other|Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.
62677581|NCT05775575|EXPERIMENTAL|TQB3909 tablets|200-1000mg of TQB3909 tablets once a day; Oral administration under fast condition, 28 days as a cycle.
62677582|NCT01684254||Children with Cerebral Palsy (CP)|
62677583|NCT03725735|EXPERIMENTAL|CBT for PG with emotion regulation|A new treatment protocol for problem gamblers, CBT for problem gambling with emotion regulation, has a focus on emotion regulation, a component that has been lacking in current published research.
62677584|NCT06689891|EXPERIMENTAL|Video-based pelvic floor muscle therapy (PFMT)|Patients will complete a series of surveys before and after the intervention. They will complete 8 weeks of video-based PFMT with an initial and final in-person session with a pelvic floor therapist.
62677585|NCT00409227|ACTIVE_COMPARATOR|1|double blind placebo control
62677586|NCT00409227|PLACEBO_COMPARATOR|2|placebo control blinded arm
62677587|NCT04288531||Pregnant and pregnant to be on iodine supplementation|Women in preconception, pregnant and lactating, receiving iodine supplementation
62677588|NCT04288531||Pregnant and pregnant to be not on iodine supplementation|Women in preconception, pregnant or lactating, not receiving iodine supplementation
62677589|NCT04288531||Women of childbearing age|Women of childbearing age not planning to become pregnant.
62677590|NCT04430621|EXPERIMENTAL|FSH|FSH, 300 IU s.c.
61918959|NCT00712062|EXPERIMENTAL|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
62118365|NCT05076435|ACTIVE_COMPARATOR|Usual care (standard care)|"There will be no upper limit for the use of either IV or oral/enteral fluids~1. IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~2. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~3. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
62118366|NCT04655131|ACTIVE_COMPARATOR|Protein consumption : 0 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate
62118367|NCT04655131|EXPERIMENTAL|Protein consumption : 12.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate
62118368|NCT04655131|EXPERIMENTAL|Protein consumption : 25 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate
62118369|NCT04655131|EXPERIMENTAL|Protein consumption :37.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate
62473976|NCT00579345|ACTIVE_COMPARATOR|FLU (cTIV or eTIV_a) + PV|23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
62473977|NCT05246293|EXPERIMENTAL|Tofacitinib Arm|Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.
62473978|NCT02311686|EXPERIMENTAL|10 g ethanol|Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.
62473979|NCT02311686|EXPERIMENTAL|20 g ethanol|Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.
62473980|NCT02311686|EXPERIMENTAL|40 g ethanol|Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.
62473981|NCT02311686|EXPERIMENTAL|60 g ethanol|Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.
62473982|NCT02311686|EXPERIMENTAL|80 g ethanol|Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.
62473983|NCT06293196|EXPERIMENTAL|standard Chinese acupoint eye exercise group|The volunteers performed a set of standard Chinese acupoint eye health exercises.
62473984|NCT06293196|EXPERIMENTAL|fake acupoint eye exercise group|Volunteers performed a group of fake acupoint eye health exercises, the acupoint design in the place without acupoints.
62473985|NCT06293196|NO_INTERVENTION|simple eye closure group|The volunteers only closed their eyes and did not perform acupressure.
62473986|NCT06293196|NO_INTERVENTION|simple distance observation group|The volunteers only looked far without acupressure.
62473987|NCT05954598|EXPERIMENTAL|probiotic|The intervention group received 12 weeks of probiotic intervention from the beginning of the study,and at the start of the study at week 13, both groups received 12 consecutive weeks of probiotic intervention
62473988|NCT05954598|PLACEBO_COMPARATOR|placebo|The waiting group received 12 consecutive weeks of placebo intervention from the start of the study, and at the start of the study at week 13, both groups received 12 consecutive weeks of probiotic intervention
62677591|NCT04430621|PLACEBO_COMPARATOR|Control|Placebo, s.c.
62118370|NCT04655131|EXPERIMENTAL|Protein consumption : 50 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate
62118371|NCT04655131|EXPERIMENTAL|Protein consumption : 62.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate
62473989|NCT01891994|EXPERIMENTAL|Eltrombopag|Administration of eltrombopag at a dose of 150mg/day for 6 months
62473990|NCT05275998|EXPERIMENTAL|Sentinel Group 1|10 HIV-1 infected subjects will receive one infusion of 2400 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
62473991|NCT05275998|EXPERIMENTAL|Sentinel Group 2|10 HIV-1 infected subjects will receive one infusion of 3200 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
62473992|NCT05275998|EXPERIMENTAL|Sentinel Group 3|10 HIV-1 infected subjects will receive one infusion of 4800 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
62473993|NCT05275998|EXPERIMENTAL|Core Group 1|20 HIV-1 infected subjects will receive 4800 mg infusions of each antibody, TMB-365 and TMB-380 every 8 weeks and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 52.
62473994|NCT06219044|EXPERIMENTAL|symptomatic ovarian endometrioma|patients aged between 18 and 40 years with clinical and/or ultrasound diagnosis of symptomatic ovarian endometrioma
62473995|NCT05479487|EXPERIMENTAL|Fluzoparib+Apatinib combination|
62473996|NCT05479487|ACTIVE_COMPARATOR|Fluzoparib Monotherapy|
62677592|NCT06339762|EXPERIMENTAL|Experimental|Self-Compassion Training
62677593|NCT06339762|NO_INTERVENTION|Control|Self-Compassion Training no
62677594|NCT05725525|OTHER|Wearable Device Intervention|An open label, non randomized trial that requires all participants to wear a Garmin watch throughout the course of the trial (\~12 weeks).
62677595|NCT06268717|ACTIVE_COMPARATOR|Food challenge with pork meat containing alpha-gal, then pork meat without alpha gal sugar|Participants receive a food challenge, consuming pork meat that contains alpha-gal. After a \>10-day washout period, participants undergo a food challenge with pork which does not contain alpha-gal.
62677596|NCT06268717|ACTIVE_COMPARATOR|Food challenge with pork meat without alpha gal sugar, then pork meat containing alpha-gal|Participants receive a food challenge consuming pork meat that does not contain alpha-gal sugar. After a \>10-day washout period, participants undergo a food challenge with pork which does contain alpha-gal.
62118372|NCT02602106|EXPERIMENTAL|Intervention group|"The aquatic exercise program included a total of three 50-55 minutes session per week. Pregnant women started at 9 weeks and finished at 38-39 weeks.~Each session included 10 minutes of warm up and 10 minutes of cool down including an specific pelvic floor muscle training. The core section of the session included aerobic and strength moderate exercise in water during 25 to 30 minutes"
62118373|NCT02602106|NO_INTERVENTION|Control group|Sedentary healthy pregnant women
62118374|NCT03618849|EXPERIMENTAL|Sham tDCS|Post initial screening and baseline data collection, all study participants (a single cohort of patients) will receive a single dose of sham tDCS for 20 minutes over the left dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex in conjunction with Mozart piano sonata. For sham tDCS, the current will be ramped up and immediately ramped down for 30 seconds. The sham tDCS session will be preceded and followed by behavioral assessments.
62473997|NCT02216006|ACTIVE_COMPARATOR|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner."
62677597|NCT00862277||Group 1: Menactra® from Previous Studies|Subjects previously received only one dose of meningococcal vaccine, Menactra® in Study MTA04, MTA12, MTA19, or MTA21.
62677598|NCT00862277||Group 2: Menomune® from Previous Study|Subjects previously received only one dose of meningococcal vaccine, Menomune® in Study MTA04
62677599|NCT00862277||Group 3: Control|Meningococcal vaccine-naive age matched subjects
62677600|NCT03423953||Anatomic|Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.
62677601|NCT03423953||Reverse|Patients who have received the Reverse version of the Comprehensive Nano.
62677602|NCT06514248|NO_INTERVENTION|Reader Study without AI (Baseline )|During the baseline reading session the radiologist will mark each location of qualified nodules and assign a score. If at least one suspicious nodule is observed, the radiologist will also indicate a Lung-RADS score (i.e., 2, 3, 4A, 4B, or 4X) at the end of case interpretation.
62677603|NCT06514248|ACTIVE_COMPARATOR|Reader Study with AI (Aided by V5med Lung AI)|Perform another reader study using the V5med Lung AI as the aided read. The reader is asked to mark all potential nodules not less than 4mm assisted by V5med Lung AI. Some or majority of ROIs' parameters will be pre-filled by V5med Lung AI. The reader will make final determination for each location. The marked location, LOS score, Lung-RADS score, and time spent will be recorded for the statistical analyses and compared to the first arm study.
62677604|NCT02627638|OTHER|Osteopathic treatment|
62736314|NCT04300205|EXPERIMENTAL|Sham high intensity LED light treatment|Participants set up to be treated with light device but after being masked, the device is moved off the wound
62473998|NCT02216006|ACTIVE_COMPARATOR|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation the effect of preoxygenation is eliminated with an anti-preoxygenation maneuver."
62473999|NCT01472263|EXPERIMENTAL|Pentoxifylline|
62118375|NCT03618849|EXPERIMENTAL|1-mA tDCS|Post sham-tDCS, we will determine the eligibility of the participant to receive 1 mA of real tDCS based on the occurrence of adverse events and seizures occurring within 5 days of the sham session. After a minimum of 5 days post-sham stimulation (and typically around 7 days later), the participant will receive a single dose of 1-mA current (for head circumference \>52 cm; children with head circumference 43-52cm will receive 0.5-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 1-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 1-mA tDCS session will be preceded and followed by behavioral assessments.
62306276|NCT02396147|EXPERIMENTAL|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
62306277|NCT02082561|EXPERIMENTAL|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The F-SET protocol is consistent with current CBT protocols for anxiety disorders.
62474000|NCT01472263|PLACEBO_COMPARATOR|Placebo|
62474001|NCT05436860||presence of hepatic hyperechogenicity on ultrasound evaluation|
62677605|NCT03005574|EXPERIMENTAL|TSW-HP|TSW-HP Intervention implemented by a cognitive specialist over a 6-month treatment period which includes 24 hours (1 hour per week) of facilitated cognitive exercise sessions, which will be supplemented by approximately 24 hours of home practice sessions on a tablet computer.
62677606|NCT03005574|ACTIVE_COMPARATOR|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program, which includes a one hour cognitive exercise practice session per week at Brooklyn Community Services (BCS) for 6 months. This group will not receive home based cognitive practice exercises.
62677607|NCT01722734|NO_INTERVENTION|Control|Patients in the control arm only got a generic health message at the end of the study.
61918960|NCT02128360|ACTIVE_COMPARATOR|Minimal stimulation protocol|Low dose Letrozole 2.5 mg over 5 days, starting from cycle day 2, overlapping with low dose gonadotropins, starting from day 3 of the Letrozole at 150 units per day. GnRH antagonist to avoid premature LH surge will be introduced when one or more of the growing follicles reached approximately 14 mm in size
62474002|NCT05436860||absence of hepatic hyperechogenicity on ultrasound evaluation|
62474003|NCT02711449|EXPERIMENTAL|Methylprednisolone|125 mg Methylprednisolone intravenously approximately 30 minutes prior to skin incision
62474004|NCT02711449|PLACEBO_COMPARATOR|Placebo|0.9% Saline intravenously approximately 30 minutes prior to skin incision
62474005|NCT04717960|ACTIVE_COMPARATOR|study group group (1)|the group which will undergo submucosal injection of platelet rich plasma
62474006|NCT04717960|NO_INTERVENTION|comparative group group (2)|patients using the usual lines of medical treatment like nasal douching and lubricants
62474007|NCT02820350|OTHER|Treatment|Treatment arm only
62474008|NCT01032083|ACTIVE_COMPARATOR|Citalopram|An SSRI antidepressant
62474009|NCT01032083|PLACEBO_COMPARATOR|Placebo|
62474010|NCT01816997|PLACEBO_COMPARATOR|Control|IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
61918961|NCT02128360|ACTIVE_COMPARATOR|High dose protocol|High dose of gonadotropins (≥300 IU/day) starting from cycle day 3. GnRH antagonist will be introduced to avoid premature LH surge when one or more of the growing follicles will reach approximately 14 mm in size
62677608|NCT01722734|ACTIVE_COMPARATOR|Short Message|Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
62677609|NCT01722734|ACTIVE_COMPARATOR|Long message|Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
61918962|NCT05891964|EXPERIMENTAL|Secukinumab|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
61918963|NCT04252833|EXPERIMENTAL|CT-044 600 mg|The dose to be utilized for the evaluation of food effect will be CT-044 600 mg single dose.
61918964|NCT05991921|EXPERIMENTAL|"Transcutaneous Electrical Nerve Stimulation"|TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each.Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort. All participants in the TENS, received all other routine obstetric care provided by hospital healthcare professionals.
62118376|NCT03618849|EXPERIMENTAL|2-mA tDCS|Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current (if head circumference \>52cm; children with head circumference 43-52cm will receive 1-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments.
62118377|NCT02212522||Isis-Diab patients|French T1D patients with genetic data (GWAS), and environmental data (questionnaire and environmental databases), clinical data
62118378|NCT02212522||Isis-Diab controls|French control population with genetic data (GWAS) and environmental data (questionnaire and environmental databases
62118379|NCT05390736|EXPERIMENTAL|STEADI Intervention|For those assigned to the STEADI intervention arm, the clinical research nurse conducted standardized assessments to identify a patient's risk factors for falls. The STEADI assessments included: 1) a review of comorbidities; 2) medication review; 3) review of patient's falls history; 4) assessment of feet and footwear; 5) assessment of visual acuity; and 6) assessment of gait and balance; 7) review of home safety risks; and 8) assessment of potential vitamin D deficiency. Nurses would use assessment results to make recommendations which would then be relayed to the patient through their provider at their upcoming primary care visit.
62677610|NCT06446778||Saccular aneurysms|Patients with saccular aneurysms were enrolled.
62677611|NCT06446778||Non-saccular aneurysms|Patients with non-saccular (i.e., fusiform, dissecting, blood blister-like) aneurysms were enrolled.
62677612|NCT04406519||Hemophilia Group|The inclusion criteria in the hemophilia group were as follows; patients aged 6 to 18 years who developed HA in at least one of the lower limb joints due to severe haemophilia (total lower limb HJHS ≥3); to be receiving prophylaxis but have no major bleeding that could affect the musculoskeletal system in the past two weeks; and who did not perform regular physical activity and sports.
62118380|NCT05390736|NO_INTERVENTION|Control|After being enrolled in the study, the patient would receive usual care from their provider.
62118381|NCT05390736|EXPERIMENTAL|Physical Therapy Assessment Only|For those assigned to the PT assessment only arm, the clinical research nurse would only conduct gait and balance assessments and would make recommendations about need for physical therapy services, conveyed to primary care provider for referrals.
61918965|NCT05991921|SHAM_COMPARATOR|Plasebo|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
61918966|NCT05991921|NO_INTERVENTION|Control|Participants in the control group were not dependent on TENS. All participants in the control group received all other routine obstetric care provided by hospital healthcare professionals.
62677613|NCT04406519||Control Group|The control group was consisted of healthy peers. The exclusion criteria in the control group were as follows: who had any auditory and visual impairment; who underwent orthopedic injuries including lower limb; and who had any neurological or cognitive impairment that could affect balance.
61918967|NCT02069288|EXPERIMENTAL|1|Fludrocortisone
61918968|NCT02069288|PLACEBO_COMPARATOR|2|Placebo
62118382|NCT05390736|EXPERIMENTAL|Medical management assessment only|For those assign to the medical management assessment arm, only patients' medication usage would be assessed for polypharmacy (using 5 or more medications) or use of pharmaceutical classes that increase risk for falls. Recommendations for making changes to dosing levels or reducing number of medications would be conveyed to primary care provider.
62118383|NCT00776451||1|Subjects diagnosed with Dry AMD
62677614|NCT02961582|EXPERIMENTAL|Sacral Neuromodulation|
61918969|NCT05228457|ACTIVE_COMPARATOR|Active Transcranial Magnetic Stimulation|Active Intensive iTBS involves intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over the left dorsal lateral prefrontal cortex (L-DLPFC).
61918970|NCT05228457|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham Intensive iTBS involves using the coil's electric stimulation functionality that allows for the delivery of a brief electric pulse to the scalp simultaneous to the TMS pulse, which mimics the scalp sensation from active stimulation.
62677615|NCT02961582|OTHER|Personalized Conservative Treatment|
62677616|NCT01568229|EXPERIMENTAL|AMG 747 - Dose 1|
62677617|NCT01568229|EXPERIMENTAL|AMG 747 - Dose 2|
62118384|NCT04313543|EXPERIMENTAL|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. There is 3 days for wash out period. These tests will be repeated for 3 times for baseline glucose calculation. After that, volunteers take 50 g of longan syrup in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. Glycemic index of longan syrup is calculated from area under the curved of blood glucose after longan syrup taking divided to mean of area under the curved of blood glucose after glucose taking
62306278|NCT02082561|NO_INTERVENTION|Waitlist|The waitlist control condition was comprised of patients randomly assigned to the waitlist condition (WL). Individuals in this condition were reassessed after five weeks and were then offered treatment, but were no longer followed.
62474011|NCT01816997|ACTIVE_COMPARATOR|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
62677618|NCT01568229|EXPERIMENTAL|AMG 747 - Dose 3|
62677619|NCT01568229|PLACEBO_COMPARATOR|Placebo Comparator|
62677620|NCT04900935|EXPERIMENTAL|POISE|"The intervention will be a structured palliative care intervention in which patients will meet with a palliative care clinician who has been trained on a manual with specific topics to be covered in each of the four visits:~* Three surveys: baseline, 12-week, and 20-week post-enrollment~* Four 60-minute visits with a trained palliative care clinician~* Semi-structured exit interview~* Chart review"
62118385|NCT05509842|EXPERIMENTAL|Open label treatment|All subjects then will receive open-label treatment (Tx) for six days within an fourteen-day span (Visits 3-8). Briefly, a newer form of rTMS called intermittent theta burst stimulation (iTBS) will be used that mimics endogenous theta rhythms, which can improve induction of synaptic long-term potentiation and influence functional connectivity. A 10-min iTBS sessions will be applied to the basal ganglia-cerebellar-cortical network immediately after the subject has primed and activated the network by performing a precision force tracking task for up to 10 min. The subject will undergo 5 sessions of the force task and stimulation per day, with each session separated by 40 min.
62306279|NCT06084780|EXPERIMENTAL|Intestinal, Multivisceral or Modified Multivisceral Transplantation|Participants will undergo intestinal or modified multivisceral transplantation according to their disease extent. Participants will be followed for 12 months from the day of transplantation. Participants will undergo routine clinical follow-up according to standard protocols for the management of participants after visceral organ transplantation and standard oncological follow-up for participants with PMP.
62118386|NCT05283616|EXPERIMENTAL|pegfilgrastim 3mg|Pegfilgrastim 3mg per chemotherapy cycle
62118387|NCT05283616|ACTIVE_COMPARATOR|pegfilgrastim 6mg|Pegfilgrastim 6mg per chemotherapy cycle
62306280|NCT05071508||Preterm Infants|Premature infants (born between 25 and 34 + 6 weeks gestational age) admitted to the University of Minnesota Masonic Children's Hospital NICU
62306281|NCT00738725||1|Survey only
62118388|NCT03400124|ACTIVE_COMPARATOR|ISBCS|The intervention group will undergo cataract surgery of both eyes on the same day (ISBCS)
62306282|NCT00738725||2|Imaging group
62306283|NCT00738725||3|Non-imaging group
62306284|NCT04015557|EXPERIMENTAL|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
62306285|NCT04015557|EXPERIMENTAL|Acetaminophen + N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
62306286|NCT02488278|NO_INTERVENTION|Self-Monitoring of Glucose Blood Measurements|Self-Monitoring of Glucose Blood Measurements using the GlucoMe Glucose Monitoring Device and App
62306287|NCT02035384||All patients|
62677621|NCT04900935|NO_INTERVENTION|Usual care|Patients randomized to usual care will receive usual oncology care. They may access standard palliative care as clinically indicated.
62118389|NCT03400124|ACTIVE_COMPARATOR|DSBCS|The usual care / control group will undergo cataract surgery of both eyes on separate days, with a time period of at least two weeks between surgeries (DSBCS).
62306288|NCT00636818|EXPERIMENTAL|Atomoxetine|
62306289|NCT05641454|EXPERIMENTAL|ElevATP supplement|
62306290|NCT05641454|PLACEBO_COMPARATOR|Maltodextrin placebo|
62306291|NCT06102161|EXPERIMENTAL|Wedge resection|Wedge resection is performed for early-stage lung cancer to remove a wedge-shaped section of lung tissue.
62118390|NCT01285830|PLACEBO_COMPARATOR|Placebo|
62306292|NCT01742923|PLACEBO_COMPARATOR|Usual care|Usual care
62306293|NCT01742923|EXPERIMENTAL|Complex tailored intervention|"The interventions consists of 3 elements:~1. Medication review with recommendations focused on antihypertensives and statins and adherence to guidelines and patient´s adherence to medications~2. Consultation with a pharmacist using motivational interviewing techniques~3. Follow-up telephone calls one month and six months after inclusion"
62306294|NCT06265896|EXPERIMENTAL|Kinesio taping +Pelvic floor exercise training|They will be treated by Elastic Kinesio-tape of (K-Active) brand which will be applied over abdomen, which will be changed every 3 days and this will be maintained along four weeks, plus conventional pelvic floor exercises; 30 minutes, 3 times/week for 12 sessions.
62306295|NCT06265896|ACTIVE_COMPARATOR|Pelvic floor exercise training|They will be treated by conventional pelvic floor exercises; 30 minutes, 3 times/week for 12 sessions.
62306296|NCT03466710|ACTIVE_COMPARATOR|Colposcopy arm|Patients received colposcopy as per standard of care
62306297|NCT03466710|EXPERIMENTAL|Pap arm|Patients received a Pap test only
62306298|NCT03466710|EXPERIMENTAL|HPV arm|Patients received an HPV test only
62118391|NCT01285830|ACTIVE_COMPARATOR|Lactobacillus reuteri|
62118392|NCT04333758|EXPERIMENTAL|Jintronix Intervention|"2 consecutive phases of intervention for all participants using Jintronix virtual reality telerehabilitation software.~Phase 1 consisted of 9 (3/week for 3 weeks) 45-min/session clinic-based sessions conducted by study team therapist, with concurrent caregiver training.~Phase 2 consisted of 20 (5/week for 4 weeks) 45min/session home-based sessions supervised by trained caregiver, with telemonitoring by study team therapist."
62677622|NCT05860400||Pre-treatment Group|IR-CAD patients before receiving comprehensive treatment.
62677623|NCT05860400||Post-treatment Group|IR-CAD patients after receiving comprehensive treatment.
62677624|NCT00443287|PLACEBO_COMPARATOR|1|
62677625|NCT00443287|EXPERIMENTAL|2|dose level 1
62677626|NCT00443287|EXPERIMENTAL|3|dose level 2
62677627|NCT00443287|EXPERIMENTAL|4|dose level 3
62677628|NCT00443287|ACTIVE_COMPARATOR|5|
62677629|NCT02953964|EXPERIMENTAL|Behavioral: perceptual-based memory encoding training|Participants receive perceptual-based memory encoding training
62677630|NCT02953964|EXPERIMENTAL|Behavioral: Semantic-based memory encoding training|Participants receive semantic-based memory encoding training
62677631|NCT02953964|ACTIVE_COMPARATOR|Behavioral : control group|Participants receive cognitive stimulation intervention
62677632|NCT04211155|EXPERIMENTAL|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62677633|NCT04211155|EXPERIMENTAL|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62677634|NCT04211155|EXPERIMENTAL|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62677635|NCT04211155|EXPERIMENTAL|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
62677636|NCT03966118|EXPERIMENTAL|Ramucirumab + Avelumab + Paclitaxel|Single-Arm
62677637|NCT03379493|EXPERIMENTAL|ET190L1 ARTEMIS™ T cells|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
62677638|NCT01415453|EXPERIMENTAL|Retinitis Pigmentosa|Subject will have retinitis pigmentosa and will be legally blind in one or both eyes
62677639|NCT01961011||Cohort #1: Bilateral carpal tunnel release|Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
62677640|NCT01961011||Cohort #2: Unilateral carpal tunnel release|Cohort #2: Patients undergoing unilateral carpal tunnel release fir bilateral carpal tunnel syndrome. Patients will chose which hand they wish to have operated on. Patient will plan on undergoing carpal tunnel release on the unoperated side at a later date. Inclusion criteria include any adult patient indicated for unilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, and any protected patient population.
62677641|NCT04380636|EXPERIMENTAL|pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo|Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.
62677642|NCT04380636|EXPERIMENTAL|pembrolizumab+chemoradiation→pembrolizumab+olaparib|Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.
62118393|NCT05426057|EXPERIMENTAL|eHealth Familias Unidas|Participants in this group will receive eHealth Familias Unidas-Mental Health. The intervention consists of nine video parent group sessions, one video adolescent session, and four family sessions (parents participate in a total of 13 sessions, adolescents participate in a total of five sessions) that will be delivered by a facilitator to the parent-child dyad via web-conferencing software across 13 weeks.
62677643|NCT04380636|ACTIVE_COMPARATOR|chemoradiation→durvalumab|Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.
62677644|NCT05893537|ACTIVE_COMPARATOR|CT1812 200 mg|Drug: CT1812 Active Study Drug
62677645|NCT05893537|PLACEBO_COMPARATOR|Placebo|Placebo
62677646|NCT04882215|EXPERIMENTAL|Adaptive Training (AT)|For AT participants, difficulty of the training tasks is progressively increased in response to task performance.
62118394|NCT05426057|NO_INTERVENTION|Prevention as Usual Control|In this condition, participants will not receive an intervention, only the standard of care services which may include information and referral.
62118395|NCT05996588|ACTIVE_COMPARATOR|Propofol|Propofol at a rate of 50 microgram/kg/min
62677647|NCT04882215|ACTIVE_COMPARATOR|Non Adaptive Training (NA)|For NA participants, task difficulty is fixed at a relatively low level across all sessions.
62677648|NCT05516966|EXPERIMENTAL|Group A|Participants receive low dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
62118396|NCT05996588|EXPERIMENTAL|Sevoflurane|Sevoflurane inhalation with oxygen via nasal prongs at a concentration 4-5% to achieve a MAC of 0.25
62118397|NCT05339477||Cohort group|Diagnosis of a type 1 myocardial infarction registered in SWEDEHEART Age 18-79 years at discharge from hospital
62118398|NCT04030767|EXPERIMENTAL|lip repositioning technique with Botox injection.|"Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity (Binder et al., 1998).~Therefore, the technique is a useful adjunct in the esthetic improvement of the smile and provides better results when combined with resective gingival surgery(Pedron \& Mangano, 2018)."
62474012|NCT01816997|EXPERIMENTAL|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
62118399|NCT04030767|ACTIVE_COMPARATOR|lip repositioning technique.|Lip repositioning aims to limit the retraction of elevator smile muscles. Lip repositioning results in a shallow vestibuler restricting of the muscle pull; Thereby limiting the gingival display during smiling.(Makkiah, 2017) It is a less invasive, viable substitute for patients, has fewer post-operative complications and provides a faster recovery compared to orthognathic surgery(Grover, Gupta, \& Luthra, 2014).
62677649|NCT05516966|EXPERIMENTAL|Group B|Participants receive medium dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
62474013|NCT02877433|ACTIVE_COMPARATOR|Roxolid short implant, 4 mm length (4)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
62677650|NCT05516966|EXPERIMENTAL|Group C|Participants receive high dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
62677651|NCT05516966|ACTIVE_COMPARATOR|Group D|Participants receive Dulaglutide 1.5 mg by multiple subcutaneous injection
62677652|NCT01404065|EXPERIMENTAL|Active tDCS + visual illusion|Subjects will receive active tDCS while watching a visual illusion movie (legs walking on a treadmill). Stimulation will last for 20 minutes.
62474014|NCT02877433|EXPERIMENTAL|Roxolid short implant, 4 mm length (2)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
62474015|NCT04766697|EXPERIMENTAL|Receive Intervention|All 20 couples will receive the 8-session adapted intervention.
62474016|NCT05239832|EXPERIMENTAL|V-01 COVID-19 Vaccine|10 μg(0.5ml)/vial, one dose administrated by intramuscular injection
62118400|NCT01080872||Titanium-NO coated stent|Patients receiving titanium-nitride-oxide coated stents during the intervention.
62474017|NCT03340376|EXPERIMENTAL|atezolizumab monotherapy|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle until progressive disease
62118401|NCT01080872||Everolimus eluting stent|Patients receiving everolimus eluting stents during the intervention.
62118402|NCT01964469|PLACEBO_COMPARATOR|Written self-management action plan|Usual Care: Evidence-based best practice within the primary care asthma program including written self-management action plan and regular clinical review.
62474018|NCT03340376|EXPERIMENTAL|atezolizumab combined with doxorubicin|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle. Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
62474019|NCT03340376|ACTIVE_COMPARATOR|doxorubicin monotherapy|Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
62474020|NCT01893008|EXPERIMENTAL|Usual care + Inspiratory Muscle Training (IMT)|
62474021|NCT01893008|NO_INTERVENTION|Usual care (no IMT)|
62677653|NCT01404065|SHAM_COMPARATOR|Sham tDCS + visual illusion|Subjects will receive sham tDCS stimulation (30 seconds ramp up/ramp down) while watching a visual illusion movie (legs walking on a treadmill)
61918971|NCT03689933|EXPERIMENTAL|root analog implant|The tooth indicated for extraction will be extracted atraumatically using periotome, socket preservation using Iodoform packing strips, and then optical scanning of the remaining tooth structure with optical scanner will be made to obtain a 3D virtual model, this model will be modified by addition of macro-retentions strictly to the interdental area to avoid any fracture in thin cortical bone, the cervical portion of implant circumference will be decreased by 0.1 to 0.2 mm to avoid pressure resorption of alveolar crest of bone and addition of prepared crown stump for the future crown to be placed.
61918972|NCT03689933|ACTIVE_COMPARATOR|conventional stock root-form titanium implant|Using a conventional implant as a comparator as it's the gold stander in restoring the non-restorable teeth.
61918973|NCT05718999||With Incisional Hernia|The incisional hernia was defined according to the EHS guidelines as a mass in the abdominal wall with or without a visceral outlet or palpable in the surgical site determined by clinical examination or tomography, this group will present this complication.
62118403|NCT01964469|EXPERIMENTAL|mobile & web based action plan|Evidence-based best practice within the primary care asthma program, replacing the written action plan with the Breathe mobile health and web-based application.
62474022|NCT03266393|EXPERIMENTAL|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
62677654|NCT01404065|OTHER|Healthy Subjects|Healthy subjects will receive both interventions (active and sham) in a randomized and counterbalanced order. Each stimulation session will be at least 1 week apart to prevent carry-over effects
62677655|NCT04170075|NO_INTERVENTION|Usual Care (UC)|Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire.
62736315|NCT01642901|EXPERIMENTAL|Zoledronic Acid 5 mg IV infusion|Single infusion of 5 mg intravenous zoledronic acid given within 21 days of acute traumatic spinal cord injury.
61918974|NCT05718999||Without Incisional Hernia|The incisional hernia was defined according to the EHS guidelines as a mass in the abdominal wall with or without a visceral outlet or palpable in the surgical site determined by clinical examination or tomography, this group will not present this complication.
62118404|NCT01964469|NO_INTERVENTION|Administrative data set|Health services use will be evaluated comparatively against our intervention population and our control and we will include health services utilization data from one year prior randomization.
62474023|NCT03266393|EXPERIMENTAL|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
62118405|NCT03426839|ACTIVE_COMPARATOR|Conventional group|In the conventional group (group 1) haemostasis strategy guided by conventional coagulation tests will be carried out.
62474024|NCT05956925|NO_INTERVENTION|Control|Following the educational session, the control group participants' BP, ASA24® Dietary Assessment Tool (ASA24; sodium intake), and pre-test knowledge on HTN will be obtained (using Qualitrics). Four weeks later, the participants were scheduled for a follow-up meeting to collect each participant's BP, ASA24, and post-test knowledge on HTN (using Qualitrics).
62474025|NCT05956925|EXPERIMENTAL|MOBILE Intervention Group|Intervention participants were required to take daily BP, provide their motivation level, and send them to the research assistant to receive the appropriate text messages.
62474026|NCT05038293|EXPERIMENTAL|Automated mouthpiece-based toothbrush|Under observation of study staff, participants assigned to the automated mouthpiece-based toothbrush will insert a properly fitted mouthpiece and use the automated device directly over the sink.
62474027|NCT05038293|ACTIVE_COMPARATOR|Manual toothbrush|Under observation of study staff, participants assigned to the manual toothbrush will be timed brushing their teeth directly over the sink using a pre-dispensed quantity of toothpaste on bristles dampened with water.
62474028|NCT06560086|EXPERIMENTAL|Intact aborted fetal testicular tissue treated with ketoconazole|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
61918975|NCT04709939||Patient Participants|Adults patients who are discharged from the hospital on outpatient parenteral antibiotic therapy.
62677656|NCT04170075|EXPERIMENTAL|Whole body vibration (WBV)|Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
62118406|NCT03426839|ACTIVE_COMPARATOR|Point of care group|In the point of care group (group 2) transfusion algorithms guided by point-of-care (POC) tests will be applied. We will use viscoelastic thromboelastometry and impedance aggregometry.
62474029|NCT06560086|EXPERIMENTAL|Intact aborted fetal testicular tissue treated with luteinizing hormone|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
62677657|NCT05136521|EXPERIMENTAL|300 mg trazodone hydrochloride (HCl) prolonged-release tablets (new polymer)|Subjects treated with 300 mg trazodone HCl prolonged-release tablets containing a new polymer,
62677658|NCT05136521|ACTIVE_COMPARATOR|Trittico®, 300 mg trazodone HCl prolonged-release tablets (Contramid®)|Subjects treated with Trittico®, 300 mg trazodone HCl prolonged-release tablets containing Contramid®
62677659|NCT04612231|ACTIVE_COMPARATOR|T-STEP Intervention|The T-STEP is a comprehensive 12-week transition program that will be delivered in a community college setting. The curriculum includes 36 hours of group-based instruction delivered within a traditional school academic semester (i.e., 24 ninety-minute classes across 12 weeks). Students also participate in a weekly community-based internship to practice the skills learned in the intervention group (2 hours per week for 12 weeks). In addition, students participate in 12 hours of manualized individual counseling services that are traditionally available on a college campus (e.g., job exploration/career counseling, academic counseling, and self-advocacy counseling).
62677660|NCT04612231|ACTIVE_COMPARATOR|Counseling Only Intervention|Participants in the Counseling Only condition will receive the same manualized counseling sessions that are included in the T-STEP program. Specifically, 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
62677661|NCT04920292|EXPERIMENTAL|Single Dose of 100mg Oxfendazole versus Placebo|8 participants will receive a single oral dose of 100mg of oxfendazole. 2 participants will receive a single oral dose of placebo.
62677662|NCT04920292|EXPERIMENTAL|Single Dose of 400mg Oxfendazole versus Placebo|8 participants will receive a single oral dose of 400mg of oxfendazole. 2 participants will receive a single oral dose of placebo.
62677663|NCT04920292|EXPERIMENTAL|Multiple Doses of 400mg Oxfendazole versus Placebo|"8 participants will receive multiple oral doses of 400mg of oxfendazole on 5 consecutive days.~2 participants will receive multiple oral doses of placebo on 5 consecutive days."
62677664|NCT04168411|EXPERIMENTAL|Symptomatic treatment group|The patients were allocated to wear a double layered elasticated bandage for treatment 5th metatarsal base fractures (Zone 1).
62118407|NCT05686434|EXPERIMENTAL|Osimertinib adjuvant therapy group|Patients must be enrolled within 10 weeks of complete surgical excision and receive oral Osimertinib at a dose of 80 mg once a day for a planned duration of 3 years (156 weeks).
62118408|NCT04906278|OTHER|Amniotomy group|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip.
62118409|NCT04906278|OTHER|No-amniotomy group|No-amniotomy will be done
62118410|NCT04719377|EXPERIMENTAL|Powerme midline catheter|Powerme midline catheter
62118411|NCT04719377|SHAM_COMPARATOR|peripheral intravenous catheter|BD Pegusas peripheral intravenous catheter
62118412|NCT05603520||healthy volunteers|
62118413|NCT05603520||patients with aortic stenosis|
62118414|NCT05603520||patients with aortic aneurysms|
62118415|NCT00630786|EXPERIMENTAL|Panitumumab plus conatumumab|Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
62118416|NCT04077632|EXPERIMENTAL|tDCS (anodal)|Real transcranial direct current stimulation tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
62677665|NCT04168411|ACTIVE_COMPARATOR|Cast group|The patients were given a below-knee cast for treatment 5th metatarsal base fractures (Zone 1).
62677666|NCT03721965|EXPERIMENTAL|Itacitinib + Corticosteroids|
62677667|NCT05885997|EXPERIMENTAL|Intervention Clinics, Pre-Implementation Period|Usual care
62677668|NCT05885997|EXPERIMENTAL|Intervention Clinics, Post-Implementation Period|Access to Supported HBPM program plus a multifaceted implementation strategy designed to increase uptake of the program by primary care patients with uncontrolled hypertension
62677669|NCT05885997|OTHER|Control Clinics, Pre-Implementation Period|Usual care
62677670|NCT05885997|OTHER|Control Clinics, Post-Implementation Period|Usual care
62306299|NCT00482846|EXPERIMENTAL|Palifermin & Melphalen|"Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is \>40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3~Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
62306300|NCT05219565|EXPERIMENTAL|Attractive Targeted Sugar Bait (ATSB)|Clusters within the ATSB arm will have 2 ATSBs hung on all eligible structures in the cluster where consent from the corresponding compound has been given.
62306301|NCT05219565|NO_INTERVENTION|Control|Clusters within the control arm will not receive ATSBs.
62306302|NCT01695369|ACTIVE_COMPARATOR|Senofilcon A|Senofilcon A; Comfilcon A
62306303|NCT01695369|EXPERIMENTAL|Comfilcon A|Comfilcon A; Senofilcon A
62474030|NCT06560086|NO_INTERVENTION|Intact aborted fetal testicular tissue treated with none|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium.
62474031|NCT01762605|EXPERIMENTAL|Supportive Care|No casting or splinting, supportive care only by parents
62474032|NCT01762605|ACTIVE_COMPARATOR|Cast|Casting for 4 weeks
62474033|NCT01392794|EXPERIMENTAL|orally-disintegrating (OD) tablet precedence group|
62474034|NCT01392794|EXPERIMENTAL|conventional tablet precedence group|
62474035|NCT06073691|EXPERIMENTAL|Exercise intervention|On each training day, the activity started with a 5-minute stretching and warm-up session; then, a 15-minute walk at 65% of the maximum heart rate (MHR), followed by a 30-second run at 85% MHR, and finally another 15-minute walk at 65% MHR. The running time was gradually increased in individualized and supervised sessions. The exercise intensity was predetermined based on the patient's baseline cardiopulmonary function, and the heart rates (HR) were assessed using a Polar RS300X heart rate monitor.
62474036|NCT06073691|PLACEBO_COMPARATOR|Placebo|The participants might receive an active pharmacological treatment or a matching placebo
62474037|NCT00873639||A|
62474038|NCT02209285|NO_INTERVENTION|Control group|The control group will receive usual care, which is provided by the community care access centre (CCAC). Usual care may include in-home visits by regulated health care providers, personal support workers, and care coordination through the community care access centre. Case conferences may occur on an as-needed basis.
62474039|NCT02209285|ACTIVE_COMPARATOR|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month self-management intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
61918976|NCT04709939||Physician Participants|Infectious disease physicians who prescribe OPAT to their patients but were not involved in the study.
61918977|NCT04592263||Group 1 - Qualitative phase|4 focus groups and 6 semi-structured interviews.
61918978|NCT04592263||Group 2 - Quantitative phase|Pilot study of the tools developed from phase 1.
61918979|NCT05029973|EXPERIMENTAL|Treatment Group|HAIC Combined With Sintilimab and Bevacizumab Biosimilar
62306304|NCT00749632|ACTIVE_COMPARATOR|1|
62474040|NCT02255292|EXPERIMENTAL|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study.
62677671|NCT01063803|EXPERIMENTAL|Arm 1: ATN-103_30mg|
62677672|NCT01063803|EXPERIMENTAL|Arm 2: ATN-103_80 mg|
62677673|NCT03918031|ACTIVE_COMPARATOR|PFI for Smoking & Distress Tolerance|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking and distress tolerance.
62306305|NCT00749632|ACTIVE_COMPARATOR|2|
62306306|NCT00749632|ACTIVE_COMPARATOR|3|
62474041|NCT04206332|EXPERIMENTAL|Part A, Group 1: CIS43LS (5 mg/kg IV)|CIS43LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0)
62474042|NCT04206332|EXPERIMENTAL|Part A, Group 2: CIS43LS (5 mg/kg SC)|CIS43LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
62474043|NCT04206332|EXPERIMENTAL|Part A, Group 3: CIS43LS (20 mg/kg IV)|CIS43LS (20 mg/kg) administered by IV infusion (Day 0)
62474044|NCT04206332|EXPERIMENTAL|Part A, Group 4A: CIS43LS (40 mg/kg IV)|CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
61918980|NCT06492343|EXPERIMENTAL|real NFB from DMN|Participants will receive NFB from their DMN
62474045|NCT04206332|EXPERIMENTAL|Part A, Group 4B: CIS43LS (40 mg/kg IV)|CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
62677674|NCT03918031|ACTIVE_COMPARATOR|PFI for Smoking Only|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking only (no distress tolerance component).
62677675|NCT04616235|PLACEBO_COMPARATOR|CON|This group will do intense aerobic exercise without concomitant IL-6R blockade
62677676|NCT04616235|ACTIVE_COMPARATOR|BLOCK|This group will do intense aerobic exercise with concomitant IL-6R blockade
62677677|NCT06695767|EXPERIMENTAL|Neurobehavioral therapy|
62677678|NCT04213274|PLACEBO_COMPARATOR|Placebo - placebo|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to treatment (SDAS = 0) one more dose of placebo
62474046|NCT04206332|NO_INTERVENTION|Part A, Group 5: CHMI Controls|Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI); however, Group 5 did not undergo CHMI because of restrictions related to coronavirus disease 2019 (COVID-19)
62474047|NCT04206332|EXPERIMENTAL|Part B, Group 6: CIS43LS (5 mg/kg SC)|CIS43LS (5 mg/kg) administered by SC injection (Day 0)
62677679|NCT04213274|OTHER|Placebo - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) subcutaneous single injection of 80 mg RPH-104
62677680|NCT04213274|EXPERIMENTAL|80 mg RPH-104 - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to the treatment (SDAS = 0) one subcutaneous injection of placebo
62677681|NCT04213274|EXPERIMENTAL|80 mg RPH-104 - 160 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) one more subcutaneous injection of 80 mg RPH-104
62118417|NCT04077632|SHAM_COMPARATOR|tDCS (sham)|Sham transcranial direct current stimulation tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
62118418|NCT03168048|EXPERIMENTAL|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
61918981|NCT06492343|EXPERIMENTAL|sham NFB from motor cortex|Participants will receive NFB from their motor cortex
61918982|NCT02312284||Radiotherapy/Chemoradiotherapy|Pre- or postoperative or palliative radiotherapy/chemoradiotherapy based on 5-fluorouracil or Capecitabine +/-Oxaliplatin
61918983|NCT02312284||Surgery|Transabdominal resection or transanal excision
62118419|NCT04911933|EXPERIMENTAL|Intervention|The form of treatment involve systemic family therapy sessions every two weeks about an hour each.
62677682|NCT05153486|EXPERIMENTAL|Group A|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
62677683|NCT05153486|ACTIVE_COMPARATOR|Group B|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
62677684|NCT05153486|ACTIVE_COMPARATOR|Group C|Surgical ablation
62736316|NCT01642901|PLACEBO_COMPARATOR|normal saline 0.9%|Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.
62474048|NCT04206332|EXPERIMENTAL|Part B, Group 7: CIS43LS (20 mg/kg IV)|"CIS43LS (20 mg/kg) administered by IV infusion (Day 0)~Part B, Group 7 participants included participants previously enrolled in Part A who received either 5 mg/kg IV (1), 5 mg/kg SC (1) or 20 mg/kg IV (2) in the first part of the study and newly enrolled Part B participants"
62474049|NCT04206332|OTHER|Part B, Group 8: CHMI [CIS43LS (40 mg/kg IV) in Part A]|Part B, Group 8 participants included participants previously enrolled in Part A who received CIS43LS (40 mg/kg IV) in the first part of the study but did not receive CIS43LS in Part B of the study. Group 8 participants were enrolled to complete the controlled human malaria infection (CHMI).
62474050|NCT04206332|EXPERIMENTAL|Part B, Group 9: CIS43LS (40 mg/kg IV)|CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
62474051|NCT04206332|OTHER|Part B, Group 10: CHMI Controls|Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI)
61918984|NCT02312284||Chemotherapy|Pre- or postoperative chemotherapy including 5-fluorouracil/leucovorin with oxaliplatin, Capecitabine, etc
62474052|NCT04206332|EXPERIMENTAL|Part C, Group 11: CIS43LS (1 mg/kg IV)|CIS43LS (1 mg/kg) administered by IV infusion (Day 0)
62474053|NCT04206332|EXPERIMENTAL|Part C, Group 12: CIS43LS (5 mg/kg IV)|CIS43LS (5 mg/kg) administered by IV infusion (Day 0)
62474054|NCT04206332|EXPERIMENTAL|Part C, Group 13: CIS43LS (5 mg/kg SC)|CIS43LS (5 mg/kg) administered by SC injection (Day 0)
62474055|NCT04206332|EXPERIMENTAL|Part C, Group 14: CIS43LS (10 mg/kg IV)|CIS43LS (10 mg/kg) administered by IV infusion (Day 0)
62736317|NCT02077777|EXPERIMENTAL|5-ASA|Mesalazine 800 mg orally t.i.d for 3 months
61918985|NCT04951739||Achalasia cardia patients - post peroral endoscopic myotomy|All the patients who will undergo peroral endoscopic myotomy for the treatment of achalasia cardia patients.
61918986|NCT00607932|EXPERIMENTAL|Brassica Vegetables Diet Intervention|
62736318|NCT02077777|NO_INTERVENTION|No treatment|no treatment
62118420|NCT04911933|NO_INTERVENTION|Waitlist Control|Participants assigned to the control condition will be placed on a waitlist for future enrollment. After primary data collection has ceased, those assigned to the control arm will receive the identical intervention delivered in the experimental condition.
62118421|NCT01596946|ACTIVE_COMPARATOR|Contact tracing mode test at clinic|Conventional mode of contact tracing where the partners were asked by either the index patient or demanded by the counsellor to attend a clinic for C. trachomatis testing. The date of testing for chlamydia of the study subject i e a sexual partner to a chlamydia infected index patient was noted. Those partners being C trachomatis positive were referred to the STD-clinic for contact tracing and following the same study arm a the index patient.
62474056|NCT04206332|EXPERIMENTAL|Part C, Group 15: CIS43LS (10 mg/kg SC)|CIS43LS (10 mg/kg) administered by SC injection (Day 0)
62474057|NCT04206332|OTHER|Part C, Group 16: CHMI Controls|Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI)
62677685|NCT04191096|EXPERIMENTAL|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
62677686|NCT04191096|PLACEBO_COMPARATOR|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
62677687|NCT01795339|EXPERIMENTAL|AZD3293|Part 1: Up to 6 sequential cohorts of healthy elderly subjects are planned, with multiple ascending doses, starting with 5 mg (subject to confirmation by the Safety Review Committee) Part 2: Up to 16 mild-to-moderate AD patients administered one to up to 3 dosage levels of AZD3293
62677688|NCT01795339|PLACEBO_COMPARATOR|Placebo|Part 1: Placebo given (2 subjects in each cohort) Part 2: Placebo given (up to 4 subjects)
62677689|NCT04181463|EXPERIMENTAL|Arm I (isopropyl alcohol)|Patients receive isopropyl alcohol via nasal inhalation.
62677690|NCT04181463|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo via nasal inhalation.
62118422|NCT01596946|EXPERIMENTAL|Self-sampling at home|The intervention: Self-sampling of sexual partners to infected index patient for chlamydia by urine test or vaginal sampling at home. They sent the kit tube to a microbiological laboratorium for analysis. The test kit was sent by post by the counsellor at the STD-clinic or distributed via the index patient. The partner in this arm was informed about the test result from the STD-clinic and those tested C trachomatis positive were given an appointment for treating and contact tracing as soon as possible. Their partners were not randomised but following the same mode. The days from the counselling conversation with the index patient to the date of testing was measured and compared with partners tested following arm 1 mode.
62118423|NCT03617978|EXPERIMENTAL|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
62118424|NCT03617978|EXPERIMENTAL|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
62118425|NCT03617978|EXPERIMENTAL|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
62474058|NCT01677754|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
62474059|NCT01677754|EXPERIMENTAL|RO4602522 1 milligram (mg)|Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
62474060|NCT01677754|EXPERIMENTAL|RO4602522 5 mg|Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
62474061|NCT03166345|EXPERIMENTAL|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
62474062|NCT03166345|EXPERIMENTAL|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
62677691|NCT00160875|EXPERIMENTAL|Cisplatin, Irinotecan|
62474063|NCT03166345|NO_INTERVENTION|No intervention|The control arm.
62474064|NCT01093989|PLACEBO_COMPARATOR|Immediate iron|Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
62118426|NCT03617978|EXPERIMENTAL|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
62118427|NCT06555757||Patients with heart failure|Diagnosed with chronic stable heart failure NYHA Class 3 or 4 (either during most recent cardiology/heart failure clinic visit, or ADHF during recent/current hospitalization).
62118428|NCT03319706|EXPERIMENTAL|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
62118429|NCT03319706|ACTIVE_COMPARATOR|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
62118430|NCT06240663|EXPERIMENTAL|Fasted|Half the participants completed this exercise intervention in the fasted state.
62118431|NCT06240663|EXPERIMENTAL|Fed|Half the participants completed this exercise intervention in the fed state.
62118432|NCT02027558|EXPERIMENTAL|Behavioral treatment|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
62118433|NCT02027558|ACTIVE_COMPARATOR|Active control|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
62118434|NCT06170593|EXPERIMENTAL|Treatment group|Participants will receive injections of 1% triamcinolone into at least 1 and up to 3 facial inflammatory acne lesions. Participants will return to clinic at 24, 48, 72 hours, 7 days, and 14 days following injection for follow up assessment and photography.
62118435|NCT00200135||1|Treated and released from ED (minor injuries)
62118436|NCT00200135||2|Trauma, admitted to the hospital (injured)
62118437|NCT00200135||3|Fatalities reported by the coroner (deaths)
62118438|NCT00200135||4|Reported by the police (No medical treatment)
62118439|NCT05603338|ACTIVE_COMPARATOR|LSG|just laparoscopic sleeve gastrectomy without banding
62118440|NCT05603338|EXPERIMENTAL|LSG with omental band|laparoscopic sleeve gastrectomy with omental banding
62118441|NCT04014803|ACTIVE_COMPARATOR|Prasugrel plus Aspirin arm|"Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily\* will be given for one year.~\* Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement."
62474065|NCT01093989|ACTIVE_COMPARATOR|Delayed iron|
62474066|NCT04798144|EXPERIMENTAL|Cryotherapy group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at 2.5°C in the refrigerator using EndoVac negative pressure irrigation system.
62677692|NCT04026451|EXPERIMENTAL|Intervention|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SEF95 obtained by SedLine® monitor to keep a SAS 1-2. The target of SEF95 will be 10-13 Hz to keep SAS 1-2.
62306307|NCT06070129||Patients with massive pulmonary embolism or high-risk patients|"* Characterized by evidence of low-cardiac-output syndrome or clinical shock attributed to PE as the underlying cause, based on 1 or more of the following: systemic arterial systolic blood pressure\<90 mm Hg, need for positive inotrope or systemic vasoconstrictor support, need for mechanical circulatory support, cardiac arrest, or profound bradycardia (heart rate\<40 bpm).~* CT pulmonary angiography demonstrating a thrombus which occludes greater than 50% of the pulmonary artery (PA) cross-sectional area or occludes two or more lobar arteries.~* Echocardiography both Trans thoracic and Trans esophageal shows right ventricular (RV) systolic dysfunction, RV dilation, or a RV/left ventricular (LV) diameter ratio of \>0.9 on four chamber view.~* Elevated cardiac troponin T and I above normal limits."
62306308|NCT06070129||Patients with sub massive pulmonary embolism or intermediate -high risk|"* Systolic blood pressure \>90 mmHg and tachycardia (heart rate \> 100 bpm).~* CT pulmonary angiography shows that 30% to 50% of the pulmonary vasculature is occluded.~* Echocardiography both Trans thoracic and Trans esophageal shows right ventricular (RV) systolic dysfunctions, RV dilation, or a RV/left ventricular (LV) diameter ratio of \>0.9 on four chamber view.~* Elevated cardiac troponin T and I above normal limits."
62474067|NCT04798144|PLACEBO_COMPARATOR|Control group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at room temperature in the refrigerator using EndoVac negative pressure irrigation system.
62736319|NCT05454462|EXPERIMENTAL|KM-001 0.3%|KM-001 0.3% cream will be applied to the affected area twice daily for 4 consecutive weeks.
62118442|NCT04014803|ACTIVE_COMPARATOR|Clopidogrel plus Aspirin arm|Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.
62118443|NCT03789786||Cases (+SDR)|Patients with cerebral palsy that underwent an SDR
62118444|NCT03789786||Controls (-SDR)|Matched patients with cerebral palsy but did not undergo an SDR
62118445|NCT05677633|EXPERIMENTAL|Leukine Treatment|48 week regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
62118446|NCT06656377|EXPERIMENTAL|optimizing exercise timing, intensity and duration with Prediabetes post meal|The study is a sequential study design where a cohort of 25 will enter timing, intensity and duration protocols of exercise over 12 visits 7 days apart.
62118447|NCT00583167||A1|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA \>20,000 copies/mL. CD4+ T cell count \>200 cells/mm3. Group A1 will undergo continuous CSF ( cerebrospinal fluid) sampling via intrathecal catheter.
62118448|NCT00583167||A2|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA \>20,000 copies/mL. CD4+ T cell count \<200 cells/mm3. Group A2 will undergo continuous CSF sampling via intrathecal catheter.
61918987|NCT00607932|EXPERIMENTAL|Pill|
61918988|NCT00531986|EXPERIMENTAL|Monotherapy|Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
61918989|NCT00531986|ACTIVE_COMPARATOR|Continued ART|Continuation Therapy, conventional triple HAART
62306309|NCT04021472|EXPERIMENTAL|Text message|Participants receive text messages about healthy eating or physical activity.
62306310|NCT03844971|EXPERIMENTAL|Computer assisted surgery|Intervention will be fabrication of patient specific surgical guide for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction using patient computed tomography with the aid of computer aided surgical simulation software
62118449|NCT00583167||B|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA \>20,000 copies/mL. Group B will not undergo continuous CSF sampling, but will undergo sparse CSF sampling by lumbar punctures.
62306311|NCT02817607|EXPERIMENTAL|Surgery|
62306312|NCT04230538|EXPERIMENTAL|DJO Walker|Application of DJO Walker
62306313|NCT04230538|ACTIVE_COMPARATOR|Traditional plaster cast|Application of traditional plaster cast
62306314|NCT02924792||Reinfusion - Fast1|Case: Autologous reinfusion through Fast1 sternal needle. (Pyng Medical) CE marked/FDA Approved
62474068|NCT01281891|EXPERIMENTAL|Local Infiltration Analgesia|Combination of ropivacaine, ketorolac and adrenaline
62118450|NCT05184946|EXPERIMENTAL|Anti-PD1 combined with SOX|Camrelizumab will be administered one day before SOX regimen.
62118451|NCT05567822|ACTIVE_COMPARATOR|esmolol group|loading dose of esmolol 0.05 mL/kg and maintenance dose of esmolol 0.3 mL/kg/h
62118452|NCT05567822|PLACEBO_COMPARATOR|placebo group|loading dose of 0.9% sodium chloride 0.05 mL/kg and maintenance dose of 0.9% sodium chloride 0.3 mL/kg/h
62118453|NCT06549673||Patients with cirrhosis|The patient cohort will have the primary aetiological factor of liver disease controlled, low liver stiffness measurement of below 25 kPa by vibration-controlled transient elastography, and the absence of high-risk varices on upper gastrointestinal endoscopy.
62118454|NCT03804918|EXPERIMENTAL|Interventional group: All participants|Given access to a selected breaking bad news mobile learning resource (VitalTips application).
62118455|NCT01052246|EXPERIMENTAL|Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser|
62118456|NCT01052246|ACTIVE_COMPARATOR|Clindamycin 1% + benzoyl peroxide 5%|
62118457|NCT01714193|EXPERIMENTAL|Canagliflozin + oral contraceptive|Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin.
62118458|NCT02916758|EXPERIMENTAL|Let's Go Community Mobility Program|Participation in 4 week program
62118459|NCT05274334|EXPERIMENTAL|intervention group|Assessment of de novo lipogenesis non-invasively in exhaled breath in overnight-fasted humans by triggering feeding response by deuterium resolved mass spectrometry.
62118460|NCT01787760|EXPERIMENTAL|Test Soft Contact Lens B|Lenses will be worn in a daily disposable modality
62118461|NCT01787760|EXPERIMENTAL|Test Soft Contact Lens C|Lenses will be worn in a daily disposable modality
62306315|NCT02924792||Reinfusion - T.A.L.O.N|Case: Autologous reinfusion through T.A.L.O.N sternal needle. (Vidacare) CE Marked/FDA approved
62306316|NCT02924792||Reinfusion - Intravenous line|Control: Autologous reinfusion through standard intravenous line
62306317|NCT00408681|EXPERIMENTAL|Arm I|Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
62118462|NCT01787760|ACTIVE_COMPARATOR|Spectacle Lenses|Control spectacle lenses worn daily.
62118463|NCT03201224||Group without image transmission|"Before Group"
62306318|NCT00430040|EXPERIMENTAL|carvedilol|carvedilol
62474069|NCT01281891|ACTIVE_COMPARATOR|Intrathecal morphine|Morphine special (preservative-free) injected intrathecally
62736320|NCT05454462|EXPERIMENTAL|KM-001 1%|KM-001 0.3% cream will be applied to the affected area twice daily for 4 consecutive weeks.
62736321|NCT05454462|PLACEBO_COMPARATOR|Vehicle arm|Vehicle cream will be applied to the affected area twice daily for 4 consecutive weeks.
62118464|NCT03201224||Group with image transmission|"After Group"
62118465|NCT01812148||Peritoneal Mesotheliomas|Cytoreductive surgery and HIPEC
62118466|NCT03098810|PLACEBO_COMPARATOR|Normal children|Placebo
62118467|NCT03098810|EXPERIMENTAL|Malnourished children|Oral zinc sulphate syrup
62118468|NCT03380390|EXPERIMENTAL|Oxymetazoline + Energy-Based Therapy|Participants will receive energy-based therapy (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.
62118469|NCT04713371|OTHER|Single arm. Subjects receiving treatment.|Efficacy of Cryosurgical Freezing and Multiplex Immunochemotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria.
62118470|NCT04093908||multi-center validation cohort|We collect retrospective data from several international centers containing preoperative variables (demographical and clinical) and postoperative outcome (UPDRS II, III, IV) one year postoperatively, and merge these data to one validation cohort.
62118471|NCT00888108|EXPERIMENTAL|docetaxel +ABT-263|
62306319|NCT00430040|ACTIVE_COMPARATOR|lisinopril|lisinopril
62306320|NCT01938625|EXPERIMENTAL|Part 1|Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
62306321|NCT01938625|EXPERIMENTAL|Part 2|Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
62306322|NCT03681860|OTHER|Group 1 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 5 x10\^9 vp
62306323|NCT03681860|OTHER|Group 2 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 2.5 x10\^10 vp
61918990|NCT06040268|EXPERIMENTAL|Advair HFA (salmeterol 126 ug/fluticasone 270 ug) twice daily for up to 7 days|Participants will inhale salmeterol 126 ug and fluticasone 270 ug twice daily for up to 7 days
61918991|NCT06040268|PLACEBO_COMPARATOR|Placebo|Participants will inhale placebo (same puff number) twice daily for up to 7 days
61918992|NCT04250090||Long-term type ureteral stent set|Patients with Long-term type ureteral stent set due to ureteral stricture.
62306324|NCT03681860|OTHER|Group 3 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 5 x10\^9 vp
62306325|NCT03681860|OTHER|Group 4 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10\^10 vp
62306326|NCT03681860|EXPERIMENTAL|Group 5/6 Randomised Comparison|30 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10\^10 vp followed by MVA85A boost versus 30 adolescents who are EMaBS participants, to receive BCG revaccination
62474070|NCT04053296||The first pregnancy with PAH group|
62306327|NCT04453150|EXPERIMENTAL|Standard hypocaloric diet|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits 3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
62474071|NCT04053296||The second pregnancy with PAH group|
62474072|NCT02069158|EXPERIMENTAL|PF-05212384, Carboplatin, Paclitaxel|starting dose of PF-05212384: 95 mg iv weekly Dose of Carboplatin: 5 AUC every 28 days Dose of Paclitaxel: 80 mg/m2 on days 1, 8 and 15
62474073|NCT03422653|ACTIVE_COMPARATOR|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
62677693|NCT04026451|ACTIVE_COMPARATOR|Control|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SAS (1-2). SedLine® monitor will be also used in these patients but the screen will be covered.
62474074|NCT03422653|PLACEBO_COMPARATOR|Placebo|IV Placebo administered after each dialysis session (3 times/week)
62677694|NCT02002195||modified folfox|Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
62474075|NCT01566721|EXPERIMENTAL|Cohort A: SC Herceptin by Needle/Syringe|Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
62677695|NCT05402085|EXPERIMENTAL|High Protein Diet|Diet consisting of 40% carbohydrate, 40% protein, 20% fat, with Glycemic Index \~55-65.
62677696|NCT05402085|EXPERIMENTAL|High Fat Diet|Diet consisting of 40% carbohydrate, 40% fat (25% monounsaturated fatty acids), 20% protein, with Glycemic Index \~55-65.
62677697|NCT05402085|EXPERIMENTAL|High Carbohydrate-Low Glycemic Index Diet|Diet consisting of 60% carbohydrate, 20% fat, 20% protein, with Glycemic Index \~45-50.
62677698|NCT05402085|PLACEBO_COMPARATOR|High Carbohydrate-High Glycemic Index Diet|Diet consisting of 60% carbohydrate, 20% fat, 20% protein.
62677699|NCT03701308|ACTIVE_COMPARATOR|Arm I (daunorubicin, cytarabine)|"INDUCTION: Patients receive daunorubicin IV on days 1-3 and cytarabine via CIVI over 168 hours on days 1-7. Patients with residual disease indicated by bone marrow examination receive a second induction including daunorubicin IV on days 1-2 and cytarabine CIVI over 12 hours on days 1-5.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Additionally, all patients undergo MUGA or ECHO during baseline, and bone marrow aspirate, bone marrow biopsy, and blood collection throughout the study."
62736322|NCT01321255|EXPERIMENTAL|FDC Fixed Dose Combination|
61918993|NCT04266938|ACTIVE_COMPARATOR|Prospective RAPID|The prospective RAPID arm will include all patients who meet inclusion criteria and who start BIC/F/TAF within 7 days of HIV diagnos
61918994|NCT04266938|ACTIVE_COMPARATOR|Prospective Non- RAPID|The prospective non-RAPID arm will include all patients identified as having new HIV diagnosis per health department records, but who failed to establish care at the 550 Clinic and begin BIC/F/TAF within one week of diagnosis
61918995|NCT04266938|ACTIVE_COMPARATOR|Retrospective Non- RAPID|The retrospective Non-RAPID arm will include historic controls who enrolled in the treatment program from 2012, when universal ART guidelines were implemented, until prior to the implementation of RAPID start of ART.
61918996|NCT04352127|EXPERIMENTAL|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and routine clinical monitor on non-dominant hand
61918997|NCT04352127|EXPERIMENTAL|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and routine clinical monitor on dominant hand
61918998|NCT05544981|ACTIVE_COMPARATOR|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing \~5 mmol nitrate
62736323|NCT01321255|ACTIVE_COMPARATOR|Conventional treatment|
62677700|NCT03701308|EXPERIMENTAL|Arm II (uproleselan, daunorubicin, cytarabine)|"INDUCTION: Patients receive uproleselan IV QD on day 1 and then every 12 hours on days 2-10. Patients also receive daunorubicin IV on days 2-4 and cytrarabine CIVI over 168 hours on days 2-8 over 168 hours. Patients with residual disease indicated by bone marrow examination receive a second induction including uprleselan IV QD on day 1 and then every 12 hours on days 2-8, daunorubicin IV on days 2-3, and cytarabine CIVI over 120 hours on days 2-6.~CONSOLIDATION: Patients who achieve a CR or CRi receive uproleselan IV QD on day 1 and every 12 hours on days 2-8 and cytarabine IV over 3 hours on days 2-6. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Additionally, all patients undergo MUGA or ECHO during baseline, and bone marrow aspirate, bone marrow biopsy, and blood collection throughout the study."
62306328|NCT04453150|EXPERIMENTAL|Intermittent fasting 16/8 (early fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 12 am. to 8 pm.), maintaining 16 fasting hours (from 8 pm. to 12 am. the following day).
61918999|NCT05544981|PLACEBO_COMPARATOR|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
61919000|NCT05906238|EXPERIMENTAL|STEREOBES|This arm will follow a program developed specifically for this project. It will include specific workshops on obesity stigma issues which are not part of the standard program.
61919001|NCT05906238|ACTIVE_COMPARATOR|CONTROL|"This arm will follow the standard therapeutic patient education program proposed by La Vie La Santé."
61919002|NCT01017575|EXPERIMENTAL|Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
61919003|NCT01017575|EXPERIMENTAL|Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
61919004|NCT01017575|PLACEBO_COMPARATOR|Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
61919005|NCT01017575|EXPERIMENTAL|Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)|Non-Responder
61919006|NCT01017575|EXPERIMENTAL|Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Non-Responder
61919007|NCT03790007|ACTIVE_COMPARATOR|Transversus Abdominis Plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
61919008|NCT03790007|ACTIVE_COMPARATOR|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
61919009|NCT03790007|ACTIVE_COMPARATOR|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the gallbladder excision area-periportal area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periportal area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
61919010|NCT03790007|NO_INTERVENTION|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
61919011|NCT02314390|EXPERIMENTAL|G-MBCT|Group-Mindfulness-Based Cognitive Therapy
61919012|NCT02314390|EXPERIMENTAL|I-MBCT|Individual-Mindfulness-Based Cognitive Therapy
61919013|NCT06132828|EXPERIMENTAL|DR30206|Subjects receive DR30206 monotherapy intravenously(IV) until no more benefits from treatment.
61919014|NCT03500185|EXPERIMENTAL|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
61919015|NCT03500185|ACTIVE_COMPARATOR|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
61919016|NCT03155360||Infant with colics|"Infants with colics according to Wessel definition :~* Recurrent episodes of irritability, fussing or crying from birth to 4 months of age~* Episodes last for 3 hours per day ; on 3 days per week ; for 3 weeks~* Episodes can not be attributed to another disorder"
61919017|NCT03155360||Infant without colics|
61919018|NCT04466345|EXPERIMENTAL|Semaglutide|Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
61919019|NCT04466345|PLACEBO_COMPARATOR|Placebo|Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).
61919020|NCT03891667|EXPERIMENTAL|8 Week Disulfiram|Patients in this group receive disulfiram for 8 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg for week 3, and 500 mg daily for week 4 to week 8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
62474076|NCT01566721|EXPERIMENTAL|Cohort B: SC Herceptin by SID|Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
62677701|NCT05072041|EXPERIMENTAL|Test group|Degradable embolic microsphere (Nexsphere™)
61919021|NCT03891667|ACTIVE_COMPARATOR|4 Week Disulfiram|Patients in this group receive disulfiram for 4 weeks followed by placebo capsules for 4 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg during week 3, and 500 mg daily during week 4. Placebo capsules are given during weeks 5-8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
62677702|NCT05137613|ACTIVE_COMPARATOR|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
62677703|NCT05137613|ACTIVE_COMPARATOR|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
62677704|NCT06559150|EXPERIMENTAL|Treatment Arm 1: Ensifentrine|
61919022|NCT02854475|EXPERIMENTAL|Proband group|Raman spectroscopy and venous blood collection
62677705|NCT06559150|PLACEBO_COMPARATOR|Treatment Arm 2: Placebo|
62677706|NCT01234987||Breast cancer|
62677707|NCT01234987||Colon cancer|
62677708|NCT01234987||Lung Cancer|
62306329|NCT04453150|EXPERIMENTAL|Intermittent fasting 16/8 (late fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 8 am. to 4 pm.), maintaining 16 fasting hours (from 4 pm. to 8 am. the following day).
62306330|NCT04453150|EXPERIMENTAL|Alternate-day fasting|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
62306331|NCT04453150|EXPERIMENTAL|Ketogenic diet|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein.
62474077|NCT04904705|ACTIVE_COMPARATOR|Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"It will be given a home program. Then The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach will be applied by video conferencing method in a total of 10 sessions, 2 sessions per week, through 5 weeks, and a total of 12 sessions with initial and final evaluations.~The Cognitive Orientation for Daily Activity Performance (CO-OP) approach is a person-oriented, performance-solving. and problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills."
62677709|NCT04444297|ACTIVE_COMPARATOR|2D telemedicine|2D telemedicine first, followed by crossover to 3D telemedicine with no washout period
62677710|NCT04444297|EXPERIMENTAL|3D Telemedicine|3D telemedicine first, followed by crossover to 2D telemedicine with no washout period
62677711|NCT04566510|EXPERIMENTAL|Royal Guard|alpha-cypermethrin + pyriproxyfen (PPF)
62677712|NCT04566510|ACTIVE_COMPARATOR|PermaNet 3.0|deltamethrin + piperonyl butoxide (PBO)
62677713|NCT02992431|ACTIVE_COMPARATOR|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
62306332|NCT00968344|EXPERIMENTAL|Leucine|3-4 g Leucine added to daily meals during bed rest
62306333|NCT00968344|PLACEBO_COMPARATOR|Placebo|3-4 g Alanine added to daily meals during bed rest
62306334|NCT02662439|EXPERIMENTAL|BCM group|The patients are measured by Body Composition Monitor (BCM) and both the patient and the physician know the results and adjust the diuretic therapy accordingly.
62306335|NCT02662439|PLACEBO_COMPARATOR|Control group|The patients are measured by Body Composition Monitor (BCM) but neither the patient nor the physician know the results, the physician adjusts the diuretic therapy as usual, according to the protocols.
62306336|NCT01208181|EXPERIMENTAL|Etoricoxib 60 mg/Etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
62677714|NCT02992431|EXPERIMENTAL|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
62677715|NCT05382325|EXPERIMENTAL|MK-1484|Participants will receive MK-1484 every 3 weeks (Q3W) or 21-day cycle at escalating dose levels from 0.2-60 mg for up to a total of 35 cycles (up to approximately 24 months).
62677716|NCT05382325|EXPERIMENTAL|MK-1484 + Pembrolizumab|Participants will receive MK-1484 Q3W at escalating dose levels from 10-60 mg plus pembrolizumab 200 mg once every 21-day cycle for up to a total of 35 cycles (up to approximately 24 months).
62306337|NCT01208181|EXPERIMENTAL|Etoricoxib 60 mg/Etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
62474078|NCT04904705|ACTIVE_COMPARATOR|Home Program|It will be given a home program only.
62474079|NCT03038009|ACTIVE_COMPARATOR|One-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
62677717|NCT02615496||Educational materials: Physicians|
62677718|NCT02615496||Educational materials: Patients|
62677719|NCT05682144|EXPERIMENTAL|Autologous Plasmablasts (B cells)|Dose Level: 5 x 10e7 cells/kg on Day 0
62677720|NCT06674187|ACTIVE_COMPARATOR|Regular|"The stoma surgery will be performed using conventional non-molding suturing techniques. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Perform routine suturing around the stoma without additional mesentery shaping.~3. Form the stoma, ensuring a tight fit of the surrounding tissues."
62677721|NCT06674187|EXPERIMENTAL|Mesenteric Molding Suturing|"During the stoma surgery, the mesentery will be shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Separate the mesentery around the stoma and shape it into a sturdy support structure.~3. Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~4. Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
62677722|NCT05140980||"women aged 18 to 25 group"|"women aged 18 to 25 group: women aged 18 to 25 with or without sexual activity"
62677723|NCT04082442|EXPERIMENTAL|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in ACS patients.
62677724|NCT04082442|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously using an autoinjector/pen in ACS patients .
62677725|NCT00353574|EXPERIMENTAL|Darusentan 50 mg|Darusentan 50 mg administered orally once daily
62677726|NCT00353574|EXPERIMENTAL|Darusentan 100 mg|Darusentan 100 mg administered orally once daily
62677727|NCT00353574|EXPERIMENTAL|Darusentan 300 mg|Darusentan 300 mg administered orally once daily
62677728|NCT06054464|EXPERIMENTAL|Part 1: PC14586 and rabeprazole|Healthy participants will receive a single, oral dose of PC14586 on day 1. On days 11-13, participants will receive an oral daily dose of rabeprazole. On day 14, participants will receive a co-administration dose of rabeprazole and PC14586. Rabeprazole will be given 1 hour prior to PC14586. Participants will be given a low-fat meal 30 minutes prior to PC14586 dosing.
61919023|NCT05144334|EXPERIMENTAL|BTX-1188 Dose Cohort 1|Starting dose of BTX-1188 administered orally per dosing schedule
61919024|NCT05144334|EXPERIMENTAL|BTX-1188 Dose Cohort 2|First dose escalation of BTX-1188 administered orally per dosing schedule
61919025|NCT05144334|EXPERIMENTAL|BTX-1188 Dose Cohort 3|Second dose escalation of BTX-1188 administered orally per dosing schedule
61919026|NCT05144334|EXPERIMENTAL|BTX-1188 Dose Cohort 4|Third dose escalation of BTX-1188 administered orally per dosing schedule
61919027|NCT05144334|EXPERIMENTAL|BTX-1188 Dose Cohort 5|Fourth dose escalation of BTX-1188 administered orally per dosing schedule
61919028|NCT05144334|EXPERIMENTAL|BTX-1188 Dose Cohort 6|Fifth dose escalation of BTX-1188 administered orally per dosing schedule
61919029|NCT05144334|EXPERIMENTAL|BTX-1188 Dose Cohort 7|Sixth dose escalation of BTX-1188 administered orally per dosing schedule
61919030|NCT01346215|EXPERIMENTAL|Actparin® - Laboratorio Bergamo|
61919031|NCT01346215|ACTIVE_COMPARATOR|Heparin sodium - APP Pharmaceuticals|
62306338|NCT01208181|EXPERIMENTAL|Etoricoxib 90 mg|The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
62306339|NCT01208181|PLACEBO_COMPARATOR|Placebo|The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
62306340|NCT01984814|EXPERIMENTAL|Stem cell|Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation
62306341|NCT01984814|NO_INTERVENTION|Control|No cell transplantation was done
62677729|NCT06054464|EXPERIMENTAL|Part 2: PC14586 and famotidine|Healthy participants will receive a single, oral dose of PC14586 on day 1. On days 11-13, participants will receive a twice daily, oral dose of famotidine. On day 14, participants will receive PC14586 two hours before a dose of famotidine. Participants will be given a low-fat meal 30 minutes prior to PC14586 dosing.
62677730|NCT04667728|EXPERIMENTAL|intervention group (IGr)|The IGr participants wore a professional continuous glucose monitoring (CGM) sensor (iPro™2) during the first six days of the study. Following this period, IGr participants had a medical consultation for the CGM results and treatment adjustments. Additionally, they received a personalized diet plan from a dietitian. After three months, the IGr participants again wore the CGM sensor for one week. These participants also followed the regular institutional Comprehensive Diabetes Care program care plan.
62677731|NCT04667728|NO_INTERVENTION|control group (CGr)|The control group followed the regular institutional Comprehensive Diabetes Care program care plan.
62677732|NCT06532344|EXPERIMENTAL|ONO-7913+ONO-4538+mFFX|
62677733|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
62677734|NCT01680055||AA-ATG|Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine
62677735|NCT06064695|EXPERIMENTAL|Whole-body Electrical Muscle Stimulation (WB-EMS) Exercise|"Participants with MG will receive the WB-EMS Exercise intervention 2 times per week for 4 weeks. Participants will only perform Level 1 exercise programs (simple movements) in the Strength Training Mode. These programs are 20-minute videos led by exercise professionals. They are full-body workouts. They consist of 10-12 exercises performed for 14 repetitions. Each repetition takes 4 seconds to complete (the time that the stimulation is on) and is followed by a 4 second rest (the time that the stimulation is off). All exercises occur in a double-limb stance position. Most exercises occur with feet in wide base of support, hips width or more apart. All exercises are modifiable by the healthcare professional administering and monitoring the intervention based on participant's safe and available range of motion (i.e. arm movements, torso positions, extent of knee bend).~Healthy Control participants will not complete the intervention."
62677736|NCT05809154||Neurogenic lower urinary tract dysfunction|Lower urinary tract dysfunction due to any neurological condition like spinal cord injury, multiple sclerosis and others.
62677737|NCT05809154||Non-Neurogenic lower urinary tract dysfunction|Lower urinary tract dysfunction in absence of any neurological pathology.
62306342|NCT04978753|EXPERIMENTAL|treatment|Anlotinib (12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week) combine with Almonertinib (110mg, orally once a day)
62474080|NCT03038009|EXPERIMENTAL|Twelve-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
62474081|NCT03024515|EXPERIMENTAL|Standard Practice Arm|Standard Practice Arm with opioids titration of physicians' choice
62474082|NCT03024515|EXPERIMENTAL|Structured Tritration Arm|Structured titration method with predefined titration steps with the use of oxycodone immediate-release and oxycodone sustained-release preparations.
62474083|NCT05244798|EXPERIMENTAL|Group of sintilimab combined with neoadjuvant chemotherapy|sintilimab (D1 administration) was given in combination with chemotherapy (TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
62474084|NCT05244798|EXPERIMENTAL|Group of sintilimab combined with neoadjuvant chemoradiotherapy|sintilimab (D1) was administered in combination with concurrent chemoradiotherapy. Chemotherapy regimen: TP regimen: albumin-paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
62677738|NCT05809154||Chronic pelvic pain|Chronic pelvic pain as defined by the EAU guidelines.
62677739|NCT05809154||Urodynamic normal Bladder function|Normal urodynamic findings and absence of chronic pelvic pain.
61919032|NCT05448976|ACTIVE_COMPARATOR|Saliva and serum collection of patients and samples molecules analysis|aliva and serum sampling Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MY,EY) from each participant. Saliva and serum were then stored at -80 °C until analysis.
62118472|NCT02799706|ACTIVE_COMPARATOR|GnRH agonist + radiation therapy (RT)|"As the study investigates the effect of a drug given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) + A GnRH-agonist will be given for the duration selected for each patient.~A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.~Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm."
62118473|NCT02799706|EXPERIMENTAL|GnRH antagonist + radiation therapy (RT)|"As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) +a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy.~Each institution has to adhere to the chosen duration of treatment for all patients throughout the study"
62118474|NCT01490541||Gastric intestinal metaplasia patient|
62118475|NCT00644475|EXPERIMENTAL|2|Imidapril
62677740|NCT02520947|EXPERIMENTAL|Bispectral index|The group that desflurane titrated according to bispectral index monitoring
62677741|NCT02520947|OTHER|Minimum alveolar concentration|The group that desflurane consumption titrated according to minimum alveolar concentration monitoring
62118476|NCT00644475|ACTIVE_COMPARATOR|1|Candesartan
62118477|NCT02353988|EXPERIMENTAL|bicalutamide|This is a multi-center, open-label, phase II study to evaluate the anti-tumor activity and safety of bicalutamide administered orally daily to patients with estrogen receptor (ER)-negative/ progesterone receptor (PgR)-negative/ androgen receptor (AR)-positive metastatic breast cancer. Eligible patients will receive bicalutamide at a dose of 150mg PO daily.
62118478|NCT02353988|ACTIVE_COMPARATOR|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable
62118479|NCT02541916|EXPERIMENTAL|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
62677742|NCT03293563||Patients|Adult patients with kidney cancer
62118480|NCT02878330|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
62306343|NCT04476264||transscleral IOL fixation|the use of a novel adjustable single 8-0 polypropylene suture for scleral fixation without conjunctival dissection
62306344|NCT05824208|EXPERIMENTAL|Bi-weekly pregnancy yoga-based sessions for 8 weeks|
62306345|NCT03932955|EXPERIMENTAL|MC-19PD1 CAR-T Cells|
62474085|NCT05244798|OTHER|Group of neoadjuvant chemoradiotherapy|The control group received neoadjuvant chemoradiotherapy and the regimen was as follows:Chemotherapy regimen: TP regimen: albumin paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
62474086|NCT06216561|EXPERIMENTAL|CRS-HIPEC + LSTA1|Experimental Arm
62474087|NCT06216561|ACTIVE_COMPARATOR|CRS-HIPEC alone|Control Arm
62474088|NCT04262934|EXPERIMENTAL|Cholecalciferol treatment|Arm A : Cholecalciferol 100.000 UI - oral - every month
61919033|NCT05448976|EXPERIMENTAL|Salivary and serum arginine metabolites ADMA and SDMA observation|"IL-6 levels in collected samples were determined by ELISA kits and analyzed according to manufacturers' instructions, with colorimetric assessment performed using a microplate reader at 450 nm with the assay detection range between 7.8 and 500 pg/mL. Concentrations were determined based on the respective assay standard curve. All samples were analyzed in duplicate, and the average was used in subsequent calculations.~Determination of methylated arginine metabolites:~The ADMA, SDMA, homoArg, arginine and L-NMMA levels in saliva and serum were assessed by a liquid chromatography-mass spectrometry (LC MS/MS)\* method, which was a modification of the method of Di Gangi et al."
62474089|NCT04262934|ACTIVE_COMPARATOR|No treatment|Arm B : No vitamin D administration
62474090|NCT04215510|EXPERIMENTAL|endonasal endoscopic surgery group|143 participants in group 1 will undergo endoscopic surgery
61919034|NCT01975987|EXPERIMENTAL|Intubation with the Bonfils fiberscope|"* Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope~* Intubation will be performed with the Bonfils fiberscope with the patient in supine position with head and neck in neutral position~* Bonfils fiberscope will be inserted from the right side of the patient's mouth, alongside the molars and advanced underneath the epiglottis. With the tip of the Bonfils in satisfactory position, the endotracheal tube will be advanced into the trachea using gentle rotary motions. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
61919035|NCT03072771|EXPERIMENTAL|ASCT + BEAM + Blinatumomab|"* Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:~  * carmustine is typically given intravenously (IV) at a dose of 300 mg/m\^2 on Day -7~ * etoposide is typically given IV at a dose of 100 mg/m\^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)~ * cytarabine is typically given IV at a dose of 100 mg/m\^2 BID on Days -6, -5, -4, and -3 (8 doses)~ * melphalan is typically given IV at a dose of 140 mg/m\*2 on Day -2~* Auto-SCT will take place on Day 0 as per institutional guidelines~* Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks)."
61919036|NCT01116479|ACTIVE_COMPARATOR|Haemoglobin (<6.0 mmol/l)|Blood transfusion thresholds:Haemoglobin \< 6.0 mmol/l (9.9 g/dL)
61919037|NCT01116479|EXPERIMENTAL|Haemoglobin (< normal range)|Blood transfusion threshold: Haemoglobin \< 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males
61919038|NCT05261776|EXPERIMENTAL|Group-A|Group-A will receive pilates exercise and standard care
61919039|NCT05261776|ACTIVE_COMPARATOR|Group-B|Group-B will receive brisk walk and standard care
62118481|NCT02878330|EXPERIMENTAL|MEDI8897 50 mg|Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
62118482|NCT03400969|ACTIVE_COMPARATOR|Glycerol 17 %|Oral moisturizer
62474091|NCT04215510|ACTIVE_COMPARATOR|radiation therapy group|143 participants in group 2 will undergo radiation therapy(IMRT)
62474092|NCT03306030|ACTIVE_COMPARATOR|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
62474093|NCT03306030|EXPERIMENTAL|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
62474094|NCT05500703|EXPERIMENTAL|Dexmedetomidine group|1.5 µg kg-1 h-1 dexmedetomidine
62474095|NCT05500703|ACTIVE_COMPARATOR|Opioid group|0.9% sodium chloride injection
62474096|NCT05934825|EXPERIMENTAL|Injectable suspension of allogeneic adult mesenchymal stem cells|Patients will receive an injectable suspension of allogeneic adult mesenchymal stem cells from adipose tissue intralesionally.
62474097|NCT05934825|PLACEBO_COMPARATOR|Placebo|Patients will receive the cell-free suspension vehicle: 49% DMEM without phenol red, 1% L-Alanine LGlutamine and 50% hyaluronic acid
62677743|NCT02088580|EXPERIMENTAL|Triple Chronotherapy|Total sleep deprivation, Sleep phase advance, and Bright light therapy.
62474098|NCT05157477|EXPERIMENTAL|VR-Group|The participants who are randomized into 'CBT-based VR exposure program' (CBT+VR group) will receive the individual intervention weekly with a total of 8 sessions. The therapists, PI (Chien YL) and a clinical psychologist who is familiar with ASD psychopathology and CBT approach, will provide the CBT-based VR exposure intervention for each individual every week based on the above protocol. The participants complete the homework (i.e., relaxation and real-life exposure) between the sessions, and record 'anxiety level' before, during, and after the real-life exposure. The outcome measures will be scheduled at the end of intervention (8th week) within one week of program closure.
62118483|NCT03400969|ACTIVE_COMPARATOR|Aequasyal (OGT)|Oral moisturizer
62118484|NCT03400969|ACTIVE_COMPARATOR|Salient (new product)|Oral moisturizer
62474099|NCT05157477|EXPERIMENTAL|CBT-GROUP|The 'CBT alone' intervention applies the same protocol excluding VR exposure, which is replaced by traditional role play with the therapist.
62118485|NCT04367415||Normal uterine cavity on office hysteroscopy|If the uterine cavity is normal the patient will be allocated as group A.
62118486|NCT04367415||uterine cavity shown one or more polyps on office hysteroscopy|If there is one or more polyp(s) the patient will be allocated as group B. Localization and size estimation of the polyp(s) is mandatory.
62118487|NCT03703037||Cohort|"This will be a nested case-control study. Women with low risk pregnancies at or beyond 41 weeks, who will be referred to our Maternal-fetal unit and admitted 1 to 2 days prior to induction of labour according institutional protocol will constitute the cohort.~Then women with intrapartum abnormal fetal heart rate tracings (cases) will be identified and match with controls. The primary outcome will be to obtain odds ratios for the Doppler ultrasound parameters (middle cerebral artery pulsatility index, mean uterine artery pulsatility index and Middle cerebral artery pulsatility index to mean uterine artery pulsatility index ratio) and Ultrasound assessment of amniotic fluid index that would be associated with intrapartum category III fetal heart rate tracing."
62118488|NCT03703037||Cases|"Cases will be patients with abnormal intrapartum cardiotocogram (category III fetal heart rate tracing).~Intervention: Ultrasound and Doppler ultrasound"
62118489|NCT03703037||Controls|"Those will be patients with normal intrapartum cardiotocogram (category I fetal heart rate tracing) or category II that converted into category I after intrauterine resuscitation methods.~Intervention: Ultrasound and Doppler ultrasound"
62118490|NCT05949255|EXPERIMENTAL|Probiotic|Subjects will receive a probiotic supplement to take by mouth daily.
62118491|NCT05949255|PLACEBO_COMPARATOR|Placebo|Subjects will receive a placebo to take by mouth daily.
62118492|NCT04497727||Patients undergoing routine colonoscopy|Patients with and without hypertension who routinely undergo colonoscopy
62118493|NCT05870241|EXPERIMENTAL|Ga-As Laser|the patients will receive Ga-As Laser and traditional therapy three times a week for three months
62118494|NCT05870241|EXPERIMENTAL|Microcurrent Electrical Stimulation|the patients will receive Microcurrent Electrical Stimulation and traditional therapy three times a week for three months
62118495|NCT05870241|ACTIVE_COMPARATOR|traditional therapy|the patients will receive traditional therapy three times a week for three months
62118496|NCT04051255|EXPERIMENTAL|Smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgingival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients has prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
62118497|NCT04051255|EXPERIMENTAL|Non-smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
62118498|NCT04686942||Before sonazoid|US detection liver metastases before sonazoid
62118499|NCT04686942||After sonazoid|US detection liver metastases after sonazoid
62306346|NCT05374356|ACTIVE_COMPARATOR|High spinal anesthesia|"1. Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).~2. Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated.~3. Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation."
62306347|NCT05374356|NO_INTERVENTION|Control group|"1. Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated.~2. Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation."
62306348|NCT05814029|EXPERIMENTAL|The group which mobilization with movement technique applied by clinician|17 individuals in this group, after evaluations, mobilization with movement technique applied by clinician and after that same evaluations will be applied
62306349|NCT05814029|EXPERIMENTAL|The group which mobilization with movement technique applied by individual himself|17 individuals in this group, after evaluations, mobilization with movement technique applied by individual himself and after that same evaluations will be applied
62306350|NCT05814029|NO_INTERVENTION|Control Group|16 individuals in this control group, Relevant Extremity will assume a lunge position on a firm mattress with the foot in a weight-bearing stance and the foot in a neutral position. The person will feel uncomfortable and/or the parts will suddenly lunge until the end of their range of motion. No mobilization technique will be applied
62306351|NCT05683132|EXPERIMENTAL|Trauma-Informed CBT-I|This intervention includes trauma-informed adaptations to standard treatment for insomnia, CBT-I
62306352|NCT05683132|ACTIVE_COMPARATOR|PTSD Psychoeducation|This intervention includes psychoeducation about PTSD symptoms modeled after usual care in a VA Women's Health Clinic.
62306353|NCT02723435|EXPERIMENTAL|Midostaurin|Beginning 30 days post-HCT, participants receive oral midostaurin twice-a-day in 28-day treatment cycles, continuing up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62306354|NCT02699775||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
62306355|NCT04555213|EXPERIMENTAL|Dose Escalation Cohort 1 - NOX66 400mg|NOX66 400 mg suppository OD
62474100|NCT05157477|NO_INTERVENTION|Control group|The participants who are randomized into control group will be regularly followed in a naturalistic outpatient clinic setting (every 2-4 week). During the clinic, sensory and socioemotional problems will be discussed face-to-face for 10 to 20 minutes, some self-help books will be recommended.
62474101|NCT06223763||Primary cytoreductive surgery|Patients underwent primary cytoreductive surgery between January 1, 2018, and December 31, 2019. After that, they underwent adjuvant therapy.
62474102|NCT06223763||Interval cytoreductive surgery|Patients underwent primary first course of neoadjuvant chemotherapy between January 1, 2018, and December 31, 2019. After neoadjuvant chemotherapy, the patient underwent interval cytoreductive surgery and then, adjuvant chemotherapy.
62474103|NCT02821728|EXPERIMENTAL|Normal diet|No dietary intervention
62474104|NCT02821728|EXPERIMENTAL|Dietary intervention|3 portions of broccoli soup per week
62474105|NCT02294604|EXPERIMENTAL|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
62474106|NCT02294604|ACTIVE_COMPARATOR|Group I|Traditional scrub formation with 10 % povidone-iodine
62474107|NCT02294604|ACTIVE_COMPARATOR|Group C|Traditional scrub formation with 4% chlorhexidine
62474108|NCT02662933|EXPERIMENTAL|Bedside Assessment Measures|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
62474109|NCT00727480|EXPERIMENTAL|A|Ultrasound Imaging of fingertips
62306356|NCT04555213|EXPERIMENTAL|Dos Escalation Cohort 2 - NOX66 600mg|NOX66 600 mg suppository OD
62306357|NCT04555213|EXPERIMENTAL|Dose Escalation Cohort 3 - NOX66 800mg|NOX66 800 mg daily (400 mg suppository BID)
62306358|NCT04555213|EXPERIMENTAL|Dose Escalation Cohort 4 - NOX66 1200mg|NOX66 1200 mg daily (600 mg suppository BID)
62474110|NCT03450057|EXPERIMENTAL|Single arm trial receiving daratumumab with dexamethasone (DaraD)|Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Dexamethasone was administered according to the standard recommended dose of 40 mg (20 mg for patients \> 75 years of age) orally once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
62474111|NCT02788240|EXPERIMENTAL|Peg GCSF with standard medical therapy|
62474112|NCT02788240|ACTIVE_COMPARATOR|Placebo with standard medical therapy|
62474113|NCT05361330|EXPERIMENTAL|The experimental group: Shuganjieyu capsule|Shuganjieyu capsule combined with Fluoxetine
62306359|NCT04555213|EXPERIMENTAL|Dose Escalation Cohort 5 - NOX66 1800mg|NOX66 1800 mg daily (600 mg suppository TID)
62306360|NCT04555213|EXPERIMENTAL|Dose Expansion - NOX66 Recommended Phase 2 Dose|Dose Expansion: NOX66 RP2D
62306361|NCT04345549|EXPERIMENTAL|Ayurveda|All the participants were advised to self-isolate for 7-days and maintain hygiene and self-care as per recommended guidelines. Along with that, participants were advised to constitution based Ayurveda treatment using herbs, life style and yoga.
62306362|NCT02154971||Patients|HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
62306363|NCT02154971||Control|non-HIV (matched for age and gender)
62306364|NCT03264040||Observation|Patients with Mannosidosis disease or high-grade suspicion for Mannosidosis disease
62306365|NCT03605901|ACTIVE_COMPARATOR|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
62306366|NCT03605901|EXPERIMENTAL|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 8 breaths/min, induction of general anesthesia and intubation will proceed.
62306367|NCT02968030|EXPERIMENTAL|Muscle strength|Evaluate the effects of a eight weeks program of strengthening exercise on balance and functional mobility in irregular active elderly women
62306368|NCT05776537|OTHER|Group (1) confirmed bronchial asthma and group (2) bronchial asthma rule out|After completing all the clinical, functional, radiologic, and endoscopic assessment, the patients were classified into two groups: Group (1) (89 patients) whose diagnosis confirmed to be bronchial asthma and group (2) (111 patients) with diagnoses other than bronchial asthma.
62306369|NCT01634347|EXPERIMENTAL|Propranolol and memory reactivation|
62306370|NCT01634347|PLACEBO_COMPARATOR|Placebo and memory reactivation|
62474114|NCT05361330|PLACEBO_COMPARATOR|The control group: Shuganjieyu capsule simulator|Fluoxetine monotherapy
62474115|NCT01748591||PICOPREP treatment|PICOPREP powder for oral solution according to standard clinical practice
62474116|NCT00749294||Observation|
62474117|NCT02543489|OTHER|Flex IM Rod|
62474118|NCT01907919||conventional group,RM-GIC|1. Group A: Five teeth were treated with traditional rotating instruments, the cavities were prepared with diamond drills by turbine, multiple-blade drills by headpiece for removing the decayed dentine and, after cleaning and control of bleeding with cotton pellets with saline solution,RM-GIC (3M ESPE, USA) light-hardening paste was placed gently on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA).
62677744|NCT02326688|EXPERIMENTAL|stroke patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~* Two separated measurements are recorded with a 6-hours interval~* A third measurement provided by a second examinator is conducted"
62677745|NCT02326688|EXPERIMENTAL|control patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~* Two separated measurements are recorded with a 6-hours interval~* A third measurement provided by a second examinator is conducted"
62306371|NCT05187169|ACTIVE_COMPARATOR|Treatment A|4.0 mg VS-6766, following an overnight fast of at least 10 hours
62306372|NCT05187169|ACTIVE_COMPARATOR|Treatment B|4.0 mg VS-6766, administered 30 minutes after the start of a high-fat/high-calorie meal breakfast
62306373|NCT05128240|PLACEBO_COMPARATOR|Placebo|4x1g corn oil capsules
62306374|NCT05128240|EXPERIMENTAL|Ceto 10|4x1g capsules containing containing broad spectrum marine oil from north atlantic fish
62306375|NCT06511388||Observational|Patients receive anthracycline once a day or split between 2-3 days per SOC. Patients undergo 2D-STE throughout the study and have their medical records reviewed on study.
62306376|NCT03476850|ACTIVE_COMPARATOR|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
62306377|NCT03476850|ACTIVE_COMPARATOR|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
62306378|NCT04631718||MRI based abdominal QSM|Participants with known or suspected iron overload with past serum ferritin \>500 will be recruited in this study.
62306379|NCT01344122|ACTIVE_COMPARATOR|KPI training only|Study sites randomized to this arm will receive a knowledge, perceptions and information (KPI) training for community correctional and treatment staff to address knowledge, perceptions, and information regarding local resources about MAT.
62306380|NCT01344122|EXPERIMENTAL|KPI plus OLI|Study sites randomized to this arm will receive the KPI training plus a Organizational Linkage Intervention (OLI) that will: (a) establish a local Pharmacotherapy Exchange Council (PEC) among agencies important for the implementation of MAT in community corrections; (b) facilitate a strategic planning process within the PEC to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole; and (c) identify a community corrections coordinator in one of the local agencies to operationalize and implement the strategic plan.
62306381|NCT02169076|ACTIVE_COMPARATOR|CRT-On|Cardiac Resynchronization Therapy enabled on ICD/Pacemaker device
62306382|NCT02169076|SHAM_COMPARATOR|CRT-Off|Cardiac Resynchronization Therapy disabled on ICD/Pacemaker device
62306383|NCT00820040|EXPERIMENTAL|Permacol|
62306384|NCT00849212|EXPERIMENTAL|1|
62306385|NCT04124367|ACTIVE_COMPARATOR|Verum|
62306386|NCT04124367|PLACEBO_COMPARATOR|Control|
62306387|NCT04132726|EXPERIMENTAL|Test|Experimental group which employed with massage treatment
62474119|NCT01907919||Diode 808 nm laser-assisted group|"2. Group B : Five teeth cavities were prepared as the same with group one with traditional rotating instruments, hemostatic and cavities sterilization were achieved by a diode 808 nm (Picasso- AMD, USA) laser using following parameters:~* Hemostatic: 1.5 W, CW, fiber diameter 400µm, in contact, 2s per 1mm, vertical and horizontal scanning movement on exposure site.~* Cavity sterilization: 1W, CW, fiber diameter 400µm, in contact, 2mm per s, circular movement.~After hemostatic and cavity sterilization, RM-GIC (3M ESPE, USA) light-hardening paste was placed on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA)."
62474120|NCT06420869||Group 1|The study group 1, comprised 23 subjects, comprising both males and females, with an age range of between 18 and 25 years. The subjects exhibited a thoracic kyphosis angle of ≥40° and had not undergone treatment for kyphosis in the previous six months.
62306388|NCT04132726|PLACEBO_COMPARATOR|Placebo|Placebo group which employed with non-effective treatment
62306389|NCT04132726|NO_INTERVENTION|Control|no treatment
62306390|NCT02786862|EXPERIMENTAL|Ventilation|Measurements were made for conventional and independent at 1:1 proportion ventilation in supine position; then independent ventilation was discontinued and patient was moved to right or left decubitus position due to left or right lung surgery. Then were made measurements for conventional anaesthetic practices and followed independent at 1:1, 2:1, 3:1, 5:1 proportions ventilation routines. Constantly were monitored expired volume, peak respiratory pressure, dynamic compliance separately for each lung. Measurements covered also hemodynamic (MAP, HR) and oxygenation (SpO2). These attributes were documented at each point of the study. Subsequently, the control system was disconnected and performed typical anaesthetic procedures for thoracic surgery with a one-lung ventilation procedure.
62306391|NCT01774448|NO_INTERVENTION|Waitlist Control|Participants in the control group will undergo a non-intervention 8-week period while on the 'waitlist control' then will be crossed-over to the Mindfulness-Based Cognitive Therapy intervention.
62306392|NCT01774448|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy is an 8-week intervention, one session per week for 2 hours, where participants will learn and practice formal and informal mindfulness meditation, and participate in group discussion and inquiry.
62474121|NCT06420869||Group 2|The study group 2, comprised 23 subjects, comprising both males and females, with an age range of between 18 and 25 years.The subjects were selected based on the criteria that their thoracic kyphosis angle was less than 40° and that they did not exhibit any spinal deformities.
62474122|NCT03347435|EXPERIMENTAL|Genotype/ phenotype guided group|The patients randomized to the genotype/phenotype guided group undergo genetic tests for CYP2C19\*2, CYP2C19\*17 and ABCB1 3435 genetic variants immediately after diagnosis of ACS and receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables.
62474123|NCT03347435|ACTIVE_COMPARATOR|phenotype only guided group|The patients randomized to the phenotype only guided group receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care on the basis of clinical algorithm alone.
62677746|NCT04928339|EXPERIMENTAL|PIFB intervention|bilateral PIFB with a mixture of standard 0.25% bupivacaine (15 mL) and 133 mg liposomal bupivacaine (10mL)
62677747|NCT04928339|SHAM_COMPARATOR|Saline Control|bilateral PIFB with 25 mL saline only
62677748|NCT02618187|EXPERIMENTAL|Weekly SER-287, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
62118500|NCT02762006|EXPERIMENTAL|Durvalumab + Tremelimumab with Nephrectomy|"Following systemic therapy, patients will undergo nephrectomy. Adjuvant therapy will be administered within 4-6 weeks of surgery. Subsequent follow-up will then be completed to assess adverse event resolution and long-term outcomes.~* Cohort 1: Durvalumab x 1 dose (n=6)~* Cohort 2: Durvalumab + Tremelimumab x 1 dose (n=6)~* Cohort 2a: Durvalumab + Tremelimumab x 1 dose (n=12)~* Cohort 3: Durvalumab + Tremelimumab x 1 dose (n=9)~Cohorts 1 and 2: Adjuvant dosing of Durvalumab x 1 beginning 2-8 weeks after surgery.~Cohort 2a: Durvalumab monotherapy until 1 year after nephrectomy.~Cohort 3: Adjuvant dosing of durvalumab + tremelimumab x 1 beginning 2-8 weeks after surgery, then durvalumab monotherapy until 1 year after nephrectomy."
62118501|NCT01603784|EXPERIMENTAL|Combined|Aerobic Exercise + Cognitive Training
62118502|NCT01603784|EXPERIMENTAL|Exercise|Aerobic Exercise + Health Education
62118503|NCT01603784|EXPERIMENTAL|Cognitive|Home Exercise + Cognitive Training
62677749|NCT02618187|PLACEBO_COMPARATOR|Daily placebo, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once daily placebo for 8 weeks
62677750|NCT02618187|EXPERIMENTAL|Daily SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
62677751|NCT02618187|EXPERIMENTAL|Weekly SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
62677752|NCT06047717|EXPERIMENTAL|Virtual Reality (VR) Driving Task: Cortically Blind Cohort|"Persons who have sustained cortical blindness will perform a driving task in VR, in which they must steer through a series of parameterized turns while maintaining their virtual vehicle centered between the two red lines delineating the road edge."
62118504|NCT01603784|EXPERIMENTAL|Control|Home Exercise + Health Education
62306393|NCT03906877|EXPERIMENTAL|Injection laryngoplasty group (IL)|The patients in the first group will receive an IL of hyaluronic acid in the paralyzed vocal fold within a maximum of three months after the onset of symptoms. The Ear-Noise-Throat (ENT) physician will perform the injection in office, under topical anaesthesia.
62306394|NCT03906877|EXPERIMENTAL|Voice therapy group (VT)|Patients from the second group will be involved in 15 sessions of thirty minutes of voice therapy, twice a week, and will have to do home practice. Patients will have to record these training sessions. Initiation of this intervention should also take place within the first three months after the onset of symptoms. They will also receive an injection of physiological saline under the skin of the neck (sham of injection).
62474124|NCT00462228|EXPERIMENTAL|Memantine|Subjects will be titrated up to 20 mg of memantine per day for 12 weeks, followed by placebo for 12 weeks
62474125|NCT00462228|PLACEBO_COMPARATOR|Placebo|Subjects will be titrated up to 20 mg of placebo per day for 12 weeks, followed by memantine for 12 weeks
62474126|NCT00836056|EXPERIMENTAL|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
62474127|NCT00836056|ACTIVE_COMPARATOR|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
62677753|NCT06047717|EXPERIMENTAL|Virtual Reality (VR) Driving Task: Healthy Control Cohort|"Healthy controls with no vision loss will perform a driving task in VR, in which they must steer through a series of parameterized turns while maintaining their virtual vehicle centered between the two red lines delineating the road edge."
62677754|NCT06563349|EXPERIMENTAL|Magnesium Sulfate|10% magnesium sulfate intravenous bolus of 0.5 ml/kg (maximum 20 ml) over 5 min before induction of anesthesia followed by magnesium sulfate infusion at 0.15 ml/kg/h (maximum 6 ml/h) intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
62118505|NCT04792554||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
62306395|NCT03906877|SHAM_COMPARATOR|Sham group|The patients of the third group will be treated following the traditional wait-and-see policy. They will receive an injection of physiological saline under the skin of the neck and will be seen during 15 sessions of 30 minutes, twice a week. Therefore, this will be a sham procedure for both IL and VT.
62306396|NCT03877406|ACTIVE_COMPARATOR|Control group|up-titration of standard medication including monotherapy or combination of Metformin, Sulfonylurea, DPP4 inhibitor
62306397|NCT03877406|EXPERIMENTAL|Study group|addition of empagliflozin 10mg qd on standard oral antihyperglycemic agents
62474128|NCT01547377|EXPERIMENTAL|zinc and selenium supplementation|Patients received 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation during 4 months
62118506|NCT06228846|EXPERIMENTAL|Study treatment|Method of Administration: Single dose period: Single oral ; Multiple dose period: Oral , QD.
62306398|NCT04008212||EVAR aneurysm|
62474129|NCT01547377|PLACEBO_COMPARATOR|rosuvastatin + placebo|Patients received 10 mg rosuvastatin concomitantly placebo pills similar zinc and selenium supplementation
62474130|NCT00969943||Cocaine-dependent Men|
62474131|NCT00969943||Cocaine-dependent Women|
62474132|NCT00969943||Control Men|
62474133|NCT00969943||Control Women|
62474134|NCT00840099|EXPERIMENTAL|1|
62474135|NCT00840099|ACTIVE_COMPARATOR|2|
62677755|NCT06563349|PLACEBO_COMPARATOR|Control|0.9% NaCl (sodium chloride) intravenous bolus of 0.5 ml/kg (maximum 20 ml) over 5 min before induction of anesthesia followed by 0.9% NaCl infusion at 0.15 ml/kg/h (maximum 5ml/h) intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
62677756|NCT02267525|EXPERIMENTAL|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
62677757|NCT02267525|EXPERIMENTAL|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
62118507|NCT02122445|EXPERIMENTAL|Low Back Pain|Lower body exercises before and after the application of Cramer Sports Motion tape
62118508|NCT00657943|EXPERIMENTAL|1M|Metformin + Levemir x1
62118509|NCT00657943|PLACEBO_COMPARATOR|1P|Placebo + Levemir x1
62118510|NCT00657943|EXPERIMENTAL|2M|metformin + NovoMix
62474136|NCT01209793|EXPERIMENTAL|Dose 1|(3:1, active: placebo)
62474137|NCT01209793|EXPERIMENTAL|Dose 2|(3:1, active: placebo)
62474138|NCT01209793|EXPERIMENTAL|Dose 3|(3:1, active: placebo)
62118511|NCT00657943|PLACEBO_COMPARATOR|2P|Placebo + NovoMix
62474139|NCT01209793|EXPERIMENTAL|Dose 4|(3:1, active: placebo)
62474140|NCT01209793|EXPERIMENTAL|Dose 5|(3:1, active: placebo)
62677758|NCT02267525|EXPERIMENTAL|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
62677759|NCT02267525|PLACEBO_COMPARATOR|Placebo|Placebo capsules QD x 12 weeks
62118512|NCT00657943|EXPERIMENTAL|3M|Metformin + 4x therapy
62118513|NCT00657943|PLACEBO_COMPARATOR|3P|Placebo + 4x therapy
62677760|NCT05618626|EXPERIMENTAL|Physical exercise and dietary intervention for NAFLD|The exercise program will consist of muscular strength and aerobic exercises; additionally, each session will start and end with low intensity warm-up and cool down periods. The program will be divided in months. Months 1-2, twice a week directly-supervised exercises group sessions, and 1 telehealth session. Months 3-6, once a week directly-supervised group session and twice a week home-based telehealth. Months 7-12, Monthly telephone support. Months 12, 24 and 36, All participants (control and intervention arms) will receive a full evaluation. In the dietary intervention, investigators proposed a diet rich in anti-inflammatory components, legumes and in dietary fiber. The baseline evaluation of nutritional condition includes: anthropometry, bioimpedance analysis, hepatobiliary ultrasound, Fibroscan,blood lipids, and a battery of metabolic markers and a diet survey, Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24). Both interventions are performed in parallel.
62736324|NCT02653586|EXPERIMENTAL|"program In Favor of Resilience Self"|"The program In Favor of Resilience Self was delivered to adolescence aged 15-17, over 2 months. The program contained nine weekly, 90-min lessons that focus on enhancing self- resilience, self-esteem, self-image, body image. All students completed a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
62118514|NCT02323529|EXPERIMENTAL|Nitisinone treatment group|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.
62118515|NCT02705937|EXPERIMENTAL|Dairy product|The product will be taken for 14 days
62118516|NCT02705937|ACTIVE_COMPARATOR|Aequasyal mouth spray medical device|The spray will be taken for 14 days
62306399|NCT04008212||Stenosis|
62306400|NCT05738980|EXPERIMENTAL|anti-Tim3-blocked RAK cells|ubjects were randomly assigned to receive anti-TIM-3 blocked RAK cells or untreated RAK cells.
62306401|NCT05738980|EXPERIMENTAL|Unblocked RAK cells|ubjects were randomly assigned to receive anti-TIM-3 blocked RAK cells or untreated RAK cells.
62474141|NCT04512430|EXPERIMENTAL|Experimental: Neo-Adjuvant Immunotherapy|"* Neoadjuvant treatment: (Atezolizumab: 1200 mg, IV infusion+Bevacizumab: 15mg/Kg mg, IV infusion+Carboplatin: AUC6, IV infusion+Pemetrexed: 500 mg/m2, IV infusion) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery.Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~* Surgery: Surgery must be done within the 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3).~* Adjuvant treatment: Atezolizumab: 1200 mg, IV infusion Q4W (+/- 3 days) for 6 months (6 cycles) Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+7 days) from surgery and for 6 months (6 cycles)."
62306402|NCT03851861|EXPERIMENTAL|Mediterranean Diet|Participants will be given individualized diet education on the Mediterranean diet and instructed to follow the diet for the 5-week intervention period. Individualized diet education will be administered by a licensed, registered dietitian nutritionist (RDN) followed by weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
62306403|NCT00981435|EXPERIMENTAL|Artificial Tears|Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
62306404|NCT00981435|EXPERIMENTAL|Non-steroidal anti-inflammatory|Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
62306405|NCT00981435|EXPERIMENTAL|Steroid|Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
62306406|NCT04396457|EXPERIMENTAL|Pembrolizumab+Pemetrexed|"200 mg of pembrolizumab is intravenously infused over 30 minutes and more on day 1.~500 mg/m\^2 of pemetrexed is intravenously infused over 10 minutes and more on day 1.~\*Administration of folic acid and vitamin B12 is started 1 week before the start of treatment with pemetrexed.~And repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the pembrolizumab administration is 35 cycles, and the pemetrexed administration will continue until the treatment cessation criteria are met."
62306407|NCT02842814|EXPERIMENTAL|Full withdrawal|Intervention: 'Drug free'.
62306408|NCT02842814|EXPERIMENTAL|GC withdrawal|Intervention: 'HCQ' .
62474142|NCT02493868|EXPERIMENTAL|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Direct-entry participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Open-label Induction Phase. Participants will initiate a new oral antidepressant on Day 1 of this phase. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to esketamine will self-administer intranasal esketamine (same dose) once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
62474143|NCT02493868|EXPERIMENTAL|Placebo Plus Oral Antidepressant|Optimization Phase: Transferred-entry participants will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to intranasal placebo will self-administer intranasal placebo once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
62474144|NCT05053763|OTHER|Experimental: age<65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
62474145|NCT05053763|OTHER|Active Comparator:age ≥65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
62474146|NCT03298880|OTHER|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
62118517|NCT04969172|ACTIVE_COMPARATOR|1010 Exosome|103 patients will receive either 1010 exosome particles.
62118518|NCT04969172|PLACEBO_COMPARATOR|Placebo|52 patients will receive placebo- saline.
62118519|NCT04043364|EXPERIMENTAL|LIVE|A multicomponent intervention focusing on Learning, Innovation, Volunteers and Empowerment organized by a local coordinator.
62118520|NCT04043364|NO_INTERVENTION|Treatment as usual|Care coordination and facilitation as usual.
62118521|NCT03034681|OTHER|Vojta|Vojta therapy consists in activating certain overall and innate locomotion patterns or complexes: reflex creeping and reflex rolling, which provokes the contraction of striated muscle in the entire body in a determined coordination with the central nervous system (CNS). These patterns are triggered from different positions (prone, supine and side lying) and only with certain stimulation. They contain all the locomotion components: automatic postural control, uprighting and phase movements. This therapy allows for the changing from pathological patterns to painless and cheaper patterns. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
62118522|NCT03034681|ACTIVE_COMPARATOR|TENS|TENS procedure used at our unit consists in applying a high frequency current (80Hz), which is the most effective way to combat pain, for a phase duration of 60-200 microseconds at a comfortable range. Electrodes are placed on the skin over the sciatic nerve path, the (-) cathode on the most painful area as it is the most stimulating and the (+) another is placed distal. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
62306409|NCT02842814|EXPERIMENTAL|No withdrawal|Intervention: 'GC+HCQ' .
62306410|NCT00364910|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|Participants will receive cognitive behavioral therapy
62306411|NCT00364910|ACTIVE_COMPARATOR|Educational session and treatment as usual|Participants will receive an educational session and treatment as usual
62306412|NCT00474227|EXPERIMENTAL|A|behavioral intervention, group therapy including nutritional guidance and physical exercise
62306413|NCT00474227|NO_INTERVENTION|B|comparison group, one time explanation of importance of proper nutrition. This group receives no group therapy or organized exercise sessions or nutritional guidance. They are wait listed for this program.
62306414|NCT02609477|EXPERIMENTAL|Istradefylline 40 mg|40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)
62306415|NCT02609477|EXPERIMENTAL|Istradefylline 80 mg|80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)
62306416|NCT02609477|EXPERIMENTAL|Istradefylline 160 mg|160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)
62306417|NCT02609477|ACTIVE_COMPARATOR|Phentermine 45 mg|45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)
62306418|NCT02609477|ACTIVE_COMPARATOR|Phentermine 90 mg|90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)
62306419|NCT02609477|PLACEBO_COMPARATOR|Placebo|Placebo (4 × placebo tablets + 3 × placebo capsules)
62306420|NCT04585763|EXPERIMENTAL|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|
62306421|NCT02628379||Class 1, 2, or 3 alterations, with targeted therapy|Patients put on targeted therapies matched to specific genomic alterations.
62306422|NCT02628379||Site-specific therapy determined by tissue of origin testing|Patients put on therapy determined by tissue of origin testing (e.g., CancerTYPE ID)
62306423|NCT02628379||Empiric CUP therapy|Patients put on empiric treatment at physician discretion
62306424|NCT03303599||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
62474147|NCT02922777|EXPERIMENTAL|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
62474148|NCT03507491|EXPERIMENTAL|Gemcitabine + Nab-paclitaxel|Participants receiving gemcitabine and nab-paclitaxel for refractory and/or relapsed solid tumors of childhood.
62118523|NCT00476255|ACTIVE_COMPARATOR|Enhanced Standard Care|Instructional materials
61919040|NCT03231150|ACTIVE_COMPARATOR|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
62677761|NCT05618626|NO_INTERVENTION|Standard of care|Participants in the control arm first have a baseline evaluation of the nutritional condition, with anthropometry evaluation, bioimpedance analysis, hepatobiliary ultrasound, Fibroscan, blood lipids, a battery of metabolic markers, and a diet survey, Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24). After the evaluation period, participants received one counseling session, including written material, with advice to follow a healthy diet rich in fruits and vegetables, whole-grain foods, low in salt and sugars, and recommendations for an exercise plan of at least 30 minutes of aerobic exercise three times a week.
61919041|NCT03231150|EXPERIMENTAL|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
62118524|NCT00476255|EXPERIMENTAL|Motivational Intervention|Motivational interview
62118525|NCT03058965|EXPERIMENTAL|[18F]MNI-958|To evaluate \[18F\]MNI-958, a tau targeted PET radioligand.
62474149|NCT06380023||coughing with suction|Suction performed on manikin in simulated setting
62677762|NCT04903288|EXPERIMENTAL|Eladocagene Exuparvovec|Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10\^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.
62677763|NCT03614780|EXPERIMENTAL|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
62118526|NCT05054764||Participants with CLTI and BTK lesions planned for revascularization|The study population will be CLTI patients presenting with lower limb tissue loss (ulcer or gangrene) and BTK lesions who are candidates for revascularization for limb salvage.
62118527|NCT02655835|EXPERIMENTAL|Internet Mindfulness Meditation Intervention|Six-week internet mindfulness meditation training program including handouts and daily guided meditations
62118528|NCT02655835|EXPERIMENTAL|Access|Written information handouts on mindfulness meditation and access to guided daily meditations
62118529|NCT04567043|EXPERIMENTAL|Mindfulness-Oriented Recovery Enhancement+JITAI|Participants will attend a telehealth Mindfulness-Oriented Recovery Enhancement (MORE) group plus mindfulness JITAI weekly for eight weeks.
62118530|NCT04567043|ACTIVE_COMPARATOR|Supportive Psychotherapy|Participants will attend a telehealth supportive psychotherapy group weekly for eight weeks.
62118531|NCT03663842|EXPERIMENTAL|Neural tissue management|Myofascial release technique; Hip joint mobilization technique; Cross-fiber friction over the sacroiliac joints; Neural mobilization to improve sciatic nerve excursion.
62118532|NCT02839018||Central nervous system (CNS) group|n=50 patients with presumed low prevalence of ICU-AW
62118533|NCT02839018||Severe sepsis/shock group|n=50 patients with presumed high prevalence of ICU-AW
62118534|NCT04105868|EXPERIMENTAL|Neurofeedback|Participants will receive feedback about their attention to negative distractors during each trial using activity from their brain waves, which will help them reduce their attention to distractors.
62118535|NCT06079840|EXPERIMENTAL|MBSR-AAC app|Participants will receive the MBSR-AAC app for 8-weeks.
62118536|NCT06079840|ACTIVE_COMPARATOR|Comparison|Participants will receive information regarding caregiver services and resources for 8-weeks.
61919042|NCT00636701|EXPERIMENTAL|Primed rTMS|Receive 10 min. of 6-Hz rTMS Repetitive Transcranial Magnetic Stimulation at 90% RMT (3,600 pulses). Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
62118537|NCT04296019|EXPERIMENTAL|Fruquintinib|Patients who achieved stable disease (SD) or partial response (PR) or complete response (CR) following palliative first-line treatment will receive maintenance therapy with fruquintinib.
62118538|NCT04296019|NO_INTERVENTION|Observation|Patients who achieved SD or PR or CR following palliative first-line treatment will receive treatment-free observation.
62118539|NCT02010372|EXPERIMENTAL|Reminder Recall Reports|Training in how to use reminder-recall reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
62118540|NCT02010372|EXPERIMENTAL|Audit-Feedback/Immunization Forecasting Reports|Training in how to use audit-feedback/immunization forecasting reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
62118541|NCT02010372|NO_INTERVENTION|Control|No intervention will be administered to this group.
62118542|NCT02852681|OTHER|15 mg E4/3 mg DRSP without food|Treatment A (Reference): a single 15 mg E4/3 mg DRSP tablet without food (fasted).
62118543|NCT02852681|OTHER|15 mg E4l/3 mg DRSP with food|Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed)
62118544|NCT04009577|EXPERIMENTAL|Cohort 1 (LEM 5 mg)|"Participants who were taking zolpidem tartrate (ZOL) at least 3 but fewer than 5 nights per week, for each of at least 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.~Participants who meet both criteria for intermittent (Cohort 1) and frequent ZOL use (Cohort 2A and 2B) for 1 week each of the last 2 weeks of the 3-week Screening Period will be assigned to Cohort 1 and also will receive LEM 5mg."
62118545|NCT04009577|EXPERIMENTAL|Cohort 2A (LEM 5 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
62118546|NCT04009577|EXPERIMENTAL|Cohort 2B (LEM 10 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 10 mg administered as a tablet, orally for up to 2 weeks.
62118547|NCT03102710|EXPERIMENTAL|tDCS Enhancement|In this group, the transcranial direct current stimulation (tDCS) stimulates the areas of the brain being examined in this study to increase their activity.
62118548|NCT03102710|EXPERIMENTAL|tDCS Inhibition|In this group, the transcranial direct current stimulation (tDCS) inhibits the areas of the brain being examined in this study to decrease their activity.
62118549|NCT03102710|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation (tDCS) does not provide real stimulation though you will not know this until your debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
62118550|NCT01125319|OTHER|patients Hemophagocytic lymphohisticytosis group|
62118551|NCT01125319|OTHER|group control patient|
62474150|NCT06380023||coughing with suction covered by surgical mask|Suction performed on manikin in simulated setting
61919043|NCT00636701|PLACEBO_COMPARATOR|Unprimed rTMS)|Receive 10 min. of sham rTMS Repetitive Transcranial Magnetic Stimulation. Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
61919044|NCT03648723||Diabetic nephropathy|Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
61919045|NCT03648723||Non-diabetic nephropathy|This group consisted of diagnosis with nephropathy without diabetes mellitus.
62118552|NCT01125319|OTHER|healthy control group|
62118553|NCT06677593||Patients|Patients with COPD or cancer
62118554|NCT03302819|EXPERIMENTAL|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
62118555|NCT03302819|EXPERIMENTAL|Imaging characteristics and performance|Patients attending the symptomatic clinic
62118556|NCT03302819|EXPERIMENTAL|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
62118557|NCT05371288|EXPERIMENTAL|No Multivitamin and Magnesium|"Subjects randomized into Group A will take the following amount for 28 days~* 4 capsules of NAC (600mg each) once in the morning and once in the evening~* 1 tablet (600mg) of Alamax CR once in the morning and once in the evening~* 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening"
62118558|NCT05371288|ACTIVE_COMPARATOR|Multivitamin and Magnesium|"Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days.~* 4 capsules of NAC (600mg each) once in the morning and once in the evening~* 1 tablet (600mg) of Alamax CR once in the morning and once in the evening~* 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening"
62118559|NCT04871750|EXPERIMENTAL|Soy protein|30 g powder/day, contains 50 mg of isoflavones
62118560|NCT04871750|PLACEBO_COMPARATOR|Casein protein|30 g powder/day, no isoflavones
62677764|NCT03445845|EXPERIMENTAL|targeting IL-23/17 axis|"The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.~Blood specimen at each visits"
62118561|NCT01243619|EXPERIMENTAL|FLT PET|This is a single arm trial, in which all patients receive three FDG-PET scans and three FLT-PET scans, before, during and after pre-operative chemoradiation for esophageal cancer.
62118562|NCT06676956|ACTIVE_COMPARATOR|Linear EBUS First|Patients will undergo a mediastinal lymph node evaluation with EBUS first, followed by biopsy followed by robotic-assisted bronchoscopy
62306425|NCT05079035|EXPERIMENTAL|Experimental: TTAX03|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is suspended in a volume of 2.0mL of sterile, preservative free 0.9% NaCl.
62118563|NCT06676956|ACTIVE_COMPARATOR|Robotic-assisted bronchoscopy first|Patients will undergo a robotic-assisted bronchoscopy first, followed by a mediastinal lymph node evaluation with EBUS second
62118564|NCT01839981|EXPERIMENTAL|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62118565|NCT05165082|EXPERIMENTAL|Timolol plus cryotherapy|Apply topical timolol solution twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen once every other week (on the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
62118566|NCT05165082|PLACEBO_COMPARATOR|Placebo plus cryotherapy|Apply placebo (normal saline) twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen once every other week (on the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
62118567|NCT06405880|EXPERIMENTAL|Pharmacist-led care pathway|Participants in the intervention arm will receive the care using a shared decision-making pharmacist-led care pathway designed to guide the cardiovascular (CV) risk reduction process. The pharmacist-led care pathway is modelled after the largest CV risk reduction randomized controlled trial in a community pharmacy setting (RxEACH Study), and based upon the latest CV risk reduction guidelines, such as C-CHANGE. This pathway will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to calculate the participant's estimated CV risk. The participant and pharmacist will be guided by the care pathway to review the participant's estimated CV risk and contributing CV risk factors and engage in shared decision-making to manage the participant's CV risk factors using lifestyle changes and/or pharmacological treatment as clinically appropriate.
62118568|NCT06405880|NO_INTERVENTION|Usual Care|The control group will involve facilitated relay of information to participants' family physician. Participants in the control group will have their pharmacist collect information informing the patient's CV risk. Participants will then be given a letter that contains their values for CV risk factors (including blood pressure, HbA1c, and lipid panel), and they will be advised to present it to their family physician. No specific suggestions for CV risk reduction will be detailed in the letter. In the case where the patient does not have a family physician, they can be referred to a physician walk-in clinic. A follow-up appointment in 6-months' time will be booked for with all participants in the control group.
62118569|NCT04492631|EXPERIMENTAL|Probiotic|Powdered probiotic with a carrier.
62118570|NCT04492631|PLACEBO_COMPARATOR|Placebo|Carrier only.
62306426|NCT05079035|PLACEBO_COMPARATOR|Control: Saline|2.0mL of sterile, preservative free 0.9% NaCl alone
62677765|NCT03445845|ACTIVE_COMPARATOR|TNF blocker|"• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:~The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow.~Blood specimen at each visits"
62474151|NCT06380023||coughing with suction covered by enclosure tent|Suction performed on manikin in simulated setting
62474152|NCT00378547|PLACEBO_COMPARATOR|Paracetamol|Oral paracetamol 1 g + placebo + placebo
62677766|NCT06567860|EXPERIMENTAL|Late season influenza vaccine|Every participant receives the 2023 influenza vaccine between May-June 2024, and then the 2024 influenza vaccine in September-October 2024. Blood draws are taken at Day 0, 30, and 90 post-vaccination.
62677767|NCT02773537|ACTIVE_COMPARATOR|Randomization Group 1|Femoral nerve catheter and sciatic nerve block
62677768|NCT02773537|ACTIVE_COMPARATOR|Randomization Group 2|Adductor canal catheter and selective tibial block
62677769|NCT02773537|ACTIVE_COMPARATOR|Randomization Group 3|Adductor canal catheter only
62677770|NCT06439082|EXPERIMENTAL|Crizanlizumab (SEG101) at 5.0 mg/kg|Participants receive Crizanlizumab (SEG101) at 5.0 mg/kg and standard of care.
62677771|NCT06439082|PLACEBO_COMPARATOR|Placebo|Participants receive the placebo drug and standard of care.
62677772|NCT05829317|EXPERIMENTAL|Magnesium Sulfate|4g Magnesium sulfate (100mL) BID, given intravenously over 2 hours, for a total of 10 doses
62677773|NCT05829317|PLACEBO_COMPARATOR|0.9% NaCl|100mL 0.9% NaCl BID, given intravenously over 2 hours, for a total of 10 doses
62677774|NCT05876312|EXPERIMENTAL|Phase 1 - Active ADX-038 administered to HP|For each cohort in Phase 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
62677775|NCT05876312|PLACEBO_COMPARATOR|Phase 1- Placebo administered to HP|For each cohort in Phase 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
61919046|NCT01690338|ACTIVE_COMPARATOR|Vecuronium Bromide|Patients who will be performed general anesthesia and tracheal intubation. Vecuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
61919047|NCT01690338|ACTIVE_COMPARATOR|cisatracurium|Patients who will be performed general anesthesia and tracheal intubation. Cisatracurium will be used during surgery and tracheal extubation is scheduled when surgery is over.
62677776|NCT05876312|EXPERIMENTAL|Phase 2a - ADX-038 administered to PNH participants|This will be initiated at the dose level determined by the Safety Review Committee from SAD in HPs. The treatment of PNH participants is an open-label study.
61919048|NCT01690338|ACTIVE_COMPARATOR|rocuronium|Patients who will be performed general anesthesia and tracheal intubation. Rocuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
62118571|NCT03161327|OTHER|ABI|ABI will be performed in patient
62118572|NCT03105219|EXPERIMENTAL|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
62118573|NCT03105219|SHAM_COMPARATOR|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
62677777|NCT06245603|EXPERIMENTAL|Arm A (interventional arm)|patients receive Hydeal Cyst intravesical instillations during the BCG or MMC therapy period.
62677778|NCT06245603|NO_INTERVENTION|Arm B (control arm)|patients receive only standard therapy (BCG or MMC).
62677779|NCT01193231||Acuvail 0.45%|Each subject will be randomized to the eye that they will use Acuvail in for 3 days after PRK
62677780|NCT01193231||Systane Ultra Preservative Free Tears|Each subject's contralateral eye (other eye) will use Sytane for 3 days after PRK surgery.
62677781|NCT01064622|ACTIVE_COMPARATOR|Arm I (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients are unblinded and may crossover to arm II.
62677782|NCT01064622|EXPERIMENTAL|Arm II (gemcitabine hydrochloride and vismodegib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62677783|NCT05215561||Cosentyx|Cosentyx for Subcutaneous Injection
62677784|NCT06347744|PLACEBO_COMPARATOR|Placebo Control 1|Rest Product Form 1 - control
62677785|NCT06347744|EXPERIMENTAL|Active Product 1.1|Rest Product Form 1 - active product 1
62677786|NCT06347744|PLACEBO_COMPARATOR|Placebo Control 2|Rest Product Form 2 - control
62677787|NCT06347744|EXPERIMENTAL|Active Product 2.1|Rest Product Form 2 - active product 1
62677788|NCT02957227||1|cohort 1: Older adults with memory impairment
61919049|NCT04333043||Hearing Aids|Hearing Aids use
61919050|NCT06010875|EXPERIMENTAL|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62118574|NCT03686891|EXPERIMENTAL|Experimental|Skin prick tests with four native legumes
62677789|NCT02957227||2|cohort 2: Age matched healthy controls
62677790|NCT04883086||diabetic group ( Case)|Total of 91 participants diagnosed with diabetes type 2
62677791|NCT04883086||Non diabetic group (control)|Total of 91 participants healthy and not diagnosed with diabetes Mellitus
62677792|NCT05336721|EXPERIMENTAL|Experimental: Chiauranib + capecitabine|Patients receive the combined treatment of Chiauranib plus capecitabine, 21 days as a cycle until objective disease progression.
62677793|NCT06077071|EXPERIMENTAL|ViewRay MRidian|Participants will receive five (5) doses of radiation therapy over four (4) weeks. The first dose will be given during week 1; after at least 36 hours from the first dose, participants will receive the second dose. The remaining doses will be three (3) doses will be administered once per week during weeks 2, 3, and 4. The treatment plan may change at the discretion of the treating physician. Participants will have three additional doses each week in Weeks 2, 3, and 4.
61919051|NCT06010875|EXPERIMENTAL|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
61919052|NCT00260611|EXPERIMENTAL|Oxaliplatin and Taxotere|Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or \>50% increase in serum PSA.
61919053|NCT02265601|EXPERIMENTAL|computer-based decision aid|"Making Your Wishes Known: Planning Your Medical Future- Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team."
61919054|NCT02265601|ACTIVE_COMPARATOR|standard care|paper/pencil living will form
61919055|NCT06461429|EXPERIMENTAL|Pregnancy Domain 01: Antibiotics in preterm prelabour rupture of membranes (PPROM)|"ClinicalTrial.gov Trial Registration: (Not yet submitted)~Population: Pregnant women and people with PPROM \<37 weeks' gestation and active neonatal management anticipated.~Interventions: Randomised to receive routinely used broad-spectrum antibiotic prophylaxis"
61919056|NCT06461429|EXPERIMENTAL|Neonatal Domain 01: Caffeine therapy for prevention of apnoeas of prematurity|"ClinicalTrial.gov Trial Registration: (Not yet submitted)~Population: Very preterm infants born \<32 weeks' gestation, up to 10 days old, with any clinical indication to commence caffeine treatment (any of: prevention of apnoea, treatment of apnoea, or with the aim of improving longer-term outcomes.~Interventions: Randomised to receive high, medium and low-dose caffeine citrate."
61919057|NCT01856764|EXPERIMENTAL|0.5% Roflumilast Cream|Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
61919058|NCT01856764|PLACEBO_COMPARATOR|Vehicle Cream|Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
61919059|NCT03185117||All patients|Adult patients scheduled to undergo a total knee arthroplasty or total hip arthroplasty, who give written informed consent to participate in the study.
61919060|NCT00862108|EXPERIMENTAL|Methylphenidate|
61919061|NCT01967784|EXPERIMENTAL|Study Group|Participants age 9 to 17 years will receive a dose of Quadrivalent Influenza Vaccine
61919062|NCT04597372|EXPERIMENTAL|Tamsulosin|"10 capsules will be distributed to subjects to be taken daily. Each capsule contains 0.4mg of Tamsulosin. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
61919063|NCT04597372|PLACEBO_COMPARATOR|Placebo|"10 capsules will be distributed to subjects to be taken daily. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
61919064|NCT00003930|EXPERIMENTAL|Arm 1|Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.
61919065|NCT02632903|EXPERIMENTAL|Intravenous Zoledronic Acid|Intravenous Zoledronic Acid 0.025mg/kg at baseline and 6 months
61919066|NCT06197399|EXPERIMENTAL|Detethering Surgery|Participants in this arm will undergo detethering surgery, a traditional surgical intervention that involves releasing the spinal cord from its abnormal attachment. All surgeries will be performed by trained and experienced neurosurgeons following standardized protocols.
62118575|NCT04016870|ACTIVE_COMPARATOR|New Device|New pacemakers will be sourced from pacemaker manufacturers.
62118576|NCT04016870|EXPERIMENTAL|Reconditioned Device|Donated devices are inspected according to specific protocols that evaluate physical and electrical (battery longevity) suitability for future use. Devices deemed to be acceptable are shipped to a third-party vendor (NEScientific) for disassembly, cleaning and re-sterilization.
62118577|NCT05657795|NO_INTERVENTION|Manual oxygen control|Standard ventilation with inspired oxygen concentration adjusted manually as per unit's protocol.
62118578|NCT05657795|OTHER|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|Ventilation with Oxygenie software (closed-loop automated oxygen control system), adjusted by clinical staff as necessary
62118579|NCT05232669|ACTIVE_COMPARATOR|Cocoa extract + multivitamin|
61919067|NCT06197399|EXPERIMENTAL|Spinal Column Shortening Surgery|Participants in this arm will undergo spinal column shortening surgery, a surgical technique aimed at reducing tension on the spinal cord by shortening the vertebral column. All surgeries will be conducted by trained and experienced neurosurgeons following standardized protocols. Postoperative care will be similar in both arms to minimize confounding variables.
61919068|NCT05009082|ACTIVE_COMPARATOR|Arm 1|Chemotherapy followed by maintenance with niraparib
61919069|NCT05009082|ACTIVE_COMPARATOR|Arm 2|Chemotherapy in combination with bevacizumab followed by maintenance with bevacizumab and niraparib
61919070|NCT01253330|NO_INTERVENTION|Comparison 1st|Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
61919071|NCT01253330|EXPERIMENTAL|Participant 1st|Enrollment in the CMSText website text messaging system during first 3 months of study participation.
61919072|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
62118580|NCT05232669|ACTIVE_COMPARATOR|Cocoa extract + multivitamin placebo|
62118581|NCT05232669|ACTIVE_COMPARATOR|Cocoa extract placebo + multivitamin|
62118582|NCT05232669|PLACEBO_COMPARATOR|Cocoa extract placebo + multivitamin placebo|
62306427|NCT01864135|EXPERIMENTAL|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
62306428|NCT01872351||pre and 12 months post ENT|"Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.~ENT consists of:~Daily conditioning exercise: 35-40 minutes~Nutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) ½ tab bid.~Diet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
62306429|NCT02614846|EXPERIMENTAL|Hetrombopag Olamine|All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.
62306430|NCT03659435|EXPERIMENTAL|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
62306431|NCT03659435|ACTIVE_COMPARATOR|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
62306432|NCT00932464|EXPERIMENTAL|1|Neratinib Fasted
62306433|NCT00932464|EXPERIMENTAL|2|Neratinib Fed
62306434|NCT06673355|EXPERIMENTAL|patients will receive frameworks made of high-performance polymer|patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon, the framework will be digitally produced by the milling technology using a dental CNC machine. the bone changes and occlusal wear will be assessed at the time of insertion (as a baseline), after 6 months and after 12 months.
62306435|NCT06673355|ACTIVE_COMPARATOR|patients will receive frameworks made of porcelain fused to titanium|patients will receive frameworks made of porcelain fused to titanium, the titanium will be produced digitally by 3d printing using the selective laser melting technology. Bone changes and wear of occlusal surfaces will be assessed at time of insertion (baseline, after 6 months and after 12 months
62306436|NCT02221427|ACTIVE_COMPARATOR|Static labour progression curve (F)|Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
62306437|NCT02221427|EXPERIMENTAL|Dynamic progression curve (Z)|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
62306438|NCT02986451|EXPERIMENTAL|Intervention|All patients received clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Dexamethasone (40 mg) was given orally on days 1, 8, 15, and 22. Clarithromycin (500 mg) was given orally twice daily.Lenalidomide (25 mg) was given orally daily on days 1 to 21
62118583|NCT00969371|EXPERIMENTAL|Lenstec Tetraflex IOL implantation|patients in Study arm received TetraFlex Lens
62118584|NCT00969371|ACTIVE_COMPARATOR|Control IOL|commercially approved PCIOL implanted
62118585|NCT00626418|PLACEBO_COMPARATOR|1|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
62306439|NCT00964418|EXPERIMENTAL|IDeg|
62306440|NCT00964418|ACTIVE_COMPARATOR|IGlar|
62306441|NCT04100421||Mild renal injury|CKD patients with eGFR ≥ 60 ml∙min-1∙ (1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
62306442|NCT04100421||Moderate renal injury|CKD patients with eGFR between 30 ml∙min-1∙(1.73 m2)-1 to 60 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
62306443|NCT04100421||Severe renal injury|CKD patients with eGFR \< 30 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
62306444|NCT04100421||Hemodialysis|uremic patients on hemodialysis therapy
62306445|NCT04100421||Peritoneal dialysis|uremic patients on peritoneal dialysis
62306446|NCT04100421||Healthy control|Healthy volunteers with no history of kidney diseases or any chronic diseases which may lead to renal injury.
62474153|NCT00378547|EXPERIMENTAL|Paracetamol + Pregabalin|Oral paracetamol 1g + oral pregabalin 300 mg + placebo
62118586|NCT00626418|ACTIVE_COMPARATOR|2|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
62474154|NCT00378547|EXPERIMENTAL|Paracetamol + pregabalin + dexamethasone|Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg
62474155|NCT01859858|EXPERIMENTAL|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
62474156|NCT01859858|EXPERIMENTAL|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
62474157|NCT06111170|ACTIVE_COMPARATOR|Compression dressing|Compression dressing was applied to one of the eyelids which was chosen by randomization postoperatively
62306447|NCT03737864|ACTIVE_COMPARATOR|Motivational Interview|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
62306448|NCT03737864|EXPERIMENTAL|Patient navigation and MI|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification plus patient navigation for 30 days, or until the patient is successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
62306449|NCT04520789|SHAM_COMPARATOR|RD control group|Conventional Surgery for Retinal Detachment
62306450|NCT04520789|EXPERIMENTAL|RD treatment group1|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study
62474158|NCT06111170|NO_INTERVENTION|no dressing|No dressing was applied on the other eyelid (control group)
62118587|NCT06112977|ACTIVE_COMPARATOR|Immediate prepectoral implant-based breast reconstruction without surgical mesh.|Prepectoral implant (expander or fixed volume) breast reconstruction without mesh
62118588|NCT06112977|ACTIVE_COMPARATOR|Immediate prepectoral implant- based breast reconstruction with surgical mesh|Prepectoral implant (expander or fixed volume) breast reconstruction with mesh (biological or synthetic)
62118589|NCT03460756|EXPERIMENTAL|Ganaxolone|Oral
62118590|NCT03460756|PLACEBO_COMPARATOR|Placebo|Oral
62118591|NCT01970618|EXPERIMENTAL|Part A: single dose escalation (healthy subjects)|
62118592|NCT01970618|EXPERIMENTAL|Part B: 7 day repeat dose (healthy subjects)|
62118593|NCT01970618|EXPERIMENTAL|Part C: 14 day repeat dose (COPD patients)|
62118594|NCT06547164|EXPERIMENTAL|Part A: Midazolam + Camizestrant|Participants will receive a single oral dose of midazolam on Day 1 in Period 1, followed by oral dose of camizestrant OD from Day 2 to Day 6 in Period 2, and then single oral dose of midazolam with camizestrant on Day 7 with PK sampling on Day 7 to Day 8 in Period 3.
62118595|NCT06547164|EXPERIMENTAL|Part B: Camizestrant + Carbamazepine|Participants will receive a single oral dose of camizestrant on Day 1 with PK sampling on Day 1 to Day 4 in Period 1, followed by low oral doses of carbamazepine BID on Day 4 to Day 6, mid oral doses of carbamazepine BID on Day 7 to Day 9 and high oral doses of carbamazepine BID on Day 10 to Day 24 with single oral dose of camizestrant on Day 22 with PK sampling on Day 25 in Period 2.
62118596|NCT02798835|ACTIVE_COMPARATOR|Adductor Canal block|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
62118597|NCT02798835|ACTIVE_COMPARATOR|Adductor canal block with dexamethasone|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
62474159|NCT03899077|ACTIVE_COMPARATOR|Arm A|The standard hormonal treatment in combination with salvage radiotherapy is ADT by a LHRH agonist or antagonist for 24 weeks. LHRH agonists and antagonists include leuprolide, goserelin, triptorelin, and degarelix.
62474160|NCT03899077|EXPERIMENTAL|Arm B|Patients will receive 6 cycles (each cycle is 30 days) of the study drug (4x 60mg tablets daily in a single intake).
61919073|NCT05165745|OTHER|Cisgender Women and Trans Individuals (CWTI)|Cisgender women and trans individuals (CWTI) who are taking PrEP, have considered and decided not to take PrEP, or who have discontinued PrEP.
61919074|NCT02669654|EXPERIMENTAL|Day-care management of Severe Pneumonia|management in Day-care clinic
62118598|NCT02798835|ACTIVE_COMPARATOR|Adductor canal catheter|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
62118599|NCT04878991||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the study embryologist. The embryo transfer outcome will be compared to the Metabolomics result to determine the NPV and PPV of Metabolomics vs implantation."
62118600|NCT06676800|EXPERIMENTAL|Yiqi Gubiao pill|
62118601|NCT06676800|PLACEBO_COMPARATOR|Yiqi Gubiao Pill placebo|
62118602|NCT04276402|EXPERIMENTAL|Right side of the maxilla|
62118603|NCT04276402|NO_INTERVENTION|Left side of the maxilla|
62306451|NCT04520789|ACTIVE_COMPARATOR|RD treatment group2|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study, postoperative intervention
62306452|NCT06394063|EXPERIMENTAL|Telitacicept|Telitacicept 160mg is administered subcutaneously every other week for 26 times on the background of standard therapy.
62306453|NCT06394063|PLACEBO_COMPARATOR|Placebo|Placebo is administered subcutaneously every other week for 26 times on the background of standard therapy.
62306454|NCT04169477|EXPERIMENTAL|cTENS-mTENS|Patients randomized in this arm will test cTENS mode first, the subjects will be crossed over to the mTENS form
62306455|NCT04169477|EXPERIMENTAL|mTENS-cTENS|Patients randomized in this arm will test mTENS mode first, the subjects will be cross over to the cTENS mode
62474161|NCT04932863||Subjects with cancer of any type and stage under active or prior medical treatment|BNT162b2 mRNA Covid-19 Vaccine as two injections, 21 days apart, of 30 μg per dose in the deltoid muscle.
62118604|NCT02098382||Dilapan-S|125 Patients with / without caesarean section in their medical history
62118605|NCT01924767|EXPERIMENTAL|BI 10773 (dose group 3)|multiple doses as tablet
62474162|NCT05362786|EXPERIMENTAL|Dose Arm 1|Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) in two intravenous infusions of 100x10\^6 cells at time zero and three months
62474163|NCT05362786|EXPERIMENTAL|Dose Arm 2|Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) single intravenous infusion of 200x10\^6 cells
62474164|NCT06422845|EXPERIMENTAL|Dissolve AV Peripheral Scoring Drug-coated Balloon|Subjects in this group are treated with Dissolve AV Peripheral Scoring Drug-coated Balloon dilatation catheter
62474165|NCT05522361|EXPERIMENTAL|Open-label crossover|Participants crossover to 36 months of open-label risdiplam mono therapy following a comparable period of nusinersen treatment.
62474166|NCT02603003|PLACEBO_COMPARATOR|Cisplatin|Cisplatin
62118606|NCT01924767|EXPERIMENTAL|BI 10773 (dose group 4)|multiple doses as tablet
62118607|NCT01924767|EXPERIMENTAL|BI 10773 (dose group 1)|multiple doses as tablet
62118608|NCT01924767|EXPERIMENTAL|BI 10773 (dose group 2)|multiple doses as tablet
62118609|NCT06261996|ACTIVE_COMPARATOR|Fospropofol group|Fospropofol is administered to patients after admission to the roomat a pumping rate of 1 mg/kg/h.
62118610|NCT06261996|PLACEBO_COMPARATOR|Propofol group|Propofol is administered after admission to the room at a pumping rate of 0.5 mg/kg/h.
62118611|NCT06328985|EXPERIMENTAL|Rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
62118612|NCT06328985|ACTIVE_COMPARATOR|Rehabilitation therapy+Nasogastric tube feeding|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
62118613|NCT05095246|EXPERIMENTAL|Cohort 1 (KB407)|A single dose of KB407 administered on Day 0
62118614|NCT05095246|EXPERIMENTAL|Cohort 2 (KB407)|Two (2) doses of KB407 administered at Day 0 and Day 14
62118615|NCT05095246|EXPERIMENTAL|Cohort 3 (KB407)|Four (4) doses of KB407 administered at Day 0, Day 7, Day 14, and Day 21
62118616|NCT05588193|EXPERIMENTAL|Post Visit Outreach (PVO)|Outreach by trained patient navigators/educators after patients' ED visit for education, counseling, linkage to preventive/sexual health care.
62118617|NCT05588193|EXPERIMENTAL|Tele-Sexual Healthcare (TSH) visit during the ED visit|Tele-sexual health visit with a specialist offered during the ED visit to patients.
61919075|NCT02669654|NO_INTERVENTION|Existing Treatment Centre (ETC)|Severe Pneumonia management in Existing Treatment Centre
62118618|NCT02599818|EXPERIMENTAL|NavSTAR|Participants in this arm will receive services from the NavSTAR Patient Navigation team. The Patient Navigator will work with patients for up to 3 months post-hospital discharge to resolve internal barriers (e.g., ambivalence about treatment; low motivation; competing life demands, etc.) and external barriers (e.g., lack of transportation; lack of ID card, etc.) to appropriate utilization and engagement in addiction treatment and medical care. Interventions include motivational interventions and patient navigation with proactive case management, tailored to participants' specific needs.
62118619|NCT02599818|NO_INTERVENTION|TAU (Treatment as Usual)|Participants in this arm will receive usual care, which includes in-hospital services from a multidisciplinary substance use disorder consultation liaison team.
62118620|NCT06376513|OTHER|Patients who have undergone penile prosthesis implantation > 3 months ago and their partner|Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
62118621|NCT02550808||Heart failure|
62118622|NCT02550808||Chronic obstructive pulmonary disease|
62118623|NCT02550808||Chronic kidney disease|
62118624|NCT02550808||Malignancy|
62118625|NCT02550808||Controls|
62118626|NCT05786898|EXPERIMENTAL|NEAR TSA|Neuropsychological and Educational Approach of Cognitive Remediation, adapted for autism (NEAR-TSA)
62118627|NCT05570188|EXPERIMENTAL|Treatment group|Patients will get infused with anti-CD19 CAR-NK cells within 1 week after hematopoietic stem cell infusion.
62118628|NCT05078424|EXPERIMENTAL|CBT Treatment group|This group receives CBT interventions that aim to improve mental well-being, depressive and anxiety symptoms in young people.
62118629|NCT05078424|NO_INTERVENTION|Wait-list Control group|This group does not receive CBT intervention but will receive appropriate intervention after the CBT treatment group and follow-up phases complete.
62306456|NCT02741531|EXPERIMENTAL|Intervention|Patients in this group will have their bladder filled with 150 cubic centimeters (cc) of saline solution prior to being moved to the PACU.
62474167|NCT02603003|PLACEBO_COMPARATOR|Pemetrexed|Pemetrexed
62474168|NCT02603003|EXPERIMENTAL|Jinfukang|Jinfukang
62474169|NCT03769025|EXPERIMENTAL|Remote Observed Dosing|One group will be assigned to Remote Observed Dosing (ROD) and will have all of their Suboxone® doses remotely observed. The intervention is remote observed dosing
62474170|NCT03769025|ACTIVE_COMPARATOR|Attention Control|The attention control (AC) group will not have their dosing observed but will send a text message confirming they have taken their study medication to the study team daily matching contact with the study team. Text message confirming that they have taken their study medication is the intervention
62306457|NCT02741531|NO_INTERVENTION|Control|patients in this group will have their bladders drained completely prior to being moved to the PACU as is the current standard of care.
62306458|NCT03069638|EXPERIMENTAL|Intranasal dexmedetomidine|Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
62306459|NCT03069638|ACTIVE_COMPARATOR|Nitrous oxide inhalation|Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
62306460|NCT02489630|EXPERIMENTAL|Ketamine|0.1 mg/kg ketamine + opiate analgesic
62306461|NCT02489630|PLACEBO_COMPARATOR|Placebo|0.1 mL/kg normal saline + opiate analgesic
62306462|NCT00262106|PLACEBO_COMPARATOR|Placebo|placebo
62306463|NCT00262106|ACTIVE_COMPARATOR|PRO 2000/5 Gel 0.5%|PRO 2000/5 Gel 0.5%
62306464|NCT00069121|ACTIVE_COMPARATOR|5-Fluorouracil/Leucovorin (5-FU/LV)|Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m\^2 IV bolus injection + 5-FU 425 mg/m\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m\^2 by two-hour IV infusion + 5-FU 500 mg/m\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).
62306465|NCT00069121|EXPERIMENTAL|Capecitabine in Combination with Oxaliplatin (XELOX)|Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).
62306466|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) \[n=30\] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
62306467|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) \[n=30\] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
62306468|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \\ prominent symptom/sign\[n=30\]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
62474171|NCT02334644|EXPERIMENTAL|1|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
62118630|NCT06676865||adult Diabetic patients scheduled for surgery under general anesthesia.|"Were included patients with known cases of diabetes mellitus, aged more than 18 years, undergoing surgery under general anesthesia with endotracheal intubation.~This study excluded patients with physical or intellectual disabilities preventing cooperation, Malformations, trauma, tumors, or infections of the maxillofacial region and upper airways, a history of burns or cervicofacial irradiation, and neurosurgical conditions causing temporomandibular pseudoankylosis. Additional exclusions included patients with conditions causing hand joint stiffness (e.g., carpal tunnel syndrome, Dupuytren's disease, scleroderma, rheumatoid arthritis), restricted cervical mobility (due to osteoarthritis, ankylosing spondylitis, or cervical trauma), a history of difficult intubation as well as pregnancy (including up to six weeks postpartum)"
62306469|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) \[n=30\] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
62306470|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) \[n=30\]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
62306471|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign \[n=30\]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
62306472|NCT02803034|EXPERIMENTAL|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62306473|NCT06370247|OTHER|patients With T2DM, willing to fast Ramadan and treated with SGLT2 inhibitors|Egyptian male and female Muslim patients, aged ≥ 18 years old. With T2DM, willing to fast Ramadan and treated with SGLT2 inhibitors (empagliflozin, dapagliflozin) as an add-on to metformin or other oral hypoglycemic agent.
62306474|NCT02621385|EXPERIMENTAL|Tradipitant|One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16
62474172|NCT02334644|PLACEBO_COMPARATOR|2|Placebo
62474173|NCT01794715|EXPERIMENTAL|Ultrasound performed by nurses|Examinations including ultrasound examinations
62474174|NCT01794715|ACTIVE_COMPARATOR|Ultrasound not performed|Examinations not including ultrasound examinations, otherwise active
62474175|NCT06558656|EXPERIMENTAL|Fasting-Fed|Fasting-Fed
62474176|NCT06558656|EXPERIMENTAL|Fed-Fasting|Fed-Fasting
62474177|NCT05801484|EXPERIMENTAL|Linezolid continuous infusion|In the intervention arm, Linezolid is administered 600 mg as loading dose as an infusion lasting one hour (flow rate 300 ml/h), followed by continuous infusion of 1200 mg linezolid over 24 hours (flow rate 25 ml/h) which is immediately initiated. The continuous infusion is administered until the end of the treatment.
62306475|NCT03177252|EXPERIMENTAL|Scalp block with lidocaine and bupivacaine|"* Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine~* Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
62474178|NCT05801484|ACTIVE_COMPARATOR|Linezolid Intermittent administration|In the comparator arm, 600 mg dose of Linezolid is administered as one-hour infusion (flow rate 300 ml/h). Two doses at 12-h intervals are infused until the end of the treatment.
62474179|NCT03144453|EXPERIMENTAL|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
62474180|NCT03144453|ACTIVE_COMPARATOR|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
62474181|NCT02471820|EXPERIMENTAL|Lenalidomide, adriamycin & dexamethasone|Lenalidomide 25 mg administered orally for the first 21 days of each 28-day-cycle, plus Adriamycin i.v. on days 1,2,3 \& 4 of every cycle, plus Dexamethasone 40 mg orally on days 1, 8, 15 \& 22 of every cycle for 4 cycles
62306476|NCT03177252|PLACEBO_COMPARATOR|Scalp block with saline|"* Scalp block with saline~* Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
62474182|NCT05675033|OTHER|study arm|This is a single arm study.
62474183|NCT05229133|EXPERIMENTAL|Refractive correction using CLEAR|Subjects 18+ years old with myopic (-0.50 to -10.00 D) astigmatism (up to -5.00 D) treated bilaterally with FEMTO LDV Z8 using CLEAR application.
61919076|NCT00783770||30-33 weeks|mother infant pairs with gestation of 30-33 weeks
61919077|NCT00783770||34-37 weeks|mother infant pairs with gestation of 34-37 weeks
61919078|NCT00783770||38-42 weeks|mother infant pairs with gestation of 38-42 weeks
62474184|NCT02729714|ACTIVE_COMPARATOR|Suvorexant or Placebo|10 Suvorexant or Placebo mg orally at bedtime with an optional up-titration to 15 mg Suvorexant or Placebo orally at bedtime after 2 weeks. The first treatment period will be 4 weeks. Subjects will be randomized 1;1 to receive Suvorexant or matching placebo. Followed by a 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant
61919079|NCT01467427|EXPERIMENTAL|NNC-0156-000-0009|
61919080|NCT02189954|ACTIVE_COMPARATOR|Group Routine Care|The placement according to the manufacturer's instructions.
61919081|NCT02189954|EXPERIMENTAL|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
61919082|NCT04249609|EXPERIMENTAL|High Carbohydrate Meals Around Exercise|On day 1, high CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will consist of pasta, meat ball and orange juice. On the day 2, participants will exercise for 60 minutes and then in 60 minutes will consume morning meal, providing 30% of their total daily energy requirements. Morning meal will consist of oats, skimmed-milk, banana and seedless raisins.
61919083|NCT04249609|EXPERIMENTAL|Low Carbohydrate Meals Around Exercise|On day 1, low CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will based on burger, cheese, mushroom, nuts, and butter.On the day 2, participants will exercise fro 60 minutes and then in 60 will consume morning meal, providing 30% of their total daily energy requirements. Meal will consist of white bread, egg, cheese, olive oil, nuts, and olives.
62474185|NCT02729714|PLACEBO_COMPARATOR|Placebo or Suvorexant|First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
62474186|NCT03749252|EXPERIMENTAL|CNS Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing CNS contrast-enhanced MRI
62474187|NCT03749252|EXPERIMENTAL|CNS Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing CNS contrast-enhanced MRI
62306477|NCT01755481|EXPERIMENTAL|Probiotics F19|F19 in an infant formula
62306478|NCT01755481|EXPERIMENTAL|Whey protein concentrate|Whey protein concentrate in an infant formula
62306479|NCT00244218|EXPERIMENTAL|Treatment Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
62306480|NCT00244218|PLACEBO_COMPARATOR|Control Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
62306481|NCT04652024|NO_INTERVENTION|CONTROL GROUP|Girls in the control group received pelvic floor muscle exercise (kegel exercise) daily in the outpatient clinic 12 weeks.
62474188|NCT03749252|EXPERIMENTAL|CNS Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing CNS contrast-enhanced MRI
62677794|NCT04138082|EXPERIMENTAL|High-dB Environment|While performing the spinal anesthesia, the participants were exposed to a pre-recorded soundtrack of one of the investigators' operating rooms while the anesthesiology team was performing a spinal anesthesia. It included instruments noise and discussion but alarms, pulse oximetry and discussion with the patient were removed. The level of the soundtrack was set to be at 70 dB with peaks up to 100 dB, this level was recorded for every participant with Iphone™ application SoundMeter X 10.3 by Faber Acoustical, which has been both choosed in accordance with similar studies. The average noise was measured using the LEq value on a ''A'' scale (dB(A)) which correlate with frequencies perceived by the human ear. Speakers where placed at each corner of the room. Since literature describe that noise can initially enhance performance but is a transitory effect, the investigators decided to expose the experimental group to the maximum level of noise without any gradation.
62118631|NCT02398565||Cohort|"Patients with a history of ventral hernia repair (umbilical/epigastric and incisional) with subsequent pregnancy~Ventral hernia repair - perioperative factors of interest:~- mesh vs sutured repair, age, planned vs emergency repair, open vs laparoscopic approach,~Pregnancy and delivery - factors of interest:~- vaginal vs caesearan section, single vs multiple pregnancy~Subgroup of patients with mesh repair:~- subanalysis on main attributes~Subgroup of patients with sutured repair:~- mono- vs multifilament, slowly vs rapidly absorbable"
62118632|NCT01694823|EXPERIMENTAL|CS-ACI|"Group/Cohort Label： pretherapy post-treatment~Group/Cohort Description ：The CS-ACI is used to prepare cell sheet and implant to the Cartilage defects.The arm of safety and efficacy are compared preoperative observation with postoperative observation."
62118633|NCT06105710||Asthma|Participants with a history of asthma
62118634|NCT06105710||Healthy Controls|Participants without a history of asthma
62306482|NCT04652024|EXPERIMENTAL|STUDY GROUP|Girls in the study group received the same physical therapy program given to the control group in addition to anorectal biofeedback for six sessions per week. in addition to kegel exercise
62118635|NCT01185769|EXPERIMENTAL|High fat|500 mg of tocotrienol will be administered at single dose after consumption of high fat diet
62118636|NCT01185769|EXPERIMENTAL|Low fat|500 mg of tocotrienol will be administered at single dose after consumption of low fat diet
62118637|NCT05824546|EXPERIMENTAL|uSINE-PAMS-guided|Patients will undergo LP using uSINE-PAMS-guided technique
62306483|NCT00947154|EXPERIMENTAL|Open-label aripiprazol|Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
62306484|NCT03348683|EXPERIMENTAL|Propranolol|2mg of IV push
62306485|NCT03348683|PLACEBO_COMPARATOR|Placebo|an equivalent quantity in milliliters of normal saline
62306486|NCT01900548|EXPERIMENTAL|Whey protein (HPHL)|Whey protein supplementation and resistance training for four month.
62306487|NCT01900548|EXPERIMENTAL|Soy protein (HPLL)|Soy protein supplementation and resistance training for four month.
62306488|NCT01900548|PLACEBO_COMPARATOR|Placebo (P)|Maltodextrin supplementation and resistance training for four month.
62474189|NCT03749252|EXPERIMENTAL|Body Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
62474190|NCT03749252|EXPERIMENTAL|Body Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
62677795|NCT04138082|NO_INTERVENTION|Low-dB Environment|The control group performed the same spinal anesthesia simulation scenario but without any soundtrack. The ambient noise in the room was recorded with the same method for each participant.
62677796|NCT05882006||cases|IBD patients (including Crohn's disease and Ulcerative colitis)
62677797|NCT05882006||controls|Age, sex, and calendar-year matched controls sampled from non-IBD patients to be a round number of at least four times the number of cases
62306489|NCT02139410||IGF-1 1st and 2nd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
62306490|NCT02139410||IGF-1 3rd and 4rd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
62306491|NCT02694029|ACTIVE_COMPARATOR|ABC (Active Breathing Coordinator ), Then VRT|Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
62306492|NCT02694029|ACTIVE_COMPARATOR|VisionRT (VRT), Then ABC|VisionRT-based deep inspiration breath-hold to assist radiation therapy. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH
62306493|NCT02162979|EXPERIMENTAL|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
62474191|NCT03749252|EXPERIMENTAL|Body Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
62306494|NCT02162979|PLACEBO_COMPARATOR|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
62118638|NCT01691963|NO_INTERVENTION|Control group|"In the control group, anaesthesia will be induced in the same way as mentioned above for the intervention group. Also in this group, intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula. The glottic view will be scored in this position using the Cormack and Lehane classification system. If correct laryngoscope positioning cannot be achieved with a size 3 blade, a size 4 blade will be used. Hereafter, the patient's trachea will be intubated once the optimal view of the larynx had been obtained. Intubation attempts will be scored in the same way as mentioned above for the intervention group."
62118639|NCT01691963|EXPERIMENTAL|Epiglottic downfolding|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
62118640|NCT00355940|EXPERIMENTAL|1|
62118641|NCT00355940|ACTIVE_COMPARATOR|2|
62118642|NCT05756010|EXPERIMENTAL|interventional group|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach.
62118643|NCT05756010|SHAM_COMPARATOR|conrol group|General exercises
62118644|NCT05731466|OTHER|CardioMems (Clinical Indication)|Single Arm, CardioMems implantation on clinical indication. No control group. Every participant is his/her own control (longitudinal follow-up)
62118645|NCT03958734|OTHER|Low physical activity/fitness|Participants will be classified as into low-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
62118646|NCT03958734|OTHER|High physical activity/fitness|Participants will be classified as into high-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
62118647|NCT01230047|EXPERIMENTAL|Psychoeducational Course|In this arm, clients receive the psychoeducational course.
62118648|NCT01230047|NO_INTERVENTION|Treatment-as-usual/Waiting list|Clients assigned to this condition will receive treatment-as-usual (TAU) and be placed on a waiting list.
62118649|NCT04870645|EXPERIMENTAL|Diagnostic (advanced MRI)|Patients undergo conventional and advanced MRI over 60 minutes within 14 days before the start of scheduled brain radiation treatment. Patients then undergo 7 additional MRI over 60 minutes each between 4-16 weeks apart. Patients may receive gadolinium and/or iopamidol during MRI scans.
62118650|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
62118651|NCT06062212||Transpulmonary pressure group|
62118652|NCT04720014|EXPERIMENTAL|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training.
62118653|NCT00588809|EXPERIMENTAL|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
62118654|NCT01576523|EXPERIMENTAL|Low, then medium, C1-esterase inhibitor dose|
62118655|NCT01576523|EXPERIMENTAL|Medium, then low, C1-esterase inhibitor dose|
62306495|NCT00545818|EXPERIMENTAL|Group-1, Implant length 6 mm|Subjects treated with OsseoSpeed™ implant, length: 6 mm
62306496|NCT00545818|OTHER|Group-2, Implant length 11 mm|Subjects treated with OsseoSpeed™ implant, length: 11 mm
62306497|NCT00964795|EXPERIMENTAL|Open-label Intravitreal Aflibercept Injection|Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.
62306498|NCT04509089|EXPERIMENTAL|Experimental|Congestive heart failure patients scheduled for pulmonary artery catheterization (Swan-Ganz)
62118656|NCT01576523|EXPERIMENTAL|Medium, then high, C1-esterase inhibitor dose|
62306499|NCT01113528|EXPERIMENTAL|Regenerative therapy|
62118657|NCT01576523|EXPERIMENTAL|Low, then high, C1-esterase inhibitor dose|
62118658|NCT01576523|EXPERIMENTAL|High, then low, C1-esterase inhibitor dose|
62118659|NCT01576523|EXPERIMENTAL|High, then medium, C1-esterase inhibitor dose|
62118660|NCT06241989|EXPERIMENTAL|Intervention|The intervention group will receive health education supported by motivational interviewing.
62118661|NCT06241989|NO_INTERVENTION|Control|
62118662|NCT05218733|ACTIVE_COMPARATOR|G1 Group: (Erector Spinae Plane Block (ESPB) Group)|
62118663|NCT05218733|ACTIVE_COMPARATOR|G2 Group: (Intra thecal morphine (ITM) Group)|
62118664|NCT05218733|OTHER|G3 Group: (Control Group)|
62118665|NCT00748150|EXPERIMENTAL|1|
62118666|NCT03951649|EXPERIMENTAL|Occipital Nerve block|"1. Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.~2. Site of injection will be cleaned with an alcohol swab.~3. 5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.~4. After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved."
62306500|NCT01113528|PLACEBO_COMPARATOR|Sugar pill|
62677798|NCT04530552|EXPERIMENTAL|Treatment (apalutamide)|Patients receive apalutamide PO on study. Patients also undergo collection of blood samples throughout the study.
62677799|NCT00374985|EXPERIMENTAL|one arm|
62677800|NCT05618847|EXPERIMENTAL|active cycle of breathing technique with acapella|"Sit up with good posture to use the Acapella. Take in a fairly deep breath and hold it for about 3 seconds. Place the Acapella mouthpiece in your mouth. Seal your lips tightly around the mouthpiece.~Exhale as much as possible (but not to forcefully) through the mouthpiece. Keep your cheeks as firm as possible when you exhale. Try not to inhale through the device.~Repeat this maneuver for 10 breaths. Try to resist coughing during this phase. After these 10 blows, perform 3 huffs, then a big cough to bring the sputum up and out. Try not to swallow the mucus"
62677801|NCT05618847|ACTIVE_COMPARATOR|active cycle of breathing technique|Ask patient to breathe in and out gently through nose if he/she can. If patient breathe out through their mouth. Ask patient to let go of any tension in body with each breath out. Gradually try to make the breaths slower. Ask patient to take a long, slow, deep breath in, through nose. Try to keep chest and shoulders relaxed. Repeat 3-5 times. Huff is exhaling through an open mouth and throat instead of coughing. It helps move sputum up in airways so that patient can clear it in a controlled way. To 'huff' ask patient to squeeze air quickly from lungs, out through open mouth and throat, as if trying to mist up a mirror or glasses. Ask to use abdominal muscles to help squeeze the air out, but do not force it so much that cause wheezing or tightness in chest. Huffing should always be followed by breathing control.
62306501|NCT00376688|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62677802|NCT04645693||HIV Subjects with Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with no diagnosis of non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
61919084|NCT02895009|OTHER|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
62118667|NCT03951649|ACTIVE_COMPARATOR|Oral Acetaminophen/Caffeine Group|Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)
62677803|NCT04645693||HIV Subjects without Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with a diagnosis of one or more systemic non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
62306502|NCT02844738|EXPERIMENTAL|StroMed + platelet rich plasma (PRP)|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
62306503|NCT01720771|ACTIVE_COMPARATOR|Probiotic tablet|a tablet with three probiotic streptococci strains (S. uberis KJ2, S. oralis KJ3 and S. rattus JH145) at a concentration of 3x108 CFU
62677804|NCT06034314|EXPERIMENTAL|People with HIV (PWH) with Cannabis use|PWH with cannabis use
62677805|NCT06034314|EXPERIMENTAL|People without HIV (PWoH) with Cannabis use|PWoH with Cannabis use
62118668|NCT05339763|ACTIVE_COMPARATOR|radiation group|Those are patient with rectal cancer who underwent preoperative neoadjuvant chemo radiotherapy before surgery.
62118669|NCT05339763|ACTIVE_COMPARATOR|non radiation group|Those are patient with rectal cancer who did not receive preoperative neoadjuvant chemo radiotherapy before surgery.
62118670|NCT04795128|OTHER|IBI322|Single arm
62118671|NCT06448364|EXPERIMENTAL|Part 1A: PF-07329640 (αLTβR) Monotherapy|PF-07329640 (αLTβR) monotherapy at prescribed dose and frequency in 28-day cycles
62677806|NCT00358579|ACTIVE_COMPARATOR|Adrenaline|
62677807|NCT00358579|ACTIVE_COMPARATOR|Vasopressin|
62677808|NCT01204372|EXPERIMENTAL|Treatment|Gemcitabine - Trastuzumab - Erlotinib
62474192|NCT01434147|EXPERIMENTAL|induction chemotherapy + radiochemotherapy|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine induction chemotherapy: starts within 28 days after bioptical diagnosis. All patients are administered with capecitabine (Xeloda®) 1000 mg/m2 bid during 14 days (d1-d14), oxaliplatin 130 mg/m2 and bevacizumab (Avastin®) 7.5 mg/kg body weight on day 1; repetition days 22 and 43 (3 cycles) Combined radiochemotherapy: starts at the earliest one week after concluded third cycle of induction chemotherapy. Radiotherapy takes place on 5 x 5 days (dose: 1.8 Gy; cumulative dose: 45 Gy). For chemotherapy patients are administered with capecitabine (Xeloda®) 825mg/m² bid, on each radiation day during the first 4 weeks of radiochemotherapy.
62306504|NCT01720771|PLACEBO_COMPARATOR|Sugar pill|The same tablet but without active probiotic bacteria
62474193|NCT03545828||Good neurological outcome|CPC 1 and 2 at 6 month after ROSC
62474194|NCT03545828||Poor neurological outcome|CPC 3 to 5 at 6 month after ROSC
62474195|NCT02417298|ACTIVE_COMPARATOR|Ketamine|Ketamine 0.3 mg/kg intravenous push followed by ketamine infusion at 0.1 mg/kg/hr for 3 hours
62474196|NCT02417298|PLACEBO_COMPARATOR|Saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
62677809|NCT04595370|EXPERIMENTAL|AZD9977 Dose A + dapagliflozin 10 mg|Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.
62677810|NCT04595370|EXPERIMENTAL|AZD9977 Dose B + dapagliflozin 10 mg|Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.
62118672|NCT06448364|EXPERIMENTAL|Part 1B: PF-07329640 (αLTβR) + bevacizumab|PF-07329640 (αLTβR) + bevacizumab dose escalation in NSCLC and MSS CRC at prescribed dose and frequency in 28-day cycles
62306505|NCT00465569|EXPERIMENTAL|Active Treatment|Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
62677811|NCT04595370|EXPERIMENTAL|AZD9977 Dose C + dapagliflozin 10 mg|Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.
62677812|NCT04595370|EXPERIMENTAL|Dapagliflozin 10 mg|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
62677813|NCT02455856|EXPERIMENTAL|JNJ-42847922 plus Itraconazole|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6 and itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
62677814|NCT03468426|EXPERIMENTAL|BI 836880 + ezabenlimab|
62677815|NCT06253793||ASD Experimental group|Children with Autism Spectrum Disorder (ASD) enrolled in the DENVER protocol. Same chronological age (1.5 years to 5 years of age) than children with ASD NOT enrolled in the DENVER protocol. Those children will be recruited and tested at the Alps-Isere Hospital Center (Saint-Egreve, France)
62118673|NCT06448364|EXPERIMENTAL|Part 1C: PF-07329640 (αLTβR) + sasanlimab|PF-07329640 (αLTβR) + sasanlimab dose escalation in NSCLC, melanoma, UC, and MSS CRC at prescribed dose and frequency in 28-day cycles
62306506|NCT00465569|PLACEBO_COMPARATOR|Placebo|
62306507|NCT01626040||PEG-P prep|Children taking the one day polyethylene glycol powder preparation for outpatient colonoscopy
62118674|NCT06448364|EXPERIMENTAL|Part 2A: PF-07329640 (αLTβR) + bevacizumab|PF-07329640 (αLTβR) + bevacizumab dose expansion in NSCLC 2L+ and MSS CRC 2L+ at prescribed dose and frequency in 28-day cycles
62118675|NCT06448364|EXPERIMENTAL|Part 2B: PF-07329640 (αLTβR) + sasanlimab|PF-07329640 (αLTβR) + sasanlimab dose expansion in NSCLC, melanoma, UC, and MSS CRC at prescribed dose and frequency in 28-day cycles
62306508|NCT03530540|EXPERIMENTAL|Intervention|Active shockwaves
62474197|NCT02596100|EXPERIMENTAL|Tablet|80mg immediate release tablet
62474198|NCT02596100|EXPERIMENTAL|Capsule|80mg immediate release capsule
62306509|NCT03530540|PLACEBO_COMPARATOR|Placebo|Placebo shockwaves
62306510|NCT01287117|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
62306511|NCT01287117|EXPERIMENTAL|Omalizumab 75 mg|Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period.
62306512|NCT01287117|EXPERIMENTAL|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period.
62306513|NCT01287117|EXPERIMENTAL|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
62474199|NCT01196000|ACTIVE_COMPARATOR|Arm I|Patients undergo standard conventional laparoscopic resection.
62474200|NCT01196000|EXPERIMENTAL|Arm II|Patients undergo robotic-assisted laparoscopic resection.
62474201|NCT02658318||Pierre Robin Syndrome (PRS)|Cleft palate patients with the Pierre Robin Syndrome.
62677816|NCT06253793||ASD Control group|Children with Autism Spectrum Disorder (ASD) en NOT enrolled in the DENVER protocol. Same chronological age (1.5 years to 5 years of age) than children with ASD enrolled in the DENVER protocol. Those children will be recruited and tested at the Savoie Hospital Center (Chambery, France) and at the Grenoble University Hospital (Grenoble, France).
62677817|NCT06253793||TD control group|Typically developing (TD) children with the same developmental age than children with ASD. Those children will be recruited and tested at the University Grenoble Alps (Grenoble, France).
62677818|NCT03434301|ACTIVE_COMPARATOR|Mesh with absorbable tack fixation|Mesh with absorbable tack (ReliaTack™) fixation
62677819|NCT03434301|ACTIVE_COMPARATOR|Mesh with non-absorbable fixation|Mesh with non-absorbable (Protack™) fixation
62306514|NCT02054650|EXPERIMENTAL|Osteopathic Manual Treatment (OMT)|The OMT protocol will be delivered following an examination for somatic dysfunction at each treatment session. The protocol will target the thoracic, lumbosacral, iliac, and pubic regions using the following techniques: high-velocity, low-amplitude thrusts; moderate-velocity, moderate-amplitude thrusts; soft tissue including stretching, kneading, and pressure; myofascial stretching and release; counterstrain; muscle energy; and other optional techniques as time permits and indicated. The intervention will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
61919085|NCT02895009|EXPERIMENTAL|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. In experimental group, TR Band deflation is commenced at the 1st hour with 3 mL air released, and at the 2nd hour with 5ml, and at the 3rd hour with the remainder air in the bladder, and the TR Band is removed at the 12th hour.
61919086|NCT05909527|EXPERIMENTAL|Treatment group|"Dose escalation: After enrollment ,Participants complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climming test: 0.50E6/kg±20%, 1.00E6/kg±20%、2.00E6/kg±20%.~Dose Expansion: During or after the dose increase process, if a certain dose group is determined to have preliminary anti-tumor effects and controllable safety, it can be extended at this dose level to further evaluate the tolerance and safety of CD7 CAR-T injection, and to preliminarily evaluate its effectiveness."
61919087|NCT03642093|EXPERIMENTAL|Frail|Subjects assessed and determined to be Frail and meet trial eligibility criteria will be enrolled on Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
61919088|NCT03642093|ACTIVE_COMPARATOR|Not Frail|Subjects assessed and determined to be Not Frail and meet trial eligibility criteria will be enrolled on Not Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
61919089|NCT03934697|EXPERIMENTAL|Imaginal Exposure Session|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
61919090|NCT01563146||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2006 and May the 31st 2007.
61919091|NCT01661985|ACTIVE_COMPARATOR|Drug: Azithromycin 1g|Azithromycin 1 g,single dose (per os)
61919092|NCT01661985|ACTIVE_COMPARATOR|Drug: Doxycycline/lymecycline 9/10days|Tetracycline either as Doxycycline or during June and July lymecycline (due to lower risk of photo-sensitivity) given for treatment in 9(10)days (per os).
61919093|NCT01661985|ACTIVE_COMPARATOR|Azithromycin 1.5 g|Patients not randomized but receiving the first line treatment when a confirmed Mg infection
61919094|NCT03413943|EXPERIMENTAL|explicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
61919095|NCT03413943|EXPERIMENTAL|implicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
61919096|NCT03413943|SHAM_COMPARATOR|sham gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
62118676|NCT06448364|EXPERIMENTAL|Part 2C: PF-07329640 (αLTβR) + SOC|PF-07329640 (αLTβR) + SOC (anti-PD-1+ platinum-based chemo) dose expansion for αPDx-naïve NSCLC 1L at prescribed dose and frequency in 28-day cycles
62474202|NCT02658318||non-PRS|Cleft palate patients without the Pierre Robin Syndrome.
61919097|NCT03291418|EXPERIMENTAL|ATB-346 OR Placebo|Intervention: Drug: ATB-346 dosed orally at 250 mg once daily for 14 days Intervention: Drug: Placebo (for ATB-346) dosed once daily for 14 days
61919098|NCT03291418|ACTIVE_COMPARATOR|Naproxen sodium|Intervention: Drug: naproxen sodium dosed orally at 550 mg twice daily for 14 days
61919099|NCT02480725||CJD (Creutzfeldt-Jakob disease) patients|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
62118677|NCT06448364|EXPERIMENTAL|Part 2D: PF-07329640 (αLTβR)|PF-07329640 (αLTβR) dose expansion in advanced solid tumors at prescribed dose and frequency in 28-day cycles
62118678|NCT04663464|EXPERIMENTAL|abaloparatide-SC (Period 1) followed by abaloparatide-sMTS (Period 2)|Abaloparatide-SC injection (Period 1) followed by abaloparatide-sMTS application (Period 2). Abaloparatide-SC is a drug-device combination product consisting of abaloparatide, an active synthetic peptide analog of parathyroid hormone related peptide (PTHrP), administered to the periumbilical region via an injection pen. Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide.
62118679|NCT04663464|EXPERIMENTAL|Abaloparatide-sMTS (Period 1) followed by abaloparatide-SC (Period 2)|Abaloparatide-sMTS (Period 1) application followed by Abaloparatide-SC injection (Period 2).
62118680|NCT03571711||Meropenem therapy in SBP|Patients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
62474203|NCT03701191|EXPERIMENTAL|Grpup A (Test group)|Inverted periosteal pedicle flap will be carried out
62474204|NCT03701191|ACTIVE_COMPARATOR|Group B (Control group)|Coronally advanced flap with subepithelial connective tissue graft
62677820|NCT06590558|EXPERIMENTAL|Treatment (tolinapant, eribulin)|Patients receive tolinapant PO QD on days 1-7 and 15-21 and eribulin IV over 2-5 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, tissue biopsy, chest X-ray, and CT or MRI throughout the study.
62677821|NCT01989585|EXPERIMENTAL|Arm I (dabrafenib, trametinib)|ARM I: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA, MRI or CT, biopsy, and collection of blood samples throughout the trial.
61919100|NCT02480725||non-CJD patients with a type of dementia|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
62118681|NCT04594759|EXPERIMENTAL|Treatment Group|
62306515|NCT02054650|SHAM_COMPARATOR|Sham OMT|Sham OMT will involve hand contact, active and passive range of motion, and sham techniques that simulate OMT (including optional OMT techniques), but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force. Sham OMT will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
62306516|NCT00388739|ACTIVE_COMPARATOR|Usual care|Systemic steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day). Subjects will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor. Children in the control group that do not own a nebulization compressor will be given a prescription for an albuterol MDI with mask and spacer with instructions to deliver 2 puffs (90mcg per actuation) 3 times a day as a standard chronic care regimen. Instructions to follow-up with their primary care physician in 3-5 days (as is standard care practice) will be given at discharge for patients in the control or treatment arm.
62306517|NCT00388739|EXPERIMENTAL|Usual care + 6 months of inhaled steroids|In addition to the usual care described above, patients randomized to the intervention/experimental arm will also be given a one month supply as well as a prescription (for a 6 month supply) for Budesonide respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
62306518|NCT01065480|ACTIVE_COMPARATOR|Live Teleconference Supervision|Clinicians from participating substance abuse treatment programs receive live supervision by MI trainer via teleconference while in session with client.
62677822|NCT01989585|EXPERIMENTAL|Arm II (dabrafenib, trametinib, and navitoclax)|Patients receive navitoclax PO QD days -7 to -1 of cycle 1 only. Patients also receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA, MRI or CT, biopsy, and collection of blood samples throughout the trial.
62677823|NCT03543020||Patients|Patients undergoing Radiation therapy to brain
61919101|NCT02480725||CSF samples of non-CJD patient used as control|CSF samples : Thrombin activity will be assayed.
61919102|NCT00805376|EXPERIMENTAL|Group A: DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
62118682|NCT01849055|PLACEBO_COMPARATOR|Placebo|Placebo matching LY3023703 administered orally, once daily (QD), for 28 days
62118683|NCT01849055|EXPERIMENTAL|LY3023703|Escalating doses (2.5 milligram \[mg\] up to 30 mg) of LY3023703 administered orally, QD, for 28 days
62118684|NCT01849055|ACTIVE_COMPARATOR|Celecoxib|400 mg celecoxib administered orally, QD, for 28 days. (Positive control.)
62118685|NCT05422651||patients with fever|All subjects will receive the currently recognized routine test of fever according to their disease and corresponding etiological treatment if needed and no additional intervention and treatment will be added for subjects
62306519|NCT01065480|ACTIVE_COMPARATOR|Taped Review Supervision|Clinicians from participating substance treatment programs audio record session with client and receive supervision after the session by MI trainer.
62306520|NCT05131971|EXPERIMENTAL|Cohort 1: Participants receiving GSK3888130B at dose level 1|
62306521|NCT05131971|PLACEBO_COMPARATOR|Cohort 1: Participants receiving placebo|
62306522|NCT05131971|EXPERIMENTAL|Cohort 2: Participants receiving GSK3888130B at dose level 2|
62306523|NCT05131971|PLACEBO_COMPARATOR|Cohort 2: Participants receiving placebo|
62306524|NCT05131971|EXPERIMENTAL|Cohort 3: Participants receiving GSK3888130B at dose level 3|
62306525|NCT05131971|PLACEBO_COMPARATOR|Cohort 3: Participants receiving placebo|
62306526|NCT05131971|EXPERIMENTAL|Cohort 4: Participants receiving GSK3888130B at dose level 4|
62306527|NCT05131971|PLACEBO_COMPARATOR|Cohort 4: Participants receiving placebo|
62677824|NCT00984633|EXPERIMENTAL|0.6 mg/kg intubation dose + sevoflurane|
62118686|NCT04974008|EXPERIMENTAL|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
62306528|NCT05131971|EXPERIMENTAL|Cohort 5: Participants receiving GSK3888130B at dose level 5|
62306529|NCT05131971|PLACEBO_COMPARATOR|Cohort 5: Participants receiving placebo|
62474205|NCT05836545|ACTIVE_COMPARATOR|Midazolam|The patient with midazolam
62677825|NCT00984633|EXPERIMENTAL|0.9 mg/kg intubation dose + sevoflurane|
62677826|NCT00984633|EXPERIMENTAL|0.6 mg/kg intubation dose + propofol|
62677827|NCT00984633|EXPERIMENTAL|0.9 mg/kg intubation dose + propofol|
62677828|NCT05980455|ACTIVE_COMPARATOR|Control Sleep Cycle|Baseline device programming parameters will be used during study participation. No modification to Enterra® device programming will be in effect during waking or sleeping hours.
62677829|NCT05980455|EXPERIMENTAL|Arm 1 Sleep Cycle|"Device programming parameters participants have at enrollment will be used during waking hours.~During sleeping hours, the Enterra® device will cycle through modified programming over the course of 6 hours. Each hour, the Enterra® device will deliver 30 minutes of reduced stimulation, followed by 30 minutes of waking hours stimulation. At the end of the 6-hour sleep cycle, the Enterra® device will return to waking hours programming."
62677830|NCT05980455|EXPERIMENTAL|Arm 2 Sleep Cycle|"Device programming parameters participants have at enrollment will be used during waking hours.~During sleeping hours, the Enterra® device will cycle through modified programming over the course of 8 hours. Each hour, the Enterra® device will deliver 45 minutes of reduced stimulation, followed by 15 minutes of waking hours stimulation. At the end of the 8-hour sleep cycle, the Enterra® device will return to waking hours programming."
62677831|NCT06531473|EXPERIMENTAL|2J 40hz Laser Energy|Patients will under go their Holmium Laser Enucleation procedure with the laser setting: 2J 40hz
62677832|NCT06531473|EXPERIMENTAL|2J 50hz Laser Energy|Patients will under go their Holmium Laser Enucleation procedure with the laser setting: 2J 50hz
62677833|NCT06531473|EXPERIMENTAL|2J 60hz Laser Energy|Patients will under go their Holmium Laser Enucleation procedure with the laser setting: 2J 60hz
62677834|NCT05061134|EXPERIMENTAL|Main study: Ceralasertib + Durvalumab|Participants will receive ceralasertib on Days 1 to 7 plus durvalumab Day 8, once in 28 days (Q28D), until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
62118687|NCT00959946|EXPERIMENTAL|1|In part 1 (phase 1), ascending and descending multiple oral doses of bosutinib + capecitabine. Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14 + bosutinib 200 mg QD; capecitabine 625 mg/m2 BID on days 1-14 + bosutinib 300 mg QD. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID and bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
62118688|NCT03769506|EXPERIMENTAL|ASP-1929 Photoimmunotherapy|Use of ASP-1929 Photoimmunotherapy
62677835|NCT05061134|EXPERIMENTAL|Main study: Ceralasertib|Participants will receive ceralasertib on Days 1 to 7, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
62677836|NCT05061134|EXPERIMENTAL|Biopsy Sub-study: Ceralasertib + Durvalumab|From Cycle 1, participants will receive combination of ceralasertib twice daily (BD) Days 1 to 7 plus durvalumab Day 8, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.
62677837|NCT05061134|EXPERIMENTAL|Biopsy study: Ceralasertib|During Cycle 0, participants will receive ceralasertib on Days 1 to 7, followed by an off-treatment period between Days 8 to 28.
62677838|NCT01399086||Fulvestrant|
62677839|NCT04188626|EXPERIMENTAL|Driving session|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving.
62677840|NCT06694025||Efluelda group|A single dose of 0.7 mL is administered as approved by MFDS.
62677841|NCT05206435|ACTIVE_COMPARATOR|Electronic Cigarettes|Participants in this arm are randomized to receive electronic cigarettes for the 6-week study period.
62677842|NCT05206435|ACTIVE_COMPARATOR|Nicotine Lozenges|Participants in this arm are randomized to receive nicotine lozenge for the 6-week study period.
62677843|NCT06267508||Cohort A|HIV-exposed infants and their mothers enrolled in the study
62677844|NCT06267508||Cohort B|HIV-positive infants, identified in the first 12 weeks, and their mothers will be rolled over from Cohort A to Cohort B for long-term follow-up for up to 12 months.
62677845|NCT04540900|ACTIVE_COMPARATOR|KB301|non-integrating HSV-1 vector expressing human type III collagen
61919103|NCT00805376|EXPERIMENTAL|Group B: DNX-2401 + Surgery|DNX-2401 injection + Tumor removal
62306530|NCT05131971|EXPERIMENTAL|Cohort 6: Participants receiving GSK3888130B at dose level 6|
62306531|NCT05131971|PLACEBO_COMPARATOR|Cohort 6: Participants receiving placebo|
62677846|NCT04540900|PLACEBO_COMPARATOR|Placebo|sterile isotonic saline
62118689|NCT03769506|ACTIVE_COMPARATOR|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
62306532|NCT05131971|EXPERIMENTAL|Cohort 7: Participants receiving GSK3888130B at dose level 7|
62474206|NCT05836545|EXPERIMENTAL|Remimazolam|The patient with remimazolam
62474207|NCT00033917|ACTIVE_COMPARATOR|1|indomethacin
62677847|NCT03623490|EXPERIMENTAL|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
62677848|NCT03623490|NO_INTERVENTION|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
62677849|NCT04929028|EXPERIMENTAL|High-risk stratum (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO during screening as clinically indicated, sigmoidoscopy/colonoscopy, anoscopy/proctoscopy or digital rectal exam and CT throughout the study as well as blood sample collection during screening and EOT.
62736325|NCT02653586|NO_INTERVENTION|control group|The control group didn't receive the intervention program, instead they received a lecture on wised nutrition. In addition the control group completed the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program.
62677850|NCT04929028|EXPERIMENTAL|Low-risk stratum (mitomycin|Patients receive mitomycin IV on day 1 and either fluorouracil IV on day 1 or capecitabine PO BID on Monday-Friday until the completion of radiation therapy at the discretion of the treating physician. Patients also undergo IMRT QD for 20-23 treatment sessions over 6 weeks. Patients also undergo digital rectal exam, anoscopy/proctoscopy and CT throughout the study, receive FDG IV and undergo PET/CT, PET/MRI and /or MRI during screening and follow-up as well as blood sample collection during screening and EOT. Some patients undergo lymph node biopsy during screening at the discretion of the treating physician.
62677851|NCT05746884|EXPERIMENTAL|Experimental Group with PuraStat®|Endoscopic mucosectomy or endoscopic ampullectomy with standard resection technique, per-procedure hemostasis at operator discretion and application of PuraStat®
62677852|NCT05746884|ACTIVE_COMPARATOR|Control Group|Endoscopic mucosectomy or endoscopic ampullectomy with standard resection technique, per-procedural hemostasis at operator discretion
62677853|NCT03797326|EXPERIMENTAL|Pembrolizumab + Lenvatinib (Arm 1)|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
62677854|NCT03797326|EXPERIMENTAL|Lenvatinib Monotherapy (Arm 2)|Participants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
62677855|NCT04681937|EXPERIMENTAL|Hyaluronic Acid + Physical Therapy|4 ml hyaluronic acid (subacromial)
62677856|NCT04681937|EXPERIMENTAL|Platelet-Rich-Plasma (PRP) + Physical Therapy|4 ml platelet-rich-plasma (subacromial)
62677857|NCT04681937|EXPERIMENTAL|Steroid + Physical Therapy|methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) (subacromial)
62677858|NCT04681937|EXPERIMENTAL|Placebo (serum saline) + Physical Therapy|4 ml serum saline (subacromial)
62677859|NCT01574495|EXPERIMENTAL|Error Augmentation-Control|
62306533|NCT05131971|PLACEBO_COMPARATOR|Cohort 7: Participants receiving placebo|
62306534|NCT04118361|EXPERIMENTAL|Patients with AVS isolated at emergencies|Enrollment of patients with AVS isolated at emergencies
62306535|NCT01383122|ACTIVE_COMPARATOR|Active device|Functional pulsed electromagnetic field device
62306536|NCT01383122|PLACEBO_COMPARATOR|Placebo - inactive device|Inactive pulsed electromagnetic field device
62306537|NCT05333718||Newly diagnosed T2DM|"To assess and characterize the relevant subgroups (clusters) of type 2 diabetes at diagnosis in our population.~This objective will be addressed using the 6 main variables that have been used so far in previous studies in other populations to develop disease groupings, that is, age, GAD antibodies, body mass index, glycosylated hemoglobin (HbA1c), and estimates of the evaluation of the homeostatic model 2 of β-cell function and insulin resistance."
62306538|NCT00095121|PLACEBO_COMPARATOR|Placebo (PLB)|Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
62306539|NCT00095121|EXPERIMENTAL|Adefovir Dipivoxil (ADV)|Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
62306540|NCT01457339|EXPERIMENTAL|SPD489 (Lisdexamfetamine dimesylate)|
62306541|NCT01457339|PLACEBO_COMPARATOR|Placebo|
62677860|NCT01574495|EXPERIMENTAL|Control-Error Augmentation|
62677861|NCT04218682|EXPERIMENTAL|Immediate Game Use|AYACS randomly assigned to this arm will immediately play the Shadow's Edge Game following enrollment for a duration of 7 weeks. Following the designated 7-week game-play period, they will continue to have access to the game. They will continue to receive all usual care health care throughout and following the study.
62677862|NCT04218682|NO_INTERVENTION|Wait-List Comparison Group|AYACS randomly assigned to this arm will begin to play the Shadow's Edge game 7 weeks following enrollment. They will continue to receive all usual health care throughout and following the study.
62677863|NCT06594159|EXPERIMENTAL|LY4065967 Part A|A single dose of LY4065967 administered orally
62677864|NCT06594159|PLACEBO_COMPARATOR|Placebo Part A|Placebo administered orally
62677865|NCT06594159|EXPERIMENTAL|LY4065967 Part B|Multiple doses of LY4065967 administered orally
62677866|NCT06594159|PLACEBO_COMPARATOR|Placebo Part B|Placebo administered orally
62677867|NCT06594159|EXPERIMENTAL|LY4065967 Part C|LY4065967 administered orally
62306542|NCT05750667|EXPERIMENTAL|Penn Medicine (health system)-mediated|Probands receive automated text messages and/or emails through the Way to Health (WTH) platform containing information about FH and cascade screening from Penn Medicine, and a request to identify first-degree biological relatives. Probands choose whether to contact relatives themselves or share contact information so that automated text messages and/or emails can be sent by Penn Medicine to relatives directly via WTH. If probands opt to contact relatives themselves (self-contact), they receive tips on how to do this effectively. If probands opt for Penn Medicine to contact their relatives (direct contact), relatives receive information via WTH about FH and instructions for screening. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
62474208|NCT00033917|PLACEBO_COMPARATOR|2|placebo
62474209|NCT00573066|EXPERIMENTAL|Dosing level|A predetermined dose of Dexmedetomidine
62474210|NCT06366061||Randomization|A randomization will be done for the order of the different TTE measurments, but all patients are going the same TTE measurements after all
62677868|NCT06594159|EXPERIMENTAL|LY4065967 and Rosuvastatin Part D|LY4065967 and Rosuvastatin administered orally
62677869|NCT03449381|EXPERIMENTAL|Dose Escalation|
62118690|NCT03781336|EXPERIMENTAL|Mindfulness-based self-care|Mindfulness-based self-care (5 weeks)
62118691|NCT03781336|NO_INTERVENTION|Life as usual control|Life as usual control (5 weeks)
62118692|NCT00785863|PLACEBO_COMPARATOR|Placebo|
62118693|NCT00785863|ACTIVE_COMPARATOR|Remifentanil|
62118694|NCT00785863|ACTIVE_COMPARATOR|Ketorolac and remifentanil|
62118695|NCT00785863|ACTIVE_COMPARATOR|Parecoxib and remifentanil|
62118696|NCT01538719|PLACEBO_COMPARATOR|Placebo|2:1 randomization
62118697|NCT01538719|ACTIVE_COMPARATOR|Rilonacept|2:1 randomization
62118698|NCT04783246|EXPERIMENTAL|Group A- Intervention/Non-Intervention|Participants in this arm will initially be randomized to the intervention period and will receive the interventions for 11 weeks followed by no interventions for 11 weeks.
62118699|NCT04783246|ACTIVE_COMPARATOR|Group B- Non-Intervention/Intervention|Participants in this arm will initially be randomized to the non-intervention period for 11 weeks followed by the intervention period for 11 weeks.
62118700|NCT01885806|EXPERIMENTAL|Repetitive TMS|"Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:~Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
62118701|NCT01885806|SHAM_COMPARATOR|Sham TMS|Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.
62118702|NCT05692908|EXPERIMENTAL|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
62118703|NCT01234844|OTHER|care of guinea pigs|"Each patient serves as own control receiving pet therapy and usual occupational therapy on alternate days."
62118704|NCT05223205|EXPERIMENTAL|Air group|Air tamponade after vitrectomy.
62677870|NCT03449381|EXPERIMENTAL|Dose Expansion|
62677871|NCT06695403|EXPERIMENTAL|Pilates Exercise (supervised versus telerehabilitation)|"1. Pilates Exercise: The Pilates method is a low-intensity form of movement based on body control, which works the body in a complete way, promoting physical and mental health. PET is different when compared to traditional exercises, which, in turn, tend to isolate the working muscles and have specific training approaches using repetitive motions.~2. Telerehabilitation: Telehealth is emerging as a key method for delivering essential healthcare. Primary care research suggests that telehealth is acceptable and has potential to overcome geographical barriers for individuals needing many times rehabilitation by eliminating the need for extensive and costly travel"
62118705|NCT05223205|EXPERIMENTAL|SF6 group|10% SF6 tamponade after vitrectomy.
62118706|NCT01147380|EXPERIMENTAL|Small dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells( mainly NK cells) is between 10 and 100 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate. Patient of this arm receive small dose of liver NK cell inoculation as described.
62118707|NCT01147380|EXPERIMENTAL|Large dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells(mainly NK cells) is between 100 and 1000 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate.Patient of this arm receive large dose of liver NK cell inoculation as described.
62736326|NCT00989677||Rheumatoid Arthritis|
62736327|NCT06442566|EXPERIMENTAL|open label BUP|
62736328|NCT06442566|ACTIVE_COMPARATOR|Real vs Placebo BUP|
62736329|NCT06442566|ACTIVE_COMPARATOR|Real vs Sham TMS|
62306543|NCT05750667|EXPERIMENTAL|Family Heart Foundation-mediated|After using WTH to conduct an identity screen and giving probands an option to opt-out of having their information shared with Family Heart Foundation (FHF), FHF reaches out directly to probands via an FHF-employed navigator. During an initial call, the navigator introduces the proband to navigation services, conducts a social history, and initiates a plan for contacting relatives. Probands choose whether to contact relatives themselves (self-contact) or have FHF contact relatives directly (direct contact). Those who choose self-contact receive personalized coaching to address barriers and concerns. For direct contact relatives, FHF will call these relatives directly. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
62474211|NCT06464120|EXPERIMENTAL|Incremental load training group|This training plan is a single training，The load intensity of strength training for athletes :（5,4,3）RM×1 time ×1set for half squat jump
62474212|NCT06464120|EXPERIMENTAL|Constant load training group|This training plan is a single training，This training plan is a single training，Constant load of strength training for athletes :90%1RM×3 time ×1set for half squat jump
62474213|NCT01421277||Participants Enrolled in Protocol Version (V)1.1|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study.
62474214|NCT01421277||Participants Enrolled in Protocol V2|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study.
62474215|NCT00445445||Patients|Histologically confirmed breast cancer that was diagnosed between the years 2002-2004
62474216|NCT00445445||Healthy participants|Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
62474217|NCT01608269|OTHER|ABC/3TC (Epzicom), NRTI|
62474218|NCT04383366||Patients with keratoconus|
62474219|NCT03161158|ACTIVE_COMPARATOR|Ultrafiltration Group|Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
62474220|NCT03161158|OTHER|Control group (Usual care IV diuretics)|Guideline-directed therapy including IV loop diuretics according to treatment algorithm.
62474221|NCT06280781|NO_INTERVENTION|Standard care (Control) Arm|PSA 3 monthly in year 1 and then 6 monthly with rectal exam annually. MRI will be carried out at 12 months (if not had one at diagnosis). If a diagnostic MRI was carried out, a 12 month MRI scan will not be required. A biopsy will be required if indicated due to changes in rectal exam or PSA. Follow-up for 5 years.
62474222|NCT06280781|EXPERIMENTAL|Intervention Arm|Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI scans annually. As per international PIRADS committee guidance the surveillance MRIs will be biparametric MRI scans which last approximately 15 minutes and exclude gadolinium contrast injection. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4.
62474223|NCT06196281|EXPERIMENTAL|wooble board proprioceptive training|The group A will perform the wobble board proprioceptive training program lasting for four weeks. Both the training programs consisted of one-leg and double-leg static and dynamic balance drills
61919104|NCT03877081|EXPERIMENTAL|Probiotics. Intervention patients|This patients will receive 2 doses of oral probiotics a day, for seven days
62474224|NCT06196281|EXPERIMENTAL|multi-station proprioceptive training|The group B will perform the multi-station proprioceptive training program lasting for four weeks. Both the training programs consisted of one-leg and double-leg static and dynamic balance drills basic exercise single length stance walk, Jumper exercise, resistance exercise
62474225|NCT01759277|ACTIVE_COMPARATOR|Control|Femoral perineural local anesthetic infusion
62474226|NCT01759277|EXPERIMENTAL|Experimental|Adductor canal perineural local anesthetic infusion
62474227|NCT06281847|EXPERIMENTAL|Open Label CCTx-001 infusion|CCTx-001 infusion 2 to 7 days after completion of LDC
62474228|NCT04354493|EXPERIMENTAL|Baseline and Training|This group consists of a baseline and training conditions only.
62474229|NCT04354493|EXPERIMENTAL|Baseline, Training, and Control|This group stops training condition sooner and returns to a control to evaluate carry-over effects.
61919105|NCT03877081|PLACEBO_COMPARATOR|Placebo group|This patients will receive 2 doses of oral placebo a day, for seven days
61919106|NCT02051816|ACTIVE_COMPARATOR|VL and AO|Video laryngoscopy and apneic oxygenation
62474230|NCT04887818|EXPERIMENTAL|Topical diltiazem + lidocaine|
62474231|NCT04887818|ACTIVE_COMPARATOR|Topical nifedipine + lidocaine|
62736330|NCT05523830||Healthy Subjects|56 healhty subjects will be recruited for the current study
62306544|NCT05750667|NO_INTERVENTION|Usual Care|Probands randomized to this arm will not receive any contact from the research team or Family Heart Foundation regarding cascade screening (i.e., no intervention).
62306545|NCT04778761|NO_INTERVENTION|Usual Care|Usual care entails receiving usual medical care by the home-based care team.
62306546|NCT04778761|EXPERIMENTAL|Video intervention|In addition to usual care, the intervention will entail having a visit by a trained study clinician to provide access to the ACP video. The study clinician will discuss the content of the video and answer any questions.
62306547|NCT06283251|EXPERIMENTAL|PediRISE Program Group|"Participants will be randomized in a 1:1 fashion and will be stratified by site. Participant parents will complete:~* Baseline survey in-person, by telephone, or virtually.~* PediRISE program orientation with study team member, in-person or virtual.~* Optional meeting with certified benefits counselor.~* Receive fixed funds twice a month for 6 months.~* Standard supportive care from social worker and/or resource specialist to identify and discuss available resources.~* End of study survey."
62306548|NCT06283251|NO_INTERVENTION|Usual Care Group|"Participants will be randomized in a 1:1 fashion and will be stratified by site. Participant parents will complete:~* Baseline survey in-person, by telephone, or virtually, and orientation with study team member.~* Standard supportive care from social worker and/or resource specialist to identify and discuss available resources.~* End of study survey."
62306549|NCT04135625|ACTIVE_COMPARATOR|Full Intervention|The full intervention group will receive three egg laying chickens that will be presented as a gift to the child by their religious leader (imam or priest) during a gifting ceremony, as well as Integrated nutrition and agricultural (INA) education training sessions.
62306550|NCT04135625|ACTIVE_COMPARATOR|Education Only|The education only intervention group will receive 3 chickens given in manner similar to animal distribution programs and the INA training sessions.
62306551|NCT04135625|NO_INTERVENTION|Control|The control group will receive no chickens gifted and no INA training sessions.
62306552|NCT01317849|EXPERIMENTAL|vitamin supplements|
62306553|NCT01317849|PLACEBO_COMPARATOR|Placebo|
62306554|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
62736331|NCT05142696|EXPERIMENTAL|Dose Level 1 (DL1)|Dose Level 1 (DL1): \[177Lu\]Lu-DOTA-TATE 100 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then \[177Lu\]Lu-DOTA-TATE 100 mCi plus atezolizumab 1200 mg in the maintenance period.
62118708|NCT01833364|EXPERIMENTAL|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
62306555|NCT02951923|EXPERIMENTAL|Bovine colostrum|8 weeks of Bovine colostrum power, 60g per day
62306556|NCT02951923|ACTIVE_COMPARATOR|Soy powder|8 weeks of Soy powder, 60g per day
62306557|NCT04653415|ACTIVE_COMPARATOR|Study Group|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
62118709|NCT04828642|ACTIVE_COMPARATOR|Supplementation group|Antioxidant vitamins (Vitamin C (1000 mg) + Vitamine E (235 mg))
62118710|NCT04828642|PLACEBO_COMPARATOR|Placebo group|Placebo supplementation with the same aspect as supplementation
62306558|NCT04653415|PLACEBO_COMPARATOR|Controls group|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - saline solution.
62306559|NCT01606488|OTHER|Surgical Group|"Subjects scheduled to undergo total knee or total hip replacement at the SFVAMC.~Subjects in this arm of the study will undergo the florbetapir PET scan once prior to their surgery.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
62306560|NCT01606488|OTHER|Non-surgical group|"Subjects being seen in at the SFVAMC orthopedic clinic for knee or hip pain but are not anticipating surgical intervention.~Subjects in this arm will not undergo the florbetapir PET scan.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
62306561|NCT03604614|EXPERIMENTAL|HIPEC and chemotherapy|Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）
62306562|NCT03604614|SHAM_COMPARATOR|Without HIPEC|Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）
62306563|NCT02490540|EXPERIMENTAL|Anesthesiologist quided analgesia|Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
62306564|NCT02490540|EXPERIMENTAL|ANI guided analgesia|Sufentanil ANI analgesia based on ANI analgesia monitor figures.
62306565|NCT02490540|EXPERIMENTAL|SPI guided analgesia|Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
62306566|NCT06482060|ACTIVE_COMPARATOR|Conventional group|
62306567|NCT06482060|EXPERIMENTAL|Digital workflow group|
62306568|NCT05986656|EXPERIMENTAL|Atlas correction|Basic group.
62306569|NCT06330753|OTHER|Feasibility and Acceptability of Trauma-informed Care Plans (TICP)|"Per our IRB protocol - Patient participants and clinician participants will be asked (via a survey) to rate their:~Acceptability of the Trauma-informed Care Plan, the Appropriateness of the TICP and the feasibility of the TICP. The intervention is the TICP place in the Electronic Medical Record right below the patient's name (on the Storyboard)."
62306570|NCT00668967|OTHER|Reference|marketed extended release verapamil tablet
62306571|NCT00668967|OTHER|Test|reformulated extended release verapamil tablet
62306572|NCT01015443|EXPERIMENTAL|Investigational Arm|Tecemotide (L-BLP25) + Single low dose cyclophosphamide + Best supportive care (BSC)
62306573|NCT01015443|PLACEBO_COMPARATOR|Control Arm|Saline + Placebo + Best supportive care (BSC)
62306574|NCT00539721|EXPERIMENTAL|Rolapitant Dose 1|
62306575|NCT00539721|EXPERIMENTAL|Rolapitant Dose 2|
62736332|NCT05142696|EXPERIMENTAL|Dose Level 2a (DL2a)|Dose Level 2a (DL2a): \[177Lu\]Lu-DOTA-TATE 150 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumab 1200 mg in induction period, then \[177Lu\]Lu-DOTA-TATE 150 mCi plus atezolizumab 1200 mg in the maintenance period.
62118711|NCT01282944|EXPERIMENTAL|Combined Financial Incentive & Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Subjects connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. Participants also receive weekly feedback regarding which participants in the peer group achieved their walking goals during the previous week.~Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200.~Financial incentive and peer network terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
62306576|NCT00539721|EXPERIMENTAL|Rolapitant Dose 3|
62306577|NCT00539721|EXPERIMENTAL|Rolapitant Dose 4|
62306578|NCT00539721|ACTIVE_COMPARATOR|Ondansetron|
62306579|NCT00539721|PLACEBO_COMPARATOR|Placebo|
62306580|NCT03962049|EXPERIMENTAL|Normal Hepatic Function|Healthy participants with Normal Hepatic Function
62474232|NCT02665715|EXPERIMENTAL|Low carbohydrate/Standard carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
62474233|NCT02665715|EXPERIMENTAL|Standard carbohydrate/Low carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
62474234|NCT04724187|EXPERIMENTAL|intrauterine misoprostol and oxytocin|there will be added effect of misoprostol to stimulate uterine contraction along with oxytocin
62474235|NCT04724187|ACTIVE_COMPARATOR|oxytocin|only oxytocin will stimulate uterine contraction
62677872|NCT04032431|EXPERIMENTAL|Telerehab VR intervention|The telerehab VR intervention consists of a custom-made software running on a computer connected with a commercial VR device (i.e. Oculus Rift). PwMS will be requested to reproduce several ADLs from the three main areas of self-care, dressing and meal preparation. The user can physically see his/her hands within the virtual scenario and, during the exercise, the hand coordinates are continuously recorded. Thus, data on 3D trajectory, speed, accuracy on target placement and movement smoothness, will be accessible. They will be stored in the PC and also be remotely sent to the clinical center for further analysis/processing. Both target position and task complexity will define the exercise difficulty, which can be modified automatically, on the basis of the previous performance or manually modified by the user
62677873|NCT04032431|ACTIVE_COMPARATOR|Conventional therapy|Conventional therapy will focus on task-related upper-limb treatments while in a sitting or prone position, representing the standard care in MS. Several manual techniques, therapy tools and objects of ADL will be allowed during treatment. No restrictions will be placed on the material used (ie, ADL, reaching and grasping material). Use of additional electrical or mechanical therapy devices (ie, support arm systems, splints) will be avoided. The interventions will be conducted on a one-on-one basis in the physiotherapy or occupational therapy department of each participating center. Training and therapy content will be tailored to each participant's preferences, the agreed movement aims and the motor function level of each MS patient.
62677874|NCT06689644|EXPERIMENTAL|Experimental group|This group will receive the nootropic supplement for 60 days.
62677875|NCT06689644|PLACEBO_COMPARATOR|Control group|This group will receive a placebo supplement for 60 days
62677876|NCT06694870||Hospital|Transcutaneous monitoring in the hospital
62677877|NCT06694870||Home|Transcutaneous monitoring at home
62677878|NCT01157429|ACTIVE_COMPARATOR|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
62677879|NCT01157429|PLACEBO_COMPARATOR|Placebo pill|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
62677880|NCT05714501|EXPERIMENTAL|Single Arm|Millipede System
62677881|NCT05816317|EXPERIMENTAL|Single-Session Mechanism Focused Intervention (SSMFI)|
62677882|NCT05816317|ACTIVE_COMPARATOR|Treatment as Usual|
62474236|NCT02553564|EXPERIMENTAL|Intervention group|"Checklist driven clinical encounter after hospital discharge~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.~\* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
62474237|NCT02553564|NO_INTERVENTION|Usual care group|"Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.~\* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
62474238|NCT03474757||SPAF patients in Colombia_Rivaroxaban|First time users of rivaroxaban in the Audifarma database
62474239|NCT03474757||SPAF patients in Colombia_Dabigatran|First time users of dabigatran in the Audifarma database
61919107|NCT02051816|ACTIVE_COMPARATOR|DL and AO|Direct Laryngoscopy and apneic oxygenation
62474240|NCT03474757||SPAF patients in Colombia_Apixaban|First time users of apixaban in the Audifarma database
62474241|NCT02109263|EXPERIMENTAL|saccharose|20% saccharose
61919108|NCT02051816|ACTIVE_COMPARATOR|VL and no AO|Video Laryngoscopy and no apneic oxygenation
61919109|NCT02051816|ACTIVE_COMPARATOR|DL and no AO|Direct Laryngoscopy and no apneic oxygenation
62306581|NCT03962049|EXPERIMENTAL|Mild Hepatic Impairment|Presence of Mild Hepatic Impairment (score of 5 to 6, on the Child Pugh scale and with features of cirrhosis due to any etiology)
62306582|NCT03962049|EXPERIMENTAL|Moderate Hepatic Impairment|Presence of Moderate Hepatic Impairment (score of 7 to 9, on the Child Pugh scale and with features of cirrhosis due to any etiology)
62306583|NCT03962049|EXPERIMENTAL|Severe Hepatic Impairment|Presence of Severe Hepatic Impairment (score of 10 to 15 on the Child Pugh scale and with features of cirrhosis due to any etiology)
62306584|NCT03591952|ACTIVE_COMPARATOR|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
62306585|NCT03591952|EXPERIMENTAL|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
62306586|NCT00121225|EXPERIMENTAL|Arm I|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
62306587|NCT02859701|EXPERIMENTAL|AK002|AK002 will be administered as an intravenous (IV) infusion in 8 cohorts of single escalating doses and two cohorts with multiple doses
62306588|NCT02859701|PLACEBO_COMPARATOR|Placebo|Placebo administered as anl IV infusion
62306589|NCT02031900||Undergoing EGD|
62306590|NCT00768378|EXPERIMENTAL|Perceived stimulation|When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
62306591|NCT00768378|EXPERIMENTAL|Subliminal stimulation|When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
62306592|NCT00532259|EXPERIMENTAL|CT-011|The monoclonal antibody termed CT-011 (currently, pidilizumab).
62306593|NCT00603044|ACTIVE_COMPARATOR|Fluticasone furoate|55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
62306594|NCT00603044|NO_INTERVENTION|No treatment|
62474242|NCT02109263|PLACEBO_COMPARATOR|breast-feeding|breast-feeding
62474243|NCT03874715|EXPERIMENTAL|Switching: NovoLog/SAR341402|Participants self-administered subcutaneous (SC) injection daily prior to the start of a meal during the 16-week treatment period, starting with NovoLog (100 units per milliliters \[U/mL\]) for the first 4 weeks, then SAR341402 (100 U/mL) for 4 weeks, followed by NovoLog (at same dose) for 4 weeks and then SAR341402 (at same dose) for the last 4 weeks on top of mandatory background therapy with Lantus (Insulin glargine, 100 U/mL) as basal insulin.
62474244|NCT03874715|ACTIVE_COMPARATOR|Non-Switching: NovoLog|Participants self-administered SC injection of NovoLog (100 U/mL) daily prior to the start of a meal during the 16-week treatment period on top of mandatory background therapy with Lantus (Insulin glargine, 100 U/mL) as basal insulin.
62677883|NCT06671665|ACTIVE_COMPARATOR|calcium supplementation|It will consist of 20 postmenopausal women. They will receive calcium supplementation daily for 12 weeks.
62677884|NCT06671665|EXPERIMENTAL|calcium supplementation + manual therapy|It will consist of 20 postmenopausal women. They will receive the same calcium supplementation daily in addition to manual therapy (in form of craniosacral technique \& general visceral mobilization) for 12 weeks.
62306595|NCT02189330|EXPERIMENTAL|Tafamidis|
62306596|NCT02189330|EXPERIMENTAL|Tafamudus Free Acid|
62306597|NCT02189330|EXPERIMENTAL|20 mg new soft gelatin capsule|
62306598|NCT02189330|EXPERIMENTAL|4 capsules of 20 mg tafamidis of commercial formulation|
62677885|NCT04297761|PLACEBO_COMPARATOR|Filtered air|Subjects will be exposed once to filtered air for 2 hours with alternating 15 minutes of exercise (cycle ergometer) and rest.
62306599|NCT02189330|EXPERIMENTAL|4 capsules of 12.2 mg tafamidis of free acid tablet|
62306600|NCT06064318||Primary cohort|All patients with a primary knee arthroplasty performed in Denmark between Jan 1st 1998 and 31st December 2021.
62306601|NCT06064318||Revision cohort|All patients with a revision knee arthroplasty performed in Denmark between Jan 1st 1998 and 31st December 2021
62306602|NCT06281873|EXPERIMENTAL|closure of the OAF with PRF application|This study was conducted on 9 patients. application of PRF membrane
62306603|NCT02372162||Group A - TACE|"Patients with transarterial chemoembolization (TACE) will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
62677886|NCT04297761|EXPERIMENTAL|Wood Smoke|Subjects will be exposed to air containing wood smoke for 2 hours with alternating 15 minutes of exercise (cycle ergometer) and rest.
62677887|NCT03856177|EXPERIMENTAL|Neutral|A neutral mood induction will include reading a dull text while listening to non-evocative music for 5-15 minutes.
62677888|NCT03856177|EXPERIMENTAL|Evocative|A mood induction procedure will be utilized. The procedure consists of a combination of re-experiencing an autobiographical sad personal event while listening to their choice of one of four sad music selections commonly used in mood induction. Visual analogue scale ratings will assess momentary sadness prior to, following, and at subsequent time points around the mood induction procedure.
62306604|NCT02372162||Group B - Sorafenib|"Patients with Sorafenib treatment will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
62677889|NCT03656562|EXPERIMENTAL|Cohort 1 VAY736|"Blinded treatment phase:~VAY736 administered subcutaneously (s.c.) every 4 weeks as multiple doses of VAY736 150 mg (total dose being VAY736 300 mg) until Week 25 + Standard of Care (SoC) for systemic lupus erythematosus (SLE).~Open-label treatment phase:~VAY736 administered subcutaneously (s.c.) every 4 weeks as multiple doses of VAY736 150 mg (total dose being VAY736 300 mg) until Week 49."
61919110|NCT03818984|EXPERIMENTAL|Safer Conception Intervention|Men will participate in 3 counseling sessions with a lay counselor. In the first session, the counselor will share information on the various safer conception strategies and help the participant think about developing a healthy plan. In the following 2 sessions, the counselor and the participant will work together to develop a healthy baby plan using motivational interviewing and problem solving. In the 2 booster sessions, the counselor and the participant will check in to evaluate the success of the plan and make changes as necessary.
61919111|NCT03744000|PLACEBO_COMPARATOR|Immediate stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate stenting group.
62118712|NCT01282944|NO_INTERVENTION|Active Control|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or peer networks in this group."
62118713|NCT01282944|EXPERIMENTAL|Financial Incentive Arm|Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 2 months.
62118714|NCT01282944|EXPERIMENTAL|Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period.~Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant will be given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. All participants in a peer network will receive a list of ways in which his or her new network could support each individual's walking goals. Participants will also receive weekly feedback regarding which participants in the peer group were successful in achieving their walking goals during the previous week.~Peer network is terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
62118715|NCT06675370||Indıviduals with chronic low back pain|
62118716|NCT01179334|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
62118717|NCT01179334|PLACEBO_COMPARATOR|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
62118718|NCT03919864|OTHER|CONNECT Intervention Group|CONNECT includes a multi-component e-tool with the following: (1) a brief educational video that seeks to empower and educate caregivers about the importance of self-care and benefits of supportive care resource use; (2) an assessment of multidimensional supportive care needs (e.g., psychological, behavioral, social, financial, educational, spiritual); (3) a tailored resource list that includes local and national resources corresponding to caregivers needs (Table1); and (4) an optional automated referral to a caregiver navigator to facilitate connection to resources.
62118719|NCT03919864|OTHER|CONTROL Group|Control arm participants will receive a generic (i.e., not tailored) printed list of hospital, community, and national supportive care resources. Control participants will not receive the educational video, complete the E-tool Preference survey, or have an option for an automated referral to a caregiver navigator
62118720|NCT04566458||Single arm|Her2 positive mBC patients who have received at least 3 lines of treatment in the metastatic setting.
62118721|NCT05819099||Training Set|
62118722|NCT05819099||Test Set|
62118723|NCT05819099||Verification Set|
62118724|NCT00992173|EXPERIMENTAL|Ultratrace Iobenguane I 131|
62118725|NCT03538912|OTHER|Biomarker group|patient follow the Biomarker strategy
62118726|NCT03538912|OTHER|Routine group|patient follow the routine strategy
62118727|NCT00735384||Patients with critical illness myopathy|Patients with,e.g., sepsis, with secondary myopathy
62118728|NCT00735384||Patients with Primary Myopathies|Patients with primary myopathy, e.g., Duchenne Muscular Dystrophy, Myotonia
62118729|NCT00628862|EXPERIMENTAL|F 4.5 bid|Formoterol 4.5 ug twice daily (bid)
62118730|NCT00628862|EXPERIMENTAL|F 9.0 bid|Formoterol 9.0 ug bid
62118731|NCT00628862|PLACEBO_COMPARATOR|PBO|Placebo
62306605|NCT01596205|EXPERIMENTAL|Robot intervention|Participants were given baseline assessments and randomly assigned into 3 groups; 24 with robot assisted cognitive training group (Robot intervention group), 24 with experienced behavioral therapist group (Conventional intervention group), and 37 without cognitive training (Control group).It was explained that there was a waiting list, therefore, participants in control group had an opportunity to participate in cognitive training program after a delay of 12 weeks for the intervention.
62306606|NCT01596205|ACTIVE_COMPARATOR|Conventional intervention|conventional cognitive training group - pen and pencil with experienced behavioral therapists
62306607|NCT01596205|NO_INTERVENTION|Control group|
62118732|NCT03491696|EXPERIMENTAL|Patients|It is an open label study, designed with 14 patients, men and women, from 18 to 60 years old, hospitalized for a characterized depressive episode (as defined by International Classification of Diseases version 10 criteria). They have to be refractory to an antidepressant treatment prescribed in primary care medicine and have a Dexamethasone Suppression Test (DTS) non-suppression status. All patients included will take the association of SSRI/SNRI and METYRAPONE for 28 days.
62118733|NCT02808338|ACTIVE_COMPARATOR|Philips BiPAP AutoSV Advanced System One|"The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.~P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto"
62118734|NCT02808338|EXPERIMENTAL|Modified Philips BiPAP ASV|The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
62118735|NCT02808338|ACTIVE_COMPARATOR|ResMed S7 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16"
62118736|NCT02808338|ACTIVE_COMPARATOR|ResMed S9 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off"
62118737|NCT02910388|EXPERIMENTAL|LLETZ with colposcopy|The LLETZ procedure will be performed under direct colposcopic vision
62118738|NCT02910388|ACTIVE_COMPARATOR|LLETZ without colposcopy|The LLETZ procedure will be performed without colposcopy
62118739|NCT06318624|EXPERIMENTAL|Intervention Group|Movement with Motion technique of Mulligan Concept to the ankle joint and taping will be performed on the participants in the Intervention Group.
62118740|NCT06318624|SHAM_COMPARATOR|Sham Group|Movement with Motion technique of Mulligan Concept to the ankle joint with lower amplitude and taping with minimal tension will be performed on the participants in the Sham Group.
62118741|NCT05056051|ACTIVE_COMPARATOR|Post-EET Surveillance Group: WATS-3D samples followed by Forceps biopsies|Sampling will occur with WATS-3D followed by forceps biopsies. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
62306608|NCT00003270|EXPERIMENTAL|Arm 1|Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0
62306609|NCT02798523|EXPERIMENTAL|Up to 2 hours post infusion|Healthy volunteers received a single intravenous dose of 250 mg of methylprednisolone and blood was collected between one to two hours after the start of the infusion.
62306610|NCT02798523|EXPERIMENTAL|Up to 4 hours post infusion|Healthy volunteers received a single intravenous dose of 250 mg of methylprednisolone and blood was collected between two hours to four hours after the start of the infusion.
62306611|NCT05374941|EXPERIMENTAL|Stimulation not synchronized with breathing|Participants will be injected with the StimAire Model S Injectable neurostimulator for the hypoglossal nerve, using a wearable without a breathing sensor.
62306612|NCT05374941|EXPERIMENTAL|Stimulation during inhalation only|Participants will be injected with the StimAire Model S Injectable neurostimulator for the hypoglossal nerve, using a wearable with a breathing sensor.
62306613|NCT03520179||SMA TYPE 1|genetically confirmed SMA
62306614|NCT03520179||SMA TYPE 2|genetically confirmed SMA
62306615|NCT03520179||SMA TYPE 3|genetically confirmed SMA, Ambulant and non-ambulant
62306616|NCT01243593|EXPERIMENTAL|Treatment Group|
62306617|NCT01243593|ACTIVE_COMPARATOR|Control Group|
62306618|NCT02606786|EXPERIMENTAL|stabilization exercises|Lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
62306619|NCT01215630||Healthy subjects|Men Women Age; 18-75
62306620|NCT06346912|EXPERIMENTAL|Administration of CD19-BAFF Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62736333|NCT05142696|EXPERIMENTAL|Dose Level 2b (DL2b)|Dose Level 2b (DL2b): \[177Lu\]Lu-DOTA-TATE 150 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumad 1200 mg in induction period, then \[177Lu\]Lu-DOTA-TATE 200 mCi plus atezolizumab 1200 in the maintenance period.
61919112|NCT03744000|ACTIVE_COMPARATOR|Deferred stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred for 3-7 days in the deferred stenting group.
61919113|NCT04006782|OTHER|Narrow dental implants in multiple fixed prosthesis|
61919114|NCT03736707|EXPERIMENTAL|Selective HFOV|Selective HFOV will be provided
62306621|NCT06476080|NO_INTERVENTION|Control group|800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)
62306622|NCT06476080|ACTIVE_COMPARATOR|Erector spinae group|800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)+ 25 ml bupivacaine 0.25% plus 8 mg dexamethasone
62306623|NCT06476080|ACTIVE_COMPARATOR|Serratus anterior group|800 mg acyclovir, 5 times / day, orally administered, for one week, acetaminophen 1000 mg per day, topical calamine lotion)+ 25 ml bupivacaine 0.25% plus 8 mg dexamethasone
62306624|NCT05733481|OTHER|Patients with the presence of coronary arterial de novo or restenotic chronic total occlusion.|Successful crossing of the targeted chronic total occlusion, defined as angiography confirmed guidewire placement in the true lumen without utilization of a re-entry device.
62306625|NCT03499054|NO_INTERVENTION|control group|Hemodialysis patients in the control group who receive only routine nursing care during hemodialysis
62306626|NCT03499054|EXPERIMENTAL|exercise group|The exercise group are asked to perform breathing exercises during hemodialysis for the study period of 3 months.
62306627|NCT04369339|EXPERIMENTAL|Other High Risk HPV Positivity|Colposcopy performed to women with High risk HPV positive ,negative for intraepithelial lesions or malignancy cytology
62306628|NCT04369339|ACTIVE_COMPARATOR|HPV16/18|Colposcopy performed to women with HPV 16/18 positive ,negative for intraepithelial lesions or malignancy cytology
62306629|NCT05879263|EXPERIMENTAL|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
62306630|NCT05879263|ACTIVE_COMPARATOR|CONTINUOUS ENTERAL NUTRITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
62306631|NCT00217438|EXPERIMENTAL|Arm I (high dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine IV over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
62306632|NCT00217438|ACTIVE_COMPARATOR|Arm II (low dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
62306633|NCT06295783||Head and Neck Cancer (HNC) Questionnaire|"Participants will be asked to fill out three head and neck cancer (HNC) questionnaires during your visits to the clinic:~1. The MDASI-HN questionnaire (standard-of-care) has 28 questions.~2. The EORTC QLQ-HN35 questionnaire has 35 questions.~3. The EORTC QLQ-30 questionnaire has 30 questions."
62306634|NCT02388230||Patients 4 or more years post radiotherapy|IMPORT or FAST trial patients who received breast RT previously and are receiving four years (or more) follow-up assessment and have hardening of their breast as a result of breast radiotherapy.
62474245|NCT06290284|EXPERIMENTAL|Long Peripheral Catheter|The procedure to place a LPC includes these steps: before inserting the catheter, the nurse will perform routine preliminary (non sterile) inspection of the arm to identify an insertion site. After selecting the insertion site, the nurse will release the tourniquet, with non-sterile gloves, and disinfect the skin around the insertion site. While allowing the antiseptic to act, the nurse will apply the tourniquet, and pull lightly with the thumb of the non-dominant hand to keep the vein from moving. After the needle has been inserted in the vein lumen, the guide wire is advanced and the catheter is inserted using the catheter wings. As the catheter is being inserted, the sheath (housing) is removed and then the wings. Before attaching the catheter to an extension without a needle or to a 3-way stopcock, it should be connected to a statlock to ensure it is safely fixated. A transparent, semi-permeable dressing will allow for daily visual inspection of the insertion site.
62474246|NCT06290284|ACTIVE_COMPARATOR|Peripheral Intra-Venous Catheter|The procedure to place a PIVC includes these steps: before inserting the catheter, the nurse will perform routine preliminary (non sterile) inspection of the arm to identify an insertion site. After selecting the insertion site, the nurse will release the tourniquet, with non-sterile gloves, and disinfect the skin around the insertion site. While allowing the antiseptic to act, the nurse will apply the tourniquet, and pull lightly with the thumb of the non-dominant hand to keep the vein from moving. The needle will be inserted at a 10-30 degree angle about 1-2 cm distal from the catheter insertion site. Holding the needle firmly, the nurse will advance the cannula for its entire length into the lumen, remove the needle, and connect the cannula via an extension to a 3-way stopcock. A transparent, semi-permeable dressing will allow for daily visual inspection of the insertion site.
62474247|NCT04548141|EXPERIMENTAL|Active adults|Adults coming for a visit for sports activity participation and submitted the SAPHIR questionnaire
62677890|NCT03656562|PLACEBO_COMPARATOR|Cohort 1 VAY736 Placebo|"Blinded treatment phase:~VAY736 matching placebo administered subcutaneously (s.c.) every 4 weeks as multiple doses of placebo 0 mg until Week 25 + Standard of Care (SoC) for systemic lupus erythematosus (SLE).~Open-label treatment phase:~VAY736 administered subcutaneously (s.c.) every 4 weeks as multiple doses of VAY736 150 mg (total dose being VAY736 300 mg) until Week 49."
61919115|NCT03736707|ACTIVE_COMPARATOR|CMV|CMV will be provided
62474248|NCT02527109|PLACEBO_COMPARATOR|Placebo|Intra-anal placebo administered BID.
62474249|NCT02527109|EXPERIMENTAL|Nifedipine 12 mg/day|Intra-anal Nifedipine 12 mg administered OD.
62474250|NCT02527109|EXPERIMENTAL|Nifedipine 24 mg/day|Intra-anal Nifedipine 12 mg administered BID.
62306635|NCT02388230||Patients 0 to 2 years post breast radiotherapy|Patients who are (1) undergoing, or undergone recently breast RT (general population) and have undergone a clinical assessment either during RT or at 3 month follow-up that found moderate or severe oedema, or (2) IMPORT patients who have received RT and are receiving one or two year follow-up, at which moderate or severe oedema is reported.
62306636|NCT04341610|ACTIVE_COMPARATOR|ASC|100 million allogeneic adipose-derived mesenchymal stromal cell
62474251|NCT01924377|OTHER|standard circumferential pulmonary vein isolation (CPVI)|standard circumferential pulmonary vein isolation by radiofrequenvy ablation
62306637|NCT04341610|PLACEBO_COMPARATOR|Placebo|Saline
62474252|NCT01924377|EXPERIMENTAL|CPVI + Rotor|standard circumferential pulmonary vein isolation + rotors' identification and ablation'
62474253|NCT05171179|OTHER|Intravenous lidocaine|Intravenous (IV) lidocaine infusion without Pecs block (standard of care per ERAS protocol)
62474254|NCT05171179|ACTIVE_COMPARATOR|Blocks+Bupivacaine|Use of Pecs block types I and II with bupivacaine as local anesthetic
62474255|NCT05171179|EXPERIMENTAL|Blocks+Bupivacaine+Exparel|Use of Pecs block types I and II with mixture of bupivacaine and Exparel\* (\*Must include bupivacaine at lower dose to decrease intra-operative variability in pain control due to delayed onset of Exparel and in ability to use lidocaine infusion with injection of Exparel)
62474256|NCT01794039|EXPERIMENTAL|Arm A (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may crossover to arm B.
62474257|NCT01794039|EXPERIMENTAL|Arm B (pomalidomide, dexamethasone)|Patients receive pomalidomide PO daily on days 1-21 and dexamethasone as in arm A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62474258|NCT04742543|EXPERIMENTAL|Virtual reality glasses|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure with Virtual reality glasses on
62474259|NCT04742543|NO_INTERVENTION|No intervention. standard treatment|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure without virtual reality glasses (no intervention)
62474260|NCT03944330|ACTIVE_COMPARATOR|a treatment group|All study participants were provided with a standard hospital diet that provided B25-30 kcal/kg/day
62474261|NCT03944330|NO_INTERVENTION|control group|All study participants were not intervened with diet
62474262|NCT01701492||Stem Cell Transplant Survivors|All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
62474263|NCT01701492||Normal control participants|Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
62118742|NCT05056051|ACTIVE_COMPARATOR|Post-EET Surveillance Group: Forceps biopsies followed by WATS-3D samples|Sampling will occur with forceps biopsies followed by WATS-3D. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
62118743|NCT06398912|EXPERIMENTAL|Music Intervention|Participants will be exposed to an organized sound stimulus (music) during the EEG measurement
62474264|NCT06458491||TENSI+ posterior tibial nerve stimulation for overactive bladder|patients who have benefited from treatment with the TENSI+ device in the context of overactive bladder
62474265|NCT03505463||Injured participants|
62474266|NCT03505463||Healthy participants|
62474267|NCT02386618|OTHER|Local residual neoplasia|Patients with local residual neoplasia in 3 months after endoscopic resection of colorectal lateral spreading tumors diagnosed endoscopically and/or histologically
62474268|NCT00481637||Cancer patients|SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.
62474269|NCT00481637||Normal|Normal volunteers
62474270|NCT02777372|EXPERIMENTAL|Sertraline|To determine the impact of short term luteal phase treatment with Sertraline 50mg tablets (PMDD group only) on acoustic startle response across the menstrual cycle. Sertraline 50 mg tablets are administered daily from ovulation until menses onset.
62474271|NCT02777372|NO_INTERVENTION|Control|No intervention.
62474272|NCT05815745|ACTIVE_COMPARATOR|Right ventricular pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice)
62474273|NCT05815745|EXPERIMENTAL|Physiological pacing|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
62474274|NCT03756441|EXPERIMENTAL|Experimental: Mindfulness group|This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion protocol. They will group with have eight meetings, one per week, during a half hour and will learn the techiques to practice everyday during the week.
61919116|NCT02446743|EXPERIMENTAL|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
62118744|NCT06398912|NO_INTERVENTION|Control Group|Participants will not be exposed to an organized sound stimulus at any point of the EEG measurement
62118745|NCT06647641||CurePSP Genetics Program|Adults with PSP, CBD or MSA
62118746|NCT03189316|OTHER|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
62474275|NCT03756441|ACTIVE_COMPARATOR|Psychotherapy group|This group will learn group problem solving techniques during eight weeks
62118747|NCT03189316|OTHER|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
62306638|NCT00003937|EXPERIMENTAL|Pilot 1 - Doxorubicin Intensification without Ifosfamide|Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.
62474276|NCT02148497|OTHER|Dry Eye Disease or Sjogren's Disease|Capturing images of the tear surface using the multi-colored Placido disk
62474277|NCT02148497|OTHER|Control|Capturing images of the tear surface using the multi-colored Placido disk
61919117|NCT02446743|ACTIVE_COMPARATOR|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
61919118|NCT04737057|ACTIVE_COMPARATOR|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding injections and drilling. It is one of a number of biologically orientated strategies for managing dental decay
62118748|NCT03335969|EXPERIMENTAL|pre colon irrigation diaries followed by post diaries|4 week bowel movement and rescue medication diaries will be compared to same diaries used 4 weeks after the colon irrigation procedure
62118749|NCT00888979|EXPERIMENTAL|Nicotrol with Behavioral Counseling|Nicotrol Inhaler: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
62118750|NCT03754218|EXPERIMENTAL|Amnion membrane product treatment area|The prepared amnion membrane powder will be directly applied to the prepared donor wound site (Site A). The wound will then be covered with the SOC dressing.
62118751|NCT03754218|ACTIVE_COMPARATOR|SOC Wound Covering treatment area|The donor wound site (Site B) will be covered per SOC (Standard of care).
62118752|NCT04016025|ACTIVE_COMPARATOR|cream|Treatment with topical Methylprednisolone aceponate 0,1% cream (Advantan®) plus Basic care (Bepanthen® Sensiderm)
62118753|NCT04016025|ACTIVE_COMPARATOR|fatty ointment|Treatment with topical Methylprednisolone aceponate 0,1% fatty ointment (Advantan®) plus Basic care (Bepanthen® Sensiderm)
62118754|NCT04979988||Japanese patients with ALK+ NSCLC who received lorlatinib|lorlatinib as the second-line or later therapy after failure of alectinib treatment as the firstline therapy
62118755|NCT01185782|EXPERIMENTAL|SJ-0021 group|
62118756|NCT01185782|ACTIVE_COMPARATOR|Purified pituitary gonadotropin group|
62118757|NCT01315314|NO_INTERVENTION|conventional PDF (Stay safe)|
62118758|NCT01315314|ACTIVE_COMPARATOR|low GDP PDF (Balance)|
62118759|NCT00992238|EXPERIMENTAL|Flavoxate Hydrochloride Tablets, 100mg|
62118760|NCT00992238|ACTIVE_COMPARATOR|Urispas® Tablets, 100mg|
62118761|NCT06015542|EXPERIMENTAL|Self-administration of Elranatamab|It is a feasibility study assessing the feasibility and safety of self-administration of Elranatamab in the homes of the patients. The intervention of the study is self-administration of Elranatamab by the patient, thereby changing the administration from an outpatient setting to a home setting. The patients will function as their own controls, as treatment will be given alternately at home and in the outpatient clinic.
62118762|NCT01208311||Patients with Hepatitis C Cirrhosis|Patients with Hepatitis C Cirrhosis
62118763|NCT06549582|EXPERIMENTAL|intervention group|Fundamental medical treatment+Taohong Tongluo Xiaoban Prescription Incorporating the Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose.
62118764|NCT06549582|ACTIVE_COMPARATOR|control group|Fundamental medical treatment The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
62118765|NCT05147688|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62118766|NCT04501276|EXPERIMENTAL|Part A : Dose escalation of ADG116 monotherapy|
62118767|NCT04501276|EXPERIMENTAL|Part B : Dose escalation of ADG116 combined with anti PD1 drug|
62118768|NCT04501276|EXPERIMENTAL|Part C : Dose escalation of ADG116 combined with ADG106|
62118769|NCT03784768|EXPERIMENTAL|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
62118770|NCT03784768|ACTIVE_COMPARATOR|Control Group|Patients in the control group will be received 60-minute conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
62118771|NCT05677438|EXPERIMENTAL|Test Group1|
62118772|NCT05677438|EXPERIMENTAL|Test Group2|
62474278|NCT04825314|ACTIVE_COMPARATOR|Bactiguard urethral catheter|Group A: Fifty Patients with urethral catheter using noble metal alloy coated catheter (Bactiguard AB, Stockholm ,Sweden).
62474279|NCT04825314|ACTIVE_COMPARATOR|Silicone Foley urethral catheter|Group B: Fifty Patients with urethral catheter using silicone Foley catheter (Well Lead, Guangzhou, China).
62474280|NCT05890261|EXPERIMENTAL|Young healthy subjects|Young healthy subjects
62118773|NCT05677438|EXPERIMENTAL|Test Group3|
62118774|NCT05677438|PLACEBO_COMPARATOR|Placebo Group|
62306639|NCT00003937|EXPERIMENTAL|Pilot 2 - Doxorubicin Intensification with Ifosfamide|Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29
62118775|NCT02711293|EXPERIMENTAL|ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard plus enhanced nutrition counseling.
62118776|NCT02711293|EXPERIMENTAL|ART home delivery + no enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard counseling.
62118777|NCT02711293|EXPERIMENTAL|No ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home to provide enhanced nutrition counseling. Participants will not receive ART home delivery.
62118778|NCT02711293|NO_INTERVENTION|Standard of care|Participants in this arm receive facility-based ART care and no enhanced nutrition counseling. They receive community health worker visits as per the standard of care in Dar es Salaam.
62118779|NCT03697876|EXPERIMENTAL|PRO-165|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
62118780|NCT03697876|ACTIVE_COMPARATOR|1. Artelac® Nightime Gel|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
62118781|NCT04151407|EXPERIMENTAL|601 dose level 1 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
62118782|NCT04151407|EXPERIMENTAL|601 dose level 2 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once
62118783|NCT04151407|EXPERIMENTAL|601 dose level 3 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once
62118784|NCT04151407|EXPERIMENTAL|601 dose level 4 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
62118785|NCT04151407|EXPERIMENTAL|601 dose level 5 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(3.75mg), Vitreous injection, injection once;
62118786|NCT04151407|EXPERIMENTAL|601 dose level 6 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously.
62118787|NCT04151407|EXPERIMENTAL|601 dose level 7 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously.
62118788|NCT03730922|EXPERIMENTAL|A: Delayed-immediate reconstruction|"Primary Surgery: Skin sparing mastectomy (nipple sparing if appropriate) and axillary surgery according to guidelines or protocol. Reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix.~Delayed reconstruction: Final reconstruction with any reconstructive procedure - being it autologous or implant-based (one- or two-stage, +/- acellular dermal matrix (ADM)) - is performed 6-12 months after completion of chemotherapy and PMRT. Any contralateral procedure is allowed when doing the delayed surgery, but not in relation to the initial cancer surgery."
62118789|NCT03730922|ACTIVE_COMPARATOR|B: Delayed reconstruction|"Primary surgery: Total mastectomy and axillary surgery according to guidelines or protocol.~Delayed reconstruction: 6-12 months after completion of PMRT: final recon-struction with any reconstructive procedure - being it autologous or implant-based (one-or two-stage, +/- ADM). Any contralateral procedure is allowed at any time point after PMRT has been delivered This arm has been closed nov 2023"
62118790|NCT03697616|EXPERIMENTAL|Ridge augmentation with sticky bone and GBR|Ridge augmentation using Autologous concentrated Growth factors (CGF) enriched bone graft matrix (sticky bone) and guided bone regeneration using native collagen membrane in horizontally deficient maxilla
62118791|NCT02867670||Transcranial Magnetic Stimulation of Motor Cortex|All study participants will receive real TMS stimulation over the primary motor cortex in order to collect physiological measures which will later be correlated with measures of neuroplasticity. There is NO placebo stimulation.
62118792|NCT02867670||Transcranial Magnetic Stimulation of Language Cortex|All study participants will receive real TMS stimulation over the language cortex and a control site (i.e. vertex). Transient changes in speech production will be recorded and compared to measures of neuroplasticity. There is NO placebo stimulation.
62118793|NCT00012935|OTHER|Arm 1|
62118794|NCT03003845||Interstitial Cystitis|Patients with Interstitial Cystitis will be followed with Questionnaires and blood collection at 3, 6,and 12 months
62306640|NCT00003937|EXPERIMENTAL|Pilot 3 - Ifosfamide/Etoposide Intensification|Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33
62306641|NCT04403737|NO_INTERVENTION|Usual Care|Patients in the control arm will have a Rothman Index calculated but this will not be visible to providers.
62474281|NCT04244877|EXPERIMENTAL|Rifaximin|Rifaximin 550 mg by mouth twice daily for eight weeks.
61919119|NCT04737057|EXPERIMENTAL|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a promising therapeutic agent for managing caries lesions in young children and those with special care needs
62118795|NCT05168553|EXPERIMENTAL|Revasularization|
62118796|NCT05168553|ACTIVE_COMPARATOR|Conventional endodontic treatment|
62118797|NCT05370430|EXPERIMENTAL|B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells]|BAFFR-CAR T cells in participants with r/r B-NHL
62118798|NCT06225882||Lumasiran|Patient with primary hyperoxaluria type 1 who has been treated with Lumasiran, since the beginning of the ATU (temporary authorization for use) and in post-marketing.
62118799|NCT06323902||Patients with giant full thickness macular hole|13 patients with a diagnosis of macular hole with a total thickness greater than 400 microns were chosen. Without prior vitreoretinal surgery
62118800|NCT03702673|EXPERIMENTAL|Treatment A|K-877 CR Tablet A
62306642|NCT04403737|EXPERIMENTAL|Intervention|Patients in the intervention arm will have a Rothman Index calculated and will be visible to providers. Providers will be given a set of clinician-specific recommended-use protocols that they will be encouraged to follow based on the RI thresholds achieved by patients.
62306643|NCT02629393|EXPERIMENTAL|ORGN001 (formerly ALXN1101)|
62306644|NCT01674764||Early surgical intervention = Cohort 1|≤ 12 hours after the tSCI
62306645|NCT01674764||Late surgical intervention = Cohort 2|\> 12 hours and \< 14 days after the tSCI
62306646|NCT01903915||Patients|Schizophrenia group
62306647|NCT01903915||Control|Healthy control group
62306648|NCT02234011|EXPERIMENTAL|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
62306649|NCT02234011|EXPERIMENTAL|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
62306650|NCT03064282|PLACEBO_COMPARATOR|Placebo|Drug free base as placebo
62306651|NCT03064282|EXPERIMENTAL|group two- papaverine arm|papaverine in a suitable base
62736334|NCT05142696|EXPERIMENTAL|Dose Level 3a (DL3a)|Dose Level 3a (DL3a): \[177Lu\]Lu-DOTA-TATE 200 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then \[177Lu\]Lu-DOTA-TATE 200 mCi plus atezolizumab 1200 mg in the maintenance period.
62118801|NCT03702673|EXPERIMENTAL|Treatment B|K-877 CR Tablet B
62118802|NCT03702673|EXPERIMENTAL|Treatment C|K-877 CR Tablet E
62118803|NCT03702673|EXPERIMENTAL|Treatment D|K-877 IR Tablet
62118804|NCT03336424|EXPERIMENTAL|Non-invasive investigations group|Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry
62118805|NCT03336424|EXPERIMENTAL|Invasive investigations group|urodynamic study including: cystomanometry, pressure flow study, EMG
62118806|NCT03620214||healthy children|Healthy children consulting at the odontology department of Reims CHU for carious screening or orthodontic diagnosis; excluding research
62118807|NCT05041491|EXPERIMENTAL|BREAK Intervention|Participants in the BREAK condition will perform 5-minute bouts of brisk walking hourly for 9 hours/day, 5 days/week for 3 months.
62306652|NCT06297304|EXPERIMENTAL|Physical Activity Intervention|One arm : all volunteers will receive an intervention program based on sedentary behavior reduction and physical activity promotion.
62306653|NCT01112215|ACTIVE_COMPARATOR|azathioprine|
62306654|NCT01112215|ACTIVE_COMPARATOR|Enteric-coated Mycophenolate Sodium|
62306655|NCT02526849|EXPERIMENTAL|Fecal microbiota transplantation (FMT)|On day 1-6, patients received 100ml fresh FMT by nasointestinal tube, once per day. The nasointestinal tube was placed in the patient's proximal jejunum through endoscopy. Then, donor fecal microbiota was infused within 5 minutes through nasointestinal tube.
62306656|NCT02526849|EXPERIMENTAL|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
62306657|NCT01676116|EXPERIMENTAL|Insulin degludec/liraglutide + OADs|
62306658|NCT01676116|ACTIVE_COMPARATOR|Liraglutide or exenatide + OADs|
62306659|NCT01325493|PLACEBO_COMPARATOR|Normal Saline|Normal Saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
62306660|NCT01325493|ACTIVE_COMPARATOR|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
62306661|NCT03275870|EXPERIMENTAL|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
62306662|NCT04282928|ACTIVE_COMPARATOR|Routine treatment group|"Participants will receive the treatment according to the treatment principle of severe and critical cases in Influenza diagnosis and treatment plan (2019 version)"
62306663|NCT04282928|EXPERIMENTAL|HUC-MSCs adjuvant Group|Participants will receive intravenous infusion of definitive HUC-MSCs (1×10\^6 cells/Kg × body weight(kg), which was selected by immunomodulatory assay through coculture with BV2 cell) on the basis of the routine treatment.
62306664|NCT00989703|EXPERIMENTAL|1|GLPG0259 25/50/75 mg/day for 14 days
62306665|NCT00989703|PLACEBO_COMPARATOR|2|placebo for 14 days
62306666|NCT05275413|EXPERIMENTAL|family-based mHealth intervention|The expectant mothers and their family members (fathers and grandparents) in this group will receive health education and support and family support via a smartphone app.
62474282|NCT04097483|EXPERIMENTAL|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention, centered on motivational interviewing and cognitive behavioural therapy for adherence and depression.
62474283|NCT04097483|NO_INTERVENTION|Control group|Control group with treatment as usual (TAU).
62474284|NCT06486298|ACTIVE_COMPARATOR|Vacuum Drain insertion at abdominoplasty surgery|insert the active drain after adominoplasty with radivac container
62474285|NCT06486298|EXPERIMENTAL|Passive Drain insertion at abdominoplasty surgery|insert the passive drain after adominoplasty with collecting bag
62736335|NCT05142696|EXPERIMENTAL|Dose Level 3b (DL3b)|Dose Level 3b (DL3b): \[177Lu\]Lu-DOTA-TATE 200 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3, and atezolizumab 1200 mg in induction period, then \[177Lu\]Lu-DOTA-TATE 250 mCi plus atezolizumab 1200 mg in the maintenance period.
62118808|NCT05041491|ACTIVE_COMPARATOR|ONE Intervention|Participants in the ONE condition will perform 45 minutes of brisk walking as a single continuous bout, 5 days/week for 3 months.
61919120|NCT02953158|EXPERIMENTAL|Haas Avocado|Haas Avocado commercially available Behavioral: Dietary recommendations Recommendation: a hypocaloric weight loss diet
61919121|NCT02953158|ACTIVE_COMPARATOR|Dietary Counseling|Behavioral: Dietary Counseling Recommendation: equally hypocaloric usual American diet.
62118809|NCT01587755|OTHER|Topical Treatment Optimizing Program|Optimized care
62118810|NCT01587755|OTHER|non-Topical Treatment Optimizing Program|Standard care
62118811|NCT05485402|PLACEBO_COMPARATOR|Control group (Group A)|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil), maltodextrin, and nutritional and physical activity recommendations
62118812|NCT05485402|EXPERIMENTAL|Intervention group (Group B)|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil), maltodextrin, and nutritional and physical activity recommendations
62118813|NCT05485402|EXPERIMENTAL|Intervention group (Group C)|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil), prebiotic supplementation (FOS and inulin), and nutritional and physical activity recommendations
62118814|NCT03343938|EXPERIMENTAL|Closed Station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
62118815|NCT03343938|NO_INTERVENTION|Open flow cabinet|Embryo handling is performed inside a conventional open flow cabinet without a controlled environment.
62118816|NCT03737682||hemostasis achievement|in which hemostasis at the exposure site was achieved in five minutes were included in group A
62118817|NCT03737682||No hemostasis achievement|in which hemostasis at the exposure site couldn't be achieved in five minutes where included in group B
62118818|NCT03608839|EXPERIMENTAL|0,01ml dexamethasone solution|One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
62118819|NCT03608839|EXPERIMENTAL|0,03 ml dexamethasone solution|One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
62118820|NCT03608839|EXPERIMENTAL|0,05 ml dexamethasone solution|One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
62118821|NCT02538263|EXPERIMENTAL|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
62118822|NCT02538263|NO_INTERVENTION|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
62118823|NCT05989646|EXPERIMENTAL|Transcutaneous Electric Nerve Stimulation (TENS)|Sacral TENS
62118824|NCT05908942||RF group|32 patients with knee osteoarthritis to undergo radiofrequency treatment of genicular nerves
62118825|NCT05908942||Phenol group|32 patients with knee osteoarthritis to undergo phenol treatment of genicular nerves
62118826|NCT02006940|EXPERIMENTAL|Alveoflex, in vivo imaging miniprobe|All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special minirobe Alveoflex before and after the treatment. Records will be done and analyzed prospectively with the included software for endomicroscopic system.
62118827|NCT03035123|NO_INTERVENTION|"Usual care"|Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
62118828|NCT03035123|EXPERIMENTAL|Interventional|"Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.~Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.~To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer."
62118829|NCT00959582|EXPERIMENTAL|1|18-F-FDG PET/CT imaging
62118830|NCT04191486|EXPERIMENTAL|T-817MA (448 mg)|
62118831|NCT04191486|PLACEBO_COMPARATOR|Placebo|
62118832|NCT06676397|OTHER|Severe Asthma Patients : Biologic Naïves|Severe Asthma Patients : Biologic Naïves
62474286|NCT01891461|EXPERIMENTAL|Floseal|"Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.~Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used."
62474287|NCT01891461|NO_INTERVENTION|standard of care|For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.
62474288|NCT05851391|OTHER|Burst Suppression EEG Target|Anesthetic will be titrated to achieve burst suppression on continuous EEG (50-99% attenuation/suppression) for 24 hours.
62474289|NCT05851391|OTHER|Seizure Suppression EEG Target|Anesthetic will be titrated to achieve seizure suppression on continuous EEG for 24 hours.
62474290|NCT04757792||No NSAID|included patients who did not receive NSAID prior to having COVID-19 disease
62474291|NCT04757792||Apsirin|included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease
62474292|NCT04757792||Celecoxib|included patients who received celecoxib (CEL) prior to having COVID-19 disease
62474293|NCT04757792||Miscellaneous|included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease
62474294|NCT01944072|OTHER|60%|aerobic exercise training intensity of 60%Wmax
62474295|NCT01944072|OTHER|80%|aerobic exercise training intensity of 80%Wmax
62474296|NCT04917328|EXPERIMENTAL|Patient with clinical suspicion of deep vein thrombosis|
62474297|NCT02494479|ACTIVE_COMPARATOR|50mg of Purisol daily|One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days
62474298|NCT02494479|ACTIVE_COMPARATOR|100mg of Purisol daily|One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days
62474299|NCT02494479|ACTIVE_COMPARATOR|200mg of Purisol daily|Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days
62474300|NCT02494479|PLACEBO_COMPARATOR|Placebo daily|Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days
62474301|NCT02232776|EXPERIMENTAL|Losartan treatement|All patients had received losartan treatment for 24 weeks.
62474302|NCT02740647|EXPERIMENTAL|Intervention group|Intervention group will be getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery.
62474303|NCT02740647|PLACEBO_COMPARATOR|Control group|the Control group will be getting intra-venous Placebo (0.9% 50 ml of sodium chloride) for 5 days.
62474304|NCT06427161|ACTIVE_COMPARATOR|Group Ipatients were treated with LLLT.|patients were treated with LLLT.
62474305|NCT06427161|ACTIVE_COMPARATOR|Group II|patients were treated with dextrose injection.
62677891|NCT03656562|EXPERIMENTAL|Cohort 2 CFZ533|"Blinded treatment phase:~CFZ533 administered intravenously (i.v) every 4 weeks as multiple doses of CFZ533 150 mg, based on body weight (BW) of the patients (10 mg/kg (\>= 50 kg BW) and 13 mg/kg (\< 50 kg BW)) until Week 25 + Standard of Care (SoC) for systemic lupus erythematosus (SLE).~Open-label phase:~CFZ533 administered intravenously (i.v) every 4 weeks as multiple doses of CFZ533 150 mg, based on body weight (BW) of the patients (10 mg/kg (\>= 50 kg BW) and 13 mg/kg (\< 50 kg BW)) until Week 49."
62474306|NCT04766450|ACTIVE_COMPARATOR|Group 1, NAC group|Group 1, NAC group (n=30): Patients will receive conventional therapy for diabetic neuropathy in addition to High Dose N-acetyl cysteine (2400 mg/day divided into two doses) daily for 3 months
62474307|NCT04766450|NO_INTERVENTION|Group 2, Control group|Group 2, Control group (n= 30): Patients will receive conventional therapy for diabetic neuropathy alone for 3 months.
62677892|NCT03656562|PLACEBO_COMPARATOR|Cohort 2 CFZ533 Placebo|"Blinded treatment phase:~CFZ533 matching placebo administered intravenously (i.v) every 4 weeks as multiple doses of placebo 0 mg, based on body weight (BW) of the patients (10 mg/kg (\>= 50 kg BW) and 13 mg/kg (\< 50 kg BW)) until Week 25 + Standard of Care (SoC) for systemic lupus erythematosus (SLE).~Open-label phase:~CFZ533 administered intravenously (i.v) every 4 weeks as multiple doses of CFZ533 150 mg, based on body weight (BW) of the patients (10 mg/kg (\>= 50 kg BW) and 13 mg/kg (\< 50 kg BW)) until Week 49."
62118833|NCT06676397|OTHER|Severe Asthma Patients: Responders to Biologics|Severe Asthma Patients: Responders to Biologics
62474308|NCT01001403|EXPERIMENTAL|nafamostat|The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
62474309|NCT01001403|PLACEBO_COMPARATOR|Control|The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
62474310|NCT00808418|EXPERIMENTAL|Cohort|
62474311|NCT05595590|EXPERIMENTAL|Tislelizumab + Pulse radiation|Participants receive pulsed radiationtherapy concurrent with 3 cycles of Tislelizumab followed by an additional 32 cycles of Tislelizumab alone as maintenance therapy.
62474312|NCT03391284|EXPERIMENTAL|Oral Acetominophen Arm|1000 mg acetominophen oral
62677893|NCT06366958|OTHER|group 1|arthroscopic excision
62677894|NCT06366958|OTHER|group 2|open excision
62118834|NCT06676397|OTHER|Severe Asthma Patients: Non Responders to Biologics|Severe Asthma Patients: Non Responders to Biologics
62118835|NCT06676397|OTHER|Mild asthmatics|Mild asthmatics
62118836|NCT06676397|OTHER|Healthy Controls|Healthy Controls
62118837|NCT06234644|ACTIVE_COMPARATOR|Group A|The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC).
62474313|NCT03391284|ACTIVE_COMPARATOR|Intravenous|1000 mg acetominophen intravenous
62474314|NCT05934565|EXPERIMENTAL|Mindful Steps|Multi-modal web intervention including: pedometer with individualized step-count goals, motivational and educational content, online community forum, mind-body videos (short themed clips that support walking, plus library of mind-body exercises), online group mind-body exercise classes, star incentive system; educational booklet
62474315|NCT05934565|NO_INTERVENTION|Usual Care|Pragmatic usual care (standard care through participant's healthcare provider including pharmacological treatment and general advice for physical activity); educational booklet
62474316|NCT06560853|EXPERIMENTAL|School health programme (SHP)|"SHP developed by Healthy Learners (HL) in collaboration with the Ministry of Education (MOE), which follows the WHO guidelines on school health activities. HL supports the upgrading of basic sanitation facilities and construction of a dedicated 'health room' in the school; trains selected teachers to become school health workers (SHWs) who deliver health and sanitation education, coordinate deworming and vitamin A supplementation in the school, and assess sick learners in the school health room using a clinical decision support system (CDSS), either treating in school or referring to the local health centre. At the health centre, children referred by SHWs are given priority by health care workers who see them within 30 minutes of arriving at the facility. Schools also create student networks (a buddy system) whereby learners monitor each other's absence and coordinate with SHWs, who can then follow up with the household."
62677895|NCT04744129|ACTIVE_COMPARATOR|NN414|To investigate the role of NN414 compared with placebo in migraine patients.
61919122|NCT02755038||premenopausal and postmenopausal women|One group will include 20 premenopausal women under the age 40 years old, with regular menstruation cycles and without any illness or medication including birth control pills or steroidal ointments, and without known diagnosis of polycystic ovaries or fertility disorder. The second group will include 20 postmenopausal women over the age of 60, with no menstruation at least for the last five years, and without hormone therapy or treatment of any Steroidal therapy for the last year.
62118838|NCT06234644|ACTIVE_COMPARATOR|Group B|The Group B (Control group) will receive the treatment with conventional Gait training.
62118839|NCT05261815|EXPERIMENTAL|Ultrasound therapy|"* Continuous ultrasound therapy for 15 minutes~* Traction for 30 minutes~* Spinal decompression exercises for 20 min"
62118840|NCT05261815|EXPERIMENTAL|High Intensity Laser Therapy|"* High intensity laser for 10 minutes~* Traction for 30 minutes~* Spinal decompression exercises for 20 min"
62118841|NCT04705922|EXPERIMENTAL|Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]|Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
62118842|NCT04705922|EXPERIMENTAL|Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]|Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.
61919123|NCT01695668|EXPERIMENTAL|Lotemax|Loteprednol Etabonate 0.5%
61919124|NCT01695668|ACTIVE_COMPARATOR|Restasis|Cyclosporine
61919125|NCT05342532|ACTIVE_COMPARATOR|High Dose Dual Therapy|This regimen includes a 14-day course of amoxicillin 1 g three times daily and omeprazole 40 mg three times daily.
62474317|NCT06560853|ACTIVE_COMPARATOR|Deworming and vitamin A supplementation|Healthy Learners will enusre reliable delivery of the national deworming programme twice a year, during the same period as in the SHP arm, for comparability of the effect of prevention alone to the full SHP.
62474318|NCT06560853|NO_INTERVENTION|Status quo|Schools to operate as usual with no intervention other than the usual activities planned and organized by the government, as set out the 2006 School Health and Nutrition Policy, until the end of the trial.
62474319|NCT04180709|EXPERIMENTAL|Sleepio Intervention + Treatment As Usual (TAU)|Participants will receive the online Sleepio intervention to be completed approximately once per week, at least 6 sessions during the 8-week period, and complete daily sleep diaries. In addition they will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis CPFT or Early Intervention in Psychosis Services NSFT care team.
62474320|NCT04180709|NO_INTERVENTION|Treatment As Usual (TAU) alone|Participants will continue their treatment as usual (TAU) with their Early Intervention in Psychosis care team. They will however be offered access to the Sleepio intervention during the follow-up period of the study.
62474321|NCT05514860|ACTIVE_COMPARATOR|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
62474322|NCT05514860|ACTIVE_COMPARATOR|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
62474323|NCT03568838|EXPERIMENTAL|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
62474324|NCT03568838|NO_INTERVENTION|Standard Therapy|Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
62474325|NCT00654030|EXPERIMENTAL|1650-G Vaccine|Patients receive 2 injections of 1650-G Vaccine given 4 weeks apart, for a total of 52 weeks on study.
62474326|NCT03810118|EXPERIMENTAL|Treatment|All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
62474327|NCT06092450||MIBC|patients with pathologically confirmed MIBC after radical cystectomy
62474328|NCT03733444|EXPERIMENTAL|GLPG1690, 600 milligrams (mg)|Participants received GLPG1690 (ziritaxestat) 600 mg as film-coated tablet orally, once daily (mean treatment duration was 332.9 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
62474329|NCT03733444|EXPERIMENTAL|GLPG1690, 200 mg|Participants received GLPG1690 (ziritaxestat) 200 mg as film-coated tablet orally, once daily (mean treatment duration was 336.9 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
62474330|NCT03733444|EXPERIMENTAL|Placebo|Participants received GLPG1690 (ziritaxestat) matching placebo tablets orally, once daily (mean treatment duration was 346.2 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
62474331|NCT04924660|EXPERIMENTAL|TXA127 (4/20/2022 Arm Closed to Accrual)|An investigational peptide agonist of Mas receptors.
62474332|NCT04924660|EXPERIMENTAL|TRV027 (4/20/2022 Arm Closed to Accrual)|An investigational peptide biased agonist of the AT1 receptor.
62474333|NCT04924660|PLACEBO_COMPARATOR|Placebo|"NaCl 0.9% infused to match the duration of the agent for TXA127, TRV027, and APN01.~Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
62474334|NCT04924660|EXPERIMENTAL|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
62474335|NCT04444050|EXPERIMENTAL|Part 1 Single Ascending Dose (SAD): Panel 1|
62118843|NCT04705922|EXPERIMENTAL|Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]|Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.
62118844|NCT04464421|EXPERIMENTAL|Contingency management (CM)|Participants received incentives for urine toxicology with a positive result for Buprenorphine metabolites at each of the first four visits after initiation of Buprenorphine-Naloxone.
62474336|NCT04444050|EXPERIMENTAL|Part 1 SAD: Panel 2|
62474337|NCT04444050|EXPERIMENTAL|Part 1 SAD: Panel 3|
62474338|NCT04444050|EXPERIMENTAL|Part 1 SAD: Panel 4|
62474339|NCT04444050|EXPERIMENTAL|Part 1 SAD: Panel 5|
62118845|NCT04464421|EXPERIMENTAL|BSM|BSM (Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion) participants had one-on-one behavioral intervention sessions at each of the first four visits after initiation of Buprenorphine-Naloxone.
62118846|NCT05483335||Medical Student in the final two clinical years (Clerkship years)|All the current medical students of College of Medicine and Health Sciences in United Arab Emirates University in the clinical years (fifth and sixth years in a 6-year MD programme) also called as clerkship years, will be invited into this study to assess for burnout syndrome using a validated tool via Mind GardenTM using Malasch Inventory for Burnout Syndrome and also to identify any other factors which may be contributing to stress/burnout.
62118847|NCT03540667||Single group study|The study population will include patients presenting for primary elective unilateral total hip and knee arthroplasty.
62118848|NCT03768869|EXPERIMENTAL|Low Risk: Oupatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
62474340|NCT04444050|EXPERIMENTAL|Part 1 SAD: Panel 6|
61919126|NCT05342532|ACTIVE_COMPARATOR|Standard triple therapy|This regimen includes a 14-day course of clarithromycin 500 mg twice daily, omeprazole 40 mg twice daily, and amoxicillin 1g twice daily.
62306667|NCT05275413|EXPERIMENTAL|mother-only mHealth intervention|The expectant mothers in this group will receive health education and support via a smartphone app.
62306668|NCT05275413|ACTIVE_COMPARATOR|Health education|The expectant mothers in the control group will receive health education via a smartphone app.
62474341|NCT04444050|EXPERIMENTAL|Part 1 SAD: Optional Split-dose Panel|
62474342|NCT04444050|EXPERIMENTAL|Part 2 Multiple Ascending Dose (MAD): Panel 1|
62474343|NCT04444050|EXPERIMENTAL|Part 2 MAD: Panel 2|
62474344|NCT04444050|EXPERIMENTAL|Part 2 MAD: Panel 3|
61919127|NCT01276197|EXPERIMENTAL|Arm 1: Story-Telling DVD|Participant will receive a DVD with informational and story-telling components
61919128|NCT01276197|ACTIVE_COMPARATOR|Arm 2: Non-Storytelling DVD|Participant will receive an informational DVD
61919129|NCT06080581||Mitochondrial myopathy|Individuals with pathogenic mtDNA mutations
61919130|NCT06080581||Control|Individuals without mtDNA mutations
61919131|NCT01476644|OTHER|Glaucoma Patients|Moderate glaucoma patients with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma were included to complete annual visits over a 4 year period. Each visit included (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measures: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (VRQoL) (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).
61919132|NCT04110600|ACTIVE_COMPARATOR|Coffee group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia And will have 100 ml of coffee after 2,4 and 6 hours~Then outcomes will be assessed as per time frame"
61919133|NCT04110600|ACTIVE_COMPARATOR|Pepper mint oil group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia This group will have 100 ml of pepper mint oil After 2,4 and 6 hours~Then outcomes will be assessed as per time frame"
61919134|NCT01400438|EXPERIMENTAL|patients group with Herceptin|Patients beginning Herceptin in adjuvant after chemotherapy
61919135|NCT01400438|ACTIVE_COMPARATOR|Control group|patient not beginning Herceptin after chemotherapy : control group
62306669|NCT05960955|EXPERIMENTAL|Part 1 cohort 1|Subjects receive cadonilimab combination chemotherapy(SOX) neoadjuvant therapy 3 cycles.
62306670|NCT05960955|EXPERIMENTAL|Part 1 cohort 2|Subjects receive cadonilimab combination chemotherapy(SOX) and AK117 neoadjuvant therapy 3 cycles.
62306671|NCT05960955|EXPERIMENTAL|Part 2 cohort 1|Subjects receive cadonilimab combination chemotherapy(FLOT) neoadjuvant therapy 4 cycles.
62306672|NCT05960955|EXPERIMENTAL|Part 2 cohort 2|Subjects receive cadonilimab combination chemotherapy(FLOT) and AK117 neoadjuvant therapy 4 cycles.
62474345|NCT04444050|EXPERIMENTAL|Part 2 MAD: Panel 4|
62474346|NCT04444050|EXPERIMENTAL|Part 2 MAD: Optional (to be determined) Panel|
62474347|NCT04444050|EXPERIMENTAL|Part 3 MAD in Japanese Participants (J-MAD): Panel 1|
62474348|NCT04444050|EXPERIMENTAL|Part 3 J-MAD: Panel 2|
62474349|NCT04444050|EXPERIMENTAL|Part 3 J-MAD: Panel 3|
62306673|NCT04652362|EXPERIMENTAL|Growth Mindset Intervention|
62474350|NCT04444050|EXPERIMENTAL|Part 3 J-MAD: Optional (to be determined) Panel|
62474351|NCT00510172|ACTIVE_COMPARATOR|1|Active treatment
62474352|NCT00510172|PLACEBO_COMPARATOR|2|Placebo
62474353|NCT03494894||patients with Cystic Fibrosis and Primary Ciliary Dyskinesia|
62474354|NCT02241863|EXPERIMENTAL|Multifaceted intervention|Patients, their caregivers and family members will received the educational and motivational interventions
62474355|NCT02241863|ACTIVE_COMPARATOR|Active Comparator|Usual Care The usual care group received routine counseling performed by the psychiatrist and nurses.
62677896|NCT04744129|PLACEBO_COMPARATOR|Saline|To investigate the role of NN414 compared with placebo in migraine patients.
62677897|NCT03975829|EXPERIMENTAL|Dabrafenib and/or trametinib|"Patients in this study may receive one of the following treatments received in the parent study which are:~* Patients who received monotherapy of either of dabrafenib or trametinib~* Patients who received combination of dabrafenib and trametinib~  * Patients who discontinued treatment on parent study are still offered to participate in long-term follow-up"
61919136|NCT05272644|ACTIVE_COMPARATOR|urethral hypermobility-surface electromyographic biofeedback only|Participant will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
61919137|NCT05272644|EXPERIMENTAL|urethral hypermobility-surface electromyographic biofeedback and electrical stimulation|Participant will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
61919138|NCT05272644|ACTIVE_COMPARATOR|intrinsic sphincter deficiency-surface electromyographic biofeedback only|Participant will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
61919139|NCT05272644|EXPERIMENTAL|intrinsic sphincter deficiency-surface electromyographic biofeedback and electrical stimulation|Participant will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
61919140|NCT01048489|OTHER|Lifestyle counseling|
61919141|NCT01048489|NO_INTERVENTION|No counseling|
61919142|NCT01702181|PLACEBO_COMPARATOR|Placebo|Matching placebo.
61919143|NCT01702181|ACTIVE_COMPARATOR|Tacrolimus|Tacrolimus 0.1% ointment twice daily for 28 days.
61919144|NCT01702181|EXPERIMENTAL|OPA-15406|
61919145|NCT04491097|EXPERIMENTAL|Experimental: Panavia V5 resin cement|Resin cement with non-MDP monomer
61919146|NCT04491097|ACTIVE_COMPARATOR|Experimental: Panavia F2.0 resin cement|Resin cement with MDP monomer
61919147|NCT03986762|EXPERIMENTAL|Open Label Clav|
61919148|NCT03949491|EXPERIMENTAL|3-D virtual planning and medical modeling of breast|"3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction.~* Preoperative CT-Angiogram of the abdominal wall~* Volumetric analysis preformed~* 3D printed models made~* Pre operative BREAST-Questionnaires given~* Free tissue transfer performed: Operative/Dissection Time Recorded~* Flap/Abdominal donor site complications recorded~* Standard Digital Photography and Harris Scoring~* BREAST-Questionnaires given at 3, 6 months"
61919149|NCT06239818|EXPERIMENTAL|Treatment: Photobiomodulation therapy (PBMt)|
61919150|NCT06239818|ACTIVE_COMPARATOR|Control|
62118849|NCT03768869|ACTIVE_COMPARATOR|Low Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
62118850|NCT03768869|ACTIVE_COMPARATOR|High Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
62118851|NCT01454661|ACTIVE_COMPARATOR|placebo mother - LGG infant|Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
62306674|NCT04652362|ACTIVE_COMPARATOR|Supportive Therapy Intervention|
61919151|NCT00856531||1|
61919152|NCT00856531||2|
61919153|NCT00856531||3|
61919154|NCT00856531||4|
61919155|NCT00856531||5|
62306675|NCT00989326|ACTIVE_COMPARATOR|CONTROL group|The patients receive standard of care for 18 months. The CONTROL group patients will be equipped with Home Monitoring. However, the Home Monitoring data will not be used for patient surveillance; i. e. the patient will be followed in the conventional manner.
62677898|NCT05648214|EXPERIMENTAL|Part A: ALN-PNP Dose 1 or PB|8 Participants, Randomized 6:2
62677899|NCT05648214|EXPERIMENTAL|Part A: ALN-PNP Dose 2 or PB|8 Participants, Randomized 6:2
62677900|NCT05648214|EXPERIMENTAL|Part A: ALN-PNP Dose 3 or PB|8 Participants, Randomized 6:2
62677901|NCT05648214|EXPERIMENTAL|Part A: ALN-PNP Dose 4 or PB|8 Participants, Randomized 6:2
62677902|NCT05648214|EXPERIMENTAL|Part A: ALN-PNP Dose 5 or PB|8 Participants, Randomized 6:2
62306676|NCT00989326|EXPERIMENTAL|ACTIVE group|The patients are followed by Home monitoring only. Every patient must be seen by his physician 18 months after enrolment for regular follow-up. Within this period, the additional Pace Maker follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception or patient/physician call
61919156|NCT00856531||6|
62118852|NCT01454661|PLACEBO_COMPARATOR|placebo mother - placebo infant|Placebo is administered to both the lactating mother and her infant.
62118853|NCT01454661|ACTIVE_COMPARATOR|LGG mother - placebo infant|The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
62118854|NCT01454661|ACTIVE_COMPARATOR|LGG+Bb-12 mother - Placebo infant|A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
62118855|NCT01454661|ACTIVE_COMPARATOR|Pacebo mother - LGG+Bb-12 infant|Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
62118856|NCT01169311|EXPERIMENTAL|HEEA Stapler|hemorrhoidopexy using Covidien EEA Hemorrhoid and Prolapse Stapling Set
62118857|NCT05245786|EXPERIMENTAL|Treatment (64Cu labeled M5A antibody and imaging)|Patients receive 64Cu labeled M5A antibody IV over 5 minutes on day 0 pre standard of care chemo/radiotherapy and on day 0 post chemo/radiotherapy. Patients also undergo 64Cu-M5A PET scan on day 1 pre chemo/radiotherapy and on day 1 post chemo/radiotherapy.
62118858|NCT02158091|EXPERIMENTAL|IPI-145|"Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation.~* Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy.~* Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing."
62118859|NCT05732701|EXPERIMENTAL|Intervention|Algorithm-guided DAPT duration
62118860|NCT05732701|ACTIVE_COMPARATOR|Standard|Standard-of-care DAPT duration
62118861|NCT01012453|NO_INTERVENTION|Hand Eczema in health care workers|
62118862|NCT04145492|ACTIVE_COMPARATOR|Vitamin K2 group|15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.
62118863|NCT04145492|ACTIVE_COMPARATOR|Cholecalciferol group|15 patients will take 10 ug of vitamin inactive vitamin D daily in addition to the standard therapy for 4 months.
62118864|NCT04145492|ACTIVE_COMPARATOR|Vitamin K2 and Cholecalciferol group|15 patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D to daily in addition to the standard therapy for 4 months.
62118865|NCT04145492|NO_INTERVENTION|Control group|15 patients will take the standard therapy.
62118866|NCT04905225||Ascending aortic replacement|Ascending aortic replacement in ascending aortic aneurysm in men and women
62118867|NCT01461655|PLACEBO_COMPARATOR|Topical retinoid - Placebo|
62118868|NCT01461655|ACTIVE_COMPARATOR|Topical retinoid-NSAID|
61919157|NCT00856531||7|
61919158|NCT00856531||8|
61919159|NCT00856531||9|
62118869|NCT05082714|EXPERIMENTAL|tocilizumab|tocilizumab plus usual care
62306677|NCT03654547|EXPERIMENTAL|Dose Escalation|Eligible adult patients with advanced solid tumors will be enrolled into Dose Escalation cohorts and treated with TT-00420 at different dose cohorts. Starting dose will be 1 mg p.o., q.d. An ABLRM guided by the EWOC principle will evaluate the risk of under-dose or over-dose for the dose tested in each cohort and provide the recommendation dose for next cohort. Dose Escalation Teleconference will be held after the last evaluable patient complete Cycle 1 treatment in each dose cohort to evaluate DLT, determine MTD and/or DRDE.
62306678|NCT03654547|EXPERIMENTAL|Dose Expansion|A Dose Expansion cohort will be opened to enroll patients with selected advanced solid tumors and evaluate the safety, PK and preliminary efficacy of TT-00420 to determine the recommended phase 2 dose in patients with advanced solid tumors.
62306679|NCT01046149|EXPERIMENTAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
61919160|NCT00856531||10|
61919161|NCT00856531||11|
61919162|NCT00856531||12|
61919163|NCT00856531||13|
61919164|NCT00856531||14|
61919165|NCT00856531||15|
62118870|NCT05082714|EXPERIMENTAL|baricitinib|baricitinib plus usual care
62118871|NCT01124188|EXPERIMENTAL|Study Intervention Arm|Higher-dose venlafaxine and Problem Solving Therapy for Depression and Pain (PST-DP)
62118872|NCT01124188|ACTIVE_COMPARATOR|Active Control|Higher-dose venlafaxine and supportive management (SM)
62474356|NCT00697476|EXPERIMENTAL|Vorinostat/Topotecan|"Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2"
62474357|NCT02897791|EXPERIMENTAL|Impaired Rt. Hemisphere patients|20 first stroke patients
62474358|NCT02897791|EXPERIMENTAL|control|20 healthy adults without any known damage to the right hemisphere. The two groups will be matched concerning sex, age, educational level and socio-economic status.
62474359|NCT03147768|EXPERIMENTAL|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
62474360|NCT02286154|EXPERIMENTAL|Hydroxyurea|"All enrolled participants will receive hydroxyurea, but upon enrollment, participants will be identified as part of the New Cohort or Old Cohort New Cohort participants include those who are not receiving hydroxyurea therapy upon study entry. Old Cohort participants include those who are already receiving hydroxyurea therapy upon study entry. New Cohort participants will have starting dose predicted using PK/PD data and Old Cohort participants will continue dosing per clinical guidelines."
62474361|NCT01686386|EXPERIMENTAL|Dose escalation benda lena dexa|"Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.~Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days."
62474362|NCT02319824|EXPERIMENTAL|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
62306680|NCT01046149|ACTIVE_COMPARATOR|Stress management|Cognitive reconstructive strategies for stress management
62306681|NCT03429556|PLACEBO_COMPARATOR|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
62306682|NCT03429556|EXPERIMENTAL|Botulinum Neurotoxin Serotype E Dose 1|Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
62474363|NCT03810703|PLACEBO_COMPARATOR|placebo arm|Participant will receive placebo oral capsule during this four hour session.
61919986|NCT02480907|ACTIVE_COMPARATOR|Internet-based support group|Parents of \~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the Internet-based support group for parents, including material from the manual and the DVD and additional information available online within a structured program. Over the course of three months, parents will get access to the 8 support sessions online with the instruction to work out the program at home. Additionally email support is offered after completing each session.
62306683|NCT03429556|EXPERIMENTAL|Botulinum Neurotoxin Serotype E Dose 2|Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
62474364|NCT03810703|EXPERIMENTAL|amphetamine 10 mg arm|Participant will receive d-amphetamine 10 mg oral capsule during this four hour session.
62474365|NCT03810703|EXPERIMENTAL|amphetamine 20 mg arm|Participant will receive d-amphetamine 20 mg oral capsule during this four hour session.
62474366|NCT00118235|EXPERIMENTAL|Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)|Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62474367|NCT02570477|ACTIVE_COMPARATOR|Fecal Microbiota Transplantatio|Fecal Microbiota Transplantation of stool from healthy donor to recipient.
62474368|NCT02570477|ACTIVE_COMPARATOR|Standard Therapy|125mg Vancomycin four times per day
62474369|NCT03913065||Included patients|Cardiac arrest patients from sites participating in the TTM-2 CT-substudy still unconscious 48 hours after cardiac arrest are routinely examined with head computed tomography as soon as possible after inclusion.
62474370|NCT06542458||Study Population|Adults ages 50 years and older who are fluent in English and are diagnosed with subjective cognitive concerns (SCD) or objective cognitive decline with mostly intact functioning (MCI diagnosis) as part of clinical work up
62474371|NCT06282874|EXPERIMENTAL|BM/LM cohort|Fifty eligible subjects will be divided into a BM cohort (brain parenchymal metastasis only) and an LM cohort (leptomeningeal metastasis ± brain parenchymal metastasis)
62474372|NCT05358860|EXPERIMENTAL|Acne Scars|
62474373|NCT00838630|EXPERIMENTAL|1|
62474374|NCT00838630|ACTIVE_COMPARATOR|2|
62474375|NCT05570487||N0A Group|patients with negative lymph nodes and resected lymph nodes less than 15
62474376|NCT05570487||N0B Group|patients with negative lymph nodes and resected lymph nodes no less than 15
62474377|NCT05570487||N+A Group|patients with positive lymph nodes and resected lymph nodes less than 15
62474378|NCT05570487||N+B Group|patients with positive lymph nodes and resected lymph nodes no less than 15
62474379|NCT03142165|EXPERIMENTAL|BMS-986263|
62474380|NCT03142165|PLACEBO_COMPARATOR|Placebo|
62474381|NCT06558981|EXPERIMENTAL|Radiotherapy + RAI|Patients in the experimental group would receive radiotherapy and RAI.
62474382|NCT06558981|ACTIVE_COMPARATOR|RAI|Patients in the control group would receive RAI.
62677903|NCT05648214|EXPERIMENTAL|Part A: Optional ALN-PNP Dose 5 or PB|"8 Participants, Randomized 6:2~This is an optional cohort, if there is a need for additional dose characterization of ALN-PNP."
62474383|NCT04490005||Acute brain injury|"Intensive care unit (ICU) admission after ABI, including traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH)~• Age 18 years old."
62474384|NCT05432687|OTHER|patient before Robotic-assisted Radical Prostatectomy|evaluation of deep abdominal wall before surgery : cough test + ulstrasonography of transversus abdominis
62474385|NCT04527107|EXPERIMENTAL|THR-149 dose level 1|
62474386|NCT04527107|EXPERIMENTAL|THR-149 dose level 2|
62474387|NCT04527107|EXPERIMENTAL|THR-149 dose level 3|
62474388|NCT04527107|EXPERIMENTAL|THR-149 + sham|
62474389|NCT04527107|EXPERIMENTAL|THR-149 + aflibercept flip-over|
62474390|NCT04527107|ACTIVE_COMPARATOR|Aflibercept + THR-149 flip-over|
62474391|NCT04527107|ACTIVE_COMPARATOR|Aflibercept + sham|
62474392|NCT06084494|EXPERIMENTAL|Test Condition 1|Variable Test Condition 1 WBGT 28 °C Clothing High Visibility Air Temperature 40 °C RH % 20 % Vapor Pressure 2.3 kPa Walking Speed 5 km/h Time 70 min
62474393|NCT06084494|EXPERIMENTAL|Test Condition 2|Variable Test Condition 2 WBGT 28 °C Clothing High Visibility Air Temperature 40 °C RH % 20 % Vapor Pressure 2.3 kPa Walking Speed 8 km/h Time 70 min
62306684|NCT03429556|EXPERIMENTAL|Botulinum Neurotoxin Serotype E Dose 3|Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
62474394|NCT06084494|EXPERIMENTAL|Test Condition 3|Variable Test Condition 3 WBGT 28 °C Clothing High Visibility Air Temperature 31 °C RH % 70 % Vapor Pressure 3.1 kPa Walking Speed 5 km/h Time 70 min
62474395|NCT06084494|EXPERIMENTAL|Test Condition 4|Variable Test Condition 4 WBGT 28 °C Clothing High Visibility Air Temperature 31 °C RH % 70 % Vapor Pressure 3.1 kPa Walking Speed 8 km/h Time 70 min
62474396|NCT05066217|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: Matching Placebo - Cohort 2 Matching placebo will be administered twice a day (BID) in equally divided doses with food.
62474397|NCT05066217|EXPERIMENTAL|Active|"Drug: EPX-100 drug product is an oral aqueous solution of clemizole hydrochloride and provided in a concentration of 5 mg/mL.~Other Name: Cohort 1"
62474398|NCT00811655|EXPERIMENTAL|Pre-Operative SRS|SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.
61919987|NCT02480907|NO_INTERVENTION|Control group - TAU|Parents of \~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will get treatment as usual and take part in conventional parental intervention groups.
62474399|NCT01499186|NO_INTERVENTION|Control group|There will be no participation in a training program. The control group will perform all measurements.
62474400|NCT01499186|EXPERIMENTAL|Intervention group|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators. These subjects will perform all measurements.
62474401|NCT00652418|ACTIVE_COMPARATOR|Arm 1|
62474402|NCT00652418|EXPERIMENTAL|Arm 2|
62474403|NCT05439057|EXPERIMENTAL|Remimazolam group|Remimazolam is started during induction of anesthesia at the rate of 0.3 mg/kg/hr and stopped 20 minutes before end of operation.
62474404|NCT05439057|PLACEBO_COMPARATOR|Control group|0.9% normal saline is started during induction of anesthesia at the rate of 0.3 ml/kg/hr and stopped 20 minutes before end of operation.
62474405|NCT02115347|EXPERIMENTAL|Ertugliflozin 15 mg - Moderate Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
62474406|NCT02115347|OTHER|Ertugliflozin 15 mg - Healthy Participants|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
62474407|NCT02115347|EXPERIMENTAL|Ertugliflozin 15 mg - Mild Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
62474408|NCT05867862|NO_INTERVENTION|Conventional dental care|The instructions regarding OH given to the children and their parents will be the same than the one usually given by the maxilla-facial surgeons or the orthodontists during their annual follow-up visits. If the patients are in need of dental care, they will be encouraged to contact their dentist.
62677904|NCT05648214|EXPERIMENTAL|Part A: JPN ALN-PNP Dose 4 or PB|8 Japanese Participants only, Randomized 6:2
62677905|NCT05648214|EXPERIMENTAL|Part A: JPN ALN-PNP Dose 5 or PB|8 Japanese Participants only, Randomized 6:2
62677906|NCT05648214|PLACEBO_COMPARATOR|Part B: Placebo|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
61919988|NCT02483052|EXPERIMENTAL|RejuvenAir|RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
62306685|NCT00004909||Oral chemotherapy|
62306686|NCT00004909||Parenteral chemotherapy|
62306687|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
62306688|NCT01401140|ACTIVE_COMPARATOR|St Thomas|
62306689|NCT01401140|EXPERIMENTAL|Custodiol|
62306690|NCT05758038||group 1|Patients with benign thyroid nodules undergo RFA
62306691|NCT05758038||group 2|Patients with benign thyroid nodule undergo MWA
62677907|NCT05648214|EXPERIMENTAL|Part B: ALN-PNP Dose 3|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
61919166|NCT02054871|EXPERIMENTAL|EGFR 30-60|"Experimental: RIPC Remote preconditioning Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles."
62118873|NCT06353282|EXPERIMENTAL|MDMA Psychotherapy|Open-label fixed-dose trial whereby 10 youth with treatment-resistant PTSD will be recruited. Treatment-resistant depression is defined as having continued DSM-5 diagnosis of PTSD following at least 3 months of psychotherapy and (either separately or combined) at least 3 months SSRI pharmacotherapy. Prior to entering the trial, youth will undergo a preliminary medical and psychiatric screening to determine eligibility. Eligible youth will then proceed to 3-month MDMA-assisted psychotherapy, which includes 13 sessions of psychotherapy with two MDMA experimental medication sessions of 80mg and 120mg, respectively. Study assessments will include a baseline assessment, weekly assessments throughout the course of the treatment trial, and assessments at 3 months and 6 months post-treatment.
62474409|NCT05867862|EXPERIMENTAL|Oral hygiene improvement|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist. During this consultation the children will be incited to have a better OH, oral and written explanations will be provided. The goal is to have the best understanding of the importance of a good OH and brushing technique from the children and the parents.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months, in order to try and keep the child and parent motivation to a maximum and also assess the OH of the patient."
62306692|NCT00064701|EXPERIMENTAL|Tacrolimus|Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
62306693|NCT00064701|ACTIVE_COMPARATOR|Tacrolimus Modified Release|Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
62306694|NCT00064701|ACTIVE_COMPARATOR|Cyclosporine|Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
61919167|NCT02054871|EXPERIMENTAL|EGFR 60-90|Experimental: RIPC Remote preconditioning. EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
62306695|NCT02838550|EXPERIMENTAL|MOI and PEDOMETER|Accessing to a motivational online intervention and wearing an unblinded pedometer (in order to receive feedback of the steps taken).
62306696|NCT02838550|EXPERIMENTAL|MOI (without PEDOMETER)|Accessing to a motivational online intervention and wearing a blinded pedometer (in order to not receive feedback of the steps taken).
62118874|NCT01424540|EXPERIMENTAL|Treatment A|GSK2336805 150mg
62118875|NCT01424540|PLACEBO_COMPARATOR|Treatment B|GSK2336805 Placebo
62118876|NCT04628715|EXPERIMENTAL|Supervised RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The main goal during this intervention is to breath at resonance frequency which is slower than the usual breathing frequency. Participants will be guided towards this lower breathing frequency by using appropriate breathing techniques and the provision of a breathing pacer during the supervised sessions. During home practice, the participants will be provided with an application which will visualise a breathing pacer at their resonance frequency. At the third session, participants will no longer receive a breathing pacer but are instructed to breath in phase with their heart rate which is visualised on the computer screen instead of the breathing pacer.
62118877|NCT04628715|SHAM_COMPARATOR|Supervised sham RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The sham-control treatment will follow the same steps as outlined in the supervised intervention arm. However, the participants in this control group will not receive any information regarding their own heart rate and they will not practice at their resonance frequency. Instead, a default mode will be shown during the sessions and in their application for home practice.
62118878|NCT04628715|EXPERIMENTAL|Non-supervised RSA biofeedback|1 short guided session (30 minutes) and daily practice (20 minutes; 4 bouts of 5 minutes) for 5 weeks. The biofeedback protocol will be provided by an application, similar to the supervised protocol but without guidance throughout the sessions, except for the first session. During this first session, the information will be provided about the application and the heart rate sensor (Polar band) which will detect changes in heart rate during the training. In addition, the resonance frequency of the participant will be determined so they can practice breathing at this frequency for the next 5 weeks.
62118879|NCT04628715|NO_INTERVENTION|No intervention|No intervention is given.
62306697|NCT02838550|NO_INTERVENTION|CONTROL|Wearing a blinded pedometer (in order to not receive feedback of the steps taken).
62306698|NCT02217735|EXPERIMENTAL|Writing Intervention - Expressive Arm|Participants are asked to write about the most traumatic or stressful experience of their entire lives in three, 20 minute writing sessions.
62306699|NCT02217735|ACTIVE_COMPARATOR|Writing Intervention - Neutral Arm|Participants are asked to write about what they did the day before, refraining from including emotional details.
62306700|NCT06342167|EXPERIMENTAL|Concurrent immunotherapy and radiotherapy|Sintilimab + radiotherapy + enteral nutritional emulsion (TPF-T)
62474410|NCT06172894|EXPERIMENTAL|APN401|Intravenous infusion of APN401 in 3-weekly (i.e. 21 days) intervals for a maximum of 4 doses at either 1.5x10\^7 PBMCs/kg (i.e., Dose Level 1) or 4.5x10\^7 PBMCs/kg (i.e., Dose Level 2), depending on assigned cohort
61919168|NCT02054871|NO_INTERVENTION|EGRF 30-60|"No Intervention: Remote preconditioning control Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Patients randomised to this group will receive routine care."
61919169|NCT02054871|NO_INTERVENTION|EGRF 60-90|No Intervention: Remote preconditioning control EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Patients randomised to this group will receive routine care.
61919989|NCT00107926|EXPERIMENTAL|licarbazepine|
61919990|NCT00107926|PLACEBO_COMPARATOR|Placebo|
62118880|NCT05591144|EXPERIMENTAL|STOP group|a 10mg/d tapering 14-day course of oral prednisone intervention (the initial dose: 1mg/kg/day, max 60mg/day) in combination with ginkgo biloba agent (120mg, three times/day)
62306701|NCT01738399|EXPERIMENTAL|Coffee|Subjects take 4 cups of coffee mix per day for 24 weeks
62306702|NCT01738399|PLACEBO_COMPARATOR|Placebo|Subjects take 4 cups of placebo per day for 24 weeks
62306703|NCT01479205||mite allergic patients without SIT|patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy
62306704|NCT01479205||mite allergic patients with SIT|patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy
62306705|NCT05710874|EXPERIMENTAL|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
62306706|NCT05710874|EXPERIMENTAL|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoride) paste (MI Paste Plus®) in addition to twice daily use of conventional toothpaste..
62306707|NCT05710874|EXPERIMENTAL|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
62306708|NCT05710874|PLACEBO_COMPARATOR|Conventional|Twice daily use of conventional toothpaste.
62306709|NCT01639482||Citalopram|Patients with bipolar disorder
62306710|NCT01639482||Placebo|Patients with bipolar disorder
62474411|NCT03144050||0|Control - no diabetes
62474412|NCT03144050||1|Diabetes
62474413|NCT03144050||2|Diabetes w/neuropathy
62474414|NCT03144050||3|Diabetes with vascular disease
62474415|NCT03144050||4|Diabetes w/healed ulcer
62474416|NCT03144050||5|Diabetes with current ulcer
62118881|NCT05591144|PLACEBO_COMPARATOR|placebol group|Patients took oral standardized Ginkgo biloba extracts (120 mg daily) three times a day.
62118882|NCT03943459|NO_INTERVENTION|Control|20 Patients on placebo
62118883|NCT03943459|NO_INTERVENTION|Atorvastatin|20 patients treated with atorvastatin 80 mg/day
62118884|NCT03943459|EXPERIMENTAL|Quercetin|20 patients treated with quercetin 500 mg/day
62118885|NCT06676020||Febrile Convulsion Group|
62118886|NCT06676020||Control Group|
62118887|NCT01027624||Hyperchlesterolaemia|Participants undertreated with hypercholesterolaemia
62118888|NCT02387099|ACTIVE_COMPARATOR|Conventional Everolimus dosing according to label|"everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)~+ further treatment according to standard of care"
62118889|NCT02387099|EXPERIMENTAL|3 week Dose Induction of Everolimus|"an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)~+ further treatment according to standard of care"
62118890|NCT00001304|EXPERIMENTAL|PTH 1-34|All patients received twice daily synthetic Human Parathyroid Hormone 1-34.
62118891|NCT00001304|EXPERIMENTAL|Calcitriol & Calcium|All patients received twice daily Calcitriol and Calcium 1000mg divided into four doses daily.
62118892|NCT06354283|EXPERIMENTAL|Intervention|Progressive muscle relaxation techniques were explained to the women from the couples assigned to the Intervention Group by a researcher. In addition to relaxation exercises, deep breathing movements were also explained to the women and progressive muscle relaxation exercises and breathing exercises were performed together. The importance of the exercises and how to do them were explained to the women for about 30 minutes by the researcher and then demonstrated practically for 30 minutes. Each progressive muscle relaxation exercise session lasted approximately 20-25 minutes. The women in the intervention group continued the exercises at home three times a week for four weeks. The women in the intervention group were telephoned once a week by the researcher to provide reminders and counseling regarding the study
62118893|NCT06354283|NO_INTERVENTION|Control|"The study was announced on social media and online to identify women and men who met the sample selection criteria. Couples who scored between 20-40 on the New Sexual Satisfaction Scale for women and 11 or higher on the Arizona Sexual Life Scale for men and women were randomized into two groups. A data collection form was applied to the couples included in the sample.~The Control Group was followed up by continuing the daily routine. At the end of two and four weeks, the New Sexual Satisfaction Scale and Arizona Sexual Life Scale were administered to all women and their partners."
62118894|NCT04189770||Observational (questionnaire, accelerometer, EMA, survey)|Patients and partners complete questionnaires over 60 minutes about demographic information, stress, coping, and lifestyle behaviors at baseline and end of study. Patients and partners also receive an accelerometer and complete EMA questionnaire on stress, coping, physical activity, and eating behaviors over 5-10 minutes QID (7:30 am, 11:30 am, 3:30 pm, and 7:30 pm) via an smartphone app for 14 days. Patients and partners also complete a survey on nutrition BIW for a total of 4 surveys.
62118895|NCT01964937|EXPERIMENTAL|Group 1|"At Months 0 and 1, participants in Group 1 will receive one injection of AIDSVAX B/E ® administered intramuscularly (IM) in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid.~At Months 3 and 6, participants will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
62118896|NCT01964937|EXPERIMENTAL|Group 2|"At Months 0 and 1, participants in Group 2 will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive the AIDSVAX ® B/E vaccine administered IM in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid."
62118897|NCT01964937|EXPERIMENTAL|Group 3|"At Months 0 and 1, participants in Group 3 will one injection of the AIDSVAX B/E vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid.~At Months 3 and 6, participants will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
62118898|NCT01964937|EXPERIMENTAL|Group 4|"At Months 0 and 1, participants in Group 4 will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid."
62118899|NCT01964937|EXPERIMENTAL|Group 5|At Months 0, 1, 3, and 6, participants in Group 5 will receive one injection of the DNA-HIV-PT123 vaccine administered in the left deltoid and one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid.
62118900|NCT00815750|OTHER|Phase I - Information Gathering|
62118901|NCT00815750|OTHER|Phase 2 - Decision Aid|
62118902|NCT04632368|ACTIVE_COMPARATOR|Transcendental Meditation Intervention Arm|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to a randomized group of eligible HCPs ( N=40)providing care during COVID-19 pandemic.
62306711|NCT03321812|EXPERIMENTAL|decalcification bone scaffold|Decalcification bone scaffold is a novel tissue engineered acellular matrix scaffold with the closest biomechanics and structure to normal cartilage.
62306712|NCT03321812|ACTIVE_COMPARATOR|Microfracture|Microfracture is a conventional treatment for cartilage lesions of the knee.
62306713|NCT05631925|ACTIVE_COMPARATOR|Group bolus|Propofol will be administered in bolus doses of 0.5mg/kg. Doses will be determined according to the clinical condition of the patient.
61919170|NCT01307605|ACTIVE_COMPARATOR|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
62118903|NCT04632368|NO_INTERVENTION|Treatment as usual(TAU) Control Arm|Control group consists of eligible HCPs who are randomized to control group(N=40) and would not receive any intervention. At the end of 3 month study period, control group participants would be eligible for TM training.
62306714|NCT05631925|ACTIVE_COMPARATOR|Group infusion|Propofol will be administered as 10mg/kg/hour infusion. The infusion dose will be adjusted so that the Bispectral index (BIS) is in the range of 40-60.
62474417|NCT00002831|EXPERIMENTAL|Deoxyazacytidine + Busulfan + Cyclophosphamide|Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation
62474418|NCT02649179|EXPERIMENTAL|local infiltration with ropivacaine|patients were to receive 0.75% ropivacaine
62474419|NCT02649179|PLACEBO_COMPARATOR|local infiltration with 0.9% saline|patients were to receive placebo
62474420|NCT01992991|EXPERIMENTAL|Transcranial direct current stimulation|Anodal stimulation
62474421|NCT01992991|SHAM_COMPARATOR|Sham stimulation|30 sek of Transcranial direct current stimulation
62474422|NCT01931722|ACTIVE_COMPARATOR|Branched chain amino acid|Branched chain amino acid as food supplement
62474423|NCT01931722|ACTIVE_COMPARATOR|Weight training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1RM (repetition maximum). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
62474424|NCT04715893|EXPERIMENTAL|Ostomy belt group|Participants in this group will receive ostomy belts for eight weeks.
62474425|NCT01747135|EXPERIMENTAL|Open label|
62474426|NCT00829673|EXPERIMENTAL|1|
62306715|NCT04427657|ACTIVE_COMPARATOR|Controls|39 patients with knee osteoarthritis undergoing arthroscopic debridement
62306716|NCT04427657|EXPERIMENTAL|Cases|39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
62474427|NCT00829673|ACTIVE_COMPARATOR|2|Focalin®
62474428|NCT01068821|ACTIVE_COMPARATOR|Egg crate foam mattress|Patients will be placed on egg-crate foam mattress instead of a gel pad by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
62474429|NCT01068821|ACTIVE_COMPARATOR|Gel pad|Patients will be placed on gel pad instead of egg-crate foam mattress by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
62474430|NCT02952456||Bereaved families|Person who have lost a loved one from an epilepsy-related death with interview with a psychologist
61919171|NCT01307605|ACTIVE_COMPARATOR|Rituximab plus Lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
62306717|NCT06005506|ACTIVE_COMPARATOR|Probiotic + fiber|"These subjects will be given a passive symbiotic preparation again consisting of two sticks of 1500mg each to be taken once a day:~* Purple Sachet - Prebiotic - Composed of 500mg acacia fiber (Fibregum®) with high prebiotic activity and 500mg mai starch. Excipients and flavorings.~* White Sachet - Probiotic - 30 Billion bacterial strains Lactobacillus plantarum LP (PBS067- EU Collection DSM 24937), Lactobacillus acidophilus L."
62474431|NCT02952456||Patients with épilepsy|Patients with épilepsy with interview with a psychologist
62474432|NCT02952456||Relatives of patients with epilepsy|Relatives (Parents / spouse/ Husband) of patients with epilepsy with interview with a psychologist
62474433|NCT06099652|EXPERIMENTAL|group A|611 300 mg Q2W, subcutaneous (SC) injection
62474434|NCT06099652|EXPERIMENTAL|group B|611 450 mg Q2W, subcutaneous (SC) injection
62474435|NCT06099652|PLACEBO_COMPARATOR|placebo group|placebo Q2W, subcutaneous (SC) injection
62474436|NCT04206358|EXPERIMENTAL|treatment group|The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001), Once every 2 weeks
62474437|NCT01913405|EXPERIMENTAL|BAX855|"Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.~Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed."
62474438|NCT06158386|EXPERIMENTAL|Chidamide combined with Linperlisib|
61919172|NCT04356976|EXPERIMENTAL|Ventralex|Repair with Ventralex hernia patch in sublay position
61919173|NCT04356976|ACTIVE_COMPARATOR|Stratafix|Repair with Stratafix suture
61919174|NCT02723318|EXPERIMENTAL|Financia Coaching & Social Services Referrals|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
61919175|NCT02723318|ACTIVE_COMPARATOR|Social Services|Enrollment in the control arm offers access to social services referrals.
62474439|NCT05922696|ACTIVE_COMPARATOR|Group A|Group A: Weekly Cholecalciferol: 25 eligible hemodialysis patients on oral cholecalciferol 50.000IU Cholecalciferol, once weekly, for 3 months' duration
62474440|NCT05922696|ACTIVE_COMPARATOR|Group B|Group b: Monthly Cholecalciferol: 25 eligible hemodialysis patients on oral cholecalciferol 200.00IU Cholecalciferol, once monthly, for 3 months' duration
62474441|NCT04102085||Mothers under 30|no intervention will be administered
62474442|NCT03574558|EXPERIMENTAL|MD-Logic Switch Advisor|MD-Logic Switch Advisor Algorithm for personalized automated determination of insulin pump settings for subjects with type 1 diabetes switching from MDI to pump therapy and vice versa
62474443|NCT02460653|NO_INTERVENTION|Current|Current level of HFNC support
62474444|NCT02460653|EXPERIMENTAL|Low|Low flow range per kg.
62474445|NCT02460653|EXPERIMENTAL|Medium|Medium flow range per kg.
62474446|NCT02460653|EXPERIMENTAL|High|High flow range per kg
62474447|NCT02181140|OTHER|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
62474448|NCT01033877|EXPERIMENTAL|TdaP vaccine|
62474449|NCT01033877|ACTIVE_COMPARATOR|Td vaccine|
62474450|NCT05050071|ACTIVE_COMPARATOR|Calcium hydroxide (7 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
62474451|NCT05050071|EXPERIMENTAL|Allium sativum (7 days)|is a species of bulbous flowering plant in the onion genus Allium
62474452|NCT05050071|EXPERIMENTAL|Combination (7 days)|combination between Calcium hydroxide and Allium sativum
62474453|NCT05050071|ACTIVE_COMPARATOR|Calcium hydroxide (14 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
62306718|NCT06005506|EXPERIMENTAL|Probiotic + Prebiotic|"These subjects will be given an active symbiotic preparation consisting of two differently colored sticks of 1500mg each to be taken once a day:~* Purple Sachet - Active Prebiotic - 500 mg of Fibregum®, a slow-fermenting prebiotic fiber and 500 mg of standardized extract of pigmented Zea Mays L fruit, rich in anthocyanins and polyphenols. Excipients and flavorings.~* White Sachet - Probiotic - 30 Billion Bacterial Strains Lactobacillus plantarum LP (PBS067- EU Collection DSM 24937), Lactobacillus acidophilus LA (PBS066 - EU Collection DSM 24936) and Bifidobacterium animalis subsp. lactis BL (BL050 - Eu Collection DSM 25566)."
62474454|NCT05050071|EXPERIMENTAL|Allium sativum (14 days)|is a species of bulbous flowering plant in the onion genus Allium
62474455|NCT05050071|EXPERIMENTAL|Combination (14 days)|combination between Calcium hydroxide and Allium sativum
62474456|NCT05956561||only one group|all patients seeking delayed dental implant placement above 18 years and medical free, no previous augmentation or sinus lifting
61919176|NCT05338398|PLACEBO_COMPARATOR|Control Group (Group 1): Standard Therapy|"Group 1 will receive standard therapy with conventional oral care to prevent oral mucositis consisting of oral hygiene and rinses/mouthwashes with saline solutions 3-5 times daily.~Half of the subjects in Group 1 will also receive Bocaliner™ devices"
61919177|NCT05338398|EXPERIMENTAL|Intervention Group (Group 2): Benzydamine mouthwash|Group 2 will receive benzydamine mouthwashes 3-5 times daily. Half of the subjects in Group 1 will also receive Bocaliner™ devices.
62118904|NCT06068244|EXPERIMENTAL|3D printed crowns|Participants received 3D printed resin crowns
62118905|NCT06068244|ACTIVE_COMPARATOR|Zirconia crowns|Participants received ready made zirconia crowns
62306719|NCT01812304|EXPERIMENTAL|hands-on training|probands perform predefined maneuvers to manage a vaginal breech hands-on after one instruction
62306720|NCT01812304|ACTIVE_COMPARATOR|frontal teaching|Probands perform predefined maneuvers to resolve a vaginal breech after forntal teaching
62306721|NCT01980446|OTHER|1:Mismatch negativity|Presence of the mismatch negativity during the cortical auditory-evoked potential would predict a favorable outcome in comatose survivors after cardiac arrest.
62306722|NCT01793207||Normal|Subjects who had a normal colonoscopic examination (No polyps, masses or any evidence of colorectal neoplasia)
62306723|NCT01793207||colorectal cancer|Patients with endoscopic and histopathological evidence of colorectal cancer
62306724|NCT01793207||Adenoma|Patients with colorectal adenomas only detected on colonoscopy
62306725|NCT01793207||Hyperplastic polyps|Patients with hyperplastic polyps detected on colonoscopy.
62306726|NCT02830373||LVIS stents group|patients with unruptured intracranial saccular aneurysms which located in the internal carotid artery or vertebra-basilar artery will be treated with a LVIS stent with coils
62306727|NCT02182037|EXPERIMENTAL|BIBT 1011 BS|
62306728|NCT02182037|PLACEBO_COMPARATOR|BIBT 1011 BS placebo|
62474457|NCT00467363|ACTIVE_COMPARATOR|Aspirin|81mg of low-dose aspirin plus 400micrograms of folic acid.
62474458|NCT00467363|PLACEBO_COMPARATOR|Placebo|400micrograms of folic acid.
62474459|NCT05643976|ACTIVE_COMPARATOR|Standard-of-care cardiac rehabilitation (SOC CR)|
62474460|NCT05643976|EXPERIMENTAL|Cardiac Rehabilitation + KardioPAC (CR+KardioPAC)|
62474461|NCT06356766|EXPERIMENTAL|Telerehabilitation Group|Modified Duran Protocol via telerehabilitation
61919178|NCT00842452|EXPERIMENTAL|Oral Topotecan|
62306729|NCT01690832|ACTIVE_COMPARATOR|standard saline infusion|standard i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure.
62306730|NCT01690832|ACTIVE_COMPARATOR|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.
62306731|NCT06013787|EXPERIMENTAL|Intervention Group|"In the communities randomized into the intervention arm, the pregnant women who enrolled in the study received a month long prenatal health education intervention called Nuestras Historias, a digital story curriculum. This video-based curriculum was delivered by by community health workers during their normal home visits and group visits."
62306732|NCT06013787|NO_INTERVENTION|Control Group|In the communities randomized to the control arm, the pregnant women who enrolled in study had normal visits and group visits with community health workers and received standard prenatal health education, but with no video intervention.
62306733|NCT01606722||Darunavir-ritonavir monotherapy|HIV-infected patients with undetectable viral load for at least for 6 months on stable therapy and no darunavir related mutations in the HIV-protease gene
62306734|NCT01744899||Prolonged sitting|Includes individuals who spent an average of at least 6 hours a day sitting over the past year.
62474462|NCT06356766|ACTIVE_COMPARATOR|Face-to-face Rehabilitation Group|Modified Duran Protocol
62474463|NCT04852978|EXPERIMENTAL|Wave 1 Dose 1|
62474464|NCT04852978|EXPERIMENTAL|Wave 1 Dose 2|
62474465|NCT04852978|EXPERIMENTAL|Wave 1 Dose 3|
62474466|NCT04852978|EXPERIMENTAL|Wave 1 Vaccine only|
62474467|NCT04852978|EXPERIMENTAL|Wave 2 Dose 1|
62474468|NCT04852978|EXPERIMENTAL|Wave 2 Dose 2|
62474469|NCT04852978|EXPERIMENTAL|Wave 2 Vaccine only|
62474470|NCT04852978|EXPERIMENTAL|Wave 3 Dose 1|
61919179|NCT03500679|EXPERIMENTAL|Group 1: ExPEC4V (JNJ-63871860)|Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram \[mcg\]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.
62474471|NCT04852978|EXPERIMENTAL|Wave 3 Dose 2|
62474472|NCT04852978|EXPERIMENTAL|Wave 3 Vaccine only|
62474473|NCT04852978|EXPERIMENTAL|Wave 4 Dose 1|
62474474|NCT04852978|EXPERIMENTAL|Wave 4 Vaccine only|
62474475|NCT06502340||patient|All patients who will undergo elective robotic-assisted laparoscopic radical prostatectomy
62474476|NCT02687126|OTHER|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
62306735|NCT01744899||Control|Includes individuals who spent 4 hours or less/day sitting over the past year.
62306736|NCT01828125|ACTIVE_COMPARATOR|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
62306737|NCT01828125|ACTIVE_COMPARATOR|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
62306738|NCT06209957|ACTIVE_COMPARATOR|Group I|Local corticosteroid injection in group I: 1 ml of triamcinolone acetonide (40 milligram/1.0 mL) was locally injected in the wrist using a 25-gauge needle, which was slowly inserted 1 cm proximal to the distal wrist-flexion crease just on the radial side of the palmaris longus tendon. The injection was held if the patient experienced pain or a sensation of pins and needles in the median nerve distribution.
62306739|NCT06209957|ACTIVE_COMPARATOR|Group II|Local PRP injection in group II: 2 ml of PRP was injected using the same technique of corticosteroid local injection after 2-step centrifugation of the patient's blood using a specific device. Non-steroidal anti-inflammatory drugs were avoided for two weeks before and after the procedure to prevent the possibility of inhibition of platelet function.
62474477|NCT04638179||HF-PAC|(1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.
62118906|NCT01772420|EXPERIMENTAL|Arm A (lenalidomide, eltrombopag olamine)|"Patients with baseline platelet counts \>= 50,000 receive lenalidomide PO daily or QOD on days 1-21. If platelet counts fall below 50,000, patients discontinue lenalidomide and receive eltrombopag olamine PO daily or QOD until platelet count is maintained above 50,000 for 2 weeks. Patients then resume lenalidomide PO daily or QOD. If platelets fall below 50,000 again, patients receive eltrombopag olamine as before. When platelet counts are maintained above 50,000 for 2 weeks, patients resume lenalidomide concurrently with eltrombopag for all subsequent courses.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
62118907|NCT01772420|EXPERIMENTAL|Arm B (eltrombopag olamine, lenalidomide)|"Patients with baseline platelet counts \< 50,000 receive eltrombopag olamine PO daily or QOD on days 1-28 until platelet count is maintained above 50,000 for 2 weeks. Patients then receive treatment as in Arm A.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
62118908|NCT04429230|ACTIVE_COMPARATOR|Real tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
62118909|NCT04429230|SHAM_COMPARATOR|Sham tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
62118910|NCT00411099|EXPERIMENTAL|1|
62118911|NCT00411099|EXPERIMENTAL|2|
62118912|NCT00411099|PLACEBO_COMPARATOR|3|
62118913|NCT02753413|EXPERIMENTAL|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
62118914|NCT02753413|ACTIVE_COMPARATOR|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
62306740|NCT02589587|ACTIVE_COMPARATOR|sleeve gastrectomy|Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.
62306741|NCT02589587|OTHER|no intervention|Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.
62306742|NCT05041543|EXPERIMENTAL|NTX-101 Group A|Day 1: One time administration, single drop. 4 subjects randomized 3:1 to NTX-101 or placebo.
62306743|NCT05041543|EXPERIMENTAL|NTX-101 Group B|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
62306744|NCT05041543|EXPERIMENTAL|NTX-101 Group C|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
62306745|NCT05041543|EXPERIMENTAL|NTX-101 Group D|Day 1: One time administration, two drops. Day 3-7: Two time administration, two drops each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
62306746|NCT05041543|EXPERIMENTAL|NTX-101 Group E|Day 1: One time administration, four drops. Day 3-7: Two time administration, four drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
61919180|NCT03500679|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.
61919991|NCT04043780|EXPERIMENTAL|Decompression prototype splint|The patients of this group will wear the decompression prototype splint.
61919992|NCT04043780|ACTIVE_COMPARATOR|standard splint|The patients of this group will wear a standard splint.
62118915|NCT00131144|EXPERIMENTAL|Octreotide Acetate in Microspheres 20 mg|20 mg will be administered im once every 4 weeks
62118916|NCT00131144|EXPERIMENTAL|Octreotide Acetate in Microspheres 30 mg|30 mg will be administered im once every 4 weeks
62306747|NCT05599217||Case group (CSDH group)|CSDH patients recruited from neurosurgical department at 4 medical centres in China, which have apparent clinical symptoms and are confirmed by computed tomography or magnetic resonance imaging.
62306748|NCT05599217||Control group (Healthy group)|non-CSDH, age- and gender-matched patients recruited from ophthalmology, otolaryngology, and physical examination department at 4 medical centres in China.
62306749|NCT01277146|EXPERIMENTAL|OMP-59R5|
62306750|NCT02537860|EXPERIMENTAL|Three PVB injections|Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
62118917|NCT00131144|PLACEBO_COMPARATOR|Placebo|
62474478|NCT04638179||HF-non PAC|(2)The control group received traditional health education in general care and routine health care.
62474479|NCT02295163|SHAM_COMPARATOR|Sham procedure|injection of NACL 0,9% in the stellate ganglion
62118918|NCT05061641|ACTIVE_COMPARATOR|progesterone 200mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 200mg
62118919|NCT05061641|EXPERIMENTAL|progesterone 400mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 400mg
62474480|NCT02295163|EXPERIMENTAL|Stellate ganglion block|injection of Bupivacaine 0,5% in the stellate ganglion
62306751|NCT02537860|EXPERIMENTAL|Five PVB injections|Patients will receive five PVB injections between T11 and L3.
62306752|NCT02226068|OTHER|CsA-ECP|Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given
62306753|NCT02226068|OTHER|ECP-CsA|Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given
62306754|NCT01962454|EXPERIMENTAL|Arm 1|Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
62474481|NCT06559020|EXPERIMENTAL|kangroo mother care|he KMC group will receive continuous skin-to-skin contact between mother and infant for 24 hours a day, with support and training in kangaroo positioning and exclusive breastfeeding.
62677908|NCT05648214|EXPERIMENTAL|Part B: ALN-PNP Dose 4|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
62677909|NCT05648214|EXPERIMENTAL|Part B: ALN-PNP Dose 5|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
62118920|NCT05061641|EXPERIMENTAL|progesterone 600mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 600mg
61919181|NCT06522191|EXPERIMENTAL|Cross-Education (CE) Group|Participants in the CE group will receive repetitive task practice through a robotic rehabilitation (RR) device on the less-affected upper extremity for 20 minutes, twice a week, for 5 weeks, in addition to a physical therapy (PT) program provided 5 days a week. This CE training will be conducted prior to the RR sessions performed on the more affected UE within the PT intervention to facilitate cross-education and support motor priming. In this study, RR applications will utilize an intelligent feedback RR system (A2- Guangzhou Yikang Medical Equipment Industrial Co., Ltd., China).
62118921|NCT01240837|ACTIVE_COMPARATOR|glucose|
62118922|NCT01240837|ACTIVE_COMPARATOR|sucrose|
62474482|NCT06559020|NO_INTERVENTION|conventional care|The control group will receive conventional neonatal care, which includes placing newborns in open cots with appropriate heating or cooling based on weather conditions. Mothers will receive guidance on the benefits of exclusive breastfeeding and support to initiate breastfeeding, but will not have the structured kangaroo mother care provided to the experimental group.
62474483|NCT04570215|ACTIVE_COMPARATOR|Gotcha! Therapy Application|"Participants will receive the Gotcha therapy daily for six weeks.Participants are required to use the app everyday for a maximum of 45 minutes. After this time they enter a twelve week block with no therapy or maintenance of therapy (see Gotcha maintenance arm).~This aim of this arm is to invesitgate the efficacy of the Gotcha therapy for proper-noun anomia in mild-moderate patients with dementia (Alzheimer's disease, vascular dementia and mixed)"
62677910|NCT04829214|EXPERIMENTAL|OTO-313|
62677911|NCT04829214|PLACEBO_COMPARATOR|Placebo|
62118923|NCT01240837|EXPERIMENTAL|palm sugar|
62118924|NCT01530698|EXPERIMENTAL|single step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for single-step antigen loading and TLR activation (TriMix-DC)
62118925|NCT01530698|ACTIVE_COMPARATOR|two step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for antigen loading and separately for TLR activation
62118926|NCT03443037||Amantadine group|Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician
62118927|NCT03443037||Control group|Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin
62118928|NCT02081274||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease between 2009 and 2013 in Samsung Medical Center
62118929|NCT06500962|PLACEBO_COMPARATOR|Usual Care|
62118930|NCT06500962|EXPERIMENTAL|Navigation + Usual Care|
62118931|NCT06500962|EXPERIMENTAL|Text Messaging + Usual Care|
62118932|NCT06500962|EXPERIMENTAL|Navigation + Text Messaging + Usual Care|
62118933|NCT02817724|ACTIVE_COMPARATOR|m-Health group|BENECA System: The m-health group will use the BENECA app for 8 weeks.
62118934|NCT02817724|EXPERIMENTAL|Integral Group|BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.
62118935|NCT02578108|ACTIVE_COMPARATOR|no diagnostic genicular nerve blocks|no diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
62118936|NCT02578108|ACTIVE_COMPARATOR|diagnostic genicular nerve blocks|Set of diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
62677912|NCT05026385|EXPERIMENTAL|Intervention|"The intervention group will receive initial nutrition and exercise consultations with a Registered Dietitian (RD) and Clinical Exercise Physiologist (CEP) to personalize the study protocol and recommendations to their needs. The intervention period (3 months) includes: a) whole-body resistance training exercise sessions completed three-times per week (at-home with loaned equipment and/or in-person at the research gym); b) biweekly nutrition education provided through video conferencing; and c) biweekly OA self-management support provided through video conferencing.~After the 3 month intervention, participants will receive bimonthly phone calls from a study staff member to encourage continued behavior changes during the 6 month maintenance phase."
62118937|NCT06512961|ACTIVE_COMPARATOR|Group Traditional BFR|This group will perform the training protocol with traditional BFR, using a pressure cuff as an occluder on both arms.
62118938|NCT06512961|EXPERIMENTAL|Group BFR TF|This group will perform the training protocol with BFR using TF on both arms.
62118939|NCT04956757|EXPERIMENTAL|Intervention Group|"exercise program consists of progressive scapula retraction exercises will be applied three times a week total 24 sessions.~Home exercise program will also advised two times a day."
62118940|NCT04956757|NO_INTERVENTION|Control Group|Control group will not perform scapula retraction exercises. AHD values of the control group will be compared to intervention groups both retracted and non-retracted conditions.
62474484|NCT04570215|ACTIVE_COMPARATOR|Gotcha! Therapy Application: Maintenance|"Participants will receive the Gotcha therapy for six weeks as described in the Gotcha arm. After this time they enter a twelve week block of maintenance of therapy gains made in the initial six week therapy block.~The maintenance block consists of a weekly test of the Gotcha outcome measure to monitor the therapy gains made during the therapy block. If any previously correctly named person is incorrectly named during these weekly tests then the participant must complete a 'top-up' therapy session. They will then be tested again the following week.~The aim of this arm is to compare Gotcha maintenance with Gotcha, to see if extra testing and therapy is required to maintain gains made during an initial intense therapy block."
62474485|NCT03429959|EXPERIMENTAL|SOCKNLEG|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
62474486|NCT03429959|ACTIVE_COMPARATOR|SIGVARIS Cotton|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
62474487|NCT02157623|EXPERIMENTAL|Red Light PDT and Blue Light PDT|The tumor clearance with one side treated with Levulan and Red light PDT, and the contralateral side treated with Blue light PDT.
62474488|NCT06429540|EXPERIMENTAL|Partially Demineralized Dentin Block|The Partially Demineralized Dentin Block will be prepared using the Tooth Transformer device to grind the extracted tooth and partially demineralize it. Leukocyte-Platelet Rich Fibrin (L-PRF) and liquid fibrinogen will then be added to create a block graft.
62118941|NCT00805571||Adult|Adult patients with end-stage kidney disease awaiting kidney transplantation.
62118942|NCT00805571||Pediatric|Children with end-stage kidney disease awaiting kidney transplantation.
62118943|NCT04783454|EXPERIMENTAL|Intervention|"* single (online) educational video on how the prevention program is designed and general advice on (how to adopt) a healthy lifestyle~* 12-week training program: 2 sessions of 60 minutes per week, with the focus of the first session on cardiovascular exercises, and the focus of the second session on mobility and strengthening exercises"
62474489|NCT06429540|ACTIVE_COMPARATOR|Xenograft|The Xenograft procedure will involve filling the socket with deproteinized bovine bone mineral, followed by the placement of a collagen membrane to cover the socket
62118944|NCT04783454|NO_INTERVENTION|control|no intervention (wait and see approach)
62118945|NCT05559346|EXPERIMENTAL|Research Group|Diplegic Cerebral Palsy
62118946|NCT05559346|ACTIVE_COMPARATOR|Control Group|Diplegic Cerebral Palsy
62118947|NCT05857813|EXPERIMENTAL|ASD teens and their caregiver|"Teens: (1) aged 11-20 years, currently enrolled in school between the sixth grade of elementary school and the third year of high school; (2) with a clinical diagnosis of ASD from a licensed mental health or medical professional based on DSM-5; (3) experiencing social difficulties as reported by parents in a structured intake interview; (4) scored ≧ 26 on the caregiver-reported Autism Spectrum Quotient (AQ), indicating clinical impairment associated with ASD (5) demonstrating verbal fluency in Chinese (6) with a full-scale IQ \> 70 on WAIS-IV; (7) with motivation to participate in the intervention; (8) with a caregiver who was fluent in Chinese and willing to participate as a social coach in the study.~Parents: (1) demonstrating verbal fluency in Chinese (2) with motivation to participate in the intervention and assist their children to do the homework assignments."
62118948|NCT06604871|EXPERIMENTAL|MiniMed™ 780G system with DS5|Subjects 2-6 years old with type 1 diabetes wearing the MiniMed™ 780G insulin pump in combination with the DS5 CGM.
62118949|NCT02960269|EXPERIMENTAL|Telehealth team assessment|Team assessment for back pain with nurse practitioner and physical therapist via telehealth
62118950|NCT03015454|EXPERIMENTAL|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the UCSF electronic health record.
62118951|NCT03015454|ACTIVE_COMPARATOR|Without InSight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the UCSF electronic health record.
62306755|NCT01962454|PLACEBO_COMPARATOR|Arm 2|Run-in Phase: All participants will receive oral D2O for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50 mL 70% D2O TID for 7 days, followed by a 50mL 70% D2O dose BID for the next 2 weeks. Treatment Phase: Subjects will receive testosterone IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks
62306756|NCT02238613|EXPERIMENTAL|radioactive stent|The radioactive stent carrying seeds iodine 125 is made of Polytetrafluoroethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the irradiation group patients.
62474490|NCT03060863|NO_INTERVENTION|1. Comparison|Families in this group will not receive any of the interventions.
62118952|NCT03617653|OTHER|Group A - Intervention|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis, Exercise intervention from Visit 2 to Visit 13, End of 3 month assessment.
62118953|NCT03617653|OTHER|Group B- Control|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis \& End of 3 month assessment.
62118954|NCT03264235|EXPERIMENTAL|Group 1 Exoskeleton|Both training groups will undergo inpatient physical therapy of the same duration and intensity. Group 1 will complete stair training wearing the Keeogo Exoskeleton in inpatient physical therapy.
62118955|NCT03264235|ACTIVE_COMPARATOR|Group 2 Traditional Therapy|Group 2 will complete traditional stair training in inpatient physical therapy.
62118956|NCT00675246|EXPERIMENTAL|A|Antenatal corticoid therapy
62118957|NCT01385384|OTHER|NeuRx|
62306757|NCT02238613|OTHER|plastic stent|The plastic stent is made of polyethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the conventional group patients.
62306758|NCT06206876|EXPERIMENTAL|Treatment (FL118)|Patients receive FL118 PO on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT or MRI throughout the trial. Patients may optionally undergo biopsy at screening and on study.
62306759|NCT01199341|EXPERIMENTAL|Treatment A|AZD1981, low dose, + Warfarin
62306760|NCT01199341|EXPERIMENTAL|Treatment B|AZD1981, high dose, + Warfarin
62306761|NCT06011070|EXPERIMENTAL|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
62306762|NCT06011070|NO_INTERVENTION|Control|No intervention Control
62118958|NCT06676410|EXPERIMENTAL|Codivir®|"The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step.~In Weeks 0-24, all participants will receive:~* Single solid formulation (in 1 tablet) 1x/day with:~  * Tenofovir (TDF) 300 mg~ * Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day From V0 (W0, D0) to V6 (W12, D84) participants randomized to Codivir® will receive Codivir® as complementary therapy to the above antiretrovirals on alternate days (every other day).~At V6 (week 12) treatment with Codivir® will end."
62118959|NCT06676410|ACTIVE_COMPARATOR|Antiretrovirals (ARTs)|"In Weeks 0-24, all participants will receive:~* Single solid formulation (in 1 tablet) 1x/day with:~  * Tenofovir (TDF) 300 mg~ * Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day"
62118960|NCT00588302|EXPERIMENTAL|A, 1|All patients received an open-label moexipril during the study period.
62306763|NCT03957083|ACTIVE_COMPARATOR|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62306764|NCT03957083|ACTIVE_COMPARATOR|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62306765|NCT03957083|ACTIVE_COMPARATOR|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62306766|NCT03957083|ACTIVE_COMPARATOR|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62306767|NCT03957083|ACTIVE_COMPARATOR|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62306768|NCT03957083|ACTIVE_COMPARATOR|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62306769|NCT01749059||Congenital Heart Defect|
62306770|NCT01293669|EXPERIMENTAL|TC-6987|
62306771|NCT01293669|PLACEBO_COMPARATOR|Placebo|
62306772|NCT02048878||Insomnia group|"Assessment of physiologic hyper-arousal across the two following domains:~1. Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~2. Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
62474491|NCT03060863|EXPERIMENTAL|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
62118961|NCT01111526|EXPERIMENTAL|LBH589, in Addition to Glucocorticoids|Phase I Dose Escalation, Followed by Phase II Treatment at Maximum Tolerated Dose (MTD) of LBH589, in Addition to Glucocorticoids.
62118962|NCT03532711||Chemotherapy|FOLFOX/XELOX/FOLFIRI
62306773|NCT02048878||Matched Control Group|"Assessment of physiologic hyper-arousal across the two following domains:~1. Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~2. Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
62306774|NCT03461926|EXPERIMENTAL|HAPA-treatment|(SB-related planning + daily text messages)
62306775|NCT03461926|NO_INTERVENTION|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
62306776|NCT04934202||Patients from the 1st epidemic wave|"One year after their discharge from the initial hospitalization, patients who presented symptoms during the evaluation in COMEBAC 1st wave in summer 2020 will benefit from a telephone assessment on the same schedule as that detailed above. If symptoms persist, they will be called to the day hospital for an assessment similar to the one detailed above."
62474492|NCT03060863|EXPERIMENTAL|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
62474493|NCT03060863|EXPERIMENTAL|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
62474494|NCT03060863|EXPERIMENTAL|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
62474495|NCT02412384||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
62474496|NCT02412384||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
62474497|NCT02412384||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
61919182|NCT06522191|SHAM_COMPARATOR|Control Group|Participants in the control group will be given lower extremity-focused exercises for 20 minutes, twice a week, for 5 weeks before the RR application included in the PT program, in order to eliminate the potential effect of the additional treatment provided in the study.
62677913|NCT05026385|NO_INTERVENTION|Usual Care|The control group will follow standard care procedures, which includes their usual activities. The control group will receive bimonthly contact during the study period through phone calls with a study staff member to encourage retention. However no recommendations or advice on nutrition, exercise or self-management will be provided.
62118963|NCT06047522|EXPERIMENTAL|Intervention|The participant will benefit from three immersion sessions with the virtual reality headset, either individually or in a group session, accompanied by a team member trained in the use of the headset (psychomotrician, occupational therapist, doctor, psychologist, facilitator). At each session, the scale of observed emotions and the cybermalaise questionnaire will be completed (T1, T2, T3). At sessions 1 (T1) and 3 (T3), the investigator will administer the ECPAI behavior scale.
62118964|NCT05585775|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
62120032|NCT04586686|OTHER|Group 2: left ovarian biopsy|Patients in group 2 will undergo a laparoscopy for an ovarian biopsy from the left ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels \<2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
62306777|NCT04934202||Patients from the 2nd epidemic wave|"As during the evaluation carried out during the 1st wave, the detection of persistent symptoms will be done in two stages:~* During a teleconsultation, to which all eligible patients will be invited, systematically looking for general, neurological, cognitive and respiratory symptoms~* During a hospitalization in an outpatient clinic to which all survivors who have stayed in an intensive care unit (ICU) will be invited and, among patients who have not stayed in an ICU, those who have residual symptoms detected during the teleconsultation."
62306778|NCT06099054|EXPERIMENTAL|pigtail group|composed of 40 patients in which pleural effusion will be drained using pigtail catheter under US guidance
61919183|NCT05791903|EXPERIMENTAL|Experimental Group|In the application process, individuals in the experimental group will receive care based on Kolcaba's comfort theory and comfort behaviour checklist during their stay in the ICU.
61919184|NCT05791903|NO_INTERVENTION|Control Group|In this study, the control group will receive standard care.
62474498|NCT02412384||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
62677914|NCT01640535|EXPERIMENTAL|Test arm|Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg
62677915|NCT01640535|ACTIVE_COMPARATOR|Comparator arm I|Matching placebo of Montelukast sodium 10mg + Levocetirizine dihydrochloride 5 mg
61919185|NCT02463552|PLACEBO_COMPARATOR|Placebo|
61919186|NCT02463552|EXPERIMENTAL|Naproxen|
62118965|NCT05585775|ACTIVE_COMPARATOR|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
62118966|NCT06257888||breast cancer patients under navigation|breast cancer patients, intervention = patient navigation
62118967|NCT04668391|EXPERIMENTAL|Quadratus lumborum block|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament.
62118968|NCT04668391|ACTIVE_COMPARATOR|Thoracic epidural analgesia|Thoracic epidural analgesia at the level of T7-10.
62118969|NCT01061424|ACTIVE_COMPARATOR|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
62118970|NCT01061424|EXPERIMENTAL|community health worker|community health worker provides home visits for education
62306779|NCT06099054|ACTIVE_COMPARATOR|ICT group|composed of 40 patients in which pleural effusion will be drained using ICT
62306780|NCT03020693|EXPERIMENTAL|Invasive electrostimulation combined with exercises.|Dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to therapeutic intensity) combined with exercises program.
62306781|NCT03020693|ACTIVE_COMPARATOR|Placebo electrostimulation and exercises.|Sham dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to non-therapeutic intensity) with surface electrodes combined with exercises program.
62306782|NCT03993743|EXPERIMENTAL|CD147-CART|Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery
62306783|NCT00652821|EXPERIMENTAL|A|Subjects received Kali product under fed condition
62306784|NCT00652821|ACTIVE_COMPARATOR|B|Subjects received Ortho-Mcneil product under fed conditions
62306785|NCT04050748|PLACEBO_COMPARATOR|Early Rehabiliation|6 weeks of non-weight bearing in addition to basic stretching exercises.
62306786|NCT04050748|ACTIVE_COMPARATOR|Accelerated Rehabilitation|Patients will be non-weight bearing for 2 weeks. After 2 weeks patients were transitioned to a boot with two heel wedges and were weight bearing as tolerated. At 4 weeks, patients were transitioned to one wedge, and at 6 weeks patients were weight bearing as tolerated in a flat shoe. Each heel wedge was ¾ inch tall. After 6 weeks, patient's in both groups underwent identical rehab regimens per protocol
62306787|NCT00947102||Pancreatic tubular adenocarcinoma|Patients with pancreatic tubular adenocarcinoma
62306788|NCT03158584|ACTIVE_COMPARATOR|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
62474499|NCT06008704|OTHER|PD patients with central chronic pain|Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included
61919187|NCT00421447||Breast Cancer patients|A group of women with breast cancer prescribed Anastrozole
62474500|NCT06008704|OTHER|PD patients without pain|Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included
62474501|NCT03827707|EXPERIMENTAL|Noise|
61919188|NCT00421447||Healthy women wit no breast Cancer|A group of healthy women wit no breast cancer prescribed Anastrozole
61919993|NCT01936402|EXPERIMENTAL|5-6cm Chest compression depth|"Control group is trained for 5-6cm Chest compression depth during education.~Depth 5-6cm, Rate 100-120/min, Full chest recoil"
62474502|NCT03827707|SHAM_COMPARATOR|Silence|
62306789|NCT03158584|ACTIVE_COMPARATOR|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
62306790|NCT03158584|ACTIVE_COMPARATOR|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
62306791|NCT03550339|ACTIVE_COMPARATOR|SURG|subjects attending bariatric surgery
62306792|NCT03550339|ACTIVE_COMPARATOR|DIET|subjects attending dietary weight loss program
62306793|NCT03550339|ACTIVE_COMPARATOR|HAES|subjects attending Health At Every Size weight management program
62306794|NCT03888495|EXPERIMENTAL|Gender socialization (GS)|Gender socialization workshops raised awareness on gender, its social construction and inequality, notions of masculinity and femininity, division of labor, access and control over resources. The workshop also included skill-building sessions on effective communication and negotiation and relationship building.
61919189|NCT02417948|EXPERIMENTAL|Arm I (educational brochure, online educational tutorial)|Participants receive a skin cancer educational and preventive brochure distributed by the National Cancer Institute and watch a 30-minute online tutorial video called X-Plain about skin cancer, preventative behaviors, and skin self-examinations.
61919190|NCT02417948|ACTIVE_COMPARATOR|Arm II (educational brochure)|Participants receive an educational brochure as in Arm I.
62306795|NCT03888495|EXPERIMENTAL|GS + Financial literacy (FL)|Financial literacy workshops promoted knowledge and skills in budgeting, financial planning and accessing and using financial services and income generating activities.
62306796|NCT03888495|EXPERIMENTAL|GS + FL + Family planning|Family planning counseling was provided to couples by family planning providers from nearby facilities. Couples were encouraged to seek services in facilities of their choice. A voucher system provided financial support for the poorest couples.
62306797|NCT03888495|NO_INTERVENTION|Control|Couples were interviewed at baseline, and will be interviewed at endline.
62306798|NCT04244825|EXPERIMENTAL|Cohort 1a BLD-2660|900 mg (6 x 150 mg capsules) BID
62306799|NCT04244825|EXPERIMENTAL|Cohort 1b BLD-2660|900 mg (6 x 150 mg capsules) BID (Optional)
62306800|NCT04244825|EXPERIMENTAL|Cohort 2 BLD-2660|600 mg (4 x 150 mg capsules) BID
62306801|NCT04244825|EXPERIMENTAL|Cohort 3 BLD-2660|300 mg (2 x 150 mg capsules) BID
62474503|NCT06302114|EXPERIMENTAL|Athletes in overhead sports|15 years and older elite overhead athletes (swim, tennis, basketball,volleyball) were included in the study.
62677916|NCT01640535|ACTIVE_COMPARATOR|Comparator arm II|Montelukast sodium 10mg + matching placebo of Levocetirizine dihydrochloride 5mg
62677917|NCT06461273|EXPERIMENTAL|Lifestyle Medicine|"20 Patients will participate in a lifestyle medicine program that includes activities and lessons in urban agriculture, nutrition education, culinary education, and exercise with a team that includes a chef, physician, farmer, and physical therapist.~This group will meet one day per week for a 3-hour period for a total of 12-weeks."
62306802|NCT04244825|PLACEBO_COMPARATOR|Cohort 1a Placebo|900 mg (6 x 150 mg capsules) BID
62306803|NCT04244825|PLACEBO_COMPARATOR|Cohort 1b Placebo|900 mg (6 x 150 mg capsules) BID (Optional)
62306804|NCT04244825|PLACEBO_COMPARATOR|Cohort 2 Placebo|600 mg (4 x 150 mg capsules) BID
62306805|NCT04244825|PLACEBO_COMPARATOR|Cohort 3 Placebo|300 mg (2 x 150 mg capsules) BID
62306806|NCT05619848|EXPERIMENTAL|Mild fat infiltration|Fat infiltration rate is less than 30%
62306807|NCT05619848|EXPERIMENTAL|Moderate fat infiltration|Fat infiltration rate is 30%\~50%
62306808|NCT05619848|EXPERIMENTAL|Server fat infiltration|Fat infiltration rate is greater than 50%
62306809|NCT05284110|EXPERIMENTAL|Walking breaks (WALK)|During this session, participants will be requested to remain seated during 4 hours, but the sitting will be interrupted every 30 min with a 3-min light-intensity walking.
61919994|NCT01936402|EXPERIMENTAL|6-7cm chest compression depth|"Experimental group is trained for 6-7cm Chest compression depth during education.~Depth 6-7cm, Rate 100-120/min, Full chest recoil"
62306810|NCT05284110|NO_INTERVENTION|Prolonged sitting (SIT)|During this session, participants be requested to remain seated during 4 uninterrupted hours (excepted for visiting the toilet) in a comfortable chair
62306811|NCT00814710|EXPERIMENTAL|Synflorix & Tritanrix-HebB/Hib Group|Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
62306812|NCT00814710|ACTIVE_COMPARATOR|Hiberix group & Tritanrix-HebB Group|Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
62306813|NCT01430247|OTHER|Amblyopia screening|
62306814|NCT03312855|EXPERIMENTAL|Revacept 80 mg|single dose, intravenous
62306815|NCT03312855|EXPERIMENTAL|Revacept 160 mg|single dose, intravenous
62306816|NCT03312855|PLACEBO_COMPARATOR|Placebo|single dose, intravenous
62118971|NCT02272959|EXPERIMENTAL|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral stimuli.
62118972|NCT02272959|PLACEBO_COMPARATOR|Placebo Group|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns using only neutral stimuli.
62306817|NCT02411123|EXPERIMENTAL|IDgenetix Neuropsychiatric Test Panel Intervention|The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
62306818|NCT02411123|NO_INTERVENTION|control|The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
62474504|NCT03772522|EXPERIMENTAL|Immediate dk Leadership Intervention|"Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.~After the delayed intervention group takes the intervention, the two groups are joined into a single arm."
62474505|NCT03772522|PLACEBO_COMPARATOR|Delayed dk Leadership Intervention|"Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses."
62677918|NCT06461273|ACTIVE_COMPARATOR|Food is Medicine|As a comparison group, 20 patients will be randomized to participate in a 12-week medically tailored grocery program.
62677919|NCT06461273|NO_INTERVENTION|Usual Care|The usual care arm will serve as the control group with a total of 20 patients. The control arm will undergo the standard of care and continue their current treatment plan as coordinated with their primary care physician throughout the course of the study.
62306819|NCT01745055|EXPERIMENTAL|CP-690,550 (tofacitinib) 30 mg q12h|Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h
62306820|NCT03856450|ACTIVE_COMPARATOR|Control-arm group|The control-arm group will consist of healthy volunteers with no known prior trauma in the wrists. The diagnostic truth for subjects in the control-arm will be no fracture and the treatment truth will be no treatment.
62474506|NCT05088343|EXPERIMENTAL|Treatment|rosuvastatin alone and then in combination with hetrombopag
62306821|NCT03856450|EXPERIMENTAL|Test-arm group|The test-arm group will consist of subjects who present with a wrist injury and initial SOC X-ray imaging results show a confirmed or suspected distal radius or scaphoid fracture, for which additional diagnostic imaging shall be ordered. Diagnostic truth for subjects in the test-arm will be the per-subject clinical diagnosis and the treatment truth will be the per-subject treatment received.
62677920|NCT00420056|EXPERIMENTAL|PD-0332991|
62677921|NCT06688760|EXPERIMENTAL|Surgery plus low dose radiotherapy|"Surgery:~Endoscopic Nasopharyngectomy: Radical resection of primary lesion using nasal endoscopy.~Retropharyngeal Lymphadenectomy: Radical retropharyngeal LNs resection using nasal endoscopy.~Radiotherapy:~Low Dose Raiotherapy:~Low dose radiotherapy target area: CTV1: tumor bed area; For cases where the margin of the primary lesion is negative but less than 3mm, the margin area should be included; It should also include all cervical lymph nodes located above the cricoid cartilage detected by CT/MRI, regardless of size; CTV2: Low risk infiltration area.~Intensity modulated radiation therapy prescription dose: CTV1: 36.00Gy/15Fr/2.40Gy; CTV2: 30.00Gy/15Fr/2.00Gy."
62677922|NCT06688760|EXPERIMENTAL|Surgery|"Endoscopic Nasopharyngectomy: Radical resection of primary lesion using nasal endoscopy.~Retropharyngeal Lymphadenectomy: Radical retropharyngeal LNs resection using nasal endoscopy.~Bilateral Upper Neck Lymph Node Dissection: the specific cleaning area is the lymph nodes upon the Hyoid bone regions."
62677923|NCT02104011|EXPERIMENTAL|Patient|
62118973|NCT01951508|OTHER|Methylphenidate, Modafinil, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but four treatment conditions in the same subject.
62118974|NCT00396084|EXPERIMENTAL|Gatifloxacin|10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.
62118975|NCT00396084|ACTIVE_COMPARATOR|Isoniazid|20 subjects to receive isoniazid 300 mg orally once daily for 7days.
62118976|NCT00396084|EXPERIMENTAL|Levofloxacin|10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.
62118977|NCT00396084|EXPERIMENTAL|Linezolid every 12 hours|10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.
62118978|NCT00396084|EXPERIMENTAL|Linezolid once daily|10 subjects to receive linezolid 600 mg orally once daily for 7days.
62306822|NCT04364217|OTHER|Treatment|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz
62306823|NCT01724606|EXPERIMENTAL|Radiotherapy with Sorafenib|This is a single institution, open label, prospective, phase I clinical trial using standard 3+3 design. Histologically confirmed metastatic adenocarcinoma of the breast with radiologic evidence of new and/or progressive brain metastases (BM) with a clinical indication for WBRT will be enrolled.
62306824|NCT01094483|EXPERIMENTAL|1|PN400 + ASA
62306825|NCT01094483|PLACEBO_COMPARATOR|2|Placebo + ASA
62474507|NCT03057210|NO_INTERVENTION|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
62474508|NCT03057210|EXPERIMENTAL|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
62474509|NCT03057210|EXPERIMENTAL|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
62474510|NCT03057210|EXPERIMENTAL|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
62118979|NCT00396084|EXPERIMENTAL|Moxifloxacin|10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.
62118980|NCT02694978|EXPERIMENTAL|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter \[mL\]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
62118981|NCT02694978|ACTIVE_COMPARATOR|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
62736336|NCT05142696|EXPERIMENTAL|Dose Level 4 (DL4)|Dose Level 4 (DL4): \[177Lu\]Lu-DOTA-TATE 250 mCi with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 and atezolizumab 1200 mg in induction period, then \[177Lu\]Lu-DOTA-TATE 250 mCi plus atezolizumab 1200 mg in the maintenance period.
61919191|NCT03044639|EXPERIMENTAL|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
61919192|NCT03044639|EXPERIMENTAL|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
61919193|NCT03044639|EXPERIMENTAL|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
61919194|NCT03044639|EXPERIMENTAL|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
61919195|NCT02571036|EXPERIMENTAL|Escalation|Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. \[Closed for Enrollment\]
62306826|NCT00850499|EXPERIMENTAL|VELCADE and fludarabine (Group A)|VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
62306827|NCT00850499|ACTIVE_COMPARATOR|fludarabine and rituximab (Group B)|fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
62306828|NCT00715715|NO_INTERVENTION|1|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients not treated with steroids: The patients will receive 6 weeks of sugar pills (placebo) before taking Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
62474511|NCT03057210|EXPERIMENTAL|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
62474512|NCT06281340|EXPERIMENTAL|Experimental group|The patients included in the experimental group will receive a session of manual physiotherapy using joint gliding techniques, myofascial and manipulative techniques of the tobioperoneoastotalar and subtalar joints. The intervention will be performed on both ankles.
62118982|NCT06375265|EXPERIMENTAL|Digital CBT-I|Preoperative digital CBT-I with the CBT-I Coach app and up to 4 weekly sessions
62118983|NCT06375265|ACTIVE_COMPARATOR|Sleep Health Education|Preoperative sleep health education materials
62306829|NCT00715715|EXPERIMENTAL|2|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
62306830|NCT01152138|ACTIVE_COMPARATOR|Open Cell Stent|Open cell stent (Driver™ or Integrity™,Medtronic), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
62306831|NCT01152138|ACTIVE_COMPARATOR|Closed Cell Stent|Closed cell stent (Presillion Plus™, Cordis), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
62306832|NCT00563940||1|
62306833|NCT00563940||2|
62306834|NCT00852930|EXPERIMENTAL|laser alone|The intervention was therapist administered low level laser therapy using low level laser, number of sessions based upon patient response
62306835|NCT00852930|ACTIVE_COMPARATOR|mld alone|The intervention was therapist administered manual lymphatic drainage (mld) using standard massage techniques,number of sessions based upon patient response
62306836|NCT00852930|EXPERIMENTAL|laser and mld combined|The intervention was therapist administered low level laser and mld using low level laser and standard massage techniques, number of sessions based upon patient response
62474513|NCT06281340|PLACEBO_COMPARATOR|Control group|Patients included in the control group will receive a placebo manual physical therapy session, simulating joint sliding techniques, myofascial and manipulative techniques of the tobioperoneoastotalar and subtalar joints, without any stimulus other than the pressure exerted by the physical therapist with his hands when mobilizing the foot. The placebo intervention will be performed on both ankles.
62474514|NCT02278835|OTHER|level1|Patients classified in level 1 were randomized in the breathing exercises group or incentive spirometry group
62118984|NCT01576484|PLACEBO_COMPARATOR|Placebo Matched to Alirocumab|Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
62306837|NCT02786537|ACTIVE_COMPARATOR|EBR/GZR (elbasvir/grazoprevir) with RBV|Patients received 1 EBR/GZR (elbasvir/grazoprevir) (Zepatier) tablet (50/100mg) once daily for 12 to 16 weeks (provider discretion) with Ribavirin (RBV) 200 mg/tablet, 1-3/day, taken 1-2 times per day (dosage at discretion of provider).
62306838|NCT02786537|ACTIVE_COMPARATOR|EBR/GZR (elbasvir/grazoprevir)|Patients received 1 EBR/GZR (elbasvir/grazoprevir) tablet (50/100 mg) once daily for 12 to 16 weeks (provider discretion) (without Ribavirin)
62306839|NCT02786537|ACTIVE_COMPARATOR|SOF/LDV (sofosbuvir/ledipasvir) with RBV|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) (Harvoni) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks with ribavirin (RBV) (at discretion of provider). RBV taken as 200 mg/tablet(capsule), 1-3 pills/day, 1-2 times/day.
62306840|NCT02786537|ACTIVE_COMPARATOR|SOF/LDV (sofosbuvir/ledipasvir)|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks without ribavirin (RBV) (per discretion of provider)
62474515|NCT02278835|OTHER|level2|Patients classified in level 2 were randomized in the Intermittent Positive Pressure Breathing group or Continuous Positive Airway Pressure group
62474516|NCT04342650|ACTIVE_COMPARATOR|Intervention|CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration.
62474517|NCT04342650|PLACEBO_COMPARATOR|Placebo|Placebo tables of equal characteristics and duration of treatment.
61919196|NCT02571036|EXPERIMENTAL|Expansion Cohort 1|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. \[Closed for Enrollment\]
62118985|NCT01576484|EXPERIMENTAL|Alirocumab 150 mg|Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.
62118986|NCT04759066|EXPERIMENTAL|Experimental|Participants will wear HEALiX device
62120033|NCT06258668||Participants diagnosed with moderate-to-severe plaque psoriasis|
61919197|NCT02571036|EXPERIMENTAL|Expansion Cohort 2|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. \[Closed for Enrollment\]
62474518|NCT06597370||Group 1|20 persons who have received the Oxford/AstraZeneca vaccine (ChAdOx1 nCoV-19).
62474519|NCT06597370||Group 2|20 persons who have received the vaccine Gamaleya National Center(Sputnik V)
62474520|NCT06597370||Group 3|20 persons who have received the Pfizer/BioNTech vaccine (BNT162b2).
62677924|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
61919198|NCT02571036|EXPERIMENTAL|Expansion Cohort 3|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. \[Closed for Enrollment\]
62118987|NCT05408559|ACTIVE_COMPARATOR|Avmacol ES|Processed SFN-rich extract will be purchased from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals \<100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals \>200 lb. SFN (Avmacol Extra Strength) will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
62306841|NCT02786537|ACTIVE_COMPARATOR|PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) with RBV (Phase 1 only)|"Patients received Pr0D (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) orally daily with food for 12 to 24 weeks with RBV (Ribavirin). Ombitasvir/Paritaprevir/Ritonavir (12.5/75/50 mg/tablet) -2 tablets once daily with food for 12 to 24 weeks and 1 dasabuvir tablet (250 mg) twice daily with food for 12 to 24 weeks.~RBV (200 mg/pill) 1-3 pills/day, 1-2 times/day (use and dosage at provider discretion). Total daily RBV dosage ranged from 200 to 1200 mg."
62474521|NCT06597370||Group 4|20 persons who have received the Sinovac (CoronaVac) vaccine.
62677925|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
62677926|NCT05698992||Experimental group|Patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden, and who are planned to undergo curative surgery treatment at Skåne University Hospital. n=100 (anticipated)
62677927|NCT05698992||Historical control group|The historical control group consists of patients, living in Southern Sweden, who underwent esophageal or gastric cancer surgery between 2013 - 2021 at Skåne University Hospital. n=100 (anticipated)
62677928|NCT06688812|EXPERIMENTAL|Group A Perceptual Motor Training with Routine Physical Therapy|Group A will receive treatment session of 60 minutes including Perceptual motor training for 40 minutes along with routine physical therapy of 20 minutes. Treatment session will be given 4 days per week for 8 weeks. Effects will be measured at baseline, 4th week and post intervention.
61919199|NCT02571036|EXPERIMENTAL|Expansion Cohort 4|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.\[Closed for Enrollment\]
62474522|NCT00879918|EXPERIMENTAL|Nicotine pharmacokinetics|circadian smoking protocol and IV pharmacokinetic protocol
62474523|NCT05350917|EXPERIMENTAL|Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate|One arm study
62474524|NCT02535611|ACTIVE_COMPARATOR|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
61919200|NCT02571036|EXPERIMENTAL|Expansion Cohort 5|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.\[Closed for Enrollment\]
61919201|NCT02571036|EXPERIMENTAL|Expansion Cohort 6|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. \[Closed for Enrollment\]
61919202|NCT02571036|EXPERIMENTAL|Expansion Cohort 7|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. \[Closed for Enrollment\]
61919203|NCT02571036|EXPERIMENTAL|Expansion Cohort 8|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.\[Closed for Enrollment\]
62474525|NCT02535611|PLACEBO_COMPARATOR|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
62474526|NCT04284319|EXPERIMENTAL|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
62474527|NCT04180280|ACTIVE_COMPARATOR|Phone Delivered|Participants receive 5 sessions of phone-delivered behavioral counseling to improve HIV care.
62474528|NCT04180280|ACTIVE_COMPARATOR|Office Delivered|Participants receive 5 sessions of office-delivered behavioral counseling to improve HIV care.
62474529|NCT02209194||Aortoiliac Aneurysms Iliac Aneurysms|Endovascular repair of aortoiliac or iliac aneurysms
62474530|NCT04774705|EXPERIMENTAL|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|
62474531|NCT04774705|PLACEBO_COMPARATOR|Control group|For the SNV placebo group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
62474532|NCT00448591|EXPERIMENTAL|1|
62474533|NCT00659763||A|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill the ROM III criteria for IBS
62474534|NCT00659763||B|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill he ROME III criteria for IBS
62474535|NCT04011917||Caseload group|
61919204|NCT02571036|EXPERIMENTAL|Expansion Cohort 9|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). \[Closed for Enrollment\]
62306842|NCT02786537|ACTIVE_COMPARATOR|PrOD (ombitasvir/paritaprevir/ritonavir and dasabuvir)|Patients received 2 ombitasvir/paritaprevir/ritonavir tablets (12.5/75/50 mg) once daily and 1 dasabuvir (250 mg) tablet twice daily with food for 12 to 24 weeks without Ribavirin (as per provider instructions)
62306843|NCT04323189|OTHER|Crossover AB|Subjects in arm A will first receive placebo daily for 7 days in the first intervention followed by sitagliptin 100mg/d for 7 days in the crossover intervention.
62306844|NCT04323189|OTHER|Crossover BA|Subjects in arm B will first receive sitagliptin 100mg/d for 7 days in the first intervention followed by placebo for 7 days in the crossover intervention.
62306845|NCT03048448|EXPERIMENTAL|Fevipiprant 450mg|450mg Film Coated Tablet
62306846|NCT02393092|EXPERIMENTAL|BVA Only|Study participants in this arm will only receive a Brief Violence Awareness (BVA) intervention.
62306847|NCT02393092|EXPERIMENTAL|BVP Only|Study participants in this arm will only receive a Brief Violence Prevention (BVP) intervention.
62306848|NCT02393092|EXPERIMENTAL|Emerging Leaders plus BVP|Study participants in this arm will participate in the Emerging Leaders: East End curriculum at the Boys and Girls Club of Metro Richmond, Martin Luther King Jr. Middle School site. They will also receive a Brief Violence Prevention (BVP) intervention.
62306849|NCT01824602|EXPERIMENTAL|Group 1|Eslicarbazepine acetate 1800 mg
62306850|NCT01824602|EXPERIMENTAL|Group 2|Eslicarbazepine acetate 1200 mg
62677929|NCT06688812|EXPERIMENTAL|Group B Repetitive Facilitation Exercises with Routine Physical Therapy|Group B will receive treatment session of 60 minutes including Repetitive facilitation exercises for 40 minutes along with routine physical therapy of 20 minutes. Treatment session will be given 4 days per week for 8 weeks. Effects will be measured at baseline, 4th week and post intervention.
62118988|NCT05408559|PLACEBO_COMPARATOR|Placebo|Placebo caplets containing microcrystalline cellulose will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals \<100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals \>200 lb. Placebo will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
62306851|NCT01824602|EXPERIMENTAL|Group 3|Eslicarbazepine acetate 600 mg
62306852|NCT01824602|PLACEBO_COMPARATOR|Group 4|Placebo pills
62118989|NCT06071624|EXPERIMENTAL|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
62306853|NCT05444244|ACTIVE_COMPARATOR|Brain Health Community Registry Recruitment|
62306854|NCT05444244|NO_INTERVENTION|Standard Recruitment|
62677930|NCT05698563|OTHER|Patient group|Patients with rheumatoid arthritis and forefoot pain.
62306855|NCT03163238|ACTIVE_COMPARATOR|Group D|One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
62306856|NCT03163238|PLACEBO_COMPARATOR|Group S|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
62306857|NCT03294304|EXPERIMENTAL|Nivolumab, Cisplatin, & Gemcitabine|
62306858|NCT02355093|EXPERIMENTAL|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
62474536|NCT04011917||Prediction group|
62474537|NCT01507051|EXPERIMENTAL|Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939)|Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
62306859|NCT02355093|ACTIVE_COMPARATOR|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
62306860|NCT02203552|EXPERIMENTAL|Arm I (minocycline hydrochloride)|Beginning 1 week prior to chemotherapy, patients receive minocycline hydrochloride orally PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
62474538|NCT01507051|PLACEBO_COMPARATOR|Warfarin followed by Placebo|Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
62474539|NCT01507051|ACTIVE_COMPARATOR|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
62474540|NCT03290326|EXPERIMENTAL|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.
62474541|NCT02856386|EXPERIMENTAL|polyphenol supplement|Dietary supplement administered 8 mL once daily
62677931|NCT05698563|OTHER|Control group|Patients with other rheumatic diseases and absence of forefoot pain.
61919205|NCT02571036|EXPERIMENTAL|Expansion Cohort 10|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. \[Closed for Enrollment\]
61919206|NCT02571036|EXPERIMENTAL|Extension Cohort|150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.
62118990|NCT05004935|EXPERIMENTAL|beetroot juice|single intake of beetroot juice containing 800mg nitrates
62118991|NCT05004935|ACTIVE_COMPARATOR|nitrates|single intake of 800mg nitrates (NaNO3)
62118992|NCT06297135|EXPERIMENTAL|Behavioral intervention group|Parents who enroll in the program will receive a series of 6 videos (\~7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
62118993|NCT05085990|EXPERIMENTAL|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
62118994|NCT06122727|EXPERIMENTAL|CUSTOM|patients will undergo primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with a design specifically based on each patient's real knee morphology and using PSI surgical technique and instrumentation.
62118995|NCT06122727|ACTIVE_COMPARATOR|TRADITIONAL|patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of the guided intramedullary femur and extramedullary tibia).
62118996|NCT00592813|EXPERIMENTAL|1|
62118997|NCT00592813|PLACEBO_COMPARATOR|cardiovascular education (attention control)|
62306861|NCT02203552|PLACEBO_COMPARATOR|Arm II (placebo)|Beginning 1 week prior to chemotherapy, patients receive placebo PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
62118998|NCT06068439|EXPERIMENTAL|Treated group|
62118999|NCT06068439|PLACEBO_COMPARATOR|Comparator group|
62119000|NCT00386516|EXPERIMENTAL|GM-CT-01, 5-FU|GM-CT-01 (280 mg/m2) combined with 5-FU (600 mg/m2) given 4 consecutive days in a 28 days cycle until disease progression.
62119001|NCT00922649|OTHER|A|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of ≥ 2 OAs
62306862|NCT03260023|EXPERIMENTAL|TG4001/Avelumab|
62474542|NCT01107093|PLACEBO_COMPARATOR|Placebo|
62474543|NCT01107093|ACTIVE_COMPARATOR|CDB-2914|
62474544|NCT01705574|EXPERIMENTAL|E/C/F/TDF|E/C/F/TDF + ATV placebo + RTV placebo + FTC/TDF placebo
62474545|NCT01705574|ACTIVE_COMPARATOR|ATV + RTV+ FTC/TDF|ATV + RTV + FTC/TDF + E/C/F/TDF placebo
62677932|NCT04385836|ACTIVE_COMPARATOR|alpha one antitrypsin group|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) add to 2cm of normal saline solution as nebulizer every 12 hours for 5 days
62677933|NCT04385836|PLACEBO_COMPARATOR|placebo group|we will give 8 ml of normal saline as nebulizer every 12 hours for 5 days
62677934|NCT04429971|EXPERIMENTAL|Immediate PreP initiation|"PreP screening program with immediate PrEP (iPrEP) initiation in the ED using a PrEP starter pack with facilitated linkage to care."
62677935|NCT04429971|ACTIVE_COMPARATOR|Out-patient care for PrEP initiation|PrEP screening program with referral to out-patient care for PrEP initiation
62677936|NCT04429971|EXPERIMENTAL|PreP Screening Program|Part 1: Targeted ED-based patients
62736337|NCT05142696|EXPERIMENTAL|Phase II Experimental arm|\[177Lu\]Lu-DOTA-TATE at recommended dose declared in phase I part in combination with carboplatin, etoposide and atezolizumab (experimental arm)
62736338|NCT05142696|OTHER|Phase II Control arm|Carboplatin, etoposide and atezolizumab alone (control arm)
62306863|NCT03260023|EXPERIMENTAL|Avelumab|Applicable for Phase II part 2.
62306864|NCT02623361|PLACEBO_COMPARATOR|Sham|
62306865|NCT02623361|ACTIVE_COMPARATOR|Fascia Iliaca Compartment Block|
62306866|NCT02956889|EXPERIMENTAL|Vismodegib & Radiotherapy|"Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.~Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles"
62306867|NCT05821543|EXPERIMENTAL|Reduxin Forte|Arm 1 (n=120) received metformin+sibutramine p. o., 1 tablet (850 mg + 10 mg) once per day. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.
62306868|NCT05821543|ACTIVE_COMPARATOR|Reduxin|Arm 2 (n=120) received sibutramine+ microcrystalline cellulose (MCC) p. o., 1 capsule (10 mg + 158.5 mg) once per day in the morning. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.
62677937|NCT02520154|EXPERIMENTAL|Treatment (carboplatin, paclitaxel, and pembrolizumab)|"NACT: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~ADJUVANT THERAPY: Beginning 3-6 weeks after surgery, paclitaxel IV over 1 hour on days 1, 8, and 15, patients receive carboplatin IV over 1 hour on day 1, and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity."
62119002|NCT00922649|OTHER|B|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of basal insulin ± OAs
62119003|NCT00922649|OTHER|C|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen basal-bolus insulin ± OAs
62119004|NCT02932709||Patients admitted of Psychiatry|Only patients who had a suicide attempt admitted to the Department of Emergency Psychiatry.
62119005|NCT03854253|EXPERIMENTAL|Long introducer 6Fr-25cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using long introducer sheath 6Fr-25cm
62119006|NCT03854253|ACTIVE_COMPARATOR|Short introducer 6Fr-10cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using short introducer sheath 6Fr-10cm
62119007|NCT06291233|EXPERIMENTAL|Virtual Interview Training|
62119008|NCT06291233|ACTIVE_COMPARATOR|Services-as-usual|
62119009|NCT01191892|PLACEBO_COMPARATOR|Placebo|Carboplatin, Gemcitabine and Placebo
62119010|NCT01191892|EXPERIMENTAL|vandetanib|Carboplatin, Gemcitabine and vandetanib
62119011|NCT02749968|ACTIVE_COMPARATOR|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
62306869|NCT04165395|NO_INTERVENTION|Control group|The control group will receive the standard of care adopted at Hôpital du Sacré-Coeur de Montréal in terms of pressure ulcers prevention in the SCI population.
62306870|NCT04165395|EXPERIMENTAL|Intervention group|In addition to undergoing the identical standard-of-care as the control group, all patients in this group will receive a prophylactic five-layer foam dressing placed directly on the sacral area and a Heelmedix boot installed alternately on both legs
62306871|NCT00661765|ACTIVE_COMPARATOR|Chantix immediate release tablet formulation|
62119012|NCT02749968|PLACEBO_COMPARATOR|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
62119013|NCT00118066|EXPERIMENTAL|Arm I|Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
62119014|NCT00118066|OTHER|Arm II|Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
62119015|NCT00892593|EXPERIMENTAL|1 Fecal Immunochemical Testing-Surveillance|Fecal Immunochemical Testing performed at yearly intervals.
62306872|NCT00661765|EXPERIMENTAL|Varenicline transdermal delivery system|
62119016|NCT00892593|NO_INTERVENTION|2 Usual Care - Surveillance|
62119017|NCT00892593|NO_INTERVENTION|3 Usual Care - Screening|
62119018|NCT00892593|EXPERIMENTAL|4 Fecal Immunochemical Testing-Screening|Fecal Immunochemical Testing yearly, beginning at year 6.
62306873|NCT04318574|EXPERIMENTAL|Interventional|Balance, Agility, Strengthening Exercise (BASE) class intervention - a 6-week exercise class to determine the change in balance performance, fear of falling and self-efficacy
62119019|NCT02078804|EXPERIMENTAL|Colonoscopy|20 000 subjects will be invited to an once-only colonoscopy.
62119020|NCT02078804|EXPERIMENTAL|FIT for occult blood|60 000 persons will be invited to take a fecal test for hemoglobin year 1 and year 3. If test-positive, they will be referred to colonoscopy.
62119021|NCT02078804|NO_INTERVENTION|Controls|120 000 matched persons will be identified in the Swedish Register of the total population and will be used as controls.
62119022|NCT02474147|EXPERIMENTAL|Type 2 diabetics|Patients with type 2 diabetes Interventions: processed meat hamburger and vegan sandwich
62119023|NCT02474147|ACTIVE_COMPARATOR|Obese subjects|Obese subjects without diabetes Interventions: processed meat hamburger and vegan sandwich
62119024|NCT02474147|ACTIVE_COMPARATOR|Healthy lean controls|Healthy lean controls Interventions: processed meat hamburger and vegan sandwich
62120034|NCT03522558|EXPERIMENTAL|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
62474546|NCT01705574|EXPERIMENTAL|Open-Label Extension Phase|After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an unblinding visit at Week 60. Participants who are virologically suppressed at Week 48 during the double-blinded treatment phase will have the option to enter the open-label extension phase. Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+ RTV + FTC/TDF arm will be re-randomized to receive either open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or open-label ATV + RTV+ FTC/TDF.
62119025|NCT02068430|EXPERIMENTAL|Riboflavin 0.1% & UV-X™ Illumination System|UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
62306874|NCT03994640|EXPERIMENTAL|Cannabis cream|Cannabis cream topical skin application in experimental group
62306875|NCT03994640|PLACEBO_COMPARATOR|Placebo cream|Placebo cream topical skin application in control group
62119026|NCT03612882||Western University Students|Online questionnaire
62119027|NCT01733238|EXPERIMENTAL|PNT2258|PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
62119028|NCT06336486|ACTIVE_COMPARATOR|intermittent pneumatic compression +pregabalin|Patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
62119029|NCT06336486|OTHER|pregabalin|only pregabalin treatment was continued.
62119030|NCT00223795|ACTIVE_COMPARATOR|Single point cane|People with knee osteoarthritis underwent gait analysis with a cane
61919207|NCT02979327|EXPERIMENTAL|Adderall first, then Placebo|Participants will receive an Adderall capsule at the first study visit, then a Placebo capsule at the second study visit.
62306876|NCT04396912||Control, s/p TT, without complication|Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)
62306877|NCT04396912||Experimental, s/p TT with only VCP|Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)
62306878|NCT04396912||Experimental, s/p TT with only H|Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)
62306879|NCT04396912||Experimental, s/p TT with both VCP+H|"Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H);~Subgroups:~4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent)~Please answer:~* Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?)~* Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?"
62306880|NCT04942548|EXPERIMENTAL|HFpEF|Patients diagnosed with obesity related heart failure with preserved ejection fraction(HFpEF)
62306881|NCT04942548|EXPERIMENTAL|PH-HFpEF|Patients diagnosed with obesity related pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF)
62306882|NCT00002676|EXPERIMENTAL|CHOD + BVAM + WBRT|Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions.
62306883|NCT06487884|EXPERIMENTAL|escape games|This group was played a 45-minute escape game.
61919208|NCT02979327|EXPERIMENTAL|Placebo first, then Adderall|Participants will receive a Placebo capsule at the first study visit, then an Adderall capsule at the second study visit.
61919209|NCT01511393||Questionnaire|None. Non-interventional study.
61919210|NCT06309407|EXPERIMENTAL|Chest and Hand Dosimeters|Subjects will wear both chest and hand dosimeters during all radiation procedures performed at the Comprehensive Pain Center during the study period.
62119031|NCT00223795|NO_INTERVENTION|No cane|Patients with knee osteoarthritis undergo gait analysis without a cane
62119032|NCT06676358||Group 1: Non-Smokers with gingivitis|Patients with no history of cigarette use were assigned to the non-smoking group. Gingivitis was diagnosed based on the presence of bleeding on probing in at least 10% of all assessed sites and the absence of attachment and bone loss.
62119033|NCT06676358||Group 2: Smokers with gingivitis|Smoking status was categorized as follows: patients in the smoking group were those who smoked more than ten cigarettes daily and had a smoking history exceeding five years. Gingivitis was diagnosed based on the presence of bleeding on probing in at least 10% of all assessed sites and the absence of attachment and bone loss.
62306884|NCT06487884|NO_INTERVENTION|control group|This group was not allowed to play any games other than routine nursing education.
62306885|NCT03410147|OTHER|Concentration A|Concentration of 13C-sodium octanoate in enteral nutrition is 0.3 mg/ml
61919211|NCT06309407|ACTIVE_COMPARATOR|Chest Dosimeter|Subjects will wear only a chest dosimeter during all radiation procedures performed at the Comprehensive Pain Center during the study period.
61919995|NCT05799690|EXPERIMENTAL|DUAL-TASK+AOT-MI|Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) for six weeks.
62306886|NCT03410147|OTHER|Concentration B|Concentration of 13C-sodium octanoate in enteral nutrition is 1.0 mg/ml
62306887|NCT03410147|OTHER|Concentration C|Concentration of 13C-sodium octanoate in enteral nutrition is 3.0 mg/ml
62119034|NCT06676358||Group 3: Smokers with mild moderate periodontitis|Smoking status was categorized as follows: patients in the smoking group were those who smoked more than ten cigarettes daily and had a smoking history exceeding five years. The classification of periodontitis stages was primarily based on clinical attachment loss (CAL), radiographic bone loss, and tooth loss criteria. Specifically, CAL of 1-2 mm was classified as periodontitis stage I, 3-4 mm as stage II (mild moderate periodontitis.)
62119035|NCT06676358||Group 4: Non-Smokers with mild moderate periodontitis|Patients with no history of cigarette use were assigned to the non-smoking group. The classification of periodontitis stages was primarily based on clinical attachment loss (CAL). Specifically, CAL of 1-2 mm was classified as stage I, 3-4 mm as stage II (mild moderate periodontitis).
62306888|NCT02947750|EXPERIMENTAL|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
62474547|NCT03354286|EXPERIMENTAL|Developmental & Technological Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving. Identify and troubleshoot barriers to keeping young children in Auto Mode.
62306889|NCT02947750|ACTIVE_COMPARATOR|Exercise training + 6R-BH4 placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the study drug 6R-BH4.
62119036|NCT06676358||Group 5: Smokers with severe periodontitis|Smoking status was categorized as follows: patients in the smoking group were those who smoked more than ten cigarettes daily and had a smoking history exceeding five years. Clinical attachment loss of 1-2 mm was classified as and ≥5 mm as stages III-IV. The criteria for tooth loss included up to four teeth lost for stage III, and five or more teeth lost due to periodontitis for stage IV (severe periodontitis)
62119037|NCT06676358||Group 6: Non-Smokers with severe periodontitis|Patients with no history of cigarette use were assigned to the non-smoking group. Clinical attachment loss of 1-2 mm was classified as and ≥5 mm as stages III-IV. The criteria for tooth loss included up to four teeth lost for stage III, and five or more teeth lost due to periodontitis for stage IV (severe periodontitis)
62119038|NCT02964195|EXPERIMENTAL|Rifaximin Group|Rifaximin 400 mg bid for 2 month,
62119039|NCT02964195|NO_INTERVENTION|Control|Routine endoscopic treatment without prophylactic use of antibiotics
62119040|NCT05821322|ACTIVE_COMPARATOR|Temporary target of 8.3 mmol/L|Current commercial artificial pancreas thresholds. Temporary target set 60 minutes before the intervention.
62119041|NCT05821322|EXPERIMENTAL|Temporary target of 8.8 mmol/L|Temporary target set 60 minutes before the intervention
62119042|NCT05821322|EXPERIMENTAL|Temporary target of 9.3 mmol/L|Temporary target set 60 minutes before the intervention
62119043|NCT02701855||Hypertension and progressive MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
62119044|NCT02701855||Hypertension and stable MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
62474548|NCT03354286|EXPERIMENTAL|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
61919212|NCT02696187|EXPERIMENTAL|KOLwebben|Patients in the experimental group will be introduced to KOL-webben during their ordinary visits to the primary care center. All patients will receive a pedometer
61919213|NCT02696187|NO_INTERVENTION|Control group|Other than receiving a pedometer the patients in the control group will not receive any intervention.
61919214|NCT02138526|ACTIVE_COMPARATOR|fasted|Intake of pazopanib in agreement with drug label - fasted state
61919215|NCT02138526|EXPERIMENTAL|Continental breakfast|Intake of a reduced equivalent pazopanib dose with a continental breakfast
61919216|NCT01846520|EXPERIMENTAL|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
61919217|NCT01846520|NO_INTERVENTION|Arm II (usual care)|Participants receive usual care.
62119045|NCT02701855||Hypertension, without MCI|60 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
62677938|NCT05894798|EXPERIMENTAL|Intervention|The acupuncture nurse holds the child by the hand and speaks to it calmly for about a minute. The children receive acupuncture at point LI 4 in the grip of the thumb on the upper side of the hand, bilaterally, with a sterile disposable needle with dimensions 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
62677939|NCT05894798|NO_INTERVENTION|Controll|The children in the control group do not receive acupuncture. However, they spend the same amount of time with the acupuncture nurse, are addressed and are touched in the same way as the children in the intervention group, but do not get stung.
61919218|NCT01614379||Healthy control subject|10 healthy control subjects for statistical comparison
61919219|NCT01614379||Type 1 diabetic patient|40 type 1 diabetic patients with diabetic foot ulcers.
61919220|NCT05598827|EXPERIMENTAL|Watch the Tik Tok|Unlimited Tik Tok viewing was encouraged from 24 hours before chemotherapy until the seventh day after chemotherapy.
62119046|NCT05454163||Exposed patients|
61919221|NCT05598827|NO_INTERVENTION|Tik Tok is not allowed|Viewing of Tik Tok was prohibited from 24 hours before chemotherapy until the seventh day after chemotherapy.
61919996|NCT05799690|ACTIVE_COMPARATOR|DUAL-TASK|Dual-task gait and balance training with vision of landscape videos for six weeks.
61919997|NCT05799690|EXPERIMENTAL|DUAL-TASK+AOT-MI_DOUBLE|Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) repeated two times (twelve weeks: 6 + 6).
62119047|NCT05454163||Non exposed patients|
62119048|NCT01590836|EXPERIMENTAL|IDeg-->IDegAsp|
62119049|NCT03264755|ACTIVE_COMPARATOR|cortical excitability in smokers|
62119050|NCT03264755|ACTIVE_COMPARATOR|cortical excitability in nonsmokers|
62306890|NCT02947750|ACTIVE_COMPARATOR|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
62306891|NCT02947750|PLACEBO_COMPARATOR|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
62306892|NCT02947750|ACTIVE_COMPARATOR|Exercise training + histidine and beta-alanine|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
62306893|NCT02947750|ACTIVE_COMPARATOR|Exercise training + histidine and beta-alanine placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the histidine and beta-alanine supplementation.
62306894|NCT05822856||Patients with RA without inflammation with persistent chronic pain|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
62306895|NCT05822856||Patients with an active RA (in inflammatory flare)|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
62306896|NCT05822856||Patients with RA in remission without pain|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
62306897|NCT05822856||fibromyalgia patients|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
62306898|NCT05822856||Control subjects: healthy volunteers|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
62306899|NCT03396081|EXPERIMENTAL|PRADO-IC|
62306900|NCT03396081|OTHER|Usual care|
62306901|NCT03244371|EXPERIMENTAL|Co infected HIV and HCV patients|
62306902|NCT06402253|EXPERIMENTAL|Music Composition / Edition|Teenage participants assigned to the 'Music Composition / Edition' (MUS) intervention will receive the 3-month Music Composition Intervention, completing self-reporting weekly measures of mood and social media usage, as well as a pre- and a post-intervention evaluation in which cognitive, mental-health, mood, social media usage and neuroimaging measures will be obtained.
62306903|NCT06402253|ACTIVE_COMPARATOR|Photography Composition / Edition|Teenage participants assigned to the 'Photography Composition / Edition' or Visual-Arts (VIS) intervention will receive the 3-month Photography Composition/Edition Intervention, completing self-reporting weekly measures of mood and social media usage, as well as a pre- and a post-intervention evaluation in which cognitive, mental-health, mood, social media usage and neuroimaging measures will be obtained.
62306904|NCT06402253|NO_INTERVENTION|Control|"Teenage participants assigned to the 'Passive Control' (CON) arm will complete self-reporting weekly measures of mood and social media usage during 3 months, as well as a pre- and a post-intervention evaluation in which cognitive, mental-health, mood, social media usage and neuroimaging measures will be obtained.~Once their participation in the study is complete, controls will be offered to complete the intervention of their choosing, according to the availability of teaching artists and locations to perform this."
62306905|NCT00881829||Healthy volunteer|Smoker or non-smoker
62306906|NCT05859958||ABO + Group|All patient with blood type that does not include Rhesus Factor and COVID-19 Diagnosis
62306907|NCT05859958||ABO - Group|All patient with blood type that does not include Rhesus Factor and COVID-19 Diagnosis
62306908|NCT02039388|OTHER|High risk patients for breast and/or ovarian cancer|
62306909|NCT03047538|ACTIVE_COMPARATOR|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
62306910|NCT03047538|ACTIVE_COMPARATOR|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
62306911|NCT03866551|EXPERIMENTAL|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
62306912|NCT01604564||Colitis Ulcerosa|Colitis Ulcerosa With creation of IPAA
62306913|NCT01604564||Familial Adenomatous Polyposis|Familial Adenomatous Polyposis with creation of IPAA
62306914|NCT01959360|ACTIVE_COMPARATOR|direct lateral|
62306915|NCT01959360|EXPERIMENTAL|minimal invasive|
62306916|NCT01959360|EXPERIMENTAL|modified minimal invasive|
62306917|NCT01554215|EXPERIMENTAL|Mom Power Intervention Group|Participants that are randomly assigned to be in the intervention group will be invited to learn about parenting and self-care skills information at a community location, facilitated by two trained and experienced clinicians in a group setting. They will benefit from the en-vivo experience of being supported as a parent and will receive feedback and support about their challenges and strengths in parenting.
62306918|NCT01554215|ACTIVE_COMPARATOR|Mom Power Attentional Control Group|Participants randomly assigned to this group will receive parenting and self-care skills information through the mail weekly.
62306919|NCT02464319|ACTIVE_COMPARATOR|Experimental: hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
62306920|NCT02464319|PLACEBO_COMPARATOR|Placebo Comparator: hrIL-2 placebo|1 million U doses of placebo s.c. injection
62306921|NCT00946270|EXPERIMENTAL|Group 3 CC-4047 + Prednisone|CC-4047 0.5 mg orally daily starting on day 1 through 28. Prednisone given during first 3 cycles of therapy. It will be dosed orally at the dose of 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
62306922|NCT00946270|EXPERIMENTAL|Group 1 CC-4047|CC-4047 3.0 mg orally daily starting on day 1 through 21.
62306923|NCT00946270|EXPERIMENTAL|Group 2 CC-4047|CC-4047 0.5 mg orally daily starting on day 1 through 28.
62306924|NCT05349461|ACTIVE_COMPARATOR|Complete contact|
62306925|NCT05349461|ACTIVE_COMPARATOR|Incomplete contact|
62306926|NCT02873221|ACTIVE_COMPARATOR|Usual Care|Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
62306927|NCT02873221|EXPERIMENTAL|Ubrogepant 50 mg|Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
62677940|NCT02373163|ACTIVE_COMPARATOR|Diuretic|Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM
62306928|NCT02873221|EXPERIMENTAL|Ubrogepant 100 mg|Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
62306929|NCT03138915|EXPERIMENTAL|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
62306930|NCT06133010|EXPERIMENTAL|mRNA-1647|CMV-seronegative and CMV-seropositive participants will receive 3 intramuscular (IM) injections of mRNA-1647 vaccine on Days 1, 29, and 57.
62306931|NCT06133010|EXPERIMENTAL|Placebo|CMV-seronegative and CMV-seropositive participants will receive 3 IM injections of mRNA-1647 vaccine-matching placebo on Days 1, 29, and 57.
62306932|NCT06010810|EXPERIMENTAL|3 % Topical Tranexamic Acid|Patients will receive 3% Topical Tranexamic Acid, on half of the face, twice a day for a total duration of 2 months
62306933|NCT06010810|EXPERIMENTAL|4 % Topical Hydroquinone|Patients will receive 4% Topical Hydroquinone, on half of the face, twice a day for a total duration of 2 months.
62306934|NCT01399346|EXPERIMENTAL|1 bolus of insulin aspart 18 IU|Subcutaneous administration of insulin aspart as one bolus of 18 IU at one injection site.
62306935|NCT01399346|EXPERIMENTAL|9 bolus of insulin aspart a 2 IU|Subcutaneous administration of insulin aspart as 9 separately and simultaneously applied bolus of 2 IU at 9 separate injection sites
62306936|NCT03317808|ACTIVE_COMPARATOR|Heavy slow resistance exercise|
62306937|NCT03317808|PLACEBO_COMPARATOR|Traditional supervised exercise|
62474549|NCT03354286|EXPERIMENTAL|Nutrition, Set Point, & C:I Ratio|Provide education on a variety of properties of food and how they affect blood glucose levels. Optimize the use of carbohydrate to Insulin ratios, insulin duration of action, and use of temporary target glucose set point in the 670G pump and the Quick bolus feature to gain better glycemic control.
62474550|NCT03354286|EXPERIMENTAL|Hypoglycemia management|Focus on hypoglycemia management to avoid hyperglycemia, review fear of hypoglycemia
62677941|NCT02373163|ACTIVE_COMPARATOR|Calcium-channel blocker|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
61919222|NCT05152264|ACTIVE_COMPARATOR|TENS (transcutaneous electrical nerve stimulation)|Patients with endometriosis-related chronic frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) randomized to transcutaneous electrical nerve stimulation as add-on treatment in addition to conventional analgesic treatment. Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
61919223|NCT05152264|ACTIVE_COMPARATOR|Conventional analgesic treatment|Patients with endometriosis related chronic frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) randomized to conventional analgesic treatment for 8 weeks. After 8 weeks the patients are treated with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
61919224|NCT05152264|ACTIVE_COMPARATOR|External control group|Patients with endometriosis-related pain that is not frequent or without high pain intensity (\< 4 according to Numeric Rating Scale, NRS) constitute an external control group. The patients are treated with transcutaneous electrical nerve stimulation as add-on treatment in addition to conventional analgesic treatment. Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
61919998|NCT05799690|ACTIVE_COMPARATOR|DUAL-TASK_DOUBLE|Dual-task gait and balance training with vision of landscape videos repeated two times (twelve weeks: 6 + 6).
62119051|NCT05093218|EXPERIMENTAL|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: \<5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
62119052|NCT05093218|PLACEBO_COMPARATOR|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
62119053|NCT06390943|OTHER|Obj 1 Infants receiving facility-based FSP+; Obj 2 infants receiving transition-to-home FSP+|
62119054|NCT03207568|EXPERIMENTAL|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
62119055|NCT00938535|EXPERIMENTAL|Obesity Prevention|
62119056|NCT00938535|NO_INTERVENTION|Usual Care|This arm includes usual care.
62119057|NCT01305291|PLACEBO_COMPARATOR|tea only without fibersol-2|"* On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~* The evening meal will be a standardized meal for all subjects (11).~* They are allowed to consume water up until 1 hr before the test.~* Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~* The beverage will be consumed at 10 am.~* Blood samples will be taken at specified time points prior to after the treatments."
62306938|NCT04336176|ACTIVE_COMPARATOR|PulseFlow DF boot|PulseFlow DF boot
62306939|NCT04336176|ACTIVE_COMPARATOR|Usual Care|Measurements will be taken from patients wearing usual standard of care
62306940|NCT04336176|SHAM_COMPARATOR|Sham|Sham shoe (closest to barefoot or baseline pressures)
62306941|NCT02187640|EXPERIMENTAL|Self-administered acupressure|A 10-day self-administered acupressure program was implemented by the participants who were adult psychiatric in-patients and randomly assigned into this treatment group. The patients would receive a 3-session training of this therapy conducted by a qualified acupressure therapist and each session lasted about an hour. They would be assessed by the trainer to ensure that they are able to identify the five acupoints and applied a constant and an appropriate pressure on each acupoint before actual implementation.
62306942|NCT02187640|SHAM_COMPARATOR|Sham control group|Sham control group: Patients would receive 3-session training and be assessed by the trainer. However, they would be trained to locate five non-acupoints adjacent to the actual acupoints and with minimal pressure applied.
62474551|NCT03354286|PLACEBO_COMPARATOR|Minimal Intervention|A short communication detailing the percentage of time spent in range and in Auto Mode and if the goals have been met.
62677942|NCT02373163|ACTIVE_COMPARATOR|Angiotensin Receptor Blocker|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
62306943|NCT03823638|EXPERIMENTAL|D-Mannitol|Oral Supplement of the investigated substance: D-Mannitol powder (manufacturer Roquette)
62306944|NCT03823638|PLACEBO_COMPARATOR|Placebo|Oral Supplement of the placebo: Dextrose monohydrate powder (manufacturer Roquette)
61919999|NCT05799690|NO_INTERVENTION|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare gait, neuropsychological, serum and functional magnetic resonance imaging characteristics at baseline.
62306945|NCT01593748|EXPERIMENTAL|Experimental|Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
62474552|NCT05209347|NO_INTERVENTION|NoCDO|Participants will be evaluated without a CDO
62474553|NCT05209347|EXPERIMENTAL|CDO-A|The first study CDO will be designated CDO-A
62474554|NCT05209347|EXPERIMENTAL|CDO-B|The second study CDO will be designated CDO-B
62474555|NCT00520988|EXPERIMENTAL|1|Usual care plus use of Interactive Voice Recognition system
62474556|NCT00520988|NO_INTERVENTION|2|Usual care
62474557|NCT05636319|EXPERIMENTAL|Test group 1: ABO1020|Intramuscularly inject 15 μg of ABO1020 into lateral deltoid region of the upper arm of subjects on D0 and D28, respectively.
62474558|NCT05636319|PLACEBO_COMPARATOR|Test group 2: Placebo|Intramuscularly inject 0 μg of placebo into lateral deltoid region of the upper arm of subjects on D0 and D28, respectively.
62474559|NCT05260697|EXPERIMENTAL|Sexual Counselling Group|Sexual Counselling with PLISSIT model
62474560|NCT05260697|NO_INTERVENTION|Control Group|no intervention group
62119058|NCT01305291|ACTIVE_COMPARATOR|tea only with fibersol-2 (10 g)|"* On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~* The evening meal will be a standardized meal for all subjects.~* They are allowed to consume water up until 1 hr before the test.~* Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~* The beverage will be consumed at 10 am.~* Blood samples will be taken at specified time points prior to and after the treatments.~* Ingredient only test will be done without the meal to determine independent effects of Fibersol-2."
62119059|NCT01305291|PLACEBO_COMPARATOR|tea without fibersol-2 and meal|"* On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~* The evening meal will be a standardized meal for all subjects.~* They are allowed to consume water up until 1 hr before the test.~* Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~* The test meal and beverage will be consumed at 10 am.~* The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~* Tea containing test materials will accompany the meal.~* Blood samples will be taken at specified time points prior to and after the treatments."
62120035|NCT03522558|ACTIVE_COMPARATOR|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
62306946|NCT01593748|ACTIVE_COMPARATOR|Standard of Care|Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
62306947|NCT02984475|ACTIVE_COMPARATOR|treatment arm|30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
62474561|NCT06562166|EXPERIMENTAL|ART|
62474562|NCT06562166|NO_INTERVENTION|IGRT|
62474563|NCT04400890|ACTIVE_COMPARATOR|Resveratrol with Vitamin D3|Resveratrol 1000mg four times per day for 15 days. Vitamin D3 100,000 IU on day 1
62474564|NCT04400890|PLACEBO_COMPARATOR|Placebo with Vitamin D3|Placebo capsules 4 times per day for 15 days. Vitamin D3 100,000 IU on day 1
62474565|NCT03961230|EXPERIMENTAL|Oral Chinese medicine|Participants in experimental group will receive Jueyin granule two times daily after meals three times per week for 8 weeks.
62474566|NCT03961230|PLACEBO_COMPARATOR|Oral Chinese medicine placebo|Participants in placebo group will receive Jueyin granule placebo two times daily after meals three times per week for 8 weeks.
62474567|NCT06373185|EXPERIMENTAL|SESPB|Participants received ultrasound-guided SESPB before the surgery
62474568|NCT06373185|ACTIVE_COMPARATOR|CAUDAL|Participants received ultrasound-guided caudal block before the surgery
62474569|NCT02344732|ACTIVE_COMPARATOR|Standard Group|topical Maxitrol™ six-hourly and homatropine 2% six-hourly
62306948|NCT02984475|NO_INTERVENTION|control arm|30 patients receiving blood transfusion and taking iron-chelating therapy.
62306949|NCT01919411|EXPERIMENTAL|Amoxicillin-Potassium Clavulanate|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.
62306950|NCT01919411|PLACEBO_COMPARATOR|Placebo|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.
62119060|NCT01305291|EXPERIMENTAL|tea with 5 g fibersol-2 and meal|"* On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~* The evening meal will be a standardized meal for all subjects.~* They are allowed to consume water up until 1 hr before the test.~* Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~* The test meal and beverage will be consumed at 10 am.~* The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~* Tea containing test materials will accompany the meal.~* Blood samples will be taken at specified time points prior to and after the treatments."
62119061|NCT01305291|EXPERIMENTAL|tea with 10 g fibersol-2 and meal|"* On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~* The evening meal will be a standardized meal for all subjects.~* They are allowed to consume water up until 1 hr before the test.~* Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~* The test meal and beverage will be consumed at 10 am.~* The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~* Tea containing test materials will accompany the meal.~* Blood samples will be taken at specified time points prior to and after the treatments."
62306951|NCT00003248|EXPERIMENTAL|Arm I|"Patients receive fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction. Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks.~Patients are followed every 3 months for 1 year, and then every 6 months thereafter."
62306952|NCT00003248|EXPERIMENTAL|Arm II|Patients receive fludarabine induction. Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.
62306953|NCT01805115|EXPERIMENTAL|Oral misoprostol|The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
62306954|NCT01805115|EXPERIMENTAL|Sublingual misoprostol|The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
62306955|NCT01805115|EXPERIMENTAL|Vaginal misoprostol|The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
62306956|NCT01805115|EXPERIMENTAL|Control|The no-misoprostol group did not administer the medication of misoprostol before the procedure
62474570|NCT02344732|EXPERIMENTAL|Oxygen Group|standard medical treatment of topical Maxitrol™ six-hourly and homatropine 2% six-hourly, plus systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 3 days
62677943|NCT02495935|EXPERIMENTAL|OkuStim®|The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.
62677944|NCT02495935|SHAM_COMPARATOR|Sham-OkuStim®|Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.
62306957|NCT05585853|EXPERIMENTAL|Virtual Reality application group|Virtual reality glasses (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) compatible with the mobile phone (Lenovo P2a42) with the Android operating system will be worn and the patient will be watched (underwater world, open-air museum tours, beach trips and nature scenes) by patients for an average of 10 minutes during chest tube removal.
61920000|NCT04623008|EXPERIMENTAL|Goal-Oriented Episodic Future Thinking (GOEFT) Intervention|In addition to usual prenatal care, intervention participants will receive a 20-week intervention via web and individual health counseling. The intervention topics focus on stress management, healthy eating, and physical activity.
62119062|NCT03199781|EXPERIMENTAL|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
62119063|NCT03833154|EXPERIMENTAL|SoC SBRT + Durvalumab Therapy (Main Cohort)|"SBRT~Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met."
62119064|NCT03833154|PLACEBO_COMPARATOR|SoC SBRT + Placebo Therapy (Main Cohort)|"SBRT~Placebo (matching placebo for infusion) every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met."
62119065|NCT03833154|EXPERIMENTAL|SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, open-label separate cohort)|"SBRT~Osimertinib 80mg every day \[qd\] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT"
62119066|NCT06000072|EXPERIMENTAL|Telerehabilitation|Telerehabilitation sessions including core exercises
62119067|NCT06000072|ACTIVE_COMPARATOR|Video-based|Core exercises by watching pre-recorded videos
62119068|NCT04307407|EXPERIMENTAL|Aerobic Exercise|The aim is for participants to complete three weekly sessions of supervised aerobic treadmill based exercise for five months. Session duration varies from 20-60 minutes, with exercise intensity ranging from 55-95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate), will be determined by the CPET performed by certified exercise physiologists at baseline.
62306958|NCT05585853|NO_INTERVENTION|Standard of care|Only standard care will be given and no application will be made.
62306959|NCT02011503|EXPERIMENTAL|dHACM|Application of multi-layer compression therapy with application of dHACM.
62306960|NCT02011503|OTHER|Control|Application of multi-layer compression therapy without application of dHACM.
62306961|NCT03868722|EXPERIMENTAL|Treatment arm|Treatment with Acalabrutinib and Venetoclax is initiated within 14 days after randomization.
62306962|NCT03868722|NO_INTERVENTION|Observation arm|Observation period is initiated within 14 days after randomization.
62677945|NCT06695000|EXPERIMENTAL|digital CBT-I|
62677946|NCT06695000|NO_INTERVENTION|Waitlist Control|
62677947|NCT06685965|EXPERIMENTAL|Low dose|low dose of RE03
62677948|NCT06685965|EXPERIMENTAL|High dose|High dose of RE03
62677949|NCT06685965|PLACEBO_COMPARATOR|Placebo control|Matching Placebo
62677950|NCT06067230|EXPERIMENTAL|Part A: mRNA-1345 Dose 1|Single injection of mRNA-1345 administered intramuscularly (IM) on Day 1.
62677951|NCT06067230|EXPERIMENTAL|Part A: mRNA-1345 Dose 2|Single injection of mRNA-1345 administered IM on Day 1.
62677952|NCT06067230|EXPERIMENTAL|Part B: mRNA-1345 Dose 2|Two injections of mRNA-1345 administered IM on Day 1 and Day 57.
62677953|NCT04096885||InSurg cohort|Patients who undergo elective or emergency surgery at the Department of Visceral Surgery and Medicine, Inselspital, Bern, who gave informed consent.
62677954|NCT05439863||TAVR in aortic valve disease|
62677955|NCT05394571||Newly diagnosed diabetes|Patients who have been diagnosed with type 2 diabetes within a month
62677956|NCT05394571||Had controlled diabetes before|Patients who had at least two HbA1c levels =\<%7,5 before enrollment
62677957|NCT05394571||Had moderately uncontrolled diabetes|Patients who had at least two HbA1c levels between %7,5 and %9,49 before enrollment
62677958|NCT05394571||Had poorly controlled diabetes|Patients who had at least two HbA1c levels above %9,5 before enrollment
62677959|NCT04936269||Group 1|Children under five years old
62677960|NCT05100017|ACTIVE_COMPARATOR|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours after ureteroscopy as needed for pain in addition to the standard postoperative pain regimen (Tylenol 1000mg every six hours, Tamsulosin 0.4mg daily, phenazopyridine 200mg every eight hours, and diclofenac 50mg every eight hours).
62677961|NCT05100017|ACTIVE_COMPARATOR|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily after ureteroscopy as needed for pain in addition to the standard postoperative pain regimen (Tylenol 1000mg every six hours, Tamsulosin 0.4mg daily, phenazopyridine 200mg every eight hours, and diclofenac 50mg every eight hours).
62677962|NCT06561204|EXPERIMENTAL|FMET + ADA dentifrice|Baseline and 30-day outcome measures will be collected to evaluate the impact of FMET + ADA dentifrice on clinical indicators of gingivitis, plaque, and patient perceptions.
62677963|NCT06561204|NO_INTERVENTION|Conventional electronic toothbrush + ADA dentifrice|Baseline and 30-day outcome measures will be collected to evaluate the impact of conventional electronic toothbrush + ADA dentifrice on clinical indicators of gingivitis, plaque, and patient perceptions.
62677964|NCT06561204|OTHER|FMET + Foam|Baseline and 30-day outcome measures will be collected to evaluate the impact of FMET + foam on clinical indicators of gingivitis, plaque, and patient perceptions.
61919225|NCT02597816|OTHER|Three dimensional ultrasound|Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
61919226|NCT05649202||All inmates entering the CPPLS|Patients with positive HCV serology
62677965|NCT02502838||Prolapse surgery without TVT|Patients who plan to undergo prolapse repair alone
62119069|NCT04307407|NO_INTERVENTION|Standard care|Participants in this arm will not receive any follow-up on exercise during the intervention period.
62677966|NCT02502838||Prolapse surgery with TVT|Patients who plan to undergo prolapse repair with an additional TVT procedure
62677967|NCT03760666|EXPERIMENTAL|Brequinar/Brequinar + Ribavirin|Brequinar and ribavirin were dosed orally; brequinar starting doses ranged from 200 mg/m2 to 500 mg/m2. Brequinar doses were adjusted by cohort for starting dose and regimen (either twice-weekly or once-weekly). In addition, the dose for each participant was also adjusted (either escalated or decreased) based on safety, brequinar PK and levels of dihydroorotate (DHO). Ribavirin 1000 mg twice a day (bid) was added in combination with brequinar for the final 3 study participants.
62677968|NCT04651296|EXPERIMENTAL|compassion meditation|10 week, group-based manualized compassion meditation training
62677969|NCT04651296|ACTIVE_COMPARATOR|health education|10 week, group-based manualized health education protocol
62677970|NCT01087619|NO_INTERVENTION|Follow-up|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are followed only
62119070|NCT04307407|OTHER|Reference Group|Participants in this arm are age-matched women with no history of any malignant disease, which will undergo similar assessments at baseline and post-intervention and also follow similar exercise intervention as the breast cancer survivors randomized to the Aerobic exercise arm
62119071|NCT04977856|EXPERIMENTAL|Guided ICBT|Participants in guided ICBT will receive internet-delivered CBT with therapist support. The treatment consists of 8 online modules with interactive features such as videos and illustrations, delivered over a maximum of 10 weeks. The main treatment focus is behavioral activation. The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The caregiver's program also consists of 8 chapters, including psychoeducation about depression and how to support their adolescent in treatment. The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support.
62119072|NCT04977856|EXPERIMENTAL|Self-guided ICBT|The self-guided arm is identical to the guided arm, however without the therapist support. To ensure patient safety, there will be clear instructions to the patients and primary caregivers on how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
62119073|NCT04977856|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical, or a combination of both. The content of TAU and the treatment techniques used will be monitored.
62119074|NCT06300996|EXPERIMENTAL|Spinal Cord Stimulation|All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the cervical epidural (C4-T1 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
62119075|NCT02587130|EXPERIMENTAL|communicating and none-communicating patients|20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)
62119076|NCT04704778|ACTIVE_COMPARATOR|Transcutaneous|Transcutaneous electrostimulation and uso of oclusal splint
62119077|NCT04704778|ACTIVE_COMPARATOR|Percutaneous|Percutaneous electrostimulation and splint
62119078|NCT04704778|PLACEBO_COMPARATOR|Control|Oclusal splint
62120036|NCT05724472|EXPERIMENTAL|Study Group 1|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10\^6 pfu intramuscularly Day 1
62120037|NCT05724472|EXPERIMENTAL|Study Group 2|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10\^7 pfu intramuscularly Day 1
62474571|NCT06626776|EXPERIMENTAL|lateral sinus lift with bone augmenation|
62474572|NCT06626776|EXPERIMENTAL|lateral sinus lift with extended platelet rich fibrin|
62474573|NCT00836667|EXPERIMENTAL|1|
62474574|NCT00836667|ACTIVE_COMPARATOR|2|
62474575|NCT05914857|EXPERIMENTAL|Intervention group|Patients in the intervention group will be administered Dapagliflozin 10 mg/day in addition to lifestyle intervention.
62474576|NCT05914857|PLACEBO_COMPARATOR|Control group|Patients in the control group will be given lifestyle intervention only.
62474577|NCT02013154|EXPERIMENTAL|DKN-01 150 mg plus paclitaxel|DKN-01 150 mg administered on Days 1 and 15 and paclitaxel 80 mg per meter squared of body surface area (mg/m2) administered on Days 1, 8, 15, and 22
62474578|NCT02013154|EXPERIMENTAL|DKN-01 300 mg plus paclitaxel|DKN-01 300 mg administered on Days 1 and 15 and paclitaxel 80 mg per meter squared of body surface area (mg/m2) administered on Days 1, 8, 15, and 22
62474579|NCT02013154|EXPERIMENTAL|DKN-01 150 mg plus pembrolizumab|DKN-01 150 mg administered on Days 1 and 15 and pembrolizumab 200 mg administered on Day 1
62474580|NCT02013154|EXPERIMENTAL|DKN-01 300 mg plus pembrolizumab|DKN-01 300 mg administered on Days 1 and 15 and pembrolizumab 200 mg administered on Day 1
62474581|NCT02013154|EXPERIMENTAL|DKN-01 300 mg monotherapy|DKN-01 300 mg administered on Days 1 and 15
61919227|NCT01277081|ACTIVE_COMPARATOR|Paracetamol hot drink|Hot drink containing paracetamol
61919228|NCT01277081|ACTIVE_COMPARATOR|Paracetamol tablets|Paracetamol tablets
62306963|NCT06034730||Lung Cancer Patients|patients undergoing surgery for histologically proven NSCLC
62306964|NCT06034730||Healthy Control Patients|patients undergoing surgery for benign extra-thoracic disease who had undergone chest X-rays/chest CT-scan, proved to be negative during preoperative evaluation.
62306965|NCT06463912||People who inject drugs in Armenia-Colombia|Persons over 18 years who injected drugs (PWID), living in the city of Armenia-Colombia.
62306966|NCT05421754|EXPERIMENTAL|ANNE Sleep|After consent, subjects will wear the ANNE Sleep system with HST for 1 night and 3 nights with ANNE sleep system alone.
62306967|NCT02852369|EXPERIMENTAL|Task Oriented Training|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
62474582|NCT05326386|NO_INTERVENTION|Control|Via the Way to Health platform, all participants will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.
62474583|NCT05326386|EXPERIMENTAL|Intervention|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
62474584|NCT04949334|EXPERIMENTAL|Dofin Breathing Strength Builder|Usual post stroke care and respiratory muscle training
62474585|NCT04949334|NO_INTERVENTION|Usual post stroke care|Usual post stroke care
62474586|NCT03956862|EXPERIMENTAL|GB001|GB001 40 mg once per day (QD) for 16 weeks
62474587|NCT03956862|PLACEBO_COMPARATOR|Placebo|Placebo QD for 16 weeks
62474588|NCT05971420|EXPERIMENTAL|VR group|VR activity-based training
62474589|NCT05971420|ACTIVE_COMPARATOR|Exercise group|Exercise-based training (Baduanjin)
62474590|NCT02451267|EXPERIMENTAL|positive CPR: research group|physical therapy treatment with aerobic exercise
62474591|NCT02451267|EXPERIMENTAL|negative CPR: research group|physical therapy treatment with aerobic exercise
62474592|NCT02451267|ACTIVE_COMPARATOR|positive CPR: control group|physical therapy treatment
62474593|NCT02451267|ACTIVE_COMPARATOR|negative CPR: control group|physical therapy treatment
62474594|NCT02606708|EXPERIMENTAL|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
62474595|NCT04887480|ACTIVE_COMPARATOR|Negative Wound Pressure Therapy|Negative Pressure Would Therapy
62474596|NCT04887480|ACTIVE_COMPARATOR|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation
62677971|NCT01087619|EXPERIMENTAL|Surgery|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are treated with parathyroid surgery
62677972|NCT05741710|EXPERIMENTAL|Methylone|
62677973|NCT05741710|PLACEBO_COMPARATOR|Placebo|
62474597|NCT03798262|ACTIVE_COMPARATOR|Gluten|Patients receive 16 g of gluten acutely and afterwards 2 glutenfree muffins with 8 g of gluten for 5 days sub-acutely
62474598|NCT03798262|PLACEBO_COMPARATOR|Placebo|Patients receive 16 g of whey protein acutely and afterwards 2 glutenfree muffins for 5 days sub-acutely
62474599|NCT03506386||Multiple Myeloma Participants|Participants with multiple myeloma (MM) were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.
62474600|NCT05992025|NO_INTERVENTION|Observation|Observation with the OURA ring and no digital meetings. The participants are offered delayed randomization after the study period. This group's outcome from the delayed randomization will be for the exploratory analysis, i.e., not in the primary analysis.
62474601|NCT05992025|EXPERIMENTAL|Physical activity|12 weeks of physical activity guidance with short discussions via online group meetings according to a schedule. The participants in this arm will conduct moderate-intensity exercises for at least 150 minutes per week. Brisk walks are the primary choice of activity; alternatively, swimming, cycling, or dancing to the physical exertion according to the Borg scale can be performed.
62306968|NCT05337943|EXPERIMENTAL|Cognitive Behavioral Therapy-Insomnia (CBT-I)|CBT-I treatment will receive 1 session every week, for 8 weeks (8 total sessions). The CBT-I sessions will be provided by a pool of clinical PhD psychology students by a trained professional. Each visit will be conducted via telehealth. Sessions will include discussions regarding such topics as sleep restriction, stimulus control and sleep hygiene. Review of sleep diaries will occur during the sessions.
62306969|NCT05337943|EXPERIMENTAL|Bright Light Therapy|Bright Light treatment will consist of 8 weeks of daily use of the Re-timer device. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of \~500 lux lm/m2. Subjects will be instructed to use the device for 30 minutes within two hours of waking, in the morning on the full brightness setting.
62306970|NCT05337943|NO_INTERVENTION|Standard Care|Subjects will continue the care they routinely receive.
62306971|NCT06388720|EXPERIMENTAL|Intervention group|Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml
62474602|NCT05992025|ACTIVE_COMPARATOR|Sleep hygiene intervention|12 weeks of sleep exercises. The lifestyle intervention of sleep will be delivered via an online group, with recommended home practices between sessions. Topics covered will include sleep education, sleep hygiene, and practices to improve sleep quality.
62474603|NCT03836560|ACTIVE_COMPARATOR|Usual group|"Usual group with nicotine patch only:~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches."
62677974|NCT06277830||Adults with autoimmune myasthenia gravis|Existing patients at MassGeneral Hospital's MG clinic, ages 18-80, with autoimmune, AChR or MuSK antibody positive generalized myasthenia gravis.
62677975|NCT05199155|EXPERIMENTAL|NerVFIX|Biological regeneration nerve conduit of allogeneic artery or vein from umbilical cord used as a conduit for gap \< 2 cm or as a wrap after peripheral nerve suture
62677976|NCT01791400|OTHER|sumatriptan|Patients who underwent 6 mg sumatriptan subcutaneous one time
62677977|NCT01791400|OTHER|Metoclopramide|Patients who underwent 20 mg Metoclopramide intravenous one time
62677978|NCT06694363||1 - initiating treatment|10 patients with a genetic diagnosis of APDS type 1 or type 2 who are to be treated with a selective PI3Kδ inhibitor, Lenolisib.
62677979|NCT06694363||2 - already on treatment|4 patients with a genetic diagnosis of APDS type 1 or type 2 already treated with a selective PI3Kδ inhibitor, Lenolisib.
62677980|NCT02004275|EXPERIMENTAL|Arm I (pomalidomide, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
62677981|NCT02004275|EXPERIMENTAL|Arm II (pomalidomide, dexamethasone, ixazomib)|Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62677982|NCT05038735|EXPERIMENTAL|Alpelisib plus fulvestrant|Alpelisib 300 mg orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15, and on Day 1 on every Cycle thereafter, in a 28 days cycle.
62677983|NCT05038735|PLACEBO_COMPARATOR|Alpelisib-matching placebo plus fulvestrant|Alpelisib-matching placebo orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15 and on Day 1 on every Cycle thereafter, in a 28 days cycle. Participants who have disease progression per RECIST v1.1 as assessed by BIRC will have the option to crossover to be treated with alpelisib plus fulvestrant
62677984|NCT06105892|EXPERIMENTAL|BNC Active|Binocularly normal controls receiving active therapy
62677985|NCT06105892|SHAM_COMPARATOR|BNC Sham|Binocularly normal controls receiving sham therapy
62306972|NCT05980026|ACTIVE_COMPARATOR|oral omega-3 fatty acids supplementation|Intervention group included pediatric patients with diabetic nephropathy receiving oral omega-3 fatty acids supplementation on a daily basis.
62306973|NCT05980026|PLACEBO_COMPARATOR|Placebo comparator|Placebo group or control patients received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
62306974|NCT04611477|PLACEBO_COMPARATOR|Placebo|One capsule/day to be taken orally 30 minutes before breakfast
62306975|NCT04611477|ACTIVE_COMPARATOR|Synbiotic365 Ver 5|One capsule/day to be taken orally 30 minutes before breakfast
62677986|NCT06105892|EXPERIMENTAL|PTCI Active|Post-traumatic Convergence Insufficiency participants receiving active therapy
62677987|NCT06105892|SHAM_COMPARATOR|PTCI Sham|Post-traumatic Convergence Insufficiency participants receiving sham therapy
62119079|NCT05790096|ACTIVE_COMPARATOR|Reference Drug - Granulokine®|"Reference Drug - Granulokine® is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.~Granulokine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization."
62119080|NCT05790096|EXPERIMENTAL|Test Drug - Filgrastine®|"Test Drug -~Filgrastine® is presented in boxes containing vials containing 1 mL of solution for injection and 300 µg of filgrastim.~Filgrastine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization."
62306976|NCT04611477|ACTIVE_COMPARATOR|Synbiotic365 Ver 7|One capsule/day to be taken orally 30 minutes before breakfast
62306977|NCT01450137|EXPERIMENTAL|Tocilizumab|Tocilizumab 8mg/kg every 4 weeks until week 52.
62306978|NCT01450137|PLACEBO_COMPARATOR|Placebo|Placebo every 4 weeks until week 52.
62306979|NCT05771571|PLACEBO_COMPARATOR|Control|The meal contained mashed potatoes, homogenized with refined olive oil.
62306980|NCT05771571|OTHER|Interventional|The meal contained mashed potatoes, homogenized with the functional olive oil, enhanced with orange peel extract
62306981|NCT04642664|EXPERIMENTAL|Apatinib plus Camrelizumab|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
62306982|NCT03069339|EXPERIMENTAL|Carvedilol+EVL|
62306983|NCT03069339|EXPERIMENTAL|Carvedilol|
62677988|NCT04634331|ACTIVE_COMPARATOR|Traditional Multi-Modal Training|A physical therapist will provide 1:1 multi-modal training. Multi-modal training is the simultaneous performance of a motor and a cognitive task (i.e. marching while answering math questions)
62119081|NCT06656689||Rezum Group|Patients who underwent Rezum water vapor thermal therapy treatment for BPH
62119082|NCT00834834|ACTIVE_COMPARATOR|Fluoxetine|Participants will receive fluoxetine with clinical management, which may involve switching medication to citalopram, another SSRI.
62119083|NCT00834834|ACTIVE_COMPARATOR|Dialectical behavior therapy|Participants will receive dialectical behavioral therapy (DBT).
62306984|NCT03069339|ACTIVE_COMPARATOR|EVL|
62306985|NCT02032875|EXPERIMENTAL|Post-liver Transplant Cohort|Participants with liver transplant received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets daily for 12 weeks and were followed for 24 weeks post treatment.
62306986|NCT02032875|EXPERIMENTAL|Cirrhotic Cohort|Cirrhotic participants received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets orally for 12 weeks and were followed for 24 weeks post-treatment. Cirrhotic participants who received a liver transplant while on study treatment were eligible (\>3 months post transplant) for a treatment extension of daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (dose based on hemoglobin level) tablets orally for an additional 12 weeks
62306987|NCT01367743|ACTIVE_COMPARATOR|epinephrine|
62306988|NCT01367743|ACTIVE_COMPARATOR|norepinephrine|
62306989|NCT03312010|EXPERIMENTAL|High Frequency|Subjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
62306990|NCT03312010|SHAM_COMPARATOR|Sham|Subjects receiving Sham (non-active) treatment over T9 exiting nerve roots. Subjects and assessors blinded to randomization. Subjects and assessors to be unblinded if pain scores are 30 mms or higher with VAS after 1-month follow-up. Upon this moment subjects to receive active stimulation
62474604|NCT03836560|ACTIVE_COMPARATOR|Intervention group|"Nicotine patch and nicotine gum:~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required."
62474605|NCT00960297|EXPERIMENTAL|Carboplatin/Paclitaxel/Bevacizumab|Preoperative chemotherapy and bevacizumab
62736339|NCT02221635||rTMS+Risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.At the same time,risperidone (2-4mg) was took orally.
61919229|NCT05421403|ACTIVE_COMPARATOR|Surgical|
62119084|NCT00258895|EXPERIMENTAL|DAPTACEL Primed|Participants received Daptacel in Study P3T06.
62119085|NCT00258895|EXPERIMENTAL|Pentacel Primed|Participants received Pentacel in Study P3T06
62119086|NCT06676228|EXPERIMENTAL|Experimental Group|"FORT consists of 6 sessions in total, the scopes of the sessions are detailed below:~Session 1 (Acquiring new skills to cope with Fear of Cancer Recurrence (FCR)) HOMEWORK: Daily practice of progressive muscle relaxation exercise; creation of a thought record~Session 2 (Providing information on symptoms of cancer recurrence and increasing tolerance to uncertainty) HOMEWORK: Listening to recordings of relaxation exercises every day; practising self-calming, keeping a record of thoughts~Session 3 (Developing coping skills) HOMEWORK: Practise guided imagery daily; debunk erroneous beliefs about the benefits of worrying; keep a thought log~Session 4 (Deepening the underlying fears) HOMEWORK: Reading the worst case fear scenario every day, practising daily self-care and mindfulness practices~Session 5 (Moving beyond specific fears) HOMEWORK: Writing goals and priorities for the future~Session 6 (Review and conclusion) Reviewing all the discussed content"
62306991|NCT05222802|EXPERIMENTAL|Dose Escalation (Part 1)|ERAS-801 will be orally administered to study participants with recurrent GBM in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
62306992|NCT05222802|EXPERIMENTAL|Dose Expansion (Part 2)|ERAS-801 will be orally administered at the recommended dose (as determined from Part 1) to study participants with recurrent GBM harboring alterations in EGFR.
62306993|NCT04801914||Matrix Metalloproteinases|Value of serum matrix metalloproteinase activity before and one month after PTBD
62306994|NCT04071665|EXPERIMENTAL|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion for treatment of scoliosis
62306995|NCT04071665|ACTIVE_COMPARATOR|transforaminal lumbar interbody fusion|transforaminal lumbar interbody fusion
62306996|NCT05041764||PCR positive|samples that are positive for the detection of SARS-CoV2. The SARS-CoV2 sequence of positive samples is provided, together with an indication about patient's neigborhood, corresponding to one of the 21 different spots which wastewater was analyzed
62306997|NCT05041764||PCR negative|samples that are p negative for the detection of SARS-CoV2. T
62306998|NCT01821963|EXPERIMENTAL|Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir|Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (\< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.
62306999|NCT00826605||Urobilinogen increase|Increase in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
62307000|NCT00826605||Weight Loss at Term|Weight loss since previous prenatal appointment after 37 weeks gestation
62307001|NCT02797561||Tandem lesion evaluated by FFR|
62307002|NCT02086773|EXPERIMENTAL|Low transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 7 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
62307003|NCT02086773|ACTIVE_COMPARATOR|High transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 8 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
62307004|NCT03610412|ACTIVE_COMPARATOR|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
62307005|NCT03610412|PLACEBO_COMPARATOR|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
62307006|NCT02333838|EXPERIMENTAL|Reduced toxicity conditioning regimen|"Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.~The conditioning regimen will include:~* IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)~* IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~* IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)~* IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)~In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:~* IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)~* IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~* IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)~* IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)"
62307007|NCT04889703|EXPERIMENTAL|15% Trichloroacetic acid (TCA) chemical peel|15% trichloroacetic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
62307008|NCT04889703|EXPERIMENTAL|30% Salicylic acid chemical peel|30% salicylic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
62307009|NCT02200107|EXPERIMENTAL|self management education|self management education program delivered by family doctor in primary care clinics and during and physical therapy design
62307010|NCT02200107|NO_INTERVENTION|control|Routine follow up according to standard practice
62307011|NCT01042301|EXPERIMENTAL|Long-term type 1 diabetic patients|Long-term type 1 diabetic patients
62736340|NCT02221635||Risperidone|Risperidone (2-4mg) was took orally.
62307012|NCT01042301|ACTIVE_COMPARATOR|control patients|control patients
62307013|NCT01042301|EXPERIMENTAL|diabetic and transplanted patients|diabetic and transplanted patients
62307014|NCT01042301|EXPERIMENTAL|subjects with high risk for diabetes|subjects with high risk for diabetes
62307015|NCT01042301|EXPERIMENTAL|patients with recent type 1 diabetes|patients with recent type 1 diabetes
62307016|NCT01042301|EXPERIMENTAL|patients with Latent Autoimmune Diabetes|patients with Latent Autoimmune Diabetes
62307017|NCT03995771||Children and adolescents with knee pain|Children and adolescents (8-19 years old) presenting to general practice for knee pain
62307018|NCT02875951||ER positive, HER2 negative breast cancer patients|Postmenopausal patients with hormone receptor positive, HER2 receptor negative breast cancer
62307019|NCT04146532|PLACEBO_COMPARATOR|Placebo|Single dose of a 500mg placebo tablet.
62307020|NCT04146532|ACTIVE_COMPARATOR|Aspirin 500MG|Single dose of a 500 mg aspirin tablet.
62307021|NCT01178918||Healthy volunteers from recipients of H1N1 vaccine|
62307022|NCT05394077|EXPERIMENTAL|Active Release Technique|Using Active Release Technique
62307023|NCT05394077|EXPERIMENTAL|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
62307024|NCT04478422|EXPERIMENTAL|Muscle strengthening with vascular occlusion|Quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, with partial occlusion to blood flow. The occlusion equipment will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017).
62736341|NCT03846427|EXPERIMENTAL|Zanubrutinib|Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
62736342|NCT05801146|EXPERIMENTAL|Botulinum toxin type A(HG102)|
62736343|NCT05801146|ACTIVE_COMPARATOR|Botulinum toxin type A(Botox®)|
62736344|NCT01469936|EXPERIMENTAL|PERMEAPROTECT|
62736345|NCT01469936|PLACEBO_COMPARATOR|PLACEBO|
61919230|NCT05421403|PLACEBO_COMPARATOR|non-Surgical|
62307025|NCT04478422|ACTIVE_COMPARATOR|Conventional muscle strengthening|Conventional quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, without occlusion to blood flow.
62307026|NCT04853329|EXPERIMENTAL|PartA- Arm A|"Arm A 1-6 subjects will be enrolled at dose levels of CPO107 at (1, 3, 6, 12, 20 mg/kg).~Each subject group will receive multiple cycles of a weekly dose of CPO-107 (1 cycle=21 days=3 treatments)."
62307027|NCT04853329|EXPERIMENTAL|PartA- Arm B|Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks (1 cycle=21 days=1 treatment). The starting dose for Arm B will be the dose level below the Arm A level that provides an equivalent dose over a 3-week period.
62307028|NCT04853329|EXPERIMENTAL|Part B|Part B with either: second or greater relapse OR refractory patients, as defined by not achieving a CR after 2 cycles of a standard first line chemoimmunotherapy regimen or not achieving a CR following 1 cycle of a second line chemotherapy regimen.
62307029|NCT02287246|EXPERIMENTAL|Extended-Release liposomal bupivacaine|20mL Extended-release liposomal bupivacaine injected into the posterior vaginal wall following surgery
62307030|NCT02287246|ACTIVE_COMPARATOR|Placebo (normal saline)|20mL normal saline injected into the posterior vaginal wall following surgery
62307031|NCT02104180|ACTIVE_COMPARATOR|TulleGras M.S.|
62307032|NCT02104180|ACTIVE_COMPARATOR|Urgotul|
62307033|NCT06196840|EXPERIMENTAL|LX102 Dose 1|LX102 will be administered at the assigned dose level as a single dose subretinal injection on Day 0
62307034|NCT06196840|EXPERIMENTAL|LX102 Dose 2|LX102 will be administered at the assigned dose level as a single dose subretinal injection on Day 0
62677989|NCT04634331|EXPERIMENTAL|Augmented Reality Multi-Modal Training|Multi-modal training will be administered via the Microsoft HoloLens 2 augmented reality head set. Augmented reality allows user to see the real world, and inserts holograms into the environment. For example, the user could see boxes on the ground that they need to step around when walking. The boxes are not real, but rather a hologram that only the user can see. The augmented reality device will instruct the participant on the motor and cognitive task that should be performed simultaneously in a similar manner to the physical therapist in the traditional multi-modal training group. The intervention will be overseen by a physical therapist.
61919231|NCT05886517|EXPERIMENTAL|TAVI procedure|Patients will be evaluated at baseline to access their eligibility for the procedure. The day of TAVI patients will be prepared for the procedures as the institution's standard practice for an invasive percutaneous endovascular procedure. During the pre hospital discharge period, patients will be monitored and will receive standard post-procedure care as judged appropriate by PI. At 30 days from the procedure a Fu visit will be made in order to access survival and adverse clinical events.
62307035|NCT06196840|ACTIVE_COMPARATOR|Control group|Aflibercept at a fixed regimen will be administered.
62307036|NCT02376439||Siblings|Siblings will consume four test meals after 4 different exposures, including two types of koolaid, a control and a smell condition.
62307037|NCT02677740|EXPERIMENTAL|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
62307038|NCT02677740|EXPERIMENTAL|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
62307039|NCT03168061|EXPERIMENTAL|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
62307040|NCT00844077||Barrett's metaplasia|Barrett's intestinal metaplasia, confirmed via pathology, undergoing standard of care endoscopic screening.
62307041|NCT03759652||infected, before-after studyt: 2003|neurosurgical patients; 2003: the beggining of active and target HAI surveillance
62307042|NCT03759652||infected, before-after studyt: 2017|neurosurgical patients; 2017: the effective of active and target HAI surveillance
62307043|NCT02417415|EXPERIMENTAL|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
62307044|NCT02417415|SHAM_COMPARATOR|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
62307045|NCT06511154|EXPERIMENTAL|Treatment group|Patients in this group are the group in which a physiotherapy program consisting of cognitive rehabilitation and core-based upper extremity exercises will be applied.
62307046|NCT06511154|ACTIVE_COMPARATOR|Control group|Patients in this group are the group in which a physiotherapy program consisting of core-based upper extremity exercises will be applied.
62307047|NCT05644730|EXPERIMENTAL|FUSION closed loop glucose control system|All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours
61919232|NCT01281527|EXPERIMENTAL|Paliperidone Palmitate|Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)
61919233|NCT01203176|ACTIVE_COMPARATOR|Post-menopausal symptomatic women|
61919234|NCT01203176|EXPERIMENTAL|Post-menopausal asymptomatic women|
62474606|NCT05251155||Standard vision chart.|Best corrected visual acuity measured by standard chart projector.
62474607|NCT05251155||Mobile based vision chart.|Best corrected visual acuity measured by mobile based chart with screen mirroring over 24 inch monitor.
62474608|NCT01593007|EXPERIMENTAL|Inspiratory Muscle Training|Inspiratory Muscle Training
62474609|NCT01593007|PLACEBO_COMPARATOR|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
62474610|NCT05111223|EXPERIMENTAL|TMS targeting OFC anterior networks|Participants will receive TMS and sham targeting the OFC network.
62474611|NCT05111223|EXPERIMENTAL|Experimental: TMS targeting posterior OFC networks|Participants will receive TMS and sham targeting the posterior OFC network.
62474612|NCT00699296|EXPERIMENTAL|1|
62474613|NCT01042665||primary open angle glaucoma|"Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included."
62120038|NCT05724472|EXPERIMENTAL|Study Group 3|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10\^8 pfu intramuscularly Day 1
62474614|NCT01042665||Ocular Hypertensive group|Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p\>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam
62677990|NCT06586164|ACTIVE_COMPARATOR|TCT + TAU|Subjects will complete 30 hours of Targeted Cognitive Training (TCT) in addition to their Treatment as Usual (TAU)
62677991|NCT06586164|NO_INTERVENTION|TAU|Subjects will participate in their standard Treatment as Usual (TAU) PRRC program
62677992|NCT05705804|EXPERIMENTAL|Group P|Pitavastatin 4mg group
62677993|NCT05705804|EXPERIMENTAL|Group PE|Pitavastatin 4 mg Ezetimibe 10 mg combined administration group
62677994|NCT05705804|ACTIVE_COMPARATOR|Group A|Atorvastatin 40 mg administration group
61919235|NCT01283243||HIV patients with normal liver status|HIV patients without abnormal liver function and chronic liver disease
61919236|NCT00572143|ACTIVE_COMPARATOR|1|Postoperative follow-up of ca coli patients at the surgical outpatient dpt
62120039|NCT03768310|EXPERIMENTAL|CD19.CAR-multiVST for Group A|"Group A: Patients with no evidence of disease after having a bone marrow transplant.~T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10\^7cells/m2 and the highest will be 10 x10\^7cells/m2."
61919237|NCT00572143|ACTIVE_COMPARATOR|2|Postoperative follow-up of ca coli patients by GP's
61919238|NCT05853627|EXPERIMENTAL|Mismatch reactivation condition|"The participant will recite their trauma narrative to the psychologist for 10-20 minutes. However, during each recitation, a mismatch condition, different for each session, will be added to the reactivation procedure by having the participant do the following (in order of sessions."
62120040|NCT03768310|EXPERIMENTAL|CD19.CAR-multiVST for Group B|"Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant.~Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10\^7cells/m2 and the highest will be 10 x10\^7cells/m2."
62120041|NCT06150053||R-CHOP-14|
62120042|NCT06150053||R-mini-CHOP|
62120043|NCT04852302|EXPERIMENTAL|Arm 1|Remote CALM therapy for participants with newly or recurrent PCNST
62120044|NCT05222087|ACTIVE_COMPARATOR|Arm 1: SoC systemic therapy|
62120045|NCT05222087|EXPERIMENTAL|Arm 2: radiotherapy to lung primary, delivered before cycle three of SoC systemic therapy|
62120046|NCT06225427|EXPERIMENTAL|Treatment (gilteritinib)|Patients receive gilteritinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography at screening and blood sample collection, CT scan and MRI at screening and on study. Additionally, patients may undergo a tumor biopsy pre-treatment and at end of treatment.
62120047|NCT06113146|EXPERIMENTAL|ultra-processed slow eating rate diet then the ultra-processed fast eating rate diet|Participants assigned to this arm will receive an ultra-processed slow eating rate diet for two weeks, followed by a two week washout period and a two week ultra-processed fast eating rate diet.
62120048|NCT06113146|EXPERIMENTAL|ultra-processed fast eating rate diet then the ultra-processed slow eating rate diet|Participants assigned to this arm will receive an ultra-processed fast eating rate diet for two weeks, followed by a two week washout period and a two week ultra-processed slow eating rate diet.
62120049|NCT01664871|EXPERIMENTAL|Levels of SIlver and Fluoride in Plasma|
62474615|NCT03098394|EXPERIMENTAL|Rapid Turnaround Test|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
62474616|NCT03098394|ACTIVE_COMPARATOR|Usual Care|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.
62474617|NCT00952250|ACTIVE_COMPARATOR|Targeted Feedback Reports|Conventional feedback reports
62677995|NCT04783168|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting.
62677996|NCT04783168|ACTIVE_COMPARATOR|Arm II (usual care, Fitbit)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting. Patients also receive a Fitbit to monitor step count
62677997|NCT04783168|EXPERIMENTAL|Arm III (usual care, Fitbit, Fitbit app)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and walking in the postoperative setting. Patients also receive a Fitbit device, install and use the Fitbit app on a smartphone. Postoperative step goals are as follows: Postoperative day (POD) 1: 25% of baseline. Subsequent days will be increased by 10% until patient reaches baseline daily step number. Five automatic daily reminders (delivered by the Fitbit Inspire HR\^TM device itself) to meet a minimum of 250 steps an hour. Postoperatively, patients will be invited to participate in a private group with a leaderboard that consists of step numbers of other participants in the study in an anonymous fashion.
62677998|NCT03932786||Retrospective(biospecimens, vision assessment, questionnaires)|
62677999|NCT03932786||Prospective (biospecimens, vision assessment, questionnaires)|
62307048|NCT00736281|NO_INTERVENTION|Placebo Food Drops|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
62307049|NCT00736281|ACTIVE_COMPARATOR|Food Drops|Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).
62307050|NCT05585372|NO_INTERVENTION|control group|The control group will receive general stability exercises and neurodynamic mobilization only
62307051|NCT05585372|EXPERIMENTAL|CT guided opening mobilization of cervical intervertebral foreman|"Grade four manual therapy mobilization of cervical intervertebral foreman guided by 3 dimensions computed tomography (CT) as following :~1. Determining the poper direction of cervical IVF by 3D CT.~2. the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~3. cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~4. Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~5. Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
62307052|NCT01183858|EXPERIMENTAL|Erlotinib 150 mg|Erlotinib 150 mg single daily oral dose until disease progression.
62307053|NCT01183858|EXPERIMENTAL|Erlotinib 300 mg|Erlotinib 300 mg single daily oral dose until disease progression.
62307054|NCT05335122|EXPERIMENTAL|OTX-TIC Low Dose|Travoprost Intracameral Implant low dose
62307055|NCT05335122|EXPERIMENTAL|OTX-TIC High Dose|Travoprost Intracameral Implant high dose
62307056|NCT05335122|ACTIVE_COMPARATOR|Durysta|Bimatoprost Intracameral Implant 10 µg
62307057|NCT02443844|ACTIVE_COMPARATOR|First group|Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer
62474618|NCT00952250|EXPERIMENTAL|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement.
62474619|NCT02200224|EXPERIMENTAL|Rapid Testing/Treatment Group|All subjects enrolled in the rapid testing group will receive rapid CT/NG and TV testing in addition to the CT/NG Nucleic Acid Amplification Test (NAAT) and wet mount testing that is currently used in the ED.
62474620|NCT02200224|NO_INTERVENTION|Control|All subjects enrolled in the control group will receive CT/NG and TV testing according to the current standard of care for Johns Hopkins ED.
62474621|NCT03217539|EXPERIMENTAL|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
62474622|NCT03217539|NO_INTERVENTION|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
62474623|NCT00833937|EXPERIMENTAL|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
62474624|NCT00833937|ACTIVE_COMPARATOR|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
62678000|NCT03055013|EXPERIMENTAL|Arm A (nivolumab + nephrectomy)|"Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 2 cycles. Patients then undergo partial or radical nephrectomy 7-28 days later. Patients then receive nivolumab over 30 IV on day 1. Treatment repeats every 14 days for 6 cycles, and then every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients enrolled after Amendment 4 receive nivolumab IV over 30 minutes on day 1. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
62307058|NCT02443844|ACTIVE_COMPARATOR|Second Group|Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer
62307059|NCT05727774|EXPERIMENTAL|Hot water condition|Participants do the water biking training for two weeks, 1 hour a day, in hot water temperature (35°C)
62307060|NCT05727774|SHAM_COMPARATOR|Neutral water condition|Participants do the water biking training for two weeks, 1 hour a day, in neutral water temperature (25°C)
62307061|NCT03624998|EXPERIMENTAL|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
62307062|NCT01165229|EXPERIMENTAL|Zoster vaccine group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
62307063|NCT01165229|PLACEBO_COMPARATOR|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
62307064|NCT00124540|PLACEBO_COMPARATOR|1|placebo resembling misoprostol
62307065|NCT00124540|EXPERIMENTAL|2|misoprostol
62474625|NCT02714062|PLACEBO_COMPARATOR|Placebo|Days 1-56: Placebo
62474626|NCT02714062|EXPERIMENTAL|VI-0521 Mid Dose|"* Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~* Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)"
62474627|NCT02714062|EXPERIMENTAL|VI-0521 Top Dose|"* Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~* Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~* Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~* Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
62474628|NCT04733755|EXPERIMENTAL|Beauty Image|
62678001|NCT03055013|ACTIVE_COMPARATOR|Arm B (nephrectomy only)|Patients undergo partial or radical nephrectomy within 8 weeks after registration followed by observation.
61920001|NCT04623008|NO_INTERVENTION|Usual Prenatal Care|The usual prenatal care group will receive usual care from their providers
62119087|NCT06676228|ACTIVE_COMPARATOR|Control Group (active comparator)|"The cognitive-behavioural therapy (CBT) oriented control group consisted of a total of 6 sessions. The scopes of the sessions are given in detail below.~Session 1: Introduction and cancer-focused psychoeducation with CBT HOMEWORK: Keeping a thought diary~Session 2: Addressing the underlying causes of thoughts HOMEWORK: Keeping a thought diary about underlying beliefs~Session 3: Recognising conflicts HOMEWORK: Task: Keep a diary of thoughts about disagreements (what gives us pleasure and what we should master)~Session 4: Effective communication techniques HOMEWORK: Keeping a diary about the use of the word good enough~Session 5: Discussion of the definitions of anxiety and depression~Session 6: Anger Management HOMEWORK: HOMEWORK: Keeping a diary about the use of the breathing exercise"
62119088|NCT05510544|EXPERIMENTAL|Experimental arm: plerixafor, G-CSF|plerixafor in combination with granulocyte colony stimulating factor (G-CSF) for CD34+ HSC mobilization in poorly mobilized lymphoma patients
62307066|NCT01912885|PLACEBO_COMPARATOR|Group TENS 0-1|Electrodes will be fixated to one leg and sessions will be held once a week.
62307067|NCT01912885|EXPERIMENTAL|Group TENS 1-1|Electrical stimulation of the posterior tibial nerve of one leg once a week.
62307068|NCT01912885|EXPERIMENTAL|Group TENS 1-2|Electrical stimulation of the posterior tibial nerve of one leg twice a week.
62307069|NCT01912885|EXPERIMENTAL|Group TENS 2-1|Electrical stimulation of the posterior tibial nerve of two legs once a week.
62307070|NCT01912885|EXPERIMENTAL|Group TENS 2-2|Electrical stimulation of the posterior tibial nerve of two legs twice a week.
62474629|NCT04733755|PLACEBO_COMPARATOR|Placebo Control|
62474630|NCT00840632|EXPERIMENTAL|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
62474631|NCT00840632|ACTIVE_COMPARATOR|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
62474632|NCT03380845|ACTIVE_COMPARATOR|Fraxel Restore on one side of the face|"Fraxel Restore on one side of the face~Fraxel Restore: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
62307071|NCT04207073|NO_INTERVENTION|Control group|No intervention.
62307072|NCT04207073|EXPERIMENTAL|Exercise group|Participants in the exercise group will perform 2 sets of 5 repetitive Median nerve mobilization exercises (total of 20 sessions) per day for 10 days.
62307073|NCT01507246|ACTIVE_COMPARATOR|IV morphine sulfate|Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
62307074|NCT01507246|EXPERIMENTAL|EXPAREL (bupivacaine liposome injectable suspension)|EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.
62307075|NCT06489678|NO_INTERVENTION|Usual Care|For the control arm, standard bronchoscopy (±virtual or electromagnetic navigation, r-EBUS, and 2-dimensional fluoroscopy) will be employed, using various types of bronchoscopes (±ultra-thin bronchoscopes) and biopsy tools (needle, cryoprobe, forceps) at the investigator's discretion.
62307076|NCT06489678|ACTIVE_COMPARATOR|Cone-beam CT and robotic assisted bronchoscopy|Usual care with Cone-beam CT and the added option for the use of robotic assisted bronchoscopy (Ion endoluminal System, Intuitive) during the procedure. A connection between the cone-beam CT and the robotic system (NaviLink) is also possible.
61919239|NCT05853627|ACTIVE_COMPARATOR|Standard reactivation condition|The intervention will be the same for each of the six intervention sessions. The participant will recite to the psychologist the narrative they previously composed for 10-20 min. The psychologist will congratulate the participant for having succeeded in this task and advise them they are finished for the day.
62119089|NCT02735616||study|"15 CVA patients, 1-3 weeks after their first stroke. The patients will be hospitalized in the neurology department at the geriatric Beit-Rivka hospital at Petah-Tiva, Israel.~patients with pacemaker or those who use Beta-Blocker drugs, as well as patients with cerebellar injury, will be excluded from the research"
62119090|NCT02735616||control|15 patients from the orthopedic department at the same hospital, matching by age and gender to the study group.
62119091|NCT04810793||Amoxicillin-Levofloxacin-Esomeprazole-containing quadruple group|Patients in amoxicillin-levofloxacin-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
62119092|NCT04810793||Amoxicillin-Furazolidone-Esomeprazole-containing quadruple group|Patients in amoxicillin-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
62119093|NCT04810793||Tetracycline-Furazolidone-Esomeprazole-containing quadruple group|Patients in tetracycline-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
62119094|NCT04810793||Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group|Patients in amoxicillin-levofloxacin-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
62119095|NCT04810793||Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group|Patients in amoxicillin-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
62119096|NCT04810793||Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group|Patients in tetracycline-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
62119097|NCT05943171|EXPERIMENTAL|Digital RITch®CBT|(Digital RITch®CBT) is a Digital Avatar Assisted Interactive CBT Treatment
62119098|NCT05943171|ACTIVE_COMPARATOR|Standard CBT|Standard CBT is a human administered CBT Treatment
62119099|NCT03599453|EXPERIMENTAL|Treatment (chemokine modulation therapy)|Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo additional biopsy. Following biopsy and chemokine modulation therapy, participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
62119100|NCT00605982|EXPERIMENTAL|1|Women with core biopsy proven DCIS with or without microinvasion seen for surgical consultation at Memorial Sloan-Kettering Cancer Center and for whom operative intervention is planned.
62119101|NCT03796247||multiple sclerosis|
62119102|NCT03796247||healthy control|
62119103|NCT02271971|EXPERIMENTAL|Vitamin D3 supplementation|Subjects in the experimental arm will receive a daily 5.000 IU vitamin D3 capsule during 6 weeks.
62474633|NCT03380845|ACTIVE_COMPARATOR|Fractora on the other side of the face|"Fractora on the other side of the face~Fractora: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
62474634|NCT00834067|EXPERIMENTAL|1|
61919240|NCT06455618|EXPERIMENTAL|stent-less PCNL|In group 1, a nephrostomy tube is indwelled in the patient's body before the end of PCNL.
61919241|NCT06455618|ACTIVE_COMPARATOR|stent PCNL|In group 2, a nephrostomy tube and a ureteral stent are indwelled in the patient's body before the end of PCNL.
62474635|NCT00834067|ACTIVE_COMPARATOR|2|
61919242|NCT03555838|EXPERIMENTAL|Active tDCS|Participants in this arm will receive 20 minutes of 2 mA transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
62119104|NCT02271971|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will receive a daily placebo capsule during 6 weeks.
62474636|NCT03167515|EXPERIMENTAL|074-6751 Lotion|
62474637|NCT03447353|EXPERIMENTAL|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
62474638|NCT03447353|EXPERIMENTAL|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
62474639|NCT03447353|EXPERIMENTAL|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
62678002|NCT05737693|EXPERIMENTAL|0.2mg/kg ketamine with psychotherapy|Two infusions of low dose Ketamine combined with trauma-focused psychotherapy. Low dose ketamine infusion will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state of ketamine infusion of 0.2 mg/kg for 40 minutes.
62678003|NCT05737693|EXPERIMENTAL|0.5mg/kg ketamine with psychotherapy|2. Two infusions of Ketamine combined with trauma-focused psychotherapy. Low dose ketamine infusion will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state of ketamine infusion of 0.5 mg/kg for 40 minutes.
62678004|NCT05737693|ACTIVE_COMPARATOR|Midazolam with psychotherapy|Midazolam combined with trauma-focused psychotherapy. Midazolam infusion procedure will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusion at a rate 0.045 mg/kg for 40 minutes.
62678005|NCT02255383|OTHER|PERSONA TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
62678006|NCT02057666|EXPERIMENTAL|Tasquinimod|One capsule (0.25, 0.50 or 1 mg), taken orally once a day with water and food (preferably the main evening meal).
62474640|NCT03447353|EXPERIMENTAL|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
62474641|NCT06554717|ACTIVE_COMPARATOR|Tesamorelin Plus Exercise|Tesamorelin SV 1.4 mg given subcutaneously daily plus home-based semi-supervised exercise intervention
62678007|NCT02057666|PLACEBO_COMPARATOR|Placebo|One capsule, taken orally once a day with water and food (preferably the main evening meal).
62678008|NCT05925972|ACTIVE_COMPARATOR|Grup ESP|The group to which erector spina plane block will be applied
62678009|NCT05925972|ACTIVE_COMPARATOR|Grup OSTAP|The group to which oblique subcostal transversus abdominis plane block will be applied
62119105|NCT04820933|EXPERIMENTAL|Doravirine plus emtricitabine and tenofovir alafenamide fumarate|PIFELTRO (doravirine) 100 mg tablet one daily for 3 months Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate) tablet one daily for 3 months
62119106|NCT06449300|EXPERIMENTAL|low volume (LVT) resistance training|3 sessions of 12 exercises per week for 8 weeks . Split-strength training method will be applied. After participants' 1RM maximums were determined, training loads were calculated separately for each participant. All workouts will be conducted by certified trainers to ensure they are performed in the correct training format. Each training session lasted approximately 60 minutes. The weekly training loads of all participants will be increased by 5%. In the MVT group, 3 sets of 8-12 repetitions: between sets intervals: of 120 seconds will be performed.
62119107|NCT06449300|ACTIVE_COMPARATOR|moderate volume (MVT) resistance training|4 sessions of 12 exercises per week for 8 weeks . Split-strength training method will be applied. After participants' 1RM maximums were determined, training loads were calculated separately for each participant. All workouts will be conducted by certified trainers to ensure they are performed in the correct training format. Each training session lasted approximately 60 minutes. The weekly training loads of all participants will be increased by 5%. In the MVT group, 3 sets of 8-12 repetitions: between sets intervals: of 120 seconds will be performed.
62119108|NCT06449300|ACTIVE_COMPARATOR|high volume (HVT) resistance training|5 sessions of 12 exercises per week for 8 weeks . Split-strength training method will be applied. After participants' 1RM maximums were determined, training loads were calculated separately for each participant. All workouts will be conducted by certified trainers to ensure they are performed in the correct training format. Each training session lasted approximately 60 minutes. The weekly training loads of all participants will be increased by 5%. In the MVT group, 3 sets of 8-12 repetitions: between sets intervals: of 120 seconds will be performed.
62119109|NCT04518748|EXPERIMENTAL|Y-90 SIRT followed by SBRT|Y-90 SIRT followed by SBRT
62119110|NCT04136470||NSCLC|This cohort will consist of 100 patients with non-small cell lung cancer (NSCLC).
62119111|NCT04136470||MEL|This cohort will consist of 30 patients with melanoma (MEL).
62120050|NCT02999477|EXPERIMENTAL|Nab-Paclitaxel|"* 2 weeks Nab-Paclitaxel Run in~* Biopsy will be performed~* Post mono therapy Nab-Paclitaxel administered weekly~* Post mono therapy Pembrolizumab administered every 3 weeks~* Agents administered for a total of 15 weeks"
62120051|NCT02999477|EXPERIMENTAL|Pembrolizumab|"* 2 weeks Pembrolizumab Run in~* Biopsy will be performed~* Post mono therapy Nab-Paclitaxel administered weekly~* Post mono therapy Pembrolizumab administered every 3 weeks~* Agents administered for a total of 14 weeks"
62474642|NCT06554717|PLACEBO_COMPARATOR|Placebo Plus Exercise|Identical placebo given subcutaneously daily plus home-based semi-supervised exercise intervention
62474643|NCT00793832|ACTIVE_COMPARATOR|1|Supervised exercise.
62678010|NCT06202989|EXPERIMENTAL|Multiprofen-CC™|Standard care pain medications and topical Multiprofen-CC™ (1g TID) for 6 weeks after surgery
62120052|NCT02206672|OTHER|Micro reinjection of autologus adipose tissue|
62474644|NCT00793832|ACTIVE_COMPARATOR|2|Diet Advice
62474645|NCT06062277|OTHER|Single Arm Study|"Paired cohort before and after study. Each participant will act as their own control.~All participants will receive the intervention: study drug colchicine 0.5mg orally once daily for a treatment period of 30 days."
62474646|NCT04962594|EXPERIMENTAL|Experimental formulas (EF) group|Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) supplemented with pre- and probiotic(s)
62474647|NCT04962594|ACTIVE_COMPARATOR|Control formulas (CF) group|Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) not supplemented
62474648|NCT04962594|ACTIVE_COMPARATOR|Breastfed (BF) group|Breast milk
62307077|NCT00393458|EXPERIMENTAL|Indacaterol 300 μg plus placebo to formoterol|Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62474649|NCT05176600|EXPERIMENTAL|Bimanual group|In this group, patients will perform a robotic rehabilitation based on bimanual serious games
62474650|NCT05176600|ACTIVE_COMPARATOR|Unimanual group|In this group, patients will perform a robotic rehabilitation based on unimanual serious games
62474651|NCT04030091|EXPERIMENTAL|3 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 3 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
62474652|NCT04030091|EXPERIMENTAL|2 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 2 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
62474653|NCT05463822|EXPERIMENTAL|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
62678011|NCT06202989|PLACEBO_COMPARATOR|Control|Standard care pain medications and visually identical topical placebo (1g TID) for 6 weeks after surgery
62678012|NCT06684353||COPD patients in ICU with high risk of mortality (non survivors)|COPD patients on NIV / MV
62119112|NCT01281813|EXPERIMENTAL|Continued Treatment with DRV in Combination with rtv|HIV-1 infected children participants (aged less than \[\<\] 12 years) will continue to receive darunavir (DRV) 200 to 600 milligrams (mg) as oral suspension twice daily (BID) along with ritonavir (rtv) 32 to 100 mg as oral solution/suspension BID. HIV-1 infected adolescent participants (aged 12-17 years) will continue to receive DRV 200 to 600 mg as oral suspension BID along with rtv 32 to 100 mg as oral solution/suspension BID. Dosing for children and adolescent participants will be based on body weight (per parent study TMC114-TiDP29-C232). HIV-1 infected adult participants (aged greater than or equal to \[\>=\] 18 years) will continue to receive DRV 800 mg (2 tablets of 400 mg) orally every day (qd) along with rtv 100 mg tablet (per parent study TMC114-C211) or DRV 600 mg tablet orally BID along with rtv 100 mg tablet (per parent study TMC114-C214 or TMC114-TiDP31-C229).
62474654|NCT02874677|NO_INTERVENTION|Control|Routine activities
62474655|NCT02874677|EXPERIMENTAL|Experimental|Effort reeducation program : 3 sessions of 20 minutes per week during 6 weeks
62474656|NCT05664919|EXPERIMENTAL|Drug group|3500 participants will use SA58 Nasal Spray in drug group.
62474657|NCT05664919|NO_INTERVENTION|Blank control group|3500 participants won't be given medication in blank control group.
62678013|NCT06684353||COPD patients in ICU with low risk of mortality ( survivors )|COPD patients on NIV / MV
62678014|NCT06431646|EXPERIMENTAL|Intervention Group|Web-based education with weekly updates about PMS (definition, symptoms, treatment etc.) and management (especially, non-pharmacologic strategies) for 4 weeks
62678015|NCT06431646|NO_INTERVENTION|Control Group|No special intervention
62119113|NCT05939063|ACTIVE_COMPARATOR|LRAMPS group|Patients who meet the inclusion and exclusion criteria will undergo laparoscopic radical antegrade modular pancreatosplenectomy (LRAMPS) surgery.
62119114|NCT05939063|EXPERIMENTAL|LDP group|Patients who meet the inclusion and exclusion criteria will undergo laparoscopic distal pancreatosplecnectomy (LDP) surgery.
62474658|NCT06081569||Alzheimer's disease|the diagnosis of AD is according to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD.
62474659|NCT06081569||Mild cognitive impairment|the diagnosis of MCI refers to the criteria defined by Peterson in 2004.
62678016|NCT04166864|EXPERIMENTAL|SCC-Determined TMS|
62307078|NCT00393458|EXPERIMENTAL|Indacaterol 600 μg plus placebo to formoterol|Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62307079|NCT00393458|ACTIVE_COMPARATOR|Formoterol 12 μg plus placebo to indacaterol|Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62678017|NCT04328727|EXPERIMENTAL|eltrombopag|Participants will receive eltrombopag in combination with r-ATG and CsA.
62678018|NCT06694467|EXPERIMENTAL|Intervention group|An official diabetes education program and family empowerment model where employed, designed to provide people with diabetes and their families the information and abilities they need to manage their condition effectively. Types of diabetes, blood sugar control, self-monitoring methods, nutrition, meal planning, physical activity recommendations, medication management, and problem-solving approaches are all included in these programs
62307080|NCT00393458|PLACEBO_COMPARATOR|Placebo to indacaterol plus placebo to formoterol|Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62307081|NCT00283829|OTHER|I|Docetaxel followed by IL-2
61919243|NCT03555838|SHAM_COMPARATOR|Sham tDCS|Participants in this arm will receive 20 minutes of sham transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
61919244|NCT05270161|EXPERIMENTAL|Test Group 1 (T1)|Multiple gingival recessions in the anterior region of the mandible treated with the tunnel technique.
62307082|NCT05000801|EXPERIMENTAL|DC vaccine|Vaccination with autologous or HLA-matched donors' WT1/TERT/survivin loaded DCs plus follow-up care.
62307083|NCT04723537|EXPERIMENTAL|Part A: Upamostat 200 mg|Each day participants will receive a single 200 mg dose of upamostat along with a single matching placebo, for a total of 14 days.
62307084|NCT04723537|EXPERIMENTAL|Part A: Upamostat 400 mg|Each day participants will receive two 200 mg doses of upamostat, for a total of 14 days.
62307085|NCT04723537|PLACEBO_COMPARATOR|Part A: Placebo|Each day participants will receive two matching placebos, for a total of 14 days.
61919245|NCT05270161|EXPERIMENTAL|Test Group 2 (T2)|Isolate gingival recessions in the anterior region of the mandible treated with the laterally closed tunnel technique.
62307086|NCT04723537|EXPERIMENTAL|Part B: Upamostat|Based on dose selected from Part A, each day participants will receive EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days.
62307087|NCT04723537|PLACEBO_COMPARATOR|Part B: Placebo|Based on dose selected from Part A, each day participants will receive EITHER a single matching placebo OR two matching placebos, for a total of 14 days.
62307088|NCT05096169|EXPERIMENTAL|Clomiphene citrate 25 mg daily for 12 weeks|
62307089|NCT05096169|EXPERIMENTAL|Clomiphene citrate 50 mg every other day for 12 weeks|
62678019|NCT06694467|NO_INTERVENTION|Control group|Patients diagnosed with type 1 diabetes mellitus for six months or more and had not attended any form of structured diabetes education including hospital-based classes or community group diabetes education classes for the preceding month of the study. These parameters were adopted to ensure that study takes place in a controlled environment and targets the aspects of intervention of study.
62474660|NCT06081569||Control|participants who are age-matched with AD and MCI participants, without cognitive impairment.
62474661|NCT05748535|EXPERIMENTAL|Unilateral Right Ear|Auricular vagus nerve stimulation performed through the unilateral right ear.
62474662|NCT05748535|EXPERIMENTAL|Unilateral Left Ear|Auricular vagus nerve stimulation performed through the unilateral left ear.
62474663|NCT05748535|EXPERIMENTAL|Bilateral Ear|Auricular vagus nerve stimulation performed through the bilateral ear.
62474664|NCT01250912|EXPERIMENTAL|Imaging Tracer|No arms, the Radio tracer will be used in all subjects imaging tests.
62474665|NCT04381130|EXPERIMENTAL|EF-009|In both the Phase I and Phase IIa portions of the study, subjects will be evaluated for response every 8 weeks after EF-009 wafer implantation for up to 2 years, by CT, PET/CT or MRI (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be assessed based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST v1.1). The total study duration for each subject consists of screening, treatment, and extended follow-up period and survival follow-up period.
62474666|NCT03523039|EXPERIMENTAL|Hemoadsorption|Hemoadsorption is performed using a CytoSorb® cartridge.
62474667|NCT03523039|NO_INTERVENTION|Control|Post-cardiac arrest management will be conducted as per institutional protocols.
62474668|NCT04226027|EXPERIMENTAL|T2.coach|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center) and are asked to use T2.coach for 6 months.
62474669|NCT04226027|NO_INTERVENTION|Control|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center).
62307090|NCT02045537||Fractures|Patients in follow up from 1st Jan 1997 to 1st Jan 2012 with any fracture (pathologic)
62307091|NCT02233725|ACTIVE_COMPARATOR|Definity Perflutren Suspension|Injection of Definity Perflutren Injectable Suspension- which travels in the bloodstream throughout the body. These microbubbles are identifiable on ultrasound imaging, and studies of the liver and kidney have identified it as a useful adjunct to identifying vascular lesions. Areas of regular blood flow will not have as large a concentration of the microbubble agent as will areas that have increased blood flow and neovascularisation. It has been well documented that cancerous solid lesions undergo neovascularisation and have increased blood flow to the area.
62307092|NCT04181281||young adult|18 - 40 years old (n=10) Healthy male or female and able to give informed, written consent.
62474670|NCT00446563|EXPERIMENTAL|Amlodipine + Valsartan|Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
62474671|NCT00446563|ACTIVE_COMPARATOR|Losartan + Hydrochlorothiazide|Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
62474672|NCT02564965|OTHER|Greater than 50% Necrosis|Subjects who have greater than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
62474673|NCT02564965|OTHER|Less than 50% Necrosis|Subjects who have less than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
62474674|NCT02523963|EXPERIMENTAL|study group|"children with developmental delays participated 6 sessions of family work shop~1. The family work shop has 5 courses, with 6 families in one course.~2. Intervention of one course: 2-3 hours per session, one time per week, for a total of 6 weeks."
62678020|NCT04991519||Stroke Survivors|Participants have had a left-hemisphere stroke with or without aphasia, or a stroke elsewhere in the brain causing aphasia. They are given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
62474675|NCT02523963|NO_INTERVENTION|control|children with normal development not participate the work shop followed up at before, and 6 weeks later
61919246|NCT05270161|ACTIVE_COMPARATOR|Control Group 1 (C1)|Multiple gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
62474676|NCT06626529|EXPERIMENTAL|Mindfulness|Intervention group participants will practice mindfulness following a ten-minute video of guided mindfulness meditation for craving and addiction.
62474677|NCT06626529|SHAM_COMPARATOR|Scenery video|Control group participants will watch a ten-minute video of calming music and images.
62678021|NCT04991519||Controls|Participants are matched to aphasia cohort in age, educational background, race, and gender but have no history of brain injury. They are also given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
62307093|NCT04181281||older adult|70 years or older (n=10) Healthy male or female and able to give informed, written consent.
62678022|NCT06639503|NO_INTERVENTION|Peri-incisional local anesthesia|subjects randomized to peri-incisional local anesthesia administration will receive an injection of 25 ml of 0.25% bupivacaine across all incisions at the time of wound closure (standard of care)
62307094|NCT04181281||AKI patients|Admitted patients with AKI stage 3
62307095|NCT03191175||HIV patients|
62307096|NCT03191175||Control patients|
62307097|NCT00887081|EXPERIMENTAL|Interferon and Ribavirin|Patients with hemoglobinopathy will receive Interferon and Ribavirin
62678023|NCT06639503|EXPERIMENTAL|Genicular nerve blockade|Subjects randomized to genicular nerve block will receive a fluoroscopic guided injection of 5 ml of 0.25% bupivacaine at the described locations of the superolateral genicular nerve, super medial genicular nerve, inferomedial genicular nerve, recurrent fibular nerve, and infrapatellar branch of the saphenous nerve under fluoroscopic guidance at the time of wound closure
62678024|NCT03511209|EXPERIMENTAL|CBTI plus Taper method A|Participants in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBTI) plus the novel hypnotic tapering method.
62119115|NCT00664430|OTHER|Calcitriol challenge followed by paricalcitol|Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.
62119116|NCT04819815||Type 1 diabetes mellitus|"Patients~Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue (fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated."
62119117|NCT04819815||Healthy Controls|Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue ( fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated.
62119118|NCT05618236||neostigmin+atropin|This will be the group of patients decurarized with neostigmine+atropine,
62119119|NCT05618236||sugammadeks|This will be the group of patients decurarized with sugammadex.
62119120|NCT04177017|EXPERIMENTAL|Experimental group|The experimental group is the one that participates in the intervention
62119121|NCT04177017|NO_INTERVENTION|Control group|The control group belonged to the same school but did not participate in the intervention. Instead, they continued with regular curricular classes
62119122|NCT02886858|EXPERIMENTAL|tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
62119123|NCT02886858|SHAM_COMPARATOR|Sham tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
62119124|NCT01059877|ACTIVE_COMPARATOR|1072nm Infrared Photobiomodulation|Received treatment for dementia with transcranial 1072nm infrared light stimulation.
62119125|NCT01059877|PLACEBO_COMPARATOR|Placebo|Placebo device simulated transcranial photobiomodulation
62119126|NCT03026036||MDD|Patients with current Major Depressive Disorder
62119127|NCT03026036||rMDD|Patients with a history of Major Depressive Disorder
62119128|NCT03026036||HC|Healthy control participants
62119129|NCT05007678|NO_INTERVENTION|Standard of Care|The usual care will be offered as per current advice on management of hospitalised patients.
62119130|NCT05007678|ACTIVE_COMPARATOR|leflunomide|Patients admitted to the hospital COVID-19 positive and within 2 weeks of symptoms' onset will be treated with loading dose of 100 mg leflunomide for 3 days, followed by 20 mg once daily. Participants with ALT/AST levels 2 times above upper limits of normal reference range will receive 10mg instead of 20mg.
62119131|NCT03883542||serous BOT|simple serous BOT ovarian tissue
62119132|NCT03883542||serous BOT with non-invasive implants|BOT ovarian tissue presenting with non-invasive implants
62119133|NCT03883542||sBOT with micropapillary grow pattern|BOT ovarian tissue presenting with micropapillary grow pattern
62119134|NCT03883542||serous BOT with invasive implants|sBOT ovarian tissue presenting with invasive implants at the time of diagnosis
62119135|NCT06108271|EXPERIMENTAL|ETT-T|Endotracheal tube Triglotix®
62119136|NCT06108271|ACTIVE_COMPARATOR|ETT-C|Endotracheal tube conventional
62307098|NCT05859815||Directional preference responder|This group is comprised of participants who responded to repeated movements in a direction (e.g., neck flexion) that significantly improved their symptoms and/or their ability to move their head/neck.
61919247|NCT05270161|ACTIVE_COMPARATOR|Control Group 2 (C2)|Isolate gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
62119137|NCT05250336||Patients with Primary Breast Cancer|"The pretherapeutic cores or specimen from patients who meet the following criteria were subjected for analysis~INCLUSION CRITERIA Primary Breast cancer Completed scheduled treatment at SGPGI Adequate quality histopathology material available in Department of Pathology archives With minimum 6 months follow up~EXCLUSION CRITERIA Insufficient data Incomplete treatment Insufficient follow up information Insufficient histological material for review"
62119138|NCT00658996|EXPERIMENTAL|SofLens DD Toric|Bausch \& Lomb SofLens Daily Disposable Toric Contact Lens
62119139|NCT00658996|ACTIVE_COMPARATOR|Ciba Vision Toric Lens|Ciba Vision Focus Dailies Toric Contact Lens
62119140|NCT03461575|EXPERIMENTAL|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
62119141|NCT03461575|ACTIVE_COMPARATOR|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
62119142|NCT03461575|ACTIVE_COMPARATOR|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
62119143|NCT00486759|EXPERIMENTAL|Bevacizumab + rituximab + CHOP|Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).
62307099|NCT05859815||Directional preference non-responder|This group is comprised of participants who did not respond to repeated movements in any specific direction that significantly improved their symptoms and/or their ability to move their head/neck.
62474678|NCT04664556||Cohort of invasive pneumococcal disease in children|
61919248|NCT05270161|EXPERIMENTAL|Gel Group (G)|The donor area on the palate will be treated using hyaluronic acid gel and green tea applied by the participant 3 times a day for 7 days.
61919249|NCT05270161|ACTIVE_COMPARATOR|Clot Group (CO)|No material will be placed in the donor area, only the clot will be kept in position by means of sutures.
62307100|NCT01470339|PLACEBO_COMPARATOR|placebo|migraine patients to receive placebo treatment
62307101|NCT01470339|ACTIVE_COMPARATOR|duloxetine|migraine patients to receive duloxetine
62307102|NCT03436589|NO_INTERVENTION|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
62307103|NCT03436589|EXPERIMENTAL|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
62307104|NCT02928640|EXPERIMENTAL|ClariCore System|ClairCore System study designed for data collection to build the prostrate tissue classification algorithm.
62307105|NCT01522495|EXPERIMENTAL|SPY Imaging|SPY Imaging Prior to Amputation or Debridements (50 participants)
62307106|NCT01522495|NO_INTERVENTION|No SPY Imaging|Amputation or Debridements as Standard of Care (50 participants)
62474679|NCT04528784|EXPERIMENTAL|Intervention|Transcutaneous tibial nerve stimulation will be applied as follows: 18 sessions of 30 minutes duration, delivered three times a week over a 6 week period using TENS device with 10 Hertz (Hz), and pulse width 200µs. The intensity of stimulation will be at the sensory and motor threshold by tingling sensation on sole of the foot with flexion of big toe and /or fanning of other toes.
62474680|NCT03199872|EXPERIMENTAL|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
62678025|NCT03511209|ACTIVE_COMPARATOR|CBTI plus Taper method B|Participants in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBTI) plus the usual tapering method used by the VA.
62678026|NCT06585423|ACTIVE_COMPARATOR|Medical grade acrylic tip covered by a sterile commercially available bandage contact lens|
62678027|NCT06585423|ACTIVE_COMPARATOR|Medical grade acrylic tip coated with medical grade silicone of a thickness < 100 µm|
62678028|NCT06585423|ACTIVE_COMPARATOR|Medical grade acrylic tip coated with medical grade silicone of a thickness > 100 µm|
62678029|NCT06465602|EXPERIMENTAL|Nicotinamide supplementation group|At the beginning and end of the study, blood samples will be taken for the measurement of IL-6, CCL2, TNF-alpha, and NFL, and participants will be assessed using the Short Physical Performance Battery (SPPB), quadriceps dynamometry (LY-D Lynx Dynamo), quadriceps oxygen saturation (with NIRS), and posturography to determine the center of pressure (COP) area with the HUR BTG4 posturography system, and SmartBalance® software. Subjects will receive 1.5 grams per day of nicotinamide, orally, for 30 days. During this period, they will undergo a home-based physical training program guided by a physiotherapist. The sessions will be 50 minutes long (10 minutes warm-up, 30 minutes strength and balance training, and 10 minutes flexibility), twice a week.
62678030|NCT06465602|PLACEBO_COMPARATOR|Placebo group|Same physical evaluation and blood sampling as the experimental group. The subjects will receive 1.5 grams per day of placebo (talc, the medium in which nicotinamide is prepared), orally, for 30 days. The bottle and the capsules will be of the same physical characteristics (shape, color, and flavor) in both groups. During that period, patients will assess patient adherence and possible adverse effects.
62474681|NCT03017885||Group A|Patients who started treatment with nintedanib \& docetaxel after 23rd January, 2017 and have discontinued the drug at the time of participation in the active surveillance.
62678031|NCT03072342|ACTIVE_COMPARATOR|Intensive Periodontal Treatment (IPT)|
62678032|NCT03072342|PLACEBO_COMPARATOR|Control Periodontal Treatment (CPT)|
62678033|NCT06097481|EXPERIMENTAL|NICI-HF|This arm will receive the NICI-HF intervention with regular emails from a therapist for 3 months.
61919250|NCT02803515|EXPERIMENTAL|Patient with HIPEC|
61919251|NCT02803515|SHAM_COMPARATOR|Patient without HIPEC|
61919252|NCT01206387|EXPERIMENTAL|active product|Desoximetasone Spray 0.25%
61919253|NCT01206387|PLACEBO_COMPARATOR|placebo comparator|vehicle
62474682|NCT03017885||Group B|Patients who started treatment with nintedanib \& docetaxel after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance .
62474683|NCT03017885||Group C|Patients who have been newly prescribed nintedanib \& docetaxel at the time of participation in the active surveillance.
61919254|NCT00812695|NO_INTERVENTION|1|
61919255|NCT00812695|ACTIVE_COMPARATOR|2|CPAP
61919256|NCT03143491|EXPERIMENTAL|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
61919257|NCT03143491|EXPERIMENTAL|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
61919258|NCT03143491|EXPERIMENTAL|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
62474684|NCT00716690|EXPERIMENTAL|treatment|
61919259|NCT02370576||control|Healthy women after elective cesarean section.Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
62307107|NCT01522495|EXPERIMENTAL|Validation Against Angiogram|"Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention.~(30 participants)"
62678034|NCT06097481|PLACEBO_COMPARATOR|Sham control|This arm will receive regular emails with information about heart failure for 3 months.
61919260|NCT02370576||emergency|Healthy women after emergency cesarean section. Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
61919261|NCT02912143||newly diagnosed children with hemophilia|no intervention
61919262|NCT03954327|EXPERIMENTAL|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir|one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
62307108|NCT01522495|EXPERIMENTAL|Establishing Normal Values|To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
62678035|NCT05828823|EXPERIMENTAL|Clinically-matched Incremental Hemodialysis ( CMIHD)|Randomized group to have hemodialysis prescription tailored based on residual kidney function and clinical manifestations starting at twice weekly.
61919263|NCT03954327|PLACEBO_COMPARATOR|Placebo|Identical tablets resembling one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
61919264|NCT00002779|EXPERIMENTAL|fludarabine + octreotide|Patients receive fludarabine IV over 10-30 minutes on days 1-5. Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. Treatment repeats every 28 days for 4-6 courses. Patients then receive octreotide alone for 6-8 courses. Some patients may then receive another 12 courses of octreotide alone, for a total of 2 years of treatment. Patients are followed every 3 months for 5 years or until disease progression.
61919265|NCT03501771|EXPERIMENTAL|Acupuncture|Acupuncture needle will be administered.
62307109|NCT02082184|EXPERIMENTAL|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
62678036|NCT05828823|ACTIVE_COMPARATOR|Conventional Hemodialysis (CHD)|Randomized group to conventional three times a week hemodialysis.
61919266|NCT00805233|EXPERIMENTAL|1|Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
61919267|NCT00805233|ACTIVE_COMPARATOR|2|ranibizumab injection alone.
61919268|NCT04335201|EXPERIMENTAL|Arm Label|with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
61919269|NCT01850433|EXPERIMENTAL|Internet CBT|
61919270|NCT04044027|NO_INTERVENTION|Control Group|
61919271|NCT04044027|EXPERIMENTAL|Intervention Group|
62678037|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
61919272|NCT06343714|EXPERIMENTAL|SAD Cohort 1|Participants in this cohort will receive SAD dose 1 of FB1003 or Placebo.
61919273|NCT06343714|EXPERIMENTAL|SAD Cohort 2|Participants in this cohort will receive SAD dose 2 of FB1003 or Placebo.
61919274|NCT06343714|EXPERIMENTAL|SAD Cohort 3|Participants in this cohort will receive SAD dose 3 of FB1003 or Placebo.
61919275|NCT06343714|EXPERIMENTAL|SAD Cohort 4|Participants in this cohort will receive SAD dose 4 of FB1003 or Placebo.
61919276|NCT06343714|EXPERIMENTAL|SAD Cohort 5|Participants in this cohort will receive SAD dose 5 of FB1003 or Placebo.
61919277|NCT06343714|EXPERIMENTAL|MAD Cohort1|Participants in this cohort will receive MAD dose 1 of FB1003 or Placebo.
61919278|NCT06343714|EXPERIMENTAL|MAD Cohort 2|Participants in this cohort will receive MAD dose 2 of FB1003 or Placebo.
61919279|NCT06343714|EXPERIMENTAL|MAD Cohort 3|Participants in this cohort will receive MAD dose 3 of FB1003 or Placebo.
61919280|NCT00958490|ACTIVE_COMPARATOR|First walking group|Group walking at 2 months postop
61919281|NCT00958490|ACTIVE_COMPARATOR|Second group walking|Group walking at 3 months postop
61919282|NCT00396448|EXPERIMENTAL|CP-945,598 Treatment B|
61919283|NCT00396448|EXPERIMENTAL|CP-945,598 Treatment A|
61919284|NCT00396448|PLACEBO_COMPARATOR|Placebo|
61919285|NCT01514370|EXPERIMENTAL|IFN beta 1a 44 mcg TIW + curcumin (BCM95)|
61919286|NCT01514370|PLACEBO_COMPARATOR|IFN beta 1a 44 mcg TIW + placebo|
61919287|NCT04330820|EXPERIMENTAL|Venetoclax+Cytarabin+ Mitoxantron|The treatment plan combines a fixed dose of venetoclax and mitoxantrone with increasing doses of cytarabine (V-MAC).
61919288|NCT04512339|ACTIVE_COMPARATOR|Dupilumab|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive dupilumab injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
61919289|NCT04512339|PLACEBO_COMPARATOR|Placebo|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive placebo injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
61919290|NCT00713570||A,1,II|
61919291|NCT00761150|EXPERIMENTAL|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
62119144|NCT00486759|ACTIVE_COMPARATOR|Placebo + rituximab + CHOP|Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).
62119145|NCT03885817|EXPERIMENTAL|Exercise training and nutritional guide|Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.
62307110|NCT02082184|ACTIVE_COMPARATOR|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
62474685|NCT03313323|EXPERIMENTAL|Zirconium-ipilimumab|Zirconium-ipilimumab is an experimental tracer and is administered at start of ipilimumab treatment and after second infusion 3 weeks later
62474686|NCT06238791||Chronic venous disease group|
62678038|NCT05855551|EXPERIMENTAL|Arm 1 - base cash + BCC|pregnant women in this arm will receive the standard package (800 BDT each month), and in addition intensive group-based BCC on nutrition with a focus on how to improve their dietary intake during pregnancy
62678039|NCT05855551|EXPERIMENTAL|Arm 2 - base cash + BCC + food|pregnant women in this arm will receive the standard package (i.e., arm 1) and in addition a monthly food basket. The monthly food basket will provide 10 kg micronutrient fortified rice, 3.5 kg of lentils, and 1000 ml of oil, valued at 1000 BDT.
62678040|NCT05855551|EXPERIMENTAL|Arm 3 - base cash + BCC + top-up cash|"pregnant women in this arm will receive the standard package (i.e., arm 1) and in addition a monthly top-up cash of 1000 BDT to be added to the base amount that is part of the standard program."
61919292|NCT00761150|EXPERIMENTAL|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
61919293|NCT00761150|PLACEBO_COMPARATOR|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
61919294|NCT05240586|EXPERIMENTAL|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
61919295|NCT05240586|ACTIVE_COMPARATOR|acupuncture therapy|The physicians will choose the type and number of acupuncture therapy according to participants' conditions.
61919296|NCT05240586|ACTIVE_COMPARATOR|physical therapy, medication(prn)|The physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
61919297|NCT04099771|EXPERIMENTAL|Ketamine|A total of 20 patients identified as having suicidal ideation will receive ketamine at 0.5mg/kg infused intravenously over 40 minutes.
61919298|NCT03318718|EXPERIMENTAL|TOF measurement|TOF and MEP measurement after Anesthesia with non-depolarizing NMBA Rocuronium
62678041|NCT03024671|EXPERIMENTAL|patch test|Patients with patch test of cosmetics
62736346|NCT00635349|ACTIVE_COMPARATOR|Non-steroidal Anti-inflammatory Drug (NSAIDs)|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.
61919299|NCT00804037|ACTIVE_COMPARATOR|Ethanol|
61919300|NCT00804037|ACTIVE_COMPARATOR|Ethanolamine Oleate|
61919301|NCT02593045|EXPERIMENTAL|IPH4102|
61919302|NCT05945680|PLACEBO_COMPARATOR|Placebo|Normal saline for intravenous administration.
61919303|NCT05945680|ACTIVE_COMPARATOR|Tranexamic acid|Tranexamic Acid for intravenous administration.
61919304|NCT03125291|NO_INTERVENTION|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
62119146|NCT03885817|ACTIVE_COMPARATOR|Standard follow-up care|Standard recommendations regarding physical activity and nutrition.
62119147|NCT02118077|EXPERIMENTAL|G17DT|250 µg administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 µg every 6 months at investigator's discretion.
62119148|NCT02118077|PLACEBO_COMPARATOR|Placebo|Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months.
62474687|NCT06238791||Chronic venous disease and lipedema group|
62474688|NCT04306133|EXPERIMENTAL|PENG BLOCK AND WOUND INFILTRATION|Participants receiving PENG block combined to wound infiltration
62474689|NCT04306133|ACTIVE_COMPARATOR|WOUND INFILTRATION|Participants receiving wound infiltration alone
62678042|NCT06169423|OTHER|Educative intervention|"A first theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. This session would be the prebriefing. After this session, the complete simulation, with subsequent evaluation of it giving feedback to the students (debriefing). After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation."
62678043|NCT05638139|EXPERIMENTAL|SygeLIX-F + SygeLIX-G|Combination of SygeLIX-F, a plug made of an assembly of umbilical cord lining and Wharton's jelly in the form of a cylinder of porous structure, and SygeLIX-G, a Wharton's jelly gel reconstituted in a syringe.
61919305|NCT03125291|EXPERIMENTAL|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
62678044|NCT06567873||Cannabis Users|The cannabis user group will be comprised of patients who report preoperative cannabis use. This group will receive the ultrasound exam to assess stomach contents.
62678045|NCT06450340|EXPERIMENTAL|Tai Chi exercise group|Sessions lasted 60 minutes each and took place three times a week for 12 weeks for Tai Chi exercise group.
61919306|NCT02914145|OTHER|Participants|Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign
62119149|NCT06426602|EXPERIMENTAL|mindBEAGLE trial participants|"Patients identified as disorders of consciousness admitted to UPMC Rehabilitation Institute will be considered for the trial. As patients will not be able to communicate, health care proxy will provide consent. Participants will undergo 3 trials across 5 days within a 10-day period (2-3 hours each ) to assess if they are responding to the device."
62678046|NCT06450340|OTHER|Jogging group|Sessions lasted 60 minutes each and took place three times a week for 12 weeks for Jogging group.
62678047|NCT04189757|EXPERIMENTAL|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
61919307|NCT00879879|EXPERIMENTAL|Losartan|50 mg tablets of losartan taken daily by mouth for 1 year
62119150|NCT05667454|ACTIVE_COMPARATOR|Low dose atropine|Atropine 0.05% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
62119151|NCT05667454|ACTIVE_COMPARATOR|High dose atropine|Atropine 0.5% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
62119152|NCT03473522|EXPERIMENTAL|anodal tDCS +Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs. Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
62119153|NCT03473522|SHAM_COMPARATOR|Sham tDCS+ Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
62119154|NCT06677372|EXPERIMENTAL|Healthy subjects|
62119155|NCT02994017|OTHER|cystic fibrosis patients|
62119156|NCT04290117|EXPERIMENTAL|ACT-Chrono|First Acceptance and Commitment (ACT) training, followed by chronobiological training
62119157|NCT04290117|EXPERIMENTAL|Chrono-ACT|First chronobiological training, followed by ACT training
62119158|NCT04290117|OTHER|Chrono|First no training, followed by chronobiological training
62119159|NCT04290117|OTHER|ACT|First no training, followed by ACT training
62119160|NCT00617201|EXPERIMENTAL|1|Atomoxetine
62119161|NCT00617201|PLACEBO_COMPARATOR|2|Matched Placebo
62474690|NCT03247933|EXPERIMENTAL|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
62474691|NCT03247933|NO_INTERVENTION|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.~Clinical practice."
62474692|NCT03793972|EXPERIMENTAL|Triage with referral to primary care|Triage and referral according to eMTS.
62474693|NCT03793972|ACTIVE_COMPARATOR|Triage without referral to primary care|Weekends with usual care
62119162|NCT01663519|EXPERIMENTAL|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
62307111|NCT04706598|EXPERIMENTAL|Intravesical therapy group|"Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg. The recommended phase II dose(RP2D) to be decided after safety run-in.~The cycle is divided into an induction course and a maintenance course. The induction course is initiated 2 weeks after TURBT and repeat once a week for 6 weeks . After that, the maintenance course starts every 3 weeks. The maximum duration of dosing is 2 years."
62307112|NCT05153005||Talaromycosis|Participants: AIDS patients complicated with Talaromycosis. Intervention(s): To use the specific antigen of taloromyces marneffei which is mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and qPCR, dd-PCR and mass spectrometry identification in the diagnosis and efficacy evaluation of AIDS patients complicated with Talaromycosis.
62307113|NCT05153005||Pneumocystis pneumonia|Participants: AIDS patients complicated with Pneumocystis pneumonia Intervention(s)：To use (1,3)- β- D-glucan (G antigen) , qPCR, dd-PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies.
62474694|NCT00096447|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62678048|NCT06230055|EXPERIMENTAL|intrathecal chemotherapy through Ommaya reservoir in combination with systematic chemotherapy|Intrathecal chemotherapy through Ommaya reservoir: MTX, 10-12mg, q3w. Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), or iribrin(1.4mg/m2, d1,8, q3w, iv).
62119163|NCT01663519|EXPERIMENTAL|Custom made insoles 35 shore|Custom made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate
62119164|NCT01663519|EXPERIMENTAL|55 shore Custom made insoles|Custom made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate
62307114|NCT05153005||Cryptococcus|Participants: AIDS patients complicated with Cryptococcus Intervention(s)：To use (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen(CrAg) serological detection, qPCR, DD PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies of disease.
62474695|NCT03253003|EXPERIMENTAL|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
62474696|NCT04549272||Patients with Patent Foramen Ovale|
62474697|NCT04311320|EXPERIMENTAL|Low-Resource Oxygen Blender|This is a single-arm study. All participants will receive respiratory support using the investigational device.
62678049|NCT06230055|ACTIVE_COMPARATOR|systematic chemotherapy|Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), or iribrin(1.4mg/m2, d1,8, q3w, iv).
61919308|NCT01919840|ACTIVE_COMPARATOR|Group C|• conventional protocol, volume replacement with massive bleeding.
62119165|NCT05598151|EXPERIMENTAL|HM97662|Tablet, oral administration, once daily (QD), continuous dosing
62119166|NCT03760835|EXPERIMENTAL|Dual-release hydrocortisone|
62119167|NCT03760835|ACTIVE_COMPARATOR|Conventional glucocorticoids|
62119168|NCT01036412|EXPERIMENTAL|Chlorhexidine Gel Therapy|Following 2 x 5-minute applications of 2.5 ml in clinic, 2 x 5.0 ml syringes of 1% chlorhexidine gluconate gel, self-administered for a 5-minute application Week 2 \& Week 4
62119169|NCT03085316|EXPERIMENTAL|Investigational Device|Patient who meets eligibility to be implanted with the St. Jude Medical Infinity™ Implantable Pulse Generator System (P140049), St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) Directional Lead and Extension (P140009), Swift-Lock™ Anchor (K092371), Butterfly anchor (P140009), manufactured by St. Jude Medical, Inc.
62678050|NCT03104517|EXPERIMENTAL|AMDC-USR (iltamiocel)|Autologous muscle-derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) is the study product.
62678051|NCT03104517|PLACEBO_COMPARATOR|Placebo|Placebo control is the vehicle solution used for the study product.
62678052|NCT04220190|EXPERIMENTAL|Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T cells|80 x 10\^6 cells per infusion (no host conditioning)
62678053|NCT04220190|EXPERIMENTAL|Phase 1/2 Only, Single-agent RAPA-501 T cells (dose level Arm 1)|Dose level 1 is 20 x 10\^6 cells/infusion
62678054|NCT04220190|EXPERIMENTAL|: Phase 1/2 Only, Single-agent RAPA-501 T cells (dose level Arm 2)|Dose level 2 is 80 x 10\^6 cells/infusion
62119170|NCT00903227|EXPERIMENTAL|Low Dose|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
62119171|NCT00903227|EXPERIMENTAL|Combined|One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).
62119172|NCT00903227|EXPERIMENTAL|High dose|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
62119173|NCT05499559||Joint Academy|The participants receive the digital treatment of Joint Academy.
62119174|NCT04424641|EXPERIMENTAL|GEN1044|
62119175|NCT04141943|EXPERIMENTAL|VR|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality
62119176|NCT04141943|NO_INTERVENTION|Printed document|The patients who are allocated to the Printed document arm will receive information about radiotherapy via printed document.
62307115|NCT05982977|EXPERIMENTAL|Acupuncture rehabilitation group|Acupuncture rehabilitation intervention was given on the basis of conventional rehabilitation therapy.Disinfected with 75% alcohol and applied the needles at a depth of 25-35mm. Acupuncture stimulation of Lianquan (CV23) and Fengchi (GB20). The needles were retained for 30 minutes/time, once a day, and 5 days/week for a total of 4 weeks.
62307116|NCT05982977|ACTIVE_COMPARATOR|Conventional rehabilitation group|This group participants would take swallowing training 30 minutes/time, once a day, 5 days/week, a total of 4 weeks of intervention. At the same time, stroke basic treatment, nutritional support and other symptomatic treatment
62119177|NCT04215406||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
62119178|NCT02044588||HBsAg negative kidney allograft donor|
62307117|NCT03730896|NO_INTERVENTION|standard care group|Normal manual therapy interventions Clinician will decide normal course of treatment
62307118|NCT03730896|EXPERIMENTAL|Dry needling|Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment
62307119|NCT04079777||Clinical diagnosis of severe acute pancreatitis|"1, with typical clinical manifestations, such as abdominal pain or nausea and vomiting, accompanied by epigastric tenderness or peritoneal irritation.~2. Pancreatin content in serum, urine or abdominal cavity puncture fluid increases.~3. Image examination (ultrasound, CT) showed pancreatic inflammation or pancreatic inflammation seen by surgery or confirmed by autopsy pathology.~4, can except other similar clinical manifestations of lesions."
62307120|NCT04079777||mtDNA|"Mitochondrial DNA is the genetic material in mitochondria. Mitochondria can produce energy (ATP) for cells, which is a special form of ribonucleic acid found in mitochondria of cells. Mitochondria are organelles that provide energy (ATP) to cells. There are usually many DNA molecules in a mitochondria.~They carry their own DNA--mtDNA, and mutations in these genes can cause mitochondrial diseases. Although the symptoms of the disease are changeable, organs that consume more energy, such as brain, muscle and heart, are usually affected. Since mitochondria are transmitted through egg cells, related diseases will be inherited from the mother."
62307121|NCT02693964||Postmenopausal women with T1D|Postmenopausal between 45-70 years of age and having T1D for at least 10 years
62307122|NCT02693964||Postmenopausal women without diabetes|Postmenopausal between 45-70 years of age without diabetes
62307123|NCT04964726|EXPERIMENTAL|Real-time fMRI dyadic neurofeedback|
62307124|NCT01843322|EXPERIMENTAL|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
62307125|NCT00208468|OTHER|European Hip|A cementless femoral component for use in total hip replacement
62307126|NCT00208468|ACTIVE_COMPARATOR|Zweymüller|A cementless femoral component for use in total hip replacement
62307127|NCT00208468|ACTIVE_COMPARATOR|CLS Spotorno|A cementless femoral component for use in total hip replacement
62678055|NCT04220190|EXPERIMENTAL|Phase 1/2 Only, RAPA-501 + PC Regimen (Arm 3A)|RAPA-501 T cell therapy preceded by the 3-day pentostatin-cyclophosphamide (PC) regimen
62678056|NCT03355261|EXPERIMENTAL|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
62119179|NCT02044588||HBsAg positive kidney allograft donor|HBsAg positive kidney allograft donor
62119180|NCT02165761|ACTIVE_COMPARATOR|GORE® Hybrid Vascular Graft|GORE® Hybrid Vascular Graft
62119181|NCT02165761|OTHER|Non-heparin bonded synthetic graft|Non-heparin bonded synthetic graft
62119182|NCT06677502|EXPERIMENTAL|Cerebrolysin arm.|Patients in group CER received Cerebrolysin infusion at the dose of 50 mL solved in 0.9% NaCl for seven consecutive days, after delirium diagnose.
62119183|NCT06677502|PLACEBO_COMPARATOR|Control arm.|Patients in group K (control) received 0.9% NaCl for seven consecutive days.
62119184|NCT00716144|ACTIVE_COMPARATOR|A|Talarozole 0.5 mg
62119185|NCT00716144|ACTIVE_COMPARATOR|B|Talarozole 1.0 mg
62119186|NCT00716144|ACTIVE_COMPARATOR|C|Talarozole 2.0 mg
62119187|NCT00716144|PLACEBO_COMPARATOR|D|Talarozole matching Placebo
62678057|NCT03355261|EXPERIMENTAL|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
62307128|NCT05343910|EXPERIMENTAL|Aromatherapy massage group|Experimental: aromatherapy massage group The oil mixture used in this study (1:, 1:, 1: 1, 20cc rosemary, 20cc mint, 20cc ginger, 20cc black pepper), 80% of the mixture obtained from the total 4% (3.2cc) carrier oil (100% almond oil=96.8cc) and then combined with abdominal massage. Before implementing the procedure in the experimental group (n=25), information about what an abdominal and aroma massage is, how long it will take, and how it will be applied was provided to the participants. The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
62307129|NCT05343910|NO_INTERVENTION|Control group|Individuals in the control group (n=24) did not receive any type of aroma massage application.
62678058|NCT03355261|EXPERIMENTAL|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
62678059|NCT03355261|EXPERIMENTAL|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
62474698|NCT03114891|EXPERIMENTAL|First Round: fMRI-guided Target/Video, Second Round: 6cm Target/Task|"First round: This site of stimulation will be created from participants' individualized resting connectivity data. We will identify a cortical target in the left prefrontal cortex (LPFC) that influences the subgenual anterior cingulate cortex (sgACC). Two daily sessions (\~10min apart) of intermittent theta-burst stimulation will be administered to this fMRI-guided target for 10 consecutive weekdays. Between the two iTBS sessions, participants will watch a relaxing nature video.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their 'standard' target (6cm anterior of their hand knob). Between the two iTBS sessions, participants will complete a working memory task."
62474699|NCT03114891|EXPERIMENTAL|First Round: 6cm Target/Video, Second Round: fMRI-guided Target/Task|"First round: This 'standard' target will be identified by measuring 6cm anterior of the hand knob. Two daily sessions (\~10min apart) of intermittent theta-burst stimulation will be administered to this to this target for 10 consecutive weekdays. Between the two iTBS sessions, participants will watch a relaxing nature video.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their fMRI-guided target (cortical target influencing sgACC). Between the two iTBS sessions, participants will complete a working memory task."
62678060|NCT03444688|ACTIVE_COMPARATOR|CT, Control Group|Conventional Gait Training
62474700|NCT03114891|EXPERIMENTAL|First Round: fMRI-guided Target/Task, Second Round: 6cm Target/Video|"First round: This site of stimulation will be created from participants' individualized resting connectivity data. We will identify a cortical target in the left prefrontal cortex (LPFC) that influences the subgenual anterior cingulate cortex (sgACC). Two daily sessions (\~10min apart) of intermittent theta-burst stimulation will be administered to this fMRI-guided target for 10 consecutive weekdays. Between the two iTBS sessions, participants will complete a working memory task.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their 'standard' target (6cm anterior of their hand knob). Between the two iTBS sessions, participants will watch a relaxing nature video."
62678061|NCT03444688|EXPERIMENTAL|WT, Experimental Group|Gait rehabilitation with walker
62678062|NCT06566365|EXPERIMENTAL|Group LB|Patients that undergoing subcostal TAP block identified as being in the luteal phase by inquiring about the date of their last menstrual period.
62678063|NCT06566365|EXPERIMENTAL|Group FB|Patients that undergoing subcostal TAP block identified as being in the follicular phase by inquiring about the date of their last menstrual period.
62678064|NCT06566365|NO_INTERVENTION|Group L|Patients identified as being in the luteal phase by inquiring about the date of their last menstrual period.
62678065|NCT06566365|NO_INTERVENTION|Group F|Patients identified as being in the follicular phase by inquiring about the date of their last menstrual period.
62678066|NCT03565588|EXPERIMENTAL|Education session with fixed incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs to the health facility with payments conditional on being circumcised.
62678067|NCT03565588|EXPERIMENTAL|Education session with lottery incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs but with conditional lottery financial incentives.
62678068|NCT03565588|NO_INTERVENTION|Control arm|No intervention will be administered to the control arm
62678069|NCT04593329|EXPERIMENTAL|TIRADENTES|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet Tiradentes association, oral;~1 capsule tramadol placebo, oral;~1 tablet dipyrone placebo, oral."
62678070|NCT04593329|ACTIVE_COMPARATOR|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet dipyrone, oral;~1 tablet Tiradentes association placebo, oral;~1 capsule tramadol placebo, oral."
61919309|NCT01919840|EXPERIMENTAL|Group ROTEM|• Protocol according to the different tests to be performed with thromboelastography
61919310|NCT01360775|EXPERIMENTAL|nutritional counseling|Supervision and monitoring of nutritional status of patients in the home care program, after making nutritional advice
61919311|NCT01360775|NO_INTERVENTION|Not nutritional counseling|
61919312|NCT03303703|NO_INTERVENTION|Control|Usual cardiac rehabilitation and social phone calls for attention control.
61919313|NCT03303703|EXPERIMENTAL|Intervention|RENEwS intervention is five 60-minute group educational sessions.
61919314|NCT04932070|EXPERIMENTAL|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
61919315|NCT05174364||Epidural Block|Epidural block for the control group will be done before induction of general anesthesia. Patients will be positioned in the sitting position, an 18-gauge Tuohy needle will be inserted into epidural space of Th 11-12 intervertebral space under aseptic condition. In the medial approach, the site of the insertion of the needle is between the spaces created by the vertebral spinous processes. Upon locating the desired spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle
62307130|NCT03887832|EXPERIMENTAL|SBSI intervention|Mothers is this arm will download the SMBI intervention app onto their smartphone. They will be shown a video from the app and how to share videos with others. After hospital discharge, mothers will receive a weekly media package (video, associated prompt(s), and activity) via the SMBI for six months.
62678071|NCT04593329|ACTIVE_COMPARATOR|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 capsule tramadol, oral;~1 tablet dipyrone placebo, oral;~1 tablet Tiradentes association placebo, oral."
61919316|NCT05174364||Quadratus Lumborum Block|Bilateral QL block type 3 (anterior) for the intervention group will be performed on both sides of the patient after induction of general anesthesia. Patient will be positioned in semi-lateral decubitus and using low-frequency ultrasonography (USG) guidance attached to inferior lumbar region (Petit's triangle) that is consisted of inferior iliac crest and bordered by two muscles such as latissimus dorsi muscle in the posterior, abdominal external oblique muscle in the anterior. The USG will display the Shamrock sign, where the transverse process of vertebrae L4 role as the trunk, erector spinae muscle on the posterior side, psoas major (PM) on the anterior side, and QL muscle on the lateral side. After the visualization of QL and PM muscles, the Contiplex R needle will be directed parallel to the posterior side of the ultrasound probe until the tip of needle is confirmed in the border of QL and PM muscle
61919317|NCT00579085|PLACEBO_COMPARATOR|1|
61920002|NCT02687659|EXPERIMENTAL|Study group using TEMIS system|using TEMIS system during physical exercises: walking, biking, running
62307131|NCT03887832|ACTIVE_COMPARATOR|Infant standard of care|Mothers in this arm will receive the standard of care for newborn and infants including education and a list of resources.
61920003|NCT04988633|EXPERIMENTAL|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App.
62307132|NCT05337449|ACTIVE_COMPARATOR|silver diamine fluoride|
61920004|NCT04988633|EXPERIMENTAL|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice.
62307133|NCT05337449|ACTIVE_COMPARATOR|conventional composite resin restoration|
62678072|NCT06618534|EXPERIMENTAL|Azithromycin|Persons with microbiologic documentation of N. meningitidis carriage will receive a single, standard dose of azithromycin.
61919318|NCT00579085|EXPERIMENTAL|2|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline with or without ketamine for four hours (25 ml/hr) daily for 10 days. The maximum intravenous ketamine infusion dose for this study will be 0.35 mg/kg/hr, not to exceed 25 mg/hr (100 mg of ketamine over a 4 hour period). On the first day, the intravenous ketamine infusion will be set to 50% of the maximum rate. On the second day, the intravenous ketamine infusion will be increased to 75% of the maximum rate. On the third day, the intravenous ketamine infusion will be increased to the maximum rate. The daily ketamine infusion rate is maintained at this level for the duration of the ten day study."
61919319|NCT00756925||1|Cocaine dependent females
61919320|NCT00756925||2|Cocaine dependent males
61919321|NCT00550056|EXPERIMENTAL|1|NET
61919322|NCT00550056|EXPERIMENTAL|2|TC
62307134|NCT01614457|EXPERIMENTAL|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
62307135|NCT01614457|PLACEBO_COMPARATOR|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
61919323|NCT00550056|NO_INTERVENTION|3|Monitoring Group
62307136|NCT01282814|EXPERIMENTAL|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules.
61919324|NCT04610697|EXPERIMENTAL|Cognitive Remediation|"Participants in the cognitive remediation condition will complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
61919325|NCT04610697|ACTIVE_COMPARATOR|Active control|"Participants in the active control condition will also complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
62307137|NCT01282814|ACTIVE_COMPARATOR|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
62307138|NCT02285010|PLACEBO_COMPARATOR|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
61919326|NCT03007069|EXPERIMENTAL|Autogenous bone graft (Gold Standard).|Patients with defective maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and collagen membrane to be used for bone augmentation around exposed threads of inserted dental implants.
61919327|NCT03007069|ACTIVE_COMPARATOR|MPM Augmentation.|Mineralized plasmatic matrix (MPM) to be used without collagen membrane to augment the defect in the maxillary bone and cover the exposed threads of the dental implants.
62307139|NCT02285010|ACTIVE_COMPARATOR|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
62307140|NCT06345781|EXPERIMENTAL|Abdominal Functional Electrical Stimulation|All participants enrolled will receive the intervention.
61919328|NCT01410071||sphincter of oddi dysfunction|endoscopic therapy vs conservative care
61919329|NCT00384111|EXPERIMENTAL|1|Participants will receive standard R-CVP followed by Zevalin Therapeutic Regimen (Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin).
61919330|NCT00384111|ACTIVE_COMPARATOR|2|Participants will receive standard R-CVP.
61919331|NCT02430506|PLACEBO_COMPARATOR|Placebo|1.0 mL sterile buffer administered by intramuscular (IM) injection to deltoid area on days 0 and 56.
61919332|NCT02430506|EXPERIMENTAL|AERAS-402|1.0 mL containing 3 x 10\^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non-animal source) and water. Administered intramuscular (IM) injection to deltoid area on days 0 and 56.
62307141|NCT00722605|EXPERIMENTAL|1|cone-beam CT based
62307142|NCT05054946|ACTIVE_COMPARATOR|Endometrioma|Participants who will have endometrioma after histopathological evaluation.
61919333|NCT04944862|EXPERIMENTAL|CDX-0159 1.5mg/kg|CDX-0159 1.5mg/kg administered once
62307143|NCT05054946|ACTIVE_COMPARATOR|Mature cystic teratoma (dermoid cyst)|Participants who will have mature cystic teratoma (dermoid cyst) after histopathological evaluation.
62307144|NCT05054946|ACTIVE_COMPARATOR|Serous or mucinous cystadenoma|Participants who will have serous or mucinous cystadenoma after histopathological evaluation.
62307145|NCT06417684|ACTIVE_COMPARATOR|Amitriptyline|amitriptyline, tablet, 25 mg, once daily, 90 days
62307146|NCT06417684|ACTIVE_COMPARATOR|Lifestyle Modification|Written and video instructions to help improve restful sleep, mealtime regularity, avoidance of dietary triggers, and exercise for 90 days.
62307147|NCT05345522|EXPERIMENTAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg as the low dose group.
62307148|NCT05345522|EXPERIMENTAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg as the middle dose group.
62307149|NCT05345522|EXPERIMENTAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg as the high dose group.
62307150|NCT05292677|EXPERIMENTAL|Intervention (Steroid/Anesthetic Mixture)|The steroid/anesthetic mixture will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
62678073|NCT05919823|EXPERIMENTAL|KarXT|
62678074|NCT05919823|PLACEBO_COMPARATOR|Placebo|
61919334|NCT04944862|EXPERIMENTAL|CDX-0159 3mg/kg|CDX-0159 3.0 mg/kg administered once
61919335|NCT04944862|PLACEBO_COMPARATOR|Placebo|Normal saline administered once
61919336|NCT01163513||White population|
61919337|NCT01163513||Indian|
61919338|NCT01163513||Pakistani|
61919339|NCT01163513||Bangladeshi|
62678075|NCT05956392|EXPERIMENTAL|Screen-use reduction + Sleep extension|For the intervention group, participants are required to follow an agreed schedule where one hour of their daily screen-use time during school days will be repurposed for additional sleep during the two-week manipulation period.
61919340|NCT01163513||Other|other South Asian
61919341|NCT04240353||COPD group|Patients with high-risk COPD with recent exacerbation requiring hospitalisation (within last 12 months) or hypercapnia respiratory failure and/or sleep disordered breathing meeting criteria for provision of home NIV.
61919342|NCT06147973|EXPERIMENTAL|Acceptance-based Treatment (ABT)|ABT will consist of 18, 90-minute group sessions over 6 months.
61919343|NCT06147973|SHAM_COMPARATOR|Health Education (HE) Comparison|HE will include nine, 75-minute group health education sessions handouts over 6 months.
62678076|NCT05956392|NO_INTERVENTION|Free-living control|For the control group, participants will remain under free-living conditions (no restrictions on their screen-use time or sleep time) during the two weeks.
61919344|NCT01844479|ACTIVE_COMPARATOR|Standard innersole|"Per sequence cross over design. Order of testing innersoles was randomized and each testing condition lasted 15 minutes.~The industry standard diabetic innersole will be used as the active comparator"
62678077|NCT06566196|EXPERIMENTAL|Patients Undergoing Clinically indicated Cardiac Cath|
62678078|NCT02819544|ACTIVE_COMPARATOR|Ropivacaine|Ropivacaine 7.5 mg/mL administration
62678079|NCT02819544|PLACEBO_COMPARATOR|Sodium chloride|NaCl 0.9% administration
62119188|NCT06447675|EXPERIMENTAL|Hyperthermic Baths|Patients with CDKL5 deficiency assigned to hyperthermic baths will have their body immersed in a hot water (40\~42°C) bath for 20 min per session.
62119189|NCT00311363|EXPERIMENTAL|GEn (XP13512) 1200 mg|GEn (XP13512) 1200 mg
61919345|NCT01844479|EXPERIMENTAL|Diabetic Foot Orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
62307151|NCT05292677|PLACEBO_COMPARATOR|Placebo (Normal Saline)|The placebo (Normal Saline) will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
61919346|NCT04426578|EXPERIMENTAL|Perhexiline|
61919347|NCT04426578|PLACEBO_COMPARATOR|Placebo|
61919348|NCT01633580|PLACEBO_COMPARATOR|Day 2 group|Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
61919349|NCT01633580|ACTIVE_COMPARATOR|Day 4 group|Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
61919350|NCT01973530|ACTIVE_COMPARATOR|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
61919351|NCT01973530|OTHER|continuous femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
61919352|NCT06084598|EXPERIMENTAL|BMS-986446|
61919353|NCT06084598|EXPERIMENTAL|Placebo|
62119190|NCT00311363|PLACEBO_COMPARATOR|Placebo|Placebo
62119191|NCT03399370|EXPERIMENTAL|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
62119192|NCT03399370|PLACEBO_COMPARATOR|Saline Solution|Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.
62119193|NCT02806557||High risk group|"Defined as risk of severe neutropenia \>20% or risk of neutropenic infective complications \>10%, with severe neutropenia defined as absolute neutrophil count \<1.0 x10\^9/L.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
62119194|NCT02806557||Frequently given regimens|"Defined as high number of cases of neutropenia, but risk of severe neutropenia \<5%.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
62119195|NCT02806557||Prophylactic GCSF|"Patients on primary prophylactic granulocyte colony stimulating factor (GCSF).~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
62119196|NCT01175317|EXPERIMENTAL|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
62119197|NCT01175317|OTHER|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
62119198|NCT02602743|EXPERIMENTAL|remifentanyl, ketamine|Experimental:Remifentanyl and ketamine Remifentanyl vial 2 mg, Ketamine vial 500mg/10 mlt by intravenous. 2 mg/kg ketamine and 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
62119199|NCT02602743|ACTIVE_COMPARATOR|propofol, ketamine|"Active comparator:Propofol and ketamine Propofol injectable emulsion vial 200 mg/20 mlt, Ketamine vial 500mg/10 mlt by intravenous.~2 mg/kg ketamine and 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started."
62119200|NCT01331863|EXPERIMENTAL|single arm surgery|Airway and/or pulmonary Vessels Transplantation
62119201|NCT01980069|EXPERIMENTAL|Neostigmine arm|Neostigmine arm
62119202|NCT01980069|ACTIVE_COMPARATOR|Sugammadex arm|Sugammadex arm
62119203|NCT05857436|EXPERIMENTAL|apical periodontitis|60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
62119204|NCT05857436|EXPERIMENTAL|control|A total of 30 volunteers who were determined to be systemically and orally healthy (not having AP indication), were included in the study as the control group.
62119205|NCT01535144|EXPERIMENTAL|degradable metallic device|
62119206|NCT01535144|ACTIVE_COMPARATOR|non-degradable metallic device|
62119207|NCT06102525|EXPERIMENTAL|Part 1 Cohort 1|RZ-001 Dose 1 and VGCV
62119208|NCT06102525|EXPERIMENTAL|Part 1 Cohort 2|RZ-001 Dose 2 and VGCV
62119209|NCT06102525|EXPERIMENTAL|Part 1 Cohort 3|RZ-001 Dose 3 and VGCV
62119210|NCT06102525|EXPERIMENTAL|Part 1 Cohort 4|RZ-001 Dose 4 and VGCV
62119211|NCT06102525|EXPERIMENTAL|Part 1 Cohort 5|RZ-001 Dose 5 and VGCV
62119212|NCT06102525|EXPERIMENTAL|Part 2|RZ-001 Dose 6 and VGCV
62119213|NCT00375453|EXPERIMENTAL|Arm 1|
62119214|NCT05516927||Cancer Group|"* Collect Subject Data~* Collect Blood Specimen"
62119215|NCT05516927||Non-cancer Group|"* Collect Subject Data~* Collect Blood Specimen"
62307152|NCT05812508||pterygium surgery with bare scleral technique|corneal topograghy before and after surgery
62307153|NCT05812508||pterygium surgery with conjunctival autograft technique|corneal topograghy before and after surgery
62307154|NCT03689738|EXPERIMENTAL|Potato condition|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g RS per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
62307155|NCT03689738|ACTIVE_COMPARATOR|Control condition|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
61919354|NCT06523751|EXPERIMENTAL|Trabeculopuncture|Individuals undergo neodymium-doped yttrium aluminum garnet (Nd:YAG) trabeculopuncture prior to ab interno trabeculectomy.
61919355|NCT06004453||Cohort A|Supra-regional HFU Centers and HFU Focus Hospitals
61919356|NCT06004453||Cohort B|Non-HFU Hospitals
62307156|NCT00634673|OTHER|TT|patients homozygous for Thr54 (TT)
62307157|NCT00634673|OTHER|AA|patients homozygous for Ala54 (AA)
62307158|NCT01532661||observational study|haemorrhagic trauma received rFVIIa
61919357|NCT06004453||Cohort C|HFU Residential Cardiologists
61919358|NCT06004453||Cohort D|Non-HFU Residential Cardiologists
61919359|NCT06004453||Cohort E|General practitioners
61919360|NCT04257097|ACTIVE_COMPARATOR|Group A - control group|25 patients will undergo bone regeneration with a titanium reinforced PTFE Mesh (RPM - Osteogenics Lubbock Texas USA), manually shaped and modeled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption (Vitala - Osteogenics Lubbock Texas USA)
61919361|NCT04257097|EXPERIMENTAL|Group B - Test group|25 patients undergo bone regeneration with a custom-made titanium mesh (Yxoss CBR - Reoss Filderstadt Germany), digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption (Bio-Gide - Geistlich Baden Baden Germany)
62307159|NCT01708564|EXPERIMENTAL|Cohort 1|10 patients administered a single low dose of rhFVIIa
62307160|NCT01708564|EXPERIMENTAL|Cohort 2|10 patients administered a single intermediate dose of rhFVIIa
62307161|NCT01708564|EXPERIMENTAL|Cohort 3|10 patients administered a single high dose of rhFVIIa
62307162|NCT04817540|EXPERIMENTAL|Single arm, Herzuma arm|
62307163|NCT03169283|EXPERIMENTAL|Cereal 1|A cereal high in viscous dietary fiber B glucan
61919362|NCT03380936|ACTIVE_COMPARATOR|Arm 1 - conversion to Envarsus XR|Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet \[Envarsus\]) with goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
61919363|NCT03380936|ACTIVE_COMPARATOR|Arm 2 - plasma exchange and IVIG|Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
62307164|NCT03169283|ACTIVE_COMPARATOR|Cereal 2|A cereal without B glucan
61919364|NCT01289782|EXPERIMENTAL|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
61919365|NCT01289782|PLACEBO_COMPARATOR|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
62307165|NCT02362438|EXPERIMENTAL|10X|Highest dose in the escalation scheme
62307166|NCT02362438|EXPERIMENTAL|1X|Lowest dose in the escalation scheme
62307167|NCT02362438|EXPERIMENTAL|3.3X|2nd dose increase in escalation scheme
62307168|NCT02362438|EXPERIMENTAL|5X|3rd dose increase in escalation scheme
62307169|NCT02907944|NO_INTERVENTION|Usual Care- Control|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
62474701|NCT03114891|EXPERIMENTAL|First Round: 6cm Target/Task, Second Round: fMRI-guided Target/Task|"First round: This 'standard' target will be identified by measuring 6cm anterior of the hand knob. Two daily sessions (\~10min apart) of intermittent theta-burst stimulation will be administered to this to this target for 10 consecutive weekdays. Between the two iTBS sessions, participants will complete a working memory task.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their fMRI-guided target (cortical target influencing sgACC). Between the two iTBS sessions, participants will watch a relaxing nature video."
62474702|NCT05405881|OTHER|Children with upper motor neuron lesions|With the Proprioception Measurement Tool (PROMT) following modalities are assessed: joint movement sense, joint position sense, and active position sense. The child has to wear on each leg two Shimmer Sensors on the lower limb and the foot. The child sits on a table or bench, and the feet are free-hanging. A table is positioned in front of the child to place the smartphone or convertible notebook at a distance where the child can press the digital button. The table with an additional U-table platform prevents the child's view towards the legs. The duration of these three tests is 20 minutes. The comparator assessments on each level of the ICF-CY are conducted, and a feasibility questionnaire (detailed described under chapter outcome measures)
62678080|NCT03639051|EXPERIMENTAL|Active Treatment|Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
62307170|NCT02907944|EXPERIMENTAL|Implementation Facilitation|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..
62307171|NCT03550950|EXPERIMENTAL|Single Ascending Dose (SAD) IV Cohort|Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
62307172|NCT03550950|EXPERIMENTAL|Subcutaneous (SC) Cohort|Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
61919366|NCT04306185|EXPERIMENTAL|OVARIAN FRAGMENTATION|Ovarian fragmentation through laparoscopy in patients who meet criteria ( Poor ovarian responders and poor ovarian reserve).
62307173|NCT02373930|EXPERIMENTAL|Part 1 Cohort 1- Sequence 1|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication. All treatments will be administered in fed state.
61919367|NCT05523687|EXPERIMENTAL|Single, oral dose of [14C]-PC14586|Healthy, male participants will receive a single, oral dose of \[14C\]-PC14586
61919368|NCT01445886|EXPERIMENTAL|Indigo Naturalis Extract in Oil|A 5-ml eye drop bottles contain indigo naturalis powder mixed with olive oil, and the concentration was 200 ug indirubin per ml. Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
62307174|NCT02373930|EXPERIMENTAL|Part 1 Cohort 1- Sequence 2|Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication. All treatments will be administered in fed state.
62678081|NCT03639051|SHAM_COMPARATOR|Sham Control|Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.
61919369|NCT01445886|ACTIVE_COMPARATOR|Calcipotriol solution|Calcipotriol solution (Daivonex® scalp solution, calcipotriol 50 ug/ml) was purchased from LEO Pharmaceutical Products, Ltd. (Ballerupt, Denmark) and also distributed into 5-ml eye drop bottles for this trial.Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
62307175|NCT02373930|EXPERIMENTAL|Part 1 Cohort 1- Sequence 3|Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication. All treatments will be administered in fed state.
62307176|NCT02373930|EXPERIMENTAL|Part 1 Cohort 1- Sequence 4|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication. All treatments will be administered in fed state.
62307177|NCT02373930|EXPERIMENTAL|Part 1 Cohort 1- Sequence 5|Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication. All treatments will be administered in fed state.
62474703|NCT05405881|OTHER|Children without UMN lesions (developing typically)|With the Proprioception Measurement Tool (PROMT) following modalities are assessed: joint movement sense, joint position sense, and active position sense. The child has to wear on each leg two Shimmer Sensors on the lower limb and the foot. The child sits on a table or bench, and the feet are free-hanging. A table is positioned in front of the child to place the smartphone or convertible notebook at a distance where the child can press the digital button. The table with an additional U-table platform prevents the child's view towards the legs. The duration of these three tests is 20 minutes. A feasibility questionnaire (detailed described under chapter outcome measures)
62474704|NCT02259244|EXPERIMENTAL|Mediterranean diet+physical activity|Mediterranean diet based on 1573 kcal/day with the goal of consumption of 30 ml/day of olive oil, 56g/week of nuts, 3-4 servings/week of fish, 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat
62474705|NCT02259244|ACTIVE_COMPARATOR|Hypolipemic reduction diet+physical activity|Hypolipemic reduction diet based on 1287 kcal/day with the goal of consumption of 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat, non-fat or low-fat dairy products
61919370|NCT01827358|EXPERIMENTAL|Group 1|Subjects receive a 5-day course of mupirocin calcium ointment 2 % 20 mg intranasally applied every 8 hours and a topical skin application (umbilical and perianal area) of mupirocin calcium cream 2% 20 mg applied every 8 hours for a total of 15 doses
62307178|NCT02373930|EXPERIMENTAL|Part 1 Cohort 1- Sequence 6|Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication. All treatments will be administered in fed state.
61919371|NCT01827358|NO_INTERVENTION|Group 2|No treatment
62119216|NCT02571387|EXPERIMENTAL|Mindfulness|Computerized mindfulness-based intervention. 10 minutes per day, every day for 12 months of MP3 listening. Guidelines are in line with main mindfulness-based interventions (MBSR, MBCT, ACT). Participants can choose between 4 audio recordings (sessions): awareness of the breathing, awareness of postures and bodily sensations, acceptance of thoughts and emotions, and awareness of bodily sensations and related thoughts and emotions while executing 5 squats.
62119217|NCT02571387|SHAM_COMPARATOR|Sham meditation|"Computerized sham meditation intervention. 10 minutes per day, every day for 12 months of MP3 listening. The unique guideline is to meditate at the beginning of each session. Participants can choose between 4 audio backgrounds: forest, night, beach, and river."
62307179|NCT02373930|EXPERIMENTAL|Part 2 Cohort 2- Sequence 1|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
62119218|NCT02571387|NO_INTERVENTION|Treatment as usual|Usual care in a nutrition pole in France: nutrition, diet, exercise.
62307180|NCT02373930|EXPERIMENTAL|Part 2 Cohort 2- Sequence 2|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
61919372|NCT05806684||Prematures with jaundice and ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
62119219|NCT01897298|EXPERIMENTAL|Urban training Intervention|Patients will be advised to walk in the defined urban trails.
62119220|NCT01897298|NO_INTERVENTION|Usual care|Patients will continue their usual care
61919373|NCT05806684||Prematures with ROP without jaundice.|Infants who, despite presenting ROP, did not develop jaundice.
62119221|NCT05440981|EXPERIMENTAL|Temporarily implanted nitinol device (iTind) group|Subjects will undergo iTind for the treatment of male LUTS.
62119222|NCT05967819|NO_INTERVENTION|Control|Participants will be asked to maintain their usual physical activity and lifestyle habits.
62119223|NCT05967819|EXPERIMENTAL|Exercise Stress|The duration of participant's weekly running or cycling mileage will be increased by 30% while intensity is maintained.
62119224|NCT05967819|EXPERIMENTAL|Psychosocial Stress|Participants will be asked to complete cognitive function tasks designed to be stressful while maintaining their usual physical activity habits.
61919374|NCT06214494|EXPERIMENTAL|Interventional Cohort|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion 2x weekly for 16 Sessions totaling a minimum of 75 minutes weekly.
62307181|NCT02373930|EXPERIMENTAL|Part 2 Cohort 2- Sequence 3|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
62307182|NCT02373930|EXPERIMENTAL|Part 2 Cohort 3- Sequence 4|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
62307183|NCT02373930|EXPERIMENTAL|Part 2 Cohort 3- Sequence 5|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
62307184|NCT02373930|EXPERIMENTAL|Part 2 Cohort 3- Sequence 6|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
62307185|NCT02373930|EXPERIMENTAL|Part 2 Cohort 4- Sequence 7|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
62307186|NCT02373930|EXPERIMENTAL|Part 2 Cohort 4- Sequence 8|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
62307187|NCT02373930|EXPERIMENTAL|Part 2 Cohort 4- Sequence 9|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of \>=9 days between doses of study medication.
61919375|NCT06214494|ACTIVE_COMPARATOR|Control Cohort|High-Intensity Treadmill Training 2x weekly for 16 Sessions totaling a minimum of 75minutes weekly.
61919376|NCT05765227|OTHER|LID#224381, then AOHG MF|Lehfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second in pre-determined order. Each study lens type will be worn bilaterally (in both eyes) for approximately 2 days. CLEAR CARE will be used for nightly cleaning and disinfection.
62307188|NCT05337722|EXPERIMENTAL|App+fixed MI|The participants will use the SFT2.0 app and receive a fixed number of 4 counseling video sessions during pregnancy up to 1-month postpartum.
62474706|NCT01171963|EXPERIMENTAL|Rotarix Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Rotarix™ vaccine, liquid formulation, at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccines were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Rotarix™ vaccine. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Rotarix™ and OPV vaccines were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
61919377|NCT05765227|OTHER|AOHG MF, then LID#224381|Lotrafilcon B multifocal contact lenses worn first, with lehfilcon A multifocal contact lenses worn second in pre-determined order. Each study lens type will be worn bilaterally (in both eyes) for approximately 2 days. CLEAR CARE will be used for nightly cleaning and disinfection.
61919378|NCT06352385||Children aged 4 -6|This is a non intervention-observation only study.
61919379|NCT06352385||Children aged 9 -11|This is a non intervention-observation only study.
62119225|NCT05967819|EXPERIMENTAL|Exercise + Psychosocial Stress|Participants will be asked to complete cognitive function tasks designed to be stressful while the duration of their weekly running or cycling mileage is increased by 30% and intensity maintained.
62119226|NCT02667808||Focus Group|Participants with HIV and receiving antiretroviral therapy (ART) will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
62119227|NCT02667808||Questionnaire|Participants with HIV will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
61919380|NCT06352385||Students aged 13 -15|This is a non intervention-observation only study.
61919381|NCT06352385||Students aged 17-20|This is a non intervention-observation only study.
61919382|NCT05292144||Coronary Artery Disease (CAD)|
61919383|NCT02891005|EXPERIMENTAL|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
61919384|NCT02891005|EXPERIMENTAL|common balloon catheter|Patients treated with common balloon catheter
61919385|NCT05972603|EXPERIMENTAL|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left in wound for 3 minutes following final implantation.
61919386|NCT05972603|EXPERIMENTAL|1.0 g Vancomycin powder into the wound|additional 1.0 g Vancomycin powder into the wound
61919387|NCT04650854|EXPERIMENTAL|Rozanolixizumab dosage regimen 1|Study participants randomized/assigned to dosage regimen 1 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
62307189|NCT05337722|EXPERIMENTAL|Adaptive app + as-needed MI|The participants will use the SFT2.0 app and receive as-needed prenatal and postnatal video counseling sessions (between 1 and 10 sessions) during pregnancy up to 1-month postpartum.
62119228|NCT05499351|EXPERIMENTAL|Adult group in immunogenicity and safety study of combined immunization|300 participants will be randomly divided into 3 subgroups of 100 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
62307190|NCT05337722|ACTIVE_COMPARATOR|Control|Participants will receive low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session.
62307191|NCT00009867|EXPERIMENTAL|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
62307192|NCT03063255|ACTIVE_COMPARATOR|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
62307193|NCT03063255|ACTIVE_COMPARATOR|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
62736347|NCT00635349|EXPERIMENTAL|Tramadol Hydrochloride Plus Acetaminophen|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
62119229|NCT05499351|EXPERIMENTAL|Elderly group in immunogenicity and safety study of combined immunization|300 participants will be randomly divided into 3 subgroups of 100 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
62307194|NCT03542552|ACTIVE_COMPARATOR|Nifidipne|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
62119230|NCT05499351|EXPERIMENTAL|Adult group in safety observation study of combined immunization|1200 participants will be randomly divided into 2 subgroups of 600 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
62307195|NCT03542552|EXPERIMENTAL|Magnisum sulphate|Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
62307196|NCT05780840|EXPERIMENTAL|Dihydroxyacetone|
62474707|NCT01171963|PLACEBO_COMPARATOR|Placebo Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Placebo at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccine were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Placebo. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Placebo and the OPV vaccine were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
62474708|NCT03977129|EXPERIMENTAL|QFR group|
62307197|NCT05780840|PLACEBO_COMPARATOR|Placebo|
62307198|NCT05922683|EXPERIMENTAL|Vivomixx|Participant in the treatment arm will receive a daily dose of the probiotic Vivomixx for 8 weeks.
62307199|NCT05922683|PLACEBO_COMPARATOR|Placebo|Participant in the control arm will receive a daily dose of a placebo (microcrystalline maltose) for 8 weeks.
62307200|NCT01300143|ACTIVE_COMPARATOR|TACE|Patients will be treated by 2 or 3 cures of hyperselective TACE. The first one at week 0 and the second one at week 8. If required, a third cure of TACE could be done at week16.
62307201|NCT01300143|EXPERIMENTAL|TACE + RTC|Patients will be treated by one cure of TACE at week 0. Then, patients will be treated within two weeks by external conformational radiotherapy of 54 grey fractioned in 18 sessions during 3-4 weeks.
62307202|NCT04194931|EXPERIMENTAL|Mixed BCMA/CD19 CAR-T Transfer|Subjects with BCMA/CD19+ multiple myeloma will be infused with CD19-targeting CAR T Cells and BCMA-targeting CAR T Cells in one time or in parts
62307203|NCT04468672|ACTIVE_COMPARATOR|Day worker|Men and women who work only day shift for at least 3 consecutive days of the week
62307204|NCT04468672|ACTIVE_COMPARATOR|Night worker|Men and women who work only night shift for at least 3 consecutive days of the week
62307205|NCT06512974|EXPERIMENTAL|NeuroTrainer Intervention|The NeuroTrainer intervention involves using a VR-based cognitive training program designed to improve attention and executive function in students with ADHD. Participants will engage in 30-minute sessions, approximately three times a week for 12 weeks, performing game-like tasks that integrate physical activity and adapt to their performance level.
62307206|NCT06512974|NO_INTERVENTION|Control Condition|The control condition involves students receiving standard educational interventions without the use of NeuroTrainer. These activities include regular classroom instruction and typical academic tasks designed to support learning, without the additional cognitive training provided by the VR program.
62307207|NCT02669563|EXPERIMENTAL|Stage 1|"Subjects (n = 4 to 10) will be injected once with 20 mCi of \[13N\]ammonia and receive a 20 minute PET scan. They will then be injected once with 6.5 mCi of one of the two new drugs under study, \[18F\]4F-MHPG or \[18F\]3F-PHPG, and receive a 60 minute PET scan.~On a second visit to the clinic, subjects will be injected once with 6.5 mCi of \[18F\]3F-PHPG or \[18F\]4F-MHPG (whichever was not used for the first visit) and receive a 60 minute PET scan."
62307208|NCT02669563|EXPERIMENTAL|Stage 2|"Subjects (n = 20 to 26) will be injected with 20 mCi of \[13N\]ammonia and receive a 20 minute PET scan.~They will then be injected once with 6.5 mCi of \[18F\]4F-MHPG or \[18F\]3F-PHPG (whichever was chosen based on Stage 1 of the study) and receive a 60 minute PET scan. On a second visit to the clinic, subjects will be injected once with 20 mCi of \[11C\]HED and receive a 40 minute scan."
62307209|NCT01768299|EXPERIMENTAL|Mifepristone at home 24 hours before miso dosing starts|"All women will receive study packet one containing mifepristone to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
62474709|NCT03977129|ACTIVE_COMPARATOR|CAG group|
62474710|NCT04816253|PLACEBO_COMPARATOR|Normal saline|Normal saline irrigation after extraction and No drug placed in tooth socket
62474711|NCT04816253|ACTIVE_COMPARATOR|Gengigel|Gengigel (Hyaluronic acid) placed after extraction
62474712|NCT04816253|ACTIVE_COMPARATOR|Methylprednisolone|Methylprednisolone will be given intravenous to a patient half an hour before the surgery
62474713|NCT04816253|ACTIVE_COMPARATOR|Methylprednisolone and Gengigel|Methylprednisolone will be given intravenous to a patient half an hour before the surgery and Gengigel (Hyaluronic acid) placed after extraction
62474714|NCT04738539||Patients with or being evaluated for neurogenic bladder|Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics testing.
62474715|NCT06130436|SHAM_COMPARATOR|Sham-Remote Ischemic Conditioning|Sham remote ischemic conditioning (Sham-RIC) is applied in the perioperative using an automated Sham-RIC device.
62474716|NCT06130436|ACTIVE_COMPARATOR|Remote Ischemic Conditioning Once Daily|Remote ischemic conditioning (RIC) is applied in the perioperative using an automated RIC device once daily.
61919388|NCT04650854|EXPERIMENTAL|Rozanolixizumab dosage regimen 2|Study participants randomized/assigned to dosage regimen 2 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
61919389|NCT05649839|ACTIVE_COMPARATOR|conventional garment|
61919390|NCT05649839|EXPERIMENTAL|prototype garment|
61919391|NCT00236951|ACTIVE_COMPARATOR|Venofer + erythropoietin (responders)|
62474717|NCT06130436|ACTIVE_COMPARATOR|Remote Ischemic Conditioning Twice Daily|Remote ischemic conditioning (RIC) is applied in the perioperative using an automated RIC device twice daily.
62307210|NCT01768299|EXPERIMENTAL|Mifepristone and first dose of misoprostol simultaneously.|"Will receive study packet one containing placebo to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
62307211|NCT04259710|PLACEBO_COMPARATOR|Pedometer only|participants will be given a pedometer and instructed how to use it, but will not participate in the goal setting intervention.
62119231|NCT05499351|EXPERIMENTAL|Elderly group in safety observation study of combined immunization|1200 participants will be randomly divided into 2 subgroups of 600 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
62307212|NCT04259710|ACTIVE_COMPARATOR|Pedometer and intervention|participants will be given a pedometer and participate in a weekly goal setting meeting with the investigator and will receive weekly tips.
62474718|NCT02659358||Biosensor + Patient Reported Outcomes (PRO)|Participants will wear a biosensor (Fitbit Charge HR®) continuously for a period of 15 days and respond to PROMIS questionnaires. This is not a chemotherapy or treatment-intervention trial.
62474719|NCT02559063|EXPERIMENTAL|Vision-based speed of processing|Vision-based speed of processing training will use the INSIGHT online program (Posit Science), which includes five games (i.e., Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All games share visual components, and the tasks become increasingly more difficult and require faster reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
61919392|NCT00236951|ACTIVE_COMPARATOR|erythropoietin only (responders)|
61919393|NCT00236951|ACTIVE_COMPARATOR|Venofer+erythropoietin(non-responders)|
61919394|NCT00236951|ACTIVE_COMPARATOR|erythropoietin only (non-responders)|
61919395|NCT02832583|EXPERIMENTAL|Mesotherapy of PRP-HA into the cheeks|Three sessions of PRP-HA prepared with RegenKit BCT-HA Cellular Matrix into each cheek separated by 1 month interval.
61919396|NCT02652767|EXPERIMENTAL|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
62119232|NCT04297917|EXPERIMENTAL|Healthy Volunteers with low dose vaccination|5 Healthy Volunteers receiving low dose vaccination
61920005|NCT04676360|EXPERIMENTAL|(BELANTAMAB MAFODOTIN|"* Belantamab mafodotin will be administered intravenously on day 1 of a 21-day cycle.~* Treatment is intended to be administered on an outpatient basis."
62119233|NCT04297917|EXPERIMENTAL|Healthy Volunteers with high dose vaccination|5 Healthy Volunteers receiving high dose vaccination
61920006|NCT03004248|EXPERIMENTAL|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
62119234|NCT04297917|EXPERIMENTAL|Chronic Hepatitis B participants with low dose vaccination|6 participants with Chronic Hepatitis B infection receiving low dose vaccination
62119235|NCT04297917|EXPERIMENTAL|Chronic Hepatitis B participants with high dose vaccination|6 participants with Chronic Hepatitis B infection receiving high dose vaccination
62119236|NCT04297917|EXPERIMENTAL|Healthy Volunteers who have had COVID-19 AZD1222 vaccine|15 participants who have had 2 doses of COVID-19 AZD1222 vaccine
62307213|NCT04259710|EXPERIMENTAL|Pedometer, intervention and implementation intentions|participants will be given a pedometer and participate in the weekly goal setting as above. In addition, 3 times during the intervention they will fill out a form that encourages performance of implementation intentions.
62307214|NCT02426086|EXPERIMENTAL|Imetelstat 4.7 mg/kg|
62307215|NCT02426086|EXPERIMENTAL|Imetelstat 9.4 mg/kg|
62307216|NCT04507074|EXPERIMENTAL|Patients With Obesity|40 subjects aged 35-60 with simple obesity (BMI ≥ 30 kg / m2) and chronic low back pain.
62307217|NCT04507074|ACTIVE_COMPARATOR|Normal-Weight Patients|20 subjects aged 35-60 with normal body weight (BMI ≤ 24.9 and ≥ 18.5 kg/m2) suffering from chronic low back pain.
62307218|NCT01515072|NO_INTERVENTION|No Remote Ischemic Preconditioning|The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
62307219|NCT01515072|EXPERIMENTAL|Remote Ischemic Preconditioning|The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
62307220|NCT05165394|PLACEBO_COMPARATOR|Placebo|Participant follows Placebo schedule (57 days)
62307221|NCT05165394|EXPERIMENTAL|Antidepressant|Participant follows NBI-1065846 schedule (57 days)
62307222|NCT03156153|EXPERIMENTAL|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
62307223|NCT03156153|PLACEBO_COMPARATOR|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
62307224|NCT01765712|PLACEBO_COMPARATOR|Control Group|Patients will be randomized into the treatment arm using a computer generated randomization table (simple randomization). Patients in the control arm of the study will undergo Anterior cruciate ligament reconstruction using Autologous bone patellar tendon bone autograft. At the end of the surgery, their graft donor site will have bone graft chips placed into the bony defect and the wound will be closed using sutures.
61919397|NCT02652767|SHAM_COMPARATOR|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
62119237|NCT04297917|EXPERIMENTAL|Healthy Volunteers who have had Pfizer/Moderna mRNA COVID 19 vaccine|15 participants who have had Pfizer/Moderna mRNA COVID 19 vaccine
62119238|NCT01013012|ACTIVE_COMPARATOR|Group A|Group A : saline 1 ml + ramosetron 6μg/kg
62307225|NCT01765712|EXPERIMENTAL|Platelet Rich Plasma|Patients randomized into the treatment arm of the study will undergo Anterior cruciate ligament reconstruction with Autologous bone patellar tendon bone autografts. At the start of the surgery,just after the administration of anesthesia, 10cc of blood will be withdrawn from the patients IV by the anesthesiologist. This sample will be spun down into 3-5cc of Platelet Rich Plasma which will be added to the patients bone graft chips and placed into the donor site at the end of the case.
62307226|NCT06270992||Lung cancer group|"192 patients diagnosed with lung cancer with the following inclusion criteria:~* To be between the ages of 18 and 65,~* Not having been previously diagnosed with and treated for lung cancer,~* Not having received any cancer treatment in the last 2 years,~* Not having been operated on within the last two years,~* Not having a hospitalization history in the last year,~* Not having used antibiotics in the last six months,~* Not having used products manufactured to support the oral microbiome, such as probiotic (lozenges, sublingual drops) for at least the last six months,~* Not being pregnant, not breastfeeding,~* Not having undergone dental procedures such as root canal treatment, implants, prostheses, tooth extraction, fillings in the last 6 months, Not having dominant immune-origin lesions , viral-origin lesions, dominant bacterial infections like tonsillitis, and/or thermal or chemical mucosal traumas in the mouth."
62474720|NCT02559063|ACTIVE_COMPARATOR|Mental leisure activities|Mental leisure activities control activities were chosen to: 1) control for computer, online experience \[and amount of time\]; 2) not induce acute stress (i.e., without time management, speed component, or novel cognitive stimuli); 3) simulate participants' everyday mental activities; and 4) entertain participants to keep them from dropping out. Cross-word, Sudoku, and solitaire games will be used, which were also used in previous VSOP training study as control exercises. Participants can choose to practice any combination of games. At the end of their participation, the MLA control group will be provided with free 6-week access to the VSOP training program.
62474721|NCT01683474|EXPERIMENTAL|Venus A-Valve|single arm with intervention that percutaneous implantation of the Venus MedTech Aortic Valve Prosthesis
62119239|NCT01013012|EXPERIMENTAL|Group B|Group B : dexamethasone 4 mg + ramosetron 6μg/kg
62119240|NCT00949975|ACTIVE_COMPARATOR|1|AZD9668 active treatment
62119241|NCT00949975|ACTIVE_COMPARATOR|2|AZD9668 active treatment
62119242|NCT00949975|ACTIVE_COMPARATOR|3|AZD9668 active treatment
62119243|NCT00949975|PLACEBO_COMPARATOR|4|AZD9668 placebo treatment
62119244|NCT06188611|EXPERIMENTAL|Huazhi Rougan granule|Take with boiling water ,3 times a day, for 24 weeks;
62119245|NCT06188611|PLACEBO_COMPARATOR|Placebo granule|Take with boiling water ,3 times a day, for 24 weeks;
62119246|NCT04722237|EXPERIMENTAL|Immediate Acceptance and Commitment Therapy|Receiving 6-to-12 weekly sessions of Acceptance and Commitment Therapy immediately after allocation. Each session will be up to one hour in length.
62120053|NCT02928874|EXPERIMENTAL|Caloric compensation|Twenty-five minutes before breakfast, participants will be asked to consume in full one of two oatmeal preloads that will vary in ED. The order of preload conditions will be randomized across groups of children participating in the visits.
62307227|NCT06270992||Benign lung disease group|"192 patients diagnosed with non-cancer diseases with the following inclusion criteria:~* To be between the ages of 18 and 65,~* To have visited our clinic with complaints related to the lungs and/or respiratory tract,~* Not having been diagnosed with lung cancer after clinical evaluation,~* Not having received any cancer treatment in the last 2 years,~* Not having been operated on within the last two years,~* Not having a hospitalization history in the last year,~* Not having used antibiotics in the last six months,~* Not having used products manufactured to support the oral microbiome, such as probiotics for at least the last six months,~* Not being pregnant or breastfeeding,~* Not having undergone dental procedures such as root canal treatment, implants, prostheses, tooth extraction, fillings in the last 6 months,~* Not having dominant immune-origin lesions, viral-origin lesions, dominant bacterial infections like tonsillitis, and/or thermal or chemical mucosal traumas in the mouth."
62474722|NCT05351892|EXPERIMENTAL|Treatment A-B|Participants will receive a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
61919398|NCT04647890|EXPERIMENTAL|FT011 200mg|200mg once daily for 12 weeks
61919399|NCT04647890|EXPERIMENTAL|FT011 400mg|400mg once daily for 12 weeks
62119247|NCT04722237|NO_INTERVENTION|Waitlist Control|Receiving no intervention during a 12-week wait, though no restrictions will be placed on the use of other services. After the wait participants will receive 6-to-12 weekly sessions of Acceptance and Commitment Therapy. Each session will be up to one hour in length.
62119248|NCT04658030|EXPERIMENTAL|VR 360 video surgery preparation|Preparing pediatric patients for surgery with a newly developed VR 360 degree video. Maximum 30 minutes, one time.
62119249|NCT04658030|ACTIVE_COMPARATOR|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
62119250|NCT03798080|EXPERIMENTAL|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning with or without metformin for 30 weeks
62119251|NCT03798080|ACTIVE_COMPARATOR|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day with or without metformin for 30 weeks
62474723|NCT05351892|EXPERIMENTAL|Treatment B-A|Participants will receive a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
62474724|NCT04289870|EXPERIMENTAL|Innoventric Trillium™ Stent Graft Single Arm|Single-arm, open label, multi-center study
62474725|NCT01619891|ACTIVE_COMPARATOR|Vitamin D|Vitamin D 100mcg per day
62474726|NCT01619891|PLACEBO_COMPARATOR|Placebo|Standard optimal therapy
62474727|NCT00697983||Fracture cohort|Patients of 50 years and above with a clinical, non-pathological fracture, who attend an osteoporosis outpatient clinic at the Maastricht University Medical Center for standard medical care (including bone densitometry by DXA-scan).
62474728|NCT00796653|EXPERIMENTAL|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
62307228|NCT06270992||Healthy control group|"292 individuals without lung cancer or another lung disease diagnosis with the following inclusion criteria:~* To be between the ages of 18 and 65,~* Not to have a diagnosed lung disease or suspicion thereof,~* Not to have complaints related to the lungs and/or respiratory tract,~* Not to have alcohol or severe substance dependency,~* Not having a hospitalization history in the last year,~* Not having used antibiotics in the last six months,~* Not having used products manufactured to support the oral microbiome, such as probiotics (lozenges, sublingual drops) for at least the last six months,~* Not being pregnant or breastfeeding,~* Not having undergone dental procedures such as root canal treatment, implants, prostheses, tooth extraction, fillings in the last 6 months,~* Not having dominant immune-origin lesions, viral-origin lesions, dominant bacterial infections like tonsillitis, and/or thermal or chemical mucosal traumas in the mouth."
62307229|NCT05565924|EXPERIMENTAL|Group-A|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill (100% weight-bearing; n=14) 3 times/week for 12-weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
62307230|NCT05565924|EXPERIMENTAL|Group-B|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training (70% weight-bearing; n=13) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) 3 times/week for 12 weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
62307231|NCT05565924|EXPERIMENTAL|Group-C|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training (50% weight-bearing; n=14) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA), 3 times/week for 12 weeks plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
62307232|NCT05565924|EXPERIMENTAL|group-D (30% weight-bearing; n=13)|"This group received moderate-intensity aerobic exercise training (30% weight-bearing; n=13) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) 3 times/week for 12 weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
62474729|NCT00796653|EXPERIMENTAL|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
62474730|NCT00796653|ACTIVE_COMPARATOR|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
62474731|NCT00796653|PLACEBO_COMPARATOR|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
62119252|NCT05219617|EXPERIMENTAL|Carisbamate 200 mg BID arm|"Age: 4 to \<12y\* Titration: 2 mg/kg BID Maintenance: 4 mg/kg BID~Age: ≥12 y Titration: 100 mg BID Maintenance: 200 mg BID"
62119253|NCT05219617|EXPERIMENTAL|Carisbamate 300 mg BID arm|"Age: 4 to \<12y\* Titration: 2.75 mg/kg BID Maintenance: 5.5 mg/kg BID~Age: ≥12 y Titration: 150 mg BID Maintenance: 300 mg BID"
62736348|NCT03380637||Pregnant and non-pregnant females|The pregnant females posted for elective lower segment cesarean section and non-pregnant females posted for elective surgeries are scanned by ultrasound in the pre recovery room. The visibility of the gastric antrum is assessed. The qualitative and quantitative assessment is made and is compared.
62119254|NCT05219617|PLACEBO_COMPARATOR|Placebo matched to 200 mg BID arm|"Age: 4 to \<12y\* Titration: Volume equivalent to 2 mg/kg BID Maintenance: Volume equivalent to 4 mg/kg BID~Age: ≥12 y Titration: Volume equivalent to 100 mg BID Maintenance: Volume equivalent to 200 mg BID"
62474732|NCT02510391|EXPERIMENTAL|PIPA|Modularized treatment for anxiety in children ages 3-7 years old
62474733|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI\<25 kg/m2) and 20 overweight or obese (BMI\>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
61919400|NCT04647890|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 12 weeks
61919401|NCT02346578|EXPERIMENTAL|Enzalutamide|Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
61919402|NCT02346578|ACTIVE_COMPARATOR|Flutamide|Flutamide 125 mg administered orally three times a day as one tablet after meal
62736349|NCT00576628|EXPERIMENTAL|C.E.R.A|Participants received methoxy polyethylene glycol-epoetin beta (Continuous Erythropoietin Receptor Activator \[C.E.R.A\]) subcutaneously every four weeks for 44 weeks. The participants received initial dose of 1.2 microgram per kilogram (mcg/kg) of C.E.R.A. Once the Hemoglobin (Hb) concentration was attained within the target range of 11.0 and 13.0 gram per deciliter (g/dL), the dose was adjusted to maintain the Hb concentration within the target range.
62119255|NCT05219617|PLACEBO_COMPARATOR|Placebo matched to 300 mg BID arm|"Age: 4 to \<12y\* Titration: Volume equivalent to 2.75 mg/kg BID Maintenance: Volume equivalent to 5.5 mg/kg BID~Age: ≥12 y Titration: Volume equivalent to 150 mg BID Maintenance: Volume equivalent to 300 mg BID"
62307233|NCT05565924|SHAM_COMPARATOR|group-E (control group; n=14)|"Served as a control group and participated in no aerobic exercise training on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) during the study, but received oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
62307234|NCT00519623|EXPERIMENTAL|PassPort(R) Transdermal Insulin Delivery System|
62678082|NCT02155855|EXPERIMENTAL|Telemedicine|"Telemedicine group will test blood glucose at least 4 times a day Each time the meter time-stamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit."
62678083|NCT02155855|ACTIVE_COMPARATOR|Control|Control Subjects will continue routine care which requires blood glucose testing at least 4 times a day. Parents will use customary ways to communicate (pager, email, fax or phone) with the Diabetes team, if they are concerned about glycemic control..
62678084|NCT04189042||Parkinson Group|Patients with Parkinson's Disease (Hoehn and Yahr stage 1-4)
62678085|NCT04189042||Healthy Control|Healthy People
62678086|NCT03752073|EXPERIMENTAL|Trans-cervical cervical balloon|17 F non-latex Foley catheter will be placed and balloon filled with 30 cc of sterile normal saline.
62678087|NCT03752073|EXPERIMENTAL|Hygroscopic cervical dilators|Dilapan-S hygroscopic dilators will be placed into the cervix at the level of the internal os.
62678088|NCT00675233|EXPERIMENTAL|Treatment PDT|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
62678089|NCT05675293|EXPERIMENTAL|EXPERIMENTAL ARM|
62678090|NCT05675293|ACTIVE_COMPARATOR|CONTROL ARM|
62678091|NCT03876808|EXPERIMENTAL|Convective pre-warming|Undergo convective warming during the preoperative preparations, completed for a minimum of 60 minutes prior to entering the operating room
62678092|NCT03876808|NO_INTERVENTION|Standard of care|Undergo standard of care, which includes providing each patient with blankets and sheets, as well as more blankets on patient request.
62678093|NCT03958604|EXPERIMENTAL|Burst Spinal Cord Neurostimulation|Burst spinal cord stimulation. When this fails, tonic stimulation targeting the DRG wil be applied
62678094|NCT04755062|EXPERIMENTAL|Micronutrient-dense plant-rich Intervention|The intervention will consist of a 2-hour 'immersion' group session, followed by weekly 1-hour group sessions over the following 11 weeks. Groups of no more than 15 individuals will meet weekly for 12 weeks with a trained Lifestyle Coach. Group sessions, held at the Twin Arrows Casino, will provide participants with instructions, assistance with goal setting, support, encouragement, cooking demonstrations, Casino (workplace) dining tours, and will socially engage with other participants. Participants will be requested to follow the mNDPR nutrition protocol for the first 12 weeks. Each week the participants will use a simple tracking method to self-monitor their daily compliance with the nutrition protocol. Lifestyle Coaches will monitor adherence and verify attendance. Instructional materials discussed each week will provide resources and methods to overcome common barriers to dietary change including (i) meal prepping, (ii) social gatherings, and (iii) family resistance.
62119256|NCT04809090|ACTIVE_COMPARATOR|SMT Group|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews
62119257|NCT04809090|EXPERIMENTAL|SMT+CA|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews and subjects will use an APP together a CA (Conversational Agent) an Artificial Intelligence.
62119258|NCT04809090|EXPERIMENTAL|Only CA|This group will receive only an APP together a CA (Conversational Agent) an Artificial Intelligence.
62119259|NCT04809090|NO_INTERVENTION|Waiting-List|This group will not receive any intervention
62307235|NCT01916577|ACTIVE_COMPARATOR|Plerixafor (Mozobil) Control Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
62307236|NCT01916577|EXPERIMENTAL|Plerixafor (Mozobil) Experimental Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
62119260|NCT01948960|NO_INTERVENTION|standard care|everolimus dose is continued independently of everolimus AUC
62119261|NCT01948960|ACTIVE_COMPARATOR|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
62307237|NCT04170140||Prescribers of Dengvaxia|Healthcare professionals who are current or past prescribers of Dengvaxia
62307238|NCT02884115|ACTIVE_COMPARATOR|Retreatment group|Serofast early syphilis cases retreated with three doses benzathine penicillin
62119262|NCT02705183|ACTIVE_COMPARATOR|A: Surgery & Post-operative radiotherapy|Surgery \& Post-operative radiotherapy
61919403|NCT00209651|EXPERIMENTAL|1|Irinotecan and S-1
62119263|NCT02705183|NO_INTERVENTION|B: Surgery only|Surgery only
62119264|NCT01771588|EXPERIMENTAL|New human milk fortifier|New human milk fortifier
62119265|NCT01771588|ACTIVE_COMPARATOR|Currently marketed fortifier|Currently marketed fortifier
62119266|NCT01771588|EXPERIMENTAL|New human milk fortifier with new Ca source|a subgroup of patients will receive the new milk fortifier containing a new source of calcium.
62307239|NCT02884115|NO_INTERVENTION|Control group|Absence of any retreatment
62307240|NCT05777525|NO_INTERVENTION|Echography|Ultrasound skin measurements will be taken before and after the enriched cream treatment.
62307241|NCT05777525|NO_INTERVENTION|"Visiopor PP-34 camera"|"Measurements of the skin will be taken by Visiopor PP-34 camera before and after the treatment with enriched cream."
62307242|NCT05777525|NO_INTERVENTION|Mycological culture|Skin samples will be taken and analyzed by mycological culture before and after treatment with enriched cream
62678095|NCT04755062|ACTIVE_COMPARATOR|Wait-list Control|Participants in the wait-list control group will be requested to maintain their typical eating patterns during a 12-week waiting period, until they are scheduled to start the intervention 13-weeks later.
62678096|NCT04919590|EXPERIMENTAL|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
62678097|NCT04919590|OTHER|Assessment only control|After an initial enrollment message, participants will be contacted monthly to assess e-cigarette use. At the end of the study data collection period, they will receive information on how to sign up for This is Quitting if they are interested in the program.
62119267|NCT05235698||Patients with long COVID diagnosis|Ophthalmological examinations performed as part of the care Addition of GlycoCheck for the study
62119268|NCT01234116|ACTIVE_COMPARATOR|Kaletra|Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
61919404|NCT01791556|NO_INTERVENTION|Standard of Care|clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
62119269|NCT01234116|ACTIVE_COMPARATOR|Raltegravir|Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
62119270|NCT02787941|EXPERIMENTAL|Intervention group|The intervention group will receive the pharmacist-delivered multifaceted intervention with two counselling sessions in addition to usual care.
62119271|NCT02787941|NO_INTERVENTION|Control group|The control group will receive usual care without the pharmacist-delivered multifaceted intervention.
62119272|NCT06170450|EXPERIMENTAL|Cyclic SNM|Programming of the SNM device will occur as per standard protocol in discussion between patient and SNM representative. The intervention will be to set the device to cycling stimulation program mode.
62119273|NCT06170450|ACTIVE_COMPARATOR|Continuous SNM|"Programming of the SNM device will occur as per standard protocol in discussion between patient and SNM representative. The intervention will be to set the device to continuous stimulation programming (SNM is continuously stimulating without off periods)"
62307243|NCT05777525|EXPERIMENTAL|treatment application|The essential oil enriched cream will be applied to study participants.
62307244|NCT01267435|OTHER|determining correct tunnel positions|
62307245|NCT02190487||TAS group|patients who had thoracic aortic surgery due to dissection
62307246|NCT04706390||Health care workers|500-1000 health care workers prioritized for early vaccination
62307247|NCT04706390||prioritized patient populations|2000 individuals in patient populations prioritized for vaccinations
62307248|NCT02424669|EXPERIMENTAL|recently diagnosed ALS patients|
62307249|NCT02424669|EXPERIMENTAL|not recently diagnosed ALS patients|
62307250|NCT02424669|ACTIVE_COMPARATOR|patients with peripheral neuropathy, recently diagnosed|
62307251|NCT03714841|EXPERIMENTAL|CRP value|The patients point of care CRP value is known by the treating physician
62307252|NCT03714841|ACTIVE_COMPARATOR|CRP value unknown|The patients point of care CRP value is not known by the treating physician
62307253|NCT06510842|EXPERIMENTAL|Intervention arm|Additional insertion of a lumbar drainage.
62307254|NCT06510842|ACTIVE_COMPARATOR|Control arm|Standard of care consists of drainage of CSF via EVD with or without intraventricular thrombolysis.
62307255|NCT04537637||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62307256|NCT01772979|EXPERIMENTAL|Trabectedin|"Trabectedin 1.3 mg/m2 q 21 days~Patients will receive trabectedin until disease progression or unacceptable toxicity"
62307257|NCT00651040|ACTIVE_COMPARATOR|Prednison|"Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.~ARM 1 has only Prednisone"
62307258|NCT00651040|ACTIVE_COMPARATOR|Prednison + methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
62307259|NCT00656214|ACTIVE_COMPARATOR|A|Patients with symptomatic oral lichen planus
62307260|NCT00656214|PLACEBO_COMPARATOR|B|Patients with symptomatic oral lichen planus
62307261|NCT05340400||Patients diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
62678098|NCT04919590|OTHER|Waitlist control|After an initial enrollment message, participants will receive no contact from study staff except for 1-month and 7-month follow-up assessments. At the end of the study data collection period, they will receive information on how to sign up for This is Quitting if they are interested in the program.
62678099|NCT04319198|EXPERIMENTAL|Sacituzumab Govitecan-hziy|"Participants will receive sacituzumab govitecan-hziy at the dose that they were receiving in the parent study until they experience toxicity, disease progression, loss of clinical benefit, withdrawal of consent, lost to follow-up, or Sponsor termination of the study is documented. Participants who continued to receive sacituzumab govitecan-hziy in the Gilead sponsored parent study after disease progression (PD), may continue to receive sacituzumab govitecan-hziy until there is no clinical benefit as determined by the treating physician.~No participant will receive more than 10 mg/kg dose of sacituzumab govitecan-hziy."
62678100|NCT05094037|EXPERIMENTAL|Treatment group|Patients will be given additional counseling
62678101|NCT05094037|ACTIVE_COMPARATOR|Control group|Patients will be given standard of care.
61919405|NCT01791556|EXPERIMENTAL|HIV-1 viral load testing|viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
61919406|NCT02732522|EXPERIMENTAL|Misoprostol sublingual|
62119274|NCT01773980||Patient and Clinic Intervention|"The patient intervention consists of a single 90-minute interactive in-person session.~The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff."
62119275|NCT01773980||Patient Intervention Only|The patient intervention consists of a single 90-minute interactive in-person session.
62119276|NCT01773980||Clinic Intervention Only|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
62119277|NCT01773980||Neither Clinic nor Patient Intervention|Consists of no intervention
62119278|NCT05751499||CASE GROUP|"1. Both male \& Female patients~2. Age group 18-60 Years~3. Diagnosed with nonspecific low back pain in acute/flared stage"
62678102|NCT03609944|SHAM_COMPARATOR|EUS + Sham|Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.
62119279|NCT05751499||CONTROL GROUP|MALE AND FEMALE AGE GROUP 18 TO 60 YEARS NOT SUFFERING FROM LOW BACK PAIN
62119280|NCT06012331|EXPERIMENTAL|Concentrated Growth Factor (CGF)|Concentrated growth factor (CGF) is relatively a new generation of platelet concentrate product, it contains more cytokines and growth factors compared with PRP and PRF also promotes the proliferation, migration, and differentiation of stem cells
62678103|NCT03609944|EXPERIMENTAL|EUS + ERCP with miES|Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.
62119281|NCT06012331|ACTIVE_COMPARATOR|Blood Clot (BC)|Inducing bleeding to facilitate healing is a common surgical procedure. The blood clot formed after hemorrhage, acts as a scaffold and rich source of growth factors, and could play an important role in tissue repair in the canal. The growth factors could stimulate differentiation, growth, and maturation of fibroblasts, odontoblasts and cementoblasts, from the immature undifferentiated mesenchymal cells in the newly formed tissue matrix
62119282|NCT02754479|EXPERIMENTAL|Laser treatments|Each subject will receive a combination of 532 nm and/or 1064 nm Nd:YAG laser treatment
62678104|NCT06077747|EXPERIMENTAL|Coil embolization of lumbar vein|Subjects with confirmed Nutcracker physiology, retrograde lumbar vein flow, and epidural venous plexus congestion with a high pressure headache will have coil embolization of the lumbar vein.
62678105|NCT04488419|EXPERIMENTAL|Dosage|Daily subcutaneous (SC) injection of 40mg ATH-1017
62678106|NCT04488419|PLACEBO_COMPARATOR|Placebo|Daily subcutaneous (SC) injection of Placebo
62678107|NCT06081348|ACTIVE_COMPARATOR|Sertraline|
61919407|NCT02732522|ACTIVE_COMPARATOR|Misoprostol vaginal|
61919408|NCT03699384|EXPERIMENTAL|Azacitidine and Avelumab|All enrolled patients will receive 1 cycle of AZA followed by cycles of combination AZA+Avelumab.
61920007|NCT02002585|EXPERIMENTAL|RDN and optimal medical therapy|Renal denervation will be performed using the available denervation device with a european approval according to current guidelines. The same device will be used for all patients in this arm to avoid efficacy bias.
61919409|NCT02923544|EXPERIMENTAL|total laparoscopic or robotic-assisted hysterectomy|The YUMI manipulator will be placed at the start of each case. During the surgery, the surgeon will track any intraoperative complications. The surgeon fellow will also note the feasibility of placing the uterine manipulator.After surgery, the surgeon will complete the product evaluation form.
61919410|NCT05428982|EXPERIMENTAL|Postoperative Modified Trendelenburg group|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours
62474734|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (\<21 days or \>35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI\<25kg/m2) and 20 overweight or obese (BMI\>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
62474735|NCT01480544|NO_INTERVENTION|Mothers at endline|Data collected on new mothers (up to three weeks after childbirth) in 180 clusters with 100 mothers in each cluster at endline.
61919411|NCT05428982|NO_INTERVENTION|Control|Patients underwent the laparoscopic hysterectomy were positioned in a neutral position
61919412|NCT04052724|EXPERIMENTAL|Intervention group LINGI|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
61919413|NCT04052724|NO_INTERVENTION|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
62119283|NCT01052233|ACTIVE_COMPARATOR|Arthroscopic partial meniscectomy|Arthroscopic partial resection of degenerative tear of medial meniscus
62474736|NCT01480544|EXPERIMENTAL|Treatment 1|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for clinical improvements in quality of maternity care in the providers' patient populations and the catchment areas served by the providers.
61919414|NCT00194675|ACTIVE_COMPARATOR|Testosterone gel + oral placebo|Testosterone 1% gel 7.5 topical daily + placebo dutasteride orally daily
61919415|NCT00194675|ACTIVE_COMPARATOR|Testosterone gel + oral dutasteride|Testosterone 1% gel 7.5 topical daily + dutasteride 0.5 mg orally daily
62119284|NCT01052233|SHAM_COMPARATOR|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
62678108|NCT06081348|PLACEBO_COMPARATOR|Placebo|
61919416|NCT01150474|EXPERIMENTAL|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
61919417|NCT01150474|PLACEBO_COMPARATOR|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
61919418|NCT01285947|OTHER|Naive Subjects|Subjects who have not previously undergone energy-based dermatologic procedures in the past.
61919419|NCT01285947|OTHER|Non-Naive Subjects|Subjects who have previously undergone energy-based dermatologic procedures in the past.
61919420|NCT02095431||with AKI and without AKI|development of AKI by sCr and by novel biomarkers
61919421|NCT00973349|EXPERIMENTAL|3.75_(50)MF59|50% of MF59 with 3.75 µg A/H1N1 antigen
61919422|NCT00973349|EXPERIMENTAL|7.5 w/o MF59|0% of MF59 with 7.5 µg A/H1N1 antigen
62119285|NCT04000269|EXPERIMENTAL|Treatment Group|Treatment with 'Soterix MxN Neuromodulation device (high definition transcranial direct current stimulator) using HD-Targets for optimal neural targeting will be provided to participants and will include 20 minutes of stimulation coupled with conventional OT treatment during and after the intervention. There will be a total of 10 sessions over about a 2 week period.
62119286|NCT04000269|SHAM_COMPARATOR|Sham group|Sham stimulation will consist of using the devices auto-sham feature. The exact same setup/device will be used during both groups. This is considered a control for the experiment. Both groups will receive similar physical occupational and speech therapy
61919423|NCT00973349|EXPERIMENTAL|7.5_(50)MF59|50% of MF59 with 7.5 µg A/H1N1 antigen
61919424|NCT00973349|EXPERIMENTAL|7.5_(100)MF59|100% of MF59 with 7.5 µg A/H1N1 antigen
61919425|NCT00973349|EXPERIMENTAL|15 w/o MF59|0% of MF59 with 15 µg A/H1N1 antigen
62119287|NCT06273891|ACTIVE_COMPARATOR|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days
62119288|NCT06273891|ACTIVE_COMPARATOR|Azithromycin|Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days
62119289|NCT04576858||Cohort 1: Surgical resection + perioperative chemotherapy|
62119290|NCT04576858||Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery|
62119291|NCT04576858||Cohort 3: Definitive chemoradiotherapy|
62119292|NCT04576858||Cohort 4: Chemotherapy with the aim to prolong life expectancy|
62119293|NCT04576858||Cohort 5: Non-chemotherapeutic palliation|E.g. Palliative radiotherapy
62307262|NCT05340400||Patients not diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
62307263|NCT05899725|ACTIVE_COMPARATOR|Cohort 1: severe CIP with the treatment of corticosteroids|severe CIP with the treatment of corticosteroids
62307264|NCT05899725|EXPERIMENTAL|Cohort 2: severe CIP with the treatment of corticosteroids and Ruxolitinib|severe CIP with the treatment of corticosteroids and Ruxolitinib
62307265|NCT01916369|EXPERIMENTAL|CTX DP|Human neural stem cell product, single dose administered once only, increasing doses
62307266|NCT00969722|EXPERIMENTAL|ARM I|Intravenous MAb-3F8 plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
62307267|NCT00969722|ACTIVE_COMPARATOR|ARM II|Oral 13-cis-Retinoic Acid (RA) plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
62307268|NCT05624372||Investigator|Child and Adolescent Psychiatrists, Speech Therapists
62307269|NCT05624372||Participant|Kids aged 4-18 diagnosed with ADHD
62474737|NCT01480544|EXPERIMENTAL|Treatment 2|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for improvement in maternal and infant health outcomes in the providers' patient populations and in the catchment areas served by the providers.
62307270|NCT01108991|ACTIVE_COMPARATOR|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
62307271|NCT01108991|EXPERIMENTAL|Physical activity self-management|Cognitive behavioral counseling to increase lifestyle physical activity delivered over five months plus six weeks of COPD self-management education and usual care
62307272|NCT01993355|ACTIVE_COMPARATOR|TAU|Control group. Treatment as usual (TAU): Physiotherapy program for CLBP.
61919426|NCT00973349|EXPERIMENTAL|15_(50)MF59|50% of MF59 with 15 µg A/H1N1 antigen
61919427|NCT00973349|EXPERIMENTAL|15_(100)MF59|100% of MF59 with 15 µg A/H1N1 antigen
62307273|NCT01993355|EXPERIMENTAL|Intervention 1 Relaxation techniques-sophrology|Intervention group 1: TAU + relaxation techniques-sophrology program.
62307274|NCT01993355|EXPERIMENTAL|Intervention 2 Cognitive-behavioral therapy|Intervention group 2: TAU + cognitive-behavioral therapy.
61919428|NCT00973349|EXPERIMENTAL|30 w/o MF59|0% of MF59 with 30 µg A/H1N1 antigen
62307275|NCT00784069|EXPERIMENTAL|1|Lactic Acid (Dermacyd Breeze)
62474738|NCT01480544|NO_INTERVENTION|Control|Data collected on new mothers (up to three weeks after childbirth) and providers with no incentives
62474739|NCT00961207|ACTIVE_COMPARATOR|Aliskiren in Macroalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.
62474740|NCT00961207|ACTIVE_COMPARATOR|Aliskiren Microalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks
61919429|NCT01987531|EXPERIMENTAL|left ventricular epicardial pacing lead|Enrolled patients will have a temporary left ventricular epicardial pacing lead placed in addition to the standard right ventricular and right atrial temporary epicardial pacing leads after open cardiac chamber cardiac surgery.
61919430|NCT02496572||Short-course MDR-TB regimen patients|"Short course MDR-TB treatment regimen. New presumptively diagnosed MDR TB patients (adults and children) with Xpert® MTB/RIF or Hain MTBDR, or confirmed with Hain MTBDR plus on positive cultures if initial molecular tests negative or confirmed from MGIT culture/DST if initial molecular tests negative;~Children (\<14 years old) suspected of MDR TB without bacteriological confirmation but documented as a close contact of a confirmed MDR TB patient"
61919431|NCT05072327|EXPERIMENTAL|Mohs surgery conbind with cryotherapy|patients in this group received both Mohs surgery and cryotherapy.
61919432|NCT05072327|ACTIVE_COMPARATOR|Mohs surgery|patients in this group received only Mohs surgery.
61919433|NCT03631355|ACTIVE_COMPARATOR|ACL Reconstruction w/ BTB Autograft + IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients received two individual doses of intravenous TXA intra-operatively.
61919434|NCT03631355|NO_INTERVENTION|ACL Reconstruction w/ BTB Autograft, no IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients did not receive two individual doses of intravenous TXA intra-operatively. Only the consented surgery was performed.
61919435|NCT01580748|EXPERIMENTAL|Treatment arm|single arm study
61919436|NCT05029570|EXPERIMENTAL|Conduction System Pacing and AV node ablation|Atrioventricular node ablation and subsequent conduction system pacing
61919437|NCT05029570|NO_INTERVENTION|Medical treatment for rate control of AF|Pharmacological rate control based on clinical practice guidelines
62678109|NCT02096159|EXPERIMENTAL|Antibiotics|trimethoprim-sulfamethoxazole oral suspension, 4 mg/kg (0.5 mL/kg) twice daily for 10 days
62678110|NCT02096159|PLACEBO_COMPARATOR|Placebo|placebo oral suspension, 0.5 mL/kg twice daily for 10 days
62678111|NCT02594956|ACTIVE_COMPARATOR|With Nasogastric Decompression|This group will receive conventional care according to the protocol of the service in place with removal of the nasogastric tube the 3rd postoperative day if the flow is \< 500ml / 24h, if not removal will take place on the 5th postoperative day.
62678112|NCT02594956|EXPERIMENTAL|Without Nasogastric decompression|The nasogastric tube will be take off at the end of the surgery, just after the extubation.
62678113|NCT03491085|ACTIVE_COMPARATOR|tonsillictomy with antibiotics|
62678114|NCT03491085|NO_INTERVENTION|tonsillictomy Without Antibiotics|
62678115|NCT05804292||Community sample|Questionnaires administration
62119294|NCT02888457|OTHER|AOM (acute otitis media)|Infants (6-30 months of age) with acute otitis media
62119295|NCT02888457|OTHER|DCC (day-care centers)|Healthy infants (6-30 months of age) attending day-care centers
62119296|NCT06333132|EXPERIMENTAL|Obese subjects with type 2 diabetes mellitus|Individualized weight-loss nutritional intervention
62119297|NCT02886221|OTHER|HV patients|patients with symptomatic Hallux Valgus treated my Reverdin-Isham Osteotomy
62119298|NCT04063410|EXPERIMENTAL|Screening (pPCA)|Patients undergo standard of care CTA and undergo pPCA MRI for up to 60 minutes before surgery.
62119299|NCT03394976||Study population|Participants will be enrolled passively at health centres. Passive enrolment will include patients referred to or presenting directly at the health facilities.
62119300|NCT01740310|EXPERIMENTAL|High Elaboration Video Arm|Women randomized to this arm will be exposed to a handheld/electronic tablet device-based video with detailed vaccine-related information designed to invoke a high level of attention to the message and thought (elaboration) while processing information.
62119301|NCT01740310|EXPERIMENTAL|High Elaboration Interactive Tutorial Arm|Women will be exposed to a handheld/electronic tablet device-based intervention designed to invoke a high level of attention to the message and thought (elaboration) while processing information through an interactive question/answer format.
62119302|NCT01740310|PLACEBO_COMPARATOR|Low Elaboration / Control Arm|Women randomized to the control arm will be provided standard CDC vaccine information statements that will likely lead to low elaboration information processing.
62678116|NCT05804292||Subjects with obesity and comorbid eating disorder|Questionnaires administration
62678117|NCT05804292||Subjects with obesity without comorbid eating disorder|Questionnaires administration
62474741|NCT02832063|ACTIVE_COMPARATOR|B244 arm|B244 dose administered in a 1:1 (active vs placebo) ratio
62474742|NCT02832063|PLACEBO_COMPARATOR|Placebo arm|Placebo dose administered in a 1:1 (active vs placebo) ratio
62474743|NCT01832350|EXPERIMENTAL|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
62474744|NCT01767103|EXPERIMENTAL|Normal Hepatic Function (healthy volunteers)|Healthy volunteers with normal hepatic function received a single 33 mg/kg dose of Ferriprox®.
62474745|NCT01767103|EXPERIMENTAL|Mild Hepatic Failure|Subjects with mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points received a single 33 mg/kg dose of Ferriprox®.
62474746|NCT01767103|EXPERIMENTAL|Moderate Hepatic Failure|Subjects with moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points received a single 33 mg/kg dose of Ferriprox®.
62474747|NCT03207503||MDD patients|Participants ages 35-75 determined to be clinically depressed via structured clinical interview. No interventions will be administered as part of this study.
61919438|NCT06355674|EXPERIMENTAL|Breastfeeding education group|"Adolescent mothers included in the breastfeeding education group will receive practical breastfeeding training using the lactation simulation model and newborn baby mannequin for 1.5-2 hours conducted by the researchers.~One week and one month after postnatal day 7, the Postnatal Breastfeeding Self-Efficacy Scale - Short Form and the Maternal-Infant Attachment Scale will be administered again to mothers in both groups.~Anthropometric measurements of all babies will be repeated and recorded at the end of the 1st, 2nd, 3rd, and 4th weeks following postnatal day 7.~After the completion of the study, adolescent mothers in the control group who request it will receive breastfeeding education using the lactation simulation model provided by the researchers."
62474748|NCT03207503||non-MDD patients|Participants ages 35-75 determined to be lifetime free of psychiatric conditions as assessed by structured clinical interview. No interventions will be administered as part of this study.
62474749|NCT04024163|EXPERIMENTAL|Benznidazole|Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days
62474750|NCT06601894||Males|The study will be conducted on CBC count special PLT for adult Males of different ages with sickle cell anemia.
62474751|NCT06601894||Children|The study will be conducted on CBC count special PLT for adult Males of different ages with sickle cell anemia.
62678118|NCT02221297|EXPERIMENTAL|Supplement product with plant stanol ester|
62119303|NCT03981042|NO_INTERVENTION|Control group|waiting for a 3-minute delay after injection of the atracurium before laryngoscopy
62119304|NCT03981042|EXPERIMENTAL|Monitoring group|waiting for the TOF ratio at 0 at the corrugator supercilli before laryngoscopy
62119305|NCT02131181||Delirium|Patients with delirium and patients without delirium
62119306|NCT01430611|EXPERIMENTAL|Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine|
62119307|NCT01430611|ACTIVE_COMPARATOR|Lanzhou Institute Meningococcal A+C Polysaccharide Vaccine|
62119308|NCT03506880|EXPERIMENTAL|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
62119309|NCT03506880|EXPERIMENTAL|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
62119310|NCT03506880|NO_INTERVENTION|Control|TAU
62119311|NCT01820195|ACTIVE_COMPARATOR|Intravenous N Acetyl Cystein|1200 mg IV N- Acetyl Cystein half an hour before contrast administration. This group will also take oral placebo
62119312|NCT01820195|PLACEBO_COMPARATOR|Placebo|Patients on both oral placebo and IV placebo just like patients on oral and IV N-acetyl cystein groups in regard of dose and timing.
62119313|NCT01820195|ACTIVE_COMPARATOR|Oral N Acetyl Cystein|Patients on 600 mg oral N-Acetyl Cystein bid started at the day before contrast exposure and continue until the next day of contrast exposure.These patients will also take IV placebo
62119314|NCT00767013|EXPERIMENTAL|AVS, CAD|DSCT
62119315|NCT00079183|EXPERIMENTAL|Sirolimus|Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician. Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is started. Topical therapy, including psoralen and UVA irradiation (PUVA), glucocorticoid creams, topical tacrolimus, oral beclomethasone, topical azathioprine and ophthalmic glucocorticoids may be given at the discretion of the managing physician in consultation with the transplant center.
62119316|NCT06542133||Observational, Single Arm, Non Randomized|Aveir leadless pacemaker system patients
62119317|NCT03921450|EXPERIMENTAL|Inhibitory repetitive transcranial magnetic stimulation (rTMS)|1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
62119318|NCT03921450|ACTIVE_COMPARATOR|Facilitatory intermittent theta burst stimulation (iTBS)|"Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.~total of 15 sessions in 3 weeks"
62119319|NCT03921450|PLACEBO_COMPARATOR|Placebo|1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
62119320|NCT03921450|NO_INTERVENTION|Waiting group|This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm
62119321|NCT04781439|NO_INTERVENTION|non-switching|control group
62119322|NCT04781439|EXPERIMENTAL|IV-to-PO conversion within 48-72 hours|early switching
62119323|NCT04781439|EXPERIMENTAL|IV-to-PO conversion after 72 hours|late switching
62474752|NCT06601894||Females|The study will be conducted on CBC count special PLT for adult Males of different ages with sickle cell anemia.
62474753|NCT03502395|ACTIVE_COMPARATOR|Group I|Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
62307276|NCT03232112|ACTIVE_COMPARATOR|Exenatide 2 MG Injection|Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
62307277|NCT03232112|PLACEBO_COMPARATOR|BD PosiFlush (saline)|The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
62307278|NCT05003245|EXPERIMENTAL|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
62307279|NCT05003245|ACTIVE_COMPARATOR|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
62307280|NCT06177613|EXPERIMENTAL|With blank culture|
62307281|NCT06177613|SHAM_COMPARATOR|Without blank culture|
62307282|NCT02809248|ACTIVE_COMPARATOR|coated stent|the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
62307283|NCT02809248|ACTIVE_COMPARATOR|uncoated stent|the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
62307284|NCT04166396|EXPERIMENTAL|A: Cystic fibrosis|Patients with CF will be randomly assigned to resveratrol or placebo.
62307285|NCT04166396|EXPERIMENTAL|A: Healthy Controls|Healthy controls will be randomly assigned to resveratrol or placebo
62307286|NCT04166396|EXPERIMENTAL|B: Cystic Fibrosis|Patients with CF will be randomly assigned to NR or placebo.
62307287|NCT04166396|EXPERIMENTAL|B: Healthy Controls|Healthy controls will be randomly assigned to NR or placebo
62307288|NCT06017323|EXPERIMENTAL|Dose Level 1:Proglumide TID with Gemcitabine and Nab-Paclitaxel|Proglumide given three times a day with gemcitabine and nab-paclitaxel
62307289|NCT06017323|EXPERIMENTAL|Dose Level 2:Proglumide BID with Gemcitabine and Nab-Paclitaxel|Proglumide given two times a day with gemcitabine and nab-paclitaxel
61919439|NCT06355674|NO_INTERVENTION|Control group|"Adolescent mothers in the control group will continue with routine breastfeeding and follow-up at the family health center.~One week and one month after postnatal day 7, the Postnatal Breastfeeding Self-Efficacy Scale - Short Form and the Maternal-Infant Attachment Scale will be administered again to mothers in both groups.~Anthropometric measurements of all babies will be repeated and recorded at the end of the 1st, 2nd, 3rd, and 4th weeks following postnatal day 7.~After the completion of the study, adolescent mothers in the control group who request it will receive breastfeeding education using the lactation simulation model provided by the researchers."
62307290|NCT01845389|EXPERIMENTAL|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
62307291|NCT01845389|ACTIVE_COMPARATOR|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
62474754|NCT03502395|PLACEBO_COMPARATOR|Group II|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
62474755|NCT00925860|EXPERIMENTAL|non invasive ventilation approach|pure hypoxemic patients admitted to ICU treated by non-positive pressure mechanical ventilation
61919440|NCT06255639||MM patient candidate to vertebroplasty|
62307292|NCT05417529|EXPERIMENTAL|Treatement Group|Participants received music therapy intervention
62474756|NCT00925860|NO_INTERVENTION|conventionally ventilated|pure hypoxemic patients treated by conventional ventilatory support
62474757|NCT00742547|NO_INTERVENTION|Control group|No telephone counseling + usual care
62474758|NCT00742547|EXPERIMENTAL|Telephone Counseling|Telephone counseling + usual care
62307293|NCT05417529|ACTIVE_COMPARATOR|Control Group|Patients in control group receive premedication
62307294|NCT03115255|EXPERIMENTAL|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
62307295|NCT00758615|EXPERIMENTAL|I|Walking School Bus Intervention
62307296|NCT00758615|NO_INTERVENTION|C|Usual school procedures for student transportation to school
62474759|NCT02288221|EXPERIMENTAL|With non pharmacological therapeutic|Installation of ICT at patient's home
62474760|NCT02288221|ACTIVE_COMPARATOR|Without non pharmacological therapeutic|No change at patient's home
62474761|NCT01612091|EXPERIMENTAL|Monitoring Messenger|
62474762|NCT01612091|ACTIVE_COMPARATOR|Control|Traditional tools (monitors, paper records)
62474763|NCT03601819|EXPERIMENTAL|Pacritinib|200 mg twice daily (with possible dose reduction to 100 mg twice daily)
62678119|NCT02221297|PLACEBO_COMPARATOR|Placebo supplement product|
62474764|NCT03253510|EXPERIMENTAL|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
62678120|NCT06072430|EXPERIMENTAL|VBI-S|Treatment with VBI-S
62119324|NCT00028769|EXPERIMENTAL|Hormone therapy, estramustine, etoposide and paclitaxel|Hormone therapy (leuprolide, bicalutamide, nilutamide, goserelin, flutamide), estramustine, etoposide and paclitaxel
62307297|NCT03909685|EXPERIMENTAL|the intervention arm|During the course of the study, the participants in the intervention arm will use the Ask RoSE application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy
62307298|NCT03909685|NO_INTERVENTION|a waitlist control arm|The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm
62474765|NCT03253510|ACTIVE_COMPARATOR|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
62119325|NCT05216692|EXPERIMENTAL|Experimental group|The foot strengthening protocol will last 4 weeks with 2 sessions per week and is composed of 3 exercises targeting forefoot and midfoot region strength as well as enhancing plyometric capabilities of the foot complex.
62119326|NCT05216692|ACTIVE_COMPARATOR|Control group|The standard literature foot strengthening protocol will last 4 weeks with 3 sessions per week and is composed of one exercise targeting the strength of the foot medial arch.
62119327|NCT04148040|EXPERIMENTAL|G-POEM for infantile hypertrophic pyloric stenosis|The procedure includes four steps: a) a transversal mucosal incision was performed at the proximal antrum. b) a submucosal longitudinal tunnel was created across the pyloric ring. c) full-thickness pyloromyotomy was performed, with a little extension of the antrum. After pyloromyotomy, an ultrathin gastroscope was used to inspect the mucosa and pyloric outlet. d) after careful hemostasis, the mucosal entry was closed by clips.
62119328|NCT01834703|ACTIVE_COMPARATOR|UAE treatment|After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
62119329|NCT01834703|ACTIVE_COMPARATOR|HIFU|After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
62307299|NCT00836563||Forearm Arteriovenous Loop Graft|Participants with planned forearm loop arteriovenous graft placement for hemodialysis or forearm loop arteriovenous graft placed within the previous 7 days will have the upper arm vessels assessed following forearm loop arteriovenous graft placement for size changes and timing of changes.
62474766|NCT00376493|ACTIVE_COMPARATOR|1|Use of antibiotics after hospital discharge
62119330|NCT06241235|EXPERIMENTAL|Part 1: Dose Escalation|Part 1 is a dose escalation study of ZG005 combined with paclitaxel and platinum-based ± bevacizumab to evaluate the tolerability and safety of the combination regimen
62119331|NCT06241235|EXPERIMENTAL|Part 2: Dose Expansion|Part 2 is a dose expansion study to further evaluate the initial efficacy and safety of the combination regimen
62119332|NCT04001517|EXPERIMENTAL|Neflamapimod|40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing \<80 kg or the TID regimen if weighing ≥80 kg
62119333|NCT04001517|PLACEBO_COMPARATOR|Placebo|40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing \<80 kg or the TID regimen if weighing ≥80 kg
62119334|NCT06333717|EXPERIMENTAL|High-fibre bread|Six slices (180 g) of whole grain rye bread divided over the meals during the day for 3 weeks
62119335|NCT06333717|PLACEBO_COMPARATOR|Control bread|Six slices (180 g) of control bread containing refined wheat and oat flour divided over the meals during the day for 3 weeks
62307300|NCT03091556||The individuals taking XLGB Pill|The overall individuals taking XLGB Pill with recommended dosage and achieving the inclusion criteria.
62307301|NCT06077981|ACTIVE_COMPARATOR|Hydroxyethylamide Group|15 will be from the hydroxyethylamide Group, where the submucosal endoscopic dissection will be performed with submucosal injection of hydroxyethylamide.
62474767|NCT00376493|PLACEBO_COMPARATOR|2|Use of placebo
62474768|NCT06559982|PLACEBO_COMPARATOR|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
62474769|NCT06559982|EXPERIMENTAL|Brown seaweed and tart cherry blend|
62678121|NCT05645692|ACTIVE_COMPARATOR|Arm A|Participants will receive intravenous (IV) atezolizumab every 3 weeks (Q3W).
62678122|NCT05645692|EXPERIMENTAL|Arm B|Participants will receive IV tobemstomig Q3W.
62678123|NCT05645692|EXPERIMENTAL|Arm C|Participants will receive IV tobemstomig + IV tiragolumab Q3W.
62678124|NCT03003897||Soluble Fiber Treatment|Participants receiving soluble fiber.
62678125|NCT03003897||Placebo Treatment|Participants receiving placebo.
62678126|NCT01742052|EXPERIMENTAL|MT-1303-Low|MT-1303-Low Dose
62307302|NCT06077981|ACTIVE_COMPARATOR|Hyaluronic acid group (TS-905 Blue Eye)|15 will be from the Hyaluronic acid group (TS-905 Blue Eye), where the submucosal endoscopic dissection with submucosal injection of hyaluronic acid (TS-905 Blue Eye) will be performed.
62474770|NCT05238181||The autoimmune gastritis group|Autoimmune gastritis is diagnosed if the anti-parietal cell antibody titer is positive and higher than 1:10 (ImmuGloTM COMVI mouse kidney/stomach IFA kit, Immco Diagnostics, Inc. Buffalo NY, USA).
62307303|NCT03525977|NO_INTERVENTION|Control|Patients in the control arm will receive pain control via traditional oral and intravenous pain medications such as opioids and non-steroidal anti-inflammatory medication as needed.
62307304|NCT03525977|EXPERIMENTAL|Fascia iliaca block|Patients in the intervention arm will receive the regional fascia iliaca block performed by the anesthesiologists on call.
62307305|NCT01403129||Keratoconus-Suspect|A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
62307306|NCT01403129||Keratoconus-Related|A person who is genetically related to someone with keratoconus. Will have either or both Artemis-2 exam and OCT exam.
62307307|NCT01403129||Age-Matched Normal|"A person who is approximately the same age as subjects who have been enrolled in the study.~Will have either or both Artemis-2 exam and OCT exam."
62307308|NCT04107012|EXPERIMENTAL|Clear Aligner|Group 1 treated with clear aligners
62474771|NCT05238181||The controls|The patients who are enrolled to validate pathogenesis after H. pylori infection. H. pylori infection is diagnosed by histological assessment. The matched controls are needed to be confirmed to have negative anti-parietal cell antibody.
62474772|NCT02440763||Spinocerebellar ataxia type 1,2,3 and 6|Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.
62307309|NCT04107012|ACTIVE_COMPARATOR|Fixed appliance|Group 2 treated with conventional fixed appliances
62307310|NCT00469235|PLACEBO_COMPARATOR|1|50ng dose group
62307311|NCT00469235|PLACEBO_COMPARATOR|2|200ng dose group
62307312|NCT01101074||6-23 months|
62307313|NCT01101074||2-8 years|
62307314|NCT01101074||9-17 years|
62307315|NCT01101074||18-44 years|
62307316|NCT01101074||45-60 years|
62307317|NCT01101074||>60 years|
62307318|NCT05319535|ACTIVE_COMPARATOR|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in the investigators' prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
62678127|NCT01742052|EXPERIMENTAL|MT-1303-Middle|MT-1303-Middle Dose
61919441|NCT03628261|OTHER|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
62307319|NCT05319535|EXPERIMENTAL|Enhanced REP|Enhanced REP begins with the same activities as Foundational REP. Sites randomized to receive Enhanced REP will continue with Foundational REP and also receive higher intensity support for a period of approximately 4 months. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship and CONNECT, a complexity science-based bundle of interaction-oriented activities designed to supplement implementation efforts by promoting team function and readiness for change. Facilitation will be provided by Function QUERI team members.
62307320|NCT05058872|EXPERIMENTAL|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg - once a day for 21 days
62307321|NCT05058872|PLACEBO_COMPARATOR|Placebo|Placebo once a day for 21 days
62307322|NCT03852212|NO_INTERVENTION|Control Group|The control group did not received any treatment
62307323|NCT03852212|EXPERIMENTAL|Manipulation|Experimental group received the osteopathic maneuver and the blood value were measured at baseline, after 2,5 and 10 minutes.
62307324|NCT00933946|EXPERIMENTAL|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
62307325|NCT06239311|ACTIVE_COMPARATOR|Methotrexate|Participants will receive 16 to 24 weekly subcutaneous injections of 20 mg . In case of intolerance of the 20 mg dose, a reduction to 15 mg per week is possible.
62307326|NCT06239311|PLACEBO_COMPARATOR|Placebo|Participants will receive 16 to 24 weekly subcutaneous injections
62307327|NCT02975648|ACTIVE_COMPARATOR|Usual Care|At discharge, paticipants received guidance from health professionals. The paticipants had a medical return five to seven months after the percutaneous coronary intervention.
62307328|NCT02975648|EXPERIMENTAL|Educational model + follow up|The paticipants received the hospital's instructions at discharge and participated in the educational program (booklets with telephone follow-up). The paticipants had a medical return five to seven months after discharge
62307329|NCT05968950|EXPERIMENTAL|Thoracic spine ultrasound localization|Single arm where patients undergo both types of skin localization Experimental ( Ultrasound ) correlating with standard of care which is Thoracic spine fluoroscopy
61919442|NCT03628261|OTHER|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
62307330|NCT00775307|PLACEBO_COMPARATOR|B|Placebo 400 mg/day (24 weeks)
62307331|NCT00775307|EXPERIMENTAL|A|Pazopanib 400 mg/day (24 weeks)
62307332|NCT03901378|EXPERIMENTAL|Single Arm|Pembrolizumab 200mg IV day 1 with Carboplatin AUC 6 IV day 1 or Cisplatin 80mg/m2 day 1 with etoposide 100mg/m2 days 1-3 of 21 day cycle. Repeat 4-6 cycles to be followed by maintenance Pembrolizumab 200mg IV day 1 every 21 days until progression or intolerance for up to 2 years.
62307333|NCT01455727|EXPERIMENTAL|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
62307334|NCT01455727|ACTIVE_COMPARATOR|Usual care|Patients received usual care directed by their physician.
62307335|NCT00579904|ACTIVE_COMPARATOR|walnuts|Patients will be randomized to receive walnuts
62307336|NCT00579904|ACTIVE_COMPARATOR|almonds|Patients will be randomized to receive almonds
62307337|NCT01226667|ACTIVE_COMPARATOR|Flexible Dose|flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks
62307338|NCT01226667|ACTIVE_COMPARATOR|Fixed Dosing|75 mg BID for one week and increased to 150 mg BID for 7 weeks
62307339|NCT04154540|EXPERIMENTAL|demyelinating hereditary neuropathy|adult patients with demyelinating hereditary neuropathy type CMT 1A.
62307340|NCT04154540|EXPERIMENTAL|demyelinating inflammatory neuropathy|adult patients with acquired demyelinating inflammatory neuropathy.
62307341|NCT01418755|EXPERIMENTAL|platelet rich plasma injection|Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
62678128|NCT01742052|EXPERIMENTAL|MT-1303-High|MT-1303-High Dose
62678129|NCT01742052|PLACEBO_COMPARATOR|Placebo|Placebo
62678130|NCT05877365|NO_INTERVENTION|Diet Only|Following the same diet as the Purification group
62678131|NCT05877365|EXPERIMENTAL|Purification|Following a diet along with whole food based supplementation
62678132|NCT04560309|EXPERIMENTAL|Glutamine|Intravenous L-alanyl-L-glutamine 0.5 mg/kgbw
62307342|NCT04887311|EXPERIMENTAL|Cohort 1|"Group 1 Patients ≥13 years old will receive a total daily dose of 1200 mg/day.~Group 2 - Group 4~Patients 4-12 years old will receive group weight-tiered doses at 17 mg/kg:~Group 2~* Patients aged 4-12 years weighing 15kg to \<25 kg will take 340 mg/day. Group 3~* Patients aged 4-12 years weighing 25kg to \<35 kg will take 510 mg/day. Group 4~* Patients aged 4-12 years weighing ≥35 kg will take 850 mg/day."
62119336|NCT01818713|EXPERIMENTAL|2B3-101|A single dose of 2B3-101 (a glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) will be administrated intravenously once per cycle. To minimize the risk of infusion reactions, 5% of the total dose of 2B3-101 (in mg) will be administrated over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes
62119337|NCT01018836|EXPERIMENTAL|Riluzole; Radiation Therapy|
62119338|NCT05988307|EXPERIMENTAL|receive percussion massage gun and conventional physical therapy program|
62119339|NCT05988307|OTHER|receive conventional physical therapy program only for knee osteoarthrities|
62119340|NCT03709758|EXPERIMENTAL|Venetoclax+Daunorubicin+Cytarabine|"* Venetoclax administered orally on days 1 to 11 daily~* Daunorubicin administered intravenously on days 2-4~* Cytarabine administered on days 2-8 by continuous IV infusion"
62119341|NCT04100148|EXPERIMENTAL|SyncAV Arm|Treatment Arm
62119342|NCT04100148|ACTIVE_COMPARATOR|Fixed AV Delay Arm|Control Arm
62119343|NCT01909258||The study population.|"Healthy volunteers 20 to 40 years of age.~Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention: EOS measure of pelvic extension reserve."
62119344|NCT02126878|ACTIVE_COMPARATOR|Kenalog 20mg|20mg/ 2ml and local anesthetic
62119345|NCT02126878|ACTIVE_COMPARATOR|Kenalog 40mg|40mg/ 2ml with local anesthetic
62307343|NCT01335646|ACTIVE_COMPARATOR|Surgery|
62307344|NCT01335646|ACTIVE_COMPARATOR|Non-operative|
62307345|NCT00870493|EXPERIMENTAL|I|each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
62474773|NCT06254781|EXPERIMENTAL|Luspatercept in metastatic AGCT of the ovary|Luspatercept, 1.0 mg/kg, subcutaneously, every three weeks
62678133|NCT04560309|PLACEBO_COMPARATOR|Control|Intravenous NaCl 0.9%
62119346|NCT02126878|ACTIVE_COMPARATOR|Kenalog 80mg|80mg/ 2ml and local anesthetic
62119347|NCT04612348||NJ tube fed|Critically ill children receiving nutrition via a nasojejunal feeding tube.
62119348|NCT04612348||NG tube fed|Critically ill children receiving nutrition via a nasogastric feeding tube.
62119349|NCT01336439|ACTIVE_COMPARATOR|M group|A total of 25U of botulinum toxin type A was injected into each side masseter muscle in this arm.
62119350|NCT01336439|ACTIVE_COMPARATOR|MT group|A total of 25U of botulinum toxin type A was injected into each side masseter and temporal muscle in this arm.
62119351|NCT01806428||aPC treatment group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis treated with activated protein C at 24 mcg/Kg/h for 96 hours
62119352|NCT01806428||Control group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis not treated with activated protein C because of contraindications
62119353|NCT00333658|EXPERIMENTAL|1|Intervention
62119354|NCT00333658|NO_INTERVENTION|2|Work Services
62119355|NCT04305405|EXPERIMENTAL|Dose 1|Below 35 kilos
62119356|NCT04305405|EXPERIMENTAL|Dose 2|Greater than/equal to 35 kilos
62119357|NCT06262139|EXPERIMENTAL|MT218|Each patient will receive a single intravenous injection of MT218 while being scanned with standard MR imaging sequences/protocol. The first cohort of four subjects will receive 0.02 mmol/kg, second cohort of four subjects will receive 0.04 mmol/kg, and third cohort of four subjects will receive 0.06 mmol/kg of MT218.
62119358|NCT00723450|PLACEBO_COMPARATOR|placebo|Placebo Controlled
62119359|NCT00723450|EXPERIMENTAL|lamictal|Flexible Dosing
62119360|NCT06676124|EXPERIMENTAL|Piper crocatum Cookie Group|Participants in this group will receive bioactive-rich cookies containing Piper crocatum extract, known for its antioxidant and anti-inflammatory properties. They will consume two cookies daily for 12 weeks, each formulated with a standardized 10% concentration of the ethyl acetate fraction of Piper crocatum extract. The intervention aims to modulate renal biomarkers associated with diabetic nephropathy
62119361|NCT06676124|PLACEBO_COMPARATOR|Placebo Cookie Group|Participants in this group will receive placebo cookies that are identical in appearance, taste, and texture to the Piper crocatum cookies but do not contain the active Piper crocatum extract. They will consume two cookies daily for 12 weeks. This group serves as a comparison to evaluate the effects of the Piper crocatum extract in the intervention group
62119362|NCT06513546|EXPERIMENTAL|PLL001 dose 5x|PLL001 lowest dose (Poly-l-Lysine conjugates with acetate, butirate, lactate, propionate) daily subcutaneous injections
62119363|NCT06513546|EXPERIMENTAL|PLL001 dose 10x|PLL001 highest dose (Poly-l-Lysine conjugates with acetate, butirate, lactate, propionate) daily subcutaneous injections
62307346|NCT00870493|ACTIVE_COMPARATOR|II|each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks
62307347|NCT04210570|EXPERIMENTAL|Memsorb GA|Memsorb Filter will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
62307348|NCT04210570|ACTIVE_COMPARATOR|CGA GA|Chemical CO2 absorber (CGA) will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
62307349|NCT04210570|EXPERIMENTAL|Memsorb low-flow|Memsorb Filter will be used during low flow general anesthesia (GA)
62307350|NCT04210570|EXPERIMENTAL|CGA low flow|Chemical CO2 absorber (CGA) will be used during low flow general anesthesia (GA)
62307351|NCT04210570|EXPERIMENTAL|Memsorb laparoscopic surgery|Memsorb Filter will be used during general anesthesia for laparoscopic surgery
62678134|NCT00501943|ACTIVE_COMPARATOR|Riluzole|Riluzole + Avonex
62678135|NCT00501943|PLACEBO_COMPARATOR|Placebo|placebo + Avonex
62474774|NCT02807597|EXPERIMENTAL|Phase I Dose Level 1: LS301|"* Patient will undergo surgery 4-24 hours after administration of LS301 (0.05 mg/kg)~* Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
62474775|NCT02807597|EXPERIMENTAL|Phase I Dose Level 2: LS301|"* Patient will undergo surgery 4-24 hours after administration of LS301 (0.075 mg/kg)~* Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
62307352|NCT04210570|EXPERIMENTAL|CGA laparoscopic surgery|Chemical CO2 absorber (CGA) will be used during laparoscopic surgery
62307353|NCT00900848||8|8 patients
62474776|NCT02807597|EXPERIMENTAL|Phase I Dose Level 3: LS301|"* Patient will undergo surgery 4-24 hours after administration of LS301 (0.1 mg/kg)~* Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
61919443|NCT05324176|ACTIVE_COMPARATOR|Gillian-Barre|Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration.
61919444|NCT05324176|ACTIVE_COMPARATOR|Myasthenia Gravis|Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration.
62678136|NCT03787212|EXPERIMENTAL|MiBo ThermoFlo / Bruder mask|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
62678137|NCT03787212|EXPERIMENTAL|Bruder Mask / MiBo ThermoFlo|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
61919445|NCT05324176|ACTIVE_COMPARATOR|control|Patients hospitalized with neurological disorders without affection of the respiratory system.
61919446|NCT02935374|ACTIVE_COMPARATOR|Amoxicillin|The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
62307354|NCT01571986||NIV|All patients with acute respiratory failure treated with non-invasive ventilation who give informed consent about treatment of their clinical data
62307355|NCT03811951|EXPERIMENTAL|Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
61919447|NCT02935374|ACTIVE_COMPARATOR|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
62307356|NCT03811951|EXPERIMENTAL|Non-Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
62474777|NCT02807597|EXPERIMENTAL|Phase I Dose Expansion: LS301|"* Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I dose escalation portion)~* 9 patients will be enrolled (6 invasive ductal carcinoma and 3 DCIS)~* Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
62474778|NCT02807597|EXPERIMENTAL|Phase II: LS301|"* Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I portion)~* Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
61919448|NCT02935374|NO_INTERVENTION|Wait and see|The children with acute otitis media will be monitored without antimicrobial treatment.
61919449|NCT02935374|OTHER|Macrolide|The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.
61919450|NCT06458075|NO_INTERVENTION|Control|Control clinicians will continue usual care.
61919451|NCT06458075|ACTIVE_COMPARATOR|CO-LEAD|CO-LEAD clinicians will receive training in the intervention.
62119364|NCT06513546|PLACEBO_COMPARATOR|placebo|Saline daily subcutaneous injections
62119365|NCT01787773|EXPERIMENTAL|Veniti Inferior Vena Cava Filter|
62119366|NCT04818255|EXPERIMENTAL|Disclosure|Participants who demonstrated decisional capacity for and interest in disclosure (or whose care partner is able to do so) will receive the participant's personalized PET amyloid and tau biomarker status, as well as information about the meaning and clinical utility of this information and recommendations for next steps (e.g., discussing findings with his/her provider).
62119367|NCT03934658|EXPERIMENTAL|Active Treatment Arm|Intervention with the NightWare Therapeutic System every night.
62119368|NCT03934658|SHAM_COMPARATOR|Sham Arm|NightWare Therapeutic System every night with interventions not-enabled.
62119369|NCT04381143|ACTIVE_COMPARATOR|Aspirin|Aspirin tablet 100mg daily
62119370|NCT04381143|PLACEBO_COMPARATOR|Matching Placebo|Placebo tablet 1 pill daily
62119371|NCT02425111|EXPERIMENTAL|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
62119372|NCT01094405|EXPERIMENTAL|EBV Vaccine|
62119373|NCT03863834|EXPERIMENTAL|Treatment arm|Subjects receive the RFAL treatment
62119374|NCT00211913|EXPERIMENTAL|vaccine|single dose of StaphVAX®
62119375|NCT00211913|PLACEBO_COMPARATOR|placebo|single dose
62119376|NCT04408937|EXPERIMENTAL|tropifexor AM 200 micrograms and Placebo (PM)|Tropifexor 200 μg (AM) and Placebo (PM) once daily each
62119377|NCT04408937|EXPERIMENTAL|tropifexor PM 200 micrograms and Placebo (AM)|Tropifexor 200 μg (PM) and Placebo (AM) once daily each
62119378|NCT02994719||Neurological Disease subjects|Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.
62119379|NCT02994719||Healthy control subjects|The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.
62119380|NCT02994719||Ataxia Subjects|The ataxia subjects will participate in an additional cohort that will test and validate the gait model.
62119381|NCT02994719||Huntington Disease Subjects|The Huntington Disease subjects will participate in an additional cohort that will test and validate the gait model.
62119382|NCT04349150|EXPERIMENTAL|Virtual reality|Participants on this arm will have their colonoscopy initiated under virtual reality instead of standard sedatives and narcotics
62119383|NCT06467279||TOTAL INTRAVENOUS ANESTHESIA GROUP|After premedication, anesthesia induction will be performed as per routine. Upon reaching the target Bispectral Index (BIS) level (40-60) and ensuring muscle relaxation, the airway will be secured with an appropriately sized endotracheal tube or laryngeal mask airway (LMA). The target concentration of Propofol in the effect site will be set at 3 mcg/ml using a Target-Controlled Infusion (TCI) device. Controlled ventilation will be conducted with 50% oxygen/air mixture, adjusting mechanical ventilation parameters to maintain End-Tidal Carbon Dioxide (EtCO2) levels between 35-45 mmHg.
62119384|NCT06467279||The Patient Group Receiving Inhalation Anesthesia|Patients will be induced with the same anesthesia as Group I, and BIS values will be adjusted to be between 40-60 at the routinely used inhalation gas level of sevoflurane. Patients will be given controlled ventilation with 50% Oxygen/air, and mechanical ventilation materials will be adjusted so that the end tidal carbon dioxide level (EtCO2) will be 35-45 mmHg.
62474779|NCT04960917|EXPERIMENTAL|eHealth literacy workshop|Community members from pre-existing municipality groups will participate in a workshop aimed to raise their ehealth literacy level.
62474780|NCT03584919|ACTIVE_COMPARATOR|EM doxycycline|patients with EM who received doxycycline
62474781|NCT03584919|ACTIVE_COMPARATOR|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
62119385|NCT05089097||Inhibitors of serotoninergic reuptake on|"patients with a diagnosis of depressive syndrome requiring treatment with Inhibitors of serotoninergic reuptake drugs excluding neurodegenerative diseases and on treatment with antidepressants for more than three months.~Intervention: evaluation of the presence of postoperative delirium with the CAM-ICU score upon awakening and for the following 48 hours."
62474782|NCT03584919|PLACEBO_COMPARATOR|controls|control subjects without history of Lyme disease
62474783|NCT01268787|ACTIVE_COMPARATOR|EV 71 vaccine 5ug|EV71 Vaccine 5ug
62474784|NCT01268787|EXPERIMENTAL|EV 71 vaccine 10ug|EV71 vaccine 10ug
62474785|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are \</= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
62474786|NCT00681161|OTHER|A|
62119386|NCT05089097||Inhibitors of serotoninergic reuptake off|"patients without a diagnosis of depressive syndrome requiring treatment with Inhibitors of serotoninergic reuptake drugs excluding neurodegenerative diseases and not in treatment with antidepressants.~Intervention: evaluation of the presence of postoperative delirium with the CAM-ICU score upon awakening and for the following 48 hours."
62119387|NCT01583712|EXPERIMENTAL|Endomicroscopy|All patients included in the study will undergo endomicroscopy of the upper GI-tract including the reachable parts of the small bowel.
62119388|NCT04507945|EXPERIMENTAL|living quality|
62474787|NCT03315247|NO_INTERVENTION|Treatment as Usual|Participants assigned to the Treatment as Usual group will attend routine clinic visits at the Toronto Western Hospital Bariatrics Surgery Program (TWH-BSP). These visits generally include education on bariatric surgery and nutrition. Patients meet with select members of the multidisciplinary team at 1, 2, and 3 years post-surgery, and may attend an optional monthly support group. Participants' service utilization (i.e., attendance at optional sessions) will be documented and compared across groups.
62474788|NCT03315247|EXPERIMENTAL|Telephone-Based CBT|"The Tele-CBT intervention will be delivered 1 year following bariatric surgery. Participants will receive 6 weekly Telephone-based Cognitive Behavioural Therapy sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration and scheduled at a time convenient for the participants."
62474789|NCT05806957||Device: Color Fundus Photography with Non-Mydriatic and Mydriatic Cameras|
62119389|NCT04507945|EXPERIMENTAL|complication|
62119390|NCT02083575|ACTIVE_COMPARATOR|vitamin c|25 heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator.
62474790|NCT03663322|EXPERIMENTAL|OMT Protocol|Subjects assigned to this arm will have selected osteopathic manipulative treatment techniques administered during the treatment sessions
62474791|NCT03663322|SHAM_COMPARATOR|OMT-Sham Protocol|Subjects assigned to this arm will have sham-osteopathic manipulative treatment techniques administered during the treatment sessions
62474792|NCT04444583||HFpEF|HF patients with preserved ejection fraction (HFpEF)
62474793|NCT04444583||HFrEF|HF patients with reduced ejection fraction (HFrEF)
62474794|NCT02775045||Eosinophil esophagitis|Adult patients (\>18 yr) will be recruited from the Gastroenterology clinic following a diagnostic endoscopy for esophageal dysfunction with predominant symptom(s) of solid food dysphagia and/or esophageal food impaction. Patients with esophageal biopsy showing greater than 15 eosinophil/hpf (pathology results typically available within three business days) despite greater than two months use of high dose proton pump inhibitor will be invited to participate and enroll in the study within 1 week of the endoscopy.
62474795|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
62474796|NCT03575585|EXPERIMENTAL|Comparator: No Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
62119391|NCT02083575|OTHER|iron chelator|Included 25 heavily iron-loaded thalassemia patients, not receiving adjuvant vitamin c with iron chelator.
62307357|NCT06092502|ACTIVE_COMPARATOR|Traditional Physiotherapy Program|This group included strengthening exercises will be applied, including various joint movements and strengthening exercises applied in physiotherapy clinics.
62307358|NCT06092502|EXPERIMENTAL|Traditional Physiotherapy Program and Graded Motor Imagery Therapy|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
62307359|NCT06075615||dacomitnib|
62307360|NCT03675399|EXPERIMENTAL|Supra-threshold isometric exercise|Participants will perform 10 isometric external rotation supra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
62307361|NCT03675399|EXPERIMENTAL|Infra-threshold isometric exercise|Participants will perform 10 isometric external rotation infra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
62474797|NCT03575585|EXPERIMENTAL|Active1: Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, and received a personalized feedback report.
62119392|NCT04313868|EXPERIMENTAL|Phase 1A.1: Peripheral IV|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given intravenously on three consecutive days and the presence of the HSV-TK-m2 expression is monitored by \[18F\]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
62119393|NCT04313868|EXPERIMENTAL|Phase IA.2: Hepatic Artery Infusion|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given as a single hepatic artery infusion (HAI) on two successive days and the presence of the HSV-TK-m2 expression is monitored by \[18F\]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
62119394|NCT04313868|EXPERIMENTAL|Phase IA.3: Intratumoral Injection|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given via injection directly into the tumor lesions on one day and the presence of the HSV-TK-m2 expression is monitored by \[18F\]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
62120054|NCT02928874|EXPERIMENTAL|Eating in the absence of hunger (EAH)|During both study visits, children's EAH will be assessed after lunch and again after dinner. The order of presenting the low and high ED snacks will be counterbalanced across meals.
62120055|NCT02393001||Dermatology patients|Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin.
62120056|NCT04838158|ACTIVE_COMPARATOR|Intervention group|Those cases who underwent operative treatment and isokinetics evaluation.
62307362|NCT03675399|NO_INTERVENTION|Control|Participants will remain resting.
62307363|NCT03350711||Microbiota Enrichment Program (MEP)|Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
62307364|NCT03976830||Children diagnosed with cancer|Patients diagnosed with childhood cancer in participating sites in Central American countries
62307365|NCT02400346|EXPERIMENTAL|Adjunct brexpiprazole|All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition
62474798|NCT03575585|EXPERIMENTAL|Active2: No feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
62474799|NCT03575585|EXPERIMENTAL|Active3: Feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, and received a personalized feedback report.
62120057|NCT04838158|OTHER|Control group|Those who were control group of healthy subjects to compare to normative data
62307366|NCT00621933||All Patients Receiving Cataract Surgery|All Patients Receiving Cataract Surgery
62307367|NCT03322657|ACTIVE_COMPARATOR|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
62307368|NCT03322657|EXPERIMENTAL|Sugammadex|Sugammadex 4 mg/kg at the end surgery
62307369|NCT02554643|EXPERIMENTAL|Diet & Soccer|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Soccer training, 3 times a week, during 12 weeks"
62307370|NCT02554643|EXPERIMENTAL|Diet & Running|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Running training, 3 times a week, during 12 weeks"
62307371|NCT02554643|ACTIVE_COMPARATOR|Diet|Nutritional Intervention (Diet) once a week, during 12 weeks
62307372|NCT02906046|PLACEBO_COMPARATOR|placebo Weight in Lower Limbs|placebo Weight in Lower Limbs
62678138|NCT01520714|EXPERIMENTAL|Medtronic passive fixation LV lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
62678139|NCT01520714|EXPERIMENTAL|Medtronic 4195 Active Fixation LV Lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
62678140|NCT04514549||Cohort 1|will enroll approximately 5 patients with pronounced respiratory dysfunction. Patients may be enrolled with tremors and or seizures. All patients will be observed via Emerald to capture sleep staging, movement and breathing for up to approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. MC10 nPoint data will be captured for at least two 24-hour periods in each of the 4 weeks to assess patch placements for breathing detection. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 1 progresses.Preliminary results from Cohort 1 will determine if Emerald will continue to be evaluated and will inform on MC10 nPoint optimizations for Cohort 2. If preliminary results indicate Emerald is not an effective device, then Emerald will be discontinued
62678141|NCT04514549||Cohort 2|will enroll approximately 15 patients. Patients with pronounced respiratory dysfunction, tremors, seizures, and/or other expanded features of Rett syndrome deemed appropriate may be enrolled. If Emerald is continued, all patients are observed via Emerald to capture sleep staging, movement and breathing up to for approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 2 progresses.
62678142|NCT03149380|EXPERIMENTAL|Intervention|Subjects will be given access to educational content on AD using interactive learning strategies
62678143|NCT03149380|SHAM_COMPARATOR|Time-neutral control|Subjects will be given access to time-neutral general educational content on AD
62678144|NCT04257513||Healthy controls subjects|Subjects without known family history of HD, or tested negative for the HD expansion mutation.
62307373|NCT02906046|OTHER|0,5 kg Weight in Lower Limbs|0,5 kg Weight in Lower Limbs
62678145|NCT04257513||Symptomatic HD subjects|Subjects HD gene expansion carriers who have clinical diagnostic motor symptoms of defined HD, and disease stage I to III.
62678146|NCT04257513||Presymptomatic HD subjects:|Subjects HD gene expansion carriers who not have clinical diagnostic motor features of HD.
62678147|NCT05865535|EXPERIMENTAL|Cohort 1|IV infusion of AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
62678148|NCT05865535|EXPERIMENTAL|Cohort 2|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
62678149|NCT05865535|EXPERIMENTAL|Cohort 3|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
62678150|NCT05865535|EXPERIMENTAL|Cohort 4|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
61919452|NCT04344327||Patients with COVID-19|Patients hospitalized in conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)
61919453|NCT06142890|ACTIVE_COMPARATOR|No cooling intervention (control)|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
61919454|NCT06142890|EXPERIMENTAL|Ceiling fan generating airflow|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
61919455|NCT04541251|EXPERIMENTAL|Camrelizumab + Nab-paclitaxel + Carboplatin|
62307374|NCT02906046|OTHER|1,0 kg Weight in Lower Limbs|1,0 kg Weight in Lower Limbs
62307375|NCT05907915|EXPERIMENTAL|laser group|active low level laser therapy and conventional medical treatment.
62678151|NCT05865535|EXPERIMENTAL|Cohort 5|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
62678152|NCT06522529|EXPERIMENTAL|Experimental: Quasi-experimental uncontrolled, before-and-after.|The intervention will consist of the use of a multifaceted implementation strategy based in the continuous quality improvement cycle model and in implementation science theories, model and frameworks to be developed in clinical practice according to the study unit in question and the scope of action.
62678153|NCT03718403|EXPERIMENTAL|Single arm open labeled intervention study|Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
62678154|NCT04581629|EXPERIMENTAL|Cohort 1: Ascending + Steady-State Dose|"Period 1: Participants will receive an ascending dose of encaleret once daily for the first 3 days. Participants will then receive an individualized dose of encaleret twice daily for 2 days.~Period 2: Participants will receive encaleret twice daily for 5 days at a single dose level based on responses from Period 1.~Period 3: After completion of Period 2, participants will be eligible to receive encaleret for an additional 24 weeks.~Long-Term Extension (LTE): At the end of the study, participants will also have an option to receive encaleret for up to an additional 2 years."
62474800|NCT02291250|EXPERIMENTAL|Sugar matched water with polycal OGTT|"1. Control: sugar matched (matched to currant sugar content) water with polycal~2. Blackcurrants (200grams) with polycal~3. Blackcurrants (200grams) with glucose~4. Greencurrants (200grams) with polycal Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
62678155|NCT04581629|EXPERIMENTAL|Cohort 2: Steady-State Dose|"Participants will directly be enrolled into Period 2, and receive encaleret twice daily at a dose based on data and responses from Cohort 1 Period 1.~Period 2: Participants will receive encaleret twice daily for 5 days.~Period 3: After completion of Period 2, participants will be eligible to receive encaleret for an additional 24 weeks.~LTE: At the end of the study, participants will also have an option to receive encaleret for up to an additional 2 years."
61919456|NCT05739864|EXPERIMENTAL|Donor FMT (D-FMT)|Patients enrolled in this arm will receive donor FMT
61919457|NCT05739864|PLACEBO_COMPARATOR|Placebo FMT (P - FMT)|Patients enrolled in this arm will receive placebo FMT
62678156|NCT00932503|NO_INTERVENTION|PDS II|PDS II® loop suture was used for abdominal wall closure
61919458|NCT04308798|EXPERIMENTAL|Control group|No surgical glove changing during total knee arthroplasty procedure
61919459|NCT04308798|EXPERIMENTAL|Treatment 1 group|Changing surgical glove after draping and before cementation during total knee arthroplasty procedure
61919460|NCT04308798|EXPERIMENTAL|Treatment 2 group|Changing surgical glove before cementation during total knee arthroplasty procedure
61919461|NCT04255797|EXPERIMENTAL|experimental group|The experimental group will perform massage in an incubator. The researchers provide a natural plant-based massage oil for the parents.
62307376|NCT05907915|PLACEBO_COMPARATOR|placebo group|placebo laser and conventional medical treatment
62307377|NCT05070338|EXPERIMENTAL|Guideline-Based Nudges|
62678157|NCT00932503|ACTIVE_COMPARATOR|Vicryl plus|"antiseptic coated Vicryl plus was used for abdominal wall closure"
61919462|NCT04022161|PLACEBO_COMPARATOR|Nitrogen|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
62307378|NCT05070338|EXPERIMENTAL|Peer-Based Nudges|
62307379|NCT05070338|NO_INTERVENTION|Control|
62307380|NCT00920309|EXPERIMENTAL|Rapamycin|"Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml."
62307381|NCT00920309|PLACEBO_COMPARATOR|Standard of Care-Placebo|Standard of Care
62678158|NCT05655507|EXPERIMENTAL|Zuranolone|Participants will be enrolled to receive Zuranolone orally, during the daytime on Day 1 and in the evening on Days 2 to 14. The first 10 enrolled participants will receive 50 mg (participants with a body weight of 54 kg or greater) or 40 mg (participants with a body weight less than 54 kg) once daily. The remaining participants will receive 40 mg once daily with the opportunity to down titrate to 30 mg if 40 mg is not tolerated.
62678159|NCT06631339|EXPERIMENTAL|Technical Intervention (n=132)|Technical refinement of classroom lighting + Sham LightUP phone application (s-LightUP)
62678160|NCT06631339|EXPERIMENTAL|Digital Intervention (n=132)|Standard classroom lighting + Interventional LightUP phone application (i-LightUP)
62678161|NCT06631339|PLACEBO_COMPARATOR|Control Group (n=132)|Standard care or control group which involves standard classroom lighting + Sham LightUP app (s-LightUP).
62678162|NCT01123525|EXPERIMENTAL|Adenosine cardioplegia|Adenosine cardioplegia
62678163|NCT01123525|ACTIVE_COMPARATOR|Control|Standard hyperkalemic cardioplegia
62678164|NCT04422132|ACTIVE_COMPARATOR|ARM 1 - 2 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 32.5 Gy in 5 fractions. Patients receiving 32.5 Gy in 5 fractions cannot be treated on consecutive days.
62678165|NCT04422132|ACTIVE_COMPARATOR|ARM 2 - 4 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 55 Gy in 20 fractions.
62678166|NCT01649583|EXPERIMENTAL|Jaw Dynasplint System|
62678167|NCT01649583|NO_INTERVENTION|Control Arm|
62307382|NCT04886765|EXPERIMENTAL|ALMB-0168|"Dose Escalation Cohort ：The accelerated titration and traditional 3+3 design will be used in the dose-escalation phase. Seven dose cohorts will be evaluated. ALMB-0168 will be administered intravenously once every 3 weeks until either the disease progresses or intolerable toxicity occurs.~Dose Expansion Cohort: Based on the results of Part I, 1-3 dose expansion cohorts will be started to further evaluate the safety and efficacy of ALMB-0168."
62307383|NCT01478347|EXPERIMENTAL|rMenB+OMV NZ|Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
62307384|NCT01050062||Micombi® Combination Tablet AP|
62307385|NCT01050062||Micombi® Combination Tablet BP|
62307386|NCT04169828|EXPERIMENTAL|Ondansetron premedication|Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate.
62307387|NCT04169828|ACTIVE_COMPARATOR|Ondansetron as needed|Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion
62307388|NCT02309710|EXPERIMENTAL|ShangRing|ShangRing administered to men seeking medical male circumcision
62678168|NCT02852005|EXPERIMENTAL|Group 1: MVA/HIV62B + Placebo|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
62678169|NCT02852005|EXPERIMENTAL|Group 2: MVA/HIV62B + AIDSVAX B/E|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
62678170|NCT02852005|EXPERIMENTAL|Group 3: MVA/HIV62B + Placebo|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
62678171|NCT02852005|EXPERIMENTAL|Group 4: MVA/HIV62B + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
62678172|NCT02852005|EXPERIMENTAL|Group 5: Placebo + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
62678173|NCT06168799|EXPERIMENTAL|Ilofotase alfa|
62678174|NCT06168799|PLACEBO_COMPARATOR|Placebo|
62678175|NCT04572230||Evolve EU|Selected hospitals for participation
62678176|NCT04572230||Evolve FR|All hospitals in France using the device
62678177|NCT05068830|EXPERIMENTAL|Exercised plasma (ExPlas)|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 ExPlas transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
62678178|NCT05068830|ACTIVE_COMPARATOR|Octaplasma|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 Octaplasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
62678179|NCT05068830|PLACEBO_COMPARATOR|Saline|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods)
62678180|NCT01783236|PLACEBO_COMPARATOR|Saline Placebo|Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
62678181|NCT01783236|ACTIVE_COMPARATOR|IV Acetaminophen|Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
62678182|NCT06681220|EXPERIMENTAL|Study Drug Combination|Biomarker positive patients will be randomized 2:1 to study drug (PARP inhibitor 200mg/day +TMZ 40mg/day daily) or (Standard of Care) Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion each cycle x21 days until disease progression or intolerable toxicity
62678183|NCT06681220|ACTIVE_COMPARATOR|Standard of Care|Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion each cycle x21 days until disease progression or intolerable toxicity
62678184|NCT06681220|ACTIVE_COMPARATOR|Biomarker Negative Standard of Care|Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion each cycle x21 days until disease progression or intolerable toxicity
62678185|NCT05877287|EXPERIMENTAL|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
62678186|NCT05877287|NO_INTERVENTION|control group|No application will be made.
62678187|NCT02597361|ACTIVE_COMPARATOR|Irbesartan|Irbesartan: 150 or 300 mg o.d. for 2 years.The up-titration of irbesartan from 150 mg to 300 mg o.d. occurs during the first 8 weeks following randomization and will be driven by clinical, hemodynamic and biological (plasma creatinine and K) tolerability.
62678188|NCT02597361|PLACEBO_COMPARATOR|Placebo|Placebo once or twice per day for 2 years.
62678189|NCT03741842|EXPERIMENTAL|COMBO-KEY group|"The participants in the intervention group will receive a home visiting and phone coaching self-management programme (Coaching Ongoing Momentum Building On stroKe rEcovery journeY COMBO-KEY) which is underpinned by Bandura's constructs of self-efficacy and outcome expectation."
62678190|NCT03741842|NO_INTERVENTION|Usual care group|The participants in the usual care group will receive usual rehabilitation services offered, including services by a community rehabilitation network such as exercise training, physical rehabilitation, or activities organised by stroke support groups.
62678191|NCT01497093|EXPERIMENTAL|Pomalidomide/Bortezomib/Dexamethasone|1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
62678192|NCT04861805|OTHER|Vienna Aortic Valve|transcatheter aortic valve implantation (TAVI)
62678193|NCT06074185|NO_INTERVENTION|Continue current care|In this arm, participants will be treated using the existing EMS protocol, and evaluate patient outcomes.
62120058|NCT02384070|EXPERIMENTAL|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
62120059|NCT02384070|ACTIVE_COMPARATOR|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
62120060|NCT02384070|EXPERIMENTAL|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
62678194|NCT06074185|EXPERIMENTAL|Treatment bundle and checklist|In this arm, we will implement a new treatment protocol with the study bundle, and evaluate patient outcomes.
62678195|NCT03177070|EXPERIMENTAL|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
62678196|NCT04129970|EXPERIMENTAL|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
62678197|NCT01358305|ACTIVE_COMPARATOR|Whey Protein Isolate|
62678198|NCT01358305|EXPERIMENTAL|Protein Blend (soy, whey and casein)|
62678199|NCT05257083|ACTIVE_COMPARATOR|Arm A: DVRd + ASCT+DVRd (Standard Therapy)|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 4 induction cycles. Followed by ASCT and 2 cycles of DVRd consolidation, and lenalidomide maintenance therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each cycle 1-6. Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6. Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
62678200|NCT05257083|EXPERIMENTAL|Arm B: DVRd followed by Ciltacabtagene Autoleucel|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 6 induction cycles.~Participants will receive a conditioning regimen (cyclophosphamide 300 mg/m\^2 intravenous \[IV\] and fludarabine 30 mg/m\^2 IV daily for 3 days) and Cilta-cel infusion 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg), followed by lenalidomide post CAR-T cell therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each cycle 1-6.~Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6.~Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist of 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
62678201|NCT00544687|EXPERIMENTAL|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
62678202|NCT00544687|EXPERIMENTAL|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
62678203|NCT00544687|ACTIVE_COMPARATOR|3|0.1% mometasone furoate
62678204|NCT00544687|ACTIVE_COMPARATOR|4|0.1% nortriptyline HCl
62678205|NCT00544687|ACTIVE_COMPARATOR|5|Karison® Creme (clobetasol-17-propinate 0.05%)
62678206|NCT00544687|PLACEBO_COMPARATOR|6|Vehicle (placebo)
62678207|NCT06593665|OTHER|Intrathecal Morphine|Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
62678208|NCT06593665|OTHER|Intravenous Methadone|Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
62678209|NCT01098357|EXPERIMENTAL|Biochaperone PDGF-BB low dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
62678210|NCT01098357|EXPERIMENTAL|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
62678211|NCT01098357|ACTIVE_COMPARATOR|Regranex|Becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson \& Johnson) is a topical gel of rhPDGF-BB conditioned in a gel tube.
62678212|NCT01098357|EXPERIMENTAL|Very Low Dose BioChaperone PDGF-BB|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
62678213|NCT02642679|EXPERIMENTAL|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
62678214|NCT05691439|EXPERIMENTAL|"Sleep extension and advance Lark Routine"|Participants go to bed 90 minutes earlier than their typical average bedtime to extend sleep duration and advance sleep timing
62678215|NCT05691439|ACTIVE_COMPARATOR|"Regular sleep duration and timing Owl Routine"|Participants go to bed at their typical average bedtime
62307389|NCT02812680||Esophageal Cancer Patients - Blood Draw|Look at blood samples to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy in patients with Esophageal Adenocarcinoma.
62678216|NCT06689969|ACTIVE_COMPARATOR|patients with narrow ridge received small diameter implant in conventional method.|
62678217|NCT06689969|ACTIVE_COMPARATOR|patients with narrow ridge received implant by OD technique using densah bur.|
62678218|NCT06658249|EXPERIMENTAL|Core Stabilization Exercises with Foot-Ankle Strengthening Program|Core Stabilization Exercises with Foot-Ankle Strengthening Program along with simple conventional treatment.
62678219|NCT06658249|ACTIVE_COMPARATOR|Foot-Ankle Strengthening Program|Foot-Ankle Strengthening Program along with simple conventional treatment
62678220|NCT03816826|EXPERIMENTAL|laser|athletes with acute soft tissue injuries will be recruited in the study , patients will be treated using the the laser therapy
62307390|NCT02812680||Healthy volunteers - Blood Draw|Comparators for the esophageal cancer group
62678221|NCT03816826|EXPERIMENTAL|strain/counter strain|athletes with acute soft tissue injuries will be treated with with strain counter strain technique
62678222|NCT03816826|EXPERIMENTAL|combination therapy|combination of laser therapy along with strain counter strain technique to visualize the effect the
62678223|NCT04094610|EXPERIMENTAL|Repotrectinib (TPX-0005)|"Phase 1~Oral repotrectinib (TPX-0005):~Safety and tolerability at different dose levels~Phase 2~Oral repotrectinib (TPX-0005): 3 cohorts~Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ROS1 gene fusions or other ROS1 aberrations"
62678224|NCT06343883|EXPERIMENTAL|Safety Check - high pressure application|Small cohort to be collected prior to other study cohorts. Highest of 3 pressures of interest will be applied to the S1 (somatosensory cortex) with a follow-up MRI conducted 24-72 hours post.
62678225|NCT06343883|EXPERIMENTAL|EEG|Electrical stimulation utilized to generate SEPs, performed pre and post LIFU application. One of three LIFU pressures will be applied. One per study visit (3), randomized order. EEG collected throughout visit (outcome measure).
62678226|NCT06343883|EXPERIMENTAL|fMRI|Electrical stimulation utilized to generate SEPs, performed pre and post LIFU application. One of three LIFU pressures will be applied. One per study visit (3), randomized order. fMRI collected throughout visit (outcome measure).
62678227|NCT06169579|EXPERIMENTAL|ND-003 tablets_Dose 1|Adult patients with solid tumors receiving 40 mg of ND-003 tablets once daily (dose escalation cohort).
62678228|NCT06169579|EXPERIMENTAL|ND-003 tablets_Dose 2|Adult patients with solid tumors receiving 80 mg of ND-003 tablets once daily (dose escalation cohort).
62307391|NCT00283712|EXPERIMENTAL|Infliximab|"Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
62307392|NCT00283712|PLACEBO_COMPARATOR|Placebo Comparator|"Participants are randomized to receive intravenous infusions of placebo (5 mg/kg comprised of a white lyophilized powder reconstituted in 10 mL of Sterile Water for Injection, USP) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
62307393|NCT00746538|EXPERIMENTAL|1|metallic stent group
62474801|NCT02291250|EXPERIMENTAL|Blackcurrants with polycal OGTT|"1. Blackcurrants (200grams) with polycal~2. Blackcurrants (200grams) with glucose~3. Greencurrants ( 200grams) with polycal~4. Control: sugar matched (matched to currant sugar content) water with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
62474802|NCT02291250|EXPERIMENTAL|Blackcurrants with glucose OGTT|"1. Blackcurrants (200grams) with glucose~2. Greencurrants (200grams) with polycal~3. Control: sugar matched (matched to currant sugar content) water with polycal~4. Blackcurrants (200grams) with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
62474803|NCT02291250|EXPERIMENTAL|Greencurrants with polycal OGTT|"1. Greencurrants (200grams) with polycal~2. Control: sugar matched (matched to currant sugar content) water with polycal~3. Blackcurrants (200grams) with polycal~4. Blackcurrants (200grams) with glucose~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments."
62474804|NCT03444090|EXPERIMENTAL|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size \<10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size \>10 mm will be performed only during withdrawal of the scope.
62474805|NCT03444090|ACTIVE_COMPARATOR|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
62474806|NCT06438224|EXPERIMENTAL|Extracorporeal shock wave therapy (ESWT)|Those in the ESWT group were asked to select the most hypertrophic and retracting scars for treatment. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals.
62474807|NCT06438224|SHAM_COMPARATOR|sham group|the sham group was treated using an adapter that had the same shape but did not emit any energy
62474808|NCT03351244|EXPERIMENTAL|BI 409306 50 mg|1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
62474809|NCT03351244|EXPERIMENTAL|BI 409306 25 mg|1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
62678229|NCT06169579|EXPERIMENTAL|ND-003 tablets_Dose 3|Adult patients with solid tumors receiving 160 mg of ND-003 tablets once daily (dose escalation cohort).
62678230|NCT06169579|EXPERIMENTAL|ND-003 tablets_Dose 4|Adult patients with solid tumors receiving 300 mg of ND-003 tablets once daily (dose escalation cohort).
62678231|NCT06169579|EXPERIMENTAL|ND-003 tablets_Dose 5|Adult patients with solid tumors receiving 500 mg of ND-003 tablets once daily (dose escalation cohort).
62678232|NCT06169579|EXPERIMENTAL|ND-003 tablets_Dose 6|Adult patients with solid tumors receiving 800 mg of ND-003 tablets once daily (dose escalation cohort).
62307394|NCT00746538|ACTIVE_COMPARATOR|2|plastic stent group
62307395|NCT02201810|EXPERIMENTAL|2nd level intervention: Rate Reduction|Rate reduction intervention
62307396|NCT02201810|EXPERIMENTAL|2nd level intervention: Recycling|Recycling Group
62307397|NCT02201810|EXPERIMENTAL|2nd level intervention: Choice|Choice Group
62307398|NCT06148610||NewSpringForMe cohort|Patients with hematological diseases intended to be allotransplanted (bone marrow or Hematopoietic Stem Cells)
62307399|NCT00739128|ACTIVE_COMPARATOR|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intramuscular route
62307400|NCT00739128|ACTIVE_COMPARATOR|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intradermal route
62307401|NCT02914626|EXPERIMENTAL|Ranibizumab|Standard of care therapy plus intravitreal ranibizumab injections
62474810|NCT03351244|PLACEBO_COMPARATOR|Placebo|1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
62474811|NCT01858493|EXPERIMENTAL|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
62474812|NCT01858493|SHAM_COMPARATOR|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
62474813|NCT03097107|EXPERIMENTAL|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks
62474814|NCT03097107|EXPERIMENTAL|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks
62474815|NCT03097107|EXPERIMENTAL|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks
62474816|NCT03097107|PLACEBO_COMPARATOR|Placebo|Placebo tablet orally once a day for 12 weeks
62474817|NCT00878020|ACTIVE_COMPARATOR|Arm 1|BMS-830216 (10 mg)
62474818|NCT00878020|ACTIVE_COMPARATOR|Arm 2|BMS-830216 (30 mg)
62474819|NCT00878020|ACTIVE_COMPARATOR|Arm 3|BMS-830216 (100 mg)
62474820|NCT00878020|ACTIVE_COMPARATOR|Arm 4|BMS-830216 (300 mg)
62307402|NCT02914626|SHAM_COMPARATOR|Control|Standard of care therapy
62307403|NCT00298532|NO_INTERVENTION|standard therapy|"The use of a before-after controlled study design and 36-month time periods will mirror the approach of our Adult OPALS Study. The Control (before) Period represents the 36 months immediately prior to the introduction of ALS programs at each study community. The Intervention (after) Period is comprised of the 36 months immediately after each community has met all standards for a full ALS program, as defined below. Data will be pooled across communities but the start date for the periods will vary for each community as each will require different amounts of time to prepare their ALS program. A 6- to 36-month Run-in period will separate the Control and Intervention Periods and will allow for training and implementation of the ALS program. Data from the Run-in period will not be considered in the primary analysis. The study periods may be summarized as follows: a) Control (Before) Period b) Run-in Period c) Intervention (After) Period."
62474821|NCT00878020|ACTIVE_COMPARATOR|Arm 5|BMS-830216 (600 mg)
62474822|NCT00878020|ACTIVE_COMPARATOR|Arm 6|BMS-830216 (1200 mg)
62474823|NCT04354974|ACTIVE_COMPARATOR|Eco Program (Ecological Cognitive Training for Mood Disorders)|"Duration: four months, 16 sessions~* Frequency: One one-hour session and one hour of personal work per week~* Modalities: Paper and pencil exercises and manipulable tools~* Objective: Learning problem-solving strategies for use in daily life~* Modules: Psychoeducation, Information Processing, Memory, Concept Formation, Functional Disorders"
62474824|NCT04354974|ACTIVE_COMPARATOR|ThOR Program (Remission Oriented Therapy)|"Duration: four months, 16 sessions~* Frequency: One one-hour session and one hour of personal work per week~* Modalities: Paper tools and verbal exchange with the patient~* Objective: Improvement of the patient's quality of life~* Themes: Mood, social skills, autonomy, motivation, sleep"
62474825|NCT05322967|ACTIVE_COMPARATOR|Morning intake|Intake of antihypertensive medication in the morning
62474826|NCT05322967|ACTIVE_COMPARATOR|Bedtime intake|Intake of antihypertensive medication at bedtime
62474827|NCT03810950|EXPERIMENTAL|Social Stress Test|Participants undergo the Trier Social Stress Test before Barlab-Exposure
62474828|NCT03810950|ACTIVE_COMPARATOR|Control Condition|Participants reads newspaper before Barlab-Exposure
62474829|NCT04093245|NO_INTERVENTION|Phase I-A (Local project set-up)|An executive committee will oversee the entire project. This committee, led by the nominated PI and Director of Nursing, will meet every 4 weeks during this four-year project. The team may include, depending on the hospital site: an administrator, the ED Director, the ED Head nurse, a community and/or hospital-based geriatric nurse specialist, an ED physician, a hospitalist, a geriatrician, a family physician, a home care nurse/coordinator, an inpatient unit manager, the research coordinator, and a local patient/caregiver. Each local team will be responsible for selecting and implementing the ACE intervention(s) best suiting their milieu, and will include locally identified champions to lead the local implementation.
62678233|NCT06169579|EXPERIMENTAL|ND-003 tablets_Expansion 1|"Adults patients with solid tumors harboring NTRK or RET Fusion or Mutation (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of ND-003 tablets as determined in the dose escalation part, one to two dose cohorts are set."
62678234|NCT06169579|EXPERIMENTAL|ND-003 tablets_Expansion 2|"Adults patients with solid tumors harboring NTRK or RET Fusion or Mutation (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of ND-003 tablets as determined in the dose escalation part, one to two dose cohorts are set."
62678235|NCT05960929|EXPERIMENTAL|Treatment Arm|A single dose of Calfactant at 6ml/kg administered via the Infasurf Aero™ Nebulizer until completion.
62119395|NCT05496907|EXPERIMENTAL|Intervention|"After the participants consent, they will be asked to complete 7 validated questionnaires. An interview will also take place to determine severity of psychiatric symptoms using the Brief Psychiatric Rating Scale. A physical assessment will be conducted including Blood pressure, BMI and Blood Tests for HbA1c, Glucose test, Total Cholesterol, Renal Function.~Participants in the intervention arm will see the diabetes nurse up to 10 times, during these sessions motivational interviewing will be used to discuss areas to improve, goal setting and action planning. Participants and the nurse will collaboratively discuss practical strategies to improve their HbA1c, blood pressure, cholesterol, BMI and mental health.~The same measures that were completed at the beginning will be re-assessed again at 6 months."
62307404|NCT06464406|EXPERIMENTAL|Control condition completed first|In this arm, the Control condition (traditional maximal cardiorespiratory exercise test) will be completed first, and the Virtual Reality condition (traditional maximal cardiorespiratory exercise test with the addition of virtual reality video) will be completed second.
62119396|NCT05496907|NO_INTERVENTION|Control|Participants will be asked to complete the same 7 validated questionnaires, the brief psychiatric rating scale and a physical health assessment at the start. The will continue to receive standard care from their usual care professionals. The same measures that were completed at the beginning will be re-assessed again at 6 months.
62119397|NCT00848627||Males|60 years of age or older Smokers or history of smoking
62119398|NCT01755897|EXPERIMENTAL|Adjuvant Chemotherapy (Arm A)|Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.
62119399|NCT01755897|ACTIVE_COMPARATOR|Concurrent radiochemotherapy, CCRT (Arm B)|Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.
62119400|NCT04071964||Groupe 1|Patients with colorectal cancer undergoing resection with anastomosis
62307405|NCT06464406|EXPERIMENTAL|Virtual Reality condition completed first|In this arm, the Virtual Reality condition (traditional maximal cardiorespiratory exercise test with the addition of virtual reality video) will be completed first, and the Control condition (traditional maximal cardiorespiratory exercise test) will be completed second.
62307406|NCT00939263||1|cohorts 1 (item weighting phase): 100 children with Eosinophilic Esophagitis, 150 adults with Eosinophilic Esophagitis
62119401|NCT04071964||Groupe 2|Patients with colorectal cancer undergoing resection without anastomosis (Abdominoperineal resection)
62119402|NCT04071964||Groupe 3|"Patients with rectal cancer without surgery (Watch and wait)"
62119403|NCT04071964||Groupe 4|Control group consisting of patients who do not have surgical pathologies of the colon and rectum
62119404|NCT00711126|EXPERIMENTAL|Arm 1|HVTs
62119405|NCT00711126|EXPERIMENTAL|Arm 2|HVTs
62307407|NCT00939263||2|cohorts 2 (evaluation phase): 200 children with Eosinophilic Esophagitis, 200 adults with Eosinophilic Esophagitis
62307408|NCT02660554|NO_INTERVENTION|Usual care|In the usual care arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be given at the discretion of the care team. If bacterial cultures are negative for MRSA at 72 hours, the treating physician will be prompted to discontinue MRSA therapy.
62307409|NCT02660554|EXPERIMENTAL|Polymerase Chain Reaction|In subjects randomized to the polymerase chain reaction (PCR) arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be determined by the results of the PCR test. In subjects who are clinically stable, results from the PCR must be available prior to the administration of MRSA therapy. Subjects with a positive MRSA PCR will be administered MRSA therapy. In subjects with a negative MRSA PCR, MRSA therapy will be withheld. In subjects randomized to the automated PCR arm who are clinically unstable, empiric MRSA therapy will be allowed until the PCR is completed. In these cases of unstable subjects, empiric MRSA therapy will be discontinued if the PCR is negative.
62307410|NCT05784792|NO_INTERVENTION|Lugol -|No pre-operative Lugol Solution preparation
62474830|NCT04093245|EXPERIMENTAL|Phase I-B (Implementation):|The investigators will implement the context-adapted ACE program with the support of administrators and local implementation teams who will have the responsibility to roll out the different elements of the intervention within their respective hospitals. It may include a series of systematic pre-discharge, post-discharge and across transitions period interventions for eligible patients: 1) a GEM nurse to support patients during the post-discharge transition period, 2) pre- and post-hospitalization medication list reconciliation, 3) systematic discharge summaries given to patients and/or caregiver, and sent to their family physician, 4) a planned follow-up appointment with their family physician, 5) a systematic follow-up phone call, 6) access to wiki-based patient-oriented KT tools, 7) access to a community-based telemonitoring service.
62678236|NCT05960929|SHAM_COMPARATOR|Control Arm|Low flow respiratory air alone through the InfasurfAero™ Nebulizer until completion.
62678237|NCT06691516|EXPERIMENTAL|computer guide cortical shell technique in anterior mandible 3d defect|in study group there are bone harvesting guide and two fixation guides
62119406|NCT00711126|EXPERIMENTAL|Arm 3|HVTs
62119407|NCT00711126|EXPERIMENTAL|Arm 4|HVTs
62119408|NCT00711126|EXPERIMENTAL|Arm 5|HVTs
62119409|NCT00711126|EXPERIMENTAL|Arm 6|HVTs
62119410|NCT02566707|EXPERIMENTAL|PRADAII regimen|Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
62119411|NCT00716924|EXPERIMENTAL|1|300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
62119412|NCT00716924|EXPERIMENTAL|2|600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
62119413|NCT00716924|EXPERIMENTAL|3|600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
62119414|NCT03720210|EXPERIMENTAL|RFA group|RFA
62119415|NCT04669249|EXPERIMENTAL|PROCare|Technology-enabled, reward-based recovery platform
62119416|NCT04669249|NO_INTERVENTION|Control|Treatment-as-Usual
62474831|NCT04093245|EXPERIMENTAL|Phase IC (Study description)|Results from each center will be analysed over time. Guided by previous work in healthcare governance, the investigators will analyze the impact of the sequential interventions within the context of a major health reform in Quebec aiming at implementing an integrated health system and within the PI program's overall goal of creating a Learning Health System. This will be accomplished by conducting a comparative case study across the four study sites to compare the barriers, facilitators and local solutions implemented to gain a better understanding about how the ACE program could eventually be scaled up elsewhere.
62474832|NCT05385640||CPSP group|Patients who developed chronic pain 3 months after surgery
62474833|NCT05385640||UN-CPSP group|Patients who did not develop chronic pain 3 months after surgery
62474834|NCT03615105|EXPERIMENTAL|Radiation, Thiotepa & Cyclophosphamide|
62474835|NCT03615105|EXPERIMENTAL|Busulfan, Fludarabine & Melphalan|
62474836|NCT03615105|EXPERIMENTAL|Clofarabine, Thiotepa & Melphalan|
62474837|NCT01738269||Apparently healthy subjects|
62474838|NCT01738269||Non-malignant conditions subjects|
62474839|NCT01738269||Malignant conditions subjects|
62474840|NCT00940693|ACTIVE_COMPARATOR|duloxetine|
62474841|NCT00940693|PLACEBO_COMPARATOR|placebo|
62474842|NCT06560697|EXPERIMENTAL|Cervical Boost with SABR|patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy
62474843|NCT06560697|ACTIVE_COMPARATOR|Cervical Boost with Intracavitary Brachytherapy|Patients with CC clinical stages IB3-IIIC1 will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.
61919463|NCT04022161|EXPERIMENTAL|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled nitric oxide (iNO) will be weaned and discontinued.
62120061|NCT05898152||Adult patients with catamenial epilepsy|A questionnaire regarding the menstrual cycle and the catamenial epilepsy will be administrated to the participants.
61919464|NCT02404532|EXPERIMENTAL|1|
62120062|NCT05578053||locally advanced/metastatic HR+ breast cancer patients|HR+ postmenopausal or premenopausal and locally advanced or metastatic breast cancer patients who had received or had not received prior systemic therapy.
62120063|NCT05311137||Closed-loop Group|Groups of Patients Adhering to Closed-Loop Therapy.
62120064|NCT05311137||No Closed-loop Group|Patients who have not undergone closed-loop treatment or patients who have not undergone standard surgery and medication.
62120065|NCT05311137||Exchange Group|Groups of patients with delayed compliance with closed-loop therapy for atrial fibrillation.
62120066|NCT05814211|EXPERIMENTAL|Investigational device - newly developed intermittent catheter|"Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (CH12 and CH14) for urinary drainage. The investigational device is for single use.~Randomization will decide the order of investigational device/comparator device and which of the two comparator devices the subject will receive in the comparator study period."
62120067|NCT05814211|ACTIVE_COMPARATOR|Comparator device (#1 OR #2)|"SpeediCath Eve or SpeediCath Compact Plus Female (CH12 and CH14). Both comparators are CE marked Coloplast products.~Randomization will decide the order of investigational device/comparator device and which of the two comparator devices the subject will receive in the comparator study period."
62120068|NCT01464736|EXPERIMENTAL|Physical Training Group|This group performed aerobic physical training in treadmill.
62120069|NCT01464736|EXPERIMENTAL|NIV Trained|"This group performed aerobic physical training associated with ventilation in the bilevel modality (BiPAP®), using a nasal mask as an interface.~On evaluation day, the levels of inspiratory positive airway pressure (IPAP) (between 10 and 15cmH2O) and expiratory positive airway pressure (EPAP) (between 4 and 6cmH2O) were defined, varying according to the comfort level of each patient."
62120070|NCT06478238|EXPERIMENTAL|calcium folinate treatment group|"Drug: calcium folinate Phase I: calcium folinate infusion intravenously for 5 consecutive days at a dose of 1mg/kg/day in two divided doses per day. Then it was changed to oral administration at a dose of 2mg/kg/day during hospitalization.~Phase II: long-term oral medication at a dose of 2mg/ kg/day in two daily doses."
62120071|NCT05926596|EXPERIMENTAL|Robotic Exoskeleton|All participants will be interfered with a wearable robotic exoskeleton.
62120072|NCT04077151|EXPERIMENTAL|Intervention Recipients|PrEP Demonstration Project intervention will be given
62120073|NCT02320123|EXPERIMENTAL|Patients - intervention|For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
62120074|NCT02320123|NO_INTERVENTION|Patients - Control|Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
62120075|NCT01029717|EXPERIMENTAL|Standard polyurethane Central Venous Catheter|"Standard polyurethane Central Venous Catheter~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
62120076|NCT01029717|ACTIVE_COMPARATOR|Antibiotic impregnated polyurethane CVC|"Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
62678238|NCT06691516|ACTIVE_COMPARATOR|free hand cortical shell technique in anterior 3d defect|in control group, the bone harvesting and shells fixation will done with free hand technique
62678239|NCT04980872|EXPERIMENTAL|Miransertib|Participants with either PROS or PS receive miransertib orally once daily between 5 and 35 mg/m\^2 based on prior approved dosing for up to 48 cycles. A cycle is 28 days long.
62678240|NCT03334305|EXPERIMENTAL|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
62678241|NCT03334305|EXPERIMENTAL|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
62678242|NCT04720833|EXPERIMENTAL|dried plum (100 g dried plum)|Participants will receive 100 g dried plum daily plus 500 mg calcium and 300 IU vitamin D daily
62678243|NCT04720833|PLACEBO_COMPARATOR|Calcium and vitamin D|Participants will receive 500 mg calcium and 300 IU vitamin D daily
62678244|NCT01433081|ACTIVE_COMPARATOR|Magnesium sulfate infusion|Administration of magnesium suflate
62678245|NCT01433081|PLACEBO_COMPARATOR|Placebo|.9 normal saline infusion
62678246|NCT02142829|ACTIVE_COMPARATOR|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
62678247|NCT02142829|ACTIVE_COMPARATOR|On-Q Pain Ball|Device for delivering bupivacaine.
62678248|NCT01835431|EXPERIMENTAL|Insulin degludec/insulin aspart|
62678249|NCT01835431|ACTIVE_COMPARATOR|Insulin detemir|
61919465|NCT01676597|EXPERIMENTAL|rifaximin and pentoxifylline|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
61919466|NCT01676597|ACTIVE_COMPARATOR|pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
62120077|NCT01029717|ACTIVE_COMPARATOR|Heparin bonded polyurethane CVC|"Heparin bonded polyurethane CVC~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
62678250|NCT06338670|EXPERIMENTAL|Cochlear™ Osia® System|Participants will receive the Osia 3 and Osia® 2 sound processors. They will then complete a series of assessments designed to evaluate the clinical performance of these two sound processors. These assessments will take place across four study visits.
62678251|NCT04852601|EXPERIMENTAL|ToolboxDetect Strategy|"All practices randomized to the intervention arm will implement the ToolboxDetect battery as the standard of care routine cognitive assessment to fulfill the Medicare Annual Wellness Visit (AWV) requirement. The 7-8 minute ToolboxDetect battery contains self-administered versions of the NIH ToolBox Picture Sequence Memory Test (PSM) and the NIH ToolBox Dimensional Change Card Sorting (DCCS). PSM measures episodic memory and DCCS tests executive functioning.~The validated ToolboxDetect application will be imparted either as an application on an iPad or on a PC desktop/laptop computer commonly found in a clinical exam room for EHR access."
62736350|NCT02469701|EXPERIMENTAL|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.~Either cryoablation or thermal ablation may be performed as per standard institutional policies.~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
62678252|NCT04852601|NO_INTERVENTION|Enhanced Usual Care|"At Northwestern Medicine, cognitive assessments included in Annual Wellness Visits or other routine or sick/problem-based visits vary by practice and also by clinician. However, the choice of test was limited to either a Mini-Cog©, Montreal Cognitive Assessment (MoCA), or Mini Mental Status Exam (MMSE).~While we will not make any explicit recommendations to these practices with regard to their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to an Epic SmartData element, which will allow the clinician to record the results of the test as discrete data (which can then be queried), and that 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will also be provided to each clinic's medical leadership."
62678253|NCT04065854|NO_INTERVENTION|Control|The control group will receive standard brief falls assessment and advice.
62678254|NCT04065854|ACTIVE_COMPARATOR|Intervention|Therapy intervention.
62678255|NCT03935048|EXPERIMENTAL|Higher Protein, Low Glycemic Load with Potatoes|Higher Protein, Low Glycemic Load with Potatoes (HPLG-P): low- to moderate- glycemic load meals containing white potatoes. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
62678256|NCT03935048|ACTIVE_COMPARATOR|Higher Protein, Low Glycemic Load with Processed Potatoes|Higher Protein, Low Glycemic Load with Processed Potatoes (HPLG-PP): low- to moderate- glycemic load meals containing processed white potato products. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
62678257|NCT03935048|PLACEBO_COMPARATOR|Higher Protein, Low Glycemic Load - Control|Higher Protein, Low Glycemic Load (HPLG-C): low- to moderate- glycemic load meals containing control carbohydrate (e.g. rice, pasta). Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing control carbohydrate sources.
62678258|NCT06695364|OTHER|anket|Not all classes were included in the study
62678259|NCT04902066|EXPERIMENTAL|Cognitive Behavioural Virtual Reality Therapy (CBT-VR)|The CBT-VR consists of traditional CBT with the augmentation of virtual reality exposure. The virtual reality exposure comprises four virtual social environments (a bus, café, street, and supermarket). These are daily social situations that generally elicit paranoid thinking in patients with a schizophrenia spectrum disorder. While virtually engaging in these distressing situations, the therapist will facilitate a CBT dialogue aimed at generating alternative (i.e. non-threatening) thinking, diminishing safety behaviours (e.g. social isolation), and building up new coping strategies. This is expected to alleviate distress, anxiety, and improve daily social functioning. Preliminary findings reveal this virtual reality program to be well-tolerated and highly effective in reducing paranoia and anxiety in psychosis. Patients will be offered 10 individual sessions.
62678260|NCT04902066|ACTIVE_COMPARATOR|Traditional Cognitive Behavioural Therapy|The treatment in the CBT group will follow the core principles of CBT used for psychotic disorders. The CBT treatment facilitates an individualised, problem-oriented approach, and uses key CBT techniques such as developing a problem and goal list, normalising psychotic-like experiences, evaluation of appraisals, and removing or diminishing safety behaviour. Patients will be offered 10 individual sessions.
62678261|NCT01044693|PLACEBO_COMPARATOR|Placebo capsule|Placebo capsule
62678262|NCT01044693|EXPERIMENTAL|Nebivolol 5 mg|Nebivolol 5 mg capsule
62119417|NCT04169399|EXPERIMENTAL|Toripalimab plus SBRT|Participants received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Participants recevied Stereotactic body radiotherapy. Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
62119418|NCT02491554|ACTIVE_COMPARATOR|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based DBS implantation in the thalamic/subthalamic region (Vim-cZI) starting as awake surgery with a brief general anesthesia for stimulator implantation at the end of surgery.
62119419|NCT02491554|EXPERIMENTAL|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided DBS implantation in the dentato-rubro-thalamic bundle (DRT) in general anesthesia.
62678263|NCT01044693|ACTIVE_COMPARATOR|Metoprolol tartrate 50 mg|Metoprolol tartrate 50 mg single oral dose
61920008|NCT02002585|NO_INTERVENTION|optimal medical therapy alone|Group of patients who will be treated only with optimal medical therapy and will not be denervated. Subsequently, the patients will be followed in our cardiology and nephrology department according to the study flowchart for 3 years according to the standard of care in our institution for patients with chronic renal insufficiency.
61920009|NCT05158647|PLACEBO_COMPARATOR|control group|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
62119420|NCT01021410||Acetaminophen Group|Subjects who completed COMIRB 06-1265 and were assigned to the acetaminophen treatment group for that study.
62119421|NCT02512965|ACTIVE_COMPARATOR|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
62119422|NCT02512965|EXPERIMENTAL|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
62119423|NCT06259058|EXPERIMENTAL|NALIRIFOX + SBRT + NALIRIFOX + Surgery + NALIRIFOX|Patients receive 3 cycles of NALIRIFOX followed by SBRT (30Gy/5Fx). Then undergo surgery and receive 6 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV.
62307411|NCT05784792|ACTIVE_COMPARATOR|Lugol +|Pre-operative Lugol preparation (10 drops per day orally three times a day for 7 days for an amount of 10,5 ml of Lugol solution that contains 1,68 gr of Iodine).
62307412|NCT05191082|SHAM_COMPARATOR|Control Group (CG)|The palatal wound area will not receive any treatment
62678264|NCT01044693|ACTIVE_COMPARATOR|Sildenafil 25 mg|Sildenafil 25 mg single oral dose
62678265|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
62678266|NCT04253171|ACTIVE_COMPARATOR|Lithoplasty lesion preparation|Balloon lithoplasty will be used as lesion preparation.
62678267|NCT04253171|ACTIVE_COMPARATOR|Conventional lesion preparation|Conventional and modified balloons will be used as lesion preparation.
62307413|NCT05191082|EXPERIMENTAL|Silk Fibroin Film - SF|The palatal wound area will receive silk fibroin film as a dressing
62678268|NCT06413134|PLACEBO_COMPARATOR|6-weeks breathing on APAP|Patients will breathe on APAP for 6 weeks simulating normal therapy. Usage, leak, P95/P90 and AHI will be recorded and averaged over the duration.
62678269|NCT06413134|EXPERIMENTAL|6-weeks breathing on TheraPAP|Patients will breathe on TheraPAP for 6 weeks, which is the therapy under evaluation. Usage, leak, P95/P90 and AHI will also be recorded and averaged over the duration.
62678270|NCT04635982|PLACEBO_COMPARATOR|Placebo Group|With regard to the Kinesiotape technique, 2 I-shaped tapes were placed at the quadriceps, following the same direction of the muscle fibres and with no tension. At the gluteus, 2 I-shaped tapes were applied following the same direction of the muscle fibres and with no tension.
62678271|NCT04635982|EXPERIMENTAL|Experimental Group|In rectus femoris, origin was under the anterosuperior iliac spines, and taping finished with a Y-shape pattern under the patella. After that, an I-shaped KT was applied over vastus medialis and vastus lateralis muscles in both quadriceps. Finally, subjects were taped with a Y-shaped KT at the gluteus maximus muscles. Tape tension was between 25% and 50%.
62678272|NCT04635982|NO_INTERVENTION|Control Group|It has not done any intervention in this group.
62678273|NCT05730660|EXPERIMENTAL|Intervention group|
62678274|NCT05730660|PLACEBO_COMPARATOR|Placebo group|
62119424|NCT06259058|ACTIVE_COMPARATOR|NALIRIFOX + Surgery + NALIRIFOX|Patients receive 6 cycles of NALIRIFOX. Then undergo surgery and receive 6 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV.
62119425|NCT05745376|EXPERIMENTAL|Intervention Center|The intervention will include: (1) assisting ECEs with conducting self-assessments; (2) connecting ECEs with local farmers and food producers; (3) providing technical assistance for menu changes, procuring healthy food, identifying and implementing best feeding practices and policies for the environment; (4) delivering nutrition education; and (5) connecting parents/guardians with local food resources and affordable fresh food to be consumed at home
62119426|NCT05745376|NO_INTERVENTION|Comparison|No programming at center, only surveys
62307414|NCT05191082|EXPERIMENTAL|Neurotensin-loaded Silk Fibroin Film - SF + NT|The palatal wound area will receive a neurotensin-loaded silk fibroin film as a drug delivery system
62474844|NCT01375920|ACTIVE_COMPARATOR|Metyrapone, daily medication|500 milligrams Metyrapone to be taken orally twice daily for 3 weeks.
62474845|NCT01375920|PLACEBO_COMPARATOR|placebo|a matched placebo will be given for patients to take twice daily
62119427|NCT00533013|ACTIVE_COMPARATOR|Usual care|Management of heart failure is provided by primary practitioners and consultant cardiologists
62678275|NCT02504385|EXPERIMENTAL|Virtual Reality Timocco|The study group will integrate the use of Timocco in occupational therapy sessions. The session will begin with 15 minutes of spatial activity involving sensory-motor practice, 15 minutes of activity in a virtual environment, and 15 minutes of structured activity at a desk.
62678276|NCT02504385|ACTIVE_COMPARATOR|Conventional OT intervention|The control group will be given conventional occupational therapy without using Timocco. In order to ensure that the therapy sessions in this group have a structure similar to that one used in the study group, each session will include 25 to 30 minutes of spatial sensory-motor activity, followed by 15 to 20 minutes of structured practice at a desk.
62678277|NCT06284252|NO_INTERVENTION|Control group|This is the group that takes theoretical lessons and does not play virtual games. Students will receive physical examination training and participate in laboratory practices. Pre-test and post-test skill evaluation will be made.
62678278|NCT06284252|EXPERIMENTAL|Initiative group|Students will participate in theoretical training and laboratory practice. Students will play three different virtual game simulations. Students will participate in pre-test and post-test skill practice.
62678279|NCT04880590||Sex Intercourse|women with a heterosexual sexual relationship after embryo transfer
62678280|NCT04880590||Non sex intercourse|women without a heterosexual sexual relationship after embryo transfer
62678281|NCT06578195||Symptomatic ALS on-site participants|Symptomatic ALS Participants who are completing on-site visits at one of the 35 participating ALL ALS sites.
62678282|NCT06578195||Symptomatic ALS off-site (remote) participants|Symptomatic ALS Participants who are completing visits study visits remotely through video-conferencing. Home Phlebotomy is being used to collect blood from these participants.
62678283|NCT06578195||Control participants|Control participants who do not have a diagnosis of ALS , Progressive Muscular Atrophy (PMA) or Primary Lateral Sclerosis (PLS). These participants complete on-site visits.
62119428|NCT00533013|EXPERIMENTAL|Disease Management|Disease management led by nurse specialists in regional Heart Failure Clinics and a national Call Center. Tele-Monitoring of body weight, pulse rate and blood pressure is performed at participants' homes.
62119429|NCT03529396|EXPERIMENTAL|1a: Chloroquine + 5th-day Primaquine|\[ARM HALTED PREMATURELY DUE TO SAFETY CONCERNS\]
62474846|NCT05841628|EXPERIMENTAL|Port wine stain|The port wine stain will be treated with the DermaV laser. Within the single port wine stain, one area will be treated with standard settings (single pulse high fluence). Four other areas will be treated with multi-pulse low fluence settings. A sixth area will be an untreated control.
62474847|NCT01450592||Group 1|
62678284|NCT06635889|EXPERIMENTAL|50 ml of 0.25% bupivacaine|
62678285|NCT06635889|PLACEBO_COMPARATOR|placebo of 50 ml of Normal Saline|
62678286|NCT00580203||1|Patients with head and neck cancers
62678287|NCT06694350|EXPERIMENTAL|Pembrolizumab+Flutamide|Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
62119430|NCT03529396|EXPERIMENTAL|1b: Chloroquine + 8-week Primaquine|26 G6PD deficient patients. Directly observed therapy.
62119431|NCT03529396|ACTIVE_COMPARATOR|1c: Chloroquine + 12-week Chloroquine|26 G6PD deficient patients. Control group in terms of safety. Directly observed therapy.
62474848|NCT01450592||Group 2|
62474849|NCT02603055|EXPERIMENTAL|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
62474850|NCT02603055|ACTIVE_COMPARATOR|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co., Ltd. three doses, 30μg/0.5ml per dose
62474851|NCT04533594|EXPERIMENTAL|NOVELA|Hospice family caregivers will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the video (3-6 mins) over the course of 4 hospice telehealth visits.
62678288|NCT01144351|EXPERIMENTAL|ELND002|ELND002 sc injection
62678289|NCT01144351|PLACEBO_COMPARATOR|Placebo|placebo injection
62119432|NCT03529396|ACTIVE_COMPARATOR|2: Standard chloroquine + primaquine|52 G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.
62678290|NCT04880356||Retrospective study|collection of retrospective data from adult patients with ultra-rare inherited neurological diseases
62678291|NCT04880356||Prospective study|prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years
62678292|NCT00829478|PLACEBO_COMPARATOR|1|Usual Care
62678293|NCT00829478|EXPERIMENTAL|2|Intervention
62678294|NCT04739345|ACTIVE_COMPARATOR|Group 1|Non-severe patients should meet all following conditions: (1) Epidemiology history, (2) Fever or other respiratory symptoms, (3) Typical CT image abnormities of viral pneumonia, and (4) Positive result of RT-PCR for SARS-CoV-2 RNA.
62678295|NCT04739345|PLACEBO_COMPARATOR|Group 2|Severe patients should meet at least one of the following conditions: (1) Shortness of breath, RR ≥ 30 times/min, (2) Oxygen saturation (Resting state) ≤ 93%, (3) PaO2/FiO2 ≤ 300 mmHg.
61920010|NCT05158647|ACTIVE_COMPARATOR|MgSo4 group|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used.
61920011|NCT04622631||PRRT positive|patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans
62120078|NCT03546907|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to SAR440340 administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W). Participants were treated for a minimum of 24 weeks and up to a maximum of 52 weeks (last dose administered at Week 50, End of Treatment (EOT) visit occurred 2 weeks after last administration of IMP i.e., at Week 52).
62120079|NCT03546907|EXPERIMENTAL|SAR440340|Participants received SAR440340 300 milligrams (mg) administered as 2 SC injections Q2W. Participants were treated for a minimum of 24 weeks and up to a maximum of 52 weeks (last dose administered at Week 50, EOT visit occurred 2 weeks after last administration of IMP i.e., at Week 52).
62120080|NCT05568264|EXPERIMENTAL|Physical Therapy Intervention|Infants enrolled in this arm will receive the intervention in addition to standard of care
62474852|NCT00545506|ACTIVE_COMPARATOR|conventional bandage|conventional bandage on sternal wound after skin closure after cardiac surgery. conventional gauze covered with elastic adhesive (Medipore™ Dress-it) The designated bandage will be positioned in the operating room by the surgeons after the skin will be closed. The conventional elastic bandage consists of several layers of gauze covered with a special adhesive bandage
62678296|NCT04410133|EXPERIMENTAL|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
62678297|NCT03586453|EXPERIMENTAL|Osimertinib|Osimertinib: Oral, once a day, dosage determined per protocol
62678298|NCT03540485|EXPERIMENTAL|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
62678299|NCT03540485|PLACEBO_COMPARATOR|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
62678300|NCT02402231|EXPERIMENTAL|Omalizumab|Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.
62678301|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
62678302|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
62120081|NCT05568264|NO_INTERVENTION|Standard of Care|Infants enrolled in this arm will receive standard of care
62678303|NCT02297035|EXPERIMENTAL|PPA patients|Experimental (Patients responding to current diagnostic criteria for Primary Progressive Aphasia (PPA) patients) : Behavioural testing, Brain imaging (MRI, PET), Genetic screening (APOE, Progranulin)
62678304|NCT02297035|EXPERIMENTAL|healthy controls|Healthy controls : Behavioural testing, Brain imaging (MRI, PET).
62678305|NCT02262273||Serous ovarian cancer:|Women with platinum-sensitive recurrent serous ovarian cancer
62678306|NCT00159874|EXPERIMENTAL|Sildenafil high dose|As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
62678307|NCT00159874|EXPERIMENTAL|Sildenafil Low dose|
62307415|NCT04422587||RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
62474853|NCT00545506|ACTIVE_COMPARATOR|warming bandage|The Warm-Up bandage consists of an adhesive shell and a foam frame that supports a clear window about one cm above the surface of the wound. A battery-powered heating card can then be inserted into the window to provide gentle warming of the wound. The surface temperature of heating card is fixed at 38°C, and heat is usually provided for two hours at a time. That is, the experimental bandage will be continuously applied to the wound and heated to 38°C using a two-hour on/off cycle.
62678308|NCT00159874|EXPERIMENTAL|Sildenafil medium dose|As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
62678309|NCT02129010||Subarachnoid hemorrhage with and without Terson syndrome|Patients with aneurysmatic subarachnoid hemorrhage with and without Terson syndrome
62678310|NCT01410487||Obese group|
62678311|NCT04745806|EXPERIMENTAL|ActiGraft|Whole blood clot (WBC) gel
62678312|NCT05991466|ACTIVE_COMPARATOR|Group(A)|Spinal anaesthesia will be performed with 0.5% hyperbaric bupivacaine 10-12 mg and TAP block will be performed with 30 ml 0.25% bupivacaine in each side.
61920012|NCT04622631||PRRT negative|no response to PRRT treatment
62120082|NCT02033018|EXPERIMENTAL|Aflibercept injection|Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection
62120083|NCT04847219|PLACEBO_COMPARATOR|Professional flash glucose mornitoring|Professional flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via capillary blood glucose tests, but nor FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
62678313|NCT05991466|ACTIVE_COMPARATOR|Group (B)|Spinal anaesthesia will be performed with 0.5% hyperbaric bupivacaine10-12 mg and TAP block will be performed with 50 mcg Dexmedetomidine added to 30ml 0.25% bupivacaine in each side.
62678314|NCT05991466|ACTIVE_COMPARATOR|Group (C)|Spinal anaesthesia will be performed with 0.5% hyperbaric bupivacaine 10-12 mg added to 5 mcg dexmedetomidine. TAP block will be performed with 30ml 0.25% bupivacaine in each side.
62474854|NCT02670772|ACTIVE_COMPARATOR|Stavudine|Stavudine 20mg twice daily for 96 weeks
62474855|NCT02670772|ACTIVE_COMPARATOR|Tenofovir Disoproxil Fumarate|Tenofovir 300mg once daily for 96 weeks
62474856|NCT02221921|EXPERIMENTAL|MicroPort's Transcatheter Aortic Valve and Delivery System|single arm with intervention that percutaneous implantation of the MicroPort's Transcatheter Aortic Valve and Delivery System
62474857|NCT01521533|EXPERIMENTAL|NOX-A12|
62474858|NCT03081481|EXPERIMENTAL|PRX302|intraprostatic administration
62474859|NCT04383574|EXPERIMENTAL|Experimental Vaccine-medium dosage|24 participants in medium-dosage group in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants in medium-dosage group in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 ,1 dose of booster immunization 6 months after primary immunization(the third dose ) and the second booster dose (the fourth dose) 1 year after the second dose.
62119433|NCT04631003|OTHER|Dynamic testing|"There are only one arm in this study. All patients get the same diagnostics and therapy. The preoperative assessments consist of an arthroCT of the wrist as well as the collection of demographic data, accident mechanism, medication intake, etc. within the scope of the usual medical history on the emergency ward. With the arthro-CT, in addition to the fracture balance, the proof of a possible rupture of the scapholunary tape apparatus takes place.~The dynamic determination of the scapholunary instability takes place during the osteosynthesis of the radius fracture.~With the dynamic functional test, the change of the scapholunary distance is assessed by illumination by movement of the wrist from the radial abduction into the ulnar abduction, before and after the execution of the osteosynthesis of the distal radius fracture.~Subsequently, the results of the scapholunary dissociation of the arthro-CT are checked with the results of the intraoperative dynamic test for correlation."
62119434|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters \>/= 12 mm, treated with mechano-chemical ablation (MOCA)
62307416|NCT05568745|EXPERIMENTAL|Balloon+oxytocin|Mecanical cervical ripening will be done by transcervical balloon (Teleflex French Dufour catheter CH20 reference 174000). Oxytocin will be started 6 hours after balloon insertion. At H12 balloon will be removed and induction continued by oxytocin alone.
62307417|NCT05568745|ACTIVE_COMPARATOR|Oral misoprostol|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations. (Oxytocin can be started at least 4 hours after the last misoprostol administration if patient remains not in labour.)
62307418|NCT04562337|EXPERIMENTAL|SHR1316+Chemotherapy +Radiotherapy|Paiticipant receive SHR-1316 、Chemotherapy and Radiotherapy
62307419|NCT02628730|ACTIVE_COMPARATOR|Ablation Index Group|PVI using radiofrequency ablation (RFA) guided by Ablation Index.
62307420|NCT02628730|OTHER|Reference Group (Contact Force Group)|That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
62307421|NCT05249595|EXPERIMENTAL|Group A - Particiapnts without neurological disorders|Individuals without neurological disorders will be recruited (Group A).
62307422|NCT05249595|EXPERIMENTAL|Group S - Participants with iSCI or transverse myelitis|Individuals with neurological disorders, like iSCI or transverse myelitis, will be recruited (Group S). These individuals usually have weakened ankle joint functionalities but can walk independently.
62307423|NCT03513380|EXPERIMENTAL|Exergaming|free access to the exergame PedalTanks
62307424|NCT03513380|NO_INTERVENTION|Control|recommended to continue with their normal daily routine
62474860|NCT04383574|EXPERIMENTAL|Experimental Vaccine-high dosage|24 participants in high-dosage group in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants in high-dosage group in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 ,1 dose of booster immunization 6 months after primary immunization(the third dose) and the second booster dose (fourth dose) 1 year after the second dose .
62474861|NCT04383574|PLACEBO_COMPARATOR|Placebo|24 participants including 12 at medium dosage stage and 12 at high dosage in phase Ⅰ will receive two doses of placebo according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 50 participants in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
62474862|NCT04383574|EXPERIMENTAL|Experimental Vaccine-low dosage|100 participants at low dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
62474863|NCT03296722|NO_INTERVENTION|Control group|The control group comprised 41 patients, which was to go once a month to receive nutritional intervention with the prescription of a hypocaloric diet on the part of the nutritionist. The control group had a monthly monitoring for 3 months.
62736351|NCT01268592|EXPERIMENTAL|positive cancer diagnosis|female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
62119435|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
62307425|NCT03607682|EXPERIMENTAL|Prevention (TTF therapy, NovoTTF-200A device)|
62307426|NCT02273973|PLACEBO_COMPARATOR|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
62307427|NCT02273973|EXPERIMENTAL|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
62307428|NCT01843556|EXPERIMENTAL|E2022 Tape Formulation|
62307429|NCT05246410|EXPERIMENTAL|Spot stent system|A system that loaded multi low radial force stents on one catheter.
62307430|NCT05246410|ACTIVE_COMPARATOR|Self-Expanding peripheral stent system|A conventional stent system that commonly used.
62307431|NCT03040050|OTHER|Men scheduled for prostate biopsy randomized to Control|
62119436|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
62307432|NCT03040050|EXPERIMENTAL|Men scheduled for a prostate biopsy randomized to Intervention|
62119437|NCT05263037|EXPERIMENTAL|56-day skills-based VR program|participants in the EaseVRx-8w arm will participate in an 8-week interventional program and continue to be followed for 24 months following completion of tx
62119438|NCT05263037|EXPERIMENTAL|56-day skills-based VR program followed by an extended 56-day on-demand period|participants in the EaseVRx-8w plus extended on-demand arm will enroll in an 8-week interventional program and be offered an extended 8-week ondemand period, and continue to be followed for 24 months after the completion of treatment
62307433|NCT04230577|ACTIVE_COMPARATOR|Real LED Intervention|Participants receive 15 Real (active) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal). Parameters: NIR, 810nm, pulsed at 10 Hz, 50% duty cycle, synchronized for a 20-minute treatment time. Total Energy Dose per head set plus intranasal: 225 J/cm2+ 15 J/cm2 = 240 J/cm2 per 20 min LED treatment. Total Energy Dose delivered (3x/Week, 5 Weeks) = 3600 J/cm2. The light from these LEDs is not visible to the eye. There is no potential for eye damage because the LEDs are not laser light. The head frame device falls within the FDA category General Wellness, low-risk devices, and no medical claims are made. It is approved for use by the VA Boston Healthcare System Safety Committee and Institutional Review Board.
62307434|NCT04230577|SHAM_COMPARATOR|Sham LED Intervention|Participants receive a series of 15 Sham (control) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal) containing Sham LEDs, synchronized for a 20-minute treatment time (3x/Week, 5 Weeks). Sham and Real devices are identical in look and feel, except no photons are emitted from the Sham devices.
62678315|NCT01033370|OTHER|Open label, non-randomized, pilot study|All subjects who provide consent for trial participation with an acute aortic emergency and elevated BP (systolic blood pressure \[SBP\] ≥120 mm Hg) requiring IV antihypertensive therapy for up to 48 hours will be administered an infusion of clevidipine to evaluate the efficacy and safety of the IV drug.
62119439|NCT05263037|SHAM_COMPARATOR|56-day control (Sham VR)|participants in the first control arm will receive 2D Sham VR virtual reality content during the 8-week interventional program and continue to be followed for 24 months after the completion of treatment. participants in the Sham VR group will receive the same Pico G2 4K headset as participants in the immersive VR groups, but rather than view 360-degree, 3D, interactive content specially selected for efficacy, they will only have access to 2D nature footage with neutral music layered on top that is selected to be neither overly relaxing nor distracting. The experience of Sham VR is similar to watching a large-screen TV, but it is not interactive. The advantage of Sham VR is that it controls for the novelty and immersion of the hardware and isolates the effect of VR skill-based training
61920013|NCT02900001|ACTIVE_COMPARATOR|Early invasive strategy|Patients undergo coronary angiography within 24 hours after admission and have percutaneous coronary intervention or coronary artery bypass grafting as soon as possible during the index hospitalization if appropriate.
61920014|NCT02900001|EXPERIMENTAL|Deferred invasive strategy|Patients undergo coronary angiography and appropriate revascularization after at lest 72 hours from admission in the index hospitalization.
62119440|NCT05263037|SHAM_COMPARATOR|• 56-day control (Sham VR plus 8w extended on-demand)|participants in the second control arm will receive 2D Sham VR virtual reality content during the 8-week interventional program and be offered an extended 8-week on-demand period, after which they will continue to be followed for 24 months after the completion of treatment.Participants in the Sham VR group will receive the same Pico G2 4K headset as participants in the immersive VR groups, but rather than view 360-degree, 3D, interactive content specially selected for efficacy, they will only have access to 2D nature footage with neutral music layered on top that is selected to be neither overly relaxing nor distracting.
62307435|NCT02799940||Computed tomography in acute respiratory distress syndrome|The lung on computed tomography (CT) in patients with acute respiratory distress syndrome (ARDS) has revealed a heterogeneous pattern of lung injury, with areas of normal lung interspersed with altered regions: ground-glass opacification and consolidation among the most frequent. It has been performed quantitative assessments of ARDS by means of CT, thus enabling a correlation of such pathologic details with physiologic, clinical parameters and with patient outcomes. Therefore, the primary objective of the study is to determine the correlation between the extent of oxygenation (PaO2/FiO2) and the degree of consolidation (total CO) in the CT. The secondary objectives are to determine: the correlation between the driving pressure, ventilator variables and the total CO; the independent variables associated with total CO; differences in the CT with respect to the total lung-disease score (total CO plus total value of ground-glass opacification) between survivors and nonsurvivors.
62119441|NCT00922220|ACTIVE_COMPARATOR|stationary bike|Participants rode a stationary bike for five minutes
62307436|NCT05518786||HUCA|Patients recruited at the University Central Hospital of Oviedo
62307437|NCT05518786||Taulí|Patients recruited at Parc Taulí Foundation/Hospital (Sabadell)
62307438|NCT05518786||Paz|Patients recruited at University Hospital of La Paz (Madrid)
62474864|NCT03296722|EXPERIMENTAL|Intervention group|The intervention group made up of 42 patients using the transtheoretical model and MI through sessions group and sessions individual with topics of healthy eating habits taught by a nutritionist, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy and confrontation of barriers given by a psychologist. The intervention group had a monthly monitoring for 3 months. The diet that was prescribed to the intervention group was with the characteristics of the DASH diet.
62474865|NCT04643067|ACTIVE_COMPARATOR|KPG-818 low dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
62307439|NCT03941548|EXPERIMENTAL|CTP-543 12 mg BID|Participants received 1 x 12 milligrams (mg) CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.
62307440|NCT03941548|EXPERIMENTAL|CTP-543 24 mg QD|Participants received 24 mg (2 x 12 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.
62307441|NCT03477188|EXPERIMENTAL|Somatosensorial and Vestibular Exercises Group|This group of patients received patients with acute stroke. It will be applied somatosensorial and vestibular rehabilitation additional conventional therapy
62307442|NCT03477188|ACTIVE_COMPARATOR|Conventional Group|This Group patients received patient with acute stroke. It will be applied classical physiotherapy and conventional exercises.
62307443|NCT02648230|EXPERIMENTAL|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
62678316|NCT03173508|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
62307444|NCT02521350||Control|- older than 40 years patients with no specific gender, who will stay at least one night in hospital will be included into our study. And cardiovascular, urological surgery patients and patients with known renal insufficiency will be excluded.
62307445|NCT01343615|ACTIVE_COMPARATOR|carotid stenting|
61919467|NCT00323869|EXPERIMENTAL|Bevacizumab + carboplatin + gemcitabine|"Bevacizumab in combination with carboplatin and gemcitabine:~•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.~Carboplatin was administered before the gemcitabine infusion:~•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles~Bevacizumab was administered 1 hour after end of all chemotherapy infusions:~•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity"
61919468|NCT00453388|EXPERIMENTAL|Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
61919469|NCT00453388|EXPERIMENTAL|Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
62474866|NCT04643067|ACTIVE_COMPARATOR|KPG-818 mid dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
61919470|NCT00453388|EXPERIMENTAL|Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
61919471|NCT00453388|EXPERIMENTAL|Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
61919472|NCT02468011|EXPERIMENTAL|Vibration|Whole body vibration with 35 Hz
62678317|NCT03173508|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
61919473|NCT06312969|EXPERIMENTAL|Intervention group with video game-based training|"Cognitive training through 3 types of video games:~* Serious games or brain-training games.~* Exer-gaming~* Skill-training games Method of administration~The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern:~* Brain-training game: sessions of 7-12 minutes with a frequency of 4 days a week.~* Exer-gaming: sessions of 15-20 minutes 2 days a week.~* Skill-training games: sessions of 15-20 minutes 2 days a week."
61919474|NCT06312969|NO_INTERVENTION|Waiting group (no training)|Patients in waiting group will not receive treatment whilst the 3 month period.
61919475|NCT01101191|EXPERIMENTAL|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
61919476|NCT01101191|ACTIVE_COMPARATOR|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
61919477|NCT03477929|EXPERIMENTAL|ganirelix|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
61919478|NCT03477929|EXPERIMENTAL|cetrorelix|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
61919479|NCT00579007||1|Women with a strong family history of breast cancer.
61919480|NCT01186497|EXPERIMENTAL|Treatment sequence AEBDC|
61919481|NCT01186497|EXPERIMENTAL|Treatment sequence BACED|
61919482|NCT01186497|EXPERIMENTAL|Treatment sequence CBDAE|
61919483|NCT01186497|EXPERIMENTAL|Treatment sequence DCEBA|
61919484|NCT01186497|EXPERIMENTAL|Treatment sequence EDACB|
61919485|NCT01685346|EXPERIMENTAL|Biofeedback|biofeedback-mediated stress management (BFSM)
62119442|NCT00922220|ACTIVE_COMPARATOR|lumbar extension exercises|Participants performed four sets of fifteen lumbar extension exercises over five minutes
62119443|NCT00922220|EXPERIMENTAL|spinal manipulative therapy|Participants received spinal manipulative therapy to the low back
62119444|NCT03347942|EXPERIMENTAL|Intervention|During a period of 30 days the research participant in the intervention group will be instructed to wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before being served again if he or she feels the need.
62119445|NCT03347942|OTHER|Control|The control group will also serve the dish the same way, but you can serve additional portion without waiting.
62119446|NCT02383108|ACTIVE_COMPARATOR|Standard of Care group (SOC)|triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
62119447|NCT02383108|EXPERIMENTAL|DTG+DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
62119448|NCT01371968|EXPERIMENTAL|alfentanil|patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
62119449|NCT02425449|EXPERIMENTAL|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
62119450|NCT02425449|EXPERIMENTAL|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
62119451|NCT02425449|EXPERIMENTAL|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
62119452|NCT02425449|EXPERIMENTAL|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
62119453|NCT02425449|EXPERIMENTAL|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
62119454|NCT03350542|EXPERIMENTAL|SYNERGY 48 mm|SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
62119455|NCT03396692|ACTIVE_COMPARATOR|Control Arm|Pain management use intravenous morphine patient-controlled analgesia (PCA)
62119456|NCT03396692|EXPERIMENTAL|Posterior exo-thoracic fascia block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine
62119457|NCT03396692|EXPERIMENTAL|Paravertebral block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine
62119458|NCT04466904|EXPERIMENTAL|IBI362 low dose cohort|Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.
62119459|NCT04466904|EXPERIMENTAL|IBI362 medium dose cohort|Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
62119460|NCT04466904|EXPERIMENTAL|IBI362 high dose cohort|Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
62678318|NCT05467150|EXPERIMENTAL|Probiotic Supplement|Participants (mothers) randomized to this arm will take one Culturelle® Digestive Daily Probiotic Capsule per day from study enrollment through the first postpartum month. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG
62119461|NCT06360744|OTHER|Vaccine Johnson and Johnson/Janssen Covid-19 vaccine|Johnson \& Johnson/Janssen Covid-19 vaccine.
62119462|NCT06374199|ACTIVE_COMPARATOR|Nuts and Extra Virgin Olive Oil|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil (EVOO) and nuts
62119463|NCT06374199|EXPERIMENTAL|Nuts, Extra Virgin Olive Oil, and Medically Tailored Meals|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil (EVOO), nuts, and medically tailored meals
62307446|NCT01343615|ACTIVE_COMPARATOR|carotid endarterectomy|
61919486|NCT05546801|EXPERIMENTAL|questionnaire|Questionnaire on postnatal development
61919487|NCT04571515|EXPERIMENTAL|MR-107A-01 15 mg once in a 24-hour period|Oral tablet one day of dosing
61919488|NCT04571515|EXPERIMENTAL|MR-107A-01 10 mg once in a 24-hour period|Oral tablet one day of dosing
61919489|NCT04571515|EXPERIMENTAL|MR-107A-01 15 mg twice in a 24-hour period|Oral tablet one day of dosing
62119464|NCT06676345||Patients with post-infarction mechanical complications|All the patients diagnosed with post-infarction mechanical complications, independently from the treatment assigned (surgical, percutaneous or conservative)
62307447|NCT06034223|EXPERIMENTAL|Conventional Physical Therapy + Proprioceptive Training Using Head Mounted Laser|"Conventional physical therapy along with proprioceptive training, head relocation practice that is relocating the head back to the natural head posture and to pre determined postions in range with eyes open. Tracing figure of eight with eyes open.~3 days per week for 4 weeks, 15 repititions, 1 set."
62307448|NCT06034223|OTHER|Conventional Physical Therapy only|"Conventional physical therapy, cervical range of motion (flexion, extension, lateral flexion and rotation), isometric exercises of neck muscles, stretching (scalene, trapezius, sternocleidomastoid), TENS, heating pad.~3 days per week for 4 weeks, 15 repitions, 1 set."
62119465|NCT05800405|EXPERIMENTAL|Treatment (leukapheresis, external beam radiation, CAR-T)|Patients undergo leukapheresis per standard of care, undergo external beam radiation therapy, and undergo CAR T-cell infusion per standard of care on study. Patients undergo PET/CT throughout the study and may undergo MRI during screening. Patients also undergo blood sample collection throughout the study.
62307449|NCT03392129|EXPERIMENTAL|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week, 40 minutes each session) of treatment with the Ai Chi Method and educational interventions in relation to asthma.
62307450|NCT03392129|ACTIVE_COMPARATOR|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
62678319|NCT05467150|NO_INTERVENTION|No intervention|Participants (mothers) randomized to this arm will agree to continue not taking any over the counter probiotic supplements from study enrollment through the first postpartum month.
62678320|NCT06567691|ACTIVE_COMPARATOR|EUS Gastrojejunostomy|Patient will undergo an Endoscopic Ultrasound (EUS) Gastrojejunostomy procedure
62119466|NCT06520345|EXPERIMENTAL|177Lu-TLX591 + Enzalutamide or Abiraterone or Docetaxel|"Lutetium (177Lu) rosopatamab tetraxetan (177Lu-TLX591) 76 mCi (±10%) given approximately 14 days apart, plus SOC.~SOC is either:~Concurrent enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.~or~Concurrent abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)~or~Sequential Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles."
62120084|NCT04847219|ACTIVE_COMPARATOR|Personal flash glucose mornitoring|Personal flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
62307451|NCT05969080|EXPERIMENTAL|T-SIB|Participants randomized to the Treatment for Self-Injurious Behaviors (T-SIB) condition will receive nine sessions of T-SIB.
62307452|NCT05969080|ACTIVE_COMPARATOR|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
62307453|NCT01115712|ACTIVE_COMPARATOR|Pioglitazone 30 mg|Pioglitazone 30 mg
62307454|NCT01115712|PLACEBO_COMPARATOR|Placebo|Placebo
62307455|NCT00939172|EXPERIMENTAL|TTP607|
62307456|NCT00663858|EXPERIMENTAL|Cetrorelix 78+78|
62307457|NCT00663858|EXPERIMENTAL|Cetrorelix 78 + Placebo|
62307458|NCT00663858|PLACEBO_COMPARATOR|Placebo|
62307459|NCT02559505|EXPERIMENTAL|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
61919490|NCT04571515|EXPERIMENTAL|MR-107A-01 10 mg twice in a 24-hour period|Oral tablet one day of dosing
62307460|NCT02559505|EXPERIMENTAL|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
61919491|NCT04571515|PLACEBO_COMPARATOR|Placebo twice in a 24-hour period|Placebo tablet one day of dosing
62307461|NCT02559505|EXPERIMENTAL|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
62307462|NCT02559505|EXPERIMENTAL|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
62678321|NCT06567691|ACTIVE_COMPARATOR|Surgical Gastrojejunostomy|Patient will undergo Surgical Gastrojejunostomy procedure.
62678322|NCT05882903|EXPERIMENTAL|Betamethasone Dipropionate Nasal Cream 0.0644% Treatment|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
62678323|NCT03178890|EXPERIMENTAL|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
62678324|NCT04743141|EXPERIMENTAL|Active|rimegepant 75 mg, 50 mg or 35 mg ODT
62678325|NCT05649553|EXPERIMENTAL|Intervention Group|"Experimental: Intervention Group Application of the Introductory Information Form and the Quality of Life Scale in Children with Diabetes Mellitus (PedsQL 3.0 Diabetes Scale) test Giving digital game and video animation-based diabetes education to the children in the experimental group, in addition to the education given by the diabetes nurse, Applying the first post-training follow-up test to children in the experimental and control groups 3 months after the training.~Applying the post-training-2nd follow-up test to the children in the experimental and control groups 6 months after the training."
62678326|NCT05649553|NO_INTERVENTION|Control Group|The control group received routine nursing care in the endocrine policlinic.
62678327|NCT05156398|ACTIVE_COMPARATOR|Rimegepant / BHV3000|Rimegepant 75mg or 50mg (2 X 25mg) ODT
62678328|NCT05156398|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
62119467|NCT06520345|ACTIVE_COMPARATOR|Control Arm (Enzalutamide or Abiraterone or Docetaxel)|"SOC is either:~Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.~or~Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)~or~Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles"
62119468|NCT04864925|EXPERIMENTAL|Colgate Total Clean Mint|Brush with toothpaste for a minimum of 2 minutes
62119469|NCT04864925|ACTIVE_COMPARATOR|Tom's Botanically Bright Peppermint|Brush with toothpaste for a minimum of 2 minutes
62119470|NCT00777244|NO_INTERVENTION|Follow-up|Arm B
62119471|NCT00777244|EXPERIMENTAL|Mitotane|Arm A
62307463|NCT02559505|EXPERIMENTAL|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
62307464|NCT02559505|EXPERIMENTAL|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
62678329|NCT06412198|EXPERIMENTAL|Lead-In|Participants enrolled in the Lead-In phase, the dose of adagrasib participants receive will depend on when the participant join this study. The first group of participants will receive the starting dose level of adagrasib. If intolerable side effects are seen, a second group of participants will be enrolled to receive a lower dose. One (1) of these 2 doses will be chosen as the recommended dose of adagrasib.
62678330|NCT06412198|EXPERIMENTAL|Expansion|Participants enrolled in the Expansion phase, participants will receive adagrasib at the recommended dose that was found in the Lead-In phase.
62678331|NCT03641677|EXPERIMENTAL|EVLP|
62678332|NCT03641677|ACTIVE_COMPARATOR|Control|
62307465|NCT02559505|EXPERIMENTAL|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
62678333|NCT01665794|EXPERIMENTAL|PdC Group|Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
62678334|NCT01665794|EXPERIMENTAL|PdC + Dara Group|Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
62678335|NCT04880889|EXPERIMENTAL|BL 3000 (active) and Pantogar matching Placebo|One capsule, once a day for 180 days for BL3000 and one capsule three times a day for Pantogar-Placebo.
62678336|NCT04880889|ACTIVE_COMPARATOR|Pantogar and BL3000 matching placebo|One capsule, three times a day for 180 days
62678337|NCT06630676|EXPERIMENTAL|Education|Educational initiative on back pain
62678338|NCT06630676|ACTIVE_COMPARATOR|Control|Control initiative (non-comprehensive overview)
62119472|NCT05430334|EXPERIMENTAL|Combination One - 16μg/s protonated nicotine flux|The investigators will test the subjective effects of nicotine flux (16μg/s) coupled with one ratio of nicotine form (100% protonated). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
62678339|NCT06694142|EXPERIMENTAL|Rosy app|
62678340|NCT04191616|EXPERIMENTAL|Carfilzomib combined with pomalidomide and dexamethasone|Carfilzomib, pomalidomide, and dexamethasone (KPd)
62678341|NCT06681727||Patients|Patients belonging to Primary care with help seeking for acute psychiatric symptoms
62678342|NCT02166762|EXPERIMENTAL|QLV interval measurement|QLV measurements collected during implantation of CRT-D device
62307466|NCT02559505|EXPERIMENTAL|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
62307467|NCT01767233|EXPERIMENTAL|Pancreatic stenting|Pancreatic stenting versus observation
62307468|NCT01309126|EXPERIMENTAL|Arm 1: Imprime PGG + cetuximab|Biological/Vaccine + Drug
62307469|NCT01309126|ACTIVE_COMPARATOR|Arm 2: cetuximab|Drug
62474867|NCT04643067|ACTIVE_COMPARATOR|KPG-818 high dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
62307470|NCT01274767||High risk cohort|Patients having history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have a negative test for H. pylori based on histology
62119473|NCT05430334|EXPERIMENTAL|Combination Two - 32μg/s protonated nicotine flux|The investigators will test the subjective effects of nicotine flux (32μg/s) coupled with one ratio of nicotine form (100% protonated). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
62119474|NCT05430334|EXPERIMENTAL|Combination Three - 16μg/s free base nicotine flux|The investigators will test the subjective effects of nicotine flux (16μg/s) coupled with one ratio of nicotine form (100% free base). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
62119475|NCT05430334|EXPERIMENTAL|Combination Four - 32μg/s free base nicotine flux|The investigators will test the subjective effects of nicotine flux (32μg/s) coupled with one ratio of nicotine form (100% free base). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
62119476|NCT05430334|PLACEBO_COMPARATOR|Placebo - Combination Five - 0μg/s nicotine flux|The investigators will test the subjective effects of nicotine flux (0μg/s) placebo. Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
62119477|NCT05488366|EXPERIMENTAL|A: Pembrolizumab + Radiation Therapy|Patients receive pembrolizumab 400 mg intravenous every 42 days; Radiation therapy in 1 to 10 fractions.
62307471|NCT01274767||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
62307472|NCT01269034|EXPERIMENTAL|Part A|Exenatide and long acting insulin before the boost.
61919492|NCT02730897||VATS|Patients operated by means of minimal invasive technique (VATS or roboticVATS)
61919493|NCT02730897||Open|Patients operated by means of open thoracotomy
62307473|NCT01269034|ACTIVE_COMPARATOR|Part B|Rapid and long acting insulin before the boost
62307474|NCT01269034|ACTIVE_COMPARATOR|Part C|long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost
62307475|NCT01269034|NO_INTERVENTION|Healthy controls|healthy controls without any medication before the boost.
61920015|NCT02306733|ACTIVE_COMPARATOR|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv)
62678343|NCT03983655|EXPERIMENTAL|Real High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.
61920016|NCT02306733|ACTIVE_COMPARATOR|Oxytocin|100 women with atonic PPH will receive oxytocin 10 IU (Syntocinon® Novartis, Switzerland) slowly intravenous.
61920017|NCT04319679|EXPERIMENTAL|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm\^2, tolerable range
61920018|NCT04319679|SHAM_COMPARATOR|Control group|Sham therapy
61920019|NCT02457273|EXPERIMENTAL|Assigned Interventions|TLC 388
61920020|NCT01551940|EXPERIMENTAL|Botox|Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %
62119478|NCT05488366|EXPERIMENTAL|B: Radiation Therapy with or without standard of care checkpoint inhibitor immunotherapy|Patients who are currently receiving a checkpoint inhibitor immunotherapy regimen will be allowed to continue their regimen at their treating oncologist's discretion. Radiation therapy will be delivered in 1 to 10 fractions starting on Day 1.
62307476|NCT02767050||GROUP 1: CONTROL GROUPS|Patients with no habit history of tobacco are included in group 1.
62307477|NCT02767050||GROUP 2: SMOKING TOBACCO|Patients with a history of tobacco consumption in the form of smoking.
62307478|NCT02767050||GROUP 3: SMOKELESS TOBACCO|Patients with a history of tobacco consumption in the form of chewing.
62307479|NCT03484026|EXPERIMENTAL|BioFe Medical Food|Consumption of BioFe Medical Food in a single cohort of up to 8 female subjects with iron deficiency.
62307480|NCT00565955|ACTIVE_COMPARATOR|A1|Children Between 5-15 Years of Age Receiving Montelukast
62307481|NCT00565955|PLACEBO_COMPARATOR|A2|Children Between 5-15 Years of Age Receiving Placebo
62307482|NCT02280811|EXPERIMENTAL|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
62307483|NCT05300529|EXPERIMENTAL|Vestibular Rehabilitation Exercises|Vestibular Rehabilitation Exercises focused on eye stabilization and Vestibulo-Oculo Reflex (VOR). Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
62307484|NCT05300529|SHAM_COMPARATOR|Conventional Rehabilitation exercises|Conventional rehabilitation exercises: stretching and walking. Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
62307485|NCT03746262||Patients - Stage I treated with surgery|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations, and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
61920021|NCT01551940|PLACEBO_COMPARATOR|Placebo|Placebo injection : NaCl 0.9 %
62119479|NCT05025267|OTHER|Enteral Tube-fed Adults|Adults being fed an enteral formula with a feeding tube
62307486|NCT03746262||Patients - Stage I treated with radiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
62307487|NCT03746262||Patients - Stage II treated with surgery & chemotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
62307488|NCT03746262||Patients - Stage III treated with chemoradiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
62307489|NCT02625038|EXPERIMENTAL|Interventional|3D-planned osteotomies with patient-specific guides
62307490|NCT04350515|EXPERIMENTAL|Cyberball: Other Exclusion|Cyberball Paradigm - the avatar will be excluded by the player
62307491|NCT04350515|EXPERIMENTAL|Cyberball: Player Exclusion|Cyberball Paradigm - the player will be excluded by the other players
62307492|NCT03338556|ACTIVE_COMPARATOR|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
62307493|NCT03338556|PLACEBO_COMPARATOR|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
62307494|NCT03338556|ACTIVE_COMPARATOR|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
62119480|NCT03903081|EXPERIMENTAL|100 mg single dose|It includes two groups, one group is pilot study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=2) . Another group is formal study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=8) or matching placebo (N=2)
62119481|NCT03903081|EXPERIMENTAL|300 mg single dose|Healthy subjects, receiving a single dose of 300 mg HEC110114 tablet (N=8) or matching placebo (N=2)
61919494|NCT04798807||Hospitalized non-critical services patients|"Patients, who were hospitalized in the clinics (hematology, neurology, gastroenterology, nephrology, endocrine, pulmonary disease and cardiology) of Malatya Training and Research Hospital, were screened both Nutritional Risk Screening 2002 (NRS-2002) and Subjective Global Assessment (SGA) tools within the first days of admission to the patients.~The nutritional status of patients categorized according the screening tools.~Nutritional Risk Screening 2002 (NRS-2002) : The patients were classified as being nutritionally risk (NRS+): total score ≥ 3 or nutritionally risk-free (NRS-): total score \< 3 according to NRS 2002 results.~Subjective Global Assessment (SGA) The SGA screening provides three alternative categories for nutritional classification: well nourished (A); mild-to-moderately malnourished (B); or severely malnourished (C)."
61919495|NCT04955860||Study Group|Individuals with bilateral posterior crossbite will be included.
61919496|NCT04955860||Control Group|Individuals with no anterior and/or posterior crossbite and transversal malocclusion will be included.
61919497|NCT01285687|NO_INTERVENTION|Standard Analgesic Treatment|
61919498|NCT01285687|EXPERIMENTAL|Standard Analgesic Treatment with Acupuncture|Patients will receive standard analgesic treatment and in addition acupuncture.
61919499|NCT01156727||SURVEY: 6 months post-deployment|Michigan Army National Guard soldiers 6 months post deployment between August 2011 and December 2013
62119482|NCT03903081|EXPERIMENTAL|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
62119483|NCT03903081|EXPERIMENTAL|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC110114 tablet (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study
62119484|NCT03903081|EXPERIMENTAL|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg HEC110114 tablet (N=8) or matching placebo (N=2)
62119485|NCT03903081|EXPERIMENTAL|1200 mg single dose|Healthy subjects, receiving a single dose of 1200 mg HEC110114 tablet (N=8) or matching placebo (N=2)
62119486|NCT03903081|EXPERIMENTAL|1600 mg single dose|Healthy subjects, receiving a single dose of 1600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
62474868|NCT04643067|PLACEBO_COMPARATOR|Placebo arm|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
62119487|NCT03903081|EXPERIMENTAL|600 mg multiple doses|Healthy subjects, receiving 600 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
62119488|NCT03903081|EXPERIMENTAL|800 mg multiple doses|Healthy subjects, receiving 800 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
62119489|NCT03903081|EXPERIMENTAL|1000 mg multiple doses|Healthy subjects, receiving 1000 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
62474869|NCT00931697|EXPERIMENTAL|AD 452 (+) mefloquine|
61919500|NCT01156727||SURVEY: 12 months post-deployment|Michigan Army National Guard soldiers 12 months post deployment between August 2011 and December 2013.
61919501|NCT01156727||INTERVIEWS|Michigan Army National Guard soldiers 12-24 months post deployment between October 2011-April 2014. Also key stakeholders from the B2B program.
62119490|NCT02894151|ACTIVE_COMPARATOR|LNG-IUS|"LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.~It was inserted only first time entry in the study."
62119491|NCT02894151|ACTIVE_COMPARATOR|DMPA|DMPA was given in trimonthly intramuscular injection.
62119492|NCT06666725|NO_INTERVENTION|Control|Participant will order food and beverages from three menus. The menus will not contain any added sugar labels.
62307495|NCT03338556|PLACEBO_COMPARATOR|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
62119493|NCT06666725|EXPERIMENTAL|Large, black, icon-only label, 50% daily value|Participant will order food and beverages from three menus containing labels next to items that contain equal to or higher than half the daily value of added sugar (greater than or equal to 25 grams). The label will be on the right of the item, colored black, icon only design, and height that is 150% of size of the menu text height.
62307496|NCT01381523||Study-treatment naive insured adults with migraine|Adult health care plan members with a pharmacy claim for a combination product of sumatriptan and naproxen sodium (SumaRT/Nap) and propensity score matched controls with a pharmacy claim for a single-entity triptan
62307497|NCT01381523||Insured adults with migraine who switch study treatment|Adult health plan members with a pharmacy claim for SumaRT/Nap following at least one single-entity triptan pharmacy claim in the previous 6 months and propensity-score matched controls who switched from one single-entity triptan to another
62307498|NCT02758795|PLACEBO_COMPARATOR|CONTROL|A placebo nutrient drink with no anti-inflammatory bioactivity (measure by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy \~ 160 kcal
62307499|NCT02758795|ACTIVE_COMPARATOR|NUTRIENT|A nutrient drink with confirmed anti-inflammatory bioactivity (measured by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy \~ 160 kcal
62307500|NCT02660658|OTHER|Intrathecal dexmedetomidine|"Up-down sequential allocation~The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance"
62307501|NCT03703531||Patients resuscitated in Istria county|Cardiopulmonary resuscitation performed for OHCA
62307502|NCT01968876|NO_INTERVENTION|Standard Care|The control group will not use the medication adherence app
62307503|NCT01968876|EXPERIMENTAL|Medication Adherence Smartphone App|The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.
62307504|NCT06512298||Transfusion-dependent thalassemia major (TDTM)|Patients suffering from homozygous transfusion-dependent Thalassemia Major.
61919502|NCT05794451||Healthy controls|Adults aged 60 and above without cognitive impairment
61919503|NCT05794451||Mild cognitive impairment|Adults 60 and above with mild cognitive impairment
61919504|NCT05794451||Alzheimer's disease|Adults diagnosed with Alzheimer's disease
61919505|NCT06057155||acute brain injury|Intra Cerebral Hemorrhage Subarachnoid Hemorrhage, Aneurysmal Trauma, Brain Stroke, Ischemic
62119494|NCT06666725|EXPERIMENTAL|Large, black, icon-only label, 100% daily value|Participant will order food and beverages from three menus containing labels next to items that contain equal to or higher than the total daily value of added sugar (greater than or equal to 50 grams). The label will be on the right of the item, colored black, icon only design, and height that is 150% of size of the menu text height.
62307505|NCT06512298||Thalassemia Minor|Patients suffering from heterozygous transfusion-independent Thalassemia Minor.
62307506|NCT06512298||Healthy controls|Healthy adult controls without any prevalent substance use (nicotine, alcohol etc.).
62307507|NCT06512298||Glioma patients|Adults with high/low-grade glioma, a tumor size \> 3cm that require resection with access to the ventricular system without ventricular hemorrhage.
62307508|NCT06512298||ICU patients|Adults with brain hemorrhage (intracranial, subdural, subarachnoidal), treated with a ventricular shunt.
62307509|NCT06512298||Patients undergoing diagnostic lumbar-puncture (plastic-naive)|Adults that receive a diagnostic lumbar puncture in an outpatient setting.
62474870|NCT00931697|ACTIVE_COMPARATOR|Racemic mefloquine|
62474871|NCT00931697|PLACEBO_COMPARATOR|Placebo|
61919506|NCT02142985|EXPERIMENTAL|crystalloid solution|vascular filling with 500 ml of crystalloid solution within 10 minutes
62307510|NCT03692273|EXPERIMENTAL|Laser|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz.
62307511|NCT03692273|EXPERIMENTAL|0.5mm punch biopsy|0.5mm punch biopsy area. This area will receive 0.5mm punch biopsies 75 per cm2 at a depth of 5mm.
62307512|NCT03692273|NO_INTERVENTION|No treatment|3x3cm2 area designated as no treatment that will serve as a control
62307513|NCT05533125|EXPERIMENTAL|Rituximab|1000mg rituximab intravenously once
62307514|NCT05533125|PLACEBO_COMPARATOR|Placebo|0mg rituximab (placebo) intravenously once
61919507|NCT04149392|EXPERIMENTAL|CGM intervention|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge which will be downloaded at their outpatient follow up clinic visit 6-14 days later. At the follow-up visit medications may be modified based on downloaded glucose data. During the already scheduled post-discharge follow up appointment the CGM sensor data will be downloaded by clinic staff. The diabetes medications will be reconciled and the downloaded data will be reviewed with the patient. Based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
61919508|NCT03342300|EXPERIMENTAL|Arm A|participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
62119495|NCT06666725|EXPERIMENTAL|Small, red, icon-plus-text label, 50% daily value|Participant will order food and beverages from three menus containing labels next to items that contain equal to or higher than half the daily value of added sugar (greater than or equal to 25 grams). The label will be on the right of the item, colored red, icon plus text design, and height that is 100% of size of the menu text height.
62119496|NCT06666725|EXPERIMENTAL|Small, red, icon-plus-text label, 100% daily value|Participant will order food and beverages from three menus containing labels next to items that contain equal to or higher than the total daily value of added sugar (greater than or equal to 50 grams). The label will be on the right of the item, colored red, icon plus text design, and height that is 100% of size of the menu text height.
62119497|NCT00148369||Observational Group|Subjects previously administered GDNF and have discontinued the drug.
62307515|NCT00591383|EXPERIMENTAL|Single Arm|Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
62119498|NCT02032849|ACTIVE_COMPARATOR|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
62307516|NCT04850950|EXPERIMENTAL|Arm 1|Tenofovir alafenamide fumarate discontinued at delivery date.
62307517|NCT04850950|EXPERIMENTAL|Arm 2|Tenofovir alafenamide fumarate discontinued at postpartum month 1.
62474872|NCT01124175|EXPERIMENTAL|Generic Test Product|Losartan 100 mg Tablets
62474873|NCT01124175|ACTIVE_COMPARATOR|Reference Listed Drug|Cozaar® 100 mg Tablets
61919509|NCT03342300|PLACEBO_COMPARATOR|Arm B|participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
62474874|NCT06413186|EXPERIMENTAL|Delivery of the placenta by mixed method|"In this group; As soon as the baby is born, 10 IU oxytocin will be administered IV to the woman.~The newborn will be placed on the mother's chest for skin-to-skin contact, Uterine tone will be evaluated while the baby is at the mother's breast, The cord will be clamped late (after the pulse in the cord stops/within 1-3 minutes after the baby is born), The placenta will be delivered physiologically."
62119499|NCT02032849|EXPERIMENTAL|Manual air-impingement operation|A method which we invented to clear subglottic secretion
62474875|NCT06413186|ACTIVE_COMPARATOR|Delivery of the placenta by active method|"In this group; As soon as the baby is born, 10 IU oxytocin will be administered IV to the woman.~The newborn will be placed on the mother's chest for skin-to-skin contact, Uterine tone will be evaluated while the baby is at the mother's breast, The cord will be clamped late (after the pulse in the cord stops/within 1-3 minutes after the baby is born), The placenta will be removed with controlled cord traction."
62678344|NCT03983655|SHAM_COMPARATOR|Sham High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.
62678345|NCT06483828|NO_INTERVENTION|Control group|Baseline MY-ACDAS and HRV-Biofeedback assessment followed with dental procedures (dental charting and oral prophylaxis). HRV-Biofeedback will be recorded during dental procedures. Once completed, post dental procedures assessment of MY-ACDAS and HRV-Biofeedback will be recorded.
62678346|NCT06483828|EXPERIMENTAL|Intervention group|Baseline MY-ACDAS and HRV-Biofeedback assessment followed Dental Anxiety Coping Module. The participants will continue with dental procedures (dental charting and oral prophylaxis). HRV-Biofeedback will be recorded during dental procedures. Once completed, post dental procedures assessment of MY-ACDAS and HRV-Biofeedback will be recorded.
62678347|NCT05112237||Retrospective|All patients who meet the eligibility criteria will be eligible for retrospective chart review.
62678348|NCT05112237||Prospective|100 patients meeting the eligibility criteria will be followed for 5 years, in addition to a retrospective chart review. Assessments will be completed as part of a participant's regular schedule of physician visits, no additional visits will be required. Aside from a simple annual blood draw, assessments are non-invasive, including a Quality of Life questionnaire.
62678349|NCT06694480|EXPERIMENTAL|Dose Escalation|"Patients will be sequentially enrolled at progressively higher dose levels to receive FID-022 as monotherapy. According to the study design, maintaining the dose level or moving down a dose level will possibly happen when conditions are met.~Intravenous Administration of FID-022, infusion on day 1 and 8 of each 21-day cycle:~Dose level 1: 20 mg/m2. Dose level 2: 40 mg/m2. Dose level 3: 60 mg/m2. Dose level 4: 80 mg/m2. Dose level 5: 100 mg/m2. Dose level 6: 120 mg/m2."
62678350|NCT03375307|EXPERIMENTAL|Cohort I (olaparib)|Patients that have cancer-associated DNA-repair gene mutations receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT, MRI, PET/CT, or bone scan and optional tumor biopsy and bone marrow biopsy on study.
62678351|NCT03375307|EXPERIMENTAL|Cohort II (biospecimen collection)|Patients that do not have cancer-associated DNA-repair gene mutations undergo blood sample collection at baseline. Additionally, patients undergo CT, MRI, PET/CT, or bone scan and optional tumor biopsy and bone marrow biopsy on study.
62678352|NCT06694064|EXPERIMENTAL|Mta group|after pulpotomy the pulp stumps subgected to mta material
62678353|NCT06694064|EXPERIMENTAL|Grape seed group|after pulpotomy the pulp stumps subjected to grape seed
62678354|NCT00887133||1|Patients consulting Western Medicine outpatient clinics for a new episode of illness
62678355|NCT05675020|EXPERIMENTAL|Parent-Adolescent Dyad|"Each parent-adolescent dyad will receive the intervention (educational program delivered via a 45-minute presentation via Zoom).~The educational program will promote healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines. The educational presentation will include 5-10 minutes of education regarding recommendations versus reality for nutrition, PA, screen time, and sleep, 20-25 minutes of education regarding ways to improve healthy lifestyle knowledge and behaviors, 10 minutes for questions and discussion."
62119500|NCT00813904|EXPERIMENTAL|rThrombin, 1000 IU/mL|
62119501|NCT06182397|ACTIVE_COMPARATOR|MagicTouch PTA sirolimus DCB|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
62307518|NCT03444025|EXPERIMENTAL|Group A|Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
62678356|NCT02429167|EXPERIMENTAL|PoNS Device|Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
62678357|NCT02429167|SHAM_COMPARATOR|Sham PoNS Device|The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
62678358|NCT01679665|EXPERIMENTAL|320U /0.5ml in children (from 2 to 5 years old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28
62678359|NCT01679665|PLACEBO_COMPARATOR|0/0.5ml placebo in children (from 2 to 5 years old)|0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28
62678360|NCT05889000||main group|304 patients with verified CPVD
62678361|NCT05889000||comparison group|93 participants without signs of CPVD.
62119502|NCT06182397|PLACEBO_COMPARATOR|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
62474876|NCT02009774||Controll group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
62474877|NCT02009774||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.
62474878|NCT01126203|EXPERIMENTAL|selective laser trabeculoplasty (SLT)|
62678362|NCT05398627|EXPERIMENTAL|Amygdala Neurofeedback|Participants will undergo real-time fMRI neurofeedback training to increase their amygdala response while recalling positive autobiographical memories. 2 sessions will occur within a one week period.
62678363|NCT01190371|OTHER|Artesunate|Confirmation of artemisinin tolerance
62678364|NCT06490874||CGM device - Metformin|Individuals will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years). The CGM device will be used in blinded mode for both participants and providers (i.e., neither will be able to see glucose values).
61919510|NCT00821327|EXPERIMENTAL|Study Arm|Gemcitabine, Cisplatin, Sunitinib
62678365|NCT06490874||CGM device - Insulin|Individuals will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years). The CGM device will be used in blinded mode for both participants and providers (i.e., neither will be able to see glucose values).
61919511|NCT05370456|EXPERIMENTAL|Xenogenic collagen matrix (XCM) + Hyaluronic acid (HA)|Multiple coronally advanced flap technique (mCAF) with the use of a XCM in combination with local application of a HA gel
62678366|NCT06695351||GIFTED|Patients with high cognitive abilities
61919512|NCT05370456|ACTIVE_COMPARATOR|Xenogenic collagen matrix (XCM)|Multiple coronally advanced flap technique (mCAF) with the use of a XCM
61919513|NCT06032897|NO_INTERVENTION|control group|The control group who participated in routine activities
62474879|NCT01126203|EXPERIMENTAL|Argon laser trabeculoplasty (ALT)|
62678367|NCT04867408||Main group|Patients with/suspected Inflammatory Bowel Disease attending for an endoscopic procedure
62678368|NCT04867408||Control|Patients without Inflammatory Bowel disease attending for an endoscopic procedure
62307519|NCT03444025|NO_INTERVENTION|Group B|Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
62307520|NCT00616473||1 Nursing Home Staff|Direct care staff
62307521|NCT00616473||2 Family Members|Family members/Significant other of nursing home resident.
62474880|NCT04582019|ACTIVE_COMPARATOR|Patients with polyurethane DJ stent|Polyurethane DJ stent, 6Fr. The stent will be removed using flexible cystoscopy.
62474881|NCT04582019|ACTIVE_COMPARATOR|Patients with polyurethane DJ stent with magnet|Polyurethane DJ stent with magnet (Blackstar, Urotech), 7Fr. The stent will be removed under ultrasound control using a magnetic retriever
62474882|NCT04607499||Pregnant women|Pregnant women without intervention
62307522|NCT01001585|EXPERIMENTAL|slow induction with sevoflurane|Only children with a BIS greater than 95 prior to inhalation of sevoflurane will be included in the study. Inductions will be done using a tight fitting mask with continuous monitoring of end tidal gas concentrations. During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached. Inspired sevoflurane will be increased only after end tidal concentration of sevoflurane is constant for at least one minute. Each induction (except for the patients requiring very low doses of sevoflurane) will take approximately 10 minutes.
61919514|NCT06032897|EXPERIMENTAL|experimental group|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The individualized music listening were performed twice a week for four weeks, for a total of eight times.
62119503|NCT05674357|EXPERIMENTAL|Individualized Evidence-Based Therapy in Cancer (Patients)|"This arm will enroll patient participants receiving evidence-based therapy as part of the protocol.~Participants will complete:~* 6-16 sessions of therapy 1x/week. Sessions are virtual or in-person at the Massachusetts General Hospital Cancer Center.~* Surveys and questionnaires pre- and post-treatment.~At the discretion of the therapist and the supervising therapist, the participant may receive up to 4 booster sessions after completion of the specific treatment protocol."
62307523|NCT03541577||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo FFR measurement with the TruePhysioTM Microcatheter and the Pressure Wire
61919515|NCT06454175|EXPERIMENTAL|HPV-vaccine group|According to the 0, 2, and 6 months immunization schedule, intramuscular injection of the upper arm deltoid muscle, 3 doses of the 15-HPV vaccine
62474883|NCT04166630|EXPERIMENTAL|ICU Acquired Weakness Group|Participants with a score less than 48 on the Medical Research Council (MRC) Scale will be classified as having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
62119504|NCT05674357|EXPERIMENTAL|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|This arm will enroll therapist participants as part of the protocol. Therapists participants will enroll in the study and receive training in delivering evidence-based therapy to patients in the cancer center. Therapists will complete pre and post-measures of therapist self-efficacy and competence, as well as a semi-structured exit interview.
62474884|NCT04166630|EXPERIMENTAL|No ICU Acquired Weakness Group|Participants with a score of 48 or greater on the Medical Research Council (MRC) Scale will be classified as not having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
62474885|NCT02365012|PLACEBO_COMPARATOR|Placebo|Placebo given three times a day for 2 weeks
62474886|NCT02365012|ACTIVE_COMPARATOR|Midodrine|Midodrine 2.5 mg given three times a day for one week followed by 5 mg given three times a day for one week
62474887|NCT02618083|EXPERIMENTAL|retinal detachment|color Doppler ultrasound of the eye
62474888|NCT05820360|EXPERIMENTAL|People with Serious Mental Illness|The target groups are adult (18 to 65 years) and elderly (over 65 years) patients with a Serious Mental Illness. Inclusion criteria: presence of SMI and behavioral problems, willingness and ability to participate in this research.
62474889|NCT02760732|EXPERIMENTAL|drug eluting balloon group|patients with unstable angina were randomised to drug eluting balloon group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon(Flextome Cutting Balloon, Boston Scientific Corporation, US) pre-dilation first and then drug eluting balloon(Sequent please; B. Braun, Melsungen, Germany) .
62474890|NCT02760732|EXPERIMENTAL|drug eluting stent group|patients with unstable angina were randomised to this group for drug eluting stent (YINYI® Polymer-free Drug-coated (Paclitaxel) Coronary Stent System, Liaoning Biomedical Materials R\&D Center Co., Ltd. China) implantation.
62474891|NCT02000362|EXPERIMENTAL|Treatment|"cohort 1. 5.0 x 10\^7 stem cells after registration~cohort 2. 1.0 x 10\^8 stem cells after registration"
62474892|NCT00614263||Blinded Group|SEDline output is unknown to anesthesiologist.
62474893|NCT00614263||Unblinded Group|SEDline output is known to anesthesiologist.
62119505|NCT03201562|EXPERIMENTAL|Aceclidine+tropicamide combination|Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)
62474894|NCT03989648|ACTIVE_COMPARATOR|Esmarch bandages|
62678369|NCT06065540|EXPERIMENTAL|CagriSema 2.4 mg/2.4 mg|Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks.
62678370|NCT06065540|EXPERIMENTAL|CagriSema 1.0 mg/1.0 mg|Participants will receive once-weekly s.c injections of 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks.
62474895|NCT03989648|ACTIVE_COMPARATOR|simple leg elevation|
62474896|NCT05163119|NO_INTERVENTION|Control Group|Commercial cell-phone blocking app installed on smartphone, but app will be inactive.
62474897|NCT05163119|EXPERIMENTAL|Commercial Cellphone-Blocking App|Commercial cellphone-blocking app that blocks handheld cellphone use while driving, but allows emergency calls and phone use after pressing the passenger button will be installed on smartphone.
62474898|NCT05163119|EXPERIMENTAL|Driving Mode|Driving mode blocks handheld phone use while driving or facilitates hands free use (exact functionality dependent on smartphone type and service provider).This group will also have the commercial cell-phone blocking app installed on smartphone, but app will be inactive.
62678371|NCT06065540|ACTIVE_COMPARATOR|Semaglutide 2.4 mg|Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 68 weeks.
62474899|NCT05126485|EXPERIMENTAL|Randomizing Control and Biofeedback Phases|"The gait training and data collection procedure is split into two phases: a control phase and a biofeedback phase. The order of these phases is randomized across participants to reduce the probability of systematic error due participants warming-up or fatiguing between trials. Each phase consists of a pre-test, gait retraining session, and one or more post-tests."
62474900|NCT02618577|EXPERIMENTAL|Edoxaban|"Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
62119506|NCT03201562|ACTIVE_COMPARATOR|Aceclidine|Aceclidine single dose
62678372|NCT06065540|ACTIVE_COMPARATOR|Semaglutide 1.0 mg|Participants will receive once-weekly s.c injection of 1.0 mg semaglutide for 68 weeks.
62678373|NCT06065540|ACTIVE_COMPARATOR|Cagrilintide 2.4 mg|Participants will receive once-weekly s.c injection of 2.4 mg cagrilintide for 68 weeks.
62678374|NCT06065540|PLACEBO_COMPARATOR|Placebo 2.4 mg/2.4 mg|Participants will receive once-weekly s.c injection of placebo matched to 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks.
62678375|NCT06065540|PLACEBO_COMPARATOR|Placebo 1.0 mg/1.0 mg|Participants will receive once-weekly s.c injection of placebo matched to 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks.
62678376|NCT05415397|EXPERIMENTAL|Celecoxib|Celecoxib 400 mg/day, 2 capsules (200 mg) daily, 12 weeks
61919516|NCT06454175|PLACEBO_COMPARATOR|Placebo group|According to the 0, 2, and 6 months immunization schedule, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
61919517|NCT01776385|EXPERIMENTAL|Group patients|Patients with Malignant Pleural Mesothelioma (all stages)
61919518|NCT01776385|PLACEBO_COMPARATOR|Control group|Patients with pneumothorax or of benign tumor of the thyroid
62119507|NCT03201562|SHAM_COMPARATOR|Vehicle|Vehicle single dose
62678377|NCT05415397|PLACEBO_COMPARATOR|Placebo|Placebo, 2 capsules daily, 12 weeks
62119508|NCT03690037|EXPERIMENTAL|Intervention Group 1|Intervention Group 1: 1g intravenous Tranexamic Acid 100 milligrams (MG)/ML peri-operatively plus 1g oral Tranexamic Acid 500mg Tablets every 8hrs for up to 24hrs
62119509|NCT03690037|EXPERIMENTAL|Intervention Group 2|Intervention Group 2: 1g intravenous Tranexamic Acid 100 MG/ML peri-operatively
62119510|NCT03690037|NO_INTERVENTION|Control Group 3|Standard care - no TXA
62119511|NCT01936792||mild traumatic brain injury|Subjects with mild traumatic brain injury
62119512|NCT01936792||Controls|Controls with no premorbid health conditions
62678378|NCT04969107|ACTIVE_COMPARATOR|transanal TME (taTME)|patients with rectal cancer receiving transanal TME
62678379|NCT04969107|ACTIVE_COMPARATOR|abdominal TME (abTME)|patients with rectal cancer receiving open, laparoscopic or robotic TME
62474901|NCT02618577|ACTIVE_COMPARATOR|ASA or Placebo|Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
62474902|NCT05978726||ticagrelor maintenance treatment group|Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and ticagrelor 90mg twice daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
62474903|NCT05978726||clopidogrel maintenance treatment group|Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and clopidogrel 75mg once daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
61919519|NCT01859104|OTHER|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
61919520|NCT05875103|EXPERIMENTAL|Cognitive cortical neurodegenerative diseases and stroke PATIENTS|
62474904|NCT02110394||bendamustine and rituximab|
62678380|NCT03506633|EXPERIMENTAL|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ and second day will be Placebo. Testing will take place forty-minutes after MitoQ/placebo intake. There will be a 2-week washout between testing days.
62678381|NCT03506633|EXPERIMENTAL|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.
61919521|NCT04800666|EXPERIMENTAL|Facial Nerve Block Group|Facial Nerve Block and oral Mecobalamin Tablets
61919522|NCT04800666|EXPERIMENTAL|Stellate Ganglion Block Group|Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
61919523|NCT04800666|EXPERIMENTAL|D Group|Facial Nerve Block
61919524|NCT04800666|OTHER|C Group|control
62678382|NCT04094090|EXPERIMENTAL|Pulsed, accelerated|4 mW, 10-15 sec on, 10-15sec off, 45 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
62678383|NCT04094090|EXPERIMENTAL|Pusled, accelerated|8 mW, 10-15 sec on, 10-15 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
62678384|NCT06688552|ACTIVE_COMPARATOR|Traditional set training|Traditional set method and drop set method are widely used training methods in bodybuilding. Studies have shown that these methods have similar effects on muscle hypertrophy, increasing lean body mass and other metabolic variables when applied in equal volumes. However, there is no comparative study on the effects of these methods on fatigue and proprioceptive mechanism. In this context, it is thought that it is important to reveal the effects of traditional and drop set training methods on these two variables in order to take necessary measures to protect athlete health and improve athlete performance.
62678385|NCT06688552|ACTIVE_COMPARATOR|Drop set training|Traditional set method and drop set method are widely used training methods in bodybuilding. Studies have shown that these methods have similar effects on muscle hypertrophy, increasing lean body mass and other metabolic variables when applied in equal volumes. However, there is no comparative study on the effects of these methods on fatigue and proprioceptive mechanism. In this context, it is thought that it is important to reveal the effects of traditional and drop set training methods on these two variables in order to take necessary measures to protect athlete health and improve athlete performance.
62678386|NCT06219707|EXPERIMENTAL|Electro-Acupuncture group|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable. The alternating stimulation is believed to produce maximal biochemical responses in the brain \[1\].
62678387|NCT06219707|SHAM_COMPARATOR|Sham-Acupuncture group|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted (actual penetration of the skin) at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli. The sham points aren't acupuncture points nor located on meridians \[2\].
62678388|NCT06488222|EXPERIMENTAL|Docetaxel and Gemcitabine|All subjects will be treated with docetaxel and gemcitabine in 2 phases (induction and maintenance) following transurethral resection. Docetaxel and gemcitabine will be given weekly for six weeks during induction and will then be given every 30 days until up to 12 months after the start of induction therapy during maintenance.
62678389|NCT03397719|ACTIVE_COMPARATOR|Control Group|This group will receive treatment as usual. Each participant will receive three hours of in-vivo parent coaching per week for 6 months.
62678390|NCT03397719|EXPERIMENTAL|Treatment Condition|This group will receive an additional component which will involve videotaping parent/child interactions at home for thirty minutes a week. Each week, the therapist will select sections of the video to review with the parent during one of the parent coaching sessions.
62678391|NCT05083364|EXPERIMENTAL|ARO-C3 (Healthy Volunteers)|1 or 2 doses of ARO-C3 by subcutaneous (sc) injection
62678392|NCT05083364|PLACEBO_COMPARATOR|Placebo (Healthy Volunteers)|placebo calculated volume to match active treatment by sc injection
62678393|NCT05083364|EXPERIMENTAL|ARO-C3 (Adult Patients with C3G or IgAN)|3 doses of ARO-C3 by sc injection
62678394|NCT03166631|EXPERIMENTAL|Part A: 5 mg BI 891065|BI 891065 alone
62678395|NCT03166631|EXPERIMENTAL|Part A: 15 mg BI 891065|BI 891065 alone
62678396|NCT03166631|EXPERIMENTAL|Part A: 25 mg BI 891065|BI 891065 alone
62678397|NCT03166631|EXPERIMENTAL|Part A: 50 mg BI 891065|BI 891065 alone
62678398|NCT03166631|EXPERIMENTAL|Part A: 100 mg BI 891065|BI 891065 alone
62678399|NCT03166631|EXPERIMENTAL|Part A: 200 mg BI 891065|BI 891065 alone
62678400|NCT03166631|EXPERIMENTAL|Part A: 400 mg BI 981065|BI 891065 alone
61919525|NCT05276648|EXPERIMENTAL|ESP BLOCK|erector spina plane block applied
62678401|NCT03166631|EXPERIMENTAL|Part B: 50 mg BI 891065 QD + 240 mg BI 754091|BI 891065 in combination with BI 754091
62678402|NCT03166631|EXPERIMENTAL|Part B: 200 mg BI 891065 QD + 240 mg BI 754091|BI 891065 in combination with BI 754091
62678403|NCT03166631|EXPERIMENTAL|Part B: 400 mg BI 891065 QD + 240 mg BI 754091|BI 891065 in combination with BI 754091
61919526|NCT05276648|ACTIVE_COMPARATOR|no ESP BLOCK|those who did not apply erector spina plan block
62678404|NCT03166631|EXPERIMENTAL|Part B: 200 mg BI 981065 BID + 240 mg BI 754091|BI 891065 in combination with BI 754091
62678405|NCT01272622|OTHER|Arm I|"Children and adolescents \>= 18 years of age new diagnosed with craniopharyngioma~* \>= 5 years of age and with incomplete resected tumor =\> randomized in two arms: immediate irradiation after surgery"
62678406|NCT01272622|OTHER|Arm II|incomplete resection, wait and watch, MRI-controls every 3 months, and irradiation at the time of progression of residual tumor
62678407|NCT06687941|EXPERIMENTAL|AST-201|
61919527|NCT04441866|ACTIVE_COMPARATOR|Automated algorithms|Automated 3D techniques in measuring fetal biometry and reconstructing standard anatomical planes
61919528|NCT04441866|PLACEBO_COMPARATOR|Standard technique|Standard 2D assessment
61919529|NCT04459429|EXPERIMENTAL|NHF by smaller cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the smaller cannula
62678408|NCT06548581||Patients who have had joint arthrodesis procedures using the SpeedPlate™ Rapid Compression Implants|Patients 14 years of age or older that have had MTP and/or TMT joint fixation with the SpeedPlate™ Rapid Compression Implants will be eligible to participate based on inclusion and exclusion criteria established in the study protocol.
62678409|NCT06342960|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)|Dosing with KYV-101 CAR T cells
62678410|NCT06342960|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)|Recommended Phase 2 Dose
62678411|NCT01478087|OTHER|Mysorba(single-arm)|
62678412|NCT06009978|ACTIVE_COMPARATOR|Additional treatment with NMES after Achilles Tendon rupture|"Neuromuscular electrical stimulation 2 times a day á 15 minutes during the week 3-8 after the Achilles Tendon rupture.~Patients will also follow ordinary standard rehabilitation for Achilles Tendon rupture"
62678413|NCT06009978|NO_INTERVENTION|Control group|Patients will follow ordinary standard rehabilitation for Achilles Tendon rupture
62678414|NCT05463705|EXPERIMENTAL|Intervention to address diffusion of responsibility|PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.
62678415|NCT05463705|EXPERIMENTAL|Intervention to address diffusion of responsibility + simplification of prescribing|"PCPs will receive the same contact addressing diffusion of responsibility as in the Intervention to address diffusion of responsibility arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by routing their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress."
62678416|NCT05463705|NO_INTERVENTION|Usual care|PCPs in this arm will receive no additional outreach or resources than standard MGH primary care practice.
62678417|NCT05241834|EXPERIMENTAL|Phase 1A: LOXO-260 Dose Escalation|LOXO-260 administered orally
62678418|NCT05241834|EXPERIMENTAL|Phase 1B: LOXO-260 Dose Expansion|LOXO-260 administered orally
62678419|NCT04960943|EXPERIMENTAL|Pyrotinib|Pyrotinib with or without paclitaxel/trastuzumab treatment
62678420|NCT00948454||Light smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
62678421|NCT00948454||Heavy Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
62678422|NCT00948454||Non Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Female subjects will also have a pregnancy test done on the test day.
62678423|NCT01657942|EXPERIMENTAL|ExABlate MR Guided Focus Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
62678424|NCT05492994|EXPERIMENTAL|Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
62678425|NCT02991859|EXPERIMENTAL|Arm AB - FF followed by FP|Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose \[TDD\] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
62119513|NCT01304277|EXPERIMENTAL|Replagal® (0.2 mg/kg, IV, EOW)|"Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)~Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF"
62736352|NCT05454800|EXPERIMENTAL|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Individuals with AIS in this group, in accordance with the Schroth classification, individually planned, aimed at correcting and stabilizing the spine in three dimensions, an exercise program will be applied in 45-60 minutes sessions, 2 days a week, for 8 weeks, a total of 16 sessions. In addition to corrective exercises specific to scoliosis, physical activity counseling will also be given.
62736353|NCT05454800|EXPERIMENTAL|Scoliosis Specific Corrective Exercises|Individuals with AIS in this group, in accordance with the Schroth classification, individually planned, aimed at correcting and stabilizing the spine in three dimensions, an exercise program will be applied in 45-60 minutes sessions, 2 days a week, for 8 weeks, a total of 16 sessions.
62119514|NCT05318885|EXPERIMENTAL|Forward leaning position|The children in asthma attacks were administered nebulization three times, during which the study group children were placed in the forward-leaning position.
62119515|NCT05318885|NO_INTERVENTION|Fowler position|The children in asthma attacks were administered nebulization three times, during which the control group children in the routine Fowler's position.
62119516|NCT01048931|EXPERIMENTAL|single-port LAVH|single port LAVH
62678426|NCT02991859|EXPERIMENTAL|Arm AC - FF followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
62119517|NCT03703518|EXPERIMENTAL|Mixed reality|"Mixed reality exercise program using the Microsoft Hololens Roboraid game. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
62474905|NCT02482090|EXPERIMENTAL|Patient group|"All patients receive the same treatment. Alle patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~Stem Cells are harvested a minimum of 3 weeks before treatment for potential later use if the patients are having difficulties recovering from the lymphodepleting chemotherapy.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5.~Interleukin-2 is administered in an i.v. continous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days.~Stem Cells can be administered after treatment if needed."
62119518|NCT03703518|ACTIVE_COMPARATOR|Conventional exercise group|Conventional exercise program in cervical region based in deep neck flexors and deep neck extensors, isometric contraction during 6-8 seconds. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions.
62119519|NCT06612762|EXPERIMENTAL|Naringenin|The daily ingestion of capsules containing naringenin
61919530|NCT04459429|EXPERIMENTAL|NHF by larger cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the larger cannula
62119520|NCT06612762|PLACEBO_COMPARATOR|Control|Patients will receive placebo capsules
62119521|NCT05297864|EXPERIMENTAL|Niraparib Treatment|Patients will be treated with individualized starting dose of Niraparib.
62119522|NCT05706168|NO_INTERVENTION|Control group|The participants in this category will not undergo any structured exercise training for the duration of the study.
62474906|NCT01067183|EXPERIMENTAL|breathing and biofeedback device|This group of physicians were trained in the use of the relaxation breathing technique and the biofeedback device, and then used this portable stress reduction tool on a daily basis with twice weekly visits with the research team. After the 28 day RCT, they were invited to continue to use the device at their discretion during a trial extension from day 28-56 to see if any effect measured was maintained.
62474907|NCT01067183|NO_INTERVENTION|control arm|This group did not undergo training in the breathing technique and use of the PSMD during the RTC trial day 0-28, but were visited twice weekly by the research team to collect outcome data. During the trial extension Day 28-56, this group did undergo a 1 hr training session with the PSMD and invited to use it at their discretion over the 28 days. Effectiveness outcome data (day 28-56) was collected at day 56.
62474908|NCT04802694|EXPERIMENTAL|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
61919531|NCT02604017|EXPERIMENTAL|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
62119523|NCT05706168|EXPERIMENTAL|Treadmill Group|The targeted treadmill exercise dosage will consist of 1.)a session duration=30mins, 2.) frequency=3times/wk and 3.) Intensity= (60-84% heart rate reserve (HHR).4.) overall program duration=3months.
61919532|NCT02604017|EXPERIMENTAL|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
61919533|NCT01652911|EXPERIMENTAL|Cell Pouch|Participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
61919534|NCT04094077|EXPERIMENTAL|Aguix + Stereotactic Radiation|
61919535|NCT04507854|EXPERIMENTAL|Operated athletes|
61919536|NCT02764021|EXPERIMENTAL|1.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
61919537|NCT02764021|ACTIVE_COMPARATOR|2.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
62119524|NCT05706168|EXPERIMENTAL|Cycle ergometer Group|The targeted cycling exercise dosage will consist of 1.) a session duration=30mins, 2.) frequency=3times/wk and 3.) Intensity= (60-84% heart rate reserve (HHR).4.) overall program duration=3months.
62474909|NCT04802694|EXPERIMENTAL|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube.
62474910|NCT04802694|ACTIVE_COMPARATOR|Adhesive product|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube.
62474911|NCT05606744|ACTIVE_COMPARATOR|Eccentric exercise|Only multi-joint eccentric exercise
62474912|NCT05606744|EXPERIMENTAL|Eccentric training with blood flow restriction|Multi-joint eccentric exercise with blood flow restriction
62474913|NCT01990391|PLACEBO_COMPARATOR|Cassava flavored flour|The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
62474914|NCT01990391|EXPERIMENTAL|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
62474915|NCT05327491|EXPERIMENTAL|Treatment Sequence ABC|"Participants will be administered sotorasib orally in the following order:~Period 1 - as 1 tablet (test 1) Period 2 - as 2 tablets (reference) Period 3 - as 1 tablet (test 2)"
61919538|NCT05962346|EXPERIMENTAL|FETO Group|Participants will undergo fetal endoscopic tracheal occlusion (FETO) surgical procedure between 27 weeks 0 days and 29 weeks 6 days gestation.
62474916|NCT05327491|EXPERIMENTAL|Treatment Sequence BAC|"Participants will be administered sotorasib orally in the following order:~Period 1 - as 2 tablets (reference) Period 2 - as 1 tablet (test 1) Period 3 - as 1 tablet (test 2)"
62474917|NCT00911235|EXPERIMENTAL|Fesoterodine Alone|Reference treatment
62474918|NCT00911235|OTHER|fesoterodine plus fluconazole|Test treatment
61919539|NCT01779076|EXPERIMENTAL|100% oxygen during extubation|In this arm the intervention will consist of 100 % oxygen.
61919540|NCT01779076|EXPERIMENTAL|30% oxygen during extubation|In this arm the intervention will consist of 30 % oxygen.
62119525|NCT01379014|EXPERIMENTAL|Decision Aid Tool|Intervention group - receives the decision aid tool in booklet form and is introduced to it by an investigator.
62474919|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
62474920|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
62474921|NCT05654922|EXPERIMENTAL|ARINA-1 plus standard of care|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH); fixed dose, 4 mL solution inhaled twice daily via nebulization plus standard 3-therapy immunosuppression regimen and azithromycin
62474922|NCT05654922|OTHER|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
62474923|NCT01975623|EXPERIMENTAL|Intervention Group|Pulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
62474924|NCT04799314|EXPERIMENTAL|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose 200mg frequency 1 time for 2 months duration 2 years
62474925|NCT04799314|NO_INTERVENTION|No intervention|No intervention
62119526|NCT01379014|NO_INTERVENTION|Control|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
62119527|NCT00715494|NO_INTERVENTION|Group 1 - Control|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
62119528|NCT00715494|EXPERIMENTAL|Group 2 - Intervention|Participants in the experimental group will receive a focused set of interdisciplinary home-based interventions over a 12 week period.
62119529|NCT03830736|PLACEBO_COMPARATOR|Control product|A glucose solution (glucose and water) based on 42 gram carbohydrates.
62119530|NCT03830736|EXPERIMENTAL|Oat Beverage 1|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
62119531|NCT03830736|EXPERIMENTAL|Oat Beverage 2|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
62678427|NCT02991859|EXPERIMENTAL|Arm AD - FF followed by ELLIPTA Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.
62678428|NCT02991859|EXPERIMENTAL|Arm BA - FP followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
62474926|NCT06248879|EXPERIMENTAL|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
62678429|NCT02991859|EXPERIMENTAL|Arm BC - FP followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
62678430|NCT02991859|EXPERIMENTAL|Arm BE - FP followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.
62119532|NCT03830736|EXPERIMENTAL|Oat Beverage 3|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
61919541|NCT06438146|EXPERIMENTAL|Lirgalutide|"Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week on treatment period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study."
62119533|NCT03830736|EXPERIMENTAL|Oat Beverage 4|The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
61919542|NCT04645485|EXPERIMENTAL|Experimental arm|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).
62119534|NCT06553911|NO_INTERVENTION|No Intervention|Non-intervention
62307524|NCT04545307|EXPERIMENTAL|Allogenic transplant of BM-MSCs|"Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo button (pellet) is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
62678431|NCT02991859|EXPERIMENTAL|Arm CA - BUD followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
62736354|NCT03569878|EXPERIMENTAL|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
62736355|NCT03569878|ACTIVE_COMPARATOR|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
62119535|NCT06553911|EXPERIMENTAL|Artificial Intelligence-based medical imaging interpretation group|Using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
62119536|NCT01686906|EXPERIMENTAL|Bowman layer graft implantation|
62119537|NCT00833365|ACTIVE_COMPARATOR|Early treatment|Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old
62119538|NCT00833365|ACTIVE_COMPARATOR|Late treatment|Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old.
62119539|NCT02139046|ACTIVE_COMPARATOR|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62119540|NCT02139046|ACTIVE_COMPARATOR|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62307525|NCT05178134|ACTIVE_COMPARATOR|The wet formulation of ETVAX.|The wet formulation consists of a liquid suspension of inactivated bacteria (ETEX 21-24) and LCTBA in one vial, freeze-dried dmLT adjuvant in a second vial, and effervescent buffer granules in a separate sachet. Prior to administration, the buffer is dissolved in 150 ml tap water, followed by the addition of the content of the vaccine vial (inactivated bacteria mixed with LCTBA) and reconstituted and diluted adjuvant dmLT from the second vial.
62307526|NCT05178134|ACTIVE_COMPARATOR|The partially dried formulation of selected components of ETVAX.|The partially dried formulation, dmLT and LCTBA are spray-dried and mixed with the buffer granules and stabilizing excipients in a sachet. Prior to administration, the content of the buffer sachet (buffer, dmLT, and LCTBA) is dissolved in 150 ml tap water, followed by the addition of a liquid suspension of inactivated bacteria (ETEX 21-24).
62678432|NCT02991859|EXPERIMENTAL|Arm CB - BUD followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
62678433|NCT02991859|EXPERIMENTAL|Arm CE - BUD followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.
62119541|NCT02139046|EXPERIMENTAL|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62119542|NCT02139046|EXPERIMENTAL|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
61919543|NCT03494777|EXPERIMENTAL|Adherence-based incentivization|"Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.~This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.~Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group."
62119543|NCT02139046|PLACEBO_COMPARATOR|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62119544|NCT06092203||Patients|Pediatric patients who underwent treatment for utrollithiasis.
62119545|NCT06092203||Control|Cross-matched group of healthy children.
62119546|NCT00977223|EXPERIMENTAL|Aprepitant|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
62119547|NCT00977223|PLACEBO_COMPARATOR|placebo|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
62119548|NCT05174065|EXPERIMENTAL|Apremilast|Apremilast will be administered to participants twice daily (BID)
62474927|NCT06248879|ACTIVE_COMPARATOR|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
62736356|NCT05410925|EXPERIMENTAL|r-SAK group|intravenous injection of single-bolus 5 mg r-SAK in 3 min
62736357|NCT05410925|PLACEBO_COMPARATOR|placebo group|intravenous injection of placebo in 3 min
62736358|NCT05075018||Healthcare Workers with COVID-19 Infection|Healthcare workers who have been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
62119549|NCT05174065|EXPERIMENTAL|Placebo and Apremilast|Matching placebo will be administered to participants twice daily (BID) until week 16. After week 16, Apremilast will be administered to participants BID.
62119550|NCT06676930|ACTIVE_COMPARATOR|Colonoscopy with AI|Trainee using AI during colonoscopy inspection
62474928|NCT03538327|EXPERIMENTAL|Silybin|50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose \>155 mg/dl, during the OGTT.
62474929|NCT04131842|EXPERIMENTAL|ExFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive external focus of attention visual feedback.
62678434|NCT02991859|EXPERIMENTAL|Arm DA - ELLIPTA Placebo followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
62678435|NCT02991859|EXPERIMENTAL|Arm EB - DISKUS Placebo followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
62474930|NCT04131842|EXPERIMENTAL|ExFOCUS Auditory|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive auditory feedback.
62678436|NCT02991859|EXPERIMENTAL|Arm DC - ELLIPTA Placebo followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
62678437|NCT00790660|EXPERIMENTAL|ASP1941 Lowest Dose|Oral
62119551|NCT06676930|ACTIVE_COMPARATOR|Colonoscopy without AI|Trainee not using AI during colonoscopy inspection
62119552|NCT01679951|PLACEBO_COMPARATOR|Placebo|
62474931|NCT04131842|EXPERIMENTAL|InFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive internal focus of attention visual feedback via video.
62474932|NCT04131842|ACTIVE_COMPARATOR|NoFeedback|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and receive no feedback.
62678438|NCT00790660|EXPERIMENTAL|ASP1941 Low Dose|Oral
62678439|NCT00790660|EXPERIMENTAL|ASP1941 Medium Dose|Oral
62678440|NCT00790660|EXPERIMENTAL|ASP1941 High Dose|Oral
62678441|NCT00790660|PLACEBO_COMPARATOR|Placebo|Oral
62678442|NCT05837923|PLACEBO_COMPARATOR|Placebo Control 1|Relief Product Form 1 - control
62678443|NCT05837923|EXPERIMENTAL|Active Product 1.1|Relief Product Form 1 - active product 1
62678444|NCT05837923|EXPERIMENTAL|Active Product 1.2|Relief Product Form 1 - active product 2
62678445|NCT05837923|PLACEBO_COMPARATOR|Placebo Control 2|Relief Product Form 2 - control
62678446|NCT05837923|EXPERIMENTAL|Active Product 2.1|Relief Product Form 2 - active product 1
62678447|NCT05837923|PLACEBO_COMPARATOR|Placebo Control 3|Relief Product Form 3 - control
62678448|NCT05837923|EXPERIMENTAL|Active Product 3.1|Relief Product Form 3 - active product 1
62678449|NCT05837923|EXPERIMENTAL|Active Product 3.2|Relief Product Form 3 - active product 2
62119553|NCT01679951|EXPERIMENTAL|JNJ-38518168 (3 mg/d)|
62119554|NCT01679951|EXPERIMENTAL|JNJ-38518168 (10 mg/d)|
62119555|NCT01679951|EXPERIMENTAL|JNJ-38518168 (30 mg/d)|
62474933|NCT03129373|EXPERIMENTAL|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)~* Maximum 3 application by the technician in charge of the study.~* Apply between 15 to 20 sec on hand and 40 sec on feet."
62474934|NCT03129373|ACTIVE_COMPARATOR|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):~* Maximum 3 application by the technician in charge of the study.~* Apply between 15 to 20 sec on hand and 40 sec on feet."
62678450|NCT05837923|EXPERIMENTAL|Active Product 3.3|Relief Product Form 3 - active product 3
62307527|NCT04562324|EXPERIMENTAL|Experimental:|NF group participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin or norepinephrine reuptake inhibitors (SNRI) or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics
62307528|NCT04562324|EXPERIMENTAL|Healthy Experimental:|Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
62678451|NCT06469372|EXPERIMENTAL|Intervention Arm|Patients who are identified by the deep learning model as being at high risk for undiagnosed cardiac amyloidosis who are enrolled in the study.
62678452|NCT03697408|EXPERIMENTAL|Itacitinib and everolimus|
62678453|NCT06689345|OTHER|Healthy subjects|Once a week, each subject will receive a random stimulation in one of the following areas: (i) the afferent portion of the vagal nerve on the Cymba Conchae of the left ear (taVNS); (ii) rPMS on an efferent portion of the vagal nerve on the neck; (iii) rTMS intermittent theta- burst on the left DLPFC; (iv) simulated taVNS (SHAM) on helix left ear or.
62307529|NCT04562324|SHAM_COMPARATOR|Healthy Sham Comparator|Sham group participants receive 24 min NF sessions with pseudo-random numbers, 2-3 days per week, for 2 weeks
62474935|NCT03129373|ACTIVE_COMPARATOR|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):~* Maximum 3 application by the technician in charge of the study.~* Apply between 15 to 20 sec on hand and 40 sec on feet."
62678454|NCT06689345|EXPERIMENTAL|Chronic Pain and post Covid Syndrom - Active|These volunteers will receive 30 minutes of taVNS on the afferent portion of the vagal nerve on the ears.
62678455|NCT06689345|SHAM_COMPARATOR|Chronic Pain and post Covid Syndrom - Sham|These volunteers will receive 30 minutes of simulated taVNS on the afferent portion of the vagal nerve on the ears. For this, the equipment will be programmed to be on only for 1 minute.
62678456|NCT06184724|EXPERIMENTAL|Post Implementation|"Participants will be recruited from two surgery clinics in the Post-Implementation group. They will receive care using an implementation package for CGA use before surgery.~The control group will be historic baseline data. That is, older surgical patients who were treated Pre-Implementation. These patients would have received standard, routine clinical care without the use of the implementation package."
62678457|NCT05092516|EXPERIMENTAL|Active tDCS|This group will receive daily active stimulation (2 mA) to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.
62678458|NCT05092516|SHAM_COMPARATOR|Sham tDCS|This group will receive daily sham stimulation to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.
62678459|NCT05577065|EXPERIMENTAL|Active|Arm receiving investigational product (probiotic)
62678460|NCT05577065|PLACEBO_COMPARATOR|Placebo|Arm receiving placebo
62678461|NCT04509011|EXPERIMENTAL|Fluobeam® LX|Fluobeam® LX is used to detect autofluorescens and identify and evaluate parathyroid glands
62678462|NCT04509011|NO_INTERVENTION|Control|In the control group, the parathyroid glands are identified and evaluated by eye (ocular examination).
62678463|NCT03101670|EXPERIMENTAL|filgotinib|
62678464|NCT03101670|PLACEBO_COMPARATOR|placebo|
61919544|NCT03494777|EXPERIMENTAL|Viral suppression-based incentivization|"Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.~This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'."
62678465|NCT06240143|EXPERIMENTAL|A: 2x low dose intradermal|2 cycles of intradermal ipilimumab 0.5 mg + nivolumab 1 mg every 3 weeks
62678466|NCT06240143|EXPERIMENTAL|B: 6x low dose intradermal|6 cycles of intradermal ipilimumab 0.5 mg + nivolumab 1 mg every week
62678467|NCT06240143|EXPERIMENTAL|C: 2x higher dose intradermal|2 cycles of intradermal ipilimumab 10 mg + nivolumab 20 mg every 3 weeks
62678468|NCT06240143|EXPERIMENTAL|D: intradermal + intravenous|intradermal ipilimumab + nivolumab according to the optimal intradermal regimen plus 2 cycles of intravenous nivolumab 240mg every 3 weeks
62678469|NCT03382561|EXPERIMENTAL|Arm A (nivolumab, CE)|Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
62678470|NCT03382561|ACTIVE_COMPARATOR|Arm B (CE)|Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62678471|NCT05545306|ACTIVE_COMPARATOR|Set 1|+150% LPF +150% SOF -50% +200% LPF +200% SOF Fasting -25%
62678472|NCT05545306|ACTIVE_COMPARATOR|Set 10|+200% LPF -25% Fasting +200% SOF -50% +150% LPF +150% SOF
62678473|NCT05545306|ACTIVE_COMPARATOR|Set 2|+150% LPF +200% LPF -50% +150% SOF Fasting -25% +200% SOF
62678474|NCT05545306|ACTIVE_COMPARATOR|Set 3|+150% LPF Fasting +150% SOF -25% +200% SOF +200% LPF -50%
62678475|NCT05545306|ACTIVE_COMPARATOR|Set 4|Fasting -25% +200% LPF -50% +200% SOF +150% SOF +150% LPF
62678476|NCT05545306|ACTIVE_COMPARATOR|Set 5|-25% +150% SOF +200% LPF +150% LPF Fasting +200% SOF -50%
62678477|NCT05545306|ACTIVE_COMPARATOR|Set 6|Fasting +200% LPF +200% SOF -50% +150% LPF -25% +150% SOF
61919545|NCT03494777|NO_INTERVENTION|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.
61919546|NCT02231047|EXPERIMENTAL|64N Nutraceutical|Powdered 64N Nutraceutical 40 mg/kg/day mixed in 12 ounces of a culturally appropriate warm drink for 1 week (7 days).
62678478|NCT05545306|ACTIVE_COMPARATOR|Set 7|-50% +200% SOF -25% +150% SOF Fasting +200% LPF +150% LPF
62678479|NCT05545306|ACTIVE_COMPARATOR|Set 8|-50% +150% SOF +200% SOF +150% LPF -25% +200% LPF Fasting
62678480|NCT05545306|ACTIVE_COMPARATOR|Set 9|+150% SOF -25% +150% LPF +200% SOF Fasting +200% LPF -50%
62678481|NCT06223009|EXPERIMENTAL|Single ascending doses of cNP8|Subjects will be randomized to receive either a single dose of cNP8 or placebo (6:2). The doses will be studied sequentially starting with the lowest cNP8 dose.
62119556|NCT05579366|EXPERIMENTAL|Part A, B, C|PRO1184 monotherapy in escalating doses in Part A and at the recommended dose in Part B and C.
62307530|NCT04562324|SHAM_COMPARATOR|Sham Comparator|Sham Comparator: Sham group participants receive 24 min NF sessions with pseudo-random numbers, 2-3 days per week, for 2 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors (SNRI), benzodiazepines, tricyclic antidepressants, other antidepressants, antipsychotics, other sedative-hypnotics
62307531|NCT04977505||Pushlock|Patients with recurrent shoulder dislocation received surgery fixed by pushlock
62307532|NCT04977505||Gryphon|Patients with recurrent shoulder dislocation received surgery fixed by Gryphon
62119557|NCT05579366|EXPERIMENTAL|Part D1|PRO1184 in combination with carboplatin
62307533|NCT06364748|ACTIVE_COMPARATOR|Smart Cuff Group|Smart blood pressure cuff
62307534|NCT06364748|PLACEBO_COMPARATOR|Control Group|Standard of care
62307535|NCT05237544||leftover dried blood spot material|All samples used will be leftover dried blood spot material from the Newborn Screening Lab at Great Ormond Street Hospital.
62307536|NCT05237544||anonymous known SMA positive blood spots|The anonymous known SMA positive blood spots will be provided by an external company (Biogen),
62474936|NCT04827394|EXPERIMENTAL|Intervention group|In the intervention group, the infant will be placed on the thermal mattress, then wrapped.
62474937|NCT04827394|NO_INTERVENTION|Control group|In the non-intervention group, the infant will be delivered onto the sterile field as per standard of care.
62474938|NCT02350231|ACTIVE_COMPARATOR|The progesterone vaginal pessary group|Where they will have progesterone vaginal pessary (Prontogest 400 mg) daily at bed time from 28 weeks of pregnancy till delivery in addition to tonic and calcium
62474939|NCT02350231|PLACEBO_COMPARATOR|Tonics group|Where they will receive only tonics and calcium from 28 weeks of pregnancy till delivery
62119558|NCT05579366|EXPERIMENTAL|Part D2|PRO1184 in combination with bevacizumab
62119559|NCT05579366|EXPERIMENTAL|Part D3|PRO1184 in combination with pembrolizumab
62307537|NCT00091793|EXPERIMENTAL|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
62307538|NCT00091793|PLACEBO_COMPARATOR|Placebo|Placebo given day 1, month 6, month 12 and month 18
62307539|NCT02185469|ACTIVE_COMPARATOR|pneumatic retinopexy group|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
62307540|NCT02185469|ACTIVE_COMPARATOR|vitrectomy group|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
62474940|NCT00223925|PLACEBO_COMPARATOR|Placebo|
62474941|NCT00223925|EXPERIMENTAL|Maribavir (100 mg twice daily)|
62474942|NCT00223925|EXPERIMENTAL|Maribavir (400 mg twice daily)|
62474943|NCT00223925|EXPERIMENTAL|Maribavir (400 mg once daily)|
62119560|NCT06676332|SHAM_COMPARATOR|control|traditional physical therapy program
62119561|NCT06676332|EXPERIMENTAL|motor imagery|multisensory motor imagery training plus the traditional physical therapy program
62119562|NCT04560855||Covid19 Patients|Patients diagnosed as COVID-19 positive and managed on an outpatient basis.
62119563|NCT01189513|EXPERIMENTAL|SCH 900105|10 mg/kg intravenous Days 1, 8 and 15 of 30 day cycle.
62119564|NCT01292252|EXPERIMENTAL|Treatment|Forteo, Terapeptide 20 ug subcutaneous injection
62119565|NCT01292252|PLACEBO_COMPARATOR|Control|Saline placebo
62119566|NCT04584099|EXPERIMENTAL|Biopsy Removed Post Tx|All subjects had one radiofrequency treatment before scheduled biopsy or abdominoplasty on tissue to be removed during abdominoplasty immediately post treatment, 10 days post treatment, 20 days post treatment, and/or 30 days post treatment.
62119567|NCT04617652|ACTIVE_COMPARATOR|Group M|Magnesium group
62119568|NCT04617652|PLACEBO_COMPARATOR|Group C|Control group
62119569|NCT05437783|ACTIVE_COMPARATOR|Healthy Bangladeshi Bangalee volunteers|Bangladeshi bangalee participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
62307541|NCT02403206|EXPERIMENTAL|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
62307542|NCT02403206|ACTIVE_COMPARATOR|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
62307543|NCT06008379|EXPERIMENTAL|dose escalation and dose expansion|all subjects enrolled in the part of dose escalation and dose expansion will receive 7MW3711 by introvenous infusion
62474944|NCT00937898|EXPERIMENTAL|DASH Diet|High fruit and vegetable, low sodium diet
62474945|NCT00937898|ACTIVE_COMPARATOR|Average American Diet|Typical American diet (16% protein, \~50% carbohydrate, 33% fat)
62474946|NCT04987411||Hemorrhagic group|Patients with bleeding confirmed with eFAST or CT.
62474947|NCT05149066|EXPERIMENTAL|Experimental group|"The experimental group was administered a 9-sessions weekly programme in the school context.~It completed three assessment moments: pre-intervention, post-intervention and a 3-months after the intervention follow-up."
62474948|NCT05149066|NO_INTERVENTION|Control group|The control group did not receive any intervention. It completed three assessment moments: pre-intervention, post-intervention and a 3-months after the intervention follow-up.
62474949|NCT02129894|ACTIVE_COMPARATOR|abdominal binder|Post cesarean section patients will get a abdominal binder placed
62474950|NCT02129894|NO_INTERVENTION|No Abdominal Binder|Post cesarean section patients will not have abdominal binder
61919547|NCT02231047|SHAM_COMPARATOR|No 64N Nutraceutical|Culturally appropriate 12 ounce warm drink daily for 1 week (7 days).
61919548|NCT02398227|EXPERIMENTAL|HOPE|Cognitive Behavioral Treatment Program for PTSD
61919549|NCT02398227|ACTIVE_COMPARATOR|PCT|Present Centered Therapy for PTSD
61919550|NCT02739672|EXPERIMENTAL|TAH tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet
61919551|NCT02739672|ACTIVE_COMPARATOR|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
61919552|NCT02793128|EXPERIMENTAL|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
61919553|NCT00686998|EXPERIMENTAL|AZD2624|AZD2624 40 mg
62120085|NCT06676176||Observational|This study will be an observational study of a cohort of psoriatic arthritis patients who have failed to achieve sufficient response to standard non-biologic therapy. As they start their next treatment, this study aims to investigate the evolution of these patients in terms of the clinical, molecular and cellular profiles within the joint lining, peripheral blood and skin.
62307544|NCT06008379|EXPERIMENTAL|cohort expansion|all subjects enrolled in the part of cohort expansion will be treated by 7MW3711 will receive 7MW3711 by introvenous infusion
62678482|NCT06223009|PLACEBO_COMPARATOR|Single doses of placebo administered|Subjects will be randomized to receive either a single dose of cNP8 or placebo (6:2).
62678483|NCT05577715|EXPERIMENTAL|MORAb-202|
62678484|NCT02390635|EXPERIMENTAL|Diagnostic (18F-FDG PET/CT, whole body PET/MRI)|Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.
62678485|NCT02340676|EXPERIMENTAL|ECP plus IL-2|"* Extracorporeal Photopheresis (ECP) standard-of-care~* Daily subcutaneous (SC) interleukin-2 (IL-2) (Proleukin®) during predetermined weeks of treatment cycle"
62678486|NCT06551701||No statin|Patients who are identified with ASCVD who do not take a statin or do not take the recommended dose.
62678487|NCT00920270|ACTIVE_COMPARATOR|antibiotic|conventional antibiotics
62678488|NCT00920270|EXPERIMENTAL|colistin group|nebulized colistin
62678489|NCT06691386|EXPERIMENTAL|Randomization Sequence 1 = ABFCED|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product A~Test Product B~Reference Product F~Test Product C~Test Product E~Test Product D"
62678490|NCT06691386|EXPERIMENTAL|Randomization Sequence 2 = BCADFE|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product B~Test Product C~Test Product A~Test Product D~Reference Product F~Test Product E"
62678491|NCT06691386|EXPERIMENTAL|Sequence 3 = CDBEAF|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product C~Test Product D~Test Product B~Test Product E~Test Product A~Reference Product F"
62678492|NCT06691386|EXPERIMENTAL|Sequence 4 = DECFBA|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product D~Test Product E~Test Product C~Reference Product F~Test Product B~Test Product A"
62678493|NCT06691386|EXPERIMENTAL|Sequence 5 = EFDACB|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Test Product E~Reference Product F~Test Product D~Test Product A~Test Product C~Test Product B"
62678494|NCT06691386|EXPERIMENTAL|Sequence 6 = FAEBDC|"Usage of Test and Reference study products in controlled use and ad libitum use sessions during the 6 day in-clinic period in following order:~Reference Product F~Test Product A~Test Product E~Test Product B~Test Product D~Test Product C"
62678495|NCT01517776|EXPERIMENTAL|Cilengitide and metronomic temozolomide|Cilengitide 1800 mg/m² i.v. twice weekly and Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
62678496|NCT06688825|EXPERIMENTAL|Subjects on the waiting list for kidney transplant at VCUHS with BMI greater than 35 kg/m2.|This project will be a single-arm feasibility study, with a treatment intervention that includes three interrelated components: (1) the use of medications for weight loss, (2) patient education using a proven weight loss curriculum, and (3) technology tools for making healthy lifestyle choices.
61919554|NCT00686998|OTHER|Olanzapine|Olanzapine 15 mg
61919555|NCT00686998|PLACEBO_COMPARATOR|Placebo|Matching Placebo
61919556|NCT04507880|EXPERIMENTAL|RTSA group|Participants with a complex proximal humerus fracture given a RTSA
61919557|NCT04507880|ACTIVE_COMPARATOR|Hemiarthroplasty group|Historical cohort of participants, operated with a hemiarthroplasty of the shoulder
61919558|NCT01133327|EXPERIMENTAL|Adapt Carotid Stent System|Intervention with Adapt Carotid Stent System with the FilterWire EZ System
61919559|NCT02209129||women at high risk for breast cancer|
61919560|NCT03562871|EXPERIMENTAL|Cohort A1|Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle
61919561|NCT03562871|ACTIVE_COMPARATOR|Cohort A2|Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle
61919562|NCT03562871|EXPERIMENTAL|Cohort B1|Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
62120086|NCT05550740|EXPERIMENTAL|RLRL therapy|In addition to SVS, participants will be treated with RLRL twice a school day.
62120087|NCT04045106|EXPERIMENTAL|PNF pattern|"PNF patterns were performed using Dynamic of reversals technique which is characterized as active motion alternating from one direction (agonist) to the opposite (antagonist) without relaxing. The cervical patterns consisted of~1. Cervical flexion with right rotation followed by extension with left rotation.~2. Cervical flexion with left rotation followed by extension with right rotation."
62474951|NCT01987765||Relestat Ophthalmic Solution 0.05%|Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
62474952|NCT04471363||Cancer Specific Exercise Education|This subsample of participants will watch an audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
62474953|NCT04471363||Control|All participants will be asked to indicate their exercise knowledge, self-efficacy, beliefs and intentions.
62678497|NCT04618965|PLACEBO_COMPARATOR|Control (Placebo) group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
62678498|NCT04618965|EXPERIMENTAL|Intrathecal dexmedetomidine group|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
61919563|NCT03562871|ACTIVE_COMPARATOR|Cohort B2|Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
62678499|NCT04618965|EXPERIMENTAL|Intravenous dexmedetomidine group|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
61919564|NCT04648501|EXPERIMENTAL|Dual-task group|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
62307545|NCT04188158|EXPERIMENTAL|Intervention Group|3 cycles XELOX + Surgery+ 5 cycles XELOX
62307546|NCT04188158|OTHER|Control group|Surgery + 8 cycles XELOX
62307547|NCT00861042|EXPERIMENTAL|1|
62307548|NCT04982913|EXPERIMENTAL|Single dose of HEC116094（Part A, Cohort 1）|Healthy subjects receive sinele dose of HEC116094
62307549|NCT04982913|EXPERIMENTAL|Single dose of HEC116094（Part A, Cohort 2）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
62307550|NCT04982913|EXPERIMENTAL|Single dose of HEC116094（Part A, Cohort 3）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
62307551|NCT04982913|EXPERIMENTAL|Single dose of HEC116094（Part A, Cohort 4，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC116094 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
62474954|NCT06208215|PLACEBO_COMPARATOR|SoC (Standard-of-Care) + RZ358 (5 mg/kg) or Placebo|Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
62474955|NCT06208215|PLACEBO_COMPARATOR|SoC + RZ358 (10 mg/kg) or Placebo|Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
62474956|NCT06208215|EXPERIMENTAL|Open Label Arm, SoC + RZ358 (start 5mg/kg and increase to 10 mg/kg per protocol schedule|Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
62678500|NCT04227522|EXPERIMENTAL|Arm A (Rucaparib)|Rucaparib treatment (starting dose 600 mg, twice daily) after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
62678501|NCT04227522|PLACEBO_COMPARATOR|Arm B (Placebo)|Placebo treatment after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
62678502|NCT04704128||Case group|women with primary stomatodynia
62678503|NCT04704128||Control group|women without oral disease
62474957|NCT02443220|EXPERIMENTAL|distal-proximal group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu"
62474958|NCT02443220|ACTIVE_COMPARATOR|regional group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Juque"
62474959|NCT02443220|SHAM_COMPARATOR|control group|"no TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu ."
61919565|NCT04648501|ACTIVE_COMPARATOR|Single-task group|Single-task (conventional balance, coordination and cognitive training- active control) group participants will receive 10 minutes of warm-up, 20 minutes of conventional balance and coordination exercises that are in accordance to previously published literature, 20 minutes of cognitive training as single-task (same 4 tasks provided for the CIBT) and 10 minutes of cool down. In addition, falls prevention strategies will also be taught.
61919566|NCT03654742|ACTIVE_COMPARATOR|ECTE/Electrosurgery|Extracapsular tonsillectomy (ECTE) with monopolar electrosurgery
61919567|NCT03654742|EXPERIMENTAL|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
61919568|NCT03654742|EXPERIMENTAL|ICTE/Coblator|Intrapsular tonsillectomy (ICTE) with coblator
61919569|NCT01834859|EXPERIMENTAL|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
61919570|NCT01834859|EXPERIMENTAL|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
62119570|NCT05437783|ACTIVE_COMPARATOR|Healthy Bangladeshi minor ethnics volunteers|Bangladeshi minor ethnics participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
62119571|NCT05938894|EXPERIMENTAL|EFfect-food choices|Participants will complete four online games at least biweekly during the study.
62119572|NCT05938894|ACTIVE_COMPARATOR|Control|Participants will complete four online games at least biweekly during the study.
62678504|NCT03673722|EXPERIMENTAL|MDP only|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern through interaction with the online LEAP2 platform
62119573|NCT00004124|ACTIVE_COMPARATOR|bicalutamide, goserelin|androgen deprivation
62119574|NCT00004124|EXPERIMENTAL|bicalutamide, goserelin, mitoxantrone, prednisone|androgen deprivation plus mitoxantrone, prednisone
62119575|NCT05283395|EXPERIMENTAL|Rocklatan|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, one drop in each eye in the evening for 12 weeks
62119576|NCT05058170||Renal transplant patients|
62307552|NCT04982913|EXPERIMENTAL|Single dose of HEC116094（Part A, Cohort 5）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
62307553|NCT04982913|EXPERIMENTAL|Single dose of HEC116094（Part A, Cohort 6）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
62474960|NCT04082858|EXPERIMENTAL|Ketamine|Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
62474961|NCT04082858|ACTIVE_COMPARATOR|Midazolam|Participants will receive twice-weekly infusions of midazolam at 0.045mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
62678505|NCT03673722|EXPERIMENTAL|MDP plus PA|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern AND to increase Physical Activity using a mixture of structured and non-structured activities through interaction with the online LEAP2 platform
62678506|NCT03673722|PLACEBO_COMPARATOR|Control|Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and British Heart Foundation (BHF) guidelines
61919571|NCT05984849|EXPERIMENTAL|HPV game group|parent-child dyads receive HPV game intervention
61919572|NCT05984849|EXPERIMENTAL|COVID game group|parent-child dyads receive COVID game intervention
61919573|NCT05984849|NO_INTERVENTION|Usual care|parent-child dyads receive usual care (no intervention)
61919574|NCT04291378|ACTIVE_COMPARATOR|Photon radiation therapy|The patient is treated with standard radiation therapy based on photons
61919575|NCT04291378|EXPERIMENTAL|Proton radiation therapy|The patient is treated with experimental radiation therapy based on protons
61919576|NCT01230125|EXPERIMENTAL|Mapracorat|Ophthalmic suspension 3%
62119577|NCT05521880|OTHER|Historical outcomes with standard of care treatment|Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared
62119578|NCT02738840|EXPERIMENTAL|Prodigy MRI or Proclaim Elite MR|"The Prodigy MRI system is only MR conditional for scans of the head and extremities (upper except shoulder, lower except hip).~The Proclaim Elite system is MR conditional for scans of the head, extremities or any other body part."
62119579|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
62119580|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
62119581|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
62119582|NCT01508507||Cholera cases group|"Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
62119583|NCT01508507||Control group|"A randomly selected age matched individual, who have been living in the study area and did not seek care for diarrheal illness in the study health center since vaccination is defined as control"
62119584|NCT00732953|ACTIVE_COMPARATOR|1|Genous stent implantation with paclitaxel-eluting balloon therapy
62119585|NCT00732953|ACTIVE_COMPARATOR|2|Genous stent implantation
62120088|NCT04045106|EXPERIMENTAL|PNF stretching|PNF stretching was done using contract-relax-antagonist contract (CRAC) technique for cervical flexors, extensors, right and left lateral flexors, right rotators and left rotators.
62678507|NCT03914326|EXPERIMENTAL|Oral semaglutide|One tablet daily for 3.5 to 5 years
62678508|NCT03914326|PLACEBO_COMPARATOR|Placebo|One tablet daily for 3.5 to 5 years
62678509|NCT04044248||TIPS-obliteration|Patients undergoing combined transjugular intrahepatic portosystemic shunt (TIPS) creation plus transvenous obliteration for the treatment of gastric varices (GVs).
62678510|NCT01234714||Major liver resection|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (\>=3 segments).
62678511|NCT03981198|OTHER|RAP treatment|Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.
62678512|NCT05937165|ACTIVE_COMPARATOR|Standard Dose Freeze-dried Blueberry Powder|Consumption of 24 g of freeze dried blueberry powder for 3 consecutive days.
62678513|NCT05937165|EXPERIMENTAL|Higher Dose Freeze-dried Blueberry Powder|Consumption of 48 g of freeze dried blueberry powder for 3 consecutive days.
61919577|NCT01230125|PLACEBO_COMPARATOR|Vehicle|Vehicle of mapracorat ophthalmic suspension
62678514|NCT03004131|EXPERIMENTAL|fixed drug combination|MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet
62678515|NCT03004131|PLACEBO_COMPARATOR|Placebo|Nasal spray with no active dose plus Placebo tablet
62678516|NCT03004131|ACTIVE_COMPARATOR|active control|fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)
62678517|NCT03997734|EXPERIMENTAL|Treatment A-AB001|Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.
61919578|NCT03395132|EXPERIMENTAL|Fucicort® Lipid cream|Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.
61919579|NCT03395132|ACTIVE_COMPARATOR|Fucidin cream +betamethasone cream|The combination treatment with Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream. Twice daily for two weeks.
61919580|NCT03395132|PLACEBO_COMPARATOR|Vehicle cream|The vehicle cream, also named as Fucicort® Lipid cream vehicle, is the identical cream of Fucicort Lipid cream but without the active ingredient. Twice daily for two weeks.
62474962|NCT01721850|ACTIVE_COMPARATOR|control formula|infants are fed a commercial stage 1 infant formula during the first 4 months of life, according to protocol
62474963|NCT01721850|EXPERIMENTAL|intervention formula 1 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
62474964|NCT01721850|EXPERIMENTAL|intervention formula 2 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
61919581|NCT04172129||NANOS|NANOS™ Neck Preserving Hip Stem
61919582|NCT06400017|EXPERIMENTAL|Intraoperative and One month after the operation microelectrode stimulation of DBS|By comparing the behavioral characteristics of the memory paradigm under microelectrode stimulation during DBS operation and the characteristics of the electrophysiological signals behind it, as well as the behavioral characteristics of the memory paradigm under electrical stimulation and the characteristics of brain network activity during DBS startup one month after surgery, we analyzed the regulatory effect of substantia nigra DBS on memory network
61920022|NCT04095533||Sepsis|"Starting at admission to ICU, patients admitted to a mixed medical-surgical ICU will be assessed every second day to determine their muscle size as measured by ultrasound, and their muscle strength as measured clinically using the Medical Research Council strength assessment at the bedside.~One-time Measures:~* Illness severity as measured by the SOFA score within the first 24 hours of admission.~* duration of mechanical ventilation~* duration of stay in the ICU~* duration of stay in the hospital"
62678518|NCT03997734|EXPERIMENTAL|Treatment B-AB001|Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
62678519|NCT03997734|ACTIVE_COMPARATOR|Treatment C|Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.
62678520|NCT03997734|PLACEBO_COMPARATOR|Treatment A-Placebo|Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.
62678521|NCT03997734|PLACEBO_COMPARATOR|Treatment B-Placebo|Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
62678522|NCT03808467|EXPERIMENTAL|CRT + TAU|Cognitive Remediation Therapy + Treatment As Usual
62678523|NCT03808467|OTHER|TAU only|Treatment As Usual
62678524|NCT04912531|NO_INTERVENTION|Usual Care Arm|No intervention will be given to patients in the usual care arm.
62678525|NCT04912531|EXPERIMENTAL|Virtual Reality and Olfactory Stimuli Arm|Patients will undergo a virtual reality and olfactory stimuli therapy session at their appointment where they receive their pulmonary function test, 90 minutes before surgery, and each day they recover in the hospital. In addition, patients will receive nighttime olfactory stimulation using a bedside olfaction device.
61919583|NCT06114108|EXPERIMENTAL|Intervention group: Local consolidative treatment (LAT) & Systemic Therapy|"All patients undergo standard of care (SoC) first-line systemic therapy according to the results of the molecular analysis obtained from the diagnostic biopsy, as per standard of the respective center.~Patients will undergo additional complete surgical resection of the primary tumor with mediastinal lymph node sampling or radical radiotherapy (preferred stereotactic body radiotherapy (SBRT) to the primary tumor. Surgery and/or SBRT to the metastases will be performed before or after the treatment of the primary tumor according to the clinical need. Thereafter, the treatment will be followed by systemic anticancer treatment as SoC."
62678526|NCT05429502|EXPERIMENTAL|Phase I-part A: Ribociclib + Topotecan and Temozolomide|Participants with r/r NB, MB, HGG, MRT or RMS will be treated with ribociclib in combination with topotecan and temozolomide to determine MTD and/or RP2D. Ribociclib dose will be escalated with topotecan and temozolomide.
61919584|NCT06114108|ACTIVE_COMPARATOR|Control group: Systemic Therapy|Patients of the control group will receive systemic anticancer treatment alone chemotherapy, chemo-immunotherapy, immunotherapy alone, or targeted treatment).
62119586|NCT04052919|EXPERIMENTAL|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
61919585|NCT00999921|EXPERIMENTAL|Tamoxifen|10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months
62119587|NCT00369733|EXPERIMENTAL|Single arm|Aranesp adminsitered every other week for 52 weeks
62307554|NCT04982913|EXPERIMENTAL|Single dose of HEC116094（Part A, Cohort 7）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
62307555|NCT04982913|EXPERIMENTAL|Mulltiple doses HEC116094（ Part B, Cohort 1）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
62307556|NCT04982913|EXPERIMENTAL|Mulltiple doses HEC116094（ Part B, Cohort 2）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
62474965|NCT01073657|EXPERIMENTAL|Supported Education|Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
62678527|NCT05429502|EXPERIMENTAL|Phase I- Part B: r/r NB Cohort|Participants with r/r NB will be treated with ribociclib in combination with topotecan and temozolomide at the PR2D identified from Phase I-Part A
62678528|NCT05429502|EXPERIMENTAL|Phase I- Part B: r/r MB Cohort|Participants with r/r MB will be treated with ribociclib in combination with topotecan and temozolomide at the PR2D identified from Phase I-Part A
62678529|NCT05429502|EXPERIMENTAL|Phase I-Part B: r/r HGG Cohort|Participants with r/r HGG will be treated with ribociclib in combination with topotecan and temozolomide at the PR2D identified from Phase I-Part A
62119588|NCT00516386|EXPERIMENTAL|Insulin like growth factor- 1 (IGF-1)|Adolescent girls with AN meeting inclusion criteria were administered recombinant human (rh) rhIGF-1 at a dose of 35-40 mcg/k twice daily by subcutaneous injections for a 7-10 day period.
62119589|NCT02968472|EXPERIMENTAL|prophylactic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
62119590|NCT02694666|EXPERIMENTAL|Vibration training group|The vibration group will receive 8-week controlled whole-body vibration training as the intervention on the Galileo Med L device
62119591|NCT02694666|PLACEBO_COMPARATOR|Placebo training group|The placebo group will receive 8-week placebo training on the Galileo Med L device
62678530|NCT05429502|EXPERIMENTAL|Phase I-Part B: r/r MRT Cohort|Participants with r/r MRT will be treated with ribociclib in combination with topotecan and temozolomide at the PR2D identified from Phase I-Part A
61919586|NCT00999921|EXPERIMENTAL|Evening Primrose Oil|1000 mg daily for 3 months
61919587|NCT02582255|EXPERIMENTAL|Sabin mOPV2 1 dose|IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
62119592|NCT06673277|EXPERIMENTAL|Prolonged cooling at 8 ℃ then 10 ℃|The device will be set to circulate water through the cuff around the knee at 8 ℃ for the first 30-minutes, then at 10 ℃ for the subsequent 90-minutes.
62119593|NCT06673277|EXPERIMENTAL|Prolonged cooling at 8 ℃ then 12 ℃|The device will be set to circulate water through the cuff around the knee at 8 ℃ for the first 30-minutes, then at 12 ℃ for the subsequent 90-minutes.
61919588|NCT02582255|EXPERIMENTAL|SABIN mOPV2 2 doses|IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)
61919589|NCT02255578|OTHER|IVF treatment|Fertility, as determined by egg quality parameters, as well as metabolic parameters, will be assessed following Endobarrier treatment in PCOS during IVF treatment.
62119594|NCT03444649|EXPERIMENTAL|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with Standard chemotherapy (Idarubicin and Cytarabine)
62307557|NCT04982913|EXPERIMENTAL|Mulltiple doses HEC116094（ Part B, Cohort 3）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
62307558|NCT04982913|EXPERIMENTAL|Mulltiple doses HEC116094（ Part B, Cohort 4）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
62307559|NCT04982913|EXPERIMENTAL|The interaction with Oseltamivir of HEC116094（ Part C）|Healthy subjects received HEC116094 in cycle 1, Oseltamivir in cycle 2, and a combination of HEC116094 and Oseltamivir in cycle 3.There are washout periods between the first cycle and the second cycle and between the second cycle and the third cycle
62307560|NCT03019055|EXPERIMENTAL|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
61919590|NCT02255578|OTHER|clomiphene citrate treatment|Ovulation rate in response to clomiphen citrate after Endobarrier treatment in PCOS.
62307561|NCT03019055|EXPERIMENTAL|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
62678531|NCT05429502|EXPERIMENTAL|Phase I- Part B: r/r RMS Cohort|Participants with r/r RMS will be treated with ribociclib in combination with topotecan and temozolomide at the PR2D identified from Phase I-Part A
62678532|NCT05429502|EXPERIMENTAL|Phase II- Ribociclib+Topotecan and Temozolomide|Participants with r/r NB will be treated with ribocilib in combination with topotecan and temozolomide at the RP2D defined from Phase I part A.
62119595|NCT01984086|EXPERIMENTAL|Part A|Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg
62678533|NCT05429502|PLACEBO_COMPARATOR|Phase II: Placebo+Topotecan and Temozolomide|Participants with r/r NB will be treated ribociclib matching placebo in combination with topotecan and temozolomide
62119596|NCT01984086|EXPERIMENTAL|Part B|Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)
62119597|NCT01994122||People who have dropped out of school|
62119598|NCT01994122||College students (control group)|
62119599|NCT05569837|EXPERIMENTAL|Regular meal pattern|Participants will follow a regular meal pattern for 14 days
62119600|NCT05569837|EXPERIMENTAL|Irregular meal pattern|Participants will follow an irregular meal pattern for 14 days
62119601|NCT05133063|EXPERIMENTAL|Gratitude intervention|Participants will complete a gratitude letter where they spend eight minutes writing a letter of gratitude. The individual writes about his feelings of gratitude through a letter, based on a written instruction.
62119602|NCT05133063|ACTIVE_COMPARATOR|Control intervention.|Participants spend eight minutes writing a note describing the lab in which the study is being run.
62119603|NCT02158754||Corus CAD (ASGES)|Subjects receiving CorusCAD (ASGES) gene expression test as part of their diagnostic workup for typical and/or atypical symptoms of obstructive coronary artery disease.
62678534|NCT05556967|EXPERIMENTAL|Immulina Dietary Supplementation|Immulina Dietary Supplementation (200 mg per capsule) 4-200 mg capsules given by mouth once on the only study visit day.
62678535|NCT03438032||SSc-ILD|SSc-ILD subjects will be defined by those who fulfill 2013 American College of Rheumatology SSc criteria and have forearm modified Rodnan skin scores (mRSS) ≥1 (a validated, semi-quantitative scoring system for dermal fibrosis) and clinically relevant SSc-interstitial lung disease (ILD). A subject will be defined as having ILD if they have radiographic evidence for ILD and a forced vital capacity \<70% on pulmonary function test (PFT).
62678536|NCT03438032||Control|Healthy control subjects recruited from the Northwestern community will complete demographic and basic medical forms to ensure health
62678537|NCT03497286|EXPERIMENTAL|Treatment|Participants in the treatment condition will be enrolled in the text-based mentorship program and will be able to engage with their assigned mentor as much or as little as they choose.
62678538|NCT03497286|ACTIVE_COMPARATOR|Control|Participants in the control condition will receive periodic informational texts related to the growth and development of their new baby.
62678539|NCT05445843|EXPERIMENTAL|Cohort A- PD-L1<1%|Participants whose tumors harbor a KRAS G12C mutation and a PD-L1 expression \<1%, regardless of STK11 mutation status.
62678540|NCT05445843|EXPERIMENTAL|Cohort B- PD-L1≥ 1% and STK11 mutation|Participants whose tumors harbor a KRAS G12C mutation, a PD-L1 expression ≥ 1% and an STK11 co-mutation.
62119604|NCT02158754||Control|Matched subjects in the same practice that did NOT receive Corus CAD (ASGES) as part of their diagnostic workup.
62119605|NCT04533659|ACTIVE_COMPARATOR|Control group|This group will receive 4-week diabetes nutrition education with digital self-monitoring for diet and blood glucose.
62120089|NCT04045106|SHAM_COMPARATOR|control|Participants allocated to the control group received ineffective passive ROM.
62474966|NCT01073657|ACTIVE_COMPARATOR|General Peer Support|Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.
62678541|NCT03387579|EXPERIMENTAL|Smoflipid 20%|Patients randomized to this arm will receive the composite fish oil lipid, Smoflipid, at standard dosing up to 3 g/kg/day. Patients will be started on a dose of 1 g/kg/day and titrated up to maximum dose. As enteral nutrition is advanced the lipid dose will be weaned per study protocol and dietary recommendations.
62678542|NCT03387579|EXPERIMENTAL|Intralipid 20% Reduction|Patients randomized to this arm will receive soy-based lipid (Intralipid) at a dose of 1 g/kg/day throughout their enrollment in the study.
62119606|NCT04533659|EXPERIMENTAL|Intervention group|This group will receive 4-week personalized behavioral nutrition intervention with digital self-monitoring for diet and blood glucose and diabetes nutrition education. Participants will discuss the personalized nutrition change goals and recommendations based on metabolic profiling for assessing dietary patterns.
62119607|NCT00114244|EXPERIMENTAL|Arm I (sorafenib tosylate)|Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
61919591|NCT04067583||Physicians with recent aflibercept experience|Ophthalmologists who have prescribed and/or administered aflibercept in the past 6 months
62678543|NCT03387579|OTHER|Intralipid 20% Historic|Patients who retrospectively received soy-based lipid (Intralipid) at standard dosing of 2-3 g/kg/day were eligible for inclusion. Patients in this group were matched to prospective patients based on diagnosis, gestational age, and length of lipid therapy.
62119608|NCT00114244|EXPERIMENTAL|Arm II (sorafenib tosylate, gemcitabine hydrochloride)|Patients receive 400 mg oral sorafenib as in Arm I and 1000 mg/m2 gemcitabine IV over 100 minutes on days 1, 8, and 15.
62678544|NCT05151380|OTHER|Women with CO2 laser MonaLisa Touch ® sessions|Women with 3 sessions of CO2 laser MonaLisa Touch ®
62678545|NCT05571163|EXPERIMENTAL|Treatment Sequence AB|"Participants will be administered AMG 510 in the following order:~Period 1 (treatment A) - AMG 510 as oral tablets. Period 2 (treatment B) - AMG 510 as tablets dispersed in water."
62678546|NCT05571163|EXPERIMENTAL|Treatment Sequence BA|"Participants will be administered AMG 510 in the following order:~Period 1 (treatment B) - AMG 510 as tablets dispersed in water. Period 2 (treatment A) - AMG 510 as oral tablets."
62678547|NCT06476821|EXPERIMENTAL|Arm 1|
62678548|NCT06476821|EXPERIMENTAL|Arm 2|
62119609|NCT01446068|EXPERIMENTAL|Lean Subjects|
62119610|NCT01446068|EXPERIMENTAL|Obese subjects|
62119611|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
62119612|NCT01239316|EXPERIMENTAL|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62119613|NCT05501249|EXPERIMENTAL|Aquatic Exercise Group|Aquatic class 45 minutes, 3 times a week, for 8 weeks
62678549|NCT03768674||Inpatient cohort (Target group)|"Inpatient at mental health centre/ psychiatric hospital due to severe self-harm. Duration \> 4 weeks and/or \> five admissions last year.~Assessment of diagnoses, functioning and health services"
62119614|NCT05501249|NO_INTERVENTION|Control Group|Usual care for 8 weeks and one hour education session on fall prevention.
62119615|NCT06553209|EXPERIMENTAL|Group 1|
62119616|NCT06553209|EXPERIMENTAL|Group 2|
62307562|NCT03019055|EXPERIMENTAL|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
62307563|NCT03019055|EXPERIMENTAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
62307564|NCT03147027||VT ablation group|
62119617|NCT06553209|EXPERIMENTAL|Group 3|
62119618|NCT06553209|EXPERIMENTAL|Group 4|
62119619|NCT06553209|EXPERIMENTAL|Group 5|
62119620|NCT06553209|EXPERIMENTAL|Group 6|
62119621|NCT06553209|EXPERIMENTAL|Group 7|
62119622|NCT02726490|ACTIVE_COMPARATOR|Glyburide|"* Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~* The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.~* The dose of glyburide will be increased as needed to a maximum of 20mg /day.~* Antenatal testing will be initiated at 28 weeks~* Patients will receive monthly growth scans"
62119623|NCT02726490|ACTIVE_COMPARATOR|Glucovance|"* Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~* The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.~* Patients will receive monthly growth scans~* Antenatal testing will be initiated at 28 weeks."
62119624|NCT04829539|EXPERIMENTAL|Group I (BBT-CI)|Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
62119625|NCT04829539|ACTIVE_COMPARATOR|Group II (HEAL)|Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
62307565|NCT03147027||medication group|
62119626|NCT05377151|EXPERIMENTAL|mobile application (mHealth) intervention only|- the subjects will receive mobile application (mHealth) intervention only
62307566|NCT01893177|EXPERIMENTAL|Elderly subjects aged over 60 years|
62307567|NCT01893177|EXPERIMENTAL|Adults from 18 to 60 years old inclusive|
62307568|NCT01738035|EXPERIMENTAL|NEFECON 8 mg/day|NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months
62307569|NCT01738035|EXPERIMENTAL|NEFECON 16 mg/day|NEFECON 16 mg/day (4 active capsules daily) for 9 months
62307570|NCT01738035|PLACEBO_COMPARATOR|Placebo|Placebo (4 placebo capsules daily) for 9 months
62119627|NCT05377151|EXPERIMENTAL|mobile application (mHealth) intervention and dietitian consultation|- the subjects will receive the information from both mobile application (mHealth) and dietitian consultation
62119628|NCT05377151|NO_INTERVENTION|standard usual care- dietitian consultation|- the subjects will receive all the related information from the standard usual care- dietitian consultation
62119629|NCT05863195|EXPERIMENTAL|Arm A (HAI, floxuridine, standard chemotherapy)|Patients undergo surgery to place the HAI pump, followed by SPECT/CT on study. Patients then receive floxuridine via the HAI pump on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician: FOLFOX, FOLFIRI, or OX/IRI with or without cetuximab IV and/or panitumumab IV on study. Patients also undergo CT scans throughout the trial.
62119630|NCT05863195|ACTIVE_COMPARATOR|Arm B (standard chemotherapy)|Patients receive one of the following standard chemotherapy regimens per the treating physician: FOLFOXIRI, FOLFOX, FOLFIRI, or OX/IRI with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on study. Patients also undergo CT scans throughout the trial.
62307571|NCT00960557|EXPERIMENTAL|Combretastatin A1 Diphosphate|
62307572|NCT00783289|PLACEBO_COMPARATOR|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
62307573|NCT00783289|EXPERIMENTAL|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
62678550|NCT03768674||Outpatient comparison cohort|"Admitted to treatment within Norwegian Network of personality-focused treatment during 2017-2018.~Assessment of diagnoses, functioning and health services"
62678551|NCT05032599|EXPERIMENTAL|CD5 CART|All patients who receive CD5 CART cell infusion
61919592|NCT03252340||Drug: ADSTEM Inj.|Participants in Phase I clinical trials treated with ADSTEM Inj.
61919593|NCT06150144|EXPERIMENTAL|Patients with intralesional 5-fluorouracil.|
62119631|NCT02455752|ACTIVE_COMPARATOR|Reroperitoneal Group|LE-TME
62119632|NCT04184336||Persons of all ages|Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy
62119633|NCT04756323|EXPERIMENTAL|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
62307574|NCT00783289|EXPERIMENTAL|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
62307575|NCT00783289|EXPERIMENTAL|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
62307576|NCT03502746|EXPERIMENTAL|Nivolumab + Ramucirumab|Nivolumab 240mg IV + Ramucirumab 8mg/kg IV
62307577|NCT03160144|EXPERIMENTAL|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
62307578|NCT03160144|NO_INTERVENTION|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
62307579|NCT01539629||Pulse Width|One group reflecting two different pulse widths.
62307580|NCT02944747|EXPERIMENTAL|Education & paper based calendar|"The participants will be counseled on importance of remembering LMP. In addition, a free calendar will be provided to the participant who will be asked to record menstrual bleeding and spotting dates in each month. The women will be asked to record no bleeding if she did not bleed for any particular month. Likewise, if anybody forgets to record, she will ask to keep a record of it in the subsequent month. Female counselors from the study team will conduct the group or individual education sessions."
61919594|NCT06150144|ACTIVE_COMPARATOR|Patients with Surgery|
61919595|NCT03783702|EXPERIMENTAL|Experimental group|Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.
62119634|NCT04756323|EXPERIMENTAL|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
62119635|NCT04756323|PLACEBO_COMPARATOR|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
62119636|NCT04756323|EXPERIMENTAL|medium dosage on day 0, 28(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
62678552|NCT00715897|EXPERIMENTAL|Treatment- HBOT|HBOT treatment: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
62678553|NCT00715897|NO_INTERVENTION|control-HBOT|Cross group: Patients in the cross group were evaluated three times-baseline, after 2 months control period of no treatment and after a consequent 2 month of HBOT
62678554|NCT06358651|EXPERIMENTAL|Fasedienol Nasal Spray|
62678555|NCT06358651|PLACEBO_COMPARATOR|Placebo Nasal Spray|
62678556|NCT01043029|EXPERIMENTAL|aleglitazar|
62678557|NCT01043029|ACTIVE_COMPARATOR|pioglitazone|
62119637|NCT04756323|EXPERIMENTAL|high dosage on day 0, 28(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
62119638|NCT04756323|PLACEBO_COMPARATOR|placebo on day 0, 28(18~59years)|Two doses of placebo on the schedule of day 0,28
62119639|NCT04756323|EXPERIMENTAL|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62678558|NCT05848050|OTHER|brain metastases from solid cancer|Excision of the cerebral metastasis
62678559|NCT03177915|ACTIVE_COMPARATOR|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
62678560|NCT03177915|ACTIVE_COMPARATOR|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
62678561|NCT03247712|EXPERIMENTAL|Treatment Cohort 1|Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
62678562|NCT03247712|EXPERIMENTAL|Treatment Cohort 2|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
62678563|NCT03247712|EXPERIMENTAL|Treatment Cohort 3|Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
62678564|NCT03247712|EXPERIMENTAL|Treatment Cohort 4|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
62678565|NCT05621044|EXPERIMENTAL|FitBrothers smartphone active app|"Participants will be expected to engage with the FitBrothers app on a daily basis. Daily alerts and notifications will engage users in daily use of the app and provide up-to-date information on users' progress. Participant responses will also be used to evaluate additional or on-going support of users' needs (e.g., increase/ decrease prompts based on user preferences, tailored messages around a set goal, etc.). To protect privacy and to ensure that the participant is the person completing the app activities, KB will uniquely identify the user's smartphone based off the device's hardware footprint. The app will upload all app activity data to the KB secured web server database."
62678566|NCT05621044|ACTIVE_COMPARATOR|Comparator app|Nike Training Club is a free app available on iOS and Android platforms. The app is designed to increase fitness in users through a variety of mechanisms. Similar to FitBrothers, men will be able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior. Unlike the FitBrothers app, the Nike Training Club app was not developed with input from African American men, does not track health information (e.g. blood pressure, blood glucose), does not have a theoretical basis, and does not have specific strategies for maintenance.
62678567|NCT05887661|EXPERIMENTAL|hypovolemic phlebotomy (HP)|patients in this group undergoing laparoscopic hepatectomy was performed with goal-directed LCVP based on hypovolemic phlebotomy (HP)
62678568|NCT05887661|NO_INTERVENTION|Control|patients in this group undergoing laparoscopic hepatectomy was performed with LCVP but no hypovolemic phlebotomy (HP)
62678569|NCT05128032|EXPERIMENTAL|Sequence A: Standard microcatheter for Mapping #1 and PEDD device for Mapping #2.|Participants with either hepatocellular carcinoma (HCC) or colorectal liver metastases tumors receiving standard of care radioembolization treatment will be randomly assigned to undergo a routine mapping procedure first using a standard microcatheter 2-21 days before their radioembolization treatment day. Then on day of radioembolization treatment, an extra mapping procedure using the PEDD device catheter will be done just prior to the treatment.
62678570|NCT05128032|EXPERIMENTAL|Sequence B: PEDD device for Mapping #1 and standard microcatheter for Mapping #2.|Participants with either hepatocellular carcinoma (HCC) or colorectal liver metastases tumors receiving standard of care radioembolization treatment will be randomly assigned to undergo a routine mapping procedure first using the PEDD device catheter 2-21 days before their radioembolization treatment day. Then on day of radioembolization treatment, an extra mapping procedure using a standard microcatheter will be done just prior to the treatment.
62119640|NCT04756323|EXPERIMENTAL|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62736359|NCT05075018||Healthcare Workers without COVID-19 Infection|Healthcare workers who have not been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
62119641|NCT04756323|PLACEBO_COMPARATOR|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
62307581|NCT02944747|EXPERIMENTAL|Education & SMS system|Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
62474967|NCT06035315|NO_INTERVENTION|Control|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given government micronutrients; and perform ultrasound examinations each trimester and regular laboratory examination.
61919596|NCT03783702|ACTIVE_COMPARATOR|Control group|Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).
61919597|NCT01680133||NGT|Normal glycaemic healthy control men, age between 45-65, BMI 25-35 kg/m2
61919598|NCT01680133||T2D|Type 2 diabetic men, age 45-65 yrs, BMI 25-35, diagnosed \>5yrs and Hba1c 7-9%
61919599|NCT01680237|ACTIVE_COMPARATOR|Cognitive behavior therapy|"1. Identification of bodily sensations, cognitions and safety behaviors characteristic of the individual patient~2. Modification of dysfunctional beliefs and assumptions using socratic questioning and behavioral experiments~3. Exposure in-vivo~4. Relapse prevention"
62119642|NCT04756323|EXPERIMENTAL|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62119643|NCT04756323|EXPERIMENTAL|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62119644|NCT04756323|PLACEBO_COMPARATOR|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
62119645|NCT03072953|OTHER|APD334|APD334 active treatment for 12 weeks.
62119646|NCT05924958|EXPERIMENTAL|Eprolidone intervention in patients with chronic heart failure|The Pulidone group received conventional medication combined with 25 mg/day of Eprolidone, gradually increasing to 50 mg/day for 4 consecutive weeks
62119647|NCT05924958|NO_INTERVENTION|Patients in the conventional treatment group|Other conventional anti chronic heart failure drugs for the conventional treatment group taking non aldosterone receptor blockers
62119648|NCT03900442|EXPERIMENTAL|PTX-100|IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles
62120090|NCT03601780|ACTIVE_COMPARATOR|Local wound infiltration|local wound infiltration plus usual care
62120091|NCT03601780|PLACEBO_COMPARATOR|Control|usual care only
62678571|NCT04717908|EXPERIMENTAL|PZA sensitivity guided all oral regimen|"This regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide. Then based on molecular PZA drug sensitivity results, patients will be divided into three sub-groups.~The regimen for PZA-S patients, consisting of bedaquiline, linezolid, cycloserine and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week).~PZA-R sub-group regimen, consisting of bedaquiline, linezolid, cycloserine and clofazimine ,are given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) .~PZA-U sub-group continue the previous regimen, consisting of bedaquiline, linezolid, cycloserine , clofazimine and pyrazinamide ,until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) ."
62678572|NCT06190613|OTHER|Combination peer navigation and mHealth Intervention|Peer navigation and SMS text message medication reminders
62307582|NCT02944747|EXPERIMENTAL|Education & smart-phone application|Smart phones with an application and an inbuilt reminder system will be provided free of cost to participants who will be asked for recording menstruation dates. Experienced programmer from icddr,b will be involved in developing the application. Again, participants will be asked to record bleeding dates each month and will upload the data in the central server via internet. If participants fail to record the dates and upload the data, an automatic reminder will be sent.
62678573|NCT06190613|NO_INTERVENTION|Control|standard of care
62678574|NCT05813093|EXPERIMENTAL|Accelerated iTBS treatment|accelerated iTBS treatment protocol over 5 consecutive days
62678575|NCT05624957|EXPERIMENTAL|lidocaine|The patients will undergo shoulder arthroscopy with lidocaine epinephrine fluids irrigation.
62678576|NCT05624957|PLACEBO_COMPARATOR|control group|The patients will undergo shoulder arthroscopy with epinephrine fluids irrigation only.
62678577|NCT04778709|EXPERIMENTAL|Bone Graft A|Bone Graft A: Mixture of 25% small-particle cortical, 25% large particle cortical, 25% small particle cancellous, 25% large particle cancellous allograft
62678578|NCT04778709|ACTIVE_COMPARATOR|Bone Graft B|Bone Graft B: 100% large particle cancellous allograft
62678579|NCT06110689||Fontan|Patients undergoing cardiac MRI for Fontan,
62119649|NCT01801410|ACTIVE_COMPARATOR|Misoprostol|Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
62119650|NCT01801410|ACTIVE_COMPARATOR|Foley Catheter|Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
62119651|NCT00771446|EXPERIMENTAL|ELAD (plus Standard of Care)|Treatment with ELAD in addition to standard of care therapy Standard of care therapy defines uniform treatment for ascites, esophageal varices, dietary recommendations, etc.
62119652|NCT00771446|OTHER|Standard of Care (Control)|Standard of care treatment Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
62307583|NCT02944747|NO_INTERVENTION|Comparison|The participants will not receive any of the interventions that are focused in this study.
62307584|NCT06108479|EXPERIMENTAL|DF6215 Dose Escalation|Dose escalation cohorts of DF6215 in sequential ascending order.
62307585|NCT06108479|EXPERIMENTAL|DF6215 Safety/PK/PD|Expansion cohorts of DF6215 in multiple dose levels after evaluation for safety in the DF6215 Dose Escalation arm. Additional Pharmacokinetic (PK) and Pharmacodynamic (PD) samples included in this arm.
62678580|NCT06110689||Healthy controls|Patients undergoing thoracic MRI for chest wall deformity.
62678581|NCT02467881|ACTIVE_COMPARATOR|Physical Activity Increase (GLB-MOD)|Participants randomized to this arm will follow the traditional GLB program with an activity goal of 150 minutes per week of moderately intense physical activity similar to a brisk walk. Progression of the activity goal each week is slow and safe with increases of no more than 30 minutes per week. Participants are requested to try and achieve 20-30 minutes per day of moderate activity but, to allow for flexibility, that amount can be split into 10 minute increments. Self-reported monitoring for this group includes keeping track of weight, daily food intake as well the number of minutes each day spent being active as part of their planned activity goal. This is all recorded in the self-monitoring keeping track book.
62678582|NCT02467881|ACTIVE_COMPARATOR|Sedentary Time Decrease (GLB-SED)|"The GLB curriculum will be adapted to direct participants to decrease the time they spend sitting in a day rather than to increase moderate+ physical activity as is the case in the current GLB program. In order for the participant to become aware of how much time they spend sitting and where most of their sitting time occurs, they will fill out a 7 Day Sedentary Diary that consists of daily entry of time spent sitting over the course of one week. Participants will be asked to eliminate a 45 minute sitting bout in a day with non-sitting activity. They will initially be asked to eliminate 45 minutes of sitting for two days in that week. This will increase one day a week until 7 days in a week are met."
62678583|NCT02467881|OTHER|6-month delayed (DELAYED)|Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
62678584|NCT05530707|EXPERIMENTAL|Microbiome|13 participants using the product for 30 days. Aims to evaluate the quantification of S. Aureus in the skin before and after usage.
62678585|NCT05530707|EXPERIMENTAL|Clinical Trial|36 participants using the product for 60 days. Aims to evaluate the clinical, subjective and instrumental usage.
61919600|NCT01680237|ACTIVE_COMPARATOR|Exposure in-vivo|"1. Preparation of a brief behavior analysis of the individual case and construction of a hierarchy of relevant (internal and external) phobic situations~2. Exposure with internal stimuli~3. Exposure with external stimuli~4. Relapse prevention~Remark: In this condition there is no active work with the patient's catastrophic cognitions"
62678586|NCT01183182|EXPERIMENTAL|Needle Guidance|Lung biopsies performed with the needle guidance system.
62119653|NCT06677060|EXPERIMENTAL|Baxdrostat/Dapagliflozin|Participants randomised to the baxdrostat/dapagliflozin arm will initially receive a dose of baxdrostat lower dose and dapagliflozin. For participants that meet the up-titration criteria, baxdrostat may be up-titrated to higher dose.
62119654|NCT06677060|EXPERIMENTAL|Placebo/Dapagliflozin|Patients will receive a dose of dapagliflozin in combination with matching placebo
62678587|NCT05753683|ACTIVE_COMPARATOR|Standard: mHealth-Women's CoOp|Participants assigned to receive an evidence-based mHealth alcohol and other drug use and sexual risk reduction intervention for young African American women. The app will be installed on each participant's smartphone by study staff after randomization.
62678588|NCT05753683|EXPERIMENTAL|Enhanced: mHealth-Women's CoOp+Group|Participants assigned to receive an evidence-based mHealth alcohol and other drug use and sexual risk reduction intervention for young African American women, in addition to a virtual peer group component. The app with a link to the virtual group will be installed on each participant's smartphone by study staff after randomization.
62678589|NCT06119581|EXPERIMENTAL|Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab|LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62678590|NCT06119581|EXPERIMENTAL|Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab|LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
61919601|NCT04378452||COM-COVID cohort|Individuals of \>16 years old evaluated during the COVID-19 outbreak by an anonymous survey and willing to respond. Expected timeframe for the collection of completed surveys: March 31th, 2020-September 30th, 2020\]
62119655|NCT02887625|EXPERIMENTAL|Combination Therapy|pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week
62119656|NCT02887625|ACTIVE_COMPARATOR|Insulin Therapy|"insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) \<110 mg/dl.~and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c \<7.0% and postprandial plasma glucose (PPG) \<140 mg/dl"
62678591|NCT06119581|EXPERIMENTAL|Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum|LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62678592|NCT06119581|EXPERIMENTAL|Part A: LY3537982 plus Pembrolizumab|LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62119657|NCT06676098|EXPERIMENTAL|IANBD guided Inferior Alveolar Nerve block (IANB) injection|Participants will receive a guided IANB using an IANBD.
61919602|NCT03785743|EXPERIMENTAL|TLPD|Total laparoscopic pancreaticoduodenectomy for pancreatic cancer
61919603|NCT03785743|EXPERIMENTAL|OPD|Open pancreaticoduodenectomy for pancreatic cancer
62119658|NCT06194734|EXPERIMENTAL|KC1036|KC1036 will be administrated.
62119659|NCT06194734|ACTIVE_COMPARATOR|Investigator's choice of chemotherapy|Irinotecan, Docetaxel or S-1 will be administrated.
62119660|NCT06086080|OTHER|Control group|Standard care: knee brace for 2 weeks, physical therapy, sham taping (2-weeks)
62119661|NCT06086080|EXPERIMENTAL|Intervention group|Knee taping for 4-weeks, knee brace for 1 week, physical therapy
62119662|NCT01228916|EXPERIMENTAL|Tobacco Cessation and Secondhand Smoke Reduction|Community based interventions to raise awareness regarding secondhand smoke exposure, clean indoor air laws, smokefree homes, risks of tobacco use and benefits of cessation; include talks, healthcare provider training, radio public service announcements and talk shows, tleevision interviews, cessation classes and individual sessions, health fairs, community marches for smokefree spaces, materials and resources for assisting in tobacco use cessation, estsablishing smokefree homes, adhering to smokefree laws
62119663|NCT01228916|NO_INTERVENTION|Delayed Intervention Control|Assessment only during comparison period (no interventions will be provided over and above any secular trends in communities); delayed intervention will be provided at end of 1 year comparison period
62307586|NCT06108479|EXPERIMENTAL|DF6215 Expansion in Advanced Melanoma|Expansion cohort enrolling 20 patients with advanced melanoma who have progressed after an anti-PD-1 containing regimen using the dose selected for Phase 1b identified in the DF6215 Dose Escalation arm.
62678593|NCT06119581|PLACEBO_COMPARATOR|Part A: Placebo plus Pembrolizumab|Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62678594|NCT06119581|EXPERIMENTAL|Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum|LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62678595|NCT06119581|PLACEBO_COMPARATOR|Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum|Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
62678596|NCT06035497|EXPERIMENTAL|Administration of BMS-986369|
62678597|NCT02799290|NO_INTERVENTION|CONTROL|No intervention
62678598|NCT02799290|EXPERIMENTAL|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
62678599|NCT02799290|EXPERIMENTAL|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
62678600|NCT02289014|NO_INTERVENTION|Wait-list control group|Wait-list control group
62678601|NCT02289014|EXPERIMENTAL|Active treatment group|online stress Management program
62678602|NCT03192332|EXPERIMENTAL|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
62119664|NCT06524700|ACTIVE_COMPARATOR|A|
62307587|NCT06411184|EXPERIMENTAL|Regulatory T-Lymphocytes|Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
62307588|NCT04526977||Cases|HIV-1 infected individuals with previous or current diagnosis of SARS-CoV-2 infection, defined as the presence of suggestive symptoms and a positive PCR from the nasopharyngeal swab.
62678603|NCT03192332|ACTIVE_COMPARATOR|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
62678604|NCT06057337|EXPERIMENTAL|"Families with Pride (Familias con Orgullo)"|Participants in this group will receive the Families with Pride (Familias con Orgullo) intervention. The intervention consists of seven multi parent group sessions, three multi adolescent group sessions, and four family sessions (parents participant in a total of 11 sessions, adolescents participate in a total of seven sessions) that will be delivered by a facilitator to the parent-child dyad across 12 weeks.
62678605|NCT06057337|NO_INTERVENTION|Community Practice|In this condition, participants will not receive an intervention, only the standard of care services for up to 12 weeks.
62678606|NCT01371565|EXPERIMENTAL|mifepristone|
62678607|NCT04471844|EXPERIMENTAL|Optune® + RT + TMZ for 6 weeks|Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression.
62678608|NCT04471844|ACTIVE_COMPARATOR|RT +TMZ for 6 weeks|RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression.
62678609|NCT06606405||Scapular Dyskinesis Group|adolescent volleyball players with scapular dyskinesis
62678610|NCT06606405||Control Group|adolescent volleyball players without scapular dyskinesis
62119665|NCT06524700|ACTIVE_COMPARATOR|B|
62678611|NCT03390400|ACTIVE_COMPARATOR|Anterior Capsulotomy before Lens Fragmentation|Anterior capsulotomy will be performed by femtosecond laser before lens fragmentation
62678612|NCT03390400|ACTIVE_COMPARATOR|Lens Fragmentation before Anterior Capsulotomy|Lens fragmentation will be performed by femtosecond laser before anterior capsulotomy
62678613|NCT05381636|ACTIVE_COMPARATOR|Control group|Systemic intravenous chemotherapy with albumin paclitaxel 125 mg / m2 for D1, D8 + cisplatin 75 mg / m2 for D1, every 3 weeks for 1 cycle
62678614|NCT05381636|EXPERIMENTAL|Study group|esophageal arterial infusion chemotherapy
62678615|NCT03760640|EXPERIMENTAL|LY900014|Participants received 100 units per milliliter (U/mL) of LY900014 administered via continuous subcutaneous insulin infusion (CSII) by the Medtronic MiniMed 670G insulin pump.
62678616|NCT03760640|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Participants received 100 U/mL of Insulin lispro (Humalog) administered via CSII by the Medtronic MiniMed 670G insulin pump.
62678617|NCT03112369|EXPERIMENTAL|Narrative Exposure Therapy (NET)|Counseling program
62678618|NCT03112369|EXPERIMENTAL|Motivational Interviewing w/Skills Training (MIST)|Counseling program
62307589|NCT04526977||Controls|HIV-1-infected individuals of the same age (range, 5 years) and sex, who not have been diagnosed of clinical (asymptomatic) or confirmed SARS CoV-2 infection, but were positive for IgG antibodies (controls group 1) or with no evidence of SARS-CoV-2 infection (no previous neither current symptoms, negative for IgM/IgG antibodies, controls group 2)
62307590|NCT06289725||patients with genotype B|
62307591|NCT06289725||patients with genotype C|
62678619|NCT04702750|EXPERIMENTAL|Experimental group|
62678620|NCT06567561|EXPERIMENTAL|Whole Food Plant-Based Diet|Participants will be asked to consume and predominantly vegan, whole-foods diet, with the addition of fish, eggs, and fermented dairy.
62678621|NCT06567561|ACTIVE_COMPARATOR|Usual Firehouse Diet|Participants will be asked to consume their usual firehouse meals.
62678622|NCT01862965|EXPERIMENTAL|PredEver|Prednisone and Everolimus
62678623|NCT04702672|EXPERIMENTAL|Type 2 diabetes|Adults with T2D. Hemoglobin A1C between 42-78 mmol/l. No use of insulin or once-weekly glucagon-like peptide-1 (GLP-1) or acarbose. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
62678624|NCT04702672|EXPERIMENTAL|Non-diabetics|Adults without T2D. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
62307592|NCT04705480|EXPERIMENTAL|Pregabalin|
62678625|NCT04941898||TAK-660 15-50 international units per kilograms (IU/kg)|Participants will receive TAK-660 15-50 IU/kg slow intravenous injection every 8- 24 hours until the bleeding is resolved or wound healing.
62678626|NCT06238921|EXPERIMENTAL|SG + Zimberelimab with SRS|Treatment will be initiated with SRS followed 1 week later by SG on days 1 and 8 (10mg/kg) with zimberelimab on day 1 (360 mg IV) repeated every 3 weeks follow-up imaging response assessments will be conducted at q9 week intervals.
62119666|NCT00787033|EXPERIMENTAL|1|Dose escalation study with Expansion Cohorts at RP2D and Schedule
62119667|NCT05038228||NVAF High GI bleed risk|NVAF patients with a high risk of gastrointestinal bleeding
62119668|NCT05432934|EXPERIMENTAL|Dexamethasone|Dexamethasone 16mg will be added to local anesthetic solution for TAP blocks. 4mg will be injected at 4 anterior abdominal wall sites in a laparoscopically-administered TAP block. This is a single intraoperative dose.
62119669|NCT05432934|NO_INTERVENTION|Local anesthetic only|Local anesthetic (bupivacaine 0.25) 1mL/kg will be used for TAP blocks.
62307593|NCT04705480|EXPERIMENTAL|Gabapentin|
62307594|NCT04705480|ACTIVE_COMPARATOR|Neither Pregabalin nor Gabapentin|
62307595|NCT01164501|EXPERIMENTAL|BI 10773 low dose|BI 10773 tablets once daily
62307596|NCT01164501|EXPERIMENTAL|BI 10773 high dose|BI 10773 tablets once daily
62307597|NCT01164501|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching BI 10773
62307598|NCT03431948|EXPERIMENTAL|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
62678627|NCT05671679|EXPERIMENTAL|Intervention|The intervention group will use SNAQ app for the first 3 weeks (baseline to V1) of the study.
62119670|NCT02139748|ACTIVE_COMPARATOR|Dental Implant & ADM|Dental implant placement plus simultaneous grafting use one layer of ADM.
62307599|NCT03431948|EXPERIMENTAL|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
62474968|NCT06035315|ACTIVE_COMPARATOR|Interventions|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
62474969|NCT00747097|EXPERIMENTAL|1|gemcitabine+cetuximab
62474970|NCT01616381|ACTIVE_COMPARATOR|Sildenafil|Sildenafil tablets 40 mg x 3 daily
62678628|NCT05671679|ACTIVE_COMPARATOR|Control|The control group will continue estimating the carbohydrate count using their traditional methods for the first three weeks of the study (baseline to V1).
62678629|NCT05521399||Aim#1 Development|Developing dedicated multiparametric cardiac MRI protocols that account for a wide range of body sizes and patient physiology (e.g., heart rates, breathing patterns) of heart transplant recipients, is critical for the wide age range in HTx from pediatric to adult. Second, to facilitate clinical translation and multi-site portability of the often time-consuming data analysis. Methodology, to be employed and developed artificial intelligence (AI) deep learning concepts to enable automated cardiac MRI analysis across large cohorts. The hypothesis to be tested is that automated AI analysis can detect altered cardiac MRI metrics with improved efficiency and reduced inter-rater variability
62119671|NCT02139748|EXPERIMENTAL|Dental Implant & ADM & bone xenograft|Dental implant placement plus simultaneous grafting use one layer of ADM with bovine xenograft.
62119672|NCT03829813|EXPERIMENTAL|Patients|Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
62307600|NCT05734937|EXPERIMENTAL|gastric assessment of gastric volume|ultrasound assessment of gastric volume in Preoperative and postoperative period in right lateral decubitus position in pediatric patients
62307601|NCT01513915|ACTIVE_COMPARATOR|A parent only group CBT|"There was a Group cognitive behavioral intervention -based on parent training component of FRIENDS program- for parents of children with anxiety disorders who were allocated to intervention group."
62307602|NCT01513915|NO_INTERVENTION|Waiting list group|Parents of children with anxiety disorders who met the inclusion criteria and gave written informed consent and were allocated to wait list group.
62307603|NCT03373786|EXPERIMENTAL|RG-012 Single Dose|1.5 mg/kg RG012 subcutaneous injection
62307604|NCT03373786|EXPERIMENTAL|RG012 Every Other Week|1.5 mg/kg RG012 subcutaneous injections every other week
62307605|NCT06244186|EXPERIMENTAL|Probiotics|Take one packet (6 grams) of powder orally once daily. The probiotics contain fruit juice powder (strawberry, cranberry, black currant), sucralose, anhydrous citric acid, maltodextrin, silicon dioxide, and Lactobacillus delbrueckii subsp. Bulgaricus.
62307606|NCT06244186|PLACEBO_COMPARATOR|Placebo|Placebo contains fruit juice powder (strawberry, cranberry, black currant), sucralose, anhydrous citric acid, maltodextrin, and silicon dioxide.
62307607|NCT01859351|EXPERIMENTAL|WX-037|PI3K inhibitor
62307608|NCT01859351|EXPERIMENTAL|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
62474971|NCT01616381|PLACEBO_COMPARATOR|Placebo|Placebo tablet x 3 daily
62474972|NCT04360447|EXPERIMENTAL|Reformer pilates group|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
62119673|NCT03829813|EXPERIMENTAL|Family|Family participation in music therapy treatment sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour.
62307609|NCT01598818||Visual acuity|Comparison of best visual acuity and refraction using the First Sight Refractive System with autorefraction in subjects with refractive error.
62307610|NCT04901897|EXPERIMENTAL|kalifilcon A|kalifilcon A daily disposable contact lens
62474973|NCT04360447|ACTIVE_COMPARATOR|Home exercise group|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
62474974|NCT04030845||breast reconstruction|
62474975|NCT04030845||oncoplastic breast-conserving surgery|
62474976|NCT06215976|ACTIVE_COMPARATOR|Metformin|(39) patients taking metformin (500 mg twice daily) with cisplatin (70 mg/m2) and gemcitabine (1000 mg/m2) (GC) protocol
62474977|NCT06215976|NO_INTERVENTION|Control|(39) patients taking cisplatin (70 mg/m2) gemcitabine (1000 mg/m2) (GC) protocol without metformin
62474978|NCT03173235||Infertile women|Women which desire to have children but are probable infertile between 18 and 45 year old
62474979|NCT03173235||healthy women|Healthy women without systemic diseases in the age of 18 to 45 years
62474980|NCT01795872|OTHER|Several diagnostic procedures|
62307611|NCT04901897|ACTIVE_COMPARATOR|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
62678630|NCT05521399||Aim#2 Cardiac MRI in Pediatric HTx & Donor-Recipient Mismatch|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children. The anticipated enrollment of n=80 (20 per year) pediatric HTx patients (\<21 years) in years 2-5 at Lurie Children's Hospital. Inclusion criteria include a clinically indicated routine cardiac MRI for HTx graft surveillance. The hypothesis to be tested is that cardiac MRI measures can inform pediatric donor selection by providing important new data on the impact of donor-recipient mismatch (e.g. age, sex, heart size, etc.) on changes in tissue and function of the transplanted heart.
62474981|NCT04131374|EXPERIMENTAL|Virtual Reality Intervention|Virtual Reality Intervention: Each Person Living with Dementia-caregiver dyad will receive 10 weekly sessions of tailored reminiscence therapy delivered via virtual reality. Each session will last for a period of 15-30 minutes.
62474982|NCT06475924|OTHER|Cesarean Scar Defect (CSD)|"cesarean scar niche/defect (CSD) by transvaginal ultrasound that is defined as indentation at the site in the cesarean section scar with a depth of at least 2 mm that was agreed upon in 2019 by a European task force"
62474983|NCT00859872|EXPERIMENTAL|oral group|risperidone oral solution combination clonazepam oral
62474984|NCT00859872|ACTIVE_COMPARATOR|IM group|haloperidol IM injection
62474985|NCT05177991|ACTIVE_COMPARATOR|Liposomal Bupivacaine (Exparel)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
62678631|NCT05521399||Aim#3 Longitudinal patient outcome study|"The study will research the diagnostic value of cardiac MRI to improve the monitoring of heart transplant recipients for the major complications of acute cardiac rejection (ACR) and cardiac allograft vasculopathy (CAV). The anticipated follow-up enrollment of a total of 80 HTx patients during years 2-5 with a minimum of 5-year follow-up (20 HTx patients/year returning for HTx surveillance, baseline MRI scan was performed during the initial funding period. To clarify, our aim isn't to perfectly match donor-recipient but rather to study the clinical implications of mismatch and to help define the threshold for too much mismatch. In other words, today human beings sometimes don't accept a heart if the mismatch will be too great, this is sometimes hard to do and literature is scarce, especially in terms of functional rather than anatomic implications. Our goal is that this study could better inform these decisions."
62678632|NCT05954962|ACTIVE_COMPARATOR|CONTROL GROUP|"The patient will start to administer: (1) daily subcutaneous injections of gonadotropins on day 1 of ovarian stimulation (2) daily subcutenous injections of ganirelix (antagonist) on day 5 or 6 of ovarian stimulation. Both medication will be stopped 1-2 days before egg retrieval."
62119674|NCT03829813|EXPERIMENTAL|Administration and Staff|Staff/Administration are not participants in music therapy, but rather have observed sessions, or worked as co-treating clinicians with music therapists for patient participants.
62307612|NCT04901897|ACTIVE_COMPARATOR|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
62307613|NCT04512079|ACTIVE_COMPARATOR|Prophylactic Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min)
62307614|NCT04512079|ACTIVE_COMPARATOR|Full Dose Enoxaparin|Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
62307615|NCT04512079|EXPERIMENTAL|Apixaban|Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
62119675|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
62307616|NCT04993742|EXPERIMENTAL|MOMS Intervention|"Women that are currently in the Mentors Offering Maternal Support (M-O-M-S) research program as well as pregnant women entering prenatal care in the first trimester, who are not in the M-O-M-S program may participate in the study.~Arms Assigned Interventions Experimental: M-O-M-S Intervention M-O-M-S intervention is 10, 1 hour prenatal mentored support groups~No Intervention: Routine Prenatal Care Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines"
62307617|NCT04054908||Cohort A|Patients treated with oral fluoropyrimidine (Capecitabine (CAP)) as part of standard of care (SOC) chemotherapy
62119676|NCT02740686||Frequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the frequent exacerbators group based on whether they have had 2 or more hospitalisations for exacerbations or have taken 2 or more courses on steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
62120092|NCT04618224||Control group|"* 70 patients with normal vision (NVG) with adequate literacy of written Greek language~* 30 patients with low vision (LVG) with adequate literacy of written Greek language~These patients are tested on the digital reading test DDART."
62307618|NCT04054908||Cohort B|Patients treated with Trifluridine/Tipiracil (TAS-102) including those receiving it in combination with Y-90 radioembolization as part of a clinical trial
62307619|NCT04054908||Cohort C|Patients receiving CAP plus immunotherapy (pembrolizumab) and bevacizumab as part of a clinical trial.
62307620|NCT06334835||Childhood Acute Lymphoblastic Leukemia patients|Bone marrow mononuclear cells from childhood acute lymphoblastic leukemia of T cells
62474986|NCT05177991|ACTIVE_COMPARATOR|Bupivacaine (Marcaine)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
62678633|NCT05954962|EXPERIMENTAL|STUDY GROUP|The patient will start to administer: (1) daily subcutaneous injections of gonadotropins on day 1 of ovarian stimulation (2) daily oral capsules of natural micronized progesterone on day 1 of ovarian stimulation. Both medication will be stopped 1-2 days before egg retrieval.
62678634|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
62307621|NCT06334835||Healthy subjects|Cord blood mononuclear cells from healthy volounteers
62307622|NCT06201299|EXPERIMENTAL|Chair-based Exercise Group|Exercises will be performed with chair support.
62307623|NCT06201299|EXPERIMENTAL|Standard Exercise Group|Exercises will be performed using theraband.
62307624|NCT02813538||IGC and thromboelastometry|Patients that have hyper, normo o hypcoagulability measured by tromboelastometry and anticoagulant proteins levels early after major liver resection and clinical evolution and patients with liver funcion impairment or without it, measured by indocyanine green clearance early after surgery and clinical evolution
62307625|NCT02396862||Patients with moderate to severe Hemophilia A / Cohort 1|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)
62307626|NCT00789204|EXPERIMENTAL|GPR|Global Postural Re-Education
62307627|NCT00789204|ACTIVE_COMPARATOR|SEP|Standard Exercise Programm
62307628|NCT02225886|EXPERIMENTAL|Ascorbic acid|Patients will receive a 300 mg intravenous ascorbic acid, 3 times a week, postdialysis, except for the dialysis sessions when iv iron is administered.
62678635|NCT03129607||Observation group|Patients without POPF will be included into observation group.
62307629|NCT02225886|PLACEBO_COMPARATOR|Control group|Patients will receive 100 mL saline solution, 3 times a week, with associated medication, except but the dialysis sessions when iv iron is administered.
62307630|NCT00379938|EXPERIMENTAL|1|25 micrograms + MF59 (n=26)
62307631|NCT00379938|EXPERIMENTAL|3|2.5 micrograms + MF59 (n=26)
62307632|NCT00379938|PLACEBO_COMPARATOR|4|saline (n=11)
62474987|NCT01137539|EXPERIMENTAL|Gynecare TVT-SECUR system|All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
62474988|NCT04166734|OTHER|Initial safety cohort|Patients will receive an initial dose of pembrolizumab in week 1 dosed at 200 mg. They will then receive SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
62678636|NCT03586609|EXPERIMENTAL|Treatment (cladribine, cytarabine, venetoclax, azacitidine)|See Detailed Description.
62678637|NCT06695871|NO_INTERVENTION|Control group|The routine clinical outpatient follow-up protocol was implemented, and a postoperative rehabilitation health manual was provided to patients the day following LEEP surgery. Outpatient evaluations were subsequently conducted at 1 month, 3 months, and 6 months post-surgery.
62736360|NCT05087368|EXPERIMENTAL|Stage 1 - Formulation-finding for SCB-2019 - Group 1|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 1: (N=30) Day 1: SCB-2019 (9 μg) alum;"
62307633|NCT00379938|EXPERIMENTAL|2|25 micrograms alone (n=26)
62307634|NCT02990884|ACTIVE_COMPARATOR|block and ketamine|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
62307635|NCT02990884|ACTIVE_COMPARATOR|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
62307636|NCT02990884|ACTIVE_COMPARATOR|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
62307637|NCT05890391|EXPERIMENTAL|Time-Restricted Eating|Individuals in the TRE group applied a diet limited to 8 hours for 8 weeks.
62307638|NCT05890391|EXPERIMENTAL|Energy-Restricted Diet|Individuals in the ERD group followed a diet specially prepared for them for 8 weeks.
62307639|NCT00852644|EXPERIMENTAL|56 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
62307640|NCT00852644|EXPERIMENTAL|62 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
62307641|NCT00852644|EXPERIMENTAL|68 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
62474989|NCT04166734|OTHER|Expansion cohort|An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at 200 mg in week 1. This will be followed in by SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
62474990|NCT06041945|ACTIVE_COMPARATOR|Standard Arm CADe|Standard, high-definition colonoscopy with the use of CADe assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
62474991|NCT06041945|ACTIVE_COMPARATOR|Standard Arm CADe/CADx|Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
62474992|NCT06041945|EXPERIMENTAL|Leave-In-Situ Arm|"Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION, NEC).~Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology."
62474993|NCT04418310|ACTIVE_COMPARATOR|Lay open and curettage|Lay open and curettage in Pilonidal sinus
62474994|NCT04418310|ACTIVE_COMPARATOR|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method in the treatment of sacrococcygeal pilonidal sinus disease
62474995|NCT04889014|ACTIVE_COMPARATOR|Personal genomic educational testing (PGET)|PGET group participants received their own pharmacogenomic testing results prior to the course modules covering material tested in the knowledge assessment
62474996|NCT04889014|PLACEBO_COMPARATOR|No personal genomic educational testing (NPGET)|No PGET (NPGET) group participants did not receive their own pharmacogenomic testing results until after study completion.
62474997|NCT03183986|ACTIVE_COMPARATOR|Phototherapy 478 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 478 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
62474998|NCT03183986|ACTIVE_COMPARATOR|Phototherapy 459 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 459 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
62474999|NCT04480762|EXPERIMENTAL|SHR-1703-Subcutaneous administration of Dose 1|A single subcutaneous injection of SHR-1703 (Dose 1) or Placebo
62475000|NCT04480762|EXPERIMENTAL|SHR-1703-Subcutaneous administration of Dose 2|A single subcutaneous injection of SHR-1703 (Dose 2) or Placebo
62475001|NCT04480762|EXPERIMENTAL|SHR-1703-Subcutaneous administration of Dose 3|A single subcutaneous injection of SHR-1703 (Dose 3) or Placebo
62475002|NCT04480762|EXPERIMENTAL|SHR-1703-Subcutaneous administration of Dose 4|A single subcutaneous injection of SHR-1703 (Dose 4) or Placebo
62475003|NCT04480762|EXPERIMENTAL|SHR-1703-Subcutaneous administration of Dose 5|A single subcutaneous injection of SHR-1703 (Dose 5) or Placebo
62475004|NCT05790824|EXPERIMENTAL|Spa therapy|Protocol of spa therapy in rheumatology for 3 weeks
62120093|NCT04618224||Study group|The same patients as those in the control group (NVG, LVG) are tested on the online version of the Greek digital reading test DDART (wDDART).
62475005|NCT05205876|NO_INTERVENTION|Control (Dexcom app)|This group will use the Dexcom application for management of their blood glucose for the duration of the study (8 weeks).
62475006|NCT05205876|EXPERIMENTAL|Intervention (Eddii app)|This group will use the Dexcom application for the initial 2 weeks of the study, and switch to using the Eddii application on Day 14 of the study for the remaining 6 weeks of the study.
62475007|NCT05988983||OTC users|Participants using the oral contraceptive pill purchased over the counter
62475008|NCT05988983||Rx users|Participants using the oral contraceptive pill received by a prescription
62475009|NCT02514330|EXPERIMENTAL|Interval Training at 1% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 1% incline, Final Drop Jump (20;30;40 cm)
62736361|NCT05087368|EXPERIMENTAL|Stage 1 - Formulation-finding for SCB-2019 - Group 2|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 2: (N=30) Day 1: SCB-2019 (9 μg) CpG 1018/alum;"
62120094|NCT04271449|EXPERIMENTAL|Cerebellum tDCS|Cerebellum tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
62120095|NCT04271449|EXPERIMENTAL|Primary motor cortex|Primary motor cortex tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
62120096|NCT04271449|SHAM_COMPARATOR|Sham tDCS|Sham tDCS arm will serve as a sham comparator for other experimental conditions. This arm will be subdivided into two groups depending on the localisation of the electrodes (cerebellum placement vs primary motor cortex placement).These two subgroups will be divided again in two subgroups depending on the task exposed (pointing vs throwing).
62120097|NCT05657496|ACTIVE_COMPARATOR|Steroid|A 6mL injection at the initial visit of triamcinolone 40 mg/1 mL (Kenalog) with 5 mL of 1% lidocaine
62120098|NCT05657496|EXPERIMENTAL|Platelet-rich Plasma|An injection at the initial visit of approximately 4-6 mL of PRP
62307642|NCT00852644|EXPERIMENTAL|56 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
62307643|NCT00852644|EXPERIMENTAL|62 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
62307644|NCT00852644|EXPERIMENTAL|68 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
62475010|NCT02514330|EXPERIMENTAL|Interval Training at 10% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 10% incline, Final Drop Jump (20;30;40 cm)
62475011|NCT02514330|NO_INTERVENTION|Control|Procedure: Initial Drop Jump (20;30;40 cm), 20 min Rest, Final Drop Jump (20;30;40 cm)
62678638|NCT06695871|EXPERIMENTAL|Intervention group|A postoperative rehabilitation health manual was provided to patients the day following LEEP surgery. The nursing team, possessing over one year of clinical experience in gynecological nursing and psychological counseling, collaborated with clinicians to deliver health consultation services. They conducted in-person consultations lasting 10-15 minutes during routine outpatient follow-ups at 1, 3, and 6 months post-surgery. Patients were assessed based on the challenges encountered in postoperative rehabilitation and sexual life, and tailored guidance services were administered. Additionally, online counseling and guidance services were offered at 2, 4, or 5 months following surgery.
62678639|NCT00310180|EXPERIMENTAL|Group 1 (Oncotype DX recurrence score =< 10)|Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.
61919604|NCT00911443|EXPERIMENTAL|Dacarbazine + Interferon alpha + thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
61919605|NCT00911443|EXPERIMENTAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
62119677|NCT02740686||Infrequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the infrequent exacerbators group based on whether they have had no more than 1 hospitalisation for exacerbations or have not taken more than 1 course of steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
62119678|NCT02740686||Healthy smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and currently smoke.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. A resting blood sample will be taken from these patients and used to compare baseline measurements with the COPD groups.
62119679|NCT02740686||Healthy never smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and have never smoked.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. Resting blood samples will be taken from these patients and used to compare baseline measurements with the COPD groups.
62307645|NCT01166269|EXPERIMENTAL|Grass-Allergen x 6|This arm will receive 6 injections of allergen.
62307646|NCT01166269|ACTIVE_COMPARATOR|grass-allergen x 3 and placebo x 3|this arm will receive 3 injections of allergen, and 3 injections of placebo.
62307647|NCT01166269|PLACEBO_COMPARATOR|placebo x 6|this arm will receive 6 injections of placebo.
62307648|NCT00334750||There is no intervention in this study|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
62307649|NCT03309670||Formers young patients|all patients hospitalized between 2006 and 2010 in the Pass'Aje unit
62307650|NCT00546351|EXPERIMENTAL|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
62475012|NCT03987633||Displaying trait of interest|There are 19 disease areas under investigation. Enrolled patients are segmented into cohorts based on data collected through questionnaires and medical histories. This data-driven approach does not allow for precisely predefined cohorts for the diseases under investigation. Therefore, as a default, the two general predefined cohorts are set as either displaying or not displaying a trait that would form the basis of an investigation.
62475013|NCT03987633||Not displaying trait of interest|Please see above.
62475014|NCT03840291|EXPERIMENTAL|Edoxaban treatment|"1. Men or women aged ≥ 20 years with NVAF patients who has LAA thrombi documented by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication are eligible.~2. Patients in this group are taking Lixiana® (Edoxaban) 60mg for resolution of left atrial appendage thrombi~3. Reduced (30mg) dose is administered in patients with one or more of the following clinical factors:~   * Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)~  * Low body weight ≤ 60 kg~  * Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin,dronedarone, erythromycin, or ketoconazole."
62678640|NCT00310180|EXPERIMENTAL|Group 2, Arm I (experimental)|Patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
62678641|NCT00310180|ACTIVE_COMPARATOR|Group 2, Arm II (standard)|Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
62307651|NCT05171738|ACTIVE_COMPARATOR|group(1)|Group I: will include ten patients undergo maxillary molar distalization using skeletally anchored distal jet appliance with MOPs that will be performed buccally on repeated basis on two sides before and during maxillary molar distalization
62119680|NCT03822650||Prospective|"Subjects who meet eligibility criteria and enroll in the prospective arm will be assessed every 6 months ± 4 weeks for a period of up to 3 years, according to the Schedule of Assessments.~Subjects in the Prospective arm may also participate in the Retrospective arm."
62307652|NCT05171738|ACTIVE_COMPARATOR|group(2)|Group II:will include ten patients undergo maxillary molar distalization using skeletally anchored distal jet appliance with MOPs that will be performed both buccally and palatally on repeated basis on two sides before and during maxillary molar distalization.
62307653|NCT03590561|EXPERIMENTAL|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
62307654|NCT03590561|NO_INTERVENTION|Control diet|Participants will eat regular diet.
62307655|NCT02067221|ACTIVE_COMPARATOR|RIRS (retrograde intrarenal surgery)|Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
62307656|NCT02067221|EXPERIMENTAL|MPCNL (mini-perc)|"A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.~Patients will be randomized and assigned to each group at the ratio 1:1"
62307657|NCT00928915|EXPERIMENTAL|Prothrombin complex concentrate (PCC)|intravenously, 30 IU/kg
62678642|NCT00310180|EXPERIMENTAL|Group 3 (Oncotype DX recurrence score >= 26)|Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in group two who are assigned to receive both types of treatment.
62119681|NCT03822650||Retrospective|Upon confirmation of eligibility criteria, the site will obtain an Informed Consent/Assent form and release of medical records from the subject/legally authorized representative to allow review of the medical records from the subject's primary care physician and/or specialists to confirm the CLN5 diagnosis and disease course. To facilitate collection of the medical records, a caregiver interview will be completed at initial enrollment then once yearly for up to 3 years.
62119682|NCT05500664|ACTIVE_COMPARATOR|Lavender|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
62119683|NCT05500664|NO_INTERVENTION|Control|
62307658|NCT00928915|EXPERIMENTAL|Fresh frozen plasma (FFP)|intravenously, 20ml/kg
62307659|NCT06398392|EXPERIMENTAL|Drug: radiation dosimetry and biodistribution|6 healthy adult volunteers (3 men and 3 women) will be assigned to the radiation dosimetry group. \[18F\]PBR111 will be administered once.
62307660|NCT01430195|EXPERIMENTAL|Afamelanotide + NB-UVB: Experimental|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 4 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total).
62307661|NCT01430195|ACTIVE_COMPARATOR|NB-UVB alone: Active Comparator|Subjects in this arm will receive NB-UVB light only (administered thrice weekly, 72 treatments in total).
62307662|NCT04307966||Intervention|537 pre-adolescent grade 6 learners and their parent (n=537) were invited to participate. Trained educators delivered lessons about HIV and obesity to all Grade 6 students at 5 government-run schools. The classroom curriculum for students required delivery of a five-hour face-to-face intervention delivered weekly through 10 30-minute lessons. Students were asked to communicate their learnings to their parents at home. Parents were requested to read through the lesson in a workbook and to sign acknowledgement that they had read the content. The workbook contained shared student-parent homework activities that took approximately 30 minutes per week. Data was only collected from Learners (n=425) and parents (n= 427)who had consented to the study. A pretest was conducted. The intervention was then implemented. A posttest was conducted afterwards. Both parents and learners answered self-reported questionnaires.
62307663|NCT02739412|EXPERIMENTAL|Interleukin-2|IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.
62307664|NCT00330824|EXPERIMENTAL|antibiotic steroid (single vial)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
62475015|NCT00670761|ACTIVE_COMPARATOR|1|treatment with 600mcg oral misoprostol
62736362|NCT05087368|EXPERIMENTAL|Stage 1 - Formulation-finding for SCB-2019 - Group 3|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 3: (N=30) Day 1: SCB-2019 (30 μg) CpG 1018/alum;"
62119684|NCT01104415|EXPERIMENTAL|Telotristat etiprate - Core Phase|Following a 2-week Run-In Period, participants received telotristat etiprate capsules at a starting dose of 150 mg, orally three times daily (TID) for 14 days in the Core Phase. Dose escalations (250 mg, 350 mg, 500 mg) occurred serially every 14 days, up to a maximum dosage of telotristat etiprate 500 mg TID, as guided by specific clinical criteria for dose escalation. Upon completion of 12 weeks of treatment, participants were eligible to receive telotristat etiprate in the optional Open-label Extension Period.
62119685|NCT01104415|EXPERIMENTAL|Telotristat etiprate - Extension Period|Participants received telotristat etiprate at their highest tolerated dose (250 mg or 500 mg), orally, TID for 124 weeks in the Open-label Extension Period. If neither dose was tolerated participants were discontinued from the study and completed the 2-week Follow-up Visit.
62119686|NCT04781595|ACTIVE_COMPARATOR|Watermelon|Watermelon powder containing 3 g of L-citrulline.
62119687|NCT04781595|ACTIVE_COMPARATOR|Beetroot|Beetroot powder containing 8 mmol of nitrate.
62119688|NCT04781595|ACTIVE_COMPARATOR|Watermelon + beetroot|Watermelon powder containing 3 g of L-citrulline and Beetroot powder containing 8 mmol of nitrate.
62119689|NCT04781595|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62119690|NCT06038617|EXPERIMENTAL|Simultaneous vaccination arm|The simultaneous vaccination group will receive routine childhood vaccinations and mRNA COVID-19 vaccination at Visit 1, followed by a health education visit without vaccination at Visit 2.
62119691|NCT06038617|EXPERIMENTAL|Sequential vaccination arm|The sequential vaccination group will receive routine childhood vaccinations at Visit 1, followed by a health education visit with mRNA COVID-19 vaccination at Visit 2.
62119692|NCT01948648|ACTIVE_COMPARATOR|Colesevelam|3.75g/day for 6 weeks
62307665|NCT00330824|ACTIVE_COMPARATOR|antibiotic / steroid (2 vials)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
62307666|NCT00465738|EXPERIMENTAL|incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 5.0 mL resulted in a dose of 20 units per 1.0 mL."
61919606|NCT00911443|EXPERIMENTAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
62307667|NCT00465738|ACTIVE_COMPARATOR|incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 mL sterile of NaCl 0.9% solution without preservatives. Dilution with 2.0 mL resulted in a dose of 50 units per 1.0 mL."
62307668|NCT00550238|EXPERIMENTAL|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
62307669|NCT06587568|EXPERIMENTAL|Mobile chat messaging|Mobile chat messaging + Screening-based alcohol intervention
62307670|NCT06587568|ACTIVE_COMPARATOR|Brief intervention|Screening-based alcohol intervention only
62307671|NCT04282577||patients with chron's disease|
62307672|NCT04282577||patients with ulcerative cholitis|
62307673|NCT04475094||COHORT|All patients will have had a clinically-indicated PET revealing at least one reversible perfusion defect followed by a research-indicated cardiac PET study between 3 and 8 weeks post-successful coronary artery stenting.
62307674|NCT04553887|EXPERIMENTAL|Cohort 1|Previously treated NSCLC patients with EGFR exon 20 insertion mutantion
62307675|NCT04553887|EXPERIMENTAL|Cohort 2|NSCLC Patients with uncommon EGFR Mutation
62736363|NCT05087368|EXPERIMENTAL|Stage 1 - Formulation-finding for SCB-2019 - Group 4|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 4: (N=30) Day 1: ChAdOx1-S;"
61919607|NCT00911443|EXPERIMENTAL|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
61919608|NCT00911443|ACTIVE_COMPARATOR|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
62119693|NCT01948648|ACTIVE_COMPARATOR|Fish Oil|1g/day for 6 weeks
62119694|NCT01948648|ACTIVE_COMPARATOR|Combination of Fish Oil and Colesevelam|3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks
62119695|NCT00539799|ACTIVE_COMPARATOR|1|Long-term low-dose prednisolone (5 - 7.5 mg/day)
62119696|NCT00539799|PLACEBO_COMPARATOR|2|
62119697|NCT02274896|EXPERIMENTAL|PD catheter group|All patients will receive the Bayston PD catheter
62119698|NCT03923491|EXPERIMENTAL|Healthy Feeding, Healthy Eating|The experimental arm will receive three home over the first three months of the intervention.Visits will be conducted by a community health worker (CHW) trained in Motivational Interviewing. The home visits will include video-feedback on a meal; in-home cooking demonstrations; tailored text-messages, and mailed materials. During the last three months of the intervention, CHW will conduct monthly phone calls, together with mailed materials and text messages. The intervention will be tailored for families based on the child's appetitive traits and eating behaviors.
62119699|NCT03923491|ACTIVE_COMPARATOR|Reading and Readiness|The Reading and Readiness group will receive information on school readiness promotion. Materials will be adapted and delivered by the community health worker (CHW) with a similar dose and schedule as the intervention group (three home visits and three phone calls). During the home visits, the CHW will show a video that models early childhood caregiver-child activities and demonstrates simple methods to interact with their children. They will also send a video of themselves reading with a child, receive text-messages based on these materials as well as the print materials during the last three months of the intervention.
62307676|NCT05308108||Children with Obstructive Sleepapnea|
62307677|NCT01998646|EXPERIMENTAL|ASP4058 Tablet Dose Escalation Cohort|
62307678|NCT01998646|EXPERIMENTAL|ASP4058 Tablet - Fasting conditions|
62475016|NCT00670761|ACTIVE_COMPARATOR|2|treatment with 400mcg sublingual misoprostol
62475017|NCT00670761|ACTIVE_COMPARATOR|3|treatment with Manual Vacuum Aspiration (MVA)
62475018|NCT02186691|EXPERIMENTAL|RV and LV ejection fraction assesment|assesment RV and LV ejection fraction after PVR measured by MRI
62678643|NCT03683199|EXPERIMENTAL|Cleft lip nasal deformity|"•Anthropometric evaluation of the nose (will be measured pre and post-operative) This represents the objective evaluation. It will be done by measuring the angles and ratios of the nose and its relation to the face. Common parameters will be measured from the photos (frontal, oblique, lateral and basal views) for all the patients to compare the pre-operative measures with the post-operative ones.~MSCT flesh mode will be used to measure nose related angels and ratios. It also gives idea about nasal skeleton pre-operative for proper design of the operative strategy, and it will be done post-operative for assessment and comparizon."
62678644|NCT04621929|EXPERIMENTAL|Allocated to intervention/treatment|Daily phentermine/topiramate x 18 months
62678645|NCT04621929|ACTIVE_COMPARATOR|Allocated to pragmatic control|Remain on their current regimen
62678646|NCT06481969|EXPERIMENTAL|Group A-SVF group|Qualified participants will be randomized into either of two groups. Participants in this group will undergo lower abdominal liposuction, preparation of SVF and ovarian injection, other standard assisted reproductive treatments are similar and parallel between two groups.
61919609|NCT01649479|OTHER|Suspected Obstetrical APS; confirmed APS|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients have APS.~All patients included in this study will have the following interventions:~* antiphospholipid antibody tests~* thrombophilia bloodwork~* psychiatric evaluation"
62119700|NCT05817968|EXPERIMENTAL|Esophageal manometry using a solid state sensor vs. balloon catheter|Placement of both a solid state and balloon esophageal pressure (Pes) catheter. Pes recordings of these catheters will be acquired simultaneously during both controlled mechanical ventilation and assisted mechanical ventilation, for 10-15 minutes per phase. Ventilator settings/protocol will be as per standard-of-care.
62119701|NCT06302491|EXPERIMENTAL|AND017 capsules 8 mg|
62119702|NCT06302491|EXPERIMENTAL|AND017 capsules 12 mg|
62119703|NCT06302491|EXPERIMENTAL|AND017 capsules 16 mg|
62475019|NCT00819754|EXPERIMENTAL|IXO regimen + bevacizumab|This is phase I/II safety and efficacy study. There is only one arm of Irinotecan, Xeloda and Oxaliplatin (IXO) regimen with Avastin (bevacizumab)
62475020|NCT00692939|EXPERIMENTAL|1|High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
62119704|NCT06302491|PLACEBO_COMPARATOR|AND017 Placebo capsules|
62119705|NCT02537704|EXPERIMENTAL|Group Lifestyle Balance Program|"Participants will be assigned to an adaptation of the Group Lifestyle Balance Program, a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.~Additionally, participants will attend at least one monthly visit with a nutritionist (individually).~The lifestyle objectives for participants will be as follows:~1. To lose 5-10% of initial weight through healthy eating.~2. To do 150 minutes of physical activity each week."
62119706|NCT06088225|EXPERIMENTAL|Distance -image screen|Distance -image screen is a device to make image in the distance of 6-meters when reading and learning at near. The investigators will ask the subjects to use the distance - image screen for 12 month
62119707|NCT04114968||Intervention group|Eligible women residing in the Central Denmark Region will be assigned to intervention group. Women in the intervention group receive an invitation for HPV-based cervical cancer screening by attending either 1) GP-based screening or 2) HPV self-sampling. The self-sampling kit includes the dry Evalyn brush self-sampling device (Rovers Medical Devices B.V, Oss, Netherlands), written and picture-based user instructions on how to collect and mail the self-sample, and a prestamped return envelope addressed to the Department of Pathology, Randers Regional Hospital.
62119708|NCT04114968||Control group|Eligible women residing in the other five Danish regions (North, Central, South, Zealand and Capital ) will be assigned to control group. Women in the control group will receive usual care, which for 65-69 year-old women is opportunistic cervical cancer screening at the GP
62120099|NCT00604019|ACTIVE_COMPARATOR|Dopamine|Patients that get Dopamine as an infusion for hypotension
62475021|NCT04882163|EXPERIMENTAL|CC-220 + Polatuzumab vedotin + rituximab- Cohort A|Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
62475022|NCT04882163|EXPERIMENTAL|CC-220 + Tafasitamab- Cohort B|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
62475023|NCT04882163|EXPERIMENTAL|CC-220 + Rituximab + Chemo (Cohort C)|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
62678647|NCT06481969|OTHER|Group B-Control group|Qualified participants will be randomized into either of two groups. Participants in this group will be treated according to the current clinical routine of the reproductive center, other standard assisted reproductive treatments are similar and parallel between two groups.
62736364|NCT05087368|EXPERIMENTAL|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 5|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 5: (N=100) Day 1 (boost) -SCB-2019;"
61919610|NCT01649479|OTHER|Sus. Obst. APS, confirmed thrombophilia|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients are thrombophilic.~All patients included in this study will have the following interventions:~* antiphospholipid antibody tests~* thrombophilia bloodwork~* psychiatric evaluation"
62119709|NCT05311319|EXPERIMENTAL|HAIC+Anlotinib (4 Cycles) +TQB2450 (4 Cycles)|HAIC treatment was performed one month after surgery, and Anlotinib and TQB2450 for 4 cycles.
62119710|NCT05311319|EXPERIMENTAL|HAIC+Anlotinib (8 Cycles) +TQB2450 (4 Cycles)|HAIC treatment was performed one month after surgery, and Anlotinib for 8 cycles and TQB2450 for 4 cycles.
62678648|NCT05389800|EXPERIMENTAL|Aerobic Exercise (Moderate-Intensity Interval Training)|"Preoperative program: 120 seconds of moderate intensity exercise (64-76% HRmax, 12-13 in rate of perceived exertion (RPE), based on ACSM) and 120 seconds of passive rest in a total of 4 cycles. The basic program will last about 14 minutes, plus 6 minutes for warm-up and recovery. The program will be performed twice a day.~Postoperative program: 120 seconds of moderate intensity exercise (64-76% HRmax, 12-13 in RPE, based on ACSM) and 120 seconds of passive rest in a total of 8 cycles. The basic program will last about 30 minutes, plus 6 minutes for warm-up and recovery. The program will be performed 3 times a week for a total of 8 weeks."
62678649|NCT05389800|NO_INTERVENTION|Control|"Preoperatively: mild intensity activities focusing on memory and attention performing with upper limb movements using the interactive platform Kinems. The program will last about 20 minutes. To ensure that the intensity of activities is mild, there will be a simultaneous recording of heart rate, while at the end of each session the RPE scale will be evaluated.~Postoperatively: none"
62678650|NCT01111487|ACTIVE_COMPARATOR|Group I|This group will use a pressure level of 10 cmH2O.
61919611|NCT01649479|OTHER|Suspected Obstectrical APS; unconfirmed|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork cannot confirm APS, nor thrombophilia.~All patients included in this study will have the following interventions:~* antiphospholipid antibody tests~* thrombophilia bloodwork~* psychiatric evaluation"
61919612|NCT04609111|ACTIVE_COMPARATOR|No aspirin|To start prasugrel monotherapy before the index percutaneous coronary intervention (PCI) and to change into clopidogrel monotherapy at 1-month after the PCI.
62307679|NCT01998646|EXPERIMENTAL|ASP4058 Tablet - Fed conditions|
61919613|NCT04609111|ACTIVE_COMPARATOR|1-month DAPT|To start dual antiplatelet therapy comprising of aspirin and prasugrel before the index percutaneous coronary intervention (PCI) and to change into aspirin monotherapy at 1-month after the PCI.
62475024|NCT04882163|EXPERIMENTAL|CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)|Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
61919614|NCT05456945|EXPERIMENTAL|Acupressure|Before the injection, patients will be asked to lie in the prone position. The acupressure point (UB32) will be located on the side to be injected. The UB32 point is located in the sacrum region, below the medial and posterior superior iliac spine, in the second sacral foramen. The acupressure point UB32 will be pressed circularly with a stopwatch for 1 minute. Then the acupressure point will be pressed three times in sequence with the thumb directly (pressure equal to 4.5 kg/cm2). Diclofenac sodium (75mg/3ml) will be injected after acupressure.
62119711|NCT00094575|ACTIVE_COMPARATOR|Arm 1|Standard Open Repair of Abdominal Aortic Aneurysm
62119712|NCT00094575|ACTIVE_COMPARATOR|Arm 2|Endovascular Repair of Abdominal Aortic Aneurysm
62120100|NCT00604019|ACTIVE_COMPARATOR|Norepinephrine|Patients that get norepinephrine as an infusion for hypotension
62307680|NCT01998646|PLACEBO_COMPARATOR|Placebo|
62307681|NCT01914718|EXPERIMENTAL|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
62307682|NCT05413694|EXPERIMENTAL|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
62307683|NCT05127772|EXPERIMENTAL|single dose of HEC93077（pilot trial arm）|Healthy subjects receive single dose of HEC93077
62307684|NCT05127772|EXPERIMENTAL|single dose of HEC93077（Cohort 1）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
62119713|NCT05640791|EXPERIMENTAL|Gemcitabine, cisplatin, nab-paclitaxel, durvalumab|Participants receive nab-paclitaxel over 30 minutes, cisplatin over 60 minutes, and gemcitabine over 30 minutes on days 1 and 8; durvalumab over 60 minutes on days 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
62307685|NCT05127772|EXPERIMENTAL|single dose of HEC93077（Cohort 2）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
62119714|NCT03316521|EXPERIMENTAL|Single Ascending Dose (SAD)|"In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). All cohorts will include at least four subjects each. Additional subjects may be added in any cohort if necessary.~AMY-101 will be administered as a SQ or IV injection. Subjects in each cohort will be dosed sequentially, to allow for close safety monitoring. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee. Subsequent dose levels will be administered until either the maximum tolerated dose (MTD) or the study maximum dose (SMD) is reached based on specified dose escalation criteria."
62475025|NCT04882163|EXPERIMENTAL|CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E|Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
62475026|NCT04882163|EXPERIMENTAL|CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)|Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
62475027|NCT01845376|EXPERIMENTAL|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
62475028|NCT01845376|EXPERIMENTAL|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
62678651|NCT01111487|ACTIVE_COMPARATOR|Group II|This group will use a pressure level of 15 cmH2O.
62678652|NCT04524000|EXPERIMENTAL|Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)|Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular).
62678653|NCT04524000|EXPERIMENTAL|Cohort 2: CDK4/6 inhibitor naive (Part 2)|Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
62307686|NCT05127772|EXPERIMENTAL|single dose of HEC93077（Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC93077 or placebo will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
62307687|NCT05127772|EXPERIMENTAL|single dose of HEC93077（Cohort 4）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
62307688|NCT05127772|EXPERIMENTAL|single dose of HEC93077（Cohort 5）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
62307689|NCT05127772|EXPERIMENTAL|single dose of HEC93077（Cohort 6）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
61919615|NCT05456945|EXPERIMENTAL|Shotblocher|Before the injection, patients will be asked to lie in the prone position. The protruding surface of the Shotblocker will be placed in the area just before the injection so that the point of entry with the needle will not be contaminated. Pressure will be applied by keeping the Shotblocker constant throughout the process. The injector will be quickly inserted through the gap in the middle of the shortblocher. Shotblocker will be removed after drug administration.
61919616|NCT05456945|NO_INTERVENTION|Control group|No intervention will be applied before the injection
62307690|NCT05127772|EXPERIMENTAL|single dose of HEC93077（Cohort 7）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
62307691|NCT05127772|EXPERIMENTAL|multiple doses of HEC93077（ Cohort 8）|Healthy subjects receive multiple doses of HEC93077 or matching placebo
62307692|NCT05127772|EXPERIMENTAL|multiple doses of HEC93077（ Cohort 9, Group 1)|Healthy subjects receive multiple doses of HEC93077 or matching placebo
62307693|NCT05127772|EXPERIMENTAL|multiple doses of HEC93077（ Cohort 9, Gruop 2)|Hyperuricemia subjects receive multiple doses of HEC93077 or matching placebo
62307694|NCT05127772|EXPERIMENTAL|multiple doses of HEC93077（ Cohort 10)|Healthy subjects receive multiple doses of HEC93077 or matching placebo
62475029|NCT01845376|EXPERIMENTAL|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
62475030|NCT01109966|ACTIVE_COMPARATOR|Amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
62475031|NCT01109966|ACTIVE_COMPARATOR|New amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
62475032|NCT01928147|EXPERIMENTAL|PPI-383 single dose escalation in healthy volunteers|There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
62475033|NCT01928147|EXPERIMENTAL|PPI-383 multiple doses in healthy volunteers|Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
62475034|NCT01928147|EXPERIMENTAL|PPI-383 multiple dose escalation in HCV Subjects|Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
62475035|NCT02310386|ACTIVE_COMPARATOR|activated BEMER-device|Activated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
62475036|NCT02310386|SHAM_COMPARATOR|inactivated BEMER-device|Inactivated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
62475037|NCT03128762||Cases|"Patients in this group are asthmatic (see inclusion/exclusion) criteria.~Intervention: ILC2 levels in blood"
62475038|NCT03128762||Controls|"Controls are non-asthmatic subjects that are age and gender matched to asthma cases.~Intervention: ILC2 levels in blood"
62475039|NCT05200663|EXPERIMENTAL|"Tamoxifen"|Group A patients will receive tab tamoxifen 10 mg twice a day for total of six months.
62475040|NCT05200663|ACTIVE_COMPARATOR|"Tamoxifen and Antioxidant"|Group B patients will receive tab tamoxifen 10 mg twice a day and cap. vit E 400mg once a day for total of six months.
62475041|NCT01519661|EXPERIMENTAL|Tobramycin Inhalation Powder (TIP)|Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
62475042|NCT05750394|ACTIVE_COMPARATOR|Single Layer Closure|"Single layer closure using the following technique:~a. Closure of the myometrium and serosa with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique. The endometrium should be excluded."
62475043|NCT05750394|ACTIVE_COMPARATOR|Double Layer Closure|"Double layer closure using the following technique:~1. Closure of the full thickness of the myometrium with one (1) Monocryl suture on a CT needle using a running locked technique. The endometrium should be excluded.~2. Imbrication of the first layer with one (1) Monocryl suture on a CT needle using a running un-locked technique"
62475044|NCT05750394|ACTIVE_COMPARATOR|Triple Layer Closure|"Triple layer closure of Endometrium, Myometrium and Serosa (EMS) using one of the the following two techniques:~1. Closure of the endometrium and 2-4 mm of internal myometrium with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique~2. Closure of the remaining myometrium and serosa with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique~or~1. Closure of the endometrium and 2-4 mm of internal myometrium with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique~2. Closure of the remaining myometrium with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique~3. Closure of the serosa with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique"
62678654|NCT04524000|EXPERIMENTAL|Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)|Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
61919617|NCT05143359|EXPERIMENTAL|Wharfe and Pederson difficulty index|Assessment of Difficulty in third molar extraction using Wharfe and Pederson difficulty index
61919618|NCT05143359|ACTIVE_COMPARATOR|Winters difficulty index|Assessment of Difficulty in third molar extraction using Winters difficulty index
61919619|NCT02016547|EXPERIMENTAL|abciximab IV and thrombectomy|abciximab IV (0.25mg/kg by IV bolus, following by 0.125μg/kg by 12 hours IV drip) and thrombectomy
61919620|NCT02016547|ACTIVE_COMPARATOR|alteplase|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
61919621|NCT03714737|EXPERIMENTAL|Experimental 1|Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
61919622|NCT03714737|ACTIVE_COMPARATOR|Positive control 1|Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
61919623|NCT03714737|EXPERIMENTAL|Experimental 2|Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
61919624|NCT03714737|EXPERIMENTAL|Experimental 3|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
61919625|NCT03714737|ACTIVE_COMPARATOR|Positive control 2|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
62475045|NCT00633594|EXPERIMENTAL|rituximab/bortezomib/lenalidomide|"Patients in Phase I \& II to receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles up to 6 cycles.~Phase I: Cohorts of 3 patients will be enrolled at escalating dose levels to determine the maximum tolerated dose (MTD). Doses may be de-escalated if necessary.~Phase II: patients will be treated with the MTD determined in Phase I."
62475046|NCT06118918|EXPERIMENTAL|The interventional arm (participants who will received the cardiac rehabilitation program|this arm will receive the cardiac rehabilitation program after completing the cardiac surgery and being assessed for eligibility.
62119715|NCT03316521|EXPERIMENTAL|Multiple Dose (MD)|Depending on the results of the SAD, multiple doses of AMY-101 will be administered at the dose which has been identified as the dose which saturates target C3, for a duration that results to an exposure level equivalent to the maximum exposure achieved in the SAD. The dose and dosing interval will be determined based on the PK data obtained in the SAD part of the study. Each MD cohort will include at least four subjects and may be expanded with additional subjects if necessary. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee.
62307695|NCT05045053|EXPERIMENTAL|xiidra group|patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking
62307696|NCT05045053|NO_INTERVENTION|control group|patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups
62307697|NCT01240018|PLACEBO_COMPARATOR|Placebo|
62307698|NCT01240018|ACTIVE_COMPARATOR|High dose Lb. casei|
62307699|NCT05621512|EXPERIMENTAL|Intervention|"The intervention implies a letter of invitation for a session between the employee, the department manager, and a midwife concerning workplace risk assessment and agreement on feasible work adjustments if necessary. A second session within gestational week 26-28 is scheduled to follow-up and readjust if necessary. A systematic frame for sessions is developed by the research team and conclusions from the sessions are registered within a piloted standardized template.~The employee and the manager can initiate contact with the midwife at any time, e.g in case of new symptoms or discomfort and need for support or guidance. If sick leave is considered, a new session is recommended and may be scheduled at any time.~To ensure transparency of guidance and workplace adjustments for other relevant healthcare professionals, the employee is asked to inform her general practitioner (GP) and midwife of the program."
62307700|NCT05621512|NO_INTERVENTION|Usual practice|"Hospital pregnancy policy is usual practice and implies a meeting between the pregnant employee and her manager concerning an individual risk assessment. A risk assessment-template can be downloaded from the hospital website.~If minimizing potential risks by adjustments is not possible the employee should be redeployed. If redeployment is not possible the pregnant employee may be absent due to pregnancy related symptoms.~The pregnant employee is requested to inform her GP about agreements."
62307701|NCT01557010|EXPERIMENTAL|Treatment A|
62307702|NCT01557010|EXPERIMENTAL|Treatment B|
62307703|NCT01557010|EXPERIMENTAL|Treatment C|
62307704|NCT01557010|PLACEBO_COMPARATOR|Treatment D|
62307705|NCT03088150|ACTIVE_COMPARATOR|Surgical resection|Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.
62475047|NCT06118918|NO_INTERVENTION|the control arm (who will receive the usual care)|the control group will receive the usual care ( the usual instruction and general advice from the physicians and the nurses)
62475048|NCT04788823|NO_INTERVENTION|Control|Group 1 will represent controls and will not receive prednisone in the 3-year post-op period.
61919626|NCT03714737|EXPERIMENTAL|Experimental 4|Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
61919627|NCT03714737|ACTIVE_COMPARATOR|Positive Control 3|Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
62119716|NCT02779517||Focus groups- Patients|Subjects with or without an upper extremity disability will be asked to observe and interact with the mobile service robot.
62119717|NCT02779517||Focus Groups-clinicians|Clinicians with neuro-rehab experience.
62119718|NCT04020718|EXPERIMENTAL|Early assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 4 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
62119719|NCT04020718|EXPERIMENTAL|Late assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 8 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
62307706|NCT03088150|EXPERIMENTAL|Thermal ablation|Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.
62307707|NCT04950738|EXPERIMENTAL|Acupuncture with press tack needle group (Acu)|Patients in acupuncture group will receive traditional Chinese acupuncture using Press Tack Needle (PYONEX 0.20 x l.5mm made by Seirin Corporation). The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), LI 4 (He Gu), SP 3 (Tai Bai,) ST 44 (Nei ting), LIV 3 (Tai Chong). The treatment will use bilateral acupuncture Interventions will be given on day 1, 3, and 5 after patient's enrolment.
62475049|NCT04788823|EXPERIMENTAL|Prednisone Monthly - Scheduled|Group 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered.
61919628|NCT03714737|EXPERIMENTAL|Experimental 5|Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
61919629|NCT03714737|ACTIVE_COMPARATOR|Positive Control 4|Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
61919630|NCT06505967|EXPERIMENTAL|Qualia NAD+|
61919631|NCT06505967|PLACEBO_COMPARATOR|Placebo|
62119720|NCT00947817|EXPERIMENTAL|patient|
62119721|NCT00947817|OTHER|control|
62120101|NCT05185921|EXPERIMENTAL|Cognitive-behavioral therapy virtual|The intervention will be provided by 2 psychotherapists. The total of sessions will be eight carried out weekly, for 2 to 3 months. They will also receive standard treatment, i.e. psychiatric management with or without drugs.
62475050|NCT04788823|EXPERIMENTAL|Prednisone Monthly - As Needed|Group 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered.
62475051|NCT04788823|EXPERIMENTAL|Prednisone Every Other Week|Group 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks
62475052|NCT00908128|EXPERIMENTAL|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
62475053|NCT00908128|ACTIVE_COMPARATOR|CellCept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
62678655|NCT03606590|EXPERIMENTAL|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
62678656|NCT05431127|OTHER|High Dose Inspiratory Muscle Training|Inspiratory Muscle Training 3 times a week over 26 weeks
62678657|NCT06695468|EXPERIMENTAL|Quadratus lumborum block (QLB group)|patients will receive bilateral QLB with a 40-ml mixture of 20 ml of 0.5% levobupivacaine diluted with 20 ml of 0.9% N.S. (20 ml to be injected on each side).
62678658|NCT06695468|EXPERIMENTAL|Rectus sheath block (RSB group)|patients will receive bilateral RSB with a 60 ml mixture of 1.5 mic/kg dexmedetomidine added to 30 ml of 0.5% levobupivacaine diluted with 30 ml of 0.9% N.S. (30 ml to be administered on each side, divided into 15 ml for the upper segment and 15 ml for the lower segment).
62678659|NCT01708954|EXPERIMENTAL|Arm A (erlotinib)|Patients receive erlotinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61919632|NCT00708071|EXPERIMENTAL|1|One side of the face is treated with FS VH S/D 4; the other side of the face is treated using standard of care.
62120102|NCT05185921|NO_INTERVENTION|Control|They will only receive standard treatment, i.e. psychiatric management with or without drugs.
62120103|NCT03598478|EXPERIMENTAL|TC-MPT group|Tai Chi-muscle power training group
62120104|NCT03598478|ACTIVE_COMPARATOR|TC group|Tai Chi group
62120105|NCT03598478|ACTIVE_COMPARATOR|MPT group|Muscle power training group
62120106|NCT03598478|NO_INTERVENTION|Control group|Usual medical care is allowed.
62120107|NCT05881577||Cases|The primary study population will consist of subjects with AR
62120108|NCT05881577||Matched controls|children with no history of AR
62120109|NCT05881577||Sibling controls|siblings of the subjects in the case group with no history of AR
62120110|NCT02703714|EXPERIMENTAL|Pembrolizumab and GM-CSF|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
62120111|NCT04257435|ACTIVE_COMPARATOR|Traditional Behavioral Health Treatment|
62120112|NCT04257435|EXPERIMENTAL|Positive Psychological Group Treatment|
62120113|NCT02716220|EXPERIMENTAL|'Percutaneous Coronary Intervention' /Scaffold Implantation|PCI for enrolled subjects: implantation of the DREAMS 2G Drug-Eluting Coronary Scaffold System
62120114|NCT06676462|EXPERIMENTAL|Video laryngoscopy with visionPRO|Video laryngoscopy will be performed with the visionPRO (HEINE® Optotechnick, Gilching, Germany)
62120115|NCT06676462|ACTIVE_COMPARATOR|Video laryngoscopy with Glidescope|Video laryngoscopy will be performed with the GlideScope (Verathon Inc., Bothell, USA)
62120116|NCT04287894|EXPERIMENTAL|Cohort 1A (firste cohort)|1 course Durvalumab (1500mg) + Tremelimumab (75mg) + 1 course of Durvalumab (1500mg) followed by CRT
62120117|NCT04287894|EXPERIMENTAL|Cohort 2A|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
62120118|NCT04287894|ACTIVE_COMPARATOR|Cohort 2B|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
62120119|NCT01531075|EXPERIMENTAL|ENGERIX-B|
62120120|NCT01531075|EXPERIMENTAL|Sci-B-Vac|
62120121|NCT04352283|NO_INTERVENTION|palpation|Usual method to determinate needle puncture site
62120122|NCT04352283|EXPERIMENTAL|Ultrasound|Ultrasound preprocedural exam used to determinate needle puncture site
62120123|NCT00485940|ACTIVE_COMPARATOR|1|Prucalopride 2 mg
62120124|NCT00485940|PLACEBO_COMPARATOR|3|Placebo
62120125|NCT00485940|ACTIVE_COMPARATOR|2|Prucalopride 4 mg
62120126|NCT02304913|EXPERIMENTAL|Hypoglossal acupuncture|Single treatment of hypoglossal needle acupuncture during the chemotherapy administration: Treated points will be Jinjin (Golden Liquid/EX-HN12) left beside the lingual frenulum and Yuye (Jade Fluid/EX-HN13) right beside the lingual frenulum. Both points are treated in quick succession with immediate removal of the needle.
62120127|NCT02304913|SHAM_COMPARATOR|Sham acupuncture|Single treatment of hypoglossal sham acupuncture uring the chemotherapy administration: Treated points will be 1 to 1.5 cun (a cun is defined as the width of the patient's thumb at the knuckle) beside the verum acupuncture points Jinjin and Yuye using the dull side of the needle.
62120128|NCT02304913|ACTIVE_COMPARATOR|Dietary recommendations|This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.
62120129|NCT04135989|OTHER|Cre8 AES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
62119722|NCT00565110|NO_INTERVENTION|Enhanced Usual Care|EUC patients receive medical center standard oncology care and supportive services routinely provided to all patients with cancer. In addition, EUC patients are given a patient focused and a family focused educational pamphlet on depression and cancer and a listing of financial and community resources (in Spanish for Spanish-speaking patients). With patient consent, as described in the informed written consent, the treating oncologist is informed via medical chart note if EUC patients screen positive for major depression. Treating oncology attending physicians, fellows and residents are invited to attend a didactic session led by the study psychiatrist on treating depression in cancer patients.
62119723|NCT00565110|EXPERIMENTAL|ADAPt-C intervention|Intervention patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
62119724|NCT05065684||rhBMP-2 and rhBMP-7|patients who have been treated with rhBMP-2 or rhBMP-7 for long bone non-union or acute fractures
62119725|NCT05065684||No-BMP|patients who have been treated with standart care, i.e. non-union resection and autologous bone graft
62119726|NCT06461455|OTHER|LID230451, then ULTRA MFfA|Lehfilcon A multifocal for astigmatism contact lenses worn in Period 1, followed by samfilcon A multifocal for astigmatism contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during typical contact lens wearing hours for at least 8 hours per day during each wear period \[30 days (-2/+1)\]. Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE.
62119727|NCT06461455|OTHER|ULTRA MFfA, then LID230451|Samfilcon A multifocal for astigmatism contact lenses worn in Period 1, followed by lehfilcon A multifocal for astigmatism contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during typical contact lens wearing hours for at least 8 hours per day during each wear period \[30 days (-2/+1)\]. Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE.
62119728|NCT03874650|EXPERIMENTAL|Activity Planning Group|"Those in the Activity Planning group receive training and practice in identifying realistic and safe activities in everyday life that may be enjoyable or rewarding to complete. They gain practice in scheduling activities and identifying and overcoming barriers to completion, such as memory problems, avoidance, sticking to habitual patterns and physical and transport issues.~The intervention will consist of weekly 1 hour group sessions over 8 weeks, as below:~Introduction to Group Therapy Identifying Enjoyable Activities The Automatic Pilot and Planning Pleasurable Activities Goal Review and Balancing Enjoyable and Routine Activities Identifying Solutions to Goal Attainment Increasing Mastery and Managing Fatigue Active Approaches to Engagement Relapse Prevention"
62119729|NCT03874650|EXPERIMENTAL|Activity Engagement Group|"Individuals randomised to this arm will meet weekly for 8 weeks for 1 hour and engage in various potentially rewarding and meaningful social activities such as board games, crafting, and puzzles. Participants in this group will not receive specific training on activity scheduling or overcoming barriers to activity participation. Rather the aim is that participants gain experience of positive reinforcement from the activities and that this explicitly or implicitly challenges potentially negative predictions about such situations and encourages generalised increases in positive activity beyond the group setting. The group will cover activities such as board games, t-shirt making, puzzles, painting, pub quizzes, figurine painting, origami/paper-craft, and clay sculptures."
62119730|NCT03874650|PLACEBO_COMPARATOR|Waitlist Group|In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
62119731|NCT05051319||Elderly participants living at home|Participants over the age of 65, living at home, not having mental and communication problems that would prevent the evaluations, and volunteering to participate in the study. The sociodemographic information of the participants such as gender, duration of education, living environment and people with whom they live were recorded. In addition, information about the medical condition of geriatric individuals, such as body mass indexes and the number of drugs used, was also recorded in the form. In order to evaluate the cognitive status of the participants, the Standardized or Standardized Mini-Mental Test for the Uneducated was used according to their educational status. The Center for Disease Control Health-Related Quality of Life-4 Scale (CDC HRQoL-4) was used to assess quality of life, and the Geriatric Depression Scale was used to assess emotional status. In addition, the presence of pain and pain levels according to body regions were determined with a 6-point Likert-type scale.
62119732|NCT05573191|EXPERIMENTAL|LP group|The experimental group received 1.5 mg/kg lidocaine intravenously,after 90s, the corresponding dose of propofol was injected intravenously at 30mg/kg/h, and to observe Whether consciousness disappears or not，recording NTI values, heart rate, oxygen saturation, mean arterial pressure and drug side effects in the baseline state, 90s after lidocaine administration, 60s and 120s after propofol administration
62119733|NCT05573191|PLACEBO_COMPARATOR|P group|Replace lidocaine with equal volume normal saline,Others are the same as the experimental group.
62119734|NCT02376517|ACTIVE_COMPARATOR|Educational program|Participants randomized to the intervention group will receive the educational program at the baseline visit.
61919633|NCT01866553|EXPERIMENTAL|Nilotinib, Pegylated interferon α2b|"Patients will be treated with nilotinib 300 mg BID during the first 3 months. Then the combination phase ensues with continued daily nilotinib 300 mg BID combined with PegIFN 25 ug/week for 3 months up to the Month 6 time point. If the patient has no more than grade 1 non-hematological toxicity or grade 2 hematological toxicity, the dose will be increased to 40 μg/w until Month 12. The follow-up phase with daily nilotinib 300 mg BID covers the next 12 months period (Month 12 to 24). until Month 12, which is followed by monotherapy phase of nilotinib 300 mg BID. Overall study duration for the individual patient is 24 months."
61919634|NCT00730028|EXPERIMENTAL|Limited Abscess|Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
61919635|NCT00730028|EXPERIMENTAL|Cellulitis or Larger Abscess|Subjects with cellulitis only or abscess \> 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.
61919636|NCT00384527|EXPERIMENTAL|1|
61919637|NCT00384527|ACTIVE_COMPARATOR|2|
62475054|NCT04656353|EXPERIMENTAL|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online psychosocial program and the questionnaire and distress survey. They will be asked to use the website within two weeks and then to complete the questionnaire and distress survey after using it and mail them back in a self-addressed stamped envelope. The participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted.
61919638|NCT04853303|EXPERIMENTAL|Hypnosis VR|The experimental group will receive a 15-minute hypnosis using virtual reality when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain.
61919639|NCT04853303|NO_INTERVENTION|Control|The control group will receive no intervention.
61919640|NCT03924271|EXPERIMENTAL|ONCOLOGY|Patient with a cancer
61919641|NCT01527266|EXPERIMENTAL|carbohydrate mouth rinse fasted|sucrose mouth rinse in the fasted state
61919642|NCT01527266|EXPERIMENTAL|carbohydrate mouth rinse fed|sucrose mouth rinse fed state
61919643|NCT01527266|PLACEBO_COMPARATOR|Placebo mouth rinse fed|placebo (non-caloric sweetened drink) in the fed state
62307708|NCT04950738|PLACEBO_COMPARATOR|Placebo group press tack placebo (Con)|Patients randomized to the control group will receive a press lack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to the acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), L1 4 (He Gu), SP 3; (Tat Bai), ST 44 (Ne1 tmg), LIV 3 (Tat Chong). Interventions will be given on days 1, 3, and 5 after the patient's enrolment.
62307709|NCT00282802||1|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort
62307710|NCT04416516|EXPERIMENTAL|Arm 1, Patients with 1 Tumour|"Participants with 1 Target Tumour will receive 3 x ASN-002 1.0x10(11) Injections~+ VISMODEGIB (150 mg) daily for 4 weeks."
62119735|NCT02376517|NO_INTERVENTION|Control|Participants randomized to the control group will receive the educational program at the follow-up visit.
62119736|NCT04580901|EXPERIMENTAL|Group interpersonal psychotherapy|Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
62119737|NCT04580901|NO_INTERVENTION|Usual care|Usual care refers to any care that the women wish to access, and there are no limits on the women in either group. It may include, but is not limited to, the family physician, obstetrician, and/or midwife, participation in regional standard perinatal depression programming, private therapy, online therapies, medication, etc.
62119738|NCT03354039|EXPERIMENTAL|Tamoxifen 20 mg once daily|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.
62119739|NCT03354039|PLACEBO_COMPARATOR|Matching placebo once daily|Patients randomised to placebo will be administered matching placebo.
62119740|NCT01268813|EXPERIMENTAL|Exhaled breath uptake blood test|Diabetic patients receiving oral hypoglycemic drug will be tested for biomarkers in their breath and blood samples
62119741|NCT01268813|NO_INTERVENTION|Exhaled breath and blood test|Breath and blood samples will be collected from healthy volunteers and analyzed using Gas Chromatography-Mass Spectroscopy. The results will be compared to the experimental arm.
62119742|NCT00082810|EXPERIMENTAL|Treatment (tipifarnib, fulvestrant)|Patients receive fulvestrant intramuscularly on day 1 and oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity\*.
62119743|NCT01348880|EXPERIMENTAL|Arm1|
62119744|NCT01348880|PLACEBO_COMPARATOR|Arm2|
62119745|NCT01793662|ACTIVE_COMPARATOR|Open aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
62119746|NCT01793662|EXPERIMENTAL|Laparoscopic aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
62119747|NCT05148897||All Women can participate|among 500 women, over 6 months by random selection and they will be asked to answer the questions of prepared and copied questionnaire sheet.
62307711|NCT04416516|EXPERIMENTAL|Arm 2, Patients with 3 or more Tumours|Participants with 3 or more Target Tumours will receive 3 x ASN-002 1.0x10(11) Injections (per tumour) + VISMODEGIB (150 mg) daily for 4 weeks.
62307712|NCT04416516|EXPERIMENTAL|Arm 6 Patients with 3 or more Tumours|Participants with 3 or more Target Tumours will receive 3 x ASN-002 1.5x10(11) Injections (per tumour) + VISMODEGIB (150 mg) daily for 4 weeks
62307713|NCT01570491|ACTIVE_COMPARATOR|ultrasound-guided spinal anesthesia|participants will randomly assigned to use ultrasound-guided technique for block placement by Anesthesiologist.
62307714|NCT01570491|PLACEBO_COMPARATOR|standard spinal anesthesia|randomized participants will be given standard spinal anesthesia insertion technique for block placement by Anesthesiologist
62307715|NCT03291002|EXPERIMENTAL|Cohort A|Dose escalation of CV8102
62307716|NCT03291002|EXPERIMENTAL|Cohort B|Optional expansion cohorts of CV8102
62307717|NCT03291002|EXPERIMENTAL|Cohort C|Dose escalation of CV8102 + anti-PD-1 therapy
62307718|NCT03291002|EXPERIMENTAL|Cohort D|Optional expansion of CV8102 + anti-PD-1 therapy
62307719|NCT02785757|EXPERIMENTAL|Patients with adenocarcinoma|60 Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy
62307720|NCT02214589|ACTIVE_COMPARATOR|Oral glucose and NNS|Oral glucose and NNS
62307721|NCT02214589|ACTIVE_COMPARATOR|Oral glucose and facilitated tucking and NNS|Oral glucose, facilitated tucking and NNS
62307722|NCT02214589|ACTIVE_COMPARATOR|Facilitated Tucking and NNS|Facilitated tucking and NNS
62307723|NCT05400460|OTHER|ASBR group|Anterior cruciate ligament reconstruction using STG, absorbable interface nails and ASBR procedures.
61919644|NCT01527266|PLACEBO_COMPARATOR|Placebo mouth rinse fasted|placebo (non-caloric sweetened drink) in the fasted condition
62119748|NCT02613676|EXPERIMENTAL|TcB screening before discharge|Participants in this group will be screened for jaundice using the JM 105 transcutaneous device. The TcB value will be plotted on the Bhutani nomogram to assess the risk category. Infants who are categorised as high risk according to the nomogram will require blood sampling for TsB and assessment for need for phototherapy.
62119749|NCT02613676|OTHER|Standard care (visual inspection)|Participants in this group will be managed routinely according to the current standard of care where babies are assessed for jaundice by visual inspection. Babies in this group will require blood draw for TsB if there are visibly jaundiced
62119750|NCT04705376|ACTIVE_COMPARATOR|Breg Polarcare|Patients within the Breg Polarcare treatment arm will use the Breg Polarcare device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Thermazone device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
62119751|NCT04705376|EXPERIMENTAL|Thermazone|Patients within the Thermazone treatment arm will use the Thermazone device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Breg Polarcare device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
62119752|NCT06612879|EXPERIMENTAL|Omaveloxolone|Participants will receive a single oral dose of omaveloxolone on Day 1.
62119753|NCT02814643|EXPERIMENTAL|Benralizumab|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
62119754|NCT02814643|PLACEBO_COMPARATOR|Placebo|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
62119755|NCT02186236||Lung and Colorectal cancer patients|Eligible people who consent to participation will provide urine (both in lung cancer and colorectal cancer) and blood (in lung cancer only) samples at pre-specified times.
62119756|NCT02747602|EXPERIMENTAL|Group ABC|AC-1204, caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast
62119757|NCT02747602|EXPERIMENTAL|Group BCA|caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast, AC-1204
62119758|NCT02747602|EXPERIMENTAL|Group CAB|caprylic triglyceride high fat breakfast, AC-1204, caprylic triglyceride oil standard breakfast
62119759|NCT03763721|EXPERIMENTAL|iOCT optimized protocol (iOCT-p)|In the iOCT optimized protocol (iOCT-p) group, graft apposition will be assessed with special detail for graft orientation, interface fluid, and any peripheral folds as described by Xu et al. Potential tissue manipulations will be therefore based on the iOCT image. Apposition of the graft will be obtained using a complete filling of the anterior chamber with 20% sulphur hexafluoride (SF6) endotamponade for 1-2 minutes, whilst the OCT image is assessed and any graft manipulation can be performed if deemed necessary. After this period, the gas is partly exchanged for BSS (Balanced Salt Solution, Alcon) to achieve a bubble with a diameter of approximately the same size of the graft (i.e. 8.5mm)
62119760|NCT03763721|ACTIVE_COMPARATOR|current practice protocol (CP-p)|In the current practice protocol (CP-p), graft apposition will be obtained using a complete and pressurized (approx. 65mmHg) filling of the anterior chamber with 20% SF6, for 8 minutes. Tissue manipulations, such as corneal swiping, will be performed as deemed necessary by the surgeon, based on the en face view from the conventional microscope image. The intraocular pressure is normalized by exchanging the SF6 gas for BSS, to achieve a gas bubble approximately the size of the graft (i.e 8.5mm). Now, the graft apposition is assessed using iOCT, to ensure all trial patients eventually undergo advanced iOCT imaging. Should this iOCT image reveal improper graft adherence or any other irregularity, the surgeon will perform additional manipulations or interventions as deemed necessary
62119761|NCT03999866|ACTIVE_COMPARATOR|satisfaction of instructor|visual analogy scale of the satisfaction of the instructor was recorded
62119762|NCT03999866|ACTIVE_COMPARATOR|satisfaction of the patient|visual analogy scale of the satisfaction of the patient was recorded
62119763|NCT03999866|ACTIVE_COMPARATOR|duration of view|duration of the visualization the vocal cords was recorded
62119764|NCT06554353||Subjects with dyspnea referred for Cardiopulmonary Exercise Testing|Subjects with unexplained dyspnea referred for Cardiopulmonary Exercise Testing.
62119765|NCT03812978|NO_INTERVENTION|Control|Standard treatment
62119766|NCT03812978|EXPERIMENTAL|Intervention|Standard treatment and intervention (Smart phone application)
62119767|NCT02557542|EXPERIMENTAL|One Stop Vein Clinic|Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
62119768|NCT02557542|ACTIVE_COMPARATOR|Normal Care Pathway|Patients randomised to this group will be invited to the Normal Care Pathway
62119769|NCT00437346|ACTIVE_COMPARATOR|Group A|Patients is given thorough information based on the tests taken plus medical treatment.
62307724|NCT05400460|OTHER|CASBR group|Anterior cruciate ligament reconstruction using STG, absorbable interface nails and CASBR procedures.
62119770|NCT00437346|ACTIVE_COMPARATOR|Group B|Patients receive simple written information based on the tests taken plus medical treatment.
62307725|NCT05400460|OTHER|DB group|Anterior cruciate ligament reconstruction using STG, absorbable interface nails and DBR procedures.
62678660|NCT01708954|EXPERIMENTAL|Arm B (cabozantinib)|Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61919645|NCT01673750||Participants|Participants will have documented HIV infection and are aware of their diagnosis. They will complete a one-time questionnaire.
61919646|NCT04542538||COVID-19 critical care patients|All patients who have received intensive care with COVID-19 in Sweden until May 27, 2020. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
62475055|NCT04656353|EXPERIMENTAL|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
62119771|NCT04358354|EXPERIMENTAL|FOLFOXiri group|Irinotecan 150 mg/m2 iv drip d1; Oxaliplatin 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
62475056|NCT02210182|EXPERIMENTAL|Oral pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
62475057|NCT02210182|PLACEBO_COMPARATOR|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
62678661|NCT01708954|EXPERIMENTAL|Arm C (erlotinib+cabozantinib)|Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62678662|NCT01708954|EXPERIMENTAL|Arm Z (erlotinib+cabozantinib; step II)|Patients achieving disease progression in Arm A or Arm B may receive erlotinib and cabozantinib as patients in Arm C. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62678663|NCT06042855|EXPERIMENTAL|Arm G - Metformin|"Metformin IR tablets will be self-administered orally according to the following dosing schedule:~* 500 mg on Day 1;~* 500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and~* 500 mg in the morning and 2 x 500 mg (a total of 1000 mg) in the evening on Day 6 through Day 14."
62678664|NCT06042855|PLACEBO_COMPARATOR|Arm G - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
62119772|NCT04358354|ACTIVE_COMPARATOR|FOLFOX group|Oxaliplatin: 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
62678665|NCT00510562|EXPERIMENTAL|1|Assessment for cranial strain patterns, followed by indirect osteopathic treatment of dysfunctions found on assessment, followed by reassessment.
62678666|NCT00510562|SHAM_COMPARATOR|2|Assessment for cranial strain patterns, followed by laying on of hands, followed by reassessment.
61919647|NCT04542538||Sepsis critical care patients|All patients who have received intensive care with severe sepsis or septic shock in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
62119773|NCT02471755|ACTIVE_COMPARATOR|Electro-acupuncture Group|
62119774|NCT02471755|PLACEBO_COMPARATOR|Sham Electro-acupuncture Group|
62119775|NCT02710708|EXPERIMENTAL|Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)|Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.
62119776|NCT00149838|EXPERIMENTAL|Active prefrontal rTMS phase1|Phase I participants receiving rTMS
62119777|NCT00149838|PLACEBO_COMPARATOR|Sham rTMS phase 1|Phase I participants receiving sham stimulation
62119778|NCT00149838|EXPERIMENTAL|rTMS extension|rTMS. Phase II participants, all of whom did not meet remission requirements after phase 1. They all receive active open label rTMS
62119779|NCT00149838|EXPERIMENTAL|Open label antidepressant regimen|All patients who met remission who were then transitioned to medications after the TMS trial was completed.
62119780|NCT03053388|EXPERIMENTAL|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
62119781|NCT03053388|ACTIVE_COMPARATOR|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
62119782|NCT03830866|EXPERIMENTAL|Durvalumab (intravenous infusion)|durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization
62678667|NCT05647122|EXPERIMENTAL|Module 1 AZD9592 Monotherapy|"Module 1 has two parts:~Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592.~Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 as monotherapy in select solid tumors"
62678668|NCT05647122|EXPERIMENTAL|Module 2 AZD9592 Combination with Osimertinib|"Module 2 has two parts:~Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with Osimertinib.~Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with Osimertinib in NSCLC EGFRm"
62307726|NCT03078361|ACTIVE_COMPARATOR|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
62307727|NCT03078361|ACTIVE_COMPARATOR|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
62307728|NCT04924725|EXPERIMENTAL|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area under CEH mode was performed.
62307729|NCT04924725|ACTIVE_COMPARATOR|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4).
62307730|NCT05629962|EXPERIMENTAL|Bemnifosbuvir (BEM)|
62307731|NCT05629962|PLACEBO_COMPARATOR|Placebo|
62307732|NCT04804852||study population|Patient diagnosed with head \& neck carcinoma at diagnosis
62307733|NCT00419250|EXPERIMENTAL|dose-escalation to 5 mg lenalidomide (len)|escalate up to 5 mg once daily / 28-day cycle
62307734|NCT00419250|EXPERIMENTAL|dose-escalation to 10 mg lenalidomide (len)|escalate up to 10 mg once daily / 28-day cycle
62307735|NCT00419250|EXPERIMENTAL|dose-escalation to 15 mg lenalidomide (len)|escalate up to 15 mg once daily / 28-day cycle
62307736|NCT00419250|EXPERIMENTAL|dose-escalation to 20 mg lenalidomide (len)|escalate up to 20 mg once daily / 28-day cycle
62678669|NCT05647122|EXPERIMENTAL|Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin|"Module 3 has two parts:~Part A aims to determine the safety, tolerability and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC)"
62307737|NCT00419250|EXPERIMENTAL|dose-escalation to 25 mg lenalidomide (len)|escalate up to 25 mg once daily / 28-day cycle
62475058|NCT02005497|EXPERIMENTAL|HealthLinks|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email to implement a worksite wellness program and adopt evidence-based practices.
62475059|NCT02005497|ACTIVE_COMPARATOR|HealthLinks+|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email plus support to form a worker wellness committee to implement a worksite wellness program and adopt evidence-based practices.
62475060|NCT02005497|NO_INTERVENTION|Delayed Control|Worksites in this arm will not receive an intervention during the study. After they have provided their final follow-up data, they will receive the HealthLinks intervention.
62475061|NCT04887766|ACTIVE_COMPARATOR|Active|GS300: Three (3) GS300 capsules \[approximately 0.65 grams (g)\] two (2) times per day ingested 10 minutes (min) before meals (i.e., lunch and dinner) - total of 3.9 g per day
62678670|NCT03643991|EXPERIMENTAL|Weighted Blanket Cohort|Subjects will receive weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).
62678671|NCT03643991|NO_INTERVENTION|Control Cohort|Subjects will receive treatment as usual while inpatient, no blanket.
62678672|NCT06396403||HbSS patients without SCR|Adult sickle cell patients with the HbSS genotype and without sickle cell retinopathy
62678673|NCT06396403||HbSS patients with PSCR|Adult sickle cell patients with the HbSS genotype and proliferative sickle cell retinopathy
62678674|NCT06396403||HbSC patients without SCR|Adult sickle cell patients with the HbSC genotype and without sickle cell retinopathy
62678675|NCT06396403||HbSC patients with PSCR|Adult sickle cell patients with the HbSC genotype and proliferative sickle cell retinopathy
62678676|NCT03075943|EXPERIMENTAL|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
61919648|NCT04542538||ARDS critical care patients|All patients who have received intensive care with ARDS in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
62119783|NCT03830866|PLACEBO_COMPARATOR|Placebo (matching placebo for intravenous infusion)|placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)
62119784|NCT03148496|EXPERIMENTAL|Biologic Mesh and Small Bites|Biologic mesh placement and small bites used for suturing.
62119785|NCT03148496|EXPERIMENTAL|Small Bites and No Biologic Mesh|Small bites used for suturing with no placement of biologic mesh
62119786|NCT03148496|EXPERIMENTAL|Biologic mesh and Large Bites|Biologic mesh placement and large bites used for suturing
62119787|NCT03148496|ACTIVE_COMPARATOR|Large Bites and no biologic mesh|Large bites used for suturing and no placement of biologic mesh.
62119788|NCT04778917|EXPERIMENTAL|Small dose low molecular weight heparin|Low molecular weight heparin calcium 100 units / kg/day, subcutaneous injection, 5-10 days of treatment or D-dimer recovery normal.
62119789|NCT04778917|EXPERIMENTAL|High dose of low molecular weight heparin|low molecular weight heparin calcium 200 units /kg/day, subcutaneous injection, treatment for 7 days or D-dimer return to normal.
62119790|NCT04778917|PLACEBO_COMPARATOR|Vacuity contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
62119791|NCT04778917|NO_INTERVENTION|contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
62119792|NCT02964429|EXPERIMENTAL|Diacap Pro High-Flux|1.3/ 1.6/ 1.9 sqm
62119793|NCT05741996|EXPERIMENTAL|Effetcs of Taping type and Orthosis on Pain,|The order of the elastic taping, rigid taping, and braces was randomized using a computer-generated random sequence created before the research (Random.org). Both knees of each participant were taped and braced. The participants were allowed to become accustomed to the applied elastic taping, rigid taping, and braces before the gait analysis and evaluations. All the taping techniques and braces were similar for all the participants. The participants performed four evaluation condition trials at baseline and with the elastic taping, rigid taping, and braces after 45 minutes.
62119794|NCT05741996|EXPERIMENTAL|Effetcs of Taping type and Orthosis on Gait and functionality|"The Western Ontario and McMaster Universities Turkish Version 3.1 (WOMAC) index is a self-administered questionnaire that assesses three aspects of a patient's health status -pain, stiffness, and physical function - in those with lower limb Osteoarthritis.~Gait analysis was conducted using a 3-dimensional VICON gait analysis system (Workstation Version 4.0, Oxford, UK). Each participant was assessed four times before and after the applications."
62119795|NCT01591733|EXPERIMENTAL|Treatment Arm|All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
62119796|NCT05857371|SHAM_COMPARATOR|Control group|"The surgeon trained to lipoaspiration procedure will perform lipoaspiration for the ADSVF cryopreservation under local anesthesia with sedation.~The patients of the control group benefices to urethrotomy (standard care) under general anesthesia. The surgical surgical technique necessitates performing three incisions with a cold endoscopic knife in the stenosis to obtain enlargement of urethral lumen on the length of the fibrosis at 3, 9 and 12 o' clock.~For patients randomised in the control group, lippoaspiration will be performed for cryopreservation of the autologous ADSVF and potential second administration of ADSVF in case of UrS recurrency. UrS recurrence or primary failure is defined as a recurrence without a period of post procedure improvement). Recurrence incoming before 21 months post experimental treatment will be treated according to the study in order to have a minimum follow-up of 3 months."
62119797|NCT05857371|EXPERIMENTAL|Experimental group|"The surgeon trained to lipoaspiration procedure will perform lipoaspiration for the ADSVF cryopreservation under local anesthesia with sedation.~The patients of the control group benefices to urethrotomy (standard care) under general anesthesia. The surgical surgical technique necessitates performing three incisions with a cold endoscopic knife in the stenosis to obtain enlargement of urethral lumen on the length of the fibrosis at 3, 9 and 12 o' clock.~For theses patients -randomised in the experimental group - the experimental cell drug will be customised-made to each patient's lesion and included a dose between 16 and 56 million\* viable nucleated cells (VNCs) of fresh or thawed autologous Adipose-derived -Stromal Vascular Fraction, resuspended in saline (0, 9%) - 5% human serum albumin (50 mg/mL) final packaged in 2 to 7 syringes of 1 mL at a concentration of 8 million CNV / mL, individually closed with a tamper-proof Luer Lock cap and labelled to ensure double-blindness."
61919649|NCT05095493|EXPERIMENTAL|zinc, then placebo|Participants first received oral zinc acetate 50 mg tab each day for 7 days before scheduled BoNT injection. 3 months later participants received oral placebo (matching oral zinc) tablet each day for 7 days before scheduled BoNT injection.
62307738|NCT06513104|EXPERIMENTAL|NNC0519-0130 + OC+ paracetamol|All participants will initiate treatment with paracetamol (once) and oral contraceptive (Levonorgestrel + Ethinylestradiol) treatment only followed by a period with NNC0519-0130 treatment only, thereafter a period with NNC0519-0130, paracetamol (once) and oral contraceptive treatment.
62678677|NCT03075943|PLACEBO_COMPARATOR|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
62678678|NCT01029873|EXPERIMENTAL|ALT-801|
62678679|NCT03081078|EXPERIMENTAL|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
62678680|NCT03081078|EXPERIMENTAL|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
62678681|NCT03081078|NO_INTERVENTION|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
62678682|NCT06570603|PLACEBO_COMPARATOR|Psychoeducational Control|Participants will receive psychoeducation only
62678683|NCT06570603|EXPERIMENTAL|Self-Efficacy (Only)|Single session intervention focusing on increasing self-efficacy to manage distress. Will include brief psychoeducation about emotion, then a focus on agency and self-criticism, using stressors the participant provided from the previous week, with an aim to teach self-compassion skills that will improve self-efficacy.
62678684|NCT06570603|EXPERIMENTAL|Willingness (Only)|Single session intervention focused on increasing willingness to allow distress. Will include brief psychoeducation about emotion, then a discussion of values and how allowing and experiencing emotions nourishes values, experiencing discomfort enhances growth. Will use stressors from the prior week as examples.
62678685|NCT06570603|EXPERIMENTAL|Combined Willingness and Self-Efficacy|Single session intervention focused on increasing both willingness and self-efficacy. Will include brief psychoeducation about emotion, then a combination of using values and self-compassion to increase both allowing and self-efficacy.
62678686|NCT05447078|PLACEBO_COMPARATOR|Placebo|inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 16 weeks duration.
62678687|NCT05447078|EXPERIMENTAL|Immulina TM 200 mg/day|Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 2 placebo capsules given by mouth in the evening for 16 weeks duration.
62678688|NCT05447078|EXPERIMENTAL|Immulina TM 400 mg/day|Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 1-200 mg capsule and 1 placebo capsule given by mouth in the evening for 16 weeks duration.
62678689|NCT05447078|EXPERIMENTAL|Immulina TM 800 mg/day|Immulina Dietary supplementation (200 mg per capsule); 2-200 mg capsules given by mouth in the morning and 2-200 mg capsules given by mouth in the evening for 16 weeks duration.
62678690|NCT00923507||Patients|Patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstr(SqrRoot)(Delta)m macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL).
62475062|NCT04887766|PLACEBO_COMPARATOR|Placebo|Placebo: Three (3) placebo capsules two (2) times per day 10 min before meals (i.e., lunch and dinner)
62678691|NCT03971045|EXPERIMENTAL|Pembrolizumab and metronomic cyclophosphamide|.Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
62678692|NCT00972478|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62678693|NCT05290818|ACTIVE_COMPARATOR|Manual Total Knee Arthroplasty|"This group will receive a conventional manual Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert. The surgeon will then make bone cuts using a manual jig and a hand held saw to prepare the bone surfaces for the implant. A measured resection technique will be employed with a three degree tibial slope. The surgeon will use a conventional jig alignment technique for intramedullary referencing for the femur and extra medullary referencing for the tibia. Once the implant is in position the knee is then balanced by the feel though a range of movement and soft tissue releases will be performed as required to balance the knee in flexion and extension."
62475063|NCT01160926|EXPERIMENTAL|AZD6244 + capecitabine + radiotherapy|10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
61919650|NCT05095493|EXPERIMENTAL|placebo, then zinc|Participants first received placebo tablet (matching oral zinc) each day for 7 days before scheduled BoNT injection. 3 months later participants received oral zinc acetate 50 mg tablet each day for 7 days before scheduled BoNT injection.
61919651|NCT01854944|EXPERIMENTAL|Brexpiprazole 1mg to 4mg|"Three cohorts of subjects will be evaluated:~- Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole."
61919652|NCT03239028||Danish National Birth Cohort|
61919653|NCT00395538|OTHER|Biopsy|Subjects are randomized to have the second bone biopsy done 1,2, or 4 years after the start of PTH.
62307739|NCT02332915|EXPERIMENTAL|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
62307740|NCT02332915|EXPERIMENTAL|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
62475064|NCT01160926|EXPERIMENTAL|Cediranib + capecitabine + radiotherapy|10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
62678694|NCT05290818|EXPERIMENTAL|Robotic Assisted Unicompartmental Knee Arthroplasty|This group will receive the cemented Restoris MCK (Mako, Stryker) with a highly crossed linked (X3) polyethylene insert through a less invasive to the knee joint. Instead of using a manual jig and a hand held burr will be used to prepare the bone surfaces for the implant, the MAKO robotic arm will be used by the surgeon to cut the bone at the required alignment. The information from the CT scan will be used to create a 3D model of the patient's bony anatomy and will used to plan the positioning of the implant. Once the trackers are in place registration of the knee joint surface is performed. The specified bone cuts are then performed using the robotic arm, aiming to gap balance the knee through a full range of movement.
62678695|NCT00930787|EXPERIMENTAL|Strattice Reconstructive Tissue Matrix|Use of Strattice Reconstructive Tissue Matrix to support hernia repair
62678696|NCT00930787|ACTIVE_COMPARATOR|Proceed Surgical Mesh|Use of Proceed Surgical Mesh to support hernia repair
62678697|NCT05935215|EXPERIMENTAL|iptacopan 200 mg b.i.d.|open label arm of iptacopan 200 mg b.i.d.
62678698|NCT06034275|EXPERIMENTAL|Dose Escalation of VIP943 (QW)|Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW).
62678699|NCT06034275|EXPERIMENTAL|Dose Escalation of VIP943 (BIW)|Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration twice weekly (BIW).
62678700|NCT06691763|NO_INTERVENTION|Pretest T0|Usual care
62678701|NCT06691763|NO_INTERVENTION|Pretest T1|Usual care
62678702|NCT06691763|EXPERIMENTAL|Post-test T2|PSAI
62678703|NCT00420407|EXPERIMENTAL|I|Vasopressin
62678704|NCT00420407|PLACEBO_COMPARATOR|2|bolus of NS (normal saline) followed by continuous infusion of NS, no vasopressin added
61919654|NCT04132245|EXPERIMENTAL|obesity prevention|Families were randomized to an obesity prevention intervention arm or a general health control arm.
62307741|NCT03551886|EXPERIMENTAL|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
62678705|NCT03721107|EXPERIMENTAL|Cohort C: Blautix|Participants diagnosed with Irritable bowel syndrome subtype C (IBS-C) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10\^10 to10\^11 most probable number (MPN).
62678706|NCT03721107|PLACEBO_COMPARATOR|Cohort C: Placebo|Participants diagnosed with IBS-C received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.
62678707|NCT03721107|EXPERIMENTAL|Cohort D: Blautix|Participants diagnosed with Irritable bowel syndrome subtype D (IBS-D) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10\^10 to10\^11 MPN.
62678708|NCT03721107|PLACEBO_COMPARATOR|Cohort D Placebo|Participants diagnosed with IBS-D received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.
62678709|NCT05017948|EXPERIMENTAL|Intervention|Discharge medication regimen instructions will be provided upon discharge after being assessed using the MWRS, optimized, and assessed by the prescriber.
62678710|NCT05017948|NO_INTERVENTION|Standard of Care|Discharge medication regimen instructions will be provided upon discharge after being assessed by the prescriber.
62678711|NCT02604667||Group 1: Cancer and Stroke|Patients with active solid tumor cancer and acute ischemic stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
62678712|NCT02604667||Group 2: Stroke and No Cancer|Patients with acute ischemic stroke and no cancer. Will undergo blood tests and transcranial Doppler microemboli detection study.
61919655|NCT04132245|EXPERIMENTAL|behavioral intervention|there are two arms in this study. An active intervention arm and a control arm
61919656|NCT00550251|ACTIVE_COMPARATOR|Acupressure Bands|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
62678713|NCT02604667||Group 3: Cancer and No Stroke|Patients with active solid tumor cancer and no stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
61919657|NCT00550251|PLACEBO_COMPARATOR|Placebo|Elasticated wrist bands without active bead.
61919658|NCT04969796|EXPERIMENTAL|REACH Hope|Participants receive the REACH behavioral intervention coupled with the Department of Defense Hope Box app.
61919659|NCT04969796|ACTIVE_COMPARATOR|Wait list control|Participants receive the REACH behavioral intervention coupled with the Department of Defense Hope Box app.
61919660|NCT06167174||MMF treatment|Patients that have been diagnosed as III/IV ± V LN and treated with MMF 2g/d in combination with glucocorticoid.
62307742|NCT03551886|ACTIVE_COMPARATOR|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
62307743|NCT04125745|EXPERIMENTAL|CXA-10|Oral CXA-10 300 mg once daily for 12 weeks
62307744|NCT04686890|ACTIVE_COMPARATOR|postoperative opiod (morphine) consumption|patient-controlled analgesia (15 minutes. lock time, 2 ml bolus= total 1 mg morphine intravenously, limited to maximum 4 bolus / per hour )
62678714|NCT00148538|ACTIVE_COMPARATOR|1|resistance exercise
62678715|NCT00148538|ACTIVE_COMPARATOR|2|Aerobic and Resistance exercise
62678716|NCT03967574|EXPERIMENTAL|Real tDCS|Participants received the full tDCS intervention for a total of 20 minutes, one time, two weeks following the CSI
62307745|NCT04686890|ACTIVE_COMPARATOR|peroperative continuous opioid (remifentanil) consumption|continuous remifentanil infusion was given during the whole procedure
62678717|NCT03967574|SHAM_COMPARATOR|Sham tDCS|The patients were set up in an identical way as with the real tDCS group, but only received active stimulation for 30 seconds, after which the current was gradually stopped. The participants continued wearing the electrodes until the end of the 20 minutes treatment.
62678718|NCT03967574|NO_INTERVENTION|Control|Participants received no further intervention two weeks following their CSI
62678719|NCT00572481|OTHER|Sentinel Lymph Node Biopsy Only|Axillary Reverse Mapping
61919661|NCT06167174||CYC treatment|Patients that have been diagnosed as III/IV ± V LN and treated with CYC 0.5g IV per two weeks in combination with glucocorticoid.
61919662|NCT04934631||CBT-ED trainees and therapists.|Qualified clinicians delivering CBT-ED throughout a variety of treatment settings, working with adult eating disorder patients. Clinicians will audio-record CBT-ED therapy sessions with their eating disorder patients.
61919663|NCT04934631||Eating Disorder patients.|Adult (18+ years) eating disorder patients currently accessing CBT-ED from one of the CBT-ED therapists/trainees stated above. Patients will have one of their therapy sessions audio-recorded.
62475065|NCT06196307||No cardiovascular adverse events (MACE) occurred during the 1-month period|No cardiovascular adverse events (MACE)，which include all-cause death, myocardial infarction, emergency revascularization, cardiogenic shock, cardiac arrest/ventricular fibrillation, stroke, and so on. Follow-up visits are conducted by in-person or telephone and registration is carried out.
62678720|NCT00572481|OTHER|Full Axillary Lymph Node Dissection|Axillary Reverse Mapping
62678721|NCT04769986|EXPERIMENTAL|Mobile Mindfulness-Based Relapse Prevention (mMBRP)|Participants will complete the Mindfulness Coach app program that is enhanced with additional modules containing MBRP content.
62678722|NCT04769986|ACTIVE_COMPARATOR|Active control|Participants will complete a course of an exercise/healthy eating app program that is matched in time and effort to the intervention condition app.
62678723|NCT01652105|EXPERIMENTAL|Diet|New developed diet
61919664|NCT04934631||Raters/Judges.|Either experts or non-experts in the field of CBT-ED. Raters will use the CBTS-ED to assess clinician competence when listening to the therapy session audio-recordings.
61919665|NCT01106469|EXPERIMENTAL|001|JNJ-41443532 25mg tablet once daily
61919666|NCT01106469|EXPERIMENTAL|002|JNJ-41443532 100mg tablet once daily
61919667|NCT01106469|EXPERIMENTAL|003|JNJ-41443532 250mg tablet once daily
62678724|NCT01652105|ACTIVE_COMPARATOR|Prodimed|Standard VLCD
62678725|NCT06549725|ACTIVE_COMPARATOR|Patients with Pancreatic cancer|"Participants with histologically confirmed diagnosis of resectable Pancreatic cancer.~Arm 1 will undertake one visit (baseline) for blood sampling - lipidomics, CA 19-9 and CEA, HbA1c.~At baseline their participation ends."
61919668|NCT01106469|EXPERIMENTAL|004|JNJ-41443532 500mg once daily (with 250mg tablets)
62475066|NCT06196307||Group of cardiovascular adverse events (MACE) occurring during 1 month|Cardiovascular adverse events occur, the rest of the same as in the previous group
62475067|NCT01950715|OTHER|sacral nerve stimulation|A single armed study to evaluate the on the gastro-colic response in IBS patients treated with sacral nerve stimulation
62678726|NCT06549725|EXPERIMENTAL|Patient at risk of Pancreatic cancer|"Participants without Pancreatic cancer but at higher risk of this cancer disease due to their predispositions.~Arm 2 will come for two or three visits depending on results at baseline. On each visit blood sampling (lipidomics, CA 19-9 and CEA, HbA1c, hCG) and medical imaging by EUS, MR or CT will be performed.~Their participation ends with the diagnosis of Pancreatic cancer or after 12 months of follow-up."
62678727|NCT01658878|EXPERIMENTAL|Non-infected: Nivolumab|Nivolumab intravenous solution on specific days
61919669|NCT01106469|EXPERIMENTAL|005|JNJ-41443532 1000mg once daily (with 250mg tablets)
61919670|NCT01106469|EXPERIMENTAL|006|JNJ-41443532 1500mg once daily (with 250mg tablets)
61919671|NCT01106469|PLACEBO_COMPARATOR|007|Placebo Matching placebo
62119798|NCT02896699|EXPERIMENTAL|PrEP Intervention Group|Group training session including HIV Education, PrEP Education, Following the training session Booster phone calls HIv and syphillis testing
62119799|NCT02896699|ACTIVE_COMPARATOR|Control Group|Group HIV risk vignettes
62678728|NCT01658878|EXPERIMENTAL|HCV-infected: Nivolumab|Nivolumab intravenous solution on specific days
62307746|NCT04686890|ACTIVE_COMPARATOR|postoperative numerated rating scale|at the 1, 3, 6, 12 and 24 th hour postoperatively - numerated rating scale score was evaluated and recoded as 0= no pain (better), 10: unbearable pain (worse)
62307747|NCT01535937|EXPERIMENTAL|Ketamine|0.5 mg/kg of ketamine IV over 40 minutes
62678729|NCT01658878|EXPERIMENTAL|HBV-infected: Nivolumab|Nivolumab intravenous solution on specific days
62678730|NCT01658878|EXPERIMENTAL|Nivolumab|Nivolumab intravenous solution on specific days
62678731|NCT01658878|ACTIVE_COMPARATOR|Sorafenib|Sorafenib tablets on specific days
62678732|NCT01658878|EXPERIMENTAL|Nivolumab plus Ipilimumab Combination|Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
62678733|NCT01658878|EXPERIMENTAL|Child-Pugh B|Nivolumab intravenous solution on specific days
62678734|NCT01658878|EXPERIMENTAL|Nivolumab plus Cabozantinib Combination|Nivolumab intravenous solution + cabozantinib oral tablets on specific days
62307748|NCT01535937|ACTIVE_COMPARATOR|midazolam|0.025 mg/kg IV over 40 minutes
62307749|NCT04825873||Cohort 1|Prospective observation of participants with non-small cell lung cancer (NSCLC)
62678735|NCT01658878|EXPERIMENTAL|Nivolumab plus Ipilimumab plus Cabozantinib|Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
62307750|NCT04825873||Cohort 2|Prospective observation of participants with squamous cell carcinoma of head and neck (SCCHN)
62307751|NCT04825873||Cohort 3|Retrospective observation of participants with NSCLC
62307752|NCT04825873||Cohort 4|Retrospective observation of participants with SCCHN
62307753|NCT04720352|SHAM_COMPARATOR|Sham Comparator|Sham delivers non therapeutic levels of radiofrequency and cryogen
62307754|NCT04720352|EXPERIMENTAL|Active Arm|Active arm delivers radiofrequency and cryogen
62307755|NCT05741073||resected HR-cSCC|Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting
62307756|NCT05741073||advanced cSCC|Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2)
62307757|NCT05741073||advanced BCC|Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3)
62307758|NCT00687050|ACTIVE_COMPARATOR|1|HIV-positive hemodialysis patients (as a high risk group for cachexia) will be given daily drinks of Renilon 7.5 (125 ml, 2 kcal/ml) as peroral supplemental nutrition on top to their recommended high-protein, high-caloric diet.
62678736|NCT05836987|EXPERIMENTAL|AFSW Guided DOAC|All participants randomized to the experimental arm will be provided with an AFSW that will be linked to the participants Apple watch and the secure REACT-AF app within the Eureka cloud. The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
62307759|NCT00687050|NO_INTERVENTION|2|Chronic hemodialysis patients randomized to no peroral supplemental nutrition
62307760|NCT00687050|ACTIVE_COMPARATOR|3|Chronic hemodialysis patients randomized to peroral supplemental nutrition.
62307761|NCT04201912|PLACEBO_COMPARATOR|control patients|Evaluation of Toll like receptor activity from whole saliva obtained from control patients
62307762|NCT04201912|ACTIVE_COMPARATOR|Periodontal patients without diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients without diabetes
62307763|NCT04201912|ACTIVE_COMPARATOR|Periodontal patients with diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients with diabetes
62307764|NCT03329872||Patients group|Patients follow-up in hospital will have data collection
62307765|NCT04918173|EXPERIMENTAL|Atenativ treatment|Patients will receive a single intravenous infusion of Atenativ for PK analysis. Patients will receive a single intravenous dose followed by maintenance doses administered every 24 hours for approximately 2-7 days for surgical patients and approximately 5 days for parturients
62307766|NCT04718064|EXPERIMENTAL|fingolimod with standard therapy|Patients will be treated with intravascular therapy and fingomod.
62307767|NCT04718064|PLACEBO_COMPARATOR|Placebo with standard therapy|Patients will be treated with intravascular therapy and placebo.
62307768|NCT05395169|EXPERIMENTAL|medical treatment|Control group:Will be consisted of 25 females suffering from PMS will receive medical treatment in form of vit, B6, ca supplements and minerals (vitatron), once daily(1capsule), for 12 weeks.
62475068|NCT05734677|EXPERIMENTAL|psychotherapeutic intervention with class risk A (low risk, no invasive procedure)|an eight-week emotion regulation group intervention
62678737|NCT05836987|ACTIVE_COMPARATOR|Continuous DOAC therapy|All participants randomized to the control arm will remain on previously prescribed FDA-approved DOAC regimen as indicated by current practice standards. These participants will continuously take DOAC through the course of the study as prescribed by the participants primary physician unless otherwise contraindicated. Participants in the control arm will also use the REACT-AF mobile app within the Eureka platform via Apple watch for study follow-up activities, but the participants will not receive an AFSW and any personally owned Apple Watch will not be loaded with the customized REACT-AF detection algorithm nor participant notification apps.
62678738|NCT06292299||Patient attending for overnight cardiorespiratory polysomnography sleep study|Any patient attending the Royal Hospital for Children, Glasgow sleep laboratory for overnight cardiorespiratory polysomnography for evaluation of sleep disordered breathing. Pneumowave device will collect data from patients alongside standard clinical monitoring.
62678739|NCT06292299||Patients in the neonatal unit, Royal Hospital for Children, Glasgow, at risk of central apnoea|Any patient currently in the Queen Elizabeth University Hospital campus neonatal unit at risk of central apnoea receiving standard care (this may include mechanically ventilated patients). Pneumowave device will collect data from patients alongside standard clinical monitoring.
62678740|NCT01333657||SIRS|"1. temperature \>38 ℃ or \<36℃;~2. pulse rate\>90 beats/min;~3. ventilatory rate\>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)\<32mmHg;~4. white blood cell count\>12,000μL-1 or \<4000μL-1 or \>10% immature cells"
62678741|NCT01333657||Sepsis|"1. sepsis: SIRS plus infection;~2. severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~3. septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
62678742|NCT05558670||coma|
62678743|NCT05558670||VS/UWS|
62678744|NCT05558670||MCS|
62678745|NCT05558670||EMCS|
62678746|NCT04895358|EXPERIMENTAL|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg administered by intravenous infusion (IV) on Day 1 of each 21-day cycle (Q3W) PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle (Q4W), 2) nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m\^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m\^2 by oral administration (PO) twice a day (BID) on Days 1-14 Q3W for up to 35 administrations.
62678747|NCT04895358|ACTIVE_COMPARATOR|Placebo + Chemotherapy|Participants receive placebo (normal saline or dextrose) IV on Day 1 Q3W PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m\^2 IV on Days 1, 8, and 15 Q4W, 2) nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m\^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m\^2 PO BID on Days 1-14 Q3W for up to 35 administrations.
62678748|NCT01942980|OTHER|conventional postoperative whole-brain radiation therapy|conventional postoperative whole-brain radiation therapy (40 Gy in 20 fractions of 2 Gy)
62678749|NCT01942980|OTHER|whole-brain radiation therapy with hippocampal avoidance|Radiation therapy with hippocampal avoidance
62678750|NCT01755156|EXPERIMENTAL|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
62678751|NCT01755156|PLACEBO_COMPARATOR|Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
62678752|NCT00714363|ACTIVE_COMPARATOR|1|LASIK
62678753|NCT00714363|ACTIVE_COMPARATOR|2|SBK
62678754|NCT06372483|EXPERIMENTAL|Part 1, Cohort 1:1 - VMX-C001|Single dose active.
62678755|NCT06372483|PLACEBO_COMPARATOR|Part 1, Cohort 1:1 - Placebo|Single dose placebo.
62678756|NCT06372483|EXPERIMENTAL|Part 2, Cohort 2:1 - VMX-C001 + Rivaroxaban|Single dose active in combination with DOAC.
62678757|NCT06372483|PLACEBO_COMPARATOR|Part 2, Cohort 2:1 - Placebo + Rivaroxaban|Single dose placebo in combination with DOAC.
62678758|NCT06372483|EXPERIMENTAL|Part 2, Cohort 2:2 - VMX-C001 + DOAC|Optional cohort - Single dose active in combination with selected DOAC.
62119800|NCT04660214|ACTIVE_COMPARATOR|Vessel sealing device|Endoscopic diverticulectomy is performed with the LigaSure (TM) device
62119801|NCT04660214|ACTIVE_COMPARATOR|Dissecting Knife device|Endoscopic diverticulectomy is performed with the SB-Knife(TM) device
62119802|NCT02045836|EXPERIMENTAL|Co-Ad Group|Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
62119803|NCT02045836|ACTIVE_COMPARATOR|Control Group|Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
62119804|NCT01613274|EXPERIMENTAL|Gum chewing|Chewing mint flavored sugarless gum for 10-20 minutes three times a day following colon resection.
62119805|NCT01613274|PLACEBO_COMPARATOR|no gum chewing|no gum chewing
62119806|NCT01716858|EXPERIMENTAL|A single-arm study|
62119807|NCT05850091|PLACEBO_COMPARATOR|Group A|Participants will receive placebo daily
62119808|NCT05850091|ACTIVE_COMPARATOR|Group B|Participants will receive rosuvastatin 20mg daily and placebo daily
62119809|NCT05850091|ACTIVE_COMPARATOR|Group C|Participants will receive colchicine 0.6mg daily and placebo daily
62119810|NCT05850091|ACTIVE_COMPARATOR|Group D|Participants will receive rosuvastatin 20mg daily and colchicine 0.6mg daily
62119811|NCT01064817|EXPERIMENTAL|PRM-151|PRM-151 (recombinant human serum amyloid P, recombinant human pentraxin 2)
62119812|NCT01064817|PLACEBO_COMPARATOR|Placebo|Placebo
62119813|NCT03093467|EXPERIMENTAL|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
62678759|NCT06372483|PLACEBO_COMPARATOR|Part 2, Cohort 2:2 - Placebo + DOAC|Optional cohort - Single dose placebo in combination with selected DOAC.
62678760|NCT06372483|EXPERIMENTAL|Part 2, Cohort 2:3 - VMX-C001 + DOAC|Optional cohort - Single dose active in combination with selected DOAC.
62678761|NCT06372483|PLACEBO_COMPARATOR|Part 2, Cohort 2:3 - Placebo + DOAC|Optional cohort - Single dose placebo in combination with selected DOAC.
62678762|NCT06372483|EXPERIMENTAL|Part 2, Cohort 2:4 - VMX-C001 + DOAC|Optional cohort - Single dose active in combination with selected DOAC.
61919672|NCT03098771|EXPERIMENTAL|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
61919673|NCT03098771|EXPERIMENTAL|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
62475069|NCT00958334|EXPERIMENTAL|Proellex 25 mg|Two Proellex® 12.5 mg capsules once daily
62119814|NCT03093467|ACTIVE_COMPARATOR|Control|Patients receive psychiatric treatment and psychotherapy as usual.
62119815|NCT04906954|OTHER|Neuromuscular electrical stimulation (NMES)|"30 NMES sessions will be performed by patients for 30 min, for a period of 8 weeks, according to a standardized protocol.~The number of sessions per week will be gradually increased to reach 5 sessions/week at week 4."
62119816|NCT06030713|ACTIVE_COMPARATOR|Cord clamped after antibiotic prophylaxis|Umbilical cord clamped after 1g of cephazolin
62119817|NCT06030713|EXPERIMENTAL|Cord clamped before antibiotic prophylaxis|Umbilical cord clamped before 1g of cephazolin
62678763|NCT06372483|PLACEBO_COMPARATOR|Part 2, Cohort 2:4 - Placebo + DOAC|Optional cohort - Single dose placebo in combination with selected DOAC.
62119818|NCT00281008|EXPERIMENTAL|Cohort A|Loading doses followed by weekly maintenance doses
62119819|NCT00281008|EXPERIMENTAL|Cohort B|Loading doses followed by weekly maintenance doses
61919674|NCT00464243|EXPERIMENTAL|Volinanserin|2 mg volinanserin tablets orally once daily
62119820|NCT00281008|EXPERIMENTAL|Cohort C|Loading doses followed by weekly maintenance doses
62119821|NCT00281008|EXPERIMENTAL|Cohort D|Loading doses followed by extended weekly maintenance doses
62119822|NCT03181763|EXPERIMENTAL|MDMA|Participants receive 100 mg MDMA
62119823|NCT03181763|PLACEBO_COMPARATOR|Placebo|Participants receive inactive placebo
62119824|NCT03911479|EXPERIMENTAL|Bariatric Surgery Group|
62119825|NCT03911479|OTHER|Clinical Threatment|Convencional treatment in a public tertiary outpatients care unit
62475070|NCT00958334|EXPERIMENTAL|Proellex 12.5 mg|One Proellex® 12.5 mg capsules once daily
62475071|NCT00958334|PLACEBO_COMPARATOR|Placebo|Capsule once a day
62475072|NCT02062489|ACTIVE_COMPARATOR|Tamoxifen|20mg(2#)/day, PO, daily, five years
62475073|NCT02062489|PLACEBO_COMPARATOR|Placebo|2#/day, PO, daily, five years
62475074|NCT05236634|ACTIVE_COMPARATOR|Group A|Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks.
62475075|NCT05236634|ACTIVE_COMPARATOR|Group B|Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks.
62678764|NCT02219451|EXPERIMENTAL|exercise training|We studied twenty-six chronic heart failure outpatients and they were assigned to 2 groups: Untrained (n=13) and trained (n=13).
62678765|NCT05181475|EXPERIMENTAL|Sodium Oligomannate Capsules (GV-971)|The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening
62678766|NCT04535479|EXPERIMENTAL|Individuals with spasticity resulting from stroke|This is an experimental intervention in which individuals will receive dry needling to relieve spasticity in the target muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
62678767|NCT04535479|EXPERIMENTAL|Individuals with no known neurological injury|This is an experimental intervention in which individuals will receive dry needling of an arm or leg muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
62678768|NCT04236414|EXPERIMENTAL|Cohort A: ≥12 to <18 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
62678769|NCT04236414|EXPERIMENTAL|Cohort B: ≥3 to <12 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
62678770|NCT04236414|EXPERIMENTAL|Cohort C: ≥6 months to <6 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart. Patients in Cohort C will receive a predetermined number of each sprinkle capsule strength (15 and 19.5 mg,) to make up the required dose. Olaparib sprinkle capsules will be administered to the child by the parent/caregiver. Patients in Cohort C are not required to fast including PK sampling days. The dispensed granules should be swallowed whole and not chewed, crushed, dissolved or divided, and should be consumed within 30 minutes of preparation.
62678771|NCT04236414|EXPERIMENTAL|Signal identification|A secondary analysis of response in patients recruited into the signal identification phase will be conducted. Patients included in this analysis must have documented evidence of a deleterious or suspected deleterious germline or tumour HRR gene mutation. A minimum of 10 patients across age and dose cohorts with deleterious or suspected deleterious HRR mutations will be enrolled.
62736365|NCT05087368|EXPERIMENTAL|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 6|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 6: (N=50) Day 1 (boost) -ChAdOx1-S;"
62307769|NCT05395169|EXPERIMENTAL|the same medication, in addition to DASH diet and aerobic exercise|Study group: Will be consisted of 25 females suffering from PMS will Receive the same medication as in group (A) in addition to the DASH diet and aerobic exercise for 30 minutes,3 times/week,for 12 weeks.
62475076|NCT05236634|ACTIVE_COMPARATOR|Group C|Forty patients with LUTS due to BPH will be given combined therapy(tamsulosin 0.4 mg and tadalafil 5 mg) for 12 weeks.
62475077|NCT01515592|EXPERIMENTAL|15 mcg/kg|
62475078|NCT01515592|EXPERIMENTAL|20 mcg/kg|
62475079|NCT01515592|EXPERIMENTAL|25 mcg/kg|
62475080|NCT06558162|EXPERIMENTAL|Mindfetalness Group|"The method is based on noting the quality of perceived movements, which develops maternal awareness of the health of the foetus. The method requires the mother to lie on her left side while her baby is awake and for 15 minutes focus on exactly how the baby moves, taking into account the strength, type and frequency of movement. However, the number of fetal movements is not counted during this time.~It is also very important to understand the attitudes of the pregnant women, because a positive attitude may improve the perception of the pregnant woman and thus increase compliance with the method, whereas a negative attitude may hinder compliance with the method. Therefore, it will be important to create a positive attitude during the counselling of pregnant women in this group."
62475081|NCT06558162|ACTIVE_COMPARATOR|Sadovsky Group|This method involves counting the movements over a set period of time (usually 30 minutes to 2 hours). The mother should count the fetal movements at the same time every day. In this counting technique, mothers are especially asked to count after 3 meals during the day. Fetal movements are usually active in the evening. During the counting process, the mother should make sure that the baby is awake and should be calm, resting, eating, using the toilet, lying on her side and placing her hands on her abdomen. When the mother perceives the first movement of the baby, she should start recording on the monitoring chart given to her and continue counting and recording until the 10th movement is completed. If she counts less than 10 movements in the first 30 minutes, she should continue recording.
62475082|NCT05093205|EXPERIMENTAL|Part A|To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of atorvastatin (20 mg tablet) and midazolam (5 mg syrup).
62475083|NCT05093205|EXPERIMENTAL|Part B|To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of an Oral Contraceptive (Levonorgestrel 0.15 mg and Ethinyl Estradiol 0.03 mg tablet).
61919675|NCT00464243|PLACEBO_COMPARATOR|Placebo|tablets orally once daily
61919676|NCT02044575||Critically ill patients|Intensive care unit patients with refractory septic shock
62307770|NCT02307968||inner thigh insulin injection|inject insulin at inner thigh site is the intervention arm. So we inject insulin at this site to see if this site is suitable for insulin injection.
62307771|NCT02307968||outer thigh insulin injection|outer thigh site for insulin therapy is the usual site
62307772|NCT02234622|EXPERIMENTAL|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
61919677|NCT03684252|OTHER|Control|Treatment as usual
61919678|NCT03684252|EXPERIMENTAL|Intervention|CBT-based intervention
62307773|NCT02234622|ACTIVE_COMPARATOR|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
62307774|NCT04215549||Participants|OCD patients come from 13 hospitals located in the north, south, east and west of China
62307775|NCT04891601|ACTIVE_COMPARATOR|Group II MA Mesh alone repair|patient use mesh alone as treatment of inguinal hernia
62307776|NCT04891601|ACTIVE_COMPARATOR|Group I CMD Combined Mesh & darn|patients utilize both mesh and darn repair
62307777|NCT00722176|EXPERIMENTAL|1|BL-1020 10 mg
62307778|NCT00722176|EXPERIMENTAL|2|BL-1020 10-30 mg
62307779|NCT00722176|ACTIVE_COMPARATOR|3|risperidone
62307780|NCT01543308||coronary heart disease|
62307781|NCT01543308||healthy control group|
62307782|NCT01863862|EXPERIMENTAL|Clinical complete responders.|Patients with complete clinical response obtained 8 weeks after chemoradiation or 10 weeks after short-course radiation.
62307783|NCT05939323||Investigation Team|"Questionnaires assessed adolescents and their parents ①Adolescents aged 14-25 years old (including 14,25 years old) and their parents, who agreed to participate in the study~②Investigate whether they have family communication difficulties and whether they have negative internet use behaviors"
62307784|NCT05674773||IBD patients with advanced neoplasia|"IBD patients with advanced neoplasia (high-grade dysplasia or colorectal cancer) treated with:~* proctocolectomy~* (sub)total colectomy~* partial colectomy~* endoscopic resection"
62307785|NCT00844246|EXPERIMENTAL|SRS|School Readiness Specialist (SRS) will administer the screening questionnaire to the subject during the intervention period, at the subject's 9, 18, 24 and 30 month visits. They will then see their PCP for a well child visit in which the results of the test will be interpreted, developmental counseling and/or anticipatory guidance provided as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
62307786|NCT00844246|EXPERIMENTAL|Provider|Primary Care Physician (PCP) will do the developmental screening at the subject's 9, 18, 24 and 30 month well child visits. Once the screening questionnaire is complete the PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
62307787|NCT00844246|NO_INTERVENTION|Routine|Subjects randomized to routine surveillance will receive routine preventive care as well as developmental surveillance at all well child visits, including the 9, 18, 24 and 30 month visits. EI referral will be completed, at the discretion of the provider, if the PCP observes a developmental delay during surveillance or the caregivers raise a specific concern about the child's development.
62307788|NCT04215692|EXPERIMENTAL|Ultrasound Guided Fluid Therapy|
62307789|NCT04215692|NO_INTERVENTION|Conventional Fluid Therapy|
62307790|NCT04567836||The asymptomatic medical staff cohort|"The cohort of asymptomatic / paucisymptomatic operators will include the cohort of operators who will test positive in the serological analysis.~From the entire population of hospital workers (over 3000), three controls will be identified for each operator who tested positive for the serological test that were analyzed on the same day and were negative for the serological test."
62307791|NCT04567836||The symptomatic medical staff cohort|The cohort of symptomatic hospital workers who tested positive for the swab includes 250 operators.
62307792|NCT05606705|EXPERIMENTAL|Baked Milk|Baked milk introduction into diet
61919679|NCT04622228|EXPERIMENTAL|LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with atezolizumab. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
61919680|NCT04968639||Axial pain positive group|Postoperative VAS score ≥ 3 points at 3-month follow-up
61919681|NCT04968639||Axial pain negative group|Postoperative VAS score ≤ 2 points at 3-month follow-up
61919682|NCT05419427|EXPERIMENTAL|Denosumab Solution for injection in single use prefilled syringe 60 mg permL|Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months, Route of Administration-Subcutaneous injection
62119826|NCT00617019||Parkinson's patients|Observational study to compare rates of impulse control disorders in patients taking different medications for Parkinson's Disease
62307793|NCT00059761|EXPERIMENTAL|Sequence A: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
62307794|NCT00059761|EXPERIMENTAL|Sequence B: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
62307795|NCT00059761|EXPERIMENTAL|Sequence A: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
62307796|NCT00059761|EXPERIMENTAL|Sequence B: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
62475084|NCT06319625|EXPERIMENTAL|Stellate ganglion block+Rehabilitation therapy|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
61919683|NCT05419427|ACTIVE_COMPARATOR|Prolia® Solution for injection in single use prefilled syringe 60 mg per mL|Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months,Route of Administration-Subcutaneous injection
62119827|NCT02431663|EXPERIMENTAL|ketamine up to 100 mcg/kg/min|Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
62475085|NCT06319625|PLACEBO_COMPARATOR|Rehabilitation therapy+placebo block|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
62475086|NCT04908852||Cohort 1|This is a prospective, longitudinal, observational exploratory study. Ten subjects will be enrolled and will complete baseline and week 4 blood draws and symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
62475087|NCT03423485|EXPERIMENTAL|Study arm|Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device
62475088|NCT01904344|OTHER|Sensor testing and validation|
62475089|NCT04376203||Control|any patient with indications for thyroidectomy other than confirmed preoperative cancer
62475090|NCT04376203||Thyroid microcarcinoma|either preoperative detection or random finding after thyroidectomy of another indication.
61919684|NCT05740995||Neoadjuvant Anti-PD-1 Plus Chemotherapy Group|Patients with locally advanced resectable ESCC (cT3-4aN0-1M0) who receive neoadjuvant anti-PD-1 plus chemotherapy and donate biological samples
62307797|NCT00059761|EXPERIMENTAL|Sequence A: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
62307798|NCT00059761|EXPERIMENTAL|Sequence B: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
62475091|NCT00817219|EXPERIMENTAL|TACLONEX ointment|
62475092|NCT02305394|EXPERIMENTAL|PK group (ketamine and propofol)|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
62475093|NCT02305394|ACTIVE_COMPARATOR|P group (propofol group)|propofol 1.5 mg/kg and normal saline \[weight(kg)×0.3÷10\]ml will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
62475094|NCT00541788|EXPERIMENTAL|1|Administration of Common Sage
61919685|NCT05304832|EXPERIMENTAL|AquaPlyo group|Participants in this group received the AquaPlyo training program
61919686|NCT05304832|ACTIVE_COMPARATOR|Control group|Participants in this group received the standard exercise program.
62475095|NCT05604430||Ventilator patients|Patients being ventilated by the ZOLL 731 Series ventilator in accordance with device labeling and Agency protocols in a pre-hospital setting.
62475096|NCT02816996|EXPERIMENTAL|Hand-holding|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
61919687|NCT00235001|EXPERIMENTAL|1|
61919688|NCT05368454|EXPERIMENTAL|Integrated Solution|
61919689|NCT05368454|ACTIVE_COMPARATOR|Standard of Care|
62119828|NCT02431663|ACTIVE_COMPARATOR|midazolam & thiopental & propofol|"Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.~Maximum duration of infusion for each drug will be 48 hours."
62119829|NCT00993369||Healthy newborns conceived naturally|
62119830|NCT00993369||Healthy newborns conceived with IVF|
62119831|NCT06034665|OTHER|Exercise|All patients will receive an exercise rehabilitation program tailored to their needs.
62119832|NCT06555991|OTHER|SIRSI and TSK-SI|The SIRSI and TSK-SI as well as the WOSI and RTS-, Clinical- and Demographic Information are gathered. The SIRSI and TSK-SI are re-administered one week later
62119833|NCT00568659|EXPERIMENTAL|1|
62475097|NCT02816996|EXPERIMENTAL|Stress Ball|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
62678772|NCT03235492|EXPERIMENTAL|SmartAlbu|If a participant agrees, after obtaining informed consent, the investigator will measure and record temperature, blood pressure, heart rate, height and weight. The participant will be given detailed instruction on how to hold the container and will be asked to spit (or deposit) their saliva up to the indicated line. The procedure will be performed twice to study the reproducibility of the test. The participant will then be asked to have a standard blood draw of 2-3 mls of blood into a vacutainer tube for analysis of HbA1c at the central lab and 1-2 mls of blood for glycated albumin for assay analysis, and a finger stick for point of care HbA1c measurement.
62678773|NCT06089980||Acute kratom exposure|Participants who regularly consume kratom will orally self-administer a single serving of the participants commercial kratom product under direct observation in order to evaluate acute physiological, subjective, and cognitive effects and determine pharmacokinetics. This will occur during the first 24 hours of study participation. Participants will undergo direct observation and assessment for after ceasing all kratom product use. Physiological, subjective, and cognitive effects during this supervised withdrawal will be assessed.
62307799|NCT00753922|OTHER|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
62307800|NCT00753922|OTHER|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
62307801|NCT00753922|OTHER|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
62307802|NCT00753922|OTHER|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
62307803|NCT05593601|ACTIVE_COMPARATOR|Neomycin|Patients enrolled in this arm will receive Neomycin.
62307804|NCT05593601|NO_INTERVENTION|Non neomycin|Patients enrolled in this arm will not receive any interventions.
62307805|NCT03247998|EXPERIMENTAL|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, \& David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
62307806|NCT03247998|EXPERIMENTAL|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
62307807|NCT03388970|EXPERIMENTAL|research group|normal saline 100ml+ vitamin K1 20mg ivgtt qd day0 and day1。
62307808|NCT03388970|PLACEBO_COMPARATOR|placebo group|normal saline100ml + normal saline 2 ml ivgtt qd day0 and day1
62475098|NCT02816996|NO_INTERVENTION|Nothing|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
62475099|NCT04906772|EXPERIMENTAL|Group KD|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
62475100|NCT04906772|ACTIVE_COMPARATOR|Group KP|participants received loading of ketamine 1 mg/kg and propofol 1 mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25 µg/kg/hr dexmedetomidine throughout the procedure.
62475101|NCT05467111|EXPERIMENTAL|Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines) 24-48 hours prior to each cycle of anthracyclines.
62475102|NCT05467111|NO_INTERVENTION|Control|Patients will receive standard treatment for each type of tumor proposed by the hospital. This group of patients will be provided with the international recommendations on physical exercise for cancer patients.
62475103|NCT06509568|EXPERIMENTAL|Neoadjuvant chemoradiotherapy followed by immunotherapy (nCRIT)|Patients in the nCRIT group will receive neoadjuvant concurrent chemoradiotherapy: radiation therapy will be administered using IMRT or VMAT with involved-field irradiation at a dose of PTV 41.4 Gy/23 fractions/31 days. Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC 2) for five weeks, given on the days of radiotherapy. Patients who do not progress on CT and meet immunotherapy criteria will receive fixed-dose toripalimab (200 mg IV) on days 8 and 29 after chemoradiotherapy, followed by minimally invasive esophagectomy four weeks after completing immunotherapy.
62678774|NCT04556825|EXPERIMENTAL|Study group|Arthroscopic treatment with PRP injection
62307809|NCT02347358|EXPERIMENTAL|IV r-tPA with JRecanTM blood FR device|Dual IV r-tPA therapy and adjunctive treatment with JRecanTM blood flow recanalisation device
62307810|NCT02347358|ACTIVE_COMPARATOR|IV r-tPA|IV infusion of r-tPA
62307811|NCT04031014|EXPERIMENTAL|Active treatment|Treatment with the active treatment protocol of the BTL EMSELLA device twice per week for six treatments total
62307812|NCT04031014|SHAM_COMPARATOR|Sham treatment|Treatment with the sham protocol of the BTL EMSELLA device twice per week for six treatments total
62307813|NCT03351673|EXPERIMENTAL|endometrial volume 2D TVS|perimenopausal women who bleed are examined by 2D TVS and the calculated endometrial volume using a specific formula and followed by endometrial biopsy for correlation with the pathological findings
62678775|NCT04556825|PLACEBO_COMPARATOR|Control group|Arthroscopic treatment with normal saline injection
62475104|NCT06509568|ACTIVE_COMPARATOR|Neoadjuvant chemoimmunotherapy (nCIT)|Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and toripalimab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
61919690|NCT03608761|EXPERIMENTAL|Rebamipide 2%|"1. - wash-out: 2 weeks~2. - rebamipide 2% four times a day for 3 months~3. - controls will be taken at day zero, 30 and 90.~4. - wash-out: 2 weeks~5. - autologous serum for 3 months"
61919691|NCT03608761|EXPERIMENTAL|Autologous serum|"1. - wash-out: 2 weeks~2. - autologous serum four times a day for 3 months~3. - controls will be taken at day zero, 30 and 90.~4. - wash-out: 2 weeks~5. - rebamipe 2% for 3 months"
62119834|NCT00492791||Endoscopic Capsule|Patient enrolled for performing an endoscopic capsule
62307814|NCT03504033|EXPERIMENTAL|Xenon|Xenon concentration of 50-60 % will be used for maintenance of general anesthesia and will be adjusted to maintain Bispectral index (BIS) value between 40 and 60.
62307815|NCT03504033|ACTIVE_COMPARATOR|Desflurane|Desflurane concentrations of 4-5%/0.8 minimum alveolar concentration (MAC) respectively will be used for maintenance of general anesthesia and will be adjusted to maintain BIS index value between 40 and 60.
62307816|NCT03777930|EXPERIMENTAL|chemotherapy group|the patients were recepted chemotherapy alone
61919692|NCT03608761|EXPERIMENTAL|autologous serum and rebamipide 2%|rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed
61919693|NCT03228199|OTHER|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
61919694|NCT03228199|OTHER|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
61919695|NCT01455129|ACTIVE_COMPARATOR|tiotropium group|18 mcg tiotropium, once daily, inhaled by HandiHaler
61919696|NCT01455129|PLACEBO_COMPARATOR|placebo group|matching placebo, once daily, inhaled by HandiHaler
62475105|NCT00760825|EXPERIMENTAL|Vaccine|killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)
62475106|NCT04924920|EXPERIMENTAL|Intervention EEO_SIGH|Single arm intervention. All the patients will receive the two tests (SIGH and EEOT) in 1:1 random sequence order
61919697|NCT04290390|ACTIVE_COMPARATOR|Annovera (alone)|Annovera taken alone (without itraconazole or rifampin)
61919698|NCT04290390|ACTIVE_COMPARATOR|Annovera with itraconazole use|Subjects will dose with 200 mg/day of itraconazole for five days before Annovera insertion and through Days 1 to 8 of Annovera use
61919699|NCT04290390|ACTIVE_COMPARATOR|Annovera with rifampin use|Subjects will dose with 600 mg/day rifampin for 8 days, between Days 4 to 11 of Annovera use during their respective treatment cycles
62119835|NCT03855891|EXPERIMENTAL|Study group|A group of patients with blood tests
62119836|NCT05656846|EXPERIMENTAL|Experimental: PulseNmore ES™|"Experimental: PulseNmore ES™:~The study population will be recruited between 12 and 14 weeks of gestation. These patients will be followed using a twice weekly virtual visit by a member of the study team. This visit will include a short survey of obstetrical complaints such as contractions leakage of fluid and decreased fetal movements, as well as a brief sonographic survey using the portable ultrasound device."
62307817|NCT03777930|EXPERIMENTAL|chemotherapy combined with TH and MG group|the patients were recepted chemotherapy combined with thalidomide and megestrol
62307818|NCT03777930|EXPERIMENTAL|the best supportive treatment group|the patients were recepted the best supportive without chemotherapy
62307819|NCT03777930|EXPERIMENTAL|the best supportive treatment combined with TH and MG group|the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
62475107|NCT05389722|EXPERIMENTAL|Part 1|
61919700|NCT01092065|EXPERIMENTAL|AFQ056 100 mg (Bid)|
61919701|NCT01092065|PLACEBO_COMPARATOR|Placebo|
61919702|NCT03248700|EXPERIMENTAL|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
61919703|NCT04213573|EXPERIMENTAL|Group 1: topical application of silver diamine fluoride|38% silver diamine fluoride liquid
61919704|NCT04213573|ACTIVE_COMPARATOR|Group 2: topical application of MI varnish.|MI Varnish:5% sodium fluoride varnish which also contains RECALDENT™\* (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate
61919705|NCT05776797|EXPERIMENTAL|Atrioventricular junction ablation (AVJA) in patients with cardiac resynchronization therapy (CRT)|Patients with cardiac resynchronization therapy (CRT) randomized in this arm will undergo atrioventricular junction ablation.
61919706|NCT05776797|ACTIVE_COMPARATOR|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Patients with cardiac resynchronization therapy (CRT) randomized in this arm will receive optimal medication treatment.
62307820|NCT05653908|EXPERIMENTAL|Daily monitoring|
62307821|NCT05612997||Relative Validation Arm|
62307822|NCT04349930|EXPERIMENTAL|Cannabidiol|CBD vaginal suppository
62475108|NCT05389722|EXPERIMENTAL|Part 2|
62475109|NCT05389722|EXPERIMENTAL|Part 3|
61919707|NCT03455764|EXPERIMENTAL|MCS110+ Trametinib + Dabrafenib [Phase I Dose Level 1]|"* MCS110 2.5mg/kg will be administered intravenously every 3 weeks.~* Dabrafenib 150mg is given orally every 12 hours.~* Trametinib 2mg is given orally daily"
61919708|NCT03455764|EXPERIMENTAL|MCS110 + Trametinib + Dabrafenib [Phase 2]|"* MCS110 will be administered intravenously every 3 weeks. The Dosage will be determined by the DLT of Phase 1~* Dabrafenib 150mg is given orally every 12 hours.~* Trametinib 2mg is given orally daily"
62475110|NCT03475303|EXPERIMENTAL|early hospital discharge|women will be discharged early from hospital 12 hours postoperatively after elective cesarean sections.
62307823|NCT04349930|PLACEBO_COMPARATOR|Placebo|Placebo vaginal suppository
61919709|NCT03455764|EXPERIMENTAL|MCS110+ Trametinib + Dabrafenib [Phase I Dose Level -1]|"* MCS110 1.25 mg/kg was administered intravenously every 3 weeks.~* Dabrafenib 150mg is given orally every 12 hours.~* Trametinib 2mg is given orally daily"
62307824|NCT02545374|EXPERIMENTAL|Telemedicine|"In the telemedicine arm, all patients will be supported by Telemedicine protocol according to the development of telemedicine in the region.~The use of teleconsultation allows the couple expert doctor / nurse expert to perform a complex of wound assessment consultation and / or chronic. The use of telemedicine allows for acts of telecare, when the nurse applicant sought a remote support of an expert nurse (under the responsibility of a doctor) for the realization of an act. The use of tele-expertise enables physicians to remotely bring special expertise to improve patient care."
62307825|NCT02545374|ACTIVE_COMPARATOR|Control|"In the control arm, patient care depend on his home, as is currently the case:~* If it is in the action zone of Cicat-LR network, then it will be supported by an expert nurse of the network that are physically visit the patient's home-lon is the protocols established by the network.~* If not, then it will be supported by the customs of the attending physician and nursing teams who follow him."
62307826|NCT04132544|EXPERIMENTAL|Intervention group|"* a standardized gerontological evaluation (EGS) and a fall balance performed at home by a Gerontological Assessment Nurse~* the proposal for a Proposal for a personalized intervention plan (PIP) to correct potentially reversible and modifiable factors~* a close follow-up by the Gerontological Assessment Nurse for the implementation of the PIP throughout the follow-up period of 24 months (6 home visits and 5 telephone follow-ups)."
62307827|NCT04132544|ACTIVE_COMPARATOR|Comparison group - usual care|Usual Care with the provision of documentation on simple recommendations for the prevention of falls and aging well.
62307828|NCT05477771|EXPERIMENTAL|Anterior tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the anterior part were categorized in the anterior tear group.
62307829|NCT05477771|EXPERIMENTAL|Middle tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the middle part were categorized in the middle tear group.
62475111|NCT01978743|EXPERIMENTAL|Raltegravir|Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
62678776|NCT05463055|EXPERIMENTAL|single-arm objective performance criteria|According to the National Medical Products Administration (NMPA) Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the participants with disease control should be at least 95%. The primary safety endpoints is that participants with Common Terminology Criteria for Adverse Events (CTCAE) grade 3 toxic reaction should be lower than 5%, CTCAE grade 4 and 5 toxic reaction rate is 0%. Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria.
62678777|NCT04098744|EXPERIMENTAL|Artesunate vaginal insert|Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.
62678778|NCT04098744|PLACEBO_COMPARATOR|Placebo vaginal inserts|Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4.
61919710|NCT03455764|EXPERIMENTAL|MCS110+ Trametinib + Dabrafenib [Phase I Dose Level 2]|"* MCS110 5mg/kg was administered intravenously every 3 weeks.~* Dabrafenib 150mg is given orally every 12 hours.~* Trametinib 2mg is given orally daily"
61919711|NCT03455764|EXPERIMENTAL|MCS110+ Trametinib + Dabrafenib [Phase I Dose Level 3]|"* MCS110 10mg/kg was administered intravenously every 3 weeks.~* Dabrafenib 150mg is given orally every 12 hours.~* Trametinib 2mg is given orally daily"
62307830|NCT05477771|EXPERIMENTAL|Posterior tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the posterior part were categorized in the posterior tear group.
62307831|NCT04632147|EXPERIMENTAL|Pranayama Group|Participants in this group will apply a 45-minute training program at home, consisting of 5 minutes of Ujjayi pranayama, 5 minutes of Nadi-Shodhana pranayama and 5 minutes of Sukha pranayama, 7 days a week for 8 weeks, 3 times a day. In addition, they will perform a 15-minute session 3 day a week for 8 weeks, under the online supervision of a physiotherapist. The training program will last 8 weeks.
62475112|NCT04308850|EXPERIMENTAL|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
62475113|NCT04308850|NO_INTERVENTION|Control|The other group do not interfere.
62475114|NCT01462279|EXPERIMENTAL|Thiamine|Open label - 200mg IV
62475115|NCT05704426||Retrospective|Patients with available data for 6 months before the implantation of the Optimizer implantation and at least 8 months after the implantation of the optimizer at the time the study is initiated and patients with available data for 6 months before the implantation of the Optimizer implantation, but less than 8 months of follow up after Optimizer implantation at the time of the study initiation.
62475116|NCT05704426||Prospective|Patients prior to the implantation of the Optimizer that will take place as per standard of care.
62475117|NCT03429582|ACTIVE_COMPARATOR|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
62475118|NCT03429582|EXPERIMENTAL|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
62475119|NCT03429582|EXPERIMENTAL|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
62678779|NCT06338267||Main|Participants who are not in a separate interventional treatment trial
62678780|NCT06338267||Intervention|Participants who are also in a separate interventional treatment trial
62119837|NCT05656846|ACTIVE_COMPARATOR|Control Standard Ultrasound|A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
62119838|NCT05503446|EXPERIMENTAL|Oral Immunotherapy, in-hospital supervision for updosing|Active oral immunotherapy, with all updosing visits taking place in hospital
62307832|NCT04632147|NO_INTERVENTION|Control Group|No intervention will be made to this group.
62307833|NCT03928470|EXPERIMENTAL|EsoDuo Tab. 20/800mg|EsoDuo Tab. 20/800mg
62307834|NCT03928470|ACTIVE_COMPARATOR|Nexium Tab. 20mg|Nexium Tab. 20mg
62307835|NCT03914352|EXPERIMENTAL|PD-1 antibody group|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
62307836|NCT03914352|ACTIVE_COMPARATOR|Controlled group|In this group entrolled patients were treated with TACE in the 30 days after hepatic resection.
62307837|NCT01418872|ACTIVE_COMPARATOR|Healthy Breakfast|"The activity will be performed at the school dining hall, scheduling 1 hour for breakfast,within the school hours, with maximum 50 children per turn It involves placing a table mat, a cup, a plate and two slices of bread per child, plus 1-liter bottle of milk for each four children and 1-liter bottle of oil for each twelve. The dining hall will be all set up before the students come in.~Participatory lesson : Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, The role of dairy products at breakfast,The role of fruits at breakfast, Importance of exercise for cardiovascular health, The role of unhealthy habits: sedentary lifestyle.~The students will be invited to take the table mat and the cup, in which is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity.~A pamphlet of the NAOS strategy will also be delivered."
62475120|NCT02284490|EXPERIMENTAL|Treatment Arm|Pemetrexed 900 mg/m² every 21 days until disease progression.
62475121|NCT06627764|EXPERIMENTAL|Familia SER (Salud, Estrés y Resilencia) Group|Participants will attend six intervention sessions.
62475122|NCT06627764|NO_INTERVENTION|Control Group|Participants will not receive SER Familia sessions.
62475123|NCT01350908|OTHER|Blood sampling|
62475124|NCT00850148|EXPERIMENTAL|Melles|
62475125|NCT00850148|EXPERIMENTAL|Anwar|
62678781|NCT05587998|EXPERIMENTAL|Morphine then AZD4041 then Morphine + AZD4041|Participants will receive a single intravenous (IV) dose of morphine Dose Level 1 on Day 1. From Day 2 to Day 15, participants will receive an oral dose of AZD4041 Dose Level 1, once daily for 14 consecutive days. On Day 15, participants will receive an oral dose of AZD4041 Dose Level 1 in combination with a single IV dose of morphine Dose Level 1.
62119839|NCT05503446|EXPERIMENTAL|Oral Immunotherapy, virtual supervision for updosing|Active oral immunotherapy, with all updosing visits taking place with virtual supervision
62119840|NCT05503446|NO_INTERVENTION|Control arm: allergen avoidance|
62119841|NCT04861454||surgical|internal browbexy and brassier suture were done after blepharoplasty
62475126|NCT01144494|ACTIVE_COMPARATOR|Intraocular pressure lowering drug|Eyedrops for lowering intraocular pressure
62475127|NCT01144494|PLACEBO_COMPARATOR|Artificial Tears|Lubricated eye drops
62475128|NCT06563271|ACTIVE_COMPARATOR|Group Dexketoprofen|Dexketoprofen 50 mg will be administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
62475129|NCT06563271|ACTIVE_COMPARATOR|Group Ibuprofen|Ibuprofen 100 mg/ml will be administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
62475130|NCT06563271|ACTIVE_COMPARATOR|Group Paracetamol|Paracetamol 10 mg/ml will be administered parenterally.
62475131|NCT03187522|EXPERIMENTAL|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
62475132|NCT05319847|EXPERIMENTAL|Intervention arm|Daily Skin Supplement - Fountain of Youth
62475133|NCT05916131|EXPERIMENTAL|Hypoglycemia Symptom Detection Training|To provide Hypoglycemia Symptom Detection Training intervention.
62475134|NCT05916131|EXPERIMENTAL|Education Plus|To provide Education Plus intervention.
62475135|NCT05916131|EXPERIMENTAL|Hypoglycemia Symptom Detection Training and Education Plus|To provide both Hypoglycemia Symptom Detection Training and Education Plus interventions simultaneously.
62475136|NCT05916131|OTHER|Usual Care|Continuing usual care after basic education.
62475137|NCT06407700|EXPERIMENTAL|Brugger's exercise with Kendall exercise.|Participants in this group will receive Brugger's exercise with Kendall Exercise.
62475138|NCT06407700|ACTIVE_COMPARATOR|Brugger's exercise|Participants in this group will receive Brugger's exercise.
62475139|NCT06560294|ACTIVE_COMPARATOR|Micronized purified flavonoid fraction (Daflon ®)|Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
62475140|NCT06560294|EXPERIMENTAL|Glue embolization|Patients will receive transcatheter glue embolization.
62475141|NCT03400020|EXPERIMENTAL|Ascorbic acid|Ascorbic acid 1000 mg in normal saline IV 2 hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
61919712|NCT06299423|EXPERIMENTAL|Howdy Senior® device|Patients will undergo standard perioperative management. Additionally, patients will perform three preoperative and twelve postoperative HOWDY Senior® assessments. The assessment consists of a nocturnal electrocardiogram (ECG) measure and a morning rest Heart Rate Variability (HRV) measure of five minutes.
61919713|NCT06299423|NO_INTERVENTION|Standard perioperative management|Patients belonging to the historical cohort of comparison, who underwent standard perioperative management and surgical intervention between January 2021 and January 2022.
61919714|NCT01567228|NO_INTERVENTION|routine counseling (control group)|Children will receive typical counseling for obesity prevention, dental caries prevention, or school problems per routine standards for pediatrician anticipatory guidance
61919715|NCT01567228|EXPERIMENTAL|CHICA GIS|In randomly assigned experimental clinics, physicians will counsel patients to increase physical activity, seek dental care, or seek academic support services such as tutoring; this counseling will be assisted by an experimental intervention which consist of an electronic medical record that prompts specific counseling in conjunction with a geographic information system. The enhanced electronic medical record will map community resources to support physician counseling and lifestyle modification
62475142|NCT03400020|PLACEBO_COMPARATOR|Normal saline|Normal saline IV infusion 2 hours before the operation and for three days after operation.
62475143|NCT02464553|EXPERIMENTAL|Group A|1x periradicular therapy in one intervertebral space, corresponding with pain radiating dermatome
62678782|NCT05587998|PLACEBO_COMPARATOR|Morphine then Placebo then Morphine + Placebo|Participants will receive a single IV dose of morphine Dose Level 1 on Day 1. From Day 2 to Day 15, participants will receive an oral dose of placebo matched to AZD4041, once daily for 14 consecutive days. On Day 15, participants will receive an oral dose of placebo matched to AZD4041 in combination with a single IV dose of morphine Dose Level 1.
62678783|NCT06694922||Young people|This study evaluated the validity and reliability of the Food and Nutrition Literacy Assessment Tool (FNLAT) in a sample of 849 Turkish adults. Reliability was tested using Cronbach's alpha, test-retest, and Pearson correlation, while construct validity was analyzed via factor analysis. Data were processed with SPSS and AMOS software.
62678784|NCT04160221|ACTIVE_COMPARATOR|12 hours interval|Mifepristone followed by Misoprostol treatment
62678785|NCT04160221|ACTIVE_COMPARATOR|24 hours interval|Mifepristone followed by Misoprostol treatment
62678786|NCT05747027|EXPERIMENTAL|Laparoscopic abdominal ventral rectopexy|
62475144|NCT02464553|EXPERIMENTAL|Group B|2x periradicular therapy in two intervertebral spaces, the first corresponding with pain radiating dermatome the second according magnetic resonance visualization where stenosis is situated
62678787|NCT05747027|EXPERIMENTAL|Transvaginal sacrospinous rectopexy|
61919716|NCT04452929|ACTIVE_COMPARATOR|Randomized treatment phase: Erenumab|Erenumab 140 mg single subcutaneous injection at baseline
61919717|NCT04452929|PLACEBO_COMPARATOR|Randomized treatment phase: Placebo|Saline placebo single subcutaneous injection at baseline
61919718|NCT04452929|OTHER|Open-label extension treatment phase: Erenumab|Erenumab 140 mg monthly subcutaneous injection for six months after completion of the randomized, double-blinded, placebo-controlled study phase during the open-label extension
62678788|NCT04721691|ACTIVE_COMPARATOR|IP|Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Epidiolex at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
62678789|NCT04721691|PLACEBO_COMPARATOR|Placebo|Placebo is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe. The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Placebo at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
62678790|NCT04287647|ACTIVE_COMPARATOR|Transpyloric stent|In this group, patient's will be randomized to receive a transpyloric stent for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
62678791|NCT04287647|SHAM_COMPARATOR|Sham|In this group, patient's will be randomized to sham for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
62678792|NCT02907957|ACTIVE_COMPARATOR|Caudal|Participants receiving a caudal neuraxial blockade, as clinically indicated.
62678793|NCT02907957|SHAM_COMPARATOR|No Caudal|Participants not receiving a caudal neuraxial blockade, as clinically indicated.
62678794|NCT05235256|ACTIVE_COMPARATOR|SPGB Group|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
62678795|NCT05235256|ACTIVE_COMPARATOR|GONB Group|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
62475145|NCT04313855|EXPERIMENTAL|Chronic post-operative pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
62678796|NCT06642168||Victims of sport-related sudden cardiac arrest (SCA) : resuscitated SCA and non-resuscitated SCA|"Following a sport-related sudden cardiac arrest (SCA), resuscitation attempts are frequently made due to the high likelihood of witnesses at the scene. These resuscitation efforts are successful in more than 40% of cases. The study population will therefore be divided into two groups: a group of resuscitated SCA victims (SCA group) and a group of non-resuscitated or unsuccessfully resuscitated victims (SCD group).~The RESOUDRE study is an observational study focusing on individuals who have experienced SCA. Depending on the outcome-whether the individual survives or not-the etiological assessment will differ. While the study design refers to two distinct groups for clarity, they represent a single population, and no statistical comparison between the two groups will be made."
62678797|NCT02839733||Cerebral Palsy|Children and young adults with Cerebral Palsy.
62678798|NCT02839733||Healthy Volunteer|Children and young adults healthy volunteer
61919719|NCT02607644|EXPERIMENTAL|Laryngeal Tube (LT)|VBM Laryngeal Tube (Intervention)
62678799|NCT05659251|EXPERIMENTAL|Serplulimab|"Preoperative neoadjuvant therapy for 3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.~Serplulimab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death."
62678800|NCT06691399|PLACEBO_COMPARATOR|Routine oral care (Group 1)|Group (1) will receive routine oral care twice daily with gauze for cleansing and tooth brushing
61919720|NCT02607644|ACTIVE_COMPARATOR|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA)
61919721|NCT00001503||1/All Patients|Patients who were previously enrolled on a CCR protocol and need follow-up by CCR Investigators.
62678801|NCT06691399|ACTIVE_COMPARATOR|Chlorhexidine oral care|Group (1) will receive routine oral care twice daily with gauze for cleansing and tooth brushing plus oral care with chlorohexidine solution (concentration 1.2%)
62678802|NCT06694649||Independent aerobic exercise|
62678803|NCT06694649||Primary care physiotherapy in own area|
62678804|NCT06694649||Full internal prehabilitation program|
62678805|NCT01972919|EXPERIMENTAL|Radiation therapy plus chemotherapy|MR guided dose escalated radiation therapy plus concurrent chemotherapy in unresectable non-metastatic pancreas cancer. Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction and concurrent Gemcitabine or Capecitabine.
62678806|NCT02615691|EXPERIMENTAL|Previously untreated patients (PUPs)|"Part A (Main Study): Participants age \<3 years and not experienced two joint bleeds will receive on- demand treatment of 10-80 international unit per kilogram (IU/kg) of BAX 855 intravenously depending on the severity of the bleeding episode and age \<3 years or after a maximum of two joint bleeds will receive prophylaxis treatment with dose of 25-80 IU/kg of BAX855 IV (based on investigator discretion) once weekly for up to 100 EDs.~Part A (Surgery): In participants, the administration of BAX 855 will be individualized based on the participants IR and half-life. For major surgery to achieve the target level of 80-100% FVIII in plasma of normal FVIII level and for minor surgery \>=30-60% FVIII levels for dental or other invasive surgery.~Part B (Immune tolerance induction \[ITI\]): Participants will receive prophylaxis treatment of 100-200 IU/kg BAX 855 IV daily or 50 IU/kg three time in a week and will be reduced to twice weekly to maintain FVIII trough level of 1% for further 3 months."
61919722|NCT00617643|ACTIVE_COMPARATOR|2|Triomune® 30 one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
62678807|NCT06226415|ACTIVE_COMPARATOR|The comparison group|The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
62678808|NCT06226415|EXPERIMENTAL|The observation group|"The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
62678809|NCT02511769|EXPERIMENTAL|WEB-MAP CBT|Web-MAP Group. Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
62678810|NCT02511769|ACTIVE_COMPARATOR|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
62678811|NCT04892173|EXPERIMENTAL|Arm A|NBTXR3, as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. NBTXR3 is given as a single intratumoral injection as a dose of 33% of the Gross Tumor Volume
62678812|NCT04892173|ACTIVE_COMPARATOR|Arm B|Investigator's choice of RT alone or RT in combination with cetuximab
61919723|NCT00617643|EXPERIMENTAL|1|Triomune® 30 one tablet twice daily for two weeks
61919724|NCT04950114|EXPERIMENTAL|200 mg Dose Cohort|Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level.
61919725|NCT03969992|OTHER|nCPAP alone|Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary
61919726|NCT03969992|EXPERIMENTAL|Drug: Low Dose AeroFact|AeroFact-low dose SF-RI 1
62678813|NCT06695065||Study group adult with ulcerative colitis|50 Adult patients with ulcerative colitis
62678814|NCT06695065||control group|50 age and sex matched control group.
62678815|NCT05748171|EXPERIMENTAL|Inotuzumab ozogamicin|"Each participant in the InO arm will receive 1 course (3 doses) of InO, as follows:~* Day 1: 0.8 mg/m2~* Days 8 (±1 day) and Day 15 (±1 day): 0.5 mg/m2/dose"
62678816|NCT05748171|ACTIVE_COMPARATOR|ALLR3|"Mitoxantrone 10 mg/m2 on Days 1 and 2 Vincristine 1.5 mg/m2 (max single dose 2 mg) administered on Days 3, 10, 17 and 24 Dexamethasone 20 mg/m2/day administered orally (or IV) divided into two daily doses (maximum 40 mg/day) as two 5-day blocks on Days 1-5 and Days 15-19.~PEG-asparaginase 1000 units/m2 IV administered on Days 3 and 17. In case of hypersensitivity/allergic reaction to PEG-asparaginase, each dose of PEG-asparaginase will be replaced by Erwinia-asparaginase at a dose of 20,000 units/m² IV or IM every other day for a total of 6 doses"
62678817|NCT06678854|EXPERIMENTAL|First Responders|
62678818|NCT01743703|OTHER|whole body MRI|diagnostic whole body MRI, and skeletal imaging following guidelines (whole body radiographic and scintigraphic screening)
62678819|NCT05980403||Lymph node metastasis negative|Superficial esophageal squamous cell carcinoma with negative lymph node metastasis
62678820|NCT05980403||Lymph node metastasis positive|Superficial esophageal squamous cell carcinoma with positive lymph node metastasis
62678821|NCT04561609|ACTIVE_COMPARATOR|CO2 treated|Patients receiving treatment with transcutaneous application of gaseous CO2 on lower limbs
62678822|NCT04561609|PLACEBO_COMPARATOR|control|Patients receiving placebo treatment with air on lower limbs
62678823|NCT06215118|EXPERIMENTAL|Part 1 Dose Escalation|Non-randomized elranatamab plus iberdomide
62678824|NCT06215118|EXPERIMENTAL|Part 2 Dose Randomization|Randomized elranatamab plus iberdomide
62678825|NCT05685069||Standardized work-up|A standardized workup procedures including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, stroke laboratory, risk factor assessment and noninvasive angiography of the cervical and intracranial arteries will be performed.
62678826|NCT06021522|EXPERIMENTAL|Ecopipam 1.8 mg/kg/day|Ecopipam tablets will be administered orally (PO) once daily in the evening without regard to meals at concentrations 11.2, 22.4, 33.6, 44.8, 67.2 and 89.6 milligrams (mg) containing 12.5, 25, 37.5, 50, 75 and 100 mg ecopipam HCl, respectively in 4-week titration phase to achieve a target dose of 1.8 milligram per kilogram per day (mg/kg/day) ecopipam (2 mg/kg/day ecopipam HCl). Participants will be evaluated for safety at each baseline visit and at all treatment visits up to 24 months and at follow up visits at 7 and 14 days after last dose of ecopipam.
62678827|NCT02955550|EXPERIMENTAL|PNK-007 and rhIL-2|Melphalan per institutional practices (within Day -5 to 01), ASCT (Day 0), PNK-007 at varying dose levels (within Day 7 to Day 14) and rhIL-2 every other day starting day of PNK-007 administration.
62678828|NCT01324466|PLACEBO_COMPARATOR|Vehicle|Vehicle
62678829|NCT01324466|ACTIVE_COMPARATOR|Active|Active NB-001(0.3%)
62678830|NCT02883049|EXPERIMENTAL|DS HR B-ALL (RER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
62678831|NCT02883049|EXPERIMENTAL|DS HR B-ALL (SER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
62678832|NCT02883049|EXPERIMENTAL|Group I Arm A (HR B-ALL)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
62678833|NCT02883049|EXPERIMENTAL|Group I Arm B (HR B-ALL) (CLOSED 03/19/2018)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
62678834|NCT02883049|ACTIVE_COMPARATOR|Group II Arm A (VHR B-ALL - Control Arm)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
62678835|NCT02883049|EXPERIMENTAL|Group II Arm B (VHR B-ALL - Exp Arm1) (CLOSED 02/15/2017)|"Patients receive consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
62678836|NCT02883049|EXPERIMENTAL|Group II Arm C (VHR B-ALL - Exp Arm 2) (CLOSED 09/12/2014)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
62678837|NCT02883049|EXPERIMENTAL|Group III PH-like predicted TKI-sensitive kinase mutation|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
62678838|NCT06105463|EXPERIMENTAL|Women with Multiple Sclerosis|Women diagnosed with Multiple Sclerosis by a certified neurologist
62678839|NCT06105463|ACTIVE_COMPARATOR|Women without Multiple Sclerosis|Women not diagnosed with multiple sclerosis
62678840|NCT01965483|EXPERIMENTAL|Weekly radiation|once-weekly breast irradiation
62678841|NCT05073757||Orthognatic surgery|Orthognathic surgery patients, adults or minors whose bone maturity is sufficient according to the investigator.
62678842|NCT06673043||SLE Patients|Open-lable arm with SLE patients who received anifrolumab treatment in the frames of NDP in Poland.
62678843|NCT06367153|EXPERIMENTAL|repaglinide + midazolam + bupropion then BI 1569912 + repaglinide + midazolam + bupropion|repaglinide + midazolam + bupropion (reference treatment, R) then BI 1569912 + repaglinide + midazolam + bupropion (test treatment, T)
62678844|NCT01941628|EXPERIMENTAL|Rocuronium|In this group rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
62678845|NCT01941628|ACTIVE_COMPARATOR|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
62678846|NCT05040542||Infant Cohort|Healthy infants aged from 0-72 months.This is an observational trial so no intervention will be provided, with exception of study assessments, including fMRI.
62678847|NCT04570280|PLACEBO_COMPARATOR|Range of Motion Exercises|The patients in the control group will be given the practice of range of motion exercises for 12 weeks, 3 days a week for 50 minutes (1 day accompanied by a physiotherapist).
62678848|NCT04570280|ACTIVE_COMPARATOR|Range of Motion and Resistive Exercises Group|Patients in this group will be given joint range of motion and resistive exercises with sandbag to the lower extremity for 12 weeks, 3 days a week for 50 minutes (1 day in the presence of a physiotherapist). For the exercises with resistance, the repetition maximum will be calculated and the intensity of the exercises will be adjusted in accordance with the DeLorme protocol.
62678849|NCT04570280|ACTIVE_COMPARATOR|Range of Motion and Aerobic Exercises Group|Joint range of motion exercises and aerobic exercises on the treadmill will be given to the aerobic exercise arm, 3 days a week for 12 weeks (1 day in the presence of a physiotherapist). For aerobic exercises, the maximum heart rate of the patients will be calculated during exercise and the exercise intensity will be determined by increasing the target heart rate level during the exercise.
62678850|NCT02605616|EXPERIMENTAL|Active drug AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
62678851|NCT02605616|PLACEBO_COMPARATOR|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
62678852|NCT06635109||Mild carpal tunnel syndrome|
62678853|NCT06635109||Middle carpal tunnel syndrome|
61919727|NCT03969992|EXPERIMENTAL|Drug: High Dose AeroFact|AeroFact-high dose SF-RI 1
62307838|NCT01418872|EXPERIMENTAL|Didactic concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
62307839|NCT00893711|ACTIVE_COMPARATOR|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.
62678854|NCT06635109||Severe carpal tunnel syndrome|
62678855|NCT03083730|EXPERIMENTAL|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
61919728|NCT02388048|EXPERIMENTAL|Ibrutinib + Ofatumumab|"IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).~OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.~After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity."
62475146|NCT02849457|PLACEBO_COMPARATOR|Delayed Vigabatrin (Placebo)|Randomization will only occur after detection of epileptiform activity on EEG. Participants randomized to this arm will be treated with matching placebo until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on placebo, they will be eligible for Open label vigabatrin. Participants will be followed until 36 months of age.
62475147|NCT02849457|EXPERIMENTAL|Early Vigabatrin|Randomization will only occur after detection of epileptiform activity on EEG. Participants randomized to this arm will be treated with vigabatrin until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on vigabatrin, they will be eligible for Open label vigabatrin. Participants will be followed until 36 months of age.
62678856|NCT04452370|EXPERIMENTAL|oral Etoposide+Anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
62678857|NCT02544815|ACTIVE_COMPARATOR|Digoxin|Oral digoxin 0.25 mg: one pill per day for 30 consecutive days.
62678858|NCT02544815|PLACEBO_COMPARATOR|Placebo|Oral placebo for 30 days.
62678859|NCT05524948|EXPERIMENTAL|Experimental Dentifrice|Participants will be instructed to brush twice daily (for 1 minute, morning and evening) with the experimental dentifrice (0.454% Stannous Fluoride with 0.3% Zinc Chloride) for 3 weeks.
62307840|NCT00893711|PLACEBO_COMPARATOR|Placebo|Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
62678860|NCT05524948|ACTIVE_COMPARATOR|Reference Dentifrice|Participants will be instructed to brush twice daily (for 1 minute, morning and evening) with the reference dentifrice (Regular Fluoride Dentifrice) for 3 weeks.
62307841|NCT00893711|ACTIVE_COMPARATOR|L.reuteri + vit D|L. reuteri DSM 17938 (10\^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months
62307842|NCT00893711|PLACEBO_COMPARATOR|Vit D Placebo|vitamin D3 (400 UI) five drops/day for 3 months
62307843|NCT03509506|NO_INTERVENTION|Non-App Group|"The participants will be instructed to continue their daily routine, track their daily steps with a pedometer, and record their daily steps on the Activity Log paper form."
62678861|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).~No intervention but only observational."
62678862|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).~No intervention but only observational."
62678863|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR \< 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).~No intervention but only observational."
62678864|NCT01415323||Acutely admitted psychiatric in-patients|
62119842|NCT06676904|ACTIVE_COMPARATOR|Higher Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 50 x 10\^9/L up to 7 days of life, and then for a platelet transfusion threshold of 35 x 10\^9/L at 7 or more days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
62119843|NCT06676904|OTHER|Lower Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 25 x 10\^9/L up to 7 days of life, and then for a platelet transfusion threshold of 20 x 10\^9/L at 7 or more days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
62307844|NCT03509506|EXPERIMENTAL|App Group|The participants will be trained how to use the mobile application (Heart Failure Health Storyline (HFHS)) to track their health status, physical activity, manage their medications schedule, and explore the other features that the application has. Additionally, they will receive a pedometer to track their daily steps and record their data on the mobile application.
62307845|NCT00839163|EXPERIMENTAL|Arm 1|
62307846|NCT00839163|EXPERIMENTAL|Arm 2|
62307847|NCT00839163|EXPERIMENTAL|Arm 3|
62307848|NCT00839163|EXPERIMENTAL|Arm 4|
62307849|NCT00839163|ACTIVE_COMPARATOR|Arm 5|
62678865|NCT01326897|ACTIVE_COMPARATOR|Comparison Group|Comparison group participants will be given health education materials.
62678866|NCT01326897|EXPERIMENTAL|Intervention'|This group will receive the intervention (Healthy Homes/Healthy Families) as described below.
62678867|NCT05338450|EXPERIMENTAL|Clemastine Fumarate|
62678868|NCT05338450|PLACEBO_COMPARATOR|Placebo|
62678869|NCT04619147||Patients without invasive fungal infections (IFI)|This will be our control cohort. Most of the patients would have been on posaconazole prophylaxis.
62678870|NCT04619147||Patients with invasive fungal infections (IFI)|This will be the group that we will be interested in. IFI would be diagnosed based on EORTC/ MSG definitions, and most of them would have been on posaconazole prophylaxis. Underlying risk factors of acquiring IFI in this cohort of patients will be compared with that of the control cohort.
62678871|NCT05702047|ACTIVE_COMPARATOR|Nose-only breathing|Participants will be instructed to breathe only through their nose (mouth closed) during rest and submaximal exercise.
62678872|NCT05702047|ACTIVE_COMPARATOR|Mouth-only breathing|Participants will be instructed to breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
62678873|NCT03791697|ACTIVE_COMPARATOR|Telephone Group|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes."
62678874|NCT03791697|NO_INTERVENTION|In Person Clinic Visit Group|For the patient randomized into the clinic group, the clinic visit will entail questions about common postoperative complications (including fever, nausea/vomiting, pain, urinary symptoms, constipation, etc.). As per usual, vital signs and a focused physical examination will be completed at the clinic visit. All clinic visits will be performed by an FPRMS fellow and/or attending physician
62307850|NCT00848991|ACTIVE_COMPARATOR|Precedex|In the operating room routine anesthesia monitors will be placed and vital signs will be recorded continuously using data collection software. A routine propofol anesthetic will be administered to subjects randomized to the control group or a Precedex infusion with propofol for subjects randomized to the treatment group. Precedex infusion will be started after induction of general anesthesia. Vital signs (SBP, DBP, MAP) will be recorded continuously throughout the surgery. At the end of the case subjects will be extubated and the blinded observer will assess emergence from anesthesia based on hemodynamic stability and tolerance of the endotracheal tube. Videotaping of emergence will be used to assist in the evaluation of emergence of anesthesia and extubation.
62307851|NCT00848991|ACTIVE_COMPARATOR|Propofol|Propofol for emergence from anesthesia
62736366|NCT05087368|EXPERIMENTAL|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 7|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 7: (N=50) Day 1 (boost) -CoronaVac;"
62307852|NCT00098631|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62307853|NCT03985137||HIV-infected patients|Male patient presenting at a follow-up consultation for HIV infection or following a Sexual Viral Exposure (EVA) accident, pre-exposure prophylaxis (PrEP) or screening for a Sexually Transmitted Infection (IST).
62119844|NCT06647017|EXPERIMENTAL|Active tAN + standard of care|Participants randomized to the active group will have an earpiece applied and receive 30 minutes of active tAN therapy immediately prior to the dialysis port placement procedure. When the 30-minute tAN session is complete, the system will be turned off, unplugged, and the earpiece will be removed.
62307854|NCT05767541|EXPERIMENTAL|Pilates group|The Pilates technique consists of a series of low-impact exercises that build strength and flexibility throughout the body. All exercises performed 3 days in a week, 3 visits per week total of 9 sessions. In first week participants will perform 1 set of each exercise with 10 repetitions. In second week 2 sets of each exercise with 12 repetitions and in the third week both groups will perform 3 sets of each exercise with 15 repetitions with a rest interval of 2-3 minutes between sets.
62475148|NCT02849457|NO_INTERVENTION|Watchful Waiting (Control Group)|Enrolled participants in this arm are those who never develop EEG abnormalities or clinical seizures during the length of the study. While all participants who enrolled in the study started in this group, participants were randomized upon development of EEG epileptiform activity. All participants who completed the study without developing EEG epileptiform activity or clinical seizures are reported in this group.
62119845|NCT06647017|SHAM_COMPARATOR|Sham tAN + standard of care|Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on. These participants will receive 30 minutes of sham tAN therapy immediately prior to the dialysis port placement procedure. When the 30-minute tAN session is complete, the system will be turned off, unplugged, and the earpiece will be removed.
62119846|NCT03973944|OTHER|Cardiac resynchronization therapy|AV coupling by atrio-biventricular pacing
62119847|NCT05800977|EXPERIMENTAL|Prizloncabtagene Autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion.
62119848|NCT04554082||Preoperative Clinical characteristics and metabolic biomarkers|BMI and biochemical parameters including trace elements in patients undergoing laparoscopic sleeve gastrectomy before surgery
62119849|NCT04554082||9 months' Postoperative metabolic biomarkers|BMI and biochemical parameters including trace elements in patients 9 months after laparoscopic sleeve gastrectomy
62307855|NCT05767541|ACTIVE_COMPARATOR|Resistance group|Resistance exercises are anaerobic physical exercises, uses low number of repetitions with adjustable intensity contribute to hypertrophy of the muscle fibers and increase in muscle strength. All exercises performed 3 days in a week, 3 visits per week total of 9 sessions. In first week participants will perform 1 set of each exercise with 10 repetitions. In second week 2 sets of each exercise with 12 repetitions and in the third week both groups will perform 3 sets of each exercise with 15 repetitions with a rest interval of 2-3 minutes between sets.
62307856|NCT03399890||Group S|Group S: Group sugammadex Patients in this group received sugammadex at the end of the surgery, as neuromuscular reversal agent. Neurological physical exam time was recorded.
62307857|NCT03399890||Group N|"Group N: Group Neostigmine~Patients in this group received neostigmine at the end of the surgeryas neuromuscular reversal agent. Neurological physical exam time was recorded."
62307858|NCT06295926|EXPERIMENTAL|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide+Cisplatin/Carboplatin) with Serplulimab, and followed by consolidation Serplulimab
62307859|NCT03952286|EXPERIMENTAL|Intervention|ED-Dispensing with home and school supervision
62307860|NCT03952286|OTHER|Control|ED-Dispensing with home supervision
62307861|NCT04075227|EXPERIMENTAL|0.2% loteprednol etabonate|This group was treated with subconjunctival 5-FU injection and topical 0.2% loteprednol etabonate every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
62307862|NCT04075227|ACTIVE_COMPARATOR|0.1% dexamethasone|This group was treated with subconjunctival 5-FU injection and topical 0.1% dexamethasone (CD-oph) every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
62307863|NCT00680732|EXPERIMENTAL|A1|Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)
62307864|NCT00680732|EXPERIMENTAL|A2|Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)
62307865|NCT00680732|EXPERIMENTAL|B1|Iron and folic acid (IFA) and weekly chloroquine (CQ)
62307866|NCT00680732|EXPERIMENTAL|B2|Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)
62307867|NCT05539053|EXPERIMENTAL|NAC short course|patient received CMT(Paclitaxel) and NAC 2400 mg/day one week per each cycle of CMT
62307868|NCT05539053|EXPERIMENTAL|NAC long course|patient received CMT(Paclitaxel) and NAC 2400 mg/day every day for 9 weeks
62307869|NCT05539053|NO_INTERVENTION|control|patient received CMT(Paclitaxel) only
62307870|NCT03708692||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
62307871|NCT03708692||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
62307872|NCT05992779||Patient elderly implanted|Patients over 80 years old, primo implanted between 2011 and 2021
62307873|NCT01720667|EXPERIMENTAL|Intravenous levetiracetam|Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
62119850|NCT03009864|EXPERIMENTAL|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
62119851|NCT03009864|PLACEBO_COMPARATOR|Placebo|"Treatment with placebo corresponding to each dose of Tangshen Prescription~, every bag weighs 4.87g, take it one bag each time, two times a day."
62475149|NCT05747950|OTHER|Vibration group|"Vibration is defined as a mechanical stimulus characterized by oscillating movements.~has been defined.The first method is a hand held as a local vibration application that can be applied directly to the widest part of the muscle with the object.is named. The second method, called whole body vibration, is a vibration source applied on the platform. Participants immediately after the sessions in addition to conventional physiotherapy.~Upper extremity flexor on the hemiplegic side in supine position, 8 weeks, 3 sessions per week with a CE certified vibration device with a frequency of 50-110 Hz and an amplitude of 1-4 mm. Local vibration will be applied for 15 minutes each."
62119852|NCT02430740|OTHER|control group|standard care recFSH
62307874|NCT01720667|ACTIVE_COMPARATOR|Intravenous phenobarbital|Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance
62475150|NCT05747950|OTHER|Modified Constraint-Induced Movement Therapy group|Modified Constraint-İnduced Movement Therapy is a rehabilitation technique that promotes 'repetitive' use of the affected upper extremity in people with upper extremity neurological motor deficits. Constraint-İnduced Movement Therapy upper extremity after stroke it is a rehabilitation approach used to increase functional use. post stroke Approximately 20-25% of surviving patients can meet the motor criteria of mCIMT. Participants In addition to conventional treatment, they can use their intact extremities at home with a shoulder stabilization orthosis.Restraint, grasping on the hemiplegic side, using spoons and forks, combing hair daily life activities, 8 weeks, 3 days a week, and approximately 3 hours Modified Constraint-İnduced Movement Therapy m(CIMT) will be applied.
62119853|NCT02430740|EXPERIMENTAL|study group|modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC
62119854|NCT00639002|EXPERIMENTAL|Ruxolitinib then Ruxolitinib + Dexamethasone|Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
62119855|NCT00851708|ACTIVE_COMPARATOR|NAC|treatment
62307875|NCT03393351|EXPERIMENTAL|Shared decision-making program|
62307876|NCT03393351|ACTIVE_COMPARATOR|Usual care|
62307877|NCT01689506|EXPERIMENTAL|Volulyte|Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
62307878|NCT01689506|ACTIVE_COMPARATOR|Human Serum Albumin|5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)
62678875|NCT04011189|EXPERIMENTAL|Videotaping|"First phase: Patients will complete questionnaire, pain score in pre-anaesthetic clinic. Their face and body pose are videotaped. Patients are reviewed on pain scores with videotaping at 12-36 hrs, 36 hrs till before discharge post-operatively.~Second phase: Patients will complete questionnaires, pain score, videotaping in pre-operative/-procedural/inpatient/outpatient consultation waiting areas. After surgery/procedure/consultation, i) Surgery: Patients rate pain scores with videotaping at 12-36 hrs, 36 hrs till before discharge.~ii) Procedure: Patients are asked on questionnaire, pain score, videotaping. iii) Consultation: Patients are asked on questionnaire, pain score, videotaping on next consultation.~Third phase: Patients will complete questionnaire and pain score in preoperative areas. They are videotaped while wearing a physiological wristband to monitor heart rate and body temperature. After surgery, pain score is rated while being videotaped with wristband."
62678876|NCT04480853|EXPERIMENTAL|Fingolimod|Open label Fingolimod 0.5 mg capsule taken once daily, oral.
62678877|NCT05494736|EXPERIMENTAL|Panel A: MK-8527 1.0 mg|Participants receive a single oral dose of MK-8527 1.0 mg.
62678878|NCT05494736|EXPERIMENTAL|Panel B: MK-8527 0.5 mg|Participants receive a single oral dose of MK-8527 0.5 mg.
62678879|NCT05494736|EXPERIMENTAL|Panel C: MK-8527 0.25 mg|Participants receive a single oral dose of MK-8527 0.25 mg.
62678880|NCT05494736|EXPERIMENTAL|Panel D: MK-8527 0.25 mg|Participants receive a single oral dose of MK-8527 0.25 mg.
62678881|NCT01688401|EXPERIMENTAL|IA melphalan|IA melphalan is administered via the basilar artery.
62678882|NCT00667979|EXPERIMENTAL|Arm 1|
62678883|NCT00667979|PLACEBO_COMPARATOR|Arm 2|
62678884|NCT06646042|EXPERIMENTAL|Period 1|ibuzatrelvir single oral dose on Day 1.
62678885|NCT06646042|EXPERIMENTAL|Period 2|carbamazepine BID oral doses on Day 1-15. ibuzatrelvir single oral dose on Day 14.
62307879|NCT05180669|EXPERIMENTAL|OARSCM|OARSCM (n = 51) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
62307880|NCT05180669|SHAM_COMPARATOR|TAU with MyMAT|TAU (n = 51) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
62307881|NCT01300936||patients with abdominal wall hernias|
62678886|NCT01812941|OTHER|Burn: blood collection|Procedure: Blood draws as the intervention.
62678887|NCT01812941|OTHER|trauma: blood collection|blood to be collected at different time intervals. Blood draw as the intervention
62678888|NCT01812941|OTHER|healthy volunteers: blood collection|Blood draws as the intervention
62119856|NCT00851708|NO_INTERVENTION|control|
62678889|NCT05370144|EXPERIMENTAL|Hypofractionated neoadjuvant concurrent chemoradiotherapy|"Drug: Carboplatin and Taxol (paclitaxel)~Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously for 5 weeks on Days 1,8,15,22 and 29.~Radiation: Hypofractionated radiation"
62119857|NCT00356265|EXPERIMENTAL|CKD|
62119858|NCT00356265|ACTIVE_COMPARATOR|Hypertension group|
62678890|NCT05918302|EXPERIMENTAL|Experimental arm|Treatment with 6 cycles of 7.5 ± 0.7 GBq 177Lu-edotreotide. The prescribed treatment administration is as follows: a 6 (±2) weeks interval between cycles 1 and 2 followed by all remaining cycles (3-6) given 8 (± 1) weeks after the previous cycle), where possible, or until disease progression, intolerable toxicity or death, whichever occurs first.
62678891|NCT05918302|ACTIVE_COMPARATOR|Control arm|Everolimus 10 mg orally once daily (QD) until disease progression or intolerable toxicity or death, whichever occurs first.
62119859|NCT00356265|ACTIVE_COMPARATOR|Normotensive group|
62119860|NCT06081686|EXPERIMENTAL|Phase I:[177Lu]Lu-XT033 Injection|During dose verification phase,Patients received \[177Lu\]Lu-XT033 Injection 1.11Gbq（30mCi）/1.85Gbq（50mCi）intravenously every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
62119861|NCT06081686|EXPERIMENTAL|Phase II:[177Lu]Lu-XT033 Injection|During dose expansion phase,patients received \[177Lu\]Lu-XT033 Injection at R2PD based on phase I.
62119862|NCT02108106|EXPERIMENTAL|AG-348|Single oral dose of AG-348
62119863|NCT02108106|PLACEBO_COMPARATOR|Placebo|Single oral dose of placebo
62119864|NCT04302844|ACTIVE_COMPARATOR|Imago Relationship Therapy (IRT)|Couples will receive 12 to 16 Imago relationship therapy sessions (90 minutes each; one session per week) with an experienced and certified Imago Relationship therapist.
62307882|NCT05546788|ACTIVE_COMPARATOR|hydroxylated polymethyl flavones group|SRP then hydroxylated polymethyl flavones addition
61919729|NCT05354674||ARM A|Chemotherapy regimens are determined based on the clinical experience of specialists
61919730|NCT05354674||ARM B|Chemotherapy regimens are determined based on the multimodal deep learning signature
61919731|NCT02985931||Suspected CAD subjects|
62119865|NCT04302844|ACTIVE_COMPARATOR|Waitlist with Bibliotherapy followed by Workshop|Couples will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read during that time. After 12 weeks and the 12-week assessment has been completed, couples will receive a Getting the Love You Want workshop.
62307883|NCT05546788|ACTIVE_COMPARATOR|Chlorohexidine group|SRP then Chlorohexidine gel application
62678892|NCT03084900|EXPERIMENTAL|Patient-Centered Decision Support|Intervention - computer decision support in diabetes clinic. Investigators will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures. The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
62119866|NCT01001078|ACTIVE_COMPARATOR|I-Gel supraglottic airway device|Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
61919732|NCT05857423|OTHER|Control Group|Preterm infants who are applied gentle human touch by nurses
61919733|NCT05857423|EXPERIMENTAL|Experimental Group|Preterm infants who are applied gentle human touch by mother
61919734|NCT02005198||Survey|
61919735|NCT06281301|OTHER|no additional information|
61919736|NCT06281301|EXPERIMENTAL|education tool|
61919737|NCT02942329|EXPERIMENTAL|apatinib and SHR-1210|Every patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effects.
61919738|NCT00527670||Normal Controls|Healthy patients undergoing laparoscopic surgery for cholelithiasis, appendicitis, and adrenalectomy.
61919739|NCT00527670||Recurrent Hernia|Patients presenting for laparoscopic repair of ventral or incisional hernias.
62119867|NCT01001078|ACTIVE_COMPARATOR|LMA Supreme supraglottic airway device|Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
62119868|NCT01001078|ACTIVE_COMPARATOR|Standard endotracheal tube|A Standard endotracheal tube will be inserted in case both other airway devices (LMA Supreme and iGel) devices fail to provide adequate ventilation.
62119869|NCT03956641|EXPERIMENTAL|experimental: observational cohort|Evaluation of the physical condition and the quality of life
62119870|NCT04503356|ACTIVE_COMPARATOR|OMNI as a standalone procedure|
62119871|NCT04503356|ACTIVE_COMPARATOR|OMNI combined with cataract surgery|
62119872|NCT05516641|EXPERIMENTAL|Prebiotic|Soluble Corn Fiber
62119873|NCT05516641|PLACEBO_COMPARATOR|Control|Maltodextrin
62119874|NCT02539212|ACTIVE_COMPARATOR|microwave ablation|microwave ablation
62307884|NCT05546788|PLACEBO_COMPARATOR|placebo group|SRP then placebo gel application
62307885|NCT05893082|EXPERIMENTAL|Intervention|Placement of the F2 device in the aorta to cover the great cerebral vessels.
62307886|NCT06292481|EXPERIMENTAL|Brunnstorm Movement therapy|this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
61919740|NCT02536833|EXPERIMENTAL|0.03 mg SM04690|Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
61919741|NCT02536833|EXPERIMENTAL|0.07 mg SM04690|Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
61919742|NCT02536833|EXPERIMENTAL|0.23 mg SM04690|Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
61919743|NCT02536833|PLACEBO_COMPARATOR|Placebo|Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
61919744|NCT02425527|EXPERIMENTAL|The rehabilitation gaming|The rehabilitation gaming group (n=30) will use an internet browser-based digital brain training program CogniFit (https://www.cognifit.com), with a selection of about 33 games.The participants will use the rehabilitation gaming for at least 30 min per day over a period of 8 weeks.
61919745|NCT02425527|ACTIVE_COMPARATOR|The entertaining gaming|The entertaining gaming group (n = 30) will use commercial digital games with Sony Playstation 3 (PS3) consoles, played with wireless Sony DualShock gamepad controllers. The participants will be guided to play the console for at least 30 min per day over a period of 8 weeks
62119875|NCT02539212|ACTIVE_COMPARATOR|radiofrequency ablation|radiofrequency ablation
62119876|NCT04299984||Open Conversions|Patients undergoing total or partial endograft explantation for any EVAR complication.
62678893|NCT03084900|NO_INTERVENTION|Standard Care|Standard pediatric diabetes care will be compared to the computerized decision support system.
62678894|NCT04632381|ACTIVE_COMPARATOR|Active Arm, Zota Cohort 1|0.01 mg/kg zotatifin
62307887|NCT06292481|EXPERIMENTAL|Combined Brunnstorm Movement therapy and low level laser therapy|this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
62307888|NCT06508983|EXPERIMENTAL|SG301 Injection in combination with pomalidomide and dexamethasone|Participants will receive SG301 Injection in combination with pomalidomide and dexamethasone. Treatment cycles have a duration of 28 days. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
62307889|NCT06508983|PLACEBO_COMPARATOR|Placebo in combination with pomalidomide and dexamethasone|Participants in Stage 2 who randomized to this arm will receive placebo in combination with pomalidomide and dexamethasone. Treatment cycles have a duration of 28 days. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
62307890|NCT00662870|EXPERIMENTAL|DAPTACEL Lot 1|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 1
62307891|NCT00662870|EXPERIMENTAL|DAPTACEL Lot 2|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 2
62307892|NCT00662870|EXPERIMENTAL|DAPTACEL Lot 3|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 3
62307893|NCT00662870|ACTIVE_COMPARATOR|Pentacel|Participants receiving Pentacel vaccine
62307894|NCT02317731|NO_INTERVENTION|Routine|Subjects will ingest the bowel preparation from a cup
62307895|NCT02317731|EXPERIMENTAL|Straw|Subjects will ingest the bowel preparation with a straw
62475151|NCT05747950|OTHER|Control group|Control group in the training group, will be given a program that includes joint range of motion exercises, strengthening exercises, mobility and transfer activities, and various activities in order to increase participation in daily life activities as a routine conventional treatment in 60-minute sessions, 3 days a week, for 8 weeks.
61919746|NCT02425527|NO_INTERVENTION|"Do-nothing"|"The passive control group Do-nothing group (n = 30) will not have gaming activities organized by the project."
61919747|NCT04200378||Subjects undergoing TMVr|Subjects with severe, symptomatic primary mitral regurgitation (MR) scheduled to undergo a transcatheter mitral valve repair (TMVr) as standard of care will have intra-op baseline and post repair blood draws. Pre-procedure and post-procedure transthoracic echocardiograms (TTE) will assess the hemodynamic implications of the repair.
61919748|NCT04228575|EXPERIMENTAL|Extended Contact|Clients in the Extended Contact condition will be asked at the 6 week mark if they like they can extend their treatment and receive up to 12 weeks of support. They will be informed that this may be helpful if they feel they have fallen behind in reviewing of the materials, if they would like to receive support while they work on supplementary resources or if they would like extended support while they work on core lessons. If they would like additional support, participants will answer questions presented on the website about their desire for this additional support what they would like to focus on during this time. Those clients who indicate that they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks. Those that do not request the additional support will end treatment as planned at the end of 8 weeks.
62119877|NCT04299984||SemiConversions|Patients undergoing open or laparoscopic surgery for any EVAR complication (mostly endoleak correction) with complete endograft preservation.
62119878|NCT00866866|EXPERIMENTAL|N-Acetyl Cysteine|
62119879|NCT00866866|PLACEBO_COMPARATOR|Placebo|
62307896|NCT02525172|EXPERIMENTAL|ITT|immune modulation therapy
62307897|NCT00929630|EXPERIMENTAL|glue (Tissucol ) treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
62307898|NCT00929630|ACTIVE_COMPARATOR|Seton treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
62307899|NCT03339427|ACTIVE_COMPARATOR|vitamin D,capsule|A total of 150 subjects were recruited in the vitamin D supplementation group.
62307900|NCT03339427|OTHER|control|A total of 150 subjects were recruited in the control group.
62307901|NCT00521963|EXPERIMENTAL|E|
62307902|NCT02194296|EXPERIMENTAL|Ambroxol hydrochloride - lozenge|
62307903|NCT02194296|ACTIVE_COMPARATOR|Ambroxol hydrochloride - syrup|Mucosolvan®
62307904|NCT00934063||A|
62475152|NCT05391165|EXPERIMENTAL|Experimental group|ntervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
62475153|NCT05391165|NO_INTERVENTION|Control group|I declare that I will not change my lifestyle during the study process.
62475154|NCT04123548|EXPERIMENTAL|StrataGraft|On Day 1, participants received a single application of up to 1:1 meshed StrataGraft skin tissue on up to 3 DPT wound(s) totaling no more than approximately 2000 square centimeters (cm\^2) in area.
62475155|NCT00824291|PLACEBO_COMPARATOR|1|
62678895|NCT04632381|ACTIVE_COMPARATOR|Active Arm, Zota Cohort 2|0.02 mg/kg zotatifin
62678896|NCT04632381|ACTIVE_COMPARATOR|Active Arm, Zota Cohort 3|0.035 mg/kg zotatifin
62678897|NCT04632381|PLACEBO_COMPARATOR|Placebo|5% dextrose injection, USP
62119880|NCT06385886||Individuals diagnosed with Sickle Cell Disease (SCD) but not receiving care from an SCD specialist.|Individuals diagnosed with Sickle Cell Disease (SCD) but unaffiliated from SCD specialist care. These individuals will be connected to a linkage coordinator (trained staff) to provide a patient-centered approach to engagement with SCD specialist care.
62119881|NCT06231355|EXPERIMENTAL|Lipo-bupivacaine|Paravertebral block is performed with liposomal bupivacaine.
62119882|NCT06231355|ACTIVE_COMPARATOR|Bupivacaine|Paravertebral block is performed with bupivacaine.
62119883|NCT04905186||healthy adults|This is a cross-over study with no intervention.
62119884|NCT05482399|EXPERIMENTAL|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
62119885|NCT05482399|NO_INTERVENTION|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
62307905|NCT00934063||B|
62495878|NCT00530348|ACTIVE_COMPARATOR|Interferon Beta-1a|
62678921|NCT04518657|EXPERIMENTAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and oneonone video chats with a behavioral coach.The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory.Each course consists of an introduction,the primary content,and a take home message.The interactive courses include embedded,supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps,and these steps will be entered into the website so progress can be monitored.The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries.The chats are conducted facetoface through an online videoconferencing platform.The chats occur 7 times during the first 2 months,4 times during the second 2 months,and twice during the final 2 months of the intervention.
62678922|NCT04518657|SHAM_COMPARATOR|Wellness for MS (WellMS)|Provides an internet website and oneonone video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity.The materials are transformations of brochures provided by the National MS Society,including Gait or Walking Problems:The Basic Facts;MS and Your Emotions;Pain:The Basic Facts; Solving Cognitive Problems;Taming Stress in MS;Food for Thought:MS and Nutrition;and Vitamins,Minerals,and Herbs:An Introduction.The delivery of the internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition,and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
62678923|NCT05857540|EXPERIMENTAL|Plyometric training group|Participants in this group will receive upper extremity plyometric training in body weight or with weight ball and strengthening exercises with band, dumbbell and barbell. The difficulty and intensity of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
62120176|NCT06668597|EXPERIMENTAL|Psychoeducation Program|The experimental group will receive a motivational psychoeducational intervention consisting of four phases: Phase 1 (Pre-adaptation Psychoeducation): The intervention begins with the pulmonologist's decision for home adaptation to CPAP for the patient diagnosed with OSA. The participant will receive necessary materials and an educational video (25 minutes) within two days before the provider's home visit. Phase 2 (Motivational Interview): After the first night of CPAP use, the participant will have a brief motivational interview via phone. Phase 3 (Psychological Support Interview): One week after the provider's intervention, the participant will have a support interview regarding the adaptation process (40 minutes). This first week is a high-risk period for device abandonment. Phase 4 (Monitoring Interview): Two weeks after the provider's intervention, the participant will have a monitoring interview (30 minutes) to check for any difficulties during the adaptation process.
62120177|NCT06668597|NO_INTERVENTION|Treatment as usual|The patient, following the visit with the pulmonologist specializing in sleep medicine, who has been diagnosed with OSA, will be invited to proceed with the home adaptation process for the CPAP device by the staff.
62120178|NCT06450730|EXPERIMENTAL|CBT face-to-face + app|Combines face-to-face CBT sessions with online activities and resources trough a mobile app
62678924|NCT05857540|ACTIVE_COMPARATOR|Strengthening training group|Participants in this group will receive upper extremity strengthening exercises with band, dumbbell and barbell. The intensity of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
62120179|NCT06450730|NO_INTERVENTION|TAU Group|TAU Group Patients of the control group continued their usual treatment.
62120180|NCT04339374||Ex vivo imaging|"* Patients with known adenomatous polyps or malignancies in the colon or rectum undergoing resection will be considered for enrollment~* Participation will include imaging of both normal and known pathologic portions of the specimen ex vivo immediately following resection. The specimen will then undergo fixation and standard pathologic evaluation, with subsequent correlation between imaging and pathologic findings.~* This data will also be used to develop a convolutional neural network (CNN) to assist in interpreting photoacoustic imaging data."
62120181|NCT04339374||In vivo imaging|"* Patients with distal rectal lesions (benign or malignant tumors within 15cm of the anal verge) will be enrolled for the in vivo imaging portion of the study~* Participation will include an intraoperative, in vivo evaluation of the tumor with a novel endorectal photoacoustic ultrasound probe as well as ex vivo imaging post-resection as described above. Following the induction of anesthesia, patients will undergo a 20 minute endorectal imaging evaluation performed by their colorectal surgeon. After imaging, the patient will then undergo standard-of-care surgical resection of the rectum. The resection specimen will then be imaged ex vivo as performed in the ex vivo cohort of this study.~* For this portion of the pilot, enrollment will be limited to 40 participants"
62120182|NCT05774444|PLACEBO_COMPARATOR|Vegetable oil + Carbohydrate|The vegetable oil will be a placebo control for the Krill oil (4g/day). The carbohydrate will be a placebo control for the Krill protein (20g)
62120183|NCT05774444|EXPERIMENTAL|Vegetable oil + Krill protein|The vegetable oil will be a placebo control for the Krill oil (4g/day). Krill protein will be our active intervention (20g)
62339575|NCT05796505|EXPERIMENTAL|ADVANCE Steering Committee chosen interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
62339576|NCT00948818|EXPERIMENTAL|Linaclotide|Linaclotide 290 micrograms
62339577|NCT00948818|PLACEBO_COMPARATOR|Placebo|Matching placebo
62495879|NCT04172480||acute HIV1 infection|Patient infected by HIV1, prior treatment initiation
62495880|NCT04172480||chronic HIV1 infection|Patient infected by HIV1, untreated or without treatment since at least 3 months
62495881|NCT04172480||HIV2 infection|Patient infected by HIV2, untreated or without treatment since at least 3 months
62495882|NCT05005013|EXPERIMENTAL|Active tDCS + Mindfulness|
62495883|NCT05005013|SHAM_COMPARATOR|Sham tDCS + Mindfulness|
62678925|NCT03891953|EXPERIMENTAL|DKY709|DKY709 monotherapy
62475172|NCT06485531|SHAM_COMPARATOR|Pursed Lips Breathing|Pursed Lip Breathing Exercise was applied to the patients before and after the surgery for 15 minutes. After the application, FVC, FEV1, and FEV1/FVC values were measured with a spirometer (Contec Spirometer SP70B, Contec Medical Systems Co., Ltd., China) and recorded in the Patient Follow-up Form. (Annex-3). In cases where the patient did not perform well, the measurement was repeated at least three times and the best data was taken. Systolic and diastolic blood pressure, heart rate, respiratory rate, and peripheral oxygen saturation, which are thought to affect the results of FVC, FEV1, and FEV1/FVC values, were also measured and recorded before and after the application. In addition, hematocrit level, analgesia dose, and amounts used during the day were recorded daily and in the Patient Follow-up Form. Pain levels were evaluated 4 times daily (10:00-14:00-22:00-06:00) during the 0th to 6th days after surgery and recorded on the Visual Analog Scale Form.
62475173|NCT06485531|NO_INTERVENTION|Control|No intervention was made to the control group patients. FVC, FEV1 and FEV1/FVC values of the patients were measured with a spirometer (Contec Spirometer SP70B, Contec Medical Systems Co., Ltd., China) before the surgery and for 7 days after the surgery. In cases where the patient did not perform well, the measurement was repeated at least three times and the best data was taken. Systolic and diastolic blood pressure, heart rate, respiratory rate, and peripheral oxygen saturation, which are thought to affect the results of FVC, FEV1, and FEV1/FVC values, were also measured and recorded at 15-minute intervals. In addition, the hematocrit level, the dose, and amount of analgesia used during the day were recorded daily and in the Patient Follow-up Form. Pain levels were evaluated 4 times daily (10:00-14:00-22:00-06:00) during the 0th to 6th days after surgery and recorded on the Visual Analog Scale Form.
61920134|NCT06202651|EXPERIMENTAL|Nd:YAG Laser Interventional Cohort|"Participants include Granular Corneal Dystrophy patients.~On visit 1, participants will undergo visual acuity testing, slit-lamp examination, intra-ocular pressure (IOP) measurement, Scheimpflug tomography, anterior-segment optical coherence tomography (AS-OCT), and slit-lamp photography of the cornea.~On the same visit or on a separate visit within 1 month, the participants will undergo the Nd:YAG Laser treatment. At the investigators' discretion, after the procedure, participants might need to administer generic topical antibiotic eye drops three times daily for a week.~One week post-intervention (visit 2), the participant will repeat visual acuity testing, slit-lamp examination, IOP measurement, Scheimpflug tomography, AS-OCT, and slit-lamp photography of the cornea.~Three months post-intervention (visit 3), the participant will repeat visual acuity testing, slit-lamp examination, IOP measurement, Scheimpflug tomography, AS-OCT, and slit-lamp photography of the cornea."
62475174|NCT00974935|EXPERIMENTAL|Cohort 1|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01 mcg intramuscular.
62475175|NCT00974935|EXPERIMENTAL|Cohort 2|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.1 mcg intramuscular.
62475176|NCT00974935|EXPERIMENTAL|Cohort 3|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.5 mcg intramuscular.
62475177|NCT00974935|EXPERIMENTAL|Cohort 4|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 2.5 mcg intramuscular.
62475178|NCT00974935|EXPERIMENTAL|Cohort 5|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 10 mcg intramuscular.
62475179|NCT00974935|EXPERIMENTAL|Cohort 6|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular.
62678926|NCT03891953|EXPERIMENTAL|DKY709 + PDR001|Combination therapy with DKY709 and PDR001
61920135|NCT00847171|EXPERIMENTAL|Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine|Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine
61920136|NCT05214378|EXPERIMENTAL|Treatment Arm|The investigators will test an alternative pattern of sacral root stimulation in individuals who are already implanted with the device. Study participants will act as their own controls.
61920137|NCT02885168|EXPERIMENTAL|Shock + Treatment|Patients treated with activated protein C
62475180|NCT00974935|EXPERIMENTAL|Cohort 7|Two doses of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular 21 days apart.
62475181|NCT02719652||symptomatic ICAD|symptomatic intracranial atherosclerosis diseases
62475182|NCT02719652||asymptomatic ICAD|asymptomatic intracranial atherosclerosis diseases
62475183|NCT06187363||Patients managed by tubularized incised plate procedure|Patients with redo hypospadias repair using tubularized incised plate procedure
62475184|NCT06187363||Patients treated by procedures other than tubularized incised plate procedure|Patients with redo hypospadias repair using other procedures
62678927|NCT06695494||All participants|Blood sample collection for gene panel array testing and simultaneous research purposes
62678928|NCT05528588|EXPERIMENTAL|≥ 12 BAN-ADHF, Furoscix|Patients with diuretic resistance as determined by a BAN-ADHF score ≥ 12 will receive Furoscix over 5 hours at 8 mg/mL.
62678929|NCT05528588|EXPERIMENTAL|<= 11 BAN-ADHF, Furoscix|Patients without diuretic resistance as determined by BAN-ADHF score \<= 11 will receive Furoscix over 5 hours at 8 mg/mL.
62678930|NCT05528588|ACTIVE_COMPARATOR|≥ 12 BAN-ADHF, control|Patients with diuretic resistance as determined by a BAN-ADHF score ≥ 12 will receive home dose oral diuretic.
62678931|NCT05528588|ACTIVE_COMPARATOR|<= 11 BAN-ADHF, control|Patients without diuretic resistance as determined by BAN-ADHF score \<= 11 will receive home dose oral diuretic
62678932|NCT05543382||Implanted group|This group will be participants with urinary urge incontinence (UUI) who have been previously implanted with an Axonics System and are satisfied with therapy
61920138|NCT02885168|OTHER|Shock|Patients not treated with activated protein C
62120184|NCT05774444|EXPERIMENTAL|Krill oil + Carbohydrate|The Krill oil will be the active supplement for the intervention (4g/day). The carbohydrate will be a placebo control for the Krill protein (20g)
62475185|NCT01157130|EXPERIMENTAL|Intervention Group|Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
62475186|NCT01157130|NO_INTERVENTION|Control Group|The control group will receive basic information on physical activity but not be instructed.
62678933|NCT05543382||De Novo group|This group will be participants who are newly implanted with an Axonics System.
62308362|NCT05475691||Type 3 SMA (with and without disease-modifying treatment (DMTs))|"* Participants of both sexes who presented the first signs and symptoms of Spinal Muscular Atrophy starting after eighteen months of age and have a genetic report confirming 5q SMA.~* No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~* Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~* The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
62308363|NCT05475691||Type 4 SMA (with and without disease-modifying treatment (DMTs))|"* Participants of both sexes and that the first symptoms of Spinal Muscular Atrophy appeared from the second or third decade of life and have a genetic report confirming 5q SMA.~* No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~* Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~* The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
62308364|NCT04432441|ACTIVE_COMPARATOR|Therapeutic physical exercise program for scapulo-humeral stabilitation|Therapeutic physical exercise program for scapulo-humeral stabilitation
62308365|NCT04432441|ACTIVE_COMPARATOR|Therapeutic physical exercise program for scapulo-humeral stabilitation + Electrostimulation|Therapeutic physical exercise program for scapulo-humeral stabilitation + Electrostimulation
62308366|NCT03227861|EXPERIMENTAL|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
62308367|NCT00637728|ACTIVE_COMPARATOR|1|Megestrol acetate concentrated suspension 110 mg/mL
62308368|NCT00637728|PLACEBO_COMPARATOR|2|Placebo suspension
62339578|NCT02565771||Young adult survivors of childhood cancer|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992 with deregulation ANS or autonomic imbalance.
62475187|NCT06125535||Hypoinflammatory|By means of latent class analysis, a sub-phenotype of LUTX recipients with down-regulated inflammatory biomarkers
62475188|NCT06125535||Hyperinflammatory|By means of latent class analysis, a sub-phenotype of LUTX recipients with up-regulated inflammatory biomarkers
62475189|NCT04890418|ACTIVE_COMPARATOR|Study drug|0.3 mg/kg intravenous ketamine diluted into 10mL saline after the realization of peripheral nerve block (PNB), before tourniquet set up and beginning of surgery
62678934|NCT00860431|NO_INTERVENTION|1|Standard-of-care (conservative treatment)
62678935|NCT00860431|EXPERIMENTAL|2|AST-120 6g/day (3 times a day)
62678936|NCT01748552|PLACEBO_COMPARATOR|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A
62678937|NCT01748552|EXPERIMENTAL|LY2922083 (Part A)|Single ascending dose of LY2922083 (starting at 0.5 milligrams \[mg\]) administered orally to healthy participants in up to 2 of 3 study periods in Part A
62678938|NCT01748552|PLACEBO_COMPARATOR|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
62678939|NCT01748552|EXPERIMENTAL|LY2922083 (Part B)|Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
62120185|NCT05774444|EXPERIMENTAL|Krill oil + Krill protein|Both the Krill oil (4g/day) and the Krill protein will be the active intervention supplements (20g)
62120186|NCT03107806|OTHER|Glucose monitoring by OptiScanner®|Glucose monitoring and intervention guided by OptiScanner®
62120187|NCT03107806|OTHER|Blinded continuous glucose monitoring|Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements
62475190|NCT04890418|PLACEBO_COMPARATOR|Placebo|10 mL 0.9% saline after the realization of PNB, before tourniquet set up and beginning of surgery
62678940|NCT01534715|EXPERIMENTAL|IMGN529|Dose escalation study, dosing done every 3 weeks.
62120188|NCT04219930||epileptic children|fifty patient with epilepsy
62120189|NCT04219930||Healthy controls|thirty healthy control
62120190|NCT06676592|EXPERIMENTAL|Participants scheduled for head and neck surgery|Participants are scheduled to undergo head and neck surgery in the Surgery Head and Neck Service at MSK
62120191|NCT03089840|EXPERIMENTAL|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
62120192|NCT04102462|EXPERIMENTAL|Multiple rising dose part|
62120193|NCT04102462|EXPERIMENTAL|Midazolam part|
62120194|NCT06246435||Prediabetic group|The prediabetic group (HbA1c ≤ 6.5, n = 25)
62120195|NCT06246435||T2MD group|(HbA1c ≥ 6.5, n = 25).
62139585|NCT06699524||drug-resistant group|Organoid resistance and sensitivity are indicated by an IC50 value ≥23.815 μmol/L and \< 23.815 μmol/L, respectively. According to the PDTO drug testing, 42 patients were classified into the drug-sensitive group, and 80 patients into the drug-resistant group。
61920139|NCT00482352||Ancillary-Correlative (marker identification, molecular test)|Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia).
62678941|NCT06097988|EXPERIMENTAL|ABIO3419|Patients will be included consecutively to receive ABIO3419 by intra-articular injection
62678942|NCT06615375|EXPERIMENTAL|Shigella4V2 High dose|1 high dose of Shigella4V2 will be injected intramuscularly in the deltoid muscle
62678943|NCT06615375|EXPERIMENTAL|Shigella4V2 Low dose|1 low dose of Shigella4V2 will be injected intramuscularly in the deltoid muscle
62678944|NCT06615375|PLACEBO_COMPARATOR|Placebo|1 dose of PBS will be injected intramuscularly in the deltoid muscle
61920140|NCT03828370|ACTIVE_COMPARATOR|Usual & Customary Information Group|"Study Cohort Assessment:~Baseline 3 month follow-up/ post-test 9 month follow-up/post test \& Interlock Ignition Device"
61920141|NCT03828370|EXPERIMENTAL|B-SMART Intervention Group|"Study Cohort Assessment:~Baseline Web App Intervention 3 month follow-up/ post-test 9 month follow-up/post test \& Interlock Ignition Device"
61920142|NCT06066801|EXPERIMENTAL|Bedside blind bone biopsy procedure|Bedside blind bone biopsy procedure performed by a physician of the participating center through healthy skin with bone trocar following local and light systemic anesthesia. Samples will be analyzed for microbiology and histopathology
61920143|NCT06066801|ACTIVE_COMPARATOR|Standard bone biopsy procedure|Standard BB procedure (surgical or radiological) performed according to the local standard of care of each participating center and done through healthy skin and under locoregional anesthesia. Samples will be analyzed for microbiology and histopathology
61920144|NCT04179890||Uncommon EGFR mutation cohort|"This arm included patients with Non-Small Cell Lung Cancer (NSCLC) carrying uncommon mutations in the epidermal growth factor receptor (EGFR) who were treated with the following Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) as first or second-line therapy:~* Afatinib (Gi(l)otrif®):50mg or 40mg or 30mg or 20mg tablet once daily as indicated in the approved labels of afatinib (Gi(l)otrif®).~* Erlotinib (Tarceva®): 25mg or 100mg or 150mg tablet once daily as indicated in the approved labels of erlotinib (Tarceva®).~* Gefitinib (IRESSA®): 250mg tablet once daily as indicated in the approved labels of gefitinib (IRESSA®).~* Osimertinib (Tagrisso®): 80 mg or 40 mg tablets once daily as indicated in the approved labels of osimertinib).~In the first- or second-line with a threshold of start of treatment of at least 12 months respectively prior to data entry."
61920145|NCT04179890||Sequencing cohort|"This arm included Non-Small Cell Lung Cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation positive who received the following treatment sequence:~- Afatinib (Gi(l)otrif®): 50mg or 40mg or 30mg or 20mg tablet once daily as indicated in the approved labels of afatinib (Gi(l)otrif®) as first line therapy, in the case the T790M resistance mutation was developed (second line therapy) the patients received osimertinib (Tagrisso®): 80 mg or 40 mg tablets once daily as indicated in the approved labels of osimertinib; the threshold of start of osimertinib at least 10 months prior to data entry."
61920146|NCT03625271|NO_INTERVENTION|Control|All subjects will undergo same study procedures. Subjects in the Control Arm will receive treatment as usual by the prescribing clinician/investigator. The prescribing clinician/investigator will not receive the PEER Report of probable medication response for a control arm subject.
61920147|NCT03625271|EXPERIMENTAL|Experimental|All subjects will undergo same study procedures. Subjects in the Experimental Arm will receive treatment as usual by the prescribing clinician/investigator. However, the prescribing clinician/investigator will receive the PEER Report of probable medication response for an experimental arm subject. The report will provide additional data/information regarding probable medication response for an experimental arm subject to the prescriber .
61920148|NCT02663687|EXPERIMENTAL|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
61920149|NCT02663687|PLACEBO_COMPARATOR|Placebo|3 Subjects will receive placebo for each cohort
62308369|NCT03450889||Intervention arm|This study uses only one arm. All patients in this intervention arm will be surveyed using the aforementioned study protocol, which means patients will undergo a colonoscopy (or sigmoidoscopy in patients with previous subtotal colectomy) with surveillance intervals of either 1 or 2 years, depending on the amount and type of polyps resected during previous surveillance.
62308370|NCT00072189|EXPERIMENTAL|Treatment (7-hydroxystaurosporine)|Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62678945|NCT04147234|EXPERIMENTAL|Arm A: BI 1387446|superficial lesions
62678946|NCT04147234|EXPERIMENTAL|Arm B: BI 1387446 in combination with ezabenlimab (BI 754091)|superficial lesions
62678947|NCT06293287|PLACEBO_COMPARATOR|placebo|The control group will receive an injection of a placebo (0.9% saline solution) of equal volume once daily.
62678948|NCT06293287|ACTIVE_COMPARATOR|enoxaparin sodium|Subjects in the experimental group will be administered subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily.
62678949|NCT04744831|EXPERIMENTAL|T-DXd 5.4 mg/kg Q3W|Participants will be randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).
62678950|NCT04744831|EXPERIMENTAL|T-DXd 6.4 mg/kg Q3W|Participants will be randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
62678951|NCT05908656|OTHER|Persons with electronic health records suggestive of Gaucher disease|
62678952|NCT01095965|EXPERIMENTAL|Lifestyle education|Nutrition education comprised of 4 components: Curriculum (8 weeks), follow-up meetings (4 monthly plus 2-bimonthly), education materials for use at home and vegetable gardening demonstrations.
62678953|NCT02781285||1group one|patients with standard TCM diagnosis and treatment of gastric cancer
62678954|NCT02781285||2 group two|patients take Chinese Medicine but not with standard TCM diagnosis and treatment of gastric cancer
62678955|NCT02781285||3group three|patients take no Chinese Medicine
62678956|NCT05857878|PLACEBO_COMPARATOR|Placebo|
62678957|NCT05857878|EXPERIMENTAL|Dose Group 1|
62678958|NCT05857878|EXPERIMENTAL|Dose Group 2|
62678959|NCT05857878|EXPERIMENTAL|Dose Group 3|
62678960|NCT05857878|EXPERIMENTAL|Dose Group 4|
62308371|NCT04102891|EXPERIMENTAL|Study arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect\&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the Flemish food-based dietary guidelines. Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
62308372|NCT04102891|NO_INTERVENTION|Control arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect\&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the guidelines from the newly developed microbiota modulation diet (MMD). Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
62308373|NCT05446298|EXPERIMENTAL|1 mg/kg ONC-392 and 200 mg pembrolizumab|Arm A: Pembrolizumab 200 mg will be administered by IV infusion over 30 minutes, followed by ONC-392 at 1.0 mg/kg will be administered by IV infusion over 60 minutes, q3w.
62678961|NCT05857878|EXPERIMENTAL|Dose Group 5|
62678962|NCT05857878|EXPERIMENTAL|Dose Group 6|
62678963|NCT06578338||Children aged above 24 months old and below 6 years of age|Children aged above 24 months old and below 6 years of age with no structural abnormalities of the lower limbs or orthopaedic conditions
62678964|NCT03964909|EXPERIMENTAL|Diagnostic (fMRI, CVR MRI, rs-fMRI)|Patients undergo standard of care fMRI, CVR MRI over 3 minutes, and rs-fMRI over 6 minutes 1 month before and within 6 weeks after standard of care surgery.
62678965|NCT05463952|EXPERIMENTAL|vepdegestrant|Daily oral dosages of vepdegestrant
62678966|NCT03855839||Healthy participants|Participants will be ask to perform a repetitive upper limb task while posture is being monitored.This will be done while wearing a posture shirt, compression shirt or no shirt.
62678967|NCT05203237|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC once in healthy participants
62308374|NCT05446298|EXPERIMENTAL|2 mg/kg ONC-392 and 200 mg pembrolizumab|Arm B: Pembrolizumab 200 mg will be administered by IV infusion over 30 minutes, followed by ONC-392 at 2.0 mg/kg will be administered by IV infusion over 60 minutes, q3w.
62308375|NCT01351519|EXPERIMENTAL|Aminolevulinic Acid (AL)|
62308376|NCT03667131|EXPERIMENTAL|Enalapril Maleate|Enalapril Maleate 5 mg every 12 hrs for 90 days.
62308377|NCT03667131|EXPERIMENTAL|Placebo|Substance that lacks in itself therapeutic action.
62308378|NCT03808207|EXPERIMENTAL|Intervention group|Increase of the average intake of dietary DHA: dietary advices concerning the concentration of docosahexaenoic acid (DHA) in several foods; the recommended daily or weekly intake of different food options (animal, vegetal) in order to reach the average intake of 300-350 mg DHA/day
62308379|NCT03808207|NO_INTERVENTION|Control group|No specific dietary advice; Only endorsement and promotion of breastfeeding.
62308380|NCT01683500|EXPERIMENTAL|shock wave therapy|intervention: shock wave therapy with Modulith SLK (Storz)
62475191|NCT03546283|PLACEBO_COMPARATOR|Control|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebo group, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
62475192|NCT03546283|EXPERIMENTAL|CEGI treatment|The patients with hypertensive intracerebral hemorrhage will be randomized into giving drug CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
62475193|NCT04045197|EXPERIMENTAL|Intervention group|In the intervention group; informed consent forms, Relaxation Focused Nursing Care and routine nursing care in the hospital were performed. Then data collection tools were applied.
62475194|NCT04045197|NO_INTERVENTION|Control group|Women in the control group received routine nursing care in the hospital and data collection tools were applied at the same hours as the intervention group.
62475195|NCT02354339|EXPERIMENTAL|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
61920150|NCT00337350|ACTIVE_COMPARATOR|rosiglitazone|rosiglitazone 4mg/day
61920151|NCT00337350|PLACEBO_COMPARATOR|placebo|matched placebo for 4mg rosiglitazone
61920152|NCT02097927|EXPERIMENTAL|High energy, low sensory|Mango-flavour beverage
61920153|NCT02097927|EXPERIMENTAL|Low energy, high sensory|Mango-flavour beverage
62308381|NCT02977091||GH deficiency or idiopathic short stature|growth hormone (GH) deficiency or idiopathic short stature children before they start GH treatment
62308382|NCT02977091||short stature|healthy short children
62308383|NCT03537690|EXPERIMENTAL|Treatment (FID-007)|Participants receive FID-007 IV over 60 minutes on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62308384|NCT01130415||Patients treated with sacral neuromodulation|
62308385|NCT01195168||PCOS cohort|Women with PCOS as diagnosed by the NIH criteria
62308386|NCT01195168||Control cohort|Women without PCOS
62308387|NCT00502710|EXPERIMENTAL|RO4876904 1|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
62475196|NCT02354339|PLACEBO_COMPARATOR|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
61920154|NCT02097927|EXPERIMENTAL|High energy, high sensory beverage|Mango-flavour beverage
61920155|NCT05179551|EXPERIMENTAL|Proximal Medial Gastrocnemius Recession Surgery|Patients will be operated with Proximal Medial Gastrocnemius Recession Surgery (PMGR) ad modum Barouk.
61920156|NCT03465423||patients with nonfunctioning pituitary tumor|patients with nonfunctioning pituitary tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
62308388|NCT00502710|EXPERIMENTAL|RO4876904 2|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
62308389|NCT00502710|EXPERIMENTAL|RO4876904 3|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
62120196|NCT02073123|EXPERIMENTAL|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).~Patients will continue until they experience disease progression or limiting toxicity."
62308390|NCT00502710|EXPERIMENTAL|RO4876904 4|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
61920157|NCT03465423||patients with pituitary somatotroph tumor|patients with pituitary somatotroph tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
62308391|NCT00502710|PLACEBO_COMPARATOR|Placebo|Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
62678968|NCT05203237|EXPERIMENTAL|VK2735 (Part A)|Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.
62678969|NCT05203237|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants
62678970|NCT05203237|EXPERIMENTAL|VK2735 (Part B)|Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.
61920158|NCT02987660|EXPERIMENTAL|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
61920159|NCT02987660|ACTIVE_COMPARATOR|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
61920160|NCT03804034|EXPERIMENTAL|Occlusal trauma group|an occlusal interference was placed on the lower teeth as follows. Articulating paper was used to mark the contact area between the upper and lower premolars indicated for extraction. Once established, the marked area on the lower premolar was acid-etched with 37% phosphoric acid for 15 s, washed, and dried. A bonding agent was placed and light-cured for 15 s, and finally, a 1- to 2-mm block of resin was placed over the contact area and light-cured for 40 s. Articulating paper was used again to verify that only the premolars that were going to be extracted had contact during normal occlusion as well as in lateral movements. Patients were given chewing gum and indications to repeat 20 masticatory cycles for 30 s, followed by a 30-s rest interval, and repeat the sequence again for a period of 30 min. This chewing cycle was repeated three times every 8 h for the first 24 h
62308392|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
62678971|NCT05203237|PLACEBO_COMPARATOR|VK2735 (Part C )|Placebo administered orally daily for 28 days in healthy participants
62678972|NCT05203237|EXPERIMENTAL|VK2735 (Part C)|Escalating doses of VK2735 administered daily (PO) in healthy participants.
62678973|NCT03528642|EXPERIMENTAL|Treatment (telaglenastat, temozolomide, RT)|Patients receive telaglenastat PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
62120197|NCT02073123|EXPERIMENTAL|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
61920161|NCT03804034|EXPERIMENTAL|Moderate orthodontic force group|A convertible standard buccal tube was bonded over the buccal face of the first molar with resin and a McLaughlin, Bennett, and Trevisi slot size 0.022 bracket was bonded over the buccal face of the premolars. One 0.0017 × 0.025 in titanium molybdenum alloy wire cantilever was inserted into each first molar tube, and the wire was bent buccally to form a helix. The cantilever was clinched to the distal end of the tube, and a tipping and extrusive force was applied on the premolar. The activation angle was 45° with a force of 56 g, which was applied to the tooth for 24 h before it was extracted.
62308393|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
62308394|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
62308395|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
62678974|NCT03422731|EXPERIMENTAL|Cohort I (TMLI+FLT/TMLI)|Patients may undergo optional fluorothymidine F-18 PET scan over 2 hours at baseline, on days 30 and 100, at 1 year, and at time of relapse. Patients undergo DECT and water-fat MRI scan over 30 minutes at baseline, on days 30 and 100, at year 1, and at time of relapse. Patients also undergo collection of bone marrow and blood samples at baseline, on days 30 and 100, and at 1 year. Patients undergo fluorothymidine F-18 PET, DECT, and water-fat MRI as in TMLI+FLT.
62308396|NCT05417828||Participant with Chronic stroke|"1. Participants over 18 years of age~2. Participants should be able to understand the verbal cues during the training"
62308397|NCT03767010|EXPERIMENTAL|Control (no PLM)|Control: Pre, post, delayed test Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
62308398|NCT03767010|EXPERIMENTAL|Experimental (PLM)|Experimental: PLM group (pre, post, delayed test, PLM) Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
62678975|NCT03422731|ACTIVE_COMPARATOR|Cohort II (TBI)|Patients undergo collection of bone marrow at baseline, day 30, time of relapse, and at 1 year.
62678976|NCT00527748|NO_INTERVENTION|Standard of care|Patient ankle range of motion will be assessed at clinic visit. No stretching exercises with the device, but will be provided standard care through physiotherapist in acute cases, and no stretching exercises for chronic patients. Reassessment will be done at six weeks and 10 weeks.
61920162|NCT03804034|EXPERIMENTAL|Occlusal trauma and moderate orthodontic force group|the combination of occlusal trauma and orthodontic force .
61920163|NCT03804034|NO_INTERVENTION|Control Group|No experimental device to produce occlusal trauma or orthodontic forces
61920164|NCT01810965|EXPERIMENTAL|Cohort|
61920165|NCT05244980|EXPERIMENTAL|MAD Cohorts 1-4 TDM-105795 topical solution|Multiple dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01% or 0.02%
61920166|NCT05244980|PLACEBO_COMPARATOR|Placebo for TDM-105795 topical solution|Multiple dose administration of Placebo forTDM-105795 Topical Solution
61920167|NCT03709329|EXPERIMENTAL|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
61920168|NCT03709329|ACTIVE_COMPARATOR|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
61920169|NCT03825471|EXPERIMENTAL|electrotherapy|Patients undergoing CES and general anesthesia in colon cancer surgery
61920170|NCT03825471|PLACEBO_COMPARATOR|Opioid Anesthetics|Patients undergoing general anesthesia in colon cancer surgery
61920171|NCT05628961|EXPERIMENTAL|Cohort 1: 100 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
61920172|NCT05628961|EXPERIMENTAL|Cohort 2: 200 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
61920173|NCT05628961|EXPERIMENTAL|Cohort 3: 500 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
61920174|NCT05628961|EXPERIMENTAL|Cohort 4: 1200 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
61920175|NCT05628961|EXPERIMENTAL|Cohort 5: 2500 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
61920176|NCT05628961|EXPERIMENTAL|Cohort 6: 5000 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
61920177|NCT05628961|EXPERIMENTAL|Cohort 7: 7500 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
61920178|NCT06110520|EXPERIMENTAL|Violet + / Lens +|Subjects use a violet light emitting lamp (device intervention - minimally invasive as it's simply a source of light) with CR-39 lenses for their refractive correction. The lamp introduces violet light (Violet +) and the CR-39 lenses allow for the transmission of violet light through the lenses (Lens +).
62120198|NCT02073123|EXPERIMENTAL|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.~Nivolumab administered intravenously at 240 mg every 2 weeks."
62139586|NCT03461666|ACTIVE_COMPARATOR|Cognitive Behavior Therapy-Insomnia|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
62120199|NCT05209386|EXPERIMENTAL|Patient Participants|"This single-group study will recruit patients through the PI's clinical practice who are undergoing invasive neurophysiological monitoring (sEEG) with clinically necessary placement of electrodes in the supratemporal plane.~All participants will complete the same behavioral response paradigms."
62308399|NCT02273115|ACTIVE_COMPARATOR|Nulliparous - Foley only|Nulliparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
62308400|NCT02273115|ACTIVE_COMPARATOR|Nulliparous - Foley and oxytocin|Nulliparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
62308401|NCT02273115|ACTIVE_COMPARATOR|Multi(primi)parous - Foley only|Multiparous and primiparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
62308402|NCT02273115|ACTIVE_COMPARATOR|Multi(primi)parous - Foley and oxytocin|Multiparous and primiparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
62308403|NCT00645242|EXPERIMENTAL|Arm A|
62308404|NCT06407518|EXPERIMENTAL|Midazolam oral solution Group|The intervention drug is midazolam oral solution at a dose of 7-10mg. The starting dosage is 7mg, with subsequent individual increases of 1mg up to a maximum dose of 10mg if patients do not achieve sleep within 30 minutes of administration. The individual dose wil be consistently maintained at the corresponding level every night until the surgery.
62308405|NCT06407518|PLACEBO_COMPARATOR|Control Group|Placebo is a solution of midazolam oral solution that looks, tastes, and appears the same as the intervention drug, similar to the experimental group increment method.
62308406|NCT03921229|EXPERIMENTAL|Intervention|6-months of 11 web-based intervention (tele-coaching) sessions (9 biweekly sessions and 2 monthly sessions) of approximately 30 minutes each; continued use of eTrack nebulizer and vest monitor photo capture as measures of adherence.
62308407|NCT01963637|EXPERIMENTAL|Patients with morbid obesity|Patients with morbid obesity and who requires a gastric bypass or a Sleeve gastrectomy as a 1st bariatric procedure.
62308408|NCT01847547||Dabigatran|
62678977|NCT00527748|EXPERIMENTAL|Non-Measuring Ankle Exerciser|Subjects will train using only one combination of movement, dorsiflexion with inversion. This is done by manipulating the ring so that the medial and anterior ropes are taut. Subject will start with 3 minute warm-up. Subject will then manipulate the ring so that the foot moves into dorsiflexion with inversion until a point of tolerable discomfort is felt; subject will hold this position for 30 seconds. Stretch will be repeated 10 times, each day, for six weeks. Reassessment will be done at six weeks and 10 weeks.
62120200|NCT04414904||Case group|"* Men 18-50 years of age~* Already attending hospital for another reason~* High risk of prior COVID-19 infection:~  * EITHER Prior positive COVID-19 PCR test result~ * OR history suggestive of COVID-19 illness"
62139587|NCT03461666|ACTIVE_COMPARATOR|Focus Of Attention|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
62308409|NCT01847547||Warfarin|
62308410|NCT02557503|EXPERIMENTAL|Oxaliplatin by HAIC after TACE|To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
62308411|NCT02557503|NO_INTERVENTION|Fluorouracil by HAIC after TACE|To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
62475197|NCT04238754|EXPERIMENTAL|Epidiolex (CBD) Then Placebo|Participants first receive 8 mL of Epidiolex (800 mg of cannabidiol) + 16 mL of inactive cherry syrup delivered every 12 hours for 48 hours total (4 doses) during which prescribed methadone is withheld. After 1 week, they receive 20 mL of inactive cherry syrup delivered every 12 hours for 48hours total (4 doses) during which prescribed methadone is withheld.
62678978|NCT01682603|EXPERIMENTAL|Botulinum toxin A|BoNT-A (BOTOX 300U)
62678979|NCT02112916|ACTIVE_COMPARATOR|Arm A (combination chemotherapy)|Patients receive combination chemotherapy without bortezomib. See Detailed Description.
62308412|NCT03531229|PLACEBO_COMPARATOR|Placebo|Placebo to Lu AF76432
62120201|NCT04414904||Control Group|"* Men 18-50 years of age~* Already attending hospital for another reason~* Low risk of prior COVID-19 infection:~  * EITHER Negative positive COVID-19 PCR test result within last 4 weeks~ * OR no history suggestive of COVID-19 illness"
62139588|NCT03461666|ACTIVE_COMPARATOR|Combined-CBT-I and FOA Group|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
62139589|NCT03461666|ACTIVE_COMPARATOR|Sleep Hygiene|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
62308413|NCT03531229|EXPERIMENTAL|Lu AF76432|Lu AF76432
62308414|NCT00705510|ACTIVE_COMPARATOR|A|
62308415|NCT00705510|PLACEBO_COMPARATOR|B|
61920179|NCT06110520|EXPERIMENTAL|Violet + / Lens -|Subjects use a violet light emitting lamp (device intervention - minimally invasive as it's simply a source of light) with polycarbonate lenses for their refractive correction. The lamp introduces violet light (Violet +) while the polycarbonate lenses block the transmission of violet light through the lenses (Lens -).
62308416|NCT03988712||Iron deficiency anaemia with bowel symptoms|Patients with IDA presenting with bowel symptoms like change in bowel habits, weight loss and abdominal mass other than rectal bleed
62308417|NCT03988712||Iron deficiency anaemia with no bowel symptoms|Patients with IDA with no bowel symptoms
61920180|NCT06110520|PLACEBO_COMPARATOR|Violet - / Lens +|Subjects use a lamp with NO violet light (Violet -) with CR-39 lenses for their refractive correction. CR-39 lenses allow for the transmission of violet light through the lenses (Lens +).
61920181|NCT03931343|EXPERIMENTAL|Thoracolumbar interfascial plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
61920182|NCT03931343|ACTIVE_COMPARATOR|Erectro spinae plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
61920183|NCT01574079|ACTIVE_COMPARATOR|Traditional Physical Therapy|The control group will receive traditional physical therapy interventions directed at neuromuscular rehabilitation.
61920184|NCT01574079|EXPERIMENTAL|Physical Therapy plus Mirror Therapy|The mirror therapy will entail 15 minutes of exercises for the lower extremities focusing on ankle dorsiflexion, knee flexion, and hip flexion.
61920185|NCT03009370||Recurrent miscarriage|RM is defined as three or more pregnancy losses at\< 20 weeks of gestation.
61920186|NCT05695664|EXPERIMENTAL|Ibuprofen|patient received 800 mg of Ibuprofen IV
61920187|NCT05695664|EXPERIMENTAL|Ketorolac|Patients received Keterolac 30 mg IV
61920188|NCT04187079||IPF|Patients diagnosed with idiopathic pulmonary fibrosis after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
61920189|NCT04187079||Other ILDs|Patients diagnosed with other interstitial diseases other than IPF after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
61920190|NCT02865343|ACTIVE_COMPARATOR|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
61920191|NCT02865343|PLACEBO_COMPARATOR|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
61920192|NCT06349070|ACTIVE_COMPARATOR|Technology supported (Low Touch) Strategy|During the control period (low touch), asynchronous videos summarizing healthy lifestyle content will be delivered via text messaging.
62139590|NCT01078909|EXPERIMENTAL|300mg Fish Oil (EPA + DHA) Supplement|
62139591|NCT01078909|EXPERIMENTAL|600mg Fish Oil (EPA+DHA) Supplement|
62139592|NCT01078909|EXPERIMENTAL|900mg Fish Oil (EPA + DHA) Supplement|
62139593|NCT01078909|EXPERIMENTAL|1800mg Fish Oil (EPA + DHA) Supplement|
62308418|NCT03988712||Iron deficiency anaemia with rectal bleeding|Patients with IDA and rectal bleeding
62308419|NCT02755636|EXPERIMENTAL|PCPHC intervention|PCPHC intervention during 6-month intervention period plus study assessments at baseline, 6, and 12 months
62308420|NCT02755636|ACTIVE_COMPARATOR|Usual care|Usual primary care plus study assessments at baseline, 6, and 12 months
61920193|NCT06349070|EXPERIMENTAL|Community Health Worker (High Touch Group)|During the intervention period (high touch) asynchronous and synchronous learning whereby content will be delivered by trained M-CHWs who are equipped to directly address social determinants of health-related needs and barriers to prenatal care.
61920194|NCT02863601||pregnant|pregnant women prescribed buprenorphine
61920195|NCT02863601||postpartum|Postpartum women prescribed buprenorphine
62139594|NCT01078909|PLACEBO_COMPARATOR|Placebo|
62139595|NCT01493882|PLACEBO_COMPARATOR|Placebo|
61920196|NCT01687036|OTHER|Cryoablation|Cryoablation
62308421|NCT02334969|EXPERIMENTAL|Experimental group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
62308422|NCT02334969|ACTIVE_COMPARATOR|Control group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time
62475198|NCT04238754|PLACEBO_COMPARATOR|Placebo Then Epidiolex|Participants first receive 20 mL of inactive cherry syrup delivered every 12 hours for 48hours total (4 doses) during which prescribed methadone is withheld. After 1 week washout, they receive 8 mL of Epidiolex (800 mg of cannabidiol) + 16 mL of inactive cherry syrup delivered every 12 hours for 48 hours total (4 doses) during which prescribed methadone is withheld.
62475199|NCT02431221|EXPERIMENTAL|Intervention|Perhexiline maleate will be supplied in 100 mg and 25 mg tablets. It will be initially administered at a dose of 200 mg once a day in tablet form for at least six months. After initiation of dosing, perhexiline dosing will be determined using plasma level guided dose adjustment. Dosing decisions will be made by an unblinded dose control center.
62678980|NCT02112916|EXPERIMENTAL|Arm B (combination chemotherapy, bortezomib)|Patients receive combination chemotherapy with bortezomib (4 doses at 1.3 mg/m\^2 during Induction and 4 doses at 1.3 mg/m\^2 during Delayed Intensification). See Detailed Description.
61920197|NCT00814801|PLACEBO_COMPARATOR|Placebo|
62120202|NCT03996863|EXPERIMENTAL|Otoband efficacy on CINV|"Participants will wear the Otoband during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The Otoband will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the OtoBand is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the OtoBand 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
62120203|NCT03996863|PLACEBO_COMPARATOR|Placebo device efficacy on CINV|"Participants will wear the placebo device during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The placebo device will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the device is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the device 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
62120204|NCT01633606||Acute patients|Patients admitted to the surgical and general ICU (including burn unit), to the coronary care unit, to the emergency department high care zone, to the medical ICU, to the medical medium care unit
62139596|NCT01493882|EXPERIMENTAL|JNJ-39758979 30 mg/d|
62139597|NCT01493882|EXPERIMENTAL|JNJ-39758979 100 mg/d|
62139598|NCT01493882|EXPERIMENTAL|JNJ-39758979 300 mg/d|
62308423|NCT06116344||experimental|experimental: patients with a condition
62308424|NCT06116344||control group|control group: patients without condition
62308425|NCT00643539|EXPERIMENTAL|1|
62308426|NCT00643539|EXPERIMENTAL|2|
62308427|NCT06673004|EXPERIMENTAL|Ovarian tissue recipient|Any recipient that receives ovarian tissue transplantation
62308428|NCT04837885|EXPERIMENTAL|68Ga-DOTA-peptides PET/CT|68Ga-DOTA-peptides injections for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
62308429|NCT04837885|EXPERIMENTAL|LUTATHERA® by intra-arterial hepatic injection (IAH)|One treatment dose of LUTATHERA® by intra-arterial hepatic injection after conventional treatment by 4 intravenous administrations
62308430|NCT04630015||Observational (surveys)|Patients complete surveys over 5-10 minutes at baseline (i.e. before participating in the program), and at 9 and 15 weeks follow up on the impact of COVID-19 on survivorship. Patients also complete a survey assessing how patients rate telehealth classes in the Survivorship Wellness program.
62308431|NCT00542828|EXPERIMENTAL|Thymoglobulin|
62308432|NCT03427775||pre-MP3|before implementation of the multimodal analgesia protocol
61920198|NCT00814801|EXPERIMENTAL|Galantamine 16 mg/day|
62308433|NCT03427775||post-MP3|after implementation of the multimodal analgesia protocol
62308434|NCT04507217|EXPERIMENTAL|Eligible patients|tislelizumab (200mg) in combination with pemetrexed (500mg/m2) and carboplatin (AUC=5) intravenously on day 1 of a 3-week cycle for 4 cycles. Afterwards, patients without disease progression were treated with maintenance treatment with tislelizumab (200mg) plus pemetrexed (500mg/m2) every 3 weeks up to 24 months or until disease progression, unacceptable toxicity, or death.
62308435|NCT06060080|EXPERIMENTAL|Clinical Study on PEG-rhG-CSF in the Treatment of Lymphoma/Multiple Myeloma|In this study, lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
62308436|NCT03205787|EXPERIMENTAL|Trifolium pratense|Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
62678981|NCT02380872|ACTIVE_COMPARATOR|Connective tissue graft|Connective tissue graft Soft tissue harvested from palatum of the subjects.
62678982|NCT02380872|EXPERIMENTAL|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
61920199|NCT00814801|EXPERIMENTAL|Galantamine 24 mg/day|
61920200|NCT06171490|ACTIVE_COMPARATOR|Product Sequence 1|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
62475200|NCT02431221|PLACEBO_COMPARATOR|Placebo|Placebo will be administered once a day in tablet form for at least six months. Tablets will be identical in size and shape to perhexiline tablets. Adjustments in placebo dosing will be made by an unblinded dose control center to mimic decisions made for subjects in the experimental arm.
62475201|NCT05026294|EXPERIMENTAL|Experimental group I|The experimental group received plyometric training
62475202|NCT05026294|EXPERIMENTAL|Experimental group II|The experimental group received flat feet rehabilitation training
62120205|NCT00976937|EXPERIMENTAL|Lixisenatide|2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24 along with placebo matching to sitagliptin 100 milligram (mg) capsule orally QD up to Week 24.
62308437|NCT02864303|OTHER|Patients with Alzheimer disease|Saliva samples were collected on this patients
62308438|NCT05702944|SHAM_COMPARATOR|Phenoxybenzamine before surgery|Phenoxybenzamine, an alpha receptor blocker, is taken at least 2 to 5 weeks before surgery
62308439|NCT05702944|ACTIVE_COMPARATOR|No phenoxybenzamine before surgery|Phenoxybenzamine, an alpha receptor blocker, is not taken before surgery
62308440|NCT03288467|ACTIVE_COMPARATOR|Root canal treatment with 5% NaOCl|Root canal treatment with 5% NaOCl: 5 ml of 5% sodium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 5% sodium hypochlorite.
62475203|NCT05026294|NO_INTERVENTION|Control group|The Control group didn't receive intervention
62475204|NCT04574219|OTHER|Feasibility/Acceptability|This arm will be used to assess the feasibility and acceptability of using FaceTime during induction.
62475205|NCT04574219|OTHER|Coaching prior to surgery|
62475206|NCT04574219|OTHER|Coaching day of surgery|
62475207|NCT00962611|EXPERIMENTAL|Copanlisib|
62120206|NCT00976937|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
62120207|NCT01060137|EXPERIMENTAL|001|fentanyl matrix Fentanyl transdermal patch 12 - 25mcg/hr can increase with 12 - 25mcg/h based on pain assessment
62120208|NCT04045977|EXPERIMENTAL|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
62308441|NCT03288467|ACTIVE_COMPARATOR|Root canal treatment with 1% NaOCl|5 ml of 1% soium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 1% sodium hypochlorite.
62308442|NCT04325815||CADDIE|The endoscopist will be assisted with CADDIE system to detect polyps. The endoscopist will perform optical diagnosis of polyps with the assistance of the CADDIE's polyp characterisation function.
62308443|NCT04325815||Standard Procedure|In addition to routine colonoscopy the endoscopist will perform optical diagnosis of detected polyps without the assistance of the CADDIE.
62475208|NCT01831362|EXPERIMENTAL|Focused Attention (FA)|This 8 week program consists solely of focused attention practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
62475209|NCT01831362|EXPERIMENTAL|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
62475210|NCT01831362|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused attention and open- monitoring practices
62475211|NCT04583657|PLACEBO_COMPARATOR|Control|"Consumption of two classical eggs per day during three months. The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%."
62475212|NCT04583657|EXPERIMENTAL|Test|Consumption of two test eggs per day during three months. These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%, total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
62475213|NCT02811666|EXPERIMENTAL|Patients operated for liver or pancreas cancer|
61920201|NCT06171490|ACTIVE_COMPARATOR|Product Sequence 2|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
61920202|NCT06171490|ACTIVE_COMPARATOR|Product Sequence 3|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
61920203|NCT06171490|ACTIVE_COMPARATOR|Product Sequence 4|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
61920204|NCT05155462||Patient treated for defined symptomatic chronic lower extremity ischemia|
61920205|NCT01949285|SHAM_COMPARATOR|Grp#1: sham stimulation|"Group #1: Baseline clinical assessment; followed by two weeks training with no stimulation; then four weeks training + sham Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment; then four weeks training + effective non-sham Transcutaneous Spinal Cord Stimulation; repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
62475214|NCT01364532|EXPERIMENTAL|Transulnar arterial access|Transulnar arterial access for coronary angiography, ad-hoc or elective PCI
61920206|NCT01949285|ACTIVE_COMPARATOR|Grp#2: Control|"Group #2: Baseline clinical assessment; followed by two weeks training with no Transcutaneous Electrical Spinal Cord Stimulation; then four weeks training + effective Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
61920207|NCT00796354|ACTIVE_COMPARATOR|NRL920|
61920208|NCT00796354|PLACEBO_COMPARATOR|Placebo|
61920209|NCT01631656|EXPERIMENTAL|Azelaic Acid plus Laser|Azelaic acid 15% twice daily on half the face for 6 weeks, plus laser treatment with Nd:Yag laser once at 2 weeks.
61920210|NCT01631656|ACTIVE_COMPARATOR|Laser only|laser treatment on all face once at 2 weeks with no azelaic acid on one side of the face
61920211|NCT00006487|ACTIVE_COMPARATOR|chemo/RT with tirapazamine|induction and consolidation: cisplatin, etoposide, tirapazamine, radiation therapy
61920212|NCT04025281|ACTIVE_COMPARATOR|Extra virgin olive oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
61920213|NCT04025281|ACTIVE_COMPARATOR|Refined olive oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
61920214|NCT00848003|ACTIVE_COMPARATOR|1. Active|"Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)~Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days"
61920215|NCT00848003|PLACEBO_COMPARATOR|2. Placebo|Strawberry flavored yogurt
61920216|NCT00609362|ACTIVE_COMPARATOR|Rosiglitazone|25 women age 60 to 75 years receiving rosiglitazone 8 mg/day
61920217|NCT00609362|PLACEBO_COMPARATOR|Placebo|25 women 60 to 75 years of age receiving placebo once a day for 14 weeks
61920218|NCT04270903||Phototype I - II|EPR measurement at the surface of the skin (arm)
61920219|NCT04270903||Phototype III - IV|EPR measurement at the surface of the skin (arm)
61920220|NCT04270903||Phototype V - VI|EPR measurement at the surface of the skin (arm)
61920221|NCT02963961|EXPERIMENTAL|Cognitive Training|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
61920222|NCT02963961|NO_INTERVENTION|No Training|Patients will not undergo preoperative cognitive training. Patients will receive standard preoperative care.
61920223|NCT02911207|EXPERIMENTAL|Intervention arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during the following six months
61920224|NCT02911207|ACTIVE_COMPARATOR|control arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during six months but they will start 6 months later after randomization
61920225|NCT02748603||Patient with non ST Elevation - Acute Coronary Syndrome|
61920226|NCT02748603||Patient with stable Coronary Artery Disease (CAD)|
61920227|NCT01145911||Glaucoma patients|Glaucoma patients
62475215|NCT01364532|ACTIVE_COMPARATOR|Transradial arterial access|Transradial arterial access for coronary angiography, ad-hoc or elective PCI
62120209|NCT04045977|ACTIVE_COMPARATOR|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
62475216|NCT04543357||All participants|Household contacts of a DMD patient in an interventional study of fordadistrogene movaparvovec.
62475217|NCT03616730||Heart Disease in pregnancy group|Fifty women will be recruited with structurally and functionally abnormal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Women who are unable to give informed consent will not be included.
62678983|NCT01924065|ACTIVE_COMPARATOR|Transesophageal Echocardiography group|This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion
61920228|NCT05262959|EXPERIMENTAL|Donafenib|Donafenib: 0.1g po. BID. And it will be taken on the first day of the study. PD-1: 200mg ivgtt. Q3W. It will be used at the same time as Donafenib. TACE: The first treatment will be carried out 2-3 weeks after taking Donafenib.
61920229|NCT04562753|ACTIVE_COMPARATOR|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
61920230|NCT04562753|ACTIVE_COMPARATOR|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
62678984|NCT01924065|ACTIVE_COMPARATOR|Oral anticoagulant Group|This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.
62678985|NCT00290420|EXPERIMENTAL|Chloroquine profilaxis|"Prevention: chloroquine profilaxis~Prevention of malaria attacks with chloroquine profilaxis taken once a week"
62678986|NCT00290420|NO_INTERVENTION|No prevention|Treatment of malaria attack with chloroquine when they occur
62678987|NCT06174532|PLACEBO_COMPARATOR|Traditional method|Patients with mandibular tumors will be treated by the traditional method
62678988|NCT06174532|ACTIVE_COMPARATOR|Virtual surgical planning method|Patients with mandibular tumors will be treated by traditional method with virtual surgical planning
62678989|NCT02043847|EXPERIMENTAL|Cohort 1Total Marrow Irradiation (TMI) 3Gy|3Gy with standard high dose melphalan prior to autologous stem cell rescue
62678990|NCT02043847|EXPERIMENTAL|Cohort 2 Total Marrow Irradiation (TMI) 6Gy|6Gy with standard high dose melphalan prior to autologous stem cell rescue
62678991|NCT02043847|EXPERIMENTAL|Cohort 3 Total Marrow Irradiation (TMI) 9Gy|9Gy with standard high dose melphalan prior to autologous stem cell rescue
62678992|NCT06688903|EXPERIMENTAL|Intervention|
62678993|NCT03347539||Nexplanon|This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant.
61920231|NCT03312751|EXPERIMENTAL|Emapalumab|
61920232|NCT04632914|EXPERIMENTAL|trunk stabilizing exercise|trunk stabilizing exercises three times/week for four weeks
62308444|NCT01720251|PLACEBO_COMPARATOR|placebo|SC injections of placebo
62678994|NCT03347539||Removal participants|This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
62678995|NCT03227627|EXPERIMENTAL|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
62678996|NCT03227627|ACTIVE_COMPARATOR|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
62678997|NCT02369679|EXPERIMENTAL|Precast Adjustable Compression Wrap|Precast Adjustable Compression Wrap will be adjusted by the physiotherapist each visit
61920233|NCT04632914|ACTIVE_COMPARATOR|cardiac rehabilitation programe|cardiac rehabilitation program three times/week for four weeks
62120210|NCT04003805|EXPERIMENTAL|Switching from Smoking Cigarettes to SREC|
62308445|NCT01720251|EXPERIMENTAL|AllerT low dose|SC injections of AllerT 25 or 50 micrograms
61920234|NCT05160610|EXPERIMENTAL|Intervention group|receiving multilevel intervention, electronic monitoring and stroke registry participation
61920235|NCT05160610|NO_INTERVENTION|Control group|receiving routine care , electronic monitoring and stroke registry participation
61920236|NCT04620707|EXPERIMENTAL|RGS based therapy|
61920237|NCT04620707|ACTIVE_COMPARATOR|Treatment as usual|
61920238|NCT00706069|EXPERIMENTAL|1|Vinorelbine oral plus Capecitabine
61920239|NCT02345746|EXPERIMENTAL|Hepatic Artery Infusion|Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil
62308446|NCT01720251|EXPERIMENTAL|AllerT full dose|SC injections of AllerT 50-100 micrograms
62678998|NCT02369679|ACTIVE_COMPARATOR|Multilayer Compression Bandages|Multilayer Compression Bandages will be adjusted by the physiotherapist each visit
62678999|NCT04317534|EXPERIMENTAL|Arm A- Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks x 9 cycles
62679000|NCT04317534|NO_INTERVENTION|Arm B - Observation|Observation only
62679001|NCT04576481|ACTIVE_COMPARATOR|Group 1: Texting|Consist of daily text messages on shared reading
62679002|NCT04576481|EXPERIMENTAL|Group 2: Regret|Will consist of Group 1 plus social comparisons.
62679003|NCT04576481|EXPERIMENTAL|Group 3: Lottery|Will consist of Group 2 plus availability of a weekly lottery.
62679004|NCT06051292|EXPERIMENTAL|Fast decremental|fast decremental catheter volume titration will be applied
61920240|NCT02414139|EXPERIMENTAL|Cohort 1a: Pre-treated patients with MET GCN ≥ 10 (2/3L)|Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)
61920241|NCT02414139|EXPERIMENTAL|Cohort 1b:Pre-treated patients with MET GCN ≥ 6 and < 10 (2/3L)|Pre-treated patients with MET GCN ≥ 6 and \< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)
61920242|NCT02414139|EXPERIMENTAL|Cohort 2: Pre-treated patients with MET GCN ≥ 4 and < 6 (2/3L)|Pre-treated patients with MET GCN ≥ 4 and \< 6 treated with INC280 at 400mg BID as second or third line (2/3L)
61920243|NCT02414139|EXPERIMENTAL|Cohort 3: Pre-treated patients with MET GCN < 4 (2/3L)|Pre-treated patients with MET GCN \< 4 treated with INC280 at 400mg BID as second or third line (2/3L)
62475218|NCT03616730||Control Group|Fifty women will be recruited with structurally normal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Any woman on cardiac or antihypertensive medications (beta blockers, calcium channel blockers, hydralazine) will be excluded. Women who are unable to give informed consent will not be included.
62475219|NCT02663960|EXPERIMENTAL|fixed citrate doses protocol|Fixed citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which was set to meet a circuit citrate concentration of 4 mmol/l (duration: the maximum time is 72 hrs).
62475220|NCT02663960|ACTIVE_COMPARATOR|adjusted citrate doses protocol|Adjusted citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which the starting infusion rate be set 2.5 % of blood flow ( dosage range: 160-250ml/h) and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l (duration: the maximum time is 72 hrs. )
62475221|NCT04365153|ACTIVE_COMPARATOR|High Dose Intervention|600 mg of canakinumab (8 mg/kg for patients \</= 40 kg)
62475222|NCT04365153|ACTIVE_COMPARATOR|Low Dose Intervention|300 mg of canakinumab (4 mg/kg for patients \</= 40 kg)
62475223|NCT04365153|PLACEBO_COMPARATOR|Control|Placebo
62475224|NCT01826058|EXPERIMENTAL|Stereotactic body radiation therapy|"SBRT in one to four fractions~Irradiated total RT dose to gross tumor volume (GTV) according to fraction size~* 1 fx: 16 to 24 Gy~* 2 fx's: 20 to 26 Gy~* 3 fx's: 21 to 30 Gy~* 4 fx's: 24 to 36 Gy"
62475225|NCT00963482|EXPERIMENTAL|Intervention group|Cognitive-behavioural smoking cessation program
62475226|NCT00963482|OTHER|Control group|Autogenic training
62475227|NCT05383794||Control|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
62475228|NCT05383794||Periodontitis|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
62475229|NCT05383794||Cardiovascular disease|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
62475230|NCT05383794||Periodontitis + cardiovascular disease|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
62679005|NCT06051292|ACTIVE_COMPARATOR|Conventional|conventional catheter volume titration will be applied
62679006|NCT05324787|EXPERIMENTAL|Grency venous stent system|
62679007|NCT05498038|NO_INTERVENTION|Healthy Control Service Members|Non-concussed, age-matched SM will serve as a healthy control group (HC) for comparing CSM to normal physiology and to control for the effect of time and of aerobic exercise. They will not be given intervention.
61920244|NCT02414139|EXPERIMENTAL|Cohort 4: Pre-treated patients with MET mutation regardless of MET GCN (2/3L)|Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)
61920245|NCT02414139|EXPERIMENTAL|Cohort 5a: Treatment-naïve patients with MET GCN ≥10 (1L)|Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)
62475231|NCT01610804||CSCR-Patients|Patients suffering from Central Serous Chorioretinopathy
62475232|NCT01610804||Healthy Subjects|Healthy subjects with (assumed) normal choroidal thickness
62475233|NCT01593852|ACTIVE_COMPARATOR|Regular X-ray dose settings|For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
62679008|NCT05498038|NO_INTERVENTION|Concussed Service Members PRA|CSM allocated to this group will complete PRA protocols/ will receive treatment as usual.
62679009|NCT05498038|EXPERIMENTAL|Concussed Service Members PRA+Exercise|CSM allocated to this group will complete PRA protocols/ will receive treatment as usual and will receive an exercise program in addition to PRA.
61920246|NCT02414139|EXPERIMENTAL|Cohort 5b: Treatment-naïve patients with MET mutation regardless of MET GCN (1L)|Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)
61920247|NCT02414139|EXPERIMENTAL|Cohort 6.1 (expansion of Cohort 1a): Pre-treated patients MET GCN ≥ 10 without MET mutation (2L)|Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)
61920248|NCT02414139|EXPERIMENTAL|Cohort 6.2 (expansion of Cohort 4): Pre-treated patients with MET mutation (2L)|Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)
62339579|NCT02172079|EXPERIMENTAL|Real mobilization-with-movement (MWM)|For the MWM group, an accessory posterior-lateral gliding movement in the humeral head combined with a movement of active shoulder flexion will be applied. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior aspect of the head of the humerus
62475234|NCT01593852|EXPERIMENTAL|Reduced X-ray dose settings|For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing
62475235|NCT04893057||Pregnant women|Women admitted to hospital for a live birth.
62475236|NCT04893057||Blood donors|Subjects qualified for whole blood donation
62475237|NCT02902211|EXPERIMENTAL|Ankle foot orthosis|Patients will wear an off-the-shelf, carbon composite AFO that is adjusted for them for three months. The patients will be asked to wear the AFO at all times except when they are in bed or showering/bathing. The instructions given to the patients about walking will be to follow the instructions from their doctor regarding risk factor management and exercise.
62679010|NCT02218151|EXPERIMENTAL|Patient-Centered Medical Home (PCMH)|"Day-to-Day Care:~Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
61920249|NCT02414139|EXPERIMENTAL|Cohort 7 (expansion of Cohort 5b): Treatment-naïve with MET mutation regardless of MET GCN (1L)|Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)
61920250|NCT01992159|PLACEBO_COMPARATOR|Placebo|Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
61920251|NCT01992159|EXPERIMENTAL|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
61920252|NCT01992159|EXPERIMENTAL|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
61920253|NCT01992159|EXPERIMENTAL|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
62475238|NCT02902211|ACTIVE_COMPARATOR|Control|Patients will be asked to follow the instructions from their doctor regarding risk factor management and exercise for three months.
62475239|NCT06559618|EXPERIMENTAL|Phage Arm|A sterile solution of one to three individual phages (cocktail) (3 x 10\^8 plaque forming units \[PFU\]) phage(s) will be administered intravesicularly (instilled into the participant's bladder via catheter) twice a day for 7 days. The name of the active treatment IP is TAILФR Phage Cocktail (TPC).
62475240|NCT06559618|PLACEBO_COMPARATOR|Placebo Arm|Sterile 0.9% saline solution will be instilled into the bladder via catheter twice a day for 7 days
62475241|NCT01867164|EXPERIMENTAL|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
61920254|NCT06108986|EXPERIMENTAL|tabata training|Group A will perform tabata that includes squats, push up, side jump, medicine ball pass, commando dance, plank, skip rope, burpees. three sessions per week for six weeks.
62339580|NCT02172079|SHAM_COMPARATOR|Sham mobilization-with-movement (MWM)|The sham condition will replicate the treatment condition except for the hand positioning. The therapist locates one hand over the belly of the pectoralis major muscle and the other over scapula without applying any pressure. The patient will be asked to move the arm in a similar manner as in the MWM group
62475242|NCT01867164|EXPERIMENTAL|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
62679011|NCT02218151|ACTIVE_COMPARATOR|Standard Care|"These subjects will begin as inpatients or outpatients, where advanced practice providers (APPs) (nurse practitioners and physician assistants) will perform histories and physical exams. Nurses will collect labs and providers will enter orders in our electronic health record (EHR). All steps will be repeated daily until discharge to home. Suitability for discharge is determined by standard clinical criteria including stable blood counts, freedom from active or severe complications (e.g. active infection, severe GVHD), and ability to care for self.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
62679012|NCT05058040|EXPERIMENTAL|GV-971|The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening
61920255|NCT06108986|EXPERIMENTAL|plyometric training|Group B will perform plyometric training that includes squats, ankle hopes, jumps in a place, lunges, shuffling, stair jump exercises. three sets of eight reps, three sessions per week for six weeks.
61920256|NCT02906488||Patients with Parkinson's Disease|
61920257|NCT03963375|OTHER|Group 1: LP at Baseline and Week 5|Group 1: LP at Baseline and end of Week 5. Week 5 is the optimal time point for assessing cladribine concentrations in CSF
62475243|NCT06562699|EXPERIMENTAL|Group A|21 participants. They will be generated using numbers from 1 to 63, divided into three groups denoting with letters A, B, and C. Randomization will be generated using (www.randomization.com).
62679013|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
62679014|NCT05339659|ACTIVE_COMPARATOR|Control|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking.
61920258|NCT03963375|OTHER|Group 2: LP at Baseline and Week 10|"Group 2: LP at Baseline and end of Week 10. Week 10 is the expected nadir time for lymphocyte and monocyte levels in CSF"
61920259|NCT03963375|OTHER|Group 3: LP at Baseline and End of Year 1|Group 3: LP at Baseline and end of Year 1. To assess if cladribine effects on CSF markers are maintained at the end of the first treatment cycle
61920260|NCT03963375|OTHER|Group 4: LP at Baseline and End of Year 2|Group 4: LP at Baseline and end of Year 2. To assess if cladribine effects on CSF markers are maintained at the end of the last treatment cycle
61920261|NCT02378025|EXPERIMENTAL|Yoga Group|Postures, meditation, breathing exercises
61920262|NCT02378025|ACTIVE_COMPARATOR|Pain Management Wellness Group|Behavioral medicine
61920263|NCT04692740|EXPERIMENTAL|Chlorambucil|
62475244|NCT06562699|EXPERIMENTAL|Group B|21 participants. They will be generated using numbers from 1 to 63, divided into three groups denoting with letters A, B, and C. Randomization will be generated using (www.randomization.com).
62475245|NCT06562699|ACTIVE_COMPARATOR|Group C|21 participants. They will be generated using numbers from 1 to 63, divided into three groups denoting with letters A, B, and C. Randomization will be generated using (www.randomization.com).
62679015|NCT05339659|EXPERIMENTAL|Experimental|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking + additional experimental content targeted to smokers living with HIV who are ambivalent about quitting smoking.
62679016|NCT05478707|PLACEBO_COMPARATOR|Placebo|Saline subcutaneous injection, volume matched to dulaglutide, i.e. 0.5 mL weekly for 14 weeks
61920264|NCT01823510|EXPERIMENTAL|Ticagrelor + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
61920265|NCT01823510|ACTIVE_COMPARATOR|Clopidogrel + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
61920266|NCT05352776|EXPERIMENTAL|AtaCor EV-ICD Lead System|Subjects implanted with the AtaCor EV-ICD Lead Model AC-7001
61920267|NCT00973570|EXPERIMENTAL|"Intervention group"|"The intervention group benefits from the TABADO program"
61920268|NCT00973570|NO_INTERVENTION|"Control group"|"The control group not benefit from any specific intervention other than the treatment and education usually available"
61920269|NCT01721577|EXPERIMENTAL|Phase 1: AXL1717, 300mg|In the first phase, 10-20 patients will be enrolled and treated with 300mg (original range of starting dose was 300-520mg) BID of AXL1717 for 28 days. The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 and to assess the safety and toxicity of AXL1717. The study has a 3+3 design and the first cohort will be treated with 300 mg AXL1717 BID for 28 days repeated in up to 5 cycles. The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RP2D. Non-progressing patients may be treated for a total of five 28-day cycles (24 weeks).
61920270|NCT06313021||stroke group|stroke group
62475246|NCT02950805|EXPERIMENTAL|Placebo + AZD5634|Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
61920271|NCT05509946|EXPERIMENTAL|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg administered an hour before surgery
62475247|NCT02950805|EXPERIMENTAL|AZD5634 + Placebo|Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
62475248|NCT01193712|OTHER|on-table non-responder|patients who do not show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
62120211|NCT04003805|EXPERIMENTAL|Switching from Smoking Cigarettes to Nicotine Mini-Lozenge|
62120212|NCT04003805|NO_INTERVENTION|Usual Brand Cigarettes|
62120213|NCT01563380|EXPERIMENTAL|PRP arm|Platelet-rich plasma was applied over the wound including the capsule, medial and lateral recesses.
62339581|NCT04914832|EXPERIMENTAL|All individuals who register on the National Vaccination Registry|This will be open-label, single-arm implementation study in Eswatini. All individuals who register on the National Vaccination Registry will be eligible for enrolment. Participants will receive appointments for vaccination using the registry.
62679017|NCT05478707|ACTIVE_COMPARATOR|Dulaglutide|Dulaglutide (0.75 mg/0.5 mL weekly for 2 weeks, then 1.5 mg/0.5 mL weekly for 12 weeks) subcutaneous injection
62339582|NCT01870024|ACTIVE_COMPARATOR|1: Lorazepam + Placebo|\[ L + P \] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
62339583|NCT01870024|ACTIVE_COMPARATOR|2: Clonazepam + Placebo|\[ C + P \] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
62679018|NCT05478707|ACTIVE_COMPARATOR|Exercise training|Supervised high intensity interval training on a stationary bicycle will be conducted 3 days per week for 14 weeks. Participants will warm up at low intensity for 3 min then repeat 1-min bouts of 100% peak power output followed by 1-min recovery at 50 W. Training will start with 6 intervals per session, increasing by 2 intervals every 2 weeks. Sessions will end with a 10-min cool-down.
62120214|NCT01563380|NO_INTERVENTION|Control Arm|
62120215|NCT00004266|EXPERIMENTAL|Nifedipine|Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
62120216|NCT00004266|EXPERIMENTAL|Lisinopril|Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
62120217|NCT00004266|EXPERIMENTAL|Nifedipine and simvastatin|Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.
62139599|NCT02150616|EXPERIMENTAL|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
62475249|NCT01193712|NO_INTERVENTION|on-table responders|patients who do show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
62475250|NCT00407147|NO_INTERVENTION|Control|Standard treatment
62475251|NCT00407147|EXPERIMENTAL|PCT|PCT guided arm
62475252|NCT05329103|EXPERIMENTAL|PEEL-224 Dose Escalation|PEEL-224 is administered intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle. The study will begin at a low starting dose and will increase between cohorts according to mTPI-2 until a recommended phase 2 dose is determined. Approximately 10 dose levels are anticipated to be studied.
62679019|NCT03737994|EXPERIMENTAL|ALK L1198F mutation (alone or combination with ALK inhibitor)|Patients with ALK L1198F mutation (alone or in combination with another ALK mutation) receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62475253|NCT05329103|EXPERIMENTAL|PEEL-224 Dose Confirmation|An additional arm of patients will be enrolled after dose escalation is completed to confirm the recommended phase 2 dose.
62120218|NCT00004266|EXPERIMENTAL|Lisinopril and simvastatin|Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.
62308447|NCT05783258|EXPERIMENTAL|CAF+tSCTG|15 sites will be treated.The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the level of the maxillary tuberosity. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
62308448|NCT05783258|ACTIVE_COMPARATOR|CAF+L-PRF|15 sites will be treated.The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm,2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession. Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa. The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of bone.A partial thickness dissection will be performed in the apical portion of the flap to obtain complete passivation.The L-PRF membranes will be realized centrifuged venous blood collected in two 10-ml sterile tubes at 3000 rpm for 10 minutes and squeezing the fibrin clot. L-PRF membranes will be superimposed to crete a double layer of about 2 mm thickness.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
62308449|NCT05632497||Anorexia patients|Hospitalized anorexia patients with body mass index \< 15.
62120219|NCT02076451|EXPERIMENTAL|2 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
62308450|NCT05632497||Healthy controls|Health volunteers: 18 years or older with body mass index between 18.5 and 25.
62308451|NCT04265989|EXPERIMENTAL|coronary artery aneurysm with branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, accompany with branches origin from the aneurysm
62308452|NCT04265989|EXPERIMENTAL|coronary artery aneurysm without branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, without any branch origin from the aneurysm
62308453|NCT04265989|EXPERIMENTAL|Coronary artery aneurysm with localized stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. localized stenosis defined as lesion to more than 70% stenosis and length less than 20 mm
62308454|NCT04265989|EXPERIMENTAL|Coronary artery aneurysm with diffuse stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. Diffuse stenosis defined as lesion to more than 70% and length more than 20 mm
62308455|NCT01235533|EXPERIMENTAL|N-3 fatty acids|Participants in this arm were received three capsules of n-3 fatty acids. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g。
62308456|NCT01235533|PLACEBO_COMPARATOR|Placebo|Participants in this arm were received three identical capsules per day. All capsules included olive oil.
62308457|NCT02494908|ACTIVE_COMPARATOR|Healthy controls|Healthy controls with no known neurological disease matched for sex and age with the patients group
62308458|NCT02494908|ACTIVE_COMPARATOR|IPD patients|Men and women diagnosed with idiopathic parkinson's disease
62475254|NCT03607253|OTHER|Men|Healthy young men aged between 18-25 years
62475255|NCT03607253|OTHER|Women|Healthy young women aged between 18-25 years
62475256|NCT02604420||Transplant, no TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant but do not meet the criteria for a thrombotic microangiopathy in the one year follow up period. No interventions anticipated.
62475257|NCT02604420||Transplant, +TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant and meet the criteria for a thrombotic microangiopathy in the one year follow up period. Possible interventions include observation, treatment of an underlying infection or GvHD, use of plasma exchange, or use of anti-complement therapy (eculizumab or other anti-complement drug). Eculizumab is used as a 900mg intravenous infusion over 35 minutes, given weekly for 4 weeks, then 1200mg every other week. Patients must be vaccinated against meningococcus 2 weeks before starting drug or, if that is not feasible because of the physician's assessment of the severity of the TMA, given prophylactic antibiotics for the 2 week period before immunization has taken hold.
62475258|NCT01794845|EXPERIMENTAL|Erbitux, Taxotere, LD Fractionated RT|Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)
62475259|NCT03596294|EXPERIMENTAL|Treatment sequence AB|"Period A:~Saline + clazosentan~Period B:~Rifampicin + clazosentan"
61920272|NCT05509946|ACTIVE_COMPARATOR|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg twice a day and pregabalin 75 mg twice a day administered starting from 3 days before surgery
61920273|NCT05509946|PLACEBO_COMPARATOR|Placebo|Placebo
62120220|NCT02076451|EXPERIMENTAL|8 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
61920274|NCT03523000|ACTIVE_COMPARATOR|Active Solution followed by Inactive Placebo Solution|"Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml~6 hour washout followed by~Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline"
62120221|NCT02076451|EXPERIMENTAL|16 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
62139600|NCT02150616|EXPERIMENTAL|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
62679020|NCT03737994|EXPERIMENTAL|C1156Y|Patients with Cy1156Y mutation receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62120222|NCT02076451|EXPERIMENTAL|24 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
62475260|NCT03596294|EXPERIMENTAL|Treatment sequence BA|"Period B:~Rifampicin + clazosentan~Period A:~Saline + clazosentan"
62475261|NCT02233985|ACTIVE_COMPARATOR|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
62475262|NCT02233985|EXPERIMENTAL|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
62679021|NCT03737994|EXPERIMENTAL|Compound mutation|Patients with a compound mutation receive lorlatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61920275|NCT03523000|PLACEBO_COMPARATOR|Inactive Placebo Solution followed by Active Solution|"Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline~6 hour washout followed by~Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml"
61920276|NCT00907062|EXPERIMENTAL|Gingko biloba|60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
62475263|NCT05948683|EXPERIMENTAL|Familiar partner with placebo|Participant engages in social interaction with 'familiar' partner under placebo
62475264|NCT05948683|EXPERIMENTAL|Familiar partner with MDMA|Participant engages in social interaction with 'familiar' partner under MDMA
62679022|NCT03737994|EXPERIMENTAL|F1174|Patients with F1174 receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62679023|NCT03737994|EXPERIMENTAL|G1202 (including G1202del and G1202R)|Patients with G1202 (including G1202del and G1202R) receive either lorlatinib PO QD or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61920277|NCT01888887|EXPERIMENTAL|Cetaphil Daily Facial Cleanser|All subjects receive Cetaphil Daily Facial Cleanser
62120223|NCT03183518|EXPERIMENTAL|Test Product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
62120224|NCT03183518|OTHER|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
62120225|NCT00724217|EXPERIMENTAL|Normal weight|BMI \< 26
62120226|NCT00724217|EXPERIMENTAL|Overweight|BMI \>= 26
62120227|NCT03703219||Mother Touch Program|Forty days of rest period of the mother after delivery, Full body massage, diet and belly binding methods were administered by trained carer.
62120228|NCT03703219||Usual care Program|comparison cohort were followed in usual care under the supervision of health professionals.
61920278|NCT02609997|EXPERIMENTAL|Single-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a single-piece IOL
61920279|NCT02609997|EXPERIMENTAL|Three-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a three-piece IOL
61920280|NCT01818960|ACTIVE_COMPARATOR|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
61920281|NCT01818960|ACTIVE_COMPARATOR|IRA-PCI|IRA only PCI with planned staging for non-IRA lesions
61920282|NCT04140136|ACTIVE_COMPARATOR|Treatment group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients.The investigational product is to be administered twice daily, at a dose of 400mg per day.
61920283|NCT04140136|PLACEBO_COMPARATOR|Placebo group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients. The placebo is similar in appearance but does not contain tocotrienols and consist of palm oil.
61920284|NCT03489421||HIV Infected|
62120229|NCT05817630||Group A|Group A: 3 months SO Tamponade
62120230|NCT05817630||Group B|Group B: 6 months SO Tamponade
62120231|NCT00448721|EXPERIMENTAL|Perifosine|Perifosine will be administered orally at 100mg PO daily with food. One treatment cycle will consist of 42 days (6 weeks).
62120232|NCT02043483||CPAP|Patients with moderate/severe OSAS will be treated with CPAP
62120233|NCT02043483||Control|Patients with snoring will not be subject to treatment with CPAP
62120234|NCT00908817|ACTIVE_COMPARATOR|triamcinolone|
62339584|NCT01870024|ACTIVE_COMPARATOR|3: Clonazepam + Fosphenytoin|\[ C + F \] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
62679024|NCT03737994|EXPERIMENTAL|I1171|Patients with I1171 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61920285|NCT03489421||Un-infected controls|Controls without HIV from a historical pre-approved-IRB-protocol database
61920286|NCT05380999||Patients with pulmonary nodules (diameter ≤3cm) plan to diagnosis benign and malignant|Patients with pulmonary nodules (diameter ≤3cm) plan to use biopsy or surgery or treatment to diagnosis benign and malignant.
61920287|NCT02037152|NO_INTERVENTION|Waitlist|Participants randomized to this arm are instructed that they will have access to the study intervention after four weeks. Waitlist group participants are prompted to answer weekly questionnaires.
61920288|NCT02037152|EXPERIMENTAL|Active treatment|"The active treatment group will be instructed to use the app-guided body scan exercise daily for six days per week over a period of four weeks. The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. Before and after each use of the body scan, users complete a single-item scale measuring pain intensity/distress. Users are prompted to complete all other questionnaires at weekly or four-week intervals. The app includes access to a graphical display showing changes in average pain level. Subjects also have access to a section of frequently asked questions about the practice."
62120235|NCT00908817|PLACEBO_COMPARATOR|chlorhexidine|
62120236|NCT03185780|EXPERIMENTAL|Treatment|Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
62475265|NCT05948683|EXPERIMENTAL|Unfamiliar partner with placebo|Participant engages in social interaction with 'unfamiliar' partner under placebo
62475266|NCT05948683|EXPERIMENTAL|Unfamiliar partner with MDMA|Participant engages in social interaction with 'unfamiliar' partner under MDMA
62120237|NCT06312618|ACTIVE_COMPARATOR|Group 1: Propofol group|children will be randomized to receive propofol 1mg/kg over 10 minutes
62120238|NCT06312618|ACTIVE_COMPARATOR|Group 2: Dexmedetomidine group|children will be randomized to receive dexmedetomidine 0.2 mcg/kg over 10 minutes
62120239|NCT05172752|OTHER|Citizen Science Training|Study participants in this condition will participate in training and in-home sampling for disinfection by-products.
62139601|NCT02150616|ACTIVE_COMPARATOR|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
62679025|NCT03737994|EXPERIMENTAL|L1196 (including L1196M)|Patients with L1196 (including L1196M) mutation receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, or ensartinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62120240|NCT05172752|OTHER|Stakeholder Consultation Core Membership|Study participants in this condition will participate in quarterly meetings and deliberative activities of the project's Stakeholder Consultation Core.
61920289|NCT04375475|EXPERIMENTAL|Bright Changyou probiotic flavored yogurt|Bright Changyou probiotic flavored yogurt contains 5.0×10\^8cfu/g of probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum ST-Ⅲ (7mg/kg), and 1.5% of inulin
62308459|NCT02850198|EXPERIMENTAL|Scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
62339585|NCT02428452|EXPERIMENTAL|Treatment|Six-month Social ABCs parent-training program received immediately
62475267|NCT03569059|EXPERIMENTAL|Early Robotic/VR Therapy (EVR)|Subjects in this group will receive state-of-art inpatient usual care therapy plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated 5-30 days post stroke.
62475268|NCT03569059|EXPERIMENTAL|Delayed Robotic/VR Therapy (DVR)|Subjects in this group will receive state-of-art usual care therapy (inpatient and outpatient) plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated within 31-60 days post stroke.
62475269|NCT03569059|NO_INTERVENTION|Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care.
61920290|NCT04375475|ACTIVE_COMPARATOR|Bright Changyou lactobacillus flavored yogurt|Bright Changyou flavored yogurt contains probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum ST-Ⅲ (7mg/kg)
62120241|NCT05752513|PLACEBO_COMPARATOR|Group 1|18 pregnant women scheduled for classical cesarean hysterectomy for placenta accreta
62120242|NCT05752513|EXPERIMENTAL|Group 2|18 pregnant women scheduled for bladder last cesarean hysterectomy
62120243|NCT04740164|EXPERIMENTAL|Arm I (ERCP with LMA Gastro)|Patients undergo ERCP with LMA Gastro.
62475270|NCT03569059|EXPERIMENTAL|Dose-Matched Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care plus an extra hour of state-of-art usual care.
62475271|NCT05108467||Case|Severe sepsis with or without shock
62679026|NCT03737994|EXPERIMENTAL|MET amplification|Patients with MET amplification receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61920291|NCT04375475|ACTIVE_COMPARATOR|Bright flavored yogurt|Bright flavored yogurt contains Lactobacillus bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus casei LC2W (0.1 mg/kg)
62120244|NCT04740164|ACTIVE_COMPARATOR|Arm II (ERCP with standard nasal cannula)|Patients undergo ERCP with standard nasal cannula.
62120245|NCT01985269|ACTIVE_COMPARATOR|Home visits|Minimal physical examination at home Drug adherence/pill counts
62120246|NCT01985269|NO_INTERVENTION|Control|Normal standard of care
62139602|NCT02150616|PLACEBO_COMPARATOR|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
62475272|NCT05108467||Comparison|Severe dehydration with shock
62475273|NCT00985894|EXPERIMENTAL|Teledermatology|Online Telemedicine Group
62475274|NCT00985894|ACTIVE_COMPARATOR|Usual Care|Conventional in-office care
62120247|NCT01305733|ACTIVE_COMPARATOR|local infiltration analgesia|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
62120248|NCT01305733|PLACEBO_COMPARATOR|saline injection|The normal saline injection are used in the control group in the same manner than in the RKA group.
62120249|NCT00869817||1|Mutation Positive
62120250|NCT00869817||2|Mutation Negative
62308460|NCT02850198|SHAM_COMPARATOR|Sham scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. with shame electroacupuncture. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
62679027|NCT03737994|EXPERIMENTAL|No ALK-resistance mutations|Patients with no ALK-resistant mutations receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, ensartinib PO QD, or pemetrexed IV over 10 minutes on day 1 with or without either cisplatin IV or carboplatin IV on day 1. ALK inhibitor cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Pemetrexed-based treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance treatment of pemetrexed may continue until disease progression or unacceptable toxicity.
62679028|NCT03737994|EXPERIMENTAL|V1180|Patients with V1180 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62679029|NCT06695884|EXPERIMENTAL|Excitatory TMS|For condition 1a, 3600 pulses of 10-Hz TMS or 3600 pulses of cTBS. 10 Hz rTMS (110% RMT stimulation intensity; 10 Hz frequency; 5 s on and 26 s off; 3600 pulses per session; total duration of 40 min). cTBS (80% RMT, (3 pulses at 50 Hz with a repeated frequency of 5 Hz, 200 ms intervals, containing 1800 pulses, 60 second break, 1800 pulses; total duration of 5 minutes).
62120251|NCT06247085|EXPERIMENTAL|pegtibatinase|
62120252|NCT06247085|PLACEBO_COMPARATOR|placebo|
62120253|NCT06013878||Informal Caregivers|Informal caregivers who provide transfer assistance to an individual with a disability
62120254|NCT06013878||Individuals who use transfer assistance|Individuals who require assistance with transfers moving from one surface to the other
62679030|NCT06695884|EXPERIMENTAL|Inhibitory TMS|For condition 1b, 600 or 1200 pulses of iTBS. iTBS will be administered at 80% of each participant's RMT in a burst-firing pattern (3 pulses at 50 Hz) for a 2 s train, followed by an 8 s period of rest. Across sessions, participants will receive one of two iTBS protocols (randomized): 600 pulses (190 s) or 1200 pulses (570 s).
62120255|NCT00478738|OTHER|GSK961081|GSK961081
62120256|NCT05214924|EXPERIMENTAL|Injectable platelet-rich fibrin injection|Each of the participants from iPRF injection group will receive two injections of iPRF with an interval of 30 days.
61920292|NCT01639508|EXPERIMENTAL|Cabozantinib|This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion. Patients in GROUP D will have tumors with a RET fusion and have progressed on a selective RET TKI.
62475275|NCT03611608|EXPERIMENTAL|300 mg LY3316531 Dose 1|LY3316531 administered IV
62475276|NCT03611608|EXPERIMENTAL|LY3316531 Dose 2|"The optional additional cohort (Dose 2) was not implemented as the data desired for treatment effect on dermal blood flow (DBF) was generated at the initial Dose 1 (300mg LY3316531)~LY3316531 administered IV"
62475277|NCT03611608|PLACEBO_COMPARATOR|Placebo|Placebo administered IV
62475278|NCT03967938|EXPERIMENTAL|Olaparib|tablets of 300mg twice daily until disease progression
62475279|NCT01695538|EXPERIMENTAL|Yoga|Participants will be asked to practice yoga 3 days per week, at a minimum and encouraged to practice 7 days per week, for 1 year.
62475280|NCT03689595||Specimen Collection|"* Samples of blood (2-4 tablespoons) from 4 tubes will be collected~* Analysis will be performed on the blood to test for multiple myeloma precursor conditions."
62475281|NCT06558864|EXPERIMENTAL|Subiculum RF-TC group|SEEG recording and Subiculum RF-TC minimal invasive treatment for mTLE-HS
62120257|NCT05214924|ACTIVE_COMPARATOR|Platelet-rich plasma injection|Each of the participants from PRP injection group will receive two injections of PRP with an interval of 30 days.
62308461|NCT05460507|EXPERIMENTAL|Retreatment with Rhenium Liposome|Each participant will receive a single administration of 186RNL. The proposed dose is up to 8.8 mL as a single administration with an administered dose of 22.3 mCi.
62308462|NCT02641704||Multidisciplinary program|Multidisciplinary program designed and administered by the Competence- and Integration Center in Sonderborg Municipality
62308463|NCT02873546|ACTIVE_COMPARATOR|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
62308464|NCT02873546|SHAM_COMPARATOR|sham tDCS on left DLPFC (F3)|Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
62475282|NCT06331338|EXPERIMENTAL|New health education:use [Decision Cycle for Person-Centered Glycemic Management ]|It is a person-centered approach to care. Treatment goals and plans should be cotreated with people with diabetes based on their individual preferences, values, and goals.
62475283|NCT06331338|ACTIVE_COMPARATOR|Traditional diabetes self-management education|It is a educator-centered approach to care.
62475284|NCT00187720|EXPERIMENTAL|OCT2-variant Group|Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
62475285|NCT00187720|EXPERIMENTAL|OCT2-reference Group|Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.
62475286|NCT06264960|ACTIVE_COMPARATOR|Music therapy|After the patient was taken to the angiography laboratory, music was played using a digital MP3 player approximately 10 minutes before the angiography procedure began.
62475287|NCT06264960|ACTIVE_COMPARATOR|Breathing exercise|Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography
62475288|NCT06264960|NO_INTERVENTION|Control Group|All data collection steps were applied identically to the control group patients, except for music application and deep breathing exercises. All patients in the study group received the same routine care.
62475289|NCT00335348|EXPERIMENTAL|Bortezomib and Dexamethasone|
62679031|NCT02596893|EXPERIMENTAL|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
62475290|NCT06559111|EXPERIMENTAL|Bracing group|Participants in the bracing group had a cast for 2 weeks after the surgery followed by ankle brace for 4 weeks.
62475291|NCT06559111|ACTIVE_COMPARATOR|Casting group|Participants in the casting group had a cast for 6 weeks after the surgery.
62475292|NCT01031394|ACTIVE_COMPARATOR|Group 1|1 aerobic and 1 resistance training per week
62475293|NCT01031394|ACTIVE_COMPARATOR|Group 2|2 aerobic and 2 resistance training each per week
62475294|NCT01031394|ACTIVE_COMPARATOR|Group 3|3 aerobic and 3 resistance training per week
62475295|NCT06533345|EXPERIMENTAL|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment
62475296|NCT06533345|EXPERIMENTAL|Dry Needling|Dry Needling
62475297|NCT06533345|EXPERIMENTAL|Autonomic Recalibration|Autonomic Recalibration
62475298|NCT06533345|EXPERIMENTAL|Nutrition|Nutrition
62475299|NCT06533345|EXPERIMENTAL|Behavior Change Coaching|Behavior Change Coaching
62475300|NCT06533345|EXPERIMENTAL|Counseling Psychology|Counseling Psychology
62475301|NCT06533345|EXPERIMENTAL|Multiple|Multiple
62475302|NCT04437199|ACTIVE_COMPARATOR|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
62475303|NCT04437199|PLACEBO_COMPARATOR|AC-SD-03P|Placebo formulation, twice daily. Administered orally
62475304|NCT05315726|EXPERIMENTAL|Phase 1|
62475305|NCT05315726|EXPERIMENTAL|Phase 2: Intervention group|
62475306|NCT05315726|ACTIVE_COMPARATOR|Phase 2: control group|
62475307|NCT03016858|EXPERIMENTAL|NIIASV|undergoing Thoracoscopic Bullectomy Surgery under nonintubated intravenous anesthesia with spontaneous ventilation(NIIASV)
62120258|NCT02281838|EXPERIMENTAL|Target systolic BP <140mmHg|Systolic blood pressure will be reduced to \<140 mmHg within 1 hour of randomization.
62120259|NCT02281838|ACTIVE_COMPARATOR|Target systolic BP <180mmHg|Systolic blood pressure will be reduced, to \<180 mmHg within 1 hour of randomization.
62120260|NCT01147341|PLACEBO_COMPARATOR|placebo|Placebo (0.9% sodium chloride) given as 2 subcutaneous (sc) injections at weeks 0, 2, and 4, followed y 1 sc injection given an weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
62475308|NCT03016858|ACTIVE_COMPARATOR|IASLV|undergoing Thoracoscopic Bullectomy Surgery under intubated anesthesia with single-lung mechanical ventilation(IASLV)
61920293|NCT00266851|ACTIVE_COMPARATOR|Azithromycin|Active adjunctive treatment
61920294|NCT00266851|PLACEBO_COMPARATOR|Placebo|Adjunctive placebo
62308465|NCT01237548||All participants|Normal People who have smoked Water-pipe, at least once before.
61920295|NCT00266851|OTHER|Observational Cohort|Eligible participants who declined randomization, offered enrollment in parallel, open-label azithromycin treatment arm
62475309|NCT04972864|ACTIVE_COMPARATOR|Exercise training group|Individuals in the treatment group were given respiratory exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) and inspiratory muscle training with the Threshold IMT (T-IMT) device. Inspiratory muscle training was applied for 30 minutes, 3 times a day, 7 days a week for 6 weeks.
62139603|NCT04031365|EXPERIMENTAL|Acupuncture and Cognitive Behavioral Therapy|Participants will receive four sessions of a brief acupuncture therapy in addition to a brief cognitive behavioral therapy.
62475310|NCT04972864|PLACEBO_COMPARATOR|Control training group|Breathing exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) were taught in the control group and only the exercise link containing these exercises was sent.
62475311|NCT00305123||1|12,000 children 5 to 16 years of age attending the 4 public elementary schools in Djikoroni-para-Sébénikoro, Bamako, Mali.
62475312|NCT05613686|EXPERIMENTAL|contralateral 1Hz+ipsilateral iTBS 1|Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 1
62475313|NCT05613686|EXPERIMENTAL|contralateral 1Hz+ipsilateral iTBS 2|Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 2
62475314|NCT05613686|ACTIVE_COMPARATOR|contralateral 1Hz|Patients received contralateral 1 Hz and ipsilateral sham iTBS
62475315|NCT01528150||Accent MRI System|Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
62475316|NCT05301881|OTHER|Surgery, radiotherapy or radiofrequent ablation|The oligoprogresive lesion(s) will be treated with Surgery, radiotherapy or radiofrequent ablation depending on the location of the lesion. treatment will be standard of care and will be decided by the treating team of the patient.
61920296|NCT01843478|EXPERIMENTAL|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
61920297|NCT01843478|PLACEBO_COMPARATOR|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
61920298|NCT04767308|EXPERIMENTAL|Arm 1|"The tolerability and safety of CT125A cells will be assessed according to the 3+3 dose escalation design. There will be three dose levels, 1×10\^6, 2×10\^6, and 3×10\^6, CAR+T cells/kg. For each level, 1-3 subjects will be enrolled. If no dose limited toxicity (DLT) occurs, next level will be assessed for DLT. If DLT occurs in one subject, 3 more subjects will be enrolled in this cohort for the evaluation of DLT. If DLT occurs in ≤ 1/6 subjects, next level will be assessed for DLT. If DLT occurs in ≥ 2 subjects, no more subjects will be enrolled in this cohort and dose escalation will be canceled. For each cohort, following subjects can only receive CT125A infusion at least 14 days after the first subject received CT125A infusion. If DLT occurs in 2 subjects at Dose Level 1, whether to explore a lower dose will be determined by the investigator. After dose escalation phase is completed, the dose for extension phase will be determined based on safety and PK data."
61920299|NCT01214174|EXPERIMENTAL|Dose 1|513ug
61920300|NCT01214174|EXPERIMENTAL|Dose 2|776ug
62475317|NCT06333171|ACTIVE_COMPARATOR|Group A: 4-aminopyridine|dalfampridine (generic) 10 mg capsule po every 12 hours
62308466|NCT00745030|EXPERIMENTAL|1|Ramelteon (TAK-375) 8mg tablets
62308467|NCT00745030|PLACEBO_COMPARATOR|2|Placebo 8 mg tablets
62120261|NCT01147341|ACTIVE_COMPARATOR|active treatment with Cimzia|400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 0, 2, and 4, followed by 1 sc injection at weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
62120262|NCT04835181|EXPERIMENTAL|Electroacupuncture combined with umbilical moxibustion|
62308468|NCT06498271|EXPERIMENTAL|Experimental group|Personalized and automated digital coaching smartphone application
62120263|NCT04835181|ACTIVE_COMPARATOR|Electroacupuncture|
62120264|NCT06300489|EXPERIMENTAL|irinotecan liposomes+capecitabine+chemoradiotherapy|There are three dose groups inciuding wild-type (GG+6/6)，unit site mutant (GG+6/7 or GA+6/6) and double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)。Every group will receive irinotecan liposomes injection and capecitabine based chemoradiotherapy.
62120265|NCT01809392|EXPERIMENTAL|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
62120266|NCT01809392|NO_INTERVENTION|no decitabine|
62308469|NCT06498271|NO_INTERVENTION|Comparator group|Usual care
62308470|NCT03846362|EXPERIMENTAL|intermediate risk MRD2>0,1%|MRD2\>0,1% - FLA - MRD3 - HSCT
62308471|NCT00542347|ACTIVE_COMPARATOR|1|"* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
62308472|NCT00542347|ACTIVE_COMPARATOR|2|"* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
62475318|NCT06333171|PLACEBO_COMPARATOR|Group B: Placebo|Placebo-1 capsule po every 12 hours
62308473|NCT04302181|EXPERIMENTAL|Stellate Ganglion Block|One time administration of a stellate ganglion block
62679032|NCT02596893|EXPERIMENTAL|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
62475319|NCT01888523|EXPERIMENTAL|Everyday experiences writing|Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
62475320|NCT01888523|EXPERIMENTAL|Expressive writing|Involves logging in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
62475321|NCT02892747|EXPERIMENTAL|Educational Program for prevention of malnutrition|In addition to the usual nutritional assessment, the patients in the experimental arm benefit of a personalized educational program for prevention of malnutrition. This program aims to monitor energy and protein intake in addition to managing sodium intake, notably by offering personalized menu ideas and recipes.
62679033|NCT02596893|EXPERIMENTAL|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
61920301|NCT01214174|EXPERIMENTAL|Dose 3|1046ug
62308474|NCT02767570|EXPERIMENTAL|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback. The goal of the training is to encourage participants to adopt an altered foot progression angle in an attempt to alter the distribution of forces crossing the knee joint. Training will occur once a week for six weeks. This will be followed by a 46-week home and community-based walking program to practice and internalize the new personalized, gait pattern and to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to enhance internalization of the new foot progression angle.
62308475|NCT02767570|EXPERIMENTAL|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback. The goal of the training is to encourage participants to maintain a consistent foot progression angle in an attempt to minimize the variability in the forces crossing the knee joint. Training will occur once a week, for 6 weeks. This will be followed by a 46-week home and community-based walking program to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to maintain foot progression angle consistency.
62308476|NCT04872985|EXPERIMENTAL|Arm 1: Pyrotinib+ AC/EC followed by T|400 mg Pyrotinib orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 260mg/m2 nab-paclitaxel once every 3 weeks for 4 cycles, or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously). Pyrotinib starts with a dose of 240 mg once daily for one week, followed by 320 mg once daily for the next week, before transitioning to 400 mg once daily as maintenance therapy.
62308477|NCT04872985|PLACEBO_COMPARATOR|Arm 2: Placebo+ AC/EC followed by T|400 mg placebo orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 260mg/m2 nab-paclitaxel once every 3 weeks for 4 cycles, or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
62308478|NCT03565107||Female Patients|ICSI treatment because of male subfertility
62308479|NCT03320148|EXPERIMENTAL|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
62475322|NCT02892747|NO_INTERVENTION|Control|In the control arm, patients are followed-up by the cardiologist and the nutritionist, and did not benefit of the personalized educational program for prevention of malnutrition.
62475323|NCT04836598|ACTIVE_COMPARATOR|Multiport laparoscopic cholecystectomy|controlled group
62475324|NCT04836598|ACTIVE_COMPARATOR|Bikini line laparoscopic cholecystectomy|bikini line 2 ports
62475325|NCT06462066|EXPERIMENTAL|Glubran® Tiss|"The application of treatment will be performed by the Investigator that will be instructed for the application of Glutack/Glubran® Tiss 2 system.~Glutack® is a user-friendly device for the atraumatic laparoscopic fixation of hernia mesh. Providing precise and consistent delivery of Glubran® Tiss 2/Glubran® 2 with every pull of the trigger, to minimize surgical complications and the potential pain associated with the use of tacks and staples."
62475326|NCT06462066|ACTIVE_COMPARATOR|Glubran® 2|"The application of treatment will be performed by the Investigator that will be instructed for the application of Glutack/Glubran® 2 system.~Glutack® is a user-friendly device for the atraumatic laparoscopic fixation of hernia mesh. Providing precise and consistent delivery of Glubran® Tiss 2/Glubran® 2 with every pull of the trigger, to minimize surgical complications and the potential pain associated with the use of tacks and staples."
62475327|NCT00927069|EXPERIMENTAL|Group A|Patients who have shown an unsatisfactory response to 3 months of etanercept 50 mg twice a week without dose reduction prior to screening.
62679034|NCT02596893|PLACEBO_COMPARATOR|Placebo|Placebo once daily (QD) until the Week 52 Visit
62679035|NCT03673228|EXPERIMENTAL|Intervention Group|"Participants randomized to the Intervention Arm will receive counseling that includes:~* A Visit prior to discharge~* Follow up calls after discharge~* Text Messaging Support~* Caregiver Support"
62679036|NCT03673228|ACTIVE_COMPARATOR|Standard treatment|Patients will receive current usual care.
62475328|NCT00927069|EXPERIMENTAL|Group B|Patients who showed a satisfactory response to 3 months or more of etanercept 50 mg twice a week followed by a loss of response after dose reduction to 50 mg etanercept once a week prior to screening.
62475329|NCT00927069|EXPERIMENTAL|Group A dose increase at Week 12|Patients in group A who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
62475330|NCT00927069|EXPERIMENTAL|Group B dose increase at Week 12|Patients in group B who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
62475331|NCT06169605|EXPERIMENTAL|Patients with squamous cell carcinoma of the tongue and floor of the mouth|Intervention group
62475332|NCT04197492|EXPERIMENTAL|HSRT With Anlotinib|"* Hypofractionated stereotactic radiotherapy using CyberKnife 25Gy/5fx, 5 days a week for 1 week.~* Anlotinib once daily (12mg/d) orally administered on days 1-14 of a 21-day cycle until disease progression or treatment intolerance."
62475333|NCT03040362|EXPERIMENTAL|[14C]-lasmiditan|\[14C\]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
62475334|NCT02924363||Single arm (cardiac MRI & hematocrit blood sample)|Patients will undergo a pre- \& post- MitraClip procedure cardiac magnetic resonance imaging (CMR) scan with an FDA cleared MRI scanner and with or without an FDA approved contrast dye. The scan and the blood draw to assess the hematocrit is research, the MitraClip procedure is standard of care for these patients.
62475335|NCT02197481|ACTIVE_COMPARATOR|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
62475336|NCT02197481|EXPERIMENTAL|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
62308480|NCT03320148|ACTIVE_COMPARATOR|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, and prescribe medications and/or refer based on their assessment findings and patient preferences.
62308481|NCT05508568||Non-muscle invasive bladder cancer patients in follow-up|Patients with a previous diagnosis of non-muscle invasive bladder cancer, attending a urology clinic for the purposes of bladder cancer recurrence monitoring.
62308482|NCT05966701|EXPERIMENTAL|SSGJ-613|SSGJ-613，SC
62308483|NCT05966701|PLACEBO_COMPARATOR|Placebo|Placebo, SC
62475337|NCT01527006|EXPERIMENTAL|perampanel|Age Cohort 1 ( greater than or equal to 7 to less than 12 years of age at time of consent/assent) and age Cohort 2 ( greater than or equal to 2 to less than 7 years of age).
62475338|NCT03100422|EXPERIMENTAL|ARMin|Therapy with the arm therapy robot ARMin
62475339|NCT03100422|ACTIVE_COMPARATOR|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
62475340|NCT00709254|ACTIVE_COMPARATOR|Treatment Group A|Subjects received an i.v. dose of fentanyl (200 µg)
62475341|NCT00709254|EXPERIMENTAL|Treatment Group B|Subjects received a single dose of 3 mL AeroLEF (500 µg/1 mL)
62475342|NCT00709254|EXPERIMENTAL|Treatment Group C|Subjects received multiple doses of 3 mL AeroLEF (500 µg/1 mL) every 12 hours for a total of five doses over a 3 days
62308484|NCT06209697|ACTIVE_COMPARATOR|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months. Red clover capsules contained 40 mg of standardized red clover isoflavones in each capsule \[genistein (1 mg), daidzein (1 mg), biochanin A (23 mg) and biochanin B (formononetin, 15 mg)\].
62475343|NCT06366048||PHLF group|One group was defined as post-operative liver failure accroding to the PHLF definition of 50-50 criteria and ISGLS criteria.
62475344|NCT06366048||No PHLF group|One group was defined as no post-operative liver failure accroding to the PHLF definition of 50-50 criteria nor ISGLS criteria.
62475345|NCT03853954|EXPERIMENTAL|Methoxyflurane|Dosage form: inhalation Dosage: 3 mL methoxyflurane per inhaler, to be self-administered Frequency: maximum one inhaler (3 mL) per patient Duration: \<15 minutes
62475346|NCT00875550|ACTIVE_COMPARATOR|Dexmedetomidine Low Dose|
62475347|NCT00875550|ACTIVE_COMPARATOR|Dexmedetomidine High dose|
62475348|NCT03327805|EXPERIMENTAL|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 4 weeks prior to and during the testing period.
62475349|NCT03327805|PLACEBO_COMPARATOR|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 4 weeks prior to and during the testing period.
62475350|NCT03490058||Young women|Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
62475351|NCT05262985|OTHER|Treatment with Durvalumab+|Comparison of standard treatment verses the addition of Durvalomab to the standard protocol.
62475352|NCT05796869|NO_INTERVENTION|Control Group|"At the beginning of the study, data collection tools Personal Information Form, Premenstrual Syndrome Scale and Food Craving Scale will be applied to the control group.~No intervention will be made in the control group. Measurement tools will be applied for the post-test."
62475353|NCT05796869|EXPERIMENTAL|Experimental Group|All young women with a Premenstrual Syndrome Scale total score of 110 and above will be included in the study. Since all women who have a Premenstrual Syndrome Diagnostic Scale of 110 and above, volunteer to participate in the study and meet the inclusion criteria will be included in the study, no additional sample selection will be made. The application and control group will be determined on random.org among the group that constitutes the sample of the study. Laughter therapy sessions will be administered face to face to the application group once a week for 2 months by a researcher with a laughter therapy certificate. At the end of two months, the Personal Information Form, Premenstrual Syndrome Scale, and the Food Craving Scale will be administered again to both the application group and the control group.
62475354|NCT03115177|ACTIVE_COMPARATOR|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
62475355|NCT03115177|ACTIVE_COMPARATOR|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
62475356|NCT03839121||single arm: CRT-DX|
62475357|NCT03023956||ANF|anatomic neck fractures of proximal humerus
62475358|NCT03023956||SNF|surgical neck fractures of proximal humerus
62475359|NCT01400087|ACTIVE_COMPARATOR|Cap-attached Colonoscopy|
62475360|NCT01400087|PLACEBO_COMPARATOR|Regular colonoscopy|
61920302|NCT01110070|EXPERIMENTAL|ChonDux plus microfracture|
62120267|NCT01199575|EXPERIMENTAL|Revlimid + Rituximab|"A: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.~Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity."
62120268|NCT01667302|EXPERIMENTAL|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
62120269|NCT01813812|EXPERIMENTAL|DA-6034 45mg|two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
62120270|NCT01813812|EXPERIMENTAL|DA-6034 90mg|two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
62120271|NCT01813812|ACTIVE_COMPARATOR|Rebamipide 300mg|two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
62120272|NCT05865938||PASCAL-Group|M-TEER using MitraClip
62120273|NCT05865938||MitraClip-Group|M-TEER using PASCAL
62120274|NCT01092494||OC use|OC use after postoperative gonadotropin-releasing hormone agonist treatment
62475361|NCT00992147|EXPERIMENTAL|autologous cultured adipocytes|
62475362|NCT05278325|EXPERIMENTAL|Telephone Intervention|Two planned phone call by health care professionals after 8 and 16 weeks adjusting acute and preventive treatment
62475363|NCT05278325|NO_INTERVENTION|Business as usual|No planned phone calls
62475364|NCT00687063||A|
62475365|NCT01686451|EXPERIMENTAL|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
62475366|NCT01686451|ACTIVE_COMPARATOR|Simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
62475367|NCT06560749|EXPERIMENTAL|Intervention Group|The experimental group will be submitted to supervised training sessions, three times per week, for 12 weeks, of aerobics exercises, as well as treatment as usual (TAU)
62475368|NCT06560749|NO_INTERVENTION|Control Group|the control group will be submitted exclusively to treatment as usual (TAU)
62475369|NCT06053905||Asthmatic Child|Children with asthma between 6-11 years old
61920303|NCT01110070|ACTIVE_COMPARATOR|Microfracture|
62120275|NCT01092494||OC non-use|Only postoperative gonadotropin-releasing hormone agonist treatment
62120276|NCT01976936|EXPERIMENTAL|High Dose Lovastatin|High dose lovastatin (640 mg daily for three days) will be administered orally
61920304|NCT01997385|ACTIVE_COMPARATOR|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
62679037|NCT01008527|EXPERIMENTAL|Infusion and Peptide Administration|Patients get the study drug Oncovir poly IC:LC with or without CP 870-893. Up to 6 groups of 3 to 10 patients each will be treated in this study. The first group (between 3 and 6 patients) gets peptide vaccine with poly IC:LC. Second, third and fourth groups of 3 to 6 patients receive peptide vaccine with poly IC:LC and the antibody CP 870,893 at increasing doses from 0.01, 0.025 and 0.05 mg/kg. CP 870-893 will be given to 10 patients at a dose of 0.1 mg/kg to patients in the fifth group, and 0.2 mg/kg to the sixth group. The CP 870,893 will be given as an intravenous infusion over 30 minutes and will be given once every 2 weeks for the first 6 infusions. CP-870-893 will then be given every 4 to 6 weeks for 3 injections. The final 3 injections of CP 870,893 will be given every 8 to 12 weeks. These infusions will take place on weeks 1, 3, 5, 7, 9, 11, 17, 21, 25, 33, 41, and 53 for a total of 12 infusions.
61920305|NCT01997385|EXPERIMENTAL|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
61920306|NCT00470184|EXPERIMENTAL|Chemo|Oxaliplatin 85 mg/m2 will be administered IV on days 1, 15 and 29. Capecitabine 1250 mg/m2 will be administered in 2 divided daily doses P0 or via enteral tube, on radiation days only (Monday- Friday/ weekly). Capecitabine will be continued until the final dose of radiotherapy
62475370|NCT06053905||Healthy Controls Group|Healthy children between 6-11 years old
62679038|NCT03976323|EXPERIMENTAL|Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m\^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m\^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4).~If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21-day cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until progressive disease, physician decision or intolerable toxicity."
62679039|NCT03976323|ACTIVE_COMPARATOR|Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m\^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m\^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy. For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21 day-cycle for up to 31 cycles PLUS maintenance pemetrexed IV 500 mg/m\^2 on Day 1 of each 21-day cycle. In the Maintenance Phase, the participant continues to receive maintenance pemetrexed until progressive disease, physician decision or intolerable toxicity."
62475371|NCT01649167||Overweight/obesity|Pregnant women with overweight/obesity
62475372|NCT01649167||gestational diabetes|Pregnant women with gestational diabetes
61920307|NCT03345342|EXPERIMENTAL|PP1M: Transition Phase|Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
62120277|NCT01976936|ACTIVE_COMPARATOR|Low Dose Lovastatin|Lovastatin 80 mg daily for three days will be administered orally to patients who were taking statin therapy at the time of enrolment
62120278|NCT01976936|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally to patients who were NOT taking statin therapy at the time of enrolment
62120279|NCT02419261|ACTIVE_COMPARATOR|Adductor Canal Blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
62475373|NCT01649167||normal weight|Pregnant women with normal weight
62475374|NCT02622737|EXPERIMENTAL|Functional Training|Functional exercise training program
62475375|NCT02622737|EXPERIMENTAL|Stationary Bike|Stationary bike training program
61920308|NCT03345342|EXPERIMENTAL|PP1M/PP3M: Maintenance Phase|All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
62475376|NCT02622737|EXPERIMENTAL|Exergaming|Virtual Reality Exposure Therapy
62475377|NCT04865653|EXPERIMENTAL|Oral drinking solution of LSD base|Oral drinking solution of 0.1 mg LSD base in 96% ethanol
62679040|NCT06319274|EXPERIMENTAL|Iloprost|Patients randomized to active treatment (n=225 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
62679041|NCT06319274|PLACEBO_COMPARATOR|Isotonic saline|Patients randomized to placebo treatment (n=225 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
62308485|NCT06209697|PLACEBO_COMPARATOR|placebo|Placebo capsules were ordered to be prepared with the same color, taste and smell as the red cover capsules. Placebo capsules were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
62679042|NCT03021005|EXPERIMENTAL|Self Testing Kit|"This group will be provided a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the I Want The Kit website."
62679043|NCT03021005|NO_INTERVENTION|No Self Testing Kit|"This group will not receive a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will not receive referral cards for their partners or peers for them to request a free HIV self-testing kit from the I Want The Kit website."
62120280|NCT02419261|ACTIVE_COMPARATOR|Femoral Nerve Blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
62120281|NCT03637231|OTHER|Standard and ultra-low-dose CAC scoring|
62120282|NCT05827393|ACTIVE_COMPARATOR|group A|15 patients with large angle esotropia
62475378|NCT04865653|EXPERIMENTAL|Solid orodispersible film containing LSD base|Solid orodispersible film containing 0.1 mg LSD base
62120283|NCT05827393|ACTIVE_COMPARATOR|group B|15 patients with large angle exotropia
62120284|NCT03818204|EXPERIMENTAL|Experimental Group|"The purpose of the experimental group is to test the intervention. Participants will have their acuity measured (refraction as needed), slit lamp with Nafl \& NEI scale, visual functioning questionnaire (VFQ), cognitive assessment (MOCA).The eye lid will be prepped and video recorded.The masked clinical staff will then apply the polarized magnets and perform a number of measurements to ascertain effectiveness of intervention.~-Intervention - Magnetic Levator Prosthesis (MLP)"
62120285|NCT03818204|OTHER|Control/Normal Vision Group|"The purpose of the normal vision group is to test the experimental setup prior to enrolling ptosis patients. If the measurements of the normal vision group are found to be non-different to the experimental group, the data will be pooled.~-Intervention - Magnetic Levator Prosthesis (MLP)"
62475379|NCT04865653|EXPERIMENTAL|Oral drinking solution of LSD tartrate|Oral drinking solution of 0.146 mg LSD tartrate in water
62120286|NCT06271590|EXPERIMENTAL|MagicTouch Sirolimus-Coated Balloon (SCB)|Magic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold.
62308486|NCT05763940|EXPERIMENTAL|OmegaBoost (QD)|Participants assigned the study supplement OmegaBoost, taken once daily (QD).
62308487|NCT05763940|EXPERIMENTAL|OmegaBoost (BID)|Participants assigned the study supplement OmegaBoost, taken twice daily (BID).
62120287|NCT06271590|ACTIVE_COMPARATOR|Drug eluting stents (DES)|Everolimus eluting stents (EES) or Zotarolimus eluting stents (ZES)
62308488|NCT05763940|ACTIVE_COMPARATOR|Nature Made (soft gel)|Participants assigned the Nature Made (soft gel), taken twice daily.
62308489|NCT05763940|ACTIVE_COMPARATOR|Nature Made (gummy)|Participants assigned the Nature Made (gummy), taken twice daily.
62475380|NCT04865653|EXPERIMENTAL|Intravenous administration of LSD tartrate|Intravenous administration of 0.146 mg LSD tartrate in water
62475381|NCT04865653|PLACEBO_COMPARATOR|Placebo|Placebo for all formulations
62475382|NCT00915694|EXPERIMENTAL|Single arm|NFV-RT-Tem
62679044|NCT06582641|EXPERIMENTAL|Peer Group Connection - Middle School (PGC-MS)|
62679045|NCT06582641|NO_INTERVENTION|Class as usual|
62475383|NCT01468272|ACTIVE_COMPARATOR|reference treatment|Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
62475384|NCT01468272|EXPERIMENTAL|CHF 1535 NEXT DPI|CHF 1535 50/6 NEXT DPI
61920309|NCT03345342|EXPERIMENTAL|PP6M or Placebo: Double-Blind Phase|Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.
61920310|NCT03345342|EXPERIMENTAL|PP3M: Double-Blind Phase|Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.
61920311|NCT02573038|EXPERIMENTAL|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
61920312|NCT02238171||Chronic Obstructive Pulmonary Disease|
61920313|NCT01043900|PLACEBO_COMPARATOR|Sham rTMS|Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
61920314|NCT01043900|ACTIVE_COMPARATOR|Active rTMS|Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
61920315|NCT03680469|ACTIVE_COMPARATOR|standard early rehabilitation|The standard early rehabilitation program after acute stroke is an intervention regularly utilized in the stroke center of National Taiwan University Hospital.
61920316|NCT03680469|EXPERIMENTAL|adding early out-of-bed mobilization|The adding early out-of-bed mobilization treatment will be defined as the patients with acute ischemic stroke who receive out-of-bed mobilization treatment in addition to standard early rehabilitation care.
62308490|NCT02770287|EXPERIMENTAL|Venus Freeze Diamond Polar treatment|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
61920317|NCT01407042||mb-UKA|Patients with unicondylar osteoarthritis of the knee
61920318|NCT02923258|EXPERIMENTAL|Experimental|Concurrent Chemoradiotherapy With Docetaxel and IMRT
61920319|NCT02923258|ACTIVE_COMPARATOR|Control|Concurrent Chemoradiotherapy With Cisplatinum and IMRT
62308491|NCT01505062|EXPERIMENTAL|SAR421869 (Cohort 1)|Starting dose of SAR421869 given through one subretinal injection.
61920320|NCT04198818|EXPERIMENTAL|Dose escalation study of HH2710|to determine the MTD of HH2710 and/or Recommended Phase II dose (RP2D).
61920321|NCT01487577|EXPERIMENTAL|Mycophenolate mofetil|Pharmacokinetics-based targeting of mycophenolate mofetil
61920322|NCT00817284|EXPERIMENTAL|arm I|Bevacizumab + Irinotecan and concomitant radiotherapy
61920323|NCT00817284|EXPERIMENTAL|Arm II|Bevacizumab and Temozolomide and concomitant radiotherapy
61920324|NCT04807140|EXPERIMENTAL|Toripalimab|Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days
61920325|NCT04807140|EXPERIMENTAL|Toripalimab + Carboplatin+ Nab-paclitaxel|"* Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~* Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~* Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
61920326|NCT04256889|EXPERIMENTAL|nfant(R) feeding system|Addition of nfant(R) technology, along with visual assessments and cue-based feeding practices, to facilitate an infant's progression to full oral feeding and potentially improve developmentally supportive feeding practices.
61920327|NCT01439347|EXPERIMENTAL|Vincristine Sulfate Injection (VSI)|VSI dosed at 1.4 mg/m\^2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes.
62308492|NCT01505062|EXPERIMENTAL|SAR421869 (Cohort 2)|Escalating dose of SAR421869 given through one subretinal injection.
61920328|NCT01439347|EXPERIMENTAL|Marqibo|Marqibo dosed at 2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
62475385|NCT06368219|ACTIVE_COMPARATOR|midazolam- ketamine combination|- Group A: 25 patients will receive ketamine (0.5 mg/kg) plus midazolam (0.05 mg/kg
62475386|NCT06368219|ACTIVE_COMPARATOR|propofol- ketamine combination|- Group B: 25 patients will receive ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)(
61920329|NCT06073990|EXPERIMENTAL|Brief Behavioral Treatment for Insomnia (BBTi)|In the post-intervention group, the investigators collected data at the 1-week, 2-week, and 3-week marks following the intervention.
61920330|NCT02798614|ACTIVE_COMPARATOR|10-day cast|Removal of plaster cast 10 Days after reduction
61920331|NCT02798614|NO_INTERVENTION|1-month cast|Removal of plaster cast 1 month after reduction
61920332|NCT00595777|NO_INTERVENTION|1. Comparison|The centres allocated to the comparison group will continue to provide usual care only.
61920333|NCT00595777|EXPERIMENTAL|2. Experimental|The EPAT package consists of an educational programme, which deals with the common barriers to effective cancer pain control and the bedside pain tool.
61920334|NCT00371761|EXPERIMENTAL|PegIntron|PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
61920335|NCT00371761|ACTIVE_COMPARATOR|Adefovir|Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
61920336|NCT05210764||propofol|General anesthesia is induced and maintained mainly with propofol.
61920337|NCT05210764||sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
61920338|NCT05210764||ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
62308493|NCT01505062|EXPERIMENTAL|SAR421869 (Cohort 3)|Escalating dose of SAR421869 given through one subretinal injection.
62308494|NCT01505062|EXPERIMENTAL|SAR421869 (Cohort 4)|Maximum tolerated dose (MTD) of SAR421869 given through one subretinal injection.
62308495|NCT01505062|EXPERIMENTAL|SAR421869 (Cohort 5)|MTD of SAR421869 given through one subretinal injection.
62308496|NCT00447421|EXPERIMENTAL|A|
62679046|NCT05535244|EXPERIMENTAL|Cohort A1: Prior BCMA antibody-drug conjugate (ADC) or chimeric antigen receptor T (CAR-T)|Participants in Cohort A1 will be treated at the double step-up split dosing regimen.
62679047|NCT05535244|EXPERIMENTAL|Cohort A2: Prior BCMA Bispecific|Participants enrolled into exploratory Cohort A2 will receive the same dosing regimen as Cohort A1.
62679048|NCT05535244|EXPERIMENTAL|Cohort B1: Prior BCMA CAR-T|Participants enrolled in expansion Cohort B1, will be given cevostamab at the selected dosing regimen.
62679049|NCT05535244|EXPERIMENTAL|Cohort B2: Prior BCMA Bispecific|Expansion Cohort B2 will be opened, after the initial results from Cohort A2, at the same dose as per Cohort B1.
62679050|NCT05912166|EXPERIMENTAL|Wakeful Spanish|Wakeful Spanish is the Spanish-language version of Wakeful, developed at Northwestern University. It is a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs.
62679051|NCT06471998|EXPERIMENTAL|Localized Tissue Hydration with standard care|Localized tissue injections of saline in the routine management of pain and functional disability in patients with chronic common low back pain.
62679052|NCT04428281|EXPERIMENTAL|Cohort A1 RO7248824|Participants 5-12 years
62679053|NCT04428281|EXPERIMENTAL|Cohort A2 RO7248824|Participants 5-12 years
62679054|NCT04428281|EXPERIMENTAL|Cohort A3 RO7248824|Participants 5-12 years
62679055|NCT04428281|EXPERIMENTAL|Cohort A4 RO7248824|Participants 5-12 years
62679056|NCT04428281|EXPERIMENTAL|Cohort A5 RO7248824|Participants 5-12 years
62679057|NCT04428281|EXPERIMENTAL|Cohort B1 RO7248824|Participants 1-4 years
62679058|NCT04428281|EXPERIMENTAL|Cohort B2 RO7248824|Participants 1-4 years
62679059|NCT04428281|EXPERIMENTAL|Cohort B3 RO7248824|Participants 1-4 years
62475387|NCT02297763|ACTIVE_COMPARATOR|quetiapine|quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
62120288|NCT04562636|EXPERIMENTAL|Environment-focused Meatless Monday messages|Four environmental messages from the Meatless Monday campaign.
62475388|NCT02297763|PLACEBO_COMPARATOR|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
62679060|NCT04428281|EXPERIMENTAL|Cohort B4 RO7248824|Participants 1-4 years
62679061|NCT04428281|EXPERIMENTAL|Cohort B5 RO7248824|Participants 1-4 years
62679062|NCT04428281|EXPERIMENTAL|LTE: Cohort EA1 RO7248824|New participants (age 5-12) enrolling directly in the LTE part
62679063|NCT04428281|EXPERIMENTAL|LTE: Cohort EA2 RO7248824|Participants continuing from multiple ascending dose (MAD) cohorts A1 and A2
62679064|NCT04428281|EXPERIMENTAL|LTE: Cohort EA3 RO7248824|Participants continuing from MAD cohorts A3 and A4
62679065|NCT04428281|EXPERIMENTAL|LTE: Cohort EA4 RO7248824|Participants continuing from MAD Cohort A5
62679066|NCT04428281|EXPERIMENTAL|LTE: Cohort EB1 RO7248824|New participants (age 1-4) enrolling directly into the LTE
62679067|NCT04428281|EXPERIMENTAL|LTE: Cohort EB2 RO7248824|Participants continuing from MAD cohorts B1 and B2
62679068|NCT04428281|EXPERIMENTAL|LTE: Cohort EB3 RO7248824|Participants continuing from MAD cohorts B3 and B4
62679069|NCT04428281|EXPERIMENTAL|LTE: Cohort EB4 RO7248824|Participants continuing from MAD Cohort B5
62679070|NCT04428281|EXPERIMENTAL|OOE: RO7248824|Participants in the LTE part of the study will be given the opportunity to participate in the OOE part.
62679071|NCT05623020|EXPERIMENTAL|Part 1, Dose Level 1: Elranatamab + Daratumumab + Lenalidomide|
62679072|NCT05623020|EXPERIMENTAL|Part 1, Multiple Dose Levels, Elranatamab + Daratumumab + Lenalidomide|
62679073|NCT05623020|EXPERIMENTAL|Part 2 Randomized Arm A: Elranatamab + Daratumumab + Lenalidomide|
62679074|NCT05623020|ACTIVE_COMPARATOR|Part 2 Randomized Arm B: Daratumumab + Lenalidomide + Dexamethasone|
62679075|NCT05623020|EXPERIMENTAL|Part 1: Elranatamab + Lenalidomide|
62679076|NCT05623020|EXPERIMENTAL|Part 2: Randomized Arm A: Elranatamab + Lenalidomide|
62679077|NCT01468961|EXPERIMENTAL|Internet-based CBT|
62679078|NCT03812172||Blacks/Hispanics with Heart Failure|Blacks/Hispanics with heart failure due to transthyretin cardiac amyloidosis will be identified by 99mTc-PYP (or 99mTc-HDP) scintigraphy. Those with transthyretin cardiac amyloidosis will be further subtyped into those with a genetic cause (ATTRm) and those with a non-genetic cause (ATTRwt - wild type transthyretin cardiac amyloidosis).
61920339|NCT03579654|EXPERIMENTAL|Arm 1 - Proscavax vaccine treatment|In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.
61920340|NCT03579654|NO_INTERVENTION|Arm 2 - Active Surveillance|In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.
61920341|NCT01249118|EXPERIMENTAL|Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
61920342|NCT01249118|EXPERIMENTAL|Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
61920343|NCT01249118|EXPERIMENTAL|Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion|Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
61920344|NCT03583242||DME treat with antiangiogenic|"* 3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.~* 1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
62475389|NCT04012892|EXPERIMENTAL|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10\^4 cells/kg in 36-96 hours
62679079|NCT04103606|EXPERIMENTAL|immediate-use App group (iApp group)|Participants in the iApp group start using the app immediately (Time 0; T0) for 16 consecutive days (until Time 1; T1).
62120289|NCT04562636|EXPERIMENTAL|Health-focused Meatless Monday messages|Four health messages from the Meatless Monday campaign.
62120290|NCT04562636|OTHER|Neutral Message|Four neutral messages about checking one's credit score.
61920345|NCT03221075||Invasive Aspergillosis|
61920346|NCT04199598|EXPERIMENTAL|Treatment A (test product): Abediterol (2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
62120291|NCT04798248|EXPERIMENTAL|Momentary Affect Regulation - Safer Sex Intervention|Momentary Affect Regulation - Safer Sex Intervention (MARSSI) is the treatment condition. MARSSI aims to enhance an individual's motivation to change risk behaviors, provides skills to address depression's effects on behavior, and prompts and reinforces healthy affect regulation, cognitive behavioral skill use, and behavior change in daily life.
62120292|NCT04798248|SHAM_COMPARATOR|Podcast Health Group|The Podcast Health Group is the control counterfactual condition.
62120293|NCT02163876|EXPERIMENTAL|HuCNS-SC cells|Intramedullary transplantation of HuCNS-SC cells in the cervical spine
62120294|NCT02163876|NO_INTERVENTION|non-surgery arm|non-surgery arm
62120295|NCT02678091|EXPERIMENTAL|Patients|Patients with an orbital mass
62308497|NCT05652660|EXPERIMENTAL|Rosuvastatin with/without ARV-471|Rosuvastatin administered as a single dose in Period 1 and Period 2. ARV-471 administered as a single dose in Period 2.
62308498|NCT05863429||Individuals who have never been vaccinated against COVID-19|Individuals who have never been vaccinated against COVID-19 and who have applied to the study centers to be vaccinated with TURKOVAC within the scope of the routine vaccination program.
62475390|NCT05402202|EXPERIMENTAL|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
62475391|NCT05402202|ACTIVE_COMPARATOR|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment
62679080|NCT04103606|ACTIVE_COMPARATOR|delayed-use App group (dApp)|Participants in the dApp group start using the app at Time 1 (T1; 16 days after the iApp group) and use the app for the following 16 days (Time 2; T2).
62679081|NCT05379985|EXPERIMENTAL|Experimental: RMC-6236|"Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations.~Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, Melanoma, gynecological cancer or other solid tumors not previously specified).~RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)"
62679082|NCT06121635|EXPERIMENTAL|ts-DCS Group|Active ts-DCS and sham t-DCS will be applied simultaneously. 2mA intensity ts-DCS will be applied, with the active electrode being the cathode. The cathode will be placed the spinous process of T10 vertebral process, while the anode will be placed on the left deltoid. 2mA intensity t-DCS will be applied, with the active electrode being the anode. The International EEG 10/20 System will be used to electrode placement. The anode will be placed on the left M1, while the catode will be placed on the right supraorbital region. In the sham application, the placement of the electrodes will be the same as the active stimulation but It's will be stopped after 30 seconds. This sham procedure has been reported to be a good pseudostimulation method. ts-DCS and t-DCS will be administered using a stimulator (TCT Research Limited, Hong Kong). In both stimulations, 2 electrodes (35 cm2) immersed in saline solution will be used. The stimulations will be applied in 20 min sessions, 3 days/4 weeks.
62697315|NCT05006248|EXPERIMENTAL|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
62697316|NCT04605250|OTHER|Adults undergoing abdominal surgery with laparotomy|Respiratory variability before and after abdominal surgery
62697317|NCT06001255|EXPERIMENTAL|HS-20093|Participants will receive HS-20093 at 8 mg/kg.
62120296|NCT02401646|EXPERIMENTAL|Polygoni Multiflori Radix complex|Participants randomized to the experimental group will take one capsule of Polygoni Multiflori Radix complex extract (250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
62120297|NCT02401646|PLACEBO_COMPARATOR|Starch|Participants randomized to the placebo group will take one capsule of placebo(250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
62120298|NCT06555159|EXPERIMENTAL|Continuous aerobic physical exercise program with progressive intensity loads|Exercise prescription: jogging, swimming, and static cycling, three times a week with a duration of 60 minutes per exercise session with a progressive intensity, which will start at 57%-63% of the maximum heart rate (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks.
62120299|NCT06555159|ACTIVE_COMPARATOR|Continuous aerobic physical exercise|Intervention: Performing aerobic physical exercise: walking at 57% to 76% of HRmax.
62120300|NCT03151655|EXPERIMENTAL|MATTeRS Video|
62120301|NCT03151655|ACTIVE_COMPARATOR|Didactic Video|
62120302|NCT06315049|EXPERIMENTAL|Music therapy group|It is formed from all the participants in the study. They participated in the music therapy sessions.
62120303|NCT04352803|EXPERIMENTAL|Autologous Adipose Derived Mesenchymal Cells|Conventional treatment plus MSC's IV
62120304|NCT04352803|NO_INTERVENTION|Untreated|Conventional treatment only
62120305|NCT00971789|EXPERIMENTAL|Sirolimus Patients|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.
62120306|NCT00362869|EXPERIMENTAL|1|Dosage 1X10\^9 given orally in a sodium bicarbonate solution
62120307|NCT00362869|EXPERIMENTAL|2|Dosage 5X10\^9 given orally in a sodium bicarbonate solution
62120308|NCT00362869|PLACEBO_COMPARATOR|5|Sodium bicarbonate placebo solution
62120309|NCT00362869|EXPERIMENTAL|4|Dosage 5X10\^10 given orally in a sodium bicarbonate solution
62120310|NCT00362869|EXPERIMENTAL|3|Dosage 1X10\^10 given orally in a sodium bicarbonate solution
62120311|NCT06107582||Pediatric Primary Immune Thrombocytopenia|Immune thrombocytopenia (ITP) : defined according to the international working group criteria
62120312|NCT04496362|EXPERIMENTAL|subcutaneous heparin anticoagulation|Experimental arm
62120313|NCT04496362|NO_INTERVENTION|systemic intravenous anticoagulation|SOC arm
62308499|NCT05863429||Previously primary vaccinated individuals|"1. Those who have previously received two doses of Sinovac - Coronavac vaccine, who will receive the booster vaccine for the first time as TURKOVAC;~2. Those who have previously received two doses of the BioNTech Comirnaty vaccine, who will receive the booster vaccine for the first time as TURKOVAC;~3. Those who have previously received the primary vaccination of Sinovac - Coronavac Vaccine and who have received at least one dose of the booster vaccine of TURKOVAC and have accepted the second booster dose vaccination,~4. Individuals who have previously received the primary vaccination of the BioNTech Comirnaty Vaccine and who have received at least one dose of the booster vaccine of the TURKOVAC and who have agreed to the second booster dose vaccination."
62308500|NCT05863429||Individuals who have only received TURKOVAC vaccine before|Only individuals who have previously been vaccinated of TURKOVAC will also be invited to be included in the study retrospectively.
62120314|NCT00390299|EXPERIMENTAL|Arm A (resection cavity administration)|Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
62308501|NCT04073212|EXPERIMENTAL|Intervention 1 DN+HSLE|Patients in the intervention 1 Dry Needling (DN)+heavy Slow Load Exercise (HSLE) group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon followed by DN, HSLE and a standardized shoulder strengthening exercise program.
62308502|NCT04073212|ACTIVE_COMPARATOR|Intervention 2 Control|"Patients in the control group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon and a standardized exercise program. Dry needling nor heavy slow load exercise will not be integrated into the control plan of care."
62308503|NCT04910750|ACTIVE_COMPARATOR|Intervention Arm 1 - Pulse oximetry and Clinical Decision Support Algorithm|Facilities in intervention arm 1 will be provided with handheld pulse oximeters and tablet-based clinical decision support algorithms, with pulse oximetry, CDSA and IMCI refresher training
62308504|NCT04910750|ACTIVE_COMPARATOR|Intervention Arm 2 - Pulse oximetry alone|Facilities in intervention arm 2 will be provided with handheld pulse oximeters and paper-based guidance (pulse oximetry job aid and IMCI chart booklet integrating pulse oximetry), with pulse oximetry and IMCI refresher training
62308505|NCT04910750|NO_INTERVENTION|Control Arm - Routine Primary Health Care|Facilities in the control arm will be provided with IMCI refresher training
62120315|NCT00390299|EXPERIMENTAL|Arm B (intratumoral and resection cavity administration)|Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
62308506|NCT05429814|EXPERIMENTAL|Experimental|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
62308507|NCT05429814|NO_INTERVENTION|control group|control group will receive standard practice
62308508|NCT05528276|ACTIVE_COMPARATOR|standard Tubularized incised plate urethroplasty (sTIPU)|
62120316|NCT05832086|EXPERIMENTAL|Fasting Mimicking Diet|Intermittent fasting using a fasting mimicking diet
62120317|NCT05832086|PLACEBO_COMPARATOR|Standard Anti-Cancer Diet|Standard Anti-Cancer Diet
62120318|NCT02178020||knee arthroplasty, standard polyethylene|total knee arthroplasty with Standard Compression Molded tibial Polyethylene Liner
62120319|NCT02178020||knee arthroplasty, Highly Cross-Linked (XLP) polyethylene|knee arthroplasty with Highly Cross-Linked tibial Polyethylene Liner
62697318|NCT00583154|EXPERIMENTAL|1|BLI-801 Dose 1
62139604|NCT04031365|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Participants in this group will receive a brief cognitive behavioral therapy in addition to four telephone follow-ups.
62139605|NCT00644566|NO_INTERVENTION|TAU|Treatment as usual. These subjects and their providers were told to pursue treatment services as they normally would do.
62308509|NCT05528276|ACTIVE_COMPARATOR|Preputial inlay graft urethroplasty (PIGU)|
62308510|NCT04293848|EXPERIMENTAL|music with low-sinusoidal sound (vibrations)|Participants will listen to music and low-sinusoidal sound (vibroacoustic therapy).
62697319|NCT00583154|EXPERIMENTAL|2|BLI-801 Dose 2
62697320|NCT00583154|EXPERIMENTAL|3|BLI-801 Dose 3
62697321|NCT00583154|EXPERIMENTAL|4|BLI-801 Dose 4
62697322|NCT06640673||PD-MCI|Parkinson's disease with Mild Cognitive Impairment
61920347|NCT04199598|EXPERIMENTAL|Treatment B (Test Product): Abediterol (4.8 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
62120320|NCT05952206|EXPERIMENTAL|Angiolite and abbreviated DAPT|"Acute coronary syndrome patients:~* Need for OAC: TAT + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6 months.~* No need for OAC: DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1M. Only the same P2Y12 inhibitor up to 12M.~Chronic coronary syndrome patients:~* Need for OAC: TAT + clopidogrel + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.~* No need for OAC: DAPT with acetylsalicylic acid + clopidogrel for one month. Only clopidogrel up to 12M."
62139606|NCT00644566|EXPERIMENTAL|shared care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
62308511|NCT04293848|PLACEBO_COMPARATOR|Control Group|Participants will listen to music alone.
62308512|NCT00241111|OTHER|Zometa|
62308513|NCT00678496|EXPERIMENTAL|1|CBT software delivered at home or in a primary care facility (n=12)
61920348|NCT04199598|EXPERIMENTAL|Treatment C(Test Product):Abediterol(2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via OMRON NE-C900-E nebulizer following an overnight fast of at least 8 hours
62308514|NCT00678496|OTHER|2|Treatment as usual (n=12)
62308515|NCT04440241|EXPERIMENTAL|Test group|submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
62308516|NCT04440241|EXPERIMENTAL|Control group|non submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
62308517|NCT04964401|ACTIVE_COMPARATOR|Thoracic Paravertebral Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the thoracic 5 spinous process, the US-compatible needle will be advanced to the paravertebral area with in-plane technique, and 20 ml of 0.25% bupivacaine hydrochloride will be injected into this area.
62475392|NCT05705219|EXPERIMENTAL|3-dimensional multi-parametric ultrasound imaging (3D-MPUS)|Participants will receive sulfur hexafluoride IV and undergo 3D-MPUS imaging over 20 minutes.
62308518|NCT04964401|ACTIVE_COMPARATOR|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
62308519|NCT04649853||Acute Wounds|Patient with either traumatic or surgical wounds
62679083|NCT06121635|EXPERIMENTAL|t-DCS Group|Active t-DCS and sham ts-DCS will be applied simultaneously. 2mA intensity t-DCS will be applied, with the active electrode being the anode. The International EEG 10/20 System will be used to electrode placement. The anode will be placed on the left M1, while the catode will be placed on the right supraorbital region. 2mA intensity ts-DCS will be applied, with the active electrode being the cathode. The cathode will be placed the spinous process of T10 vertebral process, while the anode will be placed on the left deltoid. In the sham application, the placement of the electrodes will be the same as the active stimulation but It's will be stopped after 30 seconds. This sham procedure has been reported to be a good pseudostimulation method. ts-DCS and t-DCS will be administered using a stimulator (TCT Research Limited, Hong Kong). In both stimulations, 2 electrodes (35 cm2) immersed in saline solution will be used. The stimulations will be applied in 20 min sessions, 3 days/4 weeks.
62679084|NCT06121635|SHAM_COMPARATOR|Control Group|Sham ts-DCS and sham t-DCS will be applied simultaneously. 2mA intensity ts-DCS will be applied, with the active electrode being the cathode. The cathode will be placed the spinous process of T10 vertebral process, while the anode will be placed on the left deltoid. 2mA intensity t-DCS will be applied, with the active electrode being the anode. The International EEG 10/20 System will be used to electrode placement. The anode will be placed on the left M1, while the catode will be placed on the right supraorbital region. In both stimulations, the placement of the electrodes in Sham application will be the same as in active stimulation, but it will be stopped after 30 seconds. ts-DCS and t-DCS will be administered using a stimulator (TCT Research Limited, Hong Kong). In both stimulations, 2 electrodes (35 cm2) immersed in saline solution will be used. The stimulations will be applied in 20 min sessions, 3 days/4 weeks.
62679085|NCT06689696||POAG|primary open angle glaucoma (POAG) including normal tension glaucoma
62679086|NCT06689696||POAG suspect|status as POAG suspect including ocular hypertension (OHTN)
62120321|NCT05952206|EXPERIMENTAL|Xience stent family and abbreviated DAPT|"Acute coronary syndrome patients:~* Need for OAC: TAT + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.~* No need for OAC: DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Only the same P2Y12 inhibitor up to 12M.~Chronic coronary syndrome patients:~* Need for OAC: TAT + clopidogrel + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.~* No need for OAC: DAPT with acetylsalicylic acid + clopidogrel for one month. Only clopidogrel up to 12M."
62679087|NCT06689696||Healthy|no prior diagnosis of POAG/POAG suspect
62679088|NCT01715545||day-3 poor quality embryos|
62308520|NCT04649853||Chronic Wounds|Patient with chronic wounds either peripheral vascular disease related or surgical/traumatic wound
62308521|NCT04649853||Pressure Injuries Present on Admission|Patient admitted with one or more pressure injury of any stage on admission
62308522|NCT04649853||At Risk for Pressure Injury|Patient admitted with risk for pressure injury and has no pressure injuries at time of admission. Identified as at risk for based on mobility.
62308523|NCT06128941|EXPERIMENTAL|Normobaric hypoxia (SRH)|Participants will carry out training sessions in a normobaric hypoxia chamber at a simulated altitude of 3000 meters (FiO2 14.5%)
62308524|NCT06128941|EXPERIMENTAL|Hypoventilation (SRH-VLH)|Participants will be asked to exhale to residual functional capacity, immediately before starting each sprint, and to hold their breath until the end of the sprint
62308525|NCT06128941|ACTIVE_COMPARATOR|Normoxia (SRN)|Participants will carry out training sessions in normoxia (FiO2 20.9%)
62308526|NCT03463317|EXPERIMENTAL|LAA closure group|Left atrial appendage closure by use of CE-mark approved LAA closure devices followed by post procedure treatment (antiplatelet therapy e.g. acetylsalicylic acid, clopidogrel)
62308527|NCT03463317|ACTIVE_COMPARATOR|Best medical care group|No left atrial appendage closure. Treatment with best medical care (NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or VKA (phenprocoumon, warfarin)
62308528|NCT04092036||Unstable patients|Patients on mechanical ventilation, 18 years or older and developing hypotension (Mean arterial blood pressure) \<65 mmHg
62308529|NCT02053246|EXPERIMENTAL|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
62679089|NCT01715545||developmental stage|day3 poor quality embryos day4 morular day-5/6 blastocyst
62679090|NCT06695676||Patients on Lurasidone|Patient who are admitted by the psychiatry clinic of our center and meet the inclusion criteria
62679091|NCT05243017|EXPERIMENTAL|Cohort 1|Low dose AMT-130 (6 × 10\^12 gc/subject)
62679092|NCT05243017|EXPERIMENTAL|Cohort 2|High dose AMT-130 (6 × 10\^13 gc/subject)
62679093|NCT05243017|EXPERIMENTAL|Cohort 3|"Low dose AMT-130 (6 × 10\^12 gc/subject)~High dose AMT-130 (6 × 10\^13 gc/subject)"
62697323|NCT06640673||PD-nMCI|Parkinson's disease without Mild Cognitive Impairment
62697324|NCT06640673||Healthy control|Healthy participants matched for age and gender with the experimental groups
62308530|NCT03045380|EXPERIMENTAL|Game based rehabilitation|Game based rehabilitation will be administered once a week for 8 weeks.
62679094|NCT05556187|NO_INTERVENTION|Usual fixed oxygen dose|"* The oxygen dose will be as usual.~* The patient's activity level will be monitored using SENS.~* The patient will be asked to wear a wrist pulse oximeter to monitor pulse rate and saturation."
62475393|NCT00804856|EXPERIMENTAL|Phase I Schedule A. Volasertib 150 mg+LDAC|Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
62475394|NCT00804856|EXPERIMENTAL|Phase I Schedule A. Volasertib 200 mg+LDAC|Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
62475395|NCT00804856|EXPERIMENTAL|Phase I Schedule A. Volasertib 250 mg+LDAC|Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
61920349|NCT04199598|EXPERIMENTAL|Treatment D (Reference Product): Abediterol (2.5 μg)|Randomized subjects will receive single dose treatment of Abediterol (as napadisylate) inhalation powder via dry powder inhaler (DPI) following an overnight fast of at least 8 hours
61920350|NCT03407339|ACTIVE_COMPARATOR|Shared Oral Care Intervention|
61920351|NCT03407339|NO_INTERVENTION|Control|
61920352|NCT00719433|EXPERIMENTAL|1|
61920353|NCT00719433|ACTIVE_COMPARATOR|2|
62120322|NCT05952206|ACTIVE_COMPARATOR|Angiolite and standard of care DAPT|"Acute coronary syndrome patients:~* Need for OAC: Recommendations of the current ESC guideline: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~* No need for OAC: Recommendations of the current ESC guideline: DAPT with acetylsalicylic acid and prasugrel or ticagrelor is recommended up to 12M.~Chronic coronary syndrome:~* Need for OAC: Recommendations of the current ESC guidelines: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~* No need for OAC: Recommendations of the current ESC guidelines: DAPT composed of acetylsalicylic acid + clopidogrel up to 6M. Then, continue with acetylsalicylic acid."
62120323|NCT05952206|ACTIVE_COMPARATOR|Xience stent family and standard of care DAPT|"Acute coronary syndrome patients:~* Need for OAC: Recommendations of the current ESC guideline: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~* No need for OAC: Recommendations of the current ESC guideline: DAPT with acetylsalicylic acid and prasugrel or ticagrelor is recommended up to 12M.~Chronic coronary syndrome:~* Need for OAC: Recommendations of the current ESC guidelines: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~* No need for OAC: Recommendations of the current ESC guidelines: DAPT composed of acetylsalicylic acid + clopidogrel up to 6M. Then, continue with acetylsalicylic acid."
62120324|NCT04631744|EXPERIMENTAL|Cabozantinib Arm|
62697325|NCT03220633|EXPERIMENTAL|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
62697326|NCT03220633|PLACEBO_COMPARATOR|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
61920354|NCT01022723||Lung Cancer patients|Lung Cancer (particular focus on non smokers with adenocarcinoma)
61920355|NCT01022723||Patients with Nasopharyneal carcinoma|Patients with Nasopharyneal carcinoma
62308531|NCT03045380|ACTIVE_COMPARATOR|Conventional rehabilitation|Conventional physiotherapy program will be administered once a week for 8 weeks.
62475396|NCT00804856|EXPERIMENTAL|Phase I Schedule A. Volasertib 300 mg+LDAC|Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
62475397|NCT00804856|EXPERIMENTAL|Phase I Schedule A. Volasertib 350 mg+LDAC|Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
62475398|NCT00804856|EXPERIMENTAL|Phase I Schedule A. Volasertib 400 mg+LDAC|Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
62475399|NCT00804856|EXPERIMENTAL|Phase I Schedule B. Volasertib 150 mg|Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
62475400|NCT00804856|EXPERIMENTAL|Phase I Schedule B. Volasertib 200 mg|Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
62475401|NCT00804856|EXPERIMENTAL|Phase I Schedule B. Volasertib 350 mg|Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
61920356|NCT01022723||Breast Cancer patients|Breast cancer patients
61920357|NCT01022723||Prostate Cancer patients|Prostate cancer patients
62120325|NCT00493402|EXPERIMENTAL|combined chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.
62308532|NCT03045380|NO_INTERVENTION|No intervention|Waitlist
62308533|NCT04222621||Pregnant women|
62308534|NCT03548428|EXPERIMENTAL|A|SBRT + Atezolizumab
62308535|NCT03548428|ACTIVE_COMPARATOR|B|SBRT
61920358|NCT01022723||Colorectal Cancer patients|Colorectal cancer patients
61920359|NCT01022723||Gastric Cancer patients|Gastric cancer patients
61920360|NCT00955383|ACTIVE_COMPARATOR|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
61920361|NCT00955383|PLACEBO_COMPARATOR|Placebo|Matching placebo
62308536|NCT04194593||Glioma|FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)
62308537|NCT02312986|EXPERIMENTAL|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
62475402|NCT00804856|EXPERIMENTAL|Phase I Schedule B. Volasertib 400 mg|Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
61920362|NCT02457585|EXPERIMENTAL|experimental group|"anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).~evaluation of response at 30weeks by PET CT, acute phase reactants, symptom~No placebo group"
61920363|NCT03194490|EXPERIMENTAL|The combined intervention group|The combined intervention group will receive the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).
61920364|NCT03194490|ACTIVE_COMPARATOR|The standard intervention|The standard intervention group will receive cervical mobilization and home program (ROM exercises).
61920365|NCT04686487|OTHER|Stereotactic Ablative Radiotherapy|Stereotactic body radiation therapy delivered to the thick heart muscle at the point of obstruction
61920366|NCT05391971|EXPERIMENTAL|Stellate Ganglion Block (SGB) Group|
61920367|NCT05391971|PLACEBO_COMPARATOR|Control Group|
62120326|NCT00493402|EXPERIMENTAL|combined chemotherapy without embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.
62308538|NCT04673903|EXPERIMENTAL|Intervention group|"The intervention group will be instructed to include the Copenhagen adduction exercise into their warm up before training session (3 times per week) during one season (6 months).~The Copenhagen adduction exercise is a body-weight exercise which mainly works the groin and hip adductor. It has a large eccentric component, meaning the muscles are working whilst lengthening."
62308539|NCT04673903|ACTIVE_COMPARATOR|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
62308540|NCT02633111||Patients with aggressive B-cell Non-Hodgkin lymphoma|This is a non-therapeutic protocol aimed to assess the ability of Adaptive clonoSEQ® MRD assay to detect clinical relapse in DLBCLwhen compared to conventional approaches for detecting relapse such as patient-reported symptoms, clinical exams, and CT scans.
62308541|NCT00152256|EXPERIMENTAL|1|
62475403|NCT00804856|EXPERIMENTAL|Phase I Schedule B. Volasertib 450 mg|Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
62475404|NCT00804856|EXPERIMENTAL|Phase I Schedule B. Volasertib 500 mg|Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
62475405|NCT00804856|EXPERIMENTAL|Phase I Schedule B. Volasertib 550 mg|Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
62475406|NCT00804856|ACTIVE_COMPARATOR|Phase II Schedule C. LDAC|Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
62475407|NCT00804856|EXPERIMENTAL|Phase II Schedule A. Volasertib 350 mg+LDAC|Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
62475408|NCT01736878|EXPERIMENTAL|Sorafenib tablets|Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity
61920368|NCT02063971|EXPERIMENTAL|Skin aging|Anti-age product will be applied once a day, in the evening, on half face and neck for an uninterrupted period of 12 weeks and the placebo cream in the morning with the same modalities. On the contralateral face side (right or left side according to a previous randomisation list), the volunteers will apply the placebo cream twice a day
61920369|NCT06326970||99mTc-FAPI imaging in heart diseases|Participant involves patients with myocarditis, hypertension, arrhythmia, myocardial infarction, dilated cardiomyopathy, and cardiac tumors.
61920370|NCT02656212|EXPERIMENTAL|(+)-epicatechin 30mg|10 subjects will be randomized to a 30mg dose of synthetic (+)-epicatechin
61920371|NCT02656212|PLACEBO_COMPARATOR|placebo|5 subjects will be randomized to a placebo
61920372|NCT04644783|EXPERIMENTAL|Blood test with assays|10 participants with FPIES exhibiting reactions to more than 2 foods will be recruited.
61920373|NCT04132375|ACTIVE_COMPARATOR|Stage 1 - high treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F\[ab'\]2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).
61920374|NCT04132375|ACTIVE_COMPARATOR|Stage 1 - Low treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F\[ab'\]2 fragments) and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
61920375|NCT04132375|PLACEBO_COMPARATOR|Stage 1 - Placebo arm|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
62120327|NCT00493402|EXPERIMENTAL|single agent chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
62120328|NCT03942835|EXPERIMENTAL|Healthy participants aged from 6 to 90 year-old|
62120329|NCT03942835|EXPERIMENTAL|patients with ADHD with no treatment|patients with ADHD aged from 6 to 90 year-old with no treatment
62308542|NCT00152256|EXPERIMENTAL|2|
62308543|NCT00152256|PLACEBO_COMPARATOR|3|
62308544|NCT00077233|ACTIVE_COMPARATOR|Arm A: FOLFIRI|Patients receive irinotecan 180 mg/m\^2 over 90 minutes on day 1, then leucovorin 400 mg/m\^2 over 2 hours followed by 5FU 400 mg/m\^2 IV bolus injection then 5FU 2400 mg/m\^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. One cycle of therapy is 8 weeks.
62308545|NCT00077233|EXPERIMENTAL|Arm B: FOLFIRI + C225|Patients receive irinotecan 180 mg/m\^2 over 90 minutes, then leucovorin 400 mg/m\^2 IV over 2 hours followed by 5FU 400 mg/m\^2 IV bolus injection then 5FU 2400 mg/m\^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. Patients also receive cetuximab 400 mg/m\^2 IV over 120 minutes day 1, then 250 mg/m\^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
62679095|NCT05556187|EXPERIMENTAL|Automated oxygen titration|"* The O2matic equipment will be installed in the home of the patients. The SpO2-target will be set at 90-94%~* The patient's activity level will be monitored using SENS.~* The patient will be asked to wear a wrist pulse oximeter to monitor pulse rate and saturation and send the information to O2matic. O2matic will adjust the oxygen flow between 0.5-8 l/min according to the algorithm in the devise aiming at the SpO2-target interval.~* The patients will use their usual portable oxygen devises for use when being active outdoor. They are allowed a higher oxygenflow if needed."
62120330|NCT03942835|EXPERIMENTAL|patients with ADHD with treatment|patients with ADHD aged from 6 to 90 year-old with psychostimulant treatment (Methylphenidate)
62120331|NCT03705442|PLACEBO_COMPARATOR|Placebo|Placebo
62120332|NCT03705442|EXPERIMENTAL|Probiotics|Omni-Biotic 10
62308546|NCT00077233|ACTIVE_COMPARATOR|Arm C: FOLFOX|Patients receive oxaliplatin 85 mg/m\^2 IV infused over 120 minutes, then leucovorin 400 mg/m\^2 IV over 2 hours followed by 5 FU 400 mg/m\^2 IV bolus injection then 5 FU 2400 mg/m\^2 continuous IV infusion over 46-48 hours every 2 weeks.
62339586|NCT02428452|NO_INTERVENTION|Control|Participants randomized to the Control group do not receive the Social ABCs parent training program for the 6-month control phase. Control participants may access other approved community services as outlined in the study protocol and consent during the Control Phase, which is considered 'treatment as usual'. After the 6-month Control Phase, participants are offered the Social ABCs parent training program.
62679096|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
62679097|NCT06233461|EXPERIMENTAL|TAK-279 Dose 1|Participants will be randomized to receive TAK-279 Dose 1 capsules with TAK-279 placebo-matching capsule orally.
62679098|NCT06233461|EXPERIMENTAL|TAK-279 Dose 2|Participants will be randomized to receive TAK-279 Dose 2 capsules with TAK-279 placebo-matching capsule orally.
62679099|NCT06233461|EXPERIMENTAL|TAK-279 Dose 3|Participants will be randomized to receive TAK-279 Dose 3 capsules orally.
62679100|NCT06233461|EXPERIMENTAL|Placebo|Participants will be randomized to receive TAK-279 placebo-matching capsules orally.
62679101|NCT04818086|ACTIVE_COMPARATOR|Lemborexant Arm|Study Drug Dosage: 5 mg of lemborexant (Time 1) , and 10 mg of lemborexant (Time 2) combined with 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
62308547|NCT00077233|EXPERIMENTAL|Arm D: FOLFOX + C225|Patients receive oxaliplatin 85 mg/m\^2 IV infused over 120 minutes, then leucovorin 400 mg/m\^2 over 2 hours followed by 5 FU 400 mg/m\^2 IV bolus injection then 5 FU 2400 mg/m\^2 continuous IV infusion over 46-48 hours every 2 weeks. Patients also receive cetuximab 400 mg/m\^2 IV over 120 minutes day 1, then 250 mg/m\^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
62679102|NCT04818086|PLACEBO_COMPARATOR|Placebo Arm|Comparative placebo combined with 16 mg/4 mg of buprenorphine-naloxone sublingually as a film (at both Time 1 and Time 2)
62308548|NCT05294042|EXPERIMENTAL|Paraprofessional Navigation Condition|Paraprofessional Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
62308549|NCT05294042|NO_INTERVENTION|Wait-List as Usual|Participants will be assigned as wait-list as usual (active wait list) at each agency.
62475409|NCT01736878|PLACEBO_COMPARATOR|Placebo tablets|Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator
62475410|NCT04290858|EXPERIMENTAL|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
62679103|NCT05630053|ACTIVE_COMPARATOR|Cementless Persona Keel Knee System|Persona PPS CoCr Cementless Femur and Persona OsseoTi Keel Cementless Tibia
62679104|NCT05630053|ACTIVE_COMPARATOR|Cemented Persona Keel Knee System|Persona Keel Cemented Tibia
62679105|NCT04093882||Cognitive normal|Individuals who do not show clinical or neuropsychological deficits.
62679106|NCT04093882||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
62679107|NCT04093882||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
62120333|NCT05678972|EXPERIMENTAL|Mindfulness group|Participants in the mindfulness group will be expected to complete a self-help online mindfulness-based intervention, delivered over a 4-week period via an e-learning mental health platform. They will be assessed at three different time points: (1) before the intervention (pre-test assessment), (2) right after the 4-week intervention (post-test assessment), and (3) four weeks after the intervention (follow-up assessment).
62120334|NCT05678972|NO_INTERVENTION|Waitlist control group|The participants in waitlist control group will be offered access to the online mindfulness course after the study has ended.
62120335|NCT03314675|OTHER|CRT-D Measurements|Pre-specified measurements and additional follow-ups
62308550|NCT01040832|EXPERIMENTAL|Cetuximab plus EMD 1201081|
62308551|NCT01040832|ACTIVE_COMPARATOR|Cetuximab monotherapy|
62308552|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
62679108|NCT04082689|ACTIVE_COMPARATOR|Assisted Infant Toilet Training-Group A|"Parents to Children randomized to group A will be instructed in how infant toilet training is performed by the investigators. They receive a book in Swedish concerning infant toilet training and a brief summary of the book made by the investigators. The parents are encouraged to begin infant toilet training as early as possible, 0-2 months of age~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
62679109|NCT04082689|ACTIVE_COMPARATOR|Assisted Infant Toilet Training- Group B|"Parents to Children randomized to group B will be instructed in how infant toilet training is performed by the co-workers doing the ultrasound measure of rectal diameter at 9 months. They receive a book in Swedish concerning infant toilet training and a brief summary of it made by the investigators. They start infant toilet training at the age of 10-11 months.~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
62679110|NCT06393985|EXPERIMENTAL|Decitabine,venetoclax and blinatumomab|
62679111|NCT06209086|ACTIVE_COMPARATOR|incisal capped twin block|"The incisal capped Twin Block, which was used for the first group composed of two parts. The upper part had labial bow over labial surface of upper anterior teeth using Adam and ball clasps for retention.~The lower part included ball clasp between lower anterior teeth and Adam clasp on lower first premolar with the additional modifications:~* The lower incisors were capped with acryl.~* lower incisors were relieved from the lingual side with wax."
62697327|NCT06062472|EXPERIMENTAL|Probiotics|Probiotic capsules contain 10 billion CFU (colony forming units) of Lactobacillus paracasei, 2 caps daily use
62120336|NCT01972763|ACTIVE_COMPARATOR|Ranibizumab 1 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 1), patients will receive 1 mg of Ranibizumab monthly for the remainder of the study, if persistent or worse subretinal fluid with or without intraretinal cysts on SD-OCT is present.
62475411|NCT04290858|NO_INTERVENTION|Control|The control group will receive the standard of treatment without any active, placebo or sham Comparator.
62308553|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
62679112|NCT06209086|ACTIVE_COMPARATOR|skeletal anchored twin block|"This appliance was constructed as the modified Twin Block used for the incisal capped appliance in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally."
62679113|NCT06694298|EXPERIMENTAL|SYS6020|
62679114|NCT05975125|EXPERIMENTAL|Iron supplement with Vitamin C|"Vitamin C with Iron supplement~Drug:~Vitamin C 500mg Triferdine(Component: Iodine 0.15 mg, Iron 60.81 mg, Folic acid 0.4 mg)"
62679115|NCT05975125|NO_INTERVENTION|Iron supplementation alone|Iron supplement alone Drug: Triferdine Component: Iodine 0.15 mg, Iron 60.81 mg, Folic acid 0.4 mg
62679116|NCT02705820|EXPERIMENTAL|single arm study|experimental treatment with maintenance pembrolizumab
62679117|NCT04669093|EXPERIMENTAL|Placebo|All participants will participate in two sessions, one with a placebo suggestion that matches the participant's motivational style, and one with placebo suggestion that does not match their motivational style, in a pseudo-random order.
62679118|NCT04669093|EXPERIMENTAL|Control|Each session will also include a control phase, in which the same cream will be applied, and participants will be instructed that the cream has no analgesic effects.
62679119|NCT04967274|EXPERIMENTAL|Spinal cord injured subjects|
62679120|NCT02470871|EXPERIMENTAL|Low-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa \[activated\] \[ie, comparator drug 1\] or pdFVII \[ie, comparator drug 2\]), followed by a single dose of CSL689 at the low dose
62679121|NCT02470871|EXPERIMENTAL|High-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa \[activated\] \[ie, comparator drug 1\] or pdFVII \[ie, comparator drug 2\]), followed by a single dose of CSL689 at the high dose.
62475412|NCT06559514|EXPERIMENTAL|Group-based multi-component psycho-educational inventions (GMC-PEIs)|Group-based multi-component psycho-educational interventions. The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
62308554|NCT03682588|EXPERIMENTAL|Functional exercise group|Functional exercise program with 14 exercises, two times/week, during 14 weeks. Two sets of 10 repetitions each, with 30 seconds interval.
62308555|NCT03682588|ACTIVE_COMPARATOR|Stretching exercise group|Stretching exercise program with 17 exercises, two times/week, during 14 weeks and each movement was repeated by three times and held for 20 seconds each
62308556|NCT01275248|EXPERIMENTAL|Ondansetron 0.5 mg|Ondansetron oral tablet 0.5 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
62308557|NCT01275248|EXPERIMENTAL|Ondansetron 0.75 mg|Ondansetron oral tablet 0.75 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
62475413|NCT06559514|NO_INTERVENTION|Controls group|Waitlist control group
62495884|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:~1. Prolonged mechanical ventilation (longer than 96 hours)~2. Tracheostomy~3. Sepsis~4. Serious injury (burn)~5. Stroke (hemorhagic or ischemic)~6. Traumatic brain injury"
62308558|NCT01275248|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
62308559|NCT04883073|EXPERIMENTAL|Endo App use|use of Endo App during trial
62308560|NCT04883073|NO_INTERVENTION|control|no use of Endo App during trial
62308561|NCT04654325|OTHER|Patients attending to the COVID19 screening facility|Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan
62495885|NCT03390257|EXPERIMENTAL|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
62495886|NCT04182555|EXPERIMENTAL|Newborns in St.Olavs Hospital and Haugesund Hospital|All newborns will be examined through 4 different methods of determining jaundice.
62679122|NCT06041828|EXPERIMENTAL|Study group|Standard oral hygiene and Lumoral Treatment home-use
62679123|NCT06041828|ACTIVE_COMPARATOR|Control group|Standard oral hygiene only
62679124|NCT06425731|EXPERIMENTAL|Dance for PD (in-person)|Participants will engage in Dance for PD classes in-person in their usual fashion, and within a group-based setting, for a total of three sessions. Oxygen uptake, heart rate and perceived exertion will be measured throughout specific Dance for PD classes.
62679125|NCT06425731|EXPERIMENTAL|Dance for PD (virtual/remote)|Participants will engage in Dance for PD classes online in their usual fashion, and within a group-based setting, for a total of two sessions. Heart rate and perceived exertion will be measured throughout the Dance for PD classes.
62679126|NCT03495895|EXPERIMENTAL|Minding the Baby|Families are visited weekly beginning in the mother's third trimester of pregnancy up through the child's first birthday, at which point visits take place biweekly up through the child's second birthday.
62679127|NCT03495895|OTHER|Control|Usual care control condition. Families in the control Group receive the usual care that is offered to families in the target group
62679128|NCT02065804|EXPERIMENTAL|Active drug|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
62679129|NCT02065804|PLACEBO_COMPARATOR|Placebo|10 ml of normal saline deposited by ultra-sound guidance around the spermatic cord
62697328|NCT06062472|EXPERIMENTAL|Heat-Treated Probiotics|heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
62308562|NCT06046508||Sigle arm study|Patients with migraine headache with aura (MHA), patent foramen ovale (PFO) and previous neurological event (transient ischemic attack -TIA- or stroke) with clinical indication for percutaneous correction of the defect according to guidelines will be enrolled
62308563|NCT06672250||experimental|a thrombosis patient with cancer .
62308564|NCT06672250||control|a thrombosis patient without cancer
62308565|NCT05914753|EXPERIMENTAL|Experimental group|Experimental group: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
62308566|NCT05914753|PLACEBO_COMPARATOR|Control group|Control group: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
62308567|NCT04155385|ACTIVE_COMPARATOR|Measurement-only|Patients will complete weekly measures of treatment progress and goals; however, the information from these measures will not be shared with clinicians or patients.
62308568|NCT04155385|EXPERIMENTAL|Measurement and feedback|Patients will complete weekly measures of treatment progress and goals; the information from these measures will be shared with clinicians.
62308569|NCT04701086|EXPERIMENTAL|Cationorm Pro|Cationorm Pro is an ophthalmic sterile unpreserved eye drops emulsion (N=40) Posology: One Drop in each eye 4 times daily for 84 days
62120337|NCT01972763|ACTIVE_COMPARATOR|Ranibizumab 0.5 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 2), patients will receive 0.5 mg of Ranibizumab monthly for the remainder of the study, if complete resolution of subretinal fluid on SD-OCT is present.
62308570|NCT04701086|ACTIVE_COMPARATOR|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
62308571|NCT05888337||Contoura LASIK with Phorcides planning strategy|
62475414|NCT02253420|EXPERIMENTAL|Copanlisib with and without concomitant Itraconazole (Arm A)|"To evaluate the effect of Itraconazole on the pharmacokinetics of Copanlisib (BAY80-6946) and safety in patients with advanced solid tumor. Cycle 1 of the study will be conducted in 2 parts: Part 1 and part 2:~* Part 1 of Cycle 1: 6 patients will be enrolled and will receive 12 mg of copanlisib on Day 1 and Day 15. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~* Part 2 of Cycle 1: 20 patients will be enrolled and receive copanlisib doses of either 12 mg, 30 mg or 60 mg on Days 1 and 15 with the same dose administered on both days. Copanlisib dose for Part 2 will be based on safety and copanlisib pharmacokinetics in Part 1. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~* Cycle 2 and subsequent cycles: All patients will receive copanlisib doses of 60 mg on Days 1, 8 and 15."
62475415|NCT02253420|EXPERIMENTAL|Copanlisib with and without concomitant Rifampin (Arm B)|"To evaluate the effect of Rifampin on the pharmacokinetics of Copanlisib (BAY 80-6946) and safety in patients with advanced solid tumor or non-Hodgkin's lymphoma in Cycle 1. Approximately 30 subjects will receive 60mg of copanlisib on Cycle 1 Day 1 and Cycle 1 Day 15. Rifampin will be administered once a day from Cycle 1 Day 10 to Day 21. Holter monitoring will be performed on Cycle 1 Day -1 and Cycle 1 Day 1 to evaluate the effect of copanlisib on the QT/QTc assessment.~Cycle 2 and subsequent cycles, all patients will receive copanlisib dose of 60 mg on Days 1, 8 and 15. Holter monitoring will be performed on Cycle 3 Day 1 and Cycle 6 Day 1."
62475416|NCT01488058|OTHER|Group 2|Waitlist control
62120338|NCT00855686|EXPERIMENTAL|Memantine|
62120339|NCT00855686|PLACEBO_COMPARATOR|Placebo|
62120340|NCT06277401|EXPERIMENTAL|Intervention|Progressive high-load resistance training program performed twice weekly for 12 weeks
62120341|NCT06277401|ACTIVE_COMPARATOR|Standard care|The standard care group will receive instructions on a neuromuscular training program with focus on knee stability and function performed at low intensities to be conducted twice weekly for 12 weeks
62308572|NCT05888337||Contoura LASIK with manifest refraction planning strategy|
62308573|NCT03830138||Acute coronary syndrome patients:|One hundred patients with acute coronary syndrome.
62308574|NCT03830138||Controls:|Fifty healthy control
62308575|NCT02729961|EXPERIMENTAL|Treatment (brentuximab vedotin, ceritinib)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive ceritinib PO QD on days 8-21 of course 1 and on days 1-21 for all subsequent courses. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62308576|NCT03676309|PLACEBO_COMPARATOR|placebo|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
62308577|NCT03676309|ACTIVE_COMPARATOR|nutraceutical oral capsule|nutraceutical oral capsule 920 mg twice a day for 12 weeks
62308578|NCT01210937|EXPERIMENTAL|CEA and TCD monitoring|CEA involves a neck incision and physical removal of the plaque from the inside of the artery.During the surgery, the patient will be monitored by TCD.
62308579|NCT03040583||ASSESS (PHRC) patients|Primary Sjögren's Syndrome Patients who have already participated to the study ASSESS
62308580|NCT06340594||Group A (ERCP 1st approach)|The patients first underwent ERCP followed by standard 4 port LC.
62308581|NCT06340594||Group B (LC 1st approach)|The patients first underwent LC followed by ERCP.
62308582|NCT01733706|ACTIVE_COMPARATOR|Standard counseling|a psychologist will provide standard counseling
62308583|NCT01733706|EXPERIMENTAL|No nicotine electronic cigarette|patients will receive standard counseling as well as an electronic cigarette
62308584|NCT01912040||Patients|Administration of 123Iodine MIBG to the patients referred .
62475417|NCT01488058|EXPERIMENTAL|Group 1|CBM intervention (OxIGen) plus Internet based Cognitive Behavioural Therapy for depression
62679130|NCT06450171|EXPERIMENTAL|Galleri MCED Test|"Participants will be enrolled and will complete:~* Baseline questionnaires and blood test.~* Post-test questionnaires.~* Follow-up assessments for a negative GRAIL Galleri test include recommended cancer screenings and a follow up phone call with study staff 1 year after the GRAIL Galleri blood test.~* Follow-up assessments for a positive GRAIL test may include clinic visits, lab tests with additional blood work-ups, biopsies, surgical procedures, or imaging assessments such as ultrasound, Computed Tomography (CT) scans, or an Magnetic Resonance Imaging (MRI) scans.~* If cancer status is confirmed, participants will complete a post-diagnostic questionnaire."
62679131|NCT04484662|OTHER|Potted Mint Plants Intervention|We will measure 2 indoor environments (living room and bedroom) for placing potted plants. We will analyze the effect of potted mint plants on indoor air quality, fungal and bacterial concentration, and explore the correlation between the intervention of potted mint plants and cardiovascular health.
62120342|NCT00006505|EXPERIMENTAL|Transplant|Islet cell transplantation
62120343|NCT01323777|EXPERIMENTAL|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
62120344|NCT03547479|NO_INTERVENTION|Control|Participants receive current standard of care (DOTS)
62679132|NCT02243826|EXPERIMENTAL|N20|One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure.
62679133|NCT02243826|OTHER|compressed air|The second group will inhale compressed air during the same period of time
62120345|NCT03547479|EXPERIMENTAL|VDOT only|Participants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
62120346|NCT03547479|EXPERIMENTAL|VDOT + mobile money incentives|Participants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
62120347|NCT01707758||pancreatic cancer|This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
62120348|NCT03285685|EXPERIMENTAL|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
62120349|NCT03285685|EXPERIMENTAL|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
62120350|NCT03285685|SHAM_COMPARATOR|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
62679134|NCT05785767|EXPERIMENTAL|A: fianlimab+cemiplimab|Phase 2: fianlimab (HD) Phase 3: fianlimab (chosen dose)
62308585|NCT02817438|EXPERIMENTAL|Online Intervention|Participants randomized to the online intervention arm will be given access to the Good Days Ahead program for 12 weeks.
62679135|NCT05785767|EXPERIMENTAL|B: fianlimab+cemiplimab|Phase 2: fianlimab (LD) Phase 3: fianlimab (chosen dose)
62679136|NCT05785767|EXPERIMENTAL|C: cemiplimab monotherapy+placebo|Phase 2 and Phase 3
62679137|NCT02660346|ACTIVE_COMPARATOR|Group A - Daptomycin or Vancomycin|Standard of Therapy of physician's choice, usually daptomycin 6-8 mg/kg IVPB daily or vancomycin IVPB adjusted dose per site protocol with a goal vancomycin trough level: 15-20 mcg/mL.
62679138|NCT02660346|EXPERIMENTAL|Group B - Daptomycin with Ceftaroline|Daptomycin (6-8 mg/kg/day IVPB daily) with Ceftaroline (600 mg IVPB q8hr) to start within 72hrs of hospital admission. Daptomycin will be renally adjusted per package insert. Ceftaroline will be renally adjusted per institutional renal dosing recommendations for Q8h.
62679139|NCT05647382|ACTIVE_COMPARATOR|Lung injury group|Lung injury is defined as lung damage when the patient has an oxygen and index below 300 24 hours after cardiopulmonary bypass
62679140|NCT05647382|SHAM_COMPARATOR|Non-lung injury group|Patients with oxygen and an index above 300 24 hours after cardiopulmonary bypass are defined as non-lung injury
62679141|NCT04484441||Fetal surgical intervention group|Pregnant adult women carrying a fetus with a diagnosed congenital anomaly and scheduled to undergo fetal surgical intervention at Mayo Clinic.
62679142|NCT04484441||Control group - normal pregnancy|Pregnant adult women with normal ultrasound findings. These women will be matched with the subjects enrolled in the intervention cohort for parity, maternal age, ethnicity, fetal sex and gestational age at time of surgical intervention.
62679143|NCT01682720|PLACEBO_COMPARATOR|Placebo 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
62679144|NCT01682720|EXPERIMENTAL|SOF 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
62679145|NCT01682720|EXPERIMENTAL|SOF 24 Weeks (GT3)|SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.
62679146|NCT04415710||Group|Women with diagnosed Sjogren syndrome
62679147|NCT06585709|EXPERIMENTAL|Active rTMS|A total of 50-sessions of standard iTBS (1800 pulses) will be delivered. rTMS-sessions will be ideally administered over 1-week (10-sessions-per-day, 50-minutes inter-session-interval, 5-days), but there will be flexibility in the delivery paradigm so long as participants complete all sessions of rTMS within 6 weeks and come in at least twice per week.
62679148|NCT06585709|SHAM_COMPARATOR|Sham rTMS|Double-blind sham-rTMS in an identical fashion to the active-rTMS condition will be delivered.
62679149|NCT01964560|EXPERIMENTAL|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:~* Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing \<30 kg~* LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to \<50 kg~* LCM 300 mg/day (tablets) for subjects weighing ≥50 kg~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
62679150|NCT06508450|ACTIVE_COMPARATOR|Just Do You|Just Do You Core Intervention
62679151|NCT06508450|EXPERIMENTAL|Just Do You-A|Just Do You plus Component A
62120351|NCT05251688|OTHER|participants|The participants were encountered two times (before and after the application of cryoanalgesia).
62308586|NCT02817438|NO_INTERVENTION|Waitlist|Participants randomized to the waitlist arm will wait for 12 weeks without doing an online intervention.
62308587|NCT02978014|EXPERIMENTAL|ProSpare Arm|ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)
62679152|NCT06508450|EXPERIMENTAL|Just Do You-B|Just Do You plus Component B
62679153|NCT06508450|EXPERIMENTAL|Just Do You-C|Just Do You plus Component C
62308588|NCT02978014|NO_INTERVENTION|Non-ProSpare Arm|Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)
62475418|NCT01354418|EXPERIMENTAL|Phenylephrine HCl Extended Release - Fasted|Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods
62679154|NCT06508450|EXPERIMENTAL|Just Do You-AB|Just Do You plus Components A and B
62679155|NCT06508450|EXPERIMENTAL|Just Do You-AC|Just Do You plus Components A and C
62679156|NCT06508450|EXPERIMENTAL|Just Do You-CB|Just Do You plus Components C and B
62679157|NCT06508450|EXPERIMENTAL|Just Do You-ABC|Just Do You plus Components A B and C
62679158|NCT06687291||Participants identified with postoperative delirium|Participants identified with postoperative delirium will be asked (at the routine follow-up meeting after surgery) to participate in an qualitative interview in order to understand the participant's experience of postoperative delirium.
62697329|NCT06062472|PLACEBO_COMPARATOR|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use
62697330|NCT03960944|EXPERIMENTAL|Yoga in School Group|30-mins yoga sessions were conducted in schools for 8-weeks
62697331|NCT03960944|NO_INTERVENTION|Control Group|Usual Activities in school
62308589|NCT00969618|EXPERIMENTAL|Atomoxetine|
62339587|NCT06115434||salvage cystectomy|patients will undergo salvage cystectomy after failure of bladder preservation protocol
61920376|NCT04132375|ACTIVE_COMPARATOR|Stage 2 - Selected active treatment arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of 4 mg/kg INM004 and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).~In the case, the low treatment regime is selected subjects will receive an intravenous dose of 4 mg/kg INM004"
61920377|NCT04132375|ACTIVE_COMPARATOR|Stage 2 - Placebo arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo, each dose separated by 24 h (± 2 h)~In the case, low treatment regime is selected subjects will receive a single intravenous dose of Placebo"
61920378|NCT02402478||Stable coronary artery disease|Patients with chest pain
61920379|NCT00393640|ACTIVE_COMPARATOR|A|Breast pump given and used on regular intervals
61920380|NCT00393640|NO_INTERVENTION|B|
61920381|NCT00393640|ACTIVE_COMPARATOR|c|Breast pump given to be used on regular interval
61920382|NCT00393640|NO_INTERVENTION|D|
61920383|NCT02596750|ACTIVE_COMPARATOR|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
61920384|NCT02596750|SHAM_COMPARATOR|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
61920385|NCT00412490||Smoking Behavior Group|Individuals Having Surgery for Oral Cavity Cancer.
61920386|NCT02117427|EXPERIMENTAL|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
61920387|NCT02117427|EXPERIMENTAL|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
61920388|NCT02117427|EXPERIMENTAL|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
61920389|NCT02376283|OTHER|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
61920390|NCT02376283|OTHER|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
61920391|NCT02376283|OTHER|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
61920392|NCT02376283|OTHER|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
61920393|NCT02376283|OTHER|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
61920394|NCT02376283|OTHER|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
62308590|NCT02574299|NO_INTERVENTION|1: Normal hearing children without SLI, transversal group|Normal hearing children without Specific Language Impairment (SLI),Transversal group for test-retest measures
62308591|NCT02574299|NO_INTERVENTION|2: Normal hearing children without SLI, longitudinal group|Normal hearing children without Specific Language Impairment (SLI), longitudinal group without training
62475419|NCT01354418|EXPERIMENTAL|Phenylephrine HCl Extended Release - Fed|Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
61920395|NCT04070976|ACTIVE_COMPARATOR|Standard treatment|Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A.
61920396|NCT04070976|EXPERIMENTAL|Experimental treatment|Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.
61920397|NCT01856023|ACTIVE_COMPARATOR|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
61920398|NCT01856023|ACTIVE_COMPARATOR|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
61920399|NCT06111547|EXPERIMENTAL|Cohort 1: TAK-279 30 mg|Participants will receive a single dose of TAK-279 30 milligram (mg) oral tablet on Day 1 followed by Day 6 to Day 19 once daily under fasted condition.
61920400|NCT06111547|EXPERIMENTAL|Cohort 2: TAK-279 60 mg|Participants will receive a dose of TAK-279 60 mg (2\*30mg) oral tablets on Day 1 followed by Day 6 to Day 19 once daily under fasted condition.
61920401|NCT06111547|PLACEBO_COMPARATOR|Cohort 1 and 2: Placebo 30 mg or 60 mg|Participants will receive TAK-279 30 mg or 60 mg (2\*30mg) matching placebo oral tablets on Day 1 followed by Day 6 to Day 19 once daily under fasted condition.
61920402|NCT02721186|EXPERIMENTAL|MDA with DHAp and SLD Primaquine|MDA will be conducted at two time points with an approximate four-week interval. All consenting and eligible community members will be administered age-appropriate treatment dose of dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and single low dose (0.25mg/kg) primaquine (Primaquine, Remedica Ltd., Cyprus) in house-to-house campaigns.
61920403|NCT02721186|NO_INTERVENTION|Control|The control arm (no MDA) will have the standard care offered by the Ministry of Health and Social welfare which applies to both arms. This includes passive case detection of individuals seeking treatment at local health facilities, and universal coverage of long lasting insecticide treated bed nets and indoor residual spraying in the study areas.
62679159|NCT06687291||CASE-study participants|"All included participants in the CASE-study.~* The assessment of cognitive function will be performed using the validated 4AT Test (4AT). Cognitive impact will be assessed at baseline before neoadjuvant chemotherapy (if chemotherapy is indicated) and at patient admission for surgery, postoperative day 1, 3 and 7, and at follow-up 4-8 weeks after surgery.~* Risk factors for POD will be explored by investigate the relationship between postoperative delirium, chemotherapy preoperative depression, frailty, quality of life, malnutrition and sarcopenia. Patients will report health-related quality of life using the validated EORTC QLQC-C30 and EORTC QLQ-OG25 questionnaires. Frailty and depression will be measured preoperatively with Clinical Frailty Scale (CFS-9) and the Patient Health Questionnaire (PHQ-9). Malnutrition is evaluated by using Patient-Generated Subjective Global Assessment (PG-SGA). Sarcopenia is assessed through CT-scan, which is conducted as part of clinical routine."
62679160|NCT05720520|EXPERIMENTAL|Mobile Application Group|Participants will use mobile application
62679161|NCT05720520|NO_INTERVENTION|Control Group|Participants only will take traditional education method
62475420|NCT01354418|ACTIVE_COMPARATOR|Phenylephrine HCl Immediate Release - Fasted|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods
62679162|NCT05587543|EXPERIMENTAL|CAR-T|Target A positivity was assigned to CAR-T cell therapy.
61920404|NCT05037188|EXPERIMENTAL|COVID-19 vaccine candidate (BCD-250) low dose|The participants will receive the low dose of BCD-250
61920405|NCT05037188|EXPERIMENTAL|COVID-19 vaccine candidate (BCD-250) high dose|The participants will receive the high dose of BCD-250
62120352|NCT01066923|EXPERIMENTAL|Daily ASA, Active cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, aspirin immediately post exercise
62120353|NCT01066923|EXPERIMENTAL|Daily ASA, Active cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, placebo immediately post exercise
62120354|NCT01066923|EXPERIMENTAL|Daily ASA, Passive cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
62120355|NCT01066923|EXPERIMENTAL|Daily ASA, Passive cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
62475421|NCT01354418|ACTIVE_COMPARATOR|Phenylephrine HCl Immediate Release - Fed|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
62679163|NCT05587543|EXPERIMENTAL|TCR-T|Target A negative, Target B positive and Target C positive were assigned to TCR-T cell treatment group.
62679164|NCT04569097|EXPERIMENTAL|Patient group|lingual strengthening
62679165|NCT04569097|NO_INTERVENTION|Controls|No history of dysphagia (swallowing disorder) or minimal to mild dysphagia not requiring a strengthening program
62679166|NCT02363127|EXPERIMENTAL|Prolutex|Subcutaneous progesterone
62679167|NCT02363127|ACTIVE_COMPARATOR|Progeffik|Vaginal progesterone
61920406|NCT05037188|EXPERIMENTAL|Cohort 1/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
61920407|NCT05037188|PLACEBO_COMPARATOR|Cohort 1/Placebo|The participants will receive placebo
61920408|NCT05037188|EXPERIMENTAL|Cohort 2/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
61920409|NCT05037188|PLACEBO_COMPARATOR|Cohort 2/Placebo|The participants will receive placebo
61920410|NCT01084447|PLACEBO_COMPARATOR|control group|In placebo muscular training group the respiratory exercise was used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA) no load.
61920411|NCT01084447|ACTIVE_COMPARATOR|trained group|In trained group the respiratory exercise used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)the load was initially set at 40% of the maximal inspiratory pressure.
61920412|NCT04667143|EXPERIMENTAL|Retagliptin 100 mg, Henagliflozein 10 mg, plus metformin XR|
62339588|NCT06115434||radical cystectomy|patients who will undergo radical cystectomy without going through bladder preservation
62679168|NCT05449132|EXPERIMENTAL|RTX-GRT7039|Participants will receive a intra-articular injection of RTX-GRT7039 during the 52-week double-blind treatment period.
61920413|NCT04667143|EXPERIMENTAL|Retagliptin 100 mg, Henagliflozein 5 mg, plus metformin XR|
62120356|NCT01066923|EXPERIMENTAL|Daily placebo, active cool, Acute ASA|Two weeks of daily placebo prior to exercise, active cooling following exercise, aspirin immediately post exercise
62120357|NCT01066923|EXPERIMENTAL|Daily placebo, active cool, Acute placebo|Two weeks of daily placebo prior to exercise, active cooling following exercise, placebo immediately post exercise
62120358|NCT01066923|EXPERIMENTAL|Daily placebo, Passive cool, Acute ASA|Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
62679169|NCT05449132|PLACEBO_COMPARATOR|Placebo|Participants will receive a intra-articular injection of placebo matching RTX-GRT7039 during the 52-week double-blind treatment period.
62679170|NCT03955185|EXPERIMENTAL|Minimally invasive surgery|The patients will receive laparoscopic or robotic assisted radical hysterectomy with improved surgery details: 1) Uterine manipulator type Cup-shaped uterine manipulator is prohibited, uterus hanging wire is allowed. 2) Avoid tumor cells shedding into the pelvis: A. Cut the vagina with the transvaginal method, B. Cut the vagina after closed loop ligation of the vagina. After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
62679171|NCT03955185|ACTIVE_COMPARATOR|Open abdominal surgery|The patients will receive traditional radical hysterectomy.After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
62679172|NCT05763862|EXPERIMENTAL|Genetic testing|"Patients randomised to testing will have blood drawn for testing of CYP2C19 LOF mutations. Physicians of patients who test positive for an LOF mutation (intermediate and poor metabolizers) will be notified of the mutation with recommendations of possible alternative antiplatelet regimens suggested. Aspirin will be the recommended monotherapy, and aspirin in combination with ticagrelor or dipyridamole will be the recommended dual antiplatelet regimen. Decision of alternative medications used in patients with LOF mutations will be left to the discretion of the primary physician. Patients in the genotype guided antiplatelet therapy group who do not have LOF mutations will be left to continue the original intended antiplatelet regimen (this may be clopidogrel monotherapy, or in combination with aspirin).~No randomisation for patients with known CYP2C19 status prior to recruitment as these patients will be recruited as a comparison arm for outcomes measurements."
62679173|NCT05763862|NO_INTERVENTION|Standard medical therapy|Patients on this arm will be placed on clopidogrel monotherapy, or in combination with aspirin, which is the original intended antiplatelet regimen.
62679174|NCT05704049|EXPERIMENTAL|Cohort 1: manual administration|Isatuximab will be administered manually for 8 minutes on Day 1 of Cycle 1 followed by 6 minutes from Day 8 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participants may receive other treatments as rescue medication or background medication.
62679175|NCT05704049|EXPERIMENTAL|Part 1 Cohort 2: manual administration|Isatuximab will be administered manually for 6 minutes on Day 1 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participants may receive other treatments as rescue medication or background medication.
62679176|NCT05704049|EXPERIMENTAL|Part 2 Randomized Cohort: OBDS to manual|Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.
62679177|NCT05704049|EXPERIMENTAL|Part 2 Randomized Cohort: Manual to OBDS|Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.
62679178|NCT05754112||ACPA/RFpos asyntomatic individuals|ACPA and/or RF positive individuals without active arthritis
62679179|NCT05754112||Naive Active RA|Treatment-naive active RA (disease duration\<1 year)
62679180|NCT05754112||Resistant RA|Active despite treatment RA
62679181|NCT05754112||Remission RA|RA in sustained clinical and ultrasound remission
62679182|NCT05754112||Control Group|Individuals asymptomatic for joint inflammation without ACPA/RF positivity
62679183|NCT03318874|EXPERIMENTAL|Blephasteam|Heat delivery device, to be used according to guidelines from manufacturer.
62120359|NCT01066923|PLACEBO_COMPARATOR|Daily placebo, Passive cool, Acute placebo|Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
62679184|NCT03318874|ACTIVE_COMPARATOR|THERA°PEARL Eye Mask|Heat delivery device, to be used according to guidelines from manufacturer.
61920414|NCT04667143|EXPERIMENTAL|Retagliptin placebo, Henagliflozein 10 mg, plus metformin XR|
62120360|NCT00446550|EXPERIMENTAL|Afegostat Tartrate Treatment Regimen 1|For the first 2 weeks, afegostat tartrate was administered orally at a dose of 225 milligrams (mg) once daily (QD) for 7 consecutive days, followed by no study medication for 7 consecutive days. After 2 weeks, participants then took 225 mg afegostat tartrate QD for 3 consecutive days, followed by no study medication for 4 consecutive days. This 3-days-on/4-days-off treatment regimen was followed for 22 weeks.
62308592|NCT02574299|OTHER|3: Normal hearing children with SLI, longitudinal group|Normal hearing children with Specific Language Impairment (SLI), longitudinal group with training
62308593|NCT02574299|NO_INTERVENTION|4: Normal hearing adults without SLI, transversal group|Normal hearing adults without Specific Language Impairment (SLI), transversal group for test-retest measures
62475422|NCT02944617|EXPERIMENTAL|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF-TKI treatment.
62308594|NCT02574299|NO_INTERVENTION|5: Normal hearing adults without SLI, longitudinal group|Normal hearing adults without Specific Language Impairment (SLI), longitudinal group without hearing aids (HA)
62308595|NCT02574299|OTHER|6: Hearing Impaired candidates for HA, longitudinal group|Hearing Impaired adult candidates for hearing aids (HA), longitudinal group with hearing aids (HA)
62679185|NCT06695481||Conventional|In this group, only patients who had facet joint medial branch conventional RF applied to the patients who benefited after diagnostic injection into the facet joint were selected.
62679186|NCT06695481||Combined|This group was selected retrospectively from patients who benefited from diagnostic injection into the facet joint and who underwent pulsed rf in addition to facet joint medial branch conventional rf.
61920415|NCT04667143|EXPERIMENTAL|Retagliptin placebo, Henagliflozein 5 mg, plus metformin XR|
62308596|NCT04696406||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours
62679187|NCT06244199|EXPERIMENTAL|T2CR Intervention|Participants randomized to the T2CR intervention arm will receive a transitional care program designed to supplement usual care following an acute heart event. Study personnel will follow T2CR Intervention participants for the course of the 12-month study period to assess endpoints in comparison to the Usual Care arm.
62679188|NCT06244199|ACTIVE_COMPARATOR|Usual Care|Participants randomized to the Usual Care are will receive usual care at the discretion of their clinical providers. Study personnel will follow Usual Care participants for the course of the 12-month study period to assess endpoints in comparison to the T2CR intervention arm.
62679189|NCT06084286|EXPERIMENTAL|CAR-T cell therapy|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
62679190|NCT06380400|EXPERIMENTAL|Foot bath intervention group|Pregnant women are given a foot bath during the first stage of labour.
62679191|NCT06380400|NO_INTERVENTION|Routine midwifery care control group|Pregnant women receive routine midwifery care during the first stage of labour.
62679192|NCT06187935||pulmonary nodule group|Patients with pulmonary nodules less than 3cm on CT imaging.
62679193|NCT06254482|EXPERIMENTAL|PTC518 5 mg|Participants will receive PTC518 5 mg tablets once daily orally for 24 months.
62679194|NCT06254482|EXPERIMENTAL|PTC518 10 mg|Participants will receive PTC518 10 mg tablets once daily orally for 24 months.
62120361|NCT00446550|EXPERIMENTAL|Afegostat Tartrate Treatment Regimen 2|Afegostat tartrate was administered orally at a dose of 225 mg QD for 7 consecutive days, followed by no study medication for 7 consecutive days. This 7-days-on/7-days-off treatment regimen was followed for 24 weeks.
62679195|NCT06254482|EXPERIMENTAL|PTC518 20 mg|Participants will receive PTC518 20 mg tablets once daily orally for 24 months.
62679196|NCT06429124|EXPERIMENTAL|Interventional|Participants will be instructed to follow a 16/8 regimen characterized by 16 hours of fasting and an 8-hour eating window daily, on approximately 5 days/week, for 3 months. Previous research has shown that 16 hours of fasting is feasible, safe and well-tolerated among older adults, and that most persons report easy adjustment (Anton, Lee et al. 2019, Lee, Sypniewski et al. 2020). The intervention will be implemented through individual and group sessions with participants and will involve extensive education, coaching, guidance, and support throughout the 3-month intervention. Educational materials on lifestyle factors including physical activity will be provided to each participant. We will be also be collecting data on physical activity and sedentary behavior. These data will be co-variates when we conduct the statistical analysis.
62679197|NCT06159725|PLACEBO_COMPARATOR|Placebo|Matching placebo, 100mL normal saline
62679198|NCT06159725|EXPERIMENTAL|5 mg/kg CMTX-101|5mg/kg CMTX-101 in 100mL normal saline
62679199|NCT06159725|EXPERIMENTAL|30 mg/kg CMTX-101|30 mg/kg CMTX-101 in 100mL normal saline
62679200|NCT06159725|EXPERIMENTAL|15 mg/kg CMTX-101|15 mg/kg CMTX-101 in 100mL normal saline
62679201|NCT05966194|EXPERIMENTAL|RRx-001 Pre-Treatment (8mg RRx-001) + Chemoradiation Therapy (CRT)|Pretreatment consists of 8 mg RRx-001 given twice weekly during the 2 weeks prior to the start of CRT (4 doses total) followed by the CRT treatment period
62679202|NCT05966194|EXPERIMENTAL|RRx-001 Pre-Treatment (4mg RRx-001) + Chemoradiation Therapy (CRT)|Pretreatment consists of 4 mg RRx-001 given twice weekly during the 2 weeks prior to the start of CRT (4 doses total) followed by the CRT treatment period.
62679203|NCT05966194|PLACEBO_COMPARATOR|Placebo Pre-Treatment + Chemoradiation Therapy (CRT)|No doses of RRx-001 will be administered. Patients assigned to this arm will receive placebo twice weekly during the 2 weeks prior to the start of CRT followed by the CRT treatment period.
62120362|NCT05249036|EXPERIMENTAL|Ultrasound guided arterial cannulation|Anaesthetist will use real-time ultrasound guidance to guide arterial cannulation
62120363|NCT05249036|ACTIVE_COMPARATOR|Palpation guided arterial cannulation|Anaesthetist will use palpation (standard-of-care) technique to guide arterial cannulation
62120364|NCT03411278|EXPERIMENTAL|Deep Oscillation (DO) self treatment|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2). The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
62120365|NCT03411278|NO_INTERVENTION|No intervention, control|No intervention
62679204|NCT06695585|ACTIVE_COMPARATOR|Higher volume intravesical lidocaine|200 ml of 2% lidocaine without epinephrine intravesical instillation 20-30 minutes prior to bladder botox.
62679205|NCT06695585|ACTIVE_COMPARATOR|Lower volume intravesical lidocaine|30 ml of 2% intravesical lidocaine without epinephrine instilled into the bladder 20-30 minutes prior to bladder botox.
62679206|NCT06643247|ACTIVE_COMPARATOR|Drug group|Control group
62679207|NCT06643247|EXPERIMENTAL|Drugs combined with electroacupuncture group|Observation group
62679208|NCT01169909|EXPERIMENTAL|Ranibizumab treatment|Patients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose.
62679209|NCT05686252|ACTIVE_COMPARATOR|30 degrees|Baby is held at 30 degrees during kangaroo mother care in the NICU
62679210|NCT05686252|ACTIVE_COMPARATOR|60 degrees|Baby is held at 60 degrees during kangaroo mother care in the NICU
62679211|NCT01825252|EXPERIMENTAL|Social Network Intervention|Approximately 20% of people in this condition will be trained to have discussions endorsing less risky behaviors with their social network members.
62679212|NCT01825252|ACTIVE_COMPARATOR|Counsel, Test, and Treat|People in this arm will only receive standard-of-care counseling, testing, and treatment for HIV and STDs.
62679213|NCT06688227|OTHER|Isolated Core Stability Program|The control group consists of basic core exercises which include the activation of transversusabdominins and multifidus muscles and progressive strengethening of these muscles in all positions using swiss balls and floor mats. All exercises were done for at least 3 sets of 15 repetitions to build proper core stability.
61920416|NCT04667143|EXPERIMENTAL|Retagliptin 100 mg, Henagliflozein placebo, plus metformin XR|
62308597|NCT04696406||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation.
62308598|NCT04893837||Standard care plus infrascans|"All participants will receive regular clinical neurological assessments as ordered by the clinical care team. In addition, a research team member will perform an infrascan. This process will be repeated hourly at the same timepoint as the clinical neurological assessments. If a patient's neurological status deteriorates at any time point, and the medical team orders an early (unplanned) CT scan, the neurological data collection will cease once the patient is sent to CT.~Infrascan results will not be shared with the clinical care team, and will not guide the participants' care in any way."
62475423|NCT02944617|ACTIVE_COMPARATOR|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
62475424|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
62120366|NCT06676202|EXPERIMENTAL|Experimental group|- The patient will be given progressive relaxation exercises at the 12th, 24th, and 48th hours after the surgery. Before the application, information will be obtained about whether the patient has any complications and patients who develop complications due to the surgery will be excluded from the research group. As a result of the screening of progressive relaxation exercise studies in the literature, no standard duration and frequency information was found regarding the effectiveness of progressive relaxation exercise (Haut et al, 2018). In the literature review, it is seen that the total number of sessions varies as well as different applications such as being applied at the 6th, 12th, 24th hours after surgery or on the 2nd day after surgery (Tanrıverdi, 2021). In addition, studies conducted to reduce anxiety, pain, and stress after surgery may vary according to the length of hospitalization (Sertbaş and Bahar, 2004). Based on this information, it was learned that the approximate h
62120367|NCT06676202|NO_INTERVENTION|Control Group|"* After the 33 patients admitted to the clinic, the Patient Introduction Form and Beck Anxiety Scale will be filled out after information and consent.~* After the total knee replacement surgery, 50 hours will be waited and then the Patient Introduction Form and Beck Anxiety Scale will be filled out again.~* Progressive relaxation exercises will not be applied to the control group patients, but the pre-test and post-test data will be applied in the same time periods as the experimental group.~* Pre-test application 1 day before the surgery (Since the patient may be too tense just before the surgery, 1 day before was preferred. Patients who are taken to surgery on the same day due to an emergency will be excluded from the research group.)~* Post-test application 50 hours after the surgery and later (Relaxation exercises will be applied to the experimental group at 12-24 and 48 hours. The 48th hour, when the exercise ends, will not be preferred for the post-test, the patient"
62120368|NCT06214117|EXPERIMENTAL|Group R|Induction of anesthesia:Anesthesia will induced with remimazolam at 0.3-0.5 mg/kg; Maintenance of anaesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h).
62120369|NCT06214117|PLACEBO_COMPARATOR|Group S|Induction of anesthesia:Anesthesia will induced with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min; Maintenance of anaesthesia:Anesthesia depth was maintained at 1-1.5 MAC by sevoflurane.
62120370|NCT03281694|OTHER|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
62120371|NCT02952768|OTHER|ultrasound training|The aims were to develop a novel, resuscitative ultrasound-circulation-airway-breathing (US-C-A-B) protocol, to implement a short curriculum for ultrasound training and to assess the feasibility.
62120372|NCT01091233||Paracentesis|Paracentesis as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
62120373|NCT04674449|ACTIVE_COMPARATOR|Intervention Group - Stratified Medicine|All randomised participants will receive stratified medicine. The subjects will undergo functional coronary angiography involving guidewire-based coronary function tests (interventional diagnostic procedure, IDP) as an adjunct to invasive coronary angiography. The IDP results will be disclosed to the catheter laboratory clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and IDP findings.
62308599|NCT00772967|EXPERIMENTAL|Placebo, Naproxen, Ultracet|Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
62679214|NCT06688227|EXPERIMENTAL|Integrated Core Stability Program|"An individualized protocol was designed for these cricketers targeting static and dynamic core stability, with integration of balance, endurance and power component.~Tranversusabdominis and multifidus strengthening is combined with upper extremity motions to work on the fast bowling action i.e throwing of the players.~At the same time lower extremity balance and strengthening is also included to ensure the high speed of sprint."
62679215|NCT06695598|EXPERIMENTAL|Fast-Fed|Period 1: A single oral dose of 1 tablet under fasting condition, Period 2: A single oral dose of 1 tablet under fed condition
62679216|NCT06695598|EXPERIMENTAL|Fed-Fast|Period 1: A single oral dose of 1 tablet under fed condition, Period 2: A single oral dose of 1 tablet under fasting condition
62308600|NCT00772967|EXPERIMENTAL|Naproxen, Ultracet, Placebo|Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
62339589|NCT06350058|EXPERIMENTAL|Age group of 18-49 years old|Using a dose escalation trial, divided into 2 dose groups with 25 participants in each group.
62308601|NCT00772967|EXPERIMENTAL|Ultracet, Placebo, Naproxen|Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
62308602|NCT00772967|EXPERIMENTAL|Placebo, Ultracet, Naproxen|Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
62308603|NCT00772967|EXPERIMENTAL|Naproxen, Placebo, Ultracet|Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
62308604|NCT00772967|EXPERIMENTAL|Ultracet, Naproxen, Placebo|Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
62308605|NCT04936880|EXPERIMENTAL|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
62308606|NCT04936880|ACTIVE_COMPARATOR|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
62308607|NCT00550628||resection of a non-sarcomatous primary colon neoplasm|The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.
62308608|NCT06331585|EXPERIMENTAL|Experimental arm|"Experimental: LDRT on oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy~1. LDRT: Patient undergoes LDRT using a medical linear gas pedal (5Gy/5f)~2. Biopsy: Collect pathological tissues from oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy before LDRT (5Gy/5f) and up to 24h after LDRT"
61920417|NCT00013195|OTHER|Arm 1|
62120374|NCT04674449|SHAM_COMPARATOR|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also receive the IDP at time of the angiogram. The results of the IDP will be concealed from the catheter laboratory clinician who will be blinded. The cardiac physiologist / clinical scientist will remain unblinded for the purpose of data recording and quality assurance. The sham procedure is intended to be the same as in the Intervention Group. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and IDP findings.
62120375|NCT02240550|ACTIVE_COMPARATOR|ProFlor Hernia Repair System|A 3-D hernia mesh
62120376|NCT02240550|ACTIVE_COMPARATOR|Lichtenstein Hernia Repair|Using flat polypropylene mesh
62120377|NCT05817370|EXPERIMENTAL|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
62120378|NCT05817370|NO_INTERVENTION|Standard Screening and treatment of HSIL|The standard screening and treatment of HSIL outlined by the International Anal Neoplasia Society
62120379|NCT00534937|ACTIVE_COMPARATOR|Standard compression|Patients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
62120380|NCT00534937|EXPERIMENTAL|Flexitouch|Patients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).
62308609|NCT01031095|EXPERIMENTAL|Low dose intracoronary heparin|Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
61920418|NCT04073303|ACTIVE_COMPARATOR|Botulinum Toxin Type A (BOTOX®)|Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments
61920419|NCT04073303|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter
61920420|NCT05235503|EXPERIMENTAL|20mg Oxycodon (capsule) + 100 mg Bedrocan (vaporized)|As stated above
61920421|NCT05235503|PLACEBO_COMPARATOR|Placebo oxycodon (capsule) + 100 mg Bedrocan (vaporized)|As stated above
62120381|NCT00777816|ACTIVE_COMPARATOR|1|
62120382|NCT00777816|PLACEBO_COMPARATOR|2|
62120383|NCT00917865|EXPERIMENTAL|FACBC Imaging|Dynamic FACBC PET of primary prostate carcinoma.
62120384|NCT03973970||Test Arm 1- T-SPOT.TB assay|Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
62679217|NCT06566703|EXPERIMENTAL|All Nation Snuff Out Smokeless|This is a culturally targeted smokeless tobacco cessation program developed for American Indian communities. It includes group sessions via Zoom, individual telephone counseling, and educational materials.
62679218|NCT06566703|EXPERIMENTAL|Wait List Control - Healthy Living|Participants randomized to this arm are provided with information about healthy living while they wait for their turn at the intervention arm. Participants learn about diet, exercise, and stress reduction. They receive the All Nations Snuff Out Smokeless intervention after a six-month waiting period.
62679219|NCT06688916||Individuals with SCI - Behavioral assessment|"15 individuals with SCI will perform a comprehensive behavioral assessment of embodiment (see Interventions). A clinical assessment of sensory-motor symptoms will also be carried out."
62679220|NCT06688916||Individuals with SCI - Behavioral assessment and fMRI|"25 individuals with SCI will perform a comprehensive behavioral assessment of embodiment and neural correlates of embodiment will be explored by means of an fMRI procedure (see Interventions). A clinical assessment of sensory-motor symptoms will also be carried out."
61920422|NCT04733612|EXPERIMENTAL|SMS Group|In addition to traditional treatment received three to four informative SMS messages per week during the 6-month period
61920423|NCT04733612|NO_INTERVENTION|Control Group|Followed in accordance with the traditional treatment schedule
62679221|NCT06688916||Healthy controls - Behavioral assessment|"15 healthy controls will perform a comprehensive behavioral assessment of embodiment (see Interventions)."
62679222|NCT06688916||Healthy controls - Behavioral assessment and fMRI|"25 individuals with SCI will perform a comprehensive behavioral assessment of embodiment and neural correlates of embodiment will be explored by means of an fMRI procedure (see Interventions)."
62679223|NCT03769116|EXPERIMENTAL|Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2|Participant will receive delandistrogene moxeparvovec at Part 1 followed by matching placebo at Part 2 followed by an open-label extension at Part 3.
61920424|NCT02577432|ACTIVE_COMPARATOR|(S) separate.|fentanyl and hyperbaric bupivacaine (sequentially)
61920425|NCT02577432|ACTIVE_COMPARATOR|(M) mixed|fentanyl and hyperbaric bupivacaine.(mixed)
61920426|NCT01383668|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD on days 1-28 and gold sodium thiomalate IM on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61920427|NCT04447612|EXPERIMENTAL|Durvalumab arm|"Induction phase: Durvalumab 1500mg via intravenous infusion every 4 weeks, with chemotherapy gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.~Concurrent phase: Durvalumab 1500mg via intravenous infusion every 4 weeks for 2 cycles, with cisplatin 100mg/m2 via intravenous infusion every 3 weeks for 3 cycles.~Maintenance phase: Durvalumab 1500mg daily via intravenous infusion every 4 weeks for 8 cycles."
61920428|NCT04447612|ACTIVE_COMPARATOR|Standard of care arm|"Induction phase: Chemotherapy with gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.~Concurrent phase: Cisplatin 100mg/m2 on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles."
62308610|NCT01031095|ACTIVE_COMPARATOR|Standard treatment arm|Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
62308611|NCT02864875|NO_INTERVENTION|Control|Not to receive an early replacement of fibrinogen
62679224|NCT03769116|EXPERIMENTAL|Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2|Participant will receive matching placebo at Part 1 followed by delandistrogene moxeparvovec at Part 2 followed by an open-label extension at Part 3.
62679225|NCT06078514||Loop electrosurgical excision procedure (LEEP)|Women directed to colposcopy examination due to cytological abnormality or repeated HPV-positivity and undergone a LEEP procedure due to HPV-related cervical lesion
62308612|NCT02864875|EXPERIMENTAL|Intervention|Receive early replacement through fibrinogen concentrate (50mg per kg of body weight)
62308613|NCT00810160|ACTIVE_COMPARATOR|1|Permeate
62679226|NCT06078514||Colposcopy only|Women directed to colposcopy examination due to cytological abnormality or repeated HPV-positivity with no indication to LEEP
62679227|NCT02169401||Treated subjects|All subjects recruited and treated with the Axium Neurostimulator
62308614|NCT00810160|ACTIVE_COMPARATOR|2|GOS
61920429|NCT05386628|ACTIVE_COMPARATOR|control group|Conventional physiotherapy program (joint movement exercises, local relaxation techniques, etc.) will be applied to the participants in this group.
62308615|NCT00810160|ACTIVE_COMPARATOR|3|Bifidobacterium infantis
61920430|NCT05386628|EXPERIMENTAL|Manual lymphatic drainage group|In addition to the conventional physiotherapy program, manual lymphatic drainage (including upper limb extremity and anterior/posterior axillar-axillar anastomoses and axilla-inguinal anastomosis) will be applied to the participants in this group.
62120385|NCT03973970||Test Arm 2-QuantiFERON-TB Gold Plus assay|Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
62679228|NCT03987880|ACTIVE_COMPARATOR|4.0 mm zone|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
61920431|NCT05386628|EXPERIMENTAL|Myofascial relasing group|In addition to the conventional physiotherapy program, myofascial chain relasing techniques will be applied to the participants in this group.
62308616|NCT00810160|ACTIVE_COMPARATOR|4|Bifidobacterium animalis
62679229|NCT03987880|EXPERIMENTAL|3.5 mm zone|PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
62679230|NCT06419101||dementia progression|dementia-P (Compared with the baseline, MMSE score declined ≥ 4 points per year)
61920432|NCT05386628|EXPERIMENTAL|Lymphatic drainage and myofascial releasing group|In addition to the conventional physiotherapy program, manual lymphatic drainage (including upper limb extremity and anterior/posterior axillar-axillar anastomoses and axilla-inguinal anastomosis) and myofascial chain relasing techniques will be applied to the participants in this group.
61920433|NCT01415739||Novel Molecular NSCLC Classification (H & E staining, IHC)|Previously collected tissue samples are analyzed via H\&E staining and IHC.
61920434|NCT03800303|EXPERIMENTAL|two-week family-based treatment|Active treatment includes a two-week family-based partial hospitalization treatment utilizing and integrated therapeutic design.
62120386|NCT02712658|ACTIVE_COMPARATOR|terbutaline|terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
62120387|NCT02712658|PLACEBO_COMPARATOR|Placebo|placebo is administered as isotonic saline (10 ml)
62120388|NCT00064714|EXPERIMENTAL|Group 1|Group 1 will receive immunosuppression and AC2993; then immunosuppression only
62308617|NCT03990948||Patients with obesity|In 100 patients with obesity, blood samples will be collected.
62308618|NCT03990948||Patients with a Sleeve Gastrectomy|In 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
62308619|NCT03990948||Patients with a Roux-en-Y Gastric Bypass|In 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
62308620|NCT05133427|EXPERIMENTAL|Areas with de-novo or recurrent BCC|Areas with non-nodular de-novo or recurrent BCC area will be treated by high intensity focused ultrasound.
62308621|NCT01691729|OTHER|Ostomy 1|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy AccessoryProduct/Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2
62308622|NCT01691729|OTHER|Ostomy 2|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1
62679231|NCT06419101||dementia stabilization|dementia-S (Compared with the baseline, MMSE score decreased \< 4 points per year）
62308623|NCT01691729|OTHER|Ostomy 3|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product
62308624|NCT01691729|OTHER|Ostomy 4|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product
62308625|NCT01691729|OTHER|Ostomy 5|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2
62308626|NCT01691729|OTHER|Ostomy 6|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #1
62308627|NCT06382688|EXPERIMENTAL|NR (Cohorts 1&2)|IV administered 500 mg of sterile Niagen® (nicotinamide riboside chloride) diluted, in 500 ml of saline
62308628|NCT06382688|ACTIVE_COMPARATOR|Active Comparator (Cohorts 1&2)|IV administered 500 mg of sterile nicotinamide adenine dinucleotide in 500 ml of saline
62308629|NCT06382688|OTHER|Oral Comparator (Cohort 1 only)|orally administered 500 mg of sterile Niagen® (nicotinamide riboside chloride) in capsules
62308630|NCT06382688|PLACEBO_COMPARATOR|Placebo (Cohort 1 only)|IV administered 500 ml of saline
62679232|NCT02605967|EXPERIMENTAL|Spartalizumab 400 mg Q4W|anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab
62679233|NCT02605967|ACTIVE_COMPARATOR|Chemotherapy|commonly used chemotherapy as per investigator's choice
62308631|NCT04661319|EXPERIMENTAL|video editing training group|"- inclusion criteria~1. trainees in general surgery~2. No experience of laparoscopic cholecystectomy~3. Less than 5 experiences of laparoscopic surgery~4. Uncomplicated symptomatic gallstone disease~The experimental group received video editing training"
62308632|NCT04661319|EXPERIMENTAL|traditional training group|"- inclusion criteria~1. trainees in general surgery~2. No experience of laparoscopic cholecystectomy~3. Less than 5 experiences of laparoscopic surgery~4. Uncomplicated symptomatic gallstone disease~The control group received tradtional training"
62339590|NCT06350058|EXPERIMENTAL|Age group of 1-5 years old|Using a dose escalation trial, divided into 2 dose groups with 25 participants in each group.
62679234|NCT01944761|EXPERIMENTAL|Exercise Training|The 16 participants in this group will be quasi-randomized based on the order of recruitment to start the 12 week exercise intervention without delay (immediate condition).
62120389|NCT00064714|EXPERIMENTAL|Group 2|Group 2 will receive AC2993 only; then neither immunosuppression nor AC2993
62120390|NCT00064714|EXPERIMENTAL|Group 3|Group 3 will receive immunosuppression and AC2993; then immunosuppression and AC2993
62308633|NCT02908477|EXPERIMENTAL|De-escalated Adjuvant Radiation Therapy|Docetaxel 15 mg/m2 days 1, 8 + Radiation Therapy (RT) 30 Gy/1.5 Gy fractions twice daily (b.i.d.) days 1-12 only (intermediate risk) or 36 Gy/1.8 Gy b.i.d. fractions (high risk)
61920435|NCT01888003|ACTIVE_COMPARATOR|Anemia Treatment Group (AMG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb \< 13.0 g/dL and MCV \< 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive an ESA (PROCRIT) and iron (Venofer) preoperatively.
62120391|NCT00064714|EXPERIMENTAL|Group 4|Group 4 will receive AC2993 only; then AC2993 only
62679235|NCT01944761|EXPERIMENTAL|Delayed Exercise Training|The 16 participants in this group will be quasi-randomized based on the order of recruitment to start the 12 week exercise intervention after a 12 week no exercise training period (delayed condition).
62679236|NCT04281576|EXPERIMENTAL|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with XELOX. For HER-2 positive patients, Trastuzumab is given together with XELOX.
62679237|NCT04439903|EXPERIMENTAL|Web-based Simulation Tool (WST)|
62679238|NCT06164756||Experimental: Ketamine Infusion|Participants who received 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)
62679239|NCT06164756||Placebo Comparator: Saline Infusion|Participants who received 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)
61920436|NCT01888003|OTHER|Conventional Treatment Group (CTG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb \< 13.0 g/dL and MCV \< 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive our current, conventional perioperative standard of care, which does not involve any preoperative anemia management (other than laboratory testing). CTG patients will undergo routine perioperative laboratory testing/screening.
61920437|NCT01888003|OTHER|Non Anemia Group (NAG)|Group of patients who are not anemic preoperatively, who will receive our current, conventional perioperative standard of care.
61920438|NCT06178705|EXPERIMENTAL|Treatment Group|"Experimental Group:~Participants in experimental group would receive 8-10 sessions of intervention based helpful parenting program"
62120392|NCT02632305|EXPERIMENTAL|Treatment|"Eligible patients will receive nab-paclitaxel in combination with gemcitabine + cisplatin at the recommended phase II dose based on the phase I study completed in metastatic pancreas cancer patients.~The doses of study drugs will be as follows:~* nab-Paclitaxel 100 mg/m2 day 1 and 8 every 21 days~* Cisplatin 25 mg/m2 day 1 and 8 every 21 days~* Gemcitabine 800 mg/m2 day 1 and 8 every 21 days~Nab-paclitaxel will be administered first followed by cisplatin and then gemcitabine on day 1 and 8 of each treatment cycle. Cycles will be 3 weeks in length (21 days)."
62120393|NCT01790529|EXPERIMENTAL|Early Prophylaxis|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
62120394|NCT01790529|ACTIVE_COMPARATOR|Late Prophylaxis|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
62120395|NCT00600548|EXPERIMENTAL|1.1|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.
62120396|NCT00600548|ACTIVE_COMPARATOR|1.2|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).
62308634|NCT02908477|ACTIVE_COMPARATOR|Standard of Care Treatment|RT 60 Gy/2 Gy fractions daily (qday) days 1-40. For high risk, add weekly Cisplatin 40 mg/m2 (Around days 1, 8, 15, 22, 29, 36)
62308635|NCT01231191|ACTIVE_COMPARATOR|IV Acetaminophen|Intraoperative IV acetaminophen administered
62679240|NCT04487730|EXPERIMENTAL|"Engage & Connect Psychotherapy"|"Engage \& Connect, a modified adapted version of Engage. Its principal intervention is social reward exposure - facilitating engagement in rewarding and meaningful social activities with significant others. In Engage-S therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding social activities of their choice."
62679241|NCT04487730|ACTIVE_COMPARATOR|Symptom Review and Psychoeducation (SRP)|In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.
62120397|NCT00600548|EXPERIMENTAL|2.1|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.
62120398|NCT00600548|ACTIVE_COMPARATOR|2.2|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).
62120399|NCT05491031|EXPERIMENTAL|Multiple sclerosis|
62308636|NCT01231191|PLACEBO_COMPARATOR|IV Placebo|Intraoperative IV normal saline administered
62308637|NCT03952650|EXPERIMENTAL|1a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
62308638|NCT03952650|EXPERIMENTAL|1b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
62308639|NCT03952650|EXPERIMENTAL|2a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2\&amp;3 post PfSPZ
62308640|NCT03952650|EXPERIMENTAL|2b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2\&amp;3 post PfSPZ
62308641|NCT03952650|EXPERIMENTAL|3a|Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)
62308642|NCT03952650|EXPERIMENTAL|3b|Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)
62308643|NCT03952650|PLACEBO_COMPARATOR|4a|Receiving normal saline with 75 mg pyrimethamine day 0 post injection
62475425|NCT02186821|EXPERIMENTAL|Ceritinib 750 mg|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
62475426|NCT06340633|EXPERIMENTAL|SPI-1005 400 mg twice daily (BID)|Oral administration of ebselen (SPI-1005) 400 mg BID for 180 days
62308644|NCT03952650|PLACEBO_COMPARATOR|4b|Receiving normal saline with 75 mg pyrimethamine days 2\&amp;3 post injection
62308645|NCT03952650|PLACEBO_COMPARATOR|4c|Receiving normal saline with weekly chloroquineibuprofen (if necessary)
62120400|NCT03594396|EXPERIMENTAL|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
62120401|NCT06570473|EXPERIMENTAL|Empagliflozin|Participants in the empagliflozin arm will receive 10 mg by mouth once daily and standard of care.
62120402|NCT06570473|EXPERIMENTAL|Ranolazine|Participants in the ranolazine arm will receive ranolazine 500 mg by mouth twice daily, which will be increased to 1000 mg twice daily after 2 weeks (unless concurrently using moderate CYP 3A4 inhibitors, then dose is limited to 500 mg twice daily) and will receive standard of care.
62308646|NCT03952650|EXPERIMENTAL|5a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)
62120403|NCT06570473|NO_INTERVENTION|Standard of Care|Participants in this group will receive standard of care.
62475427|NCT06340633|PLACEBO_COMPARATOR|Placebo|Oral administration of matching placebo BID for 180 days
62475428|NCT03835715|EXPERIMENTAL|Vortioxetine|
62475429|NCT05907421||NSSI|
62475430|NCT05907421||HC|
62475431|NCT02671526|EXPERIMENTAL|Computerized Plasticity-based Adaptive Cognitive Training|
62475432|NCT04440592|EXPERIMENTAL|MT-7117|Oral tablet of MT-7117 once a day.
61920439|NCT06178705|NO_INTERVENTION|Control Group|"Control Group:~Participants in the control group will not receive the said intervention of helpful parenting program."
62120404|NCT00084903|EXPERIMENTAL|Fluorescence Spectroscopy|
62120405|NCT01483248|EXPERIMENTAL|Intervention|Conventional therapy plus MenSCs treatment
62308647|NCT03952650|EXPERIMENTAL|5b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
62308648|NCT03952650|EXPERIMENTAL|6a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2\&amp;3 post PfSPZ (if necessary)
62308649|NCT03952650|EXPERIMENTAL|6b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2\&amp;3 post PfSPZ (if necessary)
62308650|NCT00770861|ACTIVE_COMPARATOR|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
62308651|NCT00770861|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets, oral administration
62308652|NCT02277132|ACTIVE_COMPARATOR|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery
62308653|NCT02277132|PLACEBO_COMPARATOR|Placebo|Placebo tablets three times daily orally from randomization until delivery
62475433|NCT04440592|PLACEBO_COMPARATOR|Placebo|Oral tablet of placebo once a day.
62475434|NCT03201523|EXPERIMENTAL|Intervention|Community members will be exposed to multiple interventions designed through the participatory approach, integrating the socio-ecological model.
62475435|NCT04421508|ACTIVE_COMPARATOR|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 125 mcg/kg IBW/hour
62475436|NCT04421508|SHAM_COMPARATOR|Placebo|Pulsed inhaled N2, 99.999% gas
62475437|NCT06279338|EXPERIMENTAL|Azacitidine|Combining azacitidine with classic BUCY2 regimen as conditioning regimen
62475438|NCT04702581|EXPERIMENTAL|PCV alone|Administration of 6 cycles of PCV chemotherapy alone.
62475439|NCT04702581|ACTIVE_COMPARATOR|RT + PCV|Radiotherapy followed by administration of PCV chemotherapy.
62475440|NCT05901870||Russian Adults (18+)|Russian adults who meet the inclusion criteria (described below) will be participants of RNHTS.
62495887|NCT06265038|OTHER|Prospective, single-arm, open-label clinical trial.|Single center, prospective cohort, single-arm, open-label clinical trial Standard-of-care \& Sanatmetal ReSpace TiCell Cage implantation A single-center study is sufficient to provide confirmatory data on performance and safety of the investigational device.
62495888|NCT04142658|EXPERIMENTAL|Apixaban|Apixaban 5 mg twice daily(BID) or 2.5 mg BID
62495889|NCT04142658|ACTIVE_COMPARATOR|Warfarin|Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)
62495890|NCT01564901||Cohort|
62120406|NCT01483248|ACTIVE_COMPARATOR|No intervention|"Conventional therapy plus placebo treatment:~Oral or intravenous administration"
62308654|NCT02214173|EXPERIMENTAL|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
62308655|NCT02214173|PLACEBO_COMPARATOR|placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
62308656|NCT05212246|EXPERIMENTAL|5% Imiquimod Cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
62308657|NCT05212246|PLACEBO_COMPARATOR|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
62308658|NCT02447107||Outpatients|Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
62679242|NCT06690073|ACTIVE_COMPARATOR|Control|Conventional Physical Therapy (CPT) was administered to the control group three times per week for six weeks (45 minutes per session). CPT treatments such as mat activities, assisted movements, weight-bearing strategies, and gymnasium training were given to the control group.
61920440|NCT04255927|EXPERIMENTAL|Coated Polyglactin 910 with Triclosan|Coated Polyglactin 910 with Triclosan
62120407|NCT01091454|EXPERIMENTAL|Treatment (cisplatin and brostallicin)|Patients receive cisplatin IV over 2 hours on day 1 and brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62308659|NCT01520922|EXPERIMENTAL|Ofatumumab plus bendamustine|In this single arm, Phase II study, each patient who is willing to participate and is found eligible according to the inclusion and exclusion criteria will enter the treatment phase. Eligible subjects will be allocated to receive the following study treatments depending upon their previous CLL treatment status: Subjects with Untreated CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (90 mg/m2, Days 1 and 2; every 28 Days). Subjects with Relapsed CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (70 mg/m2, Days 1 and 2; every 28 Days).
62120408|NCT01764815|EXPERIMENTAL|Directional lead|
62679243|NCT06690073|EXPERIMENTAL|Experimental|"the experimental group received the previously mentioned CPT treatment as well as MRP for sitting to standing for six weeks, for a total duration of 45 minutes per session (30 minutes of CPT treatment followed by 15 minutes MRP), three sessions per week.~MRP of sitting and standing activities: The physical therapist was standing in front of the participant, who was sitting in an armrest-equipped chair. Participants were initially taught to keep their feet back, followed by forward trunk positioning. The physical therapist then aided the activity by holding the involved side of the hand and shoulder, where the subject had informed to execute anterior trunk bending more quickly, if the participant did not do it well or performed it in an abnormal manner. Finally, participants were instructed to press down through the affected foot, stand up as quickly as possible, and bring their hips anterior. The physical therapist suggested pressing down through the participant's knee along the shaft"
62679244|NCT02912520||Patients with antibiotic therapy|Patients with antibiotic therapy for 2 weeks.
62679245|NCT02912520||Patients without antibiotic therapy|Patients without any antibiotic therapy in the last 3 months.
62679246|NCT06323473|EXPERIMENTAL|Treatment|Maitake given alongside systemic chemotherapy and/or CD4/6 inhibitors
62120409|NCT02368171||Obstructive sleep apnea with pulmonary hypertension|Patients with AHI\> 5/h and pulmonary hypertension with RVSP\>35 mmHg on Echo
62679247|NCT05739643|EXPERIMENTAL|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|N=3 patients with Infantile or Late Infantile Krabbe disease will receive a single infusion at the low dose
61920441|NCT04255927|ACTIVE_COMPARATOR|Coated Polyglactin 910 without Triclosan|Coated Polyglactin 910 without Triclosan
62120410|NCT02368171||control|patients with AHI\<5/h and RVSP\<35 mmHg on Echo
62120411|NCT02368171||OSA with no Pulmonary hypertension|patients with AHI\>5/h, but RVSP\<35 mmHg on Echo
62679248|NCT05739643|EXPERIMENTAL|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|N=3-6 patients with Infantile or Late Infantile Krabbe disease will receive a single infusion at the high dose
62679249|NCT03564730|ACTIVE_COMPARATOR|Total Knee Arthroplasty (TKA)|Patient will have complete replacement - Simultaneous vs Staged
62679250|NCT03564730|ACTIVE_COMPARATOR|Unicompartmental Knee Arthroplasty (UKA)|Patient will have half-knee replacement (partial) - Simultaneous vs Staged
62679251|NCT06564623|EXPERIMENTAL|Arm A - mBTCvax, Durvalumab and Tremelimumab|
62120412|NCT01917097||Dexmedetomidine patients|Patients that received dexmedetomidine during their surgery.
62679252|NCT00545948|OTHER|Arm A-Vinorelbine|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
62120413|NCT01917097||No Dexmedetomidine|Patients that didn't receive dexmedetomidine during surgery.
62120414|NCT06401551|EXPERIMENTAL|CPO Pro IOL|CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
62679253|NCT00545948|OTHER|Arm B-Pemetrexed|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
62120415|NCT06401551|EXPERIMENTAL|CPO IOL|CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
62120416|NCT05942963|EXPERIMENTAL|Group A|SOC+ Empagliflozin + Pioglitazone
62120417|NCT05942963|EXPERIMENTAL|Group B|SOC +Empagliflozin
62120418|NCT05942963|EXPERIMENTAL|Group C|SOC+ Pioglitazone
62120419|NCT05942963|ACTIVE_COMPARATOR|Group D|SOC only
62120420|NCT05375188|EXPERIMENTAL|Group D|Dexmedetomidine was given as an infusion of 0.4 μg/kg/h from induction of anesthesia for 24 hours.
62120421|NCT05375188|PLACEBO_COMPARATOR|Group C|Equal volume of normal saline.
62120422|NCT03328715|ACTIVE_COMPARATOR|study group|only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
62120423|NCT03328715|SHAM_COMPARATOR|controll group|only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
62120424|NCT01796782|ACTIVE_COMPARATOR|Xeloda|Subjects will receive Xeloda until progression
62120425|NCT01796782|EXPERIMENTAL|QYHJ Granules|patients will receive QYHJ Granules until progression
62120426|NCT03573999|ACTIVE_COMPARATOR|Mannitol 20%|Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.
62120427|NCT03573999|EXPERIMENTAL|Hypertonic saline 7.5%|Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening
62120428|NCT06676917|EXPERIMENTAL|Datopotamab deruxtecan (Dato-DXd)|"Dato-DXd, administered as 6 mg/kg intravenous (IV) infusion on day 1 (D1) of each 21-day cycle until unacceptable toxicity, disease progression, patient's consensus withdrawal, death, or discontinuation from the study treatment for any other reason, whichever occurs first.~Concomitant prophylactic dexamethasone mouthwash will be recommended to prevent stomatitis, anti-emetic agents will be highly recommended for preventing nausea/vomiting, antihistamines and antipyretics will be required for preventing infusion-related reactions (IRR) and the use of artificial tears will be advised for the prevention of ocular surface events."
62120429|NCT03603184|EXPERIMENTAL|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
62308660|NCT02989948|EXPERIMENTAL|Main Arm - Physician-modified fenestrated endovascular graft|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
62308661|NCT02989948|EXPERIMENTAL|Expanded Access Arm - Physician-modified fenestrated endovascular graft.|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal, thoracic, or abdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair in an expanded use population.
62308662|NCT05065021|EXPERIMENTAL|Initial/Cohort C|Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.
62679254|NCT06695741|EXPERIMENTAL|hypo-CASH|ALG/CsA and herombopag and reduced dose of cyclophosphamide
62308663|NCT05065021|EXPERIMENTAL|Cohort A|"Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
62679255|NCT06274047|EXPERIMENTAL|Arm 1|Participants will receive 6 months of standard-of-care androgen deprivation therapy (ADT) and radiation therapy.
62475441|NCT02890992|EXPERIMENTAL|Cohort 1 - Alirocumab 30 mg Q2W: <50 kg|"Period 1: Participants with body weight less than (\<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT).~Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still \< 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
62475442|NCT02890992|EXPERIMENTAL|Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg|"Period 1: Participants with body weight greater than or equal to (\>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
62475443|NCT02890992|EXPERIMENTAL|Cohort 2 - Alirocumab 40 mg Q2W: <50 kg|"Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still \< 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
62475444|NCT02890992|EXPERIMENTAL|Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg|"Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130."
62679256|NCT06274047|EXPERIMENTAL|Arm 2|Participants will receive 6 months of apalutamide and radiation therapy.
62679257|NCT06274047|EXPERIMENTAL|Arm 3|Participants will receive 24 months of standard-of-care androgen deprivation therapy (ADT) and radiation therapy.
62308664|NCT05065021|EXPERIMENTAL|Cohort B|"Paclitaxel, by vein (intravenously), once a week. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
61920442|NCT04999774||School-age children|"Each SAC will be asked to supply fecal and blood samples for testing with:~* Stool microscopy~* Baermann method~* Real-time PCR for S. stercoralis~* Lateral flow rapid test~* ELISA serology (NIE/SsIR and IgG Ratti)"
61920443|NCT02240147|EXPERIMENTAL|home-based exercise training|
61920444|NCT02240147|NO_INTERVENTION|Control group|
62120430|NCT03603184|PLACEBO_COMPARATOR|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
62120431|NCT02689180|PLACEBO_COMPARATOR|Withdraw of furosemide|Withdraw of of 40 or 80 mg of furosemide per day
62308665|NCT01121406|EXPERIMENTAL|BI 6727|Patients receive BI 6727 infusion every 3 weeks
62679258|NCT06274047|EXPERIMENTAL|Arm 4|Participants will receive 6 months of ADT, apalutamide, and radiation therapy.
61920445|NCT01733927|EXPERIMENTAL|Rapid testing for HIV|The intervention consisted in administer an oral rapid test for HIV (OQA) to people that also had taken an ELISA test to compare their tests results. Group 1 consisted of 344 participants who did not know their HIV status; Group 2 consisted of 153 participants who were previously confirmed to be HIV positive. The participants were instructed to obtain their own oral fluid sample using the testing devices provide by the OQA rapid test kits. Project team members, certified to interpret OQA results, registered each test outcome on a data form using the same code number that the participant was assigned for the ELISA test.
62120432|NCT02689180|ACTIVE_COMPARATOR|Maintenance of furosemide|Maintenance of 40 or 80 mg of furosemide per day
61920446|NCT04475809|PLACEBO_COMPARATOR|Group C|high intra-abdominal pressure
62308666|NCT01121406|ACTIVE_COMPARATOR|Cytotoxic|At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin
62679259|NCT00666575|EXPERIMENTAL|Gabapentin|
62679260|NCT00666575|PLACEBO_COMPARATOR|Placebo|
61920447|NCT04475809|ACTIVE_COMPARATOR|Group L|low intra-abdominal pressure
61920448|NCT04475809|ACTIVE_COMPARATOR|Group LR|low intra-abdominal pressure with pulmonary recruitment maneuver group
61920449|NCT04475809|ACTIVE_COMPARATOR|Group LS|low intra-abdominal pressure with intraperitoneal saline infusion group
61920450|NCT03783247|EXPERIMENTAL|FIB|hip fracture with fascia Iliaca block
62120433|NCT03462589|EXPERIMENTAL|SY-008 dose 1|A single dose of SY-008 (2\~30mg) taken orally.
62120434|NCT03462589|EXPERIMENTAL|SY-008 dose 2|A single dose of SY-008 (2\~30mg) taken orally.
62120435|NCT03462589|EXPERIMENTAL|SY-008 dose 3|A single dose of SY-008 (2\~30mg) taken orally.
62120436|NCT03462589|EXPERIMENTAL|SY-008 dose 4|A single dose of SY-008 (2\~30mg) taken orally.
62120437|NCT03462589|EXPERIMENTAL|SY-008 dose 5|A single dose of SY-008 (2\~30mg) taken orally.
62339591|NCT06350058|EXPERIMENTAL|Age group of 6-12 months old|"Using a dose escalation trial, divided into 2 dose groups with 25 participants in each group.~In addition, a dose exploration trial was conducted, with a total of 225 subjects aged 6-12 weeks enrolled, with 100 participants in both high-dose and low-dose groups, and 25 participants in the placebo control group"
62679261|NCT06688279|EXPERIMENTAL|Plyometric exercises protocol|"14 female fast bowlers will receive 8 weeks of upper and lower body plyometric exercises protocol. The session will last for 60 minutes and 3 times per week. 5 minutes warm up with dynamic stretching and 5 minutes cool down period with static stretching and 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set (total 3 sets).~Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step. Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
62308667|NCT01954290|ACTIVE_COMPARATOR|Hypertonic Saline (3%) and/or Mannitol arm|"The subjects in this arm will be given hypertonic saline and/or Mannitol.~For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome.~For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance."
62308668|NCT01954290|EXPERIMENTAL|Conivaptan arm|The subjects in this arm will be given infusion of Conivaptan.
62308669|NCT00673673|EXPERIMENTAL|1|FOLFOX in combination with bevacizumab
62120438|NCT03462589|PLACEBO_COMPARATOR|SY-008 matching placebo|from 6mg to 30mg
62120439|NCT03626558|EXPERIMENTAL|Distroke patients|"For every patient include in the study, ultrasound measures at the admission/discharge of hospitalization will be realized.~All the patients will see each other suggested participating in a new collection of remote ultrasound measures of the stroke (around 2-3 months). These measures will be made during the usual consultation proposed by the department of neurology. This medical consultation is a part of the follow-up post--stroke recommended by the High Authority of Health. These measures will allow us to highlight the kinetics of recovery of the diaphragmatic function except any intervention of reeducation of muscles inspirers."
62120440|NCT04570046||TD-PD patients undergoing MRgFUS thalamotomy|A total of 10 patients with tremor dominant PD underwent MRgFUS thalamotomy. Their clinical and imaging data were collected.
62120441|NCT04570046||MR-ET patients undergoing MRgFUS thalamotomy|A total of 58 patients with medication-resistant ET underwent MRgFUS thalamotomy. Their clinical and imaging data were collected.
62679262|NCT06688279|EXPERIMENTAL|Standard exercises protocol|"14 female fast bowlers will receive their standard exercise protocol. The session will last for 60 minutes and 3 times per week.~Following exercises would be performed.~* Push ups.~* Sit ups.~* Lunges~* 500 m running.~* Squats Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
62679263|NCT05195632|EXPERIMENTAL|Treatment arm (Safety Lead-in and Pivotal arm)|Encorafenib will be administered as a fixed, flat oral dose of 450 mg QD in combination with binimetinib as a fixed, flat oral dose of 45 mg BID.
62679264|NCT06404684|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|The current CBT-manual is based on the CBT-manual used for hypersexual disorder, which was developed by ANOVA and evaluated scientifically, (Hallberg 2017, 2019, 2020), but has now been adapted to better meet the current target group. The CBT manual addresses specific sexual problematic behaviors but also contains interventions to deal with comorbidity (e.g. depression and anxiety). The treatment consists of 10 modules and is given by a psychologist (face to face or video).
62679265|NCT06695455|EXPERIMENTAL|experimental arm - dysphagic parkinson patient|dysphagic parkinson patient
62679266|NCT04720170|OTHER|Single Arm|This is a 26 week, single arm, single-site, Investigator-initiated, exploratory trial evaluating the efficacy of the standard of care revascularization of the lower extremity with the addition of revascularization of the lateral plantar artery and anterior pedal loop of the foot as treatment for participants with PAD, diabetic neuropathy and have a clinical diagnosis of type 1 or type 2 diabetes whose main symptoms are numbness and/or tingling of the feet with or without pain.
62679267|NCT04545489|EXPERIMENTAL|Intervention group|Participants randomized to the intervention will have 4 visits over 12 months with study staff. In addition, they will also receive focused communication from the interventionist (nurse or pharmacist), with additional BP monitoring support and medication management for 12 months.
62120442|NCT06396611|EXPERIMENTAL|Resistance Exercise Training|Patients in the REx program are submitted to resistance machine exercises for the major muscle groups aiming to achieve the intensity of 80% of 1-Repetition Maximum (1-RM). A warmup and cool down of 10 and 5 minutes, respectively, were included in each session aiming workloads of 60%-85% of peak heart rate (HRp). Enrolment through the REx program resistance machines will be conducted from major muscle groups to minor muscle groups, from polyarticular to monoarticular exercises, and alternating between agonist and antagonist contraction according to the following laydown: Leg Press -\> Leg Curl -\> Leg Extension -\> Chest Press -\> Latissimus Pulldown -\> Shoulder Press -\> Triceps Extension -\> Biceps Curl -\> Abdominal Crunch.
62308670|NCT05564624|NO_INTERVENTION|Control|No usage instructions. Continue regular eating habits for the duration of the study.
62120443|NCT06396611|NO_INTERVENTION|Conventional Care (Control Group)|Control group patients received advice to follow their habitual physical activity routines and are contacted bimonthly to ensure participant retention in the study.
62308671|NCT05564624|EXPERIMENTAL|Fasting Mimicking Diet|Use the test products, ProLon(TM) Fasting Mimicking Diet, during the scheduled 5-day period in place of the usual meals (breakfast, lunch, dinner, snack) according to the instructions. Use the test product for 5 days for 3 cycles, beginning on day 1, day 30, and day 60.
62308672|NCT00638846|EXPERIMENTAL|senofilcon A toric|senofilcon A, daily wear, toric contact lens worn for two weeks
62679268|NCT04545489|ACTIVE_COMPARATOR|Education control group|Participants randomized to the education control group will have 4 visits over 12 months and will receive education materials related to CVD risk reduction.
62679269|NCT04987450||Study population|Plasma levels of SIRT-1, IL-6, FGF-23, sclerostin, calcium, phosphate, PTH and urine excretion of total protein, albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients receive three intravenous daily pulses of methylprednisolone of 500 mg followed by oral prednisone 0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the steroid treatment.
62679270|NCT05828901||Relapsing Remitting Multiple Sclerosis starting Ozanimod|
62679271|NCT05828901||Relapsing Remitting Multiple Sclerosis stopping Ozanimod|
62679272|NCT06556394|EXPERIMENTAL|RAG-17|RAG-17 is administered by intrathecal injection to subjects with Amyotrophic Lateral Sclerosis (ALS) with Superoxide Dismutase Type 1 (SOD1) Gene Mutation
62679273|NCT06556394|PLACEBO_COMPARATOR|Placebo|Placebo is administered by intrathecal injection to subjects with Amyotrophic Lateral Sclerosis (ALS) with Superoxide Dismutase Type 1 (SOD1) Gene Mutation
62679274|NCT06671366|EXPERIMENTAL|External and internal shoulder rotation force|shoulder external and internal rotation force objectively using a Cybex dynamometer in a specific position (seated with the arm at 45° abduction and 30° elevation)
62679275|NCT05890573|EXPERIMENTAL|Bailing capsule group|Bailing capsule group:6 Bailing capsules,po, tid,12 weeks.
62679276|NCT05890573|NO_INTERVENTION|Blank group|Blank group:no anti-fibrosis treatment is given.
62308673|NCT00638846|ACTIVE_COMPARATOR|balafilcon A toric|balafilcon A, daily wear, toric contact lens worn for two weeks
62308674|NCT00871858|ACTIVE_COMPARATOR|Arm A (ANA)|Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.
62308675|NCT00871858|EXPERIMENTAL|Arm B (FULV)|Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.
62308676|NCT02688855|EXPERIMENTAL|Investigational Group|Standard Rigid Fixation + Active OL1000 device
62308677|NCT02688855|SHAM_COMPARATOR|Control Group|Standard Rigid Fixation + Sham OL1000 device
62679277|NCT05996068|ACTIVE_COMPARATOR|trauma patients with arterial line insertion|the after phase, actively recruited patients who are eligible for arterial line insertion
62679278|NCT05996068|NO_INTERVENTION|trauma patients without arterial line insertion|the before phase, retrospectively data collection from the past
62679279|NCT04541693|OTHER|Hip revision|Revision to cup and stem, cup only or stem only.
62679280|NCT06694532|EXPERIMENTAL|high molucular weight hyalurinic acid .|patients injected e high molucular weight hyalurinic acid .
62120444|NCT03470142|ACTIVE_COMPARATOR|traditional laparoscopy-assisted surgery|The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
62120445|NCT03470142|EXPERIMENTAL|total laparoscopic surgery with no incision (NOSES)|The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice such as anal.
62308678|NCT05413447|EXPERIMENTAL|Patients receiving digital consultations|The intervention group receive multifaceted digital consults including 1) digital data sharing (e.g. exchange of pharmacotherapy use, home measured vital signs, etc), 2) patient education via an eLearning, and 3) digital guideline recommendations to treating physicians. The consultations are performed remotely unless there is an indication to perform the consult physically.
62308679|NCT05413447|NO_INTERVENTION|Standard care|If the patient is drawn into the control group the patient will receive standard care. Clinicians are free to use all standard modes of communication, and are not specifically encouraged to use remote types of communication. The clinicians are not informed about the assignment of a patient to the control group to optimally capture remote practice.
62308680|NCT00735332|EXPERIMENTAL|Single-Arm|
62308681|NCT02188446|EXPERIMENTAL|Smoking and alcohol cessation education|
62308682|NCT02188446|NO_INTERVENTION|Standard treatment|Standard treatment is information about benefits of stopping drinking and smoking before surgery and if wanted, advice about who to contact to get support.
62475445|NCT02890992|EXPERIMENTAL|Cohort 3 - Alirocumab 75 mg Q4W: <50 kg|"Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT.~Period 2: Participants with body weight \< 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still \< 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was \> = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
62475446|NCT02890992|EXPERIMENTAL|Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg|"Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT.~Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
62120446|NCT01924975|ACTIVE_COMPARATOR|Landmark group|An operator is not allowed to use an ultrasound. A 22 or 24 G catheter will be advanced blindly toward the expected location of the saphenous vein at the level of the medial malleolus. Once blood appears in the hub, then the catheter will be advanced into the saphenous vein.
62308683|NCT00404768|EXPERIMENTAL|Treatment|GSK221149A
62308684|NCT00404768|PLACEBO_COMPARATOR|Placebo|Placebo
62308685|NCT03478124||PSP patients|Patients suffering from Progressive Supranuclear Palsy (PSP)
62308686|NCT03478124||PD Patients|Patients suffering from Parkinson's disease (PD)
62308687|NCT05484063|EXPERIMENTAL|Intervention|Intervention group will receive a multicomponent, mobility-focused intervention during the course of inpatient admission.
62308688|NCT05484063|NO_INTERVENTION|Control|The control group will receive usual care as per current ward practice.
62308689|NCT06399081||Gangrenous cholecystitis|Defined based on intraoperative findings or pathological diagnosis
62475447|NCT02890992|EXPERIMENTAL|Cohort 4 - Alirocumab 150 mg Q4W: <50 kg|"Period 1: Participants with body weight \< 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight \< 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48."
62679281|NCT06694532|EXPERIMENTAL|low molcular weight hyaurinic acid|patients injected with low molucular weight hyalurinic acid .
62308690|NCT06399081||Non-gangrenous cholecystitis|Non-gangrenous cholecystitis, such as chronic cholecystitis, acute cholecystitis, acute attack of chronic cholecystitis
62308691|NCT01520792|EXPERIMENTAL|Paracetamol|
62308692|NCT00483951||Patients with known or suspected cardiovascular disease|Patients referred to protocol with known or suspected cardiovascular disease for further evaluation.
62308693|NCT05615714|EXPERIMENTAL|Paresthesia-Free Stimulation|Duration: 2 weeks
62120447|NCT01924975|ACTIVE_COMPARATOR|Ultrasound group|An operator will identify the saphenous vein by using ultrasound with a linear transducer (L15-7io) in short axis view. A 22 or 24 G catheter will be advanced until the tip of the needle is seen on the ultrasound image. The needle is then advanced until blood appears in the hub. The catheter is then advanced into the saphenous vein.
62120448|NCT02245581|ACTIVE_COMPARATOR|SVV-guided fluid management|SVV : Stoke volume variation
62308694|NCT05615714|SHAM_COMPARATOR|Sham Stimulation|Duration: 2 weeks
62308695|NCT05027269|EXPERIMENTAL|Part A Single Dose: AOC 1001 Dose Level 1|AOC 1001 will be administered once.
61920451|NCT03783247|EXPERIMENTAL|PENG|Hip fracture with Pericapsular nerve group block
62120449|NCT02245581|ACTIVE_COMPARATOR|CVP-guided fluid management|CVP : Central venous pressure
62120450|NCT03429530||Group1|20 patients with chronic HCV
62120451|NCT03429530||GroupII|20 patient with chronic HCV related liver cirrhosis
62120452|NCT03429530||GroupIII|40 patients with chronic HCV related liver cirrhosis complicated by hepatocellular cacinoma
62120453|NCT03429530||group IV|20 healthy blood donors will also be included as a control group
62308696|NCT05027269|PLACEBO_COMPARATOR|Part A Single Dose: Placebo|Saline will be administered once.
62308697|NCT05027269|EXPERIMENTAL|Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2 & 3|AOC 1001 will be administered three times.
62475448|NCT02890992|EXPERIMENTAL|Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg|"Period 1: Participants with body weight \>= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight \>= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48."
62308698|NCT05027269|PLACEBO_COMPARATOR|Part B Multiple Ascending Dose: Placebo|Saline will be administered three times.
62308699|NCT01415440|EXPERIMENTAL|Psychostimulant|30-70 mg capsule of Lisdexamfetamine once daily for 12 weeks
62308700|NCT01415440|PLACEBO_COMPARATOR|Placebo|30-70 mg capsule of placebo (sugar pill) once daily for 12 weeks
62308701|NCT04359953|EXPERIMENTAL|Hydroxychloroquine|Patient will take 200mg of Hydroxychloroquine twice a day during 14 days
61920452|NCT01589627|EXPERIMENTAL|experimental|Patients will be treated with the Standard of Care physical therapy, NSAIDs as well as a Wrist Extension Dynasplint
61920453|NCT01589627|NO_INTERVENTION|Control|Patients will receive standard of care physical therapy and NSAIDS
62308702|NCT04359953|EXPERIMENTAL|Azithromycin|Patient will take 250mg of Azithromycin twice a day during 14 days
62475449|NCT04627467|EXPERIMENTAL|Chloroquine 150mg base|Volunteers received chloroquine tablets orally at days 0, 15, 30, 45, 60 and 75.
62475450|NCT00693628|ACTIVE_COMPARATOR|Shrinker|Patients receive 20-30 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
62475451|NCT00693628|NO_INTERVENTION|No Shrinker|Control group - participants will not receive an intervention (compression shrinker).
62475452|NCT00693628|ACTIVE_COMPARATOR|Shrinker 2|Patients receive 30-40 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
62475453|NCT04411966|EXPERIMENTAL|18F-fluorothymidine PET|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
62475454|NCT00104910|EXPERIMENTAL|Treatment (brachytherapy, radiation, cetuximab, cisplatin)|Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)\* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
62475455|NCT04904718|EXPERIMENTAL|DreaMed Advisor Pro tool used for insulin optimization|
61920454|NCT06286371|EXPERIMENTAL|Study Group|This study has only one group, the group includes patients with laparoscopic endometriosis surgery (douglasectomy).
62308703|NCT04359953|EXPERIMENTAL|Telmisartan|Patient will take 40mg of Telmisartan twice a day during 14 days
62308704|NCT04359953|NO_INTERVENTION|Usual Care|No intervention
62308705|NCT06662539|EXPERIMENTAL|Petrelintide Dose 1|Participants will self-inject petrelintide dose 1 subcutaneously once a week.
61920455|NCT04964284|EXPERIMENTAL|rhTSH group|Patients received thyroid hormone suppression therapy (Euthyrox) . rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
62120454|NCT03623997||Stable isotope labeled iron II sulfate|All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.
62475456|NCT00647686|EXPERIMENTAL|1|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
62475457|NCT00647686|ACTIVE_COMPARATOR|2|Fentanyl Transdermal System 25 mcg/h
62475458|NCT02545283|EXPERIMENTAL|Idasanutlin plus Cytarabine|Participants will receive induction therapy idasanutlin and cytarabine for 5 Days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.
62308706|NCT06662539|EXPERIMENTAL|Petrelintide Dose 2|Participants will self-inject petrelintide dose 2 subcutaneously once a week.
62308707|NCT06662539|EXPERIMENTAL|Petrelintide Dose 3|Participants will self-inject petrelintide dose 3 subcutaneously once a week.
62308708|NCT06662539|EXPERIMENTAL|Petrelintide Dose 4|Participants will self-inject petrelintide dose 4 subcutaneously once a week.
62475459|NCT02545283|PLACEBO_COMPARATOR|Placebo plus Cytarabine|Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.
62475460|NCT03154047|EXPERIMENTAL|Open label|Open Label Study Drug NEOD001
61920456|NCT04964284|EXPERIMENTAL|Thyroid hormone withdrawal group|After randomization, patients with thyroid hormone withdrawal therapy(i.e. Stop taking thyroid hormone for 14 days, and then monitor the level of thyroid-stimulating hormone every week). When TSH\>30mU/L, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
62308709|NCT06662539|EXPERIMENTAL|Petrelintide Dose 5|Participants will self-inject petrelintide dose 5 subcutaneously once a week.
62308710|NCT06662539|PLACEBO_COMPARATOR|Placebo|Participants will self-inject matching placebo to petrelintide subcutaneously once a week.
62308711|NCT06481189|EXPERIMENTAL|"GNR-086 (JSC GENERIUM, Russia)"|canakinumab biosimilar
62308712|NCT06481189|ACTIVE_COMPARATOR|Ilaris® (Novartis Pharma Stein AG, Switzerland)|canakinumab
62308713|NCT03828292|EXPERIMENTAL|Part 1: Belantamab mafodotin Monotherapy|
62308714|NCT03828292|EXPERIMENTAL|Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone|
62308715|NCT03828292|EXPERIMENTAL|Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone|
62308716|NCT03078491|EXPERIMENTAL|Intervention|The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
61920457|NCT00812344|EXPERIMENTAL|1|
61920458|NCT00812344|ACTIVE_COMPARATOR|2|AZD0837 + Ketoconazole
61920459|NCT00473746|EXPERIMENTAL|Phase I Dose Escalation|
62120455|NCT06063733|EXPERIMENTAL|Digital PLB intervention|"Participants will perform the following tasks during the intervention:~1. Register a personal account on the theory-based pursed lip breathing intervention protocol software system installed on smartphones(DT-PLB).~2. Acquire knowledge and skills related to pursed lip breathing by watching instructional videos.~3. Practice Pursed Lip Breathing for 10 minutes per session, three times daily for eight weeks, as per reminders and guidance provided by the software.~4. Earn health points by completing specific actions as instructed.~5. Optionally post individual texts on the peer forum for peer support within the DT-PLB software.~6. Complete two outcome assessments as scheduled."
62308717|NCT03078491|NO_INTERVENTION|Attention Control|The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels
62308718|NCT01359982|EXPERIMENTAL|RRx-001|
62308719|NCT00295893|ACTIVE_COMPARATOR|Docetaxel, Doxorubicin Hydrochloride, and Cyclophosphamide|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.
62475461|NCT04655261||Participants Treated With Venetoclax + Obinutuzumab|Participants will receive venetoclax (Venclexta) in combination with Obinutuzumab according to local label.
62475462|NCT04137575|EXPERIMENTAL|ConquerFear-Group|ConquerFear-Group is a psychological intervention developed specifically for fear of cancer recurrence
62475463|NCT04137575|PLACEBO_COMPARATOR|Relaxation Training|The Relaxation Training serves as a placebo comparator and is not developed specifically to target fear of cancer recurrence.
61920460|NCT00473746|EXPERIMENTAL|Phase II Dose Treatment|
61920461|NCT04131218|EXPERIMENTAL|Obese group|n=8, 25≤BMI≤39.9kg/m²
62475464|NCT05955534|PLACEBO_COMPARATOR|Control Group|The control group will receive percutaneous bedside tracheostomy along with gastrostomy methods other than PUG, including but not limited to Percutaneous Endoscopic or Radiologic Gastrostomy (PEG or PRG, respectively), or surgical gastrostomy.
61920462|NCT04131218|EXPERIMENTAL|Morbidly obese group|n=8, BMI≥40kg/m²
61920463|NCT04621357|EXPERIMENTAL|Patient with intracerebral haemorrhage|Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.
61920464|NCT03923985|ACTIVE_COMPARATOR|Active Arm|1 tablet / day of probiotic containing 10 Mld L. crispatus during two months
61920465|NCT03923985|NO_INTERVENTION|Control Arm|No treatment
61920466|NCT01958112|EXPERIMENTAL|GSK1120212 (trametinib) and GSK2141795|GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
62475465|NCT05955534|EXPERIMENTAL|Intervention Group (TPUG)|The intervention group will receive concomitant percutaneous bedside tracheostomy and PUG.
61920467|NCT04697381|EXPERIMENTAL|somatropin - GH naïve pediatric cohort|All participants will receive somatropin.
61920468|NCT04697381|EXPERIMENTAL|somatropin - GH treated pediatric cohort|All participants will receive somatropin
61920469|NCT04697381|EXPERIMENTAL|somatropin - adult cohort|All participants will receive somatropin
61920470|NCT02312427|EXPERIMENTAL|Outpatient arm|After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
61920471|NCT02312427|EXPERIMENTAL|Hospitalization arm 1|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
62679282|NCT05411198|EXPERIMENTAL|XEN45 (Glaucoma Gel Stent)|Participants will receive XEN45 implanted using an ab externo approach on Day 1.
62308720|NCT00295893|EXPERIMENTAL|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel and Carboplatin|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
61920472|NCT02312427|EXPERIMENTAL|Hospitalization arm 2|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
62120456|NCT04529278|EXPERIMENTAL|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
62120457|NCT06538558|EXPERIMENTAL|Cohort A|10 participants will be recruited. The first two participants will receive placebo followed by eight participants who will receive active drug (tezampanel) at the lowest dose level.
62120458|NCT06538558|EXPERIMENTAL|Cohort B|10 participants will be recruited. The first two participants will receive placebo followed by eight participants who will receive active drug (tezampanel) at the next highest dose level.
62679283|NCT02662582|EXPERIMENTAL|CK-2127107 1000 mg, then placebo|Participants received CK-2127107 500 milligram (mg), orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
62120459|NCT06538558|EXPERIMENTAL|Cohort C|10 participants will be recruited. The first two participants will receive placebo followed by eight participants who will receive active drug (tezampanel) at the next highest dose level.
62120460|NCT06538558|EXPERIMENTAL|Cohort D|10 participants will be recruited. The first two participants will receive placebo followed by eight participants who will receive active drug (tezampanel) at the next highest dose level.
62120461|NCT06554860|EXPERIMENTAL|Experimental.|receive a scapular PNF exercise program in addition to conventional Exercise ,
62120462|NCT06554860|EXPERIMENTAL|Experimental|receive a scapular Blackburn stabilization exercises in addition to conventional Exercise
62120463|NCT06554860|OTHER|control group|Exercise only
62120464|NCT03783754|EXPERIMENTAL|Triple Pill (Active Treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
62120465|NCT03783754|PLACEBO_COMPARATOR|Placebo|received via blinded study oral capsules
62120466|NCT03114904|OTHER|"Usual weaning management"|
62120467|NCT03114904|OTHER|Introduction to H2 for the discontinuation of therapeutics|
62120468|NCT01576952|EXPERIMENTAL|ISV-303|0.075% bromfenac in DuraSite vehicle dosed BID
62475466|NCT00003659|EXPERIMENTAL|intermediate or high risk chronic lymphocytic leukemia|This is a single-arm open-label pilot study designed to assess the antileukemic activity of a regimen containing sequential administration of fludarabine, high-dose cyclophosphamide, and rituximab.
62120469|NCT01576952|PLACEBO_COMPARATOR|DuraSite Vehicle|DuraSite Vehicle dosed BID
61920473|NCT01608854||24 Hour Antibiotics|Patients were randomized to receive 24 hours of postoperative antibiotics following spine surgery
62120470|NCT05593159|ACTIVE_COMPARATOR|Dentin Conditioning & RM-GIC|"Dentin Conditioning:~After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried.~RM-GIC:~RM-GIC (Fuji II LC) will be applied in \<2mm incremental layers afterward light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity."
62120471|NCT05593159|EXPERIMENTAL|1-step adhesive & Cention N|"1-step adhesive: A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).~Cention N:~The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)"
62679284|NCT02662582|EXPERIMENTAL|Placebo, then CK-212710 1000 mg|Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
62475467|NCT01948258|OTHER|Clearblue Advanced Fertility Monitor|Use of Clearblue Fertility Monitor
62679285|NCT06494371|EXPERIMENTAL|Chimeric antigen receptor T cells LCAR-HL30 cells|Each subject will receive LCAR-HL30 cells.
62679286|NCT01798823||EIB+A+|"* children with EIB and asthma~* History, physical, LF, SPT, blood sample, FeNO, EBC"
62679287|NCT01798823||EIB+A-|"* children with EIB without asthma~* History, physical, LF, SPT, blood sample, FeNO, EBC"
62679288|NCT01798823||EIB-A+|"* children without EIB and asthma~* History, physical, LF, SPT, blood sample, FeNO, EBC"
62679289|NCT01798823||EIB-A-|"* children without EIB without asthma~* History, physical, LF, SPT, blood sample, FeNO, EBC"
62679290|NCT06359561||single arm|Up to 40 subjects eligible for SCS trial and permanent implant with a minimum of pain intensity of 5/10 on NRS at baseline will be enrolled.
62120472|NCT05593159|EXPERIMENTAL|Dentin roughness & Gingival retentive groove preparation & Cention N|"Dentin roughness:~Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)~Gingival retentive groove preparation:~Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.~Cention N:~The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)"
62120473|NCT04738565|EXPERIMENTAL|Probiotic|The mixture of 3 probiotic strains in the following proportions: 50% Lactobacillus casei ŁOCK 0919, 25% Lactobacillus rhamnosus ŁOCK 0908, 25% Lactobacillus rhamnosus ŁOCK 0900 (Latopic® preparation, Biomed S.A., Cracow, Poland).
62679291|NCT04754074|EXPERIMENTAL|Behavioral Education and personalized coaching|
62308721|NCT00295893|EXPERIMENTAL|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel, Carboplatin and trastuzumab|Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.
62308722|NCT03162718|OTHER|single arm|exercise
62679292|NCT06212739|EXPERIMENTAL|Laser|Patients treated using fistula laser closure.
62679293|NCT06212739|ACTIVE_COMPARATOR|LIFT|Patients treated using ligation of intersphincteric fistula tract.
61920474|NCT01608854||Duration Antibiotics|Patients were randomized to receive antibiotics for the duration of time a spinal drain was in place following spinal surgery
61920475|NCT04167371|EXPERIMENTAL|Biofeedback|
61920476|NCT04167371|PLACEBO_COMPARATOR|Placebo|
62308723|NCT03117933|ACTIVE_COMPARATOR|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
62308724|NCT03117933|EXPERIMENTAL|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
62308725|NCT03117933|EXPERIMENTAL|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
62308726|NCT01296386|EXPERIMENTAL|IC84, 75 µg w/ Alum|75 µg w/ Alum (microgram with Alum)
62475468|NCT04678440|EXPERIMENTAL|Healthy Volunteers|Study participants will undergo a single dynamic \[18F\]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of \[18F\]F-AraG.
62475469|NCT04678440|EXPERIMENTAL|Non-Small Cell Lung Cancer Patients (NSCLC)|Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic \[18F\]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic \[18F\]F-AraG PET/CT scan on the uEXPLORER total-body scanner.
62475470|NCT00834418|EXPERIMENTAL|Leflunomide|Leflunomide 20 mg Tablet
62475471|NCT00834418|ACTIVE_COMPARATOR|Arava™|Arava™ 20 mg Tablet
62475472|NCT00987740|EXPERIMENTAL|Hemolung Respiratory Assist System|
62475473|NCT03399812|EXPERIMENTAL|Whey protein isolate|
62475474|NCT03399812|ACTIVE_COMPARATOR|Pea protein isolate|
62475475|NCT01452815|PLACEBO_COMPARATOR|1|Drug: placebo
62475476|NCT01452815|EXPERIMENTAL|2|10mg TZP-102
62475477|NCT01452815|EXPERIMENTAL|3|20mg TZP-102
62475478|NCT06424457|EXPERIMENTAL|group A (VATS)|(group A) will receive VATS decortication as their definite management
62475479|NCT06424457|EXPERIMENTAL|group B (open thoracotomy)|(group B) will be assigned to open thoracotomy
62475480|NCT04954573|OTHER|Morphea|
62475481|NCT04954573|OTHER|Sclerotic graft-versus-host disease (GVHD)|
62475482|NCT01212848|EXPERIMENTAL|TMS|
62475483|NCT01212848|SHAM_COMPARATOR|Sham|
62475484|NCT01066598|EXPERIMENTAL|Rituximab plus prednisone|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d Treat 61 Patients
62475485|NCT03676764|ACTIVE_COMPARATOR|Biannual mass oral azithromycin|Bi-annual Mass Azithromycin distribution to all children 1-60 months old in participating communities
62475486|NCT03676764|PLACEBO_COMPARATOR|Biannual mass oral placebo|Bi-annual Mass Placebo distribution to all children 1-60 months old in participating communities
62475487|NCT03676764|PLACEBO_COMPARATOR|Targeted oral placebo|Targeted placebo to children 5 to 12 weeks old at vaccine visit or other healthy child visit
62475488|NCT03676764|ACTIVE_COMPARATOR|Targeted oral azithromycin|Targeted azithromycin to children 5 to 12 weeks old at vaccine visit or other healthy child visit
62475489|NCT05918835|EXPERIMENTAL|High-frequency repetitive transcranial magnetic stimulation (HF-rTMS)|Target: Region of right DLPFC with greatest resting-state functional connectivity to dorsal striatum (individualized functional target) Protocol: 10 pulses/sec, 4s trains, 120% MT, 3000 pulses/session
62475490|NCT05918835|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation (sham rTMS)|Target: Region of right DLPFC with greatest resting-state functional connectivity to dorsal striatum (individualized functional target) Protocol: same as HF-rTMS, with sham coil
62475491|NCT03913559|EXPERIMENTAL|Inotuzumab ozogamicin|"Experimental:Inotuzumab Ozogamicin (InO) Patients with B cell acute lymphoblastic leukemia (B-ALL) that is showing early signs of relapsing (coming back) or is not responding to treatment (refractory).~Interventions:methotrexate, hydrocortisone and cytarabine into the central nervous system (called triple intrathecal chemotherapy or IT chemotherapy) during this study.~Premedication: diphenhydramine, acetaminophen and methylprednisolone"
62475492|NCT01607918|EXPERIMENTAL|Sequential therapy 10 days|Sequential therapy
61920477|NCT04144023|EXPERIMENTAL|Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF)|Prior to standard of care surgery, patients treated at dose levels 1 and 2 receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1 of each cycle. Treatment repeats every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients treated at dose level 3 receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on days 1, 4, 8, and 15 for 1 cycle. Patients also undergo ECHO and collection of blood samples throughout the trial and may undergo biopsy on trial.
62308727|NCT01296386|EXPERIMENTAL|IC84, 75 µg w/o Alum|75 µg w/o Alum (microgram without Alum)
62308728|NCT01296386|EXPERIMENTAL|IC84, 200 µg w/ Alum|200 µg w/ Alum (microgram with Alum)
62308729|NCT01296386|EXPERIMENTAL|IC84, 200 µg w/o Alum|200 µg w/o Alum (microgram without Alum)
62308730|NCT04419506|PLACEBO_COMPARATOR|Placebo, Antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
62475493|NCT01607918|ACTIVE_COMPARATOR|Triple therapy 14 days|Triple therapy
62475494|NCT04266405|PLACEBO_COMPARATOR|Placebo drink|
62679294|NCT05624632||Cognitively unimpaired|Cognitively unimpaired participants from BBRC-sponsored studies
62679295|NCT04568902|EXPERIMENTAL|Dose Escalation Part: H3B-6545 300 mg|Participants will receive H3B-6545 300 milligram (mg) tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
62475495|NCT04266405|EXPERIMENTAL|Collagen and Zhuyin Drinks|
61920478|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
62120474|NCT04738565|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin - a substance in which probiotic strains have been suspended.
62120475|NCT05596994|ACTIVE_COMPARATOR|Light Intervention Therapy (LIT) then Sham LIT|The LIT will begin at the patient's home and will be presented for 10 weeks. A washout period of 1 month will be scheduled to diminish carryover effects of the first therapy arm, then patients will begin the Sham LIT.
62120476|NCT05596994|ACTIVE_COMPARATOR|Sham LIT then Light Intervention Therapy|LIT will be performed identical to Arm 1, except for switchover of active LIT and Sham. A washout period of 1 month will be scheduled to diminish carryover effects of the LIT arm.
62120477|NCT04393246|ACTIVE_COMPARATOR|Standard of care|Standard of care
62120478|NCT04393246|EXPERIMENTAL|EDP1815|1.6 x 10\^11 cells dosage-in-capsule orally twice per day for up to 7 days (with the option to extend up to 14 days), on top of standard of care
62120479|NCT04393246|EXPERIMENTAL|Dapagliflozin and Ambrisentan|Ambrisentan 5mg tablet orally once per day for up to a maximum of 14 days and Dapagliflozin 10mg tablet orally once per day for up to a maximum of 14 days, on top of standard of care
62120480|NCT06677398|EXPERIMENTAL|Group A|Experimental group that used one of the debriefing methods
62308731|NCT04419506|EXPERIMENTAL|BI 1015550, Antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
62475496|NCT00459420|PLACEBO_COMPARATOR|Placebo|
62475497|NCT00459420|EXPERIMENTAL|Caffeine|
62475498|NCT03506763|PLACEBO_COMPARATOR|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
61920479|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
62120481|NCT06677398|EXPERIMENTAL|Group B|Experimental group that used one of the debriefing methods
62120482|NCT06677398|OTHER|Group C|A control group that used none of the debriefing methods
62120483|NCT04920617|EXPERIMENTAL|Arm 1: DPX-Survivac, pembrolizumab, CPA|Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart. Pembrolizumab will be administered on the first day of every three week cycle at a flat dose of 200 mg. CPA will be self-administered 50 mg BID for 7 days on and 7 days off starting on D0.
62120484|NCT04920617|EXPERIMENTAL|Arm 2: DPX-Survivac, pembrolizumab|Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart. Pembrolizumab will be administered on the first day of every three week cycle at a flat dose of 200 mg. Subjects randomized to Arm 2 will not receive CPA.
62475499|NCT03506763|ACTIVE_COMPARATOR|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
62475500|NCT03506763|ACTIVE_COMPARATOR|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
62120485|NCT04042545|EXPERIMENTAL|inhaled THC/CBD (PPP001)|PPP001 (cannabis dosing capsule with THC/CBD) inhalation with a device
62120486|NCT04042545|PLACEBO_COMPARATOR|Placebo|Placebo inhalation with a device
62120487|NCT02899000|EXPERIMENTAL|Acne treatment|"Topical adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (one application daily for 12 weeks)~Oral doxycycline hyclate, 200 mg per day (two 50-mg tablets twice daily for 12 weeks)"
62120488|NCT01320657|ACTIVE_COMPARATOR|InOvation C|Active Self-ligating Bracket
62120489|NCT01320657|PLACEBO_COMPARATOR|Ovation|Conventional Bracket
62120490|NCT01320657|EXPERIMENTAL|Damon Q|Self-ligating bracket
62120491|NCT01573598|PLACEBO_COMPARATOR|Placebo|Dose-matched placebo capsules, oral administration
62120492|NCT01573598|EXPERIMENTAL|Vilazodone 20mg|Vilazodone tablets, 20 mg per day, oral administration
62120493|NCT01573598|EXPERIMENTAL|Vilazodone 40mg|Vilazodone tablets, 40 mg per day, oral administration
62120494|NCT00629941|EXPERIMENTAL|1|
62120495|NCT00420654|ACTIVE_COMPARATOR|A1|
62120496|NCT00420654|PLACEBO_COMPARATOR|A2|
62475501|NCT00968812|ACTIVE_COMPARATOR|Glimepiride|Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
62679296|NCT04568902|EXPERIMENTAL|Dose Escalation Part: H3B-6545 450 mg|Participants will receive H3B-6545 450 mg tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
62679297|NCT04568902|EXPERIMENTAL|Antihistamine Prophylactic Administration Part|Participants will receive prophylactic treatment with non-sedating systemic antihistamine, orally, once from Cycle 1 Day 1 until Cycle 1 Day 28, followed by H3B-6545 450 mg tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
62308732|NCT04419506|PLACEBO_COMPARATOR|Placebo, Non-antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
62308733|NCT04419506|EXPERIMENTAL|BI 1015550, Non-antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
62308734|NCT02459171||Participants|"Subjects who meet eligibility requirements and consent to participate.~Interventions: Blood sample, nasal wash, throat swab, questionnaire"
62308735|NCT00986193|ACTIVE_COMPARATOR|Conventional Aortic Valve Surgery|Insertion of a biological valve
62308736|NCT00986193|EXPERIMENTAL|Transapical Aortic Valve Implantation|Transapical implantation of an Edwards SAPIENtm valve
62308737|NCT04855877|ACTIVE_COMPARATOR|Oral Tranexamic Acid|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
62308738|NCT04855877|PLACEBO_COMPARATOR|Placebo|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
62308739|NCT05861947|EXPERIMENTAL|AUR106|25mg to 100 mg, Currently planned dose levels are 25 mg QD, 50 mg QD, 25 mg BID, 50 mg BID, 100 mg BID
62308740|NCT02348047|ACTIVE_COMPARATOR|Conventional ventilation|Conventional ventilation - manual mode
62308741|NCT02348047|EXPERIMENTAL|ASV|Intellivent ASV ( Adaptative Support Ventilation )Ventilation- automatic mode
62475502|NCT00968812|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
62475503|NCT00968812|EXPERIMENTAL|Canagliflozin 300 mg|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
62475504|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
62679298|NCT04568902|EXPERIMENTAL|Randomization Part|Participants will be randomized in 1:1 ratio to receive H3B-6545 450 mg, tablets, orally, once daily in 28 days cycle either with non-sedating systemic antihistamine prophylactic administration from Day 1 until Day 28 of Cycle 1 OR without antihistamine prophylactic administration until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
62679299|NCT03385642||Chondromimetic|Treatment of osteochondral defect in the knee with Chondromimetic device(s) in previous study 0MCM0107
62679300|NCT06496971|ACTIVE_COMPARATOR|Standard of care (SoC) BEV alone|SoC group will follow the standard operating procedures of BEV (10 mg/kg intravenous (IV) infusion over 30-90 minutes, following the instructions in the drug package insert).
62120497|NCT00420654|OTHER|A3|
62120498|NCT04891458|EXPERIMENTAL|Patients received lighter sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 0-2.
62120499|NCT04891458|EXPERIMENTAL|Patients received heavier sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 3-5.
62120500|NCT04891458|EXPERIMENTAL|Patients received lighter sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 0-2.
62120501|NCT04891458|EXPERIMENTAL|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 3-5.
62120502|NCT00346333|EXPERIMENTAL|Lutein plus 15,000 IU/d Vitamin A|Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
62120503|NCT00346333|PLACEBO_COMPARATOR|Control plus 15,000 IU/d Vitamin A|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
62120504|NCT05979324|EXPERIMENTAL|ABAStroke Digital Therapeutics|50 patients using ABAStroke with standard treatment after a stroke.
62308742|NCT03167697|EXPERIMENTAL|Synergy|This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
62308743|NCT03167697|ACTIVE_COMPARATOR|Routine|This group will continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.
62308744|NCT01426386|EXPERIMENTAL|5.2 µg|
62308745|NCT01426386|EXPERIMENTAL|6.9 µg|
62308746|NCT01426386|EXPERIMENTAL|8.6 µg|
62308747|NCT01426386|EXPERIMENTAL|10.3 µg|
62308748|NCT01426386|EXPERIMENTAL|12.1 µg|
62308749|NCT01426386|ACTIVE_COMPARATOR|11 µg FbM (150 IU)|
62308750|NCT00414440|EXPERIMENTAL|Everolimus|Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day \[5 mg b.i.d.\]).
62308751|NCT00414440|PLACEBO_COMPARATOR|Placebo|Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
62308752|NCT01095861|EXPERIMENTAL|FlexTip ETT|FlexTip ETT
62308753|NCT01095861|PLACEBO_COMPARATOR|Control|Standard Flexible ETT Mallinckrodt Hi-Lo cuffed tracheal tube Catalog # 86114 Mallinckrodt, ST. Louis, MO, 63134
62308754|NCT01158950|EXPERIMENTAL|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
62308755|NCT01158950|PLACEBO_COMPARATOR|Placebo|Drug: Placebo for tolcapone administered at study visit
62308756|NCT02024581|ACTIVE_COMPARATOR|10% East Indian sandalwood oil cream|East Indian sandalwood oil in a cream formulation administered twice a day for ninety (90) days
62308757|NCT02024581|PLACEBO_COMPARATOR|Placebo cream|A scented cream formulation administered twice a day for ninety (90) days
62475505|NCT06392438|EXPERIMENTAL|IPL group|Participants will receive 0.09% cyclosporine drops dosed at bid for 16 weeks. Participants receive 3 IPL sessions at 3-weeks interval in the last 2 months of the study. IPL treatments will be given with Lumenis M22 with a 590nm filter, pulse duration of 6-50ms (3 pulses/trigger) and fluence will be determined after determining the skin type (Fitzpatrick scale) of the participant.
62475506|NCT06392438|SHAM_COMPARATOR|Sham-IPL group|Participants will receive 0.09% cyclosporine drops dosed at bid for 16 weeks. Participants receive 3 IPL sessions at 3-weeks interval in the last 2 months of the study. IPL treatments will be given with Lumenis M22 with a 590nm filter, pulse duration of 6-50ms (3 pulses/trigger) and fluence will be determined set at 10 J/cm2. A plastic filter will recover the IPL prism, preventing the light to reach the skin of the participant.
62475507|NCT00112463|EXPERIMENTAL|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
62679301|NCT06496971|EXPERIMENTAL|Microbubble-mediated FUS treatment with BEV (FUS-MB+BEV)|FUS-MB+BEV group will follow the standard operating procedures of BEV (10 mg/kg intravenous (IV) infusion over 30-90 minutes, following the instructions in the drug package insert). After at least 30 minutes, patients will be administered microbubbles (MB) (SonoVue® ) at a dose of 0.1 mL/kg, along with optimal ultrasound exposure doses determined by the acoustic emission feedback FUS power control algorithm of the NaviFUS System.
62679302|NCT06161194|EXPERIMENTAL|Intervention Group (IG)|IG will perform the home-exercise program supported by the digital real-time exercise feedback prototype for digitally guided training.
61920480|NCT01752712|EXPERIMENTAL|CBSST + oxytocin|Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
61920481|NCT01752712|PLACEBO_COMPARATOR|CBSST + placebo|Cognitive Behavioral Social Skills Training with placebo nasal spray. The placebo nasal spray bottles will be matched in appearance to the oxytocin nasal spray bottles and similarly administered intranasally in two doses (morning and evening).
62120505|NCT05979324|NO_INTERVENTION|Control group|50 people using standard treatment after a stroke.
62120506|NCT03365622|ACTIVE_COMPARATOR|IV acetaminophen and placebo pills|
62120507|NCT03365622|PLACEBO_COMPARATOR|placebo IV (normal saline) + oral acetaminophen|
62308758|NCT02832492||PNR+|Patients who will show pupil near response during PNR assessment.
62308759|NCT02832492||PNR-|Patients who will not show pupil near response during PNR assessment.
62679303|NCT06161194|ACTIVE_COMPARATOR|Control Group (CG)|The CG will perform a usual care home-exercise by means of printed hand-outs describing each exercise.
62308760|NCT01580475|EXPERIMENTAL|Lifestyle (exercise training)|Training, detraining and retraining
61920482|NCT01466595|EXPERIMENTAL|Arm A: Treatment with rifaximin|Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
62475508|NCT01117220|PLACEBO_COMPARATOR|2|
62475509|NCT01117220|ACTIVE_COMPARATOR|1|
62475510|NCT00315562|EXPERIMENTAL|Early|Early
62475511|NCT00315562|ACTIVE_COMPARATOR|Delayed|Delayed
62475512|NCT00834964|EXPERIMENTAL|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
62120508|NCT04125433|EXPERIMENTAL|Medicaid Emergency Department High Utilizers|"This Arm will include the following individuals~* Up to 400 Adults age 18 to 65~* New York State Medicaid Managed Care Members~* Have utilized emergency department services 6 or more times in a 12-month period~* Have been assigned to the Pilot Project by their Medicaid Managed Care Plan"
62120509|NCT05944822||Essure|patient who underwent removal of the Essure® contraceptive implant
62120510|NCT05944822||Control with no endometriosis/adenomyosis|patient who underwent benign laparoscopic gynecological surgery and with no diagnosis of endometriosis or adenomyosis
62120511|NCT05944822||Control with endometriosis/adenomyosis|patient who underwent benign laparoscopic gynecological surgery and with diagnosis of endometriosis or adenomyosis
62120512|NCT05297448|EXPERIMENTAL|Rifaximin SSD-40mg IR|
62120513|NCT05297448|PLACEBO_COMPARATOR|Placebo|
62308761|NCT03900676|EXPERIMENTAL|VB-1953 topical gel - 2% QD|VB-1953 topical gel - 2% QD
62308762|NCT03900676|EXPERIMENTAL|VB-1953 topical gel - 2% BID|VB-1953 topical gel - 2% BID
62308763|NCT03900676|PLACEBO_COMPARATOR|VB-1953 topical gel- 0% (Vehicle) QD|VB-1953 topical gel- 0% (Vehicle) QD
62308764|NCT03900676|PLACEBO_COMPARATOR|VB-1953 Vehicle|VB-1953 topical gel- 0% (Vehicle) BID
62308765|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
62679304|NCT06626347|EXPERIMENTAL|TREAT-ED|"* Emerging adult patients with type 1 diabetes assigned to groups of eight participants on average.~* Four diabetes self-management education and support group sessions delivered virtually each session lasting 30-45 minutes.~* Group sessions scheduled at intervals decided up on by participants."
62308766|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
62308767|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
62679305|NCT06359535|EXPERIMENTAL|HSK21542-60μg|HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
62308768|NCT03401606|ACTIVE_COMPARATOR|Remifentanil|remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
62308769|NCT03401606|ACTIVE_COMPARATOR|Dexmedetomidine|dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
62308770|NCT03697369||Observation group|Individuals with T1D ages 0-20 years who switched management modality from MDI to pump as part of their clinical care and were followed up prospectively in the next 12 months.
62308771|NCT00177346|EXPERIMENTAL|CAS with cerebral protection|
62308772|NCT00177346|ACTIVE_COMPARATOR|CAS without cerebral protection|
62308773|NCT02437669|EXPERIMENTAL|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
62308774|NCT05836961|EXPERIMENTAL|BNP enrolled|Pregnant women in their first or second trimester who have been enrolled in BNP
62308775|NCT05836961|NO_INTERVENTION|BNP non-enrolled|Pregnant women in their first or second trimester who are not enrolled in BNP
62308776|NCT00754767|EXPERIMENTAL|Arm I|Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
62308777|NCT00754767|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
62679306|NCT06359535|EXPERIMENTAL|HSK21542-120μg|HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
62679307|NCT06359535|EXPERIMENTAL|HSK21542-180μg|HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
62679308|NCT06359535|PLACEBO_COMPARATOR|Placebo|A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
62679309|NCT03142958||Integra® Cadence™ Total Ankle System|
62120514|NCT02620761|PLACEBO_COMPARATOR|Control|Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
62120515|NCT02620761|EXPERIMENTAL|Fenoldopam|Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.
62120516|NCT01283750|NO_INTERVENTION|Augmented Usual Care|
62120517|NCT02577419|EXPERIMENTAL|Target Fortification|
62308778|NCT01850381|EXPERIMENTAL|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
62475513|NCT00834964|ACTIVE_COMPARATOR|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
62679310|NCT06526169||Ethnicity: Chinese|
62679311|NCT06526169||Ethnicity: Malay|
62120518|NCT02577419|EXPERIMENTAL|Higher Initial Concentration|
62120519|NCT02577419|ACTIVE_COMPARATOR|Portagen Growth Reference|
62120520|NCT02695381|EXPERIMENTAL|Etodolac-lidocaine Topical Patch|Therapy with experimental drug
62120521|NCT02695381|PLACEBO_COMPARATOR|Placebo|Therapy with placebo
62679312|NCT06526169||Ethnicity: Indian|
62679313|NCT00536523||Patients Receiving Chemotherapy|Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned
62679314|NCT00569127|EXPERIMENTAL|Arm I (octreotide acetate and bevacizumab)|Patients receive depot octreotide acetate IM and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62679315|NCT00569127|EXPERIMENTAL|Arm II (octreotide acetate and recombinant interferon alfa-2b)|Patients receive octreotide acetate IM as in arm I on day 1 and recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62308779|NCT01850381|PLACEBO_COMPARATOR|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
62308780|NCT00922935|EXPERIMENTAL|Cresco early loading|The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) at 10 days of post surgery
62308781|NCT00922935|EXPERIMENTAL|Cresco late loading|"Healing caps will be placed until loading. The minimum waiting time is 4 weeks, but not before try ins to ensure a perfect fit. The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) within 42-56 days (6 to 8 weeks) of surgery."
62475514|NCT02316015|EXPERIMENTAL|Intervention group|Children in the intervention group will receive a protein-energy enriched milk (Infatrini®, or in the case of children on a partial or fully hydrolized milk Infatrini Peptisorb®). The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day). The intervention will be carried out during the first 7 days of hospitalisation, or until the day of discharge (if hospitalized for less than 7 days).
62308782|NCT00922935|ACTIVE_COMPARATOR|Straumann system late loading|Straumann components loading at 6-8 weeks post surgery
62308783|NCT01030042|EXPERIMENTAL|Cetuximab/Irinotecan|Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)
62475515|NCT02316015|NO_INTERVENTION|Control group|Children in the control group will receive their regular milk. The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day).
62475516|NCT01415986|EXPERIMENTAL|Subjects receiving Temoporfin|
62308784|NCT01030042|ACTIVE_COMPARATOR|FOLFOX 4|FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab
62308785|NCT01388400|EXPERIMENTAL|Conventional intervention for upper limb reaching|Reaching or holding cones, cups, etc. in all planes with and without gravity or loading
62308786|NCT01388400|EXPERIMENTAL|VR treatment|The Virtual Reality (VR) therapy group received the treatment in the GestureTek VR environment which focused on reaching movements of the affected upper limb using virtual games and a virtual supermarket.
62308787|NCT02127762|EXPERIMENTAL|Mindfulness Based Stress Reduction|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
62308788|NCT02127762|NO_INTERVENTION|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
62308789|NCT03167619|EXPERIMENTAL|A - olaparib alone|Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
62308790|NCT03167619|EXPERIMENTAL|B - olaparib plus durvalumab|Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
62308791|NCT01073189|EXPERIMENTAL|Intra-Renal Fenoldopam|Intra-Renal Fenoldopam: Patients randomized to this wing will undergo placement of Angiodynamics Benefit catheter and receive intra-renal infusion of fenoldopm mesylate
62308792|NCT01073189|ACTIVE_COMPARATOR|Diuretic Control|Patients in the control group will be randomized to receive intra-venous diuretics as a comparator control
62308793|NCT06221644||MSA patients group|The patient cohort consisted of 30 MSA-C and 30 MSA-P cases, diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists
62308794|NCT06221644||healthy controls (HCs) group|30 gender and age-matched HCs were included
62308795|NCT06407362||Patients who had undergone septoplasty|
62308796|NCT02246270|EXPERIMENTAL|Intravesical heparin|Recurrent UTI subject receives intravesical heparin once every week for 6 weeks
62308797|NCT02246270|ACTIVE_COMPARATOR|Placebo|Recurrent UTI subject receives intravesical saline once every week for 6 weeks
62475517|NCT01299454|ACTIVE_COMPARATOR|Normal|
62308798|NCT03358628||Osteosarcoma|Osteosarcoma patients with metastatic relapsed or unresectable progressive disease (total n= up to 20) following resection of the primary lesion and adjuvant chemotherapy.
62475518|NCT01299454|ACTIVE_COMPARATOR|Mild|
62475519|NCT01299454|ACTIVE_COMPARATOR|Moderate|
62475520|NCT01299454|ACTIVE_COMPARATOR|Severe|
62475521|NCT06559670|OTHER|Preterm babies|All the newborns will be studied to identify babies who will develop later (at 36 weeks of postcomptional age) Chronic Lung Disease of prematurity
62308799|NCT02894515|EXPERIMENTAL|Test/Reference|Single dose of commercial tablet Treatment A (Test) in period I. Followed by single dose of clinical tablet Treatment B (Reference) in period II. First and second dose administration will be separated by a washout period of at least 7 days
62308800|NCT02894515|EXPERIMENTAL|Reference/Test|Single dose of clinical tablet Treatment B (Reference) in period I. Followed by single dose of commercial tablet Treatment A (Test) in period II. First and second dose administration will be separated by a washout period of at least 7 days
62308801|NCT05146622||Formative Research|Outdoor workers in the United States.
62308802|NCT04373369|EXPERIMENTAL|Vorolanib + Atezolizumab|Consenting and eligible participants who have no evidence of tumor progression after 3 to 4 cycles of standard-of-care induction therapy will receive atezolizumab intravenously (IV) every 3 weeks and vorolanib by mouth daily.
62308803|NCT01596595||Medically Indicated for ICD or CRT-D|Medically Indicated for ICD or CRT-D implantation per guidelines
62308804|NCT06512090|EXPERIMENTAL|LGI steam bread intervention group|The participant in this group takes LGI steam bread as staple food instead of diabetic diet during the study period.
61920483|NCT01466595|NO_INTERVENTION|Arm B: No study treatment|No study treatment for 4 weeks
62308805|NCT06512090|ACTIVE_COMPARATOR|Diabetic diet group|he participant in this group takes diabetic diet during the study period.
62308806|NCT01583647|EXPERIMENTAL|MK-0524A 1 g/20 mg (Panel A)|Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
62308807|NCT01583647|EXPERIMENTAL|MK-0524A 2 g/40 mg (Panel B)|Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
62308808|NCT02333539|EXPERIMENTAL|Tailored feedback|Participants are provided a Tailored Feedback report based on data downloaded from their insulin pumps. Summaries are provided about insulin pump adherence behaviors and recommendations for improvement are made.
62308809|NCT02333539|EXPERIMENTAL|Problem Solving|Participants receive a problem-solving session based on data downloaded from their insulin pumps. An insulin pump adherence behavior that needs improvement is targeted; goals are set and solutions generated.
62308810|NCT02333539|NO_INTERVENTION|Treatment as Usual|Standard of care as provided by the endocrinologist occurs.
62308811|NCT01906840|EXPERIMENTAL|drug: turmeric capsule|Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks
62308812|NCT01906840|PLACEBO_COMPARATOR|Drug: placebo,capsule|Intervention is daily starch capsules 500 mg for 8 weeks
62308813|NCT01594099|ACTIVE_COMPARATOR|Radiotherapy alone|
62308814|NCT01594099|EXPERIMENTAL|Radiotherapy plus cisplatin|
62475522|NCT05252377|EXPERIMENTAL|Breathing Exercise Group|Breathing exercise program; It was prepared by the researchers in accordance with the literature and based on the studies in which breathing exercise was applied to reduce invasive pain experienced during cannulation, blood collection and postoperative pain. Patients will be given an exercise based on rhythmic breathing. The exercise will be started before the cannulation application, the patient will be told to perform the breathing exercise twice, and he will be asked to continue doing the breathing exercise until the cannulation process is completed. The patient will wait by taking five normal breaths between each breathing exercise. The patient will be told that he can count by using his fingers in the steps he is asked to count up to three.
62308815|NCT01594099|EXPERIMENTAL|Radiotherapy plus liposome paclitaxel|
62308816|NCT04296292||AMBITION Trial Participants|Individuals who have been enrolled into the AMBITION trial
62308817|NCT04296292||The next-of-kin of AMBITION Trial Participants|Individuals who have provided consent for an AMBITION trial participant who had an abnormal mental status at baseline
62475523|NCT05252377|NO_INTERVENTION|Control Group|No intervention will be made by the researcher on the patients in this group, and a pain assessment will be made by the nurse in charge of dialysis immediately after the cannulation procedure by the dialysis nurse working in the unit.
62475524|NCT03730363|EXPERIMENTAL|Pentamidine + ICE|Pentamidine, Ifosfamide, Carboplatin, and Etoposide (ICE) by IV Infusion.
62475525|NCT03804749|EXPERIMENTAL|Group 1-1|The dose of suramin sodium is 10 mg/kg
61920484|NCT05022875|EXPERIMENTAL|Experimental app intervention|The complete Healthcare CEO app will be used for intervention in the experimental group.
62308818|NCT04296292||AMBITION Researchers|Individuals working on the AMBITION trial
62308819|NCT06477341|NO_INTERVENTION|control group|patients of head and neck cancer receiving radiotherapy , who did not receive any nutritional support during radiotherapy
62308820|NCT06477341|ACTIVE_COMPARATOR|nutritional support grouped|patients of head and neck cancer receiving radiotherapy , who receive any nutritional support during radiotherapy whether oral or intravenous like dipeptivine for mucositis
62308821|NCT01363505||Acute CHF patients|Acute CHF patients with BARD Intra-abdominal pressure monitors in ICU
62475526|NCT03804749|PLACEBO_COMPARATOR|Group 1-2|The placebo is 0.9% sodium chloride injection
61920485|NCT05022875|SHAM_COMPARATOR|Control app intervention|"Participants in the control group will only install the CEO's Profile and Health Tracking interfaces of the Healthcare CEO app."
62308822|NCT00443560||Instrumental Vaginal Delivery (IVD)|Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
62308823|NCT00443560||Spontaneous Vaginal Delivery (SVD)|The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.
62308824|NCT00847717|EXPERIMENTAL|1|IIb preserving neck dissection
62308825|NCT00847717|OTHER|2|Conventional neck dissection
62308826|NCT06265948||The sample will be randomly assigned into one of two equal groups ((Group-I (n|"Sample size calculation was carried out using G\*Power 3 software (Faul et al., 2007)1 calculated minimum sample of 80 patient candidate for cancer surgery will be needed.~The sample will be randomly assigned into one of two equal groups ((Group-I (n=40):~will receive standard general anesthesia as control, and Group III (n=40): will receive~Ketofol in addition to the standard general anesthesia. The calculated sample will be~needed to detect an effect size of 0.1~in the RM-ANOVA (within group-between groups~and interaction) on repeated measurements (every 2-hours postoperatively) for the~mean VAS score, with an error probability of 0.05 and 95% power."
62308827|NCT04885049|EXPERIMENTAL|Group A|Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
62308828|NCT04885049|EXPERIMENTAL|Group B|Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
62679316|NCT05683275|EXPERIMENTAL|IASTM|"In addition to the home exercise program application, IASTM application will be made for 4 weeks. IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute (Cheatham et al., 2019). The instruments will be applied to the soft tissue at 30º-60º angles, using vaseline as an intermediate, with a multidirectional stroking movement."
62120522|NCT04080258|EXPERIMENTAL|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMTh). Patients in the OMTh group will receive 5 Osteopathic manipulative therapies: the first at baseline, the second after 1 week, the third after 3 weeks, and then 2 more treatments on a monthly basis. The protocol will last for three months.
62308829|NCT01793545||Endometrial Cancer Cohort|Women with abnormal bleeding or other conditions associated with increased risk ofendometrial cancer.
62308830|NCT04558008|EXPERIMENTAL|Online MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
62475527|NCT03804749|EXPERIMENTAL|Group 2-1|The dose of suramin sodium is 15mg/kg
62475528|NCT03804749|PLACEBO_COMPARATOR|Group 2-2|The placebo is 0.9% sodium chloride injection
62679317|NCT05683275|EXPERIMENTAL|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application. Ultrasound gel will be used as an intermediate in the application. No anesthetic substance will be used before and after the application. Cold applications will be recommended for those who have pain after the application.
62679318|NCT05683275|EXPERIMENTAL|Home Exercise|Static stretching and eccentric strengthening exercises specific to the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks. For strengthening exercises, all patients will be asked to use green (medium resistance) elastic bands, hold them in a tense position for 10 seconds, let them back passively, and rest for 1 minute between sets. In the stretching exercise, they will be asked to stay in the most tense position for 30-45 seconds and rest for 30 seconds between stretching. In case of a painful situation, they will be asked to be informed about their information.
62120523|NCT04080258|SHAM_COMPARATOR|Light Touch Therapy|Participants to the LTT group will receive the protocol at the same date of the OMTh group.
62679319|NCT04971837|EXPERIMENTAL|Two Visits Including A Test Meal|Separated by a minimum of 4 days.
62120524|NCT04893213|ACTIVE_COMPARATOR|Baseline availability|Baseline availability of lower energy meal options
62120525|NCT04893213|EXPERIMENTAL|Increased availability|Increased availability of lower energy meal options
62120526|NCT04045886|EXPERIMENTAL|Online Educational Modules group|anesthesia residents are randomized to watch educational videos which is the intervention.
62120527|NCT04045886|ACTIVE_COMPARATOR|Reading two research papers group|anesthesia residents are randomized to read 2 research papers which is the active comparator
62679320|NCT04971837|EXPERIMENTAL|Five Visits Not Involving A Test Meal|Separated by a minimum of 14 days.
62120528|NCT06261372|NO_INTERVENTION|control group|The control group received conventional dialysis treatment.
62120529|NCT06261372|OTHER|intervention group|In addition to conventional treatment, mindfulness meditation combined with progressive muscle relaxation training was implemented during the interdialytic period.
62120530|NCT00812617|EXPERIMENTAL|Mineral water 1|
62120531|NCT00812617|EXPERIMENTAL|Mineral water 2|
62120532|NCT05691738|EXPERIMENTAL|Exercise Group|Information will be given about diabetes and its complications.Modified Otago Exercise will be applied by the physiotherapist.Participants will be given a home program
62120533|NCT05691738|OTHER|Control Group|Information will be given about diabetes and its complications.Participants will be given a home program
62120534|NCT03379935||Bipolar radial head arthroplasty|Patients treated with bipolar head arthroplasty due to radial head fracture
62120535|NCT03379935||Unipolar radial head arthroplasty|Patients treated with unipolar head arthroplasty due to radial head fracture
62120536|NCT04390958|EXPERIMENTAL|Neoadjuvant chemotherapy group|Total 6 perioperative chemotherapy composed of nab-paclitaxel, cisplatin and capecitabine every 21 days
62120537|NCT02731339|EXPERIMENTAL|Women with Urinary incontinence|
61920486|NCT01415193|EXPERIMENTAL|Selective Tibial Nerve Block|
61920487|NCT01415193|ACTIVE_COMPARATOR|Control: Sciatic Nerve Block|
62120538|NCT02731339|EXPERIMENTAL|Women without Urinary incontinence|
62120539|NCT05700513|ACTIVE_COMPARATOR|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
62120540|NCT05700513|PLACEBO_COMPARATOR|Placebo|Placebo capsules containing maltodextrin
62120541|NCT00596648|EXPERIMENTAL|Phase 1 Arm|Escalating doses of XL184 + erlotinib
62120542|NCT00596648|EXPERIMENTAL|Phase 2 Arm 1|XL184 + erlotinib (dose determined from Phase 1 portion of study)
62120543|NCT00596648|EXPERIMENTAL|Phase 2 Arm 2|XL184 administered as a single agent
62120544|NCT00345761|EXPERIMENTAL|Step 1|
62120545|NCT00345761|EXPERIMENTAL|Step 2|
62120546|NCT00345761|EXPERIMENTAL|Step 3|
62308831|NCT04558008|NO_INTERVENTION|Wait-list control|Usual practice
62308832|NCT05751005|EXPERIMENTAL|Collagen Supplementation 6 months|Participants were randomized into one of three treatment groups for 6 months (Placebo, 10 g/d collagen peptides, or 20 g/d collagen peptides).
62308833|NCT05751005|EXPERIMENTAL|Collagen Supplementation 9 months|Participants were randomized into one of three treatment groups (Placebo, 10 g/d collagen peptides, or 20 g/d collagen peptides) for additional 3 months after successful completion of the 6 month time point (total of 9 months).
62308834|NCT03937986|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62475529|NCT03804749|EXPERIMENTAL|Group 3-1|The dose of suramin sodium is 20mg/kg
62475530|NCT03804749|PLACEBO_COMPARATOR|Group 3-2|The placebo is 0.9% sodium chloride injection
62475531|NCT01359696|EXPERIMENTAL|A|
62308835|NCT03937986|EXPERIMENTAL|Suvorexant Dose 1|Subjects will be maintained on oral suvorexant dose 1. Cocaine will be administered acutely during suvorexant dose 1 maintenance. Placebo will be administered acutely during suvorexant dose 1 maintenance.
62679321|NCT04370847||Lung Ultrasound (LUS) Examination|Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients
62679322|NCT02569775|EXPERIMENTAL|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
62120547|NCT02086370|ACTIVE_COMPARATOR|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
62120548|NCT02086370|EXPERIMENTAL|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
62679323|NCT06013800||Same Volume Status (Clinical and Point-of-Care Ultrasound)|The patient has the same volume status clinically and by point-of-care ultrasound
62679324|NCT06013800||Different Volume Status (Clinical or Point-of-Care Ultrasound)|The patient has a different volume status clinically or by point-of-care ultrasound
62679325|NCT06695715|EXPERIMENTAL|Mindfulness|"The Mindfulness Training program will be based on the Mindfulness-Based Stress Reduction (MBSR) program and Jon Kabat-Zinn's Mindful Awareness practices, but will also include elements of self-compassion and acceptance.~Intervention: During the six weeks of the program, participants will take part in a guided 45-minute formal session. Examples of formal guided meditations include mindfulness of breath and mindfulness of thoughts, feelings, and physiological sensations. Informal meditation practices will consist of brief pauses throughout the day, during which participants will voluntarily direct their attention to the present moment without judgment. Finally, participants will be provided with 10 audio recordings of guided meditations, recorded by a member of the research team, to support formal meditation at home (10-15 minutes four times a week), as well as a series of readings focused on the concepts of acceptance and self-compassion."
62120549|NCT04910555||women over 65 years old with OAB|Community-dwelling women over 65 years old, with non-neurogenic OAB, with or without UI
62120550|NCT00598208|EXPERIMENTAL|1|60 µg Org 36286 (corifollitropin alfa)
62120551|NCT00598208|EXPERIMENTAL|2|120 µg Org 36286 (corifollitropin alfa)
62120552|NCT00598208|EXPERIMENTAL|3|180 µg Org 36286 (corifollitropin alfa)
62120553|NCT00598208|ACTIVE_COMPARATOR|4|Follitropin beta injection
62120554|NCT04764448|EXPERIMENTAL|Belcesiran Cohort 1|
62120555|NCT04764448|PLACEBO_COMPARATOR|Placebo Cohort 1|
62120556|NCT04764448|EXPERIMENTAL|Belcesiran Cohort 2|
62120557|NCT04764448|PLACEBO_COMPARATOR|Placebo Cohort 2|
62308836|NCT03937986|EXPERIMENTAL|Suvorexant Dose 2|Subjects will be maintained on oral suvorexant dose 2. Cocaine will be administered acutely during suvorexant dose 2 maintenance. Placebo will be administered acutely during suvorexant dose 2 maintenance.
62308837|NCT03937986|EXPERIMENTAL|Suvorexant Dose 3|Subjects will be maintained on oral suvorexant dose 3. Cocaine will be administered acutely during suvorexant dose 3 maintenance. Placebo will be administered acutely during suvorexant dose 3 maintenance.
62308838|NCT05306678|EXPERIMENTAL|Prolonged sitting|Prolonged sitting
62308839|NCT05306678|EXPERIMENTAL|Breaking sitting|Breaking prolonged sitting
62308840|NCT05216991||TetraGraph monitoring on dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
62308841|NCT05216991||TetraGraph monitoring on non-dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
62308842|NCT01197573|ACTIVE_COMPARATOR|Standard DCD liver transplant|Standard method of liver transplant utilizing a DCD organ
62120558|NCT04764448|EXPERIMENTAL|Belcesiran Cohort 3|
62120559|NCT04764448|PLACEBO_COMPARATOR|Placebo Cohort 3|
62120560|NCT06676215|EXPERIMENTAL|Intervention Arm|complementary food supplemented with indispensable amino acid (IAA) mix
62120561|NCT06676215|EXPERIMENTAL|Control Group|complementary food without IAA mix
62120562|NCT05589506|EXPERIMENTAL|Removable partial denture PEEK|Removable partial denture using PEEK-acrylic resin
62120563|NCT01353170|EXPERIMENTAL|Prevalent hd patients|Patients undergoing three consecutive cross-over hd session with 3 different dialysate calcium concentrations
62120564|NCT05018325|ACTIVE_COMPARATOR|Arm 1: Colonoscopy 6 minute withdrawal time|-Undergo colonoscopy with the standard 6-minute withdrawal time followed by a tandem colonoscopy of at least another 6-minute withdrawal time.
62120565|NCT05018325|EXPERIMENTAL|Arm 2: Colonoscopy 9 minute withdrawal time|-Undergo a 9-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time.
62120566|NCT05018325|EXPERIMENTAL|Arm 3: Colonoscopy 12 minute withdrawal time|-Undergo colonoscopy with a 12-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time
62308843|NCT01197573|ACTIVE_COMPARATOR|rTPA Treatment Liver Transplant|Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA
62308844|NCT01197573|ACTIVE_COMPARATOR|Standard DCD kidney transplant|Standard method of kidney transplant utilizing a DCD organ
62679326|NCT06695715|EXPERIMENTAL|HRV Biofeedback Training (HRV-BF)|The HRV BF training will last for 6 weeks. There will be five training sessions per week, including four home sessions and one in-person session at the Neurociencia del Bienestar group laboratory (CTS-1129) at the Faculty of Psychology of the University of Seville. Each session will last 20 minutes. The laboratory session will be conducted using the Procomp Infiniti biofeedback equipment (Thought Technologies). For the home HRV-BF sessions, we will use a novel methodology recently described (Schumann et al., 2021). The heart rate will be recorded using a sensor embedded in a strap that will be worn around the participant's chest (H10/H7 heart rate sensor; Polar Electro Oy, Kempele, Finland). Via Bluetooth, the mobile app EliteHRV (Elite HRV LLC, 2017) will collect data from the sensor, store the recordings, and display the heart rate. The heart rate oscillations will be shown on the participants' smartphone screens as real-time visual feedback of their heart rate.
62679327|NCT06695715|EXPERIMENTAL|Interoceptive Training|During the 6 weeks of the program, participants in this group will complete a 45-minute formal guided interoceptive training session at the Faculty of Psychology. During these sessions, the focus will be on developing internal body awareness through various strategies. Participants will learn to pay attention to internal sensations such as breathing and muscle tension using guided techniques. The program will include exercises to feel the flow of breath and relax specific areas of the body. The trainer will provide feedback and adjust techniques based on the participants' needs. Instructions will be given on how to integrate these practices into daily life to improve self-care and self-regulation. Finally, participants will be provided with 10 audio recordings of guided interoceptive exercises, recorded by a member of the research team, to support formal training at home (10-15 minutes, four times a week).
62679328|NCT06695715|NO_INTERVENTION|Waiting list control group|Participants assigned to the waitlist control group will be key to ensuring the validity and reliability of the results of this project, allowing for precise and controlled comparisons of the effectiveness of the different training programs. These participants will also be evaluated at the beggining and the end, even though they will not participate in any training program. Once the program is completed, they will be offered the opportunity to participate in some of the training programs used in this project.
62679329|NCT05261490|EXPERIMENTAL|Phase 1: Dose Escalation|"In the Phase 1 (dose escalation):~Cycle 1 for dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1, Day 8, Day 15 and Day 22 in combination with PLD on Day 1 of 28-day cycle. Beginning with Cycle 2 at dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. For Phase 1, dose level 3, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. Dose level 3 will be biweekly regimen from the start."
62679330|NCT05261490|EXPERIMENTAL|Phase 2: Dose Expansion|"In the Phase 2 (dose expansion):~maplirpacept (PF-07901801) will be administered with selected dose from the escalation phase by intravenous infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and 15 in subsequent cycles in combination with Pegylated Liposomal Doxorubicin 40 mg/m2 by intravenous infusion on Day 1 of each 28-day cycle."
62120567|NCT03753594||H group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.5% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests at 5 min were assessed before the block and at 5-min intervals till 30 min after the block.
62120568|NCT03753594||L group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.25% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests were assessed at 5 min before the block and at 5-min intervals till 30 min after the block.
62475532|NCT03444792|EXPERIMENTAL|Group I (dilation group)|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure. - If failed we will use artery forceps to dilate cervix
62475533|NCT03444792|NO_INTERVENTION|Group II (non dilatation group)|the surgeon will perform cesarian section without attempting cervical dilatation
62475534|NCT00272779|ACTIVE_COMPARATOR|Atazanavir (ATV) + Ritonovir (RTV)|Participants were administered an oral dose of ATV 300 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of ATV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
62475535|NCT00272779|ACTIVE_COMPARATOR|Lopinavir (LPV) + RTV|Participants were administered an oral dose of LPV 400 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of LPV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
62120569|NCT05278871|EXPERIMENTAL|CSI ultrasound measurement|Participants will have standard volumetric tape measurement across multiple arm locations for lymphedema followed by CSI ultrasound measurements of the same anatomic sites.
62120570|NCT02089698|ACTIVE_COMPARATOR|Reversed tip|Reversed Kelman tip
61920488|NCT01546480||Pain patients|Patients with unexplained chronic abdominal pain 12 months after elective cholecystectomy
62120571|NCT02089698|EXPERIMENTAL|Mini-flared|Mini-flared Kelman tip
62308845|NCT01197573|ACTIVE_COMPARATOR|rTPA Treatment Kidney Transplant|Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA
62679331|NCT01937468|EXPERIMENTAL|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
62679332|NCT05490446|EXPERIMENTAL|Core Period: Phase 2a - Tebapivat 5 mg|Participants will receive 5 milligrams (mg) tebapivat orally, once daily for up to 16 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.
61920489|NCT01546480||Operated painfree Patients|Painfree patients 12 months after elective cholecystectomy
61920490|NCT01546480||Nonoperated painfree patients|Painfree patients with no previous abdominal operation
61920491|NCT03304496|EXPERIMENTAL|Nitroglycerin|"The intervention group will receive a subcutaneous cocktail with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine."
61920492|NCT03304496|PLACEBO_COMPARATOR|Control|The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
61920493|NCT03504930||Impact of biotherapy on postoperative morbidity|Impact of biotherapy on postoperative morbidity in ulcerative colitis
61920494|NCT00263276|EXPERIMENTAL|Arm 1|
61920495|NCT00263276|EXPERIMENTAL|Arm 2|
62120572|NCT03508310|EXPERIMENTAL|Intervention|29-minute clinic waiting room video intervention that includes three vignettes and a 2-part animation sequence about main characters who model overcoming challenges to optimal HIV care. The video was played on continuous loop in recognition of typically short patient wait times. Waiting room posters used images from the video to direct patients' attention to the video and reinforce prevention messages.
62308846|NCT02517879|EXPERIMENTAL|Group 1 - 1-3 days|Community health worker hang-up visit 1-3 days after the community point distribution
61920496|NCT00263276|EXPERIMENTAL|Arm 3|
61920497|NCT00263276|EXPERIMENTAL|Arm 4|
61920498|NCT00263276|EXPERIMENTAL|Arm 5|
61920499|NCT00263276|PLACEBO_COMPARATOR|Arm 6|
61920500|NCT00263276|ACTIVE_COMPARATOR|Arm 7|
61920501|NCT04197687|EXPERIMENTAL|Arm I - No pCR (trastuzumab emtansine, TPIV100, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive TPIV100 ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of TPIV100 ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
61920502|NCT04197687|PLACEBO_COMPARATOR|Arm II - No pCR (trastuzumab emtansine, placebo, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive placebo ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of placebo ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
61920503|NCT04197687|EXPERIMENTAL|Treatment (pCR)|Patients receive standard of care maintenance therapy with trastuzumab and pertuzumab for 1 year in the absence of disease progression or unacceptable toxicity.
61920504|NCT01683773|EXPERIMENTAL|Group A|Two doses of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection)
61920505|NCT01683773|EXPERIMENTAL|Group B|One dose of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection)
61920506|NCT01683773|EXPERIMENTAL|Group C|Three doses of AERAS-402 (1x10\^11 vp intramuscular injection)
61920507|NCT01469117||Pediatric developmental disabilities|Children aged 1-13 years old with development disabilities, requiring enteral tube feeding for at least 14 days
61920508|NCT01381146|EXPERIMENTAL|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
62120573|NCT03508310|NO_INTERVENTION|Comparison|Historical comparison condition. Patients were exposed to standard waiting room environment (absent of intervention video and posters).
62679333|NCT05490446|EXPERIMENTAL|Core Period: Phase 2b - Tebapivat 10 mg|Participants will receive 10 mg tebapivat, orally, once daily for up to 24 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.
62679334|NCT05490446|EXPERIMENTAL|Core Period: Phase 2b - Tebapivat 15 mg|Participants will receive 15 mg tebapivat, orally, once daily for up to 24 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.
62679335|NCT05490446|EXPERIMENTAL|Core Period: Phase 2b - Tebapivat 20 mg|Participants will receive 20 mg tebapivat, orally, once daily for up to 24 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.
62679336|NCT06686212|EXPERIMENTAL|Group A: Sensory re-education program, strengthening exercises and kinesio taping|"The patient will be given a session of 60 minutes 3 days in a week which includes : Splinting (15 minutes), Topical anesthesia spray (10 minutes ) and wrist massage (10 minutes).~* PNF using upper extremity (D2) pattern (5 minutes).~* Strengthening exercises (20 minutes) and Kinesio taping for 12 weeks."
62679337|NCT06686212|EXPERIMENTAL|Group B:Neural mobilization of median nerve, strengthening exercises and kinesio taping.|"The patient will be given a session of 60 minutes 3 days in a week which includes: ,Median nerve mobilization through various steps of gliding. (30 minutes).~* Free the bird exercise. (10 minutes).~* Strengthening exercises (20 minutes) and kinesio taping for 12 weeks."
62120574|NCT04778124|OTHER|Patients with hemorrhoidal disease undergoing HAL-RAR|This is a single-arm trial, in which all patients with grade II hemorrhoidal disease resistant to conservative treatment, grade III and IV hemorrhoidal disease underwent HAL RAR surgery.
62120575|NCT06334549|EXPERIMENTAL|Ephedrine-Propofol|receive ephedrine 0.15mg/kg (configured concentration 6mg/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
62120576|NCT06334549|EXPERIMENTAL|Phenylephrine-propofol|receive phenylephrine 2.5ug/kg(configured concentration 100ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
62308847|NCT02517879|EXPERIMENTAL|Group 2 - 5-7 days|Community health worker hang-up visit 5-7 days after the community point distribution
62679338|NCT05849116||High flow nasal cannula|preterms infants who are connected to high flow nasal cannula
62120577|NCT06334549|EXPERIMENTAL|Norepinephrine-propofol|receive norepinephrine 0.2ug/kg(configured concentration 8μg/ml) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
62679339|NCT05849116||Continuous positive airway pressure|preterms who are connected to continuous positive airway pressure
62679340|NCT06685796|EXPERIMENTAL|Cohort 1：Carboplatin and Gemcitabine|"Carboplatin injection, dosage:AUC 2 ×(creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 of each cycle, with a 21-day cycle.~Gemcitabine hydrochloride for injection, dosage:1000mg/m², frequency and duration of administration: administered on days 1 and 8 of each cycle, with a 21-day cycle."
62120578|NCT06334549|ACTIVE_COMPARATOR|Ephedrine-sevoflurane|receive Ephedrine 0.15mg/kg(configured concentration 6mg/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
62120579|NCT06334549|ACTIVE_COMPARATOR|Phenylephrine-sevoflurane|receive phenylephrine 2.5ug/kg(configured concentration 80ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
62120580|NCT06334549|ACTIVE_COMPARATOR|Norepinephrine-sevoflurane|receive norepinephrine 0.2ug/kg(configured concentration 8ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
62120581|NCT02138006|EXPERIMENTAL|Intensive insulin treatment|Intensive insulin treatment
62120582|NCT02138006|ACTIVE_COMPARATOR|Standard insulin treatment|Standard insulin treatment
62120583|NCT04681079||Crossover Sequence 1|Subjects randomized to receive commercially available albuterol sulfate via MDI with spacer first, followed by albuterol sulfate via nebulizer with filtered mouthpiece.
62120584|NCT04681079||Crossover Sequence 2|Subjects randomized to receive commercially available albuterol sulfate via nebulizer with filtered mouthpiece first, followed by albuterol sulfate via MDI with spacer.
62308848|NCT02517879|EXPERIMENTAL|Group 3 - 10-12 days|Community health worker hang-up visit 10-12 days after the community point distribution
62679341|NCT06685796|EXPERIMENTAL|Cohort 2：BEBT-209 Capsules plus Chemotherapy (Carboplatin and Gemcitabine)|"BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner, and on days 2 and 9, take orally once before breakfast.~Carboplatin injection, dosage: AUC 2 × ( creatinine clearance rate + 25), frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle.~Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle."
62679342|NCT06685796|EXPERIMENTAL|Cohort 3：BEBT-209 Capsules plus Chemotherapy (Carboplatin and Gemcitabine)|"BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.~Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle.~Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle."
62679343|NCT05853939|EXPERIMENTAL|Visual Cortex, 1 Hz rTMS, Attended|
62308849|NCT02517879|EXPERIMENTAL|Group 4 - 15-17 days|Community health worker hang-up visit 15-17 days after the community point distribution
61920509|NCT01381146|OTHER|TAU|treatment as usual -- participants have access to all other jail programs and services
62475536|NCT00080951|EXPERIMENTAL|irinotecan + oxaliplatin + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV and fluorouracil IV over 90 minutes on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before each chemotherapy course, and at the end of treatment.~Patients are followed every 3 months until 5 years after registration."
62475537|NCT02846363||Patients included in the Rhône region from France|public awareness campaign
62475538|NCT02846363||Patients included in the control region (Isère, France)|
62679344|NCT05853939|EXPERIMENTAL|Visual Cortex, 1 Hz rTMS, Unattended|
62679345|NCT05853939|EXPERIMENTAL|Visual Cortex, 10 Hz rTMS, Attended|
62679346|NCT05853939|EXPERIMENTAL|Visual Cortex, 10 Hz rTMS, Unattended|
62679347|NCT05853939|SHAM_COMPARATOR|Visual Cortex, Sham, Attended|
62679348|NCT05853939|SHAM_COMPARATOR|Visual Cortex, Sham, Unattended|
61920510|NCT05065775|EXPERIMENTAL|Dexmedetomidine|Single intranasal 100 µg bolus dose of dexmedetomidine
62475539|NCT03650985|EXPERIMENTAL|TOCTD|Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent, will be involved. Fetoscope technique will be administered in suitable patients.
61920511|NCT02142010|OTHER|paclitaxel liposome injection plus cisplatin|
61920512|NCT04218123|EXPERIMENTAL|Venlafaxine Arm|
61920513|NCT04218123|PLACEBO_COMPARATOR|Placebo|
62475540|NCT01763177|NO_INTERVENTION|No oxygen|No given oxygen at post-anesthetic care unit
62475541|NCT01763177|ACTIVE_COMPARATOR|Oxygen|Oxygen nebulizer via face mask, Fraction of inspired oxygen (FiO2) 0.4, flow 8 liter per minute (LPM) for 30 minutes
62475542|NCT02530333|NO_INTERVENTION|Basketball Control|Control group of basketball players
62679349|NCT04128748|EXPERIMENTAL|Treatment (CPX-351, quizartinib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3 and 5 and quizartinib PO on days 6-19. Patients who do not respond to treatment during cycle 1 receive CPX-351 IV on days 1 and 3 and quixartinib PO on days 6-19 during cycle 2. Treatment repeats every 28 days for up 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive CPX-351 over 90 minutes on days 1 and 3 and quizartinib PO on days 4-28 of cycle 1. Treatment with CPX-351 repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive quizartinib PO on days 1-28 in the absence of disease progression or unacceptable toxicity."
62679350|NCT04298658||HIV and Insomnia|Participants will test positive for HIV and Insomnia.
62679351|NCT04298658||HIV Without Insomnia|Participants will test positive for HIV and test negative for Insomnia.
62679352|NCT04298658||Non HIV with Insomnia|Participants will test negative for HIV and test positive for Insomnia.
61920514|NCT02106039|EXPERIMENTAL|intensive monitoring|more intensive monitoring strategy of blood glucose and clinical review
61920515|NCT02106039|NO_INTERVENTION|standard monitoring|glucose monitoring followed the prevailing practice at each site
62308850|NCT02517879|PLACEBO_COMPARATOR|Group 5 - No hang-up visit|Did not receive any hang-up visit after the community point distribution
62679353|NCT04298658||Non HIV Without Insomnia|Participants will test negative for HIV and test negative for Insomnia.
61920516|NCT04812678|ACTIVE_COMPARATOR|Physiotherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines"
61920517|NCT04812678|EXPERIMENTAL|Physiotherapy and Fasciatherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines, associated with Fasciatherapy Danis Bois Method"
61920518|NCT04812678|EXPERIMENTAL|Fasciatherapy|Fasciatherapy Danis Bois Method
62120585|NCT04217850|EXPERIMENTAL|500 kcal Energy Deficit|The goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
62120586|NCT01560416|ACTIVE_COMPARATOR|ARM A - Fulvestrant|Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.
62475543|NCT02530333|EXPERIMENTAL|Basketball intervention|Intervention group of basketball players
62475544|NCT02530333|NO_INTERVENTION|Soccer Control|Control group of soccer players
62475545|NCT02530333|EXPERIMENTAL|Soccer Intervention|intervention group of soccer players
62679354|NCT05782244|ACTIVE_COMPARATOR|Sildenafil citrate low dose|Sildenafil citrate 20 mg, oral, TID
62679355|NCT05782244|PLACEBO_COMPARATOR|Placebo|Placebo, oral, TID
62679356|NCT05782244|ACTIVE_COMPARATOR|Sildenafil citrate medium dose|Sildenafil citrate 40 mg, oral, TID
62679357|NCT05782244|ACTIVE_COMPARATOR|Sildenafil citrate high dose|Sildenafil citrate 80 mg, oral, TID
62679358|NCT01008046|EXPERIMENTAL|combined N-acetyl cysteine - CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
62679359|NCT01008046|ACTIVE_COMPARATOR|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.
62679360|NCT01235416|ACTIVE_COMPARATOR|AMG 706 50mg|50 mg, once daily. (Cohort 1)
62679361|NCT01235416|ACTIVE_COMPARATOR|AMG 706 75mg|75 mg, twice daily. (Cohort 2)
62679362|NCT01235416|ACTIVE_COMPARATOR|AMG 706 125mg|125 mg, once daily. (Cohort 3)
61920519|NCT01251471|EXPERIMENTAL|Escitalopram|Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks
61920520|NCT03464695|ACTIVE_COMPARATOR|O2matic|Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.
61920521|NCT03464695|NO_INTERVENTION|Manual|Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.
61920522|NCT01151098|EXPERIMENTAL|BTDS 5, 10 or 20|Buprenorphine transdermal patch
61920523|NCT00696475|EXPERIMENTAL|1|Diazoxide equivalent dose
61920524|NCT00696475|EXPERIMENTAL|2|Diazoxide equivalent dose
61920525|NCT00696475|EXPERIMENTAL|3|Diazoxide equivalent dose
61920526|NCT00696475|PLACEBO_COMPARATOR|4|
61920527|NCT04652180|EXPERIMENTAL|Robot-assisted thoracic approach in Ivor Lewis esophagectomy|Robot-assisted thoracic approach in Ivor Lewis esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
61920528|NCT04652180|ACTIVE_COMPARATOR|Open transthoracic approach in Ivor Lewis esophagectomy|Traditional open transthoracic esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
62120587|NCT01560416|ACTIVE_COMPARATOR|Arm B - Fulvestrant+Ganetespib|"Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle~Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression."
62475546|NCT01747694|EXPERIMENTAL|Multi-respiratory muscle training|Patients will perform multi-repiratory muscle training programe for 12 weeks
62679363|NCT02324829||Total joint replacement|Patients who has undergone lower body total joint replacement surgery.
62679364|NCT05311982|ACTIVE_COMPARATOR|DLPFC-L F3 (Block A)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A)
61920529|NCT06314620|ACTIVE_COMPARATOR|Participants who underwent ICC with normal saline flushing and heparin lock|Participants who underwent intercostal chest catheter with normal saline flushing with heparin lock. Instillation done with 20 mls of Normal Saline flush followed by heparin saline lock, every 6 hours by a three way stopcock.
62308851|NCT02153515|EXPERIMENTAL|Fingerprick of autologous blood (FAB)|Fingerprick of autologous blood (FAB) four times a day for 2 months
62308852|NCT03680677||Cancer Directed Therapy or Best Supportive Care|Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care
62308853|NCT03680677||Transplant|Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy
62308854|NCT04292847|EXPERIMENTAL|Geriatric Assessment|Participants fill out the geriatric assessment during a clinic visit and receive recommendations based on results
61920530|NCT06314620|ACTIVE_COMPARATOR|Participants who underwent ICC with normal saline flushing without heparin lock|Participants who underwent intercostal chest catheter with normal saline flushing without heparin lock. Instillation done with 20 mls of Normal Saline flush , every 6 hours by a three way stopcock.
62120588|NCT06172517|EXPERIMENTAL|Othesis intervention|This group with custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
62120589|NCT06172517|NO_INTERVENTION|Control group|Without orthesis prescriptions by podiatrists.
62120590|NCT03696862|EXPERIMENTAL|collagen plug|collagen plug used to seal the socket after atraumatic extraction of the badly deacayed teeth with immediate implant placement and bone graft
62308855|NCT05441046|EXPERIMENTAL|Genakumab|genakumab plus tislelizumab 200 mg
62475547|NCT01747694|NO_INTERVENTION|Diaphragmatic breathing|Patients will be taught diaphragmatic breathing technique routinely. To practice at home lasting 12 weeks
61920531|NCT03499301||Chronic pain|Patients with chronic pain when arrived to emergency room.
62120591|NCT01354769||Non-intubated patients|
62120592|NCT01354769||Intubated patients|
62308856|NCT03784430|ACTIVE_COMPARATOR|Implant|Immediate dental implant placement
62308857|NCT03784430|EXPERIMENTAL|Implant+CTG|Immediate dental implant placement with CTG.
62308858|NCT04627350||LDCT|Single arm - all patients undergo low-dose CT (LDCT) examination of lungs
62308859|NCT01787591|EXPERIMENTAL|Acute Fat-Free Milk Ingestion|Participants will ingest 1 cup of fat-free milk with 15 mg deuterium-labeled alpha-tocopherol.
62308860|NCT01787591|EXPERIMENTAL|Acute Low-Fat Milk Ingestion|Participants will ingest 1 cup of low-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
62308861|NCT01787591|EXPERIMENTAL|Acute Full-Fat Milk Ingestion|Participants will ingest 1 cup of full-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
62308862|NCT01787591|EXPERIMENTAL|Acute Soy Milk Ingestion|Participants will ingest 1 cup of soy milk with 15 mg deuterium-labeled alpha-tocopherol.
62308863|NCT04827537|EXPERIMENTAL|20-hydroxyecdysone group|water sports athletes with Giardia infection will receive 20-hydroxyecdysone (100 mg (one pill) x two times a day orally), 10 consecutive days
62308864|NCT04827537|ACTIVE_COMPARATOR|metronidazole group|"water sports athletes with Giardia infection will receive metronidazole, 500 mg (one pill) x two times a day orally, 10 consecutive days~, and placebo preparations, respectively"
62679365|NCT05311982|ACTIVE_COMPARATOR|tDCS combined in DLPFC-L (F3) and DLPFC-R (F4)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in tDCS combined in DLPFC-L (F3) and DLPFC-R (F4)
62679366|NCT05311982|NO_INTERVENTION|Sham (Block C)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in tDCS Sham
62679367|NCT06691750|EXPERIMENTAL|Study Group: Uterine repair with barbed suture|Uterine closure following cesarean section is carried out using an unlocked single-layer barbed suture with an endometrium-free technique.
62679368|NCT06691750|ACTIVE_COMPARATOR|Control Group: Uterine repair with conventional smooth suture|Uterine repair following cesarean section is performed using a conventional smooth polyglactin suture with a continuous single-layer, endometrium-free technique, in accordance with the standard procedure at our center.
62679369|NCT06549049|EXPERIMENTAL|Arm 1: Experimental|Participants receiving experimental TSC-PTSD treatment.
62308865|NCT04827537|PLACEBO_COMPARATOR|placebo group|water sports athletes with Giardia infection will receive placebo preparation, 100 mg (one pill) x two times a day orally, 10 consecutive days
61920532|NCT03499301||No chronic pain|Patients without chronic pain when arrived to emergency room.
61920533|NCT04230018||primary and metastasis lesion|tissue of colorectal cancer primary lesion and tissue of colorectal cancer metastasis were obtained
61920534|NCT03826576|EXPERIMENTAL|Intervention Group|Intervention group will receive a Multicomponent Intervention.
62120593|NCT04540497|EXPERIMENTAL|VIB0551|Inebilizumab administered as an IV infusion.
62120594|NCT04540497|PLACEBO_COMPARATOR|Placebo|Placebo administered as an IV infusion.
62308866|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
62679370|NCT06549049|ACTIVE_COMPARATOR|Arm 2: Active Control|Participants receiving sleep psychoeducation control.
62679371|NCT03381651|ACTIVE_COMPARATOR|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT
62120595|NCT02315469||Observational (geriatric assessment)|At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
62120596|NCT06042439|EXPERIMENTAL|Morning (AM)|Exercise starting before 10:01 AM
62120597|NCT06042439|EXPERIMENTAL|Evening (PM)|Exercise starting after 3:59 PM
62120598|NCT00928213|EXPERIMENTAL|1|Control not treated, no placebo
62120599|NCT00928213|EXPERIMENTAL|2|Patient treated with low molecular weight heparin after repeated pregnancy loss
62120600|NCT00928213|EXPERIMENTAL|3|Patient super from first trimester bleeding treated with progesterone
62120601|NCT01180192|EXPERIMENTAL|oxygen|
62308867|NCT05252520|EXPERIMENTAL|JNJ-77474462|Participants will receive a single subcutaneous (SC) Dose 1 of JNJ-77474462 on Day 1 in Cohort 1, a single SC Dose 2 of JNJ-77474462 on Day 1 in Cohort 2 and a single SC Dose 3 of JNJ-77474462 on Day 1 in Cohort 3.
62308868|NCT02263365|NO_INTERVENTION|Control|
62308869|NCT02263365|EXPERIMENTAL|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
62308870|NCT02439385|EXPERIMENTAL|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
62308871|NCT03213639|EXPERIMENTAL|study group|Patients will take esomeprazole single dose of 40 mg orally once a day
62679372|NCT03381651|ACTIVE_COMPARATOR|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT
62308872|NCT03213639|PLACEBO_COMPARATOR|control group|Patients will take an inert tablet similar in appearance, color and consistency
62308873|NCT04075604|EXPERIMENTAL|Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)|
61920535|NCT03826576|NO_INTERVENTION|Control Group|Control group will not receive any kind of intervention, only it will receive information about AMED criteria and allergens of food.
61920536|NCT01389362|ACTIVE_COMPARATOR|Chinese Herbal Medicine|2 sachets of Chinese Herbal Medicine to be taken daily
61920537|NCT01389362|PLACEBO_COMPARATOR|Placebo arm|2 sachets to be taken daily
62120602|NCT01365208||advanced nasopharyngeal carcinoma|
62120603|NCT00479648|ACTIVE_COMPARATOR|1|Inactivated trivalent influenza vaccine
62120604|NCT00479648|EXPERIMENTAL|2|CSL412 formulation
62120605|NCT00479648|EXPERIMENTAL|3|CSL412 formulation
62120606|NCT00479648|EXPERIMENTAL|4|CSL412 formulation
62120607|NCT02708069|OTHER|e-Unstuck condition|Parents in the e-Unstuck condition will be asked to complete each of the e-Unstuck modules (one per week) over the course of the nine-week intervention, in addition to reading the UOT manual.
62120608|NCT02708069|OTHER|In-Person condition|Parents participating in the in-person condition will be asked to attend two in-person trainings (approximately 125 and 100 minutes respectively) on the Unstuck and On Target (UOT) curriculum, in addition to reading the UOT manual.
62120609|NCT05593523||Aim 1: Partial Thickness Burn Wounds|"Participants with 1-30% total body surface area (TBSA) partial thickness burn wounds admitted to the University of Wisconsin (UW) Burn Center within 24 hours of burn injury and expected to be admitted for 3 days.~Indocyanine green angiography (ICGA) fluorescence imaging immediately after administration of 7mg of ICG, and second window indocyanine green (SWIG) fluorescence imaging \~24 hours after administration of up to 5 mg/kg ICG of human burn wounds. ICGA within 72 hours of admission with the OnLume Clinical Imaging System (CIS). SWIG fluorescence imaging will also be performed perioperatively if applicable."
62120610|NCT05593523||Aim 2: Deep Partial or Full Thickness Burn Wounds|"Participants with 1-30% total body surface area (TBSA) deep partial or full thickness burn wounds that will likely require surgery.~ICGA fluorescence imaging immediately after administration of 7mg of ICG, and second window indocyanine green (SWIG) fluorescence imaging \~24 hours after administration of up to 5 mg/kg ICG of human burn wounds. Imaging will occur with the OnLume Clinical Imaging System (CIS)."
62120611|NCT06555380||The one-year intervention group|Children aged 5-10 with obesity who participated in the one-year multifactorial family-centered lifestyle intervention.
62120612|NCT06555380||The three-year intervention group|Children aged 5-10 with obesity who participated in the three-year multifactorial family-centered lifestyle intervention.
62120613|NCT06555380||The non-intervention group|Children with obesity living in one of the municipalities who were never invited to participate in the interventions.
62120614|NCT06386627||Post-stroke persons|
62120615|NCT06386627||Healthy volunteers|
62120616|NCT03607708|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
62308874|NCT04075604|EXPERIMENTAL|Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ|
62308875|NCT04075604|ACTIVE_COMPARATOR|Arm C: Palbociclib+ANZ|
62308876|NCT04187001||Judges|Professionals that assess the content validity of the exercise protocol
62308877|NCT04187001||Target population|People that assess the exercise protocol for cultural adaptation
62339592|NCT00652431|EXPERIMENTAL|Vytorin + Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 + VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
62679373|NCT04032262|OTHER|Parkinson's Disease Relationship to the GI track|Patients with Parkinson's.
62308878|NCT00495846|EXPERIMENTAL|A|"1. Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~2. Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of \>6 cm in size or multiple nodules of \>3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study"
61920538|NCT04219462|ACTIVE_COMPARATOR|study group|twenty men receive extracorporeal shock wave (ESWT) twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura +sildenafil 5mg once daily for 3 months.
62308879|NCT00495846|OTHER|B|Historical controls
62308880|NCT02007239|EXPERIMENTAL|treatment|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
62679374|NCT06690892|EXPERIMENTAL|Experimental Group|The experimental group will participate in the 12-week beef dietary intervention study. Participants will be provided with 5 portions of ready-to-eat beef in frozen packages per week. Each portion of beef provided to this group will weigh 5 ounces.
62679375|NCT06690892|PLACEBO_COMPARATOR|Control Group|The control group will participate in the 12-week beef dietary intervention. Participants will be provided with 5 portions of ready-to-eat beef in frozen packages per week. Each portion of beef provided to this group will weigh 1 ounces.
62308881|NCT01607723|OTHER|NAVA ventilatory mode|
62475548|NCT06319976|EXPERIMENTAL|open chain exercises for rotator cuff muscles and advices for postural correction|Group will be subdivided into three subgroups according to their body mass index to normal, over weight and obese type1. All subjects will receive open chain exercises for rotator cuff muscles and advices for postural correction.
62308882|NCT01607723|OTHER|PAV+ ventilatory mode|
62475549|NCT06319976|ACTIVE_COMPARATOR|Advices for Postural correction|Group will be subdivided into three subgroups according to their body mass index to normal, over weight and obese type1. All subjects will receive advices for postural correction. .
62475550|NCT02008097|EXPERIMENTAL|Liver transplant without a stent|Liver Transplant patients without a stent who are referred for liver ultrasound will have will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System .
62475551|NCT02008097|EXPERIMENTAL|Liver transplant with a stent|Liver transplant patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for liver ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
62475552|NCT02008097|EXPERIMENTAL|Renal artery disease without a stent|Patients with hypertension or impaired renal function who are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
62475553|NCT02008097|EXPERIMENTAL|Renal artery disease with a stent|Patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
62475554|NCT02008097|EXPERIMENTAL|Pregnancy, Normal|Pregnant women referred for an obstetrical ultrasound to evaluate a normal pregnancy; for example, to determine gestation or gestational age will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
62679376|NCT02613507|EXPERIMENTAL|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
62679377|NCT02613507|ACTIVE_COMPARATOR|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
62679378|NCT02398474|EXPERIMENTAL|iliac crest bone graft with a TFP block|Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
62308883|NCT00539344|EXPERIMENTAL|1|
62679379|NCT02398474|ACTIVE_COMPARATOR|local anesthetic infiltration of the surgical site.|RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
62679380|NCT05664646|SHAM_COMPARATOR|Without stimulation|For study 1, exercise endurance time and heart rate recovery will be measured after arm ergometry without stimulation. For study 2, body core temperature and thermal comfort will be reported without stimulation.
62679381|NCT05664646|ACTIVE_COMPARATOR|With stimulation|For study 1, exercise endurance time and heart rate recovery will be measured after arm ergometry with stimulation. For study 2, body core temperature and thermal comfort will be reported with stimulation.
62679382|NCT06300307|EXPERIMENTAL|ATX-01|ATX-01 is a formulation of the anti-microRNA 23b (anti-miR-23b), known as X82108, a novel type of antisense oligonucleotide
62679383|NCT06300307|PLACEBO_COMPARATOR|Placebo|Placebo to ATX-01
62308884|NCT01264315|OTHER|Lenalidomide in maintenance|
62308885|NCT00642616|EXPERIMENTAL|Technosphere® Insulin (Asthma)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
62308886|NCT00642616|ACTIVE_COMPARATOR|Usual Care (Asthma)|Usual anti diabetic care in Diabetic participants with Asthma
62308887|NCT00642616|EXPERIMENTAL|Technosphere® Insulin (COPD)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
62308888|NCT00642616|ACTIVE_COMPARATOR|Usual Care (COPD)|Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
62308889|NCT00599586|EXPERIMENTAL|group 1|specific acupoints of Shaoyang meridians
62308890|NCT00599586|EXPERIMENTAL|Group 2|Non-specific acupoints of Shaoyang meridians
62308891|NCT00599586|EXPERIMENTAL|group 3|Acupoints of other meridians
62308892|NCT00599586|SHAM_COMPARATOR|group 4|Non-acupoints
62308893|NCT06143579|EXPERIMENTAL|Treatment|FOLFOX-HAIC + Lenvatinib + Envolizumab
62308894|NCT05332899|EXPERIMENTAL|Influenza Challenge Model with Influenza A H3N2 Strain|Participants exposed to a previously validated influenza challenge model with influenza A H3N2 strain (A/Perth/16/2009 H3N2).
62339593|NCT00652431|ACTIVE_COMPARATOR|Vytorin|VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
62475555|NCT02008097|EXPERIMENTAL|Pregnancy, High Risk|Pregnant women referred for an obstetrical ultrasound to evaluate a high risk pregnancy due to a medical condition present before or during pregnancy for either the mother or the baby will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System. Examples of risk factors include placenta previa, vaginal bleeding, suspected multiple gestation, suspected uterine abnormality, suspected fetal growth abnormality, advanced maternal age, a prior C-section, prior low birth weight baby, and prior preterm birth.
62475556|NCT02837991|EXPERIMENTAL|CDX-014|"During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~The planned dose of CDX-014 depends on the cohort assigned at enrollment."
62475557|NCT05985772|ACTIVE_COMPARATOR|Non-operative Control (ARM 1)|Subjects randomized to the non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
62475558|NCT05985772|EXPERIMENTAL|Operative Intervention (ARM 2)|Subjects randomized to the operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment. All surgically treated subjects, regardless if repairs were performed acutely or after cross over, will receive identical postoperative rehabilitation.
62475559|NCT05552482||Patients with ESRD with early AVF failure|Patients with ESRD who underwent AVF access creation surgery with early AVF failure
62475560|NCT05552482||patients with ESRD without early AVF failure|Patients with ESRD who underwent AVF access creation surgery without early AVF failure
62475561|NCT01141374|NO_INTERVENTION|control group without treatment|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
62475562|NCT01141374|EXPERIMENTAL|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
62475563|NCT01141374|EXPERIMENTAL|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
62475564|NCT05422521|EXPERIMENTAL|identification of predictive and prognostic biomarkers|
62475565|NCT06602544|EXPERIMENTAL|Multi-visit ambulatory activities with soft robotic apparel|Participants will engage in ambulatory activities (i.e. straight-line walking, turning) with and without the assistance of robotic apparel, performed across multiple visits under various freezing-of-gait (FoG) provoking scenarios
62475566|NCT05074576|EXPERIMENTAL|Mulligan group|In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied.
62475567|NCT05074576|OTHER|Control group|Electroterapy agents are applied in the contro group
62679384|NCT04883645|EXPERIMENTAL|Experimental: Topical Aldara|"All patients receive the same treatment (there is no placebo arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria."
62679385|NCT01496859|EXPERIMENTAL|Baska|
62679386|NCT04128228|OTHER|Alcohol use disorder with early trauma|Individuals with alcohol use disorder participated in an equivalent 8-week outpatient treatment program.
62679387|NCT04128228|OTHER|Alcohol use disorder without early trauma|Individuals with alcohol use disorder participated in an equivalent 8-week outpatient treatment program.
62308895|NCT03553017||Participants with eye disease|A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
62308896|NCT05346757|OTHER|miRFec test|The miRFec test corresponds to the combination of fecal hemoglobin concentration and fecal miRNA expression
62308897|NCT05835258|EXPERIMENTAL|Melatonin with phenyl capsaicin|Participants will consume one capsule of 1 mg of melatonin with phenyl capsaicin
62308898|NCT05835258|ACTIVE_COMPARATOR|Melatonin without phenyl capsaicin|Participants will consume one capsule of 1 mg of melatonin without phenyl capsaicin
62475568|NCT00840476|EXPERIMENTAL|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
62679388|NCT04128228|NO_INTERVENTION|Controls with early trauma|Control participants did not receive any treatment.
62679389|NCT04128228|NO_INTERVENTION|Controls without early trauma|Control participants did not receive any treatment.
62475569|NCT00840476|ACTIVE_COMPARATOR|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
62475570|NCT04559386|EXPERIMENTAL|Overall trial|People who complete the questionnaire.
62475571|NCT05044364|EXPERIMENTAL|China clevidipine butyrate injection|Yangtze River Pharmaceutical Group Co., Ltd.
62679390|NCT00705965|EXPERIMENTAL|1|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
62679391|NCT00705965|ACTIVE_COMPARATOR|2|Usual cardiological care including one information session.
62679392|NCT01656447||Patients with Scleroderma|Patients who have been diagnosed at any point in their life with Scleroderma will compose the cohort.
62679393|NCT04149457|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
62308899|NCT06513520||Patients in acute medical situation|Patients over 75 with polypathology hospitalised in geriatric wards, in acute situation: for example, patients presenting with an infection, cardiac decompensation, a complicated fall, acute renal failure, any acute or decompensated cardiovascular pathology, any discovery of cancer that has not been stabilised.
62308900|NCT06513520||Patients in stable medical situation|Patients over 75 with polypathology hospitalised in geriatric wards, in a stable situation: these are patients who have not had an episode of decompensation or infection for at least 7 days.
62475572|NCT05044364|ACTIVE_COMPARATOR|Original research clevidipine butyrate injection|Fresenius Kabi Austria Gmb H (Austria)
62475573|NCT03789565||Group 1. Healthy individuals from periodontal perspective:|GI \< 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
62475574|NCT03789565||Group 2. Individuals diagnosed with Gingivitis|GI \> 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
62475575|NCT03789565||Group 3. Individuals diagnosed with CP|GI \> 1, PD ≥ 5 mm, CAL ≥ 3 mm, with apparent bone loss on radiography.
62475576|NCT03696745|PLACEBO_COMPARATOR|Placebo|preterm infants with severe hypoxic ischemic encephalopathy receive only 0.9% Sodium-chloride
62475577|NCT03696745|EXPERIMENTAL|infusion|preterm infants with severe hypoxic ischemic encephalopathy will receive up to 4 infusions of their own volume reduced cord blood stem cells. The number of doses will be determined by the amount of available cord blood stem cells. The dose for each infusion is 5x107 cells/kg
62120617|NCT03607708|ACTIVE_COMPARATOR|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
62308901|NCT01268397|ACTIVE_COMPARATOR|ORIF|Open reduction and internal fixation with a volar plate
62475578|NCT05669547|NO_INTERVENTION|Control|Patients currently on multiple daily injections (MDI) + continuous or flash glucose monitoring (CGM; FGM) or on a hybrid closed loop (HCL).
62679394|NCT04149457|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
62679395|NCT01000766||Acute drug-induced liver injury|
62308902|NCT01268397|ACTIVE_COMPARATOR|plaster treatment|Closed reduction and plaster treatment
62475579|NCT05669547|EXPERIMENTAL|Intervention|Patients on dual hormone fully closed loop (DHFCL) therapy.
62679396|NCT06688838||glucocorticoid+ DMARDs|glucocorticoid+ DMARDs
62679397|NCT06688838||glucocorticoid+TNFi|glucocorticoid+TNFi
62679398|NCT06688838||glucocorticoid+Tofacitinib|glucocorticoid+Tofacitinib
62679399|NCT01386385|EXPERIMENTAL|Arm I (RT, veliparib, carboplatin, paclitaxel)|Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
62679400|NCT01386385|ACTIVE_COMPARATOR|Arm II (3D-CRT, placebo, carboplatin, paclitaxel)|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
62679401|NCT06687057|EXPERIMENTAL|Biofeedback|The actual administration of the HRV-Biofeedback protocol: 5 HRV biofeedback training sessions of 45 minutes each, conducted biweekly.
62679402|NCT06687057|PLACEBO_COMPARATOR|Placebo|Placebo condition: 5 control sessions of 45 minutes each, conducted biweekly.
62308903|NCT06365476|EXPERIMENTAL|Focused Extracorporeal Shock Wave Therapy|Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting three specific muscles: the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. Each muscle will receive 1,500 shockwave shots per session, accumulating to a total of 4,500 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions.
62308904|NCT06365476|PLACEBO_COMPARATOR|Placebo-Controlled Shockwave Therapy|Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves.
62120618|NCT04086966|EXPERIMENTAL|Metastatic Prostate Cancer Arm|\[68Ga\]PSMA-11 PET/MRI or PET/CT for guiding the radiation treatment plan in patients with known or suspected locally metastatic prostate cancer
62308905|NCT04033679|EXPERIMENTAL|Active TDCS|In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.
62120619|NCT04482400|EXPERIMENTAL|NEAT!2|Participants randomized to this arm will use the NEAT!2 app and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
62308906|NCT04033679|SHAM_COMPARATOR|Sham TDCS|In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.
62308907|NCT01172171|ACTIVE_COMPARATOR|Melatonin|The randomized patients will receive 10 ml 0,1 mg/ml melatonin intracoronarily and 49 mg intravenously.
62308908|NCT01172171|PLACEBO_COMPARATOR|Isotonic saline|The randomized patients will receive 10 ml isotonic saline (NaCl)and 490 ml intravenously.
62475580|NCT03986801|EXPERIMENTAL|PASS pharmaceutical interview|
62339594|NCT00652431|ACTIVE_COMPARATOR|Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 for a total of 7 days of treatment
62475581|NCT03986801|NO_INTERVENTION|Usual management out of hospital|
62475582|NCT06559891|EXPERIMENTAL|TIVUS™ Renal Denervation System|Following angiogram, subjects found anatomically eligible and randomized to the renal denervation arm will be treated with the TIVUS™ Renal Denervation System.
62475583|NCT06559891|SHAM_COMPARATOR|Sham|For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
62475584|NCT03267381||Arm 1a|Stage III melanoma diagnosis (biopsy-proven lymph node positive (this is either clinically palpable or enlarged nodes detected by imaging, which are then biopsied and have macroscopic disease).
62475585|NCT03267381||Arm 1b|Stage III after sentinel node biopsy (microscopic disease diagnosed on sentinel node biopsy).
62679403|NCT04111549|EXPERIMENTAL|Home-based telehealth GOALS|Participants in this arm will receive the GOALS intervention via in-home video telehealth.
62679404|NCT04111549|ACTIVE_COMPARATOR|In-person GOALS|Participants in this arm will receive the GOALS intervention in the traditional in-person format.
62120620|NCT04482400|ACTIVE_COMPARATOR|MyKneeGuide|Participants randomized to this arm will use the MyKneeGuide app/website and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
62308909|NCT06156202|ACTIVE_COMPARATOR|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
62308910|NCT06156202|EXPERIMENTAL|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
62308911|NCT01678846|EXPERIMENTAL|Good School Toolkit|Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
62308912|NCT01678846|NO_INTERVENTION|Control|Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.
62308913|NCT03576872|EXPERIMENTAL|Psychoeducational intervention|"* Psychoeducational will be conducted prior to chemotherapy.~* Teach session will occur prior and during administration of chemo~* A small quiz will be conducted to asses understanding of the educational binder"
62308914|NCT05542615|EXPERIMENTAL|Patient|Sixty patients with chronic Viral C hepatitis, who have been treated with direct-acting antivirals, with a sustained viral response and who still have advanced fibrosis (F3-F4).
62308915|NCT04685473|EXPERIMENTAL|T-1101 (Tosylate)|
62679405|NCT05527314|EXPERIMENTAL|Remimazolam|"1. Induction of anesthesia Slowly inject Remimazolam 0.4-0.8 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional Remimazolam (0.05 mg/kg each time) is allowed. After the LoC, fentanyl 3-4 ug/kg and cisatracurium besilate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~2. Maintenance of anesthesia Remimazolam 1\~2 mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 20 %."
62120621|NCT02020616|EXPERIMENTAL|LY3053102|Stage 1: Escalating dose (7 milligrams \[mg\] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks
62120622|NCT02020616|PLACEBO_COMPARATOR|Placebo|Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks
62120623|NCT02020616|ACTIVE_COMPARATOR|Exenatide Extended-Release (ER)|Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks
62120624|NCT02020616|EXPERIMENTAL|LY3053102 + Exenatide ER|Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks
62120625|NCT03778099|EXPERIMENTAL|Cinnamon Group|Two capsules of cinnamon 500mg twice per day after meals (2g/day). All capsules will be given simultaneously with the clomiphene citrate medication (standard treatment for infertility in women with PCOS). Participants will be asked to keep their normal lifestyle including daily food and physical activity level.
62120626|NCT03778099|PLACEBO_COMPARATOR|Placebo Group|"Placebo capsules will contain 450 mg of starch and 50 mg of cinnamon powder (to improve blindness regarding taste and odor). Color, shape, and size of placebo capsules will be exactly the same as the cinnamon capsules.~2g/day along with clomiphene citrate"
62120627|NCT04364594|EXPERIMENTAL|affected individual|Patients affected by Coronavirus 19 admitted to the hospital setting
62120628|NCT06390826|EXPERIMENTAL|Treatment (sunitinib)|Patients receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
62120629|NCT02957136|EXPERIMENTAL|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
62120630|NCT02957136|NO_INTERVENTION|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
62120631|NCT04645550|EXPERIMENTAL|Apixaban with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Apixaban 2.5mg bid for six months.
62308916|NCT01503931||Alcohol-dependent patients|"* men and women, aged 18 to 75~* legally effective, written informed consent for participation within the study~* right handedness~* no other psychiatric disorder according to ICD 10~* no psychotropic substances within the last 7 days"
62308917|NCT01503931||Healthy control subjects|"* men and women, aged 18 to 75~* legally effective, written informed consent for participation within the study~* right handedness~* no psychiatric disorder according to ICD 10~* no psychotropic substances within the last 7 days"
62679406|NCT05527314|ACTIVE_COMPARATOR|Sevoflorane|"1. Induction of anesthesia After the sevoflurane volatilization tank is adjusted to 8 % and the fresh gas flow rate is 5 L/min, the suitable mask connects with the outlet of the loop and covers the nose of the child. After the LoC, the sevoflurane volatilization tank is set to 3 % and the fresh gas flow rate is 2 L/min to maintain autonomous respiration. At the same time, fentanyl 3-4 ug/kg and cisatracurium besilate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~2. Maintenance of anesthesia Continuous inhalation of sevoflurane concentration 2 %-3 % and remifentanil 0.1-0.3 ug/kg/min intravenous pump to maintain sedation and assistant analgesia, and cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 20 %."
62679407|NCT03706833|EXPERIMENTAL|Edwards PASCAL System - CLASP IID|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with degenerative mitral regurgitation
61920539|NCT04219462|SHAM_COMPARATOR|control group|twenty men will receive sham treatment underwent identical therapy with Extracorporal shock wave therapy (ESWT) application with a similar appearance and sound as the active low intensity extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
61920540|NCT02875574||All participants|
61920541|NCT05779735|NO_INTERVENTION|Group 1 : control|The mode of delivery will be determined by clinical examens (digital examination)
62120632|NCT04645550|EXPERIMENTAL|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for six months irrespective of the occurrence of portal vein thrombus.
62120633|NCT04645550|EXPERIMENTAL|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for six months.
62120634|NCT04587908|EXPERIMENTAL|TAS-205|
62308918|NCT06076330|EXPERIMENTAL|20% albumin infusion with plasmalyte|"* Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance~* S. albumin \> 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr~* S. albumin \< 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr"
62339595|NCT03159377||Patients scheduled for a chest CT|Inpatients or outpatients scheduled for a chest CT in our medical center
62339596|NCT04791683|NO_INTERVENTION|Control|Infertile couples in the control group were selected by randomization, routine protocols in the clinic were applied
62679408|NCT03706833|ACTIVE_COMPARATOR|Abbott Mitraclip System - CLASP IID|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients with degenerative mitral regurgitation
62679409|NCT03706833|EXPERIMENTAL|Edwards PASCAL System - CLASP IIF|Transcatheter mitral valve repair with the Edwards PASCAL System in patients on guideline directed medical therapy with functional mitral regurgitation
62679410|NCT03706833|ACTIVE_COMPARATOR|Abbott Mitraclip System - CLASP IIF|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients on guideline directed medical therapy with functional mitral regurgitation
62679411|NCT03706833|EXPERIMENTAL|Edwards PASCAL System - Single-Arm Registry|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with mitral regurgitation who were deemed non-randomizable by a central screening committee (CSC) due to complex anatomical features described in the current MitraClip Instructions for Use (IFU) but were considered suitable for the PASCAL system.
61920542|NCT05779735|EXPERIMENTAL|Group 2 : Transperineal ultrasound measurements of AOP|"The mode of delivery will be determined by clinical examens (digital examination) and ultrasound measurement of the AOP :~* vaginal delivery is encouraged if AOP measurement is \>120°~* cesarean delivery is encouraged if AOP measurement is \<= 120°"
62120635|NCT04587908|PLACEBO_COMPARATOR|Placebo|
61920543|NCT02113839|ACTIVE_COMPARATOR|No frequent exacerbators|"Patients without exacerbations: 0 or 1 that did not required hospitalization in the previous year.~Interventions:~* Spirometry~* Emogas analysis~* Modified Borg Dyspnea Scale~* CO Exhaled breath~* P01~* FeNO"
62308919|NCT06076330|ACTIVE_COMPARATOR|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose|"5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose~* In case of failure to attain a sustained MAP \>65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC~* Group A: Plasmalyte bolus of 15-20 ml/kg over 15-30 mins~* Group B: 5ml/kg of 5% albumin over 15-30 mins"
62308920|NCT04864795||Single Cohort|Patient data will be collected from patient records and/or during a routine clinical visit. This will include treatments prescribed, routine assessments and measurements collected at routine clinical visits, as well as hospitalisations and other relevant patient data.
62308921|NCT05333562|OTHER|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
62475586|NCT03267381||Arm 2|Stage IV- will need to stratify by current treatment with immunotherapy, targeted therapy, none
62120636|NCT03770507|EXPERIMENTAL|Treadmill Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
62308922|NCT05333562|ACTIVE_COMPARATOR|Motor control exercise with neural mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
62308923|NCT01837082|ACTIVE_COMPARATOR|Iron|ferric carboxymaltose
62308924|NCT01837082|PLACEBO_COMPARATOR|Placebo|Sodium chloride 0.9%
62308925|NCT04329949|EXPERIMENTAL|Relacorilant with nab-paclitaxel|Patients will be treated with relacorilant, administered orally, once daily in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
62308926|NCT06405204|EXPERIMENTAL|myo-inositol|myo-inositol (1gm capsules bd ) plus folic acid 400 mcg per day
62679412|NCT06463899|EXPERIMENTAL|WITH catheter|"A multi-perforated catheter arm benefiting from opioid analgesia (Patient controlled Analgesia ((PCA)) morphine (bolus-only mode or morphine titration if PCA not available), nefopam, non-steroidal anti-inflammatory drugs, ketamine, pregabalin and paracetamol associated with analgesia by continuous infusion of local anesthetics (ropivacaine) via two multi-perforated catheters"
62679413|NCT06463899|ACTIVE_COMPARATOR|WITHOUT catheter|"A control arm benefiting from opioid analgesia (PCA morphine in bolus mode alone or morphine titration if PCA not available), nefopam, non-steroidal anti-inflammatory drugs, ketamine, pregabalin and paracetamol."
62679414|NCT04558138|EXPERIMENTAL|Discharge day of surgery|Patient discharges day of surgery and given surveys to complete at home on post operative day (POD) #1 and #7.
61920544|NCT02113839|ACTIVE_COMPARATOR|Frequent exacerbators|"Patients with frequent exacerbations: ≥2 or ≥1 if it required hospitalization in the previous year.~Interventions:~* Spirometry~* Emogas analysis~* Modified Borg Dyspnea Scale~* CO Exhaled breath~* P01~* FeNO"
62308927|NCT06405204|EXPERIMENTAL|melatonin|melatonin 1 capsule every night orally before going to bed plus folic acid 400mcg per day
62308928|NCT06405204|EXPERIMENTAL|co-enzyme Q10|co-enzyme Q10 100mg per day plus folic acid 400 mcg per day
62308929|NCT06405204|PLACEBO_COMPARATOR|control group.|will receive folic acid 400 mcg per day
61920545|NCT02233946|EXPERIMENTAL|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
61920546|NCT02233946|NO_INTERVENTION|Screening with Treatment as Usual|Screening with Treatment as Usual
61920547|NCT05796336|EXPERIMENTAL|Passive lip taping|Will receive passive baby feeding plate and conventional steri strip
61920548|NCT05796336|EXPERIMENTAL|Custom-made tape|will receive passive baby feeding plate and custom-made tape (Steri Srip and orthodontic elastics)
62120637|NCT03770507|EXPERIMENTAL|Cyclo Ergometer Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
62120638|NCT05000944|EXPERIMENTAL|breakfast omission (BO)|No breakfast will be provided until the lunch time at \~12:30. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
62308930|NCT01174784|EXPERIMENTAL|Treatment|The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.
62308931|NCT02776930||Return to Duty after Rehab from Injury|Patients deemed healthy enough to return to full duty without any restrictions after completing a course of rehabilitation for a lumbar/thoracic spine or lower extremity injury.
62308932|NCT02726867|ACTIVE_COMPARATOR|levetiracetam|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 4000 mg levetiracetam.
62308933|NCT02726867|ACTIVE_COMPARATOR|lacosamide|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 600 mg lacosamide.
62475587|NCT02437747|EXPERIMENTAL|SRP+ Aloe Group|Scaling and root planing was done along with application of aloe vera gel as an adjunct in selected sites.
62679415|NCT04558138|NO_INTERVENTION|Discharge post operative day 1|Patient Discharges POD #1 and completes survey prior to discharge. Patient given surveys to complete POD #7 at home.
62679416|NCT04128215|ACTIVE_COMPARATOR|Older Men|
62679417|NCT04128215|ACTIVE_COMPARATOR|Older Postmenopausal Women|
62120639|NCT05000944|EXPERIMENTAL|early-morning breakfast consumption (EM-BC)|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at \~08:30 for EM-BC. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
62308934|NCT02726867|ACTIVE_COMPARATOR|ketamine|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 2.5 mg/kg ketamine.
62308935|NCT02726867|ACTIVE_COMPARATOR|phenobarbital|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin (PHT) with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after PHT loading will receive intravenously (i.v.) phenobarbital 15 mg/kg.
62308936|NCT01753518|ACTIVE_COMPARATOR|Subcuticular suture|Subcuticular suture has been used for many years to close skin incisions.
62308937|NCT01753518|ACTIVE_COMPARATOR|Subcuticular staple|Subcuticular staples are a newer modality than suture, but are currently an accepted and widely used skin closure technique.
62308938|NCT03424551|EXPERIMENTAL|Vibrator|Local or Whole body vibration was applied at six different frequencies to Healthy control and spastic spinal cord injury. For local vibration, vibration frequencies were 50, 85, 140, 185, 235 and 265 Hz . For whole body vibration, vibration frequencies were 35, 37, 39, 41, 43 and 45 Hz
62308939|NCT06193083||Qualitative study|The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period).
62308940|NCT06193083||Quantitative study|"Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).~The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy."
62308941|NCT04086940|ACTIVE_COMPARATOR|esmolol(breviblock) group|Patients in group E received a loading dose of esmolol(breviblock) 1 mg/kg in 50 ml isotonic saline over 30 minutes before induction of anesthesia, then followed by an infusion of esmolol 10 µg/kg/min until the end of the surgery.
62308942|NCT04086940|ACTIVE_COMPARATOR|non esmolol group|Patients in group N received 50 ml of isotonic saline over 30 min, followed by an infusion of isotonic saline at same rate of group E till the end of the surgery.
62308943|NCT06667804|EXPERIMENTAL|Laughter yoga group|Laughter yoga group
62308944|NCT06667804|NO_INTERVENTION|Control group|No intervention was applied to the patients in the control group.
62120640|NCT05000944|EXPERIMENTAL|mid-morning breakfast consumption (MM-BC).|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at \~10:30 for MM-BC (i.e., two hours after EM-BC). Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
62120641|NCT03534869|EXPERIMENTAL|Ear Acupuncture and Oral Analgesics|"The acupuncture treatment consisted of three acupuncture needles on the dominant ear according to French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point that is used to increase the anaesthetic effect according to both French and Chinese traditions.~Additional oral analgesics (NSAID) could be supplied at any time upon patients request during hospitalization. Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy."
62120642|NCT03534869|ACTIVE_COMPARATOR|Oral Analgesics Only|Postoperative standard oral analgesic therapy (NSAID) supplied at any time upon patients request during hospitalization. Oral ibuprofen would be given as first line therapy, while oral paracetamol would be given as second line therapy.
62120643|NCT00482378|EXPERIMENTAL|Sm 153 lexidronam|
62308945|NCT03604328|EXPERIMENTAL|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
62308946|NCT02232789|EXPERIMENTAL|Mephedrone|Mephedrone 200 mg, single dose, oral administration
62308947|NCT02232789|ACTIVE_COMPARATOR|3,4-methylenedioxymethamphetamine|3,4-methylenedioxymethamphetamine (MDMA) 100 mg, single dose, oral administration
62120644|NCT04979299|EXPERIMENTAL|wheelchair group|"Patients included in the  wheelchair  group will be asked to sit in a wheelchair during the interview;"
62120645|NCT04979299|NO_INTERVENTION|Control group|Patients included in the control group will sit in a regular chair during the interview.
62308948|NCT02232789|PLACEBO_COMPARATOR|Lactose|Placebo, single dose, oral administration
62308949|NCT00058370|EXPERIMENTAL|histologic proof of medulloblastoma|This is a single-arm study of post-operative radioimmunotherapy (intrathecal 131-I-3F8), reduced-dose craniospinal radiation therapy (1800 cGy), primary site boost (to 5400 cGy) via IMRT and standard chemotherapy.
62679418|NCT03210662|EXPERIMENTAL|Treatment (EBRT, pembrolizumab)|Beginning on day 1, patients undergo fractionated EBRT daily for 5 consecutive days a week for up to 12 or 22 treatments. Patients also receive pembrolizumab IV over 1 hour on day 2. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62679419|NCT03240055|EXPERIMENTAL|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
62679420|NCT03240055|PLACEBO_COMPARATOR|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
62679421|NCT06398418|OTHER|Open Label|R-5780 Probiotic
62679422|NCT05214027||Participants|This study follows a randomised crossover design. All participants will undergo a single 60-minute treadmill-based exercise intervention, and a resting period for equal duration in a randomised order.
62679423|NCT05233917|EXPERIMENTAL|Olive oil group|Olive oil use，25-30 g per day for six month
62679424|NCT05233917|EXPERIMENTAL|MLCT oil group|MLCT oil use，25-30 g per day for six month
62679425|NCT00825448|EXPERIMENTAL|2|patient in hospital a week before the date of surgery for the treatment of his addiction alcohol
62679426|NCT00825448|NO_INTERVENTION|1|no treatment of his addiction alcohol during a week before the date of surgery
62679427|NCT06101329|EXPERIMENTAL|Randomized Phase: Lenacapavir (LEN) Group|Participants will receive subcutaneous (SC) lenacapavir (LEN) 927 mg on Day 1 and Week 26 and oral LEN 600 mg on Days 1 and 2.
62679428|NCT06101329|EXPERIMENTAL|Randomized Phase: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Group|Participants will receive oral F/TDF (200/300 mg) daily for 52 weeks.
62679429|NCT06101329|EXPERIMENTAL|PK Tail Phase: F/TDF|After the completion of the Randomized Phase, participants in LEN group will be transitioned to receive F/TDF and participants in F/TDF group will continue to receive F/TDF in the PK Tail Phase. All participants will receive F/TDF, once daily for 78 weeks beginning 26 weeks after the last LEN injection.
62679430|NCT04944017|EXPERIMENTAL|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
62120646|NCT06342063|ACTIVE_COMPARATOR|Physiotherapy with Blood Flow Restriction Group|This group underwent a physiotherapy protocol while using Blood Flow Restriction adjunctive therapy prior to ACL reconstruction.
62679431|NCT04944017|PLACEBO_COMPARATOR|Saline Infusion|Participants will receive 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry
62679432|NCT04900376||vaccinated group|
62679433|NCT04900376||unvaccinated group|
62679434|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
62475588|NCT02437747|SHAM_COMPARATOR|SRP Group|Only scaling and root planing was done on the opposite side.
62679435|NCT05988892|EXPERIMENTAL|Community Oncology patients entering cancer survivorship|Patients participate in a virtual cancer rehabilitation program with weekly virtual visits by a cancer exercise specialist who provides a personalized synchronous exercise plan and receive bi-weekly phone calls/emails over 12 weeks. Patents also wear a Fitbit on study.
62679436|NCT04869410|ACTIVE_COMPARATOR|Broselow Tape|Patient will given an intubation using uncuffed endotracheal tube size based on Modified Broselow Tape
62679437|NCT04869410|ACTIVE_COMPARATOR|Cole Formula|Patient will given an intubation using uncuffed endotracheal tube size based on Cole Formula
62679438|NCT04245865|EXPERIMENTAL|Arm A, standard treatment + tocotrienol|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + tocotrienol OR capecitabine + bevacizumab + tocotrienol
62679439|NCT04245865|PLACEBO_COMPARATOR|Arm B, standard treatment + placebo|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + placebo OR capecitabine + bevacizumab + placebo
62679440|NCT01546779|EXPERIMENTAL|lung function|
62679441|NCT02620865|EXPERIMENTAL|Treatment (anti-CD3 x anti-EGFR BATs)|Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.
62679442|NCT04848571|PLACEBO_COMPARATOR|control group|Pregnant women who received IVF and not taken Chinesene fetal protection medicine until sampling
62679443|NCT04848571|EXPERIMENTAL|medicine group|Pregnant women who received IVF and have taken Chinesene fetal protection medicine from the fourth week during early pregnancy
62308950|NCT04580602||ADR Group|Major Bleeding BARC Bleeding Criteria Type 2,3,5
62475589|NCT04966299|ACTIVE_COMPARATOR|Sucrose|15 participants receive 25g sucrose per day during 5 weeks
62679444|NCT05890001|EXPERIMENTAL|BLI5100 Low Dose|Patients will take BLI5100 Low Dose once daily, orally, for up to 29 weeks.
62679445|NCT05890001|EXPERIMENTAL|BLI5100 High Dose|Patients will take BLI5100 High Dose once daily, orally, for up to 29 weeks.
62679446|NCT06250257|ACTIVE_COMPARATOR|Control group|This group of study participants are expected to receive placebo (sucrose pills to be used) plus standard Guideline-directed medical therapy (GDMT).
62679447|NCT06250257|EXPERIMENTAL|Treatment group|This group of study participants are expected to receive oral daily bromocriptine 2.5 mg for 8 weeks plus standard Guideline-directed medical therapy (GDMT).
62679448|NCT01724307|ACTIVE_COMPARATOR|Asthma positive to Methacholine Challenge Testing|Asthma diagnosis by positive Methacholine Challenge Testing
62679449|NCT01724307|ACTIVE_COMPARATOR|Asthma positive to Eucapnic voluntary hyperventilation testing|Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
62679450|NCT04294160|EXPERIMENTAL|Dabrafenib + LTT462 backbone arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
62679451|NCT04294160|EXPERIMENTAL|Dabrafenib + LTT462 + trametinib triplet arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
62679452|NCT04294160|EXPERIMENTAL|Dabrafenib + LTT462 + LXH254 triplet arm 2|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
62679453|NCT04294160|EXPERIMENTAL|Dabrafenib + LTT462 + TNO155 triplet arm 3|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
62679454|NCT04294160|EXPERIMENTAL|Dabrafenib + LTT462 + spartalizumab triplet arm 4|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
62679455|NCT04294160|EXPERIMENTAL|Dabrafenib + trametinib + TNO155 triplet arm 5|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
62679456|NCT04294160|EXPERIMENTAL|Dabrafenib + LTT462 + Tislelizumab triplet arm 6|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
62679457|NCT03539198||Locoregional|Patients with recurrent locoregional head and neck cancer
62679458|NCT03539198||Metastatic|Patients with recurrent metastatic head and neck cancer
62679459|NCT05509192|EXPERIMENTAL|MTPI group|
62679460|NCT05509192|ACTIVE_COMPARATOR|Classic Induction group|
62679461|NCT01565694|EXPERIMENTAL|Solifenacin succinate|"Participants aged 5 years to \< 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52)."
62679462|NCT06096038|EXPERIMENTAL|Chimeric Antigen Receptors|blood will be collected to prepare the iC9.CAR-CSPG4 T cells. Disease-fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells. In part 2, the iC9.CAR-CSPG4 T cells are given by infusion after completion of lymphodepletion chemotherapy.
62679463|NCT02858661|EXPERIMENTAL|Patients diagnosed with clinical meningitis|Patients admitted in emergency rooms for clinical meningitis, for which a nasopharyngeal swab will be performed in order to confirm the etiological diagnosis of meningitis
61920549|NCT05384145|OTHER|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
62475590|NCT04966299|EXPERIMENTAL|Erythritol|15 participants receive 36g eryhtritol per day during 5 weeks
62679464|NCT03388788|EXPERIMENTAL|Normal Weight|Healthy lean controls \[18.5\<BMI\<25 kg/m2 and WC \<94/80 (men and women respectively)\] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
62679465|NCT03388788|EXPERIMENTAL|Overweight|Healthy obese \[30≤BMI\<40 and waist circumference (WC) ≥94/80 (men and women respectively)\] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
62679466|NCT01286272|EXPERIMENTAL|Arm A (ofatumumab, bendamustine hydrochloride)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1 and bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses."
61920550|NCT00336180|EXPERIMENTAL|HW|The experimental group (HW) receives 18 classroom-based lessons on leisure motivation, life skills, and skills to avoid substance use and sexual risk.
61920551|NCT04080687||Fallers|The patients who had fallen during the 6 months prior to the study onset
61920552|NCT04080687||Non-fallers|The patients who had not fallen during the 6 months prior to the study onset
62475591|NCT04966299|EXPERIMENTAL|EryClot-Pilot Erythritol|3 participants receive 50g erythritol dissolved in 300mL water once during the visit
62679467|NCT01286272|EXPERIMENTAL|Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses."
62679468|NCT01681303|EXPERIMENTAL|AST-120 group|Administration of AST-120
62679469|NCT01681303|NO_INTERVENTION|2|
62679470|NCT01625078|EXPERIMENTAL|Baska mask|
62679471|NCT03907631||Acute Severe Ulcerative Colitis|Patients hospitalised for acute severe ulcerative colitis will be invited to participate. Participants will be treated at the discretion of their treating physicians as per standard of care. We expect some participants will undergo an endoscopic assessment, some participants will be treated with standard versus accelerated infliximab dosing, permitting comparisons, in addition to other treatment strategies.
62679472|NCT06695104|ACTIVE_COMPARATOR|Produce Rx Program Only (Control)|YMCA Produce Prescription Program deliveries of fresh produce bags once per week for 52 weeks.
62679473|NCT06695104|EXPERIMENTAL|Produce Rx Program + Diabetes Prevention Program|YMCA Produce Prescription Program deliveries of fresh produce bags once per week for 52 weeks plus the Diabetes Prevention Program via 26 virtual coaching and support sessions over 12 months.
62679474|NCT06691919|EXPERIMENTAL|Direct Endoscopic Necrosectomy|Subjects randomized to the endoscopy arm will undergo direct endoscopic necrosectomy using the Powered Endoscopic Debridement System which has CE-Mark 613797 and FDA De Novo clearance in the United States (DEN200016).
62679475|NCT06691919|EXPERIMENTAL|Transgastric Surgical Necrosectomy|Patients randomized to the surgical arm will undergo open or minimally invasive (laparoscopic) transgastric surgical necrosectomy (SN). In either approach, the peritoneal cavity is entered to identify the stomach through which an anterior gastrotomy is made. The retrogastric necrosum is identified either using a finder needle or ultrasound and accessed through a posterior cystgastrostomy. Transgastric SN is then manually performed, and any cyst fluid fully evacuated. The anterior gastrotomy is then closed allowing any residual necrosis or pancreatic enzyme to efflux into the stomach and enter the upper GI tract. As with endoscopy, patients with retrogastric collections are observed for a sufficient period to ensure full maturation of the necrosum.
62679476|NCT06565546|EXPERIMENTAL|CYP2D6 genotype testing-treatment|CYP2D6 genotype testing performed preoperatively with results used to guide prescribing of opioid analgesics during the postoperative period to control pain. In addition, participants will receive standard of care postoperative pain medications.
62679477|NCT06565546|ACTIVE_COMPARATOR|CYP2D6 genotype testing-control|CYP2D6 genotype testing performed preoperatively, results will be delayed until after operative procedure. Participants will receive standard of care postoperative pain medication prescriptions for pain management.
62679478|NCT00926900|ACTIVE_COMPARATOR|D-cycloserine|
62679479|NCT00926900|PLACEBO_COMPARATOR|Placebo|
62475592|NCT04966299|ACTIVE_COMPARATOR|EryClot-Pilot Glucose|3 participants receive 75g glucose dissolved in 300mL water once during the visit
62475593|NCT04966299|ACTIVE_COMPARATOR|EryClot-Pilot Fructose|3 participants receive 25g fructose dissolved in 300mL water once during the visit
62120647|NCT06342063|SHAM_COMPARATOR|Physiotherapy without Blood Flow Restriction Group|This group underwent a physiotherapy protocol without using Blood Flow Restriction adjunctive therapy prior to ACL reconstruction.
62120648|NCT05622786|EXPERIMENTAL|High-Intensity Treadmill Gait Training (HIGT)|High-intensity walking physical therapy with some low intensity therapy.
62120649|NCT05622786|ACTIVE_COMPARATOR|Low Intensity Physical Therapy|Low-intensity gait activities, exercises (such as lower extremity strength training with or without weights or electrical stimulation, sit to stands from a chair, mat exercises for upper/lower extremities and core strength, etc.), stretches, balance training activities, and other therapeutic activities (such as transfers, bed mobility training, etc.).
62120650|NCT01477879|ACTIVE_COMPARATOR|Versabase/20% S. purpurea extract|
62120651|NCT01477879|PLACEBO_COMPARATOR|placebo (versabase gel only)|placebo used will be versabase gel alone
62475594|NCT04966299|EXPERIMENTAL|EryClot Erythritol|10 participants receive 50g erythritol dissolved in 300mL water once during the visit
62475595|NCT04966299|EXPERIMENTAL|EryClot Xylitol|10 participants receive 33.5g xylitol dissolved in 300mL water once during the visit
62475596|NCT04966299|PLACEBO_COMPARATOR|EryClot Water|10 participants receive 300mL water once during the visit
62475597|NCT03979508|EXPERIMENTAL|Cohort A Group 1; Cohort B Group 3 (surgery)|Patients undergo standard of care surgical resection.
62475598|NCT03979508|EXPERIMENTAL|Cohort A Group 2; Cohort B Group 4 (abemaciclib, surgery)|Patients receive abemaciclib PO BID on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.
62475599|NCT02762422|EXPERIMENTAL|Phlebotomy plus normal saline|Four serial phlebotomy procedures followed by infusion of normal saline
62475600|NCT02762422|EXPERIMENTAL|Phlebotomy plus intravenous iron|Four serial phlebotomy procedures followed by infusion of intravenous iron sucrose
62475601|NCT02762422|PLACEBO_COMPARATOR|Sham Phlebotomy|Four serial sham phlebotomy procedures followed by infusion of normal saline
62679480|NCT05284513|OTHER|Phase 1|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
62679481|NCT05284513|OTHER|Phase 2|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
62679482|NCT05284513|OTHER|Phase 3|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
62679483|NCT05284513|OTHER|Phase 4|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
62679484|NCT05284513|OTHER|Phase 5|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
62679485|NCT01749293|EXPERIMENTAL|Haploidentical Transplant|All subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
62679486|NCT06690606||external validation cohort|"The external validation cohort was composed of primary EOCRC patients who underwent radical resection at Putuo Hospital and Yueyang Hospital, both affiliated with Shanghai University of Traditional Chinese Medicine. The cohort includes patients diagnosed between January 2014 and June 2024.~Inclusion criteria: Patients with pathologically confirmed primary EOCRC, aged under 50 years, and who received radical surgery (stages I-III according to the AJCC 7th edition).~Exclusion criteria: Patients with multiple primary cancers, survival time under 1 month, or missing critical data."
62679487|NCT03907566||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals, and Turkish version of the Eating Assessment Tool.
62679488|NCT04380025|EXPERIMENTAL|Mirtogenol|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) the experimental group will also take Mirtogenol. Mirtogenol is a dietary supplement composed of bilberry and pycnogenol which are botanical compounds with antioxidant properties. The active components of bilberry are flavonoid anthocyanosides (anthocyanins). Anthocyanosides are the only flavonoids able to reach the eye as a target organ in experimental animals. Unchanged anthocyanosides demonstrated after oral administration that it is absorbed and distributed into ocular tissues, showing its ability to pass through the blood-aqueous and blood retinal barriers.6
62679489|NCT04380025|PLACEBO_COMPARATOR|Lactose based Placebo|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) this control group will also take an identical placebo. This placebo is a inactive lactose based product of the same color and size capsule.
62679490|NCT01693237|ACTIVE_COMPARATOR|Group psychotherapy|20 sessions of systemic and narrative group psychotherapy
62679491|NCT01693237|EXPERIMENTAL|Group psychotherapy with feedback|20 sessions of systemic and narrative group psychotherapy with session-to-session feedback to patient and therapist.
62679492|NCT04477512|EXPERIMENTAL|Level 1: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 20 mg. Participants can continue to receive treatment for up to 2 years.
62679493|NCT04477512|EXPERIMENTAL|Level 2: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 40 mg. Participants can continue to receive treatment for up to 2 years.
62679494|NCT04477512|EXPERIMENTAL|Expansion: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be dependent on recommended dose found in first part of study. Participants can continue to receive treatment for up to 2 years.
62679495|NCT05507164|OTHER|Temporo-masseteric Nerve Block Administration|Non-randomized administration of the TMNB injection (unilateral) followed by bite force distribution and surface EMG assessment of the temporalis and masseter muscles on the side of the injection
62679496|NCT03463239|EXPERIMENTAL|Autologous tissue engineered corpora|All subjects enrolled will undergo a corpora cavernosum biopsy. Endothelial and smooth muscle cells will be isolated and expanded, then seeded onto a scaffold that will later be implanted into the subject.
62679497|NCT06343532|EXPERIMENTAL|SXC-2023|SXC-2023: 800mg once a day for 7 days
62679498|NCT06343532|PLACEBO_COMPARATOR|SXC-2023 Placebo|Placebo: 800mg once a day for 7 days
61920553|NCT04123028||eosinophilic COPD patient|COPD patient with blood eosinophil equal or \> 300 cells/µL
62120652|NCT03601910|EXPERIMENTAL|A group|"1. Period 1: D308 10mg Tab. 1T~2. Period 2: CKD-380 10mg Tab. 1T"
62120653|NCT03601910|EXPERIMENTAL|B group|"1. Period 1: CKD-380 10mg Tab. 1T~2. Period 2: D308 10mg Tab. 1T"
61920554|NCT04123028||non-eosinophilic COPD patient|COPD patient with blood eosinophil \< 300 cells/µL
61920555|NCT02164149||Quality of colon cancer surgery|Patients with primary colon cancer
61920556|NCT03954652|OTHER|Cohort 1: Intellectual disability|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
62120654|NCT05429346||Genital herpes treated before third trimester|Pregnant women with genital herpes infection receiving treatment before the 3rd trimester.
62120655|NCT05429346||Genital herpes treated during third trimester|Pregnant women with genital herpes infection receiving treatment during the 3rd trimester.
62120656|NCT05429346||Genital herpes untreated|Pregnant women with untreated genital herpes infection.
62120657|NCT05429346||Control Group|Pregnant women (controls) with neither genital herpes infection nor treatment.
62308951|NCT04580602||Control Group|No ADR or treatment failure, case-control matched to experimental groups
62120658|NCT04581317|EXPERIMENTAL|Phase 1 (meals only)|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.MOW will once a week deliver in-person enough frozen meals to cover lunch for 5 days and breakfast for 7 days. Study staff will call the participants twice a week to ask 5 questions about their health, mood, and meal consumption.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure Fried Frailty Phenotype(FFP), MHS, CES-D, MOCA, Activities of Daily Living (ADL)/Instrumental activities of daily living(IADL)s, NSI, and ZCBI. Caregivers will not receive meals during this first phase as the focus is on the nutritional status of the cognitively impaired older adult.
62679499|NCT06521853|EXPERIMENTAL|PEEK With Autogenous Bone Graft|maxillary sinus elevation using PEEK device and placement of autogenous bone graft
62679500|NCT06521853|EXPERIMENTAL|PEEK With Xenograft|maxillary sinus elevation using PEEK device and placement of xenograft
62679501|NCT06248177|ACTIVE_COMPARATOR|Group 1|6 weeks daily consumption of one probiotic capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one placebo capsule
62120659|NCT04581317|EXPERIMENTAL|Phase 2 (Meals + Amazon Echo Show 8 (AES 8) basic usage)|Participants will have meals delivered and the AES device installed for basic usage
62308952|NCT04580602||Treatment Failure Group|Major Adverse Cardiovascular Events (MACE)
62308953|NCT05518591|EXPERIMENTAL|CFT & BPR|6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining.
62308954|NCT05518591|NO_INTERVENTION|Treatment As Usual|Those in the treatment as usual arm are not being asked to engage in anything additional to their regular treatment plan. They will, however, be given the option to participate in the psychological intervention after the study has ended, if they elect to do so.
62308955|NCT02502422|OTHER|Classic laryngeal mask airway|single arm
62679502|NCT06248177|ACTIVE_COMPARATOR|Group 2|6 weeks daily consumption of one placebo capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one probiotic capsule
62120660|NCT04581317|EXPERIMENTAL|Phase 3 (meals + AES 8 advanced )|Participants will have meals delivered and the AES device installed for advanced usage
62308956|NCT04601272||Breast Cancer Screening|Women between the ages of 35-55 when they received a decision aid for breast cancer screening with no prior diagnosis of breast cancer. These people will see items only pertaining to breast cancer screening.
62308957|NCT04601272||Colon Cancer Screening|Men and women between the ages of 45-75 when they received a decision aid for colon cancer screening with no prior diagnosis of colon cancer. These people will see items only pertaining to colon cancer screening.
62308958|NCT04601272||Prostate Cancer Screening|Men between the ages of 45-74 when they received a decision aid for prostate cancer screening with no prior diagnosis of prostate cancer. These people will see items only pertaining to prostate cancer screening.
62308959|NCT04460027|EXPERIMENTAL|W-SUDs|
62308960|NCT04460027|NO_INTERVENTION|Wait List Control|
62308961|NCT04685603|EXPERIMENTAL|AV-COVID-19 (0.1 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
62308962|NCT04685603|EXPERIMENTAL|AV-COVID-19 (0.33 mg antigen, 0 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
62308963|NCT04685603|EXPERIMENTAL|AV-COVID-19 (1.0 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
62308964|NCT04685603|EXPERIMENTAL|Experimental: AV-COVID-19 (0.1 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
62308965|NCT04685603|EXPERIMENTAL|AV-COVID-19 (0.33 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
62308966|NCT04685603|EXPERIMENTAL|AV-COVID-19 (1.0 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
61920557|NCT03954652|OTHER|Cohort 2 Retinal diseases|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
62120661|NCT03221023|EXPERIMENTAL|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
61920558|NCT03954652|OTHER|Cohort 3: Rare tumors in childhood|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
62308967|NCT04685603|EXPERIMENTAL|AV-COVID-19 (0.1 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
62308968|NCT04685603|EXPERIMENTAL|AV-COVID-19 (0.33 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
62308969|NCT04685603|EXPERIMENTAL|AV-COVID-19 (1.0 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
62308970|NCT02446366|EXPERIMENTAL|Treatment (hypofractionated SBRT)|Patients undergo 5, 10, or 15 fractions of hypofractionated SBRT daily over 1-3 weeks.
62475602|NCT04320420|EXPERIMENTAL|Experimental arm|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~* 3 supervised APA sessions/week on site:~  * two muscle strengthening sessions, stretching, flexibility in the gym~ * a cardio session (Nordic Walking: outdoors)~* at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~* 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~* If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~* the first 3 months:~  * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~ * 1-hour cardio session/week independently~* the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
62475603|NCT03733314|EXPERIMENTAL|E6011|
62475604|NCT03733314|PLACEBO_COMPARATOR|Placebo|
62475605|NCT01997983|EXPERIMENTAL|TC-3 Gel with Botox|open label observational study
62475606|NCT04859517|EXPERIMENTAL|ADG20|Participants will be dosed on Day 1 with ADG20 IM
62475607|NCT04859517|PLACEBO_COMPARATOR|Placebo|Participants will be dosed on Day 1 with placebo IM
61920559|NCT03291171|EXPERIMENTAL|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
61920560|NCT03291171|NO_INTERVENTION|Waiting-list control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
61920561|NCT04706117|OTHER|Canalicular obstruction|
61920562|NCT01915927|OTHER|1|Only 1 arm: treatment with MSC-AFP
62120662|NCT03221023|PLACEBO_COMPARATOR|Saline|These patients will receive intrawound saline + IV antibiotics alone
62120663|NCT04563117||Automatic registration|
62308971|NCT00574977|EXPERIMENTAL|A|Subjects who have been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection
62308972|NCT00574977|EXPERIMENTAL|B|Subjects will include those who have not been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection.
62475608|NCT03545451|EXPERIMENTAL|Neurofeedback rehabilitation with videogames|Neurofeedback rehabilitation with videogames
62308973|NCT00574977|EXPERIMENTAL|C|Subjects will be those who have been vaccinated with vaccinia virus (small pox)and will be receiving the vvCD-CDSR via intravenous infusion
62308974|NCT02156700||Liver tumors|Measurement of tumor stiffness by Shear wave elastography - SWE™
62308975|NCT02997189|ACTIVE_COMPARATOR|OTO-104|One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
62308976|NCT02997189|NO_INTERVENTION|Control|The ear not receiving OTO-104 will receive no treatment
62308977|NCT03906695|EXPERIMENTAL|10-Day Schedule|"10-Day Schedule~Investigational Medicinal Products (IMP) will be administered for 10 days in total per 4 weeks, i.e. a 28-day cycle."
62308978|NCT03906695|EXPERIMENTAL|5-Day Schedule A|"5-Day Schedule A~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
62308979|NCT03906695|EXPERIMENTAL|5-Day Schedule B|"5-Day Schedule B~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
62308980|NCT03906695|EXPERIMENTAL|5-Day Schedule C|"5-Day Schedule C~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
62120664|NCT04563117||Point-based registration|
62308981|NCT03906695|EXPERIMENTAL|7-Day Schedule|"7-Day Schedule~IMP will be administered for 7 days in total per 4 weeks, i.e. a 28-day cycle."
62308982|NCT01845025|EXPERIMENTAL|FOM 12 mcg + FP|Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
62308983|NCT01845025|ACTIVE_COMPARATOR|fluticasone propionate (FP)|fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
62308984|NCT06045572|EXPERIMENTAL|women diagnosed with breast cancer before cancer treatment|
62679503|NCT02181413|PLACEBO_COMPARATOR|Placebo|Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons.
62120665|NCT03024606|ACTIVE_COMPARATOR|texting group|text messages focused on smoking cessation and pregnancy
62120666|NCT03024606|NO_INTERVENTION|control group|No text messages
62308985|NCT01019408|ACTIVE_COMPARATOR|CQ25|Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
62308986|NCT01019408|ACTIVE_COMPARATOR|CQ40|Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
62120667|NCT01689272|EXPERIMENTAL|Kidney transplantation|Kidney transplantation from alive relative donor.
62308987|NCT04430582||Hypoglycemia after gastric bypass surgery - post-bariatric hypoglycemia (PBH)|Participants with PBH, recruited from the Joslin Hypoglycemia Clinic and from other hypoglycemia studies at Joslin.
62308988|NCT04430582||Post-gastric bypass participants without a history of hypoglycemia|Participants with a history of Roux-en-Y gastric bypass, but without a diagnosis of hypoglycemia, or symptoms of hypoglycemia, recruited by advertisement flyers at postoperative surgical clinics at local hospitals (such as Brigham and Women's and Beth Israel Deaconess Hospitals), research match, and from other hypoglycemia studies at Joslin.
62308989|NCT02340104|EXPERIMENTAL|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of \[\^13C4D3\^15N\]-baricitinib over 1.5 hours.
62308990|NCT03976856|EXPERIMENTAL|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
62308991|NCT05590403|EXPERIMENTAL|Adults HA-RSV Group|Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.
62308992|NCT05590403|PLACEBO_COMPARATOR|Adults HA-Placebo Group|Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.
62308993|NCT05590403|EXPERIMENTAL|Adults AIR-RSV Group|Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.
62120668|NCT03070483|EXPERIMENTAL|Vitamin D|Participants will all receive supplementation with cholecalciferol 5000 IU and calcium citrate 1000 mg daily for 3 months
62120669|NCT03393078|ACTIVE_COMPARATOR|Real Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
62120670|NCT03393078|SHAM_COMPARATOR|Sham Stimulation|The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
62308994|NCT05590403|PLACEBO_COMPARATOR|Adults AIR-Placebo Group|Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.
61920563|NCT04589715|EXPERIMENTAL|electroacupuncture group|patients will receive electroacupuncture at 3 acupoints(Bladder meridian of foot-taiyang 33 and 35#BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 4 weeks, then 3 times/week for 4 weeks, and then once/week for 4 weeks(24 times in total in 3 months), and be followed up for 6 months after treatment. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 ×40 mm at SP 6. Standardized electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6.
61920564|NCT04589715|SHAM_COMPARATOR|sham electroacupuncture group|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz.
61920565|NCT02625883||Survivors|Patients with out-of-Hospital resuscitation and return of spontaneous circulation. Structured interview for quality of life (questionnaire) one year after resuscitation.
61920566|NCT03303482|EXPERIMENTAL|Intervention Group|
61920567|NCT03303482|NO_INTERVENTION|Waitlist Control Group|
61920568|NCT04483687|EXPERIMENTAL|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
61920569|NCT04483687|EXPERIMENTAL|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
61920570|NCT04483687|PLACEBO_COMPARATOR|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
61920571|NCT04483687|EXPERIMENTAL|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.~After study-wide unblinding, participants will receive filgotinib 200 mg."
61920572|NCT04483687|EXPERIMENTAL|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.~After study-wide unblinding, participants will receive filgotinib 100 mg."
61920573|NCT04394182|EXPERIMENTAL|An experimental group receiving radiotherapy|an experimental group with a poor or no response to standard medical treatment and without invasive mechanical ventilation (IMV) will receive ultra low-dose lung radiotherapy (0.8 Gy single dose)
62120671|NCT06127836|EXPERIMENTAL|patients undergoing preoperative lymphoscintigraphy|Patients will undergo radiocolloid lymphoscintigraphy before their surgery; the surgeon will be blinded to the results of this procedure. The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only.
62120672|NCT03458546|EXPERIMENTAL|Roflumilast and R-CHOP|
61920574|NCT04308811|OTHER|platelet rich plasma group|intrauterine platelet rich plasma injection and intrauterine balloon insertion after hysteroscopic lysis of intrauterine adhesions
62120673|NCT03209037|EXPERIMENTAL|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
61920575|NCT04308811|OTHER|amniotic membrane graft group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon covered by freeze-dried amniotic membranes.
62308995|NCT05590403|EXPERIMENTAL|OA-RSV Group|Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.
62308996|NCT03868553||Under-10|
62308997|NCT03868553||Under-12|
62308998|NCT03868553||Under-16 female|
62308999|NCT03868553||Under-16 male|
62309000|NCT02240628|ACTIVE_COMPARATOR|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
62309001|NCT02240628|PLACEBO_COMPARATOR|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
62309002|NCT04272125|EXPERIMENTAL|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
61920576|NCT04308811|OTHER|intrauterine balloon group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon
61920577|NCT02551250||Study|Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
61920578|NCT05765981|EXPERIMENTAL|Aromatic L-amino acid decarboxylase (AADC) deficiency|This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.
61920579|NCT05950139|EXPERIMENTAL|Advanced ALK+ NSCLC|All patients will receive the intervention
62309003|NCT00510692|EXPERIMENTAL|2g/day Eicosapentanoic Acid (EPA)|"Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.~Endoscopy and biopsies taken as described under intervention."
62120674|NCT03209037|NO_INTERVENTION|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
62120675|NCT01331824|EXPERIMENTAL|Amrubicin|35 mg/m2/day intravenously
62120676|NCT01832480|ACTIVE_COMPARATOR|MTZ 2 g|Single dose MTZ
62679504|NCT02181413|EXPERIMENTAL|Ixazomib Citrate|Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.
61920580|NCT03254368|EXPERIMENTAL|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
61920581|NCT03254368|EXPERIMENTAL|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
62120677|NCT01832480|EXPERIMENTAL|MTZ 500 mg twice daily x 7 days|Multi dose MTZ
62120678|NCT01159704|EXPERIMENTAL|Network plus HIV Counseling&Education|"Social network peer education model plus HIV testing and counseling; the C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
62120679|NCT01159704|ACTIVE_COMPARATOR|HIV Counseling and Education (C&E) only|"HIV testing and counseling C\&E; the C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
62120680|NCT01886625|EXPERIMENTAL|Sympathicotomy|unilateral single-port VATS sympathicotomy
62309004|NCT00510692|PLACEBO_COMPARATOR|Placebo|Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.
62309005|NCT04936425|EXPERIMENTAL|OTSC Stentfix|
62679505|NCT06686498|NO_INTERVENTION|Usual treatment|A waiting group that will function as a control group, which will receive its treatment as usual (TAU) called Group A. For ethical considerations, Group A will receive intervention once its impact has been proven through the present study
61920582|NCT03254368|EXPERIMENTAL|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
61920583|NCT03254368|EXPERIMENTAL|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
62679506|NCT06686498|EXPERIMENTAL|Intervention and usual treatment|An experimental group called Group B, will receive both the usual treatment (TAU) and the intervention.
61920584|NCT03254368|PLACEBO_COMPARATOR|Placebo (D)|Placebo subcutaneous injection once every 3 days
61920585|NCT00739596|EXPERIMENTAL|Aliskiren Hydrochlorothiazide (HCTZ)|
61920586|NCT00739596|ACTIVE_COMPARATOR|Amlodipine|
62120681|NCT04635267||patients with ARDS|
62120682|NCT04567407|EXPERIMENTAL|Bilateral erector spinae blocks|All enrolled patients will have bilateral erector spinae blocks (with catheters for postoperative local anesthetic infusion) placed by the by a member of the clinical regional anesthesia team (under the supervision of a member of the research team) in a sterile fashion after the cardiac surgical procedure is completed. Postoperative continuous infusion of local anesthetic (ropivacaine) via the nerve block catheter is initiated and managed by the Acute Pain Service (per standardized, clinical weight-based protocols).
62120683|NCT05352035||Prospective cohort|This cohort will enroll a total of 300 patients prospectively
62309006|NCT04936425|NO_INTERVENTION|Stent Suturing|
62309007|NCT04968561||cohort 1|"Adult patients~* Admitted in the ENT and Cervico-Facial Surgery department of the Gabriel Montpied University Hospital in Clermont-Ferrand.~* From November 2020 to October 2021,~* Requiring endoscopic sinus surgery~* With good quality imaging (CT scan and/or MRI)"
62679507|NCT06690060|EXPERIMENTAL|Mind-Body Intervention|A Novel Mind body technique for the intervention will be taught in lectures and group discussion sessions
61920587|NCT03119207|EXPERIMENTAL|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
62120684|NCT02764307|EXPERIMENTAL|Aerosolized drug depositions|Aerosol drug deposited on the inhaled and exhaled filters and the residual dose were evaluated delivered by four types of nebulizer: 1) a constant jet nebulizer, a breath enhanced nebulizer, a manual-actuated nebulizer, and a breath-actuated nebulizer.
62120685|NCT01551433||Pts scheduled for Ivor Lewis esophagectomy|During the operation, once the gastric conduit has been mobilized and positioned, and once the anastomotic site has been identified by the surgeon, the assigned RSA will provide the Wipox instrument to the fellow (the primary surgeon will be blinded to the result) who will then obtain one measurement from the anastomotic site.
61920588|NCT03119207|NO_INTERVENTION|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
61920589|NCT03119207|NO_INTERVENTION|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
62120686|NCT05360043|EXPERIMENTAL|LPNY side|1064-nm LPNY (Gentle YAG, Candela ®, USA)
62120687|NCT05360043|EXPERIMENTAL|NAFL side|1565-nm NAFL(ResurFX mode, M22, Lumenis ®, Yokneam, Israel)
62120688|NCT02202499|ACTIVE_COMPARATOR|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
62120689|NCT02202499|ACTIVE_COMPARATOR|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
62120690|NCT02202499|ACTIVE_COMPARATOR|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
62475609|NCT06269744|EXPERIMENTAL|Proactive Screening Outreach|Participants assigned to the interventional arm will receive proactive outreach of mailed Fecal Immunochemical Tests (FIT) to screen for colorectal cancer.
62679508|NCT06690983||Single Group Assignment|Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
61944453|NCT04757285||healthcare providers worked in Intensive Care Units|"35 physicians (28 males and 7 females) and 35 nurses (10 males and 25 females). All volunteers were in good physical health Exclusion criteria included hypertension, diabetes mellitus, obesity BMI ≥30, subjects with serum sodium ≤135 or ≥ 145 mmol /L at baseline or females receiving contraceptive pills.~Assigned participants were clinically evaluated for as hypertension, DM, dyslipidemia, renal function."
61944454|NCT04764773||Case|Patient who had COVID19 infection
61944455|NCT04764773||control|healthy volunteer who were age and sex matched with our patients
61944456|NCT04226560|EXPERIMENTAL|41% Silicone hydrogel Soft contact lenses (SHSCL)|Healthy adult males or females age ≥20-45 years of age
62309008|NCT02061995|EXPERIMENTAL|PREOB® Intravenous Infusion|
62679509|NCT04579380|EXPERIMENTAL|Tucatinib + Trastuzumab (+ Fulvestrant)|Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
62679510|NCT03948789|ACTIVE_COMPARATOR|A Myomectomy|Removement of uterine fibroids by myomectomy
62679511|NCT03948789|EXPERIMENTAL|B MRgFUS-TUF|Removement of uterine fibroids by Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy (MRgFUS-TUF)
62120691|NCT05006729||RURAL cohort study|A longitudinal research project in ten rural counties in Alabama, Kentucky, Louisiana, and Mississippi enrolling approximately 4,600 participants from these communities, examining several different aspects of their health, including heart and lung function.
62120692|NCT02418013|EXPERIMENTAL|Fresh cord blood(experimental group A)|16 males and 16 females are assigned to the experimental group A. Dropout is 20 percent in each gender.
62120693|NCT02418013|EXPERIMENTAL|Frozen cord blood(experimental group B)|16 males and 16 females are assigned to the experimental group B. Dropout is 20 percent in each gender.
62475610|NCT06269744|NO_INTERVENTION|Standard of Care|Participants assigned to the standard of care group will receive usual care (i.e., opportunistic screening for colorectal cancer).
62120694|NCT02418013|EXPERIMENTAL|Frozen plasma(experimental group C)|16 males and 16 females are assigned to the experimental group C. Dropout is 20 percent in each gender.
62120695|NCT02418013|PLACEBO_COMPARATOR|Placebo group|16 males and 16 females are assigned to the Placebo group. Dropout is 20 percent in each gender. Total participants are 64 in males and 64 in females.
62120696|NCT01084850||Diabetes Type II|Patients with type 2 Diabetes Mellitus
62120697|NCT01084850||Control|Patients with no diabetes
62120698|NCT06676371|ACTIVE_COMPARATOR|Conventional Hemiarch group (HAR)|"Under general anesthesia and transesophageal echocardiogram monitoring, a median sternotomy will be performed. Patients will be placed on cardiopulmonary bypass using arterial inflow from the femoral artery, axillary artery, or direct aortic cannulation, along with right atrial appendage venous cannulation. Systemic cooling to 25 degrees Celsius will commence, followed by thiopental coma and circulatory arrest. The aorta will be trimmed to the distal ascending aorta or proximal arch, and antegrade cerebral perfusion will be initiated to the brachiocephalic branch.~The distal anastomosis will connect a vascular graft to the distal ascending aorta or aortic arch. After completing this, systemic perfusion and rewarming will begin, followed by the proximal anastomosis with the vascular graft. After de-airing, the aorta will be de-clamped, and the patient will be weaned from cardiopulmonary bypass and decannulated. Hemostasis and sternal closure will follow standard institutional protocols"
62475611|NCT03916263|EXPERIMENTAL|Traditional Treatment|Participant receives recommendations for caloric intake, exercise and prescription for metformin if indicated
62475612|NCT03916263|OTHER|One-On-One Low Starch Dietary Instruction|Participant receives One-On-One Low Starch Dietary Instruction from Study Collaborator
62475613|NCT03916263|OTHER|Low Starch Dietary Instruction by Video|Participant receives Low Starch Dietary Instruction by Video Link
62309009|NCT04550507|EXPERIMENTAL|Group A: Mindful Sensory Awareness|Group A: Mindful Sensory Awareness receives the mindful sensory awareness intervention during the first 8-week period, and receives no active intervention delivery during the second 8-week period.
62309010|NCT04550507|OTHER|Group B: Mindful Sensory and Body Awareness|Group B: Mindful Sensory and Body Awareness receives no active intervention delivery during the first 8-week period, and during the second 8-week period receives an intervention combining the mindful sensory awareness content received by Group A with the mindful body awareness check-in approach.
62309011|NCT01284556|PLACEBO_COMPARATOR|Placebo|placebo tablets
62679512|NCT00485342|NO_INTERVENTION|standard dose|"the reference strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg)"
62120699|NCT06676371|ACTIVE_COMPARATOR|Total Arch Replacement and Frozen Elephant Trunk group (TARFET)|"Under general anesthesia and transesophageal echocardiogram monitoring, a median sternotomy will be performed. Patients will be placed on cardiopulmonary bypass via femoral, axillary, or direct aortic cannulation. Systemic cooling to 25 degrees Celsius will lead to thiopental coma and circulatory arrest. The aorta will be trimmed to the distal arch, with antegrade cerebral perfusion initiated.~Distal anastomosis will connect a vascular graft to the distal arch, followed by visceral perfusion, rewarming, and proximal anastomosis. After de-airing, the aorta will be de-clamped, and the patient will be weaned from bypass and decannulated. Hemostasis and sternal closure will follow standard protocols.~Arterial cannulation sites for HAR and TARFET will be determined by the surgeon based on the clinical scenario."
62120700|NCT00483093|EXPERIMENTAL|A|
62309012|NCT01284556|EXPERIMENTAL|60 mg group|Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.
61920590|NCT05572554|EXPERIMENTAL|Foot Bath Group|"This group of elderly people were taught the foot bath practically by a researcher at the pre-study meeting and were given the Foot Bath Information Brochure and a personalized water thermometer. The other researcher administered the Elderly Information Form and PSQI to all elderly people before the study using individual interviews lasting approximately 15 minutes and pen and paper method. The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks. In addition, the PSQI, which provides information about sleep quality, type, and severity of sleep disturbance, was applied to the elderly before the study (pretest), 4th week (interim measurement/1st measurement), and at the end of the study (8th week) for a total of 3 times during 8 weeks."
61944457|NCT04226560|ACTIVE_COMPARATOR|ACUVUE® VITA™|Healthy adult males or females age ≥20-45 years of age
62309013|NCT01284556|EXPERIMENTAL|100 mg group|Patients titrated to 100mg phenobarbital maintenance period, then titrated down
62309014|NCT02227407|EXPERIMENTAL|Energy expenditure, gait pattern, RGOs|using motion capture system and forceplates to monitor gait pattern while wearing reciprocating gait orthoses to calculate the mechanical energy cost
62309015|NCT03927976|EXPERIMENTAL|Path2Quit|After assessment eligibility, given consent, information about text messaging will be collected and participants enrolled in the Path2Quit culturally specific text message program and feedback will be collected on their experience.
62309016|NCT05255614|ACTIVE_COMPARATOR|First Group|the participants will start training on the pelvic trainer and assessment will be via assessment via a checklist. Then at a later time, they will be trained on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator.
62309017|NCT05255614|ACTIVE_COMPARATOR|Second Group|the participants will start training on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator. Then at a later time, they will be trained on the pelvic trainer and assessment will be via assessment via a checklist.
62679513|NCT00485342|EXPERIMENTAL|adjusted dose|individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
62679514|NCT04089085|OTHER|One group pilot|The experimental group will receive the intervention, which is an 8-week (30 minute session per week) asthma educational and cognitive behavioral skills program.
62309018|NCT04623931|EXPERIMENTAL|Treatment (temozolomide, radiation therapy)|Patients receive temozolomide PO daily and radiation therapy over 5 days a week (weekdays only) for 6 weeks. Beginning 28 days after the last dose of radiation therapy, patients receive temozolomide PO for 12 months in the absence of disease progression or unacceptable toxicity.
62309019|NCT01382069|PLACEBO_COMPARATOR|Placebo|Placebo
62309020|NCT01382069|EXPERIMENTAL|Dimethandrolone Undecanoate|DMAU group with different doses 100, 200 and 400 groups
61920591|NCT05572554|NO_INTERVENTION|Control Group|No application was made to the elderly in this group. Only the PSQI, which gives information about sleep quality, type, and severity of sleep disturbance, was administered to the elderly before the study (pretest), at the 4th week (interim measurement/1st measurement), and at the end of the study (8th week) for a total of 3 times for 8 weeks.
62120701|NCT03897413|EXPERIMENTAL|Sequence 1|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fed state in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
62120702|NCT03897413|EXPERIMENTAL|Sequence 2|Participants received a single oral dose of 0.75 mg S-888711 in the fed state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
62120703|NCT03897413|EXPERIMENTAL|Sequence 3|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state in period 2, and a single oral dose of 0.75 mg S-888711 in the fed state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
62679515|NCT05529173|EXPERIMENTAL|treatment|Application of Povidone-Iodine 10% prior to surgery to Nares
62679516|NCT05529173|PLACEBO_COMPARATOR|placebo|Application of 0.9% Sodium Chloride (NaCl) solution prior to surgery to Nares
62679517|NCT04189588|ACTIVE_COMPARATOR|Cohort A|Cetirizine HCl 10 mg/mL: a single 1 mL injection.
62679518|NCT04189588|ACTIVE_COMPARATOR|Cohort B|Diphenhydramine 50 mg/mL: a single 1 mL injection.
62679519|NCT02868710|EXPERIMENTAL|Individualized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: HR \> VT1; 5.6 kcal/kg/wk Week 2: HR \> VT1; 8.4 kcal/kg/wk Week 3: HR \> VT1; 11.2 kcal/kg/wk Week 4: HR ≥ VT1 to \<VT2; 11.2 kcal/kg/wk Week 5-6: HR ≥ VT1 to \<VT2; 11.2 kcal/kg/wk Week 7: HR ≥ VT1 to \<VT2; 12.6 kcal/kg/wk Week 8: HR ≥ VT1 to \<VT2; 14 kcal/kg/wk Week 9-10: HR ≥ VT2; 14 kcal/kg/wk Week 11-12: HR ≥ VT2; 15.4 kcal/kg/wk"
62679520|NCT02868710|EXPERIMENTAL|Standardized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: 40-45% HRR; 5.6 kcal/kg/wk Week 2: 40-45% HRR; 8.4 kcal/kg/wk Week 3: 40-45% HRR; 11.2 kcal/kg/wk Week 4: 50-55% HRR; 11.2 kcal/kg/wk Week 5-6: 55-60% HRR; 11.2 kcal/kg/wk Week 7: 55-60% HRR; 12.6 kcal/kg/wk Week 8: 55-60% HRR; 14 kcal/kg/wk Week 9-10: 60-65% HRR; 14 kcal/kg/wk Week 11-12: 60-65% HRR; 15.4 kcal/kg/wk"
62120704|NCT04368858|EXPERIMENTAL|Cohort 1 : experimental group|Participants will be involved in an evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 1 year with evaluations (occurrence of fall) taking place at 6 months and at 1 year.
62120705|NCT00222326|EXPERIMENTAL|Pelvic floor muscle training|Pelvic floor muscle training: clinic and rooms exercise training
62120706|NCT00222326|NO_INTERVENTION|Usual care|Usual care as provided by the surgeon and hospital staff
62120707|NCT06588257|OTHER|Men who have sex with men with HIV|Evaluate the acceptability, uptake, and completion of HPV vaccination.
62120708|NCT06588257|OTHER|Transgender women with HIV|Evaluate the acceptability, uptake, and completion of HPV vaccination.
62339597|NCT04791683|EXPERIMENTAL|Experimental|"1. st interview: Application of data collection tools~2. nd meeting: Sexual counseling (1 week after the first interview)~3. rd interview: Sexual counseling (1 week after the first session)~4. th meeting: Sexual counseling (1 week after the second session)~5. th interview: Telephone interview (2 months after the first assessment)~6. th interview: re-application of data collection tools, including the final evaluation"
62339598|NCT02527551|OTHER|Haptic massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
62339599|NCT06080776|EXPERIMENTAL|SH-1028 tablets|
62339600|NCT06080776|PLACEBO_COMPARATOR|Placebo SH-1028 tablets|
62339601|NCT02082145|NO_INTERVENTION|Control|Treated according to local protocol for diabetic peripheral neuropathy
62679521|NCT02868710|NO_INTERVENTION|Control|"non-exercise control group~Testing at baseline and post-program (12 weeks)"
62679522|NCT02181621|PLACEBO_COMPARATOR|Solosite gel|Hydrogel with preservatives, used to create a moist wound environment.
62679523|NCT02181621|ACTIVE_COMPARATOR|Iodosorb|Cadexomer iodine gel
62679524|NCT00600431||1|Study group: 16 children under 18 years undergoing systemic chemotherapy
62679525|NCT00600431||2|Control group: 16 age and sex matched healthy children under 18 years
62679526|NCT06457321|OTHER|Receive conventionally made denture first then denture made from partial digital method.|"Participants will be receiving their Denture 1 made from conventional method first and provide feedback at the 1-month and 2-month Denture 1 post-issue review visits.~Participants will then return the Denture 1 to the attending clinician and receive the Denture 2 made from partial digital method and provide feedback at the 1-month and 2-month post-issue Denture 2 review visits."
62679527|NCT06457321|OTHER|Receive denture made from partial digital method first then conventionally made denture.|"Participants will be receiving their Denture 1 made from partial digital method first and provide feedback at the 1-month and 2-month Denture 1 post-issue review visits.~Participants will then return the Denture 1 to the attending clinician and receive the Denture 2 made from conventional method and provide feedback at the 1-month and 2-month post-issue Denture 2 review visits."
62679528|NCT03575000|EXPERIMENTAL|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
62339602|NCT02082145|EXPERIMENTAL|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
61920592|NCT03690323|EXPERIMENTAL|RFA|"RFA: laparotomy is performed followed by radiofrequency ablation of the tumor.~After recovery of the RFA patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel + gemcitabine or gemcitabine monotherapy"
61920593|NCT03690323|ACTIVE_COMPARATOR|Chemotherapy|"Patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel plus gemcitabine or gemcitabine monotherapy"
62339603|NCT02523664|ACTIVE_COMPARATOR|Hydrocortisone|10 mg hydrocortisone orally
62679529|NCT04650841|EXPERIMENTAL|Naloxone Group|Participants will receive 4mg naloxone nasal spray.
61920594|NCT04727281|EXPERIMENTAL|dialysis patients|Patients included in the study will be recruited from the dialysis units in Alexandria University Hospitals.
62339604|NCT02523664|PLACEBO_COMPARATOR|Placebo|placebo orally
62475614|NCT01214135||1|Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).
61920595|NCT02361580|EXPERIMENTAL|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
61920596|NCT02361580|NO_INTERVENTION|No Diary|Control Group
61920597|NCT02895997|EXPERIMENTAL|Clinical Operations Room Staff|Clinicians and critical care nurse volunteers from the clinical operations room (COR) staff at Emory University Hospital will travel to Sydney Australia to deliver telemedicine.
61920598|NCT01306877|EXPERIMENTAL|EEA Hemorrhoid and Prolapse Stapling Set|
61920599|NCT01306877|ACTIVE_COMPARATOR|Endosurgery Proximate PPH03 Stapling Set|
61944458|NCT00611208|EXPERIMENTAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diptheria toxin)
61944459|NCT03671980|EXPERIMENTAL|Web-intervention|30 participants using a self-management website and home faecal calprotectin smartphone monitoring instead of usual outpatient follow up as a means of managing their inflammatory bowel disease for 6 months after stopping an IBD medication.
61944460|NCT05824572|ACTIVE_COMPARATOR|Audio|Researchers will audio record both in-person and telehealth visits of participants in the intervention group.
62679530|NCT04650841|EXPERIMENTAL|Saline Group|Participants will receive saline in the nasal spray.
62679531|NCT06260748|EXPERIMENTAL|Group 1 Diarrhea-Evaluable|Diarrhea-evaluable participants aged 12-75 years old who did not use continence aids that precluded assessment or evaluation of stool frequency and consistency during the screening/baseline period; randomized 1:1 to receive either placebo or CDCA.
61920600|NCT04508764|NO_INTERVENTION|Usual Care|"* For approximately the first 6 months of the study, or until 75 patient with cancer who is initially approached in clinic (probands) are enrolled, the investigators will be enrolling probands into the Usual Care group. During this time, the investigators will clarify usual care regarding cascade genetic testing for each participating clinic and proband participant. The investigators will do this by proband participant surveys, as well as initial provider semi-structured interviews.~* Proband: Complete Cascade Genetic Testing survey. The survey will also contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. At 6 months, there will be a follow-up survey~* Family Member: Complete survey at study entry and at 6 month follow-up"
61920601|NCT04508764|EXPERIMENTAL|FACT Toolkit (FACTT)|"* Proband: Introduced to FACTT and will complete Cascade Genetic Testing survey. The survey will contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. The probands will also fill out assessments of each FACTT component. At 6 months, there will be a follow-up survey.~* Family Member: Introduced to FACTT and will complete surveys at study entry and 6 month follow-up. They will also fill out assessments of each FACTT component"
61920602|NCT04817527|EXPERIMENTAL|Edaravone Dexborneol|
61920603|NCT04817527|NO_INTERVENTION|conventional therapy|conventional therapy of acute ischemic stroke after Endovascular Therapy based on Chinese guidelines for endovascular therapy
62120709|NCT06588257|OTHER|Men who have sex with men without HIV|Evaluate the acceptability, uptake, and completion of HPV vaccination.
62120710|NCT06588257|OTHER|Transgender women without HIV|Evaluate the acceptability, uptake, and completion of HPV vaccination.
62120711|NCT06392711|ACTIVE_COMPARATOR|MSCs Dose Level 0 into one submandibular gland|6 subjects will receive Mesenchymal Stromal Cells (MSC) at Dose Level 0, which is 10 (8-12) x10\^6 MSCs in a single submandibular gland. If this dose is deemed tolerable when injected into a single submandibular gland, this dose will be administered to both submandibular glands in the initial subjects in the dose escalation arm.
62120712|NCT06392711|ACTIVE_COMPARATOR|MSCs into both submandibular glands - Dose Escalation Cohort|8-18 subjects in the Dose Escalation phase of study will receive MSCs into both submandibular glands. The initial subjects in this cohort will receive Dose Level 0: 10 (8-12) x10\^6 MSCs/gland. If this dose is tolerated, subsequent subjects will receive Dose Level 1: 20 (16-24) x10\^6 MSCs/gland. The highest tolerated dose (recommended phase II dose or RP2D) will be administered to the subjects in the Expansion Cohort.
62120713|NCT06392711|ACTIVE_COMPARATOR|MSCs into both submandibular glands - Expansion Cohort|12 subjects in Expansion Cohort will receive MSCs into both submandibular glands at the RP2D.
62475615|NCT05206318|EXPERIMENTAL|20 participants with topical cysteamine cream|Participants with post-inflammatory hyperpigmentation will apply topical cysteamine cream for a 16 weeks period.
61920604|NCT03901703|ACTIVE_COMPARATOR|Dorsiflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their dorsiflexor muscles alongside standard functional progressive strengthening exercises.
61920605|NCT03901703|ACTIVE_COMPARATOR|Plantarflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their plantarflexor muscles alongside standard functional progressive strengthening exercises.
61920606|NCT03901703|ACTIVE_COMPARATOR|Dorsiflexor and Plantarflexor Muscle strengthening Group|The children in this group will receive functional exercises aiming to strengthen both their dorsiflexor and plantarflexor muscles alongside standard functional progressive strengthening exercises.
61920607|NCT04604847|OTHER|Total knee arthroplasty|patient operated for a total knee arthroplasty
61944461|NCT05824572|PLACEBO_COMPARATOR|Usual care|Participants will receive Usual Care
61920608|NCT05503121||Study Group|"The volunteer group planned to be included in the study will consist of individuals diagnosed with Nonspecific Low Back Pain who applied to Istinye University Physiotherapy and Rehabilitation Application and Research Center (Isu Fizyotem).~21 volunteers with low back pain will be included in the study."
61920609|NCT05503121||Contol Group|The control group will consist of healthy individuals. 21 healty volunteers will be included in the study.
61920610|NCT02590302|OTHER|Dyads receiving the Implementation Phase|Dyad 1 (CHEO-YSB) Dyad 2 (CGH-CCH) Dyad 3 (WDMH-CCH) Dyad 4 (QCH-YSB)
61920611|NCT06274905|EXPERIMENTAL|EMLA cream|EMLA cream 5% 25g lidocaine, 25g prilocaine; Astra Zeneca. Topically applied followed by Tegaderm dressing to cover. Length of duration monitored and recorded as part of study
61920612|NCT06274905|PLACEBO_COMPARATOR|EMLA placebo|Aqueous cream ((Ultrapure Laboratories®️, Mayo, Ireland) applied topically followed by covering with Tegaderm dressing. Length of duration monitored and recorded as part of study
61920613|NCT06274905|EXPERIMENTAL|Ethyl chloride spray|Ethyl chloride spray (Cryogesic®, Fannin Ltd, Dublin, Ireland). Applied topically to surgical site prior to LA injection. Spray at distance of 5-10cm for 4-8 seconds until skin slightly blanched and the fluid allowed to evaporate.
62339605|NCT02295735|EXPERIMENTAL|Mepilex® Border|If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
62339606|NCT02295735|NO_INTERVENTION|Control|Standard pressure ulcer prevention according to hospital standard
62339607|NCT04144855|EXPERIMENTAL|TQB3474 injection|Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.
62475616|NCT05206318|SHAM_COMPARATOR|20 participants with topical vehicle control cream|Participants with post-inflammatory hyperpigmentation will apply topical vehicle-control cream for a 16 weeks period.
62475617|NCT04564053|EXPERIMENTAL|LNA043|LNA043
61920614|NCT06274905|NO_INTERVENTION|Control group|No intervention administered
61920615|NCT04111952|EXPERIMENTAL|Additional laser treatment|Women receiving a single laser treatment.
61920616|NCT04111952|SHAM_COMPARATOR|Sham laser treatment|Women receiving sham laser treatment.
61920617|NCT03137576|ACTIVE_COMPARATOR|Paravertebral block (PVB)|"Intraoperative pain management~1. Sedation~   Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~2. Paravertebral Block~Post operative pain management~* Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~* Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
61920618|NCT03137576|EXPERIMENTAL|Erector Spinae Plane Block (ESPB)|"Intraoperative pain management~1. Sedation~   Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~2. Erector Spinae Plane Block~Post operative pain management~* Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~* Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
61920619|NCT03722290|EXPERIMENTAL|Metformin|Metformin 500mg twice a day per os for 9 weeks
61920620|NCT05796778|EXPERIMENTAL|subomohyoid suprascapular nerve|superficial probe of ultrasound was placed in the transverse plane to visualize the superior trunk in the short axis. The suprascapular nerve was identified as it branched off from the superior trunk and traced until it coursed beneath the inferior belly of the omohyoid muscle.
61920621|NCT05796778|ACTIVE_COMPARATOR|Interscalene brachial plexus|ultrasound-guided interscalene block involves imaging the C5 and C6 roots at approximately the level of the cricoid cartilage, just distal to where they emerge from behind their respective transverse processes and where they lie in the groove between the anterior and middle scalene muscles
61920622|NCT01178996|EXPERIMENTAL|Thymosin alpha 1|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
61944462|NCT04255030|EXPERIMENTAL|First stage: Self-directed Coping Together|
62475618|NCT04564053|PLACEBO_COMPARATOR|placebo|
62475619|NCT02435043|EXPERIMENTAL|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management
62475620|NCT02435043|ACTIVE_COMPARATOR|Treatment as usual|standard management after stroke
62475621|NCT01660789|OTHER|Lifestyle intervention|Lifestyle intervention.
62475622|NCT02317263|ACTIVE_COMPARATOR|Testosterone gel|Apply gel once a day for 96 weeks
62475623|NCT02317263|PLACEBO_COMPARATOR|Placebo gel|Apply gel once a day for 96 weeks
62475624|NCT04489641|EXPERIMENTAL|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau et al., 2010). This intervention is provided by clinical psychologist in primary care."
62475625|NCT04489641|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Medication provided by a general practitioner.
62475626|NCT05215535|EXPERIMENTAL|MRI group|An abbreviated MRI of the liver/abdomen
62475627|NCT05215535|ACTIVE_COMPARATOR|CT group|A combined single venous and 3 min equilibrium phase CT of the abdomen/liver
62475628|NCT06111248|NO_INTERVENTION|Control group|638 patients receiving the usual, standard management for anesthesia when undergoing surgery lasting \> 60 min and involving intermediate or major non-cardiac risk.
62679532|NCT06260748|ACTIVE_COMPARATOR|Group 2a Non-Diarrhea Evaluable|Non-diarrhea-evaluable participants aged 12-75 years old who do not have stable, clinically burdensome diarrhea or their diarrhea cannot be fully characterized.
62679533|NCT06260748|ACTIVE_COMPARATOR|Group 2b Pediatrics|Participants aged 2 to less than 12 years old with or without clinically burdensome diarrhea.
62679534|NCT04830709||PARPi maintenance cohort (PMC)|patients who received at least one dose of PARPi as 1L MTX after 1L platinum-based CTX
62679535|NCT04830709||Bevacizumab maintenance cohort (BMC)|patients who continue to receive at least one dose of bevacizumab after 1L platinum-based CTX and who have not received PARPi MTX treatment
62679536|NCT04830709||No maintenance cohort (NMC)|patients who never received any 1L MTX treatment (PARPi or bevacizumab)
62679537|NCT05531344|EXPERIMENTAL|Composite Steep-pulse Treatment Device|Composite Steep-pulse(High-frequency irreversible electroporation) Treatment Device
62679538|NCT05531344|ACTIVE_COMPARATOR|Tamsulosin|Tamsulosin Hydrochloride Sustained Release Capsules, 0.2mg, once a day,3 months
62679539|NCT02835521|EXPERIMENTAL|Intervention Group|Patients will receive the reception treatment before the joint injection
62475629|NCT06111248|EXPERIMENTAL|Experimental group|638 patients undergoing surgery lasting \> 60 min and involving intermediate or major non-cardiac risk who have been managed by staff trained in the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
62475630|NCT04360694|EXPERIMENTAL|Incremental hemodialysis|Procedure: Incremental hemodialysis. It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
62679540|NCT02835521|ACTIVE_COMPARATOR|Control Group|patient will receive a joint injection
62679541|NCT04993768|EXPERIMENTAL|TPN-101, Dose A|
62679542|NCT04993768|EXPERIMENTAL|TPN-101, Dose B|
62679543|NCT04993768|EXPERIMENTAL|TPN-101, Dose C|
62679544|NCT04993768|PLACEBO_COMPARATOR|Placebo|
62679545|NCT06495554|EXPERIMENTAL|PROM assessment and ctDNA detection during surveillance|All participants (n=295) included in the prospective clinical study
62309021|NCT04054713|ACTIVE_COMPARATOR|Chromoendoscopy with acetic acid and targeted biopsies|Acetic acid is prepared at a concentration of 2.5%, after initial cleaning is done, it will be applied with a 7 French spray catheter, starting the proximal application performing a uniform application on the area of intestinal metaplasia an then will be timed for mucous visualization in search of areas of loss of acetowhitening, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the esophageal face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal (glands evenly distributed with normal or abnormal crypt density (compact crypts with increased density; focal irregularity or disorganized crypts; absence of a cryptic pattern), once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
62679546|NCT06495554|NO_INTERVENTION|Standard surveillance|Historical controls (n=1,000) who will be identified by the Danish Gynecological Cancer Database
62339608|NCT05086289|EXPERIMENTAL|LY3526318|Participants received 250 mg of LY3526318 orally, once daily for the first 4 weeks of treatment period and were switched to placebo once daily for the next 4 weeks of the treatment period.
62475631|NCT04360694|ACTIVE_COMPARATOR|Conventional hemodialysis|Procedure: Conventional hemodialysis. It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
62475632|NCT04700787|EXPERIMENTAL|Sulopenem|Sulopenem intravenous 1000 mg (single dose) on Day 1 followed by oral sulopenem etzadroxil/probenecid 500 mg/500 mg (single dose) on Day 2.
62475633|NCT02875769|EXPERIMENTAL|Test: Mouthwash CPC+Zn+F|To rinse with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
62679547|NCT06246721|ACTIVE_COMPARATOR|Subjects Agree Self-management Group|Women with pelvic organ prolapse requires ring pessary for treatment. Those who agree to join the study and agree to learn how to self-management of vaginal pessary.
62679548|NCT06246721|PLACEBO_COMPARATOR|Subjects Refuse Self-management Group|Women with pelvic organ prolapse requires ring pessary for treatment. Those who agree to join the study and refuse to learn how to self-management of vaginal pessary.
62679549|NCT05041582|EXPERIMENTAL|Real tDCS + Citalopram + Rehabilitation|"* Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks~* Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
62679550|NCT05041582|SHAM_COMPARATOR|Sham tDCS + Citalopram + Rehabilitation|"* Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks~* Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
62679551|NCT05041582|PLACEBO_COMPARATOR|Real tDCS + Placebo + Rehabilitation|"* Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks~* Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
61944463|NCT04255030|EXPERIMENTAL|First stage: Minimally guided telephone support (lay coaching)|
61944464|NCT04255030|EXPERIMENTAL|Second stage: High intensity Motivational Interviewing (MI)|
62679552|NCT05041582|PLACEBO_COMPARATOR|Sham tDCS + Placebo + Rehabilitation|"* Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks~* Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
62120714|NCT04943770||WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|"Patients will be randomised 4:4 to a specific stimulating rates order (A, B, C, D) for approx. 3-6 weeks per rate (12-24 weeks in total). Each period is followed by a wash-out phase.~At each frequency systematic assessment of the sweet-spot(s) will be performed. Various pulse width and amplitude values may be used to optimize therapy (up to 1KHz). These programmes will be saved in the subject's remote control based on the pre-generated rate randomization sequence."
62120715|NCT04838886|EXPERIMENTAL|Exercise group|The intervention group will be received telerehabilitation-based pilates training three times a week for 6 weeks.
62309022|NCT04054713|ACTIVE_COMPARATOR|Seattle protocol|Take random biopsies by quadrants every 2 centimeters biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction begins, taking tissue every 2cm from the 4 quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
62309023|NCT04786288|EXPERIMENTAL|Aromatherapy|"22 elderly participants received M technique hand massage that lasted for 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the hand massage.~Intervention: massage with lavender essential oil mixed in a carrier oil"
62475634|NCT02875769|ACTIVE_COMPARATOR|Positive control: Mouthwash CHX|To rinse with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
62475635|NCT02875769|PLACEBO_COMPARATOR|Negative control A: No rinsing|No rinsing with pre-procedural mouthwash + full mouth dental prophylaxis using ultrasonic scaler.
62679553|NCT05253326|EXPERIMENTAL|Exercises Group|Patients will be taught Progressive Muscle Relaxation Exercises before the surgery and will be applied twice a week for 2 months after the surgery.
62679554|NCT05253326|NO_INTERVENTION|Control Group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital.
62679555|NCT05073510||BlueDop Vascular Expert (BVE)|PAD assessment with BVE
62120716|NCT04838886|NO_INTERVENTION|Waitlist|The control group will be a wait-list group without any additional specific treatment.
62120717|NCT00622531||BNP Open|Subjects treated based on clinical assessment and knowledge of BNP values
62120718|NCT00622531||Control|Subjects treated based on clinical assessment alone
62120719|NCT03290248|PLACEBO_COMPARATOR|Vehicle|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
62120720|NCT03290248|ACTIVE_COMPARATOR|B 244 1x (low dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
62120721|NCT03290248|ACTIVE_COMPARATOR|B244 4x (mid dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
62120722|NCT03387319|EXPERIMENTAL|Racialized Stressful Event Recall|Participants in this study are recall a stressful event related to race.
62120723|NCT03387319|EXPERIMENTAL|Non-racialized Stressful Event Recall|Participants in this study arm recall a stressful event unrelated to race.
62120724|NCT05695911|EXPERIMENTAL|Limb Load Biofeedback Training Intervention|The limb-load biofeedback training focuses on altering habitual movement patterns to promote proper prosthetic limb loading with an emphasis on between-limb loading symmetry. Participants randomized to the EXP group will receive 12 biofeedback training sessions (1 in-person, 11 telehealth) tapered over 40 weeks.
62120725|NCT05695911|PLACEBO_COMPARATOR|Attention Control Intervention|The CTL group intervention will include the same standard of care rehabilitation sessions as the EXP group and receive the same computer tablets for telehealth sessions as the EXP group. The CTL group will also have attention control educational sessions at the same frequency, timing, and duration as the EXP group limb-load biofeedback sessions (12 total sessions) with the first session being an in-person session at the Week 24. There will be no biofeedback training intervention in the CTL group. As such, there will be no behavioral intervention or wearable sensors provided to the CTL group. The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group.
62120726|NCT03399968|EXPERIMENTAL|ESWT|Application of shockwaves non-invasively at the level of injury
62120727|NCT03399968|PLACEBO_COMPARATOR|Placebo ESWT|Positioning of the therapy head at the injury level without application of shockwaves
62120728|NCT03227757|EXPERIMENTAL|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm.
62120729|NCT04525170|EXPERIMENTAL|HPT treated|daily wear Hexafocon A rigid contact lens treated with Hydra PEG surface coating
62120730|NCT04525170|EXPERIMENTAL|untreated|daily wear Hexafocon A rigid contact lens
62309024|NCT04786288|PLACEBO_COMPARATOR|Placebo|"odourless baby oil was used for the application of the M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.~Intervention: other: massage with no fragrance baby oil"
62309025|NCT04786288|NO_INTERVENTION|Control|Participants in this group didn't receive any type of intervention from the researcher except the routine hospital management.
62309026|NCT05793073||Pre-intervention group|
62475636|NCT02875769|PLACEBO_COMPARATOR|Negative control B: Water|To rinse with pre-procedural mouthwash containing water from a three-way syringe (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
62475637|NCT04813354|EXPERIMENTAL|ELLIPTA/ BREEZHALER/Questionnaire version 1|Participants received placebo ELLIPTA Dry Powder Inhaler (DPI) followed by placebo BREEZHALER DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and visual analogue scale (VAS) on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 1 on Day 1.
61920623|NCT01178996|PLACEBO_COMPARATOR|Placebo|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
62475638|NCT04813354|EXPERIMENTAL|ELLIPTA/ BREEZHALER/Questionnaire version 2|Participants received placebo ELLIPTA DPI followed by placebo BREEZHALER DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and VAS on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 2 on Day 1.
62679556|NCT05574764|ACTIVE_COMPARATOR|Teachers|This cohort includes K-12 teachers. Schools will offer all teachers the professional development program called Cultivating Awareness and Resilience in Education (CARE) . CARE will be presented in three in-person training sessions over two to three months during the school year. Tools include mindful awareness practices and caring and emotion skills training. Each intervention workshop includes 30 to 35 participants and a facilitator, who is part of the CARE team. The workshops will be held at a location selected by the school, likely on their campus.
62679557|NCT05574764|ACTIVE_COMPARATOR|Staff, Non-Administrative|This cohort includes non-administrative staff. Schools will offer all non-administrative staff the professional development program called Cultivating Awareness and Resilience in Education (CARE) . CARE will be presented in three in-person training sessions over two to three months during the school year. Tools include mindful awareness practices and caring and emotion skills training. Each intervention workshop includes 30 to 35 participants and a facilitator, who is part of the CARE team. The workshops will be held at a location selected by the school, likely on their campus.
61920624|NCT00922701|EXPERIMENTAL|Peritoneal Dialysis Solution|
61920625|NCT01057901|EXPERIMENTAL|Flibanserin 100 mg|Flibanserin 100 mg administered at bedtime
61920626|NCT01057901|PLACEBO_COMPARATOR|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
62309027|NCT05793073||Post-intervention group|
62309028|NCT00749099|PLACEBO_COMPARATOR|Phase I|All subject participate in Phase I
62475639|NCT04813354|EXPERIMENTAL|BREEZHALER/ ELLIPTA/Questionnaire version 1|Participants received placebo BREEZHALER DPI followed by placebo ELLIPTA DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and VAS on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 1 on Day 1.
62475640|NCT04813354|EXPERIMENTAL|BREEZHALER/ ELLIPTA/Questionnaire version 2|Participants received placebo BREEZHALER DPI followed by placebo ELLIPTA DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and VAS on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 2 on Day 1.
61920627|NCT00244842|PLACEBO_COMPARATOR|Placebo Comparator: 1|Placebo
61920628|NCT00244842|ACTIVE_COMPARATOR|Voclosporin 0.2 mg/kg po BID|Voclosporin 0.2 mg/kg po BID
62120731|NCT04484480|EXPERIMENTAL|Balance training|Patients included in the study group, who received 3-month proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
62120732|NCT04484480|NO_INTERVENTION|Control group|Patients included in the control group who did not received any intervention
62309029|NCT00749099|ACTIVE_COMPARATOR|Phase II|All subject participate in Phase II
62309030|NCT04103918|OTHER|Jalucomplex® 2|Jalucomplex® 2 (Linear Hyaluronic Acid) Injection: follow the instruction for use
61920629|NCT00244842|ACTIVE_COMPARATOR|Voclosporin 0.3 mg/kg po BID|Voclosporin 0.3 mg/kg po BID
61920630|NCT00244842|ACTIVE_COMPARATOR|Voclosporin 0.4 mg/kg po BID|Voclosporin 0.4 mg/kg po BID
61920631|NCT03787563|ACTIVE_COMPARATOR|Active Herbal tea|One tea bag infusion three times a day each before breakfast, lunch and dinner.
61920632|NCT03787563|PLACEBO_COMPARATOR|Placebo Tea|Similar looking tea bag infusion three times a day each before breakfast, lunch and dinner.
62120733|NCT01816958||chronic depression and/or pain|co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
62120734|NCT03179722|EXPERIMENTAL|Intervention group: Frenchspeaking patients|Intervention: Medication review
62309031|NCT03077048|NO_INTERVENTION|Low protein diet|Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
62309032|NCT03077048|EXPERIMENTAL|Supplemented low protein diet|Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
62679558|NCT05574764|ACTIVE_COMPARATOR|Staff, Administrative|This cohort includes administrative staff. Schools will offer all administrative staff the professional development program called Cultivating Awareness and Resilience in Education (CARE) . CARE will be presented in three in-person training sessions over two to three months during the school year. Tools include mindful awareness practices and caring and emotion skills training. Each intervention workshop includes 30 to 35 participants and a facilitator, who is part of the CARE team. The workshops will be held at a location selected by the school, likely on their campus.
61920633|NCT04381338|EXPERIMENTAL|Rehabilitation in COVID-19 patients in ICU|"Every person admitted to ICU for ARDS with a confirmed diagnosis of COVID-19 Motor program~* Intubated patient GCS \>8: passive mobilization; postural positioning GCS\< 8: passive and active-assist mobilization; postural positioning~* Extubated patient~  * If strength \< 3 MRC: passive and/or active-assist; functional retraining~ * If strength ≥3 MRC: active-assist and active; strength training; functional retraining Pulmonary Rehabilitation~* Intubated patient GCS \>8: postural positioning GCS\< 8: postural positioning, cautious inspiratory muscle training~* Extubated patient~  * If strength \< 3 MRC: postural positioning, positive pressure expiration exercise,inspiratory muscle training~ * If strength ≥3 MRC: postural positioning, positive pressure expiration exercise, inspiratory muscle training The intensity of exercise will prescribed based on the results of the PFIT. and modified Borg Scale.~Frequency of sessions: 3×15 min/day"
61920634|NCT04381338|NO_INTERVENTION|COVID-19 in ICU without Rehabilitation|Standard of care without rehabilitation in ICU
61920635|NCT00821067|ACTIVE_COMPARATOR|1|A 6 gm/day (3 gm/bid) dose of D-ribose
62120735|NCT03179722|EXPERIMENTAL|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
62120736|NCT05137223||Adolescent Only Focus Groups|20 early adolescents (ages 10-14) with physician-diagnosed persistent asthma (i.e., prescribed a controller medication) receiving care at a FQHC
62120737|NCT05137223||Caregiver Only Focus Groups|20 informal caregivers (e.g., parent, grandparent) of early adolescents with physician-diagnosed persistent asthma receiving care at a FQHC
62120738|NCT05137223||Adolescent and Caregiver Focus Groups|10 adolescents with physician-diagnosed persistent asthma receiving care at a FQHC and their caregivers (both of whom did not participate in either previous group for a total of 20 participants in the group cohort)
62120739|NCT02238418|EXPERIMENTAL|Usual vitamin D supplementation|
62120740|NCT04275193|EXPERIMENTAL|Zishenqing|The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks
62309033|NCT05976737|EXPERIMENTAL|Fasting state|In this trial, 32 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given either the test formulation (T) Entacapone, Levodopa and Carbidopa Tablets (II) or the reference formulation (R) Entacapone,Levodopa and Carbidopa Tablets (II) in 240 milliliter (mL) of warm water. 1 tablet 100mg/25mg/200mg orally per cycle.
62679559|NCT05514444|EXPERIMENTAL|MK-4464|Participants will receive an intravenous (IV) infusion of MK-4464 administered in escalating doses every 3 weeks for up to 35 cycles. Escalation to subsequent MK-4464 doses will be based on safety of previous dose.
62679560|NCT05514444|EXPERIMENTAL|MK-4464 + Pembrolizumab|Participants will receive an IV infusion of MK-4464 administered in escalating doses and a 200 mg IV infusion of Pembrolizumab every 3 weeks for up to 35 cycles. Escalation to subsequent MK-4464 doses will be based on safety of MK-4464 monotherapy arm.
61920636|NCT00821067|PLACEBO_COMPARATOR|2|A 6 gm/day (3 gm/bid) dose of dextrose.
61920637|NCT00457964|EXPERIMENTAL|Administration of RAD001|
61920638|NCT01483586|EXPERIMENTAL|KLTc high dose|6 KLTc gelcaps taken four times a day
62120741|NCT04275193|PLACEBO_COMPARATOR|Placebo|The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks
62120742|NCT01852526|EXPERIMENTAL|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
62120743|NCT01852526|ACTIVE_COMPARATOR|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
62120744|NCT05448807|EXPERIMENTAL|participants receiving oraverse injection after local anaesthetic administration|participants receive phentolamine mesylate (Oraverse) injection after the completion of their dental procedures with ratio 1:1 to LA in children weighed 30 kg and more while in children less than 30 kg only half of the amount of the cartridge is administrated.
62120745|NCT05448807|NO_INTERVENTION|participants with no drug after local anaesthetic administration|participants don't receive any reversal agent or placebo after the completion of their dental procedures.
62120746|NCT00592241|NO_INTERVENTION|A|Subject is diagnosed as a diabetic, or subject is parent/guardian of a diabetic child age under 18 years.
61920639|NCT01483586|EXPERIMENTAL|KLTc low dose|3 KLTc gelcaps taken four times a day
61920640|NCT01369654|EXPERIMENTAL|Computerized decision aid|
61920641|NCT04951232|EXPERIMENTAL|Test group (cinnarizide maleate injection group)|
61920642|NCT04951232|PLACEBO_COMPARATOR|control group (placebo group)|
61920643|NCT00997542|ACTIVE_COMPARATOR|Allopurinol|
61920644|NCT00997542|PLACEBO_COMPARATOR|Placebo|
61920645|NCT04025476||VKH patients|acute VKH patients
62309034|NCT05976737|EXPERIMENTAL|Fed state|In this trial, 36 healthy subjects are planned to be enrolled in postprandial. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given a high-fat, high-calorie meal 30 minutes prior to dosing, which was completed within 30 minutes. 30 minutes after the start of the meal, the test formulation (T) Entacapone,Levodopa and Carbidopa Tablets (II) or the reference formulation (R)Entacapone,Levodopa and Carbidopa Tablets (II) were administered in 240 milliliter of warm water. Take 1 tablet 100mg/25mg/200mg orally per cycle.
62120747|NCT02651480|EXPERIMENTAL|Vegan Group|Participants in the intervention group will follow a low-fat, plant-based diet for 14 weeks, and will attend nutrition classes in the form of a weekly support group.
62120748|NCT02651480|ACTIVE_COMPARATOR|Control Group|The control group will follow an unrestricted diet with no instruction.
62120749|NCT04820361|PLACEBO_COMPARATOR|Placebo|oral spray
62120750|NCT04820361|ACTIVE_COMPARATOR|Sativex®|.It contains Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
62120751|NCT01081145|EXPERIMENTAL|Extended-release Guanfacine HCl|
62120752|NCT01081145|PLACEBO_COMPARATOR|Placebo|
62120753|NCT02817984|EXPERIMENTAL|Treatment Group|Participants (n=10) will be enrolled and assigned chronologically to one of five excision time points: Weeks 2 (n=10), 4 (n=2), 6 (n=2), 8 (n=2), and 12 (n=2) post-injection. Implants will be injected on Day 0. All participants will be administered up to five (5) 2 milliliter (mL) subcutaneous injections of acellular adipose tissue (AAT) via sterile injection into the area identified for planned excision. Total injected AAT volume per patient will not exceed 10 mL.
62120754|NCT05110534|EXPERIMENTAL|Intervention group|Received two additional preventive oral hygiene appointments; one week before the general anaesthesia treatment and one week after the general anaesthesia.
62120755|NCT05110534|NO_INTERVENTION|Control group|Received only standard prevention, without two additional preventive oral hygiene appointments before and after the general anaesthesia.
62120756|NCT06245863|EXPERIMENTAL|Negative pressure and Laser: Combined Therapy|Vacuum therapy combined with laser on back pain.
62120757|NCT06245863|EXPERIMENTAL|Positive Pressure and Laser: Combined Therapy|Rollers combined with laser on back pain.
62120758|NCT06245863|EXPERIMENTAL|Ultrasound and Laser: Combined Therapy|Ultrasound combined with laser on back pain.
62120759|NCT06245863|ACTIVE_COMPARATOR|Laser|Infrared Laser on back pain.
62120760|NCT06245863|PLACEBO_COMPARATOR|Placebo Laser|The placebo laser treatment.
62120761|NCT00736853|EXPERIMENTAL|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|
62120762|NCT00736853|EXPERIMENTAL|Tramadol Hydrochloride Plus Acetaminophen (Double Blind)|
62120763|NCT00736853|PLACEBO_COMPARATOR|Placebo (Double-Blind)|
62339609|NCT05086289|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally, once daily, for 8-weeks treatment period.
61920646|NCT04025476||control|health people age/sex match to the VKH patients
61920647|NCT04384588|EXPERIMENTAL|Cancer patients with COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
62120764|NCT03010553|EXPERIMENTAL|Oropharynx|Tumors of the oropharynx T1T2N0 treated with radiotherapy
62120765|NCT03010553|EXPERIMENTAL|Larynx|Tumors of the T1T2N0 larynx treated by surgery, laser or robot
62120766|NCT01901510|ACTIVE_COMPARATOR|chromoendoscopy|The intervention arm will have Indigo carmine added to the colonic preperation to perform chromoendoscopy
62120767|NCT01901510|OTHER|Control|The control arm will have minimal Indigo carmine added to the colonic prep in a concentration which will not be enough to perform chromoendoscopy
62120768|NCT03244579|EXPERIMENTAL|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
62339610|NCT05855928|OTHER|Electrical Stimulation and Mime Therapy|
62120769|NCT03244579|EXPERIMENTAL|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (\>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
62120770|NCT03244579|NO_INTERVENTION|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
62120771|NCT05641311|EXPERIMENTAL|Cohort 1: Japanese Participants|All Japanese participants will receive a single dose of ALXN1840 15 milligrams (mg) in Dosing Period 1 and will receive a single dose of ALXN1840 60 mg in Dosing Period 2.
62679561|NCT05514444|EXPERIMENTAL|MK-4464 + Pembrolizumab + Zirconium 89 (89Zr)-MK-4464|Participants will receive an IV infusion of 89Zr-MK-4464 + IV infusion of MK-4464 on Cycle 1 Day 1, followed by an IV infusion of MK-4464 + a 200 mg IV infusion of pembrolizumab starting on Cycle 2 Day 1 and every 3 weeks for up to 35 cycles. Each cycle=3 weeks. MK-4464 doses will be based on safety of MK-4464 monotherapy arm. Participants may receive a 200 mg IV infusion of pembrolizumab on cycle 36.
62679562|NCT03399773|EXPERIMENTAL|Treatment (chemotherapy, TBI, NLA101)|"Patients receive either regimen A or regimen B.~REGIMEN A: Patients (10 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0.~REGIMEN B: Patients (10 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 2-4 hours on days -5 and -4. Patients undergo TBI QD on days -2 and -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0.~All patients undergo bone marrow aspirate and biopsy as clinically indicated during screening and on study. Patients undergo MUGA or ECHO, and CT during screening. Patients also undergo blood sample collection on study."
62679563|NCT05898594|EXPERIMENTAL|Screening: Low-Dose Computed Tomography Screening|"Participants will undergo study procedures as outlined:~* Complete questionnaires pre- and post- low-dose computed tomography (LDCT) test.~* Visit Massachusetts General Hospital facility for a LDCT screening test."
62679564|NCT05670197||Service users|Service users with experience of schizophrenia spectrum psychosis
62679565|NCT05670197||Mental health staff|Mental health staff who work within an adult NHS service providing mental health support to people who experience schizophrenia spectrum psychosis / severe mental health problems
62679566|NCT01366014|EXPERIMENTAL|ARRY-371797|
62679567|NCT01366014|ACTIVE_COMPARATOR|Oxycodone HCl ER|
62679568|NCT01366014|PLACEBO_COMPARATOR|Placebo|
62679569|NCT06694428||Patients|Pregnant women with prescription of a CMV serology including the search for CMV IgG and IgM antibodies, care at the Necker-Enfants Malades or Paul Brousse hospitals, with positive CMV IgM antibodies or in the grey zone of the technique and for whom the date of start of pregnancy is known.
62679570|NCT00007774|EXPERIMENTAL|1|Olanzapine
61920648|NCT04384588|EXPERIMENTAL|Cancer patients with COVID 19 infection and risk factors|All patients will be treated with 1 or more convalescent plasma units
61920649|NCT04384588|EXPERIMENTAL|Non-Cancer patients COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
62120772|NCT05641311|EXPERIMENTAL|Cohort 2: Non-Japanese Participants|All non-Japanese participants will receive a single dose of ALXN1840 15 mg in Dosing Period 1 and will receive a single dose of ALXN1840 60 mg in Dosing Period 2.
62120773|NCT06673147|EXPERIMENTAL|Intervention group|It will be receiving Nordic walking training
62120774|NCT06673147|NO_INTERVENTION|Control Group|This group will receive a standard prenatal care, which included routine obstetric check-ups and general advice on physical activity
62679571|NCT00007774|ACTIVE_COMPARATOR|2|Haloperidol
62679572|NCT04544111|EXPERIMENTAL|Cohort A-BRAF WT tumors|Cohort A (BRAF WT tumors): trametinib (T) 2mg by mouth daily plus PDR001 400mg IV every 4 weeks
62679573|NCT04544111|EXPERIMENTAL|Cohort B-BRAF Mutant|Cohort B (BRAF Mutant, resistant to previous BRAF inhibitors): dabrafenib (D) 150 mg twice daily (OR at dose the patient previously tolerated) plus PDR001 400mg IV every 4 weeks.
62679574|NCT04779593|EXPERIMENTAL|experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin."
62679575|NCT04779593|ACTIVE_COMPARATOR|control group|"Patients treated with bloodletting according to current guidelines ferritin alone"
62679576|NCT05035927|EXPERIMENTAL|Open Label Oral Psilocybin|
62679577|NCT06237764||Genetics in exfoliation glaucoma|Prospective recruited patients suffering from exfoliation glaucoma.
62679578|NCT06694805|EXPERIMENTAL|CAB LA + RPV LA Group|Participants receive initial injections at Day 1 and Month 1, followed by maintenance injections every 2 months for up to 24 months.
62679579|NCT06694805|ACTIVE_COMPARATOR|Oral ART Control Group|Participants continue to take their current oral ART for 6 months, including a final dose at their first injection visit.
61920650|NCT04384588|EXPERIMENTAL|Non-cancer patients COVID 19 (+) and risk factors|All patients will be treated with 1 or more convalescent plasma units
61920651|NCT05857228||Primary epithelial cells|Population: The investigators will use frozen dissociated cells from our biobank in earliest possible format (P0 or P1) to preserve original viruses and epigenetic marks. Polyp samples from T2 CRSwNP will be selected according to clinical phenotype together with blood test and histology.
61920652|NCT05857228||Patients in remission of CRSwNP|Population: Perfect sinus cavity outcome after ESS under continued intranasal corticosteroids (INCS) or dupilumab.
62120775|NCT03833648|NO_INTERVENTION|Arm 1 - Usual Care|No intervention, patients will receive treatment as usual. Patients will download the UControl Pain app on their personal cell phones and will complete the four study surveys via the app or via REDCap.
62679580|NCT03972098||ra patients|The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 \[8\]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young.
62120776|NCT03833648|EXPERIMENTAL|Arm 2 - UControl Pain App with Education|Patients will install the UControl Pain app on their personal cell phones. The app will include educational information about pain management, e.g., using acetaminophen and NSAIDs for pain, as well as information on addiction and safe storage of medications. Subjects will also complete the four study surveys via the app or via REDCap.
62679581|NCT03972098||healthy control|healthy person, similar population
62120777|NCT02010138|ACTIVE_COMPARATOR|Small Extent Group (SG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the SG. The small-extent peeling was performed in SG.
62679582|NCT03671148|EXPERIMENTAL|Risankizumab|Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
62679583|NCT03671148|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
62679584|NCT06044623|EXPERIMENTAL|Lower initial dose of CDK 4/6-inhibitor (vulnerable/frail patient cohort)|-1 level dose reduction as initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 100 mg x 1 for 21 days with 7 days off; or Ribociclib 400 mg x 1 for 21 days with 7 days off; or Abemaciclib 100 mg x 2 daily added to endocrine therapy.
62679585|NCT06044623|ACTIVE_COMPARATOR|Full initial dose of CDK 4/6-inhibitor (vulnerable/frail patient cohort)|Full initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 125 mg x 1 for 21 days with 7 days off; or Ribociclib 600 mg x 1 for 21 days with 7 days off; or Abemaciclib 150 mg x 2 daily) added to physician's choice endocrine therapy.
61920653|NCT05857228||Effect of sinus surgery on the sinus virome|Population: Patients undergoing ESS for CRSwNP, including at least 30% of subjects with aspirin sensitivity.
62679586|NCT06044623|OTHER|Full initial dose of CDK 4/6-inhibitor (fit patient cohort)|Full initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 125 mg x 1 for 21 days with 7 days off; or Ribociclib 600 mg x 1 for 21 days with 7 days off; or Abemaciclib 150 mg x 2 daily) added to physician's choice endocrine therapy.
62679587|NCT02129881|EXPERIMENTAL|Autologous regulatory T Cell Product|"Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed below:~Prednisolone Day 0: 500 mg IV (250mg pre-op, 250mg intra-op) Day 1: 125 mg IV Day 2 to 14: 20.0 mg/day oral Week 3 to 4: 15.0 mg/day oral Week 5 to 8: 10.0 mg/day oral Week 9 to 12: 5.0 mg/day oral Week 13 to 14: 2.5 mg/day oral Week 15 to End: Cessation Mycophenolate Mofetil (MMF) Day -7 to -2: 500 mg/day oral Day -1 to 14: 2000 mg/day oral Week 3 to 36: 1000 mg/day oral Week 37 to 40: 750 mg/day oral Week 41 to 44: 500 mg/day oral Week 45 to 48: 250 mg/day oral Week 49 to End: Cessation Tacrolimus Day -4 to 14: 3-12 ng/ml oral Week 3 to 12: 3-10 ng/ml oral Week 13 to 36: 3-8 ng/ml oral Week 37 to End: 3-6 ng/ml oral"
62679588|NCT04117087|EXPERIMENTAL|Treatment Phase|KRAS Vaccine Peptide, Nivolumab and Ipilimumab
62679589|NCT04117087|EXPERIMENTAL|Reinduction Treatment Phase|KRAS Vaccine Peptide, Nivolumab and Ipilimumab
62679590|NCT03566667|ACTIVE_COMPARATOR|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
62679591|NCT03566667|OTHER|Standard care|Usual standard care
62679592|NCT01637571|ACTIVE_COMPARATOR|Dexilant|60mg of Dexilant QD for 12 weeks
62679593|NCT01637571|PLACEBO_COMPARATOR|Placebo|60mg of Dexilant placebo QD for 12 weeks
61920654|NCT05857228||Healthy volonteers|Population: Participants with no sino-nasal symptoms and normal sense of smell as assessed by UPSIT-40 testing.
61920655|NCT03410264|EXPERIMENTAL|CR-EXP|Cognitive restructuring before exposure with response prevention (45 minute intervention).
62120778|NCT02010138|ACTIVE_COMPARATOR|Large Extent Group (LG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the LG. The large-extent peeling was performed in LG.
61920656|NCT03410264|EXPERIMENTAL|EXP-CR|Exposure with response prevention before cognitive restructuring (45 minute intervention).
62339611|NCT05855928|EXPERIMENTAL|Electrical Stimulation and PNF Technique|
62679594|NCT04072432|EXPERIMENTAL|120 mg|
61920657|NCT03410264|ACTIVE_COMPARATOR|Stress Management|Stress management skills.
61920658|NCT02234856|NO_INTERVENTION|conventional residency training|no intervention
61920659|NCT02234856|EXPERIMENTAL|Laparoscopic Hysterectomy trainer|Intervention: An educational video and web-based e-module will be created. The final product will be reviewed by the expert contributors. Once approved, these tools will be showcased to a voluntary focus group of Obstetrics and Gynecology residents at the University of Toronto. A quantitative assessment of effectiveness of this tool will be performed through the use of pre- and post-tests of knowledge. A qualitative needs assessment will also be performed using post-viewing surveys. If found to be effective, this educational tool will be incorporated in the University of Toronto Obstetrics and Gynecology residency curriculum.
61920660|NCT04564118||Group 1|retrospective data on treatment from EMC
62339612|NCT02503176|EXPERIMENTAL|KCT-0809|
62679595|NCT04072432|EXPERIMENTAL|240 mg|
62679596|NCT04072432|EXPERIMENTAL|360 mg|
62679597|NCT03984461|ACTIVE_COMPARATOR|Group A - PRP plus Lipoaspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate). Total Volume varies by joint.
62309035|NCT05321953|ACTIVE_COMPARATOR|Standard of Care Physical Therapy With No Study Intervention|Participants will receive 6 weeks of standard physical therapy and have reported satisfaction and respond with a numerical value of ≤3 on a chronic constipation numeric scale. Participants will receive no additional study interventions.
62309036|NCT05321953|EXPERIMENTAL|Standard of Care Physical Therapy With Study Intervention|Participants who receive 6 weeks of standard physical therapy and have reported non satisfaction and respond with a numerical value of \>3 on a chronic constipation numeric scale and have been cleared of pelvic floor muscle dyssynergia. Participants will receive an additional 8 weeks of study intervention.
62679598|NCT03984461|ACTIVE_COMPARATOR|Group B - PRP plus Bone Marrow Aspirate|Equal proportions of PRP plus bone marrow aspirate. Total Volume varies by joint.
62679599|NCT03984461|ACTIVE_COMPARATOR|Group C - PRP plus Lipoaspirate plus Bone Marrow Aspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate) plus bone marrow aspirate. Total Volume varies by joint.
62679600|NCT05431088|ACTIVE_COMPARATOR|Part A|"Initially, participants will be randomized 1:1 to 100 mg and 150 mg daily. Upon review of the 150 mg safety data from at least 6 participants, there will be 1:1:1 randomization: 100 mg, 150 mg, and up to 200 mg.~Participants will then receive maintenance once daily doses through Week 12."
62679601|NCT05431088|PLACEBO_COMPARATOR|Part B|Following the selection of the optimal safe and effective dose from Part A of the study, Part B of the study will assess the efficacy and safety of 48 weeks of the optimal dose, compared to placebo
62679602|NCT05431088|EXPERIMENTAL|Part C|100 mg dose in cohort C1, dose level for cohorts C2 to C4 to be determined based on emerging data
62679603|NCT03822325||Observational Cohort|
62120779|NCT03038217|EXPERIMENTAL|ACT group|Group of patients with pathologically confirmed Stage II-III colorectal cancer who receive postoperative treatment with chemotherapeutic agent (ACT) using Capecitabine +/- Oxaliplatin.
62120780|NCT03038217|EXPERIMENTAL|Non-ACT group|Group of patients with pathologically confirmed stage II colorectal cancer who receive no adjuvant chemotherapy.
62120781|NCT03038217|EXPERIMENTAL|LR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo local resection (LR)
62309037|NCT03063073|PLACEBO_COMPARATOR|Group I (Bupivacaine group)|ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
62309038|NCT03063073|ACTIVE_COMPARATOR|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection \[Precedex\] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
62679604|NCT03625648|EXPERIMENTAL|PTX|Active drug
62679605|NCT03625648|PLACEBO_COMPARATOR|Placebo|Placebo
62679606|NCT02152982|EXPERIMENTAL|Arm I (temozolomide, veliparib)|Patients receive temozolomide PO QD on days 1-5 and veliparib PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.
62679607|NCT02152982|PLACEBO_COMPARATOR|Arm II (temozolomide, placebo)|Patients receive temozolomide as in Arm I and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.
62679608|NCT04017468|ACTIVE_COMPARATOR|Treatment Arm|The powdered vancomycin will be placed subcutaneously over the closed muscle fascia (suprafascially) at the end of the surgery during wound closure.
61920661|NCT04564118||Group 2|Treatment assignment using medicBC CDSS platform in the same cohort of patients
61920662|NCT02497976|ACTIVE_COMPARATOR|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
61920663|NCT02497976|PLACEBO_COMPARATOR|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
62309039|NCT04410783|OTHER|Before group|Mechanically ventilated emergency department patients receiving standard post-intubation sedation prior to an educational initiative on the importance of ED-based targeted sedation
62679609|NCT04017468|NO_INTERVENTION|Control Arm|The control group receiving only a standard preoperative antimicrobial prophylaxis administered intravenously.
62679610|NCT06548672|EXPERIMENTAL|Part 1: Phase 1a Dose Escalation|Participants will receive BC3195 administered as an intravenous infusion every 3 weeks (Q3W) or according to an alternative dosing regimen, as recommended by the safety monitoring committee (SMC). Multiple dose cohorts will be enrolled. Participants will be monitored for dose limiting toxicities (DLTs) during the DLT assessment period, lasting 21 days. The SMC will determine the recommended phase 2 dose (RP2D) to be administered in Part 2 based on the safety, tolerability, PK, and anti-tumor activity of BC3195
61920664|NCT02960997|EXPERIMENTAL|Sirolimus, then Placebo|Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.
61920665|NCT02960997|PLACEBO_COMPARATOR|Placebo, then Sirolimus|Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.
61920666|NCT06142526|EXPERIMENTAL|treatment group|DividPro film implantation right before the closure of surgical incision wound
61920667|NCT06142526|NO_INTERVENTION|control group|Only standard care without any anti-adhesion related products.
61920668|NCT05272085|ACTIVE_COMPARATOR|Ultrasound Guided Lavage Group|"The physical examination, pain scoring, functional scale, disability scale, special tests, direct radiography findings and ultrasonographic imaging findings of the patients in this group before the treatment and 1 month after the treatment will be evaluated and will be recorded. Size of calcific deposits and Gartner classification will be evaluated on direct radiography. Size, shape, acoustic shadowing, power doppler activity of calcific deposits and other bursitis, tendinitis, ruptures, effusion in the shoulder will be evaluated on ultrasonographic imaging.~Patients in this group will be treated with ultrasound-guided lavage."
61920669|NCT05272085|ACTIVE_COMPARATOR|Ultrasound Guided Subacromial Bursa Injection Group|"The physical examination, pain scoring, functional scale, disability scale, special tests, direct radiography findings and ultrasonographic imaging findings of the patients in this group before the treatment and 1 month after the treatment will be evaluated and will be recorded. Size of calcific deposits and Gartner classification will be evaluated on direct radiography. Size, shape, acoustic shadowing, power doppler activity of calcific deposits and other bursitis, tendinitis, ruptures, effusion in the shoulder will be evaluated on ultrasonographic imaging.~Patients in this group will be treated with ultrasound-guided subacromial bursa injection with corticosteroid and lidocaine."
61920670|NCT06259500||anorexia nervosa|
61920671|NCT06259500||healthy controls|
61920672|NCT03792984|PLACEBO_COMPARATOR|Metformin + Placebo|
61920673|NCT03792984|EXPERIMENTAL|Calcium carbonate + Vitamin D3 + Metformin|
61920674|NCT05607836|EXPERIMENTAL|Intu-Brite|Use of new laryngoscope - IntuBrite for intubation
62120782|NCT03038217|EXPERIMENTAL|RR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo radical resection (RR)
62309040|NCT04410783|OTHER|After group|Mechanically ventilated emergency department patients receiving post-intubation sedation after an educational initiative aimed at improving sedation practices in the ED
61920675|NCT05607836|ACTIVE_COMPARATOR|Macintosh|Use of standard laryngoscope with Macintosh blade for intubation
62679611|NCT06548672|EXPERIMENTAL|Part 2: Phase 1b Dose Expansion|Participants will receive BC3195 at the RP2D identified in Phase 1a. Approximately 3 to 4 expansion cohorts will be enrolled using a Simon's 2-stage design. Expansion cohorts will focus on tumor types that may derive benefit from BC3195 treatment, including head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), breast cancer (BC), non-small cell lung cancer (NSCLC), endometrial cancer (EMC), urothelial cancer (UC), colorectal cancer (CRC), ovarian cancer (OC), pancreatic cancer, and prostate cancer.
62120783|NCT00488657|EXPERIMENTAL|1|In the ear device to provide altered auditory feedback
61920676|NCT04729946|EXPERIMENTAL|Pure-Vu Treatment|Participants in this arm will undergo colonoscopy using the Pure-Vu cleansing device.
61920677|NCT04781777|NO_INTERVENTION|Control group|Dexmehtasone and local anesthetics in carpal tunnel syndrome
61920678|NCT04781777|ACTIVE_COMPARATOR|Insulin group|insulin added to dexamehtasone and local anesthetics
61920679|NCT00790361||Control|"Controls (healthy volunteers) will have two scans (fMRI, MRS and DTI) six months apart to determine reproducibility.~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
61920680|NCT00790361||CCS Participants|"CCS participants will have three scans (fMRI, MRS and DTI), one acutely (up to 48 hours after injury), one subacutely (15 days after injury), and one late (6 months after injury).~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
61920681|NCT06219551|ACTIVE_COMPARATOR|Usual care|Usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic.
61920682|NCT06219551|EXPERIMENTAL|Intervention|The intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp.
61920683|NCT02017600|EXPERIMENTAL|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
62120784|NCT01117480||Moderate-to-severe rheumatoid arthritis|Participants with moderate-to-severe rheumatoid arthritis treated with adalimumab in routine clinical practice
62309041|NCT04952012||ATA-positive|
62309042|NCT04952012||ATA-negative|
62309043|NCT03690414|ACTIVE_COMPARATOR|Experimental BHVI2 eye drops|20 participants will receive one drop per eye every night for four weeks.
62309044|NCT03690414|ACTIVE_COMPARATOR|0.02% Atropine eye drops|20 participants will receive one drop per eye every night for four weeks.
62309045|NCT03690414|ACTIVE_COMPARATOR|Experimental BHVI2 plus 0.02% atropine|20 participants will receive one drop per eye every night for four weeks.
62309046|NCT02062177|EXPERIMENTAL|propofol group|70 patients (35 upper endoscopy - 35 colonoscopy)
61920684|NCT03340428|EXPERIMENTAL|Transition Community Adherence Club (TCAC)|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
61920685|NCT03340428|NO_INTERVENTION|Care as usual (CAU)|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
61920686|NCT02399618|EXPERIMENTAL|Capsulized freeze-dried FMT|Reconstitution of normal flora with capsulized freeze-dried fecal inoculum
61920687|NCT01622127||incisional hernias|
61920688|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
61920689|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
62679612|NCT06334120||Male patients with nmCRPC or mHSPC|Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator.
62679613|NCT03749174|ACTIVE_COMPARATOR|Long acting anesthetic block/plaster|Intervention 1: Blockade will be given supraclavicularly with Long acting local Anesthetic (n=30) combined with post operative plaster immobilization.
62679614|NCT03749174|ACTIVE_COMPARATOR|Short acting anesthetic block/plaster|Intervention 2: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) combined with plaster immobilisation postoperatively
61920690|NCT03810404|EXPERIMENTAL|Sodium bicarbonate supplementation|Group taking oral SB supplementation in a different-dose regimen.
61920691|NCT03810404|PLACEBO_COMPARATOR|Placebo treatment|Group taking oral supplementation with placebo (NaCl).
61920692|NCT02978131||Patients with a clinical diagnosis of TB|Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
61920693|NCT00456807|EXPERIMENTAL|Cervarix Group|Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).
61920694|NCT00456807|PLACEBO_COMPARATOR|Placebo Group|Subjects who received 3 doses of placebo during the primary study (NCT00294047).
61920695|NCT02283177|EXPERIMENTAL|Cohort A|Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.
61920696|NCT02283177|EXPERIMENTAL|Cohort B|Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.
61920697|NCT05771168||AUS|Male patients undergoing surgery for stress urinary incontinence using artificial urinary sphincter (AUS)
62309047|NCT02062177|ACTIVE_COMPARATOR|midazolam group|70 patients (35 upper endoscopy - 35 colonoscopy)
62679615|NCT03749174|ACTIVE_COMPARATOR|Short acting anesthetic block/orthotic|Intervention 3: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) and combined with orthosis for postoperative immobilisation
62679616|NCT03749174|ACTIVE_COMPARATOR|General Anesthesia and plaster|Intervention 4: General anesthesia wil be administered for surgical procedure combined with postoperative plaster immobilisation (n=30),
61920698|NCT05771168||Sling|Male patients undergoing surgery for stress urinary incontinence using slings
61920699|NCT06363864||Healthy individuals|
61920700|NCT06363864||Metabolic syndrome patients|
61920701|NCT05004454|EXPERIMENTAL|Bacillus subtilis BS50|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
61920702|NCT05004454|PLACEBO_COMPARATOR|Placebo|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
61920703|NCT05684731|EXPERIMENTAL|Experimental: KM1 + Chemotherapy|"Biological: KM1 Administer via intraperitoneal infusion for 3 or 6 doses Q3D.~Drug: Chemotherapy: Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
61920704|NCT04463511|EXPERIMENTAL|PB BCC: Polyethylene Bag Before Cord Clamping|Immediately after delivery, while still attached to placental circulation, infants will be placed in a PB. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire for ongoing care. In the case of caesarean section a sterile bag will be used and prepared observing sterile techniques. A member of the neonatal team donned in sterile gown and gloves will assist the obstetrician in placing the infant in the PB.
62309048|NCT05896176||Pediatric Sleep Questionnaire (PSQ) +|Patient who obtained a score of 7 or more on the PSQ
62495891|NCT04673825|EXPERIMENTAL|Intervention: patient initiated care + telemonitoring|Patients in the intervention group will only have a scheduled outpatient visit at baseline and after 1 year. Patients will answer questionnaires and have routine blood tests done before every visit. At 6 months, there will be a remote monitoring check-up and results will be checked by the physician. If indicated, a telephone or video call can take place or a physical visit can be planned. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
62679617|NCT02362412|EXPERIMENTAL|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
61920705|NCT04463511|NO_INTERVENTION|PB ACC: Polyethylene Bag After Cord Clamping|Infants will not be placed in a PB immediately after birth. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire where they will be placed in a PB.
62679618|NCT02362412|EXPERIMENTAL|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
61920706|NCT04028661|EXPERIMENTAL|Intervention group|use of 3D printed Modified Twin Block Appliance.
61920707|NCT04028661|NO_INTERVENTION|Untreated control group|No treatment phase of 8 months.
61920708|NCT03295526|NO_INTERVENTION|Control group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and systematic pelvic lymphadenectomy
61920709|NCT03295526|EXPERIMENTAL|Experimental group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and selective enlarged lymph node dissection.
62679619|NCT06017128|EXPERIMENTAL|Intervention|The experimental group will consist of individuals who will undergo total hip replacement surgery and receive sexual counseling along with an educational booklet.
62679620|NCT06017128|NO_INTERVENTION|Control|The control group will be comprised of individuals undergoing total hip replacement surgery without receiving sexual counseling.
62679621|NCT02060188|EXPERIMENTAL|Nivolumab Monotherapy|
62679622|NCT02060188|EXPERIMENTAL|Nivolumab + Ipilimumab|
62679623|NCT02060188|EXPERIMENTAL|Nivolumab + Ipilimumab Cohort C3|
62679624|NCT02060188|EXPERIMENTAL|Nivolumab + Ipilimumab + Cobimetinib Cohort C4|
62679625|NCT02060188|EXPERIMENTAL|Nivolumab + BMS-986016 Cohort C5|
62679626|NCT02060188|EXPERIMENTAL|Nivolumab + Daratumumab Cohort C6|
62679627|NCT01504399||Microscopic:|Microscopic (single nostril, direct endonasal with nasal speculum)transsphenoidal nasal surgery
62679628|NCT01504399||Endoscopic|Fully endoscopic: (bi-nostril, no nasal speculum) transsphenoidal pituitary surgery
62679629|NCT06695572|EXPERIMENTAL|Fast-Fed|Period 1: A single oral dose of 1 tablet under fasting condition, Period 2: A single oral dose of 1 tablet under fed condition
62679630|NCT06695572|EXPERIMENTAL|Fed-Fast|Period 1: A single oral dose of 1 tablet under fed condition, Period 2: A single oral dose of 1 tablet under fasting condition
62679631|NCT06685380||Self Awakening|
62679632|NCT06685380||Control|
62679633|NCT01725282|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets once daily before bedtime for 7 weeks.
62309049|NCT05896176||Pediatric Sleep Questionnaire (PSQ) -|Patient who obtained a PSQ score less than 7
62309050|NCT01304862|EXPERIMENTAL|Self-management intervention|
62309051|NCT01304862|ACTIVE_COMPARATOR|Educational Videos about Healthy Living|
62309052|NCT01878071||Single group cross sectional|
62309053|NCT04859491|ACTIVE_COMPARATOR|Carbohydrate|Carbohydrate in the amount of 1.2 g/kg of body weight (bw). Gatorade®, Chicago, IL, USA.
62679634|NCT01725282|EXPERIMENTAL|Quetiapine 50 mg|Participants received quetiapine extended release (XR) 50 mg tablets once daily before bedtime for 7 weeks.
62679635|NCT01725282|EXPERIMENTAL|Quetiapine 150 mg|After 2 days of up-titration, participants received quetiapine XR 150 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 50 mg tablets once daily for 1 week.
62309054|NCT04859491|ACTIVE_COMPARATOR|Carbohydrate-Protein|Carbohydrate in the amount of 0.8 g/kg bw (Gatorade®, Chicago, IL, USA) plus protein in the amount of 0.4 g/kg bw (biPro Elite, Agropur Inc., Appleton, WI, USA).
62309055|NCT04859491|PLACEBO_COMPARATOR|Placebo|Flavored water (G Zero, Gatorade®, Chicago, IL, USA).
62309056|NCT01274377|EXPERIMENTAL|Recipients Using 3-5/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 Human Leukocyte Antigen (HLA) Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
62679636|NCT01725282|EXPERIMENTAL|Quetiapine 300 mg|After 4 days of up-titration, participants received quetiapine XR 300 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 150 mg tablets once daily for 1 week.
62679637|NCT00461812|EXPERIMENTAL|Mometasone|
62679638|NCT00461812|EXPERIMENTAL|Advair|
62679639|NCT01391299|ACTIVE_COMPARATOR|botulinum toxin Type A (40 Units)|Botulinum toxin Type A 40 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
62679640|NCT01391299|ACTIVE_COMPARATOR|botulinum toxin Type A (30 Units)|Botulinum toxin Type A 30 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
62679641|NCT01391299|PLACEBO_COMPARATOR|placebo (Normal saline)|Placebo (Normal saline) injected into bilateral forehead and frown line areas on Day 1.
62679642|NCT05704036|NO_INTERVENTION|Observational Study|Participants will complete three study visits (baseline, 6 months, and 12 months) involving DXAs (bone density assessment), x-rays, blood draws, and questionnaires.
62679643|NCT05704036|EXPERIMENTAL|Transdermal Estradiol/Cyclic Progesterone|Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month.
62679644|NCT06660446|NO_INTERVENTION|Control Group|The control group will receive the usual care and indications.
62679645|NCT06660446|EXPERIMENTAL|Intervention Group|The interventional group will add a exercise program.
62679646|NCT06636487|EXPERIMENTAL|pulmonary tele-rehabilitation (PTR)|Recieve supervised PTR 2/weekly, session duration of 60 min; 35 min of exercise and 25 min of patient education for 10-weeks. Delivered from Hvidovre/Bispebjerg Hospital to groups of 3 - 5 patients who exercise at home and communicate via tablet-camera. After 10-weeks of PTR, participants are offered once weekly PTR for 60 minutes in groups of 4-8 patients throughout a 65-week maintenance period
62679647|NCT06636487|EXPERIMENTAL|Home-based pulmonary rehabilitation (HPR)|HPR is an individual self-initiated home-based PR program. Patient goal is to achieve at least 20 min of self-initiated muscle-endurance based exercise 3 days/ weekly for 10-weeks The first session is a home visit by an experienced respiratory physiotherapist and with focus on establishment of exercise goals, formal exercise prescription and education. The home visit is followed by 1/weekly session for 10-weeks.The sessions is delivered from Hvidovre/ Bispebjerg Hospital via tablet-camera or telephone call. After 10-weeks of HPR, participants are offered once weekly PTR for 60 min in groups of 4-8 patients throughout a 65-week maintenance period.
61920710|NCT02958384|EXPERIMENTAL|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62475641|NCT06561035|EXPERIMENTAL|Opiate Sparing|"Discharge medications:~1. Medrol Dosepak, take per package instructions from postoperative day 1 to postoperative day 6.~2. Diclofenac 75 milligram (mg) twice per day from postoperative day 7 to postoperative day 14.~3. Tylenol 1000 mg three times per day from postoperative day 1 to postoperative day 14.~4. Gabapentin 100 mg three times per day from postoperative day 1 to postoperative day 14.~5. Methocarbamol (Robaxin) 750mg twice per day from postoperative day 1 to postoperative day 14.~6. Promethazine 25 mg every 8 hours as needed for nausea.~7. Aspirin 81 once per day from postoperative day 1 to postoperative day 30.~8. Senokot-S (Sennosides and Docusate) as needed for constipation.~9. 10 tablets of Tramadol 50mg as needed for moderate breakthrough pain only.~10. 5 tablets of oxycodone 5mg as needed for severe breakthrough pain only.~11. Supervised physical therapy to start within postoperative day 2 and postoperative day 7."
62679648|NCT06636487|ACTIVE_COMPARATOR|Control|Control group will receive usual care; medication, scheduled follow-up visit and possible phone contact with GP or the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.
62679649|NCT03644446||Bisoprolol 5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction \< 50%. Consecutive patients at the CHU de Caen.
62679650|NCT03644446||Bisoprolol 7.5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction \< 50%. Consecutive patients at the CHU de Caen.
61920711|NCT05811650|EXPERIMENTAL|Oral Health Intervention group|Those receiving intervention of oral health and counselling.
61920712|NCT05811650|PLACEBO_COMPARATOR|Control group|Those who are not receiving counseling and promotion interventions
62679651|NCT03644446||Bisoprolol 10mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction \< 50%. Consecutive patients at the CHU de Caen.
62309057|NCT01274377|EXPERIMENTAL|Recipients Using 6/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 HLA Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
62309058|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
62309059|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
62309060|NCT05182515|NO_INTERVENTION|Standard of Care|Standard of care including Dexamethasone
62309061|NCT05182515|EXPERIMENTAL|Therapeutic plasma exchanges|Drug: Therapeutic plasma exchanges at day 1, 3 and 5 plus Standard of care including Dexamethasone
62309062|NCT01525511|EXPERIMENTAL|Group A|Primaquine only followed by Dihydroartemisinin-piperaquine and followed by Primaquine together with Dihydroartemisinin-piperaquine.
62679652|NCT05557292|EXPERIMENTAL|Cohort A 1(Dose Escalation, Recurrent Non-surgical GBM)|Participants will start at dose level 1 (6 mg) of RMC-5552 administered intravenously. Participants will receive RMC-5552 weekly in 21-day cycles until disease progression or unacceptable toxicity.
62679653|NCT05557292|EXPERIMENTAL|Cohort A2 (Dose Escalation, Recurrent Non-surgical GBM)|Participants receive dose level 2 (12 mg) of RMC-5552 administered intravenously if the toxicity profile from participants in dose level 1 (A1) is acceptable. Participants will receive RMC-5552 weekly in 21-day cycles until disease progression or unacceptable toxicity.
62679654|NCT05557292|EXPERIMENTAL|Cohort B (Dose Expansion, Recurrent Surgical GBM)|Participants will receive a single dose of RMC-5552 at the RP2D approximately 4 hours prior to participants' scheduled surgical resection as part of standard of care. After recovering from surgery (about 3-6 weeks), participants will continue receiving RMC-5552 weekly in 21-day cycles until disease progression or unacceptable toxicity.
62679655|NCT05557292|EXPERIMENTAL|Cohort C (Dose Expansion, Recurrent Non-surgical GBM)|Participants will be given the RP2D of RMC-5552 weekly in 21-day cycles until disease progression or unacceptable toxicity
61920713|NCT04746742|ACTIVE_COMPARATOR|Tunneled femoral catheter|20 patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
61920714|NCT04746742|ACTIVE_COMPARATOR|Femoral artery-femoral arteriovenous graft|a straight or loop configuration 28patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
61920715|NCT02744001|EXPERIMENTAL|Low Added Sugar Diet|Menu containing \<10% of total daily energy intake from added sugars.
62120785|NCT03870607|EXPERIMENTAL|Prebiotics and probiotics group|This group will receive standard nutritional guidance from the institutional routine and prebiotics in combination with probiotics, starting one week before the start of Ch-RT and daily throughout the treatment up to 6 to 8 weeks post Ch-RT at the time of evaluation response (primary outcome).
62120786|NCT03870607|NO_INTERVENTION|Control group|This group will lead nutritionally based just before starting Ch-RT.
62309063|NCT01525511|ACTIVE_COMPARATOR|Group B|Primaquine only followed by Primaquine together Dihydroartemisinin-piperaquine and followed by Dihydroartemisinin-piperaquine only.
62339613|NCT05696171|ACTIVE_COMPARATOR|Manual insertion|Manual insertion of the cochlear implant
62339614|NCT05696171|EXPERIMENTAL|Robotized insertion|Robotic insertion of the cochlear implant
62309064|NCT05677945|EXPERIMENTAL|(Group I Experimental Group):Simvastatin mixed with modified triple antibiotic (3Mixtatin)|"Patients will then be allocated into either one of the groups alternatively after access cavity preparation depending on the mix to be used as follows:~for this group:~* 2mg of pure Simvastatin powder will be added to the 1:1:1 3Mix powder and will be stored together in an air tight porcelain container to avoid the exposure to moisture and light.~* Upon clinical application the 3Mixtatin powder will be mixed with normal saline to form a paste and is then applied in the same manner as the Modified 3Mix-MP paste."
62475642|NCT06561035|ACTIVE_COMPARATOR|Opiate Based|"Discharge medications:~1. Diclofenac 75 milligram (mg) twice per day from postoperative day 1 to postoperative day 14.~2. Tylenol 1000 mg three times per day from postoperative day 1 to postoperative day 14.~3. Gabapentin 100 mg three times per day from postoperative day 1 to postoperative day 14.~4. Methocarbamol (Robaxin) 750mg twice per day from postoperative day 1 to postoperative day 14.~5. Promethazine 25 mg every 8 hours as needed for nausea.~6. Aspirin 81 once per day from postoperative day 1 to postoperative day 30.~7. Senokot-S (Sennosides and Docusate) as needed for constipation.~8. 10 tablets of Tramadol 50mg as needed for moderate breakthrough pain only.~9. 5 tablets of oxycodone 5mg as needed for severe breakthrough pain only.~10. Supervised physical therapy to start within postoperative day 2 and postoperative day 7."
62309065|NCT05677945|ACTIVE_COMPARATOR|Group II Control group Modified triple antibiotic mix in propylene glycol (3Mix)|"* Removal of enteric coating/capsule of the three antibiotic tablets using a surgical blade.~* 500 mg Metronidazole tab~* 500 mg Ciprofloxacin tab~* 200 mg Cefixime caps~* Pulverization of each of the drug, will be done using a pestle \& mortar, stored in an air tight porcelain container to avoid the exposure to moisture \& light.~* Pulverized powders will be stored at a temperature of 16°C.Powder should be allowed to be cooled to the room temperature before initiating the preparation of 3Mix-MP paste.~* Powders will be mixed in the proportion of: 1:1:1 by volume (Hoshino et al., 1988).~* Vehicle that will be used is Systane eye drops (Kharadly et al., 2022) it contains the two main components propylene Glycol (Macrogol) \& polyethylene glycol.~* The prepared antibiotic powder is mixed with the prepared vehicle in the ratio of 7:1 by volume. The two steps above are done after access cavity preparation to obtain a fresh mix."
62309066|NCT04696744||CTCO|adults with squamous cell carcinoma of the oropharynx with a curative aim
62309067|NCT01319760|SHAM_COMPARATOR|Standard of care|Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
62309068|NCT01319760|EXPERIMENTAL|Impella 2.5|24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
62120787|NCT03005678|ACTIVE_COMPARATOR|Denosumab|denosumab subcutaneous 60mg every 6 months
62120788|NCT03005678|PLACEBO_COMPARATOR|Alendronate|alendronate 70mg orally every week
62120789|NCT05368025||Newly diagnosed Oropharyngeal cancer patients|Newly diagnosed oropharyngeal cancer patients will be enrolled into the study. Patients will receive both mobile health systems and be asked to complete swallowing exercises and report symptoms daily for a period of 6 months. Following completion of the study, this group will be interviewed individually to gain insight into the user experience of using both systems
62120790|NCT04233931|EXPERIMENTAL|participant|all participants in the study receive the mobile app.
62120791|NCT04775290|EXPERIMENTAL|Arm Yoga (YG)|Patients assigned to the YG arm participate in yoga classes
62120792|NCT04775290|NO_INTERVENTION|Arm control (CG)|Patients assigned to the CG arm will follow the normal course of radiotherapy.
62120793|NCT06677450|ACTIVE_COMPARATOR|Exercise Group|Exercise program
62309069|NCT03270787|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Comparator: controlled group Placebo,10pills,tid,po
62120794|NCT06677450|EXPERIMENTAL|Pain Neuroscience Education Group|Pain neurosicence education with exercise program
62120795|NCT02744859|EXPERIMENTAL|Calorie Label|"Labels will read \[lower calorie bound\] - \[upper calorie bound\] calories per container. 2,000 calories a day is used for general nutrition advice but calorie needs vary."
62120796|NCT02744859|EXPERIMENTAL|Warning Label|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay."
62120797|NCT02744859|EXPERIMENTAL|Warning Label with Graphics|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay. These labels will also have graphic depictions of each health condition above the corresponding text."
62120798|NCT02744859|NO_INTERVENTION|No label|We will also have a condition where no labels are presented-- business as usual.
62120799|NCT04554628|ACTIVE_COMPARATOR|Urinary human neutrophil gelatinase-associated lipocalin|Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement
62309070|NCT03270787|EXPERIMENTAL|Compound danshen dripping pills|Compound danshen dripping pills Compound danshen dripping pills ,10pills,tid,po
62679656|NCT06384781|EXPERIMENTAL|Peer Support Specialist Intervention|Eligible participants will be linked to a peer support specialist. Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with opioid use disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for 3 months post-baseline utilizing the newly validated checklist.
62679657|NCT04837846||Prospective CCTA Arm|
62679658|NCT06688006|EXPERIMENTAL|Experimental: climate change short animation film|Before enrolling the pregnant women in the intervention group, the informed consent form, the personal information form, the climate change awareness scale for pregnant women and the climate change hope scale (pre-test) will be completed. The researcher will then give a 30-minute training presentation on the climate crisis to the pregnant women individually in the conference room on the third floor of the maternity hospital. Two weeks after the training, the worker will open a meeting session via Microsoft Teams or Google Meet, and a short animated film will be watched on this platform as a reminder. Four weeks after the viewing of the short animation film, another meeting session will be set up via Microsoft Teams or Google Meet and the link to the survey form will be shared online and the final evaluations (post-test - questions on climate change, climate change awareness scale and hope scale for preventing climate change) will be carried out.
62679659|NCT06688006|NO_INTERVENTION|Control|No application will be made to the pregnant women in the control group, and the informed consent form, personal information form, Climate Change Pregnancy Awareness Scale and Climate Change Prevention Hope Scale (pre-test) will be completed at the first interview. During this time, a sign will be hung on the door to prevent anyone from entering or leaving the room. Six weeks after the first interview, the link to the survey form (Questions about Climate Change, Climate Change Pregnant Awareness Scale and Climate Change Prevention Hope Scale) will be shared with the pregnant women via Microsoft Teams or Google Meet and their final evaluation (post-test) will be conducted. A video interview will be conducted with the control group in a Microsoft Teams or Google Meet meeting to ensure that real people completed the form. At the end of the study, an educational booklet and a short animated film on climate change will be sent online.
62309071|NCT05185232||Patients with complex congenital heart disease|Complex congenital heart disease will be defined by previously published classification including those listed in the American heart association/ American college of cardiology guidelines for the care of adults with congenital heart disease.
62309072|NCT05185232||Patients with non-complex congenital heart disease|Non-complex congenital heart disease will be defined by previously published classification including those listed in the American heart association/ American college of cardiology guidelines for the care of adults with congenital heart disease.
62309073|NCT04086043|EXPERIMENTAL|Endovascular Denervation|
62309074|NCT01959204|OTHER|Active|Open label pharmacokinetic study of oxycodone.
62309075|NCT04512885||Patients with type 1 diabetes|
62309076|NCT04512885||Health professionals|
62679660|NCT06679452|EXPERIMENTAL|35 participants randomly assigned to the EFT intervention|The research will include 35 individuals aged 65 years or older, of both genders, who meet the study's inclusion criteria. Therapy sessions will be conducted individually and in person, in offices suited for psychological practice. Participants residing in senior housing will have the option, subject to agreement with their institution, to have sessions conducted in their facilities. Each session will last one hour and occur weekly over a three-month period, resulting in a total of 12 sessions per participant, in accordance with the EFT protocol for resolving emotional injuries established by Meneses and Greenberg (2019) and adjusted for this population/purposes by Almeida and Cunha (2024);
62679661|NCT06679452|NO_INTERVENTION|35 participants include in a control group (CG).|35 participants included in a control group (CG), in the form of a waitlist.
62679662|NCT05712889|EXPERIMENTAL|Dose Escalation of VIP236 (Q3W)|Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 of each 21-day cycle
62679663|NCT05712889|EXPERIMENTAL|Dose Escalation of VIP236 (Q2W)|Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 and D15 of each 28-day cycle.
62679664|NCT05380453|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
62120800|NCT04554628|ACTIVE_COMPARATOR|Urinary human kidney injury molecule 1 (U-KIM1)|Urinary human kidney injury molecule 1 (U-KIM1) measurement group
62309077|NCT05581719|EXPERIMENTAL|Stage 1 (Allocetra-OTS monotherapy)|Dose escalation of Allocetra-OTS up to 10 x 10\^9 cells by IV or IP administration.
62309078|NCT05581719|EXPERIMENTAL|Stage 2.1 (Allocetra-OTS in combination with anti-PD-1 therapy)|Dose escalation of Allocetra-OTS up to 10 x 10\^9 cells by IV or IP administration, with IV nivolumab 240 mg.
62120801|NCT02139943|EXPERIMENTAL|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
62120802|NCT02139943|EXPERIMENTAL|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
62309079|NCT05581719|EXPERIMENTAL|Stage 2.2 (Allocetra-OTS in combination with anti-PD-1 therapy)|Dose escalation of Allocetra-OTS up to 10 x 10\^9 cells by IV or IP administration, with IV tislelizumab 200 mg.
62309080|NCT02857465|EXPERIMENTAL|Epidural analgesia + DEXAMETHASONE|Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
62309081|NCT02857465|PLACEBO_COMPARATOR|Epidural analgesia + PLACEBO|Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
62309082|NCT04652258|OTHER|Treatment arm|"The patients will be administered Tocilizmab (Actemra) at the following dosage :~* First dose: 8mg/kg, max. 800mg iv. during 60min~* If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose"
62309083|NCT05537428|EXPERIMENTAL|Musical Intervention|Participants will work together in a group with other voice hearers, making music with a trained facilitator for 4 weekly sessions
62309084|NCT04541823|EXPERIMENTAL|Desflurane|Patients allocated to this arm will receive desflurane during the maintenance of anesthesia.
62309085|NCT04541823|PLACEBO_COMPARATOR|Propofol|Patients allocated to this arm will receive propofol during the maintenance of anesthesia
62679665|NCT05380453|EXPERIMENTAL|Secukinumab|Participants will receive secukinumab as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
62679666|NCT06671054|EXPERIMENTAL|AP1189 40 mg|12 weeks daily treatment of oral AP1189 40 mg as add-on to Methotrexate (MTX)
62679667|NCT06671054|EXPERIMENTAL|AP1189 70 mg|12 weeks daily treatment of oral AP1189 70 mg as add-on to Methotrexate (MTX)
62679668|NCT06671054|EXPERIMENTAL|AP1189 100 mg|12 weeks daily treatment of oral AP1189 100 mg as add-on to Methotrexate (MTX)
62679669|NCT06671054|EXPERIMENTAL|Placebo|12 weeks daily treatment of oral AP1189 matching placebo as add-on to Methotrexate (MTX)
62679670|NCT00646022||Arm 1|Participants who undergo extended evaluation for disease at NIH
62679671|NCT00646022||Arm 2|Participants who do not undergo extended screening or evaluation for disease at NIH
62679672|NCT06345703|EXPERIMENTAL|Arm1|NS-136 SAD Dose 1
62679673|NCT06345703|EXPERIMENTAL|Arm2|NS-136 SAD Dose 2
62679674|NCT06345703|EXPERIMENTAL|Arm3|NS-136 SAD Dose 3
62679675|NCT06345703|EXPERIMENTAL|Arm4|NS-136 SAD Dose 4
62679676|NCT06345703|EXPERIMENTAL|Arm5|Arm5 NS-136 MAD Dose 1
62679677|NCT06345703|EXPERIMENTAL|Arm6|Arm5 NS-136 MAD Dose 2
62679678|NCT06345703|EXPERIMENTAL|Arm7|FE Grp A
62679679|NCT06345703|EXPERIMENTAL|Arm8|FE Grp B
62679680|NCT06345703|PLACEBO_COMPARATOR|Arm9|NS-136 SAD Dose 1 PBO
62679681|NCT06345703|PLACEBO_COMPARATOR|Arm10|NS-136 SAD Dose 2 PBO
62679682|NCT06345703|PLACEBO_COMPARATOR|Arm11|NS-136 SAD Dose 3 PBO
62120803|NCT02139943|PLACEBO_COMPARATOR|Placebo|Each participant will receive matching placebo once daily for 18 weeks
62120804|NCT01271452|ACTIVE_COMPARATOR|Vistabel®|botulinum toxin type A (Vistabel®)
62120805|NCT01271452|ACTIVE_COMPARATOR|Bocouture®|botulinum toxin type A (Bocouture®)
62679683|NCT06345703|PLACEBO_COMPARATOR|Arm12|NS-136 SAD Dose 4 PBO
62679684|NCT06345703|PLACEBO_COMPARATOR|Arm13|NS-136 MAD Dose 1 PBO
62679685|NCT06345703|PLACEBO_COMPARATOR|Arm14|NS-136 MAD Dose 2 PBO
62679686|NCT05238220||continue valganciclovir prophylaxis|continue valganciclovir prophylaxis for up to 12 months total when anti-CMV immunity absent
62679687|NCT05238220||discontinue valganciclovir prophylaxis|discontinue valganciclovir prophylaxis when anti-CMV immunity present after routine care prophylaxis
62679688|NCT04949451|PLACEBO_COMPARATOR|TRF-C|Follows time restricted feeding protocol.
62679689|NCT04949451|EXPERIMENTAL|TRF-P|Follows time restricted feeding protocol, consumes protein supplement
62679690|NCT04949451|EXPERIMENTAL|TRF-S|Follows time restricted feeding protocol, consumes ketogenic supplement
62679691|NCT03643588|EXPERIMENTAL|HYAJOINT Plus group|The HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
62679692|NCT03643588|ACTIVE_COMPARATOR|Hyalgan group|The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
62679693|NCT01512251|OTHER|No Previous Treatment|150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.
62679694|NCT02375256|EXPERIMENTAL|AERAS-402|3 x10\^10 viral particles per 0.5 mL suspended in 10 mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL.
62679695|NCT02375256|ACTIVE_COMPARATOR|Placebo|1.0 mL sterile vaccine buffer containing 10mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL
62679696|NCT05974111||Ischemic Stroke|"Patients presenting at emergency department / Intensive Care unit with ischemic stroke~* registration of baseline clinical data~* registration of baseline blood parameters (in context of standard of clinical care)~* additional blood sampling at 5 time points during 1st week with the purpose of full coagulation testing and cell free DNA methylation"
62679697|NCT05974111||Haemorrhagic stroke|"Patients presenting at emergency department / Intensive Care unit with haemorraghic stroke (spontaneous intracranial bleeding, no trauma)~* registration of baseline clinical data~* registration of baseline blood parameters (in context of standard of clinical care)~* additional blood sampling at 5 time points during 1st week with the purpose of full coagulation testing and cell free DNA methylation"
62120806|NCT00518869|EXPERIMENTAL|Treatment group|PG2 plus standard chemotherapies
62120807|NCT00518869|PLACEBO_COMPARATOR|Placeo group|Placebo plus standard chemotherapies
62679698|NCT05974111||Aneursmal Subarachnoid Haemorrhage|"Patients presenting at emergency department / Intensive Care unit with aneurysmal subarachnoid haemorrhage~* registration of baseline clinical data~* registration of baseline blood parameters (in context of standard of clinical care)~* additional blood sampling at 5 time points during 1st week with the purpose of full coagulation testing and cell free DNA methylation"
62679699|NCT00770809|EXPERIMENTAL|Arm I (THL)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
62679700|NCT00770809|ACTIVE_COMPARATOR|Arm II (TH)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.
62309086|NCT00907725|OTHER|1|serum BhCG follow-up
62679701|NCT00770809|EXPERIMENTAL|Arm III (TL)|Patients receive paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)
62120808|NCT00964197|EXPERIMENTAL|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
62120809|NCT06483308|OTHER|Radiotherapy|
62679702|NCT05449067|EXPERIMENTAL|Automated Peritoneal Dialysis (APD)|In APD, a mechanical device is employed to assist in the delivery and drainage of dialysate. Continuous Cycling Peritoneal Dialysis (CCPD)means patients receive four automated exchanges of 2 liters of dialysate each over 10 hours a night, with 2 liters left in the peritoneal cavity during the daytime. The overall dialysate volume is 10 liters.
62679703|NCT05449067|ACTIVE_COMPARATOR|Continuous Ambulatory Peritoneal Dialysis (CAPD)|CAPD involves the manual instillation of 2 liters(L) of dialysis fluid into the peritoneal cavity, four times a day. This typically means three short dwells during the daytime and a long dwell overnight. The total volume of dialysate is 8 liters.
62679704|NCT03979794|EXPERIMENTAL|Be-WEL Intervention|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
62679705|NCT03979794|NO_INTERVENTION|Standard Care|Standard Care consists of the standard care patients typically receive from their medical team.
62679706|NCT04012710|ACTIVE_COMPARATOR|Laparoscopy|Abdominal conventional laparoscopy for salpingo-oophorectomy
62679707|NCT04012710|ACTIVE_COMPARATOR|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
62120810|NCT04455516||repair group|The first operation in these patients was meniscus repair
62309087|NCT00907725|OTHER|2|ultrasonographic follow-up
62679708|NCT06695273|EXPERIMENTAL|AI-Assisted Group (AI Group)|Physicians receive CHD probability estimates from an AI model based on retinal photographs. The AI tool provides individualized CHD probabilities, leveraging retinal biomarkers associated with cardiovascular risk.
62120811|NCT04455516||nonfailure group|These patients had a successful first operation
62120812|NCT04455516||failure group|In these patients, the first meniscus repair operation failed
62120813|NCT05246098||Adults|Adult survivors of COVID-19 or acute respiratory infection admitted to participating ICUs. Adults are defined as greater than or equal to, 18 years old. We will include adults with a confirmed diagnosis of COVID-19 or those with suspected or proven acute respiratory infection with onset within 14 days of ICU admission and requiring invasive mechanical ventilation, non-invasive ventilation, or high-flow oxygen therapy.
62309088|NCT03721328|EXPERIMENTAL|Experimental|Joint irrigation with vancomycin and tobramycin
62309089|NCT05609422|ACTIVE_COMPARATOR|control group|Received the designed physical therapy program.
62309090|NCT05609422|EXPERIMENTAL|study group|Received a designed physical therapy program in addition to scooter bord activities.
62309091|NCT00609440|OTHER|A|A single case study, of a patient that was submitted to a physiotherapeutic treatment.
62309092|NCT00090285|EXPERIMENTAL|qHPV Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
62309093|NCT00090285|PLACEBO_COMPARATOR|Placebo|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
62339615|NCT06013605|EXPERIMENTAL|Intervention Group|Participants did walking exercise and usual care (leg straightening)
62679709|NCT06695273|ACTIVE_COMPARATOR|Guideline-Based Group (Guideline Group)|Physicians use a PCE calculator to calculate the 10 year ASCVD risk. This approach aligns with current clinical guidelines to assist in decision-making.
62679710|NCT04009135|EXPERIMENTAL|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
62120814|NCT05246098||Pediatrics|Pediatric survivors of COVID-19, MIS-C, or acute respiratory infection admitted to participating pediatric intensive care units (PICUs). The investigators define children as less than 18 years old. We will include pediatric patients with COVID-19, those with multi-system inflammatory syndrome in children (MIS-C), and those with suspected or proven acute respiratory infection with onset within 14 days of ICU admission and requiring invasive mechanical ventilation, non-invasive ventilation, or high-flow oxygen therapy.
62309094|NCT02764866|EXPERIMENTAL|Sleep testing|Enrolled patients with lung cáncer will undergo home sleep testing during their initial oncologic evaluation, prior to treatment.
62475643|NCT01676194|EXPERIMENTAL|Intra-arterial administration of DC BeadsR|Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
62475644|NCT01676194|NO_INTERVENTION|Control|Usual care
62475645|NCT05443750|EXPERIMENTAL|Motivational Behavioral Economic Intervention|Web-based alcohol risk reduction brief intervention
62475646|NCT05443750|ACTIVE_COMPARATOR|Health Education|Web-based health education material
62475647|NCT05878626|EXPERIMENTAL|Group A|receive Anodal TDCS with spongy electrodes applied to the M1 (supplementary motor area) of the skull which corresponds to C3 and C4 on the 10/20 EEG system. The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
62475648|NCT05878626|SHAM_COMPARATOR|Group B|receive conventional treatment in the form of motor relearning program (MRP). And Sham application of anodal TDCS
62475649|NCT00840073|EXPERIMENTAL|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
62475650|NCT00840073|ACTIVE_COMPARATOR|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
62679711|NCT04009135|EXPERIMENTAL|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
62679712|NCT04009135|PLACEBO_COMPARATOR|Attention Control (AC)|Patients in the control condition will be given access online psychoeducation about depression and chronic pain. They will be provided weekly phone calls to query symptoms and well-being.
61920716|NCT02436655|NO_INTERVENTION|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
61920717|NCT02436655|ACTIVE_COMPARATOR|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
62120815|NCT01720550|EXPERIMENTAL|PG2 High Dose|Astragalus Polysaccharides 500 mg
62120816|NCT01720550|EXPERIMENTAL|PG2 Low Dose|Astragalus Polysaccharides 250 mg
62309095|NCT05285852|EXPERIMENTAL|Dry Needling|For application of the Dry Needling the individual should be in the supine position. To facilitate the approach and adhesion of the Sternocleidomastoid Muscle, the person's neck is placed ipsilaterally in the slightly lateral flexed position. Consequently, the therapist identified the active Trigger Points in the Sternocleidomastoid Muscle and cleansed the surface using an antiseptic solution. Using the insertion pipe, the dry needle inserted into the muscle. For the separation of neurovascular structure from muscle belly the needle is carried out in an anterior-posterior direction. A compression of 90 secs with a cotton swab will be applied at the needling site immediately after removing the needle to reduce the intensity and duration of pain. The variables will then be measured immediately following the processing session. Six sessions of Dry Needling will be applied to each patient and there will be a gap of at least 48 hours between each session.
62475651|NCT03125473|EXPERIMENTAL|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
62679713|NCT00782379|EXPERIMENTAL|Myeloablative Haploidentical Transplant|All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.
62679714|NCT04105634|EXPERIMENTAL|Inflammation group|Patient diagnosed with Cardiac Amyloidosis
62679715|NCT04105634|EXPERIMENTAL|Amyloid group|Patient diagnosed with Cardiac Amyloidosis
61920718|NCT05307939|EXPERIMENTAL|Screening, active surveillance, and treatment (Arm A)|Participants who meet criteria for the treatment phase (a post-operative HPV ctDNA which rose from initial undetectable to meet HPV16 ctDNA criteria and have no clinical or radiographic evidence of gross disease) will undergo delayed standard of care adjuvant radiation (50-60 Gy administered in 1.8-2 Gy fractions) based on the patient's initial pathology. Treatment will be initiated within 4 weeks of a NavDx result. Subjects will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed.
62679716|NCT05117125||VAP|Enrolled participants that fully meet the criteria of VAP.
62309096|NCT05285852|PLACEBO_COMPARATOR|Placebo Dry Needling|Following identification of the trigger point in the muscle, the surface would be cleaned with an antiseptic solution. For placebo Dry Needling, which only causes a pricking sensation, a blunt needle will be applied to the trigger points without penetrating the skin after application of a certain pressure to the skin. The protocol will be applied six times, with a two-day pause between treatments. Like the intervention group, the variables will be measured immediately after the processing session.
62679717|NCT05117125||Suspect VAP|Enrolled participants that develop signs of VAP but lack some variable, for instace new radiographic infiltrate or microbiological finding compatible with VAP.
62679718|NCT05117125||No VAP|Enrolled participants that do not develop VAP.
62679719|NCT04658368||Control|Participants with a history of major limb amputation at the University of Wisconsin (UW) that did not undergo TMR
62679720|NCT04658368||Retrospective TMR|Participants with a history of major limb amputation that underwent primary or secondary TMR with attending plastic surgeon at UW
62679721|NCT04658368||Prospective Secondary TMR|Participants who are scheduled to undergo secondary TMR at the UW
62679722|NCT04658368||Prospective Primary TMR|Participants who are scheduled to undergo primary TMR at the UW
62679723|NCT06645704|EXPERIMENTAL|[14C]-EP262 25 mg|Administered orally.
62679724|NCT02719366|EXPERIMENTAL|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
62679725|NCT02719366|ACTIVE_COMPARATOR|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
61920719|NCT05307939|EXPERIMENTAL|Screening and deescalated treatment (Arm B)|"Participants who meet criteria for the de-escalated treatment phase (Arm B) will undergo adjuvant radiation (30 Gy administered in 2 Gy fractions) with concurrent chemotherapy.~They will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed and the Study calendar."
61920720|NCT04195126|NO_INTERVENTION|Control group|Patients are treated according to most recent guidelines in burn trauma and corresponding emergency and intensive therapy. All patients included are treated with early continous veno-venal renal replacement therapy.
61920721|NCT04195126|ACTIVE_COMPARATOR|Treatment group|Besides treatment strategies of the control group, the investigators start early haemadsorption treatment right after patient admission (and inclusion).
61920722|NCT00938964|EXPERIMENTAL|Lidocaine|Lidocaine infusion for 48 hours
62309097|NCT01524289|EXPERIMENTAL|Anacetrapib|Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period.
62309098|NCT01524289|PLACEBO_COMPARATOR|Placebo|Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.
62309099|NCT02556762|EXPERIMENTAL|SMART boost|Radiotherapy with simultaneous modulated accelerated boost
62309100|NCT02556762|ACTIVE_COMPARATOR|Standard dose RT|Standard dose radiotherapy
62679726|NCT05400941|ACTIVE_COMPARATOR|Practice Led Intervention|Clinic staff will participate in learning collaborative and practice facilitation as well as receive expert consultation and audit and feedback.
61920723|NCT00938964|PLACEBO_COMPARATOR|Placebo|Normal saline infusion for 48 hours
61920724|NCT02166372||Obese diabetic patients|Diabetic patients with BMI over 25 Age 20 to 67 Diabetes medically controlled at our center for at least six months
61920725|NCT05430256||Premature children with neurological developmental disorder(such as ADHD)|Premature children with neurological developmental disorder (such as ADHD): n = 200
61920726|NCT05430256||Premature children with neurological developmental disorder(such as ASD)|Premature children with neurological developmental disorder (such as ASD): n = 50
61920727|NCT05430256||Premature infants with no neurodevelopmental disorders|Premature infants with no neurodevelopmental disorders: n = 200
61920728|NCT05430256||Age and gender match in non-preterm children|Age and gender match in non-preterm children: n = 200
61920729|NCT05897944||COPD|Participants with clinically diagnosed Chronic obstructive pulmonary disease. Total 34 recruitment, 18 Female, 16 Male
61920730|NCT05897944||HC|Participants without Chronic obstructive pulmonary disease diagnosis. Total 38 recruitment, 20 Female, 18 Male
61920731|NCT00760084|EXPERIMENTAL|A|Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
61920732|NCT03174496||Children aged 4-7 years|
61920733|NCT03174496||Children and adolescents aged 8-16 years|
62120817|NCT02452918|EXPERIMENTAL|Oritavancin 1200 mg Without Concomitant Warfarin Therapy|Oritavancin as a single 1200 mg IV dose administered over 3 hours in participants with ABSSSI who were not on concomitant warfarin therapy
62679727|NCT05400941|NO_INTERVENTION|Standard of Care|No intervention.
62679728|NCT01642667|PLACEBO_COMPARATOR|primary PCI|
62679729|NCT01642667|ACTIVE_COMPARATOR|prouk-PCI|
62679730|NCT04860336||Pregnant women less than or equal to 14w0d gestation|
62679731|NCT02584244|EXPERIMENTAL|Patients with colorectal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
62475652|NCT03125473|EXPERIMENTAL|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
62475653|NCT03125473|EXPERIMENTAL|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
62309101|NCT03029962|EXPERIMENTAL|Experimental: Girl2Girl|Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
62475654|NCT03125473|EXPERIMENTAL|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
62309102|NCT03029962|NO_INTERVENTION|No Intervention: Health Lifestyle|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 7-weeks in length (Week 7 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
62475655|NCT05928156|EXPERIMENTAL|Myeloma Coach or CLL Coach Mobile App|"Participants diagnosed with Multiple Myeloma will use the Myeloma Coach app and participants diagnosed with CLL (chronic lymphocytic leukemia) will use the the CLL Coach app. Pattern Health apps are built around patterns of scheduled activities. Users will encounter a list of activities to engage with for the day. There is also an option to complete activities in an ad hoc fashion."
62475656|NCT05928156|PLACEBO_COMPARATOR|Springboard Beyond Cancer informational website|
62475657|NCT04750707|OTHER|single arm|Single arm, open label of hydroxyurea starting at 20mg/kg and increased to 30mg/kg depending on clinical need and according to standard guidelines
61920734|NCT06338332||Nasogastric tube|Patients with right sided obstructive colon cancer will receive non-surgical decompression with a nasogastric probe. Prior to the definitive oncological resection, patients undergo preoperative optimisation which involves the engagement of a dietician and physiotherapist. Patients eligible for elective resection will have their resection 7-10 days after initial decompression.
62120818|NCT02452918|EXPERIMENTAL|Oritavancin 1200 mg With Concomitant Warfarin Therapy|Oritavancin as a single 1200 mg IV dose administered over 3 hours in participants with ABSSSI who were on concomitant warfarin therapy at a standard dose and dosing schedule
62120819|NCT06677606|EXPERIMENTAL|PENG block group|patients will receive PENG block after skin closure, .Patients will be placed in the supine position. The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle .
62120820|NCT06677606|ACTIVE_COMPARATOR|PAI group|PIA BLOCK For subjects randomized to PAI , LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
62309103|NCT04438135|ACTIVE_COMPARATOR|active test|
62309104|NCT04438135|PLACEBO_COMPARATOR|placebo test|
62309105|NCT00987766|EXPERIMENTAL|Treatment|Gemcitabine + Oxaliplatin + Erlotinib
62309106|NCT04244045|EXPERIMENTAL|Experimental group 1|suboccipital muscle inhibition plus passive stretch of hamstring muscle.
62309107|NCT04244045|EXPERIMENTAL|Experimental group 2|Neural slump strtch position plus passive stretch of hamstring muscle.
62309108|NCT04244045|ACTIVE_COMPARATOR|Control group|passive stretch of hamstring muscle
62309109|NCT03921892|OTHER|In-person parenting education|Participants will complete two six-hour in-person parenting education sessions on two consecutive Saturdays
62309110|NCT03921892|ACTIVE_COMPARATOR|On-line parenting education|Participants will complete on-line parenting education at the times and locations of their choice over a two-week period.
62339616|NCT06013605|EXPERIMENTAL|Control Group|Participants did usual care (leg straightening)
62475658|NCT01554007||Crohn's disease|Korean patients diagnosed with Crohn's disease
62475659|NCT04491721||Rituximab Biosimilar HLX01 in Combination With CHOP|Rituximab Biosimilar HLX01 in Combination With CHOP,in Previously Untreated Subjects With CD20+ DLBCL.
62309111|NCT06668831||Subjects on maintenance hemodialysis|"The study envisages the enrolment of:~* adult subjects (\>18 years of age) who are able to sign an informed consent.~* on maintenance HD (for at least 3 months)~* without history of cardiac arrhythmias at study recruitment define as atrial fibrillation or pace-maker assisted cardiac rhythm"
61920735|NCT06338332||Ileostomy|Patients with right sided obstructive colon cancer will receive a ileostomy. Prior to the definitive oncological resection, patients undergo preoperative optimisation which involves the engagement of a dietician and physiotherapist. Patients eligible for elective resection will be operated at least 7 days after initial decompression and no later than 4 weeks after initial presentation.
61920736|NCT06338332||Right-sided stent|Patients with right sided obstructive colon cancer will receive a right-sided stent. Prior to the definitive oncological resection, patients undergo preoperative optimisation which involves the engagement of a dietician and physiotherapist. Patients eligible for elective resection will be operated at least 7 days after initial decompression and no later than 4 weeks after initial presentation.
61920737|NCT04690205|EXPERIMENTAL|End of Life (EOL) Care at at Home|End of Life (EOL) Care at at Home intervention entails the following: patient-reported symptoms and home monitored vital signs and body weight with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
61920738|NCT03551080|ACTIVE_COMPARATOR|Endotoxin|0.8 ng lipopolysaccharide/kg body weight injection
61920739|NCT03551080|PLACEBO_COMPARATOR|Placebo|Saline injection
61920740|NCT01656174||No Treatment|
61920741|NCT03767803||Positive Preeclampsia group|A group with diagnosis of preeclampsia within 24 hours of testing and pre-term delivery
61920742|NCT03767803||Study Cohort|A group without diagnosis of preeclampsia. Also includes a group without diagnosis of preeclampsia within 24 hours of testing, but who have subsequent worsening or re-emergence of signs and symptoms of preeclampsia, and are later diagnosed with preeclampsia and have pre-term delivery.
61920743|NCT01124630|EXPERIMENTAL|CS-1008 with FOLFIRI|Experimental drug CS-1008 in combination with FOLFIRI
61920744|NCT04086875|EXPERIMENTAL|Phase 1 (focus groups)|Participants attend focus groups on adherence to hormone therapy.
61920745|NCT04086875|EXPERIMENTAL|Phase II Group 1 (text messages)|Participants receive text messages twice weekly for 6 months to remind and motivate participants about AHT adherence.
62309112|NCT03248466|PLACEBO_COMPARATOR|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
62309113|NCT03248466|EXPERIMENTAL|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
62475660|NCT04491721||MabThera in Combination With CHOP|MabThera in Combination With CHOP，in Previously Untreated Subjects With CD20+ DLBCL.
61920746|NCT04086875|ACTIVE_COMPARATOR|Phase II Group II (usual care)|Participants receive usual care.
61920747|NCT00469261|EXPERIMENTAL|Doxycycline|Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy
62309114|NCT03248466|NO_INTERVENTION|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
61920748|NCT00469261|ACTIVE_COMPARATOR|Standard Therapy|Pts with AMI treated with Primary PCI and current medical therapy
61920749|NCT05018936|EXPERIMENTAL|treatment group|Hetrombopag would be started with 5mg/day. The dosage would be increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The maximum dosage is 15mg/day.
61920750|NCT03384797||Healthy Volunteers|
62309115|NCT01483573|EXPERIMENTAL|straight leg raise|stretch the muscle
62309116|NCT01483573|EXPERIMENTAL|neural mobilization|stretch the nerve
62475661|NCT06553664|EXPERIMENTAL|Trial group|Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
62309117|NCT06212440|EXPERIMENTAL|A|Sentinel LN biopsy by mapping with Radioactive isotope(RI) and Indocyanine Green Fluorescence (ICG-F)
61920751|NCT03384797||Parkinson's Disease|
62309118|NCT06212440|EXPERIMENTAL|B|Sentinel LN biopsy by mapping with Radioactive isotope(RI) and vital dye
62475662|NCT02362997|EXPERIMENTAL|Diffuse large B cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
62309119|NCT06212440|EXPERIMENTAL|C|Sentinel LN biopsy by mapping with vital dye and Fluorescence (ICG-F)
62475663|NCT02362997|EXPERIMENTAL|Classical Hodgkin lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
62475664|NCT02362997|EXPERIMENTAL|Peripheral T cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
62475665|NCT01880853|EXPERIMENTAL|group 1|screening with mammography alone
61920752|NCT00623584|EXPERIMENTAL|1|Patients in this arm randomly receive a corneal graft cultured in a serum free culture medium
61920753|NCT00623584|ACTIVE_COMPARATOR|2|Patients in this arm randomly receive a corneal graft cultured in a serum supplemented culture medium
61920754|NCT01358071|EXPERIMENTAL|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
62309120|NCT06213701|EXPERIMENTAL|Healthy Minds Program (HMP) app|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
62309121|NCT06213701|ACTIVE_COMPARATOR|Psychoeducation app|Participants will receive access to the 4-week HMP Foundations module with guided meditation practices removed. The active control will include only the didactic content included in HMP without the guided meditation practices.
62309122|NCT06213701|NO_INTERVENTION|Usual Care|Participants will receive access to HMP at the end of the study and will be encouraged to continue with their usual care.
62309123|NCT00994370||liver cancer|Patients referred for SIRT will be considered for this investigation. These patients will predominantly have stage IV colorectal metastases with liver dominant metastases or hepatocellular carcinoma. A team of oncologists, interventional radiologists, radiation oncologists and oncologic surgeons will determine that the patients are not candidates for surgical resection or ablative therapy. The patients will then be screened to confirm the patient's eligibility to receive standard of care SIRT treatment. SIRT treatment and imaging studies included in this investigation are standard of care for the patients' liver dominant disease.
62475666|NCT01880853|EXPERIMENTAL|group 2|screening with ultrasonography alone
62475667|NCT01880853|EXPERIMENTAL|group 3|screening with both mammography and ultrasound
62475668|NCT04194801|EXPERIMENTAL|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|
62475669|NCT04194801|EXPERIMENTAL|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|
62475670|NCT04194801|EXPERIMENTAL|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|
62475671|NCT06627699||Patients receiving the Maxx Freedom Total Knee System for primary TKA|TARGETED PATIENTS Adult male and female patients greater than 18 years of age Candidate for primary TKA GENERAL EXCLUSIONS Active infection Revision / conversion TKA (Prior UKA or HTO)
62475672|NCT03853616|EXPERIMENTAL|Phase I: DL 0: 1x10e5 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
62495892|NCT04673825|NO_INTERVENTION|Control group|The standard care group will have a scheduled outpatient visit at baseline and after 1 year, and in between as usual, scheduled at the discretion of the treating rheumatologist. Prior to each visit, patients complete questionnaires in SpA-Net and have routine blood tests done. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
61920755|NCT01358071|ACTIVE_COMPARATOR|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
61920756|NCT02704910|PLACEBO_COMPARATOR|Voluntary subject|Patient without parkinson disease, without deep brain stimulation
61920757|NCT02704910|ACTIVE_COMPARATOR|Patients|Subthalamic stimulation
61920758|NCT03117088|ACTIVE_COMPARATOR|Checklist ISBAR 3|online-based checklist for standardized handovers
61920759|NCT03117088|PLACEBO_COMPARATOR|Checklist VICUR|comparator Checklist
62309124|NCT02690896|EXPERIMENTAL|UCF Behavioral Intervention Group|The intervention group will be the UCF Caregiver Support. Participants will receive a 90 minute group session, once a week, for a period of 6 consecutive weeks.
62309125|NCT02690896|ACTIVE_COMPARATOR|Community Comparison Group|Comparison group members will come from potential local support groups include, but are not limited to, the support group at the Faith Assembly of God church, the caregiver support group at the First Baptist Church of Orlando, and the caregiver support group at the Alzheimer's and Dementia Resource Center.
62679732|NCT02584244|EXPERIMENTAL|Patients with esophageal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
62679733|NCT02584244|EXPERIMENTAL|Pancreatic cancer patients receiving neoadjuvant chemotherapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
61920760|NCT01739855|ACTIVE_COMPARATOR|Calcium/Vitamin D|"All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:~daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)"
61920761|NCT01739855|NO_INTERVENTION|No Calcium/Vitamin D|All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
61920762|NCT03674931|EXPERIMENTAL|musical practice|Intensive weekly musical keyboard training over 12 months
62309126|NCT05519943|EXPERIMENTAL|group cognitive behavioral therapy intervention|
61920763|NCT03674931|ACTIVE_COMPARATOR|music education|Recreative weekly musical courses without practice over 12 months
61920764|NCT01933789|EXPERIMENTAL|Feedback Group|Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
61920765|NCT01933789|NO_INTERVENTION|Comparison/Usual Care Group|Subjects will only complete surveys and assessments.
61920766|NCT04350398|EXPERIMENTAL|Hippotherapy treated group|"During the initial week of intervention, sessions will be mainly carried on horseback. We will use the movement of the horse: (i) to allow patient re-appropriating her body and find harmony; (ii) to initiate rehabilitation of movements (shoulder, neck, upper extremity, whole body), gesture and femininity. The goal is to reconstruct a harmonic body image both in the private and public sphere, through different techniques. A few walking sessions may be needed to reinforce some landmarks.~During the short stages the work will be mainly done by walking alongside the horse. These reinforcement periods act like a trampoline, necessary to have a new momentum providing the opportunity to take a step back from the everyday, to regenerate somehow. The reaction time is generally optimized considering the imprint done during the initial long stage. One of the main themes that come up during this period is fear (relapse, the future, not achieving the goals, pain, relationship issues, etc.)."
61920767|NCT04350398|PLACEBO_COMPARATOR|Conventional therapy treated group|Patients in the control group are followed by dedicated personnel of the Montpellier Institut du Sein. This personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
61920768|NCT04304157|EXPERIMENTAL|satisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
61920769|NCT04304157|EXPERIMENTAL|unsatisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
61920770|NCT03204786|EXPERIMENTAL|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
62309127|NCT05519943|EXPERIMENTAL|Treatment as usual (TAU)|
62309128|NCT02532543|ACTIVE_COMPARATOR|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
62309129|NCT02532543|ACTIVE_COMPARATOR|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
62309130|NCT02532543|ACTIVE_COMPARATOR|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
62309131|NCT02532543|ACTIVE_COMPARATOR|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
62309132|NCT01887834|PLACEBO_COMPARATOR|Kyodophilus matching placebo capsules|"Kyodophilus Matching Placebo Capsules~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
62309133|NCT01887834|ACTIVE_COMPARATOR|Kyodophilus multi strain probiotic capsules|"Kyodophilus multi-strain probiotic capsules~The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
62309134|NCT01623466|EXPERIMENTAL|AG890-6.5|Evaluate levonorgestrel delivery in AG890-6.5
62309135|NCT01623466|EXPERIMENTAL|AG890-12.5|Evaluate levonorgestrel delivery in AG890-12.5
62309136|NCT05508152|SHAM_COMPARATOR|Wound irrigation with saline|After the closure of the aponeurosis, and before the closure of the skin, the subcutaneous layer of the wound will be rinsed with a determined volume (depending on the diameter of the incision) of a saline solution. Then, a gauze soaked with the same solution will be placed in the wound for 3 minutes.
62309137|NCT05508152|EXPERIMENTAL|Wound irrigation with antibiotic|After the closure of the aponeurosis, and before the closure of the skin, the subcutaneous layer of the wound will be rinsed with a determined volume (depending on the diameter of the incision) of amoxicillin-clavulanate in saline solution. Then, a gauze soaked with the same solution will be placed in the wound for 3 minutes.
62309138|NCT04408157|EXPERIMENTAL|Self-management booklet|Self-management booklet: developed drawing on existing evidence and work conducted by researchers at the Health Psychology section at KCL, tailored to the current circumstances in response to the COVID-19 pandemic.
61920771|NCT03204786|EXPERIMENTAL|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
61920772|NCT03204786|PLACEBO_COMPARATOR|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
61920773|NCT01414452||STEMI patients|Patients with ST elevation myocardial infarction,lasting \<12 hour, who were succesfully treated with primary PCI
61920774|NCT04443751|EXPERIMENTAL|SHR-1702 monotherapy|SHR-1702 monotherapy, given intravenously (IV); dose escalation and dose expansion.
62309139|NCT04408157|NO_INTERVENTION|Education only (waiting-list)|Participants allocated to the waiting-list control arm will receive a link via email to educational materials related to COVID produced by King's College London for an online event and will be provided with the self-management booklet after completing the T2 assessment and qualitative interview. The topics covered in the online event are the same as the ones included in the self-management booklet, without structured guidance and behaviour change techniques to facilitate behaviour change.
61920775|NCT06477328|ACTIVE_COMPARATOR|Telemedicine group|"The study participants were evaluated through telemedicine visits at specific intervals after the baseline visit, with the following schedule:~* 1st visit: At day 10 post-baseline~* 2nd visit: At the end of the 1st month~* 3rd visit: At the end of the 3rd month~These visits were conducted by the principal investigator using telemedicine. Additional telemedicine visits were arranged for patients in the telemedicine group as required."
61920776|NCT06477328|NO_INTERVENTION|Control group|The visits for the control group, due to being conducted face-to-face in the outpatient clinic, were carried out by the routine attending physician at the clinic, who was not aware of the study. As suggested in the discharge recommendations during the baseline visit (0th visit) for the control group, they were advised to return for a follow-up visit on the 10th day and to schedule these follow-up appointments through the hospital's system. No intervention was made to facilitate the scheduling of these appointments.
61920777|NCT02325856|ACTIVE_COMPARATOR|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
62309140|NCT01486680|ACTIVE_COMPARATOR|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|
62309141|NCT01486680|ACTIVE_COMPARATOR|Laparoscopic Sleeve Gastrectomy|
61920778|NCT02325856|PLACEBO_COMPARATOR|Control group|Dry weight determined by clinical symptoms
61920779|NCT01215864|EXPERIMENTAL|TCD-717|
61920780|NCT01525901|EXPERIMENTAL|Insulin-Like Growth Factor-1 (IGF-1)|Injection
61920781|NCT01525901|PLACEBO_COMPARATOR|Normal saline|Injection
62309142|NCT03054727||Villalta phone score > or = to 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score \> or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score \> or = to 5 at the end of the follow-up call
62309143|NCT03054727||Villalta phone score < 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score \< 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score \< 5 at the end of the follow-up call
62309144|NCT04920448|EXPERIMENTAL|N-Acetylcysteine 150 mg/kg|Single intravenous injection of N-Acetylcysteine (150 mg/kg in 15 minutes).
62309145|NCT01225068|EXPERIMENTAL|Milnacipran|milnacipran 50 mg bid; can be increased to 100 mg bid
62309146|NCT01225068|PLACEBO_COMPARATOR|Placebo|Placebo
62339617|NCT04812418|EXPERIMENTAL|Group (A)|120 mg of eschscholtzia extract and 50 mg of valerian extract by tablet, without support 28 days
61920782|NCT02486562||People diagnosed with Multiple Sclerosis|
61944465|NCT02048969|EXPERIMENTAL|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of flumazenil will be administered to the patient at a rate of 0.1 mg flumazenil per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
62679734|NCT02584244|EXPERIMENTAL|Pancreatic cancer patients not receiving neoadjuvant chemo|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
62679735|NCT02584244|EXPERIMENTAL|Gastric cancer patients who have received neoadjuvant therapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
61920783|NCT02663583||Intensity-Modulated Proton Therapy or( IMPT) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
62120821|NCT05647070|EXPERIMENTAL|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
62120822|NCT01075217|EXPERIMENTAL|Isovue 250 (iopamidol)|
62120823|NCT01075217|ACTIVE_COMPARATOR|Visipaque 270 (iodixanol)|
62309147|NCT00095303|EXPERIMENTAL|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
62309148|NCT00095303|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
62120824|NCT00976625|NO_INTERVENTION|1|Control group without intervention. Treatment group with aortic valve replacement.
62120825|NCT00976625|OTHER|2|
62309149|NCT03560895||Group I|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Flexicare-UK) ) with its outer diameter determined by ultrasonography.
62339618|NCT04812418|PLACEBO_COMPARATOR|Group (B)|Placebo 28 days
62679736|NCT02584244|EXPERIMENTAL|Patients with early stage gastric cancer or precancerous lesions|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
62679737|NCT03704922|EXPERIMENTAL|≤10 day Blood|Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events.
62120826|NCT04195568|EXPERIMENTAL|Surpass Evolve Flow Diverter System|This is a prospective single arm study in which all subjects who present for flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment (Surpass Evolve Flow Diverter).
62120827|NCT01269853|EXPERIMENTAL|Arm 2|
62120828|NCT01269853|EXPERIMENTAL|Arm 1|
62120829|NCT06554158|EXPERIMENTAL|treatment arm|50Gy in 25 fractions to the neck at risk for tumor recurrence, excluding the primary site
62120830|NCT04004468|ACTIVE_COMPARATOR|Standard Periodization Training|Utilization of traditional periodization strength training model
62120831|NCT04004468|ACTIVE_COMPARATOR|Conjugate Training|Utilization of conjugate strength model
62120832|NCT03396146|EXPERIMENTAL|Type1diabetes with exocrine pancreatic function insufficiency|12 ml total blood tubes volume Fecal sample
61920784|NCT02663583||TransOral Robotic Surgery (TORS) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
61920785|NCT02043379|EXPERIMENTAL|IVIG|Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
61920786|NCT02043379|PLACEBO_COMPARATOR|Normal Saline|Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.
61920787|NCT01477203|ACTIVE_COMPARATOR|Escitalopram|50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
61920788|NCT01477203|NO_INTERVENTION|Remitted Patients|
61920789|NCT01477203|NO_INTERVENTION|Healthy Controls|
61920790|NCT02503995|ACTIVE_COMPARATOR|No intervention|Participants not undertaking any additional exercise
62495893|NCT04800926|EXPERIMENTAL|Xavier wheelchair controller|Surface electromyography control of wheelchair
62120833|NCT03396146|EXPERIMENTAL|Type1diabetes without exocrine pancreatic function insuficienc|12 ml total blood tubes volume Fecal sample
62120834|NCT03396146|ACTIVE_COMPARATOR|Type 3c diabetes|12 ml total blood tubes volume Fecal sample
62120835|NCT05325853|EXPERIMENTAL|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
62120836|NCT05325853|ACTIVE_COMPARATOR|Proparacaine|0.5% Proparacaine Hydrochloride
62309150|NCT03560895||Group II|Patients will be anesthetized using uncuffed endotracheal tube (Flexicare-UK) with its outer diameter determined by ultrasonography.
62495894|NCT03791541|NO_INTERVENTION|No Intervention|Only surveys will be done and re admissions tracked. No additional interventions based on survey results will be done.
62495895|NCT03791541|EXPERIMENTAL|Intervention|"Pharmacist Services~Surveys plus increased outpatient pharmacist/pharmacy student services including but not limited to pre and post clinic visit phone calls, prescription counseling, and helping with adherence and compliance with medications. Increased services will be given based on survey results."
62495896|NCT05068661|ACTIVE_COMPARATOR|Combined Spinal Epidural|10 mcg of preservative-free fentanyl and 2 mg of preservative-free isobaric 0.25% bupivacaine will be administered into the intrathecal space to initiate analgesia. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
62495897|NCT05068661|ACTIVE_COMPARATOR|Dural Puncture Epidural|A 25-G Whitacre needle will be used to puncture the dura. An initiation dose of 20 mL of ropivacaine 0.1% with fentanyl (2 mcg/mL) will be administered. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
62495898|NCT01182792|EXPERIMENTAL|Antioxidant|
62495899|NCT01182792|PLACEBO_COMPARATOR|Control|
62679738|NCT03704922|EXPERIMENTAL|≥30 day Blood|Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events.
62679739|NCT06547359|ACTIVE_COMPARATOR|obicetrapib with and without co-administration of ezetimibe|Ezetimibe 10mg tablets daily from Days 1-17 plus obicetrapib 10mg tablets on Day -9 and Day 8
62679740|NCT06547359|ACTIVE_COMPARATOR|ezetimibe with and without co-administration of obicetrapib|Obicetrapib 10mg tablets daily from Days 1-15 plus ezetimibe10mg tablets on Day -3 and Day 12
61920791|NCT02503995|EXPERIMENTAL|Water-based exercise group|Participants assigned to a water-based exercise group
62309151|NCT04382651|EXPERIMENTAL|MAS825 + SoC|Single dose of MAS825 10 mg/kg by intravenous infusion in addition to SoC
61920792|NCT02503995|EXPERIMENTAL|Land-based exercise group|Participants assigned to a land-based exercise group
62309152|NCT04382651|PLACEBO_COMPARATOR|Placebo + SoC|Single dose of matching Placebo by intravenous infusion in addition to SoC
61920793|NCT01593722|ACTIVE_COMPARATOR|diethylcarbamazine|diethylcarbamazine 8 mg/kg single oral dose
61920794|NCT01593722|ACTIVE_COMPARATOR|ivermectin|ivermectin 200 mcg/kg single oral dose
61920795|NCT00603421|EXPERIMENTAL|1|Patient benefits from treatment as usual plus access to a crisis 24 hour phone line.
61920796|NCT00603421|ACTIVE_COMPARATOR|2|Patient benefits from treatment as usual
61920797|NCT04271280||High Risk and Very High Risk Dyslipidemic Participants|Participants are classified as High and Very High Risk (as assessed by the Framingham risk score for High Risk participants and the SMART score for Very High Risk participants) as well as if previously or newly diagnosed.
62309153|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
62679741|NCT01725308|PLACEBO_COMPARATOR|Placebo|Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
62679742|NCT01725308|EXPERIMENTAL|FK949E 150 mg|After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
62309154|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
62679743|NCT01725308|EXPERIMENTAL|FK949E 300 mg|After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
62679744|NCT01725308|EXPERIMENTAL|Placebo / FK949E|Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
62309155|NCT01098968|NO_INTERVENTION|Normal PE|2 Physical Education sessions / week
62309156|NCT01098968|EXPERIMENTAL|PE Volume|4 Physical Education sessions/week (increased volume)
62309157|NCT01098968|EXPERIMENTAL|PE Volume + Intensity|4 Physical Education sessions/week of high intensity (increased volume and intensity)
62309158|NCT04220892|EXPERIMENTAL|Pembrolizumab plus Pemetrexed|Pembrolizumab plus Pemetrexed
61920798|NCT04188171|EXPERIMENTAL|Polidocanol foam sclerotherapy|"During the intervention period the participants are observed at 3-week intervals (maximum of 3 sessions).~The required number of polidocanol foam sclerotherapy sessions (maximum of 3) is determined by clinical and anoscopic evaluation (if the participant is non-symptomatic and/or there is no significant hemorrhoidal disease on anoscopy, the patient will not be a candidate for additional instrumental therapy moving directly to the follow-up period). After each session all patients were instructed to adopt dietary measures and adequate hydration maintaining therapy with systemic venotropic, topical and laxative if necessary.~After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
61920799|NCT04934943||Intervention _mini_FC|"The fluid challenge consists of 4 ml\*Kg of Crystalloids' solution infused over 10 minutes, administered via either a central or a peripheral line.~1. The patient is already connected to the PICCO monitoring for clinical purpose of hemodynamic monitoring (before study enrollment)~2. The MOSTCARE system is connected to the MONITOR of the patient (and not to the patient itself) by means of a cable inserted into the connections system.~3. The echocardiography will be performed by a senior intensivist/cardiologist. The stroke volume is calculated by measuring VTI and diameter at the same point. This is best performed by measuring the diameter of the LVOT in the parasternal long axis (PLAX) view"
62309159|NCT04220892|EXPERIMENTAL|Pembrolizumab plus Abemaciclib|Pembrolizumab plus Abemaciclib
61920800|NCT01247181|EXPERIMENTAL|Mobile phone text message|
62309160|NCT04923971|ACTIVE_COMPARATOR|0C Trial|Participants will be sitting in a chair performing hand dexterity tasks in 0C (32F) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
62309161|NCT04923971|ACTIVE_COMPARATOR|-10C Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C (14F) conditions.Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
62309162|NCT04923971|ACTIVE_COMPARATOR|-20C Surrogate Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C + 3m/s wind (14F+6 mph wind) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
62309163|NCT02167477|ACTIVE_COMPARATOR|Laryngoscopy sequence 1|Macintosh laryngoscopy Storz C-MAC, standard blade Storz C-MAC, D-BLADE
62309164|NCT02167477|ACTIVE_COMPARATOR|Laryngoscopy sequence 2|Macintosh Storz C-MAC, D-BLADE Storz C-MAC, standard blade
61920801|NCT01247181|ACTIVE_COMPARATOR|No Mobile phone text message|Usual care provided at clinic
62309165|NCT01586663|EXPERIMENTAL|Experimental Group|Splint group
62309166|NCT01586663|ACTIVE_COMPARATOR|Control Group|Drug treatment
62309167|NCT04214795||Infants born after a complete course of antenatal steroids.|Preterm Infants born with less than 32 w GA whose mothers had received a complete course (two doses of celestone in the period between 24 hours and 7 days before delivery.
62679745|NCT01725308|EXPERIMENTAL|FK949E 150 mg / FK949E|After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
62120837|NCT05575869|EXPERIMENTAL|Experimental group: Access to online PRONEtect educational material|A website with educational material (simulation video, protocol, checklist).
62120838|NCT05575869|ACTIVE_COMPARATOR|Control group: Classic one-hour lecture|Didactive presentation by the usual nursing school lecturer.
62309168|NCT04214795||Infants born without a complete course of antenatal steroids|Preterm Infants born with less than 32 w GA whose mothers did not received any dose of celestone or an uncompleted course (less than 24 hours or more than 7 days from delivery).
62120839|NCT03220425|EXPERIMENTAL|Insulin detemir|
62120840|NCT03220425|ACTIVE_COMPARATOR|NPH insulin|
62120841|NCT04202393|EXPERIMENTAL|Integrated Treatment Adherence Program (ITAP)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
62120842|NCT04202393|ACTIVE_COMPARATOR|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
62120843|NCT05261568|EXPERIMENTAL|experimental group|"The first application is carried out by a researcher close to the polyclinic with care and demonstration.~The application will be suggested by hanging it from side to side in sitting position. They will be informed about the same application conditions in their own practice at home.~The program, which will last for 6 weeks, will continue from the home environment after a video surveillance observed by the beneficiary.~Periods of entry and exit times thanks to the mobile program. It will be done over the phone by the people who will come for 6 weeks. history book, lack of tools, etc. a website will be searched. Adhering to application products through study. A total of 42 sessions for 6 weeks, 7 days a week. About 30min. It is used to benefit from training to benefit from sustained progression. Apart from that, he can enjoy wearing it by dressing casually and casually."
62120844|NCT05261568|NO_INTERVENTION|control gruop|"The control group did not receive any intervention other than their own treatment during the study.~will not be applied. Progressive relaxation exercise application to the individuals included in the control group personal information form, Pittsburgh sleep quality index, fatigue severity scale will be applied as test-post-test."
62120845|NCT03737097|EXPERIMENTAL|Online Spaced Education|The intervention cohort will participate in an online spaced education on fall prevention education developed for patients with multiple sclerosis.
62120846|NCT03737097|ACTIVE_COMPARATOR|Brochure Education|The control cohort will receive the fall prevention education in bolus through a Brochure developed by the National Multiple Sclerosis Society. The brochure was translated to portuguese and will be used in the study with authorization of the Society.
62120847|NCT05571722|ACTIVE_COMPARATOR|Control group: Vancomycin|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
62120848|NCT05571722|EXPERIMENTAL|Experimental group: linezolid|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
62120849|NCT03197246|EXPERIMENTAL|IVECG and chest X-ray|The patients in this group will be examined with perioperative IVECG for PICC tip placement, as well as standard postoperative chest X-ray.
62120850|NCT03197246|ACTIVE_COMPARATOR|Standard|Standard method, PICC tip placement confirmed by postoperative chest X-ray .
62495900|NCT02473055|EXPERIMENTAL|Kangaroo care|kangaroo Care was skin-to-skin, chest-to-chest placement of preterm infant wearing only a diaper placed up against mother's chest and covered in one receiving blanket folded into fourth
62495901|NCT02473055|NO_INTERVENTION|control|control infants remained prone in an incubator wearing only diaper
62495902|NCT01581892|EXPERIMENTAL|Bone marrow stem cells|Bone marrow is obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for mixing with osteogenic matrix.
62495903|NCT05311150|ACTIVE_COMPARATOR|Narrow band imaging bronchoscopy|The narrow band imaging mode uses two narrow bands of light with wavelengths of 390-445 nm and 530-550 nm.
62495904|NCT05311150|ACTIVE_COMPARATOR|White light bronchoscopy|The white light bronchoscopy mode uses the entire range of white light wavelengths, 400-700 nm.
62495905|NCT05642949|EXPERIMENTAL|Dose Escalation - All Participants|All participants enrolled in the dose escalation part.
62495906|NCT05642949|EXPERIMENTAL|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
62495907|NCT02789839|EXPERIMENTAL|Healthy volunteer|Blood test Medullar test
62309169|NCT03671369||Cervarix Group|The study group comprised of 9-25 year-old male and female subjects who were administered with 3 doses of Cervarix vaccine, according to a 0, 1, and 6 months schedule, as per locally approved prescribing information (PI) in Korea. The 9-14 years old subjects were vaccinated with 2 doses, according to a 0 and 6-12 months schedule. In the 2-dose schedule, if the second dose was administered before 5 months after the first dose, the third dose vaccination was required. In the 3 doses schedule, if the vaccination schedule required flexibility, the second dose was administered between 1 and 2.5 months and the third dose was administered between 5 and 12 months after the first dose.
62309170|NCT02486068|EXPERIMENTAL|ABSORB scaffold|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with ABSORB scaffold.
62475673|NCT03853616|EXPERIMENTAL|Phase I: DL 1: 5x10e5 MB-CART19.1 cells|Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
62475674|NCT03853616|EXPERIMENTAL|Phase I: DL 2: 1x10e6 MB-CART19.1 cells|Dose evaluation will start in Cohort 3 with Dose Level 2, sparing Dose Level 1. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
62475675|NCT03853616|EXPERIMENTAL|Phase I: DL 3: 3x10e6 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.
62120851|NCT06509841|OTHER|Conventional rehabilitation treatment group|Adopting conventional rehabilitation training methods for TSCI patients, including: ① posture training; ②Joint rehabilitation training; ③Breathing training; ④Muscle strength training, 7 times a week, with continuous treatment for 4 weeks.
62120852|NCT06509841|EXPERIMENTAL|Acupuncture treatment rehabilitation group|Routine rehabilitation treatment combined with acupuncture and moxibustion treatment, the acupuncture measures taken are mainly Dumai points. Once a day. 5 times a week, continuous treatment for 4 weeks.
62120853|NCT00971022||Low-income Populations|
62120854|NCT05625334|EXPERIMENTAL|Arm 1: I-ASA 100mg, then C-ASA 162mg tablet|"Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.~Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA)."
62120855|NCT05625334|EXPERIMENTAL|Arm 2: C-ASA 162mg tablet, then I-ASA 100mg|"Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA).~Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI."
62120856|NCT03919292|EXPERIMENTAL|Neratinib + Divalproex Sodium - Dose Escalation Cohort|Neratinib by mouth (PO) once daily + Divalproex Sodium (Valproate) by mouth (PO) twice daily on days 1-28 of each course.
62120857|NCT03919292|EXPERIMENTAL|Colon|Colon Cancer (RAS-mutated) - Phase II dose expansion at recommended phase II dose (RP2D)
62120858|NCT03919292|EXPERIMENTAL|Glioblastoma (GBM)|Glioblastoma with a RAS-mutation or EGFR alteration at RP2D
62120859|NCT03919292|EXPERIMENTAL|Ocular Melanoma (OM)|Phase II dose expansion at RP2D
62120860|NCT03919292|EXPERIMENTAL|Other Cancer|"Other Cancer (RAS-mutated) at RP2D"
62309171|NCT02486068|ACTIVE_COMPARATOR|Xience|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with Xience Prime.
62309172|NCT01652196|EXPERIMENTAL|Aflibercept (combination chemotherapy)|Patients receive aflibercept and fluorouracil and then continuously over 46 hours on days 1 and 15.If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted. Correlative Studies are required to be available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.DCE MRI (dynamic contrast-enhanced magnetic resonance imaging)images at weeks 0, and after 8 weeks +/- 1 week of treatment(after Cycle 2). 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG).FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers,including colorectal cancer (99-102).
62120861|NCT03919292|EXPERIMENTAL|Pancreatic Cancer|RAS-mutated pancreatic cancer at RP2D
62120862|NCT02894242|EXPERIMENTAL|F&P Deimos Nasal Pillows Mask|Participants to use nasal pillows mask in-home for 2 weeks.
62120863|NCT01742481|EXPERIMENTAL|Education and empowerment program|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
62120864|NCT01742481|PLACEBO_COMPARATOR|self-guided empowerment and education|participants have information packet but receive no individualized support or assistance
62120865|NCT05394896|EXPERIMENTAL|HPI group|Conventional therapy and monitoring with ACUMEN sensor (Edwards Lifesciences, Irvine, USA) and Hemosphere platform (Edwards Lifesciences, Irvine, USA) of invasive blood pressure. Strategy to prevent hypotension based on HPI index, Eadyn and dP/dTmax.
62309173|NCT01731288||vulvodynia|Women with vulvodynia
62309174|NCT01731288||control|Women without vulvar pain
62309175|NCT01979510|EXPERIMENTAL|MK-0663B|MK-0663B (etoricoxib 90 mg immediate release \[IR\]/tizanidine 6 mg modified release \[MR\]) capsules once daily for 8 days.
62309176|NCT01979510|EXPERIMENTAL|DOLOCAM PLUS®|DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
62309177|NCT00971321|EXPERIMENTAL|GSK 2340272A F1 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 1 (F1) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (\<) 12 months at study entry.
62309178|NCT00971321|EXPERIMENTAL|GSK 2340272A F2 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 2 (F2) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (\<) 12 months at study entry.
62309179|NCT03205969|EXPERIMENTAL|Functional mobile game|Functional mobile game for chemotherapy side effect education
62309180|NCT06296810||PD|Subjects with PD who have an implanted Medtronic DBS system with a Percept IPG.
62120866|NCT05394896|ACTIVE_COMPARATOR|Control group|Conventional therapy according to standard monitoring in the operating room which includes invasive blood pressure monitoring.
62309181|NCT06207344|ACTIVE_COMPARATOR|Dexmedetomidine and propofol|After anesthesia induction, dexmedetomidine was infused intravenously at 1 μg/kg within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Propofol was infused intravenously at 4-12mg/kg/h to maintain the depth of anesthesia (patient state index between 25-50 monitored by Masimo SedLine).
62309182|NCT06207344|EXPERIMENTAL|Dexmedetomidine and desflurane|After anesthesia induction, dexmedetomidine was infused intravenously at 1 μg/kg within 15 min, and then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was used to maintain the depth of anesthesia (patient state index between 25-50 monitored by Masimo SedLine).
62475676|NCT03853616|EXPERIMENTAL|Phase II - Recommended dose MB-CART19.1|Phase II will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively.
62475677|NCT04378621|EXPERIMENTAL|Pharmacological anti-inflammatory treatment|Use of anti-rheumatic treatment with TNF-α inhibitor (subcutaneous injection given once or twice a week) or JAK inhibitor (per oral tablet once or twice a day)
62475678|NCT04378621|EXPERIMENTAL|Physical hand training|Physical hand training 10 min twice daily while on stable treatment
62475679|NCT01926119|EXPERIMENTAL|TMS Intervention - 5 days|Application of Transcranial Magnetic Stimulation (TMS) once per day over 5 days.
62475680|NCT00477594|EXPERIMENTAL|Mipomersen 200 mg per week|Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
62475681|NCT00477594|EXPERIMENTAL|Mipomersen 200 mg every other week|Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
62679746|NCT01725308|EXPERIMENTAL|FK949E 300 mg / FK949E|After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
62679747|NCT04080232|EXPERIMENTAL|Lung MRI|lung MRI concordance as compared to chest CT-scan for the description of morphological abnormalities necessary for the diagnosis of BOS after HSCT. It will be evaluated using lung MRI performed after inclusion (D0) using a standardized procedure
62679748|NCT05107934|EXPERIMENTAL|RPH-104 80 mg|Patients will receive RPH-104 dose 160 mg subcutaneously on Day 0, and 80 mg on Day 7, Day 14 and thereafter once in two weeks.
62679749|NCT05107934|PLACEBO_COMPARATOR|Placebo|Patients (who achieved clinical response defined above by the randomized withdrawal baseline) will receive placebo subcutaneously once every 2 weeks.
62679750|NCT01698905|EXPERIMENTAL|Nilotinib|Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening
62679751|NCT05803551|EXPERIMENTAL|Ketamine Group|Adult patients who have been in the Mayo Clinic Florida ICU for one week with moderate or severe depression will receive intravenous (IV) ketamine
62679752|NCT05803551|PLACEBO_COMPARATOR|Placebo Group|Adult patients who have been in the Mayo Clinic Florida ICU for one week with moderate or severe depression will receive intravenous (IV) placebo
61920802|NCT01046760||Rolandic Epilepsy|Patients older than seven years old with clinical and electroencephalographic diagnosis of Rolandic Epilepsy
61920803|NCT02393586|EXPERIMENTAL|Faropenem/augmentin|Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
61920804|NCT02393586|EXPERIMENTAL|Rifampicin/faropenem/augmentin|Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
61920805|NCT02393586|EXPERIMENTAL|Rifampicin|Rifampicin 10mg/kg
62120867|NCT03456336|ACTIVE_COMPARATOR|Active Treatment Group|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other.
62309183|NCT01815567||controlled hypertension|hypertension with medication controlled
62309184|NCT01815567||uncontrolled hypertension|non-controlled hypertension
62309185|NCT01815567||hypertensive urgency|hypertensive urgency no previous history or antihypertensives
62309186|NCT01815567||asymptomatic normotensive|asymptomatic normotensive control group
62309187|NCT03778229|EXPERIMENTAL|osimertinib + savolitinib|osimertinib + savolitinib
62309188|NCT03778229|PLACEBO_COMPARATOR|placebo + savolitinib|placebo + savolitinib
62679753|NCT04867954||Healthy volunteers|7 healthy participants will be recruited.
62679754|NCT04867954||Patients with small, low-risk GEV|Patients with small, low-risk Gastroesophageal varices (GEV) will be recruited.
62679755|NCT04867954||Patients with large, high-risk GEV|Patients with large, high-risk Gastroesophageal varices (GEV) will be recruited.
61920806|NCT03867409|EXPERIMENTAL|Concordant virtual human|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
62679756|NCT04867954||Patients scheduled for screening or surveillance esophagogastroduodenoscopy (EGD)|"100 patients diagnosed with cirrhosis and scheduled for screening or surveillance esophagogastroduodenoscopy (EGD) procedure will be recruited. Participants will complete a single research visit, lasting approximately 2 hours, that will include the following procedures:~* Participants will fast for 12 hours prior to arriving.~* An IV will be placed and a blood sample collected (\~11 mL, if necessary).~* All participants will undergo research MRI lasting approximately 1.5 hours"
62679757|NCT04867954||Obese patients|20 obese patients will be recruited
62679758|NCT02596984|EXPERIMENTAL|caspofungin|Caspofungin will be administered according to the international recommendation.
62679759|NCT05269940|EXPERIMENTAL|ZX-101A Dose Level A|ZX-101A administered orally at level A once daily
62475682|NCT02691130|EXPERIMENTAL|A: M-001 0.5mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 0.5mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
62679760|NCT05269940|EXPERIMENTAL|ZX-101A Dose Level B|ZX-101A administered orally at level B once daily
62679761|NCT05269940|EXPERIMENTAL|ZX-101A Dose Level C|ZX-101A administered orally at level C once daily
62679762|NCT05269940|EXPERIMENTAL|ZX-101A Dose Level D|ZX-101A administered orally at level D once daily
62679763|NCT05269940|EXPERIMENTAL|ZX-101A Dose Level E|ZX-101A administered orally at level E once daily
62679764|NCT03878069||Patients with ADA-SCID in need of ERT treatment|"All participants will receive Revcovi. For analysis purposes, there will be three groups, who differ with respect to ERT history:~* Adagen-naïve: Subjects starting on ERT for the first time~* Adagen-transitioning: Subjects switching from Adagen to Revcovi~* STP-2279-002 participants: Subjects who had taken part in an earlier Phase III trial of Revcovi (study STP-2279-002) in which they had been switched from Adagen to Revcovi. This last group differs from the Adagen-transitioning group in that they will have been on Revcovi the longest."
62679765|NCT06345118|EXPERIMENTAL|Intervention group|"The intervention group receives supervised Otago exercise program and baseline treatment for type2 diabetes mellitus:~The Otago exercise program aims to increase muscle strength and improve the patient's balance. The training duration is 24 weeks, the frequency is thrice a week, and the intensity gradually increases based on the Personal Therapist (PT) assessment.~Baseline treatment for diabetes: Recommendations according to American Diabetes Association guidelines, which include instructions to follow the diet and exercises as recommended for older type 2 diabetic patients"
61920807|NCT03867409|EXPERIMENTAL|Dis-concordant virtual human|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
62309189|NCT00853905|EXPERIMENTAL|Treatment 1(Triesence)|glaucoma surgery with 0.2cc Triesence adjunct.
62679766|NCT06345118|NO_INTERVENTION|Control group|"The control group receives the baseline treatment for type2 diabetes mellitus:~Baseline treatment for diabetes: Recommendations according to American Diabetes Association guidelines, which include instructions to follow the diet and exercises as recommended for older type 2 diabetic patients"
62679767|NCT02375802|EXPERIMENTAL|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
62679768|NCT05988931|ACTIVE_COMPARATOR|Web Program + App|Brief intervention web program (rooted in Motivational Interviewing) recommended at enrollment with parent/caregiver recommended to download and use app (with strategies to talk to youth about drinking prevention).
62679769|NCT05988931|ACTIVE_COMPARATOR|Web Program + App + Text Messages|Brief intervention web program (rooted in Motivational Interviewing) recommended at enrollment with parent/caregiver recommended to download and use app (with strategies to talk to youth about drinking prevention) plus youth receive 8 weeks of text messages.
62679770|NCT05051735|EXPERIMENTAL|Paracetamol|Paracetamol P.O. 500 mg 2 tablets four times a day for 7 days
62679771|NCT05051735|PLACEBO_COMPARATOR|Placebo|Placebo P.O. 2 tablets four times a day for 7 days
62679772|NCT05158166|EXPERIMENTAL|Administration of Daxi|Injectible daxibotulinumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) is an investigational botulinum toxin type A which has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and cervical dystonia and may offer longer-lasting results when compared with onabotulinumtoxinA. Dosage will be same number of units as prior Botox A dose.
62679773|NCT02226653|EXPERIMENTAL|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
62679774|NCT02226653|EXPERIMENTAL|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
62679775|NCT06695624|ACTIVE_COMPARATOR|group with sphenopalatine ganglion block|Sphenopalatine ganglion block will be performed for participants undergoing septoplasty.
62679776|NCT06695624|NO_INTERVENTION|group without sphenopalatine ganglion block|Sphenopalatine ganglion block will not be performed for participants undergoing septoplasty
62679777|NCT05568095|EXPERIMENTAL|Domvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice)|Participants in this arm will receive Domvanalimab and zimberelimab doses once every 4 weeks (Q4W) in addition to chemotherapy with FOLFOX (oxaliplatin, leucovorin, fluorouracil) once every 2 weeks (Q2W) or Domvanalimab and zimberelimab once every 3 weeks (Q3W) in addition to chemotherapy with CAPOX (capecitabine and oxaliplatin) Q3W.
62679778|NCT05568095|ACTIVE_COMPARATOR|Nivolumab + FOLFOX/CAPOX (PI Choice)|Participants in this arm will receive Nivolumab Q2W and FOLFOX Q2W or Nivolumab Q3W + CAPOX Q3W.
62475683|NCT02691130|EXPERIMENTAL|B: M-001 1.0mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 1.0mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
62475684|NCT02691130|PLACEBO_COMPARATOR|C: Saline & H5N1 influenza vaccine|"Biological/Vaccine: Two saline administrations followed by H5N1 influenza vaccine~Two administrations of saline followed by 3mcg Alum/H5N1 influenza vaccinated intervals of 19-23 days"
62679779|NCT05847686|EXPERIMENTAL|Treatment (psilocybin, therapy)|Patients receive psilocybin PO and participate in group and individual therapy sessions on trial.
62679780|NCT03865355||Cohort 1 / High grade Glioma|"Cohort 1:~1. Histologically confirmed high-grade glioma (grade III and grade IV (glioblastoma (GBM)))~2. Planned treatment (surgery followed by radiation therapy (RT) alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
62679781|NCT03865355||Cohort 2 / Low grade Glioma|"Cohort 2:~1. Histologically confirmed low-grade (grade I/II) glioma~2. Planned treatment either expectant monitoring or surgery followed by RT alone or Chemotherapy alone or a combination of RT/Chemotherapy"
61920808|NCT03867409|EXPERIMENTAL|Concordant text|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
62679782|NCT03865355||Cohort 3 / Conditionally healthy volunteers|"Cohort 3:~1. No oncological disease was diagnosed~2. Planned treatment (reconstructive surgery after craniofacial trauma)"
61920809|NCT03867409|EXPERIMENTAL|Dis-concordant text|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
61920810|NCT02914587|EXPERIMENTAL|ARTAS System|Implantation with the ARTAS System.
62309190|NCT00853905|ACTIVE_COMPARATOR|Treatment 2 (balanced salt solution BSS)|glaucoma surgery with balanced salt solution, the standard technique.
62475685|NCT01138540|ACTIVE_COMPARATOR|Semirecumbent position|Semirecumbent position of patients on mechanical ventilation in the bed of the ICU
61920811|NCT02914587|ACTIVE_COMPARATOR|Manual Implantation|Implantation manually.
62309191|NCT05051085|EXPERIMENTAL|"Internet-delivered treatment: SpilleFri."|"All participants receive the internet-delivered therapist-assisted 8-modules treatment program SpilleFri."
62475686|NCT01138540|EXPERIMENTAL|lateral-Trendelenburg position|lateral-Trendelenburg position of patients on mechanical ventilation in the bed of the ICU
62475687|NCT04437303|ACTIVE_COMPARATOR|Continuation of oral anticoagulants|
62679783|NCT04474158|EXPERIMENTAL|Creating Peace|Creating Peace uses a group discussion format with activities that explore race, gender, sexual identity, and social class. Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
62679784|NCT04474158|ACTIVE_COMPARATOR|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth. Participants receive a 12 session job readiness training with linkages to businesses and employment opportunities. Discussions include a wide range of topics related to career exploration and job readiness.
61920812|NCT05630300|EXPERIMENTAL|Facility-based Ag-RDT COVID-19 testing - reactive|Out-patient department patients who utilized a COVID-19 Ag-RDT professional-use test in an OPD clinical setting with reactive test result
62309192|NCT01804595|EXPERIMENTAL|Sunscreen|To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
62309193|NCT01804595|EXPERIMENTAL|Text Message Reminders|"As cues to action, this group will receive 60 cellular telephone text-messages on three random mornings per week during the month of May, June, July, August, and September when UV rays are the highest. Using an internet text-messaging service, the messages will be computer generated and sent to Operating Engineers and contain information about weather conditions and various reminders (e.g., Put on sunscreen today or Wow, it's a hot one, you know what to do!)."
62309194|NCT01804595|EXPERIMENTAL|Sunscreen and Text Message Reminders|Just as multimodal interventions such as surgery and radiation can be used to treat skin cancer, multimodal behavioral interventions may reduce sun burning and prevent skin cancer. To determine if the combination of these interventional components results in improvements above and beyond the individual parts, both sunscreen and text messaging interventions will be provided in addition to education.
62309195|NCT01804595|ACTIVE_COMPARATOR|Education|A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
62679785|NCT06305624|EXPERIMENTAL|Connections App|The Connections app is based on principles of effective care for substance use disorders, such as sustained duration, peer support, improving coping skills in high-risk situations, assertive outreach, self- monitoring, prompts, and action planning. The theoretical foundation of CHESS Health is self-determination theory, which holds that an individual's adaptive functioning can be improved if the patient feels (1) competent, (2) related to others, and (3) internally motivated rather than coerced in one's actions.
62679786|NCT06305624|NO_INTERVENTION|Treatment as Usual|
61920813|NCT05630300|EXPERIMENTAL|Facility-based Ag-RDT COVID-19 testing - non-reactive|Out-patient department patients who utilized a COVID-19 Ag-RDT professional-use test in an OPD clinical setting with non-reactive test result
61920814|NCT05630300|EXPERIMENTAL|COVID-19 Ag-RDT self-testing - agree to self-test|Participants who receive and take a COVID-19 Ag-RDT self-test (female sex workers, Boda boda drivers, household contacts)
61920815|NCT05630300|NO_INTERVENTION|COVID-19 Ag-RDT self-testing - refuse to self-test|Participants who receive but refuse to take a COVID-19 Ag-RDT self-test (female sex workers, Boda boda drivers, household contacts)
62475688|NCT04437303|ACTIVE_COMPARATOR|Interruption of oral anticoagulants|
61920816|NCT06518694|EXPERIMENTAL|Group1|Βeta-Blockers therapy will be discontinued (with tapering) while the remaining guideline-directed optimal medical therapy for HF is maintained
61920817|NCT06518694|NO_INTERVENTION|Group2|The patients will continue their usual guideline-directed optimal medical therapy for HF, including Βeta-Blockers therapy, without modification.
61920818|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
61920819|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
61920820|NCT01860846||Participants with moderate to severe Crohn's Disease|Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
61920821|NCT06192589|ACTIVE_COMPARATOR|Cannabidiol (Part 1)|Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days.
61920822|NCT06192589|PLACEBO_COMPARATOR|Placebo (Part 1)|Subjects in this arm will receive oral solution placebo twice a day for 28 days.
61920823|NCT06192589|ACTIVE_COMPARATOR|Cannabidiol and Citalopram Drug Interaction (Part 2)|Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17).
61920824|NCT06192589|ACTIVE_COMPARATOR|Cannabidiol and Morphine Drug Interaction (Part 2)|Subjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12).
61920825|NCT04403490|EXPERIMENTAL|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
62309196|NCT00222846|ACTIVE_COMPARATOR|A|Attention control
61920826|NCT04403490|ACTIVE_COMPARATOR|Conventional intervention|Conventional physical and occupational therapy
61920827|NCT00782327|EXPERIMENTAL|1|Losartan
61920828|NCT00782327|PLACEBO_COMPARATOR|2|Placebo
61920829|NCT00797342|OTHER|first of three dosing cohorts|
61920830|NCT00797342|OTHER|second of three dosing cohorts|
61920831|NCT00797342|OTHER|third of three dosing cohorts|
61920832|NCT02272387|ACTIVE_COMPARATOR|Vitamin D3 (cholecalciferol) treatment|50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
62679787|NCT04031963||No treatment|Those with colon cancer and with adenomatous polyp and those without a previously mentioned condition.
62679788|NCT04834388|EXPERIMENTAL|Anakinra High dose|500mg i.v. loading dose, followed by continuous iv infusion with 2mg/kg/h over 3 days
61920833|NCT02272387|PLACEBO_COMPARATOR|Vitamin D placebo|Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)
61920834|NCT02099812||Obese|Obese individuals
61920835|NCT02099812||Non-obese|Non-obese individuals
61920836|NCT00156702|ACTIVE_COMPARATOR|1|
61920837|NCT00156702|NO_INTERVENTION|2|
61920838|NCT01705782|NO_INTERVENTION|Saline|Only saline is given.
61920839|NCT01705782|PLACEBO_COMPARATOR|+ Saline|Endotoxin is given + Placebo (Saline)
61920840|NCT01705782|ACTIVE_COMPARATOR|+ amino acids|Endotoxin is given + amino acids (intravenously)
61920841|NCT02633618|EXPERIMENTAL|Analgecine|3ml, 2 times per day, continuous infusion for two weeks.
61920842|NCT02633618|ACTIVE_COMPARATOR|Neurotropin|3ml, 2 times per day, continuous infusion for two weeks.
61920843|NCT04782960|ACTIVE_COMPARATOR|20 patients receive Subconjunctival bupivacaine of the end of the surgery|20 patients receive Subconjunctival bupivacaine in the end of operation and monitoring postoperative pain score
61920844|NCT04782960|PLACEBO_COMPARATOR|20 patients receive Subconjunctival placebo in the end of operation|20 patients receive Subconjunctival placebo in the end of operation and monitoring postoperative pain score
61920845|NCT00911742|EXPERIMENTAL|1 Tramadol Contramid Once A Day|
61920846|NCT00911742|ACTIVE_COMPARATOR|2 Zytram (R)|
61920847|NCT01285960|EXPERIMENTAL|ExAblate treatment UF V2|ExAblate MRgFUS Treatment
61920848|NCT02581540||Suspected Cardiac Chest Pain|This cohort is observed for the incidence of MACE (death, non-fatal myocardial infarction and emergency revascularisation)
62309197|NCT00222846|EXPERIMENTAL|B|Intervention
62475689|NCT05277363||Prospective cohort|Parents/caregivers of participants with SURF1 deficiency will provide information regarding diagnosis, onset of symptoms, and course of the disease and participants will be assessed prospectively over time using standardized qualitative and quantitative tools.
62679789|NCT04834388|EXPERIMENTAL|Anakinra Low dose|100mg s.c. loading dose, followed by subcutaneous administration of 100mg twice daily for 3 days.
62679790|NCT04834388|NO_INTERVENTION|Standard care|Standard care group
62679791|NCT05168566|EXPERIMENTAL|Sutetinib Maleate Arm|Sutetinib capsules monotherapy
62679792|NCT05101798|EXPERIMENTAL|5-aminolevulinic acid hydrochloride (Gleolan®)|Gleolan® is available in colorless glass vials containing 1.5 g 5-aminolevulinic acid hydrochloride (Gleolan®) Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW).
61920849|NCT02530567|EXPERIMENTAL|Intervention|"The measurement of portosystemic pressure gradient will be performed before liver biopsy.~Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.~The MRI machine used is the Siemens 3T."
62120868|NCT03456336|ACTIVE_COMPARATOR|Expectant Management Group|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
62120869|NCT02569866|ACTIVE_COMPARATOR|Antibiotics Group|Capsules containing cephalexin/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
62120870|NCT02569866|PLACEBO_COMPARATOR|Placebo Group|Capsules containing placebo/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
62120871|NCT05594576|EXPERIMENTAL|ENDOCUFF VISION® Endoscopic Cap coupled with GI GENIUS™ Artificial Intelligence (AI)|
62120872|NCT05594576|ACTIVE_COMPARATOR|GI GENIUS™ Artificial Intelligence (AI) alone|
62120873|NCT05594576|ACTIVE_COMPARATOR|ENDOCUFF VISION® endoscopic cap alone|
62120874|NCT06076980|PLACEBO_COMPARATOR|Placebo group|placebo group (100 ml normal saline over 15 minutes)
62120875|NCT06076980|EXPERIMENTAL|bolus group|bolus group (1000mg/100 ml paracetamol over 15 minutes)
62309198|NCT04713345|EXPERIMENTAL|Experimental group|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
62309199|NCT04713345|SHAM_COMPARATOR|Control group|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
62309200|NCT03453086|ACTIVE_COMPARATOR|Group I:|These patients will receive single ipsilateral Ultrasound TPVB which performed with the patient in the sitting position at the level of the T4 with the probe in a vertical position 2.5-3 cm lateral to the midline. The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes which visualized with the superior costo-transverse ligament and the pleura visible in between . After this, 15-20 cc of bupivacaine 0.25% will be injected
62309201|NCT03453086|ACTIVE_COMPARATOR|Group II :|These patients will receive serratus anterior plane block. The block will be performed while the patient is in the supine position by using a linear Ultrasound probe of high frequency (6-13 MHz) after sheathing. The probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted inferiorly and laterally, until the 5th rib is identified in the midaxillary line. The latissimus dorsi (superficial and posterior) , teres major (superior) and serratus muscles (deep and inferior) will be then easily identifiable by U/S overlying the fifth rib.
62309202|NCT05491642|EXPERIMENTAL|Up-titration Scheme 1|Participants will receive 12 days treatment in total.
62309203|NCT05491642|EXPERIMENTAL|Up-titration Scheme 2|Participants will receive 12 days treatment in total.
62309204|NCT05491642|EXPERIMENTAL|Up-titration Scheme 3|Participants will receive 12 days treatment in total.
62679793|NCT02225938||Intensive care survivors|Patients surviving an admission to an intensive care unit
62679794|NCT06321393|EXPERIMENTAL|Telerehabilitation-Based group|A 7-week core stabilization exercise with abdominal drawing-in maneuver technique consist of 2 stages including the first stage (week 1-2) and the second stage (week 3-7) consisting of exercise program for 20-min sessions, with 3 sessions per week for 7 weeks. These exercise program will be provided to the participants via a weekly videocall with the main researcher as a telerehabilitation program.
62679795|NCT06321393|ACTIVE_COMPARATOR|Clinic-Based group|The control group or clinic-base group will be provided the 7-week core stabilization exercise with abdominal drawing-in maneuver technique, the same as the experimental group, but control groups received the exercise program at the clinic according to the usual methods. At the first session of each week, an appointment will be set, and then the specific exercise for each week will be delivered and trained by the main researcher at the clinic. After completing weekly training, participants will perform their exercise routine as part of their daily home program.
62679796|NCT01536769||Parkinson patients|Parkinson patients, symptom onset \> 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases
61920850|NCT03961074||Exposure group|Chinese women with iron deficiency anemia (IDA) during pregnancy.
62120876|NCT06076980|EXPERIMENTAL|Extended infusion group|Extended infusion (1000mg/100 ml paracetamol over 3 hours)
62120877|NCT03581357|ACTIVE_COMPARATOR|Control/Waitlist (Anxiety Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
62120878|NCT03581357|ACTIVE_COMPARATOR|Mindfulness App (Anxiety Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
62679797|NCT01536769||Control subjects|No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases
62679798|NCT04522375|EXPERIMENTAL|FP-045|The study will enroll a total of 6 young adult/adolescent patients progressing through three dose levels, followed by a minimum of 8 and up to 12 pediatric patients progressing through up to three dose levels.
62679799|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
62679800|NCT04589988|EXPERIMENTAL|REBIL- Intervention arm|Participants in this arm will receive the Removing Environmental Barriers to Independent Living (REBIL) intervention.
62679801|NCT04589988|OTHER|Waitlist Attentional control|Participants in this arm will receive life interview visits provided by a trained occupational therapist (OT) or OT student remotely for an equivalent amount of time to the treatment group. The waitlist control group will be offered the REBIL intervention after the 6-month follow-up is completed.
62679802|NCT06694597|EXPERIMENTAL|Astragalus membranaceus|
62679803|NCT06694597|NO_INTERVENTION|Routine treatment|
62679804|NCT06687694||Participants with psychosis symptoms|
62679805|NCT06687694||Control Participants|
62679806|NCT05127785||Medical Management|Patients deemed not candidates for advanced heart failure interventions.
62679807|NCT05127785||Left Ventricular Assist Device (LVAD)|Recipients of a left ventricular assist device
62679808|NCT05127785||Heart Transplant|Recipients of a heart transplant.
62309205|NCT06641765|NO_INTERVENTION|Control group (Group 1)|"Will undergo standard glycaemic monitoring (HbA1c and finger-prick glucose) along with 10 days double-blinded CGM sessions scheduled at months 0, 3, 6, and 9.~Glucose-lowering treatment is adjusted by an endocrinologist or a diabetes nurse at months 0, 3, and 6.~CGM data will be double-blinded, and treatment adjustments will be based on usual monitoring of HbA1c and finger-prick glucose."
62495908|NCT05245955|EXPERIMENTAL|Robotic assessment of sensory hand function|This arm involves a group of persons with Parkinson's disease and an age-matched control group. Both groups undergo the assessments of kinaesthesia and haptic perception of the hand implemented on the ReHapticKnob.
62495909|NCT05123885||Experimental:|Adult patients who benefited, between the start of 2015 and January 1, 2021, from a LifeVest after a myocardial infarction, followed by the implantation of an ICD before March 1, 2021.
62679809|NCT03924869|EXPERIMENTAL|SBRT+Pembolizumab|Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks PLUS pembrolizumab 200 mg via intravenous (IV) infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
62679810|NCT03924869|PLACEBO_COMPARATOR|SBRT+Placebo|Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gy total) over approximately 2 weeks PLUS placebo (normal saline solution) via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
62679811|NCT01694186|SHAM_COMPARATOR|sham injection|sham injection
62679812|NCT01694186|EXPERIMENTAL|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
62679813|NCT06107686|EXPERIMENTAL|Corhort A|YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic NSCLC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
62679814|NCT06107686|EXPERIMENTAL|Corhort B|YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic BC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
62679815|NCT06107686|EXPERIMENTAL|Corhort C|YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic HNSCC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
61920851|NCT03961074||Control group|Chinese women without iron deficiency anemia (IDA) during pregnancy.
61920852|NCT03064581|EXPERIMENTAL|Intervention|Gender-specific culturally tailored social-support informed educational intervention session.
62495910|NCT00967395|EXPERIMENTAL|Healing|patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject.
62495911|NCT00967395|SHAM_COMPARATOR|Sham healing|Same design of room as with the healing, while in this case a student is behind the screen
62679816|NCT06107686|EXPERIMENTAL|Corhort D|YL202 is provided as the lyophilized powder, 200 mg/vial. Other locally advanced cancer patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
62679817|NCT03862053|ACTIVE_COMPARATOR|Manuka honey eyedrops|optimel manuka eyedrops 10 ml used as directed in a CAC (Conjunctival allergen challenge) study
62679818|NCT03862053|PLACEBO_COMPARATOR|Normal saline 0.9% eyedrops|sterile normal saline eyedrops used as directed in a CAC (conjunctival allergen challenge) study
62679819|NCT03615599||Seventh-day Adventists|This is a prospective cohort study of 96,000 members of the Seventh-day Adventists Church in the United States and Canada age 30 and older at the time of enrollment who are proficient in English language.
62679820|NCT02100033|EXPERIMENTAL|acupuncture|acupuncture manipulation
61920853|NCT03064581|NO_INTERVENTION|Control|Usual care with delayed intervention at the end of study.
62679821|NCT06685913|EXPERIMENTAL|Ketone supplementation|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com)
62679822|NCT06685913|PLACEBO_COMPARATOR|Placebo|Placebo with bitter agent to flavour match
62679823|NCT05546385|ACTIVE_COMPARATOR|Active device|
62679824|NCT05546385|PLACEBO_COMPARATOR|Sham device|
62679825|NCT04718896|EXPERIMENTAL|Bimekizumab Dose A|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
62679826|NCT04718896|EXPERIMENTAL|Bimekizumab Dose B|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
62679827|NCT06135012|EXPERIMENTAL|Transection with CUSA|Transection of pancreatic tissue using cavitron ultrasonic surgical aspirator (CUSA) and using metal clips for closing small intraparenchymal blood vessels and pancreatic branch ducts.
62679828|NCT06135012|SHAM_COMPARATOR|Transection with scalpel/stapler|Standard transection of pancreatic tissue with a surgical scalpel without selective closure of small blood vessels and branch pancreatic ducts (in pancreaticoduodenectomy).
62679829|NCT05920616|OTHER|Hospitalized|Participants who were hospitalized due to their COVID-19 illness.
62679830|NCT05920616|OTHER|Non-Hospitalized|Participants who had COVID-19 but did not require hospitalization secondary to their illness.
62679831|NCT02142803|EXPERIMENTAL|Treatment (TORC1/2 inhibitor INK128, bevacizumab)|Patients receive TORC1/2 inhibitor INK128 PO QD on days 1-28 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62679832|NCT05882214|PLACEBO_COMPARATOR|maltodextrin group|4 capsule with 1000mg ''maltodextrin''
62679833|NCT05882214|EXPERIMENTAL|β-nicotinamide mononucleotide group|4 capsule with 1000mg ''β-nicotinamide mononucleotide''
62120879|NCT03581357|ACTIVE_COMPARATOR|Control/Waitlist (Neuropathy Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
62120880|NCT03581357|ACTIVE_COMPARATOR|Mindfulness App (Neuropathy Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
62120881|NCT02219178|EXPERIMENTAL|RsqVD|Oral lenalidomide 25mg days 1 - 14 of 21 day schedule Subcutaneous bortezomib 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule Oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
62120882|NCT06461624|EXPERIMENTAL|GPC3 CAR-T (CBG166)|
62120883|NCT03950869|EXPERIMENTAL|Negative Expectations|Expectations on the severity and frequency of intrusions are increased while expectations on the controllability of intrusions are decreased.
62309206|NCT06641765|ACTIVE_COMPARATOR|Intermittent CGM (Group 2)|"Will have intermittent access to 10 days of open CGM scheduled at months 0, 3, 6 along with double-blinded CGM at month 9.~Glucose-lowering treatment is adjusted by an endocrinologist or a diabetes nurse at months 0, 3, and 6.~The objective is to adjust their glucose-lowering treatment to ensure patients spend less than 1% of their time with glucose levels below 3.9 mmol/L and more than 60% of the time within the target range (3.9 to 10.0 mmol/L)."
62679834|NCT04641975|EXPERIMENTAL|Mirabegron (5 to <12 Years)|Participants aged 5 to \< 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg \[PED25\]) on day 1. Participants with a body weight ≥ 35 kilogram (kg) received tablet and participants with a body weight\< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the pediatric equivalent dose of 50 mg \[PED50\] based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
62679835|NCT04641975|PLACEBO_COMPARATOR|Placebo (5 to <12 Years)|Participants aged 5 to \< 12 years received placebo matched to mirabegron orally once daily based on weight PED25 on day 1. Participants with a body weight ≥ 35 kg received tablet and participants with a body weight\< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the PED50 based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
62120884|NCT03950869|EXPERIMENTAL|Positive Expectations|Expectations on the severity and frequency of intrusions are decreased while expectations on the controllability of intrusions are increased.
62120885|NCT03950869|NO_INTERVENTION|No Expectation Manipulation|Expectations on the severity and frequency of intrusions and on the controllability are neither increased nor decreased.
62120886|NCT04287114|EXPERIMENTAL|Healthy young men and women|Single group consisting of 10 men and 10 women
62120887|NCT04997746||educational pharmaceutical guidelines|Qualified listening of participants; General pharmaceutical educational guidelines on the use of medicines; Manufacture and supply of medicine organizer boxes.
62120888|NCT04997746||Nursing Educational Guidelines|"Nursing educational guidelines; Qualified listening to participants to resolve doubts related to their comorbidities and aging, bringing comfort in relation to their anxieties.~Nursing interventions will occur through verbal educational guidelines given individually and according to the reality of each participant assessed by the research, based on the nursing diagnoses obtained from the North American Nursing Diagnosis Association - NANDA-I (definitions and classification 2018- 2020) 11th edition."
62309207|NCT06641765|ACTIVE_COMPARATOR|Continuous CGM (Group 3)|"Will have continuous access to open CGM throughout the entire duration of the study from month 0-9.~Glucose-lowering treatment is adjusted by an endocrinologist or a diabetes nurse at months 0, 3, and 6.~The objective is to adjust their glucose-lowering treatment to ensure patients spend less than 1% of their time with glucose levels below 3.9 mmol/L and more than 60% of the time within the target range (3.9 to 10.0 mmol/L)."
62679836|NCT04641975|EXPERIMENTAL|Mirabegron (12 to <18 Years)|Participants aged 12 to \< 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight PED25 on day 1. Participants with a body weight ≥ 35 kg received tablet and participants with a body weight\< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the PED50 based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
62679837|NCT04641975|PLACEBO_COMPARATOR|Placebo (12 to <18 Years)|Participants aged 12 to \< 18 years received placebo matched to mirabegron orally once daily based on weight PED25 on day 1. Participants with a body weight ≥ 35 kg received tablet and participants with a body weight\< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the PED50 based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
62309208|NCT03306771||Metabolic syndrome risk factors|Candidates for bariatric surgery who have metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
62309209|NCT03306771||No metabolic Syndrome risk factors|Candidates for bariatric surgery who lack metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
62309210|NCT01541605|ACTIVE_COMPARATOR|methylphenidate|
62309211|NCT01541605|PLACEBO_COMPARATOR|placebo|
62309212|NCT01300377|ACTIVE_COMPARATOR|Bupivacaine / Lidocaine|Lidocaine/Bupivacaine mixture - 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
62309213|NCT01300377|ACTIVE_COMPARATOR|Lidocaine|Lidocaine - 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
62309214|NCT02795910|EXPERIMENTAL|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions
62475690|NCT00933530|EXPERIMENTAL|Cohort 1 - Dose Level A (0.03g/day)|"0.03g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.03g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.03g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
62495912|NCT00967395|NO_INTERVENTION|Control|Business as usual in the third arm
62495913|NCT06251895||mild DKA|pH \< 7.3 or serum bicarbonate \<18 mmol/L
62495914|NCT06251895||moderate DKA|pH \< 7.2 or serum bicarbonate \<10 mmol/L
62679838|NCT05977179|EXPERIMENTAL|Dietary intervention to mitigate Post-Acute COVID-19 Syndrome|During the intervention, participants will receive an individual dietary plan from a Registered Dietitian (RD) that emphasizes nutrients with high anti-inflammatory activity, which can be obtained from various foods and supplements (e.g., vitamin D, omega-3, and quality protein). Additionally, participants will actively participate in weekly dietary sessions that cover topics from 'What's On Your Plate?', specifically tailored to address the nutrition recommendations for older adults in the Dietary Guidelines for Americans 2020-2025.
62120889|NCT04997746||Nutritional Educational Guidelines|Obtaining anthropometric measurements (weight, in kilograms, height (in meters), knee height, arm and calf circumference (in centimeters) to trace the participant's nutritional profile and, subsequently, personalized and appropriate nutritional guidelines will be carried out for each situation The calculation of the Body Mass Index (BMI) must be performed by dividing the weight (W) in kilograms (kg) by the square of the height (H) in meters (m) and indicates the individual's nutritional status. The BMI for the elderly (LIPSCHITZ, 1994 apud TAVARES et al., 2015) determines underweight less than or equal to 22kg / m2, adequate or eutrophic weight between 22 and 27kg / m2 and overweight result greater than or equal to 27kg / m2 .
62120890|NCT05089084|EXPERIMENTAL|ARO-APOC3 (plozasiran)|"4 doses of plozasiran by subcutaneous (sc) injection (randomized period)~8 doses of plozasiran by sc injection (open-label period)"
62309215|NCT02795910|ACTIVE_COMPARATOR|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will receive no outreach education training.
62309216|NCT06668870|EXPERIMENTAL|Supportive Messaging|Supportive messaging is a behavioral intervention delivered to motivate patients to engage with targeted patient-generated data collection tools. Participants will be asked to complete patient-generated data. At baseline, all patients will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information. At baseline and regular intervals throughout follow up, the supportive messaging arm will receive added text messaging to engage patients and deliver personalized reminders to complete monitoring tasks.
62495915|NCT06251895||severe DKA|pH \< 7.1 or serum bicarbonate \<5 mmol/L
62120891|NCT05089084|PLACEBO_COMPARATOR|Placebo|calculated volume to match active treatment by sc injection (randomized period)
62120892|NCT01153451|NO_INTERVENTION|Usual Care|Responsible inpatient and ambulatory physicians assigned to usual care will not receive any email(s) of patients' test results generated from the notification system.
62120893|NCT01153451|OTHER|Email Notification|Responsible inpatient and ambulatory physicians will receive automated email(s) of patients' tests results finalized post-discharge generated from the notification system. Finalized results will be batched such that no provider will receive more than one email per day.
62679839|NCT05977179|OTHER|Attention Control|Participants in the control group will receive an equal amount of social attention, in terms of both dose and duration, comparable to that provided in the intervention group. Topics covered during these sessions will focus on healthy aging, including oral health, hearing loss, eyesight, and ensuring a safe environment by addressing issues such as gas leaks, fire hazards, and fall prevention. No dietary information will be included in these discussions.
62120894|NCT03956004|EXPERIMENTAL|Experimental|Full decision aid, consisting of education on osteoarthritis and treatment options, preferences and values elicitation, and personalized risk/benefit estimates based on patient's response to patient-reported outcome measures.
62120895|NCT03956004|ACTIVE_COMPARATOR|Control|Education component of the decision aid only.
62309217|NCT06668870|ACTIVE_COMPARATOR|No Supportive Messaging|Participants will be asked to complete patient-generated data. At baseline, participants will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information. Participants will not receive added text messaging to engage patients and deliver personalized reminders to complete monitoring tasks.
62679840|NCT06356350|ACTIVE_COMPARATOR|Core based exercise group|This group will be undergone core based exercises program
62120896|NCT02488980|EXPERIMENTAL|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
62120897|NCT02488980|ACTIVE_COMPARATOR|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
62120898|NCT02488980|PLACEBO_COMPARATOR|Placebo|Placebo
62120899|NCT01523158|OTHER|Immunotherapy|Open label study of changes to cellular responses following immunotherapy
62120900|NCT06203639|EXPERIMENTAL|UR Caregiver group|Participants will be asked to use the UR Caregiver app daily (e.g., at least 15 minutes/day) for 8 weeks and complete and practice one module per week. On the eighth week, participants will be asked to review one of the past modules of their choice.
62120901|NCT06203639|ACTIVE_COMPARATOR|Active control|Participants will be asked to use the app daily (e.g., at least 15 minutes/day) for an 8-week period.
62120902|NCT06203639|NO_INTERVENTION|Non-app using control|Participants in this group will not be using any apps in the study.
62120903|NCT03995446|EXPERIMENTAL|low-level laser therapy|808nM wavelength, power density of 300mW
62120904|NCT03995446|SHAM_COMPARATOR|Sham laser acupuncture treatment|received the same manner except for joule.
62120905|NCT04797416|ACTIVE_COMPARATOR|1-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 1 hour.
62120906|NCT04797416|EXPERIMENTAL|6-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 6 hours.
62679841|NCT06356350|ACTIVE_COMPARATOR|Neuromuscular exercises group|This group will be undergone conventional neuromuscular exercises program
62120907|NCT04797416|EXPERIMENTAL|12-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 12 hours.
62120908|NCT06115993|EXPERIMENTAL|Part Ia: dosing in healthy participants|SAD of 75 mg, 150 mg, 300 mg and 450 mg AHB-137 and MAD of 150 mg and 300 mg AHB-137 by subcutaneous injections within a month in healthy participants.
62120909|NCT06115993|EXPERIMENTAL|Part Ib: dosing in CHB participants|"Dose escalation cohort: MAD of 150 mg and 300 mg AHB-137 by subcutaneous injections within a month in CHB participants who are under stable NAs therapy.~Dose expansion cohort: Multiple doses of 300 mg AHB-137 by subcutaneous injections within a month in CHB participants who are under stable NAs therapy."
62120910|NCT06115993|EXPERIMENTAL|Part IIa: proof of concept|Multiple doses of 225 mg or 300 mg AHB-137 by subcutaneous injections within 24 weeks in CHB participants who are under stable NAs therapy.
62120911|NCT05925985||Propel|Patients implanted with Propel model implants
62120912|NCT05925985||Propel Mini|Patients implanted with Propel Mini model implants
62120913|NCT05925985||Propel Contour|Patients implanted with Propel Contour model implants
62120914|NCT04777968|NO_INTERVENTION|Control Group (A) : RMGI restoration without SDF and KI.|• RMGI restoration without SDF and KI.
62120915|NCT04777968|EXPERIMENTAL|Intervention Group (B): Pretreatment with SDF and KI prior to RMGI restoration.|• Pretreatment with SDF and KI prior to RMGI restoration.
62120916|NCT04762875|EXPERIMENTAL|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days
62120917|NCT00595205||Group IS|Subjects \<1 year of age with definite intussusception cases who had received Rotarix™.
62120918|NCT02864238||Pre intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2013 prior to the institution of the electronic milestone pathway
62120919|NCT02864238||post intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2014 after the electronic milestone pathway had been instituted
62309218|NCT01052285|PLACEBO_COMPARATOR|Placebo|TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
62309219|NCT01052285|ACTIVE_COMPARATOR|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
62475691|NCT00933530|EXPERIMENTAL|Cohort 2 - Dose Level B (0.1g/day)|"0.1g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.1g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.1g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
62475692|NCT00933530|EXPERIMENTAL|Cohort 3 - Dose Level C (0.25g/day)|"0.25g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.25g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.25g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
62679842|NCT04725903|EXPERIMENTAL|Treatment (proton beam therapy)|Patients undergo conventionally fractionated or hypofractionated proton beam therapy daily on Monday-Friday directed to the prostate, pelvic lymph nodes, and para-aortic lymph nodes. Patients may receive an optional high-dose rate brachytherapy boost. Androgen deprivation therapy is required but left to the discretion of the treating physician.
62679843|NCT06284798|EXPERIMENTAL|NNC0650-0013: Subcutaneous dose|Participants will receive NNC0650-0013 subcutaneously in an ascending dose manner.
62120920|NCT00851669|EXPERIMENTAL|IPT|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
62120921|NCT00851669|ACTIVE_COMPARATOR|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
62120922|NCT02434107|EXPERIMENTAL|Completion Lymphadenectomy|Completion Lymphadenectomy and monitoring afterwards
62120923|NCT02434107|EXPERIMENTAL|Clinical Monitoring (Palpation and node ultrasound)|Monitoring only
62120924|NCT00807144|EXPERIMENTAL|Prolonged-Release Tacrolimus|Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy
62120925|NCT00807144|ACTIVE_COMPARATOR|Standard-Release tacrolimus|Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy
62120926|NCT06359327|PLACEBO_COMPARATOR|placebo|
62120927|NCT06359327|ACTIVE_COMPARATOR|Pep19 2 mg|
62120928|NCT06359327|ACTIVE_COMPARATOR|Pep19 5 mg|
62120929|NCT00831272|EXPERIMENTAL|Naltrexone|50mg/day of naltrexone
62120930|NCT00831272|PLACEBO_COMPARATOR|Placebo|Placebo
62120931|NCT00616733|EXPERIMENTAL|1|
62120932|NCT00616733|EXPERIMENTAL|2|
62120933|NCT00616733|EXPERIMENTAL|3|
62309220|NCT01052285|EXPERIMENTAL|Transversus abdominis plane block|25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
62309221|NCT01613235|NO_INTERVENTION|No intervention|No induced hypertension (reference group)
62120934|NCT03615495||Flourish device|The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients.
62309222|NCT01613235|ACTIVE_COMPARATOR|Induced hypertension|Patients who are randomised to this arm will have their blood pressure raised with vasopressors and fluids. Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
62309223|NCT00609271|EXPERIMENTAL|1|low carbohydrate diet
62309224|NCT00609271|ACTIVE_COMPARATOR|2|low fat diet
62495916|NCT02261181|EXPERIMENTAL|XONRID|"Patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients.~Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines. The use of other topical medications for the treatment of dermatitis will be not permitted during the study."
62679844|NCT06284798|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to NNC0650-0013 subcutaneously.
62679845|NCT06284798|EXPERIMENTAL|NNC0650-0013: Intravenous dose|Participants will receive NNC0650-0013 in an ascending dose manner intravenously.
62679846|NCT04180423||Off-the-Shelf Total Knee Arthroplasty Patients|
62679847|NCT04180423||Conformis iTotal Total Knee Arthroplasty Patients|
62679848|NCT06694818|ACTIVE_COMPARATOR|healthy subjects not presenting insomnia symptoms|Group of healthy subjects not presenting insomnia symptoms (SCI\>16)
61920854|NCT02274701|EXPERIMENTAL|Holistic Needs Assessment|Participants (patients) complete a self-reported paper assessment that asks them to indicate whether they have any emotional, practical, financial and/or clinical concerns. The patient then takes this completed assessment into their consultation. It is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. A care plan is then written based on this assessment.
61920855|NCT02274701|NO_INTERVENTION|Control|The control group entails standard care - routine consultation between the patient and clinician.
62120935|NCT00898846||UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
62309225|NCT04727112||asthma and rhinitis|Screening of patients with upper and lower airway symptoms
62309226|NCT04727112||asthma and rhintis follow-up|same Group as screened in 2000, was followed up three years later
62309227|NCT01599351|ACTIVE_COMPARATOR|Prone|Patients were in prone position along the ERCP procedure.
62309228|NCT01599351|ACTIVE_COMPARATOR|Left lateral decubitus|Patients were in left lateral decubitus along the ERCP procedure.
62309229|NCT01300117||with extracorporeal circulation|Patients undergoing cardiac surgery with the use of an extracorporeal circulation
62309230|NCT01300117||without extracorporeal circulation|Patients undergoing cardiac surgery without the use of extracorporeal circulation (OPCAB)
62309231|NCT03339102||Participants who received Humira®|Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
62309232|NCT01893788|ACTIVE_COMPARATOR|Aliskiren|Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers.
62679849|NCT06694818|EXPERIMENTAL|Group of healthy subjects presenting insomnia symptoms|Group of healthy subjects presenting insomnia symptoms (SCI≤16)
62679850|NCT04130022|OTHER|Fasted Children|
62679851|NCT01142388|EXPERIMENTAL|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
62679852|NCT01142388|EXPERIMENTAL|Arm II (cixutumumab, paclitaxel)|Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
62679853|NCT06059248|NO_INTERVENTION|head sniffing position group|The sniffing position group used the conventional method of endotracheal intubation, the operation method was the same as that of the elevation position group, after the anterior part of the tracheal tube was inserted into the glottis, the head was still kept in the backward position, and the tube core was pulled out by another anesthesiologist (the core extubation force was less than 10N), and the endotracheal tube was inserted at the same time.
62679854|NCT06059248|EXPERIMENTAL|head elevation position group|"The operation methods of the research group are: left hand laryngoscope, inserted into the laryngeal cavity, fully exposed glottis, right hand tracheal tube from the right corner of the mouth into the mouth, direct vision to insert the anterior part of the endotracheal tube into the glottis, and then the assistant pulls out the tube core (the strength of the extubation core is less than 10N), so that the patient's jaw is adducted, the head remains in the elevation position, and the endotracheal tube is inserted at the same time"
62679855|NCT03037008|ACTIVE_COMPARATOR|continent men after RALP|perineal sonography, questionnaires, 24h pad tests
61920856|NCT00479583|ACTIVE_COMPARATOR|A|
61920857|NCT00479583|ACTIVE_COMPARATOR|B|
62120936|NCT00898846||Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
62120937|NCT00502736|EXPERIMENTAL|1|
62309233|NCT01893788|ACTIVE_COMPARATOR|Eplerenone|Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers
62309234|NCT03749642|EXPERIMENTAL|trazodone/gabapentin 2.5/25 mg|One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
62309235|NCT03749642|EXPERIMENTAL|trazodone/gabapentin 5/50 mg|One capsule, three times a day, for 8 weeks.
62309236|NCT03749642|EXPERIMENTAL|trazodone/gabapentin 10/100 mg|One capsule, three times a day, for 8 weeks.
62309237|NCT03749642|PLACEBO_COMPARATOR|placebo|Two capsules, three times a day, for 8 weeks.
62309238|NCT03749642|ACTIVE_COMPARATOR|Gabapentin|"according to the following scheduling dosage regimen:~* 100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);~* 300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);~* 400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);~* 300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2)."
62120938|NCT06677008||Disposable endoscopic linear cutter stapler|
62495917|NCT03727139||Rasagiline 1 mg|Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.
62679856|NCT03037008|ACTIVE_COMPARATOR|incontinent men after RALP|perineal sonography, questionnaires, 24h pad tests
62679857|NCT05389371|ACTIVE_COMPARATOR|Alberta Healthy Living Program|An integrated community-based chronic disease management program available to residents of Alberta.
62120939|NCT02960659|ACTIVE_COMPARATOR|Metformin|Standard release metformin (500 mg tablets) was initiated and titrated to maximum dose of metformin 1000 mg twice daily over 3 weeks and continued for 12 weeks
62120940|NCT02960659|EXPERIMENTAL|Metformin and liraglutide|Standard release metformin (500 mg tablets) and liraglutide (0.6mg) were initiated and titrated to maximum dose of metformin 1000 mg twice daily, and liraglutide 1.8 mg daily over 3 weeks and continued for 12 weeks
62120941|NCT00552097|EXPERIMENTAL|EZ/Simva|
62120942|NCT00552097|PLACEBO_COMPARATOR|Placebo/Simva|
62120943|NCT01522092|EXPERIMENTAL|escitalopram|escitalipram tablets 5mg, 10 mg and 20 mg, once a day for 12 months
62120944|NCT05300061|EXPERIMENTAL|Personal Values Intervention|Brief personal values intervention
62120945|NCT05300061|EXPERIMENTAL|Prosocial Values Intervention|Brief prosocial values intervention
62120946|NCT05300061|NO_INTERVENTION|Control|No intervention control
62120947|NCT02377726|EXPERIMENTAL|Internet self-help with support|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules. Patients will have access to Alkoholhjälpen counselor support through secure comments at every module they complete.
62120948|NCT02377726|EXPERIMENTAL|Internet self-help|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules.
62309239|NCT03502135|EXPERIMENTAL|Intranasal Anesthesia|Two intranasal sprays of tetracaine HCl and oxymetazoline HCl nasal spray anesthetic administered 4 minutes apart into the nostril corresponding to the side of the treated tooth. If inadequate anesthetic response obtained within 10 minutes, a third spray will be administered and assessed for effective anesthesia after 4 minutes.
62309240|NCT04072770|EXPERIMENTAL|Pea|Mashed potatoes meal containing pea protein isolate intrinsically labelled with 15N and 2H
62679858|NCT05389371|EXPERIMENTAL|Alberta Obesity Centre Program|Evidence-based medical management of obesity using a multidisciplinary approach.
62679859|NCT06670586|ACTIVE_COMPARATOR|conventional IVF (cIVF)|The oocytes of this arm will be fertilized using conventional In Vitro Fertilization (cIVF)
62679860|NCT06670586|ACTIVE_COMPARATOR|Intracytoplasmic Sperm Injection (ICSI)|The oocytes of this arm will be fertilized using Intracytoplasmic Sperm Injection (ICSI)
62120949|NCT02377726|ACTIVE_COMPARATOR|Information|Brief information on resources that can be accessed through the open access website Alkoholhjälpen: Information on alcohol and health, where and how to find treatment and an internet discussion forum.
62679861|NCT02924402|EXPERIMENTAL|Non-CLL B Cell Malignancies (Group NHL) Part A|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
62679862|NCT02924402|EXPERIMENTAL|CLL/SLL (Group CLL) Part A|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
62120950|NCT02190006||Polycystic ovarian syndrome|Women with polycystic ovarian syndrome undergoing ICSI
62120951|NCT05679154|EXPERIMENTAL|Team-focused Implementation|
62120952|NCT05679154|ACTIVE_COMPARATOR|Standard Implementation|
62120953|NCT02705586|EXPERIMENTAL|only one arm - open label study|2 hour video based mindfulness-based stress reduction class once a week for 10 weeks.
62120954|NCT03802032|EXPERIMENTAL|Study Group|15g of Topical Xylocaine gel
62309241|NCT04072770|ACTIVE_COMPARATOR|Casein|Mashed potatoes meal containing casein isolate intrinsically labelled with 15N and 2H
62309242|NCT03518515|EXPERIMENTAL|White potato (French fries)|Participants will be asked to consume 1 serving of French fries each day for 30 days.
62309243|NCT03518515|EXPERIMENTAL|White potato (French fries), +seasoning|Participants will be asked to consume 1 serving of French fries with added seasoning each day for 30 days.
62309244|NCT03518515|ACTIVE_COMPARATOR|Almond|Participants will be asked to consume 1 serving of almonds (calorie-matched to other arms) day for 30 days.
62309245|NCT03854487|EXPERIMENTAL|Mirror therapy|
62309246|NCT03854487|SHAM_COMPARATOR|Sham mirror|
62679863|NCT02924402|EXPERIMENTAL|Non-CLL B Cell Malignancies (Group NHL) Part B|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
62120955|NCT03802032|PLACEBO_COMPARATOR|Control group|15g of KY Jelly
62120956|NCT00237770|PLACEBO_COMPARATOR|Arm 1|Placebo control (normal saline) is employed on a separate visit during procedure.
62120957|NCT03857971|OTHER|Coronary OCT imaging of non flow-limiting lesion|Coronary OCT imaging will be performed of fractional flow reserve (FFR) negative lesions to assess plaque morphology.
62120958|NCT05859542||Group A|The group A included 18 trainees, who started the session with videolaryngoscope followed by the direct laryngoscope.
62120959|NCT05859542||Group B|The group B included 17 trainees, who started the session with the direct laryngoscope followed by the videolaryngoscope.
62309247|NCT03854487|ACTIVE_COMPARATOR|Covered mirror|
62679864|NCT02924402|EXPERIMENTAL|CLL/SLL (Group CLL) Part B|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
62679865|NCT02924402|EXPERIMENTAL|Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
62679866|NCT02924402|EXPERIMENTAL|Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion|XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
62679867|NCT06514729|EXPERIMENTAL|Group VCV+CPAP|Ventilation side volume control ventilation+continuous positive pressure ventilation on the non ventilation side
62679868|NCT06514729|EXPERIMENTAL|Group PCV+CPAP|Ventilation side pressure control ventilation+continuous positive pressure ventilation on the non ventilation side
62495918|NCT02798406|EXPERIMENTAL|DNX-2401 + pembrolizumab|Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.
62120960|NCT06064357|EXPERIMENTAL|Transverese friction massage + Conventional Physio Therapy|"Transverse friction massage: Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf muscle on both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval after that massage will be performed on next group of muscle.4 session per week lasting for 6 weeks.~Conventional Therapy:~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf muscles (10 repetitions with at least 8 seconds hold) 4 times a week lasting for 6 weeks"
62120961|NCT06064357|EXPERIMENTAL|Tissue flossing technique + Conventional Physio Therapy|"Tissue floss bands: These band will be applied on Rectus femoris, hip adductors, calf muscle and hamstring muscle of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap a few inches below and few inches above the area and then 10 Reps of rom will be actively performed by the participants and then after 10 Reps remove the band and the rest interval is 2 mint after that next group of muscle will be wrap. 4 sessions per week lasting for 6 weeks.~Conventional Therapy: Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf muscles (10 repetitions with at least 8 seconds hold) 4 times a week lasting for 6 weeks."
62120962|NCT02128607|ACTIVE_COMPARATOR|Real SNAG|A real sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
62679869|NCT06514729|EXPERIMENTAL|Group PRVC+CPAP|Ventilation side pressure regulated volume control ventilation+continuous positive pressure ventilation on the non ventilation side
62120963|NCT02128607|PLACEBO_COMPARATOR|Sham SNAG|A sham (placebo) sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
62309248|NCT05121337|EXPERIMENTAL|Dietitian-Assisted DASH groceries|Participants will order groceries sufficient to meet their caloric needs each week for 12 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions. During the remainder of the study (months 4-12), participants will be asked to apply what they learned without the provision of groceries.
62309249|NCT05121337|ACTIVE_COMPARATOR|Self-directed shopping (referent assignment)|Participants will receive a monthly stipend over a 3 month period and some basic information about healthy eating. The stipend is not restricted to foods. During the remainder of the study (months 4-12), participants will be asked to continue their typical shopping without the provision of the monthly stipend.
62120964|NCT00881842|EXPERIMENTAL|1|
62309250|NCT03127020|EXPERIMENTAL|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
62309251|NCT03928873|EXPERIMENTAL|Low energy ESWT|"Low energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks)"
62309252|NCT03928873|EXPERIMENTAL|High energy ESWT|"High energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks)"
62309253|NCT03928873|SHAM_COMPARATOR|Sham treatment|All participants will receive sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks.
62309254|NCT02226016|EXPERIMENTAL|Ptosis|Device (measurement of levator strength in patients with upper lid ptosis)
62309255|NCT01417286|EXPERIMENTAL|Radiation Therapy|Patients undergo hypofractionated accelerated radiation therapy over 11 weekdays (for 15 elapsed days) within 21-63 days after last surgery or last course of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
62309256|NCT06152601|EXPERIMENTAL|Group experimental|Patient between 12 and 18 years old with a spinal surgery for idiopathic scoliosis programmed. Immediately postoperatively, during his stay in a PACU or ICU, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position.
62309257|NCT01717846|EXPERIMENTAL|Arm 1|Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
62679870|NCT05555732|EXPERIMENTAL|Dato-DXd + Pembrolizumab + Platinum Chemotherapy|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).
62120965|NCT02412748|ACTIVE_COMPARATOR|Financial Literacy Program|"The Financial Literacy Program (FLP) attention control condition will not receive any information on fatherhood. They will participate in a nine-session financial education program, called Money Smart, which has modules that will be facilitated by a group leader that focus on banking, borrowing, checking accounts, money management, saving, establishing and repairing a credit history, using credit cards responsibly and learning about borrowing and home ownership. They will also receive a booster session 6 weeks after the final session that focuses on setting financial goals."
62120966|NCT02412748|EXPERIMENTAL|BBTF Intervention|"The Building Bridges to Fatherhood (BBTF) intervention employs the following key features: a collaborative model for working with parents; vignettes of father-child models engaged in situations typical of non-resident fathers with young children for stimulating discussion and problem-solving; group discussion format, which allows fathers to support one another and share ideas on using program principles to fit within the contexts of fatherhood; homework assignments that help fathers practice the new skills at home; weekly handouts summarizing the major points discussed each week, which can be shared with others and used to gain greater support from extended family; and a Leader's Manual that standardizes the program across groups and group leaders."
62309258|NCT01717846|OTHER|Arm 2 or group 2|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
62679871|NCT05555732|EXPERIMENTAL|Dato-DXd + Pembrolizumab|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab.
62120967|NCT00795054||allogeneic stem cell recipients|Pediatric and adult allogeneic stem cell transplant recipients and their care givers.
62120968|NCT01573130|EXPERIMENTAL|Initial treatment group|Group receives treatment.
62120969|NCT01573130|NO_INTERVENTION|Waiting list control group|The waiting list control group receives treatment after 9 weeks, before which they do weekly ratings.
62120970|NCT06395870|EXPERIMENTAL|LUCAR-G39D cells product|Each subject will be given a single-dose LUCAR-G39D cells infusion at each dose level.
62120971|NCT00839371|ACTIVE_COMPARATOR|Midazolam|i.v. midazolam titration until adequate depth of sedation
62120972|NCT00839371|ACTIVE_COMPARATOR|Propofol|i.v. propofol titration until adequate depth of sedation
62120973|NCT06673316|EXPERIMENTAL|Intervention group|Participants in the experimental group will receive a 3-hour design thinking workshop. The workshop will cover the five stages of design thinking, allowing students to apply these principles to real-world healthcare challenges in their future practice
62120974|NCT06673316|NO_INTERVENTION|Control group|will NOT receive design thinking workshop
62120975|NCT01065220|EXPERIMENTAL|hormone treatment for MtF|"* cyproterone acetate~* estradiol~* alpha-5-reductase-inhibitor"
62120976|NCT01065220|EXPERIMENTAL|hormone treatment for FtM|"* testosterone undecanoate~* lynestrenol"
62120977|NCT04577612|EXPERIMENTAL|Group 1|150 mg CBD
62120978|NCT04577612|EXPERIMENTAL|Group 2|300 mg CBD
62120979|NCT04577612|EXPERIMENTAL|Group 3|600 mg CBD
62120980|NCT04577612|PLACEBO_COMPARATOR|Group 4|Placebo MCT oil
62309259|NCT01645930|EXPERIMENTAL|Ixazomib+Lenalidomide+Dexamethasone|Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)
62495919|NCT02575456|EXPERIMENTAL|Group A|(4×10\^10vp/vial, 4 vials): 1 ml sterilization injection water per dose to dilute 2 vials (4×10\^10 vp/vial), one shot in each arm, total dose of 1.6×10\^11vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
62679872|NCT05555732|ACTIVE_COMPARATOR|Pembrolizumab + Pemetrexed + Platinum Chemotherapy|Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\^2 or carboplatin area under the curve \[AUC) 5\]).
61920858|NCT04552262|EXPERIMENTAL|BAY2327949 / Placebo|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
62120981|NCT06384547|EXPERIMENTAL|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
62120982|NCT06384547|EXPERIMENTAL|5 infusions of VRDN-001 3 mg/kg|5 infusions of VRDN-001 3 mg/kg
62120983|NCT03696771|EXPERIMENTAL|NJH395|Includes non-breast HER2-positive advanced malignancies
62120984|NCT04128319|EXPERIMENTAL|T-Guard Treatment|Patients will receive T-Guard for treatment of steroid-refractory acute GVHD.
62120985|NCT02038868|EXPERIMENTAL|ASP4901 group|After the main enrollment, patients will receive an oral dose of ASP4901 once daily for 4 weeks (double-blind treatment period).
62120986|NCT02038868|PLACEBO_COMPARATOR|Placebo group|After the main enrollment, patients will receive an oral dose of placebo once daily for 4 weeks (double-blind treatment period).
62120987|NCT02038868|ACTIVE_COMPARATOR|Tamsulosin group|After the main enrollment, patients will receive an oral dose of tamsulosin once daily for 4 weeks (double-blind treatment period).
62120988|NCT01532310||Pregnant women taking belimumab|Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
62495920|NCT02575456|EXPERIMENTAL|Group B|(4×10\^10vp/vial, 2 vials): 1 ml sterilization injection water per dose to dilute 1 vial (4×10\^10vp/vial), total dose of 8×10\^10vp, one shot in each arm. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
62679873|NCT05743140||CMD group, Non-CMD group|CMD group: participants whose CaIMR shows ≥25U. Non-CMD group: participants whose CaIMR less than 25U.
62679874|NCT05561140|EXPERIMENTAL|Voxeletor + SOC (Standard of Care)|
62679875|NCT05561140|PLACEBO_COMPARATOR|Placebo + SOC (Standard of Care)|
62309260|NCT03517722|EXPERIMENTAL|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
62679876|NCT06687824|EXPERIMENTAL|Black Tea-Extract Impregnated Sterile Gauze|
62679877|NCT06687824|ACTIVE_COMPARATOR|Colour-Blinded Sterile Gauze|
62679878|NCT06389591|EXPERIMENTAL|Arm 1: pp65 RNA-LPs (DP1) before biopsy|Randomized 1:1 to receive pp65 RNA-LPs (DP1) starting before tumor biopsy/resection. All patients will receive three pp65 RNA-LP vaccines (DP1) before receiving full dose monthly RNA-LPs (RNA loaded lipid particles, RNA-LPs, DP2).
62120989|NCT01532310||Infants|Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
62120990|NCT01622413|EXPERIMENTAL|Endscopy|
62120991|NCT01622413|ACTIVE_COMPARATOR|Microsurgery|
62120992|NCT03268577||Prevention (diet and activity tracking)|Patients complete the ASA24 about foods, cooking methods, and other aspects of diet every 2 months for up to 6 times, and complete ACT24 about activities and time reporting every 2 months for up to 6 times. Patients also complete DHQ-II questionnaires at the beginning and end of the study about the frequency and portion sizes of foods consumed over the past 12 months, provide a 7-day food checklist twice with the DHQ-II, and provide a 4-day food record twice, once every 6 months. Physical activity monitors are worn to measure movement at different intensity levels and sitting or standing periods, twice during the study with 6 months between each time they are worn.
62120993|NCT01895218|EXPERIMENTAL|Iron isomaltoside 1000 (Monofer®)|
62120994|NCT01895218|ACTIVE_COMPARATOR|Standard medical Care|
62679879|NCT06389591|EXPERIMENTAL|Arm 2: pp65 RNA-LPs (DP1) after biopsy|Randomized 1:1 to receive pp65 RNA-LPs (DP1) starting after tumor biopsy/resection. All patients will receive three pp65 RNA-LP vaccines (DP1) before receiving full dose monthly RNA-LPs (RNA loaded lipid particles, RNA-LPs, DP2).
62679880|NCT04181762|EXPERIMENTAL|secukinumab|A blinded, weekly, subcutaneous (s.c.) secukinumab 300 mg loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.
62120995|NCT05905172|EXPERIMENTAL|Hydronidone group|Patients were given three capsules of hydronidone three times a day for 5 years.
62309261|NCT03517722|EXPERIMENTAL|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
62309262|NCT04332692|EXPERIMENTAL|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~* Clinical examination focusing on congestion~* Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~* Blood sample retrieved for biological assessment and biobanking~* Telephone follow-up"
62679881|NCT04181762|PLACEBO_COMPARATOR|placebo|A blinded, weekly, subcutaneous (s.c.) matching placebo loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.
62679882|NCT06432452|EXPERIMENTAL|Bosentan|Bosentan 62.5 mg twice daily Uptitrated to 125mg twice daily if tolerated after 4 weeks Total 10 weeks
62679883|NCT06432452|PLACEBO_COMPARATOR|Placebo|Placebo 62.5 mg twice daily Uptitrated to 125mg twice daily if tolerated after 4 weeks Total 10 weeks
62679884|NCT02430610|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Uterine Cervical Neoplasms
62679885|NCT02430610|NO_INTERVENTION|Control|The patients without treatment
62679886|NCT03254641||hypogondal men|men referred for hCG stimulation test
62679887|NCT02629809|EXPERIMENTAL|Treatment (iFCG)|See Detailed Description.
62679888|NCT05001165|EXPERIMENTAL|Intervention|Patients with perceived gaps in performance measures for guideline-directed medical therapies for heart failure with reduced ejection fraction will be chart-reviewed and called impromptu to receive point of care medication titration or reintegration into routine heart failure clinic. Patients lost to follow-up may be better identified using the HFrEF panel management tools.
62120996|NCT05905172|PLACEBO_COMPARATOR|The placebo group|Patients were given three capsules of placebo three times a day for 5 years.
62120997|NCT03703856|ACTIVE_COMPARATOR|Memantine|
62120998|NCT03703856|PLACEBO_COMPARATOR|Placebo|
62120999|NCT01284907|ACTIVE_COMPARATOR|Vit D|
62121000|NCT01284907|PLACEBO_COMPARATOR|Placebo drops|
62121001|NCT02599935|EXPERIMENTAL|educational intervention and supplements|structured educational intervention and dietary supplements
62121002|NCT02599935|ACTIVE_COMPARATOR|usual interventions|Usual treatment without nutritional supplements or structured assessment
62121003|NCT04226664|ACTIVE_COMPARATOR|Intervention|Bariatric surgery will consist of laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy performed at the discretion of the surgeon and according to local standards.
62121004|NCT04226664|NO_INTERVENTION|Control|Medical Weight Management (MWM) corresponds to the standard medical practice for weight loss that is available at the local participating centre, and thus reflects the local standard of care.
62309263|NCT05460780|EXPERIMENTAL|MATTISSE TEC|Patient included receive MATTISSE TEC
62309264|NCT01533155|ACTIVE_COMPARATOR|NKTR-118/ Quinidine|One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)
62309265|NCT01533155|PLACEBO_COMPARATOR|NKTR-118/ Placebo|One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)
62475693|NCT00933530|EXPERIMENTAL|Cohort 4 - Dose Level D (0.5g/day)|"0.5g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.5g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.5g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
62495921|NCT02575456|PLACEBO_COMPARATOR|Group C|(0 vp/ vial, 2 vials):1 ml sterilization injection water per dose to dilute 1 vial, total dose of 0 vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
62679889|NCT05001165|NO_INTERVENTION|Usual Care|A control group of patients with HFrEF will receive routine primary and cardiology care as currently indicated in routine scheduled clinic grids. Patients are at the discretion of their primary care and cardiology clinicians regarding whether further HFrEF optimization is warranted. While panel management data is available to all clinicians, clinical workflows and responsibilities do not encourage the use of panel data or response to performance measurement for HFrEF.
62121005|NCT01962844|OTHER|Nutritional treatment|All patients received an individualized diet plan and balanced. The diet was calculated according to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of of total energy value
62309266|NCT01533155|ACTIVE_COMPARATOR|NKTR-118/ Quinidine/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)
62495922|NCT01633307|EXPERIMENTAL|Experimental|Intervention (Teaching program)
62495923|NCT01633307|NO_INTERVENTION|Control group|No teaching program
62495924|NCT00616096|EXPERIMENTAL|1|
62679890|NCT06688123|EXPERIMENTAL|SHR-3167 group A|
62679891|NCT06688123|EXPERIMENTAL|SHR-3167 group B|
62679892|NCT06688123|ACTIVE_COMPARATOR|Insulin glargine group|
62679893|NCT06688474||Bruxism Cohort|2 male participants with diagnosed Bruxism will wear the device for 21 days, over a 6+ hour sleep period each night.
62679894|NCT04877691|EXPERIMENTAL|Anifrolumab|Solution for injection in aPFS
62679895|NCT04877691|PLACEBO_COMPARATOR|Placebo|Solution for injection in aPFS
62679896|NCT04691492|EXPERIMENTAL|Friends-Based Motivational Interview (FMI) Group|Will participate in the Friends-Based Motivational Interview (FMI) program.
62679897|NCT04691492|NO_INTERVENTION|Wait List Control|The Wait List Control group will also be offered to participate in the Friends-Based Motivational Interview Program but at a deferred date (12 weeks later).
62679898|NCT02424786|OTHER|Intervention group|"Medication lists from the patients randomized in the intervention group will be evaluated by the research physician with the help of STOPP/START criteria.~Feedback of this screening will be given to the team responsible for patient treatment."
61920859|NCT04552262|EXPERIMENTAL|Placebo / BAY2327949|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
62121006|NCT01962844|EXPERIMENTAL|extra virgim coconut oil group|Oil from coconuts (cocos nucifera L.) contains a high proportion of medium chain fatty acids, principally the lauric acid (12:0), in proportions that range from 45 to 50%
62121007|NCT04970979||patients with coronary artery disease|patients with coronary artery disease
62309267|NCT01533155|PLACEBO_COMPARATOR|NKTR-118/ Placebo/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)
62309268|NCT03613428|EXPERIMENTAL|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
62309269|NCT00153166|EXPERIMENTAL|Patients with PAD (Including diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
62309270|NCT00153166|ACTIVE_COMPARATOR|PAD (Excluding Diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
62309271|NCT00153166|ACTIVE_COMPARATOR|Healthy Controls|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
62679899|NCT02424786|NO_INTERVENTION|Control|Patients in this arm will receive standard pharmacological treatment
62309272|NCT03811600||OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
62309273|NCT03811600||Non OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index \<15 per hour
62495925|NCT06347627|EXPERIMENTAL|Group 1 (I x S x S x F)|"Participants in Group 1 will view a message in an X (former Twitter) format composed of Individual x Safety x Storytelling x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62495926|NCT06347627|EXPERIMENTAL|Group 2 (O x S x S x F)|"Participants in Group 2 will view a message in an X (former Twitter) format composed of Organization x Safety x Storytelling x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62121008|NCT05947305|PLACEBO_COMPARATOR|Surgical Blade|A surgical blade will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
62121009|NCT05947305|EXPERIMENTAL|Mucotome|A mucotome will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
62121010|NCT05947305|EXPERIMENTAL|Diamond Bur|A diamond bur will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
62121011|NCT05947305|EXPERIMENTAL|Er:YAG Laser|A dental laser will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
61920860|NCT06206070|EXPERIMENTAL|The Hong Kong version of Westmead Feeling Program 2|The treatment group will receive the WFP2-HK program which consists of 15 school-based training sessions over 18 weeks. Three parent- and teacher-training workshops will be delivered separately and preceding each Child Module by coaches or advisors. A booster session will be conducted for the treatment group after 5 months upon completion of the training programs.
61920861|NCT06206070|NO_INTERVENTION|Waitlist Group|While the treatment group is receiving training, the waitlist group will be waiting. After 18 weeks of waiting and when the treatment group completes the training. The waitlist group will receive the same training program as that of the treatment group, but no booster session will be provided to the waitlist group.
61920862|NCT00048087|EXPERIMENTAL|Iressa + Docetaxel|
61920863|NCT01784627|NO_INTERVENTION|Treatment at Usual|Participants in this group will receive treatment as usual (TAU) from their provider, which may or may not include screening and brief advice regarding alcohol use.
61920864|NCT01784627|EXPERIMENTAL|c-ASBI|Participants in this group will receive the computerized alcohol screening and brief intervention (c-ASBI).
62121012|NCT04694885|NO_INTERVENTION|Standard of Care|The control group will receive the standard of psycho-oncological care.
61920865|NCT00461331|ACTIVE_COMPARATOR|Insulin 1|Either insulin Aspart or insulin Lispro were randomized to be insulin 1.
61920866|NCT00461331|ACTIVE_COMPARATOR|Insulin 2|Between insulin Aspart and insulin Lispro, the one that was not used as insulin 1 was then used as the second insulin for the second arm of the study.
62309274|NCT06509100|EXPERIMENTAL|Altitudes Condition|Individuals whose loved ones are experiencing first-episode psychosis (FEP) and receiving services from OASIS, SHORE, Eagle, Encompass, AEGIS, and WeCare2), STEP programs, or community services will be recruited to participate in a digital platform, Altitudes, for 6 months as part of an adjunct service to the clinic's services. Participants will have access to and encouraged to use the educational and therapeutic content as well as the moderated online community network during their time engaging with the platform. They will be asked to complete a battery of measures at baseline, 3-months, and 6 months.
62679900|NCT04747626|EXPERIMENTAL|Treatment|Implantation of a physician-modified endovascular stentgraft(s) to treat the proximal aorta in subjects with aortic disease involving multiple segments.
62679901|NCT02113813|EXPERIMENTAL|ASP8273 Dose Escalation cohort (part 1)|oral
62121013|NCT04694885|EXPERIMENTAL|Standard of Care + Structured Hypnotherapy|The intervention group will receive the standard of psycho-oncological care plus 10 hypnotherapeutic sessions every two weeks.
62679902|NCT02113813|EXPERIMENTAL|ASP8273 Response Expansion cohort (part 1)|oral
62679903|NCT02113813|EXPERIMENTAL|ASP8273 and Midazolam RP2D Expansion cohort (part 2)|oral
62121014|NCT00623792|NO_INTERVENTION|1|Usual preoperative care
62679904|NCT02113813|EXPERIMENTAL|Food Effect Fasted cohort (part 2)|oral
62121015|NCT00623792|EXPERIMENTAL|2|Preoperative Lifestyle Intervention
62121016|NCT04456218|EXPERIMENTAL|Biliary stone|Participants who meet the criteria of biliary stone enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
61920867|NCT03608423|EXPERIMENTAL|Surgical treatment|Minimally-invasive endoscopy-guided surgery or hematoma aspiration, additional to standard medical treatment.
62309275|NCT02396407|ACTIVE_COMPARATOR|Combined water, sanitation, and hygiene|Water quality, Sanitation, Handwashing
62309276|NCT02396407|NO_INTERVENTION|Non-intervention arm|None. Households will continue their usual practices.
62309277|NCT02436798||Pediatric patients|"Children \<6 months to 18 years of age receiving ondansetron for management of:~1. Post-operative nausea and vomiting~2. Chemotherapy-induced nausea and vomiting"
62475694|NCT00933530|EXPERIMENTAL|Cohort 5 - Dose Level E (1.0g/day)|"1.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 1.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 1.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
62495927|NCT06347627|EXPERIMENTAL|Group 3 (I x E x S x F)|"Participants in Group 3 will view a message in an X (former Twitter) format composed of Individual x Effectiveness x Storytelling x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62679905|NCT02113813|EXPERIMENTAL|Food Effect Fed cohort (part 2)|oral
62679906|NCT02113813|EXPERIMENTAL|Exon 20 Cohort (part 2)|oral
62679907|NCT05039632|EXPERIMENTAL|Cohort I (NBTXR3, Abscopal, Anti PD-1 / PD-L1|COHORT I: Patients receive NBTXR3 intratumorally on day 1. Patients also receive ( anti-PD-1/L-1) intravenously (IV) on day 8. Beginning day 15, patients undergo Abscopal radiation therapy over 1-2 weeks. Cycles with ( anti-PD-1/L-1) repeat every 3-6 weeks per standard of care up to 2 years in the absence of disease progression or unacceptable toxicity.
62679908|NCT05039632|EXPERIMENTAL|Cohort II (NBTXR3, RadScopal, Anti PD-1 / PD-L1|COHORT II: Patients receive NBTXR3 intratumorally on day 1. Patients also receive ( anti-PD-1/L-1) IV on day 8. Beginning day 15, patients undergo RadScopal radiation therapy over 1-2 weeks. Cycles with ( anti-PD-1/L-1)repeat every 3-6 weeks per standard of care up to 2 years in the absence of disease progression or unacceptable toxicity.
61920868|NCT03608423|NO_INTERVENTION|Standard medical management|Standard medical treatment (treatment of bloodpressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration)
61920869|NCT03960021|EXPERIMENTAL|Single arm|Each patient is treated with 2 RFA interventions.
61920870|NCT05156476|ACTIVE_COMPARATOR|Genicular nerve block-iPACK group|"Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Genicular nerve block will be performed on the the superomedial, the superolateral, the inferomedial and inferolateral genicular nerve.~Drug: a total of 30 ml of ropivacaine 0.5% (150 mg) will be used for this treatment arm."
62121017|NCT04456218|EXPERIMENTAL|Biliary stricture|Participants who meet the criteria of biliary neoplasm enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
62121018|NCT00494780|ACTIVE_COMPARATOR|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
62121019|NCT00494780|ACTIVE_COMPARATOR|Active Comparator 2|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg
62309278|NCT02436798||Female patients|"Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:~1. Hyperemesis gravidarum~2. Post-operative nausea and vomiting"
62309279|NCT00683553|EXPERIMENTAL|I5NP drug|
62309280|NCT00683553|PLACEBO_COMPARATOR|Placebo|
62309281|NCT04419415|EXPERIMENTAL|Skipping breakfast and maintain habitual physical activity|Subject will skip breakfast and maintain habitual physical activity.
62309282|NCT04419415|EXPERIMENTAL|High protein breakfast and maintain habitual physical activity|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and maintain habitual physical activity.
62309283|NCT04419415|EXPERIMENTAL|Skipping breakfast and exercising three times per week|Subject will skip breakfast and participate in organized exercise-training three times per week (and maintain habitual physical activity)
62679909|NCT06440746|EXPERIMENTAL|Arm1:OKZ 64 mg q4w|SC injections of OKZ 64 mg q4w
62679910|NCT06440746|PLACEBO_COMPARATOR|Arm2:Placebo|SC injections of Placebo q4w
62309284|NCT04419415|EXPERIMENTAL|High protein breakfast and exercising three times per week|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
62309285|NCT04939896||Compliance with rehabilitation|The patients' compliance with rehabilitation was followed up at 2, 6, 8, 12 and 24 weeks after onset, respectively
61920871|NCT05156476|ACTIVE_COMPARATOR|Femoral triangle block-iPACK group|Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0.5% (150 mg) will be used for this treatment arm
61920872|NCT05156476|ACTIVE_COMPARATOR|Local Infiltration Analgesia (LIA)|LIA (performed by surgeon) Method: Blind injection Drug: a total of 200 ml of 0.2% ropivacaine will be used (400 mg). Of this, 150 ml of ropivacaine 0.2% will be mixed with 1 mg of adrenaline.
62679911|NCT05216146|EXPERIMENTAL|Experimental|Specially designed program for physical fitness enhancement
62309286|NCT06163781|EXPERIMENTAL|Blood culture taken based on machine learning tool|
61920873|NCT00877474|EXPERIMENTAL|Arm 1|PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.
61920874|NCT04307745||Physiotherapist|
62121020|NCT02704741|EXPERIMENTAL|all subjects|"Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.~Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).~Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic."
62309287|NCT06163781|NO_INTERVENTION|Blood culture taken based on the treating physician|
62309288|NCT00108810|EXPERIMENTAL|Transdermal Ketoprofen Patch with CHADD|
62309289|NCT00108810|PLACEBO_COMPARATOR|Placebo patch and a dummy heating unit|
62309290|NCT04789824|EXPERIMENTAL|Investigation group|Eye Hygiene (warm compress, eyelid massage, and eyelid cleaning)
62309291|NCT04789824|NO_INTERVENTION|Control Group|No intervention
62309292|NCT05195359|ACTIVE_COMPARATOR|Allocation to Sleep Improvement App|Participants will be instructed to engage with the Dein Schlaf. Dein Tag. smartphone app, log their behaviors in-app, and track their sleep daily for the duration of the study (12 weeks). Participants will be instructed to start the sleep tracking device via their iOS device before lying down in bed and turning off the lights to go to sleep. In the morning, participants will turn off the sleep tracking device as soon as they wake up and decide to leave the bed. At the three time points (baseline, 6 weeks, and 12 weeks), participants will be instructed to complete online assessments on self-reported sleep quality, health perception, psychosocial factors and sleep-permissive behaviors (i.e., preventative health)
62309293|NCT05195359|NO_INTERVENTION|Allocation to Waitlist Control Group|At the three time points (baseline, 6 weeks, and 12 weeks) participants assigned to the wait-list control group will be instructed to complete online assessments on self-reported sleep quality, health perception, psychosocial factors and sleep-permissive behaviors (i.e., preventative health)
62309294|NCT06438367|EXPERIMENTAL|Experimental: TGRX-326|healthy subjects will be given 60mg/100uCi\[14C\]TGRX-326 in suspension
62309295|NCT05431686|EXPERIMENTAL|SMA visit intervention arm|SMAs will occur once every 3 months, and consist of 4-6 underserved youth with T1D and their primary diabetes caregiver
62679912|NCT05216146|ACTIVE_COMPARATOR|Control|A regular program of physical exercise
62679913|NCT06454487|EXPERIMENTAL|CR+IHG|Cardiac Rehabilitation (usual care) PLUS Isometric Hand grip training
61920875|NCT04307745||Doctor|
61920876|NCT04307745||Physical trainer|
61920877|NCT04307745||Trainer|
61920878|NCT03309046|EXPERIMENTAL|REACH Individual Session|The individual sessions intervention focuses on education, skills building, and support. It will be delivered in six sessions by telephone over three months. A Caregiver Notebook will include comprehensive materials for all sessions and topics. Treatment fidelity will be monitored and ensured through assessment of intervention delivery, receipt, and enactment. The intervention is targeted and individualized to the concerns of the specific caregiver and care recipient through a risk assessment. The Risk Assessment (RA) assesses the main caregiving risk areas for the specific caregiving dyad. The RA is used to tailor the intervention for care recipient behaviors or safety issues and/or caregiver centered issues/concerns related to health, physical and emotional well being, and/or social support.
61944466|NCT02048969|PLACEBO_COMPARATOR|Saline|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
62121021|NCT05929105||observation group|
62121022|NCT05929105||control group|
62309296|NCT02844608|OTHER|Quality of Life|Administration of Quality of Life questionnaires
62309297|NCT02308280|EXPERIMENTAL|Bortezomib post-transplantation|"Non myeloablative allogeneic transplantation followed by Bortezomib for 1 year after a Bortezomib-based induction and autologous stem cell transplantation.~Bortezomib: 1,3 mg/m2 subcutaneously every 2 weeks for 26 injections."
62309298|NCT00565500|EXPERIMENTAL|1|
62309299|NCT00565500|EXPERIMENTAL|2|
62309300|NCT00565500|PLACEBO_COMPARATOR|3|
61920879|NCT03309046|ACTIVE_COMPARATOR|Education Webinar|For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
62121023|NCT02891525|ACTIVE_COMPARATOR|50g glucose intragastric|50g glucose dissolved in 250mL tap water given via nasogastric tube
62309301|NCT01161836|EXPERIMENTAL|iniparib|"Segment 1: 400 mg \[14C\]-iniparib single administration~Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy"
62309302|NCT03186469|ACTIVE_COMPARATOR|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
62309303|NCT03186469|ACTIVE_COMPARATOR|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
62309304|NCT03186469|OTHER|Behavioral: Standard of Care Control|Standard of care.
62475695|NCT00933530|EXPERIMENTAL|Cohort 6 - Dose Level F (2.0g/day)|"2.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 2.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 2.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
62121024|NCT02891525|ACTIVE_COMPARATOR|25g fructose intragastric|25g glucose dissolved in 250mL tap water given via nasogastric tube
62121025|NCT02891525|ACTIVE_COMPARATOR|220mg acesulfame-K intragastric|220mg acesulfame-K dissolved in 250mL tap water given via nasogastric tube
62309305|NCT02106208|EXPERIMENTAL|Cheese diet|A 4-week experimental diet with all meals and foods be provided to participants, including 90g of regular cheddar cheese daily per 2500 kcal. The diet will contain 13% of saturated fat (SFA), 14% of mono-unsaturated fat (MUFA), 5% of polyunsaturated fat (PUFA) and 53% of carbohydrate (CHO).
62309306|NCT02106208|EXPERIMENTAL|Butter diet|A 4-week experimental diet with all meals and foods be provided to participants, the diet will contain 13% of SFA mostly from butter. The diet will contain 14% of MUFA, 5% of PUFA and 53% of CHO.
62309307|NCT02106208|EXPERIMENTAL|CHO diet|A 4-week experimental diet with all meals and foods will provided to participants. The diet will contain 60% of CHO, 6% of SFA, 14% of MUFA and 5% of PUFA.
62309308|NCT02106208|EXPERIMENTAL|MUFA diet|A 4-week experimental diet with all meals and foods be provided to participants. The diet will contain 21% of MUFA, 6% of SFA, 5% of PUFA and 53% of CHO.
62309309|NCT02106208|EXPERIMENTAL|PUFA diet|A 4-week experimental diet with all meals and foods will be provided to participants. The diet will contain 12% of PUFA, 14% of MUFA, 6% of SFA and 53% of CHO.
62679914|NCT06454487|ACTIVE_COMPARATOR|CR|Cardiac Rehabilitation (usual care) Only
62121026|NCT02891525|PLACEBO_COMPARATOR|250mL tap water intragastric|250mL tap water given via nasogastric tube
62121027|NCT00281489|EXPERIMENTAL|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
62121028|NCT00281489|ACTIVE_COMPARATOR|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
62121029|NCT06677385|EXPERIMENTAL|Conventional scaling and debridement in young aged patients|scaling and debridement
62121030|NCT06677385|EXPERIMENTAL|Conventional scaling and debridement of old aged patients|
62121031|NCT06677385|EXPERIMENTAL|diode laser as adjunctive to conventional scaling and debridement for old age patients|
62121032|NCT06677385|EXPERIMENTAL|diode laser as adjunctive to conventional scaling and debridement for young age patients|
62121033|NCT01385254||siblings and mothers of Very Low Birth Weight infants|50 older siblings (closest in age) and mothers of very low birthweight (VLBW) infants, born at \<33 weeks gestation and \<1500 grams at birth
62309310|NCT06672016|EXPERIMENTAL|This is a single-arm study.|"The study patch is a transdermal system that contains the active ingredient progestin.~This study is an open-label, single-arm study. This means that all participants in the study will receive the study patch"
62309311|NCT00757523|ACTIVE_COMPARATOR|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation).
62309312|NCT00757523|EXPERIMENTAL|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation).
62309313|NCT04097288|EXPERIMENTAL|Single dose citalopram|A blinded single dose 40 mg citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
62309314|NCT04097288|ACTIVE_COMPARATOR|Single dose reboxetine|A blinded single dose 8 mg reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
62121034|NCT01385254||siblings and mothers of healthy infants|50 siblings (closest in age) and mothers of healthy, full-term infants (between 38-42 weeks gestation and lacking medical conditions that require a hospital stay past the mother's discharge date)
62121035|NCT01518478|OTHER|20 Non-atopic|Non-atopic, healthy control.
62121036|NCT01518478|OTHER|20 ADEH- (mild to severe AD)|Atopic Dermatitis without previous or current Eczema Herpeticum.
62309315|NCT04097288|PLACEBO_COMPARATOR|Single dose placebo citalopram|A blinded single dose visually identical placebo pill to citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
62121037|NCT04857502|EXPERIMENTAL|Diagnostic (99mTc-PSMA-I&S, SPECT/CT)|The first 5 patients receive an initial dose of undergo 99mTc-PSMA-I\&S IV followed by 5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I\&S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I\&S IV before standard of care surgery.
62121038|NCT00739765|EXPERIMENTAL|1 Interpersonal Psychotherapy (IPT)|Participants will receive interpersonal psychotherapy.
62121039|NCT00739765|ACTIVE_COMPARATOR|2 Prolonged Exposure (PE)|Participants will receive prolonged exposure therapy.
62309316|NCT04097288|PLACEBO_COMPARATOR|Single dose placebo reboxetine|A blinded single dose visually identical placebo pill to reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
62475696|NCT00933530|EXPERIMENTAL|Cohort 7 - Dose Level G (3.0g/day)|"3.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 3.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 3.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period."
62495928|NCT06347627|EXPERIMENTAL|Group 4 (O x E x S x F)|"Participants in Group 4 will view a message in an X (former Twitter) format composed of Organization x Effectiveness x Storytelling x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62495929|NCT06347627|EXPERIMENTAL|Group 5 (I x S x S x M)|"Participants in Group 5 will view a message in an X (former Twitter) format composed of Individual x Safety x Storytelling x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62121040|NCT00739765|ACTIVE_COMPARATOR|3 Relaxation therapy|Participants will receive relaxation therapy.
62121041|NCT01755949|ACTIVE_COMPARATOR|Chronic atrial fibrillation, colchicine|Colchicine 0.6 mg PO BID. Subjects not undergoing ablation.
62121042|NCT01755949|PLACEBO_COMPARATOR|Chronic atrial fibrillation, placebo|Matching placebo. Subjects not undergoing ablation.
62121043|NCT01755949|ACTIVE_COMPARATOR|Pre-ablation, sinus rhythm, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
62309317|NCT01365767||Crohn Disease|Patients with Crohns Disease referred to referred to a Magnetic Resonance Imaging Scan.
62309318|NCT00534846|PLACEBO_COMPARATOR|A placebo|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
62309319|NCT00534846|ACTIVE_COMPARATOR|B toremifene|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
62309320|NCT03176212|ACTIVE_COMPARATOR|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
61944467|NCT04040946|OTHER|TEMP-TDM with MIBI|Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET
62475697|NCT04776447|EXPERIMENTAL|Experimental: Atezolizumab plus induction chemotherapy plus CT-radiotherapy|"Induction Treatment:~Atezolizumab: 1200mg, IV infusion Carboplatin: AUC5, IV infusion Paclitaxel: 200 mg/m2 The treatment will start within 1-5 days from enrollment. The treatment will be 3 cycles administered at 21-day intervals.~Concurrent Chemotherapy (CT)-Radiotherapy Treatment:~Chemotherapy and radiotherapy treatment will be at the discretion of the principal investigator of each site. It is recommended to use as concurrent chemotherapy treatment a platinum based doublet.~After the 3rd cycle of the induction treatment, concurrent treatment will start, 1st concurrent cycle will be administered from day 1 of cycle 3 of induction treatment.~Concurrent chest radiotherapy will be administered starting at day 1 of cycle 1 of concurrent chemo-radiotherapy.~Maintenance with Atezolizumab:~Atezolizumab: 1200mg, IV infusion After the 3rd cycle of the concurrent treatment, Atezolizumab maintenance treatment will start from day 1 of cycle 6 and will be administered for 12 months."
62475698|NCT00829764|EXPERIMENTAL|1|Doxycycline Monohydrate
62475699|NCT00829764|ACTIVE_COMPARATOR|2|Vibramycin Monohydrate®
62309321|NCT03176212|PLACEBO_COMPARATOR|Control|In this arm, subjects consumed a beverage with identical macronutrients
62679915|NCT03266640|EXPERIMENTAL|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
62679916|NCT06689501|ACTIVE_COMPARATOR|Intervention Arm|
62679917|NCT06689501|PLACEBO_COMPARATOR|Placebo-control arm|
62679918|NCT05441449|EXPERIMENTAL|Arm 1: Cooling Vest|Phase 1: After satisfying bench testing criteria, AB participants will wear the wet cooling vest at maximal settings for 2 hours in the seated position in a warm thermal chamber (35°C), to determine: (1) minimum skin temperatures beneath the cooling vest and (2) subjective thermal sensation of their skin beneath the cooling vest.
62679919|NCT05441449|EXPERIMENTAL|Arm 2: Cooling Vest|Phase 2: Participants with Hi-SCI will wear the wet vest (experimental condition) in a warm thermal chamber (35°C) for up to 2 hours in the seated position, to determine: (1) change in Tcore and (2) perception of heat and thermal comfort.
62679920|NCT05441449|NO_INTERVENTION|Arm 3: No Vest|Phase 2: Participants with Hi-SCI will wear no vest (control condition) in a warm thermal chamber (35°C) for up to 2 hours in the seated position, to determine: (1) change in Tcore and (2) perception of heat and thermal comfort.
62679921|NCT03000803|EXPERIMENTAL|Early Total Caloric Intake|The Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
62679922|NCT03000803|ACTIVE_COMPARATOR|Late Total Caloric Intake|The Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
62679923|NCT05325944|EXPERIMENTAL|Self-guided digital intervention for NSSI|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface.
62121044|NCT01755949|PLACEBO_COMPARATOR|Pre-ablation, sinus rhythm, placebo|Matching placebo. Subjects undergoing ablation.
62309322|NCT06510478|EXPERIMENTAL|Intervention Group|Who receives intervention. Life Skill intervention will be administered in 12 sessions.
62309323|NCT06510478|PLACEBO_COMPARATOR|Control Group|Who do not receive any intervention.
62309324|NCT06510478|ACTIVE_COMPARATOR|Waitlist Control Group|Who are on the waitlist and will receive intervention components if the intervention is proven to be effective.
62309325|NCT04881877|EXPERIMENTAL|Synthetic nitrite Condom|Participants will be randomized to condom use order. Participants will be provided with 5 synthetic nitrite condoms at the first visit and switched to 5 of either the latex graphene condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study
62309326|NCT04881877|EXPERIMENTAL|Latex and graphene Condom|Participants will be randomized to condom use order. Participants will be provided with 5 latex graphene condoms at the first visit and switched to 5 of either the synthetic nitrite condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study.
62309327|NCT04881877|EXPERIMENTAL|Standard latex condom:|Participants will be randomized to condom use order. Participants will be provided with 5 latex condom at the first visit and switched to 5 of either the latex graphene condom or synthetic nitrite condoms at visit 2 and 3. All couples will use each of the 3 condom types during the study.
62309328|NCT02477098|EXPERIMENTAL|Pre RSB|patients who receive preoperative rectus sheath block of ropivacaine hydrochloride and receive postoperative rectus sheath block of saline
62309329|NCT02477098|EXPERIMENTAL|Post RSB|patients who receive preoperative rectus sheath block of saline and receive postoperative rectus sheath block of Ropivacaine hydrochloride
62309330|NCT05574543|EXPERIMENTAL|0.25 mg AGA111|0.25 mg AGA111 in autologous blood coagulum (ABC) is locally delivered at the intervertebral space.
62309331|NCT05574543|EXPERIMENTAL|0.5 mg AGA111|0.5 mg AGA111 in ABC is locally delivered to the participants at the intervertebral space.
62309332|NCT05574543|PLACEBO_COMPARATOR|Placebo|Placebo in ABC is locally delivered at the intervertebral space.
61944468|NCT04040946|OTHER|F18-choline PET|Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy
62121045|NCT01755949|ACTIVE_COMPARATOR|Pre-ablation, AF, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
62121046|NCT01755949|PLACEBO_COMPARATOR|Pre-ablation, AF, placebo|Matching placebo. Subjects undergoing ablation.
62121047|NCT05723133|ACTIVE_COMPARATOR|Active Comparator: Control group: Manual Toothbrush|Patients will receive oral hygiene instructions and a new manual toothbrush
62309333|NCT01441544|EXPERIMENTAL|VAREITY|
62121048|NCT05723133|EXPERIMENTAL|Test group: Electric Toothbrush without visual feedback|Patients will receive the same oral hygiene instructions and an electric toothbrush without daily personal feedback using the brushing application.
62309334|NCT01441544|EXPERIMENTAL|NON-VARIETY|
61920880|NCT02249962||Overall cohort: HIV+ women on Option B+ and their infants|Women (n=8000) visiting an antenatal clinic for care who will be followed prospectively for Malawi standard treatment outcomes and pregnancy outcomes as patients on Option B+
62121049|NCT05723133|EXPERIMENTAL|Test group: Electric Toothbrush with visual feedback|Patients will receive the same oral hygiene instructions and an electric toothbrush with daily personal feedback using the brushing app (Oral-B app).
62309335|NCT01815437|ACTIVE_COMPARATOR|2000 IU Vitamin D3- Cholecalciferol|Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.
62309336|NCT01815437|ACTIVE_COMPARATOR|2000 IU Vitamin D2- Ergocalciferol|Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.
62309337|NCT01815437|EXPERIMENTAL|2000 IU Mushroom Vitamin D2|Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks
62309338|NCT01815437|PLACEBO_COMPARATOR|Mushroom Extract|Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.
62309339|NCT03835338|EXPERIMENTAL|Test Group|The test group will receive Pulmonary Vein Isolation, LAA Isolation and LAA Occlusion with the WATCHMAN LAAC Device
62309340|NCT03835338|ACTIVE_COMPARATOR|Control Group|The control group will receive Pulmonary Vein Isolation
62309341|NCT05113524|EXPERIMENTAL|Dance|Dance intervention for 3 months, 2 times/week (1 instructor lecture session and 1 home session following a prepared video), 2 hours per week. Dance is a safe and effective form of activity, which has been used in PD population (Delabary et al., 2017; Sharp and Hewitt, 2014). Participants take part in a dance class specifically for people with PD lead by a qualified dance instructor. The dance class typically include a warm-up, dance related activities (specific to the genre of the class) and a cool-down.
62309342|NCT05113524|ACTIVE_COMPARATOR|Control Group|Controls, not alter their personal lifestyle, but undergo the same testing as the exercise intervention group.
62309343|NCT01396525|EXPERIMENTAL|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|
62309344|NCT01373905|ACTIVE_COMPARATOR|Sustained lung inflation|recruitment was done using CPAP of 30 Cm/ H2o for 30 seconds
62679924|NCT05325944|EXPERIMENTAL|Digital intervention for NSSI with coaching|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface. This arm will additionally receive lightweight coaching which consists of a one 20-30 minute engagement call at the beginning of treatment. Thereafter, coaches will check in with participants via medium of participants choice twice per week and respond to patient texts, calls, or emails.
62121050|NCT06353165|ACTIVE_COMPARATOR|Group I|toothpaste brushing 2/day for 2 minutes
62121051|NCT06353165|EXPERIMENTAL|Group II|toothpaste brushing 2/day for 2 minutes
62121052|NCT02473419||Vayarin|Vayarin x 16 weeks
62121053|NCT02473419||Placebo|Placebo x 16 weeks
62121054|NCT02473419||Vayarin and Placebo|Placebo x 8 weeks and then Vayarin x 8 weeks
62121055|NCT06676527||Experimental cohort.|Subjects who progressed after first-line treatment and switched to second-line treatment regimens including vorolanib. The first-line treatment which patients received can be other tyrosine kinase inhibitors (TKIs) or TKIs combined with immunotherapy drugs. Provided vorolanib is contained in the second-line regimen, the patient then can be considered for inclusion in the study.
62121056|NCT01222910|EXPERIMENTAL|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
62309345|NCT01373905|ACTIVE_COMPARATOR|Stepwise PEEP elevation|Recruitment was done using stepwise elevation of PEEP followed by determination of the alveolar collapsing pressure
62309346|NCT05597046||Healthcare Professionals|Planning Phase Interviews
62309347|NCT03816163|EXPERIMENTAL|zolbetuximab +nab-paclitaxel + gemcitabine|Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
62309348|NCT03816163|ACTIVE_COMPARATOR|nab-paclitaxel + gemcitabine|Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
62309349|NCT01154725|OTHER|Habitual stoma care|habitual patient education
62309350|NCT01154725|EXPERIMENTAL|Patient education and rehabilitation|patient education and rehabilitation
62309351|NCT05453253|EXPERIMENTAL|interventional 6 months interval between OCV doses|This intervention arm will modify the recommended interval for administration of the second Euvichol-Plus®, which will be extended to 6 months.
62309352|NCT05453253|EXPERIMENTAL|interventional 12 months interval between OCV doses|This intervention arm will modify the recommended interval for administration of the second Euvichol-Plus®, which will be extended to 12 months.
62309353|NCT05453253|ACTIVE_COMPARATOR|control arm (standard 14-day interval)|Participants will receive the oral cholera vaccine, Euvichol-Plus®, according to the manufacturer instructions: 2 doses two weeks apart.
62679925|NCT05325944|ACTIVE_COMPARATOR|Active control|The active control arm will receive 8 weekly modules with psychoeducational components only, without the interaction features or EMA for personalization.
62121057|NCT01222910|ACTIVE_COMPARATOR|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
62679926|NCT00792948|EXPERIMENTAL|Treatment (chemotherapy, transplant, maintenance)|See Detailed Description
61920881|NCT02249962||Sub-cohort A: first HIV diagnosis|Women (n=300) who present to the antenatal care clinic and are diagnosed for the first time with HIV. These women will be started on Option B+ as anti-retroviral treatment, per Malawi Ministry of Health standard of care.
61920882|NCT02249962||Sub-cohort B: subsequent pregnancies failing 1st line ART|Women (n=150) who have failed first-line treatment (TDF/3TC/EFV) based on HIV RNA levels and CD4 count. These women will be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
61920883|NCT02249962||Sub-cohort C: subsequent pregnancies who default from 1st line|Women (n=150) who are HIV+ and have a subsequent pregnancy who have not been adherent to first-line (Option B+: TDF/3TC/EFV). These women will be re-initiated on first-line treatment for 3 months, then evaluated to assess whether continuation on first-line treatment is sufficient, or if they need to be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
62679927|NCT04825587|EXPERIMENTAL|Concomitant ACL and ALL reconstruction|The participant will undergo both the ACL and ALL reconstruction surgery.
62121058|NCT00542035|EXPERIMENTAL|ARRY-371797|
62121059|NCT00542035|EXPERIMENTAL|Placebo, ARRY-371797|
62679928|NCT04825587|EXPERIMENTAL|ACL reconstruction alone|The participant will undergo only ACL reconstruction surgery.
62679929|NCT05930067|OTHER|Pinnacle Gription|Pinnacle Gription Acetabular Cup
62121060|NCT00542035|PLACEBO_COMPARATOR|Placebo|
62121061|NCT02999022|EXPERIMENTAL|Lithium carbonate|Lithium carbonate 300mg capsule; once per day for 2 weeks.
62309354|NCT00960817|ACTIVE_COMPARATOR|1. Routine treatment|Control group
62309355|NCT00960817|EXPERIMENTAL|2. Dipyridamole treatment|Group that receives Dipyridamole treatment
61920884|NCT04258137|EXPERIMENTAL|Experimental procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
62121062|NCT02999022|PLACEBO_COMPARATOR|Lactose placebo|Lactose placebo capsule; once per day for 2 weeks.
62121063|NCT06188754|EXPERIMENTAL|Time Restricted Eating (TRE) for 8 weeks|Participants will receive an intro to TRE and then throughout 8 weeks they will receive brief online psychoeducation several times per week with optional weekly coaching sessions. TRE involves restricting the window of eating to 10 hours/ day, most typically by avoiding eating in the first 1-2 hours after awakening and in the 2-4 before sleep. Those with an eating window \> 14 hours will be asked to restrict their eating to 12 hours in the first week, then 10 hours in week 2. To select the period, investigators will ask Ss to review baseline logs to consider sleep, eating, family meals and social commitment schedules, and any special energy demands, such as exercise. During the eating window, no restrictions are placed on the type or quantity of food consumed. The investigators will instruct participants to follow their habitual diet within their 10-hour eating window and to aim to consume the same number of calories per day as they did at baseline.
62121064|NCT06188754|ACTIVE_COMPARATOR|Mediterranean diet for 8 weeks|"Participants will receive a several page introduction to the mediterranean diet, and then will receive support throughout the 8 week intervention to follow this food plan, including brief online psychoeducation that will be sent several times per week, and optional weekly coaching sessions.~The mediterranean diet is a plan for healthy eating based on how people eat in the mediterranean region. Individuals will be encouraged to consume vegetables (6 servings/day), fruits (2-4 servings/day), whole grains (daily), legumes (3-4 times per week), nuts (.5 oz per day), and oily fish (2 servings/week). Participants will be encouraged to choose lean meats and other sources of protein over red meat and processed meats. Sweets, refined cereals, alcohol, and wine or alcohol will be labelled as extras, and participants will be encouraged to limit consumption of extras."
62679930|NCT05930067|OTHER|Pinnacle Dual Mobility|Pinnacle Dual Mobility System
62679931|NCT05995665|EXPERIMENTAL|EsoGLOVE with Trigno Biofeedback (EMG sensors) group|The EsoGLOVE + Trigno Biofeedback Group subjects will receive EsoGLOVE with Trigno Biofeedback (EMG sensors) training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day
62679932|NCT05995665|ACTIVE_COMPARATOR|Graded Repetitive Arm Supplementary Program (GRASP) Group|The GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day
62679933|NCT02684292|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles.
62679934|NCT02684292|ACTIVE_COMPARATOR|Brentuximab vedotin|Participants receive BV 1.8 mg/kg (maximum 180 mg per dose) IV on Day 1 of each 3-week cycle for up to 35 cycles.
62679935|NCT00292370|OTHER|Arm 1: Open Label (OL) Paroxetine|Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
62679936|NCT00292370|PLACEBO_COMPARATOR|Arm 2 OL Paroxetine + DB Placebo|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
62121065|NCT05874986|OTHER|Training group (n=320)|All the participants from data collection I and the other arm from data collection II.
62475700|NCT03413839|EXPERIMENTAL|PSSE Group|Individuals will receive at least 6 sessions of physiotherapeutic scoliosis specific exercises (PSSE) (Schroth) physical therapy. Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
62679937|NCT00292370|EXPERIMENTAL|Arm 3: OL Paroxetine + DB Quetiapine|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
61920885|NCT04258137|NO_INTERVENTION|Standard procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managedby initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
62309356|NCT00881205|EXPERIMENTAL|Rivastigmine|Rivastigmine patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
62309357|NCT00881205|PLACEBO_COMPARATOR|Placebo|Placebo patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
62309358|NCT06158672|EXPERIMENTAL|Emotional freedom technique group|Emotional freedom technique will be applied to menopausal women in the emotional freedom technique group.
62309359|NCT06158672|PLACEBO_COMPARATOR|Sham Emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will receive sham emotional freedom technique.
62309360|NCT06158672|NO_INTERVENTION|Control group|Menopausal women in the control group will not receive any intervention.
61920886|NCT04258137|EXPERIMENTAL|Experimental procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
61920887|NCT04258137|NO_INTERVENTION|Standard procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
62121066|NCT05874986|OTHER|Control group (n=80)|The other arm from data collection II.
62121067|NCT00936507|EXPERIMENTAL|Low-ED, small portion|
62309361|NCT03385668|EXPERIMENTAL|Pirfenidone|All patients will receive Pirfenidone
62121068|NCT00936507|EXPERIMENTAL|Low-ED, large portion|
62121069|NCT00936507|EXPERIMENTAL|High-ED, small portion|
62309362|NCT04354051|EXPERIMENTAL|Sodium nitrite|
62309363|NCT05293938||OCA Treatment Group|PBC patients with a history of UDCA failure who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021)
62309364|NCT05293938||Control Group|PBC patients with a history of UDCA failure who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021)
62679938|NCT01029964|ACTIVE_COMPARATOR|6-9 years|Age at start of treatment
62679939|NCT01029964|ACTIVE_COMPARATOR|10-13 years|Age at start of treatment
62679940|NCT01029964|ACTIVE_COMPARATOR|14-16 years|Age at start of treatment
62679941|NCT01029964|NO_INTERVENTION|Control 6-9 years|Untreated control group
62121070|NCT00936507|EXPERIMENTAL|High-ED, large portion|
62121071|NCT03925558|ACTIVE_COMPARATOR|Probiotic formula|Lactobacillus strains
62309365|NCT02243176|EXPERIMENTAL|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
62309366|NCT02243176|ACTIVE_COMPARATOR|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
62309367|NCT02333045|EXPERIMENTAL|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
62309368|NCT02333045|EXPERIMENTAL|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
62309369|NCT01137630|EXPERIMENTAL|K40a|K40a is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
62309370|NCT01137630|EXPERIMENTAL|K40b|K40b is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
62309371|NCT01137630|PLACEBO_COMPARATOR|Placebo|Placebo is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
62309372|NCT01004107|EXPERIMENTAL|Radiesse Injectable Dermal Filler|Device: Radiesse Injectable Dermal Filler
62309373|NCT01004107|ACTIVE_COMPARATOR|Delayed Treatment|Cross over to treatment with Radiesse Injectable Dermal Filler at 3 Months
62309374|NCT01788085|EXPERIMENTAL|pH monitoring procedure|Bravo pH monitoring procedure
62309375|NCT03406195|EXPERIMENTAL|healthy older adults|Healthy older adults who will receive TMS
62309376|NCT02806427||enterally fed adults|Adults subjects with a condition for which a calorically dense enteral formula is appropriate, with established enteral access, anticipated to require enteral tube feeding for at least 3 days.
62679942|NCT06690021|EXPERIMENTAL|group 1|Classical Thoracolumbar Interfascial Plane Block
62679943|NCT06690021|EXPERIMENTAL|group 2|Modified Thoracolumbar Interfascial Plane Block
62679944|NCT01830101|EXPERIMENTAL|TMZ plus concurrent re-irradiation|TMZ plus concurrent re-irradiation
62679945|NCT01830101|EXPERIMENTAL|TMZ alone|TMZ alone
62309377|NCT04230850|ACTIVE_COMPARATOR|Mildly Impaired Group|This group will consist of participants with 35-50 degrees of lumbar flexion.
62309378|NCT04230850|ACTIVE_COMPARATOR|Moderately Impaired Group|This group will consist of participants with 20-34 degrees of lumbar flexion.
62309379|NCT04230850|ACTIVE_COMPARATOR|Highly Impaired Group|This group will consist of participants with less than 20 degrees of lumbar flexion.
62309380|NCT03991793||Sepsis|Severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
62309381|NCT03991793||Control|Absence of severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
62475701|NCT03413839|OTHER|Conventional PT Group|Individuals will receive at least 6 sessions of conventional physical therapy (PT). Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
61920888|NCT00400114|EXPERIMENTAL|sunitinib|
62121072|NCT03925558|PLACEBO_COMPARATOR|Placebo formula|Placebo
62121073|NCT05136092|EXPERIMENTAL|Cohort 1: HFCS (fructose-fed)|"On the day of Surgery, between two and three hours before surgery.~Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery. Subjects will be reminded the day before the surgery to drink the solution."
62309382|NCT03505866|OTHER|Mutual support groups of HIV|HIV-positive people who did not enroll in a community home-based care intervention and receiving regular HIV services and support from mutual support groups of HIV
62309383|NCT05617092|EXPERIMENTAL|Intervention group|intervention group will receive a physiotherapy individualized treatment
62309384|NCT05617092|NO_INTERVENTION|Control Group|No intervention in women with injury in the levator ani
62309385|NCT05617092|NO_INTERVENTION|Healthy controls|A group of women without injury that will be invited to filling in the questionnaires that will be carried out in the study three, six months and one year postpartum.
62679946|NCT04857983|PLACEBO_COMPARATOR|TCT + PBO|Subjects will be assigned to take placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
62679947|NCT04857983|ACTIVE_COMPARATOR|TCT + MEM|Subjects will be assigned to take memantine and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
62679948|NCT03033576|ACTIVE_COMPARATOR|Arm I (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
61920889|NCT06374251|EXPERIMENTAL|Supportive Care (narrative medicine sessions)|Patients participate in narrative medicine sessions over 60 minutes Q2W for 3 sessions.
61920890|NCT03858465|ACTIVE_COMPARATOR|25 mg of ephedrine|participants who will receive intravenous 1,25mg/min ephedrine during 20 minutes (total dosage is 25 mg of ephedrine).
62309386|NCT04751279||Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (<5 years)|Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score \<2) and recent diagnosis (\<5 years)
62309387|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (<5 years|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (\<5 years)
62309388|NCT04751279||Patients with pulmonary sarcoidosis without signs of activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis without signs of activity (Benamore score \<2), persistent form (\>5 years)
61920891|NCT03858465|ACTIVE_COMPARATOR|0,3 mg of phenylephrine|participants who will receive intravenous 0,015mg/min phenylephrine during 20 minutes (total dosage is 0,3mg of phenylephrine).
62309389|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (\>5 years)
61920892|NCT01285440||Diagnostic Imaging|
62475702|NCT04350723|EXPERIMENTAL|Intervention - Awake Proning|"The oxygen mask or NIPPV or HFNC will be initiated at the treating team's discretion. The patient will be observed for 15 minutes to ensure that: SPO2 \> 90% and the patient is tolerating oxygen mask or NIPPV or HFNC treatment.~Once the patient achieves the above parameters within 15 minutes of initiating oxygen therapy through any modality, the healthcare team will start awake proning."
62679949|NCT03033576|EXPERIMENTAL|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62679950|NCT06694623|ACTIVE_COMPARATOR|apically positioned flap alone|apically positioned flap alone
62121074|NCT05136092|EXPERIMENTAL|Cohort 2: D-Xylose (xylose-fed)|"On the day of Surgery, between two and three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it betweentwo and three hours before surgery. Subjects will be reminded the day before the surgery to drink the solution."
62121075|NCT05031390|EXPERIMENTAL|Physiotherapist-led training|Physiotherapy-led training of patients with FAIS
62475703|NCT04350723|NO_INTERVENTION|Control - Standard of Care|"The patient will receive usual care without proning at the discretion of the treating team.~The oxygen mask or NIPPV or HFNC will be initiated, the choice of starting oxygen mask versus NIPPV versus HFNC will be up to the treating team, the patient will be observed for 15 minutes to ensure that: SPO2 \> 90% and the patient is tolerating NIPPV or HFNC treatment."
62121076|NCT05072743|EXPERIMENTAL|Post-Concussion Patients with Non-Apneic Sleep Disorder|Patients will be treated with PBMT using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
62121077|NCT02685488|ACTIVE_COMPARATOR|Transcranial Ultrasound Power|Transcranial Ultrasound Power
62309390|NCT03952130|EXPERIMENTAL|LY900014|Participants received 100 units per milliliter (U/mL) LY900014 subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
62309391|NCT03952130|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Participants received 100 U/mL insulin lispro SC 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
62679951|NCT06694623|ACTIVE_COMPARATOR|apically positioned flap with FGG strip|apically positioned flap with FGG strip
62679952|NCT04553536|ACTIVE_COMPARATOR|Opioid analgesics|Mu-opioid receptor agonists (remifentanil, sulfentanil) will be used as the only analgesic(s) in the surgery.
62679953|NCT04553536|EXPERIMENTAL|Ketamine|Esketamine will be used as the only anagesic in the surgey.
61920893|NCT02050971|ACTIVE_COMPARATOR|Autologous cord blood transfusion|Treatment Group 1 Interventions: collected autologous whole cord blood at birth will be transfused for the preterm neonate
61920894|NCT02050971|SHAM_COMPARATOR|Standard treatment for neonatal anemia|Treatment Group 2 Interventions: transfusion of allogeneic whole peripheral blood or any of its components at a time of anemia of prematurity development
61920895|NCT05915559|EXPERIMENTAL|Tonsillectomy|
61920896|NCT01542177||Pancreatic cancer|
61920897|NCT06282367||Bowel preparation for colonoscopy using Polyethylene glycol|
61920898|NCT06282367||Bowel preparation for colonoscopy using oral Lactulose|
61920899|NCT00468767|EXPERIMENTAL|1|Atrial fibrillation (AF) duration of 3 hours to 7 days.
61920900|NCT00468767|EXPERIMENTAL|2|AF duration of \>7 days to \<45 days
61920901|NCT05151627|EXPERIMENTAL|KINESIO TAPING AND CONVENTIONAL PHYSICAL THERAPY|Application of Kinesio taping following Transcutaneous Electrical Nerve Stimulation and Knee Exercises
61920902|NCT05151627|EXPERIMENTAL|CONVENTIONAL PHYSICAL THERAPY|Application of Transcutaneous Electrical Nerve Stimulation and Knee Exercises
61920903|NCT01203254|PLACEBO_COMPARATOR|Placebo|
62309392|NCT03726216||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in France
62679954|NCT05436444|EXPERIMENTAL|1|All participants receive challenge virus
62679955|NCT05614336|OTHER|Cystic Fibrosis patients|Patients with cystic fibrosis, regardless of age, genetic profile, transplant status and disease severity will be eligible to participate in the study.
62679956|NCT06686810||Patients undergoing Endoscopic Retrograde CholangioPancreatyopgraphy for PSC|Patients undergoing Endoscopic Retrograde CholangioPancreatyopgraphy (ERCP) to dilate dominant biliary strictures related to Primary Sclerosing cholangitis (PSC)
62475704|NCT03750903|EXPERIMENTAL|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
62679957|NCT06689657|OTHER|Adolescent group therapy (CARES) and parent group therapy (RNV)|"In the adolescent group, they will attend 8 group sessions during 1 month (2 sessions/week). There also will be a boost session 3 month after the last session.~Parents will attend 4 group sessions during 1 month too (1 session/week). There will be 2 boost sessions : 1 month and 3 month after the last session~Patients will be randomized in each group with blinded assessment"
62475705|NCT03750903|ACTIVE_COMPARATOR|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
61920904|NCT01203254|ACTIVE_COMPARATOR|Cholestagel|
61920905|NCT00333203|EXPERIMENTAL|NGOIS|
61920906|NCT00333203|ACTIVE_COMPARATOR|BSS Plus|
62121078|NCT02685488|SHAM_COMPARATOR|Transcranial Ultrasound Sham|Transcranial Ultrasound Sham. Unknown to both participants and experimenters, the ultrasound will not stimulate.
62121079|NCT03100227|ACTIVE_COMPARATOR|PET [18F] FDG|Each subject will have a PET scan at \[18F\] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
62121080|NCT03100227|SHAM_COMPARATOR|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
61920907|NCT00880165|ACTIVE_COMPARATOR|Arm 1|In-laboratory testing followed by continuous positive airway pressure treatment
61920908|NCT00880165|ACTIVE_COMPARATOR|Arm 2|Home unattended testing followed by continuous positive airway pressure treatment
62121081|NCT03013504|EXPERIMENTAL|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by \>1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
62475706|NCT05170607||PV associated atrial fibrillation|
62475707|NCT05170607||non-PV associated arrhythmic focuses|
62475708|NCT05170607||Healthy volunteers|
61920909|NCT02741388|EXPERIMENTAL|Selinexor + immunochemotherapy|"Selinexor will be administered orally on Day1, 3, 8 and 10 of each 3-week cycle with an immunochemotherapy, R-DHAOx (Group A: rituximab + dexamethasone + oxaliplatin + cytarabine) or R-GDP (Group B: rituximab + dexamethasone + gemcitabine + cisplatin) for 3 cycles (choice of the immunochemotherapy left at the investigator's decision before patient's inclusion).~Different dose levels of selinexor will be examined sequentially in each group: 20 mg flat (DL-1), 40 mg flat (DL1), 60 mg flat (DL2), 80 mg flat (DL3)."
61920910|NCT04387760|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine is widely used to treat autoimmune diseases, due to its immunomodulatory properties, such as systemic lupus erythematosus and rheumatoid arthritis, with an excellent safety profile. In vitro studies have suggested that their mode of action in COVID-19 disease is blockade of SARS-CoV-2 transport from endosomes to endolysosomes, which appears to be a requirement to release the viral genome.
61920911|NCT04387760|EXPERIMENTAL|Favipiravir|Favipiravir is an antiviral drug that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses (i.e. arenaviruses, bunyaviruses and alphaviruses).
61920912|NCT04387760|ACTIVE_COMPARATOR|Standard clinical care|Supportive care according to local guidelines
62679958|NCT06689657|EXPERIMENTAL|Adolescent groupe therapy (CARES) only|"In the adolescent group, they will attend 8 group sessions during 1 month (2 sessions/week).~There will be a boost session 3 month after the last session~Patients will be randomized in each group with blinded assessment"
62475709|NCT04078763|EXPERIMENTAL|visual-auditory feedback|Patients included in this arm will follow the rehabilitation protocol with visual-auditory feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
62475710|NCT04078763|EXPERIMENTAL|visual feedback|Patients included in this arm will follow the rehabilitation protocol with visual feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
62121082|NCT03013504|ACTIVE_COMPARATOR|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by \>1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
62309393|NCT04241003|EXPERIMENTAL|SmartDrive - baseline and intervention|One arm for all users. Baseline - two weeks data collection documenting usage of wheelchair prior to intervention. Introduction of SmartDrive, a time period to get used to the SmartDrive and then two weeks data collection documenting usage of wheelchair with the intervention.
62309394|NCT05056480||Parents/caregivers|Parents/caregivers of children \<20 years old who received interdisciplinary care coordination within the Pediatric Complex Care Integration (PCCI) program
62309395|NCT05056480||Clinical staff|PCCI care management staff participating in implementation of the PCCI program
61920913|NCT02240173|EXPERIMENTAL|Jobelyn + Haloperidol|Combination of the conventional drugs and Jobelyn
62121083|NCT05908799||Pembrolizumab + Chemotherapy|Exposure Group
62121084|NCT05908799||Chemotherapy|Reference Group
62121085|NCT04512651|EXPERIMENTAL|Intervention Group (IG)|The GI dancers, submitted to tibiotarsal thrust manipulation
62121086|NCT04512651|SHAM_COMPARATOR|Control Group (CG)|For the CG was performed the simulation of the technique, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
62309396|NCT06511609|EXPERIMENTAL|double-flap technique（DFT）|Laparoscopic proximal gastrectomy with double flap anastomosis group
62309397|NCT06511609|ACTIVE_COMPARATOR|double-tract reconstruction（DTR）|Laparoscopic proximal gastrectomy with double-tract anastomosis group
62121087|NCT06675942|EXPERIMENTAL|Oscillation and Lung Expansion|
62121088|NCT06675942|EXPERIMENTAL|High-frequency chest wall oscillation|
62309398|NCT00360022|EXPERIMENTAL|Joint Visits|Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
62309399|NCT00360022|NO_INTERVENTION|Control|Transition patients in the control group will transfer care to adult GI provider in typical manner.
62309400|NCT00172380|EXPERIMENTAL|docetaxel and cisplatin|docetaxel 36mg/m2 and cisplatin 75mg/m2
62339619|NCT01319643|EXPERIMENTAL|Oxygenation, rigorous normal|Patients admitted in intensive care unit for 3 days. Administration of the lowest inspiratory fraction dose of oxygen to maintain oxygen peripheral saturation (SpO2) between 94 and 98% or an arterial partial pressure of oxygen (PaO2) between 70 and 100 mmHg. No oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
62339620|NCT01319643|NO_INTERVENTION|Oxygen, free conventional|Patients admitted in intensive care units for 3 days. Administration of oxygen inspiratory fractions to maintain SpO2 over 97%, up to a PaO2 of 150 mmHg. Oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
61920914|NCT02240173|ACTIVE_COMPARATOR|Haloperidol + Placebo|Combination of the conventional drug + Placebo
62679959|NCT01580722|OTHER|early|patients underwent \< 8 weeks reconstruction after injury
62309401|NCT05171530|EXPERIMENTAL|Lenvatinib with taxane drugs treatment for advanced gastric cancer|"Experimental: Lenvatinib plus taxane drugs The subjects in this arm will receive a Lenvatinib combined with single-agent taxanes therapy. A standard dose of chemotherapy: paclitaxel 135mg/m2 every 3 weeks or docetaxel 75mg/m2 every 3 weeks will be administrated. Lenvatinib is exploring four doses of 4mg, 8mg, 12mg, and 16mg, orally once a day every 3 weeks. In the first cycle, lenvatinib was administered 5 days before chemotherapy，once a day. Chemotherapy lasts up to 6 cycles, and lenvatinib continues to be administered until the disease progresses, intolerable side effects, or death.~Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and there is no obvious DLT within 21 days before the next subject can be treated.~Interventions:~* Drug: Paclitaxel or Docetaxel~* Drug: Lenvatinib"
62309402|NCT04462042|ACTIVE_COMPARATOR|Photon radiotherapy|Conventional photon radiation is delivered by volumetric arc therapy/intensity modulated radiotherapy/helical tomotherapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases \>2 cm is 57.5 Gy in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy.
61920915|NCT05551637|NO_INTERVENTION|control group|(n=300): Children eat usual dietary (not using Oral Nutritional Supplementation) for 3 months. After that, they will use the product in 3 months
62679960|NCT01580722|OTHER|delay|patients underwent \> 8 weeks reconstruction after injury
62679961|NCT01385995|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure (CPAP)|
61920916|NCT05551637|EXPERIMENTAL|specific intervention group|"(n=300): Children eat usual dietary and using 2 glasses (49,2 gr powdered milk x 180 ml boil water/time x 2 times/day) of the Oral Nutritional Supplementation as the side meals. The product provides GOS, Calcium, Probiotics, HMO, DHA, and Taurine within 3 months of use.~The product will be provided for subjects at school in 5 days per week (From Monday to Friday) and at home on weekend."
62309403|NCT04462042|EXPERIMENTAL|Proton radiotherapy|Proton radiation is delivered by spot scanning. Proton plans will be produced by single field optimisation/single field uniform dose or multifield optimisation/intensity modulated proton therapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases \>2 cm is 57.5 Gy(RBE) in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy(RBE) in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy(RBE).
62309404|NCT01667744|PLACEBO_COMPARATOR|Placebo|Placebo pill
62309405|NCT01667744|EXPERIMENTAL|Citalopram|Drug
62309406|NCT02252978|EXPERIMENTAL|Arm I (ciprofloxacin)|Patients receive ciprofloxacin PO BID for 2 weeks.
62309407|NCT02252978|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 2 weeks.
62309408|NCT06672887|EXPERIMENTAL|Intervention group|Employers randomized to the intervention group will get a personal link to the MiLES intervention.
62679962|NCT01385995|SHAM_COMPARATOR|Sham-Continuous Positive Airway Pressure (CPAP)|
62679963|NCT06084052|OTHER|Path Active|Participants randomised to use the device
62679964|NCT06084052|OTHER|Control Group|Participants randomised to care as usual
62679965|NCT06686420|EXPERIMENTAL|B. longum|Participants will be instructed to consume the capsule containing the live B. longum strain.
62679966|NCT06686420|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to consume the placebo capsule without any live bacteria.
61920917|NCT02382250||Catheterization Group|These are patients recruited from Bellevue Hospital and NYU Hospital Cardiac Catheterization Laboratories
61920918|NCT03624530|EXPERIMENTAL|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
61920919|NCT03624530|NO_INTERVENTION|No TKI therapy|Prophylactic TKI will not be given.
61920920|NCT06154200|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle gel applied to eyelids twice per day
61920921|NCT06154200|ACTIVE_COMPARATOR|Testosterone gel 4.5%|Testosterone gel 4.5% applied to eyelids twice per day
61920922|NCT03844477|EXPERIMENTAL|single-injection QLB(quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
61920923|NCT03844477|PLACEBO_COMPARATOR|Placebo control|Single-injection of QLB with NS is given preoperatively
61920924|NCT01646060|EXPERIMENTAL|Blood Draw|
61920925|NCT00882492|ACTIVE_COMPARATOR|1|This active arm is a continuous infusion of GLP-1 during cardiac surgery
62679967|NCT01433965|EXPERIMENTAL|Phase I Dose Escalation|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
62475711|NCT02605265|ACTIVE_COMPARATOR|Capecitabine Alone|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
62475712|NCT02605265|EXPERIMENTAL|Capecitabine with Irinotecan|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
61920926|NCT00882492|PLACEBO_COMPARATOR|2|This is a continuous infusion of normal saline solution infusion as placebo at (1.5 pmol/kg/min)
62309409|NCT06672887|NO_INTERVENTION|Control group|"The employees randomized to the control group will receive care as usual from their employer, as well as from their reintegration consultant or occupational physician. Their employer will not have access to the MiLES intervention during the study period. However, they will gain access for 6 months following a waiting-list period of 12 months."
62309410|NCT04145947||triple negative breast cancer|triple negative breast cancer patients with age ≤ 60 years old
62309411|NCT03076567||case|Stomach cancer cases from two previously conducted studies in China
62309412|NCT03076567||control|Controls from two previously conducted studies in China
62475713|NCT05816564|EXPERIMENTAL|Experimental Group|This is group that will receive the attention bias modification intervention that is programmed to train attention to positive stimuli 100% of the time. Both groups will receive the preceding 3-day brief mindfulness training.
62475714|NCT05816564|PLACEBO_COMPARATOR|Placebo/Control Group|"This is group that will receive the sham attention bias modification intervention that is programmed to train attention to positive stimuli 50% of the time. Both groups will receive the preceding 3-day brief mindfulness training."
62475715|NCT01255241||othopaedic surgical intervention|children with lower limbs deformities
61920927|NCT01209962||Cohort|"The majority of recruited patients will be treated on protocol HUM00004531 A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer."
62121089|NCT01735019|EXPERIMENTAL|group 1|administration of remifentanil with target-controlled infusion (TCI) system at a given concentration during anesthetic emergence
62121090|NCT03201549|EXPERIMENTAL|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
62121091|NCT02969863|ACTIVE_COMPARATOR|Usual Care Arm - Monitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
62121092|NCT02969863|ACTIVE_COMPARATOR|Usual Care Arm - Unmonitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
62121093|NCT02969863|EXPERIMENTAL|Bihormonal Bionic Pancreas - Monitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
62121094|NCT02969863|EXPERIMENTAL|Bihormonal Bionic Pancreas - Unmonitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
62121095|NCT02969863|EXPERIMENTAL|Insulin Only Bionic Pancreas - Monitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
62121096|NCT02969863|EXPERIMENTAL|Insulin Only Bionic Pancreas - Unmonitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
62309413|NCT01318902|EXPERIMENTAL|Dose Escalation Cohort: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
62475716|NCT04940312||Usual Care Group|Individuals with heart failure receiving standard medical care
62475717|NCT04940312||Intervention Group 1 (pedometer-monitoring only)|Individuals with heart failure receiving a pedometer for measurement of daily step count
61920928|NCT05652829||Children aged 9-12|We are recruiting 30 children aged 9-12 with one parent.
61920929|NCT02653261|EXPERIMENTAL|Tranexamic Acid|Tranexamic Acid (TXA): bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
61920930|NCT02653261|PLACEBO_COMPARATOR|Placebo|An equal volume of saline
61920931|NCT05606718|EXPERIMENTAL|dapagliflozin group|GDMT and dapagliflozin 10mg once daily
61920932|NCT05606718|ACTIVE_COMPARATOR|control group|GDMT only
62475718|NCT04940312||Intervention Group 2 (app-based coaching)|Individuals with heart failure receiving an individualized, app-based physical activity coaching on the basis of pedometer-based assessment of daily step count
62475719|NCT05355441||Multidisciplinar pain treatment patients|Major trauma patients with moderate, severe or incapacitating pain will be referred to consultation specialized in chronic pain and psychology. Patients will be evaluated, in terms of quality of life, before and after the treatment.
62475720|NCT03157193|EXPERIMENTAL|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
62475721|NCT03157193|SHAM_COMPARATOR|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
61920933|NCT05809739|EXPERIMENTAL|Treatment Group|"Device: STYLAGE® Hydro~1 mL up to 2.0 mL per area will be injected in the face, neckline and neck (optionally) at each injection session."
61920934|NCT04029532||Non-overweight/obese & normal weight|Body mass index (BMI) \< 24.0 kg/m\^2
61920935|NCT04029532||Overweight and obese|Body mass index (BMI) \>= 24.0 kg/m\^2
61920936|NCT01095471|EXPERIMENTAL|PCV13|Initial vaccination with PCV13
62475722|NCT03157193|NO_INTERVENTION|Control 2 Group|No gel application, only standard perimplantitis treatment.
62309414|NCT01318902|EXPERIMENTAL|Dose Escalation Cohort: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
62679968|NCT06688240||prescribed for ONIVYDE treatment according to the ONIVYDE China mainland SmPC|this is a prospective, single-arm, multicenter, open-label and non-interventional study
62679969|NCT06694909|EXPERIMENTAL|tDCS + PNS with action observation|
61920937|NCT01095471|EXPERIMENTAL|PCV7|Initial intervention with PCV7
61920938|NCT06053008|OTHER|Geriatric individuals|The relationship among pain perception, temporomandibular joint disorder severity and spine health
61920939|NCT00908011|ACTIVE_COMPARATOR|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
61920940|NCT00908011|ACTIVE_COMPARATOR|Standard Care|Increased dose of rosuvastatin to 20mg/day
61920941|NCT02403388||Multiprofessional primary care offices with PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
61920942|NCT02403388||Multiprofessional primary care offices without PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
61920943|NCT06268145|EXPERIMENTAL|Fixed Sequence 1|Participants will receive single dose of ECC5004 F1 at fasted state, followed by F2 at fasted state, F1 at fed state and F2 at fed state in four treatment periods.
61920944|NCT06268145|EXPERIMENTAL|Fixed Sequence 2|Participants will receive a single dose of ECC5004 F2 at fasted state, followed by F1 at fasted state, F2 at fed state, and F1 at fed state with four treatment periods.
61944469|NCT01191411|ACTIVE_COMPARATOR|Mailed invitations for FIT test kits|"Fecal Immunochemical Tests (FIT) kits from Polymedco Incorporated are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer using a Polymedco home FIT kit. Mailed invitation to complete a free one sample home FIT kit. Automated and live phone call reminders to promote screening completion, plus usual medical care.~Patients with abnormal FIT results are navigated to complete a diagnostic colonoscopy."
62475723|NCT06562517|NO_INTERVENTION|Control-Standard care|No intervention will be performed on the nurses in this group. After the research is completed, access to the website will be provided to the nurses in the control group.
62475724|NCT06562517|EXPERIMENTAL|Intervention Group|The group will use the digital training modules developed for sustainable pediatric oncology nursing education for six months.
62475725|NCT04932837||migrant worker residents|The target population will be the 124 residents in the 2 migrant worker residences who were included in the previous seroprevalence study and those who arrived at the 2 residences since September 1st, 2020
62475726|NCT05278130|ACTIVE_COMPARATOR|Intervention Arm|The intervention-arm will have a pelvic exam performed with vaginal swab collection at their initial obstetric visit (standard of care). The women undergoing the intervention will then subsequently undergo additional vaginal swab collections in 2 week intervals starting at 16 weeks gestational age until 34 weeks gestational age. Subjects will be informed of the results of the vaginal swab. If positive for an infection, subjects will be provided with the appropriate treatment in pregnancy.
62679970|NCT06694909|EXPERIMENTAL|sham tDCS + sham PNS with action observation|
62679971|NCT06694909|EXPERIMENTAL|tDCS + PNS without action observation|
62679972|NCT06694909|ACTIVE_COMPARATOR|sham tDCS + PNS with action observation|
62475727|NCT05278130|NO_INTERVENTION|Control Arm|The control arm will undergo the standard of care with vaginal swab collection at their initial obstetric visit. The control arm will not undergo additional vaginal swab collections unless otherwise indicated under standard of care (further testing for bacterial vaginosis is completed in women who describe symptoms with the diagnosis or present for preterm contractions and/or pelvic cramping). There will be no placebo for the control group.
62475728|NCT00556322|EXPERIMENTAL|1|
62475729|NCT00556322|ACTIVE_COMPARATOR|2|
62475730|NCT00846560||1 ALS patients|
62679973|NCT06694909|ACTIVE_COMPARATOR|tDCS + sham PNS with action observation|
62679974|NCT03905174|ACTIVE_COMPARATOR|Standard treatment|A porous collar for either distal or proximal femoral replacements
62679975|NCT03905174|ACTIVE_COMPARATOR|standard treatment + HA|A porous collar with hydroxyapatite (HA) for either distal or proximal femoral replacements
62679976|NCT03905174|ACTIVE_COMPARATOR|standard treatment + HA + autogenic cells|A porous collar with hydroxyapatite (HA) and stem cells for either distal or proximal femoral replacements
62679977|NCT06035510|EXPERIMENTAL|whey protein supplement|Participants are given lactose-free Isolated whey protein 23 gm (containing with whey protein isolate 98.7 % ,Soya lecithin 1.3 % ) which mixed with water 350 ml at 6 p.m prior to surgery and 6.00 a.m. at first day after post surgery
61944470|NCT01191411|ACTIVE_COMPARATOR|Mailed invitations for a colonoscopy|"Invitation to schedule a colonoscopy are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer with colonoscopy. Mailed invitation to complete one free colonoscopy. Automated and live phone reminders to promote screening completion, plus usual medical care.~Patients with abnormal polyps or adenomas will follow standard clinical protocol after their procedure."
62475731|NCT00846560||2 Healthy subjects|
62475732|NCT06176534|EXPERIMENTAL|A|nab-paclitaxel 130mg/m2，day 1 and day 8 Capecitabine 2000mg/m2，from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8
62475733|NCT06176534|ACTIVE_COMPARATOR|B|palbociclib/Dalpiciclib Letrozole/Anastrozole/fulvestrant
62475734|NCT02175602|EXPERIMENTAL|Cohort 2|Sertraline (50 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Sertraline (50 milligrams each morning) days 23-29
62475735|NCT02175602|EXPERIMENTAL|Cohort 1|Escitalopram (10 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Escitalopram (10 milligrams each morning) days 23-29
62475736|NCT06563362|EXPERIMENTAL|Elective target volume de-escalation arm|
62475737|NCT00147498|EXPERIMENTAL|5 mg BID|CP 690,550 5 mg BID
62475738|NCT00147498|EXPERIMENTAL|15 mg BID|CP 690,550 15 mg BID
62679978|NCT06035510|NO_INTERVENTION|standard operative care|Participants followed standard operative care
62679979|NCT05264675||Primary suture|primary suture of EPL
62679980|NCT05264675||EIP- transfer|transfer of the EIP to EPL
62679981|NCT06448143|EXPERIMENTAL|Weight-based dose|
62679982|NCT02759263|EXPERIMENTAL|Working Memory Intervention|The group randomized to the Working Memory intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the adolescents' responses, time spent on each task, and evolution curves.
62679983|NCT02759263|NO_INTERVENTION|Control group - Standard of Care|Adolescents randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, an adolescent in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like adolescents assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
62679984|NCT05362799|ACTIVE_COMPARATOR|GROUP 1|GROUP 1: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
62475739|NCT00147498|EXPERIMENTAL|30 mg BID|Oral tablets administered at a dose of 30 mg BID for 6 weeks
62475740|NCT00147498|PLACEBO_COMPARATOR|Placebo|Placebo
62475741|NCT03612232|EXPERIMENTAL|Cabozantinib|oral cabozantinib as tablets continuously (60 mg single dose, tablets)
62679985|NCT05362799|ACTIVE_COMPARATOR|GROUP 2|GROUP 2: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
62679986|NCT05362799|ACTIVE_COMPARATOR|GROUP 3|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
62679987|NCT05362799|ACTIVE_COMPARATOR|GROUP 4|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
61920945|NCT04113811|EXPERIMENTAL|Microwave needle thermoablation of prostate cancer|The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.
62475742|NCT01665690|EXPERIMENTAL|Intervention period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
62475743|NCT01665690|NO_INTERVENTION|Control Period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
62475744|NCT00910052|EXPERIMENTAL|Fibrin sealant|received intraoperative fibrin sealant
62475745|NCT00910052|NO_INTERVENTION|Control|No fibrin sealant
62475746|NCT01255085|EXPERIMENTAL|10 g of yellow pea fiber|
62679988|NCT05784597|EXPERIMENTAL|Cohort A|3 female + 3 male patients with a primary tumor only
62679989|NCT05784597|EXPERIMENTAL|Cohort B|Patients with a primary tumor and/or advanced/metastatic disease with a quantifiable number of lesions
62679990|NCT05538130|EXPERIMENTAL|Monotherapy Dose Escalation (Phase 1a)|Participants will receive PF-07799544
61920946|NCT00762593|EXPERIMENTAL|1|transvaginal electrical stimulation with a home use programmable device used 30 minutes every day during 8 weeks
61920947|NCT00762593|PLACEBO_COMPARATOR|2|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
61944471|NCT01191411|ACTIVE_COMPARATOR|Visit Based Care|"No invitation to complete colorectal cancer screening.~Intervention: Usual medical care. Patients will continue to see their regular physician, and follow their physician's regular standard of care."
62679991|NCT05538130|EXPERIMENTAL|Phase 1b Substudy B Combination Dose Escalation|Participants will receive PF-07799544 and PF-07799933
62679992|NCT05538130|EXPERIMENTAL|Phase 1b Substudy B Combination Dose Expansion|Participants will receive PF-07799544 and PF-07799933
62679993|NCT05538130|EXPERIMENTAL|Phase 1b Substudy C Combination Dose Expansion|Participants will receive PF-07799544 and PF-07799933
62475747|NCT01255085|EXPERIMENTAL|20 g of yellow pea fiber|
62475748|NCT01255085|EXPERIMENTAL|10 g of yellow pea protein|
62475749|NCT01255085|EXPERIMENTAL|20 g of yellow pea protein|
62475750|NCT01255085|EXPERIMENTAL|Control Tomato Soup|
62475751|NCT01855035|EXPERIMENTAL|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
62475752|NCT01855035|OTHER|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
62475753|NCT00723710||Intron A|Patients with malignant melanoma who are free of disease post-surgery but at high risk for systemic recurrence.
62121097|NCT03922334|EXPERIMENTAL|Navigation Group|Women who are randomized into NNM2 will be assigned to a patient navigator. The patient navigator will meet with the patient during pregnancy and after delivery occurs for introductions and education. The patient navigator will offer support and resources (transportation, community referrals, support for your mental health, connection to your doctors, etc.). The navigator will also help to schedule postpartum medical appointments, and will remind the patients of these appointments via text, email, or phone calls. The navigator will continue to provide psychosocial support, social needs support, and continued linkage to resources through one-year postpartum.
62121098|NCT03922334|NO_INTERVENTION|Non-navigation cohort|No navigation will be provided; women will receive usual care.
62121099|NCT05845528|PLACEBO_COMPARATOR|Respondres placebo effect|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~* The patients will receive tDCS stimulation treatment prefrontal cortex dorso lateral~* According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~* Placebo stimulation uses a 2 milliamperes current during in the first minutes, in the 10 min and in 19 minutes."
62121100|NCT05845528|ACTIVE_COMPARATOR|No respondres placebo effect|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~* The patients will receive tDCS stimulation treatment prefrontal cortex dorso lateral~* According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~* Active stimulation uses a 2 milliamperes current during 20 minutes."
62121101|NCT02749318|EXPERIMENTAL|Experimental Group|Consented patients who complete the initial Experimental Group Questionnaire, receive a prophylaxis, have the IL-1 genetic test for risk of severe periodontitis performed, their dental records monitored for 18 months post-enrollment, and answer a Study Completion Questionnaire 18 months post-enrollment.
62309415|NCT01318902|EXPERIMENTAL|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were not treated with any other proteasome inhibitor (PI). Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
62309416|NCT01318902|EXPERIMENTAL|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until PD or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were previously treated with any other PI. Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
62309417|NCT06216886|EXPERIMENTAL|OnabotulinumtoxinA|Intradermal injections will be placed in the affected trigeminal territories according to a specific facial map that we have developed.
62309418|NCT06216886|PLACEBO_COMPARATOR|Saline|The same procedure will be followed as above, but saline will be injected instead of onabotA
62309419|NCT00105729|OTHER|Arm 1|
62309420|NCT02514057||Healthy|Volunteers over 18 years
62309421|NCT02514057||Gastrointestinal disorders|Over 18 and with any gastrointestinal or liver disorder
62309422|NCT02514057||Non-gastrointestinal disorders|Over 18 and with any medical condition requiring hospital attention in which there is no primary gastrointestinal or liver disease
62309423|NCT02759822||Group A: Acute Lymphoblastic Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy)~Preferred conditioning:~* Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120)~Alternative conditionings:~1. Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200)~2. Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)"
62309424|NCT02759822||Group B: Acute Myeloid Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200~Alternative conditionings:~1. Bu9,6 + Flu150 + TBI200~2. Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF"
62309425|NCT00783510||HUMIRA® Treatment Arm|For patients taking HUMIRA®
62309426|NCT00783510||Methotrexate Treatment Arm|For patients taking Methotrexate
62309427|NCT06402773|EXPERIMENTAL|Device intervention|
62309428|NCT01839994|EXPERIMENTAL|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
62309429|NCT01839994|ACTIVE_COMPARATOR|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
62309430|NCT04024228|EXPERIMENTAL|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
62309431|NCT04024228|ACTIVE_COMPARATOR|Group 2: QIV-SD|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
62309432|NCT04301453|EXPERIMENTAL|Maternal Scent Group|Infants in this group will be exposed to a breast pad worn by their mothers to extract maternal scent. This exposure will last 24 hours.
62309433|NCT04301453|NO_INTERVENTION|Control Group|Infants in this group will receive standard of care.
62309434|NCT00787735|EXPERIMENTAL|Integrated Care|Integrated Substance Abuse and Psychiatric Care (ISAP). Subjects received both their substance abuse and psychiatric care within the ATS clinic. Counseling compliance will be measured over time.
62475754|NCT03264352|ACTIVE_COMPARATOR|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
62475755|NCT03264352|PLACEBO_COMPARATOR|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
62309435|NCT00787735|ACTIVE_COMPARATOR|Parallel Care|Parallel Substance Abuse and Psychiatric Care (PSAP). Subjects received their substance abuse treatment at the ATS clinic. Their psychiatric care was received at Community Psychiatry. Counseling compliance will be measured over time.
62309436|NCT01385943||Skin Cancer|Patients from dermatology practices throughout Europe that have a skin lesion or tumor requiring a biopsy for diagnosis.
62309437|NCT01954628|EXPERIMENTAL|AQX-1125|1 x AQX-1125 capsule daily
62475756|NCT05915091|EXPERIMENTAL|Dry Needling|
62475757|NCT05915091|OTHER|Cross Friction Massage|
62475758|NCT05382052||Study group|The study is based on a blood sample analysis in stage IIIA non-small lung cancer patients that are going to receive neoadjuvant treatment in the real world. The patients participating in this non-interventional study will not receive treatment in relation to the study. Prospective information about treatment after neoadjuvant treatment and after the last blood extraction will not be collected.
62679994|NCT00382928|NO_INTERVENTION|Standard of Care Group|Patients will receive standard of care measures in case of cardiac arrest. They will not receive AECD monitoring or intervention
62121102|NCT02749318|NO_INTERVENTION|Usual Care Group|Consented patients who complete the initial Usual Care Group Questionnaire, receive a prophylaxis and have their dental records monitored for 18 months post-enrollment.
62121103|NCT04801563|OTHER|SINGLE ARM|
62121104|NCT01977638|EXPERIMENTAL|CXD101|Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
62121105|NCT06150287|ACTIVE_COMPARATOR|Probiotics Group|Participants will receive one probiotics capsule daily for six months immediately after the onset of post-surgical non-infectious diarrhea.
62121106|NCT06150287|PLACEBO_COMPARATOR|Placebo Group|Participants will receive one placebo capsule daily for six months immediately after the onset of post-surgical non-infectious diarrhea.
62121107|NCT02729701|EXPERIMENTAL|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
62121108|NCT02234739|EXPERIMENTAL|active treatment|Chinese patients with invasive pulmonary aspergillosis treated by voriconazole, who has COPD as underlying condition
62121109|NCT04353674|SHAM_COMPARATOR|Control|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo standard of care
62121110|NCT04353674|ACTIVE_COMPARATOR|SLEDD with a L-MOD|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
62121111|NCT02570711|EXPERIMENTAL|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
62309438|NCT01954628|PLACEBO_COMPARATOR|Placebo|1 x Placebo capsule daily
62309439|NCT06510465|EXPERIMENTAL|HER2 negative breast cancer cohort|Human Epidermal Growth Factor Receptor 2 (HER2 ) negative breast cancer utidelone and cisplatin
62121112|NCT02570711|EXPERIMENTAL|Regimen 2|Nab-paclitaxel and gemcitabine
62309440|NCT06510465|EXPERIMENTAL|HER2 positive breast cancer cohort|Human Epidermal Growth Factor Receptor 2 (HER2 ) positive breast cancer utidelone，cisplatin，tratuzumab and pertuzumab (both Intravenous preparations or subcutaneous preparations can be used)
62309441|NCT06148519|EXPERIMENTAL|Using 2WIN-S portable refractor for amblyopia screening|
62309442|NCT03027037||Remitted Major Depression Group|Women in this group will have experienced at least one episode of major depression in their lifetime, but no episodes in the two months prior to study enrollment.
62121113|NCT05601830|EXPERIMENTAL|QN-030a|QN-030a in Adult subjects with MRD
62121114|NCT06370572|NO_INTERVENTION|Pre-implementation|PLWD presenting to the ED with reported hip pain in the year preceding implementation of the PAINAD EHR prompt
62121115|NCT06370572|EXPERIMENTAL|Post-implementation|PLWD presenting to the ED with reported hip pain in the 10 months following implementation of the PAINAD EHR prompt
62121116|NCT05542862|EXPERIMENTAL|SpikoGen vaccine|Single booster dose of SpikoGen Covid-19 vaccine
62121117|NCT06231069|EXPERIMENTAL|Multi-nutrient supplementation during training|
62121118|NCT06231069|PLACEBO_COMPARATOR|Placebo during training|
62121119|NCT03239899|EXPERIMENTAL|HIV Participants|Participants who received 200 mg of Pembrolizumab administered as a one-time intravenous infusion over 30 minutes during the treatment phase of the study.
62121120|NCT03216538|ACTIVE_COMPARATOR|AS101 1% oral solution|Daily dose 0.4 ml administered orally
62121121|NCT03216538|PLACEBO_COMPARATOR|Placebo|Daily dose of 0.4 ml administered orally
62121122|NCT01482975|EXPERIMENTAL|Smoking and Alcohol Prevention|TTM expert system
62121123|NCT01482975|ACTIVE_COMPARATOR|Diet and Exercise|TTM expert system
62309443|NCT03027037||Control Group|Women in this group will never have experienced any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Axis I psychological disorder.
62309444|NCT05721261|EXPERIMENTAL|Active treatment|
62309445|NCT05721261|SHAM_COMPARATOR|Sham treatment|
62309446|NCT01668069|EXPERIMENTAL|Ondansetron|study drug
62309447|NCT01668069|NO_INTERVENTION|Doxylamine and Pyridoxine (vitamin B6)|other nausea treatment in use
62309448|NCT03598777|EXPERIMENTAL|Dysport - Dose Escalation stage 1|Intramuscular injection of Dysport on day 1 of each cycle.
62309449|NCT03598777|PLACEBO_COMPARATOR|Placebo - Dose Escalation stage 1 and Dose Expansion stage 2|Intramuscular injection on day 1 of cycle 1.
61920948|NCT06415851|EXPERIMENTAL|mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody|"Induction therapy: mFOLFOX6 regimen + bevacizumab. mFOLFOX6 regimen: Oxaliplatin 85 mg/m2 ; LV 400 mg/m2; 5-FU 400 mg/m2, Intravenous bolus injection, day 1, then maintain 1200mg/(m2∙d) × 2d continuous intravenous infusion (total volume 2400mg/m2, infusion 46-48h), q2w; Bevacizumab: 5mg/kg; lasting 2 cycles.~Combination therapy: mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody. mFOLFOX6 regimen: Oxaliplatin 85 mg/m2 intravenously infused for 90-120 minutes on day 1; LV 400 mg/m2 intravenous infusion for 2 hours, combined with oxaliplatin injection time on day 1; 5-FU 400 mg/m2, Intravenous bolus injection, day 1, then maintain 1200mg/(m2∙d) × 2d continuous intravenous infusion (total volume 2400mg/m2, infusion 46-48h), q2w; bevacizumab: 5mg/kg, intravenously Infusion, day 1, q2w; Slulimab: 200 mg, intravenous infusion, day 1, q2w. Every 2 weeks is a cycle."
61920949|NCT02516735|EXPERIMENTAL|Group 1|I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
61920950|NCT02516735|ACTIVE_COMPARATOR|Group 2|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
61920951|NCT04169347|OTHER|Active|This is an open label study single arm
61920952|NCT00613197|EXPERIMENTAL|1 Epanova|
62309450|NCT03598777|ACTIVE_COMPARATOR|Dysport - Dose Expansion stage 2|Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.
62309451|NCT05948878|ACTIVE_COMPARATOR|Retrograde Directional Test|Subjects during the Retrograde Directional Test will have the three taping methods placed on their left and/or right antecubital fossa region to superficially secure an IV catheter (i.e., the catheter will be placed on top of the participant's skin and not in the vein but will be taped as if the catheter was placed intravenously). Six total measurements will be obtained of which three will be using the Retrograde Directional Test (i.e., each taping method will undergo testing for each directional method). The order of placing the different taping methods and the direction testing will be randomized.
62679995|NCT00382928|EXPERIMENTAL|AECD Monitoring + Standard of Care Group|Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital. Defibrillation of pulseless VT/VF by AECD.
62679996|NCT03765359|ACTIVE_COMPARATOR|metforminhydrochloride|Metformin medication starts on 12-14 weeks of gestation. The starting dosage is 1 tablet (500 mg) x1 and it is increased gradually 1 tablet a week up to 2+2 tablets (2000mg) daily. Duration of the treatment is approximately until one week before delivery. Otherwise metformin treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
62679997|NCT03765359|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo tablets starts on 12-14 weeks of gestation. The starting dosage is 1 tablet x1 and it is increased gradually 1 tablet a week up to 2+2 tablets daily. Duration of the treatment is approximately until one week before delivery. Otherwise placebo treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
62679998|NCT06359626|EXPERIMENTAL|Sequence Group A|30 subjects, Cross-over, Single dose of YHR2401 on day 1, Single dose of YHP2205 on day 8
61920953|NCT00613197|PLACEBO_COMPARATOR|2 Placebo|
61920954|NCT04687618|EXPERIMENTAL|Automatic control of FiO2|Infants randomized to this arm will be monitored using automatic oxygen control system on the High Flow Nasal Cannula. When infants oxygen saturation are out of the target range the OAM module on HFNC will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation in the target range.
62121124|NCT03416842|EXPERIMENTAL|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
62121125|NCT02448446|ACTIVE_COMPARATOR|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
62121126|NCT02448446|ACTIVE_COMPARATOR|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
62121127|NCT01611467|EXPERIMENTAL|20 mg oral CC-223 with microtracer|A single 20-mg oral dose of CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
62121128|NCT01611467|EXPERIMENTAL|20 mg oral CC-223 fasting|A single 20-mg oral dose of CC-223 tablet under fasting conditions
62309452|NCT05948878|ACTIVE_COMPARATOR|90 Degrees Directional Test|Subjects during the 90 Degrees Directional Test will have the three taping methods placed on their left and right antecubital fossa region, superficially taping an IV catheter (i.e., the catheter will be placed on top of the participant's skin and not in the vein but will be taped as if the catheter was placed intravenously). Six total measurements will be obtained of which three will be using the 90 Degrees Directional Test (i.e., each taping method will undergo testing for each directional method). The order of placing the different taping methods and the direction testing will be randomized.
61920955|NCT04687618|ACTIVE_COMPARATOR|Manual Control of FiO2|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
61920956|NCT04291274||inhalation anesthesia group|Unilateral and Bilateral cochlear implantation,which used inhalation anesthesia
61920957|NCT04291274||intravenous anesthesia group|Unilateral and Bilateral cochlear implantation, which used intravenous anesthesia
61920958|NCT03504579|EXPERIMENTAL|rt-fMRI neurofeedback aimed at STG|One session of rt-fMRI neurofeedback from the patient's STG.
61920959|NCT03504579|SHAM_COMPARATOR|sham rt-fMRI|One session of rt-fMRI neurofeedback from the patient's motor cortex.
62121129|NCT01611467|EXPERIMENTAL|20 mg oral CC-223 fed|A single 20-mg oral dose of CC-223 tablet under fed conditions
62121130|NCT05766969|EXPERIMENTAL|CBD/PEA|Subject will receive a 42-day supply of 10/50 mg CBD/PEA sublingual tablets to be taken 3 times a day for 42 days.
62121131|NCT05766969|PLACEBO_COMPARATOR|Placebo Control|A placebo sublingual tablet to be taken three times a day for 42 days.
61920960|NCT02094495||breast cancer group|Taking tamoxifen
61920961|NCT02201511|EXPERIMENTAL|Arm 1|
61920962|NCT02201511|EXPERIMENTAL|2|
61920963|NCT02201511|EXPERIMENTAL|3|
61920964|NCT02201511|EXPERIMENTAL|4|
62309453|NCT01917825|EXPERIMENTAL|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
62679999|NCT06359626|EXPERIMENTAL|Sequence Group B|30 subjects, Cross-over, Single dose of YHP2205 on day 1, Single dose of YHR2401 on day 8
62309454|NCT02017249|EXPERIMENTAL|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
62309455|NCT02017249|PLACEBO_COMPARATOR|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
62309456|NCT02609893|ACTIVE_COMPARATOR|Modified Directly Observed Therapy|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) observed daily dosing (modified for non-observed Saturday and Sunday dosing) for 8 weeks
61920965|NCT04016740|EXPERIMENTAL|Multimodal General Anesthesia|"Intraoperative~The anesthesiologists involved in this study will be trained to infer differences in anti-nociception, unconsciousness movement and changes during other perioperative events by monitoring EEG. They will also be trained in titrating hypnotic and nociceptic medications based on changes in EEG.~1. Routine anesthetic induction~2. Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.25% ropivacaine on either side of the sternum after anesthetic induction but before surgical incision~3. Ketamine (0.06 to 0.12 mg.kg/hr)~4. Remifentanil (0.05-0.2 mcg/kg/min)~5. Dexmedetomidine (0.2-1.0 mcg/kg/hr)~6. Rocuronium intermittent bolus (TOF)~7. Propofol infusion ± Sevoflurane titrated based on EEG monitoring~Postoperative~1. Standard pain management protocol~2. Dexmedetomidine infusion 0.2-1.4 mcg/kg/hr (EEG guided)~3. Infusion continued till extubation~4. Propofol infusion may be added/used for sedation based on the treating physician's discretion"
61920966|NCT04016740|OTHER|Standard Practice with EEG monitoring|The initial 2 patients will receive standard anesthesia practice and perioperative EEG monitoring will be recorded to learn the patterns associated with our standard practice.
61920967|NCT05675605|EXPERIMENTAL|Phase 1 Dose Escalation|Multiple doses of TY-1091 for oral administration. Intervention: Drug: TY-1091
61920968|NCT05675605|EXPERIMENTAL|Phase 2 Dose Expansion|Multiple doses of TY-1091 for oral administration. Intervention: Drug: TY-1091
61920969|NCT05841121|EXPERIMENTAL|Dexamethasone group|The intervention is antenatal dexamethasone. Participants in the intervention group will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
61920970|NCT05841121|NO_INTERVENTION|Control group|Participants in the control group will be received standard care.
61920971|NCT03723603|EXPERIMENTAL|Fibrillar Collagen Powder Dressing|
62121132|NCT01786525|EXPERIMENTAL|House Calls only|60-minute educational intervention in patient's home which will be delivered by a health educator.
62309457|NCT02609893|ACTIVE_COMPARATOR|Unobserved Dosing|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) provided weekly (7 tablets) for unobserved daily dosing for 8 weeks
62680000|NCT06690203|OTHER|A. Combining NRICM102 decoction with standard treatment for 12 weeks|Combining NRICM102 decoction with standard treatment for 12 weeks
62680001|NCT06690203|OTHER|B. Combining NRICM102 decoction with standard treatment for 24 weeks|Combining NRICM102 decoction with standard treatment for 24 weeks
62680002|NCT05948943|EXPERIMENTAL|Adult participants, alpelisib dose 1 (Stage 1)|Adult participants (≥18 years of age) who will receive dose 1 of alpelisib an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1)
61944472|NCT04280835|EXPERIMENTAL|Group Psychoeducation that Focused on Social Skill Development|The Psychoeducation program that focused on social skill development, consists of 8 sessions, one day a week, each lasting an average of 60 Minutes. Psychoeducation was conducted in three groups and each of them consisted of eight patients.
62121133|NCT01786525|ACTIVE_COMPARATOR|House Calls + Web-Based Decision Support|Home based intervention plus web-based patient-centered decision support program that will be offered to participants following the home based intervention.
62121134|NCT01786525|NO_INTERVENTION|Control|100 patients on the Organ Transplant Tracking Record who are not receiving the study intervention
62309458|NCT00071773|ACTIVE_COMPARATOR|Modified Early Treatment Diabetic Retinopathy Study (ETDRS)|modified-ETDRS
62309459|NCT00071773|ACTIVE_COMPARATOR|Mild Macular Grid (MMG)|MMG technique
62309460|NCT04507750|EXPERIMENTAL|camrelizumab+apatinib mesylate|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
62309461|NCT04634123|EXPERIMENTAL|Primary anterior teeth pulpotomy by White Portland Cement|
62309462|NCT04634123|OTHER|Primary anterior teeth pulpotomy by White MTA|
62475759|NCT04727398|OTHER|Cataract patients who was scheduled for phacoemulsification|Wide-field optical coherence tomography was performed before the surgery, and then was done at 1, 3, 6 and 12 months following the phacoemulsification.
62475760|NCT00836004|EXPERIMENTAL|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
62475761|NCT00836004|ACTIVE_COMPARATOR|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
62121135|NCT05393726|EXPERIMENTAL|Suprainguinal Fascia Iliaca Block group|Patients will receive ultrasound-guided suprainguinal fascia iliaca block injection 40 ml of bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.
62475762|NCT06561503||cases group|Metabolic Cases
62121136|NCT05393726|EXPERIMENTAL|Lumbar Erector Spinae Plane Block group|Patients will receive ultrasound-guided lumber erector spinae plane block (L-ESPB) injection 40ml bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.
62121137|NCT05393726|NO_INTERVENTION|control group|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia by using I.V. fentanyl (1µg/kg), with elevation of mean arterial blood pressure for more than 20% of their baseline values, additional bolus doses of fentanyl 0.5 µg /kg.
62121138|NCT03702647|EXPERIMENTAL|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
62121139|NCT03702647|PLACEBO_COMPARATOR|Normal Saline|30mL of normal saline placed in the POEM tunnel
62121140|NCT02135042|ACTIVE_COMPARATOR|Arm I (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62121141|NCT02135042|EXPERIMENTAL|Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)|Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62121142|NCT02135042|ACTIVE_COMPARATOR|Arm III (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen as in Arm I of Phase II.
62121143|NCT02135042|EXPERIMENTAL|Arm IV (chemoradiation, observation)|Patients undergo clinical observation.
62121144|NCT00917241|EXPERIMENTAL|MMI+IID group|MMI,methimazole；IID,intrathyroid injection of dexamethasone
62121145|NCT00917241|ACTIVE_COMPARATOR|MMI Group|MMI,methimazole
62121146|NCT01843569|EXPERIMENTAL|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
62121147|NCT02399865|EXPERIMENTAL|YSBNT Group|Six 50 minute YSBNT sessions (delivered by a trained YSBNT practitioner) for over a maximum period of 12 weeks
62121148|NCT02399865|NO_INTERVENTION|Treatment as Usual Group|Usual care delivered by treatment-as-usual practitioners
62121149|NCT01624844|EXPERIMENTAL|Calculation of dural sac volume|
62309463|NCT04930250|EXPERIMENTAL|Oat bran fibre processed with method A|Beverage powder with 12% oat bran processed with method A
62309464|NCT04930250|EXPERIMENTAL|Oat bran fibre processed with method B|Beverage powder with 12% oat bran processed with method B
62309465|NCT04930250|EXPERIMENTAL|Oat bran fibre processed with method C|Beverage powder with 12% oat bran processed with method C
62309466|NCT04930250|ACTIVE_COMPARATOR|Minimally-processed oat bran (positive control)|Beverage powder with minimally-processed oat bran (Positive Control)
62309467|NCT04930250|PLACEBO_COMPARATOR|Readily-digestible carbohydrate (negative control)|Beverage powder with readily digestible carbohydrate (Negative Control)
62475763|NCT06627829|EXPERIMENTAL|Group A|
62475764|NCT06627829|EXPERIMENTAL|Group B|
62475765|NCT06627829|ACTIVE_COMPARATOR|Control group|
62475766|NCT01655654|NO_INTERVENTION|Cohort 1|All employees within the acute care hospital that signed the informed consent form and provided their individual data.
62475767|NCT01655654|ACTIVE_COMPARATOR|Cohort 2|All subjects of cohort 1 who also are considered hypertensive and participated in one or more study interventions, which include behavioral interventions (an increase in physical activity, or dietary changes) or who have a primary care provider visit to discuss hypertension.
62475768|NCT01881165|EXPERIMENTAL|Cranberry|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate).
62475769|NCT01881165|PLACEBO_COMPARATOR|Placebo|A capsule containing control formulation
62475770|NCT04306068|EXPERIMENTAL|Experimental group|Athletes included in the experimental group will perform a plyometric exercise protocol. Each session will consist of a 4-station circuit with 1 minute rest between each station and 30 seconds between sets
62680003|NCT05948943|EXPERIMENTAL|Adult participants, alpelisib dose 2 (Stage 1)|Adult participants (≥18 years of age) who will receive dose 2 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1).
62680004|NCT05948943|EXPERIMENTAL|Pediatric participants (6-17 years of age), alpelisib dose 2 (Stage 1)|Pediatric participants 6-17 years of age who will receive dose 2 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1)
62121150|NCT05845645|EXPERIMENTAL|Part A|Study participants enrolled and randomized to this arm will receive a single dose of UCB0599 in 3 different formulations according to a pre-specified sequence during both Treatment Periods in the absence of esomeprazole, and the Treatment Periods in the presence of esomeprazole.
62309468|NCT02282332|EXPERIMENTAL|Patiens Discharged on Ticagrelor|Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
62309469|NCT06442241|EXPERIMENTAL|Group 1 (LYB005 low dose without adjuvant; young adults)|Young adults (18-59 years old) will receive a single injection of low dose LYB005 (30μg) without adjuvant on Day 1.
62309470|NCT06442241|EXPERIMENTAL|Group 2 (LYB005 middle dose without adjuvant; young adults)|Young adults (18-59 years old) will receive a single injection of middle dose LYB005 (60μg) without adjuvant on Day 1.
62309471|NCT06442241|EXPERIMENTAL|Group 3 (LYB005 high dose without adjuvant; young adults)|Young adults (18-59 years old) will receive a single injection of high dose LYB005 (120μg) without adjuvant on Day 1.
62309472|NCT06442241|EXPERIMENTAL|Group 4 (LYB005 low dose with adjuvant; young adults)|Young adults (18-59 years old) will receive a single injection of low dose LYB005 (30μg) with adjuvant on Day 1.
62680005|NCT05948943|EXPERIMENTAL|Pediatric participants (6-17 years of age), alpelisib dose 3 (Stage 1)|Pediatric participants 6-17 years of age who will receive dose 3 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1).
62680006|NCT05948943|EXPERIMENTAL|Adult participants, alpelisib (Stage 2)|Adult participants (≥18 years of age) who will receive alpelisib at the dose selected for confirmatory phase in adult participants (Stage 2)
62680007|NCT05948943|PLACEBO_COMPARATOR|Adult participants, placebo (Stage 2)|Adult participants (≥18 years of age) who will receive matching placebo
62680008|NCT05948943|EXPERIMENTAL|Pediatric participants (6-17 years of age), alpelisib (Stage 2)|Pediatric participants (6-17 years of age) who will receive alpelisib at the dose selected for confirmatory phase in pediatric participants (Stage 2)
62680009|NCT05948943|PLACEBO_COMPARATOR|Pediatric participants (6-17 years of age), placebo (Stage 2)|Pediatric participants (6-17 years of age) who will receive matching placebo
62680010|NCT05948943|EXPERIMENTAL|Pediatric participants (2-5 years of age), alpelisib (Stage 2)|Pediatric participants of 2-5 years who will dose 3 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier
62680011|NCT04879732|OTHER|ACTIS hip stem|All participants will receive the ACTIS hip stem.
62680012|NCT04963413|EXPERIMENTAL|Autologous DCs derived from PBMC loaded with RNA|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
62680013|NCT06114485|EXPERIMENTAL|Digital Mental Health Intervention (DMHI)|Participants randomized to Arm 1 will be sent an Amazon Alexa device, with a newly designed VIPA treatment program installed, and will receive a guidebook to help the older adult understand the device and utilize the VIPA treatment program to its fullest potential.
62680014|NCT06114485|ACTIVE_COMPARATOR|Control Treatment (CT)|Participants randomized to Arm 2 will be sent an Amazon Alexa device with guidebook to help the older adult understand how to use the device.
62680015|NCT06132360|EXPERIMENTAL|cohort 1|or placebo
62309473|NCT06442241|EXPERIMENTAL|Group 5 (LYB005 middle dose with adjuvant; young adults)|Young adults (18-59 years old) will receive a single injection of middle dose LYB005 (60μg) with adjuvant on Day 1.
62680016|NCT06132360|EXPERIMENTAL|Cohort 2|or placebo
62680017|NCT06132360|EXPERIMENTAL|Cohort 3|or placebo
62680018|NCT06132360|EXPERIMENTAL|Cohort 4|or placebo
62680019|NCT03328273|OTHER|Arm A Part 1 and 2|DISCONTINUED (ceralasertib monotherapy)
62680020|NCT03328273|EXPERIMENTAL|Arm B Part 1 and 2|ceralasertib + acalabrutinib in combination
62309474|NCT06442241|EXPERIMENTAL|Group 6 (LYB005 high dose with adjuvant; young adults)|Young adults (18-59 years old) will receive a single injection of high dose LYB005 (120μg) with adjuvant on Day 1.
62309475|NCT06442241|PLACEBO_COMPARATOR|Group 7 (placebo; young adults)|Young adults (18-59 years old) will receive a single injection of placebo on Day 1.
62475771|NCT04306068|NO_INTERVENTION|Control group|Athletes included in the control group will follow their usual warm-up routine.
62680021|NCT05230407||Women after Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES)|Study population will include all women after hysterectomy or adnexal surgery by vNOTE technique
62680022|NCT06694883||Ulcerative colitis in remission period|
62680023|NCT06059339|ACTIVE_COMPARATOR|PENG Block and Spinal Anesthesia|The patients receive PENG block with 20 ml 0,25% bupivacaine for postoperative pain management at the beginning of the surgery. Before the block performance, patients received spinal anesthesia at the L3-L4 level with 20 mg heavy bupivacaine. All patients will receive the same postoperative multimodal analgesia regimen, which includes intravenous paracetamol 1000 mg every 6 hours and intramuscular diclofenac 75 mg every 12 hours. In addition, intravenous patient-controlled analgesia (PCA) with morphine will be administered for 48 hours postoperatively, with a bolus dose of 1 mg and a lockout interval of 10 minutes (no basal rate). If the Numeric Rating Scale (NRS) exceeds 4, intravenous tramadol (1.5 mg/kg) will be administered as rescue analgesia.
62680024|NCT06059339|ACTIVE_COMPARATOR|Lumbar Erector Spinae Plain Block and Spinal Anesthesia|The patients receive LESP block for postoperative pain management at the beginning of the surgery. The LESP block will be provided with 40 ml 0,25% bupivacaine under ultrasonography. Following the block performance, patients received spinal anesthesia at the L3-L4 level with 20 mg heavy bupivacaine. All patients will receive the same postoperative multimodal analgesia regimen, which includes intravenous paracetamol 1000 mg every 6 hours and intramuscular diclofenac 75 mg every 12 hours. In addition, intravenous patient-controlled analgesia (PCA) with morphine will be administered for 48 hours postoperatively, with a bolus dose of 1 mg and a lockout interval of 10 minutes (no basal rate). If the Numeric Rating Scale (NRS) exceeds 4, intravenous tramadol (1.5 mg/kg) will be administered as rescue analgesia.
62680025|NCT06059339|ACTIVE_COMPARATOR|PENG Block and Lumbar Erector Spinae Plain Block and Spinal Anesthesia|The patients receive LESP block and PENG block for postoperative pain management at the beginning of the surgery. The LESP block (40 ml) and PENG block (20 ml) will be provided with 0,25% bupivacaine each under ultrasonography. Patients receive spinal anesthesia at the L3-L4 level with 20 mg heavy bupivacaine. All patients will receive the same postoperative multimodal analgesia regimen, which includes intravenous paracetamol 1000 mg every 6 hours and intramuscular diclofenac 75 mg every 12 hours. In addition, intravenous patient-controlled analgesia (PCA) with morphine will be administered for 48 hours postoperatively, with a bolus dose of 1 mg and a lockout interval of 10 minutes (no basal rate). If the Numeric Rating Scale (NRS) exceeds 4, intravenous tramadol (1.5 mg/kg) will be administered as rescue analgesia.
62680026|NCT01217411|ACTIVE_COMPARATOR|Arm I (WBRT or SRS)|Patients with \>= 4 brain lesions undergo WBRT as in phase I and patients with =\< 3 brain lesions undergo SRS as in phase I.
62680027|NCT01217411|EXPERIMENTAL|Arm II (WBRT or SRS and RO4929097)|Patients with \>= 4 brain lesions receive RO4929097 and undergo WBRT as in phase I and patients with =\< 3 brain lesions receive RO4929097 and undergo SRS as in phase I.
62121151|NCT05845645|EXPERIMENTAL|Part B|Study participants enrolled to this arm will receive pre-specified doses of UCB0599 or Placebo in a pre-specified sequence during the Treatment Period.
62309476|NCT06442241|EXPERIMENTAL|Group 8 (LYB005 low dose without adjuvant; older adults)|Older adults (≥60 years old) will receive a single injection of low dose LYB005 (30μg) without adjuvant on Day 1.
62309477|NCT06442241|EXPERIMENTAL|Group 9 (LYB005 middle dose without adjuvant; older adults)|Older adults (≥60 years old) will receive a single injection of middle dose LYB005 (60μg) without adjuvant on Day 1.
62309478|NCT06442241|EXPERIMENTAL|Group 10 (LYB005 high dose without adjuvant; older adults)|Older adults (≥60 years old) will receive a single injection of high dose LYB005 (120μg) without adjuvant on Day 1.
62309479|NCT06442241|EXPERIMENTAL|Group 11 (LYB005 low dose with adjuvant; older adults)|Older adults (≥60 years old) will receive a single injection of low dose LYB005 (30μg) with adjuvant on Day 1.
62309480|NCT06442241|EXPERIMENTAL|Group 12 (LYB005 middle dose with adjuvant; older adults)|Older adults (≥60 years old) will receive a single injection of middle dose LYB005 (60μg) with adjuvant on Day 1.
62680028|NCT03285893||Native Hawaiian cigarette smokers|oral cell DNA adducts
62680029|NCT03285893||White (European Americans) cigarette smokers|oral cell DNA adducts
62680030|NCT03285893||Japanese American cigarette smokers|oral cell DNA adducts
62680031|NCT05059522|EXPERIMENTAL|Arm 1|Avelumab monotherapy as specified by sub-study protocol B9991001C
62680032|NCT05059522|EXPERIMENTAL|Arm 2|Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
62121152|NCT01970891|EXPERIMENTAL|Freezing of Gait amelioration|Effect of neuromuscular stimulation device will be assessed on Freezing of Gait amelioration
62309481|NCT06442241|EXPERIMENTAL|Group 13 (LYB005 high dose with adjuvant; older adults)|Older adults (≥60 years old) will receive a single injection of high dose LYB005 (120μg) with adjuvant on Day 1.
62680033|NCT05059522|EXPERIMENTAL|Arm 3|Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
62680034|NCT05059522|EXPERIMENTAL|Arm 4|Avelumab monotherapy as specified by sub-study protocol B9991009C
62121153|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the short term|3 patients biopsied 3-5 weeks post implantation of ProFlor
62121154|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the midterm|5 patients biopsied 3-4 months post implantation of ProFlor
62121155|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the long term|4 patients biopsied between 3-4 months post implantation of ProFlor
62121156|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the extra long term|3 patients biopsied more than 3 years after implantation of ProFlor
62121157|NCT06213324|EXPERIMENTAL|Ketamine|Participants in the ketamine arm will receive a single infusion of ketamine
62309482|NCT06442241|ACTIVE_COMPARATOR|Group 14 (AREXVY; older adults)|Older adults (≥60 years old) will receive a single injection of positive control AREXVY on Day 1.
62309483|NCT02433249|ACTIVE_COMPARATOR|1 Physical Activity|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. All participant receive Fitbit Ones and are asked to use them on a daily basis.
62309484|NCT02433249|EXPERIMENTAL|2 Interpersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
62121158|NCT06213324|PLACEBO_COMPARATOR|Placebo|Participants in the placebo arm will receive a single placebo infusion of normal saline
61920972|NCT02370446||patient gets personalized medication log|Patients in the intervention group will receive a personalized medication log that includes all treatment medications (IV and oral), days of treatment and medication specific information such as timing or diet restrictions. The personalized medication log and patient education materials (fact cards) will be placed in a clear plastic envelope that the patient can carry with them throughout treatment.
62680035|NCT05059522|EXPERIMENTAL|Arm 5|Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
62309485|NCT02433249|EXPERIMENTAL|3.Intrapersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
62309486|NCT02433249|EXPERIMENTAL|4.Full Intervention|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal and interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
62680036|NCT05059522|EXPERIMENTAL|Arm 6|Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
61920973|NCT02370446||patient gets standard of care|Current MSKCC standards of professional nursing practice require the professional nurse to develop a plan of care that includes teaching the patient and support system the prescribed prescriptions / regimen and all doses, route, length of treatment, side effects and safety precautions.
61920974|NCT04153071|EXPERIMENTAL|Unipolar microplasma RF treatment|Single cutaneous unipolar microplasma RF treatment, with variable treatment parameters
61920975|NCT04163731||stable patient, referred for a VO2 peak test|All stable patients above 18 years, referred for a VO2 peak test as part of their standard management in the Louis Pradel Hospital (Hospices Civils de Lyon, Lyon) and without acute clinical event in the last 3 months. All patients who accept to participate will undergo a self-questionnaire of 10 minutes.
62121159|NCT03143348||Control/Nonsurgical|Infants with postnatally confirmed acyanotic congenital heart disease not expected to require surgery in the first six months of life.
62121160|NCT03143348||Surgery w/o bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery without cardiopulmonary bypass.
62121161|NCT03143348||Surgery w/ bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
62121162|NCT05203861|EXPERIMENTAL|Positive Affect Treatment|15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
62121163|NCT05203861|ACTIVE_COMPARATOR|Negative Affect Treatment|15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.
62121164|NCT02059980|EXPERIMENTAL|Response inhibition training|Eight 45-minute sessions of computerized training on response inhibition over a 4 week period
62121165|NCT02059980|PLACEBO_COMPARATOR|Placebo Control Training|Eight 45-minute sessions of computerized placebo control training over a 4 week period
62121166|NCT02163252|ACTIVE_COMPARATOR|Standard|A 12-week internet-based weight loss program that involves weekly video lessons, a self-monitoring platform where participants submit their weight, calorie, and activity information, and weekly automated feedback.
62309487|NCT00390923|EXPERIMENTAL|1|
62309488|NCT00390923|PLACEBO_COMPARATOR|2|
62309489|NCT05719064|EXPERIMENTAL|Adaptive Cell Phone Support|Computer-delivered cell phone support (reminders, problem-solving, referrals to resources) and responsive human coaching (phone calls, test messages, in-app messaging) to improved medication adherence.
62309490|NCT05719064|EXPERIMENTAL|Computer-Delivered Cell Phone Support|Computer-delivered cell phone support (reminders, problem-solving, referrals to resources)
62309491|NCT05719064|ACTIVE_COMPARATOR|Automated Text Reminders|Scheduled one-way text automated message reminders to take medication
62309492|NCT03391492||influenza group|All consecutive patients older than 18 years ,admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
62309493|NCT03391492||control group|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza,
62309494|NCT04984135||Enrolled patients|Patients fulfilling the study criteria were included.
62680037|NCT05059522|EXPERIMENTAL|Arm 7|Avelumab in combination with Axitinib as specified by sub-study B9991027C.
62309495|NCT04243369|OTHER|Experimental - Collaboration Live software|
61920976|NCT03735173|ACTIVE_COMPARATOR|Pegged through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through a Subscapularis Peel (SP) manipulation.
61920977|NCT03735173|ACTIVE_COMPARATOR|Pegged through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through subscapularis tenotomy (ST) manipulation.
61920978|NCT03735173|ACTIVE_COMPARATOR|Keeled through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through a Subscapularis Peel (SP) manipulation.
62475772|NCT04704531|EXPERIMENTAL|Group 1|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) BID in OU during 30 days.
62680038|NCT05059522|EXPERIMENTAL|Arm 8|Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
62680039|NCT06675981|EXPERIMENTAL|Real Acupuncture|Acupuncture at nine acupoints. Patients received 6 sessions of acupuncture (three sessions per week or every other day) for two consecutive weeks
62680040|NCT06675981|SHAM_COMPARATOR|Non-acupuncture at real-acupoint|The acupuncture simulation device will be used to perform acupuncture at the same acupoints as those of the real acupuncture group.
62680041|NCT06675981|SHAM_COMPARATOR|Shallow acupuncture at real-acupoint|At the same acupoint in the acupuncture group, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
61920979|NCT03735173|ACTIVE_COMPARATOR|Keeled through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through subscapularis tenotomy (ST) manipulation.
61920980|NCT06278974||Control Group1|This group includes children and adolescents who are correcting myopia using peripheral defocus spectacles. These spectacles are a novel corrective measure, designed to control myopia progression by creating a defocus zone around the periphery of the lenses.
61920981|NCT06278974||Control Group2|This group consists of children and adolescents using orthokeratology lenses for myopia correction. Orthokeratology lenses are specially designed rigid contact lenses worn overnight to temporarily reshape the cornea, aiming to reduce dependency on glasses or contact lenses during the day.
61920982|NCT06278974||Control Group3|This group includes children and adolescents who are using standard single-vision frame glasses for myopia correction.
61920983|NCT04934280|OTHER|2D transvaginal ultrasonography|
61920984|NCT03923478|EXPERIMENTAL|ABI-M201|"Cohort A: 1 capsule one time a day~Cohort B: 1- 5 capsules one time a day"
61920985|NCT03923478|PLACEBO_COMPARATOR|Placebo|"Cohort A: 1 capsule one time a day~Cohort B: 1-5 capsules one time a day"
61920986|NCT04650646|EXPERIMENTAL|Hypoglycaemic clamp i combination with exercise|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with an exercise session. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
62121167|NCT02163252|EXPERIMENTAL|Early intervention|Participants randomized to Early Intervention will receive the same internet-based weight loss program compared to the Standard group. In addition, Early Intervention participants achieving less than optimal weight loss following several weeks of treatment will be given the opportunity to come to the Weight Control and Diabetes Research Center for an individual visit. At this visit, an interventionist will discuss with the participant any barriers that he or she may be experiencing and recommend alternate strategies to assist in their weight loss. One such strategy would be to recommend the use of meal replacement products or portion controlled meals. In addition to this one-time visit, the interventionist will follow up with the participant via phone weekly, for 2 weeks following this in-person visit.
62680042|NCT06675981|SHAM_COMPARATOR|Shallow acupuncture at non-meridian and non-acupoint|At non-meridian and non-acupoint, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
62121168|NCT04591067||Hip Dysplasia group|Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
62121169|NCT01100125|EXPERIMENTAL|sitagliptin|
62121170|NCT01100125|ACTIVE_COMPARATOR|insulin dose increase|
62121171|NCT01269749|OTHER|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
62309496|NCT02599467|EXPERIMENTAL|case group 1: ALND|"Inclusion criteria: unilateral breast cancer surgery with Axillary lymph node dissection (ALND) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording."
61920987|NCT04650646|EXPERIMENTAL|Hypoglycaemic clamp in combination with bed rest|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with bed rest. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
61920988|NCT05351398||PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
61920989|NCT05351398||Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
61920990|NCT03097354||Non-students|Ad-hoc sample of German adults, not currently enrolled at a university, lifetime alcohol users, no intervention/observational survey study design
61920991|NCT03097354||University students|Ad-hoc sample of German adults, currently enrolled at a university (most likely in Dresden, Germany), lifetime alcohol users, no intervention/observational survey study design
61920992|NCT02381457||Pregnancies undergoing prenatal microdeletion screening|"Pregnant women undergoing non-invasive prenatal screening for microdeletion and aneuploidy syndromes.~No drug will be administrated, this cohort will undergo a non invasive prenatal blood test and then follow up data and specimens will be collected for research analysis."
61920993|NCT01948310|ACTIVE_COMPARATOR|Ranolazine plus Exercise|Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
61920994|NCT01948310|PLACEBO_COMPARATOR|Placebo plus Exercise|Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
61920995|NCT00246688|EXPERIMENTAL|Sagopilone, 0.5 h infusion|Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
62680043|NCT06675981|NO_INTERVENTION|Waiting-list group|No acupuncture treatment will be given during the study period.
62680044|NCT05495230|OTHER|Usual care|"Practices in the control group provide care as usual, which consists of the SDM programmes according to the national care standards and General Practice guidelines (NHG) for DM2, COPD and CVD. According to these protocolised programmes, patients with COPD, CVD or DM2 visit their general practice at a standard frequency per year (1 - 4 times) and standard monitoring measurements and topics are discussed.~The practices that are randomised to the control group will not receive any additional training related to this study."
62680045|NCT05495230|EXPERIMENTAL|Person-centred integrated care intervention|The core of the person-centered and holistic approach is a cyclical process. The practice nurse in the general practice will act as case manager and can consult the general practitioner or other health providers when necessary. The first step in the intervention is assessing the integral health status of the patient (health across multiple domains, including physiological measurements and symptoms of disease), using a (preferably digital) questionnaire at home and physical measurements. The second step is discussing the results with the patient in a semi-structured way. Personal goals are formulated in the third step. In the fourth step, the healthcare professional and patient will choose through shared-decision making the most appropriate interventions and support to achieve these goals, which are documented in a personal healthcare plan. Next, referrals are made if necessary and the treatment is started. An evaluation is planned and carried out, if necessary multiple times.
62680046|NCT05478824||Allergic Asthma|BMI ≥ 30 kg/m2
62680047|NCT05478824||Non-allergic Asthma|BMI ≥ 30 kg/m2
62121172|NCT01269749|OTHER|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
62680048|NCT04276701|EXPERIMENTAL|Systemic lupus erythematosus (SLE)|
62121173|NCT05985512|OTHER|Insomnia Disorder|Patients with insomnia disorder
62680049|NCT05979272|ACTIVE_COMPARATOR|TAU-only|Treatment as usual
62680050|NCT05979272|EXPERIMENTAL|TAU + TECH|Treatment as usual, plus TECH app
62121174|NCT03030248|ACTIVE_COMPARATOR|Vancomycin treated group|This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.
62309497|NCT02599467|EXPERIMENTAL|case group 2: SLNB|"Inclusion criteria: unilateral breast cancer surgery with Sentinel Lymph Node Biopsy (SLNB) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording"
62680051|NCT06466161|ACTIVE_COMPARATOR|Group 1 Upper arm cylindrical cuff|"In Group 1 the upper arm cylindrical cuff is inflated first and the blood pressure is measured.~After one minute has elapsed, the forearm conical cuff is inflated and blood pressure measured."
62680052|NCT06466161|EXPERIMENTAL|Group 2 Forearm conical cuff|In Group 2 the forearm conical cuff is inflated first and the blood pressure is measured. After one minute has elapsed, the upper arm cylindrical cuff is inflated and blood pressure measured.
61920996|NCT00246688|EXPERIMENTAL|Sagopilone, 3 h infusion|Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
61920997|NCT02125773|EXPERIMENTAL|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator.
61920998|NCT02125773|NO_INTERVENTION|Control|Subjects in the control arm will not be provided with the results of the risk calculators.
61920999|NCT00600860||MDS patients|Patients with MDS according to current WHO criteria and International Prognostic Scoring System (IPSS) classification
62121175|NCT03030248|PLACEBO_COMPARATOR|Placebo group|This group will be given placebo oral capsules every 6 hours for 14 days.
62309498|NCT02599467|ACTIVE_COMPARATOR|control group|"Matched by age and dominant arm to each case. Exclusion criteria: current painful conditions involving their neck or dominant upper-extremity, and chronic pain conditions or use of pain relievers.~Procedure: ULNT 1 and EMG recording."
62309499|NCT03863392|EXPERIMENTAL|oral|patients undergoing induction of labour using misoprostol oral solution
62309500|NCT03863392|EXPERIMENTAL|vaginal|patients undergoing induction of labour using vaginal misoprostol
62309501|NCT06126445|ACTIVE_COMPARATOR|Battery operated toothbrush|battery operated toothbrush
62309502|NCT06126445|ACTIVE_COMPARATOR|Manual toothbrush|Manual toothbrush
62309503|NCT05176028|EXPERIMENTAL|Control group|conventional physiotherapy
62680053|NCT05024786||control group|
62680054|NCT05024786||CQI group|
62680055|NCT04107285||Neurocognitive evaluation prior to and following CART|
62680056|NCT03932201||Previously treated patient (PTPs) with hemophilia A|Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
62680057|NCT06604598|ACTIVE_COMPARATOR|PCT-placebo-placebo|Paracetamol (Bernofarm) 1 gr iv; placebo (normal saline alike paracetamol); placebo (normal saline alike dexamethasone) will be given two times administration, interval 8 hour, within the PCT-placebo intervention.
62680058|NCT06604598|ACTIVE_COMPARATOR|IBU-PCT-placebo|Ibuprofen (Peinlos) 400 mg iv; Paracetamol (Bernofarm) 1 gr iv; and placebo (normal saline alike dexamethasone) will be given two times administration, interval 8 hour, within the IBU-PCT-placebo intervention.
62680059|NCT06604598|EXPERIMENTAL|IBU-PCT-DEX|Ibuprofen (Peinlos) 400 mg iv, Paracetamol (Bernofarm) 1 gr iv, dexamethasone (Phapros) 5 mg iv will be given two times administration, interval 8 hour, within IBU-PCT-DEX intervention.
62680060|NCT06691373|NO_INTERVENTION|Control Condition|5-minute rest
62680061|NCT06691373|ACTIVE_COMPARATOR|Static Stretching of 30 seconds|Static stretching of the quadriceps and hamstrings for 30 seconds
62680062|NCT06691373|ACTIVE_COMPARATOR|Static Stretching of 90 seconds|Static stretching of the quadriceps and hamstrings for 90 seconds
61921000|NCT05198778|EXPERIMENTAL|Test group 1: Renal impairment patient|Administer URC102, single-dose
62309504|NCT05176028|EXPERIMENTAL|Intervention group|conventional physiotherapy and fascial release
62309505|NCT02640612|EXPERIMENTAL|BI 695501|
62309506|NCT05837260||Cohort 1|Patients with newly diagnosed iodine refractory thyroid cancer on surveillance
62309507|NCT05837260||Cohort 2|Patients with locally advanced and / or metastatic (Stage 3 \& 4) medullary thyroid cancer
62309508|NCT05837260||Cohort 3|Patients with iodine refractory thyroid cancer or advanced/metastatic unresectable MTC due to commence systemic treatment or already on systemic treatment
62309509|NCT05837260||Cohort 4|Patients with newly diagnosed anaplastic thyroid cancer
62309510|NCT02477865|EXPERIMENTAL|PEX168(100µg)|PEX168(100µg),100µg,Subcutaneous injection,once a week,for 52 weeks.
62309511|NCT02477865|EXPERIMENTAL|PEX168(200µg)|PEX168(200µg),200µg,Subcutaneous injection,once a week,for 52 weeks.
62309512|NCT02477865|PLACEBO_COMPARATOR|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week for 24 weeks,followed by PEX168(100µg or 200µg) qw sc for 28 weeks.
61921001|NCT05198778|EXPERIMENTAL|Test group 2: Renal impairment patient|Administer URC102, single-dose
62309513|NCT04370249||Patient with suspected COVID-19 infection|Patients admitted and managed in an emergency department under suspicion of COVID-19 infection who received a pleuro-pulmonary ultrasound on admission
62309514|NCT01924715||ISTDP|Patients provided Intensive Short term Dynamic Psychotherapy
62309515|NCT01924715||Control Group|Patients referred for ISTDP but never seen for any reason
62309516|NCT06483893|ACTIVE_COMPARATOR|thyroid cartilage plane block group (TCPB Group)|Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
62309517|NCT06483893|ACTIVE_COMPARATOR|traditional superior laryngeal nerve block group (Traditional SLNB Group)|Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
62309518|NCT03320512|EXPERIMENTAL|P3|Participants will use P3
62309519|NCT03320512|EXPERIMENTAL|P3+|Participants will use P3+
61921002|NCT05198778|EXPERIMENTAL|Control group: Healthy adult people|Administer URC102, 2 doses
61921003|NCT01894815|EXPERIMENTAL|Active tDCS / placebo pill|transcranial direct current stimulation, using the parameters specified in Interventions.
62309520|NCT03320512|PLACEBO_COMPARATOR|Control|Participants will receive the standard of care
61921004|NCT01894815|ACTIVE_COMPARATOR|Sham tDCS / escitalopram|Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).
61921005|NCT01894815|PLACEBO_COMPARATOR|Sham tDCS / placebo pill|"For sham tDCS, the device is automatically turned off after 30 second of stimulation and remains turned off during the 30-min session.~For placebo pill, the pill has the same size, taste and color than escitalopram, and placebo and escitalopram will be provided in identical bottles, differing only according to a random-generated number placed in the label."
61921006|NCT01887743|EXPERIMENTAL|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
61921007|NCT00349271|EXPERIMENTAL|Stem Cell therapy|Stem Cell therapy
62309521|NCT05033210|OTHER|Control Group|The control group will receive Psychological First Aid (PFA) and Care as Usual (CAU)
62309522|NCT05033210|EXPERIMENTAL|Treatment Group|The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2), in addition to Psychological First Aid (PFA) and care as usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress (K10 \> 15.9) at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.
61921008|NCT00349271|ACTIVE_COMPARATOR|Standart therapy|Standart therapy
62309523|NCT06384339||Clients|Adult clients in a secure setting (i.e. prison or forensic mental health psychiatry
62309524|NCT06384339||Staff|Adult staff in a secure setting (including forensic healthcare staff, social workers, probation officers, prison offers, education staff)
62680063|NCT02021318|EXPERIMENTAL|Roxadustat|Participants received roxadustat orally according to the tiered weight-based approach, with starting dose of 70 mg (milligram) given thrice weekly (TIW) to participants weighing up to 70 kg (kilogram) and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL (gram per deciliter) and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat up to a maximum of 104 weeks.
62680064|NCT02021318|ACTIVE_COMPARATOR|Darbepoetin alfa|Participants received initial dose of darbepoetin alfa based upon the weight (either 0.45 μg/kg (microgram per kilogram), as a single subcutaneous or intravenous (IV) injection once weekly or 0.75 μg/kg, as a single subcutaneous injection once every 2 weeks) as per European Summary of Product Characteristics (EU SmPC) along with IV iron supplementation according to the standard of care. Dose-adjustment was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which darbepoetin alfa dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received darbepoetin alfa for up to a maximum of 104 weeks.
62680065|NCT04598919|ACTIVE_COMPARATOR|Saracatinab|saracatinib 125 mg once daily by mouth for 24 weeks
62680066|NCT04598919|PLACEBO_COMPARATOR|Placebo|matching placebo once daily by mouth for 24 weeks
62680067|NCT06652828|ACTIVE_COMPARATOR|Conventional Treadmill Training (CTT)|
61921009|NCT05577468|EXPERIMENTAL|tegoprazan|Participants will receive Tegoprazan tablets Esomeprazole magnesium enteric-coated tablets placebo Bismuth potassium citrate capsules Amoxicillin capsules Clarithromycin tablets
61921010|NCT05577468|ACTIVE_COMPARATOR|Esomeprazole|Participants will receive Tegoprazan tablets placebo Esomeprazole magnesium enteric-coated tablets Bismuth potassium citrate capsules Amoxicillin capsules Clarithromycin tablets
62309525|NCT06664567||Systematic provision of screening tests by GPs|The general practitioner systematically delivers the screening kit with justification and modalities of realization at an even age between 50 and 74 years to the patient who comes to consult for whatever reason, who is at intermediate risk of colorectal cancer and who falls under the generalized screening. The practitioner is helped in his approach by an initial training in the identification of the age, delivery of a poster, a study sheet, stickers and goodies, sending a quarterly letter on the progress of the study and contact with the coordination team.
62309526|NCT06664567||Delivery of screening test according to GP's usual practice|the GP will issue the CRC screening kit in accordance with his/her usual practice.
62309527|NCT03881163|EXPERIMENTAL|Single dose regime of N-acetylcysteine (NAC)|On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.
62309528|NCT03881163|EXPERIMENTAL|Multiple dose regime of N-acetylcysteine (NAC)|On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.
62309529|NCT01623687|ACTIVE_COMPARATOR|Regenerex|
62309530|NCT01623687|ACTIVE_COMPARATOR|Lub cup|
62309531|NCT01623687|ACTIVE_COMPARATOR|SP II|
62309532|NCT01623687|ACTIVE_COMPARATOR|Corail|
62309533|NCT01663350||All-risk pregnant women|All-risk pregnancies undergoing conventional forms of prenatal screening
62309534|NCT03046238|ACTIVE_COMPARATOR|dexmetedomedine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
62309535|NCT03046238|PLACEBO_COMPARATOR|control|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
62309536|NCT02018250|EXPERIMENTAL|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis\[4-\[(hydroxyimino) methyl\]-pyridinium\] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
62309537|NCT02018250|PLACEBO_COMPARATOR|Placebo|filtered cottonseed oil for injection. Three and a half milliliter aliquots of the placebo are placed in each 5-mL vial and administered intramuscular (i.m.) to the anterior thigh.
62309538|NCT02018250|EXPERIMENTAL|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis\[4-\[(hydroxyimino) methyl\]-pyridinium\] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
62309539|NCT02018250|EXPERIMENTAL|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis\[4-\[(hydroxyimino) methyl\]-pyridinium\] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
62309540|NCT02018250|EXPERIMENTAL|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis\[4-\[(hydroxyimino) methyl\]-pyridinium\] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
62309541|NCT06668506||Mucotra® SR Tab|Mucotra® SR Tab Rebamipide 150mg
62309542|NCT03320733|EXPERIMENTAL|Surgical|"Includes patients who will undergo surgery for their pancreatic cysts.~In addition to the routine pre-operative CT abdomen performed for surgical planning purposes, these patients will receive Dual Energy CT scan with subtraction imaging before surgery."
61921011|NCT00392821|EXPERIMENTAL|RAD001 and Sorafenib|RAD001 and Sorafenib
61921012|NCT00733889|EXPERIMENTAL|1|
61921013|NCT01562873|EXPERIMENTAL|Ruxolitinib-Cohort A|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of \>/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
62121176|NCT02754999|EXPERIMENTAL|SANGUINATE™|As Needed Dosing of SANGUINATE
62309543|NCT03320733|EXPERIMENTAL|Surveillance|"Includes patients who are undergoing surveillance for their pancreatic cysts.~Dual Energy CT scan with subtraction imaging will be performed in addition to the standard-of-care surveillance method of MRI scans."
62475773|NCT04704531|EXPERIMENTAL|Group 2|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
62475774|NCT04704531|EXPERIMENTAL|Group 3|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) 6 times per day in OU during 30 days.
61921014|NCT01562873|EXPERIMENTAL|Ruxolitinib-Cohort B|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of \>/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
62309544|NCT05089305|EXPERIMENTAL|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications for the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07.
62309545|NCT02128490|ACTIVE_COMPARATOR|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62309546|NCT02128490|ACTIVE_COMPARATOR|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62309547|NCT02128490|EXPERIMENTAL|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62309548|NCT02128490|EXPERIMENTAL|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62475775|NCT01038960|EXPERIMENTAL|Exercise training|training
62680068|NCT06652828|EXPERIMENTAL|Perturbation-Based Balance Training (PBT)|
62680069|NCT06494150|EXPERIMENTAL|nab-sirolimus + Fulvestrant|Patients will be treated with the combination nab-sirolimus (100 mg/m2 intravenous injection on day 1 and 8 of each 21-day cycle) and fulvestrant (500mg intramuscular injection on days 1 and 15 of cycle 1 and then every 21 days).
62680070|NCT06168578||Group I (ARM-): After intubation, 5 cmH2O PEEP will be applied until the end of the operation|"* First ONSD measurement will be performed 5 minutes after intubation with the patient in supine position (T0)~* A second ONSD measurement will be performed 10 minutes after intubation with the patient in supine position. (T1)~* ONSD will be measured for the third time 5 minutes after pneumoperitoneum is established with 12-13 mmHg. (T2)~* At 10 minutes of Trendelenburg position (45⁰), ONSD will be measured for the fourth time (T3).~* In Trendelenburg position (45⁰), ONSD will be measured for the fifth time after removal of the uterus. (T4)~* After the supine position is assumed before extubation and pneumoperitoneum is terminated, ONSD will be measured for the sixth time before the neuromuscular blocker is reversed. (T5)"
62680071|NCT06168578||Group II (ARM+): After intubation, 5 cmH2O PEEP will be applied until the end of the operation|"* ONSD will be measured 5 minutes after intubation with the patient in supine position (T0)~* ARM will be applied 10 minutes after intubation, and ONSD will be measured for the second time when the peak pressure is reached. (T1)~* ONSD will be measured for the third time 5 minutes after pneumoperitoneum is established with 12-13 mmHg. (T2)~* At 10 minutes of Trendelenburg position (45⁰), ONSD will be measured for the fourth time (T3).~* Trendelenburg position (45⁰), ARM will be applied after the uterus is removed, and ONSD will be measured for the fifth time when the peak pressure is reached. (T4)~* After the supine position is assumed before extubation and pneumoperitoneum is terminated, ONSD will be measured for the sixth time before the neuromuscular blocker is reversed. (T5)"
62680072|NCT06228326|EXPERIMENTAL|Dose Escalation of KB707 Administered via Nebulization|Dose escalation of single-agent KB707 in 3 cohorts in a standard 3+3 design.
62680073|NCT06228326|EXPERIMENTAL|Dose Expansion of KB707 Administered in Combination with Keytruda|Dose expansion cohort: KB707 administered in combination with Keytruda in approximately 60 subjects with NSCLC.
62680074|NCT06228326|EXPERIMENTAL|Dose Expansion of KB707 Administered in Combination with Keytruda and Chemotherapy|Dose expansion cohort: KB707 administered in combination with Keytruda and chemotherapy in approximately 60 subjects with NSCLC.
62680075|NCT04951453||Aneurysmal subarachnoid haemorrhage|Patients with SAH (see eligibility criteria below). Planned enrollment: 50 patients.
62680076|NCT04951453||Intracerebral haemorrhage|Patients with ICH (see eligibility criteria below). Planned enrollment: 50 patients.
62680077|NCT04951453||Traumatic Brain Injury|Patients with TBI (see eligibility criteria below). Planned enrollment: 50 patients.
62680078|NCT05030441|EXPERIMENTAL|Ivosidenib|-Ivosidenib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg daily for up to 5 years. Each cycle is 28 days.
62680079|NCT05418920|EXPERIMENTAL|the trial group (left-opening single-flap group)|left-opening single-flap group
62680080|NCT05418920|ACTIVE_COMPARATOR|the control group (double-flap group)|double-flap group
62121177|NCT03759743|EXPERIMENTAL|Probiotics|
62309549|NCT02128490|PLACEBO_COMPARATOR|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
62309550|NCT05144178||Mild and moderated COVID -19 patient treated out side the hospital sitting|Reviewing files of such group that had been received Sotrovimab
62309551|NCT02167555|ACTIVE_COMPARATOR|Wild Bluberries|Active Comparator
62475776|NCT01038960|NO_INTERVENTION|Not training|No organized training
62475777|NCT05657860|SHAM_COMPARATOR|Placebo|
62475778|NCT05657860|EXPERIMENTAL|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
62475779|NCT02744794|EXPERIMENTAL|Treatment with cryotherapy|Treatment with dermal cooling system.
62475780|NCT03202459|ACTIVE_COMPARATOR|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
62121178|NCT03759743|PLACEBO_COMPARATOR|Placebo|
62121179|NCT01325233|EXPERIMENTAL|PG2 Injection|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
62680081|NCT06460051|ACTIVE_COMPARATOR|Maxillary nerve block before bimaxillary osteotomy|Patients receive ultrasound-guided suprazigomatic maxillary nerve block after nasotracheal intubation before bimaxillary osteotomy.
62680082|NCT06460051|EXPERIMENTAL|Maxillary nerve block after bimaxillary osteotomy|Patients receive ultrasound-guidedsuprazygomatic maxillary nerve block after bimaxillary osteotomy before extubation.
62680083|NCT05366660|EXPERIMENTAL|CIED's interrogation/programming|All the patients will be included in this single arm to interrogate/programm their CIED
62680084|NCT00557739|EXPERIMENTAL|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
62680085|NCT00557739|EXPERIMENTAL|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
62680086|NCT00557739|ACTIVE_COMPARATOR|3|0.1% mometasone furoate
61921015|NCT06041776|EXPERIMENTAL|Befotertinib + Icotinib placebo|Befotertinib (75 mg or 100 mg orally, once daily) and Icotinib placebo(125 mg orally, three times daily)，in accordance with the randomization schedule
62680087|NCT00557739|ACTIVE_COMPARATOR|4|0.05% nortriptyline HCl
62680088|NCT00557739|ACTIVE_COMPARATOR|5|0.1% nortriptyline HCl
62680089|NCT00557739|PLACEBO_COMPARATOR|6|Vehicle (placebo)
62680090|NCT03915756|EXPERIMENTAL|With drain|Participants who received a drain during surgery
62680091|NCT03915756|NO_INTERVENTION|Without drain|Participants who did not receive a drain during surgery
62680092|NCT02761057|EXPERIMENTAL|Arm I (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.
61921016|NCT06041776|ACTIVE_COMPARATOR|Icotinib + Befotertinib placebo|Icotinib (125 mg orally, three times daily) and Befotertinib placebo (75 mg or 100 mg orally, once daily)，in accordance with the randomization schedule
61921017|NCT03673410|ACTIVE_COMPARATOR|Laparoscopic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.
61921018|NCT03673410|EXPERIMENTAL|Robotic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.
62121180|NCT01325233|PLACEBO_COMPARATOR|Placebo|Powder for Injection, 500 ml normal saline, tiw, 2 weeks
62309552|NCT02167555|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62309553|NCT02133937|EXPERIMENTAL|High Concentration Liquid Formulation (HCLF)|
62309554|NCT02133937|ACTIVE_COMPARATOR|Lyophilized formulation|
62309555|NCT02498223|EXPERIMENTAL|research arm|50 subjects (healthy soldiers, male and female) from combat units will undergo the experiment protocol.
62309556|NCT05358886|ACTIVE_COMPARATOR|Study Drug|25mg BID BPN14770
62309557|NCT05358886|PLACEBO_COMPARATOR|Placebo|Placebo
62309558|NCT05590299|ACTIVE_COMPARATOR|Fish oral immunotherapy|Fish oral immunotherapy to be taken daily for 12 months.
62309559|NCT05590299|PLACEBO_COMPARATOR|Placebo|Placebo oral immunotherapy to be taken daily for 12 months.
62309560|NCT05313230||CITRASAFE|Patient underwent CITRASATE dialysis session
62309561|NCT04705298|PLACEBO_COMPARATOR|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
62309562|NCT04705298|EXPERIMENTAL|Prebiotic|Oligofructose-enriched inulin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
62309563|NCT01674426|EXPERIMENTAL|Cognitive behavior therapy|Cognitive behavior therapy consisting of 16 sessions over 20 weeks
62309564|NCT01674426|PLACEBO_COMPARATOR|observation|Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed
62309565|NCT00552305|EXPERIMENTAL|Lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
62309566|NCT03094247|ACTIVE_COMPARATOR|Conventional RUTF (S-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
62309567|NCT03094247|EXPERIMENTAL|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
62309568|NCT03094247|EXPERIMENTAL|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
62309569|NCT01716169|EXPERIMENTAL|Helicoll|"Helicoll will be applied to one chronic wound (approximately 6 months or more duration).~Wound designations of control or Helicoll were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as A or B. Then the envelope was opened which designated whether A or B would receive control or Helicoll."
62309570|NCT06512987|EXPERIMENTAL|Interactive ICU Diary Group|Patients in this group will use a technology-driven, interactive ICU diary from the first day of ICU admission until discharge. Through the diary platform, patients can share their feelings and needs, while family members can send supportive messages, pictures, and videos. Healthcare providers will use the platform to connect with families and monitor patient conditions. The goal is to reduce psychological distress, specifically anxiety, depression, and stress, during the ICU stay.
62309571|NCT06512987|NO_INTERVENTION|routine care|Patients in this group will receive standard ICU care without the use of the interactive ICU diary.
62309572|NCT05386433|PLACEBO_COMPARATOR|standard-of-care|Standard-of-care of COVID-19 includes oxygen inhalation, antibiotics, traditional medicine, etc.
62680093|NCT02761057|EXPERIMENTAL|Arm II (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.
62680094|NCT02761057|EXPERIMENTAL|Arm III (crizotinib closed to accrual 12/5/18)|Patients receive crizotinib PO BID on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.
62475781|NCT03202459|ACTIVE_COMPARATOR|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
61921019|NCT03645018|EXPERIMENTAL|diagnosis with tomosynthesis (DTS)|"Single arm.~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
62121181|NCT03799536|EXPERIMENTAL|Sequence AB|Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62121182|NCT03799536|ACTIVE_COMPARATOR|Sequence BA|Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62475782|NCT03202459|PLACEBO_COMPARATOR|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
62309573|NCT05386433|EXPERIMENTAL|standard-of-care plus Paxlovid|standard-of-care of COVID-19 plus Paxlovid
61921020|NCT05504720|EXPERIMENTAL|Pembrolizumab Trastuzumab|Single arm with pembrolizumab (200 mg flat dose over 30 min IV) on day 1, 22 and 43 plus trastuzumab (loading dose 8 mg/kg IV over 90 min at day 1 and maintenance dose 6 mg/kg IV over 30 min) on day 22 and 43 plus FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of pembrolizumab+trastuzumab + FLOT followed by pembrolizumab (200 mg flat dose) and trastuzumab (6 mg/kg) alone for up to 11 further cycles (Q3W).
61921021|NCT02869984|EXPERIMENTAL|Treatment|ramosetron treatment for 4 weeks from 1mo after anterior resection for rectal cancer
61921022|NCT02869984|NO_INTERVENTION|Control|No treatment
62121183|NCT05127226|EXPERIMENTAL|Part 1 MAD: Cohort A|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
62309574|NCT00686205|EXPERIMENTAL|ABBOTT PRISM HIV O Plus assay for Specificity|All subjects will have their blood tested by the investigational HIV test.
62309575|NCT00686205|NO_INTERVENTION|ABBOTT PRISM HIV O Plus Assay for Sensitivity|Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.
62309576|NCT03332953|OTHER|E-cigarette|Subjects will be asked to vape various e-cigarettes at three concentrations of nicotine and sweet flavor (9 stimuli per subject). The subject will be asked to make ratings for the overall liking or disliking of the e-cigarette, followed by ratings on perceived intensities of sensations.
62475783|NCT05213286|OTHER|Patients referred for assessment of ASD, non-ASD psychiatric patients and control group|All three groups will be tested with RAADS-R-DK and ZAQ. The results from these diagnostic tests will be compared to gold standard clinical assessments in specialized multidisciplinary teams
62475784|NCT06515405||Not exposed to early hydrocortisone|
62475785|NCT06515405||Exposed to early hydrocortisone|
62475786|NCT04147845|EXPERIMENTAL|Fractional Carbon dioxide laser and triamcinolone acetonide|"Group I:Fractional Carbon dioxide laser (CO2 Laser) and triamcinolone acetonide (TrA; 10 mg/ ml) (14, 15) The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
62495930|NCT06347627|EXPERIMENTAL|Group 6 (O x S x S x M)|"Participants in Group 6 will view a message in an X (former Twitter) format composed of Organization x Safety x Storytelling x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
61921023|NCT01488968|ACTIVE_COMPARATOR|Standard|Standard Radiation Treatment
61921024|NCT01488968|EXPERIMENTAL|Hypofractionated|Hypofractionated
61921025|NCT03894592|ACTIVE_COMPARATOR|Virtual Reality analgesia|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive the intervention which is a virtual reality headset providing immersive interactive content in the video format
62121184|NCT05127226|EXPERIMENTAL|Part 1 MAD: Cohort B|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
62121185|NCT05127226|EXPERIMENTAL|Part 1 MAD: Cohort C|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
62121186|NCT05127226|EXPERIMENTAL|Part 1 MAD: Cohort D|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
62121187|NCT05127226|EXPERIMENTAL|Part 1 MAD: Cohort E|ION582 will be administered as IT injection of over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
62309577|NCT03011242||Longitudinal Cohort: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis starting standard of care treatment with a TNFi or non-biologic DMARD.
62680095|NCT02761057|EXPERIMENTAL|Arm IV (savolitinib closed to accrual 12/5/18)|Patients receive savolitinib PO QD on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.
62680096|NCT00986102|OTHER|001|doripenem 500mg vial by injection every 8 hours for 5 to 14 days
62680097|NCT04713007|EXPERIMENTAL|Group 1|Supportive Care Materials and Resources
62680098|NCT04713007|EXPERIMENTAL|Group A|Ted Talks/Educational videos
62680099|NCT05861752||Clinical cohort|"Patients seeking treatment with Paraphilic disorders, compulsive sexual behavior disorder and/or sexsomnia. These will be explored separately within each condition.~For procedures, see the Detailed description heading"
62680100|NCT05861752||Healthy controls|"Sex- and age-matched controls will be recruited through special research units, and through advertising on e.g. in newspapers, websites and on social media.~If the person gives written consent, a structured medical assessment is carried out including assessment of psychiatric co-morbidity and medical history.~The control person will then answer the same questionnaires as the research subjects in the clinical population. They also will be tested regarding impulsivity and provide blood samples."
62680101|NCT05177328|EXPERIMENTAL|ShA9|All participants will receive ShA9 active treatment on one of their ventral arms and placebo on their contralateral arm. The assignment of ShA9 and placebo to the dominant and non-dominant arms will be randomized.
62680102|NCT05302609|EXPERIMENTAL|SclerFIX|Patch of umbilical cord lining membrane sutured on top of the scleral defect.
62680103|NCT06688344|ACTIVE_COMPARATOR|Intervention group|fESWT
62680104|NCT06688344|SHAM_COMPARATOR|Control group|
62680105|NCT06401772|EXPERIMENTAL|body posture group|During post-operative hospitalization, patients will receive routine treatment and keep Intracranial Hypotension Targeted (IHT) Body Posture as long as possible, with the maximum to 14 to 18 hours daily.Body Posture education for patients after discharge, which is keeping IHT Body Posture when on bed rest and sleeping within 3 months as long as possible and recording time every day.Specifically, IHT therapy requires CSDH patients to raise their lower limbs 30° higher over the horizontal level of their head. All leg-lift pads were customized from the same manufacturer and provided to participants by the research group. For patients with unilateral CSDH, the head should be tilted towards the hematoma affected side and opposite side lying should be avoided as much as possible. For patients with bilateral CSDH, there is no need for the head lateralization. To avoid food reflux and aspiration pneumonia, IHT therapy was strictly prohibited within 2 hours after each meal.
62680106|NCT06401772|NO_INTERVENTION|control group|Patients will be required to keep supine position. In addition to IHT Body Posture, patients will receive treatment as same as body posture group.
62121188|NCT05127226|EXPERIMENTAL|Part 2 Group 1|ION582 will be administered as IT injection of over a period of 49 weeks, with additional dosing intervals.
62121189|NCT05127226|EXPERIMENTAL|Part 2 Group 2|ION582 will be administered as IT injection of over a period of 49 weeks, with additional dosing intervals.
62121190|NCT05127226|EXPERIMENTAL|Part 3 Group 1|ION582 will be administered as IT injection of over a period of 145 weeks, with additional dosing intervals.
62309578|NCT03011242||Assay Development: Healthy or Psoriatic Arthritis|Individuals that are healthy or with a diagnosis of Psoriatic Arthritis will be enrolled for blood draws for assay development and/or for an ultrasound for development of techniques and scoring system validation.
62495931|NCT06347627|EXPERIMENTAL|Group 7 (I x E x S x M)|"Participants in Group 7 will view a message in an X (former Twitter) format composed of Individual x Effectiveness x Storytelling x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62680107|NCT04210089|EXPERIMENTAL|Soft Cast with a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast with removable cam boot.
62680108|NCT04210089|EXPERIMENTAL|Soft Cast without a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast.
62680109|NCT04210089|NO_INTERVENTION|Conventional|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will use conventional offloading including total contact casting, removable cast boots (cam boots), CROW boots, bracing, AFO's, offloading shoes, insoles, padding, shoe modifications, crutches, wheelchairs, rollabout, and surgical correction.
62680110|NCT06484400|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT) Group|Participants in this group will receive Cognitive Behavioral Therapy, which involves identifying and modifying negative thought patterns and behaviors to alleviate symptoms of depression and anxiety. Therapy sessions are conducted in person and on a one-on-one basis, ensuring tailored and direct therapeutic engagement. Each participant will attend 12 weekly sessions, each lasting approximately one hour.
62121191|NCT05127226|EXPERIMENTAL|Part 3 Group 2|ION582 will be administered as IT injection of over a period of 145 weeks, with additional dosing intervals.
62121192|NCT03483519|EXPERIMENTAL|Prehabilitation|Patients in the Prehabilitation Group and are randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
62309579|NCT03011242||Cross-Sectional: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis in good disease state on stable non-biologic DMARDS or on stable TNFi.
62309580|NCT03540121|EXPERIMENTAL|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
62309581|NCT03540121|NO_INTERVENTION|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
62309582|NCT04814823||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
62309583|NCT01507194|ACTIVE_COMPARATOR|Ondansetron 4 mg|
62309584|NCT01507194|EXPERIMENTAL|Vestipitant 6 mg|
62309585|NCT01507194|EXPERIMENTAL|Vestipitant 12 mg|
62309586|NCT01507194|EXPERIMENTAL|Vestipitant 18 mg|
62309587|NCT01507194|EXPERIMENTAL|Vestipitant 24 mg|
62475787|NCT04147845|EXPERIMENTAL|Microneedling with Dermapen and triamcinolone acetonide|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~Triamcinolone acetonide in concentration of 10 mg/ml (0.1 ml containing 1 mg of triamcinolone) will be applied on each lesion twice, before and after performing microneedling.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
62680111|NCT06484400|EXPERIMENTAL|Ericksonian Hypnotherapy Group|This group will receive Ericksonian Hypnotherapy, a therapeutic approach that utilizes techniques of hypnosis and suggestion to access and alter subconscious processes, aiming to reduce psychological distress associated with depression and anxiety. Similar to the CBT group, sessions are delivered in person on a one-on-one basis, with a total of 12 weekly sessions, each one hour long.
62121193|NCT03483519|ACTIVE_COMPARATOR|Standard of Care|Patients in the Standard of Care will not receive an additional an exercise program, patients will receive the usual care received by all orthopaedic patients.
62121194|NCT03097250||PKU Subjects|Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
62475788|NCT04147845|EXPERIMENTAL|Fractional Carbon dioxide laser and Platelet-rich plasma|"The same laser parameters as group I will be used, followed by application of freshly prepared PRP. The applied PRP will be spread over the whole affected area.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
62475789|NCT04147845|EXPERIMENTAL|Microneedling with Dermapen and Platelet-rich plasma|"Microneedling using dermapen is performed as Group II. Microneedling is preceeded and followed by intermittent application of freshly prepared PRP. The applied PRP will be spread over the whole affected area and again rolled till pinpoint bleeding points are noticed.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
62475790|NCT03803774|EXPERIMENTAL|Treatment (intensity modulated re-irradiation therapy (IMRRT), birinapant)|Beginning on day 1, patients undergo intensity modulated re-irradiation therapy (IMRRT) 5 days a week (Monday-Friday). Participants also receive birinapant intravenous (IV) over 30 minutes on days 2 and 9 of each cycle. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
62475791|NCT01978730|EXPERIMENTAL|high dose group of SaiLuoTong capsule|take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
62475792|NCT01978730|EXPERIMENTAL|low dose group of SaiLuoTong capsule|take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
62475793|NCT01978730|PLACEBO_COMPARATOR|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
62475794|NCT03383263||Children with juvenile arthritis|Children with diagnosed polyarticular juvenile arthritis according to International League of Associations for Rheumatology (ILAR) criteria treated with HUMIRA (adalimumab) in the routine clinical settings in the Russian Federation
62475795|NCT05318690|EXPERIMENTAL|PlayGait (Exoskeleton)|Experimental lower-limb device.
62680112|NCT06484400|NO_INTERVENTION|Control Group|Participants in this group will not receive any active intervention during the study period. This group serves as a control to measure the natural progression of depression and anxiety symptoms without therapeutic intervention. Participants will be monitored throughout the study and will be offered therapeutic sessions after the study's conclusion as compensation for their participation.
62680113|NCT06177990|EXPERIMENTAL|CAN-DO Immediate program group|Each participant will be engaged in a baseline interview. Subsequently, each will be asked to take part in follow-up interviews at points 2, 4, 6, and 8 months following the launch of their cohort.
62680114|NCT06177990|ACTIVE_COMPARATOR|Attention Control program group|"Participants will receive an online course about Healthy Living for the first 4 months after randomization.~After the Attention Control participants complete their 4-month interview, they will be invited to participate in the CAN-DO program."
62121195|NCT03097250||Controls|Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.
62309588|NCT01507194|EXPERIMENTAL|Vestipitant 36 mg|
62309589|NCT01119040|EXPERIMENTAL|NOTES PEG Rescue|A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.
62309590|NCT04606615||Adults: AD + FA|Adults: atopic dermatitis and food allergy to peanut
62121196|NCT04484701||PSMA-11 PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
62309591|NCT04606615||Adults: AD - FA|Adults: atopic dermatitis and no food allergy
62309592|NCT04606615||Adults: NC|Adults: Normal Control
62475796|NCT05318690|ACTIVE_COMPARATOR|Baseline|Baseline condition without using any prescribed lower-limb orthoses.
62475797|NCT06243796|EXPERIMENTAL|Flap fixation|After completing the modified radical mastectomy procedure, the researcher will use absorbable suture (vicryl), multiple alternating stitches 2.5 cm apart between the subcutaneous tissues of the skin flaps and the underlying muscles at various parts of the flap and also, at the wound edge.
62475798|NCT06243796|NO_INTERVENTION|Non flap fixation|After mastectomy, the researcher will close the wound in the conventional method.
62475799|NCT03950362|EXPERIMENTAL|Radiotherapy associated to immunotherapy|"* Radiotherapy: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder~* Concomitant administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)"
62475800|NCT04075578||female with urinary incontinence|Female ≥ 18 years, suffers from urinary incontinence by idiopathic overactive bladder, inadequately treated by 2 anticholinergic medicines during a period of 3 months for each of them or stopped for intolerance or adverse events
62475801|NCT05819918||Calcifediol|
62475802|NCT05819918||Best therapy available|
62475803|NCT02995720|EXPERIMENTAL|1|A fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin
62680115|NCT06177990|ACTIVE_COMPARATOR|Usual care group|Participants randomized to the Usual care group will not receive intervention from the study but after they complete their 4-month interview, they will be invited to participate in the CAN-DO program.
62121197|NCT05190419|EXPERIMENTAL|Orismilast modified release tablets 20 mg BID|Oral, twice daily morning and evening for 16 weeks
62121198|NCT05190419|EXPERIMENTAL|Orismilast modified release tablets 30 mg BID|Oral, twice daily morning and evening for 16 weeks
62309593|NCT04606615||Children: AD+ Peanut|Children: atopic dermatitis and food allergy to peanut
62475804|NCT02995720|ACTIVE_COMPARATOR|2|Co-administration of Fimasartan/Amlodipine combination drug and Rosuvastatin
62680116|NCT03596983|EXPERIMENTAL|Short Sleep Patients|Intervention: Self-management for Adequate Sleep Intervention (SASI). SASI was developed Dr. Michael Grandner. SASI is based on Cognitive Behavioral Therapy for Insomnia (CBTI), an established and effective approach for treating insomnia. Like CBTI, SASI extends sleep duration based on sleep efficiency (the proportion of time spent sleeping during a sleep episode). Bed times and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains \>90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules.
62475805|NCT06558370|ACTIVE_COMPARATOR|Empty bladder group|"Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
62680117|NCT04829656||Clinical Cohort|Enrolled via the 5 participating clinics at LBDA Research Centers of Excellence.
62309594|NCT04606615||Children: AD + Milk|atopic dermatitis and food allergy to milk
62680118|NCT04829656||Virtual Cohort|Enrolled via the LBDA.
62680119|NCT06023368|EXPERIMENTAL|Sterile Vapocoolant Spray|Num vapocoolant spray will be administered as a single use canister around the port
62680120|NCT06023368|ACTIVE_COMPARATOR|EMLA Cream|Numbing (EMLA) cream will be applied around the port.
62680121|NCT04695119||Adult patients with septic shock|"All adult (\>=18 yo) patients admitted to participating ICUs with septic shock defined according to the Sepsis III criteria.~Purely observation study with no intervention. Patients are exposed to septic shock and treatment according to standard departmental protocols at each centre."
62680122|NCT06689631|EXPERIMENTAL|Treatment group|The intervention consisted of a Respiratory Physiotherapy session including: mucociliary clearance techniques (prolonged slow expiration and provoked cough), bronchodilator when prescribed and nebulisation with 3% hypertonic saline.
62309595|NCT04606615||Children: AD + Egg|atopic dermatitis and food allergy to egg
62309596|NCT04606615||Children: AD only|atopic dermatitis and no food allergy
62309597|NCT04606615||Children: NC|Normal Control
61921026|NCT03894592|NO_INTERVENTION|Control|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive no intervention
62121199|NCT05190419|EXPERIMENTAL|Orismilast modified release tablets 40 mg BID|Oral, twice daily morning and evening for 16 weeks
62121200|NCT05190419|PLACEBO_COMPARATOR|Placebo tablets BID|Oral, twice daily morning and evening for 16 weeks
62121201|NCT05474105|EXPERIMENTAL|Oral Nutritional Supplement|Daily active oral nutritional supplement (ONS) for 3 months + standard care
62121202|NCT05474105|NO_INTERVENTION|Control|Standard care
62309598|NCT01565746|EXPERIMENTAL|Radium-223 dichloride [50 kBq/kg]|
62309599|NCT01565746|EXPERIMENTAL|Radium-223 dichloride [100 kBq/kg]|
62309600|NCT01565746|EXPERIMENTAL|Radium-223 dichloride [expansion]|
62309601|NCT05134974|ACTIVE_COMPARATOR|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
62309602|NCT05134974|PLACEBO_COMPARATOR|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
62309603|NCT04358250|EXPERIMENTAL|direct superior approach|Direct superior approach 25 patients
62309604|NCT04358250|ACTIVE_COMPARATOR|posterolateral approach|posterolateral approach 25 patients
62475806|NCT06558370|ACTIVE_COMPARATOR|Bladder distension group|"Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
61921027|NCT03792425|OTHER|implant with immediate temporization|Immediate nonfunctional loading
61921028|NCT03792425|OTHER|Delayed implant without temporization|Conventional loading protocol
61921029|NCT05939011|EXPERIMENTAL|Well-formulated ketogenic diet (WFKD)|The researchers aim to enroll 20 healthy adults recruited from Kansas City and surrounding areas for an 8-week WFKD diet intervention. Study personnel will obtain baseline (week 0), mid-point (week 4), and end-of-study (8 weeks) blood samples, anthropometrics, and dietary intake data. Fecal microbiome samples and dual energy x-ray absorptiometry (DXA) are collected at baseline and 8-weeks. Blood samples collected at baseline and 8-week visits will be measured for metabolic biomarkers, inflammatory biomarkers, and RNA. The blood sample collected at the 4-week visit will include glucose, insulin, insulin resistance, and beta-hydroxybutyrate to track diet adherence and adjust the diet as needed.
62680123|NCT05570318|ACTIVE_COMPARATOR|Polyethylene glycols|"This group consists of children who have already been treated with oral laxatives (PEG) for at least 2 months, but still experience symptoms of constipation and fecal incontinence.~Their PEG dosage will be adjusted to the ideal dose for the individual child (this will be evaluated by a health care professional), with the minimum dosage being the maintenance dose of 0,5mg/kg/day, and the maximum dosage being the disimpaction dose of 1,5mg/kg/day"
61921030|NCT00357032|EXPERIMENTAL|Treatment (belinostat)|Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
61921031|NCT04330196|EXPERIMENTAL|Glucose condition|In the experimental condition patients ingest 200ml of water containing 75g of glucose
61921032|NCT04330196|PLACEBO_COMPARATOR|Control condition|In the control condition patients ingest 200ml of water sweetened with 700mg of aspartame
61921033|NCT06097780|PLACEBO_COMPARATOR|Placebo|Arm 1: Nine intravenous placebo administrations in twelve months.
61921034|NCT06097780|EXPERIMENTAL|Intravenous NestaCell® administrations|Arm 2: Nine intravenous NestaCell® administrations in twelve months.
61921035|NCT01205581|ACTIVE_COMPARATOR|Leukemia-HD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
62309605|NCT03450850|OTHER|NOVOTTF-200A|NOVOTTF-200A treatment in Bevacizumab-Naïve Subjects with Recurrent WHO Grade III Malignant Astrocytoma
62680124|NCT05570318|EXPERIMENTAL|Polyethylene glycols and low volume trans anal irrigation|This group consists of children who have already been treated with oral laxatives (PEG) for at least 2 months, but still experience symptoms of constipation and fecal incontinence. PEG dose will be adjusted in the same manner as in group a, but this group will also receive daily treatment with low volume trans anal irrigation.
61921036|NCT01205581|ACTIVE_COMPARATOR|Leukemia-SD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
61921037|NCT01205581|ACTIVE_COMPARATOR|Solid Tumor-HD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
61921038|NCT01205581|ACTIVE_COMPARATOR|Solid Tumor-SD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
61921039|NCT01205581|ACTIVE_COMPARATOR|HIV-HD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
62309606|NCT01429649|EXPERIMENTAL|ablation|Cryoablation or Radiofrequency ablation for the pGGO
62680125|NCT02914678|NO_INTERVENTION|Existing treatment|Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
62309607|NCT01429649|NO_INTERVENTION|Follow up CT scann|The patients will receive follow up with CT scan every 6-9 months.
62680126|NCT02914678|EXPERIMENTAL|More liberal treatment|Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
61921040|NCT01205581|ACTIVE_COMPARATOR|HIV-SD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
61921041|NCT04264052||CBE & MRI|Forty healthy volunteers split in different age ranges (20-30 years n=10, 30-40 years n=10, 40-50 years n=10 and 50-60 years n=10) will undergo two airway assessments at rest and during exercise. The exercise assessments will be a continuous bronchoscopy during exercise (CBE-1st visit) and magnetic resonance imaging (MRI-2nd visit) separated by at least three days to ensure for a sufficient cardiorespiratory and musculoskeletal recovery.
61944473|NCT04280835|NO_INTERVENTION|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
62475807|NCT02774785|EXPERIMENTAL|Device Arm|Randomized for MarginProbe device to be used during surgical procedure
61921042|NCT03319966||Oculomotor Dysfunction|This group consists of subjects with mTBI who have been diagnosed with OMD by objective OD measurements. These subjects will undergo neurovision rehabilitation used to treat oculomotor dysfunction following traumatic brain injury per usual clinical standard of care at the HCMC TBI Clinic.
61921043|NCT00674167|EXPERIMENTAL|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel and cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
61921044|NCT00674167|EXPERIMENTAL|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
62121203|NCT04456543|EXPERIMENTAL|Pressure monitoring group|In the pressure monitoring group, garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg for 2 months. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
62121204|NCT04456543|ACTIVE_COMPARATOR|conventional treatment group|In the conventional treatment group, non-surgical standard treatment of burn scars except for pressure monitoring was performed in the same manner. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
62121205|NCT04283552|EXPERIMENTAL|Dynamic PET Imaging|"* Dynamic PET/CT imaging will begin at approximately the same time as the clinically prescribed radiotracer injection and will continue until approximately the start of the clinical scan~* A subset of patients (up to 30 scheduled to undergo FDG or DOTATATE PET/CT imaging) will be asked to return within 7 days for a repeat imaging study."
62121206|NCT03182010|EXPERIMENTAL|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
62121207|NCT03182010|ACTIVE_COMPARATOR|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
62121208|NCT02846389|EXPERIMENTAL|Moderate Exercise|Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week).
62121209|NCT02846389|NO_INTERVENTION|Control Group|No exercise
62121210|NCT01592448||Usual Care|"Participants will be shown standard (defined as currently commercially available) over-the-counter and prescription medicine bottles and asked questions regarding safety and use. Participants will also be shown additional standard over-the-counter bottles and asked whether these comparison bottles could safely be taken in addition to the primary products shown."
62309608|NCT00956644|EXPERIMENTAL|irbesartan/amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks
62309609|NCT00956644|ACTIVE_COMPARATOR|amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks
61921045|NCT00674167|EXPERIMENTAL|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycles.
61921046|NCT03359343||experts|In this group, two experts distinguish a set of polyps on LCI images as adenoma or non-adenoma.
62309610|NCT05895851||RON|
61921047|NCT03359343||non-experts|In this group, two non-experts distinguish the set of polyps(the same to experts group) on LCI images as adenoma or non-adenoma.
62309611|NCT05895851||non-RON|non-RON but with radiiation treatment
61921048|NCT03359343||Computer-aided diagnosis system|In this group, a newly developed computer-aided diagnosis system will be used to distinguish a set of polyps as adenoma or non-adenoma.
62309612|NCT05895851||Normal|
62309613|NCT02900677|EXPERIMENTAL|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks.
62309614|NCT02900677|NO_INTERVENTION|Control|usual care
62309615|NCT02449564|EXPERIMENTAL|sirolimus|sirolimus 1mg daily
61921049|NCT04373668|NO_INTERVENTION|Control, optimised usual care|Treatment delivered as usual in the care home
61921050|NCT04373668|EXPERIMENTAL|Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP|Care homes to receive all three interventions: Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP interventions
61921051|NCT04661020|EXPERIMENTAL|Administration of CD19 CAR T-cells|
61921052|NCT01915966|EXPERIMENTAL|Cardamom, ginger and orange juice gelatin|Dietary Supplement
61921053|NCT01915966|ACTIVE_COMPARATOR|Camomile infusion with lemon juice|Dietary Supplement
61921054|NCT03052933|EXPERIMENTAL|Copanlisib/gemcitabine|
61921055|NCT02898116|EXPERIMENTAL|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for one to two 28-day cycles, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
61921056|NCT03405636|EXPERIMENTAL|Xeltis Pulmonary Valved Conduit|PV Conduit for RVOT reconstruction
61921057|NCT02599948||Patients hospitalised in ICU|Patients hospitalised in ICU
61921058|NCT03332550||purulent peritonitis|Hinchey 3
61921059|NCT03332550||faecal peritonitis|Hinchey 4
62309616|NCT03396549|EXPERIMENTAL|real tDCS|20 min of 2 mA tDCS over the right and left dorsolateral prefrontal cortex
62309617|NCT03396549|SHAM_COMPARATOR|new sham tDCS|20 min 2 mA tDCS over the left and right sensorimotor cortex
62309618|NCT02128581|PLACEBO_COMPARATOR|Saline|a saline infusion will be started and maintained till the end of the study at 1300 (300 minutes).
62309619|NCT02128581|ACTIVE_COMPARATOR|Exendin-9,39 @ 300|Exendin-9,39 @ 300pmol/kg/min
62309620|NCT02128581|ACTIVE_COMPARATOR|Exendin-9,39 @ 750|Exendin-9,39 @ 750pmol/kg/min
62309621|NCT00640783|EXPERIMENTAL|1|Mediterranean diet
62309622|NCT00640783|ACTIVE_COMPARATOR|2|Control diet
62475808|NCT02774785|NO_INTERVENTION|Control Arm|Randomized for surgical procedure to happen as per standard care
61921060|NCT05651568|EXPERIMENTAL|Periodized resistance training|It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.
62309623|NCT06637540|EXPERIMENTAL|RescueDoppler patch with probe is attached to patients undergoing cardiac surgery.|The RescueDoppler probe and patch are placed on the left side of the patient's neck in both preoperative and during surgery settings. The RescueDoppler system is connected to a screen with real-time bloodflow monitoring. The the blood flow curves are blinded for other health personell. After the cardiac surgery, the velocity curves are processed by the research team and synchronized with hemodynamic and respiratory data for analysis.
61921061|NCT05651568|EXPERIMENTAL|High intensity interval training|It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30-35 minutes.
61921062|NCT05606653|OTHER|didgeridoo players|subjects having a regular practice of didgeridoo
61921063|NCT05606653|OTHER|oboe players|subjects having a regular practice of the oboe
62309624|NCT03854955|EXPERIMENTAL|iScribes|Device-based scribing service used for dictation and documentation.
62309625|NCT03854955|NO_INTERVENTION|Traditional Dictation|Standard dictation and documentation methods used.
62309626|NCT04233346|EXPERIMENTAL|Ponatinib|CP-CML:Chronic Phase Chronic Myeloid Leukemia; AP-CML:Accelerated Phase Chronic Myeloid Leukemia; BP-CML:Blast Phase Chronic Myeloid Leukemia; Ph+ ALL:Ph+ Acute Lymphoblastic Leukemia;
62680127|NCT06184763||ELEXACAFTOR/TEZACAFTOR/ IVACAFTOR treated patients|"Patients ≥ 12 years old with cystic fibrosis followed at the Renee Sabran Hospital, heterozygous for the F508del mutation of the CFTR gene, treated with ELEXACAFTOR/ TEZACAFTOR/ IVACAFTOR.~Intervention: 6-minute walk test before and after starting treatment."
62680128|NCT03944876|EXPERIMENTAL|Botox injections towards SPG|Botulinum Toxin type A injections
61921064|NCT05606653|OTHER|control|control subjects without diagnosed SAS, at low risk of SAS on the Berlin questionnaire and the STOP BANG questionnaire
62309627|NCT02257606|NO_INTERVENTION|Control group (persons with MS)|no training
62309628|NCT02257606|EXPERIMENTAL|Experimental group (persons with MS)|Robot-assisted training
62309629|NCT03375710|EXPERIMENTAL|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
62309630|NCT05295329|EXPERIMENTAL|Test group|Take compound salvia miltiorrhiza dropping pills
62309631|NCT05295329|PLACEBO_COMPARATOR|placebo group|Take a placebo
62309632|NCT00641940|EXPERIMENTAL|1|Girls in Transition (GT) program
62309633|NCT00641940|OTHER|2|Waitlist control
62680129|NCT03944876|PLACEBO_COMPARATOR|Controls|placebo injections
62680130|NCT06681194|ACTIVE_COMPARATOR|Triamcinolone only|Patients in the triamcinolone group receive triamcinolone 0.5% applied topically to the hypergranulation tissue during their inpatient stay. Upon discharge, patients continue with the same triamcinolone 0.5% treatment, applying it once daily to affected areas in the outpatient setting. Treatment continues until either resolution of hypergranulation tissue (typically within 3-4 weeks) or until 8 weeks have passed without resolution, at which point the patient is considered a treatment failure if open areas persist. Standard wound care practices including appropriate dressings and antibiotics are maintained throughout the treatment period.
61921065|NCT02263131|EXPERIMENTAL|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
61921066|NCT02263131|ACTIVE_COMPARATOR|TIV PFS|VAXIGRIP Prefilled Syringe INJ.
61921067|NCT00322153|PLACEBO_COMPARATOR|Placebo|Oral administration, once daily.
61921068|NCT00322153|ACTIVE_COMPARATOR|Memantine ER|28mg, once daily. Oral administration for 24 weeks.
61921069|NCT03096145|EXPERIMENTAL|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
61921070|NCT04349293|EXPERIMENTAL|Patients with cancer|
61921071|NCT00818675|EXPERIMENTAL|Ridaforolimus|
61921072|NCT00818675|PLACEBO_COMPARATOR|Placebo|
61921073|NCT05313100|ACTIVE_COMPARATOR|Smokers|The patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking were included in the smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.
61921074|NCT05313100|SHAM_COMPARATOR|Nonsmokers|The patients who never smoked were included in the non-smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.
61944474|NCT02751866|ACTIVE_COMPARATOR|Active supplement, low carbohydrate|Whole fruit berry powder, low carbohydrate diet
62309634|NCT04569539|EXPERIMENTAL|Ultrasound|Ultrasound measurements of the cricothyroid membrane
62309635|NCT03890224|NO_INTERVENTION|Control group|no home non-invasive ventilation (NIV), only hospital NIV
62309636|NCT03890224|ACTIVE_COMPARATOR|Non-targeted home NIV|Nocturnal home non-invasive ventilation (NIV)
62309637|NCT03890224|ACTIVE_COMPARATOR|Targeted home NIV|Nocturnal home non-invasive ventilation (NIV) with high monitoring
62309638|NCT03890224|ACTIVE_COMPARATOR|Rescue home NIV|home non-invasive ventilation (NIV) on demand
62309639|NCT02851654||Dry eye syndrome|Meibomian gland dysfunction responsible of moderate to severe dry eye syndrome
62309640|NCT06091423|EXPERIMENTAL|Experimental|XELOX combined with Fruquintinib and Sintilimab
62475809|NCT03394235|EXPERIMENTAL|Long-pulsed, 1064nm Nd-YAG laser|All participants will receive long-pulsed, 1064nm Nd-YAG laser treatments with three different parameters at the occipital area.
62738526|NCT06335537|EXPERIMENTAL|Urocit-K, then Baking Soda|After being off Urocit-K for two weeks, participants will collect two 24-hour urine tests to document hypocitraturia or low urine pH for calcium oxalate or uric acid stone formers, respectively. Participants will take Urocit-K 30 mEq AM and 30 mEq PM for four-weeks. During the last two days of the four-week drug period, two 24-hour urine collections will be obtained, and the participants will enter another washout period of two weeks before switching over to Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in AM and ½ Teaspoon (29.5 mEq) in PM for four weeks. During the last two days of this study arm, two 24-hour urine collections will be obtained. A basic metabolic panel blood test will be obtained at the end of the study arm.
62309641|NCT00676039|ACTIVE_COMPARATOR|1|"Crossover Effexor / NOVO-Venlafaxine~Examination of the bioequivalence of Effexor (Wyeth Pharmaceuticals) and NOVO-Venlafaxine (NOVOPHARM).~Both drugs will be given at the dose of 75 mg/day (one capsule per day) for 4 consecutive days. A washout period (corresponding to 10 half-life of the active metabolite desmethylvenlafaxine) will be respected after receiving each medication."
62309642|NCT00676039|ACTIVE_COMPARATOR|2|"Crossover Celexa/Gen-citalopram~Examination of the bioequivalence of Celexa (Lundbeck, Brand Name) and Gen-Citalopram (Genpharm, Generic). Both drugs will be given at the dose of 40 mg/day (one tablet per day) for 8 consecutive days. A washout period (corresponding to 10 half-life of citalopram) will be respected after receiving each medication."
62309643|NCT01478750|EXPERIMENTAL|emulsified fat, orally|At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
62309644|NCT01478750|EXPERIMENTAL|intragastric administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
62309645|NCT01478750|EXPERIMENTAL|intraduodenal administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
62309646|NCT01478750|EXPERIMENTAL|intragastric, non-emulsified fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
62309647|NCT02113748|EXPERIMENTAL|Downhill walking training|Exercise training including treadmill walking with a negative inclination.
62309648|NCT02113748|ACTIVE_COMPARATOR|Conventional walking training|Exercise training including treadmill walking without inclination. Possible to progress training intensity with positive inclinations.
62309649|NCT03557372|EXPERIMENTAL|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
62309650|NCT01435525||Nexium|
62309651|NCT04273243||Subjects who received AT-GTX-501 gene transfer|Subjects with CLN6 Batten disease who previously received AT-GTX-501 in the preceding study (Study AT-GTX-501-01).
62309652|NCT01105338|ACTIVE_COMPARATOR|Green tea drink|Green tea drink
61944475|NCT02751866|PLACEBO_COMPARATOR|Placebo, Control|placebo powder, higher carbohydrate diet
62309653|NCT01105338|ACTIVE_COMPARATOR|Green tea capsules|Green tea capsules
62309654|NCT01105338|PLACEBO_COMPARATOR|Green tea placebo capsules|Green tea placebo capsules
62309655|NCT01105338|ACTIVE_COMPARATOR|Lycopene capsules|Lycopene capsules
62475810|NCT05587790|EXPERIMENTAL|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 45-minutes. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
62309656|NCT01105338|PLACEBO_COMPARATOR|Lycopene placebo capsules|Lycopene placebo capsules
62309657|NCT01105338|ACTIVE_COMPARATOR|Tomato rich diet|Tomato rich diet
62309658|NCT06062173||Adherent perirenal fat group|The surgeon considers perirenal fat to be adherent.
62309659|NCT06062173||Non-adherent perirenal fat group|Perirenal fat is considered nonadherent by surgeons.
61921075|NCT01872234|EXPERIMENTAL|Device Arm: Two Lead CRT-P|Intervention: Device: Two-lead CRT-P. Patients will be implanted with a two lead CRT-P system: right atrial lead, left ventricular lead and a dual chamber pacemaker. Patients in this group will also be under optimal pharmacologic therapy.
61921076|NCT01872234|NO_INTERVENTION|Control: Optimal Pharmacologic Therapy|The control group will be managed on optimal pharmacologic therapy only. They will not be implanted with a device.
62309660|NCT00600002|EXPERIMENTAL|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
61921077|NCT03582228|EXPERIMENTAL|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback"
62309661|NCT02463591|EXPERIMENTAL|Beriplex 50 IU/Kg|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Placebo).
62309662|NCT02463591|PLACEBO_COMPARATOR|Placebo|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Placebo identically in appearance to Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Beriplex).
61921078|NCT06523374|OTHER|Endoscopic brush cytology|"Each participant will receive all interventions. A routine endoscopy will be planned during which several minimally invasive interventions will be performed:~drawing a blood sample (standard of care), brush cytology (not standard of care) and biopsies (standard of care) during the endoscopy."
62475811|NCT00678639|EXPERIMENTAL|Emergency Department (ED) Observation unit|Emergency Department observation unit- Cardiac Magnetic Resonance Imaging (MRI) Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
62475812|NCT00678639|NO_INTERVENTION|Usual care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
62121211|NCT01592448||Written Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. This flier will be passively hanging within sight of the participant in the room, but no verbal explanation of the flier will be given to the participant. (This is designed to represent a passive education campaign such as posters in drug stores that may be used should these icons be adopted by manufacturers.)"
62121212|NCT01592448||Written + Verbal Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. Research personnel will also verbally go through the flier with the participant and answer any questions in a standardized fashion. (This is designed to represent an active education campaign such as pharmacist counseling that may be used should these icons be adopted by manufacturers.)"
62121213|NCT02641990|EXPERIMENTAL|Group 1|ITCA 650 20/60 mcg/day, ITCA placebo
62121214|NCT02641990|EXPERIMENTAL|Group 2|ITCA placebo, ITCA 650 20/60 mcg/day
62309663|NCT00796783||1|Patients with presumed Cushing's disease who have failed pituitary surgery and/or radiation and require medical treatment for recurrent or persistent Cushing's syndrome.
62309664|NCT06443112||history-indicated cerclage group (group1)|Group 1 included patients with history-indicated cerclage, who had second-trimester pregnancy loss associated with painless cervical dilatation in the absence of labor or placental abruption, or previous cerclage due to painless cervical dilatation in the second trimester.
61921079|NCT04961970|EXPERIMENTAL|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin
62121215|NCT03185156|EXPERIMENTAL|propofol group|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
62309665|NCT06443112||(Group 2) patients with ultrasound-indicated cerclage|Group 2 comprised patients with ultrasound-indicated cerclage, who had a history of spontaneous preterm birth before the 34th week previously and their cervical length was \<25 mm before the 24th week of gestation in the current singleton pregnancy, or who had \<10 mm cervical length in the current singleton pregnancy without history.
61921080|NCT04961970|ACTIVE_COMPARATOR|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and cisplatin
61921081|NCT06179368||Hypothroid group|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothroid patients will be enroled in this group.
62121216|NCT03185156|PLACEBO_COMPARATOR|control group|first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump
62309666|NCT06443112||Group 3 consisted of patients undergoing rescue cerclage|Group 3 consisted of patients undergoing rescue cerclage, who had premature cervical dilatation and exposure of fetal membranes in the vagina, was detected in ultrasound or speculum examination of the cervix.
62309667|NCT04853797|ACTIVE_COMPARATOR|Levcromakalim - Ivabradine|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of ivabradine (15 mg orally).
62309668|NCT04853797|PLACEBO_COMPARATOR|Levcromakalim - Placebo|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of placebo.
62309669|NCT04208373|EXPERIMENTAL|Panel 1: JNJ 64417184 plus Itraconazole|Participants will receive single oral dose of JNJ 64417184 on Day 1 followed by itraconazole once daily on Days 6 to 13 along with a single dose of JNJ 64417184 on Day 9 orally.
62309670|NCT04208373|EXPERIMENTAL|Panel 2: JNJ 64417184 plus Etravirine|Participants will receive single oral dose of JNJ-64417184 on Day 1 followed by etravirine twice daily on Days 6 to 19 along with single dose of JNJ 64417184 on Day 15.
62475813|NCT01555645|EXPERIMENTAL|Stress management Individual format|The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
62121217|NCT01703897||Obese patients|
62121218|NCT05527717|ACTIVE_COMPARATOR|Culprit-lesion only PCI arm|Patients will receive culprit-lesion only PCI.
62309671|NCT05906446|EXPERIMENTAL|Intervention|Regular exercise sessions incorporating balance, resistance training, and walking to accommodate diminished endurance, with synergistic protein and nutritional supplementation
62309672|NCT02583152||MPS patient cohort|Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
62309673|NCT02859415|EXPERIMENTAL|Phase I/Escalating doses of Mithramycin|Escalating doses of Mithramycin
62309674|NCT02859415|EXPERIMENTAL|Phase II/Mithramycin administered at Maximum Tolerated Dose (MTD)|Mithramycin administered at MTD
62309675|NCT03867253|ACTIVE_COMPARATOR|ORY-2001 Low dose|0.6mg ORY-2001 capsule
62475814|NCT01555645|EXPERIMENTAL|Stress management Group format|Participants will meet for 2 hours every week for a total of 20 hours. In the intervals between the group meetings patients will be asked to do homework. Homework entails practicing problem-solving techniques, keeping a diary, practicing relaxation or physical activities. Each group meeting has a specific subject, i.e. What is stress and stress behaviors, Stress related symptoms, How to manage anger and negative thoughts, Self-registrations and behavioral changes, Future perspectives, Cancer, stress and relations, Expectations and demands, Body, pleasure and sexuality.
62475815|NCT04518956|EXPERIMENTAL|Inter maxillary fixation and exposure to shockwave therapy|
62121219|NCT05527717|EXPERIMENTAL|Immediate multi-vesesl PCI arm|Patients will receive immediate multi-vessel PCI.
62121220|NCT05776680|EXPERIMENTAL|Psychological Support Course|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
62121221|NCT05776680|NO_INTERVENTION|Control group|Participants in control group will receive usual course.
62121222|NCT06677463|EXPERIMENTAL|An experimental study on the effect of virtual reality glasses on women during childbirth|An experimental study on the effect of virtual reality glasses on women during childbirth
62475816|NCT04518956|EXPERIMENTAL|Inter maxillary fixation and exposure to low intensity pulsed|
62475817|NCT04518956|ACTIVE_COMPARATOR|Inter maxillary fixation only|
62475818|NCT00834743|EXPERIMENTAL|1|
62475819|NCT00834743|ACTIVE_COMPARATOR|2|
62475820|NCT02738086|EXPERIMENTAL|Early PABC Intervention|GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
62121223|NCT05475405|EXPERIMENTAL|Scapulothoracic mobilization along with conventional physical therapy for mechanical neck pain.|"conventional physical therapy:~Scapulothoracic mobilization:~Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula."
61921082|NCT06179368||Euthroid group|throid fuction will be evaluated on admission of hepatic failure patients, and the euothroid patients will be enroled in this group.
61921083|NCT03129256|EXPERIMENTAL|Apatinib & S-1|Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg\~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
61921084|NCT04387825|EXPERIMENTAL|Experimental group|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
62121224|NCT05475405|ACTIVE_COMPARATOR|IASTM with conventional physical therapy for mechanical neck pain|"Conventional Physical Therapy:~IASTM (Instrument Assisted Soft Tissue Technique):~Patient sitting or prone lying Restrictions and myofascial adhesions assessed prior to treatment fanning strokes at 45 degree angles to skin be applied using the tool"
62121225|NCT02825485|OTHER|Control Group|The control patients will be the patients with antenatal hydronephrosis who get a routine VCUG to evaluate for vesicoureteral reflux, as part of routine care.
62121226|NCT02825485|NO_INTERVENTION|Observation Group|Receives no intervention
62121227|NCT01549756||Qualitative Research|Experiential/opinion based research
62121228|NCT01347125|EXPERIMENTAL|ImCardia|Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
62121229|NCT01347125|NO_INTERVENTION|AVR control group|Aortic stenosis patients candidates for aortic valve replacement
61921085|NCT04387825|NO_INTERVENTION|Control|Evolution and medical therapy effects were observed in the control group.
61921086|NCT03053765|ACTIVE_COMPARATOR|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
61921087|NCT03053765|EXPERIMENTAL|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
61921088|NCT03053765|EXPERIMENTAL|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
62309676|NCT03867253|ACTIVE_COMPARATOR|ORY-2001 High dose|1.2mg ORY-2001 capsule
61921089|NCT03053765|NO_INTERVENTION|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
62121230|NCT04065932|EXPERIMENTAL|BMS-985165-01 prototype formulation 1|
62121231|NCT04065932|EXPERIMENTAL|BMS-986165 Tablet|
61921090|NCT00673270|EXPERIMENTAL|1|Fludrocortisone and Hydrocortisone
62121232|NCT04065932|EXPERIMENTAL|BMS-985165-01 prototype formulation 2|
62121233|NCT04065932|EXPERIMENTAL|BMS-985165-01 prototype formulation 3|
62309677|NCT03867253|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62121234|NCT04065932|EXPERIMENTAL|BMS-985165-01 prototype formulation 3 or 4|
62309678|NCT01652833||Round 1|survey of 150 oncologists
62309679|NCT01652833||Round 2|survey of 150 oncologists approximately 12 months after round 1
62309680|NCT01652833||Round 3|survey of 150 oncologists approximately 24 months after round 1
62121235|NCT04065932|EXPERIMENTAL|BMS-985165-01 prototype formulation 3, 4 or 5|
62121236|NCT05528341|EXPERIMENTAL|NKG2D-CAR-NK92 cells immunotherapy|Preparation of NKG2D-CAR-NK92 cells suspended in saline solution.
62309681|NCT06205134|EXPERIMENTAL|6 Healthy volunteers, sequence ABC|"Three drug administrations to each subject, each administration on a separate day.~treatment order: A B C"
62309682|NCT06205134|EXPERIMENTAL|6 Healthy volunteers, sequence BAC|"Three drug administrations to each subject, each administration on a separate day.~treatment order: B A C"
62309683|NCT02247830|EXPERIMENTAL|1 Chamomilla recutita gel|Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
62121237|NCT04973735|EXPERIMENTAL|30mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
62121238|NCT04973735|EXPERIMENTAL|150mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
61921091|NCT00673270|EXPERIMENTAL|2|Fludrocortisone and placebo of Hydrocortisone
61921092|NCT00673270|EXPERIMENTAL|3|Placebo of Fludrocortisone and Hydrocortisone
61921093|NCT00673270|PLACEBO_COMPARATOR|4|Placebo of Fludrocortisone and placebo of Hydrocortisone
61921094|NCT02797054|EXPERIMENTAL|Tailored Intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
61921095|NCT02797054|OTHER|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
61921096|NCT02797054|OTHER|Usual Care|Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
61921097|NCT03325660|ACTIVE_COMPARATOR|study group|whole body vibration
62309684|NCT02247830|EXPERIMENTAL|2 Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the area irradiated three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
62309685|NCT02247830|NO_INTERVENTION|Control Group (Usual Care)|The usual care consists of nursing consultation with instructional material (Manual guidelines) that is already done systematically in service. This query is made with all patients starting radiotherapy. Here, guidelines are provided about skin care and hydration, using topical moisturizing soap solution over the bath. Such information is contained in the manual that is provided to the patient during the consultation.
62309686|NCT03992235|EXPERIMENTAL|Study Group|Chest physiotherapy + educational material
62309687|NCT03992235|OTHER|Control group|Chest physiotherapy
62309688|NCT00345371|ACTIVE_COMPARATOR|Topiramate|Subjects will receive topiramate (in tablet form) up to 200 mg/day for 13 weeks.
62309689|NCT00345371|PLACEBO_COMPARATOR|Placebo Oral Tablet|After randomization subjects will receive topiramate matched placebo (in tablet form), up to 200 mg/day for 13 weeks.
62309690|NCT02514070|EXPERIMENTAL|EPA-rich fish oil arm then DHA-rich fish oil arm|Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm
62309691|NCT02514070|EXPERIMENTAL|DHA-rich fish oil arm then EPA-rich fish oil arm|Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm
62309692|NCT04865081|EXPERIMENTAL|VACCIN box group|The anesthesiologist will intubate the participants in the VACCIN box group while using the VACCIN box that will be placed over the participants' head.
62309693|NCT04865081|NO_INTERVENTION|Control group|Enrolled participants in the control group will be intubated without the use of the VACCIN intubation box (standard anesthesia).
61921098|NCT03325660|NO_INTERVENTION|control group|No intervention
62121239|NCT04973735|EXPERIMENTAL|600mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
62309694|NCT01970150|EXPERIMENTAL|1|In this intervention patients receive 5 days a week for 4 weeks of rTMS treatment with real coil
62309695|NCT03865069|ACTIVE_COMPARATOR|automated oxygen control with VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) with automated pressure control (Volume Guarantee®).
62309696|NCT03865069|ACTIVE_COMPARATOR|automated oxygen control without VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) without automated pressure control (Volume Guarantee®).
61921099|NCT04470921||Choice for Opportunistic Salpingectomy|Women who will undergo a gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved, can opt for an opportunistic salpingectomy.
61921100|NCT03882775|EXPERIMENTAL|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
62121240|NCT04973735|EXPERIMENTAL|1200mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
61921101|NCT03882775|ACTIVE_COMPARATOR|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
61921102|NCT01840839|EXPERIMENTAL|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
62121241|NCT04973735|EXPERIMENTAL|2400mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
61921103|NCT01840839|SHAM_COMPARATOR|no stimulation|Sham stimulation during periods of SWS
61944476|NCT03624985|EXPERIMENTAL|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
61944477|NCT03624985|PLACEBO_COMPARATOR|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
61944478|NCT01321060|ACTIVE_COMPARATOR|Conservative treatment|Conservative treatment group with only drugs.
61944479|NCT01321060|EXPERIMENTAL|Continuous catheter drainage|Once the diameter of the fluid collection is more than 6cm, continuous catheter drainage will be applied.
61944480|NCT01321060|EXPERIMENTAL|Repeated aspiration|Once the diameter of the fluid collection is more than 6cm, aspiration is applied and draw the tube out immediately after aspiration.
61944481|NCT03664180|EXPERIMENTAL|anticoagulation|
61944482|NCT03664180|PLACEBO_COMPARATOR|No anticoagulation|
61944483|NCT05345860|EXPERIMENTAL|TNBC with high risk or MRD+|"TNBC patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
61944484|NCT05345860|EXPERIMENTAL|HER2+ with high risk or MRD+|"HER2+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
62121242|NCT04973735|PLACEBO_COMPARATOR|Placebo|Placebo is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
62121243|NCT02076958|ACTIVE_COMPARATOR|Traditional/classroom|Community health advisors trained using traditional/classroom methods and provided with technical assistance/support as needed
62121244|NCT02076958|EXPERIMENTAL|Technology|Community health advisors trained using technology/online methods and provided minimal technical assistance/support
62121245|NCT05650125||Patients with solid organ cancer|Prospective biosampling of blood/tissue
61944485|NCT05345860|EXPERIMENTAL|ER+ with high risk or MRD+|"ER+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
61944486|NCT05345860|EXPERIMENTAL|TNBC with low risk and MRD-|"TNBC patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
61944487|NCT05345860|EXPERIMENTAL|HER2+ with low risk and MRD-|"HER2+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
61944488|NCT05345860|EXPERIMENTAL|ER+ with low risk and MRD-|"ER+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
61944489|NCT00547573|ACTIVE_COMPARATOR|2|10 mg tadalafil tablet
61944490|NCT00547573|ACTIVE_COMPARATOR|3|20 mg tadalafil tablet
61944491|NCT00547573|PLACEBO_COMPARATOR|1|placebo tablet
61944492|NCT00479323|OTHER|1|Immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera.
62309697|NCT03989063|EXPERIMENTAL|Amputees (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
62680131|NCT06681194|ACTIVE_COMPARATOR|Silver nitrate only|During the inpatient phase, patients in this group receive treatment with silver nitrate sticks applied directly to the hypergranulation tissue. Upon discharge, patients transition to using 0.5% silver nitrate solution for outpatient care, which is applied once daily to the affected areas. The switch to solution form for outpatient treatment is made because it is less painful and easier to apply, particularly on difficult-to-access areas of the body. Treatment continues until either resolution of hypergranulation tissue (typically occurring within 3-4 weeks) or until 8 weeks have passed without resolution, at which point the patient is considered a treatment failure if open areas persist. Throughout the treatment period, standard wound care practices including appropriate dressings and antibiotics are maintained.
62680132|NCT06681194|EXPERIMENTAL|Combination group|The combination group receives treatment with silver nitrate sticks applied directly to the hypergranulation tissue during their inpatient stay. Upon discharge, patients switch from silver nitrate to triamcinolone 0.5%, which they apply once daily to affected areas in the outpatient setting. This treatment continues until either resolution of hypergranulation tissue (typically within 3-4 weeks) or until 8 weeks have passed without resolution, at which point the patient is considered a treatment failure if open areas persist. Standard wound care practices including appropriate dressings and antibiotics are maintained throughout. This combination approach aims to leverage both the initial cauterizing and antimicrobial effects of silver nitrate with the subsequent anti-inflammatory benefits of triamcinolone.
62680133|NCT02953457|EXPERIMENTAL|Treatment (olaparib, tremelimumab, durvalumab)|Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
62680134|NCT04736121|EXPERIMENTAL|Open-label Single Arm|Open-label single arm study evaluating treatment with hepatic arterial injection of SIR-Spheres.
62680135|NCT02268851|EXPERIMENTAL|CLL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~* Each Cycle = 28 days~* TGR-1202 (oral): Starting on Day 1 administered daily.~* Ibrutinib (oral): Starting on Day 1 administered daily."
62680136|NCT02268851|EXPERIMENTAL|MCL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~* Each Cycle = 28 days~* TGR-1202 (oral): Starting on Day 1 administered daily.~* Ibrutinib (oral): Starting on Day 1 administered daily."
62680137|NCT00392509|EXPERIMENTAL|2|Unfractionated Autologous Mononuclear Bone Marrow
61921104|NCT01280955|EXPERIMENTAL|Transplant Recipients|Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
62309698|NCT03989063|ACTIVE_COMPARATOR|Amputees (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
62309699|NCT03989063|EXPERIMENTAL|Diabetes (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
62309700|NCT03989063|ACTIVE_COMPARATOR|Diabetes (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
62309701|NCT06326151|ACTIVE_COMPARATOR|Health Education Programme|"Why: Upon discharge from the hospital, at the end of the baseline assessment, caregivers will receive instructions and recommendations for maintaining an active and healthy lifestyle. This will be done by encouraging self-care and good practices in caring for their dependent family member, as part of a health education programme. The benefits of an active lifestyle and general guidelines are emphasized.~What (materials): Instructions and recommendations for a health education programme.~What (procedures): Participants will receive instructions and recommendations on how to maintain an active and healthy lifestyle, promoting self-care and good practices in caring for their dependent family member.~How: The caregiver will receive the material individually at the time of referral, before being discharged from the hospital.~When and for how long: The intervention consists of a single session and details of the time and duration will be provided to participants."
62680138|NCT04087655|EXPERIMENTAL|Exercise training|Eight weeks of interval exercise training
62680139|NCT05377216|EXPERIMENTAL|Stellate ganglion block|All subjects will undergo stellate ganglion block during their VT ablation procedure
61921105|NCT04551144||Transmen|Subjects starting testosterone therapy as part of standard of care for gender incongruence
61921106|NCT04551144||transwomen|Subjects starting estradiol therapy as part of standard of care for gender incongruence
61921107|NCT05697744||obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
62475821|NCT02738086|EXPERIMENTAL|Wait-List Control Intervention|GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.
62475822|NCT02560402||Patients with sepsis or trauma|Adult patients, admitted to the intensive or medium care unit with sepsis or trauma
61921108|NCT05697744||Morbid obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
62475823|NCT02086214|EXPERIMENTAL|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
61921109|NCT05135312|OTHER|Etanercept|50mg etanercept subcutaneously twice weekly for 3 months, followed by once weekly for another 3 months for a total duration of 6 months or 24 weeks.
61921110|NCT02533791|EXPERIMENTAL|low dose group|4×10\^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
62475824|NCT02086214|PLACEBO_COMPARATOR|Control|LYCRA® non-compressive sleeve initially used in burn therapy : \< 5 mmHg.
61921111|NCT02533791|EXPERIMENTAL|high dose group|1.6×10\^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
62475825|NCT06400147|EXPERIMENTAL|Strategy Training|The strategy training intervention teaches individuals to develop personalized goals, self-assess their performance of daily activities, and develop and evaluate strategies designed to overcome barriers and improve their performance of daily activities. Participants use a workbook to support their application of the strategy training.
62475826|NCT06400147|ACTIVE_COMPARATOR|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The study team will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
62475827|NCT06090994|EXPERIMENTAL|Huaier Granule|Oral administration of Huai'er granules, 10g once, 3 times a day, continued until the end of the study, intolerable toxicity, withdrawal from the study for any reason, disease progression or death, whichever occurs first; Or the researcher determines that the subject no longer benefits. It is recommended that Huai'er Granules be used for the first time within 14 days-2 months after surgery. Please refer to the drug instructions for specific usage.
62475828|NCT06090994|ACTIVE_COMPARATOR|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks，please refer to the drug instructions for specific usage.
62475829|NCT05661097|ACTIVE_COMPARATOR|Small hernia ring group with continuous suture|Continuous suture of hernia ring with barbed wire\<3cm
62475830|NCT05661097|ACTIVE_COMPARATOR|Small hernia ring group with discontinuous full-thickness suture|Intermittent full layer suture to close hernia rings\<3cm
62475831|NCT05661097|ACTIVE_COMPARATOR|Large hernia ring group with continuous suture|Continuous suture of hernia ring with barbed wire\>3cm
62475832|NCT05661097|ACTIVE_COMPARATOR|Large hernia ring group with discontinuous full-thickness suture|Intermittent full layer suture to close hernia rings\>3cm
62475833|NCT05661097|EXPERIMENTAL|Large hernia ring group with continuous suture and discontinuous full-thickness suture|Continuous suture with barbed thread and discontinuous full-thickness suture to close hernia rings\>3cm
62475834|NCT06471556|EXPERIMENTAL|IV Methylprednisolone pulses|
62475835|NCT00561015|EXPERIMENTAL|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2|Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase). Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
62475836|NCT00561015|EXPERIMENTAL|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
61921112|NCT02533791|PLACEBO_COMPARATOR|placebo group|placebo
61921113|NCT02948218|ACTIVE_COMPARATOR|Shanghai Longhua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
62121246|NCT03284086|OTHER|paraplegic|Well-trained participants with a spinal cord injury (\<Th1) were included in this group.
62680140|NCT06327490|EXPERIMENTAL|ICG-guided manual lymphatic drainage|
62680141|NCT06327490|ACTIVE_COMPARATOR|Traditional manual lymphatic drainage|
62680142|NCT04695782|EXPERIMENTAL|Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)/44fx (1.25 Gy per fraction), two daily|
62475837|NCT00561015|ACTIVE_COMPARATOR|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
62495932|NCT06347627|EXPERIMENTAL|Group 8 (O x E x S x M)|"Participants in Group 8 will view a message in an X (former Twitter) format composed of Organization x Effectiveness x Storytelling x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
61921114|NCT02948218|ACTIVE_COMPARATOR|Shanghai Guanghua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
62121247|NCT03284086|OTHER|able bodied|Upper-body trained, able-bodied participants were included in this group.
62680143|NCT04695782|EXPERIMENTAL|Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)/46-52 fx (1.25 per fraction) two daily|
62680144|NCT03911271|EXPERIMENTAL|Loading dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
62680145|NCT03911271|EXPERIMENTAL|Low dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
62680146|NCT03911271|PLACEBO_COMPARATOR|Placebo|"In phase 1 (treatment phase), the participants (n=50) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
62680147|NCT03241420||Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
62680148|NCT03241420||Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
62680149|NCT04615988||Participants being treated with immunotherapy|Participants who are to receive standard of care immunotherapy targeting PD-1 or PDL1 as treatment for malignancy
62121248|NCT00718939|OTHER|Rheos ON|Study participants in this arm will have the device turn on for six months and remains on.
62121249|NCT00718939|OTHER|Rheos OFF|Study participants in this arm will have the device turned off for 6 months and then turned on.
62121250|NCT03557008|ACTIVE_COMPARATOR|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
62121251|NCT03557008|ACTIVE_COMPARATOR|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
62680150|NCT05999851|EXPERIMENTAL|Principal arm|The entire cohort of participants will undergo all experimental procedures. Participants who will develop hypertensive disorders of pregnancy and matched participants with healthy pregnancies will also undergo serum endothelial and angiogenic markers assessment.
62680151|NCT01326637|EXPERIMENTAL|intervention|Received the intervention: previsit planning phone call with filled out patient overview document \& clinician huddle
62680152|NCT01326637|NO_INTERVENTION|observation|Received usual care
62475838|NCT00561015|EXPERIMENTAL|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase). Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
62475839|NCT00561015|EXPERIMENTAL|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
62475840|NCT00561015|ACTIVE_COMPARATOR|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
62680153|NCT01667952||Cancer Survivors|The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
62680154|NCT06546735|EXPERIMENTAL|N0728|in the test group will be required to take 1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®. 2 tablets a day, in the morning, after feeding for 84 days.
62680155|NCT06546735|ACTIVE_COMPARATOR|Vesomni®|in the control group will be required to take 1 tablet of Vesomni® and 1 tablet of the placebo of the test drug. 2 tablets a day, in the morning, after feeding for 84 days.
62680156|NCT06214520|EXPERIMENTAL|Intervention|Intervention Group
62121252|NCT05289466|OTHER|Single-arm|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
62121253|NCT01266265||Tyvaso|The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.
62121254|NCT01266265||Control|The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.
62680157|NCT06214520|ACTIVE_COMPARATOR|Control 1|Control group 1
62680158|NCT06214520|NO_INTERVENTION|Control 2|Control group 2
62121255|NCT03573284|EXPERIMENTAL|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
62121256|NCT03916835|OTHER|Music Therapy during cleaning care 1|"This group receives music therapy during cleaning care 1 and not during the cleaning care 2.~Each patient will act as their own control"
62680159|NCT06678997|EXPERIMENTAL|Zinc-L carnosine/Polaprezinc|This group will receive Zinc-L carnosine/Polaprezinc (Hepilor Liquido) 1 hour after meals: 2.5 ml twice a day in infants weighing \<5 kg or 5 ml twice a day in infants weighing \>5 kg.
62680160|NCT06678997|ACTIVE_COMPARATOR|Thickened formula|Infants will receive thickened but not hydrolyzed formula
62680161|NCT06694181||Cardiology|The primary objective in this clinical case scenario is to evaluate an ML model utilizing real-time cardiac telemetry, as well as other clinical, demographic, and imaging structured data sources, among hospitalized, intensive care unit (ICU) patients to predict impending inhospital cardiac arrest, identify potentially reversible causes of cardiac arrest, and predict which patients may have impending cardiac arrest due to shockable rhythms i.e. ventricular tachycardia (VT) or ventricular fibrillation (VF).
62475841|NCT04510545||Treatment Group|All patients will undergo CAD of any diminutive polyps found in the rectosigmoid on colonoscopy
62121257|NCT03916835|OTHER|Music Therapy during cleaning care 2|"This group receives music therapy during cleaning care 2 and not during the cleaning care 1.~Each patient will act as their own control"
62121258|NCT03187860|EXPERIMENTAL|Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)"
62475842|NCT03311594|EXPERIMENTAL|Low Alcohol Consumption and No Pain Induction|Condition 1: Low alcohol consumption Condition 2: No pain group
62475843|NCT03311594|EXPERIMENTAL|Low Alcohol Consumption and Pain Induction|Condition 1: Low alcohol consumption Condition 2: Pain group
61921115|NCT02948218|ACTIVE_COMPARATOR|Huadong hospital of Fudan University|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
62121259|NCT03187860|EXPERIMENTAL|Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))~Intervention: Bronchial Biopsy + ALI culture"
62475844|NCT03311594|EXPERIMENTAL|Moderate Alcohol Consumption and No Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: No pain group
62680162|NCT06694181||Oncology - Breast Cancer|The primary objective in this clinical case scenario is to evaluate an ML model utilizing structured and unstructured data from clinical, demographic, and tumor molecular and germline sequencing, among outpatients with cancer, to predict short-term mortality and/or symptom decline. The model for prediction to treatment response in breast cancer patients will be compared with two prognostic tools: 1) Conversation Connect, a previously validated machine learning mortality prediction tool that has been used at the University of Pennsylvania for routine clinical decision support, and 2) the Elixhauser Comorbidity Index, a comorbidity-based prognostic index used commonly in research and risk-adjustment.
62121260|NCT03187860|EXPERIMENTAL|Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD~Intervention: Bronchial Biopsy + ALI culture"
62475845|NCT03311594|EXPERIMENTAL|Moderate Alcohol Consumption and Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: Pain group
62121261|NCT03187860|EXPERIMENTAL|Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.~Intervention: Bronchial Biopsy + ALI culture"
62309702|NCT06326151|EXPERIMENTAL|Interdisciplinary Psychoeducational Programme|"Why: The programme is based on an interdisciplinary psychoeducational intervention from the fields of occupational therapy and psychology.~What (materials): projector, computer, screen, presentation of content, stationery, chairs, tables and self-recording of home tasks.~What (procedures): Patients assigned to the experimental group will follow an interdisciplinary psychoeducational programme structured and supervised at the University of Salamanca, consisting of a health education programme combined with an interdisciplinary psychoeducational programme from the perspective of psychology and occupational therapy.~Who will carry out the interventions: modules: (I) understanding the syndrome or disease and managing difficult everyday caring situations or behaviours, (II) emotions and misconceptions about caring, and (III) self-care (Table 1).~When and for how long: Each participant will receive 4 sessions per month for 3 months, for a total of 12 sessions."
62309703|NCT02369510|EXPERIMENTAL|Low-dose epinephrine|100micrograms of epinephrine group
62309704|NCT02369510|EXPERIMENTAL|High-dose epinephrine|200micrograms of epinephrine group
62309705|NCT02369510|PLACEBO_COMPARATOR|No epinephrine|0.2ml saline
62309706|NCT02642861|ACTIVE_COMPARATOR|Cyclobenzaprine|Cyclobenzaprine administration for 2 weeks
62309707|NCT02642861|PLACEBO_COMPARATOR|PLacebo|Calcium carbonate for 2 weeks
62309708|NCT06315881|EXPERIMENTAL|PHASE I ARM I (low FBN R/S ONP)|Participants insert low free-base nicotine (FBN) R/S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
62309709|NCT06315881|EXPERIMENTAL|PHASE I ARM II (low FBN > 99% S ONP)|Participants insert low FBN \> 99% S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
62309710|NCT06315881|EXPERIMENTAL|PHASE I ARM III (high FBN R/S ONP)|Participants insert high R/S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
62309711|NCT06315881|EXPERIMENTAL|PHASE I ARM IV (high FBN > 99% ONP)|Participants insert high FBN \> 99% S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
62309712|NCT06315881|EXPERIMENTAL|PHASE I ARM V (Usual brand ST or cigarette)|Participants insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes. Patients also undergo blood sample collection at 0, 5, 15, 30, 60, and 90 minutes.
62309713|NCT06315881|EXPERIMENTAL|PHASE II ARM I (low FBN R/S ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert low FBN R/S ONP for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
62475846|NCT03311594|PLACEBO_COMPARATOR|Placebo Alcohol Consumption and No Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: No pain group
62475847|NCT03311594|EXPERIMENTAL|Placebo Alcohol Consumption and Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: Pain group
62121262|NCT04470258|OTHER|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|A realistic simulation will be carried out, centered on the heuristic evaluation, by a multiprofessional team (N= 6), to evaluate the performance of the new equipment in the execution of the pre-defined skills. The prototype will be tested on a mannequin by the research team and on healthy volunteers by health professionals, where physiological parameters and interface comfort will be evaluated.
62121263|NCT04470258|OTHER|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The second phase will consist of a clinical trial, in the application of the non-invasive respiratory device in 10 patients with respiratory failure by COVID-19, to assess its clinical effectiveness, through the analysis of the physiological variables and patient comfort.
62475848|NCT03311594|PLACEBO_COMPARATOR|Control and No Pain Induction|Condition 1: No alcohol consumption Condition 2: No pain group
62475849|NCT03311594|EXPERIMENTAL|Control and Pain Induction|Condition 1: No alcohol consumption Condition 2: Pain group
61921116|NCT02948218|ACTIVE_COMPARATOR|Shanghai Yueyang Integrated hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
62309714|NCT06315881|EXPERIMENTAL|PHASE II ARM II (low FBN > 99% S ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert to low FBN \> 99% S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
62309715|NCT06315881|EXPERIMENTAL|PHASE II ARM III (high R/S ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert to high R/S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
62309716|NCT06315881|EXPERIMENTAL|PHASE II ARM IV (high FBN > 99% ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert high FBN \> 99% S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
62309717|NCT06097585||SGLT2I Group|the case group that will receive SGLT2I in the treatment
62309718|NCT06097585||non - SGLT2I Group|the control group that will not receive SGLT2I in the treatment
62309719|NCT00994565|NO_INTERVENTION|Usual care|
62309720|NCT00994565|ACTIVE_COMPARATOR|Activity monitoring and distance counseling|
62309721|NCT03403244|EXPERIMENTAL|US-MR image fusion-guided PTED|US-MR image fusion-guided PTED: the puncture procedure during PTED was performed under the guidance of ultrasound-MR fusion technique.
62309722|NCT03403244|ACTIVE_COMPARATOR|fluoroscopy-guided PTED|fluoroscopy-guided PTED: the puncture procedure during PTED was performed under the guidance of fluoroscopy.
62309723|NCT02672956|EXPERIMENTAL|Supraumbilical entry group|Umbilical port will be insert to supra umbilical area.
62309724|NCT02672956|EXPERIMENTAL|Intraumbilical entry group|Umbilical port will be insert to intra umbilical area.
62309725|NCT02672956|EXPERIMENTAL|Infraumbilical group|Umbilical port will be insert to infra umbilical area.
62309726|NCT02552407||Manual Aspiration Thrombectomy with PCI|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to Manual Aspiration Thrombectomy followed by percutaneous coronary intervention (PCI).
62309727|NCT02552407||PCI Alone|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to percutaneous coronary intervention (PCI) alone without manual aspiration thrombectomy.
61921117|NCT03027479|EXPERIMENTAL|Case group|women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples
61921118|NCT03027479|OTHER|Control group|women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples
61921119|NCT01727700|PLACEBO_COMPARATOR|Placebo|Matching Placebo Once-Daily
62309728|NCT01099033||Hiatal/Paraesophageal hernia patients|patients with hiatal or paraesophageal hernias
62475850|NCT03508011|EXPERIMENTAL|IMP4297|
62475851|NCT02281084|EXPERIMENTAL|Monotherapy: Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
62475852|NCT02281084|EXPERIMENTAL|Combination Therapy: Oral Azacitidine and Durvalumab|Oral Azacitidine 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous (IV) infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
62475853|NCT03702608|OTHER|EluNIR 38mm|
62475854|NCT05318898|EXPERIMENTAL|Regular diet with vegetable protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetable protein sources.
62309729|NCT01099033||control group|patients without hiatal or paraesophageal hernias who are undergoing crural dissection for heller myotomy, or who are undergoing gastric bypass surgery
62475855|NCT05318898|ACTIVE_COMPARATOR|Regular diet with animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
62121264|NCT03823534|EXPERIMENTAL|Experimental Arm|For the first 24 hours following surgery, patients younger than 65 years old will be administered a maximum of 120 mg/day bolus IV ketorolac (30 mg every 6 hours). Patients older than 65 years old or with history of advanced renal impairment will receive a maximum of 60 mg/day bolus IV ketorolac (15 mg every 6 hours). All patients may also be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate- severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. At discharge, they will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours, quantity 50. Those with preexisting liver disease will be prescribed the equivalent in oxycodone and will not receive acetaminophen for mild pain.
62475856|NCT01528462||Expedited Treatment of Sleep Disorders|Please see below.
62475857|NCT00905606|EXPERIMENTAL|1|Topiramate Tablets, 25 mg
62475858|NCT00905606|ACTIVE_COMPARATOR|2|Topamax® Tablets, 25 mg
62475859|NCT01767363||5-alpha reductase inhibitors with or without alpha-blockers|Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
62475860|NCT01767363||Alpha-blockers|Men using alpha-blockers over the course of the study period.
62475861|NCT00741858|EXPERIMENTAL|DuraGen (sutureless)|Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.
62475862|NCT00741858|ACTIVE_COMPARATOR|DuraGuard (suturable)|Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.
62680163|NCT06694181||Sepsis|The primary objective in this clinical case scenario is to develop and evaluate an ML model that utilizes multidmodal clinical data (e.g., structured EHR data such as demographics, laboratory test results, and vital signs; unstructured EHR data including the text of clinical encounter notes and, where available, waveforms from real-time cardiac, hemodynamic, and respiratory monitoring devices) to predict the need for initiation of broad-spectrum antimicrobial therapy for hospitalized patients with sepsis. With a focus on implementable and explainable AI, we will produce well calibrated predictions that are also clinically meaningful at the bedside to aid real-time decision-making about diagnosis and treatment initiation. The model for timely diagnosis and intervention in sepsis will be compared with widely used commercial and open-source sepsis prediction models.
62309730|NCT00479362|EXPERIMENTAL|1 Warfarin Uninterrupted|Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
62680164|NCT03048019||Tirofiban Therapy|patients randomized to tirofiban therapy
61921120|NCT01727700|EXPERIMENTAL|Aripiprazole 5 mg or 10 mg|Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
61921121|NCT01727700|EXPERIMENTAL|Aripiprazole 10 mg or 20 mg|Aripiprazole 10 mg 20 mg Immediate Release Once-Daily
61944493|NCT03529331|ACTIVE_COMPARATOR|Morphine Sulfate Immediate Release|ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
62309731|NCT00479362|ACTIVE_COMPARATOR|2 Warfarin Interrupted|Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
62309732|NCT00479362|SHAM_COMPARATOR|3 Aspirin Group|Patients with aspirin therapy during implantation
62309733|NCT00479362|OTHER|4 No Antithrombotic Group|No antithrombotic treatment during operations
62309734|NCT03954171|OTHER|Patients treated with platinum based-chemotherapy|
62309735|NCT04427592|EXPERIMENTAL|pregnant women with placenta accreta spectrum|The participants were subjected to ultrasound to diagnose placenta accreta spectrum followed by new conservative surgical technique.
62309736|NCT00121732|EXPERIMENTAL|A|
62475863|NCT01827566|ACTIVE_COMPARATOR|gluten|10 grams of gluten in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
62475864|NCT01827566|PLACEBO_COMPARATOR|gluten free flour|10 grams of gluten free flour in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
62475865|NCT06415045|EXPERIMENTAL|BI 1015550 without food, then BI 1015550 with food|
62475866|NCT06415045|EXPERIMENTAL|BI 1015550 with food, then BI 1015550 without food|
62475867|NCT05886660|EXPERIMENTAL|DPI-386 Nasal Gel|DPI-386 Nasal Gel, 0.4 mg
62475868|NCT05886660|EXPERIMENTAL|Placebo Comparator|Placebo Nasal Gel
62475869|NCT05886660|EXPERIMENTAL|DPI-386 Nasal Gel and Sensory Augmentation DPI-386 Nasal Gel, 0.4 mg|8-Channel K-Tactile Belt, Engineering Acoustics, Inc., Casselberry, FL
62475870|NCT05886660|EXPERIMENTAL|Placebo Comparator and Sensory Augmentation Placebo Nasal Gel|8-Channel K-Tactile Belt, Engineering Acoustics, Inc., Casselberry, FL
62475871|NCT04028180|EXPERIMENTAL|Midge Repellency|Treatment of forearm with insect repellent and exposure to midges every 1 hour for 12 hours
62475872|NCT03527017||General Population|Adults living in Germany.
62475873|NCT03527017||IQOS Users|Adult current IQOS users (at the time of survey) living in Germany who are registered in the Germany IQOS User Database and agreed to be contacted for research purposes at the time of registration.
62680165|NCT03048019||Cangrelor Therapy|patients randomized to cangrelor therapy
62309737|NCT00121732|EXPERIMENTAL|B|
62309738|NCT02718846|EXPERIMENTAL|Meniace and Isobide|co-administration Isobide solution and Meniace tablets
62475874|NCT03022786|NO_INTERVENTION|Understanding patient perspective|Patients will be interviewed who have been diagnosed with stasis dermatitis. The Principal Investigator will learn their perspective on their leg swelling, impact on quality of life, and obstacles to wearing compression stockings
62309739|NCT02718846|ACTIVE_COMPARATOR|Meniace|single administration Meniace tablets
61921122|NCT03062410|OTHER|Electronic PRO|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
62309740|NCT04101422|NO_INTERVENTION|Development of Augmented Reality (AR) Application|Investigators will collaborate with an AR software specialist to develop AR stimuli that are embedded within a basic digital application.
62680166|NCT06007794|EXPERIMENTAL|JUMP group|This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day. In addition, an ultrasound of the thigh is performed to measure the size of the quadriceps on 5 different measurements.
61921123|NCT04084678|EXPERIMENTAL|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the individual maximum tolerated dose (maximum dose of 1400 mcg)
62121265|NCT03823534|PLACEBO_COMPARATOR|Control|Following surgery, patients will be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate-severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. They will also be given a placebo injection of normal saline every 6 hours for the first 24 hours following surgery. At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours PRN quantity 50, unless they have preexisting liver disease, in which case they will be prescribed the equivalent in oxycodone. They will not receive a nerve block.
62309741|NCT04101422|EXPERIMENTAL|Pilot Testing of AR Application|AR stimuli (smoking, e.g, cigarette, ashtray, lighter; and non-smoking, e.g., pen, notebook, eraser) will be piloted on a small group of smokers to receive feedback and modify as needed. Participants will answer questions from a 10 point Likert scale that will asses urge from 1 (absolutely no urge to smoke) to 10 (strongest urge to smoke) and reality/co-existence (how realistic the item looks, and it's integration into the environment), from 1 (Not at all) to 10 (Very Much). Participants will then be asked additional open-ended questions about the quality of the images following the ratings of the images.
62309742|NCT04101422|EXPERIMENTAL|Laboratory Validation of AR Stimuli Session 1: Cue Reactivity|Participants will attend 1st lab based session that will test cue-reactivity. Participant will be randomized to view either AR images, or in vivo items first. Order of presentation of items will also be randomized within the type (AR or in vivo).Session 1 should last under 1 hour.
62475875|NCT03022786|NO_INTERVENTION|Refining tool kit|"Using in-depth interviews for our inpatients selected using the same criteria as in Phase 1 and independent focus groups of providers, The study staff will obtain feedback to refine the items in our toolkit before implementing them in January 2017.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
62680167|NCT05229354|EXPERIMENTAL|Intervention followed by challenge|Participants receiving TV005 and then challenged with the rDEN2Δ30-7169 attenuated virus strain.
62680168|NCT05229354|EXPERIMENTAL|Placebo followed by challenge|Participants receiving placebo and then challenged with the rDEN2Δ30-7169 attenuated virus strain.
61921124|NCT04084678|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets (oral)
61921125|NCT01009281|EXPERIMENTAL|AIN457|
61921126|NCT02283151|OTHER|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d). Supplementation of multivitamins and minerals was provided per day.
61944494|NCT03529331|ACTIVE_COMPARATOR|Oxycodone/Acetaminophen (Percocet),|ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
61944495|NCT03529331|ACTIVE_COMPARATOR|Hydrocodone/Acetaminophen (Vicodin)|ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
62680169|NCT06297343||Adult patients with chronic renal failure|Adult patients with chronic renal failure for whom arteriovenous fistula creation is planned
62309743|NCT04101422|EXPERIMENTAL|Laboratory Validation of AR Stimuli Session 2: Extinction|Participants will be randomized into either the extinction or control group. 28 trials of AR cues will be presented for each group. Both groups will receive the same neutral cue in Trial 1 (to establish baseline urge) and the same smoking cue in Trial 2 (for pre-test cue-reactivity). The extinction group will receive smoking cues for trials 3-26, whereas the control group will receive neutral cues. Both groups will receive matched smoking cues for trial (27) followed by matched neutral cues for the final trial (28), for post-test cuereactivity. Each cue will be presented for 1 minute and will be shown 4 times in trials 3-26. Following each cue, participants will complete the single-item measure of urge. Following the final trial (28) for both groups, participants will be presented with one of their own cigarettes and asked to take at least one puff. Latency to smoke will later be determined using time stamps on the video recording. Session 2 is expected to last 1.25 hours.
62309744|NCT04101422|EXPERIMENTAL|Testing AR Application|Participants will be instructed to use the AR app that presents smoking-related stimuli (cigarette, ashtray, lighter) in locations/situations where they typically smoke with the goal of at least 5 uses per day for 7 days. Usage and rating data will be collected in real-time. Participants will also be asked to rate their urge to smoke on the smartphone app at selected times. Participants will complete a telephone interview to provide additional feedback on the app, answer questions related to smoking behavior, and receive an in-person interview on their perceptions of the app as a potential cessation tool. Participants will use the smart phone application for 7 days.
62309745|NCT02648815|ACTIVE_COMPARATOR|Percutaneous catheter drainage group|Percutaneous catheter drainage (PCD) of necrotic tissue and pathological collections formed during acute pancreatitis
62309746|NCT02648815|ACTIVE_COMPARATOR|Abdominal paracentesis evacuation group|Abdominal paracentesis drainage (APD) of peritoneal fluid during acute pancreatitis
62309747|NCT01154946||DAC group|patients who show detrusor after-contraction during voiding cystometrography (CMG)
62309748|NCT01200511|EXPERIMENTAL|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
62309749|NCT03048097|EXPERIMENTAL|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
62309750|NCT04628871||Subjects who received SB-318|Subjects who received SB-318 in clinical study SB-318-1502
62309751|NCT04628871||Subjects who received SB-913|Subjects who received SB-913 in clinical study SB-913-1602.
61921127|NCT02283151|EXPERIMENTAL|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). Carbohydrate-rich foods, such as white rice, steamed bread and tubers, were substituted with fish, poultry and plant oil. All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar (106 Kcal: 2.8 g carbohydrate, 11.2 g protein and 5.6 g fat; Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat (i.e., beef, lean pork, skinned chicken, fish) at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
62309752|NCT04628871||Subjects who received SB-FIX|Subjects who received SB-FIX in clinical study SB-FIX
62309753|NCT05084547||Case|Subjects with Bronchiectasis
62309754|NCT05084547||Control|Healthy Controls
61921128|NCT02666703|EXPERIMENTAL|Study (CytoSorb)|In the study group (20 patients) the CytoSorb filter will be installed in the CPB in a parallel circuit. An additional roller pump will drive the blood through the filter with a constant flow of 400 ml/min (max flow).
62309755|NCT01464697|EXPERIMENTAL|oral micronized progesterone|Oral micronized progesterone is Prometrium 300 mg at bedtime daily
62309756|NCT01464697|PLACEBO_COMPARATOR|Placebo Comparator|Placebo
62309757|NCT00667277|EXPERIMENTAL|bevacizumab (Avastin)|Use of bevacizumab (Avastin) in the treatment of myelofibrosis.
62309758|NCT01737164|EXPERIMENTAL|Aerobic Exercise - Older Subjects|Subjects aged 65 and higher will perform 16 weeks of moderate intensity exercise
62309759|NCT01737164|EXPERIMENTAL|Aerobic Exercise - Young Subjects|Subjects 18-30 years old will perform 16 weeks of moderate intensity exercise
62309760|NCT05296057|EXPERIMENTAL|Participants Receiving VR-Exposure Therapy Treatment|All participants will be receiving the experimental VR-exposure therapy treatment.
62309761|NCT04752813|EXPERIMENTAL|BPM31510, Vitamin K1, RT and TMZ|"Subjects will receive a BPM31510 96hr infusion once weekly for 8 wk. Prophylactic Vitamin K1 at a recommended dose of 10 mg will be given intramuscular (IM) to all subjects prior to the beginning of each week of therapy.~After 2 wk of treatment with BPM31510, subjects will start concurrent standard RT and TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment."
62475876|NCT03022786|OTHER|Implementation|Our patient education materials and toolkit include an order set to help providers guide patients to adhere to compression, the gold standard of care for this condition. This will also direct patients to know who to contact if itching or pain persists, what the patient can do at home, when to go to the hospital, as well as information on financial and home care assistance as it relates to managing their chronic condition.
62475877|NCT04389489||COVID-19|Pregnant women with COVID-19 who have given birth
62475878|NCT04389489||Control|Healthy pregnant women who have given birth
62680170|NCT06535139|EXPERIMENTAL|Clinician-targeted training|All clinicians and nurses will be assigned to participate in a training on how to recommend or discuss the HPV vaccine.
62680171|NCT06535139|EXPERIMENTAL|Clinician-targeted training and Parent-targeted motivational aids|All clinicians and nurses will be assigned to participate in a training on how to recommend or discuss the HPV vaccine. Also, clinics will send reminder/recall messages to parents about the HPV vaccine and offer phone-based motivational interviews.
61921129|NCT02666703|NO_INTERVENTION|Control|In the control group (20 patients) no filter will be installed on the CPB.
61944496|NCT00334685|EXPERIMENTAL|[S,S]-Reboxetine + Pregabalin|
61944497|NCT00334685|ACTIVE_COMPARATOR|Pregabalin|
62309762|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：~* Clinical diagnosis of Posner-Schlossman Syndrome~* Able to communicate with doctor and understand this study~Exclusion criteria:~* Not be able to communicate with doctor and understand this study~* One or more authorized investigators think he or she will suffer from any severe risks from the study"
62309763|NCT03233477||cataract|"Inclusion criteria：~* Clinical diagnosis of age-related cataract~* Prepare for cataract operation~* Open angle and intraocular pressure is normally at anytime~* No family history of glaucoma~Exclusion criteria:~* Patients above 65 years old~* With Secondary ocular hypertension~* Have the history of receiving any ophthalmologic operation or anti-viral therapy~* With diabetes mellitus~* With autoimmune disease~* Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
62309764|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：~* Both eyes involved~* Open angle~* Progressive glaucomatous optic neuropathy~* Specific visual field loss of glaucoma~* Intraocular pressure above the up limit of normal people~Exclusion criteria:~* Patients above 65 years old~* With Secondary ocular hypertension~* Have the history of receiving any ophthalmologic operation or anti-viral therapy~* With diabetes mellitus~* With autoimmune disease~* Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
62309765|NCT03411733||acne vlugaris group|Included recruited patients with acne vulgaris Intervention: Blood and stool samples collection
62309766|NCT03411733||Control group|Included healthy participants Intervention: Blood and stool samples collection
62309767|NCT03644992||Thromboembolic Disease|the patients who undergo gynecological operations but develop thromboembolic disease
62309768|NCT04315363|EXPERIMENTAL|Intervention|Brain MRI and Motivational Behavioral Intervention
61921130|NCT02666703|ACTIVE_COMPARATOR|Corticosteroid|In the corticosteroid group (20 patients), 1 gram of methylprednisolone will be added in the priming solution of CPB machine. No filter will be installed on the CPB.
62121266|NCT04395326||24 months follow-up|"Single-group study Patients have been included for up to 4 weeks after the initiation of Second Generation Antipsychotic (SGA) treatment (baseline)~Patients under 18 years of age, previously naïve of antipsychotics, starting an SGA or who started an SGA treatment for less than 4 weeks, followed longitudinally at one of the selected recruiting centers, regardless of the diagnosis that motivated the prescription. Comedications and combination of APs are allowed, as this is an observational study.~The exclusion criteria are the following: participants diagnosed before or at the baseline with diabetes, dyslipidemia, high blood pressure, thyroid dysfunction, hepatic disease, a disorder that can lead to hyperprolactinemia or another disorder that may interfere with the development of the side effects studied in this research, participants taking a drug intended to treat one of the conditions mentioned above before starting the SGA treatment, and pregnancy."
62121267|NCT06553547|EXPERIMENTAL|Tenapanor Cohort 1|Tenapanor 2 mg BID
62121268|NCT06553547|EXPERIMENTAL|Tenapanor Cohort 2|Tenapanor 5 mg BID
62121269|NCT06553547|EXPERIMENTAL|Tenapanor Cohort 3|Tenapanor 10 mg BID
62121270|NCT06553547|EXPERIMENTAL|Tenapanor Cohort 4|Tenapanor 15 mg BID
61944498|NCT03505554|EXPERIMENTAL|Lorlatinib|100 mg QD
62121271|NCT06553547|EXPERIMENTAL|Tenapanor Cohort 5|Tenapanor 20 mg BID
62121272|NCT06553547|EXPERIMENTAL|Tenapanor Cohort 6|Tenapanor 25 mg BID
61944499|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
62309769|NCT04315363|ACTIVE_COMPARATOR|Active control|Brain MRI and Control Behavioral Intervention
62309770|NCT06250842||Long-term benzodiazepine use group|Continuous use of benzodiazepines for ≥3 months
62309771|NCT06250842||Non-benzodiazepine use group|No history of prior benzodiazepine use
62309772|NCT06250842||Healthy Controls|Healthy Controls
62309773|NCT04361110||Acute intestinal ischaemia|Abdominal CT scan within 48 hours preoperative.
62309774|NCT04361110||Controls|Abdominal CT scan within 48 hours preoperative.
62475879|NCT03651219|EXPERIMENTAL|experimental group|Patients use Apatinib Mesylate tablets combined with Irinotecan.
62475880|NCT03651219|ACTIVE_COMPARATOR|controlled group|Patients use Irinotecan
62680172|NCT06535139|EXPERIMENTAL|Clinician-targeted training, Parent-targeted motivational aids, and Healthcare Access|All clinicians and nurses will be assigned to participate in a training on how to recommend or discuss the HPV vaccine. Also, clinics will send reminder/recall messages to parents about the HPV vaccine and offer phone-based motivational interviews. Plus, clinics will have access to healthcare access assistance.
62475881|NCT02732821||Gastric Per Oral Endoscopic Myotomy|All patients presenting with Gastroparesis will undergo Per oral endoscopic gastric myotomy
62309775|NCT01611077|OTHER|Single Arm|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
62475882|NCT05615454|EXPERIMENTAL|Experimental group|(BEMER activated)
62475883|NCT05615454|PLACEBO_COMPARATOR|Comparison group|(BEMER deactivated)
62475884|NCT02601560|EXPERIMENTAL|MEDI6012 24 mg IV|Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
62475885|NCT02601560|EXPERIMENTAL|MEDI6012 80 mg IV|Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
62475886|NCT02601560|EXPERIMENTAL|MEDI6012 240 mg IV|Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
62475887|NCT02601560|EXPERIMENTAL|MEDI6012 800 mg IV|Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
62680173|NCT00816673|PLACEBO_COMPARATOR|placebo|
62309776|NCT05203965|EXPERIMENTAL|FHP; Mavoglurant-Placebo|Family History Positive (FHP) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
62309777|NCT05203965|EXPERIMENTAL|FHP; Placebo-Mavoglurant|Family History Positive (FHP) or alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
62309778|NCT05203965|EXPERIMENTAL|FHN; Mavoglurant-Placebo|Family History Negative (FHN) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
62309779|NCT05203965|EXPERIMENTAL|FHN; Placebo-Mavoglurant|Family History Negative (FHN) for alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
62475888|NCT02601560|EXPERIMENTAL|MEDI6012 80 mg SC|Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
62475889|NCT02601560|PLACEBO_COMPARATOR|Placebo Intravenous (IV)|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
62475890|NCT02601560|EXPERIMENTAL|MEDI6012 600 mg SC|Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
62475891|NCT02601560|PLACEBO_COMPARATOR|Placebo Subcutaneous (SC)|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
62475892|NCT04487158|ACTIVE_COMPARATOR|Small Changes|
62475893|NCT04487158|EXPERIMENTAL|INSPIRE|
62475894|NCT02574377|EXPERIMENTAL|A: myDC vaccination|intranodal injection with tumor peptide-loaded myeloid dendritic cells
62475895|NCT02574377|EXPERIMENTAL|B: pDC vaccination|intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
62475896|NCT02574377|EXPERIMENTAL|C: combined myDC/pDC vaccination|intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
62475897|NCT03697798|ACTIVE_COMPARATOR|Children aged between 7-10 years of age|Healthy children from 7 up to 10 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country. They will receive Boostrix®-IPV combination vaccine.
62475898|NCT03697798|ACTIVE_COMPARATOR|Children aged between 11-15 years of age|Healthy children from 11 up to 15 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country aiming for comparable numbers of participants with aP vs wP vaccination background. They will receive Boostrix®-IPV combination vaccine.
62680174|NCT00816673|EXPERIMENTAL|Circadin|
62475899|NCT03697798|ACTIVE_COMPARATOR|Adults aged between 20-34 years of age|Healthy young adults from 20 up to 34 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
62475900|NCT03697798|ACTIVE_COMPARATOR|Adults aged between 60-70 years of age|Older adults from 60 up to 70 years of age determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
62475901|NCT04374630|EXPERIMENTAL|Arm 1|Arm 1 is afuresertib 125 mg PO QD + paclitaxel 80 mg/m2 intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 3 week cycle.
62475902|NCT04374630|ACTIVE_COMPARATOR|Arm 2|Arm 2 is paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15 of a 3 week cycle
62680175|NCT06500845|EXPERIMENTAL|Intervention group|Bevel marginal design endocrown for endodontically treated teeth
62475903|NCT02087553||Transfused pediatric patients|Children who might receive packed red blood cell (PRBC) transfusion will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Transfusion of red blood cells will be done according to standard of care.
62680176|NCT06500845|ACTIVE_COMPARATOR|Control group|Butt marginal design endocrown for endodontically treated teeth
62680177|NCT05064670|EXPERIMENTAL|Exercise|The intervention group will, in addition to routine clinical care according to (inter-) national guidelines, receive an exercise program of resistance and aerobic exercise delivered live online by an upskilled exercise professional in group exercise classes twice weekly for 3 months
62680178|NCT05064670|NO_INTERVENTION|Control|The control group will receive routine clinical care according to (inter-) national guidelines
62680179|NCT05962138|EXPERIMENTAL|Sleepio (dCBT-I)|"6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online.~Participants will also receive a booklet with general advice for patients with fibromyalgia, including sleep hygiene."
61921131|NCT02431247|EXPERIMENTAL|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination \[FDC\]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
61921132|NCT02431247|ACTIVE_COMPARATOR|DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC|Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
61921133|NCT02267642|EXPERIMENTAL|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
61921134|NCT03372889|ACTIVE_COMPARATOR|Patient educaiton materials Print based|Patients are randomly assigned to view print based educational material.
62475904|NCT02087553||Saline/Albumin infusion|Children who might receive albumin or saline for volume resuscitation will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Infusion will be done according to standard of care.
62475905|NCT05580692|EXPERIMENTAL|Patient Cohort|All Patients are within the same arm
62475906|NCT04374773|EXPERIMENTAL|Estradiol|1 week treatment with 0.3 mg/24 hr transdermal estradiol
62475907|NCT04374773|EXPERIMENTAL|Cortisol|1 week treatment with 30 mg hydrocortisone daily, administered in 2 divided doses
62475908|NCT03040648|EXPERIMENTAL|cervical TFEB under DSA|cervical TFEB was performed under DSA
61921135|NCT03372889|ACTIVE_COMPARATOR|Patient educaiton materials Media Based|Patients are randomly assigned to view media based educational material.
61921136|NCT01680549|ACTIVE_COMPARATOR|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
61921137|NCT01680549|PLACEBO_COMPARATOR|Placebo|Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
62475909|NCT03040648|ACTIVE_COMPARATOR|TFEB under RTF|cervical TFEB was performed under RTF
61921138|NCT00882401|ACTIVE_COMPARATOR|Ergocalciferol (oral)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
61921139|NCT00882401|PLACEBO_COMPARATOR|Placebo|Matching placebo at same dose schedule as ergocalciferol
61921140|NCT05299788|NO_INTERVENTION|The routine analgesia group|The routine analgesia and warming protocol was applied to patients in the control group.The routine postoperative analgesic treatment protocol at the unit comprises the administration of 75 mg IM (Intramuscular) Diclofenac Sodium before the patient wakes up, 30 mg intravenous (IV) Tramadol if the patient complains of pain when awake (maximum dose of 100 mg/day), and 10 mg/day Morphine Sulfate. In addition to, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for warming.
61921141|NCT05299788|EXPERIMENTAL|The routine analgesia+active external warming+ice application group|In addition to the routine analgesia protocol, the study group was administered non-pharmacological pain control interventions.
61921142|NCT03076229|EXPERIMENTAL|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
61921143|NCT03076229|EXPERIMENTAL|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
61921144|NCT03329781|EXPERIMENTAL|Trial|350 mg of BCM-95, 1 capsule per day, for 21 days.
62475910|NCT05385601||Healthy young athletes (Eye-Tracker®T2 + e-VOG)|Subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
62475911|NCT05385601||Healthy young athletes (e-VOG + Eye-Tracker®T2)|Subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
62475912|NCT03100084||I. Post Dates|"Pregnant women referred for clinical post term evaluation and/or labour induction.~Blood sampling."
62475913|NCT03100084||II. Induction of Labour|"Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).~Blood sampling."
62475914|NCT03100084||III. All Outpatients|"Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.~Blood sampling"
62475915|NCT03100084||IV. Diabetes in Pregnancy|Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.
62680180|NCT05962138|NO_INTERVENTION|Treatment as usual|Participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
62680181|NCT06575595|EXPERIMENTAL|Treatment A|Single dose delivered subcutaneously (SC) with an autoinjector
62680182|NCT06575595|EXPERIMENTAL|Treatment B|Single dose of concentration A delivered SC with syringe and vial
62680183|NCT06575595|EXPERIMENTAL|Treatment C|Single dose of concentration B delivered SC with syringe and vial
62680184|NCT05821088|EXPERIMENTAL|Treatment (tafasitamab, lenalidomide, ICE regimen)|Patients receive tafasitamab IV, lenalidomide PO, etoposide IV, ifosfamide IV and carboplatin IV on study. Patients undergo PET or CT, and undergo blood sample collection throughout the study. Patients may undergo tissue biopsy on study.
62680185|NCT05014230|OTHER|Treatment as Usual|Opioid medication, as prescribed in routine care
62680186|NCT05014230|EXPERIMENTAL|Open Label Placebo + Treatment as Usual|Opioid medication, as prescribed in routine care + Honest placebos
62680187|NCT06284278|EXPERIMENTAL|Diaphragmatic breathing exercise group|Diaphragmatic breathing exercise through telehealth
61921145|NCT03329781|PLACEBO_COMPARATOR|Control|350 mg of starch, 1 capsule per day, for 21 days
61921146|NCT03843710|EXPERIMENTAL|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
62309780|NCT04176822|EXPERIMENTAL|Educational Animated Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched an educational animated movie through VR Goggles. The educational animated movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
62680188|NCT06284278|ACTIVE_COMPARATOR|Pelvic stabilization exercise group|Pelvic stabilization exercise through telehealth
62680189|NCT06689683|ACTIVE_COMPARATOR|250 shocks|In our clinic, it is standard practice to perform a fluoroscopic check after every 250 shocks during the SWL session. Group 1 was fluoroscopically monitored every 250 shocks.
62680190|NCT06689683|ACTIVE_COMPARATOR|500 shocks|Group 2 was fluoroscopically monitored every 500 shocks.
62680191|NCT06072586|EXPERIMENTAL|Recurrent high-grade glioma participants with EGFR alterations|
62680192|NCT06072586|EXPERIMENTAL|Recurrent high-grade glioma participants with EGFR fusion|
62680193|NCT04596631|EXPERIMENTAL|Semaglutide - max. tolerated dose|Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
62680194|NCT04596631|PLACEBO_COMPARATOR|Placebo (semaglutide)|Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
61921147|NCT03843710|EXPERIMENTAL|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
61921148|NCT03843710|EXPERIMENTAL|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
61921149|NCT03843710|EXPERIMENTAL|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
61921150|NCT05265871||Refractory chronic cough|Subjects would be performed induced sputum test, ATP and capsaicin cough provocation test.
61921151|NCT05265871||Healthy control|Subjects would be performed induced sputum test, ATP and capsaicin cough provocation test.
61921152|NCT05589090|EXPERIMENTAL|Intervention group|Super Skills for Life intervention
61921153|NCT05589090|NO_INTERVENTION|Wait-list group|Children in this group did not receive any phycological (public or private) intervention during the eight-week duration of the SSL program. They were informed that children in this group will receive the intervention once the follow-up visit is completed.
61921154|NCT04385407|ACTIVE_COMPARATOR|SOF + RBV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:\<75 kg, 1000 mg; \>75 kg, 1200 mg).
62680195|NCT02323581|EXPERIMENTAL|TAAA (thoracoabdominal aortic aneurysm) Study Arm|"Either the Off-the-Shelf TAAA device or the Physician-Specified TAAA Device will be implanted.~The Off-the-Shelf TAAA Device is a standard configuration Zenith t-Branch with four branches for the mesenteric arteries and the renal arteries.~The Physician-Specified TAAA Devices may include a combination of up to 5 fenestrations and branches for mesenteric and renal arteries. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards."
61944500|NCT01238354|ACTIVE_COMPARATOR|Without friend|Being in the weight loss programme without friend or family member
62121273|NCT06553547|PLACEBO_COMPARATOR|Placebo|Matching placebo
62309781|NCT04176822|EXPERIMENTAL|Documentary Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched a documentary movie through VR Goggles. The documentary movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
62309782|NCT04176822|NO_INTERVENTION|Control Group|No intervention was made, pain and fear levels were measured using scales only.
62475916|NCT03100084||V. Reduced Fetal Movements|"Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.~Blood sampling."
62475917|NCT03100084||VI. Hypertensive Disorders in Pregnancy|"Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.~Blood sampling."
62475918|NCT03100084||VII. All Labour Admissions|All pregnant women ≥37+0 GW admitted for labour. Blood sampling.
62475919|NCT05749887|OTHER|salvage sugery|Salvage surgery for patients diagnosed locally advanced cervical cancr with residual tumor after standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy+ brachytherapy)
62680196|NCT02323581|EXPERIMENTAL|Aortic Arch Study Arm|Physician-specified aortic arch stent graft device with up to 3 antegrade and/or retrograde branches or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery\] to treat aortic aneurysms involving the aortic arch in patients at high risk for open surgery.
62680197|NCT06177912|EXPERIMENTAL|V116|Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1
62309783|NCT06673030|ACTIVE_COMPARATOR|Group 1 (Tell-Show-Do)|
62309784|NCT06673030|EXPERIMENTAL|Group 2 ( Tell-Show-Play-Doh)|
62309785|NCT06673030|EXPERIMENTAL|Group 3 (Kaleidoscope glasses )|
62309786|NCT04977544|ACTIVE_COMPARATOR|drug only|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
62309787|NCT04977544|EXPERIMENTAL|vert combine with drug|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
62309788|NCT05102981||emergency stoma|an emergency procedure including stoma construction, as first procedure at or shortly after diagnosis of colon or rectal cancer
62475920|NCT05831449|EXPERIMENTAL|CPL-01|Local infiltration of study drug
62475921|NCT05831449|ACTIVE_COMPARATOR|Ropivacaine HCl|Local infiltration of study drug
62475922|NCT05831449|PLACEBO_COMPARATOR|Placebo|Local infiltration of study drug
62475923|NCT05401786|EXPERIMENTAL|Anti-CTLA-4, SBRT and PD1|"Participants will receive 1 dose of ipilimumab (1mg/kg intravenously) on day 1. After 1 week the participants will receive SBRT (3x8Gy) on at least 1 but no more than 4 tumor lesions.~Within 1 week of the last radiation fraction participants will start with cemiplimab (350mg intravenously every 3 weeks) until disease progression, unacceptable toxicity, patient request for discontinuation, or up to 2 years of treatment"
62680198|NCT06177912|ACTIVE_COMPARATOR|PPSV23|Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
62680199|NCT02245724|EXPERIMENTAL|Stem Cell|Bone marrow mononuclear cell transplantation
62680200|NCT06083142|EXPERIMENTAL|Active FMT|Active FMT (5 doses) over 7 days. Each dose contains 15 capsules.
62309789|NCT05102981||Planned stoma|a planned procedure including stoma construction, as first procedure after diagnosis of colon or rectal cancer
62680201|NCT06395714|EXPERIMENTAL|Personnalized physiotherapy|"Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist in charge of their rehabilitation.~These instructions will be adapted according to the results of the composite test and the items identified. The scores of the various functional tests in the composite test will be evaluated to establish the key elements to be taken into account for subsequent management. These instructions will necessarily be personalized according to the scores."
61921155|NCT04385407|ACTIVE_COMPARATOR|SOF + RBV (Experienced)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:\<75 kg, 1000 mg; \>75 kg, 1200 mg).
62680202|NCT06395714|ACTIVE_COMPARATOR|Usual physiotherapy|"Following completion of the ankle go test, patients in active comparator group will undergo conventional rehabilitation following surgery."
62680203|NCT01927861|EXPERIMENTAL|0.033 mg/kg/day|
62680204|NCT01927861|EXPERIMENTAL|0.066 mg/kg/day|
62121274|NCT02794480|EXPERIMENTAL|Placebo ELLIPTA DPI (QD) in P1 and Placebo AZ MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily (QD) for 28 days and Placebo AZ MDI taken as two inhalations twice daily (BD) for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
62680205|NCT01173458||Blood Draw|"Approximately 1 and one-half teaspoons of blood will be drawn at times specified.~* one sample prior to treatment initiation~* one sample after completion of treatment~* one sample every 6 to 8 weeks during follow up visits~* one sample at the time of Relapse"
62680206|NCT03361007||Common carotid artery access for TAVI|Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.
62680207|NCT04016402||Study Group|All participants enrolled in the study
62680208|NCT05997615|EXPERIMENTAL|Part 1: AMX-500 Monotherapy Dose Escalation|AMX-500 will be administered as a monotherapy in patients with mCRPC over a 21-day cycle
61921156|NCT04385407|ACTIVE_COMPARATOR|SOF + SMV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
62309790|NCT04510727|EXPERIMENTAL|OCT Guided C&D Group|Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C\&D.
62309791|NCT03693027|EXPERIMENTAL|PTx800|Qualified subjects will dissolve one oral lozenge (PTx800 lozenges) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
62309792|NCT03693027|PLACEBO_COMPARATOR|Placebo|Qualified subjects will dissolve one oral lozenge (placebo control) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
62475924|NCT01247701|EXPERIMENTAL|Umbilical Cord Blood Transplant|Busulfan,Cyclophosphamide, Fludarabine, Cord Blood Stem Cell Infusion
62475925|NCT01269086|NO_INTERVENTION|Usual Care|Traditional care with no systematic assessment of family member´s health problems or risk factors.
62309793|NCT05881850|EXPERIMENTAL|Intervention group|After the participants are given the necessary information about the research and written consent is obtained, the introductory information form, Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale will be applied by the researcher to the women in the intervention group who meet the inclusion criteria in the study to collect pre-test data just before the education program begins. Twelve weeks after finishing the education program the Osteoporosis Awareness Scale and the Osteoporosis Health Belief Scale will be administered to collect the posttest data.
62680209|NCT05997615|EXPERIMENTAL|Part 2: AMX-500 Monotherapy Dose Expansion|AMX-500 will be administered as a monotherapy in patients with mCRPC over a 21-day cycle
61921157|NCT04385407|ACTIVE_COMPARATOR|SOF + SMV (Expereined)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
62121275|NCT02794480|EXPERIMENTAL|Placebo AZ MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive AZ MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
61921158|NCT05965648|OTHER|Families FORWARD|This is a single-arm trial of a new transition planning program for families of youth on the autism spectrum. The program includes six or seven bi-weekly parent sessions, three of which are optional for the youth to attend. The program will be facilitated by community-based service providers who work with transition-aged youth on the autism spectrum and/or their families.
61921159|NCT05523518|EXPERIMENTAL|The Buzzy® group|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
62121276|NCT02794480|EXPERIMENTAL|Placebo ELLIPTA DPI (QD) in P1 and Placebo GSK MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily for 28 days and Placebo GSK MDI taken as two inhalations twice daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period.
62121277|NCT02794480|EXPERIMENTAL|Placebo GSK MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive GSK MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
62475926|NCT01269086|EXPERIMENTAL|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
62680210|NCT01509456|ACTIVE_COMPARATOR|Potassium Bicarbonate|
62680211|NCT01509456|NO_INTERVENTION|Control|
62738527|NCT06335537|EXPERIMENTAL|Baking Soda, then Urocit-K|After being off Urocit-K for two weeks, participants will collect two 24-hour urine tests to document hypocitraturia or low urine pH for calcium oxalate or uric acid stone formers, respectively. Participants will take Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in AM and ½ Teaspoon (29.5 mEq) in PM for four weeks. During the last two days of the four-week drug period, two 24-hour urine collections will be obtained, and the participants will enter another washout period of two weeks before switching over to Urocit-K 30 mEq AM and 30 mEq PM for four weeks. During the last two days of this study arm, two 24-hour urine collections will be obtained. A basic metabolic panel blood test will be obtained at the end of the study arm.
62680212|NCT06669494||Cohort|"This exploratory study aims to investigate the relationship between activity levels/muscle mass and clinical indicators. ., assuming an estimated Spearman's rank correlation of 0.7, a sample size of 43 participants would yield a two-sided 95% confidence interval with a margin of error of 0.17. Considering a dropout rate of 15%, a total of 51 participants is required.~This study will begin enrolling ICU patients with weakness following approval from the Institutional Review Board (IRB). With an estimated enrollment rate of fewer than one participant per week, the enrollment period is expected to last approximately 12 months.~-Lifelog via Wearable Device (Accelerometer::Fitbit) Participants will wear the Fitbit Charge 5 from the time of study registration after ICU admission until two weeks post-ICU discharge.~If the participant meets the criteria for sarcopenia based on bioelectrical impedance analysis (BIA), a nerve conduction study will be conducted"
62309794|NCT05881850|NO_INTERVENTION|Control group|After the participants were given the necessary information about the study and written consents were obtained, the Introductory Information Form, Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale will be applied to the women in the control group who met the inclusion criteria in order to collect the pre-test data. Twelve weeks after finishing the education program, the Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale will be applied to collect the post-test data.
62309795|NCT04905329||"Patients with high and gray zone risk reccurrence early breast cancer"|
62309796|NCT04905329||Patients with gastointestinal cancers|
62309797|NCT04905329||Patients with gynecological malignancies|
62680213|NCT06129734|EXPERIMENTAL|Low dose maintenance chemotherapy|Participants will receive low dose chemotherapy as a maintenance therapy post-transplant. Participants must enroll by post-transplant day 40. Treatment will consist of once weekly 5 mg/m2 decitabine followed by 400 mg venetoclax orally approximately 6 hours afterwards. Participants will continue maintenance therapy for one year or unacceptable toxicity. Participants will otherwise receive post Allogeneic hematopoietic stem cell transplant (alloSCT) care and disease monitoring as per institutional standards.
62680214|NCT05250583|EXPERIMENTAL|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring.
62680215|NCT01742299|EXPERIMENTAL|imatinib mesylate|The starting dose of imatinib should be the same as the last dose that was given in the parent imatinib study (400 mg/day to 600 mg/day). After this, the dose of imatinib is based on the investigator's judgment.
62738528|NCT03032211|EXPERIMENTAL|Treatment|Alfapump
62738529|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
62309798|NCT01982110|EXPERIMENTAL|Mindfulness Based Therapy|Craving to Quit mobile application is provided for participants
61921160|NCT05523518|EXPERIMENTAL|the AccuVein® group|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
62309799|NCT01982110|ACTIVE_COMPARATOR|Behavioral Smoking Cessation|NCI Quit Pal via a mobile phone application is provided for participants
62309800|NCT04057963|EXPERIMENTAL|Conventional plus Functional Inspiratory Muscle Training Group|Conventional program plus functional inspiratory muscle training will be carried out three sessions per week during the six weeks. The content of the program will be the same as for the conventional group. Additional functional inspiratory muscle training will be began with 50% of the maximal inspiratory pressure value in a specific device and it will be progressed 5% every week according to the tolerance.
62738530|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1\~3 years
62738531|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3\~5 years
62738532|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
62738533|NCT06531187|EXPERIMENTAL|gamified group|The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).
62738534|NCT06531187|ACTIVE_COMPARATOR|conventional small group discussion|The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP).
62738535|NCT04176874||Diastasis of the rectus abdominis muscles|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
62738536|NCT03160248|EXPERIMENTAL|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
62738537|NCT03160248|EXPERIMENTAL|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
62738538|NCT05314543|EXPERIMENTAL|Track cyclists and rowers (males and females)|All female and male rowing and track cycling athletes at the national or international national or international level, registered in a selection process and likely to represent France at the likely to represent France at the 2024 Olympics will be asked to take part to take part in this study.
62738539|NCT01388049|EXPERIMENTAL|virus detection|
62738540|NCT01258790|SHAM_COMPARATOR|Sham Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, in the form of Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using a Sham TMS coil.
62738541|NCT01258790|EXPERIMENTAL|Active Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using an Active Magstim Figure-8 TMS coil.
62738542|NCT04166578||Mydrane group|Patients were randomly selected to the group receiving intracameral 0.2 ml Mydrane (a solution of 1% lidocaine and 0.025% of adrenaline ) during phacoemulsification.
62738543|NCT04166578||Reference group|Patients were randomly selected to the group receiving intracameral a combination of intracameral solution of lignocaine 1% and adrenalin 0.025% (0.2 ml) during phacoemulsification.
62309801|NCT04057963|ACTIVE_COMPARATOR|Conventional Physiotherapy Program|Conventional program will be carried out three sessions per week during the six weeks. Cervical mobilization techniques (glidings-grade 2) of cyriax will be applied in the direction of lateral flexion and rotation. Stretching exercises, craniovertebral flexion exercise and scapulothoracic strengthening exercises will be performed.
62680216|NCT04798339|EXPERIMENTAL|Phase 1b: Dose Level 1|Patients will be treated at dose level 1: Canakinumab 150 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
62680217|NCT04798339|EXPERIMENTAL|Phase 1b: Dose Level 2|Patients will be treated at dose level 2: Canakinumab 300 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
62680218|NCT04798339|EXPERIMENTAL|Phase 2: Treatment at Maximum Tolerated Dose|Patients will be treated with Darbepoetin alfa subcutaneously at a dose of 300 mg on days 1 and 15 of each cycle plus the maximum tolerated dose of Canakinumab.
62680219|NCT05849662|EXPERIMENTAL|Lower-risk patients|Lower-risk patients are defined as having a mutational burden of one clonal alteration AND a low DNA methylation classification.
62309802|NCT02597595|EXPERIMENTAL|patients|thirty children with beta thalassemia major, with age range from 4-18 years, will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
61921161|NCT05523518|NO_INTERVENTION|The control group|With the pediatric patients in the control group, no intervention will be performed before or during the procedure, and routine IV catheterization will be carried out without the use of any device.
62680220|NCT05849662|EXPERIMENTAL|High-risk patients|High-risk patients are defined as having as having a mutational burden of more than one clonal alteration AND/OR an intermediate or high DNA methylation classification.
62121278|NCT02565069|EXPERIMENTAL|Treatment group|Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias
62121279|NCT02477670|PLACEBO_COMPARATOR|Placebo|Placebo capsules administered twice a day over a 12-week period
62121280|NCT02477670|EXPERIMENTAL|AVP-786|AVP-786 dose 2 capsules administered twice a day over a 12-week period
62121281|NCT02570542|ACTIVE_COMPARATOR|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
61921162|NCT00939952|ACTIVE_COMPARATOR|ertapenem 500 mg IV x1|All patients will receive ertapenem 500 mg IV once.
62121282|NCT02570542|EXPERIMENTAL|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
62121283|NCT06479668|EXPERIMENTAL|Autism Spectrum Disorder|
62309803|NCT02597595|NO_INTERVENTION|controls|thirty healthy children of matched age and sex
61944501|NCT01238354|EXPERIMENTAL|With friend|Having the friend or family member stay together with the patient for 2-3 days for every 3 week stay at the clinic in the weight loss programme
62121284|NCT06479668|EXPERIMENTAL|Attention Deficit Disorder with or without Hyperactivity|
62121285|NCT01354795|EXPERIMENTAL|1.EUS-FNA with or without suction|During EUS FNA is performed, with or without self-retracting 10-mL syringe
62121286|NCT01354795|EXPERIMENTAL|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet into the needle or injecting air
62309804|NCT01887210|EXPERIMENTAL|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
62309805|NCT01887210|ACTIVE_COMPARATOR|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
62680221|NCT06436183|EXPERIMENTAL|Dose 1|Camoteskimab
62680222|NCT06436183|EXPERIMENTAL|Dose 2|Camoteskimab
62680223|NCT06436183|PLACEBO_COMPARATOR|Placebo|Dummy version of the study drug
62680224|NCT05206604|EXPERIMENTAL|PF-07295324|Ointment
62680225|NCT05206604|EXPERIMENTAL|PF-07259955|Cream
62680226|NCT05998616|EXPERIMENTAL|Exercise Training Program|Participants will receive a theory-based, remotely-delivered exercise training program that includes aerobic and resistance exercise training.
62680227|NCT05998616|ACTIVE_COMPARATOR|Flexibility Program|Participants will receive a remotely-delivered flexibility program, focusing on improving flexibility and range of motion.
62738544|NCT06661356|NO_INTERVENTION|Standard Care Arm|Participants randomized to the standard care arm will receive PrEP at a SGM-affirming health facility from a physician or nurse.
62738545|NCT06661356|EXPERIMENTAL|COMPrEP Intervention|Participants randomized to the COMPrEP intervention will receive PrEP from peer lay workers at private community locations.
62738546|NCT06660160|EXPERIMENTAL|Intervention Group (IG)|Patients over 18 years old of both sexes, who have been undergoing HD for at least three months, generally in three sessions per week that are in the room that was randomized to do exercise.
62738547|NCT06660160|NO_INTERVENTION|Control Group (CG)|Patients over 18 years old of both sexes, who have been undergoing HD for at least three months, generally in three sessions per week that are in the room that was randomized to will continue with the usual treatment.
62680228|NCT06479863|OTHER|INJECTION|"patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks. SC injections will be administered by the study staff and the patient will be monitored for 30 minutes after the initial first injection. During the remainder of the study, injections can be administered at home by the patient or caregiver after injection training provided by the study staff. Designated persons will be observed to confirm their ability to perform the injections.~The dosing window of the study treatment is within ±7 days from the scheduled dose date."
62680229|NCT03162536|EXPERIMENTAL|Phase 1: Dose Escalation and Determination of RP2D|Phase I: Dose Escalation and determination of RP2D, multiple dose levels of nemtabrutinib to be evaluated (Up to approximately 22 months).
62680230|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort A|Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) participants with at least 2 prior systemic therapies and previously treated with a covalent Bruton's tyrosine kinase inhibitor (BTKi) who must have a documented BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until progressive disease (PD), unacceptable adverse events (AEs), or discontinuation at investigator's discretion (up to approximately 64 months).
62121287|NCT03411291||Diet: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy to lower cholesterol pre-electing to lower cholesterol by diet for three months. Candidates in this arm have pre-elected to lower cholesterol by diet as described under the care of their treating physicians. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 (three) months.
62680231|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort B|R/R CLL/SLL participants who have failed or were intolerant to a BTKi with documentation of the absence of BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62121288|NCT03411291||Statin: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy pre-electing to lower their cholesterol using atorvastatin (Lipitor) 20 mg per day as prescribed by their treating physician per standard of care. There are no research-related interventions for this group. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 months.
62680232|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort C|Richter's transformation (RT) participants who have failed at least one prior therapy receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62309806|NCT04820985||Women undergoing IVF|
62309807|NCT01660165||Observational|Pregnant women
62680233|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort D|Follicular Lymphoma (FL) participants who have failed at least 2 prior systemic therapies and are histology grade 1, 2, or 3A receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62475927|NCT02537093|ACTIVE_COMPARATOR|Synchronous telepsychiatry (STP)|Control Arm/Synchronous telepsychiatry (STP): After baseline assessment, subjects will be assessed by a psychiatrist using live interactive videoconferencing every 6 months for a 1 year follow up (3 STP assessments: baseline plus 2 assessments). A report with treatment recommendations following American Psychiatric Association guidelines will be sent to the PCP who will be able to have adlib telephone or email consultations with the telepsychiatrist. The telepsychiatrist will have access to all previous clinical information about the patients.
62680234|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort E|Mantle Cell Lymphoma (MCL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62680235|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort F|Marginal Zone Lymphoma (MZL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62680236|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort G|High-grade B-cell lymphoma (BCL) participants who have failed at least 2 prior systemic therapies and have known MYC and BCL2 and/or BCL6 translocations confirmed by flourescence in situ hybridization (FISH) or overexpression by immunohistochemistry (IHC) receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62680237|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Cohort H|Waldenström macroglobulinemia (WM) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62309808|NCT04306042||Treatment|Patients diagnosed with primary stage IIIB-IV squamous cell lung cancer and treated in 92 medical centers between 01 September 2019 and 30 June 2020 will be targeted for study inclusion.
62680238|NCT03162536|EXPERIMENTAL|Phase 2: Expansion Food Effect Cohort I|B-cell Non-Hodgkin's lymphoma (NHL), CLL/SLL and WM participants receive up to 65 mg of nemtabrutinib fasted (1 hour prior to or 2 hours after meal) and non-fasted per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
62680239|NCT06662292|ACTIVE_COMPARATOR|Team Program|Teams randomized to this arm will be provided with personal physical activity goals focused on moderate-to-vigorous intensity aerobic physical activity minutes and steps. They will also be provided with a Fitibt wearable smartwatch for self-monitoring physical activity, receive weekly electronic feedback for the first month of the intervention about their physical activity progress, and have access to a mobile-compatible study web app containing behavior change content and physical activity progress information.
62680240|NCT06662292|EXPERIMENTAL|Team+Training Program|Teams randomized to this arm will receive the same intervention as the Team study arm, as well as digitally delivered social support training.
62309809|NCT03836638|EXPERIMENTAL|Low dose young subjects|Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face
62309810|NCT03836638|EXPERIMENTAL|Low dose older subjects|Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face
62680241|NCT03680508|EXPERIMENTAL|TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)|Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62680242|NCT06048705|EXPERIMENTAL|GSK3901961|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive high dose of GSK3901961 after completing lymphodepleting chemotherapy. The first study participant receiving GSK3901961 will receive the total assigned dose as 2 separate infusions 7 days apart, in aliquots of 30% (first infusion) and 70% (second infusion) of the total target dose, respectively. Based on the dose limiting toxicities reported in the first participant, then all subsequent participants treated with GSK3901961 will receive the full dose as a single, i.e., one-time, infusion.
62680243|NCT06687707||Physiotherapist|
62309811|NCT03836638|ACTIVE_COMPARATOR|high dose older subjects|Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)
62309812|NCT00410371|EXPERIMENTAL|GI267119|25 mg ODT tablet strength
62475928|NCT02537093|EXPERIMENTAL|Asynchronous telepsychiatry (ATP)|Intervention Arm (ATP): All ATP assessments at 6 monthly intervals post baseline will be conducted by an ATP trained clinician. This interview will be video recorded.The ATP clinicians will then fill out a standardized medical template that will be reviewed by a psychiatrist who will provide a written assessment and psychiatric treatment plan. He will have access to any previous assessments and the PCP will also have continuing access to this psychiatrist by phone or email between the 3 consultations.
62680244|NCT05608291|EXPERIMENTAL|Fianlimab HD + Cemiplimab|Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab
62680245|NCT05608291|EXPERIMENTAL|Fianlimab LD + Cemiplimab|Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab
62680246|NCT05608291|ACTIVE_COMPARATOR|Pembrolizumab|Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo
62680247|NCT04690348|ACTIVE_COMPARATOR|Resection without brachytherapy|Patients will undergo craniotomy.
61921163|NCT04088604|EXPERIMENTAL|LY01610-Dose Escalation|The starting dose was 30 mg/m2 IV and the subsequent dose was increased according to the protocol of 60 mg/m2, 90 mg/m2, 120 mg/m2, 150 mg/m2, 180mg/m2. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
62121289|NCT00065260|EXPERIMENTAL|r-ATG /cyclosporine|A randomized trial of rabbit anti-thymocyte globulin (r-ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
62121290|NCT00065260|EXPERIMENTAL|Alemtuzumab (Campath-1H)|A randomized trial of rabbit anti-thymocyte globulin (ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
62309813|NCT05971329|EXPERIMENTAL|Pilot Study of ZetaFuse Bone Graft for the Treatment of Cervical Degenerative Disc Disease|Involves the use of a medical device. The prepared ZetaFuse Bone Graft is packed into the hollow space of a PEEK interbody before surgical implantation.
62309814|NCT05659121|EXPERIMENTAL|EksoGT group|Participants in the intervention group will receive 12 sessions of robotic exoskeleton training incorporated into their conventional physiotherapy session.
62309815|NCT05659121|NO_INTERVENTION|Control group|Participants in the control group will only undergo outcome measures assessment. They will continue with their conventional physiotherapy and the frequency and type of activity at physiotherapy will be recorded.
62309816|NCT05126615|EXPERIMENTAL|Patients with auriculotherapy|Mastectomy operated patient then, auriculotherapy
62309817|NCT05126615|PLACEBO_COMPARATOR|Patient with placebo|Mastectomy operated patient then, they received placebo
62309818|NCT03398772|EXPERIMENTAL|Experiment|Comprehensive Health Coaching Program
62309819|NCT03398772|NO_INTERVENTION|Control|Guideline-based usual care
62475929|NCT01753375|ACTIVE_COMPARATOR|Vitamin D3|Administered orally on weekly basis
62475930|NCT01753375|PLACEBO_COMPARATOR|Placebo|To be administered orally on weekly basis
62475931|NCT00966589|SHAM_COMPARATOR|conservative treatment|physiotherapy
62680248|NCT04690348|EXPERIMENTAL|Resection plus brachytherapy|Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.
62680249|NCT05087680|ACTIVE_COMPARATOR|Control Group|Control group will include one 30-minute PrEP education session.
62680250|NCT05087680|EXPERIMENTAL|ACTPrEP|ACTPrEP will include a 60-minute initial session and 30-minute sessions at 2, 6, and 12 weeks.
62680251|NCT00752271||1|24 adults with meniscal damage for which arthroscopy is clinically indicated
62680252|NCT00752271||2|8 adults who have already undergone meniscal resection to serve as positive controls
62680253|NCT06585462|EXPERIMENTAL|Single Ascending Dose (SAD) in Participants with Obesity (Part A)|In Part A participants will enroll into SAD cohorts and will be randomized to receive AMG 513 or placebo subcutaneously (SC) or intravenously (IV).
62680254|NCT06585462|EXPERIMENTAL|Multiple Ascending Dose (MAD) in Participants with Obesity (Part B)|In Part B participants will enroll into MAD cohorts and will be randomized to receive AMG 513 or placebo SC.
62680255|NCT05499169||16 patients with CAA-related ICH|16 patient above the age of 55 that fit the inclusion criteria. CAA-related ICH is defined as an ICH that meets the criteria for definite or probable CAA according to the Modified Boston Criteria.
62680256|NCT05499169||16 patients with HA-related ICH|16 patient above the age of 55 that fit the inclusion criteria. HA-related ICH is defined as ICH located in the basal ganglia, thalamus, or the deep white matter and the presence of hypertension defined as: on treatment for hypertension, or known with high blood pressure (two measurements systolic blood pressure (SBP) \>140 or diastolic blood pressure (DBP) \>90 mmHg) but not treated for hypertension.
62680257|NCT03019653|ACTIVE_COMPARATOR|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
62680258|NCT03019653|ACTIVE_COMPARATOR|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
62680259|NCT01561612|EXPERIMENTAL|Intervention|Breastfeeding promotion according to World Health Organization's Baby Friendly Hospital Initiative
62680260|NCT01561612|NO_INTERVENTION|Control|Usual care
62680261|NCT02917538|EXPERIMENTAL|Intervention group|In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
62680262|NCT02917538|ACTIVE_COMPARATOR|Control group|In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
62680263|NCT05849376|EXPERIMENTAL|EMIT Intervention|Immediate access to EMIT intervention
61921164|NCT04088604|EXPERIMENTAL|LY01610-Dose Extension|According to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 were further evaluated in 6 - 8 patients. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
61944502|NCT01892267|EXPERIMENTAL|Self-propelled PEGJ feeding tube|Patients in this arm will receive self-propelled balloon PEGJ tube.
61944503|NCT01892267|ACTIVE_COMPARATOR|Standard PEGJ feeding tube|Patients in this arm will receive the standard commercially availabel PEGJ tube.
62309820|NCT04446585|NO_INTERVENTION|Control sites|"* For all 1-1-2 calls with suspected cardiac arrest to the emergency dispatch center will activate a two-tiered response consisting of dispatch of an ambulance with an emergency medical technician, a physician-staffed mobile emergency care unit, and citizen first responders through the Heart Runner app.~* The medical dispatcher offers telephone assisted cardiopulmonary resuscitation (CPR) to bystanders. Furthermore, if more than two bystanders are present and an AED is accessible within 1½ minute travel distance (depending on the type of terrain), then one bystander is guided to localize and retrieve the AED."
62475932|NCT00966589|ACTIVE_COMPARATOR|surgery|laparoscopic hernioplasty (TEP)
62475933|NCT01730638|EXPERIMENTAL|TF2 antibody/68Ga-IMP-288|TF2 coupled with 68 Ga-IMP-288
62475934|NCT00848146|EXPERIMENTAL|NOTES-Assisted Lap Chole|These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
62680264|NCT05849376|OTHER|Waitlist Control|Delayed access to EMIT intervention
62680265|NCT02635672|EXPERIMENTAL|Dose escalation of VIP152 (BAY 1251152) / PART 1 (Completed)|Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL
62680266|NCT02635672|EXPERIMENTAL|Dose expansion of VIP152 (BAY 1251152) / PART 2|Investigating VIP152 (BAY 1251152) in a dose expansion cohort in patients with solid tumors and aggressive NHL
62680267|NCT02635672|EXPERIMENTAL|Dose escalation of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 3|Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose escalation cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.
62680268|NCT02635672|EXPERIMENTAL|Dose expansion of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 4|Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose expansion cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.
62738548|NCT03465137|EXPERIMENTAL|Immediate therapy|Participants randomized to the immediate therapy arm will receive a weekly individual psychotherapy intervention called Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
62475935|NCT01192932||COPD|COPD patients aged 40 or more, with a smoking history of \> 10 pack-years, a post-bronchodilator FEV1/VC \< 0.7 and an optimal treatment according to GOLD guidelines will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5 years.
62680269|NCT06404086|OTHER|Hypersomnia Arm (Appendix A)|"This is a double-blind, phase 2, randomized, placebo-controlled interventional trial of a wake-promoting drug (modafinil or solriamfetol) to treat hypersomnia, defined by elevated scores (\> 60) on the PROMIS 8a SRI scale, in participants with PASC. Participants will be randomized to study drug or control. Participants who meet the eligibility criteria for modafinil will receive either active modafinil or modafinil-matched control. If modafinil is contraindicated, participants will be assessed for solriamfetol. If participants are eligible for solriamfetol, they will receive either active solriamfetol or solriamfetol-matched control. If solriamfetol is contraindicated, participants will be excluded from Appendix A. Modafinil and solriamfetol will be analyzed as a single wake-promoting drug condition versus control. The intervention duration will be 10 weeks.~Anticipated enrollment is 474 participants. Details about the Hypersomnia Appendix are available under NCT06404099."
62680270|NCT06404086|OTHER|Complex PASC related Sleep Disturbances (CPSD) Arm (Appendix B )|"This is a double-blind, phase 2, randomized, placebo-controlled, interventional trial that combines brief education and a tailored sleep timing prescription for CPSD with therapies that modify circadian timing for participants who report poor sleep quality or daytime sleep-related impairment, defined by elevated scores (≥60) on the PROMIS 8b SD scale, in participants with symptoms that occurred or worsened after COVID-19 infection. Interventions involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to 1 of 4 groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive BBT-CPSD. It is a 2x2 factorial design schema. The intervention duration will be 8 weeks.~Anticipated enrollment for this appendix is 600 participants. Additional details about the CPSD Appendix are available under NCT06404112."
62309821|NCT04446585|EXPERIMENTAL|Intervention sites|"As a supplement to the standard care as described in the control arm, the following will be supplied:~* Strategical deployment of AEDs with 24:7 availability and 1½ minute walking distance to every residence within the area. The AEDs will be registered with the AED network and thus linked to the emergency dispatch center.~* The emergency dispatch center will retrieve data from used AEDs.~* For each interventional area, approximately 120 residents will receive a course in CPR and AED use and subsequently be recruited as citizen responders so that they can be activated through the HeartRunner app in case of a nearby cardiac arrest."
62309822|NCT03342443|EXPERIMENTAL|memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
62309823|NCT03342443|PLACEBO_COMPARATOR|placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
62680271|NCT04584320||Premature neonates with necrotizing enterocolitis|
62680272|NCT04584320||Premature neonates without necrotizing enterocolitis|
62680273|NCT04597112|EXPERIMENTAL|Myofascial Release Group|Intervention group, who received conventional therapy and myofascial release therapy.All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. In the intervention group, the myofascial release technique will be applied to the wrist flexors and extensors, elbow flexors and extensors, pectoralis, supraspinatus, infraspinatus, trapezius muscles, starting from the fingers after the conventional treatment, 3 days a week for 4 weeks.
62309824|NCT03402763|NO_INTERVENTION|Control Arm|Participants receive a short informational handout on the process and choices involved in advance care planning.
62309825|NCT03402763|EXPERIMENTAL|Intervention|Participants are shown a 6-minute video that describe CPR, breathing tube placement, and mechanical breathing support in addition to the general process of advance care planning.
62309826|NCT05430659||EBL equal or more than 500 ml|The intraoperative estimated blood loss equal or more than 500 ml
62309827|NCT05430659||EBL less than 500 ml|The intraoperative estimated blood loss less than 500 ml
62309828|NCT00793104|OTHER|CR Plug|Placement of allograft CR Plug in primary injury site
62309829|NCT02277886|EXPERIMENTAL|Alginos plus Nexium|sodium alginate 20ml (50mg/ml) once at bed time, and esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
62309830|NCT02277886|ACTIVE_COMPARATOR|Nexium alone|esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
62309831|NCT01300286|EXPERIMENTAL|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
62309832|NCT03789188||Healthy Volunteers|CC Registered Nurses
62309833|NCT04060992|EXPERIMENTAL|Early Follicular Phase|Women enrolled will be anywhere from cycle day 1 through 5 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
62309834|NCT04060992|ACTIVE_COMPARATOR|Late Follicular Phase|Women enrolled will be anywhere from cycle day 8 through 13 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
62475936|NCT01502696|EXPERIMENTAL|PEG IFN alfa-2b|
62475937|NCT01502696|NO_INTERVENTION|Observation|
62309835|NCT04060992|ACTIVE_COMPARATOR|Luteal Phase|Women enrolled will be anywhere from cycle day 21 through cycle day 26 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
62680274|NCT04597112|ACTIVE_COMPARATOR|Exercise Group|The control group will consist of patients who received conventional therapy and exercise therapy. All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. After conventional treatment, a program consisting of neck extension, lateral flexion and rotation range of motion, stretching of the trapezius muscles and strengthening of the neck extensor muscles will be applied to the control group in the presence of a physiotherapist 3 days a week for 4 weeks.
62680275|NCT05770622|EXPERIMENTAL|Vancomycin first-dose trough dose adjustment calculation|Participants will have individualised model-based intermittent vancomycin dosing using the Vanc App dosing calculator (as used in VANC APP Part 1, see clinicaltrials.gov ID: NCT04044703). A first-dose trough concentration will be measured for each participant and the clinician will then enter that concentration into the web application ('First-dose trough dose adjustment calculator'). A dose adjustment will be generated by the calculator if the predicted steady-state level is outside of target range. If the predicted steady-state level is within target range (10-20mg/L) the calculator will recommend continuing with the same dose. The vancomycin concentration is then measured at steady state to determine if the target concentration has been achieved.
62680276|NCT06694220|EXPERIMENTAL|Tailored preventive exercises and traditional exercises group|The participants will practice tailored preventive exercises and traditional exercises for at least 6 weeks.
62680277|NCT06694220|ACTIVE_COMPARATOR|Traditional exercises group|The participants will practice d traditional exercises for at least 6 weeks.
62680278|NCT06689930|NO_INTERVENTION|STAC-CAB Members|Staying Healthy After Childbirth - Community Advisory Board members (8-12 members)
62680279|NCT06689930|NO_INTERVENTION|Lived Experience Group Members|Lived Experience Group members (8-12 members)
62680280|NCT06689930|EXPERIMENTAL|PDSA Cycle Participants and CBO Staff|Black pregnant or postpartum persons and Community Based Organization Staff
62680281|NCT04125719|EXPERIMENTAL|Primay PD-1 resistance|Cohort 1 will include 15 patients who progressed within 3 months (primary resistance) of starting PD-1 therapy
61921165|NCT04088604|EXPERIMENTAL|LY01610 with 5-Fu -Dose Escalation|"Dose Escalation:~Based on the results of the first stage, three doses of low, medium and high doses were selected in combination with a fixed dose of 5-Fu to determine the DLT, MTD, PK characteristics and the preliminary efficacy. 5-Fu, 400mg/m2 will be administered intravenously on days 1, followed by 600 mg/m2 given as a 22-hour continuous infusion on day 1 and 2, every 2 weeks."
62309836|NCT02062931|EXPERIMENTAL|Stem Cell Preparation and Injection|"Stem Cell Preparation and Injection:~Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
62475938|NCT01055041|EXPERIMENTAL|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
62475939|NCT01055041|EXPERIMENTAL|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks
62680282|NCT04125719|EXPERIMENTAL|Secondary PD-1 resistance|Cohort 2 will include 15 patients who progressed after at least 3 months of PD-1 therapy
61944504|NCT01254071|EXPERIMENTAL|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
62475940|NCT01055041|EXPERIMENTAL|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
62121291|NCT04908371|ACTIVE_COMPARATOR|Selective Trunk Block (SeTB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. After identifying the three trunks of the brachial plexus, ultrasound guided selective trunk block will be done using local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 20ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
62121292|NCT04908371|ACTIVE_COMPARATOR|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC-BPB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove. The unique sonomorphology of the C7 transverse process will be used as the key anatomical landmark to identify the individual elements of the brachial plexus. Under ultrasound guidance, local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 30ml) will be injected at the interscalene groove and at the supraclavicular fossa in order to anesthetize the whole upper limb.
62121293|NCT00660439|EXPERIMENTAL|A|Treatment group, receives Narrative Exposure Therapy immediately after first assessment. Patients are assessed 1 and 6 months after treatment.
62309837|NCT04127136|EXPERIMENTAL|Study Group|The cases were analyzed for the change in the severity of binge eating disorder in the program. The data collection was performed via socio-demographic information form, binge eating disorder evaluation (BEDE) form, and progress record forms. BEDE was a structured form exclusively using DSM-5 BED diagnosis and the severity criteria. Progress record form included weekly session content that was administered by a physician, dietitian, psychologist, and the physiotherapist and the monthly individual meetings data. BEDE and progress record forms were applied before the trainings that focuses on cognitive change and repeated every four weeks for 20 weeks. The patients were planned to receive 80 hours of training by the physician, dietitian, psychologist, and the physiotherapist.
62309838|NCT03742804|EXPERIMENTAL|G100 injections|All patients will receive 6 intratumoral G100 injections alone over 5 weeks. There will be a 4-week break for restaging. Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
62309839|NCT00827203|EXPERIMENTAL|Cohort|
62309840|NCT03497962||ITU patients|25 patients will be recruited from the Intensive Care Unit/ High dependency unit Inclusion- Adults (\>18years) with community acquired pneumonia (CAP).
62309841|NCT03497962||Healthy volunteer|24 healthy adult volunteers will be recruited to establish a comparison data set and to extend the laboratory observations to include other bacterial pathogens.
62309842|NCT01910662|EXPERIMENTAL|Part A:|Subjects in the Part A will receive an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the upper right forearm and an ID injection of 0.1 mL of buffer in the lower right forearm and lower and upper left forearm on Day 1.
62309843|NCT01910662|EXPERIMENTAL|Part B:Cohort 1A|Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
62475941|NCT02856347|OTHER|PET 18-FDOPA|"18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).~PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).~Other series of images will be done 50 min after tracer injection. Images will be interpreted."
62475942|NCT01911676|EXPERIMENTAL|PF-03463275 Active Dose #1|Active dose between 40mg
62475943|NCT01911676|EXPERIMENTAL|PF-03463275 Active Dose #2|Active dose between 60mg
62475944|NCT01911676|PLACEBO_COMPARATOR|Placebo|Placebo- no active dose of PF-03463275.
62475945|NCT03748381|EXPERIMENTAL|Trifocal IOL|The patients will receive two different diffractive trifocal IOLs in each eye (AT Lisa tri vs. Rayner trifocal) during cataract surgery
61921166|NCT04088604|EXPERIMENTAL|LY01610 with 5-Fu -Dose Extension|"Similarly, according to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 combined with a fixed dose of 5-Fu were further evaluated in additional 6 - 8 patients.~In dose escalation and dose extension stages, both LY01610 and fixed dose 5-Fu will be given once every 2 weeks."
62475946|NCT06102850|EXPERIMENTAL|Intervention Condition, CTI-YAMH|Participants receive the CTI-YAMH intervention in conjunction with rapid rehousing supports for the 6 month intervention
62680283|NCT06686043|EXPERIMENTAL|Treatment group|The treatment group will be compared to a historical control. The investigator will evaluate the immune changes within the tumor microenvironment and validate why the combination immunotherapy study elicited such a robust immune response which led to complete resolution of the cancer, in comparison to the standard of care, chemoradiation. In this study, participants will undergo a series of treatment visits during and after radiation therapy to assess the effectiveness of the experimental combination therapy.
62680284|NCT01331330|ACTIVE_COMPARATOR|Group B|Low Programming
61921167|NCT04088604|ACTIVE_COMPARATOR|Hydrochloride Injection- pharmacokinetics comparative study|After receiving the MTD of LY01610, another 8 subjects were enrolled and given Irinotecan Hydrochloride Injection（captol ®） (180mg/m2) once every 2 weeks. Upon completion of the pharmacokinetics study, the sponsor will continue to provide the study drug treatment free of charge, and the researcher will conduct treatment and examination according to the subject's situation, without collecting any safety and efficacy data of the subject.
61921168|NCT01569464|ACTIVE_COMPARATOR|Rotigotine|Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.
61921169|NCT01569464|PLACEBO_COMPARATOR|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours~7 weeks"
61921170|NCT01255787|EXPERIMENTAL|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.
62121294|NCT00660439|NO_INTERVENTION|B|Waiting list control group, receives no intervention for 3 months after first assessment. A second assessment is then administered and patients receives Narrative Exposure Therapy. Patients are assessed 1 and 6 months after treatment.
62475947|NCT06102850|NO_INTERVENTION|Treatment as Usual Condition|Participants will be assigned to a housing program at another agency that provides rapid rehousing with usual supports
61921171|NCT01255787|EXPERIMENTAL|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
61921172|NCT01255787|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
61921173|NCT01255787|EXPERIMENTAL|Vortioxetine 20 mg|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.
61921174|NCT06536231|EXPERIMENTAL|Passive leg raising and Remote ischemic conditioning|Supine position was followed by the passive leg raising (PLR) maneuver. After completing the PLR test, participants were placed in the supine position for 5 min. Thereafter, remote ischemic conditioning (RIC) was performed. After the RIC procedure, the patient is left in supine position for 5 minutes. Then the PLR test was repeated, after which the participants were placed in a supine position for another 5 min at rest. When the patient fluid responder, physician in charge may decide to perform a fluid infusion (500 mL of crystaloids). The PLR test can also be performed to make decision for fluid removal. This decision is triggered by a negative PLR test in the later phase of ICU treatment. If the physician has decided to administer a fluids, systemic hemodynamics and peripheral perfusion index are measured immediately after completion of the fluid infusion.
62475948|NCT05905718||Spinomed orthosis group|
62475949|NCT05905718||Biofeedback orthosis group|
62680285|NCT01331330|EXPERIMENTAL|Group A|Normal Programming
62680286|NCT06221254|EXPERIMENTAL|Intervention- COBMINDEX application|The intervention in this arm is to learn during the first 3 months, cognitive, behavioral and mindfulness based stress reduction with daily exercise using a research dedicated application. Than, additional 9 months of practicing daily only with the application.
62680287|NCT06221254|ACTIVE_COMPARATOR|Control- COBMINDEX with Human therapist|The intervention in this arm is to learn during the first 3 months, cognitive, behavioral and mindfulness based stress reduction with daily exercise with human therapist, and than practicing daily only with the application.
62495933|NCT06347627|EXPERIMENTAL|Group 9 (I x S x D x F)|"Participants in Group 9 will view a message in an X (former Twitter) format composed of Individual x Safety x Scientific data x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62680288|NCT02103946|ACTIVE_COMPARATOR|Serratus anterior muscle plane block|Serratus anterior muscle plane block with general anesthesia MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\\Kg Fentanyl, 1-2 mic\\Kg Paracetamol, 1000 mg\\6 hours Fam® (Ketorolac), 30 mg
62495934|NCT06347627|EXPERIMENTAL|Group 10 (O x S x D x F)|"Participants in Group 10 will view a message in an X (former Twitter) format composed of Organization x Safety x Scientific data x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62680289|NCT02103946|ACTIVE_COMPARATOR|Paravertebral block|Paravertebral block with general anesthesia. MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\\Kg Fentanyl, 1-2 mic\\Kg Paracetamol, 1000 mg\\6 hours Fam® (Ketorolac), 30 mg
62680290|NCT06523153|EXPERIMENTAL|VYD2311|Injection in healthy volunteer
62680291|NCT06523153|PLACEBO_COMPARATOR|Placebo|Injection in healthy volunteer
62680292|NCT06484595|EXPERIMENTAL|ARM I (Clinical trial navigator, SOC)|Patients meet with a clinical trial navigator to understand activities involved with clinical trials, identify financial barriers to clinical trial participation, and review available financial resources. Patients receive ongoing access to the Guide via a check in meeting once monthly for up to 6 months. Patients also receive SOC supportive care services.
62121295|NCT05707871|ACTIVE_COMPARATOR|Usual Brand of Cigarettes|Participants will smoke 2-3 cigarettes of their usual brand
62680293|NCT06484595|ACTIVE_COMPARATOR|Arm II (SOC)|Patients receive SOC supportive care services.
62680294|NCT04103645|EXPERIMENTAL|Treatment arm|Vactosertib intra-patient dose finding cohort.
62680295|NCT05441345||SBS patients|
61921175|NCT04637828|EXPERIMENTAL|GNS561 plus standard of care|All patients in this Arm will be treated with 200mg oral capsule of GNS561, once a day, for 10 days and with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
62121296|NCT05707871|EXPERIMENTAL|Research Cigarettes (SPECTRUM)|Participants will smoke 1-2 SPECTRUM cigarettes
62121297|NCT00192491|ACTIVE_COMPARATOR|2|FluMist
62680296|NCT06522568|NO_INTERVENTION|Usual Care|Usual care.
62680297|NCT06522568|EXPERIMENTAL|MyMammogram|Patient uses MyMammogram prior to appointment.
62680298|NCT06522568|EXPERIMENTAL|MyMammogram plus provider communication|Patient uses MyMammogram prior to appointment. Provider receives a summary from MyMammogram prior to appointment.
62680299|NCT06057454|ACTIVE_COMPARATOR|Active Comparator|R-5280, Taken Twice a day, orally with food for 12 weeks (84 days)
62680300|NCT06057454|PLACEBO_COMPARATOR|Placebo Comparator|Food starch, taken twice a day, orally with food for 12 weeks (84 days)
61921176|NCT04637828|NO_INTERVENTION|standard of care|All patients in this Arm will be treated with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
61921177|NCT04048785|NO_INTERVENTION|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
61944505|NCT02394483|EXPERIMENTAL|Cohort A active|2 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
61944506|NCT02394483|PLACEBO_COMPARATOR|Cohort A placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
61944507|NCT02394483|EXPERIMENTAL|Cohort B active|4 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
61944508|NCT02394483|PLACEBO_COMPARATOR|Cohort B placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
62121298|NCT00192491|PLACEBO_COMPARATOR|3|Placebo
62121299|NCT00192491|ACTIVE_COMPARATOR|1|FluMist with other solution
61944509|NCT02394483|EXPERIMENTAL|Cohort C active|6 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
62680301|NCT01045265||Raltegravir treated men|Single group study of seminal plasma pharmacokinetics of raltegravir in men receiving chronic raltegravir therapy
62680302|NCT06468176|EXPERIMENTAL|Intervention group|Study therapy will include a mixed intervention by a neuropsychologist and a program based on a digital tool
62680303|NCT06468176|NO_INTERVENTION|Control group|Usual management of the cognitive complaint according to the habits of center
62680304|NCT06649773|EXPERIMENTAL|Noiiglutide Injection|
62680305|NCT06649773|PLACEBO_COMPARATOR|Noiiglutide Placebo|
62680306|NCT06541249|EXPERIMENTAL|Myelofibrosis (MF)|18 patients with MF will be enrolled
62680307|NCT06541249|EXPERIMENTAL|Polycythemia vera (PV)|18 patients with MF will be enrolled
62680308|NCT06541249|EXPERIMENTAL|Essential thrombocythemia (ET)|18 patients with MF will be enrolled
61921178|NCT04048785|EXPERIMENTAL|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
61921179|NCT05696860|EXPERIMENTAL|Monitorization with Capnography|Patients followed with capnography and standard monitorization
61921180|NCT05696860|NO_INTERVENTION|Monitorization Without Capnography|Patients followed with standard monitorization
61921181|NCT06200194|EXPERIMENTAL|DIMS lens|DIMS spectacle lenses. Daily wear for 1.5 years.
62121300|NCT05960695|EXPERIMENTAL|The Experimental Group|"The experimental group will be given both stretching and relaxation exercises. Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught.~Deep breathing exercises will be taught as relaxation exercises. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds."
62121301|NCT05960695|ACTIVE_COMPARATOR|The Control group|"The Control group will be given only stretching exercises. Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught.~Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds."
62121302|NCT05539755|EXPERIMENTAL|Non-surgical therapy of peri-implantitis|Subjects over 18 years old were consecutively included in the study if they present at least one implant in function for more than 1 year diagnosed with peri-implantitis following the case definition of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions (Berglundh et al., 2018).
62121303|NCT06672042|EXPERIMENTAL|Proactive Nursing Care model using a mobile application and software platform|"* Includes weekly data monitoring by the study team clinical nurse coordinators with communication through phone, email, or patient portal with documentation in the EMR~* Email delivery of data summary reports on each child's data to their outpatient providers, Unrestricted research team approved healthcare team provider access to this data through the CHAMP App PARAMETER web portal,~* Follow-up communications from providers to parents at provider discretion, and initiation of Health interventions by providers as deemed clinically appropriate from their review of the data collected and their knowledge of the participant.~* Parents will enter home monitoring data daily into the CHAMP App as fitting with their discharge regimen: This may include Feeding, oxygen saturation, heart rate, videos, weight (home scale), or a combination of these."
62309844|NCT01910662|EXPERIMENTAL|Part B:Cohort 1B|Subjects in the Part B Cohort 1B arm will receive a SC immunisation of 5 mg KLH in the right deltoid on Day 1. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH in the lower right and lower left forearm. On Day 43 subjects will then receive an ID injection of 0.1 mg KLH in the upper right and upper left forearms (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
62309845|NCT01910662|EXPERIMENTAL|Part B:Cohort 2|Subjects in the Part B Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper right and upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 2 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
62680309|NCT05980299|EXPERIMENTAL|experimental|The experimental arm involves a brief positive interaction around a preferred activity or personal care routine.
61921182|NCT06200194|EXPERIMENTAL|0.01% Atropine|0.01% Atropine. One drop per eye, per day, for 1.5 years.
62680310|NCT04480580||Hospitalized patients|
62680311|NCT02620852|ACTIVE_COMPARATOR|Annual Arm|Women in this arm will receive Athena standard of care mammography screening, including annual mammograms. They will complete a health questionnaire and receive screening advice based on a basic risk assessment.
61921183|NCT06200194|NO_INTERVENTION|Usual care|Usual care including promoting outdoor time
61921184|NCT01383512|EXPERIMENTAL|Rehabilitation robotics|Subjects will be practicing an Armeo Spring rehabilitation program in addition to their usual care (1.5h/day,5d/week) 1h/day 5d/week 4 weeks.
61921185|NCT01383512|ACTIVE_COMPARATOR|Self-rehabilitation|Subject will associated to there classical care 1 hours, 5 days per week during 4 weeks, of self rehabilitation.
61921186|NCT01383512|OTHER|Healthy volunteer|20 healthy volunteer will be recruiting and using ARMEO Spring. All volunteer will repeat 5 times the same program on the medical device.
61921187|NCT05038904|EXPERIMENTAL|Acalabrutinib|Participants will be given acalabrutinib (four doses of 100 mg of acalabrutinib to be taken orally twice daily).
62680312|NCT02620852|EXPERIMENTAL|Risk-Based Arm|Women in this arm will receive risk-based screening, where risk is calculated based on a model including personal history, family history, and genetic testing. All women in the risk-based arm complete a health questionnaire, provide a saliva sample for genetic testing, and receive screening advice based on a comprehensive risk assessment. Women in this arm will be tested for a panel of 9 genes related to breast cancer risk as well as a panel of SNPs, which can further modify risk. Women will be assigned a screening start date, screening stop date, and screening frequency.
62680313|NCT03367351|EXPERIMENTAL|Web-Based Educational Intervention|Participants receiving the Web-Based Educational Intervention will be enrolled to the research protocol for six weeks of module-based learning and online discussion sessions and followed for a total of 3-months post CGM implementation to collect study measures.
62680314|NCT03367351|PLACEBO_COMPARATOR|Standard of Care|Participants will receive standard clinical care. Similar study measures will be collected to compare between groups.
62680315|NCT06132503|EXPERIMENTAL|Phase 1 Single Arm Multicenter Study to Assess the Safety and Tolerability of LP-284|The Phase 1a dose escalation portion of the study will identify the maximum tolerated dose (MTD) and/or optimal dose(s) of LP-284 as the RP2D, based on all available safety, PK, PD, and/or preliminary efficacy data. Phase 1b will consist of the dose expansion portion in a separate cohort(s) of patients to further evaluate the safety of LP-284 at the RP2D and obtain preliminary estimates of clinical activity of LP-284 in patients with DLBCL and MCL.
62680316|NCT04229381|EXPERIMENTAL|Supportive Care (physical therapy, muscle relaxation)|Patients participate physical therapy sessions consisting of cardiovascular and resistance training exercises in person or online and also undergo progressive muscle relaxation sessions once weekly for up to 12 weeks.
62680317|NCT04702139|ACTIVE_COMPARATOR|patient with game-ready splint|Installation of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
62680318|NCT04702139|PLACEBO_COMPARATOR|patient with standard splint|Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
62309846|NCT01910662|EXPERIMENTAL|Part C: Cohort 1|Subjects in the Part C Cohort 1 will receive an ID injection of 0.1 mL PBS in the upper right forearm on Day 1. On Day 2 subjects will receive an ID injection of 0.1 ml PBS in the upper left forearm.
62309847|NCT01910662|EXPERIMENTAL|Part C: Cohort 2|Subjects in the Part C Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 1 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
62680319|NCT06658756|EXPERIMENTAL|I-CBT|Internet cognitive-behavioral therapy
62680320|NCT06658756|NO_INTERVENTION|TU|Treatment as Usual
62680321|NCT06686589||Crohn's patients undergoing routine intestinal ultrasound exam|
62680322|NCT04305041|EXPERIMENTAL|Pembrolizumab + Quavonlimab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus quavonlimab IV plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62680323|NCT04305041|EXPERIMENTAL|Pembrolizumab + Quavonlimab + Lenvatinib|Participants will receive pembrolizumab IV plus quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62680324|NCT04305041|EXPERIMENTAL|Pembrolizumab + all-trans retinoic acid (ATRA)|Participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days for a total treatment duration of up to approximately 2 years
62680325|NCT03646617|ACTIVE_COMPARATOR|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks or every 4 weeks until disease progression.
62680326|NCT03646617|EXPERIMENTAL|HFRT|The dose of hypofractionated radiation therapy (HFRT) will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
62680327|NCT06344286|ACTIVE_COMPARATOR|Infants receiving MEN|The babies fed with minimal enteral nutrition during TH constituted the study group
62680328|NCT06344286|PLACEBO_COMPARATOR|Infants receiving placebo|The babies who were given distilled water during TH
62680329|NCT00540761|EXPERIMENTAL|OFDI imaging|OFDI catheter advanced to the distal coronary artery
62309848|NCT01786018|EXPERIMENTAL|1|"* Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)~* Busulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)~* Fludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
62680330|NCT00540761|EXPERIMENTAL|Intravenous Ultrasound|Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
62309849|NCT02725385||Ancillary-Correlative (stress and coping)|"PART I:~Participants complete a questionnaire that measures several psychological constructs including stress, anxiety, depression, coping mechanisms, uncertainty, positive and negative emotions, and life satisfaction over 15-30 minutes.~PART II:~Participants undergo a Trier Social Stress Test during a laboratory session over 1.5 hours."
62309850|NCT05414968|EXPERIMENTAL|Pilot Feasibility Arm|Each participant will receive the same 45-minute intervention on 10 days spread over no more than 14 days total. At the end of each session, pain will be assessed on scales such as the Defense and Veterans Pain Rating Scale (DVPRS) to establish the safety and feasibility of the proposed intervention.
62309851|NCT05197101|EXPERIMENTAL|nulliparous women with estimated fetal weight ≥3500g at 39-40 weeks of gestation|
62309852|NCT01009112|EXPERIMENTAL|CBT for Insomnia|"Patients change their sleep times and habits in order to reduce alertness and over thinking when they are trying to sleep. This helps them learn how to sleep overnight in one solid block of time"
62475950|NCT03687762|ACTIVE_COMPARATOR|Cognitive Therapy (CT) Condition|"Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
62309853|NCT01009112|EXPERIMENTAL|Imagery Rehearsal Therapy|"Patients rescript the narrative of a nightmare to eliminate the distressing elements and create a new pleasant dream scene. They then rehearse this scene in their imagination at least twice each day. This reduces the frequency and intensity of the target nightmare and often reduces other nightmares, too."
62309854|NCT01009112|EXPERIMENTAL|Prolonged Exposure|This behavioral treatment for PTSD involves 1) systematic and repeated exposure to objects and situations that are avoided due to trauma-related distress, 2) prolonged, repeated recounting of trauma memories through visualization, and 3)therapist-guided discussions of thoughts and emotions related to the exposure exercises. The goals of PE are to reduce the anxiety and distress elicited by trauma-related memories and situations, show patients these memories and situations are distinct from the trauma, and teach patients they can tolerate the distress caused by these memories and situations.
62309855|NCT01009112|ACTIVE_COMPARATOR|Suportive Care Therapy|This is an active therapy where the focus of the intervention is on helping patients better understand their emotional response to their PTSD and sleep symptoms.
62309856|NCT00021866||Carbamazepine|Children and their mothers exposed to Carbamazepine monotherapy in utero
62309857|NCT00021866||Phenytoin|Children and their mothers exposed to phenytoin in utero
62309858|NCT00021866||Lamotrigine|Children and their mothers exposed to Lamotrigine in utero
62309859|NCT00021866||Valproate|Children and their mothers exposed to Valproate in utero
62309860|NCT02700581|ACTIVE_COMPARATOR|low PEEP conventional ventilation|PEEP 2 mmHg tidal volume 10ml/kg
62309861|NCT02700581|EXPERIMENTAL|moderate PEEP conventional ventilation|PEEP 7 mmHg tidal volume 10ml/kg
62309862|NCT02700581|EXPERIMENTAL|low PEEP protective ventilation|PEEP 2 mmHg with tidal volume 6 ml/kg
62309863|NCT02700581|EXPERIMENTAL|moderate PEEP protective ventilation|PEEP 7 mmHg tidal volume 6ml/kg
62475951|NCT03687762|ACTIVE_COMPARATOR|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
62475952|NCT03687762|ACTIVE_COMPARATOR|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
62475953|NCT05574647|NO_INTERVENTION|Standard: mpMRI|Participants will undergo mpMRI. Blinding will not be possible. Once the MRI report is issued, the local clinical team will make a decision about advising whether a biopsy is necessary or not.
62309864|NCT05569577|EXPERIMENTAL|Additional hCG injection|An additional hCG injection of 2000-5000IU would be performed 48 hours following routine hCG trigger on the basis of supplementation of estrogen and dydrogesterone in IHH patients.
62309865|NCT05569577|PLACEBO_COMPARATOR|No additional hCG injection|Only estrogen and dydrogesterone would be given for luteal phase support in IHH patients.
62309866|NCT06664034|EXPERIMENTAL|Multi-component intervention|After the intervention implementation, all cancer patients presenting to oncology clinical visits that meet eligibility criteria will receive the multi-component intervention.
62309867|NCT03556696|EXPERIMENTAL|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
62309868|NCT03556696|ACTIVE_COMPARATOR|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
62475954|NCT05574647|ACTIVE_COMPARATOR|Intervention 1: bpMRI|Participants will undergo bpMRI. Blinding will not be possible. Once the MRI report is issued, the local clinical team will make a decision about advising whether a biopsy is necessary or not.
62680331|NCT02596490|EXPERIMENTAL|Phase 1: Couple-Based Mindfulness Disclosure Group|"Phase 1:~Couples participate in 2 guided meditation sessions. During the sessions, participants do deep breathing and visualization exercises then asked to review the exercises. Participants also asked for feedback about the instructions. Participants complete a written review about the program and a questionnaire about their general health and well-being. Each session will last about 60-90 minutes."
62475955|NCT05574647|NO_INTERVENTION|Standard: Visual estimation targeted and systematic biopsy|Randomisation 2 will only be relevant if participants are advised by their clinical team to have a biopsy based on their MRI and other clinical factors. Participants advised to have a biopsy will undergo a visual estimation targeted biopsy
62475956|NCT05574647|ACTIVE_COMPARATOR|Intervention 2: Image-fusion targeted and systematic biopsy|Randomisation 2 will only be relevant if participants are advised by their clinical team to have a biopsy based on their MRI and other clinical factors. Participants advised to have a biopsy will undergo an image fusion targeted biopsy.
61921188|NCT00745615|EXPERIMENTAL|Double-Blind: Laquinimod 0.3 mg|Participants who will be receiving laquinimod 0.3 milligram (mg) tablet once daily orally in double-blind core study, will continue to receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
62121304|NCT06672042|NO_INTERVENTION|Standard of care control arm|"* No proactive monitoring or communication from the research coordinators~* Follow-up communications from providers to parents at their general healthcare providers discretion, and Initiation of health interventions by providers as deemed clinically appropriate from their review of the data collected and reported by parents via patient portal, phone, and in-person communications and their knowledge of the participant.~* Parents will be provided a paper log that they will utilize for recording their child's home monitoring data and turn in at the end of the month~* Parents will write down the home monitoring data fitting with their child's discharge regimen: This may include Feeding, oxygen saturation, heart rate, videos, weight (home scale), or a combination of these.~* Optional: Parents can utilize the App if they allocate to Arm 2 (Paper) at first, with a combined weekly check-in with the research coordinators. The parents will get a chance to fill out SUS after month of use"
62121305|NCT05504941|EXPERIMENTAL|Study Intervention: DSA|additional diagnostic cerebral DSA
62121306|NCT01320215|EXPERIMENTAL|Robot arm|The patients in this arm will have a robot-assisted promontofixation.
62121307|NCT01320215|ACTIVE_COMPARATOR|Non-robot arm|The patients in this arm with have a promotofixation via a laparoscopy, but without robot assistance.
62121308|NCT03233633|OTHER|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
62121309|NCT02354885|NO_INTERVENTION|Tranexamic Acid|TXA administered to multiple trauma patients in the helicopter or ambulance
62121310|NCT06555718|OTHER|Intervention group (Peer support)|"Peer mentors will be determined among the participant patients in accordance with the peer mentor guide selection criteria.~The determined peer mentors will participate in the Peer Mentor Training Programme.~Implementation of the research; Peer support programme for the intervention group will be carried out for 10 weeks in accordance with the peer guide-client implementation plan Standard follow-up and training programme will be applied to the control group in accordance with the procedures of the institution.~The data collection forms used in the research process will be collected at the stages specified in the study flow plan and data entry will be made by the researcher."
62121311|NCT06555718|OTHER|Control group (Standart care)|No intervention will be made by the researcher to the control group. The standard care of the institution will be applied to the patients.
62121312|NCT00634452|EXPERIMENTAL|MDX-1401|MDX-1401 iv at various doses
62309869|NCT02734550|ACTIVE_COMPARATOR|Control|Diagnosis of invasive candida infection according to standard of care.
62309870|NCT02734550|EXPERIMENTAL|(1,3)-β-D-glucan guidance|Treatment according to BDG-result
62309871|NCT01139866||Group 1: SABER™-Bupivacaine|Received 5.0 mL SABER™-Bupivacaine in previous C803-017 trial
62309872|NCT01139866||Group 2: SABER™-Placebo|Received 5.0 mL SABER™-Placebo in previous C803-017 trial
61921189|NCT00745615|EXPERIMENTAL|Double-Blind: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally in double-blind core study, will continue to receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
62121313|NCT05480358|EXPERIMENTAL|ProlonADTM|The ProlonADTM diet, which will be taken by the patient once a month for 5 days, is a low-calorie and low-protein diet, and provides all the micronutrients necessary to avoid malnutrition. The diet will be performed in twelve consecutive months. The components of the diet will be approximately 30% calorie restricted and 50% protein restricted but supplemented with 50% of the RDA in vitamins and minerals and also supplemented with both nonessential and essential amino acids identified in animal studies to be effective. Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43%carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
62121314|NCT05480358|PLACEBO_COMPARATOR|Placebo diet|One meal which substitute or lunch or dinner for 5 days, without calories restriction.
62121315|NCT00470899|EXPERIMENTAL|placental drainage|
62121316|NCT00470899|NO_INTERVENTION|no drainage of fetal blood|
62121317|NCT02574026|EXPERIMENTAL|Psychomotor tasks|20 healthy subjects and 10 tetraplegic patients will participate to acquisition of MEG, EEG, MRI data during a motor tasks
62309873|NCT02598713|EXPERIMENTAL|Aspiration Markers|Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.
62309874|NCT06394999|EXPERIMENTAL|mifepristone 50 mg|mifepristone 50 mg once weekly
62309875|NCT00446212|ACTIVE_COMPARATOR|1|Propofol based anaesthetic maintenance with propofol effect-site steered target-controlled infusion, in addition to fentanyl and non-opioid analgesics
62475957|NCT05600907|EXPERIMENTAL|Single arm study|Eligible CGD patients will receive one time infusion of study product along with Alemtuzumab and TBI as part of HSCT conditioning regimen
62475958|NCT00947908|EXPERIMENTAL|A|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
62680332|NCT02596490|EXPERIMENTAL|Phase 2: Couple-Based Mindfulness Disclosure Group|"Phase 2:~Participants complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires. After completing the last session, about 4 weeks later, participants complete the same questionnaires again. Participants also complete a program review.~Couples participate in 4 guided meditation sessions with a trained meditation instructor. Participants do deep breathing and visualization exercises. All meditation and discussion sessions videotaped.~Participants continue daily meditation practice and some other short exercises at home."
62680333|NCT02596490|EXPERIMENTAL|Phase 3: Couple-Based Mindfulness Disclosure Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
62680334|NCT02596490|EXPERIMENTAL|Phase 3: Cancer-Related Discussion Program Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner take part in a discussion program, 1 discussion session each week for 4 weeks with a trained interventionist. These are one-on-one sessions. Issues discussed for couples coping with cancer. Each session will last about 60 minutes."
62121318|NCT05590273|EXPERIMENTAL|Proof-of-concept trial|Inform CALM adaptations for caregivers of patients with brain cancer.
62475959|NCT04962945|ACTIVE_COMPARATOR|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
62475960|NCT04962945|ACTIVE_COMPARATOR|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
62475961|NCT00599079|EXPERIMENTAL|Azithromycin|Azithromycin combined with 2 other drugs given 3 times weekly for MAc lung disease
62475962|NCT04255420|EXPERIMENTAL|SPG Block|Sphenopalatine ganglion block using cotton-tipped applicators soaked in 1% lidocaine will be performed.
62475963|NCT04255420|ACTIVE_COMPARATOR|Standard Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg.
62475964|NCT02107456|EXPERIMENTAL|Dry Needling|The taut band of trigger point in upper trapezius muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
61921190|NCT00745615|EXPERIMENTAL|Double-Blind: Placebo/Laquinimod 0.3 mg|Participants who will be receiving placebo matching to laquinimod 0.3 mg tablet once daily orally in double-blind core study, will receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
62309876|NCT00446212|ACTIVE_COMPARATOR|2|Desflurane based anaesthetic maintenance with manually controlled administration in 100% oxygen in addition to fentanyl and non-opioid analgesics
61944510|NCT02394483|PLACEBO_COMPARATOR|Cohort C placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
62680335|NCT02596490|OTHER|Phase 3: Attention Control (AC) Group|Participant completes 13 questionnaires at baseline and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
62680336|NCT03325803|EXPERIMENTAL|150μm-AFL-PDT|
62680337|NCT03325803|EXPERIMENTAL|350μm-AFL-PDT|
62680338|NCT03325803|EXPERIMENTAL|500μm-AFL-PDT|
62680339|NCT04816292|ACTIVE_COMPARATOR|Hot Snare Polypectomy|If an eligible polyp 10-15 mm (as compared by the size of the snare) is found, according to the randomized group, HSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
62680340|NCT04816292|EXPERIMENTAL|Cold Snare Polypectomy|If an eligible polyp 10-15 mm (as compared by the size of the snare) is found, according to the randomized group, CSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
62680341|NCT06219122|EXPERIMENTAL|A CAPTS intervention for people with personality disorders.|Experimental: Control Period - Intervention Period Multiple baseline single case experimental design wherein all patients are first assigned to the control condition (or control period) are then assigned to the intervention condition (or intervention period) and finally to the follow-up period (control period). Patients are randomized for the time (t) at which they start with the intervention.
62680342|NCT06214481|EXPERIMENTAL|Rocatinlimab|Participants will receive a single SC dose of rocatinlimab.
62121319|NCT06676839|EXPERIMENTAL|Intervention group|"Participants will receive the complete ICOPE intervention, personalized to their deficit during 60 months (36 months, followed by a 24-month extension)~The intervention include : 1) a screening (every 6 months), using the ICOPE tool 2) a comprehensive assessment of the 6 functions; 3) a personalized intervention aimed at correcting the trajectory of functional decline, based on the participants' choices and preferences; 4) a follow-up of the intervention. All results are communicated to the primary care physician.~Follow-up visits take place annually at 12, 24, 36, 48 and 60 months. Data related to the outcomes are collected by the research nurse, blinded to the randomization arm.~Participants will benefit from telephone follow-up 1.5 months after the inclusion visit and between each visit at 6, 18, 30, 42, and 54 months, to support them in implementing their personalized intervention plan and to collect life events occurred between the 2 visits."
62121320|NCT06676839|NO_INTERVENTION|Control group|"During the comparative phase, participants randomized into the Control group will be referred to their primary care physician to receive usual care tailored to their health status. During the 24 months-extension phase they will benefit from the complete ICOPE as defined in the intervention group.~Follow-up visits take place annually at 12, 24, 36, 48 and 60 months. Data related to the outcomes are collected by the research nurse, blinded to the randomization arm.~The team will schedule phone calls for all participants at 6, 18, 30, 42, and 54 months to record life events.~During the extension phase, participants will benefit from phone call follow-up between each annual visit at 42 months and 54 months, to support their personalized intervention plan."
62121321|NCT06073769||Participants receiving oral azacitidine maintenance therapy|
62121322|NCT04563559|OTHER|DEXTENZA vs prednisolone acetate 1%)|Subjects will randomly receive Dextenza or prednisolone acetate 1% in the first eye after surgery. At the time of the second eye surgery, the other eye will receive the drug that the first eye did not receive. Subjects will receive both drugs during the course of the study and therefore there is only 1 ARM for this study.
62475965|NCT00834249|EXPERIMENTAL|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
62680343|NCT00345592|EXPERIMENTAL|Device managed arm|Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
62680344|NCT00345592|ACTIVE_COMPARATOR|Traditional arm|Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.
62680345|NCT04090359|EXPERIMENTAL|Dual Mobility|If patients are randomized to the dual mobility cohort, they will receive a dual mobility prosthesis at the surgeon's discretion. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
62680346|NCT04090359|ACTIVE_COMPARATOR|Conventional, Single-bearing hip implant|If patients are randomized to the conventional, single bearing cohort, surgeons will use their preferred implant design at their discretion using a 36 or 40mm head, depending on the diameter of the cup and manufacturer specifications. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
62309877|NCT04431869||Mothers that contract SARS-CoV-2 during pregnancy|"To evaluate evidence for in-utero vascular accidents that may manifest as intestinal atresias and limb abnormalities in the first 30 days of life as well as rates of preterm labor, fetal growth restriction and spontaneous abortions in pregnant females that contract the SARS-CoV-2 virus during gestation.~A multidisciplinary approach in conjunction with maternal fetal medicine (MFM), neonatology, and pathology will identify, and recruit infants whom were exposed to COVID-19 while in-utereo. This project will run in parallel with the institution's COVID-19 in Pregnancy Biobank that intends to obtain needed epidemiological and clinical data linked to biosamples to provide insight into SARS-CoV-2 in pregnant women and their infants. This study will request access to enrolled women infected during gestation and their neonates to assess for the conditions suggestive of in-utero vascular accidents such as intestinal atresias or limb anomalies."
62680347|NCT05226884||Clareon IOL Group|Patients with bilateral implantation of Clareon IOLs.
62309878|NCT04431869||Infants noted to have intestinal atresias or limb anomalies|"To evaluate children identified in the neonatal intensive care unit (NICU) as having evidence of intestinal atresias or limb anomalies for potential asymptomatic carriers of COVID-19 that could have contracted the disease during the pregnancy.~Mothers of children identified will undergo SARS-CoV-2 antibody testing to identify the possibility of asymptomatic carriers which may have occurred during the pregnancy."
62680348|NCT05226884||Eyhance IOL Group|Patients with bilateral implantation of EyhanceIOLs.
62680349|NCT04179656|EXPERIMENTAL|Pyrotinib Treatment|This arm for HER2-postive solid tumor
62680350|NCT04796818|EXPERIMENTAL|Diagnostic (IVIM DWI)|Patients undergo IVIM DWI over 10 minutes during standard of care MRI within 30 days of starting chemotherapy and after 4-6 cycles of preoperative chemotherapy.
62680351|NCT03515304|EXPERIMENTAL|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
62680352|NCT03515304|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
62680353|NCT01340118|EXPERIMENTAL|Budesonide|Patients with FeNO level greater than 25 ppb were randomly allocated to one of two groups. Randomisation was stratified by baseline FeNO. In one group (treatment group), participants were assigned to once daily treatment with 400 µg budesonide. In the other group (non-treatment group), participants did not receive any medication.
62680354|NCT01340118|NO_INTERVENTION|remain untreated|
62680355|NCT05026619|PLACEBO_COMPARATOR|Control|Receives a fact sheet on diabetes in Singapore
62309879|NCT04727216|ACTIVE_COMPARATOR|Continuous DRG-S Dosing|2 week stimulation program using continuous DRG-S dosing at standard stimulation parameters
62680356|NCT05026619|EXPERIMENTAL|Fertility-related information|Receives accurate information on age-related fertility
62680357|NCT05026619|EXPERIMENTAL|Policy-related information|Receives accurate information on local policy initiatives related to age at marriage and childbearing
62680358|NCT06157827|EXPERIMENTAL|LBL-024+Etoposide+Carboplatin/Cisplatin|LBL-024+Etoposide+Carboplatin/Cisplatin Injection，dose A、dose B or dose C; Q3W
62680359|NCT06157827|EXPERIMENTAL|Atezolizumab+Etoposide+Carboplatin|Atezolizumab+Etoposide+Carboplatin Injection，dose A ; Q3W
62680360|NCT04135352|EXPERIMENTAL|V938 Dose A + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose A of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously once every 3 weeks (Q3W) beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
62680361|NCT04135352|EXPERIMENTAL|V938 Dose B + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
62680362|NCT04135352|EXPERIMENTAL|V938 Dose C + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
62680363|NCT04135352|EXPERIMENTAL|V938 Dose D + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
61921191|NCT00745615|EXPERIMENTAL|Double-Blind: Placebo/Laquinimod 0.6 mg|Participants who will be receiving placebo matching to laquinimod 0.6 mg (2 tablets of placebo) once daily orally in double-blind core study, will receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
61944511|NCT02394483|EXPERIMENTAL|Cohort D active|8 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
62309880|NCT04727216|EXPERIMENTAL|1 minute on: 1 minute off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 1 minute off intermittent DRG-S dosing at standard stimulation parameters
62309881|NCT04727216|EXPERIMENTAL|1 minute on: 2 minutes off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 2 minutes off intermittent DRG-S dosing at standard stimulation parameters
62680364|NCT04135352|EXPERIMENTAL|V938 Dose B + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
61921192|NCT00745615|EXPERIMENTAL|Open-Label: Laquinimod 0.3 mg/Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.3 mg tablet once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
62121323|NCT06390852|EXPERIMENTAL|Treatment (larotrectinib [LOXO-101])|Patients receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
62121324|NCT03928912||without fracture nonunion|The patients who undergone surgery after tibial shaft fracture did not exist fracture nonunion
62309882|NCT05149755|EXPERIMENTAL|Medtronic Evolut PRO+, or Evolut FX,TAVR System, & guideline-directed management & therapy (GDMT)|Medtronic Evolut PRO+ TAVR or Evolut FX TAVR Systems, \& guideline-directed management \& therapy
62309883|NCT05149755|NO_INTERVENTION|Clinical site determined guideline-directed management and therapy (GDMT) alone|Clinical site determined guideline-directed management and therapy (GDMT) alone
61921193|NCT00745615|EXPERIMENTAL|Open Label: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
61921194|NCT01452009|EXPERIMENTAL|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|
61921195|NCT01452009|ACTIVE_COMPARATOR|TRAVATAN®|TRAVATAN® administered one drop once daily
61921196|NCT01198379|EXPERIMENTAL|Aspirin|
61921197|NCT01198379|PLACEBO_COMPARATOR|Sugar pills|Hemodialysis (HD) patients receive placebo not containing aspirin in this study.
61921198|NCT03950037|EXPERIMENTAL|Medical intervention|Participants are hospitalized for 15-30 days while they receive the antiparasitic drug albendazole along with supportive drugs including dexamethasone and omeprazole.
61921199|NCT02789332|ACTIVE_COMPARATOR|Paclitaxel with Carboplatin (PwCb)|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
62121325|NCT03928912||with fracture nonunion|The patients who undergone surgery after tibial shaft fracture existed fracture nonunion
62309884|NCT02001350||Resistant hypertension|
62309885|NCT03341403|ACTIVE_COMPARATOR|Synbiotic group|"severe asthmatic patients (ACQ\> 1.5 and beclomethasone \> 200 µg per day) will receive Probiotical ®/Bactecal® (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months."
62309886|NCT03341403|PLACEBO_COMPARATOR|Placebo group|severe asthmatic patients (ACQ\> 1.5 and beclomethasone \> 200 µg per day) will receive a placebo (3 pills a day) during 3 months.
62309887|NCT01619228||Premature Infants|Infants born at \< 37 weeks gestational age
62309888|NCT01619228||Full Term Infants|Infants born at equal to or greater than 37 weeks gestational age
62309889|NCT01619228||Adults|Adults are parents of infants enrolled in the study
62309890|NCT05282706|EXPERIMENTAL|Pain Symptoms Arm|Subjects who will receive physical or occupational therapy experiencing pain prior to therapy session.
62309891|NCT05282706|EXPERIMENTAL|Nausea Symptom Arm|Subjects who will receive physical or occupational therapy experiencing nausea prior to therapy session.
62309892|NCT05282706|PLACEBO_COMPARATOR|Placebo Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session.
61921200|NCT02789332|EXPERIMENTAL|Paclitaxel with Olaparib (PwO)|"paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (65 patients)~followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery."
62680365|NCT04135352|EXPERIMENTAL|V938 Dose C + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
62680366|NCT04135352|EXPERIMENTAL|V938 Dose D + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
61921201|NCT03517488|EXPERIMENTAL|XmAb20717|XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
61921202|NCT00636220||A, Observational|
61921203|NCT02607839|PLACEBO_COMPARATOR|normal saline|normal saline intravenous infusion
62680367|NCT04135352|EXPERIMENTAL|Dose Expansion Arm A, Melanoma|This arm will enroll only participants with with a diagnosis of stage III (unresectable) and Stage IV melanoma (any line of therapy). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
61921204|NCT02607839|ACTIVE_COMPARATOR|glucose|glucose intravenous infusion
61921205|NCT02025556|EXPERIMENTAL|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
61921206|NCT02025556|EXPERIMENTAL|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
61921207|NCT02025556|PLACEBO_COMPARATOR|Placebo|Subcutaneous Placebo Administered Monthly x 3
61921208|NCT04080076|ACTIVE_COMPARATOR|ACTHar gel combined with Tacrolimus|ACTHar Gel units 2 times per week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks
61921209|NCT04080076|ACTIVE_COMPARATOR|ACTHar gel|ACTHar Gel units 2 times per week for 52 weeks
61921210|NCT03251664||Anemic|Hemoglobin \<11 g/l
61921211|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
61921212|NCT05829200|OTHER|Asymptomatic Carotid Disease|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute Transcranial Doppler (TCD)study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
61921213|NCT05829200|OTHER|Symtomatic Carotid Disease|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute Transcranial Doppler (TCD)study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
61921214|NCT02622360||Dyslexia|Individuals with confirmed dyslexia.
61921215|NCT02622360||Control|Healthy control subjects.
61921216|NCT02866487||Asthmatics|"0-5 years of age: Intermittent cough, wheeze, chest symptoms AND one or more of the following: Eczema Eosinophilia Elevated total IgE Positive family history~6-17 years of age: Physician diagnosis Current treatment with one or more asthma medications Recurrent episodes of cough, wheeze, chest discomfort, pain"
61921217|NCT02866487||Age-Similar Non-asthmatic Controls|Age-similar controls will undergo diagnostic bronchoscopy for clinical indications in the absence of known asthma, including recurrent pneumonia, congenital lung anomalies, prolonged cough, suspected laryngeal abnormalities, and suspected aspiration syndromes. Inclusion in the final set to be determined post-procedure based on BAL granulocyte profiles. To be included as a control, participants must have pauci-granular BAL counts (less than 2 percent eosinophils and less than 4 percent PMN), no positive allergen sensitization, and no positive viral or bacterial studies from analysis of BAL fluid.
62309893|NCT05282706|NO_INTERVENTION|Standard of Care Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session that decline the option to use an aromatherapy patch.
61921218|NCT05811533|EXPERIMENTAL|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
61944512|NCT02394483|PLACEBO_COMPARATOR|Cohort D placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
61944513|NCT02394483|EXPERIMENTAL|Cohort E active|10 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
62121326|NCT04706078||thick-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thick-gingiva (outline if the probe cannot be seen through the gingival)
62309894|NCT04870177|EXPERIMENTAL|Advanced gynecological neoplasms|
62309895|NCT03385356|ACTIVE_COMPARATOR|1000 IU of vitamin D per day|Half of randomized patients will receive 1000 IU of vitamin D per day
62309896|NCT03385356|ACTIVE_COMPARATOR|4000 IU of vitamin D per day|Half of randomized patients will receive 4000 IU of vitamin D per day
61944514|NCT02394483|PLACEBO_COMPARATOR|Cohort E placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
62309897|NCT03927729|EXPERIMENTAL|Penthrox|Patients with moderate to severe post-traumatic acute pain will be included in the emergency room.
62309898|NCT02524080|OTHER|Emergency Department|Triage to optimal healthcare level
62680368|NCT04135352|EXPERIMENTAL|Dose Expansion Arm B, HNSCC|This arm will only enroll participants with a diagnosis of advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
62680369|NCT05156814|EXPERIMENTAL|Fixed-dose Combination (FDC) estradiol / dydrogesterone|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
62680370|NCT05156814|ACTIVE_COMPARATOR|Combination therapy with estradiol and dydrogesterone|Duphaston®, 10 mg and Divigel, 0.1%
62680371|NCT05156814|ACTIVE_COMPARATOR|non-hormonal therapy|Cimicifuga racemosa rhizomatum extract (Klimadynon®)
62309899|NCT02524080|OTHER|Healthcare Center|Triage to optimal healthcare level
62680372|NCT04940052|EXPERIMENTAL|Dabrafenib plus trametinib|Participants will be treated with dabrafenib twice daily and trametinib once daily
62680373|NCT04940052|PLACEBO_COMPARATOR|Placebo dabrafenib plus placebo trametinib|Participants will receive placebo dabrafenib twice daily and placebo trametinib once daily
62680374|NCT04850274|EXPERIMENTAL|Remote Therapy Intervention|Youth will receive the maximal dose of six S-RTI therapy sessions delivered by a remote therapist with no alteration in intensity
62680375|NCT04850274|EXPERIMENTAL|Artificial Intelligence Remote Therapy Intervention|Youth will first receive a remote therapy session in the Emergency Department (ED). The RL system will then make decisions about the intensity of each subsequent therapy session (the initial decision is seven days post ED visit and bi-weekly \[i.e., every other two weeks\] thereafter) for the next 11 weeks. Potential treatment decisions include a 30-minute remote therapy session delivered via phone or video chat (mirroring the S-RTI), a less intensive tailored Motivational Interviewing (MI)-adherent electronic remote therapy (delivered by an electronic robot), or an assessment only without intervention.
62680376|NCT04850274|NO_INTERVENTION|Enhanced Usual Care|The youth's retaliatory risk will be assessed and a pamphlet with referrals for violence, substance use, and mental health services will be provided.
62680377|NCT05964166|EXPERIMENTAL|Tetragraph|
62680378|NCT05522829|EXPERIMENTAL|Cohort 1: Group SCTV01E-1|3 doses of SCTV01E-1
62309900|NCT01251523|ACTIVE_COMPARATOR|PACE Plus|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
62309901|NCT01251523|ACTIVE_COMPARATOR|PACE|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
62309902|NCT01251523|NO_INTERVENTION|Control|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
62680379|NCT05522829|ACTIVE_COMPARATOR|Cohort 1: Group SCTV01E|3 doses of SCTV01E
62680380|NCT05522829|EXPERIMENTAL|Cohort 2: Group SCTV01E-1|2 doses of SCTV01E-1
62680381|NCT05522829|ACTIVE_COMPARATOR|Cohort 2: Group SCTV01E|2 doses of SCTV01E
62680382|NCT03912415|EXPERIMENTAL|BCD-100|BCD-100 3 mg/kg Q3W
62680383|NCT03912415|PLACEBO_COMPARATOR|Placebo|
62680384|NCT06315894|EXPERIMENTAL|Experimental|People with post-COVID syndrome following the intervention
62680385|NCT06315894|NO_INTERVENTION|Control|People with post-COVID syndrome not following the intervention
62680386|NCT05715346|EXPERIMENTAL|LEV102 Topical Gel, 2.0%|
62680387|NCT05715346|EXPERIMENTAL|LEV102 Topical Gel, 1.0%|
62680388|NCT05715346|PLACEBO_COMPARATOR|Vehicle|
62309903|NCT03270085|ACTIVE_COMPARATOR|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.~The last period, is the treatment testing period. This consists of a full transit \& urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
62475966|NCT00834249|ACTIVE_COMPARATOR|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
62121327|NCT04706078||thin-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thin-gingiva (outline of the probe can be seen through the gingival)
62475967|NCT01383291||Pelvic floor prolapse|Those who underwent prolift and those who underwent IVS
62680389|NCT06691074|ACTIVE_COMPARATOR|Flower configuration|Ablation of the CTI using a Farapulse catheter in flower configuration
62121328|NCT00145743|EXPERIMENTAL|1|Patient's reported questionaire, profile in 10 dimensions (EORTC) and referees' report with treatment recommendations
62121329|NCT00145743|EXPERIMENTAL|2|Patient's reported questionaire; no recommendations given
62121330|NCT04813419|ACTIVE_COMPARATOR|right face|The right side of face of subjects
62121331|NCT04813419|EXPERIMENTAL|left face|The left side of face of subjects
62121332|NCT06073860||Participants with myelodysplastic syndrome or beta thalassemia who will begin luspatercept treatment|
62121333|NCT02167906|EXPERIMENTAL|hand oa patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
62475968|NCT04187352|EXPERIMENTAL|CS1001+ Fluorouracil+Cisplatin|
62475969|NCT04187352|ACTIVE_COMPARATOR|Placebo+ Fluorouracil+Cisplatin|
62475970|NCT01194791|EXPERIMENTAL|Lenalidomide, Cyclophosphamide and Dexamenthasone|
62475971|NCT02288195|EXPERIMENTAL|Chemotherapy|Patients receive neoadjuvant chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.Patients without disease progression undergo low-anterior resection (LAR) with total mesorectal excision (TME) and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days). Patients with disease progression undergo chemoradiation as in group chemoradiotherapy before proceeding to LAR with TME.
62475972|NCT02288195|EXPERIMENTAL|Chemoradiotherapy|Patients receive capecitabine 825 mg/m² twice daily concurrently with radiation therapy for 5 days per week. Patients also undergo intensity-modulated radiation therapy 5 days a week for approximately 5.5 weeks. Patients then undergo LAR with TME and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days) .
62475973|NCT01725529|EXPERIMENTAL|TMC435 150 mg|Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
62680390|NCT06691074|ACTIVE_COMPARATOR|Basket configuration|Ablation of the CTI using a Farapulse catheter in basket configuration
62680391|NCT06435520|EXPERIMENTAL|Digital cognitive behavioral therapy combined with structured medication tapering|dCBTI delivered in tandem with SMT during intervention phase.
62121334|NCT02167906|ACTIVE_COMPARATOR|without Hand OA patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
62121335|NCT02202824|EXPERIMENTAL|Survey questionnaire version 1|Study participants will receive version 1 of the survey questionnaire
62121336|NCT02202824|EXPERIMENTAL|Survey questionnaire version 2|Study participants will receive version 2 of the survey questionnaire
62121337|NCT02202824|EXPERIMENTAL|Survey questionnaire version 3|Study participants will receive version 3 of the survey questionnaire
62121338|NCT01474707|EXPERIMENTAL|Group one|Group1 will view the knowledge-based video only
62121339|NCT01474707|EXPERIMENTAL|Group two|Group two will view the motivational video only
62121340|NCT01474707|EXPERIMENTAL|Group three|Group three will view both knowledge-based and motivational videos
62121341|NCT01474707|EXPERIMENTAL|Group four|Group four will view the printed educational pamphlet and will not view either video
62121342|NCT06220071||Vertebral metastases|Patients affected by spinal metastases that are not surgically treated
62121343|NCT02740595|EXPERIMENTAL|Nicotine|Use an e-cig filled with liquid with nicotine
62121344|NCT02740595|EXPERIMENTAL|no nicotine|Use an e-cig filled with liquid without nicotine
62475974|NCT01725529|EXPERIMENTAL|TMC435 100 mg|Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
62475975|NCT01725529|PLACEBO_COMPARATOR|Control|Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.
62475976|NCT00101647|EXPERIMENTAL|1|
62475977|NCT02224586||light treatment|clinical routine treatment according to the doctor's advice
62475978|NCT02392286|ACTIVE_COMPARATOR|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
62475979|NCT02392286|ACTIVE_COMPARATOR|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
61921219|NCT05811533|EXPERIMENTAL|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated.
62121345|NCT02740595|SHAM_COMPARATOR|sham comparator|Use an empty e-cigarette (sham control)
62309904|NCT03270085|PLACEBO_COMPARATOR|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.~The last period, is the treatment testing period. This consists of a full transit \& urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
62475980|NCT05985343|OTHER|Neostigmine/Glycopyrrolate|Patients assigned to the control arm receive the standardized reversal neostigmine dose with on-label dosing (0.03-0.07mg/kg) and a fixed ratio of glycopyrrolate
62475981|NCT05985343|OTHER|Sugammadex|Patients randomized to the experimental arm will receive an IV dose of sugammadex according to the package insert of 2 mg/kg for ≥ 2 twitches, 4 mg/kg for 1-2 post-tetanic twitches
62475982|NCT05332002|OTHER|4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),|"A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:~1. Odd Cycles (e.g. 1, 3, 5, etc...) - mFOLFOX6 initiated on days 1 \& 15: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~2. Even Cycles (e.g. 2,4,6, etc...) - FOLFIRI initiated on days 1 \& 15: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~3. Nivolumab (optional, in-line with labelled approval) - 240 mg every 2 weeks"
62475983|NCT00906399|PLACEBO_COMPARATOR|Placebo|Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
62475984|NCT00906399|EXPERIMENTAL|Peginterferon Beta-1a Q2W|125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
62680392|NCT06435520|EXPERIMENTAL|Structured medication tapering alone|Structured medication tapering delivered alone with general sleep hygiene information.
61921220|NCT05770531|ACTIVE_COMPARATOR|Arm A (biospecimen banking)|Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for banking on study. Patients undergo CT or MRI during screening and on study.
62309905|NCT03672617||Children and adolescents|Children and adolescents, who administer growth hormone (GH) themselves (self-injections) will be asked to complete the questionnaire.
62309906|NCT03672617||Parents/legal guardians|Parents/legal guardians who administer the GH to their child will be asked to complete the questionnaire.
62680393|NCT06690801||Children with moderate to severe ARDS|
62680394|NCT04495998|OTHER|Motor Neurological Soft Signs|motor test and an interview for the participants
61944515|NCT04609761|EXPERIMENTAL|IVIG treatment|Single-arm open-label
62121346|NCT04949035||COVID-19 survivors|
62121347|NCT06677125|EXPERIMENTAL|Test Group|
62121348|NCT06677125|ACTIVE_COMPARATOR|Control Group|
62680395|NCT02536339|EXPERIMENTAL|Pertuzumab + Trastuzumab|Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
62680396|NCT06003621|EXPERIMENTAL|Tiragolumab and atezolizumab|"96 patients will be treated with tiragolumab for one cycle (600mg IV over 60-90 minutes). At Cycle 2 Day 1, participants receive IV tiragolumab (600mg) and atezolizumab (1,200mg) over 60-90 minutes. Cycles of tiragolumab and atezolizumab repeat every 21 days, with infusion time decreased (if tolerable) until treatment discontinuation, with or without disease progression.~Because of the heterogeneity of eligible cancer types, and lack of knowledge about relevant cut-offs for this combination, analysis will be performed prospectively to allocate patients into 4 subgroups based on the following tumour characteristics;~* Group 1: TMB ≥ 10, assessed using NGS panel screening. n=24~* Group 2:Tumour and immune cell PD-L1 expression (TAP score) \> 20% high or PD-L1 (CD274) amplification, defined as gene copy number \> 6 on the panel. n=24~* Group 3: Tumour and immune cell PD-L1 expression (TAP score) 5% - 20% int. n=24~* Group 4: Tumour infiltrating lymphocytes CD3+CD8+ ≥ 5%. n=24"
62680397|NCT04575961|OTHER|Pembrolizumab + Chemotherapie|pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin)
61921221|NCT05770531|EXPERIMENTAL|Arm B (biospecimen evaluation, possible treatment change)|Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for ctDNA evaluation on study. Patients may receive sacituzumab govitecan IV based on ctDNA results on study. Patients undergo CT or MRI during screening and on study.
62121349|NCT04363996|EXPERIMENTAL|New Bioactive Restorative Material|Activa Presto Bioactive restorative material
61921222|NCT06438627|EXPERIMENTAL|TPC+Apatinib+Camrelizumab|Radiation: IMRT Drug: Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab (Induction chemotherapy)
62121350|NCT04363996|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer|Fuji II
62309907|NCT04740866|ACTIVE_COMPARATOR|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy \[IMRT\] technique.
62680398|NCT06686082||Subclinical psoriatic arthritis patients|
62680399|NCT06395415|EXPERIMENTAL|mobile health (mHealth)|Participants in this arm will receive a 6-week mHealth message based intervention through their smartphone. They will also have the option of requesting free nicotine replacement therapy (NRT) throughout the treatment period.
62680400|NCT06395415|ACTIVE_COMPARATOR|Standard care|Participants in this arm will receive a 5-10 minute walk-through of electronic nicotine delivery system (ENDS) and tobacco education and skills based on the most recent evidence. They will also have the options of requesting a sample of NRT.
62680401|NCT04701983|EXPERIMENTAL|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
61921223|NCT06438627|ACTIVE_COMPARATOR|GP+ Camrelizumab|Radiation: IMRT Drug: Gemcitabine, Cisplatin Combined With Camrelizumab (Induction chemotherapy)
62309908|NCT04740866|NO_INTERVENTION|Observation after radical Cystectomy|observation following radical cystectomy
62309909|NCT04740749|OTHER|Prospective group|Patients who have to undergone the implant surgery
62309910|NCT04740749|OTHER|Retrospective group|Patients that have already undergone the implant surgery
62309911|NCT06353646|EXPERIMENTAL|XH001 (dose 1)|
62680402|NCT04701983|EXPERIMENTAL|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
61921224|NCT03020290||patients with femoropopliteal lesion|patients with femoropopliteal lesion - Endovascular treatment for PAD during medical care
61921225|NCT03425019|EXPERIMENTAL|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
61944516|NCT02956070|EXPERIMENTAL|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
61944517|NCT02956070|PLACEBO_COMPARATOR|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
61944518|NCT01115361|EXPERIMENTAL|PPFP in child immunization|Women attending immunization services for their infant will receive educational brochures, group education and individual counseling on the benefits of the health timing and spacing of births,, pregnancy risk and return to fertility during the extended postpartum period (12 months), and referral to family planning services for those who are interested.
61944519|NCT01115361|NO_INTERVENTION|Control - Standard of care|The control arm will receive standard of care infant immunization services.
61944520|NCT02940080|EXPERIMENTAL|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
61944521|NCT02940080|EXPERIMENTAL|Yellow potato|350 g of steam-cooked mashed potatoes in water
61921226|NCT05208307|EXPERIMENTAL|Treatment (belantamab mafodotin, pomalidomide, dexamethasone)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 of every other cycle, pomalidomide PO QD on days 1-21, and dexamethasone PO QD on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61921227|NCT03209453|EXPERIMENTAL|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
62309912|NCT06353646|EXPERIMENTAL|XH001 (dose 2)|
62309913|NCT02319772|EXPERIMENTAL|BCX4430|BCX4430 administered as an IM injection
62309914|NCT02319772|PLACEBO_COMPARATOR|Placebo|Matched placebo administered as an IM injection
62309915|NCT05616234|EXPERIMENTAL|Exercise trial|Participants will perform a bout of exercise. In addition, a baseline and post-exercise blood sample will be drawn.
62309916|NCT03002493|EXPERIMENTAL|Eribulin mesylate + Rifampicin|
62121351|NCT02943629|EXPERIMENTAL|Non-Obese: Apneic Oxygenation: eight minute|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
62309917|NCT04596813|NO_INTERVENTION|standard of care|
62309918|NCT04596813|ACTIVE_COMPARATOR|standard of care and treatment with the Cytosorb® device|
62309919|NCT02723630|EXPERIMENTAL|Sequence A:|Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
62309920|NCT02723630|EXPERIMENTAL|Sequence B|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
61921228|NCT03209453|NO_INTERVENTION|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
61921229|NCT03804073|ACTIVE_COMPARATOR|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
61921230|NCT03804073|EXPERIMENTAL|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
61921231|NCT03816670|EXPERIMENTAL|poor responders day 2|"poor responders women stimulated with CF from day 2 of menstrual cycle"
61921232|NCT03816670|EXPERIMENTAL|poor responders day 4|"poor responders women stimulated with CF from day 4 of menstrual cycle"
61921233|NCT03816670|EXPERIMENTAL|normal responders day 2|"normal responders women stimulated with CF from day 2"
61921234|NCT03816670|EXPERIMENTAL|normal responders day 4|"normal responders women stimulated with CF from day 4"
61921235|NCT03816670|EXPERIMENTAL|high responders day 2|"high responders women stimulated with CF from day 2"
62309921|NCT02723630|EXPERIMENTAL|Sequence C|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
62309922|NCT02723630|EXPERIMENTAL|Sequence D|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
62309923|NCT02723630|EXPERIMENTAL|Sequence E|Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
62309924|NCT02723630|EXPERIMENTAL|Sequence F|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
61921236|NCT03816670|EXPERIMENTAL|high responders day 4|"high responders women stimulated with CF from day 4"
61921237|NCT03914508|EXPERIMENTAL|Memory + Behavioral Weight Loss (M+BWL)|The M+BWL program will integrate memory interventions to the BWL program. The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
61921238|NCT06477224|EXPERIMENTAL|Scooter Board Activities|Participants in this arm receive treatment involving scooter board activities, which are hypothesized to improve neck control and alleviate symptoms of dysphagia.
62309925|NCT03103750|EXPERIMENTAL|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before and day of testing, subjects will receive two doses of calcitriol (3.0mcg total), followed by PHNO injection and PET Scan #1. After PET Scan #1, subjects will receive a Dexedrine dose, followed by PHNO injection and PET Scan #2. A minimum of six days later, subjects will receive two doses of placebo for the night before and day of testing, followed by a third PHNO injection and PET scan #3. After PET scan #3, subjects will receive another Dexedrine dose, followed by PHNO injection and PET scan #4.
62475985|NCT00906399|EXPERIMENTAL|Peginterferon Beta-1a Q4W|125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).
62475986|NCT04330534|EXPERIMENTAL|BCX9930|Parts 1, 2 and 3
62475987|NCT04330534|PLACEBO_COMPARATOR|Placebo|Parts 1 and 2 only
61921239|NCT06477224|EXPERIMENTAL|Routine Physical Therapy|Participants in this arm receive conventional physical therapy treatments, which serve as the control group for comparing the effectiveness of the scooter board activities.
61921240|NCT00952627|EXPERIMENTAL|Pycnogenol|200 mg/day
61921241|NCT00952627|PLACEBO_COMPARATOR|Control|placebo
61921242|NCT04325984||Dexamethasone group|Group of patients receiving dexamethasone 8 mg as part of the multimodal analgesia.
61921243|NCT04325984||Control group|Group of patients receiving multimodal analgesia, not comprising dexamethasone; moreover, ondansetron 4 mg is administered for the control of PONV.
61921244|NCT00610584|EXPERIMENTAL|1|verum acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
61921245|NCT00610584|PLACEBO_COMPARATOR|2|minimal (sham) acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
61921246|NCT00610584|ACTIVE_COMPARATOR|3|rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))alone
61921247|NCT05249777|EXPERIMENTAL|TD0069|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with standard treatment.
61921248|NCT05249777|PLACEBO_COMPARATOR|Placebo|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with standard treatment
61921249|NCT03596632|EXPERIMENTAL|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of \[14C/12C\]-fenebrutinib under fasted conditions.
61921250|NCT00936091|PLACEBO_COMPARATOR|placebo|125 schoolchildren were allocated randomly to receive placebo
61921251|NCT00936091|ACTIVE_COMPARATOR|vitamin A supplement|125 children received vitamin A supplements capsules (200 000 IU)
62680403|NCT04701983|PLACEBO_COMPARATOR|Placebo|SC administration of matching placebo Q2W for up to 52 weeks
62680404|NCT03769168|EXPERIMENTAL|Group 1 - Secukinumab 75 mg|Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
61921252|NCT03518749|ACTIVE_COMPARATOR|1mA anodal tDCS + cognitive control training|1 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
61921253|NCT03518749|ACTIVE_COMPARATOR|2mA tDCS + cognitive control training|2 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
61921254|NCT03518749|PLACEBO_COMPARATOR|sham tDCS + cognitive control training|Sham tDCS (30 secs of tDCS) will be administered to the left dlPFC (F3) with 2mA at the beginning of a cognitive control training.
61921255|NCT00652639|EXPERIMENTAL|A|Subjects received the kali formulated products under fasting conditions
62121352|NCT02943629|OTHER|Non-Obese: Without Apneic Oxygenation|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
62475988|NCT02532439|EXPERIMENTAL|Patient group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases
61921256|NCT00652639|ACTIVE_COMPARATOR|B|Subjects received the Roche formulated products under fasting conditions
61921257|NCT05205967||Patients who received the Galleri® test.|
61921258|NCT00375869|ACTIVE_COMPARATOR|Darbopoeitin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
61921259|NCT00375869|PLACEBO_COMPARATOR|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
61921260|NCT04810572|ACTIVE_COMPARATOR|Group 1 - composition with Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition with Silymarin (Silybum marianum), in a diary dose of 140 mg for 180 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
61921261|NCT04810572|ACTIVE_COMPARATOR|Group 2 - composition without Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 180 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
62680405|NCT03769168|EXPERIMENTAL|Group 2 - Secukinumab 150 mg|Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
62475989|NCT02532439|EXPERIMENTAL|control group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain
62680406|NCT02080000|EXPERIMENTAL|Optimised V-V timing delay|V-V timing delay setting on biventricular pacemaker will be optimised guided by size of R-wave on surface ECG
62680407|NCT02080000|ACTIVE_COMPARATOR|Standard V-V timing delay|Standard settings
62680408|NCT05051410|NO_INTERVENTION|control|single visit root canal treatment will be performed with no additional irrigation.
62680409|NCT05051410|EXPERIMENTAL|intracanal cryotherapy with needle irrigation|single visit root canal treatment will be performed with additional irrigation with cold saline using needle irrigation.
62680410|NCT05051410|EXPERIMENTAL|intracanal cryotherapy using Endovac system|single visit root canal treatment will be performed with additional irrigation with cold saline using EndoVac system.
62680411|NCT06378190|EXPERIMENTAL|TranspoCART19 cells|Adult differentiated, autologous, peripheral blood T lymphocytes, expanded and genetically modified.
62680412|NCT05807893|EXPERIMENTAL|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
62680413|NCT06123468|EXPERIMENTAL|Sacituzumab-govitecan|Single arm with Sacituzumab-govitecan 10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W). Patients will receive the treatment for a maximum of 12 months.
62680414|NCT06321601|EXPERIMENTAL|Avacopan|Participants will receive avacopan twice-daily (BID) administered as oral tablets or liquid formula for 52 weeks.
62680415|NCT04365270|EXPERIMENTAL|Chitosan Glass ionomer|"purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan.~will be placed in the prepared cavity over the last layer of caries"
62680416|NCT04365270|EXPERIMENTAL|Chitosan/Titanium dioxide nanoparticles Glass ionomer|"The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid.~The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries"
62680417|NCT04365270|ACTIVE_COMPARATOR|Chlorhexidine glass ionomer|Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v
62680418|NCT04365270|PLACEBO_COMPARATOR|Glass ionomer|Stock powder and liquid Fuji IX from GC japan
62680419|NCT01573728|ACTIVE_COMPARATOR|Low Exercise Arm|Low dose exercise (50 Minutes)
62680420|NCT01573728|EXPERIMENTAL|Public Health Exercise|Public Health dose exercise (150 minutes)
62680421|NCT02999360|EXPERIMENTAL|Treatment 1|
62680422|NCT02999360|ACTIVE_COMPARATOR|Treatment 2|
62680423|NCT04460261|EXPERIMENTAL|COPD Group|Patients with COPD
62680424|NCT04460261|EXPERIMENTAL|Non-COPD Group|Non-COPD
62680425|NCT06411691|EXPERIMENTAL|SLP mKRASvax (Up to 1.8mg peptide + 0.5 mg Poly-ICLC (Hiltonol), Botensilimab and Balstilimab|
62680426|NCT05377424|EXPERIMENTAL|AIH + istradefylline (AIH+IST)|Participants enrolled in this study arm will ingest a 20mg tablet containing istradefylline. Four hours later, participants will receive acute intermittent hypoxia (AIH). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after AIH. Participants will breathe 15 episodes/session of acute low oxygen. Air concentrations will be monitored to ensure delivery of 1-minute episodes of low oxygen, with 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
62680427|NCT05377424|ACTIVE_COMPARATOR|Sham-AIH + istradefylline (sham+IST)|This is a sham counterpart to the low oxygen. Participants enrolled in this study arm will ingest a 20mg tablet containing istradefylline. Four hours later, participants will receive SHAM acute intermittent hypoxia (SHAM). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after SHAM. Participants will breathe 15 episodes/session of sham low oxygen, in which normal air is used. One-minute episodes of sham low oxygen are separated by 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
62680428|NCT05377424|ACTIVE_COMPARATOR|AIH + placebo (AIH+CON)|This is a placebo counterpart to the istradefylline drug. Participants enrolled in this study arm will ingest a 20mg tablet containing microcrystalline cellulose. Four hours later, participants will receive acute intermittent hypoxia (AIH). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after AIH. Participants will breathe 15 episodes/session of acute low oxygen. Air concentrations will be monitored to ensure delivery of 1-minute episodes of low oxygen, with 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
62680429|NCT05377424|ACTIVE_COMPARATOR|Sham-AIH + placebo (sham+CON)|This is a sham counterpart to low oxygen, and a placebo counterpart to the istradefylline drug. Participants enrolled in this study arm will ingest a 20mg tablet containing microcrystalline cellulose. Four hours later, participants will receive SHAM acute intermittent hypoxia (SHAM). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after SHAM. Participants will breathe 15 episodes/session of sham low oxygen, in which normal air is used. One-minute episodes of sham low oxygen are separated by 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
62680430|NCT06053411|EXPERIMENTAL|Arm 1: diclofenac alone (baseline)|A single dose of diclofenac (25 mg capsule) will be administered by mouth to 5 participants (minimum 2 females) genotyped as extensive metabolizers (Arm 1A) and 5 participants (minimum 2 females) genotyped as poor metabolizers (Arm 1B). Plasma and urine will be collected from 0-12 hours. A washout of at least 3 days will elapse between Arm 1 and Arm 2.
62680431|NCT06053411|EXPERIMENTAL|Arm 2: diclofenac + curcumin|A single oral dose of diclofenac (25 mg capsule) and a single oral dose of curcumin (2,000 mg tablet) will be administered by mouth to the 5 participants genotyped as extensive metabolizers. Plasma and urine will be collected from 0-12 hours.
62680432|NCT06683807|PLACEBO_COMPARATOR|Group T0|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe
61921262|NCT04810572|ACTIVE_COMPARATOR|Group3 - Low-mineral composition without Silymarin (L5)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 180 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
61921263|NCT00134537|EXPERIMENTAL|1|Interspinous process and dynamic stabilization
61921264|NCT00134537|ACTIVE_COMPARATOR|2|Conservative Care
61921265|NCT01687621||Neonates, 1 to 10 days old|Neonates between day 1-10 of life presenting to hospitals and community health centers in Southern Province, Zambia, with no prior diagnosis of omphalitis, whose guardian, aged 15 and above, is willing to allow their newborn to participate in the study.
61921266|NCT06400771|EXPERIMENTAL|1 mg/kg|1 mg/kg (IV administered over 30 minutes)
61921267|NCT06400771|EXPERIMENTAL|2 mg/kg|2 mg/kg (IV administered over 30 minutes)
61921268|NCT06400771|EXPERIMENTAL|4 mg/kg|4 mg/kg (IV administered over 30 minutes)
62309926|NCT03103750|EXPERIMENTAL|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before and day of testing, subjects will receive two doses of placebo, followed by PHNO injection and PET Scan #1. After PET Scan #1, subjects will receive a Dexedrine dose, followed by PHNO injection and PET Scan #2. A minimum of six days later, subjects will receive two doses of calcitriol (3.0mcg total) for the night before and day of testing, followed by a third PHNO injection and PET scan #3. After PET scan #3, subjects will receive another Dexedrine dose, followed by PHNO injection and PET scan #4.
62309927|NCT01319955|EXPERIMENTAL|Influenza vaccine (trivalent inactivated vaccine)|
62680433|NCT06683807|ACTIVE_COMPARATOR|Group T5|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
62680434|NCT03845166|EXPERIMENTAL|XL092 Single-Agent Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 3-6 subjects in a standard 3 plus 3 design."
62680435|NCT03845166|EXPERIMENTAL|XL092 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).
61921269|NCT06400771|EXPERIMENTAL|8 mg/kg|8 mg/kg (IV administered over 30 minutes)
61921270|NCT00510952|EXPERIMENTAL|Lispro|Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
61921271|NCT00510952|ACTIVE_COMPARATOR|Glargine|Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
61921272|NCT04348084||who developed POPF|Patients undergone curative distal pancreatectomy for PDAC who developed POPF
61921273|NCT04348084||who did not develop POPF|Patients undergone curative distal pancreatectomy for PDAC who did not develop POPF
61921274|NCT00806507||Echocardiogram + Blood Test|Additional Echocardiogram views performed in 5-10 minutes of regularly scheduled echocardiograms plus blood tests measuring of hormones and metabolic proteins (such as sugars and acids).
61921275|NCT01698281|EXPERIMENTAL|Arm A: AEZS-108|Intervention: AEZS-108 (267 mg/m\^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
62680436|NCT03845166|EXPERIMENTAL|XL092 + Atezolizumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
62121353|NCT02943629|EXPERIMENTAL|Obese: Apneic Oxygenation: five minute|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
62121354|NCT02943629|OTHER|Obese: Without Apneic Oxygenation|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
62121355|NCT00463788|EXPERIMENTAL|cisplatin and cetuximab|
62121356|NCT00463788|ACTIVE_COMPARATOR|cisplatin|
62121357|NCT01562925|ACTIVE_COMPARATOR|Red Wine|Patients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure
62680437|NCT03845166|EXPERIMENTAL|XL092 + Atezolizumab Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer (CRC).
62121358|NCT01562925|ACTIVE_COMPARATOR|White wine|
62680438|NCT03845166|EXPERIMENTAL|XL092 + Avelumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
62680439|NCT06286098|EXPERIMENTAL|(Alpha lipoic acid) Active Group|"Alpha Lipoic Acid orally along with the standard care of therapy for a duration of 6 months.~Dose: 600 mg once daily."
62121359|NCT01562925|ACTIVE_COMPARATOR|Beer|
62680440|NCT06286098|PLACEBO_COMPARATOR|(Placebo) Control Group|"Placebo along with the standard care of therapy for a duration of 6 months.~Dose: One Tablet daily."
62680441|NCT04253678||Study group|"Study participants will be started on a flexible-dose of vortioxetine (5-20 mg) followed by a baseline assessment of primary outcomes using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Perceived Deficit Questionnaire - 5 items (PDQ-5), and secondary outcomes using the EORTC Quality of life Questionnaire (QLQ-C30) and Clinical Global Impression (CGI). The assessment timelines will be at week 2, week 4, week 8, and week 12.~Side effects, if any, will be recorded using the Antidepressant Side-effect Checklist (ASEC)."
62680442|NCT04344860|ACTIVE_COMPARATOR|rVWF plus TA|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia) plus Tranexamic Acid 1 gm IV within 3 hours of delivery; and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
62680443|NCT04344860|ACTIVE_COMPARATOR|rVWF alone|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia); and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
62680444|NCT06253728|EXPERIMENTAL|Meal 1|Meal with plant protein and fiber in an intact structure
62309928|NCT01319955|ACTIVE_COMPARATOR|Inactivated polio vaccine|
62309929|NCT01392690|NO_INTERVENTION|Waiting list control - no intervention|No intervention. After the post-test they were offered the prevention program.
62309930|NCT01392690|EXPERIMENTAL|Dominique's handy tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
62309931|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
62309932|NCT02097836|EXPERIMENTAL|Single subject case series|Targeted training, 5-6 days a week for 6 months, minimum of 20 minutes per day
62680445|NCT06253728|EXPERIMENTAL|Meal 2|Meal with plant protein and fiber, where the cell structure is broken
62680446|NCT06253728|PLACEBO_COMPARATOR|Meal 3|Low protein and low fiber cereal
62680447|NCT06253728|EXPERIMENTAL|Meal 4|High protein and low carbohydrate bread with animal proteins
62680448|NCT06253728|EXPERIMENTAL|Meal 5|High protein and low carbohydrate bread with plant protein
62309933|NCT04265534|EXPERIMENTAL|Telaglenastat with Pembrolizumab and Chemotherapy|The glutaminase inhibitor telaglenastat will be administered orally, twice daily with food, every day in combination with standard-of-care pembrolizumab plus chemotherapy by intravenous (IV) infusion every 3 weeks.
62309934|NCT04265534|PLACEBO_COMPARATOR|Placebo with Pembrolizumab and Chemotherapy|Placebo will be administered orally twice daily with food every day in combination with standard-of-care pembrolizumab plus chemotherapy by IV infusion every 3 weeks.
62680449|NCT06679855|PLACEBO_COMPARATOR|Placebo|An iv infusion of placebo (0.9% saline) of equivalent volume will be administered. The infusion will be accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes) to ensure blinding is maintained.
62121360|NCT01562925|NO_INTERVENTION|Control|Patients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)
62121361|NCT06552624|EXPERIMENTAL|TR-sequence (T-test drug, R-reference drug)|Group 1 (20 volunteers, TR sequence) will take 2 tablets of Antareit (magaldrate) 800 mg chewable tablets 2 h prior to food intake in Period 1 and 2 tablets of Riopan (magaldrate) 800 mg chewable tablets 2 h prior to food intake in Period 2
62680450|NCT06679855|ACTIVE_COMPARATOR|Milrinone|An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes).
62680451|NCT03512080||Stable International Normalised Ratio|Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
62680452|NCT04512183|EXPERIMENTAL|High-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to high-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a reflective debriefing session.
62680453|NCT04512183|ACTIVE_COMPARATOR|Low-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to low-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a feedback session.
62680454|NCT05558254|ACTIVE_COMPARATOR|ROBERT|The intervention group will receive usual practice. As add-on, the intervention leg will receive 3-4 sets of 15-20 repetitions (30 seconds rest between each set) of muscle strength training for hip flexion with ROBERT® three times a week.
62680455|NCT05558254|NO_INTERVENTION|Control|Usual practice in the control group consist of 3-5 times physiotherapy a week for 8 weeks. A session last 45 minutes. The sessions are individually adapted and can contain exercise therapy, functional training, assistive devices, electrical stimulation, hydrotherapy and tread mill training.
62680456|NCT05471856|EXPERIMENTAL|BI 1703880 (Cycle 1) then BI 1703880 + ezabenlimab (Cycle 2 onwards)|
62309935|NCT03042949|EXPERIMENTAL|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
62680457|NCT06691412|EXPERIMENTAL|the group will receive obeticholic acid|The first group that will receive obeticholic acid for six months
62309936|NCT01207544|EXPERIMENTAL|fitball program|This group will undergo the fitball program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
62680458|NCT06691412|NO_INTERVENTION|the group will not receive obeticholic acid|Control group
62309937|NCT01207544|ACTIVE_COMPARATOR|Task-oriented program|This group will undergo the task-oriented motor training program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
62680459|NCT02367040|EXPERIMENTAL|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
62121362|NCT06552624|EXPERIMENTAL|RT-sequence|Group 2 (20 volunteers, RT sequence) will take 2 tablets of Riopan (magaldrate) 800 mg chewable tablets 2 h prior to food intake in Period 1 and 2 tablets of Antareit (magaldrate) 800 mg chewable tablets 2 h prior to food intake in Period 2
62309938|NCT01355432||Propofol|
62680460|NCT02367040|PLACEBO_COMPARATOR|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
62680461|NCT04267861||1|Medical records of subjects enrolled on NCI protocols 15-C-0179 and 18-C-0056
62680462|NCT06685926||Groin-Only Approach LVA|This is a group of patients who had a single incision based LVA procedure.
62680463|NCT06685926||Conventional Approach LVA|This is a group of patients who had the conventional LVA approach with multiple incisions for access.
62680464|NCT05868954|ACTIVE_COMPARATOR|American College of Obstetricians and Gynecologists (ACOG)-based Dietary Program|Routine dietary counseling program
62680465|NCT05868954|EXPERIMENTAL|Mediterranean Diet (MedDiet) Program|Well-known healthy diet that consists of a large amount of plant-based foods such as fruits, vegetables, beans, and nuts with extra virgin olive oil (EVOO) as the principal source of fat. Dairy, fish, and poultry are consumed in moderation and red meat only eaten occasionally.
62680466|NCT04836910||Study Group: Women with Polycystic Ovary Syndrome|Woen diagnosed with Polycystic Ovary Syndrome according to the Rotterdam Criteria (requires 2 out of 3 symptoms: 1. Hyperandrogenism or excess levels of androgen. 2. Oligo or anovulation. 3. Polycystic ovaries on ultrasound - over 12 follicles, 2-9 mm or increased ovarian volume),who haven't started any treatment
62309939|NCT00565422|EXPERIMENTAL|Single Arm|Escitalopram
61921276|NCT01698281|ACTIVE_COMPARATOR|Arm B: Standard (SCCC)|"commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
61921277|NCT02653404||Cases|"A blood sample necessary to perform QFT-GIT will be taken, together with other routine blood samples, from children with following diagnosis:~* latent tuberculous infection: active TB contact, TST positive, lack of clinical and RX signs of active-TB~* active TB: clinical and radiologic evidences of active-TB, positivity to microbial tests to BK~* not infected: patients evaluated as TB contacts, with negative TST and negative clinical/radiological/microbial results for TB."
62309940|NCT05870475|EXPERIMENTAL|pegylated interferon α-2b in combination with ruxolitinib group|Pegylated interferon α-2b in combination with ruxolitinib group: Pegylated interferon α-2b at a starting dose of 180ug, subcutaneous injection once a week; ruxolitinib at a starting dose of 10mg, orally administered twice daily.
62121363|NCT03932188||Control|Individuals between 13-25 years old that do not meet criteria for any prodromal syndrome, any current or past psychotic disorder, or Cluster A personality disorder diagnosis
62309941|NCT05870475|ACTIVE_COMPARATOR|Pegylated interferon α-2b group|"Pegylated interferon α-2b group: Starting dose of 180ug, subcutaneous injection once a week.~If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed; if ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed."
62121364|NCT03932188||Prodromal/Early psychosis|Individuals between 13-25 years old that meet diagnostic criteria for a prodromal syndrome or early psychosis
62121365|NCT02962141|EXPERIMENTAL|APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
62309942|NCT03425656|EXPERIMENTAL|Trastuzumab (AryoTrust)|Trastuzumab (AryoTrust) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
62309943|NCT03425656|ACTIVE_COMPARATOR|Trastuzumab (Herceptin)|Trastuzumab (Herceptin) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
62309944|NCT04923373|EXPERIMENTAL|telerehabilitation|physiotherapeutic programme brochure exercises 7/week controlled by phone every week (5x in total)
62309945|NCT04923373|ACTIVE_COMPARATOR|standard physiotherapy|"Supervised physical therapy 3/ week,~+ physiotherapeutic programme brochure 4/week"
62121366|NCT02962141|ACTIVE_COMPARATOR|OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
62121367|NCT00412321|EXPERIMENTAL|Cohort 1 (CNTO 328)|Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
62121368|NCT00412321|EXPERIMENTAL|Cohort 2 (CNTO 328)|Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
62309946|NCT05418946||Treatment group|Patient in treatment with Dapagliflozin 10 mg/day
62309947|NCT02896725|EXPERIMENTAL|Keratin dressings|Wool-derived keratin matrix dressing applied with each change of the compression bandage until healing
62309948|NCT02896725|ACTIVE_COMPARATOR|Usual care dressings|Dressing chosen from study centres' formulary of non-medicated moist wound dressings applied with each change of the compression bandage until healing
62680467|NCT04836910||Cohort Group: Women without Polycystic Ovary Syndrome|
62680468|NCT00937937|EXPERIMENTAL|Arm I|Patients receive dinaciclib IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62680469|NCT04057794|ACTIVE_COMPARATOR|Site-Based Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.
62680470|NCT04057794|ACTIVE_COMPARATOR|Centralized Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.
62121369|NCT00412321|EXPERIMENTAL|Cohort 3 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
61921278|NCT02276573|EXPERIMENTAL|Oral lichen planus disease|buccal cavity sample
62309949|NCT01434225|EXPERIMENTAL|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
62309950|NCT02792777||Interviews|Interview participants will be recruited from 3 different care settings: an acute care visit (in the emergency department), a post-acute care visit (within 1 week of a hospital discharge), and a routine primary care visit. Target sample size within each healthcare setting is 30 patients, which is the anticipated number needed for thematic saturation. The total recruitment goal for this cohort is 90-120 participants.
61921279|NCT06422273|EXPERIMENTAL|TXA|Tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients.
61921280|NCT06422273|PLACEBO_COMPARATOR|Saline|Topical Saline (placebo) administered as endobronchial topical application.
61921281|NCT03809793|ACTIVE_COMPARATOR|Acipimox ingestion|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor), muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest 250 mg of Acipimox 1 hour before each exercise session of the 12 week intervention.
62309951|NCT02792777||Concept Mapping|Concept mapping participants will be recruited from existing clinical and research databases for 3 separate concept mapping groups, each with a target of 20 patients. The total recruitment goal for this cohort is 60 people.
62309952|NCT05669885|EXPERIMENTAL|Sildenafil|Oral administration of 100 mg sildenafil.
61921282|NCT03809793|PLACEBO_COMPARATOR|No drug|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor) with muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest nothing prior to their exercise sessions during the 12-week exercise programme.
61921283|NCT05016284|EXPERIMENTAL|JW-100|Subjects applying JW-100 cream twice daily at home (experimental group).
62309953|NCT05669885|PLACEBO_COMPARATOR|Placebo|
61921284|NCT05016284|ACTIVE_COMPARATOR|EUCRISA|Subjects applying EUCRISA® (Pfizer) product twice daily at home (comparator group).
62309954|NCT06378710|NO_INTERVENTION|control group|Standard PEEP (at 7 cmH2o), Vt standardized between \[6- 8\] ml/kg theoretical ideal weight. Taking NIBP every 3 minutes.
61921285|NCT02515032|EXPERIMENTAL|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
61921286|NCT02515032|PLACEBO_COMPARATOR|Placebo|An isocaloric placebo comparator
62121370|NCT00412321|EXPERIMENTAL|Cohort 4 (CNTO 328)|Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
62680471|NCT06685120|EXPERIMENTAL|PRP+HA injection|This group of patients randomized into the treatment group, will undergo single intra-articular injection of autologous PRP+HA
62121371|NCT00412321|EXPERIMENTAL|Cohort 5 (CNTO 328)|Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
62309955|NCT06378710|EXPERIMENTAL|Optimized PEEP|Optimized PEEP (at 2 cmH2O), filling according to VES monitoring by esophageal Doppler before reversal, Vt standardized between \[6-8\] ml/kg theoretical ideal weight. Taking NIBP every 3 minutes.
62309956|NCT05073289|EXPERIMENTAL|SAPC|SAPC is a acronmy that defines Sandplay activity in psychiatry clinic
62309957|NCT05073289|ACTIVE_COMPARATOR|Control Group|
62680472|NCT06685120|ACTIVE_COMPARATOR|PRP injection|This group of patients randomized into the treatment group, will undergo single intra-articular injection of autologous PRP
62680473|NCT06685120|ACTIVE_COMPARATOR|HA injection|This group of patients randomized into the treatment group, will undergo single intra-articular injection of HA
62680474|NCT05965466|EXPERIMENTAL|Distal gastrectomy|Distal subtotal gastrectomy was performed after exclusion of contraindications to surgery. Gastrointestinal reconstruction was performed by residual gastrojejunal Roux-en-Y anastomosis. Anastomosis was performed ex vivo or in vivo.
62680475|NCT05965466|SHAM_COMPARATOR|Total gastrectomy|Total gastrectomy was performed after the exclusion of contraindications to surgery. Gastrointestinal reconstruction was performed by oesophageal jejunum Roux-en-Y anastomosis. Anastomosis was performed ex vivo or in vivo.
62680476|NCT04046952|ACTIVE_COMPARATOR|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
62680477|NCT04046952|EXPERIMENTAL|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
62680478|NCT04401475|EXPERIMENTAL|Stage 1|Stage 1 (Phase II Study) For 80% power (β = 0.20), at a significance level of 5% (α =0.05) and a 1:1 randomization ratio, a total of 316 (EB05: 158, SOC: 158) evaluable patients will be required. Allowing for 20% attrition a total of 396 patients will be recruited.
62680479|NCT04401475|EXPERIMENTAL|Stage 2|Stage 2 (Phase III Study) For a 1:1 ratio of patients treated with EB05 vs. Placebo, a cumulative one-sided alpha of 2.5% and 90% power, to detect an Odds Ratio of 2.00, a total of 586 evaluable patients will be required for Stage 2 (Phase III study). 293 of these will be treated with EB05 + SOC and 293 treated with Placebo + SOC. Allowing for 10% attrition, a total of 644 patients will be enrolled in this Stage.
62680480|NCT06559969|ACTIVE_COMPARATOR|Control|Hydromorphone administered intravenous PCA combined with a continuous bupivacaine epidural infusion
62309958|NCT04599790|EXPERIMENTAL|TACE-Len-Sin|TACE combined with lenvatinib and sintilimab.
62309959|NCT00200148|EXPERIMENTAL|1|For patients randomized to ANH
62309960|NCT00200148|ACTIVE_COMPARATOR|2|standard intraoperative management
62680481|NCT06559969|ACTIVE_COMPARATOR|Treatment|Hydromorphone combined with bupivacaine in the epidural and administered as a continuous infusion with a PCEA bolus as necessary
62680482|NCT03640988|EXPERIMENTAL|dermaPACE|Non-sterile, single, Benchtop System that is comprised of a dermaPACE Control Console, PACE Applicator and foot pedal. The PACE applicator uses shockwave technology on acute and chronic defects.
62680483|NCT00917020|EXPERIMENTAL|Active: CO2 Gas|
62680484|NCT00917020|PLACEBO_COMPARATOR|Inactive Placebo Gas|
62680485|NCT04938466||Transition to long-acting growth hormone (LAGH)|Participants in this arm will transition between daily growth hormone treatment and long-acting growth hormone treatment.
62680486|NCT04938466||Consistent daily growth hormone (DGH)|Participants in this group will continue with daily growth hormone treatment.
62680487|NCT04195477|EXPERIMENTAL|vDPP Full Study|Participants will take part in a 52 week study receiving the vDPP intervention.
62680488|NCT04651374|EXPERIMENTAL|Geko Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
62680489|NCT04651374|NO_INTERVENTION|No Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
62309961|NCT02658695||Group 1|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) \<10 mm.
62309962|NCT02658695||Group 2|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) \>10 mm.
62309963|NCT01333618|EXPERIMENTAL|curving introducer|
62309964|NCT01333618|PLACEBO_COMPARATOR|straight introducer|
62309965|NCT04298346||Case|
61921287|NCT02129218|EXPERIMENTAL|Cohort 1: Low glycemic load with standard diet|Patients follow a low glycemic load diet with a standard dietary intervention for 12 weeks.
62121372|NCT00412321|EXPERIMENTAL|Cohort 6 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
62309966|NCT04298346||Control|
62309967|NCT01379586|EXPERIMENTAL|E|ONO-4053
62309968|NCT01379586|PLACEBO_COMPARATOR|P|Placebo
62309969|NCT01412931||1) Pregnant women with a single intrauterine pregnancy|50 women with uncomplicated pregnancies and no history of preterm birth.
62309970|NCT01412931||2) Pregnant women with a single intrauterine pregnancy|50 multiparous women with history of spontaneous preterm labor or preterm premature rupture of membranes (PPROM).
62680490|NCT00558207|EXPERIMENTAL|1|ARQ 197
62680491|NCT00558207|ACTIVE_COMPARATOR|2|Gemcitabine
62680492|NCT03228537|EXPERIMENTAL|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.~SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo EPP or PD. Patients who undergo EPP will then undergo RT.~MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
62680493|NCT06502184||cohort of all patients who receive ODS surgery|laparoscopic resection rectopexy is performed
62680494|NCT04508413|OTHER|KB295|
62309971|NCT01412931||3) Pregnant women with a single intrauterine pregnancy|20 women evaluated on the labor and delivery unit because they are deemed to be at high risk for preterm birth.
62309972|NCT05216263|EXPERIMENTAL|Atogepant|Participants will receive atogepant once a day (QD) during the 24-week treatment period.
62121373|NCT00412321|EXPERIMENTAL|Cohort 7a (CNTO 328)|Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
62121374|NCT00412321|EXPERIMENTAL|Cohort 7b (CNTO 328)|Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
62121375|NCT00844636|ACTIVE_COMPARATOR|Sharp Needles|Sharp needles to close uterus, fascia and skin during cesarean section
62121376|NCT00844636|ACTIVE_COMPARATOR|Blunt Needles|Assignment to blunt needles to close uterus, fascia and skin during cesarean section
62121377|NCT03443102||SARS survivors|First-line HCWs infected during the SRAS-CoV pandemic in Peking University People's Hospital, China. Diagnose was further confirmed by SARS-CoV seropositive results.
62121378|NCT03443102||Controls|"1. Coworkers of the infected HCWs, who also exposed to SARS patients or specimens. Infection was further excluded by SARS-CoV seronegative results.~2. Healthy controls matched for age, sex and disease condition, but without exposures to SARS virus."
62680495|NCT06695689|EXPERIMENTAL|LM303|Treatment with LM303 injection
62680496|NCT03378934|EXPERIMENTAL|Berberine Arm|In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
62680497|NCT03378934|ACTIVE_COMPARATOR|Control Arm|In the Control Arm, patients will receive standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
62680498|NCT01647256|EXPERIMENTAL|Nikkomycin Z fed - fasting|"Period 1:~* Day 1: Nikkomycin Z 500 mg with high fat breakfast~Period 2:~* Day 1: Nikkomycin Z 500 mg under fasted conditions"
62680499|NCT01647256|EXPERIMENTAL|Nikkomycin Z fasting - fed|"Period 1:~* Day 1: Nikkomycin Z 500 mg under fasted conditions~Period 2:~* Day 1: Nikkomycin Z 500 mg with high fat breakfast"
62121379|NCT04898140||Healthy volunteers|Individuals who were not infected and not having been demonstrated COVID-19 symptoms since December 2019.
62121380|NCT04898140||Recovered|Individuals who were recovered from COVID-19 with different severity.
62121381|NCT04898140||Vaccinated|"Individuals who were vaccinated against SARS-CoV-2 with Sputnik V vaccine."
62121382|NCT04898140||Special group|Individuals who recovered from COVID-19 concomitant with other immune-related comorbidities (tuberculosis, chronic obstructive pulmonary disease, HIV infection, hematological neoplasia).
62121383|NCT03897127|ACTIVE_COMPARATOR|Standard arm|
62121384|NCT03897127|EXPERIMENTAL|Investigational arm|
62121385|NCT05153135||Ribociclib|Participants who initiated CDK4/6i therapy
62121386|NCT05153135||Palbociclib|Participants who initiated CDK4/6i therapy
62680500|NCT04810078|EXPERIMENTAL|Arm A|
62680501|NCT04810078|ACTIVE_COMPARATOR|Arm B|
62680502|NCT04810078|EXPERIMENTAL|Arm C|
62680503|NCT04810078|EXPERIMENTAL|Arm D|
62680504|NCT06063031|EXPERIMENTAL|Active nutritional supplement plus telerehabilitation|Active nutritional supplement plus telerehabilitation
62121387|NCT05153135||Abemaciclib|Participants who initiated CDK4/6i therapy
62121388|NCT02937831||All Study Participants|
62121389|NCT01926977|ACTIVE_COMPARATOR|Ranibizumab 0.5mg Intravitreal injection|Intravitreal injection of Ranibizumab 0.5mg once
62121390|NCT01926977|ACTIVE_COMPARATOR|Aflibercept 2.0mg Intravitreal injection|Intravitreal Aflibercept 2.0mg once
62309973|NCT02385123|EXPERIMENTAL|Seasonal Flu Vaccine/Healthy Adult Volunteers|0.5 ml of seasonal inactivated influenza vaccine (IIV) was administered intramuscularly (IM) on Day 0 of each study season, for this multi-year study. A total of 60 participants were enrolled in this study.
62309974|NCT05841849|EXPERIMENTAL|oral group|patients receive oral palonosetron and aprepitant
62309975|NCT05841849|ACTIVE_COMPARATOR|intravenous group|patients receive intravenous palonosetron and fosaprepitant
62309976|NCT02509338|EXPERIMENTAL|Electrode deep brain stimulation|Monocontact electrode deep brain stimulation
62680505|NCT06063031|PLACEBO_COMPARATOR|Placebo nutritional supplement plus telerehabilitation|Placebo nutritional supplement plus telerehabilitation
62680506|NCT04469530|EXPERIMENTAL|Maintenance Chemotherapy Regimen|"Participants with metastatic osteosarcoma, metastatic Ewing sarcoma, high-risk rhabdomyosarcoma, metastatic non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), desmoplastic small round cell tumor (DSRCT), and malignant rhabdoid tumor (MRT) in first complete remission (cohort 1) or participants with recurrent solid tumors (any histology) in second complete remission (cohort 2), receiving a maintenance chemotherapy regimen administered as a 12-month course of continuous sirolimus with celecoxib and low-dose oral etoposide alternating every 21 days with low-dose oral cyclophosphamide following the completion of standard therapy."
62121391|NCT02464852|OTHER|Snood|All recruited participants will try out the snood
61921288|NCT02129218|EXPERIMENTAL|Cohort 2: Low glycemic load with intensified diet|Patients follow a low glycemic load diet with intensified dietary intervention for 12 weeks.
61921289|NCT02129218|ACTIVE_COMPARATOR|Cohort 3: Medium glycemic load with standard diet|Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.
62121392|NCT06376383|ACTIVE_COMPARATOR|Tonsillectomy|Patients undergo standard removal of subcapsular removal of palatine tonsils
61921290|NCT02129218|ACTIVE_COMPARATOR|Cohort 4: Medium glycemic load with intensified diet|Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.
61921291|NCT05163873|NO_INTERVENTION|Trans-peritoneal|Surgery technique in the formation of permanent end colostomy
61921292|NCT05163873|EXPERIMENTAL|Extra-peritoneal|Surgery technique in the formation of permanent end colostomy
62121393|NCT06376383|EXPERIMENTAL|Tonsillotomy|Patients undergo intracapsular reduction of palatine tonsils
62121394|NCT01359436|EXPERIMENTAL|Electrosensing antibody probing system (e- Ab sensing)|
61921293|NCT00957385|ACTIVE_COMPARATOR|A|Arm A will receive Revlimid.
62309977|NCT03060577|EXPERIMENTAL|Inclisiran-only|Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.
62309978|NCT03060577|ACTIVE_COMPARATOR|Switching|Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
61921294|NCT00957385|NO_INTERVENTION|B|Arm B will not receive Revlimid but an observational arm
61921295|NCT02997267|EXPERIMENTAL|Early closure|Closure of the ileostomy 14 days after the primary operation, in which it was created.
61921296|NCT02997267|ACTIVE_COMPARATOR|Late closure|Closure of the ileostomy more than 90 days after the primary operation, in which it was created.
61921297|NCT05152914|EXPERIMENTAL|Intervention|
61921298|NCT02206243||Embozene|Patients receiving Embozene microspheres
61921299|NCT05818111|EXPERIMENTAL|low volume hydrodilatation|patient received ultrasound-guided low volume steroid hydrodilatation (4cc shincort + 4cc 2% xylocaine +2cc normal saline)
61921300|NCT05818111|ACTIVE_COMPARATOR|high volume hydrodilatation|patient received ultrasound-guided high volume steroid hydrodilatation (4cc shincort + 4cc 2% xylocaine +12cc normal saline)
61921301|NCT02330809|EXPERIMENTAL|Daily extra water intake 2L|"Timing of daily extra water intake intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
62121395|NCT06182423|EXPERIMENTAL|STEPS-CI Intervention Group|Participants will engage in a behavioral intervention for chronic pain self-management that includes watching brief educational videos on a website and weekly sessions with a community health worker.
62121396|NCT06182423|NO_INTERVENTION|STEPS-CI Control Group|Members of the control group will not receive the STEPS-CI intervention. After completing the 8-week follow-up telephone survey, control group members will be invited to take part in a virtual workshop covering key STEPS-CI content and will receive program materials.
62121397|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
62121398|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
62121399|NCT06272162|EXPERIMENTAL|Intervention arm|Patients in the intervention arm will receive locally ablative stereotactic MRgRT in addition to standard of care, consisting of 5 times 10 Gy MR guided radiotherapy.
62680507|NCT04469530|NO_INTERVENTION|Historical Control Cohort Receiving Standard Therapy|This study arm is a historical control cohort of patients matched with cohort 1 on diagnosis, age, metastatic site, and date of diagnosis. The matched historical controls will be obtained from the same treating institution as the corresponding case to account for institutional differences in treatment and supportive care. Patients in the historical control cohort received standard therapy.
62309979|NCT04111367|EXPERIMENTAL|Genotype 2 and 6 Subjects|Genotype 2 and 6 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12
62309980|NCT04111367|EXPERIMENTAL|Genotype 3 Subjects|Genotype 3 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 24
62680508|NCT06081530|EXPERIMENTAL|Part A: BI 3802876 dose group 1|
62680509|NCT06081530|EXPERIMENTAL|Part A: BI 3802876 dose group 2|
62680510|NCT06081530|EXPERIMENTAL|Part A: BI 3802876 dose group 3|
62680511|NCT06081530|EXPERIMENTAL|Part A: BI 3802876 dose group 4|
62680512|NCT06081530|EXPERIMENTAL|Part A: BI 3802876 dose group 5|
62680513|NCT06081530|EXPERIMENTAL|Part A: BI 3802876 dose group 6|
62680514|NCT06081530|PLACEBO_COMPARATOR|Part A: Placebo|
62680515|NCT06081530|EXPERIMENTAL|Part B: BI 3802876|
62680516|NCT06081530|PLACEBO_COMPARATOR|Part B: Placebo|
62309981|NCT06335940||No videoregulation|"An initial period of 40 days during which we leave the use of video-regulation to the discretion of the regulating physicians (emergency physicians or general practitioners) when they are faced with a call labelled by a medical regulation assistant (ARM) Pediatric dyspnea in a child under 10 years of age or when they themselves judge that the call falls into this category; as is the case in the current practice of the SAMU38."
62309982|NCT06335940||Videoregulation|"A 40-day period during which we will encourage regulating physicians to use video-regulation for every call concerning pediatric dyspnea in a child aged \< 10 years."
62680517|NCT06002074|EXPERIMENTAL|Stress management and resilience training|Subjects will receive a 1.5 hour one-on-one stress management and resilience consult by a certified SMART trainer followed by 16 week self-guided on-line training.
62680518|NCT04818177||Normal Weight|Normal weight is defined as BMI 18.5 - 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.
62680519|NCT04818177||Overweight or Obese|Overweight or obese is defined as BMI \> 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.
61921302|NCT02330809|EXPERIMENTAL|Daily extra water intake 1L|"Timing of daily extra water intake Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
61921303|NCT02330809|EXPERIMENTAL|Daily extra water intake 500ml|"Timing of daily extra water intake Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals~Intervention-B: Drink extra water at anytime over 24 hours"
62121400|NCT06272162|NO_INTERVENTION|Control arm|Patients randomized to the control arm will continue standard of care as described without additional local treatment.
62680520|NCT05217966|EXPERIMENTAL|Preoperative radiotherapy for early breast cancer|Radiation: Single Pre-Operative Radiation Therapy
62680521|NCT06673199|EXPERIMENTAL|Washoku diet|Participants assigned to the washoku group will be introduced to the principles of a healthy eating plate, which will be supplemented with elements of the washoku diet (30 g of roasted black soybeans and 5 g of wakame).
62680522|NCT06673199|NO_INTERVENTION|Control group|Participants assigned to the control group will receive only dietary recommendations consistent with the healthy eating plate.
62680523|NCT03039985|EXPERIMENTAL|Bruxism + lithium disilicate crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
62121401|NCT02789917|EXPERIMENTAL|Dual therapy (incl. NOAC)|Apixaban plus Clopidogrel
62680524|NCT03039985|EXPERIMENTAL|No bruxism + lithium disilicate crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
62680525|NCT03039985|EXPERIMENTAL|Bruxism + zirconia crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia.
62680526|NCT03039985|EXPERIMENTAL|No bruxism + zirconia crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia.
62680527|NCT06602752|ACTIVE_COMPARATOR|Intervention|The Vegetables for All project will create FFZs in low-income urban and peri-urban areas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will link vendors and farmers through market facilitators, support the uptake of digital solutions for vendors to access vegetables, and support district governments to improve market infrastructure. To encourage BoP parents of children 3-9 years to buy and consume more vegetables, the program will include a demand generation component.
62680528|NCT06602752|NO_INTERVENTION|Control/No Intervention|An equal number of geographic areas with similar levels of urban city to the intervention FFZs will serve as the control.
62680529|NCT06686979||Observational cohort|The observational group of patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience. No intervention would be provided based on the drug sensitive test from patient-derived organoid.
62680530|NCT03599726|EXPERIMENTAL|Active study drug: Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
62121402|NCT02789917|ACTIVE_COMPARATOR|Triple therapy (incl. VKA)|Phrenprocoumon plus Clopidogrel plus ASA
62121403|NCT02014766|ACTIVE_COMPARATOR|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
62475990|NCT03598595|EXPERIMENTAL|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61921304|NCT02330809|EXPERIMENTAL|Daily extra water intake 120ml|"Timing of daily extra water intake Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
62475991|NCT04390256|ACTIVE_COMPARATOR|Egg shell powder nanoparticles|
62680531|NCT03599726|PLACEBO_COMPARATOR|Placebo study drug: Placebo|Placebo 5 mg per day for week 1-2 or 5-6
62680532|NCT05106764||Retrospective Database Analysis|Data from patient's hospital records of the last 10 years will be collected/extracted retrospectively using epidemiological methods to test the forecasting power of the algorithm.
62309983|NCT02359123|EXPERIMENTAL|Cannabics 5mg|Patients will be treated initially for 3-4 days with 1x5mg Cannabics capsules per day for gradual adaptation. From the 5th day, patients will be treated 2x5mg capsules per 24 hours for a period of 3 months. However, since some patients may suffer from side effects mainly, dizziness and or anxiety, dosage for these patients will be reduced to 5mg per day.
62680533|NCT05998642|EXPERIMENTAL|Methotrexate, Ibrutinib +/- Rituximab|Cycles 1-6, q14 days Day 1: Methotrexate + Rituximab Days 6-14: Ibrutinib daily orally
62680534|NCT06509074|EXPERIMENTAL|Beta-blockers|Beta-blockers with alpha or NO activity will be used. Dosage according to responsible physician and current clinical practice
62680535|NCT06509074|NO_INTERVENTION|No beta-blockers|No beta-blockers
61921305|NCT01658865||Transnasal endoscopy|Healthy volunteers and patients with esophageal motor symptom will be enrolled and esophageal motility assessed by transnasal endoscopy according to clinical and manometric diagnosis
62309984|NCT05074784|ACTIVE_COMPARATOR|Control Group|Tongue depressor exercise protocol for tongue strengthening for control group. Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
62475992|NCT04390256|EXPERIMENTAL|Clove water extract|
61921306|NCT03462290|EXPERIMENTAL|Botulinum toxin|
61921307|NCT03462290|PLACEBO_COMPARATOR|placebo|
61921308|NCT05088655|EXPERIMENTAL|Treatment group A: T - R- R|
61921309|NCT05088655|EXPERIMENTAL|Treatment group B: R -T - R|
61921310|NCT05088655|EXPERIMENTAL|Treatment group C: R- R-T|
61921311|NCT05866627|EXPERIMENTAL|Afimetoran, followed by famotidine + afimetoran|
61921312|NCT05866627|EXPERIMENTAL|Famotidine + afimetoran, followed by afimetoran|
62475993|NCT04390256|EXPERIMENTAL|Carbopol|
62475994|NCT04390256|EXPERIMENTAL|Carboxymethyle cellulose|
62475995|NCT01438853|EXPERIMENTAL|TNX-832|Anti-tissue factor antibody
62475996|NCT01438853|PLACEBO_COMPARATOR|Drug Placebo|Placebo control
62475997|NCT06027710||Prefabricated allogeneic bone blocks|Group A: horizontal and/or vertical augmentation of Puros® allogeneic bone graft material (Zimmer Biomet, Winterthur, Switzerland) in the upper and/or lower jaw; type: conventional prefabricated bone blocks.
62475998|NCT06027710||CAD/CAM custom milled allogeneic bone blocks|- Group B: horizontal and/or vertical augmentation of allogeneic bone replacement material Puros® (Zimmer Biomet, Winterthur, Switzerland) in the upper and/or lower jaw; type: individually planned, CAD/CAM custom-produced bone blocks
62475999|NCT06562738|EXPERIMENTAL|Experimental: Hetrombopag arm|Takes Hetrombopag 7.5 mg/day at bedtime for at most 14 days.
62495935|NCT06347627|EXPERIMENTAL|Group 11 (I x E x D x F)|"Participants in Group 11 will view a message in an X (former Twitter) format composed of Individual x Effectiveness x Scientific data x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62680536|NCT03137407|EXPERIMENTAL|DAXI 240 U|DaxibotulinumtoxinA for injection for the treatment of plantar fasciitis (PF) with 240 U
62680537|NCT03137407|PLACEBO_COMPARATOR|Placebo|Placebo Intramuscular Injection
62680538|NCT03390673|EXPERIMENTAL|HD204|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
62680539|NCT03390673|ACTIVE_COMPARATOR|EU-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
62680540|NCT03390673|ACTIVE_COMPARATOR|US-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
62680541|NCT05130463||Patients diagnosed with type 2 diabetes mellitus|
62680542|NCT06686355|EXPERIMENTAL|Yiqilishui group|Conventional Western medicine treatment + oral or nasogastric administration of Yiqilishui formula granules, twice daily;
62680543|NCT06686355|SHAM_COMPARATOR|placebo group|Conventional Western medicine treatment + oral or nasal feeding of Yiqilishui formula placebo , twice daily.
62680544|NCT03897010|ACTIVE_COMPARATOR|Silica-calcium phosphate composite Group|Participants underwent socket augmentation procedures and dental implant placement in a staged approach. Atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. Free gingival gingival graft (1.5 to 2 mm thick) was taken from the area between the first and second premolar, 5 mm from gingival margin. Bioactive porous SCPC dental bone graft granules in the size range 90-710 micron were mixed with saline and loosely packed in the extraction sockets as per the manufacturer. The grafted SCPC granules were covered with free gingival graft obtained from the palatal tissues and sutured to stabilize the grafting material in place.
62680545|NCT03897010|PLACEBO_COMPARATOR|Control Group|Participants underwent atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. The socket left to heal.
62309985|NCT05074784|EXPERIMENTAL|Intervention Group|IOPI exercise protocol for tongue strengthening for intervention group. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
62309986|NCT04334148|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.
62680546|NCT05443334||Participants with type 2 diabetes|Participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
62680547|NCT06695182||premature coronary artery disease|
62680548|NCT03294954|EXPERIMENTAL|GINAKIT cells|GINAKIT cells will be administer to patients with Neuroblastomas on Day 0.
62680549|NCT03294954|EXPERIMENTAL|Experimental: GINAKIT cells + Etanercept.|GINAKIT cells will be administer to patients with Neuroblastomas on Day 0 in combination of Etanercept.
62680550|NCT04295759|EXPERIMENTAL|Dose-finding|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
62309987|NCT04334148|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets
62309988|NCT02904564|EXPERIMENTAL|MMP with 5-FU infusion|MMP with 5-FU infusion using tattoo device
62680551|NCT04463979||Cerebellar Tumors|Thirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection.
61921313|NCT05866627|EXPERIMENTAL|Afimetoran|
61921314|NCT05866627|EXPERIMENTAL|Famotidine, followed by afimetoran|
62309989|NCT02904564|PLACEBO_COMPARATOR|MMP with saline infusion|MMP with saline infusion using tattoo device
62309990|NCT01750021|EXPERIMENTAL|High fat low carbohydrate diet|High fat low carbohydrate diet
62309991|NCT01750021|EXPERIMENTAL|Low fat high carbohydrate diet|Low fat high carbohydrate diet
62309992|NCT00942201|ACTIVE_COMPARATOR|Single dose dexamethasone|Single dose dexamethasone 0.6 mg/kg, rounded to nearest 2 mg, max 16 mg administered in ED
62309993|NCT00942201|ACTIVE_COMPARATOR|Two dose dexamethasone|First dose in ED, a prescription for second dose to be administered on Day 3 after discharge
62309994|NCT03827876|EXPERIMENTAL|Open Label Enstilar|once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
62309995|NCT05429515|EXPERIMENTAL|HFR-SUPRA|haemodiafiltration with ultrafiltrate regeneration by adsorption on resin (HFR-SUPRA) combined with chemotherapy. HFR-SUPRA everyday for 3 days, then 3 times per week.
62680552|NCT04463979||Brain Tumors|Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison.
62680553|NCT06686459|EXPERIMENTAL|ALL-in-one group|ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)
62680554|NCT06686459|PLACEBO_COMPARATOR|IMRT group|IMRT (breast + supraclavicular + internal mammary lymph node drainage area)
62680555|NCT06679660|EXPERIMENTAL|Inferior Alveoler Nerve Block|
62680556|NCT06679660|EXPERIMENTAL|Mental/Incisive Nerve Block|
62680557|NCT06087328|ACTIVE_COMPARATOR|Arm A|21mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
62680558|NCT06087328|ACTIVE_COMPARATOR|Arm B|21mg patch + 14mg patch qd + 4mg lozenge prn minimum of 5 \& \[up to 30 per day\]
61921315|NCT03784287|EXPERIMENTAL|AX 250|All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
61921316|NCT01837706||Emergency Room Patients|
62309996|NCT05429515|ACTIVE_COMPARATOR|Hemodialysis|hemodialysis combined with chemotherapy. Hemodialysis everyday for 3 days, then 3 times per week.
62680559|NCT06087328|ACTIVE_COMPARATOR|Arm C|2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
62738549|NCT03465137|NO_INTERVENTION|Waitlist|Participants randomized to the waitlist arm will receive no intervention for 12 weeks. After this 12 week period they will receive a the same weekly individual psychotherapy intervention as the immediate therapy group: Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
62738550|NCT01939977|EXPERIMENTAL|Paricalcitol|Paricalcitol oral capsules.
61921317|NCT04969003|ACTIVE_COMPARATOR|Transgender male (TM)|\~90-second video of depressed transgender male
61921318|NCT04969003|ACTIVE_COMPARATOR|Cis-gender male (CM)|\~90-second video of depressed cis-gender male
61921319|NCT04969003|ACTIVE_COMPARATOR|Transgender female (TF)|\~90-second video of depressed transgender female
61921320|NCT04969003|ACTIVE_COMPARATOR|Cis-gender female (CF)|\~90-second video of depressed cis-gender female
61921321|NCT00576212|EXPERIMENTAL|A|Subjects in the intervention group will receive supportive telephone calls biweekly for 6 months.
62309997|NCT01936246|EXPERIMENTAL|Increased protein|Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
62309998|NCT01936246|NO_INTERVENTION|Standard diet|Infants will be given a usual diet. If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
62309999|NCT03738124|EXPERIMENTAL|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA Thoracic Stent Graft System is administered.
62680560|NCT02595879|EXPERIMENTAL|Treatment (triapine, chemoradiation)|Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.
61921322|NCT00576212|NO_INTERVENTION|B|Subjects in the control group will receive no intervention.
61921323|NCT06195761|EXPERIMENTAL|computer guided modified ridge splitting technique (study group)|The first treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide.
61921324|NCT06195761|EXPERIMENTAL|conventional modified ridge splitting technique (control group)|The second treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide
62680561|NCT04573946|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|
62680562|NCT04573946|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|
62680563|NCT04573946|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|
62121404|NCT02014766|EXPERIMENTAL|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
62310000|NCT04795180|NO_INTERVENTION|Non-irrigations|No irrigations trough the efferent limb of loop ileostomy
61921325|NCT01277042|EXPERIMENTAL|Cervarix Group|Subjects received a 3-dose vaccination course of the Cervarix™ vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
61921326|NCT01277042|ACTIVE_COMPARATOR|Engerix Group|Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
62680564|NCT04573946|ACTIVE_COMPARATOR|Vitamin D + fish oil|
62680565|NCT05293314||Adult patients with bronchiectasis (BE)|Diagnosis of bronchiectasis was performed using chest HRCT scans in suspected patients with coughing and expectoration, or long durations of haemoptysis. High-resolution images were obtained during full inspiration at 1-mm collimation and 10-mm intervals from the apex to the base of the lungs. The presence of bronchiectasis was confirmed based on the following criteria: 1) lack of tapering in the bronchi; 2) dilation of the bronchi where the internal diameter was larger than that of the adjacent pulmonary artery; or 3) visualisation of the peripheral bronchi within 1 cm of the costal pleural surface or the adjacent mediastinal pleural surface.
61921327|NCT06551103|EXPERIMENTAL|Intervention group trained in line with the Health Promotion Model|A literature review was conducted by the researchers within the scope of Health Promotion Model and a educational material was prepared. With this educational material, the patients in the intervention group were trained in four sessions lasting 25 minutes each.
61921328|NCT06551103|NO_INTERVENTION|Control group|The control group was subjected to the clinic's standard procedures.
62121405|NCT06216730|OTHER|single arm cohort study|Since this is a single arm cohort study the outcomes will be descriptive
62121406|NCT06335446||Atrial tachycardia- validation phase|The group will consist of patients with AT (whether de novo or occurring post AF ablation) that are undergoing catheter ablation.
62310001|NCT04795180|EXPERIMENTAL|Butyrate irrigations|Butyrate irrigations trough the efferent limb of loop ileostomy
62310002|NCT04795180|SHAM_COMPARATOR|Saline irrigations|Saline irrigations trough the efferent limb of loop ileostomy
62310003|NCT01819961|EXPERIMENTAL|MCT/LCT|Structural Fat Emulsion Injection 250ml per day, for 7 days
62680566|NCT05293314||Healthy control group (HC)|Control group is healthy participants.
62121407|NCT01400776|EXPERIMENTAL|WC3011 Estradiol Vaginal Cream (2 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks, followed by dosing 2 times a week for 10 weeks.
62121408|NCT01400776|PLACEBO_COMPARATOR|Vehicle (2 Times/Week)|Vehicle applied daily for 2 weeks, followed by dosing 2 times a week for 10 weeks.
62310004|NCT01819961|EXPERIMENTAL|MCT/LCT and fish oil|Structural Fat Emulsion Injection 250ml and fish oil 100ml for 7 days.
62680567|NCT05293314||Unhealthy control group (UHC)|Patients with interstitial lung disease or patients with Sarcoidosis. Interstitial lung disease is a heterogeneous pulmonary disease characterized with lung fibrosis and manifest with breathlessness. Sarcoidosis is a systemic disease of unknown etiology characterized by the formation of granulomas in various organs, mostly involved is the lungs and intrathoracic lymph nodes .
62680568|NCT01433978|ACTIVE_COMPARATOR|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, once daily and allow to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
62680569|NCT01433978|ACTIVE_COMPARATOR|Eltrombopag (Core Study)|Eltrombopag will be administered orally as 25 mg, 50 mg, or 75 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 50 mg eltrombopag once daily and allow to have their dose titrated up (maximum dose of 75 mg eltrombopag) or down (minimum dose of 25 mg eltrombopag) depending on their response to study drug.
62680570|NCT01433978|EXPERIMENTAL|Avatrombopag (Open-label Extension)|Participants who meet the eligibility requirements for the Open-label Extension (OLE) Phase or who discontinue the Core Study early because of lack of treatment effect will be eligible to continue into the OLE Phase for up to 104 weeks of open-label avatrombopag therapy. Participants who enter the OLE from the Core Study will receive a starting dose of open-label avatrombopag which will be determined by the last dose of study drug at the End of Treatment (EOT) Visit (Visit 22) of the Core Study. Participants who discontinue the Core Study early because of lack of treatment effect and enter the OLE will receive open-label avatrombopag at a starting dose of 20 mg once daily of open-label avatrombopag.
62680571|NCT03266627|EXPERIMENTAL|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
62680572|NCT04042311|EXPERIMENTAL|High-Intensity interval training (workstream 1)|High-intensity interval training performed for 20 minutes, 3 times weekly for a period of 6 weeks at 85-100% of maximal heart rate.
62738551|NCT01939977|ACTIVE_COMPARATOR|Calcifediol|Calcifediol oral drops.
62680573|NCT04740918|ACTIVE_COMPARATOR|Arm A: Trastuzumab Emtansine and Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor.
62680574|NCT04740918|EXPERIMENTAL|Arm B: Trastuzumab Emtansine and Atezolizumab|Atezolizumab 1200 mg IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.
62680575|NCT05125627|EXPERIMENTAL|Treatment A|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)~Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator"
62680576|NCT05125627|ACTIVE_COMPARATOR|Treatment B|"Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)~Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator"
62680577|NCT05406570|ACTIVE_COMPARATOR|Standardized tidal volume|Ventilation with tidal volume 6 ml/kg
62680578|NCT05406570|EXPERIMENTAL|Personalized tidal volume|Ventilation with tidal volume aiming to minimize cardiopulmonary interactions as assessed by pulse pressure variation
62680579|NCT04887805|EXPERIMENTAL|Treatment (pembrolizumab, lenvatinib mesylate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib mesylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61921329|NCT04856475|EXPERIMENTAL|HER2 metastatic breast cancer locally pretreated for previous CNS events and currently progressive|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
61921330|NCT04856475|EXPERIMENTAL|HER2 positive metastatic breast cancer patients with newly diagnosed brain metastases|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
62680580|NCT02572687|EXPERIMENTAL|Ramucirumab + MEDI4736 (NSCLC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given intravenously (IV) every 3 weeks (q3w) of a 21 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q3w. Participants may continue to receive study treatment until discontinuation criteria are met."
62121409|NCT01400776|EXPERIMENTAL|WC3011 Estradiol Vaginal Cream (3 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks, followed by dosing 3 times a week for 10 weeks.
62310005|NCT02599389|NO_INTERVENTION|Standard balloon|Angioplasty with use of standard balloons
62680581|NCT02572687|EXPERIMENTAL|Ramucirumab + MEDI4736 (Gastric/GEJ)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV every 2 weeks (q2w) of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
62680582|NCT02572687|EXPERIMENTAL|Ramucirumab + MEDI4736 (HCC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV q2w of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
62680583|NCT01266057|EXPERIMENTAL|Hydroxychloroquine + Sirolimus|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Sirolimus starting dose of 2 mg by mouth every day for a 21 day cycle.
62680584|NCT01266057|EXPERIMENTAL|Hydroxychloroquine + Vorinostat|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Vorinostat starting dose of 200 mg by mouth per day for a 21 day cycle.
62680585|NCT01602458|OTHER|Silicone Only Therapy (SOT)|Mepiform™ silicone will be utilized by SOT group.
62680586|NCT01602458|OTHER|Silicone Pressure Garment Therapy (SPGT)|Mepiform™ silicone and custom compression garments fabricated by Barton Carey™ will be utilized by SPGT group.
62680587|NCT05249348|EXPERIMENTAL|Part 1 Sequence A|Period 1 will be fed, then washout, then Period 2 will be fasted.
62680588|NCT05249348|EXPERIMENTAL|Part 1 Sequence B|Period 1 will be fasted, then washout, then Period 2 will be fed.
62680589|NCT05249348|EXPERIMENTAL|Part 2 Sequence C|Period 1 will be fed, then washout, then Period 2 will be fasted. A different dose of PC14586 will be tested.
62680590|NCT05249348|EXPERIMENTAL|Part 2 Sequence D|Period 1 will be fasted, then washout, then Period 2 will be fed. A different dose of PC14586 will be tested.
62680591|NCT05249348|EXPERIMENTAL|Part 2 Japanese Cohort|6 Japanese participants will be administered a single dose of PC14586.
62680592|NCT02527265|EXPERIMENTAL|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
62680593|NCT05390320|EXPERIMENTAL|Periodontally accelerated osteogenic orthodontics|The patients in this group will be treated by periodontally accelerated osteogenic orthodontics using fixed appliances.
62680594|NCT05390320|ACTIVE_COMPARATOR|Conventional treatment|The patients in this group will be treated using fixed appliances and conventional treatment without any surgical intervention to accelerate tooth movement.
62495936|NCT06347627|EXPERIMENTAL|Group 12 (O x E x D x F)|"Participants in Group 12 will view a message in an X (former Twitter) format composed of Organization x Effectiveness x Scientific data x Factual factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62680595|NCT06109441|OTHER|ALTB-268|ALTB-268 IP will be administered via subcutaneous injection. One loading dose will be followed by 10 weekly doses of ALTB-268 in the 12 weeks induction study phase. Additional 20 biweekly doses of ALTB-268 will be administered in the 40 week maintenance study period.
62680596|NCT06694415||Control individuals below 20 years of age|blood sample with hormone dosages
62121410|NCT01400776|PLACEBO_COMPARATOR|Vehicle (3 Times/Week)|Vehicle applied daily for 2 weeks, followed by dosing 3 times a week for 10 weeks.
62495937|NCT06347627|EXPERIMENTAL|Group 13 (I x S x D x M)|"Participants in Group 13 will view a message in an X (former Twitter) format composed of Individual x Safety x Scientific data x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62680597|NCT06543589|NO_INTERVENTION|ARM A (CPAP group)|Infants randomized to the ARM A group will be stabilized on CPAP, according to the standard procedure of each participating center.
62680598|NCT06543589|EXPERIMENTAL|ARM B (HFNC group)|For infants randomly assigned to the ARM B group, the respiratory support will be provided by devices that deliver a blend of heated and humidified gas mixture of air and oxygen at gas flows exceeding 8 L/ min via binasal cannula.
62121411|NCT04705623|EXPERIMENTAL|Intervention|The intervention group receives weekly 90 minute yoga classes over a course of 12 weeks. They are also asked to do two 45-minute yoga classes at home each week and document these in a Diary.
62121412|NCT04705623|NO_INTERVENTION|Control|The control group receives an assessment of their biofunctional status at the beginning and the end of the study (same as the intervention group).
62121413|NCT04081792|EXPERIMENTAL|1. Trial (Amputation) Soft tissue - short antibiotic arm|The intervention group consists of 1 day of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
62121414|NCT04081792|ACTIVE_COMPARATOR|1. Trial (Amputation) Soft tissue - long antibiotic arm|The control group consists of 4 days duration of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
62121415|NCT04081792|EXPERIMENTAL|1. Trial (Amputation) Bone - short antibiotic arm|The intervention group consists of 1 week of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
62121416|NCT04081792|ACTIVE_COMPARATOR|1. Trial (Amputation) Bone - long antibiotic arm|The intervention group consists of 3 weeks of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
62310006|NCT02599389|EXPERIMENTAL|Drug-coated balloons|Angioplasty with use of drug-coated balloons
62738552|NCT04497363|EXPERIMENTAL|Focused Ultrasound|On the day of the ultrasound appointment, patients will undergo ten minutes of ultrasound targeting the anterior cingulate. The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
62121417|NCT04081792|EXPERIMENTAL|2.Trial (soft tissue infection) - short antibiotic arm|The intervention group consists of 10 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
62121418|NCT04081792|ACTIVE_COMPARATOR|2. Trial (soft tissue infection) - long antibiotic arm|The control group consists of 20 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
62310007|NCT02599389|EXPERIMENTAL|Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser
62310008|NCT02997124|EXPERIMENTAL|Local Infiltration with TAP block|Ultrasound guided Transversus Abdominis Plane block is administered intraoperatively using 0.2% Ropivacaine.
62310009|NCT02997124|EXPERIMENTAL|Local Infiltration only|Local Infiltration with 0.2% Ropivacaine.
62310010|NCT01363895|ACTIVE_COMPARATOR|Percutaneous closure of LAA|Percutaneous closure of LAA
62310011|NCT01363895|ACTIVE_COMPARATOR|Catheter ablation of AF|Catheter ablation of AF
62310012|NCT03715257|ACTIVE_COMPARATOR|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
62310013|NCT03715257|ACTIVE_COMPARATOR|Tube changing catheter|"Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
62310014|NCT06377995|PLACEBO_COMPARATOR|Placebo Comparator: Control group|"Participants in the control group first rate their pain from 0 to 10 using the Numerical Pain Scale, at rest and at the end of the available range of lateral flexion and rotation. The amplitude of these movements is then assessed using a Goniometer Pro© (G-pro©). This assessment takes 10 minutes.~After the initial assessment, the researcher performs the placebo technique, which lasts 12 minutes. Finally, the initial assessment is carried out again."
62310015|NCT06377995|EXPERIMENTAL|Experimental: Diaphragm protocol|"Participants in the experimental group first rate their pain from 0 to 10 using the Numerical Pain Scale, at rest and at the end of the available range of lateral flexion and rotation. The amplitude of these movements is then assessed using a Goniometer Pro© (G-pro©). This assessment takes 10 minutes.~After the initial assessment, the researcher performs the diaphragm stretching, neuromuscular and phrenic centre inhibition technique; this treatment protocol lasts 12 minutes.~Finally, the initial assessment is carried out again"
62680599|NCT05945355|EXPERIMENTAL|Active Low Dose inspiratory muscle rehabilitation (IMR) group|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
61921331|NCT04856475|EXPERIMENTAL|HER2 positive metastatic breast cancer patients with leptomeningeal carcinomatosis|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), contrast-enhanced neuraxis brain and spine MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. CSF cytological assessment should also be performed.~Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
61921332|NCT04421807|EXPERIMENTAL|Exercise+Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
61921333|NCT04421807|ACTIVE_COMPARATOR|Only Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
62121419|NCT04081792|EXPERIMENTAL|2. Trial (osteomyelitis) - short antibiotic arm|The intervention group consists of 3 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
62121420|NCT04081792|ACTIVE_COMPARATOR|2. Trial (osteomyelitis) - long antibiotic arm|The control group consists of 6 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
62121421|NCT01385891|EXPERIMENTAL|children with advanced leukemia|
62121422|NCT03881488|EXPERIMENTAL|Arm 1 Part 1 Dose Escalation|Escalating doses of CTX-471 depending on cohort at enrollment
62121423|NCT03881488|EXPERIMENTAL|Arm 1 Part 2 Dose Expansion|Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)
61921334|NCT05341388||Patients with type 2 diabetes-SGLT2 inh|patients with type 2 diabetes who were recently prescribed an SGLT2 inhibitor
62121424|NCT03881488|EXPERIMENTAL|Arm 2 Part 1 Dose Escalation|Escalating doses of CTX-471 in combination with pembrolizumab (KEYTRUDA® ) depending on cohort at enrollment
62121425|NCT03881488|EXPERIMENTAL|Arm 2 Part 2 Dose Expansion|Two cohorts of CTX-471 (0.3 mg/kg and 0.6 mg/kg) in combination with pembrolizumab (KEYTRUDA® ) (400 mg) in three tumor type subgroups. Cohort 1 - Group 1A - NSCLC , Group 1B -SCLC and Group 1C - Melanoma. Cohort 2 Group 2A - NSCLC, Group 2B - SCLC and Group 2C -Melanoma.
62121426|NCT06306378||ASD group|Diagnosed as ASD based on DSM-V diagnostic criteria and combined with clinical manifestations.
62121427|NCT06306378||Control group|Healthy children
62680600|NCT05945355|EXPERIMENTAL|Active High Dose inspiratory muscle rehabilitation (IMR) group|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
62680601|NCT05945355|ACTIVE_COMPARATOR|SHAM|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
62680602|NCT03865706|EXPERIMENTAL|Inulin 32 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (16g twice daily) for a minimum of 7 days.
62680603|NCT03865706|EXPERIMENTAL|Inulin 16 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (8g twice daily) for a minimum of 7 days.
62680604|NCT03865706|PLACEBO_COMPARATOR|Placebo|Critically ill adults who are receiving broad-spectrum antibiotics will also receive placebo oral suspension for a minimum of 7 days.
62680605|NCT06584409|EXPERIMENTAL|Laser treatment|CM patients with unsatisfactory pharmacological effects receive laser acupuncture for 8 sessions that spanned 4 weeks. Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
62680606|NCT06584409|SHAM_COMPARATOR|Sham treatment|CM patients with unsatisfactory pharmacological effects receive sham treatment for 8 sessions that spanned 4 weeks. Sham treatment had no laser output.
62680607|NCT06687018|EXPERIMENTAL|Kaltenborn mobilisation|Kaltenborn mobilisation along with conventional treatment.
61921335|NCT05341388||Patients with type 2 diabetes-control|patients with type 2 diabetes who were recently prescribed a pre-defined antidiabetic medication other than SGLT2 inhibitors
62121428|NCT02180945||Intracranial Dural Arteriovenous Fistula|Adult patients requiring endovascular treatment of Intracranial Dural Arteriovenous Fistulae.
62121429|NCT04019873||Subjects receiving 2DR treatment|Data will be collected from HIV positive male or female adult subjects who have started 2DR with an integrase inhibitor plus a reverse transcriptase inhibitor from 2014.
62680608|NCT06687018|ACTIVE_COMPARATOR|Mulligan mobilisation|Mulligan mobilisation along with conventional treatment.
62680609|NCT05896124|EXPERIMENTAL|2mg CS0159|QD for 12 weeks
62680610|NCT05896124|EXPERIMENTAL|4mg CS0159|QD for 12 weeks
62680611|NCT05896124|EXPERIMENTAL|Placebo|QD for 12 weeks
61921336|NCT01066442|EXPERIMENTAL|BF2.649 ( Pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
62121430|NCT01568918|EXPERIMENTAL|Tamsulosin|Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
62121431|NCT01568918|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.
62680612|NCT02276833|EXPERIMENTAL|Single patient group with qualifying OA|intra-articular space injection of SVF Single patient group with pre-operative and post-operative assessments
62680613|NCT01568697||Healthy Volunteers|Healthy volunteers (with/without periodontal disease)
62680614|NCT01568697||Immune deficient patients|Subjects with known genetic immune deficiency
62680615|NCT01568697||Subjects with severe periodontitis of suspected genetic etiology and their family|Subjects with severe periodontitis of suspected genetic etiology and their family members
62680616|NCT00634855||Complicated|Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
62680617|NCT00634855||Normal|Women with normal pregnancies
62680618|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
62680619|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
62680620|NCT02100644|EXPERIMENTAL|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
62680621|NCT01366404||FFR|Patients who had FFR measurement
61921337|NCT01066442|PLACEBO_COMPARATOR|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
61921338|NCT01662414|ACTIVE_COMPARATOR|HMS 90®|
61921339|NCT01662414|PLACEBO_COMPARATOR|Placebo (Soy protein)|
62121432|NCT01711710|EXPERIMENTAL|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant
62121433|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
62121434|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
62121435|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
62121436|NCT00837746||1|Women taking risedronate for 5 years
62121437|NCT03901937|PLACEBO_COMPARATOR|Placebo|parenteral nutrition without ω-3 polyunsaturated fatty acid
62121438|NCT03901937|EXPERIMENTAL|ω-3 fatty acid|parenteral nutrition with ω-3 polyunsaturated fatty acid
62310016|NCT01821677|EXPERIMENTAL|Low Dose Danazol|Capsules, 0.5 mg/BMI Danazol with dose determined by subject's BMI at baseline, 2 capsules (5 mg, 7.5 mg, or 10 mg) twice daily, for 12 weeks.
62310017|NCT01821677|EXPERIMENTAL|High Dose Danazol|Capsules, 1.0 mg/BMI Danazol with dose determined by subject's BMI at baseline, 2 capsules (5 mg, 7.5 mg, or 10 mg) twice daily, for 12 weeks.
62310018|NCT01821677|PLACEBO_COMPARATOR|Placebo|Gelatin capsules, identical in appearance to the active capsules, filled with pharmaceutical grade lactose and magnesium stearate.
61921340|NCT00494845|EXPERIMENTAL|Intervention|8-week Mindfulness Program for chronic low back pain
62310019|NCT05418361||ACEIs group|Patients suffer from cardiovascular diseases)controlled hypertension or heart failure ) taking ACE inhibitors
62310020|NCT05418361||ARBs group|Patients suffer from cardiovascular diseases)controlled hypertension or heart failure ) taking Angiotensin receptor blockers
62310021|NCT05418361||healthy|matched healthy controls
62121439|NCT04614636|EXPERIMENTAL|FT538 Monotherapy|FT538 monotherapy in subjects with r/r AML
62310022|NCT05066893|ACTIVE_COMPARATOR|standard of care|standard of care will be given as per usual care
62310023|NCT05066893|EXPERIMENTAL|intensive monitoring|intensive monitoring every week will be given to participants
62310024|NCT03901183|EXPERIMENTAL|Interventional|Participants receive a 8 week nutritional counseling with weekly group meetings to establish a plant-based diet.
62310025|NCT03901183|NO_INTERVENTION|Control|Waiting list. Participants receive no intervention during study period, equal intervention is offered after the end of study.
62310026|NCT05796089|EXPERIMENTAL|Treatment|Participants will receive Durvalumab concurrently with chemotherapy (etoposide with carboplatin or cisplatin) for 4 cycles.
62310027|NCT00997685|EXPERIMENTAL|Capecitabine plus oxaliplatin，mCRC|
62476000|NCT02473718|EXPERIMENTAL|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
61921341|NCT00494845|ACTIVE_COMPARATOR|Comparison|8-week health education program
62121440|NCT04614636|EXPERIMENTAL|FT538 in Combination with Daratumumab|FT538 in combination with daratumumab in subjects with r/r MM
62310028|NCT05275829||Control group: Face-to-Face learning of simple interrupted suturing|"* The students watched a video demonstrating simple interrupted suturing, with the instructor commenting on the steps.~* The students then watched the video again.~* The instructor then demonstrated the procedure for the students.~* The students then practiced suturing with immediate and specific feedback provided by the instructor until he and the students were satisfied with the performance."
62310029|NCT05275829||Study group: Distance learning (tele simulation) of simple interrupted suturing|"* The instructor ran the interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform). The students used their personal smartphones or laptops with audio-video capabilities. The instructor ran the session through his smartphone.~* The instructor shared a video demonstrating simple interrupted suturing while commenting on the steps (the same video used in the control group).~* The instructor then ran the video again for the students.~* The instructor then demonstrated the skill for the students by turning on his camera.~* The students then practiced suturing, and periodically turned on their cameras to receive live and specific feedback from the instructor on their performance, until the instructor and the students were satisfied.~* No face-to-face interactions between the students and the instructor."
62310030|NCT05065424|EXPERIMENTAL|IV Atropine and Fentanyl Premedication Arm|Participants will receive premedication regimen of 20 micrograms/kilogram intravenous atropine and 0.5 micrograms/kilogram intravenous fentanyl prior to performance of LISA.
62310031|NCT05065424|PLACEBO_COMPARATOR|IV Normal Saline Placebo Arm|Participants will receive two intravenous Normal Saline infusions in quantities equivalent to the calculated volumes of atropine and fentanyl for participant's weight prior to performance of LISA.
62476001|NCT02473718|NO_INTERVENTION|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
61921342|NCT03878186|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT). Participants will receive the usual care and 6 sessions of cognitive behavioral therapy
61921343|NCT03878186|OTHER|Usual Care (UC)|Participants will receive Usual Care only
61921344|NCT02116218|EXPERIMENTAL|acupuncture|Experimental group would receive acupuncture at specific acupoints for 15 minutes.
62121441|NCT04614636|EXPERIMENTAL|FT538 in Combination with Elotuzumab|FT538 in combination with elotuzumab in subjects with r/r MM
62121442|NCT03567369|EXPERIMENTAL|Dexamethasone|Dexamethasone 4,0 mg / mL
62121443|NCT03567369|EXPERIMENTAL|Traumeel S|Traumeel 2,2 mg / mL
61921345|NCT02116218|SHAM_COMPARATOR|seed|Control group would receive another intervention that we would put Vaccaria seeds near the acupoints but without acupressure for the same period.
61921346|NCT04337385|EXPERIMENTAL|3 hours of Prolonged Sitting|Participants will sit continuously for three hours before receiving a mixed meal challenge.
61921347|NCT04337385|EXPERIMENTAL|3 hours of interrupted sitting with hourly HIIE|Participants will have their three hour sitting period interrupted with high intensity interval cycling exercise (HIIE) at 30, 90 and 150 minutes into the intervention. In each exercise bout, they will cycle at 90% peak power for 3 x 60 second periods with 75 seconds of recovery in-between.
62121444|NCT02432131||Divers with PFO|
62121445|NCT02432131||Divers without PFO|
61921348|NCT03431103|OTHER|After home exercise program|"Patients will be instructed to use the Wii Fit for 20 minutes at least twice a week for 12 weeks using specific Wii Fit exercises while on the Wii pressure sensor floor mat. The Wii Fit exercises will be as follows: 1. Basic Run (warm-up exercise by walking in place); 2.Bird's Eye, Bull's-Eye (mostly arms, requires arm flipping); 3.Free Step (lower extremity exercise); 4.Hula Hoop (gyration exercise)"
62680622|NCT05810038|EXPERIMENTAL|DBT Rimegepant/OLE Rimegepant|"DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of rimegepant orally disintegrating tablet (ODT) EOD for 12 weeks.~OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (as needed \[PRN\] dosing)."
62121446|NCT02427269||Barrett's Esophagus (BE) Surveillance|Patients who have never received ablative therapy for Barrett's Esophagus and are receiving routine care surveillance upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
62121447|NCT02427269||Barrett's Esophagus (BE) Pre-Ablation|Patients who are receiving routine care upper endoscopy with ablative therapy for their Barrett's Esophagus for the first time. Subjects will have esophageal biopsies, blood, and data collected for this study.
62680623|NCT05810038|PLACEBO_COMPARATOR|DBT Placebo/OLE Rimegepant|"DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of placebo matching to rimegepant ODT EOD for 12 weeks.~OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (PRN dosing)."
62680624|NCT05297019|EXPERIMENTAL|Arm 1: Mild pressure HBOT|"Mild pressure HBOT: 100% O2 @ 4.2 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
62680625|NCT05297019|EXPERIMENTAL|Arm 2: High pressure HBOT|"High pressure HBOT: 100% O2 @ 14 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
62680626|NCT05297019|EXPERIMENTAL|Arm 3: Crossover Arm|Patients will have 3 months of no treatment, and then be randomized to receive either high pressure or mild pressure HBOT
61921349|NCT00924417|EXPERIMENTAL|Distraction|"Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement."
61921350|NCT00924417|OTHER|Routine care|Patient managed as routine care.
61921351|NCT04610164|EXPERIMENTAL|Group 1: TXA group|Patient will receive 1 gram intravenous TXA prior to surgery
61921352|NCT04610164|NO_INTERVENTION|Group 2: Control Group|Patient will not receive TXA prior to surgery
61921353|NCT02316873|EXPERIMENTAL|Music training|twice a week one hour for 30 weeks, music training
62121448|NCT02427269||Barrett's Esophagus (BE) Post-Ablation|Patients with a history of Barrett's Esophagus who are status post ablation and are receiving routine care follow-up EGD for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
62121449|NCT02427269||Esophageal Cancer(ECA/IMC)|Patients with esophageal cancer who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
62121450|NCT02427269||Squamous Cell Carcinoma (SCC)|Patients with squamous cell cancer of the esophagus who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
61921354|NCT02316873|ACTIVE_COMPARATOR|Visual arts|twice a week one hour for 30 weeks, visual arts training
61921355|NCT03260439|OTHER|G1 (group BT)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Tramadol
62680627|NCT06565936|EXPERIMENTAL|Recurrent depression patients group|Evaluation of neuroinflammation and cerebral metabolism in the prefrontal cortex, anterior cingulate cortex, insula, and other brain regions of interest in patients with recurrent depression.
62310032|NCT03709433|EXPERIMENTAL|ACT groups and mobile app|Participants will receive six two-hour weekly sessions of acceptance and commitment therapy (ACT) in a group format. They will also access the ACT Daily mobile app, which helps participants practice ACT skills in the moment, for the duration of the study (10-14 weeks depending on when the participant completes the baseline assessment.) Sessions use metaphors, experiential exercises, and discussion to target core ACT skills: acceptance, defusion, present-moment awareness, self-as-context, values, and committed action. The mobile app includes metaphors and experiential exercises to aid with all of these skills except self-as-context. Participants will be asked to use the app to practice these skills and to complete behavioral commitments linked to their values between sessions.
62310033|NCT00679562|EXPERIMENTAL|1|
62121451|NCT05094050|EXPERIMENTAL|Arm 1: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the abdomen (Period 1), flank (Period 2), arm (Period 3) and thigh (Period 4).
62310034|NCT00679562|PLACEBO_COMPARATOR|2|
62310035|NCT04154982|EXPERIMENTAL|Pharmacological treatment|Patients are treated with NAC prior to carrying out CAP.
61921356|NCT03260439|OTHER|G2 (group B or control)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Placebo
62680628|NCT06565936|EXPERIMENTAL|First-episode depression patients group|Evaluation of neuroinflammation and cerebral metabolism in the prefrontal cortex, anterior cingulate cortex, insula, and other brain regions of interest in patients with first episode depression.
61921357|NCT03149393|EXPERIMENTAL|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
61921358|NCT03149393|ACTIVE_COMPARATOR|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
62121452|NCT05094050|EXPERIMENTAL|Arm 2: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the arm (Period 1), abdomen (Period 2), thigh (Period 3) and flank (Period 4).
62121453|NCT05094050|EXPERIMENTAL|Arm 3: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the thigh (Period 1), arm (Period 2), flank (Period 3) and abdomen (Period 4).
62121454|NCT05094050|EXPERIMENTAL|Arm 4: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the flank (Period 1), thigh (Period 2), abdomen (Period 3) and arm (Period 4).
62121455|NCT01077934||Injured Extremity without compartment syndrome|
62121456|NCT01077934||Injured extremity with compartment syndrome|
62121457|NCT06345495|EXPERIMENTAL|Ruxolitinib and Allogeneic Stem Cell Transplantation|Participants will be asked to receive study drugs and a stem cell transplant and attend study visits, at which various tests and procedures will be performed. Participants are expected to receive treatment for about 100 days, followed by a year of follow-up.
62121458|NCT05500807|OTHER|Open Label Emicizumab|Emicizumab prophylaxis
62121459|NCT06318104|ACTIVE_COMPARATOR|Tegoprazan Group|Tegoprazan 50 mg BID for 14 days, amoxicillin 1gr BID for 14 days, clarithromycin 500 mg BID for 14 days
62310036|NCT04154982|NO_INTERVENTION|Standard procedure|Patients are not treated with NAC. No placebo treatment is performed.
62680629|NCT06565936|OTHER|Healthy controls group|Evaluation of neuroinflammation and cerebral metabolism in the prefrontal cortex, anterior cingulate cortex, insula, and other brain regions of interest in healthy controls.
62121460|NCT06318104|ACTIVE_COMPARATOR|Esomeprazole Group|Esomeprazole 40 mg BID for 14 days, amoxicillin 1gr BID for 14 days, clarithromycin 500 mg BID for 14 days
62121461|NCT02329457|EXPERIMENTAL|ID varicella zoster vaccine (VZVv) group|intradermal 0.65 mL Zostavax
62310037|NCT01836601|NO_INTERVENTION|Pre-nighttime communication intervention arm|This arm is the pre-intervention arm of parents, nurses, and residents before the nighttime communication bundle has been enacted.
62310038|NCT01836601|EXPERIMENTAL|Post-nighttime communication intervention arm|This arm is the post-intervention arm of parents, nurses, and residents after the nighttime communication bundle has been enacted.
62310039|NCT05807828|OTHER|Control Group|This group will include medical students who will only watch instructional videos on basic THA skills on the cup and stem implantation before actual implantation on sawbones
62680630|NCT03975647|EXPERIMENTAL|Tucatinib + T-DM1|Tucatinib + T-DM1
62680631|NCT03975647|ACTIVE_COMPARATOR|Placebo + T-DM1|Placebo + T-DM1
61921359|NCT02313454|EXPERIMENTAL|Intranasal Application|Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
62121462|NCT02329457|ACTIVE_COMPARATOR|SC VZVv group|subcutaneous 0.65 mL Zostavax
62121463|NCT02329457|PLACEBO_COMPARATOR|ID NS Group|intradermal 0.65 mL normal saline
62121464|NCT02329457|PLACEBO_COMPARATOR|SC NS Group|subcutaneous 0.65 mL normal saline
62121465|NCT02218502|OTHER|If simple rules are conclusive|All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
62310040|NCT05807828|OTHER|VR Group|This group will include medical students who will watch instructional videos and perform three consecutive VR sessions on basic THA skills on the cup and stem implantation before actual implantation on sawbones
61921360|NCT02313454|SHAM_COMPARATOR|Extranasal Application|Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
62121466|NCT02218502|OTHER|If simple rules are inconclusive|If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
62121467|NCT00783354|ACTIVE_COMPARATOR|Continuous Treatment|
61921361|NCT04064567|ACTIVE_COMPARATOR|Enhanced Standard of Care|PrEP education and referral to a community-based PrEP provider (enhanced standard of care)
62121468|NCT00783354|EXPERIMENTAL|PRN regimen|
62121469|NCT05619016|EXPERIMENTAL|Patients with HER2 positive GEAC or HER2 low cancer (pilot)|"The participants of the study will undergo two sessions of HER2 PET and one 18F-FDG PET/CT for study purposes. The first HER2 PET is performed within 21 days before initiation of the systemic oncological treatment including HER2-targeted drugs, and is followed by tumor biopsies. A second HER2 PET and a second 18F-FDG PET will be performed adjacent to response evaluation after 3 courses of oncological therapy. Data from the PET investigations will be compared to HER2 expression analyses of the biopsy specimen and correlated to disease and survival data at follow up one year after inclusion.~Within the pilot study, participants with HER2 low mBC will undergo one HER2 PET followed by biopsies."
62121470|NCT02886637||Acinetobacter baumannii infection|Critically ill patients infect with Acinetobacter baumannii
62121471|NCT05956626|EXPERIMENTAL|Experimental: Phase1 Dose Escalation- Low Dose (3.75×10E10 vg/mL):|Low Dose (3.75×10E10 vg/mL): Subjects will receive a subretinal injection of 200 µL of OCU410ST in the low dose concentration.
62121472|NCT05956626|EXPERIMENTAL|Experimental: Phase1 Dose Escalation- Medium Dose (7.5×10E10 vg/mL):|Medium Dose (7.5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410ST in the Medium dose concentration.
62121473|NCT05956626|EXPERIMENTAL|Experimental: Phase1 Dose Escalation- High Dose (2.25×10E11 vg/mL):|High Dose (2.25×10E11 vg/mL): Subjects will receive a subretinal injection of OCU410ST in the high dose concentration.
62121474|NCT05956626|EXPERIMENTAL|Experimental: Phase 2 Dose Expansion: Dose 1 from Phase 1-Randomized Adult Arm|Subjects will receive a subretinal injection of OCU410ST with Maximum tolerated dose (MTD) from Phase 1.
62121475|NCT05956626|EXPERIMENTAL|Experimental: Phase 2 Dose Expansion: Dose 1 from Phase 1-Randomized Pediatric Arm|Subjects will receive a subretinal injection of OCU410ST with Maximum tolerated dose (MTD) from Phase 1.
62680632|NCT04666155|EXPERIMENTAL|Intermittent Colon Exoperistalsis (ICE)|Intermittent Colon Exoperistalsis (ICE) Treatment with Mowoot device. 20min daily for 12 weeks
62680633|NCT04666155|ACTIVE_COMPARATOR|Standard-of-care with Trans-anal Irrigation (Soc TAI)|Standard-of-care with Trans-anal Irrigation (Soc TAI) for chronic constipation for 12 weeks.
62121476|NCT05956626|EXPERIMENTAL|Experimental: Phase 2 Dose Expansion: Dose 2 from Phase 1-Randomized Adult Arm|Subjects will receive a subretinal injection of OCU410ST with Lower Dose than Maximum tolerated dose (MTD) from Phase 1
62121477|NCT05956626|EXPERIMENTAL|Experimental: Phase 2 Dose Expansion: Dose 2 from Phase 1-Randomized Pediatric Arm|Subjects will receive a subretinal injection of OCU410ST with Lower Dose than Maximum tolerated dose (MTD) from Phase 1
62121478|NCT05956626|NO_INTERVENTION|No Intervention- Randomized Control Adult Arm|No Intervention Control Arm: Subject will not receive any active study intervention
61921362|NCT04064567|EXPERIMENTAL|Community Health Worker Involved Enhanced Standard of Care|PrEP education, referral to a community-based PrEP provider, and referral to a CHW who will facilitate access to community-based PrEP and other healthcare and social-support services.
61921363|NCT06072027|EXPERIMENTAL|cytology|classical cytology will be done, in parallel of VISIOCYT cytology, in order to be compared
62121479|NCT05956626|NO_INTERVENTION|No Intervention- Randomized Control Pediatric Arm|No Intervention Control Arm: Subject will not receive any active study intervention
62121480|NCT04510454|EXPERIMENTAL|RT-PCR and ddPCR sampling analyses|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
62310041|NCT05975307|EXPERIMENTAL|Toripalimab plus chemoradiation|This study has only single arm in which the patients will receive induction chemotherapy plus anti-PD-1 therapy (toripalimab), followed by radiotherapy plus concurrent anti-PD-1 therapy
61921364|NCT06489379|ACTIVE_COMPARATOR|standard oxygen|
61921365|NCT06489379|EXPERIMENTAL|high flow nasal oxygen|
61921366|NCT03412071|NO_INTERVENTION|Control group|25 HIV-uninfected, uncircumcised men will be immediately circumcised following enrollment. This group will serve as the comparison to the four intervention groups.
61921367|NCT03412071|ACTIVE_COMPARATOR|Oral tinidazole group|25 HIV-uninfected, uncircumcised men will be randomized to receive oral tinidazole 2g once a day for two days.
61921368|NCT03412071|ACTIVE_COMPARATOR|Topical metronidazole (0.75%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 0.75% metronidazole cream to the foreskin twice a day for one week, and then twice a week for three weeks.
61921369|NCT03412071|ACTIVE_COMPARATOR|Topical clindamycin (2%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 2% clindamycin cream to the foreskin twice a day for one week, and then twice a week for three weeks.
61921370|NCT03412071|ACTIVE_COMPARATOR|Topical hydrogen peroxide (1%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply 1% hydrogen peroxide cream to the foreskin twice a day for one week, and then twice a week for three weeks.
61921371|NCT01486485|EXPERIMENTAL|heparinized saline priming group|Experimental group : heparinized saline priming group
61921372|NCT01486485|ACTIVE_COMPARATOR|nafamostat infusion group after heparinized saline priming|active comparator : nafamostat infusion group after heparinized saline priming
61921373|NCT05969418||Patients with neovascular macular degeneration|
61921374|NCT05969418||healty patients matched age and sex without any ocular disease|
62310042|NCT02040246|EXPERIMENTAL|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
61921375|NCT00596362|EXPERIMENTAL|1|AVASTIN
62310043|NCT02040246|ACTIVE_COMPARATOR|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
62310044|NCT00919022||Group 1|
62310045|NCT06449261|EXPERIMENTAL|Group receives C5-C6 and thoracic spine mobilization with postural correction|The patient will be made to lie in a prone position with the therapist beside her/his height- adjusted couch. Then the therapist who is certified to provide manual therapy will impart grade III+ posterior-to-anterior mobilization/lateral glide according to Maitland class cation focused on the cervical spine, C5-6 segment for 3 bouts of 30 seconds/2 days in a week for 3 weeks. Followed by the patient will be permitted to rest for a few minutes less than 10 minutes before starting the thoracic mobilisation. Thoracic mobilisation will be administered both at central and unilateral postero-anterior passive accessory intervertebral motions (PAIVMs) based on manual therapy evaluation at the thoracic spine.
62680634|NCT03012152|ACTIVE_COMPARATOR|Standard conservative group|"Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .~."
61921376|NCT04204785|NO_INTERVENTION|Pre-Education|Patient and Anesthesiologist participants completing surveys prior to OR staff education sessions.
61921377|NCT04204785|EXPERIMENTAL|Post-Education|Patient and Anesthesiologist participants completing surveys after OR staff education sessions.
62121481|NCT06199323|EXPERIMENTAL|routine treatment+swallowing rehabilitation training+acupuncture therapy|The experimental group was given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given acupuncture therapy.
62121482|NCT06199323|ACTIVE_COMPARATOR|routine treatment+swallowing rehabilitation training|The control group was given routine treatment and swallowing rehabilitation training.
62121483|NCT05755100|OTHER|Pilot study of I MOVE!+UP among Veterans with PTSD and BMI of 30 or greater.|Single arm pilot trial.
62121484|NCT06375668|ACTIVE_COMPARATOR|Probiotic|A dietary supplement in the form of capsules containing probiotic bacterial strains.
62121485|NCT06375668|PLACEBO_COMPARATOR|Placebo|Placebo capsules with the same appearance and weight as probiotic capsules.
62121486|NCT03178292|ACTIVE_COMPARATOR|Levofloxacin|Levofloxacin 500 mg daily for 5 days
62121487|NCT03178292|PLACEBO_COMPARATOR|Placebo|Placebo tab daily for 5 days
62121488|NCT02048592|ACTIVE_COMPARATOR|Impact-Nutridrink|The first arm will be given immunonutrition -Impact- for 8 weeks, afterwards the patients will return to their previous nutrition support for another 8 weeks. We expect the improvement of oxidative stress parameters after 8 weeks of immunonutriton and return to baseline values when immunonutrition is stopped
62121489|NCT02048592|ACTIVE_COMPARATOR|Nutridrink-Impact|The second group will be given their previous nutrition support (Nutridrink) for 8 weeks, afterwards the patients will be switched to immunonutrition- Impact- for another 8 weeks. In this group of patients we do not expect any change of oxidative stress parameters after the first 8 weeks. The improvement is expected at the end of the second half of study.
62121490|NCT05143658|ACTIVE_COMPARATOR|Laparoscopic Lateral Suspension Group (LLS)|Anterior and apical prolapse repair via LLS
62121491|NCT05143658|EXPERIMENTAL|Laparoscopic Pectopexy (LP)|Anterior and apical prolapse repair via LP
62121492|NCT05579106||Covid-19 patients|Mechanically ventilated and sedated adult patients with proven COVID-19 infection by PCR of nose- or airway sample. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.
62121493|NCT05579106||non-COVID-19 patients|Mechanically ventilated and sedated adult patients not infected with COVID-19 infection. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.
62121494|NCT01535833|OTHER|Robotic sacral colpopexy|To assess subjects with stage 2 pelvic organ prolapse undergoing robotic sacral colpopex
62121495|NCT02541188||breast cancer in young women is in the Maghreb|breast cancer in young women (\< 40years old) is in the Maghreb
62121496|NCT02541188||Breast cancer in young women in the western countries|Breast cancer in young women (\< 40years old) in the western countries
62121497|NCT02306577||Vancouver|HIV infected people who are current of recent illicit drug users and receive Stribild for their HIV treatment at Vancouver Infectious Diseases Centre and Regina General Hospital.
62121498|NCT01870479|EXPERIMENTAL|Live music|Patient preferred live music during chemotherapy session.
62121499|NCT01870479|ACTIVE_COMPARATOR|Taped music|Patient preferred taped music during chemotherapy
62121500|NCT01870479|NO_INTERVENTION|Control|Usual care during chemotherapy
62121501|NCT06675994||Healthy|Participants (approximately 40) 18-50 years old male and female without any major medical conditions or taking any agents or food supplements that may influence platelet function as determined by the study principal investigator.
62121502|NCT06675994||Cardiovascular Risk Factor|Participants (approximately 40) 18-50 years old male and female with at least three of the following risk factors: history of hypercholesterolemia, hypertension, overweight, current smoker, prediabetes or diabetes who are only on metformin and insulin, and a family history of coronary artery, peripheral artery, or cerebrovascular disease.
62121503|NCT00495417|ACTIVE_COMPARATOR|1|
62121504|NCT00495417|ACTIVE_COMPARATOR|2|
62121505|NCT05019417|EXPERIMENTAL|Glycerol phenylbutyrate treatment|"Name of the Investigational Medicinal product: Glycerol phenylbutyrate \[GPB\] (Ravicti oral liquid 1.1 gr/1 ml; manufacturer Horizon Pharma USA).~Dosage of GPB will follow the dosage in use for children with urea cycle disorder.~Initial dose: 5.0 gr (4.5 ml)/ meter square divided by three time a day. An escalating schedule dose of GPB will be used until normal serum T3 levels are reached.~Initial dose: 5 gr/square meter body surface area (BSA). Second visit: 10 gr/square meter BSA~The dose raising will be stopped if one of the following condition is reaches:~1. Clinically significant side effects~2. Reaching the PAA serum toxic threshold of 500 µg/ml~3. Reaching the maximal dose of GPB that is in use in urea cycle disorder: 12.4 gr (11.2 ml)/ meter square BSA divided by three times a day.~Duration of study: 4 months"
62121506|NCT02384577||Single group prospective treatment|
62121507|NCT06212141|ACTIVE_COMPARATOR|VisCalor Bulk|Thermoviscous Bulkfill composite resin Warming of the material makes it flowable for the application and then sculptable immediately afterwards (thermoviscous technology) Optimal flowing to margins and undercut regions One universal and three aesthetic shades Cannula form
62680635|NCT03012152|ACTIVE_COMPARATOR|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
62680636|NCT06064526||Group 1|The source population for this study is adult participants with severe asthma treated with dupilumab in routine clinical practice in the UK.
62680637|NCT03620981|EXPERIMENTAL|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
62121508|NCT06212141|ACTIVE_COMPARATOR|Admira Fusion x-tra|"Ormocer based bulkfill composite Purely ceramic-based, bulk fill restorative material Reliable curing of 4 mm layersby far the lowest polymerisation shrinkage (1.25 % by volume) and particularly low level of shrinkage stress, providing optimal marginal integrity.~inert, so excellent biocompatible and extremely resistant to discolouration Easy handling, simple high-lustre polishing procedure coupled with high surface hardness guarantee first-class long-term results Universal shade with chameleon effect"
62680638|NCT03620981|EXPERIMENTAL|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
62680639|NCT03620981|PLACEBO_COMPARATOR|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
62680640|NCT06351189||Control group: STATIC MODE|The patient will be positioned on the Netti Dynamic chair in static mode.
62680641|NCT06351189||Interventional group: DYNAMIC MODE|The patient will be positioned on the Netti Dynamic chair in dynamic mode.
62680642|NCT06651554|EXPERIMENTAL|Digital Platform Intervention|Key features of the digital platform intervention include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements.
62680643|NCT06651554|NO_INTERVENTION|waitlist control|No intervention will be administered to youth during their assigned waitlist control period.
62310046|NCT06449261|ACTIVE_COMPARATOR|Group receives conventional therapy|Controls will receive ultrasound therapy, passive shoulder mobilisation focussed at Glenohumeral joint, self-stretching exercises and patient education by qualified therapist according to clinical practice guidelines while the experimental group underwent spine mobilization with postural correction exercises for 3 weeks.
62310047|NCT01777438||control group|a control group of AR patients who visited the ear nose and throat (ENT) department of the University Hospitals Leuven in the same time period
62310048|NCT01777438||patients having SCIT|patients who started immunotherapy at the Department of Allergology of the University Hospitals Leuven between November 2007 and February 2010.
62310049|NCT02628223|ACTIVE_COMPARATOR|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
62310050|NCT02628223|ACTIVE_COMPARATOR|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
62310051|NCT05099991|PLACEBO_COMPARATOR|Dilapan-S|A number of Dilapan-S will be inserted for cervical preparation. The number will be determined by a standard protocol that is based on gestational age. The dilators will stay in until the next day prior to their procedure, or earlier if they fall out on their own.
62310052|NCT05099991|EXPERIMENTAL|Foley balloon|A Foley balloon will be inserted for cervical preparation and filled to 30mL of water or saline. The balloon will stay in until the next day prior to their procedure, or earlier if it falls out on its own.
62310053|NCT04346225|EXPERIMENTAL|Cohort A: Hyperpolarized C13 MRI at a single time point|Participants will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at a single time point and will receive up to two 13C pyruvate (C-1 and C-2 labeled 13C pyruvate) investigational medicinal product (IMP) injections on the day of imaging (2nd injection is optional), as well as optional MR- or CT- guided tumor biopsies at baseline and at the time of disease progression following completion of HP C-13 MRI at the corresponding time point
62310054|NCT04346225|EXPERIMENTAL|Cohort B: Hyperpolarized C13 MRI at multiple time points|Participants will undergo hyperpolarized (HP) C13 MRI at baseline and 12 weeks (+/- 8 weeks). Participants in Cohort B may undergo additional optional MR imaging at the time of disease progression. the same sequence of injections (C-1 labeled pyruvate first, C-2 labeled pyruvate second) will be used for subsequent scan time points as well.
62476002|NCT01931553|EXPERIMENTAL|Standardized attending morning rounds|"1. Pre-rounds discretion~2. Pre-rounds huddle~3. Bedside RN integration~4. Patient-centered rounding~5. Real-time order writing"
62476003|NCT01931553|NO_INTERVENTION|Usual rounding practice|Usual rounding practice (as defined by each clinical team)
62476004|NCT04870606|ACTIVE_COMPARATOR|GT0918+ standard of care|Proxalutamide 200mg, oral, QD, for continuous 14 days, plus standard of care(n=334)
62476005|NCT04870606|PLACEBO_COMPARATOR|placebo+ standard of care|Placebo 200mg, oral, QD, for continuous 14 days, plus standard of care(n=334)
62476006|NCT00365365|EXPERIMENTAL|Stratum 1 (AC->T + bevacizumab)|"HER2-negative participants administered~* doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by~* docetaxel (T) + bevacizumab for 4 cycles followed by~* bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
62476007|NCT00365365|EXPERIMENTAL|Stratum 2 (TAC + bevacizumab)|"HER2-negative participants administered~* docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by~* bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
62476008|NCT00365365|EXPERIMENTAL|Stratum 3 (TCH + bevacizumab)|"All HER2-positive participants administered~* docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by~* bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
62476009|NCT01163461|EXPERIMENTAL|Immediate Treatment|individuals will receive 60 hours of speech therapy
62680644|NCT04824066||Cardiothoracic Surgery Cohort|Adults patients who are scheduled to undergo cardiothoracic surgery and meet the inclusion and exclusion criteria.
62680645|NCT06223698|EXPERIMENTAL|Cohort 1: Aromatase inhibitors for 5 years|Cohort 1 (premenopausal at diagnosis =\> postmenopausal at randomization) 5-year tamoxifen =\> Randomized to Arm A (switching to aromatase inhibitors for 5 years).
62680646|NCT06223698|ACTIVE_COMPARATOR|Cohort 1: Tamoxifen for 5 years|Cohort 1 (premenopausal at diagnosis =\> postmenopausal at randomization) 5-year tamoxifen =\> Randomized to Arm B (continuing with tamoxifen for 5 years).
62680647|NCT06223698|EXPERIMENTAL|Cohort 2: Tamoxifen for 5 years|Cohort 2 (postmenopausal at diagnosis) 5-year aromatase inhibitors =\> Randomized to Arm A (switching to tamoxifen for 5 years).
62121509|NCT06212141|ACTIVE_COMPARATOR|Filtek One Bulk|"Conventional bulkfill compositeFocused options powered by 3M technology help you complete posterior restorations in a single bulk placement.~5 shades avaible : A1, A2, A3, B1, and C2. Excellent adaptation and sculptability for fast, easy placement. One-step placement : Tackle deep cavities with up to 5 mm depth of cure"
62476010|NCT01163461|EXPERIMENTAL|Delayed Treatment|individuals will receive 60 hours of speech therapy after 6 week delay period
62476011|NCT00753194||1|"Newborns that show a Pass On the newborn hearing screening program before hospital discharge"
62121510|NCT06172699||Subjects successfully implanted with an Abbott Assert-IQ ICM device|Holter monitoring in subjects successfully implanted with an Abbott Assert-IQ ICM device
62310055|NCT02887144|EXPERIMENTAL|SenSura test product 1pc|"Subjects randomized to treatment sequence 1test:~1. SenSura test product~2. SenSura"
62476012|NCT00753194||2|"Newborns that show a fail and will be retested in 15 days."
62476013|NCT03992222|EXPERIMENTAL|administration of a physical exercise programme|administration of a Physical exercise program for 24 weeks.
62121511|NCT06555627|EXPERIMENTAL|Exercise and High Protein Breakfast|"Children in this group will be given given breakfast each morning at 7:30 am and participate in a 30-minute bout of physically active games of moderate to vigorous intensity at 8 am.~Nutrition Intervention. For 5 days children will receive a high protein breakfast comprised of baked items (i.e. waffles with syrup) and Greek yogurt. The high protein meal will aim for 40% protein, 40% carbohydrates, and 20% fat. Meals will be served with a cup of water.~Exercise Intervention. For 5 days, a 30-min physical activity bout including a 5-minute warm up and cool down will be provided to participants in this group. The aim is for students to achieve an average heart rate above 150 for the session, not including warm up or cool down. To monitor intensity, the participant will wear heart rate monitors around their chest and waist-worn accelerometers"
62121512|NCT06555627|ACTIVE_COMPARATOR|High Protein Breakfast Only|Nutrition Intervention. For 5 days children will receive a high protein breakfast comprised of baked items (i.e. waffles with syrup) and Greek yogurt. The high protein meal will aim for 40% protein, 40% carbohydrates, and 20% fat. Meals will be served with a cup of water.
62310056|NCT02887144|EXPERIMENTAL|SenSura 1pc|"Subjects randomized to treatment sequence 2 test:~1. SenSura~2. SunSura test product"
62310057|NCT05585385|EXPERIMENTAL|Backward Walking Training|The patients will receive BW training in addition to the traditional physical therapy program for 6 weeks.
62310058|NCT05585385|EXPERIMENTAL|Balance Training|The patients will receive balance training on the Biodex balance system in addition to the traditional physical therapy program for 6 weeks.
62310059|NCT05585385|ACTIVE_COMPARATOR|conventional treatment|The patients will receive the traditional physical therapy program only for 6 weeks.
62310060|NCT01269567|ACTIVE_COMPARATOR|Drainage|Rectal excision with aspiration pelvic drainage
62310061|NCT01269567|EXPERIMENTAL|No drainage|Rectal excision without aspiration pelvic drainage
62310062|NCT03653715|EXPERIMENTAL|Test Device|Within this arm the Clerio Vision LIRIC-modified Bifocal Contact Lens is administered.
62310063|NCT03653715|ACTIVE_COMPARATOR|Control Devices|Within this arm the Johnson \& Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson \& Johnson 1-Day Acuvue Moist Contact Lens, and Clerio Vision Single Vision Contact Lens are administered.
62476014|NCT03992222|NO_INTERVENTION|control|
61921378|NCT02481427|EXPERIMENTAL|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
61921379|NCT02481427|EXPERIMENTAL|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
62310064|NCT05901181|EXPERIMENTAL|Laughter Yoga Group|When we look at the literature, the Laughter Yoga practice is held between 2 weeks and 10 weeks, once a week, 5 times a week, 2 weeks and lasting approximately 25-45 minutes. In this study, the intervention will be implemented within 8 weeks. To the women who constitute the intervention group; After giving short-term self-care training in Menopause for 8 weeks, relaxation will be applied after the practice of Laughter yoga, which starts with breathing exercises, warm-up exercises, childlike games and has different exercises in each session. The research will be carried out in the Famagusta Municipality Development Academy, in a bright hall where women can take a U shape, everyone will be face to face, and will not be disturbed during the application.
62310065|NCT05901181|NO_INTERVENTION|Control Group|Routine care was given to the control group
62310066|NCT05645666|EXPERIMENTAL|Well being therapy|The group of 16 which recieved well-being therapy
62310067|NCT05645666|NO_INTERVENTION|Control group|The group of 16 which did not recieve well-being therapy
62310068|NCT00674934|EXPERIMENTAL|1|Radiation
62310069|NCT02195115|ACTIVE_COMPARATOR|Laparoscopic cholecystectomy|surgical removal of gallbladder
62310070|NCT02195115|ACTIVE_COMPARATOR|Non-operative treatment|Administration of amitriptyline 25mg daily, Low Fat-Low Cholesterol Diet
62310071|NCT01902160|EXPERIMENTAL|Treatment (temsirolimus, brentuximab vedotin)|Patients receive temsirolimus IV over 30-60 minutes on days 1 and 8 or days 1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
62310072|NCT03032887|EXPERIMENTAL|voice prompts|Agitation (education, reminders and optimising materials) plus voice prompts
62310073|NCT03032887|OTHER|no voice prompts|only Agitation (education, reminders and optimising materials); no voice prompts
62310074|NCT04820478|EXPERIMENTAL|Beta Hydroxybutyrate Ester|3 x 10 g beta hydroxybutyrate ester per day, in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
62310075|NCT04820478|PLACEBO_COMPARATOR|Placebo|matching placebo, in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
62310076|NCT01221545|EXPERIMENTAL|A - AZD1656|AZD1656
62310077|NCT01221545|PLACEBO_COMPARATOR|B - Placebo|Placebo
62310078|NCT04336150|EXPERIMENTAL|Hypopressive exercisesE|"Hypopressive exercises described according to Dr. Caufriez~1. Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~2. Hypopressive exercises according to the original method described by Dr. Caufriez, which is based on performing the hypopressive maneuver in 33 postures that he described (1,2)."
62310079|NCT04336150|EXPERIMENTAL|Hypopressive exercises&PFM contraction|"Hypopressive exercises + active pelvic floor muscle contraction:~1. Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~2. Hypopressive exercises according to the original method described by Dr.Caufriez, which is based on performing the hypopressive maneuver in 33 postures he described, plus the active contraction of the pelvic floor muscles (PFM) during the hypopressive maneuver."
62310080|NCT04336150|EXPERIMENTAL|Hypopressive maneuver|"Hypopressive maneuver:~1. Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~2. Hypopressive maneuver with transabdominal ultrasound biofeedback."
62310081|NCT04336150|EXPERIMENTAL|Hypopressive maneuver&PFM contraction|"Hypopressive maneuver + pelvic floor muscles contraction:~1. Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~2. Hypopressive maneuver plus active contraction of the pelvic floor muscles with transabdominal ultrasound biofeedback."
62310082|NCT02439762|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|The CBT condition will cover topics such as orienting the patient to the cognitive model of suicidal thoughts, plans and behaviors and the role of substance use in increasing the likelihood of suicidal behaviors and presenting tools to help patients better manage responses to suicide-related triggers.
62476015|NCT05430776|ACTIVE_COMPARATOR|Local photobiomodulation|photobiomodulation with red and infrared laser with local application on pain points and
62476016|NCT05430776|EXPERIMENTAL|Systemic photobiomodulation|photobiomodulation with red laser with transcutaneous application in the radial artery.
62476017|NCT02188563|EXPERIMENTAL|Comprehensive intervention|New evidence-based comprehensive smoking cessation intervention including several elements that have proven successful in non-cancer patients but not used for cancer patients before.
62476018|NCT02188563|ACTIVE_COMPARATOR|Enhanced usual care|Intervention consistent with the U.S. Department of Health and Human Services guidelines for tobacco treatment.
62476019|NCT01300676|ACTIVE_COMPARATOR|Tualang Honey|Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
62476020|NCT01300676|NO_INTERVENTION|Group 2|Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
62121513|NCT06555627|ACTIVE_COMPARATOR|Exercise and High Carb Breakfast|"Exercise Intervention. For 5 days, a 30-min physical activity bout including a 5-minute warm up and cool down will be provided to participants in this group. The aim is for students to achieve an average heart rate above 150 for the session, not including warm up or cool down. To monitor intensity, the participant will wear heart rate monitors around their chest and waist-worn accelerometers.~For 5 days children will receive a high carb breakfast that will be comprised of 15% protein, 65% carbohydrates and 20% fat. Total energy content, fat, sugar, fiber, energy density, are similar between the breakfast meals."
62310083|NCT02439762|ACTIVE_COMPARATOR|Supportive Psycho-education (SPC)|The SPC condition is designed to match the CBT condition in terms of level of attention and the non-specific aspects of receiving support for a suicidal crisis and substance misuse. Specific content related to suicide risk will consist of general information about suicide-related resources available, while content related to substance use is based on a modified psycho-educational attention control treatment for alcoholism. The sessions will help patients to better understand the resources available during a suicidal crisis and how substance use impacts in their life. However, topics related to identifying thoughts and behaviors associated with suicidal crises and possible coping mechanisms will not be a part of the formal content of these SPC sessions.
62310084|NCT00855712|EXPERIMENTAL|Organ Care System|
62310085|NCT00855712|ACTIVE_COMPARATOR|Cold cardioplegia solution|
62310086|NCT02510599|EXPERIMENTAL|Solithromycin|Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
62310087|NCT06480045|ACTIVE_COMPARATOR|Group AI-USG|performed a PECS II block with AI-integrated USG
62310088|NCT06480045|ACTIVE_COMPARATOR|Group USG|performed a PECS II block with conventional USG
62310089|NCT03427840||Hypo|The participants with a superior hypogastric block
62310090|NCT03427840||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retroperitone is opened intraoperatively by the surgeon)
62310091|NCT00385086|EXPERIMENTAL|TNF-alpha blocker|Treatment with TNF-alpha blocker
62310092|NCT00385086|ACTIVE_COMPARATOR|Placebo|Treatment with placebo
62476021|NCT02514382|EXPERIMENTAL|Treatment (dexamethasone, bortezomib, wild-type reovirus)|Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62680648|NCT06223698|ACTIVE_COMPARATOR|Cohort 2: Aromatase inhibitors for 2 years|Cohort 2 (postmenopausal at diagnosis) 5-year aromatase inhibitors =\> Randomized to Arm B (continuing with AI for 2 years).
62310093|NCT06077422|EXPERIMENTAL|Exparel|"The experimental medication (Exparel) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight.~For this pilot project the investigators anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoractomies (N=24 Exparel, N=24 Marcaine) 48 Open sternotomies (N=24 Exparel, N=24 Marcaine)."
62310094|NCT06077422|ACTIVE_COMPARATOR|Marcaine|"The active comparator medication (Marcaine) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight.~For this pilot project the investigators anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoracotomies (N=24 Exparel, N=24 Marcaine) 48 Open sternotomies (N=24 Exparel, N=24 Marcaine)."
62310095|NCT01618955|ACTIVE_COMPARATOR|VIBEX MTX|VIBEX MTX dose based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status
62310096|NCT01415960|EXPERIMENTAL|Leuprolide acetate 22.5 mg depot|Leuprolide acetate 22.5 mg depot administered twice, 3 months apart
62476022|NCT04192162|EXPERIMENTAL|Group of sulfur balneotherapy and mud pack therapy|Experimental group patients underwent sulfur balneotherapy and mud pack therapy. The duration of spa therapy program was 12 days.From the blood of patients, serotonin values, parameters of complete blood count, lipid status and inflammatory markers were analyzed before and after the therapy.
62310097|NCT00744159||OC|Open colorectal resection
62310098|NCT00744159||LC|Laparoscopic colorectal resection
62680649|NCT06686550||Children scheduled to undergo elective congenital heart disease repair surgery with CPB|
62680650|NCT02240784||Acute Hepatic Porphyria|
62680651|NCT05250726|EXPERIMENTAL|MENISC-T|Segmented, devitalized and sterile meniscus graft
62680652|NCT02714543|EXPERIMENTAL|aloevera group|aloevera juice twice daily for 3 months. aloevera gel one scoop to be applied 3-4 times daily for 3 months
62680653|NCT02714543|ACTIVE_COMPARATOR|steroid group|intralesional injection of hydrocortisone 100mg and injection hyaluronic acid 1500IU once a week for 6 weeks with Capsules SM Fibro once daily for 3 months.
62680654|NCT05496231|EXPERIMENTAL|Human Papilloma Virus 9-valent (HPV9) High Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-High formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
62680655|NCT05496231|EXPERIMENTAL|Human Papilloma Virus 9-valent (HPV9) Med Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-Medium formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
62680656|NCT05496231|EXPERIMENTAL|Human Papilloma Virus 9-valent (HPV9) Low Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-Low formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
62680657|NCT05496231|ACTIVE_COMPARATOR|Gardasil 9 (Gar9) Group|Healthy females aged 16 to 26 years receive 3 doses of the marketed HPV vaccine on Day 1, Month 2, and Month 6.
62680658|NCT05249426|EXPERIMENTAL|Cohort A: BI 765063 + ezabenlimab + cetuximab|30 Signal Regulatory Protein Alpha (SIRPα) V1/V1 homozygous patients with 2nd line recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) who had received prior platinum-based therapy within the recurrent/metastatic setting.
62680659|NCT05249426|EXPERIMENTAL|Cohort B: BI 765063 + ezabenlimab + chemo (invest choice)|30 SIRPα V1/V1 homozygous patients with 2nd line recurrent/metastatic HNSCC who had received prior platinum-based therapy within the recurrent/metastatic setting.
62680660|NCT05249426|EXPERIMENTAL|Cohort C: BI 765063 + ezabenlimab|30 SIRPα V1/V1 homozygous patients with advanced or metastatic 1st line Hepatocellular Carcinoma (HCC).
62680661|NCT05249426|EXPERIMENTAL|Cohort D: BI 765063 + ezabenlimab + BI 836880|30 SIRPα V1/V1 homozygous patients with advanced or metastatic 1st line HCC.
62680662|NCT05249426|EXPERIMENTAL|Cohort E: BI 765063 + ezabenlimab + BI 836880|30 SIRPα V1/V1 homozygous patients with advanced or metastatic 2nd line HCC who progressed on therapy with atezolizumab in combination with bevacizumab.
62680663|NCT04356703||Children submitted to fetoscopic surgery|Children submitted to fetoscopic in utero myelomeningocele repair using the SAFER (Skin-over-biocellulose for Anternatal FEtoscopic Repair) technique will evaluate the neuropsicomotor development at 30 months of chronological age or older
62680664|NCT06691685|EXPERIMENTAL|ESO-T01 Injection|ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
62680665|NCT06682975|EXPERIMENTAL|ZP9830|"Up to 10 single cohorts planned:~Part A, 3 cohorts of each 8 participants with 6 participants receiving s.c. active treatment of ZP9830. Part B, 6 cohorts of each 10 participants with 8 participants receiving s.c. active treatment of ZP9830. Part C, 1 cohort of 8 participants with 6 participants receiving i.v. active treatment of ZP9830"
62310099|NCT01252888|EXPERIMENTAL|Two iStent devices and medication|Implantation of two iStents through small temporal clear corneal incision
62310100|NCT03644797||Patients|Patients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
62310101|NCT01675037||obstructive|obstructive hydrocephalus in children and adults with biological evaluation
62310102|NCT01542372|ACTIVE_COMPARATOR|Medication augmentation|In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
62310103|NCT01542372|ACTIVE_COMPARATOR|CBT augmentation|In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.
62310104|NCT05730608|OTHER|Primary breast cancer|"Patients diagnosed with new breast cancer determined to have high risk disease by a multidisciplinary team."
62310105|NCT05730608|OTHER|Recurrent breast cancer|Patients with suspected or proven locoregional recurrent breast cancer.
62310106|NCT05574972|EXPERIMENTAL|Timing Carotid Stent|
62310107|NCT05574972|ACTIVE_COMPARATOR|Carotid Wallstent|
62310108|NCT05263843||Patients|Patients with a complex congenital heart disease
62680666|NCT06682975|PLACEBO_COMPARATOR|Placebo|In each of the 10 single dose cohorts, 2 subjects will receive placebo
62680667|NCT06683924|ACTIVE_COMPARATOR|Pulsed Radiofrequency Ablation|The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.
62680668|NCT06683924|ACTIVE_COMPARATOR|Steroid Injection|Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.
62680669|NCT06160440|EXPERIMENTAL|A single dose SC1011 50mg（A1）|Drug: SC1011 tablet Treatment: No food prior to dosing
62680670|NCT06160440|PLACEBO_COMPARATOR|A single dose SC1011 150mg（A2）|Drug: SC1011 tablet Drug: SC1011-matching placebo tablet Treatment: No food prior to dosing
62680671|NCT06160440|EXPERIMENTAL|A single dose SC1011 150 mg（A3）|Drug: SC1011 tablet Drug: SC1011-matching placebo tablet Treatment: No food prior to dosing
62680672|NCT06160440|EXPERIMENTAL|A single dose SC1011 300mg（A4）|Drug: SC1011 tablet Drug: SC1011-matching placebo tablet Treatment: No food prior to dosing
62310109|NCT05263843||controls|healthy subjects
62310110|NCT04706546|EXPERIMENTAL|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
62310111|NCT04706546|OTHER|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62680673|NCT05457140|EXPERIMENTAL|Enrollees - WGS|These participants will be subject to whole genome sequencing and Phage ImmunoPrecipiation sequencing (PhIP-Seq) to identify genetic changes and novel antibodies associated with psychosis.
62680674|NCT05816187|EXPERIMENTAL|supervised without chemotherapy, radiotherapy or hormone treatment|Therapeutic exercise program based on aerobic work, strength-endurance and self-stretching of 6 weeks duration, in addition to a reinforcement of the usual self-care recommendations.
62310112|NCT04847830|EXPERIMENTAL|Laser|One side of the mouth will undergo root surface debridement using hand instruments and ultrasonic scaler, with the addition of the Er:YAG laser
62310113|NCT04847830|PLACEBO_COMPARATOR|Control|The other side of the mouth undergo root surface debridement using hand instruments and ultrasonic scaler alone
62680675|NCT05816187|EXPERIMENTAL|supervised with chemotherapy, radiotherapy or hormone treatment|Therapeutic exercise program based on aerobic work, strength-endurance and self-stretching of 6 weeks duration, in addition to a reinforcement of the usual self-care recommendations.
62680676|NCT05816187|ACTIVE_COMPARATOR|Not Supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
62680677|NCT04208178|EXPERIMENTAL|Part 1: Alpelisib + Trastuzumab + Pertuzumab|"In the Part 1, up to 3 alpelisib dose levels may be sequentially tested in 3 cohorts of subjects:~Cohort A: Alpelisib 300mg + trastuzumab (6mg/kg) + pertuzumab (420 mg) Cohort B: Alpelisib 250 mg+ trastuzumab (6mg/kg) + pertuzumab (420 mg) Cohort C: Alpelisib 200mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)"
62680678|NCT04208178|EXPERIMENTAL|Part 2: Alpelisib + Trastuzumab + Pertuzumab|Trastuzumab (6mg/kg) + pertuzumab (420 mg) in combination with 200mg alpelisib, with potential for intra-participant dose escalation to 250 mg
62121514|NCT06555627|PLACEBO_COMPARATOR|High Carb Breakfast Only|For 5 days children will receive a high carb breakfast that will be comprised of 15% protein, 65% carbohydrates and 20% fat. Total energy content, fat, sugar, fiber, energy density, are similar between the breakfast meals.
62476023|NCT04192162|ACTIVE_COMPARATOR|Group of sulfur balneotherapy, mud pack therapy and exercise|Control group of patients had mud pack therapy, sulfur balneotherapy and exercise in hygienic water. This group is a hydro group. From the blood of patients we analyzed parameters od complete blood count, serotonin values, lipid status and inflammatory markers before and after the therapy.
62476024|NCT04736186|EXPERIMENTAL|Loperamide|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21)
62121515|NCT05630508|EXPERIMENTAL|interactive mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application
62121516|NCT05630508|SHAM_COMPARATOR|Sham group - app access only|Receiving standard care, LIVEN educational material and access to the application
62121517|NCT05630508|NO_INTERVENTION|Control group - Standard care|Receiving Standard care only
62310114|NCT01274897|EXPERIMENTAL|MenACWY-CRM|Subjects received one dose of MenACWY-CRM conjugate vaccine.
62310115|NCT01274897|PLACEBO_COMPARATOR|Placebo|Subjects received the saline placebo.
62310116|NCT05126095||Trial cohort|"CBCT: before radiotherapy and once a week during radiotherapy~Body weight: before radiotherapy and once a week during radiotherapy~The Patient-Generated Subjective Global Assessment (PG-SGA): before radiotherapy, 1st week, 3rd week and the last week during radiotherapy."
62680679|NCT04208178|PLACEBO_COMPARATOR|Part 2: Alpelisib matching Placebo + Trastuzumab + Pertuzumab|Trastuzumab (6mg/kg) + pertuzumab (420 mg) in combination with 200 mg alpelisib matching placebo, with potential for intra-participant dose escalation to 250 mg
61921380|NCT06336759|ACTIVE_COMPARATOR|Retylane Defyne|"Restylane Defyne is manufactured by Q-Med AB, part of the Galderma Group.~The product is a sterilized 1ml gel syringe contain 20 mg/mL stabilized HA and 3 mg/mL lidocaine hydrochloride in a physiological buffer (phosphate buffered saline pH 7).~The participants deemed to have think skin will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each subject will be determined by the aesthetic judgement of the Treating Investigator."
61921381|NCT06336759|ACTIVE_COMPARATOR|Retylane Lyft|"Restylane Defyne is manufactured by Q-Med AB, part of the Galderma Group.~The product is a sterilized 1mL gel syringe contain 20 mg/mL stabilized HA and 3 mg/mL lidocaine hydrochloride in a physiological buffer (phosphate buffered saline pH 7).~The participants deemed to have thick skin will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each subject will be determined by the aesthetic judgement of the Treating Investigator."
61921382|NCT04285580|EXPERIMENTAL|Bimatoprost SR 10 μg|Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
61921383|NCT04285580|OTHER|LUMIGAN 0.01%|Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
61921384|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
61921385|NCT05993975|ACTIVE_COMPARATOR|BUPIPURE|"Hyperbaric Bupivacaine 0.5% (1.5 ml/7.5 mg) to be given intrathecally~Total volume 1.5 mL"
61921386|NCT05993975|EXPERIMENTAL|BUPI-DEX|"Hyperbaric Bupivacaine 0.5% (1.2 ml/6 mg)+Dexmedetomidine (0.3 mL) 3 microgram intrathecally.~Total volume 1.5 mL"
61921387|NCT04503291|EXPERIMENTAL|supra-papillary metal stent group|The distal ends of metal stents are located above the major papilla in the common bile duct.
61921388|NCT04503291|ACTIVE_COMPARATOR|trans-papillary metal stent group|The distal ends of metal stents are located below the major papilla in the duodenum.
61921389|NCT03360786|EXPERIMENTAL|Specific Protocol|The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
62121518|NCT05112146|PLACEBO_COMPARATOR|Control 10|100 ml Water taken 10 min before standard meal
61921390|NCT03360786|ACTIVE_COMPARATOR|Control Protocol|The control group will continue with their standard warm up and practice schedule but have the addition of contact time with the study physiotherapist for education regarding concussion education and injury identification.
62121519|NCT05112146|EXPERIMENTAL|Whey protein isolate 10|10 g whey protein isolate diluted in 100 ml taken 10 min before standard meal
62121520|NCT05112146|EXPERIMENTAL|Whey protein microgel 10|10g whey protein microgel in 100 ml taken 10 min before standard meal
62310117|NCT02195648|EXPERIMENTAL|Suboccipital inhibition|The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
62476025|NCT04736186|EXPERIMENTAL|Loperamide and gold bifid|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + gold bifid2g T.I.D.
61921391|NCT06477809|ACTIVE_COMPARATOR|With ARIA Glasses|"Each participant will act as their own control by performing the 12 research tasks with and without the ARIA Device, using their long cane as they choose in both conditions.~The control arm will be the participant's ordinary/preferred practice undertaking each task, referred to as non-ARIA."
61921392|NCT06477809|ACTIVE_COMPARATOR|Without ARIA Glasses|"Each participant will act as their own control by performing the 12 research tasks with and without the ARIA Device, using their long cane as they choose in both conditions.~The control arm will be the participant's ordinary/preferred practice undertaking each task, referred to as non-ARIA."
61921393|NCT04151342||Prospective|Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
61921394|NCT04151342||Retrospective|Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
61921395|NCT04151342||Comparator group|All cancer patients without rare molecular alterations in their tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy.
61921396|NCT02421003|EXPERIMENTAL|Patients|Patients undergoing heart surgery
61921397|NCT05719987|EXPERIMENTAL|Biodentine Group|study group
61921398|NCT05719987|OTHER|MTA Group|control group
61921399|NCT03729687|EXPERIMENTAL|LARCT-US|Short Course Radiation Therapy (5 x 5 Gy in 1 week, scRT) followed by 4 cycles of Pre-operative Chemotherapy using capecitabine and oxaliplatin (CAPOX) and Surgery in High-risk Rectal Cancer
62121521|NCT05112146|PLACEBO_COMPARATOR|Control 30|100 ml Water taken 30 min before standard meal
62121522|NCT05112146|EXPERIMENTAL|Whey protein isolate 30|10 g whey protein isolate diluted in 100 ml taken 30 min before standard meal
62121523|NCT05112146|EXPERIMENTAL|Whey protein microgel 30|10g whey protein microgel in 100 ml taken 30 min before standard meal
62121524|NCT05581745|EXPERIMENTAL|A2 donor transplant to O recipient|
62121525|NCT01472003|EXPERIMENTAL|ABT-806 Arm|Subjects with advanced solid tumors
62121526|NCT01472003|EXPERIMENTAL|ABT-806i Arm|Subjects with advanced solid tumors
62121527|NCT04461197|EXPERIMENTAL|ESWT + orthotic insole|(shock waves + orthotic insole +Stretches of the posterior muscle chain)
62310118|NCT02195648|NO_INTERVENTION|Control|No intervention will be done to the participants during the study. After study completion, the participants will be offered to receive the therapy.
62680680|NCT05898646|EXPERIMENTAL|Arm I (6 cycles of daratumumab)|Patients receive daratumumab subcutaneously (SC) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles on study. Patients also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patients with cardiac involvement also undergo echocardiography throughout the trial.
62121528|NCT04461197|PLACEBO_COMPARATOR|ESWT + flat insole|(shock waves + flat insole + Stretches of the posterior muscle chain)
62310119|NCT04063683|EXPERIMENTAL|Anlotinib with chemotherapy|
62476026|NCT04736186|EXPERIMENTAL|Loperamide and Montmorillonite SAN|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + Montmorillonite SAN 3 g, T.I.D.
62476027|NCT04736186|NO_INTERVENTION|Non-intervention|Do not intervene and stop diarrhea as needed
62476028|NCT05539339|EXPERIMENTAL|Arm 1|This arm includes patients with ctDNA-level-relapse glioblastoma before imaging recurrence.
62476029|NCT06560775|EXPERIMENTAL|NSO group|NSO is 1 gram Nigella sativa oil in capsules. It was purchased from CV Rizki Abadi, Tuban East Java, Indonesia, with registration number POM TR. 183314171
62476030|NCT06560775|PLACEBO_COMPARATOR|Placebo group|Placebo capsules identical appearance contain 1 gram starch
62680681|NCT05898646|ACTIVE_COMPARATOR|Arm II (18 cycles of daratumumab)|Patients receive daratumumab SC on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 18 cycles on study. Patients also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patients with cardiac involvement also undergo echocardiography throughout the trial.
61921400|NCT01992978|EXPERIMENTAL|radiofrequency-assisted resection group（RF-R)|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
61921401|NCT01992978|ACTIVE_COMPARATOR|conventional liver resection group（CLR-R）|Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical.
62121529|NCT02550197|EXPERIMENTAL|QIV Group|Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation
62121530|NCT02550197|ACTIVE_COMPARATOR|TIV Group|Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
62121531|NCT00866203|EXPERIMENTAL|HDS|modified high dose sequential therapy
62121532|NCT00866203|ACTIVE_COMPARATOR|ProMECE/CytaBOM|four additional courses of standard ProMECE/CytaBOM
62121533|NCT05660993|EXPERIMENTAL|Main arm|"Patients will receive for a maximum of 4 cycles of nivolumab 3 mg/kg on day 0 BeGEV , with subsequent assessment of response by PET-CT. Patients with CR after 2 cycles Nivo-BeGEV will proceed to ASCT.~Patients with \<CR after 2 cycles of a combination Nivo-BeGEV, with subsequent PET-CT assessment, will receive an additional 2 cycles Nivo-BeGEV. Patients with CR after 4 cycles Nivo-BeGEV will proceed to ASCT."
62121534|NCT00101010|EXPERIMENTAL|Rituximab - Combination Chemotherapy|Rituximab 375 mg/m\^2 intravenous (IV), Cyclophosphamide IV over 1-1½ hours, Pegylated doxorubicin HCl liposome 40 mg/m\^2 IV over 1 hour, Vincristine 2 mg IV, day 1, \& oral Prednisone 40 mg/m\^2 days 1 - 5; Filgrastim (G-CSF) 5 mcg/kg subcutaneously (SC) once daily beginning day 6 continuing until blood counts recover OR Pegfilgrastim 6 mg SC once on day 6 (24 hours after chemotherapy). Treatment repeats every 21 days for up to 8 courses.
62121535|NCT05021211||Low Egg Consumers|Participants who consume fewer than 1 whole egg per week
62310120|NCT00367471|ACTIVE_COMPARATOR|Group A|Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion. Doses of paclitaxel and carboplatin will be administered weekly (Day 1, 8, and 15). Trastuzumab is administered on Day 1, 8, 15, and 22. Treatment cycles are repeated every four weeks.
62310121|NCT00367471|ACTIVE_COMPARATOR|Group B|Subjects in Treatment Group B (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by a ≥15 minute intravenous infusion of carboplatin. Doses of paclitaxel, and carboplatin will be administered weekly (Day 1, 8, and 15) for three weeks with cycles repeated every four weeks.
62310122|NCT04138667|EXPERIMENTAL|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema who will undergo complex decongestive therapy
62476031|NCT06480032|EXPERIMENTAL|Blood Flow Restriction band|"Group B, comprising 16 patients (Group 2), will undergo the standard Anterior Cruciate Ligament (ACL) rehabilitation protocol without Blood Flow Restriction (BFR) for 8 weeks during their physiotherapy sessions at the Rehman Medical Institute's Outpatient Department (OPD), starting from the second post-operative visit. The cuff size will be determined based on the patient's thigh circumference.~The rehabilitation protocol will progress as follows:~* Week 2-4: Long Arc Quadriceps (LAQ) exercise progression, Shuttle exercise progression, and Post-op visit 2.~* Week 4-8: Available range LAQ, Standing terminal knee extension, and Single Limb Shuttle/Leg Press exercises."
62476032|NCT06480032|OTHER|Non-Blood Flow Restriction band|"Group B, comprising 16 patients (Group 2), will undergo the standard Anterior Cruciate Ligament (ACL) rehabilitation protocol without Blood Flow Restriction (BFR) for 8 weeks during their physiotherapy sessions at the Rehman Medical Institute's Outpatient Department (OPD), starting from the second post-operative visit. The cuff size will be determined based on the patient's thigh circumference.~The rehabilitation protocol will progress as follows:~* Week 2-4: Long Arc Quadriceps (LAQ) exercise progression, Shuttle exercise progression, and Post-op visit 2.~* Week 4-8: Available range LAQ, Standing terminal knee extension, and Single Limb Shuttle/Leg Press exercises."
62476033|NCT03501147|EXPERIMENTAL|Intervention|15 minutes of resistance training at the work place every day
62476034|NCT03501147|NO_INTERVENTION|Control|Usual work
62476035|NCT02576522|EXPERIMENTAL|brain metastatic patients|Patients with single, large brain metastases from solid tumors
62476036|NCT03962439|EXPERIMENTAL|High-Demand Photography|A structured, high-demand photography course targeting 210 hours of engagement over 16 weeks.
62476037|NCT03962439|ACTIVE_COMPARATOR|Moderate-Demand Photography|A structured, moderate-demand photography course targeting 210 hours of engagement over 16 weeks.
62476038|NCT03962439|PLACEBO_COMPARATOR|At-Home Engagement Group|Participation, alone at home, in tasks that are relatively low in intellectual engagement.
62476039|NCT04033276|ACTIVE_COMPARATOR|Rituximab|Inj Rituximab 375mg/m2 IV given on day 0
62476040|NCT04033276|ACTIVE_COMPARATOR|Combination of high-dose IVIG and Rituximab|IV Rituximab 375mg/m2 on day 0 and IV high-dose IVIG 2g/kg on day 0
62476041|NCT05408169|NO_INTERVENTION|Control|
62476042|NCT05408169|EXPERIMENTAL|1-week deadline, no planning sheet|
62476043|NCT05408169|EXPERIMENTAL|2-week deadline, no planning sheet|
62476044|NCT05408169|EXPERIMENTAL|4-week deadline, no planning sheet|
62476045|NCT05408169|EXPERIMENTAL|No deadline, with planning sheet|
62476046|NCT05408169|EXPERIMENTAL|1-week deadline, with planning sheet|
62476047|NCT05408169|EXPERIMENTAL|2-week deadline, with planning sheet|
62121536|NCT05021211||Moderate Egg Consumers|Participants who consume 5-9 whole eggs per week
62121537|NCT05021211||High Egg Consumers|Participants who consumes great than or equal to 14 whole eggs per week
62121538|NCT03141333|EXPERIMENTAL|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
62476048|NCT05408169|EXPERIMENTAL|4-week deadline, with planning sheet|
62476049|NCT03876639|ACTIVE_COMPARATOR|IPM_2/18|Application of formulation IPM_2/18
62476050|NCT03876639|ACTIVE_COMPARATOR|PAR_2/18|Application of formulation PAR_2/18
62476051|NCT06432595|EXPERIMENTAL|Instability resistance training|After pre-testing, participants were randomly assigned to two groups. The participants of the IRT group were conducted in a 12-week (July 3 to September 22, 2023) Instability resistance training program that was performed one hour and three times per week (Mondays, Wednesdays, and Fridays from 4 to 5 pm) in the Nanchang Yao Lake base.
62476052|NCT06432595|EXPERIMENTAL|Traditional resistance training|After pre-testing, participants were randomly assigned to two groups. The participants of the TRT group were conducted in a 12-week (July 3 to September 22, 2023) traditional resistance training program that was performed one hour and three times per week (Mondays, Wednesdays, and Fridays from 4 to 5 pm) in the Ganzhou Shangyou base.
62121539|NCT03141333|NO_INTERVENTION|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
62476053|NCT01013077|EXPERIMENTAL|Optive|Commercial drop.
62476054|NCT01013077|EXPERIMENTAL|Soothe|Commercial drop.
62476055|NCT01013077|EXPERIMENTAL|New Emulsion|New formulation.
62476056|NCT01093963|ACTIVE_COMPARATOR|Lisdexamfetamine|Drug
62476057|NCT01093963|PLACEBO_COMPARATOR|Placebo|Drug
62476058|NCT04945252|EXPERIMENTAL|Care Navigation group|The teachers will signpost dental caries based on ICCMS visual criteria and refer to the nearest service. Annual monitoring of caries
62680682|NCT03742102|EXPERIMENTAL|Arm 1|durvalumab + paclitaxel
62476059|NCT04945252|NO_INTERVENTION|No internvention|Caries experience (dmft) activity monitored annually
62310123|NCT02964104|EXPERIMENTAL|Insulin 287 + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
62476060|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 1 on Day 1 of each cycle Q3W
62476061|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 2 on Day 1 of each cycle Q3W
62476062|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 3 on Day 1 of each cycle Q3W
62476063|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 4 on Day 1 of each cycle Q3W
62476064|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 5 on Day 1 of each cycle Q3W
62476065|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 1|Enrolled Subjects will be randomized to receive a single-dose of DB-1303/BNT323 on a selected dose level 1 or dose level 2 Day 1 of each cycle Q3W
62476066|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 2|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476067|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 3|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476068|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 4|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476069|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 5|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476070|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Level 6|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 6 on Day 1 of each cycle Q3W
62680683|NCT03742102|EXPERIMENTAL|Arm 2|durvalumab + paclitaxel + capivasertib
62680684|NCT03742102|EXPERIMENTAL|Arm 5|durvalumab + paclitaxel + oleclumab
62680685|NCT03742102|EXPERIMENTAL|Arm 6|durvalumab + trastuzumab deruxtecan
62680686|NCT03742102|EXPERIMENTAL|Arm 7|durvalumab + datopotamab deruxtecan
62680687|NCT03742102|EXPERIMENTAL|Arm 8|durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status)
62680688|NCT05653141||Stroke patients|Adults with first-ever anterior circulation stroke
62121540|NCT00870207|OTHER|Immediate Intervention Group|The immediate intervention group will receive the TSSC pilot worksite intervention in the initial 12 week period from the pre-test/enrollment visit.
62121541|NCT00870207|OTHER|Delayed Intervention Group|The delayed intervention group will receive the TSSC pilot worksite intervention beginning in month 6 of the study (6 months from the enrollment/pre-test visit).
62121542|NCT01568073|EXPERIMENTAL|BIA 9-1067|OPC, Opicapone
62121543|NCT01568073|ACTIVE_COMPARATOR|Entacapone|Comtan®; Active comparator
62121544|NCT01568073|PLACEBO_COMPARATOR|Placebo|PLC, Placebo
62310124|NCT02964104|ACTIVE_COMPARATOR|Insulin degludec + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
62310125|NCT05394545|EXPERIMENTAL|Nu-V3 treatment arm|Treatment with the Nu-V3 Device.
61921402|NCT00329940|EXPERIMENTAL|Letrozole|to evaluate the rheumatological tolerability of Femara
62121545|NCT05473260|ACTIVE_COMPARATOR|HOSPI Group|Patients with mild acute pancreatitis randomized to in-hospital care.
62476071|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Level 7|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 at Dose Level 7 on Day 1 of each cycle Q3W
62680689|NCT00960856|EXPERIMENTAL|Fenofibric Acid 105 mg - Low-Fat Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
62680690|NCT00960856|EXPERIMENTAL|Fenofibric Acid 105 mg - Standard Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a standard breakfast.
62680691|NCT00960856|EXPERIMENTAL|Fenofibric Acid 105 mg - High-Fat/High-Calorie Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
62310126|NCT05394545|NO_INTERVENTION|Observation treatment arm (SOC, control)|Observation following stable standard of care.
62680692|NCT00960856|EXPERIMENTAL|Fenofibric Acid 105 mg - Fasted State|Fenofibric Acid 105 mg tablet administered after an overnight fast of at least 10 hours
62121546|NCT05473260|EXPERIMENTAL|HOME Group|Patients with mild acute pancreatitis randomized to early discharge and outpatient clinic follow-up.
62121547|NCT00338559||LMA group|Patients in which laryngeal mask airway (LMA) is used.
62121548|NCT00338559||ET group|Patients in which endotracheal tube (ET) is used.
62680693|NCT06690515|EXPERIMENTAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A|0,5 ml of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A injected three-dose regimen with 28 days interval between doses
62680694|NCT06690515|EXPERIMENTAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B|0,5 ml of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B injected three-dose regimen with 28 days interval between doses.
62680695|NCT06690515|ACTIVE_COMPARATOR|Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac) ®|0,5 ml of DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)® injected three-dose regimen with 28 days interval between doses.
62121549|NCT05510245|EXPERIMENTAL|Group 1|Participants without renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
62121550|NCT05510245|EXPERIMENTAL|Group 2|Participants with mild renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
62121551|NCT05510245|EXPERIMENTAL|Group 3|Participants with moderate renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
62121552|NCT05510245|EXPERIMENTAL|Group 4|Participants with severe renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
62310127|NCT04770272|EXPERIMENTAL|Arm A|2 weeks Atezolizumab monotherapy before biopsy, followed by a 12-week therapy with Paclitaxel + Carboplatin+ Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
62476072|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 6|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62310128|NCT04770272|ACTIVE_COMPARATOR|Arm B|12-week therapy with Paclitaxel + Carboplatin + Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
62310129|NCT03161418|EXPERIMENTAL|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
62121553|NCT00507689|EXPERIMENTAL|FTC/TDF+HBIg|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period.
62476073|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 7|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476074|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 8|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476075|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 9|Enrolled Subjects will be randomized to receive a single-dose of DB-1303/BNT323 on a selected dose level 1 or dose level 2 on Day 1 of each cycle Q3W
62476076|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 10|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W along with ritonavir or itraconazole to assess the DDI potential
62476077|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 11|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476078|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 12|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level 1 or dose level 2 in combination with Pertuzumab on Day 1 of each cycle Q3W
62476079|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 13|Enrolled Subjects will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476080|NCT05150691|EXPERIMENTAL|DB-1303/BNT323 Dose Expansion 14|China Only:Subjects who were previously treated with trastuzumab and taxane will receive a single-dose of DB-1303/BNT323 on a selected dose level (RP2D) Day 1 of each cycle Q3W
62476081|NCT05217108|OTHER|Fit Bit (Study Groups)|Participants wear a Fitbit every day for 8 weeks to record the number of steps you take
62476082|NCT06022419|ACTIVE_COMPARATOR|Lucerne Cast|
62476083|NCT06022419|ACTIVE_COMPARATOR|Forearm Cast and Finger Splint|
62476084|NCT03414450|EXPERIMENTAL|Dose Escalation (Phase 1A)|An adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.
62121554|NCT00507689|EXPERIMENTAL|FTC/TDF|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF in the randomized period.
62121555|NCT02735941||UC group|Patients with ulcerative colitis (active or remission)
62121556|NCT02735941||CD group|Patients with Crohn's disease (active or remission)
62121557|NCT02735941||Colon cancer group|Patients with colon cancer or metastasis
62476085|NCT03414450|EXPERIMENTAL|Dose Expansion (Phase 1B)|Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
62476086|NCT01045018|ACTIVE_COMPARATOR|mesalamine 400 mg tablet|
62476087|NCT01045018|ACTIVE_COMPARATOR|Asacol 400 mg Delayed Release Tablet|
62476088|NCT01045018|PLACEBO_COMPARATOR|Placebo delayed release tablet|
62121558|NCT02735941||control group|healthy individuals
62121559|NCT00841035|EXPERIMENTAL|Eroltinib added to standard of care|150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles
62121560|NCT05507749|EXPERIMENTAL|a group of participants receive implantable loop recorder before cryoballoon ablation|Following enrollment, an implantable loop recorder is implanted in all participants for the purpose of arrhythmia (any atrial fibrillation or atrial tachycardia) detection (Reveal LINQ, Medtronic, Minneapolis, MN).
62121561|NCT05463549|EXPERIMENTAL|Informative video|The research group will be exposed to an informative instructional film before the procedure.
62121562|NCT05463549|NO_INTERVENTION|No video|The control group will undergo amniocentesis with information given as accepted by standard-of-care.
62121563|NCT01240941|EXPERIMENTAL|MK-2206|MK-2206 maximum tolerated dose found from Phase Ib trial (under a separate NCT number) taken orally on a weekly basis
62310130|NCT03161418|EXPERIMENTAL|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
62680696|NCT05205720|EXPERIMENTAL|NB group|"Celiac plexus block (CPB) was added to the postoperative analgesia plan.~CPB: the target nerve is located in the retroperitoneal space, embedded in the fat in front of the aorta, and distributed in a network along the anterolateral wall of the aorta, just at the beginning of the celiac trunk. During direct vision (anterior) block, first expose the upper edge of the pancreas, palpate the abdominal aorta and abdominal trunk, and palpate the pulsation of the common hepatic artery and splenic artery at the level of the abdominal trunk. Use a 25g 6cm puncture needle with an extension tube and a syringe pumped back by an assistant to form a negative pressure, then the needle is inserted into the fat on both sides of the abdominal aorta. If there is no blood or fluid outflow, slowly inject 10ml of 0.5% ropivacaine each side. After pulling out the needle, observe whether there is damage and bleeding. If necessary, use low-energy electrocoagulation to stop bleeding."
62121564|NCT04121858|EXPERIMENTAL|Brain Safe App|1)Brain Safe App provides conversation starters for older adult patients on target anticholinergics. The conversation starters assist the patient to have discussions with their physicians regarding reduction in exposure to prescription anticholinergics. 2) Provides anticholinergic risk assessment.
62121565|NCT04121858|SHAM_COMPARATOR|Attention Control App|1) Attention Control App provides a medication list for older patients to use but lacks the conversation starters for patient to use with there physicians aimed at reduction in exposure to prescription anticholinergics.2) No anticholinergic risk assessment.
62121566|NCT03130439|EXPERIMENTAL|Abemaciclib|-Abemaciclib will be administered orally, twice daily on days 1 to 28
62121567|NCT00003516|EXPERIMENTAL|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
62310131|NCT02413983||CI (conventional incision)|The living liver donors underwent hepatectomy using right subcostal incision with a midline extension (conventional incision)
62310132|NCT02413983||MI (midline incision)|The living liver donors underwent hepatectomy using upper midline incision (10cm) without laparoscopic assistance
62310133|NCT02413983||TI (transverse incision)|The living liver donors underwent hepatectomy using transverse incision with laparosocpic assistance
62310134|NCT00764894||Foundation Knee|Retrospective data collection on 510(k) approved device
62121568|NCT00238212|EXPERIMENTAL|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62121569|NCT05887180|EXPERIMENTAL|PräVaNet-Intervention|Interdisciplinary Online-Board, close patient care by a specially trained nurse, E-Health-platform with physician cockpit, patient App, sensor kit (ECG-capable pulse watch, digital blood pressure monitor, digital blood glucose meter if required) and a telemonitoring/alarm system.
62121570|NCT05887180|NO_INTERVENTION|Standard of Care|Standard of Care according to currently valid guidelines.
62310135|NCT02142062||Venography and IVUS imaging guiding treatment|
62310136|NCT04430530|EXPERIMENTAL|4SCAR-CD22/CD123/CD38/CD10/CD20 infusion|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
62310137|NCT06667505|ACTIVE_COMPARATOR|CHOICE-ICD|Patients will receive access to the CHOICE-ICD App for 3 months. They will also be provided with the information booklet, similar to usual care group
62310138|NCT06667505|NO_INTERVENTION|Control|Patients will receive information booklet, that they would have received if they had not been included in this research
62310139|NCT03518957|EXPERIMENTAL|Exercise intervention|Patients who are randomised to this arm will be enrolled to the exercise programme.
62310140|NCT03518957|NO_INTERVENTION|Non-exercise|Patients who are randomised to the non-exercise group can continue their daily and physical activities as they normally would.
62310141|NCT01526226|EXPERIMENTAL|HFNC|High flow nasal cannula
62310142|NCT01526226|ACTIVE_COMPARATOR|nCPAP|Nasal CPAP
61921403|NCT05730816|EXPERIMENTAL|Magnesium Sulfate|The IV Mg will start at 1 g/hour (25 ml/hour) within one hour following induction of anesthesia and stabilization of the patient. The infusion will continue for 24 hours and serum Mg levels will be monitored every 4 hours (+/-1 hour) for 28 hours following initiation of the Mg. Dose adjustments to the Mg infusion will be made as necessary to reach target serum Mg levels (3-5 mg/dl).
61921404|NCT05730816|PLACEBO_COMPARATOR|Normal Saline|Patients randomized to placebo will receive an equal volume of normal saline (0.9% NS) placebo which will be administered as a continuous infusion at 25 ml/hour. The infusion will continue for 24 hours.
62121571|NCT03297346|OTHER|Breast cancer patients treated with RT|"Cardiac imaging and circulating biomarkers measurements to evaluate:~* myocardial dysfunction and deformation (ECHO-ST)~* coronary artery lesions and coronary artery calcium score (CT)~* myocardium including tissue abnormalities, cardiac morphology and function (MRI)~* blood-based biomarkers of cardiovascular changes (BLOOD)"
62476089|NCT02251886|ACTIVE_COMPARATOR|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
62476090|NCT02251886|ACTIVE_COMPARATOR|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
61921405|NCT03924531|EXPERIMENTAL|Mindful Awareness Program|The group that received mindfulness training.
61921406|NCT03924531|ACTIVE_COMPARATOR|Health Promotion Program|The group that received the health information.
61921407|NCT01055496|EXPERIMENTAL|Arm 1 (R-CVP)|Subjects in arm 1 will be enrolled in dose escalation cohorts that will initially evaluate an escalating dose of cyclophosphamide in combination with set doses of inotuzumab ozogamicin, vincristine, prednisone, and rituximab.
61921408|NCT01055496|EXPERIMENTAL|Arm 2 (R-GDP)|Subjects in arm 2 will be enrolled in dose escalation cohorts that will initially evaluate escalating doses of gemcitabine and/or cisplatinum in combination with set doses of inotuzumab ozogamicin, dexamethasone, and rituximab.
61921409|NCT00894374|EXPERIMENTAL|Artesunate (Pfizer)|
61921410|NCT00894374|ACTIVE_COMPARATOR|Artesunate (Arsuamoon® Tablets Guilin-China)|
61921411|NCT01692873|EXPERIMENTAL|suspected pancreatic tumor|Realization of pancreatic tumor biopsy and blood samples
61921412|NCT03425227|EXPERIMENTAL|study group / control group|"The subjects belonging to the study group carried out three sessions per week over a 6-week period. Each session involved 20 minutes of activity divided into three parts.~The subjects belonging to the control group continued to lead their daily lives in the course of which they had no physical activity scheduled."
62121572|NCT04529382||Cohort 1: Unanticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 1 will be FNAIT cases that were not antenatally treated with by maternal IVIg administration (or other forms of fetal therapy).
62121573|NCT04529382||Cohort 2: Anticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 2 will be FNAIT cases which were anticipated antenatally by maternal IVIg administration according to our local protocol.
62310143|NCT02896140||Type 2 diabetes in WhyWAIT Program|Patients with type 2 diabetes who are participating in Joslin Diabetes Center's 12-week intensive diabetes weight management program (WhyWAIT).
62310144|NCT04486521||Experimental|anti-IL-6 drugs (tocilizumab and siltuximab)
61921413|NCT02810678|NO_INTERVENTION|Control|No Intervention: Program runs as per usual. Minimal interference and visits from study staff. Main study outcomes evaluated in first and last 6 months of trial. Minimal visits to collect information on costing at control sites.
61921414|NCT02810678|ACTIVE_COMPARATOR|Intervention|Latent Tuberculosis Infection program evaluation \& diagnosis: In intervention health facilities the current Latent Tuberculosis Infection program will be evaluated and gaps in the Latent Tuberculosis Infection cascade of care will be identified. Gaps in the current cascade will be quantified and solution proposed that are unique to the problems identified in each site. In phase 2 of the study low cost solutions will be implemented and the Latent Tuberculosis Infection program scaled up and improved. Study outcomes are evaluated in the first and last 6 months of trial. Costing evaluations are done throughout the trial.
61921415|NCT05737771|OTHER|Group A|administrate DWP16001 + DWC202213 at first period, and administrate DWJ1563 at second period
62310145|NCT04486521||Active Comparator 1|Anti-IL-6 drugs (tocilizumab and siltuximab) and corticosteroids combination
62310146|NCT04486521||Active Comparator 2|corticosteroids alone
62310147|NCT05701852||cases : patients with chronic pain|
62310148|NCT05701852||controls|
62310149|NCT02081469|OTHER|Arm A:TDF for extend 24 weeks|Arm A:Continue TDF 300mg daily for extend 24 weeks after completion of chemotherapy
62310150|NCT02081469|OTHER|Arm B: TDF for extend 48 weeks|Arm B: Continue TDF 300mg daily for extend 48 weeks after completion of chemotherapy.
62476091|NCT02251886|NO_INTERVENTION|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
62476092|NCT02251886|NO_INTERVENTION|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
62476093|NCT02140580|ACTIVE_COMPARATOR|Minimally invasive surfactant therapy|Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. Poractant alfa (Curosurf) at a dosage of 200 mg/kg will be administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP.
62680697|NCT05205720|NO_INTERVENTION|GC group|The same analgesic plan as the experimental group, except that CPB is not performed.
62121574|NCT02341625|EXPERIMENTAL|Part 1: Ascending dose of BMS-986148|BMS-986148 Intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer. Alternate dose and schedules may be explored.
61921416|NCT05737771|OTHER|Group B|administrate DWJ1563 at first period, and administrate DWP16001 + DWC202213 at second period
61921417|NCT04444427|EXPERIMENTAL|Part 1: Dose Escalation|Dose escalation cohorts are planned to determine the maximum tolerated dose or recommended phase 2 dose of GLR-2007, as well as expansion cohorts and a Phase 2 cohort.
61921418|NCT04444427|EXPERIMENTAL|Part 2: Dose Expansion - Cohort A|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their non-small cell lung cancer (NSCLC) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
62121575|NCT02341625|EXPERIMENTAL|Part 2: Expansion dose of BMS-986148|BMS-986148 Intravenous injection of Maximum tolerated dose (MTD) on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
62121576|NCT02341625|EXPERIMENTAL|Part 3A: Ascending dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
62310151|NCT00446394|EXPERIMENTAL|1|
62310152|NCT00446394|ACTIVE_COMPARATOR|2|
62680698|NCT00951873|EXPERIMENTAL|A|
62680699|NCT00951873|PLACEBO_COMPARATOR|B|
62680700|NCT00951873|EXPERIMENTAL|C|
62121577|NCT02341625|EXPERIMENTAL|Part 3B: Expansion dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at or below maximum tolerated dose on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
62121578|NCT03145480|EXPERIMENTAL|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
62680701|NCT05026632|EXPERIMENTAL|Single NPI-002 Intravitreal Implant|one NPI-002 implant inserted at the time of vitrectomy
62680702|NCT05026632|EXPERIMENTAL|Double NPI-002 Intravitreal Implant|two NPI-002 implants inserted at the time of vitrectomy
62310153|NCT04012411|ACTIVE_COMPARATOR|Patient with LP|Huntington's disease patients who agreed to have LP
62310154|NCT04012411|ACTIVE_COMPARATOR|Patient without LP|Huntington's disease patient with contraindication to LP or refusal to have LP
62310155|NCT04012411|NO_INTERVENTION|Control Group|Retrospective study with biologic samples of patients without Huntington's disease
62476094|NCT02140580|SHAM_COMPARATOR|Continuation on CPAP|Standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring. CPAP will thereafter continue.
62310156|NCT05852210||Infrared CRPS Group|"This group includes people who have recently been diagnosed with CRPS type 1. Participants in the Infrared group will have their feet photographed using a:~* FLIR T420 or T62101 camera with 320\*240 resolution.~* Each image will be captured at a perpendicular angle with a 1-inch gap on all four sides.~* The patients' feet will be separated from the background using a Myler blanket.~* The camera will be normalized to the temperate range of 15°C minimum and 40°C maximum.~* Patients will complete questionnaires about the severity of their CRPS and their pain levels."
62310157|NCT05110586|EXPERIMENTAL|1st group: TENS|Tens will be applied.
62476095|NCT05053854|EXPERIMENTAL|177Lu-DOTA-Octreotate + talazoparib|Patients will receive 4 cycles of 177Lu-DOTA-Octreotate every 8 weeks, the last 3 cycles combined with talazoparib on days 2-6 of each cycle.
62476096|NCT04246476|EXPERIMENTAL|Self cueing|People living with Parkinson disease and controls walking with self-generated rhythmic cues.
62680703|NCT05026632|NO_INTERVENTION|Control|No implant inserted at time of vitrectomy
62310158|NCT05110586|EXPERIMENTAL|2nd group: Interferential current|Interferential current will be applied.
62310159|NCT01481246||Normal Aging/Cognitive Decline|Health adults as well as adults with MCI and early stage AD are being recruited in the study
62476097|NCT04246476|ACTIVE_COMPARATOR|External cueing|People living with Parkinson disease and controls walking to external rhythmic cues (i.e., music).
62476098|NCT06486623|EXPERIMENTAL|1. Supplemented group|"The supplemented group (n=12) consumed capsules with highly concentrated 18% chokeberry extract (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour). The producer of all capsules is MLD Biotrade in Poznan.~The swimmers took 2 capsules a day (before breakfast and dinner) for nearly 56 days (depending on length menstrual cycle phase). The swimmers sipped each capsule with glass of water."
62680704|NCT04918914|OTHER|Intervention|
62680705|NCT05405166|EXPERIMENTAL|Isatuximab Subcutaneous (SC)|Isatuximab dose will be administered SC weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days in duration. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days). Participants may receive other treatments as background treatment and/or rescue medication.
62680706|NCT05405166|ACTIVE_COMPARATOR|Isatuximab Intravenous (IV)|Isatuximab dose will be administered via IV infusion weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days). Participants may receive other treatments as background treatment and/or rescue medication.
62121579|NCT03145480|EXPERIMENTAL|Frail arm|ibrutinib and obinutuzumab
62476099|NCT06486623|PLACEBO_COMPARATOR|2. Placebo group|"The control group (n=10) consumed capsules that were made from chokeberry fiber. The producer of all capsules is MLD Biotrade in Poznan.~The swimmers took 2 capsules a day (before breakfast and dinner) for nearly 56 days (depending on length menstrual cycle phase). The swimmers sipped each capsule with glass of water."
62476100|NCT03325387|EXPERIMENTAL|LY3305677|Escalating doses of LY3305677 administered by subcutaneous (SC) injection
62476101|NCT03325387|PLACEBO_COMPARATOR|Placebo|Saline solution administered by SC injection
62476102|NCT03500341|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00014 sensor
62680707|NCT03258957|EXPERIMENTAL|Fresh milk group|In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
62121580|NCT01118806||medical residents, vit d|vitamin
62121581|NCT01118806||levels of vitamin d|resident
62310160|NCT00632593|ACTIVE_COMPARATOR|Circular Stapled|Patients operated performing the gastric pouch of the gastric bypass with a circular staple device
62310161|NCT00632593|ACTIVE_COMPARATOR|Handsewn anastomosis|Patients operated performing the gastric pouch of the gastric bypass in a handsewn manner
62310162|NCT05221125|EXPERIMENTAL|Psychologically-Informed Physical Therapy (PIPT)|CBT-trained physical therapist evaluation and treatment with recommendation for Spine Health follow up after ED discharge
62310163|NCT05221125|NO_INTERVENTION|Control|Usual care only
62476103|NCT03625115|NO_INTERVENTION|Usual Care (Control)|Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
62310164|NCT03352856|ACTIVE_COMPARATOR|Active|Highly purified barley starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
62121582|NCT05727202||SARS-CoV-2 infection|50 positive samples 500 negative samples
62121583|NCT05727202||Influenza A infection|50 positive samples 500 negative samples
62121584|NCT05727202||Influenza B infection|30 positive samples 500 negative samples
62310165|NCT03352856|PLACEBO_COMPARATOR|Placebo|Maize starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
62310166|NCT04927650||Screening|Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.
62310167|NCT04591288|EXPERIMENTAL|FES + Treadmill|Functional Electrical stimulation walking group.
62310168|NCT04591288|ACTIVE_COMPARATOR|Treadmill only|Treadmill walking group (no electrical stimulation).
62310169|NCT04591288|NO_INTERVENTION|Control|"Control group.~After control period of 12 weeks, they are randomized into FES + Treadmill or Treadmill group."
62476104|NCT03625115|EXPERIMENTAL|Family Navigator (Intervention)|Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.
62121585|NCT05727202||RSV infection|30 positive samples 500 negative samples
62121586|NCT05590468|EXPERIMENTAL|Nicotinamide Riboside treatment group|Subjects will receive vitamin B3 derivative Nicotinamide Riboside (NR) daily for 12 months
62121587|NCT05590468|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive a placebo daily for 12 months
62310170|NCT01425866|EXPERIMENTAL|2 years self management education|Long-term program including initial self-management education program (1 to 7 sessions, based on individual assessment), and follow-up group sessions maintained for 2 years (4-monthly assessment, empowerment, and contextual action planning; facultative additional specific thematic sessions being delivered if needed).
62310171|NCT01425866|ACTIVE_COMPARATOR|Initial self-management education|Initial self-management group education: 1 to 7 sessions (\< 3 months), based on individual assessment.
62310172|NCT05278793|EXPERIMENTAL|Intermittent|This group will receive ferrous fumarate 200mg intermittent three times a week on alternate days.
62310173|NCT05278793|ACTIVE_COMPARATOR|Daily|This group will receive ferrous fumarate 200mg once daily.
62310174|NCT01702012|EXPERIMENTAL|Almased Meal Replacement Powder|Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
62310175|NCT01702012|ACTIVE_COMPARATOR|Lifestyle Intervention|Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
62310176|NCT00085969|PLACEBO_COMPARATOR|A1 - Placebo 0.04 mL twice daily|
62310177|NCT00085969|PLACEBO_COMPARATOR|A2 - Placebo 0.04 mL once daily|
62310178|NCT00085969|PLACEBO_COMPARATOR|A3 - Placebo 0.08 mL once daily|
62310179|NCT00085969|EXPERIMENTAL|B - Exenatide 10 mcg twice daily|
62310180|NCT00085969|EXPERIMENTAL|C - Exenatide 10 mcg once daily|
62310181|NCT00085969|EXPERIMENTAL|D - Exenatide 20 mcg once daily|
62310182|NCT02481765|EXPERIMENTAL|Direct current Stimulation|High definition transcranial direct current stimulation (HD-tDCS)
62310183|NCT00144300|ACTIVE_COMPARATOR|Mirapex|Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines
62310184|NCT00144300|ACTIVE_COMPARATOR|Requip|Requip tablets three times daily (TID) dosing according to manufacturer's guidelines
62310185|NCT03551028|OTHER|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
62310186|NCT06457438|EXPERIMENTAL|Organ Donors|Samples obtained from organ donors will be included in this study arm.
62310187|NCT06457438|EXPERIMENTAL|Cell Donors|Samples obtained from cell donors will be included in this study arm.
62476105|NCT03341156|EXPERIMENTAL|Kcentra (PCC)|Half of subjects enrolled will be randomized to the Kcentra (PCC) group.
62476106|NCT03341156|ACTIVE_COMPARATOR|Frozen Plasma Product, Human|Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.
62476107|NCT05234567||Participants with Pediatric-onset HPP|Each participant will be followed for a minimum of 5 years or, if applicable, until early withdrawal. Biochemical, clinical, imaging (if clinically indicated), and functional/quality of life outcomes relevant to HPP will be assessed.
62476108|NCT01334307|EXPERIMENTAL|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
62476109|NCT01334307|PLACEBO_COMPARATOR|Control|Standard of Care
62476110|NCT01902394|EXPERIMENTAL|Whole grain rich diet|Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
61921419|NCT04444427|EXPERIMENTAL|Part 2: Dose Expansion - Cohort B|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their brain metastases of breast or NSCLC origin will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
62121588|NCT02115139|EXPERIMENTAL|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
62310188|NCT02202603|ACTIVE_COMPARATOR|Teriparatide group 1|Subcutaneous injection of Teriparatide
62310189|NCT02202603|PLACEBO_COMPARATOR|excipients|Oral pill without API
62310190|NCT02202603|EXPERIMENTAL|API|Oral administration of pill with API
62310191|NCT02202603|EXPERIMENTAL|API optimization 1|Oral administration of pill with API, for PK optimization #1
62310192|NCT02202603|EXPERIMENTAL|API optimization 2|Oral administration of pill with API, for PK optimization #2
62310193|NCT02202603|EXPERIMENTAL|API optimization 3|Oral administration of pill with API, for PK optimization #3
62310194|NCT02202603|EXPERIMENTAL|API optimization 4|Oral administration of pill with API, for PK optimization #4
62310195|NCT02202603|EXPERIMENTAL|API optimization 5|Oral administration of pill with API, for PK optimization #5
62310196|NCT02202603|EXPERIMENTAL|API optimization 6|Oral administration of pill with API, for PK optimization #6
62310197|NCT02202603|EXPERIMENTAL|API optimization 7|Oral administration of pill with API, for PK optimization #7
61921420|NCT04444427|EXPERIMENTAL|Part 2: Dose Expansion - Cohort C|Participants experiencing their first recurrence glioblastoma multiforme (GBM) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
61921421|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
61921422|NCT04890743|EXPERIMENTAL|Conventional TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
62121589|NCT06110416|OTHER|Aromatherapy|
62121590|NCT01460563|EXPERIMENTAL|Mg_orfil|patients preloaded with sodium valproate receives MgSO4 during the craniotomy.
62310198|NCT02202603|ACTIVE_COMPARATOR|Teriparatide group 2|Subcutaneous injection of Teriparatide
62310199|NCT02202603|EXPERIMENTAL|Excipients|Oral pill without API
62310200|NCT02202603|EXPERIMENTAL|API Optimized|expanded group size with API in optimized dosage and administration form.
62310201|NCT01858883|EXPERIMENTAL|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
62310202|NCT01483846|EXPERIMENTAL|AV-101|"Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.~--------------------------------------------------------------------------------"
62310203|NCT01483846|PLACEBO_COMPARATOR|microcrystalline cellulose|Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
62310204|NCT05916638||Sarcoidosis|patients diagnosed with sarcoidosis
62476111|NCT01902394|PLACEBO_COMPARATOR|Refined grain rich diet|Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
61921423|NCT04890743|EXPERIMENTAL|Pseudo-acupuncture TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
62680708|NCT04209855|EXPERIMENTAL|Mirvetuximab Soravtansine|Participants will receive single-agent mirvetuximab soravtansine (MIRV) at 6 milligrams (mg)/kilogram (kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of every 3-week cycle (Q3W).
61921424|NCT04890743|EXPERIMENTAL|Trabert ultrastimulation group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
61921425|NCT04890743|PLACEBO_COMPARATOR|Placebo group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
62310205|NCT05916638||Tuberculosis|patients diagnosed with tuberculosis
62310206|NCT01791439|EXPERIMENTAL|Lidocaine|Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.
62680709|NCT04209855|ACTIVE_COMPARATOR|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion.
62680710|NCT06689722|EXPERIMENTAL|chiropractic|chiropractic practices
62680711|NCT06689722|SHAM_COMPARATOR|placebo|sham manipulation applications
62680712|NCT06689722|ACTIVE_COMPARATOR|control|those who did not receive any intervention
62680713|NCT06695507|EXPERIMENTAL|Ruxolitinib Treatment|
62680714|NCT05909709|EXPERIMENTAL|Alocyte Low dose|Subjects will receive low dose injection in a single facet joint
61921426|NCT03091972|EXPERIMENTAL|Contact force assisted linear ablation|Left atrial linear ablation performed using the contact force sensing catheter after pulmonary vein isolation
61921427|NCT03091972|ACTIVE_COMPARATOR|control|Left atrial linear ablation performed using the catheter without contact force sensing after pulmonary vein isolation
61921428|NCT06289621|EXPERIMENTAL|Anxiety Disorders and Post-traumatic Stress Disorder (PTSD) Transdiagnostic Treatment ( FSET)|The anxiety disorders and post-traumatic stress disorder (PTSD) transdiagnostic treatment (FSET) is brief, 5-session, cognitive-behavioral intervention designed to treat symptoms associated with anxiety disorders and PTSD. The treatment is administered by lay providers (e.g., nurses) in primary care clinics in South Africa.
61921429|NCT06289621|OTHER|Enhanced Standard Care Group|The enhanced standard care group is the condition. Those in the enhanced standard care control group will receive standard care plus referrals. Upon completion of the study, they will be offered the anxiety disorder and post-traumatic stress disorder treatment (FSET).
62310207|NCT01791439|PLACEBO_COMPARATOR|Saline|Application of saline to the glossopharyngeal nerve.
62310208|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
62310209|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
62476112|NCT01902394|NO_INTERVENTION|Negative control|Subjects randomized to the negative control group will consume their own usual diet (i.e. not receive foods and beverages from the study).
62476113|NCT00868413|ACTIVE_COMPARATOR|A|FCR+ABT-263
62476114|NCT00868413|ACTIVE_COMPARATOR|B|BR+ABT-263
61921430|NCT01815203|EXPERIMENTAL|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
61921431|NCT01815203|PLACEBO_COMPARATOR|Placebo|Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.
61921432|NCT00248885|ACTIVE_COMPARATOR|1|In this group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB.
61921433|NCT00248885|EXPERIMENTAL|2|In this group (High), the goal was to maintain MAP between 80-100 mm Hg during CPB.
61921434|NCT06491667||Elevated NLR and CRP level|Elevated NLR and CRP level
61921435|NCT06491667||Normal NLR and CRP level|Elevated NLR and CRP level
61921436|NCT01555957|EXPERIMENTAL|low dose intravenous lipids|
61921437|NCT01555957|PLACEBO_COMPARATOR|high dose of intravenous lipids|
61921438|NCT03383705|EXPERIMENTAL|Treatment arm|
61921439|NCT06028100|ACTIVE_COMPARATOR|espb group|The first group underwent sacral espb at the end of surgery. The lumbosacral region was sterilised with povidine iodine and then draped with the patient in prone position. The linear ultrasound probe was placed in the midline on the spinous process of the 5th lumbar vertebra after the sterile covering had been applied. After observation of the sacrum, the level of the 2nd median crest was determined and the ultrasound probe was moved 1.5-2 cm laterally and the 2nd intermediate crest and the erector spinae muscle between the two were observed. 22 G 50 mm needle was advanced from caudal to cranial direction to the sacral crest using in-plane technique, after confirming the needle position with 1-2 ml saline, 0.25% bupivacaine 20 ml was administered, local anaesthesia was observed to spread cauda-cranially separating the erector spinae muscle from the sacral crest, the same procedure was performed on the opposite side
61921440|NCT06028100|NO_INTERVENTION|control group|The second group had no any block
62476115|NCT03305263|EXPERIMENTAL|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
62476116|NCT03305263|PLACEBO_COMPARATOR|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
62476117|NCT04952857|EXPERIMENTAL|Intervention|Vitamn D 6 lakh IU oral stat
62476118|NCT04952857|PLACEBO_COMPARATOR|Placebo|Placebo equal volume/ weight
62476119|NCT00520429|OTHER|1|This study is an open pilot; therefore all participants were given the opportunity to receive treatment.
62680715|NCT05909709|EXPERIMENTAL|Alocyte Medium dose|Subjects will receive medium dose injections in three facet joints
61921441|NCT01669707|EXPERIMENTAL|Endostar -Continued Pumping into+GP|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin
61921442|NCT01669707|ACTIVE_COMPARATOR|Endostar -injecting into +GP|Endostar that is injecting into vein with Gemcitabine -Cisplatin
61921443|NCT02184351|EXPERIMENTAL|Roxanes's clotrimazole troches|
61921444|NCT02184351|ACTIVE_COMPARATOR|Mycelex® troches|
62121591|NCT01460563|PLACEBO_COMPARATOR|control_orfil|patients preloaded with sodium valproate receives 0.9% saline as placebo.
62121592|NCT01460563|PLACEBO_COMPARATOR|control_no orfil|patients not preloaded with sodium valproate receives 0.9% saline as placebo.
62680716|NCT05909709|EXPERIMENTAL|Alocyte High dose|Subjects will receive high dose injections in five facet joints
62121593|NCT05475041||Minor liver resection|Minor liver resection (\<3 contiguous segments) in the anterolateral segments
62121594|NCT05475041||Technically major liver resection|Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (Segment 1,4a,7,8)
62680717|NCT06283589|EXPERIMENTAL|INZ-701|The study consists of a 26-day treatment period where the dose of INZ-701 will be 1.8 mg/kg once weekly. INZ-701 will be administered as a subcutaneous injection once weekly for 4 weeks on Days 3, 10, 17, and 24. The study participant's post-hemodialysis body weight on Day 1 will be used to calculate the dose to be administered.
62680718|NCT03186378|EXPERIMENTAL|Exposure Group|This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
62680719|NCT03186378|EXPERIMENTAL|Standard Group|This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
62121595|NCT05475041||Major liver resection|Major liver resection (3 or more contiguous segments)
62121596|NCT04410510|PLACEBO_COMPARATOR|Control group|Lopinavir / ritonavir \* Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine \* Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days Placebo capsule equivalent to 250mg of excipient every 12 hours for 14 days
62121597|NCT04410510|EXPERIMENTAL|Intervention group|Lopinavir / ritonavir \* Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine \* Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days
62121598|NCT03087578|EXPERIMENTAL|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
62121599|NCT03087578|ACTIVE_COMPARATOR|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
62121600|NCT02957812|EXPERIMENTAL|Orthotics|Custom made orthotic provided for study
62121601|NCT02957812|NO_INTERVENTION|Control|Wearing own footwear
61921445|NCT00267618|EXPERIMENTAL|Treatment|50% randomized to receive FHP Pain intervention
61921446|NCT00267618|NO_INTERVENTION|control|50% randomized to receive standard/usual care for recurrent headache/abdominal pain
62476120|NCT05300022|NO_INTERVENTION|Arm 1: Semi-structured Interviews|Arm 1 will be conducted from months 0-15 and will use interviews to better understand existing challenges in diabetes technology educational practices. It is not a clinical trial, but is a crucial part of what builds to the clinical trial.
62476121|NCT05300022|EXPERIMENTAL|Arm 2: Designing an App Delivered Curriculum|Arm 2 will be conducted from months 10-33 and will use information learned in arm 1 to develop and beta test an educational curriculum. Arm 2 also is not a clinical trial, but is a crucial part of what builds to the clinical trial.
62476122|NCT05300022|ACTIVE_COMPARATOR|Arm 3: TeKnO T1D: Parents Pilot Study|Arm 3 will be conducted from months 30-60 and involves a pilot and feasibility study of the newly developed educational curriculum. This is the clinical trial.
61921447|NCT03333733|EXPERIMENTAL|HENRY|Children's Centres within local authorities that have been randomised to the experimental arm, HENRY, will receive staff training to deliver the training and be asked to implement at least two programmes per year. Parents enrolled to attend HENRY programmes will then be invited to take part in the research.
61921448|NCT03333733|NO_INTERVENTION|Waiting list control|Children's Centres within local authorities that have been randomised to the control arm will continue with usual practice. Parents attending another programme (Stay and Play) will be invited to take part in the research. At the end of the follow-up period, they will be offered training to deliver HENRY programmes although this will not be compulsory.
62680720|NCT04105725|EXPERIMENTAL|BMI+Substance-Free Activity Session|Two 50-minute text messaging sessions that discuss alcohol use and experiences related to alcohol use, as well as the individual's college, career, and personal goals. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that return to the individual's goals and progress.
62121602|NCT05099575||Pregnant women who receive oxytocin|
62121603|NCT05099575||Pregnant Women who receive carbetocin|
62476123|NCT03557541|EXPERIMENTAL|Sardine group|
61921449|NCT05728775|EXPERIMENTAL|Remimazolam TIVA|Remimazolam is administered at 6-12 mg/kg/h intravenously for anesthesia induction and at 1.0-2.0 mg/kg/h for maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
61921450|NCT05728775|ACTIVE_COMPARATOR|Propofol TIVA|Propofol 1.5-2.5mg/kg is administered intravenously for anesthesia induction and propofol at 4-12mg/kg/h is used for maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
61921451|NCT05578157||Group 1|Age 55 - 60 years
61921452|NCT05578157||Group 2|Age 60 - 65 years
61921453|NCT05578157||Group 3|Age 65 - 70 years
61921454|NCT03742908|NO_INTERVENTION|saline control|Implant immersion with 100 ml sterile saline (0.9%) for 10 minutes; Breast pocket irrigation (IRRI) with 100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards. No antibiotics is used.
62476124|NCT03557541|ACTIVE_COMPARATOR|Control group|
62476125|NCT01293474||glaucoma patients|patients with diagnosis of primary open angle glaucoma
62476126|NCT01293474||control group|age matched healthy controls
62476127|NCT02601625|EXPERIMENTAL|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
61921455|NCT03742908|EXPERIMENTAL|Cefazolin/clindamycin immersion|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI) with100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards
61921456|NCT03742908|EXPERIMENTAL|Cefazolin/clindamycin immersion+ IRRI|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI): breast pocket is irrigated with100ml type III Anerdian plus 200mg cefazolin in 100 ml sterile saline (0.9%) for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead of cefazolin
62680721|NCT04105725|ACTIVE_COMPARATOR|Alcohol + Nutrition Education Session|Two 50-minute text messaging sessions the provide information on alcohol and nutrition. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that provide additional information and review previous information about alcohol use and nutrition.
62680722|NCT05626777|EXPERIMENTAL|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
62680723|NCT05626777|EXPERIMENTAL|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
61921457|NCT06271499|ACTIVE_COMPARATOR|Group I|Patients underwent radial artery catheterization using standard USG
61921458|NCT06271499|ACTIVE_COMPARATOR|Group II|Patients underwent radial artery catheterization using smart glasses integrated UGG
61921459|NCT03280927|EXPERIMENTAL|Jublia®|
61921460|NCT00728767|EXPERIMENTAL|1|
61921461|NCT00728767|PLACEBO_COMPARATOR|2|
61921462|NCT01337687|EXPERIMENTAL|Oxytocin|
61921463|NCT01337687|PLACEBO_COMPARATOR|Placebo|
61921464|NCT01997710|EXPERIMENTAL|all-ceramic inlay-retained RBFDP|Treatment with an all-ceramic inlay-retained RBFDP
61921465|NCT01997710|ACTIVE_COMPARATOR|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
62476128|NCT02601625|EXPERIMENTAL|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
62476129|NCT02601625|EXPERIMENTAL|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
62680724|NCT06691776|EXPERIMENTAL|Adapt to rotation for prostate and elective lymph node irradiation|The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. A new software (the rotation simulator) reads both the match of the bony anatomy and the match of the prostate. This software also imports the original planning CT and structures and deforms the original planning CT to match the rotations and translations of pelvis and prostate, as seen in the CBCT. Both these new radiotherapy planning structures and the deformed planning CT are exported to the radiotherapy planning software (Monaco) and used to calculate the adaptive plan. This newly calculated plan will be exported to Mosaiq to treat the patient.
61921466|NCT04143529|EXPERIMENTAL|Personalized acceptance-based mindfulness exercise|The purpose of this study is to identify whether a brief 60-second acceptance based mindfulness intervention at specific time points will reduce state trait anxiety, Mini-Mental Adjustment to Cancer Scale score, pain intensity, distress, anxiety, depression and anger
61921467|NCT04143529|PLACEBO_COMPARATOR|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 second at specific timepoints.
61921468|NCT00741962|EXPERIMENTAL|1|
61921469|NCT00741962|PLACEBO_COMPARATOR|2|
61921470|NCT00003950|EXPERIMENTAL|CPT-11 with Cyclosporine|Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
61921471|NCT00625482|ACTIVE_COMPARATOR|Boys 1|OPV as usual
61921472|NCT00625482|EXPERIMENTAL|Boys 2|OPV plus BCG
61921473|NCT00625482|ACTIVE_COMPARATOR|Girls 1|OPV as usual
61921474|NCT00625482|EXPERIMENTAL|Girls 2|OPV plus BCG
62476130|NCT02601625|PLACEBO_COMPARATOR|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
62476131|NCT02601625|PLACEBO_COMPARATOR|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
62476132|NCT02601625|PLACEBO_COMPARATOR|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
62121604|NCT05099575||Pregnant women who receive misoprostol|
62476133|NCT05422391|OTHER|Pre- post-dietary intervention|Single arm pre-post dietary intervention (caloric restriction)
62476134|NCT06448663|EXPERIMENTAL|CDD arm|This is a 32-week pilot, single site, cross-over trial of alpha-lactalbumin+ inulin + fructo-oligosaccharides vs alpha-lactalbumin + sodium butyrate + inulin + fructo-oligosaccharides. Periods I and II of the study are 12-week long together with a 4-week washout period.
62121605|NCT05099575||Pregnant women who receive ergometrine|
62121606|NCT05971563|ACTIVE_COMPARATOR|Casein|
62476135|NCT03797872|ACTIVE_COMPARATOR|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice. Commonly Initial therapy will be with methotrexate alone unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (sulfasalazine or leflunomide). In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
62476136|NCT03797872|EXPERIMENTAL|Local/IM steroid injections|Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local injections of methylprednisolone or triamcinolone to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication. All active joints will be treated with injections. Injections can be either be given as an intra-articular injection or as an intra-muscular injection. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy).
62476137|NCT04567082||Cancer group|
62476138|NCT04567082||Control group|
61921475|NCT02836600|EXPERIMENTAL|LY3039478|LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
61921476|NCT00597844|EXPERIMENTAL|1|voice evaluation and fMRI prior to surgical rehabilitation of UVCP
61921477|NCT00597844|OTHER|2|Healthy volunteers-voice evaluation and fMRI
61921478|NCT00626054|ACTIVE_COMPARATOR|1|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
61921479|NCT00626054|ACTIVE_COMPARATOR|2|Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test.
61921480|NCT02894008|EXPERIMENTAL|ChAd63- KH|Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults
61921481|NCT02894008|EXPERIMENTAL|ChAd63-KH|Single intramuscular dose of ChAd63-KH, 1x10(10)vp or, following safety review, 7.5 x 10(10)vp in adolescents
61921482|NCT01163032|EXPERIMENTAL|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
61921483|NCT01163032|PLACEBO_COMPARATOR|placebo|Placebo capsules, PO daily for 6 months
61921484|NCT02786524|NO_INTERVENTION|Standard of Care|Patients randomized to this arm receive standard symptom management care by their primary gynecologic oncologist and complete the NCCN distress thermometer and ESAS-r at each visit, every 3-4 weeks.
62121607|NCT05971563|ACTIVE_COMPARATOR|Glycomacropeptide|
62121608|NCT05971563|ACTIVE_COMPARATOR|L- amino acids|
62121609|NCT00979537|EXPERIMENTAL|Test: Nisoldipine ER Tablets, 40 mg|Nisoldipine Extended-release Tablets, 40 mg
62121610|NCT00979537|ACTIVE_COMPARATOR|Reference: Sular Tablets 40 mg|Sular Tablets, 40 mg
62121611|NCT01317446|EXPERIMENTAL|amine fluoride/stannous fluoride|Amine fluoride/stannous fluoride mouthrinse in addition to mechanical oral hygiene
62121612|NCT01317446|NO_INTERVENTION|No rinsing|Mechanical oral hygiene only
62121613|NCT05499039|ACTIVE_COMPARATOR|Group A1 (NIVMV on hypoxemic)|Use of NIV on acute hypoxemic respiratory failure patients
62121614|NCT05499039|EXPERIMENTAL|Group A2 (HFNC on hypoxemic)|Use of HFNC on acute hypoxemic respiratory failure patients
62121615|NCT05499039|ACTIVE_COMPARATOR|Group B1 (NIVMV on hypercapneic)|Use of NIV on acute hypercapneic respiratory failure patients
62738553|NCT06273735||radical prostatectomy patients with versus without MINS|The cohort consists of open and robotic-assisted radical prostatectomy patients. The rate of MINS is determined by laboratory chemistry as part of the study as well as clinically through routine visits and postoperatively through questionnaires. Intervention is not performed according to the study protocol but is part of the normal clinical course, if necessary.
62476139|NCT06427005|EXPERIMENTAL|RSF treatment arm|Participants received Fruquintinib (5 mg daily for 14 days followed by a 7-day break), oral S-1 (80-120 mg daily for 14 days, followed by a 7-day break), and raltitrexed (3 mg/m² on day 1, with a maximum dose of 5 mg) every 3 weeks.
62121616|NCT05499039|EXPERIMENTAL|Group B2 (HFNC on hypercapneic)|Use of HFNC on acute hypercapneic respiratory failure patients
62476140|NCT06028204||Biologic Naïve Group|This will aim to include 50 patients who have been referred with possible asthma or have a diagnosis of asthma, and are established on treatment in the form of bronchodilators and/or inhaled corticosteroids who are not candidates for biologic therapy at present
62476141|NCT06028204||Biologic Group|This will aim to include 10 patients who have been referred with an established diagnosis of asthma and are on treatment in the form of bronchodilators and/or inhaled corticosteroids and have been selected as suitable candidates for commencing biologic therapy.
62476142|NCT03702322|OTHER|Participants|All participants will undergo each treatment.
62476143|NCT05857774||Cases|Adult patients ≥18 years of age undergoing invasive mechanical ventilation in the ICU for any reason within 36 hours of intubation
62476144|NCT05857774||Control condition A|Non-invasively ventilated patients in the ICU within 36 hours of initiating non-invasive ventilation
62121617|NCT03470662|EXPERIMENTAL|experimental group|Care bundle
62476145|NCT05857774||Control condition B|Non-ventilated patients admitted to the ICU receiving no respiratory support or oxygen therapy alone, including high flow nasal cannula
62476146|NCT04988594|EXPERIMENTAL|Premium probiotic yogurt|Participants receive 300 g/d of yogurt with concentrated and freeze-dried probiotic cultures for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
62476147|NCT04988594|EXPERIMENTAL|Conventional yogurt|Participants receive 300 g/d of conventional yogurt for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
62476148|NCT04988594|EXPERIMENTAL|no fermented dairy|Participants followed the American Diabetes Association (ADA) recommendations without including fermented dairy.
62476149|NCT03917147||AUB in Post-Menopause|Abnormal Uterine Bleeding (AUB) in Post-Menopause
62476150|NCT03917147||Endometrial Thickening in post-menopause|Ultrasonographic detection of Thickened Endometrium in post-menopause
62121618|NCT03470662|NO_INTERVENTION|control group|routine care
62310210|NCT03584802|EXPERIMENTAL|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
62680725|NCT06691776|EXPERIMENTAL|CBCT-guided online adaptation for cervical cancer and elective lymph node irradiation|The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. With in-house software, the target areas and the OARs will be deformed to or segmented on the anatomy of the CBCT. These adjusted radiotherapy structures are then send to the radiotherapy planning software (Monaco). There, the structures are visually inspected and, if needed, manually adjusted. Afterwards, Monaco calculates a new, online adaptive radiotherapy plan. After checking, the plan is exported to Mosaiq to treat the patient.
62680726|NCT06691776|EXPERIMENTAL|CBCT-guided online adaptation for bladder cancer.|The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. With in-house software, the target areas and the OARs will be deformed or segmented to the anatomy of the CBCT. These adjusted radiotherapy structures are then send to the radiotherapy planning software (Monaco). There, the structures are visually inspected and, if needed, manually adjusted. Afterwards, Monaco calculates a new, online adaptive radiotherapy plan. After checking, the plan is exported to Mosaiq to treat the patient.
62680727|NCT06691776|EXPERIMENTAL|CBCT-guided online adaptation for lung cancer|The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. The rotation simulator reads both the registration of the primary tumor and of the lymph nodes (via the carina). This software also imports the original planning CT and structures and deforms the original planning CT to match the rotations and translations of the primary tumor and lymph nodes, as seen in the CBCT. Both these new radiotherapy planning structures and the deformed planning CT are exported to the radiotherapy planning software (Monaco) and used to calculate the adaptive plan. This newly calculated plan will be exported to Mosaiq to treat the patient.
62680728|NCT06691776|EXPERIMENTAL|CBCT-guided online adaptation for head and neck cancer|The CBCT will be matched (translated and rotated) to the original planning CT with the clinical image registration software. The rotation simulator reads the image registration of the primary tumor and the match of the lymph node areas. This software also imports the original planning CT and structures and deforms the original planning CT to match the rotations and translations of the primary tumor and lymph node areas, as seen in the CBCT. Both these new radiotherapy planning structures and the deformed planning CT are exported to the radiotherapy planning software (Monaco) and used to calculate the adaptive plan. This newly calculated plan will be exported to Mosaiq to treat the patient.
62680729|NCT06295120|EXPERIMENTAL|3 days|3 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
61921485|NCT02786524|EXPERIMENTAL|Symptom Management and Supportive Care|Patients randomized to this arm are referred to a specialized symptom management and supportive care clinic and seen within two weeks. Patients will be seen in follow-up as recommended by the symptom management providers, and at each visit they will complete the ESAS-r and NCCN distress thermometer and return their responses either in person or by mail to the study team in a pre-addressed postage paid envelope.
62121619|NCT06545214|OTHER|Patients with drug-resistant focal epilepsy|"Patients with \>3 focal to bilateral tonic-clonic seizure per year and who had undergone long-term video-EEG (VEEG) monitoring for presurgical evaluation.~After a prospective baseline, which will allow to ensure prospective seizure count for patients with epilepsy, all participants will undergo a 24-hours hospitalization. The following procedures will be carried out as part of the research:~* Video-EEG recordings~* Respiratory monitoring~* Full-night polysomnography~* 1 Hypercapnic challenge while participant is awake~* 2 Hypercapnic challenges while participant is sleeping~* Auditory stimulus All the medical devices used in this study are already in routine use at Hospices Civils de Lyon"
62121620|NCT06545214|OTHER|Healthy subjects|"Selection of healthy subjects will be performed to ensure age-matching.~After a prospective baseline, which will allow to ensure prospective seizure count for patients with epilepsy, all participants will undergo a 24-hours hospitalization. The following procedures will be carried out as part of the research:~* Video-EEG recordings~* Respiratory monitoring~* Full-night polysomnography~* 1 Hypercapnic challenge while participant is awake~* 2 Hypercapnic challenges while participant is sleeping~* Auditory stimulus All the medical devices used in this study are already in routine use at Hospices Civils de Lyon"
62310211|NCT03584802|ACTIVE_COMPARATOR|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
62310212|NCT06329453||Healthy Individuals|
62310213|NCT06329453||Individuals with neurologic diseases|
62310214|NCT06329453||Individuals with known or suspected autoimmune diseases|
62476151|NCT03917147||Endometrial Thickening in pre-menopause|Ultrasonographic detection of Thickened Endometrium in pre-menopause
62476152|NCT03917147||Pharmacological history of Tamoxifen-related therapy regimens|Patients who had been treated with Tamoxifen
62680730|NCT06295120|EXPERIMENTAL|4 days|4 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
62680731|NCT06295120|EXPERIMENTAL|5 days|5 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
62680732|NCT06295120|EXPERIMENTAL|6 days|6 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
62476153|NCT04834128|EXPERIMENTAL|γδ T cells (IMP, TCB008)|Patients will receive an infusion of γδ T cells (IMP, TCB008) following informed consent after admission to hospital for SARS-CoV-2 infection (COVID-19).
62476154|NCT00124618|EXPERIMENTAL|cetuximab/Radiation|Cetuximab (C225) and Radiation
61921486|NCT01076894|ACTIVE_COMPARATOR|epidural anesthesia|
61921487|NCT01076894|ACTIVE_COMPARATOR|intercostal anesthesia|
62680733|NCT06295120|ACTIVE_COMPARATOR|7 days|7 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
62680734|NCT04770779|EXPERIMENTAL|Mitapivat|"Double-Blind Period: Participants will receive mitapivat 100 milligrams (mg) orally, twice daily (BID) for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
62680735|NCT04770779|PLACEBO_COMPARATOR|Placebo|"Double-Blind Period: Participants will receive placebo matching mitapivat orally, BID for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
62680736|NCT03989908|EXPERIMENTAL|Co-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the same direction in the production of the microfluidic noodle.
62680737|NCT03989908|EXPERIMENTAL|Counter-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the opposite direction in the production of the microfluidic noodle.
62680738|NCT03989908|PLACEBO_COMPARATOR|Mee Sua|Mee Sua is used as a control to compare the outcome due to its similarity in textural properties
62680739|NCT05002816|EXPERIMENTAL|Belantamab Mafodotin and Elotuzumab Arm|"Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.~Belantamab mafodotin will be administered via IV infusion. There will be 3 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested, further dose reduction to 1.4mg/kg every 8 weeks will be administered."
62121621|NCT06193850||Uro-andrologic patients|Subjects belonging to general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.
62121622|NCT02050763|EXPERIMENTAL|Intervention arm|Intervention arm clusters (n=4) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services.
62121623|NCT02050763|NO_INTERVENTION|Control arm|Control arm clusters (n=7) received standard of care HIV services alone.
62121624|NCT02494999|EXPERIMENTAL|13-valent pneumococcal conjugate vaccine|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
62121625|NCT02494999|ACTIVE_COMPARATOR|Prevnar 13|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
62121626|NCT04957069||Avulsion fracture|avulsion fracture of the Achilles tendon
62680740|NCT06466603||GABA Probiotic Dose 1|Dose 1 is a GABA Probiotic containing Lactiplantibacillus plantarum 815 (1 Billion cfu/dose). Capsule taken once daily with food.
62680741|NCT06466603||GABA Probiotic Dose 2|"Dose 2 is a GABA Probiotic containing Lactiplantibacillus plantarum 815 (5 Billion cfu/dose).~Capsule taken once daily with food."
62680742|NCT06466603||Placebo Group|Non-active ingredients in the probiotic capsule include organic rice maltodextrin. Capsule taken once daily with food.
62680743|NCT01812018|EXPERIMENTAL|Endostar|Endostar, Gemcitabine, Docetaxel
62121627|NCT04957069||Rupture|Achilles tendon rupture
62121628|NCT03127358|EXPERIMENTAL|AiCure App|Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.
62121629|NCT03127358|NO_INTERVENTION|Treatment As Usual|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.
62121630|NCT03127358|ACTIVE_COMPARATOR|AiCure with gamification|Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.
61921488|NCT03103061|EXPERIMENTAL|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
61921489|NCT01165567|EXPERIMENTAL|sarpogrelate 300 mg per day|Patients in the sarpogrelate group receive sarpogrelate 300 mg per day for 24 hours before exposure to contrast agent.
61921490|NCT01165567|NO_INTERVENTION|No sarpogrelate medication|
62121631|NCT01703585||metastatic breast cancer|
62121632|NCT01703585||metastatic colorectal cancer|
62121633|NCT01703585||metastatic gynecological cancer|
62310215|NCT05447962|EXPERIMENTAL|Barbershop-Based Facilitation (BF)|Participants will receive the Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP) program manual and receive exposure to Barbershop-Based Facilitation (BF), which is designed to stimulate specific, actionable steps that community health workers (CHWs) can undertake to implement CLIP at the barbershop.
62476155|NCT04991194|EXPERIMENTAL|BIA 5-1058 1200 mg (Part I)|Subjects received 1200 mg of BIA 5-1058 once a day (od), in fasting conditions, for 10 days
62121634|NCT01703585||metastatic melanoma|
62121635|NCT01386138|EXPERIMENTAL|RBT+WHIC|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups. The four WHC modules were incorporated into the RBT sessions.
62121636|NCT01386138|ACTIVE_COMPARATOR|Psycho-education|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups.
62476156|NCT04991194|EXPERIMENTAL|BIA 5-1058 400 mg (Part II)|Subjects received 400 mg of BIA 5-1058 od, in fasting conditions, for 10 days.
62121637|NCT02827617||TP53 mutated CLL|
61921491|NCT04700033|EXPERIMENTAL|Somatic IVR|Participants with participate in Somatic IVR protocol three times per week for four weeks.
61921492|NCT04700033|ACTIVE_COMPARATOR|Distractive IVR|Participants with participate in Distractive IVR protocol three times per week for four weeks.
61921493|NCT04700033|PLACEBO_COMPARATOR|Control IVR|Participants with participate in Control IVR protocol three times per week for four weeks.
61921494|NCT01280045|EXPERIMENTAL|AROMATASE INHIBITOR|this would be compared before and after VAGINAL HYSTERECTOMY
62121638|NCT00860665||1|Observational study on consecutive persons over the age of 55 years presenting for screening colonoscopy
62121639|NCT06676267|EXPERIMENTAL|laparoscopic surgical systems|Using the Toumai laparoscopic surgical system for gynecological surgical treatment, and combining with 5G communication technology to carry out remote surgical treatment.
62121640|NCT00318019|EXPERIMENTAL|OPC Factor(TM)|
62310216|NCT05447962|ACTIVE_COMPARATOR|Self-Directed|Participants will receive the Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP) program manual.
62310217|NCT00377299|EXPERIMENTAL|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
62476157|NCT01309672|EXPERIMENTAL|Abiraterone acetate + prednisone|"Abiraterone, 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); to be taken daily~Prednisone, 5 mg, oral, 5 mg twice daily"
62680744|NCT06682637|EXPERIMENTAL|Melflufen and Dexamethasone|"* Melflufen 40 mg total dose (30 mg in patients with body weight ≤60 kg and/or in patients with eGFR\<45 mL/min) intravenously on day 1.~* Dexamethasone 10 mg orally or intravenously on day 1-2, 8-9, 15-16, 22-23."
61921495|NCT01280045|ACTIVE_COMPARATOR|GNRH ANALOG|this would be compared before and after VAGINAL HYSTERECTOMY
62310218|NCT00377299|PLACEBO_COMPARATOR|Placebo|Placebo matching active medication.
62476158|NCT04269642|PLACEBO_COMPARATOR|PT320 2.0mg Placebo|will be injected subcutaneously once a week for 48 weeks
62476159|NCT04269642|EXPERIMENTAL|PT320 2.0mg treatment 1|will be injected subcutaneously once a week for 48 weeks
61921496|NCT02102971||Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
62121641|NCT00318019|PLACEBO_COMPARATOR|Placebo|
62121642|NCT00081250|EXPERIMENTAL|Arm I|Patients receive oral creatine daily.
62121643|NCT00081250|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo daily.
62680745|NCT06688097|NO_INTERVENTION|Group A (Control Group)|No esophageal compression is applied, and FMV is performed for 4 minutes.
62310219|NCT03378206|EXPERIMENTAL|Hinged 8-figure plate|Hinged 8-figure plate is a novel devise that has modifications in order to improve the treatment effect of conventional 8-figure plate. This arm will be used to verify the effectiveness and feasibility of the modification.
62680746|NCT06688097|EXPERIMENTAL|Group B (Intervention Group)|Ultrasound-guided esophageal compression plus FMV: before the start of FMV, ultrasound is used to locate the esophagus, and pressure is applied to the esophagus at the cricoid level to collapse the esophageal lumen. Esophageal pressure is released just before tracheal intubation following 4 minutes of ventilation.
61921497|NCT06265779|EXPERIMENTAL|The experimental group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
62121644|NCT04612686||Frail|"At screening participants will be classed as frail if their Electronic Frailty Index score is \>0.24 and if their Clinical Frailty Scale score is 6. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 3 or more frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as frail.~All participants will receive the same assessment procedures."
62121645|NCT04612686||Pre-frail|"At the point of screening, participants will be classed as pre-frail if their Electronic Frailty Index score is 0.13-0.24 and if their Clinical Frailty Scale score is 4-5. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 1 or 2 frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as pre-frail.~All participants will receive the same assessment procedures."
62310220|NCT03378206|ACTIVE_COMPARATOR|conventional 8-figure plate|Conventional 8-figure plate is widespread method to treat genu varum and valgus. This arm, as a comparator, will be the control group to verify the feasibility of the novel hinged 8-figure plate.
62310221|NCT04354025|EXPERIMENTAL|Recipient: FLAG + CIML NK Cells + IL-2|-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
62310222|NCT04354025|OTHER|Donor:|-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.
62310223|NCT05864040|EXPERIMENTAL|Subjects to undergo laparoscopic radical/simple nephrectomy|Adult subjects between 18 and 90 years old, that provided informed consent prior to any clinical investigation-related procedure, who have been scheduled for a laparoscopic radical/simple nephrectomy surgery and who are able and willing to comply with all study requirements to be evaluated for each study visit.
62310224|NCT00744367|PLACEBO_COMPARATOR|Placebo|Placebo in addition to continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly.
62310225|NCT00744367|EXPERIMENTAL|Taspoglutide 10mg|Taspoglutide 10mg once weekly in addition to continued stable metformin plus pioglitazone treatment
62310226|NCT00744367|EXPERIMENTAL|Taspoglutide 10mg/20mg|Taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued stable metformin plus pioglitazone treatment.
62310227|NCT00243893|ACTIVE_COMPARATOR|Brain AVMs|This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
62310228|NCT00243893|ACTIVE_COMPARATOR|Aneurysms|
62310229|NCT04797975|EXPERIMENTAL|KDS-1000|NK cells expanded ex vivo using PM21 membrane particles:
62476160|NCT04269642|EXPERIMENTAL|PT320 2.5mg treatment2|will be injected subcutaneously every two weeks for 48 weeks. (Actually, patients will be injected PT320 2.5 mg and placebo alternately once a week.)
62680747|NCT01886872|ACTIVE_COMPARATOR|Arm I (rituximab, bendamustine hydrochloride)|Patients receive rituximab IV on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
62680748|NCT01886872|EXPERIMENTAL|Arm II (ibrutinib)|Patients receive ibrutinib PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62680749|NCT01886872|EXPERIMENTAL|Arm III (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62121646|NCT04612686||Non-frail|"At the point of screening, participants will be classed as non-frail if their Electronic Frailty Index score is 0-0.12 and if their Clinical Frailty Scale score is 1-2. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting no frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as non-frail.~All participants will receive the same assessment procedures."
62310230|NCT04797975|PLACEBO_COMPARATOR|Control|0.9% Normal Saline
62310231|NCT01364610|ACTIVE_COMPARATOR|Standard Care|Group 1 will have standard catheter based pH-metry. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour monitoring period.
62310232|NCT01364610|ACTIVE_COMPARATOR|Bravo pH Monitoring System|Group 2 will undergo unsedated peroral placement of the Bravo capsule. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour pH monitoring period.
62310233|NCT05450861|EXPERIMENTAL|SF DNA Treatment|the scalp conditioning solution with SF DNA extraction composition is applied daily and combination with hair loss medical treatment for eight weeks.
62310234|NCT05450861|PLACEBO_COMPARATOR|Placebo|the scalp conditioning solution without SF DNA extraction composition is applied daily and combination with hair loss medical treatment for eight weeks.
62310235|NCT06246825||PARABOLA cohort|Patients with paroxysmal or persistent atrial fibrillation and a high likelihood of obstructive sleep apnea
62476161|NCT04486794|EXPERIMENTAL|Treatment at baseline|
62680750|NCT02533128|PLACEBO_COMPARATOR|Liberal blood pressure management|
62680751|NCT02533128|ACTIVE_COMPARATOR|Tight blood pressure management|
62680752|NCT06684535|EXPERIMENTAL|Dexmedetomidine group|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.
62680753|NCT06684535|ACTIVE_COMPARATOR|Control group|Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline.
62476162|NCT04486794|ACTIVE_COMPARATOR|Treatment at Month 1|
62476163|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
62476164|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
62121647|NCT02962791|EXPERIMENTAL|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual, except the additional stimulation lead. Standard Echocardiography will be done at one year
62680754|NCT06095128|EXPERIMENTAL|Vedolizumab 300 mg + Tofacitinib 10 mg|Participants will receive Vedolizumab 300 mg , intravenous (IV) infusion, at Week 0, Week 2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to Week 8. Participants with clinical response at Week 8 will transition to receive vedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46.
62680755|NCT06137482|EXPERIMENTAL|IV Cohort 1 Low Dose|Randomized as described in the protocol
62310236|NCT04704765|EXPERIMENTAL|The effectiveness of receiving abdominal breathing training|The patients receiving the intervention of abdominal breathing training were in the experimental group. The experimental group received the abdominal breathing training for a total of 8 weeks. During this period, they received the abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time). The control group without training.
62310237|NCT04704765|NO_INTERVENTION|The effectiveness of not receiving abdominal breathing training|The control group who did not receive abdominal breathing training. The effectiveness assessment used the Beck anxiety inventory and physiological index (heart beats, breath and blood pressure), required to be completed by the control group.
62680756|NCT06137482|EXPERIMENTAL|IV Cohort 2 Mid Dose|Randomized as described in the protocol
62121648|NCT02962791|ACTIVE_COMPARATOR|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual. Standard Echocardiography will be done at one year
62121649|NCT03250052|EXPERIMENTAL|Part A|Period 1(fimasartan) x 7days - Period 2(fimasartan + linagliptin) x 7days
62310238|NCT03307447|EXPERIMENTAL|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
62121650|NCT03250052|EXPERIMENTAL|Part B|Period 1(linagliptin) x 7days - Period 2(fimasartan + linagliptin) x 7days
62310239|NCT04096937||Appalachian adults|Adults in Appalachia invested in well-being of youth.
62310240|NCT04096937||Appalachian youth|Youth from 7th through 12th grade.
62680757|NCT06137482|EXPERIMENTAL|IV Cohort 3 High Dose|Randomized as described in the protocol
62680758|NCT06137482|EXPERIMENTAL|IV Cohort 4 Higher Dose|Randomized as described in the protocol
62680759|NCT06137482|EXPERIMENTAL|IV Cohort 5 Highest Dose|Randomized as described in the protocol
62121651|NCT01162876|EXPERIMENTAL|saxagliptin|5 mg daily for 14days
62121652|NCT04614675|ACTIVE_COMPARATOR|Transarticular lateral release (TALR)|TALR The first toe is pulled distally for access into the lateral aspect of first MTPJ. A No.15 beaver blade is advanced from the medial incision laterally to divide the lateral capsule vertically and adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
62121653|NCT04614675|ACTIVE_COMPARATOR|Percutaneous lateral release (PCLR)|PCLR A 0.5 cm stab wound is made at lateral aspect of first MTPJ. A No. 15 beaver blade is advanced into the lateral side of MTPJ with a quarter of the blade inside the joint and verified with fluoroscope. The blade is turned laterally to face the adductor hallucis tendon. The adductor tendon is divided with lateral movement of the blade and varus manipulation of proximal phalanx. A click is heard as adequate release of adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
62121654|NCT00568854|ACTIVE_COMPARATOR|Participants with diabetes|Persons with diagnosis of diabetes. Received biological intervention: BCG
62310241|NCT04735900|EXPERIMENTAL|First-line FOLFOX/FOLFIRI and panitumumab.|Chemotherapeutic agents will be given as an intravenous infusion at a dose and interval consistent with standard institutional practice.
62310242|NCT06658808|EXPERIMENTAL|PC CARES Intervention|PC CARES Intervention Participants will attend 1-5 sessions of the PC CARES curriculum, either virtually or in-person. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
62680760|NCT06137482|EXPERIMENTAL|SC Cohort 1 Low Dose|Randomized as described in the protocol
62121655|NCT00568854|ACTIVE_COMPARATOR|Participants without diabetes|Persons with no diagnosis of diabetes and negative diabetes screening labs. Received biological intervention: BCG.
62121656|NCT05780788|EXPERIMENTAL|Canine retraction arm|Canine retraction
62121657|NCT04448158||5 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 5 years
62680761|NCT06137482|EXPERIMENTAL|SC Cohort 2 High Dose|Randomized as described in the protocol
62680762|NCT06137482|EXPERIMENTAL|IV or SC Optional Cohort|≤ Highest IV or SC Dose as described in the protocol Randomized as described in the protocol
62680763|NCT06695039|EXPERIMENTAL|[18F]FES PET/CT|
62680764|NCT04465487|EXPERIMENTAL|Dose Escalation|REGN6569 lead-in, then combo therapy
62680765|NCT04465487|EXPERIMENTAL|Dose Expansion|Randomized 1:1 between cohorts Cohort 1: Concurrent start of REGN6569 + cemiplimab Cohort 2: REGN6569 lead-in, then combo therapy
62680766|NCT06565663|EXPERIMENTAL|MaPGAS Decision Aid Intervention|Participants in this arm will be provided with access to a novel, web-based decision aid designed for individuals considering MaPGAS. The decision aid includes interactive components, educational materials regarding surgical options, risks, benefits, and patient testimonials. Participants will have unlimited access to the decision aid for four weeks prior to their surgical consultation.
62680767|NCT06565663|NO_INTERVENTION|MaPGAS Usual Care|Participants in this arm will receive the standard pre-consultation care provided by their healthcare provider, which does not include access to the novel decision aid. Standard care may include informational brochures. This group serves to compare the outcomes of traditional decision-making processes with those who use the decision aid.
61921498|NCT06265779|PLACEBO_COMPARATOR|The placebo group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
61921499|NCT03158714|EXPERIMENTAL|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
61921500|NCT03158714|EXPERIMENTAL|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
62121658|NCT04448158||10 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 10 years
62121659|NCT00908830||Cystic fibrosis|Lung transplant patients with cystic fibrosis. Measuring MPA levels in cystic fibrosis lung transplant patients for pharmacokinetic parameters.
62310243|NCT06658808|NO_INTERVENTION|No Intervention|This group will not attend the PC CARES sessions. Investigators will collect data from adults and youth at baseline, at 5 monthly timepoints as learning circles are being conducted in the community, and at follow-up (after 1 month and 6 months).
62680768|NCT05494697|EXPERIMENTAL|Ampligen / rintatolimod + SOC Chemoradiation|Subjects will receive rintatolimod \[intravenous (IV)\], up to 400 mg twice weekly plus SOC chemoradiation until disease progression
62680769|NCT05494697|NO_INTERVENTION|SOC Chemoradiation Alone|Subjects will receive SOC chemoradiation until evidence of disease progression.
62680770|NCT05494697|EXPERIMENTAL|Ampligen / rintatolimod + SOC|Subjects will receive rintatolimod \[intravenous (IV)\], up to 400 mg twice weekly plus SOC (SOC does not include chemoradiation) until disease progression
62680771|NCT05494697|NO_INTERVENTION|SOC Alone|Subjects will receive SOC (SOC does not include chemoradiation) until evidence of disease progression.
62680772|NCT05649540|ACTIVE_COMPARATOR|high dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days
61921501|NCT03158714|NO_INTERVENTION|Control|No programming is offered.
61921502|NCT05144594||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County between 2013-2017, identified by ICD-code K.58.
61921503|NCT01693302|EXPERIMENTAL|-20 minute insulin|Insulin for the meal is given 20 minutes prior to starting the meal.
61921504|NCT01693302|EXPERIMENTAL|0 minute insulin|Insulin for the meal is given immediately before starting to eat.
61921505|NCT01693302|EXPERIMENTAL|+20 minute insulin|Insulin is given 20 minutes after the start of the meal.
61921506|NCT05694000|ACTIVE_COMPARATOR|On-Stimulation|"Disease condition is assessed with stimulation turned on."
61921507|NCT05694000|PLACEBO_COMPARATOR|Off-Stimulation|"Disease condition is assessed with stimulation turned off."
61921508|NCT01554969|EXPERIMENTAL|capecitabine + ganetespib .|Capecitabine oral medication. Ganetespib IV medication
62121660|NCT00908830||Non-cystic fibrosis lung transplant|Non-cystic fibrosis lung transplant patients. Non-cystic fibrosis lung transplant patients will have MPA levels drawn after their dose to determine pharmacokinetic parameters.
62310244|NCT00215501|EXPERIMENTAL|Group A|Oral capecitabine
61921509|NCT04585139|OTHER|Phase 1 -- Introduction to Dexcom G6 CGM|A 2 week run-in wear period of blinded CGM followed by 12 weeks of wear of a Commercially available CGM
61921510|NCT04585139|ACTIVE_COMPARATOR|Phase 2 -- Comparison of an Updated G6 Transmitter to Commercial Dexcom G6 CGM|1 group will wear a Commercially available CGM for 12 weeks while the 2 group will wear an Updated CGM for 12 weeks.
61921511|NCT03442764|EXPERIMENTAL|Group 1|Active Treatment for participants with base target trough concentration
62680773|NCT05649540|EXPERIMENTAL|standard dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 1000mg bid for 14 days
61921512|NCT03442764|EXPERIMENTAL|Group 2|Active Treatment for participants with higher target trough concentration
61921513|NCT03442764|PLACEBO_COMPARATOR|Placebo|Placebo Group
61921514|NCT01473927||1|Crohn's Disease patients
61921515|NCT01473927||2|Ulcerative colitis patients
62121661|NCT03802149|EXPERIMENTAL|Ulipristal Acetate|Participants will be administered a one time dose of 90mg ulipristal acetate 18-24-hours prior to dilation and evacuation (surgical abortion) for cervical preparation.
62121662|NCT01094613|EXPERIMENTAL|Delayed Release 6MP|"6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.~The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP)."
62121663|NCT01094613|ACTIVE_COMPARATOR|Purinethol|6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
62121664|NCT04404881|EXPERIMENTAL|Bevacizumab|"* The research study procedures include: screening for eligibility, pretreatment period, study treatment, end-of-study visit, and follow-up visit. Each period consists of 12 weeks, for a total of 36 weeks.~* Pretreatment Period:Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~* Induction Period (first 3 months of bevacizumab treatment):~  * Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~ * Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~  * Hematologic Support: Iron transfusions and red cell transfusions as determined by study doctor.~ * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
62680774|NCT05649540|EXPERIMENTAL|low dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 500mg tid for 14 days
62680775|NCT05883449|EXPERIMENTAL|Safety run-in in Hodgkin Lymphoma|"4 safety run-in cohorts:~* Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)~* Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)~* Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)~* Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)"
62680776|NCT05883449|EXPERIMENTAL|Dose Level A in Hodgkin Lymphoma|Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level A (selected from cohort 1-4 of Safety run-in)
62680777|NCT05883449|EXPERIMENTAL|Dose Level B in Hodgkin Lymphoma|Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level B (selected from cohort 1-4 of Safety run-in)
62680778|NCT05883449|EXPERIMENTAL|Exploratory: AFM13 + AB-101 on CD30-positive PTCL|AFM13 + AB-101 on select CD30-positive PTCL subtypes (Dose Level A or B)
62121665|NCT00780299|ACTIVE_COMPARATOR|2|control
62121666|NCT00780299|EXPERIMENTAL|1|HDHP
62121667|NCT03655626|EXPERIMENTAL|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
61921516|NCT06035055|EXPERIMENTAL|Ceftolozane/tazobactam 9g infusion|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
61921517|NCT05742178|EXPERIMENTAL|Patient Navigation (PN)|Participants randomized to the PN arm will receive community health worker (CHW)-administered PN for cancer screening + social service needs + culturally and linguistically tailored cancer education. All individuals will complete a survey at baseline, 3 months, and 6 months.
61921518|NCT05742178|ACTIVE_COMPARATOR|Less Intensive (LI)|Participants randomized to LI arm will receive PN to social service needs + culturally and linguistically tailored cancer education materials. All individuals will complete a survey at baseline, 3 months, and 6 months. Once a participant randomized to the LI arm completes the 6-month survey, they will have the option to receive all navigational support provided by CHWs to individuals randomized to the PN arm.
61921519|NCT01244360|PLACEBO_COMPARATOR|Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
61921520|NCT01244360|ACTIVE_COMPARATOR|Dietary Supplement: resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
61921521|NCT02599675|EXPERIMENTAL|Vitamin D3|Vitamin D3 capsules for 12 weeks (2000 IU daily, equivalent to 50 ug)
61921522|NCT02599675|PLACEBO_COMPARATOR|Placebo|Placebo capsules for 12 weeks (the number of daily capsules will match that of the vitamin D-group)
62121668|NCT02889718|EXPERIMENTAL|anaesthesia with CONCERT-CL® station|During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station
62310245|NCT00215501|EXPERIMENTAL|Group B|5-fluorouracil
62680779|NCT05358639|EXPERIMENTAL|Single|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily (bid). Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated. Navitoclax will be administered daily. The initial dose of olaparib 200 mg has been selected after considering the single agent Phase I/II dose based and on ongoing combination studies on expected toxicity and evidence for reduced PARP inhibition
62310246|NCT04568174|ACTIVE_COMPARATOR|PPSGG|sterile liquid, one 1-hour infusion in SAD and multiple infusions in MAD. In SAD multiple cohorts being tested. Dosage and regime in MAD to be defined based on SAD outcome.
62310247|NCT04568174|PLACEBO_COMPARATOR|Placebo|standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
62310248|NCT02617121|ACTIVE_COMPARATOR|Gabapentin|oral gabapentin 300 mg 1 hours before induction of anesthesia
62121669|NCT01819883||Active Acromegaly|All study subjects with acromegaly will be studied twice - once during the active stage of their disease (pre-treatment) and a second time: 3 months after treatment of acromegaly. Controls will be studied at one time point.
62310249|NCT02617121|ACTIVE_COMPARATOR|ramosetron|ramosetron 0.3 mg iv at end of surgery
62310250|NCT02617121|ACTIVE_COMPARATOR|Gabapentin and ramosetron|oral gabapentin 300 mg 1 hours before induction of anesthesia ramosetron 0.3 mg iv at end of surgery
62310251|NCT05484986||Nursing students|
62310252|NCT02688010|NO_INTERVENTION|Control|No specific noise reduction strategies to restrict noise exposure less than 45 dB combined with either continuous bright light or continuous near darkness or unstructured combination of the two during the hospitalization.
62310253|NCT02688010|EXPERIMENTAL|Noise reduction and cycled light|Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
62310254|NCT02102230|EXPERIMENTAL|CBT-I|Group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
62738554|NCT04749888|EXPERIMENTAL|Targeted nurse-led home visiting|The intervention group will receive 25-29 home visits during pregnancy and the first 2 years of life conducted by child health nurses. The frequency of home visits will be determined by nurses based on the needs of the families. The content of each home visit is individually tailored to the mother's needs, skills, strengths, and capacity using parenting education materials.
62310255|NCT02102230|ACTIVE_COMPARATOR|CBT-I-MA|Group Cognitive-Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
62310256|NCT02102230|PLACEBO_COMPARATOR|PC|Desensitization Treatment for Insomnia (DTI)
62476165|NCT02296086||Group I|"Study sites in which patients perform early mobilization as per local standard of care, which is as follows:~* 2 days (at the latest) after surgery: Transfer from the bed to a sitting chair for the first time~* 4 (± 2) days after surgery: Stand up and put both feet on the ground for the first time (walking aids allowed)~* 5 (± 2) days after surgery: Walking (at least partial weight bearing, walking aids allowed)~* The patients are instructed by the investigator at the hospital about a standardized mobilization program to be followed at home"
62121670|NCT01819883||Healthy controls|
62121671|NCT03204396|ACTIVE_COMPARATOR|Intervention group|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via pen s.c. once weekly for 12 weeks.
62121672|NCT03204396|PLACEBO_COMPARATOR|Placebo group|0.5 ml normal saline (0.9% sodium chloride (NaCl)), injection s.c. via syringe once weekly for 12 weeks.
62310257|NCT01563510|EXPERIMENTAL|Laparoscopic operation|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
62310258|NCT01563510|ACTIVE_COMPARATOR|Open operation|The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
62310259|NCT00875420|EXPERIMENTAL|RAD1901 10 mg|Oral once a day for 28 days
62310260|NCT00875420|EXPERIMENTAL|RAD1901 25 mg|Oral once a day for 28 days
62121673|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
62310261|NCT00875420|EXPERIMENTAL|RAD1901 50 mg|Oral once a day for 28 days
62310262|NCT00875420|EXPERIMENTAL|RAD1901 100 mg|Oral once a day for 28 days
62310263|NCT00875420|PLACEBO_COMPARATOR|Placebo|Oral once a day for 28 days
62310264|NCT03401489|EXPERIMENTAL|PACESETTER|
62310265|NCT03401489|NO_INTERVENTION|Healthy Lifestyle Intervention Group|
62310266|NCT04159727|EXPERIMENTAL|IBD or PD patients|20 patients suffering from IBD 10 patients suffering from PD
62310267|NCT04159727|ACTIVE_COMPARATOR|Asymptomatic subjects|30 asymptomatic subjects matched to patients on age, sexe and BMI
62310268|NCT04170621|EXPERIMENTAL|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
62310269|NCT04835272|NO_INTERVENTION|control group|In the control group, the decision to decannulate was based on a 48-hour capping trial.
62310270|NCT04835272|EXPERIMENTAL|intervention group|In the intervention group, the decision to decannulate was based on suctioning frequency.
62310271|NCT03618225|ACTIVE_COMPARATOR|duloxetine group|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
62476166|NCT02296086||Group II|Study sites in which patients start walking (i.e. partial weight bearing, walking aids allowed) more than 7 days after surgery as per local standard of care
61921523|NCT03174899|EXPERIMENTAL|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
62476167|NCT00712777|ACTIVE_COMPARATOR|1|homozygote mutant: Insertion/Insertion (40 patients)
62476168|NCT00712777|ACTIVE_COMPARATOR|2|homozygote mutant: Deletion/Deletion (40 patients)
62121674|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
62121675|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
62121676|NCT01875744|EXPERIMENTAL|Polyethylene glycol small dose|Polyethylene glycol 4000: 0.3 g/kg/day for 6 weeks
61921524|NCT03174899|EXPERIMENTAL|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
62121677|NCT01875744|ACTIVE_COMPARATOR|Polyethylene glycol high dose|Polyethylene glycol 4000: 0.7g/kg for 6 weeks
62121678|NCT03611712|EXPERIMENTAL|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
62476169|NCT02380560||pPROM|50 women with preterm premature rupture of membranes with gestational age from 24 to 34 weeks assessed by ultrasound examination
62121679|NCT03611712|NO_INTERVENTION|CCRT alone arm|
62121680|NCT03519737|SHAM_COMPARATOR|Control group (tPA + sham TUS)|Control group (tPA + sham TUS) During the primary phase of the study, subjects will be randomized 1:1
62121681|NCT03519737|ACTIVE_COMPARATOR|Treatment group (tPA + TUS)|Treatment group (tPA + TUS): Lead-in phase and Primary phase
62121682|NCT05588453|EXPERIMENTAL|Treatment (UD TGFbetai NK cells, temozolomide)|Patients receive UD TGFbetai NK cells IV over 30 minutes on day 1 and temozolomide PO daily on days 1-5. Treatment with UD TGFbetai NK cells repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Cycles of temozolomide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62121683|NCT01184508|EXPERIMENTAL|LY2300559|
62476170|NCT02380560||term non-labor control|25 term non-labor control (T-CTR, n=25) with gestational age from 37 to 41 weeks assessed by ultrasound examination
62476171|NCT02380560||preterm non-labor control|25 preterm non-labor control (P-CTR, n=25) with gestational age from 24 to 34 weeks assessed by ultrasound examination
62476172|NCT04509063|OTHER|Detailed information about screening harms|
62121684|NCT01184508|PLACEBO_COMPARATOR|Placebo|
62310272|NCT03618225|PLACEBO_COMPARATOR|placebo pill group|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
62476173|NCT04509063|OTHER|Non-detailed information about screening harms|
62310273|NCT06085391|EXPERIMENTAL|REThink game|Each recruited participant randomized in the experimental group will receive the REThink game app.
62680780|NCT01902173|EXPERIMENTAL|Treatment (uprosertib, dabrafenib, trametinib)|"Dabrafenib mesylate and uprosertib (Phase I): Patients receive dabrafenib PO BID and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, and blood sample collection throughout trial. Patients may also undergo a biopsy throughout the trial.~Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib (Phase I and Phase II): Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, and blood sample collection throughout trial. Patients may also undergo a biopsy throughout the trial."
62680781|NCT02434809|EXPERIMENTAL|Patients with lung cancer|Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6, 9, 12, 15, 18, 21 and 24 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.
62680782|NCT06600802|EXPERIMENTAL|Interventional|Genetic analysis will be conducted on intial tumor sample in order to identify biomarkers
62680783|NCT06696040|EXPERIMENTAL|Pre-intervention and immediate post-intervention|
62680784|NCT06434506||NWS group|non-wire syndrome group
62680785|NCT06434506||WS group|wire syndrome group
62680786|NCT03233971||Older adults|
62680787|NCT03233971||Caregivers|
62680788|NCT03345810|ACTIVE_COMPARATOR|Control Arm A|Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W
62680789|NCT03345810|EXPERIMENTAL|Experimental Arm B|"Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3~Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W \[2 cyc\] followed by durvalumab (1125 mg; Q3W) \[ 2 cyc\] Maintenance:durvalumab (1500 mg) Q4W"
62680790|NCT03345810|EXPERIMENTAL|Experimental Arm C|"Frail or elderly patients with metastatic NSCLC; CARG- Score \> 3~Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W \[ 2 cyc\] or Gemcitabine (1000 mg/m2; D1+D8) Q3W \[ 2 cyc\] followed by durvalumab (1125 mg) Q3W \[2 cyc\] Maintenance:durvalumab (1500 mg; Q4W)"
62680791|NCT03345810|ACTIVE_COMPARATOR|Control Arm D|"Frail or elderly patients with metastatic NSCLC; CARG- Score \> 3~Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W"
62680792|NCT06496230|EXPERIMENTAL|Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder|EMPWR is a two-pronged intervention model comprised of 1) a provider-driven, telemedicine-based behavioral intervention to mitigate anxiety sensitivity and sleep deficiency and enhance peripartum buprenorphine retention, and 2) an adjunctive mobile application to promote patients' buprenorphine adherence and use of therapy skills learned through the behavioral intervention. The EMPWR therapy protocol is comprised of five 30-60-minute sessions delivered weekly or biweekly by a therapist during the second and/or third trimester of pregnancy, and three 30-minute booster sessions delivered months 1-3 postpartum.
62680793|NCT06324357|EXPERIMENTAL|Phase Ib - Cohort A: zongertinib + Trastuzumab emtansine|Dose escalation (Phase Ib)
62680794|NCT06324357|EXPERIMENTAL|Phase Ib - Cohort B: zongertinib + Trastuzumab deruxtecan|Dose escalation (Phase Ib)
62680795|NCT06324357|EXPERIMENTAL|Phase Ib - Cohort C: zongertinib + Trastuzumab deruxtecan|Dose escalation (Phase Ib)
62680796|NCT06324357|EXPERIMENTAL|Phase II - Cohort D: zongertinib + Trastuzumab emtansine|Dose optimization (Phase II).
62680797|NCT06324357|EXPERIMENTAL|Phase II - Cohort E: zongertinib + Trastuzumab deruxtecan|Dose optimization (Phase II).
62680798|NCT06324357|EXPERIMENTAL|Phase II - Cohort F: zongertinib + Trastuzumab deruxtecan|Dose optimization (Phase II).
62680799|NCT06643962|EXPERIMENTAL|Assigned interventions|Participants with EPBCR\>1.5 log (EPBCRhigh) complete the 3+7 regimen and are managed according to standard clinical practice. Participants with EPBCR≦1.5 log (EPBCRlow) receive intensified treatment with venetoclax orally along with the standard 3+7 regimen on days 5-14. A venetoclax dose ramp-up schedule is required in the first induction therapy.
62680800|NCT04452162|OTHER|Salivary Gland Tumor|
62680801|NCT01778621|EXPERIMENTAL|Acupuncture (Hwato®)|30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up.
62680802|NCT01778621|NO_INTERVENTION|No acupuncture|No intervention was done for this group of patients.
62680803|NCT05894564|EXPERIMENTAL|Arm E - Fluvoxamine 100|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 1 day, followed by a dose of 100 mg twice a day for 12 days.
62680804|NCT05894564|PLACEBO_COMPARATOR|Arm E - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
62121685|NCT05206266|EXPERIMENTAL|Turmeric, then Turmeric+Black Pepper|Participants first receive Turmeric (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper) for 1 week. After a 1 week washout, participants then receive Turmeric at the previous amount plus Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper 300mg/subject daily) for 1 week.
62310274|NCT06085391|ACTIVE_COMPARATOR|MoodWheel|The participants randomized in the control group will complete the MoodWheel app.
62310275|NCT06085391|EXPERIMENTAL|PsyPills|Participants from experimental group who do not respond to REThink game alone will receive the PsyPills app
62310276|NCT00720707|EXPERIMENTAL|(CAF+ADM+EMD)|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
62680805|NCT02838706||Elderly with hip fracture|The subjects are patients age ≥ 65 years requiring surgery for a hip fracture
62310277|NCT00720707|ACTIVE_COMPARATOR|(CAF + ADM)|root coverage procedure by using a coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM)
62310278|NCT01094899|EXPERIMENTAL|Type 1 Diabetics without Neuropathy|Adult male with type 1 diabetes and without peripherical neuropathy
62310279|NCT01094899|EXPERIMENTAL|Type 2 Diabetics without Neuropathy|Adult male with type 2 diabetes and without peripherical neuropathy
62476174|NCT02321098|EXPERIMENTAL|Investigator blinded Loceryl NL+ Cosmetic varnish|Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
61921525|NCT03174899|EXPERIMENTAL|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
62121686|NCT05206266|EXPERIMENTAL|Turmeric+Black Pepper, then Turmeric|Participants first receive Turmeric+Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper at 300mg/subject daily) for 1 week. After a 1 week washout, participants then receive Turmeric daily at the previous amount for 1 week (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper).
62680806|NCT06644768|EXPERIMENTAL|Phase 1b: Pembrolizumab + Valemetostat Tosylate|Participants will be provided with pembrolizumab at standard dose of 200 mg intravenously (IV) Q3W, and valemetostat will be provided per a dose escalation schedule, with an initial starting dose of 150 mg by mouth once daily.
62121687|NCT05457127|EXPERIMENTAL|Automatic Positive Airway Pressure (APAP) device|
62121688|NCT06285097|EXPERIMENTAL|Monotherapy dose escalation (Part 1A)|Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles
62121689|NCT06285097|EXPERIMENTAL|Combination dose escalation (Part 1B)|Participants will receive PF-07820435 orally at the prescribed dose and frequency, in combination with sasanlimab (subcutaneous injection) at a fixed dose once every 4 weeks in 28-day cycles
62121690|NCT06285097|EXPERIMENTAL|Expansion (Part 2) - Tumor specific Arm A|Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles
62121691|NCT06285097|EXPERIMENTAL|Expansion (Part 2) - Tumor specific Arm B|Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles
62121692|NCT06285097|EXPERIMENTAL|Expansion (Part 2) - Arm C|Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles
62121693|NCT01960218||acute decompensated heart failure|Adult subjects anticipating discharge from a hospitalization where the primary discharge diagnosis is acute decompensated heart failure and who are not excluded due to existing conditions.
62476175|NCT02321098|EXPERIMENTAL|Investigator blinded Loceryl NL alone|Loceryl NL once/week for 12 weeks on right or left foot toenails
62476176|NCT03082872|EXPERIMENTAL|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
62476177|NCT03082872|EXPERIMENTAL|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
62476178|NCT05640544|EXPERIMENTAL|Sound and light stimulation in Gamma band|
62476179|NCT03598894||Case NDHT|Healthy non-dipping hypertensives 'NDHT' (24h mean wake SBP \>145mmHg at baseline and a decline of \<10% between mean day time and night time systolic pressures)
62680807|NCT06644768|EXPERIMENTAL|Phase 2: Pembrolizumab + Valemetostat Tosylate|Participants will be provided with pembrolizumab at standard dose of 200 mg IV Q3W, and valemetostat will be provided per recommended phase 2 dose (RP2D)
62680808|NCT06644768|ACTIVE_COMPARATOR|Phase 2: Pembrolizumab|Participants will be provided with pembrolizumab at standard dose of 200 mg IV Q3W
62680809|NCT06686199|PLACEBO_COMPARATOR|Control group|
62680810|NCT06686199|EXPERIMENTAL|Intervention group|
62680811|NCT06399471|EXPERIMENTAL|Study Microprocessor Prosthetic Knee|Randomization to C-Leg 4.0, Rheo Knee and Power Knee
62121694|NCT00980330|EXPERIMENTAL|TMC435 100 mg 12 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.
62680812|NCT06690853|EXPERIMENTAL|experimental coordinative training|The warm-up protocols of the Experimental Group included four types of upper and lower limb coordination exercises using different-sized balls, with intensity increasing week by week. The warm-up exercises were conducted four times per week, including game day, for a total of 12 weeks.
62121695|NCT00980330|EXPERIMENTAL|TMC435 100 mg 24 Wks + PR48|Participants willl receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.
62310280|NCT01094899|EXPERIMENTAL|Type 1 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
62310281|NCT01094899|EXPERIMENTAL|Type 2 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
62476180|NCT03598894||Control NT|matched healthy normotensives 'NT' (24h mean wake SBP \<120mmHg)
62680813|NCT06690853|ACTIVE_COMPARATOR|Traditional training (control group)|The Control Group warm-up protocol only involved joint mobility exercises and muscle activation, as used in their regular training activities.
62680814|NCT06689774|EXPERIMENTAL|Enhanced Wisconsin Tobacco Quit Line (WTQL) Referral Implementation Support|Both participating sites in this pilot study will be in this experimental enhanced implementation support arm to help us iteratively enhance the feasibility, acceptability, and sustainability of implementation strategies to support WTQL referral in these sites. Salvation Army personnel at participating sites will receive implementation training and ongoing support to help enhance the fit of WTQL referral in their workflows, culture, and climate, and to enhance staff readiness to connect the consumers they serve with the WTQL. No consumer incentives for connecting with the Quit Line immediately by phone will be offered in this arm so it can serve as active comparator condition for the incentivized arm described below.
62310282|NCT04260724|ACTIVE_COMPARATOR|TMS group|Transcranial magnetic stimulation for four weeks
62476181|NCT03598894||Control DHT|matched dipping hypertensives 'DHT' (24h mean wake SBP \>145mmHg and a decline of \>10% between mean day time and night time systolic pressures)
62476182|NCT04834414|ACTIVE_COMPARATOR|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
62680815|NCT06689774|EXPERIMENTAL|Incentivized Immediate Wisconsin Tobacco Quit Line (WTQL) Referral|In this experimental condition, Salvation Army personnel will implement an incentive strategy designed to encourage Salvation Army consumers to accept immediate referral to the WTQL. The incentive strategy will be adapted by Salvation Army personnel to fit in the local context, and staff will receive training and ongoing support in implementation of the incentive strategy. The modest incentives will be added in a staggered manner across the 2 Salvation Army sites participating in this pilot trial, after at least 3 months of implementing WTQL referral without consumer incentives for immediate calls.
62680816|NCT04150757|NO_INTERVENTION|Standard Analgesia|"Patients receiving no intervention will receive no intranasal ketamine while awaiting intravenous line placement for parenteral pain control."
62680817|NCT04150757|ACTIVE_COMPARATOR|Intranasal Ketamine + Standard Analgesia|Enrolled patients will receive one dose of Intranasal Ketamine dosed at 1mg/kg (Ketamine 500mg/10 mL solution) after triage while waiting for IV placement (max 50mg).
62680818|NCT06462573|EXPERIMENTAL|Group I (study group)|in which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.
62680819|NCT06462573|EXPERIMENTAL|Group II (control group)|"in which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session."
62680820|NCT06070350|OTHER|Group 1 (LTOWB+TXA)|Concurrent administration of LTOWB and TXA
62680821|NCT06070350|OTHER|Group 2 (LTOWB+Placebo)|Concurrent administration of LTOWB and Placebo
62680822|NCT06070350|OTHER|Group 3 (CT+TXA)|Concurrent administration of CT and TXA
62121696|NCT00980330|EXPERIMENTAL|TMC435 100 mg 48 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
62121697|NCT00980330|EXPERIMENTAL|TMC435 150 mg 12 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.
62121698|NCT00980330|EXPERIMENTAL|TMC435 150 mg 24 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.
62310283|NCT04260724|SHAM_COMPARATOR|Sham group|sham coil stimulation for four weeks (Although the sound of sham coil is the same to that of real TMS during intervension, no stimulation is applied. )
62310284|NCT00878228|EXPERIMENTAL|Study Group|The study group will receive intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).
62310285|NCT00878228|PLACEBO_COMPARATOR|Control Group|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).
62310286|NCT05082870|EXPERIMENTAL|Supportive-expressive group therapy|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
62310287|NCT05082870|NO_INTERVENTION|Treatment as usual|The treatment as usual group will receive standard care only (which may include an individual psychiatric consultation).
62310288|NCT02328716|ACTIVE_COMPARATOR|Comparator|Comparator
62310289|NCT02328716|EXPERIMENTAL|Experimental|Experimental
62310290|NCT03825042|EXPERIMENTAL|Food supplement|A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
62476183|NCT04834414|EXPERIMENTAL|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
62476184|NCT04560738|EXPERIMENTAL|Administration of [14C]-CC-92480|\[14C\]-CC-92480 will be administered as an oral solution. A single oral dose of \[14C\]-CC-92480, containing approximately 2 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
62476185|NCT02470247|EXPERIMENTAL|Remote ischemic preconditioning|"Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
62680823|NCT06070350|OTHER|Group 4 (CT+Placebo)|Concurrent administration of CT and Placebo
62680824|NCT02423070||Cohort 1|Heart and Lung Transplant patients
62680825|NCT00706537|EXPERIMENTAL|CP-945598 20 mg|
62680826|NCT00706537|PLACEBO_COMPARATOR|Placebo|
62680827|NCT06525454|EXPERIMENTAL|Personalized coaching messages for glycemic management and depressive symptoms|
62680828|NCT06525454|NO_INTERVENTION|Treatment as usual|
62680829|NCT06687603|EXPERIMENTAL|EsoCheck + EsoGuard|Participants will undergo an EsoCheck test. The sample produced by the EsoCheck will be sent to LucidDx where the EsoGuard assay will be performed.
62680830|NCT05827081|EXPERIMENTAL|Ribociclib + endocrine therapy|"Participants will receive ribociclib 400 mg orally once daily on days 1 to 21 of a 28-day cycle, in combination with daily endocrine therapy (ET) for 36 months (approximately 39 cycles). ET consists of:~* For postmenopausal women: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously.~* For pre/perimenopausal women, and men: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously, combined with goserelin subcutaneously (at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used) or leuprolide subcutaneously (at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used)"
62680831|NCT03976141||a|
62680832|NCT06688149|EXPERIMENTAL|Arm A: Current management of NAFLD patients in daily clinical practice|It will be taken as a reference for comparisons and will include the diagnosis and referral criteria that have been used the two previous years. CONSTANTS, a study included in the EPOS European Project has already allowed us to approach the burden of this entity in clinical practice in two sites of this consortium (Mainz and Sevilla). An overall analysis will be conducted to harmonize current standard of care (Arm A) in our centres. The case records of all patients referred with a diagnosis of NAFLD will be reviewed and evaluated for evidence of advanced fibrosis/cirrhosis based on a composite of history, physical examination, imaging, transient elastography, and liver histology when available. HFS, NFS, and FIB-4 scores will be calculated, and patients with a priori low-risk of advanced fibrosis will be deemed to have no evidence of liver fibrosis and thus referred inappropriately.
62680833|NCT06688149|EXPERIMENTAL|Arm B: Combination of blood-based non-invasive tests (HFS, NFS, and FIB-4)|"Patients will be assigned with the following scores:~1. 0 points if the value is under the lower cut-off (HFS \<0.12; NFS\<-1.455; FIB-4 \<1.30);~2. 1 point if the value is allocated in the grey zone (HFS 0.12-0.47; NFS -1.455-0.676; FIB-4 1.30-2.67);~3. 2 points if the value is above the higher cut-off (HFS \>0.47; NFS \>0.676; FIB-4 \>2.67). We will determine the optimal cut-offs (between 0 and 6 points) for keeping patients in non-specialized units or referring them to NSUs.~   * Age corrected threshold should be implemented in patients older than 65 years in NFS (from -1.455 to 0.12) and FIB-4 (from 1.30 to 2.00)."
62680834|NCT06688149|EXPERIMENTAL|Arm C: Combination of HFS and TE|Patients will be classified using the blood-based non-invasive tests to determine the HFS and a transient Elastography (TE). Patients with a HFS score of \> 0.12 or TE \>8 kPa for both M and XL probe should be classified as patients with an intermediate-to-high risk of advanced fibrosis and will be referred to a specialist.
62680835|NCT06695962|EXPERIMENTAL|Domperidone then placebo|Domperidone 10 mg, 3/days during 28 days, - wash-out (21 days) then placebo 3/days during 28 days
62680836|NCT06695962|EXPERIMENTAL|Placebo then Domperidone|Placebo 3/days during 28 days - wash-out (21 days) - then Domperidone 10 mg, 3/days during 28 days
62680837|NCT02339675|OTHER|convential MS rehabilitation|Investigate the quality (psychometric properties) and clinical utility of several measures of the upper limb function
62680838|NCT04193189|EXPERIMENTAL|Group A, Arm 1: HEPLISAV-B (two injections)|Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.
62680839|NCT04193189|EXPERIMENTAL|Group A, Arm 2: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
62680840|NCT04193189|EXPERIMENTAL|Group A, Arm 3: ENGERIX-B (three injections)|Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.
62680841|NCT04193189|EXPERIMENTAL|Group B: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
62680842|NCT06375655|EXPERIMENTAL|Team2BF|Team2BF includes 3-4 breastfeeding-supportive messages per time interval, sent weekly from 28 weeks gestation through delivery, daily through 2 weeks postpartum, weekly from 2 to 10 weeks, and then monthly to one year. Other maternal health topics are not addressed.
62680843|NCT06375655|ACTIVE_COMPARATOR|Bright By Text|Bright By Text sends 2-4 messages per week from the first trimester through and beyond one year postpartum about a wide range of maternal and child health topics as outlined on their website; 8 messages are specifically about breastfeeding.
62680844|NCT05514535|EXPERIMENTAL|Insuline glargine U100 (reduced) + semaglutide|Participants will initially receive 0.25 milligrams (mg) once-weekly semaglutide subcutaneously (s.c.) and the dose will be gradually escalated to 2 mg as an add-on to dose-reduced insulin glargine s.c. given once-daily. Insulin glargine U100 will be reduced by 10 U at the initiation of semaglutide and then again at each semaglutide dose escalation. Insulin glargine dose will be adjusted based on the mean of three pre-breakfast self-measured plasma glucose (SMPG) values (target SMPG: 4.4-7.2 millimoles per litre (mmol/L)).
62680845|NCT05514535|ACTIVE_COMPARATOR|Insuline glargine U100 (titrated)|Participants will receive titrated insuline glargine U100 s.c. once-daily. Insulin glargine U100 dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
62680846|NCT06688682|NO_INTERVENTION|HA group|treated with intra-articular injection of hyaluronic acid solution, 2 ml per injection, and 1 ml of normal saline injection at Xuehai, Yanglingquan, and Weizhong acupoints at the same time, once a week for 4 weeks
62680847|NCT06688682|PLACEBO_COMPARATOR|PRP joint injection group|treated with intra-articular injection of PRP, 3.5 ml per injection, and 1 ml of normal saline injection at Xuehai, Yanglingquan, and Weizhong acupoints at the same time, once a week for 4 weeks
62680848|NCT06688682|EXPERIMENTAL|PRP joint injection combined with acupoint injection group|treated with intra-articular injection of PRP, 3.5 ml per injection, and 1 ml of PRP injection at Xuehai, Yanglingquan, and Weizhong acupoints at the same time, once a week for 4 weeks
62680849|NCT05652140||High-Risk with increased CRF|ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.
62121699|NCT00980330|EXPERIMENTAL|TMC435 150 mg 48 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
62121700|NCT00980330|PLACEBO_COMPARATOR|Placebo 48 Wks + PR48|Participants will receive Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
62310291|NCT03825042|PLACEBO_COMPARATOR|Placebo|Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
62310292|NCT04002323||HIV-1 ART-Naive|Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)
62310293|NCT01416610||All Participants|Participants with chronic hepatitis C, Genotype 2, 3, 1 or 4, undergoing an opioid maintenance therapy
62476186|NCT02470247|SHAM_COMPARATOR|SHAM remote ischemic preconditioning|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
62121701|NCT06643728|ACTIVE_COMPARATOR|Tirzepatide Dose 1|Participants will receive Tirzepatide subcutaneously (SC)
62310294|NCT03611140|EXPERIMENTAL|Dietary portfolio (DP)|The dietary portfolio was given daily at the breakfast and dinner for 2 months. The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein, oat, and inulin) that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
62121702|NCT06643728|ACTIVE_COMPARATOR|Tirzepatide Dose 2|Participants will receive Tirzepatide SC
62121703|NCT06643728|EXPERIMENTAL|Bimagrumab Dose 1 + Tirzepatide Dose 1|Participants will receive Bimagrumab SC and Tirzepatide SC
62121704|NCT06643728|EXPERIMENTAL|Bimagrumab Dose 1 + Tirzepatide Dose 2|Participants will receive Bimagrumab SC and Tirzepatide SC
62121705|NCT06643728|EXPERIMENTAL|Bimagrumab Dose 2|Participants will receive Bimagrumab SC
62121706|NCT06643728|EXPERIMENTAL|Bimagrumab Dose 2 + Tirzepatide Dose 2|Participants will receive Bimagrumab SC and Tirzepatide SC
62121707|NCT06643728|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo SC
62121708|NCT03691922|ACTIVE_COMPARATOR|ESP Block|Preoperative US guided active Erector Spinae Plane (ESP) block and a saline PAI
62121709|NCT03691922|OTHER|PAI with LA|Preoperative US guided ESP blockade with saline and an active Periarticular Infiltration (PAI)
62121710|NCT06174636|EXPERIMENTAL|Abdominal Pressure Rise|Application of an abdominal weight and record of respiratory mechanics data, intra-abdominal pressure variation, Electrical Impedance Tomography data
62121711|NCT01261234|EXPERIMENTAL|Cilostazol group|Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)
62310295|NCT03611140|PLACEBO_COMPARATOR|placebo (P)|The placebo (P) was given daily at the breakfast and dinner for 2 months. The placebo intervention consisted of a mixture of calcium caseinate, maltodextrins, sweetener and of artificial flavoring that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
62121712|NCT01261234|ACTIVE_COMPARATOR|Non-Cilostazol group|Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)
62310296|NCT01373554|PLACEBO_COMPARATOR|Placebo|
62310297|NCT01373554|EXPERIMENTAL|Oltipraz|
62310298|NCT02137551|EXPERIMENTAL|ABM Intervention in FQHC|Pharmacy technicians within El Rio will implement the ABM
62310299|NCT02137551|EXPERIMENTAL|ABM Intervention in a Supermarket Pharmacy|Pharmacists within Fry's will implement the ABM
62310300|NCT02137551|NO_INTERVENTION|Usual care|Patients will refill prescriptions at their usual pharmacy in the customary way.
62310301|NCT05129839|EXPERIMENTAL|Lightened and Musical Baby Mobile Group|The children in the study group were applied a lightened and musical baby mobile before sleeping at night.
62310302|NCT05129839|NO_INTERVENTION|Control Group|The children in the control group were not given lightened and musical baby mobile, and their routine sleep patterns were continued.
62476187|NCT04514757|EXPERIMENTAL|Intervention Group|Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to ear at 20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
62476188|NCT04514757|SHAM_COMPARATOR|Control Group|Sham tVNS will be performed by attaching the Parasym device to the ear and setting output to 0. Stimulation will continue until 5 days post-operatively or discharge.
62476189|NCT03692663|EXPERIMENTAL|TABP EIC treatment group|Drug: TABP EIC Experimental Interventional Therapy
62121713|NCT06522295||preeclampsia|
62121714|NCT06522295||severe preeclampsia|
62121715|NCT01599897|EXPERIMENTAL|2 µg ID93 + 2 µg GLA-SE|Low dose and antigen and low dose of adjuvant.
62121716|NCT01599897|EXPERIMENTAL|10 µg ID93 + 2 µg GLA-SE|High dose of antigen and low dose of adjuvant.
62121717|NCT01599897|EXPERIMENTAL|2 µg ID93 + 5 µg GLA-SE|Low dose of antigen and high dose of adjuvant.
62121718|NCT01599897|EXPERIMENTAL|10 µg ID93 + 5 µg GLA-SE|High dose of antigen and high dose of adjuvant.
62121719|NCT01599897|ACTIVE_COMPARATOR|2 µg ID93 alone|Low dose of antigen alone.
62121720|NCT01599897|ACTIVE_COMPARATOR|10 µg ID93 alone|High dose of antigen alone.
62121721|NCT02778958|EXPERIMENTAL|ibuprofen and morphine|iv ibuprofen 800 mg infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
62121722|NCT02778958|ACTIVE_COMPARATOR|paracetamol and morphine|iv paracetamol 1 gram infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
62121723|NCT03166449|EXPERIMENTAL|Neomune|18 patients with traumatic brain injury were given Neomune as enteral nutrition.
62121724|NCT03166449|ACTIVE_COMPARATOR|Fresubin® HP energy|18 patients with traumatic brain injury were given Fresubin® HP energy as enteral nutrition.
62121725|NCT04928248|EXPERIMENTAL|Diabetes Dashboard integrated with Disease Manager App|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated Diabetes Dashboard that is integrated with the diabetes module of the Disease Manager App).
62121726|NCT02302300|EXPERIMENTAL|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
61921526|NCT03174899|EXPERIMENTAL|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
61921527|NCT03174899|EXPERIMENTAL|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
61921528|NCT05861531|EXPERIMENTAL|Oromotor stimulation with reading curriculum|"1. Obtain baseline LENA recording 2. Review language curriculum and provide LENA linguistic feedback 3. LENA recording every 2 weeks until 36 weeks corrected 4. Review age-appropriate language curriculum and provide LENA linguistic feedback from prior weeks 5. NTrainer Pacifier System prior to oromotor stimulation at approximately 33 weeks corrected 6. The day following pre-oromotor stimulation NTrainer Pacifier System session, will conduct 10-15 minute oromotor stimulation behind curtain prior to a feeding time for 10 total days over a 2 week period 7. NTrianer Pacifier System post oromotor stimulation at approximately 35 weeks corrected 8. Final LENA feedback and PTSD screen~Assessments: 1. PSS:NICU at 36 weeks corrected 2. PPQ screen at 7, 12, and 24 months corrected 3. Child Behavior Checklist at 24 months corrected 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months"
61921529|NCT05861531|ACTIVE_COMPARATOR|Standard care with reading curriculum|"1. Obtain baseline LENA recording 2. Review language curriculum and provide LENA linguistic feedback 3. LENA recording every 2 weeks until 36 weeks corrected 4. Review age-appropriate language curriculum and provide LENA linguistic feedback from prior weeks 5. NTrainer Pacifier System prior to oromotor stimulation at approximately 33 weeks corrected 6. The day following pre no oromotor stimulation NTrainer Pacifier System session, will have no oromotor stimulation occur behind curtain for 10-15 minutes prior to a feeding time for 10 total days over a 2 week period 7. NTrainer Pacifier System post no oromotor stimulation at approximately 35 weeks corrected 8. Final LENA feedback and PTSD screen~Assessments: 1. PSS:NICU at 36 weeks corrected 2. PPQ screen at 7, 12, and 24 months corrected 3. Child Behavior Checklist at 24 months corrected 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months"
61921530|NCT03954522|EXPERIMENTAL|Expérimental|psychologist interview and psychometrics scales
61921531|NCT03824067|ACTIVE_COMPARATOR|Standard of Care Early Infant Diagnosis|Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
62121727|NCT02302300|NO_INTERVENTION|Control Group|Standard preparation
62121728|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
62121729|NCT02562391|ACTIVE_COMPARATOR|PVI+Box lesions|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.
62121730|NCT02562391|EXPERIMENTAL|PVI+Box lesions+LAA cutting|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.The left atrial appendage was removed by stapling and then cutting.
62121731|NCT06676774|EXPERIMENTAL|Part B oxytocin - Part A oxytocin - Part A Placebo - Part B Placebo|Part A will investigate the recognition of facial emotions \& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B oxytocin, 2. Part A oxytocin, 3. Part A placebo, 4. Part B placebo
62476190|NCT01526694|EXPERIMENTAL|treatment with BDT|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
62476191|NCT02004535|EXPERIMENTAL|Cochlear implantation|Cochlear implantation of the ear with severe to profound hearing loss
61921532|NCT03824067|EXPERIMENTAL|Point of Care Early Infant Diagnosis|The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
62680850|NCT05652140||High-Risk with decreased CRF|ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.
62680851|NCT05652140||Low-Risk with increased CRF|Non-ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.
61921533|NCT03920384|EXPERIMENTAL|Experimental therapy arm|16 (minimum 4, maximum 20) sessions of therapy for psychosis including new therapeutic ingredients
61921534|NCT03920384|ACTIVE_COMPARATOR|Standard Psychological Therapy for Psychosis|16 (minimum 4 maximum 20) sessions of standard psychological therapy for psychosis.
61921535|NCT03207334|EXPERIMENTAL|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase.
61921536|NCT00594451||I Multicenter Veteran's Affairs Rheumatoid Arthritis (VARA) registry|multicenter Veteran Affairs Rheumatoid Arthritis (VARA) registry
61921537|NCT00594451||II NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)|NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)
62680852|NCT05652140||Low-Risk with decreased CRF|Non-ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.
62680853|NCT02628145|EXPERIMENTAL|Resistance Training Intervention|The RT intervention will take place three times per week for approximately 12 weeks on non-consecutive days using 8-10 exercises for major muscle groups utilizing free weights and machines follow American College of Sports Medicine and National Strength and Conditioning Association guidelines for RT in older adults.
62680854|NCT02628145|ACTIVE_COMPARATOR|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
61921538|NCT00349427|EXPERIMENTAL|Rosiglitazone|4mg
61921539|NCT00349427|PLACEBO_COMPARATOR|Rosiglitazone placebo|4mg
61921540|NCT03598634|ACTIVE_COMPARATOR|Epi-on cross-linking|Intervention: Drug: Riboflavin 0.15 in 20% dextran solution
62310303|NCT02355912|EXPERIMENTAL|Evaluate a real-time adaptive neural control system|The prosthesis will be tuned, for each subject: level-ground walking, walking up and down slopes and walking up and down stairs. We anticipate that participants will visit the laboratory approximately 6-9 times over 2 months (2-3 visits for socket duplications and modifications, 2-3 visits for control system tuning, and an additional 2-3 visits for practice using the tuned system). By the end of these visits, the goal is to have a properly fitting socket and for the subjects to ambulate proficiently with the powered prosthesis. After tuning, the subjects will complete 20 ambulation circuits (level ground walking, walking up and down slopes, up and down stairs). This will provide training data for our pattern recognition control systems.
62310304|NCT02696746||Pain related conditions|Subjects with painful or painless conditions (observational study, no interventions)
62310305|NCT03976401|EXPERIMENTAL|EFX Dose 1|Main Study
62310306|NCT03976401|EXPERIMENTAL|EFX Dose 2|Main Study
61921541|NCT03598634|ACTIVE_COMPARATOR|Epi-off cross-linking|intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid
61921542|NCT01512290|ACTIVE_COMPARATOR|Theta burst treatment|patients randomized to this arm will receive 10 TBS treatments distributed over 5 days
61921543|NCT01512290|PLACEBO_COMPARATOR|sham treatment|
61921544|NCT01513369|EXPERIMENTAL|ferric carboxymaltose|Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
61921545|NCT01513369|PLACEBO_COMPARATOR|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
61921546|NCT04853381|EXPERIMENTAL|1st Group: Traditional diet recommendations|Traditional diet recommendations will apply for 4 weeks.
62310307|NCT03976401|EXPERIMENTAL|EFX Dose 3|Main Study
62121732|NCT06676774|EXPERIMENTAL|Part B oxytocin - Part A Placebo - Part A oxytocin - Part B Placebo|Part A will investigate the recognition of facial emotions \& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B oxytocin, 2. Part A placebo, 3. Part A oxytocin, 4. Part B placebo
62310308|NCT03976401|PLACEBO_COMPARATOR|Placebo|Main Study
62310309|NCT03976401|EXPERIMENTAL|EFX Dose (Cohort C)|
62310310|NCT03976401|PLACEBO_COMPARATOR|Placebo (Cohort C)|
62476192|NCT04048096|PLACEBO_COMPARATOR|Placebo|4g/day of mixed vegetable oil supplements
62476193|NCT04048096|EXPERIMENTAL|Krill|4g/day krill oil
62476194|NCT03091335|EXPERIMENTAL|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
62476195|NCT03091335|NO_INTERVENTION|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
62476196|NCT02793245|EXPERIMENTAL|Studied population|Patients will be questioned about their main characteristics (age, gender, height, weight, smoking), they will also perform a simplified a pulmonary function test (if possible).
62121733|NCT06676774|EXPERIMENTAL|Part B Placebo - Part A Placebo - Part A oxytocin - Part B oxytocin|Part A will investigate the recognition of facial emotions \& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B placebo, 2. Part A placebo, 3. Part A oxytocin, 4. Part B oxytocin
62310311|NCT01898312|EXPERIMENTAL|Mifepristone|treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
62310312|NCT01898312|PLACEBO_COMPARATOR|TrioBe|treatment with a quarter of a tablet of TrioBe every second day for 12 weeks
62310313|NCT00477451|PLACEBO_COMPARATOR|RCT Placebo|Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
62310314|NCT00477451|EXPERIMENTAL|RCT Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
62310315|NCT00477451|EXPERIMENTAL|Open Label Inhaled Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
62310316|NCT00477451|EXPERIMENTAL|Initial Inhaled Alprazolam 2 mg|Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
62310317|NCT02519764|EXPERIMENTAL|Hydration when thirsty|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
62476197|NCT04726163|NO_INTERVENTION|Tele-expertise|Basal-bolus insulin treatment with adaptation of insulin doses according to continuous glucose measurement
61921547|NCT04853381|EXPERIMENTAL|2nd Group: Low FODMAP diet|Low FODMAP diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
61921548|NCT04853381|EXPERIMENTAL|3rd Group: Gluten-free diet|Gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
61921549|NCT04853381|EXPERIMENTAL|4th Group: Low-FODMAP gluten-free diet|Low-FODMAP gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
61921550|NCT00896636||Luteal|Pre-menopausal women who undergo rFNA procedure during the luteal phase of their menstrual cycle.
61921551|NCT00896636||Follicular|Pre-menopausal women who undergo rFNA procedure during the follicular phase of their menstrual cycle.
61921552|NCT00896636||Menopause|Women who have entered menopause.
61921553|NCT03119701|EXPERIMENTAL|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
61921554|NCT03119701|PLACEBO_COMPARATOR|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
61921555|NCT00766961|ACTIVE_COMPARATOR|TAE group|Trans-catheter arterial embolization
61921556|NCT00766961|ACTIVE_COMPARATOR|Surgery group|Surgery
61921557|NCT01695200|EXPERIMENTAL|Omega-3 Fatty Acids|15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)
61921558|NCT04211805||Arm (A) TAF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Alafenamide (TAF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
61921559|NCT04211805||Arm (B) TDF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Disoproxil Fumarate (TDF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
61921560|NCT03813797|EXPERIMENTAL|Arm A: Low Pressure (5-7 mmHg)|Laparoscopic colectomy surgery with low pressure (5-7mmHg)
61921561|NCT03813797|ACTIVE_COMPARATOR|Arm B: Standard pressure (12-15 mmHg)|Laparoscopic colectomy surgery with standard pressure (12-15mmHg)
62121734|NCT06676774|EXPERIMENTAL|Part B Placebo - Part A oxytocin - Part A Placebo - Part B oxytocin|Part A will investigate the recognition of facial emotions \& body expressions in a cross-over design with a two-week wash-out period between both study visits. Part B will investigate the response of cortisol to acute psychosocial stress (TSST) with an eight-week wash-out period between both study visits. The order of group assignment is as follows: 1. Part B placebo, 2. Part A oxytocin, 3. Part A placebo, 4. Part B oxytocin
62121735|NCT01716182||transacral lumbar interbody fusion procedure|
62121736|NCT01716182||transforaminal lumbar interbody fusion procedure (TLIF)|
62310318|NCT02519764|EXPERIMENTAL|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
61921562|NCT03930160||Mortality outcome|
61921563|NCT04820127|NO_INTERVENTION|Control (usual care)|Patients in the control group will benefit from the usual care with a half-yearly visit by the specialist physician (geriatrician, neurologist or psychiatrist) according to AD French national management guidelines (HAS 2011 and HAS 2018).
61921564|NCT04820127|EXPERIMENTAL|Intervention (personalized care program)|Patients in the intervention group will benefit from personalized care preceded by a standardized assessment
61921565|NCT05193357|EXPERIMENTAL|home-based IPC device|Participants used a device produced by Maxstar Corp. (Gimpo, South Korea), which specializes in pneumatic compression appliance manufacture. The IPC device (UAM-9306NB) was cleared by National Institute of Medical Device Safety Information (NIDS) of Korea (approval number: 18-4745). This device consists of a six-chamber pneumatic sleeve and a gradient-sequential pneumatic pump.
61921566|NCT01385228|EXPERIMENTAL|"Dose Level Xa"|once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
62121737|NCT00889499|PLACEBO_COMPARATOR|Crossover study|Crossover study
62121738|NCT00889499|PLACEBO_COMPARATOR|2|Crossover Study
62310319|NCT06668428|NO_INTERVENTION|Control Group with Standard Care|Participants in the control group will not receive any intervention other than routine care after cesarean section (It is planned to provide verbal information about the procedure and brief written information about the procedure.)
62310320|NCT06668428|EXPERIMENTAL|Control Group Using Virtual Reality Glasses|The researcher will inform the women in the intervention group about the research, introduce the virtual reality glasses after obtaining written informed consent, and teach them how to use the glasses. Afterwards, the data collection form, State Anxiety Scale, and visual analog scale rating scale for pain are planned to be applied face to face to both groups. After the first mobilization, the postpartum women will watch a nature view video with virtual reality glasses (VRG) accompanied by nature sounds for 20 minutes. Each woman will watch the same video. Pain and anxiety will be re-evaluated after the application. The same application will be applied to each woman, and the glasses will be disinfected with Dermosept surface disinfectant, which provides cold sterilization, before the application.
62310321|NCT03163030|EXPERIMENTAL|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
62310322|NCT02596880|EXPERIMENTAL|Treatment|Subjects will receive sofosbuvir, daclatasvir and ribavirin
62310323|NCT01790061|EXPERIMENTAL|Standardized FMT|endoscopy Tubing Once or repeat
62310324|NCT01790061|EXPERIMENTAL|Traditional treatments|Oral Tubing
61921567|NCT01385228|EXPERIMENTAL|"Dose Level Xb"|once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
61921568|NCT03252184|EXPERIMENTAL|Phase 1 - Low level laser therapy - 1 (G1)|Low level laser therapy with energy dose of 18J will be applied on left brachial artery of the subject.
61921569|NCT03252184|EXPERIMENTAL|Phase 1 - Low level laser therapy - 1 (G2)|Low level laser therapy with energy dose of 36J will be applied on left brachial artery of the subject.
61921570|NCT03252184|EXPERIMENTAL|Phase 1 - Low level laser therapy - 1 (G3)|Low level laser therapy with energy dose of 54J will be applied on left brachial artery of the subject.
62121739|NCT00889499|PLACEBO_COMPARATOR|3|Crossover Study
62121740|NCT02627183||Paroxysmal AF + catheter ablation|Subjects with paroxysmal Atrial Fibrillation (AF) undergoing catheter ablation.
62121741|NCT02627183||Permanent/persistent AF + exercise|Subjects with permanent or persistent Atrial Fibrillation (AF) undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
62121742|NCT01684397|EXPERIMENTAL|Treatment (pazopanib hydrochloride and bevacizumab)|Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.
62121743|NCT03915886|EXPERIMENTAL|JNJ-0440 (Low Dose) or Placebo|Participants will receive single oral dose (low) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
62310325|NCT04760132|ACTIVE_COMPARATOR|Vaccine A - COMIRNATY COVID-19 vaccine|COMIRNATY (COVID-19, mRNA Vaccine) by BioNTech Manufacturing GmbH Marketing Authorisation EU/1/20/1528
62310326|NCT04760132|ACTIVE_COMPARATOR|Vaccine B - Moderna COVID-19 vaccine|"COVID-19 Vaccine Moderna dispersion for injection (COVID-19, mRNA Vaccine) by MODERNA BIOTECH SPAIN S.L.~Marketing Authorisation EU/1/20/1507/001"
62310327|NCT04760132|ACTIVE_COMPARATOR|Vaccine C - Astra-Zeneca COVID-19 vaccine|COVID-19 Vaccine AstraZeneca suspension for injection (ChAdOx1-S \[recombinant\]) by AstraZeneca AB Marketing Authorisation EU/1/21/1529/001 and /002
62310328|NCT06375798||IORT group|The IORT group received intraoperative radiotherapy with a regimen of 50-KV-X 20Gy/1f.If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.
62310329|NCT06375798||WBI group|WBI group received whole milk external irradiation with a regimen of 50Gy/25f.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously.
62476198|NCT04726163|EXPERIMENTAL|Standard|Standard treatment and adaptation of insulin doses according to the usual management of the unit
62680855|NCT06689579|EXPERIMENTAL|Unipolar|Unipolar hemiarthroplasty used for treatment of intracapsular hip fracture
62680856|NCT06689579|ACTIVE_COMPARATOR|Bipolar|Bipolar hemiarthroplasty used for treatment of intracapsular hip fracture
62680857|NCT06691295||Patients with functional neurological disorders.|This study focuses on adult subjects with newly diagnosed functional neurological disorders (less than 5 years old) and prior to therapeutic management.
62680858|NCT06690385||COPD or Emphysema|COPD according to GOLD guidelines determined by spirometry or pulmonary emphysema on previous chest CT or by CO diffusion test values less than 80%.
62310330|NCT05253807|EXPERIMENTAL|Cohort A: Squamous NSCLC|Participants with squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
62121744|NCT03915886|EXPERIMENTAL|JNJ-0440 (Medium Dose) or Placebo|Participants will receive single oral dose (medium) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
62121745|NCT03915886|EXPERIMENTAL|JNJ-0440 (High Dose) or Placebo|Participants will receive single oral dose (high) of JNJ-0440 or matching placebo under fed conditions.
61921571|NCT03252184|PLACEBO_COMPARATOR|Phase 1 - Placebo low level laser therapy - 1 (G4)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
62121746|NCT02748590|EXPERIMENTAL|Neuromodulation|
62121747|NCT00768235|EXPERIMENTAL|1: yoga group|Yoga group
62310331|NCT05253807|EXPERIMENTAL|Cohort B: Non-squamous NSCLC|Participants with non-squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
62310332|NCT03442127|OTHER|Patient Group|Program users
62310333|NCT02893254|EXPERIMENTAL|IBI303|IBI303 40mg administered subcutaneously every other week, 12cycles
62680859|NCT02206438|EXPERIMENTAL|1)C-LMA group|
62680860|NCT02206438|ACTIVE_COMPARATOR|2)Air-Q group|
62680861|NCT05837247|EXPERIMENTAL|Game-based telerehabilitation exercises|The telemonitoring-supported program will be conducted with a smartphone application synchronously. The participants will be monitored by the investigators using an online communication application during exercise sessions.The sessions will be conducted to patients' individual calender via a smartphone application and a reminder from this smartphone application will send notifications to the patients.
62121748|NCT00768235|NO_INTERVENTION|2: control group|
62121749|NCT04504916|EXPERIMENTAL|Zilovertamab Vedotin|Participants will receive intravenous (IV) zilovertamab vedotin 2.5 mg/kg on Day 1 of each repeated 21-day cycle (Q1/3W) or 1.75 mg/kg on Day 1 and Day 8 of each 21-day cycle (Q2/3W). Treatment will continue until progressive disease or discontinuation
62121750|NCT01161498|ACTIVE_COMPARATOR|Radiation/Cisplatin|Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
62680862|NCT05837247|ACTIVE_COMPARATOR|Control group|The control group will be evaluated and followed with home exercise program.
62680863|NCT06560307|ACTIVE_COMPARATOR|Control Programming Stimulation|Begin with nominal (lower stimulation) programming settings at Enterra Therapy System implantation. At treatment assignment, nominal programming will continue. Slight increases in device amplitude (stimulation) will be done at 3 Month visit and at later follow-up visits.
61921572|NCT03252184|EXPERIMENTAL|Phase 2 - Low level laser therapy - 2 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
62310334|NCT02893254|ACTIVE_COMPARATOR|Adalimumab|Adalimumab 40mg administered subcutaneously every other week
62310335|NCT02796989|ACTIVE_COMPARATOR|Healthy - Wheat Bran|Wheat bran 20 g each day
62310336|NCT02796989|PLACEBO_COMPARATOR|Healthy - Placebo|Placebo 20 g each day
61921573|NCT03252184|EXPERIMENTAL|Phase 2 - Low level laser therapy - 2 (G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
61921574|NCT03252184|PLACEBO_COMPARATOR|Phase 2 - Placebo low level laser therapy - 2 (G3)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
62310337|NCT02796989|ACTIVE_COMPARATOR|Obese - Wheat bran|Wheat bran 20 g each day
62310338|NCT02796989|PLACEBO_COMPARATOR|Obese - Placebo|Placebo 20 g each day
62476199|NCT04222790|EXPERIMENTAL|monosialic ganglioside|On the days -1, 1, and 2 of albumin paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
62476200|NCT04222790|PLACEBO_COMPARATOR|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
61921575|NCT03252184|EXPERIMENTAL|Phase 3 - Low level laser therapy - 3 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
62310339|NCT06485544|EXPERIMENTAL|Adebrelimab + Etoposide + Platinum-based Therapy|Participants in this arm will receive Adebrelimab, Etoposide, and Platinum-based therapy. Adebrelimab will be administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle. Following Adebrelimab, Etoposide will be given at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) will be administered via intravenous infusion on Day 1 of each cycle. This treatment regimen will be repeated for 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
62476201|NCT04199741||Phase I|Up to 12 participants with tumors that are found to be \>/= 50% positive for DLL3 by IHC
62476202|NCT04199741||Phase II|Up to 18 participants with tumors that are found to be \>/= 50% positive for DLL3 by IHC
62476203|NCT03774303|EXPERIMENTAL|mobile intervention|families to be prepared for day surgery with a mobile application
62476204|NCT03774303|ACTIVE_COMPARATOR|control group|families to be prepared for day surgery with current practice
62476205|NCT04801589|ACTIVE_COMPARATOR|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of either 4 mcg/mL or 8 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr."
62476206|NCT04801589|ACTIVE_COMPARATOR|Midazolam|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of either 0.5 mg/mL or 1 mg/mL midazolam. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr."
62476207|NCT01906918|EXPERIMENTAL|IRPC, Remote preconditioning|This group will be submitted to ischemic preconditioning
62476208|NCT01906918|PLACEBO_COMPARATOR|Control|This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
62476209|NCT02816450|EXPERIMENTAL|HIGH|Increase water intake to 2.5 liters per day for 4 days
61921576|NCT03252184|EXPERIMENTAL|Phase 3 - Low level laser therapy - 3(G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
61921577|NCT04499547|EXPERIMENTAL|Physical activity intervention|Will receive twice-weekly, YouTube-delivered aerobic and muscle-strengthening physical activity videos for 8 weeks.
61921578|NCT04499547|NO_INTERVENTION|General health education control|Will receive twice-weekly, YouTube-delivered videos with general health education information for 8 weeks.
62476210|NCT02816450|EXPERIMENTAL|LOW|Decrease water intake to 0.5 liter per day for 4 days
62476211|NCT03415828|EXPERIMENTAL|Ethanol gel|CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml
62476212|NCT03415828|ACTIVE_COMPARATOR|Steroid infiltration|Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml
62476213|NCT00777972|EXPERIMENTAL|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited
61921579|NCT06278909|EXPERIMENTAL|Active stimulation|"Trigeminal nerve stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, New York, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 milliampere (mA). Active stimulation will occur at 120 Hz with a 250 μs pulse width and with a duty cycle of 30 seconds on to 30 seconds off."
62680864|NCT06560307|EXPERIMENTAL|Enhanced Programming Stimulation|Begin with nominal (lower stimulation) programming settings at Enterra Therapy System implantation. At treatment assignment, moderate increases in device amplitude (stimulation) and duty cycle (on/off cycles) will be done. Further adjustments to amplitude, duty cycle, and/or frequency (rate of pulses) will be done at follow-up visits.
61921580|NCT02531334|EXPERIMENTAL|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
61921581|NCT02531334|PLACEBO_COMPARATOR|Placebo|Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
61921582|NCT06479395|EXPERIMENTAL|Pediatric Endurance and Limb Strengthening (PEDALS) program|"Phase 1: lower-extremity strengthening: Resistance will be progressed to the next higher cord when 10 revolutions will be performed in a smooth pattern while keeping the seat within the desired zone.~Phase 2: cardiorespiratory endurance: The goal of this phase is to gradually increase duration and intensity. The seat will be locked in a location that will position the participants knee in 15 to 20 degrees of flexion. The exercise duration goal will be 15 to 30 minutes. A cool down period consists of pedaling without resistance until heart rate (HR) decreases to within 20 bpm.(11)"
62121751|NCT01161498|EXPERIMENTAL|Talimogene Laherparepvec + Radiation/Cisplatin|The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63. Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
62121752|NCT05888584|EXPERIMENTAL|Intervention tool|A research recruitment tool will be available in paper and online formats and will include information on finding out about LC clinical trials, the role of research teams, embedding research into multidisciplinary team meetings and health needs assessments, communication pathways, signposting LCPs, practical considerations and reaching underrepresented groups. The tool will be used by lung cancer nurses in their daily practice as an aid to support their discussions with lung cancer patients about clinical trial opportunities. They will be asked to complete a survey at three time-points (baseline, three and six months) to measure their self-efficacy, knowledge, confidence and awareness in talking to lung cancer patients about clinical trials.
62310340|NCT06485544|ACTIVE_COMPARATOR|Etoposide + Platinum-based Therapy|Participants in this arm will receive Etoposide and Platinum-based therapy. Etoposide will be administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) will be administered via intravenous infusion on Day 1 of each cycle. This treatment regimen will be repeated for 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
62310341|NCT04052958|ACTIVE_COMPARATOR|Group 1: Strength Training|Respiratory muscle strength training
62310342|NCT04052958|ACTIVE_COMPARATOR|Group 2: Endurance Training|Respiratory muscle endurance training
62680865|NCT06690866||Pre-pubertal girls (children)|8-10 years of girls having pubertal stage 1
62680866|NCT06690866||Post-pubertal girls (adolescents)|15-17 years of girls having pubertal stage 5
62680867|NCT05156112|EXPERIMENTAL|PAP Treatment on SARRTP Unit|Veterans will receive Positive Airway Pressure device while on the 28-day SARRTP Unit.
62310343|NCT04052958|NO_INTERVENTION|Group 3: Control group|no training of respiratory muscles
62310344|NCT00669773|EXPERIMENTAL|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
62680868|NCT05156112|NO_INTERVENTION|Waitlist Control|Veterans will not receive PAP device until after 3-month Follow Up.
61921583|NCT06479395|ACTIVE_COMPARATOR|Task-Oriented Training (TOT)|The task-oriented training will focus on lower extremity strengthening comprised of the following: 1) The subjects will maintain a standing position for three seconds 2) The subjects will stand on one leg for three seconds while holding a chair with one hand 3) The subjects will stand up from a chair without using their arms 4) The subjects will stand up from a half kneeling position without using their arms 5) The subjects will kick a ball 6) The subjects has to climb up and climbed down four steps. All treatment procedures will be implemented for 40 minutes, thrice a week, for a total of eight weeks per session. including rest periods. The number of repetitions will be increased every 2 weeks up to a maximum of 15 repetitions if the participants will able to perform the training easily. (4)
62310345|NCT00669773|EXPERIMENTAL|Docetaxel|
62310346|NCT04204681||Study|Patients aged 16 years or younger who were to undergo tonsillectomy surgery were eligible for inclusion in this group. Tongue areas were measured twice by submental USG.The first measurements (TA2) were done immediately after endotracheal intubation but before insertion and placement of the tonsillar retractor. The second measurements (TA1) were done after tonsillectomy surgery and after removal of the tonsillar retractor but just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
62680869|NCT06579391|EXPERIMENTAL|Treatment|"One scoop (20 grams) of EAAs mixed in 10-12 ounces of a cold beverage to taste preference consumed orally twice daily between meals for 1 week before surgery up until 2 weeks after surgery.~Active ingredients: L-leucine (3.6g), L-lysine as L-lysine HCl (3.2g), L-phenylalanine (3.2g), L-valine (2.4g), L-threonine (2.8g), L-isoleucine (2.0g), L-methionine (0.6g), and L-histidine as L-histidine HCl (2.2g)"
62680870|NCT06579391|PLACEBO_COMPARATOR|Placebo|"One scoop (20 grams) of placebo mixed in 10-12 ounces of a cold beverage to taste preference consumed orally twice daily between meals for 1 week before surgery up until 2 weeks after surgery.~Active ingredients: alanine"
62121753|NCT05888584|NO_INTERVENTION|Control|Lung cancer nurses will undertake usual care. They will be asked to complete a survey at three time-points (baseline, three and six months) to measure their self-efficacy, knowledge, confidence and awareness in talking to lung cancer patients about clinical trials.
62121754|NCT04310072|EXPERIMENTAL|neuromuscular electrical stimulation group|"For patients who underwent NMES therapy, four electrodes (two 50/100 mm and two 50/50 mm, Compex Performance) were placed on the skin above the quadriceps muscle approximately 5 cm below the inguinal fold and 3 cm above the upper patella border.~The electrical stimulation protocol consisted of electrical current at frequency of 10 Hz, 20 seconds stimulation time (time on) and 20 seconds resting time (time off) with variable intensity (until visible muscular contraction) for one hour per day until discharge (Compex).The NMES therapy was on top of conventional rehabilitation described below."
62310347|NCT04204681||Control|This group included patients aged 16 years or younger who did not need tonsillectomy surgery and any head and neck procedures. Tongue areas of the patients were measured twice by submental USG as in the study group. TA1s were done immediately after endotracheal intubation, and TA2s were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
62310348|NCT00953121|EXPERIMENTAL|Cohort A-Grade IV No Failure|Recurrent GBM patients who have not previously failed bevacizumab, irinotecan, or carboplatin
62310349|NCT00953121|EXPERIMENTAL|Cohort B-Grade III No Failure|Recurrent Grade 3 malignant glioma patients who have not previously failed either bevacizumab, irinotecan or carboplatin
62310350|NCT00953121|EXPERIMENTAL|Cohort C-Failed Prior Therapy|Recurrent Grade IV GBM patients who have failed prior bevacizumab therapy, but not prior CPT-11 or carboplatin therapies
62310351|NCT03438422|EXPERIMENTAL|GROUP A|1 tablet a day of pollen A extract containing (140 mg aqueous extract and 8mg lipid purified pollen, aqueous extract pumpkin seed 300mg, 10mg Vitamin E)
62310352|NCT03438422|ACTIVE_COMPARATOR|GROUP B|1 tablet a day of pollen B extract containing (140 mg aqueous extract and lipid 8 mg of purified pollen)
62680871|NCT02920294|ACTIVE_COMPARATOR|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
62680872|NCT02920294|ACTIVE_COMPARATOR|Probiotic 2|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days
62680873|NCT02920294|PLACEBO_COMPARATOR|Placebo|Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
62680874|NCT02258919|EXPERIMENTAL|Decompressive craniectomy and best medical treatment|Decompressive craniectomy and best medical treatment
62121755|NCT04310072|NO_INTERVENTION|Control group|"The control group consisted of patients who performed daily active upper and lower limbs exercise in bed and in a stand position (3x10 repetitions, somewhat hard on the Borg scale)."
62121756|NCT00831675|EXPERIMENTAL|Infants <12 Months|Participants aged ≥ 6 to \< 12 months at enrollment and received 2 doses of Fluzone® Vaccine
62310353|NCT03438422|ACTIVE_COMPARATOR|GROUP C|1 tablet a day of pollen extract C containing (Pollen extract 160 mg, pumpkin seed extract, 300 mg and Vitamin E 10 mg)
62310354|NCT03438422|PLACEBO_COMPARATOR|PLACEBO|1 tablet a day of placebo
62476214|NCT00777972|ACTIVE_COMPARATOR|2|Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet
62680875|NCT02258919|ACTIVE_COMPARATOR|Best medical treatment|Best medical treatment
62680876|NCT05783596|EXPERIMENTAL|Obinutuzumab + Glofitamab for Follicular Lymphoma|"Participants will undergo study procedures as outlined:~* Imaging scans (CT or PET) at screening and after cycles 3, 7, and 12 of treatment.~* Bone marrow biopsy at baseline.~* Cycle 1~  * Days -21, -14, -7, 0 of 36 day cycle: Predetermined dose of Obinutuzumab.~ * Days 1 and 8 of 36 day cycle: Predetermined dose of Glofitamab. (First dose will be administered in the hospital.)~* Cycles 2 - 12:~  o Day 1 of 21 day cycle: Predetermined dose of Glofitamab.~* Bone marrow biopsy within 2 weeks of end of treatment.~* Imaging scans (CT or PET) at 12, 18, and 24 months after treatment initiation.~* Follow up visits up to 5 years after treatment completion."
62476215|NCT05694676||Mothers|Mothers aged 18 to 40 years, who have singleton pregnancy.
61921584|NCT00005851|EXPERIMENTAL|Treatment (nonmyeloablative donor PBSC transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.~DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD."
61921585|NCT00983788|EXPERIMENTAL|Bezafibrate|
61921586|NCT00983788|PLACEBO_COMPARATOR|Placebo|
61921587|NCT02886065|EXPERIMENTAL|PVX-410 + Citarinostat|"Participants will receive:~* 6 biweekly doses of PVX-410~* 6 biweekly doses of Hiltonol~* 3 monthly cycles of Citarinostat"
61921588|NCT02886065|EXPERIMENTAL|PVX-410 + Citarinostat + Lenalidomide|"Participants will receive:~* 6 biweekly doses of PVX-410~* 6 biweekly doses of Hiltonol~* 3 monthly cycles of Citarinostat~* 3 monthly cycles of Lenalidomide"
62476216|NCT05694676||Infants|Infants were born at 36-42 weeks of gestation without complication.
62738555|NCT04749888|NO_INTERVENTION|Control group|The control group will receive existing maternal and child health services (usual care) except for the targeted nurse-led home visits.
61921589|NCT02569827|PLACEBO_COMPARATOR|Cohort 1|"Placebo Q6H for 5 days~A total of 72 participants (18 participants per group assuming up to two drop-outs per group) will be assigned in a randomised double-blind fashion."
61921590|NCT02569827|ACTIVE_COMPARATOR|Cohort 2|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg)
61921591|NCT02569827|ACTIVE_COMPARATOR|Cohort 3|Modipafant 100 mg Q12H alternating with placebo Q12H 5 days (total of 10 modipafant doses = 1000 mg)
61921592|NCT02569827|ACTIVE_COMPARATOR|Cohort 4|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg total).
61921593|NCT03371771|EXPERIMENTAL|Volunteer-delivered Behavioral Activation|
61921594|NCT03371771|ACTIVE_COMPARATOR|MSW-delivered Behavioral Activation|
61921595|NCT02815488|EXPERIMENTAL|CHF6297 Active|
61921596|NCT02815488|PLACEBO_COMPARATOR|Placebo|
61921597|NCT03010761|EXPERIMENTAL|medication pills 1: escitalopram 10mg|10mg once daily, 8 weeks
61921598|NCT03010761|EXPERIMENTAL|medication pills 2: moclobemide 150mg|150mg once daily, 8 weeks
61921599|NCT03010761|EXPERIMENTAL|medication pills 3: Placebo - Cap|placebo once daily, 8 weeks
61921600|NCT05596123|EXPERIMENTAL|therapeutic Chinese foot massage (TCFM)|A one-to-one ratio will be used to randomly assign participants to the TCFM group or the placebo massage group.
61921601|NCT05596123|PLACEBO_COMPARATOR|The Placebo Massage Group|Six weekly 25-minute TCFM sessions will be delivered to participants in the TCFM group.
61921602|NCT03249220|EXPERIMENTAL|CBMS|
61921603|NCT03906188|EXPERIMENTAL|LitEmotion group|This group will play to LitEmotion video game.
61921604|NCT03906188|NO_INTERVENTION|Control group|This group will no do receive any intervention with the video game
61921605|NCT05998928|EXPERIMENTAL|Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells|Patients will receive lymphodepletion chemotherapy with fludarabine (30 mg/m2 body surface area) plus cyclophosphamide (300 mg/m2 body surface area) for 3 consecutive days during D-7 to D-3, followed by the infusion of BCMA-GPRC5D CAR-T cells at a single dose of 4.0×10\^6/kg ± 50%/kg for one day.
61921606|NCT02655393|EXPERIMENTAL|Mitopure 250 mg single dose|single dose of Mitopure soft gel capsules at 250 mg dose, n=8 subjects (6 Active, 2 Placebo)
61921607|NCT02655393|EXPERIMENTAL|Mitopure 500 mg single dose|single dose of Mitopure soft gel capsules at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
61921608|NCT02655393|EXPERIMENTAL|Mitopure 1000 mg single dose|single dose of Mitopure soft gel capsules at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
61921609|NCT02655393|EXPERIMENTAL|Mitopure 2000 mg single dose|single dose of Mitopure soft gel capsules at 2000 mg dose, n=8 subjects (6 Active, 2 Placebo)
62476217|NCT03432182|OTHER|very premature infants|Electroencephalography allowing sleep observation
62476218|NCT05908097|EXPERIMENTAL|Virtual Reality|"Participants in this arm will receive the following interventions:~Treatment As Usual (Empty Virtual Reality Park) Virtual Reality Avatar (Intervention)"
62476219|NCT05908097|PLACEBO_COMPARATOR|Treatment As Usual (Control)|"Participants in this arm will receive the following interventions:~Treatment As Usual (Empty Virtual Reality Park)"
62738556|NCT02323126|EXPERIMENTAL|Nivolumab and EGF816|Group 1: EGF816 150 mg QD + Nivolumab 3 mg/kg Q2W
62738557|NCT02323126|EXPERIMENTAL|Nivolumab and INC280, high cMet|Group 2A: INC280 400 mg BID, High cMET + Nivolumab 3 mg/kg Q2W
62738558|NCT02323126|EXPERIMENTAL|Nivolumab and INC280, low cMet|Group 2B: INC280 400 mg BID, Low cMet + Nivolumab 3 mg/kg Q2W
62476220|NCT05305092||chemotherapy|Premenopausal breast cancer patients receiving chemotherapy (including preoperative neoadjuvant chemotherapy) and endocrine therapy after surgery
62476221|NCT05305092||Endocrine therapy|Premenopausal breast cancer patients receiving endocrine therapy alone after surgery
62476222|NCT05305092||Healthy control|Healthy non-cancer controls
62476223|NCT03342157|EXPERIMENTAL|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
62476224|NCT03342157|EXPERIMENTAL|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
61921610|NCT02655393|EXPERIMENTAL|Mitopure 500 mg single dose-Food Effect|single dose of Mitopure admixed in yoghurt at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
62121757|NCT00831675|EXPERIMENTAL|Toddlers ≥12 Months|Participants aged ≥ 12 to \< 36 months at enrollment and received 2 doses of Fluzone® vaccine
62121758|NCT00239083|EXPERIMENTAL|EC-MPS|
62121759|NCT05430880||"CRAC patients : ICU patients ventilated and shocked"|"Patient hospitalized in intensive care.~Patient sedated and mechanically ventilated in Volume Assisted Controlled mode.~Patient with hypotension (MAP \<65 mmHg OR SAP \<90 mmHg) AND / OR under continuous infusion of Norepinephrine / Dobutamine / Epinephrine~Patient equipped with a cardiac output measurement system by transpulmonary thermodilution (PICCO®) with a femoral arterial module; as well as a central venous route in the superior vena cava territory.~Inclusion after agreement of the patient or his trusted person after validation of the inclusion criteria and verification of the absence of exclusion criteria."
62121760|NCT05736497|EXPERIMENTAL|Intervention: Digital Care Plans with Accompanying Text Messages|Investigators will recruit families and patients diagnosed with a Cancer Predisposition Syndrome within 3 years. Participants will be provided with a digital care plan and optional accompanying text message reminders.
62121761|NCT02161172||Mild traumatic brain injury|Traumatic brain injury patients with Glasgow coma score (GCS) of 13-15.
62121762|NCT05774951|ACTIVE_COMPARATOR|Arm A: standard endocrine therapy of investigator´s choice|Continue standard endocrine therapy of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen)
62476225|NCT05183191|EXPERIMENTAL|Intervention group|
62476226|NCT02092363|EXPERIMENTAL|Drug: OMP-54F28, Paclitaxel and Carboplatin|
62476227|NCT01036009|NO_INTERVENTION|Group I: Observation|Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.
62476228|NCT01036009|EXPERIMENTAL|Group II: Intervention|Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.
62495938|NCT06347627|EXPERIMENTAL|Group 14 (O x S x D x M)|"Participants in Group 14 will view a message in an X (former Twitter) format composed of Organization x Safety x Scientific data x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
61921611|NCT02655393|EXPERIMENTAL|Mitopure 1000 mg single dose-Food Effect|single dose of Mitopure admixed in yoghurt at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
61921612|NCT02655393|EXPERIMENTAL|Mitopure 250 mg multiple dose|Repeated 28 day dosing of Mitopure soft gel capsules at 250 mg dose, n=12 subjects (9 Active, 3 Placebo)
61921613|NCT02655393|EXPERIMENTAL|Mitopure 500 mg multiple 28 day dose|Repeated 28 day dosing of Mitopure soft gel capsules at 500 mg dose, n=12 subjects (9 Active, 3 Placebo)
61921614|NCT02655393|EXPERIMENTAL|Mitopure 1000 mg multiple 28 day dose|Repeated 28 day dosing of Mitopure soft gel capsules at 1000 mg dose, n=12 subjects (9 Active, 3 Placebo)
61921615|NCT02914821|NO_INTERVENTION|"Business as Usual (No Tax)"|Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
61921616|NCT02914821|EXPERIMENTAL|"General Tax (without named beneficiary)"|In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
61921617|NCT02914821|EXPERIMENTAL|"Pre-K Tax"|"In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education."
61921618|NCT02914821|EXPERIMENTAL|"Childhood Healthy Eating Tax"|"In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education."
61921619|NCT00876798|EXPERIMENTAL|1|Lixivaptan
61921620|NCT00876798|PLACEBO_COMPARATOR|2|Placebo
61921621|NCT00655135|PLACEBO_COMPARATOR|1|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received placebo administered intravenously to patients on Day 1 and Day 29.
62121763|NCT05774951|EXPERIMENTAL|Arm B: camizestrant|Camizestrant
61921622|NCT00655135|EXPERIMENTAL|2|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 0.5 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
61921623|NCT00655135|EXPERIMENTAL|3|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 2 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
61921624|NCT00188331||1|adjuvant/neoadjuvant chemotherapy
61921625|NCT00188331||2|non-chemotherapy group
61921626|NCT00188331||3|limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
61921627|NCT06002022|NO_INTERVENTION|Standard treatment|"Patients in the control arm will be treated as usual after the first-line breast cancer treatment. Specifically, in Valencia, this process entails biannual medical evaluation control visits for the first port-treatment year at the Oncology Department, including standardised blood examinations.~On top of that, patients of this group will be offered 3 supportive consultation sessions, over the phone, with generic advice on desired lifestyle choices (physical activity, dietary habits, sleep habits and social mobility) that will be helpful for managing the ongoing treatment"
61921628|NCT06002022|EXPERIMENTAL|Standard treatment + REBECCA|"Patients will be trained in the use of the complementary monitoring modules of the REBECCA mobile and online monitoring platform, which will be used longitudinally, facilitating the collection of real world data within the REBECCA framework. Their supervising health personnel will be given access to the REBECCA patient dashboard, that provides in-depth information about their lifestyle, as well as continuous REBECCA measurements for their online behaviour and self- or companion-reported measures of emotional state and quality of life.~Unlike those in the Standard care study-arm, 3 phone-based consultation sessions in the first 12 months of treatment visits will be scheduled based on system-predicted eminent life functionality and emotional state deteriorations (and potential decrease in treatment compliance), targeting the just-in-time patient support, aiming at improving treatment acceptance and efficacy"
61921629|NCT01314911|EXPERIMENTAL|Oseltamivir|
61921630|NCT01314911|PLACEBO_COMPARATOR|Placebo|
62121764|NCT04737681||Normal BMI|BMI 18.5-24.9 kg/m2
62121765|NCT04737681||Obese BMI|BMI ≥ 30 kg/m2
62310355|NCT02955186|EXPERIMENTAL|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
62310356|NCT02955186|PLACEBO_COMPARATOR|Placebo|Participants will take placebo daily for 8 days.
62310357|NCT04149522|ACTIVE_COMPARATOR|Medial Breast Tissue|Women assigned to the medial breast tissue arm, will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the medial breast tissue by clinically trained staff on day 1 of radiotherapy, the lateral segment will not be covered. The treatment area is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to the skin, then the paper frame is removed. Multiple sheets of non-overlapping film will be used to adequately cover the treatment area. During course of radiotherapy, new film may be applied by clinically trained staff in the event the film no longer adheres to the skin or comes off. Replacement of the film may be done as often as necessary. If there are signs of infection (e.g. redness, feeling warm or swollen), film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or clinically trained staff.
62310358|NCT04149522|ACTIVE_COMPARATOR|Lateral Breast Tissue|Women assigned to the lateral breast tissue arm will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the lateral breast tissue only, by trained staff on day 1 of radiotherapy. The in-field ipsilateral axilla will be included with lateral breast segment to extent necessary to cover breast or chest wall only. The skin is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to skin and paper frame is removed. Multiple sheets of non-overlapping film will be used to cover the treatment area. During course of therapy, new film may be applied as often as necessary, by trained staff if film no longer adheres to skin or comes off. If there are signs of infection (e.g. redness, feeling warm or swollen), the film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or trained staff.
62310359|NCT05195879|EXPERIMENTAL|XTR004|Single dose 6.0-8.0 mCi intravenous injection of XTR004 and investigation of XTR004 (MPI radiotracer).
62310360|NCT00211822||Pathologic Gamblers|
62680877|NCT05783596|EXPERIMENTAL|Obinutuzumab + Glofitamab for Marginal Zone Lymphoma|"Participants will undergo study procedures as outlined:~* Imaging scans (CT or PET) at screening and after cycles 3, 7, and 12 of treatment.~* Bone marrow biopsy at baseline.~* Cycle 1~  * Days -21, -14, -7, 0 of 36 day cycle: Predetermined dose of Obinutuzumab.~ * Days 1 and 8 of 36 day cycle: Predetermined dose of Glofitamab. (First dose will be administered in the hospital.)~* Cycles 2 - 12:~  o Day 1 of 21 day cycle: Predetermined dose of Glofitamab.~* Bone marrow biopsy within 2 weeks of end of treatment.~* Imaging scans (CT or PET) at 12, 18, and 24 months after treatment initiation.~* Follow up visits up to 5 years after treatment completion."
62310361|NCT00211822||Obsessive Compulsive Disorder|
61921631|NCT05920915|PLACEBO_COMPARATOR|Group K|Group K: Control group; 30 seconds (sec) will be waited before the vascular access is opened, no additional action will be taken.
61921632|NCT05920915|EXPERIMENTAL|Group M|Group M: Cold application group; Just before the vascular access was opened, a marble plaque was placed on the carotid (2-3 cm above the clavicle, on the sternocleidomastoid muscle (SCM) 2-3 cm above the clavicle) in the bilateral neck region, 4x5 cm in size, for 30 seconds.
62310362|NCT00211822||Healthy Controls|
61921633|NCT05920915|SHAM_COMPARATOR|Group S|Group S: Sham group; Before the vascular access is opened, a marble plaque of 4x5 cm with a polar sheath on it will be applied bilaterally to the neck region of the patients for 30 seconds.
61921634|NCT04428437||Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by lenvatinib.
62680878|NCT06691633|EXPERIMENTAL|Methadone Group|Participant receives a one-time preoperative dose of 10 mg of methadone
62121766|NCT04830501|EXPERIMENTAL|Dose Escalation|This study adopts an accelerated titration design (ATD) and utilizes an accelerated dose escalation phase in order to minimize suboptimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD.
61921635|NCT04428437||Non-Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by non-lenvatinib.
62310363|NCT04665544|EXPERIMENTAL|Early-stage endometrial cancer patients|"* Histologically proven endometrial cancer (any tumour type).~* Apparent early-stage endometrial cancer with intermediate or high risk prognostic factors (deep myometrial invasion or G2/G3 disease or non- endometrioid histological type), no evidence of bulky or suspicious pelvic/para-aortic lymph nodes or distant metastases on preoperative conventional imaging studies; minimum requirement for clinical staging includes expert US or pelvic MRI for local staging and abdominal US or abdominal CT scan or PET CT for distant staging.~* Performance status ECOG: 0-1.~* Age ≥18, ≤85.~* History of second primary cancer only if more than 5 years with no evidence of disease.~* Approved and signed informed consent"
62121767|NCT03165071|EXPERIMENTAL|ACT-132577 (50 mg)|8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast
62680879|NCT06691633|ACTIVE_COMPARATOR|Oxycodone Group|participant receives a one-time preoperative dose of 10 mg of oral oxycodone
62680880|NCT04254250||High risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
62121768|NCT03840486|ACTIVE_COMPARATOR|Non-rebreather mask (NRBM)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-rebreather mask (NRBM) overlying the sensor. The participants will be randomized to the order of their treatment sequence as follows: oxygen at 15 liters per minute (LPM) for 3 minutes, at 35 LPM for 3 minutes, or at flush rate (55 LPM) for 3 minutes. The maximal reading at the end of this will be recorded, then the study subjects will be allowed to rest until their EtO2 returns to their baseline. They will then be placed back on NRBM at flush rate, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
62680881|NCT04254250||Low risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
62680882|NCT06588400|EXPERIMENTAL|AOSEPT Plus (CC)|AOSEPT Plus and AOCup lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
62680883|NCT06588400|EXPERIMENTAL|AOSEPT Plus with HydraGlyde (CCP)|AOSEPT Plus with HydraGlyde and AOCup lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
62680884|NCT02062684|EXPERIMENTAL|Blisibimod|Blisibimod administered subcutaneously
62680885|NCT02062684|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62680886|NCT06688487|EXPERIMENTAL|hypoxemic extubation group|"Randomized patients exhibit relative hypoxemia, defined by an SpO2 ≤ 90% while receiving 6 liters of oxygen or FiO2 of 40%. They must not have severe hypoxemia, defined as an SpO2 \< 86% while receiving 9 liters of oxygen or FiO2 of 50%. Additionally, they must not show clinical signs of poor tolerance to the spontaneous breathing trial. Patients randomized to the hypoxemic extubation group are extubated despite the presence of relative hypoxemia after one hour of reventilation. Following extubation, a non-invasive oxygenation strategy is initiated, alternating between non-invasive ventilation and high-flow oxygen therapy for a minimum of 24 hours."
62680887|NCT06688487|NO_INTERVENTION|conventional extubation group|"Patients in the conventional extubation group also present with relative hypoxemia, defined as an SpO2 ≤ 90% on 6 liters of oxygen or FiO2 of 40% at the time of randomization, but they will only be extubated after correction of this hypoxemia. In practice, patients in the conventional extubation group are not extubated after randomization and continue on invasive ventilation. A new spontaneous breathing trial (SBT) can be performed between 2 and 6 hours after randomization, and if unsuccessful, it may be repeated daily at the discretion of the clinician. Patients in the conventional extubation group will only be extubated when their SpO2 exceeds 90% during an SBT conducted on 6 liters of oxygen or FiO2 of 40%.~After extubation, a non-invasive oxygenation strategy will be initiated, alternating between non-invasive ventilation (NIV) and high-flow oxygen therapy, for a minimum of 24 hours."
62680888|NCT06001775|EXPERIMENTAL|Patient Priorities Care Eligible Persons Living With Dementia and Mild Cognitive Impairment|Patients (and their care partners when available) will receive a packet of information about Patient Priorities Care, and when feasible, a trained facilitator(s) will initiate a Patient Priorities Care conversation with the patient or patient care partner dyad. This conversation will be documented in the Electronic Health Record.
62310364|NCT00723658|NO_INTERVENTION|Observation|Non-symptomatic patients are monitored monthly for 3 months, then every 3 months thereafter.
62476229|NCT01910688|EXPERIMENTAL|RFA treatment (Radiofrequency ablation)|If eligible for enrollment, patients receive initial RFA treatment at 0 month. Patients return to the study site at 3.5 months to review weight data since initial RFA. If the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 4 months. All patients are seen at 7.5months and if the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 8 months. All patients are seen at the study site at 12 months for final clinic weight.
62680889|NCT06688929||Axial Spondyloarthritis Patients|A cohort of adult patients diagnosed with axial spondyloarthritis (AxSpA) according to the Assessment of SpondyloArthritis International Society (ASAS) criteria. These patients will be evaluated to analyze the impact of psychosocial factors on disease progression, functionality, and quality of life.
62680890|NCT00708448|EXPERIMENTAL|All patients|All participants enrolled.
62680891|NCT04157738|EXPERIMENTAL|Fixed Group|Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
62680892|NCT04157738|ACTIVE_COMPARATOR|Insulin to carbohydrate ratio (ICR) Group|Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
62476230|NCT01149733|EXPERIMENTAL|Tamsulosin|0.4 mg Capsule
62476231|NCT01149733|ACTIVE_COMPARATOR|Flomax®|0.4 mg Capsule
62476232|NCT03100344|EXPERIMENTAL|Group 1|Nemolizumab (low dose)
62680893|NCT05282394|EXPERIMENTAL|Massage Intervention|Families will be instructed to provide parent-provided newborn abdominal massage three times per day through 5 days of life
62680894|NCT05282394|OTHER|Attention Control Intervention|Families will be provided with information about reading with baby.
62680895|NCT03989674|NO_INTERVENTION|White bread|
62476233|NCT03100344|EXPERIMENTAL|Group 2|Nemolizumab (medium dose)
62680896|NCT03989674|EXPERIMENTAL|Anthocyanin-fortified bread (2% w/w)|
62680897|NCT03989674|EXPERIMENTAL|Anthocyanin-fortified bread (4% w/w)|
62680898|NCT05785000|EXPERIMENTAL|Aerobe graded physical exercise intervention and usual care|Physical exercise program. The experimental programme is an add-on to usual care and consists of an aerobe graded exercise program performed twice a week for 12 weeks. Usual care includes all public treatments that each patient is assigned to at entry to REPCon. The provision of officially available treatments follow the Danish Health Care Act.
62680899|NCT05785000|PLACEBO_COMPARATOR|Usual care|No physical exercise program in a patient control group with PCS. This group continues with usual care, but all clinical test, interviews and MRI protocol are the same.
62680900|NCT06162468|EXPERIMENTAL|Single-arm|Gemcitabine 19 mg per 1 ml of estimated cyst fluid + paclitaxel 3 mg per 1 ml of estimated cyst fluid + 0.9% sodium chloride solution, given as a single administration
62680901|NCT05179408|EXPERIMENTAL|Targeted telerehabilitation|Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/endurance; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)
62680902|NCT05179408|ACTIVE_COMPARATOR|Waitlist|8-week waiting period prior to participating in targeted telerehabilitation
62680903|NCT04588077|EXPERIMENTAL|Cirrhosis, 3-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
62680904|NCT04588077|ACTIVE_COMPARATOR|Cirrhosis, 2-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
62680905|NCT04588077|EXPERIMENTAL|Non cirrhosis, 3-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
62680906|NCT04588077|ACTIVE_COMPARATOR|Non cirrhosis, 2-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.
62680907|NCT06426628||Test Arm|Percepta Nasal Swab test result will be returned to the physician investigator.
62680908|NCT06426628||Control Arm|Percepta Nasal Swab test result will not be returned to the physician investigator.
62680909|NCT01856192|EXPERIMENTAL|Arm A (rituximab, combination chemotherapy, lenalidomide)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1; prednisone PO on days 1-5; and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62680910|NCT01856192|ACTIVE_COMPARATOR|Arm B (rituximab, combination chemotherapy)|Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62680911|NCT05792722|OTHER|Prostate Capsule-Sparing Radical Cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
62680912|NCT05792722|OTHER|Nerve-Sparing Radical Cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
62680913|NCT05250557||Deferral of PCI group|Patients who undergo successful FFR pullback tracing and have a vessel determined to defer revascularization after FFR measurement will be included.
62680914|NCT05250557||PCI group|Patients who undergo successful FFR pullback tracing and have a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) will be included.
62680915|NCT05677126|ACTIVE_COMPARATOR|Tralement|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
62310365|NCT00723658|EXPERIMENTAL|Treatment|"Symptomatic pts: 2 cycles VTDPACE+R:~dex 40 mg PO D1-4 thalid 200 mg PO D1-4 cisplatin 10 mg/m2 IV D1-4 dox 10 mg/m2 IV D1-4 cyclophos 400 mg/m2 IV D1-4 etoposide 40 mg/m2 IV D1-4 bortezomib 1.0 mg/m2 IV D1,4,8,11 ritux 375 mg/m2 IV D1,8,15 lovenox 40 mg/d SQ D1-platelets \>50,000/mcl GCSF 10 mcg/kg/d IV D9-WBC \<2,000/mcl apheresis \>/= 20x10\^6 when WBC and CD34 within normal range, up to 4 cycles~1. st Trans: mel 200 mg/m2 IV D-1 bortezomib 1.3 mg/m2 IV D-4, -1 PBSC \>/=3.0x10\^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 500 ml IV D-1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1~2. nd Trans: BCNU 300 mg/m2 IV D-5 etoposide 200 mg/m2 IV D-5 to -2 AraC 400 mg/m2 IV D-5 to -2 mel 140 mg/m2 IV D-1 PBSC infusion \>/=3.0x10\^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 150 ml/hr IV D-5 to -1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1"
62310366|NCT01395485|EXPERIMENTAL|Cohort 2|Adolescents - Ages 13 to \<17
61921636|NCT04457219|ACTIVE_COMPARATOR|Conventional dressing with 120 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 2 hours, as per protocol. This is the standard radial care currently in use at Liverpool Heart and Chest Hospital.
61921637|NCT04457219|EXPERIMENTAL|Conventional dressing with 60 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
62310367|NCT01395485|EXPERIMENTAL|Cohort 1|Adolescents - Ages 12 to \<13
62310368|NCT01395485|EXPERIMENTAL|Cohort 4|Adults - Ages 18 to \<=50
62738559|NCT05148936|EXPERIMENTAL|At home testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be provided with COVID-19 testing provided at home by a healthcare worker.
62310369|NCT01395485|EXPERIMENTAL|Cohort 3|Adolescents - Ages 17 to \<18
62680916|NCT05677126|ACTIVE_COMPARATOR|a fixed-dose trace element combination product of zinc, copper, and selenious acid|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
62680917|NCT06428474|EXPERIMENTAL|children who are living in orphanages|Orphan children aged 6-12
62680918|NCT06436742|EXPERIMENTAL|ARGX-119|Participants receiving intravenous infusion of ARGX-119 once every other week
62680919|NCT06436742|PLACEBO_COMPARATOR|Placebo|Participants receiving intravenous infusion of placebo once every other week
62680920|NCT06457139|EXPERIMENTAL|Early Postpartum GDM Screening|Subjects who are randomly assigned to this condition will be screened for GDM with the recommended 2-hour glucose tolerance test during their postpartum hospitalization.
62680921|NCT06457139|ACTIVE_COMPARATOR|Standard of Care Postpartum Screening|Subjects randomized to the comparison condition will receive the usual standard of care. The standard of care will consist of screening with a 2 hour glucose tolerance test at 6-12 weeks postpartum.
62680922|NCT06171802|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin 1 capsule of 10 mg, once daily for six months.
62680923|NCT06171802|PLACEBO_COMPARATOR|Placebo|1 capsule of placebo, once daily for six months
62680924|NCT06328114|SHAM_COMPARATOR|sham TMS|Participants receive sham TMS
62680925|NCT06328114|ACTIVE_COMPARATOR|TMS to primary somatosensory cortex|Participants received TMS sessions at primary somatosensory cortex
62680926|NCT06567704||Non-small cell lung cancer (NSCLC)|Non-small cell lung cancer (NSCLC) patients treated with with immune checkpoint inhibitor.
62680927|NCT05532657|ACTIVE_COMPARATOR|Hearing intervention (HI) group|Participants in this group were randomized to the hearing intervention (HI) group at ACHIEVE trial baseline and received a best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist. These participants will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
62680928|NCT05532657|ACTIVE_COMPARATOR|Successful aging/Delayed hearing intervention (SA/DHI) group|Participants in this active control group were randomized to the successful aging (SA) group at ACHIEVE trial baseline and received a successful aging health education program, following the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator to control for staff-participant time and attention between the two groups. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
62680929|NCT03785132||cardiac surgery|Patients who underwent cardiac surgery with cardiopulmonary bypass
61921638|NCT04457219|EXPERIMENTAL|Haemostatic dressing with 60 minutes external compression|A haemostatic absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. This consists of a mineral-based dressing that accelerates local haemostasis. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
61921639|NCT02280473|EXPERIMENTAL|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
62680930|NCT03508700|EXPERIMENTAL|TNX-102 SL 5.6 mg|2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks
62680931|NCT06158438|EXPERIMENTAL|BTL-754-4 Treatment|Treatment with BTL-754 device with the applicator BTL-754-4 for reduction of facial wrinkles.
62680932|NCT06529692|EXPERIMENTAL|Early Stance Training|This study arm will complete 6-weeks of a split-belt treadmill training program. The program will require participants to walk on a split-belt treadmill 2 times a week for 20 minutes with the ACL leg walking at 150-170% of 1.1 m/s and the Non-ACL leg walking at 1.1 m/s.
62680933|NCT06529692|EXPERIMENTAL|Mid-Stance Training|This study arm will complete 6-weeks of a split-belt treadmill training program. The program will require participants to walk on a split-belt treadmill 2 times a week for 20 minutes with the ACL leg walking at 30-50% of 1.1 m/s and the Non-ACL leg walking at 1.1 m/s.
62680934|NCT06529692|PLACEBO_COMPARATOR|Placebo Split-Belt Training|This study arm will complete 6-weeks of a split-belt treadmill training program. The program will require participants to walk on a split-belt treadmill 2 times a week for 20 minutes with the ACL leg walking at a speed that is 10% different from 1.1 m/s and the Non-ACL leg walking at 1.1 m/s.
62680935|NCT06686368|EXPERIMENTAL|I-DROP MGD|High Molecular weight hyaluronic acid + PC containing lubricant eye drop Receiving lubricant eye drops with high molecular weight hyaluronic acid
62310370|NCT00893789|EXPERIMENTAL|1|Armodafinil 50 mg/day
62310371|NCT00893789|EXPERIMENTAL|2|Armodafinil 150 mg/day
62310372|NCT00893789|EXPERIMENTAL|3|Armodafinil 250 mg/day
62310373|NCT00893789|PLACEBO_COMPARATOR|4|Placebo
62476234|NCT03100344|EXPERIMENTAL|Group 3|Nemolizumab (high dose)
62476235|NCT03100344|PLACEBO_COMPARATOR|Group 4|Nemolizumab placebo
62680936|NCT06686368|ACTIVE_COMPARATOR|Thealoz Duo|Low Molecular weight hyaluronic acid + Trehalose containing lubricant eye dropReceiving lubricant eye drops with low molecular weight hyaluronic acid
61921640|NCT02280473|ACTIVE_COMPARATOR|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
62680937|NCT06686368|ACTIVE_COMPARATOR|Systane Complet PF|No hyaluronic acid containing lubricant eye drop Receiving lubricant eye drops without hyaluronic acid
62680938|NCT03533491|EXPERIMENTAL|App Evaluation|All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.
61921641|NCT05034666|ACTIVE_COMPARATOR|Before education|"Before alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is before applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
61921642|NCT05034666|ACTIVE_COMPARATOR|After education|"After alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is after applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
62310374|NCT03787433||ARC - Assisted Rehabilitation Care|All study participants will be asked to use ARC during for their post-stroke home based rehabilitation for up to 6 months.
62310375|NCT05114889|EXPERIMENTAL|Single Ascending Dose Healthy Volunteer|BSI-045B
62310376|NCT05114889|EXPERIMENTAL|Multiple Ascending Dose Healthy Volunteer|BSI-045B
62310377|NCT05114889|EXPERIMENTAL|Single Dose Atopic Dermatitis patients|BSI-045B
62310378|NCT02049528|EXPERIMENTAL|3 mg CC-122 reference capsule formulation|3 mg CC-122 reference capsule given by mouth with 240 mL of room temp tap water
62310379|NCT02049528|EXPERIMENTAL|3 mg CC-122 test capsule formulation|3 mg CC-122 test capsule give by mouth with 240 mL of room temp tap water
62310380|NCT02049528|EXPERIMENTAL|3 mg CC-122 test capsule + high fat meal|3 mg CC-122 test capsule given by mouth with 240 mL of room temp tap water approximately 5 minutes after eating a high-fat meal
62310381|NCT05785338||affected|patiente suspected for a cleft palate without cleft lip
62310382|NCT05785338||control|unaffected cases
62310383|NCT00463970|ACTIVE_COMPARATOR|1|Brief Intervention
62310384|NCT00463970|EXPERIMENTAL|2|Cognitive Behavioural Therapy
61921643|NCT04178083||Laparoscopic Sacrohysteropexy,|"Under general anesthesia,laparoscopic approach is used to enter the abdomen.Following this, visceral peritoneum is held with forceps from the point where the sacro-uterine ligaments adhere to the uterus.~cut with unipolar scissors to the sacrouterin ligaments approximately 2-4 cm in the midline a transverse incision is made and the posterior wall of the cervix is reached. Approx. 10-15 x2 cm polypropylene mesh 5 mm trocar is inserted into the abdomen with the help of grasper and one end three points with 2/0 non-absorbable prolene sutures in the midline cervix Intracorporeal suture technique.~After the sacral promontorium on peritona about 2 The transverse incision is made to the normal anatomical position and the appropriate mesh length is determined and the other end is fixed to the area prepared on the sacral promontorium at 3 points with 2-0 prolene. Bleeding reperitonization according to intracorporeal suture technique with 2/0 vicry"
62310385|NCT00463970|EXPERIMENTAL|3|Seal oil
62310386|NCT00463970|PLACEBO_COMPARATOR|4|Soy oil
62310387|NCT03505242|EXPERIMENTAL|BB|
62310388|NCT03505242|EXPERIMENTAL|DLT|
62310389|NCT04730323|EXPERIMENTAL|Tocilizumab Group|Tocilizumab administration protocol: Patients received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion.
62310390|NCT04730323|ACTIVE_COMPARATOR|Methylprednisolone (corticosteroid) group|Corticosteroid administration protocol: Patients received methylprednisolone 80mg/day in two divided doses as per national/local guidelines and predefined parameters of disease severity were assessed on each day.
62310391|NCT02011022|EXPERIMENTAL|3g group|The dose of MTX is 3 g/m2
62310392|NCT02011022|EXPERIMENTAL|5g group|The dose of MTX is 5g/m2
62310393|NCT02242539|EXPERIMENTAL|Height measurement poster|
62310394|NCT02242539|EXPERIMENTAL|Community-based monitoring|
62310395|NCT02242539|NO_INTERVENTION|Control|
62310396|NCT01525394|EXPERIMENTAL|Lenvatinib Capsules|
62310397|NCT01525394|ACTIVE_COMPARATOR|Moxifloxacin tablets|
62310398|NCT01525394|PLACEBO_COMPARATOR|Placebos|
62310399|NCT06337370|EXPERIMENTAL|CDSMP Group|Participants will receive the chronic disease selfmanagement program for 6 weeks.
62310400|NCT06337370|ACTIVE_COMPARATOR|Conventional Care Group|Participants will receive conventional care.
62310401|NCT01341873|EXPERIMENTAL|Group I (FCI)|FCs receive 4 sessions of an APN FCI beginning during the admission for transplant and continuing for up to 100 days after transplant.
62680939|NCT04398706|EXPERIMENTAL|Group 1|One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
62680940|NCT04398706|EXPERIMENTAL|Group 2|One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
62476236|NCT01237691|EXPERIMENTAL|HOPE supervision|Parolee supervised under California's new HOPE parole model.
62476237|NCT01237691|ACTIVE_COMPARATOR|Parole-as-usual|Parolees supervised under California parole-as-usual.
61921644|NCT04178083||Modified Laparoscopic Lateral Suspension|A 10 cm diameter trocar is passed through a 1 cm infraumbical incision. In addition, two 5 mm diameter trocar are placed on 4 cm on both sides of the spinal iliac crest, and a 5 mm diameter trocar is placed laterally in the rectus muscle at the left lateral level of the umbilicus. A Prolene network of 25 cm in length is prepared. Dissection of the uterine cavity is performed to expose a mustache. The bottom of the web is secured by suturing the web in the midline and sides of the web with 2-0 prolene. The left and right modified lateral ports are then removed by moving under the bottom of the planet with the help of the planet until the isthmus reaches the bottom of the round ligament. The lateral ports are again slid onto the mesh, placed and sutured with peritoneal 2-0 vicryil, the mesh ends are cut at the skin level and the procedure is terminated.
61921645|NCT04178083||Laparoscopic Pectopexy|"First, the peritoneal layer on the top and side of the bladder opens parallel to the round ligament toward the right pelvic sidewall.~The iliopectineal ligament is then located under the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medially of the outer iliac vein.~iliopectineal (Cooper) ligament exposing a segment of approximately 3-4 cm is formed.~After completion of the dissections, the ends of the mesh are sutured to both iliopectineal ligaments by intracorporeal suture using nonabsorbable sutures. The middle of the net is fixed with three sutures to the lower anterior segment of the uterus. The peritoneum on the mesh is sutured with an absorbable suture material."
61921646|NCT01043315||Hospitalized Cardiac Patient|Adults admitted to Coronary intensive unit being treated for acute cardiovascular conditions
62310402|NCT01341873|OTHER|Group II (control)|FCs receive standard supportive care.
62310403|NCT00984789|EXPERIMENTAL|Arm 1|
62310404|NCT00984789|ACTIVE_COMPARATOR|Arm 2|
62476238|NCT01414153|EXPERIMENTAL|Monotherapy|4.0 mg iSONEP followed by sham injection; given monthly intravitreously for 4 months
62476239|NCT01414153|EXPERIMENTAL|0.5 mg iSONEP & Lucentis/Avastin/Eylea|0.5 mg iSONEP and 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
61921647|NCT05246904|ACTIVE_COMPARATOR|audiologist arm|A research audiologist will fit the participant with the hearing devices according to usual clinical best practice procedures.
61921648|NCT05246904|ACTIVE_COMPARATOR|self-fit arm|Participants will follow manufacturer's printed instructions to complete the self-hearing test using the hearing aids and a provided app to program their hearing aids.
61921649|NCT01284933||Acute Ischemic Stroke, TIA|Patients admitted to a specialized stroke service because of an acute ischemic stroke or a transient ischemic attack (TIA).
61921650|NCT01171170|ACTIVE_COMPARATOR|carboplatin-paclitaxel-bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
61921651|NCT01171170|EXPERIMENTAL|standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
62121769|NCT03840486|ACTIVE_COMPARATOR|Non-invasive ventilator mask (NIV)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-invasive ventilator mask (NIV) overlying the sensor. Participants will be randomized to the order of their treatment sequence as follows: NIV at 50% fraction of inspired oxygen (FiO2) for 3 minutes, NIV at 75% FiO2 for 3 minutes, NIV at 100% FiO2 for 3 minutes, the maximal reading at the end of this trial will be recorded. The study subjects will be allowed to rest until their EtO2 returns to their baseline, then they will be placed back on NIV at 100% FiO2, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
62121770|NCT05287282|EXPERIMENTAL|TECAR application|
62310405|NCT00865501|EXPERIMENTAL|1|spironolactone
62476240|NCT01414153|EXPERIMENTAL|4.0 mg iSONEP & Lucentis/Avastin/Eylea|4.0 mg iSONEP followed by 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
62310406|NCT00865501|PLACEBO_COMPARATOR|2|placebo
62476241|NCT01414153|ACTIVE_COMPARATOR|Lucentis or Avastin or Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea followed by a sham injection; given monthly intravitreously for 4 months
62476242|NCT04327128|ACTIVE_COMPARATOR|Intervention group|Standard heart failure care and a digital heart failure support system
62476243|NCT04327128|OTHER|Control group|Standard heart failure care
62680941|NCT04398706|EXPERIMENTAL|Group 3|One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
62476244|NCT02350621|ACTIVE_COMPARATOR|ACDF|Anterior Cervical Discectomy and Fusion
62476245|NCT02350621|ACTIVE_COMPARATOR|miPCF|minimal invasive Posterior Cervical Foraminotomy
62476246|NCT00828295|EXPERIMENTAL|1 mcg/kg arm|Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
62476247|NCT00828295|EXPERIMENTAL|3 mcg/kg arm|Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
62476248|NCT06033274||Patients with Tricuspid Regurgitation undergoing Transcatheter Tricuspid Valve Replacement|Patients having clinically significant tricuspid regurgitation, defined according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease, requiring transcatheter tricuspid valve replacement
62476249|NCT02181647|EXPERIMENTAL|Intervention|Safe Touches Personal Safety Training for Children
62476250|NCT02181647|OTHER|Comparison|Received Safe Touches after week-1 assessment completed (delayed intervention).
62476251|NCT03832530|EXPERIMENTAL|HIV-uninfected women|"A sample of 150 women, aged 18-35, likely to be fertile based on reproductive health history, with reported personal or partner desire to have a child in the next year and who self-reports having a relationship with a partner she reports as HIV-infected or likely to be HIV-infected (e.g. taking medicine daily, goes to clinic routinely, has HIV-infected partners, he has implied that he is sick but has not disclosed). All women are offered comprehensive safe conception counseling -- this is the intervention -- inclusive of daily oral TDF/FTC as PrEP."
62476252|NCT01825447|PLACEBO_COMPARATOR|Treatment A|
62680942|NCT04398706|ACTIVE_COMPARATOR|Group 4|One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
61921652|NCT04896021|EXPERIMENTAL|Intervention|On referral to Tasmanian pathology services for blood cholesterol, intervention participants will have their blood pressure measured and collated with other cardiovascular disease risk factors. An absolute cardiovascular disease risk score is calculated, interpreted according to guideline recommendations and reported to referring doctors via the established pathology system. High risk is highlighted in red as per usual practice for pathology tests outside of normal range, and advice provided regarding appropriate action according to National Vascular Disease Prevention Alliance guidelines.
62121771|NCT05287282|ACTIVE_COMPARATOR|selected abdominal exercises program|
62121772|NCT02462369|EXPERIMENTAL|Saxagliptin|Saxagliptin 5mg/d, 52 weeks
62310407|NCT03614715|EXPERIMENTAL|CinnaGen interferon beta-1a|CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
62476253|NCT01825447|EXPERIMENTAL|Treatment B|
62476254|NCT01825447|ACTIVE_COMPARATOR|Treatment C|
62476255|NCT02479633|OTHER|gingival recession type 1|recession defects without CAL intervention:Coronally advanced flap with connective tissue graft
62476256|NCT02479633|OTHER|gingival recession type 2|gingival recession with an amount of CAL equal or smaller to the buccal CAL. Intervention: Coronally advanced flap with connective tissue graft
62476257|NCT05194020|EXPERIMENTAL|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
62310408|NCT03614715|ACTIVE_COMPARATOR|Biogen interferon beta-1a|Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
62476258|NCT02193971|ACTIVE_COMPARATOR|BS-DES with prasugrel 10mg daily|BS-DES with prasugrel 10mg daily
62121773|NCT02462369|ACTIVE_COMPARATOR|glimepiride|glimepiride 1\~4mg/d,52 weeks
62310409|NCT01525212|EXPERIMENTAL|Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075|
62310410|NCT01525212|EXPERIMENTAL|Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075|
62310411|NCT01525212|EXPERIMENTAL|Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075|
62310412|NCT01525212|EXPERIMENTAL|Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075|
62310413|NCT04392011|EXPERIMENTAL|Arm 1|"Six non-naive\* subjects (3 males, 3 females) will be administered a single low dose of a well-characterized kratom product (2 g) by mouth as a tea. These subjects may or may not choose to participate in Arms 2a and 2b. For subjects who will participate in Arms 2a and 2b, a washout period of 7 days will separate Arm 1 and Arm 2. Plasma will be collected from 0-120 hours and during the washout period. Urine will be collected from 0-120 hours.~\*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks."
62476259|NCT02193971|ACTIVE_COMPARATOR|BS-DES with prasugrel 5mg daily|BS-DES with prasugrel 5mg daily
62476260|NCT02193971|EXPERIMENTAL|BD-DES with prasugrel 10mg daily|BD-DES with prasugrel 10mg daily
62476261|NCT02193971|EXPERIMENTAL|BD-DES with prasugrel 5mg daily|BD-DES with prasugrel 5mg daily
62476262|NCT01421264|EXPERIMENTAL|Gabapentin|
62476263|NCT02765880|EXPERIMENTAL|Healthy volunteer|
62476264|NCT02765880|EXPERIMENTAL|Patients with schizophrenia|
62476265|NCT02765880|EXPERIMENTAL|Patient with bipolar disorder|
62476266|NCT03394547|ACTIVE_COMPARATOR|Active Treatment|Treatment for 2 menstrual cycles using the pulsed shortwave therapy Allay® device (BioElectronics Corp, Frederick USA)
62680943|NCT04398706|EXPERIMENTAL|Group 5|Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
61921653|NCT04896021|ACTIVE_COMPARATOR|Control|On referral to Tasmanian pathology services for blood cholesterol, control participants will have their blood pressure measured and collated with other cardiovascular disease risk factors as per the intervention arm. However, only the results relating to blood cholesterol are reported to the referring doctor, as per usual practice.
62476267|NCT03394547|PLACEBO_COMPARATOR|Placebo|Treatment for 2 menstrual cycles using a placebo device which is identical in appearance to the active device but does not emit any pulsed shortwave therapy.
62680944|NCT04398706|EXPERIMENTAL|Group 6|Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
62680945|NCT04398706|EXPERIMENTAL|Group 7|Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
62680946|NCT04398706|ACTIVE_COMPARATOR|Group 8|Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
62680947|NCT06695663|EXPERIMENTAL|Primary care clinicians group 1|PCCs with pediatric patients randomized to experimental group
62680948|NCT06695663|ACTIVE_COMPARATOR|Primary care clinicians group 2|PCCs with pediatric patients randomized to control group
62680949|NCT06695663|EXPERIMENTAL|Parent group 1|assigned to receive eGen
62680950|NCT06695663|ACTIVE_COMPARATOR|Parents group 2|assigned to receive one-session control
62680951|NCT06686537|EXPERIMENTAL|Estradiol Patch- Normal Weight women|Normal weight women (NWW) will wear a Transdermal estradiol patch for 7 days and collect urine to determine LH surge.
62476268|NCT03394547|NO_INTERVENTION|No treatment|No intervention is given and a menstrual diary is completed for 2 cycles.
62476269|NCT04548635|EXPERIMENTAL|VR-PAT|Virtual Reality administered during burn dressing changes
62680952|NCT06686537|EXPERIMENTAL|Estradiol Patch- Women with high BMI|Women with a BMI greater than 30 kg/m2 will wear a Transdermal estradiol patch for 7 days and collect urine to determine LH surge.
62680953|NCT05286385|EXPERIMENTAL|Test Order 1|CP1150, then CP1150 NF, then CP1110, then CP1150 + FF
62680954|NCT05286385|EXPERIMENTAL|Test Order 2|CP1150 NF, then CP1150 + FF, then CP1150, then CP1110
61921654|NCT01165580|EXPERIMENTAL|Single Arm|
62680955|NCT05286385|EXPERIMENTAL|Test Order 3|CP1150 + FF, then CP1110, then CP1150 NF, then CP1150
62680956|NCT05286385|EXPERIMENTAL|Test Order 4|CP1110, thenCP1150, then CP1150 + FF, then CP1150 NF
62680957|NCT03477591|EXPERIMENTAL|Evidence + PDA|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
62680958|NCT03477591|EXPERIMENTAL|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
62476270|NCT04548635|NO_INTERVENTION|Control|Dressing changes performed without Virtual Reality (other distraction methods available in the home allowed).
62476271|NCT00620893|ACTIVE_COMPARATOR|1|1. PEG-400 based artificial tear
62476272|NCT00620893|ACTIVE_COMPARATOR|2|2. Systane
62476273|NCT02557347|EXPERIMENTAL|Intervention|Aggressive fluid management
62680959|NCT03477591|SHAM_COMPARATOR|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
62680960|NCT06656572|EXPERIMENTAL|Enrollees - WGS|These participants will be subject to whole genome sequencing and Phage ImmunoPrecipiation sequencing (PhIP-Seq) to identify genetic changes and novel antibodies associated with catatonia.
62680961|NCT02344355|EXPERIMENTAL|ascorbate, radiation, temozolomide|"Concomitant therapy:~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions~Adjuvant therapy:~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
62680962|NCT06686069|PLACEBO_COMPARATOR|placebo, untreated|No treatment
62680963|NCT06686069|ACTIVE_COMPARATOR|bioarginina zero|L-arginine treatment
62680964|NCT06161025|EXPERIMENTAL|Part A: R-DXd 4.8mg/kg Q3W|Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).
62680965|NCT06161025|EXPERIMENTAL|Part A: R-DXd 5.6 mg/kg Q3W|Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).
62680966|NCT06161025|EXPERIMENTAL|Part A: R-DXd 6.4 mg/kg Q3W|Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
62680967|NCT06161025|EXPERIMENTAL|Part B: R-DXd RP3D Q3W|Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).
62476274|NCT03804593||Group 1|Diagnosis of cirrhosis and no HCC confirmed by medical imaging including MRI or CT performed within 6 months of study enrollment. If lesions are present, a Liver Imaging Reporting and Data System (LI-RADS) score of LR-1 or LR-2.
62680968|NCT06161025|ACTIVE_COMPARATOR|Part B: Investigator's Choice|Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), gemcitabine, or topotecan.
62680969|NCT06687486|EXPERIMENTAL|intervention|
62680970|NCT06687486|OTHER|control|
62476275|NCT03804593||Group 2|Diagnosis of HCC confirmed by medical imaging (MRI or CT performed within 6 months of study enrollment with LI-RADS score of LR-5) and/or biopsy with histopathology.
62680971|NCT06694077|EXPERIMENTAL|Bupivacaine with Dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
62680972|NCT06694077|EXPERIMENTAL|Bupivacaine only|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline
62680973|NCT01907789|EXPERIMENTAL|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
62680974|NCT01907789|EXPERIMENTAL|Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
62680975|NCT01907789|EXPERIMENTAL|Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
62680976|NCT05656573|EXPERIMENTAL|autologous CART-PSMA cells|"Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2(body surface area) on Day 0; Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2(body surface area) on Day 0; Cohort 3： Lymphodepletion chemotherapy with fludarabine (30 mg/m2 body surface area) plus cyclophosphamide (300 mg/m2 body surface area) for 3 consecutive days during D-7 to D-3, followed by the infusion of CART-PSMA cells at 1-3x10\^7/M\^2(body surface area) on Day 0.~Cohort 4： Lymphodepletion chemotherapy with fludarabine (30 mg/m2 body surface area) plus cyclophosphamide (300 mg/m2 body surface area) for 3 consecutive days during D-7 to D-3, followed by the infusion of CART-PSMA cells at 1-3x10\^8/M\^2(body surface area) on Day 0."
62680977|NCT06343298|PLACEBO_COMPARATOR|Placebo-matched control|Placebo-matched vehicle (vehicle minus the active component)
62680978|NCT06343298|ACTIVE_COMPARATOR|MANP|MANP in vehicle
62680979|NCT06680401||Group A|Patients newly diagnosed with advanced EE starting active surveillance
62680980|NCT06680401||Group B|Patients with new diagnosis of advanced, evolving EE, worthy of medical treatment
61921655|NCT04672681|EXPERIMENTAL|Intervention group|The intervention group will receive a 6-month play-based physical activity intervention with daily play and movement activities starting from treatment initiation.
61921656|NCT04672681|NO_INTERVENTION|Standard care|"The control group will receive standard treatment and physiotherapy if needed.~For ethical reasons, after the primary study end-point at six months, the participants and parents allocated to this group will be offered the same inspirational material and the possibility to participate in the group-based physical activity as the participants and parents allocated to the intervention group, but they will not receive education and supervision play-based physical activity with their child in the hospital room."
61921657|NCT04679545|EXPERIMENTAL|CBD|Subject will receive a 28-day supply of 20 mg CBD sublingual tablets to be taken 3 times a day for 28 days.
62476276|NCT06560008|ACTIVE_COMPARATOR|EnXtra® (300 mg) + Placebo (300 mg)|Acute Stage: Two capsules to be taken after breakfast orally 1 (single dose) x 4 periods = 4 days Sub-acute Stage: Two capsules to be taken after breakfast orally once a day for 28 days
62476277|NCT06560008|ACTIVE_COMPARATOR|Caffeine (200 mg) + Placebo (300 mg)|Acute Stage: Two capsules to be taken after breakfast orally 1 (single dose) x 4 periods = 4 days Sub-acute Stage: Two capsules to be taken after breakfast orally once a day for 28 days
62476278|NCT06560008|ACTIVE_COMPARATOR|EnXtra® (300 mg) + Caffeine (200 mg)|Acute Stage: Two capsules to be taken after breakfast orally 1 (single dose) x 4 periods = 4 days Sub-acute Stage: Two capsules to be taken after breakfast orally once a day for 28 days
62680981|NCT06680401||Group C|Patients with a previous diagnosis of advanced EE, already under active surveillance
61921658|NCT04679545|PLACEBO_COMPARATOR|Placebo Control|A placebo sublingual tablet to be taken three times a day for 28 days.
62680982|NCT06680401||Group D|Patients with a previous diagnosis of advanced EE with ongoing medical treatment
62680983|NCT06680401||Group E|Patients with localized EHE
62680984|NCT04190771|EXPERIMENTAL|TAU + multicomponent treatment NAT-FM|NAT-FM is a multicomponent non-pharmacological program based on mindfulness ingredients, pain neuroscience education, and nature exposure. NAT-FM is conceived as an add-on therapy.
62680985|NCT04190771|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for fibromyalgia, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
62680986|NCT03734536|OTHER|REGENETEN™ Bioinductive Implant|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
62680987|NCT03734536|OTHER|Arthroscopic repair of the high-grade (>50%) partial-thickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
62310414|NCT04392011|EXPERIMENTAL|Arm 2|"Arm 2 is divided into Arms 2a and 2b. Twelve non-naive subjects (6 males, 6 females) will participate in Arm 2a. Subjects who participate in this study arm will be administered an oral probe drug cocktail of dextromethorphan HBr (2 x 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-24 hours. Urine will be collected from 0-24 hours. A washout period of 7 days will separate Arms 2a and 2b.~For Arm 2b, the same 12 subjects will be administered a combination of a well-characterized kratom product (2 g) by mouth as a tea with an oral probe drug cocktail consisting of dextromethorphan HBr (2, 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-12 hours and during a midpoint collection within 5 days of the 24-hour blood collection. Urine will be collected from 0-24 hours."
61921659|NCT06302738||Non-dipper pattern at 24-hour BP monitoring|Defined as a nocturnal decrease systolic and/or in diastolic BP values \<10% compared to the corresponding daytime values;
62310415|NCT04076761|EXPERIMENTAL|Trifluridine/Tipiracil|FTD/TPI at 35 mg/m2 (based on BSA) that is administered in tablet form, orally, twice daily, within one hour of morning and evening meals, on days 1-5 and days 8-12 of a 28 day cycle.
62310416|NCT02165540|EXPERIMENTAL|Doula|Patients will have a doula support person during their procedure.
62310417|NCT02165540|NO_INTERVENTION|Routine care/No Doula|Patients will have routine care with clinical staff only.
62310418|NCT00129714|NO_INTERVENTION|wait and see|
62310419|NCT00129714|EXPERIMENTAL|collar|
62310420|NCT00129714|EXPERIMENTAL|physiotherapy|
62310421|NCT06667128|NO_INTERVENTION|Standard Care Group|Participants receive standard follow-up care with Guideline-Directed Medical Therapy (GDMT) adjustments as per the physician's usual practice.
62310422|NCT06667128|EXPERIMENTAL|Rapid Up-Titration GDMT Group with Point-of-Care (PoC) Monitoring|Patients will undergo rapid up-titration of GDMT. Their progress will be closely monitored using Point-of-Care (PoC) technology from Roche Diagnostics for NT-proBNP measurements.
62310423|NCT06667128|EXPERIMENTAL|Rapid Up-Titration GDMT Group with Hospital Monitoring|Patients will undergo rapid up-titration of GDMT. Their progress will be closely monitored using hospital-based blood tests (Roche Elecsys central laboratory platform).
62310424|NCT01566838|ACTIVE_COMPARATOR|On-q pump|Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
62310425|NCT01566838|ACTIVE_COMPARATOR|Standard of care|"Patients in this arm will not receive a pain catheter in addition to the standard of care for pain management. Standard of care will consist of a standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and maintained on a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures. Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV once, neuromuscular reversal agents, and an antiemetic (ondansetron 4mg). Patients will also be given additional narcotics (fentanyl) upon emergence, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will also be provided. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
62310426|NCT03471910|EXPERIMENTAL|Diosmin|Diosmin 600mg, one tablet once daily
62310427|NCT03471910|ACTIVE_COMPARATOR|Diosmin + Hesperidin|Diosmin 900mg + Hesperidin 100mg, one tablet once daily
62310428|NCT01101724|NO_INTERVENTION|Standard of Care|In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
62121774|NCT00703911||activated recombinant human factor VII|Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
61921660|NCT05949944|EXPERIMENTAL|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
61921661|NCT04923165||patients with stroke|Inpatients and outpatients admitted to the investigators' rehabilitation facility .
61921662|NCT01469104|PLACEBO_COMPARATOR|3 day fast|After receiving a standard diet on day 1, subject will fast on days 2, 3, and 4. Water and calorie-fee beverages will be allowed during this 72 hour period.
61921663|NCT01469104|ACTIVE_COMPARATOR|CHO-free diet|After receiving a standard diet on day 1, a carbohydrate-free diet will be provided on days 2, 3, and 4.
61921664|NCT06151184|EXPERIMENTAL|Post-concussion syndrome participants|Post-concussion syndrome participants will all receive manual chiropractic adjustment interventions.
62121775|NCT05251207|EXPERIMENTAL|carnitine|2 grams of L-carnitine per day for 12 weeks
62121776|NCT05251207|PLACEBO_COMPARATOR|leucine|2 grams of L-leucine per day for 12 weeks
62680988|NCT06227026|EXPERIMENTAL|Anti-CD19 CAR-T Cell Infusion|
62680989|NCT02527083|ACTIVE_COMPARATOR|BIA|Balanced Inhalational Anesthesia (consisting of a sevoflurane inhaled anesthestic only)
62680990|NCT02527083|ACTIVE_COMPARATOR|TIVA-K|Total intravenous anesthetic with ketamine
62680991|NCT02527083|ACTIVE_COMPARATOR|TIVA-R|Total intravenous anesthetic with remifentanil
62680992|NCT06686225|EXPERIMENTAL|Bowen's technique|This group will receive 20 mint per session for 6 weeks of bowen's technique with moderate to high intensity of soft tissue mobilization.
61921665|NCT00480974||1|Patients with Sickle cell anemia treated by Hydroxyurea
62310429|NCT01101724|EXPERIMENTAL|Intervention|Mandated Rest.
62680993|NCT06686225|EXPERIMENTAL|Bent leg raise technique.|This group will receive 15 mints per session for 6 weeks of mulligan's bent leg raise technique with moderate to high intensity of soft tissue mobilization.
61921666|NCT00522964|EXPERIMENTAL|Intervention|
62310430|NCT02603640|EXPERIMENTAL|epileptic patient|
62476279|NCT06560008|PLACEBO_COMPARATOR|Placebo (MCC 300 mg) + Placebo (300 mg)|Acute Stage: Two capsules to be taken after breakfast orally 1 (single dose) x 4 periods = 4 days Sub-acute Stage: Two capsules to be taken after breakfast orally once a day for 28 days
62476280|NCT01341730|ACTIVE_COMPARATOR|Atorvastatin 20 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg group is to take atorvastatin 20 mg and take follow up PET CT in 3 months"
62310431|NCT06227923|EXPERIMENTAL|Intervention group|Participants are transferred from the hospital ward to a small apartment with a technological assessment and monitoring established inside the hospital setting.
62476281|NCT01341730|EXPERIMENTAL|Atorvastatin 20 mg + Pioglitazone 30 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg + Pioglitazone 30 mg group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months"
62476282|NCT04205266|EXPERIMENTAL|IV Iron|Will receive 2 infusions of 510mg of ferumoxytol, administered over 15 minutes, 3-8 days apart
61921667|NCT01315236|EXPERIMENTAL|LAI 590 mg QD|LAI 590 mg QD
62310432|NCT06227923|NO_INTERVENTION|Control group|Participants remain in the hospital ward and receive normal clinical practice.
62680994|NCT04566731|ACTIVE_COMPARATOR|tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of tDCS for 20 minutes using a montage in which an anode (1.5 mA) is placed over F7 (left frontotemporal lobe) and the cathode will be place on O1 (left occipital) using the 10-20 EEG mapping system. Subjects will participate in a modified constraint-induced language therapy.
62680995|NCT04566731|SHAM_COMPARATOR|Sham tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham tDCS for 20 minutes using a montage in which an anode is placed of F7 and cathose is placed over O1. Subjects will participate in a modified constraint-induced language therapy,
61921668|NCT01315236|PLACEBO_COMPARATOR|Placebo|placebo QD
61921669|NCT01165190||Pioglitazone group|
61921670|NCT06516159||MBI-C Scale in French|
62476283|NCT04205266|ACTIVE_COMPARATOR|Oral Iron|Will receive 325mg ferrous sulfate tablets daily for 60 days
62476284|NCT06356805|ACTIVE_COMPARATOR|Active rTMS|Active rTMS of 1 Hz at an intensity of 120% RMT for 60 seconds(20 Trains), with a 45-second gap between trains giving a total of 1,200 pulses/day with the center of coil over rt DLPFC (5cm anterior to hand area). Five sessions/week for 4 consecutive weeks were applied
62680996|NCT01391494|EXPERIMENTAL|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
62680997|NCT01391494|EXPERIMENTAL|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
62680998|NCT01391494|EXPERIMENTAL|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
62680999|NCT01391494|EXPERIMENTAL|1280Eu/0.5ml (without adjuvant) in adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
62681000|NCT01391494|PLACEBO_COMPARATOR|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
62681001|NCT01391494|EXPERIMENTAL|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
61921671|NCT03293511|EXPERIMENTAL|Order of administration: oxytocin - placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
61921672|NCT03293511|EXPERIMENTAL|Order of administration: placebo - oxytocin|Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
61921673|NCT02011893|EXPERIMENTAL|Burst Stimulation|Burst Stimulation using the Prodigy system
61921674|NCT02011893|ACTIVE_COMPARATOR|Tonic Stimulation|Tonic Stimulation using the Prodigy system
62310433|NCT04634669|EXPERIMENTAL|AXS-05 (dextromethorphan-bupropion)|
62476285|NCT06356805|SHAM_COMPARATOR|Sham rTMS|Sham rTMS of 1 Hz at an intensity of 120% RMT for 60 seconds (20 Trains), with a 45-second gap between trains giving a total of 1,200 pulses/day with the coil held perpendicular to the rt DLPFC (5cm anterior to hand area). Five sessions/week for 4 consecutive weeks were applied.
62476286|NCT02723981|EXPERIMENTAL|COMBO-Stent|Implantation of COMBO-Stent and medication with (N)OAC and clopidogrel for 3 months followed by (N)OAC alone
62476287|NCT02723981|ACTIVE_COMPARATOR|Any Drug eluting or bare metal stent|Implantation of any drug eluting oder bare metal stent combined with anticoagulant medication according to ESC guidelines
62681002|NCT01391494|EXPERIMENTAL|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
62681003|NCT01391494|EXPERIMENTAL|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
62681004|NCT01391494|EXPERIMENTAL|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
61921675|NCT05896579|EXPERIMENTAL|COPD with pulmonary artery enlargement|Participants will complete testing at rest and during exercise to identify patterns of right ventricular dysfunction. If a participant decides to participate in the optional exercise training program, the participant will complete exercise training followed by repeat testing to determine the impact of exercise training on right ventricular dysfunction.
62476288|NCT01429870|ACTIVE_COMPARATOR|Steroid active treatment|Triamcinolone acetonide 0.1% in unguentum leniens topically
62476289|NCT01429870|PLACEBO_COMPARATOR|Vehicle|unguentum leniens topically
62476290|NCT03644888|ACTIVE_COMPARATOR|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW \[m kg -1 \]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F \< 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or \> 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
61921676|NCT03762915|EXPERIMENTAL|SRP with minocycline HCl microspheres|The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.
61921677|NCT03762915|NO_INTERVENTION|SRP without minocycline HCl microspheres|The control group will not have minocycline HCl microspheres, 1 mg administered.
62310434|NCT04965714|EXPERIMENTAL|Treatment (nivolumab, pegargiminase)|Patients receive nivolumab IV over 30 minutes on day 1 and pegargiminase IM at 2 days before day 1 of cycle 1, day 8 of cycle 1, days 1 and 8 of cycle 2, and day 1 of cycle 3. Treatments repeat every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection at week 7. A cycle is 14 days.
62476291|NCT03644888|EXPERIMENTAL|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
62476292|NCT03644888|SHAM_COMPARATOR|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
62476293|NCT01980771|EXPERIMENTAL|BTWB intervention|Barbershops are assigned to either experimental or active control condition. Men recruited from experimental barbershops receive a single-session group intervention focused on HIV prevention.
62476294|NCT01980771|ACTIVE_COMPARATOR|Cancer prevention and screening|Barbershops are assigned to either experimental or control condition. Men recruited from control barbershops receive information on cancer prevention and control.
62476295|NCT05662826|EXPERIMENTAL|Avatar-based Social Physical Activity|Group classes with virtual reality exercise games, talking, acting, and painting activities
62476296|NCT03136627|EXPERIMENTAL|Tivozanib (AV-951) plus Nivolumab|Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.
62681005|NCT01391494|PLACEBO_COMPARATOR|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
62681006|NCT01391494|EXPERIMENTAL|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
62681007|NCT01391494|EXPERIMENTAL|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
61921678|NCT01299701|EXPERIMENTAL|ASA404|
61921679|NCT03734484|EXPERIMENTAL|Gram type infection-specific algorithm|The experimental arm will involve patients monitored by the Gram type infection-customized version of InSight.
61921680|NCT03734484|NO_INTERVENTION|Standard treatment protocol|The control arm will involve patients treated with the regular diagnosis and treatment protocol for gram-type infection, where fluid cultures are run to determine infection type.
61921681|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
61921682|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
61921683|NCT05346367|ACTIVE_COMPARATOR|SRT (stereotactic radiotherapy)|stereotactic radiotherapy in 1 or 3 fractions of 8 Gy up to 15-24 Gy
61921684|NCT05346367|EXPERIMENTAL|fSRT (hypo fractionated stereotactic radiotherapy)|hypo fractionated stereotactic radiotherapy in 5 fractions of 7 Gy up to 35 Gy. Brain stem metastases 5 fractions of 6 Gy up to 30 Gy
62121777|NCT05251207|EXPERIMENTAL|modified circadian cycle|no sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00).
61921685|NCT02776371|EXPERIMENTAL|Modified non-clarithromycin triple therapy|H.pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
61921686|NCT02776371|ACTIVE_COMPARATOR|Sequential therapy|H.pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
62310435|NCT04442581|EXPERIMENTAL|Treatment (cabozantinib S-malate, pembrolizumab)|Patients receive cabozantinib S-malate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62310436|NCT03626051|ACTIVE_COMPARATOR|rigid tape group|
62310437|NCT03626051|EXPERIMENTAL|fibular tape group|
62310438|NCT06665568|OTHER|Ketamine|Open-label, flexibly-dosed intranasal ketamine hydrochloride
62310439|NCT02739477|EXPERIMENTAL|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
62310440|NCT01754896|EXPERIMENTAL|Mail-out/Mail-back|Mailing of FIT kit directly to patient. Mailing completed kits in for processing.
62310441|NCT01754896|EXPERIMENTAL|Mail-out/Drop-off|Mailing of FIT kit directly to patient. Dropping completed kits at lab for processing.
62310442|NCT01754896|EXPERIMENTAL|Pick-up/Mail-back|Mailed invitation to pick up lab requisition and then kit. Mailing completed kits in for processing.
62476297|NCT03796871|EXPERIMENTAL|Dermapol|Use of the experimental medical device
62476298|NCT06485700|EXPERIMENTAL|PT4A|Peer delivery of medications supported by Health Information Technology (HIT) platform.
61921687|NCT00926068|EXPERIMENTAL|HO/03/03 10µg|
62310443|NCT01754896|EXPERIMENTAL|Pick-up/Drop-off|Mailed invitation to pick up lab requisition and then kit. Dropping completed kits at lab for processing.
61921688|NCT00926068|PLACEBO_COMPARATOR|Placebo|
61921689|NCT01142128|ACTIVE_COMPARATOR|Nexium alone|Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
62310444|NCT03334214|EXPERIMENTAL|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
62310445|NCT03334214|PLACEBO_COMPARATOR|Placebo (sterile saline 0.9)|Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks
62310446|NCT06316323|EXPERIMENTAL|Group A|Silver Diamine Fluoride
61921690|NCT01142128|PLACEBO_COMPARATOR|Placebo to Nexium, alone|Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
62310447|NCT06316323|EXPERIMENTAL|Group B|Sodium Fluoride Varnish
62310448|NCT05083208|EXPERIMENTAL|PI3Kδ inhibitor Parsaclisib plus Chidamide|"Phase Ib (Explored the appropriate dose of Parsaclisib in combination with chidamide)~Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day.~Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks.~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day.~Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast."
62310449|NCT06022679||Test group SAHOS|The test group consisted of 23 patients ( 9 girls and 14 boys) recruited on the basis of polysomnography at sleep center of CHU Liege for suspected sleep disorders between 1 january 2022 and 1 april 2023, with IAH \>15
62310450|NCT06022679||Control group no SAHOS|Concerning the control group, the participants, adults volunteers are recruited among friends and families of students who collaborate with sleep center for scientific projects. These subjects have no complaints related to OSA and will have to undergo a sleep examination (ventilatory polygraphy) to certify the absence of OSA. This group consisted of 23 patients (14 girls and 9 boys).
62476299|NCT06485700|NO_INTERVENTION|Control|Participants in the control arm will receive the standard of care for hypertension or the standard of care including peer-delivery of medication.
62476300|NCT01561391|EXPERIMENTAL|Continuous infusion|
62476301|NCT01561391|EXPERIMENTAL|Bolus injection|
62476302|NCT01561391|EXPERIMENTAL|Control|
62121778|NCT05251207|ACTIVE_COMPARATOR|normal circadian cycle|sleep at night for four consecutive days
62121779|NCT01178632|EXPERIMENTAL|Passiflora, Anxiety Disorders|1 tablet Passiflora;Crataegus;Salix; PO;BID
62476303|NCT04991610|ACTIVE_COMPARATOR|Adult male|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
62121780|NCT01178632|ACTIVE_COMPARATOR|Valeriane, Anxiety Disorder|1 tablet Valeriana officinalis, PO, BID
62121781|NCT04199728|EXPERIMENTAL|Investigational group|Participants randomized to liraglutide will be started at a low dose (0.6 mg once per day) which will be gradually increased until 1.8 mg/day is reached for the 3-dose intervention and 3 mg/day is reached for the 5-dose intervention. Liraglutide will be administered by injection pen.
62121782|NCT04199728|PLACEBO_COMPARATOR|Control group|Participants in the control group will have placebo administered by injection pen following the same low dose titration to 3.0 mg once per day.
62121783|NCT06355388|EXPERIMENTAL|Active tVNS|The ear clip of the device will be positioned at the level of the patient's tragus delivering current.
62121784|NCT06355388|PLACEBO_COMPARATOR|Sham tVNS|The ear clip of the device will be positioned at the level of the patient's tragus but not delivering current.
62139607|NCT02715518|ACTIVE_COMPARATOR|FFR-guided strategy arm|"FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180ug/kg/min) or intracoronary nicorandil (2mg bolus) injection. The FFR ≤ 0.80 will be targeted for PCI using 2nd generation drug-eluting stent. In case of non-IRA stenosis \> 90%, we will judge FFR value of ≤ 0.80.~The evaluation of non-IRA stenosis by FFR will be recommended to perform during same intervention with primary PCI for IRA. However, exceptions can be made for complex lesions including ACC/AHA classification B2/C lesion where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
62139608|NCT02715518|ACTIVE_COMPARATOR|Angiography-guided strategy arm|"Non-IRA stenosis with \> 50% stenosis will be the target of PCI using 2nd generation drug-eluting stent.~As for the angiography-guided strategy arm, PCI for non-IRA stenosis will be recommended during same procedure. However, exceptions can be made for complex lesions including ACC/AHA classification B2/C lesion where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
62139609|NCT04466137|EXPERIMENTAL|YPEG-rhG-CSF 2mg|YPEG-rhG-CSF 2mg
62139610|NCT04466137|EXPERIMENTAL|YPEG-rhG-CSF 33μg/kg|YPEG-rhG-CSF 33μg/kg
62139611|NCT04466137|ACTIVE_COMPARATOR|Positive Control Group|rhG-CSF/PEG-rhG-CSF
62139612|NCT01419210|EXPERIMENTAL|Complementary and Alternative Medicine (CAM) therapies|This pilot program attends to the need for appropriate patient-centered interventions that integrate CAM with traditional care to maximize both quantity and QOL for women with ovarian cancer.
62139613|NCT01023698|EXPERIMENTAL|photocoagulation|Laser photocoagulation
62139614|NCT01303796|EXPERIMENTAL|Sapacitabine-decitabine alternating|Arm A sapacitabine administered in alternating cycles with decitabine
62139615|NCT01303796|ACTIVE_COMPARATOR|Decitabine|Arm C Decitabine
62139616|NCT04199338|EXPERIMENTAL|Randomized|Randomized
62139617|NCT02707198|NO_INTERVENTION|Group A|Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
62139618|NCT02707198|ACTIVE_COMPARATOR|Group B|Will receive prescribed antibiotics and will receive kefir only during hospital stay. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
62139619|NCT02707198|ACTIVE_COMPARATOR|Group C|Will receive prescribed antibiotics and will receive kefir during hospital stay and for the duration of the prescribed antibiotic regimen for up to a total of 30 days . Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
62139620|NCT03608293|EXPERIMENTAL|Smokers|Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
62139621|NCT03608293|ACTIVE_COMPARATOR|Non smokers|Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
62139622|NCT00968695|EXPERIMENTAL|Albumin|The subjects will be receiving albumin 20% infusions
62476304|NCT04991610|ACTIVE_COMPARATOR|Adult female|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
62681008|NCT01391494|EXPERIMENTAL|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
62139623|NCT01035372|EXPERIMENTAL|dried plum|subjects will have 25% by weight (\~ 600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder
62139624|NCT03066609|EXPERIMENTAL|Secukinumab 150mg|Secukinumab 150mg s.c.
62139625|NCT03066609|EXPERIMENTAL|Secukinumab 300mg|Secukinumab 300mg s.c.
62139626|NCT03066609|PLACEBO_COMPARATOR|Placebo|Placebo to secukinumab s.c
62139627|NCT00758550|EXPERIMENTAL|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
61921691|NCT01142128|ACTIVE_COMPARATOR|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
61921692|NCT01142128|PLACEBO_COMPARATOR|Viokase 16 + placebo to Nexium|Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone
61921693|NCT04315935|EXPERIMENTAL|butorphanol group|Butorphanol (10-20 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
61921694|NCT04315935|ACTIVE_COMPARATOR|fentanyl group|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
61921695|NCT06256627|ACTIVE_COMPARATOR|"Analyzing the effect of IFN-α- 1b, il-2, and thalidomide on negative conversion rate of MRD ."|"Analyzing the effect of interference'- α- 1b, interleukin-2, and thalidomide on negative conversion rate of MRD in AML patients who have obtained CR or CRi but are MRD positive after routine induction and consolidation chemotherapy"
61921696|NCT06256627|ACTIVE_COMPARATOR|"To evaluate whether the ITIVA regimen as maintenance treatment can improveRFS in AML patients"|"To evaluate whether the combination of recombinant human interference'- α- 1b, interleukin-2, and thalidomide, Venentoclax and Azacitidine triple alternative maintenance treatment can improve relapse free survival (RFS) in AML patients who have achieved CR or CRi through conventional induction and consolidation chemotherapy"
62121785|NCT00704184|PLACEBO_COMPARATOR|Placebo + Peg-IFN/Ribavirin|Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
62121786|NCT00704184|EXPERIMENTAL|Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
61921697|NCT03654430|OTHER|Healthy Newborns|
61921698|NCT05043285|EXPERIMENTAL|20 µg dose, 18-59 years of age (phase 1/2)|
61921699|NCT05043285|EXPERIMENTAL|20 µg dose, ≥60 years of age (phase 1/2)|
62121787|NCT00704184|EXPERIMENTAL|Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
62121788|NCT00704184|EXPERIMENTAL|Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
62121789|NCT00704184|EXPERIMENTAL|Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
62121790|NCT05880472|EXPERIMENTAL|Intervention arm|Single or multiple injections of holmium-166 microspheres (up to 150 Gy) in a single session. Intervention is not repeated.
62121791|NCT00599716|EXPERIMENTAL|1|study drug
62310451|NCT01501149|EXPERIMENTAL|DDGP regiment|DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
61921700|NCT05043285|EXPERIMENTAL|40 µg dose, 18-59 years of age (phase 1/2)|
61921701|NCT05043285|EXPERIMENTAL|40 µg dose, ≥60 years of age (phase 1/2)|
61921702|NCT05043285|PLACEBO_COMPARATOR|Placebo, 18-55 years of age (phase 1/2)|
61921703|NCT05043285|PLACEBO_COMPARATOR|Placebo, ≥60 years of age (phase 1/2)|
61921704|NCT00964080|EXPERIMENTAL|Study of MBP-426/leucovorin/5-FU|Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
61921705|NCT00375947|EXPERIMENTAL|1|Home-based hand exercise program
61921706|NCT00375947|PLACEBO_COMPARATOR|2|Sham hand cream
61921707|NCT04834765|ACTIVE_COMPARATOR|Mindfulness|Participants will be engaging in a mindfulness tasks twice per week for 5 weeks in which they will learn techniques through the use of yoga, meditation and breathwork.
62121792|NCT00599716|PLACEBO_COMPARATOR|2|vehicle control
62121793|NCT05284812|NO_INTERVENTION|Negative control population group|In population I, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) and BCG pure protein derivative (BCG-PPD) skin test results were negative.The type I population did not take chemical drugs and was not vaccinated, and was only used as immunogenicity control.
62681009|NCT01391494|EXPERIMENTAL|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
62681010|NCT01391494|PLACEBO_COMPARATOR|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
62681011|NCT04765384|EXPERIMENTAL|Groups 1-4: Ad26.COV2.S (One Dose)|Participants who are previously vaccinated (Group 1-3) and participants who are vaccine naïve (Group 4) will receive single dose of Ad26.COV2.S vaccine at standard dose level on Day 1. Participants from group 4 who are no longer pregnant may receive single booster dose of Ad26.COV2.S vaccine at standard dose level.
61921708|NCT04834765|ACTIVE_COMPARATOR|Art Therapy|Participants will engage in art therapy with the use of clay twice per week through prompts.
61921709|NCT04834765|ACTIVE_COMPARATOR|Mindfulness based Art Therapy|Participants will engage in both mindfulness activities and art therapy twice per week and will learn techniques through the use of yoga, mediation, breathwork and art.
61921710|NCT04834765|NO_INTERVENTION|Control Group|Participants will go about daily life as usual.
61921711|NCT05060484|ACTIVE_COMPARATOR|Healthy Women Aged 18 to 26 Years|1200 healthy women aged18 to 26 years are in this arm. Middle dose SCT1000 : hight dose SCT1000:Gardasil®9 : placebo =1:1:1:1. SCT1000 and Gardasil®9 will be immunized at 0, 2, and 6 months, respectively.
62310452|NCT01501149|EXPERIMENTAL|SMILE Regiment|Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment
62310453|NCT01982201|EXPERIMENTAL|Lesinurad and Tums|Day 1: 240 mL water or 240 mL water and Tums Day 2: Lesinurad 400 mg or Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg
62310454|NCT01982201|EXPERIMENTAL|Lesinurad and MINTOX|Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg
62310455|NCT00884507|PLACEBO_COMPARATOR|Placebo|
62310456|NCT00884507|EXPERIMENTAL|RO5313534 15mg|
62310457|NCT00884507|EXPERIMENTAL|RO5313534 1mg|
61921712|NCT05060484|ACTIVE_COMPARATOR|Healthy Women Aged 27 to 45 Years|600 healthy women aged 27 to 45 years are in this arm. Middle dose SCT1000 : hight dose SCT1000:Gardasil® : placebo =1:1:1:1. SCT1000 and Gardasil®9 will be immunized at 0, 2, and 6 months, respectively.
61921713|NCT04867434|ACTIVE_COMPARATOR|RZL-012 50mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses 270 mg for the high doses. Each injection point will be dosed with 7.5 mg for the high dose in a volume of 0.15 mL/injection site.
61921714|NCT04867434|ACTIVE_COMPARATOR|RZL-012 34mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses of 183.6 mg for the low dose. Each injection point will be dosed with 5.1 mg RZL-012 for the low dose in a volume of 0.15 mL/injection site.
61921715|NCT04867434|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle) subjects will be injected with a 0.15 mL vehicle per each injection site. The maximal injection volume for all groups will be up to 5.4 mL.
61921716|NCT03421327||Families at-risk for HD|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
62121794|NCT05284812|OTHER|Sentinel group|In Population Ⅱ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. First, 5 people aged 18-59 years were selected for low dose injection, 5 people aged 18-59 years were selected for high dose injection, 5 people aged ≥60 years were selected for low dose injection, and 5 people aged ≥60 years were selected for high dose injection.The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
62121795|NCT05284812|EXPERIMENTAL|Low-dose group|In population Ⅲ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅲ population were injected Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02).The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
62310458|NCT00884507|EXPERIMENTAL|RO5313534 5mg|
62310459|NCT01236885|EXPERIMENTAL|Supportive care (Glucommander)|Patients receive blood glucose management with IV insulin using Glucommander.
62310460|NCT02281058|EXPERIMENTAL|intervention group|Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.
62310461|NCT04635735|EXPERIMENTAL|Ipilimumab After Stem Cell Transplantation|The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.
62310462|NCT00873444|ACTIVE_COMPARATOR|1) Ceramic-on-Metal Bearing|A cementless acetabular cup with ceramic liner for use in total hip replacement
62310463|NCT00873444|ACTIVE_COMPARATOR|2) Metal-on-Metal Bearing|A cementless acetabular cup with metal liner for use in total hip replacement
62310464|NCT03526640|EXPERIMENTAL|Plug Arm|Participants randomized for plug arm will be treated with a plug after CT guided is conducted.
62310465|NCT03526640|NO_INTERVENTION|Non Plug arm|No Intervention, i.a. CT guided biopsy without plug.
62310466|NCT05013528|EXPERIMENTAL|Bal-A-Vis-X training Group|Bal-A-Vis-X training Group
62310467|NCT05013528|ACTIVE_COMPARATOR|Aerobic Training Group|Aerobic Training Group
62681012|NCT05225012|EXPERIMENTAL|PrEliMS Intervention|"We will ask participants to complete the psychological impact of MS scale, anxiety/depression questionnaires and visual analogue scales once a week throughout their involvement in the study (estimated to be 9 weeks). The baseline will be established over a period of the first three weeks (before participants start the intervention). Participants will also be asked to complete a second set of questionnaires (secondary measures) before starting the intervention, to assess quality of life, stress, the impact of MS, MS-related self-efficacy and fatigue.~Participants will then be invited to an optional semi-structured, feedback interview to provide qualitative information on their experience of the intervention."
62681013|NCT04189783|ACTIVE_COMPARATOR|Arm I (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity.
61921717|NCT03421327||Families at-risk for hereditary cancer|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
61921718|NCT03421327||Genetic Counselors|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
61921719|NCT04768985|EXPERIMENTAL|Treatment sequence 1: Treatment AB|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment A; Treatment B) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
62310468|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
62310469|NCT00918723|EXPERIMENTAL|Treatment (induction and maintenance chemotherapy)|"INDUCTION THERAPY: Patients receive vorinostat PO once daily on days 1-5 and 8-12; cyclophosphamide IV over 30-60 minutes and fludarabine phosphate IV over 30-60 minutes on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3 months for 2 years in the absence of disease progression or unacceptable toxicity."
62310470|NCT06408090|EXPERIMENTAL|Intervention|200 participants reviewed the PtDA decision tool for education on hospice care and subsequently completed a second survey which was identical to the first.
62310471|NCT06408090|OTHER|Interview|20 of the 200 Intervention participants will complete an interview using qualitative methods surrounding the topic of hospice care and the PtDA.
62310472|NCT06408090|NO_INTERVENTION|Control|200 of the 400 participants completed two identical surveys one month apart but did NOT review the PtDA decision tool prior to completing the second survey timepoint. Instead, these participants reviewed an 8-page attention control activity booklet. These participants are used as a control group in assessing any change in knowledge or opinions of hospice after the intervention group reviewed the PtDA.
62310473|NCT00163137|EXPERIMENTAL|Lasofoxifene 0.25 mg|lasofoxifene 0.25 mg/day
62310474|NCT00163137|ACTIVE_COMPARATOR|raloxifene|raloxifene 60 mg/day
62310475|NCT00163137|PLACEBO_COMPARATOR|Placebo|Placebo
62681014|NCT04189783|EXPERIMENTAL|Arm II (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.
62681015|NCT03420963|EXPERIMENTAL|Treatment (cyclophosphamide, etoposide, NK cells)|Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
62121796|NCT05284812|EXPERIMENTAL|High-dose group|In population Ⅳ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅳ population were injected High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02).The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
62121797|NCT05284812|EXPERIMENTAL|3 dose of High-dose group|In population Ⅴ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅴ population were injected 3 dose of High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) and 3 dose of Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo.The first, third, and sixth doses of the subjects were High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), and the second, fourth, and fifth doses were Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo. Each dose is 2 weeks apart.
62139628|NCT00758550|ACTIVE_COMPARATOR|AcrySof Natural IOL|AcrySof Natural Intraocular Lens (IOL)
62139629|NCT06440226||Placebo Group|Detailed in study, no dosages, no drugs used.
62738560|NCT05148936|ACTIVE_COMPARATOR|Mobile testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be referred to study operated mobile testing sites in the community for COVID-19 testing.
62738561|NCT05148936|OTHER|Mobile testing approach 1 (Aim 2)|Mobile testing utilizing active outreach
62476305|NCT03597243|EXPERIMENTAL|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
62476306|NCT03597243|NO_INTERVENTION|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
62476307|NCT03525522|EXPERIMENTAL|Nd:YAG Laser|Three sessions of Nd:YAG laser (1064 nm) treatment with Dynamis (Fotona, Slovenia)
62476308|NCT03525522|ACTIVE_COMPARATOR|Topical Corticosteroid Diprosone|Topical corticosteroid betamethasone (Diprosone, Merck Sharp \& Dohme, d.o.o.) for 3 months.
62310476|NCT01928030|EXPERIMENTAL|recombinant human hyaluronidase|Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21
62310477|NCT04374994|ACTIVE_COMPARATOR|intervention group|Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks
62310478|NCT04374994|PLACEBO_COMPARATOR|control group|Males with sexual dysfunction who received daily placebo tablets for four weeks
62310479|NCT02658656|ACTIVE_COMPARATOR|Exoskeleton + Standard of Care (SOC)|Patient will receive exoskeletal-assisted walking device for in home use for 4 months
62310480|NCT02658656|NO_INTERVENTION|Standard of Care (SOC)|Patient will receive standard of care (wheelchair use)
62681016|NCT05520762|EXPERIMENTAL|First choice supraglottic airway device, Then First choice endotracheal intubation|A strategy of 'first choice' supraglottic airway during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
62681017|NCT05520762|ACTIVE_COMPARATOR|First choice endotracheal intubation, Then First choice supraglottic airway|A strategy of 'first choice' endotracheal intubation during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
62681018|NCT05459935|EXPERIMENTAL|PBM Tonsil Arm|Photobiomodulation exposure of hypertrophic tonsils
62139630|NCT06440226||Actual Group|Detailed in study, no dosages, no drugs used.
62310481|NCT03419234|EXPERIMENTAL|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
62310482|NCT03419234|ACTIVE_COMPARATOR|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
62476309|NCT01673685|PLACEBO_COMPARATOR|Portable Oxygen Cylinder|Portable Oxygen Cylinder
62476310|NCT01673685|ACTIVE_COMPARATOR|Portable Oxygen Concentrator|Portable Oxygen Concentrator
62476311|NCT02812121|EXPERIMENTAL|Group MSC-1|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.
62476312|NCT02812121|EXPERIMENTAL|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.
61921720|NCT04768985|EXPERIMENTAL|Treament sequence 2: Treatment BA|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment B; Treatment A) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
62139631|NCT06440226||Standard Assessment Group|Detailed in study, no dosages, no drugs used.
62476313|NCT02812121|NO_INTERVENTION|Group Control|Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis).
61921721|NCT04215133|EXPERIMENTAL|İnspiratory muscle training group|
61921722|NCT04215133|EXPERIMENTAL|Calf muscle training group|
61921723|NCT04215133|NO_INTERVENTION|Control|
61921724|NCT04589312|ACTIVE_COMPARATOR|Pregnant women not living with HIV, Td vaccine|
62310483|NCT06547112|ACTIVE_COMPARATOR|Cohort 1: Standard dosing|G-CSF daily in the morning for up to 8 days. Evening of Day 4 (6:00 to 8:00 PM), will receive motixafortide. Morning of Day 5, a 5th dose of G-CSF within 1 hour prior to apheresis. Undergo first apheresis \~12 hours after the motixafortide. If participant does not reach the collection goal for mobilization, on Day 6, a 6th dose of G-CSF will be administered prior to the 2nd apheresis session (\~36 hours from the first motixafortide injection). If participant doesn't reach the collection goal, a 2nd dose of motixafortide will be administered on the evening of Day 6 (6:00 to 8:00 PM). Morning of Day 7, a 7th dose of G-CSF will be administered within 1 hour prior to apheresis. Will then undergo 3rd apheresis \~12 hours after the 2nd motixafortide injection. If participant still does not reach the collection goal, a 4th apheresis will be performed on Day 8 , \~36 hours from the 2nd motixafortide injection, with an 8th dose of G-CSF administered prior to the apheresis.
62310484|NCT06547112|EXPERIMENTAL|Cohort 2: Early dosing|G-CSF daily in the morning for up to 8 days. Afternoon of Day 4 (2:00 to 4:00 PM), will receive motixafortide. Morning of Day 5, a 5th dose of G-CSF within 1 hour prior to apheresis. Undergo first apheresis \~16 hours after the motixafortide. If participant does not reach the collection goal for mobilization, on Day 6, a 6th dose of G-CSF will be administered prior to the 2nd apheresis session (\~40 hours from the first motixafortide injection). If participant doesn't reach the collection goal, a 2nd dose of motixafortide will be administered on the afternoon of Day 6 (2:00 to 4:00 PM). Morning of Day 7, a 7th dose of G-CSF will be administered within 1 hour prior to apheresis. Will then undergo 3rd apheresis \~16 hours after the 2nd motixafortide injection. If participant still does not reach the collection goal, a 4th apheresis will be performed on Day 8 , \~40 hours from the 2nd motixafortide injection, with an 8th dose of G-CSF administered prior to the apheresis.
62310485|NCT04841668||Patients with recently diagnosed T2DM|This group will consist of 36 recently diagnosed T2DM, according to the World Health Organization (WHO) patients (last 6 months), who have not received treatment with metformin.
62310486|NCT04841668||Patients with long-term T2DM|The group will consist of 100 patients with long-term T2DM, according to the WHO classification, regardless of whether they take metformin or another treatment.
62310487|NCT01596829|ACTIVE_COMPARATOR|Probiotic|Probiotic consumption during and after course of antibiotic
62310488|NCT01596829|PLACEBO_COMPARATOR|Placebo|Placebo consumed during and after course of antibiotic
62310489|NCT01801397|OTHER|Teriparatide|one arm study. All patients receive teriparatide
62310490|NCT01688648|EXPERIMENTAL|Lidocaine group|a bolus dose of lidocaine 1.5 mg/kg after anesthetic induction with following lidocaine infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
62476314|NCT02753231|EXPERIMENTAL|Low physical activity program|Three Physical Education sessions / week
62476315|NCT02753231|EXPERIMENTAL|High physical activity program|Three Physical Education sessions / week (increased volume)
62139632|NCT06622226|EXPERIMENTAL|Evaluation of Tolerability|Up to 4 dose levels will be evaluated. Eligible patients will be assigned to a dose level cohort according to a traditional 3+3 dose escalation design.
62476316|NCT02753231|EXPERIMENTAL|Low and High physical activity program|Three Physical Education sessions / week (increased volume and intensity)
62476317|NCT02753231|ACTIVE_COMPARATOR|Conventional physical activity program|One Physical Education sessions / week
62495939|NCT06347627|EXPERIMENTAL|Group 15 (I x E x D x M)|"Participants in Group 15 will view a message in an X (former Twitter) format composed of Individual x Effectiveness x Scientific data x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
62681019|NCT05459935|SHAM_COMPARATOR|Tonsil Control Arm|Sham (non-powered) exposure of hypertrophic tonsils
61921725|NCT04589312|EXPERIMENTAL|Pregnant women not living with HIV, Tdap vaccine|
61921726|NCT04589312|ACTIVE_COMPARATOR|Pregnant women living with HIV, Td vaccine|
61921727|NCT04589312|EXPERIMENTAL|Pregnant women living with HIV, Tdap vaccine|
61921728|NCT05637593|EXPERIMENTAL|the RAS group|The RAS group will receive upper-limb movement training with the aid of RAS;
61921729|NCT05637593|ACTIVE_COMPARATOR|the no-RAS group|The no-RAS group will receive upper-limb movement training without the aid of RAS.
61921730|NCT00300118|EXPERIMENTAL|A|
61921731|NCT00300118|ACTIVE_COMPARATOR|B|
61921732|NCT01962922|ACTIVE_COMPARATOR|LCP-Tacro|Envarsus XR
61921733|NCT01962922|ACTIVE_COMPARATOR|Tacrolimus - IR|Tacrolimus
61921734|NCT04872530|EXPERIMENTAL|Pea-protein concentrate|Pea-protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
61921735|NCT04872530|EXPERIMENTAL|Fava-bean protein concentrate|Fava-bean protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
61921736|NCT04872530|EXPERIMENTAL|Chickpea protein concentrate|Chickpea protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
61921737|NCT04872530|EXPERIMENTAL|Red lentil protein concentrate|Red lentil protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
61921738|NCT04872530|EXPERIMENTAL|Non-essential amino acid blend|Non-essential amino acid blend dosed at 0.33 g/kg body mass in 500 ml of water.
61921739|NCT04872530|EXPERIMENTAL|Whey protein concentrate|Whey protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
62681020|NCT04146207|EXPERIMENTAL|combination therapy|"Experimental: combination therapy There is only 1 arm. Combination therapy arm includes SHR0302 and Prednisone~Prednisone 1mg/kg/d po，At the same time give SHR0302 QDpo；"
62681021|NCT05826587|ACTIVE_COMPARATOR|Control group of cardiac rehabilitation only|
62681022|NCT05826587|EXPERIMENTAL|Intervention group of additional balance and muscle strength training|
62681023|NCT06687473|EXPERIMENTAL|Bismuth-based susceptibility-guided treatment|Participants who have triple- or quadruple-drug resistant H. pylori infection are enrolled. Participants receive one of the four regimens based on susceptibility test.
62681024|NCT05169970|EXPERIMENTAL|Patients with low-intermediate risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions).
62681025|NCT05169970|EXPERIMENTAL|Patients with high risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions) with a boost of up to 45Gy to the dominant intraprostatic lesion as identified on pretreatment MRI plus hypofractionated pelvic EBRT (25Gy in 5 fractions).
62681026|NCT03776240|EXPERIMENTAL|HD201|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
62681027|NCT03776240|ACTIVE_COMPARATOR|EU-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
62681028|NCT03776240|ACTIVE_COMPARATOR|US-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
62681029|NCT04195672||Children under 3 years-old intubated/sedated in intensive care|NIPE and CBS ware measured for each included patient
62681030|NCT05162794|OTHER|Active Surgery|
62681031|NCT05162794|OTHER|Diagnostic Surgery|
62681032|NCT05162794|OTHER|No-surgery control|
61921740|NCT00712556||Flourine 18-fluorodeoxyglucose PET|PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
62681033|NCT02124980|EXPERIMENTAL|Recovery Line plus Treatment-as-Usual (RL+TAU)|The Recovery Line is an automated computer-based IVR system that provides CBT-based modules. The RL+TAU condition will include the customized therapeutic recommendations developed in Phase 1, and the contact reminders messages and time frame that maximized system use in Phase 2. Patients will receive an orientation, 24-hour access, encouragement to use the system from clinic staff reminder, and technical assistance line for system problems. Patients will receive 12 weeks of system access.
61921741|NCT04757740|ACTIVE_COMPARATOR|Platelet rich fibrin Group|Platelet rich fibrin. Group P
61921742|NCT04757740|ACTIVE_COMPARATOR|Methylprednisolone acetate|Group S
61921743|NCT02631356|PLACEBO_COMPARATOR|Ringer's lactate solution|Infusion of Ringer's lactate solution (10ml/kg) in the control group
62681034|NCT02124980|NO_INTERVENTION|Treatment-as-Usual|Treatment-as Usual involves daily methadone and associated psychosocial services. Patients are required to attend 1 group session per month and are encouraged to attend open drop-in groups available daily covering a range of topics.
62681035|NCT04409119|EXPERIMENTAL|HIS/LBB pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS, to correct the LBBB or the threshold for correcting the LBBB is \> 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead. If that is not possible either, a left ventricular (LV) lead is implanted.
61921744|NCT02631356|ACTIVE_COMPARATOR|Succinylated gelatin|Infusion of Succinylated gelatin (10ml/kg) in the test group
62681036|NCT04409119|ACTIVE_COMPARATOR|LV pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation \< 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is \> 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.
62681037|NCT06689007|EXPERIMENTAL|Implementation Intervention|
62681038|NCT03227575|EXPERIMENTAL|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
62681039|NCT03227575|EXPERIMENTAL|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
61921745|NCT04019418|PLACEBO_COMPARATOR|No Carbohydrate Drink + Rest|Participants will consume the no carbohydrate drink (300ml water) followed by a rest session
61921746|NCT04019418|ACTIVE_COMPARATOR|No Carbohydrate Drink + Exercise|Participants will consume the no carbohydrate drink (300ml water) followed by an exercise session (75% VO2 max on a cycle ergometer)
61921747|NCT04019418|ACTIVE_COMPARATOR|Carbohydrate Drink + Rest|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by a rest session
61921748|NCT04019418|EXPERIMENTAL|Carbohydrate Drink + Exercise|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by an exercise session (75% VO2 max on a cycle ergometer)
61921749|NCT03845465|ACTIVE_COMPARATOR|Education|Participants in the Education group will complete a behavioral health contract and will receive an educational packet.
62121798|NCT05284812|PLACEBO_COMPARATOR|Placebo group|In population Ⅵ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅵ population were injected Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo.The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
62139633|NCT03396107|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
62139634|NCT03396107|PLACEBO_COMPARATOR|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
62681040|NCT03227575|NO_INTERVENTION|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
62681041|NCT02577302|EXPERIMENTAL|CAN-Stim Group - CAN-Stim System|"Intervention: tibial medical device~Subjects randomized to this group will have the Protect CAN-Stim System tibial medical device implanted for the duration of the study."
62681042|NCT02577302|ACTIVE_COMPARATOR|SNS Group - Interstim® System|"Intervention: SNS Medical device~Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study."
61921750|NCT03845465|EXPERIMENTAL|PA + Education|Participants in the Positive Affect + Education group will complete a behavioral health contract and receive an educational packet. In addition, they will receive intervention components aimed at inducing positive affect.
62139635|NCT01578941|PLACEBO_COMPARATOR|Placebo|
62310491|NCT01688648|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
62738562|NCT05148936|OTHER|Mobile testing approach 2 (Aim 2)|Mobile testing utilizing baseline outreach approaches
61921751|NCT02764125|ACTIVE_COMPARATOR|Stalevo|levodopa/carbidopa/entacapone
61921752|NCT02764125|EXPERIMENTAL|levodopa MR|Levodopa MR/carbidopa/ODM-104
62310492|NCT01688648|EXPERIMENTAL|Combined infusion group|Combined lidocaine and dexmedetomidine infusion with the dose specified in single infusion group
62310493|NCT01688648|NO_INTERVENTION|Control group|The group without infusion of lidocaine or dexmedetomidine
62139636|NCT01578941|ACTIVE_COMPARATOR|Treximet|
62310494|NCT05247177|EXPERIMENTAL|Multimodal general anesthesia|General anesthesia maintained by co-administration of sevoflurane, dexmedetomidine and ketamine by using a predefined EEG density spectrum array pattern
62681043|NCT05676450|OTHER|cell-free DNA (cfDNA) samples|"cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.~Blood will be drawn 3 times (by vein)"
62681044|NCT06525870|EXPERIMENTAL|Group 1|Participants will receive 85%TCA topical application at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators.
62681045|NCT06525870|PLACEBO_COMPARATOR|Group 2|Participants will receive 3% acetic acid topical application at cervical lesion and transformation zone. Application of 3% acetic acid will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators.
62681046|NCT05262764||Patients with chronic heart failure (CHF)|
62681047|NCT05816161|EXPERIMENTAL|Neuromuscular Inhibition Technique|
62681048|NCT05816161|OTHER|Myofascial Release|
62681049|NCT05393908|ACTIVE_COMPARATOR|TAP Block Group|Participants will receive a surgeon administered TAP block consisting of liposomal bupivacaine during their repeat cesarean delivery.
62681050|NCT05393908|NO_INTERVENTION|Standard of Care Postoperative Pain Control|Participants will not receive a surgeon administered TAP block consisting of liposomal bupivacaine during their repeat cesarean delivery and will receive the routine standard of care for post-operative pain control.
62681051|NCT04799119|EXPERIMENTAL|DAID dog training|'Do As I Do' (DAID) dog training employs operant conditioning to train dogs to copy the behavior of their owner upon hearing the verbal cue 'Do it', similar to teaching a dog the rules behind the game 'Simon Says'. Once this rule has been established and generalized, something that can be achieved in dogs by practicing with only 3-6 initially learned behaviors, owners can demonstrate new actions and use the cue 'Do it' to prompt a matched, imitative, behavioral response.
61921753|NCT02722096|EXPERIMENTAL|Axillary block anesthesia|Axillary brachial plexus block anesthesia (with Ropivacaine and Lidocaine) will be performed by anesthetist 30 to 45 minutes before surgery
62476318|NCT04466553||NICO BrainPath™ Patients|"50 patients will be enrolled in Group A NICO BrainPath™ system.~The NICO BrainPath™ System has been proposed to reduce high morbidity and mortality associated with ICH through minimally invasive clot evacuation. Previous, single-center trials concluded evacuation of ICH using the BrainPath™ system as being safe and effective. Additionally, previous studies concluded that lesser ICH removal was correlated with mortality benefit and that the NICO BrainPath™ system approach was shown to be safe and effective with a high rate of clot evacuation and functional independence. This system warrants further research because of the need to optimize clinical outcome in these patients and to better define the role of hematoma evacuation in the care of these patients."
62476319|NCT04466553||Standard of Care|50 patients will be matched retrospectively of similar diagnosis, undergoing standard of care (e.g. no surgical intervention). These patients will be matched to the surgical patients based on age, gender, and location of hemorrhage.
61921754|NCT02722096|ACTIVE_COMPARATOR|Local anesthesia|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
61921755|NCT02116478|EXPERIMENTAL|gastrocnemius recession|gastrocnemius recession
62476320|NCT05036707|ACTIVE_COMPARATOR|1|Healthy Volunteer
62681052|NCT04799119|NO_INTERVENTION|Control|No intervention (waitlisted and will be provided with the experimental condition post-study completion).
62121799|NCT05284812|ACTIVE_COMPARATOR|Adjuvant group|In population Ⅶ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅶ population were injected High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02).The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
62476321|NCT05970484|EXPERIMENTAL|Intervention|Use of the DrinksRation app with all functionality
62681053|NCT02618733|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg, twice a day
62681054|NCT02618733|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75mg, once a day
62681055|NCT06333860|EXPERIMENTAL|Period A: Arm 1 Risankizumab Dose A|Participants will be centrally randomized at the Baseline (Day 1) visit to receive Risankizumab as a single SC injection
62681056|NCT06333860|EXPERIMENTAL|Period A: Arm 2 Deucravacitinib Dose A|Participants will be centrally randomized at the Baseline (Day 1) visit to receive Deucravacitinib orally once per day until the day prior to Week 16
62681057|NCT06333860|EXPERIMENTAL|Period B: Arm 2a Risankizumab Dose A (Continued)|Participants initially randomized to risankizumab (Arm 1) will continue to receive risankizumab as a single SC injection at Weeks 16, 28, and 40
62681058|NCT06333860|EXPERIMENTAL|Period B: Arm 2b Deucravacitinib Dose A|Participants initially randomized to Deucravacitinib (Arm 2) will be re-randomized at the Week 16 visit to receive Deucravacitinib orally once per day up to Week 52
62681059|NCT06333860|EXPERIMENTAL|Period B: Arm 2a Risankizumab Dose A|Participants initially randomized to Deucravacitinib (Arm 2) will be re-randomized at the Week 16 visit to receive Risankizumab as a single SC injection at Weeks 16, 20, 32, and 44
62681060|NCT05792930|EXPERIMENTAL|Experimental Group|The experimental group will receive cognitive-behavioral therapy (CBT) and biofeedback therapy.
62681061|NCT05792930|NO_INTERVENTION|Control Group|The design of control group is waiting list control; their data will be collected without intervention during the observation period. After the observation period, psychotherapy (CBT and biofeedback, the same as intervention) will be arranged.
62681062|NCT06567301|EXPERIMENTAL|Group A: Ultrasound therapy combined with Chitosan nanoparticles gel and Exercises Program|"In this group will receive ultrasound therapy coupled with chitosan-nanoparticles gel with an exercises program. The US protocol which will consist of pulsed ultrasound waves. The parameters that will be selected consists of; frequency of 1 MHz, 1 W/cm2 power delivered at an intensity of an intensity of 2.5W/ cm2 and with duty cycle of 25% and will be applied with a 5-cm diameter applicator.~The area of treatment will be cleaned to permit an effective skin applicator coupling. Each patient will be placed in a supine position for the application of ultrasound. A suitable palpation to locate the discomfort source and some passive motions to identify a range of motion restriction will be completed prior to the ultrasound application.~Ultrasound will be applied to the medial and lateral aspects of the knee in circular motions, with the probe at right angles to ensure maximum absorption of energy. Each session will last for 5 minutes."
62681063|NCT06567301|ACTIVE_COMPARATOR|Group B: Application of Extracorporeal Shockwave and Exercises Program:|This group will receive ESWT with an exercises program. Subjects will receive 5 sessions, one week apart. Before the treatment, subjects will be placed in supine to expose and prepare the treated area with the knee flexed at angle of 90° and the hip is abducted and externally rotated. The impulses will be applied on the subchondral bone at the medial and lateral tibia condyle at 2.0 cm below the joint line in anteroposterior view and 2.0 cm from the medial skin edge in lateral view. The treatment application will be as follows: 2000 impulses will be administered at (EFD) with an energy flux density ranging from 0.22-0.43 mJ / mm2 at 8 Hz. In which 0.22 mJ/mm²: likely corresponds to around 1.5-3 bars, while 0.43 mJ/mm² likely corresponds to around 3-5 bars. The probe was chosen effective treatment depth (5-20-mm focal depth), semi-movable technique of the shockwave applicator and 5 minutes duration.
61921756|NCT04062318|EXPERIMENTAL|Tactile detection task with online TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over somatosensory cortex during the tactile detection task.
61921757|NCT04062318|ACTIVE_COMPARATOR|Tactile detection task with online control TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over a control brain region during the tactile detection task. This control condition is intended to mimic the peripheral (e.g. cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
61921758|NCT00618839|EXPERIMENTAL|StrataGraft : cadaver allograft|All patients enrolled received StrataGraft skin tissue and an intrapatient control area treated with cadaver allograft in a split-wound design
61921759|NCT05486741||Myopes|myopes (≤ -1.0 D)
61921760|NCT05486741||Hyperopes|hyperopia (≥ +1.0D).
61921761|NCT05486741||Emmetropes|"emmetropes (\> -1.0 to \<~* 1.0 D)"
61921762|NCT02787070|ACTIVE_COMPARATOR|Primaquine supervised|14 days of supervised primaquine treatment (0.5mg/kg/day).
62738563|NCT05891080|EXPERIMENTAL|Safety run-in arm|In this arm, 6 patients with resectable or potentially resectable stage III non-small cell lung cancer will receive 4 circles of neoadjuvant toripalimab and JS004 combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.
61921763|NCT02787070|ACTIVE_COMPARATOR|Primaquine unsupervised|14 days of unsupervised primaquine treatment (0.5mg/kg/day).
61921764|NCT01216007|ACTIVE_COMPARATOR|TIVA|TIVA
61921765|NCT01216007|ACTIVE_COMPARATOR|Inhalational|Inhalational/volatile general anesthetic
61921766|NCT01082640|PLACEBO_COMPARATOR|Placebo|Placebo-matching capsules, orally, twice daily for up to 12 months.
61921767|NCT01082640|EXPERIMENTAL|Febuxostat 30 mg BID|Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.
61921768|NCT01082640|EXPERIMENTAL|Febuxostat 40/80 mg QD|Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was \<6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.
61921769|NCT03094039|EXPERIMENTAL|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
62121800|NCT06516042|ACTIVE_COMPARATOR|Intervention with 2 TDA rounds|TDA with DP will be administered two times with a 4 - 6 week interval between rounds to all workers in the selected farm sites
62681064|NCT06567301|PLACEBO_COMPARATOR|Group C: Exercises Program|"Patients in this group will receive only an exercises program for 3 times weekly for 4 weeks. This program includes:~(1) Warming-up (5 min); (2) strengthening exercises for the lower limbs: 3 sets of 15 repetitions: flexion SLR, abduction SLR, and extension SLR, standing knee flexion, quadriceps isometrics, 10 repetitions of 5 s, 0° and 30°; (3) aerobic exercise on a stationary bike (20 min), (4) and stretching (5 min) with a weekend break.~All patients in the three groups (A, B and C) will receive the same exercise program."
62681065|NCT05893030|EXPERIMENTAL|Intervention Group|
62681066|NCT05893030|PLACEBO_COMPARATOR|Control Group|
62681067|NCT06694896|OTHER|MCA|Multipl Congenital Anomalies
62681068|NCT05566054|EXPERIMENTAL|VAC group|Chidamide 10mg orally daily for 7 days (d1-d7), AZA 75mg/m2 daily for 7 days (d1-d7) and VEN orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); If the bone marrow assessment is CR/CRi/MLFS/PR/NR on the 21th-28th day in the first cycle, the second cycle of treatment will be started; If the bone marrow assessment is PR/NR, the patient needs to withdraw from the trial, If the bone marrow assessment is CR/CRi/MLFS, the patient will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy, continue with the same regimen until progression or recurrence of the disease, and the patients need to withdraw from the trial. If the patients were fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patients needs to withdraw from the trial if progression or recurrence of the disease.
62681069|NCT05566054|ACTIVE_COMPARATOR|VA group|AZA 75mg/m2 daily for 7 days (d1-d7) and VEN orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); If the bone marrow assessment is CR/CRi/MLFS/PR/NR on the 21th-28th day in the first cycle, the second cycle of treatment will be started; If the bone marrow assessment is still PR/NR, the patient needs to enter VEN+AZA+Chidamide group. If the bone marrow assessment is CR/CRi/MLFS, the patient will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy, continue with the same regimen until progression or recurrence of the disease, and the patient needs to withdraw from the trial. If the patients fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patient needs to withdraw from the trial if progression or recurrence of the disease.
62681070|NCT05470296|OTHER|Move & Eat 2 Live|12, 1-hour sessions with an education and motivational component and focused on nutrition, physical activity and healthy weight.
62681071|NCT06644456||Smokers with airway limitation|Smokers with FEV1\<80%
62681072|NCT06644456||Smokers without airway limitation|smokers with FEV1\>80
62681073|NCT03278340|EXPERIMENTAL|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
62310495|NCT05247177|ACTIVE_COMPARATOR|Conventional general anesthesia|General anesthesia maintained by administration of sevoflurane alone to keep a bispectral index between 40-60
62121801|NCT06516042|ACTIVE_COMPARATOR|Intervention with 3 TDA rounds|TDA with DP will be administered three times with a 4 - 6 week interval between rounds to all workers in the selected farm sites
62121802|NCT06516042|NO_INTERVENTION|Control (no TDA)|TDA with DP will not be administered to any workers in the selected farm sites
62310496|NCT04441931|EXPERIMENTAL|LY3832479|Participants received single Intravenous (IV) doses of 700, 2800 and 7000 milligrams (mg) LY3832479.
62310497|NCT04441931|PLACEBO_COMPARATOR|Placebo|Participants received single IV dose of Placebo.
62310498|NCT04174963|EXPERIMENTAL|eToke + TPsy|All participants will receive the intervention (eToke+TPsy). The intervention consists of eToke (a brief computerized intervention that uses motivational enhancement therapy to improve readiness to decrease cannabis use and increase motivation to engage in substance use treatment) AND 6-8 interactive text messages regarding cannabis use reduction over 4 weeks . Text messages will contain written content, and queries, as well as links to publicly available websites and YouTube videos.
62310499|NCT01309425|EXPERIMENTAL|001|tapentadol (CG5503) ER 25-mg TRF 25mg TRF single oral dose
62310500|NCT01309425|EXPERIMENTAL|002|tapentadol (CG5503) ER 50-mg TRF 50mg TRF single oral dose
62310501|NCT01309425|EXPERIMENTAL|003|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
62310502|NCT01309425|EXPERIMENTAL|004|tapentadol (CG5503) ER two 100-mg TRF 200mg TRF single oral dose
62476322|NCT05970484|ACTIVE_COMPARATOR|Control|Use of the BeAlcoholSmart app with all functionality
62476323|NCT02053454|ACTIVE_COMPARATOR|patisiran (ALN-TTR02)|
62476324|NCT02053454|ACTIVE_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62681074|NCT03278340|ACTIVE_COMPARATOR|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
62681075|NCT06569277|EXPERIMENTAL|The mobile application group|The research protocol was explained during the colonoscopy appointment, and patients, when they agreed to follow their diet to the mobile application, were accepted as part of the patient intervention group.
62681076|NCT06569277|NO_INTERVENTION|Control|The control group consists of patients who prepared for colonoscopy with the standard low-residue diet list.
62681077|NCT04997018|EXPERIMENTAL|Prostate cancer patients|"Intermediate-risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines. Intermediate-risk patients will be defined as:~* PSA 10-20 ng/ml or~* Gleason score = 7~* Clinical stage T2b/T2c"
62681078|NCT05970796|EXPERIMENTAL|Telehealth group|The telehealth group will receive eight sessions of individualized pelvic floor muscle training provided by a physical therapist via telehealth in 12 weeks.
61921770|NCT03094039|ACTIVE_COMPARATOR|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
61921771|NCT04075370||Single arm study|In this feasibility study, longitudinal mixed methods will be used to measure cognitive function and symptoms by objective tests, interviews, and biomarker assay in adults with brain cancer over time: prior to radiation (XRT; T1), 2-weeks post-XRT (T2), 2-3 months post-XRT (T3).
62310503|NCT02601781|EXPERIMENTAL|Primary PCI (PPCI) with BVS|Primary percutaneous coronary intervention (PPCI) with bioresorbable vascular scaffold (BVS) implantation in STEMI patients. Following the arterial route, PPCI (performed according to the international guidelines) aims to recanalize an occluded coronary artery that is then maintained patent inserting an endovascular permanent prosthesis (stent). In this study we aim to assess the results following the use of a fully bioresorbable prosthesis (BVS) during PPCI using a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation). BVS has the theoretical advantage, as compared with a permanent stent, to disappear within 24-36 months from implantation restoring the native pristine vessel state.
62310504|NCT06509516|EXPERIMENTAL|Shoulder pain history|Execution of the Modified Sleeper-Stretch three times, for thirty seconds each time, with thirty seconds between stretches, daily, for twenty-eight days. The stretch will be applied on the shoulder with history of shoulder pain.
62310505|NCT06509516|EXPERIMENTAL|No history of shoulder pain|Execution of the Modified Sleeper-Stretch three times, for thirty seconds each time, with thirty seconds between stretches, daily, for twenty-eight days. The stretch will be applied on a shoulder randomly assigned.
62310506|NCT03780517|EXPERIMENTAL|BOS172738|In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.
62476325|NCT06561724|ACTIVE_COMPARATOR|Biscuits includes maltodextrin|Maltodextrin is a generally recognized as safe (GRAS) food additive. Functional maltodextrin biscuits were prepared by stacking the biscuits on the table, followed by dispensing of 2g maltodextrin. The biscuits were covered with another piece of biscuit and 1 g of honey was used as binder. The biscuits were packed in bags under vacuum and kept at 40C for the daily supply to the participants.
62681079|NCT05970796|ACTIVE_COMPARATOR|Face-to-face group|The face-to-face group will be supervised by a female physical therapist who will provide pelvic floor muscle training twice a week for 12 weeks.
62681080|NCT06687928|EXPERIMENTAL|Subcutaneous CT-P6|Subcutaneous CT-P6 (CT-P6 SC): 600 mg/5 mL
62681081|NCT06687928|ACTIVE_COMPARATOR|Subcutaneous EU-approved Herceptin|Subcutaneous Herceptin (EU-approved Herceptin SC): 600 mg/5 mL
61921772|NCT06497036|EXPERIMENTAL|GP40141|"Lyophilized powder for solution 250 mcg in vials is diluted in sterile water for injection to a concentration of 500 mcg/ml. Administer once a week.~Cohort 1 Starting dose of romiplostim is 1 mcg/kg actual body weight. The weekly dose of romiplostim is increased in increments of 1 mcg/kg body weight until the patient's platelet count reaches ≥50 x 10\*9/L. Platelet counts are assessed weekly.~Cohort 2~* For subjects receiving Nplate®, a switch to GP40141 at an equivalent dose is recommended 7±2 days after the last Nplate® administration. The transition is equidosal since the drugs contain the same active ingredient.~* For patients receiving eltrombopag or Etrombopag-29F® (Pharmproekt, Russia)), it is recommended to switch to GP40141 at an initial dose of 1 mcg/kg the day after the last dose of eltrombopag.~The maintenance dose, dose adjustment, and maximum dose are consistent for both cohorts. Duration of therapy with study drugs will be 26 weeks."
62681082|NCT05313256|EXPERIMENTAL|Experimental group|In this arm patients will receive for epidural extension a Lidocaine epinephrine buffered with sodium bicarbonate.
62310507|NCT01595204|EXPERIMENTAL|Diagnostic Laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
62310508|NCT05839626|EXPERIMENTAL|SAR445514 RRMM Dose escalation phase (Part 1a)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
62310509|NCT05839626|EXPERIMENTAL|SAR445514 RRLCA Dose escalation phase (part 1b)|SAR445514 will be administered to participants with relapsed/refractory light chain amyloidosis (RRLCA)) using subcutaneous route (SC)
62310510|NCT05839626|EXPERIMENTAL|SAR445514 Dose level A (part 2)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
62310511|NCT05839626|EXPERIMENTAL|SAR445514 Dose level B (part 2)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
62310512|NCT05839626|EXPERIMENTAL|SAR445514 RRMM Dose expansion (part 3a)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
62310513|NCT05839626|EXPERIMENTAL|SAR445514 RRLCA Dose expansion (part 3b)|SAR445514 will be administered to participants with relapsed/refractory light chain amyloidosis (RRLCA) using subcutaneous route (SC)
62121803|NCT06338241|EXPERIMENTAL|Galibone Group|The Galibone+ experimental group includes participants receiving Galibone+ after impacted mandibular third molar extraction, testing its osteogenic properties. Galibone+ is prepared per manufacturer's instructions, potentially by immersing in sterile saline. Applied post-extraction into the socket using specialized instruments, it's compared to a control group receiving Bio-Oss, a standard xenograft material. Experimental group patients receive postoperative medications, including antibiotics and pain management. Follow-up assesses pain, inflammation, complications, and bone regeneration via radiological evaluation. Goal: Assess Galibone+'s efficacy in bone regeneration versus control.
62310514|NCT04859127||Patient Group|"The criteria for inclusion in the study were determined as voluntary patients between the ages of 18-65 with neck pain lasting more than 3 months who were clinically diagnosed with chronic neck pain by a specialist physician.~Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc."
62310515|NCT04859127||Control Group|Asymptomatic individuals between the ages of 18-65 who have not experienced neck pain during the last 1 year will be included in the control group. Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc.
62310516|NCT05346562|EXPERIMENTAL|Cannabidiol, then Placebo|Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks. After two week washout, participant receives Placebo for five weeks (matching Cannabidiol tablets)
62310517|NCT05346562|EXPERIMENTAL|Placebo, then Cannabidiol|Participant receive placebo tablets (matching Cannabidiol pills) for five weeks. After two week washout, Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks.
62681083|NCT05313256|ACTIVE_COMPARATOR|Comparator group|In this arm patients will receive for epidural extension only Lidocaine epinephrine.
62681084|NCT05019521|EXPERIMENTAL|Danicopan: 100 mg|Participants will receive danicopan 100 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
61921773|NCT06497036|ACTIVE_COMPARATOR|Nplate|"Lyophilized powder for solution 250 mcg in vials is diluted in sterile water for injection to a concentration of 500 mcg/ml. Administer once a week.~Cohort 1 Starting dose of romiplostim is 1 mcg/kg actual body weight. The weekly dose of romiplostim is increased in increments of 1 mcg/kg body weight until the patient's platelet count reaches ≥50 x 10\*9/L. Platelet counts are assessed weekly.~Cohort 2~Initial dose:~• For patients receiving eltrombopag or Etrombopag-29F® (Pharmproekt, Russia)), it is recommended to switch to at Nplate® initial dose of 1 mcg/kg the day after the last dose of eltrombopag.~The maintenance dose, dose adjustment, and maximum dose are consistent for both cohorts. Duration of therapy with study drugs will be 26 weeks."
61921774|NCT00230477|ACTIVE_COMPARATOR|Mono therapy|Hepsera
61921775|NCT00230477|ACTIVE_COMPARATOR|Combo therapy|
61921776|NCT06163469|EXPERIMENTAL|Arm I|Participants will get bladder instillations of normal saline for three months and then six months of instillations with chlorohexidine gluconate. After the instillation phase the patients will undergo an observational phase with six months of catheter exchanges without the intervention.
61921777|NCT04109898|NO_INTERVENTION|standard I-gel insertion technique|Investigator will apply the recommended (standard) I-gel insertion technique in patients
62310518|NCT01962636|EXPERIMENTAL|Umbilical Cord Blood Transplant|The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI)followed by umbilical cord blood transplant. Immunosuppressive Cyclosporine and Mycophenylate Mofetil (MMF) will be administered pre- and post UCBT.
62310519|NCT06057129|EXPERIMENTAL|Unsupervised therapy|This group will perform therapy with the ReHandyBot first with the supervision of a therapist at the rehabilitation clinic. Then, after discharge, if the participant learnt how to safely train with the device, they can bring the device home and train with it unsupervised. On the other hand, if participants are not capable of training without supervision, after discharge they perform unsupervised therapy at home with a booklet of exercises (i.e., without the robot).
62495940|NCT06347627|EXPERIMENTAL|Group 16 (O x E x D x M)|"Participants in Group 16 will view a message in an X (former Twitter) format composed of Organization x Effectiveness x Scientific data x Misinformation factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate."
61921778|NCT04109898|EXPERIMENTAL|Modified I-gel insertion technique|Investigator will apply the modified (interventional) I-gel insertion technique in patients
61921779|NCT05743517|EXPERIMENTAL|Symptom burden-tailored goal setting app|The Fit4Treatment app is designed to encourage physical activity among older women with gynecologic cancer while they are undergoing cancer therapy. The app will contain the following features 1) education about safely increasing physical activity and steps; 2) tailored patient-specific push notifications to encourage physical activity 3) syncing of Fitbit steps and transmission of these data to study staff in real time; 4) daily, weekly and monthly step progress; and 5) goal setting that incorporates prior physical activity, patient desires, and daily symptom burden. The app will prompt patients to report their symptom burden on a scale of 1-5 each morning. Based on their symptom rating and the previous days step counts (measured directly by the Fitbit) patients will be provided with three different goal choices to select. Daily activity goals increase, decrease or stay the same depending on the previous day and the patient's own goals.
62310520|NCT02747667||Eye with late IOL complication|Alle patients with IOL complication (subgroup: in-the-bag dislocation; out-of-the-bag dislocation; haptic dislocation)
62310521|NCT02747667||Eyes with no late IOl complication|
62476326|NCT06561724|EXPERIMENTAL|Biscuits includes prebiotics tartoufa inulin|Prebiotics is the term for a dietary approach that tries to precisely control the composition and operation of the gut microbiota to promote health. Functional prebiotics biscuits were prepared by stacking the biscuits on the table, followed by dispensing of 2g tartoufa inulin. The biscuits were covered with another piece of biscuit and 1 g of honey was used as binder. The biscuits were packed in bags under vacuum and kept at 40C for the daily supply to the participants.
62476327|NCT06561724|EXPERIMENTAL|Biscuits includes prebiotics chicory inulin|Prebiotics is the term for a dietary approach that tries to precisely control the composition and operation of the gut microbiota to promote health. Functional prebiotics biscuits were prepared by stacking the biscuits on the table, followed by dispensing of 2g chicory inulin. The biscuits were covered with another piece of biscuit and 1 g of honey was used as binder. The biscuits were packed in bags under vacuum and kept at 40C for the daily supply to the participants.
62476328|NCT01660594||Stable chest pain|All patients presenting with stable chest pain and referred by their general practitioners to the chest pain clinic in the hospital who had CT calcium scoring performed besides standard assessment.
62476329|NCT05671965|ACTIVE_COMPARATOR|Xylitol|20 volunteers receive 33.5g xylitol dissolved in 300mL tap water as an oral pre-load.
62476330|NCT05671965|ACTIVE_COMPARATOR|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
62476331|NCT05671965|ACTIVE_COMPARATOR|Acesulfame Potassium|20 volunteers receive 0.1675g Ace-K dissolved in 300mL tap water as an oral pre-load.
62476332|NCT05671965|PLACEBO_COMPARATOR|Water|20 volunteers receive 300mL tap water as an oral pre-load.
62476333|NCT04935164||Male patients with gender dysphoria|"* male patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~* patients without psychotropic treatments~* patients who do not benefit of hormone therapy~* patients who have not yet received gender reassignment surgery~* patients aged 18 to 60 years~* patients with normal or corrected vision~* patients without mental defect~* patients without neurological impairment"
62476334|NCT04935164||Female patients with gender dysphoria|"* female patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~* patients without psychotropic treatments~* patients who do not benefit of hormone therapy~* patients who have not yet received gender reassignment surgery~* patients aged 18 to 60 years~* patients with normal or corrected vision~* patients without mental defect~* patients without neurological impairment"
62476335|NCT04935164||Male volunteers without gender dysphoria|"* male volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~* volunteer aged 18 to 60 years~* volunteer with normal or corrected vision~* volunteer without mental defect~* volunteer without neurological impairment"
61921780|NCT05743517|EXPERIMENTAL|Exercise Partner|Participants assigned to the exercise partner component will be encouraged to discuss their step progress with their selected partner who will in turn support the participant and encourage them to stay active.
61921781|NCT05743517|EXPERIMENTAL|Provider/oncologist engagement|Participants assigned to the provider/oncologist engagement component will have their physical activity data recorded by the Fitbit shared with their oncology provider through the electronic medical record (EMR). For participants randomized to this condition, clinical staff will place an order into the EMR, allowing the patient to use the patient-facing portal MyChart to link their Fitbit to the health record. Prior to regularly scheduled clinic visits, the patient's oncology team will receive a message summarizing the participant's physical activity (average daily steps) for the prior three weeks.
62139637|NCT01932632|NO_INTERVENTION|Usual Care|This group will receive care as similar as possible to care that they received prior to the study beginning. Their attending MDs will be instructed and reminded to avoid making parallel changes in the prescribing for the control patients unless there is a specific medical indication to which they would normally respond with a medication reduction. No other reminders or prompts about the study will be provided for these patients.
62310522|NCT03667677|EXPERIMENTAL|Group 1|Tandospirone + Amlodipine
62310523|NCT03667677|EXPERIMENTAL|Group 2|Tandospirone placebo + Amlodipine
62310524|NCT03667677|EXPERIMENTAL|Group 3|Tandospirone + Amlodipine placebo
62310525|NCT03667677|PLACEBO_COMPARATOR|Group 4|Tandospirone placebo + Amlodipine placebo
62310526|NCT05804162|EXPERIMENTAL|Cagrilintide (Arm 1)|Participants will receive 0.6 milligrams (mg) of cagrilintide subcutaneously once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose moxifloxacin placebo at the end of the treatment period will be administered orally.
62310527|NCT05804162|ACTIVE_COMPARATOR|Cagrilintide Placebo (Arm 2A)|Participants will receive cagrilintide placebo subcutaenously once weekly. In addition, a single dose of moxifloxacin active prior to initiation of treatment and a single dose of moxifloxacin placebo at the end of the treatment period will be administered orally.
62310528|NCT05804162|ACTIVE_COMPARATOR|Cagrilintide Placebo (Arm 2B)|Participants will receive cagrilintide placebo subcutaneously once weekly. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose of moxifloxacin active at the end of the treatment period will be administered orally.
62310529|NCT03758677|EXPERIMENTAL|Patients who progressed after EGFR-TKI without T790M mutation|Single arm; Plan to enroll 30 cases; Patients who progressed after EGFR-TKI treatment without T790M mutation
62310530|NCT00745316|EXPERIMENTAL|1|oral Dose 1
62310531|NCT00745316|EXPERIMENTAL|2|oral Dose 2
62310532|NCT00745316|EXPERIMENTAL|3|oral Dose 3
62476336|NCT04935164||Female volunteers without gender dysphoria|"* female volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~* volunteer aged 18 to 60 years~* volunteer with normal or corrected vision~* volunteer without mental defect~* volunteer without neurological impairment"
62310533|NCT00745316|EXPERIMENTAL|4|oral Dose 4
62310534|NCT00745316|EXPERIMENTAL|5|oral Dose 5
62681085|NCT05019521|EXPERIMENTAL|Danicopan: 200 mg|Participants will receive danicopan 200 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
62310535|NCT00745316|PLACEBO_COMPARATOR|6|Placebo - 2 capsules bid
62476337|NCT01358344|EXPERIMENTAL|Standard Percentage|
62310536|NCT03940170||vistacam|
62310537|NCT03940170||ICDAS II|
62310538|NCT03940170||Fissurotomy|
62310539|NCT05102201|EXPERIMENTAL|Paro intervention group|Participants in the Paro intervention group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks.
62310540|NCT05102201|NO_INTERVENTION|control group|The control group will receive care as usual activities, such as painting, drawing, and craft, which are provided by each facility.
62310541|NCT02904967|EXPERIMENTAL|patients with recurrent VTE|
62310542|NCT02904967|ACTIVE_COMPARATOR|patients with only one episode of VTE|
62310543|NCT05170945|NO_INTERVENTION|Retrospective Cohort|Colonoscopy was performed, either early bowel preparation, late bowel preparation or no bowel preparation patients.
62310544|NCT05170945|EXPERIMENTAL|Prospective Cohort|Early bowel preparation for colonoscopy patients
62476338|NCT01358344|EXPERIMENTAL|High Percentage|
62476339|NCT05004740||Lactating birthing persons delivering at Sinai Health System or from the general population|
62681086|NCT05019521|EXPERIMENTAL|Danicopan: 400 mg|Participants will receive danicopan 400 mg qd during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
62121804|NCT06338241|ACTIVE_COMPARATOR|Control group|"The control group serves as an active comparator to the Galibone+ experimental group in this study. Participants undergo identical impacted mandibular third molar extraction procedures as the experimental group but receive a standard material, likely Bio-Oss, instead of Galibone+.~Bio-Oss, a widely used xenograft material in dental surgeries, acts as a benchmark due to its osteoconductive properties. Applied post-extraction into the socket with specialized instruments, it provides a reference for comparing Galibone+'s efficacy. Patients in the control group receive postoperative medications as per the study protocol, including antibiotics and pain management. Follow-up assesses pain, inflammation, complications, and bone regeneration via radiological evaluation."
62310545|NCT06510218||Head Start children and families|Children (261) Parents (261) Teachers (88) Program directors (18) Center directors (43)
62310546|NCT05202977|EXPERIMENTAL|SinocrownTM Transcatheter Aortic Valve Replacement System|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
62310547|NCT04791891||Low Back Pain (LBP)|"Adult women and men with self-reported LBP.~Inclusion Criteria for potential LBP participants~* At least 18 years old;~* Internet access;~* Fluent in English or French;~* Self-reported LBP.~Exclusion Criteria: No exclusion criteria will be adopted in this study.~* No exclusion criteria will be adopted in this study"
62310548|NCT02796144|ACTIVE_COMPARATOR|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
62476340|NCT01124305|ACTIVE_COMPARATOR|Traditional Instrumentation|Control group: Cases performed with traditional surgical instruments
62476341|NCT01124305|EXPERIMENTAL|Customized Patient Instrumentation|Experimental group: Cases performed with custom instruments specifically made for each patient using pre-op CT scans.
62476342|NCT04831307|EXPERIMENTAL|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
62476343|NCT02061553|SHAM_COMPARATOR|Motivation|1 in person session focused on importance of motivation followed by 8 wk SMS messages with self-selected motivational statements.
62121805|NCT01128790|EXPERIMENTAL|remote ischemic preconditioning|4 cycles of 5 mins upper limb ischemia induced by blood pressure cuff inflation 20mmHg above systolic blood pressure
62121806|NCT01128790|SHAM_COMPARATOR|Sham control|4 x 5 mins of upper limb blood pressure cuff inflation to 10mmHg (non-occlusive)
62121807|NCT02949583|EXPERIMENTAL|Punica granatum Linn.|The childrens used the mouthwash contain pomegranate 6,25% twice daily for 14 days.
62121808|NCT02949583|ACTIVE_COMPARATOR|chlorhexidine|The childrens used the mouthwash contain chlorhexidine 0.12% twice daily for 14 days.
62121809|NCT03712930|EXPERIMENTAL|Pamiparib|Participants will receive pamiparib for a period up to 1 year
62121810|NCT01235884|ACTIVE_COMPARATOR|Lactobacillus reuteri|Dietary Supplement
62121811|NCT01235884|PLACEBO_COMPARATOR|Placebo|Dietary Supplement
62476344|NCT02061553|ACTIVE_COMPARATOR|Intention|1 session of Behavioral Activation followed by 8 wk SMS messages in the form of BA- based implementation intentions.
62476345|NCT02061553|EXPERIMENTAL|BA-Tech|6 in person and 2 phone sessions of Behavioral Activation with EMA-based activity monitoring and SMS-assisted scheduling of value-based activities.
62476346|NCT03338933||Control Group|No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent.
62476347|NCT03338933||Nicotine Group|Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria for Nicotine Use Disorder. Current smoker, at least 10 cigarettes per day. No history of addiction to any other substance
62476348|NCT03338933||Nicotine and Alcohol Group|DSM-V criteria for Nicotine Use Disorder and Alcohol Use Disorder. At least 8 heavy drinking episodes in the past month. Current smoker. Alcohol free from 2 to 4 weeks. No history of addiction to other substances or gambling.
62121812|NCT01821612|OTHER|mFOLFIRINOX, chemoradiation, surgery and gemcitabine|"Each patient will receive mFOLFIRINOX therapy administered every other week for a total of 4 cycles. Each treatment cycle is a total of 14 days. This treatment program consists of four drugs (oxaliplatin 85 mg/m\^2 IV over 2 hours on day 1 followed by irinotecan 180 mg/m\^2 IV over 90 minutes on day 1 followed by, leucovorin 400 mg/m\^2 IV over 2 hours on day 1 followed by 5-FU 2400 mg/m\^2 IV over 46-48 hours).~Two to six weeks following treatment with the mFOLFIRINOX, if the tumor has not spread to other parts of the body then the patient will receive capecitabine 825 mg/m\^2, twice daily for 28 days along with radiation therapy. Patients will have surgery within 4-10 weeks of the last dose of chemoradiation if the tumor has gotten smaller or stayed the same.~Within 6-8 weeks following surgery, patients will receive gemcitabine for 2 cycles (1 cycle is 28 days). Gemcitabine will be given IV on days 1, 8 and 15 of every 28 day cycle."
62310549|NCT02796144|ACTIVE_COMPARATOR|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
62310550|NCT02796144|PLACEBO_COMPARATOR|Placebo|Matching placebos will be administered for each active drug.
62310551|NCT03366311|ACTIVE_COMPARATOR|holding position|different holding position of endotracheal tube
62310552|NCT03366311|ACTIVE_COMPARATOR|stylet shapes|banana shape versus straight-to-cuff shape
62310553|NCT03366311|ACTIVE_COMPARATOR|epiglottis lift|with epiglottis lift or without
62681087|NCT05019521|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo and will be re-randomized to one of the active treatment groups at Week 52, or to the optimal dose, if already identified.
62681088|NCT02040376|EXPERIMENTAL|Group A (Crossover Group 1)|Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.
62681089|NCT02040376|EXPERIMENTAL|Group B (Crossover Group 2)|Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.
61921782|NCT05743517|EXPERIMENTAL|Coaching|Participants assigned to the coaching intervention will receive weekly coaching calls. The study team will call them at a previously specified and mutually agreed upon time once per week to review topics related to physical activity and cancer treatment. Coaching calls will have an educational component and cover topics such as reducing sedentary behavior, benefits of increased physical activity, managing cancer treatment symptoms, social support, stress management, etc. During these calls, the topics as well as strategies and recommendations will be discussed. Barriers and facilitators will be reflected on and planned for to increased self-efficacy. Participants will engage in direct problem solving with their coach. Discussing these topics will enhance outcome expectation and increase motivation.
62121813|NCT05789472|EXPERIMENTAL|Football Group|Assessment
62121814|NCT05789472|EXPERIMENTAL|Basketball Group|Assessment
62121815|NCT05789472|EXPERIMENTAL|Volleyball Group|Assessment
62681090|NCT06036810|EXPERIMENTAL|Study Phase 1|Pre-testing and cognitive interviews for the Decision Support Tool
62310554|NCT02660580|EXPERIMENTAL|MSB11022 (Core Treatment Period)|Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
62310555|NCT02660580|ACTIVE_COMPARATOR|EU-Humira|Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
62310556|NCT02660580|EXPERIMENTAL|MSB11022 (Extended Treatment Period)|Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
62310557|NCT02660580|ACTIVE_COMPARATOR|EU-Humira/EU-Humira|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
62310558|NCT02660580|EXPERIMENTAL|EU-Humira/MSB11022|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
62310559|NCT03914547|EXPERIMENTAL|REDCHiP intervention arm|REDCHiP uses 10- video-based telemedicine sessions to deliver T1D education, behavioral parent training, and problem-solving to enhance parents' knowledge and skills. Sessions last about 45-60 minutes each.
62310560|NCT03914547|ACTIVE_COMPARATOR|Attention Control arm|ATTN uses 10- video-based telemedicine sessions to deliver general patient education specific to young children. Similar to REDCHiP, all ATTN sessions last 45-60 minutes.
62310561|NCT03977532|EXPERIMENTAL|patients with sickle cell disease|
62310562|NCT02616822|EXPERIMENTAL|trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
62310563|NCT02616822|PLACEBO_COMPARATOR|Placebo|Used for placebo substance single dose
62310564|NCT03989687|EXPERIMENTAL|glass ionomer sealant|glass ionomer sealant
62310565|NCT03989687|EXPERIMENTAL|isolation|isolation type either rubber dam or cotton roll isolation
62310566|NCT05167786|EXPERIMENTAL|Aim 1: Gait Training + Stimulation|Up to 60 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
62310567|NCT05167786|ACTIVE_COMPARATOR|Aim 1: Stimulation Only|Up to 60 minutes of transcutaneous spinal cord stimulation while resting in a comfortable position.
62310568|NCT05167786|ACTIVE_COMPARATOR|Aim 1: Gait Training + Sham Stimulation|Up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention while performing locomotion training. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
62310569|NCT05167786|SHAM_COMPARATOR|Aim 1: Sham Only|Up to 60 minutes of transcutaneous spinal cord stimulation while resting in a comfortable position during which they will receive up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention.
62310570|NCT05167786|EXPERIMENTAL|Aim 2: Gait Training + Stimulation|Up to 60 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
62681091|NCT06036810|EXPERIMENTAL|Study Phase 2|Usual Care (Control Group) or Participants utilize the Decision Support Tool with Provider guidance (Intervention Group).
62121816|NCT06120699|EXPERIMENTAL|360 Degree Expanded Diaphragm Exercises|Volunteers who complain of urinary incontinence in situations such as coughing, sneezing and laughing, who have been diagnosed with stress or stress-predominant mixed urinary incontinence by a Gynecology and Obstetrics physician, and who meet the inclusion criteria will be included in the study.
62681092|NCT05228015|EXPERIMENTAL|IK-930 Single Agent Dose Escalation|
62681093|NCT05228015|EXPERIMENTAL|IK-930 Single Agent Dose Expansion|
62681094|NCT05228015|EXPERIMENTAL|IK-930 and Osimertinib Combination Dose Escalation|
62681095|NCT01141868|EXPERIMENTAL|Internet Intervention|
62310571|NCT05167786|ACTIVE_COMPARATOR|Aim 2: Gait Training + Sham Stimulation|Up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention while performing locomotion training. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
62476349|NCT03338933||Alcohol Group|DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling.
62681096|NCT01141868|EXPERIMENTAL|Delayed Intervention|Receive access to the online Internet intervention after completing post-assessments.
62681097|NCT06695221|EXPERIMENTAL|Participants living with T2D|Randomly assigned to consume either traditional kefir or milk as a placebo.
62681098|NCT06695221|EXPERIMENTAL|Participants with higher risk of T2D|Randomly assigned to consume either traditional kefir or milk as a placebo.
61921783|NCT00746447|EXPERIMENTAL|3.0g OD|
61921784|NCT00746447|EXPERIMENTAL|1.5g OD|
61921785|NCT00746447|ACTIVE_COMPARATOR|0.5g TID|
62121817|NCT06120699|ACTIVE_COMPARATOR|Standard Diaphragm Exercises|Volunteers who complain of urinary incontinence in situations such as coughing, sneezing and laughing, who have been diagnosed with stress or stress-predominant mixed urinary incontinence by a Gynecology and Obstetrics physician, and who meet the inclusion criteria will be included in the study.
62121818|NCT04301596||SSc patients|
62121819|NCT03644329|OTHER|Control group, CT|In the CT, the postmenopausal breast cancer survivers does not perform exercise.
62310572|NCT01065428||Weaning failure|Weaning failure:(1) failed SBT; (2) reintubation and /or resumption of support following successful extubation; or (3) die 48h following extubation.
62310573|NCT01065428||Weaning successful|Weaning successful:extubation and the absence of ventilatory support 48 h following the extubation
62476350|NCT02975765|EXPERIMENTAL|Piezosurgery|Piezosurgery-assisted corticotomy will be performed to enhance teeth alignment
61921786|NCT01825954|ACTIVE_COMPARATOR|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
61921787|NCT01825954|ACTIVE_COMPARATOR|8-week RINCE|RINCE - active RINCE therapy involving 16 total treatment applications from NeuroPoint device, followed by 8 sham applications from the NeuroPoint device
61921788|NCT01825954|SHAM_COMPARATOR|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
61921789|NCT05806671|EXPERIMENTAL|Dalpiciclib, Fulvestrant With Pyrotinib|Pyrotinib 320mg/day Dalpiciclib 125 mg/day Fulvestrant 500mg
62476351|NCT02975765|NO_INTERVENTION|Traditional method|No intervention is going to be applied to the patients in this group.
62681099|NCT02777190|EXPERIMENTAL|Oral misoprostol|oral misoprostol given 25 mcg every 2 hours
62681100|NCT02777190|ACTIVE_COMPARATOR|Vaginal misoprostol|vaginal misoprostol given 25 mcg every 4 hours
61921790|NCT01115803|EXPERIMENTAL|Arm A: LY2584702 + Erlotinib|Participants received 50 mg LY2584702 once daily (QD )+ 150 mg Erlotinib QD, 50 mg LY2584702 twice daily (BID) + 150 mg Erlotinib QD, 100 mg LY2584702 BID + 150 mg Erlotinib QD and 75 mg LY2584702 BID + 150 mg Erlotinib QD.
62681101|NCT02579551|EXPERIMENTAL|Treatment (surgical excision)|Patients undergo surgical excision of the skin lesion consisting of 1 and 2 mm circumferential margins during visit 1.
62681102|NCT04893109|EXPERIMENTAL|Arm A. T-DM1 followed by Trastuzumab SC|Randomized participants will receive intravenous T-DM1 every 3 weeks for 6 cycles (18 weeks) and then Trastuzumab SC (subcutaneous) every 3 weeks for 11 cycles
62310574|NCT04293250|EXPERIMENTAL|Physical activity group|"1. Investigators employ the recommendations of the American College of Sport Medicine and the World Health Organization for adults to divide our enrolled patients having moderate-intensity as 30-60 min∙d-1 (≥150 min∙wk-1 ) or vigorous-intensity as 20-60 min∙d-1 (≥75 min∙wk-1) for 6-8 weeks preoperatively.~2. The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.~3. The operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
62310575|NCT04293250|EXPERIMENTAL|non-physical activity group|"1. No any moderate-intensity or vigorous-intensity physical activity for our enrolled patients preoperatively.~2. The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.~3. Various types of operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
62310576|NCT01686984|EXPERIMENTAL|Altered breath|The group where the investigators alter the inspiratory and expiratory aspects of a ventilated breath.
62310577|NCT02634164|NO_INTERVENTION|control|"Control Treatment with Oral Glucose Tolerance Test:~Blood glucose and insulin will be obtained following the protocol of Eicher et al (4). Participants will ingest a Placebo (inert, calorie free, stevia sweetener) with blood collections at 0,2,4,6,8,10,30 prior to a standard 75 g glucose solution, followed by blood collections at 0,2,4,6,8,10,30,60,90,120 minutes post glucose ingestion. A total of 16 blood collections will be taken."
62681103|NCT04893109|EXPERIMENTAL|Arm B: Paclitaxel with Trastuzumab SC, followed by Trastuzumab SC alone|Randomized participants will receive weekly intravenous Paclitaxel for 12 weeks (4 cycles) and Trastuzumab SC (subcutaneous) every 3 weeks for 17 cycles. The first 4 doses Trastuzumab SC are given with Paclitaxel.
62681104|NCT05942040|EXPERIMENTAL|Intervention Group|Intervention group will consist of all MA plan members eligible for community-based palliative care and of those who refused it (to calculate refusal rate) during the six month period following the introduction of tailored informational materials developed on CBPC
61921791|NCT01115803|EXPERIMENTAL|Arm B: LY2584702 + Everolimus|Participants received 50 mg LY2584702 QD + 10 mg Everolimus QD, 100 mg LY2584702 QD + 10 mg Everolimus QD and 50 mg LY2584702 BID + 10 mg Everolimus QD.
61921792|NCT04163822||group with typical imaging changes|the BPD infants with typical chest imaging findings include fibrotic opacities and cysts on CXR or CT scans during the entire hospital stay.
61921793|NCT04163822||group without typical imaging changes|the infants meet the diagnosis criteria of BPD, but lack of typical chest imaging findings
61921794|NCT03790423|EXPERIMENTAL|18F-ASIS PET|One injection of 18F-ASIS (app. 200 MBq) followed by 3 PET/CT scans 1 hour, 2 hours and 4hours post-injection
62121820|NCT03644329|EXPERIMENTAL|Lower-load resistance training (LL)|In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).
62121821|NCT03644329|EXPERIMENTAL|Higher-load resistance training (HL)|In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).
62121822|NCT03644329|EXPERIMENTAL|Higher-volume resistance training (HV)|In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).
62121823|NCT00457743|EXPERIMENTAL|SU011248|25 , 50 or 75 mg/day of SU011248
62121824|NCT03019614|EXPERIMENTAL|Group 1|"Volunteers in group 1 received the following interventions:~Chronocort® 30 mg given at night (\~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).~Chronocort® 30mg given as one 20mg capsule at night (\~ 23:00h) and as one 10mg capsule in the morning (\~ 7:00h) following the initial night-time dose (n=18).~Hydrocortisone 30mg given at night (\~ 23:00h) given as three 10mg tablets (n=18).~Each administration of IMP was separated by a washout period of at least 7 days."
62121825|NCT03019614|EXPERIMENTAL|Group 2|"Volunteers in group 2 received the following interventions:~Chronocort® 5mg given at night (\~ 23:00h) as one 5mg capsule (n=12).~Chronocort® 10mg given at night (\~ 23:00h) as one 10mg capsule (n=12).~Chronocort® 20mg given at night (\~ 23:00h) as one 20mg capsule (n=12).~Each administration of IMP was separated by a washout period of at least 7 days."
62121826|NCT06677346||Nulliparous|Women who have never given birth
62681105|NCT05942040|NO_INTERVENTION|Control Group|Control group will be a retrospective review of individuals who were eligible for community-based palliative care and of those who refused it, for the 6-month period prior to introducing the tailored informational materials. All of these individuals will have received usual care/information regarding community-based palliative care.
61921795|NCT01702051||1|patients with chronic pancreatitis treated with total or subtotal pancreatectomy
62121827|NCT06677346||Primiparous|Women who have given birth once
62121828|NCT06677346||Multiparous|Women who have given birth multiple times
62681106|NCT02694055|EXPERIMENTAL|Proactive Community Case Management (ProCCM)|Villages assigned to the experimental arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing proactive case detection in addition to integrated Community Case Management (ProCCM).
61921796|NCT01702051||2|patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
61921797|NCT01702051||3|patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
61921798|NCT01702051||4|patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck
62476352|NCT06536257||Melanoma cohort|Patients with melanoma who are yet to receive immunotherapy will undergo predictive biomarker testing and biomarker reporting.
61921799|NCT02070471|EXPERIMENTAL|LC28-0126 Dose A|LC28-0126 Dose A
62681107|NCT02694055|ACTIVE_COMPARATOR|integrated Community Case Management (iCCM)|Villages assigned to the active comparator arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing passive integrated Community Case Management (iCCM) exclusively at a fixed health post to patients who initiate their own care-seeking.
62681108|NCT04700072|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab and quavonlimab) intravenously (IV) plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
61921800|NCT02070471|EXPERIMENTAL|LC28-0126 Dose B|LC28-0126 Dose B
61921801|NCT02070471|EXPERIMENTAL|LC28-0126 Dose C|LC28-0126 Dose C
62310578|NCT02634164|EXPERIMENTAL|Leucine Supplement|Control Treatment with Oral Glucose Tolerance Test:
62310579|NCT02634164|EXPERIMENTAL|Isoleucine Supplement|Isoleucine Combined with Oral Glucose Tolerance Test:
62310580|NCT02634164|EXPERIMENTAL|Leucine and Isoleucine Supplement|Leucine and Isoleucine Combined with Oral Glucose Tolerance Test:
62476353|NCT06536257||Non-melanoma skin cancer cohort|Patients with non-melanoma skin cancers (basal cell carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma) who are yet to receive immunotherapy will have tumour tested using the predictive model.
62476354|NCT06536257||Solid tumour cohort|Patients with non-melanoma, non-skin cancer, solid tumours who are yet to receive immunotherapy will have tumour tested using the predictive model.
61921802|NCT02070471|PLACEBO_COMPARATOR|Placebo|Placebo
61921803|NCT02197455|EXPERIMENTAL|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
61921804|NCT01328171|EXPERIMENTAL|A (FOLFOXIRI + Panitumumab)|FOLFOXIRI + Panitumumab
62121829|NCT03126812|EXPERIMENTAL|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
62121830|NCT06554691||Oral Immunotherapy|Participants in this group undergo oral immunotherapy as part of their routine management of their nut allergies
62476355|NCT00838279|EXPERIMENTAL|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
61921805|NCT01328171|ACTIVE_COMPARATOR|B (FOLFOXIRI)|FOLFOXIRI
61921806|NCT03033446|EXPERIMENTAL|Y90-Radioembolization and Nivolumab|
61921807|NCT06542263||non-CPAP group|The non-CPAP group underwent catheter ablation and conventional treatment for AF combined with OSA
61921808|NCT06542263||CPAP group|The CPAP group underwent catheter ablation and CPAP treatment for AF combined with OSA
61921809|NCT03691324|EXPERIMENTAL|Intervention|Patients receive an inhalation technique education based on standardized procedure developed by The Norwegian Pharmacy Association. In addition they are offered a discharge service day before or the day of discharge; a second inhalation training and dispensing of their prescribed COPD- medicines.
61921810|NCT03691324|NO_INTERVENTION|Standard care|Patients receive standard care and follow up of their COPD-treatment
61921811|NCT01030367|EXPERIMENTAL|1|PETN
62681109|NCT04700072|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62681110|NCT05023174|EXPERIMENTAL|PRP|Patients in this treatment arm will have PRP injected into the crura of the diaphragm and coating the mesh placed during the hiatal hernia repair.
62681111|NCT05023174|ACTIVE_COMPARATOR|No PRP|Patients in this arm will undergo an identical surgical procedure, however will not have the addition of PRP injected into the cura of the diaphragm or onto the mesh placed during the hiatal hernia repair.
62681112|NCT06686849|NO_INTERVENTION|Care as Usual|In the comparison group, patients' caregivers will not be subject to any standardized follow-up procedure.
62681113|NCT06686849|EXPERIMENTAL|Low-touch: Text messaging only|The patients' primary caregiver will receive a text message that includes details about the missed appointment, and guidance on rescheduling. Up to three total reminders will be sent, spaced one week apart, if the appointment is not rescheduled in the interim.
62681114|NCT06686849|EXPERIMENTAL|High-touch: Community Health Worker outreach|Regardless of rescheduling status, the CHW will reach out to the primary phone number on file within three business days of the no-show visit. Per usual team protocol, up to three phone call attempts will be made to the primary phone number on file, followed by an attempt to the secondary phone number on file. The CHW will screen the families' needs per their usual protocol and inquire about reasons for no-showing for the scheduled appointment; additional questions will include whether they can provide support for rescheduling the no-showed visit and helping to attend it. The CHW will also have a discretionary fund available through this project to help support the family in addressing instrumental needs if existing resources are not available through the hospital, governmental services, or other organizations.
62681115|NCT05554224||Severe obesity without liver disease|Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 0-2).
62681116|NCT05554224||Severe obesity with liver disease without criteria for steatohepatitis|Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis, but their biopsies presented some liver severity (scores 3 and 4).
62681117|NCT05554224||Severe obesity with well-defined steatohepatitis and/or cirrhosis|Patients with severe obesity who met the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 5-8).
62681118|NCT04188509|EXPERIMENTAL|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a stick pack formulation (powder blend formulation packaged as stick packs). Participants aged ≥ 12 years and/or ≥ 40 kgs will receive a voxelotor dose of 1500 mg QD. Participants aged \< 12 years and \< 40 kgs will receive weight based dosing of voxelotor. The participant's weight at study entry will be used to determine the starting voxelotor dose in this study. Participants may receive study drug as long they continue to receive clinical benefit that outweighs risk as determined by the investigator and/or until the participant has access to voxelotor from an alternative source.
62681119|NCT05494359||ESCA group|"40 patients of ESCA were included through the diagnosis of gastroscopic biopsy positive.~Age, gender, esophageal cancer staging, tumor biomarkers and other laboratory test indicators, CT and other imaging examinations results, gastroscope and pathological examinations results have been collected."
62121831|NCT06554691||Avoidance diet|Participants in this group are on strict avoidance diet as part of their nut allergy management
62310581|NCT04641546|EXPERIMENTAL|Occupation-Based Intervention + Therapeutic Exercise Intervention Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of 30 minutes therapeutic exercise followed by 30 minutes of occupation-based intervention.
61921812|NCT01030367|EXPERIMENTAL|2|ISDN
61921813|NCT01030367|NO_INTERVENTION|3|
61921814|NCT03639532|EXPERIMENTAL|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
61921815|NCT03639532|ACTIVE_COMPARATOR|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
61921816|NCT02514473|EXPERIMENTAL|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
62121832|NCT03777696|ACTIVE_COMPARATOR|Misoprostol with TA|400 μg of buccal misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
62121833|NCT03777696|ACTIVE_COMPARATOR|Misoprostol with placebo to TA|400 μg of buccal misoprostol (two tablets) plus 110 ml saline by iv rout
62121834|NCT03777696|PLACEBO_COMPARATOR|placebo to Misoprostol and TA|placebo to misoprostol plus placebo to tranexamic acid
62121835|NCT02156050|ACTIVE_COMPARATOR|OBLOO device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
62310582|NCT04641546|EXPERIMENTAL|Therapeutic Exercise Control Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of therapeutic exercise only.
62476356|NCT00838279|ACTIVE_COMPARATOR|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
62476357|NCT04819009||Central District|The ETMI method will be implemented in this group
62476358|NCT04819009||North District|control
61921817|NCT02514473|PLACEBO_COMPARATOR|Placebo|Matching placebo q12h
62339963|NCT01021852|EXPERIMENTAL|Placebo/MK-6096 2.5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
61921818|NCT02165176|EXPERIMENTAL|10mg acute oral cannabis|10mg acute oral cannabis
62681120|NCT05494359||Health control|"40 healthy people who experienced negative gastroscopy and tumor biomarkers were included as healthy control.~Age, gender, gastroscope, tumor biomarkers and other laboratory test results have been collected."
62681121|NCT05494359||Reflux esophagitis|40 patients of reflux esophagitis were included. Age, gender, tumor markers and other laboratory test indicators, gastroscope and pathological examinations results have been collected.
62681122|NCT05793151|EXPERIMENTAL|ENDURE|ENDURE is a theoretically-informed, navigation-based, multilevel intervention targeting barriers to timely, equitable guideline-adherent PORT.
62681123|NCT05793151|NO_INTERVENTION|Treatment As Usual|Treatment as usual at each site consists of standard of care clinical practices
62681124|NCT05572632|EXPERIMENTAL|COPD Wellness|This arm, COPD Wellness gives low-intensity exercise component with pulmonary rehabilitation for individuals with moderate-to-severe COPD. COPD Wellness is a program that was built from the Better Breathing Program, that is a part of San Francisco Health Network (SFHN) standard care for COPD.
61921819|NCT02165176|EXPERIMENTAL|25mg acute oral cannabis|25mg acute oral cannabis
61921820|NCT02165176|EXPERIMENTAL|50mg acute oral cannabis|50mg acute oral cannabis
61921821|NCT05523440|ACTIVE_COMPARATOR|Arm 1: Niraparib|Niraparib (200mg or 300 mg based on body weight and blood platelet count), oral, once daily.
62681125|NCT05572632|ACTIVE_COMPARATOR|Usual Care|This includes access to comprehensive primary care services. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. This program consists of an evidence-based curriculum that improves disease knowledge and management skills but has no effect on symptoms or functional status. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
61921822|NCT05523440|EXPERIMENTAL|Arm 2: Niraparib and Bevacizumab|Niraparib (200mg or 300 mg based on body weight and blood platelet count), oral, once daily. Bevacizumab (15 mg/kg, IV on day 1 of each cycle).
62681126|NCT05572632|EXPERIMENTAL|COPD Wellness Plus+|This arm includes COPD Wellness Plus+. This arm is built from COPD Wellness with the addition of Health Advocates (i.e. Plus+). This intervention seeks to understand the effects of addressing social needs on overall health and wellness through Zuckerberg San Francisco General Hospital's (ZSFG) Health Advocate (HA) program; participation and engagement with the HA's will serve as an adherence strategy.
61921823|NCT01993784|EXPERIMENTAL|Nimotuzumab|the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)
61921824|NCT01744912|EXPERIMENTAL|Ublituximab + Lenalidomide|"4 cohorts, with 3 - 6 patients per cohort, as follows:~Cohort 1: Ublituximab 450 mg + Lenalidomide 10 mg Cohort 2: Ublituximab 450 mg + Lenalidomide 15 mg Cohort 3: Ublituximab 600 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1) Cohort 4: Ublituximab 900 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1) Ublituximab is an IV infusion on days 1, 8, and 15 of cycles 1 \& 2 followed by a planned maintenance with a single infusion on day 1 of cycles 3 thru 6.~Lenalidomide is taken orally on days 9 - 28 of cycle 1 followed by daily administration on Days 1 - 28 for cycles 2 thru 6. Non-hodgkins lymphoma patients may have up to a 7 day rest period (Days 21-28) in any cycle."
61921825|NCT02605837|EXPERIMENTAL|Oral Budesonide Suspension (OBS)|Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
61921826|NCT02605837|PLACEBO_COMPARATOR|Placebo|Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
62121836|NCT02156050|EXPERIMENTAL|BBLOO Device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
62121837|NCT06472206|NO_INTERVENTION|Control|The control condition includes standard health services offered at each site. All participants receive referrals to mental health, drug/alcohol treatment, and/or other HIV services as necessary. Standard of care at each site follows the Dept. of Health and Human Services HIV guidelines.
62476359|NCT04819009||Hasharon District|control
62738564|NCT05891080|EXPERIMENTAL|JS004 arm|Patients with resectable or potentially resectable stage III non-small cell lung cancer will be randomized into this arm (59 patients) and receive 4 circles of neoadjuvant toripalimab and JS004 combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.
61921827|NCT06217185|EXPERIMENTAL|Experimental arm|"Pyrotinib, Trastuzumab Combined With Taxanes~\*When taxane drugs are discontinued (after completing 6-8 cycles of treatment or due to intolerance), the therapy can be continued with the combination of metronomic capecitabine and trastuzumab, along with pyrotinib."
61921828|NCT05468853|EXPERIMENTAL|MPFC-iTBS|Transcranial magnetic stimulation delivered to the medial prefrontal cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
61921829|NCT05468853|ACTIVE_COMPARATOR|Inion-iTBS|Transcranial magnetic stimulation delivered to the inion. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
61921830|NCT00730262|EXPERIMENTAL|Single-Arm|
61921831|NCT04581447|EXPERIMENTAL|Metformin + Standard care|"The pharmacological treatment (Metformin) will start at dose of 850 mg once daily and, at one month, increased to 850 mg twice daily. The dosage will be adjusted if necessary because of gastrointestinal symptoms and information on dose change during follow-up will be collected Adherence to study medications will be assessed by pills count and plasmatic dosage (Metformin group).~All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 6 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.~Ancillary study measuring metformin-induced enterohormones secretion will be performed on a subgroup of 30 patients randomized in this arm."
61921832|NCT04581447|OTHER|Standard Care|"All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 6 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.~Ancillary study measuring metformin-induced enterohormones secretion will be performed on a subgroup of 30 patients randomized in this arm."
61921833|NCT01082380|EXPERIMENTAL|1|
61921834|NCT05547971||Radiation Encephalopathy Group|Patients with radioactive encephalopathy during follow-up
62310583|NCT06105957|EXPERIMENTAL|Core+Facilitated Weekly Group Sessions+Counselor Crafted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
62476360|NCT04819009||South District|control
62476361|NCT04819009||Jerusalem and Hasfhela District|control
62476362|NCT02537457|EXPERIMENTAL|BAY59-7939 Rivaroxaban granule|
62476363|NCT02537457|ACTIVE_COMPARATOR|BAY59-7939 Rivaroxaban tablet|
62476364|NCT02525211|EXPERIMENTAL|Ropivacaine|Ropivacaine
62476365|NCT02525211|PLACEBO_COMPARATOR|placebo|physiological saline
62476366|NCT04599998||COVID-19 inpatients|Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic
62476367|NCT02173834|OTHER|Lean subjects|Lean, young, healthy, Caucasian, male subjects
62476368|NCT02173834|OTHER|Obese subjects|Obese, Young, Healthy, Caucasian, male subjects
62738565|NCT05891080|ACTIVE_COMPARATOR|Control arm|Patients with resectable or potentially resectable stage III non-small cell lung cancer will be randomized into this arm (59 patients) and receive 4 circles of neoadjuvant toripalimab combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.
62738566|NCT02274935|EXPERIMENTAL|Gait and balance exercise|Traditional exercises focusing on gait and balance
62738567|NCT02274935|EXPERIMENTAL|Cognitive training and physical exercise|Gait and balance exercises done in combination with cognitive training (i.e. counting backwards by 7s from 98)
62476369|NCT01658774|ACTIVE_COMPARATOR|Albendazole & Vitamin C|Anthelmintics. A single dose of Albendazole (400mg) at month 0 and single dose of Vitamin C (500 mg) at 3, 6, 9 and 12 months.
62476370|NCT01658774|EXPERIMENTAL|Albendazole|Anthelmintics. A single does of Albendazole (400mg) every three months for 12 months
62476371|NCT00012974|OTHER|Arm 1|
62476372|NCT00834535|EXPERIMENTAL|1|
62476373|NCT00834535|ACTIVE_COMPARATOR|2|
62681127|NCT06138067|EXPERIMENTAL|High Intensity Approach|Patients will receive printed educational material (PEM) which will include information and resources regarding clinical trials/clinical trial participation, cancer center support services; and community resources and services available to cancer patients. The PEM will be reviewed by the clinical trial patient navigator with the patient prior to the clinic visit with the medical oncologist. If the patient is offered participation in a therapeutic clinical trial, the high intensity patient navigation begins. The patient navigator will arrange to meet with the patient to complete a needs assessment to identify and address barriers to trial participation within one week of the visit with the medical oncologist (and clinical trial offer).
62681128|NCT06138067|ACTIVE_COMPARATOR|Low Intensity Approach|Patients will receive printed educational material (PEM) which will include information and resources regarding clinical trials/clinical trial participation and community resources and services available to cancer patients. The PEM will be reviewed by the patient navigator with the patient prior to the clinic visit with the medical oncologist.
62476374|NCT03563872|ACTIVE_COMPARATOR|Active Comparator|Team-based care
62681129|NCT06597942|EXPERIMENTAL|Open-Label Active deep rTMS|"The first stage of the study will consist of protocol refinement. In this first stage of 5-10 participants, all participants will receive open-label active treatment.~Treatment will consist of 16 sessions of deep rTMS spread over 5 weeks. The induction phase of treatment will be 4 sessions per day for 3 consecutive days (with 60 minutes between sessions), followed by 1 session per week for 4 weeks.~Individual sessions will consist of 1600 pulses of 20Hz rTMS delivered in 40 pulse trains to the precuneus (using MRI structural neuronavigation) at 100% of depth-corrected motor-threshold with a 28 second intertrain interval (roughly 20 minutes per session)."
62681130|NCT06597942|EXPERIMENTAL|Randomized Active deep precuneus rTMS|The second stage of the study will consist of both active and sham treatment groups. Treatment will consist of 16 sessions of deep rTMS spread over 5 weeks. The induction phase of treatment will be 4 sessions per day for 3 consecutive days (with 60 minutes between sessions), followed by 1 session per week for 4 weeks. Individual sessions will consist of 1600 pulses of 20Hz rTMS delivered in 40 pulse trains to the precuneus (using MRI structural neuronavigation) at 100% of depth-corrected motor-threshold with a 28 second intertrain interval (roughly 20 minutes per session). The active group will receive this protocol using an active treatment coil delivering real rTMS.
62681131|NCT06597942|SHAM_COMPARATOR|Randomized Sham deep precuneus rTMS|"The second stage of the study will consist of both active and sham treatment groups. Treatment will consist of 16 sessions of deep rTMS spread over 5 weeks. The induction phase of treatment will be 4 sessions per day for 3 consecutive days (with 60 minutes between sessions), followed by 1 session per week for 4 weeks. Individual sessions will consist of 1600 pulses of 20Hz rTMS delivered in 40 pulse trains to the precuneus (using MRI structural neuronavigation) at 100% of depth-corrected motor-threshold with a 28 second intertrain interval (roughly 20 minutes per session). The placebo group will receive this protocol using a sham TMS coil delivering inactive rTMS.~Participants in the sham/placebo group will be offered a full open-label extension treatment course of active rTMS on completion of the randomized phase."
62681132|NCT01744418|EXPERIMENTAL|HAVG graft|HAVG graft implantation to study participants.
62681133|NCT06048588|EXPERIMENTAL|YN001|YN001 will be administrated intravenous by single ascending dose, multiple ascending doses weekly or twice a week.
62476375|NCT03563872|EXPERIMENTAL|Intervention|Enhanced team-based care
61921835|NCT05547971||No Radiation Encephalopathy Group|Patients without radioactive encephalopathy during follow-up
61921836|NCT00879931|EXPERIMENTAL|1|methylprednisolone
61921837|NCT00879931|PLACEBO_COMPARATOR|2|Placebo (NaCl 0.9%)
62476376|NCT03644147|EXPERIMENTAL|Treatment|Patients in this group will receive 1 gram of acetaminophen intravenously after the end of surgery.
62476377|NCT03644147|NO_INTERVENTION|Control|Patients in this group will receive 100 ml of normal saline intravenously after the end of surgery.
62476378|NCT05672030||Aspirin-exacerbated respiratory disease (AERD)|Aspirin-exacerbated respiratory disease (AERD)
62476379|NCT05672030||Aspirin-tolerant chronic rhinosinusitis with nasal polyps (CRSwNP)|Aspirin-tolerant chronic rhinosinusitis with nasal polyps (CRSwNP)
62476380|NCT05672030||Healthy controls|Individuals who do not have AERD or CRSwNP
62495941|NCT05756218|EXPERIMENTAL|Experiment|Obtaining Consent, Demographic Information Form, Teaching Material Motivation Scale and Nursing Diagnosis Perception Scale face-to-face filling Playing the game with nursing diagnosis taboo cards prepared on the day of no practice for 7 weeks
62495942|NCT05756218|NO_INTERVENTION|Control|Obtaining Consent, Demographic Information Form, Teaching Material Motivation Scale and Nursing Diagnosis Perception Scale face-to-face filling Continuing the application as in the curriculum for 7 weeks
62495943|NCT01424787||OsvaRen treatment|Dialysis patients on OsvaRen treatment
62476381|NCT05829824|EXPERIMENTAL|CareConnect (Intervention)|Participants will receive automated 'CareConnect' calls/SMS text at enrollment. The call protocol will include up to 2 calls on 2 consecutive days if no response to the first call. If there is no response to call, a follow up SMS 3-4 days later. Each CareConnect contact will include (1) assessment, (2) motivational enhancement tailored to participants' tobacco use status and importance of quitting; and (3) multiple referral options (UCSF Fontana Tobacco Treatment Center (FTTC)/tobacco treatment specialist, Quitline, or smokefreeTXT from smokefree.gov), offered after the motivational enhancement message. CareConnect will notify the UCSF tobacco treatment specialist of participants acceptance of any of the referral options. Referral options will be documented by the specialist on the participants electronic health record (EHR). All participants who have completed the CareConnect call will be contacted by research staff for a 3-month survey to be completed online or by telephone.
62476382|NCT05829824|OTHER|AutoReach (Control)|Participants will receive automated AutoReach calls/Short Message Service (SMS) text at enrollment provides one referral option (speaking with a tobacco treatment specialist) and an option for sending information on cessation resources. All participants who have completed the AutoReach call will be contacted by research staff for a 3-month survey to be completed online or by telephone.
62476383|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
62476384|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected."
62476385|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
62476386|NCT02926677|EXPERIMENTAL|Cue-Centered Therapy (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
62476387|NCT02926677|EXPERIMENTAL|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
62495944|NCT03944109|EXPERIMENTAL|SHR-1209|Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
62681134|NCT06048588|PLACEBO_COMPARATOR|Part I-Matching placebo for YN001|Matching placebo for YN001 will be administrated intravenous.
62681135|NCT06048588|ACTIVE_COMPARATOR|Part II-Rosuvastatin calcium tablets|Rosuvastatin calcium tablets will be given by orally.
62681136|NCT05936138|EXPERIMENTAL|LY3502970 (Control)|LY3502970 administered orally to participants with normal renal function
62681137|NCT05936138|EXPERIMENTAL|LY3502970 (Severe Renal Impairment)|LY3502970 administered orally to participants with severe renal impairment
62681138|NCT05936138|EXPERIMENTAL|LY3502970 (End-Stage Renal Disease)|LY3502970 administered orally to participants with end-stage renal disease (ESRD)
62681139|NCT06691841|OTHER|Normal Saline Group|oral wiping and oral care solution rinsing, oral care solution was 0.9% normal saline, and oral care frequency was 3 times a day.
62681140|NCT06691841|EXPERIMENTAL|Chlorhexidine group|oral wiping and oral care solution rinsing, oral care solution was 0.12% Chlorhexidine gluconate solution, and oral care frequency was 3 times a day.
62681141|NCT06688643|EXPERIMENTAL|ITM group|Patients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room.
62681142|NCT06688643|EXPERIMENTAL|EA group|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.
62310584|NCT06105957|EXPERIMENTAL|Core+Facilitated Weekly Group Sessions+Pre-Scripted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement."
61921838|NCT04862858|ACTIVE_COMPARATOR|Intervention|The educational outreach intervention will entail a multi-faced strategy to provide patients resources to learn more about reducing their risk for heart disease and supporting providers in the care of their patients by sharing recent guideline-recommended treatments for these high-risk individuals.
61921839|NCT04862858|NO_INTERVENTION|Control|Patients and primary care providers randomly selected and assigned to the control arm will not receive any of the educational outreach communications.
62310585|NCT06105957|EXPERIMENTAL|Core+Facilitated Weekly Group Sessions+Pre-Scripted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
61921840|NCT01412918|EXPERIMENTAL|Tinnitus|"Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device."
61921841|NCT01412918|NO_INTERVENTION|No tinnitus|Individuals without tinnitus will also be masked with the device.
62476388|NCT02926677|EXPERIMENTAL|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
61921842|NCT00708201|EXPERIMENTAL|Alvimopan|"12 milligrams (mg)~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment"
61921843|NCT00708201|PLACEBO_COMPARATOR|Placebo|"300 mg polyethylene glycol in a capsule~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery."
61921844|NCT05254054|EXPERIMENTAL|Vibration group|Participants in Vibration group will receive an 8-week whole body vibration training in addition to conventional exercise training.
61921845|NCT05254054|ACTIVE_COMPARATOR|Control group|Participants in Vibration group will only receive conventional exercise training.
61921846|NCT06311552||CMR scan on either a 1.5- or 3-Tesla scanner|
62476389|NCT05785832|EXPERIMENTAL|Intervention group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the Intervention group using t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM for 13 weeks.
62681143|NCT02775656||Prospective cohort|For a pregnancy to be enrolled in the prospective cohort, the pregnancy outcome cannot be known (ie, no prenatal diagnosis of a fetus with a congenital defect and the pregnancy is still ongoing at the time of consent).
61921847|NCT03449238|OTHER|Pembrolizumab and SRS|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
61921848|NCT01954420|OTHER|Attention Control|"Standard care + cancer education~Participants receive a single session with a research nurse to discuss the importance of understanding cancer and cancer treatment strategies, and to introduce educational recordings available on an MP3 player. The educational recordings provide a selection of publicly available American Cancer Society patient information materials addressing topics related to cancer and cancer treatment strategies. Participants are asked to listen to at least one recording per day, or more frequently as desired."
61921849|NCT01954420|EXPERIMENTAL|Cognitive-Behavioral Intervention|"Standard care + Patient-Controlled Cognitive Behavioral Intervention~Participants will receive a single training session with a research nurse including: 1) Information about the causes of cancer-related pain, fatigue, and sleep disturbance. 2) An explanation of how cognitive-behavioral interventions may affect symptoms. 3) Review of the specific cognitive-behavioral strategies provided on the MP3 player. 4) Individualized recommendations for using the cognitive-behavioral strategies. The nurse interventionist and patient will develop a written plan for practicing the strategies with recommendations to use a strategy at least once a day, or more frequently as needed."
61921850|NCT03338309||iFR-guied strategy group|1,200 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, non ST-segment elevation MI, or ST-segment elevation MI with non-culprit stenosis who underwent iFR measurement and enrolled at 5 centers in Republic of Korea.
61921851|NCT05784961|EXPERIMENTAL|Active transcranial direct current stimulation (active tDCS)|The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the L DLPFG and the cathode over the left temporo-parietal junction (L TPJ)
61921852|NCT05784961|PLACEBO_COMPARATOR|Sham tDCS|"Sham Comparator: sham transcranial direct current stimulation tDCS device allows sham stimulation. tDCS device sham technology allows optimum placebo stimulation via the same stimulation impresssion than active stimulation.~Electrode placement is the same than the active arm"
61921853|NCT04783142|OTHER|High-fiber, low-protein diet|Participants will consume a high-fiber, low-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
61921854|NCT04783142|OTHER|Low-fiber, high-protein diet|Participants will consume a low-fiber, high-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
61921855|NCT04291261|OTHER|Extracorporeal photopheresis (ECP) with Uvadex|Patients in this single Arm study all receive the intervention consisting of ECP with Uvadex plus the standard of care treatment which consists of systemic corticosteroids 2mg/kg. Response to treatment will be evaluated on day 28. Patients will receive study treatment till day 56 and thereafter be followed until 1 year.
61921856|NCT04176887|EXPERIMENTAL|Levetiracetam|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
61921857|NCT04176887|ACTIVE_COMPARATOR|Phenytoin|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
61921858|NCT01178827|EXPERIMENTAL|Sanctura XR®|Sanctura XR® (trospium chloride), 60mg once daily for 10 days
61921859|NCT01178827|ACTIVE_COMPARATOR|Oxybutynin IR|Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days
61921860|NCT01178827|PLACEBO_COMPARATOR|Oxybutynin IR placebo|Oxybutynin IR placebo three times daily for 2 days
61921861|NCT03230305||Elderly cancer patient cohort|"* Aged 70 years or over~* With solid cancer irrespective of the stage~* Pre-screened or screened for at least one ongoing clinical trial in the center~* Informed oral consent (patient, his/her legal representant, trustworthy person or family member)~* Social security affiliation"
61921862|NCT05999942|EXPERIMENTAL|Amikacin Liposome Inhalation|Participants will receive a single dose of radiolabelled amikacin loaded liposomes by inhalation on Day 1.
61921863|NCT00439465|OTHER|Ex-vivo expanded effector cells|Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)
62681144|NCT02775656||Retrospective cohort|For a pregnancy to be enrolled in the retrospective cohort, the pregnancy outcome must already be known (ie, a congenital defect has already been identified at the time of consent into the pregnancy follow-up study, or the pregnancy has been completed at the time of consent).
62476390|NCT05785832|ACTIVE_COMPARATOR|Control group|Continuation of pre-study basal-bolus insulin delivery method, plus use of study CGM (Dexcom G6).
62476391|NCT00872092||Breath test|Subjects with suspected SBBO
62681145|NCT06643689|EXPERIMENTAL|Tranilast Treatment Group|Participants in this group will receive Tranilast for the prevention of stricture after cESD of superficial esophageal tumors.
61921864|NCT03445182|ACTIVE_COMPARATOR|Control group|Local anaesthesia with conventional syringe
61921865|NCT03445182|ACTIVE_COMPARATOR|DentalVibe group|Local anaesthesia with conventional syringe + DentalVibe
62476392|NCT00426647|EXPERIMENTAL|Buprenorphine|Norspan transdermal patch
62476393|NCT00426647|ACTIVE_COMPARATOR|Tramadol|Tramadol SR tablets
62476394|NCT06318130|ACTIVE_COMPARATOR|Fixed helix, lumenless pacing lead (FHL)|Lumenless leads used are fixed helix pacing leads (SelectSecure 3830 pacing lead from Medtronic) during the LBBP procedure.
62476395|NCT06318130|ACTIVE_COMPARATOR|Extendable helix, stylet-driven leads (EHL)|Stylet-driven leads used are extendable helix pacing leads (Biotronik Solia S60 lead from Biotronik or Tendril STS pacing lead from St. Jude Medical) during the LBBP procedure.
62681146|NCT06643689|ACTIVE_COMPARATOR|Steroid Treatment Group|Participants in this group will receive steroids for the prevention of stricture after cESD of superficial esophageal tumors.
62681147|NCT06676982|EXPERIMENTAL|Treatment group|CNCT19
62681148|NCT06686927|EXPERIMENTAL|Corticosteroids combined with immunoglobulin and romiplostim|"Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.~IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.~Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month."
62681149|NCT02767687|EXPERIMENTAL|Noninvasive ventilation (NIV)|Noninvasive mechanical ventilation is a resource used to treat respiratory failure or to reestablish respiratory comfort and function. It is commonly used in the ICU with a regular mechanical ventilator and is offered using an interface that connects the machine to the patient. The interface used for adults and in this study, was a silicon facial mask that covers the nose and mouth of the patient, allowing him or her to open the eyes.
62681150|NCT06110871|EXPERIMENTAL|Working Group 1(inhaled lavender)|In study group 1, 3 drops of lavender oil will be dropped on aromastone and participants will be asked to inhale deeply 10 times. Then, participants will be allowed to inhale lavender oil for a total of 30 minutes in the waiting room where aromastone is located and in the ria application room.
62681151|NCT06110871|EXPERIMENTAL|Working Group 2: Focusing|"After the internet connection is established with the smartphone, you can click on www.youtube.com and watch the Relaxation Project 1 (SBS VR) video for the image and ask to focus."
62681152|NCT06110871|EXPERIMENTAL|Working Group 3 music|You will be able to listen to Turkish classical music for a total of 30 minutes in the RIA application waiting room and RIA application room.
62681153|NCT06110871|NO_INTERVENTION|Control Group|The care and practices will be the same as in routine IUD application.
62681154|NCT04058756|EXPERIMENTAL|PDR001|All subjects in all combination will be entered in one arm
62681155|NCT03867084|EXPERIMENTAL|Pembrolizumab|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle for up to 17 cycles.
62121838|NCT06472206|EXPERIMENTAL|Intervention CHAMPS+|Participants randomized to intervention will receive the CleverCap pill bottle, an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp. Additionally, participants will receive 10-12 sessions with CHWs, and sexual health log to keep track of their sexual behavior.
62121839|NCT06347640|ACTIVE_COMPARATOR|Induced bleeding group|revascularization of mature necrotic permanent teeth treated by induced bleeding though apex of the tooth
62121840|NCT06347640|EXPERIMENTAL|Platelet-rich fibrin (PRF) group|revascularization of mature necrotic permanent teeth treated using platelet-rich fibrin (PRF)
62121841|NCT04825366|ACTIVE_COMPARATOR|Standard educational program|Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.
62121842|NCT04825366|ACTIVE_COMPARATOR|Standard educational program combined with high intensity interval training|"Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.~Each study participant will be asked to train 3 times per week following the home-based program that will be provided to them. Participants will be asked to perform at least 2 training sessions per week with the exercise specialist on a virtual platform. The training session will consist of a 3 to 5-minute low-intensity warm-up followed by 6 to 12 1-minute bouts of high-intensity exercise interspersed with 1-minute bouts of low-intensity exercise. Each session will end with a 3-minutes cool-down period."
62121843|NCT02872753|EXPERIMENTAL|ACP GROUP|Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)
62121844|NCT02872753|OTHER|CONTROL GROUP|Patients will be treated by standard meniscectomy alone (medial or lateral)
62121845|NCT04360057|OTHER|Hand Hygiene education|
62121846|NCT04949581|EXPERIMENTAL|bioelectric therapy|patients will receive micro-current electrical stimulation three times/week for four weeks
62121847|NCT04949581|ACTIVE_COMPARATOR|cardiac rehabilitation programe|patients will receive a cardiac rehabilitation program three times/week for four weeks
62121848|NCT03668288||PID patients|Adults with primary or secondary immunodeficiency for whom human immunoglobulin-assisted recombinant human hyaluronidase treatment is initiated
62121849|NCT02949206|EXPERIMENTAL|Part 1: Cohort 1 (0.03 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.03 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching placebo on Day 1.
62121850|NCT02949206|EXPERIMENTAL|Part 1: Cohort 2 (0.1 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.1 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
62310586|NCT06105957|EXPERIMENTAL|Core+Facilitated Weekly Group Sessions+Counselor Crafted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message."
62681156|NCT03867084|PLACEBO_COMPARATOR|Placebo|Participants receive IV placebo on Day 1 of each 21-day cycle for up to 17 cycles.
62681157|NCT06558214|EXPERIMENTAL|Arm 1: Optune GIO® pre-MLA; MLA; followed by Optune GIO® + Pembrolizumab post MLA|Patients randomized to treatment arm 1 will start treatment with Optune GIO® for 3-7 days and undergo MLA and biopsy for tumor diagnosis and immune monitoring. Treatment with Optune GIO® will be paused prior to the MLA procedure until at least 10 days post MLA. Patients will then resume treatment with Optune GIO® and receive pembrolizumab 200 mg IV every 3 weeks (+/- 4 days) starting no sooner than 1 week after the start of Optune GIO®.
62476396|NCT01477476|ACTIVE_COMPARATOR|Active Treatment|14 subjects with receive active treatment with Anakinra.
62121851|NCT02949206|EXPERIMENTAL|Part 1: Cohort 3 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.3 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
62121852|NCT02949206|EXPERIMENTAL|Part 1: Cohort 4 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
62681158|NCT06558214|EXPERIMENTAL|Arm 2: Optune GIO®+Pembrolizumab pre-MLA; MLA; followed by Optune GIO® + Pembrolizumab post MLA|Patients randomized to treatment arm 2, will start treatment with Optune GIO® for 3-10 days and receive one infusion of pembrolizumab before undergoing MLA/biopsy. Patients will resume Optune GIO® no earlier than 10 days post-surgery and receive pembrolizumab 200 mg IV every 3 weeks (+/- 4 days) starting no sooner than 1 week after the start of Optune GIO®.
62681159|NCT02416388|EXPERIMENTAL|R1-IDA|Idarubicin
62681160|NCT02416388|ACTIVE_COMPARATOR|R1-DAUNO|Daunorubicin
62681161|NCT02416388|ACTIVE_COMPARATOR|R2-HDAC|High dose cytarabine
62476397|NCT01477476|PLACEBO_COMPARATOR|Placebo|7 subjects will receive the placebo comparator.
62476398|NCT01972386||Spectrum Image Analysis|
62476399|NCT03657550|OTHER|Test Drug - Reference Product - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
62681162|NCT02416388|EXPERIMENTAL|R2-IDAC|Intermediate dose cytarabine
62681163|NCT02416388|ACTIVE_COMPARATOR|R3-MAC-MTX|Methotrexate and mycophenolic acid
62681164|NCT02416388|EXPERIMENTAL|R3-MAC-MPA|Cyclosporine and mycophenolic acid
62681165|NCT02416388|ACTIVE_COMPARATOR|R3-RIC-CICLO|Cyclosporine
62121853|NCT02949206|EXPERIMENTAL|Part 1: Cohort 5 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
62121854|NCT02949206|EXPERIMENTAL|Part 1: Cohort 6 (5.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
62121855|NCT02949206|EXPERIMENTAL|Part 1: Cohort 7 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
62121856|NCT02949206|EXPERIMENTAL|Part 1: Cohort 8 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
62495945|NCT03944109|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
62495946|NCT05013619||adolescent cerebral palsy|Demographical data, the subtypes of CP, Gross Motor Functional Classification System level, circumstances of pain, pain questionnaire will be analyzed.
62681166|NCT02416388|EXPERIMENTAL|R3-RIC-MPA|Cyclosporine and mycophenolic acid
62681167|NCT02416388|EXPERIMENTAL|R4-VOS-IDAC|Intermediate dose cytarabine and vosaroxin
62681168|NCT02416388|ACTIVE_COMPARATOR|R4-IDAC (without VOS)|Intermediate dose cytarabine alone
62681169|NCT02416388|EXPERIMENTAL|R4-DEX-HDAC|High dose cytarabine and dexamethasone
62681170|NCT02416388|ACTIVE_COMPARATOR|R4-HDAC (without DEX)|High dose cytarabine alone
62681171|NCT02416388|EXPERIMENTAL|R4-VEN-IDAC|Intermediate dose cytarabine and venetoclax
62681172|NCT02416388|ACTIVE_COMPARATOR|R4-IDAC (without VEN)|Intermediate dose cytarabine alone
62681173|NCT02934217|EXPERIMENTAL|Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
61921866|NCT06488105|EXPERIMENTAL|Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) arm|In the EMERALD arm, care will vary by risk level: (1) patients with known atherosclerotic cardiovascular disease (ASCVD) will qualify for a high-intensity statin (rosuvastatin 40 mg daily) and referral to cardiology for secondary prevention, (2) patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL will receive a high-intensity statin and a cardiology referral for primary prevention, and (3) for the remaining patients, Emergency Department providers will calculate 10-year ASCVD risk using the Pooled Cohort Equations. These patients will be categorized as (3A) high risk patients (10-year risk ≥20%) who will receive a high-intensity statin and a cardiology referral and (3B) moderate risk patients (10-year risk ≥7.5% but \<20% or those with known diabetes and 10-year risk \<20%) who will receive a moderate-intensity statin (rosuvastatin 10 mg daily) and a primary care referral. EMERALD patients will also receive healthy lifestyle counseling.
61921867|NCT06488105|ACTIVE_COMPARATOR|Usual Care Arm|Patients in the usual care arm will receive the current standard of care, which consists of primary care referral and no Emergency Department statin prescription. They will also receive healthy lifestyle counseling.
61921868|NCT00702572|EXPERIMENTAL|1|Phase I dose escalating scheme
61921869|NCT00702572|EXPERIMENTAL|2|Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
62310587|NCT06105957|EXPERIMENTAL|Core+ Counselor Crafted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
61921870|NCT02392845|EXPERIMENTAL|Combination of Docetaxel (DTX) and Epirubicin (EPI)|
61921871|NCT01905111|EXPERIMENTAL|BI 853520|BI 853520 once daily in a dose escalation schedule
62310588|NCT06105957|EXPERIMENTAL|Core+ Counselor Crafted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message."
61921872|NCT01376531||acute renal failure|patients at intensive care unit with definition of acute renal failure and the need for continuous veno-venous hemodialysis
61921873|NCT02873403|EXPERIMENTAL|KNEEMO knee brace & Popular knee brace|Patients having medial knee osteoarthritis
62121857|NCT02949206|EXPERIMENTAL|Part 2: Reversal Cohort :(50 IU/kg of 4-factor PCC)|Participants will receive a 2.5 mg/kg of JNJ-64179375 or highest tolerable dose if lower than 2.5 mg/kg followed by administration of a single IV 50 International Unit per kilogram (IU/Kg) dose of a 4 factor prothrombin complex concentrate (PCC) or matching placebo on Day 1.
62476400|NCT03657550|OTHER|Reference Product - Test Drug - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
61921874|NCT02873403|EXPERIMENTAL|Popular knee brace &KNEEMO knee brace|Patients having medial knee osteoarthritis
61921875|NCT01911637|EXPERIMENTAL|VBY-036|VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
61921876|NCT01911637|PLACEBO_COMPARATOR|Placebo|Placebo
61921877|NCT00792831|EXPERIMENTAL|ITF2357|ITF2357 was supplied as hard gelatine capsules for oral administration at the strength of 100 or 50 mg. Patients had to receive ITF2357 100 mg x 2/die at 12-hour intervals, in fed conditions, for three consecutive months.
61921878|NCT03494348|NO_INTERVENTION|Cruciate Retaining Polyethylene (CR)|This is the standard Polyethylene articular surface
61921879|NCT03494348|ACTIVE_COMPARATOR|Medial Congruent Polyethylene (MC)|The intervention here will be the MC articular surface. This is the new Polyethylene articular surface with a more congruent medial side and a more flat lateral side which should better resemble natural anatomy.
61921880|NCT04300543||Group 1 MS patients|patients with multiple sclerosis
61921881|NCT04300543||Group 2 patients with other neurological disorders|patients with inflammatory or non inflammatory neurological diseases other than multiple sclerosis
61921882|NCT04300543||Group 3 healthy control|No neurological or immunological disease
61921883|NCT05002153|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|FMT capsules administration - intervention arm
62121858|NCT02949206|EXPERIMENTAL|Part 3: Subcutaneous Cohort (1.0 mg/kg of JNJ-64179375)|Participants will receive a Single Subcutaneous (SC) dose of 1.0 mg.kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching placebo on Day 1.
62121859|NCT06676969||Low flow|Low flow Anestesia
62121860|NCT06676969||High Flow|High Flow Anestesia
62681174|NCT02934217|PLACEBO_COMPARATOR|Control|one single intravenous bolus injection of Placebo Echocardiography
62310589|NCT06105957|EXPERIMENTAL|Core+Pre-Scripted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
62476401|NCT01294787|EXPERIMENTAL|indacaterol and glycopyrronium bromide (QVA149)|QVA149 delivered once daily via single-dose dry powder inhaler.
62681175|NCT06687005||Smokers with stage 3 periodontitis|
62681176|NCT06687005||Non-smokers with stage 3 periodontitis|
62681177|NCT06687005||Healthy Participant|
62681178|NCT04191135|EXPERIMENTAL|Pembrolizumab + Olaparib|This arm includes participants who randomized following completion of the induction period. After the induction period, participants received pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
62681179|NCT04191135|EXPERIMENTAL|Pembrolizumab + Carboplatin + Gemcitabine|This arm includes participants who randomized following completion of the induction period. Participants continued to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m\^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
62681180|NCT06497946|ACTIVE_COMPARATOR|SlimTrack|Use of the SlimTrack Plataform
62681181|NCT06497946|ACTIVE_COMPARATOR|SlimTrack + Diet Prescription|Use of the SlimTrack Plataform + diet prescription
62681182|NCT06497946|ACTIVE_COMPARATOR|Diet Prescription|Use of Diet Prescription
62681183|NCT06497946|NO_INTERVENTION|Controll|Tips for health with delivery of graphic material
62681184|NCT05786196|ACTIVE_COMPARATOR|iTrack Advance|Ab-interno canaloplasty utilizing the iTrack Advance microcatheter device (Nova Eye, Inc.)
62681185|NCT05786196|ACTIVE_COMPARATOR|OMNI Surgical System|Ab-interno canaloplasty utilizing the OMNI Surgical System
62681186|NCT06313957|EXPERIMENTAL|Each subject will receive LUCAR-20SP cells|Chimeric antigen receptor T cells LUCAR-20SP cells
62681187|NCT02466997|EXPERIMENTAL|Tacrolimus group|Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
62681188|NCT02466997|PLACEBO_COMPARATOR|Control group|"In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.~Counselling on natural light exposure during the duration of the trial will be given."
62681189|NCT04874961|EXPERIMENTAL|Standardized olive extract (Tensiofytol®)|3 capsules/day during dinner Per day: 334 mg olive leave dry extract and 106 mg olive fruit dry extract (Olea europaea L.), equivalent to 100 mg oleuropein and 20 mg hydroxytyrosol
62121861|NCT05485389|EXPERIMENTAL|Study group|At the beginning, knowledge test, individualized care perception and attitude scale to the elderly will be applied to the participants in the pre-test. Then, 6-hour theoretical course on the care of the elderly patient will be given to the participants included in the study. After the theoretical course, the knowledge test will be re-applied. After that, experience will be provided within the scope of first, second and third level simulation-based learning, one week apart. After the simulation experiences knowledge test, individualized care perception and attitude scale to the elderly will be applied to the participants in the post-test 1. Post-tests will be administered in the first (Post-test 2) and third (Post-test 3) months of the simulation experience.
62476402|NCT01294787|PLACEBO_COMPARATOR|placebo|Placebo, delivered once daily via single-dose dry powder inhaler.
62681190|NCT04874961|PLACEBO_COMPARATOR|Placebo|3 capsules/day during dinner
62681191|NCT06682000|EXPERIMENTAL|DWC202404 + DWC202314|
62681192|NCT06682000|PLACEBO_COMPARATOR|DWC202404 + DWC202314P|
62681193|NCT06082960|EXPERIMENTAL|Part A: GS-9911 Monotherapy Dose Escalation|Participants will receive escalating doses of GS-9911 monotherapy.
61921884|NCT05002153|PLACEBO_COMPARATOR|Placebo|Placebo capsules administration
62476403|NCT01294787|ACTIVE_COMPARATOR|tiotropium|Tiotropium delivered once daily via HandiHaler® device.
62681194|NCT06082960|EXPERIMENTAL|Part B: GS-9911 Monotherapy Dose Expansion|Participants will receive GS-9911 monotherapy at the recommended dose for expansion (RDE) determined in Part A.
62681195|NCT06082960|EXPERIMENTAL|Part C: Dose Escalation: GS-9911 + Anti-PD-1 Monoclonal Antibody|Participants will receive escalating doses of GS-9911 in combination with an anti-PD-1 monoclonal antibody (zimberelimab).
62681196|NCT06082960|EXPERIMENTAL|Part D: Dose Expansion: GS-9911 + Anti-PD-1 Monoclonal Antibody|Participants will receive GS-9911 at RDE determined in Part C in combination with an anti-PD-1 monoclonal antibody (zimberelimab).
62681197|NCT01064648|EXPERIMENTAL|Arm I (pemetrexed disodium, cisplatin, cediranib maleate))|Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
62681198|NCT01064648|ACTIVE_COMPARATOR|Arm II (pemetrexed disodium, cisplatin, placebo)|Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
62681199|NCT01633385||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
62681200|NCT01633385||Control Group|age- and sex matched to subject-group
61921885|NCT06421818|EXPERIMENTAL|Colonic TET treatment group|Baitouweng Decoction is administered through the colonic TET.
61921886|NCT06421818|PLACEBO_COMPARATOR|Colonic TET placebo group|The same volume of placebo as the colonic TET treatment group was administered through the colonic TET.
61921887|NCT06421818|ACTIVE_COMPARATOR|Rectal enema group|Baitouweng Decoction is administered through rectal enema.
61921888|NCT06421818|ACTIVE_COMPARATOR|Oral group|Baitouweng Decoction is administered through oral.
61921889|NCT01429038|EXPERIMENTAL|MSC Liver Transplantation|Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2
61921890|NCT01429038|EXPERIMENTAL|MSC Kidney Transplantation|Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2.
61921891|NCT03751774|EXPERIMENTAL|MAMAACT|Training of midwives in intercultural communication. A 6 hours course and 2 one hour booster sessions. Distribution of health education materials on warnings signs of pregnancy and health system navigation to pregnant women during antenatal care visits.
61921892|NCT03751774|NO_INTERVENTION|Control|Care as usual
61921893|NCT05953714|EXPERIMENTAL|CHLORHEXIDINE GLUCONATE GROUP|Section area is cleaned with preoperative application chlorhexidine gluconate
61921894|NCT05953714|NO_INTERVENTION|POVIDONE IODINE GROUP|Section area is cleaned with preoperative application povidone iodine
62681201|NCT06287853||Partial Thickness Tear|Patient with a diagnosis of a symptomatic primary partial-thickness tear of the supraspinatus and/or infraspinatus tendons amenable to repair.
61921895|NCT05953714|EXPERIMENTAL|CHLORHEXIDINE GLUCONATE SHOWER GROUP|Section area is cleaned with preoperative application chlorhexidine gluconate shower
61921896|NCT02105818||Systemic sclerosis|Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland (European Centre for the Rehabilitation of Scleroderma).
61921897|NCT01214148|OTHER|ORSIRO|
61921898|NCT01372982|ACTIVE_COMPARATOR|Femara|
61921899|NCT01372982|EXPERIMENTAL|Letrozole|
61921900|NCT05408468|EXPERIMENTAL|FAMCOPE-ICU|A digital eHealth emotion regulation and coping intervention.
61921901|NCT05408468|NO_INTERVENTION|Usual Care|The care and support routinely provided to SDMs of critically ill patients.
61921902|NCT02942576|EXPERIMENTAL|Edoxaban-based regimen|Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
61921903|NCT02942576|ACTIVE_COMPARATOR|VKA-based regimen|VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
61921904|NCT03905070||Study Group|The study group consisted of people who had undergone bariatric surgery and who had at least 6 months after the operation.
61921905|NCT03905070||Control Group|The control group will consist of asymptomatic individuals whose BMI is 18-25 kg / m2 and has not participated in any exercise program in the last one year.
61921906|NCT01565499|EXPERIMENTAL|Nab-Paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
62476404|NCT04045925|EXPERIMENTAL|Taïso practice|6 months of biweekly practice Taïso
61921907|NCT05271708|EXPERIMENTAL|Fespixon cream|Fespixon cream contains 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%) with appearance in yellow-green to light green color. Fespixon cream will be applied twice daily for up to 12 weeks to the linear wound.
61921908|NCT05271708|PLACEBO_COMPARATOR|Placebo Cream|Placebo cream with appearance in yellow-green to light green color, same appearance as Fespixon cream, will be applied twice daily for up to 12 weeks to the linear wound.
61921909|NCT03830177|EXPERIMENTAL|Adults|All adults in the study will receive the treatment for dry scalp.
61921910|NCT03830177|EXPERIMENTAL|Children|All children in the study will receive the treatment for dry scalp.
61921911|NCT06143605||salvage treatment group|patients with salvage treatment after endoscopic resection were diagnosed as having positive resection margin status
61921912|NCT06143605||without salvage treatment group|patients without salvage treatment after endoscopic resection were diagnosed as having positive resection margin status
62495947|NCT05013619||adolescent cerebral palsy's mother|pain questionnaire will be analyzed.
62310590|NCT06105957|EXPERIMENTAL|Core+Pre-Scripted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement."
62310591|NCT03575468|EXPERIMENTAL|Enhanced E-cigarette Coaching (EEC)|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
62310592|NCT03575468|ACTIVE_COMPARATOR|Quitline treatment as usual (TAU)|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
62310593|NCT05687760|ACTIVE_COMPARATOR|calcium hydroxide arm|intracanal medication of calcium hydroxide paste
62310594|NCT05687760|EXPERIMENTAL|bromelain arm|intracanal medication of bromelain paste (Bromelain powder with enzymatic activity of 2400 Gelatin digestion unit per Gram was mixed with saline in 1:1 proportion 1 g powder was mixed with 1 ml distilled water)
62310595|NCT06007170|EXPERIMENTAL|Treatment Group|SPIRION Laryngeal Pacemaker System Implantation and follow-up
62310596|NCT05821504|EXPERIMENTAL|Plyometric High-Intensity Interval Training|This group performed high-intensity interval training consisting of body-weight, plyometric exercises involving jumping.
62310597|NCT05821504|EXPERIMENTAL|Cycling High-Intensity Interval Training|This group performed high-intensity interval training consisting of cycling exercise.
62310598|NCT02482220|EXPERIMENTAL|High intensity|in this group, the participants will follow a high intensity physical activity program (High Intensity Interval exercise from 75 to 95% VO2max)
62310599|NCT02482220|EXPERIMENTAL|Moderate intensity|in this group, the participants will follow a moderate intensity physical activity program (Intensity from 50 to 65% VO2max)
62310600|NCT04561388|OTHER|Cochlear implant candidates with measurable residual hearing|"Electrocochleography responses to acoustic will be recorded during the cochlear implantation and the 6 first months of use of the cochlear implant.~A pure tone audiometry will be done prior and after the implantation. Speech audiometry will be done twice after the cochlear implantation."
62310601|NCT04693247|ACTIVE_COMPARATOR|Refraction with a Hand-held Refraction Device|This is the device that will be compared to a standard device.
62310602|NCT04693247|OTHER|Autorefractor|Standard Device
62681202|NCT06287853||Full Thickness Tear|Patient with a diagnosis of a symptomatic primary full-thickness tear of the supraspinatus and/or infraspinatus tendons amenable to repair.
61921913|NCT03201627|EXPERIMENTAL|treatment|
61921914|NCT05637658|NO_INTERVENTION|control group|No application will be made to the participants in the control group.
62476405|NCT02701556|EXPERIMENTAL|Bausch & Lomb (B&L) NNR06 Multi-Purpose Solution (MPS)|B \& L investigational NNR06 used as a rub care regimen (Test)
62681203|NCT05931965|NO_INTERVENTION|Antidepressant|Participants receive either escitalopram 10-20mg, sertraline 50-100mg, fluoxetine 20-40mg, duloxetine 30-60mg, mirtazapine 15-30mg, venlafaxine 75-150mg, trazodone 50-100mg, amitriptyline 25-75mg, or clomipramine 25-75mg orally daily for 4 weeks.
62681204|NCT05931965|EXPERIMENTAL|Antidepressant and L-methylfolate|Participants receive a combination of antidepressant and L-methylfolate 400µg twice daily orally for 4 weeks
62681205|NCT05931965|EXPERIMENTAL|Antidepressant and injectable mecobalamin|Participants receive a combination of antidepressant and mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
62681206|NCT05931965|EXPERIMENTAL|Antidepressant and Magnesium|Participants receive a combination of antidepressant and magnesium glycinate 400mg (Elemental: ≈120mg) twice daily orally for 4 weeks
61921915|NCT05637658|EXPERIMENTAL|Exercise group|Participants will perform aerobic exercise 3 times a week at an intensity of 60-80% of age-adjusted maximal heart reserve on the treadmill and bicycle ergometer for 4 weeks.
61921916|NCT05644847|ACTIVE_COMPARATOR|Group A (Core Stability Training Group)|Participants in the control group/ core stability training group will be instructed to perform core stability exercises which will include pelvic bridge, straight leg bridge, modified kneeling with elbow support, and leg lifts and squats, with 60 seconds rest intervals between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets weekly. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises. A total of 12 sessions will be conducted over a period of 04 weeks.
62121862|NCT03994055|EXPERIMENTAL|Anti-inflammatory Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20-30%. Fat: 30-40%. Carbohydrates: 40-50%. The diet will be individualized according to the patients' comorbidities (obesity, type 2 diabetes, hypertension, renal insufficiency).~This group will include the consumption of foods that contain immune modulating nutrients:~Omega-3 fatty acids, antioxidants, soluble fiber, probiotics. The recommendation to include these foods will be made according to the patients' access to food in their home area."
62121863|NCT03994055|ACTIVE_COMPARATOR|Low residue Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20%. Fat: 20%. Carbohydrates: 60%. Diet will have lactose restriction, fiber restriction and fat restriction."
62121864|NCT01714882|EXPERIMENTAL|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
62310603|NCT05816356|EXPERIMENTAL|Modified release formulation of decitabine and tetrahydrouridine|A modified-release combination formulation of decitabine/THU (2.5 mg/100 mg per capsule given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
62310604|NCT05816356|ACTIVE_COMPARATOR|Immediate release capsules of decitabine and tetrahydrouridine|Capsules of THU are given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water, followed by a single oral dose of decitabine given 1 hour (± 5 min) later with approximately 240 mL (8 fluid ounces) of ambient temperature water.
62310605|NCT05197244|EXPERIMENTAL|Culinary Medicine Intervention|Participants will attend a 2-hour hands-on cooking class in additional to usual care.
62310606|NCT05197244|NO_INTERVENTION|Control|Participants will receive usual care.
62310607|NCT02952742|EXPERIMENTAL|Black Cohosh Therapy|Black Cohosh will be provided in 250mg capsules. Subjects will take 2 capsules by mouth daily for a total daily dose of 500 mg. Subject's will remain on this study arm for 8 weeks.
62310608|NCT02952742|PLACEBO_COMPARATOR|Placebo|Subjects will take 2 capsules, identical to the Black Cohosh capsules, by mouth each. Subject's will remain on this study arm for 8 weeks.
62310609|NCT06672094|EXPERIMENTAL|NeuroQ|Participants will be instructed to take two (2) capsules of NeuroQ every morning with or without food starting on Day 1. Clinic staff will instruct participants to save all unused and open packages and return them to KGK Science Inc. for a determination of compliance. If a dose is missed participants are instructed to re-start their regular dosing the next day and document the missed dose in their study diary. Participants will be advised not to exceed two capsules daily.
62310610|NCT06672094|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take two (2) capsules of placebo every morning with or without food starting on Day 1. Clinic staff will instruct participants to save all unused and open packages and return them to KGK Science Inc. for a determination of compliance. If a dose is missed participants are instructed to re-start their regular dosing the next day and document the missed dose in their study diary. Participants will be advised not to exceed two capsules daily.
62476406|NCT02701556|ACTIVE_COMPARATOR|COMPLETE MPS|B\&L Multi-Purpose Solution as a rub care regimen (Control)
62738568|NCT04409561||Interventions|This patient pool shall be representative of the US population in term of the relative proportion of race/ethnicities. In addition, the population shall be enriched with patients above 60 year old as the target population of the PSP test is mostly the elderly.
62738569|NCT06147128||Active Comparator: Traditional Trained|Trainees in the Traditional trained group will have an e-learning didactic component (specifically on the steps of the procedure, clinical aspects of the procedure, published evidence etc) which they must complete before training by a procedure expert. On completion of the e-learning module the trainees will complete a summative assessment of their knowledge. The trainees will then be shown how and then trained to perform an emergency scenario where open conversion is necessary due to vessel injury during robotic surgery task. The scenario will be demonstrated initially by an expert and who will then proctor the trainees in the same technique.
62121865|NCT01714882|ACTIVE_COMPARATOR|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
62121866|NCT01350804|EXPERIMENTAL|AIN457 10mg/kg - 75 mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
62310611|NCT04391868|ACTIVE_COMPARATOR|Viagra tablet|Subjects receive a single dose of 50 mg Viagra tablet followed by plasma sampling for 14 hours.
62310612|NCT04391868|EXPERIMENTAL|Sildenafil citrate ODF without water|Subjects receive a single dose of 50 mg sildenafil ODF without water followed by plasma sampling for 14 hours.
62310613|NCT04391868|EXPERIMENTAL|Sildenafil citrate ODF with water|Subjects receive a single dose of 50 mg sildenafil ODF with water followed by plasma sampling for 14 hours.
62310614|NCT06474793|ACTIVE_COMPARATOR|Aromatherapy Intervention Group-1|Participants in the Intervention-1 group will apply a 2 ml mixture of 3% chamomile and 3% lavender oil diluted with 2% jojoba oil, dropped into the palm and rubbed into the palm..
62310615|NCT06474793|ACTIVE_COMPARATOR|Aromatherapy Intervention Group-2|Participants in the intervention-2 group will use a mixture of 3% vetiver oil diluted with 2% jojoba oil by dropping 2 ml into the palm.
62310616|NCT06474793|PLACEBO_COMPARATOR|Aromatherapy Placebo Control Group|Participants in the placebo control group will apply by dropping 2 ml of jojoba oil.
62310617|NCT04988607|EXPERIMENTAL|osimertinib plus bevacizumab|Osimertinib 80 mg (QD) in combination with Bevacizumab (15 mg/kg) (Q3W)
62310618|NCT04988607|ACTIVE_COMPARATOR|osimertinib|All patients randomized into this will only receive Osimertinib 80mg (QD)
62121867|NCT01350804|EXPERIMENTAL|AIN457 10mg/kg - 150 mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
62310619|NCT04736810|EXPERIMENTAL|AK105 plus Gemcitabine and Anlotinib Hydrochloride|
62310620|NCT04278729|EXPERIMENTAL|Nephrotic Syndrome Arm|Patients diagnosed with Nephrotic syndrome will be in this arm.
62310621|NCT04278729|EXPERIMENTAL|Healthy Arm|Healthy volunteers will be in this arm.
62310622|NCT06661265||SCCHN patients undergoing to upfront surgery with flap reconstruction followed by adjuvant treatment|Head and Neck cancer patients undergoing to upfront surgery with flap reconstruction followed by radiotherapy or chemioradiotherapy at San Raffaele Hospital between December 2017-December 2022.
62310623|NCT04534894||DM group and DCM group|DM group: type 2 diabetes with normal diastolic function DCM group: type 2 diabetes with diastolic dysfunction
62310624|NCT05010681|EXPERIMENTAL|Lenvatinib plus Sintilimab|
62310625|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
62310626|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
62310627|NCT03533790|EXPERIMENTAL|DEP-Ru|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2 mg/kg days 1 to 5,then gradually reduce; ruxolitinib 0.3mg/kg/d。This regimen was repeated after 2 weeks.
62310628|NCT03068572||NERD group|45 GERD patients without obviously abnormality were examined by conventional white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system GERD patients with the absence of mucosal breaks at conventional endoscopy,and those patients was given standard or double dose of oral proton pump inhibitor (PPI) for 2 weeks to determine the efficacy of anti-secretory therapy (the so-called PPI test).The response to PPI treatment comprised the NERD group.
62310629|NCT03068572||Control group|45 control patients were examined by white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system,those subjects who had undergone endoscopy solely for the purpose of a health check-up at the same time of the study period
62310630|NCT06436313|EXPERIMENTAL|Educational Group|Patients will receive two extra virtual educational sessions.
62310631|NCT06436313|NO_INTERVENTION|Standard-of-Care|Patients will not receive any extra educational sessions. Their education will be provided as per standard-of-care by the clinical team.
62310632|NCT05717738||TACE-Len-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus lenvatinib (Len) and anti-PD-1 antibody as conversion therapy for downstaging.
62310633|NCT05717738||TACE-A-T cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab (A) and atezolizumab (T) as conversion therapy for downstaging.
62310634|NCT05717738||TACE-B-S cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab biosimilar (Byvasda, B) and Sintilimab (Tyvyt, S) antibody as conversion therapy for downstaging.
62310635|NCT05717738||TACE-Apa-C cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus Apatinib (Apa) and Camrelizumab (C) antibody as conversion therapy for downstaging.
62310636|NCT05717738||TACE-Sor-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus sorafenib (Sor) and anti-PD-1 antibody as conversion therapy for downstaging.
62310637|NCT05717738||TACE-Don-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus donafenib (Don) and anti-PD-1 antibody as conversion therapy for downstaging.
62310638|NCT05717738||TACE-Reg-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus regorafenib (Reg) and anti-PD-1 antibody as conversion therapy for downstaging.
62310639|NCT06672848|OTHER|esp block|After anesthesia and surgical procedures, an ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T5 level. After cleaning the area with povidone-iodine before the block, the T5 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. Once the location of the needle is confirmed, a mixture of 20 ml of 0.25% bupivacaine will be applied.
62476407|NCT02529709|EXPERIMENTAL|High-protein meal condition|
62476408|NCT02529709|ACTIVE_COMPARATOR|High-monounsaturated fat meal condition|
62476409|NCT00875823||PH Patients|"Patients with:~Primary Hyperoxaluria Type I Primary Hyperoxaluria Type II Primary Hyperoxaluria NonI-NonII"
62121868|NCT01350804|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (\>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
61921917|NCT05644847|EXPERIMENTAL|Group B (Whole body Vibration Training Group)|"Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training at 50 Hz frequency.~Participants will be instructed to perform 1-3 sets of 5-12 repetitions each of pelvic bridge, straight leg bridge, modified kneeling with elbow support, and leg lifts and squats on the WBV equipment, with a 60-second rest interval between each activity. The vibration speed and no. of sets and repetitions will be increased progressively. A total of 12 sessions will be conducted over a period of 04 weeks."
62476410|NCT05827991|EXPERIMENTAL|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser
62476411|NCT05827991|ACTIVE_COMPARATOR|Minoxidil|Minoxidil for external use
62476412|NCT05827991|ACTIVE_COMPARATOR|1565nm Non-ablative Fractional Laser combined with Minoxidil for external use|1565nm Non-ablative Fractional Laser combined with Minoxidil for external use
62476413|NCT03289065||FOS Participant|FOS is a disease registry open to all Fabry participants irrespective of treatment status or type of treatment.
62310640|NCT06672848|OTHER|paravertebral block|Following anesthesia and the surgical procedure, the needle will be advanced at an angle of 30-40° under ultrasonography guidance in the paramedian sagittal plane, lateral to the T5 spinos process, and entered into the location of the superior costotransverse ligament. The location of the serum and needle will be confirmed by hydrodissection without local anesthesia. Once the location of the needle is confirmed, a mixture of 20 ml of 0.25% bupivacaine will be applied.
62310641|NCT05910463|EXPERIMENTAL|AXOMOVE Therapy|Use of a web and mobile application for remote monitoring and rehabilitation
61921918|NCT01489371|EXPERIMENTAL|Treatment (EGEN-001, pegylated liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and EGEN-001 IP over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62310642|NCT05910463|NO_INTERVENTION|Routine care|Current rehabilitation support care
62310643|NCT06630832|ACTIVE_COMPARATOR|No cooling|Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 1:3 work-rest allocation, starting with a 45 min rest break followed by a 15 min work bout for an additional 180-min of work without cooling.
62476414|NCT05859425|EXPERIMENTAL|US-guided biofeedback intervention|This group received visual feedback using real-time ultrasound (US) for transversus abdominus (TrA) activation, while performing the exercise programme. US-guided TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until the user (health professional-investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation.
62681207|NCT01707446|ACTIVE_COMPARATOR|Near-infrared reflectance spectroscopy|Bilateral NIRS (The INVOS® Cerebral/Somatic Oximeter)will be used to measure rSO2 intraoperatively and during the 24h postoperative period in the intensive care unit. In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established.
62681208|NCT01707446|NO_INTERVENTION|Blinded Near-infrared reflectance spectroscopy|In the control group, the NIRS monitor screen will be electronically blinded, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in NIRS application and unaware of the study design.
62121869|NCT01350804|ACTIVE_COMPARATOR|Abatacept|Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).
62121870|NCT00381173|EXPERIMENTAL|1|
62121871|NCT05505799|ACTIVE_COMPARATOR|Preintervention|Normal clinician intubation process
62121872|NCT05505799|EXPERIMENTAL|Postintervention|Clinician intubation process after implementation and clinician education with a procedural checklist
62121873|NCT04618614|EXPERIMENTAL|HD-tDCS S1 1 mA|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
62121874|NCT04618614|ACTIVE_COMPARATOR|HD-tDCS M1 1 mA|Single session of 15-min HD-tDCS to the right primary motor cortex with an intensity of 1 mA. The session will last approximately one hour.
62121875|NCT04618614|SHAM_COMPARATOR|Sham control|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
62121876|NCT02162446|EXPERIMENTAL|68Ga-OPS202|Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
62121877|NCT06306313|EXPERIMENTAL|Experimental|Conventional physiotherapy will be applied in a single session of 45 minutes a day, 3 days a week for 4 weeks, and in addition, robot-assisted therapy will be applied with the ReoGo Upper Extremity Exoskeleton Robot in a single session of 60 minutes a day, 5 days a week for 4 weeks. Evaluations will be made at the beginning and end of the treatment process.
62681209|NCT05787119|EXPERIMENTAL|Group 1|2 weeks Conventional therapy / 1 month ARMT / 4 weeks Conventional therapy
62681210|NCT05787119|EXPERIMENTAL|Group 2|3 weeks Conventional therapy / 1 month ARMT / 3 weeks Conventional therapy
62681211|NCT05787119|EXPERIMENTAL|Group 3|2.5 weeks Conventional therapy / 1 month ARMT / 3.5 weeks Conventional therapy
62681212|NCT05919212|EXPERIMENTAL|Patients with HER2 positive Breast cancer Stage IV|"All eligible patients to T-Dxd as second line treatment will receive T-Dxd intravenous at dose of 5,4 mg/kg every three weeks until progression disease or unacceptable toxicities.~Subjects eligible to T-Dxd and who agree to participate in the study will undergo serial blood samples for liquid biopsy (LB) until progression disease."
62121878|NCT06306313|ACTIVE_COMPARATOR|Control Group|The control group will receive only conventional physiotherapy in a single session of 45 minutes a day, 3 days a week for 4 weeks. Evaluations will be made at the beginning and end of the treatment process.
62121879|NCT00590707|ACTIVE_COMPARATOR|Deeper sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 0. This is the deeper sedation arm."
62476415|NCT05859425|ACTIVE_COMPARATOR|Control (non-US guided) group|The control group received the traditional tactile feedback from the therapist while performing the motor control exercises for TrA activation. Traditionally, assessment of TrA contraction involves palpation of the muscles. The ability to assess TrA through muscle palpation is largely dependent on examiner's skill, as TrA cannot be directly palpated (feedback sensation being limited from internal oblique muscle). To control the activation of the abdominals the therapist placed his hands on the inside of the anterior superior iliac crests (tactile feedback) and instructed the examinee to pull the abdominal wall inward without moving the spine or pelvis (verbal feedback). The same exercise protocol to the experimental group was performed in this (control) group.
62476416|NCT03289884||Control Group (CE1)|"* All patients must have cystic lesions which must exceed 30mm in diameter.~* All patients must be aged 16 or over and able to provide informed consent.~* Patients will have an MRI scan (not involving ionising radiation)~* Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~* Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent."
62121880|NCT00590707|ACTIVE_COMPARATOR|Moderate sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 4-5. This is the moderate sedation arm."
62121881|NCT00551980|EXPERIMENTAL|Cognitive and physical program|Randomized group of workers of the same institution ( City of Turin, Italy).
62121882|NCT00551980|NO_INTERVENTION|Control group|Randomized group of workers of the same institution ( City of Turin, Italy).
62121883|NCT01292681|OTHER|Multi-modality imaging|
62121884|NCT06676384|ACTIVE_COMPARATOR|Standard of Care (SoC)|This intervention arm will start with the randomisation of the first participant.
62121885|NCT06676384|EXPERIMENTAL|SoC and Oral prednisolone|This intervention arm will start with randomisation of the first participant.
62121886|NCT06676384|EXPERIMENTAL|SoC and Gut-directed budesonide|This intervention arm will start with the randomisation of the first participant.
61921919|NCT03665415|OTHER|Formative|This stage represents an initial formative phase to implement the NDGame Squad intervention with small samples of youth in order to make any modifications necessary before embarking on the full pilot in both sites in the next phase. Three (n=3) participants from the school site only will participate in an initial 4-week Game Squad intervention in the first formative phase. Participant feedback including barriers to engagement and suggestions for improvements will be obtained via parent/caregiver and child interviews post-intervention.
62121887|NCT06676384|EXPERIMENTAL|SoC and Mycophenolate mofetil (MMF)|This intervention arm will start with the randomisation of the first participant.
62121888|NCT06676384|EXPERIMENTAL|SoC and Hydroxychloroquine|This intervention arm will start with the randomisation of the first participant.
62121889|NCT06676384|EXPERIMENTAL|SoC and Non-steroidal mineralocorticoid receptor antagonist|The sixth arm may begin after the planned interim analysis conditional to the availability of the generic drug in the Indian market and will recruit an additional 117 participants with a concurrent comparator arm.
62121890|NCT02634970|EXPERIMENTAL|Ranibizumab at 0.5 mg|Single arm, intravitreal injection
62121891|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
62121892|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
62310644|NCT06630832|EXPERIMENTAL|Partial cooling|Participants perform a continuous heavy-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 1:3 work-rest allocation, starting with a 45 min rest break followed by a 15 min work bout for an additional 180-min of work with partial cooling equivalent to sitting in a shaded space (WBGT 24°C; 31.7°C and 35% RH) such as under a tree with a light breeze (simulated with pedestal fan fixed at \~2 m/s).
62310645|NCT06630832|EXPERIMENTAL|Full cooling|Participants perform a continuous heavy-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 1:3 work-rest allocation, starting with a 45 min rest break followed by a 15 min work bout for an additional 180-min of work with full cooling equivalent to sitting in air-conditioned space (e.g., room or vehicle) maintained at 22°C and 35% RH (equivalent WBGT of 16°C).
62495948|NCT01919827|EXPERIMENTAL|MSC endobronchial infusion|
62121893|NCT02874118|EXPERIMENTAL|HIV Patient population over 50 years old|
62495949|NCT04411251|EXPERIMENTAL|Outdoor|Nature-centered therapy in a near-natural area
62495950|NCT04411251|ACTIVE_COMPARATOR|Indoor|Conventional therapy in rooms mainly in a hospital building
62121894|NCT01306864|EXPERIMENTAL|Hemospray Treatment|Hemospray Kit
62121895|NCT01109745|NO_INTERVENTION|usual primary care|Number of participating children: 85
62121896|NCT01109745|EXPERIMENTAL|PELICAN Primary care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 85 children
62121897|NCT01109745|NO_INTERVENTION|usual secondary care|number of participating children: 50
62121898|NCT01109745|EXPERIMENTAL|PELICAN Secondary Care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 50 children
62121899|NCT06193005||very low adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
62121900|NCT06193005||low adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
62121901|NCT06193005||high adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
62495951|NCT02435433|EXPERIMENTAL|Ramucirumab + Best Supportive Care (BSC)|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
61921920|NCT03665415|EXPERIMENTAL|Pilot Intervention|Participants in the pilot intervention arm will receive either 10 or 14 weeks of the NDGameSquad intervention. School site participants will receive 10 weeks during the school year, followed by another 4 weeks during summer vacation. Clinic site participants will receive 10 weeks only.
62121902|NCT06193005||very high adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
62310646|NCT05604105||Sample of the Egyptian population|"Participants of Giza residents.~Inclusion criteria:~• Adult individuals (Age\>18 years).~Exclusion criteria:~* Dental students or dental practitioners; as awareness of the disease is an integral part of their profession.~* Oral cancer patients: Individuals who experience currently or previously having oral cancer.~* Individuals with mental or communication disabilities."
62310647|NCT05409885||General anesthesia group|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
62310648|NCT05409885||Spinal anesthesia group|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
62310649|NCT02240498|EXPERIMENTAL|MB-PDT, 5 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 5 minutes.
62310650|NCT02240498|EXPERIMENTAL|MB-PDT, 10 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 10 minutes.
62310651|NCT02240498|EXPERIMENTAL|MB-PDT, 15 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 15 minutes.
62310652|NCT02240498|EXPERIMENTAL|MB-PDT, 20 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 20 minutes.
62310653|NCT02240498|EXPERIMENTAL|MB-PDT, 25 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 25 minutes.
62310654|NCT02240498|EXPERIMENTAL|MB-PDT, 30 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 30 minutes.
62310655|NCT03331341|EXPERIMENTAL|Treatment (APVD)|"PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles."
62310656|NCT06517810||QUELIMMUNE Surveillance Registry Participants|All patients treated with the QUELIMMUNE device as a part of clinical practice under the approved HDE indication must be included in this registry.
62310657|NCT01713348|EXPERIMENTAL|CGM - intervention arm|Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
62310658|NCT01713348|ACTIVE_COMPARATOR|SMBG - Control arm|Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.
62310659|NCT04906005|EXPERIMENTAL|gadopiclenol|"Dose per administration: dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.025; 0.05 or 0.1 mmol/kg BW (depending on each group).~6 volunteers will receive gadopiclenol per group"
62495952|NCT02435433|PLACEBO_COMPARATOR|Placebo + BSC|Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
61921921|NCT03665415|OTHER|Pilot Waitlist Control|Participants at both sites randomized to the waitlist control arm will be asked to maintain current physical activity levels during the first 10-week period. They will then be provided the intervention equipment and training. School site control arm participants will then participate in a 4-week, unsupported summer NDGame Squad intervention. Clinic site control arm participants will not be required to participate in the NDGameSquad intervention.
61921922|NCT04729478|OTHER|Natural sleep|"Natural sleep endoscopy (NSE)~OSA patients will be endoscopically evaluated during natural sleep.~During NSE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
61921923|NCT04729478|OTHER|Drug-induced sleep|"Drug-induced sleep endoscopy (DISE)~OSA patients will be endoscopically evaluated during drug-induced sleep.~During DISE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
61921924|NCT01653782|EXPERIMENTAL|kUNDALINI YOGA|"Guided kundalini yoga sessions specific for low back pain for 1 hour, twice a week (120 minutes of instructor-led yoga) for 6 weeks. Cd recording for home practice recommended once per day.A written self care pamphlet The Back book"
61921925|NCT01653782|ACTIVE_COMPARATOR|Self care advice to stay active|Evidence based advice from caregiver to stay active and exercise
62476417|NCT03289884||CE group (CE2-4)|"* All patients must have hepatic CE, as confirmed by positive blood tests, with lesions identified on the standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.~* All patients must be aged 16 or over and able to provide informed consent.~* All patients will have an MRI scan (not involving ionising radiation)~* Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~* Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent.~* Patients from the CE group undergoing surgery or aspiration will have fluid samples sent for analysis as part of standard clinical care. These cyst fluid samples will then be transported to the MRI scanner for Ex vivo scanning."
62476418|NCT01289691|EXPERIMENTAL|Air/Oxygen Mixture|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
62476419|NCT01289691|ACTIVE_COMPARATOR|Oxygen|Patients in this group will be ventilated with only oxygen during one lung ventilation.
61921926|NCT01653782|ACTIVE_COMPARATOR|Exercise|"Guided exercise at a gym focusing on strength training. Twice a week during 6 weeks. A written self care pamphlet The Back book"
61921927|NCT00079014|EXPERIMENTAL|Treatment (triapine, doxorubicin hydrochloride)|"Patients receive doxorubicin IV over 15 minutes on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level."
62121903|NCT02849535|EXPERIMENTAL|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
62121904|NCT02849535|NO_INTERVENTION|Standard of care|In the group with standard of care, patients will have interviews with a hospital pharmacist only dedicated to the record of data for outcomes assessment. These sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion , and at the end at month 6 after the final physical session.
62121905|NCT01038648|PLACEBO_COMPARATOR|1|Advice life style at baseline only
62121906|NCT01038648|ACTIVE_COMPARATOR|sitagliptin arm : 2|"100mg/day sitagliptin~advice on life style modification at baseline only"
62310660|NCT04906005|PLACEBO_COMPARATOR|Placebo|"Dose per administration: similar dose (Volume/weight) as the one used for Gadopiclenol in the considered group.~3 volunteers will receive gadopiclenol per group"
61921928|NCT01616134|ACTIVE_COMPARATOR|Korea Red Ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.
62121907|NCT04558424|EXPERIMENTAL|Intervention group|This group will consist of 50 patients who will be treated with zinc and vitamin C at a dose of 220 mg and 1 gram orally daily for 10 days in addition to their standard treatment
62310661|NCT02119208|EXPERIMENTAL|Lifestyle counseling|
62310662|NCT03498872|ACTIVE_COMPARATOR|Able-bodied individuals|
62310663|NCT03498872|EXPERIMENTAL|Transtibial amputee|
62310664|NCT03498872|EXPERIMENTAL|Transfemoral amputee|
62310665|NCT01564654||iTotal KRS|
62310666|NCT02365857|ACTIVE_COMPARATOR|DEX-5|Dexmedetomidine \& Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
62310667|NCT02365857|ACTIVE_COMPARATOR|DEX-10|Dexmedetomidine \& Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
62310668|NCT02365857|ACTIVE_COMPARATOR|DEX-15|Dexmedetomidine \& Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
62310669|NCT02365857|ACTIVE_COMPARATOR|Control|Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
62310670|NCT04649281|OTHER|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
62681213|NCT05478018|EXPERIMENTAL|Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at \>85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 3-10 min cool-down of 50% Hrmax"
61921929|NCT01616134|PLACEBO_COMPARATOR|placebo contating constarch|
61921930|NCT05973396|ACTIVE_COMPARATOR|Control: Physical Fatigue only|Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort
61921931|NCT05973396|EXPERIMENTAL|Experiment: Mental and Physical Fatigue|Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort with mentally fatiguing task during low intensity effort pace with stroop testing during 50 seconds
61921932|NCT05648253|EXPERIMENTAL|Hyivy Intravaginal Device|Participants will receive a Hyivy intravaginal device for at-home use. Recommended use is three times per week for 12 weeks and consists of 10 minutes of heat (37-39ºC) and 10 minutes of dilation per session.
62121908|NCT04558424|PLACEBO_COMPARATOR|Placebo group|This group will consist of 50 patients who will receive placebo at a dose same dose for 10 days in addition to their standard treatment.
62121909|NCT06171425||DPAH group|patients with diffuse parenchymal lung diseases
61921933|NCT05025540||Experimental group|Experimental group1：DKD patients with Type 2 diabetes patients with DKD Experimental group2：High level DKD patients with diabetic kidney disease Stage III and IV.
62121910|NCT06171425||control group|aged matched healthy patients
62121911|NCT05264012||Cranial neurosurgery|Patients undergoing cranial neurosurgery
62310671|NCT03272477|ACTIVE_COMPARATOR|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.~Adjuvant Therapy: Standard of care"
62310672|NCT03272477|EXPERIMENTAL|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.~Adjuvant Therapy: Standard of care"
62310673|NCT05964738|EXPERIMENTAL|Diuretics withdrawal|
62310674|NCT05964738|ACTIVE_COMPARATOR|Diuretics maintenance|
62476420|NCT06560606||Cohort 1 - Biologic Basis of JIA|"The objectives for this group are to help researchers look at childhood arthritis and determine which management approach is best for each individual child.~To be eligible for this group:~Participant must be ≤ 18 years of age at time of study enrollment. Participant is suspected to have JIA. Participant has not received any treatment other than non-steroidal anti-inflammatory drugs, such as acetaminophen."
62121912|NCT05264012||Non-cranial neurosurgery|Patients undergoing non-cranial neurosurgery including spine surgery
62495953|NCT02435433|EXPERIMENTAL|Open Label Ramucirumab + BSC|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
62121913|NCT04617353|EXPERIMENTAL|Plasma|(the treatment of sterno-mediastinitis was carried out using a combined method of air-plasma flow and NO therapy)
62121914|NCT04617353|OTHER|Standard therapy|(patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage)
62310675|NCT06390618|ACTIVE_COMPARATOR|Aerobic Exercise Group (AE)|"A moderate intensity (50-60%) aerobic exercise program will be applied 3 days a week, using the karvonen method for aerobic exercise. According to the aerobic exercise intensity karvonen method, the formula (Maximal Heart Rate (220-years) - Resting Heart Rate) x 50-60% + Resting Heart Rate) will be used. 1-4. week 50%, 5-8. Exercise intensity will be increased by 60% per week."
61921934|NCT05025540||Control group|Control1：T2DM patients with Type 2 diabetes Control2：Low level DKD patients with diabetic kidney disease Stage I and II.
61921935|NCT05497700|ACTIVE_COMPARATOR|Ephedrine group|In this group, any hypotension less than 65 mm Hg will be corrected by bolus injection of 6 mg ephedrine. Bolus injection will be repeated every 3 minutes, as needed, to keep mean arterial pressure above 65 mm Hg.
61921936|NCT05497700|EXPERIMENTAL|Norepinephrine group|In this group, any hypotension less than 65 mm Hg will be corrected by bolus injection of 6 mcg norepinephrine. Bolus injection will be repeated every 3 minutes, as needed, to keep mean arterial pressure above 65 mm Hg.
61921937|NCT04975529|EXPERIMENTAL|Intervention Arm|Participants in intervention schools received access to daily, online after school programming, including live sessions with sports providers (via Zoom; rotating to provide exposure to multiple sports over the course of the intervention), weekly team meetings with a health coach (via Zoom), text-messages via the Remind app, and monthly delivery of Activity Kits with sports equipment, activity books, fresh produce, and incentives directly to their homes over 6-months.
62681214|NCT05478018|NO_INTERVENTION|Non-Exercise|Control group, therefore no supervised exercise regime. Subjects are asked to not increase habitual exercise routines.
61921938|NCT04975529|EXPERIMENTAL|Comparison Arm|Participants in comparison schools received access to the Game on Philly app with workout and sports content that could be used asynchronously, and received one activity kit delivery with sports equipment and a self-guided activity book at the start of the program.
61921939|NCT00806364||1|Blood, skin, stool/rectal swabs, buccal mucosa and bone marrow aspirate samples from approximately 250 healthy volunteer donors
61921940|NCT04722653|EXPERIMENTAL|NN0194-0499|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo, Asian participants will only receive NNC0194-0499. There will be 3 cohorts with escalating dose levels. There should be at least 4 days between dose administration of the last participant in a dose level cohort and dose administration of the first participant in the following dose level cohort.
62495954|NCT02435433|EXPERIMENTAL|Ramucirumab MEE Cohort + BSC|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
62681215|NCT05385692|EXPERIMENTAL|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
61921941|NCT04722653|PLACEBO_COMPARATOR|Placebo|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo.
61921942|NCT00510874|EXPERIMENTAL|Pumarix Formulation 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
61921943|NCT00510874|EXPERIMENTAL|Pumarix Formulation 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
61921944|NCT00510874|EXPERIMENTAL|Pumarix Formulation 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
61921945|NCT00510874|EXPERIMENTAL|Pandemrix Formulation A Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
61921946|NCT00510874|EXPERIMENTAL|Pandemrix Formulation B Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
61921947|NCT00510874|EXPERIMENTAL|Pumarix Formulation 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
61921948|NCT00510874|EXPERIMENTAL|Pumarix Formulation 5 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
61921949|NCT05860231|ACTIVE_COMPARATOR|Control arm (Foley catheter)|When randomly allocated to this arm, a conventional Foley-type catheter will be inserted during all the study period (4 weeks). At day 28 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
61921950|NCT05860231|EXPERIMENTAL|T-Control arm|When randomly allocated to this arm, the T-Control catheter will be inserted during all the study period (4 weeks). At day 28 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
61921951|NCT03242824|EXPERIMENTAL|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
62681216|NCT03874858|EXPERIMENTAL|TFR1 stage- Nilotinib|"During TFR1 stage, all patients will be treated with nilotinib 300 mg QD for up to 48 weeks (consolidation period).~* Patients with sustained DMR at the end of the consolidation period will enter the TFR1 period and nilotinib will be discontinued.~* Patients with loss of MMR will return to the standard nilotinib administration~* Patients with ≥ MMR, but without sustained DMR at the end of the consolidation period will be treated with nilotinib 300 mg QD"
62681217|NCT03874858|EXPERIMENTAL|TFR2 stage- Nilotinib+Asciminib|"During the TFR2 stage, participants will be treated with nilotinib and asciminib for up to 96 weeks (reinduction period).~* Patients with sustained DMR at the end of reinduction will enter TFR2 and asciminib + nilotinib will be discontinued.~* Patients with ≥ MMR, but without sustained DMR, at the end of the reinduction, will be treated with nilotinib monotherapy at 300 mg BID until the end of the TFR2 stage.~* Patients with loss of MMR at any time during reinduction or during nilotinib monotherapy will be discontinued from the study."
62681218|NCT06278311||Patients|This group will include individuals presenting with digestive and/or non-digestive symptoms or conditions and whose medical evaluation necessitates 'toxin assessment.'
62476421|NCT06560606||Cohort 2 - Start Biologics|"The objectives for this group are to help researchers develop a tool to predict response to therapy.~To be eligible for this group:~Participant ≤ 18 years of age at time of study enrollment. Participant has been diagnosed with JIA and arthritis is active. Participant will be starting, re-starting or switching to a new biologic therapy."
62476422|NCT06560606||Cohort 3 - Stop Biologics|"The objectives for this group are to help researchers develop a tool to predict who will remain in remission after discontinuing therapy.~To be eligible for this group:~Participant ≤ 18 years of age at time of study enrollment. Participant has been diagnosed with JIA and arthritis is inactive. Participant will be stopping or tapering biologic therapy."
62681219|NCT06278311||Healthy controls|This group will include individuals not presenting with digestive and/or non-digestive symptoms or conditions and who volunteer to provide urine samples for 'toxin assessment.'
62681220|NCT06015165|EXPERIMENTAL|Anes Group|In Anes Group, the anesthesiologist routinely works in the operating room, and will communicate with anorectal physicians through bedside visits, video telephone calls, and a hospital-wide electronic medical record system in the operating room. Anesthesiologists will evaluate the patient's pain degree and symptoms perioperatively at bedside, and will administer opioids or non-opioids at the optimal interval and standard dose until discharge. The anesthesiologist and the surgeon will jointly formulate the discharge medication plan and give the patient guidance on analgesic treatment.
62476423|NCT06560606||Cohort 4: Extreme Phenotypes|"The objective for this group is new gene discovery and drug target identification.~To be eligible for this group:~There is high suspicion of genetic contribution. Participants are severely affected with difficult to control arthritis or systemic disease.~There is unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations"
61921952|NCT04077476|ACTIVE_COMPARATOR|Online Yoga|Participants in both groups will follow a prescription of classes the research team (including a 200-hour yoga instructor) developed, and is safe and appropriate for this study population. The yoga prescription will be based on the prescription used in the current R34 study (see reference for description), and modified based on results (i.e., participant feedback). Participants will be given instructions about how to use the online yoga class platform (Udaya) during the intake appointment.
62476424|NCT02642653|ACTIVE_COMPARATOR|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
62476425|NCT02642653|PLACEBO_COMPARATOR|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
62476426|NCT03838263|EXPERIMENTAL|Experimental arm|Experimental arm with nivolumab 2 infusions (2 weeks apart) before Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
61921953|NCT04077476|EXPERIMENTAL|Online Yoga + Facebook|"In addition to what is described above, participants will be provided instructions on how to join the private Facebook group. The Facebook group will be an informal platform where participants can connect with other people in the online + SN group to share their experiences with yoga as it relates to their stillbirths. Current social media intervention research suggests careful consideration must be given to the intervention. The current intervention will be designed based on results of focus groups asking stillbirth moms who have completed an online yoga intervention what they would find helpful in a Facebook intervention. For instance, preferences included having a moderator, rules about what they can post (e.g., no rainbow babies), and discussion about both stillbirth and life in general."
62310676|NCT06390618|ACTIVE_COMPARATOR|Combined Exercise (CE) Group|The group in which biopsychosocial exercise is performed in addition to aerobic exercise is the combined exercise (CE) group. Cognitive Exercise Therapy Approach (BETY) will be applied with group exercise as a biopsychosocial exercise. In the BETY biopsychosocial model, it is aimed to achieve biological recovery with function-oriented trunk stabilization exercises, psychological recovery by expressing negative-positive thoughts during the exercises and emphasizing staying in positive thoughts, and social recovery through group treatment.
62310677|NCT06390618|NO_INTERVENTION|Control Group (C)|There will be no intervention in the control group. The change over time in the control group and individuals with post-traumatic stress disorder will be monitored.
62310678|NCT05770414|EXPERIMENTAL|Intervention group|Participants assigned to this group will receive the MTC online program after completing the pre-intervention questionnaire.
62476427|NCT03838263|ACTIVE_COMPARATOR|Control arm|Control arm: Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
62681221|NCT06015165|ACTIVE_COMPARATOR|Surg. group|According to the current perioperative management mode, patients in the surgeon-led group (Surg. group) will be given local anesthesia during the operation, and will receive routine ambulatory surgery anesthesia plan, and routine postoperative analgesia plan in the ward will be given to the patients, under the guidance of the department of pharmacy. The patients will receive rescue opioids and standardized NSAIDs until discharge.
62681222|NCT06685679|EXPERIMENTAL|Intervention group melatonin group|"Intervention group : will receive oral melatonin (Kids Daily Vit Sleep syrup) 3 mg/kg/day divided in 3 doses , after enteral feeding, for 3 consecutive days, as combined therapy to milrinone (Garofoli et al., 2021).~Human studies documented that short-term use of melatonin is safe, even in extreme doses (Andersen et al., 2016)."
62681223|NCT06685679|PLACEBO_COMPARATOR|Control group|Control group: will receive the treatment of PHN as our NICU protocol in the form of loading dose of milrinone (50 μg/kg) over 60 mins followed by a maintenance infusion (0.33-0.99 μg/kg/min) for 72 hrs. (McNamara et al., 2013) And equivalent amout of distilled water as a placebogive at same time intervals as melatoni
61921954|NCT01593462|EXPERIMENTAL|Pediatric Small Bowel Crohn's Disease|MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
62310679|NCT05770414|NO_INTERVENTION|Waitlist control group|Participants assigned to this group will not receive the MTC online program during the study period. At the end of the 8 weeks and after the post-questionnaire is completed, they will have the option to receive the MTC online program if they wish.
62476428|NCT05374876|OTHER|Investigational hand therapy (IHT)] intervention targeting the nervous system|
62476429|NCT05374876|OTHER|Traditional occupational therapy intervention targeting compensatory strategies (TOT)|
62476430|NCT03129763|EXPERIMENTAL|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
62476431|NCT03129763|EXPERIMENTAL|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
62476432|NCT03129763|EXPERIMENTAL|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
62310680|NCT02250040|ACTIVE_COMPARATOR|Control group|Conventional physiotherapy for stroke.
62121915|NCT03233919|EXPERIMENTAL|CORIC|"Comprehensive remote ischaemic conditioning (CORIC) will be induced using an automated RIC device:~Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
62121916|NCT03233919|NO_INTERVENTION|Non-CORIC|Controls did not undergo comprehensive remote ischaemic conditioning.
62121917|NCT03923946|EXPERIMENTAL|Intervention|Compassionate Imagery Intervention- up to three 1:1 sessions, up to one hour each with the primary researcher
62121918|NCT03923946|NO_INTERVENTION|Control|Treatment as usual arm
62121919|NCT00891930|EXPERIMENTAL|Panitumumab|Participants received panitumumab (6 mg/kg starting dose) with irinotecan (starting dose of 180 mg/m²) every 2 weeks (Q2W) during Part 1. Upon radiographically confirmed disease progression, participants proceeded to Part 2 of the study and received treatment with panitumumab (6 mg/kg starting dose) and ganitumab (12 mg/kg starting dose) Q2W.
62121920|NCT05636332|OTHER|New electrodes|New package of electrodes
62121921|NCT05636332|OTHER|24-hour opened electrodes|Electrodes opened 24 hours
62121922|NCT05636332|OTHER|30 day opened electrodes|Electrodes opened 30 days
62121923|NCT03047746|OTHER|TCRalpha/beta Tcell Depletion for BMF with trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) with trilineage aplasia excluding Fanconi Anemia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
62121924|NCT03047746|OTHER|TCRalpha/beta Tcell Depletion for BMF w/o trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) without trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
62121925|NCT03047746|OTHER|TCRalpha/beta Tcell Depletion for BMF w/ Fanconi Anemia|Patients with acquired or inherited bone marrow failure (iBMF) with Fanconi Anemia and related DNA Repair Disorders will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
62121926|NCT03270358|EXPERIMENTAL|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
62121927|NCT03270358|OTHER|patient without stenosis|Patient coming for their dialysis
62121928|NCT03520413|EXPERIMENTAL|PRACTICE-DM|PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
62121929|NCT03520413|ACTIVE_COMPARATOR|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
62310681|NCT02250040|EXPERIMENTAL|Target group|Techniques based on patients' functional level were added.
62310682|NCT04819425|EXPERIMENTAL|Elastic Adhesive Strips|"Endotracheal tube fixed by elastic adhesive tape (Tensoplast type adhesive tape):~The adhesive tape will be attached to the patient's face (opposite side to the endotracheal tube) and then two turns around the endotracheal tube will be made. The rest of the adhesive tape will be attached to the other side of the face (side of the endotracheal tube).~The laminated tape will be kept on the adhesive tape until it passes over the neck in order to avoid adhering to the hair.~Finally, the end of the adhesive tape will be replaced on the part already attached to the patient.~It will be changed daily and after stain or examinations if necessary."
62476433|NCT03129763|EXPERIMENTAL|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
62121930|NCT00695071|ACTIVE_COMPARATOR|A|
62121931|NCT04257136|EXPERIMENTAL|Treatment|Treatment with VBI-S
62121932|NCT02468388|EXPERIMENTAL|maltitol|
62121933|NCT02468388|ACTIVE_COMPARATOR|xylitol|
62121934|NCT02468388|PLACEBO_COMPARATOR|gum base|
62121935|NCT02468388|NO_INTERVENTION|no gum|
62121936|NCT02993588|EXPERIMENTAL|Melatonin|Melatonin 6 mg tablet once daily.
62310683|NCT04819425|ACTIVE_COMPARATOR|Lace in A Protective Sheath|"A loop is made with the lace then the endotracheal tube is passed through the loop. The loop is tightened by pulling each side on the remaining cords and a knot is made on one side of the fastener.~It will be changed daily and after stain or examinations if necessary."
62310684|NCT00676559|EXPERIMENTAL|Group 1|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
62310685|NCT00676559|EXPERIMENTAL|Group 2|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
62310686|NCT00676559|EXPERIMENTAL|Group 3|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks in combination with ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
62310687|NCT05331365|EXPERIMENTAL|Group of the construction of the composite Ankle go score and internal validations|50 patients will be include for the construction of the composite score and its internal validations. They will complete questionnaires (FAAM, ALR-RSI) and undergo tests (SLSTS, SHTS, SEBT and Figure of 8) 4 months after ankle's surgery (visit 1), 6 months after surgery (visit 2) and 12 months post surgery
62310688|NCT05331365|EXPERIMENTAL|group of the external validation stage of the composite score|50 additional patients for the external validation stage of the composite score. They will complete questionnaires (FAAM, ALR-RSI) and undergo tests (SLSTS, SHTS, SEBT and Figure of 8) 4 months after ankle's surgery (visit 1) and 6 months after surgery (visit 2)
62310689|NCT05331365|NO_INTERVENTION|Group allowing the assessment of the score's ability to discriminate|30 healthy volunteers (who did not undergone an ankle's surgery) will be included in the study to analyze the ability of composite score to discriminate. The healthy population will perform the same physical and psychological tests as Group allowing the construction of the composite Ankle go score and internal validations
62121937|NCT02993588|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily
62310690|NCT04372355|EXPERIMENTAL|Chlorite-based drug WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five
62310691|NCT05640986|EXPERIMENTAL|Patients|Risky behaviors assessed through BART-EEG among Parkinsonian patients newly treated with dopaminergic agonists
62310692|NCT05640986|ACTIVE_COMPARATOR|Control|Risky behaviors assessed through BART-EEG among healthy volunteers
62310693|NCT04129723|EXPERIMENTAL|Perianal Crohn's patient|Stopping biological therapy
62310694|NCT00077181|EXPERIMENTAL|Treatment (cytarabine and triapine)|Patients receive high-dose cytarabine IV over 2 hours on days 1-5 and triapine IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62310695|NCT03471221|EXPERIMENTAL|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
62310696|NCT03471221|NO_INTERVENTION|Control Group|Participants randomized to the Control Group will receive usual medical care.
62310697|NCT02652819|EXPERIMENTAL|FG-4592|Intervention is investigational treatment FG-4592
62310698|NCT02652819|PLACEBO_COMPARATOR|Placebo|Double blinded placebo control
62310699|NCT01541254|OTHER|Single Arm|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
62310700|NCT02065440|ACTIVE_COMPARATOR|Ebastine/Pseudoephedrine|administration of ebastine/pseudoephedrine 1cap/day for 1 week.
62310701|NCT02065440|PLACEBO_COMPARATOR|placebo|administration of placebo pill 1 cap/day for 1week
62310702|NCT05078034|ACTIVE_COMPARATOR|HFNO|High Flow Nasal Oxygen alone
62681224|NCT06679478|NO_INTERVENTION|Mobilization Performed in Routine Clinic Group|Participants undergoing gastrointestinal surgery will receive routine clinic mobilization. The investigator will not perform any interventions.
62681225|NCT06679478|EXPERIMENTAL|Early Mobilization Protocol Created in Enhanced Recovery After Surgery (ERAS) Guidelines Group|"Participants undergoing gastrointestinal surgery will watch a video 1 day before surgery that includes information about the importance of mobilization and the process.~The participant will be applied a mobilization protocol created in line with the postoperative mobilization eras (enhanced recovery after surgery) guidelines."
62121938|NCT03769571|OTHER|parental coaching program at ESDM (P-ESDM)|
62310703|NCT05078034|ACTIVE_COMPARATOR|H-NIV|Helmet Non-Invasive ventilation for a minimum of 12 hours per day with HFNO between sessions
62310704|NCT03626415|EXPERIMENTAL|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
62310705|NCT01462292|EXPERIMENTAL|GSK2402968 3 mg/kg/week|3 mg/kg/week of investigational product
62310706|NCT01462292|EXPERIMENTAL|GSK2402968 6 mg/kg/week|6 mg/kg/week of investigational Product
62310707|NCT01462292|EXPERIMENTAL|Placebo to match GSK2402968 3 mg/kg/week|Placebo
62310708|NCT01462292|EXPERIMENTAL|Placebo to match GSK2402968 6 mg/kg/week|Placebo
62681226|NCT02853773|EXPERIMENTAL|Artificial sweetener|Effects of co-ingestion of artificially sweetened beverage on the response to a test meal
62310709|NCT02551848|EXPERIMENTAL|Essential tremor treatment|"A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction.~Participants will be treated by BoNT-A injections every 12 weeks over 72 weeks. BoNT-A parameters will be determined solely by biomechanical analysis of tremulous movements in both upper extremity BoNT-A dose will range from 50-300 U per arm"
62310710|NCT02652429|EXPERIMENTAL|Inhaled Nitric Oxide (iNO)|Pulsed iNO 75 mcg/kg IBW/hour
62310711|NCT00652093|EXPERIMENTAL|Opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
62310712|NCT00652093|EXPERIMENTAL|Opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
62476434|NCT03129763|EXPERIMENTAL|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
62121939|NCT03769571|NO_INTERVENTION|CONTROL|
62681227|NCT02853773|ACTIVE_COMPARATOR|Sugar|Effects of co-ingestion of sugar-sweetened beverage on the response to a test meal
62310713|NCT00652093|EXPERIMENTAL|Placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
62681228|NCT02853773|ACTIVE_COMPARATOR|Water|Effects of co-ingestion of water on the response to a test meal
62310714|NCT00652093|EXPERIMENTAL|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
62310715|NCT00652093|EXPERIMENTAL|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
62681229|NCT06311175|ACTIVE_COMPARATOR|Standard Diet Tracking Prescription|This group will be asked to track their diet using a commercial mobile application every day for the 8 week digital weight loss intervention.
62310716|NCT00652093|EXPERIMENTAL|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
62681230|NCT06311175|EXPERIMENTAL|66% Tracking Prescription|This group will be asked to track their diet for 2 weeks, then they will get a 1 week break, track for 2 more weeks and then get a 1 week break, and then track for 2 weeks during the 8 week digital weight loss intervention.
62681231|NCT06311175|EXPERIMENTAL|50% Tracking Prescription|This group will be asked to track their diet every other week during the 8 week digital weight loss intervention.
62681232|NCT04503642||Intervention Group|The intervention consisted in the closure of the abdominal wall and skin by a second surgical team which included a board-certified surgeon and a resident.
62681233|NCT04503642||Baseline Group|During the baseline period, closure of the abdominal wall was performed by the main surgical team, the same team that performed the whole surgery.
62310717|NCT02395679|EXPERIMENTAL|MesoCancerVac|Autologous dendritic cells loaded with a mixture of 5 allogenic mesothelioma tumor cell lysates 3 to 5 vaccinations with 10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks
62310718|NCT04399278|OTHER|Group A|The EEO test will be applied first over 15 seconds and secondly over 30 seconds (each EEO test separated by 1 minute wash-out period)
62476435|NCT02060747|EXPERIMENTAL|Coordinator-based post fracture program|The intervention arm deals with the intervention of a nurse trained in the management of osteoporosis fractures assisted by a clinical research technician who will manage the logistics and reglementary aspects of the study (patient enrollment, quality and study proceedings).
62476436|NCT02060747|NO_INTERVENTION|standard care|
62681234|NCT06025058|EXPERIMENTAL|Easy Dew MD Regen Cream|In the case of the study group among the subjects of the clinical study, The experimental group apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.
62681235|NCT06025058|ACTIVE_COMPARATOR|Physiogel Stability Intensive Cream MD|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
62681236|NCT06422052||Dyspepsia with Helicobacter pylori infection|
62681237|NCT05992493||Breast-milk feeding|Exclusive breastfeeding for 4 months or more
62681238|NCT05992493||Control Formula milk feeding|Exclusive formula milk for 4 months or more
62681239|NCT05992493||HMO-Formula-milk feeding|Exclusive HMO-formula milk for 4 months or more
62681240|NCT06083493|EXPERIMENTAL|LIFUP excitation|The study will involve the enrollment of 60 participants, who will be randomly assigned to two groups, with each group consisting of 30 participants. The participants will be divided based on the type of transcranial LIFUP they will receive, either excitation or inhibition, targeting four specific thalamic areas.
62681241|NCT06083493|EXPERIMENTAL|LIFUP inhibition|The study will involve the enrollment of 60 participants, who will be randomly assigned to two groups, with each group consisting of 30 participants. The participants will be divided based on the type of transcranial LIFUP they will receive, either excitation or inhibition, targeting four specific thalamic areas.
62681242|NCT05909202|EXPERIMENTAL|Active VR Group|Nature-based immersive VR program, completion of questionnaires, and saliva and blood sample submission.
62121940|NCT00661778|EXPERIMENTAL|Bevacizumab + cisplatin + docetaxel|Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m\^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
62310719|NCT04399278|OTHER|Group B|The EEO test will be applied first over 30 seconds and secondly over 15 seconds (each EEO test separated by 1 minute wash-out period)
62310720|NCT01812720|EXPERIMENTAL|Treatment (carfilzomib, dexamethasone)|Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62310721|NCT02029430|EXPERIMENTAL|50 mg/m2 aldoxorubicin|
62310722|NCT02029430|EXPERIMENTAL|100 mg/m2 aldoxorubicin|
62310723|NCT02029430|EXPERIMENTAL|150 mg/m2 aldoxorubicin|
62310724|NCT00609128|EXPERIMENTAL|Olopatadine|one drop in one eye only two times per day at an interval of 6 to 8 hours for 1 week
62310725|NCT03065673|ACTIVE_COMPARATOR|Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
62476437|NCT03352362|EXPERIMENTAL|caldolor|intravenous caldolor injection during intraoperative period
62476438|NCT03352362|ACTIVE_COMPARATOR|denogan|intravenous denogan injection during intraoperative period
62681243|NCT05909202|SHAM_COMPARATOR|Sham VR Group|Nature-based non-immersive VR program, completion of questionnaires, and saliva and blood sample submission.
62681244|NCT05448027|EXPERIMENTAL|Low intensity laser therapy group|• Group (A): lt will include 26 participants suffering from primary dysmenorrhea who will receive low intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
62681245|NCT05448027|EXPERIMENTAL|High intensity laser therapy group|Group (B): It will include 26 participants suffering from primary dysmenorrhea who will receive high intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
62681246|NCT00968630|EXPERIMENTAL|Treatment (HIV-specific immune reconstitution after HCT)|Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, +365, and +730, and then annually thereafter as feasible.
62121941|NCT06357754||Participants treated with idecabtagene vicleucel|
62310726|NCT03065673|PLACEBO_COMPARATOR|Placebo gel|The patient will receive the application placebo gel on vestibular surface teeth, for 10 minutes.
62121942|NCT06357754||Participants treated with lisocabtagene maraleucel|
62681247|NCT06268132||Long-living individuals|Long-living individuals at least 90 years of age from the Central Federal District of Russia
62121943|NCT00687011|EXPERIMENTAL|Palonosetron-dexamethasone|
62121944|NCT03123198|EXPERIMENTAL|Dialectical Behavior Therapy|All participants receive six months of standard DBT which includes individual therapy, skills training, and as-needed phone consultation.
62121945|NCT00178399|EXPERIMENTAL|Stereotactic body radiation therapy|
62310727|NCT00943878|EXPERIMENTAL|Group 3: H1N1+placebo; H1N1+TIV; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); and Day 42, placebo.
62310728|NCT00943878|EXPERIMENTAL|Group 1: H1N1+placebo; H1N1+placebo; TIV|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, trivalent influenza vaccine (TIV).
62476439|NCT03352362|EXPERIMENTAL|combination|intravenous denogan and caldolor injection during intraoperative period
62681248|NCT00588770|ACTIVE_COMPARATOR|Arm IA (docetaxel, cisplatin)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62681249|NCT00588770|EXPERIMENTAL|Arm IB (docetaxel, cisplatin, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.
62121946|NCT00187941|OTHER|CellCept|CellCept + Prograf or Neoral + Steroids
62121947|NCT00364013|EXPERIMENTAL|FOLFOX + Panitumumab|Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
62495955|NCT02435433|PLACEBO_COMPARATOR|Placebo MEE Cohort + BSC|Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
62681250|NCT00588770|ACTIVE_COMPARATOR|Arm IIA (docetaxel, carboplatin)|Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62681251|NCT00588770|EXPERIMENTAL|Arm IIB (docetaxel, carboplatin, bevacizumab)|Patients receive bevacizumab as in Arm IB and docetaxel and carboplatin as in Arm IIA.
62681252|NCT00588770|ACTIVE_COMPARATOR|Arm IIIA (cisplatin, fluorouracil)|Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62681253|NCT00588770|EXPERIMENTAL|Arm IIIB (cisplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.
62681254|NCT00588770|ACTIVE_COMPARATOR|Arm IVA (carboplatin, fluorouracil)|Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62681255|NCT00588770|EXPERIMENTAL|Arm IVB (carboplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.
62681256|NCT05719233||Interstitial Lung disease Group|Mini-mental state examination (MMSE) Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale Nerve conduction studies High resolution Chest Computed tomography Pulmonary function Test
62681257|NCT05719233||Control Group|Mini-mental state examination (MMSE) Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale Nerve conduction studies
62681258|NCT03139253|EXPERIMENTAL|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
62681259|NCT03139253|EXPERIMENTAL|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
62681260|NCT03139253|EXPERIMENTAL|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
62681261|NCT03139253|EXPERIMENTAL|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
62681262|NCT03139253|EXPERIMENTAL|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
62681263|NCT04331769|EXPERIMENTAL|Device group: AccuCinch Ventricular Restoration System|Subjects in this arm will receive the AccuCinch Ventricular Restoration System
62681264|NCT04331769|ACTIVE_COMPARATOR|Control group: Guideline-Directed Medical Therapy|Subjects in this arm will receive guideline-directed medical therapy (GDMT)
62681265|NCT06003829|EXPERIMENTAL|Treatment A|
62681266|NCT06003829|EXPERIMENTAL|Treatment B|
62681267|NCT06003829|OTHER|Treatment C|Comparator
62495956|NCT04021407|ACTIVE_COMPARATOR|LMA|36 patients were ventilated with LMA during dacryocystorhinostomy surgery
62681268|NCT06003829|EXPERIMENTAL|Treatment D|
62681269|NCT06003829|EXPERIMENTAL|Treatment E|
62681270|NCT06003829|EXPERIMENTAL|Treatment F|
62681271|NCT05257018|EXPERIMENTAL|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24h after chemotherapy）"
62681272|NCT04994483|PLACEBO_COMPARATOR|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 52 weeks
62681273|NCT04994483|EXPERIMENTAL|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 52 weeks
62681274|NCT05346640|EXPERIMENTAL|Functional electrical stimulation in individuals with foot drop|Comparison of kinematics in stimulated and unstimulated gait using functional electrical stimulation in individuals with foot drop as a result of a neurological dysfunction
62681275|NCT06310824|EXPERIMENTAL|MAB-22|Single subcutaneous injection on Day 1
62121948|NCT00364013|ACTIVE_COMPARATOR|FOLFOX|Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
62681276|NCT06310824|ACTIVE_COMPARATOR|EU-Prolia®|Single subcutaneous injection on Day 1
62681277|NCT06310824|ACTIVE_COMPARATOR|US-Prolia®|Single subcutaneous injection on Day 1
62681278|NCT03549507|EXPERIMENTAL|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
62681279|NCT05867940|ACTIVE_COMPARATOR|Children and adolescents with physical disabilities|20 children and adolescents with physical disabilities will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
62310729|NCT00943878|EXPERIMENTAL|Group 2: H1N1+TIV; H1N1+placebo; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, placebo.
62310730|NCT00943878|EXPERIMENTAL|Group 4: TIV+placebo; H1N1+placebo; H1N1|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, trivalent influenza vaccine (TIV) + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, 15 mcg H1N1 vaccine.
62310731|NCT05021614|EXPERIMENTAL|Treatment|Transcatheter Mitral Valve Repair with Valveclip®
62310732|NCT02996305|EXPERIMENTAL|OV101 regimen 1|OV101 once daily
62310733|NCT02996305|EXPERIMENTAL|OV101 regimen 2|OV101 twice daily
62310734|NCT02996305|PLACEBO_COMPARATOR|Placebo|Twice daily
62310735|NCT04245124|EXPERIMENTAL|SMART INTERVENTION|N= 81 20 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
62310736|NCT04245124|EXPERIMENTAL|TCR|N= 81 60 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
62681280|NCT05867940|ACTIVE_COMPARATOR|Children and adolescents with intellectual disabilities|20 children and adolescents with intellectual disabilities will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
62121949|NCT05322837||Intervention|
62121950|NCT00983593|EXPERIMENTAL|Group Therapy|Group therapy following the Mind-Body Bridging program.
62121951|NCT02154217|EXPERIMENTAL|Bimatoprost|once daily
62310737|NCT05067660|ACTIVE_COMPARATOR|Cohort A - Standard-of-care template-based salvage radiotherapy|Study participants in cohort A undergo template-based salvage radiotherapy according to current standard-of-care protocol. Dose fractionations include dose of 70/2 Gy in the prostatic bed, 50/2 Gy in the pelvic lymph node area and 45/1,8 Gy in the para-aortic lymph node. To the PSMA PET-CT positive lymph nodes, a boost dose will be considered depending on the anatomic site and will be delivered with a simultaneous integrated boost technique (SIB). The typical boost dose to PSMA PET-CT positive lymph nodes is 57,5/2,3 Gy, respecting normal tissue constraints. The dose to PSMA PET-CT positive areas in the prostatic bed is 74-78/2 Gy.
62310738|NCT05067660|EXPERIMENTAL|Cohort B - PSMA PET CT-targeted stereotactic ablative radiotherapy|Study participants in cohort B undergo stereotactic ablative radiotherapy, targeted only to PSMA PET-CT-positive areas judged to be suspicious of prostate cancer metastasis by nuclear medicine physician. Dose fractionations in the experimental arm vary from 24/8 Gy to 30/10 Gy in PSMA PET-CT positive lymph nodes in pelvic or para-aortic areas. PSMA PET-CT positive areas in the prostatic bed receive a dose of 35/7 Gy.
62310739|NCT03626467|EXPERIMENTAL|Arm 1|Men infected by HIV who have sex with men
62310740|NCT04735185|ACTIVE_COMPARATOR|Intradiscal autologous stem cells|Participants in this arm will have autologous stem cells harvested through bone marrow aspiration. The stem cells that were harvested will be processed and injected into affected intradiscal spaces in the lumber spine.
62310741|NCT04735185|ACTIVE_COMPARATOR|Intradiscal corticosteroid and local anesthetic|Participants in this arm will receive an intradiscal injection of the steroid methylprednisolone and the local anesthetic bupivacaine into affected intradiscal spaces in the lumber spine.
62310742|NCT04971811|EXPERIMENTAL|Lower-energy-dense Snack|Test snack with lower-energy-dense snack food
62310743|NCT04971811|EXPERIMENTAL|Higher-energy-dense Snack|Test snack with higher-energy-dense snack food
62310744|NCT05372705|ACTIVE_COMPARATOR|Positive|"\~58-second selfie video (TikTok) of an adolescent presenting a can do / climate action / positive perspective on global warming"
62476440|NCT04850755|EXPERIMENTAL|patients with advanced solid malignancies|Patients will be dosed with selinexor once a week continuously in a 6 week cycle. Nivolumab will be administered on biweekly of each cycle . Ipilimumab will be dosed only on D1 of each cycle . Ipilimumab will continue for a maximum of 4 cycles. Nivolumab and selinexor will continue for up to 24 months or until discontinuation criteria is met.
62121952|NCT02154217|EXPERIMENTAL|Latanoprost/Timolol|once daily
62121953|NCT00223587|EXPERIMENTAL|A|1 week of treatment discontinuation
62310745|NCT05372705|ACTIVE_COMPARATOR|Negative|"\~58-second selfie video (TikTok) of an adolescent presenting an it's already too late / climate catastrophe / negative perspective on global warming"
62310746|NCT05372705|ACTIVE_COMPARATOR|Neutral|\~58-second selfie video (TikTok) of an adolescent discussing a topic unrelated to climate change or global warming
62310747|NCT06074172|PLACEBO_COMPARATOR|Placebo (visit 1 drug administration)|246mg Placebo, oral, single-dose (visit 1 drug administration)
62310748|NCT06074172|ACTIVE_COMPARATOR|Cannabidiol (visit 1 drug administration)|246mg Cannabidiol, oral single-dose (visit 1 drug administration)
62310749|NCT05822999|EXPERIMENTAL|WELT-IP|Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive CBT-I.
62310750|NCT05822999|SHAM_COMPARATOR|Sham|Eligible subjects were able to access a sham app downloaded on a mobile device (iOS and Android) which included sleep diary and general content regarding sleep.
62310751|NCT02035423|ACTIVE_COMPARATOR|Male Guidance School|Non-Fortified Milk 120IU Milk 200IU Milk
62310752|NCT02035423|ACTIVE_COMPARATOR|Female Guidance|Non-fortified Milk 120IU Milk 200IU Milk
62310753|NCT02035423|ACTIVE_COMPARATOR|Male Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
62476441|NCT06352138|EXPERIMENTAL|Epoetin alfa Megalabs® injectable in intravenous application.|Epoetin alfa Megalabs, Human recombinant epoetin alfa
62121954|NCT00986466|EXPERIMENTAL|exercise with vitamin D 800 IU/d|
62310754|NCT02035423|ACTIVE_COMPARATOR|Female Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
62310755|NCT05910593||Patient|Patients diagnosed with degenerative cervical myelopathy; will have dexterity measured once with dexterity tool being tested.
62310756|NCT05910593||Healthy|Healthy volunteers will have their dexterity measured at two time points to perform reliability analysis.
62310757|NCT04381000|NO_INTERVENTION|Control Group|The control group will not participate in any exercise program.
62310758|NCT04381000|EXPERIMENTAL|Intervention|The intervention group will participate in an exercise program for 6 weeks/ 2 sessions per week, for a total of 12 sessions of 30-45 minutes each.
62310759|NCT00816946|NO_INTERVENTION|Routine LHW Advice|Arm receiving routine advice by their local Lady Health Workers (LHWs)
62310760|NCT00816946|ACTIVE_COMPARATOR|Enhanced LHW Advice|Arm receiving enhanced nutrition and health advice from the local Lady Health Workers (LHWs)during their routine community visits.
62310761|NCT01718314|EXPERIMENTAL|Sublingual Misoprostol & Lidocaine placebo|Misoprostol 200 µg sublingually single dose and Lidocaine spray placebo
62310762|NCT01718314|EXPERIMENTAL|Lidocaine Pump Spray & Misoprostol placebo|Lidocaine Pump spray, 6 sprays to cervix (60 mg totally) and sublingual misoprotol placebo
62121955|NCT00986466|ACTIVE_COMPARATOR|exercise with placebo|
62310763|NCT02405312|EXPERIMENTAL|advance care planning|nephrologist empowers social worker to meet with patient and family.
62310764|NCT02756455||gastric cancer pts undergoing surgery|all pts receiving gastric resection for cancer, with anastomosis
62310765|NCT01359540||APEX Modular|APEX Modular Stem group
62310766|NCT01359540||ARC Stem|ARC Stem group
62310767|NCT01364467|PLACEBO_COMPARATOR|Placebo|Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
62310768|NCT01364467|ACTIVE_COMPARATOR|Guaifenesin|
62310769|NCT06372639|EXPERIMENTAL|Hippocampus Stimulation|
62310770|NCT06372639|SHAM_COMPARATOR|Sham Stimulation|
62310771|NCT02988986|EXPERIMENTAL|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
62310772|NCT02067312|EXPERIMENTAL|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the trapezius muscle
62310773|NCT02067312|SHAM_COMPARATOR|Sham Microwave diathermy|The participants will receive a thirty minutes session of Sham microwave diathermy onto the trapezius muscle
62310774|NCT01435993|EXPERIMENTAL|Active|GSK1223249 slow (60 minutes) intravenous infusion
62476442|NCT06352138|ACTIVE_COMPARATOR|Epoetin alfa Epogen® injectable in intravenous application.|USA licenced Epoetin alfa, Epogen®, Human recombinant epoetin alfa
62121956|NCT00986466|ACTIVE_COMPARATOR|no exercise with vitamin D 800 IU/d|
62121957|NCT00986466|PLACEBO_COMPARATOR|no exercise with placebo|
62310775|NCT01435993|PLACEBO_COMPARATOR|Placebo|Saline slow (60 minutes) intravenous infusion
62310776|NCT06672328|EXPERIMENTAL|Interventional Group|"The participants will receive AOT based mobility and balance exercises along with conventional therapy consisting of simple lower limb stretchings and strengthening .~The AOT-based exercises include different exercises in sitting, standing and turning stances.~The fun based activities inlcude reaching for objects, tower building and taking turns in various stances."
62310777|NCT06672328|ACTIVE_COMPARATOR|Control Group|"The participants will receive mobility and balance exercises without Action Obseravtion along with conventional therapy consisting of simple lower limb stretchings and strengthening .~The AOT-based exercises include different exercises in sitting, standing and turning stances.~The fun based activities inlcude reaching for objects, tower building and taking turns in various stances."
62476443|NCT03787641|OTHER|Protamine doze|Protamine Sulfate will be administered through an infusion pump in aliquots at a predefined rate (25 mg/min). Blood samples will be withdrawn after each aliquot and quantified for anti-Xa, IIa and ACT.
62310778|NCT00003820|EXPERIMENTAL|Rituximab 375 mg/m2 per week|"375 mg/m2 rituximab by IV infusion weekly. The initial course of treatment is 4 weeks.~Subjects who achieve an objective response or stable disease after the initial course (4 weeks) were permitted to continue additional 4-week cycles of treatment, for 3 additional courses starting every 6 months (ie, at 6; 12; and 18 months)."
62310779|NCT03009695|EXPERIMENTAL|High frequency repetitive dTMS + Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): present."
62310780|NCT03009695|EXPERIMENTAL|High frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): absent."
62121958|NCT04391101|EXPERIMENTAL|Intervention group|Administration of two units of fresh frozen plasma (between 400 and 500 ml) obtained from convalescent patients from infection by SARS-CoV-2. Convalescent plasma is defined as the plasma of patients who had PCR confirmed SARS-CoV-2 infection, who have recovered clinically, and who have positive antibodies against SARS-CoV-2.
62121959|NCT04391101|NO_INTERVENTION|Control group|Subjects assigned to the control group will receive support treatment in the intensive care unit based on institutional management guidelines. The use of antiviral, antimalarial or anti-inflammatory drugs is allowed in both groups according to the ICU protocols.
62121960|NCT00886951|EXPERIMENTAL|Access I123MNI388/I123MNI390 and brain imaging|
62121961|NCT02456506|EXPERIMENTAL|Hyperfractionated IMRT Group|IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy, irradiation interval of 6-8 hours)
62121962|NCT02456506|ACTIVE_COMPARATOR|Conventional Fraction IMRT Group|IMRT (total dose of 60Gy, division 27 times, once a day, every 2.2Gy)
62121963|NCT00596609||1|Group 1 will be subjects who receive Intrathecal Morphine.
62121964|NCT00596609||2|Group 2 will be subjects who do not receive Intrathecal Morphine.
62121965|NCT03565523|EXPERIMENTAL|Test Beet shot|Containing 385 mg nitrate
62121966|NCT03565523|PLACEBO_COMPARATOR|Placebo beverage|\<0.1 mmol nitrate in sucrose solution with beet coloring
62121967|NCT05176964||HFRT with concurrent chemotherapy and immunotherapy|CAPOX chemotherapy plus tislelizumab treatment plus split-course HFRT
62121968|NCT04528472|EXPERIMENTAL|Acupuncture Treatment|Acupuncture Treatment: main point: DU20, DU24, MS7, LI4, ST40 Oral Medicine Rehabilitation Treatment
62121969|NCT04528472|EXPERIMENTAL|Regular Treatment|Acupuncture Treatment Oral Medicine Rehabilitation Treatment
62121970|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
62121971|NCT02972801||Testicular tissue biopsy|Testicular biopsy
62121972|NCT03583125|EXPERIMENTAL|EOC 317|"Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.~Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21."
62121973|NCT00310726|EXPERIMENTAL|Abrupt Weaning|Women were counseled to abruptly wean their child at 4 months of age.
62121974|NCT00310726|ACTIVE_COMPARATOR|Exclusive breastfeeding per WHO guidelines|Women were counseled to adhere to the WHO recommendations for duration of exclusive breastfeeding.
62121975|NCT04767698|EXPERIMENTAL|Belimumab + short-term Ocrelizumab|Participants will receive Belimumab and Ocrelizumab.
62121976|NCT04767698|ACTIVE_COMPARATOR|Continued Ocrelizumab|Participants will receive Ocrelizumab only.
62121977|NCT05570435|EXPERIMENTAL|YIYANG TangLv milk powder|30g of milk powder (Nestle YIYANG TangLv milk powder) containing 789 mg Reducose® extract, standardized to contain 1% 1-deoxynojirimycin (1-DNJ), 10% of an oil mix and 8% of soluble fiber reconstituted with 180 ml of warm water.
62121978|NCT05570435|ACTIVE_COMPARATOR|skimmed milk|25g of commercially available skimmed milk powder reconstituted with 180 ml of warm water.
62121979|NCT02675088|EXPERIMENTAL|high-dose TRT|high-dose thoracic radiotherapy X-ray RT
62121980|NCT02675088|ACTIVE_COMPARATOR|standard-dose TRT|standard-dose thoracic radiotherapy XRT
62121981|NCT02338245|EXPERIMENTAL|Treatment Arm A|ASLAN001 + Capecitabine
62121982|NCT02338245|ACTIVE_COMPARATOR|Treatment Arm B|Lapatinib + Capecitabine
62121983|NCT00523107|EXPERIMENTAL|PG2|PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.
62121984|NCT00523107|PLACEBO_COMPARATOR|Placebo|500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.
62121985|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
62121986|NCT04374916|EXPERIMENTAL|Partosure® test + Premaquick® test|All patients will have the same 2 tests.
62121987|NCT05658406|ACTIVE_COMPARATOR|Group A|intraoperative infusion of 15 mL/kg/hour Ringer's lactate.
62121988|NCT05658406|ACTIVE_COMPARATOR|Group B|intraoperative infusion of 10 mL/kg/hour Ringer's lactate
62476444|NCT01776190|EXPERIMENTAL|UVA1 treatment|Low-dose UVA1 will be applied to active cutaneous lupus lesions three times a week for 10 weeks.
62476445|NCT01096433|EXPERIMENTAL|CPAP|The subjects introduced with CPAP treatment
62310781|NCT03009695|EXPERIMENTAL|Low frequency repetitive dTMS+ Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT) Frequency: 1 Hz Duration of the train: 10 min Inter-train interval: 1 min Trains number: 4 Total pulses: 2400 Total treatment duration: 43 min Cue (sight of food preferred by patient): present"
62310782|NCT03009695|EXPERIMENTAL|Low frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 1 Hz, Duration of the train: 10 min, Inter-train interval: 1 min, Trains number: 4, Total pulses: 2400, Total treatment duration: 43 min, Cue (sight of food preferred by patient): absent."
62310783|NCT03009695|SHAM_COMPARATOR|Sham|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to sham stimulation.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz (50% of patients) and 1 Hz (50% of patients), Duration of the train: 2 sec or 10 min, Inter-train interval: 20 sec or 1 min, Trains number: 80 or 4, Total pulses: 2880 or 2400, Total treatment duration: 29.3 or 43 min, Cue (sight of food preferred by patient): present."
62310784|NCT03507400|EXPERIMENTAL|non-waiting list group|Intervention: Introvision: mental and emotional self-regulation
62310785|NCT03507400|EXPERIMENTAL|waiting list group|"Intervention: Introvision: mental and emotional self-regulation~Introvision is teached to participants of the waiting-list group at least 6 weaks or more after first group"
62310786|NCT01331395|NO_INTERVENTION|IVF-No Acupuncture|IVF with no Traditional Chinese Medicine: Acupuncture
62310787|NCT01331395|ACTIVE_COMPARATOR|IVF-Acupuncture|IVF with Traditional Chinese Medicine: Acupuncture
61921955|NCT02037581|EXPERIMENTAL|Early detection and Integrated Care|"The intervention condition consisted of measures to improve early detection and treatment quality (Integrated Care).~1. Interventions for the improvement of early detection. The measures for improved early detection aiming at reducing the duration of untreated psychosis included 4-year measures to improve mental health literacy, reduce stigma and improve service utilization.~2. Measures to improve treatment quality should be achieved through extending the Hamburg model to a cross-age and interdisciplinary Integrated Care model for adolescent and young adult patients with psychotic disorders aged 12-29 years."
61921956|NCT02037581|OTHER|Standard Care|Historical control group with standard care parallelized regarding age, diagnosis and illness stage, which was treated in the period before the implementation of the intervention conditions. The control group consisted of n=105 patients with early psychosis between the ages of 12 and 29, who had been treated between January 2005 and December 2008. The central differences in comparison with the intervention conditions lie in the lack of measures for the improvement of early detection, the absence of the TACT team, as well as the regular referral to an established psychiatrist with in most cases regular contact frequency.
62310788|NCT06217159|SHAM_COMPARATOR|Poikilocapnia|Room air-breathing
62310789|NCT06217159|EXPERIMENTAL|Normocapnia|Breathing air mixture with slightly elevated CO2 to maintain PetCO2 to resting baseline levels
62310790|NCT04310137|EXPERIMENTAL|Therapist-Directed Re-loading|Participants in this arm will be instructed to increase their activity by walking 10% more steps per day than the steps recorded in the most recent activity monitoring (i.e. StepWatch) measurement (e.g. 10% more than the initial monitoring values and 10% more than the second monitoring values once they are completed).
62310791|NCT04310137|NO_INTERVENTION|Self-Directed Re-loading|Participants in this arm will be instructed to slowly increase their walking.
62310792|NCT06512428|EXPERIMENTAL|simmitinib plus irinotecan liposome|
62310793|NCT06512428|EXPERIMENTAL|irinotecan liposome|
62310794|NCT06512428|EXPERIMENTAL|irinotecan|
62310795|NCT02213757|EXPERIMENTAL|Premarin vaginal cream|Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
62310796|NCT02213757|PLACEBO_COMPARATOR|Placebo vaginal cream|Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
62310797|NCT02094105|EXPERIMENTAL|screening|endoscopy examination with iodine staining
62310798|NCT02094105|NO_INTERVENTION|control|1/10 sampling questionnaire interview for control group.
62310799|NCT06672276|ACTIVE_COMPARATOR|A: Subjects with mild renal insufficiency|This group patients were given TQD3606 only one time
62310800|NCT06672276|ACTIVE_COMPARATOR|B: Subjects with moderate renal insufficiency|This group patients were given TQD3606 only one time
62310801|NCT06672276|ACTIVE_COMPARATOR|C: Subjects with severe renal insufficiency|This group patients were given TQD3606 only one time
62310802|NCT06672276|ACTIVE_COMPARATOR|D: Health volunteers|This group patients were given TQD3606 only one time
62121989|NCT05658406|ACTIVE_COMPARATOR|Group C|intraoperative infusion of 6 mL/kg/hour Ringer's lactate.
62310803|NCT02475460|EXPERIMENTAL|HM 3 LIS|All patients implanted with the HM 3 LVAD via less invasive surgical technique
61921957|NCT03538574|ACTIVE_COMPARATOR|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
62121990|NCT05658406|PLACEBO_COMPARATOR|Group D|standard fluid management alone
62121991|NCT05702515||Adult male patients scheduled to receive a PICC insertion|Adult male patients scheduled to receive a PICC insertion using the Vascular Positioning System G4 tip navigation system
62310804|NCT01770353|EXPERIMENTAL|Pilot Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
62310805|NCT01770353|EXPERIMENTAL|Expansion Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis
62310806|NCT04946110|EXPERIMENTAL|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve.
62310807|NCT02412007|EXPERIMENTAL|Group A|"Individualized comprehensive home centred activity based programme. Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to (a) Standing up from squatting position to catch an object of interest.~(b) Squatting from standing position to pick an object of interest. (c) Walking to reach an object of interest. (d) Climbing up steps to get an object of interest. (e) Climbing down steps to keep the above object of interest. (f) Cycling (g) Kicking a football (h) Dancing"
62310808|NCT02412007|ACTIVE_COMPARATOR|Group B|"Conventional Physiotherapy Conventional physiotherapy would include and would not be limited to~1. Passive stretching exercises for spasticity reduction~2. Gait exercises~3. Walking on treadmill~4. Lower limb strengthening exercises~5. Exercises for balance improvenet"
62121992|NCT02186197||Shock and/or Respiratory Failure|
62121993|NCT06123208|EXPERIMENTAL|Whole cooked pinto bean meal|Participants will consume a meal comprised of 100 grams of whole cooked pinto beans
62121994|NCT06123208|EXPERIMENTAL|Pinto bean flour meal|Participants will consume a meal comprised of pinto bean flour equivalent to 100 grams of whole cooked pinto beans
62310809|NCT05186532|EXPERIMENTAL|Dry heat group|infra red-light therapy that supplies radiant heat or infra-red rays to produce heat to the episiotomy wound.
62310810|NCT05186532|ACTIVE_COMPARATOR|Moist heat group|warm sitz bath in which a woman is asked to sit in a warm water tub up to the hip level.
62310811|NCT04252807|EXPERIMENTAL|Intervention arm|"Distressed mothers randomized to intervention arm will receive a common elements based integrated intervention that combines evidence based elements from packages of care addressing early stimulation, responsive feeding and perinatal depression. The integrated intervention is expected to a) improve mother psychological distress, b) improve family support, c) improve child development and d) promote mother-infant interaction.~The participants will receive 15 monthly sessions at home by lay health workers. First three sessions will be delivered to the participants in the third trimester of pregnancy, followed by 12 monthly sessions afterwards."
62681281|NCT05867940|ACTIVE_COMPARATOR|Children and adolescents with autism|20 children and adolescents with autism will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
62681282|NCT05867940|ACTIVE_COMPARATOR|Adults with physical or intellectual disabilities, or with autism|20 adults with physical or intellectual disabilities, or with autism will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
62681283|NCT00003192|EXPERIMENTAL|Arm A|9-aminocamptothecin (25 mcg/m2/hr x 120hrs, days 1-5 and 8-12 of each 3 week cycle)
62681284|NCT06011889|EXPERIMENTAL|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
62681285|NCT06011889|PLACEBO_COMPARATOR|Placebo|treatment with placeboin addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
62681286|NCT06694987|EXPERIMENTAL|Implementation group.|"The study is based on the HOPE-4 protocol, where trained individuals will support participants in adhering to healthy lifestyle recommendations and support their access to a family physician to follow up on care recommendations.~The NPHWs will be allied health professionals (e.g., pharmacists, internationally trained physicians, physiotherapists, nurses). The team will train them on study goals, responsibilities, data management, and follow-up, based on the HOPE-4 training manual. Training will be given once at the beginning of their role and then once annually.~The NPHW will support the participant, if needed, in contacting the family doctor and assisting to arrange a follow-up study. If required, the family doctor can contact the NPHW. If further discussion is required or there are questions regarding the study that require further discussion, the NPHW will contact the study physician to address these issues."
62681287|NCT01871727|EXPERIMENTAL|E7777|
62681288|NCT06442228|EXPERIMENTAL|study group|Individuals who have undergone spermiogram analysis at Etlik Zübeyde Hanım Gynecology Training and Research Hospital and whose first-degree relatives have a family history of PCOS will be included in the study group. Individuals who have undergone a spermiogram in our hospital, who fulfill the inclusion criteria and who do not have a family history of PCOS will be studied as a control group.
62121995|NCT06123208|ACTIVE_COMPARATOR|Control meal|Participants will consume a control meal
62310812|NCT04252807|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|The participants in the control arm will receive the routine monthly visits by the trained Lady Health Workers (LHWs) of their respective areas.
62310813|NCT03419533||2018 school leavers|South Australian school leavers in 2018 (year 12 in 2017)
62310814|NCT03419533||2019 school leavers|South Australian school leavers in 2019 (year 12 in 2018)
62310815|NCT02542449|ACTIVE_COMPARATOR|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
62310816|NCT02542449|PLACEBO_COMPARATOR|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
62310817|NCT03412227|OTHER|Principal Anxiety Disorder|Youth with a principal anxiety disorder
62310818|NCT03412227|OTHER|Principal Depressive Disorder|Youth with a principal unipolar depressive disorder
62310819|NCT00928980|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy and withdrawal of antidepressant medication between the 4th and 5th session, patients being off medication until the end of study period (15 months).
62310820|NCT00928980|EXPERIMENTAL|Combination|Mindfulness Based Cognitive Therapy combined with the use of antidepressant medication during the study (15 months).
62310821|NCT00928980|ACTIVE_COMPARATOR|Optimal Medical Care|Treatment with optimal medical care: therapeutic dose of antidepressant medication during at least 15 months, administered in accordance with current guidelines.
62310822|NCT03380949|EXPERIMENTAL|PPI (Pain Pupillary Index)|Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is \<1.
62476446|NCT05170594|EXPERIMENTAL|Bevacizumab combined with Fluzoparib|Bevacizumab combined with Fluzoparib will be administered in patients with platinum-resistant recurrent ovarian cancer.
62681289|NCT05703256|EXPERIMENTAL|Amygdala real-time fMRI neurofeedback|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
61921958|NCT03538574|EXPERIMENTAL|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
61921959|NCT05354804|PLACEBO_COMPARATOR|Standard|Patients randomized to standard care will be sampled at admission and after 1 hour (and furthermore as clinically indicated). High sensitive Troponin T (cTnT) and standard laboratory tests will be measured in the central hospital laboratory using Cobas e801 from Roche Diagnostics and eligibility for rule-out will be judged in accordance with the ESC 0/1 hour rule-out algorithm for cTnT. ECG and HEART-score will be obtained in all patients, other clinical investigations will be ordered by the attending physician. If NSTE-ACS is low risk based on the cTnT algorithm, HEART\< 4 and non-ischemic ECG, patients will be investigated according to the ED flow chart for non-coronary acute chest pain, in order to identify differential diagnoses. Patients will be admitted or discharged based on the clinical judgement of the attending physician.
61921960|NCT05354804|ACTIVE_COMPARATOR|POC|Blood samples will be obtained at admission, standard blood tests will be measured at the central laboratory whilst high sensitive troponin I at 0 and 1 hour will be analyzed using a POC instrument from Siemens Healthineers in the ED. ECG and HEART-score will be obtained in all patients, other clinical investigations will be ordered by the attending physician. If the cTnI concentration at admission and the 1-hour delta is below a pre-specified concentration, the HEART- score \< 4, and the ECG is non-ischemic the patients will be allocated to the rule-out of NSTEMI group and investigated according to the ED flow chart for non-coronary acute chest pain, in order to identify differential diagnosis. Finally, patients will be admitted or discharged based on the clinical judgement of the attending physician.
61921961|NCT04850898|PLACEBO_COMPARATOR|Normal Saline Placebo Control|Placebo control dosed 1 time via intravenous infusion
62310823|NCT03380949|EXPERIMENTAL|SPI (Surgical Pleth Index)|Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
62476447|NCT05170594|EXPERIMENTAL|Bevacizumab combined with chemotherapy|Bevacizumab combined with non-platinum chemotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer.
62476448|NCT05170594|EXPERIMENTAL|Fluzoparib|Fluzoparib monotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer.
62476449|NCT04708028|NO_INTERVENTION|Control|No exposure to the therapy dog.
62681290|NCT05703256|SHAM_COMPARATOR|Sham feedback|Yoked sham - participants will see the amygdala activity of another subject who completed the intervention. Two sessions will be performed one week apart.
62737593|NCT06329466||Observation|"Before starting the application to the adolescents in the study (EFT) group, researcher G.C. Fast and easy application steps will be explained with the demonstration method, supported by visual presentations.~Care will be taken to provide a suitable, clean and airy environment in which the participants will feel comfortable. EFT training and applications will be held during the lunch break so that students do not experience problems such as being late for class or absenteeism. It will be taught in groups of 10-11 people in order to be sure that each participant has learned and to easily confirm the accuracy of the application. Researcher G.C. The participants will be asked to do it to themselves at the same time while they are doing it on themselves to teach the hitting points and application principles."
61921962|NCT04850898|EXPERIMENTAL|SAB-176 - 25mg/kg|Investigational Medicinal Product dosed 1 time at 25 mg/kg on day 1 via intravenous infusion
61921963|NCT04954170||RCT patients|Patients suffering from rotator cuff injury
61921964|NCT04389970|EXPERIMENTAL|Time Restricted Feeding|Participants will be asked to follow a time-restricted meal pattern (8:16 protocol)
61921965|NCT03927599||Advanced refractory tumor solid tumors patients|Patients with advanced refractory solid tumors carrying TP53 mutations and receive PARP-inhibitors in combination with the VEGFR-inhibitors therapy
62681291|NCT06686446|EXPERIMENTAL|Enhanced Education Package|"Participants randomised to the intervention arm will receive an advanced patient education toolkit and reminders delivered by email/SMS in addition to the standard education provided by their treating clinician.~The EEP will contain:~* Dosing/frequency - links for package inserts for Dymista / Ryaltris (olopatadine-mometasone)~* Correct INCS/INAH technique - the study team will ask participants to show them the correct technique in taking their nasal spray~* ASCIA AR Treatment Plan - the study team will check each participant has been provided with a plan by their treating clinician~* Weekly repeat reminders - these reminders will be sent via either SMS or email over a period of 3 months. They will instruct and remind the participant to take their INCS/INAH as per their treating clinician recommendation and why it is important to take it as instructed.~* Education Toolkit - contains links to websites of key organisations which include educational videos and other resources"
61921966|NCT05155137|EXPERIMENTAL|Riskometer + Polypill|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
61921967|NCT05155137|PLACEBO_COMPARATOR|Riskometer + Placebo|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use placebo polypill
61921968|NCT05155137|EXPERIMENTAL|No Riskometer + Polypill|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
61921969|NCT05155137|NO_INTERVENTION|No Riskometer + Placebo (Usual Care)|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the placebo polypill = usual care
61921970|NCT00833079|EXPERIMENTAL|Tacrolimus 0.1% Taro|Tacrolimus 0.1% manufactured by Taro applied for 14 days
61921971|NCT00833079|ACTIVE_COMPARATOR|Protopic - Tacrolimus 0.1%|Protopic, Tacrolimus 0.1% applied for 14 days
61921972|NCT00833079|PLACEBO_COMPARATOR|Vehicle|Tacrolimus vehicle applied for 14 days
61921973|NCT00906997|ACTIVE_COMPARATOR|Fecal occult blood testing|
61921974|NCT00906997|ACTIVE_COMPARATOR|Colonoscopy|
61921975|NCT03857152|OTHER|Patient receiving CESM|Patients will receive CESM in addition to normal standard treatment.
61921976|NCT05419479|EXPERIMENTAL|LEAD-IN: DOSE DE-ESCALATION|The lead-in dose de-escalation cohort (Phase 1b) will enroll 6 patients (up to 12 patients in 2 dose levels if needed; 6 patients per DL) to receive zimberelimab, domvanalimab, and APX005M
61921977|NCT05419479|EXPERIMENTAL|ARM A: ZIMBERELIMAB + DOMVANALIMAB + APX005M|"Participants will be randomly assigned to one of two groups~Arm A will receive domvanalimab, zimberelimab, and APX005M every two weeks through an infusion."
61921978|NCT05419479|ACTIVE_COMPARATOR|ARM B: FOLFIRI|Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion
62476450|NCT04708028|EXPERIMENTAL|Dog Therapy|Introduced to a therapy dog and allowed to pet the dog for up to 2 minutes (timed) prior to the dental procedure.
61921979|NCT05419479|EXPERIMENTAL|CROSSOVER: ZIMBERELIMAB + DOMVANALIMAB + APX005M|Participants in Arm B (control arm) who experience disease progression (as defined by RECIST v1.1) will be given the option to crossover and receive domvanalimab + zimberelimab, + APX005M in the second-line setting, provided they meet eligibility criteria
61921980|NCT05994495|EXPERIMENTAL|ARM A Molecular test|"Patients randomized to Arm A will be subjected to a microbiological test (either swabs or urine testing by NAAT). After having obtained the result of the molecular test, patients will be prescribed a targeted treatment"
61921981|NCT05994495|ACTIVE_COMPARATOR|ARM B Clinical Syndromic Approach|"Patients randomized to Arm B will be subjected to a molecular test, but they will be treated according to the current guidelines and the best practice using the clinical syndromic approach. So, patients randomized to Arm B and their physician also will be blinded to the results of the molecular test"
61921982|NCT05445934|EXPERIMENTAL|FB2001 group|FB2001 will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
61921983|NCT05445934|PLACEBO_COMPARATOR|Placebo group|Placebo will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
62476451|NCT04513587|EXPERIMENTAL|CBT-Based Weight Loss Model|CBT- Based weight loss model
62476452|NCT04513587|ACTIVE_COMPARATOR|Control|Usual Care
62476453|NCT02914990|EXPERIMENTAL|BPI-15086|BPI-15086, orally administered daily
62681292|NCT06686446|NO_INTERVENTION|Standard of care|"Participants randomised to the control arm will receive the basic standard of care education delivered by their treating clinician. After randomisation, the study team will confirm participants received:~* Correct INCS/INAH technique - the study team will ask participants to show them the correct technique in taking their nasal spray.~* ASCIA AR Treatment Plan - the study team will check each participant has been provided with a plan by their treating clinician. If the participant does not understand their plan or needs further information on dosage and frequency, study nurses/research assistants will ask the participant to contact their treating clinician to organise an appointment to be reviewed. The study team will also send a letter to the treating clinician explaining this."
62681293|NCT06032598|EXPERIMENTAL|Berry extract 1|Dietary supplement - Berry extract 1
62681294|NCT06032598|EXPERIMENTAL|Berry extract 2|Dietary supplement - Berry extract 2
62681295|NCT06032598|PLACEBO_COMPARATOR|Placebo|Dietary supplement - Placebo
62681296|NCT06689228|EXPERIMENTAL|Randomized|"The Effect of Education Based on Self-Care Deficiency Theory on Rational Drug Use in Patients Receiving Haemodialysis In the study, which will last for 2 months, the patients in the intervention group will receive pre-test training based on the Self-Care Deficiency Theory. Also weekly reminder messages will be sent regularly.~Other Names:~Education Based on Self-Care Deficiency Theory on Rational Drug Use"
62681297|NCT06695338|ACTIVE_COMPARATOR|Control Group (Submerged Approach)|Standard/Conventional approach in which guided bone regeneration simultaneous to implant placement is leaved submerged under gingival tissue by suturing looking for first intention healing.
61921984|NCT02586402|EXPERIMENTAL|Pegolsihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
61921985|NCT02586402|ACTIVE_COMPARATOR|Epoetin Alfa|Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
62681298|NCT06695338|EXPERIMENTAL|Test Group (Non-Submerged Approach)|To test approach in which guided bone regeneration simultaneous to implant placement is leaved in a non-submerged manner with second intention healing around an abutment and interproximal suturing.
62681299|NCT06254495|EXPERIMENTAL|SGN-35C|SGN-35C Monotherapy
62681300|NCT03760081|EXPERIMENTAL|ASP1650, Dose Level 1|Participants received ASP1650 dose level 1 as intravenous infusion, every two weeks (Q2W) starting on Cycle 1 Day 1(C1D1) for up to a maximum of 12 cycles, or until disease progression, toxicity requiring study treatment cessation, start of another anticancer treatment, or until study discontinuation criteria was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
62681301|NCT03760081|EXPERIMENTAL|ASP1650, Dose Level 2|Participants received ASP1650 dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criteria as met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
62737594|NCT06329466||Control|Students in the control group will not receive any intervention during the EFT application. Participants in the control group will have the MAÖKF and MSQ filled before the first session, at the end of the third cycle and at the end of the fourth cycle without the application. In order to eliminate ethical problems that may occur in the control group, EFT application will be taught to the participants in this group after the data collection process of the research is completed.
62737595|NCT02144688|EXPERIMENTAL|Change in ARVs to improve cognition|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
62737596|NCT03423030|EXPERIMENTAL|Panel A - Active|N = 6, 10 mg then 40 mg of PBTZ169 Formulation
62737597|NCT03423030|PLACEBO_COMPARATOR|Panel A - Placebo|N = 2, 10 mg then 40 mg of matching placebo
61921986|NCT02369562||Dental implant patients|All patients rehabilitated with dental implants.
62476454|NCT05410002|ACTIVE_COMPARATOR|Vegetarian N-111 group|The group will use a vegetarian diet with the active compactor N-111.
62476455|NCT05410002|ACTIVE_COMPARATOR|Non-vegetarian N-111 group.|The group will use a non-vegetarian diet with the active compactor N-111.
62476456|NCT05410002|PLACEBO_COMPARATOR|Vegetarian placebo group|The group will use a vegetarian diet with a placebo.
62476457|NCT05410002|PLACEBO_COMPARATOR|Non-vegetarian placebo control group|The group will use a non-vegetarian diet with a placebo.
62737598|NCT03423030|EXPERIMENTAL|Panel B - Active|N = 6, 20 mg then 80 mg of PBTZ169 Formulation
62737599|NCT03423030|PLACEBO_COMPARATOR|Panel B - Placebo|N = 2, 20 mg then 80 mg of matching placebo
62737600|NCT03423030|EXPERIMENTAL|Panel C - Active|N = 6, First dosing of Panel C with 160 mg PBTZ169 Formulation then Second dosing of Panel C with 160 mg PBTZ169 Native Crystalline Powder (NCP)
62737601|NCT03423030|ACTIVE_COMPARATOR|Panel C - Placebo|N = 2, 160 mg of matching placebo for the two interventions
62737602|NCT03423030|EXPERIMENTAL|Panel D - Active|N = 6, First dosing of Panel D with 320 mg PBTZ169 Formulation then Second dosing of Panel D with 320 mg PBTZ169 Native Crystalline Powder (NCP)
62737603|NCT03423030|ACTIVE_COMPARATOR|Panel D - Placebo|N = 2, 320 mg of matching placebo for the two interventions
62737604|NCT06302881||low TSR and high TSR group|The assessment of the tumor-stroma ratio (TSR) entailed measuring the percentage of tumor and stroma constituents. Based on earlier research, 5/5 was deemed as ideal threshold of TSR measurement.
62737605|NCT03177512|EXPERIMENTAL|LYNX Mobile App|
62737606|NCT03177512|NO_INTERVENTION|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
62737607|NCT05757518|EXPERIMENTAL|Experimental group|Cryo-stimulation using cryosauna after fatigue-induced exercise.
62737608|NCT05757518|NO_INTERVENTION|Control group|Without any intervention after fatigue-induced exercise.
62121996|NCT03995498|ACTIVE_COMPARATOR|Individualized carbohydrate intake|"Based on glucose sensor level, carbohydrate (orange juice, Oasis classic) will then be given as follow:~If sensor glucose level is under \< 4.5 mmol/L, the camp staff will treat hypoglycemia according to the camp procedure, If sensor glucose level is between 4.5 and 7.0 mol/L, 0.5g of CHO/kg body weight will be given, If sensor glucose level is between 7.1 and 10.0 mmol/L, 0.25g of CHO/kg body weight will be given, If sensor glucose level is between 10.1 and 15.0 mmol/L, no CHO will be given, If sensor glucose level is \> 15.1 mmol/L, the camp staff will treat hyperglycemia according to the camp procedure."
62121997|NCT03995498|ACTIVE_COMPARATOR|Usual camp protocol|As per camp routine care, there will be no mandatory glucose level measurement before the start of physical activity if no symptoms of hypoglycemia or hyperglycemia appear.
62681302|NCT06688513|SHAM_COMPARATOR|Let's Talk: Sharing information about Family Cancer Risk|Participants in the control group will complete questions about their SDH needs in the Carealth mobile app but will not have any helpful resources attached to it that meet these needs. Instead, as an attention control, control group participants will be sent to an interactive tool created and validated by the Centers for Disease Control called Let's Talk: Sharing Info About Your Family Cancer Risk. This is an interactive tool that patients can use to learn about how to talk with their family members about the family member's cancer risk.
62121998|NCT05662917||Palliative care patients|"* Palliative care patients~* Suffering from a serious and progressive illness (whatever it is)~* Hospitalized in a palliative care unit or followed at home by the hospital's mobile palliative care team"
62121999|NCT06676761||nipple sparing mastectomy without reconstruction|nipple sparing mastectomy without reconstruction
62122000|NCT04959136|EXPERIMENTAL|Ambulatory Monitoring Solution|The evaluable device (Ambulatory Monitoring Solution and its parts) is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
62122001|NCT02174393|EXPERIMENTAL|Microneedling Plus Universal Peel|"(1) Microneedling treatment by the MicroPen with a Post-Microneedling Skin Care Regimen and the (2) Universal Peel by Topix with a Post-Universal Peel Skin Care Regimen will both be performed on a monthly basis for a total of three treatment sessions each.~Microneedling will be done on Study Weeks 1, 5, and 9. Universal Peel will be done on Study Weeks 3, 7, and 11."
62122002|NCT03621826||Children with Sickle Cell Anemia|Data from patients with sickle cell anemia will be entered into a retrospective database for evaluation of implementation rates of TCD (stroke) screening). A small number of these children/parents/stakeholders will be selected by convenience sampling to participate in a survey and/or interview to assess barriers and enablers to stroke prevention therapy.
62122003|NCT05033938|ACTIVE_COMPARATOR|Early Mobilization|Post-operatively subjects receive a removable wrist splint that can be taken off for early wrist mobilization
62122004|NCT05033938|ACTIVE_COMPARATOR|Late Mobilization|Post-operatively subjects receive a splint and are not instructed to not move their wrist till the 2 week follow up visit.
62122005|NCT03339024|EXPERIMENTAL|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30:Self-administered intranasal spray as needed, max thrice daily"
62122006|NCT03339024|PLACEBO_COMPARATOR|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
62122007|NCT02971085||Active surveillance|This is the prospective cohort study with single group of active surveillance. We define our cohort group as the patients with following criteria: Men \< 80 years, pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores, pre-biopsy PSA ≤ 10ng/ml, PSA density \< 0.15 ng/ml/ml, clinical stage T1-2a, biopsy Gleason score ≤ 6, number of positive cores ≤ 2, maximum cancer involvement in any one core ≤ 20%, and no PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T).
62122008|NCT05172388|ACTIVE_COMPARATOR|Real purification|Air purifier turned on.
62476458|NCT05410002|NO_INTERVENTION|Vegetarian control group|The group will use a vegetarian diet without the active compactor N-111 or the placebo.
62310824|NCT03380949|EXPERIMENTAL|NOL (Nociception Level)|Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
62476459|NCT05410002|NO_INTERVENTION|Non-vegetarian control group|he group will use a non-vegetarian diet without the active compactor N-111 or the placebo.
62681303|NCT06688513|EXPERIMENTAL|Carealth App|Participants in the treatment group will complete questions about their SDH needs in the Carealth app. Those with SDH needs will be referred to resources to meet those needs through Findhelp embedded into the app. Participants in the treatment group will complete this information pre-surgery, which will be considered a baseline measurement at the start of their participation in the trial. Participants in the treatment group will also receive reminders based on the post-surgery discharge instructions.
62681304|NCT06694506|NO_INTERVENTION|Patients with regular follow-up for their GHD (treated with rhGH or not)|Patients with regular follow-up for their GHD (treated with rhGH or not) in a adult endocrinology department including a clinical examination and endocrine blood work-up at least once a year
62681305|NCT06694506|ACTIVE_COMPARATOR|Patients who are lost to follow-up or not regularly followed for their GHD|Patients who are lost to follow-up or not regularly followed for their GHD (or only followed by their GP with no endocrine assessment)
62681306|NCT03921541|EXPERIMENTAL|Pegzilarginase|Weekly IV infusions of pegzilarginase plus individualized disease management for 24 weeks
62681307|NCT03921541|PLACEBO_COMPARATOR|Placebo|Weekly IV infusions of placebo plus individualized disease management for 24 weeks
62681308|NCT03921541|EXPERIMENTAL|Pegzilarginase Long Term Extension|After completion of 24 weeks DB treatment, weekly IV infusions of pegzilarginase plus individualized disease management for an additional 150 weeks, with the option to receive treatment by SC after 8 weeks of the LTE study.
62681309|NCT05852717|EXPERIMENTAL|GDP + Epcoritamab + AutoSCT or CAR T-cell therapy|"Cycles 1-3 (Cycle = 21 days) Epcoritamab will be administered by subcutaneous injection Days 1, 8, and 15. Epcoritamab Day 1: 0.16mg, Day 8: 0.8mg, Day 15: 48mg except Cycle 2-Epcoritamab will administered at 48mg on Days 1, 8 and 15~Gemcitabine will be administered by IV infusion on Days 1 and 8. Gemcitabine Days 1,8: 1,000mg/m\^2~Cisplatin will be administered by IV infusion on Day 1. Cisplatin Day 1: 75mg/m\^2~Dexamethasone will be given by mouth on Days 1-4. Dexamethasone Days 1-4: 40mg~After completion of Cycle 3 Autologous stem cell transplant (AutoSCT) OR CAR T-cell therapy"
62681310|NCT05852717|EXPERIMENTAL|GDP + Epcoritamab + Epcoritamab Maintenance|"Cycles 1-3 (Cycle = 21 days) Epcoritamab will be administered by subcutaneous injection Days 1, 8, and 15 of each Cycle.~Epcoritamab Day 1: 0.16mg, Day 8: 0.8mg, Day 15: 48mg except Cycle 2-Epcoritabab will administered at 48mg on Days 1, 8 and 15~Gemcitabine will be administered by IV infusion on Days 1 and 8 of each Cycle. Gemcitabine Days 1,8: 1,000mg/m\^2~Cisplatin will be administered by IV infusion on Day 1 of each Cycle. Cisplatin Day 1: 75mg/m\^2~Dexamethasone will be given by mouth on Days 1-4 of Cycle 1 ONLY. Dexamethasone Days 1-4: 40mg~Cycles 4-9 (Cycle =28 Days) Epcoritamab will be administered by subcutaneous injection on Days 1, 8, and 15 of Cycles 4-9."
62681311|NCT06691802|EXPERIMENTAL|Shu Fei Tie group for Asthma/COPD|Patients in the Asthma/COPD experimental group were treated with Shu Fei Tie
62681312|NCT06691802|PLACEBO_COMPARATOR|Shu Fei Tie Placebo group for Asthma/COPD|Patients in the Asthma/COPD experimental group were treated with Shu Fei Tie Placebo
62681313|NCT05084378|EXPERIMENTAL|Povidone-iodine Lavage and Local Antibiotics|1 litre of 0.35% povidone-iodine lavage solution will be used. 2 grams of Vancomycin antibiotic powder will be applied to the deep joint (deep to fascia) following lavage solution and immediately prior to closure.
62681314|NCT05084378|EXPERIMENTAL|Chlorhexidine Lavage and Local Antibiotics|1 litre of 0.05% chlorhexidine lavage solution will be used. 2 grams of Vancomycin antibiotic powder will be applied to the deep joint (deep to fascia) following lavage solution and immediately prior to closure.
62681315|NCT05084378|EXPERIMENTAL|Normal Saline Lavage and Local Antibiotics|1 litre of sterile isotonic saline solution will be used. 2 grams of Vancomycin antibiotic powder will be applied to the deep joint (deep to fascia) following lavage solution and immediately prior to closure.
62681316|NCT05084378|EXPERIMENTAL|Povidone-iodine Lavage Solution with no Local Antibiotics|1 litre of 0.35% povidone-iodine lavage solution will be used immediately prior to closure.
62681317|NCT05084378|EXPERIMENTAL|Chlorhexidine Lavage Solution with no Local Antibiotics|1 litre of 0.05% chlorhexidine lavage solution will be used immediately prior to closure.
62681318|NCT05084378|ACTIVE_COMPARATOR|Normal Saline Lavage with no Local Antibiotics|1 litre of sterile isotonic saline solution will be used immediately prior to closure.
62681319|NCT02704832|NO_INTERVENTION|Arm A|"Arm A Standard oncological care: patients will be treated according to daily oncological practices as defined for each type of cancer, in the Management protocol of Oncology written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months."
62737609|NCT02415049|ACTIVE_COMPARATOR|Incremental|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
61921987|NCT03832244||Simple snoring|Patients undergoing to Sub-mental ultrasonography with Normal sleep: Fewer than 5 events per hour measured in over-night polysomnography
62737610|NCT02415049|EXPERIMENTAL|Ad-lib|This arm of patients is fed ad lib following surgery and can feed with formula or breast milk at any time and with any frequency up to 12.5ml/kg/feed
62737611|NCT05856929||Renal transplant group|
62737612|NCT03002324|ACTIVE_COMPARATOR|Current CDC Message Arm|Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.
62122009|NCT05172388|SHAM_COMPARATOR|Sham purification|Air purifier turned off.
62681320|NCT02704832|EXPERIMENTAL|Arm B|"Arm B Geriatrician Intervention: patients will be treated according to the same Management protocol of Oncology than patients in the arm Standard oncological care.~* Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the Management protocol of Geriatrics.~* The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months."
61921988|NCT03832244||Mild OSA|Patients undergoing to Sub-mental ultrasonography with Mild sleep apnea: 5 to 14 events per hour measured in over-night polysomnography
61921989|NCT03832244||Moderate OSA|Patients undergoing to Sub-mental ultrasonography with Moderate sleep apnea: 15 to 29 events per hour measured in over-night polysomnography
61921990|NCT03832244||Severe OSA|Patients undergoing to Sub-mental ultrasonography with Severe sleep apnea: 30 or more events per hour measured in over-night polysomnography
61921991|NCT01221103|EXPERIMENTAL|DOT|Combination of dexamethasone, ofatumumab and bendamustine
61921992|NCT00647218|EXPERIMENTAL|Experimental|
61921993|NCT04628832|EXPERIMENTAL|PMP Use Mandate|
62681321|NCT06688175|EXPERIMENTAL|Experimental|in the treatment of elderly patients with nasopharyngeal carcinoma
61921994|NCT04628832|EXPERIMENTAL|Prescribing Information|
62122010|NCT02100371|EXPERIMENTAL|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
62122011|NCT05261061||Old patients hospitalized in acute geriatric unit|
62122012|NCT05261061||Old patients hospitalized for other medical diagnosis in acute geriatric unit|
62122013|NCT02709655|EXPERIMENTAL|Vortioxetine 10 mg/day|
62737613|NCT03002324|EXPERIMENTAL|Cervical Cancer Message Arm|Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.
61921995|NCT04628832|EXPERIMENTAL|Prescribing Information + PMP Use Mandate|
61921996|NCT04628832|NO_INTERVENTION|Control / As-Usual|
61921997|NCT02374762||Hemodialysis Patients with AVF|Hemodialysis patients that use an arteriovenous fistula (AVF) to receive their dialysis treatments will be invited to have their AVF recorded by a digital camera for one minute prior to cannulation.
61921998|NCT05068895||Group1|Volunteers with normal glucose tolerance.
61921999|NCT05068895||Group2|type 2 diabetic patients without microvascular (retinopathy, nephropathy or neuropathy) or macrovascular (coronary, cerebrovascular or lower extremity arterial disease) complications.
61922000|NCT05068895||Group3|type 2 diabetic patients with lower extremity artery disease diagnosed through the measurement of ABI (the ratio of ankle-to-brachial systolic blood pressure).
61922001|NCT02851862||Late Onset GM2 Gangliosidosis|10-15 subjects with Late Onset GM2 Gangliosidosis
61922002|NCT03002376|EXPERIMENTAL|REGN2810|REGN2810 treatment
61922003|NCT02734433|EXPERIMENTAL|Pexidartinib|Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
61922004|NCT05320627|EXPERIMENTAL|Edoxaban treatment|
62122014|NCT02709655|EXPERIMENTAL|Vortioxetine 20 mg/day|
62122015|NCT02709655|ACTIVE_COMPARATOR|Fluoxetine 20 mg/day,|A decision has been taken to stop recruitment into this treatment arm.
62122016|NCT02709655|PLACEBO_COMPARATOR|Placebo|
62122017|NCT05308381|EXPERIMENTAL|Fasted exercise|Fasted prior to exercise
62122018|NCT05308381|EXPERIMENTAL|High protein breakfast exercise|High protein breakfast consumption prior to exercise
62122019|NCT05308381|EXPERIMENTAL|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
62476460|NCT04999501|EXPERIMENTAL|65 - 75 years|All volunteers aged 65 - 75 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
62681322|NCT05720884|EXPERIMENTAL|acupuncture group|A total 10 acupoints of bilateral PC6, PC5, SP3, KI3, and ST36 will be chosen for the intervention group, also known as the acupuncture group. The depth of acupuncture will be varied by participant by participant. After acupuncture needles be inserted, the needles will be manually manipulated to obtain pre-determined sensation, the De Qi. Then, acupuncture will remain inserted for 20 minutes.
61922005|NCT02717377|NO_INTERVENTION|Uninterrupted sitting|Subjects remained seated all day except to rise from the chair to void.
62681323|NCT05720884|PLACEBO_COMPARATOR|placebo group|Ten other points, which are not official acupoints and those are not on the median nerve or peroneal nerve, will be chosen for the placebo group.
62681324|NCT04002063|EXPERIMENTAL|CBT-D augmented with CBT MobileWork-V|Patients randomized to this condition will receive CBT-D as usual plus access to CBT MobileWork-V, a comprehensive tailored smartphone app for CBT skills practice for OEF/OIF Veterans.
62476461|NCT04999501|EXPERIMENTAL|85 years and over|All volunteers over the age of 85 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
62476462|NCT02651272|EXPERIMENTAL|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
62122020|NCT03767907|EXPERIMENTAL|Online Cognitive Behavioural Therapy|Computer-based training for cognitive behavioural therapy (CBT4CBT) consists of seven modules, and includes a series of interactive videos presenting characters portrayed by professional actors struggling with real-life situations. These characters first experience a common risky situation or problem and then demonstrate the application of a targeted skill. The program further comprises games and interactive exercises to teach and model effective use of skills and strategies.
62476463|NCT01849003|EXPERIMENTAL|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
62476464|NCT01849003|EXPERIMENTAL|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
62476465|NCT01849003|EXPERIMENTAL|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
62476466|NCT01849003|EXPERIMENTAL|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
62681325|NCT04002063|ACTIVE_COMPARATOR|CBT-D|Patients randomized to CBT-D will receive CBT-D as usual only.
62681326|NCT03008473|EXPERIMENTAL|video laryngoscope and chest CT iminge|First,the operator calculate the distance between the carina and the glottis by CT image and make a marker on the Uniblocker. Then the operator inserted the Uniblocker into the trachea and advanced toward the left main-stem bronchus via the video laryngoscope untill see marker just at the glottis then stopped the insertion .Second, a single lumen tube with appropriate size was intubated via video laryngoscope into the appropriate depth.Third,the Fiberoptic bronchoscopy(FOB) was inserted into single lumen tube to assess the position of the Uniblocker and the injuries of bronchi and carina
61922006|NCT02717377|ACTIVE_COMPARATOR|Sitting + one bout of activity|Subjects remained seated all day, except to rise from the chair to void, and to perform one bout of 30-minutes moderate-intensity walking. Physical activity was performed at 0800, after measures of vitals and basal questionnaire assessments, but before breakfast.
62476467|NCT01849003|EXPERIMENTAL|Cohort 5|"Participants will receive single doses of GS-6615 as follows:~* Day 1: 20 mg (loading dose)~* Day 2: 40 mg (loading dose)~* Days 3-7: 6 mg (maintenance dose) once daily~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
62476468|NCT01849003|EXPERIMENTAL|Cohort 6|"Participants will receive single doses of GS-6615 as follows:~* Day 1: 50 mg (loading dose)~* Day 2-3: 10 mg once daily~* Days 4-7: 20 mg once daily"
62476469|NCT05721586|EXPERIMENTAL|CURODONTTM REPAIR: + Fluoride varnish (DURAFLOR)|
62681327|NCT03008473|EXPERIMENTAL|Conventional intubation of Uniblocker|First, a conventional single lumen tube (SLT) was inserted into trachea at optimal depth via video laryngoscope. Second, a Uniblocker was inserted through SLT and directed to the left main-stem bronchus. Third, an FOB was inserted into the SLT to adjust the Uniblocker to optimal position and assessed the injuries of bronchi and carina.
62681328|NCT04408209|EXPERIMENTAL|Convalescent Plasma|Convalescent Plasma - early treatment of patients with severe COVID-19
62476470|NCT05721586|ACTIVE_COMPARATOR|Fluoride Varnish (DURAFLOR) only|
62476471|NCT06466707|OTHER|Collection of microbiome samples|Collection of skin, oral and vaginal (if applicable) microbiome samples by means of a swab and collection of fecal material using Fecotainer collection kit. No treatments will be given to the healthy volunteers.
62476472|NCT04968821|EXPERIMENTAL|Physical Activity|Participants randomized to the physical activity intervention will receive usual postoperative care and a tele-health physical activity intervention.
61922007|NCT02717377|EXPERIMENTAL|Sitting + microbursts of activity|Subjects rose from the seated position every hour for 6-hours from 0910 to 1430 to complete 5-minute bouts of moderate-intensity walking, yielding a total activity time of 30-minutes.
61922008|NCT06070571|EXPERIMENTAL|Intervention group|Bucco-adhesive films with Yarrow and Moringa extract nanoparticles
61922009|NCT06070571|ACTIVE_COMPARATOR|control group|Cholorohexiden oral gargles
61922010|NCT01983150|EXPERIMENTAL|Crush the Crave Application|Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
61922011|NCT01983150|ACTIVE_COMPARATOR|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting(45) that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
61922012|NCT02140476|EXPERIMENTAL|Thyroid Goiter|Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.
61922013|NCT02140476|ACTIVE_COMPARATOR|Papillary Thyroid Cancer|Patients of any gender or ethnical origin with papillary thyroid cancer no greater than 4 cm in diameter. Half of these patients will undergo either bipolar or conventional thyroidectomy.
61922014|NCT03695276|EXPERIMENTAL|PuSHCon model|A health coach will contact patients with poorly controlled asthma or COPD. The health coach will gather information from the patient and medical record and review the case with a pulmonary specialist. The specialist will provide recommendations to the primary care clinician based on the case review; the specialist may request an in-person patient visit if needed. The health coach will follow up with the primary care clinician and will support implementation of recommendations that the the primary care clinician accepts,
61922015|NCT03695276|ACTIVE_COMPARATOR|Usual care|Patients with poorly controlled asthma or COPD will receive the standard of care, which usually means management within primary care. The study team will provide in-service sessions on COPD and asthma guidelines to primary care clinicians in both arms. As in standard practice, a primary care clinician may refer a patient for specialty consultation or diagnostic testing at any time.
61922016|NCT02440412|EXPERIMENTAL|Massage Therapy|A 45 minutes massage therapy (manual) standardized session, based in Swedish techniques.
61922017|NCT02440412|PLACEBO_COMPARATOR|Rest condition|45 minutes of rest in supine position, listening music with headphones, and warm condition.
61922018|NCT02440412|NO_INTERVENTION|Control|Normal working condition, as a office workers (secretaries and managements employees)
61922019|NCT04118582||Prospective analisys|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).~Evaluation of RMR For the evaluation of the RMR, the values of VO2 and VCO2 will be collected by the indirect calorimetry (IC) method using the Ultima CPX metabolic analyzer (MedGraphics, USA), calibrated with each test."
62681329|NCT06327256|EXPERIMENTAL|Dose group 1|Group receiving placebo or dose 1 of BI 3000202
61922020|NCT04265768|PLACEBO_COMPARATOR|No Soft tissue augmentation surgery|No soft tissue augmentation concomitant to implant placement. Negative control group.
61922021|NCT04265768|EXPERIMENTAL|Soft tissue augmentation surgery with Fibro-Gide|"Soft tissue augmentation concomitant to implant placement with a porcine, volume-stable cross-linked collagen matrix (Fibro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland).~Test group."
61922022|NCT04265768|ACTIVE_COMPARATOR|Soft tissue augmentation surgery with patient's CTG|"Soft tissue augmentation concomitant to implant placement with a connective tissue graft (CTG) taken from the patient's palate or retromolar area.~Positive control group."
62310825|NCT03380949|ACTIVE_COMPARATOR|Control|Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
62476473|NCT04968821|OTHER|Usual Care|Participants randomized to usual care will receive postoperative care as determined by their treating surgeon.
62476474|NCT00906477|EXPERIMENTAL|Early intervention|Modified CI therapy starting between 7 and 28 days post stroke.
62681330|NCT06327256|EXPERIMENTAL|Dose group 2|Group receiving placebo or dose 2 of BI 3000202
62681331|NCT06327256|EXPERIMENTAL|Dose group 3|Group receiving midazolam, midazolam and dose 3 of BI 3000202 or midazolam and placebo, and only BI 3000202 or only placebo
62681332|NCT06327256|EXPERIMENTAL|Dose group 4|Group receiving midazolam, midazolam and dose 4 of BI 3000202 or midazolam and placebo, and only BI 3000202 or only placebo
62681333|NCT03576820|EXPERIMENTAL|Lidocaine|Subjects will receive a one time dose of 20mg of 2% lidocaine (1 mL) via nasal mucosal atomizer
62681334|NCT03576820|PLACEBO_COMPARATOR|Placebo|Subjects will receive a one time dose of 1 mL of 0.9% sodium chloride solution via nasal mucosal atomizer.
62681335|NCT06687564|EXPERIMENTAL|PIPO patients|PIPO patients with variants of interest
62681336|NCT06687564|OTHER|WT|Control arm, same experiments as for patients. Samples from specific cell lines
62681337|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
62681338|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
62681339|NCT04609566|EXPERIMENTAL|Combination Therapy|brentuximab vedotin + pembrolizumab
62681340|NCT05635409|EXPERIMENTAL|Dose 1|The starting dose of this trial is selected as a dose of cells that is likely to be the minimal therapeutic dose, i.e. 100,000 surviving DA neurons per putamen, obtained by transplanting 3.54 million STEM-PD cells per putamen.
62737614|NCT03002324|SHAM_COMPARATOR|Control Message|Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.
62737615|NCT02723552|NO_INTERVENTION|Control|Control participants undergo no intervention.
62737616|NCT02723552|EXPERIMENTAL|Exercise|Exercise group participants will undergo 16 weeks of 3x/week supervised aerobic exercise of at least 40 minutes per session. After the supervised exercise phase, they will be monitored and supported to maintain an increased physical activity level for eight months.
62122021|NCT03767907|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual consists of weekly group and/or individual psychotherapy as determined by the clinical team. Psychotherapy will include structured relapse prevention, include cognitive and behavioural techniques, motivational enhancement, mindfulness, and specialized topics (e.g., vocational training, rainbow services) as appropriate.
62681341|NCT05635409|EXPERIMENTAL|Dose 2|"To ensure that the investigators are not using a potentially suboptimal cell dose, the investigators also plan to test a higher dose, which is double the dose of dose 1, i.e., 200,000 surviving DA neurons (= 7.08 million transplanted STEM-PD cells) per putamen.~The Data and Safety Monitoring Board (DSMB) for the trial will make a recommendation for the dosing once participants 1-4 have been dosed and data is available for imaging and clinical measurements, as well as safety reports, 6 months after the last patient has been grafted. The DSMB can recommend either to: i) remain at dose 1; ii) proceed to dose 2; or, iii) wait longer to collect more data. The final decision will be made by the clinical sub-group of the Trial Management Group, after receiving confirmation of the DSMB's recommendation."
62681342|NCT06674772||Migraine Patients|Patients, male and female, with Episodic migraine, all ages.
62681343|NCT06674772||Control group|Male and female without migraine or headache
62681344|NCT04380753|EXPERIMENTAL|Treatment Arm|Subjects will be enrolled and will receive AMG 510 PO QD.
62681345|NCT00771186||children with vocal fold immobility|
62681346|NCT02165787||patients|
62681347|NCT02165787||healthy control subjects|
62681348|NCT01671774|EXPERIMENTAL|IMAB362 + ZA|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1.
62681349|NCT01671774|EXPERIMENTAL|IMAB362 + ZA + IL-2 (1 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
62681350|NCT01671774|EXPERIMENTAL|IMAB362 + ZA + IL-2 (3 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
62681351|NCT01671774|ACTIVE_COMPARATOR|IMAB362|Participants received IMAB362 only on Day 1 of each cycle every 3 weeks.
62681352|NCT06145048|EXPERIMENTAL|0.32 mg/kg VGT-309|0.32 mg/kg VGT-309 given over 15-20 minutes by syringe pump
62681353|NCT05075577|EXPERIMENTAL|Phase 1 Cohort 1|600 mg QD EPI-7386 in combination of Enzalutamide120 mg
62681354|NCT05075577|EXPERIMENTAL|Phase 1 Cohort 2|800 mg QD EPI-7386 in combination of Enzalutamide120 mg
62681355|NCT05075577|EXPERIMENTAL|Phase 1 Cohort 3|600 mg BID EPI-7386 in combination of Enzalutamide120 mg
62681356|NCT05075577|EXPERIMENTAL|Phase 1 Cohort 4|RP2D mg EPI-7386 in combination of Enzalutamide160 mg
62681357|NCT05075577|EXPERIMENTAL|Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)|RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg
62681358|NCT05075577|ACTIVE_COMPARATOR|Phase 2 Enzalutamide single agent|Enzalutamide 160 mg
62681359|NCT05078879|EXPERIMENTAL|Treatment Arm|Patients with GCPC3 will receive daily Empagliflozin for 12 months.
62681360|NCT06083467|OTHER|Diagnostic Assessments|Subjects may receive a brain MRI and neurological exam with diagnostic assessments.
62681361|NCT06686628|EXPERIMENTAL|Amlitelimab and CYP substrates|"A single oral dose of a CYP450 substrates cocktail which will include caffeine, metoprolol, midazolam, omeprazole, and warfarin will be administered.~A single dose of amlitelimab will then be administered on several days. A single oral dose of CYP450 substrates cocktail in combination with the last single dose of amlitelimab."
62681362|NCT00742742|EXPERIMENTAL|A|Nutrition advice (accroding to AHA recommendation) + 30 grams/day supplement of walnuts,walnuts were incorpatated into bread that provided to the participants
62681363|NCT00742742|SHAM_COMPARATOR|B|Registed dietians give the advice for health lyfestyle
62122022|NCT02817334|EXPERIMENTAL|indocyanine green|"As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.~Intervention: Drug: indocyanine green"
62681364|NCT05549882||HFNC success group|
62681365|NCT05549882||HFNC failure group|HFNC failure was defined as the subsequent need for invasive MV.
62681366|NCT00641212|EXPERIMENTAL|1|Budesonide
62681367|NCT00641212|PLACEBO_COMPARATOR|2|
62681368|NCT04978506|EXPERIMENTAL|BI 1569912 MRD: treatment group 1|Multiple rising dose (MRD) part
62681369|NCT04978506|EXPERIMENTAL|BI 1569912 POSO treatment group|Posology part (optional)
62681370|NCT04978506|PLACEBO_COMPARATOR|Placebo|
62681371|NCT04978506|EXPERIMENTAL|BI 1569912 MRD: treatment group 2|Multiple rising dose (MRD) part
62681372|NCT04978506|EXPERIMENTAL|BI 1569912 MRD: treatment group 3|Multiple rising dose (MRD) part
62122023|NCT06373744||metronomic chemotherapy|Patients with advanced breast cancer who received metronomic chemotherapy.
62681373|NCT04978506|EXPERIMENTAL|BI 1569912 MRD: treatment group 4|Multiple rising dose (MRD) part
62681374|NCT04978506|EXPERIMENTAL|BI 1569912 MRD: treatment group 5|Multiple rising dose (MRD) part
62681375|NCT04978506|EXPERIMENTAL|BI 1569912 MRD: treatment group 6|Multiple rising dose (MRD) part
62681376|NCT04978506|EXPERIMENTAL|BI 1569912 elderly treatment group|
62681377|NCT05656274|EXPERIMENTAL|JS1-1-01|JS1-1-01 25mg，50mg，100mg，150mg
62681378|NCT05656274|PLACEBO_COMPARATOR|Placebo|placebo 25mg，50mg，100mg，150mg
62681379|NCT06468046|EXPERIMENTAL|Mama Empoderada (Mom Power)|Behavioral: The intervention group will receive the Mama Empoderada intervention, which is a theory- based, trauma-informed, culturally tailored group intervention to promote mental health and positive parenting outcomes among trauma-exposed mothers with young children (0-5 years). Intervention participants will receive 10 group and 3 individual sessions addressing parenting, active linkage to resources (e.g., food, shelter, migration), social support, and resilience.
62737617|NCT02131090|EXPERIMENTAL|Tegaderm TM|Participants in this arm of the study will receive the Tegaderm dressing to secure the epidural catheter
62737618|NCT02131090|EXPERIMENTAL|Lock-it Plus|Participants in this arm of the study will receive the Lock-it Plus dressing to secure the epidural catheter
62122024|NCT04930718|ACTIVE_COMPARATOR|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life;
62310826|NCT03411603||INCA2 2006-07|"French National Dietary Intake Survey, conducted in 2006-2007 by the French Agency for Food, Environmental and Occupational Health Safety.~Adults aged 18y and over, n=1918 included in the analyses."
62310827|NCT03411603||NHANES 2011-12|Wave 2011-12 of the National Health and Nutrition Examination Survey, the US national dietary intake Survey, conducted by the Centers for Disease Control and Prevention (CDC) Adults aged 18y and over, n=5073 included in the analyses.
62476475|NCT00906477|ACTIVE_COMPARATOR|Delayed intervention|Modified CI Therapy starting 6 months post stroke
62495957|NCT04021407|ACTIVE_COMPARATOR|AirQ|36 patients each were ventilated with air Q airway during dacryocystorhinostomy surgery
62681380|NCT06468046|NO_INTERVENTION|Standard of care|The control group will receive standard of care programming available locally, including referrals to drop-in migrant and family supports, childcare, and referrals to reproductive, mental health, and other services. Control group participants will have the opportunity to participate in the full intervention following completion of the intervention and all questionnaires by the intervention group (post 6-month visit).
62681381|NCT06312124|EXPERIMENTAL|Participants scheduled for non-gynecologic abdominopelvic surgery|Participants will be aged ≥45 years, have at least 1 fallopian tube, will not desire or plan to have children in the future, and will be scheduled to undergo non-gynecologic abdominopelvic surgery.
62681382|NCT05378100|EXPERIMENTAL|Ketamine-Ketamine|Participants in this arm will receive two infusions of ketamine four weeks apart.
62681383|NCT05378100|EXPERIMENTAL|Ketamine-Midazolam|Participants in this arm will receive one infusion of ketamine followed four weeks later by an infusion of midazolam.
62681384|NCT05378100|EXPERIMENTAL|Midazolam-Ketamine|Participants in this arm will receive one infusion of midazolam followed four weeks later by an infusion of ketamine.
62681385|NCT06694194||NA|
62681386|NCT04825262|EXPERIMENTAL|Intervention genotyping group|"Patients who are scheduled to receive renal transplant from a living donor between January 2021 to January 2023. They will be assigned to receive the initial CYP3A5 genotype-based tacrolimus (FK) dose as determined by their CYP3A5 genotype.~CYP3A5 expresser (extensive or intermediate metabolizer) - 0.20mg/kg CYP3A5 non-expresser (poor metabolizer) - 0.15mg/kg~The starting dose of the intervention arm will be reviewed for every 10 patients recruited based on the drug levels achieved."
62681387|NCT04825262|NO_INTERVENTION|Historical Control Group|Patients who received renal transplant from a living donor between January 2016 - December 2020 and received standard weight-based dosing of tacrolimus
62681388|NCT03268499|EXPERIMENTAL|Suspension Group|Patients are treated with chemoembolization using a formulation that consists of a suspension of 100mg pure anhydrous cisplatin in 20mL Lipiodol (5mg cisplatin /mL suspension)
62681389|NCT03268499|ACTIVE_COMPARATOR|Emulsion Group|Patients are treated with chemoembolization using a formulation that consists of 10mg aqueous cisplatin (10mL) mixed with 10mL Lipiodol to form an emulsion (0.5mg cisplatin/mL emulsion)
62681390|NCT06576570|OTHER|Acute Care Surgery Attending and Resident Surgeons|"Participants will be asked to perform their normal operative work for 5 cases while being filmed. Data will be collected using the SoterTask™ software which calculates momentary data on risk and an aggregate risk level. Two standard ergonomic risk assessments: Rapid Upper Limb Assessment (RULA) or the Rapid Entire Body Assessment (REBA) are also calculated. Both assessments are current best practice standard for determining the level of ergonomic risk. The RULA and REBA data calculated by SoterTask will be compared to scores assessed by the research team from the same video recordings of the work tasks.~Following the fifth operative case, participants will view an educational presentation of surgical ergonomics and review the data summarized from the ergonomic measurement system with video of their movement with a visual guideline highlighting high-risk angles and movements including legs, arms, neck and back."
62310828|NCT00816218|EXPERIMENTAL|Pioglitazone|Fifty type 2 diabetic patients (25 diet-treated and 25 treated with diet plus sulfonylurea) will have pioglitazone, 45 mg daily; added to their therapeutic regimen. All patients will be closely monitored and, in addition to periodic contacts and clinical visits, metabolic and vascular parameters will be assessed at the beginning and after 3 and 6 months of therapy. Euglycemic hyperinsulinemic clamp with muscle biopsies will be performed at the beginning and after 6 months of treatment.
62681391|NCT02088411|ACTIVE_COMPARATOR|Diclofenac|Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
62310829|NCT05422144|EXPERIMENTAL|Treatment|Antimicrobial Skin \& Wound Cleanser and Antimicrobial Wound gel will be subsequently administered to the wound during the 28 day study duration.
62681392|NCT02088411|ACTIVE_COMPARATOR|Wobenzym|Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks.
62681393|NCT02088411|PLACEBO_COMPARATOR|Placebo|Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
62681394|NCT02225795|EXPERIMENTAL|Single Arm: All subjects|Hematopoietic stem cell transplantation
62681395|NCT05591768|EXPERIMENTAL|MBA group monopolar radiofrequency group.|Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be \< 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
62681396|NCT05591768|EXPERIMENTAL|BFA group bipolar radiofrequency group|similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures
62310830|NCT05983302|EXPERIMENTAL|Platelet-Rich Plasma-Fibrin Glue|The first intervention group (group A) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing platelet-rich plasma-fibrin glue intervention for 8 weeks.
62681397|NCT06665789|EXPERIMENTAL|Experimental|Mindfulness-based stress reduction training will be given to women selected for the experimental group for 8 weeks.
62681398|NCT06665789|NO_INTERVENTION|Control|Women in the control group receive routine care at the same hospital's polyclinics.
62681399|NCT04624204|EXPERIMENTAL|Group A - Pembrolizumab 200 mg|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg every 6 weeks (Q6W) plus olaparib matching placebo twice daily (BID) for 12 months or until specific discontinuation criteria are met.
62681400|NCT04624204|EXPERIMENTAL|Group B - Pembrolizumab 200 mg plus Olaparib 300 mg BID|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg Q6W plus olaparib 300 mg BID for 12 months or until specific discontinuation criteria are met.
62681401|NCT04624204|PLACEBO_COMPARATOR|Group C (Pembrolizumab and Olaparib Matching Placebos)|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab placebo (saline) Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab placebo (saline) Q6W plus olaparib matching placebo for 12 months or until specific discontinuation criteria are met.
62681402|NCT06683092||RETRIAL-MH|People with CF ages 6 and up with a history of new or worsening mental health symptoms (MH) while on elexacaftor/tezacaftor/ivacaftor (ETI) requiring discontinuation or change from standard dosing who start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).
62681403|NCT06683092||RETRIAL-Neuro|People with CF from RETRIAL-MH who experienced new/worsening neurocognitive symptoms while taking elexacaftor/tezacaftor/ivacaftor (ETI).
62681404|NCT06683092||RETRIAL-Liver|People with Cystic Fibrosis ages 6 and up with a history of liver-related intolerance to elexacaftor/tezacaftor/ivacaftor (ETI) requiring dose modification or discontinuation start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).
62681405|NCT03289195|EXPERIMENTAL|MRI biopsy|All patients enrolled will have had complete MR imaging response post Neoadjuvant Chemotherapy (NAC) and will undergo percutaneous MR guided biopsy.
62122025|NCT04930718|EXPERIMENTAL|Experimental group|The experimental group will also carried out a proprioceptive exercise home program with a laptop.
62122026|NCT02343211|EXPERIMENTAL|immunoglobulin|
62122027|NCT04711213|ACTIVE_COMPARATOR|Dexamethasone Dose 1|
62310831|NCT05983302|EXPERIMENTAL|Repairing Gel|The second intervention group (group B) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing repairing gel intervention for 8 weeks. The components of repairing gel are vitamin A - vitamin C - vitamin B3 - glycine amino acid. - ethanol - collagen - citric acid - glycerin - malic acid - urea - carboxymethyl cellulose - Sodium alginate - Benzoic acid - Allantoin - Bromelain - Methylene blue - Violet dimethyl sulfoxide . The formulation is patented. (PCT, IR108458)
62681406|NCT05337137|EXPERIMENTAL|Arm A: Relatlimab + Nivolumab + Bevacizumab|
62681407|NCT05337137|EXPERIMENTAL|Arm B: Placebo + Nivolumab + Bevacizumab|
62681408|NCT06539897|EXPERIMENTAL|Sexual Education Group|The intervention group contains a combination of pelvic floor exercises and sexual education. One hour of each training consists of pelvic floor exercise practice and the other hour consists of sexual health education.
62122028|NCT04711213|ACTIVE_COMPARATOR|Dexamethasone Dose 2|
62122029|NCT04711213|PLACEBO_COMPARATOR|Placebo Dose 1|
62122030|NCT04711213|PLACEBO_COMPARATOR|Placebo Dose 2|
62122031|NCT05780827||Healthy volunteers|No symptoms and signs of oral and maxillofacial dysfunction are required
62122032|NCT05780827||Patients with temporomandibular joint disorder|Patients with temporomandibular joint disorder
62122033|NCT06131268|EXPERIMENTAL|Patients with Major Depression (Group 1)|They will be evaluated at baseline (T0) and at 4 weeks from the setting of drug treatment with venlafaxine (T1)
61922023|NCT04847089|EXPERIMENTAL|Motor Imagery BCI training|Complete intervention with motor imagery BCI training. Patients recruited by physiotherapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
61922024|NCT00468039|EXPERIMENTAL|vildagliptin + metformin|
61922025|NCT01028378|EXPERIMENTAL|Topography-guided LASIK|Topography-guided LASIK for Myopia or Hyperopia
62681409|NCT06539897|NO_INTERVENTION|No education|Women are not given information about sexual function
62681410|NCT04712227||difficult intubation|patients with a difficult intubation score of 5 or more
61922026|NCT02879240|OTHER|Group animated cartoon-black screen (AB)|In this group, children will be exposed to a animated cartoon during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to a black screen in the same conditions for one other week.
61922027|NCT02879240|OTHER|Group black screen - animated cartoon (BA)|In this group, children will be exposed to a black screen during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to an animated cartoon in the same conditions for one other week.
62681411|NCT04712227||easy intubation|patients with difficult intubation score less than 5
61922028|NCT04079569|EXPERIMENTAL|Tobacco|"Participants will receive education delivered by a lay health worker on Quit Smoking For a Healthy Family. Participants will receive written information on nutrition and physical activity."
61922029|NCT04079569|ACTIVE_COMPARATOR|Healthy Living|"In this comparison arm, participants will receive education delivered by the lay health worker about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
62310832|NCT05983302|EXPERIMENTAL|Platelet-Rich Plasma-Fibrin Glue and Repairing Gel|The third intervention group (group C) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing the repairing gel with approved wound healing components and platelet-fibrin glue for 8 weeks.
62310833|NCT05983302|EXPERIMENTAL|Classical wound irrigation (control)|For 10 patients with chronic wounds, only classical wound irrigation by normal saline (0.9%) will be continued for 8 weeks.
62310834|NCT03333369|ACTIVE_COMPARATOR|Madopar Arm|A single dose of a cachet filled with 200 mg levodopa/50 mg benserazide
62681412|NCT04712227||difficult mask ventilation|group 3 and 4 by han mask ventilation grouping
62681413|NCT04712227||easy mask ventilation|group 1 and 2 according to han mask ventilation grouping
62681414|NCT05639647|EXPERIMENTAL|ATM-AVI|ATM-AVI administered iv every 6 or 8 hours and dosed according to participant's weight and kidney function for up to 14 days depending on response. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv ATM-AVI therapy
62681415|NCT05639647|ACTIVE_COMPARATOR|Best available therapy (BAT)|BAT will be selected by the investigator and administered iv. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv BAT
61922030|NCT03686644|EXPERIMENTAL|Children with Cerebral Palsy|Children with Cerebral Palsy (CP) will be included. They will have to wearing of night splint ankle foot orthoses (phase A) and then no wearing of night splint ankle foot orthoses (phase B). The phases A and B will be repeated twice. In more, they will have an ultrasound, isokinetic dynamometer and measure of quality of night sleeping.
61922031|NCT03574324|EXPERIMENTAL|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
62476476|NCT05802784|ACTIVE_COMPARATOR|Scissors arm|Patients in this group had undergone resection of the septum with hysteroscope and scissors, The scissors used was pointed, single action and semi rigid . Saline was used as the distending medium in the scissors group. Septal incision was carried out using shortening technique by incising the septum at the leading edge and continue dividing by moving from side to side (in narrow septum), or by thinning technique by which incisions will be made along each side of the septum alternately from one cornual end to the other (in broad septum). The operation was stopped if the fluid deficit exceeded 2500 ml of saline.
62681416|NCT04787042|EXPERIMENTAL|Phase 1a, Dose Escalation|"In the Phase 1a monotherapy study, the starting dose of ST-067 will be 30 μg/kg, with a total of 7 dose level cohorts planned.~The starting dose for the IV infusion monotherapy dosing will be 60 µg/kg.~Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. Up to 12 patients will be treated at the RP2D."
62310835|NCT03333369|PLACEBO_COMPARATOR|Placebo Arm|A single dose of a cachet filled with Dextrose
62310836|NCT06667440|EXPERIMENTAL|CRIOTHERAPY|Women in the intervention group will apply cryotherapy on their hypogastrium with a coldpack
62310837|NCT06667440|NO_INTERVENTION|CONTROL|
62310838|NCT05295160|OTHER|type 2 diabetes - less than 4 years duration|Patients with a duration of less than 4 years since diagnosis of type 2 diabetes, BMI \> 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
62310839|NCT05295160|OTHER|type 2 diabetes - more than 8 years|Patients with a duration of more than 8 years since diagnosis of type 2 diabetes, BMI \> 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
62310840|NCT02185599||Colposcopy with DySIS|The prospective arm will recruit patients referred for colposcopy and will be examined using DySIS.
62310841|NCT02185599||Standard colposcopy|The retrospective arm will collect historical data from colposcopy examinations performed using a standard colposcope.
62476477|NCT05802784|ACTIVE_COMPARATOR|Resectoscope arm|Patients in this group had undergone resection of the septum with Monopolar 26 French resectoscope Dilation of cervical os with Hegar's dilator (up to hegar 8 or 9) , incision of the septum using a resectoscope with the Collins knife, monopolar energy (cut 40-70 Watt) and glycine 1.5% as the distension medium, using shortening or thinning incision. The operation was stopped if the fluid deficit exceeded 1000 ml of glycine. The delivery of distension media was conducted by automated pressure delivery system. All patients were prescribed cyclic estrogen and progesterone for two months.
62476478|NCT04816461|EXPERIMENTAL|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive
62310842|NCT01620996|ACTIVE_COMPARATOR|1|Duffus Street Medical Centre
62310843|NCT01620996|ACTIVE_COMPARATOR|2|Sydney Family Practice
62310844|NCT01620996|NO_INTERVENTION|no counseling|HRA assessment pre and post but no counselling
62476479|NCT04816461|EXPERIMENTAL|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive
62737619|NCT02131090|EXPERIMENTAL|Epifix|Participants in this arm of the study will receive the Epifix dressing to secure the epidural catheter
61922032|NCT03574324|OTHER|CCRE+PF|Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy
62476480|NCT04816461|ACTIVE_COMPARATOR|SMC alone|No roommates screening and treatment
62476481|NCT06275321|EXPERIMENTAL|Synchronous-supervised online home-baased group|Group following a supervised exercise program with an exercise cancer specialist
62476482|NCT06275321|ACTIVE_COMPARATOR|Exercise recommendation group|Group following general recommendations of physical exercise
62476483|NCT06095401|EXPERIMENTAL|Inelastic adjustable compression garment (INCOM)|"Subjects randomized to the INCOM group will have a CircAid Juxtafit upper leg and knee garment combined with a lower leg garment (Medi USA, Whitsett, NC) applied to their limb at a minimum of 30mm Hg utilizing a standardized garment tensioning tool.~The experimental group will be instructed to wear their garments during all waking hours with a target wear time of \>80% of waking hours for the first three weeks after surgery."
61922033|NCT02252276|EXPERIMENTAL|Experimental|performed the same exercises and manual therapy during 4 weeks
61922034|NCT02252276|ACTIVE_COMPARATOR|Control|performed proprioceptive and strengthening exercises during 4 weeks
62310845|NCT06513767|EXPERIMENTAL|Investigational group|Use of the investigational device (zirconia dental ceramic) to perform dental restorations
62310846|NCT05760625||Migraine|In migraineurs, venous blood samples will be collected twice: outside and during migraine attacks prior to pain medication. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.
62310847|NCT05760625||Tension type of headache|In patients with tension-type headache (outside attack) and healthy controls, one single blood sample will take. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.
61922035|NCT01727778|EXPERIMENTAL|Antibody treatment|Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
61922036|NCT03549403|EXPERIMENTAL|Patient-centered telephone education|Patients receive the preoperative call home one week before the day surgery and postoperatively 3-8 days after the day surgery. On the day of surgery patients receive current education.
62122034|NCT06131268|NO_INTERVENTION|Bipolar disorder patients (Group 2)|Venlafaxine will not be administered. They will be valuated both at T0 and after 4 weeks (T1).
61922037|NCT03549403|NO_INTERVENTION|Current education practice|Patient´s education is implemented in accordance with current practice, where day surgery adult patients receive preoperative education over the phone one week prior to day surgery and postoperative education during on the day of surgery.
61922038|NCT06276985|EXPERIMENTAL|Experimental: Lipus side: closure of premolar extraction space|application of LIPUS with translation of closure of premolar extraction space that will be performed on intervention sides according to a standardized protocol
61922039|NCT06276985|NO_INTERVENTION|No Intervention: LIPUS side control side|LIPUS side:closure of premolar extraction space control side
61922040|NCT06276985|EXPERIMENTAL|Experimental:iPRF side closure of premolar extraction space|closure ofpremolar extraction space that will be performed with iPRFapplication according to a standardized protocol
62310848|NCT05760625||Cluster headache|In cluster headache patients serum samples will be collected in and outside cluster bout. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.
61922041|NCT06276985|NO_INTERVENTION|iPRF side closure of premolar extraction spacecontrol side|iPRF side canine retraction control side wihout intervention
61922042|NCT06276985|EXPERIMENTAL|Experimental: LIPUS groupMolar distalization group inrervention side|distalization assisted with LIPUS according to a standardized protocol
61922043|NCT06276985|NO_INTERVENTION|No Intervention: LIPUS groupMolar distalization group control side|distalization without LIPUS intervention
61922044|NCT06276985|EXPERIMENTAL|Experimental: iPRFgroup: distalization intervntion side|distalization will be commenced with application of iPRF according to a standardized protocol
61922045|NCT06276985|NO_INTERVENTION|No Intervention: iPRF group: distalization control side|distalization will be commenced without application of LLLT according to a standardized protocol
61922046|NCT06276985|EXPERIMENTAL|Experimental: LIPUS group: leveling and alignment|leveling and alignment assisted with LIPUS according to a standardized protocol
61922047|NCT06276985|EXPERIMENTAL|Experimental: iPRF group: leveling and alignment|leveling and alignment be commenced with application of iPRF according to a standardized protocol
61922048|NCT06276985|NO_INTERVENTION|No Intervention: leveling and alignment without intervention|leveling and alignment without intervention
61922049|NCT06276985|EXPERIMENTAL|Experimental: LIPUS group: Intrusion|intrusion assisted with LIPUS according to a standardized protocol
61922050|NCT06276985|EXPERIMENTAL|Experimental: iPRF group: Intrusion|intrusion assisted with application of iPRF according to a standardized protocol
61922051|NCT06276985|NO_INTERVENTION|No Intervention: intrusion control group|intrusion without intervention
61922052|NCT03895762||Abstral Oral Disintegrating Tablet (ODT)|Abstral Oral Disintegrating Tablet (ODT)
61922053|NCT02127398|EXPERIMENTAL|fecal microbiota transplantation|fecal microbiota transplantation
62122035|NCT06131268|NO_INTERVENTION|Healthy controls (Group 3)|Venlafaxine will not be administered. They will be evaluated only at baseline (T0).
61922054|NCT03833947|EXPERIMENTAL|lignocaine with bicarbonate|Endotracheal tube cuff was filled with mixture of 7.5% sodium bicarbonate with 2% lignocaine in a ratio of 0.5:9.5 ml
61922055|NCT03833947|ACTIVE_COMPARATOR|lignocaine with dexamethasone|Endotracheal tube cuff was filled with mixture of dexamethasone with 2% lignocaine in a ratio of 0.5:9.5 ml
61922056|NCT05836779|EXPERIMENTAL|CBL-514 up to 320mg|Participants will receive up to 320 mg per treatment session at intervals of approximately 4 weeks for up to a maximum of 2 treatments.
62122036|NCT02986269|EXPERIMENTAL|Group SB|"Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is spontaneous breathing(SB) without pressure support ventilation (PSV) under laryngeal mask airway (LMA).~General anesthesia across LMA under SB without PSV"
62122037|NCT02986269|ACTIVE_COMPARATOR|Group PSV|General anesthesia across LMA under SB with PSV Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is SB with PSV under LMA.
62310849|NCT00005963|EXPERIMENTAL|docetaxel + carboplatin|This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
62122038|NCT03982303|EXPERIMENTAL|Hemay102 at the dosage of 5mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 5mg/m2.
62122039|NCT03982303|EXPERIMENTAL|Hemay102 at the dosage of 10mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 10mg/m2.
62122040|NCT03982303|EXPERIMENTAL|Hemay102 at the dosage of 20mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 20mg/m2.
62122041|NCT03982303|EXPERIMENTAL|Hemay102 at the dosage of 40mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 40mg/m2.
62122042|NCT03982303|EXPERIMENTAL|Hemay102 at the dosage of 60mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 60mg/m2.
62681417|NCT04787042|EXPERIMENTAL|Phase 2, Expansion|Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and microsatellite instability-high (MSI-Hi) tumors at the RP2D.
62681418|NCT04787042|EXPERIMENTAL|Phase 1a, Dose Escalation, ST-067 SC + Obinutuzumab Pre-treatment|"Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design.~The starting dose for ST-067 with obinutuzumab pre-treatment will be 120µg/kg. Obinutuzumab will be administered at 1000 mg daily via IV infusion on 2 consecutive days, with the first dose given at least 7 days prior to first dose of SC ST-067."
62681419|NCT04787042|EXPERIMENTAL|Phase 1 combination therapy|Phase 1 dose escalation in combination with pembrolizumab will start at a dose of 30 µg/kg of ST-067 and 200 mg every 3 weeks of pembrolizumab. Patients will be treated every week with ST-067 and every three weeks with pembrolizumab. The MTD will be determined based on the mTPI design.
61922057|NCT02102360|EXPERIMENTAL|Minimally invasive surgical technique (MIST)|A minimally invasive surgical technique was performed to access mandibular furcation defects in the test group, aiming to perform minimal flap reflection, minimal wound, and gentle handling of the soft and hard tissue in periodontal surgery. The use of a microsurgical approach provides magnification and optimal illumination of the surgical site improving visual acuity. Further advantages may be the reduction of flap reflection during surgery, consequently advantages in wound healing process and benefits in patient's perceptions of the procedure. A less invasive surgical procedure may lead to a less cell demand in the healing process, and a potentially reduced morbidity. The minimally invasive surgical procedures were performed using microscope.
61922058|NCT02102360|EXPERIMENTAL|Conventional surgical technique (CST)|A conventional surgical technique was performed to access mandibular furcation defects in the control group.
61922059|NCT00976573|EXPERIMENTAL|Arm I (bevacizumab, paclitaxel, and carboplatin)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62122043|NCT03982303|EXPERIMENTAL|Hemay102 at the dosage of 90mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 90mg/m2.
62310850|NCT04663035|EXPERIMENTAL|Ablation Plus Tislelizumab|Patients in this arm will receive ablation followed by tislelizumab, which will be started within 3-7 days after ablation until disease progression or intolerable toxicity, for 12 months.
62476484|NCT06095401|ACTIVE_COMPARATOR|Elastic compression garment (CONTROL)|Subjects randomized to the CONTROL group will have a thigh-length elastic compression garment (thromboembolism-deterrent \[TED\] hose) applied to their limb. The control group will be instructed to wear their garments during all waking hours with a target wear time of \>80% waking hours for the first three weeks after surgery.
62476485|NCT00817440|NO_INTERVENTION|Control|control: muscle and fat biopsies and basal aminoacid and glucose turnover
62681420|NCT06333678|ACTIVE_COMPARATOR|continue standard of care (SOC) durvalumab treatment|Will continue to receive durvalumab, 10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.
62681421|NCT06333678|EXPERIMENTAL|switch sotorasib treatment until progression|Will receive sotorasib at 960 mg daily until progression. A dose de-escalation regimen based on toxicity will be implemented as below. If 120 mg cannot be tolerated, sotorasib will be discontinued and the patient will be removed from the trial.
62681422|NCT01326936|EXPERIMENTAL|Unworked VP|Online education using typical virtual patient (VP) approach. Five unworked VPs presented to subjects for study.
62681423|NCT01326936|EXPERIMENTAL|Guided Learning|Online education replaces two unworked VPs in Arm 1 with identical worked example VPs (case studies) for learners to study
62681424|NCT03976375|EXPERIMENTAL|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (\~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.
62681425|NCT03976375|ACTIVE_COMPARATOR|Docetaxel|Participants receive docetaxel at 75 mg/m\^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
62681426|NCT03976375|EXPERIMENTAL|Lenvatinib Monotherapy|Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.
62681427|NCT02009449|EXPERIMENTAL|Part A: Dose Escalation Cohort 1|Pegilodecakin (1 ug/kg) - Daily subcutaneous (SC) injections of pegilodecakin for up to 22 months
62122044|NCT03982303|EXPERIMENTAL|Hemay102 at the dosage of 120mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 120mg/m2.
62122045|NCT06397963|EXPERIMENTAL|GT307 injection treatment group|
62122046|NCT03516435|EXPERIMENTAL|Parasacral transcutaneous ES|20min./session, 2 sessions/week ,12 sessions of Parasacral transcutaneous electrical stimulation.
62122047|NCT03516435|ACTIVE_COMPARATOR|Intravaginal electrical stimulation|20min./session, 2 sessions/week ,12 sessions of Intravaginal electrical stimulation.
62122048|NCT06324240|EXPERIMENTAL|Phase Ia (TMV vaccine)|Patients receive TMV vaccine ID at weeks 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
62310851|NCT04663035|ACTIVE_COMPARATOR|Ablation Alone|Patients in this group will receive ablation therapy and then enter the follow-up phase.
62310852|NCT03311685|EXPERIMENTAL|Laparoscopic POP repair|"Patients undergoing laparoscopic surgery for the repair of pelvic organ prolapse.~vaginal tactile imager"
62310853|NCT03311685|EXPERIMENTAL|Vaginal POP repair|Patients undergoing vaginal surgery for the repair of pelvic organ prolapse. vaginal tactile imager
62310854|NCT01458340|EXPERIMENTAL|TD-9855 Dose 1|
62310855|NCT01458340|EXPERIMENTAL|Placebo|
62681428|NCT02009449|EXPERIMENTAL|Part A: Dose Escalation Cohort 2|Pegilodecakin (2.5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
62681429|NCT02009449|EXPERIMENTAL|Part A: Dose Escalation Cohort 3|Pegilodecakin (5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
62737620|NCT00989846||lung disease|patients with various chronic or acute lung diseases
61922060|NCT00976573|EXPERIMENTAL|Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)|Patients receive bevacizumab, paclitaxel, and carboplatin as in Arm I. Patients also receive everolimus PO QD on 3 days a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61922061|NCT02992132|EXPERIMENTAL|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
62310856|NCT01458340|EXPERIMENTAL|TD-9855 Dose 2|
61922062|NCT02992132|EXPERIMENTAL|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
61922063|NCT02992132|PLACEBO_COMPARATOR|Placebo|Placebo, taken as two tablets, once daily by mouth
61922064|NCT02379845|EXPERIMENTAL|Arm A|NBTXR3 + Radiotherapy
61922065|NCT02379845|ACTIVE_COMPARATOR|Arm B|Radiotherapy alone
61922066|NCT03091777|EXPERIMENTAL|Test Drug|GDC-229 gel applied vaginally as directed.
62122049|NCT06324240|EXPERIMENTAL|Phase Ib Arm A ( TMV vaccine, pembrolizumab)|Patients receive TMV vaccine ID at weeks 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV on day 1. Treatment with pembrolizumab repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
62310857|NCT03550144|EXPERIMENTAL|Awe Walk Condition|Participants were instructed to take at least one (\~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
62310858|NCT03550144|ACTIVE_COMPARATOR|Control Walk Condition|Participants were instructed to take at least one (\~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
62476486|NCT00817440|EXPERIMENTAL|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
62476487|NCT00817440|EXPERIMENTAL|Fasting|3 days of fasting and then the same as arm 1
61922067|NCT03091777|ACTIVE_COMPARATOR|Reference Drug|Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
61922068|NCT03091777|PLACEBO_COMPARATOR|Vehicle Placebo Gel|GDC-229 Vehicle
61922069|NCT02670213||NovoThirteen®|
61922070|NCT01364675|EXPERIMENTAL|Metformin+Enalapril+Simvastatin|
61922071|NCT01364675|PLACEBO_COMPARATOR|Placebo tablet|
61922072|NCT05038176|EXPERIMENTAL|Active intervention group (AI)|The active intervention group (AI) receiving the active treatment (MANUP intervention) which include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
61922073|NCT05038176|ACTIVE_COMPARATOR|Delayed intervention group (DI)|"DI participants will only receive motivational text-messages. They will then flip and receive full intervention after the AI group has completed the program."
61922074|NCT03074942|EXPERIMENTAL|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
61922075|NCT04993222|EXPERIMENTAL|Sequence TR|6 healthy subjects assigned to the sequence TR were administrated intravenously for 120 mins with the test product of amphotericin B liposome for injection in period 1 and the reference product of AmBisome® in period 2.
61922076|NCT04993222|EXPERIMENTAL|Sequence RT|6 healthy subjects assigned to the sequence RT were administrated intravenously for 120 mins with the reference product of AmBisome® in period 1 and the test product of amphotericin B liposome for injection in period 2.
62476488|NCT00685607|EXPERIMENTAL|1|loperamide-simethicone
62476489|NCT00685607|PLACEBO_COMPARATOR|2|matching placebo
62476490|NCT00835081|EXPERIMENTAL|1|
62122050|NCT06324240|EXPERIMENTAL|Phase Ib Arm B ( TMV vaccine, ipilimumab)|Patients receive TMV vaccine ID at weeks 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV on day 1. Treatment with ipilimumab repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62681430|NCT02009449|EXPERIMENTAL|Part A: Dose Escalation Cohort 4|Pegilodecakin (10 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
62681431|NCT02009449|EXPERIMENTAL|Part A: Dose Escalation Cohort 5|Pegilodecakin (20 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
62476491|NCT00835081|ACTIVE_COMPARATOR|2|
62681432|NCT02009449|EXPERIMENTAL|Part A: Dose Escalation Cohort 6|Pegilodecakin (40 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
62681433|NCT02009449|EXPERIMENTAL|Part A: Dose Expansion Cohort 1|at least 15 RCC participants will be dosed with pegilodecakin for up to 22 months
62681434|NCT02009449|EXPERIMENTAL|Part B: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~* Paclitaxel 200/175 mg/m2 IV, or~* Docetaxel 75/65 mg/m2 IV And~* Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~* Cisplatin 75mg/m2 IV"
62681435|NCT02009449|EXPERIMENTAL|Part B: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~* Paclitaxel 200/175 mg/m2 IV, or~* Docetaxel 75/65 mg/m2 IV And~* Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~* Cisplatin 75mg/m2 IV"
62681436|NCT02009449|EXPERIMENTAL|Part B: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~* Paclitaxel 200/175 mg/m2 IV, or~* Docetaxel 75/65 mg/m2 IV And~* Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~* Cisplatin 75mg/m2 IV"
62681437|NCT02009449|EXPERIMENTAL|Part B: Dose Expansion Cohort|"Daily SC injection with pegilodecakin with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~* Paclitaxel 200/175 mg/m2 IV, or~* Docetaxel 75/65 mg/m2 IV And~* Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~* Cisplatin 75mg/m2 IV"
62681438|NCT02009449|EXPERIMENTAL|Part C: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~* Oxaliplatin 85 mg/m2 IV over 2 hours~* Leucovorin 200 mg/m2 IV over 2 hours followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours~* Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours"
62681439|NCT02009449|EXPERIMENTAL|Part C: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~* Oxaliplatin 85 mg/m2 IV over 2 hours~* Leucovorin 200 mg/m2 IV over 2 hours followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours~* Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours"
62681440|NCT02009449|EXPERIMENTAL|Part C: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~* Oxaliplatin 85 mg/m2 IV over 2 hours~* Leucovorin 200 mg/m2 IV over 2 hours followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours~* Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours"
62681441|NCT02009449|EXPERIMENTAL|Part C: Dose Expansion Cohort 1|"Daily SC injection with pegilodecakin with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~* Oxaliplatin 85 mg/m2 IV over 2 hours~* Leucovorin 200 mg/m2 IV over 2 hours followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours~* Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~* 5-FU 400 mg/m2 IV bolus and~* 5-FU 600 mg/m2/day IV over 22 hours"
62681442|NCT02009449|EXPERIMENTAL|Part D: Dose Escalation Cohort 1|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle).~Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by~• Gemcitabine 1000 mg/m2 IV."
62681443|NCT02009449|EXPERIMENTAL|Part E: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle).~• Capecitabine 1000 mg/m2 po BID"
62681444|NCT02009449|EXPERIMENTAL|Part F: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
62681445|NCT02009449|EXPERIMENTAL|Part G: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle)~• Pazopanib 800 mg po QD"
62681446|NCT02009449|EXPERIMENTAL|Part H: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
62681447|NCT02009449|EXPERIMENTAL|Part I: Dose Escalation Cohort 1|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle).~• Nivolumab 3 mg/kg IV over 60 min"
62681448|NCT02009449|EXPERIMENTAL|Part H: Dose Escalation Cohort 2|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
62476492|NCT03324178|EXPERIMENTAL|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training performed once a day over the course of four weeks (four sessions each week)
62476493|NCT03324178|ACTIVE_COMPARATOR|Video game control group|Sixteen 30-minute sessions of playing video games once a day over the course of four weeks (four sessions each week)
62476494|NCT01534663|PLACEBO_COMPARATOR|Placebo|The placebo for fish oil will be safflower oil. For glutamine, soy powder will serve as the placebo.
61922077|NCT04510571|ACTIVE_COMPARATOR|Protaper Next|Protaper Next group (n=25): The instrumentation of mesial and distal canals were done according to manufacturer's recommendations using X1 and X2 (25.06) at a rotational speed of 300 rpm. Then X3 and X4 (40.06) instruments were used to enlarge distal canals in order to compare the results with the Reciproc Blue group. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
62476495|NCT01534663|ACTIVE_COMPARATOR|Glutamine/Fishoil|3.285 g of EPA and 3.285 g of Docosahexaenoic acid (DHA) and L-alanyl-glutamine (8g/d).
62476496|NCT03090568|EXPERIMENTAL|BIA 5-453 Fasting|BIA 5-453 200 mg in fasting conditions
61922078|NCT04510571|ACTIVE_COMPARATOR|Reciproc Blue|Reciproc Blue group (n=25) : The canals were shaped with in accordance with the manufacturer's recommendations. R25 (25.08) instrument was introduced into the canal with slow pecking movement within a 3 mm range each time. The flutes and remnants were cleaned after 3 pecking moves. Then R40 instrument (40.06) was selected to shape the distal canals as the #20 K file was passively introduced to the working length. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
62476497|NCT03090568|EXPERIMENTAL|BIA 5-453 Fed|BIA 5-453 200 mg in fed conditions
62681449|NCT02009449|EXPERIMENTAL|Part H: Dose Escalation Cohort 3|"Pegilodecakin (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
62476498|NCT06318156|EXPERIMENTAL|Group1(lumbar disc herniation)|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
62476499|NCT06318156|EXPERIMENTAL|Group2 (healthy control)|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
62495958|NCT05183451|EXPERIMENTAL|LG (Group A)|En- masse retraction using NiTi closed coil springs rendering 200 g/side were employed following first premolars extraction and insertion of buccal TADs to provide maximum anchorage. Retraction was done along with the application of LLLT till the end of retraction.
62681450|NCT02009449|EXPERIMENTAL|Part J: Dose Escalation Cohort 1|Pegilodecakin (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes
62681451|NCT06081439||patients|310
62681452|NCT06081439||controls|120
62681453|NCT01467856||chronic tetraplegia|
62681454|NCT06691087|ACTIVE_COMPARATOR|Normal Hearing participants|
62681455|NCT06691087|EXPERIMENTAL|Hearing-impaired with hearing aids|
62495959|NCT05183451|ACTIVE_COMPARATOR|NLG (Group B)|En- masse retraction using NiTi closed coil springs rendering 200 g/side were employed following first premolars extraction and insertion of buccal TADs to provide maximum anchorage. No LLLT was applied to this group
62495960|NCT06620757||Single Antiplatelet therapy after Left Atrial Appendage Occlusion (LAAO)|
62681456|NCT05594589|EXPERIMENTAL|Lemborexant 5 mg (LEM5)|Participants will receive one LEM5 tablet, orally, once daily for 30 nights (Day 1 up to Day 30) on each night approximately 5 minutes before participants intend to try to sleep.
62681457|NCT05594589|EXPERIMENTAL|Lemborexant 10 mg (LEM10)|Participants will receive one lemborexant 10 mg (LEM10) tablet, orally, once daily for 30 nights (Day 1 up to Day 30) on each night approximately 5 minutes before participants intend to try to sleep.
62681458|NCT05594589|PLACEBO_COMPARATOR|Placebo (PBO)|Participants will receive one lemborexant-matched PBO tablet, orally, once daily for 30 nights (Day 1 to Day 30) on each night approximately 5 minutes before participants intend to try to sleep.
62681459|NCT06643598|NO_INTERVENTION|Standard of Care Provided|In the No Intervention condition, at-risk children will receive the current standard of care, and no intervention.
62681460|NCT06643598|EXPERIMENTAL|Virtual Abecedarian Approach Intervention|In the Virtual Abecedarian Approach Intervention, children will partake in the Abecedarian Approach Intervention through a virtual format.
62495961|NCT00231582|EXPERIMENTAL|1|1
62681461|NCT05353829|ACTIVE_COMPARATOR|Per oral|Drug:per oral Methotrexate Tablets dosage 5-30mg once weekly.
62681462|NCT05353829|ACTIVE_COMPARATOR|Subcutaneous|Drug: subcutaneous Methotrexate Injection dosage 5-30mg once weekly.
62681463|NCT06695260|EXPERIMENTAL|patients with scapholunate instability|to assess the dynamic character of the scapholunate joint in patients with scapholunate instability
62681464|NCT06690827|EXPERIMENTAL|CD123 CAR-NK cells|
62681465|NCT03852615|EXPERIMENTAL|Ovarian torsion|Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that went through laparoscopic ovarian de-torsion surgery
62681466|NCT03852615|OTHER|No ovarian torsion|Control group - Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion and went through laparoscopic surgery, however no ovarian torsion has been demonstrated
62681467|NCT00861705|ACTIVE_COMPARATOR|Arm I (paclitaxel, doxorubicin, cyclophosphamide)|Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.
61922079|NCT03488823|EXPERIMENTAL|Young with Flavanol|Young patients (\< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
62681468|NCT00861705|EXPERIMENTAL|Arm II (paclitaxel, ddAC, bevacizumab)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.
62681469|NCT00861705|EXPERIMENTAL|Arm III (paclitaxel, ddAC, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.
62681470|NCT00861705|EXPERIMENTAL|Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.
62681471|NCT06674616|ACTIVE_COMPARATOR|Replicating Effective Programs (REP)|
62681472|NCT06674616|EXPERIMENTAL|Replicating Effective Programs (REP) plus coaching|
62476500|NCT04576234|EXPERIMENTAL|intermittent entral feeding group|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest) by using syringe pump and Feeds were administered according to guidelines as the head of the patient's bed was elevated at least 30 degrees from the horizontal before initiating feeding, the feeding schedule was started at a rate of 50 ml/hr in adults to promote tolerance,the administration rate of isotonic formulas increased in 20-25 ml/hr increments every eight hours until the desired rate was achieved, the tube was flushed regularly with 20 to 30 ml of warm water every four hours during continuous feeding and before and after intermittent feeding and medication administration, the gastric residual volume was checked every 4-6 hr routinely
62476501|NCT04576234|EXPERIMENTAL|, feeding bag group|Feeding bag group received hospital blended formual which was 300 ml of feeds every 2hrs with 4hrs rest at night and given in 10 minutes with following the same guidelines in the intermittent enteral feeding group
62476502|NCT06244043|ACTIVE_COMPARATOR|Initial Interventional Coaching Call Plus Email Support|
62310859|NCT00538733|EXPERIMENTAL|T-BiRD Therapy|"All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).~After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.~Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.~Patients in CR/sCR or that achieve a plateau of disease for \> 2 cycles on BiRD or T-BiRD therapy will receive maintenance."
62310860|NCT02522910|EXPERIMENTAL|Roniciclib with Docetaxel|
62310861|NCT03705494|ACTIVE_COMPARATOR|Home-based peer counselling intervention|Women planning to breastfeed who meet the study's inclusion criteria
62310862|NCT03705494|NO_INTERVENTION|Standard usual care|Women planning to breastfeed who meet the study's inclusion criteria
62310863|NCT00971646||OAB|Patients with overactive bladder syndrome
62476503|NCT06244043|ACTIVE_COMPARATOR|Initial Interventional Coaching Call No Email Support|
62476504|NCT06244043|ACTIVE_COMPARATOR|Initial Informational Coaching Call Plus Email Support|
62476505|NCT06244043|ACTIVE_COMPARATOR|Initial Informational Coaching Call No Email Support|
62495962|NCT00379353|ACTIVE_COMPARATOR|Group 1: Thalidomide|100 mg capsules orally, once a day for 14 days
62495963|NCT00379353|PLACEBO_COMPARATOR|Group 2: Placebo|Two placebo capsules orally, once a day for 14 days.
62681473|NCT06674616|EXPERIMENTAL|Replicating Effective Programs (REP) plus facilitation|
62681474|NCT06674616|EXPERIMENTAL|Replicating Effective Programs (REP) plus coaching and facilitation|
62310864|NCT00971646||Osteoporosis|Patients with osteoporosis
62310865|NCT03440112|ACTIVE_COMPARATOR|Clarithromycin (Not used anymore as of 4/2020; study aborted)|Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.
62139638|NCT01932632|EXPERIMENTAL|Medication Minimization|"1. Initial Medication Review (IMR) Completed by Attending MD and identifies potential medications to be considered for minimization as well as those UNSUITABLE (as per usual MD opinion)~2. Orders-Medication Update (OMU) (ref form) The attending MD will have identified one or more medications to be considered for minimization and in the IMR suggested a time when a reduced dose will be reviewed (recommended every 4 weeks). Each review will generate an OMU. This process will be repeated for every participant in the Medication Minimization arm until all medications are marked as having no further changes, ie no need for further OMU. At that time a participant's record will be marked as having completed medication minimization."
62310866|NCT03440112|PLACEBO_COMPARATOR|Placebo (Not used anymore as of 4/2020; study aborted)|Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.
61922080|NCT03488823|PLACEBO_COMPARATOR|Young without Flavanol|Young patients (\< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols .
62310867|NCT03440112|ACTIVE_COMPARATOR|Transdermal flumazenil (added 4/2020 as safer alternative for clarithromycin)|Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
62476506|NCT04278560|EXPERIMENTAL|Behavioral intervention plus tDCS|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of transcranial direct current stimulation (tDCS) designed to increase the excitability of the left dorsolateral prefrontal cortex.
62476507|NCT04278560|ACTIVE_COMPARATOR|Behavioral intervention plus sham stimulation|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of sham stimulation.
62476508|NCT03902548|EXPERIMENTAL|Brain uptake and kinetics in Alzheimer's patients|
62681475|NCT06350630|EXPERIMENTAL|Hydroxychloroquine|Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400/mg day
62681476|NCT06350630|PLACEBO_COMPARATOR|Placebo|
62681477|NCT03326921|EXPERIMENTAL|Treatment (CD4+ and CD8+ HA-1 TCR T cells)|Patients receive fludarabine for 1-3 doses 3-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV over 1 hour.
62681478|NCT06548971|EXPERIMENTAL|Interventional group|Patients in the interventional group will receive early antiplatelet treatment with oral aspirin within 3 hours of initiating intravenous thrombolysis. In addition, the best medical management will be administered according to the guidelines.
62681479|NCT06548971|PLACEBO_COMPARATOR|Control group|Patients in the control group will receive placebos within 3 hours of initiating intravenous thrombolysis. In addition, the best medical management will be administered according to the guidelines.
62681480|NCT04310774|EXPERIMENTAL|Consolidation therapy|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
62476509|NCT03902548|EXPERIMENTAL|Dosimetry in healthy volunteers|
62476510|NCT05591118|EXPERIMENTAL|Catheter-Directed Therapy (CDT) plus Anticoagulation|Participants will receive CDT consisting of mechanical thrombectomy (MT) or intrathrombus catheter-directed thrombolysis (CDL) using FDA-cleared devices for pulmonary embolism (PE). The exact technique and devices used will be at the discretion of the endovascular physician, within parameters defined by the PE-TRACT Manual of Operations (MOP) and accepted standard care. Before and after CDT, patients will receive standard PE therapy as in the no-CDT Arm.
62476511|NCT05591118|ACTIVE_COMPARATOR|No Catheter-Directed Therapy (No-CDT)|Standard anticoagulant therapy (FDA-approved regimen) for the treatment of PE.
62495964|NCT03092167|ACTIVE_COMPARATOR|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
62681481|NCT04480450|ACTIVE_COMPARATOR|IVIg/SCIg < 3 Years Arm|Patients with CIDP successfully treated with IVIg/SCIg for under 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
62681482|NCT04480450|ACTIVE_COMPARATOR|IVIg/SCIg > 3 Years Arm|Patients with CIDP successfully treated with IVIg/SCIg for more than 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
62681483|NCT05653752|EXPERIMENTAL|YL202 Dose escalation|YL202 will be administrated intravenously (IV) per dose level in which the patients are assigned.
62681484|NCT06678503|ACTIVE_COMPARATOR|Control Group|"1. Single legged stance:~2. Single-legged stance on the balance board~3. Single legged hop~4. Quadrant Hop:~5. Single legged Ball Catch:~6. Hop ups and downs:"
62681485|NCT06678503|EXPERIMENTAL|Experimental Group|"Participants Will perform the same exercises in addition to core exercises~The core exercises will include 12 different exercises:~Week 1 :~1. Abdominal Drawing In~2. Abdominal Drawing in with alternating lower limb movement~3. Pelvic tilting with standing~4. Forward lunge~Week 2 :~1. Bracing with bridging~2. Curl up with bracing~3. Quadruped with bracing~4. Side plank with knee flexed~Week 3 :~1. Bracing with straight leg raising~2. Quadruped leg lift with bracing~3. Bridging with bracing on a Swiss ball~4. Side plank with the knee extended~Week 4 :~1. Alternate arm and leg raise from quadruped~2. Abdominal drawing in with a squat against a wall~3. Single limb deadlift~4. Squat with overhead sustained lift"
61922081|NCT03488823|EXPERIMENTAL|Old with Flavanol|Old patients (\>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
62310868|NCT03440112|PLACEBO_COMPARATOR|Placebo cream (added 4/2020)|Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
62310869|NCT04331730|EXPERIMENTAL|AKST4290 (800 mg) + Aflibercept|Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
62476512|NCT04845802|EXPERIMENTAL|Training Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily \[morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00\], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
62476513|NCT04845802|SHAM_COMPARATOR|Sham Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily \[morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00\], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
62476514|NCT03197415|EXPERIMENTAL|PRP group|Intradisc injection of autologous platelet-rich plasma gel
62476515|NCT00829452|EXPERIMENTAL|1|
62476516|NCT00829452|ACTIVE_COMPARATOR|2|
62476517|NCT00164463|EXPERIMENTAL|Moxifloxacin|Moxifloxacin 400 mg po qd given 5 of 7 days per week
62476518|NCT00164463|ACTIVE_COMPARATOR|Isoniazid|Isoniazid 300 mg po qd given 5/7 days per week
62476519|NCT03883412|EXPERIMENTAL|Exercise Alone|16 weeks of treatment
62476520|NCT03883412|EXPERIMENTAL|Liraglutide alone|16 weeks of treatment
62476521|NCT03883412|EXPERIMENTAL|Exercise + Liraglutide|16 weeks of treatment
62476522|NCT05664763|EXPERIMENTAL|Cannabis use disorder|CUD participants participants undergo neuroimaging, cognitive testing, and EEG at baseline and following cannabis abstinence at 4 weeks follow-up. Participants will receive motivational enhancement and contingency management during the 4-week abstinence period.
62476523|NCT05664763|EXPERIMENTAL|Healthy control|Healthy control participants undergo neuroimaging, cognitive testing, and EEG at baseline.
62495965|NCT03092167|NO_INTERVENTION|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
62495966|NCT03092167|NO_INTERVENTION|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
62681486|NCT05149768|EXPERIMENTAL|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous
62310870|NCT04331730|EXPERIMENTAL|AKST4290 (1600 mg) + Aflibercept|Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
62476524|NCT00988715|EXPERIMENTAL|Treatment (PRIT, transplant)|Patients undergo pretargeted radioimmunotherapy comprising a test dose of BC8-SA conjugate IV on day -22 and 111In-DOTA-biotin IV on day -20, followed by a therapy dose of BC8-SA conjugate IV on day -14 and 90Y-DOTA-biotin IV on day -12. Patients receive fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and then peripheral blood stem cell transplant on day 0. Patients with matched related donors receive cyclosporine IV on days -3 to 56 and taper to day 180 and mycophenolate mofetil PO BID on days 0-27. Patients with matched unrelated donors receive cyclosporine IV on days -3 to 100 and taper to day 180 and mycophenolate mofetil PO TID on days 0-40 and taper to day 96.
61922082|NCT03488823|PLACEBO_COMPARATOR|Old without Flavanol|Young patients (\>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols.
61922083|NCT02038374|EXPERIMENTAL|severe asthma atopic|
62139639|NCT01357512|EXPERIMENTAL|MRI done|Subjects with MRI prior prostate biopsies
62476525|NCT04678141|OTHER|Composite and compomer materials|Children aged 5-6 years with at least two carious proximal surface primary molars
62476526|NCT02372747|EXPERIMENTAL|Delta-shaped anastomosis group|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
62476527|NCT02372747|EXPERIMENTAL|Billroth II anastomosis group|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
62476528|NCT05586490|EXPERIMENTAL|In-lab and in home feasibility testing of research device in people with Parkinson's disease (PwP)|Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2). This arm will use the experimental device in home feasibility testing (aim 3). This arm will be asked to participate in the open label extension.
62476529|NCT05586490|ACTIVE_COMPARATOR|In-home feasibility testing (alternate device)|"Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2).~This arm will use another device to compare to the experimental device for in home feasibility of using the device at home (aim 3). This arm will be asked to participate in the open label extension."
62476530|NCT05586490|OTHER|In-home feasibility testing (no device in at home portion)|Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2). For the at home portion, this arm will not use any device but have the same outcomes measured. (aim 3)
62476531|NCT06093932|EXPERIMENTAL|Lifestyle intervention + Songling Xuemaikang Capsules|"1. Therapeutic Hypertensive Lifestyle Modifications, everyday, duration: 12 weeks~2. Songling Xuemaikang Capsules, 3 capsules at a time, three times a day, duration: 12 weeks"
61922084|NCT02038374|EXPERIMENTAL|asthma non atopic|
61922085|NCT05366205|EXPERIMENTAL|Oral nutritional supplements|Patients in this arm will receive oral nutritional supplements 24-48 hours after admission，which is enteral nutrition emulsion(TPF-T).
61922086|NCT05366205|SHAM_COMPARATOR|nutrition consultation|Patients in this arm will receive nutrition consultation was given in addition to basic treatment.
61922087|NCT02658097|EXPERIMENTAL|Single Fraction Radiation Therapy (SFRT) + pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle. 8Gy will be given in a single fraction on the first day of treatment
62139640|NCT01357512|NO_INTERVENTION|no MRI|No MRI before prostate biopsies
62476532|NCT06093932|PLACEBO_COMPARATOR|Lifestyle intervention + placebo|"1. Therapeutic Hypertensive Lifestyle Modifications, everyday, duration: 12 weeks~2. placebo, 3 capsules at a time, three times a day, duration: 12 weeks"
61922088|NCT02862600|EXPERIMENTAL|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
61922089|NCT04136756|EXPERIMENTAL|Dose Escalation|"Evaluation of NKTR-255 as:~* Monotherapy~* In combination with daratumumab~* In combination with rituximab~This phase will help to determine the RP2D of NKTR-255"
61922090|NCT04136756|EXPERIMENTAL|Dose Expansion Cohort A|Evaluation of RP2D of NKTR-255 as monotherapy in patients with NHL relapsed after CAR-T
61922091|NCT04136756|EXPERIMENTAL|Dose Expansion Cohort B|Evaluation of RP2D of NKTR-255 as monotherapy and in combination with SC daratumumab in patients with R/R MM
61922092|NCT04136756|EXPERIMENTAL|Dose Expansion Cohort C|Evaluation of RP2D of NKTR-255 as monotherapy and in combination with rituximab in patients with R/R iNHL
62139641|NCT06476769|EXPERIMENTAL|blow bottle technique|There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
62139642|NCT06476769|ACTIVE_COMPARATOR|percussion|There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
62310871|NCT04331730|PLACEBO_COMPARATOR|Placebo + Aflibercept|Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment
62310872|NCT01977144|OTHER|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
62476533|NCT02956460|ACTIVE_COMPARATOR|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
62476534|NCT02956460|ACTIVE_COMPARATOR|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
62681487|NCT05157893|EXPERIMENTAL|VR analgesic therapy|Patients receive a single VR therapy lasting 15 min.
62681488|NCT03748212|ACTIVE_COMPARATOR|Group 1|D935 Cap. 1T
62681489|NCT03748212|EXPERIMENTAL|Group 2|CKD-385 Tab. 1T
62139643|NCT04586348|EXPERIMENTAL|Low Iodine Supplement|Iodine (potassium iodide) 20 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
62681490|NCT00941421|OTHER|videocapsul and OGDFE|Each patient have a Fiberoptic endoscopy by videocapsul, followed by one traditional oeso-gastro-duodenal fiberoptic endoscopy
62681491|NCT06167083||Deceased Patients|Carbapenem-resistant Gram-negative bacilli Blood Stream Infection With mortality
62681492|NCT06167083||Surviving Patients|Carbapenem-resistant Gram-negative bacilli Blood Stream Infection Without mortality
62681493|NCT06318416|EXPERIMENTAL|Early|Urine spectrophotometry for rifampin absorbance and rifampin dose adjustment at Day 14
62681494|NCT06318416|EXPERIMENTAL|Delayed|Urine spectrophotometry for rifampin absorbance and rifampin dose adjustment at Day 21
62681495|NCT04961515|EXPERIMENTAL|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 250mg qd will be used for phase II trial.~Orelabrutinib: orally daily Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks (maximum 12 total dose)"
62681496|NCT04961515|EXPERIMENTAL|Phase II|"Participants will receive orelabrutinib and sintilimab at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.~Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg) Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks"
62681497|NCT00253955|EXPERIMENTAL|1|
62681498|NCT00253955|ACTIVE_COMPARATOR|2|
62310873|NCT01977144|NO_INTERVENTION|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
62310874|NCT01092442||Retrospective Patients|Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.
62310875|NCT01092442||Prospective Patients|Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.
62310876|NCT05721625|EXPERIMENTAL|Exercise group|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
62495967|NCT01899053|EXPERIMENTAL|Dose Escalation Treatment Arm A|TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.
62681499|NCT04355689|EXPERIMENTAL|NPI-001|NPI-001 Tablet, 250 mg, BID
62310877|NCT05721625|ACTIVE_COMPARATOR|Massage group|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While postpartum women are in the sitting position, this massage will be applied on whole back.
62681500|NCT04355689|PLACEBO_COMPARATOR|Placebo|Placebo Tablet, BID
62681501|NCT06694740|EXPERIMENTAL|interferon gamma-1b injection|"Patients randomized to the experimental arm will receive :~Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)"
62681502|NCT06694740|PLACEBO_COMPARATOR|Placebo injection|Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
62681503|NCT04740879|EXPERIMENTAL|Intervention|"The Intervention condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful immediately after randomization to group."
62681504|NCT04740879|OTHER|Waitlist Control|"The Waitlist Control condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful approximately 4 months after randomization to group."
62681505|NCT03136094|PLACEBO_COMPARATOR|SBIRT+Usual Care|The control arm of the trial will receive the usual care prescribed in the Screening, Brief Intervention and Referral to Treatment (SBIRT) model.
62681506|NCT03136094|EXPERIMENTAL|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants will receive caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
62681507|NCT03674450|EXPERIMENTAL|Interventional|
62681508|NCT06617806|EXPERIMENTAL|Advanced Practice Nurse Follow-up|"The patient is followed-up by his Advanced Practice Nurse and General Practitionner~The Advanced Practice Nurse (APN) will schedule follow-ups at 1, 3, 6, 9, and 12 months post-inclusion, leveraging their full range of skills and scope of practice. At each follow-up, the APN will ensure that the initial recommendations are being followed and will adjust them according to the patient's progress. The APN will work closely with all actors involved, including the adapted physical activity professional, attending physician, pharmacist, care assistant, and nurse.~As for all participants, two CGAs will be performed at inclusion by APN and at M12 by the research nurse.~An Adapted Physical Activity (APA) program will also be included. Participants will receive an APA falls prevention program consisting of 14 sessions, each lasting 45 minutes, conducted by a professional APA teacher in the comfort of their own home."
62681509|NCT06617806|NO_INTERVENTION|Usual Care|"Short version: The patient is handled by his General Practitionner as usual after the first CGA~Extended version: As for all participants, two CGAs will be performed at inclusion by APN and at M12 by the research nurse.~An Adapted Physical Activity (APA) program will also be included. Participants will receive an APA falls prevention program consisting of 14 sessions, each lasting 45 minutes, conducted by a professional APA teacher in the comfort of their own home."
62310878|NCT05328843|EXPERIMENTAL|Group A|Subjects with mild renal insufficiency (CKD stage 2, GFR: 60-89 mL/min)
62681510|NCT03575364||Primary Analytic|Patients with unilateral acute or subacute DVT of less than 6 weeks' duration.
62681511|NCT03575364||Registry|Patients with proximal lower extremity DVT.
62681512|NCT03036488|EXPERIMENTAL|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
62122051|NCT04395235|EXPERIMENTAL|Targeted Surgical Therapy Plan|This study pointed out that 3D surgico-anatomical models lead to more precise anatomical understanding compared to CT images in terms of detail perception. The 3D models of vascular patterns proves to be the optimal design according to the experts' evaluation with its teaching effects on surgical residents. The demonstration of the hepatic source vascular anatomy and corresponding vascular patterns may provide practically useful guides in decision making related to vascular detail during living donor liver transplantation.Model CT's were measured in order to verify 1:1 modelling and the printing the process was carried out with 3D printers of Mass Portal Pharaoh xd 20 with Eryone PLA 3D printer flament (2.2LBS)/Spool, White). Measurements of the anatomical structures were compared between the original CT images, and the CT images of the 3D model. The morphometric values such as inter-arterial distances, inter-venous distances and the distance between artery and vein were noted.
62310879|NCT05328843|EXPERIMENTAL|Group B|Subjects with moderate renal insufficiency (CKD stage 3, GFR: 30-59 mL/min)
62310880|NCT05328843|EXPERIMENTAL|Group C|Subjects with normal renal function (GFR: ≥ 90 and \< 130 mL/min)
62476535|NCT04882475||MCL patients relapsed or refractory to rituximab and induction chemotherapy with curative intent|"An historical cohort of patients will be identified and selected both on a clinical base and according to the availability of Formaline-fixed paraffin-embedded (FFPE) material, frozen material or viable cryopreserved cells at Mantle Cell Lymphoma (MCL) diagnosis. Samples will be analyzed in 4 subgroups, each with different clinical specificity:~1. refractory to Induction Chemoimmunotherapy (CIT);~2. refractory to Bruton Tyrosine kinase (BTK) inhibitors (BTKi);~3. sensitive to Induction Chemoimmunotherapy (CIT);~4. sensitive to Bruton Tyrosine kinase (BTK) inhibitors (BTKi)."
62476536|NCT05547711|ACTIVE_COMPARATOR|Patients with depression|
62476537|NCT05547711|ACTIVE_COMPARATOR|Healthy controls|
62681513|NCT03036488|ACTIVE_COMPARATOR|Placebo + Chemotherapy|Participants receive placebo (normal saline solution) Q3W + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by placebo + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
62681514|NCT04899466|EXPERIMENTAL|ActiGraft|Whole blood clot (WBC) gel
62681515|NCT06689137||with dexmedetomidine group|In this study, neurological evaluation tests will be performed before and after surgery for patients who will undergo laparotomic lower and upper gastrointestinal system surgery. All patients will be followed during the perioperative period according to the standards specified in the American Society of Anesthesia guideline. Neurological evaluations will be performed at the 24th hour before surgery, on the day of surgery, and on the 1st, 3rd and 5th days after surgery. Those who underwent total intravenous anesthesia after peroperative anesthesia management will constitute this group. The total amounts of dexmedetomidine, remifentanyl consumed in this group will be recorded.
62681516|NCT06689137||without dexmedetomidine group|In this study, pre- and postoperative neurological evaluation tests will be performed on patients who will undergo laparotomic lower and upper gastrointestinal system surgery. All patients will be monitored during the perioperative period according to the standards specified in the American Society of Anesthesiologists guide. Neurological evaluations will be performed 24 hours before surgery, on the day of surgery, and on the 1st, 3rd and 5th days after surgery. Those who did not receive dexmedetomidine infusion during peroperative anesthesia management will constitute this group. The total amounts of and remifentanyl consumed in this group will be recorded.
62681517|NCT05263791|EXPERIMENTAL|Airmod|The experimental device are installed in the same patient as the reference device to compare the non-inferiority of the respiratory rate measurement.
62681518|NCT06634849|EXPERIMENTAL|PTT-4256|Oral administration of PTT-4256 tablet with water
62681519|NCT06451770|EXPERIMENTAL|Cohort 1: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-201.
62681520|NCT06451770|EXPERIMENTAL|Cohort 2: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-201.
61922093|NCT01994499|EXPERIMENTAL|videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
62122052|NCT06676787|EXPERIMENTAL|Arm 1|Wards in Kwara and Oyo states, where the DSI project provides transportation vouchers to children after vaccination, provided they are aged 0-23 months and reside in communities within the ward.
62122053|NCT06676787|EXPERIMENTAL|Arm 2|Wards in Kwara and Oyo states, where the DSI project provides monthly financing to routine immunisation primary healthcare facilities to support immunisation and other health services, provided these health facilities are located within the ward.
62310881|NCT01859429|EXPERIMENTAL|Stepped Care|Structured stepped requirement of psychosocial support
62310882|NCT01859429|NO_INTERVENTION|Care as usual|Unstructured requirement of psychosocial support
62310883|NCT00476931|EXPERIMENTAL|1|SB-509
62310884|NCT00476931|PLACEBO_COMPARATOR|2|
61922094|NCT01994499|ACTIVE_COMPARATOR|Medical pleural drainage|Medical drainage
61922095|NCT00930982|EXPERIMENTAL|Ciprofloxacin Inhale (BAYQ3939)|32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
61922096|NCT00930982|PLACEBO_COMPARATOR|Placebo|Inhalation of matching placebo twice a day
61922097|NCT03448081|ACTIVE_COMPARATOR|SNA-120 + Calcipotriene|
62476538|NCT03483194|ACTIVE_COMPARATOR|Kalinox®|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
62476539|NCT03483194|EXPERIMENTAL|Virtual Reality|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
62476540|NCT05315557|EXPERIMENTAL|Terlipressin|Terlipressin 1mg/24 hours
62476541|NCT05315557|ACTIVE_COMPARATOR|Vasopressin|Vasopressin 0.03 U/hour
62476542|NCT00593463|EXPERIMENTAL|1|Receives 2-4 of the interventions listed
62476543|NCT00897377|EXPERIMENTAL|Total resection with early radiation|Total resected LGGs treated with early radiation
62476544|NCT00897377|NO_INTERVENTION|Total resection without radiation|Total resected LGGs treated without radiation
62476545|NCT00897377|EXPERIMENTAL|Residual LGGs with radiation|Residual LGGs treated with early radiation
61922098|NCT03448081|PLACEBO_COMPARATOR|Placebo + Calcipotriene|
62310885|NCT05587985||Experimental Group|"* After randomization, 34 patients will be included in the experimental group. This group is the group to be mobilized early after surgery.~* During the data collection process, the pain level of the experimental group will be evaluated at the 8th hour after the operation, then the level of mobility will be evaluated by providing mobilization.~* At the 20th hour after the surgery, pain assessment of both groups will be made, and then their mobility will be evaluated, and their mobility levels will be evaluated."
62310886|NCT05587985||Control Group|"* After randomization, 34 patients will be included in the control group. This group is the group that did not undergo early mobilization.~* The control group will only be evaluated for pain at the 8th hour after surgery, and they will not be mobilized.~* At the 20th hour after the surgery, pain assessment of both groups will be made, and then their mobility will be evaluated, and their mobility levels will be evaluated."
62310887|NCT01883310|ACTIVE_COMPARATOR|sham tDCS + TOCT|The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
62681521|NCT06451770|EXPERIMENTAL|Cohort 3: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-201.
61922099|NCT04186689||children in fully food secure households (G1)|preschool children live in a fully food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
61922100|NCT04186689||children in marginally food secure households (G2)|preschool children live in a marginally food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
62122054|NCT06676787|EXPERIMENTAL|Arm 3|Wards in Kwara and Oyo states, where the DSI project provides transportation vouchers to children after vaccination, provided they are aged 0-23 months and reside in communities within the ward and also provides monthly financing to routine immunisation primary healthcare facilities to support immunisation and other health services, provided these health facilities are located within these wards.
62310888|NCT01883310|EXPERIMENTAL|real tDCS + TOCT|the real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
62310889|NCT02810002|EXPERIMENTAL|DEFINITE-REGULATOR|Training with DEFINITE-REGULATOR experiment infantry boots manufactured by Brill Industries, Rishon LeZion, Israel
62476546|NCT00897377|EXPERIMENTAL|Residual LGGs with chemo|Residual LGGS treated with temozolomide
62476547|NCT02907983|ACTIVE_COMPARATOR|Bupivicaine|Stellate Ganglion Block injection with bupivicaine
62476548|NCT02907983|SHAM_COMPARATOR|Saline|Saline injection
62476549|NCT04363359|EXPERIMENTAL|Quadrivalent influenza vaccine HD|Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
62476550|NCT04363359|EXPERIMENTAL|Quadrivalent influenza vaccine LD|Participants randomized to receive two injections of 0.25 mL quadrivalent influenza vaccine at Day 0 and 28.
62476551|NCT04363359|ACTIVE_COMPARATOR|Trivalent influenza vaccine Victoria|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Victoria strain at Day 0 and 28.
62681522|NCT06451770|EXPERIMENTAL|Cohort 4: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-201.
61922101|NCT04186689||children in food insecure households (G3)|preschool children live in a food-insecure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
61922102|NCT03702296|OTHER|Intervention|Patients will be provided with ear plugs and eye masks, to be used from 10pm to 6am, for 3 days post-operatively.
62476552|NCT04363359|ACTIVE_COMPARATOR|Trivalent influenza vaccine Yamagata|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Yamagata strain at Day 0 and 28.
62476553|NCT01250080|EXPERIMENTAL|Glutamine|
62476554|NCT01250080|SHAM_COMPARATOR|Control|
62476555|NCT05655845||Dysfunction group|Bowel function score(BFS,total 20 points) was approved by Rintala in 1995 and patients with a score \< 17 were considered to have bowel dysfunction.
62681523|NCT06539650|EXPERIMENTAL|Fractal Paced|Strength training in single leg extension machine, synchronizing each repetition with a fractal-like visual metronome, i.e., a metronome presenting visual external cues with variability within its temporal structure.
62681524|NCT06539650|EXPERIMENTAL|Isochronous Paced|Strength training in single leg extension machine, synchronizing each repetition with a isochronus visual metronome, i.e., a metronome presenting visual external cues withthe same pace in each repetition (without variability)
62681525|NCT06539650|EXPERIMENTAL|Self Paced|Strength training in single leg extension machine at participants self pace.
62122055|NCT06676787|NO_INTERVENTION|Control|No intervention in these wards
62122056|NCT03619616|EXPERIMENTAL|ZSP1603 (single dose)-7.5 mg (Cohort 1)|Subject adminsitered at a dose of ZSP1603 7.5 mg on day 1 under fasted condition.
61922103|NCT03702296|NO_INTERVENTION|Control|No ear plugs or eye masks provided.
62310890|NCT02810002|ACTIVE_COMPARATOR|modified Belleville 390 TROP|Standard issue infantry boot
62310891|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
62310892|NCT02365532|PLACEBO_COMPARATOR|Placebo to match GS-6615|Placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
62310893|NCT02365532|EXPERIMENTAL|GS-6615|GS-6615 or placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
62476556|NCT05655845||near-normal group|Bowel function score(BFS,total 20 points) was approved by Rintala in 1995 and patients with a score \> 17 were considered to have normal bowel habits.
62476557|NCT03530852|EXPERIMENTAL|Relizorb treatment|Patients will have tube feeds placed through chamber and evaluate wean from parenteral nutrition
62476558|NCT03868891|EXPERIMENTAL|EMST150|Subjects with or without cleft palate will use the EMST150 2 times a day for 8 weeks.
62681526|NCT05445804|EXPERIMENTAL|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.
62681527|NCT05445804|EXPERIMENTAL|Additional Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.
62681528|NCT06269601|OTHER|adolescent male basketball players|14-16 years adolescent male basketball players
62681529|NCT03941262|EXPERIMENTAL|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once a week for five weeks.
62310894|NCT02435173|EXPERIMENTAL|Part I: CDZ173|Participants consecutively received CDZ173 10 mg twice a day (b.i.d.) from Day 1 to Day 28, CDZ173 30 mg b.i.d. from Day 29 to Day 56 and CDZ173 70 mg b.i.d. from Day 57 to Day 84.
62476559|NCT03684538|EXPERIMENTAL|Group Probiotics|Patients in this group will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive probiotics (Saccharomyces boulardii) one dose per day.
62476560|NCT03684538|EXPERIMENTAL|Group Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
62681530|NCT03941262|EXPERIMENTAL|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered once a week for five weeks.
62681531|NCT03941262|EXPERIMENTAL|Cohort 3 - High dose SNK01|SNK01 (high dose) administered once a week for five weeks.
62681532|NCT03941262|EXPERIMENTAL|Cohort 4 - SNK01 with avelumab|SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.
62681533|NCT03941262|EXPERIMENTAL|Cohort 4 - SNK01 with pembrolizumab|SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.
62681534|NCT05877846|EXPERIMENTAL|Participants with Weakness|Participants will take beta-hydroxymethyl butyrate (HMB) with vitamin D3 for 12 weeks. Those participants with vitamin D3 levels \> 80 ng/dL will be provided intervention capsules without vitamin D3.
61922104|NCT01751802|EXPERIMENTAL|Ecopipam|Active substance being tested, orally once a day at bedtime
61922105|NCT01751802|PLACEBO_COMPARATOR|Placebo|Inactive substance being tested, orally once a day at bedtime
61922106|NCT00112697|EXPERIMENTAL|Arm 1|
61922107|NCT00112697|EXPERIMENTAL|Arm 2|
61922108|NCT03959228|NO_INTERVENTION|referencial diet|0.8 g/kg/day of protein
61922109|NCT03959228|EXPERIMENTAL|protein very poor diet with additional keto-analogs|0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.
62122057|NCT03619616|EXPERIMENTAL|ZSP1603 (single dose)-12.5mg (Cohort 2)|"Subject adminsitered at a dose of ZSP1603 12.5 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
62122058|NCT03619616|EXPERIMENTAL|ZSP1603 (single dose)-25 mg (Cohort 3)|"Subject adminsitered at a dose of ZSP1603 25 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
62310895|NCT02435173|EXPERIMENTAL|Part II: CDZ173|Participants received CDZ173 70 mg b.i.d. from Day 1 to Day 85.
62310896|NCT02435173|PLACEBO_COMPARATOR|Part II: Placebo|Participants received Placebo b.i.d. from Day 1 to Day 85.
62310897|NCT06316661||HFpEF|patients with HFpEF
62310898|NCT06316661||healthy volunteers|healthy volunteers matched for age and sex
62310899|NCT06142747||Control|Healthy Controls. Super-Resolution Ultrasound Imaging of Erythrocytes (SURE) of both Achilles and Patellar Tendons.
62310900|NCT06142747||Tendinopathy Achilles|Patients with Achilles Tendinopathy. Super-Resolution Ultrasound Imaging of Erythrocytes (SURE) of Achilles Tendons.
62310901|NCT06142747||Tendinopathy Patellar|Patients with Patellar Tendinopathy. Super-Resolution Ultrasound Imaging of Erythrocytes (SURE) of Patellar Tendons.
62310902|NCT06351410|EXPERIMENTAL|Eye wearing contact lens|The participant will be given two contact lenses (Lens A and B) to be placed on each eye. This phase will be repeated with C \&D and lens E \& F at different times. Each phase will have a 2 weeks wash-off period
62476561|NCT03684538|ACTIVE_COMPARATOR|Group Probiotics & Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive a combination of probiotics (Saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
62681535|NCT02522260|ACTIVE_COMPARATOR|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
62681536|NCT02522260|ACTIVE_COMPARATOR|Group 2|Intervention Aerobic exercise, bike or treadmill
62681537|NCT02522260|ACTIVE_COMPARATOR|Group 3|Standard supportive care
62476562|NCT01414322||Group 1: Patients ages 0 - 3|
62476563|NCT01414322||Group 2: Patients ages 3 - 7|
62476564|NCT01414322||Group 3: Patients ages 7 - 15|
62476565|NCT01058668|EXPERIMENTAL|Cariprazine (3-6 mg/day)|Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
62476566|NCT01058668|EXPERIMENTAL|Cariprazine (6-12 mg/day)|Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
62122059|NCT03619616|EXPERIMENTAL|ZSP1603 (single dose)-50 mg (Cohort 4)|"Subject adminsitered at a dose of ZSP1603 50 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
62122060|NCT05004402||Primiparous women|Primiparous women after vaginal delivery
62122061|NCT00979992|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62122062|NCT03078634|ACTIVE_COMPARATOR|Multi-Disciplinary clinic|
62476567|NCT01058668|PLACEBO_COMPARATOR|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
62681538|NCT06642558|EXPERIMENTAL|Low dose vaccine group in subjects aged 18-59 years - Phase 1|Subjects aged 18-59 years in phase 1 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose), by IM injection into the deltoid region of the arm.
62681539|NCT06642558|EXPERIMENTAL|High dose vaccine group in subjects aged 18-59 years - Phase 1|Subjects aged 18-59 years in phase 1 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose), by IM injection into the deltoid region of the arm.
62681540|NCT06642558|PLACEBO_COMPARATOR|Placebo group in subjects aged 18-59 years - Phase 1|Subjects aged 18-59 years in phase 1 will receive single dose of placebo, by IM injection into the deltoid region of the arm.
62122063|NCT03078634|PLACEBO_COMPARATOR|Standard Gastrointestinal clinic|
62122064|NCT05789771||patients with HR+/HER2- ABC/MBC who received abemaciclib based therapy for their ABC/MBC.|
62122065|NCT01824030|ACTIVE_COMPARATOR|FFR guided PCI arm|Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80
62122066|NCT01824030|ACTIVE_COMPARATOR|OCT guided PCI arm|"Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:~1. percentage area stenosis ≥75 %~2. percentage area stenosis between 50 and 75% and minimal lumen area \<2.5 mm2~3. percentage area stenosis between 50 and 75% and major plaque ulceration"
62476568|NCT04279730||Inpatient pulmonary rehabilitation|Multidisciplinary inpatient pulmonary rehabilitation program lasting 4 weeks (40 sessions, 2 sessions per day, 5 days per week).
62476569|NCT06195579|EXPERIMENTAL|Intervention arm|Participants receiving the intervention whilst on a waiting list for treatment as usual
62476570|NCT00621491|PLACEBO_COMPARATOR|1|Single daily dose of Placebo during six months
62476571|NCT06563206|ACTIVE_COMPARATOR|Standard Rehabilitation/Conventional|The conventional exercise therapy group will be given diathermic, electricity modality, hydrotherapy, and therapeutic exercises in the form of muscle stretching, strengthening exercises, transfer exercises, walking exercises, and hand function exercises for 3 times a week within 6 weeks.
62476572|NCT06563206|EXPERIMENTAL|Exergame|Conventional therapy coupled with virtual reality Exergame exercises on the hands for 3 times a week a time 6 weeks
62681541|NCT06642558|EXPERIMENTAL|Low dose vaccine group in subjects aged ≥60 years - Phase 1|Subjects aged ≥60 years in phase 1 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose), by IM injection into the deltoid region of the arm.
62681542|NCT06642558|EXPERIMENTAL|High dose vaccine group in subjects aged ≥60 years - Phase 1|Subjects aged ≥60 years in phase 1 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose), by IM injection into the deltoid region of the arm.
62122067|NCT06023186||Cohort 1|Clinically stable, adult patients with obstructive hypertrophic cardiomyopathy, who meet mavacamten prescribing guidelines will be prescribed mavacamten by their treating physician.
62122068|NCT02006017|EXPERIMENTAL|Group A|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary plus a recommendation and a second scenario will be accompanied by an evidence summary alone
62122069|NCT02006017|EXPERIMENTAL|Group B|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary alone and a second scenario will be accompanied by an evidence summary plus a recommendation
62122070|NCT01759771|EXPERIMENTAL|Arm 1|4,000 IU of VD3 for one year
62122071|NCT01759771|PLACEBO_COMPARATOR|Arm 2|placebo for one year
62122072|NCT05389436|EXPERIMENTAL|Experimental|The patient is discharged from the ER following X-ray, casting, charts. The patient is contacted when surgery is scheduled, and this is performed in a ambulatory setting
62122073|NCT05389436|ACTIVE_COMPARATOR|Standard|The patient is admitted from the ER, surgery is performed when possible in regards to surgical capacity and swelling. Discharged when mobilised with cast.
62122074|NCT00145314|ACTIVE_COMPARATOR|A|FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
62122075|NCT00145314|EXPERIMENTAL|B|FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
62122076|NCT00145314|EXPERIMENTAL|C|FLOX given intermittently and maintenance cetuximab
62476573|NCT06563206|EXPERIMENTAL|Robotic|conventional therapy coupled with robotic therapy exercises on the hands for 3 times a week a time of 6 weeks
62476574|NCT05843357||Observed group|No intervention will be administered on behalf of the project. The participants will be tested using ALBA and PICNIR (non-invasive) cognitive tests, and further sFAQ-CZ and GDS-CZ questionnaires will be administered. Questionnaires FAQ-CZ and MBI-C-CZ will be distributed to participants´ caretakers.
62310903|NCT05376202|EXPERIMENTAL|Phase 1: 75mg Cetuximab and 15mg Cetuximab-IRDye800CW|Patients receive 75mg of Cetuximab, followed by 15mg Cetuximab-IRDye800CW I.V. two days prior to surgery.
62310904|NCT00810329||1|This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.
61922110|NCT01729247||FeNO|Participants with asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
61922111|NCT01178255|EXPERIMENTAL|Group 1|
62122077|NCT00982098|EXPERIMENTAL|Early Rehabilitation|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).~Patients will be instructed to carry on exercises at home for the following 11 months."
62310905|NCT00810329||2|The healthy control group
62310906|NCT05200351|EXPERIMENTAL|EAT Intervention|15 sessions of EAT
62310907|NCT03295422|ACTIVE_COMPARATOR|RF ablation PVI alone|RF catheter ablation of pulmonary veins alone
62310908|NCT03295422|EXPERIMENTAL|RF ablation PVI plus LPAW|RF catheter ablation PVI plus left atrial posterior wall
62310909|NCT00846612|EXPERIMENTAL|Avastin-Doxil|
62310910|NCT04837404|OTHER|ultrasound guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Ultrasound guided femoral access will be used.
62310911|NCT04837404|OTHER|fluoroscopy guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.
62310912|NCT02732912|ACTIVE_COMPARATOR|Control|Patients in this arm will continue current standard management for sleep, which is largely reactive; if a patient requests night sedation or complains that they cannot sleep and that they want help, then zopiclone is prescribed, starting at 3.75 mg.
62122078|NCT00982098|NO_INTERVENTION|Counseling and home-based exercises|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: Patients will be instructed to carry on pelvic floor exercises at home for the year after prostatectomy."
62310913|NCT02732912|EXPERIMENTAL|Eye mask and ear plugs|General management will be as for the control group. In addition, patients in this group will be given ear plugs and eye shades (masks) to use when trying to sleep. The patient will generally be responsible for using or not using the equipment, though ward nurses may remind patients if they notice that the patient has the equipment.
62310914|NCT01729832|EXPERIMENTAL|Supportive care (image-guided breast reconstruction)|Patients undergo DIEP flap breast reconstruction using the StealthStation navigation system.
62310915|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
62310916|NCT06671912|ACTIVE_COMPARATOR|Arm I (anastrozole, letrozole, exemestane, tamoxifen)|Patients receive standard of care endocrine therapy per physician choice with either anastrozole PO, letrozole PO, exemestane PO or standard dose tamoxifen PO QD for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients may also undergo mammogram or MRI, DEXA, and blood sample collection on study.
62310917|NCT06671912|EXPERIMENTAL|Arm II (low dose tamoxifen)|Patients receive low-dose tamoxifen PO QOD for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients may also undergo mammogram or MRI, DEXA, and blood sample collection on study.
62310918|NCT00187161|EXPERIMENTAL|A|"Group A: Resected Stage I and resected abdominal Stage II~Subjects will receive two courses (3 weeks apart) of COPAD."
62310919|NCT00187161|EXPERIMENTAL|B|"Group B: Other Stage II, Stage III, Stage IV or B-ALL M blast \<70%; no CNS involvement.~Subjects in Group B will receive one week of treatment of COP."
62310920|NCT00187161|EXPERIMENTAL|C|"Group C: B-ALL with \>70% BM blasts; CNS involvement, Group B COP failures i.e., \<20% reduction Treatment Pre-Induction~Subjects will receive one week of treatment of COP."
62310921|NCT00436670|EXPERIMENTAL|AMG 317 75 mg|75 subjects
62310922|NCT00436670|PLACEBO_COMPARATOR|Placebo Arm|75 subjects
62310923|NCT00436670|EXPERIMENTAL|AMG 317 300 mg|75 subjects
62310924|NCT00436670|EXPERIMENTAL|AMG 317 150 mg|75 subjects
62310925|NCT02176967|EXPERIMENTAL|Group A (clinical observation)|Patients undergo clinical observation for 96 weeks in the absence of disease progression. Patients also undergo CT, MRI, and/or ultrasound throughout the trial.
61922112|NCT01178255|EXPERIMENTAL|Group 2|
61922113|NCT01178255|EXPERIMENTAL|Group 3|
62310926|NCT02176967|EXPERIMENTAL|Group B (clinical observation, first-line chemotherapy)|Patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients undergo surgery or receive first-line chemotherapy comprising carboplatin IV over 1 hour on day 1 (courses 1, 2, 4, 6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15 minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a PR or better is achieved, patients undergo clinical observation for 3 years. Patients also undergo CT, MRI, and/or ultrasound throughout the trial and undergo bone marrow aspiration, bone marrow biopsy, and tumor biopsy at screening and time of progression.
62310927|NCT02176967|EXPERIMENTAL|Group C (clinical observation, first-line chemotherapy)|Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years. Patients also undergo CT, MRI, and/or ultrasound throughout the trial and undergo bone marrow aspiration, bone marrow biopsy, and tumor biopsy at screening and time of progression.
62310928|NCT04651777|EXPERIMENTAL|Participants with poorly controlled moderate to severe asthma|Participants with poorly controlled moderate to severe asthma will be evaluated during and after a six week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements.
62122079|NCT02120599|ACTIVE_COMPARATOR|corn-soy-blend|This is the control group for the study, which will receive the Malawi standard of care. The treatment provided to women randomized to this arm of the study includes daily iron (60 mg) and folic acid (400 mcg) supplementation, along with 4 kg/2 weeks corn-soy blend (\~357 gm/d CSB).
61922114|NCT01178255|EXPERIMENTAL|Group 4|
61922115|NCT05064839|EXPERIMENTAL|Bony scintigraphy|Bony scintigraphy within 1 to 4 months after inclusion
61922116|NCT04676555||Ocrelizumab|Ocrelizumab is administered intravenously (IV) under the guidance of a specialized physician and followed by one-hour observation after the infusion. It requires a corticosteroid pre-medication and some antipyretics may also be administered.
61922117|NCT04676555||Ofatumumab|Ofatumumab is administered through a subcutaneous injection and allows self-administration after training.
62122080|NCT02120599|EXPERIMENTAL|corn-soy-blend + multiple micronutrients|The treatment provided to women randomized to this arm of the study includes 200gm/d CSB along with a standard maternal multiple micronutrient tablet, which together provide a comparable amount of energy, protein and micronutrients to the ready-to-use supplemental food. The micronutrient supplement known as the United Nations Children's Emergency Fund (UNICEF) / World Health Organization (WHO) / United Nations University (UNU) international multiple micronutrient preparation (UNIMMAP) is widely available and has been used in many settings worldwide in pregnant women.
62476575|NCT01923753|EXPERIMENTAL|Aerosure 15 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised."
61922118|NCT03285776||Study group|Children with coordination disorder between the ages of 5 to 7 years.
61922119|NCT03285776||control group|children with typical development between the ages of 5 to 7 years.
61922120|NCT03490279|EXPERIMENTAL|A|Lactoferrin CRX 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
61922121|NCT03490279|PLACEBO_COMPARATOR|B|Placebo 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
62476576|NCT01923753|ACTIVE_COMPARATOR|Aerosure 25 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
62476577|NCT01923753|SHAM_COMPARATOR|Aerosure sham|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
61922122|NCT01561027|EXPERIMENTAL|CNV1014802|CNV1014802 350mg on prescription (BID) for 21 days
61922123|NCT01561027|PLACEBO_COMPARATOR|Placebo|Placebo 350mg BID for 21 days
61922124|NCT03706898|EXPERIMENTAL|Elpida® fasting|Elpida® 20 mg single dose fasting
62122081|NCT02120599|EXPERIMENTAL|ready-to-use supplementary food|RUSF-P (ready-to-use supplementary food) provides 750 kcal/d, 20 g protein/d, and 200% of RDA/d for most micronutrients during pregnancy (except for vitamins A, B3, folic acid, minerals iodine, magnesium, and calcium which will remain near 100%)
62122082|NCT02041039||normal weight|non-smoking, right handed women age 18-40 years BMI between 18-25 kg/m2
62122083|NCT02041039||overweight/obese|non-smoking, right-handed women age 18-40 year BMI 30-50 kg/m2 (maximum weight 350 pounds, shoulder width no greater than 23/5 inches)
62122084|NCT05500378|OTHER|neck extension group|Neck extension group
62122085|NCT04426461|EXPERIMENTAL|Behavioral activation|
62122086|NCT04426461|EXPERIMENTAL|Exposure-based therapy|
62122087|NCT04426461|ACTIVE_COMPARATOR|Supportive therapy|
62122088|NCT03472807|OTHER|Cancer patient|"* Collection of blood sample or saliva~* Collection of a tumor sample taken before the participation of the patient in study~* Collection of blood sample if tumor sample is not available"
62476578|NCT05822479|ACTIVE_COMPARATOR|Group EOIB|A bilateral EOIB (60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
61922125|NCT03706898|EXPERIMENTAL|Elpida® after meal|Elpida® 20 mg single dose after meals
61922126|NCT03706898|EXPERIMENTAL|Elpida® (in subjects with mild hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with mild hepatic impairment (Child - Pugh Class А)
62476579|NCT05822479|OTHER|Group Control|IV morphine PCA
62476580|NCT01541033||Autism with FAH|Children diagnosed with autism with first degree relatives that have autoimmune disorders.
61922127|NCT03706898|EXPERIMENTAL|Elpida® (in subjects with moderate hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with moderate hepatic impairment (Child - Pugh Class B)
61922128|NCT03706898|EXPERIMENTAL|Elpida® & sofosbuvir & daclatasvir|Drug-drug interactions of sofosbuvir 400 mg + daclatasvir 60 mg and Elpida® 20 mg, single dose fasting
62310929|NCT03988114|EXPERIMENTAL|Abemaciclib + NSAI|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally.
62476581|NCT01541033||Autism without FAH|Children diagnosed with autism without first degree relatives that have autoimmune disorders.
62681543|NCT06642558|PLACEBO_COMPARATOR|Placebo group in subjects aged ≥60 years - Phase 1|Subjects aged ≥60 years in phase 1 will receive single dose of placebo, by IM injection into the deltoid region of the arm.
61922129|NCT03706898|EXPERIMENTAL|Elpida® & dolutegravir|Drug-drug interactions of dolutegravir 50 mg and Elpida® 20 mg, single dose fasting
61922130|NCT02809261|EXPERIMENTAL|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (3cc) between proximal carpal tunnel and median nerve.
61922131|NCT02809261|PLACEBO_COMPARATOR|Perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and median nerve.
61922132|NCT01455376|NO_INTERVENTION|Hyperosmolar sodium chloride|Patients in this group received intravenous infusion of hyperosmolar Sodium Chloride 3% at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
62122089|NCT03472807|OTHER|Parent of cancer patient|-Collection of blood sample or saliva
62476582|NCT01541033||Control|Typically developing children
62476583|NCT01208337|OTHER|Alemtuzumab induction|Intestine transplant recipients who receive induction with alemtuzumab prior to transplantation.
62476584|NCT05167474|ACTIVE_COMPARATOR|breast milk smell|The application of maternal education for the phototherapy method for newborns is to place the cotton unloaded by the mother in a container and place it close to the shape.
62476585|NCT05167474|NO_INTERVENTION|control group|No intervention was performed during phototherapy treatment in newborns.
62476586|NCT01045681|EXPERIMENTAL|BVD|Bendamustine, Velcade and Dexamethasone
62476587|NCT01956591||Axillary hyperhidrosis|Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
62122090|NCT00371085|EXPERIMENTAL|1|Video-based patient education on heart failure self care
62122091|NCT03207672|EXPERIMENTAL|Schedule 1: E7389-LF|Participants will receive E7389-liposomal formulation (LF) at a starting dose of 1.0 to 2.5 milligrams per meters squared (mg/m\^2), administered as an intravenous (IV) infusion on Day 1 of a 21-day cycle (tri-weekly).
62122092|NCT03207672|EXPERIMENTAL|Schedule 2: E7389-LF|Participants will receive E7389-LF at a starting dose of 1.0 to 1.5 mg/m\^2, administered as an IV infusion on Day 1 and Day 15 of a 28-day cycle (bi-weekly).
62122093|NCT01141010|SHAM_COMPARATOR|Plain language|Conventional plain language will be given without any psychological intervention
62122094|NCT01141010|ACTIVE_COMPARATOR|Pre-psycho-language|Prior surgery psychological linguistic intervention
62122095|NCT01141010|ACTIVE_COMPARATOR|Intra-psycho-language|Intraoperative psychological linguistic intervention
62476588|NCT01956591||Palmar hyperhidrosis|Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
61922133|NCT01455376|EXPERIMENTAL|Hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
61922134|NCT03810820|OTHER|Outpatient TAVI|Consecutive patients scheduled for outpatient TAVI.
61922135|NCT01205178|ACTIVE_COMPARATOR|Tafenoquine|Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
61922136|NCT01205178|ACTIVE_COMPARATOR|Chloroquine|Dose for first 3 days for Part B \& C of the study
61922137|NCT01205178|ACTIVE_COMPARATOR|Primaquine|once daily for first 14 days
62122096|NCT01141010|ACTIVE_COMPARATOR|Post-psycho-language|Postoperative psychological linguistic intervention
62122097|NCT01141010|ACTIVE_COMPARATOR|Combined language|Psychological linguistic intervention will be given in a combination of pre-, intra- and post-operatively
62122098|NCT02852850||Molecular Imaging With IFX-FITC|Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
62122099|NCT02722070||Healthy Controls|Age matched control for the various clinical groups
62310930|NCT05047393||Coccygodynia group|51 patients with a diagnosis of coccygodynia will be included in the study.
62310931|NCT01326286||Open Radical Prostatectomy|262
62310932|NCT01326286||Robotic Radical Prostatectomy|1303
62310933|NCT01326286||Intensity-Modulated Radiotherapy|638
62310934|NCT01326286||Interstitial Brachytherapy|171
62310935|NCT01326286||combined EBRT and Brachytherapy|143
62310936|NCT01326286||Active Surveillance|448
62310937|NCT01326286||Various other treatments|300
62681544|NCT06642558|EXPERIMENTAL|Low dose vaccine group in subjects aged 50-59 years - Phase 2|Subjects aged 50-59 years in phase 2 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose), by IM injection into the deltoid region of the arm.
62681545|NCT06642558|EXPERIMENTAL|High dose vaccine group in subjects aged 50-59 years - Phase 2|Subjects aged 50-59 years in phase 2 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose), by IM injection into the deltoid region of the arm.
62681546|NCT06642558|PLACEBO_COMPARATOR|Placebo group in subjects aged 50-59 years - Phase 2|Subjects aged 50-59 years in phase 2 will receive single dose of placebo, by IM injection into the deltoid region of the arm.
62310938|NCT02928237|ACTIVE_COMPARATOR|Real tDCS|In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
61922138|NCT03302520|EXPERIMENTAL|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
61922139|NCT03302520|ACTIVE_COMPARATOR|PEEK cage|PEEK cage for interbody fusion
61922140|NCT01661816||Within chemotherapy|30 couples, interviewed within chemotherapy (6 to 8 months after diagnosis)
61922141|NCT01661816||within Herceptin|30 couples, within herceptin treatment (the first year after diagnosis)
61922142|NCT01661816||within hormonotherapy|30 couples, within hormonotherapy (between 2 and 7 years after diagnosis)
61922143|NCT01661816||without hormonotherapy|30 couples, did not received hormonotherapy (1 year after diagnosis)
61922144|NCT01661816||end of treatment|30 couples, after end of treatments for patients who did received hormonotherapy (7 years after diagnosis)
61922145|NCT01695655||PKP|Subjects undergoing penetrating keratoplasty
61922146|NCT02992561|ACTIVE_COMPARATOR|Narrative Exposure Therapy (FORNET, adapted version)|Version of Narrative Exposure Therapy for Forensic Offender Rehabilitation including one lifeline session and 5 exposure sessions as well as 6 group sessions adapted from behavioral-therapy approaches for addiction problems.
62681547|NCT06642558|EXPERIMENTAL|Low dose vaccine group in subjects aged ≥60 years - Phase 2|Subjects aged ≥60 years in phase 2 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose), by IM injection into the deltoid region of the arm.
62681548|NCT06642558|EXPERIMENTAL|High dose vaccine group in subjects aged ≥60 years - Phase 2|Subjects aged ≥60 years in phase 2 will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose), by IM injection into the deltoid region of the arm.
61922147|NCT02992561|NO_INTERVENTION|Waitlist control or treatment as usual|No intervention or non-specific measures of support on request
62476589|NCT01956591||Plantar hyperhidrosis|Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
62476590|NCT01956591||Cranio-facial hyperhidrosis|Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
62476591|NCT01956591||Other sites hyperhidrosis|Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
62681549|NCT06642558|PLACEBO_COMPARATOR|Placebo group in subjects aged ≥60 years - Phase 2|Subjects aged ≥60 years in phase 2 will receive single dose of placebo, by IM injection into the deltoid region of the arm.
62681550|NCT05330546|EXPERIMENTAL|Osseodensification technique group|10 patients will be randomly assigned to the osseodensification group so the implant osteotomy will be prepared using densah burs
61922148|NCT03998813|EXPERIMENTAL|Locoregional analgesia by femoral triangle catheterization|
61922149|NCT03998813|ACTIVE_COMPARATOR|Tissue infiltration|
61922150|NCT00579436|ACTIVE_COMPARATOR|Fish oil group|4g Lovaza (omega-3 fatty acid) daily.
61922151|NCT00579436|PLACEBO_COMPARATOR|Control group|placebo (4 non-active capsules daily)
61922152|NCT03397654|EXPERIMENTAL|TACE followed by pembrolizumab|Trans-arterial chemoembolization (TACE) using doxorubicin solution (60 mg dose) and gelatin sponge particles; followed, at least 30 or 45 days later, by pembrolizumab solution (200 mg dose) every 3 weeks for a maximum of 1 year
61922153|NCT05344638|EXPERIMENTAL|AGS (Experimental)|AGS + Placebo of AGU
61922154|NCT05344638|ACTIVE_COMPARATOR|AGU (Active Comparator)|Placebo of AGS + AGU
61922155|NCT04048811|EXPERIMENTAL|HSK3486|HSK3486 induction + maintenance group
62122100|NCT02722070||Neurodegenerative patients|
62122101|NCT02722070||Stroke patients|
62122102|NCT02722070||Neuropsychiatric patients|
62681551|NCT05330546|ACTIVE_COMPARATOR|Ridge expansion screw group|10 patients will be randomly assigned to the ridge expansion screw group so the implant osteotomy will be prepared using ridge expansion screws
62681552|NCT06650592||All patients who were candidates for immediate lymphatic reconstruction (ILR)|All patients who were candidates for immediate lymphatic reconstruction (ILR) in the LYMPHA Database
62681553|NCT04869917|EXPERIMENTAL|Decision Aid intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid which reviews information about the benefits and risks of intensive lifestyle intervention and metformin.
61922156|NCT04048811|ACTIVE_COMPARATOR|Propofol|Propofol induction + maintenance group
61922157|NCT04048811|OTHER|Propofol HSK3486|Propofol induction + HSK3486 maintenance group
62122103|NCT01180088|EXPERIMENTAL|ANTERIOR APPROACH|SURGICAL TECHNIQUE
62122104|NCT01865890||patient on hemodialysis taking plavix|patient on hemodialysis taking plavix
62310939|NCT02928237|PLACEBO_COMPARATOR|Sham tDCS|Sham tDCS was applied using the same parameters but only for 30 seconds then the machine is deactivated.
62310940|NCT00722059|EXPERIMENTAL|1|Subjects will undergo a 3D breast Tomosynthesis imaging scan. This is a one time breast imaging scan will last approximately 15 minutes.
62310941|NCT01326962|EXPERIMENTAL|Single Arm|
62310942|NCT05017831|ACTIVE_COMPARATOR|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
62310943|NCT05017831|EXPERIMENTAL|FBT w/ Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of FBT over six months. The first 9 sessions of FBT will be preceded by adolescent-focused CRT.
62310944|NCT00520689|ACTIVE_COMPARATOR|1|
62681554|NCT04869917|EXPERIMENTAL|Text Messaging intervention|Participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent using an existing secure text messaging platform.
61922158|NCT04577352|EXPERIMENTAL|Vatiquinone|Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if ˂12 years of age and weighing ˂25 kilograms (kg) or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 72 weeks during the placebo-controlled phase and for 24 weeks during the open-label extension phase.
62681555|NCT04869917|EXPERIMENTAL|Decision Aid intervention + Text Messaging intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid. Additionally, participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent using an existing secure text messaging platform.
62681556|NCT04869917|PLACEBO_COMPARATOR|Usual Care|Usual care includes no additional intervention above the care routinely provided at the clinical partner site, Erie Family Health Center.
62681557|NCT00660959|EXPERIMENTAL|Active Comparator|lixivaptan
62122105|NCT06551909|EXPERIMENTAL|Treatment arm|The 30 patients will receive neoadjuvant stereotactic radiotherapy in 5 fractions delivering 30 GY to PTV and 35-50 GY with Simultaneous Integrated Boost (SIB) to GTV using standard chemotherapy (TMZ) after surgery. GTV will be treated with escalating dose levels from 35 to 50 Gy. Patients will be divided into groups of 5 and will receive in the absence of 2 G4 toxicities per group, the following dose levels: 35-40-42.5-45-47.5 and 50 Gy
62122106|NCT04716855||Evaluation tests|RCS cases between the ages of 19-64 (n:40) who agreed to participate were included in the study. Pain severity (Visual Analogue Scale - VAS), range of motion (Universal Goniometer), muscle test (Manual muscle test), upper extremity functional status and disability (Quick-DASH questionnaire), physical activity level (International Physical Activity Questionnaire - UFAA) ) and quality of life (Short Form-36 - SF-36) were evaluated
62681558|NCT00660959|PLACEBO_COMPARATOR|Placebo|placebo
62681559|NCT05029882|EXPERIMENTAL|Part 1 (Monotherapy Dose Escalation)|Participants with advanced solid tumors will receive escalating doses of ABBV-400.
62681560|NCT05029882|EXPERIMENTAL|Part 2i (wtEGFR Non-Small Cell Lung Cancer [NSCLC])|Participants with non-squamous wtEGFR NSCLC will receive ABBV-400 at the Recommended Phase 2 dose (RP2D).
62681561|NCT05029882|EXPERIMENTAL|Part 2ii (mutEGFR NSCLC)|Participants with non-Squamous mutEGFR NSCLC will receive ABBV-400 at RP2D.
62681562|NCT05029882|EXPERIMENTAL|Part 2iii (Squamous NSCLC)|Participants with squamous NSCLC will receive ABBV-400 at RP2D.
62681563|NCT05029882|EXPERIMENTAL|Part 3 (Gastroesophageal Adenocarcinoma/Gastroesophagel Junct|Participants with gastroesophageal adenocarcinoma will receive ABBV-400 at the RP2D.
62681564|NCT05029882|EXPERIMENTAL|Part 4 (Colorectal Cancer)|Participants with Colorectal Cancer (CRC) will receive ABBV-400 at the RP2D and various dose levels for dose optimization.
62681565|NCT05029882|EXPERIMENTAL|Part 5 (MET Amplification)|Participants with mesenchymal-epithelial transition proto-oncogene (MET) amplification will receive ABBV-400 at the RP2D and various dose levels for dose optimization.
62681566|NCT05029882|EXPERIMENTAL|Part 6 (MET Mutation)|Participants with MET mutation will receive ABBV-400 at the RP2D and various dose levels for dose optimization.
62681567|NCT05029882|EXPERIMENTAL|Part 7a (Combination Dose Escalation)|Participants with CRC will receive escalating doses of ABBV-400 in combination with bevacizumab.
62681568|NCT05029882|EXPERIMENTAL|Part 7bi (Combination Dose Optimization Low Dose)|Participants with CRC will receive the low dose determined in the dose escalation arm (Part 7a) of ABBV-400 in combination with bevacizumab.
62681569|NCT05029882|EXPERIMENTAL|Part 7bii (Combination Dose Optimization High Dose)|Participants with CRC will receive the high dose determined in the dose escalation arm (Part 7a) of ABBV-400 in combination with bevacizumab.
62681570|NCT05029882|EXPERIMENTAL|Part 7biii (Combination Comparator)|Participants with CRC will receive trifluridine/tipiracil (TAS-102) in combination with bevacizumab.
62681571|NCT06695442||Training Cohort|Participants included from March 2020 to April 2021 for model development.
62681572|NCT06695442||Validation Cohort|Participants included from May 2021 to October 2021 for model validation.
62681573|NCT06189872|OTHER|Attune Cementless, Fixed Bearing, Cruciate Retaining TKA System|Attune Cruciate Retaining TKA System
62681574|NCT06688747||Distal access|Distal radial access for coronary angiography and intervention
62681575|NCT06688747||Traditional access|Distal radial access for coronary angiography and intervention
62681576|NCT05626686|EXPERIMENTAL|CLINY reusable catheter 28 days|The investigation is designed as an open-labelled, single-arm investigation, in which the reuse CLINY catheter will be compared to single use catheters at baseline.
62681577|NCT06306144|EXPERIMENTAL|Patients receiving the Psychoeducation Intervention|Patients will participate in a 6-week psychoeducation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of exercises set by the rehabilitation clinician
62681578|NCT06306144|EXPERIMENTAL|Patients receiving the Computerised Cognitive Stimulation Intervention|Patients will participate in a 6-week cognitive stimulation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of on-line exercises set by the rehabilitation clinician.
62310945|NCT00520689|ACTIVE_COMPARATOR|2|
62681579|NCT06306144|EXPERIMENTAL|Patients receiving the Usual Care|Patients randomized to this group will complete the questionnaires and the cognitive tests but will receive no intervention
62681580|NCT04404283|EXPERIMENTAL|Experimental Arm|Brentuximab vedotin + lenalidomide + rituximab
62681581|NCT04404283|ACTIVE_COMPARATOR|Control Arm|Placebo + lenalidomide + rituximab
62681582|NCT05612295|EXPERIMENTAL|MBPP group|The Mindfulness-based Peak Performance (MBPP) program consists of eight 60-min training sessions, once weekly for 8 weeks, which aim to enhance human performance.
62681583|NCT05612295|ACTIVE_COMPARATOR|Self-talk group|The self-talk intervention serving as the active control group will be included in the current trial. In line with the MBPP intervention, the self-talk intervention is also designed to enhance athletic performance, and will consist of eight 60-min meaningful sessions, once per week for eight weeks.
62310946|NCT00520689|ACTIVE_COMPARATOR|3|
62310947|NCT00520689|ACTIVE_COMPARATOR|4|
61922159|NCT04577352|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to vatiquinone (per age and weight) orally TID for 72 weeks during the placebo-controlled phase and vatiquinone at a dose of either 200 mg orally TID if ˂12 years of age and weighing ˂25 kg or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 24 weeks during the open-label extension phase.
62681584|NCT05612295|NO_INTERVENTION|Waiting-list control|The participants in waiting-list control group are advised to maintain their everyday lifestyles and regular training. Once the participants in WC finish the experiment, they will be invited to participate in one of the 8-week interventions (i.e., MBPP or ST) based upon their preference.
62681585|NCT03949114|EXPERIMENTAL|test group|"1) Performing a weak debilitating phenotype screening on the patients before surgery;~(2) Do the early rehabilitation intervention process:"
62681586|NCT03949114|ACTIVE_COMPARATOR|Control group|1) Performing a weak debilitating phenotype screening on the patients before surgery; (2) Patients in the control group were treated according to the general nursing routine after neurosurgery;
62681587|NCT06159127|EXPERIMENTAL|SMART@Home|Use of the SMART@Home app for medication and symptom tracking, spirometry feedback
62681588|NCT06159127|NO_INTERVENTION|Control|Usual Care
62681589|NCT04964466||Amount of PDGF-BB in PRF preparation vs. GEM21|The release kinetics of PDGF-BB will be assessed for one PRF preparation from each of the six individual participants and one GEM 21S sample. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
62681590|NCT04964466||PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
62681591|NCT04964466||: Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
62681592|NCT04964466||Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
62681593|NCT05726383|EXPERIMENTAL|Treatment Arm - Iscador*P|Each Iscador® P therapy begins with a dose finding phase related to the drug' immunogenicity. In this phase, gradually increasing doses are used to determine the optimum individual dose response of the patient and to prevent excessive toxicity. The Iscador® P will be administered three times per week by subcutaneous injections (M,W,F) into the subcutaneous tissue of the thigh or abdomen. Treatment is administered according to a series of escalating doses that are given each of the three days in a week for 7 doses. There are 3 different series (Series 0, 1, and 2) and there are 7 dose vials in each series. Once the patient has reached their maximum tolerated dosing series, that series is used as the treatment regimen for the remaining weeks to a total duration of 52 weeks (13 cycles) or until disease progression. Each cycle is 4 weeks.
62681594|NCT06004674|EXPERIMENTAL|Enoxaparin Group|Participants in the enoxaparin group will be asked to take a dose of the enoxaparin once a day (40 mg daily) daily from 12 0/7 weeks and/or start of enrollment (whichever is later), and continue until 36 weeks gestational age, after which enoxaparin will be discontinued.
62681595|NCT06004674|NO_INTERVENTION|Control Group|Participants in this group will have standard care as usual, with no additional medications.
62681596|NCT06082817|EXPERIMENTAL|Active|Participants will receive 50mg oral testosterone undecanoate daily, have pharmacokinetics assessed and complete validated instruments
62681597|NCT03997591||Conventional therapy|Group doing conventional rehabilitation was assessed at T0 and then after 6 weeks of conventional therapy (occupational therapy, physical therapy, aquatic therapy, musicotherapy, others)
62681598|NCT03997591||Ready2E.A.T. therapy|Group doing Ready2E.A.T. program received a mean of 1 hour per week and was assessed at T0 and then after 6 weeks of this program implementation.
62681599|NCT04334681||UC Group|Patients operated on the un-roofing curettage method in the treatment of pilonidal disease will be analyzed in this group.
62122107|NCT00019747|EXPERIMENTAL|Arm 1 - Thalidomide once daily|Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
61922160|NCT02385188|EXPERIMENTAL|Imiquimod|Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.
62681600|NCT04334681||LF Group|Patients who have been operated with the modified Limberg flap method after rhomboid excision in the treatment of pilonidal disease will be analyzed in this group.
62681601|NCT03943511|ACTIVE_COMPARATOR|Group 1|Oral Antibiotics
62681602|NCT03943511|ACTIVE_COMPARATOR|Group 2|Standard of Care
61922161|NCT02609698|EXPERIMENTAL|Coroflex ISAR 3 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 3 months
61922162|NCT02609698|ACTIVE_COMPARATOR|Coroflex ISAR 6 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 6 months
62476592|NCT02968992|EXPERIMENTAL|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
62476593|NCT02968992|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
62476594|NCT05793086||active trigger point group|Individuals with active trigger points in trapezius
62476595|NCT05793086||latent trigger point group|Individuals with trigger points in trapezius without spontaneous pain
62681603|NCT06694337|EXPERIMENTAL|Group 1|Participants will receive 2 × 300 mg oral PEA Phytosome® tablets daily for 8-weeks as add-on to the standard of care.
62122108|NCT00019747|PLACEBO_COMPARATOR|Arm 2 - Placebo once daily|Patients receive oral placebo once daily.
62122109|NCT05981157|EXPERIMENTAL|Anrotinib plus Tirelizumab arm|Subjects receive anrotinib plus tirelizumab
62476596|NCT05793086||healthy trapezius muscle|Individuals without trigger points.
62476597|NCT00958451|ACTIVE_COMPARATOR|Paricalcitol|Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
62495968|NCT01899053|EXPERIMENTAL|Dose Escalation Treatment Arm B|TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.
62681604|NCT06694337|EXPERIMENTAL|Group 2|Participants will receive 1 × 450 mg oral PEA Phytosome® tablet, and 1 placebo tablet daily for 8-weeks as add-on to the standard of care.
62681605|NCT06694337|PLACEBO_COMPARATOR|Group 3|Participants will receive 2 × placebo tablets daily for 8-weeks as add-on to the standard of care.
62681606|NCT04210115|EXPERIMENTAL|Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy|"Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:~* FP therapy: cisplatin 75 mg/m\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)\] 1000 mg/m\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray \[Gy\] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~* FOLFOX therapy: oxaliplatin 85 mg/m\^2 AND either leucovorin 400 mg/m\^2 OR levoleucovorin 200 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m\^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year."
62122110|NCT02981888||IBS-C|all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit
62122111|NCT02981888||IBS-D|all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit
62681607|NCT04210115|PLACEBO_COMPARATOR|Placebo+FP or FOLFOX Therapy+Radiotherapy|"Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:~* FP therapy: cisplatin 75 mg/m\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~* FOLFOX therapy: oxaliplatin 85 mg/m\^2 AND either leucovorin 400 mg/m\^2 OR levoleucovorin 200 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m\^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year."
62476598|NCT00958451|ACTIVE_COMPARATOR|Ergocalciferol|Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
61922163|NCT01408329|SHAM_COMPARATOR|Control|Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.
62122112|NCT02981888||heathy control|all healthy controls will undergo an abdominal x-ray for assessment of colonic transit
62122113|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
62122114|NCT03145649||Healthy|Healthy mother-infant dyads
62476599|NCT02324660|OTHER|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
62476600|NCT04594252|EXPERIMENTAL|ALXN1840|Participants will be administered repeat doses of ALXN1840 30 milligrams (mg) for 15 days.
62476601|NCT06199219|OTHER|Intervention Group|"Sexual counseling, based on the extended (EX-PLISSIT) model was offered to women for 6-10 weeks (until a solution was achieved).~All interventions must begin with Permission. Each stage of Limited Information, Special Recommendation and Intensive Therapy is supported by Allowing. Thus, the interaction between counselors and clients is improved"
62476602|NCT06199219|NO_INTERVENTION|Control Group|No intervention pretest posttest
62122115|NCT04460313|OTHER|prospective cohort|Nasopharyngeal sample for each enrolled children
62122116|NCT04460313|OTHER|ESBL cohort|Stool or anorectal swab samples for a subgroup of children
62122117|NCT01120418|EXPERIMENTAL|Besifloxacin Ophthalmic Suspension 0.6%|Topical ocular administration three times daily (TID) for 5 days
62495969|NCT01899053|EXPERIMENTAL|Dose Escalation Treatment Arm C|TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.
62495970|NCT01899053|EXPERIMENTAL|Drug-Drug Interaction (DDI) Expansion Cohort|TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.
62122118|NCT04094532|ACTIVE_COMPARATOR|ultrasound guided transverse thoracic muscle plane block|
62122119|NCT04094532|SHAM_COMPARATOR|ultrasound guided sham block|
62681608|NCT03641560|EXPERIMENTAL|Enzalutamide group|Participants will receive Enzalutamide once daily in addition to continued androgen deprivation therapy until discontinuation criteria is met
62122120|NCT06377111|EXPERIMENTAL|C-PAN in combination with ICI|C-PAN will be taken orally once daily in the morning prior to eating. The daily oral dose of C-PAN is 2000 mg (4 capsules of 500 mg each). Subjects will receive C-PAN exclusively for a run-in period of 3 to 7 days, and then a maintenance dose as long as the patient continues to receive SOC Nivolumab and Ipilimumab. Treatment will continue until unacceptable toxicity, progression of disease (PD), start of new anticancer therapy, or for a maximum of 1 year, whichever occurs earlier, and in the absence of criteria to discontinue C-PAN.
62310948|NCT04333290|EXPERIMENTAL|Single Arm: Healthy subjects|The PET radiotracer Myeliviz (\[11C\]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time. This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution.
62310949|NCT00883428||Pergnant women|Pregnant women, of 28 weeks or more of gestation, who are seen in the Health Centers participating in the study.
62310950|NCT06039917|EXPERIMENTAL|With automatic surveillance system|Patients were reminded of the surveillance time by an automatic surveillance system after the endoscopic and pathological results were available and before the surveillance time.
62310951|NCT06039917|EXPERIMENTAL|With manual reminder|Patients were reminded of the surveillance time manually after the endoscopic and pathological results were available and before the surveillance time.
62310952|NCT06039917|NO_INTERVENTION|Normal group|The patients in the control group were observed in the clinical natural state of surveillance without automatic surveillance system or manual reminder.
62681609|NCT03824054||colorectal resection arm|Patients affected by symptomatic deep infiltrating endometriosis involving the bowel and submitted to colo-rectal resection
62681610|NCT06306157|PLACEBO_COMPARATOR|Placebo sugar capsules|Half of all enrolled patients will be randomized to receive placebo sugar capsules. Neither the patient nor treating physician will be aware of the group in which the patient was randomized into until after study conclusion. All patients will be requested to take the respective daily dose and follow the titration schedule as instructed. All patients enrolled in the study, regardless of their randomization, will have standard of care treatment for CRPS according to their symptoms and the clinical judgment of the treating clinician.
62122121|NCT03401190|EXPERIMENTAL|Low Dose Group|Phase 1: Cohorts 1 \& 2 will consist of 4 female and 4 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
62310953|NCT05198167|EXPERIMENTAL|Hyperoxygenated Fatty Acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
62310954|NCT05198167|EXPERIMENTAL|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
62310955|NCT02983838||depression with cognitive impairment|depression onset after 60 years old with subjective cognitive impairment
62310956|NCT02983838||depression without cognitive impairment|depression onset after 60 years old without subjective cognitive impairment
62310957|NCT02983838||normal control|older than 65 years, free from other neurocognitive disorder
62310958|NCT02725177|EXPERIMENTAL|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
62310959|NCT02646436|OTHER|HD treatment|Patients with absolute contraindication to the PD method - presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2\> 70%); abdominal infections; severe hyperkalemia with changes characteristic in EKG; and acute pulmonary edema - will be treated with HD.
62495971|NCT01276496|EXPERIMENTAL|Treatment (cilengitide, paclitaxel)|"Patients receive cilengitide IV over 1 hour on days\* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~NOTE: \*Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16."
62495972|NCT04681586|EXPERIMENTAL|Bright white light|
62476603|NCT05148273||intervention|After the selection process with 1 to 1 randomization method, a personal information form and Beck anxiety scale will be applied to the women selected for the case group on the day of the initiation of treatment with assisted reproductive techniques interview. Then, within an average of 10 days, there is a treatment procedure including planned drug use, messages containing drug doses, drug use, drug administration, follicle count, reminder of the times of operations such as OPU, IUI, ET, and motivational issues. Medication use, time, date, dose, application form and motivational sentences will be sent every day through the WhatsApp application. The Beck anxiety scale will be repeated on the day of IUI and ET procedures, and the effect of telehealth practices on the anxiety levels of women undergoing infertility treatment will be evaluated. During the study, the participants will be able to reach the researcher from their mobile phones whenever they want.
62681611|NCT06306157|EXPERIMENTAL|Low dose naltrexone|Half of all enrolled patients will be randomized to receive capsules with the active low dose naltrexone (LDN) ingredient. LDN will be titrated over time to minimize potential side effects, with the initial dose starting at 1.5mg and eventually increasing up to 4.5mg. Neither the patient nor treating physician will be aware of the group in which the patient was randomized into until after study conclusion. All patients will be requested to take the respective daily dose and follow the titration schedule as instructed. All patients enrolled in the study, regardless of their randomization, will have standard of care treatment for CRPS according to their symptoms and the clinical judgment of the treating clinician.
62681612|NCT05477641|ACTIVE_COMPARATOR|pericapsular nerve group block and lateral femoral cutaneous nerve block|Nerve blocks
62681613|NCT05477641|ACTIVE_COMPARATOR|fascia iliaca compartment block|Nerve block
62681614|NCT02393469|PLACEBO_COMPARATOR|Group phase 1|Two months of education and self-management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
62310960|NCT02646436|OTHER|PD treatment|Patients stage 5 (creatinine clearance \< 15 ml/min) requiring dialysis treatment immediately without absolute contraindication to the PD method will receive unplanned PD treatment. High volume PD (HVPD) will be used during the first 7 days of PD in order to achieve metabolic and fluid control. The procedure for acute PD has been published recently by our team . At this point, patients will be discharged from hospital and they will be treated by intermitent PD at the dialysis unit of the University Hospital.until their family be trained and home be prepared for the implementation of technique.
62310961|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
62476604|NCT05148273||control|In the first interview at the beginning of the treatment protocol with assisted reproductive techniques, a personal information questionnaire and beck anxiety scale will be applied to the control group selected by the 1-to-1 randomization method. Afterwards, the Beck anxiety scale will be applied again at the end of the treatment without any intervention.
62476605|NCT04927663|EXPERIMENTAL|Cohort A: Any Solid Tumor (Dosimetry Cohort)|Participants with any solid tumor malignancy with evidence of one or more metastases will receive approximately 20 millicurie (mCi) of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline.
62476606|NCT04927663|EXPERIMENTAL|Cohort B: Metastatic CRPC|Participants with metastatic CRPC will receive approximately 20 mCi of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline and optional repeat scan at the time of progression.
62476607|NCT04927663|EXPERIMENTAL|Cohort C: Solid Tumor Malignancy|Participants with any solid tumor malignancies other than prostate adenocarcinoma with one or more metastases on conventional imaging will receive approximately 20 mCi of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline and optional repeat scan at the time of progression.
62476608|NCT05658601||Cohort 1|
62476609|NCT06559566|ACTIVE_COMPARATOR|ONSD measurement with USG|After the ONSD measurement is made before anesthesia induction, general anesthesia will be given to each patient according to the institutional protocol. The ONSD measurements of the patients will be measured according to the T0, T1, T2, T3, T4, T5 time period by a person who has experience in using USG T0: Before anesthesia induction T1: First 5 minutes immediately after induction of anesthesia T2: At the end of the surgery before extubation /minute T3: Within the first hour/minute after extubation T4: 12 hours/minute after tumor resection T5. 24 hours/minute after tumor resection
62476610|NCT06559566|ACTIVE_COMPARATOR|ONSD measurement with BCT|"In patients, USG and BCT correlation comparison is planned before the operation (T0), in the first hour after the end of post-operative surgery (T3) and at the 24th hour after post-operative surgery (T5).~T0: ONSD measurement in pre-operative BCT T3: BCT ONSD measurement/minute within the first hour following the postoperative period T5: BCT ONSD measurement/minute 24 hours following the postoperative period The measurement of ONSD in BCT is; Eyeball diameter and optic nerve diameter measurements will be made on BCT transverse images at the optic nerve level and recorded."
62476611|NCT05462327|EXPERIMENTAL|Low Fresh Gas Flow in Prone Position|Low fresh gas flow (0,5 L/min during maintenance)
62476612|NCT05462327|ACTIVE_COMPARATOR|Normal Fresh Gas Flow in Prone Position|Normal flow (2 L/min) in general anesthesia.
62476613|NCT05502250|EXPERIMENTAL|Single-arm|4 cycles of gemcitabine and cisplatin (GP) + tislelizumab followed by 13 cycles of tislelizumab
62476614|NCT05925010|EXPERIMENTAL|Supplementation with soluble fibre from guar|In the intervention group, the patients consume the standardized meal instead of breakfast and add 10 g of soluble fiber in the form of Optifibre (food for special medical purposes) to this cereal porridge.
62495973|NCT04681586|PLACEBO_COMPARATOR|Dim red light|
62681615|NCT02393469|EXPERIMENTAL|Group phase 2|Pulmonary rehabilitation for two months: The same patients enter phase 1 phase 2 performing this two months of pulmonary rehabilitation are also included new patients who participate directly in phase 2
62681616|NCT02393469|EXPERIMENTAL|Group phase 3|Pulmonary rehabilitation for ten months: Participate participants of phases 1 + 2 and 2, as well as new participants enter directly in phase 3
62681617|NCT06689111|EXPERIMENTAL|Left Bundle branch Pacing|Implantation of a left bundle branch lead via sheath, to perform left bundle branch pacing
62681618|NCT06689111|ACTIVE_COMPARATOR|Conventional Bi- Ventricular pacing|Conventional resynchronization therapy using a vein through coronary sinus
62310962|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
62310963|NCT04165265|EXPERIMENTAL|Responders and Partial/non-responders|"The definition of responders to glucocorticoids is: Bowel movements ≤ 3/day without blood and normalization of CRP. In the study, this is supported by CC.~The definition of non-responders is: Bowel movements \> 8/day or 3-8/day and CRP \> 45 mg/l. The decision if the patient is a non-responder is supported by CC.~Questionnaires in CC and FC analysis with CalproSmart are performed every day until discharge or when classified as green in CC. After discharge questionnaires in CC and FC analysis are performed once every week in the following 7 weeks and a final registration at week 52. In case of disease relapse between week 7 and 52 registration in CC and FC analysis are performed on demand. Fecal samples for future use (biobank) and FC Elisa as well as blood samples are done before administration of IFX (week 2 and 6). At follow-up (week 52) it is considered whether the patient underwent colectomy or not."
62310964|NCT03955029|EXPERIMENTAL|Conventional Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow conventional Interval Training
62310965|NCT03955029|EXPERIMENTAL|Progressive Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow progressive Interval Training
62476615|NCT05925010|NO_INTERVENTION|No supplementation with soluble fibre from guar|In the control group, the patients eat the standardized meal without adding soluble fiber in the form of Optifibre.
62476616|NCT05517681|PLACEBO_COMPARATOR|non-ICG Group|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection
62476617|NCT05517681|EXPERIMENTAL|ICG Group|ICG was injected preoperatively via anoscope or anal dilator in the mucosal layer around the tumor, and surgical treatment was performed after visualization. The surgical approach was performed by laparoscopic radical rectal cancer with an intermediate approach step.The IMA root is treated with low ligation of the IMA, while lymph node dissection is performed while preserving the autonomic nerves around the IMA
62476618|NCT04188080|EXPERIMENTAL|Jarlsberg cheese starting dose|The participants obtaining an Osteocalcin increase \> 10% during the previous 6 weeks intake of Jarlsberg cheese, will get a percent reduction in the daily cheese-dose equal to the increase in the Osteocalcin level
62476619|NCT06560710||macular hole without vitreomacular tracation|Vitrectomy
62476620|NCT06560710||Stage 2 macular hole with vitreomacular tracation|Vitrectomy
62476621|NCT04325724|OTHER|Beginner psoriatic arthritis patients|Every patients consulting in dermatologic or rheumatologic department for a skin psoriasis with clinical symptoms which may lead to the suspicion of psoriatic arthritis
62122122|NCT03401190|EXPERIMENTAL|High Dose Group|Phase 2: Cohorts 3 \& 4 will consist of 8 female and 8 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
62122123|NCT03401190|NO_INTERVENTION|Standard of Care|For all cohorts, patients will be randomized 3:1 to CM4620-IE plus standard of care versus standard of care alone.
62122124|NCT03281382|EXPERIMENTAL|Investigational Arm|Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered \[18F\]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
62122125|NCT06371196|EXPERIMENTAL|Babaodan Capsule|Babaodan Capsule (State Drug License: Z10940006) is manufactured by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/carton; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk and so on.
62122126|NCT03234088|OTHER|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
62122127|NCT06383442|NO_INTERVENTION|Control group|
62310966|NCT00552799|EXPERIMENTAL|1|Penicillin VK 250 mg b.d.
62476622|NCT04325724|OTHER|Confirmed psoriatic arthritis patients|Every patients with psoriatic arthritis followed in rheumatologic department
62476623|NCT04325724|OTHER|Rheumatoid arthritis or Digital osteoarthritis patients|Followed in rheumatologic department
62476624|NCT04325724|OTHER|Skin psoriasis patients without any articular symptoms|
62476625|NCT01327391|ACTIVE_COMPARATOR|On line Hemodiafiltration|Hemodialysis patients treated with on line hemodiafiltration technic
62476626|NCT01327391|OTHER|hemodialysis|Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers
62476627|NCT00573599|EXPERIMENTAL|1|prochlorperazine and benadryl IV, saline subQ
62476628|NCT00573599|ACTIVE_COMPARATOR|2|imitrex SubQ, saline IV
62476629|NCT01383694|EXPERIMENTAL|Piperine Dose 1|Piperine 1 mM
62476630|NCT01383694|EXPERIMENTAL|Piperine Dose 2|Piperine 150 microM
62495974|NCT05694234||sugammadex group|patients who administered sugammadex
62122128|NCT06383442|EXPERIMENTAL|M-HIIT|
62122129|NCT06383442|EXPERIMENTAL|L-HIIT|
62122130|NCT05461417||D-SAD group|Patients equipped with Panthera D-SAD MAO
62122131|NCT00502229|ACTIVE_COMPARATOR|Group A|Continuing treatment
62122132|NCT00502229|ACTIVE_COMPARATOR|Group B|Gonadotrophins
62122133|NCT01250678||neurocognitive impaired|MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
62122134|NCT01250678||neurocognitive non-impaired|MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
62122135|NCT04134143|EXPERIMENTAL|Cohort 1: One Application|Participants enrolled in Cohort 1 received one application of experimental skin tissue during the first part of this trial (NCT02657876)
62310967|NCT00552799|PLACEBO_COMPARATOR|2|placebo tablet b.d.
62310968|NCT02850614|ACTIVE_COMPARATOR|Control|Fifty participants in the control condition will each receive a FitBit to track their physical activity. Instead of interfacing with a gaming app on their Chromebooks to track physical activity, control condition participants will interface with a minimalist activity tracker showing them only how many minutes of MVPA they've done over the course of the day. It is expected that after several weeks of baseline use, control condition participants will no longer find the FitBit novel. In order to encourage control condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
62476631|NCT00857454|EXPERIMENTAL|Testosterone MD-lotion|"In this open-label extension of the MTE08 trial, participants received Testosterone Metered Dose (MD)-Lotion for 60 days (dosing from Day 121 of the MTE08 trial to Day 180 of the MTE09 trial). Participants in MTE08 initially received 3.0 milliliters (mL) (60 micrograms \[mg\]) of 2% Testosterone MD-Lotion, and may have had their dose of testosterone adjusted upwards or downwards.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg)of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg)of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 2 x 1.5 mL to the other axilla).~6.0 (120 mg)of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
62122136|NCT04134143|EXPERIMENTAL|Cohort 2: Up to Five Applications|Participants enrolled in Cohort 2 may receive up to 5 applications of experimental skin tissue as required for wound healing
62122137|NCT04134143|EXPERIMENTAL|Cohort 3: Up to Ten Applications|Participants enrolled in Cohort 3 may receive up to 10 applications of experimental skin tissue as required for wound healing
62122138|NCT03443453|EXPERIMENTAL|MIV-711 ABCD|Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).
62476632|NCT03699696||65-75 years of age|Patients who are between the ages of 65 and 75, including 65 but not including 75, and receive propofol for induction of anesthesia.
62681619|NCT06613139|EXPERIMENTAL|Group A(RT)|17 subjects, Cross-over, Single dose of YHR2404 on day 1, Single dose of YHP2305 on day 8
62681620|NCT06613139|EXPERIMENTAL|Group B(TR)|17 subjects, Cross-over, Single dose of YHP2305 on day 1, Single dose of YHR2404 on day 8
62122139|NCT03443453|EXPERIMENTAL|MIV-711 CDAB|Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).
62122140|NCT05188781||Pembrolizumab combined with Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
62122141|NCT03933605|ACTIVE_COMPARATOR|midazolam and palonosetron|0.05 mg/kg of midazolam i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
62122142|NCT03933605|ACTIVE_COMPARATOR|palonosetron|the same volume (0.05 mg/kg) of normal saline i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
62122143|NCT01697969|EXPERIMENTAL|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop once daily in both eyes for 14 days
62122144|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
62122145|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
62122146|NCT04598321|EXPERIMENTAL|Planned Therapy|Talazoparib monotherapy as 1 mg capsule orally on a daily basis for three cycles, defined as a 21-day period, prior to surgery. Volunteers will continue treatment to complete three cycles, unless disease progression or unacceptable toxicity occurs.Volunteers who complete neoadjuvant treatment with talazoparib should undergo surgical cytoreduction within three weeks of their last dose of talazoparib. All volunteers should then undergo standard of care adjuvant therapy using carboplatin and paclitaxel. For volunteers, who agree to continue talazoparib as maintenance therapy, treatment should begin three weeks (+/- 2 weeks) from the end of adjuvant chemotherapy or after cytoreductive surgery alone.
62122147|NCT05863481||Laparoscopic cerclage|Patients who underwent laparoscopic cerclage at Aarhus University Hospital, Denmark in the study period
62310969|NCT02850614|EXPERIMENTAL|Intervention|Fifty participants will be randomized to the intervention condition, which will use a gaming application to encourage physical activity, as physical activity goal achievement will translate into rewards in the game. Physical activity will be tracked using a FitBit activity monitor and in order to encourage intervention condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
62681621|NCT05333029|EXPERIMENTAL|MSCs + ECP|"The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.~Participants will be followed for up to 1 year for assessment of endpoints."
62310970|NCT02812030||aflibercept in real world|Patients receiving aflibercept for diabetic macular oedema at Bristol Eye Hospital or Gloucestershire Hospitals NHS Foundation Trust
62310971|NCT01398254|OTHER|TRA|Transradial Access
62310972|NCT01398254|OTHER|TFA|Transfemoral Access
62122148|NCT04934904|EXPERIMENTAL|Experimental Group|On the basis of the clinical routine treatment of AGI in severe patients, the Experimental Group will receives ultrasound-guided erector spinae plane block with routine treatment of AGI for 7 days or until transferring to the general ward.
62122149|NCT04934904|NO_INTERVENTION|Controlled Group|the routine clinical treatment of AGI is given to severe patients, such as gastrointestinal dynamic drugs, traditional Chinese drugs and physical rehabilitation therapy
62310973|NCT04986527|ACTIVE_COMPARATOR|24 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 24 hours prior to water seal
62310974|NCT04986527|EXPERIMENTAL|48 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 48 hours prior to water seal
62122150|NCT05255224||Retrospective|Patients admitted to Mass Brigham Hospitals for cardiac surgery from 1st January 1998 to 31st December 2020
62310975|NCT01736683|EXPERIMENTAL|Sotatercept 0.1 mg/kg|Sotatercept 0.1 mg/kg
62681622|NCT06466434|EXPERIMENTAL|Prebiotic food-enriched diet (PreFED)|Participants will receive prebiotic food-enriched snacks and supportive nutritional counseling to increase prebiotic foods in the diet.
62681623|NCT06690229|EXPERIMENTAL|glass ionomer cement|Prefabricated zirconia crowns cemented with glass ionomer cement (Ketac Cem (3M ESPE, USA)) on primary maxillary incisors will be clinically evaluated at 1-week, 3-month, 6-month, and 12-month follow-ups in terms of periodontal health, plaque accumulation, wear of opposing teeth, parental satisfaction, color match, retention, marginal integrity, and contact harmony
62681624|NCT06690229|EXPERIMENTAL|dual-cure self-adhesive resin cement|Prefabricated zirconia crowns will be cemented with dual-cure self-adhesive resin cement (RelyX U200 (3M ESPE, St. Paul, USA)) on primary maxillary incisors and will be evaluated during follow-up sessions.
62681625|NCT06690229|EXPERIMENTAL|resin modified glass ionomer cement|Prefabricated zirconia crowns will be cemented with resin modified glass ionomer cement (FujiCEM Evolve (GC, Tokyo, Japan)) on primary maxillary incisors and will be evaluated during follow-up sessions.
62122151|NCT05255224||Prospective|Patients admitted to Barts Health, Liverpool Heart and Chest Hospital, or Oxford University Hospitals NHS Foundation Trust for cardiac surgery between 1st October 2021 to 31st July 2023
62681626|NCT02555358|EXPERIMENTAL|A（DOX）|Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy
62122152|NCT04813952|ACTIVE_COMPARATOR|Group M|Group M is minimal flow anesthesia group with fresh gas flow 0,5 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 0,5 L.min-1 flow under general anesthesia.
62122153|NCT04813952|ACTIVE_COMPARATOR|Group H|Group H is high flow anesthesia group with fresh gas flow 4 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 4 L.min-1 flow under general anesthesia.
62310976|NCT01736683|EXPERIMENTAL|Sotatercept 0.3 mg/kg|Sotatercept 0.3 mg/kg
62310977|NCT01736683|EXPERIMENTAL|Sotatercept 0.5 mg/kg|Sotatercept 0.5 mg/kg
62310978|NCT01736683|EXPERIMENTAL|Sotatercept 1.0 mg/kg|Sotatercept 1.0 mg/kg
62310979|NCT01736683|EXPERIMENTAL|Sotatercept 1.5 mg/kg|Sotatercept 1.5 mg/kg
62310980|NCT01736683|EXPERIMENTAL|Sotatercept 2.0 mg/kg|Sotatercept 2.0 mg/kg
62310981|NCT01589094|EXPERIMENTAL|Gemcitabine and Cisplatin (DD GC)|This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
62310982|NCT02120586|NO_INTERVENTION|Control group|Usual care
62310983|NCT02120586|EXPERIMENTAL|Respiratory training group|"Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Inspiratory Muscle training (12-weeks)"
62310984|NCT02120586|EXPERIMENTAL|Peripheral training group|"Participants will load ≥ 50% of their maximum muscle force (Kg), after which load will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Peripheral muscle training (12-weeks)"
62310985|NCT06229678|EXPERIMENTAL|Empagliflozin Group|Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months
62310986|NCT06229678|PLACEBO_COMPARATOR|Placebo group|Subjects will be randomized to receive the empagliflozin placebo for 3 months
62476633|NCT03699696||75-85 years of age|Patients who are between the ages of 75 and 85, including 75 but not including 85, and receive propofol for induction of anesthesia.
61922164|NCT01408329|EXPERIMENTAL|Hypoxic intervention|Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.
61922165|NCT00710437||1|Dexmedetomidine - used
61922166|NCT00710437||2|Dexmedetomidine - not used
61922167|NCT02410733|EXPERIMENTAL|Lipo-MERIT|7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts
62122154|NCT01294033|PLACEBO_COMPARATOR|Fractional inspired oxygen 0.21|Cardiopulmonary exercise test performed by subject on Fractional inspired oxygen 0.21
62122155|NCT01294033|ACTIVE_COMPARATOR|Fractional inspired oxygen 0.28|Cardiopulmonary exercise test performed on supplemental oxygen (Fractional inspired oxygen 0.28)
62681627|NCT02555358|ACTIVE_COMPARATOR|B（Xelox）|Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy
62681628|NCT02555358|ACTIVE_COMPARATOR|C（Xelox）|Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.
62681629|NCT05818943|EXPERIMENTAL|Radiprodil|Liquid suspension of radiprodil, at concentrations 0.25 mg/mL or 2.50 mg/mL for 1% and 10% formulation respectively. It will be administered twice a day (bid) either orally or via gastric or nasogastric tube, slowly up-titrated to the highest tolerated dose.
62681630|NCT05134519|EXPERIMENTAL|RC48 for neadjuvant chemotherapy|RC48-ADC: 2.0 mg/kg, IV drip, Q2W
62122156|NCT03009136|EXPERIMENTAL|SCRT group|3g, three times a day, each taken before or between meals
62122157|NCT03009136|PLACEBO_COMPARATOR|placebo group|3g, three times a day, each taken before or between meals
62476634|NCT03699696||85+ years of age|Patients who are 85 years of age or older, and receive propofol for induction of anesthesia.
62476635|NCT05674513|ACTIVE_COMPARATOR|Active CYP3A5 Allele|Ulipristal acetate 30mg orally x 1 dose with pharmacokinetic and pharmacodynamics testing in individuals with active CYP3A5 alleles
62476636|NCT05674513|ACTIVE_COMPARATOR|Inactive CYP3A5 Allele|Ulipristal acetate 30mg orally x 1 dose with pharmacokinetic and pharmacodynamics testing in individuals without active CYP3A5 alleles
62476637|NCT04167267|EXPERIMENTAL|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
61922168|NCT04549974|EXPERIMENTAL|Passive heat exposure|
62122158|NCT03802318|EXPERIMENTAL|HDDT group|high dose PPI induction (oral rabeprazole 20mg qid) for 3 days, then 14 days combined with amoxicillin (regular dose, daily 2 g, 500mg qid) for high frequency dual therapy.
62476638|NCT04167267|EXPERIMENTAL|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
62681631|NCT05757349|EXPERIMENTAL|Face-down position time 1-day group|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
62681632|NCT05757349|ACTIVE_COMPARATOR|Face-down position time 3-day group|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
62681633|NCT04857034|EXPERIMENTAL|Active Treatment: Deucravacitinib Dose 1|
61922169|NCT05538819||Glimepiride group|509 patients aged \>18 years with T2D and CHF had continuous glimepiride use (1-4 mg/day).
61922170|NCT05538819||Non-glimepiride group|509 patients aged \>18 years with T2D and CHF had no glimepiride use.
62122159|NCT03802318|PLACEBO_COMPARATOR|CATT group|conventional triple therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
62122160|NCT03802318|EXPERIMENTAL|LHDT group|high dose PPI (oral rabeprazole 20mg qid) induction for 3 days, then Rabeprazole 20 mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 14 days.
62122161|NCT03802318|PLACEBO_COMPARATOR|LATT group|levofloxacin base rescue therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, levofloxacin 500 mg qd)
62122162|NCT05001269|EXPERIMENTAL|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
62122163|NCT00643071|EXPERIMENTAL|1|
62122164|NCT04889131|EXPERIMENTAL|Yoga Program|12-week yoga program begins immediately
62122165|NCT04889131|ACTIVE_COMPARATOR|Wait-list Control|Wait-listed to take the Yoga Program in 12-weeks time
62122166|NCT03824262|EXPERIMENTAL|Group I|HICO-VARIOTHERM 550 and Mistral-Air Plus forced-air warming device
62122167|NCT03824262|ACTIVE_COMPARATOR|Group II|Mistral-Air Plus forced-air warming device
62122168|NCT03473340|EXPERIMENTAL|Pirfenidone Capsule|"Method of Administration: Oral (capsule)~Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily"
62122169|NCT03473340|PLACEBO_COMPARATOR|Placebo Capsule|"Method of Administration: Oral (capsule)~Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily"
62310987|NCT02256449||BVS patients|Use of bioresorbable coronary device, according to the indications of use, in daily clinical practice, in patients undergoing PCI in de novo coronary artery lesions.
62476639|NCT03625063|ACTIVE_COMPARATOR|Exercise training group|Inspiratory muscle, upper extremity aerobic exercise and progressive resistance trainings
62476640|NCT03625063|SHAM_COMPARATOR|Control training group|Upper extremity aerobic exercise and progressive resistance trainings
62681634|NCT04857034|EXPERIMENTAL|Active Treatment: Deucravacitinib Dose 2|
62681635|NCT04857034|PLACEBO_COMPARATOR|Placebo|
62681636|NCT06580743||Study group|breast cancer patients 1-12 months post surgery
62681637|NCT04879485|NO_INTERVENTION|Standard transfusion|Includes standard transfusion with a mixture of red blood cells and plasma
61922171|NCT05765656|EXPERIMENTAL|GP - pharmacist collaboration and pharmacist motivational interviewing|Once randomized, the patient will have three motivational interviews with their pharmacist. Each time, a report will be sent to the GP.
61922172|NCT05765656|NO_INTERVENTION|Usual Care|The patient is handled by his GP and the pharmacist as usual (medical encounter plus medication dispensation)
61922173|NCT01575288|PLACEBO_COMPARATOR|Maltose|
61922174|NCT01575288|EXPERIMENTAL|High-dose trehalose|
61922175|NCT03231982|EXPERIMENTAL|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
61922176|NCT03231982|ACTIVE_COMPARATOR|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
61922177|NCT02759978||Suspicion NVE|Patients with suspicion of native valve endocarditis, infective endocarditis and no intracardiac prosthetic material in situ
61922178|NCT02759978||Suspicion (PVE)|Patients with a suspicion of prosthetic valve endocarditis (PVE), infective endocarditis and one or more prosthetic valves in situ
62122170|NCT04236973|EXPERIMENTAL|clinical performance of the Truenat™ HCV assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the Common Technical Specifications 2009/886/EC (CTS) of the CE-IVDD and WHO TSS-10 (draft) for IVDs medical devices used for the qualitative and quantitative detection of Hepatitis C RNA.
62122171|NCT04236973|ACTIVE_COMPARATOR|comparison CE-IVD marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
62122172|NCT06676501|EXPERIMENTAL|ExAblate Treatment|Participants will undergo a thalamotomy contralateral to their previous treatment with MRgFUS
62122173|NCT00519389|EXPERIMENTAL|Low dose H5N1 VLP Vaccine|
62122174|NCT00519389|EXPERIMENTAL|Mid dose H5N1 VLP Vaccine|
62122175|NCT00519389|EXPERIMENTAL|High dose H5N1 VLP Vaccine|
62122176|NCT00519389|PLACEBO_COMPARATOR|Placebo|
62122177|NCT02748486|EXPERIMENTAL|Jumping To Conculsions|Metacognitive Training Jumping to conclusions module
62122178|NCT02748486|EXPERIMENTAL|Theory of Mind|Metacognitive Training To empathize... module
62122179|NCT02748486|SHAM_COMPARATOR|Control|group discussion of current events
62310988|NCT02275572|EXPERIMENTAL|Pharmacist Intervention|Primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient.
62310989|NCT02275572|NO_INTERVENTION|Control|Usual procedure.
62310990|NCT03946306|ACTIVE_COMPARATOR|Group 1|5,25% NaOCl with syringe needle irrigation alone
62495975|NCT05694234||AChEI group|patients who administered pyridostigmine-glycopyrrolate or neostigmine-glycopyrrolate
62681638|NCT04879485|ACTIVE_COMPARATOR|Plasma|Transfusion with plasma
62681639|NCT04879485|ACTIVE_COMPARATOR|Red Blood cells|Transfusion with red blood cells
62310991|NCT03946306|ACTIVE_COMPARATOR|Group 2|5,25% NaOCl with syringe needle irrigation, activated with sonic system EDDY (VDW, Munich, Germany)
62310992|NCT01251575|EXPERIMENTAL|Treatment (fludarabine, transplant, immunosuppression)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.~IMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150."
61922179|NCT02759978||Suspicion pacemaker/ICD related endocarditis|Patients with a suspicion of infective endocarditis and a pacemaker or implantable cardiac defibrillator (ICD) in situ
61922180|NCT01739400|EXPERIMENTAL|Macitentan|Macitentan 10 mg tablet, once daily.
62122180|NCT02496702|EXPERIMENTAL|Training|"The intervention is done in the form of groups of 4-5 participants per set of tiles, with 2-3 set of tiles at a time. As more set can be used it is possible to make groups of more people. The training will consist of 1.5-3 minutes of training (depending on the game) on tiles and the rest while the other 2-3 participants train (4-6 minutes of break). Then the participants will train for 1.5-3 minutes again until each participant have received a total of 13 minutes of training.~The intervention will be done 2 times a week for 12 weeks, each session lasting 1 hour and each participant receiving 13 minutes of training each time (see training plan)."
62122181|NCT02496702|NO_INTERVENTION|Control|No training.
62310993|NCT03705923|EXPERIMENTAL|Bariatric surgery|Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.
62310994|NCT03945331|EXPERIMENTAL|TESS|Transcutaneous Electrical Spinal Stimulation (TESS), used during all training sessions.
62310995|NCT03945331|EXPERIMENTAL|EES|TESS, used during the initial 6-month training period, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
62310996|NCT02383394||aborted women|women who got pregnant and have 2nd trimesteric abortion, follow up antenatal care by ultrasound and clinical monitoring
62681640|NCT06038487|EXPERIMENTAL|Test - IL ( Immediate Loading)|The maxillary denture will be immediately connected to the implants on the day of the surgery
61922181|NCT05967897|EXPERIMENTAL|Blueberries|Freeze-dried blueberry powder
61922182|NCT05967897|ACTIVE_COMPARATOR|Blueberries and Whey Protein|Freeze-dried blueberry powder and whey protein
61922183|NCT05967897|ACTIVE_COMPARATOR|Blueberries and Pea Protein|Freeze-dried blueberry powder and pea protein
62122182|NCT04970342|EXPERIMENTAL|"Sober or Double Placebo"|Subject receives alprazolam capsule containing placebo (lactose). Subject receives placebo cannabis (0% THC / 0% CBD).
62122183|NCT04970342|EXPERIMENTAL|Active Alprazolam (Xanax), Placebo Cannabis|Subject receives active 0.75 mg alprazolam capsule. Subject receives placebo cannabis (0% THC / 0% CBD).
61922184|NCT05967897|ACTIVE_COMPARATOR|Blueberries and Hemp Protein|Freeze-dried blueberry powder and hemp protein
61922185|NCT01725412|EXPERIMENTAL|Thiamine Supplementation|
61922186|NCT01725412|PLACEBO_COMPARATOR|Placebo|
61922187|NCT04539587||adjuvant hormonal therapy for breast cancer|Women more than 18 years old, with hormone receptor-positive early BC, with completed surgery as well as chemotherapy and/or radiotherapy, if indicated, and had begun their hormonal therapy for less than 6 months.
61922188|NCT06287567|EXPERIMENTAL|Lusutrombopag|Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and titrated to a maximum dose of 6 mg during week 5 and week12 based on the platelet count (PLT)
61922189|NCT01624870||CoreValve aortic valve|Implantation of CoreValve aortic valve
61922190|NCT03612856|EXPERIMENTAL|AB023 (xisomab 3G3)- Dose 1|Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
61922191|NCT03612856|EXPERIMENTAL|AB023 (xisomab 3G3)- Dose 2|Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
61922192|NCT03612856|PLACEBO_COMPARATOR|placebo|Participants will receive a single dose of placebo.
61922193|NCT05263947|EXPERIMENTAL|Arm A|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Icotinib 250 mg tablets shall be administered orally 3 times every day at least one hour before or two hours after the ingestion of food.
61922194|NCT05742347|EXPERIMENTAL|DriGo SPT|All participants will have the DriGo skin protectant textile applied to their skin fold condition.
61922195|NCT01706679|ACTIVE_COMPARATOR|Maximum therapeutic dose of ATX-101|ATX-101 10 mg/ml
61922196|NCT01706679|ACTIVE_COMPARATOR|Supratherapeutic dose of ATX-101|ATX-101 20 mg/ml
61922197|NCT01706679|ACTIVE_COMPARATOR|Moxifloxacin|moxifloxacin (400mg)
61922198|NCT01706679|PLACEBO_COMPARATOR|Placebo vehicle|placebo vehicle (PBS)
61922199|NCT04895540||Diagnosed ACM patients|
61922200|NCT04895540||First degree relatives of ACM patients|
61922201|NCT04895540||Relatives of ACM patients who have suffered an SCD|
61922202|NCT05436366|EXPERIMENTAL|Soleus Loading Response Experimental|Participants in this one arm will be administered the soleus loading response protocol by applying an ankle joint rotation during treadmill walking
62122184|NCT04970342|EXPERIMENTAL|Placebo Alprazolam (Xanax), Active Cannabis|Subject receives alprazolam capsule containing placebo (lactose). Subject receives active cannabis (6.18% THC / \<0.025% CBD).
62122185|NCT01803139|ACTIVE_COMPARATOR|Standard breast radiotherapy|The treatment is planned using 2D wedges optimisation on the central CT-planning slice.
62495976|NCT01425840|EXPERIMENTAL|Liposomal lidocaine, topical anesthesia|Efficacy of Liposomal lidocaine in topical anesthesia.
61922203|NCT05982431|EXPERIMENTAL|exercise group|60-minutes exercise program, three times a week on alternate days for 12 successive weeks.
61922204|NCT05982431|EXPERIMENTAL|placebo kinesiology taping plus exercise group|Kinesiology taping was used, however the strain was zero. Before each exercise session, the tape was changed every two days while the patients were present.
61922205|NCT05982431|EXPERIMENTAL|kinesiology taping plus exercise group|putting no stress on the opposite end and a 50% stretch from the top of the big toe to the heel along the back of the heel. After applying a 50% stretch from the top of the big toe to the second horizontal little strip between the big toe and second toe, place the ends below the toe diagonally with no stress.
61922206|NCT03487679|EXPERIMENTAL|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water only fasting and final day of habitual eating of the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
61922207|NCT05908318|NO_INTERVENTION|Control group|The control group conducts standard preoperative preparation
61922208|NCT05908318|EXPERIMENTAL|olfactory training group|The olfactory training group was performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
61922209|NCT05715879||diseased|covid infection patients
61922210|NCT04308473|EXPERIMENTAL|Arm 1: Ultra-processed Meal + Antibiotics to supress gut flora|Subjects in Arm 1 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of ultra-processed foods.
61922211|NCT04308473|EXPERIMENTAL|Arm 2: Ultra-processed Meal + No Antibiotics|Subjects in Arm 2 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of ultra-processed foods.
62122186|NCT01803139|EXPERIMENTAL|Breast IMRT|The treatment is planned 3D IMRT optimisation using all CT-planning slices.
62122187|NCT05124847|EXPERIMENTAL|TRE-Control|
62122188|NCT05124847|EXPERIMENTAL|Control-TRE|
62122189|NCT01135511|EXPERIMENTAL|Treatment 1|
62122190|NCT01135511|EXPERIMENTAL|Treatment 2|
62122191|NCT01135511|EXPERIMENTAL|Treatment 3|
62495977|NCT00818298|EXPERIMENTAL|1|ziprasidone
62495978|NCT01532908|EXPERIMENTAL|Part 1: MBL-HCV1 and Telaprevir|
62495979|NCT01532908|EXPERIMENTAL|Part 2: MBL-HCV1 and Sofosbuvir|
62122192|NCT01135511|PLACEBO_COMPARATOR|Treatment 4|
62122193|NCT01135511|ACTIVE_COMPARATOR|Treatment 5|
62122194|NCT04528264|EXPERIMENTAL|Ultrasound guided|Intraoperative high frequency ultrasound used to guide the reduction of depressed zygomatic arch.
62122195|NCT04528264|OTHER|Conventional blind reduction technique|Conventional blind reduction of zygomatic arch fracture will be conducted without any intraoperative imaging.
62310997|NCT02383394||continued women|women who got pregnant and completed her pregnancy follow up antenatal care by ultrasound and clinical monitoring
62122196|NCT03204968|NO_INTERVENTION|control|
62122197|NCT03204968|ACTIVE_COMPARATOR|Treated|
62122198|NCT00939419|OTHER|Health worker TB care group|
62122199|NCT00939419|OTHER|Community health worker TB care group|
62122200|NCT00939419|OTHER|Self-administered treatment group|
62122201|NCT03806348|EXPERIMENTAL|Resuturing|Early resuturing of perineal wound dehiscence. Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
62122202|NCT03806348|NO_INTERVENTION|Conservative treatment|Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
62122203|NCT05984836|EXPERIMENTAL|health education class|Those mothers receive Early Childhood Home-Related Injuries education regarding First Aid in Matrouh
62310998|NCT03033108|EXPERIMENTAL|Emixustat Dose 1|lowest dose of once-daily oral emixustat
62310999|NCT03033108|EXPERIMENTAL|Emixustat Dose 2|middle dose of once-daily oral emixustat
62311000|NCT03033108|EXPERIMENTAL|Emixustat Dose 3|highest dose of once-daily oral emixustat
62311001|NCT01056107|EXPERIMENTAL|ROSE-010 30 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
62311002|NCT01056107|EXPERIMENTAL|ROSE-010 100 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
62122204|NCT05984836|NO_INTERVENTION|Control group|Those mothers not receive Early Childhood Home-Related Injuries education regarding First Aid in Matrouh
62122205|NCT03753841|ACTIVE_COMPARATOR|Adjustment of oral diet|Patients who need a change in their diet regime, in whom FEES shows that they have not the adequat diet.
62122206|NCT03753841|NO_INTERVENTION|No adjustment of oral diet|Patients who have the adequat diet based on FEES findings.
62122207|NCT02492048|ACTIVE_COMPARATOR|Split Thickness Skin Graft Harvest|Retrospective review
62122208|NCT02492048|EXPERIMENTAL|Cellutome Epidermal Harvesting System|Prospective patients will receive a skin graft utilizing the Cellutome Epidermal Harvesting System
62495980|NCT03568604|EXPERIMENTAL|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
62495981|NCT01326351|EXPERIMENTAL|Regenerative Injection Therapy|
62495982|NCT01326351|SHAM_COMPARATOR|Dry needle|
62495983|NCT01326351|ACTIVE_COMPARATOR|Exercise|
62495984|NCT06160180|ACTIVE_COMPARATOR|Drug arm preoperative|Injection 2ml of 4mg dexamethasone loaded and deposited submucosally in the buccal vestibule of the extraction site after local anesthesia but before placement of the first incision.
62495985|NCT06160180|ACTIVE_COMPARATOR|Drug arm postoperative|Injection 2ml of 4mg dexamethasone loaded and deposited submucosallyin the buccal vestibule of the extraction site after finishing extraction and placement of last suture.
62495986|NCT02520193|NO_INTERVENTION|Standard mobilization strategy|
62495987|NCT02520193|EXPERIMENTAL|protocolized early mobilization strategy|
62495988|NCT01430286|EXPERIMENTAL|Psycho-educational program|This group is trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
62495989|NCT01430286|ACTIVE_COMPARATOR|Standard treatment|This group will receive treatment as usual : consultation in memory clinic every 6 months during the AD patient's consultation.
62495990|NCT03013036|OTHER|Group I|Patients between 1 and 2 years
62495991|NCT03013036|OTHER|Group II|patients between 3 and 5 years
62495992|NCT03013036|OTHER|Group III|patients between 6 and 8 years
62495993|NCT03367780||RT with curative intent for HNSCC|several schemes for radical (chemo)radiotherapy, administered in 30-35 fractions over 6-7 weeks
62681641|NCT06038487|ACTIVE_COMPARATOR|Control - DL ( Delayed Loading)|At the time of surgery, the cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as the test group.
62681642|NCT06687252||All fetuses referred to the HFME and Croix Rousse CPDPNs for antenatal diagnostic consultation (DAN)|Non-interventional retrospective study, only on datas for suspected isolated variation in genital development (VDG)
62681643|NCT04991454|OTHER|end-stage pulmonary hypertension .|subjects with end-stage PH that currently on the waitlist for lung transplant
62681644|NCT04991454|OTHER|following pulmonary arterial hypertension subjects|Following pulmonary arterial hypertension subjects upto 24 months
62681645|NCT01242215|EXPERIMENTAL|ASP group|ASP1941 and sulfonylurea
62681646|NCT01242215|PLACEBO_COMPARATOR|Placebo group|placebo and sulfonylurea
61922212|NCT04308473|EXPERIMENTAL|Arm 3: Whole Food Meal + Antibiotics to supress gut flora|Subjects in Arm 3 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of whole, unprocessed foods.
61922213|NCT04308473|EXPERIMENTAL|Arm 4: Whole Food Meal + No Antibiotics|Subjects in Arm 4 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of whole, unprocessed foods.
61922214|NCT00586326|EXPERIMENTAL|Women with DCIS|Women with DCIS
61922215|NCT04173364|EXPERIMENTAL|Experimental group : ropivacaine 0.1%|Interscalene block for arthroscopic shoulder surgery with small volume of low concentration (0.1%) of ropivacaine
61922216|NCT04173364|ACTIVE_COMPARATOR|control group : ropivacaine 0.5%|Interscalene block for arthroscopic shoulder surgery with small volume of standard concentration (0.5%) of ropivacaine
61922217|NCT05034445||Sputum group|Sputum samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (sputum 1000X)
61922218|NCT05034445||Tissue group|Clinical data review to obtain corresponding tissue samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (tissue 1000X)
62681647|NCT03690999|PLACEBO_COMPARATOR|Placebo group|Placebo product
62681648|NCT03690999|EXPERIMENTAL|Prebiotic Supplement, low dose|
62681649|NCT03690999|EXPERIMENTAL|Prebiotic Supplement, high dose|
62681650|NCT06657976|EXPERIMENTAL|Supervised Treadmill Exercise|This group will be participating in supervised treadmill exercise for 12 weeks. Participants will walk for exercise on a treadmill 3 times per week at a center while supervised by healthcare personnel.
62681651|NCT06657976|SHAM_COMPARATOR|Attention Control Group|This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.
62681652|NCT06657976|EXPERIMENTAL|Exercise Supplementation with Nitrate-Rich Beetroot Juice|"This group for non-responders will receive supervised exercise supplementation with nitrate-rich beetroot juice for an additional 12 weeks."
62681653|NCT06657976|PLACEBO_COMPARATOR|Exercise Supplementation with Placebo Beetroot Juice|"This group for non-responders will received supervised exercise supplementation with placebo beetroot juice for the additional 12 weeks."
62681654|NCT05993234||Trastuzumab deruxtecan (T-DXd)|Participants with HER2-positive gastric or gastroesophageal junction adenocarcinoma who will be treated with trastuzumab deruxtecan and part of the enrolled participants will receive conventional therapy. The participants on conventional therapy will be analyzed for exploratory purposes only.
62681655|NCT06689852|EXPERIMENTAL|Enriched|To be used twice daily during 9 month
62681656|NCT06689852|EXPERIMENTAL|Loceryl|To be used 1 per week during 9 months
62122209|NCT06674538|EXPERIMENTAL|Treatment group|Treatment with multiple patient-specific mutated cell surface proteins with chimeric antibodies
62122210|NCT05712941|EXPERIMENTAL|Letrozole 2.5mg by mouth once a day (QD) + Lerociclib 150mg by mouth twice a day (BID)|
62681657|NCT03213704|EXPERIMENTAL|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO or via NG- or G-tube BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, an x-ray, bone scan, and/or MIBG scintigraphy during screening and on study. Patients also undergo bone marrow aspiration and/or biopsy during screening and may undergo blood sample collection on study.
62681658|NCT05174312|EXPERIMENTAL|Reprieve Decongestion Management System|Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
62681659|NCT05174312|ACTIVE_COMPARATOR|Optimal Diuretic Therapy|Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC) for patients randomized to control arm of the trial.
62681660|NCT02549820|EXPERIMENTAL|FETO in CDH|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
62681661|NCT06312670|EXPERIMENTAL|EPI-7386 + Enzalutamide|EPI-7386 at 600 mg twice daily orally with standard of care Enzalutamide at 160 mg, once daily, orally for 36 months of treatment (11 cycles).
62681662|NCT05883137||Tight facemask or NIV|Preoxygenation with tight fitting facemask or NIV (non-invasive ventilation) according to the paitents need before anaesthesia induction.
62681663|NCT05883137||High Flow Nasal Oxygen and Tight facemask/ NIV|Pre and peri-oxygenation with HFNO using Optiflow Switch in addition to tight fitting facemask or NIV (non-invasive ventilation).
62681664|NCT02864914||Empagliflozin|"All eligible patients type 2 diabetes mellitus initiating Empagliflozin treatment within the study period, from existing data of routine medical care in the Clinical Practice Research Datalink (CPRD) in the United Kingdom (UK), HealthCore Integrated Research Database (HIRD) in the United States (US), and Danish Population Registries (Danish Registries) in Denmark.~The study period started on 01 August 2014, the date of empagliflozin launch in the UK, US, and Denmark. The study end date was 01 August 2019 in CPRD and Danish Registries and 31 July 2019 in HIRD."
62681665|NCT02864914||DPP-4 inhibitors|"All eligible patients with type 2 diabetes mellitus initiating Dipeptidyl peptidase-4 (DPP-4) inhibitors treatment within the study period, existing data of routine medical care in the Clinical Practice Research Datalink (CPRD) in the United Kingdom (UK), HealthCore Integrated Research Database (HIRD) in the United States (US), and Danish Population Registries (Danish Registries) in Denmark.~The study period started on 01 August 2014, the date of empagliflozin launch in the UK, US, and Denmark. The study end date was 01 August 2019 in CPRD and Danish Registries and 31 July 2019 in HIRD."
62681666|NCT03750513|EXPERIMENTAL|Treatment (LET optimized IMPT)|Patients receive LET optimized IMPT for up to 6 weeks.
62681667|NCT03505424|ACTIVE_COMPARATOR|Group 1: Standard of Care|Parents of infants born from April -mid-August 2018 (Group 1)
62681668|NCT03505424|ACTIVE_COMPARATOR|Group 2: NICU2HOME app|Parents of infants born from mid-August 2018- January 2019 (Group 2)
62681669|NCT03505424|ACTIVE_COMPARATOR|Group 3: SMART NICU2HOME app|Parents of infants born from February- June 2019 (Group 3)
62681670|NCT06686823|ACTIVE_COMPARATOR|Health Education Program|Instructions and recommendations will be provided in an informative leaflet to promote an active and healthy lifestyle, encouraging self-care and good practices. This leaflet will include the new WHO guidelines, which recommend specific measures to reduce the risk of cognitive decline. These measures are: Eating healthy foods, engaging in physical activity, maintaining social connections, playing challenging cognitive games, getting good sleep, managing stress, staying hydrated, and avoiding smoking and excessive alcohol consumption.
62681671|NCT06686823|EXPERIMENTAL|Cognitive Training Program|"The cognitive training program (CT) focused on everyday cognition (EC) will be conducted individually. Each participant will receive a dossier specifically designed for the study.~The intervention will consist of four training periods over a duration of 4 months (Period 1, P1; Period 2, P2; Period 3, P3; Period 4, P4), with 20 activities each. Each period will last one month (5 activities per week)."
62681672|NCT03484195|EXPERIMENTAL|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
62681673|NCT06679530|EXPERIMENTAL|Music Intervention|
62681674|NCT06679530|NO_INTERVENTION|Control|
62681675|NCT04081012|EXPERIMENTAL|N-acetyl Cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before endarterectomy or balloon angioplasty.
62122211|NCT05712941|PLACEBO_COMPARATOR|Letrozole 2.5mg by mouth once a day (QD) + Placebo|
62122212|NCT06100458||Protocol arm|The skin and leakage protocol was used over a 5 day baseline period. The follow up was done 25 days later by another 5 day period of protocol use to observe any changes in continence care.
62122213|NCT02147535|EXPERIMENTAL|Methylphenidate|
62122214|NCT04749017|EXPERIMENTAL|Experimental group|Avena Sativa L. consumption of 900 mg for 60 days.
62311003|NCT01056107|EXPERIMENTAL|ROSE-010 300 mcg|A glucagon-like peptide-1 (GLP-1) analogue. A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
62311004|NCT01056107|PLACEBO_COMPARATOR|Placebo|Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
62311005|NCT01601015|EXPERIMENTAL|Manual therapy|Manual therapy of Suboccipital soft tissue Inhibition treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
62311006|NCT01601015|EXPERIMENTAL|Occiput-atlas-axis joint manipulation|Is bilaterally administered. The aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction
62311007|NCT01601015|EXPERIMENTAL|Combined treatment|The group receiving combined treatment received the two previous techniques exactly with the same sequence.
62681676|NCT04081012|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals. All study medications will be prepared by the Pharmacology department, which is not involved in patient care; the name of the medication and dose of the original ampule will be erased and also an identification label will be placed with the name, registration number, bed number, date and will be indifferent for groups with the same type of ampoule, with the same type of labeling
62311008|NCT01601015|PLACEBO_COMPARATOR|Control group|Control group not receive treatment and stayed in this position for 10 minutes
62311009|NCT00881920|EXPERIMENTAL|Kappa CD28 T cells for B-CLL|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
62311010|NCT00881920|EXPERIMENTAL|Kappa CD28 T cells for B-cell lymphoma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
62311011|NCT00881920|EXPERIMENTAL|Kappa CD28 T cells for myeloma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
62311012|NCT01430728||Very low birthweight infants|
62311013|NCT02786459|EXPERIMENTAL|Post Radical Prostatectomy|"Up to n=30 evaluable male patients, between ages 30-75, who were previously diagnosed with PCa, have undergone a RP at least 6 months before imaging and who experience rising PSA (biochemical failure). The RP group (n=30) will be stratified into PSA subgroups \<0.005, 0.005-\<0.2, \>0.2.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI."
62681677|NCT01270555|EXPERIMENTAL|Bupropion|
62681678|NCT01603251|ACTIVE_COMPARATOR|Artemether-Lumefantrine|
62681679|NCT01603251|EXPERIMENTAL|Artemether-Lumefantrine + single dose Ivermectin|
62681680|NCT01603251|EXPERIMENTAL|Artemether-Lumefantrine + repeated dose Ivermectin|
62681681|NCT06691048||Adults with late diagnosis neurodevelopmental disorder|Adults with late access to diagnosis of neurodevelopmental disorder
62681682|NCT05157789|EXPERIMENTAL|Sms group|Relatives of patients who were sent SMS
62681683|NCT05157789|NO_INTERVENTION|Control Group|Relatives of patients who were no intervation
62681684|NCT05576207|ACTIVE_COMPARATOR|Arm 1|Multiple Micronutrient Supplement for Pregnant women (UNIMMAP formulation) containing 15 nutrients all at a recommended daily allowance (RDA) for pregnancy to be consumed one-per-day during pregnancy
61922219|NCT05034445||Plasma group|Clinical data review to obtain corresponding plasma samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (plasma 10000X)
62681685|NCT05576207|EXPERIMENTAL|Arm 2|Balanced energy and protein (BEP) food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the World Health Organization (WHO) for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm all pregnant women will receive this intervention
61922220|NCT05196178|EXPERIMENTAL|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
61922221|NCT04564885|EXPERIMENTAL|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis at 2 contiguous levels
62122215|NCT04749017|PLACEBO_COMPARATOR|Control group|Identically appearing placebo capsules consumed for 60 days.
62681686|NCT05576207|EXPERIMENTAL|Arm 3|Balanced energy and protein food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the WHO for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm, only low pre-pregnancy BMI women (\<18.5) will receive the BEP, the rest will receive the MMS.
61922222|NCT04564885|ACTIVE_COMPARATOR|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc at 2 contiguous levels
61922223|NCT00390234|EXPERIMENTAL|Treatment (ziv-aflibercept)|Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
61922224|NCT01507454||Local treatment|
61922225|NCT03490162|EXPERIMENTAL|Food Effect|300 mg of DM1157 (2 capsules of 150 mg) orally with high fat diet, n=6, and matching placebo (2 capsules) orally with high fat diet, n=2
62122216|NCT02244060|EXPERIMENTAL|Direct comparison|The Direct comparison against vignette (DCV) questionnaire asks subjects to estimate their own vision against vignette situations.Priming effect from vignette is designed in the arm of DCV.
62122217|NCT02244060|NO_INTERVENTION|Indirect comparison|The Indirect comparison against vignette (ICV) questionnaire asks self-assessed vision and single evaluation of vignettes.
62311014|NCT02786459|ACTIVE_COMPARATOR|Active Surveillance|"Up to n=10 men, between ages 30-75, on active surveillance with known prostate adenocarcinoma diagnosis and multiple positive biopsies.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
62122218|NCT06499246|EXPERIMENTAL|Parathyroid Transplant|Patients with permanent refractory hypoparathyroidism after total thyroidectomy will be entered in this study to undergo parathyroid transplantation from a neurologically deceased donor. Inclusion criteria are patients who have had a prior total thyroidectomy with both biochemical hypoparathyroidism and symptomatic hypocalcemia (numbness, tingling, or other neurologic symptoms) requiring daily high dose calcium (greater than 2000 mg per day), vitamin D (greater than 2 mcg of calcitriol per day) supplementation and/or intermittent IV calcium infusion. Patients for inclusion must have failed this medical management after at least 1 year of treatment and meet standard criteria for receiving organ transplant.
62681687|NCT05576207|EXPERIMENTAL|Arm 4|Balanced energy and protein food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the WHO for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm, only low pre-pregnancy BMI women (\<18.5) and those who have inadequate gestational weight gain during pregnancy will receive the BEP, the rest will receive the MMS.
62681688|NCT02446600|ACTIVE_COMPARATOR|Arm I (platinum-based chemotherapy)|See detailed description.
62311015|NCT02786459|EXPERIMENTAL|Multiple Negative Biopsies|"Up to n=20 men, between ages 30-75, who have previously undergone one/or multiple negative biopsies, with elevated PSA (≥4 ng/mL) and/or an abnormal digital rectal exam suspicious for prostate cancer with a planned sextant prostate biopsy but who do not have a definitive PCa diagnosis.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
62311016|NCT04330625|EXPERIMENTAL|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for four weekly doses
62311017|NCT00974662|EXPERIMENTAL|WST11|Treatment with WST11-mediated VTP
62311018|NCT04311905|EXPERIMENTAL|Laser activated irrigation LAI|Diode Laser activated irrigation
62311019|NCT04311905|PLACEBO_COMPARATOR|conventional root canal treatment|mock LAI , conventional root canal treatment 2.5% sodium hypochlorite
62681689|NCT02446600|EXPERIMENTAL|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
62681690|NCT02446600|EXPERIMENTAL|Arm III (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
62681691|NCT03941860|EXPERIMENTAL|Arm A (lenalidomide, ixazomib citrate)|Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.
62681692|NCT03941860|PLACEBO_COMPARATOR|Arm B (lenalidomide, placebo)|Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.
62681693|NCT01435746|EXPERIMENTAL|Liberal Transfusion|Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
62681694|NCT01435746|ACTIVE_COMPARATOR|Conservative Transfusion|Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
62681695|NCT01824966||SRC<50%|Adenocarcinoma containing \< 50% of signet ring cells
62681696|NCT01824966||SRC>50%|Adenocarcinoma containing \> 50% of signet ring cells
62311020|NCT02672839|EXPERIMENTAL|Period 1 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
62311021|NCT02672839|EXPERIMENTAL|Period 1 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
62681697|NCT03468465|EXPERIMENTAL|Medical device: Transcutaneous electrical neurostimulation|Medical device 4 weeks with daily sessions of 30 minutes
62681698|NCT03468465|ACTIVE_COMPARATOR|Solifenacin|10 mg tablet daily during 75 days maximum
62681699|NCT05490875||Carotid Ultrasound Group|Head and neck cancer survivors treated with radiotherapy, at least 2 years since end of radiotherapy with no evidence of disease will receive a carotid ultrasound to measure carotid velocities and intima-media thickness of the carotid arteries.
61922226|NCT03490162|EXPERIMENTAL|MAD 1|150 mg of DM1157 (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=2
62311022|NCT02672839|EXPERIMENTAL|Period 2 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
62311023|NCT02672839|EXPERIMENTAL|Period 2 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
62311024|NCT03020186|PLACEBO_COMPARATOR|Physical activity|Physical activity (PA) group will receive free gym memberships and the instruction necessary to engage in moderate-intensity physical activity, \~80% of which will have an aerobic component. The participants will get basic health promoting guideline for healthy diet .
61922227|NCT03490162|EXPERIMENTAL|MAD 2|300 mg of DM1157 (2 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (2 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
61922228|NCT03490162|EXPERIMENTAL|MAD 3|600 mg of DM1157 (4 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (4 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
62681700|NCT06694753|EXPERIMENTAL|Cohort 1A Group 1: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2|Participants will receive one injection of 10 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 10 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8.
62311025|NCT03020186|EXPERIMENTAL|Physical activity+ MED diet|On top of the PA intervention described in Arm 1, the participants will be guided for moderate weight loss with a traditional Mediterranean (MED) diet, low in simple carbohydrates. The diet will include 1oz/day of walnuts that will be provided free of charge.
62311026|NCT03020186|EXPERIMENTAL|Physical activity+ green-MED diet|"On top of the PA intervention described in Arm 1, the participants will guided for moderate weight loss with a MED diet, low in simple carbohydrates that will be rich in plants and polyphenols and low in processed meat. The diet will include 1oz/day of walnuts, 3-4 cups/day of green tea and \~500cc green shake/dinner based on specific strain of duckweed \[Wolffia globose, Mankai\], an aquatic plant, which might serve as a plant protein source. All the above will be provided free of charge."
62681701|NCT06694753|PLACEBO_COMPARATOR|Cohort 1A Group 2: Placebo|Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Weeks 0 and 8.
62681702|NCT06694753|EXPERIMENTAL|Cohort 2A Group 3: mRNA-1645-N332GT5|Participants will receive 10 mcg of mRNA-1645-N332GT5 to be administered as a 0.5 mL IM injection into the deltoid at Weeks 0 and 8.
62681703|NCT06694753|PLACEBO_COMPARATOR|Cohort 2A Group 4: Placebo|Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8.
61922229|NCT03490162|EXPERIMENTAL|MAD 4|900 mg of DM1157 (6 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (6 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
61922230|NCT03490162|EXPERIMENTAL|SAD 1|9 mg of DM1157 (1 capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
61922231|NCT03490162|EXPERIMENTAL|SAD 2|27 mg of DM1157 (3 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (3 capsules) orally with 240 ml of water after an overnight fast, n=2
61922232|NCT03490162|EXPERIMENTAL|SAD 3|81 mg of DM1157 (9 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (9 capsule) orally with 240 ml of water after an overnight fast, n=2
62122219|NCT04520659|EXPERIMENTAL|Group 1: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
62122220|NCT04520659|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
62311027|NCT02614794|EXPERIMENTAL|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib + capecitabine + trastuzumab
61922233|NCT03490162|EXPERIMENTAL|SAD 4|150 mg of DM1157 (1capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
61922234|NCT03490162|EXPERIMENTAL|SAD 5|300 mg of DM1157 (2 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (2 capsules) orally with 240 ml of water after an overnight fast, n=2
61922235|NCT03490162|EXPERIMENTAL|SAD 6|600 mg of DM1157 (4 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (4 capsules) orally with 240 ml of water after an overnight fast, n=2
61922236|NCT03490162|EXPERIMENTAL|SAD 7|900 mg of DM1157 (6 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (6 capsules) orally with 240 ml of water after an overnight fast (n=2)
62122221|NCT04520659|EXPERIMENTAL|Group 2: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
62122222|NCT04520659|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
62122223|NCT05317910|EXPERIMENTAL|Music intervention|Music intervention (duration 20 minutes) every day for 30 days
62122224|NCT04782817|EXPERIMENTAL|High Flow Nasal Canula Oxygen Therapy|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
62311028|NCT02614794|ACTIVE_COMPARATOR|Placebo in combination with capecitabine & trastuzumab|Placebo + capecitabine + trastuzumab
62311029|NCT03488992|EXPERIMENTAL|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
62681704|NCT06694753|EXPERIMENTAL|Cohort 1B Group 5: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2|Participants will receive one injection of 30 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 30 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8.
62681705|NCT06694753|PLACEBO_COMPARATOR|Cohort 1B Group 6: Placebo|Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8.
62681706|NCT06694753|EXPERIMENTAL|Cohort 2B Group 7: mRNA-1645-N332GT5|Participants will receive 30 mcg of mRNA-1645-N332GT5 to be administered as a 0.5 mL IM injection into the deltoid at Weeks 0 and 8.
62311030|NCT03488992|PLACEBO_COMPARATOR|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
62311031|NCT01370954||CerefolinNAC®|Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
62311032|NCT04975048|EXPERIMENTAL|Group A|Group A was consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. And it was first assigned egg yolk intervention during intervention period 1, and then macronutrient equivalent control during intervention period 2
62311033|NCT04975048|OTHER|Group B|Group B was also consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. It was first assigned macronutrient equivalent control during intervention period 1, and then egg yolk during intervention period 2
62311034|NCT04250805|ACTIVE_COMPARATOR|Lidocaine|Patients will receive Lidocaine alone during percutaneous gastrostomy under radiological guidance
62311035|NCT04250805|EXPERIMENTAL|Lidocaine and Ropivacaine|Patients will receive Lidocaine and Ropivacaine during percutaneous gastrostomy under radiological guidance
62311036|NCT06522854|ACTIVE_COMPARATOR|Oral Sildenafil 50mg|Sildenafil citrate 50mg given orally every eight hours up to 3 doses while mother is in labor
62311037|NCT06522854|PLACEBO_COMPARATOR|Placebo|Identical-appearing treatment that does not contain the test drug given orally every eight hours up to 3 doses while mother is in labor
62311038|NCT04685330||Adult patients undergoing an ultrasound-guided procedure|Adult patients undergoing an ultrasound-guided procedure, such as paracentesis, thoracentesis, or biopsy
62311039|NCT05322460|EXPERIMENTAL|Intervention group|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
62311040|NCT05322460|NO_INTERVENTION|Control group|Usual care in the nursing consultation in primary care
62495994|NCT00365053|EXPERIMENTAL|Treatment (belinostat)|Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62495995|NCT06471725|EXPERIMENTAL|Experimental|will receive a combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound.
62495996|NCT06471725|ACTIVE_COMPARATOR|Control|will be given Low-level laser therapy and low-intensity ultrasound
62495997|NCT03837158|EXPERIMENTAL|Control-group|Two Tissue Level TiZr Sand blasted long grit acid-etched (SLA) implants placed in positions 33 and 43 (diameter 3.3mm, length ≥10mm), early loading
62495998|NCT03837158|EXPERIMENTAL|Experimental-group|Four narrow-diameter implants (NDI) TiZr SLA implants in positions 34, 32, 42, and 44 (diameter 2.4mm, length ≥10mm), immediate loading
62495999|NCT01269645|ACTIVE_COMPARATOR|Usual care|"Usual care and provision of National Cancer Institute brochure Taking Part in Cancer Treatment Research Studies. Participants will be asked to read this brochure after completion of the baseline surveys and will be given a copy to take home with them."
62496000|NCT01269645|EXPERIMENTAL|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
62496001|NCT04386213|EXPERIMENTAL|Paclitaxel Drug-coated Balloon|
62496002|NCT04386213|ACTIVE_COMPARATOR|SeQuent® Please Paclitaxel Drug-coated Balloon|
62496003|NCT01108354||ADHD patients|10 male adult ADHD patients and 10 female adult ADHD patients
62496004|NCT01108354||healthy controls|20 age- and sex-matched healthy volunteers
62496005|NCT02811341|PLACEBO_COMPARATOR|A group|Using normal saline before pcle examination
62496006|NCT02811341|EXPERIMENTAL|B group|Using Scopolamine Hydrobromide before pcle examination
62496007|NCT04543084|OTHER|Single-Subject Design|Each participant will go through a baseline phase and then an intervention phase.
62681707|NCT06694753|PLACEBO_COMPARATOR|Cohort 2B Group 8: Placebo|Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8.
62681708|NCT06079398|EXPERIMENTAL|Navepegritide|Once weekly double-blinded treatment with SC injection of 100 µg/kg of Navepegritide for 52 weeks
62681709|NCT06079398|PLACEBO_COMPARATOR|Placebo for Navepegritide|Once weekly double-blinded treatment with SC injection of 100 µg/kg of Placebo for Navepegritide for 52 weeks
62681710|NCT06679062|ACTIVE_COMPARATOR|10mg and 20mg Suvorexant (SUV)|Participants will be randomly assigned to receive SUV (10mg (Days 0-6) and 20mg (Days 7-13)).
62681711|NCT06679062|PLACEBO_COMPARATOR|Placebo|Participants will be randomly assigned to receive matched placebo (Days 0-13).
62476641|NCT06033456|EXPERIMENTAL|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of the C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex.~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning ."
62681712|NCT03375164|EXPERIMENTAL|Cohort A: Delandistrogene Moxeparvovec|Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.
62681713|NCT03375164|EXPERIMENTAL|Cohort B: Delandistrogene Moxeparvovec|Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.
62681714|NCT06113614|EXPERIMENTAL|Photobiomodulation Group|The shoulder brace (Cosmedical, Mauá, SP, Brazil) contains 159 red LEDs and 159 infrared LEDs interspersed. The PBM group (standard physical therapy combined with active PBM). Participants will apply PBM at home daily for 10 minutes using a device containing 318 light-emitting diodes (LEDs), with 159 LEDs at 660 nm (28.5 mW; 12 J/cm2; 17 J per LED) and 159 LEDs at 850 nm (23 mW; 10 J/cm2; 14 J per LED). PBM and physical therapy sessions (30 minutes, twice a week) will be conducted over 12 weeks.
62681715|NCT06113614|SHAM_COMPARATOR|Control Group|In the control group (standard physical therapy combined with simulated PBM), participants will receive an identical device to the active one, but only the light from the activation plug and the sound will be triggered when they press the button, while the internal LEDs will remain off.
62681716|NCT06690749|EXPERIMENTAL|Negative pressure therapy dosage|A negative pressure value gap of 20mmHg was used between the each groups.
62681717|NCT06032715|ACTIVE_COMPARATOR|BI (Brief Intervention)|Patients whose GPs have been taught the behavioral BI intervention aiming to reduce prolonged use of Z-hypnotics.
62122225|NCT04782817|ACTIVE_COMPARATOR|Provider Choice Standard Care|Participants be assigned standard provider choice of standard care therapy physician order set.
62681718|NCT06032715|NO_INTERVENTION|BAU (Business as usual)|"Patients whose GPs have not yet been taught the BI intervention. Patients only assessed in parallel with BI group by masked assessors using same instruments as for active comparator.~This group also constitutes an open cross-over group to active intervention once the masked 6 months phase is completed."
62681719|NCT06694792||discover cohort|The discover cohort will consist in patients already collected
62681720|NCT06694792||Validation cohort|The validation cohort will include patients enrolled prospectively during the first year of the study
62681721|NCT06541964|EXPERIMENTAL|Parent-Provide Distraction Group|Parent-Provide Distraction Group
62681722|NCT06541964|EXPERIMENTAL|Windmill Toy Blowing Group|Windmill Toy Blowing Group
62681723|NCT06541964|OTHER|Control Group|Control Group
62681724|NCT06694688|OTHER|a single group of patients|"Subject will undergo the following 5 conditions in the cross-over scheme as determined by the randomization:~No compression, Class 2 compression socks, Class 3 compression socks, Class 2 compression tights and Dynabelt abdominal belt + Class 2 compression socks~."
62681725|NCT05530915|EXPERIMENTAL|Active capsule 1: Lower dose guayusa ingredient|Oral administration of 175 mg guayusa extract providing 35 mg caffeine
62681726|NCT05530915|EXPERIMENTAL|Active capsule 2: Higher dose guayusa ingredient|Oral administration of 300 mg guayusa extract providing 60 mg caffeine
62681727|NCT05530915|PLACEBO_COMPARATOR|Placebo capsule|Oral administration of 0 mg guayusa extract, 0 mg caffeine. Capsule color-matched to actives 1 and 2 to disguise potential differences in color of contents.
62681728|NCT06452277|EXPERIMENTAL|BAY2927088|Participants will receive BAY2927088 20 mg BID until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
62681729|NCT06452277|ACTIVE_COMPARATOR|Standard of care (SoC)|Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
62681730|NCT05261139|EXPERIMENTAL|Cohort 1 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir will be given by tablets or powder by mouth twice a day for 5 days (10 doses total).~Weight ≥40 kg~1. ≥12 to \<18 years~2. ≥6 to \<12 years"
62681731|NCT05261139|EXPERIMENTAL|Cohort 2 nirmatrelvir/ritonavir|nirmatrelvir/ritonavir will be given as powder by mouth twice a day for 5 days (10 doses total) Weight ≥20 to \<40 kg, ≥6 to \<18 years
62681732|NCT05261139|EXPERIMENTAL|Cohort 3 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir~≥2 to \<6 years"
62681733|NCT05261139|EXPERIMENTAL|Cohort 4 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir~≥1 month (≥28 days) to \<2 years"
62681734|NCT05261139|EXPERIMENTAL|Cohort 5 nirmatrelvir/ritonavir|nirmatrelvir/ritonavir \<1 month (\<28 days) old
62311041|NCT04445077|EXPERIMENTAL|Intervention group|The education will be delivered weekly with 60-90 minutes per lecture for eight lectures. Multiple teaching methods will be used, including lectures, structured handouts, video, role play, case study and discussion. During the study period, the research team will provide ongoing support and consultation through electronic communication and bimonthly field visits.
62681735|NCT03735498|EXPERIMENTAL|Psychological Intervention|"* Qualitative interview will be conducted~* 7-item Generalized Anxiety Disorder measure will be completed by participants via mail correspondence or online~* A psychoeducational component to address preparedness, manage expectations, and develop caregiving skills~* A psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~* A self-care component to promote caregiver health and well-being"
62681736|NCT04901078|EXPERIMENTAL|Active|KNX100 which will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
62681737|NCT04901078|PLACEBO_COMPARATOR|Placebo|KNX100 matching placebo will be provided in capsule form for oral administration. The placebo will be encapsulated in HPMC dark green opaque size 0 capsules and packaged in 100 mL HDPE bottles with PP twist-off closures.
62681738|NCT06058455|EXPERIMENTAL|IDEA3 sexual assault resistance intervention|IDEA3 curriculum will be delivered by pairs of trained facilitators over Zoom to reach up to 8 pairs of female-identified university students in four, 3-hour units. The four units will be spread over two to four weeks' time.
62681739|NCT06058455|ACTIVE_COMPARATOR|Consent workshop|Randomized participants who do not receive the intervention will receive one 60-minute session consisting of an internet delivered (Zoom) consent workshop.
62681740|NCT02567032|EXPERIMENTAL|Oxytocin|40 IU Oxytocin
62681741|NCT02567032|PLACEBO_COMPARATOR|Saline Nasal Spray|Placebo Comparator
62476642|NCT06033456|EXPERIMENTAL|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
62681742|NCT01708941|EXPERIMENTAL|Arm A (higher dose ipilimumab, HDI)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
62681743|NCT01708941|EXPERIMENTAL|Arm B (higher dose ipilimumab)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
62681744|NCT01708941|EXPERIMENTAL|Arm C (lower dose ipilimumab + HDI)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
62681745|NCT01708941|EXPERIMENTAL|Arm D (lower dose ipilimumab)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
62681746|NCT00791687||PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (\<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
62476643|NCT06033456|EXPERIMENTAL|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
62476644|NCT02111694|EXPERIMENTAL|Clear versus Opaque Bottle|This is a within-subject study; all infants will be exposed to both conditions. Order of presentation will be counterbalanced across infants.
62476645|NCT05802485|OTHER|collection of blood and tumor samples|
62681747|NCT00791687||NON PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (\<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
62681748|NCT04274218|EXPERIMENTAL|Walking perturbation - Free|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with both arms free and individuals with amputation will walk with their prosthesis.
62681749|NCT04274218|EXPERIMENTAL|Walking perturbation - Limited|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with one arm bound to their side with straps and individuals with amputation will walk without their prosthesis.
62681750|NCT04505280|EXPERIMENTAL|Active|%1 lidocaine injections to greater occipital nerve and cervical region once a week for 4 weeks
62681751|NCT04841798|OTHER|Duloxetine|Assessment of MAO-B distribution volume in the prefrontal cortex before and after duloxetine at 60 mg daily.
62681752|NCT04841798|OTHER|Rasagiline|Assessment of regional MAO-B distribution volume before and after rasagiline at 1.0 mg daily.
62122226|NCT04034745||Standard of Care telotristat ethyl (Xermelo) Treatment|Treatment of telotristat ethyl (Xermelo) with DXA scans and bionutritional assessments (24-hour food recall and taste/smell alteration) conducted 3x during telotristat ethyl treatment.
62311042|NCT04445077|OTHER|Control group|Printed materials will be given to the participants in the control group for their self-study.
62311043|NCT01728259|EXPERIMENTAL|Treatment (pomalidomide, bortezomib, and dexamethasone)|Patients receive pomalidomide PO on days 1-21; bortezomib IV or SC on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62476646|NCT03890796|EXPERIMENTAL|Dementia Care Education and Activity Scheduling Group (DE&AS)|Will received both dementia care education and activity scheduling
62476647|NCT03890796|SHAM_COMPARATOR|Dementia Care Education Group (DE)|Will received dementia care education
62311044|NCT04958564|ACTIVE_COMPARATOR|group interlock|Intra medullary device used to treat tibial shaft fractures
62311045|NCT04958564|ACTIVE_COMPARATOR|group DCP (dynamic compression plate)|dynamic compression plate used to treat tibial shaft fractures
62311046|NCT04715750|EXPERIMENTAL|Tau deposition in the brains of Alzheimer Disease and Progressive Supranuclear Palsy patients|All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose)
62311047|NCT05657977|NO_INTERVENTION|Pretest|"Pretest: The newborn connected to nCPAP will be placed in the supine position and slight extension position on the neck of the newborn to ensure airway patency. The first saliva sample will be taken to measure cortisol level in the 30th minute after the first cry from the newborn who is connected to nasal CPAP. Immediately after the saliva sample is taken in pretest group, the stress level determined by using the neonatal stress scale, vital signs (respiration, heart rate, oxygen saturation), saliva sample collection time will be recorded on the chart."
62311048|NCT05657977|EXPERIMENTAL|Posttest, swaddling|"Posttest: The swaddling method will be applied to the newborn after the first saliva sample is taken. A second saliva sample will be taken 30 minutes after swaddling to measure cortisol level. Immediately after the saliva sample is taken in posttest group, the stress level determined by using the neonatal stress scale, vital signs, saliva sample collection time will be recorded on the chart."
61922237|NCT00521001|EXPERIMENTAL|everolimus + temozolomide|"Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.~After completion of study treatment, patients are followed every 8 weeks."
61922238|NCT02771587|EXPERIMENTAL|Alcohol and energy drink|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
61922239|NCT02771587|ACTIVE_COMPARATOR|Alcohol|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
62311049|NCT00003641|OTHER|Observation|Patients undergo observation for 4 weeks.
62311050|NCT00003641|EXPERIMENTAL|Interferon Alfa-2b|Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
62311051|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose A|Participants receive favezelimab Dose A intravenous (IV) infusion on Day 1 of each 21-day cycle.
62311052|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose B|Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle.
62476648|NCT01627158|EXPERIMENTAL|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
62476649|NCT01627158|ACTIVE_COMPARATOR|Symbicort Turbuhaler|Symbicort Turbuhaler
62681753|NCT04841798|OTHER|Tranylcypromine|Assessment of regional MAO-B distribution volume before and after tranylcypromine at 30 to 60 mg daily.
61922240|NCT02771587|ACTIVE_COMPARATOR|Energy drink|3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
61922241|NCT02771587|PLACEBO_COMPARATOR|Placebo|"3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.~Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration."
62311053|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose C|Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle.
62311054|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose D|Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle.
62311055|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose E|Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle.
62311056|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose A+Pembro|Participants receive favezelimab Dose A IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62311057|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose B+Pembro|Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62311058|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose C+Pembro|Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62311059|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose D+Pembro|Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62311060|NCT02720068|EXPERIMENTAL|Part A: Favezelimab Dose E+Pembro|Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62476650|NCT01627158|EXPERIMENTAL|Charcoal and Budesonide/formoterol Easyhaler|
62476651|NCT01627158|ACTIVE_COMPARATOR|Charcoal and Symbicort Turbuhaler|
62476652|NCT05433857|NO_INTERVENTION|Control group|20 patients will receive the standard therapy for 12 weeks
62476653|NCT05433857|EXPERIMENTAL|Interventional group|20 patients will receive the standard therapy in addition to two capsules once daily of probiotic Lacteol Forte® Capsules for 12 weeks
62476654|NCT05305248|EXPERIMENTAL|Remimazolam group|Sedation with remimazolam during spinal anesthesia
62476655|NCT05305248|ACTIVE_COMPARATOR|Dexmedetomidine group|Sedation with dexmedetomidine during spinal anesthesia
62476656|NCT05545826|EXPERIMENTAL|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
62476657|NCT00245063|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62476658|NCT02213263|EXPERIMENTAL|PF-05280586|
62681754|NCT03031730|EXPERIMENTAL|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 Inhibitor KRT-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of cycles 1-12 and on days 1-2 and 15-16 of cycles 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or dexamethasone sodium phosphate IV on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity. Patients undergo echocardiography during screening and bone marrow biopsy and aspiration, and blood sample collection throughout the study.
62681755|NCT01368185||All Participants|Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
62681756|NCT06263738|ACTIVE_COMPARATOR|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes.
62681757|NCT06263738|ACTIVE_COMPARATOR|Whole Body Hyperthermia + Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session lasting up to 10 minutes.
62681758|NCT06686758|EXPERIMENTAL|low-dose LC-Z300-01|Sugar cane polysaccharide LC-Z300-01: 0.5g at a time, 2 times a day at an empty stomach and at bedtime, Oral administration.
62122227|NCT02693730||Healthy Control|Does not have diagnosis of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) and is otherwise healthy and able to participate as defined by the exclusionary criteria.
62311061|NCT02720068|EXPERIMENTAL|Part B: Favezelimab Monotherapy Dose|Participants receive favezelimab monotherapy dose IV infusion on Day 1 of each 21-day cycle.
62122228|NCT02693730||Irritable Bowel Syndrome (IBS)|Diagnosed with IBS and meets the Rome III criteria, in the absence of red flag signs (i.e., unexplained weight loss, bloody stool, fever, anemia)
62122229|NCT02693730||Ulcerative Colitis (UC)|Clinically and histologically confirmed diagnosis of ulcerative colitis
62122230|NCT03948997|EXPERIMENTAL|Treatment group|Patients with port wine stains receive PDL (1.5-10ms, 11-12.5J/cm2) with a treatment range of approximately 10\*10cm2
62122231|NCT03948997|NO_INTERVENTION|No treatment group|Patients with port wine stains have not been treated with PDL treatment
62311062|NCT02720068|EXPERIMENTAL|Part B: Favezelimab Dose F+Pembro|Participants receive favezelimab Dose F IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62311063|NCT02720068|EXPERIMENTAL|Part B: Favezelimab Dose G+Pembro|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62311064|NCT02720068|EXPERIMENTAL|Part B: Favezelimab Dose H+Pembro|Participants receive favezelimab Dose H IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
62476659|NCT02213263|ACTIVE_COMPARATOR|MabThera®|
62476660|NCT05095181||Experimental group:|patients with liver cirrhosis
62476661|NCT05095181||Control group|patients without liver cirrhosis
62476662|NCT03630471|ACTIVE_COMPARATOR|Control|Enhanced usual care (problem-solving booklets only).
62476663|NCT03630471|EXPERIMENTAL|Intervention|PRIDE 'Step 1' problem-solving intervention.
62476664|NCT06385236|ACTIVE_COMPARATOR|Dupilumab|600 mg once subcutaneously (given as two 300 mg injections), followed by 300 mg subcutaneously every other week.
62476665|NCT06385236|ACTIVE_COMPARATOR|Benralizumab|30 mg subcutaneously every 4 weeks.
62476666|NCT03362710|EXPERIMENTAL|PAD patients|"Patients referred for an arterial doppler assessment of lower limbs will be included.~Intervention is a series of examination, followed by the measurement of the ABI and an arterial echo-doppler of the lower limbs +/- transcutaneous oxygen pressure measurements in case of suspected critical limb ischemia.~A technician will perform the evaluation with simplified tools blinded to the results of vascular specialised investigations"
62681759|NCT06686758|EXPERIMENTAL|high-dose LC-Z300-01|Sugar cane polysaccharide LC-Z300-01: 1.0g at a time, 2 times a day at an empty stomach and at bedtime, Oral administration.
62681760|NCT06686758|PLACEBO_COMPARATOR|control|Identical placebo: 2 tablets, 2 times a day at an empty stomach and at bedtime, Oral administration.
62122232|NCT03946046|EXPERIMENTAL|Clinical targeting|Clinical localization method (observation and palpation of target muscles)
62122233|NCT03946046|EXPERIMENTAL|Ultrasonography targeting|Ultrason-guided method
62122234|NCT06400745|EXPERIMENTAL|CPO Pro IOL|CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
62122235|NCT06400745|ACTIVE_COMPARATOR|CPO IOL|CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
62122236|NCT01402830||001|Visual analogue scales (EVAs) This scale measures the pain intensity.
62122237|NCT04191954|ACTIVE_COMPARATOR|Fasudil eye drops (concentration 0.5 percent)|twice daily
62122238|NCT04191954|PLACEBO_COMPARATOR|receive artificial tears drop with the same frequency|
62122239|NCT02074488|EXPERIMENTAL|Fall Prevention Exercises|Participant provided with Balancing Act exercise curriculum for completion at least fifteen minutes three times a week over a six month period.
62122240|NCT02074488|OTHER|Informational brochure|Participant receives an informational brochure and orientation to brochure contents.
62122241|NCT06475508|EXPERIMENTAL|"Complarate® (JSC GENERIUM, Russia)"|tocilizumab biosimilar
62122242|NCT06475508|ACTIVE_COMPARATOR|Actemra® (F. Hoffmann-La Roche Ltd., Switzerland)|tocilizumab
62311065|NCT02720068|EXPERIMENTAL|Part B: Favezelimab Dose G+Pembro+mFOLFOX7|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS mFOLFOX7 (oxaliplatin 85 mg/m\^2 IV, leucovorin \[calcium folinate\] 400 mg/m\^2 IV and fluorouracil \[5-FU\] 2400 mg/m\^2 IV over 46 to 48 hours every 2 weeks \[Q2W\]).
62311066|NCT02720068|EXPERIMENTAL|Part B: Favezelimab Dose G+Pembro+FOLFIRI|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV administered sequentially on Day 1 of each 21-day cycle PLUS FOLFIRI (irinotecan 180 mg/m\^2 IV, leucovorin \[calcium folinate\] 400 mg/m\^2 IV and 5-FU 2400 mg/m\^2 IV over 46 to 48 hours Q2W).
62311067|NCT02720068|EXPERIMENTAL|Part B: Favezelimab/Pembrolizumab|Participants receive favezelimab/pembrolizumab (favezelimab and pembrolizumab administered as a co-formulation) IV infusion on Day 1 of each 21-day cycle.
62311068|NCT02720068|EXPERIMENTAL|Part B: Favezelimab Dose G+Pembro+Lenvatinib|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21 day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS oral lenvatinib (20 mg) each day of 21-day cycle.
62311069|NCT01103050|ACTIVE_COMPARATOR|QAV680 + Cetirizine Placebo|
62311070|NCT01103050|EXPERIMENTAL|QAV680 + Cetirizine|
62681761|NCT05212935||Children below 12 months of age receiving vaccines according to the National Vaccination Plan|"All children who received vaccination in their first 12 months of life between January 2018 and June 2022 in the Regional Vaccination Centers involved in the study.~Children will be classified in sub-groups, according to different vaccination schedules (single or co-administration) and order of vaccine uptake."
62311071|NCT01103050|ACTIVE_COMPARATOR|Cetirizine + QAV680 Placebo|
62311072|NCT01103050|PLACEBO_COMPARATOR|QAV680 Placebo + Cetirizine Placebo|
62681762|NCT06695143|EXPERIMENTAL|Treatment - SoC + fusidic acid 2% cream|4 weeks SSG (SoC) with 2 weeks twice daily topical application of fusidic acid 2% cream
62311073|NCT04760652|ACTIVE_COMPARATOR|CBT Cognitive Behavioral Therapy|Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.
62122243|NCT00478478||Acute Ischemic Stroke patients|Patients presenting with signs and symptoms consistent with a diagnosis of Acute Ischemic Stroke, who are treated with the Merci Retrieval System during a Mechanical Thrombectomy procedure.
62122244|NCT04201041|ACTIVE_COMPARATOR|trans-gluteal approach|received pudendal nerve pulsed radiofrequency through trans-gluteal approach
62122245|NCT04201041|ACTIVE_COMPARATOR|trans-vaginal approach|received pudendal nerve pulsed radiofrequency through trans-vaginal approach
62122246|NCT05468411|ACTIVE_COMPARATOR|Miracle fruit pill|A freeze-dried miracle fruit pill is orally administered prior to eating food samples.
62122247|NCT05468411|PLACEBO_COMPARATOR|Sugar candy|A chewable sugar candy is orally administered as a placebo prior to eating food samples.
62681763|NCT06695143|ACTIVE_COMPARATOR|Vehicle - SoC + vehicle cream|4 weeks SSG (SoC) with 2 weeks twice daily topical application of vehicle cream
62122248|NCT01598636|EXPERIMENTAL|Lateral Tibial Tunnel technique|
62122249|NCT04640259||EGFR|
62122250|NCT04640259||ROS1|
62122251|NCT04640259||ALK|
62476667|NCT04853563|EXPERIMENTAL|High PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 8 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. Thereafter, the PEEP level is adjusted to 1 centimetre of water higher to a minimum PEEP level of 10 with every 30 minutes.
62122252|NCT04640259||KRAS|
62122253|NCT04640259||NSCLC Other|
62122254|NCT00731185|EXPERIMENTAL|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
62122255|NCT00731185|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning
62122256|NCT02768571|EXPERIMENTAL|Cerebrolysin|"Cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation~* Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9\~10)~* Rehabilitation~  * 3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~ * 5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 \~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
62122257|NCT02768571|PLACEBO_COMPARATOR|Placebo|"Saline 100 ml/day \* 21 days with rehabilitation~* Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9\~10)~* Rehabilitation~  * 3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~ * 5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 \~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
62122258|NCT05216510|EXPERIMENTAL|Cohort 1|Healthy uninfected/unexposed subjects to SARS-CoV-2
62122259|NCT05216510|ACTIVE_COMPARATOR|Cohort 2|Subjects who have recovered from SARS-CoV-2 infection
62122260|NCT05216510|SHAM_COMPARATOR|Cohort 3|Subjects who have received a complete SARS-CoV-2 vaccine course
62122261|NCT05530577|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide via subcutaneous injections at escalating doses (0.25mg to 1.0mg) over 9 weeks.
62122262|NCT05530577|SHAM_COMPARATOR|Sham/Placebo|Participants will receive sham subcutaneous injections over 9 weeks.
62122263|NCT03876249||RSV positive group|Children who had RSV infection within the first 60 days of life
62476668|NCT04853563|ACTIVE_COMPARATOR|Low PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 5 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. In this arm, the PEEP level is adjusted to 1 centimetre of water lower to a minimum PEEP level of 3 with every 30 minutes while maintaining a partial pressure of arterial blood oxygen above 65 millimeter of mercury or oxygen saturation \>92% with pulse oxymetry.
62122264|NCT03876249||RSV negative group|Children without known RSV infection within the first 60 days of life
62122265|NCT03430414||Therapy Responders|
62122266|NCT03430414||Non-Responders|
62122267|NCT00166166|EXPERIMENTAL|Healthy Controls|Healthy subjects had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
62122268|NCT00166166|EXPERIMENTAL|Risk Factors|Non-hypertensive subjects with cardiovascular risk factors had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
62311074|NCT04760652|OTHER|TAU Treatment As Usual|Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).
62476669|NCT03877692|EXPERIMENTAL|Experimental labetalol dose|Subjects receive 40mg, 60mg, 80mg after each severe BP
62476670|NCT03877692|ACTIVE_COMPARATOR|Current standard of care|Subjects receive 20mg, 40mg, 60mg after each severe BP
62476671|NCT01108029|ACTIVE_COMPARATOR|memantine|memantine 20 mg/day (2 tablets 1 time a day in the morning)
62476672|NCT01108029|PLACEBO_COMPARATOR|placebo|2 tablets (1 time a day in the morning) during 3 months
62681764|NCT06695143|NO_INTERVENTION|Control - SoC|4 weeks SSG (SoC) only
62476673|NCT03953287|EXPERIMENTAL|Pharmacokinetic Study of Paracetamol.|"Detailed Description:~Twelve healthy young volunteers are recruited, and the experiments begin at 07:45 after an overnight fast. BMI and blod pressure are recorded and a catheter is inserted in an antecubital vein for blood samples.~At 08.00 participants take 500 mg paracetamol as a tablet with 200 ml tap water or a Paracetamol1523 capsule in random order. Subsequently, blood samples are taken every minute for 3 minutes the first hour, then every 10 minutes the following two hours. In addition, blood pressure and puls rate are measured every 20 minute the first hour, and then every 30 minutes.Side effects and time to the participants registrate any effect of the drugs are assessed in a prefabricated scheme.~The disadvantages associated with the experiment are sought monitored by adverse event registration which ends at the end of the trial. The trial day lasts 2 hours in which blood samples are taken as described above, and blood pressure and records are stored ."
62476674|NCT02300935|EXPERIMENTAL|trametinib and nab-paclitaxel|Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
62122269|NCT05689125|EXPERIMENTAL|Railroaded bougie|An endotracheal tube is loaded onto a bougie posterior to the placement of the bougie into the trachea.
62122270|NCT05689125|OTHER|Preloaded bougie|An endotracheal tube is loaded onto a bougie prior to initiating laryngoscopy.
62122271|NCT05689125|ACTIVE_COMPARATOR|Stylet|A stylet is placed within an endotracheal tube prior to initiating laryngoscopy.
62476675|NCT04560335|EXPERIMENTAL|Coach to fit|CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about 15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly.
62496008|NCT01942616|EXPERIMENTAL|Condition 1|"Each study arm contains different scenarios presented to the participant.~Condition 1 is a Perpetrator Positive scenario.~The content of the Condition 1 group is as follows:~Framing: Episodic Labeling: DV label Extraneous Information: Perpetrator positive non relevant Victim/Perp Characteristic: Negative victim"
62122272|NCT05689125|NO_INTERVENTION|Naked endotracheal tube|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation without assistance of stylet or bougie.
62122273|NCT05702658|EXPERIMENTAL|experimental arm|Individuals who receive CAPS
62122274|NCT05702658|NO_INTERVENTION|control|Individuals who receive treatment as usual
62122275|NCT02170324|EXPERIMENTAL|GLP-1 agonism group|Exenatide injection 10 ug twice daily for 10 days subcutaneously.
62122276|NCT02170324|PLACEBO_COMPARATOR|Placebo group|0.9 % sodium choride 0.1 ml twice daily for 10 days subcutaneously.
62122277|NCT00839995||Patients undergoing multi-level spine surgery|
62122278|NCT02694835|EXPERIMENTAL|DT1 UV|Delefilcon A contact lenses with Ultraviolet (UV) Absorber worn bilaterally (in both eyes) for 9 hours
62122279|NCT02694835|ACTIVE_COMPARATOR|DT1|Delefilcon A contact lenses worn bilaterally for 9 hours
62122280|NCT04709055|EXPERIMENTAL|Co-management arm (geriatric and surgical)|
62122281|NCT04709055|ACTIVE_COMPARATOR|Usual care|
62476676|NCT04560335|OTHER|Treatment as usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
62476677|NCT01975948|EXPERIMENTAL|Mental Health PSP: Physicians|Physicians training in Adult Mental Health Practice Support Program
62476678|NCT01975948|ACTIVE_COMPARATOR|Treatment as Usual: Physicians|Those administering treatment as usual for depression
61922242|NCT02301988|EXPERIMENTAL|Ipatasertib + Paclitaxel|Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
62476679|NCT01975948|EXPERIMENTAL|Mental Health PSP: Patients|Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
62476680|NCT01975948|ACTIVE_COMPARATOR|Treatment as Usual: Patients|Those receiving treatment as usual for depression
62476681|NCT06133439|NO_INTERVENTION|Phase 1|Usual care and planning period.
62476682|NCT06133439|OTHER|Phase 2|"Implementation period.~Clinics are randomized into clusters"
62476683|NCT06133439|OTHER|Phase 3|Maintenance period.
62476684|NCT05778110||TBI|Patients with traumatic brain injury.
62476685|NCT05778110||ICH|Patients with hypertensive intracranial hemorrhage.
62476686|NCT05115357|NO_INTERVENTION|Intravenous analgesia group|Patients will receive systemic intravenous analgesia only.
62476687|NCT05115357|EXPERIMENTAL|Pecto-Intercostal Fascial Block (PIFB) group|Patients will receive PIFB on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.
62476688|NCT05115357|EXPERIMENTAL|Transversus Thoracis Muscle Plane Block (TTP) group|Patients will receive TTP on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.
62476689|NCT00665470|EXPERIMENTAL|Cohort I - high dose Aldesleukin|Patients receive high-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
62476690|NCT00665470|EXPERIMENTAL|Cohort II - low dose Aldesleukin|Beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion, patients receive low-dose aldesleukin subcutaneous (SC) once daily 5 days a week for up to 6 weeks.
62476691|NCT03118557|EXPERIMENTAL|Pilates pelvic floor strengthening exercise|
62476692|NCT03517085|EXPERIMENTAL|DTX401 Cohort 1|Dose 1 (2.0 × 10\^12 GC/kg) with a reactive steroid regimen (6 weeks, at a starting dose of 40 mg/day, after alanine aminotransferase \[ALT\] elevation)
62476693|NCT03517085|EXPERIMENTAL|DTX401 Cohort 2|Dose 2 (6.0 × 10\^12 GC/kg) with a reactive steroid regimen (6 weeks, at a starting dose of 40 mg/day, after ALT elevation)
62476694|NCT03517085|EXPERIMENTAL|DTX401 Cohort 3|Dose 2 (6.0 × 10\^12 GC/kg) with an optimized reactive steroid regimen (7 weeks, at a starting dose of 60 mg/day, after ALT elevation)
62681765|NCT06695156|EXPERIMENTAL|Exploring the Effect of the Transcendental Meditation® Technique on Migraine|
61922243|NCT02301988|PLACEBO_COMPARATOR|Placebo + Paclitaxel|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
61922244|NCT01424202|EXPERIMENTAL|Group B|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications plus daily sessions of mechanical in-exsufflation (MI-E).
61922245|NCT01424202|NO_INTERVENTION|Group A|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications.
62476695|NCT03517085|EXPERIMENTAL|DTX401 Cohort 4|Dose 2 (6.0 × 10\^12 GC/kg) with a prophylactic steroid regimen (8 weeks, at a starting dose of 60 mg/day, starting on Day 1)
62476696|NCT01792726|EXPERIMENTAL|TARGIT|The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
62476697|NCT01792726|ACTIVE_COMPARATOR|External beam radiotherapy boost|The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
62476698|NCT06253403||clinic|adult women with anorexia nervosa or actual or after stabilization
62476699|NCT06253403||control|health adult women without any psychological or mental illnes
62476700|NCT01380782|EXPERIMENTAL|Bevacizumab Naive|Bevacizumab naive subjects
61922246|NCT04814901|EXPERIMENTAL|Study group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae using FAMM and assessment of success regarding patient satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection.
61922247|NCT04814901|ACTIVE_COMPARATOR|Comparator group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae and its effect on patient's satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection
62311075|NCT04251312|EXPERIMENTAL|Preoperative dental hygiene education|Patients who are scheduled for elective esophageal or lung resections who consent to participate will undergo oral hygiene education and be given an oral hygiene packet. An oral hygiene assessment using the Plaque Assessment tool will be conducted in the clinic. A Dysphagia Screening Tool questionnaire will also be administered. Patients who screen positive for dysphagia will be referred to Speech Pathology for evaluation but for the study purposes, the only data collected from the evaluation will be whether or not the participant received this intervention. A repeat dental exam will occur on the day of surgery. Patients will be followed for 30 days post operatively.
62476701|NCT01380782|EXPERIMENTAL|Prior Bevacizumab|Patients previously treated with bevacizumab
61922248|NCT04779931|EXPERIMENTAL|Convoy-Pal Intervention|Intervention participants will be sent Convoy-Pal equipment and materials. The equipment can simply be removed from the box, plugged in, and turned on to start. Research staff will provide technical support as needed during the trial. Convoy-Pal is 12-week intervention that uses the Routinify platform to deliver self-management tools and palliative care resources in the participants' home. The platform includes a tablet, charging stand, and smart watch, with additional options for mobile phone access and a website portal.
61922249|NCT04779931|ACTIVE_COMPARATOR|Waitlist Control|Participants will complete baseline assessments and will be recontacted at 11 weeks to complete follow up assessments at week 12. Participants will receive a $25 gift card for each assessment ($50 total). If they would like to try the intervention at that time, we will send them Convoy-Pal equipment and materials. They will then have 12 weeks to use the tool.
61922250|NCT06329089||Recurrent ipsilateral breast cancer|Recurrent ipsilateral breast cancer refers to the return of breast cancer in the same breast where it originally developed or was treated.
61922251|NCT04490031|NO_INTERVENTION|Midazolam group|Standard sedation for ERCP in UKMMC
61922252|NCT04490031|EXPERIMENTAL|Ketamine group|
61922253|NCT01304784|EXPERIMENTAL|Arm 1|"Regimen follows a 3-week treatment cycle.~Cisplatin 80mg/m2 given on day 1 by IV infusion over two hours every three weeks.~Capecitabine 1000 mg/m2 given orally twice daily for fourteen days each 3-week cycle.~Up to six 3-week cycles of Cisplatin and Capecitabine to be administered. Trastuzumab given as 8 mg/kg loading dose at week 1 over 90 minutes followed by 6 mg/kg every 3 weeks over 30-90 minutes.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Trastuzumab (every 3 weeks) and MM-111 (weekly) will continue until disease progression, unacceptable toxicity, or withdrawal of consent."
62122282|NCT01968226|EXPERIMENTAL|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of \[F-18\]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
62122283|NCT05886491|EXPERIMENTAL|Phase 1: Dose Escalation of GDX012|Participants will receive GDX012 weight-based dose as intravenous (IV) infusion on Day 1 of Phase 1 after lymphodepleting chemotherapy. Three dose levels of GDX012 will be tested in Phase 1. Some participants may be eligible for a second dose.
62311076|NCT04634539|EXPERIMENTAL|Gemcitabine + Nab-paclitaxel + L-glutamine|For the dose-finding portion of this study, all subjects will receive a combination of L-glutamine, gemcitabine, and nab-paclitaxel which will be preceded by a 1-week (+/- 1 day) administration of L-glutamine. This 1-week administration of L-glutamine will facilitate measurement of baseline and post-glutamine monotherapy plasma metabolite levels prior to addition of gemcitabine and nab-paclitaxel. The combination therapy will be administered over 28-day cycles during the treatment period until disease progression, treatment intolerance, or withdrawal from the study. Patients are expected to be on treatment for 12 cycles.
62476702|NCT00689364||CTTCT+CWMT|"CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least.~CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline)."
62476703|NCT00689364||CWMT cohort|CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
62476704|NCT06238388|EXPERIMENTAL|0.8 μg/kg HSK21542 Injection|0.8 μg/kg HSK21542 Injection
62476705|NCT03515694|PLACEBO_COMPARATOR|Dose of 0mg/kg TOF1|
62476706|NCT03515694|PLACEBO_COMPARATOR|Dose of 0mg/kg TOF2|
61922254|NCT01304784|EXPERIMENTAL|Arm 2|"Regiment follows a 4-week treatment cycle.~The following Lapatinib and Trastuzumab regimen will be given in combination with MM-111 in the following order:~* Trastuzumab 4 mg/kg loading dose week 1 over 90 minutes~* Followed by Trastuzumab 2 mg/kg weekly thereafter~* Lapatinib 1000 mg by mouth (PO) daily~* MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
61922255|NCT01304784|EXPERIMENTAL|Arm 3|"Regimen follows a 4-week treatment cycle Paclitaxel dosing should begin first dose on cycle 1 day 1. Paclitaxel will be administered at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab will be administered via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
61922256|NCT01304784|EXPERIMENTAL|Arm 4|"4-week treatment cycle. Lapatinib given orally. Paclitaxel dosing on cycle 1 day 1. Paclitaxel given at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab given via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 given over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
61922257|NCT01304784|EXPERIMENTAL|Arm 5|"Docetaxel, trastuzumab and MM-111 3-week treatment cycles with therapies given in the following order: 1) docetaxel, 2) trastuzumab, and 3) MM-111~Docetaxel given as an IV infusion over 60 minutes every three weeks. The infusion should be prepared as directed in the Docetaxel package insert and any institutional guidelines. All patients receiving Docetaxel should be pre-medicated as per the local institutional guidelines.~The first dose of trastuzumab is a loading dose of 8 mg/kg administered over 90 minutes followed by every three week dosing at 6 mg/kg over 60 minutes via IV infusion.~The first dose of MM-111 given over 90 minutes followed by 3 week dosing over 60 minutes in the absence of infusion-related reactions"
62311077|NCT02976831|EXPERIMENTAL|AZD0284|"Part 1A:~Following an overnight fast of at least 10 hours, each subject will receive a single dose of AZD0284 or matching placebo in the form of an oral solution with water. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 1B (food cohort):~Subjects, will receive a single dose of AZD0284 at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 2:~In Part 2, subjects will receive 1 dose level of AZD0284 (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (IMP with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
62311078|NCT02976831|ACTIVE_COMPARATOR|Placebo|"Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of placebo in the form of an oral solution with water. The first cohort will receive 4.0 mg AZD0284 or placebo on Day 1. The actual dose for subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the SRC Part 1B (food cohort): In Part 1B, subjects, will receive a single dose of placebo at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing.~Part 2: In Part 2, each subject will receive 1 dose level of placebo (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (placebo with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
62476707|NCT03515694|EXPERIMENTAL|Dose of 0 ,5mg/kg TOF1|
62476708|NCT03515694|ACTIVE_COMPARATOR|Dose of 0,5mg/kg TOF2|
62476709|NCT03515694|EXPERIMENTAL|Dose of 1mg/kg TOF1|
62476710|NCT03515694|ACTIVE_COMPARATOR|Dose of 1mg/kg TOF2|
62476711|NCT03515694|EXPERIMENTAL|Dose of 2mg/kg TOF1|
62476712|NCT03515694|ACTIVE_COMPARATOR|Dose of 2mg/kg TOF2|
61922258|NCT04526990|EXPERIMENTAL|Experimental group|20000 participants, Ad5-nCoV , single dose, Intramuscular administration
61922259|NCT04526990|PLACEBO_COMPARATOR|Placebo group|20000 participants, placebo, single dose, Intramuscular administration
62681766|NCT06324370|EXPERIMENTAL|Healthy Filipino male participants (18 to 45 yrs old)|"Healthy Filipino male participants 18 to 45 years old with optimum weight as related to height and body frame.~1.2ml/kg/dose of virgin coconut oil (VCO) will be administered orally with 240 ml of water and standardized food for a single dose, and 0.6ml/kg/dose of virgin coconut oil (VCO) with 240 ml of water and standardized food twice a day for 7 days for multiple doses."
62681767|NCT06684678|EXPERIMENTAL|Individualized automatic coaching message for glycemic management and depressive symptoms|The study will enroll patients with type 1 diabetes who are already receiving twice-monthly non-face-to-face management by a dedicated education nurse through the Type 1 Diabetes Home Care Project and Educational Consultation program. For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management.
62681768|NCT06684678|NO_INTERVENTION|Current Treatment|The study will enroll patients with type 1 diabetes who are already receiving twice-monthly non-face-to-face management by a dedicated education nurse through the Type 1 Diabetes Home Care Project and Educational Consultation program. The control group will continue their current treatment and non-face-to-face diabetes management.
62681769|NCT03382873|ACTIVE_COMPARATOR|Group Lifestyle Balance (GLB)|Standard lifestyle intervention to promote weight loss
62681770|NCT03382873|EXPERIMENTAL|Group Lifestyle Balance Plus (GLB+)|Augmented lifestyle intervention for early slow responders
62311079|NCT04397055|EXPERIMENTAL|Cottonseed Oil|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance
62476713|NCT04559503|EXPERIMENTAL|İntervention Group|Progressive relaxation exercises were applied once a day for four weeks in the intervention group in addition to the standard treatments. The patients were called 3 times each week on the telephone, and it was monitored whether they continued to do the exercises.
62476714|NCT04559503|NO_INTERVENTION|Control group|The control group received standard treatment.
62681771|NCT04984590|OTHER|IOPCL AMD MAG|All subjects will receive a 10.0 Diopter intraocular pseudophakic capsular lens magnifier (IOPCL MAG)
62681772|NCT02912611|OTHER|Moderate and High risk for AKI|
62681773|NCT05669677||Standard|Chronic liver disease
62681774|NCT06366165|EXPERIMENTAL|Students of semester 9 in Ahram Canadian University|The students receive their lectures with funny videos and memes included to link the science with it.
62681775|NCT06543121||Stroke patients|
62122284|NCT05886491|EXPERIMENTAL|Phase 2a: GDX012|Participants will receive GDX012 (weight-based) IV infusion at pre-selected one or two dose levels from Phase 1, on Day 1 after lymphodepleting chemotherapy. Some participants may be eligible for a second dose.
62122285|NCT03083197|ACTIVE_COMPARATOR|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
62122286|NCT03083197|ACTIVE_COMPARATOR|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
62122287|NCT03083197|ACTIVE_COMPARATOR|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
62122288|NCT04436393||Advanced Breast Cancer|Patients with diagnosis of advanced breast cancer
62122289|NCT03014973|EXPERIMENTAL|prostate cancer patients resistant to castration|
62122290|NCT03014973|EXPERIMENTAL|patients naif of hormonal treatment|
62311080|NCT04397055|ACTIVE_COMPARATOR|Olive Oil|Participants are given foods enriched with olive oil and instructed on how to substitute study foods into their diet to maintain caloric balance
62311081|NCT01347164|EXPERIMENTAL|Life coaching sessions|6 2-hour counseling session with trained therapist/counselor. The sessions deal with coping and stress reduction as well as sexual health.
62122291|NCT01538914|EXPERIMENTAL|PVB|Postoperative pain is controlled with local analgesics delivered via PVB.
62122292|NCT01538914|ACTIVE_COMPARATOR|PCA|Postoperatve pain is controlled with intravenous PCA.
62311082|NCT01347164|ACTIVE_COMPARATOR|HIV counseling session|One 60-minute counseling session, based on standard HIV counseling content.
62311083|NCT02217462||Pregnant women|
62496009|NCT01942616|EXPERIMENTAL|Condition 2|"Each study arm contains different scenarios presented to the participant.~Condition 2 is a Perpetrator Negative scenario.~The content of the Condition 2 group is as follows:~Framing: Thematic Labeling: Assault label Extraneous Information: Perpetrator neutral non relevant Victim/Perp Characteristic: Negative Perpetrator"
62311084|NCT01312155||Patients undergoing general anesthesia|
62311085|NCT01348919|EXPERIMENTAL|CEP-18770 Dose A|Participants will receive CEP-18770 Dose A intravenously (IV) on Days 1, 8, and 15 in each 28-day cycle. In addition, participants will receive a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.
62311086|NCT01348919|EXPERIMENTAL|CEP-18770 Dose B|Participants will receive CEP-18770 Dose B IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants will receive a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.
62496010|NCT01942616|PLACEBO_COMPARATOR|Condition 3|"Each study arm contains different scenarios presented to the participant.~The content of the Condition 3 group is as follows:~Framing: Neither Labeling: No label Extraneous Information: None Victim/Perp Characteristic: None"
62681776|NCT06543121||Hypertension patients|
62681777|NCT06184503||Paediatric patients with alpha-mannosidosis treated with Lamzede before 3 years of age|Paediatric patients with a confirmed diagnosis of alpha-mannosidosis with data for at least one pre- and one post-Lamzede treatment sample obtained when \< 3 YOA.
62681778|NCT06695793|EXPERIMENTAL|Group (A)|Interrupted Sutures: The first layer of the uterine incision will be closed using individual, separate sutures placed at regular intervals along the incision line. Each suture will be tied independently, ensuring adequate apposition of uterine tissue, followed by a second layer of running continuous sutures.
62681779|NCT06695793|EXPERIMENTAL|Group (B)|Locked Sutures: The first layer of the uterine incision will be closed using continuous sutures placed along the uterine incision, incorporating a locking technique at specified intervals to prevent unraveling. The knots will be securely tied to maintain tissue approximation, followed by a second layer of running continuous sutures.
62681780|NCT06695793|EXPERIMENTAL|Group (C)|Running Continuous Sutures: Double layer closure of uterine incision using running continuous suture used to close the uterine incision without interruption, providing seamless tissue approximation throughout the incision length.
62681781|NCT06420076|EXPERIMENTAL|Sequential CAR-T Cells Targeting (CD5/CD7 CAR T cells, chemotherapy)|Patients will be administered fludarabine phosphate intravenously (IV) over a 30-minute period on days -4 to -2. Additionally, cyclophosphamide will be administered intravenously (IV) over 60 minutes on day -2. Subsequently, patients will receive CD5/CD7 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0. Patients who exhibit positive responses to the initial dose of CD5/CD7 CAR T cells, do not experience unacceptable side effects, and have a sufficient quantity of cells available may be eligible to receive 2 or 3 additional doses of CD5/CD7 CAR T cells.
62311087|NCT01348919|EXPERIMENTAL|CEP-18770 Dose C|Participants will receive CEP-18770 Dose C IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants will receive a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.
62681782|NCT04015141|EXPERIMENTAL|Perampanel|Participants aged 1 month to less than 18 years with pediatric epileptic syndrome (Cohort 1) or aged 1 month to less than 2 years with POS (Cohort 2) will receive perampanel oral suspension or perampanel tablets, once daily up to 56 weeks.
62122293|NCT03560934|EXPERIMENTAL|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (\>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo.~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is \~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services."
62122294|NCT03560934|EXPERIMENTAL|Non Cannabis Users|Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
62122295|NCT06676722|EXPERIMENTAL|Experimental|SBRT combined with Nimotuzumab followed by Tislelizumab
62122296|NCT04734730|EXPERIMENTAL|Treatment (talazoparib, androgen deprivation therapy)|Patients receive talazoparib PO QD, abiraterone acetate PO QD, and prednisone PO QD on days 1-28. Patients also receive androgen deprivation therapy consisting of degarelix SC on day 1; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of subsequent cycles; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of cycles 2, 5, 8, and 11; or goserelin acetate SC monthly or every 3 months. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62122297|NCT03950778|ACTIVE_COMPARATOR|Septic patients receiving albumin replacement|Septic patients receiving albumin replacement 20 ml Inj Human Albumin 20% -3x100 ml- 3 day
62122298|NCT03950778|NO_INTERVENTION|Septic patients not receiving albumin replacement|
62122299|NCT01616459|EXPERIMENTAL|11Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830929A, or 11Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 11Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 11Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
62311088|NCT00827619|OTHER|1|single arm non-randomized post-market study
62476715|NCT05367986|NO_INTERVENTION|Western medicine group(WM group)|Patients in the Western medicine group received conventional treatment with Western medicine. According to International Guidelines for Management of Sepsis and Septic Shock: 2016, conventional treatment includes antibiotics and other anti-infection measures, fluid management, mechanical ventilation, and nutritional support, but does not include the use of immunosuppressants or immune enhancers including hormones, gamma globulin, and thymosin.
62681783|NCT05835895|EXPERIMENTAL|GNSC-001 (low dose)|
62476716|NCT05367986|EXPERIMENTAL|electro-acupuncture (EA) group|Patients in the electro-acupuncture group were treated with Western medicine and electro-acupuncture. Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.
62476717|NCT04013841|EXPERIMENTAL|Oral preparation|The bowel preparation prior to colorectal resection will be conducted using oral-agents
62476718|NCT04013841|EXPERIMENTAL|Enema preparation|The bowel preparation prior to colorectal resection will be conducted using rectal enema
62476719|NCT05035394|ACTIVE_COMPARATOR|Cataract surgery as stand alone|Cataract surgery as stand alone. Cataract surgery will be performed in a standardized fashion.
62476720|NCT05035394|ACTIVE_COMPARATOR|Cataract surgery in combination with Kahook Dual Blade glide goniotomy|Cataract surgery combined with Kahook Dual Blade Glide goniotomy. The goniotomy will be performed at the end of cataract surgery through the temporal cataract incision.
62476721|NCT05035394|ACTIVE_COMPARATOR|Cataract surgery in combination with iStent Inject W implantation|Cataract surgery combined with iStent Inject W. The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.
62681784|NCT05835895|EXPERIMENTAL|GNSC-001 (low dose) + transient immune-modulation (oral)|
62681785|NCT05835895|EXPERIMENTAL|GNSC-001 (high dose)|
62681786|NCT05835895|EXPERIMENTAL|GNSC-001 (high dose) + transient immune-modulation (oral)|
62311089|NCT02708212|ACTIVE_COMPARATOR|EGD-colonoscopy group|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to EGD and colonoscopy examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
62311090|NCT02708212|ACTIVE_COMPARATOR|Colonoscopy-EGD group|In this study group, patients receive a colonoscopy followed by an EGD during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to colonoscopy and EGD examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
62476722|NCT04296994|EXPERIMENTAL|Open-label Dose Escalation and Expansion Study of QL1706|"Part 1 (Dose escalation): QL1706 will be administered in sequential cohorts each receiving 1 of 4 doses of QL1706 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The PK parameters of QL1706 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
62476723|NCT00784472|ACTIVE_COMPARATOR|oxycodone|
62681787|NCT05835895|EXPERIMENTAL|GNSC-001 (high dose) + transient immune-modulation (oral + injectable)|
62681788|NCT05835895|PLACEBO_COMPARATOR|Placebo|
62681789|NCT06690788|ACTIVE_COMPARATOR|Individual intervention condition|"PreventT2 individual lifestyle intervention curriculum (2021 revised National DPP curriculum, freely available from the CDC)"
62476724|NCT00784472|ACTIVE_COMPARATOR|morphine|
62681790|NCT06690788|EXPERIMENTAL|Couple-based intervention condition|"PreventT2 Together (couple-based adaptation of PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the National DPP)"
62681791|NCT01171937|ACTIVE_COMPARATOR|Open-Label Risperidone|Risperidone oral solution (1mg/mL) qd for 8 weeks.
62476725|NCT05261802|EXPERIMENTAL|AVANCE-Houston FRAMEWorks Program Weekly Workshop Format|A trained facilitator, supported by Career and Family Coaches, leads every HMRE parenting workshop for adults via multiple delivery models: in recurring weekly workshops (2 hours each workshop for 7 weeks) and intensive weekend retreats (totaling 16 hours). Additionally, AVANCE offers the weekly workshops either virtually via Zoom or in-person. All workshop models were offered to program participants who were able to choose whether the weekly (either in-person or virtually) or the weekend (in-person only) format worked best for them. Curriculum content is consistent across all delivery methods and target hours for all participants is 14 hours.
62476726|NCT03092466|ACTIVE_COMPARATOR|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
62681792|NCT01171937|PLACEBO_COMPARATOR|Placebo|Placebo
62681793|NCT03842111||Region XI Head Start children and families|children (1049) parents (1049) classrooms/teachers (73) program directors (21) center directors (36)
62681794|NCT04052555|EXPERIMENTAL|Treatment (berzosertib, radiation therapy)|Patients receive berzosertib IV over 60 minutes BIW for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo RT 5 days a week for 5-6 weeks depending on the type of surgery undergone. Patients also undergo a collection of blood on study.
62681795|NCT05497882|EXPERIMENTAL|Training Prototype|Testing of 3 e-learning modules
62681796|NCT05097950|ACTIVE_COMPARATOR|Intervention Group|Administration of 1 gr paracetamol I.V
62681797|NCT05097950|PLACEBO_COMPARATOR|Control Group|Administration of 100 ml. sodium chloride 0.9% IV
62681798|NCT02741193|EXPERIMENTAL|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
62681799|NCT04043104|EXPERIMENTAL|1 x 10^11 vg/gland (single gland)|
62681800|NCT04043104|EXPERIMENTAL|3 x 10^10 vg/gland (both glands)|
62681801|NCT04043104|EXPERIMENTAL|3 x 10^11 vg/gland (single gland)|
62681802|NCT04043104|EXPERIMENTAL|1 x 10^11 vg/gland (both glands)|
62681803|NCT04043104|EXPERIMENTAL|1 x 10^12 vg/gland (single gland)|
62681804|NCT04043104|EXPERIMENTAL|3 x 10^11 vg/gland (both glands)|
62681805|NCT04043104|EXPERIMENTAL|3 x 10^12 vg/gland (single gland)|
62681806|NCT04043104|EXPERIMENTAL|1 x 10^12 vg/gland (both glands)|
62311091|NCT02768129|SHAM_COMPARATOR|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
62681807|NCT06592521|EXPERIMENTAL|OFE MPDS|OPTI-FREE EXPRESS MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
62122300|NCT01616459|EXPERIMENTAL|12Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 12Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 12Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
62122301|NCT01616459|ACTIVE_COMPARATOR|Synflorix Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Synflorix™ at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Synflorix™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Synflorix™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
62122302|NCT01616459|ACTIVE_COMPARATOR|Prevnar13 Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Prevnar13™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Prevnar13™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Prevnar13™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate ).
62122303|NCT02528188|ACTIVE_COMPARATOR|NSAID|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
62122304|NCT02528188|EXPERIMENTAL|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks
62122305|NCT02528188|EXPERIMENTAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks
62122306|NCT05260086|EXPERIMENTAL|Personalized aiTBS active - sham|counterbalanced crossover with sham neuronavigated stimulation
62122307|NCT05260086|ACTIVE_COMPARATOR|Conventional (F3) aiTBS active - sham|counterbalanced crossover with sham neuronavigated stimulation
62122308|NCT01465516||Hispanic, HCV genotype 1|Historical group will be a continuous group of Hispanic patients with genotype 1 who were naive to treatment and completed or initiated 48 weeks of pegylated interferon and ribavirin. Patients, who discontinued the treatment due to side effects, adherence issues, or treatment failure, will be included and analyzed based on intention to treat analysis. All patients will be stratified according to their SVR, relapse and no response rate. RVR, EVR, and ETR will be also collated and compared to the study group.
62122309|NCT04054635|EXPERIMENTAL|Regimen 1|Two applications of silver diamine fluoride (SDF) four months apart, which is the protocol frequency adopted by the Winnipeg Regional Health Authority's (WRHA) Clinical Guideline on SDF.
62122310|NCT04054635|EXPERIMENTAL|Regimen 2|Two applications of silver diamine fluoride (SDF) six months apart, which is the American Dental Association's recommendation for SDF.
62122311|NCT04054635|EXPERIMENTAL|Regimen 3|Two applications of silver diamine fluoride (SDF) one month apart, which is proposed in the American Academy of Pediatric Dentistry's clinical practice guidelines.
62122312|NCT04581850||PTSD patients|This group is composed of patients suffering from an active PTSD
62122313|NCT04581850||Control group (healthy individuals)|This group is composed of healthy individuals.
62311092|NCT02768129|EXPERIMENTAL|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
62311093|NCT04722172|EXPERIMENTAL|Acalabrutinib Combined With Obinutuzumab|Patients will receive acalabrutinib for a minimum of 13 cycles and maximum 26 cycles and Obinutuzumab will be administered during Cycles 2-7. This will be followed by treatment-free observation through the 65th cycle. Patients who progress during the observation period, per iwCLL criteria, will receive 13 cycles of acalabrutinib in combination with obinutuzumab in the retreatment phase of this study.
62311094|NCT05084989|EXPERIMENTAL|Part1: Recombinant two-component COVID-19 vaccine (CHO cell)|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
62311095|NCT05084989|PLACEBO_COMPARATOR|Part1: Placebo control|Antigen: sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
62681808|NCT06592521|EXPERIMENTAL|OFPM MPDS|OPTI-FREE PureMoist MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
62681809|NCT06592521|EXPERIMENTAL|OFR MPDS|OPTI-FREE REPLENISH MPDS and Alcon contact lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
62681810|NCT03436238||MINSS cohort|"Adult patients \>= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital.~Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com)."
62681811|NCT06687837|EXPERIMENTAL|Low dose administration|4 million autologous dopaminergic cells will be implanted into the putamen on each side of the brain
62311096|NCT05084989|EXPERIMENTAL|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|(Lot# HA202107009 and Lot# TC202205002) Recombinant two-component COVID-19 vaccine (CHO cell) Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
62311097|NCT05084989|ACTIVE_COMPARATOR|Part2: COMIRNATY® COVID-19 Vaccine, mRNA|"Antigen: nucleoside-modified messenger RNA (mRNA) encoding the viral Spike (S) glycoprotein of SARS-CoV-2, called tozinameran.~Others: ((4-hydroxybutyl) azanediyl) bis (hexane-6,1-diyl) bis (2-hexyldecanoate), 2-\[(polyethylene glycol)-2000\]-N, N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium chloride, disodium phosphate dihydrate, sucrose."
62311098|NCT02333331|EXPERIMENTAL|BYM338 70 mg|BYM338 70 mg intravenous infusion
62311099|NCT02333331|EXPERIMENTAL|BYM338 210 mg|BYM338 210 mg intravenous infusion
62311100|NCT02333331|EXPERIMENTAL|BYM338 700 mg|BYM338 700 mg intravenous infusion
62311101|NCT02333331|PLACEBO_COMPARATOR|Placebo|Placebo intravenous infusion
62311102|NCT01656616||EMS cyanide exposure patients|
62311103|NCT05081622|EXPERIMENTAL|ICC-T|5 days with 9 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
62311104|NCT05081622|NO_INTERVENTION|Monitoring condition|No intervention
62311105|NCT05921448|EXPERIMENTAL|Vaxigripetra|This arm will receive 1 dose of 0.5 mL Vaxigripetra (intra-muscular injection) and 1 dose of 0.2 mL placebo (nasal, 1 spray in each nostril).
62311106|NCT05921448|EXPERIMENTAL|Flumist|1 dose of 0.2 mL Flumist (nasal, 1 spray in each nostril) and 1 dose of 0.5 mL placebo (intra-muscular injection).
62311107|NCT02278146|EXPERIMENTAL|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
62311108|NCT02278146|EXPERIMENTAL|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
62311109|NCT03500107|EXPERIMENTAL|Blue LED 401 +/- 5 nm|The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
62311110|NCT06673420||first-year medical students at the University of Khartoum enrolled in the Anatomy thorax module|The total population comprised 360 students. Participation in the Telegram channel created for anatomy learning was voluntary, and the students were given the option to subscribe. No sampling was conducted, to ensure that all students had equal access to the benefits of the channel and we did not wish to exclude anyone ethically. An MCQs test was shared with all students either prescribed or not
62311111|NCT03451825|EXPERIMENTAL|Avelumab: 10 miligram per kilogram (mg/kg)|
62311112|NCT03451825|EXPERIMENTAL|Avelumab 20mg/kg|
62311113|NCT03008512|EXPERIMENTAL|Genexol-PM|Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
62476727|NCT03092466|PLACEBO_COMPARATOR|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
62681812|NCT06687837|EXPERIMENTAL|High dose administration|8 million autologous dopaminergic cells will be implanted into the putamen on each side of the brain
62681813|NCT06190275|EXPERIMENTAL|GT201 in combination with PD-1 inhibitors treatment group|
62681814|NCT01381887|PLACEBO_COMPARATOR|001|Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
62681815|NCT01381887|EXPERIMENTAL|002|"Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
62122314|NCT01087762|EXPERIMENTAL|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
62311114|NCT04010422||ASD group|"Inclusion Criteria:~1. Having a clinical diagnosis of autism spectrum disorder~2. Aged over 20 years; able to read and sign an informed consent form.~3. Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~1. Unable to cooperate with the examinations.~2. Younger than 20 years old"
62681816|NCT01381887|EXPERIMENTAL|003|Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
62311115|NCT04010422||TD Group|"Inclusion Criteria:~1. Aged over 20 years; able to read and sign an informed consent form.~2. Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~1. Unable to cooperate with the examinations.~2. Younger than 20 years old.~3. Having a clinical diagnosis of autism spectrum disorder"
62311116|NCT03403972|EXPERIMENTAL|Group|Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)
62311117|NCT00641147|EXPERIMENTAL|Arm I (curcumin)|Patients receive curcumin PO BID for 12 months. Laboratory Biomarker Analysis
62311118|NCT00641147|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 12 months. Laboratory Biomarker Analysis
62311119|NCT02214758|OTHER|Dietary counseling|
62311120|NCT02214758|OTHER|Oral health counseling|
62311121|NCT02214758|NO_INTERVENTION|nutrition no counseling|
62311122|NCT02214758|NO_INTERVENTION|oral health no counseling|
62311123|NCT01378663||Post congenital cardiac surgery pain management|All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA.
62311124|NCT02378753|EXPERIMENTAL|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10\^7 plaque forming units)
62311125|NCT02378753|EXPERIMENTAL|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10\^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
62681817|NCT01381887|EXPERIMENTAL|004|"Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
62681818|NCT06496243|EXPERIMENTAL|obicetrapib/evolocumab combination|obicetrapib 10 mg/dL daily for 8 weeks followed by obicetrapib 10 mg/dL daily + evolocumab 140 mg/dL every other week for 8 weeks
62311126|NCT00258154|EXPERIMENTAL|1|RotaTeq/Infanrix Hexa
62311127|NCT00258154|PLACEBO_COMPARATOR|2|Placebo/Infanrix Hexa
62311128|NCT05515562|EXPERIMENTAL|Intravenous (IV) Omadacycline|All participants will receive 5 days of IV omadacycline followed by 5 days of oral omadacycline
62311129|NCT05689827|EXPERIMENTAL|Ethyl methyl hydroxypyridine succinate + Meldonium|Arm 1 (n=80) received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10 days; total number of injections for the treatment course is 10 and then orally with the dosage regimen of 2 capsules (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) twice per day for 30 days; total number of capsules for the treatment course is 120. Second group received Placebo in the same way.
62311130|NCT05689827|PLACEBO_COMPARATOR|Placebo|Arm 2 (n=80) received Placebo in the same way.
62311131|NCT03154450|EXPERIMENTAL|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
62311132|NCT03154450|ACTIVE_COMPARATOR|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
62311133|NCT02163369|EXPERIMENTAL|Peppermint and Lavender Essential Oils|
62311134|NCT03172650||study group|non alcoholic fatty liver disease patients
62311135|NCT03172650||Control group|fatty liver patients
62311136|NCT04044534|EXPERIMENTAL|Intranasal insulin|Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).
62681819|NCT06612281|EXPERIMENTAL|Single arm|All participants will undergo the same study procedures: FIT, Gixam, and colonoscopy
62681820|NCT06675773|EXPERIMENTAL|Experimental Group|The Conscious Awareness Development Psychoeducation Program will be applied to the experimental group. Conscious awareness and self-compassion techniques will be used in the psychoeducation program sessions. Homework will be given to the participants in each session. The psychoeducation program is prepared based on conscious awareness.
62681821|NCT06675773|NO_INTERVENTION|Control Group|No application will be made to the Control Group.
62681822|NCT02616302|EXPERIMENTAL|Weight ≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
62681823|NCT02616302|EXPERIMENTAL|Weight ≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
62681824|NCT02616302|EXPERIMENTAL|Weight >30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh \>30 kg.
62311137|NCT04044534|EXPERIMENTAL|Placebo|Subjects in this arm will receive placebo.
62311138|NCT05761327|ACTIVE_COMPARATOR|Mediterranean Diet|The individuals in this group will be given a nutrition model in accordance with the Mediterranean Nutrition Program under the supervision of a dietitian for 8 weeks. Individuals will be informed about the Mediterranean diet, their questions will be answered, the current food consumption record will be examined by the dietitian and they will be asked to follow the nutrition program prepared in the most appropriate way (by considering energy, nutrient requirements and nutritional habits). Every 15 days, the nutrition program will be updated with the meetings to be made by the dietitian and the patient, and the applicability of the program will be checked through daily communication.
62311139|NCT05761327|EXPERIMENTAL|Curcumin Supplementation|In addition to the Mediterranean Diet program in the 1st group for individuals in this group; 800 mg of curcumin supplement (VeNatura Curcumin Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.
62311140|NCT05761327|EXPERIMENTAL|Resveratrol Supplementation|In addition to the Mediterranean Diet in the 1st group for individuals in this group; 250 mg resveratrol supplement (VeNatura Resveratrol Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.
62311141|NCT00798512|EXPERIMENTAL|1|Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
62311142|NCT06513260||Virtual reality application|Application of virtual reality glasses during surgical extraction of impacted lower third molars.
62311143|NCT06513260||No application|No application of virtual reality glasses during surgical extraction of impacted lower third molars.
62311144|NCT05616390|EXPERIMENTAL|experimental group|Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy
62311145|NCT00330629|ACTIVE_COMPARATOR|Standard Behavioral Treatment|"Goal setting: daily/weekly goals for calorie and fat consumption, exercise time, and behavior change.~Self-monitoring: systematically observing and recording one's behavior,45,46 which will be reviewed by the therapists, and written feedback will be provided to reinforce positive behaviors.~Feedback: therapists monitor the recorded behavior changes and provide feedback/encouragement."
62311146|NCT00330629|ACTIVE_COMPARATOR|SBT+LOV Group|In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
62311147|NCT00772395|ACTIVE_COMPARATOR|Risedronate|
62311148|NCT00772395|PLACEBO_COMPARATOR|Placebo|
62311149|NCT06671691|EXPERIMENTAL|SBRT level I: 20Gy|20Gy in 1 fraction will be delivered to the tumor
62311150|NCT06671691|EXPERIMENTAL|SBRT level II: 23Gy|23Gy in 1 fraction will be delivered to the tumor
62311151|NCT06671691|EXPERIMENTAL|SBRT level III: 26Gy|26Gy in 1 fraction will be delivered to the tumor
62311152|NCT06671691|EXPERIMENTAL|SBRT level IV: 28Gy|28Gy in 1 fraction will be delivered to the tumor
62311153|NCT06671691|EXPERIMENTAL|SBRT level V: 30Gy|30Gy in 1 fraction will be delivered to the tumor
62311154|NCT01652677|EXPERIMENTAL|Low-frequency stimulation|Stimulation mode: 1 Hz, 100% MT, 20 minutes, unaffected hemisphere
62311155|NCT01652677|EXPERIMENTAL|High frequency stimulation|Stimulation mode: 10 Hz, 80% MT, 2 seconds - stimulation, 58 seconds - rest. - 8 session; affected hemisphere
62311156|NCT01652677|SHAM_COMPARATOR|Sham stimulation|Patients will receive standard treatment (kinesotherapy, physiotherapy) and simulate of transcranial magnetic stimulation. Also patients will not know about simulation (blind group)
62311157|NCT01652677|EXPERIMENTAL|Both hemispheric stimulation|Stimulation mode: low-frequency to unaffected hemisphere than high-frequency to affected.
62311158|NCT03004014|NO_INTERVENTION|Natural Sleep|OSA subjects referred for surgical treatment will evaluated endoscopically during natural sleep
62311159|NCT03004014|OTHER|Propofol Induced Sleep|"Sleep endoscopy during propofol induced sleep~OSA subjects referred for surgical treatment will be evaluated endoscopically during propofol induced sleep"
62311160|NCT01756976||Investigational Device|The 510k cleared OrthoPAT Advance will be used in this standard of care arm.
62311161|NCT01756976||Control Group|The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.
62311162|NCT00917410|EXPERIMENTAL|SMS intervention|
62311163|NCT05336370|EXPERIMENTAL|Hypnosis|A brief hypnosis session will be provided to participants in this arm prior to immersion in the cold water.
62311164|NCT05336370|EXPERIMENTAL|Active tVNS|Participants in the active tVNS condition will receive electronic stimulation of the vagus nerve prior to immersion in the cold water.
62311165|NCT05336370|SHAM_COMPARATOR|Sham tVNS|Participants in the sham tVNS will receive the electrode similar to the active treatment, but no stimulation will be performed.
62311166|NCT00621023|EXPERIMENTAL|1|Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
62311167|NCT03614624|EXPERIMENTAL|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
62311168|NCT05627193|ACTIVE_COMPARATOR|Traditional out patient clinic|The volunteers of the study randomized into this group will be given traditional outpatient clinic follow up post surgery.
62311169|NCT05627193|ACTIVE_COMPARATOR|Teleclinic|The Volunteer of the study randomized into this group will be given teleclinic appointment for follow up post surgery.
62311170|NCT01690949|EXPERIMENTAL|PUR118 low dose|
62311171|NCT01690949|EXPERIMENTAL|PUR118 mid dose|
62476728|NCT05623735|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization (IASTM) Group While Lying Prone|"The application will take a total of 6 sessions, with two sessions per week for 3 weeks.~While individuals are lying in the prone position, the IASTM protocol will be applied bilaterally on the erector spinae and then on the hamstrings. The application will take approximately 17 minutes."
62476729|NCT05623735|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"While standing in the extended child pose (utthita balasana) stance, the IASTM protocol will be applied bilaterally on the lumbar erector spines, with the hands on them and moving back to the old position. Then, the IASTM protocol will be applied bilaterally on the hamstrings by making consecutive knee flexion-extension up to 90 degrees while the individuals are lying prone.~The application will take approximately 17 minutes."
62476730|NCT03698981|EXPERIMENTAL|Mothers Moving towards Empowerment (MME)|The MME intervention arm will complete our 8-session intervention, weekly for 60-70 minutes per session. Homework will be assigned each week and reviewed the next session. Certificates will be issued to participants who complete the intervention. Fidelity assessments for each session will be evaluated by local research personnel.
62476731|NCT03698981|NO_INTERVENTION|Treatment As Usual (TAU)|Control condition participants will receive Treatment as usual (TAU), including using free ART and antenatal services as they wish. Control condition participants are assessed on all 'Primary outcomes' at the same time points as the MME intervention group.
62311172|NCT01690949|EXPERIMENTAL|PUR118 high dose|
62476732|NCT04673201|ACTIVE_COMPARATOR|Viscotrabeculotomy group|Management of medically uncontrolled steroid induced glaucoma by viscotrabeculomy technique
62476733|NCT04673201|ACTIVE_COMPARATOR|"Trabeculectomy with MMC group"|Management of medically uncontrolled steroid induced glaucoma by trabeculotomy with MMC
62476734|NCT01837810|EXPERIMENTAL|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
62311173|NCT01466725|EXPERIMENTAL|Cohort 1|25 mg daily for 4 weeks (8 active/2 control)
62311174|NCT01466725|EXPERIMENTAL|Cohort 2|50 mg once daily for 4 weeks (8 active/2 control)
62311175|NCT01466725|EXPERIMENTAL|Cohort 3|100 mg daily for 6 weeks (8 active/2 control)
62311176|NCT01466725|EXPERIMENTAL|Cohort 4|100 mg twice daily for 6 weeks (8 active/2 control)
62311177|NCT02975154|ACTIVE_COMPARATOR|Microcurrent therapy, type A|"Microcurrent therapy: Channel A: 100 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10.~Previous treatments will be continued."
62311178|NCT02975154|ACTIVE_COMPARATOR|Microcurrent therapy, type B|Microcurrent therapy: Channel A: 25 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
62311179|NCT02975154|SHAM_COMPARATOR|Sham Microcurrent therapy|Microcurrent therapy: Channel A: 0 µA; 0 Hz; Channel B: 0 µA; 0 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
62311180|NCT02975154|NO_INTERVENTION|No Intervention|No Intervention. Previous treatments will be continued.
62476735|NCT01837810|PLACEBO_COMPARATOR|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
62476736|NCT02223585|EXPERIMENTAL|Cross-over single arm|
62476737|NCT05364853|OTHER|In-Person Testing|In this arm, participants will undergo the neuropsychological assessment of interest (DAYC-2) in-person.
62476738|NCT05364853|OTHER|Remote Testing|In this arm, participants will undergo the neuropsychological assessment of interest (DAYC-2) remotely over video/telehealth.
62681825|NCT02616302|EXPERIMENTAL|Weight >30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh \>30 kg.
62311181|NCT05303675|EXPERIMENTAL|Intervention Group|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
62681826|NCT06694324|EXPERIMENTAL|Liposomal Doxorubicin+Apatinib+Camrelizumab|The patients with advanced or unresectable de-differentiated liposarcoma will be enrolled and given Liposomal doxorubicin hydrochloride: 30 mg/m2, d1, IV over 30 min; apatinib: 250 mg, qd; and karelizumab: 200 mg, d1, IV; Q3W, continued treatment for 6 cycles followed by apatinib and camrelizumab until disease progression, development of unacceptable toxicity, or death of the patient or 2 years of treatment.
62681827|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
62681828|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
62122315|NCT01087762|EXPERIMENTAL|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
62122316|NCT01087762|PLACEBO_COMPARATOR|Placebo|"Matching Placebo to CZP injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16.~After 24 weeks, all subjects were randomized to active treatment with CZP 200 mg Q2W or CZP 400 mg Q4W."
62122317|NCT01087762|OTHER|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
62122318|NCT01087762|OTHER|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
62122319|NCT01087762|OTHER|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
62681829|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
62681830|NCT05685407|EXPERIMENTAL|Caffeine|During one of two counterbalanced experimental sessions, participants will ingest 300mg of caffeine orally via capsules.
62681831|NCT05685407|PLACEBO_COMPARATOR|Placebo|During one of two counterbalanced experimental sessions, participants will ingest placebo orally via capsules.
62122320|NCT01087762|OTHER|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
62122321|NCT00939978|ACTIVE_COMPARATOR|Venoferrum|
61922260|NCT04910373|EXPERIMENTAL|Experimental Extensively Hydrolyzed Formula|Administered during food challenge and at home feeding period
61922261|NCT04910373|PLACEBO_COMPARATOR|Placebo Extensively Hydrolyzed Formula|Administered during food challenge
61922262|NCT02916238|EXPERIMENTAL|Measurement Based Care|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
61922263|NCT02916238|ACTIVE_COMPARATOR|Enhanced Usual Care|Depression symptoms monitored at 3 month interval; results from PHQ-9 available to ART clinic physicians.
62122322|NCT00939978|PLACEBO_COMPARATOR|saline|
62311182|NCT05303675|NO_INTERVENTION|Control Group|"Preoperative: Introductory information form will be filled out. Postoperative: Standard nursing care will be applied to the patients, lymphedema upper extremity circumference measurement and symptom alert model follow-up form will be applied.~Post-Discharge: Lymphedema upper extremity circumference measurement will be explained to the patients before discharge, and they will be asked to record the 1st, 2nd, and 3rd months at home. Patients will be followed up by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
62681832|NCT04849507|ACTIVE_COMPARATOR|active taVNS|We will deliver taVNS via the BabyStrong system, with pulses paired with oral feeding, off with rest during 2 feeds a day. Current will be delivered at 0.1milliAmpere (mA) \< perceptual threshold (PT), 500microseconds, 25 Hertz (Hz).The ear electrode will be positioned on left tragus for active taVNS.
62122323|NCT00529659|EXPERIMENTAL|MK-0773|MK-0773
62122324|NCT00529659|PLACEBO_COMPARATOR|Placebo|Placebo
62122325|NCT02748265|OTHER|Inhaled Epoprostenol, phenylephrine, sevoflurane|Inhaled Epoprostenol (Flolan), phenylephrine, volatile anesthesia maintenance (Sevoflurane)
62122326|NCT02748265|OTHER|Inhaled Epoprostenol phenylephrine & Propofol|Inhaled Epoprostenol (Flolan), phenylephrine and intravenous anesthesia maintenance (Propofol)
62122327|NCT02080650|OTHER|Prostate cancer|Mesenchymal-marker based ferrofluid (c-MET)
62122328|NCT02080650|OTHER|Renal cell carcinoma|Mesenchymal-marker based ferrofluid (c-MET)
62122329|NCT02080650|OTHER|Bladder cancer|Mesenchymal-marker based ferrofluid (c-MET)
61922264|NCT03000127|EXPERIMENTAL|Single arm crossover|All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient
61922265|NCT00291733|ACTIVE_COMPARATOR|1|500mg levetiracetam for one week and 1000mg levetiracetam for one week
62681833|NCT04849507|SHAM_COMPARATOR|sham taVNS|The ear electrode positioned on left tragus as for active taVNS. We will test the PT with active stimulation, and then program a sham setting on the BabyStrong unit to deliver no current after the PT is determined.
62496011|NCT04587167|EXPERIMENTAL|HPV ECHO|Clinics randomly assigned to this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. The intervention has a curriculum of 10 sessions focused on the evidence-based Announcement Approach. Sessions will be 60 minutes in duration and held every other weekly for 4 months at regularly scheduled times.
62122330|NCT02080650|OTHER|Gastric cancer|Mesenchymal-marker based ferrofluid (c-MET)
62311183|NCT02060825||Regional saturation monitor|Patients undergoing surgical repair of hypoplastic left heart syndrome.
62311184|NCT03630068||Patients with hepatocellular carcinoma treated with microwave|
62496012|NCT04587167|EXPERIMENTAL|HPV ECHO+|Clinics randomly assigned to this arm will receive the HPV ECHO intervention plus a systems communication strategy to deliver recall notices to parents who initially decline HPV vaccination. This arm includes 12 primary care clinics in Pennsylvania.
62681834|NCT01340170|EXPERIMENTAL|Soft bone drilling protocol|A soft bone drilling protocol will be used in bone quality 3 and 4
62681835|NCT01340170|ACTIVE_COMPARATOR|Standard drilling protocol|A standard drilling protocol will be used in bone quality 1 and 2
62681836|NCT03702738|EXPERIMENTAL|NAC|Patients will be randomized to receive standard TB treatment with N-acetylcysteine 1200 mg BID x 4 months, followed by 2 months of standard TB treatment alone
62681837|NCT03702738|NO_INTERVENTION|No NAC|Patients will be randomized to receive 6 months standard TB treatment alone
61922266|NCT00291733|PLACEBO_COMPARATOR|2|placebo
61922267|NCT00291733|ACTIVE_COMPARATOR|3|After crossover arm 3 equals arm 1
61922268|NCT00291733|PLACEBO_COMPARATOR|4|After crossover arm 4 equals arm 2
61922269|NCT06184308|EXPERIMENTAL|Piolt (Aim 1) Group: Home-Based Program of Rehabilitation and Health Coaching|5-10 subjects will be assigned to complete 20 minutes of Home-based Physical Rehabilitation and Health Coaching for approximately 12 weeks to test feasibility of the home-based rehabilitation program. This will be the initial phase of the study prior to RCT phase.
61922270|NCT06184308|EXPERIMENTAL|Home-Based Program of Rehabilitation and Health Coaching|Subjects will complete 20 minutes of Home-based Physical Rehabilitation and Health Coaching for approximately 12 weeks.
62122331|NCT02080650|OTHER|Colorectal cancer|Mesenchymal-marker based ferrofluid (c-MET)
62122332|NCT02080650|OTHER|Pancreatic cancer|Mesenchymal-marker based ferrofluid (c-MET)
62122333|NCT02080650|OTHER|Non-small cell lung cancer|Mesenchymal-marker based ferrofluid (c-MET)
62122334|NCT02080650|OTHER|Advanced MET amplified solid tumor|Mesenchymal-marker based ferrofluid (c-MET)
62122335|NCT01195883|ACTIVE_COMPARATOR|Crystalloid|Lactated Ringers solution will be used for fluid replacement.
62122336|NCT01195883|ACTIVE_COMPARATOR|Colloid|Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
62122337|NCT05625282|ACTIVE_COMPARATOR|control|Weil osteotomy and plantar plate repair
62311185|NCT00988962|NO_INTERVENTION|High-Risk No Treatment|
62311186|NCT00988962|EXPERIMENTAL|High-Risk Treatment|
62311187|NCT00988962|NO_INTERVENTION|Low-Risk|
62311188|NCT05760456|EXPERIMENTAL|DIDALA|DIDALA is a herbal medicine, produced from dried mulberry leaves. The drug has been approved by the Drug Administration of Vietnam.
62311189|NCT05760456|ACTIVE_COMPARATOR|METFORMIN|
62681838|NCT01281280||VNS Therapy|
62681839|NCT01281280||Best Medical Practice|
62311190|NCT02511080|ACTIVE_COMPARATOR|Spot-on group|Use active measures against intraoperative hypothermia
62311191|NCT02511080|NO_INTERVENTION|control|standard measures against intraoperative hipothermia
62311192|NCT05337605||Hand driven tissue removal system|Endometrial polyp removed by hysteroscopic hand-driven tissue removal system in a previous study.
62311193|NCT05337605||Motor driven tissue removal system|Endometrial polyp removed by hysteroscopic motor-driven tissue removal system in a previous study.
62311194|NCT03453749|OTHER|Salovum|Patients will be given Salovum 1g/kg body weight/24 hours, divided into 6 dosages and given during 5 consecutive days.
62496013|NCT04587167|NO_INTERVENTION|Control|Clinics randomly assigned to this arm will receive no ECHO interventions. This arm includes 12 primary care clinics in Pennsylvania.
61922271|NCT06184308|NO_INTERVENTION|Usual Care|Subjects will receive clinical standard of care.
62311195|NCT05391763|OTHER|Right: removal of fascia pectoralis, left: preservation of fascia pectoralis|
62311196|NCT05391763|OTHER|Left: removal of fascia pectoralis, right: preservation of fascia pectoralis|
62311197|NCT02325999|EXPERIMENTAL|ESD and LRLD|The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
62311198|NCT02325999|NO_INTERVENTION|Endoscopic Submucosal Dissection (ESD)|The group accept Endoscopic Submucosal Dissection only.
62311199|NCT03373812|ACTIVE_COMPARATOR|anterior approach|patients having involutional ptosis undergoing anterior approach surgical ptosis repair (Levator advancement)
61922272|NCT02728778|ACTIVE_COMPARATOR|Botulinum toxin A|Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.
61922273|NCT02728778|OTHER|Acupuncture|Patients will receive four facial acupuncture treatments every two weeks.
61922274|NCT05982210|NO_INTERVENTION|Control Group|The Control Group does not have any interventions applied.
62122338|NCT05625282|EXPERIMENTAL|intervention|Weil osteotomy alone
62311200|NCT03373812|ACTIVE_COMPARATOR|posterior approach|patients having involutional ptosis undergoing posterior approach surgical ptosis repair (mullerectomy)
62311201|NCT02398123|ACTIVE_COMPARATOR|Transversus abdominis plane block|Transversus Abdominis Plane block
62311202|NCT02398123|PLACEBO_COMPARATOR|Caudal block|Caudal block
62311203|NCT05798962||Acute muscle strain|Subjects with an acute muscle strain (within 14 days post injury) in either the hamstrings or the calf muscles
62496014|NCT05560139|EXPERIMENTAL|experimental group|Participants in the experimental groups received ten -sessions a-tDCS (1.5mA, 20minutes) anodal stimulation of left DLPC over two weeks duration (five sessions per week).
62681840|NCT05128448|EXPERIMENTAL|Mobilisation with movement (MWM)|"With the participant standing, the restricted shoulder will rest on the clinician's shoulder in the following starting position: 90 degrees of glenohumeral abduction and 90 degrees of elbow flexion and hand holding a treatment belt. The belt will loop around the clinician and patient and will be held by the participant's contralateral hand. The clinician will apply and sustain a pain free caudal or posterolateralcaudal humeral head mobilisation force (whichever is more comfortable to the subject), followed by an active internal rotation (IR) performed by the patient. The IR movement will be performed to a pain free end of range. If possible, an overpressure with be requested, this is achieved by pulling the belt with the contralateral hand. The overpressure should not produce pain, if it does, it will not be performed.~3 sets of 8 repetitions will be applied, sustaining the end of available range for 2 seconds. An interval of 45 seconds will be respected amongst the repetitions."
61922275|NCT05982210|EXPERIMENTAL|Intervention Group|The Intervention Group will take part in the experimental process. A clinical practice protocol about breathing exercises and diaphragm and ribs manual therapy will be applied, in a total duration of 15 minutes, twice a week during eight weeks.
61922276|NCT04870736||Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
61922277|NCT04870736||Resusci Anne QCPR AED (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
62681841|NCT05128448|ACTIVE_COMPARATOR|Cross-body stretch|With the participant standing, the restricted shoulder will be self-stretched by conducting a horizontal adduction in 90 degrees of shoulder flexion to a level tolerated by the participant. This position will be held for thirty seconds and repeated four times. An interval of forty five seconds will be respected amongst the repetitions.
62681842|NCT05186077||Healthy Controls|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
62681843|NCT05186077||Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
61922278|NCT04870736||Resusci Baby QCPR (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
61922279|NCT04914416|PLACEBO_COMPARATOR|Verum T1|
61922280|NCT04914416|EXPERIMENTAL|Verum T2|
61922281|NCT04914416|EXPERIMENTAL|Verum T3|
61922282|NCT04914416|EXPERIMENTAL|Verum T4|
62681844|NCT05186077||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed or manic with their current episode lasting at least 6months and not responding to 2 or more adequate evidence-based treatments for BDI or BDII.
62681845|NCT06691503|EXPERIMENTAL|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)|
62681846|NCT02631031|OTHER|morning administration|administration of single oral dose valsartan (160 mg) in the morning
61922283|NCT04914416|EXPERIMENTAL|Verum T5|
61922284|NCT04914416|EXPERIMENTAL|Verum T6|
61922285|NCT04914416|EXPERIMENTAL|Verum T7|
62681847|NCT02631031|OTHER|evening administration|administration of single oral dose valsartan (160 mg) in the evening
62681848|NCT06603831|EXPERIMENTAL|3D digital surgery group|
62681849|NCT06603831|ACTIVE_COMPARATOR|2D conventional surgery group|
62681850|NCT03288025|EXPERIMENTAL|Nutrition and Exercise|5 days a week of moderate exercise and biweekly diet counseling on Low Glycemic Index/ Mediterranean Diet for 12 weeks.
62681851|NCT03288025|NO_INTERVENTION|Standard of Care|Counseling at baseline on diet as recommended by USDA and on the benefits of regular aerobic exercise.
62681852|NCT06689163|EXPERIMENTAL|HRS-1167 combined with abiraterone acetate tablets (II) and prednisone|
61922286|NCT04914416|EXPERIMENTAL|Verum T8|
61922287|NCT04914416|EXPERIMENTAL|Verum T9|
61922288|NCT04914416|EXPERIMENTAL|Verum T10|
61922289|NCT04914416|EXPERIMENTAL|Verum T11|
61922290|NCT04914416|EXPERIMENTAL|Verum T12|
61922291|NCT04914416|EXPERIMENTAL|Verum T13|
61922292|NCT04914416|EXPERIMENTAL|Verum T14|
61922293|NCT04914416|EXPERIMENTAL|Verum T15|
61922294|NCT04914416|EXPERIMENTAL|Verum T16|
61922295|NCT04914416|PLACEBO_COMPARATOR|Verum T17|
61922296|NCT01858584|EXPERIMENTAL|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
61922297|NCT01858584|ACTIVE_COMPARATOR|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
61922298|NCT01858584|NO_INTERVENTION|control group|
61922299|NCT04741178||Patient with Covid-pneumonia|Patient with CT scan of pulmonary infiltrates suggestive of Covid pneumonia
62122339|NCT04293705|EXPERIMENTAL|regular TOPS group|Patients are required to perform the regular TOPS program, composed of 10 core sessions and other eventual supplementary sessions. In addition, biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim to monitor patients' activities on problem-solving related to the TOPS program contents and the problem solving process in real life. The program has a specific focus on problem-solving, executive functions, behavioral strategies and social skills.
62311204|NCT05798962||Chronic muscle strain|Subjects with a chronic muscle strain more than 6 months prior to inclusion in either the hamstrings or the calf muscles
62311205|NCT05798962||Achilles tendon rupture|Subjects with a full Achilles tendon rupture more than 12 months prior to inclusion
62311206|NCT04312997|EXPERIMENTAL|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3 and 6
62311207|NCT04312997|PLACEBO_COMPARATOR|Sterile saline for inhalation|Sterile saline for Inhalation given by nebulization on Study Days 1, 3 and 6
62311208|NCT06218589|EXPERIMENTAL|Velacur Ultrasound|Patients 2 to 20 years of age with suspicion of MASLD or presenting to liver clinic for evaluation of liver disease, including possible MASLD receiving a Velacur ultrasound.
62311209|NCT06533384|EXPERIMENTAL|Experimental ARM|In the experimental group, patients with confirmed deleterious mutations based on germline BRCA1/2 status receive a combination of Fuzuloparib and Camrelizumab as adjuvant therapy. Patients without germline BRCA1/2 deleterious mutations receive a combination of capecitabine and Camrelizumab as adjuvant therapy.
62311210|NCT06533384|ACTIVE_COMPARATOR|Control ARM|9 cycles of Camrelizumab as adjuvant therapy.
62311211|NCT05775406|EXPERIMENTAL|Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and Lymphomas|KT-253 dosed intravenous (IV) once every three weeks in 21-day cycles
62311212|NCT05775406|EXPERIMENTAL|Phase 1 Dose Escalation Arm B in patients with R/R High Grade Myeloid Malignancies and ALL|KT-253 dosed IV once every three weeks in 21-day cycles
62311213|NCT02132338|EXPERIMENTAL|The Education Health Program|Intervention forth knowledge and attitudes necessary for self-care
62311214|NCT06207877|EXPERIMENTAL|CagriSema|Participants will receive dose 1 cagrilintide and dose 2 semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) during the maintenance period of 5 weeks.
62311215|NCT06207877|ACTIVE_COMPARATOR|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously once-weekly for 21 weeks.
62311216|NCT03183635|EXPERIMENTAL|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
62311217|NCT03183635|PLACEBO_COMPARATOR|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
62311218|NCT05018338||The study cohort|The study will enroll 10 subjects meeting the eligibility criteria, with the expectation to obtain complete data from at least 6 subjects.
62476739|NCT01239862|EXPERIMENTAL|Autologous cell transplantation|We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion criteria were age 18-50 years, chronic and accelerated silicosis, forced expiratory volume in 1s \<60% and \>40%, forced vital capacity ≥60% and arterial oxygen saturation \>90%. BMDMCs were administered through bronchoscopy (2×107 cells) into both lungs. Physical examination, laboratory evaluations, quality of life questionnaires, thoracic computed tomography scans, lung function tests, and perfusion scintigraphy were performed before the beginning of treatment and up to 360 days after BMDMC (Bone Marrow Derived Mononuclear Cells) therapy. Additionally, whole-body and planar scans were evaluated 2 and 24 h after instillation.
62476740|NCT00833586|EXPERIMENTAL|Terbinafine|Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
62311219|NCT02721004||Rheumatoid arthritis participants|Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
62311220|NCT02094846|ACTIVE_COMPARATOR|Voice messages|This group receive voice messages to reinforce given information about diet, physical activity, glycemic index
62311221|NCT02094846|PLACEBO_COMPARATOR|Messages|This group received voice messages with fun facts.
62311222|NCT01704872|EXPERIMENTAL|dose level finding ch14.18/CHO|A dose escalation design based on Phase I rules starting at 10 mg/m2/day ch14.18/CHO. This is 50% below the dose of ch14.18/SP2/0 used in a large cohort of patients. Dose escalation will be adapted to a modified Fibonacci series aiming at 10, 20 and 30 mg/m2 of ch14.18/CHO. Since this study is a bridging study aiming at a reassessment of the toxicity and determination of the pharmacokinetics of ch14.18/CHO, only a limited number of dose escalation steps (3) is implemented in the design.
62476741|NCT00833586|ACTIVE_COMPARATOR|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
62311223|NCT01690234|EXPERIMENTAL|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
62311224|NCT01690234|ACTIVE_COMPARATOR|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
62681853|NCT06689293||Study group|Participants aged over 18 with previous colorectal cancer resection for curative intent, excluding those with current ileostomy or recurrent cancer.
62476742|NCT05086003|EXPERIMENTAL|Kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation after preparation with thymoglobuline and total lymphoid irradiation
62476743|NCT04596007|EXPERIMENTAL|HEC83518 tablets|There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
61922300|NCT04529473|PLACEBO_COMPARATOR|Placebo|1 capsule per day, consumed orally, before breakfast for the duration of the study.
62311225|NCT05886192|EXPERIMENTAL|norepinephrine+vasopressin|norepinephrine+vasopressin
62311226|NCT05886192|PLACEBO_COMPARATOR|Norepinephrine|norepinephrine
62311227|NCT03070132|EXPERIMENTAL|BIIB074|Optimized oral dose three times daily (TID)
62311228|NCT03070132|EXPERIMENTAL|Placebo|Administered orally TID
62311229|NCT06361459|EXPERIMENTAL|Stop smoking|patients are stimulated to stop smoking, using the Sine Fuma program. after 4 weeks nicotine in urine will be tested. if stopped: planned for surgery. 4 weeks after surgery nicotine in urine is checked again. will be planned for surgery and evaluated
62311230|NCT06361459|ACTIVE_COMPARATOR|Continues smoking|will be planned for surgery and evaluated
62311231|NCT06361459|NO_INTERVENTION|Does not smoke|will be planned for surgery and evaluated
62311232|NCT02924675|EXPERIMENTAL|pregabalin group|
62311233|NCT02924675|PLACEBO_COMPARATOR|Placebo group|
62311234|NCT02357277|EXPERIMENTAL|Budesonide 360 mcg|Budesonide dry powder inhaler 2 puffs of 90 mcg twice daily for 4 weeks
62311235|NCT02357277|EXPERIMENTAL|Budesonide 720 mcg|Budesonide dry powder inhaler 2 puffs of 180 mcg twice daily for 4 weeks
62311236|NCT02357277|PLACEBO_COMPARATOR|Placebo|Placebo inhaler 2 puffs twice daily for 4 weeks
62311237|NCT01972425|EXPERIMENTAL|Biomarker-based diagnostic|Analyse sample on arrival
62311238|NCT01972425|NO_INTERVENTION|Routine use of antibiotics|Do not analyse the sample on arrival
62476744|NCT04596007|PLACEBO_COMPARATOR|placebo tablets|There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
62311239|NCT01450371||Interferential|The individuals are treated acutely with interferential electrical stimulation (IES) during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
62311240|NCT01450371||Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
62476745|NCT03656367|EXPERIMENTAL|All subjects|"Cross-over study (all subjects receive all interventions)~* Cheddar cheese~* Blended and homogenized cheddar cheese~* An analog milk~* An analog cheese"
61922301|NCT04529473|EXPERIMENTAL|Eubacterium hallii|1 capsule per day, consumed orally, before breakfast for the duration of the study.
61922302|NCT03373799|EXPERIMENTAL|Group 1|Video-Based Rehabilitation Group
61922303|NCT03373799|ACTIVE_COMPARATOR|Group 2|Physiotherapist-Supervised Rehabilitation Group
61922304|NCT05395273|EXPERIMENTAL|Cryocompression + standard therapy|Participants received daily crycompression by the patient to their comfort level beside the standard therapy.
62311241|NCT05243329|EXPERIMENTAL|Psilocybin treatment for treatment-resistant PTSD|"Experimental Treatment:~Experimental: Psilocybin~10mg (low dose) on Day 7~25mg (high dose) on Day 14~10mg dose (optional top-up low dose) at Month 7~Treatment Description:~Drug: Psilocybin drug product suspension~Psilocybin is manufactured as a bulk API powder. The psilocybin drug product suspension is prepared by a compounding pharmacist at the clinic site. The psilocybin drug product suspension will be mixed in a glass with water to produce the psilocybin solution for oral consumption. Subjects will be instructed to orally consume the study medication in the glass in its entirety.~Psilocybin will be administered in the following doses and at the following time points for this study:~* 1 mL of 10mg/mL (low dose) on Day 7 (10 mg)~* 2.5 mL of 10 mg/mL (high dose) on Day 14 (25 mg)~* \[Optional dose\] 1 mL of 10mg/mL (low dose) on Month 7/Day 210 (10 mg)"
62311242|NCT06672289||Pericapsular Nerve Block (PENG)|Patients will be monitored with routine monitoring under operating room conditions. After the patient's baseline VAS score and vital signs are recorded, patients will be intubated after induction of general anesthesia. After the site is cleaned, pericapsular nerve block (PENG) will be applied under USG guidance. After the procedure, the patient will be transferred to the surgical team for positioning. Blood pressure and pulse values will be recorded after the procedure and at the 30th minute of surgery. After the patients wake up, another anesthesiologist in the recovery unit will rate the pain of patients in both groups on a scale of 0-10, using the Visual Analogue Scale (VAS) to describe their pain intensity. Heart rates and noninvasive blood pressures of patients taken to the recovery unit will be measured and recorded.
62476746|NCT03656367|OTHER|Healthy subjects only (subgroup)|"If any subjects (against our hypothesis) have indices of metabolic syndrome i.e. raised fasting glucose or TG concentration, secondary analyses will be conducted to assess results without these subjects.~All subjects receive all interventions)~* Cheddar cheese~* Blended and homogenized cheddar cheese~* An analog milk~* An analog cheese"
62311243|NCT06672289||Suprainguinal Fascia Iliaca Block (SFIB)|Patients will be monitored with routine monitoring under operating room conditions. After the patient's baseline VAS score and vital signs are recorded, patients will be intubated after induction of general anesthesia. After the site is cleaned, suprainguinal fascia iliaca block (SFIB) will be applied under USG guidance. After the procedure, the patient will be transferred to the surgical team for positioning. Blood pressure and pulse values will be recorded after the procedure and at the 30th minute of surgery. After the patients wake up, another anesthesiologist in the recovery unit will rate the pain of patients in both groups on a scale of 0-10, using the Visual Analogue Scale (VAS) to describe their pain intensity. Heart rates and noninvasive blood pressures of patients taken to the recovery unit will be measured and recorded.
62311244|NCT01986205|EXPERIMENTAL|Hyperbaric Oxygen|100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
62311245|NCT01986205|PLACEBO_COMPARATOR|Minimal pressure air|Regular air at minimal pressurization for 60 minutes, 40 sessions
62311246|NCT04044547|EXPERIMENTAL|LY03003|
62311247|NCT04044547|PLACEBO_COMPARATOR|Placebo|
62311248|NCT01842464||Anterior Sacro-Spinous Support|Anterior sacro-spinous mesh implants supported patients
62311249|NCT05652192|EXPERIMENTAL|Experimental|"SBRT: Metastases were treated with SBRT, GTV 45Gy/3F/3d, each course of radiotherapy only treated metastases within 1 organ.~Chemotherapy(GP or TP) was combined with tislelizumab for 4-6 cycles and tislelizumab was maintained until 2 years or disease progression or intolerable toxicity or death.~Maintain: (1) For newly diagnosed metastatic patients, nasopharyngeal and metastatic lymph node irradiation was started 4 weeks after systemic therapy, using IMRT technique, only radiating the GTV of the nasopharyngeal and cervical region, DT 66 Gy/30 F/6 weeks was recommended. Tislelizumab was continued during radiotherapy and tislelizumab was used during maintenance."
62311250|NCT03728361|EXPERIMENTAL|Treatment (nivolumab, temozolomide)|Patients receive nivolumab IV on day 1 of a 28 day cycle. Patients also receive temozolomide PO on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62311251|NCT03524872|ACTIVE_COMPARATOR|Original CAD/CAM abutment|Patients will be rehabilitated using Sweden\&Martina implants and original (Sweden\&Martina) CAD/CAM abutments.
62311252|NCT03524872|EXPERIMENTAL|Compatible CAD/CAM abutment|Patients will be rehabilitated using Sweden\&Martina implants and compatible (New Ancorvis) CAD/CAM abutments.
62311253|NCT03183921||Cases|All ICU patients with nosocomial lower respiratory tract infection
62311254|NCT05107414||Journey II Bi-Cruciate Stabilized|Participants who have been implanted with a Smith \& Nephew Journey II BCS TKA
62311255|NCT05107414||Journey II Cruciate Retaining|Participants who have been implanted with a Smith \& Nephew Journey II CR TKA
62311256|NCT05107414||Journey II Bi-Cruciate Retaining|Participants who have been implanted with a Smith \& Nephew Journey II BCR TKA
62311257|NCT02031146|OTHER|LP|Participants undergo lumbar puncture for CSF evaluation
62311258|NCT02031146|NO_INTERVENTION|No LP|Participants do not undergo lumbar puncture and CSF is not examined.
62311259|NCT03606746|EXPERIMENTAL|Investigational Arm|A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.
62311260|NCT01548664|EXPERIMENTAL|Nintendo Wii FitTM|Fifteen minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
62311261|NCT01548664|ACTIVE_COMPARATOR|Lower extremity exercise|Fifteen minutes of lower extremity exercises that addressed balance, posture, weight shifting and strengthening were provided bilaterally, following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area
62311262|NCT05015361|EXPERIMENTAL|Treatment group A/B|Treatment group A: Remimazolam Tosilate Treatment group B: Remimazolam Tosilate
62311263|NCT05015361|ACTIVE_COMPARATOR|Treatment group C|Treatment group C: Propofol Injection.
62476747|NCT01083719|EXPERIMENTAL|FDG-PET|A comparison of FDG-PET versus MRI based target volume delineation in glioblastoma and the role of FDG-PET/CT in the alteration of MRI based target volumes.
62311264|NCT05522114|EXPERIMENTAL|Patient specific guided injection|Patients treated with HA injection in TMJ using PSG and the accuracy evaluated using MSCT.
62311265|NCT02773992||The IoT group|
62311266|NCT02773992||The routine management group|
62311267|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
62311268|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
62311269|NCT03123523||Patients group|35 patients
62311270|NCT03123523||Healthy volunteers|20 healthy volunteers
62311271|NCT05025488|EXPERIMENTAL|CALR mutated|peptide-based vaccine in patients with myeloproliferative neoplasm (myelofibrosis and essential thrombocythemia) with CALR mutations
62311272|NCT05014074|EXPERIMENTAL|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
62311273|NCT01714583||High PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) greater than or equal to 12cm.
62311274|NCT01714583||Low PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) less than 12cm.
62311275|NCT01161524|EXPERIMENTAL|Perampenal (Core Study)|Participants received perampanel 2 mg per day and up-titrated weekly in 2-mg increments to a target dose range of 8 to 12 mg per day.
62311276|NCT01161524|PLACEBO_COMPARATOR|Placebo (Core Study)|Participants received matching placebo tablets once a day (6 tablets of placebo).
62311277|NCT01161524|EXPERIMENTAL|Perampanel (Extension Phase)|During the Extension Phase, participants previously assigned to perampanel arm (Core Study) continued taking study medication at the dose achieved at the end of the Core Study once daily. Participants previously assigned to a placebo arm (Core Study) started perampanel dose at 2 mg/day and up-titrated weekly in 2-mg increments up to a maximum dose of 12 mg/day.
62476748|NCT04028440|EXPERIMENTAL|Autologous γδT cells|Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions, single infusion intravenously at a target dose of 1\~2×10e9 γδT cells (constant dose).
62476749|NCT06510998|EXPERIMENTAL|Isometric exercise|"2 minutes wall squat, with 2 minutes rest between sets~* to perform 4 sets in total/day~* at least 3 days/week~* totally for 24-weeks"
61922305|NCT05395273|NO_INTERVENTION|Standard therapy|The standard therapy include the common physical therapy interventions, which are normally used in the hospital.
62122340|NCT04293705|ACTIVE_COMPARATOR|modified TOPS group|Patients are required to perform the modified TOPS program, composed of 10 sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim of monitoring training adherence and discuss the program's contents.
62122341|NCT00376519|EXPERIMENTAL|Transplant with Treg Cells|Patients receive preparative therapy with Fludarabine, cyclophosphamide, total body irradiation and Treg infusion followed by umbilical cord blood transplantation.
62122342|NCT00235508|ACTIVE_COMPARATOR|1|Escitalopram oxalate 10 mg at bedtime
62122343|NCT00235508|ACTIVE_COMPARATOR|2|Eszopiclone 3 mg at bedtime
62122344|NCT03522337|PLACEBO_COMPARATOR|Control group|The main intervention is conventional leaflets. Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by leaflets.
62311278|NCT03987399|EXPERIMENTAL|Tailored educational intervention|The intervention will be based on previous research and results from baseline (T1). The intervention will be a one-day educational day and includes lectures and workshops with main focus on the lowest competence in pediatric postoperative pain management. Healthcare providers at the included surgical wards will be invited to participate on this educational day. As a supplement, there will be provided clinical supervision in pediatric postoperative pain management and reminders (such as lectures and posters) over a period of six months after educational day.
62311279|NCT02467114|EXPERIMENTAL|All study participants|Stimulation with TMS, a sham coil \& no intervention
62311280|NCT06672159|EXPERIMENTAL|Double sequential external defibrillation|Patient will receive first shock using two defibrillators. All other aspects of resuscitation in accordance to existing guidelines.
62311281|NCT06672159|ACTIVE_COMPARATOR|Standard treatment|Standard treatment in accordance to existing Advanced Cardiopulmonary Resuscitation-guidelines using one defibrillator in anterior-lateral placement.
62311282|NCT03886077||Hepatitis C Negative Donor Hearts|Hearts for transplantation that are not infected with Hepatitis C. (Negative NAT)
62311283|NCT03886077||Hepatitis C Infected Donor Hearts|Hearts for transplantation that are infected with Hepatitis C. (Positive NAT).
62311284|NCT06251388|EXPERIMENTAL|treatment group|AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W） after CCRT
62311285|NCT02522481|EXPERIMENTAL|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
62311286|NCT03193905|OTHER|Cotton blanket|30 hypothermia patients undergo the standard procedure with a cotton blanket during major spinal surgery
62311287|NCT03193905|OTHER|Bairhugger Full Access Underbody blanket|30 hypothermia patients undergo the Bairhugger Full Access Underbody blanket procedure during major spinal surgery (new procedure)
62311288|NCT01654575|EXPERIMENTAL|Methotrexate|25mg/week orally
62311289|NCT01654575|ACTIVE_COMPARATOR|Placebo|"Placebo-sugar tablets identical in colour and shape to methotrexate given once a week for 16 weeks."
62311290|NCT01743027|EXPERIMENTAL|AL-4943A|AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
62311291|NCT01743027|ACTIVE_COMPARATOR|PATADAY|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
62311292|NCT01743027|ACTIVE_COMPARATOR|PATANOL|Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
62311293|NCT01743027|PLACEBO_COMPARATOR|Vehicle|AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
62311294|NCT00379483|EXPERIMENTAL|Arm 1|
62476750|NCT06510998|ACTIVE_COMPARATOR|passive stretching|"14 minutes passive stretching~* at least 3 days/week~* totally 24-weeks"
61922306|NCT06400927|EXPERIMENTAL|VA-guided arm|
61922307|NCT06400927|PLACEBO_COMPARATOR|Standard-of-care arm|
61922308|NCT01076075|ACTIVE_COMPARATOR|placebo/pioglitazone|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
61922309|NCT01076075|EXPERIMENTAL|Sitagliptin|Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone
61922310|NCT01187719|NO_INTERVENTION|Control|ARV prophylaxis for PMTCT follows national guidelines.
62122345|NCT03522337|EXPERIMENTAL|Test group|The main intervention is visual pedagogy (social stories). Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by social stories.
62122346|NCT05090930|ACTIVE_COMPARATOR|Intervention team (1/1 group)|"An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure...~(10 patients)"
62122347|NCT05090930|ACTIVE_COMPARATOR|Intervention team (1/2 group)|An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure (10 patients).
62122348|NCT05090930|ACTIVE_COMPARATOR|Intervention team (1/3 group)|An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients).
62122349|NCT05090930|ACTIVE_COMPARATOR|Intervention team (1/4 group)|An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients).
62122350|NCT05090930|ACTIVE_COMPARATOR|Intervention team (2/1 groups)|"An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure.~(10 patients)"
62122351|NCT05090930|ACTIVE_COMPARATOR|Intervention team (2/2 groups)|"An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure.~(10 patients)"
62122352|NCT05090930|ACTIVE_COMPARATOR|Intervention team (2/3 groups)|An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients)
62122353|NCT05090930|ACTIVE_COMPARATOR|Intervention team (2/4 groups)|An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients)
62122354|NCT05668819|EXPERIMENTAL|TH-001|
62122355|NCT05668819|NO_INTERVENTION|Control|
62122356|NCT00788853||A|
61922311|NCT01187719|EXPERIMENTAL|phenytoin interaction|ARV prophylaxis for PMTCT follows national guidelines + start phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
62681854|NCT06691191|ACTIVE_COMPARATOR|Ticagrelor monotherapy|Ticagrelor 90 mg bid monotherapy for 21±7 days
62681855|NCT06691191|EXPERIMENTAL|Prasugrel monotherapy|Prasugrel 10 mg qd for 21±7 days
62122357|NCT01729169||Sarcoidosis patients|Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
62122358|NCT05892055||Healthy Control (HC)|Healthy controls (HC) will not have an FAPD diagnosis. The HC group receives the same procedures as the FAPD group.
62122359|NCT05892055||FAPD|Children in the FAPD group will be recruited based on the presence of an FAPD diagnosis and receive the same procedures as the HC group.
62122360|NCT04763044|OTHER|Period 1|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62122361|NCT04763044|OTHER|Period 2|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62122362|NCT04763044|OTHER|Period 3|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62681856|NCT06691607||Group A|Group A progressed to AKI
62681857|NCT06691607||Group B|Group B did not progress to AKI
62122363|NCT04763044|OTHER|Period 4|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
62122364|NCT04763044|OTHER|Period 5|1100 ppm SnF2 toothpaste only
62122365|NCT05471635||Countries worldwide|Every country in the world for which vaccination data were available and variables of interest were accessible.
62122366|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (\<50 copies/ml).
62122367|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
62122368|NCT04996680|EXPERIMENTAL|Blood flow restriction group|patients in this group will undergo a standard strength training program combined with an occlusion cuff. The cuff will reduce the amount of blood flow and therefore increase the metabolic stimulus. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
62122369|NCT04996680|SHAM_COMPARATOR|Sham group|patients in this group will undergo the same standard strength training program as the BFR-group, combined with an occlusion cuff but pressurized so there is no significant effect on the lower limb blood flow. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
62122370|NCT04996680|ACTIVE_COMPARATOR|Control group|patients in this group will undergo the same standard strength training program as the BFR-group and placebo-group, but without a tourniquet.
62496015|NCT05560139|SHAM_COMPARATOR|sham group|The sham group received ten sessions of sham stimulation for 20-minutes in each session.
62122371|NCT06553261||Patients after laparoscopic right hemicolectomy|Patients who had undergone a laparoscopic tight colectomy and had anastomotic leak.
62122372|NCT06553261||Patients after open right hemicolectomy|Patients who had undergone a laparoscopic tight colectomy and had anastomotic leak.
61922312|NCT00442468||All participants|This is a cross-sectional, non-interventional study. All enrolled subjects were asked to complete a questionnaire and pulmonary function test to assess the prevalence of airflow obstruction.
61922313|NCT06387160||ACLF|"1. Age - 18-75 years~2. Patients with ACLF(as per APASL guidelines)"
61922314|NCT02312882|EXPERIMENTAL|Tofacitinib|Participants will receive tofacitinib for 3 months.
61922315|NCT00423696|EXPERIMENTAL|bevacizumab + FOLFIRI|
62122373|NCT00837278||1 IVF|Pregnancies conceived with the use of assisted reproductive technologies. This is defined as a pregnancy conceived with all gametes being handled outside of the body.
61922316|NCT00423696|EXPERIMENTAL|bevacizumab + XELIRI|
61922317|NCT05868720|EXPERIMENTAL|Risperidone group|
62122374|NCT00837278||2 Control|Spontaneously conceived pregnancies.
62122375|NCT04233632|ACTIVE_COMPARATOR|FC2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit.
62122376|NCT04233632|ACTIVE_COMPARATOR|Cupid Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
62122377|NCT04233632|ACTIVE_COMPARATOR|Cupid 2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
62496016|NCT04848207|OTHER|Digital impression technique|- 3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
62496017|NCT04848207|OTHER|Open tray impression technique|"* Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~* A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
62496018|NCT04598958|EXPERIMENTAL|IMPROVE|A cluster of 6 health facilities are to receive the IMPROVE Intervention. The IMPROVE intervention includes: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees with particular attention to HIV-positive women to minimize loss to follow-up.
62476751|NCT05421286||PLWH ≥50 years old|"HIV-1 positive persons, Age ≥50 years old, prospectively followed in a EuroSIDA site~Exclusion Criteria: Creatine Clearance \<50, Child-Pugh C end-stage liver disease, Any ongoing severe life-threatening disease, Experiencing any of the following events prior to inclusion: myocardial infarction, stroke, an invasive cardiovascular procedure, AIDS-defining infections (diagnosed with 5 years of MISTRAL enrolment), and prior AIDS cancer on non-AIDS cancers (excluding non-melanoma skin cancers)"
62476752|NCT04630795||3D printed insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest, while the Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
62476753|NCT04267276|EXPERIMENTAL|Part 1: BI 1265162 - intravenous|
62476754|NCT04267276|EXPERIMENTAL|Part 2: BI 1265162 - oral|
62476755|NCT02080663||Proximal row carpectomy|Proximal row carpectomy
62476756|NCT05015114||Primary Sjogren's Syndrome|Participants with Primary Sjogren's Syndrome
62681858|NCT06686511||- Group A|"Will ask them to close their nose completely by their hands and take their breath only from the mouth for 2 to 3 minutes before induction of GA.~: immediately after extubation we will tell them many times at their ear that the operation has been finished and ask them to take their breath from the mouth as they counselled and trained at preoperative period"
61922318|NCT05868720|EXPERIMENTAL|Aripiprazole group|
62311295|NCT01411410|EXPERIMENTAL|Copanlisib (BAY80-6946)|The treatment of consists of repetitive cycles, each over 4 weeks. It continues until disease progression or limiting toxicity. If paclitaxel is discontinued for toxicity, BAY80-6946 may continue at the discretion of the investigator if a clinical benefit (response or stable disease for 6 months) is noted.
62311296|NCT00639067||1|"Asymptomatic High Risk Subjects. Smokers aged \>=18 undergoing chest CT.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
62476757|NCT05015114||Control group|Healthy controls
62476758|NCT01686477|ACTIVE_COMPARATOR|Unfortified Human Donor Milk|Used to make up any shortfall in mother's own milk
62476759|NCT01686477|ACTIVE_COMPARATOR|Fortified Human Donor Milk|Used to make up any shortfall in mother's own milk
62476760|NCT01686477|ACTIVE_COMPARATOR|Preterm Formula|Used to make up any shortfall in mother's own milk
62476761|NCT04533269|EXPERIMENTAL|Active|Arnica montana and Ledum palustre infused Pad
62681859|NCT06686511||● Group B|"Will start the induction of anesthesia without any preoperative counselling of nasal closure .~this group will undergo extubation and should be instructed to use their nose for breathing without Without preoperative counselling"
62681860|NCT06591975||Individials with Parkinson's Disease|Parkinson's Disease patients will be included in this study. Inclusion and exclusion criteria will be considered.
62681861|NCT06411158|ACTIVE_COMPARATOR|Interventionist-guided training|Interventionist-guided training at baseline, followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session, and then continued HEP. Home exercises will be encouraged/ augmented using a PFDN research smartphone app.
62681862|NCT06411158|ACTIVE_COMPARATOR|Home pelvic floor exercises guided by the leva® device|Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. The PFDN research smartphone app will have weekly queries of whether exercises were completed.
61922319|NCT04431427|ACTIVE_COMPARATOR|Partially Covered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
62122378|NCT02561039|EXPERIMENTAL|Ibandronate IV Infusion|Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
62122379|NCT02561039|EXPERIMENTAL|Ibandronate PO Tablet|Participants will receive ibandronate, 50 mg PO daily, for 4 months.
62122380|NCT05201976|ACTIVE_COMPARATOR|Intervention|Virtual cardiac rehab program delivered through the CardaHealth platform.
62122381|NCT05201976|ACTIVE_COMPARATOR|Control|Clinically ordered standard of care cardiac rehab program (in-person).
62122382|NCT05335798|EXPERIMENTAL|Adults with Cerebral Palsy|Adults with Cerebral Palsy who are able to be self-ambulatory for minimum 100 feet
62122383|NCT04647786|EXPERIMENTAL|Humidified and Augmented gas flows|
62476762|NCT04533269|PLACEBO_COMPARATOR|Placebo|Pad (Matching appearance with Active)
62476763|NCT01425086||Incubator temperature support|Infant will be cared for in the current ongoing policy-driven temperature support provided by the incubator and handling as per bedside nursing interventions. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 weeks).
62476764|NCT01425086||Embrace blanket warming|Infant will be placed and wrapped in the embrace blanket and cared for and monitored for temperature support and monitored by bedside nursing interventions, as needed. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 week
62681863|NCT06411158|OTHER|Education|Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
62681864|NCT04305652|NO_INTERVENTION|Control group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below )
62681865|NCT04305652|EXPERIMENTAL|Experimental group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below) The caregivers of Alzheimer's patients will be trained for 3 months according to the Progressively Lowered Stress Threshold Model with a home visit.
62122384|NCT04647786|EXPERIMENTAL|Humidified but not Augmented gas flows|
62122385|NCT04647786|EXPERIMENTAL|Not Humidified but Augmented gas flows|
62122386|NCT04647786|NO_INTERVENTION|Neither humidified nor augmented gas flows|
62122387|NCT04647786|EXPERIMENTAL|Use of finalised device (SEA CtV) in final phase|
62122388|NCT04647786|NO_INTERVENTION|Standard care (no SEA CtV)|
62122389|NCT00232349|EXPERIMENTAL|Intervention group|All subjects enrolled in study are in the intervention group.
62122390|NCT01662336||Lopinavir/Ritonavir + KASA|Patients were treated according to the standard of care provided by their respective study sites. Treatments with LPV/r and participation in the KASA program were according to the decision of the treating physician and the participant, and were not affected in any way by their decision to participate in the study.
62122391|NCT01368016|EXPERIMENTAL|Experimental NRT|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits.
62122392|NCT01368016|ACTIVE_COMPARATOR|Nicotine GUM|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits.
62122393|NCT04962282||group 1|Follow-up by telephone for researching compliance of patients receiving exercise prescriptions
62122394|NCT00473811|ACTIVE_COMPARATOR|ADA diet|Patients will be encouarged to consume foods consisted with ADA dietary recommendation
62122395|NCT00473811|EXPERIMENTAL|Low-GI|a low GI dietary education
62122396|NCT05452720|EXPERIMENTAL|Experimental Arm|This is a single-arm study. All participants in this study will undergo implantation with MASA Valve.
62122397|NCT00366873|ACTIVE_COMPARATOR|1|cow-milk based infant formula
62122398|NCT00366873|EXPERIMENTAL|2|cow-milk based infant formula with prebiotics
62122399|NCT03891927|EXPERIMENTAL|olive group|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO ( high polypheol Extra virgin olive oil)
62122400|NCT03891927|NO_INTERVENTION|non olive group|No intervention
62122401|NCT03370796|EXPERIMENTAL|Reminiscence Therapy|The Reminiscence program will consist of a set of sessions thematically sequenced topics that address the life course of the participant. Each session will integrate a group of activities that will be developed in group and will have a didactic character, privileging subjective interests and interpersonal communication.
62122402|NCT03370796|NO_INTERVENTION|Control Group|The control group shall participate in the institutional care provided by the professionals of each RSE.
62122403|NCT04297306|ACTIVE_COMPARATOR|Exercise prescription|"This group will be provided with a prescript exercise program, taken from UK National Guidance.~The advice will be directed to be undertaken for 6 weeks immediately prior to surgery."
62476765|NCT04876157|EXPERIMENTAL|Artificial intelligence-aimed ultrasound image interpretation|
62311297|NCT00639067||2|"Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
62476766|NCT03948022|ACTIVE_COMPARATOR|intramuscular progesterone|progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.
62476767|NCT03948022|ACTIVE_COMPARATOR|vaginal progesterone|crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.
62476768|NCT03948022|EXPERIMENTAL|oral dydrogesterone|oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)
62122404|NCT04297306|EXPERIMENTAL|Exercise prescription and Virtual Reality Exercise Gaming|"This group will be provided with a prescript exercise program as in Arm 1. However, this group of patients will also be presented with a Virtual Reality Headset, pre-programmed with Exercise promoted games which will be provided to support and encourage their exercise regimen.~Again this advice and support will be directed to be undertaken for 6 weeks immediately prior to surgery."
62476769|NCT04913974||Uni-condylar knee arthroplasty|A cohort of patients who will undergo uni-condylar knee replacement surgery with the Univation X system and have biomechanical anaylsis
62476770|NCT05867017||Severe COVID-19 Group|Hospitalized in ICU with COVID-19 (PCR positive) and recovered
62122405|NCT02748954|EXPERIMENTAL|Thoughts.|"Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week"
62122406|NCT02748954|EXPERIMENTAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
62122407|NCT02748954|EXPERIMENTAL|Assertiveness|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict
62122408|NCT02748954|EXPERIMENTAL|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
62122409|NCT02748954|ACTIVE_COMPARATOR|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
62122410|NCT05973812|EXPERIMENTAL|Probiotic group|All infants (3-months-old) in the probiotic group consumed an infant formula supplemented with a freeze-dried probiotic (7 log10 colony-forming units \[CFU\] of B. breve PS1 per gram of formula) for 3 months.
62122411|NCT05973812|SHAM_COMPARATOR|Control group|All infants (3-months-old) in the control group consumed the same infant formula but without probiotic supplementation.
62122412|NCT00566527|EXPERIMENTAL|Arm 1: ProQuad® at 9 and 12 months|Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.
62122413|NCT00566527|EXPERIMENTAL|Arm 2: ProQuad® at 11 and 14 months|Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.
62122414|NCT00566527|ACTIVE_COMPARATOR|Arm 3: ProQuad at 12 and 15 months|Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.
62122415|NCT03895346|EXPERIMENTAL|Mindfulness|Class meeting three times a week for six months, led by a certified mindfulness meditation instructor. Includes instruction and practice on techniques such as breathing, body scan, physical sensations, and yoga.
62122416|NCT03895346|ACTIVE_COMPARATOR|Brain Games and Puzzles|Class meeting three times a week for six months, led by a qualified instructor. Includes teaching and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
62122417|NCT05734924|ACTIVE_COMPARATOR|study group|The patient in this group will received low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT for 30 minutes /session, treatment will be conducted for 3times/week for five weeks combined with cervical stabilization exercise protocol
62476771|NCT05867017||Mild COVID-19 positive Group|COVID-19 positive (by PCR) who recovered from mild COVID-19 and were seen in outpatient clinics or ER with symptoms that did not justify hospitalization.
62476772|NCT05867017||COVID-19 negative Group|COVID-19 negative (by PCR) and seen in outpatient clinics or ER during same time period as Groups I and II.
62122418|NCT05734924|SHAM_COMPARATOR|control group|The patient in this group will sham magnetic therapy in addition to, cervical stabilization exercise protocol; treatment will conduct for 3 times/ week for five weeks.
62122419|NCT03441204|ACTIVE_COMPARATOR|LTOT 24 h/day (intervention)|Long-term oxygen therapy (LTOT) prescribed 24 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen \> 8 kPa in accordance with current routine practice and management guidelines.
62311298|NCT00639067||3|"Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
62311299|NCT00639067||4|"Apparently healthy individuals having no signs and symptoms of lung carcinoma.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
62311300|NCT03195790|ACTIVE_COMPARATOR|Medical center treatment arm|Family-based pediatric obesity treatment delivered at an urban medical center.
62311301|NCT03195790|EXPERIMENTAL|Home treatment arm|Family-based pediatric obesity treatment delivered in the family's home.
62311302|NCT06429631|NO_INTERVENTION|control group(routine CIC education)|This group has routine CIC education. They fill the scales before discharge and 12. week after discharge.
62311303|NCT06429631|EXPERIMENTAL|experimental group(routine CIC education+mobile application on telephone)|"This group has routine CIC education. Also mobile application uploaded their telephone before discharge.~They fill the scales before discharge and 12. week after discharge."
62476773|NCT03973658||First time users of hearing aids|Hearing aid fitting and usage
62476774|NCT02305225|EXPERIMENTAL|SDSR|first total then partial Sleep deprivation
62476775|NCT02305225|EXPERIMENTAL|SRSD|first partial then total Sleep deprivation
62311304|NCT06178510|OTHER|INTELLiVENT-ASV|The ventilator set parameters such as tidal volume, respiratory rate, and positive end-expiratory pressure to ensure adequate ventilation and oxygenation. The investigators monitor it and define clinical target.
62122420|NCT03441204|ACTIVE_COMPARATOR|LTOT 15 h/day (control)|Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen \> 8 kPa in accordance with current routine practice and management guidelines.
62122421|NCT03481608|ACTIVE_COMPARATOR|Olive Oil Shake|"Intervention: No Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
62311305|NCT06178510|NO_INTERVENTION|conventional ventilation|The investigators set and monitor parameters such as tidal volume, respiratory rate, and positive end-expiratory pressure to ensure adequate ventilation and oxygenation.
62311306|NCT05358834|PLACEBO_COMPARATOR|Daytime melatonin 0.0 mg|Daytime melatonin 0.0 mg
62311307|NCT05358834|EXPERIMENTAL|Daytime melatonin 0.5 mg|Daytime melatonin 0.5 mg
62311308|NCT05358834|EXPERIMENTAL|Daytime melatonin 3.0 mg|Daytime melatonin 3.0 mg
62311309|NCT05358834|PLACEBO_COMPARATOR|Nighttime melatonin 0.0 mg|Nighttime melatonin 0.0 mg
62311310|NCT05358834|EXPERIMENTAL|Nighttime melatonin 0.5 mg|Nighttime melatonin 0.5 mg
62311311|NCT05483972|EXPERIMENTAL|Whole Prediabetes Diet Intervention|The diet intervention will consist of weekly food deliveries for a total of 2-weeks. The intervention will consist of a weekly individual counseling sessions led by the team's registered dietitian nutritionist (RDN). Prior to beginning the intervention, an initial individual and/or family meeting with the RDN will be scheduled. The focus of the meeting will be for the RDN to provide information about diet instruction, meal preparation/planning, and individual and family goal setting. Meetings can occur in person, via a secure zoom videoconference, or via telephone (per participant preference) and must take place with the index parent present, as they will be responsible for taking the lead of the diet intervention or relaying the information to the primary caregiver/spouse/partner in the household who is responsible for meal preparation/cooking. Child/adolescent participants will be instructed by the RDN on how to record their dietary intake (as age-appropriate) using a food diary.
62311312|NCT06377098|ACTIVE_COMPARATOR|Oral Sildenafil 50mg|Sildenafil citrate 50mg given orally every eight hours up to 3 doses while mother is in labor
62311313|NCT06377098|PLACEBO_COMPARATOR|Placebo|Identical-appearing treatment that does not contain the test drug given orally every eight hours up to 3 doses while mother is in labor
62311314|NCT00824538|EXPERIMENTAL|sunitinib|Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer
62311315|NCT05466110|EXPERIMENTAL|Spinal Cord Stimulation Device|The spinal cord stimulators WaveWriter AlphaTM (Boston Scientific) are designed to treat chronic back or leg pain by electrically stimulating the spinal cord. It is a well established worldwide licensed device. Percutaneous lead(-s) are implanted in the epidural space of the thoracic spine during the initial procedure. After discharge a trial phase is initiated and performed according to local preferences and standard of operations (SOPs). Patients are monitored for any complications and pain reduction. If a significant pain reduction (\>50 % on the NRS scale for back pain) is achieved, the permanent implantable pulse generator (IPG) is implanted. Otherwise if the therapy remains non-beneficial throughout the trial phase, the leads will be explanted. Patients are allowed to crossover in the fusion group at any point of time.
62311316|NCT05466110|ACTIVE_COMPARATOR|Control - Lumbar Fusion surgery|The control group needs to represent the standard of care of current practice. Gold standard is lumbar fusion surgery \[Resnik 2005\]. Surgical instrumentation will be performed according to local preferences and SOPs. Safety and efficacy of these fusion techniques have been repeatedly proven
62311317|NCT03518840|OTHER|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
62311318|NCT05295615|EXPERIMENTAL|Active ECHS AD device|Experimental intervention arm
62311319|NCT06065722|ACTIVE_COMPARATOR|AKYNZEO for patient receiving MEC|Add Akynzeo to 5HT3 And dexamethasone
62311320|NCT06065722|ACTIVE_COMPARATOR|oLANZAPINE and Akynzeo to patients receiving highly emetogenic|olANZAPINE plus Akynzeo
62311321|NCT03120910|EXPERIMENTAL|Test Subjects|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensor, including nasal sensors, with the same or similar technology and materials as the Masimo FDA cleared devices and sensors.
62311322|NCT01933672|EXPERIMENTAL|PF-04937319 once-daily|
62311323|NCT01933672|EXPERIMENTAL|PF-04937319 split-dose|
62311324|NCT01933672|ACTIVE_COMPARATOR|Sitagliptin once-daily|
62311325|NCT04372589|EXPERIMENTAL|Investigational arm|Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen \>24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also acceptable, as available) if no contraindication is present; alternatively, intravenous unfractionated heparin infusion may be used.
62311326|NCT04372589|NO_INTERVENTION|Control arm|Participants will receive usual care of thromboprophylactic dose anticoagulation according to local practice.
62122422|NCT03481608|EXPERIMENTAL|Coconut Oil Shake|"Intervention: Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
62311327|NCT02218203|PLACEBO_COMPARATOR|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
62311328|NCT02218203|EXPERIMENTAL|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
62311329|NCT02218203|EXPERIMENTAL|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
62311330|NCT02218203|EXPERIMENTAL|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
62476776|NCT06268665|EXPERIMENTAL|Arm 1: High-Dose Tart Cherry Juice Supplement|1 oz tart cherry juice concentrate diluted in water up to 8oz.
62476777|NCT06268665|EXPERIMENTAL|Arm 2: Low-Dose Tart Cherry Juice Supplement|¼ oz tart cherry juice concentrate diluted in water up to 8oz.
62476778|NCT04244097|EXPERIMENTAL|B group|-Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.
62476779|NCT04244097|ACTIVE_COMPARATOR|BN group|Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.
62681866|NCT05116189|EXPERIMENTAL|Pembrolizumab + paclitaxel ± bevacizumab|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 every 3 weeks \[Q3W\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
62681867|NCT05116189|PLACEBO_COMPARATOR|Placebo + paclitaxel ± bevacizumab|Participants receive placebo via IV infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 every 3 weeks \[Q3W\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
62122423|NCT01832467|EXPERIMENTAL|cetuximab-containing chemotherapy|"* Cetuximab may be given at either one of the following schedules at the investigator's discretion:~  1. 2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.~ 2. Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.~* Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.~Regimens to be combined with biweekly cetuximab:~1. Irinotecan at 2-weekly schedule.~2. FOLFIRI (as inpatient or via ambulatory pump).~3. FOLFOX (as inpatient or via ambulatory pump)."
62122424|NCT02561871|EXPERIMENTAL|Group 1|Two subsequent Intramuscular injections of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 1 and Day 85, and one intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on Day 169.
62122425|NCT02561871|EXPERIMENTAL|Group 2|Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 1, an intramuscular injection of Ad35.RSV.FA2 (1x10\^11 vp) on Day 85 and and an intramuscular injection of placebo control consisting of the vaccine formulation buffer on Day 169.
62122426|NCT02561871|EXPERIMENTAL|Group 3|Three intramuscular injections of placebo control on Day 1, Day 85 and Day 169.
62122427|NCT01872026|EXPERIMENTAL|Part 1- single administration|The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
62122428|NCT01872026|EXPERIMENTAL|Part 2- repeated administration|The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
62122429|NCT00064012|ACTIVE_COMPARATOR|Velcade Alone|Velcade
62122430|NCT00064012|EXPERIMENTAL|Velcade plus Docetaxel|Velcade plus Docetaxel
62311331|NCT02218203|EXPERIMENTAL|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
62311332|NCT02218203|EXPERIMENTAL|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
62311333|NCT02218203|EXPERIMENTAL|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
62311334|NCT02218203|EXPERIMENTAL|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
62311335|NCT02218203|EXPERIMENTAL|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
62311336|NCT02218203|EXPERIMENTAL|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
62311337|NCT02218203|EXPERIMENTAL|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
62311338|NCT02218203|EXPERIMENTAL|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
62311339|NCT02218203|EXPERIMENTAL|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
62311340|NCT02218203|EXPERIMENTAL|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
62311341|NCT02218203|EXPERIMENTAL|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
62311342|NCT02218203|EXPERIMENTAL|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
62476780|NCT00274651|EXPERIMENTAL|Arm A|PXD101 1000 mg/m2 once daily for 5 days every 21 days
62476781|NCT00274651|EXPERIMENTAL|Arm B|PXD101 1000 mg/m2 once daily for 5 days every 21 days
62496019|NCT04598958|NO_INTERVENTION|Standard of care|A cluster of 6 health facilities receive Standard of Care. Routine health facility services offering the national standard of care for pregnant and breastfeeding women in Lesotho
62311343|NCT04666961|EXPERIMENTAL|Extended ductal carcinoma in situ with mastectomy indication|"Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation.~Tamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 :~* Tamoxifen: box of tablets dosed at 20 mg~* Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg/day as a single dose for 6 months.~Anastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg/day in a single dose for 6 months."
62311344|NCT00035815|ACTIVE_COMPARATOR|IGF-1|Insulin like growth factor, type 1 will be given 0.05 mg per kg body weight subcutaneously twice daily
62311345|NCT00035815|PLACEBO_COMPARATOR|Placebo|Placebo arm
62311346|NCT01644045|EXPERIMENTAL|Device: Teleconsultation|"In cases of acute obstructive, respiratory emergencies if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
62311347|NCT06563388|EXPERIMENTAL|Standard Therapy followed by SABR - Trial 1-3 Arm 1|
62311348|NCT06563388|EXPERIMENTAL|SABR plus Standard therapy - Trial 1-3 Arm 2|
62311349|NCT06563388|EXPERIMENTAL|Trial 4 - Immediate SABR plus standard of care|
62311350|NCT05721885|OTHER|Peri-radiotherapy nutrition management group|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score \> 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
62311351|NCT01690962|EXPERIMENTAL|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
62311352|NCT01690962|ACTIVE_COMPARATOR|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
62476782|NCT05435196|EXPERIMENTAL|Experimental|"Get the training in with high-intensity interval exercise. Will be applied through 10 sets of 60 seconds. The first 30 seconds will consist of going up and down a step 15 cm high, immediately 30 seconds of squats as fast as possible with 90° knee flexion. The recovery period between each set will be 60 seconds, with a low-intensity activity (light walking). Based on high-intensity exercise, we must achieve an effort greater than 85% of the maximum frequency, using the heart rate meter and its equivalences with the Perceived Effort Scale (RPE).~Receive a multimodal training that will consist of: resistance exercises for the main muscle groups of the extremities. In the plan, lumbopelvic, scapulothoracic and craniocervical neuromuscular efficiency exercises will also be included."
62476783|NCT05435196|ACTIVE_COMPARATOR|Control|Get the training in with high-intensity interval exercise. Will be applied through 10 sets of 60 seconds. The first 30 seconds will consist of going up and down a step 15 cm high, immediately 30 seconds of squats as fast as possible with 90° knee flexion. The recovery period between each set will be 60 seconds, with a low-intensity activity (light walking). Based on high-intensity exercise, we must achieve an effort greater than 85% of the maximum frequency, using the heart rate meter and its equivalences with the Perceived Effort Scale (RPE).
62122431|NCT03071185|EXPERIMENTAL|Group PCA+B|Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.
62122432|NCT03071185|NO_INTERVENTION|Group PCA|Only intravenous patient controlled analgesia (PCA) was used postoperatively.
62122433|NCT03071185|EXPERIMENTAL|Group PCA+B+D|Both intravenous PCA and lower limb blocks with dexmedetomidine as additivewere used.
62122434|NCT00751075|ACTIVE_COMPARATOR|1|MFNS once daily
62122435|NCT00751075|EXPERIMENTAL|2|MFNS twice daily
62122436|NCT00751075|ACTIVE_COMPARATOR|3|Amoxicillin
62122437|NCT00751075|PLACEBO_COMPARATOR|4|Placebo
62311353|NCT06027983|EXPERIMENTAL|Chimeric Receptor T-cells|"Eligible patients will undergo apheresis prior to cycle 1 therapy. Treatment comprises of trastuzumab followed by chimeric receptor T-cells in cycle 1.~During Cycle 2 onwards till disease progression, patients will receive IV or SC trastuzumab only, every 3 weeks."
62122438|NCT05659901||Pelizaeus-Merzbacher Disease Participants|Participants will undergo CSF collection and neuroimaging procedures, up to Week 106 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study period (up to 26 months).
62122439|NCT01867216|PLACEBO_COMPARATOR|Placebo|Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days
62122440|NCT01867216|EXPERIMENTAL|LY2922470|Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days
62122441|NCT00003005|EXPERIMENTAL|deoxycoformycin and cordycepin|Dose escalation for deoxycoformycin and cordycepin
62122442|NCT05919017|PLACEBO_COMPARATOR|Placebo|Placebo implant, subcutaneous abdominal implant, single dose, 10 placebo tablets implanted
62122443|NCT05919017|EXPERIMENTAL|Naltrexone implant 0.9 g|Naltrexone implant, abdominal subcutaneous implantation, single administration, implantation dose is 0.9g (6 naltrexone implants+4 placebo tablets)
62122444|NCT05919017|EXPERIMENTAL|Naltrexone implant 1.5 g|Naltrexone implant, abdominal subcutaneous implantation, single dose of 1.5g (10 naltrexone implants)
62122445|NCT05752006|EXPERIMENTAL|Crane operators|Individuals employed as crane operators in Port of Koper.
62122446|NCT05752006|ACTIVE_COMPARATOR|Control subjects|Individuals who spend more than half of their occupation time standing.
62122447|NCT06546384|EXPERIMENTAL|Liraglutide Arm|Patients assigned to this arm will be treated with liraglutide and standard of care for weight reduction (nutritional and exercise recommendations) for 16 weeks.
62681868|NCT06684977|ACTIVE_COMPARATOR|Treatment As Usual|(N=5) as a control group who will only receive TF-CBT.
62681869|NCT06684977|EXPERIMENTAL|360 Video|(N=5) to use 360° Video alongside standard TF-CBT.
62122448|NCT06546384|ACTIVE_COMPARATOR|Control Arm|Patients assigned to this arm will be treated with standard of care for weight reduction (nutritional and exercise recommendations) for 16 weeks.
62311354|NCT04272853||Athletes|440 subjects will be recruited (see calculation of the sample size for details): all subjects will be athletes, professional or non-professional, belonging to any sporting discipline, members of one of the sports federations of the Lombardy region, officially recognized by CONI (National Committee of Italian Olympic Team).
62122449|NCT04756245|EXPERIMENTAL|Virtual Reality|Participants engage in intervention procedures using virtual reality software.
62122450|NCT04756245|ACTIVE_COMPARATOR|Video Conference|Participants engage in intervention procedures using video conference software.
62311355|NCT01172288|EXPERIMENTAL|N-Acetylcysteine|NAC was titrated up to a maximum dose of 2400 mg over the course of 2 weeks. Subjects were assigned 600 mg twice a day for weeks 1-2, and then were assigned 1200 mg twice a day for the remainder of the 12 week study.
62476784|NCT04300946||TMS on the cerebellum followed by placebo TMS|TMS preceding the time prediction and language tests
62681870|NCT06684977|EXPERIMENTAL|VR Photoscan|(N=5) to use VR Photo Scan alongside standard TF-CBT.
62681871|NCT03735979|EXPERIMENTAL|Argatroban|100µg/kg bolus followed by 3µg/kg per minute for 12 hours
62681872|NCT03735979|EXPERIMENTAL|Eptifibatide|135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours
62681873|NCT03735979|PLACEBO_COMPARATOR|Placebo|
62122451|NCT02509585|EXPERIMENTAL|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
62311356|NCT01172288|PLACEBO_COMPARATOR|Placebo|Placebo: Subjects were assigned to take two capsules twice a day for weeks 1-2, and then were assigned 4 capsules twice a day for the remainder of the 12 week study.
62311357|NCT02095730|ACTIVE_COMPARATOR|Epi-On Continuous|Continuous beam of UV light treating cornea with surface epithelium present
62311358|NCT02095730|ACTIVE_COMPARATOR|Epi-Off Continuous|Continuous beam of UV light treating cornea without surface epithelium present
62311359|NCT02095730|ACTIVE_COMPARATOR|Epi-On Pulsed|Pulsed beam of UV light treating cornea with surface epithelium present
62311360|NCT02095730|ACTIVE_COMPARATOR|Epi-Off Pulsed|Pulsed beam of UV light treating cornea without surface epithelium present
62681874|NCT06297213|OTHER|Open Label|Probiotic
62681875|NCT01467284|EXPERIMENTAL|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
62681876|NCT01467284|ACTIVE_COMPARATOR|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
62311361|NCT06658002|EXPERIMENTAL|Cyclosporine A (CsA) 0.1%|After one week of hourly natamycin eye drops the participants in this arm will use this drop four times a day for one month then twice a day for one month.
62311362|NCT06658002|EXPERIMENTAL|Cyclosporine A (CsA) 2%|After one week of hourly natamycin eye drops the participants in this arm will use this drop four times a day for one month then twice a day for one month.
62681877|NCT06006585|EXPERIMENTAL|BI 771716 low dose treatment group (Single rising dose (SRD part))|
62681878|NCT06006585|EXPERIMENTAL|BI 771716 treatment group (multiple dose (MD part))|
62681879|NCT06006585|EXPERIMENTAL|BI 771716 medium dose treatment group (SRD part)|
62681880|NCT06006585|EXPERIMENTAL|BI 771716 high dose treatment group (SRD part)|
62681881|NCT04040231|EXPERIMENTAL|Malignant Pleural Mesothelioma (MPM)|Participants with previously treated Malignant Pleural Mesothelioma/MPM
62681882|NCT04211870|EXPERIMENTAL|Group Intervention|Treatment with LED clusters.
62681883|NCT01778231|EXPERIMENTAL|Vitamin Supplement|1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
62122452|NCT04496830|EXPERIMENTAL|Relapsing Remitting Multiple Sclerosis|"* Blood sample collection~* Vital signs, weight, height and BMI.~* Complete neurological examination documented in NeurEx (recorded with an iPAD).~* Clinical data questionnaire~* 25FW \& non-dominant hand 9HPT (required for calculating CombiWISE \& MS-DSS).~* Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~* Optical Coherence Tomography (OCT)~* CSF Analysis"
62476785|NCT04300946||Placebo TMS followed by TMS on the cerebellum|TMS preceding the time prediction and language tests
62476786|NCT04300946||TMS on the cerebellum set in time on waiting periods|
62476787|NCT04300946||TMS on the cerebellum not set in time on waiting periods|
62476788|NCT03417960|EXPERIMENTAL|iTBS|accelerated iTBS to Left DLPFC
62476789|NCT01959568|EXPERIMENTAL|Double tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation. After that the surgeon replaces ½ of perfluorodecalin volume by silicone oil.
62476790|NCT01959568|ACTIVE_COMPARATOR|Silicone oil tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation and perfluorodecalin-silicone oil exchange.
62476791|NCT06115291|EXPERIMENTAL|Group A: 4 scents|Participants will be asked to inhale 4 different scents 2 times a day.
62476792|NCT06115291|ACTIVE_COMPARATOR|Group B: 14 scents|Participants will be asked to inhale 14 different scents 2 times a day.
62311363|NCT06658002|PLACEBO_COMPARATOR|Placebo|After one week of hourly natamycin eye drops the participants in this arm will use this drop four times a day for one month then twice a day for one month.
62311364|NCT02718677||1. Refacto AF (NIS)|Non-Interventional Study
62311365|NCT03391011|EXPERIMENTAL|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
62311366|NCT02984878|EXPERIMENTAL|Revanesse Ultra|Revanesse Ultra open label retreatment
62311367|NCT02742389|NO_INTERVENTION|Standard counseling|This group will receive the standard counseling that all our patients would receive if they are scheduled to have urodynamic testing. This counseling will include a description of the procedure and a handout about urodynamic testing
62476793|NCT04913285|EXPERIMENTAL|Dose Escalation Monotherapy (Part A1)|Dose escalation of KIN-2787
62476794|NCT04913285|EXPERIMENTAL|Dose Escalation Combination therapy (Part A2)|Dose escalation of KIN-2787 and binimetinib
62476795|NCT04913285|EXPERIMENTAL|Dose Expansion Monotherapy (Part B1)|Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787
62681884|NCT01778231|PLACEBO_COMPARATOR|Inert oil capsule|1 capsule daily for 16 weeks
62311368|NCT02742389|OTHER|Standard + Preprocedure Telephone Call|The participants will receive the standard counseling that all our patients who are scheduled for urodynamic testing receive (just like those who are assigned to group 1). In addition, the participants will receive intervention: a pre-procedural telephone call from the investigators 1 week before their testing to talk about the procedure.
62476796|NCT04913285|EXPERIMENTAL|Dose Escalation Combination therapy (Part B2)|Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 and binimetinib
62476797|NCT05494203||spa|Untreated patients meeting the revised AS New York diagnostic criteria or the ASAS classification criteria for axial SpA. Exclusion criteria: ① Patients with rheumatoid arthritis, scleroderma, systemic lupus erythematosus and other diseases of the immune system; ② Patients who have received head and neck radiation therapy; ③ Those who have a history of using antidepressants and parasympathetic stimulants; ④ Known infection with human immunodeficiency virus (HIV) or hepatitis C virus; ⑤ Patients with sarcoidosis or tuberculosis infection. According to the existing ethical approval documents, the patients signed the informed consent.
62476798|NCT05494203||HC|healthy control. Exclusion criteria: ① Patients with rheumatoid arthritis, scleroderma, systemic lupus erythematosus and other diseases of the immune system; ② Patients who have received head and neck radiation therapy; ③ Those who have a history of using antidepressants and parasympathetic stimulants; ④ Known infection with human immunodeficiency virus (HIV) or hepatitis C virus; ⑤ Patients with sarcoidosis or tuberculosis infection. According to the existing ethical approval documents, the patients signed the informed consent.
62476799|NCT06030752|EXPERIMENTAL|Washed microbiota transplantation|WMT
62311369|NCT04211545|EXPERIMENTAL|Administration of CC-92480 and Rabeprazole|Test Formulation CC-92480 and Reference Formulation will be administered orally at 1.6 mg. Rabeprazole will be administered orally at 40 mg.
62476800|NCT02647944|ACTIVE_COMPARATOR|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
62681885|NCT06647628|EXPERIMENTAL|MK-1708 Dosage 1|Participants receive multiple doses of MK-1708 dosage 1.
62681886|NCT06647628|EXPERIMENTAL|MK-1708 Dosage 2|Participants receive multiple doses of MK-1708 dosage 2.
62681887|NCT06647628|PLACEBO_COMPARATOR|Placebo|Participants receive multiple doses of placebo.
62681888|NCT06181643|EXPERIMENTAL|Group 1: Survivorship Sleep Program with Individual Delivery + No Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
62681889|NCT06181643|EXPERIMENTAL|Group 2: Survivorship Sleep Program with Group Delivery + No Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
62681890|NCT06181643|EXPERIMENTAL|Group 3: Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session), followed by 3 monthly booster sessions.
62681891|NCT06181643|EXPERIMENTAL|Group 4: Survivorship Sleep Program with Group Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session), followed by 3 monthly booster sessions.
62681892|NCT06307015|ACTIVE_COMPARATOR|Standard of care|Standard of care treatment for patients undergoing definitive chemoradiation for oropharyngeal squamous cell carcinoma
62476801|NCT02647944|PLACEBO_COMPARATOR|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
62681893|NCT06307015|EXPERIMENTAL|De-escalation|De-escalated radiation therapy for patients undergoing surgery to the primary site followed by chemoradiation to the primary site and neck for oropharyngeal squamous cell carcinoma
62681894|NCT05783960||External validation a questionnaire|Questionnaire will be administrated to patient with chronic kidney diseases ti evaluated the consumption of salt and potassium intake. A Bayesian network and a multiple regression will be used to validated the questionary of 27 items
62681895|NCT06687265|EXPERIMENTAL|METFORMIN GROUP|
62681896|NCT06687265|PLACEBO_COMPARATOR|PLACEBO GROUP|
62681897|NCT03948620||Children whose mother prescribed antibiotics during pregnancy|"Children whose mother were prescribed an only monotherapy of macrolides or penicillins from 5 gestational weeks (GW) to delivery. A monotherapy is defined as one or more consecutive prescriptions for a single antibiotic (i.e. same drug substance) separated by no more than 30 days and uninterrupted by prescriptions for other antibiotic drug substances.~The investigators will also build a negative control cohort which includes children whose mother were prescribed an only monotherapy of macrolides or penicillins from 50 to 10 weeks before conception."
62681898|NCT02575183|EXPERIMENTAL|Varenicline (Chantix)|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: 0.5 mg orally once a day Days 4 to 7: 0.5 mg orally twice a day Days 8 to end of treatment: 1 mg orally twice a day. Intervention 'Varinecline (Chantix)' and Intervention 'Behavioral Therapy'"
62681899|NCT02575183|PLACEBO_COMPARATOR|Placebo|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive a Placebo for Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: a placebo (matched to 0.5 mg of Varenicline) orally once a day Days 4 to 7: a placebo (matched to 0.5 mg of Varenicline) orally twice a day Days 8 to end of treatment: a placebo (matched to 1 mg of Varenicline) orally twice a day.~Intervention 'Placebo (for Varenicline)' and Intervention 'Behavioral Therapy'"
62681900|NCT03680131|ACTIVE_COMPARATOR|EB01 Cream Placebo|EB01 Cream containing 0% EB01 w/w applied BID
62681901|NCT03680131|EXPERIMENTAL|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
62122453|NCT04496830|EXPERIMENTAL|Progressive Multiple Sclerosis|"* Blood sample collection~* Vital signs, weight, height and BMI.~* Complete neurological examination documented in NeurEx (recorded with an iPAD).~* Clinical data questionnaire~* 25FW \& non-dominant hand 9HPT (required for calculating CombiWISE \& MS-DSS).~* Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~* Optical Coherence Tomography (OCT)~* CSF Analysis"
62122454|NCT04496830|EXPERIMENTAL|Non-Inflammatory Neurological Diseases|"* Clinical data questionnaire~* CSF Analysis"
62122455|NCT04496830|EXPERIMENTAL|Other Non-Inflammatory Neurological Diseases|"* Clinical data questionnaire~* CSF Analysis"
62122456|NCT05834946|EXPERIMENTAL|Group T-A|7 patients with history of periodontitis
62122457|NCT05834946|EXPERIMENTAL|Group T-B|7 patients with history of periodontitis
62122458|NCT05834946|ACTIVE_COMPARATOR|Group C-A|7 patients without history of periodontitis
62122459|NCT05834946|ACTIVE_COMPARATOR|Group C-B|8 patients without history of periodontitis
62122460|NCT00501618|OTHER|Fazaclo|open label switch from generic clozapine to Fazaclo
62122461|NCT01458210|EXPERIMENTAL|Ortho-Cyclen (OC) Alone (Period 1); OC+Dulaglutide (Period 2)|"Ortho-Cyclen (OC) (0.25 milligram \[mg\] norelgestromin \[NGMN\] + 0.035 mg ethinyl estradiol \[EE\] \[active tablets\] for 21 days + non-active tablets for 7 days): A 28-day course of OC consists of 0.25 mg NGMN and 0.035 mg EE (active tablets), administered orally, once per day for 21 days, then non-active tablets, administered orally, once per day for 7 days. Participants received the first 28-day course (Lead-in) followed by 2 subsequent 28-day courses (Periods 1 and 2, respectively). Following the Lead-in period, the Period 1 sample was taken during the first 28-day course and the Period 2 sample was taken during the second 28-day course.~Dulaglutide: A single, 1.5-mg subcutaneous injection on Day 19 of Period 2."
62122462|NCT06448598||Exercise|he exercise group consisted of patients who participated in the exercise program, which involved twice-weekly sessions of aerobic exercises performed at 70% of maximum heart rate from a step test, as well as resistance exercises at 60% of one-repetition maximum strength. Within the exercise group, participants self-selected into either the intradialytic subgroup, where exercise was performed during their hemodiafiltration (HDF) sessions, or the interdialytic subgroup, where exercise took place on non-dialysis days.
62311370|NCT02685150|EXPERIMENTAL|Functional dyspepsia|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice and those who fulfill with Rome III criteria for functional dyspepsia are to be classified into this group.
62476802|NCT04084197|EXPERIMENTAL|Sequence 1|Period 1 : Fasted state + HIP1402, Period 2 : Fasted state + HIP1801
62476803|NCT04084197|EXPERIMENTAL|Sequence 2|Period 1 : Fasted state + HIP1801, Period 2 : Fasted state + HIP1402
62476804|NCT04084197|EXPERIMENTAL|Sequence 3|High fat diet + HIP1402, Period 2 : High fat diet + HIP1801
62476805|NCT04084197|EXPERIMENTAL|Sequence 4|High fat diet + HIP1801, Period 2 : High fat diet + HIP1402
62681902|NCT03680131|EXPERIMENTAL|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
62681903|NCT03680131|EXPERIMENTAL|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
62681904|NCT06689982|EXPERIMENTAL|Tofacitinib|This group will receive tofacitinib citrate sustained-release tablets at 180 consecutive days .
62681905|NCT05669703||1|Community cohort of families
62681906|NCT06618664|EXPERIMENTAL|SHR-8068 combined with Adebrelimab and Bevacizumab|
62681907|NCT06618664|ACTIVE_COMPARATOR|Sintilimab combined with Bevacizumab|
62681908|NCT06276348|EXPERIMENTAL|Enrollees|Enrolled infants will receive 3 tests (DWGS, BeginNGS, and WES). DWGS will be performed in a standard manner. BeginNGS and WES will be performed in a batch after completion of enrollment. The diagnostic sensitivity and specificity of BeginNGS and WES will be compared to DWGS (a standard clinical test compliant with the Clinical Laboratory Improvement Amendments Act).
62681909|NCT05541276|EXPERIMENTAL|Melatonin|Participants receive melatonin solution for injection 1 mg/mL in a dosage of 0.15 mg/kg body weight as a single intravenous injection approximately 30 minutes before end of surgical procedure.
62681910|NCT05541276|PLACEBO_COMPARATOR|Placebo|Participants receive isotonic sodium chloride (9mg/mL) intravenously once approximately 30 minutes before end of surgical procedure in a volume equivalent to the melatonin group for the same weight.
62122463|NCT06448598||Control|The control group did not undergo any exercise intervention or physical evaluations with a physical therapist. Data collected from the control group pertained solely to dialysis adequacy measures such as Kt/V and urea reduction ratio (URR). This allowed for comparisons between the exercise and non-exercise groups in terms of dialysis efficiency.
62122464|NCT06178978||Age-related macular degeneration|Patients with age-related macular degeneration.
62122465|NCT02640781|EXPERIMENTAL|covered stent|newly designed covered stent group
62122466|NCT02640781|ACTIVE_COMPARATOR|uncovered stent|currently used uncovered stent group
62311371|NCT02685150|EXPERIMENTAL|Acid reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice. Participants with acid reflux are to confirmed by Omeprazole test, one kind of proton-pump inhibitor (PPI) tests.
62311372|NCT02685150|EXPERIMENTAL|Bile reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging and Analysis of gastric juice. Participants with bile reflux are to be confirmed by Analysis of gastric juice.
62681911|NCT06571968|OTHER|fully guided surgical technique|The guides were designed with metal sleeves for guided drilling and guided implant placement and additional guide sleeves for the stabilization of the template by fixation screws.The implant width and length were selected for each patient according to previous 3d cone beam, and the drills of this kit were 11 mm longer than conventional drills. The surgery was performed without flap elevation. The guide was seated and fixed by means of 2-mm cortical screws in the buccal region after using of the corresponding drills.
62681912|NCT06571968|OTHER|semi guided surgical technique|The guides were designed with metal sleeves for guided drilling and guided implant placement and additional guide sleeves for the stabilization of the template by fixation screws.The implant width and length were selected for each patient according to previous 3d cone beam, and the drills of this kit were 11 mm longer than conventional drills.The surgery was performed without flap elevation. The stent was removed before the final drilling
62681913|NCT06690762|EXPERIMENTAL|Education|It consists of nutrition, physical activity, stress management, relaxation exercises and defecation training.
62681914|NCT06690762|NO_INTERVENTION|Kontrol|no intervention
62681915|NCT06654271|ACTIVE_COMPARATOR|Robotic assisted bronchoscopy (RAB)|Robotic assisted bronchoscopy with integrated cone beam computed tomography
62681916|NCT06654271|ACTIVE_COMPARATOR|Electromagnetic navigation bronchoscopy (ENB)|Electromagnetic navigation bronchoscopy (ENB) with integrated digital tomosynthesis
62681917|NCT06685952||Prone position group|"Sedation and analgesia anesthesia will be administered after the prone position.~All patients will receive standardized sedation and analgesia anesthesia with 1ug/kg sufentanil，1ug/kg/h dexmedetomidine，1mg/h midazolam，0.05-0.1ug/kg/min remifentanil. And adjust the drug speed according to the patient's respiratory rate, BIS changes.~Optic nerve sheath diameter (ONSD), carotid artery flow rate, Bispectral index (BIS), liposuction swelling fluid input, infusion volume, end-expiratory carbon dioxide, mean arterial pressure, heart rate, peripheral oxygen saturation, body temperature and respiratory rate will be measured at four time points respectively."
62681918|NCT06685952||Supine group|"Sedation and analgesia anesthesia will be administered after the supine position.~All patients will receive standardized sedation and analgesia anesthesia with 1ug/kg sufentanil，1ug/kg/h dexmedetomidine，1mg/h midazolam，0.05-0.1ug/kg/min remifentanil. And adjust the drug speed according to the patient's respiratory rate, BIS changes.~Optic nerve sheath diameter (ONSD), carotid artery flow rate, Bispectral index (BIS), liposuction swelling fluid input, infusion volume, end-expiratory carbon dioxide, mean arterial pressure, heart rate, peripheral oxygen saturation, body temperature and respiratory rate will be measured at four time points respectively."
61922320|NCT04431427|ACTIVE_COMPARATOR|Uncovered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
61922321|NCT02448680|ACTIVE_COMPARATOR|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
62122467|NCT04561544|EXPERIMENTAL|Intervention in Fall 2020|Participants will receive the intervention in Fall 2020
62122468|NCT04561544|OTHER|Intervention in Spring 2021|Control in Fall 2020
62311373|NCT02685150|EXPERIMENTAL|Health volunteers|Health volunteers for routine checkup. Participants are to undergo Endoscopic Tri-Modal Imaging as well as Analysis of gastric juice and those who show no abnormal findings are to be classified into this group.
62311374|NCT01757457|EXPERIMENTAL|Intracoronary abciximab|Intracoronary administration of an abciximab bolus during primary PCI
62311375|NCT01757457|ACTIVE_COMPARATOR|Intravenous abciximab|Intravenous standard administration of an abciximab bolus during primary PCI
62311376|NCT00761124|EXPERIMENTAL|1|Educational small group session regarding prostate cancer
62476806|NCT00271115|OTHER|Moms w/preterm infants|Mothers of preterm infants who are admitted to the newborn intensive care unit.
62476807|NCT03972683|EXPERIMENTAL|Handgrip Exercise Training Intervention|"Participants will visit the lab for baseline measurements designed to evaluate signaling mechanisms that regulate blood flow. A physician will place a catheter in the brachial artery for pharmacological infusions. The following drugs will be administered to each participant: acetylcholine, adenosine triphosphate, atropine, phenylephrine, and sodium nitroprusside (see Interventions for further details regarding each drug). The order of infusions will be randomized and blood flow will be allowed to return to baseline between each infusion (\~15 min) with the exception of atropine, which will be administered last owing to its longer half-life.~Following baseline measurements, participants will complete a 7 week handgrip exercise training intervention, then they will return to the laboratory for post-training measurements. The post-training assessments will be performed in the same manner as the baseline visit; thus, the same drugs will be infused as described above."
62311377|NCT00761124|OTHER|2|Printed material regarding general prostate cancer information provided.
62311378|NCT04345939||GenSeizer|Sputum and lavage fluids are tested for pathogens using GenSeizer
62311379|NCT04345939||PCR reverse hybridization|Sputum and lavage fluids are tested for pathogens using PCR reverse hybridization
62311380|NCT04345939||Target sequencing after incubation|Sputum and lavage fluids are tested for pathogens using Target sequencing after incubation
62311381|NCT01223248|EXPERIMENTAL|stereotactic IGIMRT using a single dose of 24 Gy|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
62311382|NCT01223248|EXPERIMENTAL|stereotactic IGIMRT 27 Gy in 3 fractions|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
62311383|NCT05286151|EXPERIMENTAL|Children who stutter|Children who stutter
62476808|NCT02982161|ACTIVE_COMPARATOR|MR308 100 mg bid|Tramadol/Celecoxib 100 mg
62476809|NCT02982161|ACTIVE_COMPARATOR|MR308 150 mg bid|Tramadol/Celecoxib 150 mg
62311384|NCT05286151|EXPERIMENTAL|Children who do not stutter|Children who do not stutter
62311385|NCT06211348|EXPERIMENTAL|Genomic Sequencing|
62311386|NCT02795156|EXPERIMENTAL|Arm 1|Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
62311387|NCT02795156|EXPERIMENTAL|Arm 2|Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
62311388|NCT02795156|EXPERIMENTAL|Arm 3|Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
62476810|NCT02982161|ACTIVE_COMPARATOR|MR308 200 mg bid|Tramadol/Celecoxib 200 mg
62476811|NCT02982161|ACTIVE_COMPARATOR|Tramadol 100 mg qid|Tramadol IR 100 mg
62681919|NCT05395494|EXPERIMENTAL|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) during 4 weeks of rTMS treatment (20 sessions) 60-120 minutes prior to rTMS treatment.
62476812|NCT02982161|PLACEBO_COMPARATOR|Placebo|Placebo to match MR308 and Tramadol IR
62476813|NCT00781794|EXPERIMENTAL|1|Dose 1
62476814|NCT00781794|EXPERIMENTAL|2|Dose 2
62476815|NCT00781794|PLACEBO_COMPARATOR|3|
62681920|NCT05395494|PLACEBO_COMPARATOR|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) 60 - 120 minutes prior to rTMS treatment.
62476816|NCT03700723|EXPERIMENTAL|Resusix|The experimental drug (Resusix) will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
62476817|NCT03700723|ACTIVE_COMPARATOR|FP24 (Frozen Plasma)|The active comparator FP24 will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
62476818|NCT00043394|EXPERIMENTAL|Cohort 1|0.04 mg/kg CpG 7909
62476819|NCT00043394|EXPERIMENTAL|Cohort 2|0.08 mg/kg CpG 7909
62476820|NCT00043394|EXPERIMENTAL|Cohort 3|0.12 mg/kg CpG 7909 Injection once weekly
62476821|NCT00043394|EXPERIMENTAL|Cohort 4|0.16 mg/kg CpG 7909
62476822|NCT01998295|ACTIVE_COMPARATOR|Artemether/lumefantrine|"Artemether/lumefantrine tablets, 6 doses, for 3 days~Dosage:~1. tablet for body weight between 5-14.9 Kilograms.~2. tablets for body weight between 15-24.9 Kilograms.~3. tablets for body weight between 25-34.9 Kilograms."
62476823|NCT04158245|EXPERIMENTAL|18F-fluciclovine PET Scan|Single intravenous administration of 18F-fluciclovine for PET Scan.
62681921|NCT04792216|EXPERIMENTAL|Wild Salmon|Wild salmon fillets in a raw form
62681922|NCT04792216|EXPERIMENTAL|Farmed Salmon|Farmed salmon fillets in a raw form
62311389|NCT02795156|EXPERIMENTAL|Arm 4|Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
62681923|NCT06691620|EXPERIMENTAL|Intervention 1 Group|The group received a nasal irrigation procedure with isotonic saline.
62311390|NCT00003139|EXPERIMENTAL|Pilocarpine hydrocloride|5mg pilocarpine hydrochloride tablets commencing 3 days prior to irradiation
62311391|NCT00003139|PLACEBO_COMPARATOR|Placebo|Placebo tablets commencing 3 days prior to irradiation
62311392|NCT03425799|PLACEBO_COMPARATOR|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
62681924|NCT06691620|EXPERIMENTAL|Intervention 2 Group|The group received a nasal irrigation procedure with hypertonic saline.
62311393|NCT03425799|EXPERIMENTAL|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
62311394|NCT04640246|EXPERIMENTAL|TBX-3400|TBX-3400 by intravenous infusion
62476824|NCT05865769||Normal children|Have FEV1 higher than median on their class
62476825|NCT05865769||subclinical pulmonary impairment|Have FEV1 lower than median on their class
62681925|NCT06691620|EXPERIMENTAL|Intervention 3 Group|The group received a nasal irrigation procedure with isotonic saline and nontraumatic nasopharyngeal aspiration.
62476826|NCT04916548|EXPERIMENTAL|Intravenous Ketamine|Open-label ketamine infusion
62681926|NCT06691620|EXPERIMENTAL|Intervention 4 Group|The group received a nasal irrigation procedure with hypertonic saline and nontraumatic nasopharyngeal aspiration.
62476827|NCT05523986|EXPERIMENTAL|Experimental: Treatment group|Vitamin D (2000IU/day) for 6 months
62681927|NCT06691490|EXPERIMENTAL|Transcranial Magnetic Stimulation Sham|Participants will engage in 4 cycling exercise visits and 4 effort-discounting task visits. Each of these 8 visits will be associated with one of the 4 stimulation conditions: vibration condition, sham vibration condition, cTBS over SMA. These 8 visits will be randomized across participant
62681928|NCT06691490|PLACEBO_COMPARATOR|TMS|cTBS over precuneus (control site).
62681929|NCT02656173|EXPERIMENTAL|Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day along with tamsulosin 0.2 mg for 12 weeks
62311395|NCT05509257|EXPERIMENTAL|Group A|All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.
62476828|NCT05523986|PLACEBO_COMPARATOR|Placebo Comparator: Control group|placebo
62476829|NCT00460733|EXPERIMENTAL|1|
62476830|NCT00460733|ACTIVE_COMPARATOR|2|
62476831|NCT02897414||Overall group of all ER/LA opioid excluding hydrocodone|
62476832|NCT02897414||Each type of opioid that has an ER/LA opioid formulation|
62681930|NCT02656173|EXPERIMENTAL|Placebo|Participants who received matching placebo once a day along with tamsulosin 0.2 mg for 12 weeks.
62311396|NCT05509257|EXPERIMENTAL|Group B|All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.
62311397|NCT02989727|EXPERIMENTAL|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
62311398|NCT02989727|PLACEBO_COMPARATOR|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
62311399|NCT02989727|EXPERIMENTAL|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
62311400|NCT02989727|PLACEBO_COMPARATOR|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
62681931|NCT01818648|EXPERIMENTAL|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
62311401|NCT04967430|EXPERIMENTAL|Treatment|To receive a dose of peginterferon lambda 180mcg SC at baseline (Day 0).
62311402|NCT04967430|PLACEBO_COMPARATOR|Placebo|"Patients in this arm will receive a single SC dose of 0.9% sodium chloride (normal saline) solution at baseline (Day 0).~A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse."
62311403|NCT06672640|EXPERIMENTAL|remote exercise group|Participants in the remote exercise group will engage in exercise sessions conducted twice weekly for eight weeks using video conferencing software. The intervention includes balance, strength, and gait training, supervised by a licensed physical therapist. Sessions are performed at participants' homes with assistance from caregivers to ensure safety and compliance.
62311404|NCT06672640|EXPERIMENTAL|in-person exercise group|Participants in the in-person exercise group will attend supervised exercise sessions at a senior welfare center twice weekly for eight weeks. The sessions, conducted by a licensed physical therapist, focus on improving balance, lower limb strength, and gait stability. The intervention is identical to the remote exercise group, except the mode of delivery is in person at the welfare center.
62311405|NCT06672640|OTHER|control group|Participants in the control group will receive an informational booklet on exercise and attend a single educational session about physical activity. They will be encouraged to maintain their usual activities, and their physical activity levels will be self-reported and periodically monitored by the research team.
62476833|NCT02897414||Overall group that includes all prescription opioids except|
62681932|NCT01818648|PLACEBO_COMPARATOR|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
61922322|NCT02448680|ACTIVE_COMPARATOR|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
62476834|NCT02897414||Comparator Group taking benzodiazepines|
62476835|NCT02897414||Comparator Group taking IR hydrocodone|
61922323|NCT02847468|EXPERIMENTAL|FDG and FCH PET|Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.
62122469|NCT02618018|EXPERIMENTAL|intraocular lens|AT TORBI 709M toric intraocular lens
62122470|NCT05290168|EXPERIMENTAL|Normal children|normal children undergoing simple surgery
62122471|NCT03061552|EXPERIMENTAL|IVCD arm|IVCD-assisted determination of target post-dialysis weight
62122472|NCT03061552|NO_INTERVENTION|conventional arm|conventional determination of target post-dialysis weight
62122473|NCT02442895||Long luteal protocol|Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)\<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
62476836|NCT01398163|EXPERIMENTAL|1 = Tested product|
62476837|NCT01398163|ACTIVE_COMPARATOR|2 = Control product|
62476838|NCT01398163|NO_INTERVENTION|3 = No product|
62681933|NCT05573906|EXPERIMENTAL|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
62681934|NCT05573906|ACTIVE_COMPARATOR|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
62122474|NCT02442895||Daily antagonist protocol|GnRH antagonist (cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed protocol from the day +6 of stimulation or with a flexible protocol from the day in which at least one follicle reached a diameter of 14mm. In both protocols GnRH antagonist was administered until the day of the assumption of hCG. Recombinant Follicle Stimulating Hormone (rFSH) was administered from the 3rd day of menstruation at a dose of 150-300 IU/die according to the characteristics of women. The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle.
62311406|NCT03418246|SHAM_COMPARATOR|GIC filling|"Intervention/treatment One group will be treated with a tooth colored filling that will be placed near the gum line (Glass Ionomer).~Placebo Comparator: GIC~Participants will have a restoration placed with GIC in the lesion near the gum line. Device: GIC Application of a tooth colored filling in the cavitated dental lesion. Other Name: Resin modified glass ionomer"
61922324|NCT02151136|EXPERIMENTAL|24% sucrose + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml 24% sucrose will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
61922325|NCT02151136|PLACEBO_COMPARATOR|Sterile water + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml sterile water will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
61922326|NCT03730454|EXPERIMENTAL|Group A. Transanastomotic Tube|Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.
62311407|NCT03418246|EXPERIMENTAL|Biodentine filling|"Intervention/treatment The second group will be treated with Biodentine that will be placed near the gum line.Experimental: Biodentine~Participants will have a restoration placed with Biodentine in the lesion near the gum line. Device: Biodentine Application of a white colored filling in dental lesion."
62311408|NCT05065138|EXPERIMENTAL|After receiving standardized training on Helicobacter pylori eradication|After the gastroenterologists receive standardized training to eradicate Helicobacter pylori, they recruit Helicobacter pylori-positive patients for treatment.
62311409|NCT05065138|NO_INTERVENTION|Before receiving standardized training on Helicobacter pylori eradication|Gastroenterologists recruited patients with Helicobacter pylori positive for treatment before receiving standardized training on Helicobacter pylori eradication.
62476839|NCT03153540|ACTIVE_COMPARATOR|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
62476840|NCT03153540|SHAM_COMPARATOR|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
62681935|NCT02207101|ACTIVE_COMPARATOR|E-OJ-01 (OXYJUN)|E-OJ-01 (OXYJUN). Dose: 01 capsule to be taken orally daily after lunch.
62681936|NCT02207101|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules \[for E-OJ-01 (OXYJUN)\] composed of microcrystalline cellulose. Dose: 01 capsule to be taken orally daily after lunch.
62681937|NCT02284854|EXPERIMENTAL|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
61922327|NCT03730454|EXPERIMENTAL|Group B. No Transanastomotic Tube|Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.
62122475|NCT02442895||Depot antagonist protocol|"GnRH antagonist (Cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed or flexible protocol until the day of the assumption of hCG. Corifollitropila alfa was used at dose of 100μg (in women with weight ≤60 kg and age ≤36 years) or 150μg (in women with weight\> 60 kg of any age or weight ≥50 kg and age greater than 36 years). Corifollitropina alfa was administered subcutaneously in the day +3 and in the day +5 or +6 was supplemented with rFSH at doses 112-300 IU/day.~The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle."
62122476|NCT02506257|EXPERIMENTAL|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
62122477|NCT02506257|EXPERIMENTAL|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
62122478|NCT02506257|EXPERIMENTAL|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
62122479|NCT02506257|PLACEBO_COMPARATOR|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
62122480|NCT01426295|EXPERIMENTAL|Caphosol|
62122481|NCT01426295|ACTIVE_COMPARATOR|Référence|•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
62122482|NCT01202955|ACTIVE_COMPARATOR|Tolcapone|Tolcapone
62681938|NCT02284854|EXPERIMENTAL|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
62681939|NCT05855109||Patients with Rheumatoid Arthritis (RA)|RA and 2 or more risk factors for developing Interstitial Lung Disease (ILD)
62681940|NCT05230758|EXPERIMENTAL|Metformin|Oral metformin will be administered approximately 500mg/m2/day for 1 week and increased to 1000mg/m2/day for 15 weeks. Doses will be rounded to increments of half tablets (250mg, 500mg, 750mg and 1000mg).
62681941|NCT05230758|PLACEBO_COMPARATOR|Placebo|Oral placebo will be administered approximately 500mg/m2/day for 1 week and increased to 1000mg/m2/day for 15 weeks. Doses will be rounded to increments of half tablets (250mg, 500mg, 750mg and 1000mg).
61922328|NCT03565471||ASD patients with surgical closure|"Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
61922329|NCT03565471||ASD patients with transcatheter closure|"Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
62122483|NCT01202955|PLACEBO_COMPARATOR|Placebo|Placebo
62681942|NCT06222957||HER2 positive group|HER2-positive (HER2+) and Estrogen receptor-positive (ER+) breast cancer patients undergoing adjuvant chemotherapy including trastuzumab.
61922330|NCT03565471||Controls|"Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
61922331|NCT06523517|EXPERIMENTAL|treatment group|Eliglustat Tartrate Capsules, either 42 mg or 84 mg taken orally twice a day for 52 weeks.
62122484|NCT04057196|EXPERIMENTAL|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 12 weeks.
62122485|NCT00710515|EXPERIMENTAL|1|with food
62681943|NCT06222957||Control group|HER2-negative breast cancer patients (HER2-) and Estrogen receptor-positive (ER+) breast cancer patients undergoing adjuvant chemotherapy without trastuzumab.
62681944|NCT05557812|EXPERIMENTAL|non-eugenol based ZOE and Ferric Sulfate|non-eugenol based ZOE and Ferric Sulfate in primary molar pulpotomy procedures.
62681945|NCT05557812|EXPERIMENTAL|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide and Ferric Sulfate in primary molars pulpotomies procedures.
62681946|NCT04688138||ischemic stroke|Patients with ischemic stroke within 7 days of onset
62681947|NCT04524429||Pre-operative Group|This is the group of participants who suffer from obesity and are awaiting bariatric surgery.
62681948|NCT04524429||Post-operative Group|This is the group of participants who suffer from obesity and have received bariatric surgery.
62122486|NCT00710515|EXPERIMENTAL|2|without food
62681949|NCT05921162||Observation of Participants exposed to 1.2E11gc/eye of vMCO-I|This is a long-term follow-up observational study of participants who previously received 1.2E11gc/eye of vMCO-I No investigational product will be administered in this study.
62311410|NCT05126225|EXPERIMENTAL|Protocol group|The intervention is modularized to eight weekly sessions of 2-hour group discussions. The facilitator applies the principle of Cognitive Behavior Therapy and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques. In five sessions, participants are introduced to the general cognitive-behavioral model of HIV stigma and are encouraged to track their thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate helpful and non-helpful coping strategies and practice applying helpful coping skills to effectively reduce their HIV stigma. In the other three sessions, participants further discuss more specific stigma that intersects with HIV stigma, including stigma in healthcare settings, access to social support, and available resources on the society levels.
62311411|NCT03691558|EXPERIMENTAL|Ketogenic diet|Subjects followed 5 weeks of ketogenic diet
62311412|NCT03691558|ACTIVE_COMPARATOR|Western Diet|Subjects followed 5 weeks of a western diet
62311413|NCT02941731|EXPERIMENTAL|Sequence 1|HIP1403→HGP0919
62681950|NCT05921162||Observation of Participants exposed to 0.6E11gc/eye of vMCO-I|This is a long-term follow-up observational study of participants who previously received 0.6E11gc/eye of vMCO-I No investigational product will be administered in this study.
62681951|NCT06655194|EXPERIMENTAL|Comparator-test-comparator|"Participants will be randomly assigned to the treatment sequence comparator-test-comparator according to a computer-generated randomization list."
62122487|NCT00073684|EXPERIMENTAL|1|Participants will receive 8 sessions of TF-CBT with narrative.
62122488|NCT00073684|EXPERIMENTAL|2|Participants will receive 8 sessions of TF-CBT without narrative.
61922332|NCT05644249|EXPERIMENTAL|Experimental treatment|Each patient will be scheduled for 3 courses of combined treatment: in total 3 PIPAC with cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 and 6 cycles of FOLFOX systemic chemotherapy.
62122489|NCT00073684|EXPERIMENTAL|3|Participants will receive 16 sessions of TF-CBT with narrative.
62122490|NCT00073684|EXPERIMENTAL|4|Participants will receive 16 sessions of TF-CBT without narrative.
62122491|NCT04925765|EXPERIMENTAL|Virtual Reality (VR) Session|All participants in this study will complete a 1 hour virtual reality session.
62122492|NCT05552469|EXPERIMENTAL|DFV890 low dose|DFV890 given as single agent at a low dose
62122493|NCT05552469|EXPERIMENTAL|DFV890 high dose|DFV890 given as single agent at a high dose
62311414|NCT02941731|EXPERIMENTAL|Sequence 2|HGP0919→HIP1403
62311415|NCT04943900|EXPERIMENTAL|Part 1A: Monotherapy (BMS-986416)|
62311416|NCT04943900|EXPERIMENTAL|Part 1B: Combination Therapy (BMS-986416 + Nivolumab)|
62311417|NCT04091867|EXPERIMENTAL|sEphB4-HSA with CRT|"sEphB4-HSA: Loading dose at fixed dose of 10mg/Kg per below schema on D1 Concurrent dose per below schema D15-43 and given on an every other week basis Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).~Cetuximab:~Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window~RT:~6930 cGy IMRT starting D15-D18"
62311418|NCT01962259|EXPERIMENTAL|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
62311419|NCT01962259|EXPERIMENTAL|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
62476841|NCT01218867|EXPERIMENTAL|Cohort 1 (1x10(6) cells (high dose IL-2)|Patients will receive (1x10(6) cells plus high dose aldesleukin
62681952|NCT06655194|EXPERIMENTAL|Test-comparator-test|"Participants will be randomly assigned to the treatment sequence test-comparator-test according to a computer-generated randomization list."
62122494|NCT06142851||Women with superficial dyspareunia|Adult women, having sexual activity with or without vaginal penetration, suffering from superficial dyspareunia, whether or not managed by health professionals.
62122495|NCT05726604|NO_INTERVENTION|3D CT Scan|Assesment of an usual cardiac dosimetry based on 3D CT scan. Only this dosimetry will be used to treat the patients. Because of the crossover model, patients are included in both arms.
62122496|NCT05726604|EXPERIMENTAL|4D CT scan with respiratory gating|Assesment of an experimental cardiac dosimetry based on 4D CT scan. Not used to treat the patients. Because of the crossover model, patients are included in both arms.
62122497|NCT04488783|EXPERIMENTAL|Glioblastoma patients|newly diagnosed GB who underwent at least partial resection of the tumor surgically
62122498|NCT03680703|EXPERIMENTAL|Internet|Guided self-help behavioral weight loss treatment delivered via the internet
62122499|NCT03680703|EXPERIMENTAL|Internet Plus Phone|Guided self-help behavioral weight loss treatment delivered via the internet with weekly phone consultations
62122500|NCT00734240|EXPERIMENTAL|A|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo
62122501|NCT00734240|EXPERIMENTAL|B|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62122502|NCT00734240|EXPERIMENTAL|C|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62122503|NCT00734240|EXPERIMENTAL|AA|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo
62122504|NCT00734240|EXPERIMENTAL|BB|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62122505|NCT00734240|EXPERIMENTAL|CC|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62122506|NCT00734240|EXPERIMENTAL|G|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62122507|NCT00734240|EXPERIMENTAL|H|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62122508|NCT00734240|EXPERIMENTAL|I|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62681953|NCT06656507|EXPERIMENTAL|Quadro Iliac Plane Block (QIPB) Arm|Patients in this arm will receive the Quadro Iliac Plane Block (QIPB) before awakening from lumbar vertebra surgery. Patients in this arm will receive the Quadro Iliac Plane Block (QIPB) before awakening from lumbar vertebra surgery. The patient will be placed in a prone position, and a low-frequency convex ultrasound transducer (2-6 MHz) will be used. The transducer will be placed in the midline at the L3 level in the transverse plane to identify the spinal process. After lateral movement, the transverse process within the erector spinae muscle will be visualized. The transducer will then be rotated to the parasagittal plane and moved caudally to identify the attachment of the Quadratus Lumborum Muscle (QLM) to the iliac crest. A 22G x 100 mm peripheral nerve block needle (Stimuplex® Ultra 360®, B-Braun, USA) will be advanced under ultrasound guidance, and 50 mg (0.25%) bupivacaine will be injected bilaterally into the fascia below the QLM.
62681954|NCT06656507|EXPERIMENTAL|Erector Spinae Plane Block (ESP) Arm|Patients in this arm will receive the Erector Spinae Plane Block (ESP) before awakening from lumbar vertebra surgery. Patients in this arm will receive the Erector Spinae Plane Block (ESP) before awakening from lumbar vertebra surgery. A linear ultrasound probe will be placed transversely over the L3 vertebra to visualize the transverse process. A block needle (Stimuplex® Ultra 360®, B-Braun, USA) will be advanced under ultrasound guidance until it contacts the transverse process. After withdrawing the needle by 1 mm, 50 mg (0.25%) bupivacaine will be injected bilaterally.
62681955|NCT01812746|EXPERIMENTAL|BIND-014|
62681956|NCT01779206|ACTIVE_COMPARATOR|Anthracycline - Taxane|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
62681957|NCT01779206|EXPERIMENTAL|Taxane - Anthracycline|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
62681958|NCT04550728|EXPERIMENTAL|FES+robot|Participants in this group will have FES during ankle robot training
62681959|NCT04550728|ACTIVE_COMPARATOR|Robot|Participants in this group will have ankle robot training only
62681960|NCT05735652||Subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel|This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to radiotherapy.
62681961|NCT05787483|EXPERIMENTAL|MindUP group|Teachers in the MindUP group will deliver the program lessons twice a week for 30 minutes (1 hour per week) for 12 weeks. Based on previous studies, 12 weeks should be sufficient to cover the content from the 17 lessons.
62681962|NCT05787483|ACTIVE_COMPARATOR|active control group|business as usual; regular wellness or SEL classes
62681963|NCT02893436||Curarized patients|
62681964|NCT02124421|ACTIVE_COMPARATOR|CRS with adjuvant IV/IP chemotherapy|Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up
61922333|NCT03157323|OTHER|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
61922334|NCT00761748|EXPERIMENTAL|SenSura|SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
62311420|NCT01962259|EXPERIMENTAL|Active commuting|Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km
62681965|NCT02124421|EXPERIMENTAL|CRS/HIPEC with adjuvant IV chemotherapy|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up
61922335|NCT00761748|ACTIVE_COMPARATOR|Convatec|Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
62311421|NCT01962259|NO_INTERVENTION|Control|Receives no intervention.
62681966|NCT06036836|EXPERIMENTAL|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) via an intravenous (IV) infusion every 3 weeks (Q3W) for 3 cycles in the neoadjuvant period and 14 cycles of adjuvant therapy. Each cycle is 21 days. Participants who do not complete all 3 neoadjuvant cycles should have additional cycles in the adjuvant period so that the total number of study intervention administrations is 17 treatment cycles.
62311422|NCT05677789||Participants The patient's CORMB score is 0 to 2|Participants The patient's CORMB score is 0 to 2
62311423|NCT05677789||Participants The patient's CORMB score is 3 to 4|Participants The patient's CORMB score is 3 to 4
62476842|NCT01218867|EXPERIMENTAL|Cohort 2 (3x10(6) cells (high dose IL-2)|Patients will receive (3x10(6) cells plus high dose aldesleukin
62476843|NCT01218867|EXPERIMENTAL|Cohort 3 (1x10(7) cells (high dose IL-2)|Patients will receive (1x10(7) cells plus high dose aldesleukin
62476844|NCT01218867|EXPERIMENTAL|Cohort 4 (3x10(7) cells (high dose IL-2)|Patients will receive (3x10(7) cells plus high dose aldesleukin
62476845|NCT01218867|EXPERIMENTAL|Cohort 5 (1x10(8) cells (high dose IL-2)|Patients will receive (1x10(8) cells plus high dose aldesleukin
62122509|NCT00734240|EXPERIMENTAL|GG|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62476846|NCT01218867|EXPERIMENTAL|Cohort 6 (3x10(8) cells (high dose IL-2)|Patients will receive (3x10(8) cells plus high dose aldesleukin
62476847|NCT01218867|EXPERIMENTAL|Cohort 7 (1x10(9) cells (high dose IL-2)|Patients will receive (1x10(9) cells plus high dose aldesleukin
62122510|NCT00734240|EXPERIMENTAL|HH|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62311424|NCT05677789||Participants The patient's CORMB score is 5 or above|Participants The patient's CORMB score is 5 or above
62311425|NCT05020184|ACTIVE_COMPARATOR|Cimetidine|Cimetidine 800mg orally twice daily
62311426|NCT05020184|PLACEBO_COMPARATOR|Placebo|Placebo capsule orally twice daily
62476848|NCT01218867|EXPERIMENTAL|Cohort 8 (1x10(9) cells (low dose IL-2)|Patients will receive (1x10(9) cells plus low dose aldesleukin
62476849|NCT01218867|EXPERIMENTAL|Cohort 9 (3x10(9) cells (low dose IL-2)|Patients will receive (3x10(9) cells plus low dose aldesleukin
62476850|NCT01218867|EXPERIMENTAL|Cohort10(1x10(10) cells (low dose IL-2)|Patients will receive (1x10(10) cells plus low dose aldesleukin
62476851|NCT01218867|EXPERIMENTAL|Cohort11(3x10(10) cells (low dose IL-2)|Patients will receive (3x10(10) cells plus low dose aldesleukin
62476852|NCT04044521|EXPERIMENTAL|Academic detailing only|Clinicians will attend an educational meeting and receive audit and feedback reports for 18 months.
62476853|NCT04044521|EXPERIMENTAL|Academic detailing+practice facilitation|"Clinicians of this group will attend an educational meeting and receive a monthly audit and feedback report for 18 months.~At month 3, clinics will be randomized to receive practice facilitation. Clinics will be asked to follow-up with the facilitators via phone or video chat monthly for months 4-9, then quarterly for months 10-18."
62476854|NCT04044521|EXPERIMENTAL|Academic detailing+practice facilitation+physician peer consul|Clinicians will receive academic detailing at month 0 and practice facilitation at month 3. At month 9, clinics will be randomized to receive physician peer consulting. Clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant.
62476855|NCT04044521|EXPERIMENTAL|Academic detailing+physician peer consulting|"Clinicians of this group will attend an educational meeting and will receive a monthly audit and feedback report for 18 months.~At month 9, clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant."
62311427|NCT03768401|EXPERIMENTAL|Educational Seminars and Wellness Clinics|"I. Community outreach educational seminars about wellness and exercise while living with a neurological physical disability and measurement of the effects of these seminars for training individuals with neurological physical disabilities and their care givers (family, therapists, community personal trainers and community funders such as Lions or Rotary Clubs) about how to create a safe cost-effective exercise program .~II. Creation and measurement of the effects of a wellness clinic for those with a neurological physical disability."
62476856|NCT00440167|ACTIVE_COMPARATOR|Arm A|
62476857|NCT00440167|ACTIVE_COMPARATOR|Arm B|
62476858|NCT00772603|PLACEBO_COMPARATOR|Placebo|Placebo - four identical tablets taken orally once daily
62476859|NCT00772603|ACTIVE_COMPARATOR|2400 mg SPN-804|2400mg OXC XR taken orally once daily as four identical tablets
62476860|NCT00772603|ACTIVE_COMPARATOR|1200mg SPN-804|1200mg OXC XR taken orally once daily as four identical tablets
62476861|NCT00893685|EXPERIMENTAL|Home telemonitoring|
61922336|NCT02474888||Rituximab|a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.
62122511|NCT00734240|EXPERIMENTAL|II|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
62122512|NCT00734240|EXPERIMENTAL|F (100 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
62122513|NCT00734240|EXPERIMENTAL|Dose-Titration 1|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
62122514|NCT00734240|EXPERIMENTAL|F (200 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
62122515|NCT00734240|EXPERIMENTAL|Dose-Titration 7|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
62311428|NCT04828876|EXPERIMENTAL|Yoga practice|The yoga practice will be held 2 days a week for 6 weeks, a total of 12 sessions. Each session is set as one hour
62311429|NCT04828876|NO_INTERVENTION|Control group|Routine maintenance will be applied
62476862|NCT00893685|NO_INTERVENTION|Usual care (control group)|
62496020|NCT04422652|ACTIVE_COMPARATOR|Strategy 1|Strategy 1: Single-blind Behavioral Activation Therapy plus placebo for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind bupropion (Phase 2) for another 8 weeks.
62311430|NCT05783401||Cohort A: palliative care center|Patients from a palliative care center (Palliativzentrum Hildegard, Basel)
62476863|NCT06133920||Immobilization Group|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
62122516|NCT02817282|OTHER|Hand hygiene implementation strategy|The implementation strategy will be tested in a stepped wedge cluster randomized trial which is based on a random sequential roll-out of the CHANGE implementation strategy to all participating NHs (n=20) for comparison. All groups (hence all NHs) start with the control situation (no CHANGE implementation activities) at the beginning of the study. At each time point, a new group of five NHs crosses over from the control situation to the implementation situation. Each group will start the implementation phase of 4 months at a different time point, directly after one of the measurements periods (Point of Time (PT) 0, PT1, PT2, PT3, PT4, PT5). The time point a group crosses over is randomized (over the groups).
62311431|NCT05783401||Cohort B: mid-size cancer center|Patients from a mid-size cancer center (Tumorzentrum Baselland)
62311432|NCT01373645|EXPERIMENTAL|Yinyi stent|subjects with Yinyi stent implantation
62311433|NCT02492711|EXPERIMENTAL|Margetuximab plus chemotherapy|Margetuximab 15 mg/kg every 21 days
62311434|NCT02492711|ACTIVE_COMPARATOR|Trastuzumab plus chemotherapy|Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 21 days
62476864|NCT06133920||Early ROM|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
62122517|NCT01563354|EXPERIMENTAL|Pasireotide LAR|Pasireotide long acting release (LAR) 60 mg will be administered as an intra muscular (i.m.) depot injection once every 28 days starting on Day 1
62122518|NCT01563354|EXPERIMENTAL|Everolimus|Everolimus 10 mg taken orally (p.o) once daily starting on Day 1
62311435|NCT02492711|EXPERIMENTAL|Margetuximab Infusion Sub-study|Margetuximab 15 mg/kg every 21 days (with or without chemotherapy), studying a shorter duration of infusion beginning in Cycle 2.
62311436|NCT03915691|ACTIVE_COMPARATOR|Isthmus targeted approach using Ripple Mapping|Intervention: Isthmus targeted approach using Ripple Mapping catheter ablation of atrial tachycardia.
62311437|NCT03915691|ACTIVE_COMPARATOR|Conventional Mapping|Intervention: conventional catheter ablation of atrial tachycardia.
62311438|NCT04188366|EXPERIMENTAL|FAMES Modification|3-month trial of FAMES. Results from modifications will be used to by stakeholders (i.e., family members, client, providers, organizational leadership,) to inform finalization and implementation of FAMES
62311439|NCT04188366|EXPERIMENTAL|FAMES Pilot Trial|Pilot testing of FAMES and implementation toolkit
62311440|NCT06672302||Breast malignant nodule group|
62476865|NCT03590808|EXPERIMENTAL|Immune checkpoint inhibitor|"Solid cancer patients who receiving immune checkpoint inhibitor patients~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
62681967|NCT06036836|EXPERIMENTAL|Pembrolizumab|Participants will receive 200 mg pembrolizumab via an IV infusion Q3W for 3 cycles in the neoadjuvant period and 14 cycles of adjuvant therapy. Each cycle is 21 days. Participants who do not complete all 3 neoadjuvant cycles should have additional cycles in the adjuvant period so that the total number of study intervention administrations is 17 treatment cycles.
61922337|NCT03484260||Case group: Testosterone Product|Male subjects prescribed testosterone in UK
62311441|NCT06672302||Breast benign nodule group|
62311442|NCT04535011|NO_INTERVENTION|Usual Care|No prevention or educational information verbally or written coinciding with current usual care
62311443|NCT04535011|EXPERIMENTAL|PPKAY|One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use
62311444|NCT04535011|EXPERIMENTAL|PPKAY with Standard Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use.~Weekly standard text booster until final follow-up (e.g., Reducing your alcohol intake to less than 4 drinks per day reduces your risk of alcohol-related consequences)"
62311445|NCT04535011|EXPERIMENTAL|PPKAY with Personalized Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use Weekly personalized text booster until final follow-up (e.g., Remember to reduce your alcohol less than 4 drinks to achieve your goal of... \[being a better husband\].)"
62311446|NCT01419171|EXPERIMENTAL|OMEGA™ Monorail Coronary Stent System|
62311447|NCT03798561|EXPERIMENTAL|82 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 82 µg/cm2 single application in 7 days or Placebo TG (6 subjects ASN008: 2 subjects placebo) (6:2)
62311448|NCT03798561|EXPERIMENTAL|164 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 164 µg/cm2 single application in 7 days or Placebo (6:2)
62311449|NCT03798561|EXPERIMENTAL|328 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 328 µg/cm2 single application in 7 days or Placebo (6:2)
62311450|NCT03798561|EXPERIMENTAL|492 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 492 µg/cm2 single application in 7 days or Placebo (6:2)
62122519|NCT01563354|EXPERIMENTAL|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily starting on Day 1
62311451|NCT03798561|EXPERIMENTAL|ASN008 TG TBD Cohort 1 or Placebo|Part B: ASN008 TG Cohort 1 daily application for 15 days or Placebo (9 subjects ASN008: 3 subjects Placebo) (9:3)
62311452|NCT03798561|EXPERIMENTAL|ASN008 TG TBD Cohort 2 or Placebo|Part B: ASN008 TG Cohort 2 daily application for 15 days or Placebo (9:3)
62311453|NCT03798561|EXPERIMENTAL|ASN008 TG TBD Cohort 3 or Placebo|Part B: Placebo TG Cohort 3 daily application for 15 days or Placebo (9:3)
62311454|NCT01549847|EXPERIMENTAL|L-carnitine and piracetam|
62311455|NCT01549847|PLACEBO_COMPARATOR|Placebo|
62681968|NCT06036836|EXPERIMENTAL|Favezelimab/Pembrolizumab + Lenvatinib (Cohort B)|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) via IV infusion Q3W for up to 35 cycles (each cycle is 21 days) PLUS lenvatinib every day (QD) 20 mg orally until disease progression, unacceptable toxicity, or discontinuation criteria are met.
62122520|NCT02200770|PLACEBO_COMPARATOR|Placebo/Inebilizumab|Aquaporin-4-antibody (AQP4-IgG) sero positive and sero negative participants will receive IV dose of placebo matched to inebilizumab on Day 1 and Day 15 of the RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on both Day 1 and Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
62311456|NCT03267329|EXPERIMENTAL|Duowell® Tab.|Once daily during 16 wks
62311457|NCT03267329|ACTIVE_COMPARATOR|Telmisartan|Once daily during 16 wks
62122521|NCT02200770|EXPERIMENTAL|Inebilizumab/Inebilizumab|AQP4-IgG sero positive and sero negative participants will IV dose of inebilizumab 300 mg on Day 1 and Day 15 of RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on Day 1 and matching placebo on Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
62311458|NCT04741243|EXPERIMENTAL|Extracorporeal shock wave therapy|was used for 15 minutes in a prone position for both groups (A\&B) before the treatment. shock wave were used to heat small areas, and allow for decrease pain, muscle spasm, and provide vasodilatation of the blood vessels supplying the area
62311459|NCT04741243|EXPERIMENTAL|dietary modification|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level.
62311460|NCT03763279|EXPERIMENTAL|Triclosan-coated barbed suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone barbed suture
62311461|NCT03763279|EXPERIMENTAL|Triclosan-coated monofilament suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone monofilament suture
62311462|NCT03763279|SHAM_COMPARATOR|Monofilament suture|Abdominal wall closure will be performed using a monofilament suture
62311463|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
62311464|NCT05452746|EXPERIMENTAL|Acupuncture|
62311465|NCT05452746|ACTIVE_COMPARATOR|Treatment as usual|
62476866|NCT03590808|ACTIVE_COMPARATOR|Cytotoxic chemotherapy|"Solid cancer patients who receiving conventional cytotoxic chemotherapy~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
62681969|NCT06036836|EXPERIMENTAL|Pembrolizumab + Lenvatinib (Cohort B)|Participants will receive 200 mg pembrolizumab via IV infusion Q3W for up to 35 cycles (each cycle is 21 days) PLUS lenvatinib QD 20 mg orally until disease progression, unacceptable toxicity, or discontinuation criteria are met.
62681970|NCT05756829|EXPERIMENTAL|High frequency, low-touch virtual health care|"Participants in this arm will receive a high frequency, low-touch virtual health care intervention through the Maple application, as an adjunct to usual T1D care. High-frequency visits will occur every 2 +/- 1 weeks for a total of 6 months.~Participants will also receive access to a virtual library to support T1D self-learning and as a guided educational tool."
62681971|NCT05756829|NO_INTERVENTION|Standard Care|Participants in this arm will receive the standard of care offered for their condition and by their clinic.
62681972|NCT02585180|ACTIVE_COMPARATOR|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
62681973|NCT02585180|EXPERIMENTAL|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
62681974|NCT01455844|EXPERIMENTAL|CaPre 1.0g|
62476867|NCT05770648|EXPERIMENTAL|K-clipTM transcatheter annuloplasty system+Guideline Directed Medical Therapy GDMT|
62476868|NCT05770648|OTHER|Guideline Directed Medical Therapy, GDMT|
62681975|NCT01455844|EXPERIMENTAL|CaPre 2.0g|
62681976|NCT01455844|PLACEBO_COMPARATOR|Placebo|
62681977|NCT05284747|EXPERIMENTAL|Evolocumab + Routine Lipid Management|Participants will receive open-label evolocumab every 2 weeks (Q2W) plus routine lipid management.
62681978|NCT05284747|ACTIVE_COMPARATOR|Routine Lipid Management|Participants will receive routine lipid management per standard of care (SoC).
62122522|NCT04769765|EXPERIMENTAL|All patients on the basic diabetic program, eligible for an individualized care pathway.|This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalizations repeated throughout the year (≥ 2/year). The feasibility will be assessed by the number of patients who have had at least 3 of the 4 planned follow-up visits, that is to say, who are eligible for the individualized care pathway.
62476869|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
62681979|NCT04837547|EXPERIMENTAL|Arm 1: Subjects with Diffuse Intrinsic Pontine Glioma (DIPG).|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10\^7 cells/kg Dose Level +1: 3 x10\^8 cells/kg Dose Level -1: 3 x10\^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
62681980|NCT04837547|EXPERIMENTAL|Arm 2: Relapsed/Refractory Neuroblastoma (NB)|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10\^7 cells/kg Dose Level +1: 3 x10\^8 cells/kg Dose Level -1: 3 x10\^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
62681981|NCT06688539|OTHER|Co-use group|E-cigarette and cannabis co-use group
62681982|NCT03430973|EXPERIMENTAL|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
62122523|NCT05220215|EXPERIMENTAL|Group A: Nordic Hamstring Exercise|"This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stretching.~Number of sets and repetitions progressively increase i-e: Week 1 - 2 sessions with 2 sets of 5 repetitions each. Week 2 - 2 sessions with 3 set of 5 repetitions each. Week 3 - 2 sessions with 4 set of 6 repetitions each. Week 4 - 2 sessions with 4 set of 8 repetitions each."
62122524|NCT05220215|EXPERIMENTAL|Group B: Hamstring Curl with Resistance Band|"This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stretching.~Number of sets progressively increase i-e: Week 1 - 2 sessions with 2 sets of 15 repetitions each. Week 2 - 2 sessions with 3 set of 15 repetitions each. Week 3 - 2 sessions with 4 set of 15 repetitions each. Week 4 - 2 sessions with 4 set of 15 repetitions each."
62122525|NCT03929770|ACTIVE_COMPARATOR|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
62122526|NCT03929770|EXPERIMENTAL|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
62122527|NCT05692635|EXPERIMENTAL|Surveillance MRI of the Brain|Brain MRI will be performed as scheduled for up to 14 months or until detection of a brain metastasis, whichever occurs first.
62476870|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
62311466|NCT02584569|EXPERIMENTAL|TAK-915|TAK-915 100 mg suspension, orally, once on Day 1. Additional TAK-915 dose levels may be incorporated based on dose level review meetings (DLRMs) following approximately every 2 participants and based on prior occupancy, duration of occupancy, safety, tolerability, and available pharmacokinetic (PK) data.
62311467|NCT05650229|EXPERIMENTAL|KL1333|Twice daily
62311468|NCT05650229|PLACEBO_COMPARATOR|Matching Placebo|Twice daily
62311469|NCT04749108|EXPERIMENTAL|Experimental: Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy performed within 4 to 6 weeks from randomization."
62681983|NCT03430973|EXPERIMENTAL|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
62311470|NCT04749108|ACTIVE_COMPARATOR|RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy) followed after 7 weeks by a proctectomy."
62476871|NCT05960747||Control group|Medical students with standard training: theoretical teaching, associated with a real-life demonstration of at least one thoracentesis by a senior doctor from our department
62476872|NCT05960747||Simulation group|Medical students with standard training + training using an augmented virtual reality simulator specially developed for thoracentesis.
62476873|NCT06456073|EXPERIMENTAL|Intervention Arm|Local percutaneous injection of E-CEL UVEC cells around the anal fissure
62476874|NCT01694212|EXPERIMENTAL|Diclofenac|Patients with diabetic retinopathy having preoperative treatment with diclofenac
61922338|NCT03484260||Control group|Matched male subjects not prescribed testosterone in the UK
62122528|NCT00477776|ACTIVE_COMPARATOR|a|Mother with diet-controlled diabetes receive Metoclopramide 10 mg 3 times a day for the first 7 days, and 2 times a day for day 8 to 10, and once a day from day 11 to day 12
62122529|NCT00477776|PLACEBO_COMPARATOR|b|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day for day 11 to 12
61922339|NCT00912665|EXPERIMENTAL|Healthy Volunteer|
61922340|NCT03986632|EXPERIMENTAL|Tundra gifts program|
61922341|NCT03986632|NO_INTERVENTION|Comparison|
61922342|NCT03335917|PLACEBO_COMPARATOR|Normobaric Normoxia|This will serve as the exercise only control trial
62122530|NCT00477776|ACTIVE_COMPARATOR|c|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day from day 11 to 12
62122531|NCT00477776|PLACEBO_COMPARATOR|d|Placebo 10 mg 3 times a day for 7 days, 2 times a day for day 8 to 10; and once a day from day 11 to 12
62122532|NCT06227637|ACTIVE_COMPARATOR|Group (A) (Muscle Energy Techniques )|Muscle Energy Techniques
62122533|NCT06227637|ACTIVE_COMPARATOR|Group( B) (Local Muscle Vibration)|Local Muscle Vibration
62122534|NCT06112899|EXPERIMENTAL|Healthy Young Men|
62311471|NCT06671535|EXPERIMENTAL|PMMA arm|Patients in the experimental group will receive maintenance hemodialysis using polymetilmethacrylate membranes for 2 months.
62311472|NCT06671535|ACTIVE_COMPARATOR|Polysulfone arm|Patients in the control group will receive maintenance hemodialysis using polysulfone membranes for 2 months.
62311473|NCT02627950|ACTIVE_COMPARATOR|Isotonic sodium chloride + Ticagrelor|46 patients with NaCl i.v. and 180 mg ticagrelor orally pre revascularization plus medical standard therapy
62311474|NCT02627950|EXPERIMENTAL|Morphinhydrochloricum + Ticagrelor|46 patients with 5 mg morphine i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
62311475|NCT02627950|EXPERIMENTAL|Morphinhydrochloricum + Ticagrelor + Metoclopramide|46 patients with 5 mg morphine i.v. and 10 mg MCP i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
62311476|NCT00677144|EXPERIMENTAL|OS (oxalipaltin+S-1)|OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
62311477|NCT00677144|ACTIVE_COMPARATOR|XELOX (oxalipaltin+capecitabine)|XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
62476875|NCT01694212|PLACEBO_COMPARATOR|Placebo|Control group having placebo treatment
62476876|NCT03370263||Benlysta intravenous (IV)|This arm will include subjects who will receive Benlysta IV. Observation period per subject will be for 52 weeks from start of Benlysta administration.
62476877|NCT03370263||Benlysta subcutaneous (SC)|This arm will include subjects who will receive BENLYSTA SC. Observation period per subject will be for 52 weeks from start of Benlysta administration.
62122535|NCT05303753|OTHER|Single group|During a 3-week baseline period, participants with self-reported GI complaints consume their own protein supplement that they use for recovery purposes after exercise, followed by a 3-week intervention period in which they maintain usage of their own product, but replace a part of this product with a fermented dairy protein with prebiotic fiber. An additional reference group of athletes without self-reported GI complaints will also be followed during a 3-week period in which they consume their own protein supplement that they use for recovery purposes after exercise.
62122536|NCT04244214||More Stamina users|This group of patients will use the app for 60 days and all information about utilization will be recorded
62311478|NCT01252329|ACTIVE_COMPARATOR|Elective lymph node treatment arm|Patients entering this arm will undergo selective nodal dissection of the draining lymph nodes with subsequent radiation and/or chemotherapy if indicated.
62311479|NCT01252329|NO_INTERVENTION|Clinical observation arm|Patients who enter into this arm will undergo regular, periodic clinical nodal observation with subsequent evaluation and treatment if indicated upon discovery of a palpable lymph node.
62311480|NCT04868240|EXPERIMENTAL|Concurrent Training Group|The experimental group will perform 16-weeks of the concurrent training exercise.
62311481|NCT04868240|NO_INTERVENTION|Control Group|Maintain their usual habits/activities, including not participate in any type of physical exercise.
62311482|NCT04797286|EXPERIMENTAL|Sildenafil|Sildenafil 20 mg by mouth three(3) times each day
62311483|NCT04797286|PLACEBO_COMPARATOR|Placebo|Placebo by mouth three(3) times each day
62311484|NCT06562816|EXPERIMENTAL|Trypsin-Chymotrypsin|This group will receive sealed envelopes containing oral formulations of Trypsin:Chymotryspin in the ratio of 6:1 with an enzymatic activity of 100000 A.U./tablet (Tab. Chymoral Forte) three times a day, 30 minutes before meals for 24 hours.
62311485|NCT06562816|ACTIVE_COMPARATOR|Naproxen Sodium|The active control group will receive oral formulation of Naproxen Sodium 550mg (Tab. Synflex) twice a day, after meals for 24 hours.
62311486|NCT04675346||Questionnaire|The EUNASS Study Questionnaire is an electronic questionnaire (using the Qualtrics programme) designed to assess management after diagnosis of melanoma and during follow-up, health status, fear of melanoma recurrence, melanoma-specific supportive care needs, sun protection behaviour, views and habits about SSE and standard socio-demographic details.
62311487|NCT04675346||Interviews|A qualitative researcher will undertake 25-30 semi-structured interviews with participants who have volunteered their contact details in the final section of the EUNASS Study Questionnaire. A purposive sampling approach will be taken for participant recruitment to this part of the study.
62311488|NCT05706467|EXPERIMENTAL|non-invasive high-frequency oscillatory ventilation|The day before the test, the patient was titrated with the oxygen concentration under non-invasive ventilation. The non-invasive continuous positive airway pressure ventilation was used, the pressure was set at 8cmH2O, and the oxygen concentration was titrated when the blood oxygen saturation was greater than 92% during non-invasive ventilation, and the oxygen concentration in the respiratory tube was constant after the test. In non-invasive high-frequency oscillatory ventilation mode, maintain the same positive airway pressure setting, and superimpose high-frequency oscillatory airflow with amplitude of 6cmH2O and oscillatory frequency of 10HZ.
62476878|NCT06062498|EXPERIMENTAL|Elacestrant Monotherapy|Elacestrant (345 mg) will be taken orally once daily for each 28-day cycle. Courses repeat until progressive disease.
62122537|NCT00461747|ACTIVE_COMPARATOR|A|"Four alternating cycles of VBMCP/VBAD + Velcade VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20. The interval between VBMCP and VBAD is 5 weeks and between VBAD and VBMCP is 4 weeks. The patients will received two cycles of VBMCP and two cycles of VBAD. After 4 weeks of last cycle of VBAD, patients will received two cycles of Velcade, 1,3 mg/ m2 iv twice a week (days 1, 4, 8 and 11), followed by 10 days without treatment"
62122538|NCT00461747|EXPERIMENTAL|B|"Six cycles of 4 weeks of Thalidomide/Dexamethasone. Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity \< grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
62122539|NCT00461747|EXPERIMENTAL|C|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is \< grade 2, the dose will be increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days."
62122540|NCT04833855|ACTIVE_COMPARATOR|Group 1: Omalizumab|Participants naive to anti-IgE therapies will receive omalizumab.
62122541|NCT04833855|PLACEBO_COMPARATOR|Group 2: Placebo|Participants naive to anti-IgE therapies will receive a placebo.
62122542|NCT04833855|EXPERIMENTAL|Group 3: Tezepelumab Dose 1|Participants naive to anti-IgE therapies will receive tezepelumab.
62311489|NCT05706467|ACTIVE_COMPARATOR|continuous positive airway pressure ventilation|The patient was titrated with non-invasive ventilator-related parameters and oxygen uptake concentration the day before the test, and the parameter setting was maintained in the formal experiment.
62311490|NCT04729127|NO_INTERVENTION|Treatment as usual|The families keep receiving their treatment as usual
62311491|NCT04729127|ACTIVE_COMPARATOR|ImPACT at a dose of 1 hour/week|ImPACT at a dose of 1 hour/week over 6 months
62122543|NCT04833855|EXPERIMENTAL|Group 4: Tezepelumab Dose 2|Participants naive to anti-IgE therapies will receive tezepelumab.
62122544|NCT04833855|PLACEBO_COMPARATOR|Group 5: Placebo|Participants previously treated with anti-IgE therapies will receive a placebo.
62122545|NCT04833855|EXPERIMENTAL|Group 6: Tezepelumab Dose 1|Participants previously treated with anti-IgE therapies will receive tezepelumab.
62122546|NCT04833855|EXPERIMENTAL|Group 7: Tezepelumab Dose 2|Participants previously treated with anti-IgE therapies will receive tezepelumab.
62311492|NCT04729127|ACTIVE_COMPARATOR|ImPACT at 4 hours/week|ImPACT at 4 hours/week over 6 months.
62681984|NCT03430973|EXPERIMENTAL|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
62311493|NCT03421223||Case|Individuals diagnosed with chronic pain
62311494|NCT03421223||Control|Individuals without chronic pain
62311495|NCT02688075||Canagliflozin Plus or Minus(+/-) Other Antihyperglycemic Agent|Participants who are receiving Canagliflozin +/- other antihyperglycemic agent (AHA) as per usual clinical practice will be observed for effectiveness, safety and PRO.
62681985|NCT03430973|EXPERIMENTAL|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
62681986|NCT03430973|EXPERIMENTAL|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=40) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) 12-pack of beer on passenger seat, or (2) 12-pack of sparkling water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
62122547|NCT01462058|ACTIVE_COMPARATOR|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 12 weeks.
62122548|NCT01462058|PLACEBO_COMPARATOR|placebo|one tablet of sugar pill per day for 12 weeks.
62311496|NCT01686503|EXPERIMENTAL|2/5 dose intradermal IPV|Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
62311497|NCT01686503|EXPERIMENTAL|1/5 dose intradermal IPV|Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
62311498|NCT01686503|ACTIVE_COMPARATOR|full dose intramuscular IPV|Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
62122549|NCT06554327|EXPERIMENTAL|intervention group|
62122550|NCT06554327|ACTIVE_COMPARATOR|control group|
62122551|NCT03400488|EXPERIMENTAL|AZD5718|Randomized subjects will receive orally once daily dose of AZD5718 oral suspension on Day 1 (SAD) and MAD from Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
62311499|NCT01686503|ACTIVE_COMPARATOR|2/5 dose intramuscular IPV|Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
62311500|NCT01927562|EXPERIMENTAL|Duodenal Treatment|The Duodenal Remodeling procedure utilizes both a trans-oral over the wire and endoscopic approach to minimally invasively ablating and remodeling the duodenum.
62311501|NCT05067777|EXPERIMENTAL|Arm I (SMT)|Patients receive SMT over 45 minutes once weekly for 6 weeks.
62311502|NCT05067777|SHAM_COMPARATOR|Arm II (LT)|Patients receive LT over 45 minutes once weekly for 6 weeks.
62311503|NCT05067777|ACTIVE_COMPARATOR|Arm III (waitlist)|Patients receive no intervention for 6 weeks.
62122552|NCT03400488|PLACEBO_COMPARATOR|Placebo|Randomized subjects will receive orally once daily dose of placebo matching AZD5718 oral suspension on Day 1 (SAD) and MAD form Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
62681987|NCT03430973|EXPERIMENTAL|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
62681988|NCT03430973|EXPERIMENTAL|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng \& Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
61922343|NCT03335917|EXPERIMENTAL|Normobaric Hypoxia|This arm will provide hypoxia by reducing the amount of oxygen concentration without changing the barometric pressure
62122553|NCT01959126|EXPERIMENTAL|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment.
62122554|NCT05896319|EXPERIMENTAL|Treatment group|Postoperative application of hyaluronic acid gels 3 times per day for 7 days after tooth extraction
61922344|NCT03335917|EXPERIMENTAL|Hypobaric Hypoxia|This arm will provide hypoxia by reducing the barometric pressure without changing the oxygen concentration (terrestrial altitude exposure)
61922345|NCT03013127|EXPERIMENTAL|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg i.v. every 3 weeks for up to 35 cycles
61922346|NCT01392482||treatment with antipsychotics|40 LHU covering about 18 millions inhabitants distributed all over Italy with a coverage of nearly 100% of Italian regions. All subjects will be included in the analysis who have received treatment with antipsychotics (typical and / or atypical) between January 1, 2009 and June 30, 2010 and diagnosed with schizophrenia and / or Bipolar Disorder.
62122555|NCT05896319|NO_INTERVENTION|Control group|No adjunctive therapy undergoing natural healing
62681989|NCT04292496|EXPERIMENTAL|Intraperative leak testing group|i) the integrity of the anastomosis can be directly observed under gastroscopy. ii) the distal of Roux limb was temporarily blocked, then the bowel of anastomosis was inflated by air, following 60 milliliter methylene blue.
61922347|NCT05521776|EXPERIMENTAL|With first trimester preeclampsia screening|Risk assessment of developing preeclampsia between 11 and 14 WG based on maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentration. Patients at high risk of preeclampsia are treated with aspirin.
62681990|NCT04292496|NO_INTERVENTION|Non-intraoperative leak testing group|Non intraoperative leak testing was performed intraoperatively.
62681991|NCT05312892|PLACEBO_COMPARATOR|Placebo|Subjects will received 2 weeks of capsules containing placebo.
62681992|NCT05312892|ACTIVE_COMPARATOR|Amlodipine|Subjects will received 2 weeks of capsules containing amlodipine.
62681993|NCT05312892|EXPERIMENTAL|Moxonidine|Subjects will received 2 weeks of capsules containing moxonidine.
62681994|NCT01323543|EXPERIMENTAL|Elaspine™|Impantation of Elaspine™ device
62681995|NCT06496659|OTHER|Segmentectomy after Induction Therapy|Surgical intervention (segmentectomy) post induction therapy for Non-Small Cell Lung Cancer
62681996|NCT03769467|EXPERIMENTAL|Cohort 1B: Checkpoint Inhibitor Naïve|Checkpoint inhibitor naive subjects during the treatment phase will receive intravenous (IV) infusion of pembrolizumab at 200 mg for adults (≥ 18 years of age) or 2 mg/kg for adolescents (12 to \< 18 years of age) prior to the administration of tabelecleucel on Day 1; and IV infusion of tabelecleucel (tab-cel) at 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 of each 21-day treatment/consolidation cycles (at least 2 cycles or up to 4 cycles). From the Maintenance Phase, subjects with stable disease or better will receive tabelecleucel on Day 1 and pembrolizumab on Day 1, Day 21, Day 42, and Day 63 of each 84- day maintenance cycle, which was continued until disease progression, unacceptable toxicity, or a total of 35 pembrolizumab infusions (including for treatment, consolidation, and maintenance) had been administered, whichever occurred first.
62681997|NCT03769467|EXPERIMENTAL|Cohort 1B: Checkpoint Inhibitor PD-1/PD-L1 Failure|Checkpoint inhibitor PD-1/PD-L1 failure subjects during the treatment phase will receive IV infusion of pembrolizumab at 200 mg for adults (≥ 18 years of age) or 2 mg/kg for adolescents (12 to \< 18 years of age) prior to the administration of tabelecleucel on Day 1; and IV infusion of tabelecleucel (tab-cel) at 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 of each 21-day treatment/consolidation cycles (at least 2 cycles or up to 4 cycles).). From the Maintenance Phase, subjects with stable disease or better will receive tabelecleucel on Day 1 and pembrolizumab on Day 1, Day 21, Day 42, and Day 63 of each 84-day maintenance cycle, which was continued until disease progression, unacceptable toxicity, or a total of 35 pembrolizumab infusions (including for treatment, consolidation, and maintenance) had been administered, whichever occurred first.
62681998|NCT03769467|EXPERIMENTAL|Cohort 2: Checkpoint Inhibitor Naïve|Checkpoint inhibitor naive subjects during the treatment phase will receive IV infusion of pembrolizumab at 200 mg for adults (≥ 18 years of age) or 2 mg/kg for adolescents (12 to \< 18 years of age) prior to the administration of tabelecleucel on Day 1; and IV infusion of tabelecleucel (tab-cel) at 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 of each 21-day treatment/consolidation cycles (at least 2 cycles or up to 4 cycles). From the Maintenance Phase, subjects with stable disease or better will receive tabelecleucel on Day 1 and pembrolizumab on Day 1, Day 21, Day 42, and Day 63 of each 84- day maintenance cycle, which was continued until disease progression, unacceptable toxicity, or a total of 35 pembrolizumab infusions (including for treatment, consolidation, and maintenance) had been administered, whichever occurred first.
62681999|NCT01150370|EXPERIMENTAL|Males undergoing circumcision|
61922348|NCT05521776|NO_INTERVENTION|Without first trimester preeclampsia screening|Usual prenatal care
61922349|NCT05108922|EXPERIMENTAL|Donanemab|Donanemab is administered intravenously (IV) every 4 weeks (Q4W).
61922350|NCT05108922|ACTIVE_COMPARATOR|Aducanumab|Aducanumab administered IV per US label.
61922351|NCT04969367||Observational (activity monitor)|Patients wear an activity monitor (Fitbit) for 90 days. Patients also undergo collection of blood samples and complete questionnaires twice weekly for up to 90 days.
61922352|NCT05547152|EXPERIMENTAL|Experimental arm|patients benefiting from rehabilitation associated with virtual reality
61922353|NCT05547152|ACTIVE_COMPARATOR|Control arm|patients benefiting from rehabilitation without virtual reality
61922354|NCT05867342|EXPERIMENTAL|Endoscopic sinus surgery|Participants receive topical 1:1000 epinephrine plus saline in one nostril, and topical 1:1000 epinephrine plus infiltration of 1% lidocaine with 1:100,000 epinephrine in the other nostril, during endoscopic visualization while undergoing Endoscopic sinus surgery (ESS).
62311504|NCT05387590|OTHER|Preventiometer Device|The Preventiometer is a physical wellness tool that assesses multiple physical wellness measures in a 60 ± 15 minutes period of time. It is intended to promote population wellness by empowering individuals to act upon the information they receive about their overall health.
62311505|NCT04953455||pre-operation|Within one month before operation of diagnoses with a ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
62476879|NCT06062498|EXPERIMENTAL|Combination Therapy|"Patients will receive either:~Elacestrant 345 mg orally once daily~+ Palbociclib 125 mg orally once daily for 21 days out of 28-day cycle OR Abemaciclib 150 mg orally twice daily OR Ribociclib 600 mg orally once daily for 21 days out of 28-day cycle"
62476880|NCT01673672|PLACEBO_COMPARATOR|Placebo|7 weekly/biweekly injections of a placebo buffer
62476881|NCT01673672|EXPERIMENTAL|CYT003 low dose|7 weekly/biweekly injections of CYT003 low dose
62476882|NCT01673672|EXPERIMENTAL|CYT003 medium dose|7 weekly/biweekly injections of CYT003 medium dose
62682000|NCT06116032||Standard of Care Checkpoint|Patients receiving standard of care FDA approved immunotherapy
62682001|NCT06116032||Bone Marrow Transplant|Patients undergoing transplant for hematologic malignancy
62682002|NCT06116032||CAR T|Patients undergoing CAR T therapy
62682003|NCT04953169|OTHER|Video|The video is information regarding biobanking
62682004|NCT04953169|OTHER|Non-Video|The non-video group will receive a written informed consent
62682005|NCT06686784|EXPERIMENTAL|School A|Middle school students at School A who participate in the after school program. They will receive after school as usual in months 1-4, followed by after school plus in months 5-8.
62311506|NCT04953455||early after operation|Within three months after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
62311507|NCT04953455||lately after operation|within three months to one year after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement
62311508|NCT04953455||healthy volunteers|Healthy people without abnormalities
62311509|NCT01810991|EXPERIMENTAL|Nd:YAG Laser|Nd:YAG 1440nm Laser
62311510|NCT03538392||PAD|
62311511|NCT03538392||AV Fistula|
62311512|NCT03538392||AV Graft|
62311513|NCT04180410|OTHER|EIT|Electrical Impedance Tomography is performed before extubation, during follow up visits of extubation and 48H after extubation
62476883|NCT01673672|EXPERIMENTAL|CYT003 high dose|7 weekly/biweekly injections of CYT003 high dose
62476884|NCT04625153|EXPERIMENTAL|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
62476885|NCT04625153|EXPERIMENTAL|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
62476886|NCT04350359|ACTIVE_COMPARATOR|Variable-dose TTNS Protocol 5 x week|"TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.~All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci."
62496021|NCT04422652|ACTIVE_COMPARATOR|Strategy 2|Strategy 2: Double-blind bupropion plus single-blind Clinical Management (CM) attention control for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind BAT (Phase 2) for another 8 weeks.
62122556|NCT02568683|EXPERIMENTAL|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO+VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion.
62122557|NCT02568683|EXPERIMENTAL|Dose Expansion: VCR+ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) may receive VCR+ENTO.
62122558|NCT02568683|EXPERIMENTAL|Dose Expansion: VCR+ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DLBCL) may receive VCR+ENTO.
62122559|NCT06488079|EXPERIMENTAL|Nutri-Score label|
62122560|NCT06488079|EXPERIMENTAL|NutrInform Battery label|
62122561|NCT06488079|SHAM_COMPARATOR|No label|
62122562|NCT05967533|EXPERIMENTAL|Fermented wheat germ|Patients receive fermented wheat germ PO daily starting 3 days prior to the start of standard of care checkpoint inhibitor therapy on days 1-56 for 8 weeks. Patients undergo blood sample collection during screening, on days 1, 4, 15, 43 and at the end of treatment visit. Patients undergo stool sample collection during screening, day 1, 4 and at the end of treatment visit.
62311514|NCT02675517||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD)guidelines
62311515|NCT03120338|EXPERIMENTAL|The Development and Wellbeing Assessment|"The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.~The DAWBA will be administered in addition to care as usual."
62311516|NCT03120338|NO_INTERVENTION|Care as Usual|Care as usual
62122563|NCT03615417|EXPERIMENTAL|HFNC - High Flow Nasal Cannula|Participants are preoxygenated by High Flow Nasal Cannula (HFNC) OptiFlow.
62122564|NCT03615417|ACTIVE_COMPARATOR|FM - FaceMask|Participants are preoxygenated by standard anesthesia FaceMask.
62311517|NCT06672679|EXPERIMENTAL|Juntos intervention|In the Juntos intervention, 24 caregiver-adolescent dyads will receive a 6 week family-based dating violence prevention intervention called Juntos. Juntos includes 6 in-person sessions and 5 at home activities and was developed by Latino caregiver-adolescent dyads. Topics include cultural values and practices, talking about dating and dating violence, rule-setting, understanding signs of healthy and unhealthy relationships, and resources for support.
62311518|NCT06672679|ACTIVE_COMPARATOR|Control group|The control arm will resource a resource guide and can be placed on a wait list to receive the intervention after the intervention is complete
62311519|NCT02418403|ACTIVE_COMPARATOR|PREPARE|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP."
62311520|NCT02418403|EXPERIMENTAL|PREPARE+financial incentive|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP; offer of $50 to complete the website and entry into $1000 lottery for discussing ACP with one's PCP."
62122565|NCT02615210|NO_INTERVENTION|Standard|Standard of care biopsies with optional SOC-directed biopsy afterwards
62311521|NCT06029712|EXPERIMENTAL|GDMT delivered in a heart failure polypill|The polypill intervention will be pharmacy-level over-encapsulation of heart failure medications (beta-blocker, SGLT2 inhibitor, mineralocorticoid receptor antagonist, and ACE/ARB/ARNI) into a single capsule. For patients on twice-daily sacubitril/valsartan, one dose will be included in the polypill and the second dose will be dispensed separately. The investigators will partner with a local community pharmacy with proficiency in over-encapsulation. For patients in the polypill arm, heart failure medications will be filled as usual, but rather than dispensing each medication separately, the pharmacy technician will hand-pack all once-daily heart failure medications into a small vegan capsule.
62311522|NCT06029712|ACTIVE_COMPARATOR|GDMT delivered as individual tablets|As described above, participants who are not already prescribed a beta blocker, SGLT2i, ACE/ARB/ARNI, and MRA will be initiated on these medications prior to randomization if no contraindications exist. Participants randomized to usual care will receive their heart failure medications as individual pills. They will have the option to receive medications by mail, clinic pick-up, or pharmacy pick-up.
62311523|NCT02293343||control group|healthy subjects
62311524|NCT02293343||IgE positive|patients with high IgE level in serum
62311525|NCT02293343||IBS patients|patients with afflictions, but no high IgE level and suspicion on histamine intolerance
62682006|NCT06686784|EXPERIMENTAL|School B|Middle school students at School B who participate in the after school program. They will receive after school plus in months 1-4, followed by after school as usual in months 5-8.
62682007|NCT04284969|NO_INTERVENTION|Control arm|Patients treated according current practice of the inclusion center. If interventions are implemented locally (geriatric assessment, nutrition, physical activity) they may be proposed to the patient.
62682008|NCT04284969|EXPERIMENTAL|Intervention arm : PROADAPT program|Patients benefiting from the PROADAPT (interventional arm) program.
62682009|NCT05337696|EXPERIMENTAL|Participants with vertebral compression fractures|Participants with vertebral compression fractures who have failed conservative care strategies.
62682010|NCT03429907|EXPERIMENTAL|Mind-Body Exercises|"Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are presented on an online application (app) that runs on participant's personal electronic device (such as a mobile phone or tablet).~Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy."
62682011|NCT03429907|OTHER|Standard of Care|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
62682012|NCT04743206|EXPERIMENTAL|PIAPD-Portable Internal Airway Percussion device|There will be an outpatient arm using the PIAPD-Portable Internal Airway Percussion Device.
62682013|NCT04743206|ACTIVE_COMPARATOR|SACD-Standard Airway Clearance device|There will be an Outpatient Arm using the SACD, VEST (High Frequency Chest Wall Oscillation VEST) Standard Airway Clearance Device.
62682014|NCT05453201|EXPERIMENTAL|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
62122566|NCT02615210|EXPERIMENTAL|Study|SOC-directed biopsies using the SpyGlass System plus standard of care biopsies
62122567|NCT06090786|OTHER|MRD evaluation|Evaluation of MRD at pre-defined timepoints in AML patients treated with Azacitidine and Venetoclax
62122568|NCT04944446|EXPERIMENTAL|Group myofascial treatment|"The trial group will also be referred by the rehabilitating doctor to the physiotherapy room, these patients will be treated by two physiotherapists with training in myofascial release therapy with which they will carry out a treatment protocol that will consist of myofascial release of the shoulder blade angle, subscapularis and global pectoral technique as well as superficial myofascial release of said musculature with a during 12-15 minutes, in addition to a 30-minute session of active kinesitherapy with exercises and mechanotherapy. Same as the control group.~These mobilizations are carried out in the absence of pain, although the difference between joint tension or stretching and pain is explained to the patient."
62682015|NCT06589518|EXPERIMENTAL|Experimental(Tenofovir alafenamide)|Tenofovir alafenamide is administered once every day with 25mg PO.
62682016|NCT05979818|EXPERIMENTAL|Propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy|Patients receive propranolol hydrochloride PO BID, pembrolizumab IV over 30 minutes of day 1 and chemotherapy IV. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62682017|NCT06377930|EXPERIMENTAL|RAP-219|Participants will receive 0.75 mg RAP-219 daily for 5 days followed by 1.25 mg RAP-219 daily for the remainder of the 8-week treatment period.
62682018|NCT06141460|EXPERIMENTAL|RRG001 Dose1|Frequency of administration: one time injection.
62311526|NCT01742351|EXPERIMENTAL|Guided internet-based cognitive behavior therapy (CBT)|
62311527|NCT02558946|ACTIVE_COMPARATOR|Physical Therapy Treatment Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit. The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 7-10 days postoperative, and 4-8 weeks postoperative .
62311528|NCT02558946|ACTIVE_COMPARATOR|Control Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit.
62311529|NCT05362162|ACTIVE_COMPARATOR|Group S|Superficial cervical plexus block; After asepsis and antisepsis are achieved, it will be performed by injecting 10 ml of the local anesthetic agent into the subcutaneous area in the anterolateral neck region, from the anatomical region that fits the carotid artery bifurcation point, under the guidance of USG.
62682019|NCT06141460|EXPERIMENTAL|RRG001 Dose2|Frequency of administration: one time injection.
62476887|NCT04350359|ACTIVE_COMPARATOR|Fixed-dose TTNS protocol|"Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes.~Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week."
62476888|NCT04350359|ACTIVE_COMPARATOR|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
62476889|NCT02184260|EXPERIMENTAL|Metamizole|
62682020|NCT06141460|EXPERIMENTAL|RRG001 Dose3|Frequency of administration: one time injection.
62682021|NCT06141460|EXPERIMENTAL|RRG001 Dose4|Frequency of administration: one time injection.
62682022|NCT06686836|ACTIVE_COMPARATOR|Control Group|Open sinus lift surgery using a bone substitute Bio-Oss®(Geistlich AG, Wolhusen, Switzerland) alone.
62682023|NCT06686836|EXPERIMENTAL|Test Group|Open sinus lift surgery lift using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®(Geistlich AG, Wolhusen, Switzerland))
62682024|NCT06680830|EXPERIMENTAL|NEU-411|Orally-administered NEU-411
62122569|NCT04944446|ACTIVE_COMPARATOR|Group Kinesitherapy treatment|"This group will be treated in a protocolized way with techniques such as passive kinesitherapy, active-assisted and active kinesitherapy to win mobility.~They consist of mobilizing the affected arm in the movements of flexion (upward), separation (towards the outer side) and rotation, these lateral decubitus (bring the hand to the nape of the neck) and internal (bring the hand to the lower back) trying to win joint amplitude.~These mobilizations are performed in the absence of pain, although the difference between joint tension or stretching and pain will be explained to the patient. The treatment will be carried out as usual with a duration of about 12-15 minutes of mobilization and about 30 minutes of active kinesitherapy with exercises and mechanotherapy, these consist of active shoulder mobility exercises. Emphasis will be placed on working with the pain threshold so as not to cause damage or negative nociceptive reactions."
62122570|NCT02683811|EXPERIMENTAL|Intervention group|Diario della Salute (DDS-2), a school-based program aimed to promote psychological well-being and to prevent cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity in preadolescents aged 11-13 years. The program is composed by 5 highly standardised interactive units led by previously trained teachers during school hours (15 hours total). Units focus on emotional and social issues related to adolescent developmental tasks. The goal is to promote the adolescent emotional and social skills.
62476890|NCT02184260|PLACEBO_COMPARATOR|Placebo|
62682025|NCT06680830|PLACEBO_COMPARATOR|Placebo|Orally-administered matching placebo
62682026|NCT04088292|ACTIVE_COMPARATOR|USAT + low dose thrombolysis|UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization
62476891|NCT06239350|OTHER|Nicotine treatment|All participants recieve active nicotine treatment for 12 weeks.
62476892|NCT02403947|EXPERIMENTAL|Mesenchymal stem cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
62496022|NCT04422652|PLACEBO_COMPARATOR|Control|Control: Clinical management attention control plus placebo for 16 weeks
62682027|NCT04088292|ACTIVE_COMPARATOR|Low dose thrombolysis|Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).
62682028|NCT04088292|NO_INTERVENTION|Heparin alone|UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)
62122571|NCT02683811|NO_INTERVENTION|Control group|No intervention aimed at preventing cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity and promoting emotional and social well-being is administered at school by teachers.
62311530|NCT05362162|ACTIVE_COMPARATOR|Group I|Intermediate cervical plexus block; After asepsis and antisepsis are achieved, it will be performed by injecting 10 ml of the local anesthetic agent under the investing fascia from the anatomical region that fits the carotid artery bifurcation point under the guidance of USG.
62311531|NCT03701789|OTHER|Patients with Rheumatoid Arthritis|In-label treatment with Baricitinib
62122572|NCT04415528|EXPERIMENTAL|Intervention group|The intervention group will begin receiving the group intervention within one - two weeks of Time 1 assessment. This group will receive Time 2 assessments at the end of the group delivery. Time 3 assessments will be administered eight weeks after the completion of group delivery.
62122573|NCT04415528|ACTIVE_COMPARATOR|Wait listed control group|The wait listed control group will be assessed at Time 1, eight weeks before receiving the intervention. This group will receive Time 2 assessments at the beginning of their group delivery. This group will complete Time 3 assessments eight weeks after the completion of group delivery.
62122574|NCT03410966|EXPERIMENTAL|Intervention group|All patients affected by paroxysmal symptomatic atrial fibrillation, and anti-arrhythmic drug refractory atrial fibrillation will receive a trans catheter ablation therapy (intervention).
62122575|NCT03801499|EXPERIMENTAL|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62122576|NCT05316220|EXPERIMENTAL|Mesalamine Dose A|Participants will receive mesalamine Dose A twice daily for 26 weeks.
62122577|NCT05316220|EXPERIMENTAL|Mesalamine Dose B|Participants will receive mesalamine Dose B twice daily for 26 weeks.
62122578|NCT04820439|EXPERIMENTAL|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|
62122579|NCT04820439|ACTIVE_COMPARATOR|Perjeta ®|
62311532|NCT03177577|PLACEBO_COMPARATOR|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
62311533|NCT03177577|ACTIVE_COMPARATOR|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
62311534|NCT02132390|EXPERIMENTAL|Arm I|Patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity
62476893|NCT02403947|PLACEBO_COMPARATOR|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
62476894|NCT05079425|EXPERIMENTAL|Part A: Fasting|Single ascending dose (SAD).
62682029|NCT06688942|EXPERIMENTAL|Horizons Digital Health Application Group|Participants will receive the Horizons mobile application for up to 6 weeks.
62682030|NCT05940246|EXPERIMENTAL|Motivational interviewing|Motivational Interviewing over the phone 1 time before surgery and 6 times (3-5 weeks interval) the first 6 months after surgery. Patients can contact a physical therapist in the first 6 months after surgery for additional questions and extra support.
62122580|NCT05604885|EXPERIMENTAL|AP1189, 60 mg|Part A: (AP1189, 60 mg); Part B: (TBD)
62122581|NCT05604885|EXPERIMENTAL|AP1189, 80 mg|Part A: (AP1189, 80 mg); Part B: (TBD)
62122582|NCT05604885|EXPERIMENTAL|AP1189, 100 mg|Part A: (AP1189, 100 mg); Part B: (TBD)
62122583|NCT05604885|PLACEBO_COMPARATOR|Placebo|Part A: (placebo); Part B: (placebo).
62122584|NCT06131359||Younger adults|age 18-35 years
62311535|NCT02132390|EXPERIMENTAL|Arm II|Patients who had CIA receive toremifene as in arm I
62311536|NCT02132390|EXPERIMENTAL|Arm III|Patients without CIA receive oral toremifene and goserelin for ovarian function suppression
62311537|NCT02132390|EXPERIMENTAL|Arm IV|Patients with CIA receive oral toremifene and goserelin for ovarian function suppression.
62311538|NCT04573777|EXPERIMENTAL|Intervention Repatha|
62311539|NCT02141308||Rare Chorioretinal Disease|Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
62311540|NCT03115385|PLACEBO_COMPARATOR|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
62476895|NCT05079425|EXPERIMENTAL|Part A: Fed|Single ascending dose (SAD).
62682031|NCT05940246|NO_INTERVENTION|Standard treatment|Standard treatment
62682032|NCT06222424|OTHER|Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023|Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge.
62122585|NCT06131359||Older adults|age over 55 years
62122586|NCT01527253|EXPERIMENTAL|Active Diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations containing important amounts of specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics)
62122587|NCT01527253|EXPERIMENTAL|Control diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations but lacks the specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics).
62122588|NCT05433935||Prospective IPMN cohort|Multi-omics analysis of 5000 prospectively collected samples.
62122589|NCT05305846|EXPERIMENTAL|TENA-PROTO2|Investigational device. Late prototype
62476896|NCT05079425|EXPERIMENTAL|Part B: Fasting|Multiple Ascending Dose (MAD)
62682033|NCT06689280|EXPERIMENTAL|Video-supervised home-based exercise training|"In-hospital exercise training: 30 min of daily one-on-one supervised exercise training using exercises from the exercise booklet Sick but Healthy and Active.~Patient-centered video-supervised home-based exercise intervention phase (weeks 0-12): 3 weekly exercise sessions (2 supervised and 1 unsupervised session/week) over 12 weeks. Each session will last 45-50 min, consisting of 10-15 min of endurance, 20-30 min of resistance, and 5 min of balance exercises. The exercise intensity will progressivly increase during the 12 weeks and be based on a target training intensity of 4-7 points on the Borg CR-10 scale.The exercise training is supplemented with weekly individualized step-count goals that progressively increase (+5%) if previous step-goals are achieved.~Self-directed maintenance exercise phase (weeks 13-24): unsupervised self-directed exercise training 3 times per week for 12 weeks with phone calls, but with less frequency (see standard care below)."
62682034|NCT06689280|NO_INTERVENTION|Standard care|"In-hospital: Patients will receive standard of care as recommended by their healthcare personnel.~Control phase (weeks 0-12): Patients are contacted biweekly by phone calls after discharge up to 12 weeks after discharge. The patients will not receive any specific recommendations regarding physical activity.~Control phase (week 13-24): The patients will continuously receive phone calls, but with less frequency (i.e., 2 calls per week in week 13-16, 1 call per week in week 17-20, and 0 call per week in week 21-24)."
62682035|NCT06547996|EXPERIMENTAL|tDCS group|In the tDCS group, the anode was placed over the left DLPFC (F3), and the cathode was placed over the contralateral supraorbital area (FP2). A direct current of 2mA was applied for 20 minutes during each stimulation session.
62682036|NCT06547996|EXPERIMENTAL|tACS group|In the tACS group, the anode was placed in the F3 region of the left dorsolateral prefrontal cortex (DLPFC), and the cathode was placed in the right supraorbital region (Fp2), and the current used was 2 mA AC at 40 Hz, with a stimulation time of 20 min.
62682037|NCT06547996|SHAM_COMPARATOR|sham group|In the sham group, the stimulation parameters, including the stimulation site and duration, were identical to those of the anodal group. However, during the 10-second ramp-up and ramp-down periods before and after stimulation, patients were unaware that the current was turned off.
62682038|NCT05253534|EXPERIMENTAL|Gamma Rhythm Stimulation Group|"Evaluation of the efficacy and safety of GlaucoT in patients with primary open-angle glaucoma (POAG).~In this study, it was planned to investigate the effect of reducing the progression of glaucomatous damage by applying 40 Hz flicker light therapy for 1 hour a day to POAG patients. It is planned to use visual field test, measurements of retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) layer thicknesses in optical coherence tomography to investigate the effectiveness of the treatment."
62682039|NCT05253534|NO_INTERVENTION|Control Group|"This group will be monitored without using the device.The data will be used only for comparison.~Considering the sample size calculations and losses, a total of 60 patients are planned to be included in the study, with 30 patients in each group."
62682040|NCT06691425|ACTIVE_COMPARATOR|Arm A: Chemotherapy alone|Patients in arm A will receive standard treatment, more specifically chemotherapy (mFOLFIRINOX or Gemcitabine/nab-paclitaxel) alone. After the 12 weeks of induction chemotherapy followed by randomization, these patients will receive another month of chemotherapy. If the patient is operated on, the maximal total duration of chemotherapy is 24 weeks.
62682041|NCT06691425|EXPERIMENTAL|Arm B: Chemotherapy with SBRT|Patients in arm B will receive SBRT in addition to chemotherapy (mFOLFIRINOX or Gemcitabine/nab-paclitaxel). After the 12 weeks of induction chemotherapy followed by randomization, these patients will receive another month of chemotherapy. Fiducial markers are implanted prior to the administration of SBRT, which will occur 7 to 28 days after chemotherapy. 5 fractions of 8 Gy will be delivered. The maximal total duration of chemotherapy for these patients is 24 weeks regardless of whether they had surgery or not.
62682042|NCT04636437|EXPERIMENTAL|DOR 100 mg + TAF/FTC (or TAF/3TC, depending on location)|By mouth daily with or without food
62682043|NCT04636437|EXPERIMENTAL|DOR 100 mg + TDF/FTC (or TDF/3TC, depending on location)|By mouth daily with or without food
62682044|NCT04636437|EXPERIMENTAL|Continuation of entry INSTI+TAF/FTC (or TAF/3TC)|
62682045|NCT02657551|EXPERIMENTAL|Regorafenib|Regorafenib tablets 80mg orally, once daily at predetermined dosage for 21 days per cycle
62682046|NCT06542484|EXPERIMENTAL|Gefapixiant arm|Participants will take 45mg of gefapixiant twice a day for 12 weeks.
62682047|NCT06551961|ACTIVE_COMPARATOR|methylcellulose|2.5 g of Inulin and 2.5g methylcellulose in 62.5 mL water given thrice daily for 7 days increasing to 5 g of Inulin and 5g methylcellulose in 125 mL water on day 8 continuing until day 14
62682048|NCT06551961|PLACEBO_COMPARATOR|Placebo|2.5 g of Inulin and 2.5g maltodextrin in 62.5 mL water given thrice daily for 7 days increasing to 5 g of Inulin and 5g maltodextrin in 125 mL water on day 8 continuing until day 14
62682049|NCT06689150|ACTIVE_COMPARATOR|Group A: Drospirenon (drospinetta)|About 100 women took Drospirenon (drospinetta) tab every day 24 and 4 placipo tablets for four days
62476897|NCT05609643||Rinvoq|Participants will receive Rinvoq as prescribed by their physician according to local label.
62476898|NCT01621945||Bras A|children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
62311541|NCT03115385|ACTIVE_COMPARATOR|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
62311542|NCT02935738|EXPERIMENTAL|Prednisolone treated men / positive SPA / IVF|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
62476899|NCT01030133|ACTIVE_COMPARATOR|Real TMS|Participants in the real Transcranial Magnetic Stimulation (TMS) group will receive real stimulation across all interventions; the operator role Real TMS and receiver role Real TMS. rTMS will be used to stimulate the left prefrontal cortex using two Neuronetics TMS machines with figure-8, iron core coils at 10Hz and at 110% of resting motor threshold \[5 second trains following each trial (25 trials per visit)\].
62496023|NCT04628975|EXPERIMENTAL|with transillumination|The nurses will use the Transillumination method for a period P1. Then these same nurses will use the control method (without transillumination) for a period P2.
61922355|NCT05337930|OTHER|Intervention arm|Study participants will use the Happyr Health app, a mobile application to support CYP with primary headaches in coping with chronic pain, for eight weeks. For this study, a research version of the app will be provided via Google Play Store Testing Tracks and Apple TestFlight. In the app, a storyline and gamification elements engage CYP in filling out their headache diary and a regular mood diary.
62122590|NCT05698069||Patients with chronic pain|Patients with non-cancer pain of more than 3 months duration.
62122591|NCT06673628|EXPERIMENTAL|Pembrolizumab plus lenvatinib|
62122592|NCT00484614|ACTIVE_COMPARATOR|1 PEM|
62122593|NCT00484614|ACTIVE_COMPARATOR|2 MRI|
62122594|NCT00212745|NO_INTERVENTION|2|Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation
62122595|NCT00212745|EXPERIMENTAL|1|Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing
62682050|NCT06689150|ACTIVE_COMPARATOR|Group B: Desogestrel (Cirazette)|About 100 women took Desogestrel (Cirazette) tablet every day
62122596|NCT02299375|EXPERIMENTAL|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
62122597|NCT02299375|EXPERIMENTAL|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
62122598|NCT03460067|EXPERIMENTAL|Arm A|Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
62122599|NCT03460067|NO_INTERVENTION|Arm B|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. Patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens such as blood and urine, for correlative studies.
62311543|NCT02935738|EXPERIMENTAL|Prednisolone treated men / negative SPA / ICSI|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
62311544|NCT02935738|NO_INTERVENTION|Control men / positive SPA / IVF|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (more than five) were then admitted to in vitro fertilization (IVF) cycle.
62311545|NCT02935738|NO_INTERVENTION|Control men / negative SPA / ICSI|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were then admitted to intracytoplasmic sperm injection (ICSI) cycles.
62311546|NCT01632878||Post Myocardial Infarction|One single cohort of Index post Myocardial Infarction patients
62311547|NCT02351037|EXPERIMENTAL|Ibrutinib Monotherapy Cohort|Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.
62311548|NCT02351037|EXPERIMENTAL|Ibrutinib + LD-AraC Combination Cohort|Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
62311549|NCT02351037|EXPERIMENTAL|Ibrutinib+Azacitidine Combination Cohort|Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).
61922356|NCT03247803|EXPERIMENTAL|Air-Q SP|air-Q Self-Pressurizing intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mecury Medical, Clearwater, FL, USA)
62122600|NCT03460067|NO_INTERVENTION|Arm C|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will not undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens, such as blood and urine, for correlative studies.
62311550|NCT03968445|EXPERIMENTAL|Recent Myocardial Infarction|
62311551|NCT03968445|EXPERIMENTAL|undergoing elective percutaneous coronary intervention|
62682051|NCT06689150|ACTIVE_COMPARATOR|Group C: Levonorgestrel (Microlute)|About 100 women took Levonorgestrel (Microlute) tablet every day
62476900|NCT01030133|SHAM_COMPARATOR|Sham TMS|Participants in the sham Transcranial Magnetic Stimulation (TMS) group will receive sham stimulation across all interventions; the operator role Sham TMS and receiver role Sham TMS. Sham Stimulation involves 5 second trains of 10Hz rTMS in pairs alternating between real TMS and eSham TMS (randomly ordered). All sham treatment will be delivered with a specially designed, manufacture-provided sham TMS coil that looks and sounds identical to a real TMS coil but no magnetic current is transferred to the participant.
62682052|NCT01840163|OTHER|CanSORT Online Tool|Comprehensive decision tool
62682053|NCT01840163|OTHER|Static version of CanSORT tool|Static version (non-interactive) version of CanSORT decision tool
61922357|NCT03247803|EXPERIMENTAL|Williams Intubating Airway|Airway Intubator, Williams, Adult Female, Single Use, Molded Surlyn Plastic, 9 cm or Airway Intubator, Williams, Adult Male, Single Use, Molded Surlyn Plastic, 10 cm
62311552|NCT00693719|EXPERIMENTAL|Etoposide and Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15. Etoposide 50 mg PO x14 days followed by 2 weeks off.
62476901|NCT01030133|OTHER|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
62682054|NCT06691321||TMP/SMZ (Control)|Patients with HIV and PCP starting treatment with trimethoprim/sulfamethoxazole (TMP/SMZ).
62682055|NCT06691321||Caspo (Study)|Patients with HIV and PCP starting treatment with caspofungin with or without clindamycin or primaquine; or switching from trimethoprim/sulfamethoxazole to caspofungin before day 7 of treatment initiation.
62122601|NCT02347436||benign prostatic hypertrophy|patients who are diagnosed with lower urinary tract symptoms caused by prostatic hypertrophy, undergo transurethral resection of the prostate, and post-surgery 24-hr ambulatory blood pressure measurement.
62122602|NCT02347436||inguinal hernia or hydrocele|patients who are diagnosed with lower urinary tract symptoms caused by inguinal hernia or hydrocele, undergo surgical inguinal hernia repair or hydrocele repair, and post-surgery 24-hr ambulatory blood pressure measurement
62122603|NCT03570957|EXPERIMENTAL|MT-2990, Low dose|Single intravenous dose
62122604|NCT03570957|EXPERIMENTAL|MT-2990, Low-middle dose|Single intravenous dose
62122605|NCT03570957|EXPERIMENTAL|MT-2990, High-middle dose|Single intravenous dose
62122606|NCT03570957|EXPERIMENTAL|MT-2990, High dose|Single intravenous dose
62122607|NCT03570957|PLACEBO_COMPARATOR|Placebo|Single intravenous dose
62122608|NCT06441539|EXPERIMENTAL|drug-eluting balloon|Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon
62476902|NCT06560827|EXPERIMENTAL|CT011 CAR-GPC3 T Cells Injection|This trial is a single-arm, open-label, exploratory trial, and no statistical hypothesis is made for sample size estimation. It is planned to enroll approximately 30 participants to receive CT011 infusion.
62682056|NCT05300737||Symptomatic carotid stenosis with low risk features|50-99% symptomatic carotid stenosis with low clinical or radiologic risk features (see inclusion criteria) Patients will receive intensive medical therapy, including dual antiplatelet therapy, high potency statins, BP control, and lifestyle modification
62682057|NCT06633042|EXPERIMENTAL|BCMA CART Group|1.0-4.0×10\^6 CAR- Tcells/kg
62682058|NCT06694675||Control group|The nasopharyngeal swab test for RSV antigen was negative for patients with no history of respiratory infection in the past six weeks before surgery.
62122609|NCT06441539|ACTIVE_COMPARATOR|drug-eluting stent|Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
62122610|NCT00030238|OTHER|Active Treatment|Subjects take calcium twice daily with meals
62122611|NCT00030238|OTHER|Control|Subjects take placebo twice daily with meals.
62122612|NCT05783726|OTHER|Control|The control arm will show the products with no label.
62122613|NCT05783726|EXPERIMENTAL|Experimental: Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
62122614|NCT05783726|EXPERIMENTAL|Experimental: Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
62122615|NCT05783726|EXPERIMENTAL|Experimental: Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
62122616|NCT04491032|ACTIVE_COMPARATOR|Low Volume|Caudal anesthesia will be performed with 0.8 ml/kg of the local anesthetic solution
62476903|NCT04537481|EXPERIMENTAL|Normal fertilization group|Sperm samples from the successful fertilization IVF cycles were collected.
62476904|NCT04537481|EXPERIMENTAL|Low fertilization group|Sperm samples from the low fertilization IVF cycles were collected.
62476905|NCT04452786|OTHER|Endoscopic sleeve gastroplasity operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
62476906|NCT04452786|OTHER|Laparoscopic sleeve gastrectomy operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
62476907|NCT01367145|ACTIVE_COMPARATOR|Omacor|
62476908|NCT01367145|PLACEBO_COMPARATOR|Placebo|
62682059|NCT06694675||RSV group|The nasopharyngeal swab of the RSV antigen test is positive.
62682060|NCT06160206|EXPERIMENTAL|Arm A (Retifanlimab, bevacizumab and HFRT)|ARM I: Patients receive retifanlimab IV over 30 minutes on day 1 and bevacizumab IV on day 1 and 15 of each cycle. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo HFRT QD, starting in cycle 1 on day 15 for 10 treatments. Patients undergo MRI or CT, as well as blood sample collection throughout the study.
62682061|NCT06160206|EXPERIMENTAL|Arm B (Bevacizumab and radiation)|Patients receive bevacizumab IV on day 1 and 15 of each cycle. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo HFRT QD, starting in cycle 1 on day 15 for 10 treatments. Patients undergo MRI or CT, as well as blood sample collection throughout the study.
62682062|NCT04782180|EXPERIMENTAL|Rapid PrEP group|Participants will receive PrEP i.e. Descovy for 12 months at the syringe services program.
62682063|NCT05909397|EXPERIMENTAL|Arm A (Investigational Arm)|"Participants will receive:~* ARV-471, orally, once daily, continuously, in a 28-day cycle, plus~* Palbociclib, orally, once daily for 21 consecutive days followed by 7 days off treatment in a 28 day cycle"
62682064|NCT05909397|ACTIVE_COMPARATOR|Arm B (Comparator Arm):|"Participants will receive:~* Letrozole, orally, once daily, continuously, in a 28-day cycle, plus~* Palbociclib, orally, once daily for 21 consecutive days followed by 7 days off treatment, in a 28-day cycle."
62682065|NCT02549300|NO_INTERVENTION|Control Group|15 patients will be included in control group. Control group will just receive advices about life style modifications, such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.
62682066|NCT02549300|EXPERIMENTAL|Study Group|15 patients will be included in study group. Study group will be treated with connective tissue massage in addition to life style modifications (such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.). Connective tissue massage will be applied 5 times a week, totally 20 sessions in a month. Each session lasts approximately 20-30 minutes. Connective tissue massage will be applied on basic part, lower thoracic, scapular, inter scapular and neck regions.
62682067|NCT04876950|EXPERIMENTAL|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-2 intervention will take biophysical measurements with the RAM technology and complete a daily recovery survey for 14 days after index hospital discharge, and nurses will review these results daily. Through scheduled video visits, patients will virtually interact with a nurse on days 1, 3, 7 and 14, and a physician on days 1 and 14. Patients will take a photograph of their wound daily for the first 7 days on the program, and nurses will review these pictures. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, they will escalate care to a pre-assigned and available physician. Two 7-day extensions to the intervention will be possible, based on the patient's need for continued support. This decision will be based on standardized criteria.
62682068|NCT04876950|NO_INTERVENTION|Standard Care|Patients randomized to standard care will receive post discharge care as per the standard of care at the hospital where they undergo surgery.
62122617|NCT04491032|ACTIVE_COMPARATOR|High Volume|Caudal anesthesia will be performed with 1.25 ml/kg of the local anesthetic solution
62122618|NCT06203197|NO_INTERVENTION|control|Patients in the control group will receive routine clinical care after surgery.
62122619|NCT06203197|EXPERIMENTAL|intervention|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)) developed within the scope of the research after the surgery.
62122620|NCT04048135|EXPERIMENTAL|Part 1: Pegozafermin 3 milligrams (mg) weekly (QW)|Participants were administered 3 mg of pegozafermin QW, via subcutaneous (SC) injection, starting on Day 1 through Day 85.
62311553|NCT04538352|EXPERIMENTAL|Once-weekly sc semaglutide combined with once-daily insulin|Patients randomized to continue with MDI will be transitioned from their existing regimen to the rapid-acting insulin product insulin aspart and their basal insulin switched to once-daily insulin degludec.
62311554|NCT04538352|EXPERIMENTAL|MDI requiring multiple daily injections of insulin|Patients randomized to MDI will be allowed to continue correction rapid-acting insulin, in addition to their prandial doses of rapid-acting insulin, throughout the duration of the study.
62311555|NCT01057628|EXPERIMENTAL|ASP1941 group|oral
62311556|NCT01057628|PLACEBO_COMPARATOR|placebo group|oral
62122621|NCT04048135|EXPERIMENTAL|Part 1: Pegozafermin 9 mg QW|Participants were administered 9 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
62311557|NCT06669741|PLACEBO_COMPARATOR|Placebo|To assess the benefits of using the Incrediwear (Shoulder Sleeve) products for patients recovering from Arthroscopic Rotator Cuff Repair surgery for postoperative pain, range of motion, and swelling. We will compare patients with Incrediwear products or placebo Incrediwear products throughout a 12-week period with follow-ups up to 1-year post-surgery. The study will be double blinded as to the active Incrediwear sleeve vs placebo.
62476909|NCT05883215||Female Patients Diagnosed with Fibromyalgia Syndrome|Female patients who give consent to participate and are diagnosed with fibromyalgia syndrome.
62476910|NCT06561009|EXPERIMENTAL|Participant Group|BAFFR CART cells
62476911|NCT03588923|ACTIVE_COMPARATOR|Cohort 1|SH229 (400 mg) or matching placebo, once daily
62476912|NCT03588923|ACTIVE_COMPARATOR|Cohort 2|SH229 (600 mg) or matching placebo, once daily
62476913|NCT03588923|ACTIVE_COMPARATOR|Cohort 3|SH229 (800 mg) or matching placebo, once daily
62476914|NCT06187441|NO_INTERVENTION|Arm A|A continuous therapy arm - continuation of therapy with Dara-Rd until PD
62311558|NCT06669741|ACTIVE_COMPARATOR|Incrediwear Product|To assess the benefits of using the Incrediwear (Shoulder Sleeve) products for patients recovering from Arthroscopic Rotator Cuff Repair surgery for postoperative pain, range of motion, and swelling. We will compare patients with Incrediwear products or placebo Incrediwear products throughout a 12-week period with follow-ups up to 1-year post-surgery. The study will be double blinded as to the active Incrediwear sleeve vs placebo.
62311559|NCT04777955|EXPERIMENTAL|Group 1, core stabilization exercises group|core stabilization exercises will be performed using swissball. Program: Sitting on the ball will include (weight shifts, forward, backward and lateral sides), (pelvic bridge), (curl-up), (curlsup with diagonal reaching), (bird-dog exercise), (push-up) exercises. The application will be carried out for 6 weeks, 3 days a week for 30-45 minutes daily.
62476915|NCT06187441|EXPERIMENTAL|Arm B|treatment free interval arm - discontinuation of therapy with Dara-Rd, which will be resumed at biochemical progression and given until PD
62476916|NCT00849576|ACTIVE_COMPARATOR|Regular Human Insulin|Single Injection
62476917|NCT00849576|ACTIVE_COMPARATOR|Inuslin Lispro (90%)|Single Injection
62476918|NCT00849576|EXPERIMENTAL|Insulin VIAject™ (75%)|Single Injection
62476919|NCT00849576|EXPERIMENTAL|Insulin VIAject™ (90%)|Single injection
62476920|NCT05130762||General Cohort|All patients who receive a VAD as standard of care in combination with needle-free connectors. A BD PureHub™ Disinfecting Cap will be placed on each eligible needle-free connector and all attachments/removals incl. reason for change will be documented up to 45 days post-enrollment date.
62476921|NCT06558994|ACTIVE_COMPARATOR|Transection arm|Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
62476922|NCT06558994|ACTIVE_COMPARATOR|Ligation arm|ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
62476923|NCT00002939|EXPERIMENTAL|Paclitaxel in combination with Irinotecan|The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
62476924|NCT02645500|EXPERIMENTAL|Physical activity message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to physical activity.~The training workshop include one core session and one booster session at one month.~Daily messages in relation to physical activity will be sent to the participants."
62496024|NCT04628975|NO_INTERVENTION|without transillumination (control method)|The nurses will use the control method for a period P1. Then these same nurses will use the Transillumination method for a period P2.
62311560|NCT04777955|EXPERIMENTAL|Group 2, electrical stimulation|"An adaptation of a pre-designed protocol will be used for the application of the Normocular Electrical Stimulation in the diaphragm. Current to be applied; Synchronous impulse at 30 Hz frequency, 1 sec beat increase time, 1 sec on (muscle contraction), 1 sec beat reduction time and 20 sec off (no warning) time. Two channels, each with two electrodes, will be placed in the seventh and eighth anterior intercostal space above and below the right and left sides of the xiphoid protrusion. The other two channels, each with two electrodes, will be placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
62311561|NCT04777955|EXPERIMENTAL|group 3, kinesiotape|"For anterior diaphragm banding, the patient will stand with arms raised. Next, the central part of the tape will be applied to the xiphoid protrusion with a tension of 50% to 70% after the maximum inhalation. While the patient is breathing, the ends of the tape will be pulled with 10 to 15% tension towards the lower ribs. To tape the rear diaphragm, the patient's body will bend forward, and the arms will be joined crosswise over the chest. After the maximum inhalation, the central part of the tape will be applied over the T10 with a tension of 50% to 70%. As the patient exhales and stretches the trunk, the ends of the tape will be attached to the lower ribs with a tension of 10 to 15%.~The supine position will be used in the Kinesiological taping of the right and left external oblique and internal oblique muscles. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
62311562|NCT04110834|EXPERIMENTAL|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
62311563|NCT04110834|EXPERIMENTAL|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
62311564|NCT04110834|PLACEBO_COMPARATOR|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to assure that the results obtained from other arms are only due to the effects of the active ingredient in the prepared gel.
62311565|NCT00984659|EXPERIMENTAL|FSC|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
62476925|NCT02645500|ACTIVE_COMPARATOR|Healthy diet message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to healthy diet .~The training workshop include one core session and one booster session at one month.~Daily messages in relation to healthy diet will be sent to the participants."
62682069|NCT06590337|PLACEBO_COMPARATOR|Placebo Control 1|Spark Product Form 1 - control
62682070|NCT06590337|EXPERIMENTAL|Active Product 1.1|Spark Product Form 1 - active product 1
62682071|NCT06590337|PLACEBO_COMPARATOR|Placebo Control 2|Spark Product Form 2 - control
62476926|NCT01445691|EXPERIMENTAL|5-ALA (Gliolan)|Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
62496025|NCT04075916|EXPERIMENTAL|Epclusa (sofosbuvir/velpatasvir)|Epclusa is taken by mouth for 12 weeks as per the FDA label.
62682072|NCT06590337|EXPERIMENTAL|Active Product 2.1|Spark Product Form 2 - active product 1
62682073|NCT02662907|EXPERIMENTAL|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
62682074|NCT02662907|OTHER|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
62682075|NCT06695091|ACTIVE_COMPARATOR|Flat occlusal scheme|occlusal design
62682076|NCT06695091|ACTIVE_COMPARATOR|Anatomic occlusal scheme|occlusal design
62311566|NCT00984659|EXPERIMENTAL|SAL|Salmeterol 50mcg DISKUS twice a day
62311567|NCT00984659|PLACEBO_COMPARATOR|Placebo|Placebo DISKUS twice a day
62311568|NCT04450914|OTHER|Health Systems - First Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the first step, health systems will be assigned to usual care (passive implementation of CV Prevention Choice).
62476927|NCT05248308|EXPERIMENTAL|Genicular artery embolization|Study participants will undergo genicular artery embolization (GAE) for treatment of chronic moderate to severe pain following knee arthroplasty or revision arthroplasty. Embolization will be performed using Embozene Microspheres.
62476928|NCT04368520|PLACEBO_COMPARATOR|Placebo|
62476929|NCT04368520|EXPERIMENTAL|Low dose vitamin D3|
62476930|NCT04368520|EXPERIMENTAL|High dose vitamin D3|
62476931|NCT04439552||CXL group|Patients who are about to undergo a corneal cross-linking (CXL) surgery to treat keratoconus.
62476932|NCT04439552||Control group|Healthy volunteers age and sex matched to the CXL group.
62476933|NCT01316055|ACTIVE_COMPARATOR|Healthy: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
62476934|NCT01316055|ACTIVE_COMPARATOR|Mild renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
61922358|NCT02360605|ACTIVE_COMPARATOR|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
61922359|NCT02360605|ACTIVE_COMPARATOR|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
62476935|NCT01316055|ACTIVE_COMPARATOR|Moderate renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
62476936|NCT00830349|EXPERIMENTAL|1|Risperidone 1 mg Tablets
62476937|NCT00830349|ACTIVE_COMPARATOR|2|Risperdal® 1 mg Tablets
62476938|NCT04304066|EXPERIMENTAL|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans
62476939|NCT03537482|EXPERIMENTAL|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
62476940|NCT04946864|EXPERIMENTAL|single arm|APG2575
61922360|NCT00076024|OTHER|Docetaxel + Placebo|Docetaxel + Placebo
61922361|NCT00076024|EXPERIMENTAL|Docetaxel + AG-013736|Docetaxel + AG-013736
62311569|NCT04450914|OTHER|Health Systems - Second Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the second step, health systems (in an order to be determined by randomization and staggered over time) will move into active implementation.
62311570|NCT04450914|OTHER|Health Systems - Third Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions.In the third step, all health systems will move to maintenance implementation.
62311571|NCT02814214||ECG+IEGM|Surface ECG and intracardiac electrogram recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy settings
62311572|NCT02819596|EXPERIMENTAL|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
62476941|NCT04946864|EXPERIMENTAL|combination arm|APG2575+palbociclib i
62476942|NCT06318117||Rice infant formula started before age of 6 months|"After inclusion (V1), infants will return for a V2 visit at 12 months (± 30 days) of age (according to the child's regular appointment calendar). No visit is imposed by the protocol.~Anthropometric data from visits to the pediatrician carried out between V1 and V2 will be collected from medical records, as well as the date of cessation of RIF, if applicable.~Retrospective data will be collected from medical files (anthropometric data, medical and feeding history) and from parents' and investigator's recall."
62682077|NCT02410200|EXPERIMENTAL|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
62122622|NCT04048135|EXPERIMENTAL|Part 1: Pegozafermin 18 mg QW|Participants were administered 18 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
62122623|NCT04048135|EXPERIMENTAL|Part 1: Pegozafermin 27 mg QW|Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
62122624|NCT04048135|EXPERIMENTAL|Part 1: Pegozafermin 18 mg Every 2 Weeks (Q2W)|Participants were administered 18 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.
62122625|NCT04048135|EXPERIMENTAL|Part 1: Pegozafermin 36 mg Q2W|Participants were administered 36 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.
62311573|NCT02819596|EXPERIMENTAL|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
62311574|NCT02819596|EXPERIMENTAL|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
62682078|NCT06615726|EXPERIMENTAL|regular physical activity group|
62682079|NCT06615726|OTHER|Control group|
62311575|NCT02819596|EXPERIMENTAL|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
62122626|NCT04048135|PLACEBO_COMPARATOR|Part 1: Placebo QW or Q2W|Participants were administered placebo matching to pegozafermin QW or Q2W, via SC injection, starting on Day 1 through Day 85.
62122627|NCT04048135|EXPERIMENTAL|Part 2: Pegozafermin 27 mg QW|Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 134.
62122628|NCT04540822|EXPERIMENTAL|peripheral venous catheter with compress|Insertion of a peripheral venous catheter with a compress inserted below the catheter-extension tube junction
62122629|NCT04540822|ACTIVE_COMPARATOR|peripheral venous catheter without compress|Insertion of a peripheral venous catheter without any compress inserted below the catheter-extension tube junction.
62122630|NCT01784653|NO_INTERVENTION|Treatment as Usual|Patients will receive the usual care from the treatment program
62122631|NCT01784653|EXPERIMENTAL|iMET|Participants will complete a self-guided computerized Motivational Enhancement Therapy
62122632|NCT01784653|EXPERIMENTAL|MET|Clinician-delivered Motivational Enhancement Therapy
62122633|NCT02888808||Erosive GERD|Gastroscopy examination.
62122634|NCT02888808||Control population|Gastroscopy examination.
62122635|NCT04788836||Obesity treatment Group|60 (minimum) to 150 (maximum) overweight/obese adults referred for or who started obesity (surgical or non-surgical) treatment within 6 months
62311576|NCT03648645|EXPERIMENTAL|AH Telemonitoring|Self measurement of blood pressure
62311577|NCT03974178|EXPERIMENTAL|Fexinidazole|"Patients with a body weight ≥ 35 kg:~* 1800 mg (3 tablets) from day 1 to 4~* 1200 mg (2 tablets) from day 5 to 10~Patients with a body weight ≥ 20 and \< 35 kg:~* 1200 mg (2 tablets) from day 1 to 4~* 600 mg (1 tablet) from day 5 to 10"
62682080|NCT06207227|EXPERIMENTAL|VITA AV Clinical System|VITA AV Clinical System
62682081|NCT06684899||Patients affected by glioblastoma|Subject with a documented diagnosis of glioblastoma (WHO criteria 2021), as confirmed by reference histopathology at San Raffaele Hospital.
62682082|NCT06684899||Healthy controls|Healthy donors will also be enrolled in the study to serve as controls in the manufacturing process and exploratory analysis. They will be recruited among healthy individuals attending our Unit
61922362|NCT02225392|ACTIVE_COMPARATOR|Delayed bronchial thermoplasty|"After randomisation they will wait for 25 weeks (control group) and then start with bronchial thermoplasty.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
61922363|NCT02225392|EXPERIMENTAL|Immediate bronchial thermoplasty|"After randomisation they start immediate with bronchial thermoplasty treatment.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
62476943|NCT06318117||Rice infant formula started after age of 6 months|"After inclusion (V1), infants will return for a V2 visit at 12 months (± 30 days) of age (according to the child's regular appointment calendar). No visit is imposed by the protocol.~Anthropometric data from visits to the pediatrician carried out between V1 and V2 will be collected from medical records, as well as the date of cessation of RIF, if applicable.~Retrospective data will be collected from medical files (anthropometric data, medical and feeding history) and from parents' and investigator's recall."
62476944|NCT00426621|EXPERIMENTAL|1|
61922364|NCT00476801|EXPERIMENTAL|UVA1 irradiation|The dose and scheduling will be similar to those being successfully used in Germany: up to 130J/cm2 from a UVA1 Sellamed irradiation device (German manufactured UVA1 light emitting device) with irradiations up to 5 times per week for up to 14 weeks on one side of the face. Then a cross-over treatment an equal length of time.
62122636|NCT04788836||Control Group|Comparison of food purchase behaviour with control subjects will be performed using an already existing cohort from a previous study. This does not required recruiting control subjects.
62476945|NCT00426621|PLACEBO_COMPARATOR|2|
62476946|NCT05790772|EXPERIMENTAL|Vigorous Exercise|50 Minutes of running on a treadmill
62682083|NCT05673291||Active working group|For the study group, dentists who have completed at least 1 year in the profession, actively working in their professional life, and 4th and 5th-year of intern dentistry students
62682084|NCT05673291||Control group|In the study, 3rd-grade dentistry students who have not yet started the clinical education process will be selected as the control group.
62682085|NCT06158477|EXPERIMENTAL|JYP0035 monotherapy dose-escalation group|PART-1 Single Dose Escalation Group
62682086|NCT06158477|EXPERIMENTAL|JYP0035 monotherapy dose-expansion group|PART-2 JYP0035 Monotherapy Dose Expansion Group
61922365|NCT00476801|NO_INTERVENTION|Control|No treatment on the opposite side of the face as the UVA1 treatment for up to 14 weeks. Then a cross-over treatment an equal length of time.
62311578|NCT03484533|ACTIVE_COMPARATOR|HIV Self-test kit|
62311579|NCT03484533|ACTIVE_COMPARATOR|Invitation letter-standard of care|
62311580|NCT02673112|EXPERIMENTAL|STEP-mhc + LS|Subjects will be asked to perform exercise at 80% of the heart rate threshold determined using the Balke protocol for 5 minutes greater than their measured minutes of MVPA/day at baseline (Subthreshold exercise program). They will also be given a light stretching protocol (5 stretches). The exercise intervention will last for 6 weeks and will be supported by weekly health coaching.
62682087|NCT03588429|EXPERIMENTAL|Sevoflurane|Anesthesia was maintained with sevoflurane.
62682088|NCT03588429|EXPERIMENTAL|Isoflurane|Anesthesia was maintained with isoflurane.
62682089|NCT06694636|EXPERIMENTAL|Intravascular Radiofrequency Ablation of Sympathetic Nerves Group|Enrolled patients will receive Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
61922366|NCT05314491||Multigen Plus CCK|
61922367|NCT05314491||Multigen Plus CCK in combination with AMF TT cones|
61922368|NCT04756674||Control Group|"Non-Covid -19 associated community acquired pneumonia with oxygen therapy required.~n=12"
62122637|NCT02561949|EXPERIMENTAL|YRI + Employment Program|Immediately following enrollment participants will complete the YRI intervention, followed by an income generating activity program.
62122638|NCT02561949|EXPERIMENTAL|Employment Program|Immediately following enrollment participants will complete an income generating activity program.
62311581|NCT02673112|ACTIVE_COMPARATOR|LS alone|Subjects will be given a light stretching program alone (5 stretches). The exercise program will last for 6 weeks.
62311582|NCT06282172|EXPERIMENTAL|Treatment with BTL-785-7|Active treatment with BTL-785-7
62311583|NCT06282172|NO_INTERVENTION|Control|No active treatment
62476947|NCT02134379||Heart Failure|Subjects have implanted Medtronic device and a primary diagnosis of left ventricular systolic dysfunction
62476948|NCT06562933|SHAM_COMPARATOR|Sham vacuum|Sham vacuum
62682090|NCT01659710||Study Babies|Study video at 50-55 weeks gestational age, motor assessments at 24m (+/- 6 months) and again at 4 years (+/- 1 year).
62682091|NCT01659710||Control Babies|Video at 50-55 weeks gestational age, motor assessment at 24 months (+/- 6 months).
62682092|NCT02923778|EXPERIMENTAL|Treatment (talimogene laherparepvec, radiation therapy)|Patients receive talimogene laherparepvec IT or via intralesional injection at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy on Monday-Friday of weeks 2-6. Patients undergo collection of blood and a tumor biopsy on study and undergo MRI throughout the trial.
61922369|NCT04756674||Oxygen Therapy|"Confirmed COVID-19 infection via PCR swab, with a new oxygen therapy requirement. NB the researchers will not be involved in the clinical decision of if the participant requires oxygen, this will be the clinical-teams decision.~n=12"
62682093|NCT02174445|EXPERIMENTAL|Imatinib|Imatinib 400-800mg, daily, maximum 6 years
62682094|NCT02174445|ACTIVE_COMPARATOR|Nilotinib|Nilotinib, 300mg, twice daily, maximum 6 years
61922370|NCT04756674||Non-Invasive ventilation therapy|"Confirmed COVID-19 infection via PCR Swab, with a clinical need for non-invasive ventilation.~NB the researchers will not be involved in the clinical decision if the participant requires non-invasive ventilation, this will be the clinical-teams decision.~n=12"
61922371|NCT02710500|EXPERIMENTAL|Cohort 1 (Low Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10\^12 in one muscle.~Intervention Drug: rAAVrh.MHCK7.DYSF.DV"
61922372|NCT02710500|EXPERIMENTAL|Cohort 2 (High Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10\^12 vg in one muscle.~Intervention Drug: rAAVrh74.MHCK7.DYSF.DV"
61922373|NCT02216825|EXPERIMENTAL|Delayed release capsule, L. reuteri NCIMB 30242|
61922374|NCT02216825|EXPERIMENTAL|Standard vegetarian capsule, L. reuteri NCIMB 30242|
61922375|NCT00640835|EXPERIMENTAL|Sublingual administration|Buprenorphine/naloxone film strip administered sublingually
62122639|NCT03881449|EXPERIMENTAL|ABILIFY MYCITE Group|"If patients are assigned to the ABILIFY MYCITE treatment group, the patients and physician will initiate the system at the baseline visit, and continue to use the system for 3 months. At any time after the first 3 months, a patient and his or her doctor will have the opportunity to either discontinue or continue using ABILIFY MYCITE for the remainder of the trial (9 additional months; 12 months total) as long as clinically appropriate with the goal of measuring adherence to improve clinical decision-making and care.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
61922376|NCT00640835|EXPERIMENTAL|Buccal administration|Buprenorphine/naloxone film strip administered buccally
61922377|NCT00814125|ACTIVE_COMPARATOR|1|Arimidex 1mg + Nolvadex placebo
61922378|NCT00814125|ACTIVE_COMPARATOR|2|Arimidex placebo + Nolvadex 20mg
61922379|NCT00814125|ACTIVE_COMPARATOR|3|Arimidex 1mg + Nolvadex 20mg
61922380|NCT04195737|EXPERIMENTAL|Root coverage with ossix volumax collagen matrix|Evaluation of root coverage achieved by collagen matrix in conjunction with coronally advanced flap in patients with multiple gingival recession.
62122640|NCT03881449|NO_INTERVENTION|Treatment as Usual (TAU) Group|"TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
62682095|NCT05156203|EXPERIMENTAL|T-1301 Capsules|T-1301 Capsules will be administered orally QD or BID in a 28-day cycle (21 days on treatment followed by 7 days off treatment) in sequential cohorts.
62682096|NCT06656221|EXPERIMENTAL|Glofitamab-Orelabrutinib-Bortezomib|"Participants will receive 2000 mg of obinutuzumab on Days 1-2 of Cycle 1, 2.5 mg of glofitamab on Day 8 of Cycle 1, 10 mg of glofitamab on Day 15 of Cycle 1, followed by 30 mg of glofitamab on Day 1 of Cycles 2-12.~Participants will receive 1.6 mg/m² of bortezomib on Days 1, 8, and 15 of Cycles 1-12.~Participants will receive 150 mg/day of orelabrutinib on Days 1-21of Cycles 1-12.~The duration of one cycle is 21 days."
62682097|NCT05243290|ACTIVE_COMPARATOR|Study Supplement: NR|26 subjects will take the supplement (nicotinamide riboside) during the first phase of the study. 300mg will be taken once a day for the 10-week period in phase one.
62682098|NCT05243290|PLACEBO_COMPARATOR|Control|26 subjects will take the placebo during the first phase of the study (10 weeks).
62682099|NCT06694558||Patients with Type 1 Diabetes|Patients with Type 1 Diabetes with or without chronic kidney disease
62682100|NCT05426681|EXPERIMENTAL|Glyburide treatment arm|
62682101|NCT06686030|EXPERIMENTAL|Cohort 1-10 (BRCAm)|AK112(10mg/kg)+chemo for 4-6 cycles, AK112 (10mg/kg)+Olaparib maintenance
62682102|NCT06686030|EXPERIMENTAL|Cohort 1-10B (non-BRCAm)|AK112(10mg/kg)+chemo for 4-6cycles, AK112(10mg/kg) maintenance
62682103|NCT06686030|EXPERIMENTAL|Cohort 1-20A (BRCAm)|AK112(20mg/kg)+chemo for 4-6cycles, AK112(20mg/kg)+Olaparib maintenance
62682104|NCT06686030|EXPERIMENTAL|Cohort 1-20B (non-BRCAm)|AK112(20mg/kg)+chemo for 4-6cycles, AK112(20mg/kg) maintenance
62682105|NCT06686030|EXPERIMENTAL|Cohort 2 (Prior ≥2L)|AK112(20mg/kg)+Olaparib
62311584|NCT02873715|ACTIVE_COMPARATOR|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
62682106|NCT06290011||Pain key group|mixed real pain treatment software, pain treatment scenarios in MR
62311585|NCT02873715|EXPERIMENTAL|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
62682107|NCT06290011||Sham MR group|TV screen 2D treatment scene with the same content provided
62682108|NCT06689878|EXPERIMENTAL|Intervention Arm Using the Mobile Cognitive Behavioral Therapy App|All participants will receive the same intervention arm, a mobile cognitive behavioral therapy (CBT) app that includes modules with educational content and teaching and practice of strategies that address the following: education about anxiety and depression and their association with stroke recovery; awareness and monitoring of emotions; behavioral activation, i.e., increasing engagement in valued and meaningful activities; increasing awareness of thinking errors and reframing negative thoughts; mindfulness; relaxation skills; increasing tolerance of anxiety in anxiety-provoking situations; and problem-solving. The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Participants will be asked to use the application for 30 minutes per day, 2 days per week, for 8 weeks.
62682109|NCT06691139||Group (A) patients with periosteal graft|patients whose underwent to myringoplasty using periosteal graft
61922381|NCT04195737|ACTIVE_COMPARATOR|Root coverage with connective tissue graft|Evaluation of root coverage achieved by connective tissue graft in conjunction with coronally advanced flap in patients with multiple gingival recession
61922382|NCT02552615|EXPERIMENTAL|body awareness therapy (BAT)|Each session started with short warm-up, continued with specific exercises. Following each session, verbal reflexions was taken for 10 minutes. Exercises fulfilled in lying, sitting, standing and walking positions. Additionally program included vocal-breathing exercises and massage. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
62311586|NCT03668548|EXPERIMENTAL|Leucine group|To receive leucine on a daily basis for 10 weeks
62311587|NCT03668548|PLACEBO_COMPARATOR|Control group|To receive a placebo supplement on a daily basis for 10 weeks
62476949|NCT06562933|ACTIVE_COMPARATOR|Interferential Current Therapy Vacuum Electrodes|Interferential Current Therapy Vacuum Electrodes
62476950|NCT06562933|ACTIVE_COMPARATOR|Interferential Current Therapy Carbon-silicon Pad Electrodes|Interferential Current Therapy Carbon-silicon Pad Electrodes
62682110|NCT06691139||(B) patients with Temporalis fascia graft|patients whose underwent to myringoplasty using Temporalis fascia graft
61922383|NCT02552615|ACTIVE_COMPARATOR|Traditional exercises|Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
62476951|NCT02485977||Pulmonary Hypertension|Adult patients with pulmonary hypertension referred for cardiac catheterization in the PI institution
62476952|NCT06356103|ACTIVE_COMPARATOR|Group I|received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines
62682111|NCT04130867||Group A: Swallow Therapy Oropharyngeal Strengthening|"Participants receiving any standard of care swallow therapy with oropharyngeal strengthening as the primary goal~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post -therapy)"
62682112|NCT04130867||Group B: Surgical Treatment Esophageal Sphincter|"Participants receiving surgical treatment for relief of upper esophageal sphincter outlet obstruction.~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post therapy)"
62682113|NCT04130867||Group C: Healthy Controls|Healthy controls (n=50) will also undergo data collection at parallel time points, without completion of a treatment paradigm.
62682114|NCT05810311|ACTIVE_COMPARATOR|Roxadustat|The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.
62682115|NCT05810311|ACTIVE_COMPARATOR|Darbepoietin alpha|The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.
62682116|NCT06689813|ACTIVE_COMPARATOR|Vitamin D group|Group A participants received vitamin D supplements orally for 8 weeks along with pelvic floor exercises
62122641|NCT05086159|ACTIVE_COMPARATOR|Traditional Education|"Traditional biomedical education for back pain and standard stress education. Education was developed from Back School, National PTSD Center, and PTSD Coach."
62122642|NCT05086159|EXPERIMENTAL|Pain Neuroscience Education|Pain neuroscience education (PNE) was developed for this research comparing pain and stress symptoms to a radar that can become hypervigilant to threat.
62311588|NCT06666855|EXPERIMENTAL|DE-117B Eye Drops|0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.
62311589|NCT06666855|ACTIVE_COMPARATOR|Latanoprost Eye Drops|0.005% Latanoprost Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.
62476953|NCT06356103|ACTIVE_COMPARATOR|Group II|received 50% of their caloric requirements as WPHF and the other 50% as standard nutritional feeding
62122643|NCT02921399||early eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
62476954|NCT00431041|EXPERIMENTAL|Solifenacin|Solifenacin succinate: 5 mg tablets, taken orally, once daily
62122644|NCT02921399||late eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
62122645|NCT04168801|EXPERIMENTAL|Early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, if he did not have them, then receives diet indicated between 16 and 24 hours after admission.
62311590|NCT03331172|EXPERIMENTAL|High Intensity Focused Ultrasound|
62476955|NCT00431041|ACTIVE_COMPARATOR|Oxybutynin IR|Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day
62476956|NCT01845272|EXPERIMENTAL|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
62311591|NCT05888714|EXPERIMENTAL|Experimental FES cycling|New medical device combining cycle ergometer use and neuromuscular electrical stimulation (FES cycling)
62476957|NCT01845272|EXPERIMENTAL|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
62682117|NCT06689813|PLACEBO_COMPARATOR|Placebo group|Group B participants received ispaghula husk tablets for 8 weeks along with pelvic floor exercises
62311592|NCT05888714|ACTIVE_COMPARATOR|Comparator FES cycling|Existing medical device combining cycle ergometer use and neuromuscular electrical stimulation (FES cycling)
62682118|NCT06678581|EXPERIMENTAL|SAP-001|Four sequentially ascending dose cohorts are set in SAD study. Three sequentially ascending dose cohorts are set in MAD study.
62682119|NCT06678581|EXPERIMENTAL|Placebo|placebo tablets for oral
62682120|NCT06678581|EXPERIMENTAL|A Randomized, Open-label, two-period crossover FE study|12 subjects are randomized in a 1:1 ratio to sequences A (fasting - fed) and B (fed - fasting).
62682121|NCT06401733|EXPERIMENTAL|Intervention Group|12-week Intensive Aerobic and Resistance Exercise Program (IAREP) intervention group
62476958|NCT06106490|ACTIVE_COMPARATOR|Suprasacapular nerve block|Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine
62122646|NCT04168801|ACTIVE_COMPARATOR|Usual oral refeeding|usual oral refeeding (UOR) Once the attending physician decided according to his clinical judgment to restart the oral feeding
62311593|NCT05888714|ACTIVE_COMPARATOR|Conventional physical therapy|Conventional physical therapy.
62311594|NCT05888714|NO_INTERVENTION|Operators|Operators will evaluate systems usability during interventions.
62476959|NCT06106490|ACTIVE_COMPARATOR|Pulsed Radiofrequency group|Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds.
62682122|NCT06401733|NO_INTERVENTION|Control Group|Subjects that receive their usual care in Jurong polyclinic.
62122647|NCT05488080|EXPERIMENTAL|Department-level audit and feedback and electronic health record-embedded clinical decision support|Clinicians will receive monthly pooled, department-level 'Equity Report Cards' that will provide aggregate information on clinical data stratified by patient race/ethnicity. Subsequently, for all visits that may be related to appendicitis or long bone fracture, clinicians will then receive real-time, electronic health record-embedded clinical decision support regarding pain management.
62476960|NCT04862767|EXPERIMENTAL|TASO-001|level 1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)(3+3) next than level 2 or level -1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)
62682123|NCT06689254|EXPERIMENTAL|Mifepristone|
62122648|NCT04783012|EXPERIMENTAL|Home removal of catheter after surgery|Patients randomized to home removal will be assigned to remove their catheters on postoperative day (POD) 2 (or if Th/F surgery, POD 4 or POD 3, respectively). They will be handed an instructional packed with visual, written and video instructions for catheter removal.
62122649|NCT04783012|ACTIVE_COMPARATOR|Office removal of catheter after surgery|Patients randomized to office removal will be assigned to return to the office on POD 2 (or if Th/F surgery, POD 4 or POD 3, respectively) for standard nurse visit with backfill, catheter removal and voiding trial in the office.
62122650|NCT02101905|EXPERIMENTAL|Group A (lapatinib ditosylate, surgery)|Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62122651|NCT02101905|ACTIVE_COMPARATOR|Reference Group (surgery, lapatinib ditosylate)|Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62122652|NCT06676566||Genetic risk without islet autoantibodies|This group has more than 10% risk of early onset of islet autoimmunity and can come to visits at 2, 6 and 10 years of age. At the visits blood samples are drawn and disease risk information and information about symptoms is given. The child will wear an accelerometer for one week after each visit.
62122653|NCT06676566||Genetic risk with 1 islet autoantibody|This group will be followed annually up to diabetes diagnosis or to 18 years of age. At the visits blood samples are drawn and disease risk information and information about symptoms is given. The child will wear an accelerometer for one week after each visit.
62476961|NCT06210984|EXPERIMENTAL|Low caffeine dose|2 mg/kg dose of caffeine (in pill form)
62476962|NCT06210984|EXPERIMENTAL|Moderate caffeine dose|5 mg/kg dose of caffeine (in pill form)
62476963|NCT06210984|PLACEBO_COMPARATOR|Placebo|5 mg/kg dose of placebo (Maltodextrin in pill form)
62311595|NCT05191329||study group|40 patients with non surgical presbyopic correction e.g. glasses and 80 patients that underwent pseudophakic presbyopic correction with multifocal or trifocal IOLs
62311596|NCT01212328|EXPERIMENTAL|Care coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
62311597|NCT01212328|ACTIVE_COMPARATOR|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
62311598|NCT02848885|EXPERIMENTAL|Active TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere parietal (P3 cathodal, P4 anodal) stimulation daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
62476964|NCT01699191|ACTIVE_COMPARATOR|Probiotic Mixture|Probiotic mixture
62476965|NCT01699191|PLACEBO_COMPARATOR|Placebo|Placebo
62682124|NCT06689254|PLACEBO_COMPARATOR|Placebo|
62682125|NCT06690580|EXPERIMENTAL|motivational interviews group|
62476966|NCT04205123||sickle cell syndrome|Inclusions of sickle cell patients aged over 17 years followed regularly in the participating centers.
62476967|NCT00575159|EXPERIMENTAL|Arm a|GSK189075
62682126|NCT06690580|NO_INTERVENTION|control group|
62682127|NCT02018809|EXPERIMENTAL|MAP Daily Notification|The subject's MAP receives daily notification about whether subject took statin.
62682128|NCT02018809|EXPERIMENTAL|MAP Weekly Notification|The subject's MAP receives weekly about how often the subject took statin during previous week.
62682129|NCT02018809|EXPERIMENTAL|MAP Missed Doses|The subject's MAP receives notification if the subject missed \>2 consecutive daily doses of statin.
62682130|NCT02018809|OTHER|Usual Care|Usual care with GlowCap.
62682131|NCT05902858|ACTIVE_COMPARATOR|Control Group|Conventional intubation with hyperangulated videolaryngoscope
62311599|NCT02848885|EXPERIMENTAL|Sham TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere sham stimulation with electrodes placed on the parietal lobes (P3 and P4) daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
62311600|NCT04453956|SHAM_COMPARATOR|Control group|Patients will receive colonoscopy without assistance of EndoAngel's any function.
62476968|NCT00575159|PLACEBO_COMPARATOR|Arm b|Placebo
62476969|NCT05870332||All patients|Patient ≥18 years old, with capacity to consent, scheduled for diagnostic colonoscopy
62682132|NCT05902858|EXPERIMENTAL|Provu TM video stylet + hyperangulated videolaryngoscope|Intubation ProVu TM video stylet combined with hyperangulated videolaryngoscope
62682133|NCT05902858|EXPERIMENTAL|Provu TM video stylet + Macintosh laryngoscope|Intubation ProVu TM video stylet combined with standard Macintosh laryngoscope
62682134|NCT05786131|EXPERIMENTAL|culprit-lesion-only revascularization|Patients will receive optimal medical therapy without further revascularization of non-culprit lesions (neither during index hospitalization nor during follow-up). Angina pectoris will be treated medically as recommended in the chronic coronary syndrome guidelines. Revascularization of non-culprit lesions will only be permitted if at least one bailout criteria is met.
62311601|NCT04453956|EXPERIMENTAL|Polyp detection function group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection function.
62122654|NCT06676566||Genetic risk with multiple islet autoantibodies|This group will come to visits every three months up to diagnosis or 18 years of age. At the visits blood samples are drawn and disease risk information and information about symptoms is given. An OGTT will be performed at some of the visits. The child will wear an accelerometer and a CGM for one week after each visit.
62311602|NCT04453956|EXPERIMENTAL|Quality monitoring function group|Patients will receive colonoscopy with the assistance of EndoAngel's quality monitoring function.
62311603|NCT04453956|EXPERIMENTAL|Polyp detection plus quality monitoring functions group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection plus quality monitoring function.
62311604|NCT03340740|EXPERIMENTAL|Cetirizine|Cetirizine 10mg (10ml) (patients age 12-17) or cetirizine 5mg (5ml) (patients age 6-11) x 1 dose at beginning of course in emergency department.
62311605|NCT03340740|PLACEBO_COMPARATOR|Placebo|Placebo 10ml (patients age 12-17) or 5ml (patients age 6-11) x 1 dose at beginning of course in the emergency department.
62311606|NCT06021795|EXPERIMENTAL|Intervention|Treatment using a customized sound audio track delivered via standard commercially available bone conduction headsets
62311607|NCT06511414|EXPERIMENTAL|Duramesh|using duramesh suture for ileostomy fascial closure
62311608|NCT06511414|ACTIVE_COMPARATOR|Control|standard ileostomy fascial closure
62311609|NCT02734732|ACTIVE_COMPARATOR|Ciprofloxacin|T. Ciprofloxacin 750mg, single dose immediately prior to prostate biopsy
62311610|NCT02734732|ACTIVE_COMPARATOR|Trimethoprim/Sulfamethoxazole|Trimethoprim/Sulfamethoxazole 160mg/800mg immediately prior to prostate biopsy
62311611|NCT02602431|ACTIVE_COMPARATOR|Extra-oral laser irradiation|infra-red wave laser, 660nm, 100mW, and 107J/cm2
62311612|NCT02602431|PLACEBO_COMPARATOR|Extra-oral placebo|Laser point will be placed in region without irradiation on.
62311613|NCT02602431|ACTIVE_COMPARATOR|Intra-oral laser irradiation|red wave laser, 660nm, 100mW, and 107J/cm2
62311614|NCT02602431|PLACEBO_COMPARATOR|intra-oral placebo|Laser point will be placed in region without irradiation on.
62311615|NCT03021525|EXPERIMENTAL|Individualized Goal Directed Therapy (iGDT)|Patients receive fluids and catecholamines following a protocol of individualized parameters achieved by extended hemodynamic monitoring.
62476970|NCT06562322|PLACEBO_COMPARATOR|placebo PBMT|Participants will be received placebo PBMT immediately before physical tests.
62682135|NCT05786131|EXPERIMENTAL|multivessel complete revascularization|Patients will receive complete revascularization of all angiographically significant non-culprit lesions, either during the index procedure, the index hospitalization, or staged within 45 days after PCI of the culprit lesion.
62682136|NCT03967522|EXPERIMENTAL|Cabozantinib treatment|All participants will be treated by 60 mg of cabozantinib once daily.
62682137|NCT05829330|ACTIVE_COMPARATOR|Outpatient|Outpatient initiation of non-invasive mechanical ventilation
62682138|NCT05829330|PLACEBO_COMPARATOR|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
62476971|NCT06562322|ACTIVE_COMPARATOR|300 J PBMT|Participants will be received PBMT at 300 J immediately before physical tests.
62476972|NCT06562322|ACTIVE_COMPARATOR|600 J PBMT|Participants will be received PBMT at 600 J immediately before physical tests.
62476973|NCT06562322|ACTIVE_COMPARATOR|1260 J PBMT|Participants will be received PBMT at 1260 J immediately before physical tests.
62476974|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
62476975|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
62476976|NCT03227991|ACTIVE_COMPARATOR|Safety Planning Intervention|SPI is a personalized approach that focuses on early identification of warning signs and execution of systematic steps to manage suicidal thoughts, created collaboratively by the patient and clinician.
62476977|NCT03227991|ACTIVE_COMPARATOR|Risk factors and Warning signs|Patients will receive a generic suicide risk factors and warning signs information handout.
62476978|NCT02702882|OTHER|Fenugreek seeds extract 500 mg|Fenugreek seeds extract ( Furosap) one caps once a day
62476979|NCT04887415|EXPERIMENTAL|Enrolled Participants|Enrolled cardiac surgical patients who underwent a 4 weeks of preoperative respiratory strength training (RST) program using two respiratory strength training devices.
62476980|NCT00152451|EXPERIMENTAL|Seletracetam|Escalating doses twice daily were to be administered.
62682139|NCT05286684|EXPERIMENTAL|Study process|Consultation, Cerebral and medullary MRI, lumbar puncture, CSF sampling, blood sample, collection of breast fluid
62682140|NCT03568058|EXPERIMENTAL|vaccine and anti-PD-1|personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
62682141|NCT03568058|EXPERIMENTAL|anti-PD1 before vaccine|anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
62682142|NCT03568058|EXPERIMENTAL|anti-PD1 and vaccine|anti-PD-1 antibody followed by personalized vaccine therapy
62682143|NCT03568058|EXPERIMENTAL|vaccine|personalized vaccine therapy
62682144|NCT04941729|EXPERIMENTAL|Study Arm (dual mobility)|OR3O™ Dual Mobility in subjects who undergo Primary THA.
62682145|NCT04941729|ACTIVE_COMPARATOR|Controlled Arm (conventional)|A conventional, single-bearing design Total Hip System in subjects who undergo Primary THA.
62682146|NCT05869773|EXPERIMENTAL|JZP258|Participants will receive 6 to 9 grams per night of JZP258 (XYWAV) for 6 consecutive weeks.
62682147|NCT02639273|EXPERIMENTAL|Drug|single dose nalmefene
62682148|NCT02639273|PLACEBO_COMPARATOR|Placebo|single dose placebo
62682149|NCT05159960|EXPERIMENTAL|180/low|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
62682150|NCT05159960|EXPERIMENTAL|180/high|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
62682151|NCT05159960|EXPERIMENTAL|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
62311616|NCT03021525|ACTIVE_COMPARATOR|Control|Patients in the control group will be treated according to established basic treatment goals.
62682152|NCT05159960|EXPERIMENTAL|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
62311617|NCT01717612|ACTIVE_COMPARATOR|Histoacryl group|the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
62682153|NCT05306145|EXPERIMENTAL|High Freqnence Irreversible Electroporation|Using high freqnence irreversible electroporation to treat patients with benign prostatic hyperplasia
62311618|NCT01717612|EXPERIMENTAL|thrombin group|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
62311619|NCT03241173|EXPERIMENTAL|Phase 1, Dose Escalation: INCAGN01949 + Nivolumab|INCAGN01949 (70, 200, 350, or 700 milligrams \[mg\]) combined with nivolumab 240 mg in participants with advanced or metastatic select solid tumors
62476981|NCT06133933||Study Cohort|Patients will have their preoperative pain threshold measured and complete postoperative pain journal, pill count, VAS, SF-12, SANE, and Satisfaction Survey in addition to the routine standard of care following perioperative management of total shoulder arthroplasty patients.
62476982|NCT01138163|EXPERIMENTAL|Docetaxel plus bavituximab 1 mg/kg|
62476983|NCT01138163|EXPERIMENTAL|Docetaxel plus bavituximab 3 mg/kg|
62476984|NCT01138163|PLACEBO_COMPARATOR|Docetaxel plus placebo|
62476985|NCT04173247|EXPERIMENTAL|KeraStat Skin Cream Arm|Patients randomized to the KeraStat arm will be provided with KeraStat Skin Cream for application as often as needed but at least twice daily, morning and evening using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
62476986|NCT04173247|ACTIVE_COMPARATOR|Routine Skin Care Arm (RSC Arm)|Patients randomized to this arm will apply commercially available products from a list provided at least twice daily using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
62476987|NCT00570609|EXPERIMENTAL|CPR Anytime|Participants will be asked to complete the program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
62476988|NCT06628102|OTHER|Incidental Pulmonary Nodule Arm|Nodule Follow up as per Fleischner Guidelines
62476989|NCT01318551|EXPERIMENTAL|Arm 1|
62476990|NCT01318551|EXPERIMENTAL|Arm 2|
62476991|NCT01318551|EXPERIMENTAL|Arm 3|
62476992|NCT01109420||1/ Cohort 1|Affected with non-medullary thyroid cancer
62476993|NCT01109420||2/ Cohort 2|Non-affected members of families with non-medullary thyroid cancer
62682154|NCT05306145|ACTIVE_COMPARATOR|Trans Urethral Resection Prostate|Using trans urethral resection prostate to treat patients with benign prostatic hyperplasia
62682155|NCT05860296|EXPERIMENTAL|Dose Escalation (Phase 1b Dose Level 1)|"Dose level 1 dose will be SLC-391 100 mg PO/BID on Days 1-21 of each cycle and Pembrolizumab 200 mg IV on Day 1 of each cycle.~All dose-escalation decisions and the rationale for progressing to the next cohort will be reviewed by the Safety Review Committee (SRC).~A subject may continue treatment with SLC-391 and pembrolizumab in 21-day cycles until the treatment discontinuation criteria are met."
61922384|NCT02552615|EXPERIMENTAL|core stabilization exercises|Exercises started to progress from static to dynamic positions in which muscle activation incorporate into functional tasks including trunk and extremity movements. Local, global muscle stability training, global muscle mobility training and strengthening training of these core structure was carried out progressively advancing more difficult. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
61922385|NCT02889276|ACTIVE_COMPARATOR|Control|Unsupervised activity
62311620|NCT03241173|EXPERIMENTAL|Phase 1, Dose Escalation: INCAGN01949 + Ipilimumab|INCAGN01949 (70, 200, 350, or 700 mg) combined with ipilimumab 1 mg/kilogram (kg) in participants with advanced or metastatic select solid tumors
62311621|NCT03241173|EXPERIMENTAL|Phase 1, Dose Escalation: INCAGN01949 + Nivolumab + Ipilimumab|INCAGN01949 combined with nivolumab 3 mg/kg and ipilimumab 1 mg/kg in participants with advanced or metastatic select solid tumors
62311622|NCT03241173|EXPERIMENTAL|Phase 1, Safety Expansion: INCAGN01949 + Nivolumab|Run-in with INCAGN01949 (70, 200, or 350 mg) x 2 doses, followed by INCAGN01949 (70, 200, or 350 mg) combined with nivolumab 240 mg in participants with advanced or metastatic select solid tumors
62476994|NCT00858754|EXPERIMENTAL|Group 1 Active Drug|Methylnaltrexone
62476995|NCT00858754|PLACEBO_COMPARATOR|Group 2 Non-Active Drug|Placebo
62311623|NCT03241173|EXPERIMENTAL|Phase 1, Safety Expansion: INCAGN01949 + Nivolumab + Ipilimumab|Run-in with INCAGN01949 x 2 doses, followed by INCAGN01949 combined with nivolumab 3 mg/kg and ipilimumab 1 mg/kg in participants with advanced or metastatic select solid tumors
62311624|NCT03241173|EXPERIMENTAL|Phase 2, Part A: INCAGN01949 + nivolumab|INCAGN01949 combined with nivolumab in programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) refractory participants with gastric cancer, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), or renal cell carcinoma (RCC)
62122655|NCT06676566||Children with stage 3 type 1 diabetes who have taken part in the study before diagnosis|Annual visits at the study center will continue for the first 5 years after diagnosis.
62311625|NCT03241173|EXPERIMENTAL|Phase 2, Part B: INCAGN01949; INCAGN01949 + nivolumab; INCAGN01949 + nivolumab + ipilimumab|INCAGN01949 alone, combined with nivolumab, and combined with nivolumab and ipilimumab in PD-1/L1 refractory participants with advanced or metastatic gastric cancer, SCCHN, NSCLC, or RCC
62476996|NCT04927013|EXPERIMENTAL|Message-based Outreach Intervention (MBI) for Survivors|Cancer survivors randomized to receive a targeted letter with a unique website login code, access to the expanded website, free genetic counseling, and short message service (SMS) reminders.
62476997|NCT04927013|ACTIVE_COMPARATOR|Standard Outreach for Survivors|Cancer survivors randomized to receive the standard outreach consisting of a standard letter with website access, access to a condensed version of the study website, and free genetic counseling.
62476998|NCT04927013|EXPERIMENTAL|Message-based Outreach Intervention for Close Relatives|Close relatives of cancer survivors who were randomized to receive the message-based outreach. Close relatives will have access to the expanded version of the study website and free genetic counseling.
62311626|NCT02414295|EXPERIMENTAL|Mesenchymal stem cell injection|Bone marrow Mesenchymal stem cell injection in the testicular tubules and testicular artery
62311627|NCT02795598|ACTIVE_COMPARATOR|Single Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided single injection supraclavicular nerve block for surgical anesthesia.
62476999|NCT04927013|ACTIVE_COMPARATOR|Standard Outreach for Close Relatives|Close relatives of cancer survivors who were randomized to receive the standard outreach. Close relatives will have access to a condensed version of the study website and free genetic counseling.
62477000|NCT04937062|EXPERIMENTAL|SLC6A1 and STXBP1|"Each participant will be enrolled for 14 weeks (4 weeks baseline, 8 weeks of drug exposure, and 2 weeks follow-up). After clinical assessment by the investigator if deemed safe and appropriate, and requested by the caregiver, participants may continue to receive the study medication (extended use), up to December 2025. Participants who remain on phenylbutyrate therapy will be followed quarterly through video visits, and yearly in-person visit. Participants who do not opt to remain on phenylbutyrate therapy will be weaned off the medication during the 2 week follow-up period."
61922386|NCT02889276|EXPERIMENTAL|Functional Resistance Training (FRT)|Supervised, group-based functional resistance training
62122656|NCT03746665|EXPERIMENTAL|meningococcal serogroup A conjugate|mothers will be vaccinated with meningococcal serogroup A conjugate vaccine between 28 - 34 weeks gestation
62122657|NCT03746665|NO_INTERVENTION|control|serological samples from 100 control mother-infant pairs already recruited as part of the PROPEL trial, (SCC1433), NCT02628886
62122658|NCT03966508|EXPERIMENTAL|hyperalgesia measurement|
62477001|NCT04937062|EXPERIMENTAL|Monogenetic Epileptic Encephalopathy|"Each participant will be enrolled for 20 weeks (5 weeks baseline, 12 weeks of drug exposure, and 2 weeks follow-up) . After clinical assessment by the investigator if deemed safe and appropriate, and requested by the caregiver, participants may continue to receive the study medication (extended use), up to December 2025. Participants who remain on phenylbutyrate therapy will be followed quarterly through video visits, and yearly in-person visit. Participants who do not opt to remain on phenylbutyrate therapy will be weaned off the medication during the 2 week follow-up period."
62477002|NCT00684697|PLACEBO_COMPARATOR|1|low iron dose
62477003|NCT00684697|ACTIVE_COMPARATOR|2|intermediate iron dose
62682156|NCT05860296|EXPERIMENTAL|Dose Escalation (Phase 1b Dose Level 2)|"Dose level 2 dose will be SLC-391 150 mg PO/BID on Days 1-21 of each cycle and Pembrolizumab 200 mg IV on Day 1 of each cycle.~All dose-escalation decisions and the rationale for progressing to the next cohort will be reviewed by the Safety Review Committee (SRC)."
62682157|NCT05860296|EXPERIMENTAL|Dose Escalation (Phase 1b Dose Level -1)|"Dose level -1 dose will be SLC-391 50 mg PO/BID on Days 1-21 of each cycle and Pembrolizumab 200 mg IV on Day 1 of each cycle.~All dose-escalation decisions and the rationale for progressing to the next cohort will be reviewed by the Safety Review Committee (SRC)."
62122659|NCT05076318|EXPERIMENTAL|Alanine-infusion|Alanine infusion taking place over a 3 hour period while monitorering metabolic changes in blood samples before and after dialysis
62122660|NCT06491732||Amyotrophic Lateral Sclerosis|Patients diagnosed with ALS
62122661|NCT03737240|EXPERIMENTAL|IDegLira|Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
62122662|NCT03737240|ACTIVE_COMPARATOR|Basal-Bolus Insulin|Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
62122663|NCT05848583|EXPERIMENTAL|Enteral Nutrition (EN) Formula|Enteral formula
62122664|NCT06386237|EXPERIMENTAL|Standardized meal with macronutrient composition 1|Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
62122665|NCT06386237|EXPERIMENTAL|Standardized meal with macronutrient composition 2|Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
62122666|NCT04409912|EXPERIMENTAL|Sirolimus coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the vessel wall by inflating the sirolimus coated balloons at 2 minutes at rated burst pressure (typically 12 to 14ATM). All the lesions within the dialysis circuit with sirolimus coated balloon.
62122667|NCT04409912|PLACEBO_COMPARATOR|Plain balloon|The plain balloon or placebo will not be coated. The plain balloon will be inflated at 2 minutes at rated burst pressure (typically 12 to 14 ATM). Plain balloon will be applied to all the narrowed segment of the dialysis circuit
62122668|NCT06677034|NO_INTERVENTION|control|
62122669|NCT06677034|EXPERIMENTAL|intervention|"Consent will be obtained from the volunteer children and parents and a WhatsApp group will be established. Parents will be asked to fill out sociodemographic forms about themselves and the child. Students whose parents have given their consent will be included in the study and a mobile game-based exercise program will be started. Each online animated game-based exercise program will be supervised by a researcher physiotherapist. Game-based exercise program sessions with animated characters will be planned for 12 weeks/3 days a week/30 minutes. Fatigue perceptions will be assessed with the Modified Borg Scale after each exercise. Children who show any symptoms will take a break from the session. The first assessment will be made before the sessions start and the final assessment will be made after the 12-week exercise program.~Game-based exercise program content:~Warm-up Exercise Program Warm-up exercise training; fun and interesting animated game-based exercise that will allow the hea"
62122670|NCT02269280|EXPERIMENTAL|Azacitidine (AZA) - Days 1 - 3|Azacitidine (AZA) Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
62122671|NCT02269280|EXPERIMENTAL|Azacitidine (AZA) - Days 1 - 5|Azacitidine (AZA) 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
62311628|NCT02795598|ACTIVE_COMPARATOR|Double Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided double injection supraclavicular nerve block for surgical anesthesia.
62339964|NCT01021852|EXPERIMENTAL|MK-6096 5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
62682158|NCT05860296|EXPERIMENTAL|ICI-Naïve (Phase 2a)|"The dose of SLC-391 will be randomized between two dose levels (50 mg and 100 mg PO/BID) as approved by the SRC in combination with Pembrolizumab.~* Tumors must have PD-L1 expression (TPS ≥1%)~* No prior systemic treatment (chemotherapy or targeted therapy) and no prior immunotherapy (SOC or investigational) in advanced or metastatic setting~* Subjects with actionable genomic alterations with approved targeted therapy in first line setting are not allowed~* Subjects with disease recurrence or progression following neoadjuvant or adjuvant therapy or definitive chemoradiation therapy are eligible.~* Prior adjuvant, neoadjuvant immunotherapy allowed if completed more than 12 months before documented relapse~A subject may continue treatment with SLC-391 and pembrolizumab in 21-day cycles until the treatment discontinuation criteria are met."
61922387|NCT06011031|EXPERIMENTAL|Novaloc attachment|"a newly developed device novaloc attachment systemmade of peek material and amorphous diamond like carbon."
61922388|NCT06011031|ACTIVE_COMPARATOR|locator attachment|a device with low-profile attachment used in cases of limited inter arch distance, provides excellent retention, possesses a self-aligning property and allow correction of implant divergence up to 20 degrees
61922389|NCT00095680|EXPERIMENTAL|001|SCIO-469 two 30-mg capsules three times daily
61922390|NCT00095680|ACTIVE_COMPARATOR|002|SCIO-469 and bortezomib The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
61922391|NCT05983146|EXPERIMENTAL|HRS-7053 Injection|
61922392|NCT01757691|EXPERIMENTAL|Fingolimod 0.5mg/daily|Oral capsule dose was given once daily for 48 weeks
61922393|NCT01757691|PLACEBO_COMPARATOR|Placebo|Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48
61922394|NCT02085915|OTHER|strip Peri Screen|
61922395|NCT03189771|EXPERIMENTAL|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
61922396|NCT03189771|PLACEBO_COMPARATOR|no occlusal surface reduction|No occlusal surface reduction after single visit root canal treatment
61922397|NCT05012787|EXPERIMENTAL|SCB-2019 Group|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
61922398|NCT05012787|PLACEBO_COMPARATOR|Control Group|Havrix and Placebo
62311629|NCT03072511|EXPERIMENTAL|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
61922399|NCT04600310|OTHER|Study Arm 1 Conventional Prep/Control|The preoperative preparation for the control group will use ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) that will be applied to the skin using a sponge-on-a-stick method; this solution is widely recognized as optimal. After the alcohol-based solution has evaporated (no less than 3 minutes), the patient extremity is draped for surgery.
61922400|NCT04600310|OTHER|Study Arm 2 ULTRAPREP Group/Intervention Arm|ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) will be poured into the ULTRAPREP bag which will be placed on the patient's extremity while in the holding area; it will be removed only after scrub time of 3 minutes is complete and the patient has been transferred to the OR, anesthetized, and positioned. The patient is draped only after the solution has evaporated (no less than 3 minutes).
61922401|NCT02555241|EXPERIMENTAL|One Baseline Session|Designated for participants #1 and #2. Participants complete 1 Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
61922402|NCT02555241|EXPERIMENTAL|Two Baseline Sessions|Designated for participants #3 and #4. Participants complete a Baseline Session followed by a 12 week wait period before repeating a Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
61922403|NCT02555241|EXPERIMENTAL|Three Baseline Sessions|Designated for participants #5 and #6. Participants complete a Baseline Session followed by two repetitions of the Baseline Session (each 12 weeks apart) and 12 weeks of standard treatment immediately following the third session. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
62311630|NCT03072511|ACTIVE_COMPARATOR|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
62311631|NCT02345161|EXPERIMENTAL|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
62311632|NCT02345161|EXPERIMENTAL|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
62311633|NCT02410369|ACTIVE_COMPARATOR|S-588410|Subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
62311634|NCT02410369|PLACEBO_COMPARATOR|Placebo|Subjects with HLA-A\*2402 in the placebo arm will receive the subcutaneous administration of placebo.
62311635|NCT04570449|EXPERIMENTAL|Fluoxetine|"Participants instructed to take fluoxetine 20 mg capsule orally daily for 8 weeks in the following schedule:~Week 1 = 1 pill (20 mg), Week 2 = 2 pills (40 mg), Weeks 3-6 = 3 pills (60 mg), Week 7 = 2 pills (40 mg), Week 8 = pill (20 mg)"
61922404|NCT02069418|EXPERIMENTAL|Experimental arm|All patients will be in the same arm. Patients are going to have two 18F-FLT-TEP and two 18F-FDG-TEP : the first ones during the two weeks before the beginning of erlotinib and the second ones will occur during the second week after the initiation of erlotinib. The order of TEP is not definite : 18F-FLT-TEP may be planned first or reciprocally. A period of 48 hours must separate two TEP.
61922405|NCT01375478||Cohort|
61922406|NCT00095927|ACTIVE_COMPARATOR|Arm A Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;~* 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).~* Subcutaneous daily amifostine at a dose of 500 mg"
61922407|NCT00095927|EXPERIMENTAL|Arm B No-Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN~- 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system)."
61922408|NCT00972855|EXPERIMENTAL|Bicalutamide|Bicalutamide 50 mg Tablet
62311636|NCT04570449|PLACEBO_COMPARATOR|Placebo|"Participants instructed to take fluoxetine placebo capsule matching fluoxetine orally daily for 8 weeks in the following schedule:~Week 1 = 1 pill, Week 2 = 2 pills, Weeks 3-6 = 3 pills, Week 7 = 2 pills, Week 8 = pill"
62477004|NCT00684697|EXPERIMENTAL|3|High Iron dose
62477005|NCT05846022|EXPERIMENTAL|Dry needling|Dry needling involves the insertion of solid monofilament needles into tender points in tight muscle bands for therapeutic purposes.
62477006|NCT05846022|SHAM_COMPARATOR|Sham needling|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
61922409|NCT00972855|ACTIVE_COMPARATOR|Casodex®|Casodex® 50 mg Tablet
62122672|NCT02269280|EXPERIMENTAL|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
62122673|NCT02269280|OTHER|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
62122674|NCT04226703||Study group|Patients over the age of 18 who underwent surgery in the ear, nose and throat department.
62311637|NCT06511726|EXPERIMENTAL|Cadonilimab plus Cisplatin and Albumin-Bound Paclitaxel as Induction therapy Followed by CCRT|This is a single-arm study. The experimental arm includes Cadonilimab + cisplatin + albumin-bound paclitaxel, for a total of 2 cycles (cisplatin 75 mg/m² + albumin-bound paclitaxel 260 mg/m² q3w, Cadonilimab 10 mg/kg q3w).
62311638|NCT01984112|EXPERIMENTAL|Intramedullary Locked Nail|
62477007|NCT00194454|EXPERIMENTAL|1|Nine session psychosocial/behavioral counseling with homework
62682159|NCT05860296|EXPERIMENTAL|ICI-Resistant (Phase 2a)|"The dose of SLC-391 will be randomized between two dose levels (50 mg and 100 mg PO/BID) as approved by the SRC in combination with Pembrolizumab.~* Received at least 2 doses of anti-PD(L)-1 monoclonal antibody (mAb) in an advanced or metastatic setting.~* Progressive disease documented during treatment or within 12 weeks from the last dose of anti-PD(L)-1 mAb.~* Maximum of 2 prior lines of cancer therapy in an advanced or metastatic setting including an anti-PD(L)-1 mAb administered either as monotherapy or in combination with other therapies.~* Subjects who received a targeted therapy for an actionable genomic alteration can participate with documented disease progression or if unable to tolerate the targeted therapy. Only these subjects are allowed to receive up to a maximum of 3 prior lines of cancer therapy in an advanced or metastatic setting.~A subject may continue treatment with SLC-391 and pembrolizumab in 21-day cycles until the treatment discontinuation criteria are met."
62122675|NCT00648011|EXPERIMENTAL|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
62122676|NCT00648011|ACTIVE_COMPARATOR|2|Accuretic™ Tablets 20 mg/25 mg
62477008|NCT00194454|ACTIVE_COMPARATOR|2|Usual clinic care with booklet describing depression following stroke
62477009|NCT01111045|ACTIVE_COMPARATOR|Arm 1|0.03 mg/ml BMP-7, single intraarticular knee injection
62477010|NCT01111045|ACTIVE_COMPARATOR|Arm 2|0.1 mg/ml BMP-7, single intraarticular knee injection
62682160|NCT05781750|EXPERIMENTAL|zetomipzomib 30 mg + standard-of-care|Initial 30 mg dose of zetomipzomib, followed by weekly doses of 30 mg zetomipzomib through 52 weeks of the treatment period.
62682161|NCT05781750|EXPERIMENTAL|zetomipzomib 60 mg + standard-of-care|Initial 30 mg dose of zetomipzomib, followed by weekly doses of 60 mg zetomipzomib through 52 weeks of the treatment period.
62122677|NCT05344001||Midlife former athletes with a prior knee injury|"Inclusion Criteria: Age 40-64 years. Prior participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., baseball, basketball, field hockey, football, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the collegiate varsity level for at least 1 season; history of at least 1 prior traumatic knee injury including but not limited to ACL or PCL rupture and/or reconstruction, medial and/or lateral meniscus tear or surgery, osteochondral defect, and/or intra-articular (i.e., tibiofemoral or patellofemoral) fracture.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement)."
62311639|NCT01984112|ACTIVE_COMPARATOR|Locked Plate|
62311640|NCT03727711|EXPERIMENTAL|Home Treatment|Participants will be taught home treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
62311641|NCT03727711|ACTIVE_COMPARATOR|Hospital Treatment|Participants will receive hospital treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
62477011|NCT01111045|ACTIVE_COMPARATOR|Arm 3|0.3 mg/ml BMP-7, single intraarticular knee injection
62122678|NCT05344001||Midlife former athletes without a prior major lower extremity injury|"Inclusion Criteria: Age 40-64 years. Prior participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., football, baseball, basketball, field hockey, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the collegiate varsity level for at least 1 season.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement); prior major lower extremity injury (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation)."
62122679|NCT05344001||Midlife controls|"Inclusion Criteria: Age 40-64 years.~Exclusion Criteria: Prior participation in a collegiate varsity sport or professional sport; neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement); prior major lower extremity injury (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation)."
62122680|NCT05344001||Young adult athletes|"Inclusion Criteria: Age 18-25 years. Participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., baseball, basketball, field hockey, football, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the varsity collegiate level.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement)."
62122681|NCT05344001||Young adult controls|"Inclusion Criteria: Age 18-25 years.~Exclusion Criteria: Prior or current participation in any collegiate varsity sport; prior major lower extremity injury or surgery (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation); current participation in competitive sport (e.g., collegiate club sport) more than 3x/week; joint replacement in the lower extremity (i.e., knee or hip replacement); current pregnancy; or neurologic condition (e.g., stroke, Parkinson's) and/or degenerative condition that impairs function."
62311642|NCT01738139|EXPERIMENTAL|Treatment (ipilimumab, imatinib mesylate)|Patients receive ipilimumab IV over 90 minutes on day 1 and imatinib mesylate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62122682|NCT05317611|ACTIVE_COMPARATOR|Intraperitoneal instillation of ondansetron and bupivacaine (group A)|Patients will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % and (4 mg) 2 ml ondansetron through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
62122683|NCT05317611|ACTIVE_COMPARATOR|Intravenous ondansetron and intraperitoneal instillation of bupivacaine (group B)|Patient will receive intravenous (4 mg) 2 ml ondansetron and intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
62477012|NCT01111045|PLACEBO_COMPARATOR|Arm 4|1 ml placebo, single intraarticular knee injection (control)
62122684|NCT05317611|SHAM_COMPARATOR|Intraperitoneal instillation of bupivacaine (group C)|patient will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
62122685|NCT04651881|EXPERIMENTAL|Group 1|"1. Period 1: Reference drug~2. Period 2: Test drug 1~3. Period 3: Test drug 2"
62122686|NCT04651881|EXPERIMENTAL|Group 2|"1. Period 1: Test drug 2~2. Period 2: Reference drug~3. Period 3: Test drug 1"
62122687|NCT04651881|EXPERIMENTAL|Group 3|"1. Period 1: Test drug 1~2. Period 2: Test drug 2~3. Period 3: Reference drug"
62122688|NCT04651881|EXPERIMENTAL|Group 4|"1. Period 1: Test drug 2~2. Period 2: Test drug 1~3. Period 3: Reference drug"
62477013|NCT01051635|EXPERIMENTAL|Cohort A|LMP400 administered IV daily for 5 days per dose escalation table.
62122689|NCT04651881|EXPERIMENTAL|Group 5|"1. Period 1: Test drug 1~2. Period 2: Reference drug~3. Period 3: Test drug 2"
62122690|NCT04651881|EXPERIMENTAL|Group 6|"1. Period 1: Reference drug~2. Period 2: Test drug 2~3. Period 3: Test drug 1"
62311643|NCT06038448|ACTIVE_COMPARATOR|Effect of normal 10ml balloon volume on postoperative CRBD in non-LUTS patients|Efficacy of normal 10ml balloon volume for prevention of postoperative catheter-related bladder discomfort in patients undergoing non-lower urinary tract surgery
62477014|NCT01051635|EXPERIMENTAL|Cohort B|LMP776 administered IV daily for 5 days per dose escalation table.
61922410|NCT04335422|EXPERIMENTAL|Robotic group|Robotic group will receive both routine physical and rehabilitation medicine program and additional upper extremity robot-assisted training by Armeo Spring. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and robotic therapy one hour/day. Routine PRM program and robotic therapy will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program plus robotic therapy).
61922411|NCT04335422|ACTIVE_COMPARATOR|Control group|Control group will receive only routine physical and rehabilitation medicine program. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program only).
62122691|NCT00880477|EXPERIMENTAL|Group A|
62122692|NCT00880477|EXPERIMENTAL|Group B|
62311644|NCT06038448|ACTIVE_COMPARATOR|Effect of reduction of 5ml balloon volume for postoperative CRBD in patients undergoing non-LUTS|Efficacy of reduction of 5ml the balloon volume for prevention of postoperative catheter-related bladder discomfort in patients undergoing non-lower urinary tract surgery
62311645|NCT01144546|EXPERIMENTAL|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before anesthesia induction
62311646|NCT04524741|EXPERIMENTAL|left atrial appendage radiography|
62477015|NCT04009434|OTHER|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy
62477016|NCT04009434|EXPERIMENTAL|TAVI/MitraClip|Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.
62122693|NCT03822572|EXPERIMENTAL|A - endurance exercise|All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan. The individual pulse-controlled endurance exercise should be performed 3 times a week. On the basis of age, weight, sex and body fat the normal weight will be calculated. The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight. The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise. Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
62311647|NCT04524741|EXPERIMENTAL|intracardiac echocardiography guidance|
62311648|NCT03670173|EXPERIMENTAL|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year. One course of osalmid treatment lasts four weeks. Response will be assessed at the end of each treatment course, and patients who have achieved MR (minor remission) or more than MR at the end of the fourth course will continue to take 1.0g tid osalmid daily for consolidation / maintenance therapy. Otherwise, patients who have not achieved MR at the end of the fourth course and patients who are assessed for PD (progression of disease) at the end of each course will receive salvage treatment, such as a combined treatment of osalmid and dexamethasone or the VCD (bortezomib, cyclophosphamide and dexamethasone) regimen.
62311649|NCT04370262|ACTIVE_COMPARATOR|SOC/Famotidine|Subjects in this study arm will receive a combination of Standard of Care (SOC) treatment and intravenous famotidine. Famotidine Injection, 10mg/mL mixed with Normal Saline is given intravenously at 120mg (30% of 400 mg oral dose). The total daily dose proposed is 360mg/day famotidine IV for a maximum of 14 days, or hospital discharge, whichever comes first. SOC will be administered as per the current clinical protocol for COVID-19.
62311650|NCT04370262|PLACEBO_COMPARATOR|SOC/Placebo|Subjects in this arm will receive the current Standard of Care treatment for COVID-19; plus placebo infusion three times daily.
62477017|NCT03755050||Sleigh Accident|Accident while using a sleigh
62477018|NCT03755050||Climbing Accident|Accident occurred while climbing (rock, ice)
62477019|NCT03755050||Cycle Accident|Accident occurred while using any form of cycle in the mountains (e.g. bike, mountainbike, e-bike)
62477020|NCT03755050||Canyoning Accident|Accident occurred while doing canyoning
62477021|NCT03755050||Hiking Accident|Accident occurred while hiking in mountainous area.
62122694|NCT03822572|OTHER|B - control arm|Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
62122695|NCT02296424|EXPERIMENTAL|Canakinumab Dose Reduction|All patients received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab was administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continued to maintain inactive disease for 24 additional weeks, canakinumab was administered at 1mg/kg every 4 weeks. If the patient continued to maintain inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
62122696|NCT02296424|EXPERIMENTAL|Canakinumab Dose Interval Prolongation|All participants received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval was prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continued to be stable with inactive disease for 24 additional weeks, canakinumab dose interval was prolonged to a regimen of 4mg/kg every 12 weeks. If the patient was clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
62122697|NCT01748565||premature infants|Infants born prematurely between 23-0/7 and 27-6/7 weeks post-menstrual age with and without bronchopulmonary dysplasia
62477022|NCT03755050||Snowshoeing Accident|Accident occurred while doing Snowshoeing
62477023|NCT03755050||Mountainous Water-sport Accident|Accident occurred while doing any type of Water-sport (e.g. canoeing, kayaking, tubing, swimming) in mountainous environment.
62477024|NCT03755050||Skiing/Snowboarding|Accident occurred while using ski or a snowboard either in backcountry or on ski slope
62477025|NCT03923660|EXPERIMENTAL|Concentric-eccentric|Concentric-eccentric
62477026|NCT03923660|EXPERIMENTAL|Eccentric-concentric|Eccentric-concentric
62477027|NCT05957003|ACTIVE_COMPARATOR|occlusions test|Combined end expiratory (EEO) and inspiratory occlusion (EIO) test. A 15-s EEO separated by a time window of 1 minute to allow the hemodynamic parameters to return to baseline followed by a 15-s EIO
62477028|NCT05957003|ACTIVE_COMPARATOR|challenge test|Tidal volume (TV) challenge test (transient increase of TV from 6 to 8 mL/kg for 1 minute)
62311651|NCT06131203||Emergency Department Burn Subjects|Subjects with Thermal Burn Injury enrolled through the emergency department
62311652|NCT06131203||Burn Center Burn Subjects|Subjects with Thermal Burn Injury enrolled through the burn center
62122698|NCT05064930|ACTIVE_COMPARATOR|Bifidobacterium lactis|Probiotic formula contains 5x109 Bifidobacterium lactis Nordbiotic™ BI040 colony forming units (CFU)/capsule
62311653|NCT05464277|ACTIVE_COMPARATOR|Intermediate normal oxygen|"For the intermediate normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 95-97% will be recommended in the light of the Improving Oxygen Therapy in Acute-illness (IOTA) meta-analysis. The acceptable lower limit of PaO2 will be set to 80 mmHg according to a recent consensus of experts endorsed by the European Society of Intensive Care Medicine. The lower-limit and higher-limit monitor alarm for SpO2 will be set at 94% and 98%, respectively.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the intermediate normal oxygen group should receive air mix."
62311654|NCT05464277|ACTIVE_COMPARATOR|High normal oxygen|"For the high normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 99-100% will be recommended. The lower-limit monitor alarm for SpO2 will be set at 98%. No upper alarm limit for SpO2 will be set.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the high normal oxygen group should receive FiO2 of 1.0."
62311655|NCT02858388|ACTIVE_COMPARATOR|SN45|Sinuclean Nebules 45
62311656|NCT02858388|PLACEBO_COMPARATOR|Sal|Saline solution
62477029|NCT06481475|EXPERIMENTAL|Low dose YY003|Participants will receive a single dose over 5 injection sites on Day 1.
62477030|NCT06481475|EXPERIMENTAL|High dose YY003|Participants will receive a single dose over 5 injection sites on Day 1.
62477031|NCT06481475|PLACEBO_COMPARATOR|Vehicle control|Participants will receive a single dose over 5 injection sites on Day 1.
62477032|NCT05697211|EXPERIMENTAL|Feraccru® 30 mg hard capsules|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily p.o., morning and evening, on an empty stomach
62682162|NCT05781750|PLACEBO_COMPARATOR|placebo + standard-of-care|Initial 30 mg dose of placebo, followed by weekly doses (30 mg or 60 mg) of placebo through 52 weeks of the treatment period.
62682163|NCT06694662|EXPERIMENTAL|Participant Group|All participants will be assessed by their dietitian and prescribed an appropriate amount of the study product, PKU EASY Microtabs Plus, to manage their phenylketonuria.
62682164|NCT06535646|EXPERIMENTAL|Home exercise program|All participants will be remotely monitored for 8-weeks, provided with a customised, structured home exercise program and activity monitor smart watch. Training volume will increase gradually. Participants will receive weekly, individualised emails supporting their exercise program, weekly telehealth coaching sessions and pre-programmed smart watch movement reminders.
62122699|NCT05064930|ACTIVE_COMPARATOR|Bacillus coagulans|Probiotic formula contains 2x109 Bacillus coagulans Nordbiotic™BC300 colony forming units (CFU)/capsule
62311657|NCT05579626|ACTIVE_COMPARATOR|high-intensity statin arm|(high-intensity statin arm): rosuvastatin 20 mg PO qd, once daily
62122700|NCT05064930|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin (starch hydrolisate) as a compound presents in probiotic formula.
62122701|NCT04616963|OTHER|FTC 200 mg / TDF 300 mg and FTC 200 mg / TAF 25 mg|"Phase I: Participants will continue or initiate F/TDF for PrEP for a minimum 12-week lead-in period prior to switching to F/TAF.~Phase II: Participants will be switched to study-provided F/TAF for PrEP until 48 weeks after initiation. Participants will receive study treatment for the duration of the study unless they meet criteria for discontinuation."
62122702|NCT03845114|ACTIVE_COMPARATOR|Continuous exercise - Basal insulin reduced by 40%|
62311658|NCT05579626|ACTIVE_COMPARATOR|low-intensity statin plus ezetimibe arm|(low-intensity statin plus ezetimibe arm ): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
62311659|NCT01332032||Reminder Letter|"A letter sent to women reminding them that are coming due or overdue for a mammogram. It contains a reminder that their primary care provider (PCP) recommends mammography screening every 1-2 years. It urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. Repeat Booster letters will be sent in subsequent years to those failing to get a mammogram."
62477033|NCT02226432|SHAM_COMPARATOR|Kinesics|- Classic Rehabilitation and Kinesic Therapy
62477034|NCT02226432|SHAM_COMPARATOR|surgery|"- Surgery:~Selective Peripheral Neurotomy is surgical a method of section on suplying peripheral nerves of motor fascicles to relieve harmful spasticity. An intraoperative stimulation of motor fascicles is done, and those which abnormal spreading on far placed myotomes are more evident are chosen to be sectioned."
62477035|NCT02226432|ACTIVE_COMPARATOR|Magnetic Stimulation|- Postoperative Antagonistic Peripheral Magnetic Stimulation with 1.5 tesla intensity, infrathreshold 80 per cent of minimal intensity able to produce always muscle contraccion. Trials repeated twice a week in sessions of 30 minutes during 6 months
62477036|NCT05039463||PRP + HA|two injections of PRP (plasma rich in platelets ), in combination with HA (hyaluronic acid)
62477037|NCT05039463||HA alone|HA (hyaluronic acid)
62477038|NCT05519150||Stone Donors|Evaluation for kidney donation \> 2 years ago, had history of kidney stones or kidney stones on imaging and successfully donated a kidney
62477039|NCT05519150||Denied donors|Evaluation for kidney donation \> 2 years ago, had history of kidney stones or kidney stones on imaging and were declined for donation due to history of kidney stones, Litholink abnormalities or Imaging findings
62477040|NCT05519150||Non-Stone Donors|Evaluation for kidney donation \> 2 years ago, with no history of kidney stones, or kidney stones on Imaging and successfully donated a kidney
62477041|NCT03875521||12 hours|
62477042|NCT03875521||< 12hours|
62477043|NCT02697747||Ultrasound education|Training in the use of ultrasound to identify the L3-L4 interspace
62682165|NCT06148948|PLACEBO_COMPARATOR|Placebo|Placebo matching BI 1584862
62682166|NCT06148948|EXPERIMENTAL|BI 1584862 dose group 1|Group receiving dose 1 of BI 1584862
62122703|NCT03845114|ACTIVE_COMPARATOR|Continuous exercise - Basal insulin reduced by 80%|
62682167|NCT06148948|EXPERIMENTAL|BI 1584862 dose group 2|Group receiving dose 2 of BI 1584862
62311660|NCT01332032||Reminder Call|"A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a mammogram within 2 weeks, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offer to schedule a mammogram for her. Repeat Booster letters will be sent and repeat scheduler calls made in subsequent years to those failing to get a mammogram."
62311661|NCT01332032||Counselor Call|"A reminder letter as above is sent first. If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet. The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule. If a woman does not schedule within 8-10 days, a counselor will call. The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing. Repeat booster letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram. techniques. Average calls last 20-30 minutes."
62311662|NCT05384743|EXPERIMENTAL|Rituximab Monotherapy|
62311663|NCT01334125|EXPERIMENTAL|Metformin|Metformin 1000 mg once daily by mouth for 9 months
62311664|NCT01334125|PLACEBO_COMPARATOR|Placebo|2 capsules once daily by mouth for 9 months
62311665|NCT00312377|ACTIVE_COMPARATOR|1|Docetaxel monotherapy
62311666|NCT00312377|EXPERIMENTAL|2|Vandetanib + Docetaxel
62311667|NCT01147965|EXPERIMENTAL|Ad5 CEA Vaccine|Single arm dose escalation study
62477044|NCT05754203|EXPERIMENTAL|Super-hyperfractionation Pulse Radiotherapy Combined With Immune Checkpoint Inhibitor|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
62311668|NCT05105243|ACTIVE_COMPARATOR|SAD Cohort 1|Each dose cohort: 8 participants (6 active:2 placebo). 5 mg.
62311669|NCT05105243|ACTIVE_COMPARATOR|SAD Cohort 2|Each dose cohort: 8 participants (6 active:2 placebo). 15 mg.
62311670|NCT05105243|ACTIVE_COMPARATOR|SAD Cohort 3|Each dose cohort: 8 participants (6 active:2 placebo). 45 mg.
62311671|NCT05105243|ACTIVE_COMPARATOR|SAD Cohort 4|Each dose cohort: 8 participants (6 active:2 placebo). 125 mg.
62311672|NCT05105243|PLACEBO_COMPARATOR|SAD Cohort 5|Each dose cohort: 8 participants (6 active:2 placebo). 250 mg.
62311673|NCT05105243|ACTIVE_COMPARATOR|MAD Cohort 1|Each dose cohort: 8 participants (6 active:2 placebo). 45mg.
62311674|NCT05105243|PLACEBO_COMPARATOR|MAD Cohort 2|Each dose cohort: 8 participants (6 active:2 placebo). 125 mg.
62311675|NCT05105243|PLACEBO_COMPARATOR|MAD Cohort 3|Each dose cohort: 8 participants (6 active:2 placebo). 250 mg.
62311676|NCT02129764|EXPERIMENTAL|Prednisone|Prednisone will be given 30mg/day for 2 weeks and then tapered off.
62311677|NCT02129764|ACTIVE_COMPARATOR|Allopurinol|Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day.
62311678|NCT05857956|EXPERIMENTAL|Proper Wild energy shot|Participants will take one bottle daily of Proper Wild Energy shot in the morning. Participants will be advised to drink one bottle in the morning, with or without a meal, depending on their preference, as a replacement for their usual first caffeinated beverage of the day.
62311679|NCT03461965|EXPERIMENTAL|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
62311680|NCT03461965|ACTIVE_COMPARATOR|Verbal Counselling|Participants in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
62496026|NCT04055233|EXPERIMENTAL|Subcutaneous irrigation with 0.04% polyhexanide solution|"Intervention: after closure of abdominal fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml antiseptic solution (0.04% polyhexanide) will be done once for ten minutes.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
62311681|NCT05662358|EXPERIMENTAL|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months
62311682|NCT05662358|ACTIVE_COMPARATOR|alendronate|oral 70 mg alendronate sodium weekly.
62311683|NCT02713750||HIV female adolescents|sexually active, HIV-infected female adolescents, 12-24 years old who are aware of their HIV status
62311684|NCT00265941|ACTIVE_COMPARATOR|RT + cisplatin|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin
62682168|NCT06148948|EXPERIMENTAL|BI 1584862 dose group 3|Group receiving dose 3 of BI 1584862
62311685|NCT00265941|EXPERIMENTAL|RT + cisplatin + cetuximab|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab
62311686|NCT06565624|EXPERIMENTAL|Nasal Stimulation|The Investigator will insert cotton swabs into both nostrils of the subject and gently probe the nasal middle cavities. Stimulation will stop once visible and obvious reflex tearing has begun.
62122704|NCT03845114|ACTIVE_COMPARATOR|Interval exercise - Basal insulin reduced by 40%|
62311687|NCT04763382|OTHER|Experimental grups: Training of caregivers|"1. Application of data collection:~   Tools as pre-test, post-test and retention test to participants in the experimental group,~2. Education:It includes the training given to the caregivers in the experimental group, delivery of the guide booklet at the end of the training~3. Android phone application: Installing on the phones of the caregivers in the experimental group of the android application, which includes the frequency of CIC application, the CIC application process steps and hospital appointments, created by the nurse for the caregivers in the experimental group and the software is made by the computer engineer.~4. One home visit and three phone calls were made in order to solve the problems that the caregivers in the experimental group experienced with the use of CIC or android use.~5. Urinalysis for children who are inserted and put into the study:All participants in the study were asked to give urine tests three times with an interval of one month after discharge."
62682169|NCT06148948|EXPERIMENTAL|BI 1584862 dose group 4|Group receiving dose 4 of BI 1584862
62682170|NCT04263727||Asthma|Non-Interventional. Patients with asthma will be screened and enrolled into the active Asthma disease-specific cohort.
62682171|NCT04263727||Chronic Obstructive Pulmonary Disease (COPD)|Non-Interventional. Patients with COPD will be screened into the inactive COPD disease-specific cohort.
62682172|NCT04263727||Idiopathic Pulmonary Fibrosis (IPF)|Non-Interventional. Patients with IPF will be screened into the inactive IPF disease-specific cohort.
62682173|NCT03648372|EXPERIMENTAL|Phase 1, Dose Escalation Cohort: TAK-981|TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1, 4, 8, and 11 in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study. If clinical safety, pharmacokinetics, and pharmacodynamics are supportive, the dosing schedule may be modified to evaluate a less intensive administration of TAK-981 on Day 1, or Days 1 and 8, or Day 1, Day 8, and Day 15 in 21-day cycles in participants with advanced or metastatic solid tumors or lymphomas. Dose levels will be escalated based on the Bayesian logistic regression modeling (BLRM). The dose escalation phase will determine the RP2D of TAK-981.
62682174|NCT03648372|EXPERIMENTAL|Phase 2, Cohort A: Nonsquamous NSCLC|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with nonsquamous non-small cell lung cancer (NSCLC).
62682175|NCT03648372|EXPERIMENTAL|Phase 2, Cohort B: Cervical Cancer|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with cervical cancer.
62682176|NCT03648372|EXPERIMENTAL|Phase 2, Cohort C: MSS-CRC|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with microsatellite-stable colorectal cancer (MSS-CRC).
62682177|NCT03648372|EXPERIMENTAL|Phase 2, Cohort D: r/r DLBCL after CAR T-cells therapy|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after prior chimeric antigen receptor (CAR) T-cells therapy.
62122705|NCT03845114|ACTIVE_COMPARATOR|Interval exercise - Basal insulin reduced by 80%|
62122706|NCT03696966|ACTIVE_COMPARATOR|Continuous Calorie Restriction|Daily calorie restriction: follow low-calorie diet (1,200-1,500 calories) daily using portion-controlled meals
62122707|NCT03696966|EXPERIMENTAL|Intermittent Very-Low Calorie Diet|Intermittent Restriction: follow very-low calorie diet (500-800) with portion-controlled meals three days per week and structured healthy eating on other days
62682178|NCT03648372|EXPERIMENTAL|Phase 2, Cohort E: r/r DLBCL without prior cellular therapy|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory DLBCL that have not received prior cellular therapy.
62122708|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
62122709|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
62122710|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
62122711|NCT01396837|EXPERIMENTAL|RedDress Wound Care System (RD1)|RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
62682179|NCT03648372|EXPERIMENTAL|Phase 2, Cohort F: r/r Follicular Lymphoma|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory follicular lymphoma (FL).
62682180|NCT06572449|EXPERIMENTAL|KarXT on empty stomach and with food|
62682181|NCT03649178|OTHER|low salt diet|low-sodium diet (50mmol/24hours x 8 weeks ) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
62682182|NCT03649178|OTHER|high salt diet|high-sodium diet (200mmol/24hours x 8weeks) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
62682183|NCT06694727|EXPERIMENTAL|Coenzyme Q10 intervention, active|100 mg capsules given twice daily, per oral use
62682184|NCT06694727|PLACEBO_COMPARATOR|Coenzyme Q10 intervention, placebo|Placebo matching coenzyme Q10
62682185|NCT06694727|EXPERIMENTAL|Selenium intervention, active|100 μg tables given twice daily, per oral use
62682186|NCT06694727|PLACEBO_COMPARATOR|Selenium intervention, placebo|100 μg tables given twice daily, per oral use
62682187|NCT06001320|EXPERIMENTAL|Letermovir group (study group)|Letermovir 480 mg once daily
62682188|NCT06001320|OTHER|Historical Control study group|Historically matched AA kidney transplant recipients who received the standard of care 450mg once a day valganciclovir prophylaxis
62311688|NCT04763382|OTHER|Control: Control grups|"1. As in the experimental group, the caregivers in the control group were pre-tested and post-tested using data collection tools.~2. No intervention was made to the caregivers in the control group.~3. However, caregivers in the control group performed urinalysis three times with an interval of one month after discharge."
62477045|NCT03306394|EXPERIMENTAL|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m²/dose. The treatment is given until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
62682189|NCT06062108||Patients with cirrhosis|Patients hospitalized during the inclusion period with cirrhosis medical history
62682190|NCT03662620|EXPERIMENTAL|ARM1|"In ARM1, 32 subjects will be assigned and the subjects will be administered comparator drug at Day1/Day43 and study drug at Day22/64."
62682191|NCT03662620|EXPERIMENTAL|ARM2|"In ARM2, 32 subjects will be assigned and the subjects will be administered study drug at Day1/Day43 and comparator drug at Day22/64."
62682192|NCT03357497|EXPERIMENTAL|Very early mobilization|This group will be mobilized in the post-operative unit by a designated physiotherapist. The intervention will be conducted accordingly with the SOMS protocol.
62682193|NCT03357497|NO_INTERVENTION|Standard post-operative care|This group will receive standard post-operative care. Mobilization will only take place if the patient request it or to facilitate god post-operative care.
62682194|NCT04456517|EXPERIMENTAL|Ranolazine, Then Placebo|- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
62682195|NCT04456517|EXPERIMENTAL|Placebo, Then Ranolazine|- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
62682196|NCT06106984|EXPERIMENTAL|Intervention|Veterans will trial the Graded Motor Imagery mobile application.
62682197|NCT05886894||Air Optix plus HydraGlyde Multifocal Daily Wear|Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection
62311689|NCT05073770|EXPERIMENTAL|N64|"Based on the penis girth measurements, eligible participants will be assigned to two groups:~Group 1: The couples who will test the 64 mm plain condom (n=25).~The test condom has the following specifications throughout the study:~The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm."
62682198|NCT05886894||Air Optix plus HydraGlyde Multifocal Extended Wear|Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
62682199|NCT05886894||Biofinity Multifocal Daily Wear|Comfilcon A multifocal soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
62682200|NCT05886894||Biofinity Multifocal Extended Wear|Comfilcon A multifocal soft contact lenses worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
62682201|NCT05983900|EXPERIMENTAL|BRIX 3000|brix 3000 used
62682202|NCT05983900|ACTIVE_COMPARATOR|Papacarie|papacarie duo used
62682203|NCT05983900|ACTIVE_COMPARATOR|Hand excavation|hand excavation used
62682204|NCT06500000||essential hypertension (EH)|According to 2010 Chinese guidelines for the management of essential hypertension (EH), EH was defined as systolic BP (SBP) ≥140 mm Hg, diastolic BP (DBP) ≥90 mm Hg, and use of antihypertensive medicine within 2 weeks and excluded from PA through ARR or diagnostic testing.
62682205|NCT06500000||idiopathic aldosteronism (IHA)|Patients were confirmed to be diagnosed with primary aldosteronism (PA) in accordance with the Endocrine Society Clinical Practice Guideline criteria. Antihypertensive drugs that may affect the renin-angiotensin-aldosterone system (RAAS) were discontinued for at least 2-4 weeks. Patients with an aldosterone-to-renin ratio (ARR) \> 3.7 (ng/dL) further underwent one of the following confirmatory tests: saline infusion test (infusion of 2 L isotonic saline within 4 h) or captopril-inhibition test (oral administration of 50 mg captopril). Adrenal CT scan and adrenal vein sampling (AVS) were performed for PA subtype classification. Patients with IHA were determined based on the absence of obvious adenoma on adrenal CT and bilateral aldosterone overproduction.
62682206|NCT06500000||aldosterone-producing adenoma (APA)|Patients were confirmed to be diagnosed with primary aldosteronism (PA) in accordance with the Endocrine Society Clinical Practice Guideline criteria. Antihypertensive drugs that may affect the renin-angiotensin-aldosterone system (RAAS) were discontinued for at least 2-4 weeks. Patients with an aldosterone-to-renin ratio (ARR) \> 3.7 (ng/dL) further underwent one of the following confirmatory tests: saline infusion test (infusion of 2 L isotonic saline within 4 h) or captopril-inhibition test (oral administration of 50 mg captopril). Adrenal CT scan and adrenal vein sampling (AVS) were performed for PA subtype classification. Patients with APA were identified based on macroadenoma \>1 cm on adrenal CT, unilateral hypersecretion of aldosterone, and pathological confirmation.
62682207|NCT02639312||1|hemifacial microsomia
62682208|NCT02639312||2|mandibular prognathism
62682209|NCT04224142||PKU sphere|PKU sphere (an FSMP) as per individual requirements determined by a dietitian.
62682210|NCT06305559|EXPERIMENTAL|Obicetrapib/Ezetimibe|obicetrapib 10 mg + ezetimibe 10 mg FDC daily
62682211|NCT06305559|PLACEBO_COMPARATOR|Placebo|Placebo on top of baseline lipid modifying therapy
62682212|NCT04070027|ACTIVE_COMPARATOR|Total Hip Arthroplasty|A standard fast-track multimodal surgical program comprising patient information, optimised pain management, and early mobilisation. Total hip arthroplasty (THA) will be performed by experienced orthopaedic surgeons in accordance with the standard posterior surgical approach. Patients will receive standard postoperative rehabilitation consisting of either a standard leaflet with a hospital-specific home-based exercise program aimed at increasing hip muscle strength and range of motion or, if considered necessary, a referral to supervised hip-specific exercise therapy delivered at private physiotherapist clinics or municipal rehabilitation. Furthermore, postsurgical procedures will follow hospital-specific procedures ranging from no postsurgical control to postsurgical assessment of the hip and rehabilitation at the physiotherapy department (after six-weeks).
62682213|NCT04070027|ACTIVE_COMPARATOR|Progressive Resistance Training|"A 12-week supervised explosive-type progressive resistance training (PRT) program with two training sessions a week. All training sessions will be conducted in municipal rehabilitation centres with one-to-one supervision and ≥48 hours of rest in between sessions. The standardised PRT program will consist of warm-up on a stationary bicycle (10 min) followed by four lower extremity exercises (50 min). Exercises will be performed unilaterally with as full range of motion as possible in sets of three separated by 60 sec of rest in the following order: leg press, hip extension, hip flexion, and hip abduction. Patients will be instructed to complete the concentric phase of each repetition as fast as possible, maintain full extension for 1 sec, and perform the eccentric phase in 2-3 sec. Hip-related pain up to 5 rated on a Numerical Rating Scale (0-10) is considered acceptable during exercises. After the 12-weeks, patients will be offered three-months of optional unsupervised PRT."
62682214|NCT06117540|EXPERIMENTAL|WX390|Participants will receive WX390 continuous oral dosing (1.1 mg once a day).
62682215|NCT05607459|EXPERIMENTAL|Dry Needling Group|This group will receive dry needling, manual therapy (consisting of a manual compression over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus) and therapeutic exercise interventions
62682216|NCT05607459|ACTIVE_COMPARATOR|Sham Dry Needling Group|This group will receive manual therapy (consisting of a manual compression over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus), therapeutic exercise interventions and a previously described sham dry needling intervention.
62682217|NCT04794478|ACTIVE_COMPARATOR|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
62682218|NCT06594913||Anorexia nervosa|Individuals with a self-reported lifetime history of anorexia nervosa.
62682219|NCT06594913||Bulimia nervosa|Individuals with a self-reported lifetime history of bulimia nervosa.
61922412|NCT05074173|OTHER|Patient Group|Participants will be enrolled in a bidirectional text messaging system from Tulane University Medical Group where they will receive and send text from their mobile phones to monitor their anti-hypertension medication regimen. Text messages will be sent: daily for medication and refill reminders; weekly for hypertension education messages and asking if a support person helped them with medication reminders. Study personnel will educate participants on proper blood pressure technique to conduct self-measured blood pressure (SMBP) at home. These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure. Participants will receive the Bluetooth blood pressure device to perform SMBP at enrollment.
62122712|NCT01129232|EXPERIMENTAL|GAD-alum|GAD-alum administered at 0 and 1 months after inclusion
62682220|NCT06594913||Binge-eating disorder|Individuals with a self-reported lifetime history of binge-eating disorder.
62682221|NCT06594913||ARFID|Individuals with a self-reported lifetime history of avoidant restrictive food intake disorder.
62682222|NCT06594913||Control|Individuals with no history of disordered eating behaviors or symptoms
62682223|NCT00808756|EXPERIMENTAL|1: Intervention|This group will be fed a diet enriched with fermentable carbohydrates.
62682224|NCT00808756|PLACEBO_COMPARATOR|2: Placebo.|The placebo group will be fed a diet without addition of fermentable carbohydrates. This placebo formula will have the same nutritional values than the intervention (energy, proteins, carbohydrates, fat, vitamins \& minerals).
62682225|NCT00808756|NO_INTERVENTION|BF|The 2 intervention groups will be compared with a breast-fed infants control group.
62311690|NCT05073770|EXPERIMENTAL|N69|"Based on the penis girth measurements, eligible participants will be assigned to two groups:~Group 2: The couples who will test the 69 mm plain condom (n=25).~The test condom has the following specifications throughout the study:~The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
62311691|NCT04444791||Cohort|This cohort study only set up one group. The habits and health status of mothers and their offspring will be followed up and observed. The participants will be divided into more than one group according to the variables (e.g. age, physical activity, dietary patterns, sleep quality.).
62682226|NCT04869449|EXPERIMENTAL|Ketoconazole|Participants will be taking 400 mg of the study drug (two 200 mg tablets) by mouth twice a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation) and in the evening after their biopsy or surgery (after the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
62682227|NCT06240208|EXPERIMENTAL|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
62682228|NCT06240208|NO_INTERVENTION|Control|Participants will be instructed to maintain habitual physical activity and dietary habits.
62682229|NCT02549638||Tissue Collection|We plan to prospectively collect 5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria. If a patient has already had a bronchoscopy and has samples available that were previously collected and stored for research at the Mayo Clinic we will use those samples.
62682230|NCT04250259|PLACEBO_COMPARATOR|Placebo|Alcoholic Cirrhosis on placebo
62682231|NCT04250259|EXPERIMENTAL|1,200 mg SAMe|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
62682232|NCT04250259|NO_INTERVENTION|Non-drinking Controls|Non-drinking healthy controls
62682233|NCT05722353|OTHER|Collection of clinical parameters, blood and stools samples|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
62682234|NCT04547712|EXPERIMENTAL|aDBS Single Threshold|Adaptive DBS Single Threshold Mode
62682235|NCT04547712|EXPERIMENTAL|aDBS Dual Threshold|Adaptive DBS Dual Threshold Mode
62682236|NCT05165966|EXPERIMENTAL|Experimental Group-High-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with high-dosage of COVID-19 vaccine (Vero cell), Inactivated.
62682237|NCT05165966|EXPERIMENTAL|Experimental Group-Medium-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with medium-dosage of COVID-19 vaccine (Vero cell), Inactivated.
62682238|NCT05206227|EXPERIMENTAL|Aerobic Exercise|Blood and skeletal muscle microdialysate collected during dynamic knee-extension exercise
62682239|NCT05206227|EXPERIMENTAL|Heating|Blood and skeletal muscle microdialysate collected during local and/or whole body heating
62682240|NCT05206227|EXPERIMENTAL|Resistance and Aerobic Exercise|Blood and urine collected during recovery from two modalities of exercise
62682241|NCT05206227|EXPERIMENTAL|Aerobic Exercise and Muscle Perfusion|Muscle perfusion measured during aerobic exercise
62682242|NCT04586231|EXPERIMENTAL|Belzutifan + Lenvatinib|Belzutifan 120 mg and lenvatinib 20 mg orally once a day
62682243|NCT04586231|ACTIVE_COMPARATOR|Cabozantinib|Cabozantinib 60 mg orally once a day
62682244|NCT03761914|EXPERIMENTAL|Colorectal Cancer (CRC) - opened but since only one subject enrolled, not included for analyses|"* N=20 (planned);~* Metastatic CRC previously treated with ≥ 2 lines of prior systematic chemotherapies~* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab"
62682245|NCT03761914|EXPERIMENTAL|Ovarian Cancer (OvC)|"* N=20 (planned);~* Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy~* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab"
62682246|NCT03761914|EXPERIMENTAL|Small Cell Lung Cancer (SCLC) - not opened|"* N=20 (planned);~* Advanced SCLC previously treated with one line of prior systemic chemotherapy~* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab"
62122713|NCT01129232|PLACEBO_COMPARATOR|Placebo|
62122714|NCT06530056|EXPERIMENTAL|Costovertebral Mobilization+Conventional Therapy|"Costovertebral mobilization:~It will be performed in 3 Different Positions to target specific regions of rib cage.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises."
62122715|NCT06530056|OTHER|Conventional Therapy|"Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises"
62122716|NCT04178239||Chronic Fatigue|MFI score \>53 points
62122717|NCT04178239||No Chronic Fatigue|MFI score \< 54 points
62122718|NCT03197090|EXPERIMENTAL|Zenicor ON|Patients allocated to the experimental group will undergo systematic short ECG monitoring
62122719|NCT03197090|NO_INTERVENTION|Zenicor OFF|In patients allocated to the control group, usual diagnostic procedures for detection of atrial fibrillation will be employed according to ESC Guidlines.
62122720|NCT03293056|EXPERIMENTAL|High-intensity Interval Hydrogynmastics|High-intensity Interval training Hydrogynmastics, 2x/week, for 3 months.
62122721|NCT03293056|ACTIVE_COMPARATOR|Hydrogynmastics Continuous Moderate|Hydrogynmastics Continuous Moderate training (HCM), 2x/week, for 3 months.
62122722|NCT02800434|EXPERIMENTAL|hand allograft|
62122723|NCT00553683|EXPERIMENTAL|poly ICLC|
62122724|NCT06255795|EXPERIMENTAL|chidamide, anti-PD1 antibody, and pegaspargase group|
62122725|NCT06255795|ACTIVE_COMPARATOR|DDGP|
62122726|NCT04333355|EXPERIMENTAL|COVID-19 patients receiving Convalescent Plasma|Convalescent Plasma from patients who recently recover from COVID-19
62122727|NCT06307548|EXPERIMENTAL|Treatment (aminolevulinic, fluorescence-guided surgery, PDT)|Patients receive aminolevulinic acid PO 2 to 4 hours prior to SOC surgery. Patients then undergo image-guided fluorescence 5-10 minutes post surgery, and intraoperative PDT 15-45 minutes post surgery. Patients also undergo CT or MRI during screening and on follow up. Patients also undergo blood sample collection throughout the trial.
62311692|NCT06408792|EXPERIMENTAL|Cellulose (OraAid) and fluid composite|"In this case, collagen sponges will be placed in the palatal wound, then the cellulose adhesive film (OraAid) will be placed on top, and this will be covered by fluid composite adhered to the teeth on their palatal wall.~Amoxicillin 750mg 1pill each 8hours during 7 days. Ibuprofen 600mg 1pill each 8hours when needed."
62477046|NCT04274374|EXPERIMENTAL|experimental arm|In the experimental arm will receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavor capsules per day
62477047|NCT04274374|ACTIVE_COMPARATOR|control arm|the control arm will received 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day
62477048|NCT05943665|EXPERIMENTAL|MDMA-AT|Participant will receive MDMA administration with assisted therapy (AT) by trained clinicians
62477049|NCT00041392|ACTIVE_COMPARATOR|Magnesium|100 mg/kg magnesium
62311693|NCT06408792|ACTIVE_COMPARATOR|Palate plate|"In this case, collagen sponges will be placed in the palatal wound, held in place by sutures, and the palatal wound will be covered with a custom-made palatal plate made just after surgery.~Amoxicillin 750mg 1pill each 8hours during 7 days. Ibuprofen 600mg 1pill each 8hours when needed."
62477050|NCT00041392|PLACEBO_COMPARATOR|0.9 % saline|100 mg/kg 0.9 % saline
62477051|NCT04605783|EXPERIMENTAL|Travelan®|Product will be started 2 days prior to arrival in overseas destination and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
62477052|NCT04605783|PLACEBO_COMPARATOR|Placebo|Placebo will be started 2 days prior to arrival in overseas destination and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
62311694|NCT06408792|ACTIVE_COMPARATOR|Cyanocrylate (periacril)|"In this case, collagen sponges will be placed in the palatal wound held by sutures and the palatal wound will be covered with cyanoacrylate tissue adhesive (Periacryl 90).~Amoxicillin 750mg 1pill each 8hours during 7 days. Ibuprofen 600mg 1pill each 8hours when needed."
62311695|NCT05728801||Superagers|SuperAgers are determined by the scores of global cognitive function. This ensured that the participants are divided by a measure relevant to the current study without directly biasing the results toward the domain of interest.
62311696|NCT05728801||Normal ageing elderly|The cases with the scores of cognitive performance within 1.5 standard deviation (SD) of age and education matched normative values derived from our cohort study, of which presented with HK MoCA score greater than 26 and CDR score equal to 0
62311697|NCT05728801||Neurocognitive disorders patients|NCD patients are deﬁned as: evidence of modest decline in one or more cognitive domains, which is set as ≥ 1.5 SD below the age- and education-adjusted normative scores; no interference with independence in everyday activities; and no comorbid major psychiatric disorders.
62311698|NCT03862378||Group One|All patients underwent gastric or colorectal cancer surgery in the participating centers will be included. Clinical data, drainage cytokine levels will be recorded.
62311699|NCT05301348|EXPERIMENTAL|Procedure|Subjects will receive PAFC procedure
62311700|NCT03873207|EXPERIMENTAL|Intervention|Pedal fat grafting followed by PopSole™ offloading device
62311701|NCT03873207|OTHER|Standard of care|Pedal fat grafting followed by standard post-operative care with padding of the insoles
62477053|NCT05048667|EXPERIMENTAL|SWT plus PRP Group|Participants will receive weekly Shockwave Therapy (SWT) and Platelet Rich Plasma (PRP) for 5 weeks. SWT will be administered weekly on Weeks 1, 2, 3, 4, and 5. PRP will be administered on Week 1 and Week 5.
62477054|NCT05048667|PLACEBO_COMPARATOR|Sham SWT plus Placebo Saline Group|Participants will receive weekly Sham Shockwave Therapy (SWT) and Placebo Saline Intracavernosal Injection (ICI) for 5 weeks. Sham SWT will be administered weekly on Weeks 1, 2, 3, 4, and 5. Placebo Saline ICI will be administered on Week 1 and Week 5.
62477055|NCT05070663||Participants with severe asthma|Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study.
62477056|NCT00841698|EXPERIMENTAL|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
62477057|NCT00841698|ACTIVE_COMPARATOR|Paxil®|Paxil 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
62477058|NCT02158494|EXPERIMENTAL|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
62477059|NCT02158494|SHAM_COMPARATOR|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation (sham device). 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
62477060|NCT05878964||Group 1|All patients affected by solid tumors already in treatment with anti-PD1/PDL1 or cyclin-dependent kinase (CDK) inhibitors.
62477061|NCT05878964||Group 2|All patients affected by solid tumors already eligible for treatment with anti-PD1/PDL1 or cyclin-dependent kinase (CDK) inhibitors.
62477062|NCT02299453|EXPERIMENTAL|Experimental|Participants receive 9 sessions of telephone-administered PT and have access to standard community-based services. As part of the 9 sessions, participants discuss the extent to which interpersonal issues such as bereavements, role transitions, interpersonal disputes, and relationship difficulties may be related to their depression.
61922413|NCT03159702|EXPERIMENTAL|MEL/FLU and Total-Body Irradiation (TBI)|"For patients who are \< 60 years.~* Melphalan: 140 mg/m2/day IV on Day: -6~* Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = \[(140-age) x weight (kg) x 0.85 (for women only)\]/ \[72 x creat (mg/dl)\].)~* TBI: 200 cGy Day: -1.~For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of \>3 (at the discretion of treating physician will have an option to receive):~* Melphalan: 70 mg/m2/day IV on Day -6.~* Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.~* TBI: 200 cGy; Days -1."
61922414|NCT02818491|PLACEBO_COMPARATOR|Control group|Patients will receive ropivacaine 0.5% 20 mls with normal saline 0.9% 2 mls
61922415|NCT02818491|ACTIVE_COMPARATOR|Dex 1|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 1 mg in 2 mls
61922416|NCT02818491|ACTIVE_COMPARATOR|Dex 2|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 2 mg in 2 mls
61922417|NCT02818491|ACTIVE_COMPARATOR|Dex 3|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 3 mg in 2 mls
62682247|NCT03761914|EXPERIMENTAL|Triple Negative Breast Cancer (TNBC) - not opened|"* N=15 (planned);~* TNBC previously treated with one line of prior systemic chemotherapy~* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab"
62682248|NCT03761914|EXPERIMENTAL|Acute Myelogenous Leukemia (AML) - not opened|"* N=15 (planned);~* AML (any age) who are not eligible for allogeneic hematopoietic stem cell transplant and have been able to achieve partial response (PR) while receiving frontline therapy with hypomethylating agents (HMAs)~* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab"
61922418|NCT02818491|ACTIVE_COMPARATOR|Dex 4|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 4 mg in 2 mls
61922419|NCT02564432||POP 10 patient cohort|This is an observational study
61922420|NCT05222490|EXPERIMENTAL|Diabetic with Ulcers|Patient with diabetic foot and ulceration diagnosed/confirmed by the study physician on the day of enrollment
61922421|NCT05222490|EXPERIMENTAL|Diabetic without Ulcers|Patient without ulcers diagnosed/confirmed by the study physician on the day of enrollment
61922422|NCT05222490|ACTIVE_COMPARATOR|Control|Generally Healthy Non-diabetic Subjects
61922423|NCT02766842|ACTIVE_COMPARATOR|EUS-FNB with ProCore needle|General anesthesia or conscious sedation will be started and an upper endoscopic ultrasound will be inserted into the participants mouth and advanced to the site of the lesion. The lesion will be punctured by the ProCore needle, then the stylet is completely removed, and negative suction pressure is applied using a 10 ml syringe for 30 seconds while the needle is stationary with the target. Then, the needle is moved back and forth several times within the target, utilizing the fanning technique. Finally, suction is released by closing the lock of the syringe and the needle is removed.
62311702|NCT06602024|EXPERIMENTAL|mRNA-1010|Participants will receive a single injection of mRNA-1010 on Day 1.
62311703|NCT06602024|ACTIVE_COMPARATOR|Fluarix® or Influsplit®|Participants will receive a single injection of active comparator (Fluarix® or Influsplit®) on Day 1.
62311704|NCT02536482|EXPERIMENTAL|Amix|Dietary supplement. The formula is based in free amino-acid to treat children with cow's milk allergy. The children should have a minimum consumption of 400 mL, daily.
62311705|NCT04624932|EXPERIMENTAL|Risk Reframing (RR) Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: reflecting on their own childhood play activities; what they got out of these experiences; outdoor play activities of the children at their center; what they do to promote children's outdoor play; what gets in the way in promoting children outdoor play.~Chapter 2: imagining themselves in six video segments where they must decide how to communicate with parents; and, whether they allow children to engage in rough and tumble play, play at heights, play with tools, play at speed/mud play, and resolve conflicts amongst themselves~Chapter 3: reflecting on their barriers and things that helped them promote and support the children's outdoor play at their center. Participants to assess whether there is anything they want to change to set a realistic goal, outlining steps for attaining that goal."
62311706|NCT04624932|SHAM_COMPARATOR|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play.~It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety."
62311707|NCT05552612||Long COVID|Patients with Long COVID
62311708|NCT05552612||Without Long COVID|Patients who do not have Long COVID
62311709|NCT03215472|EXPERIMENTAL|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
62311710|NCT03215472|EXPERIMENTAL|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
62311711|NCT06671704|EXPERIMENTAL|Cluster 1|Patients recruited and randomized to transfer from standard of care to genetic counselling in months 4-15
62311712|NCT06671704|EXPERIMENTAL|Cluster 2|Patients recruited and randomized to transfer from standard of care to genetic counselling in months 6-15
62311713|NCT06671704|EXPERIMENTAL|Cluster 3|Patients recruited and randomized to transfer from standard of care to genetic counselling in months 8-15
62311714|NCT06671704|EXPERIMENTAL|Cluster 4|Patients recruited and randomized to transfer from standard of care to genetic counselling in months 10-15
62311715|NCT06671704|EXPERIMENTAL|Cluster 5|Patients recruited and randomized to transfer from standard of care to genetic counselling in months 12-15
62311716|NCT06671704|EXPERIMENTAL|Cluster 6|Patients recruited and randomized to transfer from standard of care to genetic counselling in months 14-15
62311717|NCT02544984|PLACEBO_COMPARATOR|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
62311718|NCT02544984|EXPERIMENTAL|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
62311719|NCT06672952|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo supplement consisting of 400 mg of cellulose per day. The placebo is designed to match the appearance and dosage form of the active interventions, allowing for blinding in the study.
62311720|NCT06672952|EXPERIMENTAL|200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|Participants in this arm will receive a total of 200 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day, along with an additional 200 mg of cellulose. This will provide a daily dosage of 400 mg, maintaining blinding to ensure the placebo effect is accounted for.
62311721|NCT06672952|EXPERIMENTAL|400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|Participants in this arm will receive a total of 400 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day. This higher dose is intended to evaluate its effects on exercise performance, recovery, and cognitive function compared to the placebo and lower dose.
62311722|NCT02244697||Experimental: laryngeal ultrasound stridor|Children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre.
62311723|NCT02244697||Other: laryngeal ultrasound -control|Infants matched for age referred for ANL for reasons other than stridor will undergo US of the larynx.
62311724|NCT03383367|EXPERIMENTAL|Tempo Colo|
62311725|NCT00302237||1|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
62311726|NCT01920139|OTHER|Breast cancer and Axillary Adenopathy|Women with breast cancer with abnormal appearing ipsilateral axillary nodes undergoing fine needle aspiration and core biopsy of a lymph node.
62311727|NCT01177215||Digital chest tube|All patients will be treated with the digital chest tube device
62311728|NCT03911570||Glucosamine Sulfate Group (GS Group)|GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
62311729|NCT03911570||Control Group|Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).
62477063|NCT02299453|NO_INTERVENTION|Standard of Care|Participants receive no active intervention but do have access to standard community-based services, such as individual therapy, support groups, 12-step programs, and other social serves.
62682249|NCT06126575|EXPERIMENTAL|Subjects with normal hepatic function|Subjects with normal hepatic function will receive treatment compared to subjects with severe hepatic function
62682250|NCT06126575|EXPERIMENTAL|Subjects with severe hepatic impaired function|Subjects with severe hepatic function will receive treatment compared to subjects with normal hepatic function
62311730|NCT01095484||Rotigotine|Patients who have a documented medical necessity to receive treatment with rotigotine treatment in accordance with standard medical practice.
62311731|NCT01566344|EXPERIMENTAL|Routine heart failure therapy plus PVC suppression therapy|
62311732|NCT01566344|NO_INTERVENTION|Routine heart failure therapy|
62311733|NCT02725255|EXPERIMENTAL|Papaya seed porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
62311734|NCT02725255|ACTIVE_COMPARATOR|Albendazole and Plain porridge|Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
62477064|NCT04965454|EXPERIMENTAL|Tested with Biomarkers|For this single arm study, all enrolled subjects will undergo diagnostic testing with FCH PET/CT and genomic liquid biopsy before treatment involving an immune checkpoint inhibitor agent. A fluorine-18 fluorodeoxyglucose (FDG) PET/CT may also be performed before treatment and after 8 weeks if the pre-treatment FCH PET/CT shows low or heterogeneous tumor uptake.
62477065|NCT03548363|ACTIVE_COMPARATOR|Gingest High|200 mg/d Gingest (powdered extract obtained from Ginger rhizomes) for 4-weeks
62682251|NCT04951206|ACTIVE_COMPARATOR|Clobetasol Group|Clobetasol propionate 0.05% ointment is the active treatment arm that will be use in women with lichen sclerosus in the study per standard clinical recommendations. Participants will be instructed to apply 0.25-0.5g of the ointment to the affected tissues nightly for 4 weeks starting after the initial FxCO2 laser treatment, then 2 times a week for the remainder of the study (until final study visit).
62477066|NCT03548363|ACTIVE_COMPARATOR|Gingest low|100 mg/d Gingest (powdered extract obtained from Ginger rhizomes) + 100 mg maltodextrin for 4-weeks
62477067|NCT03548363|PLACEBO_COMPARATOR|Placebo|200 mg/d maltodextrin for 4-weeks
62477068|NCT05138003|OTHER|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
62477069|NCT04742686|NO_INTERVENTION|Usual care|
62477070|NCT04742686|EXPERIMENTAL|Intervention|
62311735|NCT02725255|PLACEBO_COMPARATOR|Plain porridge|arm receiving 300ml plain porridge daily (without papaya seeds)
62311736|NCT04500288|EXPERIMENTAL|LEFT Device Arm|Subjects in this arm will wear the LEFT device for 1 month
62311737|NCT06136338|EXPERIMENTAL|Mindfulness intervention group|intervention + routine care
62311738|NCT06136338|NO_INTERVENTION|Control group|routine care
62311739|NCT05043610|EXPERIMENTAL|WJ-MSCs intracoronary infusion + standard care|In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10\^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.
62311740|NCT05043610|ACTIVE_COMPARATOR|standard care (Control Group)|In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 240 patients will receive only conventional treatment.
62311741|NCT02517515|EXPERIMENTAL|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) for 12 weeks.
62311742|NCT02517515|EXPERIMENTAL|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) for 12 weeks.
62311743|NCT02927223|EXPERIMENTAL|Treadmill then Treadmill with Atropine|Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
62311744|NCT04340869|EXPERIMENTAL|Theobromine|Natural extract from Cocoa
62311745|NCT04340869|ACTIVE_COMPARATOR|Remin Pro|Fluoride , Hydroxyapatite , and Xylitol
62477071|NCT04642820|EXPERIMENTAL|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
62477072|NCT04642820|EXPERIMENTAL|MethamphetamineThen Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
62477073|NCT01519258|ACTIVE_COMPARATOR|PSV|Patients will be ventilated with the a conventional mode of ventilation called Pressure Support Ventilation (PSV) for 15 minutes. Mechanical ventilator settings will be set to match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
62477074|NCT01519258|EXPERIMENTAL|NAVA|Patients will be ventilated with NAVA for 15 minutes. Nava level will be titrated prior to randomization, to deliver the same peak of airway pressure obtained with the active comparator, PSV. The resulting tidal volume should match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
62477075|NCT03034694|PLACEBO_COMPARATOR|Routine Care|The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
62477076|NCT03034694|EXPERIMENTAL|Teledermatology INtervention|The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
62477077|NCT05527561|EXPERIMENTAL|Latin Dance-Rumba|Rumba dance training was shown for the 1-6 weeks.
62682252|NCT04951206|PLACEBO_COMPARATOR|Placebo Group|Placebo ointment is the control treatment arm. Participants will be instructed to apply 0.25-0.5g of the ointment to the affected tissues nightly for 4 weeks starting after the initial FxCO2 laser treatment, then 2 times a week for the remainder of the study (until final study visit).
62682253|NCT06694402|EXPERIMENTAL|focal muscle vibration combined with exercise|
62682254|NCT06694402|ACTIVE_COMPARATOR|exercise alone|
62682255|NCT05961709|EXPERIMENTAL|Cemiplimab|Participants will receive cemiplimab by vein over about 30 minutes on Day 1 of each 3-week study cycle, up to 8 cycles.
62682256|NCT05958225|EXPERIMENTAL|Personal agency, leadership and business training|Entrepreneurs will participate in a 3 day residential training (based on SEE Change's Empowered Entrepreneur training) that integrates personal agency with basic business and leadership topics. Participants will also get weekly support messages on their phone for 6 weeks and a check in by a training once a month for 3 months.
62682257|NCT05958225|NO_INTERVENTION|Control|For this study, the control participants will not receive any intervention.
61922424|NCT02766842|ACTIVE_COMPARATOR|EUS-FNB with SharkCore needle|The procedure will be done in the same manner with same endoscopic technique and method of tissue procurement. The only difference will be using the SharkCore needle to acquire tissue.
62311746|NCT04340869|EXPERIMENTAL|Combination|Remin Pro and Theobromine
62311747|NCT01874704|OTHER|biomarkers of stress|Comparison of biomarkers of stress in emergency physicians working a 24-hour shift or a 14-hour night shift
62311748|NCT03940781|EXPERIMENTAL|intervention group|We conducted a twice a week, 12-week-intervention of 'comprehensive rehabilitation'
62311749|NCT03940781|NO_INTERVENTION|control group|We kept the patients for the waiting list until after completing baseline and 12-week measurement
62311750|NCT06358885|ACTIVE_COMPARATOR|Facilitation Only (FAC)|Clinics randomized to the FAC arm will implement BAI delivery to PWH using the facilitation only approach.
62311751|NCT06358885|EXPERIMENTAL|Facilitation Plus an Experiential Brief Alcohol Intervention (EBAI+FAC)|Clinics randomized to the EBAI+FAC arm will implement BAI delivery to PWH participants using the facilitation approach. Additionally, clinic staff, irrespective of their own alcohol use, will be offered the BAI themselves prior to delivering the BAI.
62311752|NCT06653634|ACTIVE_COMPARATOR|Stable treatment|Stable treatment with methotrexate and TNFi
62311753|NCT06653634|EXPERIMENTAL|Methotrexate withdrawal|Gradual withdrawal of methotrexate
61922425|NCT01797939||Erosive reflux disease (ERD)|
62477078|NCT05527561|EXPERIMENTAL|Latin Dance-Cha Cha Cha|Cha Cha Cha dance training for the 7-12 weeks.
61922426|NCT01797939||Non-erovise reflux disease (NERD)|
61922427|NCT01797939||Functional heartburn (FH)|
62122728|NCT06676553|NO_INTERVENTION|A: Renal artery stimulation-induced systolic blood pressure rise suppressed (<20 mmHg)|No further renal denervation after standard renal denervation procedure
62311754|NCT06653634|EXPERIMENTAL|TNFi withdrawal|Gradual withdrawal of TNFi
62477079|NCT03034798||Type 1 Diabetes Exercisers|Participants performed 2 different forms of exercise of identical duration and similar total energy expenditure. One form was purely aerobic in nature and the other was intermittent, high-intensity exercise.
62477080|NCT05172947|ACTIVE_COMPARATOR|Resveratrol|Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months.
62477081|NCT05172947|PLACEBO_COMPARATOR|Placebo|"Non-interventional group, participants are receiving only Placebo once daily for 3 months.~Placebo formulated as capsule match the color and size of the active comparator,"
62682258|NCT06125327|PLACEBO_COMPARATOR|Placebo Comparator|Idiopathic pulmonary fibrosis (IPF) patients were administered placebo matching SC1011 taken orally as tablets (matching the respective SC1011 tablets) twice daily, in the morning and in the evening for 52 weeks.
62122729|NCT06676553|ACTIVE_COMPARATOR|B: Re-denervation if renal artery stimulation-induced systolic blood pressure rise not suppressed|Another round of renal denervation (main renal artery for positive proximal stimulation; branch artery for positive distal stimulation) after standard renal denervation. The definition of non-suppressed is systolic blood pressure rise \>=20 mmHg compared to baseline.
62122730|NCT06676553|PLACEBO_COMPARATOR|C: Control if renal artery stimulation-induced systolic blood pressure rise not suppressed|No further renal denervation after standard renal denervation. The definition of non-suppressed is systolic blood pressure rise \>=20 mmHg compared to baseline.
62311755|NCT03211078|EXPERIMENTAL|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
62311756|NCT03809546|PLACEBO_COMPARATOR|Placebo|
62311757|NCT03809546|ACTIVE_COMPARATOR|7.5 mg THC|
62311758|NCT03809546|ACTIVE_COMPARATOR|15 mg THC|
62477082|NCT05172947|OTHER|Resveratrol plus Pharmaceutical care|Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months with pharmaceutical care.
62477083|NCT05172947|OTHER|Placebo with pharmaceutical care|Interventional group, participants are receiving placebo along with pharmaceutical care for 3 months.
62682259|NCT06125327|EXPERIMENTAL|SC1011 200mg|Idiopathic pulmonary fibrosis (IPF) patients were administered SC1011 taken orally as tablets twice daily(200mg daily), in the morning and in the evening for 52 weeks.
62682260|NCT06043765|EXPERIMENTAL|Cognitive strategy training + real rTMS|Verum rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total)
62682261|NCT06043765|SHAM_COMPARATOR|Cognitive strategy training + sham rTMS|Sham rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total).
62682262|NCT05704244|EXPERIMENTAL|FE 999326|
62311759|NCT03940573|EXPERIMENTAL|Treatment|All patients fitted with the device.
62477084|NCT05336643|EXPERIMENTAL|Radioisotope and fluorescence guidance|Patients undergoing curative resection for rectal cancer will receive a peritumoural, submucosal administration of indocyanine green and technetium-99m nanocolloid. Intraoperatively the SENSEI gamma probe and Da Vinci Firefly will be used to identify pelvic side wall lymph nodes.
62477085|NCT06452251||vitamin D sufficient|Vitamin D sufficient group (Group S) \>20 ng/ml threshold was determined as sufficiency,
62477086|NCT06452251||vitamin d insufficient|Vitamin D insufficient group (Group IN-S) 12-20 ng/mol was determined as insufficiency.
62477087|NCT01718704|EXPERIMENTAL|Viberect device|Men in this group will begin using the Viberect device 3 days after Foley catheter removal after surgery on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting.
62477088|NCT01718704|NO_INTERVENTION|No Viberect|Men in this group will not be provided with the Viberect device
62477089|NCT06018285|NO_INTERVENTION|Treatment As Usual|Treatment as Usual
62477090|NCT06018285|EXPERIMENTAL|STARRS-PC|Intervention consists of implementation of clinical pathway for youth suicide risk
62477091|NCT02022254|EXPERIMENTAL|Semaglutide administrations|
62477092|NCT02095054|EXPERIMENTAL|Regorafenib + Cetuximab|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle. Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.~Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle. Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.~Symptom questionnaire completed at each study visit."
62477093|NCT00802763||vaginitis|
62477094|NCT00996684|EXPERIMENTAL|microplasmin, intravitreal injection|Subjects will receive one intravitreal injection of microplasmin on Day 0.
62477095|NCT00996684|PLACEBO_COMPARATOR|Placebo|Subjects will receive one intravitreal injection of the placebo on Day 0.
62477096|NCT02704585|OTHER|Nellcor|Connection to Nellcor pulse oximeter for measuring oxygen saturation after birth
62477097|NCT02704585|OTHER|Masimo|Connection to Masimo pulse oximeter for measuring oxygen saturation after birth
62477098|NCT05283850|ACTIVE_COMPARATOR|High-Calcium, High- Sodium (HCHS) group|Patients will receive a drip of blinded, intravenous, normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
62477099|NCT05283850|EXPERIMENTAL|High-Calcium, Low- Sodium (HCLS) group|Patients will receive a drip of blinded, intravenous, half-normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
62477100|NCT03612960|EXPERIMENTAL|Very low nicotine content cigarettes|Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
62477101|NCT03612960|PLACEBO_COMPARATOR|Normal nicotine content cigarettes|Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
62477102|NCT00218257|ACTIVE_COMPARATOR|Progesterone|200mg progesterone twice daily
62477103|NCT00218257|PLACEBO_COMPARATOR|Placebo|Placebo twice daily
62477104|NCT04278261|EXPERIMENTAL|Focal therapy|Using focal therapy(high-frequency Irreversible electroporation) to treat patients with localized Prostate cancer
62477105|NCT04278261|ACTIVE_COMPARATOR|Radical prostatectomy|Using laparoscopic radical prostatectomy to treat patients with localized Prostate cancer
62477106|NCT00309101|EXPERIMENTAL|1. tacrolimus|
62477107|NCT05535062|ACTIVE_COMPARATOR|Dash Protocol|Patients will be randomized after consent to receive standard Dash protocol
62477108|NCT05535062|ACTIVE_COMPARATOR|Modified Dash protocol with the New feature enabled|Patients will be randomized after consent to receive modified Dash protocol with the New feature enabled
62477109|NCT06420687|NO_INTERVENTION|Able-bodied participants|Participants without amputation were enrolled to collect normative data for system validation. Adhesive motion capture markers will be placed on both arms (upper arm, forearm, hand and finger tips), thoracic spine and sacrum. The participant wears a specialized headband/glasses with an attached camera for eye tracking. The participant will pick up and move objects of different shapes to and from various heights.
62477110|NCT06420687|ACTIVE_COMPARATOR|Transradial amputee participants|Individuals using their home prosthesis when available. Adhesive motion capture markers will be placed on both arms (upper arm, forearm, hand and finger tips), thoracic spine and sacrum. The participant will wear a headband with attached markers for eye tracking. The participant will pick up and move objects of different shapes to and from various heights.
62477111|NCT06420687|EXPERIMENTAL|Transradial amputee participants - Wrist rotation+1 dof hand|Individuals with transradial amputation fit with experimental prosthesis consisting of wrist rotation and one degree of freedom hand. Adhesive motion capture markers will be placed on both arms (upper arm, forearm, hand and finger tips), thoracic spine and sacrum. The participant will wear a headband with attached markers for eye tracking. The participant will pick up and move objects of different shapes to and from various heights.
62477112|NCT06420687|EXPERIMENTAL|Transradial amputee participants - Wrist rotation + wrist flexion +1 dof hand|Individuals with transradial amputation fit with experimental prosthesis consisting of wrist rotation, wrist flexion and one degree of freedom hand. Adhesive motion capture markers will be placed on both arms (upper arm, forearm, hand and finger tips), thoracic spine and sacrum. The participant will wear a headband with attached markers for eye tracking. The participant will pick up and move objects of different shapes to and from various heights.
62477113|NCT06420687|EXPERIMENTAL|Transradial amputee participants - Wrist rotation + multi degree freedom hand|Individuals with transradial amputation fit with experimental prosthesis consisting of wrist rotation and multi degree freedom hand. Adhesive motion capture markers will be placed on both arms (upper arm, forearm, hand and finger tips), thoracic spine and sacrum. The participant will wear a headband with attached markers for eye tracking. The participant will pick up and move objects of different shapes to and from various heights.
62477114|NCT06420687|EXPERIMENTAL|Transradial amputee participants - Wrist rotation + wrist flexion + multi degree freedom hand|Individuals with transradial amputation fit with experimental prosthesis consisting of wrist rotation, wrist flexion and multi degree freedom hand. Adhesive motion capture markers will be placed on both arms (upper arm, forearm, hand and finger tips), thoracic spine and sacrum. The participant will wear a headband with attached markers for eye tracking. The participant will pick up and move objects of different shapes to and from various heights.
62477115|NCT02138539|ACTIVE_COMPARATOR|4% Hydroquinone|4% hydroquinone applied to one side of the face.
62311760|NCT00471380|ACTIVE_COMPARATOR|Crossover group ABB|"3 period, 2 treatment cross-over model:~Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)"
62311761|NCT00471380|ACTIVE_COMPARATOR|Crossover group BAA|"3 period, 2 treatment cross-over model:~Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)."
62311762|NCT02127112|ACTIVE_COMPARATOR|Block Allograft plus Matrix Allograft|The positive control treatment will include a block allograft plus a demineralized bone matrix moldable allograft.
62311763|NCT02127112|EXPERIMENTAL|Moldable Matrix Allograft|In the test arm of the study the treatment will include a demineralized bone matrix moldable allograft.
62311764|NCT02252952|EXPERIMENTAL|Sugar Sweetened Beverages|Any beverage from a range of caffeine free, sugar sweetened drinks. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
62311765|NCT02252952|EXPERIMENTAL|Diet Beverage|Any beverage from a range of caffeine free drinks sweetened with non-caloric sweetener. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
62311766|NCT02252952|ACTIVE_COMPARATOR|Water|12 oz of water. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
62311767|NCT02585804|EXPERIMENTAL|Dapagliflozin (trade name Farxiga®)|Oral tablet, 10mg, PO, 8 weeks
62311768|NCT05485636||degenerative lumbar scoliosis postoperative group|"This group contains patients who have undergone spinal surgery for degenerative lumbar scoliosis.~No interventions are designed to be administered."
62311769|NCT03063385|EXPERIMENTAL|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
62311770|NCT03063385|ACTIVE_COMPARATOR|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
62311771|NCT06672861|OTHER|Newly diagnosed/untreated/incompletely treated for Cardiac Dysautonomia Patients|Newly diagnosed/untreated/incompletely treated for Cardiac Dysautonomia (Postural Orthostatic Tachycardia Syndrome (POTS), Inappropriate Sinus Tachycardia (IST), and Vasovagal syncope (VVS)) Patients
62311772|NCT06672861|OTHER|Previously diagnosed/treated/undergone sinus node modification for Cardiac Dysautonomia Patients|Previously diagnosed/treated/previously undergone sinus node modification for Cardiac Dysautonomia Patients (Postural Orthostatic Tachycardia Syndrome (POTS), Inappropriate Sinus Tachycardia (IST), and Vasovagal syncope (VVS)) Patients
62477116|NCT02138539|EXPERIMENTAL|Herbal depigmenting agent|Herbal depigmenting agent applied on the other side of the face.
62311773|NCT02512016|OTHER|Nulliparous Women in Third Trimester|Study Procedures
62311774|NCT05776459|EXPERIMENTAL|AC102|AC102 gel and placebo tablets
62311775|NCT05776459|ACTIVE_COMPARATOR|Prednisolone|Placebo gel and prednisolone tablets
62311776|NCT06302322|EXPERIMENTAL|Natural Thin Gums|
62311777|NCT06302322|EXPERIMENTAL|Natural Thick Gums|
62311778|NCT06302322|EXPERIMENTAL|Surgically augmented Thin Gums|
62311779|NCT05269849|EXPERIMENTAL|Oral sirolimus tablets|Sirolimus starting dose of 2 mg once daily, orally adjusted as need to maintain drug blood levels of 6-10 ng/ ml The first dose will be given at the week 12 visit and participants will be observed for 30 min
62477117|NCT02441621|OTHER|Passive leg raising|
62477118|NCT02441621|OTHER|premedication|
62477119|NCT02441621|OTHER|intubation and mechanical ventilation|
62477120|NCT02441621|OTHER|central venous catheter|
62682263|NCT04381559|EXPERIMENTAL|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
61922428|NCT04309747|EXPERIMENTAL|nanosecond knife group|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
62122731|NCT01161563|ACTIVE_COMPARATOR|Leuprolide acetate|Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area. Injection occurred either 6 months before or 6 months after injection of triptorelin pamoate suspension (Trelstar 22.5 mg) intramuscularly in the buttock.
62122732|NCT01161563|ACTIVE_COMPARATOR|Triptorelin pamoate|Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock. Injection occurred either 6 months before or 6 months after injection of polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) subcutaneously in upper or mid-abdominal area.
62122733|NCT02035969|NO_INTERVENTION|Conventional treatment (CT)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling and clinical follow up every three months. The caretaker of the child is responsible that the child will take the drugs and is provided with a pre-packed dosage form for easy remembering
62122734|NCT02035969|EXPERIMENTAL|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counselling and clinical follow up every three months. In addition adherence support is provided according to the description under intervention.
62122735|NCT00177216|EXPERIMENTAL|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
62122736|NCT00177216|EXPERIMENTAL|Excitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
62122737|NCT00177216|PLACEBO_COMPARATOR|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
62122738|NCT03414658|EXPERIMENTAL|NH: Trastuzumab + Vinorelbine|"* Trastuzumab is administered intravenously twice per cycle~* Vinorelbine is administered intravenously 3 times per cycle"
62122739|NCT03414658|EXPERIMENTAL|NHA: Trastuzumab + Vinorelbine + Avelumab|"* Trastuzumab is administered intravenously twice per cycle~* Vinorelbine is administered intravenously 3 times per cycle~* Avelumab is administered intravenously twice per cycle~* Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
62122740|NCT03414658|EXPERIMENTAL|NHAU: Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"* Trastuzumab is administered intravenously twice per cycle~* Vinorelbine is administered intravenously 3 times per cycle~* Avelumab is administered intravenously twice per cycle~* Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~* Utomilumab is administered intravenously once per cycle"
62311780|NCT06260150|EXPERIMENTAL|Experimental group|On the basis of routine nursing, the intermittent pneumatic compression device was used, lasting from the start of the operation to the end of the operation.
62311781|NCT06260150|NO_INTERVENTION|control group|The control group received routine nursing during the operation, including upper limb intravenous puncture to establish infusion channel, and anesthesiologist performed radial artery puncture and catheterization. The patients were placed in a 30° head-up, legs-down position with their legs apart, and were warmed up by a warm air blanket. The intraoperative warming device was set to infuse at 38℃, and bladder temperature was monitored. Knee-length graded compression stockings (GCS) were used for both legs during the operation.
62311782|NCT05138120|EXPERIMENTAL|Common Elements Toolbox|
62311783|NCT05138120|NO_INTERVENTION|Wait-list control|
62311784|NCT01327430|EXPERIMENTAL|Phospholipid supplementation|Supplementation of milk phospholipid
62311785|NCT03741881||Patients with haemophilia|Patients with haemophilia A or B and with or without inhibitors
62311786|NCT05324943|EXPERIMENTAL|FLT201|FLT201 is an advanced therapy investigational medicinal product (ATIMP) administered as a single intravenous infusion.
62311787|NCT00824694|ACTIVE_COMPARATOR|Intervention|The intervention will consist of targeted SMBG, provider training and patient education-all of which are focused on normalizing the most significant glucose abnormalities at any given time. SMBG will alternate between 2 strategies: glucose profiling and target monitoring. Intervention PCP's will use 380 View to identify a patient's most significant glucose elevations(s) and devise a treatment plan that includes drug type, dose increases, monitoring times, goal for the target, and stop criteria.
62477121|NCT02441621|OTHER|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
62477122|NCT02441621|OTHER|transesophageal echocardiography|
62477123|NCT02441621|OTHER|transpulmonary thermodilution catheter|
62477124|NCT06525389|ACTIVE_COMPARATOR|Deoxycholate Amphotericin B (DAmB) plus Flucytosine (5FC) placebo|DAmB (0.7mg/kg/d IV x 14 days) + 5FC placebo (25 mg/kg oral 3x daily x 14 days)
62477125|NCT06525389|EXPERIMENTAL|Deoxycholate Amphotericin B (DAmB) plus Flucytosine (5FC)|DAmB (0.7 mg/kg/d IV x 14 days) + 5FC (25 mg/kg oral 3x daily x 14 days)
62477126|NCT06525389|EXPERIMENTAL|Liposomal Amphotericin B (LAmB) plus Flucytosine (5FC) placebo|LAmB (10 mg/kg IV x 1 dose) + 5FC placebo (25 mg/kg oral 3x daily x 14 days)
62477127|NCT06525389|EXPERIMENTAL|Liposomal Amphotericin B (LAmB) plus Flucytosine (5FC)|LAmB (10 mg/kg IV x 1 dose) + 5FC (25 mg/kg oral 3x daily x 14 days)
62477128|NCT02256683|EXPERIMENTAL|Dabigatran|Dabigatran etexilate (Pradaxa®) 150 mg capsule by mouth twice daly for 3 up to 6 weeks depending on treatment response
62477129|NCT02256683|ACTIVE_COMPARATOR|Phenprocoumon|Phenprocoumon (Marcumar®) 3 mg capsule by mouth according to INR (2-3) for 3 up to 6 weeks depending on treatment response
62311788|NCT00824694|ACTIVE_COMPARATOR|Control Arms|Subjects will repeat the dose titration cycle under the guidance of a case manager until the target is reached, maximal recommended doses of medications are used, or a stop criterion is met. They will then resume glucose profiling to identify the next target. This process is repeated until all targets reach their optimal value. Control patients will monitor and be treated in the customary manner.
62311789|NCT00950781||Group|Group
62311790|NCT06472570|EXPERIMENTAL|Stereotactic radiotherapy|Patients treated with stereotactic radiosurgery boost. Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin
62311791|NCT06673160|EXPERIMENTAL|Pumping every 2 hours|Mothers of patients in this group will be assigned to pump/ express breastmilk every 2 hours.
62311792|NCT06673160|ACTIVE_COMPARATOR|Pumping every 3 hours|Mothers of patients in this group will be assigned to pump/ express breastmilk every 3 hours.
62311793|NCT01556919||Mucosal Impedance Probe|
62477130|NCT01932177|ACTIVE_COMPARATOR|Schedule A|Everolimus run-in period followed by continuous administration of everolimus and sorafenib
62477131|NCT01932177|ACTIVE_COMPARATOR|Schedule B|Sorafenib run-in period followed by continuous administration of everolimus and sorafenib
62477132|NCT01932177|EXPERIMENTAL|Schedule C|Everolimus and sorafenib in alternance
62477133|NCT01932177|EXPERIMENTAL|Schedule D|Continuous administration of everolimus and intermittent administration of sorafenib
62477134|NCT02962752|EXPERIMENTAL|Blackadder Juice|Cold pressed Blackadder blackcurrant juice. Standardised at 500mg of polyphenols per 60kg of body weight
62477135|NCT02962752|PLACEBO_COMPARATOR|Placebo|Sugar, flavour and volume matched placebo control drink.
62477136|NCT00819312|ACTIVE_COMPARATOR|Arm 1|
62477137|NCT05734157|EXPERIMENTAL|Everolimus-coated balloon|Treatment of occlusion or stenosis in Superficial Femoral Artery and Proximal Popliteal Artery with drug-coated balloon
62477138|NCT01621893||BML of the Knee|Subject has single bone marrow lesion of tibia, single BML of femur, or adjoining BML's of tibia \& femur on which a Subchondroplasty procedure is performed
62477139|NCT05163743|EXPERIMENTAL|Ketogenic Diet-obese|LCKD (1200-1400kcal/day) low in carbohydrates (\<50g per day) with a moderate protein intake (1-1.5g/kg of ideal body mass) but otherwise no other dietary restrictions. The participants will be counselled by a trained nutritionist at baseline and every two weeks, and compliance will be assessed through a 3-day dietary recall at each follow up visit and capillary beta hydroxybutyrate levels as well as urinary acetoacetate levels. The follow up visits take place at the time of the first vaccine dose, two weeks after the first vaccine dose, one week after the second vaccine dose. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
61922429|NCT02910375|OTHER|Cohort A|Patients starting golimumab therapy Week 0: 200 mg Week 2: 100 mg Week 6, 10, 14, and 18: 50 mg (\<80 kg) or 100mg (\>80 kg body weight)
61922430|NCT02910375|OTHER|Cohort B|Patients already on golimumab therapy will continue their actual treatment 50 mg every 4 weeks (\<80 kg) or 100mg every 4 weeks (\>80 kg body weight)
61922431|NCT02684318|EXPERIMENTAL|Dose Level 1|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 100 mg BID
62311794|NCT04530825|NO_INTERVENTION|Providers|"* All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline~* A subset of 5-10 providers will be recruited via email, at the baseline training,or by using snowball-sampling approach within the clinic to participate in qualitative in-depth interviews"
62122741|NCT02552186|ACTIVE_COMPARATOR|Pectus Excavatum Group|The first group (PE Group) will consist of patients presenting to the All Children's Hospital Johns Hopkins Medicine (ACH JHM) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. Clinical measurements will be obtained using calipers.
61922432|NCT02684318|EXPERIMENTAL|Dose Level 2|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 150 mg BID
62311795|NCT04530825|NO_INTERVENTION|Parents|-Semi-structured interviews
62311796|NCT04530825|ACTIVE_COMPARATOR|Patients - Wait-List Control|"* Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~* Up to 10 patients will also take part in semi-structured interviews~* A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
62311797|NCT04530825|EXPERIMENTAL|Patients - PREVENT tool|"* Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~* Up to 10 patients will also take part in semi-structured interviews~* At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
62737701|NCT06517069|EXPERIMENTAL|TEAS combined with Oxycodone|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction; Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
61922433|NCT02684318|EXPERIMENTAL|Dose Level 3|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 200 mg BID
61922434|NCT02684318|EXPERIMENTAL|Dose Level 4|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 250 mg BID
61922435|NCT02684318|EXPERIMENTAL|Dose Level 5|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 250 mg BID
62122742|NCT02552186|NO_INTERVENTION|Control Group|The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of ACH JHM undergoing CT chest for indications other than chest wall deformity.
62122743|NCT02645006|EXPERIMENTAL|Intervention arm- 3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
62122744|NCT02645006|OTHER|Control arm- 1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention
62122745|NCT06484504|NO_INTERVENTION|Control group|No intervention to be administered
62122746|NCT06484504|EXPERIMENTAL|Kombucha group|Two servings of a 16 oz commercial kombucha beverage daily for four weeks
61922436|NCT02684318|EXPERIMENTAL|Dose Level 6|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 300 mg BID
61922437|NCT02684318|EXPERIMENTAL|Dose Level 7|PM01183 + olaparib PM01183 3 mg/m² IV olaparib 300 mg BID
61922438|NCT00902161|EXPERIMENTAL|Propanolol + Placebo > Propanolol + MK0893|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8).
61922439|NCT00902161|PLACEBO_COMPARATOR|Propanolol + MK0893 > Propanolol + Placebo|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8).
61922440|NCT02284178|EXPERIMENTAL|Enhanced oral suction|Deep oropharyngeal suction with catheter
61922441|NCT02284178|SHAM_COMPARATOR|Usual Care Oral Suction|Oropharyngeal suction with suction swab
61922442|NCT02237833||Septic shock and vasopressor|Measuring cerebral oxymetry (SCO2) first 24 hours in septic shock and given vasopressors.
61922443|NCT00920829|ACTIVE_COMPARATOR|A118G A/A with Naltrexone|Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
62122747|NCT03565939|ACTIVE_COMPARATOR|Trichuris suis ova (TSO)|7500 TSO suspension, orally every second week for 24 weeks.
62122748|NCT03565939|PLACEBO_COMPARATOR|Placebo|Solution without TSO orally every second week for 24 weeks
62122749|NCT05425433|EXPERIMENTAL|Serial casted joint|Tailored serial casting intervention following 1 week of usual care
62122750|NCT02301442|EXPERIMENTAL|Exercise + behaviour change intervention|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + behaviour change intervention will be delivered by physiotherapists between weeks 1 and 11.
62311798|NCT02004340|ACTIVE_COMPARATOR|Transcutaneous auricular vagal stimulation|Transcutaneous stimulation at auricular concha
62311799|NCT02004340|SHAM_COMPARATOR|Transcutaneous auricular non-vagal stimulation|Transcutaneous stimulation at auricular edge
62311800|NCT02004340|NO_INTERVENTION|control|No transcutaneous stimulation is given
62311801|NCT04980183|EXPERIMENTAL|Arthroscopic surgical robot assisted navigation and positioning for cruciate ligament reconstruction|Patient undergoes cruciate ligament reconstruction with robot-assisted navigation and positioning under arthroscopic surgery
62311802|NCT04980183|ACTIVE_COMPARATOR|Conventional arthroscopic cruciate ligament reconstruction|The patient undergoes conventional arthroscopic cruciate ligament reconstruction
62311803|NCT01673880|OTHER|E2006 2.5 mg|
62311804|NCT01673880|OTHER|E2006 10mg|
62311805|NCT01673880|OTHER|E2006 25 mg|
61922444|NCT00920829|PLACEBO_COMPARATOR|A118G A/A with Placebo|Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks
61922445|NCT00920829|ACTIVE_COMPARATOR|A118G Any G with Naltrexone|Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
61922446|NCT00920829|PLACEBO_COMPARATOR|A118G Any G with Placebo|Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
61922447|NCT06156475|EXPERIMENTAL|Proprioception Exercise Group|Wand exercises and Proprioception exercises
62122751|NCT02301442|ACTIVE_COMPARATOR|Exercise + control education|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + control education intervention will be delivered by physiotherapists between weeks 1 and 11.
62122752|NCT02227771||Patient with chronic total occlusion|
62122753|NCT03967626|EXPERIMENTAL|Cerebral temperature target|CCT performed by the external cooling device with cerebral temperature target, measured by a intracranial sensor (coupled to the intracranial pressure device)
62122754|NCT03967626|ACTIVE_COMPARATOR|Systemic temperature target|CCT performed by the external cooling device with systemic temperature target, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).
62311806|NCT05092581|EXPERIMENTAL|casirivimab+imdevimab|
62311807|NCT05920096|EXPERIMENTAL|Intervention|A diabetes specialist nurse-led multi-component smoking cessation intervention tailored for individuals with diabetes based on evidence and theory and guided by the 5A's and 5R's framework for smoking cessation The intervention consists of three to four (30-60 minutes) smoking cessation support sessions which are to be delivered by the two diabetes specialist nurses at the Diabetes Education Unit during the study period (12 weeks). As part of the first session, participants will also be shown three very brief video clips in which a person living with diabetes explains the serious health problems he suffered from (when smoking and having diabetes). Participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) - nicotine patch and/or nicotine spray.
62311808|NCT05920096|ACTIVE_COMPARATOR|Control|Active referral to the Health Promotion and Disease Prevention Directorate's one-to-one general stop-smoking service. This counseling service is provided every fortnight within Mosta, Floriana, or Paola health centres. The number of counseling sessions (lasting around 20 minutes each) provided during the study period (12 weeks) will be based on the client's needs.
62311809|NCT05859620||Before implementation|Patients included before implementation of the PMI-screening
62311810|NCT05859620||After implementation|Patients included after implementation of the PMI-screening
62311811|NCT01516801|EXPERIMENTAL|PSA flyer|
62311812|NCT01516801|NO_INTERVENTION|Control|
62311813|NCT00974129||Patients with Infantile Hemangiomas|
62311814|NCT05932810|OTHER|Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
62682264|NCT04381559|ACTIVE_COMPARATOR|Applied Relaxation|In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response. AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety. This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition. Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety. However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
62682265|NCT04573075|OTHER|no outlet|no outlet is used after colorectal resection and forming of a primary anastomosis
62311815|NCT05932810|EXPERIMENTAL|Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood among cancer survivors. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
62311816|NCT05707065|EXPERIMENTAL|core strengthening exercises|"Participants will be positioned in supine.~* first stage participants will be taught to activate abdominal wall musculature. They will be initially trained to perform abdominal bracing.~* Then positioned in quadruped position and asked to lift alternate arms, gradually progressing to alternate leg lifts and alternate arm/leg raises to activate multifidus.~* Then side bridges (side plank) exercise for activation of quadratus lumborum and obliques.~* Then asked to perform trunk curls in crook lying, asking them to lift their upper trunk slightly (15°) from the plinth, hold the position for 5 sec.~* Perform 30 repetitions of each exercise with 8-sec hold.~* Maintain normal diaphragmatic breathing throughout the intervention"
62477140|NCT01025973||Diabetes Mellitus|Patients with type 1, type 2 or gestational diabetes mellitus
62477141|NCT01025973||Normal pregnancy|Patient without diabetes mellitus
62682266|NCT04573075|ACTIVE_COMPARATOR|loop ileostomy|loop ileostomy is applied after colorectal resection and forming of a primary anastomosis
62682267|NCT04573075|EXPERIMENTAL|ghost ileostomy|ghost ileostomy or ghost stoma (synonyms) is performed after colorectal resection and forming of a primary anastomosis
62682268|NCT06690931|EXPERIMENTAL|BCI group|Patients in the BCI group will receive 6 sessions per week during 4 weeks of BCI training with FES and VR feedback (24 sessions in total).
62682269|NCT06690931|SHAM_COMPARATOR|Control group|Patients in the control group receive 6 sessions of Motor Imagery + FES + VR therapy per week for 4 weeks (24 sessions in total). Patient in the control group will receive the same instructions as the experimental group.
62682270|NCT05037500|EXPERIMENTAL|Treatment (decitabine and cedazuridine, enzalutamide)|Patients receive decitabine and cedazuridine PO QD on either days 1-3, 1-4, or 1-5 and enzalutamide PO QD on days 1-28. Treatments repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62682271|NCT06055699||Patients with psoriasis in remission|Patients with psoriasis in remission after IL23i or IL17inhibitor treatments and who have stopped their medication for 2 to 4 weeks.
62477142|NCT01844050|EXPERIMENTAL|Chinese herbal medicine|Individualized Treatment with Chinese herbal
62682272|NCT05202171|EXPERIMENTAL|Exercise group|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
62682273|NCT05202171|ACTIVE_COMPARATOR|Standard treatment group|Standard treatment group will be given preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks.
62682274|NCT02013908|ACTIVE_COMPARATOR|Standard ED management alone|Radiographic and physical examinations to exclude fractures or other serious conditions will be performed for all patients before considering eligibility in the study. After completion of the examination, patients who have pain of at least a level 4, as measured by the Wong-Baker scale (ranges 0 to 10), will receive intravenous or intramuscular injections of non-steroidal anti-inflammatory drugs (NSAIDs) for immediate pain control. All patients will be observed 30 minutes after the administration of the NSAIDs. In patients with primary headaches who respond poorly to the initial NSAID injection, an intravenous injection of opioid analgesics will be provided. After these initial standard ED management interventions, patients who are still suffering from acute pain will be asked to participate in the trial. During the study, rescue medication for immediate pain control will be allowed for patients allocated to both groups.
62682275|NCT02013908|EXPERIMENTAL|Acupuncture plus standard ED management|The patients in this group will receive a single session of individualized acupuncture treatment delivered by a certified Korean Medicine Doctor (KMD) specialized (or in-training) in acupuncture and moxibustion medicine and with at least 3 years of clinical experience. The acupuncture formulas will be composed based on the individual patient's symptoms and at the KMD's discretion. Acupuncture treatments will be provided in line with standard ED management, the same as in the control group.
62682276|NCT02810132|ACTIVE_COMPARATOR|Metformin|Drug: Metformin Target dose: 1000 mg x 2 (if eGFR 30-60 ml/min: 500 mg x 2) Other name: Glucophage XR 500
62122755|NCT06148727|ACTIVE_COMPARATOR|Conventional heat cured overdenture group|patients received 4 interforamenal implants connected by 3 bar assembly and conventional heat cured overdenture (Control Group)
62122756|NCT06148727|ACTIVE_COMPARATOR|3d- printed overdenture group|patients received 4 interforamenal implants connected by 3 bar assembly and 3d printed overdenture (Study Group)
62477143|NCT01844050|PLACEBO_COMPARATOR|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
62477144|NCT05019261|EXPERIMENTAL|Intervention|Multi-component Family Support Intervention
62477145|NCT05019261|NO_INTERVENTION|Control|Usual ICU care
62477146|NCT03527485|OTHER|Opiate Use Disorder (OUD)|30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
62682277|NCT02810132|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62682278|NCT02315326|EXPERIMENTAL|Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A).
62682279|NCT02315326|EXPERIMENTAL|Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|The defined MTD from Arm A will then be used in an expansion cohort to further assess toxicity and clinical activity
62682280|NCT02315326|EXPERIMENTAL|Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.
62682281|NCT02315326|EXPERIMENTAL|Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.
62682282|NCT04356027||Standard of Care: Angiography, OCT, FFR, and VFR|Patients will have Pre-OCT Angiography, OCT pullbacks, a FFR measurement and a VFR analysis
62682283|NCT06688565|EXPERIMENTAL|Hativ® application|
62682284|NCT06234475|EXPERIMENTAL|Mobile health group|Smartphone mHealth support for smoking cessation by scheduled age-friendly multimedia e-messages and real-time personalized behavioral supports for 3 months.
62682285|NCT06234475|EXPERIMENTAL|Financial incentive group|An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively.
62682286|NCT06234475|EXPERIMENTAL|Combined intervention group|Smartphone mHealth support for smoking cessation by scheduled age-friendly multimedia e-messages and real-time personalized behavioral supports for 3 months and an escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively.
62682287|NCT06234475|ACTIVE_COMPARATOR|Control group|Brief advice
62682288|NCT05868148||Shoulder iD device implant|Adult patients who have reached skeletal maturity, with a functional deltoid muscle, and massive and non-repairable rotator cuff tear within one or more indications and zero contraindications who will receive the Shoulder iD Primary Reversed Glenoid device to replace the shoulder joint.
62682289|NCT06238856|EXPERIMENTAL|Cohort 1: Amikacin Dose 1 + Placebo|Participants will receive a single dose of SLIT™ amikacin at Dose 1 or matching placebo by inhalation on Day 0.
62682290|NCT06238856|EXPERIMENTAL|Cohort 2: Amikacin Dose 2 + Placebo|Participants will receive a single dose of SLIT™ amikacin at Dose 2 or matching placebo by inhalation on Day 0 upon initiation of Cohort 2.
62682291|NCT06238856|EXPERIMENTAL|Cohort 3: Amikacin Dose 3 + Placebo|Participants will receive a single dose of SLIT™ amikacin at Dose 3 or matching placebo by inhalation on Day 0 upon initiation of Cohort 3.
62311817|NCT05707065|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation|"* Rhythmic initiation (RI) Patients progressively performed voluntary relaxation, passive movements, active assisted, active resisted movements and than active movements.~* Dynamic reversals (slow reversals) Isotonic contractions of first agonists and then antagonists performed against resistance was performed initially.~* Stabilizing reversals Isotonic contractions of first agonists, then antagonists against resistance was performed in an alternate way.~* Mixture of isotonic (agonist reversals, AR) resisted concentric, contraction of agonist muscles moving with the range was performed progressively following eccentric, lengthening contraction, moving slowing to the start position. .~Total 30 min for 3 days a week for a total duration of 4 weeks was set as a optimal time frame duration. Each technique was given for 10 min."
62311818|NCT01483092|EXPERIMENTAL|inulin|
62682292|NCT05956535||AONDA contact lenses|Lotrafilcon A contact lenses worn therapeutically as a bandage lens in a continuous wear (CW) modality (lenses worn continuously including overnight) as instructed by the eye care professional.
62682293|NCT05956535||PV2 contact lenses|Balafilcon A contact lenses worn therapeutically as a bandage lens in a continuous wear (CW) modality (lenses worn continuously including overnight) as instructed by the eye care professional.
62682294|NCT01299532|EXPERIMENTAL|Macrolane VRF30|
62682295|NCT06675019|EXPERIMENTAL|Manual therapy|
62311819|NCT01483092|PLACEBO_COMPARATOR|maltodextrin|
62311820|NCT04468750|EXPERIMENTAL|Kinesiotape|Kinesiotape (Nasara, Korea) was applied for three times a week (Monday, Wednesday, and Friday) for three weeks.
62311821|NCT01773395|ACTIVE_COMPARATOR|GVAX|"GVAX vaccine~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points."
62477147|NCT03527485|OTHER|Healthy Controls (HC)|30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
62682296|NCT06675019|EXPERIMENTAL|Kinesio taping|
62682297|NCT06675019|ACTIVE_COMPARATOR|Control group|
62311822|NCT01773395|PLACEBO_COMPARATOR|Placebo|"Placebo vaccine~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points."
62311823|NCT01330381|EXPERIMENTAL|prucalopride|drug
62311824|NCT01330381|PLACEBO_COMPARATOR|Placebo|
62311825|NCT01330381|ACTIVE_COMPARATOR|PEG 4000|4-20g administered as an oral solution once daily
62311826|NCT02021968|EXPERIMENTAL|TetraVax-DV-TV003 vaccine|Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
62122757|NCT02711839|PLACEBO_COMPARATOR|Control Group|Commercial diabetic formula
61922448|NCT06156475|ACTIVE_COMPARATOR|Proprioception exercises with Electromyographic Biofeedback|Wand exercises and Proprioception exercises with Electromyographic Biofeedback
62122758|NCT02711839|EXPERIMENTAL|Treatment Group|White sweet potato formula
62311827|NCT02021968|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a single injection of placebo on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
62311828|NCT01956643|EXPERIMENTAL|gum chewing|"Gum type was standardized with all subjects receiving sugar-free xylitol gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (two tablets) 3 times daily in the morning, afternoon, and evening for 15 min. The administration of the therapy was implemented by ICU nurses and recorded in the clinical report form file. All gum-chewing patients completed their course of gum chewing until gas out."
62311829|NCT01956643|PLACEBO_COMPARATOR|Control|Routine care during NPO
62311830|NCT04509856|NO_INTERVENTION|Control Group|Routine diabetes education will given to the patients included in the Control Group by a diabetes education nurse. The diabetes education nurse has been working for 10 years in the same center.
62311831|NCT04509856|EXPERIMENTAL|Intervention Group|Intervention Group will take their diabetes education by teach-back educational strategy.
62311832|NCT03739983|EXPERIMENTAL|VRP Therapy|All subjects on this study will receive the Vaginal Renewal Program intervention. Enrolled subjects will receive inperson instruction on how to perform the VRP. Subjects will be encouraged to use the device for 3-4 days per week for 5 minutes at a time.
62311833|NCT05552716||Case Schools|All Schools identified with all incidents in which a gun is fired, or a bullet hits school property for any reason, regardless of the number of victims, time, day of the week.
62311834|NCT05552716||Control Schools|A random sample of schools that have not experienced any incidents in which a gun is fired, or a bullet hits school property for any reason, regardless of the number of victims, time, day of the week matched with a case school based on geographic state, urban/non-urban status, and elementary/middle/high school status.
62122759|NCT03196310|EXPERIMENTAL|PRP|Intra-articular injection of platelet rich plasma.
62122760|NCT03196310|ACTIVE_COMPARATOR|Corticosteroid|Intra-articular injection of kenalog.
62122761|NCT03196310|PLACEBO_COMPARATOR|Normal Saline|Intra-articular injection of normal saline
62122762|NCT01215552|EXPERIMENTAL|HT-0712|
62122763|NCT02671344||IAD group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation IAD group 'Determination of gene profiles using arrays semen'
62122764|NCT02671344||FIV group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation FIV group of gene profiles using arrays semen'
62311835|NCT03607734|OTHER|Group 1 - Interventional Treatment|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
62311836|NCT02004990|EXPERIMENTAL|Single cleansing procedure of 10% povidone iodine cleansing|10% povidone iodine cleansing
62682298|NCT06694376||Single-group study|The study has one group/cohort, which will include up to 154 people. The study team will conduct one round of semi-structured interviews with up to 42 administrators or other staff at the centralized intake system organization(s), 28 home visiting program directors and other staff responsible for overseeing outreach and enrollment, 42 home visitors and other staff responsible for conducting outreach and enrollment, and 42 families who were referred to home visiting through the selected centralized intake systems. All respondents will also complete a form to provide information about their demographic characteristics.
62682299|NCT03847818|EXPERIMENTAL|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|
62682300|NCT05327946|EXPERIMENTAL|Monotherapy dose escalation|
62311837|NCT02251730|EXPERIMENTAL|Refer for smoking cessation|Refer for smoking cessation
62311838|NCT02100553|OTHER|Non-Obese|BMI \<30 kg/m\^2
62311839|NCT02100553|OTHER|Obese|BMI \>= 30 kg/m\^2
62477148|NCT03964662|EXPERIMENTAL|Patients with stroke|Rehabilitation of patients with stroke using a new technological device: WeReha
62477149|NCT02354560|EXPERIMENTAL|Erythromycin|Oral treatment with Erythromycin 250-500mg (will be determined according to body weight) twice a day.
62682301|NCT05327946|EXPERIMENTAL|Combination therapy dose escalation|
62682302|NCT06689865|ACTIVE_COMPARATOR|HA-HCP|
62682303|NCT06689865|EXPERIMENTAL|OTC-HCP|
62682304|NCT06689865|EXPERIMENTAL|OTC-R|
62682305|NCT06689865|ACTIVE_COMPARATOR|OTC-SF|
62682306|NCT05318560|ACTIVE_COMPARATOR|Local anesthetic injection|Patients will be injected with lidocaine and given upper trapezius muscle stretching exercises. Lidocaine injection 2cc 2% will be administered to all patients using a 26 gauge, 0.45x13 mm disposable sterile needle to the affected trigger point.
62682307|NCT05318560|ACTIVE_COMPARATOR|Ozone injection|Ozone injection will be performed on patients and upper trapezius muscle stretching exercises will be given. 8 cc of oxygen/ozone gas at a concentration of 15 µg/mL will be injected into the trigger point.
62682308|NCT05318560|ACTIVE_COMPARATOR|Stretching exercise|Patients will be given a home program that includes upper trapezius muscle stretching exercises. Upper trapezius stretching exercises will be performed twice a day for at least 15 seconds, ten sets each time, for three weeks, with one hand on the patient's back and the other hand holding the side of the head and tilting it to the side until a slight tension is felt. The exercises will be explained in the text, visual and verbal forms with the exercise form.
62311840|NCT03725046|NO_INTERVENTION|Usual information transmission after ED admission|The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
62477150|NCT03526757|EXPERIMENTAL|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
62682309|NCT03745313|EXPERIMENTAL|Treatment|Treatment with the Edwards PASCAL Transcatheter Valve Repair System
62682310|NCT01153542|EXPERIMENTAL|VX-770|
62682311|NCT01153542|EXPERIMENTAL|desipramine|
62682312|NCT04419389|EXPERIMENTAL|Safety Lead-In Cohort 1|APR-246 4.5 g/d + Acalabrutinib in Subjects with R/R CLL (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
62682313|NCT04419389|EXPERIMENTAL|Safety Lead-In Cohort 2|APR-246 4.5 g/d + Venetoclax + Rituximab in Subjects with R/R CLL (APR 246 Monotherapy Lead-in; 4.5 g/d x 2).
62682314|NCT04419389|EXPERIMENTAL|Expansion Cohorts|APR-246 4.5 g/d + (Acalabrutinib, OR, (Ven+R)) in Subjects with R/R TP53-mutant CLL, and/or MCL, and/or RT
62682315|NCT04419389|EXPERIMENTAL|Safety Lead-In Cohort 3|APR-246 4.5 g/d + Venetoclax + Rituximab in Subjects with RT
62682316|NCT06368193|EXPERIMENTAL|Cardiac Surgery Patients|
62682317|NCT00736736|ACTIVE_COMPARATOR|Leg Press|Leg Press exercise for 3 times/week and sustain for 8 weeks.
61922449|NCT00167466|EXPERIMENTAL|A|4 week brushing with experimental Soladey-3 toothbrush followed by 4 week washout period followed by 4 week brushing with placebo Soladey-3 toothbrush
62477151|NCT03526757|ACTIVE_COMPARATOR|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
62682318|NCT00736736|EXPERIMENTAL|Hip Exercise|Additional hip abductor and hip external rotator strength training to leg press exercise for people in this group. All participants received exercise for 3 times per week for 8 weeks.
62682319|NCT00736736|NO_INTERVENTION|Control|Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
62682320|NCT00063362|EXPERIMENTAL|Lithium + divalproex + lamotrigine|
62682321|NCT00063362|PLACEBO_COMPARATOR|Lithium + divalproex + placebo|
62682322|NCT05685160|EXPERIMENTAL|Patient group|Patients with intermetatarsal pain have ultrasound and MRI done
62682323|NCT05685160|ACTIVE_COMPARATOR|Control group|Healthy individuals (no forefoot pain) undergo ultrasound and MRI scan of the forefoot.
62682324|NCT06222333|EXPERIMENTAL|Respiratory physiotherapy group|In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour
62682325|NCT06222333|ACTIVE_COMPARATOR|Routine treatment group|Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
62682326|NCT05358249|EXPERIMENTAL|JDQ443+trametinib|JDQ443 in combination with trametinib
62682327|NCT05358249|EXPERIMENTAL|JDQ443+ribociclib|JDQ443 in combination with ribociclib
61922450|NCT00167466|PLACEBO_COMPARATOR|B|subjects to brush with Placebo Soladey-3 toothbrush for 4 weeks followed by a 4 week washout followed by 4 week brushing with experimental Soladey-3 toothbrush
61922451|NCT05110547||Idiopathic Parkinson's disease|patients meeting the current clinical criteria whose disorders have progressed for strictly more than 2 years and strictly less than 7 years.
62682328|NCT05358249|EXPERIMENTAL|JDQ443+cetuximab|JDQ443 in combination with cetuximab
62682329|NCT06694051|EXPERIMENTAL|ptk-group|
62682330|NCT06694051|NO_INTERVENTION|limbus-group|
62682331|NCT06500442|EXPERIMENTAL|NEU-111|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohort (10 days)
62682332|NCT06500442|PLACEBO_COMPARATOR|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days)
62682333|NCT06687122|EXPERIMENTAL|4 weeks of additional daily intake of 3 whole eggs|No intervention: 4 weeks of habitual diet without daily intake of eggs (baseline) will be followed by 4 weeks of additional daily intake of 3 whole eggs then no intervention: 4 weeks of habitual diet without daily intake of eggs (washout)
62682334|NCT05761951|EXPERIMENTAL|DKN-01|Participants will receive DKN-01 by vein over about 30 minutes to 2 hours on Day 1 of each cycle, as well ason Day 15 of Cycle 1.
62682335|NCT05761951|EXPERIMENTAL|Pembrolizumab|Participants will receive pembrolizumab by vein over about 30 minutes on Day 1 of each cycle for up to 24 months.
62682336|NCT05952323|NO_INTERVENTION|Control group|"After obtaining the necessary legal and ethical permissions for data collection, the research will commence. During this stage of the study, participants who agree to take part in the research will be asked to fill out the informed consent form. To obtain the pre-test data for the research, all forms will be filled out.~Students receiving standard care and continuing practice will be provided with information about the research. Pre-test and post-test data from the control group will be obtained concurrently with the study groups."
62682337|NCT05952323|EXPERIMENTAL|Teach-back group|To obtain the pre-test data for the research, all forms will be filled out. According to the prepared educational materials for medical devices, students will be trained using the teach-back method. After the training, students will be asked to demonstrate their skills in using medical devices then two weeks after the pre-test. The researcher will use the Medical Device Usage Competency Observer Evaluation Form to assess the student's competency in using medical devices and Medical Device Usage Competency Knowledge Test and the Medical Device Usage Competency Self-Assessment Form for post-test data.
62682338|NCT05952323|EXPERIMENTAL|Video-assisted teaching group|After obtaining the pre-test data, students will be sent educational videos related to medical devices and asked to watch them. Then two weeks after sending the videos, students will be requested to demonstrate their skills in using medical devices. The researcher will assess the students' medical device usage competencies using the Medical Device Usage Competency Observer Evaluation Form, Medical Device Usage Competency Knowledge Test, and the Medical Device Usage Competency Self-Assessment Form for post-test data.
62682339|NCT05108974|EXPERIMENTAL|3 months choline bitartrate|Over the 9-month study, participants will receive a total of 3 months of choline bitartrate (19 mg/kg) and a total of 6 months of placebo
62682340|NCT05108974|EXPERIMENTAL|6 months choline bitartrate|Over the 9-month study, participants will receive a total of 6 months of choline bitartrate (19 mg/kg) and a total of 3 months of placebo
62682341|NCT02118415|EXPERIMENTAL|Interventional|Interventional group: activated autologous NK cells as a drug
62311841|NCT03725046|EXPERIMENTAL|Optimized information transmission after ED admission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
62311842|NCT01269125|ACTIVE_COMPARATOR|Endometriosis, leuprolide, IVF|Women with stage II endometriosis received GnRH-a (leuprolide) prior to an IVF attempt.
62311843|NCT01269125|ACTIVE_COMPARATOR|Endometriosis, IVF|Women with mild endometriosis who underwent an IVF attempt without prior administration of GnRH-a.
62311844|NCT01269125|ACTIVE_COMPARATOR|Tubal infertility, IVF|Women with tubal infertility underwent an IVF attempt.
62311845|NCT01825434|ACTIVE_COMPARATOR|Treatment Group|yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
62477152|NCT05458583|OTHER|Direct bonding with conventional adhesive|The fixed retainer was applied with direct bonding technique using two-step (conventional) adhesive
62311846|NCT01825434|PLACEBO_COMPARATOR|Placebol group|regular yogurt, 1 time per day for 30 days.
62477153|NCT05458583|OTHER|Direct bonding with one-step adhesive|The fixed retainer was applied with direct bonding technique using one-step adhesive
62477154|NCT05458583|OTHER|Indirect bonding with conventional adhesive|The fixed retainer was applied with indirect bonding technique using two-step (conventional) adhesive
62682342|NCT02118415|NO_INTERVENTION|Control group|Control group: BSC
62682343|NCT04879563|EXPERIMENTAL|ASCAPE-based follow-up strategy|Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions.
62477155|NCT05458583|OTHER|Indirect bonding with one-step adhesive|The fixed retainer was applied with indirect bonding technique using one-step adhesive
62477156|NCT03105947|ACTIVE_COMPARATOR|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
62477157|NCT03105947|ACTIVE_COMPARATOR|Butter|50g butter to be consumed daily for four weeks
62477158|NCT03105947|ACTIVE_COMPARATOR|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
62477159|NCT05619068||Medical treatment group|Conservative medical treatment
62477160|NCT05619068||Surgical treatment group|Direct revascularization, indirect revascularization or combined revascularization
62477161|NCT04252001|EXPERIMENTAL|Group YT|Group receives YESS! game and transition-toolkit
62477162|NCT04252001|EXPERIMENTAL|Group GT|Group receives control game and transition-toolkit
62477163|NCT04252001|EXPERIMENTAL|Group T|Group receives transition-toolkit
62477164|NCT04252001|NO_INTERVENTION|Group O|Group receives usual transition care
62477165|NCT01499602|EXPERIMENTAL|LNG-IUS|Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up.
62477166|NCT01499602|ACTIVE_COMPARATOR|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
62477167|NCT04503603|EXPERIMENTAL|Lanadelumab 300 mg|Participants will receive single dose of lanadelumab 300 mg intravenous (IV) infusion on Day 1 followed by second dose on Day 4.
62682344|NCT04236804|EXPERIMENTAL|TMC-CP01 Intervention|Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines.
62682345|NCT04236804|NO_INTERVENTION|Standard of Care|Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
62682346|NCT04114084||A. patients with MGUS and sleep apnea|
61922452|NCT05110547||atypical Parkinsonian syndromes|including the subgroups: multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration with a duration of disease progression strictly greater than 2 years and strictly less than 7 years, and meeting the current clinical criteria for each
61922453|NCT05993182|ACTIVE_COMPARATOR|Group-I|received 5mg of Ephedrine after the first hypotension \[ Base line time or starting point is first hypotension\]
62311847|NCT05450055|EXPERIMENTAL|intraperitoneal analgesic group|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump. At the same time, patients in both groups were connected with intravenous controlled intravenous controlled analgesia (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
62311848|NCT05450055|PLACEBO_COMPARATOR|control group|Before the end of surgery, patients in the control group (C group) were extensively sprayed with 20mL normal saline intraperitoneally before the peritoneum was sutured. The surgeon placed an intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. In the control group, 0.9% normal saline was injected intraperitoneally with 10mL/h, and the total volume in the pump was 720mL. At the same time, patients in both groups were connected with intravenous controlled analgesia pump (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
62682347|NCT04114084||B. patients with MGUS and no sleep apnea|
62682348|NCT04114084||C. patients with MM and sleep apnea|
62682349|NCT04114084||D. patients with MM and no sleep apnea|
61922454|NCT05993182|ACTIVE_COMPARATOR|Group-II|received 10mg of Ephedrine after the first hypotension \[ Base line time or starting point is first hypotension\]
62477168|NCT04503603|PLACEBO_COMPARATOR|Placebo|Participant will receive single dose of lanadelumab matching placebo (normal saline) IV infusion on Day 1 followed by second dose on Day 4.
62496027|NCT04055233|ACTIVE_COMPARATOR|Subcutaneous irrigation with NaCl (saline)|"Intervention: after closure of fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml NaCl (saline) will be done once for one minute.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
62682350|NCT03297060|EXPERIMENTAL|SSL Implementation Strategy|Science to Service Implementation Strategy for SBIRT adherence
62682351|NCT03297060|NO_INTERVENTION|Standard Care|Standard Care SBIRT services
62682352|NCT05640635|ACTIVE_COMPARATOR|Ventilator weaning first|
62682353|NCT05640635|ACTIVE_COMPARATOR|ECMO weaning first|
62682354|NCT06687746||Pakistan Cohort|Infants born to PRISMA-enrolled mothers in the Pakistan catchment area
62682355|NCT06687746||Kenya Cohort|Infants born to PRISMA-enrolled mothers in the Kenya catchment area
62682356|NCT06687746||Ghana Cohort|Infants born to PRISMA-enrolled mothers in the Ghana catchment area
62682357|NCT06687746||Zambia Cohort|Infants born to PRISMA-enrolled mothers in the Zambia catchment area
62682358|NCT06687746||Vellore, India Cohort|Infants born to PRISMA-enrolled mothers in the Vellore, India catchment area
62682359|NCT06687746||Hodal, India Cohort|Infants born to PRISMA-enrolled mothers in the Hodal, India catchment area
62682360|NCT06568796|EXPERIMENTAL|Focused Ekstracorporeal Shoch Wave Theraphy and Exercise|Individuals will be administered focused ekstracorporeal shoch wave theraphy 1 day a week for 4 weeks. Individuals will exercise every day
62682361|NCT06568796|EXPERIMENTAL|Trigger Point Ischemic Compression Massage and Exercise|Individuals will receive trigger point ischemic compression massage 2 days a week for 4 weeks. Individuals will exercise every day
62682362|NCT06568796|NO_INTERVENTION|Exercise|Individuals will only exercise every day.
62682363|NCT06302621|EXPERIMENTAL|DOSE ESCALATION PHASE 1A PEMIGATINIB + AFATINIB|"In the phase 1a dose escalation study participants with FGFR-altered refractory advanced solid tumors will be enrolled.~This research study involves the study drugs Afatinib and Pemigatinib."
61922455|NCT05993182|ACTIVE_COMPARATOR|Group-III|15mg bolus dose of ephedrine IV after the first hypotension \[ Base line time or starting point is first hypotension\]
62477169|NCT06562478|ACTIVE_COMPARATOR|Meditation Intervention|Aspects of Zazen will be addressed. In the first session, the practice will be conducted for a duration of 5 minutes. In the second session, the duration will be extended to 10 minutes, aiming to provide adaptation for the participants. In the third session, the practice will last for 15 minutes, during which heart rate variability will be measured using the Polar H10 chest strap and the Elite HRV mobile app, both before and after the practice, to assess acute effects. At the end of the 24 sessions, the chronic effects of the practices will be evaluated in the same manner.
62477170|NCT06562478|ACTIVE_COMPARATOR|Documentary Control|Neutral documentary on quality of life, for 30 minutes twice a week. Both groups will undergo intervention twice a week for 3 months, totaling 24 sessions. In the third session, heart rate variability assessment will be conducted to observe the acute effects of the method.
62477171|NCT04721834|ACTIVE_COMPARATOR|Low-intensity ESWT|Patient would be positioned in a supine position. Shockwaves would be delivered to the stretched penis at proximal, mid and distal penile shaft and bilateral crura of penis. (Energy: 0.1-0.25 mJ/mm2; 3000pulses per session; Frequency 3Hz) Treatment consists of 6 sessions over 5 weeks in total. It would be a twice-weekly treatment with one-week interval of resting period. Patient would be discharged home after each treatment session.
62477172|NCT04721834|SHAM_COMPARATOR|Sham ESWT|Sham therapy would be given with a modified probe which no shockwave would be emitted. A working noise would still be generated which mimicked active treatment.
62477173|NCT06411847|EXPERIMENTAL|Virtual Appointment Group|This group will receive additional virtual appointments as an adjunct to standard care
62477174|NCT06411847|NO_INTERVENTION|Control Group|The group will receive standard Care
61922456|NCT06379425|ACTIVE_COMPARATOR|Standard of Care (SOC) (acetaminophen)|one time dose of 1000mg acetaminophen orally
62311849|NCT05736731|EXPERIMENTAL|A2530|Patients receive Preconditioning Lymphodepletion (PCLD) Regimen followed by a single dose of A2B530 intravenously on day 0
62311850|NCT02021422|OTHER|Anakinra with Modified Folfirinox|"8-weeks of anakinra and modified FOLFIRINOX regimen (refer to Appendix 9 for regimen) as follows~Kineret (anakinra) Dosage Route Administration 100 mg SC Every Other Day~Modified FOLFIRINOX Drug Dose Administration Oxaliplatin 85 mg/m2 2-4 hours Irinotecan 180 mg/m2 90 minutes fluorouracil 2400 mg/m2 48 hours"
62311851|NCT05279937|EXPERIMENTAL|Prolotherapy|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
62311852|NCT05279937|ACTIVE_COMPARATOR|Control|10mL of 1% Lidocaine (Control)
62477175|NCT01094054|ACTIVE_COMPARATOR|Dietary and lifestyle modification|Patients in this arm will eat meals that are identical in size and caloric composition to those consumed by participants in the other arm who undergo adjustable gastric banding
62477176|NCT01094054|EXPERIMENTAL|Adjustable gastric banding|Subjects will undergo gastric banding as per clinical practice
62477177|NCT01466166||Pegloticase|Participants received pegloticase 8 mg by intravenous (IV) infusion every 2 weeks for up to 1 year, as prescribed by their treating physician.
61922457|NCT06379425|EXPERIMENTAL|Standard of Care (SOC) (acetaminophen) and investigational product (celecoxib + gabapentin)|one time dose of 1000mg acetaminophen orally combined with 400mg celecoxib orally, and 300mg gabapentin orally
61922458|NCT04568343|EXPERIMENTAL|small bowel bleeding patient|with suspicious small bowel bleeding,patient will recieve Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule later for evaluations
61922459|NCT06159101|EXPERIMENTAL|HLX13 group|Recombinant anti-CTLA-4 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.
61922460|NCT06159101|ACTIVE_COMPARATOR|CN-sourced ipilimumab group|CN-sourced ipilimumab
62311853|NCT02762864|EXPERIMENTAL|PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU \<234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period. For patients in the PRU-target group with PRU ≥234 seconds, rescue medicine (ticagrelor) will be added to keep PRU\<234 seconds.
62311854|NCT02762864|ACTIVE_COMPARATOR|non PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU \<234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period, regardless the levels of PRU.
61922461|NCT06159101|ACTIVE_COMPARATOR|EU-sourced ipilimumab group|EU-sourced ipilimumab
61922462|NCT06159101|ACTIVE_COMPARATOR|US-sourced ipilimumab group|US-sourced ipilimumab
61922463|NCT05251428|EXPERIMENTAL|excision of the A1 pulley|
61922464|NCT05251428|ACTIVE_COMPARATOR|incision of the A1 pulley in the standard fashion|
61922465|NCT06038474|OTHER|Descartes-08|"Drug: Descartes-08~Autologous T-cells expressing a chimeric antigen receptor directed to BCMA"
61922466|NCT02818647|ACTIVE_COMPARATOR|COLD-DISSECTION|Cold Dissection Technique
62477178|NCT06524219||unilateral intrafascial resection|Subjects whose preoperative MRIs indicate the lesions are located in the peripheral zone of one side near the capsule, unable to be performed intrafascial resection, and no major lesion or only slight lesion in the peripheral zone of the other side, are going to be conducted unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy.
62682364|NCT06302621|EXPERIMENTAL|COHORT 1: EXPANSION PHASE 1B COHORT 1 MTD/RP2D PEMIGATINIB + AFATINIB FGFR INHIBITOR-NAIVE|"In the phase Ib dose expansion study, patients with FGFR-altered cholangiocarcinoma will be recruited into 2 cohorts: FGFR inhibitor-naïve cholangiocarcinoma and FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. Cohort 1 will enroll patients with FGFR inhibitor-naïve cholangiocarcinoma.~This research study involves the study drugs Afatinib and Pemigatinib."
62682365|NCT06302621|EXPERIMENTAL|COHORT 2: EXPANSION PHASE 1B COHORT 2 MTD/RP2D PEMIGATINIB + AFATINIB FGFR INHIBITOR-PRETREATED|"In the phase Ib dose expansion study, patients with FGFR-altered cholangiocarcinoma will be recruited into 2 cohorts: FGFR inhibitor-naïve cholangiocarcinoma and FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. Cohort 2 will enroll patients with FGFR-inhibitor-pretreated and resistant cholangiocarcinoma.~This research study involves the study drugs Afatinib and Pemigatinib."
62682366|NCT05394116|EXPERIMENTAL|High dose Garetosmab|Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)
62682367|NCT05394116|EXPERIMENTAL|Low dose Garetosmab|Garetosmab is administered by IV administration Q4W
62682368|NCT05394116|EXPERIMENTAL|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.
62682369|NCT03814629|OTHER|precancerous lesions of gastric cancer|120 cases of chronic atrophic gastritis with intestinal metaplasia or dysplasia,It was randomly divided into 60 cases of treatment group and 60 cases of control group,treatment group was given Weifuchun tablets,The control group was given vitamin tablets.
61922467|NCT02818647|ACTIVE_COMPARATOR|HOT-DISSECTION|Needle Electrocautery Dissection Technique
61922468|NCT01227564|EXPERIMENTAL|ACC-001 3 μg/ QS-21 50 μg|
61922469|NCT01227564|EXPERIMENTAL|ACC-001 10 μg/ QS-21 50 μg|
61922470|NCT01227564|PLACEBO_COMPARATOR|Placebo- Phosphate buffered saline (PBS)|
61922471|NCT06240507|ACTIVE_COMPARATOR|pulsed radiofrequency group|posterior tibial nerve pulsed radiofrequency for painful calcaneal spur and plantar fasciitis
61922472|NCT06240507|ACTIVE_COMPARATOR|radiofrequency thermocoagulation group|intralesional radiofrequency thermocoagulation for painful calcaneal spur and plantar fasciitis
62477179|NCT06524219||bilateral intrafascial resection|Subjects who have low or median-risk tumors and no extracapsular extension for major lesion, are going to be conducted bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy.
62682370|NCT05879302|EXPERIMENTAL|Shared Decision Making Intervention|Receives the Shared Decision Making Intervention
62682371|NCT05879302|NO_INTERVENTION|Usual Care|Receives Usual Care, eg. usual patient education and counseling for kidney transplant candidates.
62682372|NCT05643924||Patients diagnosed with Asthma|
61922473|NCT02217540|EXPERIMENTAL|Experimental Group|Experimental Group consist of the physiotherapy standard protocol and active movement plus accessory mobilizations of the humeral head using Mulligan Concept Mobilisation with Movement.
61922474|NCT02217540|ACTIVE_COMPARATOR|Control Group|Standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
61922475|NCT03156361|EXPERIMENTAL|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
61922476|NCT03156361|ACTIVE_COMPARATOR|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
61922477|NCT03531073||Standard care cohort|This study is observational. Patients will receive standard treatment as given in usual clinical practice with no intervention as part of the study. As per current clinical practice guidelines and UK reimbursement rules for biologics in PsA, patients will receive a pragmatic treat to target approach using step up standard therapies. Patients will usually receive methotrexate first line, initially 15mg ow increasing to 25mg ow as tolerated. In case of non-response, an additional DMARD will be used (sulfasalazine up to 3g daily or leflunomide 20mg od). If two DMARDs are failed and patients are eligible for biologic therapy under UK National Institute of Health and Clinical Excellence (NICE) guidance, then biologics will be used.
62682373|NCT01460537|EXPERIMENTAL|Treatment A: Gemcitabine-Copanlisib|The treatment consists of repetitive cycles, each over 28 days. Treatment continues until disease progression or dose limiting toxicity. If gemcitabine is discontinued for toxicity, Copanlisib may be continued at the discretion of the Investigator if a clinical benefit (response or stable disease for 3 months) is noted. - Hour 0 to 0.5: Gemcitabine (1000 mg/m2 as 30-minute IV infusion) on Days 1, 8 and 15 every 28 days - Hour 1.5 to 2.5: BAY80-6946 (starting dose = 0.6 mg/kg as 60-minute IV infusion, starting 1 hour post completion of gemcitabine infusion) on Days 1, 8 and 15 every 28 days
62682374|NCT01460537|EXPERIMENTAL|Treatment B: Cisplatin-Gemcitabine-Copanlisib|Treatment consists of repetitive 21 day cycles for a maximum of 8 cycles. Treatment continues until disease progression, DLT or completion of 8 cycles. After 8 cycles, gemcitabine and Copanlisib, without cisplatin, may continue at the discretion of the Investigator until disease progression or DLT if a clinical benefit is noted (response or stable disease for 3 months). Treatment is administered on Days 1 and 8 every 21 days as follows: - Hour 0 to 1: Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 mmol of magnesium sulfate) - Hour 1 to 1.5: IV infusion of 500 ml of 0.9% NaCl over 30 min - Hour 1.5 to 2: Gemcitabine (1000 mg/m2 as 30 min IV infusion) - Hour 3 to 4: Copanlisib IV infusion at the MTD determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one Copanlisib Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
62682375|NCT05763420|EXPERIMENTAL|SBO with AH Plus Bioceramic Sealer|The teeth will be obturated using a single cone technique with AH Plus Bioceramic Sealer.
62682376|NCT05763420|ACTIVE_COMPARATOR|WVC with resin-based AH Plus Sealer|The teeth will be obturated using warm vertical compaction with resin-based AH Plus Sealer.
62682377|NCT01844986|EXPERIMENTAL|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
61922478|NCT04124718||high caries experience|80 adults will be allowed in the high caries experience group according to DMFT index DMFT\>13.9
62122765|NCT02671344||ICSI group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation 'Determination of gene profiles using arrays semen'
62122766|NCT02192606|ACTIVE_COMPARATOR|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
62122767|NCT02192606|ACTIVE_COMPARATOR|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
62122768|NCT01012388|EXPERIMENTAL|Radiesse|
62122769|NCT03814265|EXPERIMENTAL|Intervention|Laughter yoga group
62682378|NCT01844986|PLACEBO_COMPARATOR|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
62682379|NCT01104870|ACTIVE_COMPARATOR|Dose Group 1|UT-15C 0.25 mg twice daily
62682380|NCT01104870|ACTIVE_COMPARATOR|Dose Group 2|UT-15C 1.25 mg twice daily
62682381|NCT01104870|ACTIVE_COMPARATOR|Dose Group 3|UT-15C individual Maximum Tolerated Dose
61922479|NCT04124718||low caries experience|80 adults will be allowed in the high caries experience group according toDMFT index DMFT≤4
61922480|NCT03210987|ACTIVE_COMPARATOR|patient case presentation Bedside|In the bedside presentation group, patient case presentation and discussions will be at bedside with direct involvement of the patient as needed.
61922481|NCT03210987|ACTIVE_COMPARATOR|patient case presentation Outside-the-room|In the outside the room condition, case presentation and discussions will take place outside without the patient being present. After the case presentation and discussions the team will enter the room and give the patient a short summary of the medical situation, complete the medical information and examine the patient, as needed, and discuss the next steps.
61922482|NCT04884776|ACTIVE_COMPARATOR|Active arm|Subject will be instructed to take microbiome immunity formula 2 sachets daily for a total of 12 weeks.
61922483|NCT04884776|PLACEBO_COMPARATOR|Placebo arm|Subject will be instructed to take active placebo daily for a total of 12 weeks.
62122770|NCT03814265|NO_INTERVENTION|Control|No intervention
62122771|NCT00590551|EXPERIMENTAL|1-6|
62122772|NCT06588894||Type 2 Diabetes Mellitus|18-65 years old with type 2 DM for at least 5 years
62122773|NCT04895475||Lactating Mothers|Lactating mothers who plan to receive or have received the SARS-CoV-2 vaccine within 60 days.
62122774|NCT00997386|EXPERIMENTAL|busulfan, and melphalan, and alemtuzumab|Three drug regimen using busulfan, and melphalan, and alemtuzumab.
62122775|NCT04432688||Latuda®|Chinese schizophrenia patients who are receiving Latuda® in the real world
61922484|NCT02060448|EXPERIMENTAL|2wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal self-injurious thoughts and behaviors, or SITBs, (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
62122776|NCT04880434|EXPERIMENTAL|Brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma will receive conditioning chemotherapy consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg, with a maximum flat dose of 2 x 10\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 3.
62122777|NCT01859416|EXPERIMENTAL|Oral nutritional supplement|2 \* 125 mL low volume, energy and nutrient dense ONS per day (2 \* 300 kcal) in addition to usual nutritional care
62477180|NCT06524219||bilateral extrafascial resection|Subjects who have major lesion that is in the peripheral zone, MRIs that show that the lesion may invade or locate at the edge of the transitional zone, and Gleason score of 4+4 or greater, are going to be conducted bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy.
62477181|NCT00640562|EXPERIMENTAL|Quetiapine Extended Release|
62682382|NCT06545500|EXPERIMENTAL|Dose Level A|The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
62122778|NCT01859416|NO_INTERVENTION|Control|Usual nutritional care
62122779|NCT02449070|EXPERIMENTAL|Nicorandil|Receive nicorandil before primary PCI and thereafter for 6 months along with the standard therapy.
62477182|NCT00640562|ACTIVE_COMPARATOR|Risperidone|
62477183|NCT06242028||Group P (Perinuerally)|Ultrasound guided PENG block with perinuerally dexamethasone administration group
62477184|NCT06242028||Group S (Systematic)|Ultrasound guided PENG block with systemic dexamethasone administration group
62477185|NCT01470560|SHAM_COMPARATOR|Sham Yoga Group Treatment|Sham yoga group (control group) will attend 8 weekly sessions for 1-2 hours and will be lead by a certified yoga instructor. The yoga class will be based on Pantajali's Eight Fold Path which is the basis of Yoga. Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
62477186|NCT01470560|ACTIVE_COMPARATOR|MBSR Group Treatment|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
62682383|NCT06545500|EXPERIMENTAL|Dose Level B|The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
62682384|NCT06545500|EXPERIMENTAL|Dose Level C|The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
62311855|NCT04442620|EXPERIMENTAL|1st group: Physical Activity and Mediterranean Diet (PA-MD)|"A first group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 35-40% fat, 20% proteins, and 40-45% carbohydrates. Healthy fats (a maximum of 8-10% from saturated fats, \>20% from monounsaturated fats, \>10% from polyunsaturated fats and \<300 mg/day of cholesterol) and low glycaemic index foods rich in fibre (not less than 30-35g /day) are strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Such diet reflects the traditional Mediterranean Diet described in the PREDIMED (Primary Prevention of Cardiovascular Disease with a Mediterranean Diet)-Plus study.~As for physical activity, patients the participants will be recommended a 35 minutes interval training session three times a week. Physical activity sessions of 35 minutes will consist of 5 minutes warm-up, 20 minutes interval training, and 10 minutes breathing and stretching."
62477187|NCT03787758|EXPERIMENTAL|SAGE-718|
62682385|NCT06545500|PLACEBO_COMPARATOR|Dose Level D|The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
62122780|NCT02449070|NO_INTERVENTION|Control|Receive primary PCI and the standard therapy.
62682386|NCT05911295|EXPERIMENTAL|Disitamab vedotin arm|disitamab vedotin + pembrolizumab
62682387|NCT05911295|ACTIVE_COMPARATOR|Standard of care arm|gemcitabine + cisplatin OR carboplatin
62122781|NCT02416076|ACTIVE_COMPARATOR|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at the default Energy Level \[EL2\].
62311856|NCT04442620|EXPERIMENTAL|2nd group: High Meal Frequency of Mediterranean Diet (HMF-MD)|A second group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30-35% fat, 25% proteins, and 40-45% carbohydrates. Healthy fats and low glycaemic index foods will be strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Participants will be advised to consume 7 meals a day, gradually reducing the caloric content at each main meal, and to walk 10.000 steps a day.
62477188|NCT00096291|ACTIVE_COMPARATOR|Sequence Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
62477189|NCT00096291|OTHER|Sequence of neoadjuvant CT: Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
62496028|NCT03650751||stroke patients；neurologic impairment|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
62682388|NCT03249558|ACTIVE_COMPARATOR|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
62682389|NCT03249558|PLACEBO_COMPARATOR|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
62682390|NCT03249558|PLACEBO_COMPARATOR|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
62682391|NCT06357078|EXPERIMENTAL|Art Therapy|Caregivers in the art therapy group will be given art therapy practices, lasting approximately 45 minutes-1 hour, twice a week for 4 weeks. Visual and handicraft practices (painting work, collage work, mandala work, painting with felt, clay work, painting and storytelling) are done in art therapy activities that will last for 4 weeks, and it is aimed to develop personal and emotional awareness, reduce stress and increase general well-being.
62682392|NCT06357078|NO_INTERVENTION|Control|No intervention will be applied to the patients in the control group during the follow-up period, only data collection forms will be applied.
62682393|NCT03947385|EXPERIMENTAL|Dose Escalation Monotherapy|IDE196 dosed orally, twice daily (BID) for each 28-day cycle
62122782|NCT02416076|ACTIVE_COMPARATOR|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at the default Energy Level \[EL2\] .
62477190|NCT02554890|EXPERIMENTAL|sacubitril/valsartan (LCZ696)|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."
62682394|NCT03947385|EXPERIMENTAL|Dose Expansion Monotherapy|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)
62682395|NCT03947385|EXPERIMENTAL|Dose Escalation Binimetinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle
62682396|NCT03947385|EXPERIMENTAL|Dose Expansion Binimetinib Combination|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
61922485|NCT02060448|EXPERIMENTAL|2wk baseline + reappraisal (+ awareness)|"Participants will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs and behaviors (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
62311857|NCT04442620|ACTIVE_COMPARATOR|3rd group: Control diet (CD)|A third group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30% fat, 15% proteins, and 55% carbohydrates, and maintain an adequate fibre (25g/day) and cholesterol (\<250mg/day) intake. Meal frequency will be of 3-5 meals a day. Moreover, the participants will be advised to walk 10.000 steps a day.
62682397|NCT03947385|EXPERIMENTAL|Dose Escalation Crizotinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
62682398|NCT03947385|EXPERIMENTAL|Dose Expansion Crizotinib Combination|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors) Previously treated MUM, Treatment naïve MUM, MUM patients with human leukocyte antigen (HLA)-A\*02:01 positive status
62682399|NCT03947385|EXPERIMENTAL|Dose Optimization Crizotinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
62311858|NCT00831519||Macrosomial, GD|
62311859|NCT00831519||Macrosomial, control|
62477191|NCT02554890|ACTIVE_COMPARATOR|Enalapril|"Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"
62122783|NCT02416076|ACTIVE_COMPARATOR|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level \[EL4\].
62682400|NCT03947385|EXPERIMENTAL|Crizotinib Monotherapy with Crossover to Combination|Crizotinib dosed orally, twice daily (BID) for each 28-day cycle until disease progression then IDE196 added and dosed orally, twice daily (BID) for each 28-day cycle
62311860|NCT04098926|EXPERIMENTAL|Accelerated dose-integrated radiotherapy - pN0|Lymph node negative breast cancer
62682401|NCT03947385|EXPERIMENTAL|PK Substudy with Pravastatin (OBTP1B1 Substrate)|A PK substudy with approximately 18 patients will be nested within the IDE196 and crizotinib combination expansion cohort to evaluate the impact on the pravastatin PK profile by the steady state exposures of IDE196.
62682402|NCT06133712|ACTIVE_COMPARATOR|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve
62311861|NCT04098926|EXPERIMENTAL|Accelerated dose-integrated radiotherapy - pN1|Lymph node positive breast cancer
62311862|NCT01009775|EXPERIMENTAL|YM155 plus docetaxel|
62311863|NCT01496261|ACTIVE_COMPARATOR|Clopidogrel and Aspirin|
62311864|NCT01496261|EXPERIMENTAL|Coprigerl|
62311865|NCT04722133|EXPERIMENTAL|HERZUMA+mFOLFOX|
62311866|NCT03807973|EXPERIMENTAL|Fibromyalgia|
62311867|NCT03807973|EXPERIMENTAL|Chronic Fatigue Syndrome|
62311868|NCT03807973|EXPERIMENTAL|Multiple Sclerosis|
62311869|NCT03807973|EXPERIMENTAL|Healthy Controls|
62311870|NCT04319237||All Participants|
62311871|NCT02987673|EXPERIMENTAL|Mini/One anastomosis gastric bypass|Execution of a laparoscopic mini/one anastomosis gastric bypass (MGB/OAGB)
62311872|NCT02987673|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy|Execution of a laparoscopic sleeve gastrectomy (LSG)
62682403|NCT06133712|ACTIVE_COMPARATOR|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/dl) plus to 1 ml lidocaine (1%) using a 25 G needle.
62682404|NCT06133712|ACTIVE_COMPARATOR|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
62682405|NCT04560296|EXPERIMENTAL|Community-based E-Health Program|The intervention group will consist of 80 participants who will engage in Community-based E-Health Program.
62682406|NCT04560296|ACTIVE_COMPARATOR|usual self-management and follow up with doctors/nurse|The participants will receive the usual self-management and follow up with doctors/nurse as planned.
62682407|NCT06334211|EXPERIMENTAL|FP-020|100 mg capsule
62682408|NCT06334211|PLACEBO_COMPARATOR|placebo|placebo capsule
62682409|NCT01081262|EXPERIMENTAL|Arm I (carboplatin and paclitaxel)|Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
62682410|NCT01081262|EXPERIMENTAL|Arm II (oxaliplatin and capecitabine)|Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
62682411|NCT01081262|EXPERIMENTAL|Arm III (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
62682412|NCT01081262|EXPERIMENTAL|Arm IV (oxaliplatin, capecitabine, bevacizumab)|Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
62682413|NCT06651190|EXPERIMENTAL|Intervention Arm|"Participants will download the PainCaRe app from the web to their personal phone either virtually or in-person. Parents will receive app-based notifications to complete a pain assessment report once-daily. Assessments not completed will be marked as missed. Parents will also have the ability to complete ad hoc pain assessments as needed.~In response to the assessment indicating a child has pain, evidence-based, algorithm-driven pharmacological, physical, or psychological pain treatment guidance will be provided. This guidance is tailored to the age and developmental stage of the child."
61922486|NCT02060448|EXPERIMENTAL|4wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
62122784|NCT02416076|ACTIVE_COMPARATOR|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at a higher Energy Level \[EL4\] .
62311873|NCT06287047|ACTIVE_COMPARATOR|Conventional epidural group|"Conventional epidural.~."
62311874|NCT06287047|ACTIVE_COMPARATOR|DPE-25G group|Dural puncture epidural with 25-gauge spinal needle.
62311875|NCT06287047|ACTIVE_COMPARATOR|DPE-27G group|Dural puncture epidural with 27-gauge spinal needle.
62311876|NCT04701281|EXPERIMENTAL|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
62477192|NCT02656186|EXPERIMENTAL|Single-arm pretest-posttest|In this study, the subjects served as their own controls. Subjects who were eligible based on inclusion criteria first entered into a 2-week pre-intervention period, during which they received nutrition counseling to keep their routine dietary habits. This was followed by an intervention period, during which an oral nutritional supplement was used over a period of 2 weeks.
62682414|NCT06651190|NO_INTERVENTION|Control Arm|Parents randomized to the control arm (non-intervention group) will not be assigned to the PainCaRe app and their child will continue to receive standard medical and pain care.
62682415|NCT06688721|EXPERIMENTAL|EDA|Driving shifts with EDA-equipped buses
62682416|NCT06688721|NO_INTERVENTION|Control|Driving shifts with non-EDA-equipped buses
62682417|NCT06418984|NO_INTERVENTION|Control|No Interproximal reduction or attachments will be used to help correct the rotation
62682418|NCT06418984|EXPERIMENTAL|Inter proximal reduction|Interproximal reduction will be performed in this arm
62682419|NCT06418984|EXPERIMENTAL|Optimized attachments|optimized composite attachments will be added to this arm
62682420|NCT06418984|EXPERIMENTAL|IPR and optimized attachments|Both Interproximal reduction will be implemented and optimized attachments will be added to this arm
62682421|NCT01400152|ACTIVE_COMPARATOR|Passive warming with additional active warming|
62311877|NCT02322307|EXPERIMENTAL|HealthPROMISE users|These are patients who will receive HealthPROMISE application. Patients will be asked to track their quality of life and quality of care using standardized metrics. A combination of different questionnaires (i.e. Short IBD Questionnaire), symptom updates, and IBD quality indicators will be the collected during this study through the HealthPROMISE application.
62311878|NCT02322307|PLACEBO_COMPARATOR|Control Group|After entering baseline questionnaire, control patients get a link to download education application along with PIN. Once patients install app on their devices and use the PIN, the patient is considered to be enrolled in the trial from intention to treat perspective. This control app allows access to patient education content only. There is not any direct feedback on Quality of Life, quality of care and resource utilization.
62311879|NCT04366271|EXPERIMENTAL|Mesenchymal cells|Undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
62311880|NCT04366271|ACTIVE_COMPARATOR|Standard of care|Standard of care
62311881|NCT05205239|EXPERIMENTAL|Systemic sclerosis|
62311882|NCT04952883||COPD patients|The COPD questionnaire was conducted to collect the data of lung function, echocardiography and blood gas analysis, and the pulmonary vessels of HRCT were determined. Blood samples were collected for H2S-related indicators detection.
62311883|NCT04910412|EXPERIMENTAL|Anodal tDCS with gait training|Anodal tDCS will be applied over the primary motor cortex (M1) (anodal or active electrode on M1 area, cathodal or reference electrode on supraorbital area) for 20 mins with 2 mA intensity before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
62311884|NCT04910412|ACTIVE_COMPARATOR|Sham tDCS with gait training|Sham tDCS will be applied over the primary motor cortex for 20mins before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
62682422|NCT01400152|NO_INTERVENTION|Passive warming|
62682423|NCT06689787|EXPERIMENTAL|Self-Guided STAIR Coach with Real-Time Assessment|Participants randomized to this condition will receive two mobile apps.
62122785|NCT02416076|ACTIVE_COMPARATOR|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers' and 7-3.0 'Ulthera System, standard transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level \[EL4\].
62122786|NCT02416076|ACTIVE_COMPARATOR|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers'and 7-3.0 standard transducer on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFTof the face at a higher Energy Level \[EL4\].
62122787|NCT05549869|ACTIVE_COMPARATOR|group A|obese with vitligo
62122788|NCT05549869|ACTIVE_COMPARATOR|group b|obese without vitligo
62122789|NCT05549869|ACTIVE_COMPARATOR|group C|non obese with vitiligo
62682424|NCT06689787|ACTIVE_COMPARATOR|Real-Time Assessment|Participants randomized to this condition will receive one mobile app.
62682425|NCT04271488|EXPERIMENTAL|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 35 milligram (mg) tablet of tasurgratinib in the morning with 150 milliliters (mL) of water following an overnight fast of at least 10 hours.
62122790|NCT05549869|ACTIVE_COMPARATOR|group D|non obese without vitiligo
62122791|NCT00902499||NC|Normal older controls, not cognitively impaired; MMSE 27-30 and performance above education adjusted cutoff scores on the Logical Memory II subscale (LM-II Delayed Paragraph Recall) of the Wechsler Memory Scale
62122792|NCT00902499||vMCI|Very mild cognitive impairment; less severe objective memory deficit, scoring .5 to 1.5 S.D. (standard deviation) below education adjusted norms on the LM-II
62311885|NCT06468410|ACTIVE_COMPARATOR|60-minute Hatha Yoga group|• 60mHY Group: Participants will undergo a 60-minute hatha yoga session twice a week for four weeks.
62682426|NCT04271488|EXPERIMENTAL|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive 10 mg dose of tasurgratinib as capsule (2 capsules each of 5 mg) in the morning with 150 mL of water following an overnight fast of at least 10 hours.
62682427|NCT04271488|EXPERIMENTAL|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, race, gender and body weight) will receive a single 35 mg tablet of tasurgratinib in the morning with 150 mL of water following an overnight fast of at least 10 hours.
62311886|NCT06468410|ACTIVE_COMPARATOR|30-minute Hatha Yoga group|• 30mHY Group: Participants will undergo a 30-minute hatha yoga session twice a week for four weeks.
62311887|NCT06468410|PLACEBO_COMPARATOR|Control group|• Control Group: Participants will receive information about physical activity guidelines but will not engage in any structured yoga exercise during the study period.
62311888|NCT00318708|EXPERIMENTAL|clarithromycin + fluticasone|clarithromycin 500 mg twice daily (Biaxin) + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
62311889|NCT00318708|ACTIVE_COMPARATOR|placebo + fluticasone|placebo clarithromycin twice daily + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
62682428|NCT02217982|NO_INTERVENTION|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS \>6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
62477193|NCT01777711|ACTIVE_COMPARATOR|Couple condition|Couples randomized to the couple condition will undergo the experimental manipulations and both partners will complete all study measures. Both members of the couple will be given body mass index (BMI) based on measurements taken during the intervention. Both will complete three surveys on paper and do some prompted planning and goal-setting together regarding weight loss through healthier eating and physical activity.
62682429|NCT02217982|ACTIVE_COMPARATOR|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
62682430|NCT06676085|EXPERIMENTAL|New Anticoagulation Strategy Group|Combination of nafamostat and unfractionated heparin for anticoagulation, adjusting the dosage of unfractionated heparin to maintain APTT in the body for 40-45 seconds, and adjusting the dosage of nafamostat to maintain APTT in the membranous lung for 50-60 seconds during ECMO
62682431|NCT06676085|ACTIVE_COMPARATOR|control group|Anticoagulation with unfractionated heparin, regulating the dosage of unfractionated heparin to maintain APTT in the body for 50-60s during ECMO.
62682432|NCT01832194|EXPERIMENTAL|Botox|"Botox:~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
62682433|NCT06689085|EXPERIMENTAL|Participants|XYOSTED Injection (Testosterone enanthate) 50mg / 0.5 mL, 75 mg/0.5 mL, 100 mg/0.5 mL
62682434|NCT05309577|EXPERIMENTAL|Caregiver Intervention|Behavioral self-monitoring of sleep and activity up to 6 weeks, using the myRhythmWatch app, and motivational health coaching.
62122793|NCT00902499||sMCI|significant mild cognitive impairment; objective cut off of 1.5 S.D. level below education adjusted norms on the LM-II
62122794|NCT00902499||AD|Mild Alzheimer's disease; meet NINCDS/ADRDA criteria for probable AD with mild dementia severity (CDR Total = 1), MMSE 20-26
62122795|NCT01422616|EXPERIMENTAL|Low-dose rtPA (Recruitment completed in August 2015)|low-dose 0.6 mg/kg (maximum of 60 mg) i.v. rtPA
62122796|NCT01422616|ACTIVE_COMPARATOR|Standard-dose rtPA (Recruitment completed in August 2015)|standard-dose 0.9 mg/kg (maximum of 90 mg) i.v. rtPA
62682435|NCT06599073|EXPERIMENTAL|RescueDoppler patch with probe is attached to patients with cardiac arrest|The RescueDoppler probe and patch are placed on the left side of the patient's neck in both pre-hospital and in-hospital settings. The RescueDoppler system is blinded to the medical personnel during the cardiac arrest and is not used for real-time monitoring. After the cardiac arrest, the velocity curves are processed by the research team and synchronized with the ECG for analysis.
62682436|NCT06109181|EXPERIMENTAL|LX2020|Single ascending dose of LX2020, with a starting dose of 2.0 x10\^13 gc/kg, in multiple cohorts
62682437|NCT06686017||Subjects with one or two level degenerative disc disease of the lumbar spine|There are no investigational interventions. Subjects will undergo a one or two level spinal fusion procedure per the attending physician/surgeon standard practice.
62682438|NCT03621254|EXPERIMENTAL|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
62682439|NCT03621254|ACTIVE_COMPARATOR|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (\< 90-100 milliampere, patient dependent)
62682440|NCT04038008|OTHER|Sequence AB|13 subjects assigned to the sequence AB will receive a single 200 mg dose of test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 1 and a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
62682441|NCT04038008|OTHER|Sequence BA|13 subjects assigned to the sequence BA will receive a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in Period 1 and test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
62311890|NCT02562196|EXPERIMENTAL|optimized protocol chosen|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
62682442|NCT06694272||subjects with early or intermediate AMD (normal visual acuity)|"At inclusion patients will have :~* Measurements of subjective refraction, visual acuity, intraocular pressure, slit-lamp examination~* Measurement of low-luminance visual acuity~* Measurement of low-light contrast sensitivity~* Photometric (\> 30 cd/m² \> 10 min) and scotopic (DA \> 20 min) microperimetry~* Multifocal electroretinogram~* Imaging using fundus photography, OCT, OCT-A, adaptive optics and autofluorescence~* Venous blood sampling (48 mL)~After 4 years of follow-up, AMD evolution will be assessed with :~* Measurements of subjective refraction, visual acuity, intraocular pressure, slit-lamp examination~* Imaging by fundus photography, OCT, OCT-A, and autofluorescence"
62682443|NCT05544929|EXPERIMENTAL|Single-agent KFA115|KFA115 monotherapy
61922487|NCT02060448|EXPERIMENTAL|4wk baseline + reappraisal + (awareness)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
61922488|NCT02824172|EXPERIMENTAL|Cast immobilization|36 patients in the experimental cast immobilization
61922489|NCT02824172|ACTIVE_COMPARATOR|complete sport rest|36 patients in the complete sport rest group
62311891|NCT02562196|SHAM_COMPARATOR|sham tDCS|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
62311892|NCT06359249|NO_INTERVENTION|Control group|Habitual treatment
62311893|NCT06359249|EXPERIMENTAL|behavioural intervention group|Conductual treatment
62311894|NCT06359249|EXPERIMENTAL|behavioural intervention and massage group|Conductual and abdominal massage treatment
62311895|NCT02434887|EXPERIMENTAL|Experimental group|
62311896|NCT03475394|ACTIVE_COMPARATOR|Group 1 (Chlorhexidine gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 1% chlorhexidine gel administered in subsequent visits.
62311897|NCT03475394|EXPERIMENTAL|Group 2 (Morus alba gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 16% Morus alba gel administered in subsequent visits.
62311898|NCT03475394|PLACEBO_COMPARATOR|Group 3 (Placebo)|Non surgical periodontal treatment at baseline and 0.1 ml of placebo gel administered in subsequent visits.
62311899|NCT04850911|EXPERIMENTAL|Ketamine|Participants in this arm will receive a single intravenous, antidepressant dose of ketamine hydrochloride (0.5mg/kg)
62311900|NCT04850911|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride).
62682444|NCT05544929|EXPERIMENTAL|KFA115 run-in (1 cycle) + pembrolizumab|1-cycle KFA115 run-in followed by addition of pembrolizumab
62682445|NCT05544929|EXPERIMENTAL|KFA115 + pembrolizumab|KFA115 + pembrolizumab combination given concurrently
62682446|NCT05272579|EXPERIMENTAL|FFT treatment|Treatment with fecal filtrate transfer in saline solution administered by nasogastric tube
62682447|NCT05272579|PLACEBO_COMPARATOR|Placebo Treatment|Treatment with saline solution administered by nasogastric tube
62311901|NCT01355991|ACTIVE_COMPARATOR|Anticholinergic Agent|
62311902|NCT01355991|ACTIVE_COMPARATOR|Long Acting Beta 2 Agonist|
62311903|NCT01009463|EXPERIMENTAL|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62311904|NCT01009463|EXPERIMENTAL|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62311905|NCT01009463|EXPERIMENTAL|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62311906|NCT01009463|EXPERIMENTAL|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
62682448|NCT01395602|PLACEBO_COMPARATOR|placebo|placebo pill
62682449|NCT01395602|ACTIVE_COMPARATOR|cabergoline|cabergoline pill
61922490|NCT00531674|EXPERIMENTAL|1|Nutritional supplementation for pregnant and lactating women
61922491|NCT00531674|EXPERIMENTAL|2|Nutritional supplementation for children
62311907|NCT06508996||Capillary whole blood|Capillary whole blood from individuals with signs and symptoms and/or at-risk of HCV infection
62311908|NCT04115397|EXPERIMENTAL|Bisphophonate|Zolendronic acid, one infusion iv
62311909|NCT04115397|PLACEBO_COMPARATOR|Placebo|Placebo, one infusion iv
62311910|NCT04756895|EXPERIMENTAL|Bayesian method|Pharmacists will perform vancomycin dose adjustments according to AUC0-24h/MIC using the Bayesian method with a web application
62311911|NCT04756895|ACTIVE_COMPARATOR|Standard method|Pharmacists will perform vancomycin dose adjustments according to trough levels of vancomycin.
62311912|NCT00883194|EXPERIMENTAL|1|PRF-108 Gel, 4% ropivacaine
62311913|NCT00883194|PLACEBO_COMPARATOR|2|PRF-108 Gel, Vehicle
62311914|NCT00883194|ACTIVE_COMPARATOR|3|Ropivacaine Solution 0.5%
62311915|NCT00883194|EXPERIMENTAL|PRF-110, 4%|PRF-110, 4% ropivacaine
62311916|NCT03959618||dietary supplements group|dietary supplements questionary
62682450|NCT03052257|EXPERIMENTAL|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
62682451|NCT03052257|ACTIVE_COMPARATOR|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
62682452|NCT06690918||Oral cavity cancer group|The inclusion criterion was a confirmed diagnosis of oral cavity cancer undergoing surgical intervention. Patients with oral cancer resulting from metastasis from a primary tumor located in another organ were excluded.
62122797|NCT01422616|EXPERIMENTAL|Early intensive BP lowering|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents (e.g. Labetalol Hydrochloride, Metoprolol tartrate, Hydralazine Hydrochloride, Glycerol Trinitrate, Phentolamine mesylate, Nicardipine, Urapidil, Esmolol, Clonidine, Enalaprilat, Nitroprusside) will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA."
62682453|NCT06690918||Control group|The control group consisted of individuals attending the hospital for non-cancer-related conditions matched by age and sex to the case group.
62311917|NCT00623155|NO_INTERVENTION|1|Control group
62682454|NCT05726227|EXPERIMENTAL|Group Kids|Participants in the age group 6 to less than (\<) 12 years will receive once weekly subcutaneous (s.c.) injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
62682455|NCT05726227|EXPERIMENTAL|Group Teens|Participants in the age group 12 to \< 18 years will receive once weekly s.c. injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
62682456|NCT03000166|EXPERIMENTAL|Step-Up Intervention Group|Participants assigned to the Step-up intervention group will receive a 12-week physical activity intervention which includes components of education, negotiated collaboration to set individual physical activity goals during chemotherapy cycles, and tools for self-monitoring of physical activity.
62682457|NCT03000166|NO_INTERVENTION|Attention Control Group|Participants assigned to the attention control group will receive usual guidance about maintaining physical activity during chemotherapy from their oncology providers.
62682458|NCT03535987||Observational|To determine the feasibility of using myocardial PET imaging
62682459|NCT04250415||Operative Arm|
62682460|NCT04250415||Non-operative Arm|
62682461|NCT05816083|EXPERIMENTAL|Virtual Reality|All participants will receive the same intervention
62311918|NCT00623155|EXPERIMENTAL|2|Test group
62311919|NCT06671652|EXPERIMENTAL|Intervention|Participants will take part in a community building program in which Cherokee cultural, linguistic, and historical experts will met with the self-selected community groups approximately 1 x month for 5 months. Participants will complete homework assignments for each meeting and will complete a final presentation on the history and culture of their families and communities.
62311920|NCT03838250|EXPERIMENTAL|Cellgram™ (Bone marrow-derived MSCs)|Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10\^7 cells/10 mL (range: 4.5 x 10\^7 to 5.5 x 10\^7 cells/10 mL) via the hepatic artery.
62311921|NCT01618656|ACTIVE_COMPARATOR|PF-04457845|2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
62311922|NCT01618656|PLACEBO_COMPARATOR|Placebo (sugar pill)|1/3 of subjects will be randomized to placebo
62311923|NCT05661136|EXPERIMENTAL|Warm air blower|Intra-operative lower-body forced-air warming after spinal anesthesia and co-loading 1000 mL liters of IV warmed-fluids started prior to performing spinal anesthesia
62477194|NCT01777711|ACTIVE_COMPARATOR|Individual Condition|Couples randomized to the individual condition will be stratified on gender and one partner, chosen at random, will undergo the experimental manipulations and complete all study surveys while the other will not (heretofore called the active partner vs. the passive partner). The active partner will receive BMI feedback based on measurements taken during the intervention appointment, complete three surveys, and verbally state some goals and plans for weight loss to the passive partner. The passive partner will not complete any study materials or participate in the intervention during the session.
62477195|NCT03532035|EXPERIMENTAL|Brincidofovir (BCV)|"* Cohort 1: BCV 10 mg twice weekly via IV infusion over 2 hours~* Cohort 2: BCV 15 mg twice weekly via IV infusion over 2 hours~* Cohort 3: BCV In Cohort 3, the actual dose may be higher or lower than doses administered in previous cohorts; the maximum dose of IV BCV will be ≤ 25 mg."
62477196|NCT03532035|ACTIVE_COMPARATOR|Standard of Care (SoC)|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV Cidofovir (CDV), ganciclovir, or ribavirin."
62477197|NCT04932447|EXPERIMENTAL|Training Group A|Participants will perform their respiratory training (high-intensity, low-volume IMST) on a hand-held respiratory training device.
62477198|NCT04932447|SHAM_COMPARATOR|Training Group B|Participants will perform their respiratory training (low-intensity, low-volume IMST) on a hand-held respiratory training device.
62477199|NCT01105039||lap. hernia repair|undergoing laparoscopic groin hernia repair
62477200|NCT02505347|EXPERIMENTAL|No splint|will be able to move the arm as tolerated following surgery.
62477201|NCT02505347|ACTIVE_COMPARATOR|Splint|will receive a splint following surgery for 6 weeks.
62477202|NCT06464315|EXPERIMENTAL|Functional substrate mapping only without VT induction|In this experimental arm, only functional substrate mapping will be used to guide ablation of conduction slowing regions, without VT induction or mapping during VT. Ablation targets of conduction slowing will be identified as: 1) deceleration zones of conduction slowing, previously defined as 3 isochrones coalescing within 1cm radius. 2) wavefront discontinuities represented by lines of conduction block, previously defined as late potentials with at least 20ms of isoelectric segment, and 3) regions of slow conduction characterized by high peak frequency (220-500Hz), which uses spectral frequency analysis to identify signals with highest frequency as a surrogate for slow conduction. All regions exhibiting any of these 3 surrogates of slow conduction will be ablated.
62682462|NCT03537729|NO_INTERVENTION|Control|There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
62682463|NCT03537729|EXPERIMENTAL|Salient Cues|Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
62682464|NCT03537729|EXPERIMENTAL|Spaced retrieval education|This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.
62682465|NCT05836259|EXPERIMENTAL|Cohort 1|Dose for Cohort 1 will be 3E13 vg/kg
62682466|NCT05836259|EXPERIMENTAL|Cohort 2|Dose for Cohort 2 will be 6E13 vg/kg
62682467|NCT05445323|EXPERIMENTAL|Cohort 1/ Cohort 2/ Cohort 3|
62682468|NCT01386645|ACTIVE_COMPARATOR|Low GI diet|low glycemic index diet
62682469|NCT01386645|PLACEBO_COMPARATOR|High GI diet placebo|high glycemic index diet plus placebo
62682470|NCT01386645|ACTIVE_COMPARATOR|High GI diet NAC|high glycemic index diet plus N-acetylcysteine
62311924|NCT05661136|ACTIVE_COMPARATOR|Control|Co-loading of 1000 mL liters of IV warmed-fluids started prior to performing spinal anesthesia
62311925|NCT02044484|EXPERIMENTAL|Multi-component intervention|"Computer-based intervention (CBI) completed twice (separated by 2-4 months) among patients whose viral load exceeds 1000 copies/mL at time of enrollment.~One-on-one counseling from a project Health Coach (three 1-hour sessions at the clinic and two follow-up phone calls at 1 and 3 months after last session). The counseling is offered to patients who do not show a 1-log reduction in their viral load after the first CBI or whose viral load remains above 200 copies/mL after two administrations of the CBI.~Behavioral screening of patients at HIV primary care visits.~Dissemination of palm cards with empowering messages at HIV primary care visits."
62311926|NCT02044484|NO_INTERVENTION|Standard of care control|HIV patients will continue to receive existing standard of care practices at the clinic without receiving the multi-component intervention.
62682471|NCT06586957|EXPERIMENTAL|Dose Escalation|Dose escalation will assess the safety, efficacy, and PK/PD data of oral dosing NKT3964 at increasing dosage levels to determine the MTD and/or preliminary RDEs.
62682472|NCT06586957|EXPERIMENTAL|Dose Expansion|Dose expansion will include 2 RDEs selected to determine the preliminary antitumor activity and the RP2D.
62682473|NCT03495635|EXPERIMENTAL|BBBS Community-Based Mentoring|Big Brothers Big Sisters Community-Based Mentoring Program
62682474|NCT03495635|NO_INTERVENTION|Control|Not eligible to participate in a Big Brothers Big Sisters mentoring program, but may participate in other mentoring programs.
62682475|NCT06686264|EXPERIMENTAL|Core stability Group A|the core stability group includes core stability exercises along with the general back, pelvis and piriformis stretches
62682476|NCT06686264|ACTIVE_COMPARATOR|Traditional therapy group B|the traditional group includes general back, pelvis and piriformis stretches
62682477|NCT06311513|EXPERIMENTAL|Investigational Arm|Patients undergoing revision anterior cruciate ligament reconstruction surgery will get an intraoperative injection of concentrated bone marrow aspirate (cBMA).
62682478|NCT06311513|SHAM_COMPARATOR|Control Arm|Patients undergoing revision anterior cruciate ligament reconstruction surgery will get a sham incision in lieu of bone marrow harvesting.
62682479|NCT01045239|EXPERIMENTAL|Micropulse 577 nm yellow diode laser|
62477203|NCT06464315|ACTIVE_COMPARATOR|Standard VT Mapping|Standard-of-care mapping, including voltage mapping of intrinsic rhythm, entrainment, activation, and/or pace mapping, will be performed to guide VT ablation. Standard VT induction protocols will be performed.
62477204|NCT02963259||SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system|Subjects will be implanted with SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
62477205|NCT01631331|EXPERIMENTAL|Treatment (vismodegib and Mohs surgery)|Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
62477206|NCT06027528|EXPERIMENTAL|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket
62311927|NCT03977389||Population of the study|"Patient undergoing total wrist denervation between January 1995 and December 2013 at Brest CHRU, performed by the same senior surgeon.~Total wrist denervation is a routine procedure in orthopedic surgery for wrist arthritis."
62311928|NCT01570725|EXPERIMENTAL|1|Virtual reality exposure to a relaxing virtual environment. The virtual experience will be provided using immersive equipment.
62477207|NCT06027528|ACTIVE_COMPARATOR|dentin graft|extracted tooth will be grafted in the extracted socket
62477208|NCT03642808|EXPERIMENTAL|rehabilitation program|"* Duration of 8 weeks for a cycle of rehabilitation at the rate of two half-days per week~* Two interventions per half-day: 30 minutes of education and 1h30 of rehabilitation: physiotherapist, psychomotricity, adapted physical activity"
62477209|NCT03158467||Phase 1|
62477210|NCT03158467||Phase 2|
62477211|NCT03597256|EXPERIMENTAL|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
62311929|NCT01570725|EXPERIMENTAL|2|Exposure to relaxing music. The music will be selected between classical music tunes.
62311930|NCT00391638|EXPERIMENTAL|HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg|Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
62311931|NCT04762355|EXPERIMENTAL|Dose 1|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
62311932|NCT04762355|EXPERIMENTAL|Dose 2|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
62682480|NCT01045239|ACTIVE_COMPARATOR|532 nm green diode laser|
62477212|NCT03597256|NO_INTERVENTION|Control Group|No treatment
62477213|NCT03341182|ACTIVE_COMPARATOR|normal method group (group A)|A mirror is not used in tunnel view technique (conventional manner)
62477214|NCT03341182|EXPERIMENTAL|mirror use group (group B)|A mirror is used in tunnel view technique
62477215|NCT03437265|EXPERIMENTAL|PLENVU powder for oral solution|"Dose 1: Oral administration of 1 sachet (115.96 g) PLENVU Dose 1, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 1.~Dose 2: Oral administration of 2 sachets (101.91 g) comprising PLENVU Dose 2, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 2.~Additional water was permitted ad libitum during and after each dose."
62682481|NCT03600441|EXPERIMENTAL|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
62682482|NCT06686680|SHAM_COMPARATOR|Control Group: Sham ESWT Arm|All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 days to account for ongoing challenges for respiratory illness and scheduling/traveling conflicts. After collecting baseline variables and after blood is drawn, they will receive sham ESWT administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
62122798|NCT01422616|ACTIVE_COMPARATOR|Control / guideline-based BP management|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved."
62122799|NCT00988975|ACTIVE_COMPARATOR|Pelvicol graft|
62122800|NCT00988975|NO_INTERVENTION|No graft material|No graft material
62311933|NCT04762355|EXPERIMENTAL|Dose 3|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
62311934|NCT06658132|EXPERIMENTAL|remifentanil combined with esketamine|a novel anesthesia regimen of remifentanil combined with esketamine for the physiological testing phase of DBS surgery.
62682483|NCT06686680|EXPERIMENTAL|Treatment Group: ESWT Arm|All participants will review the exercise program prior to randomization and receiving treatment. Participants in the ESWT group will receive ESWT. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Radial and focused shockwave will be delivered to the knee and lower leg landmarks. The energy settings that will be used are consistent with mild to moderate ESWT which are commonly used in clinical practice to treat knee OA. During the ESWT treatment, a curtain will obscure participants from viewing their leg to blind them from treatment they are receiving. Standard protocol for the ESWT procedure will be followed, including safety assessment and monitoring. Additionally, the patient will be prescribed a post-ESWT exercise protocol that is part of the standard of care, which will be reviewed prior to first treatment and before treatment allocation is decided to minimize risk of bias.
62122801|NCT00773708|EXPERIMENTAL|1|intensify their triple-drug therapy with Raltegravir (RAL)
62122802|NCT00773708|NO_INTERVENTION|2|Continue with the same antiretroviral therapy
62122803|NCT05118581|EXPERIMENTAL|patients need vascular access|Arterial or venous cathetrization guided by ultrasound
62122804|NCT06400394|PLACEBO_COMPARATOR|Control group|Peritoneal lavage with normal saline 0.9% 1L and wound lavage with normal saline 0.9% 500ml
62122805|NCT06400394|EXPERIMENTAL|Study group|Peritoneal lavage with super-oxidised solution of at least 1L and wound lavage with super-oxidised solution of 500ml
62122806|NCT00226772|EXPERIMENTAL|OMS103HP irrigation solution|Drug
62122807|NCT00226772|PLACEBO_COMPARATOR|vehicle irrigation solution|Vehicle
62682484|NCT04846868|EXPERIMENTAL|Iclepertin arm|
62682485|NCT04846868|PLACEBO_COMPARATOR|Placebo arm|
62682486|NCT06687408||Lung cancer cohort of sleeve lobectomy in minimally invasive surgical approaches|This lung cancer cohort will retrospectively identify and enroll the participants with centrally located primary NSCLC receiving bronchial sleeve resection with or without pulmonary artery angioplasty in minimally invasive approaches (RATS or VATS) between January 2015 and September 2024 from the institutional databases. The choice of minimally invasive surgical approaches depends on the willingness of the surgeons and the participants in this study.
62122808|NCT02971176|EXPERIMENTAL|Low-dose protocol|Patients undergo low-dose protocol computed tomography-guided lung biopsy on day 1.
62122809|NCT02971176|ACTIVE_COMPARATOR|Standard-dose protocol|Patients undergo standard-dose protocol computed tomography-guided lung biopsy on day 1.
62122810|NCT05332366|EXPERIMENTAL|Delgocitinib - Delgocitinib|Participants will be blinded and randomised to delgocitinib cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
62122811|NCT05332366|PLACEBO_COMPARATOR|Placebo - Delgocitinib|Participants will be blinded and randomised to placebo cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
62122812|NCT05332366|NO_INTERVENTION|No treatment|Participants will not receive any treatment. They will only provide a molecular signature of healthy skin to act as a control.
62311935|NCT01709877|ACTIVE_COMPARATOR|Traditional multiport laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy performed by the traditional multiport technique
62311936|NCT01709877|EXPERIMENTAL|Single port laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using the reusable ENDOCONE system with dedicated curved coaxial instruments
62122813|NCT00831259||1|Incidence of silent stroke in patients with PFO
62122814|NCT00831259||2|Incidence of silent stroke in patients without PFO
62122815|NCT02514278|EXPERIMENTAL|Chemotherapy and Radiochemotherapy|"Neoadjuvant chemotherapy Folfirinox, 4 cycles:~* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2~Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)"
62122816|NCT02514278|ACTIVE_COMPARATOR|Radiochemotherapy|Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)
62122817|NCT00758810||1|Patients without cardiac rehabilitation
62122818|NCT00758810||2|Patients with cardiac rehabilitation
62122819|NCT04227288|EXPERIMENTAL|Enstilar Foam|Eligible subjects will be provided twice daily daily Enstilar Foam (calcipotriene and betamethasone dipropionate).
62122820|NCT01118377|EXPERIMENTAL|Capecitabine + radiation therapy|Participants received 9 weeks of capecitabine 650 mg/m\^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m\^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.
62122821|NCT04210505|EXPERIMENTAL|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.
62477216|NCT01442753|ACTIVE_COMPARATOR|Intervention Group|Families will be randomized to either receive the intervention (family-skills training) immediately. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
62477217|NCT01442753|ACTIVE_COMPARATOR|Control Group|Control group will receive the intervention (family-skills training) in approximately ten months. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
62477218|NCT01069536|ACTIVE_COMPARATOR|2 minutes bolus infusion|
62682487|NCT05658640|EXPERIMENTAL|Sub-study D|"Trametinib + dexamethasone + cyclophosphamide and cytarabine.~Each cycle lasts 28 days.~Cycle 1: Trametinib is given orally continuously once a day in tablets or oral formulation depending on the age and weight of the patient. Dexamethasone is given intravenously (IV)/orally on days 1 to 5. Cyclophosphamide is given IV on day 3. Cytarabine is given IV in two blocks of 4 days each one week apart from day 5.~Cycle 2 and subsequent cycles: Trametinib is given orally continuously once a day in tablets or oral formulation depending on the age and weight of the patient. Dexamethasone is given intravenously (IV)/orally on days 1 to 5. Cyclophosphamide is given IV on day 1. Cytarabine is given IV in two blocks of 4 days each one week apart from day 3.~Patients in dose level -1, receive only 1 block of cytarabine per cycle.~All patients receive age adapted intrathecal chemotherapy."
61922492|NCT03862040|EXPERIMENTAL|Cefiderocol|All participants were receiving standard of care (SOC) antibiotic treatment for pneumonia. Forty hours after the start of SOC treatment, participants will be administered 2 g doses of cefiderocol (or renally adjusted doses) infused intravenously over 3 hours, every 8 hours (or every 6 hours for participants with augmented renal function), for an expected minimum of 3 doses and up to a total of 6 doses in participants with normal renal function and participants with mild or moderate renal impairment, and for an expected minimum of 6 doses and up to a total of 9 doses in participants with severe renal impairment.
62122822|NCT04210505|NO_INTERVENTION|Concurrent Control|Standard of Care. This will be usual care at each hemodialysis center.
62311937|NCT04807153||Patients|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
62311938|NCT04807153||Healthy Controls|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
62311939|NCT02243124|ACTIVE_COMPARATOR|Group 1|cenersen IV infusion 0.3 mg/kg/day (0.1 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no Hematologic Improvement (HI) is observed.
62311940|NCT02243124|ACTIVE_COMPARATOR|Group 2|cenersen IV infusion 0.6 mg/kg/day (0.2 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
62311941|NCT02243124|ACTIVE_COMPARATOR|Group 3|cenersen IV infusion 1.2 mg/kg/day (0.4 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
62311942|NCT01104129||Control Group|Individual who has not had pancreatic cancer/IPMN; surgical resection for lesion of pancreas; history of colorectal, gastric cancer, esophageal, or head-and-neck cancer; administration of chemotherapy less than 1 week prior to enrollment; or an endoscopic procedure conducted less than 1 week prior to enrollment.
62311943|NCT01104129||Diagnosis of Pancreatic Cancer/IPMN|Patients diagnosed with Pancreatic Cancer/Intraductal Papillary Mucinous Neoplasm who are scheduled for surgical resection.
62311944|NCT05930249|NO_INTERVENTION|Standard health counseling|
62311945|NCT05930249|EXPERIMENTAL|Personalized multidomain intervention|
62311946|NCT05101421|EXPERIMENTAL|Treatment arm|To receive rice ceramide supplementation for 3 months
62311947|NCT02973672|EXPERIMENTAL|SGM-101|
62311948|NCT02891993|EXPERIMENTAL|IMPROVED Intervention|"* Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer.~* The clinical team will view reports detailing their patients' symptom burden~* Clinicians will be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
62477219|NCT01069536|ACTIVE_COMPARATOR|15 minutes slow infusion|
62477220|NCT06279039|EXPERIMENTAL|self half face control method|One side of the face was treated with exosome liquid dressing twice a day, and the other side was treated without exosome matrix for 2 weeks. The patients were followed up before treatment and 1, 3，7, 14, 28, and 56 days after treatment
62477221|NCT02838160|EXPERIMENTAL|booklet Group|
62122823|NCT00818805|EXPERIMENTAL|Olopatadine 0.1% one eye|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
62122824|NCT00818805|EXPERIMENTAL|Tranilast 0.5% one eye|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
62122825|NCT00818805|PLACEBO_COMPARATOR|Placebo (Olopatadine)|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
62311949|NCT02891993|ACTIVE_COMPARATOR|Usual Care|"* Patients randomized to Usual Care will self-report their symptoms each day using a tablet computer~* Patients will report their symptoms to their clinicians as they usually would~* Clinicians will not be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
62477222|NCT02838160|EXPERIMENTAL|Oral presentations group|
62477223|NCT02838160|EXPERIMENTAL|Clinical teaching in bedside Group|
62477224|NCT06283147|EXPERIMENTAL|RAMP Knee OA|"Patients allocated to the intervention group will continue their usual care at the GOPCs, plus enrolment into the RAMP-Knee OA program."
62477225|NCT06283147|NO_INTERVENTION|Usual Care group|"Patients allocated to the usual care arm will continue receiving their usual care at the GOPCs without any additional intervention. Usual care typically refers to the established and commonly provided treatments, interventions, and practices that patients would receive in routine clinical practice for their particular condition or disease. For GOPCs in Hong Kong, the follow-up period for all chronic diseases is typically every 4 months. Each consultation at GOPC has an average duration of 3-5 minutes, during which physicians will address all chronic diseases, including knee OA. Physicians may provide brief healthcare advice, prescribe chronic medications and analgesics if necessary, and refer patients to physiotherapy if indicated. The management approach for knee OA and other chronic diseases will be solely at the discretion of the attending physicians."
62477226|NCT03776058|EXPERIMENTAL|Cinacalcet|Participants received 65 mg cinacalcet orally twice a day for 4 weeks.
62122826|NCT00818805|PLACEBO_COMPARATOR|Placebo (Tranilast)|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
62122827|NCT06457178|EXPERIMENTAL|Acceptance and Commitment Therapy Based Intervention for Oncology Patients|Group 1 will participate in a 5-session Acceptance and Commitment Therapy-Based Intervention for Oncology Patients intervention program.
62122828|NCT06457178|ACTIVE_COMPARATOR|Psychoeducation for Oncology Patients|Group 2 will participate in a 5-session Psychoeducation for Oncology Patients program.
62122829|NCT06457178|NO_INTERVENTION|Routine Care|During this period, participants in group 3 will continue their routine treatment.
62122830|NCT05791812|EXPERIMENTAL|active treatment|2mA of tDCS for 20 min every weekday for six weeks
62122831|NCT01006824|EXPERIMENTAL|1|Capsule Endoscopy
62477227|NCT03776058|PLACEBO_COMPARATOR|Placebo|Participants received placebo to cinacalcet orally twice a day for 4 weeks.
62477228|NCT03853005|PLACEBO_COMPARATOR|Group A (controlled group)|They will not receive HVHDF treatment
62477229|NCT03853005|ACTIVE_COMPARATOR|Group B (HVHDF group)|They will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours. The survival status of all of the subjects were followed up at 28 days after being diagnosed as severe sepsis.
62682488|NCT06686329|EXPERIMENTAL|All participants|All participants will be in a single arm that undergoes three separate interventions. These interventions will include three different mealtime insulin administration: i) 15 minutes prior to eating, ii) post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM, and iii) the same conditions as ii) but with a 15-minute walk performed immediately after insulin administration.
61922493|NCT01630785||IONM patients|all patients where surgery requires IONM
62122832|NCT01006824|ACTIVE_COMPARATOR|2|Dedicated small bowel contrast radiography
62122833|NCT01061203|ACTIVE_COMPARATOR|Grazax|Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
62122834|NCT01061203|PLACEBO_COMPARATOR|Tablet with no active grass|Tablet with no active grass component. One tablet per day administered under the tongue.
62311950|NCT06220344|EXPERIMENTAL|Honey|Participants will get honey dressings in their follow-up visits to the dressing room.
62311951|NCT06220344|ACTIVE_COMPARATOR|Aseptic Iodine|Participants will get iodine solution dressings in their follow-up visits to the dressing room.
62682489|NCT05389150|EXPERIMENTAL|Group A: Pregabalin/ Tramadol Fixed dose|Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
62682490|NCT05389150|ACTIVE_COMPARATOR|Group B: Pregabalin (Lyrica®)|Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
62682491|NCT05389150|ACTIVE_COMPARATOR|Group C: Tramadol (Tradol®)|Pharmaceutical Form: Tablet Dosage: 50 mg Administration way: oral
62682492|NCT02277366||Fluorescence/Narrow Band Bronchoscopy|All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
62311952|NCT06207175|EXPERIMENTAL|Nonavalent HPV study vaccine|"Study vaccine: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) (Hereinafter referred to as Nonavalent HPV study vaccine)~Provided by: Beijing Health Guard Biotechnology, Inc.~Dosage: 0.5 mL per dose~Appearance: White, cloudy liquid suspension~Dosage form: 0.5-mL suspension for injection as a prefilled syringe~Route of administration: Intramuscular injection into the lateral deltoid muscle of the upper arm~Vaccination schedule in this study：3 injections on a 0, 2, 6-month schedule."
62682493|NCT02277366||Routine Bronchoscopy|All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.
62682494|NCT06272058|EXPERIMENTAL|Avenciguat (BI 685509) severe hepatic impairment (Child-Pugh C)|
62682495|NCT06272058|EXPERIMENTAL|Avenciguat (BI 685509) normal hepatic function|
62311953|NCT06207175|ACTIVE_COMPARATOR|GARDASIL® 9|"Control vaccine: GARDASIL® 9~Manufacturer: Merck Sharp and Dohme Corp (MSD).~Dosage: 0.5 mL per dose~Appearance: After thorough agitation, GARDASIL® 9 is a white cloudy liquid~Dosage form: 0.5-mL suspension for injection as a prefilled syringe~Route of administration: Intramuscular injection into the lateral deltoid muscle of the upper arm~Vaccination schedule：3 injections on a 0, 2, 6-month schedule."
62477230|NCT04550702||Women received Mirabegron|Women with overactive bladder syndrome received Mirabegron
62477231|NCT01686438|EXPERIMENTAL|CBT-I delivery by video teleconferencing|Groups of participants will receive a cognitive behavioral therapy for insomnia program delivered by a trained psychologist using video teleconferencing.
62477232|NCT01686438|ACTIVE_COMPARATOR|In-person CBT-I delivery|Groups of participants will receive a cognitive behavioral therapy for insomnia (CBT-I) program by meeting in-person with a trained psychologist.
62477233|NCT02184845|EXPERIMENTAL|NobelActive 3.0|
62477234|NCT01972490|EXPERIMENTAL|ARM A|patients received avastin in combination with mFOLFOX6
62477235|NCT01972490|ACTIVE_COMPARATOR|ARM B|Patients received mFOLFOX6 alone
62682496|NCT06681558|ACTIVE_COMPARATOR|Group Nasal Cannula|Oxygen will be administered to this group via a conventional nasal cannula.
62682497|NCT06681558|ACTIVE_COMPARATOR|Group Procedural Oxygen Mask|Oxygen will be administered to this group via a Procedural Oxygen Mask.
62682498|NCT05359016|EXPERIMENTAL|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
62682499|NCT03359395|ACTIVE_COMPARATOR|Alfentanil|
62682500|NCT03359395|PLACEBO_COMPARATOR|placebo|
62477236|NCT01863745|EXPERIMENTAL|nilotinib|The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
62477237|NCT01526174|EXPERIMENTAL|First Arm|Determine safety of intratympanic injection
62477238|NCT01526174|EXPERIMENTAL|Second Arm|Efficacy evaluation of 4 intratympanic injections
62311954|NCT06335238||Radiotherapy to abdominal-pelvic region|Collection of data of patients receiving RadioTherapy (RT) to abdominal-pelvic region
62311955|NCT04272307||Acute Severe Ulcerative Colitis group|
62311956|NCT04272307||Non-severe Ulcerative Colitis group|
62477239|NCT04201353|EXPERIMENTAL|Conditional Cash Transfer|Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (\~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.
62477240|NCT04201353|NO_INTERVENTION|Control|Participants attending control clinics will receive the standard of care.
62682501|NCT03772990|EXPERIMENTAL|Calcium chloride|Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass
62682502|NCT03772990|PLACEBO_COMPARATOR|0,9% Sodium Chloride|Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass
62682503|NCT06695208|EXPERIMENTAL|biodentine group|
62682504|NCT06695208|ACTIVE_COMPARATOR|xeno graft group|
62682505|NCT06152575|EXPERIMENTAL|Elranatamab|Participants will receive elranatamab monotherapy
62682506|NCT06152575|ACTIVE_COMPARATOR|Investigator's Choice|Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)
62682507|NCT04795453||assessment of usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
62682508|NCT04795453||assessment of score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
62682509|NCT04572841|EXPERIMENTAL|SAR441344|SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)
62682510|NCT04572841|PLACEBO_COMPARATOR|Placebo|Matching placebo
62477241|NCT04294303|EXPERIMENTAL|Telemonitoring|Subjects were assigned to web based telemonitoring system.
62477242|NCT04294303|OTHER|Control|Subjects were assigned to conventional monitoring.
62311957|NCT06338449|ACTIVE_COMPARATOR|Aerobic training (AT)|Aerobic exercise can include activities like swimming, running, or cycling. Scientifically, aerobic exercise is defined as any activity that uses large muscle groups, can be maintained continuously, and is rhythmic in nature. It improves the efficiency of the cardiovascular, respiratory, and circulatory systems by delivering oxygen more efficiently to the body. According to reports, aerobic exercise can help reduce fat and improve liver function.
62311958|NCT06338449|ACTIVE_COMPARATOR|Resistance training (RT)|Resistance exercise is a form of physical activity that is designed to improve muscular fitness by exercising a muscle or a muscle group against external resistance. This includes traditional weightlifting, using weight machines, resistance band exercises, bodyweight exercises, and other activities designed to build muscle strength, endurance, and size. The key principle is the muscle's ability to contract against resistance: using weights, resistance bands, or one's own body weight, the muscle is challenged, leading to muscular adaptation and growth, enhancing strength and endurance. According to reports, resistance exercise can also help improve liver function.
62311959|NCT06338449|ACTIVE_COMPARATOR|Combined aerobic and resistance training (AT + RT)|The combination of aerobic exercise and resistance exercise.
62311960|NCT06672913|NO_INTERVENTION|Pre education|The infants born at less than 32 weeks and discharged from the units in the last two months before training.
62311961|NCT06672913|ACTIVE_COMPARATOR|Post education|The infants born at less than 32 weeks and discharged between four to six months after training
62311962|NCT02042131|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|"TAU includes the following intervention components:~1. suicide risk assessment~2. supportive listening~3. provision of professional and crisis contact information~4. referral to mental health treatment and community resources~5. verbal contract for safety"
62311963|NCT02042131|EXPERIMENTAL|Standard Crisis Response Plan (S-CRP)|"CRP includes the following intervention components:~1. suicide risk assessment~2. supportive listening~3. identify personal warning signs~4. identify self-management skills~5. identify social support contacts~6. provision of professional and crisis contact information~7. referral to mental health treatment and community resources"
62311964|NCT02042131|EXPERIMENTAL|Enhanced Crisis Response Plan (E-CRP)|"The E-CRP includes the following intervention components:~1. suicide risk assessment~2. supportive listening~3. identify personal warning signs~4. identify self-management skills~5. identify reasons for living~6. identify social support contacts~7. provision of professional and crisis contact information~8. referral to mental health treatment and community resources"
62311965|NCT04045223||Epidural analgesia and fever|Group 1 will be patients with vaginal delivery and having an epidural analgesia that develop fever during delivery.
62311966|NCT04045223||Epidural analgesia and no fever|Group 2 will be patients with vaginal delivery and having an epidural analgesia that do not develop fever during delivery.
62311967|NCT04045223||No epidural analgesia|Group 3 serves as additional control group and consists of patients having no epidural analgesia and no fever.
62311968|NCT00083824|PLACEBO_COMPARATOR|Sugar Pill|Placebo
62311969|NCT00083824|EXPERIMENTAL|Estrogens, Conjugated (USP)|Conjugated Equine Estrogen 0.625 mg/day for 3 years, drug
62311970|NCT00083824|EXPERIMENTAL|Medroxyprogesterone 17-acetate|Conjugated Equine Estrogen 0.625 mg/day plus Medroxyprogesterone Acetate 2.5 mg/day
62311971|NCT06673394|OTHER|IVMP arm|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
62477243|NCT01138891||Removed breast implants for any reason|
62477244|NCT06380816|EXPERIMENTAL|Module A (UCB4594 monotherapy dose escalation)|Participants with advanced solid tumours from tumour types with known high levels of HLA-G expression (as reported in the literature) will be recruited.
62477245|NCT06380816|EXPERIMENTAL|Module B (UCB4594 monotherapy expansion)|Participants with a specific tumour type where HLA-G expression is more prevalent may be recruited to receive UCB4594 monotherapy.
62477246|NCT03256695|EXPERIMENTAL|ABS eMDPI|Participants will receive 90 micrograms (mcg) of albuterol sulfate (ABS) via eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks. ABS eMDPI is a rescue/reliever agent that includes an eModule on top of the approved PROAIR RESPICLICK® inhaler. Participants will be allowed to continue use of other COPD and non-COPD medications as advised by their physician without changes unless deemed necessary by their physician.
62477247|NCT04226248|ACTIVE_COMPARATOR|Active (Rivastigmine)|Rivastigmine Transdermal Patches
62477248|NCT04226248|PLACEBO_COMPARATOR|Placebo|Placebo Matched Transdermal Patches
62477249|NCT04454229|EXPERIMENTAL|Direct oral antibiotic challenge|Direct oral antibiotic (penicillin) challenge in patients with PEN-Fast less than 3.
62477250|NCT04454229|ACTIVE_COMPARATOR|Standard of care|Standard of care: skin testing and, if negative, oral challenge.
62477251|NCT05287763|ACTIVE_COMPARATOR|Gelatin Sponge|The palatal wound will be protected with an absorbable gelatin sponge, which will be stabilized by non-resorbable sling sutures.
62682511|NCT06695611|ACTIVE_COMPARATOR|Higher pre-dialysis blood pressure target (150-170 mm Hg systolic) (as a unit-level policy)|The approach to reach blood pressure target is up to the treating physician. Depending on baseline pre-dialysis systolic blood pressure, blood pressure may need to be raised or lowered to reach the target.
62682512|NCT06695611|EXPERIMENTAL|Lower pre-dialysis blood pressure target (110-140 mm Hg systolic) (as a unit-level policy)|The approach to reach blood pressure target is up to the treating physician. Depending on baseline pre-dialysis systolic blood pressure, blood pressure may need to be raised or lowered to reach the target.
62139644|NCT04586348|ACTIVE_COMPARATOR|Standard Iodine Supplement|Iodine (potassium iodide) 200 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
62311972|NCT06673394|ACTIVE_COMPARATOR|eculizumab arm|Eculizumab arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline). Terminal complement complex inhibition by eculizumab predisposes patients to infections by encapsulated bacteria, especially N meningitidis. Meningococcal vaccination will not be effective in this timeframe; instead, all enrolled patients will receive antibiotic prophylaxis against N meningitidis from the time of the first dose of the study drug to 8 weeks after the last administration
62311973|NCT02112266|OTHER|no mail support|no mail support during follow-up
62682513|NCT05799625|NO_INTERVENTION|Usual Care|Eligible smokers randomized to usual care will receive an educational brochure for the University of Ottawa Heart Institute's Ottawa Model for Smoking Cessation (OMSC) Community Program. The brochure will include information about the OMSC Community Program and how to register for it to receive assistance to quit smoking.
62311974|NCT02112266|OTHER|mail support|
62311975|NCT03341468|EXPERIMENTAL|Urethral catheter immobilization|Subjects randomized to the intervention group will undergo radical prostatectomy with placement of the urethral catheter per the standard of care. The urethral catheter immobilization device will be applied in the operating room prior to the patient being transported to the recovery room. Subjects will be informed on safe use of the device and must demonstrate competency in removing and replacing the device prior to discharge. Subjects will also be given an elastic leg strap, which they may use concurrently with the device. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care, at which the device will no longer be needed.
62477252|NCT05287763|EXPERIMENTAL|Collagen Sponge|The palatal wound will be protected with a collagen sponge, which will be stabilized by non-resorbable sling sutures.
62477253|NCT03463226||Low testosterone|"Patients with HF and testosterone deficiency.~* Cardiopulmonary exercise test~* Muscle Sympathetic Nerve Activity~* Dual-energy X-ray absorptiometry~* Venous occlusion plethysmography~* Blood sample collection~* Dynamometers for Handgrip Strength"
61922494|NCT04997590|EXPERIMENTAL|Umbilical cord blood mononuclear cells group|Umbilical cord blood mononuclear cells (cell number 1×108/2mL), once every two weeks, 3 times in total.
61922495|NCT04997590|ACTIVE_COMPARATOR|Staphylococcal Enterotoxin C group|Staphylococcal enterotoxin C (2mL), once every two weeks, 3 times in total.
61922496|NCT01954147|EXPERIMENTAL|SC-GLP-1|Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide
62311976|NCT03341468|NO_INTERVENTION|No urethral catheter immobilization|Subjects randomized to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care.
62682514|NCT05799625|EXPERIMENTAL|Intervention|Eligible smokers randomized to the intervention group will be asked to download the StepOne smartphone application onto their smartphone via the Apple Store or Google Play Store. They will be provided with a unique ID and unique code, which will enable them to log into the StepOne smartphone application to begin the 14-day program. Users will interact with the application in the morning and evening; the exact time of the engagement is selected by the participant and ideally at a time that maximizes the likelihood of engaging with the activity. The application incorporates interactive educational material, daily reminders, gamification, and models of habit formation to engage users. As with any other smartphone application, users can turn off notifications if they choose to do so. New content and activities will be shared daily.
62682515|NCT05886881||Air Optix Aqua Sphere|Lotrafilcon B spherical soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
62311977|NCT01855789|EXPERIMENTAL|Non-Randomized Participants (TCZ + MTX)|All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score \</=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
62311978|NCT01855789|EXPERIMENTAL|Randomized Participants (TCZ + MTX)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score \</=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
62311979|NCT01855789|ACTIVE_COMPARATOR|Randomized Participants (TCZ + PBO)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score \</=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
62311980|NCT05734872|EXPERIMENTAL|Experimental group|
62311981|NCT05734872|OTHER|Control group|
62311982|NCT03546374|EXPERIMENTAL|Primary Cohort|Patients with a history of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal atrial fibrillation) who are undergoing concomitant cardiac surgery
62311983|NCT01373177|ACTIVE_COMPARATOR|BSID-II, then Bayley-III|Receive BSID-II testing 4-8 weeks before Bayley-III testing
62477254|NCT03463226||Normal testosterone|"Patients with HF and normal plasma levels of testosterone.~* Cardiopulmonary exercise test~* Muscle Sympathetic Nerve Activity~* Dual-energy X-ray absorptiometry~* Venous occlusion plethysmography~* Blood sample collection~* Dynamometers for Handgrip Strength"
62682516|NCT05886881||Air Optix plus HydraGlyde Sphere|Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
62477255|NCT01109290||HED children|
62682517|NCT05886881||Air Optix plus HydraGlyde Toric|Lotrafilcon B toric soft contact lenses with comfort additive worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
61922497|NCT01954147|EXPERIMENTAL|SC|Umbilical Cord Mesenchymal Stem Cell Infusion
61922498|NCT01954147|EXPERIMENTAL|GLP-1|Liraglutide
61922499|NCT01954147|ACTIVE_COMPARATOR|Control|Standard Medical Treatment
61922500|NCT03310320|PLACEBO_COMPARATOR|Placebo|Placebo for AZD0284 oral solution
62311984|NCT01373177|ACTIVE_COMPARATOR|Bayley-III, then BSID-II|Receive Bayley-III testing 4-8 weeks before BSID-II testing
61922501|NCT03310320|EXPERIMENTAL|AZD0284|AZD0284 oral solution 2.5 mg/mL
61922502|NCT02859506|EXPERIMENTAL|liver transplant|
61922503|NCT02859506|ACTIVE_COMPARATOR|kidney transplant|
61922504|NCT02859506|PLACEBO_COMPARATOR|control|
61922505|NCT02859506|ACTIVE_COMPARATOR|stable liver damage|
61922506|NCT02715778||Adult Participants|
61922507|NCT02715778||Child Participants|
61922508|NCT02906462|OTHER|Usual Practices|Usual Practices
62311985|NCT06598397|NO_INTERVENTION|Condition 1|Participants will receive the Core Component.
62311986|NCT06598397|EXPERIMENTAL|Condition 2|Participants will receive the Core Component and Combination-NRT intervention.
62311987|NCT06598397|EXPERIMENTAL|Condition 3|Participants will receive the Core Component and Text Messaging intervention.
62311988|NCT06598397|EXPERIMENTAL|Condition 4|Participants will receive the Core Component as well as the Combination-NRT and Text Messaging interventions.
62311989|NCT06598397|EXPERIMENTAL|Condition 5|Participants will receive the Core Component and Peer Mentoring intervention.
62477256|NCT01109290||HED adults|
62477257|NCT01109290||Control children|
62477258|NCT01109290||Control adults|
62682518|NCT05886881||Biofinity Sphere|Comfilcon A spherical soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
62311990|NCT06598397|EXPERIMENTAL|Condition 6|Participants will receive the Core Component as well as the Combination-NRT and Peer Mentoring interventions.
62311991|NCT06598397|EXPERIMENTAL|Condition 7|Participants will receive the Core Component as well as the Text Messaging and Peer Mentoring interventions.
62682519|NCT05886881||Biofinity Toric|Comfilcon A toric soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
62311992|NCT06598397|EXPERIMENTAL|Condition 8|Participants will receive the Core Component as well as the Combination-NRT, Text Messaging and Peer Mentoring interventions.
62311993|NCT06598397|EXPERIMENTAL|Condition 9|Participants will receive the Core Component and Motivational Interviewing Counseling intervention.
62682520|NCT06295159|EXPERIMENTAL|Part 1, Arm A: Nivolumab|PD-L1 positive patients will be given Nivolumab 480 mg I.V. over 30 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for 2 a total of 2 cycles.
62682521|NCT06295159|EXPERIMENTAL|Part 1, Arm B: Nivolumab- Relatlimab-rmbw|PD-L1 negative patients will be given a combination of Nivolumab 480 mg with Relatlimab 160 mg I.V. over 60 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.
62682522|NCT06295159|EXPERIMENTAL|Part 1, Arm C: Nivolumab plus ipilimumab|PD-L1 negative patients will be given 3 mg/kg of Nivolumab plus 1 mg/kg of Ipilimumab I.V. each given over 30 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.
62682523|NCT06295159|EXPERIMENTAL|Part 2, Arm A: Ipilimumab + Nivolumab-Relatimab-rmbw|"Systemic therapy naïve locoregionally advanced melanoma patients will be given the fixed dose combination of 480 mg of nivolumab with 160 mg of relatlimab I.V. over 60 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.~In addition, a single dose of 1 mg/kg ipilimumab I.V. will be given on C1D1."
62311994|NCT06598397|EXPERIMENTAL|Condition 10|Participants will receive the Core Component as well as the Combination-NRT and Motivational Interview Counseling interventions.
62311995|NCT06598397|EXPERIMENTAL|Condition 11|Participants will receive the Core Component as well as the Text Messaging and Motivational Interview Counseling interventions.
62311996|NCT06598397|EXPERIMENTAL|Condition 12|Participants will receive the Core Component as well as the Combination-NRT, Text Messaging and Motivational Interview Counseling interventions.
62311997|NCT06598397|EXPERIMENTAL|Condition 13|Participants will receive the Core Component as well as the Peer Mentoring and Motivational Interview Counseling interventions.
62311998|NCT06598397|EXPERIMENTAL|Condition 14|Participants will receive the Core Component as well as the Combination-NRT, Peer Mentoring and Motivational Interview Counseling interventions.
62311999|NCT06598397|EXPERIMENTAL|Condition 15|Participants will receive the Core Component as well as the Text Messaging, Peer Mentoring and Motivational Interview Counseling interventions.
62312000|NCT06598397|EXPERIMENTAL|Condition 16|Participants will receive the Core Component as well as the Combination-NRT, Text Messaging, Peer Mentoring, and Motivational Interview Counseling interventions.
62312001|NCT01258829|EXPERIMENTAL|Non-invasive haemodynamic optimisation|Optimization of pressure production by the heart, as measured by systolic blood pressure in the systemic circulation
62682524|NCT06295159|EXPERIMENTAL|Part 2, Arm B1: Triplet Combination Therapy Ipilmumab + Nivolumab-Relatlimab-rmbw|"Patients with locoregionally advanced melanoma that is refractory to systemic adjuvant therapy will be given the fixed dose combination of 480 mg of nivolumab with 160 mg or relatlimab I.V. over 60 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.~In addition, a single dose of 1 mg/kg ipilimumab I.V. will be given on C1D1."
62682525|NCT06295159|EXPERIMENTAL|Part 2, Arm B2: Doublet Combination Therapy Nivolumab-Relatlimab-rmbw|Patients with locoregionally advanced melanoma that is refractory to systemic adjuvant therapy will be given the fixed dose combination of 480 mg of nivolumab with 160 mg of relatlimab I.V. over 60 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.
62122835|NCT04308330|EXPERIMENTAL|Vorinostat|"The first cycle of chemotherapy will not include the experimental agent vorinostat. This first cycle will be used to determine whether the patient can tolerate the chemotherapeutic backbone without developing a DLT.~Cycle 1~* Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.~* Temozolomide: 125 mg/m2/day PO Days 1-5.~* Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.~* Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.~Cycles 2-12~* Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.~* Temozolomide: 125 mg/m2/day PO Days 1-5.~* Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.~* Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.~* Vorinostat: Dose per escalation schema daily Days 1-5.~* Vorinostat will not be administered during Cycle 1."
62312002|NCT01258829|ACTIVE_COMPARATOR|ECHO optimisation|Optimization of AV/VV delay using the guideline recommendations
62312003|NCT05153408|EXPERIMENTAL|Part 1A: BLU-701 as monotherapy|Phase 1 dose escalation of BLU-701 as monotherapy at various dose levels
62312004|NCT05153408|EXPERIMENTAL|Part 1B: BLU-701 with osimertinib|BLU-701 in combination with osimertinib 40 mg or 80 mg tablets for oral administration
62682526|NCT05745883|EXPERIMENTAL|Phase 1b Single Dose|Single dose of DISC-0974
62682527|NCT05745883|PLACEBO_COMPARATOR|Single Dose of Placebo|Single dose of placebo
62312005|NCT05153408|EXPERIMENTAL|Part 1C: BLU-701 with platinum-based chemotherapy|"BLU-701 in combination with platinum-based chemotherapy (carboplatin and pemetrexed):~Carboplatin - IV infusion dosed to target AUC of 5-6 mg/mL min q3w~Pemetrexed - IV infusion dosed to 500 mg/m2 q3w"
62312006|NCT05153408|EXPERIMENTAL|Part 2A: BLU-701 as monotherapy|Phase 2 expansion group for BLU-701 as monotherapy at a dose determined during Part 1A in patients harboring the EGFR C797X resistance mutation
62682528|NCT05745883|EXPERIMENTAL|Phase 1b Multiple Doses|Multiple doses of DISC-0974
62682529|NCT05745883|PLACEBO_COMPARATOR|Multiple Doses of Placebo|Multiple doses of placebo
62682530|NCT01871194||Rivaroxaban|This is a non-interventional study
62682531|NCT01871194||Alternative anticoagulant therapy|This is a non-interventional study
62682532|NCT06232252|EXPERIMENTAL|Dose group (DG) 1 (very low dose)|
62682533|NCT06232252|EXPERIMENTAL|Dose group (DG) 2 (low dose)|
62682534|NCT06232252|EXPERIMENTAL|Dose group (DG) 3 (medium dose)|
61922509|NCT02906462|OTHER|Early consideration of vulnerability|Strategy promoting early consideration of patients' vulnerability
62682535|NCT06232252|EXPERIMENTAL|Dose group (DG) 4 (high dose)|
62682536|NCT05950659|EXPERIMENTAL|Intervention|
62682537|NCT05950659|NO_INTERVENTION|Control|
62682538|NCT06691711|EXPERIMENTAL|Immediate intervention|Those allocated to the immediate arm will be offered the ASIRE support package over a 10 week period immediately post randomisation. The caregiver will be provided with access to all module resources and supported through the programme by a trained practitioner (their ASPIRE facilitator) who offers information, advice and encouragement during the intervention period (providing up to 8 support sessions in total).
62682539|NCT06691711|NO_INTERVENTION|Waitlist|Participants randomised to the waitlist arm will not be denied access to any support or treatment available as part of current service provision during the waiting period. Both young people and parents/carers will be encouraged to continue engaging with any support they already receive and can be referred/self-refer to additional services as required. After the 10-week waiting period is complete, participants randomised to this arm will be offered the ASPIRE intervention as described above.
62682540|NCT06499948|EXPERIMENTAL|Succession no.1: Spironolactone followed by Dapagliflozin followed by the combined therapy arm|"The patients will be randomized to receive either Spironolactone or Dapagliflozin on top of standard therapy (stable doses of renin-angiotensin-system inhibitors) in a crossover trial design (4 weeks of treatment followed by 4 weeks of wash-out). Finally, the whole cohort will receive both Spironolactone and Dapagliflozin for another 4 weeks.~Treatment succession no.1 description: (1)1st treatment period - patients will receive Spironolactone 25 mg od on top of standard for 4 weeks; (2) 1st washout-period - treatment with Spironolactone will be stopped for 4 weeks; (3) 2nd treatment period - patients will receive Dapagliflozin 10 mg od for 4 weeks; (4) 2nd washout-period - treatment with Dapagliflozin will be stopped for 4 weeks; (5) 3rd treatment period - patients will receive Spironolactone 25 mg od plus Dapagliflozin 10 mg od for 4 weeks; (6) 3rd washout-period - treatment with Spironolactone and Dapagliflozin will be stopped for 4 weeks."
62737702|NCT06517069|EXPERIMENTAL|TEAS|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction; The same amount of normal saline was injected intravenously 5 minutes before anesthesia induction.
61922510|NCT05808283||Those with anemia according to WHO definition (Group 1)|
61922511|NCT05808283||Those without anemia according to WHO definition (Group 2)|
62312007|NCT06316089|EXPERIMENTAL|PrEPared For Release|Intervention arm
62312008|NCT06316089|NO_INTERVENTION|Standard of Care|Control arm
62312009|NCT03312946|EXPERIMENTAL|Treatment oscillating vibro|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks. Being performed twice a week, with a total duration of 50 minutes to the session, being 10 sessions total to end the treatment.
62477259|NCT00003470|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62477260|NCT03887910|EXPERIMENTAL|Enhanced Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and referrals and developmental toys.
62682541|NCT06499948|EXPERIMENTAL|Succession no.2: Dapagliflozin followed by Spironolactone followed by the combined therapy arm|"The patients will be randomized to receive either Spironolactone or Dapagliflozin on top of standard therapy (stable doses of renin-angiotensin-system inhibitors) in a crossover trial design (4 weeks of treatment followed by 4 weeks of wash-out). Finally, the whole cohort will receive both Spironolactone and Dapagliflozin for another 4 weeks.~Treatment succession no.2 description: (1) 1st treatment period - patients will receive Dapagliflozin 10 mg od on top of standard for 4 weeks; (2) 1st washout-period - treatment with Dapagliflozin will be stopped for 4 weeks; (3) 2nd treatment period - patients will receive Spironolactone 25 mg od for 4 weeks; (4) 2nd washout-period - treatment with Spironolactone will be stopped for 4 weeks; (5) 3rd treatment period - patients will receive Spironolactone 25 mg od plus Dapagliflozin 10 mg od for 4 weeks; (6) 3rd washout-period - treatment with Spironolactone and Dapagliflozin will be stopped for 4 weeks."
62312010|NCT03877185||3-Injection-Protocol Group|Women in group A (3-Injection-Protocol Group) receive a bolus late luteal dose of Degarelix, a new long acting GnRH antagonist, a sole Elonva injection in the early follicular phase followed by the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to the individual response).
62312011|NCT03877185||Multiple-Injection- Protocol Group|Women assigned to group B (Multiple- Injection- Protocol Group) are administered a single dose of Elonva (corifollitropin alfa) in the early follicular phase followed by daily GnRH antagonist doses, either fixed on day 6 of the stimulation cycle, or when 2 or 3 follicles over 12-14 mm are present. Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a, accordingly.
62312012|NCT02457052|EXPERIMENTAL|DATP +|Introduction of a device allowing a custom sitting to help patients with swallowing disorders .
62477261|NCT03887910|EXPERIMENTAL|Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and developmental screening and parent guides only.
62477262|NCT03887910|NO_INTERVENTION|Control|Usual care with developmental toys.
62682542|NCT03163264|EXPERIMENTAL|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
62682543|NCT03163264|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
62682544|NCT06675903||Diabetes|Diabetes group defined as type 2 diabetes, type 1 diabetes, receiving glucose-lowering therapy, FPG ≥ 7 mmol/l, HbA1c ≥ 48mmol/l or non-fasting plasma glucose ≥11.1 mmol/l
62682545|NCT06675903||No diabetes|No diabetes defined as HbA1c \<42mmol/mol or FPG\<6.1 mmol/L
61922512|NCT01639586|ACTIVE_COMPARATOR|D|Impact of the day care on health profit of patient
62122836|NCT03782350|EXPERIMENTAL|Tranexamic Acid Dosage 1|A bolus of 30 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 16 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 2 mg/kg.
62122837|NCT03782350|ACTIVE_COMPARATOR|Tranexamic Acid Dosage 2|A bolus of 10 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 2 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 1 mg/kg.
62122838|NCT01983371|EXPERIMENTAL|Ferumoxytol-enhanced MRI|This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.
62312013|NCT02457052|NO_INTERVENTION|DATP -|No introduction of a device allowing a custom sitting to help patients with swallowing disorders .
62312014|NCT03271255|EXPERIMENTAL|Arm Apatinib|"Apatinib-FOLFIRI:~Apatinib Mesylate Tablets 500 mg po qd; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
62477263|NCT03372187|EXPERIMENTAL|DIET-MS|This group will follow a low glycemic load diet plan prescribed to them by a health coach and will receive information on exercise as well. This group will have weekly calls with the telehealth coach and will be provided access to the eHealth platform.
62477264|NCT02364713|EXPERIMENTAL|Arm A (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62477265|NCT02364713|ACTIVE_COMPARATOR|Arm B (DOXIL, GEM, TOPA, TAXOL)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15, or paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may also receive bevacizumab IV over 30-90 minutes on days 1 and 15 with pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, or paclitaxel. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62477266|NCT04343196|EXPERIMENTAL|Group A: Low-dose DVA group|Image acquisition at a reduced X-ray dose, 0.36 µGy/frame (70% reduction) image processing by DVA
62477267|NCT04343196|ACTIVE_COMPARATOR|Group B: Normal-dose DSA group|Image acquisition at a normal dose (1.2 µGy/frame) image processing by DSA
62477268|NCT06555913|EXPERIMENTAL|Maitland Mobilization and Scapular Stabilization|This group included twenty patients suffering from shoulder disability following NDS (modified radical, selective). They received Maitland mobilization Technique and scapular stabilization exercises in addition to the traditional physical therapy program which included (ROM exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months.
62477269|NCT06555913|EXPERIMENTAL|Maitland Mobilization|This group included twenty patients suffering from shoulder disability following NDS (modified radical, selective). They received Maitland mobilization Technique in addition to the traditional physical therapy program which included (ROM exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months.
62682546|NCT06675903||Prediabetes|Prediabetes group defined as HbA1c 42-47 mmol/mol or FPG 6.1-6.9 mmol/L
62682547|NCT01314248||children weighing 10 to 15 kg|
62682548|NCT03917498|EXPERIMENTAL|Single Pre-Operative Radiation Therapy with Delayed Surgery|Single Pre-Operative Radiation Therapy with Delayed Surgery
62122839|NCT05957900|NO_INTERVENTION|Control group|Preterm neonates will receive only routine care of the unit.
62682549|NCT06688591|EXPERIMENTAL|Medication-management intervention programme to reduce the risks of MRPs|The research nurse will help the older participant and their informal caregiver to implement their target education plan (t2) aimed at empowering their medication management and promoting their active engagement in reducing the risks of MRPs
62122840|NCT05957900|EXPERIMENTAL|Multi-Sensory Stimulation group|"In the present study, it is defined as the application of tactile, visual, vestibular, kinesthetic, olfactory, auditory and oral stimulation to preterm neonates to enhance their development.~The intervention will be provided daily in mourning, quiet alert state of neonate, before feeding for 30 min., 5 days per week for two weeks."
62682550|NCT03615326|EXPERIMENTAL|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
62682551|NCT03615326|ACTIVE_COMPARATOR|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
62312015|NCT03271255|ACTIVE_COMPARATOR|Arm Bevacizumab|"Bevacizumab-FOLFIRI:~Bevacizumab Injection 5 mg/kg IV over 30 minutes,day 1; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
62682552|NCT05766254|EXPERIMENTAL|Active TMS|Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined prefrontal target for a total of 1000 pulses. Within each of the two TMS sessions, two targets will be stimulated.
62682553|NCT05766254|SHAM_COMPARATOR|Sham TMS|Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
62682554|NCT06687135|EXPERIMENTAL|KOKU|"A maximum of 196 participants will be recruited to participate in the study, across sites in Greater Manchester and Lancashire, UK.~Participants will be randomised into either;~* the experimental group (n=98); who will receive the KOKU intervention or~* the control group (n=98); who will receive the FaME/ OTAGO exercise and falls prevention information leaflets without KOKU."
62682555|NCT06687135|ACTIVE_COMPARATOR|FaME/OTAGO|"A maximum of 196 participants will be recruited to participate in the study, across sites in Greater Manchester and Lancashire, UK.~Participants will be randomised into either;~* the experimental group (n=98); who will receive the KOKU intervention or~* the control group (n=98); who will receive the FaME/ OTAGO exercise and falls prevention information leaflets without KOKU."
62682556|NCT06355778|OTHER|Opioid use disorder (OUD) group|This group takes buprenorphine and has OUD.
62682557|NCT06355778|OTHER|Buprenorphine (BUP) control group:|This group takes BUP and does not have OUD.
62122841|NCT01551056|EXPERIMENTAL|AC-170 0.24%|
62122842|NCT01551056|PLACEBO_COMPARATOR|AC-170 0%|
62122843|NCT05997836|OTHER|Wave 1|Study design is a stepped wedge; Wave 1 begins by receiving Implementation Facilitation
62122844|NCT05997836|OTHER|Wave 2|Study design is a stepped wedge; Wave 2 begins by receiving Centralized Technical Assistance before crossing over to Implementation Facilitation
62312016|NCT04022369|EXPERIMENTAL|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. Education program based on Empowerment model. Weekly motivational telephone interviews were conducted with the patients, and the home visits and telephone interviews were repeated when belived necessary. The purpose of the study were explained to all individuals involved in the study. Body movements, balance levels, exercise durations, and strengths of individuals before exercise program and after exercise program were evaluated. A booklet demonstrating the exercises was given to the patients to enhance their understanding, and they were allowed to ask questions about the exercise program during the training.
62477270|NCT06555913|EXPERIMENTAL|Scapular Stabilization|This group included twenty patients suffering from shoulder disability following NDS (modified radical, selective). They received scapular stabilization exercises in addition to the traditional physical therapy program which include (ROM exercises, stretching exercises and strengthening exercises for shoulder muscles) 3 sessions per week, for 2 months.
62682558|NCT06355778|OTHER|Healthy Controls group|This group does not take BUP and does not have OUD.
62682559|NCT01122368|EXPERIMENTAL|1 Micafungin|IV
62682560|NCT01122368|PLACEBO_COMPARATOR|2 Placebo|IV
62682561|NCT06686693|EXPERIMENTAL|Placebo|Placebo - saline
62682562|NCT06686693|EXPERIMENTAL|Intravenous iron|Iron - Injectafer 15 mg/kg up to 1000 mg
61922513|NCT01639586|ACTIVE_COMPARATOR|C|No access to a respite structure
62122845|NCT05997836|OTHER|Wave 3|Study design is a stepped wedge; Wave 3 begins by receiving Centralized Technical Assistance before crossing over to Implementation Facilitation
62122846|NCT05997836|OTHER|Wave 4|Study design is a stepped wedge; Wave 4 begins by receiving Centralized Technical Assistance before crossing over to Implementation Facilitation
62122847|NCT04901312|EXPERIMENTAL|Enhanced A-CRA (E-ACRA)|Higher intensity
62122848|NCT04901312|EXPERIMENTAL|Assertive Community Support (ACS)|Lower intensity
62122849|NCT02988817|EXPERIMENTAL|Enapotamab vedotin (HuMax-AXL-ADC)|Participants in all cohorts of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC) intravenously (IV).
62122850|NCT03474822|EXPERIMENTAL|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 30 patients in each type cancer and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites. The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
62122851|NCT00393848|EXPERIMENTAL|Experiment 2 - Experimental Group|
61922514|NCT01639586|ACTIVE_COMPARATOR|B|Respite platform
62682563|NCT05626608|EXPERIMENTAL|Directional|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
62682564|NCT05626608|ACTIVE_COMPARATOR|Conventional ring (Monopolar and Bipolar)|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
62682565|NCT05696782|EXPERIMENTAL|Quick Start Durvalumab|Standard of care test and procedures for cancer treatments along with Durvalumab treatment at physician's discretion
61922515|NCT03092804||normal pressure hydrocephalus|"Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both~The NPH patients will undergo the CSF tap test and then receive the ventriculo-peritoneal shunting surgery. They will have the examination of brain constructure neuroimaging and functional MRI prior to and posterior to the shunting."
61922516|NCT03092804||normal control|Healthy volunteers will undergo the examination of brain constructure and functional MRI.
61922517|NCT01847911|EXPERIMENTAL|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
62122852|NCT00393848|NO_INTERVENTION|Experiment 1 - Standard of care Group|
62122853|NCT00393848|EXPERIMENTAL|Experiment 1 - Experimental Group|
62122854|NCT00393848|PLACEBO_COMPARATOR|Experiment 2 - Placebo Group|
62122855|NCT06674486|EXPERIMENTAL|Group I - Receive test product first and then reference product|
62312017|NCT04022369|NO_INTERVENTION|Control Group|The patients in the control group continued their standard treatment and care. Data collection forms were applied to the patients in the control group at the first month and 12 weeks after discharge. After the study was completed, all patients in the control group were provided with home-based exercise training booklets.
62312018|NCT06302634||Center-Based Cardio-Oncology Rehabilitation (CBCORe)|Therapeutic exercise program supervised by a physiotherapist. 2 days/week, duration 1h, in the Cardiac Rehabilitation ward.
62312019|NCT06302634||Home-Based Cardio-Oncology Rehabilitation (HBCORe)|Recommendation of physical exercise and motivational interview through telephone follow-up every 2 weeks by the physiotherapist.
62312020|NCT04580719||Patiente|Patients aged 18 to 50, presenting menstrual cycles, consulting in the obstetrics and gynecology department of the University Hospital of Reims whatever the reason for consultation can participate in the study after signing the consent of no opposition. Participation in the study will not change the patient's medical management.
62477271|NCT01019421|EXPERIMENTAL|Lu AE58054|
62477272|NCT01019421|PLACEBO_COMPARATOR|Placebo|
62477273|NCT03998150|ACTIVE_COMPARATOR|HoLEP holmium laser enucleation of the prostate|holmium laser enucleation of the prostate
62477274|NCT03998150|ACTIVE_COMPARATOR|BPEP bipolar plasmakinetic enucleation of the prostate|bipolar plasmakinetic enucleation of the prostate
62477275|NCT06103058||Positive for fibromyalgia|26.5% prevalence of fibromyalgia
62682566|NCT02505672||Study group|Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma.
61922518|NCT01847911|ACTIVE_COMPARATOR|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
62122856|NCT06674486|EXPERIMENTAL|Group II - Receive reference product first and then test product|
62122857|NCT01177696|EXPERIMENTAL|psychotherapy|"The study aims to evaluate the effectiveness of an intervention of psychotherapy in improving the mental health of caregivers.~This intervention is based on theoretical approaches to care adjusted to cognitive theory, in order to be applied in primary health care centres."
62122858|NCT01177696|NO_INTERVENTION|Control|
62122859|NCT01501188|EXPERIMENTAL|Kinesio taping|Specific type of muscle and joint taping
62682567|NCT02350998|EXPERIMENTAL|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
62682568|NCT06343792|EXPERIMENTAL|RLS-0071Cohort 1|10 mg/kg Q8H RLS-0071 for 7 days
62682569|NCT06343792|EXPERIMENTAL|RLS-0071 Cohort 2|40 mg/kg Q8H RLS-0071 for 7 days
62682570|NCT06343792|EXPERIMENTAL|RLS-0071 Cohort 3|10 mg/kg Q8H RLS-0071 for 14 days with concurrent ruxolitinib
62682571|NCT06343792|EXPERIMENTAL|RLS-0071 Cohort 4|40 mg/kg Q8H RLS-0071 for 14 days with concurrent ruxolitinib
62122860|NCT01501188|PLACEBO_COMPARATOR|Kinesio taping placebo|Kinesio taping placebo
62312021|NCT05965713|EXPERIMENTAL|BCI treatment Group using the IpsiHand|"Phase 1: Group 1 subjects will receive an IpsiHand Screening System to complete a remote EEG Screening. Subjects will undergo an EEG screening protocol to ensure that a consistent control signal will be present to control the IpsiHand device. After an EEG screening session is complete, the participants screening data will be analyzed to ensure that sufficient cortical signals are present. Randomization for assignment to group 1 or 2 will then occur. Once assigned to group 1, if consistent signals are found, the participant will then continue to Phase 2.~Phase 2: Group 1 subjects will be provided with a Neurolutions IpsiHand BCI system, which combines a novel powered exoskeleton with a commercial EEG amplifier and active electrode system. The exoskeleton opens and closes the patient's hand in a three-finger pinch grip. Patients will use the BCI system on a minimum of 5 days per week for 12 weeks. Patients will complete five or more 10-minute runs of the BCI task per day."
62312022|NCT05965713|EXPERIMENTAL|Standard of Care - Home Exercise Program for Upper Extremity|"Phase 1: Group 1 subjects will receive an IpsiHand Screening System to complete a remote EEG Screening. Once randomized, the participant will be assigned to group 2 to begin standard of care treatment at home.~Phase 2: After being assigned to Group 2, subjects will serve as the control group in the study. Subjects will receive a customized home range of motion exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks to control for the non-specific motor and sensory effects of BCI training. To help ensure compliance with the at-home portion of the protocol in the control group, participants will receive daily virtual monitoring from the study clinical specialist."
62312023|NCT00402350|PLACEBO_COMPARATOR|Placebo|Subjects (2) from each of the 4 dose escalation arms
62682572|NCT06343792|EXPERIMENTAL|RLS-0071 Cohort 5|10 mg/kg Q8H RLS-0071 for 7 days and then 10 mg/kg QD RLS-0071 for 7 days with concurrent ruxolitinib
62682573|NCT06343792|EXPERIMENTAL|RLS-0071 Cohort 6|40 mg/kg Q8H RLS-0071 for 7 days and then 40 mg/kg QD RLS-0071 for 7 days with concurrent ruxolitinib
62682574|NCT06343792|EXPERIMENTAL|RLS-0071 Expansion Cohort 1|12 participants will receive 10 or 40 mg/kg Q8H RLS-0071 for 7 or 14 days
62682575|NCT06343792|EXPERIMENTAL|RLS-0071 Expansion Cohort 2|12 participants will receive 10 or 40 mg/kg Q8H RLS-0071 for 7 or 14 days
62682576|NCT06585696|ACTIVE_COMPARATOR|Botox®|CU-20101 treatment for Moderate to Severe Glabellar Striae
62122861|NCT03071653|ACTIVE_COMPARATOR|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
62122862|NCT03071653|OTHER|OMT only|Optimal Medical Therapy (OMT) only
62682577|NCT06585696|EXPERIMENTAL|CU-20101|CU-20101 treatment for Moderate to Severe Glabellar Striae
62682578|NCT06694610|EXPERIMENTAL|non-pulmonary vein ablation group|In the non-pulmonary vein ablation group, pulmonary vein isolation was not allowed, but the left atrial low-voltage area was treated first, and then the ablation route that terminated the reentry ring was treated.
62682579|NCT06694610|ACTIVE_COMPARATOR|only pulmonary vein ablation group|In the group treated with only pulmonary vein ablation route, only potential isolation of pulmonary vein was performed, and bidirectional block was the end point.
62682580|NCT06691568|ACTIVE_COMPARATOR|Active|Purifiers were active during cat allergen exposure
62682581|NCT06691568|PLACEBO_COMPARATOR|Placebo|Purifiers were inactive during cat allergen exposure
62682582|NCT04267926|PLACEBO_COMPARATOR|Placebo|Placebo
62682583|NCT04267926|ACTIVE_COMPARATOR|20mg of MitoQ|20mg of oral mitoquinol
62682584|NCT04267926|ACTIVE_COMPARATOR|40mg of MitoQ|40mg of Oral Mitoquinol
62682585|NCT06690879||addictive smart phone group|addictive smart phone users with cervicogenic headache
62682586|NCT06690879||non addictive smart phone group|non addictive smart phone users not complaining of cervicogenic headache
62682587|NCT06686472|ACTIVE_COMPARATOR|TL-925 Arm|Subjects will be dosed in clinic.
62122863|NCT02549170|EXPERIMENTAL|Epoch 1: HYQVIA/HyQvia|Participants received HYQVIA/HyQvia (rHuPH20) 80 U/g IG, following by SC injection of immunoglobulin (IGI) 10% at the same monthly equivalent IG dose as the individual participant's pre-randomized IG dose when administered every 2, 3, or 4 weeks for 30.28 weeks or until relapse.
62122864|NCT02549170|PLACEBO_COMPARATOR|Epoch 1: Placebo with rHuPH20|Participants received rHuPH20 80 U/I0 mL placebo solution, followed by SC placebo infusion at matching infusion volume as the participant's pre-randomization monthly equivalent IG dose when administered every 2, 3, or 4 weeks for 31.54 weeks or until relapse.
62682588|NCT06686472|PLACEBO_COMPARATOR|Placebo Arm|Subjects will be dosed in clinic.
62682589|NCT05416281|EXPERIMENTAL|Robotic Vacuum Intervention|This will include a home visit for environmental assessment AND a robotic vacuum intervention. Silicone wristbands will be used to evaluate exposure before and after a cleaning intervention.
62682590|NCT05416281|NO_INTERVENTION|No Intervention|This will include a home visit for environmental assessment.
62682591|NCT05797649||Heart Failure-Associated Pleural Effusion|Patients with pleural effusion with an underlying aetiology of heart failure
62682592|NCT05797649||Control group|Patients with pleural effusion due to exudative, or non-fluid overload causes
62682593|NCT03128710||Survey Group|Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment.
61922519|NCT00955227|NO_INTERVENTION|Statins only|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. Patients in this arm will be excluded if they are on ezetimibe.
62682594|NCT03128710||Focus Group|Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation.
62737703|NCT06517069|EXPERIMENTAL|Oxycodone|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Stick electrodes only but do not stimulate; Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
62312024|NCT00402350|EXPERIMENTAL|25 mcg IV and Inhaled Crossover|Single dose crossover (IV vs Inhaled)
62312025|NCT00402350|EXPERIMENTAL|Inhaled fentanyl 25 mcg x 2|Inhaled Staccato fentanyl, 25 mcg x 2
62312026|NCT00402350|EXPERIMENTAL|Inhaled fentanyl 25 mcg x 4|Inhaled Staccato fentanyl, 25 mcg x 4
62122865|NCT02549170|EXPERIMENTAL|Epoch 2: E1: Placebo Relapse - E2: GGL/KIOVIG|Participants who were enrolled to receive placebo with rHuPH20 and achieved chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) relapse during Epoch 1 received the induction dose of GGL/KIOVIG 2 g/kg bi-weekly (BW), followed by IV infusion at the same monthly equivalent dose as the participant's pre-randomization IGIV dosing regimen when administered every 3 weeks for 25.63 weeks or until relapse.
62122866|NCT02549170|EXPERIMENTAL|Epoch 2: E1: HYQVIA Relapse - E2: GGL/KIOVIG|Participants who were enrolled to receive HYQVIA/HyQvia (rHuPH20) and achieved CIDP relapse during Epoch 1 received the induction dose of GGL/KIOVIG 2 g/kg BW, followed by IV infusion at the same monthly equivalent dose as the participant's pre-randomization IGIV dosing regimen when administered every 3 weeks for 28.67 weeks or until relapse.
62312027|NCT00402350|EXPERIMENTAL|Inhaled fentanyl 25 mcg x 6|Inhaled Staccato fentanyl, 25 mcg x 6
62312028|NCT00402350|EXPERIMENTAL|Inhaled fentanyl 25 mcg x 12|Inhaled Staccato fentanyl, 25 mcg x 12
62312029|NCT02976467|EXPERIMENTAL|Fulacimstat (BAY1142524)|30 patients with left-ventricular dysfunction after acute myocardial infarction
62312030|NCT02976467|PLACEBO_COMPARATOR|Placebo|30 patients with left-ventricular dysfunction after acute myocardial infarction
62312031|NCT05712031|EXPERIMENTAL|Group2|Mandibular first or second premolar is combined with standard length(8-12mm) dental implants to support 3 unit Fixed Partial Dentures
62312032|NCT05712031|EXPERIMENTAL|Group3|Mandibular first or second premolar is combined with short dental implants(5-6mm) to support 3 unit Fixed Partial Dentures
62312033|NCT05712031|ACTIVE_COMPARATOR|Group1|Standard length (8-12mm) dental implants are inserted in posterior mandible replacing either first premolar and first molar or second premolar and second molar to support 3 unit fixed partial dentures.
62122867|NCT02549170|EXPERIMENTAL|Epoch 2: E1: Placebo Relapse - E2: GAMMUNEX-C|Participants who were enrolled to receive placebo with rHuPH20 and achieved CIDP relapse during Epoch 1 received the induction dose of GAMMUNEX-C 2 g/kg BW, followed by IV infusion at the same monthly equivalent dose as the participant's pre-randomization IGIV dosing regimen when administered every 3 weeks for 24.33 weeks or until relapse.
62122868|NCT01304849|EXPERIMENTAL|Primary|Patients with aHL will receive 2 cycles of ABVD and undergo interim PET-2 scan- those with positive scans will receive 4 additional cycles of Esc BEACOPP while those with negative scans will receive 4 additional cycles of ABVD.
62312034|NCT06672796|ACTIVE_COMPARATOR|CG|8 weeks, stretching exercise
62312035|NCT06672796|ACTIVE_COMPARATOR|SEG|8 weeks, stretching exercise and toe spread out standart protocol
62312036|NCT06672796|EXPERIMENTAL|REG|8 weeks, stretching exercise and resisted concentric and eccentric contraction protocol of toe spread out exercise
62312037|NCT02348567|ACTIVE_COMPARATOR|announced hospital surveys|Eleven hospitals will receive announced surveys (control group)
62312038|NCT02348567|EXPERIMENTAL|unannounced hospital surveys|12 hospitals will receive unannounced surveys (intervention group).
62312039|NCT02547194||No touch vein grafts|The grafts were harvested with there surrounding tissues.
62312040|NCT02547194||Conventional vein grafts.|The grafts were stripped from surrounding tissue.
62682595|NCT06690528|EXPERIMENTAL|Surgical Resection Arm|Patients in this arm will undergo surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
62682596|NCT06690528|NO_INTERVENTION|Palliative care arm|Patients in this arm will continue to be treated following palliative care, consisting in observation or continuation of chemotherapy according to investigator's choice and duration of first-line chemotherapy. If required, they will continue with systemic chemotherapy, as received during the initial treatment phase, with a chemotherapy protocol based on the Institution's approved guidelines and adjusted as for clinician's choice.
62682597|NCT00930800|OTHER|Exercise|Dance Dance Revolution (DDR)
62682598|NCT06522503|EXPERIMENTAL|intervention|
62682599|NCT06522503|NO_INTERVENTION|control|
61922520|NCT00955227|ACTIVE_COMPARATOR|Statins and ezetimibe|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. In addition, these patients will be on ezetimibe.
62312041|NCT02965703|EXPERIMENTAL|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
62312042|NCT02965703|EXPERIMENTAL|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
62312043|NCT02965703|PLACEBO_COMPARATOR|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
62312044|NCT05153395|EXPERIMENTAL|Insulin (Doppler)|Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
62312045|NCT05153395|EXPERIMENTAL|Insulin (MRI)|Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
62312046|NCT05153395|OTHER|Time Control (Doppler)|Time control only
62682600|NCT06313346|EXPERIMENTAL|Probiotic group|Subjects will consume one capsule of probiotic, daily, during 6 weeks.
62682601|NCT06313346|PLACEBO_COMPARATOR|Placebo group|Subjects will consume one capsule of placebo, daily, during 6 weeks.
62682602|NCT04238182|ACTIVE_COMPARATOR|wet cupping|smokers in this group will receive single wet cupping session
62682603|NCT04238182|ACTIVE_COMPARATOR|dry cupping|smokers in this group will receive single dry cupping session
62477276|NCT06103058||Negative for fibromyalgia|26.5% prevalence of fibromyalgia
62312047|NCT05250115||Evaluate the effectiveness, usage and patient characteristics of real-world use of Abrocitinib|"This is a 60-month, prospective, non-interventional, multicenter study to evaluate the effectiveness, usage and patient characteristics of abrocitinib in patients with moderate to severe AD in a real-world setting.~Eligible patients will be followed up from the date of first Abrocitinib prescription for 12 months. from the date of enrollment. Patients who are switched from the initial abrocitinib therapy to other therapies continue to be observed. Patient documentation is expected quarterly as per standard clinical practice."
62312048|NCT06508567|EXPERIMENTAL|2xHDR Brachytherapy|Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed recurrence after Postoperative Radiotherapy.
62312049|NCT03421847||Major Depression Group|We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography
62477277|NCT06561568|ACTIVE_COMPARATOR|Conventional physical therapy (exercise therapy) group|"Group A will receive this conventional physical therapy protocol for chondromalacia patellae~* they will perform stretches to warm up and cool down. Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~* Frequency: 3 times a week for 4 weeks."
62477278|NCT06561568|EXPERIMENTAL|Kinesio taping + Conventional physical therapy group|"Group B will be given kinesio taping with conventional physical therapy protocol for chondromalacia patellae.~.Kinesio tape will be applied on Vastus medialis Oblique and around the patella.~• Frequency: 3 times a week for 4 weeks. They will perform stretches to warm up and cool down. Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~Frequency: 3 times a week for 4 weeks."
62682604|NCT04493203|EXPERIMENTAL|Nivolumab plus Axitinib|"Nivolumab 480mg, IV, every 4 weeks, for up to two years.~Axitinib 5mg, PO, BID, for up to two years."
62682605|NCT05978232|EXPERIMENTAL|Navigator-Assisted Hypofractionation (NAVAH)|"This pilot cohort study is designed as follows:~1. Navigator discussion with patients prior to the start of radiation therapy simulation (15-30 minutes).~2. Navigator administration of survey with patients after completion of radiation therapy simulation but before the start of radiation therapy (30-45 minutes)~3. Navigator administration of post-treatment survey and financial toxicity survey instrument after the completion of radiation therapy (60 minutes)."
62682606|NCT05273437|EXPERIMENTAL|System Identification|All participants in the study will go through a system identification experiment everyday for 270 days.
62682607|NCT06691347|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing|Patients will receive EMDR as their main treatment method of PTSD. EMDR processes trauma memories while engaging in bilateral stimulation to help rewire the brain's response to trauma and decrease emotional distress.
62682608|NCT06691347|EXPERIMENTAL|Cognitive Therapy for PTSD|Patients will receive CT-PTSD as their main treatment method of PTSD. CT-PTSD focuses on techniques such as cognitive restructuring and exposure therapy to help individuals reframe trauma and reduce intrusive memories and emotional distress.
62312050|NCT03421847||Healthy Control Group|We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography.
62312051|NCT03946566||Acupuncture group|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
62312052|NCT03946566||Basic treatment group|Use basic treatments, such as western medicine.
62312053|NCT04476771|NO_INTERVENTION|TAU + waiting list|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
62312054|NCT04476771|EXPERIMENTAL|TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
62682609|NCT00359398|EXPERIMENTAL|Platelet sequestration|Sequestration of platelet rich plasma before cardiopulmonary bypass
62682610|NCT00359398|NO_INTERVENTION|Standard care|No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
62477279|NCT03911258|EXPERIMENTAL|Nasal flora in CF patient|
62477280|NCT03070119|EXPERIMENTAL|BIIB067|Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
62477281|NCT00272519|EXPERIMENTAL|Adolescent/caregiver dyads|Eight to ten adolescent/caregiver dyads
62682611|NCT03973489|EXPERIMENTAL|Wild Type (WT) MUD Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
62122869|NCT04301635||Preoperative (Pre-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, preoperative
62122870|NCT04301635||Postoperative (Post-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, postoperative
62682612|NCT03973489|EXPERIMENTAL|Common Variant (CV) MUD Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the valine codon occurring at amino acid position 288, designated V288V, SNP on the TAAR1 gene
62682613|NCT03973489|EXPERIMENTAL|Wild Type (WT) Healthy Control Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
62312055|NCT01385696|EXPERIMENTAL|group A|Genuair first, HandiHaler second
62312056|NCT01385696|EXPERIMENTAL|group B|HandiHaler first, Genuair second
62312057|NCT00955110|EXPERIMENTAL|Oxymorphone ER 15 mg|15mg
62312058|NCT00955110|ACTIVE_COMPARATOR|Oxycodone CR 30 mg|30mg
62312059|NCT00955110|PLACEBO_COMPARATOR|Placebo|
62312060|NCT00955110|EXPERIMENTAL|Oxymorphone ER 30mg|30mg
62477282|NCT02836821|EXPERIMENTAL|Apatinib|subjects receiving a single 750 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then rifampicin capsules 600 mg/day orally for 10 days with a single 750 mg oral dose of apatinib mesylate tablets co-administered on day 8 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
62477283|NCT03353896|EXPERIMENTAL|Treatment (medical device)|Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours QD. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.
62682614|NCT03973489|EXPERIMENTAL|Common Variant (CV) Healthy Control Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
62682615|NCT04195685|EXPERIMENTAL|NFB Intervention and Delayed Intervention|The NFB system will read and interpret a participant's brain wave pattern which will be instantaneously fed back to the participant providing information, to which a participant can respond accordingly. The NFB specialist assumes a coaching role with people training on the NFB special use system to assist in the achievement of a focused relaxed state, which enhances the overall brain functioning. The significance and unique aspect of NFB is the direct impact on physiological dysregulation, which is the basis of this treatment approach. Twenty, one-hour, NFB training sessions will be provided to each participant in the intervention group and Delayed intervention group (those participants who completed the Control Group activities) by a trained NFB specialist over an 8-10-week period. Participants in the intervention group will receive up to 5-sessions but usually 3 sessions a week
62682616|NCT04195685|NO_INTERVENTION|Control Group|Participants in the control group will continue with their usual treatment and will receive a 15-minute call once a week for eight weeks from an Investigator on a health topic. This will help to keep members of the control group engaged in the project and receive the same information that is offered to the intervention group members. The health topics that are generally discussed during NFB sessions include sleep hygiene, basic nutritional concepts, beverage choices, positive thinking, thought reframing, fitness, daily calming activity, and enhancement of focus strategies.
62682617|NCT03004677|EXPERIMENTAL|Continuous skin-to-skin contact|Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
62682618|NCT03004677|ACTIVE_COMPARATOR|Standard Care|Infants and parents will receive standard care provided in the NICU
62682619|NCT05013905|EXPERIMENTAL|PRA023|Participants to receive PRA023 administered by intravenous (IV) infusion.
62682620|NCT06659341|EXPERIMENTAL|Dose escalation|During dose escalation, at each dose level BAY3498264 monotherapy will be administered for 7 days as a safety run-in, prior to introduction of a combination agent (sotorasib) for 21-day treatment cycles. Intra-participant dose escalation will be implemented: participants will be able to move to a cohort offering a higher dose level of BAY3498264 provided protocol-specified criteria are met.
61922521|NCT00955227|EXPERIMENTAL|Statins and flax oil only|In this arm- 15 Patients receiving standard statin treatment as determined by their cardiologist will also receive two flaxseed oil capsules/day each containing 500 mg of ALA.
62312061|NCT00955110|ACTIVE_COMPARATOR|Oxycodone CR 60mg|60mg
62477284|NCT02895373|EXPERIMENTAL|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
62477285|NCT02895373|PLACEBO_COMPARATOR|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
62477286|NCT05264363|EXPERIMENTAL|Intervention|The main intervention is the application of the Investigational Medical Device (VIPUN Gastric Monitoring System prototype) together with the reference device (solid state high-resolution manometry) to record intraluminal pressure. The planned procedures are identical for all subjects in this single-arm investigation.
62312062|NCT03085732|ACTIVE_COMPARATOR|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
62312063|NCT03085732|NO_INTERVENTION|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
62312064|NCT06120738||smartphone addiction group|smartphone addiction will be assessed using smartphone addiction scale short version(SAS-SV) evaluation of trunk muscles performance using isokinetic dynamometer
62312065|NCT04799782|ACTIVE_COMPARATOR|Mirtazapine|The drug will be taken for a one week peroid.
62477287|NCT06039735||Patients diagnosed with previous untreated multiple myeloma|Patients diagnosed multiple myeloma by bone marrow cytology without previous chemotherapy and/or hematopoietic stem cell transplantation
62477288|NCT04820309|EXPERIMENTAL|KarXT|
61922522|NCT00955227|EXPERIMENTAL|Statins and ezetimibe and flax oil|In this arm- 15 Patients with heart disease and hypercholesterolemia that are on standard statin treatment as determined by their cardiologist, will also receive (as an intervention) ezetimibe and flaxseed oil capsules containing 500mg of ALA.
62312066|NCT04799782|PLACEBO_COMPARATOR|Placebo|The drug will be taken for a one week peroid.
62312067|NCT04596657|EXPERIMENTAL|Intervention|
62312068|NCT04596657|NO_INTERVENTION|Control|
62312069|NCT06274359|EXPERIMENTAL|Digital storytelling group|Caregivers will receive a series of digital stories by text message designed to increase influenza vaccine confidence.
62312070|NCT06274359|NO_INTERVENTION|Control group|Caregivers will receive standard care.
62312071|NCT03876340|ACTIVE_COMPARATOR|Current treatment|Patients will receive burn care treatment as dictated by the surgical team (current standard of care).
62312072|NCT03876340|EXPERIMENTAL|Algorithm-dictated treatment|Patients will receive burn care treatment as dictated by the treatment algorithm (PLOS ONE 13(11): e0206477.).
62312073|NCT05738616|EXPERIMENTAL|lenvatinib combined with TACE and camrelizumab|
62312074|NCT05738616|ACTIVE_COMPARATOR|lenvatinib combined with TACE|
62312075|NCT01665781|EXPERIMENTAL|Erythropoietin|Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
62122871|NCT04688801|ACTIVE_COMPARATOR|Chemotherapy± Radiotherapy Group|Chemotherapy± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
62312076|NCT01665781|NO_INTERVENTION|Control|No erythropoietin
62312077|NCT06235151|EXPERIMENTAL|Diagnostic Imaging with Copper Cu 64 PSMA I&T|Copper Cu 64 PSMA I\&T Injection
62312078|NCT02140320|EXPERIMENTAL|Single dose (healthy volunteers)|
62312079|NCT02140320|EXPERIMENTAL|14 day repeat dose (healthy volunteers)|
62312080|NCT02140320|EXPERIMENTAL|14 day repeat dose (asthma patients)|
62312081|NCT02140320|EXPERIMENTAL|28 day repeat dose (healthy volunteers)|
62312082|NCT06096194|EXPERIMENTAL|vitamin D3-enhanced egg|The experimental group consumed an vitamin D3-enhanced egg (\~ 400 IU). The randomization unit was the take care SEDESOL centers. All children in 3 day-care centers were given one vitamin D3-enhanced egg at breakfast, 3 times a week for 12 weeks (Monday, Wednesday and Friday).
62312083|NCT06096194|PLACEBO_COMPARATOR|Control|The control group consumed unfortified egg (\~ 43 IU Vitamin D). The randomization unit was the 6 day-care centers (SEDESOL). All children in 3 day-care centers were given unfortified egg at breakfast, 3 times a week for 12 weeks (Monday, Wednesday and Friday).
62312084|NCT01679834||Cohort|
62312085|NCT00425438|EXPERIMENTAL|Mycophenolate Mofetil|Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
62312086|NCT00425438|ACTIVE_COMPARATOR|Cyclophosphamide/Azathioprine|Participants received cyclophosphamide 0.75 grams per square meter (g/m\^2), intravenously (IV), every 4 weeks from Weeks 1 through 4, and 0.5 to (-) 1.0 g/m\^2, IV, to maintain a minimum white blood cell (WBC) count of greater than or equal to (≥) 2500 per cubic millimeter (mm\^3) every 4 weeks from Weeks 5 through 24. Participants also received azathioprine 100 mg, PO, daily for participants with a body weight of 50 to 70 kg and 150 mg, PO, daily for subjects with a body weight of more than 70 kg from Weeks 25 through 48. Participants also received prednisolone 0.75 to 1.0 mg/kg, PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
62312087|NCT05557474||Lung cancer post surgery recurrence follow up|Lung adenocarcinoma, stage IA/IB/II/IIIA post-surgery follow up
62312088|NCT02940665||Enhanced Recovery After Surgery (ERAS)|ERAS group followed the ERAS protocol. The protocol was implemented 13 months prior to the start of data collection.
62312089|NCT02940665||Conventional|Conventional group received conventional care.
62312090|NCT00875771|EXPERIMENTAL|1|"* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~* Bevacizumab: 5 mg/kg day 1, every 2 Weeks"
62312091|NCT04098614|EXPERIMENTAL|Recovery Coach Intervention|"Experimental: Recovery Coach Intervention Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR)~- Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants."
62312092|NCT04098614|NO_INTERVENTION|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
62312093|NCT01534832|EXPERIMENTAL|Smoke clearance|Smoke clearance device active
62682621|NCT06659341|EXPERIMENTAL|Backfill cohorts|Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, PK, and PD data to facilitate the selection of the optimal doses for use in further development.
62682622|NCT06659341|EXPERIMENTAL|Exploratory expansion cohorts|Exploratory expansion cohorts may be recruited to provide additional safety, PK/PD, and efficacy data.
62312094|NCT06273865||Healthy volunteers|
62312095|NCT06273865||Hemophilia A patient|
62312096|NCT02360943||PEAGE|Patients older than 75 years receiving an anticoagulant treatment for a symptomatic and confirmed PE
62312097|NCT06671132|EXPERIMENTAL|CBOT-P [CBOT + beta caryophyllene (BCP)]|CBOT device with BCP
62312098|NCT06671132|SHAM_COMPARATOR|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device
62312099|NCT04286308|EXPERIMENTAL|Brain signal data collection|Brain signal data collection at the time of deep brain stimulation (DBS) surgery.
62477289|NCT02477787|EXPERIMENTAL|treatment|patients will receive donor-derived NK cell infusion after haploidentical HCT
62122872|NCT04688801|EXPERIMENTAL|Chemotherapy + Immunotherapy ± Radiotherapy Group|Chemotherapy + Immunotherapy ± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
62122873|NCT03692013|EXPERIMENTAL|nighttime group|patients with nocturnal hypertension taking losartan at nighttime
62122874|NCT03692013|ACTIVE_COMPARATOR|daytime group|patients with nocturnal hypertension taking losartan at daytime
62122875|NCT06513936|EXPERIMENTAL|Skin care bundle|Patient who received the intervention
62682623|NCT05788328|ACTIVE_COMPARATOR|Period 1|Participants will receive dabagatrin etexilate (DE) as a single dose
62682624|NCT05788328|ACTIVE_COMPARATOR|Period 2|Participants will receive rosuvastatin as a single dose
62122876|NCT06513936|PLACEBO_COMPARATOR|Control group|Patient who receive routine intervention
62682625|NCT05788328|ACTIVE_COMPARATOR|Period 3|Participants will receive PF-07081532 daily titrated
62312100|NCT03188211|OTHER|Intervention|Clinicians allocated to intervention arm will receive an e-learning educational program based on simulation-based technologies (Dr Sim). Dr Sim provides a powerful editing system that allows to create clinical cases according to the educational need and purposes. It will be distributed on an e-learning platform, allowing the user to act in a highly interactive learning environment. Management of the virtual patients is carried out interactively and each diagnostic and or therapeutic choice will be supported by any scientific data, guidelines recommendations, drug descriptions and literature references useful to address the best choice for that specific patient as it should be in real practice.
62682626|NCT05788328|EXPERIMENTAL|Period 4|Participants will receive PF-07081532 daily and DE as a single dose
62682627|NCT05788328|EXPERIMENTAL|Period 5|Participants will receive PF-07081532 daily and rosuvastatin as a single dose
62682628|NCT05788328|ACTIVE_COMPARATOR|Period 6|Participants will receive PF-07081532 daily titrated
62682629|NCT05788328|EXPERIMENTAL|Period 7|Participants will receive PF-07081532 daily and DE as a single dose
62682630|NCT05788328|EXPERIMENTAL|Period 8|Participants will receive PF-07081532 daily and rosuvastatin as a single dose
62682631|NCT06606119||Major Trauma Injury|Severe blunt trauma patients diagnosed with shock with a long bone or pelvic fracture requiring open reduction internal fixation or intramedullary fixation.
61922523|NCT05023876|EXPERIMENTAL|IASTM group|
61922524|NCT05023876|EXPERIMENTAL|Control Group|
62312101|NCT03188211|OTHER|Control|Clinicians allocated to control arm will not receive the e-learning educational program based on simulation-based technologies (Dr Sim).
62312102|NCT01823653|EXPERIMENTAL|Treated Thigh|Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)
62312103|NCT04842344|EXPERIMENTAL|Noninvasive ventilation and ECCO2R|
62312104|NCT04842344|NO_INTERVENTION|Noninvasive ventilation|
62312105|NCT04372329|EXPERIMENTAL|CPAP4HealthySleep: System 1 (ABAB)|Participants in this group will first receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A). Next, they will receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B), re-introduction of type A for another two weeks, followed by re-introduction of type B for two weeks.
62477290|NCT02477787|NO_INTERVENTION|control|patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT
62477291|NCT06524921|ACTIVE_COMPARATOR|Metapex|Partial pulpectomy using Calcium Hydroxide with Iodoform (Metapex ) in carious primary molars with irreversible pulpitis
62682632|NCT06606119||Elective Hip Replacement|Patients undergoing elective hip replacement surgery
62682633|NCT06220266|PLACEBO_COMPARATOR|Diet control & life style modification|Diet control \& life style modification
62682634|NCT06220266|EXPERIMENTAL|PM|Pueraria mirifica
62682635|NCT05725655|EXPERIMENTAL|Hot water immersion|Patients allocated to hot water immersion will enter a bath and submerge down to the neck in warm water (40 degrees celsius) for 15 min.
62682636|NCT05725655|NO_INTERVENTION|Control|Patients allocated to control group will sit down for a 15 min rest.
62682637|NCT05970939||Telerehabilitation Usability|Telerehabilitation Usability Group
61922525|NCT03772860||Healthy volunteers|Healthy volunteers will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
61922526|NCT03772860||Left headache|Migraine patients with mostly left sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
61922527|NCT03772860||Right headache|Migraine patients with mostly right sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
61922528|NCT03772860||Bilateral headache|Migraine patients without a dominant side headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
61922529|NCT04297657|EXPERIMENTAL|intervention group|
61922530|NCT04297657|NO_INTERVENTION|control group|
61922531|NCT01191307||Shunt Implant|hydropcephalus cohort
61922532|NCT01191307||Cochlear Implant|hearing impaired cohort
62682638|NCT03258593|EXPERIMENTAL|Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg|Durvalumab + Vicineum, escalating doses. Up to 2 dose levels will be evaluated in the first 6 - 12 participants.
62682639|NCT03258593|EXPERIMENTAL|Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg|Durvalumab + Vicineum, at the maximum tolerated dose (MTD). Up to 24 participants.
62682640|NCT03258593|EXPERIMENTAL|Level 1, Durvalumab 1500mg intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg|Level 1, Durvalumab 1500mg intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg
62682641|NCT03258593|EXPERIMENTAL|Arm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)|Arm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)
62737704|NCT06517069|NO_INTERVENTION|Comparator|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Stick electrodes only but do not stimulate; The same amount of normal saline was injected intravenously 5 minutes before anesthesia induction.
62312106|NCT04372329|EXPERIMENTAL|CPAP4HealthySleep: System 2 (BABA)|Participants in this group will first receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B). Next, they will receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A), re-introduction of type B for another two weeks, followed by re-introduction of type A for two weeks.
62312107|NCT02612714|OTHER|medication status|Rosuvastatin 5 mg qd for 6 months, Quitted rosuvastatin for 6 months, Re-administrated rosuvastatin for 6 months
62312108|NCT06673108|ACTIVE_COMPARATOR|Vaginal photobiomodulation|Vaginal photobiomodulation with near-infrared (810-980nm wavelength) energy.
62312109|NCT06673108|SHAM_COMPARATOR|Sham-Light without laser energy.|Vaginal light therapy without focused laser energy.
61922533|NCT01191307||Spinal Cord Stiumulation|spinal cord injury cohort
62312110|NCT06513780||PVT|Participants who meet the inclusion criteria for portal vein thrombosis prior to liver transplantation
62682642|NCT06141031|EXPERIMENTAL|Phase I|During Phase 1, up to 2 dose levels of TTI-101 with SBRT will be tested using a 3 + 3 dose-escalation design to determine the RP2D. Up to 3 participants may be enrolled with either 0/3 or 1/3 DLT in order to more fully evaluate the safety and tolerability at a given dose level. Therefore, a minimum of 9 patients (3 at dose 0, and 6 at dose 1) and maximum 18 (6 patients at each dose level) will be enrolled in the phase 1.
61922534|NCT01191307||Vagus Nerve Stimulation|epilepsy cohort
62682643|NCT06141031|EXPERIMENTAL|Phase II|An additional 12 patients will be enrolled in phase 2 so that total of 18 patients are treated at RP2D in phase 2 (the 6 patients treated at RP2D in phase 1 will be rolled over to phase 2) of TTI-101 in combination with SBRT.
61922535|NCT01191307||Deep Brain Stimulation|dystonia cohort
61922536|NCT04030455|EXPERIMENTAL|Treatment (cisplatin, docetaxel, pembrolizumab)|Patients receive cisplatin IV over 1 hour, docetaxel IV over 1 hour (patients who develop significant adverse events to cisplatin treatment may receive carboplatin IV over 1 hour instead), and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who completely respond to the study drugs (the disease appears to go away) then receive pembrolizumab IV over 30 minutes on day 1 for 4 additional cycles in the absence of disease progression or unacceptable toxicity.
61922537|NCT01552473|ACTIVE_COMPARATOR|Brain Training Program 1|Training Program focusing on providing educational information of cognitive issues related to TBI
61922538|NCT01552473|EXPERIMENTAL|Brain Training Program 2|Program focuses on strategies to address cognitive issues following TBI
61922539|NCT01108289|EXPERIMENTAL|Oxytocin in Uniject|Community Health Officers will provide 10 IU Oxytocin in Uniject device IM immediately after delivery of baby
61922540|NCT01108289|NO_INTERVENTION|PPH Treatment Only|Community Health Officers will be able to treat for PPH only, not provide Oxytocin in Uniject
61922541|NCT00801671|ACTIVE_COMPARATOR|1|
61922542|NCT00801671|SHAM_COMPARATOR|2|
61922543|NCT03901456|EXPERIMENTAL|Phase II [Randomized]: Treatment|Participants randomized to this treatment arm will receive the Care to Plan (CtP) intervention as a part of Phase II.
61922544|NCT03901456|ACTIVE_COMPARATOR|Phase II [Randomized]: Control|"Participants randomized to a usual care control group as a part of Phase II.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
61922545|NCT03901456|EXPERIMENTAL|Phase I [Non-randomized]: Treatment|Participants enrolled in Phase I of the project to receive the intervention \[non-randomized; no comparison group\].
61922546|NCT02644200|NO_INTERVENTION|ORS|Controls treated with oral rehydration solution (standard therapy)
61922547|NCT02644200|ACTIVE_COMPARATOR|ORS+GT|Group treated with oral rehydration solution plus gelatin tannate
62312111|NCT06513780||non-PVT|Participants who meet the inclusion criteria for the absence of portal vein thrombosis prior to liver transplantation.
62312112|NCT06662188|EXPERIMENTAL|Pediatric Cohort 1|Starting Dose
62312113|NCT06662188|EXPERIMENTAL|Pediatric Cohort 2|Escalated Dose
62312114|NCT04674137|EXPERIMENTAL|XC8 100 mg|XC8 100 mg orally
62312115|NCT04674137|PLACEBO_COMPARATOR|Placebo|Placebo orally
62312116|NCT03562780|EXPERIMENTAL|Fortolin Tab 500mg|During the study session, healthy subjects will be administered a single oral dose of Fortolin Tab 500mg after an overnight fast of approximately 10 hours.
62312117|NCT03562780|ACTIVE_COMPARATOR|Panadol Caplet 500mg|During the study session, healthy subjects will be administered a single oral dose of Panadol Caplet 500mg after an overnight fast of approximately 10 hours.
62312118|NCT05717920|EXPERIMENTAL|ADX-629|
62312119|NCT03935646|EXPERIMENTAL|Stimulant Medication|Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
62477292|NCT06524921|EXPERIMENTAL|Biodentine|Pulpotomy using Biodentine in carious primary molars with irreversible pulpitis
62737705|NCT01437111|EXPERIMENTAL|Fosamax Plus|Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants
62682644|NCT04082273|EXPERIMENTAL|Femtosecond Laser for Cataract Surgery|Capsulotomy, lens fragmentation and Clear Corneal Incisions with FEMTO LDV Z8, followed by ultrasound phacoemulsification and IOL implantation.
62682645|NCT04082273|ACTIVE_COMPARATOR|Conventional Cataract Surgery|Clear Corneal Incisions, conventional capsulorhexis and ultrasound phacoemulsification and IOL implantation. Control treatment where the clear corneal incisions and capsulorhexis are performed manually and the lens fragmentation is performed with the phacoemulsification device.
62682646|NCT04331951|EXPERIMENTAL|Targeted biopsy within Sydney Protocol|"The patients with history of gastric intestinal metaplasia will be included and using targeted biopsy within Sydney Protocol; both targeted biopsy at suspicious lesions and random biopsy at no suspicious area.~* All tissues will be sent to immunohistochemistry as a gold standard.~* Sensitivity, specificity,positive predictive value, negative predictive value, accuracy will be calculated."
62682647|NCT06694129||Cohort 1|For eligible patients with advanced ROS1-positive NSCLC who have not received TKI treatment, receive entrectinib therapy until disease progression or intolerance.
62682648|NCT06694129||Cohort 2|For patients with NSCLC who have progressed after receiving first-generation ROS1 TKI crizotinib and meet the eligibility criteria, they can receive entrectinib treatment until disease progression or intolerance.
62682649|NCT06694129||Cohort 3|For patients with ROS1-positive NSCLC who have failed multi-line therapy, receive entrectinib until disease progression or intolerance.
62682650|NCT03098927|ACTIVE_COMPARATOR|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
62312120|NCT05941052|EXPERIMENTAL|Evaluation of various novel TB triage and diagnostic tests|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB. The investigators aim to enroll 450 participants per year at each of three enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.
62312121|NCT03562221|EXPERIMENTAL|Gluten free diet|Gluten free diet
62312122|NCT03562221|ACTIVE_COMPARATOR|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
62682651|NCT03098927|ACTIVE_COMPARATOR|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
62312123|NCT03562221|PLACEBO_COMPARATOR|Placebo|Placebo capsules with maize starch and without any bacteria.
62682652|NCT04895956|ACTIVE_COMPARATOR|Intra-sheath injection|In patients randomized to the intra-sheath, corticosteroids will be injected directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
62682653|NCT04895956|EXPERIMENTAL|Extra-sheath injection|In patients randomized to the extra-sheath arm, corticosteroids will be injected surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
62682654|NCT02380157|EXPERIMENTAL|Kaleorid|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
62682655|NCT02380157|PLACEBO_COMPARATOR|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
62477293|NCT06124638|EXPERIMENTAL|Self-Testing Group|Lay users (self-tester or caregiver) will be provided with a Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test kit. Each lay user will collect one mid-turbinate nasal swab from both nostrils, perform and interpret the Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test. All procedures for testing and result interpretation, including sample collection and extraction will be conducted by the lay user following the Instructions for Use provided in the kit. Participants will be asked to document their result interpretation and will pass the test to site staff, who will document their interpretation of the result. In addition, a second swab will be collected by study staff and eluted in Viral Transport Medium (VTM).
62682656|NCT05032911||Asymptomatic participants|Asymptomatic subjects should not present any pain in the cervical region during the last 3 months and no previous treatment for neck pain in order to be included in the study.
62682657|NCT05032911||Neck pain patients|Patients with neck pain should have an intensity of pain of at least 3 points out of 10 on a Visual Analog Scale and a neck pain duration of at least 3 months of evolution. Neck pain could be from nonspecific mechanical origin, associated with whiplash or with a previous medical diagnosis of degenerative or inflammatory alterations of the cervical spine, associated or not with headache and pain in the shoulder region or the upper limb.
61922548|NCT01782703||Control|Healthy subjects with no history of atopy (atopic dermatitis, asthma, or allergic rhinitis) from 0 months to 17 years of age that are age and sex matched to our atopic dermatitis subjects.
62682658|NCT04082572|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who do not respond to pembrolizumab and stop the treatment after 2 doses may undergo surgery within 6 months.
61922549|NCT01782703||Atopic Dermatitis|Children with atopic dermatitis from 0 months to 17 years of age.
62312124|NCT04908072|ACTIVE_COMPARATOR|Virtual Reality Training|Will participate in an Intensive virtual reality (R) cataract simulation course that includes a five day instructor led VR course using the Orbis-FundamentalVR cataract surgical simulator, in addition to standard resident training at the training facility.
62312125|NCT04908072|NO_INTERVENTION|Traditional Training|Will receive standard resident training at the training facility.
62312126|NCT04552119||HEALICOIL Knotless Suture REGENESORB|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless REGENESORB
62312127|NCT04552119||HEALICOIL Knotless PEEK|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless PEEK
62312128|NCT03806569|ACTIVE_COMPARATOR|MAC-cbt group treatment for adult ADHD|"The patients will be treated with psychological group treatment for 8 sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process. This will be called Mindfulness, Acceptance and Commitment-Therapy for adult Patients with ADHD"
62312129|NCT03806569|SHAM_COMPARATOR|Relaxation-group for adult ADHD|"The patients will be treated with a relaxation-treatment, long-time established as Jacobson muscle relaxing technique."
62312130|NCT06669442|EXPERIMENTAL|Guided Imagery Mindfulness|Mindfulness-based interventions (MBIs), such as guided imagery, emerge as promising alternatives for managing PTSD. Mindfulness necessitates participant training to maintain present awareness amidst wandering thoughts, fostering an attitude of non-judgmental acceptance towards thoughts and emotions. Mindfulness encourages, being present in the moment and supports emotional control.
62312131|NCT03891277|ACTIVE_COMPARATOR|Ferrous succinate|Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
62682659|NCT03223805|OTHER|Control Arm|Usual Care
62682660|NCT03223805|EXPERIMENTAL|Intervention Arm|Respiratory Distress Symptom Intervention plus Usual Care
62682661|NCT00619398|ACTIVE_COMPARATOR|1|
62682662|NCT00619398|EXPERIMENTAL|2|
62682663|NCT04376008|EXPERIMENTAL|PI-RADS 1-2|Standard prostate biopsy
62122877|NCT06671717|EXPERIMENTAL|Pralatrexate combined with Chidamide bridging allo-HSCT for Relapse/Refractory PTCL patients|Pralatrexate combined with Chidamide bridging allo-HSCT for Relapse/Refractory PTCL patients
62312132|NCT03891277|PLACEBO_COMPARATOR|placebo|placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
62682664|NCT04376008|EXPERIMENTAL|PI-RADS 3-5|Targeted and standard prostate biopsy
62682665|NCT06184087|EXPERIMENTAL|Control group|"The control group (n = 34) participated in routine childbirth education. The group received the same content via a childbirth class as the intervention group of five meetings (a total of 12.5 hours) given by a nurse midwife.~Women in the control group received a routine instructional approach which was based on lectures, videos, discussions, and practice/rehearsals."
62682666|NCT06184087|EXPERIMENTAL|Intervention group|"The intervention group (n= 36) learned with childbirth education that included interactive and constructive cognitive engagement activities.~The intervention group received the same content as the control group (a total of 12.5 hours), however, the content regarding upright positions and mobility was instructed using the ICAP constructive-interactive engagement modes."
62312133|NCT03494725|ACTIVE_COMPARATOR|Lpc-37|"Lacticaseibacillus paracasei Lpc-37 (Lpc-37), formerly Lactobacillus paracasei Lpc-37~1x 1 capsule in the morning for 5 weeks"
62682667|NCT04392362|ACTIVE_COMPARATOR|Intervention group|Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush
62682668|NCT04392362|ACTIVE_COMPARATOR|Control group|Giving adenosine Ising the recommended AHA two syringe method
62122878|NCT03799783|EXPERIMENTAL|Dexmedetomidine|2 mcg/Kg iv dexmedetomidine (this dose may be repeated up to 2 times) followed by 1-2 mcg/Kg/hour iv continuous infusion
62122879|NCT01525446|EXPERIMENTAL|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)
62122880|NCT00711217|EXPERIMENTAL|#1 Medical food|
62122881|NCT00711217|PLACEBO_COMPARATOR|#2 Control|
62122882|NCT03276871|ACTIVE_COMPARATOR|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
62122883|NCT03276871|EXPERIMENTAL|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
62122884|NCT04561219|EXPERIMENTAL|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
62122885|NCT04561219|PLACEBO_COMPARATOR|Placebo|Patients received placebo 500mg 8/8hours, for 5 days
62122886|NCT06315777|EXPERIMENTAL|normal cumulus cell oocytes complex|women with normal ovarian reserve will be utilized and analyse the cumulus cell as a baseline
62122887|NCT02339779|EXPERIMENTAL|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
62122888|NCT02339779|ACTIVE_COMPARATOR|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
62122889|NCT06290297|EXPERIMENTAL|Children with neurodevelopmental disabilities|Children aged 4 to 18 with cognitive, motor and/or speech-language impairments
62122890|NCT02354105||CZP treatment|axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
62312134|NCT03494725|PLACEBO_COMPARATOR|Placebo|"Placebo capsule manufactured to mimic Lpc-37 capsule~1x 1 capsule in the morning for 5 weeks"
62682669|NCT05019807|OTHER|WhatsApp group|The arm receives education information about diabetes and its complications, diet and physical activities through WhatsApp.
62682670|NCT05019807|OTHER|Control group|The arm does not received any education information.
62122891|NCT02841150|EXPERIMENTAL|Treatment Sequence 1|Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
62122892|NCT02841150|EXPERIMENTAL|Treatment Sequence 2|Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
62122893|NCT02389777|NO_INTERVENTION|Control UV burn|No treatment of the UV Light burn will be given
62122894|NCT02389777|ACTIVE_COMPARATOR|ST266 treated UV burn immediately|ST266 will be applied topically immediately by spray to the UV light burn wound
62122895|NCT02389777|ACTIVE_COMPARATOR|ST266 treated UV burn delayed|ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
62122896|NCT03584659|NO_INTERVENTION|Standard of care|This arm will continue standard procedure regarding side effect registration and handling
62122897|NCT03584659|EXPERIMENTAL|PRO|This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.
62312135|NCT05789004|EXPERIMENTAL|Hydrogen Peroxide 35%|In the participants of this group, the tooth whitening process will be performed with 35% hydrogen peroxide.
62312136|NCT05789004|EXPERIMENTAL|Hydrogen Peroxide 6%|In the participants of this group, the tooth whitening process will be performed with 6% hydrogen peroxide.
62312137|NCT05803564|EXPERIMENTAL|Intervention arm|
62312138|NCT05739617|SHAM_COMPARATOR|Sleep Hygiene Education|Participants will received once per month of sleep hygiene education for three months.
62737706|NCT03150550|EXPERIMENTAL|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
61922550|NCT01782703||Control with Atopy history|Healthy subjects from 0 months to 17 years of age with history of asthma, food allergies, or allergic rhinitis, but no atopic dermatitis or with positive family history of atopy
61922551|NCT02520128|OTHER|Cohort 1 (closed to recruitment)|"Cohort 1: Patients with Limb/limb girdle soft tissue sarcoma (STS) receiving (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 1:~* Pre-operative RT - 50 Gy in 25 daily fractions over 5 weeks~* Post-operative RT - 60 Gy in 30 daily fractions to the high dose planning target volume (PTV) and 52.2 Gy in 30 daily fractions to the low dose PTV treated concurrently over 6 weeks~* Post-operative RT (positive resection margins) - 66 Gy in 33 daily fractions to the high dose PTV, and 53.46Gy in 33 fractions to the low dose PTV treated concurrently over 6 ½ weeks."
61922552|NCT02520128|OTHER|Cohort 2|"Cohort 2: Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 2:~* Pre-operative RT - 50.4 Gy in 28 daily fractions over 5½ weeks~* Post-operative RT - 54 Gy in 30 daily fractions over 6 weeks~* Primary RT - 54 Gy in 30 daily fractions over 6 weeks."
62122898|NCT05817097||DPP4i|used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization) Combination therpay is acceptable.
62312139|NCT05739617|EXPERIMENTAL|Comprehensive Respiratory Training Exercise Program|Participants will received Comprehensive Respiratory Training Exercise Program twice per weeks for three months.
62122899|NCT05817097||except DPP4i|patients that did not use DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization)
62312140|NCT03910959|EXPERIMENTAL|Animal-assisted therapy|Patients receive three weeks of two AAT sessions, each lasting ca 30 minutes.
61922553|NCT02520128|OTHER|Cohort 3|"Cohort 3: Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant Radiotherapy (Intensity Modulated Radiotherapy)~Dose schedule for Cohort 3:~* Primary RT - 70 Gy in 35 daily fractions over 7 week~* Post-operative RT (non-chordoma) - primary bone sarcoma 60 Gy in 30 daily fractions over 6 weeks~* Post-operative RT (chordoma) - 70 Gy in 35 daily fractions over 7 weeks."
62122900|NCT06259409|EXPERIMENTAL|Treatment Arm|This group will receive the study device, Regenn® Negative Pressure Therapy System, a form of Negative Pressure Wound Therapy (NPWT). Regenn® Therapy manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum). Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by an attached small, dressing that the surgeon places in the surgical wound at the end of the surgery. Reduced pressure therapy is applied while the patient recovers from surgery.
62122901|NCT06259409|ACTIVE_COMPARATOR|Control Arm|This group will receive the control device, also a form of Negative Pressure Wound Therapy (NPWT), which manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum). Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by a small tube connected to a wound dressing placed over the closed surgical wound at the end of the surgery. Reduced pressure therapy is applied while the patient recovers from surgery.
62312141|NCT03910959|ACTIVE_COMPARATOR|treatment as usual|Patients receive three weeks of two control sessions, each lasting ca 30 minutes.
62312142|NCT06006728||naliri|Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy
62312143|NCT03745339||Abstinent OUD|Men and women with history of OUD, but abstinent for at least 3 weeks and not in agonist treatment
62312144|NCT03745339||Controls|Men and women with no history of a substance-use disorder (except nicotine, for matching purposes) and not using any drug for nonmedical purposes
62122902|NCT01996917|ACTIVE_COMPARATOR|Prineo closure|One breast will have skin closure with Prineo.
62122903|NCT01996917|NO_INTERVENTION|Standard Suture|One breast will be closed in the standard fashion with suture.
62312145|NCT03745339||In-treatment OUD|Men and women with opioid use disorder (OUD) being treated with an agonist (buprenorphine or methadone)
62312146|NCT05575804|EXPERIMENTAL|experimental group|Patients will receive the recommended phase 2 dose of GQ1001 determined in phase I. GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity.
62477294|NCT01015625|OTHER|A: Surgical Therapy|Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).
62312147|NCT05575804|ACTIVE_COMPARATOR|control group|Patients will receive pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
62312148|NCT03323307|EXPERIMENTAL|OCT imaging|OCT device images retina
62312149|NCT05624944|EXPERIMENTAL|Mild hepatic impairment|Patients with mild hepatic impairment will receive a single-dose of 5 mg of TS-142
62312150|NCT05624944|EXPERIMENTAL|Moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single-dose of 5 mg of TS-142
62312151|NCT05624944|EXPERIMENTAL|Normal hepatic function|Subjects with normal hepatic function will receive a single-dose of 5 mg of TS-142
62312152|NCT05013060|ACTIVE_COMPARATOR|The mixture of probiotics and microcapsulated sodium butyrate|One billion of the following strains: Bifidobacterium lactis FloraActive 32269, Bifidobacterium longum FloraActive 32946, Bifidobacterium bifidum FloraActive 32043, Lactobacillus rhamnosus FloraActive 19070-2, Lactobacillus acidophilus FloraActive 32418 and 150 mg microcapsulated sodium butyrate, and 64 mg fructooligosaccharides
62312153|NCT05013060|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62312154|NCT02949661|EXPERIMENTAL|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block using levobupivacaine
62312155|NCT02949661|ACTIVE_COMPARATOR|Local wound infiltration|Patients will receive local wound infiltration with levobupivacaine after the conclusion of surgery
62477295|NCT01015625|OTHER|B: Surgery on Demand|In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.
62737707|NCT03150550|EXPERIMENTAL|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
62477296|NCT05674734|EXPERIMENTAL|4FM/AT|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU (Treatment-As-Usual) module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at Institute of Psychiatry and Neurology (IPiN) Mental Health Centre for Mokotów and IPiN.
62477297|NCT05674734|NO_INTERVENTION|4FM/TAU|Treatment As Usual - 12 group therapy meetings at Day Care Units at IPIN and IPIN Mental Health Centre for Mokotów.
62477298|NCT06561607|EXPERIMENTAL|TQB2102 for Injection|Administered by intravenous drip, 7.5 mg/kg per dose, 21 days as a treatment cycle.
62477299|NCT06561607|ACTIVE_COMPARATOR|Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)|"Based on each patient's condition and previous treatment history, the investigator will select one of the following chemotherapy drugs for treatment.~* Capecitabine~* Paclitaxel~* Albumin Paclitaxel"
62477300|NCT04435067||Cohort A|patients in whom lung metastasis were resected for therapeutic purposes
62312156|NCT03074305|ACTIVE_COMPARATOR|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.~1. Residual stenosis after lesion preparation : %DS \<20%~2. Delivery time : \< 30 seconds~3. Total inflation time : \> at least 1 minute~4. Previous BVS : DEB diameter ratio : \> 1.0:1~5. Maximum inflation pressure : at least above nominal pressure of DEB"
62312157|NCT03074305|ACTIVE_COMPARATOR|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
62477301|NCT04435067||Cohort B|patients in whom lung metastasis were removed for diagnostic purposes only
62682671|NCT03503799||Observational Group|Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
62682672|NCT06691009|EXPERIMENTAL|Group 1 (Mechanical pleurodesis)|Pleural abrasions will be done by scrubbing the parietal and visceral pleura until a uniform aspect of bloody pleura by a piece of gauze attached to the end of a holding forceps, and intercostal tube will then placed and monitoring of lung expansion will be done through serial CXR and chest ultrasound follow up and when the lung is fully expanded the tube will be clamped for two hours and follow up CXR will be done for follow up and then the tube removed.
62682673|NCT06691009|EXPERIMENTAL|Group 2 (Chemical pleurodesis by bleomycin)|Those Patients will have indwelling pleural catheter through which pleural fluid will be drained until dryness and then pleurodesis will be done by 60 mg bleomycin dissolved in 50 ml 0.9% saline and 10 ml 2% xylocaine solution then the catheter will be clamped for 6 hours.
62682674|NCT06514898|EXPERIMENTAL|Adoptive Cellular Therapy (ACT) + PD-1 blockade with pembrolizumab|ACT + PD-1 blockade consists of the intravenous delivery of ex vivo expanded tumor-reactive lymphocytes and autologous hematopoietic stem cells (HSCs) with concomitant tumor RNA-pulsed DC vaccines followed by intravenous delivery of PD-1 blocking antibodies.
62122904|NCT02220478|ACTIVE_COMPARATOR|Signature Cutting Guides|Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
62312158|NCT05581576|EXPERIMENTAL|Pitolisant (Wakix)|Pitolisant will be titrated weekly until maximum dosage of 35.6 mg. Titration is dependent on subjects response.
62312159|NCT02742740|NO_INTERVENTION|Control|Standard of care for chemotherapy treatment.
62312160|NCT02742740|EXPERIMENTAL|Chemo Buddy|Subject receives instructions on how to use the personalized touch screen tablet and takes it home for 2 months.
62312161|NCT04143971|PLACEBO_COMPARATOR|Continiuous Low calorie diets|Low calorie diet with daily calorie restriction
62312162|NCT04143971|ACTIVE_COMPARATOR|Intermittent Fasting|Intermittent fasting every other day, in which daily calorie intake will be up to 30% of required calorie.
62477302|NCT01384591|EXPERIMENTAL|Losartan and placebo N-acetylcysteine|losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
62477303|NCT01384591|PLACEBO_COMPARATOR|Placebo losartan and placebo N-acetylcysteine|Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
62477304|NCT01384591|EXPERIMENTAL|N-acetylcysteine and placebo losartan|N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
62477305|NCT01798719|PLACEBO_COMPARATOR|Diet: Dietary Advice|Some general dietary advice about healthy dietary components, servings size and frequency of servings
62477306|NCT01798719|EXPERIMENTAL|Low glycemic index Mediterranean Diet|Low glycemic index Mediterranean Diet prescription with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
62477307|NCT01810419|EXPERIMENTAL|normal and various degrees splenomegaly|"Vscan Ultrasound (GE Healthcare, USA) Conventional Ultrasound (Ultrasonix) used to determine spleen size Crossover design, all subjects will be measured with both devices. half will have the handheld done first, then conventional half the Conventional done first, then handheld~Will complete questionaire for both:~1. Adequacy of image quality~2. What is best view obtained~3. Greatest Longitudinal Measure~4. Diagnosis~5. Diagnostic Certainty~6. Time to Complete exam"
61922554|NCT06353230|EXPERIMENTAL|Group A with 5% phenol in almond oil|Group A patients with rectal prolapse were given injection sclerotherapy with 5% phenol in almond oil,
61922555|NCT06353230|ACTIVE_COMPARATOR|Group B with hypertonic saline|Group B with rectal prolapse were given injection sclerotherapy with 15% hypertonic saline
62477308|NCT02120677|EXPERIMENTAL|Itraconazole ointment|Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days.
62477309|NCT04328935|EXPERIMENTAL|written exposure therapy|The treatment consists of written exposure therapy (WET), which is manualized trauma-focused CBT in five sessions over 5 weeks.
62682675|NCT03007693|EXPERIMENTAL|JNJ-61393215 (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 once daily for 7 days. 4 sequential cohorts will be enrolled to evaluate escalating doses which will be defined, based on safety, tolerability and pharmacokinetic (PK) data from the preceding cohorts. Dose adjustment/selection (increase/decrease) for the next cohort will be based on the JNJ- 61393215 PK profile up to and including the last day of dosing (24 hours postdose) and the safety and tolerability profile of the current cohort.
62682676|NCT03007693|PLACEBO_COMPARATOR|Placebo (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 matching placebo for 7 days.
62682677|NCT00760305|EXPERIMENTAL|1|Patients who received the Pro-Self psychoeducational intervention
62682678|NCT00760305|NO_INTERVENTION|2|Patients who received standard care
61922556|NCT06353230|ACTIVE_COMPARATOR|Group C with 50% Dextrose water|Group C with rectal prolapse were given injection sclerotherapy with 50% Dextrose water
62122905|NCT02220478|ACTIVE_COMPARATOR|Conventional Instrumentation|Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.
62122906|NCT01535963||cutaneous surgery|Patients undergoing cutaneous surgery
62122907|NCT06672484||Multiple Sclerosis|People presenting with multiple sclerosis diagnosis according to the 2017 revisions of the Mcdonald's criteria.
62682679|NCT06571318|EXPERIMENTAL|Destress and Perform Capsule-U001|
62682680|NCT06571318|EXPERIMENTAL|Destress and Perform Capsule-I001|
62682681|NCT06571318|OTHER|Placebo capsules 002|
62682682|NCT01933516|EXPERIMENTAL|GP2013|
62682683|NCT02822690||University Medical Center Groningen|all patients that died on one of the wards with the exception of children; on several wards the Hospice care will be introduced as an intervention
62682684|NCT02822690||Martini Ziekenhuis|all patients that died on one of the wards with the exception of children
62682685|NCT02822690||Ommelander ZorgGroep|all patients that died on one of the wards with the exception of children
62682686|NCT00592280|EXPERIMENTAL|Pancreas Preservation|The pancreas will be preserved before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
62122908|NCT06672484||Healthy people|Inclusion criteria for healthy controls (part A and B): inclusion of age between 18 and 65 years old, sex- and age-matched on a group level.
62682687|NCT05721729|EXPERIMENTAL|Cohort 1|Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Once and twice daily dosing will be examined.
62312163|NCT06663371|EXPERIMENTAL|Integrated Neuromuscular Training|"Integrative Neuromuscular Training (INT) is an interdisciplinary training paradigm that amalgamates cutting-edge concepts and practices from the realms of athletic training, physical therapy, biomechanics, and neuroscience. The genesis of INT dates back to the late twentieth century to the early twenty-first century, a period marked by a burgeoning understanding of motor control and neuromuscular coordination. Experts in the fields of sports science and rehabilitation began to explore a training modality designed to holistically enhance athletic performance while concurrently reducing the risk of injury.~The central tenet of INT is to optimize the coordination of the neuromuscular system and the synergistic action among muscle groups, thereby deepening functional movement training and integrating specific training components. These components include, but are not limited to, strength, balance, velocity, agility, fatigue resistance, and plyometric training. This methodology is not sol"
62477310|NCT02921893|EXPERIMENTAL|Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
62477311|NCT02921893|EXPERIMENTAL|Group II (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
62477312|NCT03682601|PLACEBO_COMPARATOR|Placebo|"15 postmenopausal women will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
62682688|NCT05721729|EXPERIMENTAL|Cohort 2|Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Twice and three times daily dosing will be examined.
62682689|NCT03606213|PLACEBO_COMPARATOR|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
62312164|NCT06663371|PLACEBO_COMPARATOR|Traditional Physical Training|Traditional Physical Training (TPT) involves a set of exercises with limited variation and fixed movement paths, conducted under stable conditions. This method primarily enhances muscle strength and endurance but often falls short in integrating with specific sports requirements and developing athletes' specialized skills.TPT emphasizes basic athletic attributes like strength, speed, and flexibility, which are vital for competition. Yet, it tends to focus on bulking up muscles and isolating body parts, potentially leading to higher injury risks and suboptimal performance.The concept of TPT is conservative, drawing on traditional sports training without fully embracing modern sports science and rehabilitation. However, as our understanding of motor control and neuromuscular coordination advances, modern training is becoming more holistic and scientific, prioritizing specialized movements, balance, and multi-joint coordination to boost the effectiveness of strength training.
62312165|NCT02583750|EXPERIMENTAL|OGTT after deprived sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sleep deprivation, then another test after three nights of sufficient sleep
62682690|NCT03606213|ACTIVE_COMPARATOR|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
62682691|NCT03606213|ACTIVE_COMPARATOR|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
62122909|NCT04912791||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
50360170|NCT06687642|EXPERIMENTAL|Experiment 1|Experiment 1 goal is to characterize semantic trajectories
50360171|NCT06687642|EXPERIMENTAL|Experiment 1'|Experiment 1' goal is to cognitively map the creative research
50360172|NCT06687642|EXPERIMENTAL|Experiment 2|Experiment 1' goal is to show that cognitive mapping is relevant to creative research creative research
50360173|NCT06687642|EXPERIMENTAL|Experiment 3|Experiment 3 aims to understand and reveal the hidden choices that underlie creativity
50360174|NCT06687642|EXPERIMENTAL|Experiment 4|Experiment 4 aims to assess the emotional influence of creativity
61922557|NCT01596543|EXPERIMENTAL|sleep deprivation|The research contains only one arm. The subjects will be tested with no sleep deprivation (which will be used as a control measurement) and with partial and complete sleep deprivation.
62122910|NCT04075942|OTHER|Atrophic Anterior Maxillary Ridges participants|Using customized Xenograft bone shell with equal mixture of autogenous and xenograft particulate bone as a graft with the modified cortical shell technique, with atrophic anterior maxilla with less than 5 mm Bucco-lingual
62122911|NCT03293498|EXPERIMENTAL|Group A|Low dose NanoFlu - Day 0; Fluzone HD - Day 21
62122912|NCT03293498|EXPERIMENTAL|Group B|High dose NanoFlu - Day 0; Fluzone HD - Day 21
61922558|NCT03763227|ACTIVE_COMPARATOR|Carbonic Anhydrase Inhibitor (CAI) Arm|Patients who have received carbonic anhydrase inhibitor (CAI) therapy namely oral acetazolamide or topical brinzolamide
61922559|NCT03763227|EXPERIMENTAL|Intravitreal ranibizumab (IVR) arm|"Intravitreal ranibizumab (IVR) injection administered to patients who have not shown adequate response or who have not tolerated CAI therapy~IVR therapy = Three 0.5mg IVR injection at monthly intervals"
61922560|NCT00700076|ACTIVE_COMPARATOR|1|
62122913|NCT03293498|ACTIVE_COMPARATOR|Group C|Fluzone HD - Day 0; Saline - Day 21
62122914|NCT03997916|OTHER|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG), also known as sleep study, in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient. There will be no separate arm to test a different device.
62477313|NCT03682601|ACTIVE_COMPARATOR|5% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 5% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
62682692|NCT03606213|ACTIVE_COMPARATOR|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
62682693|NCT05783349|OTHER|Women treated in the Medically Assisted Procreation (MAP) center of Nice|
62312166|NCT02583750|EXPERIMENTAL|OGTT after sufficient sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sufficient sleep, then another test after three nights of deprived sleep
62312167|NCT03634046|EXPERIMENTAL|PTED group|Percutaneous transforaminal endoscopic discectomy (PTED). Use German Joimax company production of intervertebral foramen mirror operation system, the prone position, by preoperative X-ray locating the skin into the needle point, intervertebral level away from the spine line 8 \~ 10 cm, 18 g needle insertion, the Kambin security triangle directly through the middle of pathological changes of intervertebral disc. After the success of the puncture, remove the needle core, injection of contrast agent, methylene blue (9:1) mixture disk imaging, replace the godet, slight rotation step by step to insert the expansion sleeve, X-ray perspective to determine work under the correct position. Radiofrequency ablation is used to form nucleus pulposus and fibrous ring and stop bleeding.
61922561|NCT00700076|PLACEBO_COMPARATOR|2|
61922562|NCT04183517|EXPERIMENTAL|Fasted|PXS-5382A administered as a single dose in the fasted state
62682694|NCT04481438|EXPERIMENTAL|exercise group|exercise group will receive acupunch exercise
62682695|NCT04481438|NO_INTERVENTION|control group|control group will maintain the regular activities of their original daily lives
62682696|NCT06324110|EXPERIMENTAL|Screening (LCS coordination)|Patients receive lung cancer screening follow-up care coordination services, delivered by a lung cancer screening care coordinator at their care site.
61922563|NCT04183517|EXPERIMENTAL|Fed|PXS-5382A administered as a single dose in the fed state
62682697|NCT06164730|EXPERIMENTAL|Cohort 1: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
62682698|NCT06164730|EXPERIMENTAL|Cohort 2: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
62682699|NCT06164730|EXPERIMENTAL|Cohort 3: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
61922564|NCT04183517|EXPERIMENTAL|Twice daily|PXS-5382A administered twice daily for 5 days in the fed state
61922565|NCT03800082|NO_INTERVENTION|Control|Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
62312168|NCT03634046|ACTIVE_COMPARATOR|RA group|Radiofrequency ablation (RA). Patients in prone position, local infiltration anesthesia, the puncture point for lesion clearance level, is apart from the spine line distance is 8 to 10 cm, in the perspective of the C-shaped arm X-ray machine; After the puncture needle was reached, the needle core was removed and the radiofrequency head was pierced through the puncture channel to the nucleus pulposus. In accordance with the method of melt into the shrinking exit, the intensity of the treatment by band 2, increased to 3 file again, according to the needle round mouth of 2, 4, 6, 8, 10, 12 o'clock to this process is repeated six times.
62312169|NCT06075004|ACTIVE_COMPARATOR|Periarticular Local Anesthetic Infiltration|60 mL of 0.25% bupivacaine with 5ug/mL epinephrine will be deposited under direct vision during surgery at the periarticular level before wound closure.
62312170|NCT06075004|EXPERIMENTAL|Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block|"45 mL of 0.25% bupivacaine with 5ug/mL epinephrine will be deposited under direct vision during surgery at the posterior periarticular level before wound closure.~After wound closure, an ultrasound-guided pericapsular nerve group block of the hip will be performed using ten mL of 0.5% bupivacaine with 5ug/mL epinephrine."
62312171|NCT06671002|OTHER|Acetaminophen/NSAID regimen|
62312172|NCT06671002|OTHER|Acetaminophen/NSAID/Opioid regimen|
62682700|NCT06164730|EXPERIMENTAL|Cohort 4: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
61922566|NCT03800082|EXPERIMENTAL|Treatment|Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check. A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness. Participants will be directed to the PC for technical problems.
61922567|NCT01362751||Nursing home residents|In this study, patients from both the somatic and the psychogeriatric department are included. For the primary endpoint 'successful rehabilitation' only the patients from the somatic departments are included.
62312173|NCT04404400|EXPERIMENTAL|Active|For CIRCI patients: hydrocortisone + fludrocortisone therapy.
62312174|NCT04404400|PLACEBO_COMPARATOR|Placebo|For CIRCI patients: hydrocortisone placebo + fludrocortisone placebo
62312175|NCT03000114|ACTIVE_COMPARATOR|Percutaneous Needle Aponeurotomy|Percutaneous Needle Aponeurotomy (PNA) involves the surgeon anaesthetizing the skin over the Dupuytren's cord, then using a small gauge needle inserted percutaneously, cutting the cord with the sharp edge of the needle using a sweeping motion. This is repeated up the length of the cord to weaken it, allowing an extension force to be applied over the finger to rupture the cord.
62312176|NCT03000114|ACTIVE_COMPARATOR|Collagenase Injection|Collagenase Injection (CI) involves the injection of collagenase clostridium histolyticum (0.58 mg), directly into the Dupuytren's cord. The patient then returns to see the surgeon within one week, has local anaesthetic is administered, and an extension force is applied to the affected digit to rupture the already weakened cord.
62312177|NCT03564249|EXPERIMENTAL|Group 1 Young patients with constipation|25 young patients that present at secondary or tertiary care with intractable constipation. They will undergo the new MRI gastrointestinal transit test (MiniCap) once before standard treatment for constipation and once after the treatment.
62477314|NCT03682601|ACTIVE_COMPARATOR|10% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 10% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
62477315|NCT05976815|NO_INTERVENTION|Control Group|The control group will receive neoadjuvant chemotherapy alone (standard of care).
62477316|NCT05976815|EXPERIMENTAL|Experimental Group|The experimental group will receive neoadjuvant chemotherapy (standard of care) in conjunction with an exercise intervention. The exercise intervention will be implemented concurrently for the full duration of the neoadjuvant chemotherapy treatment.
62477317|NCT02374385|EXPERIMENTAL|Group 1|1x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
62477318|NCT02374385|EXPERIMENTAL|Group 2|5x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
62477319|NCT02374385|EXPERIMENTAL|Group 3|3x10(6) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL.
62477320|NCT02374385|PLACEBO_COMPARATOR|Group 4|Group 4 will receive placebo (normal saline).
62477321|NCT02622386|EXPERIMENTAL|Riboflavin then Placebo|Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
62312178|NCT03564249|EXPERIMENTAL|Group 2 Healthy participants|25 young healthy controls matched for gender. They will undergo the new MRI gastrointestinal transit test (MiniCap) once.
62312179|NCT03224637|ACTIVE_COMPARATOR|radiofrequency group|radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
62312180|NCT03224637|ACTIVE_COMPARATOR|conventional group|the patients received conventional paracetamol and non steroidal antiinflammatory
62312181|NCT02267785|EXPERIMENTAL|Skill-Based Exercise|Participants assigned to this arm will complete the Skill-Based Exercise Intervention
62312182|NCT02267785|EXPERIMENTAL|Aerobic Exercise|Participants assigned to this arm will complete the Aerobic Exercise Intervention
62312183|NCT02267785|EXPERIMENTAL|Social Contact Group|Participants assigned to this arm will complete the Social Contact Intervention
62312184|NCT03025711||Pertuzumab|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
62477322|NCT02622386|PLACEBO_COMPARATOR|Placebo then Riboflavin|Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
62477323|NCT04421716|EXPERIMENTAL|Ursolic Acid|Administration of Ursolic Acid twice a day for 2 weeks
62477324|NCT04421716|EXPERIMENTAL|Curcumin|Administration of Curcumin twice a day for 2 weeks
62477325|NCT04421716|EXPERIMENTAL|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin. If subjects from Cohort 1 or 2 wish to continue in the study, they will undergo a washout period of at least 4 weeks before participating in Cohort 3
62477326|NCT01625715|NO_INTERVENTION|Case control|Routine therapy during peanut desensitization
62477327|NCT01625715|EXPERIMENTAL|ketotifen|rising doses of ketotifen
62477328|NCT06025110|EXPERIMENTAL|TCD601|Administered one of three doses of TCD601 over a 12 week treatment period.
62477329|NCT06025110|PLACEBO_COMPARATOR|Placebo|Placebo is administered over a 12 week treatment period.
62477330|NCT06295666||Healty|Periodontal healty group
62477331|NCT06295666||Periodontitis|Periodontitis group
62682701|NCT02850406|EXPERIMENTAL|Voxelotor|"Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:~* Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)~* Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)~* Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)~* Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg equivalent dose)"
62312185|NCT03025711||Trastuzumab emtansine|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
62312186|NCT01719445||RFPM/Paper and Pen Method|
62312187|NCT04689646|EXPERIMENTAL|Mind-Body Intervention 1|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 1.
62312188|NCT04689646|ACTIVE_COMPARATOR|Mind-Body Intervention 2|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 2.
62312189|NCT04689646|NO_INTERVENTION|Usual Care|Participants will continue their usual care for 26 weeks
62312190|NCT02162745|EXPERIMENTAL|Isotonic solution (NaCl 0.9%)|Single nasal irrigation with 1 ml of isotonic solution (NaCl 0.9%) per each nostril
62312191|NCT02162745|EXPERIMENTAL|Hypertonic solution (NaCl 3%)|Single nasal irrigation with 1 ml of hypertonic solution (NaCl 3%) per each nostril
62312192|NCT02162745|NO_INTERVENTION|Supportive care|Wiping the nose, positioning the child, changing a wet diaper, feeding.
62312193|NCT05777811|ACTIVE_COMPARATOR|Vertically Coronally advanced flap combined with connective tissue graft|
62312194|NCT05777811|ACTIVE_COMPARATOR|Free Gingival Graft|
62312195|NCT06332963|EXPERIMENTAL|Interoceptively Focused Treatment (IFT)|The IFT intervention will guide participants through a tailored application of present-moment focus toward experiencing awareness and acceptance of bodily signals and defusing thoughts related to those signals. For example, participants will engage in several exercises to increase awareness of body sensations, thoughts, and emotions. IFT consists of one introduction session with a clinician (\~60 minutes) the introduction session was designed as a brief introduction to acceptance- and mindfulness-based concepts with guided practice exercises and closing time for participants to briefly process challenges to execution of exercises and the experience during the session. This is followed by three IFT sessions which combine acceptance- and mindfulness-based skills practice with floatation-REST (Reduced Environmental Stimulation Therapy via floatation).
62312196|NCT06332963|ACTIVE_COMPARATOR|Exteroceptively Focused Treatment (EFT)|In the EFT condition, exercises are tailored toward experience of the present moment via external environment mindfulness (i.e., attending to experience) and defusion of thoughts. EFT consists of one introduction session with a clinician (\~60 minutes) the introduction session, similar in format to IFT, introduces acceptance- and mindfulness-based concepts. This is followed by three EFT sessions during which participants engage in brief guided skills training followed by video guided skills practice. The EFT condition is designed to increase awareness of the present moment and experience of the environment and view thoughts or emotions that may impact engagement with the current moment in a nonjudgmental way.
62312197|NCT04246229|EXPERIMENTAL|transcutaneous bilirubinometry|in this arm the bilirubin level to monitor the effect of phototherapy will be measured through transcutaneous mbiirubinometry
62312198|NCT04246229|ACTIVE_COMPARATOR|serum bilirubin|In this arm the bilirubin level to monitor the effect of phototherapy wil be measured through measurements of serum bilirubin obtained through blood draws
62312199|NCT03396471|EXPERIMENTAL|Single Arm Assignment|Pembrolizumab + External Beam Radiation Therapy
62312200|NCT02333955|EXPERIMENTAL|3 mg IV push|GCS-100
62312201|NCT00400387|OTHER|Multivitamin supplement|
62477332|NCT03238183|ACTIVE_COMPARATOR|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
62312202|NCT00400387|EXPERIMENTAL|Multivitamin supplement + dalteparin sodium|
62312203|NCT05979012|ACTIVE_COMPARATOR|Jazz Only|Jazz Group 1: Participants in this group will watch an introduction to jazz appreciation video prior to the 4-week intervention.
62312204|NCT05979012|EXPERIMENTAL|MIndfullness and Jazz|Jazz Group 2 (Mindful Jazz) Group: Participants in this group will watch an introduction to jazz appreciation and mindfulness training video, including the use of jazz for pain tolerance prior to the 4-week intervention.
62312205|NCT05979012|NO_INTERVENTION|Waitlist|Music Waitlist Group: Participants in this group will serve as a control and will not receive any intervention until the study is completed. They will complete a baseline survey and a follow-up survey at four weeks. Some videos will be sent to this group after the study is completed, without tracking their usage.
62477333|NCT03238183|PLACEBO_COMPARATOR|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
62312206|NCT02917863|EXPERIMENTAL|Solid L-Thyroxine|"Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with hypothyroidism:~0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die~1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die~Dosage in adults:~initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
62312207|NCT02917863|ACTIVE_COMPARATOR|Liquid L-Thyroxine|"Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with acquired hypothyroidism:~initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area~Dosage in adults:~initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
62312208|NCT01784549|ACTIVE_COMPARATOR|Cisplatin Docetaxel|- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles
61922568|NCT05340907|NO_INTERVENTION|Patient undergoing Bronchoscopy without use of VR device|patients undergoing flexible bronchoscopy without the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
62312209|NCT01784549|EXPERIMENTAL|Gefitinib Pemetrexed Vinorelbine Gemcitabine|"* Gefitinib day for 8 wks;~* Pemetrexed day 1 q 21 days for 3 cycles;~* Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;~* Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;~* Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;~* Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;"
62312210|NCT01849848|EXPERIMENTAL|SyB L-0501|
62682702|NCT06564818|EXPERIMENTAL|Experimental Arm A: CYB003 in 2 of 2 Dosing Sessions|Arm A participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.
62682703|NCT06564818|PLACEBO_COMPARATOR|Placebo Comparator Arm B: Placebo in 2 of 2 Dosing Sessions|Arm B participants will receive placebo in 2 of 2 Dosing Sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.
62122915|NCT04481373|EXPERIMENTAL|THRIVE|Acceptance and Commitment Therapy plus Education about HIV A master's level mental health professional will provide the 4-5 hour intervention for out-of-care PWH during a hospitalization. There are two important components to the intervention: Acceptance and Commitment Therapy (ACT) content, targeting avoidance with acceptance-based coping and active engagement in values-based living, and HIV education.
62122916|NCT04481373|OTHER|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
62122917|NCT04674436|EXPERIMENTAL|6 minute walking break|Participants will walk casually for 6 minutes following one hour of game play, then continue play for one more hour.
62122918|NCT04674436|EXPERIMENTAL|6 minute rest break|Participants will rest supine for 6 minutes following one hour of game play, then continue play for one more hour.
62312211|NCT00828386|EXPERIMENTAL|Induction chemotherapy + concurrent chemoradiotherapy|"Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):~* Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion~* Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by~* 5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.~The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks)."
62312212|NCT00828386|ACTIVE_COMPARATOR|Concurrent radiochemotherapy alone|Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
62312213|NCT05331989||patient group,healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
61922569|NCT05340907|EXPERIMENTAL|Patient Undergoing Bronchoscopy with the use of VR device|patients undergoing flexible bronchoscopy with the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
62312214|NCT06133777|EXPERIMENTAL|Respiratory Variability Monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
61922570|NCT06000176||interventional details : diagnostic test OCTA macula and ONH|interventional details : diagnostic test OCTA macula and ONH in the 3 groups
62122919|NCT04674436|NO_INTERVENTION|Continuous play|Participants will play continuous for 2 hours.
62312215|NCT02391727|OTHER|SYN004|open label study
62312216|NCT00570739|PLACEBO_COMPARATOR|Diabetic Participants: Metformin HCl+Placebo for Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
62312217|NCT00570739|EXPERIMENTAL|Diabetic participants: Metformin HCl + Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
62122920|NCT02731885|EXPERIMENTAL|Fasted Conditions|50mg of ABX464 (two 25mg capsules) /Fasted
62122921|NCT02731885|EXPERIMENTAL|Fed Conditions|50mg of ABX464 (two 25mg capsules) /Fed
61922571|NCT06321588||retrospective cohort|patients with a diagnosis of new-onset neurocognitive disorders (major and minor) with onset within the previous 24 months
62122922|NCT01803555|EXPERIMENTAL|BF Spiromax|2 inhalations of BF Spiromax at a dosage of 160/4.5 mcg and 2 inhalations of SYMBICORT placebo administered twice daily (AM and PM) during the 12-week treatment period.
62312218|NCT00570739|PLACEBO_COMPARATOR|Pre-diabetic Participants: Colesevelam Placebo|Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
62122923|NCT01803555|ACTIVE_COMPARATOR|Symbicort Turbohaler|2 inhalations of SYMBICORT TURBOHALER at a dosage of 200/6 mcg and 2 inhalations of placebo SPIROMAX administered twice daily (AM and PM) during the 12-week treatment period.
62312219|NCT00570739|EXPERIMENTAL|Pre-diabetes Participants: Colesevelam|Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
62312220|NCT06179212||CPETs|Patients will perform all 4 maximal cardiopulmonary exercise tests in randomized order. The protocols they will perform are: Modified Bruce, modified Naughton, modified Balke and the UOHI Slow Ramp.
62312221|NCT02057237|EXPERIMENTAL|single arm|Mitotane will be administered on an outpatient or inpatient basis.
62312222|NCT05534334|ACTIVE_COMPARATOR|Control arm|Surgical excision of the gingival pyogenic granuloma
62312223|NCT05534334|EXPERIMENTAL|Intervention|Intralesional injection with corticosteroids solution (1.8 mL of 100 mg hydrocortisone)
62312224|NCT00933335|EXPERIMENTAL|Single Arm|Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.
62312225|NCT02803372|EXPERIMENTAL|Intervention group|In addition to routine monitoring, invasive LiDCOrapid is used to monitor mean arterial pressure (MAP), stroke volume variation (SVV) and cardiac index (CI). Intraoperative goal-directed circulatory management is performed, i.e., to maintain MAP \> 95 mmHg, SVV \< 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery.
62312226|NCT02803372|ACTIVE_COMPARATOR|Control group|Routine monitoring is performed, which includes invasive blood pressure and urine output. Intraoperative routine circulatory management is performed, i.e., to maintain blood pressure within 20% from baseline level and urine output \> 0.5 ml/kg/h.
62312227|NCT00302601|OTHER|None relevant|Not relevant
62312228|NCT02732158|EXPERIMENTAL|Nutrition Products|Two servings per day of the sachet study product mixed with water; 1 carotenoid capsule per day
62312229|NCT02114203|EXPERIMENTAL|cohort 1 PF-04447943|
61922572|NCT06321588||prospective cohort|patients with a diagnosis of new-onset neurocognitive disorders (major and minor) with onset within the previous 24 months
61922573|NCT05731531|OTHER|Group A|Group of 50 patients who undergo BIG placement
61922574|NCT05731531|OTHER|Group B|Group of 50 patients who undergo endoscopic sleeve gastroplasty
61922575|NCT05731531|OTHER|Group C|Group of 50 patients who undergo Surgical sleeve gastrectomy
61922576|NCT05731531|OTHER|Group D|Group of 50 patients who undergo RYGB
61922577|NCT05731531|OTHER|Group E|Group of 50 healthy subjects
61922578|NCT05669248||mid covid-19 patients|Participant is diagnosed with symptomatic COVID-19 by a positive PCR for SARS-CoV-2 or antigen quicktest and meet the standard of mild COVID-19
62122924|NCT05188430|ACTIVE_COMPARATOR|Active treatment|Medical Device (Kaptufat®)
62122925|NCT05188430|PLACEBO_COMPARATOR|Placebo|Placebo
62312230|NCT02114203|EXPERIMENTAL|cohort 2 PF-04447943|
62682704|NCT02506153|ACTIVE_COMPARATOR|Arm I (high-dose recombinant interferon alfa-2B, ipilimumab)|"INDUCTION THERAPY: Patients receive high-dose recombinant interferon alfa-2B intravenously (IV) over 20 minutes on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for a total of 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive high-dose recombinant interferon alfa-2B subcutaneously (SC) on days 1, 3, and 5. Treatment repeats every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for 3 years in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan, PET scan, MRI and blood sample collection throughout the study."
62122926|NCT05519813|EXPERIMENTAL|Use Metformin for 3 months to treat PCOS|Active Comparator: Metformin (BMI\<24) Subjects: PCOS patients whoseBMI\<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
62312231|NCT02114203|PLACEBO_COMPARATOR|placebo comparator|
62312232|NCT02114203|EXPERIMENTAL|optional cohort of PF-04447943|
62312233|NCT02104310||Fluorine-18-L-dihydroxyphenylalanine|18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure
62312234|NCT06672185|EXPERIMENTAL|Dose Escalation Cohorts|ARC101 will be administered in escalating doses, with each dose escalation cohort assessing toxicity 21 days after the initial dose.
62312235|NCT06672185|EXPERIMENTAL|Dose Expansion Cohorts|ARC101 will be administered at recommended phase 2 dose(s).
62312236|NCT06661759|EXPERIMENTAL|Experimental intervention group|standard pediatric neurology care plus a hybrid in-person and digital sleep education program
62312237|NCT06661759|NO_INTERVENTION|Usual care group|standard pediatric neurology care
62312238|NCT02903511|EXPERIMENTAL|Metformin|Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
62682705|NCT02506153|EXPERIMENTAL|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, PET scan, MRI and blood sample collection throughout the study.
62312239|NCT02903511|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
62312240|NCT04440917|EXPERIMENTAL|Study group|Inductive therapy with Camrelizumab and Apatinib
62312241|NCT06513221|EXPERIMENTAL|First Line treatment|Participants will recieve chemotherapy (XELOX: Oxaliplatin injection and capecitabine tablets) combined with Bevacizumab (7.5mg/kg, q3w) as well as Adebrelimab (1200mg, q3w).
62312242|NCT06513221|EXPERIMENTAL|Second Line treatment|Participants will recieve chemotherapy (mXELIRI: capecitabine tablets plus irinotecan injection) combined with Bevacizumab (7.5mg/kg, q3w) as well as Adebrelimab (1200mg, q3w).
62312243|NCT06513221|EXPERIMENTAL|Third Line treatment|Participants will recieve Fruquintinib (4mg po d1\~d14, q3w) combined with Adebrelimab (1200mg, q3w).
62312244|NCT02946229|OTHER|MHD Population Ultrasound|Eligible subjects in a convenience population at the site (Maintenance Hemodialysis, MHD) incidentally undergoingnon-invasive cardiac, pulmonary, and abdominal ultrasound scanning on the commercially available GE Vivid S70 system for use in testing feasibility of new algorithms for processing this data.
62682706|NCT02016599||Initial cohort|Initial cohort used to develop a series of multivariate clinical deterioration indices using monitoring modalities and biospecimen collection
62312245|NCT01354691|EXPERIMENTAL|ladostigil hemitartrate|Ladostigil capsules 80 mg
62312246|NCT01354691|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62682707|NCT02016599||Validation cohort|Separate cohort of infants used to validate the clinical deterioration indices using monitoring modalities and biospecimen collection
62682708|NCT02965456|EXPERIMENTAL|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent \[%\]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
62682709|NCT02965456|PLACEBO_COMPARATOR|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
62682710|NCT02899754|EXPERIMENTAL|Intervention Group|Participants in this arm will use the lung cancer screening decision aid (LCSDecTool)
62312247|NCT03049540|ACTIVE_COMPARATOR|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
62312248|NCT03049540|PLACEBO_COMPARATOR|Placebo|Placebo 20 MG, p.o., once per day for 3 years
62312249|NCT02525224|OTHER|Nutritional Supplement|Proprietary nutritional supplement
62312250|NCT04490954|OTHER|Patients examined with MRI/CT|
62312251|NCT04490954|OTHER|Patients examined with biological electrical impedance|
62312252|NCT04248257|EXPERIMENTAL|PeACE peer coaching arm|Behavioral, PeACE, PeACE consists of 3 streamlined 30-minute psychosocial telephone counseling sessions delivered by a well-trained peer coach. Coaches are lay YARs from HBOC families demonstrating good knowledge, communication skills, and protocol mastery.
62312253|NCT04248257|ACTIVE_COMPARATOR|Community peer coaching arm|Behavioral, usual care, Participants in the usual care arm will receive navigation to peer support with a range of community groups who provide these services.
62312254|NCT01538173|EXPERIMENTAL|HES group|Application of twice a day 250ml HES 6% for three days postoperatively.
62312255|NCT01538173|ACTIVE_COMPARATOR|NaCl group|Application twice a day 500ml 9% NaCl for three days postoperatively.
62477334|NCT01639911|EXPERIMENTAL|Treated Patients with Solid Tumor|Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.
62477335|NCT05418647|EXPERIMENTAL|high dialysate Na|They will receive high dialysate sodium (Na = 141 mmol/L) for 8 weeks.
62312256|NCT06064682||Group 1: local tumor|patients with localized osteosarcoma who are scheduled to undergo diagnostic biopsy and are planned for surgical excision of the primary tumor
62312257|NCT06064682||Group 2: metastatic disease|patients with metastatic osteosarcoma who are scheduled to undergo either biopsy or surgery of metastatic disease
62682711|NCT02899754|ACTIVE_COMPARATOR|Control Group|Content that provides general information on disease prevention and health promotion unrelated to lung cancer. The information will be delivered on the same modality and take a similar amount of time to administer.
62682712|NCT05018091|ACTIVE_COMPARATOR|Group 1|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
62122927|NCT05519813|EXPERIMENTAL|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS|Active Comparator: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets (BMI\<24) Subjects: PCOS patients whoseBMI\<24 Drug: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets Generic name: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets Dosage form: 15mg/500mg Dosage: 2 tablets/day Frequency: one tablet twice a day Duration: 3 months
62122928|NCT01499771|EXPERIMENTAL|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
62312258|NCT00942708|OTHER|Fluoxetine|Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
62312259|NCT02827552|OTHER|ARPEGE BioM|N/A (not a randomized study)
62682713|NCT05018091|ACTIVE_COMPARATOR|Group 2|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
62682714|NCT05018091|ACTIVE_COMPARATOR|Group 3|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
62122929|NCT01499771|ACTIVE_COMPARATOR|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
62312260|NCT02933515|EXPERIMENTAL|Yoga and occupational therapy|twice a week for 8 weeks. one hour of group occupational therapy for fall risk factor management and one hour of yoga for balance
62312261|NCT00670917|ACTIVE_COMPARATOR|L14 acupoint|
62312262|NCT00670917|SHAM_COMPARATOR|Sham Point|
62477336|NCT05418647|EXPERIMENTAL|low dialysate Na|They will receive low dialysate sodium (Na = 136 mmol/L) for 8 weeks.
62477337|NCT06394973|EXPERIMENTAL|T4090 0.2%|
62477338|NCT06394973|EXPERIMENTAL|T4090 0.3%|
62477339|NCT06394973|ACTIVE_COMPARATOR|Rhopressa®|
62477340|NCT00759317|ACTIVE_COMPARATOR|1|venlafaxine
61922579|NCT03792243||Parastomal hernia|Patients undergoing parastomal hernia repair in Denmark between 2007 and 2017
61922580|NCT01196039|EXPERIMENTAL|A|
61922581|NCT01196039|PLACEBO_COMPARATOR|B|
62312263|NCT04848974|EXPERIMENTAL|Treatment (uproleselan, cladribine, cytarabine)|"INDUCTION THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q 12 hours on days 2-12, cladribine IV over 1-2 hours on days 1-5 and cytarabine SC BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR or CRi after cycle 1 may receive a second induction cycle.~CONSOLIDATION/MAINTENANCE THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q12 hours on days 2-1. Patients who have achieved at least CR/CRi or morphologic leukemia-free state after induction therapy receive uproleselan IV QD on days 1-12. Patients also receive cladribine IV over 1-2 hours on days 1-3 and cytarabine SC BID on days 1-10. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
62312264|NCT02061137|EXPERIMENTAL|Rett syndrome, fingolimod (FTY720)|0.5 or 0.25mg Fingolimod daily
62477341|NCT00759317|PLACEBO_COMPARATOR|2|
62477342|NCT02489461|EXPERIMENTAL|VM-1500 20 mg + ART|VM-1500 - 20 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
62477343|NCT02489461|EXPERIMENTAL|VM-1500 40 mg + ART|VM-1500 - 40 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
62477344|NCT02489461|ACTIVE_COMPARATOR|Efavirenz 600 mg + ART|Efavirenz 600 mg (Stage I and Stage II), ART
62682715|NCT06686901|PLACEBO_COMPARATOR|Smartphone-delivered inactive Therapeutic Evaluative Conditioning (inactive TEC)|Optional smartphone-delivered inactive Therapeutic Evaluative Conditioning (inactive TEC) for 30 days.
62682716|NCT06686901|EXPERIMENTAL|Smartphone-delivered active Therapeutic Evaluative Conditioning for Suicide (active TEC)|Optional smartphone-delivered active Therapeutic Evaluative Conditioning for Suicide (active TEC-S) for 30 days.
62682717|NCT06442397|EXPERIMENTAL|Anti-Inflammatory Lifestyle Intervention|A 16-week program consisting of 12 75-minute virtual group meetings
62682718|NCT05378529|OTHER|Participants with history of ASCVD|Participants with history of ASCVD with known or unknown Lp(a) values.
62682719|NCT04448912||Non-trauma damge control surgery|Patients with non-traumatic abdominal emergencies undergoing damage control surgery.
62682720|NCT04448912||Non-trauma conventional surgery|Patients with non-traumatic abdominal emergencies undergoing conventional surgery with primary abdominal closure.
62682721|NCT06427642|EXPERIMENTAL|Experimental group for children with HIE|Intravenous infusion of UCB-MNCs is given within 24 hours of being identified as a high-risk patient
62122930|NCT05844449|EXPERIMENTAL|VNZ/TEZ/D-IVA|Participants (Cohort 1: 6 through 11 years of age (inclusive); Cohort 2: 2 through 5 years of age (inclusive) and Cohort 3: 1 to less than (\<) 2 years of age) will receive VNZ/TEZ/D-IVA once daily at doses determined based on their age and weight. The age range is based on date of informed consent in parent study.
61922582|NCT04967612|EXPERIMENTAL|Virtual implantation of diffractive optical lens design A|
62682722|NCT06427642|ACTIVE_COMPARATOR|Control group for children with HIE|Mild hypothermia therapy is given for 72 hours to maintain anal temperature between 33.5°C and 34°C
61922583|NCT04967612|EXPERIMENTAL|Virtual implantation of diffractive optical lens design B|
62682723|NCT06427642|EXPERIMENTAL|Experimental group for children with BPD|Intravenous infusion of UCB-MNCs is given within 24 hours of being identified as a high-risk patient
62682724|NCT06427642|ACTIVE_COMPARATOR|Control group for children with BPD|Clinical routine treatment
62682725|NCT06427642|EXPERIMENTAL|Experimental group for children with SBS|Intravenous infusion of UCB-MNCs
62122931|NCT06269822||Cases|Group-1: Patients with TLE of both genders and aged \> 18 years old
62312265|NCT04618705|NO_INTERVENTION|control group|Participants who have not smoked for at least 10 years
62312266|NCT04618705|NO_INTERVENTION|smoking group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years.
62312267|NCT04618705|EXPERIMENTAL|smoking cessation group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years and who are planning to quit smoking.
62682726|NCT06427642|ACTIVE_COMPARATOR|Control group for children with SBS|Clinical routine treatment
62682727|NCT02905591|EXPERIMENTAL|ChemoRT + Ascorbate|Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
62682728|NCT03172559|EXPERIMENTAL|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
61922584|NCT04967612|EXPERIMENTAL|Virtual implantation of diffractive optical lens design C|
61922585|NCT05120843|OTHER|Intervention Arm|This intervention will combine care coordination and motivational interviewing strategies.
61922586|NCT02927067|ACTIVE_COMPARATOR|Valganciclovir 900 mg BID|Participants received 900 milligrams (mg) of valganciclovir along with a placebo matched to maribavir, twice daily (BID) orally for 8 weeks. Valganciclovir dose was allowed to be adjusted to 450 mg BID or 450 mg QD based on renal function impairment assessed at baseline or development of neutropenia during the study.
61922587|NCT02927067|EXPERIMENTAL|Maribavir 400 mg BID|Participants received 400 mg of maribavir along with a placebo matched to valganciclovir, BID orally for 8 weeks.
61922588|NCT04254042|ACTIVE_COMPARATOR|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
62122932|NCT06269822||Controls|Group-2: Age/gender matched healthy controls
62122933|NCT02057497||Healthy volunteers|Considered generally healthy based on medical history and physical examination as per discretion of the investigator
62122934|NCT02057497||Type 1 Diabetes|T1DM diagnosed clinically prior to start of trial examinations
62122935|NCT02057497||Type 2 Diabetes|T2DM diagnosis prior to the start of trial examinations
62122936|NCT06335628|NO_INTERVENTION|Group A: Connective Tissue Graft (CTG)|Volumetric changes between groups will be compared by matching intraoral scans before and after surgery (including follow-ups after 5 years) using the engineering software Geo-Magic®.
62122937|NCT06335628|EXPERIMENTAL|Group B: Volume Collagen Matrix Xenograft (VCMX) Geistlich Fibro-Gide®|The CTG (Group A) is the gold-standard for soft tissue augmentation, therefore it is considered the control group in this investigation.
62122938|NCT03932981|EXPERIMENTAL|Temozolomide|Chemotherapy by temozolomide
62122939|NCT05520086|EXPERIMENTAL|Single dose Allogenic Adiposse derived mesenchimal stem cells|Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells
62312268|NCT02202811|EXPERIMENTAL|Obstructive Sleep Apnea|Forced Desynchrony, OSA
62312269|NCT02202811|PLACEBO_COMPARATOR|Control|Forced Desynchrony, Control
62682729|NCT03172559|NO_INTERVENTION|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
62682730|NCT05766280|EXPERIMENTAL|Treatment|Soft Skills Training Intervention via telehealth
62682731|NCT05766280|NO_INTERVENTION|Control|Treatment as Usual (TAU)
62682732|NCT06494761|EXPERIMENTAL|All participants|
62737708|NCT02817594||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
62737709|NCT04593186|EXPERIMENTAL|Trans-oral magnifying endoscopy with NBI|Transoral magnifying endoscopy with High Definition Upper Endoscope with Narrow Band Imaging enhancement (Olympus GIF-H290Z)
62737710|NCT06407128|EXPERIMENTAL|Collection of biological samples|The samples (1ml blood sample + approximately 90-100mg of valve tissue + saliva, periodontal and feces samples) will be collected at the time of T0 inclusion in the cardiovascular surgery department.
62737711|NCT05568680|EXPERIMENTAL|SynKIR-110|Single dose gravity drip IV administration
62737712|NCT04793204|EXPERIMENTAL|fezolinetant|A single oral dose of fezolinetant will be administered with water under fasting conditions on day 1 (low dose), day 4 (medium dose) and day 7 (high dose). From day 10 to day 15, the medium dose of fezolinetant will be administered with water after breakfast once daily. On day 16, the medium dose of fezolinetant will be administered with water under fasting conditions.
62312270|NCT04418583|EXPERIMENTAL|Three-dimensional imaging|Participants receive a three-dimensional image of their chest, just prior to and after application of the Crane technique.
62312271|NCT05641623|ACTIVE_COMPARATOR|OSU6162|White, circular, coated tablets. Flexible dosage: the starting dose will be 15 mg TID and the maximal dose 45 mg TID.
62312272|NCT05641623|PLACEBO_COMPARATOR|Placebo|Coated tablets, flexible dosage, TID
62312273|NCT05823493|EXPERIMENTAL|the experimental group|
62312274|NCT05823493|ACTIVE_COMPARATOR|the control group|
62122940|NCT05520086|EXPERIMENTAL|Double dose Allogenic Adiposse derived mesenchimal stem cells|Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells at day 0 and 12,5 million cells at day 14
62122941|NCT01184664|EXPERIMENTAL|Varenicline + Active Patch|Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
62122942|NCT01184664|PLACEBO_COMPARATOR|Varenicline + Placebo Patch|Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
62122943|NCT01029587|EXPERIMENTAL|Eculizumab|Patients will receive eculizumab in conjunction with systemic anticoagulation before and after kidney transplant operation
62122944|NCT01377935||Patients exposed to Saxagliptin|
62122945|NCT01377935||Patients exposed to OAD in classes other than DPP4 inhibitors|OAD - Oral Antidiabetic Drug
62122946|NCT01884441|EXPERIMENTAL|BeGEV|Bendamustine, Gemcitabine and Vinorelbine (BeGEV)
62122947|NCT04861324|NO_INTERVENTION|Prenatal Care/Nutrition Education|Standard prenatal care with primary care physician with USDA-based federal guidelines
62122948|NCT04861324|EXPERIMENTAL|Fruit/veggie + postprandial physical activity|Nutrition education on increasing fruit and vegetable consumption and physical education on increasing postprandial physical activity for the duration from GDM diagnosis till delivery
62122949|NCT06455241|EXPERIMENTAL|HABIT|"All participants will receive HABIT - a novel occupational therapy intervention.~HABIT will include 10 sessions (2 sessions per week for 5 weeks). HABIT will include small group of 5-8 participants, so approximately 4 rounds of HABIT will be needed to reach 20 participants"
62312275|NCT06160635||Cohort A|Cohort A: Patients chronically infected with HDV. Patients with and without cirrhosis and with and without viremia will be included.
62312276|NCT06160635||Cohort B|Cohort B: Patients chronically infected with HDV and with available historical liver biopsies (5-20 years old biopsies) and clinical follow-up data or current patients willing to receive a core biopsy or fine-needle liver-cell aspirate (FNA). Patients with and without cirrhosis and with and without viremia will be included.
62312277|NCT01964365|EXPERIMENTAL|Rosuvastatin|multiple dose of Rosuvastatin 20mg
62312278|NCT01964365|EXPERIMENTAL|Fenofibric acid|multiple dose of Fenofibric acid 135mg
62312279|NCT01964365|EXPERIMENTAL|Rosuvastatin + Fenofibric acid|multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg
61922589|NCT04254042|ACTIVE_COMPARATOR|Zofenopril Arm|30 mg Zofenopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
61922590|NCT01765803|EXPERIMENTAL|Mellaril (thioridazine)|A single 50 gm dose of thioridizine (Mellaril) will be given orally at the beginning of the study
62122950|NCT01512810|NO_INTERVENTION|Low-risk for nodal involvement|No lymphadenectomy recommended
62122951|NCT01512810|EXPERIMENTAL|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
62122952|NCT01352533|ACTIVE_COMPARATOR|Running polypropylene closure|Half of every linear wound will be closed with running polypropylene sutures. This technique is Standard of Care.
62122953|NCT01352533|EXPERIMENTAL|Tissue Adhesive (Derma-Bond)|The experimental half of the wound will be randomized to receive closure with tissue adhesive alone.
62122954|NCT01352533|EXPERIMENTAL|Subcuticular polyglactin-910 combined with tissue adhesive|The experimental half of the wound will be randomized to receive closure with running subcuticular polyglactin-910 combined with tissue adhesive.
62312280|NCT00772460|ACTIVE_COMPARATOR|Forced Air|Warming with forced air (BairHugger)
62312281|NCT00772460|EXPERIMENTAL|Conductive Warming|Warming with the conductive device (HotDog)
62312282|NCT05679726|EXPERIMENTAL|Intervention group (reflexology group)|The group in which reflexology massage (foot massage) was applied once a week for 20 minutes (10 minutes on each foot) for a total of 4 weeks, and the pain scale and fatigue and stress level were measured once a week at the beginning of the study and at the end of the study 4 weeks later.
62312283|NCT05679726|NO_INTERVENTION|Control group|Pain scale once a week for 4 weeks without any application, and fatigue and stress level at the beginning of the study and at the end of the study after 4 weeks were measured in the group.
62737713|NCT06294262|ACTIVE_COMPARATOR|VaxigripTetra in healthy adults aged 18-50 years|A single, 0.5 mL intramuscular injection of VaxigripTetra without adjuvant in healthy adults aged 18-50 years (N = 12)
62122955|NCT04186546||Cases|Zephyr Valve Procedure
62122956|NCT04735341||Subjects with planned Ion Endoluminal Procedure with pulmonary nodule|
62122957|NCT02016352|EXPERIMENTAL|patient|patient CSF extraction with hydrocephalus
62312284|NCT00501852|EXPERIMENTAL|NVA237 12.5 µg|12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
62737714|NCT06294262|EXPERIMENTAL|VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 18-50 years|A single, 0.55 mL intramuscular injection of VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 18-50 years (N = 12)
62737715|NCT06294262|EXPERIMENTAL|VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 18-50 years|A single, 0.55 mL intramuscular injection of VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 18-50 years (N = 12)
62682733|NCT04775524|EXPERIMENTAL|Storytelling Through Music (STM)|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Storytelling Through Music (STM) group will participate in the study for a total of 19 weeks with 6 weeks of the STM program and 3 months follow up.~* Storytelling Through Music (STM) utilizes multiple modalities including storytelling, reflective writing, self-care skills (i.e., breathing exercises, meditation, self-compassion, body scans), and songwriting.~  * Weeks 1-4: participants are led through weekly writing workshop over an online platform (i.e., Zoom or an equivalent) to develop their stories. Simultaneous with the writing sessions are 10-minute self-care lessons~ * Week 5: Participants will be paired with a professional songwriter who will put their story into a song.~ * Week 6: During the last week, participants will have one more writing workshop to debrief about the intervention."
62682734|NCT04775524|EXPERIMENTAL|Wait List / Storytelling Through Music-Hybrid|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Waitlist control group (Storytelling Through Music-Hybrid) will participate in the study for a total of 13 weeks with 2 weeks of Storytelling Through Music-Hybrid program and 11 weeks of follow up .~* Storytelling Through Music-Hybrid involves participants listening to songs created for other healthcare professionals for 2 weeks."
62682735|NCT03672981|EXPERIMENTAL|Supportive Care (aerobic exercise and resistance training)|Patients undergo moderately intense aerobic/cardiovascular exercise over 30-60 minutes and complete 1-2 sets of 8 to 10 resistance/strength training exercises, 8 to 12 repetitions of each exercise, 3 days per week for 12 weeks. Patients also participate in weekly phone calls with an exercise physiologist to ensure adherence to the program and to provide support.
62682736|NCT05965167|EXPERIMENTAL|Treatment A EBP05 2.5 mg|Single dose of oral EBP05 2.5 mg
62682737|NCT05965167|EXPERIMENTAL|Treatment B EBP05 1.5 mg|Single dose of oral EBP05 1.5 mg
62682738|NCT05965167|EXPERIMENTAL|Treatment C Forteo 20 mg|Single SC injection of Forteo 0.02 mg
62682739|NCT05965167|EXPERIMENTAL|Treatment D EBP11 1.5 mg|Single dose of oral EBP11 1.5 mg
62682740|NCT05965167|EXPERIMENTAL|Treatment E EBP11 BID (dose determined after IA)|Based on PK data from 1st Interim Analysis BID administration of oral EBP11. The selected BID dose to be administered will be either 1.5, 2.0 or 2.5 mg.
62682741|NCT05965167|EXPERIMENTAL|Treatment F EBP11 BID (dose determined after IA)|BID administration of oral EBP11 tablets 1.5 mg tablets (3 x 0.5 mg tablets) as first dose and 2.5 mg (5 x 0.5 mg tablets) as second dose.
62682742|NCT05965167|EXPERIMENTAL|Treatment G EBP11 1.5 mg|Single dose of oral EBP11 1.5 mg
61922591|NCT00553865|EXPERIMENTAL|Group 1|OJP-2028 1mg/day
62312285|NCT00501852|EXPERIMENTAL|NVA237 25 µg|25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
62312286|NCT00501852|EXPERIMENTAL|NVA237 50 µg|50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
62312287|NCT00501852|EXPERIMENTAL|NVA237 100 µg|100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
62682743|NCT05965167|EXPERIMENTAL|Treatment I EBP22 1.5 mg|Single dose of oral EBP22 1.5 mg
61922592|NCT00553865|EXPERIMENTAL|Group 2|OJP-2028 2mg/day
61922593|NCT00553865|EXPERIMENTAL|Group 3|OJP-2028 4mg/day
61922594|NCT00553865|PLACEBO_COMPARATOR|Group 4|Placebo
61922595|NCT00553865|OTHER|Group 5|Reference drug
61922596|NCT04608942|EXPERIMENTAL|Jett Plasma Medical Lift Application|In the study group, the plasma jet will be applied to the superior and inferior eyelid margin in both eyes.
62312288|NCT00501852|PLACEBO_COMPARATOR|Placebo|Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
62312289|NCT00501852|ACTIVE_COMPARATOR|Tiotropium 18 µg|18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
62682744|NCT05965167|EXPERIMENTAL|Treatment J EBP22 1.5 mg|Single dose of oral EBP22 1.5 mg
62682745|NCT05965167|EXPERIMENTAL|Treatment K oral EBP formulation determined based on IA results|Single dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses
62682746|NCT05965167|EXPERIMENTAL|Treatment L BID of oral EBP formulation determined based on IA results|BID dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses
62682747|NCT05965167|EXPERIMENTAL|Treatment M BID of EBP05 2.5 mg|BID dose of oral EBP05 2.5 mg
62682748|NCT05965167|EXPERIMENTAL|Treatment N single dose of Treatment K|Single dose of Treatment K
62682749|NCT05965167|EXPERIMENTAL|Treatment H EBP22 2.5 mg (5 x 0.5 mg).|Singe dose of oral EBP22 2.5 mg (5 x 0.5 mg).
62682750|NCT04572243|EXPERIMENTAL|Lorcaserin (Core Study and Open-label Extension Phase)|Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (\<) 20, 20 to \<40, and greater than or equal to (\>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to \<20, 20 to \<40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
62682751|NCT04572243|PLACEBO_COMPARATOR|Placebo (Core Study) + Lorcaserin (Open-label Extension Phase)|Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to \<20, 20 to \<40, and \>=40 kg will be 5, 10, and 20 mg/day respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to \<20, 20 to \<40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
62312290|NCT01919372|ACTIVE_COMPARATOR|Conventional assistance|Usual treatment of obesity in terms of monitoring lifestyle habits
62312291|NCT01919372|EXPERIMENTAL|Telemedic assistance|telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
62312292|NCT05094440|EXPERIMENTAL|Immediate Treatment|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app intervention will be primarily monitored for one month, but followed for up to 3 months, and will be supplemented with a walk through manual and links to DBT worksheets. The intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program or greater community.
62312293|NCT05094440|ACTIVE_COMPARATOR|Waitlist and Delayed Treatment|Waitlist control whereby outpatients or members of the community will wait 1 month (4 weeks) to receive the intervention and then receive the Pocket Skills webapp for the subsequent 2 months (8 weeks). The waitlist period and subsequent intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program.
62312294|NCT02263339|EXPERIMENTAL|Aerobic Exercise|
62312295|NCT02263339|ACTIVE_COMPARATOR|Stretching Program|
62312296|NCT02263339|ACTIVE_COMPARATOR|Aerobic Exercise, Healthy Subjects|
62312297|NCT03495505|EXPERIMENTAL|WiSE-CRT eligible|Patients need to meet all the inclusion and none of the exclusion criteria in order to be eligible for the study. All these patients will receive the WiSE-CRT implant.
62312298|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
62312299|NCT03246035|ACTIVE_COMPARATOR|Control Group (Standard Care)|The control group will receive outpatient follow-up, medication advice and lifestyle guidance as prescribed at discharge from the ED or hospital.
62312300|NCT03246035|EXPERIMENTAL|Intervention Group|The intervention will consist of contacting the patient 5 days post-discharge and arranging definitive outpatient follow-up and providing targeted medical and lifestyle advice based on deficient domains identified at baseline.
62682752|NCT03976726||i-gel size #3|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
62682753|NCT03976726||i-gel size #4|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
62682754|NCT03976726||i-gel size #5|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
62682755|NCT03408808|ACTIVE_COMPARATOR|Aspiration alone|The patients will have their dorsal wrist ganglion aspirated and then pressure dressing for 48 hours.
61922597|NCT04608942|ACTIVE_COMPARATOR|Mechanical Debridement|In the control group, the mechanical debridement of the superior and inferior eyelid margin with a scalpel blade will be performed.
61922598|NCT02935543|EXPERIMENTAL|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
62312301|NCT04493749||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
62312302|NCT04493749||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
62312303|NCT01411540|EXPERIMENTAL|Whole grain diet|Subjects will eat a whole grain based diet for eight weeks. Pre-and post-diet intervention testing will determine effects on body composition. Whole grain-based are will be compared to the refined grain based diet.
62682756|NCT03408808|EXPERIMENTAL|Aspiration plus platelet rich plasma|The patients will have their dorsal wrist ganglion aspirated, and then injected with platelet rich plasma (derived from a blood sample taken at the same visit) and then pressure dressing for 48 hours.
61922599|NCT02669277|NO_INTERVENTION|group A|no platelet enhancing therapy
61922600|NCT02669277|ACTIVE_COMPARATOR|group B|Standard IVIG single dose 1.0 gm /kg/dose
62312304|NCT01411540|ACTIVE_COMPARATOR|Refined grain diet|Subjects will eat a refined grain diet for 8 weeks matched with the whole grain arm for calorie and macro nutrient intake. Pre-and post-diet testing will determine effects on body composition.
62312305|NCT03359421||Aeromedical transport|Patients transported to trauma center by helicopter
62312306|NCT03359421||Ground transport|Patients transported to trauma center by ground ambulance
62312307|NCT01401244|EXPERIMENTAL|Norditropin®|
62312308|NCT01401244|ACTIVE_COMPARATOR|Genotropin®|
62312309|NCT06187415|EXPERIMENTAL|The harm reduction mobile app|Participants in the intervention arm will receive access to all the app functions. The primary features of the app include PrEP taking diary, setting harm reduction goals, providing location of needle and syringe services program, providing accurate information on chemsex urban legends, and sending alerts to emergency contact in case of intoxication.
62682757|NCT03402581||c-mac used for intubation|obese patients intubated with c-mac videolaryngoscope
62682758|NCT03402581||mc-grath used for intubation|obese patients intubated with mc-grath videolaryngoscope
62682759|NCT06541301|EXPERIMENTAL|PICC-port arm|Implantation of a PICC-port device
62682760|NCT06541301|ACTIVE_COMPARATOR|Chest-port arm|Implantation of a Chest-port device
62682761|NCT05673902|EXPERIMENTAL|RPH-104 80 mg|"RPH-104 80 mg SC once every 2 weeks for 24-60 weeks.~(If the patient develops a pericarditis recurrence during the safety follow-up period, at the discretion of the investigator treatment with the study drug might be re-initiated according to the following regimen: a single dose of 160 mg SC (first injection) followed by a dose of 80 mg SC 7 days and 14 days after the first injection and at doses of 80 mg SC every two weeks thereafter.)"
62682762|NCT05299957||oropharyngeal squamous cell carcinoma|a total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker, or intracranial aneurysmal ferromagnetic clips), and serum glucose level \>200 mg/dl. Each enrolled patients will undergo detail clinical examination, including human papillomavirus test.
62682763|NCT04365569|EXPERIMENTAL|Individualized, nutrition and physical activity intervention|Initial in-person consult with a registered dietitian, with further in-person follow-ups and monthly telephone consults
62682764|NCT04330339|EXPERIMENTAL|Fasting|"* Eligible participants will undergo baseline assessments prior to starting the intervention.~  * Baseline assessments include measurements of weight, height, quality of life, fatigue, mood, levels of physical activity, and blood markers.~ * Participants will fast for 13 hours nightly for 12 weeks.~* Assessments will be repeated at the completion of the 12-week intervention."
62682765|NCT03626662|PLACEBO_COMPARATOR|Placebo|Single Ascending Dose Cohorts
62312310|NCT02805699|EXPERIMENTAL|Baofeikang Granule|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,cough,give BaoFeikang Granules(by Beijing KangRentang Pharmaceutical Co., Ltd.), 1 bag, twice each day.
62312311|NCT02805699|PLACEBO_COMPARATOR|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,coughand give Chinese medicine placebo (by Beijing Kang Rentang Pharmaceutical Co., Ltd., requirements and Chinese medicine BaoFeikang Granules in appearance and taste similar),1bag，twice each day.
62312312|NCT00432133|EXPERIMENTAL|1|Protection motivation theory-based tailored intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
62682766|NCT03626662|EXPERIMENTAL|AMG 890|Single Ascending Dose Cohorts
62682767|NCT06687200|EXPERIMENTAL|Experimental Arm: Setup with neutral pelvic positioning technique|Setup with neutral pelvic positioning technique (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT Mega Voltage Computed Tomography).
62682768|NCT06687200|ACTIVE_COMPARATOR|Control Arm: Standard setup|Standard setup (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT).
62682769|NCT04097860|EXPERIMENTAL|Intervention group|Will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
62682770|NCT04097860|NO_INTERVENTION|Control group|Will only be sent text messages that include the same general lactation information sent to the treatment group
62682771|NCT06224153||Patients with chronic kidney disease|
62682772|NCT06695533|EXPERIMENTAL|Study group|Eligible participants will utilize the workbook for a span of 3 months
62682773|NCT01260831|EXPERIMENTAL|Intervention Hospitals|hospitals randomized to implement bedsidePEWS documentation system (vital sign assessment record)
62682774|NCT01260831|ACTIVE_COMPARATOR|Control Hospitals|hospitals randomized to continue with their pre existing documentation system (vital sign assessment record)
62682775|NCT00666978|EXPERIMENTAL|Bupropion Arm|Subjects undergo smoking cessation intervention and take bupropion.
62682776|NCT00666978|PLACEBO_COMPARATOR|Health Education Arm|Subjects receive counseling intervention and take placebo.
62682777|NCT04551053|EXPERIMENTAL|Group A : ruxolitinib +parsaclisib|Participants will receive parsaclisib starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
62737716|NCT06294262|ACTIVE_COMPARATOR|VaxigripTetra in healthy adults aged 60 years or older|A single, 0.5 mL intramuscular injection of VaxigripTetra without adjuvant in healthy adults aged 60 years or older (N = 16)
62682778|NCT04551053|PLACEBO_COMPARATOR|Group B : ruxolitinib + placebo|Participants will receive placebo starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
62312313|NCT00432133|EXPERIMENTAL|2|Environmental access and awareness intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
62682779|NCT05522400|EXPERIMENTAL|intervention group|
62312314|NCT00432133|EXPERIMENTAL|3|Combination intervention combining protection motivation and environmental intervention components to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
61922601|NCT02669277|EXPERIMENTAL|group C|minipool IVIG product single dose 1.0 gm /kg/dose
62312315|NCT05440955|EXPERIMENTAL|active tDCS|tDCS (transcranial Direct Current Stimulation subjects) is a noninvasive brain stimulation technique that involves the passage of a small electric current through the scalp and skull to modulate brain activity \[10\]. The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device).
62312316|NCT05440955|SHAM_COMPARATOR|sham tDCS|The sham procedure is developed by the tDCS device manufacturer, which allows using the same tDCS device and the same procedure (i.e., 10 sessions delivered during five consecutive days) for both the active and sham procedures. In the sham condition, the electrodes will be placed in the same positions as in the active group; however, the stimulator will be only active for initial and final ramp up/ramp down periods, in order to mimic the sensation of active stimulation. In addition, brief pulses of 110 μA will be administered every 550 ms in order to control impedance and keep the manipulator blinded to the active or sham condition.
62312317|NCT03823768|ACTIVE_COMPARATOR|Arm 1: Control|Tacrolimus immediate release twice daily for 6 months
62312318|NCT03823768|EXPERIMENTAL|Arm 2: Intervention|Envarsus daily for 6 months.
62312319|NCT03133897|ACTIVE_COMPARATOR|Prednisone|Prednisone group: Children will receive four doses (days) of prednisone 1 mg/kg/dose once daily (maximum dose 50 mg) following the initial dose of corticosteroid received in the ED under the Nursing Medical Directive or Pre-Printed Order form.
62312320|NCT03133897|EXPERIMENTAL|Dexamethasone|"Dexamethasone group: Children will receive the approximate pharmacologic equivalent of two doses (days) of dexamethasone 0.6 mg/kg/dose (maximum dose 16 mg per dose) once daily as follows. The standard dose of prednisone/prednisolone provided in the emergency department is 2 mg/kg/dose (maximum dose 50 mg), which is approximately equivalent to 0.3 mg/kg/dose of dexamethasone. Therefore, patients who received prednisone/prednisolone in emergency department as per the current Nursing Medical Directive and Pre-Printed Order form will receive a top-up These patients will then receive a dose of dexamethasone 0.6 mg/kg (maximum dose 16 mg) 24 hours after the initial corticosteroid dose received in the Emergency Department of dexamethasone 0.3 mg/kg (maximum dose 8 mg) upon enrollment."
62312321|NCT01089725|PLACEBO_COMPARATOR|Placebo|
62312322|NCT01089725|EXPERIMENTAL|2.5 mg tanezumab SC and placebo IV|
62312323|NCT01089725|EXPERIMENTAL|5 mg tanezumab SC and placebo IV|
62312324|NCT01089725|EXPERIMENTAL|10 mg tanezumab SC and placebo IV|
62312325|NCT01089725|EXPERIMENTAL|10 mg tanezumab IV|
61922602|NCT04841915|EXPERIMENTAL|Micellar Cassein Isolate High-Protein Diet|4weeks eucaloric intake on high-protein diet with micellar cassein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
61922603|NCT04841915|EXPERIMENTAL|Whey Protein High-Protein Diet|4weeks eucaloric intake on high-protein diet with whey protein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
61922604|NCT04841915|PLACEBO_COMPARATOR|Normal Diet|4weeks eucaloric diet with normal protein content (15E%) followed by 20weeks hypocaloric intake on equivalent diet.
62312326|NCT00803088|EXPERIMENTAL|1|Treatment of airways with the Alair System
62312327|NCT05286398|PLACEBO_COMPARATOR|Control group|
62312328|NCT05286398|EXPERIMENTAL|Bradach group|
62312329|NCT05286398|EXPERIMENTAL|AEP group|
62312330|NCT03016715|EXPERIMENTAL|Treatment|Sirolimus, 2% topical ointment will be used during randomization
62312331|NCT03016715|PLACEBO_COMPARATOR|Vehicle|A placebo topical ointment will be used during randomization.
62312332|NCT02521246|EXPERIMENTAL|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 12,5 mg) a day, in the morning.
61922605|NCT05805358|NO_INTERVENTION|Conventional Imaging Group|60 participants who accepted ICI treatment will receive conventional imaging
62312333|NCT02521246|EXPERIMENTAL|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 25 mg) a day, in the morning.
62682780|NCT05522400|NO_INTERVENTION|control group|
62682781|NCT05360888|ACTIVE_COMPARATOR|Tools for Life|All youth will receive the Tools for Life (Qungasvik) intervention. Tools for Life is an evidence-based, community-developed intervention focused on providing protective cultural experiences for Alaska Native youth to address suicide risk and alcohol use.
62682782|NCT05360888|ACTIVE_COMPARATOR|Tools for Life + Motivational Interviewing Social Network intervention (MISN)|Half of the youth will will also receive MISN in addition to the Tools for Life intervention. MISN is an evidence-based treatment that augments motivational interviewing with personal social network composition and structure visualization as a means to cultivating healthy social networks and cultural worlds.
62682783|NCT02633527|PLACEBO_COMPARATOR|Placebo|Placebo, qd, oral capsule
62682784|NCT02633527|EXPERIMENTAL|100mg SPN-812|100mg SPN-812, qd, oral capsule
62682785|NCT02633527|EXPERIMENTAL|200mg SPN-812|200mg SPN-812, qd, oral capsule
62682786|NCT02633527|EXPERIMENTAL|300mg SPN-812|300mg SPN-812, qd, oral capsule
62312334|NCT02521246|ACTIVE_COMPARATOR|Comparator: Losartan+hydrochlorothiazide (Hyzaar®)|The patients will take 1 tablet (Losartan 100 mg + Hydrochlorothiazide 25 mg) a day, in the morning.
62312335|NCT05205707||Covid-19 Patients|Blood sample from admitted patients will be drawn
62312336|NCT05205707||Control Patients|Blood sample from control group will be drawn
62682787|NCT02633527|EXPERIMENTAL|400mg SPN-812|400mg SPN-812, qd, oral capsule
62312337|NCT06511505|EXPERIMENTAL|Intervention|Care teams randomized to the intervention will have access to the AI-enabled ECG-based screening tool.
62312338|NCT06511505|NO_INTERVENTION|Control|Care teams randomized to control will continue routine practice without access to the AI-enabled ECG-based screening tool.
62312339|NCT03966586|EXPERIMENTAL|Enhanced Care|Usual clinical care + intervention components
62312340|NCT03966586|ACTIVE_COMPARATOR|Usual Care|Usual clinical care and counseling
62312341|NCT04681664|EXPERIMENTAL|50 % fat diet|In the high fat group the subjects were assigned to the diet containing in average 50 % fat, 25 % proteins and 25 % carbohydrates for four weeks.
62312342|NCT00450463|ACTIVE_COMPARATOR|Flutamide Alone|Patients receive flutamide orally 3 times a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising prostatic specific antigen (PSA) levels) without metastatic disease (as evidenced on scans), may receive vaccine treatment as defined in arm II beginning 4 weeks after flutamide therapy is discontinued.
62312343|NCT00450463|EXPERIMENTAL|Flutamide + Vaccine + Sargramostim|Patients receive flutamide orally 3 times a day on days 1-28. Patients also receive recombinant vaccinia PSA vaccine subcutaneously (SC) on day 1 of course 1 only and recombinant fowlpox PSA vaccine SC on day 1 of all subsequent courses. Patients receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising PSA levels), discontinue flutamide but may continue to receive vaccine treatment.
62312344|NCT00708877|EXPERIMENTAL|All participants|
62312345|NCT06450028|ACTIVE_COMPARATOR|Bupivacaine Left, Lidocaine Right|Group 1 will receive 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine on the left side of their jaw and 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine on the right side of their jaw. This dosage will be administered once as peripheral nerve blocks at the beginning of the participant's orthognathic procedure.
62312346|NCT06450028|ACTIVE_COMPARATOR|Bupivacaine Right, Lidocaine Left|Group 2 will receive 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine on the right side of their jaw and 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine on the left side of their jaw. This dosage will be administered once as peripheral nerve blocks at the beginning of the participant's orthognathic procedure.
62312347|NCT00804440|ACTIVE_COMPARATOR|Test Product|
62682788|NCT04613089||CLN1 Disease, Haltia-Santavuori Disease|Patients with genetic mutations in the CLN1/PPT1 gene, causing a lysosomal enzyme deficiency of PPT1.
62312348|NCT00804440|ACTIVE_COMPARATOR|Reference Product|
62312349|NCT01709799|EXPERIMENTAL|Cognitive Training plus Exercise|"Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
62312350|NCT01709799|ACTIVE_COMPARATOR|Cognitive Training plus Exergames|"Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
62312351|NCT01709799|ACTIVE_COMPARATOR|Cognitive Training|Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.
62312352|NCT03515798|EXPERIMENTAL|Pembrolizumab|EC Paclitaxel + Pembrolizumab Injection
62312353|NCT03515798|ACTIVE_COMPARATOR|Standard neoadjuvant chemotherapy|EC Paclitaxel alone
62682789|NCT04613089||CLN2 Disease, Jansky-Bielschowsky Disease|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1.
62682790|NCT04613089||CLN2 Disease - ERT (Brineura) treated|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1, previously and/or currently receiving enzyme-replacement therapy (ERT) with Cerliponase alpha (Brineura).
61922606|NCT05805358|EXPERIMENTAL|Next Generation Imaging Group|30 participants who accepted ICI treatment will receive next generation imaging including MRF and MR Relaxometry and hyperpolarized 13C pyruvate DNP scanning.
62312354|NCT05283707|EXPERIMENTAL|Intervention Group|"* Continuation of standard post-cesarean section care in the clinic.~* Implementation of Paula Method Exercises Training Plan 6-8 hours after cesarean section (Paula Method Exercises Practice Card PEUK, Paula Method Exercises Video, Paula Method Exercises Flipcard)~* Paula Method Exercises; by the researcher, after cesarean section 0.day 6-8 hours, 1st day morning, 2nd day morning.~* Paula Method Exercises; It was applied by the researcher to the patient on the 0th day 6-8 hours, the 1st day in the morning, and the 2nd day in the morning after the cesarean section.~* 6-8 hours on day 0, morning on day 1, morning on day 2 after cesarean section Evaluation and recording of bowel sounds before and after Paula Method Exercises, application of McGill Pain Scale Short Form,~* Evaluation of first flatulence after cesarean section and first defecation"
62682791|NCT04613089||CLN3 Disease, Spielmeyer-Vogt-Sjögren-Batten Disease|Patients with genetic mutations in the CLN3 gene.
62682792|NCT04613089||CLN4 disease, Parry disease|Patients with genetic mutations in the CLN4/DNAJC5 gene.
62682793|NCT04613089||CLN5 Disease|Patients with genetic mutations in the CLN5 gene.
62682794|NCT04613089||CLN6 Disease, Kufs Disease Type A|Patients with genetic mutations in the CLN6 gene.
62122958|NCT02016352|OTHER|witness|patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
62682795|NCT04613089||CLN7 Disease|Patients with genetic mutations in the CLN7/MFSD8 gene.
61922607|NCT03762538||G/G group|Patients who are determined to be G/G genotype.
61922608|NCT03762538||G/A A/A group|Patients who are determined to be G/A or A/A genotypes.
62682796|NCT04613089||CLN8 Disease|Patients with genetic mutations in the CLN8 gene.
62682797|NCT04613089||CLN10 Disease|Patients with genetic mutations in the CLN10/CTSD gene, causing a lysosomal enzyme deficiency of Cathepsin D.
62682798|NCT04613089||CLN11 Disease|Patients with genetic mutations in the CLN11/GRN gene.
62682799|NCT04613089||CLN12 Disease|Patients with genetic mutations in the CLN12/ATP13A2 gene.
62682800|NCT04613089||CLN13 Disease, Kufs Disease Type B|Patients with genetic mutations in the CLN13/CTSF gene, causing a lysosomal enzyme deficiency of Cathepsin F.
62682801|NCT04613089||CLN14 Disease|Patients with genetic mutations in the CLN14/KCTD7 gene.
62682802|NCT00189878|ACTIVE_COMPARATOR|1 methotrexate|patient to receive methotrexate
61922609|NCT04884932|EXPERIMENTAL|30 kHz stimulation|"Percutaneous application of high frequency electrical current at 30 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
61922610|NCT04884932|EXPERIMENTAL|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
62122959|NCT05835219||REBYOTA™|
62312355|NCT05283707|NO_INTERVENTION|Control Group|"* Continuation of standard post-cesarean section care in the clinic.~* 6-8 hours on day 0, morning on day 1, morning on day 2 after cesarean section Evaluation and recording of bowel sounds, application of McGill Pain Scale Short Form,~* Evaluation of first flatulence after cesarean section and first degassing"
62682803|NCT00189878|PLACEBO_COMPARATOR|2 Placebo|given placebo capsules
62682804|NCT06465290|EXPERIMENTAL|Study group - Intensive ankle robot rehab|Ankle robot with motor relearning with real-time feedback, passive stretching under intelligent control; Active movement training with robotic assistance
61922611|NCT00396747|ACTIVE_COMPARATOR|A|Methotrexate
61922612|NCT00396747|ACTIVE_COMPARATOR|B|MTX + MP
62682805|NCT06465290|ACTIVE_COMPARATOR|Control group - Mild ankle robot rehab|The same wearable robot used by the study group will be used for the control group but in a limited way: no motor relearning training under real-time feedback; passive movement in the joint middle range of motion instead of passive stretching; active movement training with no robotic assistance
62312356|NCT01160367|ACTIVE_COMPARATOR|standard of care health decision making|Patient-family dyads will receive the standard of care for support of patient and family members health care decision making during a clinic appointment.
62682806|NCT00667043|ACTIVE_COMPARATOR|Study group 1|Midazolam and fentanyl; continuous intravenous infusions
62682807|NCT00667043|ACTIVE_COMPARATOR|Study group 2|Propofol and remifentanil; continuous intravenous infusion
62682808|NCT06680648|EXPERIMENTAL|Insufflation first followed by no-insufflation|
62682809|NCT06680648|ACTIVE_COMPARATOR|no-insufflation first followed by insufflation|
62682810|NCT01272258|EXPERIMENTAL|Arm 1|PRO 140
62682811|NCT01272258|PLACEBO_COMPARATOR|Arm 2|Placebo
62682812|NCT02571543|EXPERIMENTAL|Intervention|"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.~Stage 2: 17 patients will be treated either with the lower dose of 400mg or the higher dose of 800mg of Ibuprofen should the respective stage 1 have been successful (4 or more patients showing an effect)."
61922613|NCT00396747|ACTIVE_COMPARATOR|C|MTX + IFX
62312357|NCT01160367|EXPERIMENTAL|TAILORED intervention|Patients and family members who receive the TAILORED Decision Making Intervention
62312358|NCT02769871|ACTIVE_COMPARATOR|Standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at the participant's initial interview. Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
62312359|NCT02769871|EXPERIMENTAL|Neuroimages of stroke|Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
62312360|NCT02203370||all patients|All patients will be measured throughout the procedure with both devices. There no further separation into groups as both sensors can be placed on the same patient.
62477345|NCT06574620|OTHER|Resectable Cohort|Participants with resectable PDAC. Participants will provide tumour, fluid, and blood samples for genetic testing and other analyses. Tumour samples will be collected from standard resection surgery and optional biopsies. Fluid samples will be collected from a standard laparoscopy procedure. Blood samples will be collected at several timepoints throughout the study. Participants will receive standard chemotherapy (folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based) regimens.
62477346|NCT06574620|OTHER|Borderline Resectable Cohort|Participants with borderline resectable PDAC. Participants will provide tumour, fluid, and blood samples for genetic testing and other analyses. Tumour samples will be collected from standard resection surgery and optional biopsies. Fluid samples will be collected from a standard laparoscopy procedure. Blood samples will be collected at several timepoints throughout the study. Participants will receive standard chemotherapy (FOLFIRINOX or gemcitabine-based) regimens.
62477347|NCT06574620|OTHER|Locally Advanced Cohort|Participants with locally advanced PDAC. Participants will provide fluid and blood samples for genetic testing and other analyses. Fluid samples will be collected from a standard laparoscopy procedure. Blood samples will be collected at several timepoints throughout the study. Tumour samples may also be collected, if participants agree to optional biopsies. Participants will receive standard chemotherapy (FOLFIRINOX or gemcitabine-based) regimens.
62477348|NCT01717339|OTHER|Normal Subjects|Non-OSA (Obstructive sleep apnea) patients
62477349|NCT01717339|OTHER|OSA subjects|(Obstructive sleep apnea) OSA subjects
61922614|NCT05592834|EXPERIMENTAL|Positive deviance (PD)|This group will receive only the positive deviance intervention and not the PFT
62477350|NCT01796171|EXPERIMENTAL|Part A, Arm 1: 10 MBq/kg Betalutin with lower dose lilotomab pre-dosing|10 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
62477351|NCT01796171|EXPERIMENTAL|Part A, Arm 1: 15 MBq/kg Betalutin with lower dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
62477352|NCT01796171|EXPERIMENTAL|Part A, Arm 1: 20 MBq/kg Betalutin with lower dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
62477353|NCT01796171|EXPERIMENTAL|Part A, Arm 2: 10 MBq/kg Betalutin with no pre-dosing|10 MBq/kg (based on body weight) Betalutin without pre-dosing
61922615|NCT05592834|EXPERIMENTAL|Parent facilitator training (PFT)|This group will receive only the parent facilitator training intervention and not the PD
61922616|NCT05592834|EXPERIMENTAL|Parent facilitator and positive deviance(PFT/PD)|This group will receive both the PD and PFT interventions
62477354|NCT01796171|EXPERIMENTAL|Part A, Arm 2: 15 MBq/kg Betalutin with no pre-dosing|15 MBq/kg (based on body weight) Betalutin without pre-dosing
62477355|NCT01796171|EXPERIMENTAL|Part A, Arm 3: 15 MBq/kg Betalutin with rituximab pre-dosing|15 MBq/kg (based on body weight) Betalutin with rituximab pre-dosing
62477356|NCT01796171|EXPERIMENTAL|Part A, Arm 4: 15 MBq/kg Betalutin with higher dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
61922617|NCT05592834|ACTIVE_COMPARATOR|Control|This group will receive neither the PD nor the PFT interventions but care as usual.
61922618|NCT06178328||Brief psychological intervention (Things You Do)|All participants will have access to the online course materials for a period of 4 weeks from the time of enrolment. The materials are self-directed and can be accessed at any time during the 4-week period.
61922619|NCT05141825|EXPERIMENTAL|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
61922620|NCT03474315||CHF and CIED patients|600 CHF patients with ICD or CRT admitted to regulatory ambulatory visit.
61922621|NCT01629706|EXPERIMENTAL|PV+ClearCare / PV+Renu (Phase 1)|Balafilcon A contact lens pre-soaked overnight in ClearCare cleaning and disinfecting system worn in 1 eye for two hours and four hours at a time, separate days, with Balafilcon A contact lens pre-soaked overnight in renu multi-purpose solution worn in the fellow eye
62682813|NCT02571543|NO_INTERVENTION|Control|The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examination.
62682814|NCT04604366|ACTIVE_COMPARATOR|vaginal mesoprostol|Vaginal dose---800 microgram 3 hourly two doses
62682815|NCT04604366|EXPERIMENTAL|sublingual mesoprostol|Sub lingual 600 microgram 3 hourly two doses
62682816|NCT04515810|EXPERIMENTAL|Arm I (PACT)|Participants use PACT mHealth app.
62139645|NCT02698475|EXPERIMENTAL|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (\<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (\>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg; participants weighing \>100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
62682817|NCT04515810|ACTIVE_COMPARATOR|Arm II (standard care)|Participants engage in standard care with no modifications.
62682818|NCT00339365|EXPERIMENTAL|1|Promoting first relationships group
62682819|NCT00339365|ACTIVE_COMPARATOR|2|Early education support group
62682820|NCT05672615||Non-Muscle Invasive Bladder Cancer - Bacillus Calmete-Guerin (BCG) intravesical treatments|Participants who are receiving BCG intravesical treatments will be asked to provide research urine samples and blood samples prior to and during their treatment course. Participants will also be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale at the start and throughout the treatment course. Participants will be given a daily mood diary to complete at the following timepoints: 6-week induction treatment, 3-week maintenance treatment, and the 3-month follow-up. The study team will ask permission from participants to utilize excess tissue samples from standard of care procedures and biopsies. Participants' medical history and clinical data will also be collected for the study.
62682821|NCT05672615||Non-Muscle Invasive Bladder Cancer - Chemotherapy intravesical treatments|Participants who are receiving chemotherapy intravesical treatments will be asked to provide research urine samples and blood samples prior to and during their treatment course. Participants will also be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale at the start and throughout the treatment course. Participants will be given a daily mood diary to complete at the following timepoints: 6-week induction treatment, 3-week maintenance treatment, and the 3-month follow-up. The study team will ask permission from participants to utilize excess tissue samples from standard of care procedures and biopsies. Participants' medical history and clinical data will also be collected for the study.
62682822|NCT06521593|ACTIVE_COMPARATOR|patients who underwent short duration applying of tourniquet.|All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation just before cementing
62682823|NCT06521593|EXPERIMENTAL|patients who underwent long duration applying of tourniquet.|All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation
62682824|NCT02636335|EXPERIMENTAL|Bright Light|"8 a.m. study participants will be exposed to Bright Light (4500 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
62312361|NCT06103552|EXPERIMENTAL|Weight Loss Program Intervention|All study participants will be assigned to the intervention arm of this trial where they will undergo the BLOOM lifestyle program for weight loss. This program is 24 weeks in duration and includes group nutrition coaching with a dietitian, regular physician appointments and access to online support materials. Participants may also choose to pursue weight loss medication or meal replacement therapy, although this is not specifically part of the BLOOM program being studied.
62682825|NCT02636335|EXPERIMENTAL|Control|"8 a.m. study participants will be exposed to a Control Light Condition (230 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
62312362|NCT03636594|EXPERIMENTAL|Dance|This was a single arm study with all participants receiving the same intervention.
62312363|NCT02234401|EXPERIMENTAL|Non invasive ventilation (NIV)|Non invasive ventilation used for the first 7 days of study
62312364|NCT02234401|ACTIVE_COMPARATOR|Standard Care|High Flow Controlled Oxygen Therapy
62682826|NCT04990310|EXPERIMENTAL|Study Participants|On Day 1, participants will receive a single oral dose of \[14C\]-CORT113176 450 mg (3 X 150 mg lipid formulation capsules) in the fed state.
62682827|NCT05411120|EXPERIMENTAL|Long-term a Intervention: CLEAN-MED|Study arm will consume a Mediterranean like diet, while tracking their food intake for 12 months
62682828|NCT05411120|EXPERIMENTAL|Short-term, Western Diet, high MedDiet score a Intervention: C|Study arm will consume a Mediterranean like diet, while tracking their food intake for 9 weeks, With high MEdDIet score.
62312365|NCT00836160||1|
62312366|NCT00836160||2|
62312367|NCT06246552|EXPERIMENTAL|JTM201|Botulinum toxin
62312368|NCT06246552|PLACEBO_COMPARATOR|Placebo|Placebo
62312369|NCT06574828|EXPERIMENTAL|BIIB091, BIIB091-matched placebo, Moxifloxacin-matched placebo|Participants will receive BIIB091, BIIB091-matched placebo, and moxifloxacin-matched placebo orally during the inpatient period (Days -1 to 13).
62312370|NCT06574828|ACTIVE_COMPARATOR|Moxifloxacin, Moxifloxacin-matched placebo, BIIB091-matched placebo|Participants will receive moxifloxacin, moxifloxacin-matched placebo, and BIIB091-matched placebo orally during the inpatient period (Days -1 to 13).
62477357|NCT01796171|EXPERIMENTAL|Part A, Arm 4: 20 MBq/kg Betalutin with higher dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
62477358|NCT01796171|EXPERIMENTAL|Part A, Arm 5: 20 MBq/kg Betalutin with intermediate dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 60 mg/m2 (based on body surface area) lilotomab pre-dosing
62477359|NCT01796171|EXPERIMENTAL|Part B, Arm 1: 15 MBq/kg Betalutin with lower dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
62477360|NCT01796171|EXPERIMENTAL|Part B, Arm 2: 20 MBq/kg Betalutin with higher dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
62477361|NCT01796171|EXPERIMENTAL|Part B, Arm 3: 12.5 MBq/kg Betalutin with lower dose lilotomab pre-dosing|12.5 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
62477362|NCT01796171|EXPERIMENTAL|Part C: 15 MBq/kg Betalutin with lower dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
62477363|NCT05146492|ACTIVE_COMPARATOR|Patient with acute myocardial infarction without pericardial effusion|
62682829|NCT05411120|EXPERIMENTAL|Short-term, Western Diet, high MedDiet score a Intervention: W|Study arm will consume a Mediterranean like diet, while tracking their food intake for 9 weeks, With high MEdDIet score.
62682830|NCT05411120|EXPERIMENTAL|Short-term, Western Diet, low MedDiet score a Intervention: CL|Study arm will consume a western diet eating as they normally would for 9 weeks. With low MEdDIet score.
62682831|NCT05411120|EXPERIMENTAL|Short-term, Western Diet, low MedDiet score a Intervention: We|Study arm will consume a Mediterranean like diet, while tracking their food intake for 9 weeks. With low MEdDIet score.
62682832|NCT04514276|EXPERIMENTAL|consecutive fetoneonatal healthcare|inclusion criteria: pregnant woman having higher risk of early fetal growth restriction, preeclempsia living in studyregion (east-Saxony or east Thuringia) the fetoneonatal pathway consists of four consecutive parts: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
62682833|NCT04514276|NO_INTERVENTION|standard fetoneonatal healthcare|inclusion criteria: due to health insurance data by AOK PPLUS \& ikk classics propsensityscorematched pregnant women living in west Saxony and Thuringia, being not part of the intervention group receiving standard health care.
62682834|NCT01026428|EXPERIMENTAL|Safinamide + Levodopa|
62682835|NCT01026428|PLACEBO_COMPARATOR|Placebo + Levodopa|
62682836|NCT02893605||Cases|Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
62682837|NCT02893605||Controls|Controls correspond to spouses/partners of patients.
62139646|NCT01324310|EXPERIMENTAL|Romidepsin and ketoconazole|"Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.~Ketoconazole 400 mg oral once daily on Days 4-8"
62312371|NCT04164667|EXPERIMENTAL|Directed MAP (dMAP)|Participants received weekly text message directions from the ANNIE VA messaging system. The directed text messaging system provided details on which app-based meditation and exercise sessions to complete.
62477364|NCT05146492|EXPERIMENTAL|Patient with acute myocardial infarction and pericardial effusion|
62477365|NCT02414711|OTHER|No depressed|"If the result of the HSCL25 scale is inferior than 1.75, then the patient is considered as no depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
62477366|NCT02414711|OTHER|Depressed|"If the result of the HSCL25 scale is superior or equal to 1.75, then the patient is considered as depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
62682838|NCT03196089|EXPERIMENTAL|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
62682839|NCT03196089|SHAM_COMPARATOR|Sham room air|Room air will be applied similarly to oxygen
62682840|NCT06500871|EXPERIMENTAL|Diclofenac Potassium|0.4 ml diclofena potassium injection 75mg/3ml drug used as Supplemental intraligamentary injection
62682841|NCT06500871|ACTIVE_COMPARATOR|Articaine Anaesthetic solution|Articaine 4% with (1:100,000 Epinephrine) local anesthetic solution will be used as intraligamentary injection,
62682842|NCT04136288|EXPERIMENTAL|Males with erectile dysfunction (ED)|Males diagnosed with erectile dysfunction (ED) for over a year, but less than 5 years, will receive shock wave therapy via MoreNova device
61922622|NCT01629706|EXPERIMENTAL|Habitual (Phase 2)|Phase 2: Habitual contact lenses worn bilaterally on a daily wear basis for 4 weeks with habitual lens care
62477367|NCT01249651|OTHER|1|One arm: esomeprazole 40 mg
62477368|NCT04948905||Patients diagnosed as having Borderline Personality Disorder|These patients have been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
62682843|NCT05109195||MDD Participants with Insufficient Response to SSRI/SNRI (antidepressant)|Major Depressive Disorder (MDD) participants with insufficient response to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) (antidepressant) and starting an adjunctive therapy will be observed to create an external control arm (ECA) based on real world data (RWD) from electronic health records (EHR) data during routine medical care (standard of care \[SOC\]) combined with scheduled research assessments.
62682844|NCT06311331||Total Talus Replacement|50 subjects receiving the Total Talus Replacement device
62737717|NCT06294262|EXPERIMENTAL|VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 60 years or older|A single, 0.55 mL intramuscular injection of VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 60 years or older (N = 16)
62682845|NCT03374332|EXPERIMENTAL|Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)~Patients \< 70 years old: GO 9mg/m2 (3mg/m2 each dose)~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10\^7 CD3+ cells and maximum of 2x10\^7 CD3+ cells/kg irrespective of the number of CD34+ cells.~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
62477369|NCT04948905||Healthy Controls (Patients not diagnosed as having Borderline Personality Disorder )|These patients have NOT been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
62477370|NCT04204395|EXPERIMENTAL|Experimental group|"When complete the admission process, the caregiver will give a peanut ball to perform, besides the routine health brochure.~The participants will be at independent compartment."
62682846|NCT03374332|EXPERIMENTAL|Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)~Patients: \< 70 years old: GO 9mg/m2 (3mg/m2 each dose)~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10\^8 CD3+ cells and maximum of 2x10\^8 CD3+ cells/kg irrespective of the number of CD34+ cells.~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
62682847|NCT02504775|EXPERIMENTAL|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet \[500 milligram (mg) of paracetamol\] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
62682848|NCT02504775|EXPERIMENTAL|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
62682849|NCT00752362|ACTIVE_COMPARATOR|1|Percutaneous coronary intervention with bare metal stent
62682850|NCT00752362|EXPERIMENTAL|2|Percutaneous coronary intervention with paclitaxel-eluting stent
62682851|NCT00752362|EXPERIMENTAL|3|Percutaneous coronary intervention with sirolimus-eluting stent
62682852|NCT06258304|EXPERIMENTAL|GIGA-564: Dose Escalation (Phase 1A)|Up to 5 dose levels \[0.3, 1.0, 3.0, 10.0, and 20.0 milligrams per kilogram (mg/kg)\] will be evaluated sequentially. Participants will receive GIGA-564 intravenously over at least 60 minutes on Day 1 of every 3 weeks (3 weeks = 1 cycle) for up to 4 cycles until time of confirmed disease progression, unacceptable toxicity, or other reason for treatment discontinuation.
62477371|NCT04204395|NO_INTERVENTION|Control group|Take the routine health brochure. The participants will be at independent compartment.
62477372|NCT04235595|EXPERIMENTAL|Connective Tissue Manipulation|The participants were administered CTM by a physiotherapist with 11 years of experience in the application from the point at which their menstrual cycles had ended to the beginning of the next cycle. Another assessment was made immediately after the treatment and this was repeated at the second, third and fourth menstrual cycles. The CTM took an average of 20-30 minutes to complete.
62477373|NCT04235595|EXPERIMENTAL|Transcutaneous Electrical Nerve Stimulation|Following the assessment made in the participants' first menstrual cycle, on the most painful day of their second cycle (1st or 2nd day of the cycle), high-frequency TENS was applied at a frequency of 120 Hertz, at intervals of 100 µsn for 20 minutes. The intensity of the current was increased until the participant felt it.
62477374|NCT04234334|EXPERIMENTAL|Egg intake|Consumption of 2 eggs with spinach daily for breakfast for 4 weeks
62477375|NCT04234334|EXPERIMENTAL|Egg Subsitute|Consumption of 2 egg substitutes daily for breakfast for 4 weeks
62682853|NCT06258304|EXPERIMENTAL|GIGA-564: Dose Expansion (Phase 1B)|Dose expansion (Phase 1B) of selected dose levels may be initiated following the preliminary clearance of those specified dose levels from the dose escalation (Phase 1A) as determined by the Sponsor and SRC. Participants will receive up to 4 cycles of one of up to three tolerable dose levels of GIGA-564. GIGA-564 will be given intravenously over at least 60 minutes on Day 1 of every 3 weeks (3 weeks = 1 cycle) for up to 4 cycles until time of confirmed disease progression, unacceptable toxicity, or other reason for treatment discontinuation.
62682854|NCT03266653|EXPERIMENTAL|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
62682855|NCT04840875|EXPERIMENTAL|chimeric antigen receptor T cell treatment|
62682856|NCT04260607|EXPERIMENTAL|Experimental-Ketamine|single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes
62682857|NCT04260607|PLACEBO_COMPARATOR|Placebo-Saline|100ml Normal Saline infused over 40 minutes
62477376|NCT06545890|EXPERIMENTAL|Ketofol Group|Five minutes after induction; Ketofol (ketamine to propofol ratio 1:4) will be infused at a rate of 0.6 ml/kg/hr. Ketofol will be prepared by adding 40 mg of ketamine to 160 mg of propofol and diluted to 20 ml with normal saline 0.9%.
62477377|NCT06545890|EXPERIMENTAL|Dexmedetomidine|Five minutes after securing the airway, dexmedetomidine infusion will be started at a rate of 0.2 mcg/kg/hr.
62477378|NCT01882686|EXPERIMENTAL|Classification Based Cognitive Functional Therapy|
62477379|NCT00682500|EXPERIMENTAL|1|Calfactant treatment
62477380|NCT00682500|PLACEBO_COMPARATOR|2|
62477381|NCT06223932||COVID-19 diagnosed patients receiving molnupiravir|COVID-19 diagnosed patients receiving molnupiravir treatment
62122960|NCT02351648|EXPERIMENTAL|Intervention'|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
62682858|NCT02677051|PLACEBO_COMPARATOR|Placebo|About 15 subjects will be randomized into this arm, receiving pills with an inactive placebo.
62477382|NCT02822235||Crohn's Disease|Participants with diagnosis of moderate to severe Crohn's disease (CD) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and CD at Day 1 were followed up for 12 months in prospective phase.
62477383|NCT02822235||Ulcerative Colitis|Participants diagnosed with diagnosis of moderate to severe ulcerative colitis (UC) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and UC at Day 1 were followed up for 12 months in prospective phase.
62477384|NCT05294783||ACL injured patients|All the ACL injured patients recruited underwent ACL reconstruction with the same group of surgeons lead by the same chief surgeon.
62477385|NCT01919112|EXPERIMENTAL|High dose anodal tDCS|High dose tDCS (2 milliamps twice daily) for 5 days will be administered concomitantly with swallowing exercises
62477386|NCT01919112|ACTIVE_COMPARATOR|Low dose anodal tDCS|This arm will use a low dose of current administered via tDCS (2 milliamps once daily) for 5 days will be administered concomitantly with swallowing exercises
62477387|NCT01919112|SHAM_COMPARATOR|Sham Stimulation|Twice daily swallowing exercises only
62477388|NCT04451746|OTHER|Tableted hormonal drugs for contraception|Tableted hormonal drugs for contraception, 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
62477389|NCT05537129|EXPERIMENTAL|Laparoscopic Total Gastrectomy|
62477390|NCT05537129|ACTIVE_COMPARATOR|Open Total Gastrectomy|
62477391|NCT03521973|EXPERIMENTAL|Group 1- PfSPZ-Vaccine|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10\^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
62477392|NCT03521973|PLACEBO_COMPARATOR|Group 2|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
62682859|NCT02677051|EXPERIMENTAL|Sulforaphane|"About 30 subjects will be randomized into this arm, receiving pills with glucoraphanin rich broccoli seed powder containing active myrosinase resulting in sulforaphane once ingested Doses will be weight dependent with each pill resulting in \~ 50 µmol sulforaphane.~Body weight Dose of sulforaphane 34 kg \~ 50 µmol 68 kg \~ 100 µmol 102 kg \~ 150 µmol"
62682860|NCT03258554|ACTIVE_COMPARATOR|Arm I (cetuximab, radiation therapy)|Patients receive cetuximab IV weekly over 60-120 minutes. Treatment repeats every week for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo IMRT 5 fractions per week for up to 7 weeks.
62682861|NCT03258554|EXPERIMENTAL|Arm II (durvalumab, radiation therapy)|Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.
62477393|NCT03521973|EXPERIMENTAL|Group 3|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10\^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 1."
62682862|NCT06695637|EXPERIMENTAL|Study group|Individuals diagnosed with MUDs randomized for study intervention
62682863|NCT06695637|SHAM_COMPARATOR|Sham control group|Individuals diagnosed with MUDs randomized for sham intervention
62682864|NCT06688968|EXPERIMENTAL|patient with early-onset Alzheimer's disease (AD)|patients followed up at the Centre Mémoire de Ressources et de Recherche (CMRR) of Montpellier, over 60 with Alzheimer's disease who have cognitive impairment based on an MMSE (Mini Mental State Examination) ≥ 20 and live at home with a relative
62312372|NCT04164667|ACTIVE_COMPARATOR|Self-Guided MAP (sgMAP)|Participants received the intervention goals at the beginning of the study which included instruction on how to perform each of the individual components of the MAP protocol and how to use the study devices/apps, but they did not receive any further guidance during the intervention.
62682865|NCT06688968|ACTIVE_COMPARATOR|patients with parkinson's disease (PD)|patients followed up at the Center Expert Parkinson of Montpellier (CEPMo), over 60 with Parkinson's disease who have cognitive impairment based on an MMSE (Mini Mental State Examination) ≥ 20 and live at home with a relative
62312373|NCT04776369|ACTIVE_COMPARATOR|Lidocaine group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
62312374|NCT04776369|ACTIVE_COMPARATOR|Magnesium group|30 patients will receive IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
62312375|NCT04776369|ACTIVE_COMPARATOR|Combination group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. after induction of anesthesia.
62312376|NCT04776369|PLACEBO_COMPARATOR|control group|30 patients will receive IV saline 50 ml plus IV saline 50 ml over 30 min. after induction of anesthesia.
62312377|NCT01134484|EXPERIMENTAL|VTD|
62312378|NCT01134484|ACTIVE_COMPARATOR|TD|
61922623|NCT02689687|EXPERIMENTAL|Intervention|All participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.
62122961|NCT02351648|ACTIVE_COMPARATOR|Control'|Patients receive usual standard of care from the internal medicine team
62122962|NCT03426033|EXPERIMENTAL|Single dose of warfarin|Single dose of warfarin administered to obtain pharmacokinetic information.
62682866|NCT06688968|ACTIVE_COMPARATOR|Healthy control|Subjects aged over 60, with no known neurodegenerative disease, living at home with a relative in the Hérault département.
62682867|NCT05298046|EXPERIMENTAL|TAVO101: Low dose|TAVO101: TAVO101 single ascending dose IV infusion.
62122963|NCT03426033|EXPERIMENTAL|Warfarin in combination with ISIS 681257|ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.
62122964|NCT03914859|OTHER|Exposed|Urinary level of 1-hydroxypyrene, the most sensitive biomarker of PAH exposure greater than 0.1 μmol / mol creatinine
62122965|NCT03914859|OTHER|Not exposed|Urinary level of 1-hydroxypyrene, the most sensitive marker of PAH exposure below 0.1 μmol / mol creatinine
62682868|NCT05298046|EXPERIMENTAL|TAVO101: Medium dose|TAVO101: TAVO101 single ascending dose IV infusion.
62122966|NCT06186245|EXPERIMENTAL|Early feeding|If randomized to the experimental group, patient's diet will be advanced to clear liquid for the first day. On the second day, diet will be advanced to full liquid and advanced up to oral (carb controlled 1600 calories) diet as tolerated.
62682869|NCT05298046|EXPERIMENTAL|TAVO101: High dose|TAVO101: TAVO101 single ascending dose IV infusion.
62682870|NCT05298046|PLACEBO_COMPARATOR|Placebo|Placebo single ascending dose IV infusion.
62122967|NCT06186245|NO_INTERVENTION|Nothing per mouth|Patient will be kept without PO intake until they are bridged from the insulin drip
61922624|NCT03067831|EXPERIMENTAL|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
62682871|NCT06419660|EXPERIMENTAL|Esomeprazole + BI 300202 (T) then BI 300202 (R) treatment|T=test R=reference
62682872|NCT06419660|EXPERIMENTAL|BI 300202 (R) then esomeprazole + BI 300202 (T) treatment|
62682873|NCT06695702||nursing students' level of knowledge about oncology symptoms|The benefit of workbased learning on nursing students' knowledge of oncology symptom management
62682874|NCT01883973||MER guidance|Will undergo DBS implantation in the awake state using a frame based stereotactic technique and intraoperative microelectrode recording to guide final lead placement.
61922625|NCT03348384|EXPERIMENTAL|Cocaine use disorders|PET scan
61922626|NCT03348384|EXPERIMENTAL|Controls|PET scan
61922627|NCT01976078||Midazolam/Ranitidine/Esomeprazole|All enrolled subjects will have a study pharmacokinetic visit where they will be given the above cocktail of drugs along with their clinically indicated voriconazole dose, followed by blood sampling over the next 12 hours.
62122968|NCT05141149|EXPERIMENTAL|Cohort 1M|1 mg/kg of PBP1510 as monotherapy will be administered
62122969|NCT05141149|EXPERIMENTAL|Cohort 1C|1 mg/kg of PBP1510 and 1000 mg/m\^2 of gemcitabine as combination therapy will be administered
62122970|NCT05141149|EXPERIMENTAL|Cohort 2M|3 mg/kg of PBP1510 as monotherapy will be administered
62122971|NCT05141149|EXPERIMENTAL|Cohort 2C|3 mg/kg of PBP1510 and 1000 mg/m\^2 of gemcitabine as combination therapy will be administered
62122972|NCT05141149|EXPERIMENTAL|Cohort 3M|6 mg/kg of PBP1510 as monotherapy will be administered
62122973|NCT05141149|EXPERIMENTAL|Cohort 3C|6 mg/kg of PBP1510 and 1000 mg/m\^2 of gemcitabine as combination therapy will be administered
62122974|NCT05141149|EXPERIMENTAL|Cohort 4M|10 mg/kg of PBP1510 as monotherapy will be administered
62122975|NCT05141149|EXPERIMENTAL|Cohort 4C|10 mg/kg of PBP1510 and 1000 mg/m\^2 of gemcitabine as combination therapy will be administered
62122976|NCT05141149|EXPERIMENTAL|Cohort 5M|15 mg/kg of PBP1510 as monotherapy will be administered
62122977|NCT05141149|EXPERIMENTAL|Cohort 5C|15 mg/kg of PBP1510 and 1000 mg/m\^2 of gemcitabine as combination therapy will be administered
62122978|NCT00742300|EXPERIMENTAL|A|Treatment Group
62122979|NCT05350527|EXPERIMENTAL|Arm A: Web platform and video information support|After usual preoperative information delivered by surgeon, patients allocated to Arm will be able to access to video information support and web platform.
62682875|NCT01883973||MRI Guidance|Will undergo DBS implantation under general anesthesia using anatomical targeting in an operating room equipped with an intraoperative MRI to guide electrode placement
62682876|NCT05513508|EXPERIMENTAL|Intervention group|In the intervention group the first mask will be randomly chosen between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask. Thereafter, NPPV mask will be changed every 6 hours, alternating the two different interfaces. Patients wearing oro-nasal masks will receive protective dressings on nasal bridge before starting NPPV.
62682877|NCT05513508|ACTIVE_COMPARATOR|Control group|In the control group, mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Patients wearing oro-nasal masks will receive protective dressings on nasal bridge before starting NPPV. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
62682878|NCT06162312|EXPERIMENTAL|Antenatal perineal massage|daily 5-minute perineal massage from the 34th or 35th week of pregnancy until delivery
62682879|NCT06162312|NO_INTERVENTION|Control|standard antenatal, intrapartum and postpartum care
62682880|NCT05964868|EXPERIMENTAL|Liposomal Bupivacaine|This group will receive a one time 5 mL injection of liposomal bupivacaine post-operatively at the surgical site.
62682881|NCT05964868|ACTIVE_COMPARATOR|Bupivacaine with epinephrine|This group will receive a one-time 5 mL injection of 0.25% bupivacaine with 1:200,000 epinephrine post-operatively at the surgical site.
62682882|NCT05964868|PLACEBO_COMPARATOR|Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
62682883|NCT06439771|EXPERIMENTAL|Experimental: Corhort A|YL202 is provided as the lyophilized powder, 200 mg/vial. Triple-negative breast cancer (TNBC) patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
62682884|NCT06439771|EXPERIMENTAL|Experimental: Corhort B|YL202 is provided as the lyophilized powder, 200 mg/vial. HR-positive breast cancer with HER2-Zero-expression and HER2-Low-expression patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
62682885|NCT06439771|EXPERIMENTAL|Experimental: Corhort C|YL202 is provided as the lyophilized powder, 200 mg/vial. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC (excluding HER2+ patients, ie, HER2 IHC 3+ or IHC 2+/ISH+ patients) will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
62682886|NCT00658814|EXPERIMENTAL|Treatment (azacitidine, gemtuzumab)|See Detailed Description
62682887|NCT05497960|OTHER|Vivo strength training|Participants will exercise virtually, 2 days a week for 12 weeks for a 45 minute live, interactive strength training workout.
62682888|NCT04491955|EXPERIMENTAL|1/Arm 1|CEA/ MUC1 Vaccines + M7824 + N-803 (Triple Therapy).
62122980|NCT05350527|NO_INTERVENTION|Arm B: Standard Preoperative information|Patients randomized in Arm B will only receive usual preoperative information delivered by the surgeon.
62312379|NCT05602467|ACTIVE_COMPARATOR|Treatment Group|A total of 32 sessions (2 sets of 16 sessions) of TPS will be delivered, each lasting 30 minutes. Each set includes 3 sessions per week in the first 2 weeks and then 1 session per week in the subsequent 10 weeks.
62312380|NCT05602467|PLACEBO_COMPARATOR|Control Group|The control group will be recruited with the same recruitment criteria. They would receive treatment-as-usual (TAU) in the outpatient clinic without TPS intervention given.
62682889|NCT04491955|EXPERIMENTAL|2/Arm 2A|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); dose escalation of NHS-IL12.
62682890|NCT04491955|EXPERIMENTAL|3/Arm 2B|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); fixed dose of NHS-IL12.
62682891|NCT03004144|OTHER|FLOAT-Support|
62682892|NCT05800002|EXPERIMENTAL|Intravascular ultrasound guidance|
62682893|NCT05800002|ACTIVE_COMPARATOR|Angiography guidance|
62682894|NCT06695975|EXPERIMENTAL|Occupational self-analysis|"Occupational Self-Analysis program had the focus on increasing occupational awareness, making it easier for the participants to analyze their occupations, reflect on whether the activities in which they were involved were meaningful to them and learn about their supports and barriers for occupational participation which allowed modifications to their occupational routines"
62682895|NCT06695975|NO_INTERVENTION|Control group|The control group did not receive any specific intervention, and free time was simply included in their agenda within the Mental Helath Therapeutic Community.
62682896|NCT03615430|PLACEBO_COMPARATOR|Control group|saline control group, 15 mL of the saline was administered to superficial and deep surface of serratus anterior in Control group via ultrasound before the surgery
62682897|NCT03615430|EXPERIMENTAL|SPB group|Serratus plane block group, 15ml of 0.25% ropivacaine, a widely used local anesthetic for peripheral nerve block, was administered to superficial and deep surface of serratus anterior in SPB group via ultrasound before the surgery
62682898|NCT06248086|EXPERIMENTAL|Group A: ASP2802 Low Dose followed by MA-20|Participants will receive a low dose of ASP2802 on Day 0 of cycle 1. Each participant will then receive up to 2 doses of MA-20 booster in each 28-day cycle.
62682899|NCT06248086|EXPERIMENTAL|Group B: ASP2802 Intermediate Dose followed by MA-20|Participants will receive an intermediate dose of ASP2802 on Day 0 of cycle 1. Each participant will then receive up to 2 doses of MA-20 booster in each 28-day cycle, with dose level(s) selected from Group A.
62682900|NCT06248086|EXPERIMENTAL|Group C: ASP2802 High Dose followed by MA-20|Participants will receive a higher dose of ASP2802 on Day 0 of cycle 1. Each participant will then receive up to 2 doses of MA-20 booster in each 28-day cycle, with dose level(s) selected from Group B.
62682901|NCT04333862||Healthcare workers providing healthcare|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
62312381|NCT04589494|ACTIVE_COMPARATOR|tramadol group|tramadol hydrochloride 100 mg three times daily
62312382|NCT04589494|ACTIVE_COMPARATOR|morphine group|morphine 30 mg twise times daily
62312383|NCT00842517|EXPERIMENTAL|Extended|36-week duration contingency management program
62682902|NCT04333862||Healthcare workers staying at home|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
62682903|NCT04333862||Hospitalized patients|To compare the infection rate of hospitalized patients versus healthcare workers
62682904|NCT05706376|EXPERIMENTAL|Promoting Positive Family Futures|
62682905|NCT05706376|ACTIVE_COMPARATOR|Treatment as Usual|
62682906|NCT06690099||Pregnant women|Pregnant women who are RhD negative and between 12 and 28 weeks gestation
62682907|NCT05726630|EXPERIMENTAL|Divozilimab|
62682908|NCT05726630|PLACEBO_COMPARATOR|Placebo|
62682909|NCT06690619|PLACEBO_COMPARATOR|Placebo|Placebo
62312384|NCT00842517|ACTIVE_COMPARATOR|Standard|12-week duration contingency management program
62312385|NCT04729530|ACTIVE_COMPARATOR|Active|Air purifier device with standard filter cartridges installed.
62312386|NCT04729530|PLACEBO_COMPARATOR|Placebo|Air purifier device with placebo (non working) filter cartridges installed.
62682910|NCT06690619|ACTIVE_COMPARATOR|Low Dose Alpha-GPC|315 mg dose of alpha-glycerylphosphorycholine (alpha-GPC)
62682911|NCT06690619|ACTIVE_COMPARATOR|High Dose Alpha-GPC|630 mg dose of alpha-glycerylphosphorycholine (alpha-GPC)
62682912|NCT06266403|EXPERIMENTAL|People with amyotrophic lateral sclerosis, age-matched speakers|People with ALS and age-matched speakers will participate in structured communicative interaction.
62682913|NCT02554838|ACTIVE_COMPARATOR|Rehabilitation|"Rehabilitation :~* Physical activity~* Home assessment and modification"
62122981|NCT02244411|EXPERIMENTAL|Intervention group|Participants will be assigned an individual diet \& physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website \& email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables \& low-fat dairy products. Calorie goals are based upon weight at study entry \& whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing \& gradually adding bouts of ≥ 10 minutes in length. Monitoring \& Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, \& physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits \& questionnaires.
62122982|NCT02244411|ACTIVE_COMPARATOR|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
62312387|NCT05265013|EXPERIMENTAL|ASP-1929 Photoimmunotherapy Combined With Pembrolizumab|"Patients will receive the approved label dose of pembrolizumab, which is administered every 3 weeks on days 1 and 22 of each treatment cycle.~On Day 8 of each cycle, patients will receive ASP-1929 followed by illumination at accessible tumor sites using the investigational PIT690 Laser System on Day 9.~Each treatment cycle, which is driven by ASP-1929 PIT frequency of administration, will last 42 days. Patients will be treated with ASP-1929 PIT and pembrolizumab for up to 12 months with a maximum of 8 treatment cycles."
62312388|NCT06672120|EXPERIMENTAL|Intervention Group|The intervention group will receive home-based, video-supervised exercise training from a sports scientist. Training will consist of elements of moderate continuous and high-intensity endurance training as well as resistance training.
62477394|NCT03521973|PLACEBO_COMPARATOR|Group 4|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 2."
62682914|NCT02554838|EXPERIMENTAL|Rehabilitation and CBT|"Rehabilitation associated with cognitive behavioral therapy (CBT) :~* Physical activity~* Home assessment and modification~* Cognitive behavioral therapy"
62682915|NCT01504542|EXPERIMENTAL|Low-dose HS-110|2,000,000 cells/0.5mls + erlotinib 150mg orally once daily
62682916|NCT01504542|EXPERIMENTAL|High dose HS110|10,000,000 HS110 cells/0.5ml + erlotinib 150mg orally once daily.
62682917|NCT01504542|PLACEBO_COMPARATOR|Placebo vaccine + erlotinib 150mg orally once daily|Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
62682918|NCT05144997|EXPERIMENTAL|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
62682919|NCT06687629|ACTIVE_COMPARATOR|crushing|Concha bullosa crushing group
62682920|NCT06687629|ACTIVE_COMPARATOR|resection|Concha bullosa resection group
62737718|NCT06294262|EXPERIMENTAL|VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 60 years or older|A single, 0.55 mL intramuscular injection of VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 60 years or older (N = 16)
61922628|NCT04746872||Alinity m HR HPV|The Alinity m HR HPV IUO assay is a qualitative in vitro test that amplifies and detects HR HPV DNA in cervical cells collected in liquid media. The assay can differentiate between HPV 16, HPV 18, HPV 45 and non-HPV 16/18/45 genotypes \[(31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68)\].
61922629|NCT03498001|EXPERIMENTAL|Patients|
61922630|NCT02157207|PLACEBO_COMPARATOR|Placebo|Placebo will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. Placebo microcrystalline cellulose capsules will be of similar taste, color and appearance.
61922631|NCT02157207|EXPERIMENTAL|Antioxidant|"Supplementation will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. The first dose will consist of 300 mg of α-lipoic acid, 500 mg of vitamin C, and 200 IU of vitamin E, and the second dose will be 300 mg of α-lipoic acid, 500 mg of vitamin C, and 400 IU.~of vitamin E."
62122983|NCT00551577|ACTIVE_COMPARATOR|A1|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
62122984|NCT00551577|EXPERIMENTAL|A2|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
62122985|NCT04655859||severe early childhood caries|
62122986|NCT04655859||healthy children|
62122987|NCT04320771|EXPERIMENTAL|Neladenoson bialanate, mild renal impairment|Subjects with eGFR ≥60 - \<90 mL/min/1.73 received a single immediate-release (IR) tablet dose of 10 mg of neladenoson bialanate in the fasted state
62122988|NCT04320771|EXPERIMENTAL|Neladenoson bialanate, moderate renal impairment|Subjects with eGFR ≥30 - \<60 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
62122989|NCT04320771|EXPERIMENTAL|Neladenoson bialanate, severe renal impairment|Subjects with eGFR \<30 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
62122990|NCT04320771|EXPERIMENTAL|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
62122991|NCT01063140||RabAvert|
62122992|NCT01063140||Imovax|
62122993|NCT00904852|EXPERIMENTAL|Tandutinib, bevacizumab, and temozolomide|tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.
62122994|NCT05871450|EXPERIMENTAL|Participants living in Host Towns|Participants live in Host Towns, where a delegation of athletes are hosted for one week. Furthermore, Host Town coordinator organize several inclusive events.
62477395|NCT03521973|EXPERIMENTAL|Group 5|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10\^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 3."
62737719|NCT03449940|ACTIVE_COMPARATOR|Immediate repair (group 1)|"Penile explorations were done within 24 hours of presentation, under general or spinal anaesthesia.~1g Ceftriaxone IV was given.~Incision-- Subcoronal, circumferential \& degloving.~Repair-- Continuous technique with inverted knots using 3-0 polyglactin suture.~All patients were discharged from hospital within 24 hours."
62312389|NCT06672120|NO_INTERVENTION|Control Group|The control group will receive standard recommendations on physical activity.
62682921|NCT06694714|EXPERIMENTAL|0.5 ml Lidocaine with epinephrine vs. 1.0 ml Lidocaine with epinephrine|Each side of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into one side of the nose (nasal ala) and 1.0 ml of Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into the opposite nasal ala. Laterality of each anesthetic volume administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
62682922|NCT06694714|EXPERIMENTAL|1.0 ml Lidocaine with epinephrine vs 0.5 ml Lidocaine with epinephrine|Each side of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 1.0ml of Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into one side of the nose (nasal ala) and 0.5 ml of Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into the opposite nasal ala. Laterality of each anesthetic volume administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
62682923|NCT06196138|EXPERIMENTAL|Gum|Patients who will chew gum after surgery will constitute this group
62122995|NCT05871450|NO_INTERVENTION|Participants not living in Host Towns|Participants where no delegeation of athletes are hosted and no inclusive events are organized by Host Town coordinator.
62682924|NCT06196138|EXPERIMENTAL|Hot Compress|Patients who will undergo hot compress after surgery will constitute this group
62682925|NCT06196138|NO_INTERVENTION|Control|Patients who will undergo routine protocol will constitute this group
62682926|NCT06163807||Asthma patients with different severities|Asthma patients with different severities followed for 5 years. Real-life, antiasthmatic drugs selected by investigators. Clinical, analytical, biomarkers, image techniques
61922632|NCT04694456|EXPERIMENTAL|Facioscapulohumeral muscular dystrophy|Adult ambulant patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1)
61922633|NCT04570267|EXPERIMENTAL|CSL324 (Low dose)|One low dose of CSL324 administered subcutaneously on Day 1
61922634|NCT04570267|EXPERIMENTAL|CSL324 (High dose)|One high dose of CSL324 administered subcutaneously on Day 1
62122996|NCT01745016|PLACEBO_COMPARATOR|Placebo|placebo
62122997|NCT01745016|EXPERIMENTAL|Beta-Alanine|beta-alanine
62122998|NCT03282786|ACTIVE_COMPARATOR|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
62122999|NCT03282786|NO_INTERVENTION|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
62123000|NCT03282786|ACTIVE_COMPARATOR|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
62682927|NCT06163807||Severe asthma patients treated with biologics|In follow-up for 3 years and new patients. Real-life, antiasthmatic drugs selected by investigators. Clinical, analytical, biomarkers, image techniques
62312390|NCT03358862||Myopes|Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.
62682928|NCT01505426|EXPERIMENTAL|ASP1941 group|ASP1941 + metformin
62682929|NCT01505426|PLACEBO_COMPARATOR|placebo group|placebo + metformin
62682930|NCT04873856|EXPERIMENTAL|Intervention group|"Intervention contains:~1. individual nutritional plan~2. regular contact~3. friendly reminder/informal caregiver and~4. weight dairy."
62682931|NCT04873856|NO_INTERVENTION|Control Group|Standard of care
62682932|NCT05226078|EXPERIMENTAL|Four Sessions of CBT-I|
62123001|NCT03282786|NO_INTERVENTION|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
62123002|NCT05925920|ACTIVE_COMPARATOR|Active|Receive a single dose of ENT-03 sub-cutaneously
62682933|NCT05226078|EXPERIMENTAL|Eight Sessions of CBT-I|
62312391|NCT06085365|PLACEBO_COMPARATOR|Placebo Group|normal diet group
62312392|NCT06085365|EXPERIMENTAL|Immunonutrition Group|Immunonutrition (Suyusu) 250ml oral twice one day d1-d21 for two cycles
62123003|NCT05925920|PLACEBO_COMPARATOR|Placebo|Receive a single dose of placebo sub-cutaneously
62123004|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 2.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 2.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
62682934|NCT05226078|EXPERIMENTAL|Ten Sessions of CBT-I|
62682935|NCT05226078|EXPERIMENTAL|Twelve Sessions of CBT-I|
62682936|NCT02317042|ACTIVE_COMPARATOR|Standard ST Mode|"Participants underwent the first PSG study (Titration Night 1) on ST Mode ( prior to going on AutoEPAP iVAPS or Fixed EPAP iVAPS) whilst receiving their standard NIV therapy through the clinical trial device Juno. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy."
62682937|NCT02317042|EXPERIMENTAL|AutoEPAP iVAPS|"Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
62123005|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 2.75 mcg/kg|Subjects undergoing posterior spinal surgery will receive 2.75 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
61922635|NCT04570267|PLACEBO_COMPARATOR|Placebo|One dose of placebo administered subcutaneously on Day 1
61922636|NCT03457233|ACTIVE_COMPARATOR|Normal weight|18.5- 24.9 kg/m2
61922637|NCT03457233|ACTIVE_COMPARATOR|Overweight|BMI 25-29.9 kg/m2
61922638|NCT03457233|ACTIVE_COMPARATOR|Obese|BMI ≥ 30 kg/m2
62123006|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 3 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
61922639|NCT05170568|EXPERIMENTAL|T cell injection targeting CD7 chimeric antigen receptor|
62312393|NCT04452526|EXPERIMENTAL|ARM I (EARLY INTERVENTION) (educational material, reminders)|Health systems receive educational materials consisting of posters, brochures and handouts. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination
62312394|NCT04452526|EXPERIMENTAL|ARM II (DELAYED INTERVENTION)(education, reminder, usual care)|Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.
62312395|NCT02511574|EXPERIMENTAL|cervical pessary|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
62312396|NCT02511574|ACTIVE_COMPARATOR|natural progesterone|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
62477396|NCT03521973|PLACEBO_COMPARATOR|Group 6|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 4."
62477397|NCT00849823|ACTIVE_COMPARATOR|Male Sexual Health Program|
62477398|NCT00849823|EXPERIMENTAL|Focus on the Future Program|
62477399|NCT00682461|ACTIVE_COMPARATOR|Marketed formulation|Marketed nicotine replacement therapy product
62477400|NCT00682461|EXPERIMENTAL|prototype|Nicotine prototype
62477401|NCT01462708|EXPERIMENTAL|Assess [18F]MK-9470 and PET imaging|To Assess \[18F\]MK-9470 and PET imaging
62123007|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 3.25 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3.25 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
62477402|NCT03509194||Pediatric liver disease patients|Comparison of outcome of pediatric liver disease and prognostic functional liver test results and gene expression in liver biopsies.
62477403|NCT05506956|EXPERIMENTAL|Flotetuzumab Following Allogeneic Transplant|All participants will receive one cycle (28 days) of flotetuzumab. After one cycle, all participants will undergo a bone marrow biopsy to assess response and based on the response, may receive additional cycles up to a total cycle of six cycles.
62477404|NCT05472311|OTHER|Treat with thermal ablation|Women who screen positive for pre-cancer lesions of the cervix will be offered treatment with thermal ablation and the process of implementation evaluated using implementation science RE-AIM framework
62477405|NCT06559124|SHAM_COMPARATOR|Grup A: Traditional Physiotherapy + Sham Kinesiotape|"Traditional Physiotherapy: A total of 15 sessions of joint range of motion, stretching exercises and strengthening exercises will be applied 5 days a week for 3 weeks, each session lasting 45 minutes. Friction massage will be applied. In addition, ultrasound, TENS and cold packs will be applied to the patients according to their tolerance.~Sham Kinesiotape: 2 days a week, 6 times in total, following conventional physiotherapy for 3 weeks. Kinesio tape 10 cm I strips will be applied on the acromioclavicular joint in the sagittal plane and in the transverse plane from the distal deltoid without applying tension. The tape will be applied twice a week in total, remaining for 3 days and released one day after each application."
62477406|NCT06559124|EXPERIMENTAL|Grup B: Kinesiotape with Facilitation Method + Traditional Physiotherapy|In addition to traditional physiotherapy, traditional physiotherapy will be applied 2 days a week, 6 times in total, followed by 3 weeks. Kinesio tape has been developed to reflect the properties of the skin, its thickness is similar to the epidermis layer of the skin, and its elasticity is similar to the elastic properties of human skin. Participants should be informed that the patch will remain for several days and will not be removed by bathing or swimming. Kinesio tape will be applied to the deltoid muscle with the starting point at 0 tension while the arm is in a relaxed position and will be slightly heated. It will be applied in addition to traditional physiotherapy 2 days a week for 3 weeks.
62123008|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 3.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
62123009|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 4 mcg/kg|Subjects undergoing posterior spinal surgery will receive 4 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
62477407|NCT06559124|EXPERIMENTAL|Grup C: Kinesiotape with Inhibition Method + Traditional Physiotherapy|"In addition to traditional physiotherapy, traditional physiotherapy will be applied 2 days a week, 6 times in total, followed by 3 weeks.~Kinesio tape will be applied to the deltoid muscle with inhibition and mechanical correction technique, and to the supraspinatus muscle with inhibition technique twice a week, 3 days apart. First of all, it will be applied to the deltoid muscle with the inhibition technique. Y-shaped kinesio tape will be placed 3 cm below the humerus tuberculum deltoidea without stretching. During application, the shoulder will be in maximum extension and external rotation for the front arm of the Y strip, and in 45 degrees transverse flexion and horizontal adduction for the rear arm of the Y strip."
61922640|NCT03636711||experimental group|• Patient admitted to emergency for infectious syndrome Description of antibiotic protocol, according to a syndromic approach will be performed
61922641|NCT02359162|EXPERIMENTAL|P-Gemox|"P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
62123010|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 4.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 4.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
62123011|NCT05552443|EXPERIMENTAL|Intrathecal Hydromorphone 5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
62312397|NCT06570213|ACTIVE_COMPARATOR|Active Stellate Ganglion Block + Cognitive Processing Therapy|Participants in this arm will receive two active Stellate Ganglion Block Injections, two weeks apart. After receiving the first injection, participants will complete 10 sessions of Cognitive Processing Therapy over the course of one week.
62123012|NCT02769468|ACTIVE_COMPARATOR|The Back|The probe is placed lateral from the spine, 1 cm above the intergluteal cleft, and in side position to the flank between the hips and the ribs.
62312398|NCT06570213|SHAM_COMPARATOR|Placebo Injection + Cognitive Processing Therapy|Participants in this arm will receive two placebo (saline) Injections, two weeks apart. After receiving the first injection, participants will complete 10 sessions of Cognitive Processing Therapy over the course of one week.
62312399|NCT06570213|PLACEBO_COMPARATOR|Active Stellate Ganglion Block + Daily Symptom Monitoring|Participants in this arm will receive two active Stellate Ganglion Block Injections, two weeks apart. After receiving the first injection, participants will complete 5 sessions of daily symptom monitoring with a member of study staff over the course of one week.
62312400|NCT01903434|EXPERIMENTAL|Evacetrapib -- Solid Fraction Test|Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to 2 of 3 periods
62312401|NCT01903434|EXPERIMENTAL|Evacetrapib -- Solid Fraction Reference|Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to 2 of 3 periods
62682938|NCT02317042|ACTIVE_COMPARATOR|Fixed EPAP iVAPS|"Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
62682939|NCT05736913|ACTIVE_COMPARATOR|Intradermal|One dose of 30ug (0.3mL) intradermal BNT162b2
62682940|NCT05736913|ACTIVE_COMPARATOR|Intramuscular|One dose of 30ug (0.3mL) intramuscular BNT162b2
62682941|NCT06002594|EXPERIMENTAL|group low-volume irrigation|Nasal irrigation was performed using low-volume saline solution
62682942|NCT06002594|EXPERIMENTAL|group high-volume irrigation|Nasal irrigation was performed using high-volume saline solution
62682943|NCT05589714||Younger Age Cohort|"Participants ages ≥ 4 years and \< 8 years old will be designated as the Younger Age Cohort.~* Participants in this cohort will not be assigned a Vision Cohort.~* Registry/Screening Visit and Natural History Study Visits will have an abbreviated testing schedule, detailed in the Schedule of Study Visits and Procedures table."
62682944|NCT05589714||Vision Cohort 1|Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye\* at the Registry/Screening Visit: visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field\*\* diameter 10 degrees or more in every meridian of the central field
62312402|NCT03110822|EXPERIMENTAL|Rux Len and Steroid|Ruxolitinib Oral Tablet \[Jakafi\] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
62312403|NCT03110822|EXPERIMENTAL|Rux and Steroid until progression, then add Len|Subject will receive Ruxolitinib Oral Tablet \[Jakafi\] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
62682945|NCT05589714||Vision Cohort 2|Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye\* at the Registry/Screening Visit: visual acuity ETDRS letter score of 19-53 (approximate Snellen equivalent 20/100 to 20/400) or visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field\*\* diameter less than 10 degrees in any meridian of the central field
62682946|NCT05589714||Vision Cohort 3|Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye\* at the Registry/Screening Visit: visual acuity ETDRS letter score of 18 or less (approximate Snellen equivalent 20/500 or worse)
62682947|NCT03581292|EXPERIMENTAL|Treatment (radiation therapy, veliparib, temozolomide)|"CHEMORADIOTHERAPY PHASE: Patients receive veliparib PO BID and undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Beginning 4 weeks after chemoradiotherapy phase, patients receive veliparib PO BID and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
62682948|NCT04007549|EXPERIMENTAL|Individual brief motivational intervention|Individual brief motivational intervention (IBMI) on tobacco/alcohol risk reduction for the breast cancer patient; the partner receive e-mail or postal brief advices.
62682949|NCT04007549|ACTIVE_COMPARATOR|Couple-based brief motivational intervention|Couple-based brief motivational intervention (CBMI) on tobacco/alcohol risk reduction.
62682950|NCT01923974|PLACEBO_COMPARATOR|Placebo|IV formulation
62682951|NCT01923974|ACTIVE_COMPARATOR|Melatonin 10 mg|IV formulation, Melatonin 10 mg
62682952|NCT01923974|ACTIVE_COMPARATOR|Melatonin 100 mg|IV formulation, Melatonin 100 mg
62682953|NCT01872754|ACTIVE_COMPARATOR|2: Propofol|Control arm: the use of TCI of hypnotic (Propofol) during realization bronchial fibroscopy.
62682954|NCT01872754|EXPERIMENTAL|1: Remifentanil|Interventional arm: the use of TCI of morphinomimetic (Remifentanil) during realization bronchial fibroscopy.
62123013|NCT02769468|ACTIVE_COMPARATOR|Chest|The probe is placed on the chest, 1 cm above the left nipple.
62123014|NCT02769468|ACTIVE_COMPARATOR|Left Axilla|The probe is placed deep in the left axilla
62312404|NCT03110822|EXPERIMENTAL|Expanded Eligibility Criteria|Subject will receive Ruxolitinib Oral Tablet \[Jakafi\] at 15mg BID, Lenalidomide at 10mg QD, and Methylprednisolone at 40mg QOD until disease progression.
62312405|NCT03110822|EXPERIMENTAL|High-dose Ruxolitinib|Subject will receive Ruxolitinib Oral Tablet \[Jakafi\] at 20mg BID and Methylprednisolone at 40mg QOD until disease progression.
62312406|NCT04019496||Episodic Migraine|
62312407|NCT04019496||Healthy controls|equal to or less than 1 headache day/month
62312408|NCT00675285|ACTIVE_COMPARATOR|1|
62312409|NCT00675285|PLACEBO_COMPARATOR|2|
62312410|NCT00306891|EXPERIMENTAL|Cediranib 45 mg Fed|Part A: Cediranib 45 mg Fed State
62312411|NCT00306891|EXPERIMENTAL|Cediranib 45 mg Fasted|Part A: Cediranib 45 mg Fasted State
62312412|NCT00306891|EXPERIMENTAL|Cediranib 45 mg Fixed Dose|Part B: Cediranib 45 mg Fixed Dose
62312413|NCT00306891|EXPERIMENTAL|Cediranib 30 - 90 mg Dose Escalation|Part B: Cediranib 30 - 90 mg Dose Escalation
62312414|NCT05418608|EXPERIMENTAL|Aim 1|A PET study of the novel SV2A imaging tracer \[11C\]UCB-J in participants, to characterize the distribution of \[11C\]UCB-J in cortical and subcortical areas in experienced meditators compared to non-meditating controls. Subjects will undergo one PET scan with \[11C\]UCB-J and one MRI scan for anatomical identification of brain regions.
62312415|NCT04593498||ESVEA|ESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
62312416|NCT04593498||Non-ESVEA|Participants not meeting inclusion criteria
62312417|NCT05523635||Gamma 4|Subjects in the clinical investigation will undergo placement of the Gamma4 Nailing System, according to the approved Instructions for Use and Operative Technique Manual
62312418|NCT01522651|PLACEBO_COMPARATOR|Placebo|Ranolazine placebo plus dronedarone placebo for 12 weeks.
62312419|NCT01522651|EXPERIMENTAL|Ranolazine 750 mg|Ranolazine 750 mg plus dronedarone placebo for 12 weeks.
62123015|NCT04996264|EXPERIMENTAL|Varespladib-methyl|"Varespladib-methyl is an immediate-release (IR), oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.~Scaled pediatric doses of varespladib-methyl are supplied as 50 mg IR capsules for oral administration.~Adult subjects will receive an initial loading dose of 500 mg (2 × 250 mg oral tablet) varespladib-methyl upon randomization, followed by dosing with 250 mg varespladib-methyl (1 × 250 mg oral tablet) approximately 12 hours later, and subsequent twice daily (BID) dosing with 1 × 250 mg varespladib-methyl oral tablets for the remainder of the 7-day treatment period. Tablets may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation.~Pediatric subjects (5 to \< 18 years) will be administered doses of varespladib-methyl determined by allometric scaling, provided as 50 mg capsules. Age-appropriate capsules may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation."
62123016|NCT04996264|PLACEBO_COMPARATOR|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an immediate-release capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~The dosing of placebo will match that of varespladib-methyl."
62312420|NCT01522651|EXPERIMENTAL|Dronedarone 225 mg|Ranolazine placebo plus dronedarone 225 mg for 12 weeks.
62312421|NCT01522651|EXPERIMENTAL|Ranolazine 750 mg + Dronedarone 225 mg|Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.
62312422|NCT01522651|EXPERIMENTAL|Ranolazine 750 mg + Dronedarone 150 mg|Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.
62312423|NCT05670119|ACTIVE_COMPARATOR|Intervention Group|Nurses in the intervention group will be given face-to-face training on evidence-based catheter-related infection control measures. The content of the training program will also be given to the participants as written material (brochure). The training will take an average of 30 minutes. After the data collection forms are applied to the participants in the intervention group (pre-test), evidence-based training on catheter-related infection control measures will be conducted. The forms will be applied again immediately after the training (post-test) to measure the knowledge level of nurses and three months after the training (post-test) to measure the level of attitude.
62477408|NCT06558734|EXPERIMENTAL|Device: Glass-ionomer cement|The capsule was attached to the mixer and mixed for 10 seconds. The cement was evenly distributed to the crowns paying attention that there were no air voids. Then crowns were placed by pressing them onto the prepared teeth with finger pressure. At least 2 minutes and 15 seconds after mixing, the excess cement was cleaned off. Following mixing, a minimum of 4 minutes and 30 seconds was allowed for the cement to set.
62682955|NCT04156100|EXPERIMENTAL|AGEN1223|AGEN1223 is a bispecific antibody.
62312424|NCT05670119|NO_INTERVENTION|Control Group|Routine in-service training practices will be given to the control group. Data collection forms will be applied to the participants in the control group at the same time as the intervention group.
62312425|NCT04901026|ACTIVE_COMPARATOR|An in-house manikin|Participants use an in-house manikin
62312426|NCT04901026|SHAM_COMPARATOR|A manikin in market|Participants use a manikin from market
62312427|NCT03980158||Upper airway stimulation group|
62312428|NCT03980158||OSA group with conservative / no treatment|
62312429|NCT03980158||Test group without OSA|
62312430|NCT02820610|ACTIVE_COMPARATOR|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
62312431|NCT02820610|ACTIVE_COMPARATOR|Magnesium sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
62682956|NCT04156100|EXPERIMENTAL|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody
62312432|NCT02820610|PLACEBO_COMPARATOR|Control group|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
62312433|NCT05045755||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
62477409|NCT06558734|EXPERIMENTAL|Device: Resin-modified glass-ionomer cement|FujiCEM 2 (GC, Tokyo, Japan) was evenly distributed to the inner surface of the crown with the syringe and immediately placed onto the teeth with finger pressure. The crowns were placed on the prepared tooth. At least 2 minutes and 15 seconds after mixing, the excess cement was cleaned off. Following mixing, a minimum of 4 minutes and 30 seconds was allowed for the cement to set.
62312434|NCT05045755||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
62312435|NCT03631667|EXPERIMENTAL|50 ng dose|Capsule containing 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene (BaP)
62312436|NCT03631667|EXPERIMENTAL|50 ng dose plus 1250 ng phenanthrene|Capsule containing 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene (BaP) and 1250 phenanthrene
62312437|NCT03158545|PLACEBO_COMPARATOR|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
62312438|NCT03158545|ACTIVE_COMPARATOR|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
62312439|NCT03158545|ACTIVE_COMPARATOR|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
62312440|NCT04416776||Eligible patients for AI test|Device: strabismus diagnostic system.
62312441|NCT00554957||NBC|All dancers with the National Ballet of Canada will be given the opportunity to participate in the study.
62477410|NCT01143311|OTHER|ARM A|"4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor"
62477411|NCT01343303|EXPERIMENTAL|001|JNJ-39439335 2 x 5 mg tablets once daily for 21 days
62477412|NCT01343303|EXPERIMENTAL|002|JNJ-39439335 2 x 25 mg tablets once daily for 21 days
62682957|NCT03497117|OTHER|CF pulmonary exacerbation group|"Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.~LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.~PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet."
62682958|NCT00141193|PLACEBO_COMPARATOR|A|
62682959|NCT02661815|EXPERIMENTAL|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
62682960|NCT02661815|EXPERIMENTAL|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
62682961|NCT02661815|EXPERIMENTAL|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
62312442|NCT00554957||TDT|All dancers with the Toronto Dance Theatre will be given the opportunity to participate.
62312443|NCT00554957||KDC|All members of the Kibbutz Contemporary Dance company will be given the opportunity to participate.
62312444|NCT00554957||BDC|All dancers with the Batsheva Dance Company or Ensemble will be given the opportunity to participate.
62312445|NCT00554957||RSB|All dancers with the Royal Swedish Ballet will be given the opportunity to participate.
62682962|NCT02661815|EXPERIMENTAL|Phase 1 Escalation Cohort|Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).
62682963|NCT05672537|EXPERIMENTAL|Durvalumab Combined with GemCis Neoadjuvant Therapy Group|
62312446|NCT00554957||RDB|All dancers with the Royal Danish Ballet will be given the opportunity to participate.
62312447|NCT02553915|PLACEBO_COMPARATOR|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
62312448|NCT02553915|EXPERIMENTAL|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
62312449|NCT02553915|EXPERIMENTAL|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
62312450|NCT02553915|EXPERIMENTAL|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
62312451|NCT06671145|ACTIVE_COMPARATOR|group (1)catheter ablation after diagnosis of Atrioventricular Nodal Reentry Tachycardia|diagnosis Atrioventricular Nodal Reentry Tachycardia before catheter ablation
62477413|NCT01343303|OTHER|003|Naproxen 500 mg capsule every 12 hours for 21 days
62477414|NCT01343303|PLACEBO_COMPARATOR|004|Placebo Placebo tablet/capsule every 12 hours for 21 days
62477415|NCT02833181||Awake patients|Awake patients
62477416|NCT02833181||Sedated patients|
62682964|NCT05672537|EXPERIMENTAL|Surgical treatment group|
61922642|NCT02359162|ACTIVE_COMPARATOR|EPOCH|"EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
62123017|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
62123018|NCT01703923|EXPERIMENTAL|FP01 6mg or Placebo|FP01 6mg Oral
62312452|NCT06671145|ACTIVE_COMPARATOR|group (2) catheter ablation after diagnosis of orthodromic Atrioventricular Reentry Tachycardia|diagnosis of orthodromic Atrioventricular Reentry Tachycardia before catheter ablation
62477417|NCT02833181||Sedated and curarized patients|
62682965|NCT02624232||Patients with anorectal malformations|"Participants are identified through relevant diagnostic codes in ICD-10(Q 42) and ICD-9(75.120, 75.121) in patients which underwent surgery for ARM in the years 1985-2005 are included if informed consent is obtained.~Relevant questionnaires regarding symptoms and QoL are completed before the following examinations:anorectal manometry, endoanal ultrasonography, pudendal nerve conduction velocity, colon transit time, Magnetic resonans(MR)-scan of the pelvis and uroflowmetry."
62312453|NCT00635531|PLACEBO_COMPARATOR|Placebo group|
62312454|NCT00635531|ACTIVE_COMPARATOR|Alprazolam XR group|
62312455|NCT01160146||Lifestyle counseling|"Clinicians provide lifestyle management counseling regarding healthful lifestyle behaviors and daily physical activity.~1. Logging foods for accountability and counting calories~2. Close attention to portion control and appropriate serving sizes of foods consumed~3. Consumption of appropriate calorie and sugar free beverages~4. Good meal distribution and avoidance of meal skipping~5. Balance of food groups using the MyPlate concept (USDA Choose My Plate)-inclusion of all food groups with emphasis on fruits, vegetables, whole grains, low-fat dairy products and lean meat/fish/poultry~6. Increasing physical activity with reasonable, sustainable exercise or activity. Working toward a goal of at least 30 minutes, 5 days per week"
62312456|NCT06393114|EXPERIMENTAL|Fermented product|Participants will consume a fermented oat-based product daily for three weeks within their diet.
62477418|NCT05841654|EXPERIMENTAL|Azilsartan treatment group|In the Azilsartan group, Azilsartan will be added in or switched to the original antihypertensive treatment plan, starting as 20 mg Qd, and gradually increased to 40 mg Qd according to the blood pressure. If the blood pressure is still not be controlled, antihypertensive drugs other than ACEI, ARB or ARNI will be added until the blood pressure is controlled.
61922643|NCT02718950|EXPERIMENTAL|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks.
62123019|NCT01703923|EXPERIMENTAL|FP01 12mg or Placebo|FP01 12mg Oral
62312457|NCT06393114|ACTIVE_COMPARATOR|Unfermented product|Participants will consume an unfermented oat-based product daily for three weeks within their diet.
62477419|NCT05841654|ACTIVE_COMPARATOR|Conventional treatment group|In the routine treatment group, antihypertensive treatment programs other than ACEI, ARB or ARNI will be adopted, and the use of antihypertensive drugs will be adjusted until the blood pressure control is controlled.
62477420|NCT05665205|ACTIVE_COMPARATOR|Aerobic exercise plus strength|The purpose is to verify if the aerobic exercise plus a strength program improves more than aerobic exercise alone in COVID patients.
62477421|NCT05665205|SHAM_COMPARATOR|Aerobic exercise alone|The purpose is to verify if COVID patients can improve the status of their health only with an aerobic exercise program alone.
62477422|NCT02842632|OTHER|A virtual teaching|Group A will be introduced to the virtual TEE online (http://pie.med.utoronto.ca/TEE/)
62477423|NCT02842632|OTHER|B simulator|Group B will be introduced to the simulator (CAE Vimedix Simulator)
62477424|NCT02842632|OTHER|C hands on OR|group C will be introduced to the TEE training in the operation room.
62477425|NCT01891773|EXPERIMENTAL|School-based therapy|Daily dose of medication to be provided in the school setting.
62123020|NCT03646435|EXPERIMENTAL|Wearable device (Fitbit Charge 2)|The Fitbit Charge 2 is the wearable of interest for this pilot study. All 50 study participants will be requested to wear the electronic device for the duration of their stay in the hospital (maximum of 6 days). The Fitbit will passively collect health information of patients which will be tracked on mobile devices by the study investigators.
62123021|NCT01708499|EXPERIMENTAL|Study treatment|All enrolled subjects will receive one Ulthera System Treatment.
62123022|NCT03693651||Parent of a Premature infant / PP|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
62477426|NCT01891773|NO_INTERVENTION|Usual Care|Daily medication to be taken at home.
62682966|NCT02729012|ACTIVE_COMPARATOR|Case|Allergic Rhinitis Children treated with hypertonic saline solution (NACL 3%+NAHCO3)
62682967|NCT02729012|PLACEBO_COMPARATOR|Control|Allergic Rhinitis Children treated with saline solution (NACL 0,9%)
62312458|NCT06393114|NO_INTERVENTION|Habitual diet|Participants consume their habitual diet without any intervention products.
62682968|NCT02262221|NO_INTERVENTION|ARM A (Non intensive Follow up)|Follow up consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit patients will report all new symptoms and they will receive physical and fiberoptic endoscopic head and neck examination. Laboratory tests will be performed once a year. Quality of life questionnaires will be administered to patients every other visit for the first 2 years and then at each visit. A socio-economic questionnaire will be also administered at each visit. Locoregional imaging will be performed within 6 months after radiotherapy end and recommended only at the occurrence of new signs or symptoms. Patients will be contacted by a phone call between visits in order to monitor patient's reported symptoms potentially related to disease recurrence.
62682969|NCT02262221|OTHER|ARM B (Intensive Follow up)|Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
62682970|NCT01539525|EXPERIMENTAL|Motivational Interview|Motivational interview provided by a clinical research nurse or physician.
62682971|NCT01539525|ACTIVE_COMPARATOR|Motivational Interview-Electronic|Motivational Interview provided by an interactive computer program.
62682972|NCT01539525|PLACEBO_COMPARATOR|Treatment as Usual|No intervention- resource list provided.
62682973|NCT06563752|PLACEBO_COMPARATOR|Routine care|Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.
62123023|NCT03693651||Parent of a baby born on time / PT|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
62123024|NCT03860532|ACTIVE_COMPARATOR|HMPL-011 tablets|A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2)
62477427|NCT05572281|EXPERIMENTAL|Sequence A|tasimelteon liquid suspension formulation then tasimelteon capsule formulation
62477428|NCT05572281|EXPERIMENTAL|Sequence B|tasimelteon capsule formulation then tasimelteon liquid suspension formulation
62477429|NCT01307124|ACTIVE_COMPARATOR|standard dose|Arm 1:LPV/r Standard dose BW 25-35 kg 300/75 mg BW \>35-50 kg 400/100 mg
62123025|NCT03860532|ACTIVE_COMPARATOR|HMPL-011 capsules|A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6)
62312459|NCT03511638|EXPERIMENTAL|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
62312460|NCT03511638|ACTIVE_COMPARATOR|Alcon VISCOAT®|Ophthalmic viscosurgical device
62312461|NCT03305042||21-54 y|Ages 21-54 y
62312462|NCT03305042||55-74 y|Ages 55-74 y
62312463|NCT03305042||>75 y|Age \>75 y
62477430|NCT01307124|EXPERIMENTAL|low dose|Arm 2:Low dose BW 25-35 kg 200/50 mg BW \>35-50 kg 300/75 mg
62477431|NCT06624267||24 healthy participants over 60 years|Baseline measurements of: -\[15O\]H2O PET of the brain
62682974|NCT06563752|EXPERIMENTAL|Experimental|"The experimental group, referred to as the Dyad, involved both the caregiver and the patient wearing 3D glasses to watch educational VR content. The VR content included the following topics:~1. Understanding psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge of medications and their relationship to symptom stability, as well as how to manage side effects.~3. Schizophrenia as a chronic illness, drawing comparisons to other chronic diseases.~4. Signs of disease relapse.~5. How to manage persistent psychotic symptoms of schizophrenia, such as delusions, hallucinations, paranoia, and negative symptoms.~6. How to interact and communicate with the patient.~7. Coping with stress, stress management, and suicide prevention.~8. Available resources."
62682975|NCT04957927|EXPERIMENTAL|Intranasal Fluticasone Propionate Group|Intranasal Fluticasone Propionate 50mcg/actuation in each nostril 24 hourly
62682976|NCT04957927|EXPERIMENTAL|Montelukast Group|Montelukast 4mg oral granule formulation 24 hourly
62312464|NCT02050932|EXPERIMENTAL|Iron absorption assessement|"60 mg Fe as FeSO4 with stable isotopic labels participants will receive at different times of the day (total of three dosages) and follow a standardized diet scheme.~Subjects will act as their own controls during the study"
62123026|NCT03480854|NO_INTERVENTION|Baseline Analysis|To conduct studies of variation in performance across microsystems and to utilize benchmarking analyses to identify top performers.
62123027|NCT03480854|EXPERIMENTAL|The effect of continuous quality improvements (CQI)|To study the comparative improvement of selected primary process performance indicators (DMT and MRI process measures) over a 3 year period (Years 2-3) in microsystems receiving CQI interventions versus those not receiving CQI intervention, and between two different CQI intervention types (IHI Breakthrough Series and Patient Centered Medical Home).
62123028|NCT03540381||Identified neoatherosclerosis group|From the patients treated with coronary stents, the investigators functionally evaluated their HDL by measuring the CUC. the investigators also performed follow-up OCT to evaluate the presence of neoatherosclerosis. Consecutive patients were divided into two groups. The patients with neoatherosclerosis were identified neoatherosclerosis group and the remaining were not-identified neoatherosclerosis group. After that, clinical follow-up was performed to assess TLR and the investigators examined the relation between CUC, neoatherosclerosis and TLR.
62123029|NCT03540381||Not-identified neoatherosclerosis group|
62123030|NCT03210129|EXPERIMENTAL|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
62312465|NCT02289755|EXPERIMENTAL|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
62312466|NCT01253460|EXPERIMENTAL|Cyclophosphamide, Rituximab + Sapacitabine|After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.
62312467|NCT05218889|EXPERIMENTAL|surufatinib + camrelizumab + nab-paclitaxel + S-1|
62312468|NCT05218889|ACTIVE_COMPARATOR|nab-paclitaxel + gemcitabine|
62312469|NCT05917379|EXPERIMENTAL|FMT（Pure Fecal microbiota transplantation-F)|Fecal microbiota capsules(0.75g stool/capsule) (60 capsules), within 3 days, another 20 fecal microbiota capsules(0.75g stool/capsule) at week 2. Additionally, they will take placeboB for 45 days from the begining.
62312470|NCT05917379|EXPERIMENTAL|FMT(Fecal microbiota transplantation+synbiotics-M)|Fecal microbiota capsules(0.75g stool/capsule) (60 capsules), within 3 days, another 20 fecal microbiota capsules(0.75g stool/capsule) at week 2. Additionally, they will take synbiotics (Lactobacillus Helveticas+ Bifidobacterial longum + inulin) (3g/day) for 45 days from the begining.
62312471|NCT05917379|PLACEBO_COMPARATOR|Non-FMT(Synbiotics control-S)|PlaceboA capsules (60 capsules), within 3 days, another 20 placeboA capsules(0.75g stool/capsule) at week 2. Additionally, they will take synbiotics (Lactobacillus Helveticas+ Bifidobacterial longum + inulin) (3g/day) for 45 days from the begining.
62123031|NCT03210129|NO_INTERVENTION|Control Group|Patients of the control group will receive standard care alone.
62123032|NCT05495477|ACTIVE_COMPARATOR|Spontaneous breathing|Electrical impedance tomography (EIT).
62123033|NCT05495477|ACTIVE_COMPARATOR|CPAP mode|Electrical impedance tomography (EIT).
62312472|NCT05917379|PLACEBO_COMPARATOR|Non-FMT(Total Placebo-P)|PlaceboA capsules (60 capsules), within 3 days, another 20 placeboA capsules(0.75g stool/capsule) at week 2. Additionally, they will take placeboBfor 45 days from the begining.
61922644|NCT05455762|EXPERIMENTAL|Exercise group|patients in this group will participate in an 8 week program of exercise. The exercise program includes both aerobic and resistance exercise. The patients will exercise 6 days a week,3 days aerobic exercise and 3 days resistance ones. The aerobic exercise consists of 20 minutes walking. Patients will walk slowly in the first five minutes to warm up, then they walk faster and with the intensity prescribed by the physiotherapist. In the last 5 minutes the patient will walk like the first 5 minutes. The middle 10 minutes may be increased or not based on patients' weekly self-report. The resistance training include hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
62477432|NCT04020952|ACTIVE_COMPARATOR|"st.st 0.019×0.025 wire"|
62682977|NCT06608277|ACTIVE_COMPARATOR|Group A =Stellate ganglion block (SGB) with bupivacaine (LA) plus placebo ketamine (midazolam)|"Stellate ganglion block with the local anesthetic (LA) bupivacaine and placebo (1-7 mg midazolam + normal saline) ketamine.~The stellate ganglion block will be performed with approximately 8 mL bupivacaine using ultrasound or fluoroscopic guidance. The placebo ketamine will consist of an initial 1-4 mg bolus of midazolam followed by boluses or an infusion (in normal saline) of midazolam up to 7 mg, over 30-60 minutes."
62682978|NCT06608277|ACTIVE_COMPARATOR|Group B = Sham SGB plus ketamine infusion|Sham SGB will be 1-2 mL of saline given subcutaneously using ultrasound or fluoroscopic guidance. The ketamine will consist of Prior to the sham Stellate Ganglion Block procedure, the study drug ketamine or normal saline will be administered by one of the study team physicians. 100 ml bag will be administered by bolus/infusion or intermittent boluses up to 0.3 mg/kg). The ketamine infusion will start before the sham block where patients will be given 1-4 mg of midazolam + up to 0.3 mg/kg of ketamine, as bolus doses. Over the next 30-60 minutes patients will receive between 0.5-1 mg/kg total dose of ketamine, + additional midazolam as needed.
62682979|NCT06608277|EXPERIMENTAL|Group C = Stellate ganglion block (SGB) with bupivacaine LA plus ketamine infusion|These patients will receive both SGB with bupivacaine + ketamine as described above.
62682980|NCT06608277|PLACEBO_COMPARATOR|Group D = Sham SGB plus placebo ketamine (midazolam)|These patients will receive the sham SGB + placebo ketamine as described above.
62682981|NCT00178659||1 healthy volunteers|Healthy volunteers to act as controls - Recruitment is complete for this cohort
62682982|NCT00178659||2 head trauma|Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort
62312473|NCT04059809|NO_INTERVENTION|Usual Care|The control group will have usual care according to the orientation of the radiation therapy faculty responsible for the radiotherapy treatment the PBM device will be switched off
62477433|NCT04020952|EXPERIMENTAL|"st.st 0.016×0.022 wire"|
62477434|NCT04020952|EXPERIMENTAL|"st.st 0.017×0.025 wire"|
62682983|NCT00178659||3 orthopedic injury|"The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:~1. Fracture confirmed radiographically~2. No head trauma~3. No other known inflammatory process or infection~4. No history of neurological or psychiatric disorders or alcohol or drug dependency"
62682984|NCT00178659||4 Mild TBI|"The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort~1. Non-penetrating head trauma manifesting one or more of the following:~   * Loss of consciousness~  * Post-traumatic amnesia~  * Altered mental status~  * Focal neurologic deficits, seizure~2. GCS\> 12~3. No abnormalities on CT other than contusion~4. No operative Lesions~5. Length of hospital stay \< 48 hrs~6. No other known inflammatory process or infection~7. No history of neurological or psychiatric disorders or alcohol or drug dependency"
62682985|NCT00725231|ACTIVE_COMPARATOR|Arm A|Chemotherapy with dose dense CHOP-14, 6 cycles
62682986|NCT00725231|EXPERIMENTAL|Arm B|Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
62682987|NCT05609786|EXPERIMENTAL|myPlan Kenya|myPlan Kenya web-based application
62682988|NCT02084186|EXPERIMENTAL|moxibustion group|herb-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
62682989|NCT02084186|PLACEBO_COMPARATOR|bran-partitioned moxibustion|bran-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
61922645|NCT05455762|NO_INTERVENTION|Control group|The patients in this group will continue their routine life and treatment prescribed by the gastroenterologist for their condition
62123034|NCT05495477|ACTIVE_COMPARATOR|NIV- S/T mode|Electrical impedance tomography (EIT).
62312474|NCT04059809|EXPERIMENTAL|Photobiomodulation (PBM)|Additionally to the usual care, the patients will receive the PBM. Treatment will be done twice a week.
62312475|NCT05026229|EXPERIMENTAL|Dasatinib, Vincristine and Prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
62312476|NCT05026229|EXPERIMENTAL|Dasatinib, Methotrexate and Cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
62312477|NCT00810797|EXPERIMENTAL|Treatment (exemestane)|Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62477435|NCT05510908||New, primary or recurrent disease|Considering or currently receiving cancer treatment
62477436|NCT05510908||Metastic or locally advanced cancer|This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
62477437|NCT05510908||Prior cancer|Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
62682990|NCT03319654|EXPERIMENTAL|Spontaneous cycle IUI|"DNA fragmentation by TUNEL assay~DNA fragmentation will be measured both at the time of the diagnostic work-up as at the time of insemination."
62312478|NCT01001494|EXPERIMENTAL|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation
62312479|NCT01001494|EXPERIMENTAL|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation
61922646|NCT06336083|EXPERIMENTAL|Doppler ultrasound|First degree relatives of patient with diagnosed carotid web will receive an echography doppler of the carotid arteries and answer questionnaires
61922647|NCT01728714||Adults over 18 years old|Adults over 18 years old, with type 2 diabetes, HbA1c \<= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year
62312480|NCT01001494|PLACEBO_COMPARATOR|Placebo|Placebo
62312481|NCT01011062|EXPERIMENTAL|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
62312482|NCT01011062|EXPERIMENTAL|Losartan + hyperinsulinaemia|
62312483|NCT01011062|PLACEBO_COMPARATOR|Saline|Infusion of Saline as a volume control intervention
62312484|NCT04446143|OTHER|Application of mindfulness meditation prior to UDS|Those in the mindfulness medication group will listen to an audio-taped mediation, which takes 10 mins to complete.
62312485|NCT04446143|ACTIVE_COMPARATOR|No meditation prior to UDS|The control group will be seated in a quiet empty room where they wait for 10 min.
61922648|NCT01728714||Adults with HbA1c <= 8,5%|Adults over 18 years old, with type 2 diabetes, HbA1c \<= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year
61922649|NCT01384643|EXPERIMENTAL|Propofol group|
61922650|NCT01384643|PLACEBO_COMPARATOR|Control group|
62123035|NCT06499584|EXPERIMENTAL|normal hearing patients|free of sensorineural hearing loss, defined by mean hearing thresholds of less than or equal to 20 dB HL in air conduction pure tone audiometry, bilaterally on the side of the operated ear and on the non-operated side at 0.5, 1, 2 and 4 kHz.
62123036|NCT06499584|EXPERIMENTAL|hearing impaired patients|with sensorineural hearing loss defined by average hearing thresholds between 21 dB HL and 40 dB HL at 0.5, 1, 2 and 4 kHz.
62123037|NCT01197807|ACTIVE_COMPARATOR|Bulb suctioning|Bulb suctioning of mouth and nose immediately after delivery
62123038|NCT01197807|ACTIVE_COMPARATOR|Wiping|Gentle wiping of mouth then nose with soft cloth
62312486|NCT06074510|EXPERIMENTAL|PYLARIFY PET|
62312487|NCT04822922|EXPERIMENTAL|low dose|hUC-MSCs 4\*10\^5/kg/each time
62312488|NCT04822922|EXPERIMENTAL|middle dose|hUC-MSCs 8\*10\^5/kg/each time
62312489|NCT04822922|EXPERIMENTAL|high dose|hUC-MSCs 12\*10\^5/kg/each time
62123039|NCT00990730||rheumatoid arthritis subjects|60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
62123040|NCT00990730||healthy controls|20 matched controls without rheumatoid arthritis
62312490|NCT04151004|EXPERIMENTAL|Patient group|Incremental cycling test to volitional exhaustion. Constant load cycling test to volitional exhaustion. Respiratory and leg muscle endurance test to volitional exhaustion. Three respiratory muscle training interventions.
62312491|NCT04151004|ACTIVE_COMPARATOR|Control group|The control group executes the same tests as the patient group.
62312492|NCT00778323|EXPERIMENTAL|A,2, II|
62312493|NCT02413255|PLACEBO_COMPARATOR|Part 1 Cohort 1-9: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1.
62312494|NCT02413255|EXPERIMENTAL|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 mg, solution, orally once on Day 1.
62123041|NCT01750866|EXPERIMENTAL|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. Treatment will continue until disease progression, intolerable side effects, or a maximum of 10 cycles of therapy.
62123042|NCT02359370|ACTIVE_COMPARATOR|Magnesium Group|Magnesium Sulphate was administered through continuous infusion, immediately before induction of anesthesia
62312495|NCT02413255|EXPERIMENTAL|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
62312496|NCT02413255|EXPERIMENTAL|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
62312497|NCT02413255|EXPERIMENTAL|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
62312498|NCT02413255|EXPERIMENTAL|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
62312499|NCT02413255|EXPERIMENTAL|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
62682991|NCT06143072||Part 1 of study|Women who have sustained an obstetric-related anal sphincter injury (grade 3 and 4 perineal tears) AND who are symptomatic of anal/faecal incontinence within the first five years following a vaginal delivery are eligible to participate, provided they have capacity to consent.
62682992|NCT06143072||Part 2 of study|Obstetricians (consultants) and urogynaecologists who are involved in and/or oversee the care of OASI patients' post-partum in the UK.
62312500|NCT02413255|EXPERIMENTAL|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
62682993|NCT01890538|ACTIVE_COMPARATOR|Piracetam|2 g intravenous piracetam
62123043|NCT02359370|ACTIVE_COMPARATOR|Lidocaine Group|Lidocaine was administered through continuous infusion, immediately before induction of anesthesia
62682994|NCT01890538|ACTIVE_COMPARATOR|Dimenhydrinate|Dimenhydrinate 100 mg intravenous
62123044|NCT04816487|ACTIVE_COMPARATOR|Silver Diamine Flouride|Discoloration of primary carious teeth treated by SDF
62123045|NCT04816487|EXPERIMENTAL|Glutathione|Discoloration rate of primary carious teeth treated by SDF + Glutathione
62682995|NCT02844075|EXPERIMENTAL|pembrolizumab|
62682996|NCT06389682|EXPERIMENTAL|68Ga-NYM005 injection|
62682997|NCT02390999|NO_INTERVENTION|24 hours of therapeutic hypothermia|24 hours of therapeutic hypothermia to a target temperature of 32-34 degrees in comatose cardiac arrest patients is standard treatment in Denmark.
62682998|NCT02390999|EXPERIMENTAL|48 hours of therapeutic hypothermia|48 hours of therapeutic hypothermia to a target temperature of 32-34 degrees
62682999|NCT05681936||Cross-sectional study: healthy controls|
62683000|NCT05681936||Cross-sectional study: chronic traumatic SCI patients|
62123046|NCT04816487|EXPERIMENTAL|Potassium iodide|Discoloration rate of primary carious teeth treated by SDF + KI
62312501|NCT02413255|EXPERIMENTAL|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
62312502|NCT02413255|EXPERIMENTAL|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.
62312503|NCT02413255|PLACEBO_COMPARATOR|Part 2 Cohort 1-6: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.
62312504|NCT02413255|EXPERIMENTAL|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
62683001|NCT05681936||Cross-sectional study: non-traumatic SCI patients with degenerative spondylotic myelopathy|
62683002|NCT05681936||Longitudinal study: healthy controls|
62683003|NCT05681936||Longitudinal study: acute traumatic SCI patients (< 2 months after SCI)|
62683004|NCT05681936||Longitudinal study: patients with neurogenic lower urinary tract dysfunction|
62683005|NCT04629157|EXPERIMENTAL|All patients|All patients entering the study will undergo paired testing of a lateral flow device using an anterior nasal swab and an RT-PCR using a nose and throat swab.
62683006|NCT06681974|ACTIVE_COMPARATOR|control group|indications on the hygienic-dietary measures
62123047|NCT04149548||pregnant diabetic women|Fetal Ultrasound to diabetic pregnant women
62123048|NCT04149548||non diabetic pregnant women|Fetal ultrasound to non diabetic pregnant women
62123049|NCT03450096|ACTIVE_COMPARATOR|Treatment group|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
62683007|NCT06681974|EXPERIMENTAL|experimental|indications on the hygienic-dietary measures + an exercise program based on OMT for 20 weeks
62683008|NCT05218980|EXPERIMENTAL|Investigational|Yale Dining menu + 6 olives daily
62683009|NCT05218980|NO_INTERVENTION|Standard|Yale Dining menu only
62477438|NCT04873063|EXPERIMENTAL|Reference/Test|"* 3 mg BDP suppositories (R product) delivered twice daily for 7 days~* Washout period (at least 7-day and preferably no more than 9 days)~* 6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product."
62477439|NCT04873063|EXPERIMENTAL|Test/Reference|"* 6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product.~* Washout period (at least 7-day and preferably no more than 9 days)~* 3 mg BDP suppositories (R product) delivered twice daily for 7 days"
62477440|NCT01385163|NO_INTERVENTION|Control - VSLA|the wait control sample for the economic intervention
62477441|NCT01385163|OTHER|Control - Mental Health|treatment as usual based on standard psychosocial services in the area
62477442|NCT01385163|EXPERIMENTAL|Voluntary Savings/Loans Assoc|
62477443|NCT01385163|EXPERIMENTAL|Cognitive Processing Therapy|
62312505|NCT02413255|EXPERIMENTAL|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
62477444|NCT06242613||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
62477445|NCT06242613||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
62477446|NCT04308785|EXPERIMENTAL|Arm A: Atezolizumab + Tiragolumab|Participants will receive atezolizumab + tiragolumab intravenously on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and tiragolumab treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
62477447|NCT04308785|EXPERIMENTAL|Arm B: Atezolizumab + Placebo|Participants will receive atezolizumab + placebo on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and placebo treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
62477448|NCT04362085|EXPERIMENTAL|Therapeutic Anticoagulation|Therapeutic anticoagulation with LMWH or UFH (high dose nomogram). The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Therapeutic anticoagulation will be administered until discharged from hospital, 28 days or death. If the patient is admitted to the ICU or requiring ventilatory support, we recommend continuation of the allocated treatment as long as the treating physician is in agreement.
62477449|NCT04362085|NO_INTERVENTION|Standard Care|Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is considered standard care.
61922651|NCT04895800|EXPERIMENTAL|Herbal Supplement|(Phytovive™); comprised of Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
62123050|NCT03450096|NO_INTERVENTION|Control group|Patients in the control group (and in the active treatment group) will receive an opioid-based analgesia with a hydromorphone-patient controlled analgesia (PCA) depending on their analgesic demand
62312506|NCT02413255|EXPERIMENTAL|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
62312507|NCT02413255|EXPERIMENTAL|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
62312508|NCT02413255|EXPERIMENTAL|Part 2 Cohort 5: TAK-020 45 mg|TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
62312509|NCT02413255|EXPERIMENTAL|Part 2 Cohort 6: TAK-020 60 mg|TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
62312510|NCT04281927||Atrial fibrillation|Patients with presumed atrial fibrillation will undergo monitoring with the device and Holter ECG.
62312511|NCT04281927||Sinus rhythm|Patients with presumed sinus rhythm will undergo monitoring with the device and Holter ECG.
62312512|NCT04281927||Sinus rhythm and frequent extrasystoles|Patients with presumed sinus rhythm and frequent extrasystoles will undergo monitoring with the device and Holter ECG.
62477450|NCT06223191|EXPERIMENTAL|Brief Negotiated Interview|The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. Instead of telling the patient what changes he/she should make, the BNI is intentionally designed to elicit reasons for change and action steps from the patient. It gives the patient voice and choice, making any potential behavior changes all the more empowering to the patient.
62683010|NCT03191734|EXPERIMENTAL|AQUABEAM System|AQUABEAM System
61922652|NCT04895800|ACTIVE_COMPARATOR|Caffeine|Green tea caffeine extract (170 mg; to deliver 34 mg caffeine \[20% natural caffeine\]),
61922653|NCT04895800|PLACEBO_COMPARATOR|Placebo|Flavored placebo
61922654|NCT04643171|EXPERIMENTAL|Exercised group|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
61922655|NCT04643171|ACTIVE_COMPARATOR|group of electroacupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6, 5 times per week, for 12 week
62123051|NCT02807467|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
62123052|NCT02807467|ACTIVE_COMPARATOR|Propofol|Standard therapy for ICU delirium.
62312513|NCT03442426|EXPERIMENTAL|Intervention Cohort|Integrated model of primary care
62312514|NCT06140407|EXPERIMENTAL|Treatment (pembrolizumab)|Patients undergo radiation therapy and receive cisplatin or carboplatin on day 1 of each cycle and etoposide on days 1-3 for 4 cycles. Patients then receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan during screening. Patients also undergo MRI throughout the trial as well as CT. Additionally, patients undergo blood sample collection throughout the trial.
62312515|NCT03756012|ACTIVE_COMPARATOR|Low Pulse Width (<500 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths \<500 μsec.
62312516|NCT03756012|ACTIVE_COMPARATOR|High Pulse Width (>1000 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths \>1000 μsec
62312517|NCT03268174|ACTIVE_COMPARATOR|AO+Mist|AO+Mist
62312518|NCT03268174|PLACEBO_COMPARATOR|Placebo|Placebo
62312519|NCT06515223|EXPERIMENTAL|Treatment|Implantation of Epidural Spinal Cord Stimulation to target bladder and bowel function. Applied in combination with Pelvic Floor Muscle Training.
62312520|NCT02610023||Observational (Willett FFQ, Fred Hutchinson FFQ, CCAT)|After consenting to participate in this study, participants will visit the Clinical Research Center (CRC) on 3 occasions. One of the three FFQ's will be completed at each visit and there will be 4 to 6 weeks between visits. Participants will also complete a blood draw and assessment of skin carotenoids at this CRC visit. Prior to each visit, participants will complete a 3-day diet record, a daily sun exposure diary, and a 3-day activity record.
62683011|NCT06691815|EXPERIMENTAL|Unique arm|"All patients will be randomized only to the order of the test to be performed. All patients included will be performed two tes~1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg) Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin to the meassurement of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Luteoliberin 100 μg)"
62683012|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
62683013|NCT04308590|EXPERIMENTAL|Relacorilant|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
62683014|NCT04308590|PLACEBO_COMPARATOR|Placebo|Placebo matched to study drug
62123053|NCT02763033|EXPERIMENTAL|Bob's Red Mill®|"Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill® beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.~Initially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID."
62312521|NCT03838848|EXPERIMENTAL|Cohort A|Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)
62683015|NCT06374459|EXPERIMENTAL|Phase Ib: Zunsemetinib + Capecitabine|Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose along with capecitabine (1000 mg/m\^2 PO BID on Days 1-14 an every 21-day cycle). For patients enrolled in phase Ib, capecitabine is dosed on days 2-15 during cycles 1-2. Dose escalation of zunsemetinib will utilize a 3+3 design. A maximum of 3 dose levels of zunsemetinib will be tested, and the two highest dose levels which did not lead to more than 1 of 6 patients with DLT in cycle 1 will be chosen as the RP2D-L1 and RP2D-L2 for Phase II. If only one dose level of zunsemetinib was found tolerable, then only one RP2D will be chosen for Phase II.
62683016|NCT06374459|ACTIVE_COMPARATOR|Phase II Arm 1: Standard of care anti-resorptive + Capecitabine|Standard of care anti-resorptives will consist of bisphosphonate (zoledronic acid) is to be administered every 4-12 weeks, or denosumab is to be administered every 4-6 weeks, as per physician choice and institutional practice. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3.
62683017|NCT06374459|EXPERIMENTAL|Phase II Arm 2: Zunsemetinib (RP2D-L1) + Capecitabine|Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3.
62123054|NCT02763033|PLACEBO_COMPARATOR|Starch Placebo|Patients will receive an iso-caloric, non-resistant starch placebo.
62123055|NCT00186186|EXPERIMENTAL|Depakote ER|Depakote ER up to 1500 mg/day
62123056|NCT06050109||OFS continues to use after 5 years|HR-positive premenopausal female patients whose doctors believe that they can benefit from continued use of OFS after 5 years should be included in the trial group.
62312522|NCT03838848|EXPERIMENTAL|Cohort B|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W
62123057|NCT06050109||OFS discontinues to use after 5 years|The control group did not need to continue to use OFS, either leuprolide or goserelin
62123058|NCT04666506||VR as distraction during a medical procedure|Paediatric outpatients undergoing a medical procedure, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a distraction method during a potentially painful or scary procedure (e.g., vaccination, wound care, venipuncture,...).
62312523|NCT03838848|EXPERIMENTAL|Cohort C|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046
61922656|NCT02104973|EXPERIMENTAL|Lifestyle counseling|After obtaining the approval of schools and parents, will be established in schools, units in which individual attention is given to children, parents and teachers that request: the advice is aimed at training users on healthy diet and constant physical activity. Workshops with children, in which selected topics will be discussed based on the analysis of depth interviews with children, parents and teachers, and information on habits and resources gathered through questionnaires will be conducted. The intervention included the provision of information and feedback with the population through a website. The work will include participation in the selection of foods sold in schools.
62123059|NCT04666506||VR as relaxation method during a hospital stay|Paediatric inpatients, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a relaxation method during a potentially stressful hospital stay (e.g., patients with psychosomatic complaints, patients with eating disorders,...).
62123060|NCT05353517||Healthy Subjects|Device: focal muscle vibration to induce spinal plasticity theta burst stimulation and paired associative stimulation to induce plasticity in M1
62312524|NCT03838848|EXPERIMENTAL|Cohort D|1L NSCLC (EGFR-sensitive mutation (Ex19del or L858R), progression after at least one line treatemtn of EGFR TKIs, and no prior systemic platinum-containing chemotherapy), will receive KN046 5 mg/kg Q3W in combination with pemetrexed and carboplatin
62477451|NCT06223191|PLACEBO_COMPARATOR|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
61922657|NCT02104973|NO_INTERVENTION|Control|Usual care
61922658|NCT03346707||10.5 Tesla|
61922659|NCT01213550|EXPERIMENTAL|Chlorhexidine|
61922660|NCT01213550|PLACEBO_COMPARATOR|Placebo mouthrinse|
61922661|NCT02710643|NO_INTERVENTION|MRD - BEFORE RT|Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.
61922662|NCT02710643|NO_INTERVENTION|MRD + BEFORE RT AND MRD - AFTER RT|Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.
61922663|NCT02710643|EXPERIMENTAL|MRD + BEFORE RT AND MRD + AFTER RT|"Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose).~Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated."
62123061|NCT05353517||Patients with Parkinson's disease|Device: theta burst stimulation and paired associative stimulation to induce plasticity in M1 Device: focal muscle vibration to induce spinal plasticity
62123062|NCT03114267||Patient with chronic lymphocytic thyroiditis|
62123063|NCT03114267||Healthy subjects|
62123064|NCT01060514|EXPERIMENTAL|Pazopanib + Vinorelbine|
62123065|NCT00705328|EXPERIMENTAL|1|
62123066|NCT00705328|EXPERIMENTAL|2|
62123067|NCT00705328|EXPERIMENTAL|3|
62312525|NCT03838848|EXPERIMENTAL|Cohort E|≥ 2L NSCLC (failure or intolerance of 1L platinum-doublet chemotherapy; and failure of PD-1/PD-L1 checkpoint inhibitor therapy), will receive KN046 in combination with ningetinib
62312526|NCT05212532|EXPERIMENTAL|non-ICU hospitalized|Patients who are hospitalized at study enrollment but are not being treated in the ICU
62312527|NCT05212532|EXPERIMENTAL|ICU hospitalized|Patients who, at study enrollment, are being treated in the hospital ICU
62477452|NCT06223191|NO_INTERVENTION|Standards of Care|This arm includes the use of benzodiazepines (Diazepam or Lorazepam) when CIWA-Ar scale is ≥9. Other medications may include Thiamine, Potassium Chloride, oral rehydration salts, parenteral fluids, antiemetics, and gastric protectants if medically necessary. Patients undergo a psychological evaluation on the third day of admission. All patients receive at least one psychoeducational session on alcohol and substance use during their hospitalization. Psychiatric evaluation is available for those with dual diagnoses such as mood disorders, anxiety disorders, psychotic disorders, or multiple substance use. The total hospitalization time in the ward is 8 days.
62683018|NCT06374459|EXPERIMENTAL|Phase II Arm 3: Zunsemetinib (RP2D-L2) + Capecitabine|Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3. If only one dose level of zunsemetinib plus capecitabine was found tolerable in phase Ib testing, the phase II trial will proceed with 2:1 two-arm randomization with Arm 2 of capecitabine plus zunsemetinib and Arm 1 of capecitabine plus standard of care anti-resorptive agent.
62683019|NCT05101161|EXPERIMENTAL|Bidirectional Neurofeedback|
61922664|NCT04945642|EXPERIMENTAL|Treatment (HDR-BT, SBRT)|Patients undergo HDR-BT for up to 24 hours and undergo SBRT every other day or consecutive days for up to 14 consecutive chronologic days in the absence of disease progression or unacceptable toxicity.
61922665|NCT00475475|EXPERIMENTAL|1|Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
61922666|NCT00475475|EXPERIMENTAL|2|Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
61922667|NCT00475475|PLACEBO_COMPARATOR|3|Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
61922668|NCT03986515|EXPERIMENTAL|treatment group|"apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events.~SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events.~(the first dose of SHR-1210 is set on the 3-5 days after apatinib"
61922669|NCT04864080|ACTIVE_COMPARATOR|Healthy Comparison Group|Behavioral tasks and surveys online.
62683020|NCT01340534|EXPERIMENTAL|Oxygen 80% FIO2|Group of 181 patients that will receive supplemental oxygen 80% FIO2 during surgery (cesarean) and two hours after the procedure.
62683021|NCT01340534|PLACEBO_COMPARATOR|Use of air (no oxygen during surgery)|Group of 181 patients that will not receive supplemental oxygen during surgery (cesarean).
62683022|NCT06687980|EXPERIMENTAL|Dupilumab|Dupilumab subcutaneous injection as per protocol
62683023|NCT06687980|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection as per protocol
62683024|NCT01470820|ACTIVE_COMPARATOR|Distance 20 cm|The infants were randomized by sealed and opaque envelopes to one of four phototherapy regimens. Either with distance from the phototherapy device to the mattress of 20, 29, 38 or 47 cm measured by a wood stick for each infant, corresponding to the distances to the infants of averagely 12, 21, 30 and 39 cm, respectively.
61922670|NCT04864080|EXPERIMENTAL|Pain/Depression patients from clinic|MRI, TMS and EEG, and behavioral tasks and surveys online.
62477453|NCT06488911|EXPERIMENTAL|OCA 5 mg + BZF 400 mg SR|Participants will be administered with OCA 5 mg + BZF 400 mg SR once daily.
62477454|NCT02771353|ACTIVE_COMPARATOR|WT_vDIBH|Wide tangent radiotherapy in voluntary deep inspiratory breath hold
62477455|NCT02771353|ACTIVE_COMPARATOR|VMAT_FB|Volumetric modulated arc therapy in free breathing.
61922671|NCT00890188|EXPERIMENTAL|THALIDOMIDE and UFUR|
62312528|NCT02342171|EXPERIMENTAL|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children \<45kg
62683025|NCT01470820|ACTIVE_COMPARATOR|Distance 29 cm|
62477456|NCT05840133||HBV-associated HCC group|The age and gender of patients are not limited. The patient was finally diagnosed as HBV-associated HCC by imaging examination and pathology.
61922672|NCT05302661|EXPERIMENTAL|case group will receive re-education after leave hospital|The participants were randomly divided into re-education group and non re-education group according to the random number table. The re-education group will receive regular re-education not noly when they leave hospital but also after leave hospital in our preset time by telephone or wechat. The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
61922673|NCT05302661|NO_INTERVENTION|control case group will receive no re-education after leave hospital|The participants were randomly divided into re-education group and non re-education group according to the random number table. without re-education group will receive regular re-education when they leave hospital.The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
62123068|NCT04961047|EXPERIMENTAL|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
62123069|NCT04961047|ACTIVE_COMPARATOR|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
62123070|NCT03319680|ACTIVE_COMPARATOR|Citrate dialysate|Hemodialysis with citrate dialysate during 16 weeks
62123071|NCT03319680|NO_INTERVENTION|Acetate dialysate|Hemodialysis with acetate dialysate during 16 weeks
62123072|NCT02975310|EXPERIMENTAL|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
62123073|NCT02975310|ACTIVE_COMPARATOR|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
62477457|NCT05840133||negative control group|The age and sex of this group were matched with that of HBV-associated HCC patient group. The patient did not have any tumor but had HBV infection. The functions of the renal and heart were normal.
62683026|NCT01470820|ACTIVE_COMPARATOR|Distance 38 cm|
61922674|NCT00840502||Pregnant women|Pregnant women who present at the SMRU antenatal clinics on the Thai Burmese border.
62123074|NCT00666276||linezolid (Zyvox)|Patients taking Linezolid.
62477458|NCT05840133||Healthy control group|The age and sex of the healthy control group were matched with that of HBV-associated HCC patient group. There was no tumor in the liver or other parts of the body, and no tumor in the blood system. The healthy control group did not have any liver benign diseases. There are no inflammatory diseases in other parts of the body. The functions of the liver, kidney, and heart were normal.
62683027|NCT01470820|ACTIVE_COMPARATOR|Distance 47 cm|
62123075|NCT03553212|EXPERIMENTAL|High dose external beam Radiotherapy|Image-guided tomotherapy
62123076|NCT06422650|EXPERIMENTAL|Nigella Sativa|Patients will receive Nigella Sativa (500mg) capsule twice daily for 8 weeks.
62123077|NCT06422650|PLACEBO_COMPARATOR|Control|Patients will receive capsules of placebo twice daily for 8 weeks.
62123078|NCT01867632||Prospective group|Prospective cohort where all patients routinely received ADM during cleft palate surgery. A tailored piece of Acellular Dermal Matrix will be placed between the oral and nasal layers at the time of a Furlow Palatoplasty for repair of a Cleft Palate.
62737720|NCT03449940|ACTIVE_COMPARATOR|Delayed repair (group 2)|"Patients were not admitted; instead they were discharged from hospital and given an elective surgery date. Oral Diclofenac Sodium 50mg was prescribed to be taken as needed and instructions to abstain from any sexual activity.~In an ambulatory setting, surgery was done 7 - 10 days later.~1g Ceftriaxone IV was given.~Local anaesthesia (dorsal penile nerve block): 1% Lidocaine 10cc was given.~Incision--- 2 - 3cm localized incision over the site of the rolling sign.~Repair--- Continuous technique with inverted knots using 3-0 polyglactin suture."
62312529|NCT02342171|NO_INTERVENTION|standard care|The control arm will consist of historical controls having being treated with standard of care
61922675|NCT02391896|OTHER|Digital Tomosynthesis|Patient will get tomosynthesis scan
61922676|NCT02391896|OTHER|Dual energy|Patient will get dual energy scan
61922677|NCT02029599|EXPERIMENTAL|High dose group|Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1\~2 times a day, when vas=10.
62123079|NCT01867632||Retrospective group|Retrospective cohort of cleft palate patients treated at the same institution and by the same surgeon. These patients received ADM selectively for certain cases (tenuous nasal layer closure, tight oral closure, wide cleft).
62123080|NCT05003219||ERAS group|patients received posterior cervical open-door laminoplasty under ERAS mode
62123081|NCT05003219||Conventional group|patients received posterior cervical open-door laminoplasty under routine perioperative management mode
62312530|NCT05398874|ACTIVE_COMPARATOR|Ginkgo + standard|the patients received Ginkgo biloba extract in addition to standard treatment
62737721|NCT02858440|EXPERIMENTAL|DTPa-IPV/Hib Group|All subjects receive three doses of primary vaccination of the study vaccine, Infanrix-IPV/Hib (DTPa-IPV/Hib), at 3, 4.5 and 6 months of age and a single dose of booster vaccination at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
62737722|NCT05166356||Patients|A sample of patients who received the NOHARM intervention after their surgery.
61922678|NCT02029599|EXPERIMENTAL|Low dose group|"Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.~placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1\~2 times a day, when vas=10."
61922679|NCT02029599|PLACEBO_COMPARATOR|The placebo group|placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1\~2 times a day, when vas=10.
61922680|NCT03492775|ACTIVE_COMPARATOR|Arm A:Obinutuzumab single agent|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
61922681|NCT03492775|ACTIVE_COMPARATOR|Arm B:Obinutuzumab plus Bendamustine|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
61922682|NCT04309071|EXPERIMENTAL|Salivary insulin responses to mixed meal tolerance test|Saliva samples and finger prick glucose will be collected after at least 4 hours of fasting and then at 60 and 90 minutes following ingestion of a standardized meal tolerance test.
61922683|NCT04776044|EXPERIMENTAL|ATR-002|Participants will receive 900mg ATR-002 on day 1 (6 tablets with 150mg ATR-002; once daily), and 600mg ATR-002 on days 2 - 6 (4 tablets; once daily)
62312531|NCT05398874|PLACEBO_COMPARATOR|placebo + standard|the patients received a placebo in addition to the standard treatment
61922684|NCT04776044|PLACEBO_COMPARATOR|Placebo|Participants will receive matching tablets placebo on day 1 (6 tablets, once daily), and matching tablets placebo on days 2 - 6 (4 tablets per day, once daily)
62312532|NCT01713985|ACTIVE_COMPARATOR|Group A|Ulthera System Treatment Right, Thermage Left
62123082|NCT01638949|EXPERIMENTAL|Young controls|
62123083|NCT01638949|EXPERIMENTAL|Middle age controls|
62123084|NCT01638949|EXPERIMENTAL|Elderly controls|
62123085|NCT01638949|EXPERIMENTAL|Asymptomatic subjects|Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
62123086|NCT01638949|EXPERIMENTAL|Subjectif Cognitive Impariment patients|
62123087|NCT01638949|EXPERIMENTAL|Mild Cognitive Impairment patients|
62123088|NCT01638949|EXPERIMENTAL|Alzheimer Disease patients|
62312533|NCT01713985|ACTIVE_COMPARATOR|Group B|Ulthera System Treatment Left, Thermage Right
62123089|NCT01638949|EXPERIMENTAL|Non degenerative amnsesic syndrome|
62123090|NCT03503084|EXPERIMENTAL|TCC group|Classical Yang's TCC exercise
62123091|NCT02863900|EXPERIMENTAL|Experimental arm|subtypes of BC (namely luminal A and luminal B, HER2+, TN)
62123092|NCT06555848||CERAMENT G|Subjects receiving CERAMENT G as part of the surgical treatment of Osteomyelitis
62123093|NCT01843101|OTHER|Healthy volunteers|10 healthy volunteers
62123094|NCT01843101|OTHER|Corneal Neovascularisation|5 patients with corneal neovascularisation
62123095|NCT01843101|OTHER|Keratoconus|5 patients with keratoconus
62123096|NCT01470040|EXPERIMENTAL|discontinuation of aspirin therapy|
62123097|NCT01470040|SHAM_COMPARATOR|continuation of aspirin therapy|patients will continue their pre-injury dose of low-dose aspirin therapy per previous medical indication
62312534|NCT01460836||Tobramycin Solution|
62312535|NCT01460836||Aztreonam lysine|
62312536|NCT06513429|EXPERIMENTAL|CAR-T cell therapy group|Administration of IM19 CAR-T cells at a dose of 1×10\^6/kg CAR-T cells for each subject.
62312537|NCT02760602|EXPERIMENTAL|Solanezumab|Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
62312538|NCT02760602|EXPERIMENTAL|Placebo|Placebo given IV once every 4 weeks for up to 2 years.
62312539|NCT06298097|OTHER|stroke patients|Resting-state networks obtained through electroencephalography will be analyzed in a group of stroke patients.
62312540|NCT06298097|OTHER|healthy participants|Resting-state networks obtained through electroencephalography will be analyzed in a group of healthy participants.
62312541|NCT03336840|EXPERIMENTAL|Metformin|
62737723|NCT05166356||Care Team Members|Staff members who had patients on the NOHARM intervention
62312542|NCT03336840|EXPERIMENTAL|Probiotics|
62683028|NCT05394051|EXPERIMENTAL|PARK Now|"6-Week Self-Guided Program: PARK Positive Emotion Skills: The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. The maximum amount of time engaged in the PARK program for any participant is 5 hours over the 6-week period, plus completion of the REDCap surveys assessments (burnout, well-being, health behaviors). The intervention will focus on developing the following skills that will be supplemented by home practice: (1) positive events, capitalizing, gratitude; (2) mindfulness; (3) positive reappraisal; (4) personal strength and achievable goals; (5) and self-compassion.~PARK is delivered through the BrightOutcome online platform."
62683029|NCT05394051|NO_INTERVENTION|Wait List Control-PARK Later|Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up.
62683030|NCT04255563||DCB treatment|DCB (Sequent® Please) treatment will be performed for suitable patients with CAD.
62683031|NCT03307824|EXPERIMENTAL|IfabondTM|Use of the synthetic glue IfabondTM
62683032|NCT03307824|ACTIVE_COMPARATOR|sutures|Glue-Free Suture Technique
62683033|NCT06689943|ACTIVE_COMPARATOR|Tylenol as needed|Tylenol prescribed to be taken as needed for pain management for 48 hours after surgery
62683034|NCT06689943|EXPERIMENTAL|Tylenol every 6hrs|Tylenol prescribed to be taken very 6 hours for pain management for 48 hours after surgery
62683035|NCT05472181|ACTIVE_COMPARATOR|rTMS (Repetitive TMS)|The rTMS group will receive 30 minutes of excitatory rTMS (i.e., 60 trains of 10 Hz pulses for 5 second with over 120% of motor threshold) over SMA combined with speech training (for 25 seconds during the 60 inter-train intervals) for five sessions
62683036|NCT05472181|SHAM_COMPARATOR|Sham|The sham group will receive 30 minutes of sham rTMS (no magnetic stimulation) over SMA combined with speech training (for 25 seconds during the 60 inter-train intervals) for five sessions.
62683037|NCT06690710|EXPERIMENTAL|allogeneic engineered Gingival Fibroblasts (aeGF), 50 million cells|A single intra-articular (IA) injection of 50 million aeGF into one osteoarthritic knee
62683038|NCT00769379|EXPERIMENTAL|Arm I (standard WBI)|Patients undergo standard WBI over 5-6 weeks.
62683039|NCT00769379|EXPERIMENTAL|Arm II (WBI, trastuzumab)|Patients receive trastuzumab IV over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
62683040|NCT04309500|EXPERIMENTAL|Amyloid Positive (Tau Positive or Negative) Participants|Participants who receive results of elevated amyloid (whether or not tau is also elevated), indicating the presence of Alzheimer's disease brain changes.
62683041|NCT04309500|EXPERIMENTAL|Amyloid Negative (Tau Positive or Negative) Participants|Participants who receive results of not-elevated amyloid (whether or not tau is elevated), indicating the absence of Alzheimer's disease brain changes.
62683042|NCT04309500|EXPERIMENTAL|Co-Participants of Amyloid Positive (Tau Positive or Negative) Participants|Study partners of participants who receive results of elevated amyloid (whether or not tau is also elevated), indicating the presence of Alzheimer's disease brain changes.
62683043|NCT04309500|EXPERIMENTAL|Co-Participants of Amyloid Negative (Tau Positive or Negative) Participants|Study partners of participants who receive results of not-elevated amyloid (whether or not tau is elevated), indicating the absence of Alzheimer's disease brain changes.
62683044|NCT00771147||Group 1|
62683045|NCT06469281|EXPERIMENTAL|Dose Escalation|27T51 monotherapy
62683046|NCT06469281|EXPERIMENTAL|Dose Expansion - Arm A|27T51 monotherapy
62312543|NCT03336840|EXPERIMENTAL|Metformin and Probiotics|
62683047|NCT06469281|EXPERIMENTAL|Dose Expansion - Arm B|27T51+Cemiplimab
62123098|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
62312544|NCT04247932||Municipal|Individual participants receiving active labor market intervention from municipal providers
62312545|NCT04247932||Non-profit|Individual participants receiving active labor market intervention from non-profit providers
62312546|NCT04247932||Register|Matched sample from register data, no intervention provided
62312547|NCT02875522|EXPERIMENTAL|Patients with COPD|Stable patients with COPD participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
62683048|NCT06469281|EXPERIMENTAL|Dose Expansion - Arm C|27T51+Cemiplimab+Bevacizumab
62683049|NCT04790968|EXPERIMENTAL|PSMA-PET/MRI and PET/CT for detection of lymph node metastases.|"Each patients will undergo an MRI-, PET/MRI- and PET/CT-examination (on the same day) prior to treatment.~Patients in the radiotherapy cohort will additionally undergo an MRI examination after hormonal treatment, before radiotherapy."
62683050|NCT03203707|EXPERIMENTAL|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
62683051|NCT03203707|NO_INTERVENTION|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
62683052|NCT03844412|ACTIVE_COMPARATOR|peripheral treatment|5% lidocaine/5 mg/ml 0.02% estradiol compound cream
62683053|NCT03844412|ACTIVE_COMPARATOR|central treatment|tricyclic antidepressant nortriptyline pill
62683054|NCT03844412|ACTIVE_COMPARATOR|combined peripheral and central treatments|5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill
62683055|NCT03844412|PLACEBO_COMPARATOR|placebo|placebo cream and placebo pill
62683056|NCT06693973|EXPERIMENTAL|AcNK-Sup003 cell injection solution|The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
62683057|NCT00891891||Spina Bifida|140 children with spina bifida (ages 8-15)
62737724|NCT06658977|EXPERIMENTAL|Triumeq open label|Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg ('Triumeq') one tablet daily
62737725|NCT05945069|EXPERIMENTAL|TriLift|Combination of Dynamic Muscle Stimulation and Radiofrequency
62312548|NCT02875522|ACTIVE_COMPARATOR|Healthy Controls|Age, sex, BMI and activity matched controls participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
62312549|NCT05421897|EXPERIMENTAL|Rapid infusion of dinutuximab with chemotherapy|Patients will receive chemotherapy and dinutuximab via rapid infusion
62312550|NCT06158841|EXPERIMENTAL|ABBV-383|Participants will receive ABBV-383 as a monotherapy.
62312551|NCT06158841|EXPERIMENTAL|Standard Available Therapy (SAT)|Participants will receive SAT, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. SAT choices are carfilzomib + dexamethasone (Kd), elotuzumab + pomalidomide + dexamethasone (EloPd), selinexor + bortezomib + dexamethasone (SVd).
62312552|NCT04959019|EXPERIMENTAL|Immediate Exercise|immediate participation in 6-week exercise program (intervention)
62312553|NCT04959019|OTHER|Delayed Exercise|6-week delay (no-intervention control) prior to participating in exercise program
62312554|NCT01371123||On long-term PN|
62312555|NCT01371123||Never been on TPN|
62312556|NCT05826353|EXPERIMENTAL|K-321|K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
62312557|NCT05826353|PLACEBO_COMPARATOR|Placebo|Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
62312558|NCT06167369||Newly diagnosed sleep apnea patients, starting clinical prescribed positive airway pressure therapy|
62477459|NCT05660655|ACTIVE_COMPARATOR|Baricitinib 2mg and methotrexate 10mg|Baricitinib 2mg once daily plus methotrexate 10mg per week
62477460|NCT05660655|EXPERIMENTAL|Baricitinib 4mg and methotrexate 10mg|Baricitinib 4mg once daily plus methotrexate 10mg per week
62123099|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
62123100|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
62123101|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
62123102|NCT00206375|NO_INTERVENTION|1|Group 1 will be treated only with Synthroid.
62123103|NCT00206375|EXPERIMENTAL|2|Group 2 will be treated with Growth hormone, synthroid, and lupron.
62123104|NCT00206375|NO_INTERVENTION|3|Group 3 will have acute hypothyroidism and will serve as controls.
62312559|NCT06572267|EXPERIMENTAL|Mepolizumab low dose group|"Mepolizumab (Jiangsu Pacific Menok Biopharmaceutical Co), 0.05 mg/kg, monthly.~Meperizumab was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min."
62683058|NCT04423211|ACTIVE_COMPARATOR|Arm A (EBRT, short-term androgen deprivation therapy [STAD])|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET negative for extera pelvic metastases undergo SOC EBRT for 6 months. Patients also receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC for 6 months starting up to 3 months prior to EBRT but no later than 7 days after start of EBRT. All treatment continues for 6 months in the absence of disease progression or unacceptable toxicity."
62683059|NCT04423211|EXPERIMENTAL|Arm B (EBRT, STAD, apalutamide)|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A. Patients also receive apalutamide PO QD for 6 months in the absence of disease progression or unacceptable toxicity."
62683060|NCT04423211|EXPERIMENTAL|Arm C (EBRT, STAD, apalutamide)|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A. Patients also receive apalutamide PO QD as in Arm B."
62737726|NCT05037695|EXPERIMENTAL|empagliflozin + OMT|empagliflozin 25mg - Daily - at least 15 days before the PCI procedure OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
62737727|NCT05037695|NO_INTERVENTION|OMT|OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
62737728|NCT05944068|EXPERIMENTAL|Early intervention group|This group will receive the intervention immediately after baseline.
62737729|NCT05944068|OTHER|Late intervention group|This group will receive the intervention 6 months after baseline, in psychological studies called the waiting list group
62737730|NCT05934591|EXPERIMENTAL|Population Type: Under Supervision or Not Under Supervision|1 group of 24 people under supervision (those on parole, drug court, probation, or methadone maintenance) and 1 group of 24 people not under supervision (those on parole, drug court, probation, or methadone maintenance) will attend groups of the Community Wise intervention.
62737731|NCT05934591|EXPERIMENTAL|Participation Incentive: Paid and Not Paid|1 group of 24 people will receive a financial incentive and 1 group of 24 people will not receive a financial incentive for attending the Community Wise intervention.
62737732|NCT05934591|EXPERIMENTAL|Group Type: Open and Closed Group Format|1 group of 24 people will attend a closed group format and 1 group of 24 people will attend an open group format of the Community Wise intervention.
62737733|NCT06497283|EXPERIMENTAL|I (Binaural)|Binaural sound using earphone will be applied.
62737734|NCT06497283|PLACEBO_COMPARATOR|II (Placebo)|Only headphone without sound will be applied.
62737735|NCT00807586|EXPERIMENTAL|Steroid|
62312560|NCT06572267|EXPERIMENTAL|Mepolizumab middle dose group|"Mepolizumab (Jiangsu Pacific Menok Biopharmaceutical Co), 0.1 mg/kg, monthly.~Meperizumab was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min."
62312561|NCT06572267|EXPERIMENTAL|Mepolizumab high dose group|"Mepolizumab (Jiangsu Pacific Menok Biopharmaceutical Co), 0.2 mg/kg, monthly.~Meperizumab was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min."
62737736|NCT00807586|PLACEBO_COMPARATOR|Placebo|
62737737|NCT00005947|ACTIVE_COMPARATOR|sipuleucel-T|
62312562|NCT06572267|PLACEBO_COMPARATOR|Placebo group|Saline, 100 ml, intravenous infusion
62312563|NCT01041573|EXPERIMENTAL|IC51 0.5 mL|Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
62737738|NCT00005947|PLACEBO_COMPARATOR|Placebo|
62737739|NCT00589706|EXPERIMENTAL|A|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).
62737740|NCT05144893|EXPERIMENTAL|Virtual Mindfullness-Based Support Group|The virtual mindfulness-based intervention with social support groups will meet once a week for 4 weeks, each session will be 60 minutes. Each group will have 3-8 participants. The groups will be closed, meaning the same group of participants meet with the same instructor (unless a backup instructor is needed due to unavoidable reasons). Groups will be completed using the video conferencing application.
62737741|NCT03818607|OTHER|T (ABP 959) / R (eculizumab)|ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
62312564|NCT01041573|EXPERIMENTAL|IC51 0.25 mL|Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
62683061|NCT04423211|EXPERIMENTAL|Arm D (EBRT, STAD, apalutamide, RT)|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A and apalutamide PO QD as in Arm B. Patients also undergo SBRT or 3D CRT, IMRT (including VMAT), and IMPT over 3-10 fractions in the absence of disease progression or unacceptable toxicity."
62683062|NCT05065671|EXPERIMENTAL|Tolcapone|Tolcapone 100 mg by mouth once
62123105|NCT02860910|EXPERIMENTAL|Cognitive Behavioral Group Therapy|"The six CBGT sessions are outlined in the manual entitled: Managing Hot Flushes with Group Cognitive Behaviour Therapy: An Evidenced-Based Treatment Manual for Health Care Professionals (Hunter \& Smith, 2015) as follows:~Session 1: Psycho-education and the cognitive behavioural model Session 2: Stress management, improving wellbeing and identifying precipitants Session 3: Managing hot flushes using a cognitive behavioural approach Session 4: Managing night sweats and improving sleep (part one) Session 5: Managing night sweats and improving sleep (part two) Session 6: Review and maintaining changes (One alteration: Open discussion about mood disorders, anxiety and the psychological impact instead of the psychological impact of breast cancer)"
62123106|NCT04693130|EXPERIMENTAL|Mindfulness-based prenatal education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
62312565|NCT01041573|ACTIVE_COMPARATOR|Havrix 720|Havrix®720 0.5 ml im. at day 0 and month 7
62312566|NCT01041573|ACTIVE_COMPARATOR|Prevnar|Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13
62312567|NCT05555069|ACTIVE_COMPARATOR|Menthol Flavor Electronic Cigarette|400 adult cigarette smokers will receive 12 weeks of menthol-flavored electronic cigarettes.
62683063|NCT05065671|EXPERIMENTAL|Duloxetine|Duloxetine 20 mg by mouth once
62312568|NCT05555069|ACTIVE_COMPARATOR|Tobacco Flavor Electronic Cigarette|400 adult cigarette smokers will receive 12 weeks of tobacco-flavored electronic cigarettes.
62312569|NCT04125823|EXPERIMENTAL|Video game-based physical activity training|
62312570|NCT04125823|ACTIVE_COMPARATOR|Conventional physiotherapy program|
62312571|NCT05115201|EXPERIMENTAL|Test group (TG)|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
62312572|NCT05115201|ACTIVE_COMPARATOR|Control group (CG)|Patients will be treated with scaling and root planing only
62312573|NCT00945191|EXPERIMENTAL|CS-1008 with paclitaxel and carboplatin|CS-1008 will be administered with paclitaxel and carboplatin.
62312574|NCT03078517|ACTIVE_COMPARATOR|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
62312575|NCT03078517|EXPERIMENTAL|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
62683064|NCT03722628||HCC with TTT|Blood sample from all HCC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
62737742|NCT03818607|OTHER|R (eculizumab) / T (ABP 959)|Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2
62737743|NCT05561283|EXPERIMENTAL|Cohort of residents|Medical residents undergoing the leadership and meditation training
62737744|NCT03994211|EXPERIMENTAL|Part A (core phase)|60 mg pamiparib administered orally on Days 1 and 10 fasting 8 hours pre-dose 600 mg rifampin once a day from days 3 to 11 in the fasted state (at least 2 hours predose)
62737745|NCT03994211|EXPERIMENTAL|Part B (core phase)|Single dose of 20 mg pamiparib orally in the fasted state (at least 8 hours predose) on days 1 and 7 200 mg itraconazole once a day approximately 30 minutes after completing a meal Day 3 to day 8
62737746|NCT03994211|EXPERIMENTAL|Extension phase|60 mg pamiparib orally twice a day in 28-day cycles until progression of disease
62737747|NCT06134115|EXPERIMENTAL|Treatment group (Lipocet®)|Participants received Lipocet® (food supplement) 1 sachet orally once a day for 60 days
62737748|NCT06134115|PLACEBO_COMPARATOR|Control group (Placebo)|Participants received Placebo 1 sachet orally once a day for 60 days
62737749|NCT02242136|EXPERIMENTAL|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1,5 and 2 hrs depending on the needs of the participant.
62737750|NCT02242136|NO_INTERVENTION|Waiting list|
61922685|NCT03498664|EXPERIMENTAL|EMR-C group|"A plastic cap for mucosectomy (MH-597, Olympus Optical Co., Ltd, Tokyo, Japan) with an outer diameter of 17 mm and a length of 15 mm will be preloaded on the tip of the colonoscope. Inside the distal end of the cap there is a gutter which positions the opened polypectomy snare.~After submucosal injection, the cap will be applied against the lesion which will be aspirated by controlled suction, avoiding excessive protrusion of tissue in order not to trap the muscular layer.~The tissue will then be gripped with the snare and resection will be performed. A specific polypectomy snare which can be adapted into the gutter of the cap will be used (SD-221U-25, Olympus Optical Co., Ltd, Tokyo, Japan)."
61922686|NCT03498664|ACTIVE_COMPARATOR|EMR-S group|The resection will be performed using a standard polypectomy snare, which diameter will be chosen according to the size of the lesion, after lifting the lesion from the underlying layers with a submucosal injection of liquid.
61922687|NCT03442283||Supplementation|
61922688|NCT03442283||No Supplementation|
61922689|NCT02034422|EXPERIMENTAL|Specific Aim #1|Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
61922690|NCT02034422|EXPERIMENTAL|Specific Aim #2|Specific Aim 2: Determine the remediable effect of combined antioxidant treatment and exercise rehabilitation in the treatment of hypertension. Hypothesis: Acute antioxidant treatment administered prior to exercise in hypertensive patients will ameliorate the exaggerated EPR resulting in a normal and safe blood pressure response to exercise-based rehabilitation. This two-pronged approach (antioxidants and exercise training) will result in a safely achieved reduction in skeletal muscle afferent feedback facilitating improved exercise tolerance, improved muscle blood flow and ultimately reduced cardiovascular risk in this population.
61922691|NCT02819661|ACTIVE_COMPARATOR|women BMI<30 POD 1|Pregnant healthy women with BMI\<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
61922692|NCT02819661|ACTIVE_COMPARATOR|women BMI≥30 POD 1|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
61922693|NCT02819661|ACTIVE_COMPARATOR|women BMI<30 POD4|Pregnant healthy women with BMI\<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
61922694|NCT02819661|ACTIVE_COMPARATOR|women BMI≥30 POD 4|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
61922695|NCT01858636||Angio-Seal VIP Vascular Closure|
61922696|NCT06020547||Adults with Cystic Fibrosis|"All patients who met the diagnostic criteria for CF, over 18 years old, with pathological sweat chloride levels (chloride \>60 mEq/L) and two CFTR mutations were recruited.~Sweat chloride levels have been tested, and a panel of CFTR mutations screened. The CFTR genotype has been defined through the screening of the most frequent mutations and rearrangements."
61922697|NCT04534465|EXPERIMENTAL|Dosing arm 1|MiraLAX Sachet (17g) + Flavor blend (2g mannitol total)
62123107|NCT04693130|PLACEBO_COMPARATOR|Hospital-based antenatal education|Hospital-based antenatal education program.
62123108|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
62123109|NCT01199783|EXPERIMENTAL|Daptomycin|Infusion of Daptomycin (6 mg/kg bodyweight) once daily
62683065|NCT03722628||HCC without TTT|Blood sample from all HCC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
62683066|NCT03722628||LC with TTT|Blood sample from all LC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
62683067|NCT03722628||LC without TTT|Blood sample from all LC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
62683068|NCT03722628||Healthy control|MMP1-genotype polymorphism will be applied on those healthy people to detect which type of mutation occur in healthy rather than diseased.
62123110|NCT01199783|ACTIVE_COMPARATOR|Vancomycin|Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)
61922698|NCT04534465|EXPERIMENTAL|Dosing arm 2|MiraLAX Sachet (17g) + Flavor blend + additional 2g mannitol (4g mannitol total)
62477461|NCT04435847|EXPERIMENTAL|HST 001|HST 001 (also known as hair stimulating complex \[HSC\]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges.
62683069|NCT05712538|EXPERIMENTAL|ARCT-032, Healthy Adults|Ascending single doses of ARCT-032 administered to healthy adults via nebulizer
62683070|NCT05712538|PLACEBO_COMPARATOR|Placebo, Healthy Adults|Single doses of 0.9% Saline administered to healthy adults via nebulizer
62683071|NCT05712538|EXPERIMENTAL|ARCT-032,. Adults with Cystic Fibrosis|Two doses of ARCT-032 administered to adults with Cystic Fibrosis via nebulizer
62683072|NCT02540902|EXPERIMENTAL|All-poly|Knee arthroplasty with all-polyethylene tibia
61922699|NCT04534465|EXPERIMENTAL|Dosing arm 3|MiraLAX Sachet (17g) + Flavor blend + additional 4g mannitol (6g mannitol total)
61922700|NCT04534465|EXPERIMENTAL|Dosing arm 4|MiraLAX Sachet (17g) + Flavor blend + additional 6g mannitol (8g mannitol total)
61922701|NCT04534465|EXPERIMENTAL|Dosing arm 5|MiraLAX Sachet (17g) + Flavor blend + additional 8g mannitol (10g mannitol total)
61922702|NCT06522412|EXPERIMENTAL|TL_TH|The participants takeJING SI HERBAL TEA LIQUID PACKETS first for 12 weeks and then wash-out for 12 weeks, and then take JING SI HERBAL TANG HENG POWDER DRINK for 12 weeks.
61922703|NCT06522412|ACTIVE_COMPARATOR|TH_TL|The participants take JING SI HERBAL TANG HENG POWDER DRINK first for 12 weeks and then wash-out for 12 weeks, and then take JING SI HERBAL TEA LIQUID PACKETS for 12 weeks.
61922704|NCT03226873|EXPERIMENTAL|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
61922705|NCT05871983|EXPERIMENTAL|Single-Arm|This is a prospective, non-randomized, single-arm, international, multicenter, clinical study designed to evaluate the safety, efficacy, and performance of the P\&F MUNICH TMVR System in a population of patients with moderate to severe symptomatic Mitral Regurgitation.
62123111|NCT06575413|EXPERIMENTAL|Direct electrical stimulation of the Claustrum|The investigators performed direct electrical stimulation of the claustrum in drug-resistant epilepsy patients underwent SEEG monitoring.The investigators observed the neural activities before, during, and after stimulation and the claustrum-cortical network to figure out the role of claustrum in consciousness and its underlying electrophysiological mechanism.
62683073|NCT02464098||Group 1|Participants with diagnosis of hematological malignancy or solid tumor.
61922706|NCT03705078|OTHER|early TIPS|Transjugular portosytemic shunt within 72h
61922707|NCT03705078|OTHER|Glue obliteration|glue obliteration repeated sessions
61922708|NCT02517970|EXPERIMENTAL|Classical Music versus Television show|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
62312576|NCT01749735|EXPERIMENTAL|Armeo training with continuous tDCS|Subjects will receive 10 sessions of transcranial Direct Current Stimulation (tDCS)/Armeo training over 2 weeks. Training sessions will last for 40 minutes and will focus on repetitive tasks using the Armeo device that. To deliver the stimulation, the anode will be placed over the primary motor cortex (M1) of the affected hemisphere, while the cathode will be placed over the unaffected M1 area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2). Continuous stimulation will be delivered at an intensity of 1mA while the subject undergoes the 40-minute Armeo motor training sessions.
62477462|NCT04435847|PLACEBO_COMPARATOR|Placebo - Phosphate Buffered Saline|Phosphate Buffered Saline
62683074|NCT02464098||Group 2|Participants undergoing hematopoietic stem cell transplantation (HSCT).
62683075|NCT00772525|EXPERIMENTAL|Sequence 1|"placebo,1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
62123112|NCT01666704|EXPERIMENTAL|Treatment A: BMS-823778 (2mg)|
61922709|NCT06338761||Continued combustible cigarette use|continued combustible cigarettes users after PCI
61922710|NCT06338761||Switching to E-cigarette|switching to E-cigarette users after PCI
61922711|NCT06338761||Quitter|quitters after PCI
61922712|NCT05012436|EXPERIMENTAL|YHD1119 75mg, 150mg NF|CLcr (mL/min/1.73m2) \>= 60 Period 1 : YHD1119 75 mg Period 2 : YHD1119 150 mg NF
61922713|NCT05012436|EXPERIMENTAL|YHD1119 75mg|60 \> CLcr (mL/min/1.73m2) \>= 30 Period 1 : YHD1119 75 mg Period 2 : NA
62123113|NCT01666704|EXPERIMENTAL|Treatment B: BMS-823778 (15mg)|
62123114|NCT01666704|PLACEBO_COMPARATOR|Treatment C: Placebo|
62123115|NCT01919645|EXPERIMENTAL|Combined Training Group|"Combined Training - (strength + aerobics).~A combined training (CT)is performed, having aerobics exercises (AE)using a stationary bicycle and strength training in workout devices.~The strength training (ST) will be performed by isotonic exercises recruiting the main muscle groups. They exercises are: Chest Press, Leg Press, Vertical Traction, Leg Extension and Abdominal Crunch."
61922714|NCT06231836|ACTIVE_COMPARATOR|High flow nasal cannula group|
61922715|NCT06231836|ACTIVE_COMPARATOR|Nasal cannula group|
61922716|NCT00970736||1|20 healthy participants between 60 and 80 years of age. Ten men and 10 women.
61922717|NCT02775903|EXPERIMENTAL|Azacitidine + Durvalumab|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
62683076|NCT00772525|EXPERIMENTAL|Sequence 2|"placebo,1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
62683077|NCT00772525|EXPERIMENTAL|Sequence 3|"50 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
62683078|NCT00772525|EXPERIMENTAL|Sequence 4|"50 mg Nerispirdine, 1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
62123116|NCT01919645|PLACEBO_COMPARATOR|Control Group|The control group patients did not perform any intervention through physical exercises. They were oriented on Sleep Hygiene and were followed during the study. They were asked to come to the following visits (at weeks 8 and 16) and to 2 additional visits to get and then return the actigraph. During this period, they were followed through phone calls once a month and were asked for sleep hygiene and were reminded of their assessment dates.
62683079|NCT00772525|EXPERIMENTAL|Sequence 5|"400 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
62123117|NCT04496050||one|there is only one patient group. This group of patients, given the same dose and at the same time, is examined by ultrasonography to determine the thickness of the pyloric muscle.
62123118|NCT05574192|OTHER|Social Engagement Intervention|The social engagement intervention includes in-person visits by peer-workers to undertake accompanied social activities with enrolled participants. Each visit will last one hour, occur two times per month over a 12 month period. Activity categories will be self-selected by participants based on physical abilities and interests. Categories include: a) arts based activity; b) physical activity.
62123119|NCT04303156|EXPERIMENTAL|Severe Renal Impairment|Participants with severe renal impairment received a single oral dose of 60 mg MK-8591 (Islatravir) administered in capsule form.
62123120|NCT04303156|EXPERIMENTAL|Healthy|Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.
62123121|NCT02043054|EXPERIMENTAL|Liraglutide|Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
62123122|NCT02043054|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
62123123|NCT05319366||Stable angina|50 patients with stable angina will be included and tissue samples from balloon cathether and blood samples will be collected
62123124|NCT05319366||Unstable angina/non-ST-segment elevation myocardial infarction|50 patients with unstable angina/non-ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
62123125|NCT05319366||ST-segment elevation myocardial infarction|50 patients with ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
62123126|NCT05319366||Controls|50 patients without corornary arthery-related treatment will be included and tissue samples from balloon cathether and blood samples will be collected
62683080|NCT00772525|EXPERIMENTAL|Sequence 6|"400 mg Nerispirdine, 1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
62312577|NCT01749735|SHAM_COMPARATOR|Armeo training with sham tDCS|Subjects will receive the same number of 40-minute training sessions (i.e. 10 sessions) as the subjects in the experimental group. Training will take place over a period of two weeks as per the experimental group. Also, electrodes will be positioned on the scalp as per the experimental group. However, for sham transcranial Direct Current Stimulation (tDCS), the current will be delivered for only 30 seconds. The current intensity will be gradually increased and decreased to diminish its perception.
62312578|NCT02231203|PLACEBO_COMPARATOR|Placebo|2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
62312579|NCT02231203|ACTIVE_COMPARATOR|Omegaven|2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
62683081|NCT06690190||Patients|Patients with any kidney disease
62312580|NCT01120327|EXPERIMENTAL|Amlodipine|Amlodipine
62683082|NCT06690190||Healthy subjects|Subjects with normal kidneys
62683083|NCT03584386|EXPERIMENTAL|V-CAMS (aka Jaspr)|"In Phase I (formative), participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.~Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants in the Telehealth RCT will be randomly assigned to receive the V-CAMS/Jaspr companion mobile app JAH in addition to their usual outpatient care. Study assessments will be administered remotely at three time points: baseline, 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as completing setup of JAH on their personal mobile phone."
62123127|NCT05319366||Vascular surgery|25 patients who undergo will be included and tissue samples and blood samples will be collected
62312581|NCT01120327|PLACEBO_COMPARATOR|Placebo|Placebo
62312582|NCT03720080||670G/OpenAPS|Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.
62312583|NCT00060086|EXPERIMENTAL|Pomegranate Juice|Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
62312584|NCT01418768|EXPERIMENTAL|Rehabilitation|
62312585|NCT02293681||Cohort 1: Infliximab and/or NSAIDs and DMRADs|Participants receiving intravenous infusion of infliximab with or without non-steroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen and naproxen) and Disease-modifying anti-rheumatic drugs (DMRADs: methotrexate (MTX), sulfasalazine, and thalidomide) will be observed.
62683084|NCT03584386|NO_INTERVENTION|Care As Usual|"Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants enrolled in the Telehealth RCT will be randomly assigned to CAU in addition to receiving crisis safety planning. Study assessments will be administered remotely at baseline and at 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as setting up the control condition crisis stability plan."
62683085|NCT04226105|EXPERIMENTAL|GP40081|Subcutaneous (SC), up to Week 26
62683086|NCT04226105|ACTIVE_COMPARATOR|NovoMix® 30 FlexPen®|Subcutaneous (SC), up to Week 26
62683087|NCT06689319||The group to be evaluated in terms of AI literacy|
62683088|NCT03154567|PLACEBO_COMPARATOR|Yohimbine 0mg X Cue Condition (neutral)|
62683089|NCT03154567|PLACEBO_COMPARATOR|Yohimbine 0mg X Cue Condition (marijuana)|
62683090|NCT03154567|ACTIVE_COMPARATOR|Yohimbine 20mg X Cue Condition (neutral)|
62683091|NCT03154567|ACTIVE_COMPARATOR|Yohimbine 20mg X Cue Condition (marijuana)|
62683092|NCT03154567|ACTIVE_COMPARATOR|Yohimbine 40mg X Cue Condition (neutral)|
62683093|NCT03154567|ACTIVE_COMPARATOR|Yohimbine 40mg X Cue Condition (marijuana)|
62737751|NCT05257499|EXPERIMENTAL|On line debfriefing|Participants in this group will practice the skills taught as above but in the presence of the same certified instructor who will guide them throughout all the steps of HBB using a virtual platform (Webex® or Zoom®).
62737752|NCT05257499|NO_INTERVENTION|In person debriefing|Participants in this group will practice the skills taught in the virtual class on the neonatal mannequin. They are expected to work as a small group of 3 to 4 at a time. They will receive coaching, debriefing and feedback from a certified instructor who will conduct the traditional in-person training with face-to-face feedback and debriefing.
62737753|NCT04384705||caregivers|caregivers
62123128|NCT05682183|ACTIVE_COMPARATOR|Multi-domain Psychoeducation Self-management Programme|Participants will be registered at the care centre and will receive usual care from their care manager who is assigned to them when they register with the centre. Those who are randomised into the intervention arm will undergo 5-sessions of Multi-domain Psychoeducation Self-management Programme over 5 weeks.
62123129|NCT05682183|ACTIVE_COMPARATOR|Treatment as Usual|Participants will be registered at the care centre and will receive usual care from their care manager who is assigned to them when they register with the centre.
62737754|NCT02701959|PLACEBO_COMPARATOR|Low nitrate lettuce|50g of low nitrate lettuce (placebo) on single occasions
62737755|NCT02701959|ACTIVE_COMPARATOR|High nitrate lettuce|50g of high nitrate lettuce (intervention) on single occasions
62139647|NCT05558683|ACTIVE_COMPARATOR|Vojta Reflex Locomotion Therapy|The Vojta Method or Vojta Reflex Locomotion Therapy (TLRV) is a rehabilitative method for neuromusculoskeletal pathologies widely used in Europe. Its development is based on the concept of motor ontogenesis and tries to trigger innate motor reactions (reflex locomotion patterns) in the trunk and limbs from defined tactile and proprioceptive stimuli, starting from certain postures. This therapy presents differential elements with respect to other existing therapies, both for neurophysiological principles and for methodological principles. It is an active therapy, in which great concentration is required on the part of the patient, that is, both therapist and patient are the central axes of the treatment.
62312586|NCT02293681||Cohort 2: NSAIDs and DMARDs|Participants receiving NSAIDs (aspirin, ibuprofen and naproxen) and DMARDs (MTX, sulfasalazine, and thalidomide) will be observed.
62312587|NCT02075996||Pomalidomide following lenalidomide|75 patients with pomalidomide directly following lenalidomide treatment
62312588|NCT02075996||Pomalidomide following other therapy|75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
62312589|NCT03910192|EXPERIMENTAL|Mindfulness meditation coaching|Mindfulness-based coaching - participants will receive instructions on (a) mindfulness meditation and gentle mindful movement through home-based and in-class participation at the Southlake Cardiovascular Rehabilitation Clinic and (b) personal coaching support. The health coach will further assist participants through either face-to-face or telephone-based discussions. They will meet with the health coach at mutually-agreed upon on times for designated time periods.
62477463|NCT03781102|EXPERIMENTAL|Intervention|Arm 1, or intervention participants (n=60), will participate in a 16-week face-to-face diabetes prevention group program '16-Week Diabetes Prevention Program for Mothers and Children' and then will transition to a 16-week follow-up period.
62477464|NCT03781102|OTHER|Wait-listed Control|Arm 2, or wait-listed controls (n=60), will receive the typical standard of care during the first 16-weeks, followed by the 16-week face-to-face group diabetes prevention program '16-Week Diabetes Prevention Program for Mothers and Children'.
62312590|NCT03910192|ACTIVE_COMPARATOR|dietary cardiovascular risk reduction coaching|Cardiovascular risk reduction education - No change to standard of care where participants will receive instructions (in person or by phone call) on how to integrate exercise and dietary changes in your lifestyle to reduce your risk of future cardiovascular events. These instructions will be centered around the DASH dietary practices.
62312591|NCT00759473|PLACEBO_COMPARATOR|Placebo/Placebo/Placebo/Placebo|Participants were assigned to receive placebo for each of 3 cue exposure sessions and at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
62312592|NCT00759473|EXPERIMENTAL|DCS/DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 3 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
62312593|NCT00759473|OTHER|DCS/Placebo/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) at the first and third cue exposure sessions and a placebo at the second cue exposure and the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
62312594|NCT00759473|EXPERIMENTAL|DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
62312595|NCT00759473|ACTIVE_COMPARATOR|Placebo/Placebo/Placebo|Participants were assigned to placebo for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
62312596|NCT04049188|EXPERIMENTAL|Single-Fraction Palliative RT|Single-Fraction Palliative Radiation Therapy Adminstration
62477465|NCT02517294|ACTIVE_COMPARATOR|standard nasotracheal tube|Nasotracheal intubation using 'standard' side-beveled nasotracheal tubes
62477466|NCT02517294|ACTIVE_COMPARATOR|Parker flex-tip nasotracheal tube|Nasotracheal intubation using 'experimental' flex-tip midline-beveled nasotracheal tubes
62312597|NCT05157282|ACTIVE_COMPARATOR|Active TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, active transcutaneous electrical spinal stimulation (TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
62312598|NCT05157282|SHAM_COMPARATOR|Sham TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, sham transcutaneous electrical spinal stimulation (sham-TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
62477467|NCT01501786|SHAM_COMPARATOR|control|propofol and saline are administered
62477468|NCT01501786|EXPERIMENTAL|Ket10|ketamine is co-administered with propofol
62477469|NCT01501786|EXPERIMENTAL|Ket20|ketamine is co-administered with porpofol
62477470|NCT00571064|EXPERIMENTAL|1|
62477471|NCT01793558|NO_INTERVENTION|Control; passive insulation|The mothers will receive passive temperature insulation by a cotton blanket (standard procedure) after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the cotton blanket (also passive insulation without active warming) for 20 min after birth (bonding period).
62737756|NCT02727595|EXPERIMENTAL|CyclaPlex Implant|Implant device for reduction of the inter metatarsal angle (IMA) without osteotomy.
62312599|NCT05157282|ACTIVE_COMPARATOR|Active TESS + Training|Develop methodologies to promote recovery of reaching and grasping movements. To accomplish this goal, the investigators will combine TESS applied in a closed-loop manner with massed practice upper-limb training. Participants will be assigned to one of three groups in a randomized order for a controlled design: \[1) Closed-loop TESS applied during grasping + training, 2) Closed-loop TESS applied during reaching + training, and 3) Closed-loop TESS applied during grasping \& reaching + training.\] TESS for 20-min will be followed by 60 min of massed practice exercise training (total=20 sessions).
62683094|NCT00631241|EXPERIMENTAL|Intraoperative Lymphatic Mapping|Single Photon Emission Computed Tomography - First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients. Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
62312600|NCT02747628|PLACEBO_COMPARATOR|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
62683095|NCT06467656|EXPERIMENTAL|Exercise Intervention|Participants will engage in 12 months of individualized endurance-training (swimming, cycling and running) and 9 months of supplemental strengthening exercises. Exercise prescriptions will be provided to participants weekly via an app (TrainingPeaks). Sessions will vary in length from 30 min to 8 hours throughout the program.
62683096|NCT06467656|ACTIVE_COMPARATOR|Time-Aligned Control|Participants in the control arm will continue to live their lives exactly as they would if they were not enrolled in a study to allow evaluation of natural biological changes that occur across 12-months of free-living.
62683097|NCT06478615|EXPERIMENTAL|Coring out Fistulectomy with Closure of Internal Sphincter Opening|Patients underwent coring out fistulectomy with closure of internal sphincter opening
61922718|NCT02775903|ACTIVE_COMPARATOR|Azacitidine Alone|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
62312601|NCT02747628|ACTIVE_COMPARATOR|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
62683098|NCT06478615|EXPERIMENTAL|Lay Open Fistulotomy and Primary Sphincter Repair|Patients underwent lay open fistulotomy and primary sphincter repair
62683099|NCT05021562||Niraparib 200-300 milligrams (mg)|Arm description: Niraparib 200 mg, capsules, orally, once daily. For adult participants weighing 77 kilograms (kg) or more and with platelet count 150,000/mcrL or higher before the first dose of this drug, niraparib 300 mg, capsules, orally, once daily.
62683100|NCT01641666|EXPERIMENTAL|Peg2b + Ribavirin + Boceprevir|Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
62683101|NCT03882372|EXPERIMENTAL|Nasal high flow|"Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow."
62683102|NCT03882372|NO_INTERVENTION|Usual care|"Patient randomized to the control group will have no other specific intervention than their usual care.~Patients under long-term oxygen will preserve their usual flow."
62683103|NCT00674063|EXPERIMENTAL|1|Dose regimen 1
62683104|NCT00674063|EXPERIMENTAL|2|Dose regimen 2
62683105|NCT06548620|EXPERIMENTAL|RD06-04 cell infusion|
62683106|NCT02524899|ACTIVE_COMPARATOR|Cognitive Remediation Therapy and placebo|7.5 weeks of twice weekly cognitive remediation sessions
62683107|NCT02524899|EXPERIMENTAL|Guanfacine and CRT|7.5 weeks of twice weekly cognitive remediation sessions with 8 weeks of guanfacine
62683108|NCT03073070|EXPERIMENTAL|Biotin labeled RBCs in 4-10 year old diabetes children|Biotin labeled autologous RBCs will be transfused to the subjects
62683109|NCT03073070|EXPERIMENTAL|Biotin labeled RBCs in 10-18 year old diabetes children|Biotin labeled autologous red blood cells will be transfused to the subjects
62683110|NCT02553473|ACTIVE_COMPARATOR|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
62139648|NCT05558683|ACTIVE_COMPARATOR|Bobath Method|Within physiotherapy, the Bobath concept is a valid and recognized option in the treatment of patients with neurological disorders, and therefore, of those diagnosed with MS. It was developed by Karel and Berta Bobath. The Bobath concept is defined as a problem-solving approach in the assessment and treatment of people with impaired neuromotor function, becoming a valid tool as part of the comprehensive treatment of people with MS
61922719|NCT02352922|EXPERIMENTAL|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
62683111|NCT02553473|PLACEBO_COMPARATOR|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
62683112|NCT06690125||Patients with right hemisphere stroke (Without USN)|
62683113|NCT06690125||Patients with right hemisphere stroke (With USN)|
62683114|NCT03784326|EXPERIMENTAL|Cohort 1-Atezolizumab combination with Oxaliplatin and 5-fluorouracil (5-FU)|The combination of Atezolizumab with Oxaliplatin and 5-Fluorouracil IV on Days 1 and 15 of each 28-day cycle for total of 6 doses followed by surgery followed by Atezolizumab on Day 1 of each 21-day cycle for total of 24 weeks
62683115|NCT03784326|EXPERIMENTAL|Cohort 2- Atezolizumab plus and Tiragolumab with Oxaliplatin and 5-fluorouracil (5-FU)|The combination of Atezolizumab + Tiragolumab with Oxaliplatin and 5-Flourouracil IV on Days 1 and 15 of each 28-day cycle for total of 6 doses followed by surgery followed by Atezolizumab + Tiragolumab on Day 1 of each 21-day cycle for a total of 48 weeks.
61922720|NCT02352922|ACTIVE_COMPARATOR|Bupivacaine HCl|short-acting bupivacaine
61922721|NCT05814601|EXPERIMENTAL|experimental group|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
62737757|NCT06024109||SYMMCORA®|Barbed suture SYMMCORA® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
62737758|NCT06024109||V-Loc®|Barbed suture V-Loc® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
62737759|NCT04905524|OTHER|Intervention arm|All participants received the intervention in this trial (VPNP diet and supplement recommendations).
61922722|NCT05814601|NO_INTERVENTION|Control group|norepinephrine at a concentration of 5 mcg/ml is not preemptively administered
61922723|NCT02884843|ACTIVE_COMPARATOR|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction Disposable
61922724|NCT02884843|ACTIVE_COMPARATOR|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
61922725|NCT05086068|OTHER|Arthrosamid Inj|Single arm study - no comparator
61922726|NCT00573196|EXPERIMENTAL|1|
62737760|NCT06289894|EXPERIMENTAL|BRY805|
62312602|NCT02747628|ACTIVE_COMPARATOR|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
62312603|NCT02501356|ACTIVE_COMPARATOR|ISOThrive supplement 1|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
61922727|NCT06111391|ACTIVE_COMPARATOR|maxillary titanium zirconium full arch fixed prosthesis|maxillary titanium zirconium full arch fixed prosthesis and mandibular distal extension partial denture.
61922728|NCT06111391|ACTIVE_COMPARATOR|maxillary peek composite full arch fixed prosthesis|maxillary peek composite full arch fixed prosthesis and mandibular distal extension partial denture.
61922729|NCT04835467|EXPERIMENTAL|Intracoronary imaging|Intracoronary imaging during PCI
62312604|NCT02501356|ACTIVE_COMPARATOR|ISOThrive supplement 2|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
62683116|NCT02192086|EXPERIMENTAL|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
62737761|NCT05302869||Students|
61922730|NCT00597337|EXPERIMENTAL|1|Receiving FearNot
61922731|NCT00597337|NO_INTERVENTION|2|Control: Treatment as usual (normal curriculum)
61922732|NCT02945787|EXPERIMENTAL|Extended Self-help|Spanish-Language Version of the Stop Smoking for Good: The Extended Self-help condition will comprise the 11 Stop Smoking for Good booklets and 9 supportive My Story pamphlets transcreated for Spanish speaking smokers.
61922733|NCT02945787|ACTIVE_COMPARATOR|Usual Care (UC)|NCI-Produced Spanish-language Self-help Booklet: The UC control condition enhances the external validity of the study by providing a comparison to an existing, credible intervention that a smoker could receive in a medical setting or elsewhere.
61922734|NCT01135576|PLACEBO_COMPARATOR|Placebo juices|Consumption of non-iron fortified fruit juices as part of the usual diet
61922735|NCT01135576|EXPERIMENTAL|Iron fortified fruit juices|Consumption of iron fortified fruit juices as part of the usual diet
61922736|NCT02986880|EXPERIMENTAL|Group D1|Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
61922737|NCT02986880|EXPERIMENTAL|Group D2|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
61922738|NCT02986880|EXPERIMENTAL|Group D3|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
61922739|NCT02986880|EXPERIMENTAL|Group A1|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
61922740|NCT02986880|EXPERIMENTAL|Group A2|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
61922741|NCT02986880|EXPERIMENTAL|Group A3|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
62139649|NCT03317652|EXPERIMENTAL|Sodium nitroprusside and CO2 reactivity|"The subject rests in the supine position throughout the study that lasts for approximately three hours.~Interventions are:~* Hyperventilation~* 6% CO2 breathing~* Infusion of sodium nitroprusside"
62312605|NCT02501356|PLACEBO_COMPARATOR|Placebo supplement|Participants assigned to the placebo supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
62312606|NCT00950027|EXPERIMENTAL|povidone iodine|Povidone iodine
62312607|NCT00950027|PLACEBO_COMPARATOR|placebo|
62737762|NCT05302869||Physiotherapist|
62737763|NCT02763813|EXPERIMENTAL|Propulsion type appliance (Herbst)|
62737764|NCT02763813|ACTIVE_COMPARATOR|Retention type appliance (ORM)|Retention type appliance
62737765|NCT05810909|EXPERIMENTAL|ACC group|ACC group use amorphous calcium carbonate
62737766|NCT05810909|PLACEBO_COMPARATOR|control group|control group use placebo
62737767|NCT04453358|ACTIVE_COMPARATOR|Interactive coaching|Airway clearance therapy using goal setting and interactive feedback.
62737768|NCT04453358|ACTIVE_COMPARATOR|Standard of care coaching|Standard of care airway clearance therapy.
62737769|NCT04626687|EXPERIMENTAL|test DCB group|use the DCB made by Acotec Scientific
62737770|NCT04626687|ACTIVE_COMPARATOR|RESTORE DCB group|use the DCB made by CARDIONOVUM GmbH
62683117|NCT02192086|ACTIVE_COMPARATOR|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
62683118|NCT04973293|EXPERIMENTAL|Neoadjuvant treatment|"Participants will receive 4 doses of sintilimab (200 mg, IV) and bevacizumab (15 mg/kg, IV) every 3 weeks (Q3W). Participants will also receive 4 doses of carboplatin (AUC=5, IV) and pemetrexed (500 mg/m2, IV) Q3W.~Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.~After the second dose of sintilimab, bevacizumab and chemotherapy, contrast-enhanced chest CT will be performed. Patients with progression disease will receive surgery without the last 2 doses of treatment."
62683119|NCT05018598|EXPERIMENTAL|CHF5993 100/6/12.5 μg (main phase and extension phase)|"Main phase: 2 inhalations BID, Daily dose is 400/24/50 μg x 26 weeks~Open-label extension phase: 2 inhalations BID, Daily dose is 400/24/50 μg x 24 weeks"
61922742|NCT02986880|EXPERIMENTAL|Group F1|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
61922743|NCT02986880|EXPERIMENTAL|Group F2|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
61922744|NCT02986880|EXPERIMENTAL|Group F3|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
61922745|NCT02986880|PLACEBO_COMPARATOR|Group P|Patients receiving placebo in the third muscles groups
61922746|NCT01511224||Colistin monotherapy|
62312608|NCT05144542|EXPERIMENTAL|E-Cigarettes|Participants vape e-cigarettes for 26 weeks. Participants use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day for up to 182 days. Participants complete questionnaires over 50 minutes and undergo collection of urine sample at 0, 1, 7, 13, and 27 weeks, and collection of blood samples at 6, 12, and 26 weeks. Participants may also undergo measurement of CO levels at 1, 6, 12, and 26 weeks.
62312609|NCT02091011||Cohort group|Subjects who have been implanted within 30 days with a commercially available Boston Scientific ICD or a CRT-D device
62312610|NCT03687034|EXPERIMENTAL|BRCX014|Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
62477472|NCT01793558|EXPERIMENTAL|Active Warming|The mothers will receive active warming by a forced-air warming blanket after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the warming blanket for 20 min after birth (bonding period).
62683120|NCT05018598|ACTIVE_COMPARATOR|CHF1535 200/6 μg (main phase) / CHF5993 200/6/12.5 μg (extension phase only)|"Main phase: 2 inhalations BID, Daily dose is 800/24 μg x 26 weeks~Open-label extension phase: 2 inhalations BID, Daily dose is 800/24/50 μg x 24 weeks"
62683121|NCT06688201|OTHER|Other neurosurgical techniques|Those include open craniotomy, small skull window microsurgery, and endoscopic surgery.
62683122|NCT06688201|EXPERIMENTAL|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation
62123130|NCT06392451|OTHER|Blinded, Prospective Arm|"Clinical specimens shall be collected prospectively from patients with signs or symptoms of respiratory tract infection. Nasal swab (NS) in Copan universal transport media (UTM) 3 milliliters for comparator testing should be collected by a healthcare professional. Where subjects are willing and able, up to 40% of NS for the investigational device will be self-collected under the guidance and supervision of a healthcare professional.~Nasopharyngeal (NPS) specimens (optional) should only be collected by a healthcare professional. All specimens collected from children 13 years or younger should only be collected by a trained healthcare professional. Follow the Centers for Disease Control and Prevention guidelines for collecting NPS swabs, unless otherwise specified by the sponsor."
62477473|NCT01706094|EXPERIMENTAL|lying flat head position|positioning the head of the bed at zero degrees during the first 48 hours from admission of patients with acute ischemic stroke Active Comparator: upright position of the head of the bed during 48 hours from admission of patients with acute ischemic stroke
62477474|NCT05201339|ACTIVE_COMPARATOR|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
62477475|NCT05201339|EXPERIMENTAL|Head-neck rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
61922747|NCT01511224||Colistin based combination therapy|Colistin-Tigecycline, Colistin-Carbapenem, Colistin-Rifampin, Colistin-HD Unasyn
61922748|NCT01511224||Non-colistin containing regime|
61922749|NCT01511224||Glycopeptide with colistin combination|
61922750|NCT01511224||Colistin with loading dose|
62683123|NCT01530516|ACTIVE_COMPARATOR|Full brackets plus Forsus springs|Standard of care - Class II springs used after le el and alignment.
62683124|NCT01530516|EXPERIMENTAL|Xbow plus full brackets|Alternative treatment - First use the Xbow appliance and then full brackets after Class II occlusion has been corrected.
61922751|NCT06169631|EXPERIMENTAL|Experiment 1|The study will consist of 2 groups. A: no current diagnosis of anxiety or other psychological disorders. B: Current diagnosis of anxiety disorder. Results will be analyzed within and between groups. Participants will answer standardized questionnaires and other similar validated psychological scales. An ultrasound transducer will be placed on their head aimed at the brain region of interest. EEG data will be collected throughout the process. After this process, participants will answer a set of post experiment questions.
62477476|NCT04508790|EXPERIMENTAL|Treatment (leflunomide, pomalidomide, dexamethasone)|Patients receive leflunomide PO on days 1-28, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62737771|NCT04061824|EXPERIMENTAL|Patients with fixed-dose combination of 2 drugs|Medication for hypertension and dyslipidemia in these group was fixed-dose combination of 2 drugs
61922752|NCT06169631|EXPERIMENTAL|Experiment 2a|Current diagnosis of anxiety disorder is required. Participants will receive an MRI. Participants will answer standardized questionnaires and other similar validated psychological scales. An ultrasound transducer will be placed on their head aimed at the brain region of interest. EEG data will be collected throughout the process. After this process, participants will answer a set of post experiment questions
62737772|NCT04061824|ACTIVE_COMPARATOR|Patients with 2 separated drugs|Medication for hypertension and dyslipidemia in these group was 2 separated drugs for each disease.
62737773|NCT02911298|EXPERIMENTAL|Mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation is administered to subject in fasted state
62683125|NCT01674062|EXPERIMENTAL|Pertuzumab + Trastuzumab (Cohorts 1 and 2)|Females with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer will receive dual-agent treatment with pertuzumab and trastuzumab. Trastuzumab will be administered IV as 2 milligrams per kilogram (mg/kg) once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, beginning on Day 2 of Cycle 1. Thereafter, both medications will be administered on Day 1 of each 3-week cycle. Treatment will continue for a minimum of 8 cycles and may be extended until disease progression, intolerable toxicity, or death.
62683126|NCT01674062|EXPERIMENTAL|Pertuzumab +/- Trastuzumab (Cohort 3)|Females with HER2-positive metastatic breast cancer will receive single-agent treatment with pertuzumab. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, administered on Day 1 of each 3-week cycle. Participants with documented disease progression may have trastuzumab added to the regimen, per the dosing schedule described for Cohorts 1 and 2, to receive dual-agent treatment until disease progression, intolerable toxicity, or death.
61922753|NCT06169631|EXPERIMENTAL|Experiment 2b|Experiment 2b will expand on Experiment 2a protocol with multiple visits. Each visit will consist of the same activities as Experiment 2a.
61922754|NCT01208831|EXPERIMENTAL|LDE225|
61922755|NCT03614767||Successes|Patients with \>50% improvement during test procedure of sacral neuromodulation.
62312611|NCT02679066|ACTIVE_COMPARATOR|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
61922756|NCT03614767||Failures|Patients with \<50% improvement during test procedure of sacral neuromodulation.
61922757|NCT05216601|ACTIVE_COMPARATOR|MVC-COV1901|15 mcg of S-2P protein with adjuvant
61922758|NCT05216601|EXPERIMENTAL|MVC-COV1901(Beta)-15|15 mcg of S-2P protein(Beta) with adjuvant
61922759|NCT05216601|EXPERIMENTAL|MVC-COV1901(Beta)-25|25 mcg of S-2P protein(Beta) with adjuvant
61922760|NCT05825261||COPD|COPD is defined according to COPD Gold 2023 guidelines.
61922761|NCT04276454|EXPERIMENTAL|Single arm|
61922762|NCT02716896|ACTIVE_COMPARATOR|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, Glomerular Filtration rate (GFR), participant's preference, and availability of chemotherapeutic regimen.
61922763|NCT02716896|ACTIVE_COMPARATOR|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
61922764|NCT03173534|ACTIVE_COMPARATOR|TAVR + Medical Therapy|n=172 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
62683127|NCT04917510|ACTIVE_COMPARATOR|Control|Will not receive erector spinae block. Will be administered 30 mL of 0.5% Marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
62683128|NCT04917510|EXPERIMENTAL|Study|Will receive an erector spinae block prior to surgery using 30-45 mL of 0.25 bupivacaine w/ epinephrine and 5 mL of dexmedetomidine. Will be administered 30 mL of 0.5% marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
62683129|NCT06269666|OTHER|Imaging Session|Various scans will be captured
62683130|NCT06472791|EXPERIMENTAL|Centlla Asiatica|250 mg/day (1 capsules) for week 1. 500 mg/day (2 capsules) for week 2. 750 mg/day (3 capsules) for week 3. 1000 mg/ day (4 capsules) for week 4.
61922765|NCT03173534|EXPERIMENTAL|TAVR + WATCHMAN|n=177 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
62683131|NCT06472791|PLACEBO_COMPARATOR|Placebo|Matched number of capsules per week. Capsules will contain microcrystalline cellulose.
62683132|NCT04589624|ACTIVE_COMPARATOR|Arm I ( Health Volunteer MRI)|Healthy volunteers undergo MRI over 30 minutes.
62737774|NCT02911298|ACTIVE_COMPARATOR|Non-mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation is administered to subject in fasted state
61922766|NCT00731432|EXPERIMENTAL|A|Transmucosal Herbal Periodontal Patch (THPP)
62312612|NCT02679066|ACTIVE_COMPARATOR|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
62477477|NCT03740230||Hepatitis C|Participants with Hepatitis C Genotypes 1 to 6 receiving Maviret (glecaprevir/pibrentasvir) for 8, 12, or 16 weeks.
61922767|NCT00731432|PLACEBO_COMPARATOR|B|Placebo Patch
62312613|NCT05372315|OTHER|Lower Punctum Insertion (Group 1)|"DEXTENZA (dexamethasone ophthalmic insert, 0.4mg) for intracanalicular use~Group 1 (up to 40 eyes) will receive the insert in the lower punctum on the day of surgery in the OR."
61922768|NCT00667420|EXPERIMENTAL|EOXP chemotherapy|open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle
62123131|NCT05276310|EXPERIMENTAL|IMC-002|"1. Dose escalation will follow the traditional 3+3 design.~2. Dose expasion part"
62312614|NCT05372315|OTHER|Upper Punctum Insertion (Group 2)|"DEXTENZA (dexamethasone ophthalmic insert, 0.4mg) for intracanalicular use~Group 2 (up to 40 eyes) will receive the insert in the upper punctum on the of surgery in the OR."
62312615|NCT02297893|EXPERIMENTAL|Dexterity training program (HOMEDEXT)|This program is a a high intensity training program adapted from a previously published arm ability training program
62312616|NCT02297893|ACTIVE_COMPARATOR|Theraband training program|7 different Theraband exercises. Total duration is 30 minutes, trained 5 times a week over a period of 4 weeks
62477478|NCT05571462||Activity monitor group|No intervention will be applied. All patients will have activity monitors placed at the distal part of the femur and on the torso. Normal rehabilitation will be performed as usual.
62123132|NCT01764464|OTHER|Group A|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
62123133|NCT01764464|OTHER|Group B|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
62123134|NCT03020745|EXPERIMENTAL|Part 1, Cohort A : GSK3389404 30 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 30 mg or matching placebo
62477479|NCT05984303|EXPERIMENTAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Standard of care (SOC) plus a multiple administration and dose-escalasion with 2 cohorts with 3 subjects/cohort who receive doses of 1 and 2 ×10E8 cells. Each person received 3 infusions, 1 week apart, Proceed from lower dose to higher dose if no safety concerns for each cohort.
62477480|NCT06177418|ACTIVE_COMPARATOR|Standard transumbilical laparoscopic appendectomy|In this group, patients will undergo the standard transumbilical laparoscopic appendectomy procedure through a 15 mm trocar port in the umbilical region. The procedure will involve locating the appendix and removing it via an extracorporeal approach.
62123135|NCT03020745|EXPERIMENTAL|Part 1, Cohort B: GSK3389404 60 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 60 mg or matching placebo
62123136|NCT03020745|EXPERIMENTAL|Part 1, Cohort C: GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
62737775|NCT01811589|EXPERIMENTAL|Thomale-Guide|Positioning of ventricular catheter with the Thomale-Guide instrument
62312617|NCT02973646|EXPERIMENTAL|Nucleos(t)ide analogues treatment|Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.
62312618|NCT02973646|ACTIVE_COMPARATOR|Peginterferon treatment|Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.
62737776|NCT01811589|OTHER|Free-hand|Ventricular catheter placement without a guidance (free-hand)
62312619|NCT01769404|EXPERIMENTAL|LY2605541|Stable dose of LY2605541 (0.2 to 0.6 units per kilogram \[U/kg\]) administered subcutaneously (SQ) once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
62123137|NCT03020745|EXPERIMENTAL|Part 1, Cohort C1 (optional): GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
62312620|NCT01769404|ACTIVE_COMPARATOR|Insulin Glargine|Stable dose of insulin glargine (0.2 to 0.6 U/kg) administered SQ once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
62312621|NCT06141408|EXPERIMENTAL|Intervention|This is the arm engaging in the stigma-reduction and support-increasing activities.
62312622|NCT06141408|NO_INTERVENTION|Comparison|This is the arm not engaging in the stigma-reduction and support-increasing activities.
62123138|NCT03020745|EXPERIMENTAL|Part 1, Cohort D: GSK3389404 </= 240 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 \<= 240 mg or matching placebo
62123139|NCT03020745|EXPERIMENTAL|Part 2: GSK3389404 or placebo SC|Enrolled subjects will receive different parallel dose level and regimens of GSK3389404 or placebo SC at dose determined in part 1. The treatments for Part 2 are 60 mg GSK3389404 weekly, 120 mg bi-weekly GSK3389404, 120 mg GSK3389404 weekly or placebo.
62123140|NCT05016830|SHAM_COMPARATOR|Sham bilateral transcranial direct current stimulation|Sham bilateral transcranial direct current stimulation consisted of 2 milliamperes (mA) of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex, but the stimulation was turned off after 30 seconds. On Sham Stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
62123141|NCT05016830|EXPERIMENTAL|Bilateral transcranial direct current stimulation|Bilateral transcranial direct current stimulation consisted of 2 mA of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex and the stimulation was on for 20 minutes. On stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
62123142|NCT04426786|ACTIVE_COMPARATOR|Immediate intervention start: active exercise|Immediately starts the six month intervention of active exercise following the baseline scan.
62683133|NCT04589624|EXPERIMENTAL|Arm II (Thyroid Cancer Patient and other malignancies of the head and neck hpMRI)|Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
62683134|NCT01829763|EXPERIMENTAL|botox|
62123143|NCT04426786|PLACEBO_COMPARATOR|Delayed intervention start: passive exercise|Starts the six month intervention of active exercise six months after the baseline scan. During the six month delay, participants in this arm undergo passive exercise.
62312623|NCT03827148|EXPERIMENTAL|Intervention: Pharmacist-delivered pharmaceutical care|The intervention consist of a pharmacist providing pharmaceutical care with aim to improve the treatment outcomes. It will be in the form of a single face-to-face session by pharmacist. Moreover, a specially designed rheumatoid arthritis disease education literature will be provided in both Urdu and English languages to patients for home use. The patients will be provided a contact number at which the pharmacist will be available at all times for the next three months (week 12). A specially designated counselling area in the pharmacy department of the hospitals served as venues for intervention.
62312624|NCT03827148|NO_INTERVENTION|Control: Usual Care|The patient in control group will have usual care without pharmacist intervention.
62312625|NCT05635838|EXPERIMENTAL|Ruxolitinib Cream|Ruxolitinib 1.5% cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
62312626|NCT05635838|EXPERIMENTAL|Vehicle Cream|Vehicle cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
62312627|NCT06637917||Newborn|A variety of subjects will be targeted for inclusion representing differing stages of development and environments
62312628|NCT03932136|ACTIVE_COMPARATOR|SFN group|The intervention duration with SFN tablet is 52 consecutive weeks. The dosage is six active tablets (411 μmol GR) per day.
62312629|NCT03932136|PLACEBO_COMPARATOR|Placebo group|The intervention duration with placebo tablet is 52 consecutive weeks. The placebo group will be given six placebo tablets per day.
62312630|NCT05972967|EXPERIMENTAL|OMS906 Study Drug - 3 mg/kg IV with Ravulizumab IV|Up to 6 doses of 3 mg/kg at 8-week intervals
62683135|NCT04779736|OTHER|Pre-post design|The pilot intervention will be evaluated using a pre-post design.
62683136|NCT06169527||Participants with AD treated with dupilumab|Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information.
62683137|NCT06686134||liraglutide|
62683138|NCT06686134||Dulagoside|
62683139|NCT06686134||Polyethylene glycol losenatide|
62683140|NCT06686134||Semaglutide|
62683141|NCT00645138|ACTIVE_COMPARATOR|Paravertebral Block|Patients receiving Paravertebral Block.
62683142|NCT00645138|ACTIVE_COMPARATOR|General Anesthesia|Patients receiving General Anesthesia.
62737777|NCT05081167|EXPERIMENTAL|REL-1017|A 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 25 mg REL-1017.
61922769|NCT01264627|EXPERIMENTAL|Mindful Breathing (MB)|"The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. No other intervention is included. No FDA drug or device is involved."
61922770|NCT01264627|OTHER|Usual Care (UC)|Usual Care consists of the standard care made available to participants through their primary physician. No intervention is included. No FDA drug or device is involved.
61922771|NCT04455243|EXPERIMENTAL|Intervention group|
61922772|NCT04455243|PLACEBO_COMPARATOR|Control group|
61922773|NCT05761938||cohort A|pathologically confirmed membranous nephropathy
62312631|NCT05972967|EXPERIMENTAL|OMS906 Study Drug - 5 mg/kg IV with Ravulizumab IV|Up to 6 doses of 5 mg/kg at 8-week intervals
61922774|NCT05761938||cohort B|pathologically confirmed minimal change disease (MCD) or primary focal segmental glomerulosclerosis (FSGS)
62312632|NCT01904461|EXPERIMENTAL|Vacuum device surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses the innovative vacuum device to obtain wounds hemostasis
61922775|NCT00757107|EXPERIMENTAL|Taperloc Microplasty|Patients with primary osteoarthritis with Taperloc microplasty non inferiority
62123144|NCT05816486||Prospective - Longitudinal|Longitudinal follow-up cohort in which all patients who are going to receive a kidney transplant and meet the selection criteria for this study cohort will be included. This cohort will be recruited at sites that routinely perform Protocol Biopsies (PB) one year after transplant. A pre-transplant and post-transplant follow-up IMBG at 3, 6, 9 and 12 months will be performed, and additional IMBG will be carried out when an indication biopsy is required due to a suspected rejection during the patients' follow-up. A protocol biopsy will be performed after one year of follow-up of the patients.
62123145|NCT05816486||Cross-sectional|Patients in whom an Indication Biopsy (IB) is to be performed due to suspicion of rejection. This cohort may be recruited in all sites participating in the study, including sites where annual protocol biopsies are not routinely performed. An IMBG will be performed coinciding with the IB. This cohort will include patients who have had their transplant for less than 5 years.
62312633|NCT01904461|ACTIVE_COMPARATOR|Conventional surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses a bipolar forceps to obtain wounds hemostasis
62123146|NCT05816486||Control|Patients who have received a kidney transplant or a re-transplant less than 5 years before inclusion in the study and have shown a stable clinical course after 6 months from the RT, defined as: patients without previous rejection episodes nor indication biopsies, who do not show signs of renal impairment and are dnDSA negative, without changes in immunosuppressive drugs in the last 6 weeks and without opportunistic infections in the last six months before entering in the study. An IMBG will be performed coinciding with the only visit.
62123147|NCT05074836|EXPERIMENTAL|Formula Milk|"Formula milk designed for young children aged over 3 years;~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
62123148|NCT05074836|ACTIVE_COMPARATOR|Regular milk|"Regular milk (pure milk);~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
62123149|NCT05074836|OTHER|Control foods|"Grain foods: e.g., bread;~Dosage: 20-40 g/time;~Frequence: 2 times /day;~Duration: 12 months"
62123150|NCT03040596|EXPERIMENTAL|inhaled steroid + voice therapy|fluticasone inhaler, 88mcg (2 puffs), twice a day for 4 weeks + standard voice therapy
62123151|NCT03040596|OTHER|voice therapy only|standard voice therapy
62139650|NCT03502369|EXPERIMENTAL|QL group|Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
62312634|NCT01011205|EXPERIMENTAL|Dosing Regimen 1|Advagraf + MMF + Corticosteroids (Bolus)
61922776|NCT00757107|ACTIVE_COMPARATOR|Taperloc Standard|Patients with primary osteoarthritis Taperloc standard
61922777|NCT01027078||OSA|patients diagnosed with obstructive sleep apnea who do not have existing cardiovascular disease
62139651|NCT03502369|NO_INTERVENTION|C group|Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.
62312635|NCT01011205|EXPERIMENTAL|Dosing Regimen 2|Advagraf + MMF + Basiliximab + Corticosteroids (Bolus)
61922778|NCT01027078||control|patients without obstructive sleep apnea who are matched in weight and age to the OSA patients
61922779|NCT06130306||Electrical Pudendal Nerve Stimulation Group|Electrical Pudendal Nerve Stimulation
61922780|NCT06130306||Pelvic Floor Muscle Training Group|Pelvic Floor Muscle Training Plus Transanal Electrical Stimulation
61922781|NCT02039440|OTHER|Single arm|1 blood draw
61922782|NCT05053542||With or without enema before operation|Patients who had received pre-operative bowel preparation(PBP) were identified using electronic medical records. Patients prescribed an enema solution (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before surgery were allocated to the PBP group. Patients who received no PBP were allocated to none PBP group.
61922783|NCT00260078|EXPERIMENTAL|D|TDF and EFV or NVP throughout study
61922784|NCT00260078|EXPERIMENTAL|E|TDF and DRV with or without EFV throughout study
61922785|NCT00260078|EXPERIMENTAL|F|TDF and ATV and RTV with or without EFV throughout study
62312636|NCT01011205|EXPERIMENTAL|Dosing Regimen 3|Advagraf (5 days delay) + MMF + Basiliximab + Corticosteroids (Bolus)
61922786|NCT03289364|EXPERIMENTAL|Penguin Cold Caps|Penguin Cold-cap therapy will commence at least 50 minutes prior to chemotherapy infusion, and will continue for 4 hours following completion of chemotherapy.
61922787|NCT06007859||section orientation of ultrasound shear wave elastography|
61922788|NCT00558571|PLACEBO_COMPARATOR|Placebo|
62123152|NCT02961010|EXPERIMENTAL|Intervention Group|The intervention group will receive the Keeping Safe programme between 2016 and 2018. This comprises a blended package of continuing professional development training and support (plus resource materials) for teachers and school staff to enable them teach sensitive preventative education concepts through the formal statutory Personal Development curriculum, and all other informal opportunities that present in the daily life of the school. Following randomisation, intervention schools will receive the package of training and support across a 3 month period and will then implement/teach in their school across 2 school years. The intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
61922789|NCT00558571|EXPERIMENTAL|BI 10773 low dose|
61922790|NCT00558571|EXPERIMENTAL|BI 10773 medium dose|
62123153|NCT02961010|NO_INTERVENTION|Wait-list Control Group|The Wait List Control group will continue with standard practice of teaching the statutory Personal Development curriculum between 2016 and 2018. They will not receive the Keeping Safe intervention until Sept 2018 following completion of the evaluation. The Waitlist control intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
62123154|NCT03639350|EXPERIMENTAL|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
62123155|NCT03639350|ACTIVE_COMPARATOR|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
62123156|NCT05826379|ACTIVE_COMPARATOR|Control|Participants receive the adaptive daily step goal mHealth intervention
62123157|NCT05826379|EXPERIMENTAL|Treatment|Participants receive the adaptive daily step goal mHealth intervention plus interim goal setting prompts each day
62683143|NCT04946253|ACTIVE_COMPARATOR|DOCC with standard implementation (No TEAM or LEAD)|Practices in this arm will receive DOCC materials/training and technical support, but will not receive care team coaching/consultation (TEAM) or practice leadership facilitation (LEAD) after the training phase.
62123158|NCT02948114|ACTIVE_COMPARATOR|Control: Cow milk-based infant formula|Cow milk-based infant formula
62123159|NCT02948114|EXPERIMENTAL|Experimental 1: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics
61922791|NCT00558571|EXPERIMENTAL|BI 10773 high dose|
62312637|NCT04095208|EXPERIMENTAL|Experimental: Randomized phase II trial - Arm A|Combination of nivolumab and relatlimab.
61922792|NCT06423417|EXPERIMENTAL|LifeHack|"LifeHack is a guided (weekly feedback by a coach is provided) e-heath self-help application, which is based on cognitive behavioral techniques. The goal of LifeHack is to improve mental wellbeing.~The guided internet-based self-help programme LifeHack was developed based on existing literature and adapted in collaboration with university students. The programme comprises twelve modules that are delivered via computer, laptop, tablet, or mobile phone. The modules take approximately 30 minutes on 4 themes (mood management, productivity, self-worth and relationships).~Guidance:~E-coaches will be trained clinical psychology master students. E-coaches will provide asynchronous written personalized feedback to each participant through the program platform within 48 hours (counting workdays only) after session completion. The aim of the written feedback is to increase motivation and adherence of the participants."
61922793|NCT06423417|NO_INTERVENTION|Control group|Participants in the waiting list control condition will start with the programme 4 weeks after randomization.
61922794|NCT01616082|ACTIVE_COMPARATOR|Overwight/Obese with no drug|After screening, overweight/obese subjects (BMI \>27 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved.
62123160|NCT02948114|EXPERIMENTAL|Experimental 2: Cow milk-based infant formula|Cow milk-based infant formula with probiotics
62123161|NCT02948114|EXPERIMENTAL|Experimental 3: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics and probiotics
62312638|NCT04095208|EXPERIMENTAL|Experimental: Randomized phase II trial - Arm B|Treatment by nivolumab alone.
62477481|NCT06177418|EXPERIMENTAL|Transumbilical laparoscopic appendectomy + glove finger technique|In addition to the standard transumbilical laparoscopic appendectomy procedure, patients in this group will receive the glove finger technique, aimed at preventing contamination of surrounding tissues by infected tissue.
62477482|NCT03004703|EXPERIMENTAL|Active drug|Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
62477483|NCT03004703|PLACEBO_COMPARATOR|Placebo|Sodium chloride 0.9%; 100 ml i.v. once.
62477484|NCT03003091|EXPERIMENTAL|Needs-based patient education|The participants received self-administered questionnaire to choose what topics they wanted to know and how much information they would like to know. After completing the questionnaire, the participants submit the questionnaire to their physicians (investigators). The surgeon then provided patient education based on participant needs.
62477485|NCT03003091|ACTIVE_COMPARATOR|Traditional patient education|The participants received all structured information
62683144|NCT04946253|EXPERIMENTAL|DOCC with TEAM implementation|Practices in this arm will receive DOCC training and materials and one type of implementation support after the training: coaching/consultation for the provider care team (TEAM).
62683145|NCT04946253|EXPERIMENTAL|DOCC with LEAD implementation|Practices in this arm will receive DOCC training and materials and only one type of implementation support after the training: facilitation for practice leadership (LEAD).
62123162|NCT02948114|NO_INTERVENTION|Human Milk Reference|Human Milk Reference
62139652|NCT01331499|EXPERIMENTAL|Bipolar Sealer|Standard of care blood sparing techniques with bipolar sealer
62312639|NCT04317222|EXPERIMENTAL|eCRRT group|Initiated CRRT within the first 24 post-transplant hours.
62312640|NCT04317222|NO_INTERVENTION|Control group|Standard treatment.
62312641|NCT01853228|EXPERIMENTAL|Decitabine and cytarabine|
61922795|NCT01616082|ACTIVE_COMPARATOR|Overweight/obese with Phentermine|After screening, overweight/obese (BMI \>27.0 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
61922796|NCT02691962|EXPERIMENTAL|Xen Matrix AB|Subjects treated with Xen Matrix AB
62123163|NCT00554736|EXPERIMENTAL|1|In the first phase, subjects with a history of grass pollinosis, with positive skin tests to grass, will be studied out of season and will be randomized to active treatment for 4 months.
62683146|NCT04946253|EXPERIMENTAL|DOCC with TEAM + LEAD implementation|Practices in this arm will receive DOCC training and materials and both types of implementation support after the training: coaching/consultation for the provider care team (TEAM) and facilitation for practice leadership (LEAD).
62312642|NCT06080750||healthy|as a control group
61922797|NCT06127251|EXPERIMENTAL|PATH Intervention|Insufficiently active adults with obesity will be assigned to the PATH intervention.
62312643|NCT06080750||mild to moderate covid-19|mild-moderate symptoms
62312644|NCT06080750||sever covid-19.|severe symptoms
62683147|NCT06349304|EXPERIMENTAL|Freeze-dried table grape powder|Subjects in this group will be given pouches, each containing 46 g of freeze-dried table grape powder, with an instruction sheet on how to prepare the powder into a drink for consumption.They will consume one pouch a day.
62683148|NCT06349304|PLACEBO_COMPARATOR|Placebo table grape powder|Subjects in this group will be given pouches, each containing 46 g of placebo grape powder, with an instruction sheet on how to prepare the powder into a drink for consumption.They will consume one pouch a day.
62683149|NCT04806945|EXPERIMENTAL|HLX10|HLX10 + chemotherapy
62683150|NCT04806945|PLACEBO_COMPARATOR|Placebo|Placebo + chemotherapy
62683151|NCT03247673|EXPERIMENTAL|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
62683152|NCT03247673|ACTIVE_COMPARATOR|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
62683153|NCT03247673|ACTIVE_COMPARATOR|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
62683154|NCT05958875|EXPERIMENTAL|Schizophrenia early intensified treatment (EIPT): Switch to clozapine|Subject with schizophrenia, randomized to EIPT: Switch to clozapine. Brand, dosage, frequency and duration up to the investigator's discretion
62683155|NCT05958875|ACTIVE_COMPARATOR|Schizophrenia treatment as usual (TAU): second-line antispychotic|Subject with schizophrenia or related disorder randomized to TAU: switch to second-line antispychotic. Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC)
62683156|NCT04950764|EXPERIMENTAL|Seladelpar 10 mg|Part A: Single oral dose 10 mg
62683157|NCT04950764|EXPERIMENTAL|Seladelpar 10 mg or less|Part B: Multiple oral dose of 10 mg or less
62123164|NCT05858073|OTHER|Kinesio Taping.|
61922798|NCT06127251|OTHER|Control Group|Insufficiently active adults with obesity will be assigned to the attention control group.
61922799|NCT04732897|NO_INTERVENTION|Control arm|wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)
62123165|NCT05858073|PLACEBO_COMPARATOR|Placebo Kinesio Taping.|
62139653|NCT01331499|ACTIVE_COMPARATOR|Control|Standard of care blood sparing techniques without the use of bipolar sealer
62139654|NCT03188731||Pregnant Women|
62683158|NCT05671887||Cohort A: Primary lung cancers|- Examples include invasive mucinous/non-mucinous non-small cell lung cancers and multifocal carcinomas
62683159|NCT05671887||Cohort B: Metastatic cancers to the lung only|- Examples include germ cell tumors, head \& neck tumors, colorectal tumors, renal cell tumors
62683160|NCT05671887||Cohort C: Respiratory failure with a history of cancer in the last 5 years|- Examples include, but not limited to interstitial lung disease (ILD), pulmonary fibrosis (idiopathic or secondary), advanced chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH)
62683161|NCT06688305|EXPERIMENTAL|68Ga-NI-FAPI PET/CT|PET/CT imaging in patients with malignant tumors: each patient underwent a PET/CT scan after intravenous administration of 68Ga-NI-FAPI.
62683162|NCT06458192|EXPERIMENTAL|Adaptive Messaging Intervention|The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. The intervention will apply reinforcement learning to select daily messaging styles to maximize user engagement.
62683163|NCT06458192|EXPERIMENTAL|Non-Adaptive Messaging Intervention|The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. Daily messaging styles will be randomly selected.
62683164|NCT06458192|ACTIVE_COMPARATOR|Psychoeducation-only control|The 8-week intervention involves receiving several text messages per week that include weblinks to access psychoeducation information about cognitive and behavioral self-management strategies.
62683165|NCT06688019|EXPERIMENTAL|conventional oxygenation (nasal cannula) arm|conventional oxygenation arm will receive oxygen at 2L/min via nasal cannula
62683166|NCT06688019|EXPERIMENTAL|high-flow humidified oxygen-delivery system (OptiFlow THRIVE) arm|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
62683167|NCT04737603|EXPERIMENTAL|ED-initiated treatment with buprenorphine/naloxone.|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
62683168|NCT02985775|EXPERIMENTAL|Donor-derived CMVpp65-specific T cells|Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.
62683169|NCT05941000|EXPERIMENTAL|CGM paired with behavior change technique interventions, physical activity intervention first|Participants in this arm will receive a continuous glucose monitor and they will receive two behavior change technique interventions via daily text messages over the course of eight weeks, in a series of four, two-week blocks. In the first two-week block, they will receive the physical activity behavior change technique intervention. In the second and third two-week blocks, they will receive the mood behavior change technique intervention. In the fourth two-week block, they will receive the physical activity behavior change technique intervention.
61922800|NCT04732897|EXPERIMENTAL|Interventional arm|wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint
62139655|NCT01105234|EXPERIMENTAL|Calcipotriol ointment|
62683170|NCT05941000|EXPERIMENTAL|CGM paired with behavior change technique interventions, mood intervention first|Participants in this arm will receive a continuous glucose monitor and they will receive two behavior change technique interventions via daily text messages over the course of eight weeks, in a series of four, two-week blocks. In the first two-week block, they will receive the mood behavior change technique intervention. In the second and third two-week blocks, they will receive the physical activity behavior change technique intervention. In the fourth two-week block, they will receive the mood behavior change technique intervention.
62683171|NCT04677153|EXPERIMENTAL|Test and Treat plus Peer Mentors Intervention Arm|Participants offered 8 weeks of glecaprevir/pibrentasvir (GLE/PIB) at OTP plus peer support.
62683172|NCT04677153|ACTIVE_COMPARATOR|Standard of Care Referral Arm|Participants referred to offsite (non-OTP) location for HCV treatment.
62312645|NCT02413515|EXPERIMENTAL|Arm 1|Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
62312646|NCT04520698|EXPERIMENTAL|Nursing Home-level UPLIFT-AD intervention|The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.
62683173|NCT04699305||ActiGraft|Whole blood clot (WBC) gel
62312647|NCT04520698|NO_INTERVENTION|Usual Care|Usual nursing home care.
62312648|NCT04185467|NO_INTERVENTION|Usual care(both arms)|Usual care (both arms): Patients in both arms will receive usual medical, physiotherapy and nursing care according to usual protocols. This does not involve exercise rehabilitation or advice.
62683174|NCT04379271|EXPERIMENTAL|IMU-838|twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)
62683175|NCT04379271|PLACEBO_COMPARATOR|Placebo|twice-daily (BID) oral placebo (+ SoC)
62312649|NCT04185467|EXPERIMENTAL|Intervention (exercise rehabilitation)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
62477486|NCT01547286|EXPERIMENTAL|Allergic asthmatic|
62477487|NCT03936101||Prenatally Sequenced Group|750 trios with fetal structural anomalies who receive prenatal sequencing from the study
62683176|NCT06633666|EXPERIMENTAL|Acupuncture|"The acupuncture intervention will be conducted for 2 sessions per week during a 12-week treatment duration and will be followed up at week 18. This research is based on the TCM theory of individualized acupuncture. Qualified participants will first conduct TCM syndrome differentiation according to the five main manifestations of Long COVID neuropsychiatric symptoms including fatigue, anxiety/depression, cognitive impairment, memory loss, and insomnia. They will be divided into four treatment groups according to their main clinical symptoms, and the participants in the treatment group will be treated with the selected acupoints according to their disease category.~The selection of the acupoints for each syndrome type are formulated with reference to the 13th Five-Year Plan Textbook Acupuncture and Moxibustion Therapy published by the China Press of Traditional Chinese Medicine Co.,Ltd."
62683177|NCT06633666|NO_INTERVENTION|Conventional treatment|The control group will not receive acupuncture therapy. This study does not require the use of a placebo.
62683178|NCT04502186|EXPERIMENTAL|Raising Our Spirits Together Intervention|
62683179|NCT04502186|OTHER|Enhanced Control Condition|
61922801|NCT01522586|EXPERIMENTAL|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
61922802|NCT01522586|PLACEBO_COMPARATOR|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
61922803|NCT02145507|OTHER|Arm 1: Room Temperature Storage/Filtration|SOLX (Investigational Product) and AS-3 (Control)
61922804|NCT02145507|OTHER|Arm 2 : Cold storage|SOLX (Investigational Product) and AS-3 (Control)
61922805|NCT00988325|EXPERIMENTAL|Oseltamivir 3 mg|infants 3 to \<12 months
61922806|NCT00988325|EXPERIMENTAL|Oseltamivir 2.5 mg|infants 1 to \<3 months of age
62139656|NCT03783416|EXPERIMENTAL|Ixazomib (NINLARO®)|Treatment will follow a 28-day cycle. Participants will take one Ixazomib (NINLARO) capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free week, in sequence, for the duration of the trial.
61922807|NCT00988325|EXPERIMENTAL|Oseltamivir 2 mg|infants 0 to 30 days (post natal) of age
61922808|NCT01269788|ACTIVE_COMPARATOR|pH positive-omeprazole|
61922809|NCT01269788|PLACEBO_COMPARATOR|pH positive-placebo|
61922810|NCT01269788|ACTIVE_COMPARATOR|pH positive-fluoxetine|
62139657|NCT03783416|PLACEBO_COMPARATOR|Placebo|Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
62477488|NCT03936101||No Prenatal Sequencing (Unsequenced) Group|350 trios with fetal structural anomalies who do not have prenatal sequencing
62477489|NCT03807180|OTHER|Group of Tai Chi|Group of Tai Chi intervention include 18 patients with AS. Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques, will be applied by an experienced physiotherapist who is trained with Tai Chi. The training will take 60 minutes, 2 days a week and 10 weeks in total.
62683180|NCT06616766|EXPERIMENTAL|Part 1 and Part 2|Part 1: Dose escalation arm to determine the MTD Part 2: Dose expansion part to select RD. Several independent cohorts are planned.
62683181|NCT06147869|ACTIVE_COMPARATOR|photopheresis|
62683182|NCT06147869|ACTIVE_COMPARATOR|Low level laser|
62683183|NCT03304639|ACTIVE_COMPARATOR|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
61922811|NCT01269788|ACTIVE_COMPARATOR|pH negative-omeprazole|
62683184|NCT03304639|EXPERIMENTAL|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during cycle 1.
62683185|NCT02170155||Patients with CSM|
62683186|NCT02170155||Patients with spinal injury (SCI)|
62683187|NCT02170155||Healthy controls|
62683188|NCT06688955|EXPERIMENTAL|Patient with Bacteriologically Controlled Water procedure|patient with colonoscopy with Bacteriologically Controlled Water procedure
62683189|NCT06678984|EXPERIMENTAL|Treated umbilical vein allograft|
61922812|NCT01269788|ACTIVE_COMPARATOR|pH negative-fluoxetine|
61922813|NCT01269788|PLACEBO_COMPARATOR|pH negative-placebo|
61922814|NCT06071936|EXPERIMENTAL|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
61922815|NCT06071936|PLACEBO_COMPARATOR|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
61922816|NCT02914015|EXPERIMENTAL|Continuous QLB+postoperative IPCA|Single-injection of QLB (quadratus lumborum block) is given preoperatively followed with continuous infusion+ postoperative IPCA (intravenous patient control analgesia)
62123166|NCT06446726|EXPERIMENTAL|neoadjuvant low-dose radiotherapy and immunochemotherapy group|"During the neoadjuvant treatment phase, patients will undergo two cycles of low-dose radiotherapy, combined with chemotherapy and immunotherapy, each cycle lasting 21 days. The specific treatment protocol is as follows:~D1/2: Low-dose radiotherapy (4 Gy/2f) D3: Tislelizumab, fixed dose of 200 mg; Nab-paclitaxel 260 mg/m2; Cisplatin 75 mg/m2. The interval between radiotherapy and chemotherapy should not exceed 3 days. Drug infusions follow the sequence of tislelizumab → nab-paclitaxel → cisplatin/carboplatin, with at least a 30-minute interval between each infusion.~At the end of the neoadjuvant treatment, patients will undergo surgical treatment 6-8 weeks after the last treatment session."
62312650|NCT05942274|EXPERIMENTAL|Screen group|This is a single-center, non-randomized open study with a single-patient clinical trial design (i.e., the patients serve as their own control).
62312651|NCT02513940|EXPERIMENTAL|Testosterone - progesterone - placebo|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
62312652|NCT02513940|EXPERIMENTAL|Testosterone - placebo - progesterone|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
62312653|NCT02513940|EXPERIMENTAL|Progesterone - testosterone - placebo|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
62683190|NCT06678984|ACTIVE_COMPARATOR|Autologous Fascial Pubovaginal Sling|
62683191|NCT06075745|EXPERIMENTAL|Vaccine Arm|Participants in this arm will receive two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine
62683192|NCT06075745|PLACEBO_COMPARATOR|Placebo Arm|Participants will receive two doses of matching placebo of the Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine
62683193|NCT03238196|EXPERIMENTAL|Escalation|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
61922817|NCT02914015|ACTIVE_COMPARATOR|IPCA|Postoperative IPCA (intravenous patient control analgesia) is given alone
61922818|NCT06164210|EXPERIMENTAL|Traditional Sensory Integration Intervention Group|"Conventional Sensory Integration Intervention Based on Sensory Processing Theory, sensory integration intervention increases a childs ability to process and integrate sensory information and thus create more organized and adaptive behaviors. Sensory-enriched environments use fun interactive games and activities. Sensory integration intervention is carried out by creating an intervention program to create, understand, and eliminate the deficiency of the sensory process.~A conventional sensory integration intervention two sessions (per sessions 45 minutes) a week, was planned for 18-35-month-old infants at risk of ASD in both groups participating in the study. Session planning and activity selection were based on TSP-2 results. In particular, the occupational therapist supported the infant\&amp;#39;s active participation in the activities."
62683194|NCT03238196|EXPERIMENTAL|Expansion|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
62683195|NCT05657639|EXPERIMENTAL|CAV regimen|
62683196|NCT05657639|ACTIVE_COMPARATOR|MEC regimen|
62683197|NCT06559241|OTHER|Control group|Patients in the control group will receive endovascular thrombectomy and the best medical management according to the guidelines.
62123167|NCT03707691|EXPERIMENTAL|Cochlear implant users|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
62123168|NCT03707691|EXPERIMENTAL|Participants with Congenital Amusia|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
62123169|NCT03707691|EXPERIMENTAL|Control Participants|
62123170|NCT03082846|EXPERIMENTAL|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
62123171|NCT02882698|EXPERIMENTAL|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
62683198|NCT06559241|EXPERIMENTAL|14-day treatment group|Patients in the 14-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 14 days post-thrombectomy.
62683199|NCT06559241|EXPERIMENTAL|30-day treatment group|Patients in the 30-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 30 days post-thrombectomy.
62683200|NCT01257893|EXPERIMENTAL|Aspirin 81 mg|Subjects will take 81 mg aspirin per day for 10-14 consecutive days
62683201|NCT01257893|PLACEBO_COMPARATOR|Placebo|Subjects will take matching placebo capsule (excipient: methylcellulose) for 10-14 consecutive days.
62683202|NCT05424315|ACTIVE_COMPARATOR|Intervention Group|Participants will receive Dapagliflozin 10mg once daily.
62683203|NCT05424315|PLACEBO_COMPARATOR|Control Group|Participants will receive a glucose tab once daily.
62683204|NCT03608007|EXPERIMENTAL|X-396 Capsule|Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
62123172|NCT02882698|EXPERIMENTAL|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
62123173|NCT02882698|ACTIVE_COMPARATOR|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
62123174|NCT02882698|ACTIVE_COMPARATOR|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
62123175|NCT05978037|ACTIVE_COMPARATOR|Group 1: 10 µg RH5.2-VLP with Months 0,1 and 2 regimen.|This arm will receive monthly regimen of 3 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M .
62123176|NCT05978037|ACTIVE_COMPARATOR|Group 2: 10 µg RH5.2-VLP with Months 0,1 and 6 regimen.|This arm will receive 3 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M at Months 0, 1 and 6 (delayed regimen) and after Growth Inhibition Activity (GIA) immunogenicity review, will proceed to receive Controlled Human Malaria Infection (CHMI) 4 weeks after the last vaccination.
62683205|NCT06695325||Patients with type 1 and type 2 diabetes will be invited to take part in this study|Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm draw. They will do the latter again at home.
62683206|NCT01409200|EXPERIMENTAL|Arm I (antiandrogen therapy, axitinib, surgery)|Patients receive antiandrogen therapy per standard care and axitinib PO BID for 4 months. Patients then undergo radical prostatectomy and pelvic lymph node dissection.
62683207|NCT01409200|ACTIVE_COMPARATOR|Arm II (antiandrogen therapy, surgery)|Patients receive antiandrogen therapy per standard care for 4 months and then undergo radical prostatectomy and pelvic lymph node dissection.
62683208|NCT04256837|EXPERIMENTAL|VNS - Live donor kidney recipients.|Live donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
62683209|NCT04256837|SHAM_COMPARATOR|sham VNS - Live donor kidney recipients.|Live donor kidney recipients. As above, but without applying any VNS
62683210|NCT04256837|EXPERIMENTAL|VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
62123177|NCT05978037|ACTIVE_COMPARATOR|Group 3: 10 µg or 2 µg RH5.2-VLP with Months 0,1 and 6 regimen.|This arm will receive 2 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M at Months 0, 1 and 1 doses of 2 µg of RH5.2-VLP with 50 µg Matrix-M at Month 6 (delayed-fractional regimen).
62123178|NCT05978037|ACTIVE_COMPARATOR|Group 4: 10 µg RH5.2-VLP or 2 µg RH5.1 with Months 0,1 and 6 regimen.|This arm will receive 2 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M at Months 0, 1 and 1 doses of 2 µg of RH5.1 with 50 µg Matrix-M at Month 6 (delayed-fractional regimen, Prime with RH5.2-VLP then Boost with soluble RH5.1).
62123179|NCT05978037|ACTIVE_COMPARATOR|Group 5: 10 µg or 2 µg RH5.1 with Months 0,1 and 6 regimen.|This control arm will receive 2 doses of 10 µg of RH5.1 with 50 µg Matrix-M at Months 0, 1 and 1 doses of 2 µg of RH5.1 with 50 µg Matrix-M at Month 6 (delayed-fractional regimen with RH5.1).
62123180|NCT05978037|NO_INTERVENTION|Group 6: CHMI control|"This control arm will be infectivity controls, so will not receive any vaccinations.~Group 6 will only be recruited after observation of meeting positive GIA target."
62123181|NCT01814033|EXPERIMENTAL|LRU Pillow|Experimental: LRU Pillow
62123182|NCT01814033|ACTIVE_COMPARATOR|Control Group|Other: Control Group
62123183|NCT06479187|EXPERIMENTAL|PSMA-PET/CT arm|"Patients will undergo 18F-rhPSMA-7.3 PSMA PET/CT scan before and after 6 months of treatment for metastatic hormone sensitive prostate cancer.~Patients will undergo chart review every 3 months for 1 year after the second 18F-rhPSMA-7.3 PSMA PET/CT scan."
62123184|NCT01691326|EXPERIMENTAL|6 months to < 36 months of age group|Participants at 6 months to \< 36 months of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone® (Pediatric Dose).
62123185|NCT01691326|EXPERIMENTAL|3 years to < 9 years of age group|Participants at 3 years to \< 9 years of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone®.
62123186|NCT05201261||Ultrasound-guided group|Adult patients with American Society of Anesthesiologists physical status I/II/III scheduled to undergo elective Lower limb surgery under spinal anesthesia were considered for eligibility.
61922819|NCT06164210|ACTIVE_COMPARATOR|Snoezelen-Based Occupational Therapy Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
61922820|NCT03706222||Drug interaction of Elbasvir/Grazoprevir|Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.
61922821|NCT00989573|PLACEBO_COMPARATOR|Placebo|oral administration of placebo once-daily for 8weeks
62123187|NCT05729672|EXPERIMENTAL|The experimental group|The experimental group will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
62123188|NCT05729672|NO_INTERVENTION|The control group|The control group will not receive any education. Data will be collected at baseline, 1 month and 3 months after intervention.
62683211|NCT04256837|SHAM_COMPARATOR|sham VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. As above, but without applying any VNS
62683212|NCT05403151||1|Healthy Adults
61922822|NCT00989573|EXPERIMENTAL|OPC-6535 25 mg|oral administration of OPC-6535 25 mg once-daily for 8 weeks
62683213|NCT06649110|EXPERIMENTAL|LTP001 Dose 1|
61922823|NCT00989573|EXPERIMENTAL|OPC-6535 50 mg|oral administration of OPC-6535 50mg once-daily for 8 weeks
61922824|NCT03280043||Cases|Women who underwent reduction mammoplasty and then developed a hematoma which required return to the operating room for evacuation.
61922825|NCT03280043||Controls|Women who had uncomplicated reduction mammoplasty.
62123189|NCT00510887|EXPERIMENTAL|VR-FND|"Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum."
62123190|NCT02209415|ACTIVE_COMPARATOR|Standard outpatient follow-up|Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
62123191|NCT02209415|EXPERIMENTAL|Intervention PET/CT and EUS|PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
62312654|NCT02513940|EXPERIMENTAL|Progesterone - placebo - testosterone|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
62683214|NCT06649110|EXPERIMENTAL|LTP001 Dose 2|
62683215|NCT06649110|EXPERIMENTAL|LTP001 Dose 3|
62683216|NCT06649110|PLACEBO_COMPARATOR|Placebo|matching placebo
62683217|NCT06170606|EXPERIMENTAL|Cryoablation|Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System.
62683218|NCT06689306|EXPERIMENTAL|Experimental group|"Necessary explanations regarding the research will be made to the students and their verbal and written consents will be obtained.~* Application Week 1: Diagnostic Information Form (DIF), Academic Achievement Test (ABT), California Critical Thinking Disposition Scale (CCTDS), Instructional Materials Motivation Survey (IMMS) Pre-Test Applications~* In the 2nd, 3rd, 4th and 5th weeks, the topic of developing care behaviors will be covered with the 7E model.~* Application Week 7: Diagnostic Information Form (DIF), Academic Achievement Test (ABT), California Critical Thinking Disposition Scale (CCTDS), Instructional Materials Motivation Survey (IMMS) post-test applications~* Application Week 11: Diagnostic Information Form (DIF), Academic Achievement Test (ABT), California Critical Thinking Disposition Scale (CCTDS), Instructional Materials Motivation Survey (IMMS) follow-up test applications"
62683219|NCT06689306|NO_INTERVENTION|Control group|"The necessary explanations about the research will be made to the students and their verbal and written consents will be obtained.~* Application Week 1: Descriptive Information Form (DEF), Academic Achievement Test (ABT), California Critical Thinking Disposition Scale (CCTDS), Instructional Materials Motivation Survey (IMMS) Pre-Test Applications~* The topic of developing care behaviors in the 2nd, 3rd, 4th and 5th weeks will be handled through plain narration and question-answer methods.~* Application Week 7: Diagnostic Information Form (DIF), Academic Achievement Test (ABT), California Critical Thinking Disposition Scale (CCTDS), Instructional Materials Motivation Survey (IMMS) post-test applications~* Application Week 11: Diagnostic Information Form (DIF), Academic Achievement Test (ABT), California Critical Thinking Disposition Scale (CCTDS), Instructional Materials Motivation Survey (IMMS) follow-up test applications"
62683220|NCT06528093|EXPERIMENTAL|BI 765883 escalation arm|phase Ia
62683221|NCT06528093|EXPERIMENTAL|BI 765883 + gemcitabine + nab-paclitaxel escalation arm|phase Ia
62683222|NCT06528093|EXPERIMENTAL|BI 765883 + gemcitabine + nab-paclitaxel expansion arm|phase Ib
62683223|NCT02145520|EXPERIMENTAL|Magnesium sulfate|Magnesium sulfate. Single dose intravenous over one hour.
62683224|NCT02145520|PLACEBO_COMPARATOR|placebo|"Treatment will be delivered to enrolled patients as currently practice in PEC (Epinephrine nebulization +5%hypertonic saline with/without dexamethasone).~•All patients will be randomized to receive either Magnesium sulfate over 1 hour or placebo.•Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12, 16,20,24,36,48,60,72 hours, and on discharge."
62683225|NCT06673589||Social Entanglement: Couples, good friends and strangeers|
62683226|NCT06673589||good friends from the same region of the country|Plus, extensive social interaction--daily
62683227|NCT06673589||strangers from different countries|Interact minimally--less than once/week
61922826|NCT04282798|EXPERIMENTAL|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
61922827|NCT00479895|OTHER|1|Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
61922828|NCT00479895|OTHER|2|Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
62683228|NCT00203242|EXPERIMENTAL|Depacon IV and Depakote ER|Subjects will be treated in this single arm study with 2 consecutive days of IV Depacon followed by oral Depakote ER for a total of 1000 mg of Depacon and 1000 mg of Depakote ER each day.
62683229|NCT06444633|NO_INTERVENTION|Delayed-start control|Wards randomly assigned to this arm will not receive any intervention until after endline data collection in completed. During the study period, the caregivers in this group will have standard access to ORS and zinc at local health facilities and pharmacies. Some community health workers in control villages could make household visits; however, any delivery of ORS or zinc in the control group is not expected as community health workers are generally not the source of diarrhea treatment.
62312655|NCT02513940|EXPERIMENTAL|Placebo - testosterone - progesterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
62683230|NCT06444633|EXPERIMENTAL|Community Sensitization + Household visit + Information + Free pre-emptive distribution of ORS+Zinc|"Wards randomized to this arm will primarily receive four intervention components as described under the Intervention section"
62683231|NCT03607669||Healthy Controls|Healthy volunteers of similar age and gender
62683232|NCT03607669||Ischaemic Cardiomyopathy|Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
62683233|NCT03607669||Hypertrophic Cardiomyopathy|Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
62683234|NCT03607669||Dilated Cardiomyopathy|Patients with dilated cardiomyopathy and NYHA II-III heart failure
61922829|NCT06385990|EXPERIMENTAL|UTD1 in combination with capecitabine|UTD1 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
61922830|NCT04518202|EXPERIMENTAL|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
62683235|NCT05212337|ACTIVE_COMPARATOR|Denosumab|Subcutaneous injection with 60 mg Denosumab once
61922831|NCT04518202|PLACEBO_COMPARATOR|Sham patch|Sham patch applied at 6 hours before the scheduled office hysteroscopy.
61922832|NCT04138888|OTHER|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in Period 1 and a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
61922833|NCT04138888|OTHER|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in Period 1 and a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62683236|NCT05212337|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection with NaCl once
62683237|NCT00859274|EXPERIMENTAL|Budesonide|All patients receive this treatment to induce a change in asthma control
62683238|NCT02271919|EXPERIMENTAL|Group I (varenicline and placebo)|Patients receive varenicline PO QD or BID, placebo patches QD, and placebo lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
62683239|NCT02271919|PLACEBO_COMPARATOR|Group II (placebo, nicotine patch and lozenge)|Patients receive placebo tablets PO QD or BID, nicotine patches QD, and nicotine lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
62683240|NCT04732221|EXPERIMENTAL|Phase 2 Cohort MK-5475 380 µg|Participants receive MK-5475 380 µg via oral inhalation once daily for 12 week base period and for optional 24 month extension period.
62683241|NCT04732221|EXPERIMENTAL|Phase 2 Cohort MK-5475 100 µg|Participants receive MK-5475 100 µg via oral inhalation once daily for 12 week base period and for optional 24 month extension period.
62683242|NCT04732221|EXPERIMENTAL|Phase 2 Cohort MK-5475 32 µg|Participants receive MK-5475 32 µg via oral inhalation once daily for 12 week base period and for optional 24 month extension period.
62683243|NCT04732221|PLACEBO_COMPARATOR|Phase 2 Cohort Placebo|Participants receive placebo via oral inhalation once daily for 12 week base period, and one of the MK-5475 doses (380, 100, or 32 µg) for the optional 24 month extension period.
62683244|NCT04732221|EXPERIMENTAL|Phase 3 Cohort MK-5475|Participants receive one of 3 MK-5475 doses (380, 100 or 32 µg) to be selected at end of the Phase 2 Cohort, administered via oral inhalation once daily for 12-week base period and up to 60 months in the extension period
62683245|NCT04732221|PLACEBO_COMPARATOR|Phase 3 Cohort Placebo|Participants receive placebo via oral inhalation once daily for 12 week base period and up to 60 months in the extension period.
62683246|NCT06688292|EXPERIMENTAL|Taneasy 600mg granules|Dose： 600 mg/time. Use ：two times per day.
62683247|NCT06688292|ACTIVE_COMPARATOR|Actein effervescent tablets 600MG|Dose： 600 mg/time. Use ：two times per day
62683248|NCT06413758||Group I-Virtual Reality|In this group, participants will be in a virtual environment with a VR glass put on. The balance performance of the participants will be assessed with single leg stance test and bipodal stance test. The participants will be instructed to stand still and maintain balance on the forceplate in three conditions: (1) with an internal focus, (2) with an external focus, and (3) non-directional. Conditions will be applied to the participants randomly to avoid bias. Each condition will be measured three times and the mean values will be recorded as outcomes. The total displacement of center of pressure (CoP), the mean velocity of CoP, the CoP area, total mediolateral (ML) displacement, the mean velocity in ML, total anteroposterior (AP) displacement and the mean velocity in AP will assessed with K-Force Plates (Kinvent, France).
62683249|NCT06413758||Group II-Real World|The balance performance of the participants will be assessed with single leg stance test and bipodal stance test. The participants will be instructed to stand still and maintain balance on the forceplate in three conditions: (1) with an internal focus, (2) with an external focus, and (3) non-directional. Conditions will be applied to the participants randomly to avoid bias. Each condition will be measured three times and the mean values will be recorded as outcomes. The total displacement of center of pressure (CoP), the mean velocity of CoP, the CoP area, total mediolateral (ML) displacement, the mean velocity in ML, total anteroposterior (AP) displacement and the mean velocity in AP will assessed with K-Force Plates (Kinvent, France).
62683250|NCT03006315||Cohort A: <65 years|Cohort A will be comprised of participants \<65 years old and will accrue a total of 20 patients.
62683251|NCT03006315||Cohort B: >/= 65 years|Cohort B will be comprised of participants \>/= 65 years and will accrue a total of 20 patients.
61922834|NCT01799577||Gynecologist|Gynecologist can use laparoscopic surgery.
61922835|NCT06025929|EXPERIMENTAL|Maitland Group|Maitland Group received Maitland's mobilization techninque in addition to an intereferential therapy.
61922836|NCT06025929|ACTIVE_COMPARATOR|Mulligan Group|Mulligan Group received Mulligan's mobilization techninque in addition to an intereferential therapy.
62312656|NCT02513940|EXPERIMENTAL|Placebo - progesterone - testosterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
62312657|NCT00622934|ACTIVE_COMPARATOR|1|
62683252|NCT05090397|EXPERIMENTAL|Active|
62683253|NCT05090397|SHAM_COMPARATOR|Sham|
62683254|NCT06431386|EXPERIMENTAL|Esketamine + Behavioural Activation Therapy|Participants randomized to this arm will be administered esketamine treatment as per standard clinical care in conjunction with behavioural activation (BA) therapy. Both treatments will be initiated in Week 1 of the induction phase (first 4 weeks of esketamine treatment).
62683255|NCT06431386|ACTIVE_COMPARATOR|Esketamine Alone|Participants randomized to this arm will be administered esketamine treatment as per standard clinical care and will be offered a course of BA therapy (12 one hour sessions) after their completion of the trial.
62683256|NCT06222736|EXPERIMENTAL|Rocabado exercises group|The most commonly known form of exercise for Temporomandibular Disfunction is Rocabado exercises, which use 6 types of exercises 6 times a day.
62312658|NCT00622934|PLACEBO_COMPARATOR|2|
62312659|NCT01083563||RA inadequate response to methotrexate|Individuals with rheumatoid arthritis who have had an inadequate response to methotrexate and will be starting on an anti-TNF agent.
62312660|NCT01083563||RA inadequate response to anti-TNF.|Individuals with rheumatoid arthritis who have had an inadequate response to an anti-TNF and will be be given a rituximab infusion.
61922837|NCT03362307|ACTIVE_COMPARATOR|Laser Emitting group|subjects received Low-Level Laser and Light-Emitting Diodes after implant placement
61922838|NCT03362307|PLACEBO_COMPARATOR|Non Emitting group|In laser emitiiing group, subjects received Low-Level Laser and Light-Emitting Diodes after implant placement and in Non-emitting group,the same device was used while device was off.
61922839|NCT05599919|ACTIVE_COMPARATOR|Patients with COVID-19 (confirmed by RT-PCR), not requiring hospitalization|Nitric oxide releasing solution delivered up to 3 times daily
61922840|NCT05599919|PLACEBO_COMPARATOR|COVID-19 symptoms|saline delivered up to 3 times daily morning, mid-day, and evening. Maximum volume delivered: 0.56 mL Saline @ 0.9%
61922841|NCT04626310|EXPERIMENTAL|Dialectical behavior therapy - emotion regulation skills training|Dialectical behavior therapy - emotion regulation skills training
62312661|NCT00217477|EXPERIMENTAL|Paricalcitol IV in combination with Gemcitabine IV|Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62312662|NCT03940144|EXPERIMENTAL|goal-directed fluid therapy|Stroke Volume variation (SVV)-guided fluid therapy
62683257|NCT06222736|EXPERIMENTAL|Servical Core Exercises Group|The purpose of core exercises is to support the vertebral column, especially by activating the stabilizing muscles, and to develop and maintain proper cervical posture by increasing kinesthetic awareness. At the beginning of the exercises, the patient is taught to contract the deep stabilizer muscles in a controlled manner, in isolation, without contraction of the superficial muscles. Exercises 2 days a week for 8 weeks, maximum 30 minutes. The session will be actively applied by the patient for a period of time.
62683258|NCT06222736|EXPERIMENTAL|Rocabado Exercises and Servical Core Exercises Group|The most commonly known form of exercise for Temporomandibular Disfunction is Rocabado exercises, which use 6 types of exercises 6 times a day. The purpose of Servical Core exercises is to support the vertebral column, especially by activating the stabilizing muscles, and to develop and maintain proper cervical posture by increasing kinesthetic awareness. At the beginning of the exercises, the patient is taught to contract the deep stabilizer muscles in a controlled manner, in isolation, without contraction of the superficial muscles. Exercises 2 days a week for 8 weeks, maximum 30 minutes. The session will be actively applied by the patient for a period of time.
62683259|NCT06688370||Petit Drill|Treatment with the syrup for as long as necessary from D1 to D3, according to parent's judgement.
62683260|NCT06258785|EXPERIMENTAL|Tizanidine|Tizanidine 2mg will be given preoperatively prior to scheduled sacrospinous ligament suspension
61922842|NCT04626310|EXPERIMENTAL|Dialectical behavior therapy - interpersonal effectiveness skills training|Dialectical behavior therapy - interpersonal effectiveness skills training
61922843|NCT04626310|ACTIVE_COMPARATOR|Non-skills-oriented interpersonal psychotherapy group|Non-skills-oriented interpersonal psychotherapy group
62312663|NCT03940144|ACTIVE_COMPARATOR|Conventional fluid therapy|Conventional fluid therapy such as CVP and MAP guided fluid therapy
62683261|NCT06668467|EXPERIMENTAL|Experimental|Women assigned to the experimental group will receive mindfulness-based stress reduction training for 4 weeks.
62683262|NCT06668467|NO_INTERVENTION|Control|Women assigned to the control group will receive routine postpartum care services provided in the same hospital's outpatient clinics.
62123192|NCT05706480||Periodontally clinically healthy patients|In Periodontally clinically healthy patients fulfilling the eligibility criteria. The gingival tissue thickness will be measured using probe-colored periodontal probes (CPP), standard periodontal probes (SPP) and transgingival sounding with an endodontic file (ISO #20), visual judgment using photographs will be done to the three assessment methods
62312664|NCT04148430|EXPERIMENTAL|Arm 1 (CART Cell Group)|"Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days.~Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days"
62312665|NCT03667651|ACTIVE_COMPARATOR|Twice daily use treatment with EpiCeram|They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.
62477490|NCT03807180|NO_INTERVENTION|Group of control|Conventional exercises are stretching for the cervical, thoracic and lumbar flexibility, shoulder circumference, hamstring and erector spinal muscles, strengthening exercises for abdominal, back and proximal muscles. The exercises that will be taught in detail to each stage of the patient will be performed at home by the patient for 60 minutes, 2 days a week. The patients will be inspected and controlled by monthly controls.
62477491|NCT06060145|EXPERIMENTAL|Plants placed in an office environment|Participants in this group will receive an intervention of plants placed in an office environment.
61922844|NCT05612100||Observational (alopecia questionnaires and surveys)|Patients complete alopecia questionnaires and surveys and have medical records reviewed on study.
61922845|NCT01117051|PLACEBO_COMPARATOR|placebo|placebo
61922846|NCT01117051|ACTIVE_COMPARATOR|Resolor|prucalopride
62312666|NCT03667651|NO_INTERVENTION|Standard skin care|Parents are to follow standard skin care practices
61922847|NCT05947643|EXPERIMENTAL|Theophylline|Participants will dissolve the contents of the 400 mg theophylline capsules (experimental) into the sinus rinse bottle containing nasal saline.
61922848|NCT05947643|PLACEBO_COMPARATOR|Placebo|Participant will dissolve the contents of the identical-appearing lactose capsules (control) into the sinus rinse bottle containing nasal saline.
61922849|NCT05837143|EXPERIMENTAL|Active Comparator: JV001|Subjects will receive a single intracoronary infusion of JV001 at a dose of 2×10\^11vg/kg, and 6×10\^11vg/kg.
61922850|NCT00548106|EXPERIMENTAL|1|Infants will be fed the new hydrolyzate formula.
62139658|NCT05223959|EXPERIMENTAL|CaPE Intervention|CaPE is a manualized intervention consisting of 12 one-to-one psychoeducation sessions, one session per week. Each session will last for 60 minutes. All sessions will be delivered by a trained therapist who will receive two months training from senior therapists before starting intervention.
62139659|NCT05223959|NO_INTERVENTION|Treatment as Usual|Treatment as usual (TAU) will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.
62312667|NCT00607360|NO_INTERVENTION|Standard Drug Court|Participants received standard services from drug court
62477492|NCT06060145|ACTIVE_COMPARATOR|Devoid of any plant presence in an office environment|Participants in this group will be exposed to an office environment devoid of any plant presence.
62737778|NCT05081167|PLACEBO_COMPARATOR|Placebo|Three tablets of matching placebo will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 1 placebo tablet.
61922851|NCT00548106|PLACEBO_COMPARATOR|2|Nan HA infant formula
62139660|NCT03900585|EXPERIMENTAL|Interval walking|Interval walking for 10 weeks, 150 minutes per week administered by an app on the patient's telephone.
62139661|NCT03900585|NO_INTERVENTION|Control|Patients live as normal, though aerobe training restricted to a maximum of 30 minutes a week.
62312668|NCT00607360|EXPERIMENTAL|Drug Court plus Therapeutic Workplace|Participants receive standard drug court services plus therapeutic workplace intervention
62312669|NCT03115645|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
62312670|NCT03115645|NO_INTERVENTION|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
62312671|NCT05720078|EXPERIMENTAL|Adaptive, two-phase RT|
62312672|NCT03211130|EXPERIMENTAL|SystemCHANGE™|
61922852|NCT03330574||Variability of the device|We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma.
61922853|NCT03330574||Diagnosis and progression of glaucoma|Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma.
61922854|NCT03330574||Effect of medical/surgical intervention|Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems.
61922855|NCT05082532|EXPERIMENTAL|patients with critical and subcritical femoropopliteal arterial occlusions|patients presented with chronic ischemia in rest pain stage or ulcerative and gangrenous toes and by investigations long chronic total occlusion of femoropopliteal segment was documented may need stenting of the diseased segment especially if the lesion recoils after previous angioplasty. Nitinol interwoven stent has a unique design that achieves adherence to vessel wall and also malleability with the vessel and surrounding muscle motion so investigators predict more extended patency time with this interventional option and want to investigate this prediction using a scientific experimental pathway.
62312673|NCT03211130|ACTIVE_COMPARATOR|Attention-Control|
62477493|NCT05039112|OTHER|P1fA, then MyDay Toric|Verofilcon A toric contact lenses worn first, with stenfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
62737779|NCT05215470|EXPERIMENTAL|Nivolumab+Ipilimumab|Nivolumab IV 3mg/kg 3/3w + Ipilimumab 1mg/kg 3/3w 4 doses, followed by Nivolumab IV 480mg 4/4w until progression, toxicity, or up to 2 years of use.
62737780|NCT04296188|ACTIVE_COMPARATOR|serratus anterior plane block|The serratus anterior plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via patient controlled analgesia (PCA) device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
62737781|NCT04296188|ACTIVE_COMPARATOR|erector spina plane block|The erector spina plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via PCA device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
61922856|NCT03406923|NO_INTERVENTION|Usual care|Receive usual care only.
61922857|NCT03406923|EXPERIMENTAL|Health literacy-psychosocial support|Receive 6-week sessions of individual health literacy-psychosocial support in addition to usual care. The health literacy-psychosocial support intervention includes 45-minute face-to-face counseling at week 1 and week 6 as well as weekly phone calls (week 2 to week 5.)
61922858|NCT01657929|EXPERIMENTAL|20 µg H5-VLP + 2.5 µg GLA-AF given ID|
61922859|NCT01657929|EXPERIMENTAL|20 µg H5-VLP + 2.5 µg GLA-AF given IM|
61922860|NCT01657929|ACTIVE_COMPARATOR|20 µg H5-VLP alone given ID|
61922861|NCT01657929|ACTIVE_COMPARATOR|20 µg H5-VLP + 1 mg Alhydrogel(R) given IM|
61922862|NCT01657929|ACTIVE_COMPARATOR|90 µg licensed H5N1 vaccine|
61922863|NCT01772511||Questionnaire|Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
61922864|NCT03115580|ACTIVE_COMPARATOR|Rotational atherectomy|Rotational atherectomy (RA)
61922865|NCT03115580|ACTIVE_COMPARATOR|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
61922866|NCT03080974|EXPERIMENTAL|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
61922867|NCT02581839|EXPERIMENTAL|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
61922868|NCT05014412|EXPERIMENTAL|Part 1|Evaluation of step-up priming dosing
61922869|NCT05014412|EXPERIMENTAL|Part 2A|Dose determination
61922870|NCT05014412|EXPERIMENTAL|Part 2B|Dose expansion
61922871|NCT05014412|EXPERIMENTAL|Part 2C|To explore higher dose intensity
62312674|NCT03090737|EXPERIMENTAL|Nivolumab|Specified Dose on Specified Days
62477494|NCT05039112|OTHER|MyDay Toric, then P1fA|Stenfilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
61922872|NCT04114032||High-risk elective surgical patients|"The patient population to be studied are elective patients for non-cardiac surgery.~1. Age ≥ 45 years of age.~2. Undergoing intermediate or major non-cardiac surgery requiring an overnight stay in hospital.~3. With at least one of the following criteria:~   1. History of ischaemic heart disease or peripheral vascular disease (coronary equivalent)~  2. History of stroke or transient ischaemic attack~  3. History of congestive cardiac failure~  4. Diabetes currently on an oral hypoglycaemic agent or insulin~  5. Serum creatinine \>175 µmol/L (\>2.0mg/dl)"
61922873|NCT00970866|ACTIVE_COMPARATOR|Iron and Folic Acid (IFA)|
61922874|NCT00970866|ACTIVE_COMPARATOR|Multiple Micronutrient (MMN)|
61922875|NCT00970866|ACTIVE_COMPARATOR|Lipid-based Nutrient Supplements (LNS)|
62139662|NCT03875066|OTHER|A to B|Subjects were involved in an control training program (A). After 2 weeks washout period, Subjects were trained using the other program (B).
62139663|NCT03875066|OTHER|B to A|Subjects were involved in an control training program (B). After 2 weeks washout period, Subjects were trained using the other program (A).
62312675|NCT03792919|EXPERIMENTAL|Cessation of NAs treatment|Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.
62312676|NCT03792919|ACTIVE_COMPARATOR|Keep on current NAs treatment|Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.
62683263|NCT03740165|EXPERIMENTAL|Pembrolizumab + Olaparib|Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
61922876|NCT00589784|EXPERIMENTAL|Treatment|Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.
62312677|NCT03763487|EXPERIMENTAL|Patients|Ultrasound examination: scaled to spleen size (spleen volumetry) Methodology of laboratory tests: venous blood sampling
62312678|NCT03763487|NO_INTERVENTION|healthy blood donors|No intervention in this group.
62312679|NCT01350700||Patients that were treated in MW2004-011-02 study with Debrase|
62312680|NCT01350700||Patients that were treated in MW2004-011-02 with SOC|
61922877|NCT06260527|EXPERIMENTAL|Single ascending dose (SAD)|ARTS-011 and placebo will be randomized assigned and single dose administrated.
61922878|NCT06260527|EXPERIMENTAL|Multiple ascending dose (MAD)|ARTS-011 and Placebo will be randomized assigned and continuously administrated once daily for 7 days.
61922879|NCT06260527|EXPERIMENTAL|Food effect study|ARTS-011 will be single administered under the fasting and high-fat meal condition.
61922880|NCT03251677|ACTIVE_COMPARATOR|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
61922881|NCT03251677|ACTIVE_COMPARATOR|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
61922882|NCT00417482|OTHER|Risperidone-risperidone|Risperidone for 16 weeks followed by risperidone for 16 weeks
61922883|NCT00417482|OTHER|Risperidone-Placebo|Risperidone for 16 weeks followed by placebo for 16 weeks
61922884|NCT00417482|OTHER|Placebo-Placebo|Placebo for 16 weeks followed by placebo for 16 weeks
61922885|NCT03593941||Alzheimer's dementia and challenging behaviour symptoms|Care home residents \>65y No interventions as this is a pilot project
61922886|NCT03593941||Alzheimer's dementia and no challenging behavioural symptoms|Care home residents \>65y No interventions as this is a pilot project
61922887|NCT03593941||Older adults without dementia|Care home residents \>65y No interventions as this is a pilot project
61922888|NCT04778072|EXPERIMENTAL|Group 1|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
61922889|NCT04778072|EXPERIMENTAL|Group 2|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
61922890|NCT04778072|EXPERIMENTAL|Group 3|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily with matching placebo
61922891|NCT06420128||Primary care team|Patients whose general practitioner is a member of a primary care team since at least 12 months
61922892|NCT06420128||Traditional|Patients whose general practitioner is not part of a primary care team
61922893|NCT03231020||Adherent Group|Parent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
61922894|NCT03231020||Non-Adherent Group|Parent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
61922895|NCT05888571|ACTIVE_COMPARATOR|prepectoral breast reconstruction with Mesh|Immediate prepectoral breast reconstruction with Mesh
62123193|NCT05208554|EXPERIMENTAL|Family-Focused Facilitated Fitness program|Couple-based physical activity intervention commencing 14 (+/-7) days post-transplant (8 sessions with a health counselor). Sessions 1-4 will train couples in the use of communal coping strategies to support one another in achieving PA goals. Skill building will focus on instruction and practice in adaptive communication, with emphases on adaptive speaking, responsive listening, and joint decision-making and problem-solving around PA. Instruction and practice will focus specifically on communication about PA and working together (we versus me) to increase PA. Sessions 5-8 will afford check-in, review of PA progress, and troubleshooting any barriers to PA. All sessions will be dyad-based but will include delivery of individualized step goals for the next week using an adaptive approach and based on remotely-monitored Fitbit step data. Specifically, the 75th percentile rank of each participant's last 7 days of recorded days will serve as the step goal prescription for the next week.
61922896|NCT05888571|EXPERIMENTAL|prepectoral breast reconstruction without Mesh|Immediate prepectoral breast reconstruction without Mesh
61922897|NCT02455141|ACTIVE_COMPARATOR|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
61922898|NCT02455141|EXPERIMENTAL|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
61922899|NCT05319093||Early Ozanimod treatment|"In this group the effect of Ozanimod will be assessed in patients who initiated on Ozanimod treatment at study baseline (n=10).~Treatment schedule and dosage of Ozanimod and the other disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital."
61922900|NCT05319093||Medium-term Ozanimod treatment|"In this group, the effect of Ozanimod will be assessed in patients treated with Ozanimod for ≥6 months at study baseline (n=10).~Treatment schedule and dosage of Ozanimod and the other disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital."
61922901|NCT05319093||Non-Ozanimod treatment|"In this group, investigators will involve patients initiated on any disease-modifying drug (other than Ozanimod) at study initiation (n=10).~Treatment schedule and dosage of the disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital. The proposed study is purely observational and will not influence the selection, schedule or dosage of patient treatments."
61922902|NCT05319093||Untreated|In this group, MS patient will be involved who did not receive any disease-modifying drug for at least 3 months before study initiation (i.e., untreated patients, n=10)
61922903|NCT00785967|EXPERIMENTAL|1|raltegravir 400mg bid + Truvada 1 tab qd
61922904|NCT00785967|ACTIVE_COMPARATOR|2|efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
61922905|NCT04877223||CF|Patients with Cystic Fibrosis
61922906|NCT00543855|EXPERIMENTAL|3 mg Donepezil hydrochloride|
61922907|NCT00543855|EXPERIMENTAL|5 mg Donepezil hydrochloride|
61922908|NCT00543855|EXPERIMENTAL|10 mg Donepezil hydrochloride|
61922909|NCT00543855|PLACEBO_COMPARATOR|Placebo|
61922910|NCT04626466||Non-metastatic prostate, rectum, canal, endometrium, cervix or vaginal cancer Radiotherapy treatment|
61922911|NCT03416374|EXPERIMENTAL|Combination Therapy + Ixazomib Therapy|Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)
61922912|NCT05500066||Aequalis Flex Revive Shoulder System|Commercially available shoulder system available in both anatomic and reversed configurations.
62123194|NCT02399670||Decrease femoral offset|The FO of operated side was reduced more than 5mm compared with the contralateral side.
62312681|NCT05497505||Discharged patients with decision support (On-period)|For patients that have been evaluated as eligible for discharge: the current ICU discharge process will be followed based on routine clinical evaluation by the treatment team in combination with ICU discharge protocols. In addition, Pacmed Critical will be used as an additional source of information. Final discharge decision will be made by lead unit intensivist responsible for medical care.
62312682|NCT05497505||Discharged patients without decision support (Off-period)|For patients that have been evaluated as eligible for discharge: the current ICU discharge process will be followed based on routine clinical evaluation by the treatment team in combination with ICU discharge protocols. Final discharge decision will be made by lead unit intensivist responsible for medical care.
62312683|NCT05537181|EXPERIMENTAL|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
62477495|NCT00004148|EXPERIMENTAL|Arm I|Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
61922913|NCT03703570|EXPERIMENTAL|KW-6356 Low Dose|Oral administration
61922914|NCT03703570|EXPERIMENTAL|KW-6356 High Dose|Oral administration
61922915|NCT03703570|PLACEBO_COMPARATOR|placebo|Oral administration
61922916|NCT05581875|EXPERIMENTAL|Part 1 : Dose finding|"Belantamab mafodotin will be administered by intravenous infusion as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose for Part 1:~* Cohort 1: 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle~* Cohort 2: 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle~Daratumumab 1800mg SC (fixed dose) on:~Cycles 1-2: days 1, 8, 15, 22 Cycles 3-6: days 1, 15 Cycles 7+: day 1~Pomalidomide: 4 mg/d on days 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants \< 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years."
61922917|NCT02851186|EXPERIMENTAL|Electroacupuncture (EA) and Auricular Acupuncture (AA)|Subjects in the treatment group will receive EA combined with AA two hours before operation, immediately post-operation and once a day for the subsequent 5 days.
61922918|NCT02851186|SHAM_COMPARATOR|Sham acupuncture|Subjects in the control group will receive non-invasive sham procedure in the same schedule as the treatment group.
61922919|NCT02554188|PLACEBO_COMPARATOR|Control|Participants will receive Seasonal influenza (flu) vaccine.
62123195|NCT02399670||Restored femoral offset|The FO of operated side was within 5mm restored compared with the contralateral side.
62123196|NCT02399670||Increased FO|The FO of operated side was increased more than 5mm compared with the contralateral side.
62123197|NCT01908296|EXPERIMENTAL|FK949E group|receiving FK949E with and without fluvoxamine
62139664|NCT04231279|ACTIVE_COMPARATOR|ChiRhoStim Group 1|Patients undergoing EGD with ePFT for symptoms of suspected or known pancreatic insufficiency.
62139665|NCT04231279|EXPERIMENTAL|ChiRhoStim Group 2|Patients undergoing diagnostic EGD that consent to undergo ePFT.
62139666|NCT04165759||patients|Patients with lung cancer who are candidates for surgery.
62683264|NCT03740165|EXPERIMENTAL|Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
62683265|NCT03740165|ACTIVE_COMPARATOR|Placebo for Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
62683266|NCT05467098|EXPERIMENTAL|Individuals with and without Shoulder Pain|"Individuals with shoulder pain will receive dry needling to the two to four most tender points in the infraspinatus based on examiner palpation~Individuals without shoulder pain will receive dry needling to two points in the muscle belly of the infraspinatus near the insertion and below the midpoint of the spine of the scapula"
62683267|NCT05835973|EXPERIMENTAL|Sleep activity|"Actigraphy : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard). They will be provided by the company camntech.~Ancillary Study:~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months."
62683268|NCT03813290|EXPERIMENTAL|Neuro-Technological Intervention|"Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment.~Participants will also be required to fill up some questionnaires at baseline and post-intervention visits."
62683269|NCT06288659|EXPERIMENTAL|aSAH treatment based on Intraventricular ICP monitoring|In the acute phase of aSAH (following endovascular or craniotomy occlusion of the aneurysm), a ventricular ICP monitoring probe is surgically implanted. And the postoperative management of ICP is guided by quantifiable ICP parameters. The remaining treatments are consistent with those in the control group.
62683270|NCT06288659|NO_INTERVENTION|aSAH treatment without Intraventricular ICP monitoring|Only aSAH treatment surgery is performed without intraventricular ICP monitoring probe implantation. The treatment is not guided by ICP monitoring, and instead, aSAH treatment is conducted based on clinical signs and CT imaging to assess ICP.
62683271|NCT06268678|EXPERIMENTAL|Follicular|Follicular phase assessment of muscle protein synthesis.
62683272|NCT06268678|EXPERIMENTAL|Luteal|Luteal phase assessment of muscle protein synthesis
62683273|NCT02844816|EXPERIMENTAL|Treatment (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity.
62683274|NCT06051968|EXPERIMENTAL|Intervention group|Participants get hearing rehabilitation according to common practice and the online hearing support.
61922920|NCT02554188|EXPERIMENTAL|Diet|Participants will consume 2 cycles of a 5-day low calorie fasting-mimicking diet with approximately 3 weeks of gap period prior to receiving standard Seasonal influenza (flu) vaccine.
62139667|NCT01780649|EXPERIMENTAL|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)
62477496|NCT03910231|PLACEBO_COMPARATOR|Placebo|Placebo
62477497|NCT03910231|EXPERIMENTAL|15mg Tolvaptan|15mg Tolvaptan
62477498|NCT03910231|EXPERIMENTAL|30mg Tolvaptan|30mg Tolvaptan
62477499|NCT05507580|EXPERIMENTAL|Double-Blind Treatment Period Dose A|Participants will be administered updadacitinib Dose A once daily (QD) for 12 weeks.
62477500|NCT05507580|EXPERIMENTAL|Double-Blind Treatment Period Dose B|Participants will be administered updadacitinib Dose B once daily (QD) for 12 weeks.
62477501|NCT05507580|EXPERIMENTAL|Single-Blinded Treatment Period Arm A|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
62139668|NCT01780649|ACTIVE_COMPARATOR|ICSI|Intracytoplasmic sperm injection (ICSI)
62139669|NCT05440058||BIS Monitoring|Subjects will have BIS sensors applied to forehead
62683275|NCT06051968|ACTIVE_COMPARATOR|Control group|Participants get hearing rehabilitation according to common practice.
62683276|NCT05209737|EXPERIMENTAL|Trendelenburg position|Position: 10-degree Head-down position
62683277|NCT05209737|ACTIVE_COMPARATOR|Semirecumbent position|Position: 30-degree Head-up position
62477502|NCT05507580|EXPERIMENTAL|Single-Blinded Treatment Period Arm B|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
62683278|NCT06606600|EXPERIMENTAL|Intensive Kebbi robot interventions|Intensive Kebbi robot interventions will receive 30 minutes, 3 time per week for 12 weeks.
62683279|NCT06606600|NO_INTERVENTION|Thc control group|The control group will receive the usual activity.
62683280|NCT05132582|EXPERIMENTAL|Tucatinib + trastuzumab + pertuzumab|Tucatinib + trastuzumab + pertuzumab
62683281|NCT05132582|ACTIVE_COMPARATOR|Placebo + trastuzumab + pertuzumab|Placebo + trastuzumab + pertuzumab
62683282|NCT06685939||OPD|The patients who received the OPD
62683283|NCT05009069|EXPERIMENTAL|Atezolizumab + Tiragolumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab plus tiragolumab (Day 1 of each 21-day cycle for 3 cycles)."
62683284|NCT05009069|OTHER|Atezolizumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab (Day 1 of each 21-day cycle for 3 cycles)."
62683285|NCT06526520||Natural cycle|Monitoring of a natural cycle
62683286|NCT06526520||natural proliferative phase cycle|Monitoring of a natural proliferative phase cycle
62683287|NCT06526520||Hormonal replacement cycle|Monitoring of a hormonal replacement cycle
62683288|NCT04889950|EXPERIMENTAL|Tixel Group|Tixel C Group: Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
62683289|NCT04889950|ACTIVE_COMPARATOR|LipiFlow|LipiFlow: Screening and baseline visits, Treatment- 1 single treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
62683290|NCT06424860|ACTIVE_COMPARATOR|Metformin|metformin (1500mg/d) and placebo (olive oil capsule)
62683291|NCT06424860|EXPERIMENTAL|Fishoil and metformin|metformin (1500mg/d) and fish oil (4000mg/d)
62683292|NCT05604157|ACTIVE_COMPARATOR|Tourniquet|25 participants with tourniquet application
62683293|NCT05604157|NO_INTERVENTION|No tourniquet|25 participants without tourniquet application
62683294|NCT06580899|OTHER|No post-operative intra-articular catheter|Subjects that receive ONLY the existing standard of care (SOC) multimodal pain management protocol and DO NOT receive post-operative intra-articular catheter.
62683295|NCT06580899|ACTIVE_COMPARATOR|BRAND 1 intra-articular catheter|Subjects that receive the BRAND 1 intra-articular catheter pump with existing SOC multimodal pain management protocol in the immediate post-op period.
62683296|NCT06580899|ACTIVE_COMPARATOR|BRAND 2 intra-articular catheter|Subjects that receive the newer BRAND 2 intra-articular catheter pump with existing SOC multimodal pain management protocol in the immediate post-op period.
62683297|NCT04235062|EXPERIMENTAL|Fluid Expansion and Diuretic Challenge|Subject receive intravenous infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution, followed by diuretic challenge with 40mg Furosemide intravenous bolus.
62477503|NCT05507580|EXPERIMENTAL|Single-Blinded Treatment Period Arm C|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
62683298|NCT05519475|EXPERIMENTAL|ALN-HSD|Randomized 1:1
62683299|NCT05519475|PLACEBO_COMPARATOR|Placebo|Randomized 1:1
62683300|NCT06688188|EXPERIMENTAL|dynamic PET scans|PET imaging will begin at 3 minutes, 15 minutes, 30min minutes, 60 minutes and 150 minutes after injection.
62683301|NCT06171737|NO_INTERVENTION|Control (usual care)|This group will receive usual care without any support for using the decision aid and without any access to the clinician training.
62683302|NCT06171737|ACTIVE_COMPARATOR|Intervention|"The patients in this group will receive a decision aid that covers the main treatment options for aortic stenosis.~The clinicians in this group will receive a 60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies"
62683303|NCT06690112|EXPERIMENTAL|Drainage removal group|Patients who remove their draiange tube at discharge
62683304|NCT06690112|NO_INTERVENTION|Drainage maintain group|Patients who maintain their draiange tube at discharge
62683305|NCT04279769|EXPERIMENTAL|Cohort 1|CB-280 twice daily at 50 mg for 14 days
62683306|NCT04279769|EXPERIMENTAL|Cohort 2|CB-280 twice daily at 100 mg for 14 days
62683307|NCT04279769|EXPERIMENTAL|Cohort 3|CB-280 twice daily at 200 mg for 14 days
62683308|NCT04279769|EXPERIMENTAL|Cohort 4|CB-280 twice daily at 400 mg for 14 days
62683309|NCT04279769|PLACEBO_COMPARATOR|Placebo|Placebo twice daily for 14 days
62683310|NCT04486677|OTHER|Caring Cards Group|Group of Veteran card-makers.
62683311|NCT04486677|OTHER|Caring Cards Recipients|Group of Veteran card-recipients.
62683312|NCT06067334|ACTIVE_COMPARATOR|Conventional (Open tray impression technique)|After osseointegration, a conventional open tray splinted impression technique will be made for each patient on the implant/abutment level.
62683313|NCT06067334|ACTIVE_COMPARATOR|Digital impression|Scan bodies implant level/abutment level will be tightened for each patient, and a digital intraoral scanner will be used to scan the scan bodies for making implant level/abutment level digital impressions.
62683314|NCT04487821|EXPERIMENTAL|Experimental Group|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. This contained 4 types of progressive activities. Respectively every type contains 2 to 4 tasks, performed in sets of 10 repetitions for 4 weeks.~Results were obtained by using Balance scoring system, and physical performance test for speed and agility"
62683315|NCT04487821|NO_INTERVENTION|Control Group|"Control group: (Group B) Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. They were asked to perform the regular drills.~Results were obtained using Balance Error scoring system and physical performance test for speed and agility."
62123198|NCT06519253|EXPERIMENTAL|VR Music- Intervention|"Treatment Group: music intervention via virtual reality (VR)~The music intervention aims to reproduce the experience of a musical performance. During the intervention, the participants will wear a VR headset which will give them an immersive experience of attending a virtual performance. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.~The participants in the VR intervention will be seated during the 15 minutes of intervention and the research assistant will stay at their side during the entire intervention. There will be no hand-help components to the VR intervention. Should the participant express any discomfort or have any questions/concerns with the intervention, the research assistant will be available and able to answer/assist the participants."
62683316|NCT05908084|EXPERIMENTAL|HAV treatment arm|HAV will be implanted as an arterio-venous (AV) access into the forearm or upper arm
62683317|NCT05908084|ACTIVE_COMPARATOR|AVF treatment arm|AVF creation procedure (1-stage AVF or 2-stage AVF) as an arterio-venous (AV) access into the forearm or upper arm
62683318|NCT05861401|ACTIVE_COMPARATOR|control|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
62683319|NCT05861401|ACTIVE_COMPARATOR|cases|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
62683320|NCT02577575|EXPERIMENTAL|Oxytocin|40 IU Oxytocin
62683321|NCT02577575|PLACEBO_COMPARATOR|Saline Nasal Spray|Placebo Comparator
62683322|NCT04614441||Idiopathic Pulmonary Fibrosis (IPF)|
62683323|NCT04614441||Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
61922921|NCT04916782||Observational group|
62123199|NCT06519253|ACTIVE_COMPARATOR|Music- Active Control|"The participants in the active control group will listen, via a headband, the same music as the VR music intervention group.~These participants will therefore not have an immersive experience as they will only hear the music (i.e they will not be able to see the musicians playing).~The participants in the music intervention via headband will remain seated during the 15 minutes of the intervention. During the intervention, the research assistant will stay at their side. Should the participant express any discomfort or have any questions/concerns with the intervention, the research assistant will be available and able to answer/assist the participants."
62123200|NCT04583514|EXPERIMENTAL|Control|The control group will be expected to maintain their weight within 1 kg of baseline weight throughout the duration of the study.
62123201|NCT04583514|EXPERIMENTAL|Overfeeding|The overfeeding group will be subjected to a similar relative change in energy intake, in which their dietary intake will be 30% more kcal/d than needed for weight maintenance.
62477504|NCT05507580|EXPERIMENTAL|Single-Blinded Treatment Period Arm D|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
62477505|NCT02486081||children with intelligent disabilities|children with ID will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
62683324|NCT04614441||Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)|
62683325|NCT00619242|EXPERIMENTAL|sorafenib|sorafenib 2 tablets by mouth
62683326|NCT05289453|EXPERIMENTAL|study group|patients wit acute congestive glaucoma and treated bt lens extraction by phacoemulsification after IOP control
62683327|NCT01081574|EXPERIMENTAL|10 mg Bilastine once daily for 7 days|10 mg Bilastine dispersible oral tablet
61922922|NCT02138370||stage II and III colorectal cancer|
61922923|NCT04451642||Peripheral nerve block Group|Every patient scheduled during 2011-2019 for the surgery needed a peripheral nerve block were enrolled.
62123202|NCT00712335|EXPERIMENTAL|1|"Asthmatic smokers treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
62683328|NCT03241550|EXPERIMENTAL|isavuconazonium sulfate IV cohort 1: 1 to < 6 years of age|Patients will receive an intravenous (IV) loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
62683329|NCT03241550|EXPERIMENTAL|isavuconazonium sulfate IV cohort 2: 6 to < 12 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
62683330|NCT03241550|EXPERIMENTAL|isavuconazonium sulfate IV cohort 3: 12 to < 18 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
62683331|NCT03241550|EXPERIMENTAL|isavuconazonium sulfate oral cohort 4: 6 to < 12 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
62683332|NCT03241550|EXPERIMENTAL|isavuconazonium sulfate oral cohort 5: 12 to < 18 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
62683333|NCT04491110|EXPERIMENTAL|Experimental: Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
62683334|NCT04491110|SHAM_COMPARATOR|Sham Comparator: Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
62683335|NCT06691022||smoking|not smoking
62683336|NCT06057103|OTHER|ZX-7101A-1|
62683337|NCT06057103|OTHER|ZX-7101A-2|
62683338|NCT06057103|OTHER|Oseltamivir-1|
62683339|NCT06057103|OTHER|Oseltamivir-2|
62683340|NCT06057103|OTHER|Combined-1|
62683341|NCT06057103|OTHER|Combined-2|
62683342|NCT06057025|EXPERIMENTAL|Healthy patients|Drug: Sputnik Light vector vaccine for the prevention of coronavirus infection caused by the SARS CoV-2 virus (with altered antigenic composition); A total of 50 people will be randomized and receive the study drug. A single intramuscular injection of the investigational medicinal product (IMP) will be performed.
62683343|NCT02025010|EXPERIMENTAL|abiraterone acetate|"Participants will be treated with four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) orally on 28-day cycles. For participants who experience persistent or severe mineralocorticoid excess or have PSA progression, prednisone 5 mg by mouth twice daily will be added.~Patients will be treated until radiographic disease progression and unacceptable AE or taken off study for other reason."
62683344|NCT06686524|EXPERIMENTAL|Anti-CD19 UCAR-T cells|
62683345|NCT05530538|EXPERIMENTAL|BrainWeighve Intervention|4-month smartphone-based weight loss intervention for teens based on displacement theory of addictive behaviors
61922924|NCT02123628|ACTIVE_COMPARATOR|antibiotic therapy|"patients are treated with a 6 week-duration of antibiotic therapy :~* Rifampin IP and PO twice daily, 10mg/kg /12H~* Levofloxacin IV and PO 500-750mg once daily~* Doxycycline PO 200mg once daily~* Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~* Fusidic acid PO 500mg twice daily~* Linezolid IV and PO 600mg twice daily~* Ciprofloxacin IV and PO 750to 1000mg/12h~* Cefotaxime IV 100mg/kg in three IV infusions daily~* Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~* Cefepime IV ou intra-muscularly 2g /8-12h"
62477506|NCT02486081||typical-developed children (TD)|TD children will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
62683346|NCT03796286|PLACEBO_COMPARATOR|Control bar (0 g fiber)|Each subject will be randomly assigned to consume a control sports bar-type product (0 grams of fiber) at one treatment visit.
62683347|NCT03796286|EXPERIMENTAL|Medium-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 10 grams of fiber) at one treatment visit.
62683348|NCT03796286|EXPERIMENTAL|High-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 20 grams of fiber) at one treatment visit.
62683349|NCT06686563|EXPERIMENTAL|Intervention Group|"Participants in the IG will be stimulated with gamma frequency (39-42 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.~The participants will be assessed (regarding the outcomes previously described) at the baseline and reassessed after 3 months."
62683350|NCT06686563|ACTIVE_COMPARATOR|Control Group|"Participants in the CG will be stimulated with theta frequency (4-7 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.~The participants will be assessed (regarding the outcomes previously described) at the baseline and reassessed after 3 months."
62683351|NCT04315961|EXPERIMENTAL|Caffeine Maintenance|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo). During the caffeine maintenance condition, participants will ingest 200 mg of caffeine orally in capsules three times daily.
62683352|NCT04315961|PLACEBO_COMPARATOR|Placebo Maintenance|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo). The placebo maintenance condition will be identical to the caffeine maintenance condition, with the exception that the thrice daily capsules will contain placebo (microcrystalline cellulose) rather than containing caffeine.
62683353|NCT00555373|OTHER|Sirolimus|Single arm
62683354|NCT05804227|EXPERIMENTAL|Cohort 1: NF1-muated low-grade glioma|
62683355|NCT05804227|EXPERIMENTAL|Cohort 2: CIC-mutated oligodendroglioma|
62683356|NCT00949065|ACTIVE_COMPARATOR|Intravenous immunoglobulins (IvIg)|3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks
62683357|NCT00949065|PLACEBO_COMPARATOR|NaCl 0.9%|NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks
62683358|NCT03292029|OTHER|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
62683359|NCT04942327|OTHER|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
62683360|NCT01292265|EXPERIMENTAL|CZP 200 mg|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
62683361|NCT06691854|NO_INTERVENTION|Placebo group|"Pregnant women who apply to the hospital for delivery, have a cervical dilatation of 5 cm or more, agree to participate in the study and are assigned to the control group;~* A personal information form will be applied at the first clinic admission.~* Pregnant women assigned to the control group will receive routine intrapartum care provided at the hospital.~* The labor process of the pregnant woman will be recorded on the birth experience monitoring form.~* The mother and baby will receive routine postpartum care provided at the hospital.~* After delivery, the Respectful maternity care scale, Birth experience scale, Traumatic birth perception scale will be applied."
62123203|NCT00712335|EXPERIMENTAL|2|"Asthmatic smoker treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
62139670|NCT01473485|EXPERIMENTAL|ExAblate Transcranial Device|
62312684|NCT05367804|EXPERIMENTAL|Isolated plant protein|Visit 1 to 8 participants will collect faecal samples. Visits 4 to 8 in addition to the faecal sample, urinary samples (24 h urine collection) will be collected by themselves, and blood sample will be collected at the hospital. For the visits with blood collection (visits 4 to 8), subjects will come to the study centre after 10 hours of overnight fast. Subjects will have anthropometry measurements taken in the visits 4, 5, 6, and 7 using a Tanita® full body composition. Subjects will respond to questionnaires about their physical activity (once a week), Gastrointestinal Symptom rating scale (GSRS - once a week) and track their intestinal habits using Bristol scale (every day). Subjects' diet will be assessed using a web-based 24-hour diet recall (interviewed so the participants learn how to use the tool regardless of where they are) followed by multiple day records (3 times a week).
62312685|NCT05437094|OTHER|CRD-740|CRD-740 single dose administered alone
62477507|NCT01727947|EXPERIMENTAL|MSOME|Couples in which the sperm cells were analysed through MSOME
62683362|NCT06691854|EXPERIMENTAL|The group that applied the Intrapartum Care Model|"Pregnant women who apply to the hospital for delivery, have cervical dilatation of 5 cm and above, agree to participate in the study and are assigned to the intervention group;~* A Personal Information form will be applied at the first clinic admission.~* All primiparous pregnant women assigned to the intervention group will be applied the intrapartum care model by the research midwife during the labor process and after birth in line with the WHO positive birth recommendations (Table 1).~* The labor process of the pregnant woman will be recorded on the birth experience follow-up form.~* After birth, the Respectful maternity care scale, Birth experience scale, Traumatic birth perception scale will be applied."
62683363|NCT01523431|ACTIVE_COMPARATOR|Standard FOLFIRI for wild/hetero UGT1A1|Irinotecan Injection \[Camptosar\] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
62683364|NCT01523431|EXPERIMENTAL|Reduced Dose of CPT-11 for homo UGT1A1|Irinotecan Injection \[Camptosar\] (CPT-11) 90 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
62683365|NCT01523431|ACTIVE_COMPARATOR|Standard FOLFIRI for homo UGT1A1|Irinotecan Injection \[Camptosar\] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
61922925|NCT02123628|ACTIVE_COMPARATOR|12 week-duration of antibiotic therapy|"patients are treated with a 12 week-duration of antibiotic therapy :~* Rifampin IP and PO twice daily, 10mg/kg /12H~* Levofloxacin IV and PO 500-750mg once daily~* Doxycycline PO 200mg once daily~* Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~* Fusidic acid PO 500mg twice daily~* Linezolid IV and PO 600mg twice daily~* Ciprofloxacin IV and PO 750to 1000mg/12h~* Cefotaxime IV 100mg/kg in three IV infusions daily~* Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~* Cefepime IV ou intra-muscularly 2g /8-12h"
61922926|NCT05226949||Cases|"54 newborns with neonatal HSV infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
61922927|NCT05226949||Controls|"108 newborns without infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Controls will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
61922928|NCT02139800|ACTIVE_COMPARATOR|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
62123204|NCT00712335|ACTIVE_COMPARATOR|3|"Non-smoking asthmatics treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
62312686|NCT05437094|OTHER|CRD-740 and Itraconazole|CRD-740 single dose administered with Itraconazole
62312687|NCT01803802|PLACEBO_COMPARATOR|Time management|Writing prompts oriented towards objective recounting of previous day
62312688|NCT01803802|EXPERIMENTAL|Sexual schema writing|Expressive writing prompts oriented towards beliefs about sexuality
62477508|NCT00224718|ACTIVE_COMPARATOR|1|surgery - open repair
62477509|NCT00224718|EXPERIMENTAL|2|endovascular procedure
62477510|NCT01626287|EXPERIMENTAL|Black tea bag|
62477511|NCT01626287|ACTIVE_COMPARATOR|ice packs|20 randomly chosen participants will be given frozen ice packs for perineal pain relief
62477512|NCT00840216|EXPERIMENTAL|1|
61922929|NCT02139800|EXPERIMENTAL|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
61922930|NCT03639571|EXPERIMENTAL|Test|Ibuprofen 200mg TEPI medicated plaster
62123205|NCT00712335|ACTIVE_COMPARATOR|4|"Non-smoking asthmatic treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
62123206|NCT00712335|NO_INTERVENTION|5|Normal controls
62477513|NCT00840216|ACTIVE_COMPARATOR|2|
62477514|NCT00418145|EXPERIMENTAL|megadose oral methylprednisolone|1400 mg qd/5 days
62477515|NCT00418145|EXPERIMENTAL|IV methylprednisolone|1000 mg/qd/5 days
62477516|NCT04510597|ACTIVE_COMPARATOR|Arm 1: Continued Systemic Therapy Only|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
61922931|NCT03639571|PLACEBO_COMPARATOR|Placebo|Placebo TEPI Plaster
62123207|NCT00827346|ACTIVE_COMPARATOR|Group 1|600-mg double dose
62312689|NCT01803802|ACTIVE_COMPARATOR|Trauma writing|Expressive writing prompts oriented towards processing traumatic experiences
62312690|NCT04133753|EXPERIMENTAL|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
62312691|NCT04133753|NO_INTERVENTION|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
62312692|NCT02714946|ACTIVE_COMPARATOR|LA Arm|Percutaneous Laser Ablation
62312693|NCT02714946|ACTIVE_COMPARATOR|RFA Arm|Percutaneous Radiofrequency Ablation
61922932|NCT03095274|EXPERIMENTAL|Durvalumab|"Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) for 12 months in patients ≥ 30kg.~Weight-based dosing should be used for patients \<30 kg: durvalumab 20 mg/kg."
61922933|NCT03095274|EXPERIMENTAL|Tremelimumab|"Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients ≥ 30kg.~Weight-based dosing should be used for patients \<30 kg: tremelimumab 1 mg/kg Q4."
61922934|NCT05265377|EXPERIMENTAL|STELO Exoskeleton|3 treatment sessions will be performed with the Stelo exoskeleton.
62123208|NCT00827346|ACTIVE_COMPARATOR|Group 2|600/600-mg double loading dose (first dose 600 mg given immediately upon arrival at the hospital and the second dose 600 mg, 3 hours after the first loading dose for a total of 900 mg
62123209|NCT00827346|ACTIVE_COMPARATOR|Group 3|Clopidogrel 900mg
62312694|NCT02556086|EXPERIMENTAL|Daclatasvir + Sofosbuvir|Daclatasvir 30, 60, 90 mg tablet (dose is dependent on cART regimen) + Sofosbuvir 400 mg tablet oral dosing once daily for 8 weeks
62312695|NCT02224846|EXPERIMENTAL|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
62312696|NCT02224846|EXPERIMENTAL|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
62312697|NCT04498910|EXPERIMENTAL|1500 milligrams (mg) LY3451838|Participants received a single intravenous (IV) dose of 1500 mg LY3451838.
62312698|NCT04498910|PLACEBO_COMPARATOR|Placebo|Participants received a single IV dose of placebo.
61922935|NCT03663738|ACTIVE_COMPARATOR|health mobile app for T2DM patients|It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
61922936|NCT03663738|NO_INTERVENTION|Control|Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)
61922937|NCT02755688|EXPERIMENTAL|Thoracoscopic surgical ablation|Pulmonary vein isolation, ganglionic plexi ablation, left atrial appendage exclusion
61922938|NCT02755688|ACTIVE_COMPARATOR|Catheter ablation|Pulmonary vein isolation, linear lines
61922939|NCT02808572|EXPERIMENTAL|Cardiovascular risk evaluation|Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
61922940|NCT01609101|OTHER|Coopdech® videolaryngoscope|
62312699|NCT02135640|EXPERIMENTAL|denosumab 60 mg|solution
62312700|NCT02135640|EXPERIMENTAL|denosumab 120 mg|solution
62312701|NCT02135640|PLACEBO_COMPARATOR|placebo|solution
62312702|NCT06403345|EXPERIMENTAL|Single arm pre/post study|"GAP-H 12-week Intervention for People Living with Memory Loss \& Study Partners involves an OT evaluation, goal-setting, coaching and strategy training over 4-8 in-person sessions for 30-90 minutes each over 12 weeks, with 2 phone or virtual check-ins for 15-30 minutes.~GAP-H Intervention Outdoor Activity Professionals involves a site-evaluation (Accessibility, Fall risk) and education on Dementia Training, SMART Goal setting, Strategy Training for Tailoring Nature Activities, and Behavioral Activation strategies with support from the OT."
62312703|NCT03388125|ACTIVE_COMPARATOR|Injection Sclerotherapy|5% ethano lamine oleate
62312704|NCT03388125|ACTIVE_COMPARATOR|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
62312705|NCT05870007|NO_INTERVENTION|Control group|Standard treatment alone
61922941|NCT01609101|OTHER|C-MAC® videolaryngoscope|
61922942|NCT01609101|OTHER|McGrath® Series 5 videolaryngoscope|
61922943|NCT01609101|OTHER|Glidescope® Cobalt videolaryngoscope|
61922944|NCT01609101|OTHER|King Vision® videolaryngoscope|
61922945|NCT01609101|OTHER|Venner® videolaryngoscope|
61922946|NCT01609101|OTHER|McGrath MAC® videolaryngoscope|
61922947|NCT03007901|EXPERIMENTAL|Pilot Cohort 1|This Pilot Study will be conducted to allow us to evaluate and test the various study processes, including: consent/enrollment, run-in-trial monitoring, measurement tools, outcome assessment, educational materials, and especially the mindfulness-based climate action trainings. The pilot study does not include a control group, and data will not be used for efficacy outcome analysis.
61922948|NCT00941382|EXPERIMENTAL|Sibutramin-Metformin|Sibutramine-metformin therapy in a single tablet
61922949|NCT00941382|ACTIVE_COMPARATOR|Sibutramine|Sibutramine monotherapy
61922950|NCT00941382|ACTIVE_COMPARATOR|Metformin|Metformin monotherapy
61922951|NCT00515710||1|Prior gene therapy study subjects receiving AAV2-hFIX16.
61922952|NCT04539145|EXPERIMENTAL|Chocolate PTA balloon|
61922953|NCT04539145|OTHER|POBA|Intervention with regular baloon
62139671|NCT01450163|ACTIVE_COMPARATOR|Pregabalin|
62139672|NCT01450163|PLACEBO_COMPARATOR|Placebo|
62312706|NCT05870007|ACTIVE_COMPARATOR|Atorvastatin|Standard treatment + Atorvastatin 20mg QD
62312707|NCT05870007|ACTIVE_COMPARATOR|Atorvastatin AND Alkali|Standard treatment + Atorvastatin 20mg QD + Sodium Bicarbonate therapy up to 1800mg per day
62312708|NCT02267577|EXPERIMENTAL|Healthy Adults Volunteers|Men and women over the age of 18 will have their blood pressure measured with both the Sphygmo: Automatic Blood Pressure Monitor device and the GE Dinamap ProCare automatic blood pressure monitor.
61922954|NCT02889562|ACTIVE_COMPARATOR|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
62123210|NCT00827346|ACTIVE_COMPARATOR|Group 4|First dose 600 mg given immediately upon arrival at the hospital and the second dose 300 mg, 3 hours after the first loading dose for a total of 900 mg
62312709|NCT00785746|EXPERIMENTAL|core|strength training of the core muscles.
62312710|NCT00785746|NO_INTERVENTION|stretch and strength|This program consists of general stretching exercises and peripheral muscle strengthening exercises with a special emphasis on strengthening the upper extremity muscles because of their importance for ADL but not necessarily balance.
62123211|NCT04505982||Tocilizumab intravenous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, intravenous
62123212|NCT04505982||Tocilizumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, subcutaneous
62123213|NCT04505982||Sarilumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with sarilumab, subcutaneous
62139673|NCT05869331|EXPERIMENTAL|Nonoperative treatment|Patients in this group were treated with early mobilization.
62139674|NCT05869331|ACTIVE_COMPARATOR|Operative treatment|Patients in this group were treated surgically.
62312711|NCT04556604||1|First cycle of the audit on consenting practice pre intervention
62312712|NCT04556604||2|Second cycle of the audit on consenting practice to assess change following intervention
62312713|NCT04556604||3|Third cycle of the audit on consenting practice to assess long term compliance
62312714|NCT00218244|ACTIVE_COMPARATOR|1 Controlled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under a controlled use condition.
62312715|NCT00218244|ACTIVE_COMPARATOR|2 Uncontrolled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under an uncontrolled use condition.
62312716|NCT00218244|PLACEBO_COMPARATOR|3 Behavioral|Reduction in smokeless tobacco use using behavioral techniques only.
62312717|NCT06530849|EXPERIMENTAL|GC012F Injection|GC012F Injection ，Tentatively (7.0\~200.0) ×10\^6 CAR-T cells/50 mL/bag.
62477517|NCT04510597|EXPERIMENTAL|Arm 2: Nephrectomy and Continued Systemic Therapy|"Continued systemic therapy as above, plus:~Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization."
62477518|NCT03825328|EXPERIMENTAL|Chemotherapy|Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles
62477519|NCT02300103|EXPERIMENTAL|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
62477520|NCT01855750|PLACEBO_COMPARATOR|Treatment Arm A: placebo + R-CHOP|Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
62477521|NCT01855750|EXPERIMENTAL|Treatment Arm B: ibrutinib + R-CHOP|Treatment Arm B = ibrutinib + R-CHOP
62477522|NCT04994847||APOE Unimpaired Observational Trial|300 participants who are cognitively unimpaired; Yearly procedures: blood draw Every Two Year Procedures: cognitive and clinical assessments, CSF collection, MRI, and Tau and Amyloid PET scans
62477523|NCT06562348|ACTIVE_COMPARATOR|A: Standard of care|Response evaluation using imaging-based RECIST according to standard guidelines.
62477524|NCT06562348|EXPERIMENTAL|ctDNA-RECIST guided therapy approach|Response evaluation will be performed using ctDNA-RECIST instead of imaging.
62312718|NCT04579393|ACTIVE_COMPARATOR|Intervention|fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19
62312719|NCT04579393|PLACEBO_COMPARATOR|Intervention - Placebo|Placebo in combination with standard of care (SOC) for the treatment of COVID-19
62312720|NCT05187195|EXPERIMENTAL|Telerehabilitation-video group|This group will perform their exercises with prepared personalized exercise videos through the telerehabilitation system 3 days a week for 8 weeks.
61922955|NCT02889562|ACTIVE_COMPARATOR|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
62123214|NCT03403998|EXPERIMENTAL|Exercises|Neck flexors Training: Each patient will initially perform cranio-cervical flexion to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the contraction duration will be increased to 10 s, and the participant trained to perform 10 repetitions with brief rest periods between each contraction. Once one set of 10 repetitions of 10 s is achieved at one target level, the exercise will be progressed to train at the next target level up to the final target. Neck extensors training: Patients will perform cranio-cervical extension and upper cervical rotation in a prone on elbows position while maintaining the cervical spine in a neutral position, progressing to a 4-pt kneeling position.
62139675|NCT04030585|EXPERIMENTAL|robot-assisted exercise|Robot-assisted exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
62312721|NCT05187195|EXPERIMENTAL|Telerehabilitation-brochure group|This group will perform exercises with personalized exercise brochures defined through the telerehabilitation system 3 days a week for 8 weeks.
62477525|NCT05618587|EXPERIMENTAL|Lithium|Lithium 10mg po qd
62477526|NCT05618587|PLACEBO_COMPARATOR|Placebo|Placebo identically matching the lithium pills
62477527|NCT02724605|OTHER|Group A|Red blood cells unit age 14 days or less
62477528|NCT02724605|OTHER|Group B|Red blood cells unit age more than 14 days
62477529|NCT02576938|EXPERIMENTAL|Baricitinib|"Administered once daily in multiple oral dose cohorts for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
62477530|NCT02576938|PLACEBO_COMPARATOR|Placebo|"Administered orally once daily, for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
62477531|NCT00954590|EXPERIMENTAL|Dimebon (latrepirdine)|Dimebon, 20 mg orally three times daily
62477532|NCT00954590|PLACEBO_COMPARATOR|Placebo|Placebo orally three times daily
62477533|NCT04482465|OTHER|pilot study 1 arm|50 subjects with no AMD or early AMD, aged over 55, at moderate-to-high risk for AMD based on a simplified AMD risk assessment scale score \> or = 10, not taking vitamin D or trace nutriënt containing supplements
62683366|NCT04775758|EXPERIMENTAL|Atypical facial pain group|Patients with clinally diagnosed G50.1 - atypical pain condition after all necessary diagnostic measures are taken to exclude a clear organic pathology (multiple diagnostic tests including MRI, CT and consultations from other specialists). Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
62683367|NCT04775758|ACTIVE_COMPARATOR|Maxillofacial fracture pain group|Patients with maxillofacial fracture (S02.3, S02.4, S02.6.) will be subjected into control group. Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
62683368|NCT06269107|EXPERIMENTAL|IcoSema|Participants will receive once weekly IcoSema subcutaneously with or without oral anti diabetic drugs for 40 weeks.
62683369|NCT06269107|EXPERIMENTAL|Insulin glargine|Participants will receive once daily insulin glargine subcutaneously with or without oral anti diabetic drugs for 40 weeks.
62683370|NCT05930444||Normal participants|Healthy individuals who have no concerns related to their eyes.
62683371|NCT05930444||Patients with Eye-related Chief Complaints|Individuals who have specific concerns or issues related to their eyes, which they consider as the main reason for seeking medical attention or making a complaint.
62123215|NCT03403998|PLACEBO_COMPARATOR|Placebo|"The placebo group will receive placebo TENS (switched-off TENS apparatus with no perceptible stimulation). Four electrodes, 50 x 35 mm, will be placed on the neck muscles. The participant will be informed that this therapy is called a subthreshold current and they might not be able to feel any sensation underneath the electrodes during the treatment. The placebo treatment will be for 30 min twice a week for 8 weeks, as for the intervention group."
62312722|NCT06211283|EXPERIMENTAL|Treatment A, Orfiril long, 500 mg prolonged release minitablets|fasting
62683372|NCT05751811|EXPERIMENTAL|Virtual reality group|Participants under Virtual reality group will wear a virtual reality headset with immersive video content during the whole hysteroscopy.
62683373|NCT05751811|EXPERIMENTAL|Music therapy group|Participants under Music therapy group will wear a headphone playing music during the whole hysteroscopy.
62683374|NCT05751811|NO_INTERVENTION|Control group|Participants under Control group will proceed with hysteroscopy as usual practise.
62312723|NCT06211283|EXPERIMENTAL|Treatment B, Orfiril long, 500 mg prolonged release minitablets|fed
62312724|NCT06211283|ACTIVE_COMPARATOR|Treatment C, Ergenyl chrono 500 mg prolonged release tablets|fasting
62683375|NCT02853084|EXPERIMENTAL|HL2351|
62683376|NCT03093246|PLACEBO_COMPARATOR|Control group|In this group (n = 19), patients will take placebo pills and full-mouth ultrasonic debridement will be performed to treat diseased sites.
62683377|NCT03093246|EXPERIMENTAL|Test Group|In this group (n = 19), patients will take 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
62683378|NCT04126174|ACTIVE_COMPARATOR|Femtosecond limbal relaxing incision (LRI)|Eyes will be treated with arcuate incisions from a femtosecond laser system.
62312725|NCT06211283|ACTIVE_COMPARATOR|Treatment D, Ergenyl chrono 500 mg prolonged release tablets|fed
62312726|NCT02021812|EXPERIMENTAL|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
62312727|NCT05420012|EXPERIMENTAL|Vericiguat|Study drug
62312728|NCT05420012|PLACEBO_COMPARATOR|Placebo|Placebo
61922956|NCT04863209|EXPERIMENTAL|Upper cervical manipulation group|The patient will be in the supine position. The cephalic hand will make contact with one side of the patient's skull, leaving the sternocleidomastoid muscle between the third and fourth fingers. The caudal hand will make global contact with the patient's skull on the opposite side. The therapist should place his torso on the patient's head, leaving the two forearms aligned with the axis of the patient's spine, as this technique is applied to the axis of the odontoid process of the ax. With neutral flexion-extension the therapist will place the rotation parameter to the opposite side (70-80 degrees) and a small contralateral inclination. Then it will search for the driving barrier with a small axial traction movement. When the driving barrier is found, the thrust should be applied in a helical direction, increasing rotation and traction. It will be applied bilaterally.
61922957|NCT04863209|EXPERIMENTAL|Sphenopalatine ganglion group|The patient will be supine on the bench and the therapist with gloves will sit next to the patient contralateral to the manipulated sphenopalatine ganglion (SPG). One of the therapist's hands will be placed flat in contact with the apex of the patient's head to stabilize it. The patient will be instructed to open his mouth and deviate the mandible laterally to the same side of the ganglion to be treated. The therapist will then apply pressure to the SPG with the fifth finger of your other hand in the patient's mouth, moving up along the alveolar process of the maxilla teeth to reach the pterygoid process. The therapist will keep the patient's head elevated until the lateral pterygoid muscle relaxes. Then, the pressure will be applied into the pterygopalatine fossa. The therapist will then apply gentle pressure on the SPG with the pulp of the fifth finger until tissue relaxation. He will then release the contralateral SPG in the same way.
61922958|NCT04863209|NO_INTERVENTION|Control Group|The patient will lie down on the bench for 10 minutes.
61922959|NCT01504061|EXPERIMENTAL|Mederma Ultra Gel|
61922960|NCT01504061|ACTIVE_COMPARATOR|Mederma N&I|
61922961|NCT05458726|EXPERIMENTAL|Osimertinib|Osimertinib 80mg po daily
61922962|NCT05458726|SHAM_COMPARATOR|Other treatments|chemotherapy or continuation of TKI monotherapy or in combination of anti-angiogenic agents
61922963|NCT01273376|EXPERIMENTAL|RX-10100 high dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
61922964|NCT01273376|EXPERIMENTAL|RX-10100 low dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
61922965|NCT01273376|PLACEBO_COMPARATOR|Placebo|Matching placebo is to be given orally, in tablet form, twice daily, for 8 weeks
61922966|NCT01807832|OTHER|chronic cough|Capsaicine challenge in chronic cough patients
61922967|NCT01854931|OTHER|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
61922968|NCT02721979|EXPERIMENTAL|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
61922969|NCT00057122|ACTIVE_COMPARATOR|1|
61922970|NCT00057122|ACTIVE_COMPARATOR|2|
61922971|NCT00057122|ACTIVE_COMPARATOR|3|
61922972|NCT00057122|ACTIVE_COMPARATOR|4|
61922973|NCT05791370|EXPERIMENTAL|Red palm olein|Meals enriched with Red palm olein
61922974|NCT05791370|EXPERIMENTAL|Extra virgin coconut oil|Meals enriched with Extra virgin coconut oil
61922975|NCT05791370|EXPERIMENTAL|Extra virgin olive oil|Meals enriched with Extra virgin olive oil
62312729|NCT06125795||Chronic Lymphocytic Leukemia (CLL) Participants|Participants will receive oral treatments for CLL in accordance with approved local label.
61922976|NCT03049527|EXPERIMENTAL|Education, Incentives and Feedback|Education, Incentives and Feedback are all directed to all study participants.
61922977|NCT04807478||Pediatric patients|Pediatric patients with new-onset PNAC
61922978|NCT01322308|PLACEBO_COMPARATOR|sugar pill|tablet similar to comparator
62477534|NCT03031184|EXPERIMENTAL|Mirtazapine|15mg of Mirtazapine over encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
62477535|NCT03031184|PLACEBO_COMPARATOR|Placebo|Lactose powder encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
62312730|NCT05424692|EXPERIMENTAL|PTC test group|The adjuvant chemotherapy scheme was selected according to the 3D drug sensitivity test results of micro tumor (PTC) in vitro
62477536|NCT06544200|EXPERIMENTAL|Polymeric Hydrogel Matrix|single application of Polymeric Hydrogel Matrix at the completion of lung resection, in patients with moderate intraoperative alveolar air leaks (30-60 ml/respiratory act), measured at the Ventilation Mechanical Test, which consists in 1 minute volumetric ventilation with a constant flow and a peak pressure of 22 cmH2O, 12 respiratory rates per minute and a positive end-expiratory pressure (PEEP) of 5 cmH2O.
62123216|NCT04616911|ACTIVE_COMPARATOR|Rerouting seton|Placement of seton with rerouting of the fistula tract around the internal anal sphincter
62312731|NCT05424692|NO_INTERVENTION|control group|Making adjuvant chemotherapy strategy based on clinical experience
62477537|NCT06544200|NO_INTERVENTION|Control Group|no further treatment at the completion of lung resection, in patients with moderate intraoperative alveolar air leaks (30-60 ml/respiratory act), measured at the Ventilation Mechanical Test, which consists in 1 minute volumetric ventilation with a constant flow and a peak pressure of 22 cmH2O, 12 respiratory rates per minute and a positive end-expiratory pressure (PEEP) of 5 cmH2O.
62477538|NCT04814095|EXPERIMENTAL|Targeted therapy|
61922979|NCT01322308|ACTIVE_COMPARATOR|pioglitazone|30 mg tablets QD (taken once daily)
62312732|NCT01895010|EXPERIMENTAL|Acupoint and tropisetron|acupoint electric stimulation combined with tropisetron 6mg before TACE
61922980|NCT01268371|ACTIVE_COMPARATOR|Promus Element|Everolimus-eluting stent
61922981|NCT01268371|ACTIVE_COMPARATOR|Nobori|Biolimus-eluting stent with biodegradable polymer
61922982|NCT00745576|EXPERIMENTAL|1|
62477539|NCT05253443|EXPERIMENTAL|Mentalizing Imagery Therapy and caregiver skills mobile application|
62477540|NCT05253443|ACTIVE_COMPARATOR|Caregiver skills mobile application|
62477541|NCT04710758|EXPERIMENTAL|Laparoscopic total gastrectomy|The surgeon will perform LTG with D2 lymphadenectomy for patients enrolled in this group.
61922983|NCT00622076|ACTIVE_COMPARATOR|1|postoperative catheterization after anterior colporrhaphy during five days.
61922984|NCT00622076|ACTIVE_COMPARATOR|2.|postoperative catheterization after anterior colporrhaphy during two days
61922985|NCT00773383|EXPERIMENTAL|1|
62123217|NCT04616911|ACTIVE_COMPARATOR|LIFT|Ligation of the intersphincteric fistula tract
62312733|NCT01895010|ACTIVE_COMPARATOR|tropisetron|treated with tropisetron 6mg before TACE
62312734|NCT04083222|PLACEBO_COMPARATOR|Placebo|Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
62312735|NCT04083222|EXPERIMENTAL|ISIS 757456|Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
62477542|NCT04710758|ACTIVE_COMPARATOR|Open total gastrectomy|The surgeon will perform OTG with D2 lymphadenectomy for patients enrolled in this group.
62477543|NCT06167694|EXPERIMENTAL|Treatment group A|
62312736|NCT04916197|EXPERIMENTAL|Intervention group|Dexmedetomidine 0.1\~1.0 μg/kg/h for 24h after patients finished endovascular thrombectomy and returned to ICU. Maintain Ramsay score 2-3.
62312737|NCT04916197|PLACEBO_COMPARATOR|Control group|An equal dose of saline 24h after patients finished endovascular thrombectomy and returned to ICU. If the Ramsay sedation score is 1, propofol will be administrated to maintain the Ramsay sedation score at 2 to 3.
62477544|NCT01566617|OTHER|Standard Care|(1) group who will receive standard care
62477545|NCT01566617|OTHER|Standard Care and Pharmaceutical Care|(2) group who will receive standard care and pharmaceutical care
62123218|NCT04928703|EXPERIMENTAL|Arm 1|Visit 2: Placebo - Placebo; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Ketamine
62123219|NCT04928703|EXPERIMENTAL|Arm 2|Visit 2: Placebo - Ketamine; Visit 3: Placebo - Placebo; Visit 4: Placebo - Ketamine
62123220|NCT04928703|EXPERIMENTAL|Arm 3|Visit 2: Placebo - Ketamine; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Placebo
62123221|NCT05789485|EXPERIMENTAL|90 min/wk|AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
62123222|NCT05789485|EXPERIMENTAL|150 mins/wk|AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
62312738|NCT04297163|ACTIVE_COMPARATOR|Hospital management|Patient's receive no intervention, the follow up is the usual for a patient following CPAP therapy.
62312739|NCT04297163|EXPERIMENTAL|Telemedicine management|CPAP remote monitoring of patients, including a mobile application and a voicemail.
62312740|NCT06469658|ACTIVE_COMPARATOR|Group 1|
62312741|NCT06469658|EXPERIMENTAL|Group 2|
62312742|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on warfarin|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used warfarin as a secondary stroke/TIA prevention.
62312743|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on apixaban|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used apixaban as a secondary stroke/TIA prevention.
62312744|NCT01410019|EXPERIMENTAL|1|Gene transfer
62312745|NCT02291380|ACTIVE_COMPARATOR|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose, dextran and gelatin.
62312746|NCT02291380|PLACEBO_COMPARATOR|Placebo|The placebo does not include botulinum toxin A ,but includes sucrose, dextran and gelatin.
62312747|NCT03044665|ACTIVE_COMPARATOR|High-intensity statin monotherapy|Statin monotherapy
62477546|NCT02111239|NO_INTERVENTION|No imaging|No preoperative imaging is performed for this group
62477547|NCT02111239|EXPERIMENTAL|CTA|Patients randomized to this group will undergo a preoperative CTA scan.
62477548|NCT02111239|EXPERIMENTAL|MRA|Patients randomized to this group will undergo a preoperative MRA scan.
62477549|NCT05950035|EXPERIMENTAL|Immediate Intervention|Will begin treatment within 2 weeks of randomization.
62477550|NCT05950035|ACTIVE_COMPARATOR|Delayed Intervention|Will be scheduled to begin treatment within 4-6 weeks of randomization.
62139676|NCT04030585|ACTIVE_COMPARATOR|Home exercise|Home exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
62312748|NCT03044665|EXPERIMENTAL|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
62312749|NCT05294848|EXPERIMENTAL|Gaze-Contingent Feedback Training (toward threat)|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
62477551|NCT00745420|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Bone Marrow Transplant with GVHD Prophylaxis Regimen
62477552|NCT06180980|EXPERIMENTAL|Pirtobrutinib (Fasting condition)|A single oral dose of pirtobrutinib will be administered under fasted conditions.
62477553|NCT06180980|EXPERIMENTAL|Pirtobrutinib (High-fat breakfast)|"A single oral dose of pirtobrutinib will be administered under fed conditions.~There will be a washout period of 7 days between fasted and fed conditions."
62683379|NCT04126174|ACTIVE_COMPARATOR|Manual LRI|Eyes will be treated with arcuate incisions completed manually with a blade.
62683380|NCT05571696|ACTIVE_COMPARATOR|Intervention Group|Assigned to Immune Strength program
62312750|NCT05294848|ACTIVE_COMPARATOR|RT-Based Attention Bias Modification (toward threat)|"A dot-probe task of 160 trials. Trials begins with a fixation cross (+), on which the participant is asked to focus (500ms). Then two face stimuli (one angry one neutral) are presented above and below the fixation cross (500ms). After the stimuli disappear, a target probe (right- or left-pointing arrowhead) appears in place of one of the face stimuli. The participant is asked to indicate which target probe was presented using a predetermined key. The target probe will remain on the screen until response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the threat location (angry face). Thus, over multiple trials, learning is expected to occurs such that the threatening face predicts the location of the target probe, thereby achieving the desired change in attention pattern."
62312751|NCT05294848|PLACEBO_COMPARATOR|Neutral Control|This condition is also based on the dot-probe task (see Active Comparator) with a fundamental difference. In this task, only neutral faces will be displayed, and therefore, while participants are exposed to the same task parameters, there will be no attention training and there will be no exposure to threat stimuli.
62312752|NCT04886830||Appendectomy performed with single endoloop to appendiceal stump|Appendectomy performed with single endoloop for closure of appendiceal stump
62312753|NCT04886830||Appendectomy performed with two endoloops to appendiceal stump|Appendectomy performed with two endoloops for closure of appendiceal stump
62312754|NCT04886830||Appendectomy performed with a clip to appendiceal stump|Appendectomy performed with a clip for closure of appendiceal stump
62312755|NCT04021862|EXPERIMENTAL|Treatment Arm 1 (bermekimab every week)|"Loading Dose: 400 mg subcutaneous (SC) injection of bermekimab and a SC injection of matching placebo at week 0 (Baseline).~Treatment Dose: 400 mg subcutaneous injection of bermekimab administered weekly (qw) from week 1 through Week 31."
61922986|NCT06271655|EXPERIMENTAL|SPOTFIRE Arm|The intervention involves the use of a rapid point-of-care multiplex PCR test to identify viral etiology in patients with acute respiratory illness. This approach aims to provide timely and accurate diagnostic information to guide treatment decisions. Specimen samples will be collected by research staff at the time of ED presentation by NPAAS. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. In this trial, all providers will view Spotfire results before prescribing antibiotics ; failure to so so will be a protocol violation.
61922987|NCT02895633|EXPERIMENTAL|Patients with bone or peripheral soft-tissue tumor|
61922988|NCT03739840|EXPERIMENTAL|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
61922989|NCT03739840|EXPERIMENTAL|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
62123223|NCT05789485|EXPERIMENTAL|300 mins/wk|AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
62683381|NCT05571696|ACTIVE_COMPARATOR|Control Group|Assigned to 12 week waitlist, receiving usual care. Study participants assigned to the wait list will receive access to Immune Strength 12 weeks after study commencement.
62123224|NCT04594798|EXPERIMENTAL|Experimental: Polatuzumab Vedotin and R-CHOP|The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)
62312756|NCT04021862|EXPERIMENTAL|Treatment Arm 2 (bermekimab every other week)|"Loading Dose: 800 mg SC injection of bermekimab at week 0 (Baseline).~Treatment Dose: 400 mg SC injection of bermekimab administered every other week (q2w) alternating with matching placebo q2w through Week 31."
62312757|NCT04021862|PLACEBO_COMPARATOR|Placebo|"Loading Dose: Placebo matching to bermekimab (4 milliliters \[mL\]) SC injection at Week 0, (Baseline).~Treatment Dose: SC injection of matching placebo administered once weekly (qw) from week 1 to week 15 during placebo-controlled period. After completion of placebo-controlled period, participants will cross-over and receive bermekimab 400 mg SC injection qw at Week 16 through Week 31."
62312758|NCT05810779|EXPERIMENTAL|dynamic surface exercise with conventional therapy|the experimental group undergo conventional physical therapy and additional dynamic surface exercise training thrice a week for 2 months dynamic surface training will include gym balls , bolster or platform swing
62312759|NCT05810779|ACTIVE_COMPARATOR|trunk targeted training with conventional therapy|the group will receive conventional physical therapy and additional trunk targeted training thrice a week for 2 months.
62477554|NCT03113708|SHAM_COMPARATOR|Heparinisation,actual body weight|In 'Heparinisation,actual body weight' group , heparin sodium; will be done according to actual body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
62139677|NCT06510881|EXPERIMENTAL|Group A|Patients at or above age of 8 years for combined rhinoplasty and alveolar repair
62683382|NCT05217446|EXPERIMENTAL|Arm A: encorafenib, cetuximab and pembrolizumab|Participants receive encorafenib orally + cetuximab IV + pembrolizumab IV.
62683383|NCT05217446|ACTIVE_COMPARATOR|Arm B: pembrolizumab|Participants receive pembrolizumab IV.
62477555|NCT03113708|EXPERIMENTAL|Heparinisation, lean body weight|In 'Heparinisation, lean body weight' group heparin sodium will be done according to lean body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
61922990|NCT03739840|EXPERIMENTAL|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
61922991|NCT03739840|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo group will receive a combination of several placebo tablets to maintain the blinding.
62123225|NCT03185338|EXPERIMENTAL|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
62123226|NCT03185338|EXPERIMENTAL|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
62123227|NCT03185338|EXPERIMENTAL|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
62683384|NCT04635033||Intervention|2 hours of reduced FiO2 (11-15%) in the inspired air, 2-3x/week, 3 months
62139678|NCT06510881|EXPERIMENTAL|Group B|patients below 8 years for rhinoplasty alone and a planned alveolar repair in an upcoming session before canine eruption .
62139679|NCT05247437|EXPERIMENTAL|FitD full version|
62139680|NCT05247437|ACTIVE_COMPARATOR|Digital Self-Help|
62477556|NCT01568762|EXPERIMENTAL|VAK694|VAK694 was administered as a 1 hour intravenous infusion
61922992|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
62312760|NCT04044638|EXPERIMENTAL|Young Group|"Young women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
62477557|NCT01568762|PLACEBO_COMPARATOR|VAK694 Placebo|VAK694 placebo was administered as a one hour intravenous infusion
62123228|NCT03185338|EXPERIMENTAL|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
62123229|NCT03185338|EXPERIMENTAL|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
62123230|NCT03185338|NO_INTERVENTION|Control school|Control school will be evaluate but will not receive any intervention
62683385|NCT00101400|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
62683386|NCT06670677||ARM 1 G1 Aktiia users Android|Research participants are Aktiia G1 users with Android operating system, i.e. individuals who already purchased the Aktiia G1 device out of the context of the study, located in Switzerland, Germany or UK, and owning a smartphone with Android operating system.
62683387|NCT06670677||ARM 2 G1 AKTIIA users iOS|Research participants are Aktiia G1 users with iOS operating system, i.e. individuals who already purchased the Aktiia G1 device out of the context of the study, located in Switzerland, Germany or UK, and owning a smartphone with iOS operating system.
62683388|NCT06670677||ARM 3 non-Aktiia-G1-users Android & iOS|Research participants are non-Aktiia-G1 users (they do not own an Aktiia G1 device at their inclusion in the study), located in Switzerland, Germany or UK, and owning a smartphone with either iOS or Android operating system.
61922993|NCT06427915|EXPERIMENTAL|Soda consumption in fasted state|One 12oz serving of soda consumed alone after a 4 hour fasting period
61922994|NCT06427915|EXPERIMENTAL|Soda consumption with a defined carbohydrate rich meal|One 12oz serving of soda consumed with a defined carbohydrate rich meal after a 4 hour fasting period
61922995|NCT05390190|EXPERIMENTAL|Non ablative radiofrequency|Device
62123231|NCT01291615|EXPERIMENTAL|Gemcitabine group|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
62312761|NCT04044638|EXPERIMENTAL|Middle-aged Group|"Middle-aged women women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
62312762|NCT05738512|ACTIVE_COMPARATOR|Medial Flap Coblation Turbinoplasty|
62312763|NCT05738512|ACTIVE_COMPARATOR|Submucous Resection|
62123232|NCT01291615|EXPERIMENTAL|S-1 group|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks
62312764|NCT01471873||Keratoconus Group (KG)|Keratoconus group (KG) included patients with progressive keratoconus.
62477558|NCT01568762|EXPERIMENTAL|QAX576|QAX576 was administered intravenously as a 2 hour infusion
62477559|NCT01568762|PLACEBO_COMPARATOR|QAX576 placebo|QAX576 placebo was administered as a 2 hour intravenous infusion
62477560|NCT04306952|EXPERIMENTAL|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat.
62683389|NCT04803604|EXPERIMENTAL|Basic social support + communication + Ottawa guide + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
62683390|NCT04803604|EXPERIMENTAL|Basic social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6 months
62683391|NCT04803604|EXPERIMENTAL|Basic social support + communication + 1 monthly follow up call|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
61922996|NCT02548468|EXPERIMENTAL|Reduced Intensity Conditioning, DLI, PBSCT|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
62683392|NCT04803604|EXPERIMENTAL|Basic social support + communication + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
62683393|NCT04803604|EXPERIMENTAL|Basic social support + Ottawa guide + 1 monthly follow up call|2 in-person/telephone weekly sessions on 1 coaching session on providing social support, decision support tools, and a single monthly follow-up call
61922997|NCT05715801|EXPERIMENTAL|hyperbaric oxygen therapy|Ten sessions of hyperbaric oxygen therapy were completed within 4 weeks of enrollment.
61922998|NCT05715801|ACTIVE_COMPARATOR|conventional oxygen therapy|Ten sessions of conventional oxygen therapy were completed within 4 weeks after enrollment.
61922999|NCT02633852|EXPERIMENTAL|Aflibercept (EYLEA) 2mg /0.05 ml|Aflibercept (EYLEA) 2mg /0.05 ml
61923000|NCT00582283|OTHER|Diagnostic: iodine I-124 NM404 CT/PET scan|Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
62123233|NCT03816228||Experimental Flortaucipir|Participants will receive a single intravenous bolus injection of flortaucipir along with PET imaging.
62312765|NCT01471873||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
62312766|NCT02421380|EXPERIMENTAL|Hyperpolarized Pyruvate MRI Reproducibility|This is a reproducibility study of hyperpolarized \[1-13C\] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.
62683394|NCT04803604|EXPERIMENTAL|Basic social support + Ottawa guide + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
62683395|NCT04803604|EXPERIMENTAL|Basic social support + 1 monthly follow up call|1 in-person/telephone weekly sessions on providing social support and a single monthly follow-up call
62123234|NCT03843021||VAD Healthcare Providers|Adult healthcare providers of VAD therapy recipients.
62123235|NCT00970359|EXPERIMENTAL|pts with thyroid cancer with and without BRAF mutation|Patients receive selumetinib orally (PO) twice daily (BID) for 4 weeks. Within 1 month, patients with adequate RAI uptake may receive 131I per standard of care and continue selumetinib until 2 days following 131I.
62123236|NCT05415449||No groups|"Identify eligible patients--Informed Consent--Provide education and two protective wearable device--Demographic data (electronic health record)--Interview parent on device--Every month complete 30-day satisfaction survey for a total of three data collection period-Discharge from study.~Nurse data collection scheme: Study participants hospitalized at time of enrollment in study or anytime during the study period. Nurse of patients using device will complete satisfaction survey."
62123237|NCT02807493|EXPERIMENTAL|Occlusal Support Device|Support device for women in labor
62123238|NCT02807493|PLACEBO_COMPARATOR|Control|No device given for women in labor
62139681|NCT05609149||T3 Rectal cancer|Patients with T3 rectal cancer who underwent curative surgery.
62139682|NCT03828968|OTHER|Bladder scan|Bladder scan performed on resident in homes for aged
62312767|NCT03078101|EXPERIMENTAL|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG \[Jardiance\]
62312768|NCT03078101|PLACEBO_COMPARATOR|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
62312769|NCT03078101|EXPERIMENTAL|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG \[Jardiance\]
62312770|NCT03078101|PLACEBO_COMPARATOR|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
62312771|NCT02280005|EXPERIMENTAL|WAK Treatment|Use of experimental device.
62312772|NCT04174157||Prospective observational registry|This is a prospective, multi center, multinational, non-interventional observational registry.
62312773|NCT02117050|EXPERIMENTAL|Rebif® via Rebidose® auto-injector|
61923001|NCT04896775|EXPERIMENTAL|NiteCAPP CARES|Cognitive Behavioral Treatment-Insomnia. Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
61923002|NCT04896775|EXPERIMENTAL|NiteCAPP SHARES|Sleep Hygiene and Related Education. Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
61923003|NCT03850288||Anorexia Nervosa|"Patients with a diagnosis of anorexia nervosa (According to the DSM-V criteria). These patients are characterized by a restriction of food intake leading to weight loss or a failure to gain weight resulting in a significantly low body weight of what would be expected for someone's age, sex and height. Moreover, there is a fear of becoming fat or of gaining weight.Then, these patients have a distorted view of themselves and of their condition."
62312774|NCT02012972||NCD Risks|Study subjects with NCD risks or disease at enrollment. Each of these subjects will have a Referral for NCD care
62312775|NCT02012972||No NCD Risks|Study subjects without NCD risks or disease at enrollment.
62683396|NCT04803604|EXPERIMENTAL|Basic social support + monthly follow up calls for 24 weeks|1 in-person/telephone weekly sessions on providing social support and monthly follow-up calls for 6 months
62123239|NCT04567355|EXPERIMENTAL|Migraine Manager|The Migraine Manager portal intervention is comprised of 16 modules that are assigned in an individually tailored manner to participants based on their answers to a brief assessment battery. Once assessments are completed, a treatment plan consisting of recommended modules is automatically generated for patient and parent guidance, and the user is directed to the list of recommended modules. Participants will also complete online daily diaries for eight weeks.
62123240|NCT04567355|NO_INTERVENTION|Attention Control|Participants in this arm will complete the online daily diaries for eight weeks (i.e., equal time as the Migraine Manager arm) through the portal but will be restricted from receiving intervention content; they will also receive equal number of communications via the portal as the Migraine Manager arm. Data from migraine daily diaries will not be available to AC participants or their clinicians as this would likely be used clinically and lead to contamination of the control arm resulting from varying levels of intervention across participants based on their data.
62683397|NCT04803604|EXPERIMENTAL|Advanced social support + communication + Ottawa guide + 1 monthly follow up call|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
62683398|NCT04803604|EXPERIMENTAL|Advanced social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6
62683399|NCT04803604|EXPERIMENTAL|Advanced social support + communication + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
62683400|NCT04803604|EXPERIMENTAL|Advanced social support + communication + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
62312776|NCT00004184|EXPERIMENTAL|Arm I|Patients receive human anti-idiotypic monoclonal antibody vaccine (4B5) in sargramostim (GM-CSF) subcutaneously (SQ) on days 0, 14, 28, and 42. Patients receive GM-CSF alone SQ at vaccination site on days 2, 3, and 4 following immunization.
62312777|NCT00004184|EXPERIMENTAL|Arm II|Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
62683401|NCT04803604|EXPERIMENTAL|Advanced social support + Ottawa guide + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, decision support tools, and a single monthly follow-up call
62477561|NCT04306952|EXPERIMENTAL|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat.
62683402|NCT04803604|EXPERIMENTAL|Advanced social support + Ottawa guide + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
61923004|NCT03850288||Bulimia Nervosa|"Patients with a diagnosis of bulimia nervosa. According to the DSM-V criteria, these patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time, an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode, recurrent inappropriate compensatory behaviour in order to prevent weight gain, such as self-induced vomiting, misuse of laxatives, diuretics, or other medications, fasting, or excessive exercise.~The binge eating and inappropriate compensatory behaviours both occur, on average, at least once a week for three months. Moreover, there is a self-evaluation influenced by body shape and weight."
61923005|NCT03850288||Binge Eating Disorder|Patients with a diagnosis of Binge Eating Disorder. These patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time (e.g. within any 2-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode. The binge eating episodes are associated with three or more of the following: eating much more rapidly than normal, eating until feeling uncomfortably full, eating large amounts of food when not feeling physically hungry, eating alone because of feeling embarrassed by how much one is eating, feeling disgusted with oneself, depressed or very guilty afterward,marked distress regarding binge eating is present. Moreover, binge eating occurs, on average, at least once a week for three months
61923006|NCT06452082||patients on therapy with cholecalciferol|
61923007|NCT06452082||patients not on cholecalciferol therapy|
61923008|NCT02428985||Riociguat|Riociguat treatment group
62123241|NCT04575493|EXPERIMENTAL|Test Group|No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
62312778|NCT04996576|ACTIVE_COMPARATOR|intranasal injection approach sphinopalatine ganglion block|Then in one nasal side (intranasal injection group) will be chosen randomly (right or left) by closed envelopes method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia and 2 ml saline will be injected in the same place in the other nasal side (to prevent surgeon expectation of intra nasal group by seeing injection site in one side only) by surgeon assistant who will be blind for the injection content.
62312779|NCT04996576|ACTIVE_COMPARATOR|infrazygomatic approach sphinopalatine ganglion block|"In the side saline only given by the intranasal injection A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
62477562|NCT04306952|EXPERIMENTAL|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks, with optional office hoursin between the bi-weekly group sessions and one all day meditation retreat."
62683403|NCT04803604|EXPERIMENTAL|Advanced social support + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, and a single monthly follow-up call
62683404|NCT04803604|EXPERIMENTAL|Advanced social support + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, and monthly follow-up calls for 6 months
62683405|NCT05895045|EXPERIMENTAL|1.1: 8-12 yoga first|
62683406|NCT05895045|EXPERIMENTAL|1.2: 13-18 yoga first|
61923009|NCT02049671||Growth Hormone Therapy|
61923010|NCT02049671||Control Group|
61923011|NCT04251156|EXPERIMENTAL|Semaglutide|Once-weekly injections of gradually increased doses of semaglutide
61923012|NCT04251156|PLACEBO_COMPARATOR|Placebo (semaglutide)|Once-weekly injections of gradually increased doses of semaglutide placebo
61923013|NCT03481660|EXPERIMENTAL|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
61923014|NCT03481660|ACTIVE_COMPARATOR|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
61923015|NCT01613196|EXPERIMENTAL|Positron Emission Tomography|Positron Emission Tomography
62123242|NCT04575493|ACTIVE_COMPARATOR|control group|No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
62123243|NCT04583046|PLACEBO_COMPARATOR|placebo|normal saline inhalation group
62123244|NCT04583046|EXPERIMENTAL|iloprost group|iloprost inhalation group
62139683|NCT00683800|EXPERIMENTAL|1|desvenlafaxine succinate (DVS) SR
62139684|NCT00683800|PLACEBO_COMPARATOR|2|Placebo
62477563|NCT03877939||Non-pregnant patients|Patients with β-hCG test \< 10 UI/L.
62477564|NCT03877939||Patients with viable pregnancy|Patients with β-hCG test \> 10 UI/L whose pregnancy is confirmed between gestational weeks 6 and 8.
61923016|NCT04041791|ACTIVE_COMPARATOR|Benzyl penicillin/ampicillin + gentamicin & IV fluids|"Participants are assigned to receive benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Maintenance fluids will be given as a continuous infusion for at least 24 hours."
61923017|NCT04041791|EXPERIMENTAL|Ceftriaxone and IV fluids|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
62477565|NCT03877939||Patients with biochemical pregnancy|Patients with β-hCG test \> 10 UI/L and without sac observed.
62477566|NCT03877939||Patients with ectopic pregnancy|Patients with β-hCG test \> 10 UI/L whose sac is implantated outside the uterine cavity.
62477567|NCT03877939||Patients with clinical miscarriage|Patients with β-hCG test \> 10 UI/L whose sac is implanted inside the uterine cavity, but non-viable pregnancy is confirmed before gestational week 8.
62477568|NCT05967286|EXPERIMENTAL|Cohort 1, Arm A (olaparib, alpelisib)|Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
62683407|NCT05895045|EXPERIMENTAL|2.1: 8-12 yoga second|
62683408|NCT05895045|EXPERIMENTAL|2.2: 13-18 yoga second|
62683409|NCT05127200|EXPERIMENTAL|Anodal tsDCS (cervical active, lumbar sham)|"Participants will receive:~1. 20 minutes of 2.5 milliampere (mA) anodal tsDCS at the cervical level.~2. sham tsDCS at the lumbar level."
62312780|NCT02707094|OTHER|Usual Care (Medication + Exercise)|Usual Care: Participants will receive guidance on over-the-counter and prescribed pain medications to use to treat their chronic low back pain symptoms. The Research Coordinator (RC) will provide instructions for low back pain stretching and strengthening exercises. The Licensed Provider (LP) will determine if any exercises should be excluded based on their physical limitations. Participants enrolled in the usual care treatment arm will track the frequency of their back stretching and strengthening exercise sessions on the Pain Medication \& Exercise Diary. For the purpose of this study, treatment compliance will be met if participants complete the exercises a minimum of three times per week.
62477569|NCT05967286|EXPERIMENTAL|Cohort 2, Arm B (olaparib, alpelisib)|Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
61923018|NCT04041791|EXPERIMENTAL|Amoxicillin-clavulanate and IV fluids|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
61923019|NCT04041791|EXPERIMENTAL|Benzyl penicillin/ampicillin + gentamicin & NG feeds|"Participants are assigned to receive Benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
61923020|NCT04041791|EXPERIMENTAL|Ceftriaxone and NG feeds|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
61923021|NCT04041791|EXPERIMENTAL|Amoxicillin-clavulanic acid and NG feeds|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
61923022|NCT00401895|ACTIVE_COMPARATOR|1|patients treated with 10 mm stent
61923023|NCT00401895|ACTIVE_COMPARATOR|2|patients treated with 8 mm stent
61923024|NCT03590418||Intestinal stoma output|No interventions.
61923025|NCT03590418||Colonic feaces|No interventions.
61923026|NCT03590418||Healthy Control|No interventions.
61923027|NCT01367119|ACTIVE_COMPARATOR|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic prior to electroconvulsive therapy (ECT).
61923028|NCT01367119|ACTIVE_COMPARATOR|Methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic prior to electroconvulsive therapy.
61923029|NCT02606695||NuvaMap and NuvaMap OR in Thoracolumbar Spinal Fusion|
61923030|NCT02284672|PLACEBO_COMPARATOR|control|"After preoxygenation for 3 minutes, normal saline would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
61923031|NCT02284672|EXPERIMENTAL|dexmedetomidine|"After preoxygenation for 3 minutes, dexmedetomidine would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
61923032|NCT01623986||St. Michael's Hospital Patients|Patients who are referred to the St. Michael's Hospital echocardiography (ECHO) lab.
61923033|NCT01216267|ACTIVE_COMPARATOR|lansoprazole|lansoprazole for 7 days
61923034|NCT03758326|OTHER|Eating disorder|Measurement of body image via Body App and relationship to body measurement
61923035|NCT03758326|OTHER|Healthy comparison|Measurement of body image via Body App and relationship to body measurement
61923036|NCT00556231||1|Children with congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
61923037|NCT00556231||2|Children without congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
61923038|NCT00556231||3|
61923039|NCT00556231||4|
61923040|NCT00556231||5|
61923041|NCT00556231||6|
61923042|NCT00728078|EXPERIMENTAL|1|low-dose thalidomide adjuvant therapy after RFA for HCC
62477570|NCT05967286|ACTIVE_COMPARATOR|Cohort 2, Arm C (olaparib)|Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
62683410|NCT05127200|ACTIVE_COMPARATOR|Anodal tsDCS (cervical sham, lumbar active)|"Participants will receive:~1. 20 minutes of 2.5 milliampere (mA) anodal tsDCS at the lumbar level.~2. sham tsDCS at the cervical level."
62683411|NCT05367076|EXPERIMENTAL|FitABCS exercise|Web-based community-led, 12-week exercise program
61923043|NCT00728078|NO_INTERVENTION|2|control group
61923044|NCT02756065||Control|Individuals between 18-30 years old No diagnosis of Bipolar Disorder or Schizophrenia No intervention used
62683412|NCT05367076|NO_INTERVENTION|FitABCS control|Healthy control
62683413|NCT02514746|EXPERIMENTAL|Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
62123245|NCT04843306|EXPERIMENTAL|ABC technique plus biofeedback|Patients will utilize biophysical feedback and coaching during the planning and treatment sessions for radiotherapy to help patients with the ABC technique.
62123246|NCT04843306|ACTIVE_COMPARATOR|Standard of care ABC technique.|Patients will standard of care instructions for using the ABC technique during the planning and treatment sessions for radiotherapy.
62683414|NCT01028560|ACTIVE_COMPARATOR|No immunotherapy, receive standard of care asthma treatment|This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
62683415|NCT01028560|EXPERIMENTAL|Allergen immunotherapy|This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
61923045|NCT02756065||Bipolar Disorder|Individuals between 18-30 years old Diagnosis of Bipolar Disorder No intervention used
61923046|NCT02756065||Schizophrenia|Individuals between 18-30 years old Diagnosis of Schizophrenia or Schizoaffective Disorder No intervention used
61923047|NCT03718299|OTHER|tildrakizumab 100 mg|
61923048|NCT05783986||Testing group|375 patients of our hosipital,randomly divided.
62477571|NCT05967286|EXPERIMENTAL|Cohort 3, Arm D (olaparib, alpelisib)|Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
62477572|NCT06153485|EXPERIMENTAL|AutoO2|Automated Titration of Oxygen (Auto-O2) using a closed-loop system in which the oxygen flow to the participant is continuously adjusted on the basis of pulse oximetry signals to maintain a target range of oxygen saturation to meet the patient's immediate needs.
61923049|NCT05783986||Internal validation group|125 patients of our hosipital,randomly divided.
61923050|NCT05783986||External validation group|100 patients of Sun Yat-sen University Cancer Center
62477573|NCT06153485|ACTIVE_COMPARATOR|FixedO2|Fixed flow oxygen delivery administered using manual flow meters according to standard clinical procedures.
62477574|NCT05929352|EXPERIMENTAL|Musical Intervention|Participants will work together in a group with other voice hearers, making music with a trained facilitator for 4 weekly sessions
62683416|NCT03694730|EXPERIMENTAL|Pain-guided Activity Modification|Participants in the Pain guided Activity Modification group will receive an exercise program consisting of progressive patellar tendon loading exercises Outside of physical therapy treatment, these participants will modify activity based on the Pain-Monitoring Model.
62683417|NCT03694730|ACTIVE_COMPARATOR|Pain-free Activity Modification|Participants in the Pain-free Activity Modification group will receive an identical exercise program to the Pain-guided Activity Modification group. However, participants will not be allowed to participate in activities that cause patellar tendon pain or excessively load the patellar tendon (e.g. jumping) outside of physical therapy treatment.
61923051|NCT03981302|EXPERIMENTAL|Family nursing conversations|The intervention will consist of structured family nursing conversations between a nurse, the patient and their selected family members. The patients will receive the intervention and usual treatment.
62123247|NCT01202526||RYGB patients with type 2 diabetes|Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
61923052|NCT03981302|NO_INTERVENTION|Usual treatment|The patients will receive usual treatment.
61923053|NCT06104371||Node negative|Clinically node negative before neoadjuvant chemotherapy
61923054|NCT06104371||Node positive|Clinically node positive before neoadjuvant chemotherapy
61923055|NCT00381953|ACTIVE_COMPARATOR|360 PEG IFN|360 mug peginterferon alfa-2a QW
61923056|NCT00381953|ACTIVE_COMPARATOR|9 MU + 180 PEG IFN|9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
61923057|NCT00381953|ACTIVE_COMPARATOR|4,5 MU IFN + 180 PEG IFN|4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
61923058|NCT00772070|EXPERIMENTAL|Previously received TetraMenD|Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
62123248|NCT01202526||RYGB patients without type 2 diabetes|Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
62139685|NCT04929795|EXPERIMENTAL|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of music beat serving as a type of rhythmic auditory stimulation (RAS).
62683418|NCT02680496|EXPERIMENTAL|Lokomat - Treadmill - Overground|Walking order: lokomat walking, treadmill walking, overground walking
62312781|NCT02707094|EXPERIMENTAL|Biomodulator + Usual Care|Biomodulator + Usual Care treatment group: Usual care, as described above, will be provided to all participants randomly allocated to this treatment group, in addition to treatment with the Biomodulator three times per week x 4 weeks. The licensed provider will review medication and treatment logs, prescribe pain medications as indicated, and assess for treatment side effects. In addition to treatment with the Biomodulator, the participant will perform back stretching and core strengthening exercises for a minimum of three times per week as instructed and will be told to use their prescribed pain medications as needed to self-treat their low back pain symptoms (as previously described above).
62477575|NCT02787876|EXPERIMENTAL|Chemotherapy induced neutropenia|Pegteograstim 100 ug/kg (maximum 6 mg) on day 7 of the chemotherapy cycle
62477576|NCT03975075|EXPERIMENTAL|Biofeedback|Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). The biofeedback training session will be conducted using the eSense Pulse smartphone application. Participants will receive further instruction explaining how physiological information will be displayed and used as a means of training to induce a relaxed state while receiving real time feedback. Participants will be instructed on using controlled breathing to assist with reaching this relaxed state. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone.
62683419|NCT02680496|EXPERIMENTAL|Lokomat - Overground - Treadmill|Walking order: lokomat walking, overground walking, treadmill walking
62683420|NCT02680496|EXPERIMENTAL|Treadmill - Lokomat - Overground|Walking order: treadmill walking, lokomat walking, overground walking
62683421|NCT02680496|EXPERIMENTAL|Treadmill - Overground - Lokomat|Walking order: treadmill walking, overground walking, lokomat walking
62683422|NCT02680496|EXPERIMENTAL|Overground - Lokomat - Treadmill|Walking order: overground walking, lokomat walking, treadmill walking
62683423|NCT02680496|EXPERIMENTAL|Overground - Treadmill - Lokomat|Walking order: overground walking, treadmill walking, lokomat walking
61923059|NCT00772070|EXPERIMENTAL|Meningococcal vaccine-naїve|Participants have never received a Meningococcal vaccine in the past.
61923060|NCT02662218||Patients with superficial wounds|A cohort of 50 patients with superficial wounds of any etiology (see inclusion criteria), who need advanced wound care treatment in any case, will be observed over a period of 14 days; the exact duration for each patient depends upon the investigator's assessment. The observation consists of an initial visit, at least one dressing change after max. 7 days and a final visit. Patients will be treated with the CE-marked wound care product. This product is already in general use in the Netherlands and Germany. It is a sterile, bacteria-binding, super-absorbent wound dressing. Apart from the predefined study visits, daily dressing changes in accordance with daily clinical practice are possible.
61923061|NCT02469038|EXPERIMENTAL|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
62123249|NCT05685316|EXPERIMENTAL|COPLA® cartilage implant|The potential subjects will be screened against inclusion and exclusion criteria. If deemed eligible, they will be consented and enrolled. The enrolled subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery with bone marrow stimulation.
62123250|NCT00477035|EXPERIMENTAL|Autologous Cytokine-induced Killer Cells|
62123251|NCT03926884|EXPERIMENTAL|Tea1 group|"This is the treatment group. This group will be taking 2 grams of the three-seeds mixture twice a day for three weeks."
62123252|NCT03926884|PLACEBO_COMPARATOR|Tea2 group|"This is the control group. This group will be taking 0.02 grams of the three-seeds mixture once a day for three weeks."
62123253|NCT03851549|EXPERIMENTAL|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)
62312782|NCT04765462|EXPERIMENTAL|Allogeneic γδ T cell Group|Enrolled patients will be administered allogeneic γδ T cells with or without the combinations of traditional therapies, including chemotherapy, targeted therapy, radiotherapy, immune checkpoint inhibitors and others.
62312783|NCT03690518|NO_INTERVENTION|Control|Controls will have a regular follow-up without any intervention (no rehabilitation program)
62683424|NCT04652765|NO_INTERVENTION|Standard of care (SOC)|SARS-CoV-2 positive participants will receive SOC therapy alone.
61923062|NCT02469038|ACTIVE_COMPARATOR|Control|We will use ultrasound-guided conventional IV for patients in the control group.
62683425|NCT04652765|ACTIVE_COMPARATOR|SOC plus camostat|SARS-CoV-2 positive participants will receive SOC therapy as well as camostat for 7 days.
62312784|NCT03690518|ACTIVE_COMPARATOR|Rehabilitaiton|Cardiac rehabilitation: Rehabilitation will have a regular follow-up with intervention (rehabilitation program)
62683426|NCT04652765|ACTIVE_COMPARATOR|SOC plus camostat and bicalutamide|SARS-CoV-2 positive participants will receive SOC therapy as well as camostat and bicalutamide for 7 days.
62683427|NCT06054815|EXPERIMENTAL|Part 1 Group 1|"DA-1241 Dose 1~In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio."
62683428|NCT06054815|EXPERIMENTAL|Part 1 Group 2|"DA-1241 Dose 2~In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio."
62683429|NCT06054815|PLACEBO_COMPARATOR|Part 1 Group 3.1|"DA-1241 Placebo and Sitagliptin Placebo~In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio."
61923063|NCT06459141|EXPERIMENTAL|acute normovolemic hemodilution group (ANH group)|The ANH process was initiated after tracheal intubation. After completion of ANH, goal-directed fluid therapy will begin until the end of the surgery.
62683430|NCT06054815|PLACEBO_COMPARATOR|Part 2 Group 3.2|"DA-1241 Placebo and Sitagliptin Placebo~In Part 2: Participants will be randomized into 2 treatment groups and will be dosed with: DA-1241 in combination with sitagliptin (DA-1241/sitagliptin) or DA-1241/ sitagliptin placebo in a 2:1 ratio."
62123254|NCT06299293||Cases|Participants with Anorexia Nervosa
62123255|NCT06299293||Controls|Participants with a healthy weight
61923064|NCT06459141|NO_INTERVENTION|Standard Group (STD group)|After tracheal intubation, goal-directed fluid therapy will be implemented until the end of the surgery.
62312785|NCT03890276|ACTIVE_COMPARATOR|HMS EL&C training without video|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL\&C) training module. They will be able to: 1) distinguish normal and abnormal findings, 2) competently and confidently manage normal labor and birth to help prevent complications, 3) employ evidence-based practices, 4) rapidly identify and manage complications when they arise and 5) provide respectful care
61923065|NCT01234818|EXPERIMENTAL|LNG-IUS, endometrial hyperplasia|
61923066|NCT05280379||Participants with non-medullary thyroid carcinoma|30 patients with non-medullary thyroid carcinoma, who are going to get surgery
61923067|NCT05280379||Participants with colon carcinoma|30 participants with colon carcinoma, who are going to get surgery
61923068|NCT05536505|EXPERIMENTAL|MRD Positivity Post Operation|If MRD confirmed Positivity at either of the two timepoints (Time point 1: blood draw from the 3rd day to 7th day post operation. Time point 2: blood draw on the 28th day post operation), patients would receive icotinib until MRD turned Negativity. During MRD monitoring, icotinib would rechallenge
61923069|NCT05536505|NO_INTERVENTION|MRD Negativity Post Operation|If MRD confirmed negativity at both of the two timepoints (Time point 1: blood draw from the 3rd day to 7th day post operation. Time point 2: blood draw on the 28th day post operation), patients would receive ctDNA MRD monitoring.
61923070|NCT00179127|EXPERIMENTAL|Glargine|0.3u/kg of glargine, subcutaneously, once
62683431|NCT06054815|EXPERIMENTAL|Part 2 Group 4|"DA-1241 and Sitagliptin~In Part 2: Participants will be randomized into 2 treatment groups and will be dosed with: DA-1241 in combination with sitagliptin (DA-1241/sitagliptin) or DA-1241/ sitagliptin placebo in a 2:1 ratio."
62683432|NCT04290676||DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
62683433|NCT04945369|EXPERIMENTAL|Children born prematurely included in the EPIPOD protocol and now in the peripubertal period|"At inclusion in the INFANTPOD study :~* Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~* Assessment of body composition by a commercialized device called BOP-POD and by impedancemetry~* Assessment of pulse wave by a commercialized device called popmetre~* Questionnaires for analysis of eating behaviour~* Assessment of physical activity by a commercialized device called accelerometer and by questionnaire."
62683434|NCT00089583|EXPERIMENTAL|2 - 18 yrs old (FPV/RTV BID)|Cohort 1B - 2 - less than 6yrs old (FPV/RTV BID) Cohort 2 - 6 to less than 12 yrs old (FPV/RTV BID) Cohort 3 - 12 - 18 yrs old (FPV/RTV BID) Cohort 4 - 2 - 18 yrs (FPV/RTV BID)
62683435|NCT00089583|EXPERIMENTAL|2 - less than 6yrs old (FPV BID)|Cohort 1A - 2 - less than 6yrs old (FPV BID)
61923071|NCT00179127|PLACEBO_COMPARATOR|Placebo|0.3u/kg of saline, subcutaneously, once
61923072|NCT04416425||Enrolled Cohort|200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year.
61923073|NCT04758845|EXPERIMENTAL|Cocktail|Subjects will consume 1 capsule containing 2B CFU containing .5B CFU Bacillus subtilis DE111, .5B CFU Bacillus coagulans CGI314, .5B CFU Bacillus megaterium MIT411, and .5B CFU Bacillus clausii CSI08 for 45 days.
61923074|NCT04758845|EXPERIMENTAL|CGI314|Subjects will consume 1 capsule containing 1B CFU of Bacillus coagulans CGI314 for 45 days.
61923075|NCT04758845|EXPERIMENTAL|CSI08|Subjects will consume 1 capsule containing 1B CFU of Bacillus clausiiCSI08 for 45 days.
62312786|NCT03890276|EXPERIMENTAL|HMS training with video supplementation|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL\&C) training module. They will ALSO receive the training with interspersed with short video clips that that aim to improve understanding and skills acquisition ('Videos used to supplement live trainer'). Video supplementation is meant to standardize the cascaded training in the future as the training is offered at a much larger scale in low and middle income countries.
62312787|NCT05163808|ACTIVE_COMPARATOR|Study Drug|Subjects will receive 15 mg BID or 25mg BID dose of BPN14770
61923076|NCT04758845|EXPERIMENTAL|MIT411|Subjects will consume 1 capsule containing 1B CFU of Bacillus megaterium MIT411 for 45 days.
62312788|NCT05163808|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive matching Placebo
61923077|NCT04758845|NO_INTERVENTION|Placebo|Subjects will consume 1 capsule containing maltodextrin for 45 days.
61923078|NCT00602745|ACTIVE_COMPARATOR|5-Fluorouracil|
61923079|NCT00602745|EXPERIMENTAL|S-1|
62312789|NCT06263166|NO_INTERVENTION|Control group|No intervention other than usual care
61923080|NCT04533477|EXPERIMENTAL|Routine surgery with reconstructing FCS|The participants undergo FCS reconstruction during the routine standardized surgery.
61923081|NCT04533477|ACTIVE_COMPARATOR|Routine surgery|The participants undergo routine standardized surgery.
61923082|NCT05022264||Participants|All participants will have their vital signs measured with conventional techniques as well as with the new experimental medical device (labelled RIA-VS)
62312790|NCT06263166|EXPERIMENTAL|Intervention group|Received stress ball intervention and usual care
62312791|NCT01706289||diabetic mellitus screen|
62312792|NCT05152446|EXPERIMENTAL|Infusion management scheme|To implement infusion management scheme, then observe the continuous changes.
62312793|NCT02499965|ACTIVE_COMPARATOR|Topical Ethyl Chloride (Product B)|Ethyl Chloride Topical Aerosol Anesthetic applied to arm
62312794|NCT02499965|PLACEBO_COMPARATOR|Topical Sterile Water (Product A)|Nature's Tears Sterile water in an aerosol can
62312795|NCT02202681|EXPERIMENTAL|OFDI Capsule Imaging|Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
62312796|NCT06494176|EXPERIMENTAL|VRET Intervention|
62312797|NCT06494176|NO_INTERVENTION|Active Control|
62312798|NCT05690633|EXPERIMENTAL|Oropharyngeal oximetry|The use of a pulse oximeter in the oropharynx on either an oral airway or a tongue blade.
62312799|NCT04163198|EXPERIMENTAL|Insufflation optimisation|Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.
62312800|NCT04163198|EXPERIMENTAL|Exsufflation optimisation|Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF
61923083|NCT03565965|EXPERIMENTAL|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
61923084|NCT03565965|ACTIVE_COMPARATOR|Control Group (CG)|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
61923085|NCT00336583|EXPERIMENTAL|Oxaliplatin, response|relapsed or refractory non-Hodgkin's lymphoma
61923086|NCT00176722||surgical|males \& females undergoing spine surgery in the prone position
61923087|NCT01453192|EXPERIMENTAL|Raltegravir|Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
61923088|NCT04478331|NO_INTERVENTION|CONTROL|The Control group will receive the usual care. In the physical activity (PA) field, this includes two individual motivational interviews with a PA professional, and a group workshop during the first year after BS. PA recommendations will be explained to each participant, and their achievement will be encouraged and supported during these sessions. No face-to-face PA sessions will be offered as part of the usual care.
62139686|NCT04929795|ACTIVE_COMPARATOR|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
62312801|NCT01377467|EXPERIMENTAL|Denosumab|60 mg denosumab s.c. at baseline and after 6 months
62312802|NCT01377467|NO_INTERVENTION|Control|No treatment
62312803|NCT04169607|EXPERIMENTAL|individualized PEEP|"Basic ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.~Randomization: Subsequently patient was randomized, the PEEP was then maintained (individualized PEEP arm) until extubation.~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
62312804|NCT04169607|ACTIVE_COMPARATOR|PEEP 8|"Bacis ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.~Randomization: Subsequently patient was randomized , the PEEP was then reduced to 8cm H2O (PEEP8 arm) until extubation.~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
62312805|NCT03700892|EXPERIMENTAL|Cinnamaldehyde, then PG/VG|Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
62312806|NCT03700892|EXPERIMENTAL|PG/VG, then Cinnamaldehyde|Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
62312807|NCT03700892|NO_INTERVENTION|Healthy Controls|Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.
62477577|NCT03975075|ACTIVE_COMPARATOR|Control Group|"Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). Participants will be provided with the following instructions: You will be monitored with this equipment for 30 minutes. During this time frame, please try to limit movement and conversation as much as possible. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone."
62477578|NCT04704323|EXPERIMENTAL|Experimental: Phase Ia - Dose escalation|Cohorts of 3 subjects will receive intravenous \[IV\] administrations of escalating doses of CAP-100.
62477579|NCT04704323|EXPERIMENTAL|Experimental: Phase Ib - Dose expansion|Six subjects will receive intravenous \[IV\] administrations of CAP-100 at the Recommended Phase 2 Dose determined in Phase Ia - Dose Escalation of this trial.
61923089|NCT04478331|EXPERIMENTAL|ACTI-VISIO|The two PA sessions per week will be delivered via videoconferencing (developed by Mooven™). The PA program consists in tailored adapted PA sessions led by a professional specialized in adapted PA. These sessions were specifically designed to be appropriate for the population and were developed in collaboration with the authors to ensure standardization of the recommended volume of PA. The PA sessions will be given live, individually at the beginning and then in groups of four women. During sessions, the professional and the participants will interact simultaneously, and the execution of the exercises will be monitored and adapted live by the professional. To ensure the safety of the PA, a rating of perceived exertion will be requested after each session on a 10-point scale. If the RPE exceed 7, the professional specialized in adapted PA will adjust the training load. In addition to the exercises, the sessions will also include advice and tips for reaching the recommended PA level.
62312808|NCT04661618|ACTIVE_COMPARATOR|GT|12 weeks of progressive training in the first phase and 12 weeks of maintenance training in the second phase.
62312809|NCT04661618|OTHER|Control|"No intervention for the first phase and will be active comparator in the second phase.~No intervention for the first 12 weeks (first phase) and 12 weeks of progressive training in the second phase."
62312810|NCT01100021|EXPERIMENTAL|tamsulosin + avanafil|
62312811|NCT01100021|EXPERIMENTAL|Doxazosin + avanafil|
62312812|NCT04979208||Acute myocardial infarction (AMI) cohort|Adult patients with recent acute myocardial infarction admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis all recent AMI patients less than 24 hours old diagnosed by emergency physicians on the basis of suggestive clinical symptoms and electrocardiogram (ECG) criteria, cared in the 30 emergency units and 19 mobil intensive care unit, with a coronary angiography or a percutaneous coronary intervention (PCI) realized in the 11 cathlabs in Aquitaine
62312813|NCT04979208||Stroke cohort|Adult patients with recent stroke admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis recent ischemic or hemorragic stroke patients with brain imaging managed in one of the 14 participating hospitals in Aquitaine (7 stroke units and 7 primary care centers).
62477580|NCT00870662|EXPERIMENTAL|Automatic Fluid Shunt|
62477581|NCT00944294|OTHER|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
62123256|NCT04373590|EXPERIMENTAL|Decision aid (DA)|a one-page DA for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics.
62123257|NCT04373590|NO_INTERVENTION|Treatment as usual (TAU)|Treatment as usual without the DA
62139687|NCT04929795|EXPERIMENTAL|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of RAS.
62477582|NCT00944294|OTHER|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
62477583|NCT03679598|ACTIVE_COMPARATOR|Alvelestat (MPH966)|Alvelestat (MPH966) 120mg (4 30mg tablets) twice daily by mouth for 12 weeks
62477584|NCT03679598|PLACEBO_COMPARATOR|Placebo|4 Placebo tablets twice daily by mouth for 12 weeks
62477585|NCT04926818|EXPERIMENTAL|ofatumumab - 20 mg injection/ placebo|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
62477586|NCT04926818|EXPERIMENTAL|siponimod - 0.5 mg, 1 mg or 2 mg/ placebo|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
62477587|NCT04926818|ACTIVE_COMPARATOR|fingolimod - 0.5 mg or 0.25 mg/ placebo|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
62477588|NCT04198363|EXPERIMENTAL|Vonoprazan 20 mg|Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
62312814|NCT03000452|EXPERIMENTAL|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly \[QW\], every 2 weeks \[Q2W\], or every 4 weeks \[Q4W\] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
62312815|NCT04696835|EXPERIMENTAL|children with hearing aids|
62312816|NCT04696835|SHAM_COMPARATOR|control group|
62312817|NCT06650163|EXPERIMENTAL|Treatment (Zr-89 crefmirlimab berdoxam + ImmunoPET)|Patients receive Zr-89 crefmirlimab berdoxam IV over 5-10 minutes 3 days prior to scheduled surgical resection. Approximately 24 hours after receiving Zr-89 crefmirlimab berdoxam, patients undergo immuno-PET scans. Patients then undergo scheduled standard of care surgical resection of the brain tumor and brain biopsy. Additionally, patients undergo advanced physiologic and metabolic MRI and MRI prior to surgery.
62312818|NCT00865254|EXPERIMENTAL|Traditional Contingency Management|Standard treatment plus prize based contingency management.
62477589|NCT04198363|ACTIVE_COMPARATOR|Esomeprazole 20 mg|Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
62312819|NCT00865254|EXPERIMENTAL|Early Enhanced Contingency Management|Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
62312820|NCT00865254|ACTIVE_COMPARATOR|Standard Treatment|Counseling and monitoring of smoking cessation.
62312821|NCT02297217|EXPERIMENTAL|Chemotherapy with Concurrent Radiation|Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
62312822|NCT04211324||TENS group|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
62312823|NCT04211324||electro-acupuncture group|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
62312824|NCT02269319|EXPERIMENTAL|MRX-I|MRX-I tablets 800 mg given twice a day for 10 days
62312825|NCT02269319|ACTIVE_COMPARATOR|Linezolid|Linezolid 600 mg given twice a day for 10 days
62312826|NCT00970294|EXPERIMENTAL|Health Promotion Program|Supervised exercise, educational sessions, dietary counseling
62312827|NCT06387238|EXPERIMENTAL|mHSPC-PSMA|Patients with mHSPC who will receive pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.
62477590|NCT05215483|EXPERIMENTAL|Customised advice + LFT available at home|"Respondents will see an altered testing advice in text and picture in which they are allowed to use LFT with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
62477591|NCT05215483|EXPERIMENTAL|Customised advice + No LFT available at home|"Respondents will see an altered testing advice in text and picture in which they are allowed to use LFT with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
62477592|NCT05215483|EXPERIMENTAL|Regular advice + LFT available at home|"Respondents will see the regular testing advice in text and picture with the current governmental advice to visit a test facility with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
62683436|NCT06059846|EXPERIMENTAL|TBP-PI-HBr 600 mg + Dummy Infusion|Participants will receive TBP-PI-HBr 600 mg, orally and dummy infusion IV, every 6 hours from Days 1 through 10.
62139688|NCT04929795|ACTIVE_COMPARATOR|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
62312828|NCT06028776|EXPERIMENTAL|Intervention|This group will be offered 2 weekly sessions (45-60 min) of MS Ballroom Fitness for a period of 7 weeks. All other 'usual care' are allowed.
62312829|NCT06028776|NO_INTERVENTION|Control|This group will continue their habitual living, also including whatever 'usual care' they participate in.
62312830|NCT02163330|ACTIVE_COMPARATOR|Acetazolamide|active comparator group will receives 500 mg azetazolamide daily
62312831|NCT02163330|PLACEBO_COMPARATOR|sugar pill|placebo comparator group will receives placebo daily.
62312832|NCT05069363|EXPERIMENTAL|Intervention Group|All participants in this feasibility trial will receive a course of whole-body photobiomodulation therapy (18 sessions over 6 weeks)
62312833|NCT05819346|EXPERIMENTAL|Digital lifestyle intervention|Self-management mobile application covering physical activity, nutrition, and breathing/relaxation
62312834|NCT05819346|NO_INTERVENTION|Control|Usual care (study participation does not interfere with or change any other planned treatments)
62312835|NCT05671120|OTHER|Transcutaneous levator recession|
62312836|NCT03300453|EXPERIMENTAL|rAAV2/5-hNAGLU|Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).
62312837|NCT02636790|ACTIVE_COMPARATOR|Surgery wait time (< 8 weeks)|Outcomes of patients with sinus surgery of less than 8 weeks.
62312838|NCT02636790|ACTIVE_COMPARATOR|Surgery wait time (> 1 year)|Outcomes of patients with sinus surgery of more than 1 year.
62312839|NCT00775372|EXPERIMENTAL|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
62312840|NCT00775372|ACTIVE_COMPARATOR|2|Biaxin® granules 250 mg/5 mL oral suspension
62312841|NCT00746772|ACTIVE_COMPARATOR|1|Patients with oral lichen planus
62312842|NCT00746772|PLACEBO_COMPARATOR|2|Patients with oral lichen planus
62312843|NCT06670027|EXPERIMENTAL|Family voice|The patient receives family voice from significant member
62312844|NCT06670027|ACTIVE_COMPARATOR|Nature sound|Patient receives nature sounds such as waves sound, river streams, waterfalls, and walking in the forest
62139689|NCT01249209|OTHER|lifestyle advice|
62312845|NCT02393651|PLACEBO_COMPARATOR|Sham|Motor training of the affected upper extremity combined with sham tDCS.
62312846|NCT02393651|EXPERIMENTAL|tDCS|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
61923090|NCT04478331|EXPERIMENTAL|ACTI-MOBIL|The PA sessions will be delivered by an eHealth platform (developed by BePatient™) associated with an activity bracelet. The researchers enrich PA content on the platform and ensure standardization of the recommended volume of PA. The platform consists of tips for reaching the PA level, PA questionnaires, PA feedback measured by the activity bracelet, and a video demonstration of PA sessions performed by a peer. The PA sessions are automatically broadcasted twice a week for 12 weeks. To ensure the safety of the PA, the sessions were designed to be appropriate for this population and the RPE will be measured after each session on a 10-point scale. If the RPE exceeds 7 for 3 consecutive sessions, the training load will be adjusted. The platform will also include a variety of content, including dietary tips, obesity-related facts, information about surgery, and frequently asked questions.
61923091|NCT02272543|ACTIVE_COMPARATOR|Fish surimi peptide powder|Fish surimi peptide powder
62312847|NCT05090358|EXPERIMENTAL|Ketogenic Diet|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will partake in a ketogenic diet in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
62312848|NCT05090358|EXPERIMENTAL|Low Carbohydrate Diet|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will be assigned to Low Carbohydrate Diet/LCD therapy each in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
62312849|NCT05090358|EXPERIMENTAL|SGLT2i Therapy|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will be assigned to SGLT2i therapy each in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
62683437|NCT06059846|ACTIVE_COMPARATOR|Imipenem-cilastatin 500 mg + Dummy Tablets|Participants will receive imipenem-cilastatin 500 mg, IV and matched dummy tablets, orally, every 6 hours from Days 1 through 10.
62683438|NCT01248468|EXPERIMENTAL|Aspirin, acetaminophen and caffeine|AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
61923092|NCT02272543|PLACEBO_COMPARATOR|Placebo|Placebo
62683439|NCT01248468|ACTIVE_COMPARATOR|Sumatriptan (100 mg)|1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
62683440|NCT01248468|PLACEBO_COMPARATOR|Placebo|1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
62683441|NCT00979615|EXPERIMENTAL|1|Olopatadine HCL Nasal Spray, 0.6%
62683442|NCT00979615|ACTIVE_COMPARATOR|2|Azelastine HCl Nasal Spray, 137 mcg
62683443|NCT05649306||Patients not receiving a cystectomy - Standard of Care Group|Patients will receive standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
62312850|NCT01343719|EXPERIMENTAL|BI 661051 low dose, low|solution for oral administration, single dose
62312851|NCT01343719|EXPERIMENTAL|BI 661051 low dose, medium|solution for oral administration, single dose
62312852|NCT01343719|EXPERIMENTAL|BI 661051 low dose, high|solution for oral administration, single dose
62683444|NCT05649306||Patients not receiving a cystectomy - Additional Education Group|Patients will receive additional education with standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment. Patients will also be asked to complete an attendance diary documenting additional support services utilized. The Attendance Diary will be completed at 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
62312853|NCT01343719|EXPERIMENTAL|BI 661051 medium dose, low|solution for oral administration, single dose
62312854|NCT01343719|EXPERIMENTAL|BI 661051 medium dose, medium|solution for oral administration, single dose
62477593|NCT05215483|ACTIVE_COMPARATOR|Regular advice + No LFT available at home|"Respondents will see the regular testing advice in text and picture with the current governmental advice to visit a test facility with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
62477594|NCT02757105|EXPERIMENTAL|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
62477595|NCT02757105|PLACEBO_COMPARATOR|Group B|Placebo, once daily for 8 weeks
62477596|NCT03107091|EXPERIMENTAL|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
62477597|NCT04715295|EXPERIMENTAL|Doxycyclin and Rivaroxaban|Oral Doxycyclin 200 mg daily for 7 days with or without Rivaroxaban
62477598|NCT04715295|ACTIVE_COMPARATOR|National Standard|Hydroxychloroquine 400 mg daily for 5 days in combination with Azithromycin 500 mg on day 1 and 250 mg daily from day 2 through day 5
62312855|NCT01343719|EXPERIMENTAL|BI 661051 medium dose, high|solution for oral administration, single dose
62477599|NCT04737863|EXPERIMENTAL|selective root canal retreatment|retreatment process is performed to the affected root only
62477600|NCT04737863|ACTIVE_COMPARATOR|traditional root canal retreatment|retreatment process is performed to all roots
62312856|NCT01343719|EXPERIMENTAL|BI 661051 high dose, low|solution for oral administration, single dose
62312857|NCT01343719|EXPERIMENTAL|BI 661051 high dose, medium|solution for oral administration, single dose
62312858|NCT01343719|EXPERIMENTAL|BI 661051 low dose|tablet
62312859|NCT01343719|EXPERIMENTAL|BI 661051 medium dose|tablet
62312860|NCT01343719|PLACEBO_COMPARATOR|Placebo|solution for oral administratrion
62477601|NCT04596670|EXPERIMENTAL|68Ga-ICAM1-1pep PET/CT in cancer patients before radiotherapy|"Cancer patients who have not undergone radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.~Interventions:~Drug: 68Ga-ICAM-1pep Device: PET/CT"
62477602|NCT04596670|EXPERIMENTAL|68Ga-ICAM1-1pep PET/CT in cancer patients after radiotherapy|"Cancer patients post-radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.~Interventions:~Drug: 68Ga-ICAM-1pep Device: PET/CT"
62477603|NCT01115647|EXPERIMENTAL|Ready-to-Use Therapeutic Foood (RUSF)|"Caretakers will receive weekly RUSF, 350g, and will be advised to feed it(50 g d-1 or 3 tablespoons/day) in one meal or on demand. These are pre-defined quantities. However, minimum quantities required for a timely (≤15 days) recovery from moderate malnutrition will be determined during the pilot phase.~Besides supplementary food, parents will be provided with the usual nutrition counsels prevailing currently in the health services.Children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
62477604|NCT01115647|ACTIVE_COMPARATOR|CSB++|"Caretakers will receive weekly CSB++ (450g) rations. Parents will be advised to feed the CSB++ (65g d-1 diluted in 370 g water) in one meal or on demand. These are pre-defined quantities. However, minimum quantities of CSB++ required for a timely (≤15 days) recovery from moderate malnutrition in the area will be determined during the pilot phase. Besides supplementary foods, parents will be provided with the usual nutrition counsels prevailing currently in the health services, i.e. to keep on breastfeeding, to increase diet diversity and to feed frequent snacks.~Feeding practices will be also assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
62312861|NCT01038492|EXPERIMENTAL|p16 Methylation in Sputum Testing|"* Patients tested for smoking-related changes in their breathing~* shown a presentation on development of lung cancer~* complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic detail~* given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits"
62312862|NCT04759911|EXPERIMENTAL|Treatment (selpercatinib)|Patients receive selpercatinb PO BID on days 1-28. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
62312863|NCT05718076||group 1|Eyes are categorized by fundus META-PM as grade 0
62477605|NCT01115647|ACTIVE_COMPARATOR|Children Centered Counseling (CCC)|"The counsellor will spend 1 hour daily (during the 3 first days and then weekly) within the household for identifying enhancing and blocking factors and adapt consequently the treatment strategies in agreement with the caretakers.~As in the other study arms, children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be also assessed in each arm, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members.There will be no dietary supplements intervention, outside normal practices in Burkina."
62683445|NCT05649306||Patients receiving a cystectomy- Standard of Care Group|Patients will receive standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
62312864|NCT05718076||group 2|Eyes are categorized by fundus META-PM as grade 1
62312865|NCT05718076||group 3|Eyes are categorized by fundus META-PM as grade 2
62312866|NCT04838912|EXPERIMENTAL|Cool Kids ASA|The Cool Kids (Chilled) ASA anxiety program
62312867|NCT02751307|ACTIVE_COMPARATOR|metformin 500 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, the dosage was revised to 500 mg of metformin in the morning and the placebo in the evening. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
62312868|NCT02751307|ACTIVE_COMPARATOR|metformin 1000 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, 500 mg of metformin twice a day was administered. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
62312869|NCT02751307|PLACEBO_COMPARATOR|placebo; clozapine 100 mg|In the first week, one pill of placebo was given and in the second week, placebo BID was given. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
62312870|NCT02875210|EXPERIMENTAL|Patient with anterior cruciate ligament rupture|Anterior laxity of patient was measure with 4 laximeters:Telos, reference laximeter and with three other instruments called, KT-1000, GnrB and Rolimeter.
62312871|NCT01568580|EXPERIMENTAL|test drug|GreenGene
62477606|NCT04116463|EXPERIMENTAL|CDSMP|Chronic Disease Self-Management Program (CDSMP) - a 6-week, group-based behavioral intervention delivered in a 2.5 hour session each week by a trained facilitator.
62477607|NCT04116463|ACTIVE_COMPARATOR|Financial Self-Management|Financial self-management course delivered in 3 modules, with a delivery time of approximately 1 hour per module.
62312872|NCT01469923|ACTIVE_COMPARATOR|AZD2820|AZD2820 multiple injections
62312873|NCT01469923|PLACEBO_COMPARATOR|Placebo for AZD2820|Placebo for AZD2820 multiple injections
62477608|NCT03562962|OTHER|Functional Analytic Psychotherapy|"Within the baseline (A), Supportive Listening (SL) will be provided, which has been widely utilized in randomized control trials (Cuijpers et al., 2012), including the only Randomized Control Trial (RCT) conducted in FAP (Maitland \& Gaynor, 2016), as a control condition. SL is defined as a psychological treatment in which therapists do not engage in any therapeutic strategies other than active listening and offering support, focusing on participants' problems and concerns (Cuijpers et al., 2012, p. 281). In this therapy, the therapist reflects on clients' experiences and encourage them to share emotional experiences. Therapists are prohibited from giving advice, making interpretations, and providing feedback to clients (Cuijpers et al., 2012).~FAP will be introduced at phase B, where contingent reinforcement will be administered for increasing clients' alternative behaviors (CRB2) and differential reinforcement will be utilized to reduce clients' problem behaviors (CRB1)."
62312874|NCT02383719|EXPERIMENTAL|Oro-nasal mask|All patients are included in this arm. Patients in this group receive the experimental oro-nasal mask during non-invasive ventilation
62312875|NCT04291014|EXPERIMENTAL|BWLT once daily|Participants in this arm will receive bright white light therapy daily once a day (in the evening)
62312876|NCT04291014|EXPERIMENTAL|BWLT twice daily|Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).
62312877|NCT04291014|EXPERIMENTAL|BWLT weekly|Participants in this arm will receive bright white light therapy once weekly (in the evening).
62312878|NCT04291014|EXPERIMENTAL|DRLT twice daily|Participants in this arm will receive dim red light twice daily (morning and evening).
62312879|NCT04472104|ACTIVE_COMPARATOR|MBCT-S|Mindfulness-Based Cognitive Therapy for sexuality (MBCT-S) which incorporates several empirically supported therapeutic approaches, integrating elements of education, mindfulness meditation skills, and sex therapy.
62477609|NCT03192163||ResearchMatch Group|
62477610|NCT03192163||Northwestern Center for Ethnic Skin Group|
62477611|NCT00910221|ACTIVE_COMPARATOR|1|
62477612|NCT00910221|PLACEBO_COMPARATOR|2|
62683446|NCT05649306||Patients receiving a cystectomy - Additional Education Group|Patients will receive additional education with standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment. Patients will also be asked to complete an attendance diary documenting additional support services utilized. The Attendance Diary will be completed at 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
62683447|NCT06684652|EXPERIMENTAL|3TB+6SB group|For each predefined mpMRI suspicious lesion, urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained sextant six-core SB.
62683448|NCT06684652|EXPERIMENTAL|3TB+12SB group|For patients in the 3TB+12SB group, urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained fore-zone 12-core SB.
62683449|NCT06679283|EXPERIMENTAL|Open flap debridement with a chemo-electric device + PRF|A mucoperiosteal flap will be raised to visualize the peri-implant defect, granulation tissue will be removed and the implant surface will be cleaned with a chemo-electric device. Thereafter venous blood will be taken, PRF clots and membranes will be prepared after blood centrifugation. The clots and membrane will be applied into the defect. Finally the flap is closed.
62683450|NCT06679283|ACTIVE_COMPARATOR|Open flap debridement with a chemo-electric device alone|A mucoperiosteal flap will be raised to visualize the peri-implant defect, granulation tissue will be removed and the implant surface will be cleaned with a chemo-electric device. Thereafter the flap is closed.
62683451|NCT06679582|EXPERIMENTAL|Cohort 1|Luveltamab tazevibulin 3.5mg every 2 weeks
62683452|NCT06679582|EXPERIMENTAL|Cohort 2|Luveltamab tazevibulin 4.3 mg every 2 weeks
62683453|NCT06669767||Non-specific chronic low back pain|Participants with non-specific chronic low back pain (\>3 months).
62683454|NCT06669767||Control group|Healthy volunteers, without any low back pain.
62123258|NCT03697538|EXPERIMENTAL|Adductor Canal Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
62312880|NCT04472104|ACTIVE_COMPARATOR|SexEd|Sexuality education on sexual desire, sexual distress, and sexual pain.
62312881|NCT00573131|EXPERIMENTAL|Group 1|OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
62312882|NCT00573131|ACTIVE_COMPARATOR|Group 2|Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
62312883|NCT00492921|EXPERIMENTAL|Cyclophosphamide 50|Treatment with cyclophosphamide 50 mg/kg/d x 1 days.
62683455|NCT01487785|EXPERIMENTAL|LDE225+gemcitabine|Increasing doses of LDE225 (from 400 mg) once a day + 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28 day cycle.
62683456|NCT01555424|ACTIVE_COMPARATOR|High dose|
62683457|NCT01555424|ACTIVE_COMPARATOR|Reference dose|
62683458|NCT05833945||Pre-hospital and in-hospital patients|Patients recruited at the ambulance (ARM A) and at the hospital (ARM B).
62683459|NCT04698447|EXPERIMENTAL|Dietary Supplement blinded|20 subjects with the metabolic syndrome receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
62312884|NCT00492921|EXPERIMENTAL|Cyclophosphamide 100|Treatment with cyclophosphamide 50 mg/kg/d x 2 days.
62312885|NCT00492921|EXPERIMENTAL|Cyclophosphamide 150|Treatment with cyclophosphamide 50 mg/kg/d x 3 days.
62312886|NCT02286141||Intervention|Patients receiving care at primary care clinics randomized to receive the supplemental training on stratified care for back pain through the use of the StartBack Tool will be considered to be a part of the intervention group. Randomization is done at the clinic level and not at the individual patient level.
62683460|NCT04698447|PLACEBO_COMPARATOR|Placebo blinded|20 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
62683461|NCT04698447|ACTIVE_COMPARATOR|Dietary Supplement open-label|20 healthy volunteers receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
62683462|NCT06613984||Bretovameran|Korean subjects who are eligible for administration of Comirnaty Injection (Bretovameran) according to the locally authorized label
62683463|NCT04409418|EXPERIMENTAL|Experimental Group|If the patient is randomized to the experimental group (lower arm), the research staff will direct the insert to place the catheter into the forearm at least 10 cm away from the antecubital fossa.
62683464|NCT04409418|ACTIVE_COMPARATOR|Control Group|Control group (upper arm). If the patient is in the control group the research staff will direct the inserter to place the catheter into the upper arm vein at least 2 cm above the antecubital fossa.
62683465|NCT02980458|EXPERIMENTAL|Deferiprone 500 Lipomed film-coated tablets|Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
61923093|NCT03128151||Study group|Intraoperative neuromuscular monitoring and pharmacological reversion according to data sheet
62312887|NCT02286141||Control|Patients receiving care at primary care clinics randomized to receive the standard Group Health training on the updated Guidelines for Back Pain Care will be considered to be a part of the control group. Randomization is done at the clinic level and not at the individual patient level.
62312888|NCT06671288|EXPERIMENTAL|Interventional group|Patients in this group will receive balloon -blowing exercise with abdominal \& lumbar core muscle activation position Total 4 weeks protocol. Three sessions per week will be supervised by physical therapist.
62477613|NCT05422963||severe and critical COVID-19|"1. hospital admission time more than 24 hours~2. meet the standard of definition of severe and critical COVID-19 in Diagnosis and Treatment Plan for new Coronavirus Pneumonia (Ninth Edition)"
62683466|NCT02980458|ACTIVE_COMPARATOR|Ferriprox® film-coated tablets|Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
62477614|NCT05248711|EXPERIMENTAL|Daily Move|Participants (n=107) will be provided free access to and asked to register for the consumer-based mobile meditation app, Calm, on their phone. Participants will then receive an email containing one year of free access to Calm. Participants will be asked to use the Daily Move component on the Calm app for \~10 minutes per day for 8 weeks.
61923094|NCT03128151||Control group|Treated according to usual clinical practice
62683467|NCT06471751|EXPERIMENTAL|Strengthening muscles group|Home training to strengthen Inspiratory and Oropharyngeal muscles
62312889|NCT06671288|ACTIVE_COMPARATOR|Control group|"Patients will receive diaphragmatic breathing exercises. Total 4 weeks protocol.~Before and after 4 weeks pre and post interventional values will be taken."
62312890|NCT05869344|EXPERIMENTAL|Black bean protein hydrolysates (BPH) treatment|Participants received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage
62312891|NCT05869344|PLACEBO_COMPARATOR|Placebo|Participants received 120 mL non-caloric commercial beverage
62123259|NCT03697538|ACTIVE_COMPARATOR|Femoral Nerve Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
62123260|NCT04291729|EXPERIMENTAL|Ganovo+ritonavir with or without interferon nebulization|
62312892|NCT02884466|EXPERIMENTAL|Intervention group|The intervention group will receive a multidisciplinary rehabilitation intervention consisting of: 1) a pre-admission day, 2) two weeks of home-based activities, 3) two-week inpatient period, 4) four weeks of home-based activities, 5) 1st two-days inpatient follow-up, 6) six weeks of home-based activities and 7) 2nd two-days inpatient follow-up.
62312893|NCT02884466|ACTIVE_COMPARATOR|Usual care group|The usual care group will receive a four-week inpatient multidisciplinary rehabilitation intervention.
62477615|NCT05248711|NO_INTERVENTION|Usual Care|Participants (n=107) will be asked to continue with usual care/routine and complete survey measures at each time point. Participants will be provided with access to the intervention after their study participation.
62683468|NCT06471751|NO_INTERVENTION|No training group|No intervention
62123261|NCT01178801||liver cancer|Clinical data of patients with liver cancer
62123262|NCT05470517|ACTIVE_COMPARATOR|Standard of Care (Arm A)|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
62312894|NCT01765647|EXPERIMENTAL|AGY|All participants will receive the same, open-label dose of AGY
62312895|NCT03045484|EXPERIMENTAL|The moderate group|Patient who was suffering from moderate pain in the mouth, pharynx, or larynx during the treatment of chemoradiotherapy consented to take controlled-release oxycodone, oxycodone was begun at the level of mild pain. We called this the moderate group. Controlled-release oxycodone was used to relieve oral mucositis pain induced by chemoradiotherapy in this group.
62477616|NCT03950336|OTHER|"Prebiotics + Low n-6 PUFA Diet"|A combination of beta-fructans (12g/day) and a diet with reduced intake of n-6 PUFAs and higher intake of n-3 PUFAs.
62477617|NCT03950336|OTHER|"Placebo + Control Diet."|A combination of maltodextrin (5g/day) and a control diet following the guidelines of Canada's Food Guide.
62477618|NCT05080894|EXPERIMENTAL|Virtual reality|Daily 20-minute sessions of virtual reality based rehabilitation for the first 4 weeks post-operatively + standard rehabilitation protocol
62737782|NCT02152475|EXPERIMENTAL|PDT with blue light and curcumin|PDT treatment was performed with light and curcumin.The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence. The curcumin concentration of 30 mg/L was used.
61923095|NCT03116347|EXPERIMENTAL|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
61923096|NCT03116347|EXPERIMENTAL|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer \<160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer \>=160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
62737783|NCT02152475|ACTIVE_COMPARATOR|Curcumin|The curcumin concentration of 30 mg/L was used.
62737784|NCT02152475|ACTIVE_COMPARATOR|Blue light|The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence.
61923097|NCT03116347|EXPERIMENTAL|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was \>= 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
61923098|NCT05438641||Conventional Benzodiazepine-based treatment group|Conventional Benzodiazepine-based group includes any subject primarily treated with BZDP agents (e.g., diazepam, lorazepam, chlordiazepoxide).
62477619|NCT05080894|NO_INTERVENTION|Standard intervention|Standard rehabilitation protocol only
62477620|NCT05897684||Treated with avacopan for active AAV|The study will enrol approximately 250 adult patients diagnosed with AAV (MPA or GPA) treated with avacopan for active severe AAV.
61923099|NCT05438641||Benzodiazepine-Sparing|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants).
61923100|NCT00491426||<26 weeks|Subjects \<26 weeks gestational age
61923101|NCT00491426||26-29 weeks|Subjects 26-29 weeks gestational age
61923102|NCT00491426||30-32 weeks|Subjects 30-32 weeks gestational age
61923103|NCT04325399|EXPERIMENTAL|Planning|"The volitional help sheet (VHS) comprises of a list of challenges to being physically active (e.g. If I'm tempted not to go to the gym because it's cold outside) and a list of possible ways to overcome thes (e.g. then I will make myself go to the gym anyway because I know I will feel better afterward). In the experimental VHS link group, participants are asked to form if-then plans by drawing a line between challenges and solutions to link them together."
62123263|NCT05470517|EXPERIMENTAL|Standard of Care and Antibiotic instillation (Arm B)|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy and subsequent instillation of 10ml of intra-peritoneal ceftriaxone (2g)
62123264|NCT02731755|ACTIVE_COMPARATOR|Oat intervention|67.7g oatflake and 22.5g oatbran concentrate - single intake (mixed with water)
62123265|NCT02731755|PLACEBO_COMPARATOR|Control|39.4g cream of rice, 6.1g sunflower oil, 29.5g skimmed milk, 5.6g pectin powder, 6.5g cellulose and mixed with water
62312896|NCT03045484|EXPERIMENTAL|The severe group|Patients who did not ask for controlled-release oxycodone until the pain reached a moderate level during the treatment of chemoradiotherapywere called the severe group. Controlled-release oxycodone was also used to relieve oral mucositis pain induced by chemoradiotherapy in this group..
62737785|NCT05446038|EXPERIMENTAL|Multifamily Guided Self-Help Family-Based Treatment (MF-GSH-FBT)|Treatment consists of up to 12 once-weekly online group sessions, where groups are made up of parents from 4-5 different families of young people with Anorexia. Group sessions will last approximately 50-60 minutes. Prior to each group session, parents watch recorded videos about how parents can help their child with Anorexia. Only parents, and not the young person with Anorexia, attend the group sessions.
62123266|NCT02482519|OTHER|10 day overfeeding/fasting|10 day high calorie diet followed by a 10 day fast
62312897|NCT00754429|EXPERIMENTAL|A|Losartan 50mg qd for 30 weeks, if blood pressure \> 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
62477621|NCT05897684||Treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active AAV|The study will enrol approximately 250 adult patients diagnosed with AAV (MPA or GPA) treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active severe AAV.
62477622|NCT02211924|EXPERIMENTAL|BI 44847|single rising dose
62477623|NCT02211924|PLACEBO_COMPARATOR|Placebo|
62477624|NCT00031395|ACTIVE_COMPARATOR|1|
62477625|NCT00031395|ACTIVE_COMPARATOR|2|
62737786|NCT02591537|EXPERIMENTAL|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
62737787|NCT02591537|NO_INTERVENTION|Standard Tegaderm Dressing|Tegaderm will be applied.
62737788|NCT01420913|ACTIVE_COMPARATOR|Lyrica capsule(Pregabalin 150mg)|
62737789|NCT01420913|EXPERIMENTAL|YHD1119 A(Pregabalin SR 300mg)|
62737790|NCT01420913|EXPERIMENTAL|YHD1119 B(Pregabalin SR 300mg)|
62737791|NCT01420913|EXPERIMENTAL|YHD1119 C(Pregabalin SR 300mg)|
62737792|NCT01712581|EXPERIMENTAL|Healthy volunters|175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
62737793|NCT04946500||Clindamycin and Rifampicin|Patients treated with Clindamycin and Rifampicin
62737794|NCT04946500||Clindamycin and Fluoroquinolone|Patients treated with Clindamycin and Fluoroquinolone
62737795|NCT02507661|EXPERIMENTAL|alveolar ridge preservation - 2 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
62737796|NCT02507661|ACTIVE_COMPARATOR|no-preservation of alveolar ridge - 2 months|no-preservation of alveolar ridge - 2 months
62737797|NCT02507661|EXPERIMENTAL|preservation of alveolar ridge - 4 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
62737798|NCT02507661|ACTIVE_COMPARATOR|no-preservation of alveolar ridge - 4 months|no-preservation of alveolar ridge - 4 months
62737799|NCT02507661|EXPERIMENTAL|preservation of alveolar ridge - 9 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
62737800|NCT02507661|ACTIVE_COMPARATOR|no-preservation of alveolar ridge - 9 months|no-preservation of alveolar ridge - 9 months
62737801|NCT02681419|ACTIVE_COMPARATOR|Needle fenestration|Needle fenestration
62737802|NCT02681419|ACTIVE_COMPARATOR|Suture wick|suture wick using 10-0 vicryl
62737803|NCT05040971|EXPERIMENTAL|Semaglutide|Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks
62737804|NCT05040971|PLACEBO_COMPARATOR|Placebo (semaglutide)|Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks
62312898|NCT00754429|ACTIVE_COMPARATOR|B|Amlodipine 5 mg q.d for 30 weeks, if blood pressure \> 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
62312899|NCT04988893||Parturients with Normal Weight|Parturients undergoing elective caesarean delivery with a BMI \<30 (control group)
62123267|NCT01591304|ACTIVE_COMPARATOR|Group A|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.
62123268|NCT01591304|ACTIVE_COMPARATOR|Group B|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.
62312900|NCT04988893||Parturients with Morbid Obesity|Parturients undergoing elective caesarean delivery with a BMI \>40 (Study Group)
62312901|NCT00779038|EXPERIMENTAL|Fentanyl ITS|40 microgram (mcg) per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an Iontophoretic Transdermal System (ITS). Total duration of treatment will be 72 hours.
62123269|NCT06051786|EXPERIMENTAL|azelastine hydrochloride and fluticasone propionate, 137/50 mcg|The test product, azelastine hydrochloride and fluticasone propionate, 137/50 mcg is manufactured by the sponsor, administered as one spray in each nostril twice daily for 28 days.
62477626|NCT00031395|ACTIVE_COMPARATOR|3|
62477627|NCT00031395|PLACEBO_COMPARATOR|4|
62477628|NCT03402906|EXPERIMENTAL|Family-Clinician Collaboration|Participants are dyads of a stroke survivor and their family member. Family members will work closely with the Clinician to understand the status and goals of the stroke survivor, and family members will integrate Family-Mediated Treatment Procedures into their time spent with the stroke survivor at home.
62737805|NCT01597765|EXPERIMENTAL|Curcuminoids|The administrate curcuminoids is intervention for 30 patients
62123270|NCT06051786|ACTIVE_COMPARATOR|Dymista™|The active control product, Dymista™, is manufactured by Meda Pharmaceuticals, administered as one spray in each nostril twice daily for 28 days.
62123271|NCT02032069||NHBD|Non Heart Beating Donors
62123272|NCT02032069||BDD|Brain death donors
62123273|NCT01681251|EXPERIMENTAL|Intervention|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV \>13%
62123274|NCT01681251|ACTIVE_COMPARATOR|Control|Fluid titrated at the discretion of the attending anesthesiologist.
62123275|NCT01317719||Distal Biceps Ruptures|
62123276|NCT02618486|EXPERIMENTAL|Obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
62123277|NCT02618486|ACTIVE_COMPARATOR|Non obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
62123278|NCT00393484|EXPERIMENTAL|Arm A|"Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)"
62123279|NCT00393484|ACTIVE_COMPARATOR|Arm B|"Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)"
62139690|NCT05610787|EXPERIMENTAL|Active Driver Primary Arm|Up to 40 patients whom receive the Active Driver from implant.
62312902|NCT01804205|EXPERIMENTAL|Magnesium sulfate group|In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
62312903|NCT01804205|PLACEBO_COMPARATOR|Control group|Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
62312904|NCT03366844|EXPERIMENTAL|Pembrolizumab with RT Boost|"Study drug plus tumor boost before standard of care treatment"
62477629|NCT02992366|EXPERIMENTAL|socket shield (A)|"1. Following local anesthetic infiltration opposite to the root to be extracted the root is sectioned in a mesiodistal direction along its long axis as far apical as possible.~2. After sectioning the root into labial and palatal halves, the palatal half is removed with preservation of the labial root section.~3. The labial half is prepared to be Flushing or 1mm above the labial alveolar crest. Then thinned slightly to a concave contour in an apico-coronal and mesiodistal direction.~4. The implant will be inserted in place of the palatal half with the labial surface of the implant facing the labial root shield (root-implant interface)~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
62737806|NCT01597765|EXPERIMENTAL|Vitamin E|The vitamin E is intervention for 30 patients
62737807|NCT04806061|EXPERIMENTAL|sodium bicarbonate|iv sodium bicarbonate 8.4%
62312905|NCT06408194|EXPERIMENTAL|Lymphodepletion|All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
62312906|NCT06397261||adult patients undergoing elective surgery|adult patients undergoing elective surgery requiring tracheal intubation
62312907|NCT00537940|ACTIVE_COMPARATOR|A|
62312908|NCT00537940|ACTIVE_COMPARATOR|B|
62312909|NCT02313480|ACTIVE_COMPARATOR|non-massage group|received exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
62737808|NCT04806061|EXPERIMENTAL|control|standard care
62312910|NCT02313480|EXPERIMENTAL|massage group|Received massage, exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
62737809|NCT05797909||Target Population|The target population includes individuals diagnosed with PCOS by a healthcare provider, self-diagnosed with PCOS, or who are exhibiting PCOS Symptoms and willing to sign the consent.
62312911|NCT06369428||Distant Metastasis Cohort|Adult patients diagnosed with stage 4 (distant) metastatic melanoma between 2014 and 2021.
62312912|NCT06369428||Regional Metastasis Cohort|Adult patients diagnosed with stage 3 (regional) metastatic melanoma between 2014 and 2021.
62312913|NCT00649298|EXPERIMENTAL|extended hours|24 or more hours per week of hemodialysis
62123280|NCT02496975|EXPERIMENTAL|Cyclosporine A|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
62123281|NCT02496975|ACTIVE_COMPARATOR|Placebo|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
62139691|NCT05610787|NO_INTERVENTION|IKUS Comparator|All patients whom receive the (FDA approved) IKUS Driver from implant and are entered into the ACTION Registry.
62312914|NCT00649298|ACTIVE_COMPARATOR|standard hours|18 or less hours per week of hemodialysis
62312915|NCT05263882|OTHER|single arm|"* Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
62312916|NCT04575350||Cohort|no intervention.
62312917|NCT00537745|EXPERIMENTAL|Vivitrol|Vivitrol 380 mg/monthly, plus individual compliance enhancement therapy (Medication Management Therapy).
62477630|NCT02992366|ACTIVE_COMPARATOR|conventional immediate implant (B)|"1. Following local anesthetic infiltration opposite to the root to be extracted non traumatic extraction of the tooth or remaining root by periotome.~2. The implant fixture will be inserted in the empty socket by conventional manner.~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
62139692|NCT01688765||First Episode Psychosis Patients|Individuals experiencing a first episode of psychosis
61923104|NCT04325399|NO_INTERVENTION|No planning|Participants in the VHS tick group are presented with the exact same volitional help sheet as the experimental group, the only difference being that participants in this group are not asked to make if-then plans. Rather, participants in the control group are asked to tick challenges and solutions that they feel are relevant to them.
61923105|NCT05078918|EXPERIMENTAL|Comprehensive care program|Intervention group receiving newly developed comprehensive care program pre- and post-operatively.
61923106|NCT05078918|ACTIVE_COMPARATOR|Usual care|Control group receiving usual care
61923107|NCT00404703|EXPERIMENTAL|1|
61923108|NCT03059446|EXPERIMENTAL|Cenicriviroc (CVC) 150 mg|Cenicriviroc 150 mg tablet once daily in the morning with food until the study was terminated (up to approximately 4 years).
61923109|NCT01689909|ACTIVE_COMPARATOR|Zolpidem-CR|Zolpidem 6.25 or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
61923110|NCT01689909|PLACEBO_COMPARATOR|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
61923111|NCT01234727||Diabetes|Patients with Type 1 or Type 2 diabetes requiring insulin.
61923112|NCT00504036|EXPERIMENTAL|Intra-gastric balloon|Patients will receive either an air-filled or water-filled intra-gastric balloon.
61923113|NCT00504036|NO_INTERVENTION|Usual care|Usual care will be given to the patients.
61923114|NCT02857595|ACTIVE_COMPARATOR|Online Weight Loss Program|
61923115|NCT02857595|EXPERIMENTAL|Online Weight Loss Program + Nomogram|
61923116|NCT02857595|EXPERIMENTAL|Online Weight Loss Program + Nomogram + Bite Counter|
62737810|NCT05797909||Control Population|The control population includes people born biologically female who have not been diagnosed with PCOS and who also do not have symptoms of PCOS.
62737811|NCT02010242|EXPERIMENTAL|GKT137831|GKT137831 100 mg capsules twice a day
62737812|NCT02010242|PLACEBO_COMPARATOR|Placebo|Placebo capsule twice a day
61923117|NCT01417182|EXPERIMENTAL|Melanoma|
61923118|NCT01110655|EXPERIMENTAL|Intravenous hypertonic saline|
61923119|NCT01110655|EXPERIMENTAL|Oral hypertonic saline|
61923120|NCT01411930|EXPERIMENTAL|Olanzapine -> Aripiprazole|Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
61923121|NCT01411930|EXPERIMENTAL|Aripiprazole -> Olanzapine|Crossover design. Order of agents is randomized. For this arm, the order will be IM aripiprazole (1st clamp study) and IM olanzapine (2nd clamp study).
61923122|NCT05072886|EXPERIMENTAL|AT193|Topical applied daily
61923123|NCT05072886|PLACEBO_COMPARATOR|Placebo|Topical applied daily
61923124|NCT01753739|EXPERIMENTAL|Bepotastine besilate Concentration 1|Bepotastine besilate nasal spray, BID for 14 days.
61923125|NCT01753739|ACTIVE_COMPARATOR|Placebo|Placebo nasal spray BID for 14 days
61923126|NCT01753739|EXPERIMENTAL|Bepotastine besilate Concentration 2|Bepotastine besilate nasal spray, BID for 14 days.
61923127|NCT01753739|EXPERIMENTAL|Bepotastine besilate Concentration 3|Bepotastine besilate nasal spray, BID for 14 days.
61923128|NCT01753739|EXPERIMENTAL|Bepotastine besilate Concentration 4|Bepotastine besilate nasal spray, BID for 14 days.
62312918|NCT03774017|OTHER|Traditional microsurgery group|Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater. No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed. The DSA will be performed in 3 days after the operation.
62683469|NCT06690593||Monoclonal gammopathy patients|"(I) Inclusion Criteria:~1. Age 45 years or older.~2. Positive screening for monoclonal protein by MALDI-TOF MS.~3. Meeting the International Classification of Diseases, 11th Revision (ICD-11) criteria for one of the following disease types:Infectious diseases，Tumors，Blood or hematopoietic organ diseases，Immune system diseases，Endocrine, nutritional, or metabolic diseases，Nervous system diseases，Circulatory system diseases，Respiratory system diseases，Digestive system diseases，Musculoskeletal or connective tissue diseases，Urinary and reproductive system diseases.~4. Sufficient whole blood, plasma, serum, and stool samples available, with relevant case data provided.~(II) Exclusion Criteria:~1. History of intestinal tumors, irritable bowel syndrome, or inflammatory bowel disease, or diagnosed during hospitalization.~2. Antibiotic treatment in the past month.~3. Insufficient sample volume, or severe hemolysis, lipemia, jaundice, or other unqualified sample conditions."
62683470|NCT06690593||Non-monoclonal gammopathy patients|"(I) Inclusion Criteria:~1. Age 45 years or older.~2. Negative screening for monoclonal protein by MALDI-TOF MS.~3. Patients meeting ICD-11 criteria for one of the following disease types:Infectious diseases，Tumors，Blood or hematopoietic organ diseases，Immune system diseases，Endocrine, nutritional, or metabolic diseases，Nervous system diseases，Circulatory system diseases，Respiratory system diseases，Digestive system diseases，Musculoskeletal or connective tissue diseases，Urinary and reproductive system diseases.~4. Sufficient whole blood, plasma, serum, and stool samples available, with relevant case data provided.~(II) Exclusion Criteria:~1. History of intestinal tumors, irritable bowel syndrome, or inflammatory bowel disease, or diagnosed during hospitalization.~2. Antibiotic treatment in the past month.~3. Insufficient sample volume, or severe hemolysis, lipemia, jaundice, or other unqualified sample conditions."
62312919|NCT03774017|EXPERIMENTAL|Hybrid operation group|Patients receive microsurgical operation under the assistance of intraoperative DSA, endovascular embolization and/or balloon occlusion in the one-staged hybrid operating theater.
62312920|NCT00997412|EXPERIMENTAL|MA|MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
62312921|NCT00997412|ACTIVE_COMPARATOR|AZA|AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
62312922|NCT02719483|ACTIVE_COMPARATOR|rESWT + traditional conservative therapy|Radial extracorporeal shock wave therapy (rESWT) performed with the Swiss DolorClast device (EMS Electro Medical Systems, Nyon, Switzerland) plus traditional conservative therapy.
62312923|NCT02719483|OTHER|Traditional conservative therapy|Traditional conservative therapy alone.
62312924|NCT06288386|EXPERIMENTAL|Higher filler content composite|Attachments will be performed with a higher filler content flowable composite resin.
62312925|NCT06288386|ACTIVE_COMPARATOR|Lower filler content composite|Attachments will be performed with a lower filler content flowable composite resin.
62477631|NCT02885285|EXPERIMENTAL|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
62737813|NCT01634880|EXPERIMENTAL|Postoperative Radiotherapy and Panitumumab|
61923129|NCT01179035|ACTIVE_COMPARATOR|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
62312926|NCT06145490|OTHER|Panic Disorder|Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
62312927|NCT06145490|OTHER|Healthy controls|Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
62312928|NCT02973815|EXPERIMENTAL|NU-HOME Intervention|Participants randomized to the intervention condition will receive the NU-HOME family intervention program that includes group sessions with other families focused on nutrition education, cooking skills, and physical activity. The intervention program also includes individual goal setting phone calls with parents and online, complementary materials.
62312929|NCT02973815|NO_INTERVENTION|Delayed Intervention|Participants randomized to the delayed intervention condition will not receive any educational materials or training until after the final data collection. Once all data collection is completed, they will receive a shortened version of the NU-HOME intervention program that was offered to the intervention families.
61923130|NCT01179035|EXPERIMENTAL|Transitions Clinic - Parolee Targeted Care|Following randomization, subjects in this arm receive ongoing primary care in a parolee-targeted clinic. Parolee-targeted care includes care from clinicians with a knowledge of the impacts of incarceration on health and experience caring for formerly incarcerated patients, a community health worker that works in medical and social services coordination and chronic disease education, and linkages with community-based organizations serving formerly incarcerated individuals.
62312930|NCT05767957|ACTIVE_COMPARATOR|Control group|
62312931|NCT05767957|EXPERIMENTAL|Intervention group|
61923131|NCT03911310|EXPERIMENTAL|PET/CT 1: [18F]PSMA-11, PET/CT 2: [68Ga]PSMA-11|Patients in this arm will first receive the experimental radiotracer \[18F\]PSMA-11 PET/CT followed by the \[68Ga\]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
62123282|NCT03957213|EXPERIMENTAL|Active IH + CT|Acute intermittent hypoxia will be provided to the subject by delivering 15 brief exposures (\~60 seconds) of hypoxic air alternated with 15 brief exposures (\~60 seconds) of room air. The amount of oxygen delivered during hypoxic exposures may range from 15%-9% fraction of inspired oxygen, compared to 21% oxygen in normal atmospheric air. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training.
62312932|NCT04007029|EXPERIMENTAL|Treatment (fludarabine, cyclophosphamide, CD19/CD20 T-cells)|"CONDITIONING CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60 minutes 5, 4, and 3 days before cell infusion.~T-CELL INFUSION: Patients receive CD19/CD20 CAR-T cells IV on day 0. Patients with cytokine release syndrome may also receive tocilizumab IV on day 2 at the discretion of the clinical investigator."
62477632|NCT02885285|EXPERIMENTAL|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
61923132|NCT03911310|ACTIVE_COMPARATOR|PET/CT 1: [68Ga]PSMA-11, PET/CT 2: [18F]PSMA-11|Patients in this arm will first receive the experimental radiotracer \[68Ga\]PSMA-11 PET/CT followed by the \[18F\]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
61923133|NCT01568788|EXPERIMENTAL|Inactivated Influenza Vaccine|15μg HA/strain/0.5ml/syringe, Hualan Biologicals
61923134|NCT01568788|ACTIVE_COMPARATOR|Inactivated Influenza Vaccine of Pasteur|15ug HA/strain/0.5ml/syringe, Sanofi Pasteur
61923135|NCT01568788|ACTIVE_COMPARATOR|Inactivated Influenza Vaccine of GSK|15ug HA/strain/0.5ml/syringe, GSK
62123283|NCT03957213|SHAM_COMPARATOR|Sham IH + CT|A sham protocol will be administered in which 21% fraction of inspired oxygen will be delivered by the hypoxicator during hypoxic intervals, and room air will be delivered through the four-way valve during room air intervals. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training (Posit; Brain HQ).
62123284|NCT00339742||Clinic Referral controls|Controls referred by the endoscopy clinic
62123285|NCT00339742||Esophageal Cancer cases|Histologically confirmed squamous cell cancer of the esophagus
62477633|NCT02885285|EXPERIMENTAL|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
62312933|NCT01948934|EXPERIMENTAL|amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
61923136|NCT05590221|EXPERIMENTAL|Relmacabtagene Autoleucel|Participants will receive cyclophosphamide250 mg/m\^2/day intravenously (IV) and fludarabine 25 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day 1.
61923137|NCT01411072|EXPERIMENTAL|Gemcitabine|
61923138|NCT01411072|EXPERIMENTAL|5-fluorouracil|
62312934|NCT01223911|EXPERIMENTAL|A|
62312935|NCT01223911|PLACEBO_COMPARATOR|B|
62312936|NCT05485012|EXPERIMENTAL|Double-blind marijuana/placebo administration|Participants will receive double-blind administration of vaporized marijuana/placebo
61923139|NCT00285467|EXPERIMENTAL|Doxercalciferol|doxercalciferol 1 mcg capsule orally daily for 3 months. This is a form of vitamin D that does not require activation by enzymes in the liver and kidney.
62312937|NCT05485012|EXPERIMENTAL|Double-blind opioid/placebo administration|Participants will receive double-blind administration of intranasal opioid agonist/placebo
62312938|NCT06672562|EXPERIMENTAL|NECT-Y|Virtual 14-week Narrative Enhancement and Cognitive Therapy group intervention that will be co-facilitated by a clinician and peer support worker.
61923140|NCT00285467|ACTIVE_COMPARATOR|Cholecalciferol|cholecalciferol 4000 IU capsule orally daily for one month, then 2000 IU capsule daily orally for 2 months. this form of vitamin D requires activation by cells of the body.
62139693|NCT01688765||Healthy Controls|Psychiatrically healthy individuals
62139694|NCT05503368|EXPERIMENTAL|Autologous Cellular Micro-grafts suspension added to non cultured epidermal suspension (NCES)|Under local anesthesia, a 2.5 mm punch biopsy will be used to extract 3 scalp tissue specimens from the patient's occiput behind the ear, using Rigeneracons medical device (CE certified class I; Human Brain Wave, Turin, Italy). The collected specimens will be placed in Rigeneracons by adding 1.5 mL of sterile physiologic solution to the device. The device then generates a cellular suspension by rotation of Rigeneracons at 80 RPM for 2 minutes. Subsequently, the obtained suspension is diluted with an additional 3 mL sterile physiologic solution. The resulting suspension will be added to NCES and placed on one of the derma braded vitiligo patches
62683471|NCT06690593||Healthy control group|"(I) Inclusion Criteria:~1. Age 45 years or older.~2. Negative screening for monoclonal protein by MALDI-TOF MS.~3. No significant diseases found upon medical examination, and confirmed not to have any diseases related to this study.~4. Sufficient whole blood, plasma, serum, and stool samples available, and relevant case data can be provided.~(II) Exclusion Criteria:~1. History of intestinal tumors, irritable bowel syndrome, or inflammatory bowel disease, or diagnosed during hospitalization.~2. Antibiotic treatment received in the past month. Presence of severe systemic diseases, including malignant tumors.~3. Insufficient sample volume, or presence of severe hemolysis, lipemia, jaundice, or other unqualified sample conditions."
62683472|NCT04356378||"infection with coronavirus SARS-CoV2 group"|"SARS-CoV2 infected patients group: in-patient in the acute phase then requiring rehabilitation."
62683473|NCT06375564|EXPERIMENTAL|177Lu-AB-3PRGD2|177Lu-AB-3PRGD2 A maximum of 4 cycles of 80 mCi (2.96 GBq) 177Lu-AB-3PRGD2, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, every 6 weeks
62683474|NCT06678828|OTHER|The control|Control/Standard of Care arm- ClarityDX Prostate will be run for these participants. Participants and healthcare providers will be blinded to the results report and participants will be considered for prostate MRI and /or biopsy based on standard clinical criteria. Once the care path has been decided upon, the results of the ClarityDX Prostate will be shared.
62477634|NCT02885285|ACTIVE_COMPARATOR|No Exercise Class|Subjects randomly selected for the no class group will not participate in the study exercise classes. Subjects will still complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
62123286|NCT00339742||Neighborhood controls|Controls recruited from the neighborhood
62123287|NCT04992156||Patients cohort|Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FES PET/CT before the initiation of Palbociclib was included.
62123288|NCT00575523|ACTIVE_COMPARATOR|1: Atropine|Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.
62477635|NCT03896126||Gastroparesis Patients|20 gastroparesis patient ages 20-49
62477636|NCT03896126||Healthy Controls|40 healthy controls ages 20-49
62683475|NCT06678828|EXPERIMENTAL|ClarityDX Prostate|The report will be shared for participants randomized into ClarityDX Prostate arm before the healthcare team decided if an MRI and/or biopsy should be done.
62683476|NCT06058793|EXPERIMENTAL|Brigimadlin treatment|
62683477|NCT00059280|EXPERIMENTAL|1|
62683478|NCT03303066|EXPERIMENTAL|Phase 2 Part: FG-4592|Fixed starting doses (different doses for lower body weight \& higher body weight) of FG-4592 administered orally 3 times a week (TIW) for up to 26 weeks; dose adjustments to Hb levels are allowed during the study.
62683479|NCT03303066|EXPERIMENTAL|Phase 3 Part: FG-4592|Fixed starting doses (different doses for lower body weight \& higher body weight) of FG-4592 administered orally TIW for up to 26 weeks; dose adjustments to Hb levels are allowed during the study.
62683480|NCT03303066|PLACEBO_COMPARATOR|Phase 3 Part: Placebo|Placebo (matching to FG-4592) administered orally TIW for up to 26 weeks.
62683481|NCT06625086|ACTIVE_COMPARATOR|Self-Guided Exercise Group|A brochure explaining and demonstrating the exercises to be performed in treatment will be provided to 20 patients with PFPS. Patients will be asked to follow the exercise program for 6 weeks, 3 days per week, performing each exercise twice a day with 10 repetitions for each exercise.
62683482|NCT06625086|EXPERIMENTAL|Supervised Exercise Group|Twenty patients with PFPS will perform exercises taught under the supervision of a physiotherapist for 6 weeks, 3 days per week, with each exercise performed twice a day and repeated 10 times.
61923141|NCT03550651|EXPERIMENTAL|Licorice extract mouthrinse|10ml twice a day for 4 Days.
61923142|NCT03550651|EXPERIMENTAL|Hypertonic salt solution|10ml twice a day for 4 Days.
61923143|NCT03550651|ACTIVE_COMPARATOR|Essential oil mouthrinse|10ml twice a day for 4 Days.
61923144|NCT03550651|ACTIVE_COMPARATOR|Chlorhexidine Gluconate mouthrinse|10ml twice a day for 4 Days.
62123289|NCT00575523|PLACEBO_COMPARATOR|2: Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
62123290|NCT02607670|EXPERIMENTAL|TAT4 Gel|The participant will apply TAT4 Gel to the nasolabial fold area once daily.
62123291|NCT02607670|PLACEBO_COMPARATOR|Placebo|The participant will apply Placebo Gel to the nasolabial fold area once daily.
62123292|NCT04682483||Cardiogenic Shock Patients|"Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below.~1. Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP \< 60mmHg or a \>30mmHg drop in MAP from baseline, SBP \< 90mmHg or a \>30mmHg drop in SBP from baseline, Pulse \> 100, Cardiac Index \< 2.2, Cardiac Power Output ≤ 0.6 or PAPI \< 1.0.~2. Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets."
62123293|NCT01924026||Affected MHP|With Phe between 360 and 600 micromoles/L
62123294|NCT01924026||Unaffected Siblings|With normal Phe levels
62477637|NCT04443790|ACTIVE_COMPARATOR|Obesecure Capsules (Test Group)|A dose of 500mg capsule twice daily of Polyherbal formulation Obesecure was given in the test group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
62477638|NCT04443790|PLACEBO_COMPARATOR|Plasicure (Control Group)|A dose of 500mg capsule twice daily of Placebo as Plasicure was given in the control group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
62737814|NCT06451692|ACTIVE_COMPARATOR|Intervention group|The clinical pharmacist will assess the patient's medication, and perform interviews with the patient and/or the patient's attorney-in-fact. Potential medical recommendations will be discussed with the treating hospital clinician and the clinical pharmacist, and a medication plan will be developed together with the patient or the patient's attorney-in-fact. The GPs will be informed through optimized discharge summaries.
61923145|NCT03550651|PLACEBO_COMPARATOR|Distilled water|10ml twice a day for 4 Days.
61923146|NCT01393015|EXPERIMENTAL|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
62123295|NCT05638945|NO_INTERVENTION|Control Period|"Delirium screening on initial assessment of all older adults presenting to the ED is considered standard of care, but not mandated. All health system EDs have access to a validated EHR integrated delirium screening tool (brief confusion assessment method, or bCAM) and all ED nurses have received training on bCAM use. The bCAM tool is an open parameter in the EHR. For positive bCAM screens, a message is displayed, This patient has delirium, alert medical team, identify/ treat the underlying cause, ensure patient safety, nonpharmacologic interventions as first line, and avoid physical and chemical restraints. The control period will include chart reviews of patient visits occurring before implementation of the ED-DDP program."
62312939|NCT06672562|PLACEBO_COMPARATOR|Treatment as usual|No study-specific care will be provided to these participants.
62312940|NCT03641300|EXPERIMENTAL|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
62312941|NCT03641300|ACTIVE_COMPARATOR|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
62312942|NCT02698423|EXPERIMENTAL|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
62477639|NCT04176835|EXPERIMENTAL|oxytocin|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
61923147|NCT01393015|ACTIVE_COMPARATOR|Rotameter (flowmeter)|A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.
61923148|NCT05078502|ACTIVE_COMPARATOR|Intervention Vitamin D3 along with CsDMARDs|One capsule of vitamin D3 (40000IU) weekly for 8 weeks
62123296|NCT05638945|EXPERIMENTAL|Intervention Period|ED leadership at each site have identified 5-10 delirium champions (nurse educators and managers, bedside nurses) based on their interest in delirium and commitment to program participation, including training of nurses by champions. The intervention period will include chart reviews of patient visits occurring after implementation of the ED-DDP program.
62123297|NCT03133117|EXPERIMENTAL|Cerebral Bases of Central and Peripheral Visual Integration|
62123298|NCT01387334|EXPERIMENTAL|Resistance Exercise Training Program|
62123299|NCT01395758|EXPERIMENTAL|tivantinib (ARQ 197) plus erlotinib arm|"Eligible subjects will be randomly assigned to receive erlotinib plus tivantinib (ARQ 197).~Treatment will be open-label and continue until progression of disease, unacceptable toxicity, or another discontinuation criterion is met."
62312943|NCT02698423|ACTIVE_COMPARATOR|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
62312944|NCT05582837|EXPERIMENTAL|nortriptyline + topiramate|Nortriptyline (starting dose 7.5 mg) plus Topiramate (starting dose 10 mg) with appropriate dosage increase as necessary
62312945|NCT05582837|ACTIVE_COMPARATOR|hydrochlorothiazide + triamterene + placebo|hydrochlorothiazide (starting dose 25 mg) plus triamterene (starting dose 37.5 mg) with placebo being added in case of a dosage increase
62312946|NCT01408537|EXPERIMENTAL|JEVAC|JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year
62312947|NCT03088904|EXPERIMENTAL|Group A: MZ twins (IIV4)|Group A: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62312948|NCT03088904|EXPERIMENTAL|Group B: DZ twins (IIV4)|Group B: Up to 40 healthy dizygotic (DZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), and Day 6-8 and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
62477640|NCT04176835|PLACEBO_COMPARATOR|Placebo|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
62477641|NCT04215718|ACTIVE_COMPARATOR|fistulotomy group|46 patients with simple anal fistula underwent fistulotomy and marsupialization of wound edges
62477642|NCT04215718|ACTIVE_COMPARATOR|fistulectomy group|46 patients with simple anal fistula underwent fistulectomy and closure of the wound
62477643|NCT01977521|EXPERIMENTAL|Treatment|transcranial direct current stimulation (2mA)
61923149|NCT05078502|PLACEBO_COMPARATOR|Placebo of Vitamin D3 along with CsDMARDs|One capsule of placebo of vitamin D3(40000IU) weekly for 8 weeks
61923150|NCT03504670|EXPERIMENTAL|Early amniotomy|Women randomized to early amniotomy will have their membranes ruptured in usual fashion using an amniotomy hook when the cervix is less than 4cm dilated. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. Prior to amniotomy, the obstetric provider will assess whether or not the fetal head is engaged. If the fetal head is not engaged (applied to the cervix), amniotomy will be deferred. The patient will be examined every 2 hours until amniotomy can be safely performed (in keeping with our institutional standard of care to examine women every 2-4 hours in labor).
62312949|NCT03088904|EXPERIMENTAL|Group C: MZ twins (IIV4 or LAIV4)|"Group C: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).~This group was terminated in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability."
61923151|NCT03504670|EXPERIMENTAL|Late amniotomy|Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
61923152|NCT06063707||Survivors|Sepsis induced ARDS patients who survived
61923153|NCT06063707||Nonsurvivors|Sepsis induced ARDS patients who not survived
62683483|NCT06625086|EXPERIMENTAL|Web-Based Exercise Group|"Group 3 (Web-Based Exercise Group): Twenty patients with PFPS will participate in a web-based exercise program for 6 weeks, 3 days per week, with each exercise performed twice a day and repeated 10 times.~Web-Based Remote Exercise Program: The web-based application will be created using iOS and Android operating systems. Exercises specifically designed for PFPS treatment will be included in the application through video tutorials. Descriptive text explaining each exercise will be provided below each video. Information on how well each participant adheres to the exercise program, how frequently they perform each exercise, and their current status will be recorded."
62683484|NCT06675266||CASE|Fetuses with brain anomalies
62683485|NCT06675266||CONTROLS|Fetuses with brain anomaly
62683486|NCT00079781|ACTIVE_COMPARATOR|Treatment Group|Group of subjects who have undergone RNS® System implantation who are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the blinded Evaluation Period. Stimulation is enabled during the first month post-implant and may continue throughout the subject's participation in the study.
61923154|NCT02331875|EXPERIMENTAL|single arm|IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy
61923155|NCT03131453|EXPERIMENTAL|CNP520 50 mg|50 mg capsule taken orally once daily
61923156|NCT03131453|EXPERIMENTAL|CNP520 15 mg|15 mg capsule taken orally once daily
61923157|NCT03131453|PLACEBO_COMPARATOR|Placebo|Matching placebo to 15 and 50 mg CNP520 taken orally once daily
62312950|NCT05435248|EXPERIMENTAL|HS-10375|"Experimental: HS-10375（Phase 1a：Dose Escalation） Subjects with advanced or metastatic NSCLC will be enrolled in dose escalation cohorts. Dose escalation of HS-10375 will be done to determine maximum tolerated dose.~Experimental: HS-10375（Phase 1b：Dose Expansion） Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced or metastatic NSCLC having a EGFR C797S mutation.~Experimental: HS-10375（Phase 2） Subjects with locally advanced or metastatic EGFR C797S mutant NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10375 as monotherapy."
62312951|NCT02696512|EXPERIMENTAL|IBRF ACP/MCP Group 1|The Treatment group will be receiving a combination of pharmaceuticals (polypharmacy using FDA-approved products) and nutraceuticals (Nutraceutical supplementation) and median nerve stimulation (MNS)
62312952|NCT02696512|OTHER|Standard of Care Group 2|Standard of Care only
61923158|NCT06447493|EXPERIMENTAL|OMT Intervention, then Rest|10 subjects will be randomized to begin with the dominant shoulder. Investigators will measure baseline outcomes on the dominant shoulder, apply OMT treatment, measure post treatment outcomes on dominant shoulder, a 5-minute rest period as a washout period, then proceed to measure baseline measures on non-dominant shoulder, a rest that is equivalent to the time needed for OMT treatment, ending with post measurements on the non-dominant shoulder.
62312953|NCT04957498|ACTIVE_COMPARATOR|FBT|Family Based Treatment (FBT) includes up to 15 session (50-60 minutes) with a trained therapist.
62312954|NCT04957498|EXPERIMENTAL|FBT-GSH|Family Based Treatment Guided Self-Help (FBT-GSH) includes an online website with educational videos, readings, discussion groups, and journals. Parents assigned to this arm will have up to 12 coaching sessions (20-30 minutes) with a trained therapist.
62477644|NCT01977521|SHAM_COMPARATOR|Sham|Sham stimulation
62477645|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
62477646|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
62123300|NCT01395758|ACTIVE_COMPARATOR|Chemotherapy arm|Investigator's choice of single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered in 3-week cycles according to the approved label until disease progression or unacceptable toxicity. Subjects who discontinued chemotherapy can be switched to the crossover arm (tivantinib plus erlotinib) and continue treatment until disease progression or unacceptable toxicity.
62123301|NCT04878198|EXPERIMENTAL|Jogging intervention|This intervention will be a 10-week jogging program consisting of 50 sessions (5 sessions per week, 30 min per session) in each participating school. The jogging program is confined to morning sessions based on the favourable sleep outcomes from previous study. To counteract the possible influence of natural sunlight exposure, all jogging sessions will be confined to indoor setting. Each session will be conducted in an identical format with 5 minutes of warm-up activities, followed by 20 minutes of jogging (intervention), and 5 minutes of cool-down activities. Participants are instructed to jog at a moderate intensity level. The intensity level of jogging will be measured by heart rate monitor (Polar H1). Meanwhile, questionnaire will be given to the research staff assisting the jogging intervention to assess the adherence of the intervention at T2.
62123302|NCT04878198|EXPERIMENTAL|Melatonin supplement group|Participants in this intervention group will undergo a 10-week melatonin supplement intervention period, where melatonin supplement (Natrol®, Chatsworth CA) will be provided 30 minutes before bedtime. The prescription time (i.e. 30 minutes before bedtime) and the dosage of 3mg will be used because these are optimal for most of the participants as suggested by Malow and colleagues. 1 mg and 9 mg are not suggested to ensure the effectiveness of the intervention while preventing the potential daytime sleepiness. Similar to the aforementioned intervention, adherence of the intervention will be assessed at T2.
62123303|NCT04878198|EXPERIMENTAL|Combination group|Participants will receive the jogging program and supplemental melatonin dose with identical format as that in the intervention A and B (e.g., identical duration, identical manpower, identical warm-up and cool-down, identical dose, identical acclimation procedure before the intervention adherence of the intervention for this group will also be assessed at T2.
62312955|NCT04249453||Chronic low back pain with high disability|Veterans with chronic, non-specific LBP and a Roland-Morris Disability Questionnaire (RMDQ) score of \>12 (gender-balanced, n1=18)
62312956|NCT04249453||Chronic low back pain with low disability|Veterans with chronic, non-specific LBP and a RMDQ score of 12 (gender-balanced, n2=18)
62123304|NCT04878198|NO_INTERVENTION|Control group|Participants in the placebo control group will receive no jogging and melatonin supplement dosing activity. However, they will be given a placebo flavored similar to the melatonin supplement (compounded by Pharmacare, Mt. Juliet, NT®). Meanwhile, they will also be required to wear an actigraph to control for their physical activity level at the assessment points (i.e. T1, T2, and T3). They will be expected for following their daily routine without participating in any additional formal physical exercise training program throughout the whole study period (T1-T3). After T3, they will be assisted with jogging program to recognize their contribution as controls.
62123305|NCT05414786|EXPERIMENTAL|Experimental group|"* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study"
62312957|NCT04249453||Controls|Asymptomatic veterans with no recent history of LBP (gender-balanced, n3=18)
62312958|NCT01645280|PLACEBO_COMPARATOR|Group 1|
62312959|NCT01645280|EXPERIMENTAL|Group 2|
62312960|NCT01645280|EXPERIMENTAL|Group 3|
62312961|NCT01645280|EXPERIMENTAL|Group 4|
62312962|NCT01645280|EXPERIMENTAL|Group 5|
62312963|NCT04985708||Patient with AMICS are likely to benefit from MCS|later
62477647|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
62477648|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
62477649|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
62312964|NCT04985708||Develop and maintain a patient registry of AMICS|later
61923159|NCT06447493|EXPERIMENTAL|Rest, then OMT Intervention|10 subjects will be randomized to begin with the non-dominant shoulder. Investigators will measure baseline outcomes on the non-dominant shoulder, a rest period equivalent to the time needed for OMT treatment, measure post treatment outcomes on non-dominant shoulder, a 5-minute rest period as a washout period, then proceed to measure baseline measures on dominant shoulder, provide OMT treatment, ending with post measurements on the dominant shoulder.
61923160|NCT01549912||Rotator cuff tear|
61923161|NCT05540080|EXPERIMENTAL|Evaluation of change in adipose and muscle layer thickness|Evaluation of change in adipose and muscle layer thickness between pre-treatment and post-treatment based on MRI imaging and waist circumference measurements
61923162|NCT03518931|NO_INTERVENTION|Control|This arm included individuals randomized to receiving fitness information only.
61923163|NCT03518931|EXPERIMENTAL|Intervention|This arm included individuals randomized to having fitness assessments performed.
61923164|NCT02781519|ACTIVE_COMPARATOR|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
61923165|NCT02781519|PLACEBO_COMPARATOR|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
61923166|NCT01231230|EXPERIMENTAL|fluticasone/salmeterol|participants were treated fluticasone/salmeterol,
62683487|NCT00079781|SHAM_COMPARATOR|Sham Group|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the blinded Evaluation Period. Stimulation is enabled after transition into the Follow-Up Period (5th month post-implant) and may continue for the remainder of the subject's participation in the study.
62683488|NCT00079781|OTHER|Open Label Group|Group of subjects who have undergone RNS® System implantation who were not randomized or blinded to therapy status during the Evaluation Period. Stimulation may have been enabled during the first month post-implant and may have continued throughout the subject's participation in the study.
62683489|NCT06686342||Observational cohort|The observational group of patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience. No intervention would be provided based on the drug sensitive test from patient-derived organoid.
61923167|NCT01231230|EXPERIMENTAL|salmeterol|participants were treated with salmeterol
61923168|NCT01231230|EXPERIMENTAL|fluticasone|participants were treated with fluticasone
61923169|NCT01231230|PLACEBO_COMPARATOR|placebo inhalation|participants were treated with placebo
61923170|NCT01339026|ACTIVE_COMPARATOR|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
61923171|NCT01339026|ACTIVE_COMPARATOR|Clopidogrel|Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
61923172|NCT01594385|OTHER|Seprafilm|The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.
61923173|NCT01594385|NO_INTERVENTION|No Seprafilm|This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.
61923174|NCT00488878||Observational (electronic health record review)|Patients' medical records are reviewed for retrospective and prospective data collection. Patients may also have residual tissue samples collected and stored.
61923175|NCT05369260|EXPERIMENTAL|Cervical and scapular stabilization group|In this arm cervical and scapular stabilization exercises will be applied based on the telerehabilitation method via videoconference for 8 weeks, one day a week , 45-60 minutes for each session.
61923176|NCT05369260|EXPERIMENTAL|Cervical and core stabilization group|In this arm cervical and core stabilization exercises will be applied based on the telerehabilitation method via videoconference for 8 weeks, one day a week , 45-60 minutes for each session.
61923177|NCT04900168||ICP monitoring group|patients received ICP monitoring
61923178|NCT04900168||conventional treatment group|patients without ICP monitoring and received conventional treatment
61923179|NCT01795820|OTHER|Group 1 (no loading)|Patients allocated to this group will not receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start), while ticagrelor 90 mg bis in die will be administered from the day of the pharmacological shift on.
61923180|NCT01795820|OTHER|Group 2 (loading)|Patients allocated to this group will receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start). On the very day of the pharmacological shift, patients allocated in Group 2 will receive Ticagrelor 180 mg (loading dose) on the morning and Ticagrelor 90 mg on the evening, while ticagrelor 90 mg bis in die will be administered from the day after the pharmacological shift on.
62683490|NCT05612750|EXPERIMENTAL|Lupus Chronic Pain Cohort|150 participants with Lupus and Chronic Pain
62683491|NCT05612750|EXPERIMENTAL|Chronic Pelvic Pain|150 participants with Chronic Pelvic Pain
62683492|NCT05612750|EXPERIMENTAL|Young Adult (18-23) Chronic Pain|150 participants ages 18-23 with Chronic Pain
62683493|NCT05612750|EXPERIMENTAL|PRIME Sample|1200 participants with chronic pain
62683494|NCT00289978|EXPERIMENTAL|Fingolimod 1.25 mg|
62683495|NCT00289978|EXPERIMENTAL|Fingolimod 0.5 mg|
62683496|NCT00289978|PLACEBO_COMPARATOR|Placebo|
62477650|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
62477651|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
62477652|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
62683497|NCT01796470|EXPERIMENTAL|Entospletinib + idelalisib|"Entospletinib plus idelalisib at one of 4 dose combinations (400 mg/100 mg; 600 mg/100 mg; 800 mg/100 mg; 800 mg/150 mg).~After discontinuation of entospletinib+idelalisib combination therapy, and following a washout period, participants may continue to receive entospletinib 400 mg monotherapy."
62312965|NCT04985708||Classify patients based on shock severity.|later
62312966|NCT06040567||Patients with polyneuropathy|Adults (\> 18 years) diagnosed with polyneuropathy
62312967|NCT06040567||Healthy controls|Healthy adults (\>18 years)
62312968|NCT02947451|EXPERIMENTAL|Manual therapy|In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee, in a single application.
62312969|NCT02947451|EXPERIMENTAL|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application.
62312970|NCT06071286|EXPERIMENTAL|Interventional|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
62683498|NCT03407833||Obese, surgery|Obese subjects recruited from the Center for Surgical Weight loss who are undergoing weight loss surgery as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at surgical visits.
62683499|NCT03407833||Obese, nonsurgery|Obese subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
62312971|NCT05099601|EXPERIMENTAL|Silymarin alone versus silymarin and microneedling|There will be one group of patients. Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.
62312972|NCT00894530|EXPERIMENTAL|1|
62312973|NCT00894530|PLACEBO_COMPARATOR|2|
62477653|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
62477654|NCT02378935|EXPERIMENTAL|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
62477655|NCT03876054||Spinal cord stimulation (SCS)|Subjects using Abbott SCS systems
62477656|NCT03876054||Dorsal root ganglion stimulation (DRG)|Subjects using Abbott DRG system
62683500|NCT03407833||Lean control|Lean control subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
62683501|NCT03407833||Liver transplant|Lean or obese subjects who are undergoing liver transplantation as part of their standard of care. Excised liver tissue will be collected the day of procedure.
62683502|NCT05410795||Healthy people|Healthy people refer to those who exclude pancreatic related diseases, such as acute and chronic pancreatitis, pancreatic trauma, pancreatic tumor, peripancreatic lesions, diabetes and other diseases that may affect the volume of the pancreas.
62683503|NCT05410795||Chronic pancreatitis|Patients with chronic pancreatitis are considered as study subjects.
62683504|NCT05410795||Acute pancreatitis|Patients with acute pancreatitis within 144 hours after the onset of typical symptoms are considered as study subjects.
62312974|NCT04368130|EXPERIMENTAL|SIGNAL|"Program to explore the feasibility and acceptability of a smartphone-based real-time behavioral anomaly detection system (SIGNAL).~Patients will download the adapted Beiwe app onto their smartphones for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
62477657|NCT03057730|EXPERIMENTAL|Group 1: Thin Biotype|"Gingival thickness \< 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
62123306|NCT00622219|EXPERIMENTAL|Drug Testing|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
62123307|NCT00622219|NO_INTERVENTION|Control|Adolescents randomized to the control condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated) but will not be called for drug tests.
62312975|NCT02247206|EXPERIMENTAL|Behavior Therapy for Tics (CBIT)|The child 1) learns to become more aware of any sensations, or urges that may trigger tics, and 2) learn some other behavior (competing response) to do every time he/she feels the urge to tic. The child's parent is trained to provide prompts and praise for use of the competing response. The parent and family also receive psychoeducation about tics, and learn ways to reduce the impact of environmental stimuli on tic severity. The child learns relaxation techniques to reduce stress and make it easier for him/her to resist his or her tics. Prior to treatment sessions, the parent and child spend about 10 minutes discussing with the therapist any problematic issues he/she is having. At the end of treatment sessions the child is assigned some tasks to practice prior to the next session.
62312976|NCT02247206|NO_INTERVENTION|Waitlist-control Group|Participants in the waitlist-control group, do not receive behavior therapy for tics or any other treatment during the 10-week acute treatment period. Instead they child are placed on a waitlist to receive videoconference-delivered treatment following the end of the study period.
62312977|NCT02935881|ACTIVE_COMPARATOR|RFA (Stretta Procedure)|Radio Frequency Ablation (RFA) using a Stretta device.
62312978|NCT02935881|SHAM_COMPARATOR|Placebo Arm|Stretta device used but RFA will not be generated.
62312979|NCT03414567||Control Group|Non-smoker
61923181|NCT03435640|EXPERIMENTAL|NKTR-262 + bempegaldesleukin or + bempegaldesleukin with nivolumab|Phase 1: NKTR-262 in escalating doses, combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a recommended Phase 1b dose for NKTR-262 + bempegaldesleukin with nivolumab, followed by a dose-confirmation cohort.
62312980|NCT03414567||Study Group|Smoker
62312981|NCT04562623||Cohort A : High grade serous ovarian carcinoma|
62312982|NCT04562623||Cohort B :Breast carcinoma SBR grade II or III|Breast carcinoma SBR grade II or III superior to 3 cm
62312983|NCT04562623||Cohort C : Extended Breast carcinoma In situ|Extended Breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy
62312984|NCT01418222|EXPERIMENTAL|A|
61923182|NCT00905775||1 Isoflurane|The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
61923183|NCT00905775||2 Propofol|The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-
61923184|NCT03858439|EXPERIMENTAL|Intervention|Single arm study. All participants will receive dietary intervention.
62312985|NCT01418222|ACTIVE_COMPARATOR|B|
62123308|NCT00952263|EXPERIMENTAL|MBL-HCV1|
62312986|NCT02061007|EXPERIMENTAL|Scans, Surgery and Follow-up|Pre-surgery scans, surgical resection and post-surgery follow-up. All patients will receive a fluorodeoxyglucose (FDG)-PET scan as part of standard of care. This scan must be completed within 28 days of surgery for the patient to be eligible. All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered. Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
62123309|NCT04298788|PLACEBO_COMPARATOR|White dishware|standard white dishware used in the home
62123310|NCT04298788|EXPERIMENTAL|blue dishware|specially designed blue dishware, plates and bowls
62683505|NCT05773352||Tornier Perform® Humeral System - Fracture|Commercially available convertible humeral system for anatomic and reverse shoulder arthroplasty.
61923185|NCT05532787||Chest pain|Patients \>18 years of age presenting to ED with chief complaint of chest pain or cardiac symptoms suggestive of acute coronary syndrome with at least one troponin ordered, without evidence of ST-segment elevation myocardial infarction on ECG
62312987|NCT05014282|ACTIVE_COMPARATOR|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with their state's tobacco quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
62312988|NCT05014282|EXPERIMENTAL|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
62312989|NCT03870022|OTHER|18-80 years of age|Single day study collecting 1 paired breath sample from each subject using two non-invasive breath sampling devices, as well as collecting participant responses to user documentation questions and rating scales.
62312990|NCT05533242|EXPERIMENTAL|Lu-177-labeled-6A10Fab-fragments|The patient will receive a predetermined dose of Lu-177-labeled- 6A10Fab-fragments via the intracavitary reservoir. Patients will receive 3 RIT-cycles with an interval of 4 weeks. The total activity, adjusted to the volume of the RC, will be injected in 3 fractions with 50%, 25% and 25% of the total activity to achieve the desired boost to the 2 cm margin.
61923186|NCT00367770|EXPERIMENTAL|Tracleer|The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
61923187|NCT03551483|EXPERIMENTAL|ArtontheBrain|ArtontheBrain application for about 30 to 45 minutes twice per week, over 6 weeks.
62312991|NCT02035072|EXPERIMENTAL|Hypofractionated RT + Gem + Oxali|Hypofractionated radiotherapy + Gemcitabine + Oxaliplatin
62123311|NCT04564196||Induction of Labor|"Samples collected from women who present for induction of labor.~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be collected at the following time points for patients presenting for induction of labor:~A) Baseline: At presentation to labor and delivery unit and prior to initiation of augmentation of labor. A total of 1 sample.~B) End of 1st stage of labor: At complete cervix dilatation and prior to starting to push. A total of 1 sample will be taken.~C) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
62312992|NCT03067558||Accuracy evaulation|Three age groups (young infants 0 to \<2 months, children 2 to \<12 months and 12 to 59 months) will participate in the accuracy evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
62312993|NCT03067558||Consistency evaluation|Two age groups (children 2 to \<12 months and 12 to 59 months) will participate in the consistency evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
62312994|NCT03067558||Respiratory rate fluctuation evaulation|Two age groups (children 2 to \<12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
62312995|NCT06672354|EXPERIMENTAL|Otago Exercise Program Group|It includes participants receiving Otago Exercise Program, which consists of stengthening, balance exercises and walking plan.
62312996|NCT06672354|EXPERIMENTAL|Non-Immersive Virtual Reality Group|This group involves participants receiving VR training exercises by using Xbox Kinect 360.
62312997|NCT00677963|OTHER|1|Patients with symptomatic 70-99% carotid stenosis who are operated on.
62312998|NCT06594406|PLACEBO_COMPARATOR|Healthy individuals with placebo|
62312999|NCT06594406|EXPERIMENTAL|Healthy individuals with bifidobacterium|
62477658|NCT03057730|EXPERIMENTAL|Group 2: Thick Biotype|"Gingival thickness ≥ 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
62477659|NCT00835991|EXPERIMENTAL|Glyburide Metformin|Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
62477660|NCT00835991|ACTIVE_COMPARATOR|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
62477661|NCT00852163|EXPERIMENTAL|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
62477662|NCT01838681|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
62477663|NCT01838681|EXPERIMENTAL|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available ADT
62477664|NCT04402151|OTHER|Single Arm|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
62313000|NCT06594406|EXPERIMENTAL|Healthy individuals with creatine|
62313001|NCT06594406|EXPERIMENTAL|Healthy individuals with creatine and bifidobacterium|
62313002|NCT06594406|PLACEBO_COMPARATOR|Depression individuals with placebo|Depressed individuals with placebo and antidepressants
62313003|NCT06594406|EXPERIMENTAL|Depression individuals with creatine|Depressed individuals with creatine and antidepressants
62477665|NCT06150963|ACTIVE_COMPARATOR|Thyroid Biopsy (Control)|Patients within this arm received standard procedure thyroid biopsies without virtual reality.
62313004|NCT06594406|EXPERIMENTAL|Depression individuals with bifidobacterium|Depression individuals with bifidobacterium and antidepressants
62313005|NCT06594406|EXPERIMENTAL|Depression individuals with creatine and bifidobacterium|Depression individuals with creatine and bifidobacterium and antidepressants
62313006|NCT06229366|EXPERIMENTAL|OmHSPC|Patients with prostate cancer and biochemical recurrence after definitive surgery or radiation therapy, with 1-5 PSMA-positive lesions, who have not yet initiated lifelong hormone therapy.
62313007|NCT06229366|EXPERIMENTAL|mCRPC|Patients with PSMA-positive mCRPC who have prior treatment with at least one APRI and received taxane chemotherapy (or ineligible/refused); and received a maximum of 3 prior systemic therapy regimens in the mCRPC setting.
62477666|NCT06150963|EXPERIMENTAL|Thyroid Biopsy (Virtual Reality)|Patients within this arm received standard procedure thyroid biopsies with virtual reality for the length of the procedure.
62477667|NCT06150963|ACTIVE_COMPARATOR|PICC (Control)|Patients within this arm received standard procedure PICC placements without virtual reality.
62477668|NCT06150963|EXPERIMENTAL|PICC (Virtual Reality)|Patients within this arm received standard procedure PICC placements with virtual reality for the length of the procedure.
62683506|NCT03956082|OTHER|This is a prospective single arm study|"The Ultravision™ System is an FDA-cleared medical device that removes surgical smoke by means of electrostatic precipitation from the visual field during laparoscopic surgical procedures. Surgical smoke refers to the suspended particulate matter that is generated as a by-product of the combustion and other processes that are associated with the use of energy-based surgical instruments."
62123312|NCT04564196||Spontaneous Labor|"Samples will be collected from women who present in spontaneous labor~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be taken at the following endpoints:~A) End of 1st stage of labor: At completely cervix dilated and prior starting pushing. A total of 1 sample will be taken.~B) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
62123313|NCT02420613|EXPERIMENTAL|Arm I (vorinostat, radiation therapy, temsirolimus)|"CHEMORADIOTHERAPY PHASE: Patients receive vorinostat QD and undergo radiation therapy QD for 30 fractions over 6-7 weeks.~MAINTENANCE PHASE: Four to six weeks after the completion of radiation therapy, patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8 of each cycle. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity."
62313008|NCT03454139|ACTIVE_COMPARATOR|Subcostal TAP group|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,25 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia. After that, the patient is positioned to lithotomy position and the open-end catheter is inserted. After that the patient is turned to prone position and the percutaneous nephrolithotomy is performed. Tramadol 100 mg iv is administrated 20 minutes before the end of the surgery. Morphine patient controlled analgesia is planned for postoperative pain management.
62313009|NCT03454139|NO_INTERVENTION|Non- TAP group|Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
62313010|NCT06449105|EXPERIMENTAL|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"•A breath break with kindness is practiced. •Encourage them to think about how threat, impulse and sedative systems have developed in their own lives. •A safe place application is made. • Courtesy meditation is done."
62313011|NCT06449105|EXPERIMENTAL|Session 2: Threat and Self-Compassion|"•A breath break with kindness is practiced. • Building a compassionate relationship with resilience and kindness meditation: a benevolent practices are made. • A hand on your heart and a compassionate comrade practices are made."
62313012|NCT06449105|EXPERIMENTAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"•Talk about homework. •A breath break with kindness is practiced. • Establishing a compassionate relationship with desire, guided meditation to discover the inner pattern, courtesy meditation: a good friend practices are made."
62313013|NCT06449105|EXPERIMENTAL|Session 4: Internalizing compassion|"• Pretend-to-pretend practice is made for participants to observe themselves. • In addition to the previous practices, the practice of internalizing compassion is made in order to increase their expanded mindfulness. •Courtesy meditation: a neutral person, kindness towards your body, which is based on mindfulness practices and increases body awareness and mindful movement, is carried out. During the day, they will be informed that they should do the walking with kindness practice on their own"
62313014|NCT06449105|EXPERIMENTAL|Session 5: Me and others - Expanding the circle|"•A compassionate letter application is made by asking participants to think about a situation they encountered recently or some time ago and is still causing distress. It is explained that they can gain insight with this application. • Courtesy meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices are made"
62313015|NCT06449105|EXPERIMENTAL|Session 6: Growing happiness|"• Revisiting the good practice is carried out to define the five sense organs for the participants. • Forgiveness, Asking for forgiveness, forgiving others, gratitude practices are carried out. •The practice is expanded as kindness meditation: groups and all beings."
62313016|NCT06449105|EXPERIMENTAL|: Session 7: Weaving Wisdom and Compassion into Daily Life|"•Participants are made to choose a day in their life and allow a few minutes to pause in a mindful way. • A breather for wise and compassionate action, calmness meditation and joy sharing meditation practices are carried out."
62313017|NCT06449105|EXPERIMENTAL|Session 8: Living with the Heart|"•The participants are told about the applications that they can apply for, where they need help to develop compassion towards self-healing skills, and the whole training is evaluated. •The river of life application, which evaluates mindfulness in depth, is carried out. •An overall summary of the 8-session study is made and feedback is received."
62313018|NCT03873350|EXPERIMENTAL|Living kombucha|
62313019|NCT03873350|PLACEBO_COMPARATOR|Heat-sterilized kombucha|
62313020|NCT03873350|NO_INTERVENTION|Water|
62313021|NCT06512857|EXPERIMENTAL|experimental group|Hand puppet was used in the skin prick test process from the children in the experimental group.
62477669|NCT02440711|EXPERIMENTAL|mRSF-ESF|Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
62477670|NCT02440711|EXPERIMENTAL|ESF-mRSF|Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
62477671|NCT01948167|EXPERIMENTAL|Interpersonal Psychotherapy- Adolescent Skills Training|Interpersonal Psychotherapy- Adolescent Skills Training
62477672|NCT01948167|EXPERIMENTAL|Coping with Stress|Coping with Stress
62313022|NCT06512857|ACTIVE_COMPARATOR|Active comprator|Kaleidoscope was used in the skin prick test process from the children in the experimental group.
62313023|NCT06512857|NO_INTERVENTION|control group|Routine application of the unit will be made
62477673|NCT02561845||rosuvastatin group|patients who received rosuvastatin
62477674|NCT00714935|EXPERIMENTAL|3|Decision Counseling Program(DCP) combined with Coronary Artery Disease Decision Aid (CAD-DA) described in Arm 2
62477675|NCT00714935|NO_INTERVENTION|1|
62123314|NCT02420613|EXPERIMENTAL|Arm II (vorinostat, temsirolimus)|Patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
62123315|NCT00786006|EXPERIMENTAL|Arm 1|FOLFIRI.3
62123316|NCT00786006|ACTIVE_COMPARATOR|Arm 2|FOLFOX
62123317|NCT03316482|EXPERIMENTAL|Leuplin DPS 11.25mg s.c. every 12 weeks|Open
62123318|NCT06400719|EXPERIMENTAL|AVT16|Single intravenous administration of 300mg AVT16, proposed biosimilar to vedolizumab
62123319|NCT05143255|EXPERIMENTAL|KNOW Intervention|
62123320|NCT04234776|EXPERIMENTAL|Rapid-acting antidepressant|Subjects eligible to participate in the study will receive IM ketamine and will use 2 placebo tablets as randomized.
62123321|NCT04234776|ACTIVE_COMPARATOR|Comparator|Subjects eligible to participate in the study will receive IM saline and will use escitalopram 15 mg and aripiprazole 5 mg as randomized
62123322|NCT04874558||Low-dose contrast-enhanced chest CT exam|Subjects will undergo a low-dose contrast-enhanced chest CT exam with coverage from the neck base through the lungs to the upper abdomen on a third-generation dual-source CT scanner as part of their routine clinical visit based on current guidelines.
62123323|NCT06399029|EXPERIMENTAL|Experimental Intervention|This study will be performed as one-arm with no comparator.
62123324|NCT02531152|EXPERIMENTAL|SAR366234 (Dose 1)|A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days
62123325|NCT02531152|EXPERIMENTAL|SAR366234 (Dose 2)|A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days
62123326|NCT02531152|EXPERIMENTAL|SAR366234 (Dose 3)|A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days
62123327|NCT02531152|EXPERIMENTAL|SAR366234 (Dose 4)|A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days
62123328|NCT02531152|EXPERIMENTAL|SAR366234 (Dose 5)|A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days
62123329|NCT02531152|ACTIVE_COMPARATOR|Latanoprost|A dose of Latanoprost will be administered 1 drop per eye per day for 28 days
62123330|NCT03400254|EXPERIMENTAL|Phase II: Arm A|Patients will receive HCQ, 600 mg BID, for 24 weeks.
62313024|NCT05068596|EXPERIMENTAL|study groip|received the designed physical therapy program as the control group. In addition, they received progressive resistive functional strength training in the plantigrade foot position.
62313025|NCT05068596|OTHER|control group|received a designed physical therapy program
62123331|NCT03400254|EXPERIMENTAL|Phase II: Arm B|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 2 weeks administered weekly, as an intravenous dose of 150 mg.
62123332|NCT03400254|EXPERIMENTAL|Phase II: Arm C|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 6 weeks administered weekly, as an intravenous dose of 150 mg.
62123333|NCT03400254|EXPERIMENTAL|Phase II: Arm D|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 12 weeks administered weekly, as an intravenous dose of 150 mg.
62123334|NCT03400254|EXPERIMENTAL|Phase Ib Arm|Patients will receive HCQ, 600 mg BID, and GED, administered weekly as an intravenous dose of 150 mg, for 6 weeks.
62123335|NCT00719459|EXPERIMENTAL|1|Hospira Iron Sucrose
62123336|NCT00719459|ACTIVE_COMPARATOR|2|Venofer
62123337|NCT05068362|OTHER|Implant|Use of Medpor implant in auricle reconstruction in microtia
62123338|NCT04956679||Family members in the study|Community groups that meet the inclusion criteria
62313026|NCT02961764|ACTIVE_COMPARATOR|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
62477676|NCT00714935|EXPERIMENTAL|2|"Behavioral: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
62477677|NCT00856167|ACTIVE_COMPARATOR|TCM|Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
62477678|NCT00856167|ACTIVE_COMPARATOR|Self-care|Self-care for TMD developed by Dworkin, LeResche et al.
62477679|NCT03867838|EXPERIMENTAL|Stroke survivors|Stroke survivors with upper extremity motor impairments
62477680|NCT02525458|EXPERIMENTAL|QAMS-containing PMMA|PMMA containing 5% QAMS
62477681|NCT02525458|PLACEBO_COMPARATOR|QAMS-free PMMA|PMMA containing 0% QAMS
62477682|NCT04478435|ACTIVE_COMPARATOR|1 Hour post intervention|Ultrasound assessment done 1 hour after ingestion of glucose loaded drink
62477683|NCT04478435|PLACEBO_COMPARATOR|2 hours post intervention|Ultrasound assessment done 2 hour after ingestion of glucose loaded drink
62313027|NCT02961764|ACTIVE_COMPARATOR|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
62313028|NCT00487279|EXPERIMENTAL|ICD Group|ICD (Implantable Cardioverter Defibrillator)
62313029|NCT00487279|OTHER|Control Group|Medial Therapy
62477684|NCT00085293|EXPERIMENTAL|Treatment|Starting dose 6 mg/m\^2 Decitabine intravenous (IV) over 1 hour on days 1-5 and 8-12 of weeks 1 and 2 (course 1). Week 3, Iodine I 131 (131I) scanning using thyrotropin alfa injections. Participants whose scan do not demonstrate iodine uptake continue suppressive thyroid hormone therapy but no further study therapy; these participants who do show uptake undergo thyroid hormone withdrawal on weeks 4-8 and second course of decitabine (as in course 1) on weeks 7 and 8, with 131I therapy on week 9.
62477685|NCT03707587|EXPERIMENTAL|1200 mg intravenous (IV) of M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
62477686|NCT04820829|ACTIVE_COMPARATOR|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
62737815|NCT06451692|NO_INTERVENTION|Control group|Patients in the control group receive standard care without a clinical pharmacist involved in the healthcare team at ward level. Standard care consists of usual treatment from a team of hospital physicians, nurses, nurse assistants, and as needed occupational therapists, physiotherapist, and clinical dieticians. Hospital physicians and/or nurses might perform patient counselling about medication treatment during hospitalization
61923188|NCT03551483|ACTIVE_COMPARATOR|Seniors Online Victoria|Senior Online Victoria games for about 30 to 45 minutes twice per week, over 6 weeks (https://www.seniorsonline.vic.gov.au/services-information/games), after which they will participate in the ArtontheBrain intervention.
61923189|NCT03551483|OTHER|Waitlist Control|The waitlist control group will no treatment for 6 weeks, after which they will six weeks of the ArtontheBrain intervention.
61923190|NCT00137865|EXPERIMENTAL|EGEN-001|
62123339|NCT04144322|OTHER|Short Implant|17 patients will receive a 5 mm short implant.
62123340|NCT04144322|OTHER|Long Implant|17 patients will receive a sinus lift procedure, bone graft, and 10 mm implant.
62313030|NCT03417258||Patients with polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
62313031|NCT03417258||Patients without polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
62313032|NCT04295304|EXPERIMENTAL|NR600 device implantation|Retinal surgery and implantation of epi-retinal prosthesis
62313033|NCT04095416|EXPERIMENTAL|Intervention|Bilateral lower extremity ACE compression wraps in addition to standard medical care
62313034|NCT04095416|NO_INTERVENTION|Control|Standard medical care
62313035|NCT04805372|EXPERIMENTAL|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
62477687|NCT04820829|ACTIVE_COMPARATOR|Moderate RM, moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
61923191|NCT02973607||Donors|Patients who donated a kidney and took part in the original CRIB-DONOR study.
62737816|NCT02091362|PLACEBO_COMPARATOR|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
61923192|NCT02973607||Controls|Healthy subjects who took part in the original CRIB-DONOR study.
61923193|NCT04190303||Baseline (pre-intervention)|Current routine care
61923194|NCT04190303||Post-intervention|Care following development and delivery of the system-level intervention
61923195|NCT00381381|EXPERIMENTAL|1|
61923196|NCT01627171|ACTIVE_COMPARATOR|PEG Lyte|PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.
62123341|NCT03352778||IMRT|
62123342|NCT03352778||2DRT|
62123343|NCT05505071|EXPERIMENTAL|DANTE SPACE MRI Sequence|Participants will receive an additional DANTE SPACE sequence with their clinical MRI
62123344|NCT04152421|EXPERIMENTAL|Software user|
62737817|NCT02091362|EXPERIMENTAL|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
62123345|NCT01428297|EXPERIMENTAL|Cohort A and B, BPR277 and Placebo (vehicle)|
62123346|NCT01428297|EXPERIMENTAL|Part 2 BPR277|
62123347|NCT01428297|PLACEBO_COMPARATOR|Part 2 Placebo (vehicle)|
62313036|NCT04805372|PLACEBO_COMPARATOR|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
62313037|NCT03995407|ACTIVE_COMPARATOR|Control|"Participants in the control arm will receive usual care."
62313038|NCT03995407|EXPERIMENTAL|100% Whey Protein|Participants will receive 100% Whey Protein oral nutritional supplements.
62313039|NCT02502630|EXPERIMENTAL|Treated with microwave ablation|Patients undergoing MWA for pulmonary metastases from colorectal cancer.
62737818|NCT06253455|EXPERIMENTAL|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
62737819|NCT06253455|EXPERIMENTAL|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
62123348|NCT01428297|EXPERIMENTAL|Part 3 BPR277 and Placebo (vehicle)|
62123349|NCT00596310|EXPERIMENTAL|1|Screening CT
62123350|NCT00444600|EXPERIMENTAL|0.5mg Ranibizumab plus laser|
62123351|NCT00444600|EXPERIMENTAL|0.5 mg Ranibizumab plus deferred laser|
62123352|NCT00444600|EXPERIMENTAL|4 mg Triamcinolone plus laser|
62123353|NCT00444600|ACTIVE_COMPARATOR|Sham plus laser|
62737820|NCT06253455|EXPERIMENTAL|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score \> 5
62313040|NCT01399827|ACTIVE_COMPARATOR|Omega-3 Fatty Acids|1060 mg EPA Omega-3 Fatty Acids
62477688|NCT04820829|ACTIVE_COMPARATOR|Low RM, high NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
62683507|NCT06011252|OTHER|Solia S lead with any BIOTRONIK Pacemaker|"* Name: Solia S lead with any BIOTRONIK Pacemaker~* Model: Solia S45/S53/S60~* Manufacturer: BIOTRONIK SE \& Co. KG~* Method of use: LBBAP implantation for all bradycardia indications.~* Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~* Device category and grade: E3610 Cardiovascular devices, Class III"
62683508|NCT06290635||All Participants|Participants include IPF and F-ILD including progressive pulmonary fibrosis phenotype
62477689|NCT02577458|EXPERIMENTAL|CM082 plus everolimus|CM082 plus everolimus
62477690|NCT04552990|EXPERIMENTAL|Tumor Excision, No Illumination|The first four patients will not receive illumination but have their tumors excised after jet-injection (AirGent2.0) of ALA (Levulan Kerastick), and 3h incubation; this will be done to assess biodistribution of ALA through fluorescence microscopy.
62477691|NCT04552990|EXPERIMENTAL|PDT treatment with jet-injections|Patient 5-16 will receive PDT treatment with jet-injections of ALA followed by 3h incubation under occlusion and thereafter illumination with red light (total dose 75 J/cm2). In patient 5-16, the PDT treatment will be repeated after 2 weeks.
62313041|NCT01399827|PLACEBO_COMPARATOR|Placebo|
62313042|NCT04098601|EXPERIMENTAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
62683509|NCT04418505|NO_INTERVENTION|Standard of Care|This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.
62683510|NCT04418505|EXPERIMENTAL|Standard of Care + Vielight RX Plus Treatment|The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.
62683511|NCT03964233|EXPERIMENTAL|Dose Escalation - BI 907828 + ezabenlimab|All neoplasms
62683512|NCT03964233|EXPERIMENTAL|Dose Expansion - Cohort 1 BI 907828 + ezabenlimab|
62683513|NCT03964233|EXPERIMENTAL|Dose Expansion - Cohort 2 - BI 907828 + ezabenlimab|
62477692|NCT04543682|EXPERIMENTAL|First intervention group (0.125 ng/kg/min Iloprost)|The first intervention group will receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.125 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter will be inserted during the surgical procedure. Infusion of Iloprost will start 24hrs post-operatively and the dose will be delivered over 24h.
62123354|NCT06225388|EXPERIMENTAL|Compression socks|For the intervention, compression socks will be used, composed of 81% polyamide, 15% elastane and 4% polypropylene (Kendall sports, Kendall, São Paulo, Brazil). The sock offers compression of 20 to 30 mmHg in a decreasing manner with greater pressure at the ankle and less pressure at the knee joint line. Based on the manufacturer's guidelines, the sock size will be determined by measuring the calf and ankle circumference.
62313043|NCT04098601|NO_INTERVENTION|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
61923197|NCT01627171|EXPERIMENTAL|Pico Salax Split|Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.
61923198|NCT01627171|EXPERIMENTAL|Pico Salax Night Before|2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy
61923199|NCT01409759|EXPERIMENTAL|Perforator based interposion flap|In our concept the flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
61923200|NCT01409759|OTHER|Full thickness graft|
62123355|NCT06225388|PLACEBO_COMPARATOR|Placebo socks|The placebo sock will be represented by a commercial sock composed of 70% polyamide, 24% cotton and 5% elastodiene without the purpose of providing compression.
62313044|NCT00857246|EXPERIMENTAL|Induction/ surgery/ chemoRT|"1. Induction treatment (3 weeks/cycle x 4 cycles): Cisplatin and Irinotecan on days 1 and 8; Cetuximab on days 1, 8, and 15.~2. Surgery (starts 3-4 weeks after induction treatment).~3. Chemoradiation treatment (starts 4-6 weeks after surgery):~weeks 1-19: Cetuximab on day 1 of every week; week 1: 5-FU and Leucovorin (LV) x 5 days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU+ LV on days 1-4; week 9: 5-FU+ LV on days 1-3; weeks 14 and 19: 5-FU+LV x 5days"
62313045|NCT06130384|EXPERIMENTAL|Bromfenac 0.09%|At the time of the injection, the first eye will be randomized to a drop of artificial tear or bromfenac 0.09% and the second eye will receive the other agent.
62683514|NCT03964233|EXPERIMENTAL|Dose Escalation - BI 907828 + ezabenlimab + BI 754111|All neoplasms
62737821|NCT02700620|EXPERIMENTAL|Treatment group|Internet-delivered CBT
61923201|NCT03895242|EXPERIMENTAL|Group 1:First supine position,then prone position|First group was supine position then prone position.
61923202|NCT03895242|EXPERIMENTAL|Group 2:First prone position, then supine position|Second group was first prone position, then supine position.
61923203|NCT05673460|EXPERIMENTAL|Nemtabrutinib|Participants receive nemtabrutinib at specified dose orally once daily (QD) until progressive disease (PD) or discontinuation
61923204|NCT04537260|NO_INTERVENTION|Control Arm (Standard of Care)|The control group took the knowledge-based survey about induction of labor prior to meeting their provider (midwife or obstetrician) on the day of scheduled induction. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction with the labor and delivery process.
62123356|NCT04468698||Global cohort|A global cohort is built merging data from three studies
62123357|NCT03365895|EXPERIMENTAL|Diagnostic (non-enhanced MRI using MRN and DTI)|Patients undergo non-enhanced MRI of both lower extremities using MRN and DTI prior to initiation and after completion of standard of care chemotherapy.
62123358|NCT01580293|EXPERIMENTAL|Arm 1|On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
62123359|NCT01580293|EXPERIMENTAL|Arm 2|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
62313046|NCT06130384|PLACEBO_COMPARATOR|Artificial Tear|At the time of the injection, the first eye will be randomized to a drop of artificial tear or bromfenac 0.09% and the second eye will receive the other agent.
62313047|NCT04116034|EXPERIMENTAL|DSR|Up to 10 subjects will be treated with alfapump DSR system for a total treatment period of 59 days post-implantation
62477693|NCT04543682|EXPERIMENTAL|Second intervention group (0.25 ng/kg/min Iloprost)|The second intervention group will also receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.25 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. Infusion will start 24hrs post-operatively and the dose will be delivered over 24h.
62477694|NCT04543682|OTHER|Control intervention group|Control intervention: Patients will receive the standard of care procedure for such fractures, i.e. standard of care open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes).
62477695|NCT02057835|EXPERIMENTAL|BI 691751 low dose 1|BI 691751 low dose 1
62477696|NCT02057835|EXPERIMENTAL|BI 691751 low dose 2|BI 691751 low dose 2
62683515|NCT04837196|EXPERIMENTAL|Phase 1 ASP7517 Monotherapy Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses.
62123360|NCT01580293|EXPERIMENTAL|Arm 3|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
62313048|NCT00466752|EXPERIMENTAL|Treatment (enzyme inhibitor) 48hr stop|Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
62313049|NCT00466752|EXPERIMENTAL|Treatment (enzyme inhibitor) 24hr stop|tients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 day after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
62477697|NCT02057835|EXPERIMENTAL|BI 691751 middle dose|BI 691751 middle dose
62477698|NCT02057835|EXPERIMENTAL|BI 691751 high dose|BI 691751 high dose
62683516|NCT04837196|EXPERIMENTAL|Phase 1 ASP7517 + Pembrolizumab Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks starting from Cycle 1 Day 1. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
62683517|NCT04837196|EXPERIMENTAL|Phase 2 ASP7517 Monotherapy Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses
62683518|NCT04837196|EXPERIMENTAL|Phase 2 ASP7517 + Pembrolizumab Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
62123361|NCT01580293|EXPERIMENTAL|Arm 4|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
62123362|NCT05173714|PLACEBO_COMPARATOR|SLIMM + Standard RT + Placebo|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo
62313050|NCT02094469|OTHER|Cilostazol|Cilostazol 50mg and 100mg
62313051|NCT06672224|EXPERIMENTAL|Supportive Care (ICG, fluid, SPY, lymphedema assessment)|Patients receive ICG dye SC and receive fluids IV over one hour and undergo SPY imaging and lymphedema assessment on day 1. Patients also receive ICG dye and undergo imaging and lymphedema assessments again at 1, 3, 6, and 12 months on study.
62313052|NCT03414918|EXPERIMENTAL|Clarithromycin|250 mg clarithromycin diluted in 250 ml saline will be administered as a slow infusion (45 min) in a peripheral vein during AVS. This dose of clarithromycin should yield peak plasma concentrations of 2.78 mcg/mL (on average)13, which are higher than the IC50 measured in vitro (0.53-1.29 mcg/mL).
62313053|NCT04578145|OTHER|Female sex workers (FSW)|Female sex workers (FSWs) community is the only group which has implemented the study intervention. This group has been underlined as the one of key affected populations (KAPs) that hold an increasing number of HIV incidence and prevalence recently in Indonesia even though it is approximately 226,791 FSWs by 2016 and around 5,254,065 clients access their services per year (MoH, 2017). The condition will be worst because the transmission definitely will continue to clients' sexual partner and moreover, their babies if their HIV status has not been known earlier. It means that lowering the transmission of HIV infection for FSWs, it will simultaneously lower its transmission to their sexual partners and furthermore their babies.
62477699|NCT05281861|EXPERIMENTAL|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|The onlays will be constructed from Zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic system
61923205|NCT04537260|EXPERIMENTAL|Intervention Arm (Educational video)|The intervention group had the opportunity to watch the 3-minute educational video. The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8. After watching the video, the participant was asked to take the knowledge-based survey. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction.
61923206|NCT06079528|EXPERIMENTAL|Electromagnetic Stimulation combined with visceral manipulation|Consisted of 25 postmenopausal women with SUI received PEMS therapy augmented by VMT maneuvers in addition to supervised PFMT.
61923207|NCT06079528|ACTIVE_COMPARATOR|Electromagnetic Stimulation associated with general advice|Control group (B) performed the same PFMT associated with general advice with no medical treatment.
62683519|NCT06014723||Observation group|The observation group received early submaximal balloon angioplasty and medical therapy.
62683520|NCT06014723||Control group|The control group received only medical therapy.
61923208|NCT02648321|EXPERIMENTAL|Motivational Interviewing|Motivational Interviewing
61923209|NCT02648321|ACTIVE_COMPARATOR|Health Education|Health Education
61923210|NCT02259790|EXPERIMENTAL|Telmisartan/amlodipine fixed-dose combination|
61923211|NCT02259790|ACTIVE_COMPARATOR|Telmisartan tablet and amlodipine tablet|
61923212|NCT03262402|EXPERIMENTAL|HIV-infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
62123363|NCT05173714|ACTIVE_COMPARATOR|SLIMM + Guided RT + Placebo|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo
62123364|NCT05173714|EXPERIMENTAL|SLIMM + Guided RT + Semaglutide|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide
62123365|NCT01827787|EXPERIMENTAL|Cohort 1: HR+/HER2-|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
62123366|NCT01827787|EXPERIMENTAL|Cohort 2: TNBC|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
62683521|NCT05943990|EXPERIMENTAL|GSK3845097|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive high dose of GSK3845097 after completing lymphodepleting chemotherapy. The first study participant receiving GSK3845097 will receive the total assigned dose as 2 separate infusions 7 days apart, in aliquots of 30% (first infusion) and 70% (second infusion) of the total target dose , respectively. Based on the dose limiting toxicities reported in the first participant, then all subsequent participants treated with GSK3845097 will receive the full dose as a single, i.e., one-time, infusion.
62737822|NCT02700620|NO_INTERVENTION|Control group|Waitlist control
62737823|NCT01631487|EXPERIMENTAL|Japanese Group 1: JNJ-39439335/placebo (Part 1)|
61923213|NCT03262402|ACTIVE_COMPARATOR|Non-HIV infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
61923214|NCT01487473|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction|
61923215|NCT01487473|NO_INTERVENTION|Waitlist Control|
62313054|NCT02047123|EXPERIMENTAL|Raw Flaxseed|For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of raw flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
61923216|NCT04949971||High volume group|The tidal volume of the exposed group was 10ml/kg ideal body weight.
61923217|NCT04949971||Low volume group|The tidal volume of the non-exposed group was 6ml/kg ideal body weight
61923218|NCT03463031|EXPERIMENTAL|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
61923219|NCT03463031|PLACEBO_COMPARATOR|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
62313055|NCT00598130|EXPERIMENTAL|I|patients who will be treated in accordance with standard of care
62313056|NCT00598130|ACTIVE_COMPARATOR|II|patients for which the Fibrin Fleece will be applied directly on the active bleeding site.
62477700|NCT05281861|ACTIVE_COMPARATOR|Lithium disilicate (IPS e-max press) ceramic onlay restoration|The onlays will be constructed from Lithium disilicate (IPS e-max press) glass ceramic system
61923220|NCT05825612||Heterozygous Familial Hypercholesterolemia|Children and adolescents with Heterozygous Familial Hypercholesterolemia.
61923221|NCT05825612||Homozygous Familial Hypercholesterolemia|Children and adolescents with Homozygous Familial Hypercholesterolemia.
61923222|NCT05825612||Unaffected (non-FH) individuals|Children and adolescents not carrying the investigated FH mutations
62313057|NCT05247580||Hospital staff caregivers|Necker - Enfants Malades hospital' nurses, nurses' aides, residents and, doctors of medicine.
62313058|NCT05034783|EXPERIMENTAL|[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/ CT scan|Patients of Insulinoma PET/CT imaging: In two consecutive days each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of \[68Ga\]Ga-HBED-CC-exendin-4 and \[68Ga\]Ga-NOTA-exendin-4, respectively.
62477701|NCT03843190|EXPERIMENTAL|Take Off Pounds Sensibly (TOPS)|This group will receive TOPS intervention at the start of the study.
62477702|NCT03843190|OTHER|Waitlist control|This group will be the control group for 6 months. Then at the completion of the study they will receive the vouchers to participate in TOPS chapters in the community.
62683522|NCT03881878|EXPERIMENTAL|pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)"
61923223|NCT03083860|OTHER|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
61923224|NCT03083860|OTHER|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
61923225|NCT02990156|EXPERIMENTAL|Coil Embolization System|Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
61923226|NCT02990156|ACTIVE_COMPARATOR|Control device from Medronic|Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
62313059|NCT05600712|OTHER|single arm|subjects who have redapt sleeved stem implant
62313060|NCT03741439|EXPERIMENTAL|Treatment arm|Receives real treatment according to manufactures instructions. 6 sessions of low intensity shockwave treatment with an electromagnetic emitter.
62313061|NCT03741439|SHAM_COMPARATOR|Sham Arm|Receives sham treatment with same applicator, same sound, same time and number of shocks. But no real energy is delivered.
62313062|NCT06671860|EXPERIMENTAL|Routine Exercise Group The routine exercise program included the following exercises: chin stretchin|
62313063|NCT06671860|ACTIVE_COMPARATOR|Oculomotor Exercise Group The oculomotor exercise program consisted of a series of activities such a|
62313064|NCT02950623|EXPERIMENTAL|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
62737824|NCT01631487|EXPERIMENTAL|Japanese Group 2: JNJ-39439335/placebo (Part 1)|
62737825|NCT01631487|EXPERIMENTAL|Japanese Group 3: JNJ-39439335/placebo (Part 1)|
62313065|NCT02950623|PLACEBO_COMPARATOR|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
62737826|NCT01631487|EXPERIMENTAL|Caucasian Group 1: JNJ-39439335/placebo (Part 1)|
62737827|NCT01631487|EXPERIMENTAL|Caucasian Group 2: JNJ-39439335/placebo (Part 1)|
62683523|NCT03881878|EXPERIMENTAL|non-pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) :~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
61923227|NCT03583203|EXPERIMENTAL|Experimental Group|This group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
61923228|NCT03583203|NO_INTERVENTION|Control Group|The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask, Advice, Assess, Assist and Arrange).
61923229|NCT05840029||Group A: Patients who will get neoadjuvant chemotherapy based on VATS finding.|Patients will be considered to receive neoadjuvant chemotherapy if there is residual intrathoracic disease
61923230|NCT05840029||Group B: Patients who will proceed into debulking surgery based on VATS finding.|Patients will be considered to be eligible for complete debulking, if VATS showed no intrathoracic tumor or if VATS achieves complete removal of tumor nodules through intraoperative frozen section histopathological examination.
62313066|NCT05632250|OTHER|ConvaFoam dressings|All participants wounds will be assessed and allocated a dressing based upon the investigator's clinical judgement. They will receive either ConvaFoam Border, Silicone or Non-Adhesive for up to 12 weeks as part of their standard of care
61923231|NCT04766372|EXPERIMENTAL|Menu of physical activity options|"Participants in all 4 groups will receive this booklet with suggestions of ways to be physically active, e.g. YouTube workouts, cycling or jogging, sports, or design their own using a home-based exercise booklet. Participants are asked to do 3 exercise sessions of 30 minutes per week. Participants are asked to record what activity they did and the duration of the session using a method most convenient for them, e.g. notes on their phone, wall calendar or using an activity log template which we will provide.~."
62313067|NCT04760795||coping strategy based on problem|59 geriatric patients will be included on the group: coping strategy based on problem
61923232|NCT04766372|EXPERIMENTAL|Physical activity programme|Participants in the second group with receive the activity menu (as described above) as well as a detailed physical activity programme. This programme includes supportive weekly text messages, access to live workouts and access to an online social community.
62123367|NCT03104387|EXPERIMENTAL|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
62123368|NCT03104387|SHAM_COMPARATOR|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
62313068|NCT04760795||coping strategy based on emotion|59 geriatric patients will be included on the group: coping strategy based on emotion
62313069|NCT01342640|EXPERIMENTAL|Single Arm|
62313070|NCT00178412|EXPERIMENTAL|1|Treatment group
62313071|NCT00178412|ACTIVE_COMPARATOR|2|Comparison Group
62737828|NCT01631487|EXPERIMENTAL|Caucasian Group 3: JNJ-39439335/placebo (Part 1)|
62737829|NCT01631487|EXPERIMENTAL|Japanese Group 1: JNJ-39439335/placebo (Part 2)|
62737830|NCT01631487|EXPERIMENTAL|Japanese Group 2: JNJ-39439335/placebo (Part 2)|
62737831|NCT01631487|EXPERIMENTAL|Japanese Group 3: JNJ-39439335/placebo (Part 2)|
62737832|NCT06532929||EUROSCREW PLA knee (ACL) surgery|Patients included for anterior crucial ligament of knee surgery with EUROSCREW PLA
62737833|NCT06532929||EUROSCREW PLA/TCP knee (ACL) surgery|Patients included for anterior crucial ligament of knee surgery with EUROSCREW PLA/TCP
62737834|NCT06532929||EUROSCREW NG PLA knee (ACL) surgery|Patients included for anterior crucial ligament of knee surgery with EUROSCREW NG PLA
62737835|NCT06532929||EUROSCREW NG PLA knee (PCL) surgery|Patients included for posterior crucial ligament of knee surgery with EUROSCREW NG PLA
62737836|NCT06532929||EUROSCREW NG PLA ankle surgery|Patients included for ankle surgery with EUROSCREW NG PLA
62737837|NCT06532929||EUROSCREW NG PLA/TCP knee (ACL) surgery|Patients included for anterior crucial ligament of knee surgery with EUROSCREW NG PLA/TCP
62737838|NCT06532929||EUROSCREW NG PLA/TCP knee (PCL) surgery|Patients included for posterior crucial ligament of knee surgery with EUROSCREW NG PLA/TCP
62737839|NCT06532929||ISOFIX knee (ACL) surgery|Patients included for anterior crucial ligament of knee surgery with ISOFIX
62737840|NCT06532929||A'LINK'S ankle surgery|Patients included for ankle surgery with A'LINK'S
62737841|NCT06532929||A'LINK'S shoulder surgery|Patients included for shoulder surgery with A'LINK'S
62737842|NCT06532929||SUTUR'LINK surgery|Patients included for surgery with SUTUR'LINK
62737843|NCT06532929||PINS foot surgery|Patients included for foot surgery with PINS
61923233|NCT04766372|EXPERIMENTAL|Individual behaviour change support|"Participants in the third group with receive the activity menu (as described above) as well as individual behaviour change support. Each participant is partnered with a trainee sport psychology (Activity Mentor) who they have weekly video calls with to support their health behaviour change."
62123369|NCT04177459|EXPERIMENTAL|Health promoting dialogue in addition to treatment as usual|Health promoting dialogues in addition to follow-up from primary and secondary health care, and from schools, which is individually customized due to fatigue and other symptoms present.
62123370|NCT04177459|ACTIVE_COMPARATOR|Treatment as usual|Follow-up from primary and secondary health care, and from Schools, which is individually customized due to fatigue and other symptoms present..
62313072|NCT06671067|NO_INTERVENTION|Routine care group|AMI patients with cardiac insufficiency following coronary revascularization who receive the routine care without ReDS guiding
62123371|NCT01982136||Urethral stricture|patients requiring surgery for urethral stricture
62123372|NCT03476746|EXPERIMENTAL|LEO 90100 foam|"LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g).~Pilot part: 6 single applications of LEO 90100 foam on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
62313073|NCT06671067|EXPERIMENTAL|ReDS-guided care group|AMI patients with cardiac insufficiency following coronary revascularization who receive the ReDS guiding care
62313074|NCT01292395|EXPERIMENTAL|Protein level 1|
62313075|NCT01292395|EXPERIMENTAL|Protein level 2|
62313076|NCT01292395|EXPERIMENTAL|Protein level 3|
62313077|NCT04459910||Multidirectional|Arthroscopic lateral ligament repair combined with deltoid arthroscopic ligament repair.
62683524|NCT03228043|EXPERIMENTAL|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
62683525|NCT03228043|PLACEBO_COMPARATOR|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
62683526|NCT06686303|EXPERIMENTAL|Group A|Group A received the high frequency segmental vibrator.
61923234|NCT04766372|EXPERIMENTAL|Activity Programme & Behaviour Change Support|Participants in the fourth group will receive all of the above (exercise menu, live workouts, social community, support texts and weekly calls with an Activity Mentor).
61923235|NCT01936077|EXPERIMENTAL|GnRH antagomnist hyper-responders|Those defined as hyper-responders will be given recombinant LH.
61923236|NCT03439527|EXPERIMENTAL|MPC-group|All patients are treated by the same product: Autologous MPCs
61923237|NCT03439527|OTHER|NMES+MPC-group|After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy (Neuromuscular Electromagnetic Stimulation, NMES)
61923238|NCT01390220|EXPERIMENTAL|USL261|intranasal midazolam 5mg
61923239|NCT01390220|EXPERIMENTAL|Placebo|Intranasal placebo
61923240|NCT05348135|ACTIVE_COMPARATOR|Functional strength training|
61923241|NCT05348135|ACTIVE_COMPARATOR|Cognitive training|
61923242|NCT05348135|ACTIVE_COMPARATOR|Combined treatment|
61923243|NCT05348135|PLACEBO_COMPARATOR|Conventional physical therapy|
61923244|NCT02140775|EXPERIMENTAL|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
61923245|NCT02140775|ACTIVE_COMPARATOR|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
62123373|NCT03476746|ACTIVE_COMPARATOR|Dovobet® ointment|"Pilot part: 6 single applications of Dovobet® ointment on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
62683527|NCT06686303|EXPERIMENTAL|Group B|Group B received the combined effects of high frequency segmental vibrator and neuromuscular electrical stimulation.
62683528|NCT06196879|EXPERIMENTAL|Verekitug (UPB-101): 100 mg Q12W / Placebo|Participants will receive 0.5 milliliter (mL) of verekitug (UPB-101) formulated solution (containing 100 milligrams \[mg\] of verekitug \[UPB-101\]) and 2.0 mL of placebo subcutaneously in two separate injections every 12 weeks up to Week 48.
62683529|NCT06196879|EXPERIMENTAL|Verekitug (UPB-101): 400 mg Q24W / Placebo|Participants will receive 2.0 mL of verekitug (UPB-101) formulated solution (containing 400 mg of verekitug \[UPB-101\]) and 0.5 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.
61923246|NCT02972762|ACTIVE_COMPARATOR|L Group|The participants in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 50 to 60.The values of BP,P,PetCO2 will be controled in proper site. each participant will be given postoperative analgesia pump to release postoperative pain.
61923247|NCT02972762|ACTIVE_COMPARATOR|D Group|The participant in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 35 to 45.The values of BP,P,PetCO2 will be controled in proper site. The investigator use postoperative analgesia pump to control postoperative pain for each participant.
61923248|NCT05032430|EXPERIMENTAL|Calma, Conversa, y Cría (CCC)|Mindfulness-based parental stress reduction intervention
61923249|NCT05032430|ACTIVE_COMPARATOR|Enhanced Usual Care|Comparator group designed to influence health and well-being that does not include mindfulness as an active ingredient.
61923250|NCT00879944||Psoriasis|Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
62683530|NCT06196879|EXPERIMENTAL|Verekitug (UPB-101): 100 mg Q24W / Placebo|Participants will receive 0.5 mL of verekitug (UPB-101) formulated solution (containing 100 mg of verekitug \[UPB-101\]) and 2.0 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.
62683531|NCT06196879|PLACEBO_COMPARATOR|Placebo|Participants will receive 0.5 mL of matching placebo and 2.0 mL of matching placebo subcutaneously in two separate injections every 12 weeks up to Week 48.
62683532|NCT02062346|PLACEBO_COMPARATOR|Placebo|Saline placebo
61923251|NCT00879944||Atopic Dermatitis Controls|Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
62123374|NCT03383146|PLACEBO_COMPARATOR|Placebo|Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
62313078|NCT03733678|EXPERIMENTAL|Free SARC, Free LARC, Recommendation|Free SARC, Free LARC, Sequential recommendation
62313079|NCT03733678|EXPERIMENTAL|Free SARC, LARC=500, Recommendation|Free SARC, LARC=500 CFA, Sequential recommendation
62313080|NCT03733678|EXPERIMENTAL|Free SARC, LARC=1000, Recommendation|Free SARC, LARC=1000 CFA, Sequential recommendation
62313081|NCT03733678|EXPERIMENTAL|Free SARC, LARC=2140, Recommendation|Free SARC, LARC=2140 CFA, Sequential recommendation
62313082|NCT03733678|EXPERIMENTAL|Free SARC, LARC=5000, Recommendation|Free SARC, LARC=5000 CFA, Sequential recommendation
62683533|NCT02062346|EXPERIMENTAL|BQ123|Intravenous infusion of BQ123 1000nmol/min for 15min
62313083|NCT03733678|EXPERIMENTAL|Regular SARC, Free LARC, Recommendation|Regular price SARC, Free LARC, Sequential recommendation
62313084|NCT03733678|EXPERIMENTAL|Regular SARC, LARC=500, Recommendation|Regular price SARC, LARC=500 CFA, Sequential recommendation
62313085|NCT03733678|EXPERIMENTAL|Regular SARC, LARC=1000, Recommendation|Regular price SARC, LARC=1000 CFA, Sequential recommendation
62683534|NCT02062346|EXPERIMENTAL|BQ123/788|Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min
62683535|NCT02062346|NO_INTERVENTION|Assessment of forearm vascular function|Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators
62683536|NCT03487510||NO groups|no groups apply.
61923252|NCT00879944||Healthy Controls|"Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.~Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm"
61923253|NCT05427955|ACTIVE_COMPARATOR|One-level Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 30 ml of 0.25% bupivacaine hydrochloride will be injected cauda-cranially into the interfacial space below the erector spinae muscle, above the transverse process.
61923254|NCT05427955|ACTIVE_COMPARATOR|Bi-level Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T4 spinous process, 15 ml of 0.25% bupivacaine hydrochloride will be injected cauda-cranially into the interfacial space below the erector spinae muscle, above the transverse process. Next, the needle will be withdrawn till subcutaneously and the linear US probe will be placed 2-3 cm lateral to the T6 spinous process. Finally, 15 ml of 0.25% bupivacaine hydrochloride will be injected cranio-caudally into the interfacial space below the erector spinae muscle, above the transverse process.
61923255|NCT05494762|EXPERIMENTAL|Phase 1a: Dose Escalation|Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)
61923256|NCT05494762|EXPERIMENTAL|Phase 1b: Dose Expansion|BGB-B167 alone or in combination with tislelizumab (BGB-A317)
61923257|NCT02394002|EXPERIMENTAL|Brain surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
61923258|NCT02394002|EXPERIMENTAL|Spine surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
61923259|NCT02394002|ACTIVE_COMPARATOR|General surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
62683537|NCT05944393|EXPERIMENTAL|ESB block|Patients will receive preoperative ultrasound-guided bilateral single-injection ESP blocks at one or two levels before incision with 10 mL 0.2% ropivacaine per single injection. Using appropriate sterile precautions, under general anesthesia, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the erector spine, transverse process, and paravertebral space. A 22G 0,7x80 mm echogenic block needle (Stimuplex Ultra 360)) is inserted in-plane from the cranial to caudal direction until the needle tip contacts the transverse process. 1-3mL is injected to confirm the proper injection plane by visualizing the spread deep to the erector spinae muscles and superficial to the transverse process. Block is completed with 10mL of 0,2% Ropivacaine. The needle is withdrawn, and the needle entry site is wiped clean.
62737844|NCT01668446|EXPERIMENTAL|sildenafil|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
61923260|NCT03709732||Spinal cord injury|Persons with a spinal cord injury. No intervention
62123375|NCT03383146|EXPERIMENTAL|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
62313086|NCT03733678|EXPERIMENTAL|Regular SARC, LARC=2140, Recommendation|Regular price SARC, LARC=2140 CFA, Sequential recommendation
61923261|NCT03709732||Caregivers spinal cord injury|Caregivers for persons with a spinal cord injury. No intervention
61923262|NCT03709732||Controls for patients|Control group for patient cohort. No intervention
61923263|NCT05439642|OTHER|Hemophilia|Evaluation of quality of life of children with hemophilia in Turkey
61923264|NCT04231318|EXPERIMENTAL|Cingal|Single injection of Cingal: 4 milliliter (mL) dose of 88 mg (22 mg/mL) of cross-linked sodium hyaluronate with 18 mg (4.5 mg/mL) of triamcinolone hexacetonide (TH). Manufactured by Anika Therapeutics.
61923265|NCT04231318|ACTIVE_COMPARATOR|Triamcinolone Hexacetonide (TH)|Single injection of Triamcinolone Hexacetonide (TH): 1 milliliter (mL) dose of 20 mg/ml TH. Manufactured by IntraPharm.
62313087|NCT03733678|NO_INTERVENTION|Regular SARC, LARC=5000, Recommendation|Regular price SARC, LARC=5000 CFA, Sequential recommendation
62313088|NCT03733678|EXPERIMENTAL|Free SARC, Free LARC, No Recommendation|Free SARC, Free LARC, Simultaneous recommendation
61923266|NCT04231318|PLACEBO_COMPARATOR|Placebo|Single injection of Placebo: 4 milliliter (mL) dose of 0.9% saline. Manufactured by Anika Therapeutics.
61923267|NCT01108978|PLACEBO_COMPARATOR|Placebo|
61923268|NCT01108978|ACTIVE_COMPARATOR|Dehypotin|
61923269|NCT03023046|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive etoposide IV over 96 hours, doxorubicin IV over 96 hours, and vincristine sulfate IV over 96 hours on days 1-4. Patients also receive cyclophosphamide IV over 1 hour on day 5 and prednisone PO BID on days 1-5. Patients who are Ph+ also receive imatinib mesylate or dasatinib PO QD on days 1-14. Patients who are CD20+ also receive rituximab IV on day 1 or day 5. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62313089|NCT03733678|EXPERIMENTAL|Free SARC, LARC=500, No Recommendation|Free SARC, LARC=500 CFA, Simultaneous recommendation
62313090|NCT03733678|EXPERIMENTAL|Free SARC, LARC=1000, No Recommendation|Free SARC, LARC=1000 CFA, Simultaneous recommendation
62313091|NCT03733678|EXPERIMENTAL|Free SARC, LARC=2140, No Recommendation|Free SARC, LARC=2140 CFA, Simultaneous recommendation
62313092|NCT03733678|EXPERIMENTAL|Free SARC, LARC=5000, No Recommendation|Free SARC, LARC=5000 CFA, Simultaneous recommendation
62313093|NCT03733678|EXPERIMENTAL|Regular SARC, Free LARC, No Recommendation|Regular Price SARC, Free LARC, Simultaneous recommendation
62477703|NCT05459571|EXPERIMENTAL|Axicabtagene Ciloleucel|"Participant will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m\^2/day and fludarabine 30 mg/m\^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2.~Participant will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10\^6 cells/kg."
62313094|NCT03733678|EXPERIMENTAL|Regular SARC, LARC=500, No Recommendation|Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
62477704|NCT04178850|EXPERIMENTAL|GB242|3mg/kg
62477705|NCT04178850|ACTIVE_COMPARATOR|Infliximab|3mg/kg
62477706|NCT06492876|EXPERIMENTAL|FT003 Dose 1|Low dose of FT-003
62683538|NCT05944393|EXPERIMENTAL|Placebo block|Patients will receive preoperative ultrasound-guided bilateral single-injection ESP blocks at one or two levels before incision with 10 mL 0,9% normal saline per single injection. Using appropriate sterile precautions, under general anesthesia, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the erector spine, transverse process, and paravertebral space. A 22G 0,7x80 mm echogenic block needle (Stimuplex Ultra 360)) is inserted in-plane from the cranial to caudal direction until the needle tip contacts the transverse process. 1-3mL is injected to confirm the proper injection plane by visualizing the spread deep to the erector spinae muscles and superficial to the transverse process. Block is completed with 10mL of 0,9% normal saline. The needle is withdrawn, and the needle entry site is wiped clean.
62313095|NCT03733678|EXPERIMENTAL|Regular SARC, LARC=1000, No Recommendation|Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
62313096|NCT03733678|EXPERIMENTAL|Regular SARC, LARC=2140, No Recommendation|Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
62313097|NCT03733678|EXPERIMENTAL|Regular SARC, LARC=5000, No Recommendation|Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
62313098|NCT03281590||Patients with stroke|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
62313099|NCT03281590||Patients without stroke|Control subject who have the risk factors but never had stroke.
62477707|NCT06492876|EXPERIMENTAL|FT003 Dose 2|Mid dose of FT-003
62477708|NCT06492876|EXPERIMENTAL|FT003 Dose 3|High dose of FT-003
62477709|NCT05439252|EXPERIMENTAL|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening, and record exercise snacking compliance data in a log book
62477710|NCT01631552|EXPERIMENTAL|Sacituzumab Govitecan-hziy (SG) 8 mg/kg|Participants will receive sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
62477711|NCT01631552|EXPERIMENTAL|SG 10 mg/kg|Participants will receive SG 10 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
62477712|NCT01631552|EXPERIMENTAL|SG 12 mg/kg|Participants will receive SG 12 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
62477713|NCT01631552|EXPERIMENTAL|SG 18 mg/kg|Participants will receive SG 18 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
62477714|NCT03502148|EXPERIMENTAL|Open-Label, Single Arm Study of PRV111|Subjects received 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery.
62683539|NCT05856461|SHAM_COMPARATOR|Pulmonary vein isolation+sham pulmonary artery denervation (group 1)|In group 1, standard pulmonary vein isolation will be performed (with manual or remote robotic 3D navigation using radiofrequency energy) with sham pulmonary artery denervation procedure including 3D reconstruction of the pulmonary artery tree and creation of the false ablation point
62123376|NCT03621696|EXPERIMENTAL|Arm 1: POAmCRT|"* Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease~* Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~* Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.~* It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~* Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
62313100|NCT01421849|EXPERIMENTAL|Elderly with an unstable mandibular denture.|
62313101|NCT00649519|EXPERIMENTAL|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
62683540|NCT05856461|ACTIVE_COMPARATOR|Pulmonary vein isolation+pulmonary artery denervation (group 2)|In group 2, standard pulmonary vein isolation will be performed (with manual or remote robotic 3D navigation using radiofrequency energy) combined with pulmonary artery denervation procedure
62683541|NCT02241772|EXPERIMENTAL|10mg TA-8995|10mg TA-8995 once daily
62683542|NCT02241772|EXPERIMENTAL|2.5mg TA-8995|2.5mg TA-8995 once daily
62683543|NCT02241772|PLACEBO_COMPARATOR|Placebo to TA-8995|Placebo to TA-8995 once daily.
62683544|NCT06222294|EXPERIMENTAL|Remimazolam Tosilate for Injection|
61923270|NCT06156124||Adolescents having sibling with intellectual disability|Dyads of healthy Polish adolescents 16-18 y.o., who have sibling with intellectual disability and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
62123377|NCT03621696|EXPERIMENTAL|Arm 2: POAmRT|"* Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease~* Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~* Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses~* It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~* Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
62313102|NCT00649519|ACTIVE_COMPARATOR|2|Lotrel® Capsules 10 mg/20 mg
62313103|NCT02213003|EXPERIMENTAL|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
62313104|NCT03057873|EXPERIMENTAL|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
62313105|NCT03057873|PLACEBO_COMPARATOR|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
62313106|NCT01276847|EXPERIMENTAL|Ustekinumab|
62313107|NCT01276847|ACTIVE_COMPARATOR|Etanercept|
62313108|NCT01276847|NO_INTERVENTION|No treatment|
62313109|NCT06673290|EXPERIMENTAL|Low dose of sirolimus|The plasma trough concentration of sirolimus is maintained within the range of 5-8 ng/ml by adjusting sirolimus dose, for 1 year.
62477715|NCT06202755|ACTIVE_COMPARATOR|ticagrelor arm|The ticagrelor arm will receive (180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day)
62477716|NCT06202755|ACTIVE_COMPARATOR|cilostazol arm|The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day)
62683545|NCT06222294|ACTIVE_COMPARATOR|Propofol Medium and Long Chain Fat Emulsion Injection|
62683546|NCT06101069|EXPERIMENTAL|Healthy Volunteer Participants|Healthy volunteers will be recruited to evaluate the capability of MRF in conjunction with intravoxel incoherent motion (IVIM) MRI and serve as healthy control data to compare with the participant data.
62313110|NCT06673290|ACTIVE_COMPARATOR|High dose of sirolimus|The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
62313111|NCT06125210|EXPERIMENTAL|intervention group|
62313112|NCT06125210|NO_INTERVENTION|control group|
62313113|NCT03527901||Chronic periodontitis|This groups participant has radiographically moderate alveolar bone loss, CAL \> 5 mm and PD \>6 mm in several sites of each quadrant
61923271|NCT06156124||Adolescents having sibling with motor disability|Dyads of healthy Polish adolescents 16-18 y.o., who have sibling with motor disability and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
62123378|NCT03621696|EXPERIMENTAL|Arm 3: POACRT|"* Patients with clinical or pathologic T4 or clinical N3 disease~* Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~* Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)~* The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.~* It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~* Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
62477717|NCT06152458|EXPERIMENTAL|intervention group|Patients in the intervention group (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
62477718|NCT06152458|NO_INTERVENTION|control group|As a control group, we selected 20 age- and sex-matched patients with septic shock who did not receive vitamin treatment.They received the standard of care for septic shock.
62683547|NCT06101069|EXPERIMENTAL|Participants with Radiation Necrosis|The MRI scans (MRF and IVIM) will be performed on participants with newly developed necrosis prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings
62123379|NCT00885157|EXPERIMENTAL|Group A|Will receive fractional doses of IPV Intradermally
61923272|NCT06156124||Adolescents having sibling with diabetes|Dyads of healthy Polish adolescents 16-18 y.o., who have sibling with chronic somatic disease - diabetes, and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
61923273|NCT06156124||Adolescents having healthy sibling|Dyads of healthy Polish adolescents 16-18 y.o., who ave healthy sibling, and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
61923274|NCT01464983|ACTIVE_COMPARATOR|Arm 1|
62313114|NCT03527901||Generalized aggressive periodontitis|This demonstrated a generalized pattern of severe breakdown and CAL \> 5 mm and PD \> 6 mm on 8 \> teeth; minimum three of those were other than first incisors or first molars
62313115|NCT03527901||Gingivitis|This group has varying degrees of gingival inflammation, with CAL \< 2 mm, without any radiographical bone loss due to periodontitis
62313116|NCT03527901||Implant|Implants classified PD \< 5 mm, no bleeding on probing, no suppuration and no radiographic bone loss \> 0.5 mm
62477719|NCT02565160||Septic Arthritis|Patients suspected of having septic arthritis
62477720|NCT02565160||Osteoarthritis|Patients suffering with osteoarthritis undergoing an intervention
62477721|NCT02565160||Joint Revision|Patients who has a prosthetic joint in situ
61923275|NCT01464983|EXPERIMENTAL|Arm 2|
62313117|NCT03527901||Health|Probing depth (PD) \< 3mm, no gingival recession due to periodontal disease, and clinical attachment level (CAL) \< 2 mm, BOP in \< 10% of full-mouth score examination
61923276|NCT01464983|ACTIVE_COMPARATOR|Arm 3|
61923277|NCT01464983|ACTIVE_COMPARATOR|Arm 4|
61923278|NCT01464983|PLACEBO_COMPARATOR|Arm 5|
62123380|NCT00885157|ACTIVE_COMPARATOR|Group B|Will receive full doses of IPV Intramuscularly
62313118|NCT06181617||Participants diagnosed with non-obstructive hypertrophic cardiomyopathy|
61923279|NCT04481009|EXPERIMENTAL|YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
61923280|NCT04481009|EXPERIMENTAL|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
62123381|NCT05200572|EXPERIMENTAL|Cancer Patients|Dyadic Life Review will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes.
62123382|NCT04856982|NO_INTERVENTION|Part A: Natural History Run-in|Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess neurofilament light chain (NfL) levels.
62123383|NCT04856982|EXPERIMENTAL|Part B: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive tofersen 100 milligram (mg) or placebo via intrathecal (IT) injection on Days 1, 15, 29, and every 28 days thereafter for up to approximately 5.6 years.
62123384|NCT04856982|EXPERIMENTAL|Part C: Open-Label Extension|Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter up to the final maintenance dost visit. Participants who received tofersen during Part B will receive tofersen 100 mg on Days 1, 29, and every 28 days thereafter up to the final maintenance dost visit, with a dose of placebo on Day 15 to maintain the study blind. The combined duration of Part B and Part C is up to approximately 5.6 years.
61923281|NCT04481009|EXPERIMENTAL|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
62313119|NCT06181617||Participants diagnosed with obstructive hypertrophic cardiomyopathy|
62313120|NCT06181617||Control group|
62313121|NCT01084252|EXPERIMENTAL|Phase 1:Isatuximab <=1 mg/kg Q2W|Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (\<=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
62313122|NCT01084252|EXPERIMENTAL|Phase 1: Isatuximab 3mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
62313123|NCT01084252|EXPERIMENTAL|Phase 1: Isatuximab 5 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
61923282|NCT03198039|EXPERIMENTAL|Group 1|Meditation twice daily for at least two weeks prior to surgery and for four weeks after surgery
61923283|NCT03198039|EXPERIMENTAL|Group 2|Meditation twice daily for four weeks after surgery
61923284|NCT03198039|NO_INTERVENTION|Group 3|Control group - will undergo surgery and subsequent hospital stay according to the current standard of care, which does not include meditation
62123385|NCT04856982|EXPERIMENTAL|Part D: Open-Label Treatment|Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will receive tofersen100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
62313124|NCT01084252|EXPERIMENTAL|Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
62123386|NCT00989937|EXPERIMENTAL|Group 1|20 IU BID for the first week, 40 IU BID for the following two weeks, one week washout, 3 week placebo trial
61923285|NCT00937391|EXPERIMENTAL|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
62123387|NCT00989937|PLACEBO_COMPARATOR|Group 2|Three week placebo trial, one week washout, 20 IU BID for the fifth week, 40 IU BID for the following two weeks
62313125|NCT01084252|EXPERIMENTAL|Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
62477722|NCT02794584|ACTIVE_COMPARATOR|Off-pump hybrid closure|Hybrid closure is that a periventricular technique uses an occluding device to closure ventricular septal defects of patients through the delivery system by transthoracic minimally invasive small incision without cardiopulmonary bypass.
62477723|NCT02794584|PLACEBO_COMPARATOR|Control|Control group: Conventional closure of ventricular septal defects was aided with cardiopulmonary bypass.
62477724|NCT06102213|EXPERIMENTAL|Cohort A: HMO 9.0 g and B. infantis|HMO will be administered at 9.0 g orally twice a day (BID), and B. infantis will be administered orally twice a day (BID) (total of 43 days of dosing).
62477725|NCT06102213|EXPERIMENTAL|Cohort B: HMO 4.5 g and B. infantis|HMO will be administered at 4.5 g orally BID, and B. infantis will be administered orally BID (total of 43 days of dosing).
62477726|NCT06102213|NO_INTERVENTION|Cohort C|Participants in this cohort will not receive any study drug
62477727|NCT03407677|OTHER|ROTO Track|The individual patient will serve as his/her own control before intervention with ROTO Track
62477728|NCT01104025|EXPERIMENTAL|Induction Therapy|ATG, rabbit: intravenous, 5 mg/kg/dose, 5 consecutive days Dexamethasone: intravenous, 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days Etoposide: intravenous, 150 mg/m2 weekly, starting 7 days after first dose of Thymoglobulin Methotrexate and hydrocortisone: intrathecal to patients with central nervous system involvement, age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg, on day 7, 14, 21 and 42
62477729|NCT04450069|EXPERIMENTAL|Dose Escalation|CLBR001 + SWI019 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD)
62477730|NCT03969693||The patients with mediastinal malignant lymphoma|Patients whose radiation therapy field essentially encompasses anterior mediastinum; namely, the majority of malignant lymphoma patients with mediastinal involvement.
62477731|NCT00270634|ACTIVE_COMPARATOR|Low Dose Voclosporin|Low dose voclosporin
62477732|NCT00270634|ACTIVE_COMPARATOR|Mid Dose Voclosporin|Mid Dose Voclosporin
62477733|NCT00270634|ACTIVE_COMPARATOR|High Dose Voclosporin|High Dose Voclosporin
62477734|NCT00270634|ACTIVE_COMPARATOR|Tacrolimus|Standard Dose Tacrolimus
62477735|NCT00789386|EXPERIMENTAL|Remifentanil|
62477736|NCT00789386|PLACEBO_COMPARATOR|Midazolam|Active Placebo
62477737|NCT00275366|OTHER|1|
62477738|NCT01674491|EXPERIMENTAL|4.5g/day black soy peptide|4.5 g/day, 8weeks
62477739|NCT01674491|PLACEBO_COMPARATOR|placebo|similar appearance to the black soy peptide tablet, 8 weeks
62477740|NCT03137251|EXPERIMENTAL|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
62477741|NCT03137251|EXPERIMENTAL|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
62477742|NCT03137251|SHAM_COMPARATOR|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
62477743|NCT01632839||Vaginal surgery +prothesis +sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are sexually active.
62477744|NCT01632839||Vaginal surgery +prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are NOT sexually active.
62683548|NCT06101069|EXPERIMENTAL|Participants with Tumor Recurrence|The MRI scans (MRF and IVIM) will be performed on participants with newly developed recurrent prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings
62477745|NCT01632839||Vaginal surgery -prothesis + sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are sexually active.
62477746|NCT01632839||Vaginal surgery -prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are NOT sexually active.
62477747|NCT01632839||Abdominal surgery +sexuality|The 50 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are sexually active.
62477748|NCT01632839||Abdominal surgery -sexuality|The 25 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are NOT sexually active.
62477749|NCT01632839||Urinary incontinence surgery + sexuality|The 50 patients included in this group will have surgery for urinary incontinence; these patients are sexually active.
62477750|NCT01632839||Urinary incontinence surgery - sexuality|The 25 patients included in this group will have surgery for urinary incontinence; these patients are NOT sexually active.
62477751|NCT03720691|ACTIVE_COMPARATOR|Real rTMS Supplementary motor area|Real rTMS will be applied over the supplementary motor area
62477752|NCT03720691|SHAM_COMPARATOR|Sham rTMS Supplementary motor area|Sham rTMS will be applied over the supplementary motor area
62477753|NCT04776798|EXPERIMENTAL|Biomechanical Taping|"Anti pronation taping will apply bilaterally with Dynamic Tape®. The tape will attach to the dorsal aspect of the foot.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
62683549|NCT03471286|EXPERIMENTAL|Sub-Protocol A|Epacadostat
61923286|NCT02480712|EXPERIMENTAL|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
62313126|NCT01084252|EXPERIMENTAL|Phase 1: Isatuximab 10 mg/kg QW|Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
62313127|NCT01084252|EXPERIMENTAL|Phase 1: Isatuximab 20 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
62313128|NCT01084252|EXPERIMENTAL|Phase 1: Isatuximab 20 mg/kg QW|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
62313129|NCT01084252|EXPERIMENTAL|Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).
62313130|NCT01084252|EXPERIMENTAL|Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).
62123388|NCT06441786|EXPERIMENTAL|A metacognitive group therapy of depression and anxiety in youth with autism|A within group design where one clinical manualized intervention, Metacognitive therapy (MCT) for anxiety and depression, is offered in a 10-session group format to adolescents. The therapists have received special training in MCT and are experienced in using the methods. The treatment is delivered face-to-face.
62123389|NCT00428519|PLACEBO_COMPARATOR|1|
62123390|NCT00428519|ACTIVE_COMPARATOR|2|
62123391|NCT00428519|ACTIVE_COMPARATOR|3|
62123392|NCT02401763||Nasopharyngeal carcinoma and salivary gland tumor|patients diagnosed and treated in National Taiwan University Hospital
61923287|NCT03461510|EXPERIMENTAL|Type 2 Diabetes|Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
62123393|NCT03189329|ACTIVE_COMPARATOR|Group L|Patients undergoing block with 2% lidocaine hydrochloride
62123394|NCT03189329|ACTIVE_COMPARATOR|Group LB|Patients undergoing block with 0.5% levobupivacaine
62123395|NCT02957981|EXPERIMENTAL|Web-Based Counseling|Genetic information provided via an individually tailored website.
62123396|NCT02957981|ACTIVE_COMPARATOR|Standard Care|Participants are not provided with web-based education but can choose to pursue genetic counseling and testing.
62123397|NCT03672773|EXPERIMENTAL|Treatment (temozolomide, talazoparib)|Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62123398|NCT00981968|EXPERIMENTAL|Japanese Cohort|Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.
62477754|NCT04776798|PLACEBO_COMPARATOR|Placebo Taping|"Placebo Taping will apply bilaterally to each individual in the control group by the same physiotherapist, without any effect on increased pronation.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
62123399|NCT00981968|EXPERIMENTAL|Western Cohort|Single oral dose of sitaxentan sodium in 10 healthy subjects.
62123400|NCT05561881|OTHER|IPACK group|visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to a lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
62123401|NCT05561881|EXPERIMENTAL|genicular group|US transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, and A 20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming the placing of the needle next to each genicular artery a total amount of 20 ml of local anesthetic in equal increments at multiple sites
62123402|NCT05206617||Limb Girdle Muscular Dystrophy type 2L|At baseline, 1- and 3-year follow up will the outcome measures be assessed. There will be no intervention.
62123403|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
62123404|NCT02986906|EXPERIMENTAL|5% dextrose|The perineural injection with 5% dextrose is a new and potential treatment for peripheral entrapment neuropathy
62123405|NCT02986906|ACTIVE_COMPARATOR|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|The Ultrasound-guided injection with 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
62123406|NCT05756140||Patients Group|Geriatric patients in the postoperative period hospitalized in surgical wards
62313131|NCT01084252|EXPERIMENTAL|Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 414 weeks).
62477755|NCT02896010|ACTIVE_COMPARATOR|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
62123407|NCT05486364|EXPERIMENTAL|Study group|All subjects will receive both standard of care monitoring and digital rhythm monitoring using a PPG based smartphone application for AF recurrence after the PVI procedure.
62123408|NCT02457845|EXPERIMENTAL|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.~Intervention: Biological: G207"
61923288|NCT03461510|NO_INTERVENTION|Lean Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
62313132|NCT01084252|EXPERIMENTAL|Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W|Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 92 weeks).
62313133|NCT01084252|EXPERIMENTAL|Phase 2 Stage 2: Isatuximab Alone|Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 301 weeks).
62477756|NCT02896010|ACTIVE_COMPARATOR|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
62683550|NCT06674837||DEMELE-JEV Cohort 1|This group will include children aged 2-14 years who present at the hospital for reasons other than infectious disease suspicion. During the study of the project, 2000 children will be recruited at each study site. All these children will be followed up at one year and two years post-inclusion
62683551|NCT06674837||DEMELE-JEV Cohort 2|This group will include children aged 2-14 years who are hospitalized with febrile neurological syndrome (FNS)
62737845|NCT01668446|EXPERIMENTAL|Sildenafil and estradiol valerat|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
62477757|NCT02169063|EXPERIMENTAL|Diagnostic (11C-acetate, 18F-fluoride, PET)|Patients receive carbon-11 acetate IV and fluorine F 18 sodium fluoride IV over 1 minute and undergo PET at baseline and at 6-12 weeks after systemic therapy starts.
62477758|NCT00711386|EXPERIMENTAL|Cohort A|50mg dose once daily for 7 days.
62313134|NCT01084252|EXPERIMENTAL|Phase 2 Stage 2: Isatuximab + Dexamethasone|Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than \[\<\] 75 years of age; 20 mg/day \[greater than or equal to \[\>=\] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 301 weeks).
62313135|NCT01726777|PLACEBO_COMPARATOR|Control|30g normal cheddar cheese once per week
62683552|NCT05684198|EXPERIMENTAL|subcutaneous NPWT|The peritoneum and fascia will be closed as in the PC arm. Subsequently, patients will be treated with commercially available vacuum-assisted closure systems (provided by Smith\&Nephew or Hartmann) according to the manufacturer's instructions. Following fascia closure, the NPWT foam will be adjusted to the wound size to fill the wound cavity without causing excessive wound dehiscence. Subsequently, the foam will be placed in the subcutaneous tissue. The foam will not be fixated on the skin with sutures. The wound will be sealed with adhesive film. In case of air leak in problematic areas such as the navel or ostomy, ostomy paste will be used to create a tighter seal. Continuous pressure of 120 mmHg will be applied. On the 3rd day postop, the dressing will be removed and closure by secondary intention will be performed.
61923289|NCT03461510|NO_INTERVENTION|Obese Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
62477759|NCT00711386|EXPERIMENTAL|Cohort B|100mg dose once daily for 8 days.
62477760|NCT00711386|EXPERIMENTAL|Cohort C|200mg dose once daily for 8 days.
61923290|NCT03894137|EXPERIMENTAL|Grains of Paradise|
61923291|NCT03894137|PLACEBO_COMPARATOR|Placebo|
62737846|NCT04452305|EXPERIMENTAL|Spermatogonial Stem Cell Transplant & Testicular Tissue Graft|Stem cell transplantation Testicular tissue grafting
61923292|NCT05920928|EXPERIMENTAL|Long course chemoRadiotherapy (50.4Gy in 28 fr)|Neoadjuvant Long course radiotherapy (50.4 Gy in 28 fr) with concurrent capecitabine (825mg/m2) for locally advanced rectal cancer
61923293|NCT05920928|EXPERIMENTAL|Short course chemoRadiotherapy (25Gy in 5 fr)|Neoadjuvant short course radiotherapy (25 Gy in 5 fr) with concurrent capecitabine (825mg/m2) for locally advanced rectal cancer
61923294|NCT03455049|EXPERIMENTAL|Normal subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
61923295|NCT03455049|PLACEBO_COMPARATOR|Normal subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
61923296|NCT03455049|EXPERIMENTAL|Prediabetes subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
62477761|NCT00711386|EXPERIMENTAL|Cohort D|400mg dose once daily for 7 days.
62477762|NCT05295550|EXPERIMENTAL|Flexicurve-Smartphone İnclinometer Application|Measurement of thoracic kyphosis
62683553|NCT05684198|NO_INTERVENTION|primary closure|The peritoneum will be closed as a separate layer with a 2-0 multifilament absorbable suture. Subsequently, the fascia will be closed with a continuous suture using absorbable monofilament 0 sutures. Subcutaneous tissue will be rinsed twice with hypochlorite solution following peritoneal closure and fascial closure. Interrupted subcutaneous closure will be performed with absorbable multifilament 2-0 sutures. Following skin disinfection with an alcohol solution, the skin will be closed with non-absorbable monofilament 2-0 or 3-0 sutures using the interrupted mattress technique. Conventional Cosmopor® sterile gauze dressings will be applied. Unless the dressing material will be saturated, the dressing will remain unchanged until 3rd day post-op.
62683554|NCT02601365|EXPERIMENTAL|Aerosolized Sargramostim|A self-controlled, open-label study to evaluate safety of Sargramostim administered by nebulization
62683555|NCT04016428|EXPERIMENTAL|OPTIMISM Intervention|Participants will receive online delivery of a mindfulness-based program for improving sleep in pregnancy, along with the usual care they would receive from their provider.
62683556|NCT04016428|ACTIVE_COMPARATOR|Sleep Education|Participants will receive online delivery of an education program on sleep in pregnancy, along with the usual care they would receive from their provider.
62683557|NCT05164172|EXPERIMENTAL|Eptinezumab 300 mg|Participants will receive 3 intravenous (IV) infusions of eptinezumab 300 mg (weight adjusted) at Weeks 0, 12, and 24.
62123409|NCT03751943|OTHER|NanoFuse® PL Gutter|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) within one posterolateral gutter (unilateral)
61923297|NCT03455049|PLACEBO_COMPARATOR|Prediabetes subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
61923298|NCT04499599|ACTIVE_COMPARATOR|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
62123410|NCT02113072|EXPERIMENTAL|Probiotics & Beclomethasone|"It will be supplied in lyophilized form, in each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.~Beclomethasone HFA 50mcg spray - 100 mcg/day as initial treatment for primary and wheezing in this age group, at doses considered minimal, for 4 months."
61923299|NCT04499599|PLACEBO_COMPARATOR|Breakfast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a breakfast bar on day 2.
61923300|NCT04499599|EXPERIMENTAL|Fast Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar on day 2.
61923301|NCT05616715|EXPERIMENTAL|Subjects with gummy smile and with upper lip hypermobility|Periodontal plastic surgery for peek device implantation with 4 screws in the anterior maxillary area
61923302|NCT05616715|EXPERIMENTAL|Subjects with gummy smile and with short teeth and upper lip hypermobility|Gingivectomy/crown lengthening and device implantation in the anterior maxillary area. First crown lengthening procedure (CLP) will be performed creating a distance of 3mm between cementoenamel junction (CEJ). Next peek device will be position with 4 screws
61923303|NCT05616715|EXPERIMENTAL|Patiens who refuse device implantation - control group|Gingivectomy/crown lengthening procedure
61923304|NCT04618770|OTHER|Triathlon PSR Tibial Insert|Cases receiving a Triathlon Total Knee with the Triathlon PSR Tibial Insert
61923305|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
62123411|NCT02113072|ACTIVE_COMPARATOR|Beclomethasone & Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
62123412|NCT04661410|EXPERIMENTAL|Reward Re-Training|10 weekly sessions of Reward Re-Training Group Therapy.
62123413|NCT04661410|ACTIVE_COMPARATOR|Supportive Therapy|10 weekly sessions of Supportive Group Therapy.
62313136|NCT01726777|EXPERIMENTAL|Vitamin D|30g cheddar cheese containing 28,000IU vitamin D once per week
62313137|NCT00336492|EXPERIMENTAL|002|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
61923306|NCT04369170|OTHER|Group A - Control Group|Control group where an intermediate abutment is placed in between the CAD-CAM dental prostheses an the dental implant.
62313138|NCT00336492|EXPERIMENTAL|001|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
62313139|NCT00717470|ACTIVE_COMPARATOR|Prograf + MMF + Steroids|oral
62477763|NCT06227858|EXPERIMENTAL|Saffron extract supplementation (15mg, twice daily)|The experimental group will take a single capsule containing: 15mg of of saffron extract (stigma of the flower Crocus sativus), 340mg of Maltodextrin, encapsulated in hydroxypropyl methyl cellulose (HPMC), twice daily (one morning and one evening after the meal).
62683558|NCT05164172|EXPERIMENTAL|Eptinezumab 100 mg|Participants will receive 3 IV infusions of eptinezumab 100 mg (weight adjusted) at Weeks 0, 12, and 24.
61923307|NCT04369170|EXPERIMENTAL|Group B - Test Group|Test group where the CAD-CAM dental prostheses is connected directly to the dental implant
62313140|NCT00717470|ACTIVE_COMPARATOR|Advagraf (dose 1) + MMF + steroids|oral
62313141|NCT00717470|ACTIVE_COMPARATOR|Advagraf (dose 2) + MMF + steroids|oral
62313142|NCT00717470|ACTIVE_COMPARATOR|Advagraf + MMF + Basilixmab + steroids|oral
62477764|NCT06227858|PLACEBO_COMPARATOR|Control group|The Control group will take a single placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron) twice daily (one morning and one evening after the meal).
62477765|NCT00836576|EXPERIMENTAL|1|
62477766|NCT00836576|ACTIVE_COMPARATOR|2|
62477767|NCT05895383|EXPERIMENTAL|Self-adjusted nitrous oxide (SANO)|All patients will receive nitrous oxide at concentrations of minimal sedation (0-50%) throughout vasectomy.
62313143|NCT02367092|EXPERIMENTAL|Exercise Program|The exercise intervention consists of a 30 minute exercise session led by an instructor through a DVD or a video available on the internet.
62683559|NCT06425588|EXPERIMENTAL|Mask Testing|All participants will be fit tested while completing a modified version of the OSHA fit test.
62313144|NCT02367092|NO_INTERVENTION|Standard of care|Standard of care which consists of encouragement to exercise by the subject's transplant clinician.
62313145|NCT04892446|EXPERIMENTAL|Safety Run-in Cohort (Magrolimab+Daratumumab)|"Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) will receive magrolimab as per protocol and daratumumab 1800 mg subcutaneously (SC) or 16 milligrams per kilogram (mg/kg) intravenously (IV) on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days)~."
62313146|NCT04892446|EXPERIMENTAL|Safety Run-in Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days)
62477768|NCT00629122|EXPERIMENTAL|A: Tacrolimus and Nystatin Suspension|"Administer sublingual tacrolimus 2 mg every 12 hours (subject weight \< 90 kg) or 3 mg every 12 hours (subject weight \> 90kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Nystatin suspension 5 mL every 12 hours (study days 1 - 3 and 6 - 8)."
61923308|NCT03403270|EXPERIMENTAL|ENCOURAGE App Intervention|Users will download the ENCOURAGE mobile app. The App uses a time management technique (i.e. Pomodoro technique) as a strategy to provide prompts for users to engage in an activity. The App can be customized by the users to set prompts at intervals that fit into their schedule. For example, these activities can range from a stretching activity (e.g., a neck stretch), a standing activity (e.g., stand and read), or a physical activity (e.g., fill up the printer with paper, do a squat). Additionally, the App will use Behaviour Change Techniques as a strategy to support participants as they reduce their sedentary behaviour and improve their physical activity levels. The App uses a series of Behavior Change Techniques shown to be effective in promoting a more active lifestyle.
62477769|NCT00629122|EXPERIMENTAL|B: Tacrolimus and Clotrimazole Troche|"Administer sublingual tacrolimus 1 mg every 12 hours (subject weight \< 90 kg) or 2 mg every 12 hours (subject weight \> 90 kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Clotrimazole troche 10 mg every 12 hours (study day 1 - 3 and 6 - 8)."
62477770|NCT05178927|SHAM_COMPARATOR|Standard of Care-Group 1|"During treatments 1-5, radiation therapists will position the participant for treatment using the standard of care method.~During treatments 6-10, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method."
62683560|NCT04569825|ACTIVE_COMPARATOR|Local Nasal Steroid|Application of Local Nasal Steroid for the COVID-19 patients with anosmia
62683561|NCT04569825|PLACEBO_COMPARATOR|Normal Saline|Application of Normal Saline for the COVID-19 patients with anosmia
62683562|NCT06180421||PolG|Genetically confirmed PoLG patients 16 years or older
62683563|NCT06180421||PMM|Genetically confirmed Primary Mitochondrial Myopathy patients 16 years or older
62683564|NCT06689761|EXPERIMENTAL|ColCT|"Dietary Supplement: Collagen Participants ingest 15 grams specific collagen peptides daily~+ Concurrent training 12 weeks, 3x/week"
62683565|NCT06689761|PLACEBO_COMPARATOR|PlaCT|"Dietary Supplement: Placebo Participants ingest 15 grams of a placebo daily~+ Concurrent training 12 weeks, 3x/week"
61923309|NCT01384071|EXPERIMENTAL|Unstable shoes (MBT)|MBT shoes (Masai Barefoot Technology, Switzerland)
61923310|NCT01384071|SHAM_COMPARATOR|Stable shoes (Adidas)|Adidas stable shoes (Adidas Bigroar2)
61923311|NCT00586196|ACTIVE_COMPARATOR|1|
61923312|NCT00586196|PLACEBO_COMPARATOR|2|
62683566|NCT06689761|EXPERIMENTAL|ColET|"Dietary Supplement: Collagen Participants ingest 15 grams specific collagen peptides daily~+ Endurance training 12 weeks, 3x/week"
62683567|NCT06689761|PLACEBO_COMPARATOR|PlaET|"Dietary Supplement: Collagen Participants ingest 15 grams of placebo daily~+ Endurance training 12 weeks, 3x/week"
62683568|NCT04911751|EXPERIMENTAL|Low dose group|39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.
61923313|NCT05411133|EXPERIMENTAL|Phase 1a: Dose Escalation|
61923314|NCT05411133|EXPERIMENTAL|Phase 1b: Low dose Cabotamig (ARB202)|
61923315|NCT05411133|EXPERIMENTAL|Phase 1b: High dose Cabotamig (ARB202)|
61923316|NCT05411133|EXPERIMENTAL|Phase 1b: Low dose Cabotamig (ARB202) + Immune Checkpoint Inhibitor|
61923317|NCT05411133|EXPERIMENTAL|Phase 1b: High dose Cabotamig (ARB202) + Immune Checkpoint Inhibitor|
61923318|NCT02852772||PLHIV with microalbuminuria|Patient infected with HIV and well controlled by treatments, with microalbuminuria for at least 5 years
61923319|NCT02852772||PLHIV without microalbuminuria (control)|Patient infected with HIV and well controlled by treatments, without microalbuminuria, matched for age +/- 5 years
61923320|NCT05027893|ACTIVE_COMPARATOR|Active Comparator: The first tested group|Patients orally received film-coated tablets with either 400 mg of moxifloxacin. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
62683569|NCT04911751|EXPERIMENTAL|High dose group|39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.
62683570|NCT05093166|EXPERIMENTAL|Urethral reduced functionality and/or lesions due to previous hypospadias treatment failure|"The first step consists in a small oral mucosa biopsy collection by surgeon under general anaesthesia. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted.~The treatment for urethra reconstruction required a two stage urethroplasty:~1. First stage: application of Holour on the wound bed prepared according to standard surgery The penis will be immobilized for some days after this operation.~2. Second stage: surgical procedure for urethral tubularization and penile reconstruction according to standard surgical procedure.~The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics."
62683571|NCT06068075|NO_INTERVENTION|REG EWING or OSTEO: ctDNA EVALUATION|"This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease.~For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) per standard ctDNA workflow"
62683572|NCT06068075|EXPERIMENTAL|EWING ctDNA RETURN OF RESULTS|"This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease.~For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) to a commercial testing laboratory called Foundation Medicine and one tube of blood (10 mL or 2 teaspoons) to standard ctDNA workflow"
61923321|NCT05027893|ACTIVE_COMPARATOR|Active Comparator: The second tested group|Patients orally received film-coated tablets with either 400 mg of cefixime. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
61923322|NCT05027893|PLACEBO_COMPARATOR|Placebo Comparator: The control group|One third of patients received placebo-tablets containing indifferent substances with no antimicrobial action (99% microcrystalline cellulose, 0.5% silicon dioxide and 0.5% magnesium stearate, which were of the same colour and overall appearance as the used antibiotics. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
61923323|NCT02640040|EXPERIMENTAL|combined surgery|combined surgery for enrolled patients with CPT(Congenital Pseudarthrosis of Tibia): sleeve resection of the pathological soft tissues, intramedullary rod fixation, packaged lilac bone autograft,and llizarov external fixation device installation.
61923324|NCT02581943|EXPERIMENTAL|Arm I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
61923325|NCT02581943|EXPERIMENTAL|Arm II (pembrolizumab, paclitaxel, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 1 hour and carboplatin IV over 1 hour on days 1, 7 and 14. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
61923326|NCT02875925|EXPERIMENTAL|MTM|Patients will receive MTM at an individualized frequency for 1 year.
62683573|NCT00678574|EXPERIMENTAL|Premenstrual Dysphoric Disorder (PMDD) group|PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months
62683574|NCT00678574|NO_INTERVENTION|Healthy controls|
61923327|NCT02875925|NO_INTERVENTION|Control|Patients enrolled in the control group will not experience any change in their medical care.
61923328|NCT05266274|EXPERIMENTAL|The Treatment of Recurrent AML After Transplantation|
62683575|NCT03470883||endoscopic resection of a colorectal lesion|Patient having undergone endoscopic resection of a colorectal lesion stage 4 or 5 of the modified Vienna classification during the last 5 years at the institute.
62683576|NCT05996445|EXPERIMENTAL|Dose Escalation and Expansion XmAb662 administered as monotherapy|
62683577|NCT05996445|EXPERIMENTAL|Dose Escalation and Expansion XmAb662 administered in combination with pembrolizumab|
62313147|NCT04892446|EXPERIMENTAL|Safety Run-in Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 20 mg/m\^2 on Days 8, 15, 22 of Cycle 1, Days 1, 8, 15 of Cycle 2 and onward (if the carfilzomib starting dose of 20 mg/m\^2 is tolerated after Cycle 1, Day 8, the dose will be escalated to 70 mg/m\^2 on Cycle 1, Day 15 and thereafter) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)
62683578|NCT01482403|EXPERIMENTAL|Treatment Arm A|24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
61923329|NCT02175875||comatose patients|180 mg ticagrelor followed by 90 mg BID for comatose patients after cardiac arrest
61923330|NCT05561179|EXPERIMENTAL|GERD + HA injections|This group is comprised by patients with GERD, assessed previously through 24-Hour pH impedance test and esophageal manometry. The patients are submitted to HA injections at the lower esophageal level.
62477771|NCT05178927|EXPERIMENTAL|Mixed-reality guided patient setup-Group 2|"During treatments 1-5, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method.~During treatments 6-10, radiation therapists will position the participant for treatment using the standard of care method."
62477772|NCT05952544||control group|include patients who were on low protein diet only
62477773|NCT05952544||interventional group|include patients who consumed KA/EAA plus very low protein diet
62683579|NCT01482403|EXPERIMENTAL|Treatment Arm B|24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
62683580|NCT01482403|ACTIVE_COMPARATOR|Treatment Arm C (Control)|4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
62477774|NCT06617260||Neonates and mothers|"Pre-partum mothers will be eligible for recruitment if they have been admitted to the pre-partum ward (2F) at PMH. This includes mothers with:~* Pre-term labor (24-36 weeks gestation)~* Pre-eclampsia~* Post-dates (\>41 weeks gestation) The rationale for recruiting these mothers is that there is a high probability of having a baby who will ultimately be admitted to the NNU"
61923331|NCT05561179|PLACEBO_COMPARATOR|GERD without HA injections|This group is comprised by patients with GERD assessed previously through 24-Hour pH impedance test and esophageal manometry. The patients are submitted to sodium chloride at the lower esophageal level.
62123414|NCT05544643|EXPERIMENTAL|A - M30IS vs. EM30IS. First phase Mio 30, second phase Extended Mio 30.|"Subjects will be randomized to a group who will be using the Mio 30 infusion set (M30IS) for the Phase 1. All patients will be retrained on the use of the M30IS by site staff and will be asked to demonstrate proficiency. All subjects will be instructed to change sets every 3 days or at set failure (replace with another M30IS).~At day 12 or after using 4 sets (set used defined as a set that was used for more than 6 hours), the patients will return to a visit, return all the extracted catheters sets and will switch to the Extended Mio 30 infusion set (EM30IS), entering Phase 2. All patients will be trained at this visit on the use of the EM30IS by site staff and demonstrate proficiency in the use of the EM30IS. All subjects will be instructed to change sets every 7 days or at set failure (replace with another EM30IS). After 28 days or after using 4 sets, the patients will return all the extracted catheters sets."
61923332|NCT00965510|EXPERIMENTAL|Care Coordination|Patients receive care coordination to improve their diabetes.
62313148|NCT04892446|EXPERIMENTAL|Safety Run-in Cohort (Magrolimab+Bortezomib+Dexamethasone)|"Bortezomib + Dexamethasone may be initiated based on the preliminary safety and efficacy of the Carfilzomib + Dexamethasone cohort.~Participants with relapsed/refractory multiple myeloma who have had 1 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 1.3 mg/m\^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)"
62683581|NCT05776381|EXPERIMENTAL|Shared Decision Making (SDM)|Patients with an unexpected malignant colorectal polyp where a decision needs to be made concerning the management of care.
61923333|NCT00965510|NO_INTERVENTION|control|patients with type II diabetes receive usual health care
62313149|NCT04892446|EXPERIMENTAL|Dose Expansion Cohort (Magrolimab+Daratumumab)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and daratumumab 1800 mg SC or 16 mg/kg IV on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days)
62313150|NCT04892446|EXPERIMENTAL|Dose Expansion Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days)
62313151|NCT04892446|EXPERIMENTAL|Dose Expansion Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and carfilzomib 20 mg/m\^2 on Days 8, 15, 22 of Cycle 1, Days 1, 8, 15 of Cycle 2 and onward (if the carfilzomib starting dose of 20 mg/m\^2 is tolerated after Cycle 1, Day 8, the dose will be escalated to 70 mg/m\^2 on Cycle 1, Day 15 and thereafter) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)
62313152|NCT04892446|EXPERIMENTAL|Dose Expansion Cohort (Magrolimab+Bortezomib+Dexamethasone)|"Bortezomib + Dexamethasone may be initiated based on the preliminary safety and efficacy of the Carfilzomib + Dexamethasone cohort.~Participants with relapsed/refractory multiple myeloma who have had 1 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and bortezomib 1.3 mg/m\^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)"
61923334|NCT01684020|EXPERIMENTAL|ARTISS Human Fibrin Sealant|Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
61923335|NCT01684020|NO_INTERVENTION|Standard of Care|Fixation of the skin flap created during external rhinoplasty will use the standard of care
62683582|NCT05776381|NO_INTERVENTION|Historical data arm|Historical data on the management of patients with an unexpected malignant colorectal polyp from February 2018 to the end of 2022 retrieved through the Danish Colorectal Cancer Group Database, the National Pathology database and the National Patient Register.
62683583|NCT06113562|EXPERIMENTAL|Persistent hypoxemia after Obstructive sleep apnea group|Participants will receive Patent Foramen Ovale (PFO) closure and followed until repeat sleep apnea testing up to 6 months.
61923336|NCT06008626|EXPERIMENTAL|Cryosa Procedure|The purpose of this study is to evaluate the safety and effectiveness of Cryosa System applied to the tongue and soft palate in patients with clinically diagnosed obstructive sleep apnea (OSA).
61923337|NCT05500547|EXPERIMENTAL|Universal single shade resin composite restorative material|Dental restorative material
61923338|NCT05500547|ACTIVE_COMPARATOR|Nano-hybrid multi-shade resin composite restorative material|Dental restorative material
61923339|NCT01785095|EXPERIMENTAL|FSH|FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.
61923340|NCT03142061|EXPERIMENTAL|ECT|
61923341|NCT01168960|OTHER|Cognitive Behavioral Treatment|A single intervention study
62683584|NCT06054880|PLACEBO_COMPARATOR|Saline|116 subjects treated with 5 ml of saline then crossover to treatment arm
62683585|NCT06054880|EXPERIMENTAL|High Dose|58 subjects randomly treated with 5 mL of drug
62683586|NCT06054880|EXPERIMENTAL|Low Dose|58 subjects randomly treated with 2.5 mL of drug
62683587|NCT05795764|EXPERIMENTAL|Crisis Response Planning|CRP is a brief psychotherapeutic intervention that can be provided to patients at risk of suicidal behavior. When using the intervention, a provider works with the patient (1) to conduct a narrative assessment of the events preceding suicidal thoughts or behavior, and (2) to develop a personalized plan for identifying and managing distress that could escalate to a suicide attempt. The CRP, which is typically handwritten by the patient on an index card, includes personal warning signs of distress, emotion regulation strategies, reasons for living, and contact information for friends/family as well as professional (psychological/medical) and emergency resources.
62683588|NCT05795764|ACTIVE_COMPARATOR|Treatment as Usual|Existing clinical practices in the emergency department include the following elements recommended by the VA/DoD Clinical Practice Guidelines: (1) all patients are screened for suicidal ideation at every visit; (2) for those with positive screens, a suicide risk assessment interview is conducted by a mental health professional; (3) a safety planning form with means restriction (such as the Stanley-Brown; Stanley \& Brown, 2012) is completed; and (4) patients are referred for follow-up mental health treatment as needed. Other elements of TAU could include behavioral and psychotropic interventions, referrals to specialty mental healthcare, and admission for psychiatric inpatient care.
62683589|NCT03027050|EXPERIMENTAL|Titanium-prepared platelet rich fibrine|T-PRF was applied with open flap debridement in test group.
62313153|NCT03841877|EXPERIMENTAL|AH Plus-Cervical|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
62683590|NCT03027050|ACTIVE_COMPARATOR|Open Flap Debridement alone|T-PRF was not applied to control groups. Only open flap debridement was applied to control groups.
61923342|NCT04378985|EXPERIMENTAL|Wearing a wearable device (the smart watch) for 8 weeks|The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.
61923343|NCT06086691|EXPERIMENTAL|Strength Training|Strength training exercises along with caffeine supplementation
62313154|NCT03841877|EXPERIMENTAL|MTA Fillapex-Cervical|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
62313155|NCT03841877|EXPERIMENTAL|AH Plus-2mm|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
62683591|NCT06687993|EXPERIMENTAL|donepezil 2.5 mg|donepezil 2.5 mg daily for 90 days
62683592|NCT06687993|EXPERIMENTAL|donepezil 5 mg|donepezil 5 mg daily for 90 days
62683593|NCT06687993|PLACEBO_COMPARATOR|placebo|placebo daily for 90 days
62683594|NCT06426927|EXPERIMENTAL|Educational Videos|Enrolled participants will watch three educational videos in Spanish pertaining to: (1) Colorectal Cancer (CRC) symptoms; (2) CRC risk factors and (3) CRC facts, screening, treatment, and Cancer Clinical Trials (CCT).
62683595|NCT04920656||Breast cancer patients|All adult patients with a confirmed diagnosis of breast cancer, aged 18 or older at time of cancer diagnosis, will be invited to participate.
62683596|NCT06687395|OTHER|medium/high fidelity model|Group 1: training model 1 - re-assessment model 1
62123415|NCT05544643|EXPERIMENTAL|B - EM30IS vs. M30IS. First phase Extended Mio 30, second phase Mio 30|"Subjects will be randomized to a group who will be using the EM30IS for the initial Phase. All patients will be trained on the use of the EM30IS by site staff and will be asked to demonstrate proficiency. All subjects will be instructed to change sets every 7 days or at set failure (replace with another EM30IS).~At day 28 or after using 4 sets (set used defined as a set that was used for more than 6 hours), the patients will return to a visit, return all the extracted catheters sets and will switch to the M30IS, entering Phase 2. All patients will then be retrained on the use of the M30IS by site staff and demonstrate proficiency. All subjects will be instructed to change sets every 3 days or at set failure (replace with another M30IS). After 12 days or after using 4 sets, the patients will all the extracted catheters sets."
62313156|NCT03841877|EXPERIMENTAL|MTA Fillapex-2mm|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
62313157|NCT03393962|EXPERIMENTAL|OC-EIEs|Autologous ovarian cancer antigen-specific cytotoxic lymphocytes
62683597|NCT06687395|OTHER|self-made model|Group 2: training model 2 - re-assessment model 1
62477775|NCT04875117||Intervention|Participants who are due to receive their first-ever hearing aid(s) as part of their routine audiological care.
62737847|NCT06661616||Depressed patient treated with electroconvulsivotherapy|The indication for ECT treatment is established by the department's medical team. Participants are not assigned to ECT as part of this observational study.
62737848|NCT06661616||Depressed patient treated without electroconvulsivotherapy|The indication for antidepressant treatment is established by the department's medical team. Participants are not assigned to ECT as part of this observational study.
62737849|NCT06661616||Healthy volunteers|Age- and sex-matched healthy volunteers free of psychiatric disorders.
62477776|NCT04875117||Control|Participants with hearing loss who have not experienced any change in hearing aid status for at least 1 year.
62477777|NCT05625412|EXPERIMENTAL|BMS-986360|
62477778|NCT05625412|EXPERIMENTAL|BMS-986360 + Docetaxel|
61923344|NCT06086691|ACTIVE_COMPARATOR|Endurance Training|Endurance training exercises along with caffeine supplementation
61923345|NCT00218127|EXPERIMENTAL|1|LAAM WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day for 20 weeks
61923346|NCT00218127|EXPERIMENTAL|2|LAAM MaxEffect to 48 mg Adjust to effect (+/-)
62313158|NCT05866822|ACTIVE_COMPARATOR|APA (adapted physical activity)|24 APA sessions will take place, there will be 2 sessions a week for 12 weeks which will include global exercises for the upper and lower limb. One session will be 1 hour long and supervised by professionals. It will be divided in 4 cycles which will be differentiated by the intensity of its components: aerobic, strength, speed, balance, coordination and flexibility. The intensity of the sessions will be measured by RPE and heart rate monitor,
62313159|NCT05866822|EXPERIMENTAL|APA (adapted physical activity) + physical activity education (PAE)|"24 APA sessions will take place, there will be 2 sessions a week for 12 weeks which will include global exercises for the upper and lower limb. One session will be 1 hour long and supervised by professionals. It will be divided in 4 cycles which will be differentiated by the intensity of its components: aerobic, strength, speed, balance, coordination and flexibility. The intensity of the sessions will be measured by RPE and heart rate monitor,~+ 8 individuals sessions of PAE (one per week, half an hour long) that will consist of advising and setting weekly goals related to improving PA level and sedentary behavior"
62313160|NCT00702312|EXPERIMENTAL|Study group|Study group that will attend low-salt educational community programme
62313161|NCT00702312|NO_INTERVENTION|Control group|Subjects in this arm will have routine medical and dietetic treatment for low-salt reduction.
62313162|NCT06658119|EXPERIMENTAL|Tecnis Synergy ZFR00 IOL|Tecnis Synergy ZFR00 IOL will be implanted in the patient's eye during cataract surgery.
62313163|NCT06658119|PLACEBO_COMPARATOR|Tecnis Symfony ZXR00 IOL|Tecnis Symfony ZXR00 IOL will be implanted in the patient's eye during cataract surgery.
62477779|NCT05625412|EXPERIMENTAL|BMS-986360 + Nivolumab|
62477780|NCT05625412|EXPERIMENTAL|BMS-986360 + Capecitabine|
62477781|NCT05194059|EXPERIMENTAL|Experimental Group|Participants will follow a personalized activity pacing program for 16 weeks with the support of a heath band and a mobile application for tablet
62683598|NCT06686277|EXPERIMENTAL|Gong's Technique Group|The subject will sat on knee-high chair with the spine in a neutral position and comfortably extends both their arms. Therapist will stand on the side opposite to the affected side. The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand. Simultaneously, the subject will quickly and powerfully perform shoulder abduction with elbow flexion and with palm facing inside and the back of the hand facing outside. During this time, the hands of the therapist kept facing the humeral head with long axis of the palm along with the long axis of the humerus. The therapist followed the subject performing shoulder abduction, at the same speed while maintaining a little distraction, and adding acceleration in the end range.
61923347|NCT00218127|EXPERIMENTAL|3|LAAM Fixed Dose up to 48 mg 48 mg
62313164|NCT05980000|EXPERIMENTAL|Arm 1: Ramucirumab and Pembrolizumab|Patients receive ramucirumab IV and pembrolizumab IV every 3 weeks. Cycles are 21 days in length. Treatment will continue until progression or unacceptable toxicity for up to 35 cycles of treatment.
62313165|NCT05980000|ACTIVE_COMPARATOR|Arm 2: Pembrolizumab monotherapy|Patients receive pembrolizumab IV every 3 weeks. Cycles are 21 days in length. Treatment will continue until progression or unacceptable toxicity for up to 35 cycles of treatment.
62313166|NCT01868087|EXPERIMENTAL|Impact Advanced Recovery®|3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
62313167|NCT01868087|PLACEBO_COMPARATOR|Boost Plus®|3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
62313168|NCT01105351|ACTIVE_COMPARATOR|folic acid plus B6 and B12|folic 400 µg plus vitamin B12 plus B6
62313169|NCT01105351|PLACEBO_COMPARATOR|Folic acid|folic acid alone
62477782|NCT05194059|NO_INTERVENTION|Control Group|Participants will follow a personalized activity pacing program for 16 weeks without any other support
62477783|NCT04725747|EXPERIMENTAL|Midazolam/Ketamine Melt|One Midazolam/Ketamine 3mg/50mg melt administered sublingually
62313170|NCT00756977|EXPERIMENTAL|1|multi-dose preparation for oral administration prior to colonoscopy
62313171|NCT00756977|ACTIVE_COMPARATOR|2|multi-dose preparation for oral administration prior to colonoscopy
62313172|NCT00984230|NO_INTERVENTION|Breastfeeding (Reference)|
62477784|NCT04725747|ACTIVE_COMPARATOR|Midazolam Melt|Midazolam 3mg melt administered sublingually
62477785|NCT04725747|ACTIVE_COMPARATOR|Ketamine Melt|Ketamine 50mg melt administered sublingually
62477786|NCT05457920|EXPERIMENTAL|Group A (continuous treatment group)|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFNα-2b 180μg once a week, the total treatment course does not exceed 96 weeks. During treatment, when any efficacy check point reaches the disappearance of HBsAg with or without the appearance of HBsAb, at least 2 treatment units of consolidation therapy are given and then the drug is discontinued. Observed for 24 weeks after treatment.
61923348|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
61923349|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
61923350|NCT00559936|EXPERIMENTAL|Topical Avastin 1.0%|Each patient will receive topical Avastin in one eye.
61923351|NCT03396393|EXPERIMENTAL|Dihydroartemisinin 40mg|Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
61923352|NCT03396393|EXPERIMENTAL|Dihydroartemisinin 80mg|Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
61923353|NCT03396393|EXPERIMENTAL|Dihydroartemisinin 120mg|Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
61923354|NCT03396393|PLACEBO_COMPARATOR|placebo|Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
61923355|NCT00630474|ACTIVE_COMPARATOR|1|nasal application of xylometazoline
61923356|NCT00630474|PLACEBO_COMPARATOR|2|nasal application of placebo
61923357|NCT03468543|EXPERIMENTAL|Cohort 1|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days
61923358|NCT03468543|EXPERIMENTAL|Cohort 2|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days
62313173|NCT00984230|ACTIVE_COMPARATOR|Basic starter formula: BSF|
62313174|NCT00984230|EXPERIMENTAL|BSF + Lactoferrin + Probiotics + OS|
62313175|NCT00984230|EXPERIMENTAL|BSF + Lactoferrin + Probiotics|
62123416|NCT04360681|EXPERIMENTAL|Lofexidine (LFX)|LFX starting dosage is two 0.2 mg LFX tablet taken orally 2 times daily (i.e., 0.8 mg/day). At study visit 2 (Day 3), the dosage is increased to 1.2mg/day (3 tablets, BID). At visit 3 (Day 5), the dose is increased to the target dose of 1.6mg/day (4 tablets, BID). Participants enter the flexible dosing period at visit 4, at which point the LFX dose can be maintained at 1.6 mg/day or decreased to 1.2 mg/day based on symptoms and the clinical judgement of the investigator. The flexible dosing period extends through to visit 6, however, doses will be adjusted during the study as needed.
62123417|NCT04360681|PLACEBO_COMPARATOR|Placebo (PLB)|A placebo drug will be employed as the comparison group to active study drug.
62123418|NCT00783133|EXPERIMENTAL|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62123419|NCT00783133|EXPERIMENTAL|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
61923359|NCT03468543|EXPERIMENTAL|Cohort 3|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days
61923360|NCT02038829|PLACEBO_COMPARATOR|Placebo|Placebo bid
61923361|NCT02038829|EXPERIMENTAL|SUN-101 3 mcg|SUN-101 3 mcg bid
61923362|NCT02038829|EXPERIMENTAL|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
62313176|NCT06559059||Veterans|Veterans aged 18 years or older newly diagnosed with lung, colorectal, prostate or breast cancer. Patient records will be observed of Veterans with a new cancer diagnosis of the lung, prostate, breast, or colon and a telehealth visit utilizing the VA National TeleOncology Service (NTO).
62313177|NCT06559059||VA health care providers and staff members|VA health care providers and staff members participating in cancer care at NTO program medical centers, including physicians, nurse practitioners, physicians' assistants and nurses.
62313178|NCT00660140|EXPERIMENTAL|Gemcitabine + Carboplatin|"Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles."
62313179|NCT00325572|ACTIVE_COMPARATOR|Oral zinc and vitamin C supplementation|Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
62477787|NCT05457920|EXPERIMENTAL|Group B (pulse therapy group)|The treatment period is 12 weeks as a treatment unit. From the first day of baseline, subcutaneous injection of Peg-IFNα-2b 180 μg, every injection for 8 weeks, stop for 4 weeks, periodically, the total treatment course does not exceed 96 weeks. During treatment, when any efficacy check point reaches the disappearance of HBsAg with or without the appearance of HBsAb, at least 2 treatment units of consolidation therapy are given and then the drug is discontinued. Observed for 24 weeks after treatment.
62477788|NCT04164589|PLACEBO_COMPARATOR|Control|The Neuro-Adaptative Regulation will be carried out in the regime of switched off power supply in vulvo-perineal and sacral area.
62477789|NCT04164589|EXPERIMENTAL|Experimental|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacarl area.
62477790|NCT05628311|EXPERIMENTAL|IBI362 4.0 mg|"①2mg, subcutaneously (SC), once a week\* 4weeks;~②4mg, SC, once a week\* 44weeks."
62477791|NCT05628311|EXPERIMENTAL|IBI362 6.0 mg|"①2mg, SC, once a week\* 4weeks;~②4mg, SC, once a week\* 4weeks；~③6mg, SC, once a week\* 40weeks."
62477792|NCT05628311|PLACEBO_COMPARATOR|placebo|"* placebo, SC, once a week\* 24weeks;~  * 2mg, SC, once a week\* 4weeks;~    * 4mg, SC, once a week\* 4weeks；~      * 6mg, SC, once a week\* 16weeks."
62477793|NCT03545022|ACTIVE_COMPARATOR|Active acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle.The needle measuring 0.25x30mm was used as an active needle. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle as well as the placebo needle were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
61923363|NCT02038829|EXPERIMENTAL|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
62123420|NCT00835770|EXPERIMENTAL|BG00012 plus placebo|In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
62123421|NCT00835770|EXPERIMENTAL|BG00012|In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
62123422|NCT02889237|NO_INTERVENTION|Standard care|Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.
62123423|NCT02889237|ACTIVE_COMPARATOR|Calcium|Immediate administration of daily calcium supplementation (1000 mg calcium)
62123424|NCT02889237|ACTIVE_COMPARATOR|Calcium and low dose vitamin D|Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).
61923364|NCT02038829|EXPERIMENTAL|SUN-101 50 mcg|SUN-101 50 mcg bid
62123425|NCT02889237|ACTIVE_COMPARATOR|Calcium and high dose vitamin D|Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)
62123426|NCT02889237|NO_INTERVENTION|Already on treatment with Calcium or vitamin D|Patients who are already treated with Calcium or Vitamin D.
62123427|NCT00561886|EXPERIMENTAL|1|Patients with COPD receiving once 24 µg formoterol
62123428|NCT02092077|EXPERIMENTAL|TV-1106 0.554 mg|
62123429|NCT02092077|EXPERIMENTAL|TV-1106 0.924 mg/kg|
62313180|NCT00325572|PLACEBO_COMPARATOR|Oral Placebo|Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.
62313181|NCT06080347|ACTIVE_COMPARATOR|Arm_1|Anti-inflammatory Diet
62313182|NCT06080347|EXPERIMENTAL|Arm_2|Healthy Diet
61923365|NCT02038829|ACTIVE_COMPARATOR|Aclidinium 400 mcg|Aclidinium 400 mcg bid
62123430|NCT02092077|EXPERIMENTAL|TV-1106 1.20 mg/kg|
62313183|NCT00001246||1|Our studies include data from typically developing youth, and individuals with a range of psychiatric presentations from behaviorally-defined (e.g. Childhood-Onset Schizophrenia, Autism Spectrum Disorder) as well as genetically-defined (e.g. Sex Chromosome Aneuploidy) groups. Participants span a wide age range (from 3 years of age upwards).
62313184|NCT03670862||stroke|Ischemic stroke patients with sympton onset in 24 hours
62313185|NCT00117338|PLACEBO_COMPARATOR|1|Placebo
62313186|NCT00117338|ACTIVE_COMPARATOR|2|montelukast sodium
62313187|NCT06633302|EXPERIMENTAL|Exposure to indoor temperature limits daylong|Participants exposed to three consecutive days (3 days, 2 nights) in an indoor environment maintained at either 26°C at all times (condition A, recommended upper indoor temperature limits during an extreme heat event).
62313188|NCT06633302|EXPERIMENTAL|Exposure to indoor temperature limits nighttime only|Participants exposed to three consecutive days (3 days, 2 nights) to indoor overheating during the daytime (34°C, temperatures experienced in homes without air-conditioning) (9:00 to 19:00) with nighttime (19:00 to 9:00) indoor temperatures reduced to the recommended limit of 26°C.
62313189|NCT06512480||PATIENTS UNDERGOING HUGO RAS COLORECTAL RESECTION|Patients will undergo colonic or colorectal resection with the Hugo RAS robotic platform.
62313190|NCT05554900|NO_INTERVENTION|The control group|The control group received traditional amputation.The proximal nerve is blocked with lidocaine and cut off. The end of the nerve retracted as far as possible and the bleeding point is ligated if necessary.
62313191|NCT05554900|EXPERIMENTAL|The experimental group（RPNIs group）|The experimental group received regenerative peripheral nerve interface（RPNI） surgery.
62313192|NCT04277702|EXPERIMENTAL|Montelukast + standard treatment|
61923366|NCT02528266|EXPERIMENTAL|Nerve Capping Device|Implant with the experimental device
61923367|NCT03136731||Healthy family members of celiac disease|Celiac disease screening, no intervention.
62313193|NCT04277702|PLACEBO_COMPARATOR|Placebo+ standard treatment|
62313194|NCT00447954|EXPERIMENTAL|1 high dose NT-501 implant|
62313195|NCT00447954|EXPERIMENTAL|2 low dose NT-501 implant|
62313196|NCT00447954|SHAM_COMPARATOR|3 sham procedure|No implant
62313197|NCT02948595|EXPERIMENTAL|Video feedback then verbal feedback|Video feedback followed by structured verbal feedback
62477794|NCT03545022|PLACEBO_COMPARATOR|Placebo acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle. In the placebo needle, the needles were cut in 5mm, to measure 0.25x25mm. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle, as well as the placebo needle, were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
62477795|NCT02828033|EXPERIMENTAL|Rilonacept|A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
62477796|NCT03069183|ACTIVE_COMPARATOR|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
62123431|NCT02092077|ACTIVE_COMPARATOR|somatropin 0.033 mg/kg/day|Dosages may be adjusted according to findings and as necessary
62123432|NCT03146065|EXPERIMENTAL|PF-06730512|Study Drug being used in the study
62123433|NCT03146065|PLACEBO_COMPARATOR|Placebo|Placebo for IV/SC administration
62313198|NCT02948595|EXPERIMENTAL|Verbal feedback then video feedback|Structured verbal feedback followed by video feedback
62313199|NCT06672523|EXPERIMENTAL|[14C]-BMS-986504 followed by BMS-986504 Monotherapy|"Part A: Participants will receive a single oral dose of radiolabeled \[14C\]-BMS-986504 on C1D1.~Part B: Participants will receive non-radiolabeled BMS-986504, starting from C1D1 and until criteria for treatment discontinuation are met."
62313200|NCT06290505|EXPERIMENTAL|Treatment|Participants will receive 2 weeks of therapy with concurrent hypofractionated radiotherapy (30Gy/10#), weekly carboplatin (AUC2), weekly paclitaxel (50mg/m2) and durvalumab (1500mg) intravenously every 4 weeks, followed by durvalumab monotherapy continuing at 1500mg intravenously every 4 weeks until disease progression or 24 months of therapy. One to five metastases will be treated with stereotactic radiotherapy (24Gy/3#) 4 weeks after the completion of the chemoradiotherapy to the primary tumour. Monitoring of adherence to treatment will be done by attendance at booked appointments
62313201|NCT03845998|EXPERIMENTAL|three-finger method|"The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers. That is what we call the three-finger method.~The intervention is to use the three-finger method."
61923368|NCT03136731||Celiac disease index cases|Assessment of disease related factors, no intervention.
61923369|NCT01566760|EXPERIMENTAL|Treatment A, Cohort 1|
61923370|NCT01566760|EXPERIMENTAL|Treatment B, Cohort 2|
61923371|NCT01566760|EXPERIMENTAL|Treatment C, Cohort 1|
62123434|NCT04603417|OTHER|Patients|Patients with CRPS diagnosis
62123435|NCT04603417|OTHER|Controls|Healthy controls with known Neurological Disorders
62123436|NCT05910918|EXPERIMENTAL|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
62123437|NCT05910918|ACTIVE_COMPARATOR|comparison group|for the comparison group receive the general intensive care rules manual for routine care.
62313202|NCT03845998|ACTIVE_COMPARATOR|weight-related method|"The size of the laryngeal mask airway for each patient was determined by the manufacturer's weight-related guidelines. That is what we call the weight-related method.~The intervention is to use the weight-related method."
62313203|NCT02438072|OTHER|Overall population|
62313204|NCT02914743|EXPERIMENTAL|Dental Cleaning and MI Arm|Subjects in this arm will receive a dental cleaning by the hygienist as well as a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
62313205|NCT02914743|EXPERIMENTAL|MI only Arm|Subjects in this arm will not receive a dental cleaning but the hygienist will provide a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
62313206|NCT02914743|NO_INTERVENTION|Control Arm|Subjects in this arm of the study will not receive any oral health intervention while hospitalized. A medical record review will be completed, and patients will be contacted via telephone at 3, 6, and 12 months post-hospitalization to assess their oral health-related quality of life and oral health care-seeking behaviors.
62477797|NCT03069183|PLACEBO_COMPARATOR|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
62477798|NCT05315063|EXPERIMENTAL|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
62477799|NCT05315063|EXPERIMENTAL|Muscle Energy Technique (PIR)|muscle energy technique
62683599|NCT06686277|EXPERIMENTAL|Mulligan Mobilization|For shoulder abduction, therapist applied a posterolateral gliding force over the head of the humerus, while patient actively abducted his arm. For shoulder flexion, the therapist applied a posterolateral glide as patient flexed his shoulder. For shoulder internal rotation, therapist applied an inferior shoulder glide and stabilized the scapula as the patient internally rotated his shoulder, and adducted his upper arm. As the therapist pushed the shoulder into adduction in this way, the head of the humerus was distracted laterally. Therapist hand in the axilla acted as a fulcrum.For shoulder external rotation,therapist applied posterolateral glide in sitting position
62683600|NCT04832854|EXPERIMENTAL|Cohort A (PD-L1 High)|"Participants with high programmed death-ligand 1 (PD-L1) expression level will be enrolled in Cohort A and receive neoadjuvant atezolizumab plus tiragolumab for 4 cycles, followed by surgical resection and either adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles at the discretion of the investigator.~Chemotherapy may include:~* cisplatin/carboplatin + pemetrexed (for non-squamous only)~* carboplatin + gemcitabine (for squamous only)~* carboplatin + paclitaxel"
62123438|NCT05876013||BPTB group|Bone-patellar tendon- bone graft used for ACL reconstruction.
61923372|NCT01566760|EXPERIMENTAL|Treatment D, Cohort 2|
62123439|NCT05876013||Hamstring group|Double-looped semitendinosus and gracilis graft used for ACL reconstruction
62123440|NCT03427255|ACTIVE_COMPARATOR|CBT group treatment|CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
62123441|NCT03427255|OTHER|Waiting list|Six months waiting-list control condition.
62123442|NCT04075318|EXPERIMENTAL|UB-312 40 mcg|UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13
62123443|NCT04075318|EXPERIMENTAL|UB-312 100 mcg|UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13
62123444|NCT04075318|EXPERIMENTAL|UB-312 40/300 mcg|UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection
62123445|NCT04075318|EXPERIMENTAL|UB-312 300 mcg|UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13
62123446|NCT04075318|EXPERIMENTAL|UB-312 40/1000 mcg|UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection
62123447|NCT04075318|EXPERIMENTAL|UB-312 1000 mcg|UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13
62123448|NCT04075318|EXPERIMENTAL|UB-312 2000 mcg|UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13
62123449|NCT04075318|PLACEBO_COMPARATOR|Placebo|Placebo by intramuscular injection at Weeks 1, 5 and 13
62123450|NCT04075318|EXPERIMENTAL|UB-312 300/100 mcg|UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection
62123451|NCT04801498||Healthy controls|Men and women ages 18-65 years old with no major medical problems and no history of chronic pain or opioid use.
62123452|NCT04801498||Chronic pain patients not taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) that have not used any opioid medication within the past one year.
62123453|NCT04801498||Chronic pain patients taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) using chronic daily opioid use for longer than 3 months duration and taking stable doses of opioid medications for at least 30 days prior to study visit.
62123454|NCT01752166||Blood culture|Subjects have had a blood culture ordered, per routine standard of care
62123455|NCT05936411|OTHER|Healthy Subjects|
62123456|NCT05717751||experimental group|locally advanced cervical cancer treated with surgical staging
62123457|NCT06176924|EXPERIMENTAL|Active tDCS and Relaxation technique|Subjects within an experimental group had received 9 sessions of tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
62123458|NCT06176924|OTHER|Relaxation technique|Subjects in the control group are going to receive 9 sessions of relaxation technique
62123459|NCT02950948|EXPERIMENTAL|Progesterone|25 mg of progesterone will be administered daily by subcutaneous injection.
62123460|NCT02950948|PLACEBO_COMPARATOR|Placebo|25 mg of progesterone will be administered daily by subcutaneous injection.
62123461|NCT05801068|EXPERIMENTAL|Periprocedural management of FXa-inhibitor group|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to predefined protocol.
62123462|NCT05744193|ACTIVE_COMPARATOR|Commercial Liquid Human Milk Fortifier|Liquid human milk fortifier to be added to human milk
62123463|NCT05744193|EXPERIMENTAL|Liquid Human Milk Fortifier - Standard Protein|Liquid human milk fortifier to be added to human milk
62123464|NCT05744193|EXPERIMENTAL|Liquid Human Milk Fortifier - High Protein|Liquid human milk fortifier to be added to human milk
62123465|NCT00362778|SHAM_COMPARATOR|Serum saline|
62123466|NCT06677164|EXPERIMENTAL|Group (A)|patients will receive High intensity laser therapy combined with Gluteus Maximus strengthening exercise
62477800|NCT05105633|EXPERIMENTAL|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
62313207|NCT02908802|ACTIVE_COMPARATOR|Probiotic|Probiotic capsules: two capsules twice a day
62313208|NCT02908802|PLACEBO_COMPARATOR|Placebo|Probiotic capsules without the active ingredient: two capsules twice a day
62313209|NCT06431542|ACTIVE_COMPARATOR|patient-applied medication group|The doctor provided detailed instructions for the patient to self-apply Triamcinolone Acetonide Econazole Cream to the external auditory canal once daily for two weeks.
62313210|NCT06431542|EXPERIMENTAL|physician-applied medication group|The doctor applied Triamcinolone Acetonide Econazole Cream for patients once every 2 to 3 days, for a total of three applications.
62313211|NCT05552599|EXPERIMENTAL|woolen blanket|Preoperative pressure sore risk was assessed with the Braden Risk Assessment Scale. The patient's room temperature was recorded on the day of surgery before the patient was admitted for the operation. Body temperature was measured before the patient wore surgical gown. Before leaving the room, patient's body was covered with a woolen blanket. The temperature of the operating room was recorded. Body temperature was stabilized under normothermic conditions with a woolen blanket until the operation began. Body temperature was measured before anesthesia was given. Body temperature was measured in the 1st, 2nd and 3rd hour after anesthesia was given. The patient was evaluated with the Braden Risk Assessment Scale on the first, second and third postoperative days.
62313212|NCT05552599|NO_INTERVENTION|standard of care|Preoperative pressure sore risk was assessed with the Braden Risk Assessment Scale. The patient's room temperature was recorded on the day of surgery before the patient was taken to the operation. Body temperature was measured before the patient wore surgical clothes. The temperature of the operating room was recorded. Body temperature was measured before anesthesia was givenBody temperature was measured at the 1st, 2nd and 3rd hour after anesthesia was given. The patient was evaluated with the Braden Risk Assessment Scale on the first, second and third postoperative days.
62313213|NCT00128206|ACTIVE_COMPARATOR|B|isoniazid (INH) (900 mg orally) given twice weekly for 9 months
62313214|NCT00128206|ACTIVE_COMPARATOR|A|rifampin (600 mg orally) given daily for 4 months
62313215|NCT01205243||ZIAGEN®|Patients administrated ZIAGEN® at the site
62313216|NCT05431465|EXPERIMENTAL|Vita Ambria onlay|The onlays will be constructed from Zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic system.
62313217|NCT05431465|ACTIVE_COMPARATOR|IPS emax onlay|The onlays will be constructed from Lithium disilicate (IPS e-max press) glass ceramic system
62313218|NCT06319898|EXPERIMENTAL|Lavender aromatherapy sticker|Lavender aromatherapy sticker on patient Calming music from Sirius station 68 (Spa) playing via overhead speakers Overhead lights off, two lanterns lit to provide dim lighting Avoid stirrup use
62477801|NCT05105633|ACTIVE_COMPARATOR|Standard Care (which may include intravenous Alteplase)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour).
62477802|NCT00316277|EXPERIMENTAL|Buprenorphine/Nx with EMM|
62313219|NCT06319898|NO_INTERVENTION|Control - no Intervention|Non-aromatic (placebo) sticker on patient No music playing Overhead lights on Stirrups used
62313220|NCT05196698|EXPERIMENTAL|High Flow Oxygen Therapy|
62683601|NCT04832854|EXPERIMENTAL|Cohort B (PD-L1 All Comers)|"All comers, which are participants with any PD-L1 expression level, will be enrolled in Cohort B and receive neoadjuvant atezolizumab plus tiragolumab plus chemotherapy for 4 cycles, followed by surgical resection and adjuvant atezolizumab plus tiragolumab for 16 cycles.~Chemotherapy may include:~* cisplatin/carboplatin + pemetrexed (for non-squamous only)~* carboplatin + gemcitabine (for squamous only)~* carboplatin + paclitaxel"
62313221|NCT05196698|OTHER|Long-Term Oxygen Therapy|Control arm
62313222|NCT00148590|ACTIVE_COMPARATOR|Memantine plus Risperidone|6 weeks 20 mg Memantine as add-on treatment to Risperidone
62313223|NCT00148590|PLACEBO_COMPARATOR|Placebo plus Risperidone|6 weeks 20 mg Placebo as add-on treatment to Risperidone
62313224|NCT00728416|EXPERIMENTAL|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
62313225|NCT00728416|PLACEBO_COMPARATOR|Arm 2|Matching placebo nasal spray
62313226|NCT03826953|OTHER|Nurse led allergy clinic|nurse led allergy clinic
62313227|NCT03515980|EXPERIMENTAL|Mild hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh A score 5 to 6 points
62313228|NCT03515980|EXPERIMENTAL|Moderate hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh B score 7 to 9 points
62313229|NCT03515980|EXPERIMENTAL|Severe hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh C score 10 to 15 points
62313230|NCT03515980|EXPERIMENTAL|Normal hepatic function|Based on Hepatic Function Impairment as defined by the investigator
62477803|NCT00316277|ACTIVE_COMPARATOR|Buprenorphine/Nx with SMM|
62477804|NCT06266533|ACTIVE_COMPARATOR|Conventional Nutrition Education|Conventional nutrition education
62477805|NCT06266533|EXPERIMENTAL|Arts-based Nutrition Education|Arts-based nutrition education video production
62313231|NCT05457530|ACTIVE_COMPARATOR|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Participants to receive DOR/3TC/TDF tablet once daily for 48 weeks
62313232|NCT05457530|ACTIVE_COMPARATOR|Doravirine + Emtricitibine/Tenofovir alafenamide Fumerate|Participants to receive DOR + FTC/TAF tablets once daily for 48 weeks
62313233|NCT05457530|ACTIVE_COMPARATOR|Bictegravir/Emtricitibine/Tenofovir alafenamide|Participants to receive BIC/FTC/TAF tablet once daily for 48 weeks
62313234|NCT00758862|EXPERIMENTAL|1|
62313235|NCT03905434||Control|A total of 15 healthy controls will be enrolled and miRNA samples will be collected
62313236|NCT03905434||Stroke|A total of 30 acute stroke patients with large vessel occlusions will be enrolled.
62313237|NCT01852344|OTHER|Placebo Easy|Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
62313238|NCT01852344|OTHER|Placebo Hard|Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
62313239|NCT01852344|OTHER|Methylphenidate Easy|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
62313240|NCT01852344|OTHER|Methylphenidate Hard|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
62313241|NCT01677611|EXPERIMENTAL|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial.Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of either resveratrol.The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia. Subjects were instructed to abstain from foods with high resveratrol content during the entire duration of the trial.
62313242|NCT01677611|PLACEBO_COMPARATOR|Placebo|All subjects underwent a 2-week run-in period during which placebo was administered. The placebo was manufactured so that it was not distinguishable by color, form, or taste from the active drug. Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of matching placebo and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
62313243|NCT05536648|EXPERIMENTAL|Group 1 Single head toothbrush|Cerebral palsy children were given single head tooth brush along with fluoridated toothpaste for brushing.
62477806|NCT06544941|EXPERIMENTAL|Smart Bassinet (SB)|"The SB responds to an infant who is fussing or crying by initiating swaying movement and shushing sounds with white noise that incrementally increase until the infant calms or the caregiver shuts it off. It will help babies transition into life outside of the womb with ease, enabling them to feel safe and secure, which translates to more sleep."
62477807|NCT06544941|ACTIVE_COMPARATOR|HALO Bassinet (TAU)|The HALO is a commercially available bassinet that does not have any robotic/responsive actions incorporated within it.
62477808|NCT02132663|EXPERIMENTAL|Infant formula containing an alternate source of DHA|
62683602|NCT06694116|EXPERIMENTAL|Single arm study using carbon dye as a sentinel lymph node agent in early vulvar cancer|Single arm study using carbon dye as a sentinel lymph node agent in early vulvar cancer. Sterile charcoal carbon dye will be injected around vulvar tumor which will be searched in IFLND. No other arms.
62683603|NCT05262673|EXPERIMENTAL|CART/CTL/DCvac cells to treat B-ALL|
62683604|NCT03165695|EXPERIMENTAL|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
62683605|NCT03165695|PLACEBO_COMPARATOR|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
62313244|NCT05536648|EXPERIMENTAL|Group 2 Triple head toothbrush|Cerebral palsy children were given triple head tooth brush along with fluoridated toothpaste for brushing.
62683606|NCT03539640|ACTIVE_COMPARATOR|PEEP level of 5 cmH2O|During second part of the study (MRI) Diaphragm position
62683607|NCT03539640|ACTIVE_COMPARATOR|PEEP level of 10 cmH2O|During second part of the study (MRI) Diaphragm position
62683608|NCT03539640|ACTIVE_COMPARATOR|PEEP level of 15 cmH2O|During second part of the study (MRI) Diaphragm position
62683609|NCT04619888||HeartLogic cohort|Patients implanted with a defibrillator enabling HeartLogic
62683610|NCT06691256|EXPERIMENTAL|Usability Study|This study, in collaboration with Rush Alzheimer's Disease Center, plans to recruit up to 20 participants aged 65 or older, along with their caregivers, to assess the usability and human factors of the HiDO-ALZ platform.
61923373|NCT01566760|ACTIVE_COMPARATOR|Treatment E, Cohort 1 and/or Cohort 2|
62123467|NCT06677164|ACTIVE_COMPARATOR|Group (B)|patients will receive High intensity laser therapy.
62123468|NCT02400099|ACTIVE_COMPARATOR|High-protein low calorie diet (HPLC)|900 Kcal; Protein 90 g (39%); CHO 75 g (30%); Lipid 32 g (31%)
62683611|NCT06691256|EXPERIMENTAL|Field Efficacy Study - Experimental Group|Participants in the experimental group will receive the HiDO-ALZ platform for 12 months, which provides automated medication dispensing, real-time facial recognition to ensure correct medication delivery, and biometric monitoring for blood pressure and weight. This arms plan to recruit up to 25 participants aged 65 or older, along with their caregivers, to assess the usability and human factors of the HiDO-ALZ platform.
62313245|NCT05188235|EXPERIMENTAL|Infants with developmental dysplasia of the hip|Infant participants putting on a device for 15 minutes to take different measurements of the hip
62313246|NCT05188235|ACTIVE_COMPARATOR|Infants without developmental dysplasia of the hip|Infant participants putting on a device for 15 minutes to take different measurements of the hip
62313247|NCT01145391|NO_INTERVENTION|Control|Patients receive usual care.
62313248|NCT01145391|ACTIVE_COMPARATOR|Intervention|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
62313249|NCT04320303|EXPERIMENTAL|adaptive NK cells infusion post transplantation|Adaptive donors expanded NK cells infusion at day 20±3d and 27±3d post transplantation
61923374|NCT04243421|EXPERIMENTAL|Group with implants|"Flap will be elevated following the crestal and releasing incisions (if necessary).~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below."
62123469|NCT02400099|PLACEBO_COMPARATOR|Control low calorie diet (CLC)|900 Kcal; Protein. 50 g (22%); CHO 119 g (48%); Lipid 31 g (30%)
62123470|NCT01438086|ACTIVE_COMPARATOR|mecasermin low dose|
62123471|NCT01438086|ACTIVE_COMPARATOR|mecasermin high dose|
62123472|NCT01438086|PLACEBO_COMPARATOR|saline placebo|
62313250|NCT06166576|EXPERIMENTAL|Radioembolization|Hepatocellular carcinoma with localized portal vein tumor thrombosis (Vp1-Vp3) will be treated by ablative radioembolization using TheraSphere (Boston Scientific) glass microspheres
62313251|NCT01330446|EXPERIMENTAL|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
62313252|NCT01330446|PLACEBO_COMPARATOR|Placebo|1 Placebo by mouth every morning for a 28 day cycle.
62477809|NCT02132663|ACTIVE_COMPARATOR|Marketed routine infant formula|
62313253|NCT01244802||Group 1: 18 to 45 years of age|Between the ages of 18 and 45 at the time of yellow fever vaccination
62683612|NCT06691256|NO_INTERVENTION|Field Efficacy Study - Control Group|Participants in the control group will receive standard care without the HiDO-ALZ device. They will continue with their usual medication routines and any standard biometric monitoring methods as directed by their healthcare providers. This arms plan to recruit up to 25 participants aged 65 or older, along with their caregivers, to assess the standard of care and not using the HiDO-ALZ device.
61923375|NCT01816841|EXPERIMENTAL|Diagnostic (COE and DVFE)- Arm I|Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
61923376|NCT01816841|EXPERIMENTAL|Arm II - Comparison of surgical margins using COE vs. DVFE|Comparison of surgical margins using COE vs. DVFE
62313254|NCT01244802||Group 2: 55 years of age and above|Aged 55 or greater at the time of yellow fever vaccination
61923377|NCT01546064|ACTIVE_COMPARATOR|Bile duct anastomosis with T-tube|
61923378|NCT01546064|ACTIVE_COMPARATOR|Bile duct anastomosis without T-tube|
62313255|NCT00985452|OTHER|Group 2: Intervention|Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
62313256|NCT00985452|OTHER|Group 3: Intervention/financial incentive|Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
62313257|NCT00985452|OTHER|Group 1: Control|Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
62313258|NCT04548947|EXPERIMENTAL|Cold snare polypectomy with a submucosal injection|The procedure will include a cold snare polypectomy with a submucosal injection done prior to the resection.
62313259|NCT05887856|ACTIVE_COMPARATOR|Intervention Group|Volunteers in the Intervention group will receive specially designed educational program which will be aimed at reduction of pre-operative anxiety in breast cancer patients undergoing surgery as a part of their treatment.
62313260|NCT05887856|NO_INTERVENTION|Non-Intervention Group|"Non-Intervention group will get the usual standard information as per existing protocols which includes~1. Explanation of surgical procedure by primary team.~2. Information about anesthesia on pre-operative anesthesia assessment.~3. Phone call from Primary team explaining surgery details one day prior to surgery in case of day case surgery.~4. Information about surgery on admission from floor resident in case of Pre-Op Admission.~Afore mentioned practices are standard at SKMCH and RC and will remain same for both intervention and non-intervention group."
62313261|NCT04522752||Gastric Polyp|The included subjects were patients with benign epithelial gastric polyps confirmed by gastroscopy and biopsy pathology. The size and pathology type of polyps were identified. Gastroscopy and biopsy were followed up six, twelve and eighteen months later to observe the relationship between the size, pathology types of polyps and the development of gastric polyps. Other factors including the relationship between helicobacter pylori infection and polyp type were also observed.
62477810|NCT00990535|EXPERIMENTAL|Octreotide-LAR|Patients will receive every 21 days an injection of octreotide-LAR 30 mg until progression is documented.
62313262|NCT01248806||Smokers or former smokers, Aged ≥ 50|Men and women current daily smokers or former smokers, Aged ≥ 50
62313263|NCT02831868|EXPERIMENTAL|EXP|Implantation of a HAVAI device to correct HVA without osteotomy
62313264|NCT01899144|EXPERIMENTAL|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
62313265|NCT01899144|EXPERIMENTAL|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
62313266|NCT01899144|ACTIVE_COMPARATOR|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
62313267|NCT01899144|ACTIVE_COMPARATOR|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
62313268|NCT01899144|PLACEBO_COMPARATOR|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
62313269|NCT06513715|PLACEBO_COMPARATOR|CONTROL|The participants allocated in this arm will follow a treatment with placebo
62477811|NCT01112254|EXPERIMENTAL|MRI±biopsy|a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI ± biopsy results.
62477812|NCT01112254|NO_INTERVENTION|Standard care|The patients will be operated without additional exams
62477813|NCT01960920|ACTIVE_COMPARATOR|Healthy Volunteers|Dilute diesel exhaust Filtered diesel exhaust Filtered air
62123473|NCT03195426|EXPERIMENTAL|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
62313270|NCT06513715|EXPERIMENTAL|Intervention 1|The participants in this arm will receive a 150 mg dose of jubenine
62313271|NCT06513715|EXPERIMENTAL|Intervention 2|The participants in this arm will receive a 300 mg dose of jubenine
62313272|NCT06513715|EXPERIMENTAL|Intervention 3|The participants in this arm will receive a 300 mg dose of prickly pear extract
62313273|NCT04983901|EXPERIMENTAL|Group I (imipenem, cilastatin, relebactam)|Patients receive imipenem/cilastatin/relebactam IV over 30-60 minutes q6h for 2 days for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h. Patients may continue to receive imipenem/cilastatin/relebactam IVover 30-60 minutes for up to 14 days if clinically indicated by the assessment of the treating physician.
62313274|NCT04983901|ACTIVE_COMPARATOR|Group II (cefepime, meropenem, piperacillin/tazobactam)|Patients receive cefepime IV q8h for a minimum of 6 doses, meropenem IV q8h for a minimum of 6 doses, or piperacillin/tazobactam IV q6h for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h.
62477814|NCT01960920|EXPERIMENTAL|Heart Failure patients|Dilute diesel exhaust Filtered diesel exhaust Filtered air
62477815|NCT02504333|ACTIVE_COMPARATOR|AG|nab-Paclitaxel followed by Gemcitabine
62477816|NCT02504333|EXPERIMENTAL|AG-mFOLFOX|nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial
62477817|NCT00545792|EXPERIMENTAL|Avastin|Avastin
62477818|NCT04737707|EXPERIMENTAL|Dialectical Behavior Therapy (DBT)|Psychotherapy (duration 5 months) will begin within a maximum of 1 month (the time to set up the group) and will be accompanied by individual follow-up. Evaluations will be carried out within 6 months of the end of the psychotherapy in order to measure its effects.
62683613|NCT03939494|EXPERIMENTAL|Telehealth Intervention|This arm receives 26 hours of telehealth encounters with a registered dietitian in conjunction with their normal clinic/program care.
62683614|NCT03939494|NO_INTERVENTION|Standard of Care Control|This arm will participate in their normal clinic/program routine.
62683615|NCT00069953|EXPERIMENTAL|ChemoRT and selective surgery|Induction therapy of fluorouracil, cisplatin, paclitaxel, and pegfilgrastim OR filgrastim, then chemoradiotherapy of concurrent cisplatin and fluorouracil with external beam radiotherapy (RT), followed by selective salvage therapy.
62683616|NCT02767973|EXPERIMENTAL|Woodsmoke Exposure|
62683617|NCT06695026|EXPERIMENTAL|Cohort 1|"o Interventions:~Drug: RZ-001 Dose 1"
62683618|NCT06695026|EXPERIMENTAL|Cohort 2|o Interventions: Drug: RZ-001 Dose 2
62683619|NCT06695026|EXPERIMENTAL|Cohort 3|o Interventions: Drug: RZ-001 Dose 3
62683620|NCT02438397|ACTIVE_COMPARATOR|metformin+premix insulin|metformin:500mg tid
62313275|NCT02227381||Microarray / NGS test|
62683621|NCT02438397|EXPERIMENTAL|acarbose+premix insulin|acarbose:100mg tid
62683622|NCT06253676|ACTIVE_COMPARATOR|Standard Delivery of Problem Management Plus (PM+)|"For an eligible, consenting mother participant randomized to the comparator arm, our team will not provide her with active passive sensing technology. As such, no passive sensing data regarding maternal activity and health will be transmitted to or made available to trained, non-specialist providers (i.e., 'PM+ helpers').~Following enrollment, the mother participant will undergo the five intervention sessions with an assigned PM+ helper in an in-person capacity. In particular, the helper will only deliver the intervention as originally manualized; in other words, s/he will not integrate key findings/interpretations of the aforementioned passive sensing data into delivery."
62313276|NCT00564629|EXPERIMENTAL|IV acetaminophen plus oral placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.
62477819|NCT04737707|OTHER|Therapy|waiting list for 5 months before starting psychotherapy (duration 5 months). During this time, the patient can continue your usual therapeutic follow-ups. Likewise, assessments will be carried out within 6 months after the end of the psychotherapy in order to measure its effects. the patient will thus benefit from DBT regardless of the group.
62477820|NCT00617396|EXPERIMENTAL|Quetiapine treatment group|All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
62477821|NCT04196335|EXPERIMENTAL|single-arm|
62477822|NCT01890057|EXPERIMENTAL|Young adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
62683623|NCT06253676|EXPERIMENTAL|StandStrong Platform-Informed Delivery of Problem Management Plus (PM+)|"For an eligible, consenting mother participant randomized to the experimental arm, our team will provide her a smart phone (with EBM application) and her infant with a GPS beacon. Collectively, these passive sensors will non-invasively collect data regarding maternal activity and health (e.g., heart rate, step count, proximity to infant, etc.) from her and the infant. Upon acquisition of said data, we will transmit it to a data analysis engine based in a machine-learning approach and then visualize it within an application (i.e., 'dashboard') available to trained, non-specialist providers (i.e., 'PM+ helpers').~Following enrollment, the mother participant will undergo the five intervention sessions with an assigned PM+ helper in an in-person capacity. In particular, the helper will integrate key findings/interpretations of the aforementioned passive sensing data into delivery of a given session with respect to an adapted fidelity checklist."
62683624|NCT06687356|ACTIVE_COMPARATOR|Traditional surgery|Without using the intraoperative optical coherence tomography technique during surgery.
62683625|NCT06687356|EXPERIMENTAL|Surgery with intraoperative optical coherence tomography technique|Applying the intraoperative optical coherence tomography technique during surgery.
62683626|NCT03239054|EXPERIMENTAL|Study Group|Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.
62683627|NCT03239054|OTHER|Control Group|"The control group will be provided with the ACOG Pamphlet entitled Exercise during pregnancy and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled."
62123474|NCT06154239|OTHER|Arm A: Self-swab then DDT|Participants will take the self-swab sample, followed by the DDT sample at home. They will then have the clinician swab taken in the clinic.
62123475|NCT06154239|OTHER|Arm B: DDT then self-swab|Participants will take the DDT sample, followed by the self-swab sample at home. They will then have the clinician swab taken in the clinic.
62313277|NCT00564629|ACTIVE_COMPARATOR|Oral acetaminophen plus IV placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.
62313278|NCT05956574|EXPERIMENTAL|Nutrigenomix|Participants in this group will be asked to complete an oral swab at baseline. This swab will indicate their dietary needs based on their genetic composition. These personalized dietary needs will be shared with the participant; the participant will be encouraged to follow their dietary plan for the duration of the study. Participants in this group will also gradually increase their physical activity up to 300 min/week at 6 months.
62477823|NCT01890057|EXPERIMENTAL|Elderly adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
62683628|NCT02674256|ACTIVE_COMPARATOR|CRH injection|Intervention: intravenous injection of CRH 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together then the solution will be injected IV over the course of 1 minute
62123476|NCT06611839|EXPERIMENTAL|Venetoclax and Ivosidenib combined intensive chemotherapy|The study was divided into two phases: dose climbing (phase I)and dose extension (phase II).
62477824|NCT05351957|EXPERIMENTAL|dry needling|This study has only 1 arm and the control group is their baseline data
61923379|NCT03901118|EXPERIMENTAL|chiauranib plus etoposide|Patients receive the combined treatment of chiauranib plus etoposide, 28 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Etoposide is given orally, 50mg once daily for 21 days, 7 days off, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
62123477|NCT02678572|EXPERIMENTAL|Melphalan/HDS|3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.
62123478|NCT02536430|ACTIVE_COMPARATOR|Buccal infiltration of Ketorolac|A buccal infiltration of 30 mg/mL of Ketorolac Tromethamine was applied for the patients in case group.
62123479|NCT02536430|PLACEBO_COMPARATOR|buccal infiltration of Normal Saline|A buccal infiltration of Normal Saline was applied for the patients in control group.
62313279|NCT05956574|ACTIVE_COMPARATOR|Control|Participants in this group will receive a standard care dietary plan. They will also be asked to gradually increase their activity up to 300 min/week by 6 months.
62683629|NCT02674256|PLACEBO_COMPARATOR|placebo injection|"Intervention: intravenous saline injection~1mL of saline will be injected intravenously over the course of 1 minute"
62683630|NCT04619849|EXPERIMENTAL|palmaris longus and carpal tunnel|EMG measurements of median and ulnar nerves will be made in patients with palmaris longus muscle.
62683631|NCT03242070|EXPERIMENTAL|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
62683632|NCT03242070|NO_INTERVENTION|Control Group|No specific intervention will be provided to the control group participants
61923380|NCT03901118|EXPERIMENTAL|chiauranib plus paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
62123480|NCT03876210|OTHER|Sequence A|"Period 1: PK101-001, PK101-002 / Period 2: PK101~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
62123481|NCT03876210|OTHER|Sequence B|"Period 1: PK101 / Period 2: PK101-001, P101-002~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
62123482|NCT01314352|EXPERIMENTAL|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
62123483|NCT01314352|ACTIVE_COMPARATOR|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
62313280|NCT05385614|NO_INTERVENTION|Control|Control group that will receive the app after primary endpoint was assessed.
62683633|NCT04693715|EXPERIMENTAL|RNS60 0.5 mL/kg/h|RNS60 0.5 mL/kg/h infusion for 48h (up to a maximum of 60 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
62683634|NCT04693715|EXPERIMENTAL|RNS60 1 mL/kg/h|RNS60 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
62683635|NCT04693715|PLACEBO_COMPARATOR|Placebo 1 mL/kg/h|Placebo (normal saline) 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
62683636|NCT02855385||Patient group|This are patients who have current or previous history of rectal bleeding
62683637|NCT02855385||General Practitioner group|This are General practitioner who are in public or private hospitals who treat patients with rectal bleeding
62683638|NCT03391791||Genetically engineered T Cell Receptor- treated|Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial
62313281|NCT05385614|EXPERIMENTAL|Intervention|Experimental group that will receive the app at the start of their participation
62683639|NCT04386239|EXPERIMENTAL|Covid-19|Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and \<4 will be requested consent to the study.
61923381|NCT01542671|EXPERIMENTAL|Intervention|Lifestyle counseling at baseline, six, twelve months; Food and exercise log recording and feedback, motivational phone calls monthly for 12 months, 4 tailored mailings on lifestyle change, and weekly mailings on weight loss, exercise, and healthy eating for first 12 months. Maintenance mailings biweekly for six months and then monthly during the second year.
62313282|NCT05345496||WORKERS GROUP|44 physiotherapists with a history of at least 1 painful episode of work-related thumb pain in the last 3 months will be enrolled.
62313283|NCT05345496||STUDENT GROUP|44 physiotherapy students in their first academic year will be enrolled.
62313284|NCT05440760|EXPERIMENTAL|Sequence Group A|VR distraction occurring visits 1 and 2 with normal SOC therapy at visits 3 and 4.
62313285|NCT05440760|EXPERIMENTAL|Sequence Group B|VR distraction occurring visits 1 and 4 with normal SOC therapy at visits 2 and 3.
62313286|NCT05440760|EXPERIMENTAL|Sequence Group C|VR distraction occurring visits 3 and 4 with normal SOC therapy at visits 1 and 2.
62477825|NCT05852392|EXPERIMENTAL|Adapted PARENT Model|"PARENT is a team-based approach to care that utilizes a community health worker (called a coach) as part of the WCC team to provide comprehensive and family-centered preventive care services, address concerns related to family social needs, and decrease reliance on the clinician as the sole provider of preventive care services. The coach independently meets with the family at every early childhood well-child care visit to provide anticipatory guidance, social needs screening, developmental screening, and connection to needed community resources. All NCH-PCN practices will start in the control group, and then sequentially (by random assignment) move to become intervention. Practices will implement the adapted PARENT model for all well-visits, newborn through 15 months of age, and have a 9-month implementation exposure period to ensure that children ≤15 months of age at the practice have received the intervention; thereafter the practices maintain the intervention."
62477826|NCT05852392|NO_INTERVENTION|Traditional Well-Child Care|Our comparator is traditional well-child care, which follows national preventive care guidelines including structured and standardized developmental and social needs screening, and is in widespread use. These are well-child care visits led by the primary care clinician without a community health worker. All NCH-PCN practices will start in the control group, and then sequentially (by random assignment) move to become intervention.
62477827|NCT02436005|EXPERIMENTAL|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
61923382|NCT01542671|PLACEBO_COMPARATOR|Control|Lifestyle counseling at baseline, six and twelve months similar to intervention group, and infrequent non-tailored pamphlets.
62313287|NCT05440760|EXPERIMENTAL|Sequence Group D|VR distraction occurring visits 2 and 3 with normal SOC therapy at visits 3 and 4.
62313288|NCT00693355|EXPERIMENTAL|1|sodium butyrate
62477828|NCT02436005|ACTIVE_COMPARATOR|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
62477829|NCT04515095|EXPERIMENTAL|Water-only Fasting Group|Participants who voluntarily elect and are approved to water-only fast.
61923383|NCT02186366|EXPERIMENTAL|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
61923384|NCT02186366|ACTIVE_COMPARATOR|Buspirone|Buspirone by mouth 5mg three times per day for 6week
61923385|NCT03176758|ACTIVE_COMPARATOR|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
61923386|NCT03176758|ACTIVE_COMPARATOR|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
61923387|NCT01931202|PLACEBO_COMPARATOR|Double Blind-Placebo|Blinded treatment with placebo, one pill a day. If after the 4 weeks, the patient has not remitted, they will be increased to 2 pills a day.
62313289|NCT00693355|PLACEBO_COMPARATOR|2|NaCl
62313290|NCT00999752|ACTIVE_COMPARATOR|Arm A|Nebivolol to reach blood pressure control
62313291|NCT00999752|ACTIVE_COMPARATOR|Arm B|Hydrochlorothiazide for blood pressure control
62313292|NCT05537363|NO_INTERVENTION|Healthy adults|Year 1: To assess levels of agility and agility performance in relation to the motor and cognitive abilities of healthy young adults, healthy elderly, and elderly with MCI.
62313293|NCT05537363|NO_INTERVENTION|Healthy elderly and mild cognitive impairment elderly|Year 1: To assess levels of agility and agility performance in relation to the motor and cognitive abilities of healthy young adults, healthy elderly, and elderly with MCI.
62313294|NCT05537363|ACTIVE_COMPARATOR|Mild cognitive impairment elderly with health education|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
61923388|NCT01931202|ACTIVE_COMPARATOR|Double Blind-Escitalopram|Blinded treatment with either escitalopram 10mg, increased to escitalopram 20mg at week 4 if depression has not remitted.
61923389|NCT01931202|ACTIVE_COMPARATOR|Open Treatment with Escitalopram|Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.
62683640|NCT06256159|OTHER|Patients with incomplete spinal cord injury|
62683641|NCT04255043|EXPERIMENTAL|IVUS-guided DCB|In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.
62683642|NCT04255043|ACTIVE_COMPARATOR|Angiography-guided DCB|In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.
62313295|NCT05537363|EXPERIMENTAL|Mild cognitive impairment elderly with multicomponent training|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
61923390|NCT01759485|ACTIVE_COMPARATOR|Vitamin D|Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment
61923391|NCT01759485|PLACEBO_COMPARATOR|Placebo|Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment
61923392|NCT03220529|ACTIVE_COMPARATOR|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
61923393|NCT03220529|ACTIVE_COMPARATOR|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
61923394|NCT03220529|ACTIVE_COMPARATOR|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
62477830|NCT01503957|PLACEBO_COMPARATOR|Saline solution|Nasal spray
62477831|NCT01503957|EXPERIMENTAL|Nasya|Thixotropic nasal spray suspension
62683643|NCT04677595|EXPERIMENTAL|Cohort 1|Treatment Naive participants
62683644|NCT04677595|EXPERIMENTAL|Cohort 2|Participants received one or two prior lines of treatment
62683645|NCT06690970||Single Group Assignment|Each subject receive a single intravenous injection of 68Ga/18F-PSMA, and undergo PET/CT imaging within the specificed time.
62683646|NCT03054012||CAS group|computer-assisted surgery group
62683647|NCT05816590|EXPERIMENTAL|Meds@HOME Intervention|
62683648|NCT05816590|NO_INTERVENTION|Control Group|
62683649|NCT03678857|EXPERIMENTAL|Creatine Before|Receives Creatine before and placebo after training.
62683650|NCT03678857|EXPERIMENTAL|Creatine After|Receives creatine after and placebo before training.
62683651|NCT06674785|EXPERIMENTAL|Focused Extracorporeal Shock Wave|Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting four specific muscles: subscapularis, pectoralis major, latissimus dorsi, and teres major muscles. Each muscle will receive 1,000 shockwave shots per session, accumulating to a total of 4,000 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions.
62683652|NCT06674785|PLACEBO_COMPARATOR|Placebo-Controlled Shockwave Therapy|Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves.
62683653|NCT06593587|EXPERIMENTAL|RSVpreF|
61923395|NCT03220529|ACTIVE_COMPARATOR|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
61923396|NCT03220529|ACTIVE_COMPARATOR|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
61923397|NCT02149615|EXPERIMENTAL|isotretinoin|Retinal nerve fibre layer measurement in patients under isotretinoin treatment
61923398|NCT02149615|ACTIVE_COMPARATOR|lymecycline|Retinal nerve fibre layer measurement in patients under lymecycline treatment
61923399|NCT02149615|ACTIVE_COMPARATOR|minocycline|Retinal nerve fibre layer measurement in patients under minocycline treatment
61923400|NCT02149615|ACTIVE_COMPARATOR|doxycycline|Retinal nerve fibre layer measurement in patients under doxycycline treatment
61923401|NCT04105829|EXPERIMENTAL|Tooth color measurement|Tooth color changes between times (before retainer bonding, after retainer bonding, in 1 month, 3 months, 6 months and a year)
61923402|NCT00745225|EXPERIMENTAL|Active intervention arm|Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
61923403|NCT00745225|PLACEBO_COMPARATOR|placebo pill|placebo comparator
61923404|NCT03687970|EXPERIMENTAL|Group A: Painful CIPN Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
61923405|NCT03687970|ACTIVE_COMPARATOR|Group B: Control Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
61923406|NCT00590460|EXPERIMENTAL|Single Arm Study: Stem Cell Transplant|CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion
61923407|NCT03237871|EXPERIMENTAL|Survey and informational text messages|Text-message survey and informational text messages
61923408|NCT00715169|ACTIVE_COMPARATOR|1|
61923409|NCT00715169|PLACEBO_COMPARATOR|2|
62683654|NCT06593587|PLACEBO_COMPARATOR|Placebo|
61923410|NCT02547285||Shoes characteristics in elderly people|The subjects will test different characteristics on the same shoe. A single parameter vary for each test (Different insole, heel height, stem length ...)
61923411|NCT05240287|ACTIVE_COMPARATOR|Study group -adults with pes planus|"* Individuals between the ages of 20-45~* Individuals with bilateral pes planus according to the Navicular Drop Test and Foot Posture Index"
61923412|NCT05240287|OTHER|Control group -adults without pes planus (normal foot)|"* Individuals between the ages of 20-45~* Individuals without pes planus according to the Navicular Drop Test and Foot Posture Index"
61923413|NCT02827565|EXPERIMENTAL|CircuLOR-1|KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations
61923414|NCT04728672|EXPERIMENTAL|Experimental Group|Kinesio tape was applied and then outcome measures were noted.
61923415|NCT04728672|PLACEBO_COMPARATOR|Control Group|Placebo Micropore Tape was applied and then outcome measures were noted.
61923416|NCT02565927|EXPERIMENTAL|Radioactive stent|Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
61923417|NCT02565927|ACTIVE_COMPARATOR|Traditional airway stent|Patients diagnosed as MAO treated with traditional airway stent
61923418|NCT03925168|EXPERIMENTAL|Experimental|Music therapy
61923419|NCT03925168|NO_INTERVENTION|Control|No music therapy
61923420|NCT02169193|EXPERIMENTAL|99mTc-Rhenium Sulfide Nanocolloid|99mTc-Rhenium Sulfide Nanocolloid
61923421|NCT01488162||Cohort|
61923422|NCT05629104||Preserved heart function|The group will be defined as preserved left ventricular ejection fraction (LVEF) with and without hypertrophy and with and without reduced global longitudinal strain (GLS).
61923423|NCT05629104||Reduced heart function|The group will be defined as reduced LVEF
61923424|NCT02557438||Roux-en-Y Gastric Bypass|Males and females aged 13-25 undergoing Roux-en-Y gastric bypass (RYGB) surgery
61923425|NCT02557438||Vertical Sleeve Gastrectomy|Males and females aged 13-25 undergoing vertical sleeve gastrectomy (VSG) surgery
61923426|NCT02557438||Non-surgical Obese Controls|Males and females aged 13-25 who are obese and not undergoing weight loss surgery
62683655|NCT06606158||Cohort 1: Non-exposed cohort (mobile application follow-up considered as a protective factor).|Patients who, following hip arthroplasty surgery, were monitored using a mobile application designed to record physical activity data and adherence to a postoperative recovery exercise program. Patients received scheduled instructions regularly within the application, providing educational material and exercise/activity routines, but did not receive formal physical therapy outside of the application as part of the study.
62683656|NCT06606158||Cohort 2: Exposed cohort (no mobile application follow-up).|Patients who, following hip arthroplasty surgery, did not undergo follow-up via the mobile application and followed the standard recovery protocol, which includes regular clinic visits and conventional physiotherapy.
62683657|NCT05541328||Tisagenlecleucel therapy|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
62313296|NCT05537363|EXPERIMENTAL|Mild cognitive impairment elderly with agility training|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
62683658|NCT05541328||Standard of care|The real-world cohort is defined as the cohort of patients derived from the FHRD receiving SOC as the third line of therapy or later
62683659|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
62683660|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
62683661|NCT02571881|ACTIVE_COMPARATOR|Oxycodone|Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
62683662|NCT02571881|EXPERIMENTAL|Oxycodone-naloxone|Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
62683663|NCT06276075|EXPERIMENTAL|Conventional rehabilitation|patients performed daily physiotherapy, which included intensive preparatory training for standing and sitting positions, strengthening exercises, weight-bearing exercises, and balance and coordination exercises (from 40 to 60 minutes of therapy).
62683664|NCT06276075|EXPERIMENTAL|Erigo®Pro|effective therapy included 1 session on a tilting table at an angle of 42° for 20 minutes, 5 times a week (Monday to Friday) at a speed of 32 steps per minute, followed by a physiotherapy session for two weeks.
62683665|NCT06276075|EXPERIMENTAL|motor imagery (MI)|in addition to conventional physiotherapy, activity imagery during passive walking on the Erigo®Pro table was introduced. During the exercises on the table, the patients wore headphones that blocked out any external sounds, closed their eyes and their task was to imagine the sensation of their body moving (first-person imagination), differentiating the idea of walking in various real environments (park, forest, beach, snow, streets). in the city, walking at different speeds, going up and down stairs, running, etc.)
62477832|NCT05469997|EXPERIMENTAL|MeDi(KD-MCT)|The participants in this arm will first undergo the MeDi-KD intervention followed by the MeDi-MCT intervention, after an 8-week washout period.
62683666|NCT04256018|EXPERIMENTAL|LD TSEBT|"Mogamulizumab with low dose total skin electron beam therapy. •~LD (12 Gy) TSEBT will be initiated on Cycle 1 Day 2 (± 2 days) of mogamulizumab over 2 to 3 week period per standard of care (SOC), as tolerated. Mogamulizumab (1 mg/kg) will be administered over 60 minutes as follows (per SOC and FDA approved use in MF and SS):~* Cycle 1 only: Days1; 8; 15; and 22 (± 2 days)~* Cycle 2 and beyond: Day 1 and Day 15 (± 3 days)"
62683667|NCT06673485|EXPERIMENTAL|Group A : Patients received vitamin D and calcium supplementation during the healing period|"1. Monthly intramuscular injections of vitamin D3 (300,000 I.U.) for three months, concurrent with six months of oral Maxical vitamin D supplementation post-implant placement.~2. Daily intake of Maxical calcium carbonate tablets (600 mg elemental calcium) for six months."
62683668|NCT06673485|EXPERIMENTAL|Group B: Patients have not received any nutritional supplementation during the healing period.|
62683669|NCT01337310|EXPERIMENTAL|Tesetaxel|Tesetaxel administered orally once every 21 days for at least 2 cycles
62683670|NCT00767312||Patients|HIV-infected patients who are 18 years of age or older, have been enrolled in another NIH protocol.
62683671|NCT03339765|EXPERIMENTAL|Serious game intervention|Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.
62683672|NCT03339765|NO_INTERVENTION|Enhanced care as usual|If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
61923427|NCT03124238|EXPERIMENTAL|Massage|Massage therapy of the lumbar muscles in a prone position during 30 minutes
61923428|NCT03124238|NO_INTERVENTION|Control|Rest during 5 minutes in a prone position
62477833|NCT05469997|EXPERIMENTAL|MeDi(MCT-KD)|The participants in this arm will first undergo the MeDi-MCT intervention followed by the MeDi-KD intervention, after an 8-week washout period.
62683673|NCT05966727|EXPERIMENTAL|Cholestyramine intake|"1 sachet (4 grams) 3 times a day, corresponding to a daily dose of 12 grams. Preferably taken at mealtimes.~Treatment lasts 4 months."
62683674|NCT06517927|EXPERIMENTAL|Cancer survivor|
62313297|NCT05537363|ACTIVE_COMPARATOR|Healthy elderly with health education|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
61923429|NCT03512015|EXPERIMENTAL|LuCApp + Standard Care|"LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.~LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met."
61923430|NCT03512015|ACTIVE_COMPARATOR|Standard Care|Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
62313298|NCT05537363|EXPERIMENTAL|Healthy elderly with multicomponent training|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
62683675|NCT06517927|ACTIVE_COMPARATOR|Control|
62683676|NCT01341990|EXPERIMENTAL|FID 114675A|Multi-purpose disinfecting solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
61923431|NCT03317132|EXPERIMENTAL|Individual Placement and Support|One year of IPS Support
61923432|NCT03317132|NO_INTERVENTION|Treatment as usual|Treatment as usual
61923433|NCT02235259|EXPERIMENTAL|XG-104 low dose|
61923434|NCT02235259|EXPERIMENTAL|XG-104 intermediate dose|
61923435|NCT02235259|EXPERIMENTAL|XG-104 high dose|
61923436|NCT02235259|PLACEBO_COMPARATOR|Placebo|Placebo
61923437|NCT01395615||Cohort|
61923438|NCT03671473|EXPERIMENTAL|Focused|fESWT (0.05-0.29 mJ/mm2, 2000 shocks, 5 Hz)
61923439|NCT03671473|ACTIVE_COMPARATOR|Radial|rESWT (2000shocks, 4 Bar, 5Hz)
61923440|NCT03268473|EXPERIMENTAL|Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis|Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months Individuals: with both OSAS and periodontitis Intervention: Procedure: Non-surgical periodontal therapy
61923441|NCT03268473|ACTIVE_COMPARATOR|Control: non-surgical periodontal therapy in Periodontitis|Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months Individuals: only periodontitis Intervention: Procedure: Non-surgical periodontal therapy
61923442|NCT01011023|EXPERIMENTAL|WITHOUT NASOGASTRIC TUBE|1. Experimental group (EG): without NGT, by removing the NGT at the end of the surgery, once the stomach had been aspirated,
61923443|NCT01011023|ACTIVE_COMPARATOR|WITH NASOGASTRIC TUBE|2. Control group (CG): with NGT, with radiographic corroboration of correct placement after the surgery. Both groups were given: 5-day fasting because it was the therapeutic gold standard at our hospital and our country, intravenous solutions and antibiotics for 5 days, ranitidine, and analgesics, without use of any antiemetic drug. Once the fasting period ended, in the CG the NGT was clamped and withdrawn, and in both groups oral fluids and diet were started. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
62313299|NCT05537363|EXPERIMENTAL|Healthy elderly with agility training|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
62477834|NCT02339558|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62477835|NCT03948100|EXPERIMENTAL|Group I (dyadic yoga)|Patients and caregivers undergo dyadic yoga intervention session involving physical exercises and relaxation techniques over 60 minutes each for up to 15 sessions.
62683677|NCT01341990|ACTIVE_COMPARATOR|ReNu MultiPlus|Multi-purpose solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
62683678|NCT06687109||Registry Knee|
62683679|NCT06687109||Registry Hip|
61923444|NCT04449471|EXPERIMENTAL|Naproxen Tablet|Subjects will received a single 220-mg dose of naproxen sodium (Aleve) by mouth.
61923445|NCT00057681|EXPERIMENTAL|1|Participants will receive treatment with lithium for 8 to 16 weeks
62683680|NCT03023683|OTHER|Group A: 2-8 yo healthy non-twins|Participants will be given seasonal live, attenuated influenza vaccine (LAIV), FluMist® . Children with no prior influenza vaccine history will receive a second dose of LAIV at least 28 days after the first study dose.
62683681|NCT03023683|OTHER|Group B: 18-49 yo healthy non-twins|Participants will be given seasonal LAIV, FluMist® .
62313300|NCT04763265|ACTIVE_COMPARATOR|Group A (n=100): BoNT/A-DP (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures..~A volume of 0.5 mL of the properly reconstituted BoNT/A-DP should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
62477836|NCT03948100|ACTIVE_COMPARATOR|Group II (dyadic education)|Patients and caregivers undergo dyadic education program session focusing on strategies of how to manage patient and caregiver symptoms over 60 minutes each for up to 15 sessions.
62683682|NCT06668025|EXPERIMENTAL|MxA group|Perform MxA test; MxA results reported to attending clinicians; Provide MxA-based guidelines on antiviral treatment to attending clinicians; Telephone Visit at Day 30
62683683|NCT06668025|ACTIVE_COMPARATOR|Control group|Telephone Visit at Day 30
62683684|NCT06627478|ACTIVE_COMPARATOR|United States (US)-Lantus®|Single subcutaneous dose administered over three treatment periods
62683685|NCT06627478|ACTIVE_COMPARATOR|European Union (EU)-Lantus®|Single subcutaneous dose administered over three treatment periods
62477837|NCT01535222|EXPERIMENTAL|Cohort 1|3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
62477838|NCT01535222|EXPERIMENTAL|Cohort 2|3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
62683686|NCT06627478|EXPERIMENTAL|NKF-INS Glargine (G)|Single subcutaneous dose administered over three treatment periods
62683687|NCT06683586||Single group|A single group will be included in this cross-sectional study.
62683688|NCT06679153|EXPERIMENTAL|VVN461, 1.0%|VVN461 Ophthalmic Solution, 1.0%
62683689|NCT06679153|EXPERIMENTAL|VVN461, 0.5%|VVN461 Ophthalmic Solution, 0.5%
62683690|NCT06679153|PLACEBO_COMPARATOR|Prednisolone acetate, 1%|Prednisolone acetate Ophthalmic Solution, 1%
62683691|NCT01630083|ACTIVE_COMPARATOR|EOX Treatment|Participants will receive up to 8 cycles of epirubicin, oxaliplatin and capecitabine (EOX) chemotherapy treatment alone (50 mg/m\^2 epirubicin intravenously on day 1 of each cycle, 130 mg/m\^2 oxaliplatin intravenously on day 1 of each cycle, 625 mg/m\^2 capecitabine orally twice daily on days 1 to 21 of each cycle). The first dose of capecitabine to be taken in the evening of day 1.
62697332|NCT06420336|ACTIVE_COMPARATOR|Quadratus lumborum block|After induction of anesthesia and securement of appropriate airway device, the patient will be placed in position for the QL block. Using ultrasound guidance, the pediatric anesthesiology attending will perform unilateral QL block on the side of the anterior iliac bone graft harvest. The dose will be 0.2% ropivacaine, 1 mL per kilogram to a max of 20 mL with an additive of dexamethasone 4 mg. Ultrasonography will be used to identify external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A 50 mm-150 mm block needle will be advanced under ultrasound guidance. Ropivacaine will be injected slowly with frequent aspiration to rule out incorrect needle placement. The anesthetic is deposited at the lateral edge of the QL after penetrating the transversus abdominus aponeurosis. Injection will continue to be observed with real time US guidance.
61923446|NCT00057681|EXPERIMENTAL|2|Participants will receive treatment with valproate for 8 to 16 weeks
61923447|NCT00057681|EXPERIMENTAL|3|Participants will receive treatment with risperidone for 8 to 16 weeks
61923448|NCT04082039|ACTIVE_COMPARATOR|1-channel PCA|Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
61923449|NCT04082039|EXPERIMENTAL|2-channel PCA|Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
61923450|NCT05402020||Tiotropium + Olodaterol cohort|Subjects who initiated Tiotropium + Olodaterol between 1st January 2014 and 31st December 2019 according to data from the Taiwan National Health Insurance (NHI), Taiwan Cancer Registry (TCR) and Taiwan Mortality Data.
61923451|NCT05402020||Inhaled Corticosteroids (ICS) + Long-acting ß2 agonists (LABA) cohort|Subjects who initiated Inhaled Corticosteroids (ICS) + Long-acting ß2 agonists (LABA) between 1st January 2014 and 31st December 2019 according to data from the Taiwan National Health Insurance (NHI), Taiwan Cancer Registry (TCR) and Taiwan Mortality Data.
62683692|NCT01630083|EXPERIMENTAL|EOX+zolbetuximab 800/600 mg/m^2|Participants will received up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab administered as loading dose of 800 mg/m\^2 intravenously on day 1 of cycle 1 followed by 600 mg/m\^2 intravenously on day 1 of each subsequent cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (600 mg/m\^2 every 3 weeks to be administered intravenously as a 2-hour infusion) until progressive disease (PD), withdrawal of consent or unacceptable toxicity. PD per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study, an absolute increase of at least 5mm must also be demonstrated, unequivocal progression of existing non-target lesions and appearance of one or more new lesions is considered progression.
62683693|NCT01630083|EXPERIMENTAL|EOX+zolbetuximab 1000 mg/m^2|Participants will receive up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab 1000 mg/m\^2 intravenously on day 1 of each cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (1000 mg/m\^2 every 3 weeks administered intravenously as a 2-hour infusion ) until PD, withdrawal of consent or unacceptable toxicity.
62683694|NCT05066139|NO_INTERVENTION|Arm A Standard of care|"Patients will receive standard care before treatment initiation (i.e. geriatric assessment only).~Geriatric assessment includes: Mini Mental State Examination ; mini-Geriatric Depression Scale (mini-GDS) ; Body Mass Index (BMI) calculation ; Mini Nutritional Assessment (MNA) ; Time up and Go ; Cumulative Illness Rating Scale - Geriatric (CIRS-G) ; Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) questionnaires."
62683695|NCT05066139|EXPERIMENTAL|Arm B Multidisciplinary EPODIG program|Patients will undergo the same geriatric assessment as in Arm A plus EPODIG-G program before treatment initiation.
62683696|NCT02769416||Spinal Cord and Traumatic Brain Injury Subjects|Patients with a history of spinal cord and/or traumatic brain injury will provide data and samples so that they may be queried for interventional studies.
62683697|NCT02769416||Family Members and Healthy Volunteers|Healthy volunteer controls or family members may be enrolled for identification of genetic mutations.
62683698|NCT01569763|ACTIVE_COMPARATOR|hysteroscopic rollerball resection/ablation|
62683699|NCT01569763|EXPERIMENTAL|Aurora Endometrial Ablation|
62683700|NCT05371470|EXPERIMENTAL|Cardiac rehabilitation plus voice analysis|Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care and utilize a voice analysis smartphone app.
62683701|NCT05371470|NO_INTERVENTION|Cardiac rehabilitation only|Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care.
62683702|NCT06397183|EXPERIMENTAL|Mulligan Strech with Traction Group|
62683703|NCT06397183|EXPERIMENTAL|Post-Isometric Relaxation Group|
62683704|NCT02739880|EXPERIMENTAL|The study population|"The study population consists of postmenopausal patients (more than 2 years and less than 10 years) with a body mass index \<35 with sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness.~Intervention: Intra-mucosal Injections of Cross-linked Hyaluronic Acid"
62683705|NCT06497829|EXPERIMENTAL|patients with MVK deficiency|patients fulfilling inclusion criteria
62683706|NCT03434899|EXPERIMENTAL|Intervention group|Health care plan including physical exercise and online support during the entire study
62683707|NCT03434899|ACTIVE_COMPARATOR|Control Group|Health care plan including physical exercise
61923452|NCT04167956|EXPERIMENTAL|ultrasound combined with CT guided|ultrasound combined with CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
62683708|NCT05698719||STEMI patients undergoing physiological assessment of a non-culprit lesion|vFFR, FFR, RFR, dPR, CFR and IMR
62683709|NCT02439411||Dabrafenib|
62477839|NCT01535222|EXPERIMENTAL|Cohort 3|6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
62477840|NCT01535222|EXPERIMENTAL|Cohort 4|6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
62477841|NCT01535222|EXPERIMENTAL|Cohort 5|6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
62683710|NCT02439411||Dabrafenib plus Trametinib|Patients treated with Dabrafenib plus Trametinib
62683711|NCT03107299|OTHER|Control|
62683712|NCT03107299|OTHER|Send sms to patients|
62683713|NCT03107299|OTHER|pharmaceutical maintenance following medical consultation|
62683714|NCT03640624|EXPERIMENTAL|Intervention|Multidisciplinary treatment
62477842|NCT01535222|PLACEBO_COMPARATOR|Placebo|8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
62683715|NCT03640624|ACTIVE_COMPARATOR|Control|Treatment as usual
62683716|NCT00382473|EXPERIMENTAL|exercise|
62683717|NCT06026696||Patients treated for acute cerebrovascular pathology cerebrovascular disease|
61923453|NCT04167956|SHAM_COMPARATOR|CT guided|CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
61923454|NCT00252629|ACTIVE_COMPARATOR|Therapeutic nasal CPAP|Comparing change of veterans reported outcomes before and after 3 weeks treatment of therapeutic nasal CPAP with the change on sham nasal CPAP.
61923455|NCT00252629|SHAM_COMPARATOR|Sham nasal CPAP|Comparing change of symptoms and veterans reported outcomes before and after treatment of 3 weeks on sham nasal CPAP with the change on therapeutic nasal CPAP
62683718|NCT01268072||Cohort 2|Subjects who are recruited on admission to hospital for AECOPD.
62683719|NCT01268072||Cohort 1|Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
62683720|NCT04908527|EXPERIMENTAL|Walk group|Patients walked to operating room (OR)
62683721|NCT04908527|NO_INTERVENTION|Bed group|Patients go to OR while in bed
62683722|NCT05483140||Low Energy Diet Group|A low energy diet comprising of three options and lifestyle modifications as part of a digitally enabled weight loss program.
62683723|NCT04594603||Group(1): Cataract with no diabetic retinopathy|
62683724|NCT04594603||Group (2): Cataract associated with diabetic retinopathy|
62683725|NCT06634004||Moyamoya|Adults diagnosed with Moyamoya who are being considered for revascularization surgery.
62683726|NCT06634004||Control|Healthy adults who will under go a BOLD MRI for research purposes.
62683727|NCT05799157|EXPERIMENTAL|Treatment Group A (Low Dose)|Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
62683728|NCT05799157|EXPERIMENTAL|Treatment Group B (High Dose)|High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
62683729|NCT05799157|PLACEBO_COMPARATOR|Treatment Group C (Vehicle)|Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
62683730|NCT05642975|ACTIVE_COMPARATOR|Suprainguinal Fascia Iliaca Block|"The probe was placed over the inguinal ligament in close proximity to the anterior superior iliac spine and oriented in the parasagittal plane. It was then moved inferomedially along the line of the inguinal ligament to visualize the 'bow-tie' sign. After confirming the needle's position, a total volume of 30 ml of bupivacaine 0.25% was injected.~Spinal anesthesia was administered to the patients in a lateral position using 2.5 ml of 0.5% heavy bupivacaine at the L3-L4 level."
62683731|NCT05642975|ACTIVE_COMPARATOR|Erector Spinae Plane Block|"The L5, L4, and L3 transverse processes and erector spinae muscles posteriorly were identified using ultrasound. The curved 6-2 MHz transducer was initially placed at the mid-vertebral line in the sagittal plane and then shifted laterally to visualize the erector spinae muscle and transverse process of the L3 vertebra. A total volume of 40 ml of bupivacaine 0.25% was injected.~Spinal anesthesia was administered to the patients in a lateral position using 2.5 ml of 0.5% heavy bupivacaine at the L3-L4 level."
62683732|NCT05642975|ACTIVE_COMPARATOR|Spinal Anesthesia Group (control)|Spinal anesthesia was administered to the patients in a lateral position using 2.5 ml of 0.5% heavy bupivacaine at the L3-L4 level.
62683733|NCT00921544|ACTIVE_COMPARATOR|Oral Sucrose|Oral sucrose administered 2 mins prior to eye exam
62683734|NCT00921544|PLACEBO_COMPARATOR|Sterile water|0.2 mls of sterile water
61923456|NCT04041700|EXPERIMENTAL|Osia 2 system|
61923457|NCT03462069|EXPERIMENTAL|Treatment A (Test)|Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day
61923458|NCT03462069|ACTIVE_COMPARATOR|Treatment B (Reference)|Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day
61923459|NCT04410770|ACTIVE_COMPARATOR|Active intervention|Participants assigned to the active treatment arm are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 6 week outcome. The participant is encouraged to continue completing the self-ratings, but does not receive any more support calls. After 6 more weeks, the 12 week outcome is assessed the participant's involvement with the study ends.
62683735|NCT03422887|ACTIVE_COMPARATOR|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
62683736|NCT03422887|EXPERIMENTAL|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
62683737|NCT03422887|EXPERIMENTAL|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
62683738|NCT06290193|EXPERIMENTAL|Acute Normovolemic Hemodilution (ANH) Arm|
62683739|NCT06290193|NO_INTERVENTION|Standard Intraoperative Management Arm|
62683740|NCT04546243||osteosarcoma patients receiving resections|
62683741|NCT04546243||osteosarcoma patients receiving radiotherapy|
62683742|NCT03109392|EXPERIMENTAL|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
62683743|NCT03109392|EXPERIMENTAL|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
62683744|NCT03109392|ACTIVE_COMPARATOR|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
62683745|NCT06686706|EXPERIMENTAL|IASTM Group|Instrumental Assisted Soft Tissue Mobilization
62683746|NCT06686706|EXPERIMENTAL|KT Group|Kinesiotaping
62683747|NCT02658188|EXPERIMENTAL|ASP8825 group|
62683748|NCT06686381|EXPERIMENTAL|Arm A (Maintenance Avelumab)|Arm A: TURBT followed by induction Chemo/immunotherapy (DDMVAC (6 cycles) + Avelumab (6 cycles) or cisplatin/Gemzar (4 cycles) + Avelumab (6 cycles). A clinical evaluation is scheduled at 4 months post-day1 cycle 1 with CT scan/MRI for chest/abdomen/pelvis (CTCAP), Cystoscopy with Biopsy and urine cytology. Then complete or near complete responders will undergo 20 fractions of hypo-fractionated radiotherapy 55 grays followed by Avelumab every 2 weeks for 12-month maintenance phase.
62683749|NCT06686381|EXPERIMENTAL|Arm B (W&W)|Arm B: TURBT followed by induction Chemo/immunotherapy (DDMVAC (6 cycles) + Avelumab (6 cycles) or cisplatin/Gemzar (4 cycles) + Avelumab (6 cycles). A clinical evaluation is scheduled at 4 months post-day1 cycle 1 with CT scan/MRI for chest/abdomen/pelvis (CTCAP), Cystoscopy with Biopsy and urine cytology. Then complete or near complete responders will undergo 20 fractions of hypo-fractionated radiotherapy 55 grays followed by 1 year watch and wait.
62123484|NCT04423146||Patients scheduled for elective scoliosis surgery|Patients scheduled for elective scoliosis surgery will be anesthetized in TIVA mode,combining propofol and remifentanil with titration to the target BIS value. Motor evoked potentials will be measured and evaluated by members of operating team perioperatively. The quality of evoked potentials (poor vs good quality) and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
62123485|NCT04679571|EXPERIMENTAL|Targeted Albumin with Standard Medical Treatment|Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin \>3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin \>3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks
62683750|NCT04839601|EXPERIMENTAL|Evaluation Group (stimulation ON)|Group of participants that have an RNS System implanted and are being treated with responsive stimulation.
62683751|NCT02557919|EXPERIMENTAL|Motivational Interviewing Training|Staff at the intervention sites were trained in basic tobacco control and motivational interviewing. Two booster trainings were held over 6 months.
62683752|NCT02557919|OTHER|Usual Best Practice|Staff at the usual best practice sites received basic tobacco control training.
62123486|NCT04679571|ACTIVE_COMPARATOR|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year"
62123487|NCT00676234|NO_INTERVENTION|1|
62123488|NCT00676234|EXPERIMENTAL|2|Administration of intravenous rhu Epo on Day 0
62123489|NCT06677424|OTHER|NeuroCatch® Platform 2|"NeuroCatch® Platform 2 Software enables EEG data collection by recording the data during an audio stimulus presentation (i.e., the NeuroCatch® Scan). The Software plays a 6-min proprietary audio sequence stimulus. The NeuroCatch® software generates unique, randomized audio sequences specifically designed to elicit specific brain responses. Once a NeuroCatch® Scan is complete, the software automatically processes the raw EEG data to generate 6 ERP results and saves the results, the data, and details about the scan to the secure NeuroCatch® server in the cloud.~While EEG is only collected during the scan, the participant is exposed to the device from the time the cap is placed on the head until it is taken off.~During the scan, the participant will listen to an auditory stimulus sequence consisting of tones and words. This has been designed and limited to safe audio levels."
62683753|NCT03965117|EXPERIMENTAL|norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect.
62123490|NCT01580241||Surgery group|Patients with pancreatic cancer who undergo surgical treatment only
62123491|NCT01580241||Chemotherapy group|Patients with pancreatic cancer who undergo chemotherapy treatment only
62683754|NCT03825666|EXPERIMENTAL|Active|Intervention with drink pre surgery and chewing gum post surgery. No subgroups, combined intervention will be assessed. ProvideXtra® Fresenius Kabi plus standard consumer xylitol chewing gum.
62683755|NCT03825666|NO_INTERVENTION|Control|control group following standard guidelines
62683756|NCT03654326|EXPERIMENTAL|Gefapixant|Participants will receive a gefapixant 45 mg tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
61923460|NCT04410770|NO_INTERVENTION|Wait list|Wait list participants have no study activities for 6 weeks after completing the baseline assessment. After 6 weeks, list participants complete the 6 week assessment. After completing the assessment. wait list participants are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 12 week outcome and the participant's involvement with the study ends.
61923461|NCT03017781||Study Group|Offspring (15-25 years old) of parents with Bipolar Disorder (BD) with at least mild impairment in psychosocial functioning were observed to evaluate the relationship of impairment in psychosocial functioning with the manifestation of mood symptoms over 24 months
61923462|NCT03017781||Control Group|A group of offspring of bipolar parents with no impairment in psychosocial functioning will be used for comparison.
61923463|NCT04459767|EXPERIMENTAL|Vupanorsen 80 milligram (mg)|Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
62477843|NCT02230605|EXPERIMENTAL|Cognitive Exercise|The cognitive exercises will consist of a series of computer games focusing on five categories: memory, speed, attention, flexibility and problem-solving. Participants will be expected to complete 1 hour of Lumosity exercise daily for a minimum of 8 days prior to surgery. Participants will be instructed to complete no less than 15 minutes of exercise at a time throughout each day. Each hour of exercise, participants will work through at least 1 game under each category. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
62683757|NCT03654326|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
61923464|NCT04459767|EXPERIMENTAL|Vupanorsen 160 mg|Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
61923465|NCT04459767|PLACEBO_COMPARATOR|Placebo|"Participants in Cohort 1 (vupanorsen 80 mg) will receive one 0.8 mL subcutaneous injection with 0.9% sodium chloride in water.~Participants in Cohort 2 (vupanorsen 160 mg) will receive two 0.8 mL subcutaneous injections with 0.9% sodium chloride in water."
61923466|NCT01919762||Bacteremia Positive Patients|"Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).~* Acinetobacter baumannii~* Staphylococcus aureus~* Klebsiella pneumonia~* Pseudomonas aeruginosa~* Enterococcus faecalis~* Enterococcus faecium"
62313301|NCT04763265|ACTIVE_COMPARATOR|Group B (n=100): Botox Cosmetic (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures.~A volume of 0.5 mL of the properly reconstituted Botox Cosmetic should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
62313302|NCT06605066||Post-Operative|Adults aged 18 and over who have undergone cardiac or thoracic surgery, been discharged from the post-anesthesia care unit, and transferred to an inpatient setting within 3 days prior to the data collection date.
62313303|NCT02448823|EXPERIMENTAL|Stylish Events and Mass Media|Mass Media (radio, posters) and annual Stylish Man/Stylish Living Event (SMLEvent), a multimedia event promoting CHP.
62313304|NCT02448823|ACTIVE_COMPARATOR|Control arm: mass media only|Mass media
62313305|NCT02662309|EXPERIMENTAL|MPDL3280A|Patients receive 2x 3-weekly cycles of MPDL3280A (one infusion on the first day of each cycle) prior to cystectomy surgery.
62313306|NCT03088241|EXPERIMENTAL|Intervention|switch to second-line ART
62313307|NCT03088241|NO_INTERVENTION|Control|Standard of care: no switch to second-line ART
62313308|NCT03711019|EXPERIMENTAL|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
62683758|NCT06054802||ACL surgery|Pediatric subjects undergoing surgery for ACL repair.
62683759|NCT06607913|EXPERIMENTAL|Exercise|The participants will exercise 2 days a week for 16 weeks. The exercises will include 4 movements: squats, shoulder press, seated row, and bicep curl focusing on internal load and contraction velocity.
62683760|NCT06607913|NO_INTERVENTION|Usual Care|Participants will not have any study intervention visits for usual care.
62477844|NCT02230605|PLACEBO_COMPARATOR|Normal Activity|Participants randomized into the Normal Activity group will be encouraged to maintain their normal activity level prior to surgery. These participants are asked not to alter their normal daily routine of mental exertion (i.e. watching television, reading, puzzles, etc.) and not permitted to subscribe to Lumosity while in the research study. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
62477845|NCT00545805|EXPERIMENTAL|OM group|
62477846|NCT00545805|ACTIVE_COMPARATOR|CT group|Control group
62477847|NCT01531894|EXPERIMENTAL|GSK2110183 (afuresertib)|All patients received the GSK2110183 (afuresertib) treatment
62477848|NCT05329025|EXPERIMENTAL|Treatment A|Participants with squamous cell carcinoma will receive QL1706, paclitaxel and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706 until unacceptable toxicity or loss of clinical benefit.
62477849|NCT05329025|EXPERIMENTAL|Treatment B|Participants with non-squamous cell carcinoma will receive QL1706, bevacizumab, pemetrexed, and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706, bevacizumab and pemetrexed until unacceptable toxicity or loss of clinical benefit.
62683761|NCT06687551|EXPERIMENTAL|JAK inhibitor dose-tapering strategy|"The dose-tapering strategy will depend on the JAK inhibitor taken by the patient. It will be based on a 50% dose-reduction every 6 months and will comprise 2 steps:~A. Treatment with baricitinib 4 mg daily:~* Step 1 (after randomization): baricitinib 2mg daily.~* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day.~B. Treatment with filgotinib 200 mg daily:~* Step 1 (after randomisation): filgotinib 100 mg daily.~* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day.~C. Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily:~* Step 1 (after randomisation): tofacitinib 5 mg once daily.~* Step 2 (in case of CDAI ≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day.~D. Treatment with upadacitinib 15 mg daily:~• Step 1 (after randomisat"
62477850|NCT03151876|EXPERIMENTAL|ChiCGB|"Experimental: ChiCGB~Chidamide administered orally on D-7, -4, 0,+3~Cladribine administered at 10mg on D-6 to D-2~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.~Interventions:~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
62683762|NCT06687551|ACTIVE_COMPARATOR|JAK inhibitor continuous therapy strategy|"Full dose will be considered in patient taking:~* Baricitinib 4mg/day~* Filgotinib: 200mg/day~* Tofacitinib : 5mg twice daily or 11mg/day~* Upadacitinib: 15mg/day"
62683763|NCT02144246|OTHER|Pre-intervention|Patients will act as their own controls. Will have no hormones for 3 months
62683764|NCT02144246|EXPERIMENTAL|Post-intervention|Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
62683765|NCT06689176|EXPERIMENTAL|Patients undergoing radical cystectomy with urinary diversion|Patients undergoing radical cystectomy and ileal conduit or ileal neobladder will receive Irrisept ® Antimicrobial Wound Lavage as intervention
62683766|NCT06686953||the colorectal cancer group|patients diagnosed as colorectal cancer
61923467|NCT01919762||Bacteremia Negative Patients|Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species
62683767|NCT06166641||Intraoperative acquired pressure injury|Intraoperative acquired pressure injury are wounds that develop during a surgical procedure or while a patient is in the operating room. These ulcers are caused by prolonged pressure on a specific area of the body, which reduces blood flow and leads to tissue damage.
62477851|NCT05119725||Patients with atrial fibrillation|Patients with previous diagnosis of atrial fibrillation
62477852|NCT05119725||Non-AF patients with high stroke risk|Non-AF patients with high stroke risk
62477853|NCT03612440|EXPERIMENTAL|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
62477854|NCT03612440|PLACEBO_COMPARATOR|Group C|40 patients receive matching placebo (normal saline)
62683768|NCT05836025|EXPERIMENTAL|Rapamycin|Participants randomized to the treatment arm will receive 5mg/week of rapamycin orally, for 12 weeks (3 months).
61923468|NCT05357053||Anorexia nervosa patients|Anorexia nervosa patients
62683769|NCT05836025|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive placebo orally, for 12 weeks (3 months).
61923469|NCT05357053||Healthy normal weight controls|Healthy normal weight controls
61923470|NCT02770261|EXPERIMENTAL|CR group|DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
61923471|NCT02770261|ACTIVE_COMPARATOR|CP group|DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
61923472|NCT02770261|ACTIVE_COMPARATOR|PR group|DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg
61923473|NCT05852600|EXPERIMENTAL|Intervention|"Participants assigned to the intervention arm are immediately given the opportunity to view Lead with Love, and then to complete the PATHS toolkit. One month after completing PATHS, they complete a refresher module that is designed to boost the initial effects of PATHS."
62123492|NCT01580241||Neoadjuvant group|Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
62123493|NCT01580241||Adjuvant group|Patients with pancreatic cancer who undergo surgery followed by chemotherapy
62123494|NCT04088032|EXPERIMENTAL|Active|Experimental treatment
62313309|NCT03711019|ACTIVE_COMPARATOR|RUL-UB ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
62477855|NCT02088931|EXPERIMENTAL|Single infusion polyclonal Treg|"3 subjects with inflammation on their 6-month surveillance biopsy following renal transplantation will receive a single infusion of a target of 320 million ex vivo selected and expanded autologous polyclonal Tregs.~After the therapy visit the patient will return for a total of nine (9) more visits for the main part of the study: 1 and 4 days after therapy, then once a week for 4 weeks, and then 3, 6, and 12 months after you get the therapy."
61923474|NCT05852600|ACTIVE_COMPARATOR|Waitlist Control|"Participants assigned to the waitlist control arm are immediately given the opportunity to view Lead with Love. One month after viewing the film, they complete a refresher module that reviews the most important lessons from the film. Six months after being randomized, participants are then given access to the PATHS toolkit. One month after completing the PATHS toolkit, they complete a refresher module that is designed to boost the initial effects of PATHS."
61923475|NCT01742247|EXPERIMENTAL|Physiogel, Laser therapy, Moisturizer|"Experimental: Physiogel treated \& Non-treated~1 Palmitoylethanolamide, Physiogel 3 times a day for 2 weeks"
61923476|NCT05919927||Type II diabetes patients|Neuropsychological examination is done and medical information is gathered from the medical records.
62313310|NCT03711019|ACTIVE_COMPARATOR|Bitemporal ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
61923477|NCT05919927||Healthy controls|Neuropsychological examination, medical examination and laboratory tests.
61923478|NCT00996723|OTHER|1|
61923479|NCT00517803|EXPERIMENTAL|1|
62123495|NCT03236909|EXPERIMENTAL|Single-arm|Single-arm, repeated-measures study design with all subjects receiving a MED-EL cochlear implant
62123496|NCT03003637|EXPERIMENTAL|Nivolumab with or without Ipilimumab|First dose scheme will be 2x nivolumab 240 mg flat dose, weeks 1 and 3. When feasible and safe, the next patients will be treated with the following dose scheme: the combination of 1x ipilimumab 1 mg/kg + nivolumab 240 mg flat dose in week 1 and nivolumab mono-therapy 240 mg flat dose in week 3
62313311|NCT01341509|ACTIVE_COMPARATOR|FHL tendon transferred|Surgical group in which the FHL tendon was transferred
61923480|NCT00517803|PLACEBO_COMPARATOR|2|
62313312|NCT01341509|ACTIVE_COMPARATOR|FHL tendon not transferred|
62477856|NCT04354363|ACTIVE_COMPARATOR|PRP|women who will receive PRP before ICSI
62477857|NCT04354363|NO_INTERVENTION|No PRP|women who willnot receive PRP before ICSI
62477858|NCT05637125|ACTIVE_COMPARATOR|Group A|Group A received aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks.
62123497|NCT06195891|EXPERIMENTAL|Treatment (TMLI, fludarabine, melphalan, Orca-T)|"PREPARATIVE REGIMEN: Patients undergo TMLI BID on days -8 to -5, followed by fludarabine IV on days -4 to -2 and melphalan IV on day -2. Patients receiving the lowest dose of TMLI also receive thiotepa IV on days -4 and -3.~HCT: Patients receive Orca-T CD34+HSPC and Treg products IV on day 0, followed by the Orca-T tcon product IV on day 2.~GVHD PROPHYLAXIS: Patients undergoing haplo-HCT receive tacrolimus starting on day 14 and continuing until day 90 with a taper per treating physician's discretion.~Patients also undergo ECHO or MUGA scans, DECT/MRI scans, bone marrow biopsies/aspirates, and blood sample collection throughout the study."
62683770|NCT05809830|EXPERIMENTAL|LB-100 plus doxorubicin|"* LB-100 will be administered during the first 3 days of each cycle (days 1, 2, and 3) at RP2D as a 2-hour intravenous infusion (with 500 mL of physiological saline solution), every 3 weeks (21-day cycles until progression or intolerance).~* Doxorubicin will be administered only once (day 1) of each cycle at RP2D as a 20-minute infusion after completion of LB-100, every 3 weeks (up to a maximum of 6 x 21-day cycles)."
62683771|NCT05809830|ACTIVE_COMPARATOR|Doxorubicin alone|Control: Doxorubicin will be administered only once (day 1) of each cycle at RP2D as a 20-minute infusion every 3 weeks (up to a maximum of 6 x 21-day cycles).
62683772|NCT06691243|EXPERIMENTAL|Semaglutide|Once weekly injection of semaglutide
62683773|NCT06691243|PLACEBO_COMPARATOR|Placebo|Once weekly injection of placebo
62683774|NCT02071654|EXPERIMENTAL|Venus P-valve transcatheter implantation|Single arm of percutaneous implantation of Venus-P valve for treating RVOT stenosis
62683775|NCT01217047|EXPERIMENTAL|Group A|For 3 weeks, you will need to come to the ICSCI one (1) time per week during which you will perform FES cycling for 1 hour each.
62683776|NCT01217047|EXPERIMENTAL|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
62683777|NCT01217047|EXPERIMENTAL|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
62683778|NCT01217047|EXPERIMENTAL|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
62683779|NCT02898675|EXPERIMENTAL|Platelet Rich Fibrine|Platelet Rich Fibrine was applied with open flap debridement in test group.
62683780|NCT02898675|ACTIVE_COMPARATOR|Open Flap Debridement|Platelet Rich Fibrin was not applied to control groups. Only open flap debridement was applied to control groups.
61923481|NCT04146298|EXPERIMENTAL|TCR Transduced T cell therapy|"Pre-conditioning: Non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine~TCR transduced T cell infusion: mutant KRAS G12V-specific TCR transduced autologous T cells (1e9\~1e11). If the participant responds to the first infusion, the second or more infusions will be considered when the disease is progressing.~Anti-PD-1 therapy: anti-PD-1 will be administered if needed."
62313313|NCT04590729|EXPERIMENTAL|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
62683781|NCT04636580|EXPERIMENTAL|anxious parent|Parents were divided into two groups anxious and non-anxious.
62683782|NCT04636580|EXPERIMENTAL|non-anxious parent|Parents were divided into two groups anxious and non-anxious.
62683783|NCT04970589|PLACEBO_COMPARATOR|Lean/Placebo Capsule|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
62683784|NCT04970589|EXPERIMENTAL|Lean/Probiotics|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
62683785|NCT04970589|EXPERIMENTAL|Obese/Placebo Capsule|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
62683786|NCT04970589|EXPERIMENTAL|Obese/Probiotics|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
62683787|NCT04989517|EXPERIMENTAL|AT193|Topical applied daily
62683788|NCT04989517|PLACEBO_COMPARATOR|Placebo|Topical applied daily
62683789|NCT00410436|EXPERIMENTAL|Resistance Training Group|Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM).
62683790|NCT00410436|ACTIVE_COMPARATOR|Control Group|Subjects will not be performing resistance exercise but will continue performing aerobic exercise at the same volume, duration and intensity as they did at baseline.
62683791|NCT05240976|EXPERIMENTAL|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
62683792|NCT05240976|PLACEBO_COMPARATOR|NMDAE plus Placebo|An NMDA enhancer plus Placebo
62683793|NCT06634160||Study population|The study population must correspond to the research inclusion criteria. A fibroscan will be performed on each patient enrolled in the study. Each participant will also be offered a biological sample for an ancillary study.
62683794|NCT05500131||Experimental group|All participants allowed three practice trials for each test in this order: the Weight-bearing lunge test and the Single-leg squat test. Both of them were evaluated through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain)
62683795|NCT04256538||Crohn's Disease Group|Patients are diagnosed as Crohn's disease and have no history of colectomy.
62683796|NCT04256538||Ulcerative Colitis Group|Patients are diagnosed as ulcerative colitis and have no history of colectomy.
62683797|NCT04256538||Healthy Control Group|Individuals that have no past medical history.
62683798|NCT06501183|EXPERIMENTAL|Anti-CDH17 CAR-T cells|Anti-CDH17 CAR-T cells
62313314|NCT04590729|EXPERIMENTAL|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 15 minutes for 3 hours to match the total exercise duration in the first protocol.
62683799|NCT02370147|EXPERIMENTAL|Smoking reduction intervention arm|Smoking reduction intervention arm (SRI) consisting of a minimal face-to-face individual smoking reduction intervention lasted for about one minute, and five follow-up interventions lasted for about one minute each.
62683800|NCT02370147|ACTIVE_COMPARATOR|Control arm|Control arm (UC) consisting of a brief face-to-face individual exercise and dietetic advices lasted for the same intervention time as SRI, and five follow-up interventions lasted for about one minute each with different intervention contents.
62683801|NCT01724385|EXPERIMENTAL|intravitreal bevacizumab injection|intravitreal injection of bevacizumab 1.25 mg
62313315|NCT04590729|NO_INTERVENTION|Sitting|Sitting control.
62683802|NCT01887600|EXPERIMENTAL|Roxadustat|Participants received roxadustat according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for at least 52 weeks up to a maximum of 104 weeks.
62123498|NCT05426317|OTHER|Metastatic solid tumor treated with first line therapeutic of Immune Checkpoint Inhibitor|"* The determinations of soluble PDL1 and serum B2M will be taken by blood sample at diagnosis and then every 3 months for 1 year, during a consultation or treatment in an outpatient hospital.~* The measurement of the tumor PDL1 level at diagnosis will be carried out by immunohistochemistry in the anatomopathology department of Clermont Ferrand University Hospital on the tumor sample that allowed the diagnosis, which does not add an additional sample for the patient.~* Clinical and imaging examinations will be those conventionally carried out in the context of patient monitoring, the data will only be recorded in the patients' medical files."
62477859|NCT05637125|ACTIVE_COMPARATOR|Group B|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks.
62313316|NCT03488940|ACTIVE_COMPARATOR|24-hours group|"The septic patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
62313317|NCT03488940|EXPERIMENTAL|16-hours group|"The septic patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
61923482|NCT02545231|ACTIVE_COMPARATOR|Low dose 1mg pitavastatin|pitavastatin 1mg which is considered low dose statin will be administered for 36 months
62313318|NCT03488940|EXPERIMENTAL|intermittent group|"The septic patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
62683803|NCT01887600|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received matching placebo for at least 52 weeks up to a maximum of 104 weeks.
62683804|NCT04112368|EXPERIMENTAL|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
61923483|NCT02545231|ACTIVE_COMPARATOR|High dose 4mg pitavastatin|pitavastatin 4mg which is considered high dose statin will be administered for 36 months
61923484|NCT04661969||1|Foreign Substance disseminated to both lower extremities and buttocks
61923485|NCT04661969||2|Foreign Substance isolated to buttocks with moderate to severe skin changes
62123499|NCT06502353|EXPERIMENTAL|All participants (single arm)|Each patient will be given the device, BLOOM43, for use at home. It will be worn in a patient's existing bra over their right breast and the preconditioning protocol will be done 12 hours before surgery - i.e. the evening before. Patients will then attend their breast surgery the next day as planned.
62313319|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg|olmesartan medoxomil 20mg / amlodipine besylate 5 mg / hydrochlorothiazide 12.5mg
62313320|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg|
62313321|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg|
62313322|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg|
62313323|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg|
62313324|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine 20mg/5mg|olmesartan medoxomil 20mg / amlodipine besylate 5mg
62313325|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine 40mg/5mg|
61923486|NCT04661969||3|Foreign substance isolated to lower legs with mild skin changes and superficial ulcerations
62313326|NCT00923091|EXPERIMENTAL|olmesartan/amlodipine 40mg/10mg|
62313327|NCT02158221|ACTIVE_COMPARATOR|Migraine patients with high genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
62123500|NCT05949242|ACTIVE_COMPARATOR|OMNI canaloplasty with cataract surgery|participant will undergo OMNI canaloplasty with cataract surgery in one randomized eye
62123501|NCT05949242|ACTIVE_COMPARATOR|OMNI canaloplasty and Hydrus with cataract surgery|participant will undergo OMNI canaloplasty and Hydrus with cataract surgery in the contralateral eye
62123502|NCT06664762|ACTIVE_COMPARATOR|Left lateral position during colonoscopy|
62477860|NCT05649683|OTHER|Analysis of blood cytokine|"Patients will receive anti-PD1 therapy (Nivolumab/Nivo) with anti-CTLA4 therapy (Ipilimumab/Ipi) as part of routine care, as per the MA scheme followed in case of efficacy and good tolerance of Nivolumab maintenance treatment alone. The functional test for cytokines (1ml total blood on lihtium heparinate) will be performed at the initiation of ICI (J0), at week 6 (S6, after the 2nd cure), at week 11 (S11= 1st radiological evaluation, after the 4 cures of Nivo+Ipi), and, if applicable, the progression of the disease and/or the occurrence of an ESi grade 3-4. Stimulated lymphocytes from non-therapy responders will be tested in vitro by various immunomodulatory drugs.~During each sampling we will also collect 5 ml of serum on dry tube for serological constitution, 3ml on EDTA tube for performing an immunophenotyping (T, B, NK) and 3ml on EDTA tube for freezing total PBMC and setting up a biobank."
62477861|NCT04266340|PLACEBO_COMPARATOR|placebo|no premedication
62123503|NCT06664762|ACTIVE_COMPARATOR|Supine position during colonoscopy|
62477862|NCT04266340|EXPERIMENTAL|oralmidazolam|0.5 mg/kg oral midazolam group
62477863|NCT04266340|EXPERIMENTAL|intravenous midazolam|0.05 mg/kg intravenous injection midazolam group
62123504|NCT06373549||Patients with coronary artery bypass surgery due to coronary artery disease|From the patients included in the study, blood samples will be taken from the systemic venous circulation before the operation, and from the coronary sinus at 4 minutes before and after the cross-clamp, via a retrograde cardioplegia cannula into yellow capped gel tubes.
62313328|NCT02158221|ACTIVE_COMPARATOR|Migraine patients with low genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
61923487|NCT04661969||4|Foreign substance isolated to lower legs with moderate to severe skin changes and/or ulceration
61923488|NCT01097798|EXPERIMENTAL|Aliviador|
62123505|NCT06373549||Patients who underwent heart valve surgery without coronary artery disease|From the patients included in the study, blood samples will be taken from the systemic venous circulation before the operation, and from the coronary sinus at 4 minutes before and after the cross-clamp, via a retrograde cardioplegia cannula into yellow capped gel tubes.
62683805|NCT04112368|PLACEBO_COMPARATOR|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
62683806|NCT05272176|EXPERIMENTAL|Coping Long Term with Active Suicide Program (CLASP)|"The CLASP intervention is an adjunctive, telehealth-based behavioral intervention designed to reduce suicidal behavior among individuals at high risk for suicide going through periods of transition. CLASP is designed to intervene on four risk factor targets: ongoing treatment engagement, problem-solving, social and family support, and hopelessness. In addition to these general factors, the CLASP provider also has the flexibility to identify and target certain patient-specific risk factors (e.g., substance misuse) for intervention.~CLASP will begin after completion of the baseline assessment, and will continue for 6 months post-discharge. CLASP will be comprised of: a) 3 initial sessions while participants are still inpatients (can occur post-discharge if needed); b) 12 brief telehealth sessions over 6-months post-discharge; c) 6 brief SO telehealth sessions."
62683807|NCT05272176|NO_INTERVENTION|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided as part of routine care in the Veterans Health Administration (VHA) following inpatient hospitalization. Study staff will provide no additional treatment in this arm.
62313329|NCT04224558|EXPERIMENTAL|HSCT after mobilization and conditioning|"Mobilization and leukopheresis allow for stem cell harvest. Then conditioning is provided prior to stem cell transplantation, followed by post-transplant conditioning.~Interventions include:~1. Stem cell mobilization~2. Leukopheresis~3. Preparative regimen~4. Peripheral blood stem cell infusion~5. Post-PBSC infusion conditioning"
62477864|NCT04266340|EXPERIMENTAL|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
62683808|NCT05071027|EXPERIMENTAL|App Medication Reminder Group|Patients in this group will receive dual antiplatelet medication reminders.
62683809|NCT05071027|NO_INTERVENTION|Non-app Using Group|Patients in this group receive the same standard of care \[i.e. endovascular stent-based treatment of unruptured aneurysms\] as the other group, but do not receive app dual antiplatelet reminders.
62683810|NCT05856747|EXPERIMENTAL|TBP-PI-HBr 600 mg|Healthy participants meeting eligibility criteria will receive a single oral dose of TBP-PI-HBr 600 mg tablets (2 x 300 mg) on Day 1 under fasted conditions.
62683811|NCT02573896|EXPERIMENTAL|NK cells with Dinutuximab & Lenalidomide|Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of dinutuximab on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
62683812|NCT00551993|ACTIVE_COMPARATOR|2|Robotic Sacral Colpopexy
62683813|NCT00551993|ACTIVE_COMPARATOR|1|Laparoscopic Sacral Colpopexy
61923489|NCT01097798|ACTIVE_COMPARATOR|Gelol|
61923490|NCT06519110|EXPERIMENTAL|(Trial group)-Neratinib tablets|"The subjects enrolled in the study will take Neratinib tablets orally as follows: 120mg in the 1st week, 160mg in the 2nd week, and 240mg from the 3rd week until the end of treatment (starting from C1D15 to the end of treatment). During the Neratinib treatment period, loperamide will be administered on an as-needed basis based on the condition of diarrhea.~Neratinib tablets should be taken orally once daily, with the tablet to be swallowed whole with a meal, without crushing, breaking, or chewing. A continuous 28-day medication period constitutes one treatment cycle."
62123506|NCT05878158|ACTIVE_COMPARATOR|simvastatin|Drug The drug powder will be mixed with distilled water to form a paste applied in the pup chamber of immature permanent molars over the pulp stump
62123507|NCT05878158|EXPERIMENTAL|Mineral Trioxide Aggregate|Dental material It is a regenrative endodontic material prepared as apoweder that mixed with distilled water to form a paste applied in the pup chamber of immature permanent molars over the pulp stump
62123508|NCT04906161||Successful dental implant|Patients showed a successful implant placement with no complications before loading
62123509|NCT04906161||Early dental implant failure|Early complications and failure of dental implant before loading
62683814|NCT01951729|EXPERIMENTAL|Pre-diabetes|Otherwise healthy individuals exhibiting hemoglobin A1c levels between 6.0% - 7.0%
62683815|NCT06690684||PCI in patients with acute myocardial infarction|
62683816|NCT00044122||Adult Relatives|Relatives of patient with mastocytosis
62683817|NCT00044122||Adults with Mastocytosis|Adults with documented mastocytosis
62683818|NCT00044122||Pediatric Patients with Mastocytosis|Pediatric patients with documented mastocytosis
62683819|NCT00044122||Pediatric Relatives|Pediatric relatives of patients with mastocytosis
62313330|NCT06671444|EXPERIMENTAL|Group A: Severe Renal Impairment|
62313331|NCT06671444|EXPERIMENTAL|Group B: Normal Renal Impairment|
62313332|NCT05574816|ACTIVE_COMPARATOR|Patient without breast lump|No breast lump identified during mammography (ACR 1 et 2 Birads classification)
62477865|NCT00748072|PLACEBO_COMPARATOR|Saline solution|patients treated with 1 ml of s.c. saline solution
61923491|NCT03901898|EXPERIMENTAL|Training, audit, and reminders|An investigator will deliver a 20-30-minute briefing on intervention delivery to all staff at participating practices, followed by one-on-one audit training (1 hour) with the staff member responsible for conducting the audit. Each practice conducts an audit of their patients with diabetes to identify all people who have not attended retinopathy screening with the national programme. At 6 months, practices conducts a re-audit. Practice staff add electronic alerts to the records of eligible patients, to prompt GPs and nurses to remind patients. Practices are reimbursed at study entry with further payment following intervention cessation based on number of patients audited. Face-to-face verbal reminders are delivered by GPs and practice nurses to eligible patients attending for an appointment during the study period. All eligible patients receive a reminder phone call from a practice nurse and a GP-endorsed reminder letter accompanied by an information leaflet.
61923492|NCT03901898|OTHER|Wait list control|In control practices, the intervention will be delivered after 6 months. For the audit, administrators or practice nurses will use date restricted data extraction from the electronic medical record to capture data for the 12-month period prior to the intervention (study baseline) and 6 months after the study intervention period, during which they will have acted as control practices (follow-up). This will satisfy the baseline data collection prior to the delivery of the intervention to this group on study completion. This approach was chosen as collecting data at baseline (i.e. 6 months before intervention start) would constitute an intervention in those practices; knowledge of non-attenders would lead to a change in usual care as the control group would likely follow up patients immediately. Control practices will receive the same supports and training as intervention practices.
62683820|NCT06686290|EXPERIMENTAL|Post Isometric Relaxation Technique|Postisometric relaxation will be performed with the frequency of 5 times, such that it includes 30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold.
62683821|NCT06686290|EXPERIMENTAL|Static Stretching|Stretching exercise will be performed with 30 second hold and with 5 repetitions. All Exercises will be performed 3 times per week for total of 4 weeks.
62683822|NCT05751941|EXPERIMENTAL|Sipuleucel-T with NHA|Participants will continue taking New Hormonal Agents (NHA) while receiving sipuleucel-t as standard of care.
62683823|NCT05751941|EXPERIMENTAL|Sipuleucel-T without NHA|Participants will discontinue use of New Hormonal Agents (NHA) while receiving sipuleucel-t as standard of care.
62683824|NCT05513170|ACTIVE_COMPARATOR|Closed sinus lift using Densah bur|Closed sinus lifting will be performed using densah burs and then dental implants will be placed.
62683825|NCT05513170|ACTIVE_COMPARATOR|Conventional closed sinus lift using osteotomes|Sinus lifting will be performed using osteotomes and then dental implants will be placed.
62683826|NCT04389632|EXPERIMENTAL|Part A: Dose escalation|sigvotatug vedotin monotherapy
62683827|NCT04389632|EXPERIMENTAL|Part B: Dose expansion|sigvotatug vedotin monotherapy
62683828|NCT04389632|EXPERIMENTAL|Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC|sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
62683829|NCT04389632|EXPERIMENTAL|Part D: sigvotatug vedotin combination therapy in 1L NSCLC|sigvotatug vedotin + pembrolizumab +/- (carboplatin)
62683830|NCT04389632|EXPERIMENTAL|Part D: sigvotatug vedotin combination therapy in 1L HNSCC|sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
62683831|NCT05689736|EXPERIMENTAL|Motivational Enhancements + Simplification + Gamification + Low Engagement Nudge|Participants will receive the Core Essentials for Parenting (EFP) intervention and all additional engagement-focused intervention elements: motivational enhancements, simplification, gamification, and low engagement nudges.
62683832|NCT05689736|EXPERIMENTAL|Motivational Enhancements + Simplification + Gamification|Participants will receive the Core EFP intervention and motivational enhancement, simplification, and gamification intervention elements.
62683833|NCT05689736|EXPERIMENTAL|Motivational Enhancements + Simplification + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement, simplification, and low engagement nudges as intervention elements.
62683834|NCT05689736|EXPERIMENTAL|Motivational Enhancements + Simplification|Participants will receive the Core EFP intervention and motivational enhancement and simplification as intervention elements.
62683835|NCT05689736|EXPERIMENTAL|Motivational Enhancements + Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement, gamification, and low engagement nudge as intervention elements.
62683836|NCT05689736|EXPERIMENTAL|Motivational Enhancements + Gamification|Participants will receive the Core EFP intervention and motivational enhancement and gamification as intervention elements.
62683837|NCT05689736|EXPERIMENTAL|Motivational Enhancements + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement and low engagement nudge as intervention elements.
62683838|NCT05689736|EXPERIMENTAL|Motivational Enhancements|Participants will receive the Core EFP intervention and motivational enhancement as an additional intervention element.
62683839|NCT05689736|EXPERIMENTAL|Simplification + Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and simplification, gamification, and low engagement nudge as additional intervention elements.
62683840|NCT05689736|EXPERIMENTAL|Simplification + Gamification|Participants will receive the Core EFP intervention and simplification and gamification as additional intervention elements.
62683841|NCT05689736|EXPERIMENTAL|Simplification + Low Engagement Nudge|Participants will receive the Core EFP intervention and simplification and low engagement nudge as intervention elements.
62683842|NCT05689736|EXPERIMENTAL|Simplification|Participants will receive the Core EFP intervention and simplification as an additional intervention element.
62683843|NCT05689736|EXPERIMENTAL|Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and gamification and low engagement nudge as additional intervention elements.
62683844|NCT05689736|EXPERIMENTAL|Gamification|Participants will view the Core EFP and will be exposed only to gamification as an additional intervention element.
62683845|NCT05689736|EXPERIMENTAL|Low Engagement Nudge|Participants will receive the Core EFP intervention and low engagement nudge as an additional intervention element.
62683846|NCT05689736|EXPERIMENTAL|EFP Only|Participants will receive the Core EFP intervention and not be exposed to any additional intervention elements.
62683847|NCT06668220|ACTIVE_COMPARATOR|Group A: 25 patients will receive caudal block with 1 ml/kg bupivacaine 0.25% and dexmedetomidine 0.|
62477866|NCT00748072|EXPERIMENTAL|DDAVP|treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy
62313333|NCT05574816|EXPERIMENTAL|Patient with breast lump|Suspicious breast lump identified during mammography (ACR 4b, c ou ACR 5 Birads classification)
61923493|NCT05469204|OTHER|Healthy transgender adults|Healthy transgender adults will be studied on two separate study days and serve as their own control.
62477867|NCT02237820|EXPERIMENTAL|Dexamethasone|
61923494|NCT01539668||Pap sampling|Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
62477868|NCT02237820|ACTIVE_COMPARATOR|Prednisone|
62477869|NCT05013463|EXPERIMENTAL|Hydroxychloroquine and Indapamide|Oral Hydroxychloroquine, 200mg BID Oral Indapamide, 2.5 mg OD
62477870|NCT05320146||CORT118335-860 Participants|This group will include patients who participated in CORT118335-860 study and received at least one dose of miricorilant.
62477871|NCT05320146||CORT118335-861 Participants|This group will include patients who participated in CORT118335-861 study and received at least one dose of miricorilant.
62477872|NCT01101022|ACTIVE_COMPARATOR|SPD489|
61923495|NCT01049477|EXPERIMENTAL|Music therapy|Experimental arm includes women undergoing cesarean section delivery listening to music before and after c/s. STAI will be completed pre and post operatively.
61923496|NCT01049477|NO_INTERVENTION|No music group|Subjects will not listen to music before and after c/s. STAI will be completed pre and post operatively.
61923497|NCT02763761|EXPERIMENTAL|Infliximab + Prednisone|Infliximab intravenous solution (single dose) + low dose prednisone per oral for 18 days
62477873|NCT01101022|PLACEBO_COMPARATOR|Placebo|
62477874|NCT01065740|EXPERIMENTAL|patient education|individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
62477875|NCT01065740|NO_INTERVENTION|Usual care|
62477876|NCT00706277|ACTIVE_COMPARATOR|TIVA|patients receiving total intravenous anesthesia (TIVA)
62477877|NCT00706277|ACTIVE_COMPARATOR|balanced|patients receiving balanced anesthesia
62683848|NCT06668220|ACTIVE_COMPARATOR|Group B: 25 patients will receive caudal block with 1 ml/kg bupivacaine 0.25% and dexmedetomidine 1|
62313334|NCT02207192||Morbidly obese|Consecutive morbidly obese adults (BMI over or equal to 40 kg/m2) scheduled for bariatric surgery were prospectively recruited.Subjects with respiratory and cardiac history (asthma, Chronic obstructive pulmonary disease, heart failure) were excluded.
62477878|NCT00636545|EXPERIMENTAL|Part 1|Cohort 1- Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a dose of 300 mg to the first subject enrolled and, in the absence of dose-limiting toxicity, in increasing increments of 100 mg to each successive subject enrolled to a maximum dose of 1000 mg.
62477879|NCT00636545|EXPERIMENTAL|Part 2|Genasense will be administered as a 2-hour intravenous infusion twice weekly for 3 weeks at a dose established based on Part 1 of the study.
62683849|NCT06480461|EXPERIMENTAL|8.0×10^11 vg|3 subjects on 8.0×10\^11 vg for at least 4 weeks post infusion
62477880|NCT00636545|EXPERIMENTAL|Cohort 2|Also in Part 1 of the study, Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a starting dose of 1100 mg and increasing in increments of 100 mg to the MTD. Patients will be pretreated with a corticosteroid.
62477881|NCT00181805||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
62683850|NCT06480461|EXPERIMENTAL|1.6×10^12 vg|3 subjects on 1.6×1012 vg for at least 4 weeks post infusion
62683851|NCT06480461|EXPERIMENTAL|3.2×10^12 vg|3 subjects on 3.2×1012 vg for at least 4 weeks post infusion
62683852|NCT05668507|EXPERIMENTAL|REACHOUT|The REACHOUT intervention arm will receive access to the REACHOUT mobile app through which they will be able to review profiles of Peer Supporters and connect with one of their choosing. They will also have access to the other app features including a 24/7 chat room and face-to-face support via virtual happy hours. Participants will complete questionnaires (baseline, 1 month, 3 months, 6 months) and a blood draw (baseline and 6 months). Monetary compensation will be provided for their time and effort.
62477882|NCT00181805||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
62477883|NCT00529464|EXPERIMENTAL|Colposcopy|Colposcopy - a direct magnified inspection of cervix
62477884|NCT00529464|EXPERIMENTAL|Colposcopy + Fluorescence Spectroscopy|Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
62683853|NCT05668507|NO_INTERVENTION|Wait-list|The wait-list control group will receive access to the mobile app/support program after six (6) months. They will complete questionnaires and a blood draw at baseline and 6 months. Monetary compensation will be provided for their time and effort.
62123510|NCT01606124|EXPERIMENTAL|Arm I (Green Tea Catechin Extract)|Patients receive Polyphenon E PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
62477885|NCT00529464|EXPERIMENTAL|Colposcopy + LEEP Procedure|Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.
62477886|NCT01469351|ACTIVE_COMPARATOR|Drug|the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
62477887|NCT01469351|PLACEBO_COMPARATOR|placebo|non active intervention
62477888|NCT03525639|EXPERIMENTAL|Patients with Acute Myocarditis|Patients undergoing Cardiac Magnetic Resonance at baseline, 2 month, 1 year.
62477889|NCT00836849|EXPERIMENTAL|1|
62477890|NCT00836849|ACTIVE_COMPARATOR|2|
62477891|NCT06057727|NO_INTERVENTION|Control|Clinics randomized to the control arm will receive standard of care.
61923498|NCT02763761|EXPERIMENTAL|Methylprednisolone + Prednisone|Methylprednisolone intravenous solution (single dose) + high dose prednisone per oral for 40 days
62123511|NCT01606124|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
62123512|NCT02342210|OTHER|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
62123513|NCT02342210|OTHER|Group-B - Delayed Intervention|3 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP).
62123514|NCT06238869|EXPERIMENTAL|Computerized Cognitive Behavioral Therapy (CCBT)|The experimental group received a 4-week CCBT intervention, which consisted of completing 3 modules every week, each taking roughly 20 minutes.
62123515|NCT06238869|EXPERIMENTAL|Music Therapy(MT)|All the participants of Music Therapy will be treated with 12 sessions (3 sessions per week),15 minutes each time, and conducted for 4 weeks.
62313335|NCT05828940|PLACEBO_COMPARATOR|placebo|microcellulose
62313336|NCT05828940|EXPERIMENTAL|losartan|50mg losartan (Cozaar)
62313337|NCT04046484|ACTIVE_COMPARATOR|Normal Saline (Dose: Equal volume) + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
62313338|NCT04046484|EXPERIMENTAL|PMZ-1620 + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
62683854|NCT06290687|EXPERIMENTAL|Cisplatin Eligible Participants|"Participants who are deemed eligible for cisplatin-based NAC will undergo:~* Standard of care neoadjuvant systemic therapy (currently cisplatin-based chemotherapy in cisplatin-eligible participants)~* Partial cystectomy with extended pelvic lymph node dissection~* Standard of care adjuvant systemic therapy in eligible patients"
62683855|NCT06290687|EXPERIMENTAL|Cisplatin Ineligible Participants|"Participants who are deemed ineligible for cisplatin-based NAC will undergo:~* Partial cystectomy with extended pelvic lymph node dissection~* Standard of care adjuvant systemic therapy in eligible participants"
62683856|NCT03747263|EXPERIMENTAL|Individual Freeze-Catheter ablation|"The individualized time-to-effect protocol utilizing the AFA-Pro applies a freeze-cycle until documentation of PVI based on continuous real-time recordings from the Achieve catheter inside the PV. After documentation of PVI the freeze-cycle is prolonged for additional 90 seconds. If no PVI is achieved after 90 seconds or a temperature of -\<30° is not reached after 40 seconds the freeze cycle is stopped, the cryoballoon will be repositioned to possibly achieve a better position. Afterwards the freeze-cycle will be restarted. If no real-time PV signal recording can be obtained, a standard freeze-cycle of 180 seconds is applied. No bonus-freeze-cycle is applied in this protocol."
62683857|NCT03747263|ACTIVE_COMPARATOR|Fixed Freeze-Catheter ablation|The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
62683858|NCT00842465||1|benign breast diseases
62683859|NCT00842465||2|breast cancer
62313339|NCT04745832|EXPERIMENTAL|Rituximab plus Zandelisib|Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
62313340|NCT04745832|EXPERIMENTAL|Rituximab plus chemotherapy|Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles
62313341|NCT06318923|OTHER|Multiple sclerosis patients|MS patients with the relapsing-remitting form (RRMS) and Expanded Disability Status Scale (EDSS) ≤ 4
62313342|NCT06318923|OTHER|Control participants|Patients without global cognitive impairment
62313343|NCT00492622|EXPERIMENTAL|Immediate-release omeprazole release first|subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
62123516|NCT06238869|EXPERIMENTAL|Health education|The health education group will conduct a series of mental health lectures through the WeChat Mini Program on a weekly basis, with each session lasting for 30 minutes, spanning over a duration of four weeks.
62123517|NCT06238869|NO_INTERVENTION|Blank Control Group|All the participants in this group receive no intervention and undergo only psychological health screenings at designated time points.
62313344|NCT00492622|EXPERIMENTAL|Delayed-release omeprazole first|subjects receive delayed release omeprazole for 7 days then immediate release for 7 days
62313345|NCT00729430|EXPERIMENTAL|Omega-3 Fatty Acids|Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
62313346|NCT00729430|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo for 6 months.
62313347|NCT01507545|ACTIVE_COMPARATOR|MORAb-004|
62313348|NCT01507545|PLACEBO_COMPARATOR|Placebo|
62683860|NCT00842465||3|control
62313349|NCT04050007|EXPERIMENTAL|1|Preventive initiation of fluid removal
62313350|NCT04050007|OTHER|2|Curative initiation of fluid removal
62313351|NCT02227212|EXPERIMENTAL|Insulin glargine U300|Once daily subcutaneous injection for 4 weeks
62313352|NCT04634968|EXPERIMENTAL|intervention group|The interactive Brief MI-based text message communication via instant messaging apps (e.g., WhatsApp, WeChat) will be applied in the intervention group. The chatting function of WhatsApp and WeChat will be used as the intervention platform. The intervention will start on the first day after the participants join the follow-up group. The whole interactive text-communication intervention lasts for 1 month. The frequency of message communication will be at least twice a week. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
62683861|NCT06054178|EXPERIMENTAL|Fluorescein sodium during surgery|Subjects undergoing parotid surgery for benign conditions will have fluorescein sodium administered intravenously after induction, and fluorescence imaging will be performed to visualize nerves intraoperatively
61923499|NCT01654796|ACTIVE_COMPARATOR|Low Field Magnetic Stimulation|Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
61923500|NCT01654796|PLACEBO_COMPARATOR|Sham (LFMS)|Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
62683862|NCT06361446|EXPERIMENTAL|zonisamide and Acetaminophen arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive zonisamide 50 mg twice daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
61923501|NCT01654796|OTHER|Crossover Arm|Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
61923502|NCT06309537||HFpEF|symptomatic patients with heart failure with preserved ejection fraction
61923503|NCT06309537||asymptomatic PH-LHD|asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of pulmonary hypertension
61923504|NCT06309537||healthy volonteers|
61923505|NCT04991428|EXPERIMENTAL|Active trancranial direct current stimulation|Active stimulation for 15 minutes
61923506|NCT04991428|SHAM_COMPARATOR|Sham stimulation|Similar set-up but no actual stimulation
61923507|NCT05585788|OTHER|Addinex system|The Addinex system is designed to dispense opioid medication to patients on a provider-determined schedule, to track patient use of the device, and to allow for return and disposal of unused opioids. This study will determine the feasibility of using Addinex for these purposes.
61923508|NCT03300648|NO_INTERVENTION|Usual care|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees
61923509|NCT03300648|EXPERIMENTAL|Mechanical ventilation|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intubation and mechanical ventilation for a maximum of 7 days
61923510|NCT03300648|EXPERIMENTAL|Hypertonic saline|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days
61923511|NCT05274659|ACTIVE_COMPARATOR|KJ103 dose group 1|KJ103 single dose
61923512|NCT05274659|ACTIVE_COMPARATOR|KJ103 dose group 2|KJ103 single dose
61923513|NCT05274659|ACTIVE_COMPARATOR|KJ103 dose group 3|KJ103 single dose
62683863|NCT06361446|EXPERIMENTAL|Propranolol and Acetaminophen group|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive propranolol 160 mg once daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62313353|NCT04634968|PLACEBO_COMPARATOR|control group|The participants in the control group will receive general health communication twice every week via SMS. The communication lasts for 1 month. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
62683864|NCT05353751|EXPERIMENTAL|Kind Minds Program -Family|In the Family condition (KMP-Fam), both caregiver and adolescent will receive the KMP intervention via an online mindfulness program, augmented by weekly video conference support from a Community Health Worker (CHW) Kindness Coach
62683865|NCT05353751|ACTIVE_COMPARATOR|Kind Minds Program -Teen Only|In the Teen-Only condition (KMP-TO), only the adolescent will receive the KMP intervention via an online mindfulness program augmented by weekly video conference support from a CHW Kindness Coach.
61923514|NCT05274659|ACTIVE_COMPARATOR|KJ103 dose group 4|KJ103 single dose
62683866|NCT06543381|EXPERIMENTAL|Treatment (olutasidenib)|Starting 50-120 days after transplant, patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection on study.
62683867|NCT05904548|EXPERIMENTAL|Vision-MR Atrial Flutter Ablation|Type 1 Atrial Flutter ablation performed in the iCMR with the Vision-MR Ablation Catheter 2.0 and associated Advantage-MR EP recorder and stimulator system.
62683868|NCT04250402||Arm 1|"Endoscopic submucosal dissection. Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.~Other Name: ESD"
62683869|NCT04250402||Arm 2|"Distal subtotal gastrectomy with D2 lymphadenectomy. After exclusion of T4b, bulky lymph nodes, or distant metastasis case, distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally."
61923515|NCT05274659|ACTIVE_COMPARATOR|KJ103 dose group 5|KJ103 single dose
61923516|NCT05274659|PLACEBO_COMPARATOR|Matching placebo for each dose group|placebo, single dose
61923517|NCT04061473|PLACEBO_COMPARATOR|Pancreatectomized + Placebo|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 placebo tablets will be administered orally."
61923518|NCT04061473|ACTIVE_COMPARATOR|Pancreatectomized + DPP-4 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 DPP4-inhibitor tablets will be administered orally."
62313354|NCT02235285|EXPERIMENTAL|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
62683870|NCT04250402||Arm 3|Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
62313355|NCT03096028||PMNS cohort|The Pune Maternal Nutrition Study (PMNS) is a preconceptional birth cohort established in 1993 at Diabetes unit KEM hospital research center, Pune. 700 offsprings of the cohort are being followed every 6 years. Maternal vitamin B12 folate level during pregnancy were measured at 18 \& 28 weeks.
62313356|NCT06671951|EXPERIMENTAL|Vibration group|The vibration group receives an intervention with focal vibration heads from Wintecare on the rectus femoris, vastus lateralis and vastus medialis , at the same time that the athelte is doing active muscle contractions.
62313357|NCT06671951|SHAM_COMPARATOR|Sham group|The placebo group receives the same protocol but the head of the focal vibration machine is not in contact with the patient's skin.
62313358|NCT05087823|EXPERIMENTAL|Lipid, Glucose, and Mixed Meal Challenges|Participants will take part in three different meal challenges on three separate days with approximately two weeks in between. The first meal challenge is the lipid challenge, the second meal challenge is the glucose challenge and third meal challenge is the mixed-meal challenge.
62313359|NCT06016621|NO_INTERVENTION|Support as usual control Group|Participants allocated to 'support as usual' will receive routine support from their general practitioners (GPs), mental health and education/allied health professionals. Support as usual is defined as normal practice for each school in addition to the usual support from the specialist teaching teams for autism in the area, or any other additional therapies intended to support communication skills or wellbeing for autistic children. They will not receive the individual music therapy intervention or any extra support services from the research team. Any concomitant treatment or therapeutic interventions that participating children might receive will be recorded during assessment sessions before randomisation, and following the primary endpoint, specifying the kind and amount or frequency of intervention.
62313360|NCT06016621|EXPERIMENTAL|Improvisational Music Therapy|Participating children randomised to the Improvisational Music Therapy (intervention) Group will receive 30-minute individual music therapy sessions two times per week over a 12-week period. These will be delivered by academically trained Health and Care Professions Council (HCPC)-registered music therapists in the United Kingdom (master's level or equivalent) with clinical experience of working with autistic children. Each child in the intervention arm will receive 24 sessions of music therapy over a 12-week period. A music therapy training manual will be used to guide music therapists.
62683871|NCT04250402||Arm 4|Proximal gastrectomy with D2 lymphadenectomy. The type of reconstruction will be jejunal interposition with double anastomosis method.
62683872|NCT01575548|EXPERIMENTAL|Arm A (Pazopanib)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the study.
62683873|NCT01575548|PLACEBO_COMPARATOR|Arm B (Placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the study.
62683874|NCT05940649|EXPERIMENTAL|Continuous norepinephrine administration|
62683875|NCT05940649|NO_INTERVENTION|Bolus norepinephrine administration|
62683876|NCT02006836|OTHER|Diabetic|Diabetic patients use metformin or only on diet control(met or diet).18 of the patients were on metformin treatment and 2 patients were on diet control due to the early stage of this disease. On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of diabetic patients enrolled for the case control period.
62683877|NCT02006836|OTHER|Healthy|On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of volunteers enrolled for the case control period.
62123518|NCT06677255|EXPERIMENTAL|VUM02 Injection (UC-MSCs)+BAT|"In Phase I, subjects receive 3 sequential IV dose levels of VUM02 Injection (UC-MSCs):~* Phase Ia, single-dose escalation: 1x10\^6 cells/kg, or, 2x10\^6 cells/kg, or, 3x10\^6 cells/kg, single dose;~* Phase Ib, multiple-dose escalation: 1x10\^6 cells/kg, or, 2x10\^6 cells/kg, or, 3x10\^6 cells/kg, twice a week for 4 weeks, a total of 8 times.~Phase II is the dose-expansion study:~Two dose levels will be selected by the investigator and the sponsor according to the results of the Phase 1b study, with IV of VUM02 Injection twice a week for 4 consecutive weeks for a total of 8 doses.~* Study group 1: VUM02-dose 1 + BAT~* Study group 2: VUM02-dose 2 + BAT"
62123519|NCT06677255|OTHER|The control group with Best available therapy|"It is the control group of Phase II study to receive only the best available therapy (BAT).~According to BAT scheme, the drug regimen is determined by PI based on the condition of the patients."
62313361|NCT03245476|ACTIVE_COMPARATOR|manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
62313362|NCT03245476|ACTIVE_COMPARATOR|education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
62683878|NCT02006836|OTHER|Diabetic 2 - without pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 4th to 6th day with a constant dose of insulin and did not consumed Majia pomelos after meals, and this intervention was defined as blank.
61923519|NCT04061473|ACTIVE_COMPARATOR|Pancreatectomized + SGLT-2 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 SGLT-2 tablets will be administred orally."
61923520|NCT04061473|PLACEBO_COMPARATOR|Healthy + Placebo|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
62313363|NCT03260738|EXPERIMENTAL|"Robot Poppy group"|30 minutes of daily rehabilitation program (physical exercises dedicated to the mobility of the spine) supervised by Poppy robot during 3 weeks included in a 3hours daily (5 days a week) rehabilitation program.
62313364|NCT03260738|ACTIVE_COMPARATOR|Control group|Usual 3hours daily (5 days a week) rehabilitation program without robot during 3 weeks
62313365|NCT03370367|EXPERIMENTAL|Arm A|13-cis retinoic acid will be dispensed in 3.75 mg and 5 mg gelatin capsules. Take 2 capsules once a day for up to 2 years.
62313366|NCT03370367|PLACEBO_COMPARATOR|Arm B|Take 2 placebo pills once a day for up to 2 years.
62123520|NCT06204055|EXPERIMENTAL|Intramuscular Dry-Needling|(IMDN) is a minimally invasive procedure where a solid filament needle is inserted into a myofascial trigger point.
62313367|NCT00719173|EXPERIMENTAL|Arm I|Patients receive aprepitant 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving aprepitant, patients receive an infusion of cyclophosphamide on day 1. During course 2, patients crossover and receive treatment as in arm II.
62313368|NCT00719173|EXPERIMENTAL|Arm II|Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment as in arm I.
62683879|NCT02006836|OTHER|Diabetic 2 - with pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 7th to 9th day with a constant dose of insulin and consumed 100g Majia pomelos after meals (breakfast, lunch and dinner).
62123521|NCT06204055|SHAM_COMPARATOR|Sham Intramuscular Dry-Needling|). Park sham acupuncture needles (AcuPrime) will be used to perform sham needling for this group. The sham needle functions by allowing the blunted needle to cause a pricking sensation when pushed against the skin, but does not penetrate. This will allow the patient to perceive that the needle is entering the skin while also maintaining therapist-patient contact and interaction time
62313369|NCT02584621|EXPERIMENTAL|Check Yourself App With Feedback|Participants complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their visit with their health provider. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Health providers receive a summary report of health risk behaviors from Check Yourself prior to the visit.
62313370|NCT02584621|NO_INTERVENTION|Usual Care|Participants are asked to complete health risk screening questions on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
62313371|NCT02432092||Affected|participants with cardiomyopathy
62313372|NCT02432092||Family Members of affected|Family members of participants with cardiomyopathy (can be affected or unaffected)
62313373|NCT06511011|EXPERIMENTAL|mSZT-TBD granules|Modified Suan ZaoRen Tang-TianWang BuXin Dan granules
62313374|NCT06511011|PLACEBO_COMPARATOR|Placebo granules|Placebo granules
62313375|NCT00872898|EXPERIMENTAL|1|Once daily oral administration of memantine for 12 weeks.
62313376|NCT00872898|PLACEBO_COMPARATOR|2|Once daily oral administration of placebo for 12 weeks.
62313377|NCT02167204|EXPERIMENTAL|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
62313378|NCT01407562|EXPERIMENTAL|Pazopanib with paclitaxel and carboplatin|
62313379|NCT02734121|EXPERIMENTAL|Educational group intervention|The pre-consultation educational group intervention will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
62313380|NCT02734121|NO_INTERVENTION|Standard Care|Routine pre-consultation education
62313381|NCT05182203||JAK inhibitors|RA patients treated with JAK inhibitors
62313382|NCT05182203||TNF inhibitors|RA patients treated with TNF inhibitors
62313383|NCT04309721|EXPERIMENTAL|Perampanel|immediate enteral administration of Perampanel, 12 mg
62313384|NCT04309721|PLACEBO_COMPARATOR|Placebo|immediate enteral administration of placebo
62683880|NCT06690463|ACTIVE_COMPARATOR|Periarticular Lidocaine Injection|A 2.5 cc injection of 2% lidocaine will be administered to the periarticular area of the sacroiliac joint under ultrasound guidance
62683881|NCT06690463|ACTIVE_COMPARATOR|Intraarticular Lidocaine Injection|A 2.5 cc injection of 2% lidocaine will be administered to the articular area of the sacroiliac joint under ultrasound guidance
62683882|NCT06690463|ACTIVE_COMPARATOR|Periarticular and Intraarticular Lidocaine Injection|A total 5 cc injection of 2% lidocaine will be administered to the articular and periarticular areas of the sacroiliac joint under ultrasound guidance
62313385|NCT02165852|EXPERIMENTAL|Papillectomy without injection|Conventional snaring mucoal resection without submucosal injection
62313386|NCT02165852|ACTIVE_COMPARATOR|Papillectomy with injection|Conventional mucosal resction method following injeciton of diluted epinephrine mixture.
62313387|NCT05219279||HIV+ participants|"* HIV-infected between age of 20 and 65 years~* Consistently have plasma HIV RNA levels \<200 copies/mL for at least the last 12 months on a stable antiretroviral regimen with any changes made only for convenience, safety or simplicity."
62313388|NCT05219279||HIV- participants|25 age- and sex- matched HIV- subjects (healthy) will be recruited also at the UCLA Medical center who will undergo the neuroimaging examination.
62313389|NCT00990015|EXPERIMENTAL|PF-04308515|
62313390|NCT00990015|PLACEBO_COMPARATOR|Placebo|
62477892|NCT06057727|EXPERIMENTAL|Intervention Arm|Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be pre-visit text message reminders (standard messaging content). Clinician nudges will be monthly peer comparison feedback and default pended orders.
62477893|NCT06057727|EXPERIMENTAL|High Risk Intensification Arm|Patients in the intervention clinics identified as high risk for noncompletion of the flu vaccine will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.
62313391|NCT06253780||Cohort 1|Adult patients (age \> 18 years old) admitted to the NSICU at UT Southwestern Medical Center with a neurological, neurosurgical, or neurovascular diagnosis are eligible receiving Intravenous vasoactive medication infusing at the time of consent.
62313392|NCT01546220|NO_INTERVENTION|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
62313393|NCT01546220|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
62683883|NCT06542289|EXPERIMENTAL|BlinkER system treatment|A prospective single-arm multicenter pivotal study designed to evaluate the safety and effectiveness of the BlinkER System in achieving eyelid closure in participants with facial nerve palsy. Participants will receive the NeuroTrigger Basic System and use it for up to 3 months.
62683884|NCT01704989|ACTIVE_COMPARATOR|Laser pathway|Arm in which patients first randomised to receive SLT laser
62683885|NCT01704989|ACTIVE_COMPARATOR|Topical therapy|Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
62683886|NCT06689904|EXPERIMENTAL|Eye dilated with the nanodropper|For each participant, one eye (left or right) is randomly selected to be dilated with the Nanodropper.
62683887|NCT06689904|ACTIVE_COMPARATOR|Eye dilated with the standard bottle|Fellow eye is dilated with the standard eye drop bottle
61923521|NCT04061473|ACTIVE_COMPARATOR|Healthy + DPP-4 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
61923522|NCT04061473|ACTIVE_COMPARATOR|Healthy + SGLT-2 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
62123522|NCT06184152|OTHER|ILN Cohort|Patients with LR3 observations would undergo CEUS and AMRI every 6 months; patients with LR4 observations would undergo CEUS and AMRI 3 months after enrollment and every 6 months thereafter. CEUS and AMRI will preferably be done the same day to minimize burden on the patient, although will be permitted to be completed within 14 days of each other. This interval is sufficiently short to minimize the chance of intervening events. AMRI and CEUS will be performed every 3-6 months until HCC development, regression to LR-1 or LR-2 (i.e., definitely or likely benign, respectively), or end of follow-up at 24 months post-enrollment.
62123523|NCT02220816|EXPERIMENTAL|Competitive Training|The patients will receive only competitive activities designed to restore attention abilities. These include pencil-and-paper tasks completed under competitive circumstances and competitive virtual games specifically designed to treat different aspects of attention (divided, selective, sustained, etc).
62123524|NCT02220816|ACTIVE_COMPARATOR|Non-Competitive Training|The patients will receive conventional attentional training. Pencil and paper tasks focused on different aspects of attention (divided, selective, sustained, etc.) will be completed by all participant under individual or group-therapy sessions. No competitive training will be allowed.
62313394|NCT00970203|EXPERIMENTAL|Cohort A|"3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
62313395|NCT00970203|EXPERIMENTAL|Cohort B|"3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
62313396|NCT05928026|EXPERIMENTAL|Immediate Financial Support|This group will receive $500 at the completion of their baseline visit
62313397|NCT05928026|ACTIVE_COMPARATOR|Delayed Financial Support|This group will receive no financial support at their completion of their baseline visit, but will receive $500 at their 1-month visit.
62313398|NCT00455858|ACTIVE_COMPARATOR|insulin detemir|
62313399|NCT03245788|EXPERIMENTAL|Lay Navigation|Patients with even MRN.
62313400|NCT03245788|NO_INTERVENTION|Usual Care|Patients with odd MRN.
62313401|NCT05595473|EXPERIMENTAL|Cohort 1|
62313402|NCT05595473|EXPERIMENTAL|Cohort 2|
62313403|NCT05595473|EXPERIMENTAL|Cohort 3|
62313404|NCT05595473|EXPERIMENTAL|Cohort 4|
62313405|NCT03370081|EXPERIMENTAL|CAPNO+|END TIDAL CO2(EtCO2) is monitoring and PACU nurses can see the values delivered by the capnography device
62313406|NCT03370081|NO_INTERVENTION|CAPNO-|END TIDAL CO2(EtCO2) is monitoring but PACU nurses cannot see the values delivered by the capnography device
62313407|NCT06257004||AMC (Affected Mutation Carrier)|FBN1 mutation (Marfan Syndrome) - Phenotype cardiovascular severe outcome
62477894|NCT04468126|ACTIVE_COMPARATOR|standard oxygen group|In order to maintain SpO2 between 92 and 96%
62313408|NCT06257004||UMC (Unaffected Mutation Carrier)|FBN1 mutation (Marfan Syndrome) - Phenotype cardiovascular mild outcome
62313409|NCT03714412|EXPERIMENTAL|Implantation|Eligible patients will undergo implantation with the Cardiovalve system
62477895|NCT04468126|EXPERIMENTAL|high-flow nasal cannula oxygen group|At least 50 L/min adjusted in order to maintain SpO2 between 92 and 96 %
62313410|NCT01716494||Severe Asthma|Subjects with severe asthma (SARP protocol definition)
62313411|NCT01716494||Well controlled asthma|Subjects with well controlled asthma
62313412|NCT01716494||Normal control|Subjects that are healthy normals
62313413|NCT05314348|ACTIVE_COMPARATOR|Motor Neuron Disease|High-density surface EMG Ultrasound
62313414|NCT05314348|ACTIVE_COMPARATOR|Healthy controls|High-density surface EMG Ultrasound
62477896|NCT02257892||Patients|Affected patients, with symptoms or genetic mutation
62477897|NCT02257892||Unaffected/healthy relatives|Relatives without symptoms or genetic mutation
62477898|NCT02177422|EXPERIMENTAL|Telmisartan|
62683888|NCT03397641|ACTIVE_COMPARATOR|Active|x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion. Doses of HBI-3000 (Cohorts A to G) may range from 20 mg to a level at which it is expected that the drug exposure will not exceed an AUC(0-t) of 20 µg.h/mL and Cmax of 20 µg/mL (based on the NOAEL) in both 14-day repeat-dose toxicology species rat and minipig) and the expected therapeutic dose.
61923523|NCT01952470|EXPERIMENTAL|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa.
62477899|NCT04874454|EXPERIMENTAL|vocal cord movement among the stroke patients|
62477900|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
62477901|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
62477902|NCT06561373|EXPERIMENTAL|Calm and Alert Mindfulness and Yoga Intervention|The Calm \& Alert intervention uses mind, body, and breath to foster resiliency and self-regulation in students. This mindfulness-based intervention, which also incorporates yoga movements, aims to develop skills in self-awareness, self-regulation, safety, focus, attention, active listening, following directions, respect, and positive thinking (McGlauflin, 2018). The program consisted of seven lessons lasting approximately 20-30 minutes, each conducted once a week over seven consecutive weeks.
62477903|NCT06561373|NO_INTERVENTION|Control Group|This is a wait-list control group that consists of students in classrooms who will receive business-as-usual programming/instruction during the study period.
62477904|NCT06488846||Home-Based LAI-ART Administration|People living with HIV receiving LAI-ART in their homes from a trained Treatment Buddy.
62477905|NCT06488846||Clinic-Based LAI-ART Administration|People living with HIV receiving LAI-ART in clinics from healthcare providers.
62683889|NCT03397641|PLACEBO_COMPARATOR|Placebo|Matching placebo for x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion.
61923524|NCT01952470|ACTIVE_COMPARATOR|Isotonic Saline|Once daily, 5ml inhaled 0.9% normal saline.
61923525|NCT06423729|NO_INTERVENTION|Control Arm|23 patients who will receive 2nd generation sulfonylureas only, for three months.
62313415|NCT06673329|EXPERIMENTAL|brodalumab to treat irAEs in patient with solid tumors|Brodalumab 210 mg subcutaneous injection on weeks 0, 1, 2 followed by administration every 2 weeks until week 24
62313416|NCT04111822|ACTIVE_COMPARATOR|Conventional treatment of septic shock|Conventional treatment of septic shock according to current management guidelines
62313417|NCT04111822|EXPERIMENTAL|Current management plus ascorbic acyd,thiamine and vitamin C|"Conventional treatment of septic shock according to current management guidelines associated with:~i. Hydrocortisone 50 mg every 6 hours for 7 days or until discharge from the ICU with subsequent withdrawal in descending pattern for 3 days ii. Vitamin C (ascorbic acid) 1.5 gr diluted in 100 ml of 5% SG every 6 hours for 4 days (16 doses) iii. Thiamine 200 mg diluted in 100 ml of SG 5% or SF 0.9% every 12 hours for 4 days iv. Measurement of vitamin C levels prior to administration of the first dose of vitamin C"
62683890|NCT06420063|EXPERIMENTAL|Treatment (CD33/CD123 CAR T cells, chemotherapy)|Patients will be administered fludarabine phosphate intravenously (IV) over a 30-minute period on days -4 to -2. Additionally, cyclophosphamide will be administered intravenously (IV) over 60 minutes on day -2. Subsequently, patients will receive CD33/123 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0. Patients who exhibit positive responses to the initial dose of CD33/123 CAR T cells, do not experience unacceptable side effects, and have a sufficient quantity of cells available may be eligible to receive 2 or 3 additional doses of CD33/CD123 CAR T cells.
62683891|NCT06686771|EXPERIMENTAL|SBRT/Radiotherapy followed by standard of care therapy|
62313418|NCT06092398|EXPERIMENTAL|PRP and PRFG in anal fistula|the tract fistula was cleaned with betadine 10% before PRP and PRFP were applied. Then, 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. The operation time was about 20-30 minutes, the clot formation usually takes about 8 minutes, but the anesthesia was extended to 20 minutes to make sure a complete clot in the place
62313419|NCT04795440|NO_INTERVENTION|Eya-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the ejaculate (control group).
62313420|NCT04795440|EXPERIMENTAL|Test-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the testicle (study group).
61923526|NCT06423729|EXPERIMENTAL|Nicorandil Arm|23 patients who will receive a combination of 2nd generation sulfonylureas and nicorandil 10 mg twice daily,for three months.
62123525|NCT02880241|EXPERIMENTAL|Cohort 1A - P. vivax malaria|A single oral dose of up to 120mg MMV390048
62123526|NCT02880241|EXPERIMENTAL|Cohort 1B - P. falciparum malaria|A single oral dose of up to 120mg MMV390048
62123527|NCT02880241|EXPERIMENTAL|Cohort 2A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
62123528|NCT02880241|EXPERIMENTAL|Cohort 2B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
62123529|NCT02880241|EXPERIMENTAL|Cohort 3A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
62313421|NCT00375934|EXPERIMENTAL|1|
62123530|NCT02880241|EXPERIMENTAL|Cohort 3B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
62123531|NCT02282085|EXPERIMENTAL|Aripiprazole Once-Monthly|Switch to 400 mg aripiprazole once-monthly injection
62123532|NCT02282085|ACTIVE_COMPARATOR|Standard of Care|Continue current SOC oral antipsychotic medication
62123533|NCT04358549|EXPERIMENTAL|Favipiravir Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC
62123534|NCT04358549|OTHER|Standard of Care Arm|Standard of Care for 14 days
62123535|NCT03547791|ACTIVE_COMPARATOR|ACS (Group 1)|Intramuscular injection of betamethason sodium phosphate 12mg (3ml) twice 24hours apart
62123536|NCT03547791|PLACEBO_COMPARATOR|Placebo (Group 2)|Intramuscular injection of normal saline 3ml twice 24hours apart
62123537|NCT01220336|EXPERIMENTAL|Health Coaching|
62313422|NCT00375934|PLACEBO_COMPARATOR|2|
62313423|NCT01512524|OTHER|Patients With Traumatic Brain Injury|Study of the association between quality of life and MRI scans and endocrinology analysis (quantification of Growth Hormone) 18 months post-trauma.
62313424|NCT03446547|NO_INTERVENTION|Arm A|SBRT and follow-up
62313425|NCT03446547|EXPERIMENTAL|Arm B|SBRT followed by Durvalumab
62313426|NCT06672614|EXPERIMENTAL|Post-Exercise Hot Water Immersion|Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max) followed by 30 minutes post-exercise hot water immersion (40oC) for 5 consecutive days.
62313427|NCT06672614|ACTIVE_COMPARATOR|Control group|Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max); however, there will be not water immersion following exercise.
62313428|NCT06248320|EXPERIMENTAL|Sigh ventilation|"* Sigh breaths consisting of increasing positive end-expiratory pressure (PEEP) that produces a plateau pressure of 35 cmH2O (or 40 cmH2O in patients with BMIs \> 35). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation, from intubation to extubation.~* No sigh ventilation during thoracotomy~* Lung protective ventilation from intubation to extubation, consisted of low tidal volume (6-8ml/kg/pbw) and positive end-expiratory pressure setting according to ARDS low PEEP-FiO2 table"
62123538|NCT04147910|EXPERIMENTAL|KW-6356|Single oral dose of carbon-14-KW-6356.
62313429|NCT06248320|NO_INTERVENTION|Conventional ventilation|- Lung protective ventilation from intubation to extubation, consisted of low tidal volume (6-8ml/kg/pbw) and positive end-expiratory pressure setting according to ARDS low PEEP-FiO2 table
62313430|NCT01915875|EXPERIMENTAL|sophrology sessions|The sophrology is a dynamic method of physical and psychical relaxation
62313431|NCT02016066|EXPERIMENTAL|CR6261|
62313432|NCT02016066|PLACEBO_COMPARATOR|Placebo|
62313433|NCT01204112|EXPERIMENTAL|Tasocitinib (CP-690,550) plus Rifampin|
62313434|NCT02681887|PLACEBO_COMPARATOR|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 12 weeks
62313435|NCT02681887|EXPERIMENTAL|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
62477906|NCT06488846||Oral ART Administration|People living with HIV receiving oral ART medication in clinics from healthcare providers.
62477907|NCT05594420||MVR through Median sternotomy|
62477908|NCT05594420||MVR through Minimally invasive approach|
62477909|NCT02478983|EXPERIMENTAL|LMA Supreme|1 arm will receive LMA supreme for airway management
62313436|NCT01347567|EXPERIMENTAL|BNP + Health Management|Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
61923527|NCT02958189|EXPERIMENTAL|Group 1: Tweet4Wellness+Self-monitoring|This group will receive the Tweet4Wellness intervention: daily theory-based peer-to-peer discussion prompt within the private Twitter-based support group for the entire 6 months of the study. They will also receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component).
62313437|NCT01347567|ACTIVE_COMPARATOR|Health Management|Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
62477910|NCT02478983|ACTIVE_COMPARATOR|LMA Proseal|1 arm will receive LMA Proseal for airway management
62477911|NCT05760144|ACTIVE_COMPARATOR|DMPA|
62477912|NCT05760144|ACTIVE_COMPARATOR|Etonogestrel implant|
62477913|NCT06249360||Lower Limb Lymphedema|Patients with cancer-related unilateral lower limb lymphedema were enrolled.
62477914|NCT06563024|EXPERIMENTAL|18F-FET PET|The study participants receive the 18F-FET PET scan.
62477915|NCT01349218|EXPERIMENTAL|Blood sample drawn from a vein and from a heel stick|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis. A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
62477916|NCT02777580|EXPERIMENTAL|Pharmaco-invasive strategy|Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.
62477917|NCT02777580|ACTIVE_COMPARATOR|Standard primary PCI|Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.
62477918|NCT04050254|EXPERIMENTAL|Real tDCS + exercise|Transcranial direct current stimulation combined with therapeutic exercise
62477919|NCT04050254|SHAM_COMPARATOR|Sham tDCS + exercise|Sham transcranial direct current stimulation combined with therapeutic exercise
62477920|NCT04050254|NO_INTERVENTION|Control|No treatment.
62477921|NCT04074603|EXPERIMENTAL|Group A|needle-free before needle
62477922|NCT04074603|EXPERIMENTAL|Group B|needlebefore needle-free
62477923|NCT06225921|EXPERIMENTAL|Adebrelimab+Dalpiciclib(100mg)|"Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.~Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
62477924|NCT06225921|EXPERIMENTAL|Adebrelimab+Dalpiciclib(150mg)|"Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.~Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
62477925|NCT01964053|EXPERIMENTAL|PATCH Intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
62477926|NCT01964053|ACTIVE_COMPARATOR|Usual Care|The usual care group will receive standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen. No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
62477927|NCT05108779|EXPERIMENTAL|QLF32004|
62477928|NCT05155683|ACTIVE_COMPARATOR|Photobiomodulation|PBM with infrared LED application + sham ultrasound + muscle electrostimulation
62477929|NCT05155683|ACTIVE_COMPARATOR|low frequency ultrasound|LED sham PBM + LOFU + muscle electrostimulation
62477930|NCT05155683|ACTIVE_COMPARATOR|Combined treatment (PBM + LOFU)|Combined treatment (PBM + LOFU) + muscle electrostimulation
62313438|NCT01347567|PLACEBO_COMPARATOR|Control|Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
62477931|NCT05155683|SHAM_COMPARATOR|Sham Treatment|Sham combined treatment + muscle electrostimulation
62477932|NCT03725969|EXPERIMENTAL|Healthy individuals (camel milk)|
62477933|NCT03725969|EXPERIMENTAL|Healthy individuals (cow milk)|
62477934|NCT05505747|EXPERIMENTAL|Fisetin|Subjects assigned to the experimental group will take approximately 20 mg/kg/day of fisetin for 2 consecutive days, followed by a 28-day senescence washout period, and then another 2-day administration. Fisetin treatment begins at 8 weeks after surgery.
62477935|NCT05505747|PLACEBO_COMPARATOR|Placebo|Subjects assigned to the experimental group will take approximately 20 mg/kg/day of placebo (corn starch) for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration. Placebo treatment begins at 8 weeks after surgery.
62477936|NCT06157905|EXPERIMENTAL|Patients of Extensive alopecia areata|Patients of either gender, age between 18-60 years, having extensive alopecia areata (SALT\>24)
62477937|NCT01391273|EXPERIMENTAL|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
62313439|NCT06311240||Participant with CKD|Participant with CKD answering the questionnaires
62477938|NCT01391273|PLACEBO_COMPARATOR|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
62477939|NCT06299319|EXPERIMENTAL|Experimental: Psilocybin 25 mg|Participants will receive a 25 mg dose of psilocybin, twice throughout the trial, with two weeks in between doses.
62477940|NCT06119763||group A|systemic lupus erythematosus cases, diagnosed by SLICC criteria with negative levels of AntiDFS antibodies
62477941|NCT06119763||group B|systemic lupus erythematosus cases, diagnosed by SLICC criteria with positive levels of AntiDFS antibodies
62477942|NCT00834431|EXPERIMENTAL|1|
62477943|NCT00834431|ACTIVE_COMPARATOR|2|
62477944|NCT05110963|PLACEBO_COMPARATOR|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence.
62477945|NCT05110963|ACTIVE_COMPARATOR|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
62683892|NCT06686771|ACTIVE_COMPARATOR|No SBRT and switch to second-line standard of care therapy|
62683893|NCT06056102|EXPERIMENTAL|Participant Cohorts|"* Safety Run-in phase (2 subjects at UPenn)~* Cohort 1 (3-6 subjects)~* Cohort 2 (3-6 subjects)~* Cohort 3 (3-6 subjects)"
62683894|NCT06669715||Asymptomatic individuals - apparently healthy|Asymptomatic individuals - apparently healthy
62477946|NCT05110963|EXPERIMENTAL|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
62477947|NCT03785301|EXPERIMENTAL|FGM group|Diabetic patients will use FreeStyle Libre Flash Glucose Monitoring (FGM) system(unmasked) to monitor glucose level once a month for 3 months.
62683895|NCT06669715||Symptomatic individuals|Symptomatic individuals - prehypertensive and hypertensive individuals
62683896|NCT06690632|EXPERIMENTAL|WATER|ingestion of 1.5L of water 30min prior MRE acquisition
62683897|NCT06690632|ACTIVE_COMPARATOR|PEG|ingestion of 1.5L of water diluted PEG 45 min prior MRE acquisition (standard protocol)
62683898|NCT06689358|EXPERIMENTAL|General anesthesia with TPVB|0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space
62683899|NCT06689358|NO_INTERVENTION|General anesthesia alone (control group).|General anesthesia SOC alone
62123539|NCT03399916|EXPERIMENTAL|Prompt|"An email based prompt was sent- containing either a stand or move message. Exploratory variations of the prompt were designed to include the addition of a goal e.g., stand for the next 5-minutes, and/or employer support e.g., PTS says stand for the next 5 minutes."
62477948|NCT03785301|NO_INTERVENTION|SMBG group|Diabetic patients will use Standard Blood Glucose Monitoring (SMBG) to monitor glucose level for 3 months. A 14-day masked wear of FreeStyle Libre H Flash Glucose Monitoring system is included for these subjects once a month, to collect glycaemic variability data for comparison to the intervention group of the study.
62477949|NCT06164860|OTHER|Group A|started with MD
62477950|NCT06164860|OTHER|Group B|started with KD
62683900|NCT06268730|EXPERIMENTAL|SinuSonic|Participants are asked to use the SinuSonic twice daily for 5 consecutive weeks. The duration of each use is 2 minutes.
62683901|NCT01396785|EXPERIMENTAL|Active|Product 33525
62683902|NCT01396785|PLACEBO_COMPARATOR|Placebo|Product 33525 Placebo
62683903|NCT04621279||Mild HIE|Mild HIE identified in the first 6 hours of life according to the published PRIME study definition: newborn with evidence of encephalopathy (using the validated Sarnat Exam) NOT meeting prior cooling trials criteria.
62683904|NCT04014192|EXPERIMENTAL|Dapagliflozin Group|10mg/d for one week
62683905|NCT04014192|EXPERIMENTAL|Empagliflozin Group|10mg/d for one week
62683906|NCT04014192|EXPERIMENTAL|Canagliflozin Group|100mg/d for one week
62683907|NCT04014192|NO_INTERVENTION|Normal Glucose Tolerance Group|
62683908|NCT06603012|EXPERIMENTAL|GET Up PD|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training
62683909|NCT06603012|ACTIVE_COMPARATOR|Stretching and Flexibility|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training
62123540|NCT03399916|NO_INTERVENTION|No Prompt|Prompt delivery was sequentially randomized to be sent (ST) or not sent (NST) to all participants (probability of 0.5), at eight decision points per day (between 9am and 5pm), to achieve a total of 3200 randomizations across participants (160 per participant). Therefore 50% of the time, no prompt was sent.
62313440|NCT06448780|ACTIVE_COMPARATOR|Lower loading dose (20 mg/kg)|Within 24 hours after delivery, participants will receive a loading dose of 20 mg/kg caffeine citrate IV.
62683910|NCT04543253||Standard of care CS|Patients undergoing curative surgery for any type of CS who will be followed through standard of care after surgery
62683911|NCT04543253||MUSE intervention CS|Patients undergoing curative surgery for any type of CS who will be introduced to and provided MUSE for use after surgery
62683912|NCT06688409|ACTIVE_COMPARATOR|Validate home BP device|BP measured with a validated home BP device
62683913|NCT06688409|ACTIVE_COMPARATOR|Non-validated home BP device #1|BP measured with the first non-validated home BP device
62683914|NCT06688409|ACTIVE_COMPARATOR|Non-validated home BP device #2|BP measured with the second non-validated home BP device
62683915|NCT06688409|ACTIVE_COMPARATOR|Non-validated home BP device #3|BP measured with the third non-validated home BP device
62683916|NCT06536530|EXPERIMENTAL|Exergame-Based Training|Participants train with exergames (video games that include cognitive and physical training simultaneously), The training regime consists of 40-50 min sessions, two sessions per week, for a total of eight weeks of individual training.
62683917|NCT06536530|ACTIVE_COMPARATOR|Cognitive-Based Training|Participants will train only with cognitive video games. The training regime consists of 40-50 min sessions, two sessions per week, for a total of eight weeks of individual training.
62683918|NCT06536530|PLACEBO_COMPARATOR|Wait-List|Participants will not train with any program and they will not assist to any specific session.
62697333|NCT06420336|ACTIVE_COMPARATOR|Local anesthetic infiltration|Patient will undergo induction of anesthesia as deemed appropriate by the attending pediatric anesthesiologist assigned to the case. After induction of anesthesia and securement of appropriate airway device the patient will be turned over to the surgical team to proceed with the operation. The surgeon will proceed with usual injection of local anesthetic as their standard of care; this medication will be charted by the circulating nurse in the Medication Administration Record with local anesthetic type and amount. At the conclusion of the procedure, to maintain the blind, the patient will have a bandage placed where the QL block would have been performed.
62697334|NCT02078726|ACTIVE_COMPARATOR|Glucagon|1 mg glucagon given during colonoscopy
62313441|NCT06448780|ACTIVE_COMPARATOR|Higher loading dose (30 mg/kg)|Within 24 hours after delivery, participants will receive a loading dose of 30 mg/kg caffeine citrate IV.
62477951|NCT05190068|EXPERIMENTAL|Relapsed/refractory B-NHL|"The starting dose of HMPL-760 is initially set as 50 mg, and then the doses of 100 mg, 200 mg, 300 mg, and 400 mg are escalated successively (this dose gradient is assumed).~HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles."
62477952|NCT06321835||Supine Group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
62477953|NCT06321835||Prone Group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
62477954|NCT06321835||Lithotomy Group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
62477955|NCT06321835||Lateral flank group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
62477956|NCT00350753|EXPERIMENTAL|Erlotinib and bevacizumab|
62477957|NCT04512586|EXPERIMENTAL|Conduction System pacing plus AV node ablation|"A His-pacing lead in combination with a backup RV pacing lead or an LBB pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing or LBB pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. If failure to implant with these tools, other leads and sheaths can be used at the discretion of the operator. A standard DDD pacemaker or CRT-P device from Medtronic will be used.~A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed."
62477958|NCT04512586|ACTIVE_COMPARATOR|Pulmonary vein isolation|Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Pulsed field ablation can be used if available. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.
62477959|NCT05765708|EXPERIMENTAL|Motor imagery group|Motor imagery group. Only motor imagery intervention will be applied to participants.
62477960|NCT05765708|EXPERIMENTAL|Action Observation Group|Action Observation Group. Only action observation intervention will be applied to participants
62477961|NCT05765708|EXPERIMENTAL|Action Observation + Motor imagery Group|Action Observation + Motor imagery Group. Both action observation and motor imagery interventions will be applied for 5 minutes each.
62683919|NCT03556384|EXPERIMENTAL|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
62683920|NCT03464552|ACTIVE_COMPARATOR|Celecoxib group|will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy
62683921|NCT03464552|PLACEBO_COMPARATOR|Placebo group|will receive oral placebo capsule once 3 hours before the colposcopic guided biopsy
62313442|NCT02162875|EXPERIMENTAL|MDA once a year|Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg
62477962|NCT05765708|NO_INTERVENTION|Control|
62477963|NCT00980915||At risk for Acute Lung Injury|"Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI~Cases-High risk patients that do develop Acute Lung Injury"
62477964|NCT02096185|EXPERIMENTAL|3 dimensional tomosynthesis imaging|Breast specimen to be x-rayed using both conditions 3 dimensional tomosynthesis imaging 2 dimensional conventional digital imaging
62477965|NCT02096185|EXPERIMENTAL|2 dimensional digital imaging|Breast specimens to be x-rayed under both conditions 3 dimensional tomosynthesis imaging 2 dimensional digital imaging
62477966|NCT03680053|EXPERIMENTAL|PPOS group|Ovarian stimulation will use the progestin-primed ovarian stimulation (PPOS) protocol.Women will receive progesterone (oral duphaston 20mg) daily from Day 3 till the day of ovulation trigger.
62477967|NCT03680053|ACTIVE_COMPARATOR|Antagonist group|Ovarian stimulation will use the antagonist protocol. Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
62477968|NCT01125163|ACTIVE_COMPARATOR|multivitamin with iron|daily oral multivitamin providing 2mg/kg of iron
62477969|NCT01125163|PLACEBO_COMPARATOR|multivitamin without iron|daily oral multivitamin without iron
62477970|NCT03600805|EXPERIMENTAL|Placebo+52 Week Taper|Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
62683922|NCT04733482|NO_INTERVENTION|Control group|Participants in the control group received usual care during adjuvant chemotherapy. The usual care consisted of written information and verbal guidance on the adverse effects of chemotherapy and related psychological reactions.
62313443|NCT02162875|EXPERIMENTAL|MDA 2nd year CWT follwed by 2 years SBT|Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT)
62313444|NCT02162875|EXPERIMENTAL|Praziquantel every second year CWT|Treatment with praziquantel given every second year as CWT
62313445|NCT02162875|EXPERIMENTAL|MDA once a year SBT|Treatment with praziquantel as above given as 4 years of SBT
62313446|NCT02162875|EXPERIMENTAL|MDA given for 2 years as SBT|Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA
62697335|NCT02078726|PLACEBO_COMPARATOR|Placebo|1 mL normal saline
62697336|NCT05989997|EXPERIMENTAL|dose escalation|4 subgroups mass dose escalation.
62477971|NCT03600805|EXPERIMENTAL|Placebo+26 Week Taper|Participants received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
62313447|NCT02162875|EXPERIMENTAL|MDA as SBT 1year and 1 year without MDA|Treatment with praziquantel given as one years of SBT alternating with one year without treatment
62313448|NCT02765412||standard implementation|Webinar, Promotion, Tool Access, academic detailing + Audit and Feedback
62313449|NCT02765412||intensive implementation|Webinar, Promotion, and Tool Access, academic detailing + Audit and Feedback + LEAP
62313450|NCT04021784|EXPERIMENTAL|Spring Distraction System (SDS)|The SDS will be placed and fits around a standard rod of 5.5mm.
62313451|NCT04021784|EXPERIMENTAL|Necker Enfants Malade OSTeosynthesis (NEMOST)|The NEMOST is a one-way-rod that uses a ratchet type of locking mechanism. Both NEMOST devices should be placed in parallel, on the two fixator rods that are connected with a cross connector
62313452|NCT04283461|EXPERIMENTAL|Arm 1|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel)
62313453|NCT04283461|EXPERIMENTAL|Arm 10|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
62313454|NCT04283461|EXPERIMENTAL|Arm 11|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
62477972|NCT03600805|PLACEBO_COMPARATOR|Sarilumab 150mg q2w+26 Week Taper|Participants received sarilumab 150 milligrams (mg) as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
62123541|NCT02520908||HSCT|Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor
62477973|NCT03600805|PLACEBO_COMPARATOR|Sarilumab 200mg q2w+26 Week Taper|Participants received sarilumab 200 mg as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
62477974|NCT04603482|EXPERIMENTAL|Self-Management|
62477975|NCT04603482|ACTIVE_COMPARATOR|Attention Control Condition|
62683923|NCT04733482|EXPERIMENTAL|Cosmetic care group|Participants in the intervention group received cosmetic care in combination with usual care. The cosmetic care was a 3-hour, free-of-charge beauty activity, including face moisturizing steps, make-up, wigs, and breast prostheses wearing. It was provided by professional cosmeticians at a cosmetic training base before the patients finished half of their chemotherapy cycle.
61923528|NCT02958189|ACTIVE_COMPARATOR|Group 2: Self-monitoring|This group will receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component) for the first 3 months. For the second three months of the study, they will receive the Tweet4Wellness intervention in addition to their Fitbit self-monitoring.
61923529|NCT03544476|EXPERIMENTAL|Mobile phone TB treatment support app|Daily use of the mobile phone TB treatment support app plus usual care. Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
61923530|NCT03544476|ACTIVE_COMPARATOR|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
61923531|NCT06432881|EXPERIMENTAL|RD SET Sensor|All subjects are enrolled into this arm and will have Sp02 measurements obtained.
62123542|NCT02520908||Standard care|Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group
62313455|NCT04283461|EXPERIMENTAL|Arm 12|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
61923532|NCT05060523|EXPERIMENTAL|Tolvaptan with Midodrine|
61923533|NCT05060523|ACTIVE_COMPARATOR|Tolvaptan with Placebo|
62477976|NCT00604474|ACTIVE_COMPARATOR|1|
62477977|NCT01191996|EXPERIMENTAL|MIS416|MIS416, immunomodulating microparticle, given intravenously weekly
62477978|NCT05829421|EXPERIMENTAL|Impairment-specific occupational therapy (OT) intervention|Patients receive an impairment-specific OT intervention targetting problems in managing activities of daily living (ADL) due to mild-to-moderate poststroke cognitive impairments. The intervention is initiated in the stroke unit as soon as patients' medical condition allows it, and it is delivered 3 times per week until 3 months poststroke. After hospital discharge, the intervention continues in community settings.
62683924|NCT06557343||Bronchoscopy under ELFMAN|Clinical bronchoscopy performed under ELMAN study
62313456|NCT04283461|EXPERIMENTAL|Arm 13|10 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
62313457|NCT04283461|EXPERIMENTAL|Arm 14|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle after Day 209 in participants from Arm 1,4,7,10, 11, and 12 from 18 years of age or older. N=70.
62313458|NCT04283461|EXPERIMENTAL|Arm 15|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle no later than Day 394 in participants from Arm 2,3,5 and 8 from 18 years of age or older. N=50.
62313459|NCT04283461|EXPERIMENTAL|Arm 2|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
62313460|NCT04283461|EXPERIMENTAL|Arm 3|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
62313461|NCT04283461|EXPERIMENTAL|Arm 4|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
62313462|NCT04283461|EXPERIMENTAL|Arm 5|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
62477979|NCT01823263|EXPERIMENTAL|Partial sleep deprivation|Partial sleep deprivation: participants will have a 4-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed by repeated blood sampling and an 'Intake task'.
62477980|NCT01823263|EXPERIMENTAL|Normal sleep|Normal sleep: participants will have an 8-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed with repeated blood sampling and an 'Intake task'.
62477981|NCT06332170|EXPERIMENTAL|Cohort 1a|HS-20093 and Adebrelimab
62123543|NCT06676943|EXPERIMENTAL|Radical prostatectomy and Head and neck specimens|Patients undergoing surgical resection for prostate cancer or head and neck cancer.
62123544|NCT00293293|ACTIVE_COMPARATOR|Chemotherapy Alone|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
62123545|NCT00293293|EXPERIMENTAL|Standard Chemotherapy + CAM|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.
62123546|NCT02887066||Patients with thoracic pain and suspicion of ACS|
62123547|NCT06259474|EXPERIMENTAL|Group A|Group (A): 20 subjects combined HE with traditional treatments for low back pain (heat therapy, medication, and progressive strength training).
62123548|NCT06259474|ACTIVE_COMPARATOR|Group B|Group (B) :20 subjects received the same conventional treatment for low back pain as group (A), including heat therapy, medication, and progressive strength training.
62123549|NCT01130467||Normal control|
62123550|NCT01130467||pure ADHD|
62123551|NCT01130467||ADHD with comorbidity|
62123552|NCT02206763|EXPERIMENTAL|Momelotinib (MMB)+erlotinib|Participants will receive momelotinib (MMB) plus erlotinib.
62313463|NCT04283461|EXPERIMENTAL|Arm 6|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
62313464|NCT04283461|EXPERIMENTAL|Arm 7|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
62313465|NCT04283461|EXPERIMENTAL|Arm 8|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
62313466|NCT04283461|EXPERIMENTAL|Arm 9|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
62313467|NCT01864577|EXPERIMENTAL|With negative pleural suction|Patients are put on negative pleural suction at - 20 cm H2O
62313468|NCT01864577|ACTIVE_COMPARATOR|With water seal|Patients al left on water seal only
62313469|NCT05227651|EXPERIMENTAL|AK104|Patients will be treated with 1-4 cycles of neoadjuvant AK104. 2-4 weeks after the last cycle of neoadjuvant treatment, patients will undergo radical surgery.
62313470|NCT03849560|EXPERIMENTAL|Grippol® Quadri|"Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~* type A (H1N1) influenza virus antigen 5 µg;~* type A (H3N2) influenza virus antigen 5 µg;~* type B (Yamagata lineage) influenza virus antigen 5 µg;~* type B (Victoria lineage) influenza virus antigen 5 µg;~* immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
62313471|NCT03849560|ACTIVE_COMPARATOR|Grippol® Plus, trivalent (Yamagata lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~* type A (H1N1) influenza virus antigen 5 µg;~* type A (H3N2) influenza virus antigen 5 µg;~* type B (Yamagata lineage) influenza virus antigen 5 µg;~* immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
62477982|NCT06332170|EXPERIMENTAL|Cohort 1b|HS-20093, Adebrelimab and Cisplatin/ Carboplatin
62477983|NCT06332170|EXPERIMENTAL|Cohort 2a|HS-20093 and Cetuximab
62477984|NCT06332170|EXPERIMENTAL|Cohort 2b|HS-20093, Cetuximab and Cisplatin/ Carboplatin
62477985|NCT06332170|EXPERIMENTAL|Cohort 3a|HS-20093 and Enzalutamide
62477986|NCT03242213|NO_INTERVENTION|Usual Care|Standard of Care
62477987|NCT03242213|ACTIVE_COMPARATOR|Mobile App|Standard of Care and Mobile App
62683925|NCT06690957||Diagnostic Test: Single Group Assignment|Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3 , and undergo PET/CT imaging within the specificed time.
62697337|NCT02697448|ACTIVE_COMPARATOR|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
62683926|NCT06538350|EXPERIMENTAL|Telemedicine consultations|The experimental intervention will be delivered via Zoom and Video WhatsApp platforms via a secure internet connection.
62683927|NCT06538350|ACTIVE_COMPARATOR|Face-to-Face Consultations|Patients randomised to the control arm will continue with face-to-face consultations according to the standard of care.
62683928|NCT06691477||Heart Failure Cohort|
62683929|NCT06691477||Non-Heart Failure Cohort with suspected HF syndrome|
62683930|NCT00544726|ACTIVE_COMPARATOR|1|Physical training
62683931|NCT00544726|PLACEBO_COMPARATOR|2|No physical training
61923534|NCT04387383|EXPERIMENTAL|Acupuncture group|Electro-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
61923535|NCT04387383|PLACEBO_COMPARATOR|sham-acupuncture group|Sham-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
61923536|NCT03213353|EXPERIMENTAL|Treatment sequence AB|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
61923537|NCT03213353|EXPERIMENTAL|Treatment sequence BA|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
61923538|NCT00580567||1|Pathological Gamblers
61923539|NCT00580567||2|Non-Pathological Gamblers
61923540|NCT04561674|EXPERIMENTAL|Experimental Group|"The patients in the experimental group participated in Web-Based Patient Education with Colostomy and Ileostomy on computer between the third and seventh days after surgery.~The cards with the website address, username and the website QR code were given to the patients in order to be able to receive education after discharge.The patient and her family received the training from any computer or smartphone connected to the internet."
62313472|NCT03849560|ACTIVE_COMPARATOR|Grippol® Plus, trivalent (Victoria lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~* type A (H1N1) influenza virus antigen 5 µg;~* type A (H3N2) influenza virus antigen 5 µg;~* type B (Victoria lineage) influenza virus antigen 5 µg;~* immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
62477988|NCT00070148|ACTIVE_COMPARATOR|Arm 1 Oxandrolone 20 mg daily|Oxandrolone 20 mg (10 mg BID) for 12 weeks. 4 additional weeks of follow-up.
62477989|NCT00070148|ACTIVE_COMPARATOR|Megace 800 mg|Megestrol acetate 800 mg daily for 12 weeks. 4 additional weeks of follow-up.
62683932|NCT05869604|EXPERIMENTAL|HEALTHY AYA|Participants randomized to the intervention arm will receive an 8 session intervention providing instruction in cognitive and behavioral symptom coping strategies as well as behavioral strategies to improve diet and decrease sedentary time.
62683933|NCT05869604|OTHER|Education Control|Participants randomized to the education control arm will receive information about topics of relevance to adolescent and young adult cancer survivors including sleep, cognitive problems, finances, sexual health, and return to work/school.
62683934|NCT01974479|EXPERIMENTAL|anti-CD19 redirected NK cells|This is a single arm study. Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors at cell dose of 0.5 - 5 x 10\^7 CD56+ cells/kg, and up to 1 x 10\^8 CD56+ cells/Kg
62683935|NCT02349828|ACTIVE_COMPARATOR|Zovirax|Adult dose - 400 mg twice daily generic name: Acyclovir
62683936|NCT02349828|NO_INTERVENTION|No treatment|standard of care
62683937|NCT05639439|ACTIVE_COMPARATOR|Group A- Fastrach|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated through the intubating laryngeal mask airway Fastrach, while the laryngeal view through Fastrach will be evaluated using a flexible fiberoptic bronchoscope"
62683938|NCT05639439|ACTIVE_COMPARATOR|Group B- Proseal|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated through the Proseal laryngeal mask airway, while the laryngeal view through Proseal will be evaluated using a flexible fiberoptic bronchoscope"
62697338|NCT02697448|ACTIVE_COMPARATOR|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
62683939|NCT05639439|ACTIVE_COMPARATOR|Group C- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated using the I-gel supraglottic airway device, while the laryngeal view through I-gel will be evaluated using a flexible fiberoptic bronchoscope"
61923541|NCT04561674|NO_INTERVENTION|Control group|The clinical routine was applied to the control group.
62683940|NCT05639439|ACTIVE_COMPARATOR|Group D- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated using the Protector laryngeal mask airway, while the laryngeal view through Protector will be evaluated using a flexible fiberoptic bronchoscope"
62683941|NCT05137054|EXPERIMENTAL|Cohort 1: Linvoseltamab + Daratumumab|Linvoseltamab + Daratumumab
62683942|NCT05137054|EXPERIMENTAL|Cohort 2: Linvolseltamab + Carfilzomib|Linvoseltamab + Carfilzomib
62683943|NCT05137054|EXPERIMENTAL|Cohort 3: Linvoseltamab + Lenalidomide|Linvoseltamab + Lenalidomide
62477990|NCT03407287||Cardiac Catheterization|
61923542|NCT04352231|EXPERIMENTAL|High to Low Fiber Diet Intervention|Participants receive the high fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the low fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
61923543|NCT04352231|EXPERIMENTAL|Low to High Fiber Diet Intervention|Participants receive the low fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the high fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
62683944|NCT05137054|EXPERIMENTAL|Cohort 4: Linvoseltamab + Bortezomib|Linvoseltamab + Bortezomib
62313473|NCT02943551|OTHER|Providers|"Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.~Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports."
62477991|NCT03407287||Distributive shock|
62477992|NCT03407287||Vasoactive and inotropic agents|
62477993|NCT03407287||Congestive heart failure|
62683945|NCT05137054|EXPERIMENTAL|Cohort 5: Linvoseltamab + Pomalidomide|Linvoseltamab + Pomalidomide
62683946|NCT05137054|EXPERIMENTAL|Cohort 6: Linvoseltamab + Isatuximab|Linvoseltamab + Isatuximab
62683947|NCT05137054|EXPERIMENTAL|Cohort 7: Linvoseltamab + Fianlimab|Linvoseltamab + Fianlimab
62477994|NCT03407287||Atrial fibrillation|Patients with atrial fibrillation undergoing elective direct current cardioversion
62477995|NCT03407287||Patients undergoing surgery|Patients undergoing surgery requiring positive pressure ventilation and arterial line placement
62477996|NCT04499664||Blood donors|Healhy young male bloddonors, aged 30-45
62477997|NCT01966484|ACTIVE_COMPARATOR|Succinylcholine|Patient receive succinylcholine as a muscle relaxant (0,5mg/kg) after induction of general anaesthesia for rigid bronchoscopy.
62477998|NCT01966484|ACTIVE_COMPARATOR|Mivacurium|Patients receive mivacurium (0,08mg/kg) as a muscle relaxant after induction of general anaesthesia for rigid bronchoscopy. At the end of the procedure and a twitch of 25% mivacurium was reversed with neostigmine (50 microg/kg) and atropin (10 microg/kg)
62683948|NCT05137054|EXPERIMENTAL|Cohort 8: Linvoseltamab + Cemiplimab|Linvoseltamab + Cemiplimab
62683949|NCT05137054|EXPERIMENTAL|Cohort 9: Linvoseltamab + Nirogacestat|Linvoseltamab + Nirogacestat
62683950|NCT05825742|EXPERIMENTAL|Lumoral Treatment (Study group)|"Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.~Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines."
62683951|NCT05825742|OTHER|Standard of care (Control group)|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
62683952|NCT06691724||GP 01|General practitioner working with/without the tool
62683953|NCT06691724||GP 02|General practitioner working with/without the tool
62683954|NCT06691724||GP 03|General practitioner working with/without the tool
62683955|NCT06691724||GP 04|General practitioner working with/without the tool
62683956|NCT06691724||GP 05|General practitioner working with/without the tool
62683957|NCT06691724||GP 06|General practitioner working with/without the tool
62477999|NCT05383807|EXPERIMENTAL|Warna-Warni Waktu intervention|Participants in this condition are asked to view six, approximately five-minute videos (each with a number of associated short, interactive reinforcer activities), at a pace of one video per day, for 6 days.
62478000|NCT05383807|NO_INTERVENTION|Waitlist control condition|These participants are not contacted during the intervention timeframe.
62478001|NCT06253533|EXPERIMENTAL|Low-dose Group|Clinically stable HIV-infected patients under ART treatment will receive 1 mg/dose ICVAX or Placebo at 4:1 ratio. ICVAX and Placebo will be administered via intramuscular injection followed by electroporation at 0, 4th, 8th, 12th, and 36th week.
62478002|NCT06253533|EXPERIMENTAL|Medium-dose Group|Clinically stable HIV-infected patients under ART treatment will receive 2 mg/dose ICVAX or Placebo at 4:1 ratio. ICVAX and Placebo will be administered via intramuscular injection followed by electroporation at 0, 4th, 8th, 12th, and 36th week.
62478003|NCT06253533|EXPERIMENTAL|High-dose Group|Clinically stable HIV-infected patients under ART treatment will receive 4 mg/dose ICVAX or Placebo at 4:1 ratio. ICVAX and Placebo will be administered via intramuscular injection followed by electroporation at 0, 4th, 8th, 12th, and 36th week.
62478004|NCT02412085|EXPERIMENTAL|Golimumab|Subcutaneous golimumab
61923544|NCT02050542|OTHER|Targeted biopsies guided by a fusion of MRI and ultrasound|After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
61923545|NCT02050542|OTHER|Systematic biopsies|The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
62313474|NCT02943551|OTHER|Parents|"The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.~Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit."
62313475|NCT04210713|ACTIVE_COMPARATOR|AUD-Minocycline|Participants diagnosed with alcohol use disorder will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
62313476|NCT04210713|PLACEBO_COMPARATOR|AUD-Placebo|Participants diagnosed with alcohol use disorder will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
62683958|NCT06691724||GP 07|General practitioner working with/without the tool
62313477|NCT04210713|ACTIVE_COMPARATOR|Healthy Control-Minocycline|Healthy control participants will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
62313478|NCT04210713|PLACEBO_COMPARATOR|Healthy Control-Placebo|Healthy control participants will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
62313479|NCT00477373|EXPERIMENTAL|1|If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.
62313480|NCT01048515|EXPERIMENTAL|Caffeine|
62313481|NCT01048515|PLACEBO_COMPARATOR|Placebo|
62478005|NCT06626698|EXPERIMENTAL|Experimental: static stretching|Passive static stretching of the posterior leg muscles. Single session of 30 seconds per 4 sets with 30 seconds of rest
61923546|NCT02168426|ACTIVE_COMPARATOR|Guardix|6g per body
61923547|NCT02168426|ACTIVE_COMPARATOR|Seprafilm|1 sheet per body
61923548|NCT02848053||Tianqi group|used Tianqi Capsule in the REDUCES study
61923549|NCT02848053||Placebo group|used placebo in the REDUCES study
62313482|NCT02797873|EXPERIMENTAL|EIP|"Patients from the DBT unit suffering from symptoms of Emotional Instability (n=30), with different levels of ADHD symptoms as assessed by questionnaires Brown-ADD, ASRS and SDQ.~Interventions:~* fMRI - Stroop task~* fMRI - MID task~* Stop Signal task~* Structural T1 MRI scan~* Structural T2 MRI scan~* DTI MRI scan~* Resting state MRI scan~* FEFA 2~* SCID-II~* SDQ~* ASRS~* AQ~* TAS-20~* Raven's SPM~* Reading ability~* Ishihara's tests for colour deficiency~* Additional questionnaire~* Brown-ADD~* MFQ~* STAI-T~* BIS~* DAWBA~* STAI-S~* Sleepiness rating x 6~* Motivation rating x 6"
62478006|NCT06626698|EXPERIMENTAL|Experimental: EME|Electrical muscle elongation with interferential current. Dosage: 4kHz frequency and 100Hz frequency modulation amplitude. Self-adhesive surface electrodes (50x90 mm) and SONOPULS-492 equipment. Single session of 30 seconds per 4 sets with 30 seconds of rest.
62478007|NCT03110874|EXPERIMENTAL|Experimental group (one-way education)|"Experimental group (one-way education)~* Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~* video based education"
62478008|NCT03110874|ACTIVE_COMPARATOR|Control group(two-way education)|"Control group(two-way education)~* Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~* direct education"
62683959|NCT06691724||GP 08|General practitioner working with/without the tool
62683960|NCT06691724||GP 09|General practitioner working with/without the tool
62683961|NCT06691724||GP 10|General practitioner working with/without the tool
62683962|NCT06690008|EXPERIMENTAL|Experimental group (SDF group)|SDF application: -Vaseline will be used to isolate and protect the soft tissues (gums and lips); -Then, SDF will be dispensed on paraffin paper according to the dosage guide; - SDF will be applied on dental surfaces and rubbed with a micro-applicator (1'); -Patients will be asked not to eat/drink/rinse (30').
61923550|NCT03953118|PLACEBO_COMPARATOR|Placebo|
61923551|NCT03953118|ACTIVE_COMPARATOR|Azithromycin|
62683963|NCT06690008|ACTIVE_COMPARATOR|Control group NaF group)|NaF application: - NaF will be dispensed according to the dosage guide; -all tooth surfaces will be brushed with NaF; -The patient will close his/her mouth until NaF get hard; -Patients will be asked not to eat/drink/rinse (30') Do not brush teeth that day.
62313483|NCT02797873|EXPERIMENTAL|Healthy controls|"Matched healthy controls (according to age, IQ and socio economic status) recruited from high schools in Stockholm area (n=30).~Interventions:~* fMRI - Stroop task~* fMRI - MID task~* Stop Signal task~* Structural T1 MRI scan~* Structural T2 MRI scan~* DTI MRI scan~* Resting state MRI scan~* FEFA 2~* SCID-II~* SDQ~* ASRS~* AQ~* TAS-20~* Raven's SPM~* Reading ability~* Ishihara's tests for colour deficiency~* Additional questionnaire~* Brown-ADD~* MFQ~* STAI-T~* BIS~* DAWBA~* STAI-S~* Sleepiness rating x 6~* Motivation rating x 6"
62683964|NCT02534155|ACTIVE_COMPARATOR|MitraClip® Therapy|MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.
62683965|NCT02534155|ACTIVE_COMPARATOR|Surgery|Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard
62313484|NCT04635644|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Patients will receive Erector spinae plane block.
62478009|NCT01628835|EXPERIMENTAL|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided.
62478010|NCT01628835|ACTIVE_COMPARATOR|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
62478011|NCT00907907|EXPERIMENTAL|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
62478012|NCT00907907|ACTIVE_COMPARATOR|Cellcept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
62478013|NCT06626763||Experimental|Children will be measured 5 times using a pulse oximeter. The measurements will be performed consecutively without any interval between them. The first measurement will be performed without using any gloves on the patient's finger, the second measurement will be performed using transparent gloves, the third measurement will be performed using white gloves, the fourth measurement will be performed using black gloves, and the fifth measurement will be performed using blue gloves.
62478014|NCT01213797||Suicide attempter and its entourage|"Suicide attempter and its close relatives (who are living under the same roof)~Comparison of the population of the close relations of committing suicide with the data of the Research Institute and Documentation in Economy of Health (IRDES) on the French population (sample of 20.000 people, representative of 95% of the French households)."
62478015|NCT05510830|EXPERIMENTAL|Patients|The patients who meet the inclusion criteria will receive diagnostic cervical conization for pathological examinations. Then they will be followed up for at least two years with every six months' return to our clinics to test HPV and colposcopy if necessary.
62683966|NCT06513416||PPCs+ group|Patients who experienced postoperative pulmonary complications belong to the PPC positive group
62478016|NCT02072577|EXPERIMENTAL|Knowledge|Educational video.
62478017|NCT03716466||Endotracheal intubation|Cases with prophylactic endotracheal intubation during urgent endoscopy procedure for upper gastrointestinal bleeding .
62478018|NCT03716466||No airway intervention|Cases without airway intervention during urgent endoscopy procedure for upper gastrointestinal bleeding
62683967|NCT06513416||PPCs- group|Patients who experienced no postoperative pulmonary complications belong to the PPC negative group
62478019|NCT05131113|NO_INTERVENTION|Control group|The control group will receive the usual care and hygiene recommendations of the movement
62683968|NCT03193437|EXPERIMENTAL|Selinexor|Open Label Selinexor 40 mg
62683969|NCT05021042||Acute mastitis (MA)|Lactating women with confirmed acute mastitis
62478020|NCT05131113|EXPERIMENTAL|Interventionist group|The interventional group will add an individualized physical exercise program to the usual care.
62683970|NCT05021042||Subacute mastitis (SAM)|Lactating women with confirmed subacute mastitis
62683971|NCT05021042||Control (CT)|Lactating women with the absence of acute or subacute mastitis symptomatology.
62683972|NCT06385834|EXPERIMENTAL|Morning rehabilitation group|Patients were randomly assigned to the morning rehabilitation group（8:00-9:00AM） for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week.
62683973|NCT06385834|EXPERIMENTAL|Evening rehabilitation group|Patients were randomly assigned to an Evening rehabilitation group(16:00-17:00PM) for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week.
62313485|NCT04635644|ACTIVE_COMPARATOR|Intrathecal morphine ITM|Patients will receive Intrathecal morphine.
61923552|NCT03718325|OTHER|Burst-SCS/sham SCS|First, participants will receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation. Then, participants will have their stimulation adjusted to receive sham (no) SCS. Study evaluations will be completed prior to and after this sham.
62683974|NCT06385834|NO_INTERVENTION|Control group|Patients randomly assigned to the control group will receive standard care, regular follow-up, optimized medication, and recommendations for a healthy lifestyle.
62313486|NCT06672835|EXPERIMENTAL|eBASIS|eBASIS is an online, optimized, and evidence-based practice agnostic implementation strategy that addresses the behavioral component often missing from standard evidence-based practice training and consultation. It relates to motivation before and volition after the evidence-based practice training and targets behavioral intentions by improving attitudes, subjective norms, and self-efficacy. The implementation strategy is designed to be designed to be delivered within the Preparation/Adoption phase immediately prior to the Action implementation in the EPIS model.
62478021|NCT00178802|OTHER|1|thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
62683975|NCT04949087|EXPERIMENTAL|Corticosteroid Injection Group|80mg Depo-Medrol and 8cc Lidocaine ultrasound-guided intra-articular injection
62683976|NCT04949087|ACTIVE_COMPARATOR|Platelet-Rich Plasma Injection Group|15cc blood draw in Arthrex Autologous Conditioned Plasma (ACP) kit and processed per manufacturer instructions Ultrasound-guided intra-articular injection of isolated PRP
62683977|NCT06688890|EXPERIMENTAL|1. Surgical hand rub with the reference product; n-propanol 60%.|
62683978|NCT06688890|EXPERIMENTAL|2. Surgical hand rub with the product P1; Sorbectol for 1 min.|
62683979|NCT06688890|EXPERIMENTAL|3. Surgical hand rub with the product P2;Sorbectol for 3 min.|
62683980|NCT06688890|EXPERIMENTAL|4. Surgical hand rub with the product P3; Sorbectol for 5 min.|
62683981|NCT05806372||HDP with FGR|Evaluation of sera and ultrasound data on fetal growth and Doppler velocimetry in women with HDP and fetal growth restriction.
62478022|NCT04629963|EXPERIMENTAL|Aim 1: Pain Evaluation|Participants will complete the validated pain questionnaire, the Brief Pain Inventory Short Form (BPISF). Participants will receive a non-invasive physical exam and pain assessment by a pain specialist.
62683982|NCT05806372||HDP without FGR|Evaluation of sera and ultrasound data on fetal growth and Doppler velocimetry in women with HDP and without fetal growth restriction.
62683983|NCT05806372||Normotensive|Evaluation of sera and ultrasound data on fetal growth and Doppler velocimetry in normotensive women.
62683984|NCT05498220|EXPERIMENTAL|Single Arm|The subjects with diffuse large B-cell lymphoma were relapsed or refractory after the first treatment and receiving the study protocol treatment.
62683985|NCT06499909|EXPERIMENTAL|Hypnosis|Patient receives hypnosis treatment prior to surgery
62683986|NCT06499909|NO_INTERVENTION|Normal care pathway|Patient will receive standard care
62683987|NCT00214526|EXPERIMENTAL|Alair Group|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
62683988|NCT00214526|ACTIVE_COMPARATOR|Control Group|Conventional therapy with ICS+LABA.
62683989|NCT06690216|EXPERIMENTAL|[18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors|This arm involves the administration of \[18F\]AlF-NOTA-PCP2 via intravenous injection followed by whole-body PET/CT imaging one hour later. The objective is to assess the uptake of \[18F\]AlF-NOTA-PCP2 in malignant tumors and correlate it with PD-L1 expression. This imaging technique is used to evaluate PD-L1 expression in glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer patients before treatment, providing a non-invasive, repeatable, and comprehensive approach to guide immunotherapy decisions.
61923553|NCT03718325|OTHER|Sham SCS/Burst-SCS|First, participants will receive sham (no) SCS. Study evaluations will be completed prior to and after this sham. Then, participants will have their stimulation adjusted to receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation.
61923554|NCT03548090|EXPERIMENTAL|1|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
62683990|NCT06121284|EXPERIMENTAL|D-Cycloserine|Participants will orally ingest a standard 100mg dose of D-Cycloserine daily (Monday-Friday) during 2 weeks of accelerated rTMS treatments (20 sessions; 2 sessions/day separated by 1 hour). D-Cycloserine will be ingested 60-120 minutes prior to the first rTMS treatment of the day.
62313487|NCT06672835|PLACEBO_COMPARATOR|eAttention Control|eAC is an online control for eBASIS. Providers assigned to eAttention Control (eAC) will receive pre- and post-training experiences designed to mirror those received in eBASIS. These training experiences will be delivered on the same platform and be approximately the same length as the eBASIS but will not contain any eBASIS content or mechanisms of change. The eAC pre-training experience will define, describe, and advocate for evidence-based practice implementation in schools. Content in eAC will be didactic similar to a typical professional development training for providers.
62313488|NCT02013934|ACTIVE_COMPARATOR|Probiotics|Dietary supplement
62313489|NCT02013934|PLACEBO_COMPARATOR|Placebo|Dietary supplement
62313490|NCT06035380|EXPERIMENTAL|rose oil|rose oil will be used
62313491|NCT06035380|EXPERIMENTAL|mint oil|mint oil will be used
62478023|NCT04629963|NO_INTERVENTION|Aim 2: Qualitative Interview|Participants will complete individual interviews moderated by the research staff. Interviews will be based on the guide but will be minimally structured to facilitate exploration of novel topics as raised by participants and to ensure information-rich data on topics of interest. Individual interviews will be \~30-45 minutes in length, conducted in the subject's primary language with the use of an interpreter as appropriate. All interviews will be audio-recorded with participants' permission, transcribed, and translated into English for analysis.
62478024|NCT04629963|EXPERIMENTAL|Aim 3: Enrollment in a digital program assessing stress, pain, and cardiovascular health|"Continuous cardiovascular, stress, and pain data collection will occur for 6 months after enrollment. Biometric data including continuous heart rate, actigraphy, sleep, and derived physiological parameters will be collected using the wearable device. Pain and stress evaluations will be administered via a smartphone app as a survey of stress, pain, or cardiovascular symptoms.~Participants will complete surveys assessing chronic pain, mental health, trauma history, migration stress, and cardiovascular risk factors and disease Total cholesterol, HDL, LDL, triglycerides, and glucose will be measured using a lipid analyzer with a fingerstick blood sample. Height, weight, and blood pressure will also be measured."
62478025|NCT04665596|EXPERIMENTAL|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
62478026|NCT06628115|EXPERIMENTAL|Cerament|Cerament V/G implantation to forefoot or mid foot.
62478027|NCT01270594|EXPERIMENTAL|COPD Counseling Intervention|Pharmacist counseling intervention delivered via telephone.
62478028|NCT01270594|OTHER|Usual Care|
62683991|NCT06121284|PLACEBO_COMPARATOR|Placebo|Participants will orally ingest a standard 100mg dose of a microcrystalline placebo capsule daily (Monday-Friday) during 2 weeks of accelerated rTMS treatments (20 sessions; 2 sessions/day separated by 1 hour). The Placebo will be ingested 60-120 minutes prior to the first rTMS treatment of the day.
62683992|NCT04804007|EXPERIMENTAL|Maintenance Oral Etoposide|Maintenance daily oral Etoposide.
62683993|NCT04804007|NO_INTERVENTION|Observation|If randomized to Observation, subjects will jump to follow-up.
62683994|NCT03049397|EXPERIMENTAL|Supportive Care (Enhancing Connections program)|Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
62683995|NCT00421408|EXPERIMENTAL|Protein powder|Participants will receive a protein supplement daily (40 g whey protein supplement).
62683996|NCT00421408|PLACEBO_COMPARATOR|Placebo carbohydrate|Participants will receive a placebo supplement daily (40 g maltodextrin).
62683997|NCT03655639||Premature Birth|Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
62683998|NCT06690346|EXPERIMENTAL|Experimental group|Systematic oral health education
62683999|NCT06690346|OTHER|Control group|Routine oral health education
62684000|NCT00226044|NO_INTERVENTION|Oral omeprazole|Standard of care: A single dose of 1 mg/kg orally administered omeprazole.
62684001|NCT00226044|ACTIVE_COMPARATOR|Rectal omeprazole|A single dose of 1 mg/kg rectally administered omeprazole.
62684002|NCT04442750|EXPERIMENTAL|A (0.5%) group|patients will receive a single shot erector spinae block with 30 ml 0.5% bupivacaine followed by general anesthesia
62684003|NCT04442750|EXPERIMENTAL|B (0.375%) group|patients will receive a single shot erector spinae block with 30 ml 0.375% bupivacaine followed by general anesthesia
62684004|NCT04442750|EXPERIMENTAL|C (0.25%) group|patients will receive a single shot erector spinae block with 30 ml 0.25% bupivacaine followed by general anesthesia
62684005|NCT04718441|EXPERIMENTAL|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
62684006|NCT05990465|EXPERIMENTAL|Pirtobrutinib and CAR T Cells|Pirtobrutinib is an oral agent. LV20.19 CAR T cells will be administered either fresh or thawed after cryopreservation by IV injection.
62313492|NCT06035380|PLACEBO_COMPARATOR|plasebo|drinking water will be used
62313493|NCT03005535|ACTIVE_COMPARATOR|Vitaminized corn oil|Vitaminized corn oil (plus B6 and E vitamins), 30 g per day, per 8 weeks, with meals (15 g per meal)
62313494|NCT03005535|PLACEBO_COMPARATOR|Olive oil|Olive oil (not extra-virgin), 30 g per day, per 8 weeks, with meals (15 g per meal)
62313495|NCT06299007||Group 1|Patients who were admitted due to upper gastrointestinal bleeding and had anemia
62684007|NCT06687044|EXPERIMENTAL|Sleep improvement Therapy group(CBT-I)|
62684008|NCT06687044|PLACEBO_COMPARATOR|Control group (TAU)|
62684009|NCT00964522|NO_INTERVENTION|Standard care|The arm A is the one of standard education and care.
62684010|NCT00964522|ACTIVE_COMPARATOR|Nurse education and care program|The arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation.
62313496|NCT05113004|PLACEBO_COMPARATOR|Arm 1|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d"
62478029|NCT00835536|EXPERIMENTAL|1|
62478030|NCT00835536|ACTIVE_COMPARATOR|2|
62478031|NCT06485323|EXPERIMENTAL|IRM + CT scan for Pelvimetry|
62478032|NCT00573443|EXPERIMENTAL|DM 30 mg/Q 10 mg|AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
62478033|NCT00573443|EXPERIMENTAL|DM 20 mg/ Q 10 mg|AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
62478034|NCT00573443|PLACEBO_COMPARATOR|Placebo|Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks
62478035|NCT05124366|EXPERIMENTAL|Study group|Nanovitamin E, nanovitamin C and propolis extract gel
62313497|NCT05113004|OTHER|Arm 2|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d"
62313498|NCT05113004|OTHER|Arm 3|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d"
62478036|NCT05124366|PLACEBO_COMPARATOR|Placebo|Gel without nanovitamin E, nanovitamin C and propolis extract
62478037|NCT02399423|OTHER|South Asian participants|30 South Asian male participants
62478038|NCT02399423|OTHER|European participants|30 European male participants
62478039|NCT06470906|EXPERIMENTAL|Probiotic Intervention|Participants will take one dose every day with water, for 4 weeks.
62478040|NCT06470906|PLACEBO_COMPARATOR|Placebo|Participants will take one dose every day with water, for 4 weeks.
62478041|NCT05499897|PLACEBO_COMPARATOR|Group general anesthesia|(Patients who will be operated under general anesthesia): Standard ASA monitoring, induction with 2 mg/kg propofol, 0.6mg/kg rocuronium bromide, 1µcg/kg fentanyl. Maintenance with 2MAC sevoflurane + 40% air mixture. Flow 2L/min. Before extubation, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals.
62478042|NCT05499897|EXPERIMENTAL|Group interscalene|(Patients who will undergo surgery with interscalen block): 20 ml of 0.25% bupivacaine for anesthesia. Before being taken to the postoperative unit, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals.
62313499|NCT05113004|PLACEBO_COMPARATOR|Arm 4|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d"
62313500|NCT05113004|OTHER|Arm 5|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d"
62313501|NCT05113004|OTHER|Arm 6|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d"
62478043|NCT00130377|EXPERIMENTAL|cell therapy|Patient receiving active biologic
62478044|NCT00130377|PLACEBO_COMPARATOR|control|Patient receiving placebo or standard of care
62313502|NCT02307526|EXPERIMENTAL|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
62478045|NCT00641134|OTHER|A|A:Home-Based exercise program,-at discharge from in-Hospital CR program-, with one reinforcement session each month for the first 6 months.
62478046|NCT00641134|NO_INTERVENTION|B|Usual care, after CR, consisting of recommendation on usefulness of physical exercise and standard follow-up visits and functional assessment at 6 and 12 months.
62478047|NCT04535388|OTHER|LK scleral lens|LK scleral lens (Lucid Korea LTD, Seoul, Republic of Korea) are worn for 12 weeks.
62478048|NCT06623591|EXPERIMENTAL|Active Transcutaneous auricular vagus nerve stimulation|For Experimental Arm, active transcutaneous auricular vagus nerve stimulation, Patients underwent 28 consecutive daily sessions of taVNS.
62684011|NCT03139266|EXPERIMENTAL|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
62684012|NCT03139266|OTHER|Control Group|Treatment-as-usual
62684013|NCT05029999|EXPERIMENTAL|Cohort A|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
62123553|NCT05985824|EXPERIMENTAL|Applications to the Intervention Group|Patients with lung cancer admitted to the outpatient chemotherapy unit will be given pranayama breathing exercises every day for 4 weeks, covering 15-20 minutes. In patient education, the pranayama breathing exercise will be applied face-to-face by the researcher on the first day of chemotherapy treatment, before drug treatment. The application steps will be repeated until the patient learns, both by explaining and showing the patient, and if there are points that the patient cannot do, they will be corrected. When the patients are observed to perform the application fully and the chemotherapy treatments are finished, they will be asked to do the pranayama breathing exercise every day for 4 weeks, and with the same researcher 3 days a week (Monday, Wednesday, Saturday) with a smart phone whatsapp video call, the effectiveness and continuity of the application will be ensured and the patients will be monitored.
62313503|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
62313504|NCT04805931|NO_INTERVENTION|Control|Will receive a text message with standard messaging used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
62313505|NCT04805931|EXPERIMENTAL|Scarcity|Will receive a text message with a behavioral scarcity message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
62313506|NCT04805931|EXPERIMENTAL|Social good|Will receive a text message with a behavioral social good message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
62313507|NCT05237882|EXPERIMENTAL|Children and Adolescents|6 children aged 8-12 years old, 6 adolescents aged 13-17 years old, fulfilling inclusion criteria will be included
62313508|NCT06671028|ACTIVE_COMPARATOR|Ropivacaine|Popliteal block using Ropivacaine 100 mg in 20 mL
62313509|NCT06671028|EXPERIMENTAL|Ropivacaine anmd Lidocaine|Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL
62313510|NCT06671236|EXPERIMENTAL|Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)|Regulatory T cell therapy, intrathecal injection
62313511|NCT06513195|EXPERIMENTAL|EUS-PPG before and after NSBB|Patients will undergo EUS-PPG and HVPG before and after NSBB treatment and will thus serve as their own control.
62684014|NCT05029999|EXPERIMENTAL|Cohort C|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle starting on cycle 2 until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 2 and 3 only."
62684015|NCT03017911||Patients with PICC Lines|All patients included in this study have undergone PICC Line placement before enrollment.
62684016|NCT01669889||Cohort|
62684017|NCT03810495|EXPERIMENTAL|OLANI (naltrexone implant)|2 OLANI containing 60% naltrexone (1.8 g total) administered one time subcutaneously
61923555|NCT03548090|EXPERIMENTAL|2|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
62123554|NCT05985824|NO_INTERVENTION|Applications to the Control Group|A pre-test will be applied to lung cancer patients in the control group who applied to the day chemotherapy unit. After the application of the personal information form and the quality of life scale, no breathing exercises will be performed. Individuals will continue their daily lives. After 4 weeks, the quality of life scale will be administered again. After the implementation of the quality of life scale, pranayama breathing exercise training will be given to all control group patients and they will be applied for 2 sessions.(The study will begin before the patients in both the experimental and control groups receive chemotherapy, which is their routine treatment).
62123555|NCT04200365|EXPERIMENTAL|Itacitinib|
62123556|NCT03286244|EXPERIMENTAL|CM082 plus paclitaxel|"In dose-escalation part, patients will be treated in dose levels at the following daily doses of CM082 and paclitaxel to establish the MTD and RP2D:~CM082 100mg qd + paclitaxel 80mg/m2/day; CM082 150mg qd + paclitaxel 80mg/m2/day; CM082 200mg qd + paclitaxel 80mg/m2/day; In dose-expansion part, patients will be treated at the RP2D established in dose escalation part."
62123557|NCT02308618|EXPERIMENTAL|Traditional Immobilization|45 days of plaster cast immobilization After the immobilization period, subjects received instructions on how to perform a home-based exercise program
62313512|NCT02905773|OTHER|postoperative pain|postoperative pain
62313513|NCT02905773|OTHER|intensity|intensity
62478049|NCT06623591|SHAM_COMPARATOR|Sham Transcutaneous auricular vagus nerve stimulation|For sham transcutaneous auricular vagus nerve stimulation arm, Sham Comparator, patients underwent 28 consecutive daily sessions of sham-taVNS (the electrodes were fixed at the the left earlobe).
62684018|NCT05671861|EXPERIMENTAL|Part I (medical device usage, questionnaire)|Each participant will complete a single 45-minute visit in which consists of questionnaires about features that are important to them in trismus treatment, test a prototype of a trismus therapy device, and complete an online feedback questionnaire about their experience using the device.
62684019|NCT05671861|EXPERIMENTAL|Part II (medical device usage, mobile app usage)|Participants will be asked to use the device at least three times per week and up to daily for a period of 15-20 minutes over 6 weeks. Participants will be evaluated at baseline, at the 3-week (halfway) visit, and at the end of the 6-week treatment period under supervision of a speech language pathologist on study. Participants will then utilize a mobile app to help track treatment progress.
62684020|NCT05118438|EXPERIMENTAL|Nursing intervention|The recruited participants were clients of a self-sufficiency support center for sexually exploited women located in South Korea, recruited through snowball sampling after obtaining permission from the director of the support center.
62684021|NCT00940511|EXPERIMENTAL|Coordinated care|Individuals will be passively enrolled in Medicaid managed care. Those who do not opt out of managed care will be provided with care coordination.
62684022|NCT00940511|NO_INTERVENTION|Usual care|The usual care group will remain in fee-for-service Medicaid and receive services normally available through that system.
62123558|NCT02308618|EXPERIMENTAL|Early mobilization|Six weeks of physical therapy program
62123559|NCT02308618|NO_INTERVENTION|Control|Subjects had no history of lower limb injury, and were matched in age and anthropometric measurements to subjects that performed physical rehabilitation and to subjects that remained immobilized.
62123560|NCT01723410|EXPERIMENTAL|Writing condition|Subjects will be asked to write about other individuals in their lives.
62123561|NCT01723410|PLACEBO_COMPARATOR|Writing|Subjects will be asked to write about places or objects in their lives.
62313514|NCT06123429|EXPERIMENTAL|Intervention group|All participants enrolled in the study will be enrolled in the Mindfulness-Based Stress reduction course. The MBSR course will consist of weekly sessions lasting two and a half hours, involving lecture, meditation, and self-reflection. The first MBSR course will be ready for 10-12 participants in November 2023. The following course will start every month thereafter. The courses will be held online over Zoom.
62313515|NCT06667336|ACTIVE_COMPARATOR|Intermittent Suction|This suction was applied only as needed to clear secretions
62313516|NCT06667336|ACTIVE_COMPARATOR|Continuous Suction|The suction catheter was inserted at the start of laryngoscopy and maintained in the oropharynx until the moment of ETT delivery
62313517|NCT05000606|EXPERIMENTAL|A home visit program|A home visit program including five visits over three months were performed.
62313518|NCT05000606|NO_INTERVENTION|Control|No other intervention was applied to the control group other than the standard education given in the outpatient clinic
62684023|NCT01445483||1/Cohort 1|KPS\>70; Age =65; controlled primary tumor and no extracranial metastases
62684024|NCT01445483||2/Cohort 2|KPS\>70 and at least one of the following: age \>65, uncontrolled or synchronous primary disease, or extracranial metastases
62684025|NCT01445483||3/Cohort 3|KPS\<70
62313519|NCT04433520||ASD/PFO cohort|"Subjects indicated for atrial septal defect (ASD) closure with either the ASO or ASD-MF devices as well as subjects indicated for patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder.~The Amplatzer Trevisio Delivery System is to be used for facilitating percutaneous, transcatheter implantation of the occluders."
62684026|NCT04131894|NO_INTERVENTION|Control|Extraction sockets with spontaneous healing (16 sockets).
62684027|NCT04131894|ACTIVE_COMPARATOR|Dentin|Extraction sockets were filled with undemineralized autogenous dentin graft (20 sockets).
62684028|NCT04131894|ACTIVE_COMPARATOR|Dentin+PRF|Extraction sockets were filled with mixture of undemineralized autogenous dentin graft and platelet rich fibrin (PRF) (21 sockets).
62123562|NCT02444598|EXPERIMENTAL|Negative-pressure wound therapy|Vaccum Assisted Closure device. Patients will receive negative-pressure wound therapy according to manufacturer treatment guidelines.
62123563|NCT02444598|ACTIVE_COMPARATOR|Standard|Patients will be treated with conventional wound dressings according to local treatment protocols.
62123564|NCT04141865||Xen|Patients treated with a Xen microstent for glaucoma.
62313520|NCT04433520||VSD cohort|Subjects indicated for ventricular septal defect (VSD) closure with either the MuscVSD or PIVSD occluders.
62313521|NCT02836886||Sézary syndrome|Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
62313522|NCT04175912|EXPERIMENTAL|Arm A (pevonedistat)|Patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62313523|NCT04175912|EXPERIMENTAL|Arm B (pevonedistat, paclitaxel, carboplatin)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 15-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Starting cycle 5, patients may receive pevonedistat monotherapy at the discretion of treating physician.
62313524|NCT01771094|PLACEBO_COMPARATOR|Group 1 (placebo) - Water|This group will drink water in 1st trial
62313525|NCT01771094|EXPERIMENTAL|"Group 3 (Intervention) - Low Sucralose"|This group will drink Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage in 1st trial
62313526|NCT01771094|EXPERIMENTAL|"Group 2(Intervention)-High Sucralose"|This group will drink Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage in 1st trial
62313527|NCT00850772|EXPERIMENTAL|Early post-operative enteral feeding|Standard post-operative care and diet together with early post-operative enteral feeding
62313528|NCT00850772|NO_INTERVENTION|Standard post-operative care and diet|Standard post-operative care and diet only
62313529|NCT05151744|EXPERIMENTAL|Arm A: Vamikibart + Ranibizumab|Participants will receive vamikibart, 1 milligram (mg) administered as intravitreal (IVT) injection in combination with ranibizumab, 0.5 mg IVT, on Day 1 and every fourth week (Q4W) up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
62313530|NCT05151744|ACTIVE_COMPARATOR|Arm B: Ranibizumab|Participants will receive ranibizumab, 0.5 mg IVT, from Day 1 and Q4W in combination with sham up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
62684029|NCT01872182|EXPERIMENTAL|Test arm|ALS-L1023 300mg in two tablets
62684030|NCT01872182|PLACEBO_COMPARATOR|Comparator arm|placebo in two tablets
62684031|NCT02431520|EXPERIMENTAL|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for Hybrid Capture II (HCII).
62684032|NCT02431520|ACTIVE_COMPARATOR|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
62684033|NCT00684554|ACTIVE_COMPARATOR|Unobserved-at home|Buprenorphine Unobserved at home induction
62123565|NCT04141865||Aqueous shunt|Patients treated with an aqueous shunt for glaucoma.
62123566|NCT05715957||female carriers of DMD gene variants|
62123567|NCT05715957||patients with BMD|
62123568|NCT03477695|EXPERIMENTAL|Upright device|Ambulatory use of the Upright device
62123569|NCT02540746|EXPERIMENTAL|ERG Skills Training|ERG Skills Training for 12 weeks
62313531|NCT02958137||Isolated CMC|Arthroscopic Resection Arthroplasty of isolated CMC joint OA. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
62313532|NCT02958137||Pantrapezial|Arthroscopic Resection Arthroplasty of simultaneous ARA of both the CMC and the STT joints. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
62684034|NCT00684554|ACTIVE_COMPARATOR|Observed|Buprenorphine Observed in office induction
62684035|NCT02988674||Participants with Spondylarthritis|Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.
62684036|NCT06673914|ACTIVE_COMPARATOR|Control Group: Diet Group|Control Group: Diet Group Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and be followed up by a dietician.
62684037|NCT06673914|EXPERIMENTAL|Experimental: Oleuropein and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 2 capsules which100 grams of standardized oleuropein-containing olive leaf extract.
62684038|NCT05591300||Patients|Patients with acute CO poisoning needing a hyperbaric oxygen treatment
62684039|NCT05591300||Healthy controls|Healthy controls i.e., healthy phisicians than will enter the hyperbaric oxygen therapy chamber to assist the patients
62684040|NCT03720275|EXPERIMENTAL|patients with chronic neuropathy of unknown aetiology|For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
62123570|NCT02540746|EXPERIMENTAL|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
62123571|NCT02540746|EXPERIMENTAL|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
62313533|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
62313534|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
62478050|NCT04435197|EXPERIMENTAL|Arm A|"Arm 1:~A: Pembrolizumab 200mg(100mg if weight less than 50kg) IV on days 1 and 22 B: Carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~D: Ivor-Lewis or McKeown esophagectomy~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
62478051|NCT04776226|NO_INTERVENTION|Patients without depression|This group included patients without depression during enrollment of the cases.
62478052|NCT04776226|EXPERIMENTAL|Depressive patients with treatment|This group included patients wit depression but with treatment during enrollment of the cases.
62478053|NCT04776226|NO_INTERVENTION|Depressive patients wihout treatment|This group included patients without depression but withou treatment during enrollment of the cases.
61923556|NCT03548090|EXPERIMENTAL|3|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
62123572|NCT02540746|EXPERIMENTAL|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
62123573|NCT03967704|EXPERIMENTAL|Life quality evaluation|"Patients consulting the Emergency Department (SAU) or the rheumatology department of the GHPSJ (referred by a colleague orthopaedic surgeon, rheumatologist, radiologist or other) for a recent symptomatic osteoporotic dorsal or lumbar vertebral fracture, are called for a rheumatology consultation, vertebral fracture consultation.~Patients consulting in the rheumatology department during a spinal fracture consultation at the GHPSJ as well as patients hospitalized in the rheumatology department at the GHPSJ are selected consecutively.~- Arm 1 (intervention): two additional consultations with the rheumatology"
62123574|NCT05928637|EXPERIMENTAL|Sequence 1|"* Period 1: oral dose of D745 1 tablet.~* Period 2: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~* Period 3: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150."
62123575|NCT05928637|EXPERIMENTAL|Sequence 2|"* Period 1: oral dose of D745 1 tablet.~* Period 2: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~* Period 3: multiple oral dose of 1 tablet of D759 and 2 tablets of D150."
62123576|NCT05928637|EXPERIMENTAL|Sequence 3|"* Period 1: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~* Period 2: oral dose of D745 1 tablet.~* Period 3: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150."
62123577|NCT05928637|EXPERIMENTAL|Sequence 4|"* Period 1: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~* Period 2: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~* Period 3: oral dose of D745 1 tablet."
62123578|NCT05928637|EXPERIMENTAL|Sequence 5|"* Period 1: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~* Period 2: oral dose of D745 1 tablet.~* Period 3: multiple oral dose of 1 tablet of D759 and 2 tablets of D150."
62123579|NCT05928637|EXPERIMENTAL|Sequence 6|"* Period 1: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~* Period 2: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~* Period 3: oral dose of D745 1 tablet."
62123580|NCT02403596|EXPERIMENTAL|Group 1: Exacyl®: Standard treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 then 1g Exacyl® placebo at H+7 and H+11
62123581|NCT02403596|EXPERIMENTAL|Group 2: Exacyl®: Extended treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 / H+7 and H+11
62313535|NCT02420964|OTHER|Nurse instruction|Traditional injection teaching method. No video instruction
62313536|NCT02420964|OTHER|Video instruction|Video instruction that can be paused/repeated by subject
62313537|NCT04843111||Pregnant women and their offspring(s)|Pregnant women and their offspring(s) exposed to MenQuadfi® during their pregnancy or within 30 days prior to their LMP
62478054|NCT02695472|PLACEBO_COMPARATOR|Placebo Arm|One Placebo tablet, twice daily
62478055|NCT02695472|EXPERIMENTAL|40 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet and 1 placebo tablet per day
62478056|NCT02695472|EXPERIMENTAL|80 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet twice per day
62478057|NCT04145427|EXPERIMENTAL|Low Carbohydrate Diet|This arm will be randomized to low carbohydrate diet
62478058|NCT04145427|ACTIVE_COMPARATOR|Standard Dietary Advice Control Group|This arm will be randomized to control diet
62478059|NCT03905980||Vaginal delivery|woman who terminate their pregnancy by vaginal delivery
62478060|NCT03905980||Cesarean delivery|woman who terminate their pregnancy by cesarean delivery
62478061|NCT05086835|EXPERIMENTAL|Working Memory App (Active Intervention)|A visual-spatial app-based working memory intervention.
62478062|NCT05086835|ACTIVE_COMPARATOR|Visual Search App (Control Condition)|An app-based visual search task to be used as a control condition.
62478063|NCT00030186|EXPERIMENTAL|Cycle 1|60mg
62478064|NCT00030186|EXPERIMENTAL|Cycle 2|80mg dependent upon response to Cycle 1
62684041|NCT05309746||Ovarian Tissue Cryopreservation|Children faced with a fertility threatening diagnosis will be offered ovarian tissue cryopreservation. Pre-surgery assessment will be done while the child is in the hospital or in the pediatric oncology, surgery, or anesthesia clinic as an outpatient. The surgical procedure used to remove the child's ovary is called laparoscopy. It is not required for the treatment of the child's cancer or other medical condition. Laparoscopic surgery is done under general anesthesia (the child will be asleep during the surgery) in the operating room.
62684042|NCT02122185|EXPERIMENTAL|Metformin plus chemotherapy|Patients receive metformin hydrochloride PO BID and standard chemotherapy for 6 -8 cycles. Treatment with metformin hydrochloride continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
62313538|NCT03418038|EXPERIMENTAL|Arm A (ascorbic acid, combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.
62313539|NCT03418038|ACTIVE_COMPARATOR|Arm B (placebo, combination chemotherapy)|Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.
62313540|NCT03418038|EXPERIMENTAL|Arm C (ascorbic acid and combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.
62478065|NCT00030186|EXPERIMENTAL|Cycle 2b|40mg dependent upon response to Cycle 1
62123582|NCT02403596|PLACEBO_COMPARATOR|Group 3: Placebo|This group will receive a placebo of Exacyl®: 1g placebo of Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g placebo of Exacyl® at H+3 / H+7 and H+11
62684043|NCT02122185|PLACEBO_COMPARATOR|Placebo plus chemotherapy|Patients receive placebo PO BID and standard chemotherapy for 6 -8 cycles. Treatment with placebo continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
62684044|NCT02913573|EXPERIMENTAL|GA + Pec Block|Following induction of general anesthesia, the patients in the intervention group will undergo an ultrasound-guided pectoral block. With the patient in proper position, the infraclavicular and axillary regions are prepped with chlorhexidine. An US probe is placed below the third of the clavicle over the pectoralis major muscle. After identifying the appropriate anatomical structures, a 21-gauge echogenic needle is advanced under US visualization to the tissue plane between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie and 15 mL of 0.25% bupivacaine will be deposited. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
62684045|NCT02913573|NO_INTERVENTION|GA only|Patients will receive standard general anesthesia.
62123583|NCT00177931||liver transplant patients in ICU|
62478066|NCT05686694|EXPERIMENTAL|Education Group|"1. Follow-up (\<24 weeks): Questionnaire for Descriptive Characteristics of Pregnants and Informed Consent Form and pretest application Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test will be made.~2. Follow-up (\<24. Week): Watching education videos:the education will end in 3 weeks. After that,post-test application Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test will be applied. They will be asked about their intention to have an OGTT.~3. Follow-up (24-28. weeks): (Waiting after 75 mg dose is administered during OGTT): State Anxiety Scale will be applied. The OGTT implementation status of the pregnant woman will be recorded.~4. Follow-up (30-34. weeks): 6 weeks after the video education, the Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test post-test application will be made."
62684046|NCT03795870|ACTIVE_COMPARATOR|Polymeric Tube Feeds|This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
62313541|NCT03418038|EXPERIMENTAL|Arm D (ascorbic acid)|Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PICC or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.
62684047|NCT03795870|ACTIVE_COMPARATOR|Blenderized Tube Feeds|This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
62313542|NCT03418038|EXPERIMENTAL|ARM E (ascorbic acid, decitabine)|Patients receive ascorbic acid IV on days 1, 3 and 5 and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate. Patients may also take vitamin C PO on days 6-28. Patients undergo PICC or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.
62478067|NCT05686694|NO_INTERVENTION|Control Group|"1. Follow-up (\<24 weeks): Questionnaire for the Introductory Characteristics of Pregnants and Informed Consent Form, and pre-test application Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test will be made.~2. Follow-up (before OGTT implementation at 24-28 weeks): A posttest application will be madeKnowledge Level Form on Pregnancy Diabetes and Oral Glucose Tolerance Test. It will be asked about their intention to have an OGTT.~3. Follow-up (24-28. weeks) (Waiting after 75 mg dose is administered during OGTT):State Anxiety Scale will be applied face-to-face while the pregnant woman is waiting after 75 mg dose is administered during the OGTT application while she is with the pregnant woman on the test day. In addition, the OGTT implementation status of the pregnant woman will be recorded.~4. Follow-up (30-34 weeks): The post-test application of the Knowledge Level Form on Pregnancy Diabetes and Oral Glucose Tolerance Test will be made."
62478068|NCT01370369|EXPERIMENTAL|Single Testosterone Dose (Inner Thigh)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the inner thigh followed by a seven day washout period.
62684048|NCT02302833|EXPERIMENTAL|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62684049|NCT03024411|EXPERIMENTAL|Music/video games|iPod (Music/video games)
62684050|NCT03024411|NO_INTERVENTION|No intervention|No intervention
62684051|NCT05224726|EXPERIMENTAL|PRP Treatment|PRP preparation will be applied on uterine incision after closure of the first layer.
62684052|NCT05224726|NO_INTERVENTION|Control|Normal Cesarean delivery stages.
62684053|NCT05596240|EXPERIMENTAL|Dry Needling|Individuals with shoulder pain will receive dry needling to the two to four most tender points in the infraspinatus based on examiner palpation
62684054|NCT05596240|PLACEBO_COMPARATOR|Sham Dry Needling|Individuals with shoulder pain will receive sham dry needling to two points in the muscle belly of the infraspinatus near the insertion and below the midpoint of the spine of the scapula
62684055|NCT06687720|EXPERIMENTAL|MetBroma|Active Ingredients: Bromelain Mode of Usage: Take one slow-release capsule twice a day, after meal with water Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
62123584|NCT05932082|EXPERIMENTAL|myomectomy group|The study group received IVF after myomectomy.
62123585|NCT05932082|PLACEBO_COMPARATOR|control group|The control group was directed to IVF after the routine evaluation, probably including diagnostic laparoscopy.
62123586|NCT05158153|EXPERIMENTAL|ORKID Bundled Intervention|
62123587|NCT02235272|EXPERIMENTAL|XG-102|
62123588|NCT02235272|PLACEBO_COMPARATOR|Placebo|
62123589|NCT01517347|EXPERIMENTAL|Interleukin-2|Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
62123590|NCT01517347|NO_INTERVENTION|controlled group|controlled standard risk leukemia received regular transplantation without IL-2 intervention
62123591|NCT02474394|ACTIVE_COMPARATOR|Mcgrath|The endotracheal intubation will be provided using Mcgrath series 5 video laryngoscope
62123592|NCT02474394|ACTIVE_COMPARATOR|Macintosh|The endotracheal incubation will be provided using macintosh laryngoscope
62123593|NCT01892553|EXPERIMENTAL|motor/premotor cortex stimulation|Active and sham tDCS applied over the motor/premotor cortex
62123594|NCT01892553|EXPERIMENTAL|insular cortex stimulation|Active and sham tDCS applied over the insular cortex
62123595|NCT03494881|EXPERIMENTAL|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
62123596|NCT02983617|EXPERIMENTAL|Tirabrutinib + Entospletinib|Participants will receive tirabrutinib 80 mg (4 x 20 mg tablets/2 x 40 mg tablets/1 x 80 mg tablet) + entospletinib 400 mg (2 x 200 mg tablets) for up to 104 weeks.
62123597|NCT02983617|EXPERIMENTAL|Tirabrutinib + Entospletinib + Obinutuzumab|Participants will receive tirabrutinib 80 mg (4 x 20 mg tablets/ 2 x 40 mg tablets/ 1 x 80 mg tablet) + entospletinib 400 mg (2 x 200 mg tablets) for up to 104 weeks + obinutuzumab 100 mg on Day 1, 900 mg on Day 1 or 2, and 1000 mg subsequently for up to 8 doses on Day 1 of Weeks 2, 3, 5, 9, 13, 17 and 21.
62123598|NCT01598259|EXPERIMENTAL|melatonin|Subjects will receive melatonin
62123599|NCT01598259|PLACEBO_COMPARATOR|placebo|
62123600|NCT05991999|EXPERIMENTAL|The Study Group|800-meter swimming performance tests were administered to all swimmers prior to the measurement. The study group started to do stretch exercises every day for 6 weeks. At the end of six weeks, performance tests and myoton measurements were administered and analyzed for both groups.
62684056|NCT06687720|PLACEBO_COMPARATOR|Placebo|Mode of Usage: Take one slow-release capsule twice a day, after meal with water Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
62313543|NCT04346394|EXPERIMENTAL|Yohimbine|The first visit in the study has no interventional drug. Yohimbine (5mg) is administered orally during visit two, during a head up tilt test, to manipulate the noradrenergic system to determine the association between OH and NP symptoms in those with PD. Yohimbine is not administered as a treatment in this study, but as a pharmacologic tool to study the adrenergic system.
62478069|NCT01370369|EXPERIMENTAL|Single Testosterone Dose (Abdomen)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the abdomen followed by a seven day washout period.
62478070|NCT01370369|EXPERIMENTAL|Single Testosterone Dose (shoulder/upper arm)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the shoulder/upper arm.
62478071|NCT01370369|EXPERIMENTAL|Testosterone 1.25|Subjects received testosterone gel 2% at dose of 1.25 mL (one stroke) applied once daily for 10 consecutive days to the shoulder/upper arm.
62313544|NCT01579201|EXPERIMENTAL|Carbetocin|
62313545|NCT01782599|EXPERIMENTAL|Dual nicotine patch and electronic cigarette|Nicotine patch and the electronic cigarette will be administered.
62313546|NCT00296348|ACTIVE_COMPARATOR|1|
62313547|NCT00296348|EXPERIMENTAL|2|
62478072|NCT01370369|EXPERIMENTAL|Testosterone 2.50|Subjects received testosterone gel 2% at dose of 2.50 mL (two strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
62478073|NCT01370369|EXPERIMENTAL|Testosterone 3.75|Subjects received testosterone gel 2% at dose of 3.75 mL (three strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
62478074|NCT03031847|OTHER|Randomized- Pacemaker (CRT-P)|Cardiac resynchronization therapy Pacemaker
62478075|NCT03031847|OTHER|Randomized- Defibrillator (CRT-D)|Cardiac resynchronization therapy Defibrillator
62478076|NCT03031847|OTHER|Observational- Pacemaker (CRT-P)|Cardiac resynchronization therapy Pacemaker (CRT-P): Patients in this arm declined randomization in the trial and elected to participate in the observational registry
62478077|NCT03031847|OTHER|Observational- Defibrillator (CRT-D)|Cardiac resynchronization therapy Defibrillator (CRT-D): Patients in this arm declined randomization in the trial and elected to participate in the observational registry
62478078|NCT06627959|ACTIVE_COMPARATOR|Statseal|This group shall receive the StatSeal device for vascular closure
62478079|NCT06627959|ACTIVE_COMPARATOR|Figure of eight suture|This group shall receive the figure of eight suture (attached to a three-way stopcock) for vascular closure
62684057|NCT06641505|EXPERIMENTAL|Guiding rehydration group|According to the 421 fluid replacement principle, preoperative fluid replacement is performed
62684058|NCT06641505|ACTIVE_COMPARATOR|Conventional rehydration group|rehydrated within 15 minutes according to 0.2ml/kg/min.
62684059|NCT06549322|EXPERIMENTAL|The exercise in morning|Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.
62684060|NCT06549322|EXPERIMENTAL|The exercise in evening|Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.
62684061|NCT06549322|NO_INTERVENTION|The control in all day|Sit and rest in the morning and evening during the day.
62684062|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 1|Single rising dose (SRD)
62313548|NCT02988804|ACTIVE_COMPARATOR|endotracheal tube|"Procedure: Endotracheal tube~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
62313549|NCT02988804|ACTIVE_COMPARATOR|Laryngeal mask|"Procedure: Laryngeal mask~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
62313550|NCT05696366|ACTIVE_COMPARATOR|sotagliflozin 200 mg|"Each participant will receive 12-week insulin-adjunctive treatment with both: (1) SGLTi (sotagliflozin 200 mg PO each day) + Placebo and (2) SGLTi + GRA (volagidemab 35 mg subcutaneously each week), in a random-order, cross-over design with a 14-week washout period between treatment periods.~Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor."
62478080|NCT03927300||Patients without Telemonitoring with ApTelecare Software|
62478081|NCT03927300||Patients with implementation of Telemonitoring with ApTelecare|
62478082|NCT02158741|NO_INTERVENTION|Usual Primary Care|Usual Primary Care will be received by half the participants during the course of the Study
62684063|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 2|
62478083|NCT02158741|ACTIVE_COMPARATOR|Home Visits and educational support|Intervention comprised of Home Visits and group educational sessions. Home Visits and will be conducted by Diabetes Education staff in lieu of usual care conducted at the Diabetes clinic. Lifestyle support and educational will be offered in the form of monthly Diabetes Wellness Days offered in the community where nutrition, exercise and support will be given to help improve self-management of diabetes.
61923557|NCT03548090|EXPERIMENTAL|4|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
61923558|NCT03548090|EXPERIMENTAL|5|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
61923559|NCT03548090|EXPERIMENTAL|6|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
62313551|NCT05696366|ACTIVE_COMPARATOR|volagidemab 35 mg|"Each participant will receive 12-week insulin-adjunctive treatment with both: (1) SGLTi (sotagliflozin 200 mg PO each day) + Placebo and (2) SGLTi + GRA (volagidemab 35 mg subcutaneously each week), in a random-order, cross-over design with a 14-week washout period between treatment periods.~Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA)."
62478084|NCT02586844||Neuroendocrine tumors (NETs)|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
62684064|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 3|
62684065|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 4|
62684066|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 5|
62684067|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 6|
62684068|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 7|
62684069|NCT06255340|EXPERIMENTAL|SRD Part: BI 3031185 dose group 8|
62684070|NCT06255340|PLACEBO_COMPARATOR|SRD Part: Placebo matching BI 3031185|
62684071|NCT06255340|EXPERIMENTAL|FE part: BI 3031185 under fasted (Reference, R) then BI 3031185 under fed (Test,T) conditions|Food effect (FE)
62684072|NCT06255340|EXPERIMENTAL|FE part: BI 3031185 under fed (Test,T) then BI 3031185 under fasted (Reference, R) conditions|
62684073|NCT06537401|EXPERIMENTAL|Hypercaloric, High Fat Diet|For three calendar days participants will be asked to track all foods they eat and beverages they drink (habitual diet) in a mobile application. Following the three days following the habitual diet, participants will consume 165% of their estimated daily energy needs with 65% of those calories coming from fat.
62684074|NCT04845555||Patients with hemophilia A|Patients suffering from moderate or severe hemophilia A (FVIII \<5%) over the age of 12 years.
62684075|NCT06456541|EXPERIMENTAL|Experimental Extensively Hydrolyzed Formula|Administered during food challenge and at home feeding period of 7 days
62478085|NCT02586844||panNETs|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
62478086|NCT04898647|EXPERIMENTAL|Patients with confirmed HVS|presence of unexplained elsewhere fundoscopic abnormalities AND either IgM concentration above 30 g/L (densitometry) or cryoglobulin activity
62478087|NCT04898647|ACTIVE_COMPARATOR|Patients with confirmed absence of HVS|
62478088|NCT04898647|EXPERIMENTAL|Remaining patients|
62478089|NCT06559813|EXPERIMENTAL|Parent training with cognitive behavior therapy and virtual reality|A parent training program with between 6 and 10 individual, face-to-face, weekly sessions with parent
62478090|NCT01891877||Current or Former Football Players|Any former or current high school or college football players who carries sickle cell trait.
62478091|NCT03867721|EXPERIMENTAL|Ventilator PB560 (Covidien)|The non-dedicated (NON-DED) set comprised a ventilator for MPV (PB560) using a single active tubing with an exhalation valve. A custom-made arm support and plastic mouthpiece were used.
62478092|NCT03867721|EXPERIMENTAL|Ventilator Trilogy (Philips Respironics)|The dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
62478093|NCT06429592||experimental group|"Data collection tools for mothers in the experimental group after acceptance of admission to the intensive care unit \[Descriptive Characteristics Form, Parental Stress Scale: (Pediatric Intensive Care Unit), Empowerment of Parents in The Intensive Care (EMPATHIC-30) (Empowerment of Parents in Intensive Care Scale), Decision Data will be collected using the Conflict in Making and Decision Making Confident Scale (KVÇS and KEOÖ). The prepared strengthening program will be applied for a total of 5 days starting from the first day of hospitalization. While the mothers are being treated, no other treatment will be done in the unit.~Different time slots will be scheduled for each experiment. After the 5th day of the application was completed, data collection tools were used."
62478094|NCT06429592||control group|Data collection tools from mothers in the control group after admission to the intensive care unit \[Descriptive Characteristics Form, Parental Stress Scale: (Pediatric Intensive Care Unit), Empowerment of Parents in The Intensive Care (EMPATHIC-30) (Empowerment of Parents in Intensive Care Scale), Decision Data will be collected using the Conflict in Making and Decision Making Confident Scale (KVÇS and KEOÖ). The routine operation of the intensive care unit will continue and data will be collected again after 5 days of hospitalization.
62684076|NCT06456541|PLACEBO_COMPARATOR|Placebo Extensively Hydrolyzed Formula|Administered during food challenge
62123601|NCT05991999|ACTIVE_COMPARATOR|The Control Group|800-meter swimming performance tests were administered to all swimmers prior to the measurement. The control group just continued their regular training for 6 weeks. At the end of six weeks, performance tests and myoton measurements were administered and analyzed for both groups.
62313552|NCT05696366|PLACEBO_COMPARATOR|Placebo|Each participant will receive 12-week insulin-adjunctive treatment with both: (1) SGLTi (sotagliflozin 200 mg PO each day) + Placebo and (2) SGLTi + GRA (volagidemab 35 mg subcutaneously each week), in a random-order, cross-over design with a 14-week washout period between treatment periods.
62313553|NCT02743637|EXPERIMENTAL|SDX-7320|Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.
62313554|NCT04100070|OTHER|Standard monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls.~Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)"
62478095|NCT05947734|EXPERIMENTAL|robotic|
62478096|NCT05947734|NO_INTERVENTION|Control|
62478097|NCT03589313|EXPERIMENTAL|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
62478098|NCT04835363|NO_INTERVENTION|Control group|Usual care.
62684077|NCT03803943|EXPERIMENTAL|Parent-Implemented Communication Intervention (PICT)|Participants assigned to the PICT condition will receive weekly hour long intervention sessions in their home for 6 months. Parents will learn four sets of communication support strategies: (a) visual (e.g., modeling language within the child's line of sight), (b) interactive (e.g., following the child's attentional focus), (c) responsive (e.g., responding to all communicative attempts), and (d) linguistically stimulating (e.g., modeling language targets, expanding child communication).
62478099|NCT04835363|EXPERIMENTAL|OT intervention.|Patients and their caregivers assigned to the experimental group are included in an early occupational therapy intervention program.
62478100|NCT05049746|OTHER|Intervention Arm|"Participants in the intervention arm only will then be asked to look at the decision tool that includes educational materials about the diagnosis and treatment of breast cancer.~These could be written information, graphics, videos, animations, or questionnaires.~This decision tool will personalize the decision to you specifically and support your decision-making process"
62478101|NCT05049746|NO_INTERVENTION|Non-Intervention Arm|Participants undergo interviews and complete questionnaires over 1-2 hours. Patients and physicians also participate in a discussion and complete shared decision-making questionnaire over 15-30 minutes.
62684078|NCT03803943|PLACEBO_COMPARATOR|No Intervention - Business-as-usual control|Participants assigned to the BAU control group will not receive the PICT intervention.
62478102|NCT01020474|PLACEBO_COMPARATOR|Placebo|
62684079|NCT01140932|EXPERIMENTAL|Intervention|Medical and behavioural intervention
62684080|NCT01105832|EXPERIMENTAL|Proximal humeral fracture - intervention|20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
61923560|NCT03548090|EXPERIMENTAL|7|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
62123602|NCT04722003|EXPERIMENTAL|4CMenB|Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=40
62123603|NCT04722003|PLACEBO_COMPARATOR|Placebo|Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=10
62123604|NCT06266780|EXPERIMENTAL|Intervention Group|Group receiving enhanced package of postpartum family planning support
62313555|NCT04100070|OTHER|Intensive monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study.~Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits)."
62313556|NCT04085510|EXPERIMENTAL|Contrast-enhanced mammogram|All women will receive both 3D mammography and contrast-enhanced mammography for breast cancer screening; the order of interpretation will vary for each of two radiologists
62313557|NCT06451237|ACTIVE_COMPARATOR|Adapalene group|Patients received full Isotretinoin course for treatment, and maintained on every other day adapalene gel.
62313558|NCT06451237|ACTIVE_COMPARATOR|Full Iso group|Patients received full isotretinoin course for treatment, and maintained on weekend isotretinoin.
62684081|NCT01105832|NO_INTERVENTION|Proximal humeral fracture|20 patients will receive standard treatment (physiotherapy)
62684082|NCT00655356|EXPERIMENTAL|Active|
62684083|NCT00655356|PLACEBO_COMPARATOR|Placebo|
62313559|NCT06451237|ACTIVE_COMPARATOR|Clearance Iso|Patients treated by systemic isotretinoin till full clearance and for a month thereafter, and maintained on weekend isotretinoin.
62684084|NCT06151665|EXPERIMENTAL|Single Rotary file|single rotary file will be used in primary molars to preform pulpectomy then restored with zinc oxide eugenol and stainless steel crown.
62684085|NCT06151665|ACTIVE_COMPARATOR|Conventional Manual Files|Conventional Manual Stainless steel K files will be used in primary molars to preform pulpectomy then restored with zinc oxide eugenol and stainless steel crown.
62684086|NCT04343768|EXPERIMENTAL|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a|
62123605|NCT06266780|NO_INTERVENTION|Control Group|Group receiving basic postpartum family planning information
62313560|NCT02714205|EXPERIMENTAL|Transdermal Nitroglycerin|Daily transdermal nitroglycerin patch, starting at 0.2 mg/hr. Dose escalation up to 0.6 mg/hr.
62313561|NCT02714205|PLACEBO_COMPARATOR|Placebo|Daily transdermal placebo patch.
62313562|NCT03656640||Patients Receiving Gammanorm®|Patients Receiving Gammanorm®
62478103|NCT01020474|EXPERIMENTAL|drug-pregabalin|
62478104|NCT01106794||Patient samples|Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
62684087|NCT04343768|EXPERIMENTAL|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b|
62684088|NCT04343768|ACTIVE_COMPARATOR|Control group: hydroxychloroquine + Lopinavir / Ritonavir|
62684089|NCT06680232|EXPERIMENTAL|Participants in both Part 1 and 2 will receive a finite course of PBGENE-HBV.|All participants will receive a finite course of multiple IV dose administrations of PBGENE-HBV. In Part 1, this will be done in a dose escalation manner which may be evaluated further in a Part 2 expansion cohort.
62684090|NCT05287685|EXPERIMENTAL|Screen media adapted School Readiness Parenting Program|Screen media adapted School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
62684091|NCT05287685|ACTIVE_COMPARATOR|Original School Readiness Parenting Program|Original School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
62684092|NCT06017115|ACTIVE_COMPARATOR|Control group|Group 1: 2 stage approach (cover screw) (12 patients): cover screw is placed over the dental implants in the first surgery and a second surgery will be performed to expose the implants and placing a healing abutment after 2-4 months, DEVICES: COVER SCREW (first surgery) and HEALING ABUTMENT (second surgery)
61923561|NCT03548090|EXPERIMENTAL|8|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
62684093|NCT06017115|EXPERIMENTAL|Test group|Group 2: Protective plastic cap over different definitive trans-epithelial abutments are placed in the unic surgery performed (36 patients): Definitive transepithelial abutments will be placed the same day of the implant placement surgery. DEVICE: DEFINITIVE TRANSEPITHELIAL ABUTMENT
61923562|NCT03548090|EXPERIMENTAL|9|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
62684094|NCT05295953|ACTIVE_COMPARATOR|TBS (Theta burst stimulation)|Four sessions of TBS in one day
62123606|NCT03074331|EXPERIMENTAL|SOF/VEL|SOF/VEL for 12 weeks
62123607|NCT03669354||Cohort SMT|Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT
62123608|NCT03669354||Cohort OAT|Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT
62123609|NCT03669354||Cohort SMTX|Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT
62123610|NCT03669354||Cohort OATX|Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT
62123611|NCT01767714|EXPERIMENTAL|G-CSF + plerixafor|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.
62123612|NCT01767714|PLACEBO_COMPARATOR|G-CSF + Placebo|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.
62123613|NCT00681525|EXPERIMENTAL|A|ABT-335 135 mg
62123614|NCT00681525|EXPERIMENTAL|B|Atorvastatin 80 mg and Ezetimibe 10 mg
62123615|NCT00681525|EXPERIMENTAL|C|ABT-335 135 mg, Atorvastatin 80 mg and Ezetimibe 10 mg
62123616|NCT02349503|EXPERIMENTAL|NBI-77860 Dose Group1|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours).
62123617|NCT02349503|EXPERIMENTAL|NBI-77860 Dose Group 2|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
62123618|NCT02349503|EXPERIMENTAL|NBI-77860 Dose Group 3|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 2 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
62123619|NCT06515431||Laparoscopic nephrectomy|
62123620|NCT06515431||Robotic nephrectomy|
62123621|NCT04380467|EXPERIMENTAL|Vitamin D Group|Six doses of cholecalciferol 100,000units (5x aviticol 20,000units capsules) administered monthly over 20 weeks.
62123622|NCT04380467|NO_INTERVENTION|Control|No vitamin D given
62123623|NCT02021006|ACTIVE_COMPARATOR|ANTIBIOTIC PROPHYLAXIS|"Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.~The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
62123624|NCT02021006|EXPERIMENTAL|NO PROPHYLAXIS|Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years
62313563|NCT01500174|EXPERIMENTAL|active UVC device|Three times per week irradiation of wound base and periwound skin
62313564|NCT01500174|PLACEBO_COMPARATOR|Placebo UVC device|Three times per week irradiation of wound base and periwound skin
62478105|NCT01024985||multiple sclerosis|
62123625|NCT02092116|OTHER|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of \~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
62123626|NCT02092116|OTHER|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of \~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
62123627|NCT04528706|EXPERIMENTAL|MIN-102|
62684095|NCT05295953|PLACEBO_COMPARATOR|Sham TMS|Four sessions of sham TMS
62684096|NCT05254860|EXPERIMENTAL|Interrupted suture|
62684097|NCT05254860|EXPERIMENTAL|Continous suture|
62313565|NCT06298292||ZeroTP minis|Intervention: Tyrosine-free and Phenylalanine-free protein substitute in tablet form. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemia I, II, III or alkaptonuria will be recruited. Subjects will take the study product for 7 days. Subjects will replace some or their entire usual protein substitute with the new product. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute.
62313566|NCT06298292||ZeroMet minis|Intervention: Methionine-free and Cystine-enriched protein substitute in tablet form. Subjects who currently take a protein substitute for the dietary management of homocystinuria will be recruited. Subjects will take the study product for 7 days. Subjects will replace some or their entire usual protein substitute with the new product. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute.
62313567|NCT06298292||ZeroVIL minis|Intervention: Valine-, Isoleucine- and Leucine-free protein substitute in tablet form. Subjects who currently take a protein substitute for the dietary management of MSUD will be recruited. Subjects will take the study product for 7 days. Subjects will replace some or their entire usual protein substitute with the new product. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute.
62478106|NCT01024985||neuromyelitis optica|
62478107|NCT01024985||controls|
62478108|NCT06561672|EXPERIMENTAL|tramadol plus paracetamol (T)|
62684098|NCT02336555|EXPERIMENTAL|MK-8291 → Placebo|In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
61923563|NCT03548090|EXPERIMENTAL|10|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
62123628|NCT02059044|EXPERIMENTAL|ISTOP-ADE|Interactive Voice Response System + Pharmacist
62123629|NCT02059044|NO_INTERVENTION|Routine care|Routine care
62123630|NCT03953222|EXPERIMENTAL|Experimental|A single group of people with Parkinson's disease will undergo real-time feedback intervention.
62123631|NCT00513526|EXPERIMENTAL|Gardasil|Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
62123632|NCT03409913||GCA cases|In a cohort of patients suspected of GCA based on the following inclusion criteria were 1) age ≥50 years, 2) CRP\>15mg/l or ESR\>40mm/h, 3) either a) cranial symptoms, b) new-onset extremity claudication or c) weight loss \>5 kilograms or fever\>38oC for \>3 weeks, patients with a clinical diagnosis of GCA is identified.
62123633|NCT03409913||controls|Age-(+/- 3 years) and sex-matched malignant melanoma (MM) patients who had a follow-up metastatic-disease-free FDG PET/CT ≥6 months after MM resection
61923564|NCT03548090|EXPERIMENTAL|11|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
62123634|NCT00390793|EXPERIMENTAL|Treatment (chemotherapy, dasatinib)|See detailed description in outline.
62123635|NCT04745663|EXPERIMENTAL|Povidone-Iodine 0.3 %|A tampon is soaked in diluted PI 0.3% and placed on the inside of the lower eyelid of one eye, where it will release iodine molecules for 20 minutes before being removed.
62123636|NCT04745663|ACTIVE_COMPARATOR|Povidone-Iodine 5 %|Eye drops of 5% PI is the standard disinfection before eye surgery. The drops will be dripped in one eye and allowed to work for 2 minutes.
62123637|NCT06677476|EXPERIMENTAL|mobile application training group|The group that will be trained by downloading the mobile application to their mobile phones
62123638|NCT04738903|ACTIVE_COMPARATOR|Custom Q treatment group|For every patient, the eye with the greater myopic spherical equivalent (SE) will be assigned for the Custom-Q treatment group.
62313568|NCT03184701|EXPERIMENTAL|Experimental|Patients assigned to this arm receive the intervention in addition to routine standard of care. Telehealth based remote monitoring of symptoms and brain tests is the intervention in this study. A device with preloaded questionaires will be given to patients randomized to this group. The patients will respond on a daily basis for the 3 months of intervention phase.
62313569|NCT05396118|EXPERIMENTAL|Experimental|Injection of 18F-FDG and injections of hyperpolarized \[1-13C\]Pyruvate and subsequent PET/MRI/MRS scan
62313570|NCT06404008|EXPERIMENTAL|Behavioral Intervention (REST)|Participants randomized to this group will receive COPD education, research staff support, and the REST (controlled breath) intervention.
62313571|NCT06404008|ACTIVE_COMPARATOR|Control|Participants randomized to this group will receive COPD education and research staff support.
62478109|NCT06561672|EXPERIMENTAL|fentanyl(F)|
62478110|NCT03113877||Clinical Testing for Autonomic Dysfunction|COMPASS-31 Survey completion. Autonomic Reflex Screen. Thermoregulatory Swear Test.
62478111|NCT06619093||High hemolytic group|Lactate Dehydrogenase Level \> 484 IU/L
62478112|NCT06619093||Low hemolytic group|Lactacte Dehydrogenase Level less or equal to 484 IU/L
62478113|NCT04247243|EXPERIMENTAL|Rapid testing|Abbott ID NOW Strep A testing.
62123639|NCT04738903|ACTIVE_COMPARATOR|Wave-front optimized (WFO) group|For every patient, the other eye with the lesser myopic SE will be assigned for the WFO treatment group
62478114|NCT04247243|ACTIVE_COMPARATOR|Reference testing|Culture-based testing.
61923565|NCT03548090|EXPERIMENTAL|12|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
61923566|NCT03548090|EXPERIMENTAL|13|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
62123640|NCT04129658||Intervention|The patients are registered at PHCCs who agreed to participate into the study, the patients have provided an informed consent. The PHCCs (seventeen according to the power calculation) will receive an educational outreach visit by a cardiologist, discussing evidence-based treatment. The physician will decide afterwords if the treatment will be adjusted. Blood samples and electrocardiography will be collected before the intervention, data from the EMR will be collected before and after the intervention.
62123641|NCT04129658||Control|The control group will be the rest of the patients with heart failure in Southern Sweden. Data from the regional data base on medication and heath care consumption will be collected at base line and 6 and 12 months after.
62123642|NCT05756504|EXPERIMENTAL|NSAIDs|Patients in this arm will be given ketorolac injection 30 mg IV x TDS for pain management of mild to moderate acute pancreatitis
62123643|NCT05756504|EXPERIMENTAL|Opioids|Patients in this arm will be given injection tramadol IV x TDS for pain management of mild to moderate acute pancreatitis
62684099|NCT02336555|EXPERIMENTAL|Placebo → MK-8291|In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
62123644|NCT00131638|EXPERIMENTAL|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
62123645|NCT00131638|PLACEBO_COMPARATOR|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
62123646|NCT03127280|NO_INTERVENTION|Conventional Foley Care|Following surgery, the patient's Foley catheter is removed on the morning of post-operative day one.
62123647|NCT03127280|EXPERIMENTAL|Fast Tract Foley care|Following surgery, the patient's Foley catheter is removed on post-operative day zero, four hours after the completion of surgery.
62313572|NCT03076008||MPFL Reconstruction|Subjects undergoing MPFL Reconstruction
62313573|NCT02172222|EXPERIMENTAL|Sequence ABC|"1. Treatment A: BI 10773 once daily from day 1 to 5~2. Treatment B: BI10773 and linagliptin once daily from day 1 to 7~3. Treatment C: Linagliptin once daily from day 1 to 7"
62313574|NCT02172222|EXPERIMENTAL|Sequence CAB|"1. Treatment C: Linagliptin once daily from day 1 to 7~2. Treatment A: BI 10773 once daily from day 1 to 5~3. Treatment B: BI10773 and linagliptin once daily from day 1 to 7"
62313575|NCT01232946|EXPERIMENTAL|Iiraglutide|Type 2 diabetic subjects will be assigned to 3 months of treatment with 1.8mg liraglutide administered once daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
62684100|NCT04857671|EXPERIMENTAL|Botulinum toxin A injections|Botulinum toxin A (Botox)
61923567|NCT03548090|EXPERIMENTAL|14|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
61923568|NCT03548090|EXPERIMENTAL|15|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
61923569|NCT03548090|EXPERIMENTAL|16|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
61923570|NCT03548090|EXPERIMENTAL|17|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
62123648|NCT03565796|EXPERIMENTAL|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
62313576|NCT01232946|EXPERIMENTAL|insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
62313577|NCT01232946|EXPERIMENTAL|Liraglutide plus insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with a combination of liraglutide and insulin detemir in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
62313578|NCT02887846|ACTIVE_COMPARATOR|group 1|Heated humidified high-flow nasal cannula therapy device for post extubation
62313579|NCT02887846|ACTIVE_COMPARATOR|group 2|Nasal continuous positive airway pressure for post extubation
62313580|NCT04055935|EXPERIMENTAL|full thickness mucoperiosteal flap|A full thickness mucoperiosteal flap (FTMPF) was reflected on FTMPF side at the maxillary canine/premolar region by the same surgeon for all patients following the same procedures.
61923571|NCT03548090|EXPERIMENTAL|18|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
61923572|NCT03548090|EXPERIMENTAL|19|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
62313581|NCT04055935|EXPERIMENTAL|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length
62313582|NCT04055935|NO_INTERVENTION|Control for Full thickness mucoperiosteal flap|Control for Full thickness mucoperiosteal flap, in which canine retraction was done in a conventional method
62313583|NCT04055935|NO_INTERVENTION|control for Low level laser therapy group|Control for Low level laser therapy , in which canine retraction was done in a conventional method
62313584|NCT03671083||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
62313585|NCT03671083||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
62478115|NCT01575457|EXPERIMENTAL|Intervention|The Healthy Futures Program is an interactive, multi-session training program. The intervention participants will participate in College/vocational school, Job, and Career Planning activities with a career coach.
62313586|NCT05730439|EXPERIMENTAL|Arm I (usual SLT, ZYN NP, Rogue NP)|Participants receive their usual brand of smokeless tobacco at study visit 1, ZYN brand nicotine patch at study visit 2, and Rogue brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
62123649|NCT03565796|EXPERIMENTAL|Group B|AWARD advice + COSH booklet
62123650|NCT04068207|EXPERIMENTAL|Minocycline|Tablets Minocycline 100mg po per day for 12 months
62123651|NCT03666403|EXPERIMENTAL|Patients|This prospective one-year study enrolled consecutive 30 children of ≤3 years-old with suspected major airway diseases and therefore scheduled for diagnostic FB. During FB, PIP measurements and associated lumen images were obtained at six airway locations using three studied NIV modes, including 1) NIV rate: 0/min, 2) NIV rate: 10-20/min, 3) NIV rate: 5-10/min.
62123652|NCT04426500|PLACEBO_COMPARATOR|Placebo/Local Anesthesia|Direct injection of 0.25% bupivacaine into surgical wounds
62313587|NCT05730439|EXPERIMENTAL|Arm II (usual SLT, Rogue NP, ZYN NP)|Participants receive their usual brand of smokeless tobacco at study visit 1, Rogue brand nicotine patch at study visit 2, and ZYN brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
62313588|NCT05730439|EXPERIMENTAL|Arm III (ZYN NP, usual SLT, Rogue NP)|Participants receive ZYN brand nicotine patch at study visit 1, their usual brand of smokeless tobacco at study visit 2, and Rogue brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
62478116|NCT01575457|OTHER|Comparison|The Healthy Futures Program is an interactive, multi-session training program. The comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
62478117|NCT06448221|EXPERIMENTAL|RT group|receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system
62123653|NCT04426500|ACTIVE_COMPARATOR|Ultrasound-guided transversus abdominus plane (UTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
62123654|NCT04426500|EXPERIMENTAL|Laparoscopic-guided transversus abdominus plane (LTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using laparoscopic guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
62123655|NCT06677229|EXPERIMENTAL|Experimental Arm Randomized to IMP (Eletriptan HBr) + SOC|
62684101|NCT04857671|PLACEBO_COMPARATOR|placebo injections|Isotone saline water
61923573|NCT03548090|EXPERIMENTAL|20|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
61923574|NCT03548090|EXPERIMENTAL|21|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
62684102|NCT06124313|EXPERIMENTAL|Intervention Group|Participants will take one capsule of the test product every day, with water.
62123656|NCT06677229|NO_INTERVENTION|Control Arm after SCI Randomized to SOC|
62123657|NCT01343290|EXPERIMENTAL|001|Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods
62478118|NCT06448221|EXPERIMENTAL|HEART group|receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system
62478119|NCT06448221|NO_INTERVENTION|control group|which has only smartphone-based videoconferencing visits
62478120|NCT01855685|EXPERIMENTAL|Open label|X vivo gene therapy
62684103|NCT00692237|ACTIVE_COMPARATOR|1|Sildenafil 100 mg
62684104|NCT00692237|PLACEBO_COMPARATOR|2|Placebo 100 mg
62684105|NCT06078189||Control|Trapezectomy group
62684106|NCT06078189||Experimental|Arthroplasty group
62478121|NCT02566850|EXPERIMENTAL|Ekso Users|SCI subjects using Ekso
62478122|NCT05571449|EXPERIMENTAL|Experimental group|Planning of tibial plateau fracture osteosynthesis by using a three-dimensional model of the fracture.
61923575|NCT03548090|EXPERIMENTAL|22|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
62123658|NCT01914913|OTHER|BMMNCs|BMMNCs
62123659|NCT02038413||NSCLC stage I|Consecutive patients were identified from October 2009 onwards in MAASTRO clinic, Maastricht. All patients received respiratory gated CT (4DCT) scans. All were patients referred for primary radiotherapy or chemo radiation.
62123660|NCT00433199|PLACEBO_COMPARATOR|Placebo|Placebo
62123661|NCT00433199|EXPERIMENTAL|T-Gel 1.62%|Testosterone (T) gel 1.62%
62123662|NCT03022123|EXPERIMENTAL|pegylated liposomal doxorubicin|PL-doxorubicin 35-40 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
62123663|NCT03022123|ACTIVE_COMPARATOR|Epirubicin|Epirubicin 70 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
62123664|NCT00585533|OTHER|A|
62123665|NCT00951379|EXPERIMENTAL|Arm I (Pioglitazone Hydrochloride)|Three (3) Pioglitazone 15 mg capsules by mouth once daily for 24 weeks
62123666|NCT00951379|PLACEBO_COMPARATOR|Arm II (Placebo)|Three (3) placebo capsules by mouth once daily for 24 weeks
62478123|NCT05571449|OTHER|Control group|Standard planning of tibial plateau fracture osteosynthesis (by plain radiography and computed tomography imaging).
62684107|NCT05175378|ACTIVE_COMPARATOR|Intervention arm|In the intervention group, MS women received a personalized daily eating plan (specific meals, recipes, food portions) together with nutritional consultation on the Meditteranean dietary pattern, as well as physical activity guidelines. All essential aspects of the dietary plan e.g. daily energy expenditure, classification of physical activity based on the concept of metabolic equivalent (MET), caloric adjustment according to nutritional status, and macronutrient distribution were calculated by a Clinical Decision Support System (CDSS). Body mass index (BMI) was also calculated, as the ratio of reported weight (kg) to the square of height (m2). Co-existed health issues, such as constipation or esophageal reflux, were taken into consideration. All MS patients acquired personal login passwords that allowed them to get access to their personal CDSS account and track their progress in regards to body weight, physical activity, and healthy food choices consumption.
62123667|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
62123668|NCT01189331|NO_INTERVENTION|CT and FFR|
61923576|NCT03548090|EXPERIMENTAL|23|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
61923577|NCT03548090|EXPERIMENTAL|24|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
62123669|NCT00947453|EXPERIMENTAL|montelukast group|Identified patients with asthma to recieve Montelukast 10 mg (Merck Sharp \& Dohme Ltd, Herts, UK) at 0800 am once daily for 8 weeks.
62123670|NCT03385824|EXPERIMENTAL|Self-Advocacy for Independent Life (SAIL)|10 week treatment program to improve self-advocacy skills. Includes 4 in-person group sessions (3 hours per session) and two supportive phone calls; workbook and home assignments.
62123671|NCT03385824|NO_INTERVENTION|Control|SAIL workbook provided at the conclusion of the study.
62478124|NCT02844660|EXPERIMENTAL|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
62478125|NCT02844660|ACTIVE_COMPARATOR|Standard of Care|Weekly application of moist wound therapy and offloading
62123672|NCT00629850|EXPERIMENTAL|Powerlung Performer|The arm will receive the lung trainer device to use for 10 weeks
62123673|NCT00629850|NO_INTERVENTION|Control|Control. This arm will not receive any device
62123674|NCT06339892|EXPERIMENTAL|Study|Patients will stop LTV shifting to GCV/VGCV/FOS pre-emptive therapy in case of positive HCMV DNA and subsequent confirmation of productive infection by detection of DNAse-resistant HCMV plasma DNAemia. However, for safety reasons, patients of the Study arm will stop LTV and shift to pre-emptive therapy in case of HCMV DNAemia \>10,000 copies/ml whole blood in two consecutive samples, even if DNAse-resistant HCMV plasma DNAemia is negative.
62123675|NCT06339892|ACTIVE_COMPARATOR|Control|Patients will stop LTV shifting to GCV/VGCV/FOS pre-emptive therapy in case of positive HCMV DNAemia confirmed in two consecutive samples.
62478126|NCT02703194|EXPERIMENTAL|Prednisone|Prednisone mono-therapy
61923578|NCT03799172||Echinocandin group|Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
62313589|NCT05730439|EXPERIMENTAL|Arm IV (ZYN NP, Rogue NP, usual SLT)|Participants receive ZYN brand nicotine patch at study visit 1, Rogue brand nicotine patch at study visit 2, and their usual brand of smokeless tobacco at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
61923579|NCT03799172||Triazole group|Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
61923580|NCT06133738|EXPERIMENTAL|Intervention Group|Participants in this group will be given 8 sessions of a standardized exercise program, a link to access online educational sessions, in addition to internet based cognitive behavioural therapy sessions.
61923581|NCT06133738|ACTIVE_COMPARATOR|Control Group|Participants in this group will be given 8 sessions of a standardized exercise program and a link to access online educational sessions.
62123676|NCT03535558||Cohort 1: FQ With Uncomplicated Sinusitis or Bronchitis|A target cohort which includes participants exposed to an oral fluoroquinolone (FQ) with an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
62313590|NCT05730439|EXPERIMENTAL|Arm V (Rogue NP, usual SLT, ZYN NP)|Participants receive Rogue brand nicotine patch at study visit 1, their usual brand of smokeless tobacco at study visit 2, and ZYN brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
62313591|NCT05730439|EXPERIMENTAL|Arm VI (Rogue NP, ZYN NP, usual SLT)|Participants receive Rogue brand nicotine patch at study visit 1, ZYN brand nicotine patch at study visit 2, and their usual brand of smokeless tobacco at study visit 3. Participants also undergo IV line insertion and collection of blood on study
62313592|NCT04770155|ACTIVE_COMPARATOR|Beetroot juice (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (\~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).
61923582|NCT00990275|EXPERIMENTAL|Post-alcohol change in airway hyperresponsiveness.|Participants will ingest 3 ounces of vodka mixed with fruit juice within 30 min. Then provocative concentration causing a 20% fall in forced expiratory volume in 1 s (PC20FEV1) will be measured. A one-half concentration difference in the PC20FEV1 will be considered a statistically significant change in airway hyperresponsiveness.
62123677|NCT03535558||Cohort 2: FQ With Uncomplicated Acute Urinary Tract Infection|A target cohort which includes participants exposed to an oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
62123678|NCT03535558||Cohort 3: AZ with Uncomplicated Acute Sinusitis or Bronchitis|A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
62123679|NCT03535558||Cohort 4: ST with Uncomplicated Acute Urinary Tract Infection|A comparator cohort which includes participants exposed to oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
62123680|NCT02210806|ACTIVE_COMPARATOR|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
62123681|NCT02210806|ACTIVE_COMPARATOR|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
62123682|NCT02210806|PLACEBO_COMPARATOR|Placebo|One inhalation of placebo DPI . Total 0 mcg
62123683|NCT02210806|ACTIVE_COMPARATOR|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
62313593|NCT04770155|PLACEBO_COMPARATOR|Placebo (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (\~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).
62313594|NCT04770155|ACTIVE_COMPARATOR|L-citrulline (Aim 1b)|Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.
62313595|NCT04770155|PLACEBO_COMPARATOR|Placebo (Aim 1b)|Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.
62123684|NCT02210806|ACTIVE_COMPARATOR|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
62313596|NCT04770155|ACTIVE_COMPARATOR|Sildenafil (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.
62313597|NCT04770155|PLACEBO_COMPARATOR|Placebo (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
62313598|NCT04770155|ACTIVE_COMPARATOR|Bosentan (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.
62313599|NCT04770155|PLACEBO_COMPARATOR|Placebo (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
61923583|NCT02359851|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
62123685|NCT05243043||Control|Mothers who experienced premature infant resuscitation in Labor and Delivery without the information provided by a computerized informational app.
62123686|NCT05243043||Intervention (future)|Mothers who experienced premature infant resuscitation in Labor and Delivery with the information provided ahead of time by the computerized informational application.
62313600|NCT00427661|OTHER|AHCT in High Risk SCD|Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
62313601|NCT02136394||Severe/moderate acid reflux|
62313602|NCT02136394||Mild/absent acid reflux|
62313603|NCT06333847||Group 1|Patients who responded to the first invitation to participate
62313604|NCT06333847||Group 2|Patients who responded to the second invitation to participate
62313605|NCT06333847||Group 3|Patients who responded to the third invitation to participate
62313606|NCT06333847||Group 4|Patients who did not respond to inviations to participate
62313607|NCT06333847||Group 5|Patients who responded to invitations to participate and thus an amalgamation of the people from groups 1, 2 and 3
62478127|NCT02703194|EXPERIMENTAL|Prednisone and Leflunomide|Prednisone and Leflunomide combination therapy
62684108|NCT05175378|SHAM_COMPARATOR|Control arm|"Patients of the control group received general dietary advice and physical activity recommendation that was in accordance with the National Dietary Guidelines for Greek adults"
62684109|NCT06655714||Patients with adequate response|In this study, patients whose Visual Analog Scale (VAS) score decreases by 50% or more after 4 weeks of receiving the ultrasound-guided corticosteroid injection will be considered to have had an adequate response.
61923584|NCT04085367|EXPERIMENTAL|MAL 16.8% Cream|Participants received two treatment session at least 2 weeks apart. Investigator applied a thin layer of methyl aminolevulinate (MAL) hydrochloride 16.8% cream to each lesion during treatment. At 30 minutes after cream application, participants went outside in daylight for 2 hours (Daylight photodynamic therapy \[DL-PDT\]). After this time, the cream was removed by investigative site personnel by washing the skin with gentle skin cleanser.
62123687|NCT06523868|EXPERIMENTAL|Galleri MCED Test|"Enrolled participants will complete:~* Baseline visit with blood draw and questionnaires~* Return of study test result~* Online post-test questionnaire~* For a positive result, diagnostic work-up could include clinic visits, biopsy, surgery, imaging assessments such as ultrasound, Computed Tomography (CT) scans, or Magnetic Resonance Imaging (MRI) scans. If no cancer is found upon work up, a repeat MCED test may be ordered at the discretion of the principle investigator for up to 1 year from the initial MCED blood test.~* Follow-up for a negative MCED blood test could include a repeat test ordered by the principle investigator for up to 1 year from the initial MCED test or a survey or phone call by study staff approximately 1 year after the initial MCED blood test.~* Online post-diagnostic questionnaire."
62123688|NCT00664404|OTHER|fMRI|Functional Magnetic Resonance Imaging (fMRI)
62123689|NCT06611059||in-hospital designed patient specific guide|
62123690|NCT06007352|EXPERIMENTAL|Gentamicin-Based Irrigation|This group will receive 120 mg of Gentamicin in 3 L NaCl as irrigation fluid during ureteroscopy
62123691|NCT06007352|PLACEBO_COMPARATOR|3 L NaCl Irrigation|This group will receive the typical NaCl irrigation used during ureteroscopy
62123692|NCT02556138|EXPERIMENTAL|Orbera Intragastric Balloon|All subjects will be receiving the ORBERA Intragastric Balloon
62123693|NCT06414850|EXPERIMENTAL|Experimental Group (EG)|"The experimental group carried out a total of two one-hour group sessions at the three hospitals' own facilities, on a weekly basis for two consecutive weeks. The groups were formed by 8-10 participants. Sessions included the participation of one certified therapy dog, one technician specialized in AAT, an occupational therapist and a psychologist. There was a referring psychiatrist for the project at each center. Participants received their usual pharmacological treatment.~Intervention (with the additional assistance of the therapy dog): Session 1, self-efficacy (executive functions, cause-effect thinking). Session 2, emotional self-regulation and frustration tolerance."
62313608|NCT02060708|OTHER|Real HD-tDCS first, Sham HD-tDCS second|Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)
62313609|NCT02060708|OTHER|Sham HD-tDCS first, Real HD-tDCS second|Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)
62313610|NCT04692493|ACTIVE_COMPARATOR|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
62478128|NCT03923374||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 200 pregnant (\<16weeks) mothers who have opioid use disorder and are taking buprenorphine
62313611|NCT04692493|ACTIVE_COMPARATOR|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
62313612|NCT00668525|ACTIVE_COMPARATOR|2|Escitalopram low dose
62313613|NCT00668525|EXPERIMENTAL|3|Escitalopram high dose
62313614|NCT00668525|PLACEBO_COMPARATOR|1|Placebo
62313615|NCT06666361|EXPERIMENTAL|Experimental Group:receiving intervention|The experimental group participates in the Mobio Health Multimedia Hypertension Education Program, which includes a hypertension health education manual and a mobile health (m-health) intervention, aimed at enhancing participants' health literacy and promoting health-enhancing behaviors.
62313616|NCT06666361|EXPERIMENTAL|Control group :Non intervention|In the control group, participants received the same hypertension health education manual as the experimental group.
62313617|NCT06671158|EXPERIMENTAL|Measurement-based care group|Measurement-based care group
62313618|NCT06671158|ACTIVE_COMPARATOR|Treatment-as-Usual group|Treatment-as-Usual group
62478129|NCT03923374||Pregnant Mothers|Planned recruitment of 100 pregnant (\>16weeks) mothers who do not have any history of opioid use disorder.
62313619|NCT06671158|NO_INTERVENTION|Waitlist control group|Waitlist control group
62313620|NCT06228183|EXPERIMENTAL|the experimental group|Study lasts 21 days for each patient. The patients were given comprehensive rehabilitation therapy. The experimental group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
62313621|NCT06228183|ACTIVE_COMPARATOR|the control group|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The control group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
62478130|NCT00777023|EXPERIMENTAL|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
62478131|NCT00777023|EXPERIMENTAL|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
62478132|NCT00777023|PLACEBO_COMPARATOR|Sugar Pill|Placebo 1200 mg or 1800 mg
62478133|NCT05039996|ACTIVE_COMPARATOR|Intervention group|"Educational and training part. The educational part will be done once in the first visit in about 30 minutes Information and skills will be demonstrated and applied in the session through power point presentation, educational brochures, and video lessons and guided home-based practice.~Appropriate relaxation training Program~* Relaxation training comprises deep breathing exercises and progressive muscle relaxation, to perform them daily and to keep a record of them.~* Group meeting sessions for training will be held every week for the 1st 4 weeks~* Video programs will be used as relaxation facilitators.~* Patient will try these exercises for the first time in front of the researcher.~* Patients will be advised to perform them daily for 8 weeks to achieve 60 sessions and to keep a record of them.~Follow up of the intervention group adherence to instructions will be done weekly by Telephone."
62478134|NCT05039996|PLACEBO_COMPARATOR|Control group|The control group will be advised to be adherent to the prescribed medications only and try not to change the treatment plan during the study period.
62684110|NCT06655714||Patients with inadequate response|In this study, an inadequate response is defined as less than a 50% reduction in pain, as measured by the Visual Analog Scale (VAS), four weeks after the ultrasound-guided corticosteroid injection.
61923585|NCT04085367|PLACEBO_COMPARATOR|MAL Vehicle Cream|Participants received two treatment session at least 2 weeks apart. Investigator applied a thin layer of vehicle cream to each lesion during treatment. At 30 minutes after cream application, participants went outside in daylight for 2 hours (DL-PDT). After this time, the cream was removed by investigative site personnel by washing the skin with gentle skin cleanser.
62123694|NCT06414850|ACTIVE_COMPARATOR|Control Group (CG)|"The control group carried out a total of two one-hour group sessions at the hospital's own facility, on a weekly basis for two consecutive weeks. The groups were formed by 8-10 participants. Sessions included the participation of an occupational therapist and a psychologist. There was a referring psychiatrist for the project. Participants received their usual pharmacological treatment.~Intervention (same sessions without the therapy dog): Session 1, self-efficacy (executive functions, cause-effect thinking). Session 2, emotional self-regulation and frustration tolerance."
62313622|NCT01818375|EXPERIMENTAL|Goal Directed Fluid Therapy (GDFT)|"During surgery, patients in the Goal Directed Fluid Therapy (GDFT) will receive:~1. maintenance infusion of intravenous infusion of ringer lactate at a rate of 1.5 ml/Kg/hr to compensate insensible blood loss and fluid shift during surgery as recommended by perioperative fluid management guidelines for patients undergoing surgery with an enhanced recovery program and receiving a GDFT approach;~2. intraoperative intravenous boluses of colloids (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride-Voluven) guided by an algorithm based on Esophageal Doppler (ED) estimation of the stroke volume (SV) provided by the manufacture, and also used in other clinical trials."
62478135|NCT03463850|EXPERIMENTAL|Non-fracture|subjects without a lumbar fracture will have a Dexa scan and Dual Energy CT (DECT) scan for observation/evaluation
62478136|NCT03463850|EXPERIMENTAL|Fracture|subjects with one or more lumbar fractures will have a Dexa scan andDual Energy CT (DECT) scan for observation/evaluation
62478137|NCT06627166||Severe Acute Respiratory Infection (SARI)|"Nasopharyngeal swab, MINI BAL samples, Serum samples, Plasma sample, and Blood sample (RNA) will be collected from patients on day 0 (baseline) of enrollment, and on day 14 of enrollment.~SAMPLING PROCEDURES:~1. Nucleic acid extraction~2. Polymerase chain reaction (PCR) 2.1 Testing for MERS-CoV will be performed by RT-PCR 2.2 We will test for Infleunza H and N PCR for influenza H 2.3 We will also test for a panel of viruses using PCR multiplex that includes influenza A ; influenza B ; influenza C ; influenza A (H1N1) swl ; parainfluenza viruses 1, 2, 3 and 4 ; coronaviruses NL63, 229E, OC43 and HKU1; human metapneumoviruses A/B; rhinovirus ;respiratory syncytial viruses A and B; adenovirus; enterovirus; parechovirus; bocavirus.~3.16S PCR and sanger sequencing for bacterial detection 4.Metagenomics /Next Generation Sequencing 5.Microbiome bioinformatics analysis"
62478138|NCT00825331||1|patients for elective catheterization without special risks
62684111|NCT05483400|EXPERIMENTAL|Localized Head and Neck Squamous Cell Cancer|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
61923586|NCT02943252|EXPERIMENTAL|Apatinib plus S1|Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
62684112|NCT05483400|EXPERIMENTAL|Advanced or Metastatic dMMR/MSI Cancer|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
62684113|NCT05483400|EXPERIMENTAL|Anti-PD-1 Antibody Resistant Metastatic Melanoma|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
62684114|NCT05483400|EXPERIMENTAL|Basket|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
61923587|NCT01736384||Obesity|Gastric bypass surgery and non-obese controls undergoing cholecystectomy
61923588|NCT01807702|EXPERIMENTAL|13C-pyruvate,13C-Lactate and dichloroacetate|During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
61923589|NCT02571400||Patients scheduled to undergo surgery|Patients scheduled to undergo surgery at St Vincent's Private Hospital Sydney
61923590|NCT02732743|OTHER|Food Supplement Physiomanna® Baby|Dosage: 1g/kg body
61923591|NCT05702853|EXPERIMENTAL|Dose Level 1|1 x 10\^6 transduced T cells/kg (± 20%)
62313623|NCT01818375|ACTIVE_COMPARATOR|Standard Fluid Therapy|During surgery, patients will receive a maintenance infusion of intravenous infusion of ringer lactate as recommended by international guidelines and anesthesia text-books (Standard Fluid Therapy). In the Standard Fluid Therapy arm, the Esophageal Doppler (ED) monitor will be turned away from the anesthesia care provider, and the screen will be covered with an opaque card. The ED variables will be collected by an independent research personnel. Hemodynamic variables triggering extra fluid administration (Ringer Lactate or Voluven) will be decided based on the clinical judgment of the anesthetist in charge and will include: urinary output less than 0.5/ml/kg/hr, an increase in heart rate more than 20% above baseline or more than 110 beats/min, a decrease in mean systolic blood pressure less than 20% below baseline or less than 90 mmHg and intraoperative blood loss. Boluses of 200 ml of intravenous fluid will be administered until the above targets will be restored
62313624|NCT01687231|NO_INTERVENTION|Neutropenic Diet|This arm is the control and subjects will receive the standard of care neutropenic diet.
62313625|NCT01687231|EXPERIMENTAL|Non-neutropenic Diet|This arm is interventional and subjects will receive a non-neutropenic diet without restriction.
62478139|NCT00825331||2|patients for elective catheterization with special risks
62313626|NCT04832438|EXPERIMENTAL|9-ING-41 plus carboplatin|Patients will receive 9-ING-41 (15 mg/kg IV on Day 1 and Day 4) in addition to carboplatin (AUC 5 IV on Day 1) each of a 21-day cycle
62313627|NCT01662973|EXPERIMENTAL|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 48 study visit."
62313628|NCT01662973|PLACEBO_COMPARATOR|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
62478140|NCT00825331||3|patients for PCI without GP IIb/IIIa
62478141|NCT00825331||4|Patients for PCI with GPIIb/IIIa and emergencies
62478142|NCT03421717|EXPERIMENTAL|Test|Treatment/maintenance of implants postsurgically performed by the use of chitosan brushes
62478143|NCT03421717|ACTIVE_COMPARATOR|Control|Treatment/maintenance of implants postsurgically performed by the use of titanium curettes
62478144|NCT00966485|ACTIVE_COMPARATOR|80 mg ASA dose|6 months post stent on 80 mg ASA
62478145|NCT00966485|ACTIVE_COMPARATOR|500 mg ASA dose|6 months posr stent on ASA alone
62478146|NCT05163847|EXPERIMENTAL|M2SR only dose|Intranasal M2SR vaccine and intramuscular placebo dose
61923592|NCT05702853|EXPERIMENTAL|Dose Level 2|1.5 x 10\^6 transduced T cells/kg (± 20%)
61923593|NCT05702853|EXPERIMENTAL|Dose Level 3|2 x 10\^6 transduced T cells/kg (± 20%)
61923594|NCT05054244||control group|The patients in control group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires: visual analogue scale, McGill Pain questionnaire, Wound Quality of Life Index, Health Quality of Life Questionnaire, Beck depression and Beck anxiety inventory.
62478147|NCT05163847|EXPERIMENTAL|M2SR with IIV dose|Intranasal M2SR vaccine and intramuscular IIV dose
62478148|NCT05163847|ACTIVE_COMPARATOR|IIV only dose|Intranasal placebo dose and intramuscular IIV dose
61923595|NCT05054244||HBOT group|"The patients in HBOT group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue.~The HBOT sessions will be performed 5 days a week in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires as in control group."
61923596|NCT04661553|EXPERIMENTAL|Group1: patients with a low risk of premature birth|Asymptomatic patient receiving usual follow-up in the maternity ward.
61923597|NCT04661553|EXPERIMENTAL|Group2: patients with a high risk of premature birth|Symptomatic patients with cervical changes objectified by endovaginal ultrasound of the cervix with length \<20mm. Asymptomatic patients with a history of premature delivery or late miscarriage and cervical changes objectified by endovaginal ultrasound of the cervix with length \<20mm.
61923598|NCT02433158|EXPERIMENTAL|Cohort 1|Includes one adult stratum (\>18 years old) and one pediatric stratum (12-17 years old). Subjects aged 12 and over who weigh \>40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg.
62313629|NCT05983367|EXPERIMENTAL|Ompenaclid + FOLFIRI + Bevacizumab|Ompenaclid (RGX-202-01) 3000mg PO (tablets) BID; Irinotecan: 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, followed by 5-FU 2400 mg/m2 over 46 hours, on Days 1 and 15 of each 28-day cycle. Bevacizumab: 5 mg/kg on Days 1 and 15 of each 28-day cycle.
62684115|NCT06006468||Genetic risk of Type 1 diabetes|750 individuals with the highest type 1 diabetes genetic risk
62684116|NCT06006468||Genetic risk of coeliac disease|750 individuals with the highest coeliac disease genetic risk
62313630|NCT05983367|PLACEBO_COMPARATOR|Placebo + FOLFIRI + Bevacizumab|Placebo (tablets) PO + Irinotecan: 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, followed by 5-FU 2400 mg/m2 over 46 hours, on Days 1 and 15 of each 28-day cycle. Bevacizumab: 5 mg/kg on Days 1 and 15 of each 28-day cycle.
62313631|NCT06019143|EXPERIMENTAL|Arm A|Goal Attainment Scaling (GAS) with goal inventory
62313632|NCT06019143|ACTIVE_COMPARATOR|Arm B|Goal Attainment Scaling (GAS) without goal inventory
62313633|NCT02717546||Group One|Distal Tibia Fracture repaired with Zimmer MotionLoc Screw
62478149|NCT05163847|PLACEBO_COMPARATOR|Placebo only dose|Intranasal placebo dose and intramuscular placebo dose
62478150|NCT05569629|EXPERIMENTAL|Pre & post-EBBx/BB group|BW will be performed once before endobronchial biopsy and bronchial brushing, and once after endobronchial biopsy and bronchial brushing
62478151|NCT05569629|NO_INTERVENTION|Post-EBBx/BB group|BW will be performed once after endobronchial biopsy and bronchial brushing
62684117|NCT06006468||Controls|750 individuals with Neutral type 1 diabetes and coeliac disease genetic risk
62684118|NCT06366919|EXPERIMENTAL|Alexander Technique (AT)|
62684119|NCT06366919|EXPERIMENTAL|Feldenkrais Technique (FT)|
62684120|NCT00872287|ACTIVE_COMPARATOR|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
62684121|NCT00872287|ACTIVE_COMPARATOR|SILS|Single transumbilical incision laparoscopic cholecystectomy
62684122|NCT06538064||Cohort A: New Users of HyQvia|Participants with CIDP who intend to switch to HyQvia within 6 weeks after enrollment will be interviewed and data from medical records will be reviewed for 12 months.
62684123|NCT06538064||Cohort B: Current Users of HyQvia|Participants with CIDP who switched to HyQvia within 6 weeks prior to enrollment will be interviewed and data from medical records will be reviewed for 12 months.
62123695|NCT01000597|OTHER|Treatment Y|Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
62123696|NCT01000597|OTHER|Treatment Z|A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
62123697|NCT05348096|EXPERIMENTAL|Low-dose ibrutinib|Patients will receive ibrutinib 140mg/day PO in combination with oral itraconazole (100mg/day) continuously for six months.
62313634|NCT04390815|EXPERIMENTAL|Intervention|"Before starting the therapeutic procedure, all wounds will be fully washed with normal saline.~Group A patients will receive 10 units (0.1 mL) of regular insulin (manufactured by novo nordisk) in solution with 1 cc of normal saline 0.9% for each 10 cm of wound. The solution will be sprayed on the wound surface with an insulin syringe needle, once daily.~The patients in this arm will receive conventional therapy."
62313635|NCT04390815|PLACEBO_COMPARATOR|Control|Before starting the therapeutic procedure, all wounds will be fully washed with normal saline Group B patients will receive conventional topical application without insulin
62684124|NCT00912873|ACTIVE_COMPARATOR|0.1% Ropivicaine|Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
61923599|NCT02433158|EXPERIMENTAL|Cohort 2|Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
62123698|NCT01234610|EXPERIMENTAL|Exercise|Exercise
62123699|NCT01234610|NO_INTERVENTION|Control|No exercise
62123700|NCT00857545|EXPERIMENTAL|Arm I (vaccine therapy and adjuvant)|Patients receive polyvalent antigen-KLH conjugate vaccine and immunological adjuvant OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 11, 23, 35, 47, 59, 71, and 83 in the absence of disease progression or unacceptable toxicity.
62123701|NCT00857545|EXPERIMENTAL|Arm II (adjuvant)|Patients receive immunological adjuvant OPT-821 SC as in arm I.
62123702|NCT00944372|EXPERIMENTAL|Group 1|Control, age greater than or equal to 18 with normal renal function
62123703|NCT00944372|EXPERIMENTAL|Group 2|Age 18 to less than 65 with mild renal impairment
62123704|NCT00944372|EXPERIMENTAL|Group 3|Age 18 to less than 65 with moderate to severe renal impairment
62123705|NCT00944372|EXPERIMENTAL|Group 4|Age 18 to less than 65 with end stage renal impairment
62123706|NCT00944372|EXPERIMENTAL|Group 5|Age 65 to less than 75 with mild renal impairment
62123707|NCT00944372|EXPERIMENTAL|Group 6|Age 65 to less than 75 with moderate to severe renal impairment
62123708|NCT00944372|EXPERIMENTAL|Group 7|Age 65 to less than 75 with end stage renal impairment
62123709|NCT00944372|EXPERIMENTAL|Group 8|Age greater than or equal to 75 with mild renal impairment
62123710|NCT00944372|EXPERIMENTAL|Group 9|Age greater than or equal to 75 with moderate to severe renal impairment
62123711|NCT00944372|EXPERIMENTAL|Group 10|Age greater than or equal to 75 with end stage renal impairment
62123712|NCT03551535|EXPERIMENTAL|Physical Activity Intervention|Patients will be allocated to a physical activity intervention to be performed 3-5 days per week
62123713|NCT03551535|NO_INTERVENTION|Control|Patients will receive standard counseling regarding activity recommendations in pregnancy
62684125|NCT00912873|EXPERIMENTAL|0.4% Ropivicaine|Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
62684126|NCT05566782||CRES-participants|"The participants in this cohort will start rehabilitation during their inhospital stay and continue the rehabilitation course during discharge to municipality.~The rehabilitation will consist of physical exercise and measurements in relation to accelerometry, physical function and qualitative interviews regarding goal for rehabilitation."
62684127|NCT06137664|EXPERIMENTAL|Adults: High-dose (HD) nOPV1 + HD nOPV2 + HD nOPV3|Adults will receive nOPV1 (10\^6.5 Cell Culture Infectious Dose 50% \[CCID₅₀\]) plus nOPV2 (10\^5.6 CCID₅₀) plus nOPV3 (10\^6.5 CCID₅₀) on Day 1 and Day 29.
62684128|NCT06137664|ACTIVE_COMPARATOR|Adults:bOPV|Adults will receive bivalent OPV (types 1 and 3) on Day 1 and Day 29. Each dose (2 drops = 0.1 mL) contains \>10\^6.0 infective units of type 1 and \>10\^5.8 of type 3.
62684129|NCT06137664|EXPERIMENTAL|Young Children: Middle-dose (MD) nOPV1 + Low-dose (LD) nOPV2 + MD nOPV3|Children aged ≥ 1 to \< 5 years old will receive nOPV1 (10\^6.0 CCID₅₀) plus nOPV2 (10\^5.3 CCID₅₀) plus nOPV3 (10\^6.0 CCID₅₀) on Day 1 and Day 29.
62684130|NCT06137664|EXPERIMENTAL|Young Children: HD nOPV1 + HD nOPV2 + HD nOPV3|Children aged ≥ 1 to \< 5 years old will receive nOPV1 (10\^6.5 CCID₅₀) plus nOPV2 (10\^5.6 CCID₅₀) plus nOPV3 (10\^6.5 CCID₅₀) on Day 1 and Day 29.
62684131|NCT06137664|ACTIVE_COMPARATOR|Young Children: Low-dose (LD) nOPV2|Children aged ≥ 1 to \< 5 years old will receive nOPV2 (10\^5.3 CCID₅₀) on Day 1 and Day 29.
61923600|NCT05272215||Patient group|"Pre-BaS: Patients administered for BaS, Department of Endocrinology either Odense University Hospital, Odense, Denmark or Hospital of Southwest Jutland, Esbjerg, Denmark~Post-BaS: (3, 6, 12 months postoperatively, then yearly) Department of Surgery, Southwest Jutland, Esbjerg, Denmark~Pre-BC: Patients administered for BC, Department of Plastic Surgery, Odense University Hospital, Odense, Denmark or Department of Plastic Surgery, Southwest Jutland, Esbjerg, Denmark.~Post-BC: (3, 6, 12 months postoperatively, then yearly), department of Plastic Surgery, Odense University Hospital; Hospital of Southwest Jutland, Esbjerg.~Normative group: Reference scores of the general population from an international sample of 10 countries and country specific scores. This study sample is submitted for publication elsewhere."
62123714|NCT01580319|NO_INTERVENTION|Control|Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
62478152|NCT06172283|EXPERIMENTAL|Intermittent Fasting|Patients will undergo 16h periods of fasting everyday. Optionally, patients will be offered to undergo a plant-based diet consisting of 20% plant based protein, 50% carbohydrates, and 30% fat for the duration of the study.
62684132|NCT06137664|ACTIVE_COMPARATOR|Young Children: bOPV|Children aged ≥ 1 to \< 5 years old will receive bivalent OPV (types 1 and 3) on Day 1 and Day 29. Each dose (2 drops = 0.1 mL) contains \> 10\^6.0 infective units of type 1 and \> 10\^5.8 of type 3.
62684133|NCT06137664|EXPERIMENTAL|Neonates: MD nOPV1 + LD nOPV2 + MD nOPV3|Newborns will receive nOPV1 (10\^6.0 CCID₅₀) plus nOPV2 (10\^5.3 CCID₅₀) plus nOPV3 (10\^6.0 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
62684134|NCT06137664|EXPERIMENTAL|Neonates: HD nOPV1 + LD nOPV2 + HD nOPV3|Newborns will receive nOPV1 (10\^6.5 CCID₅₀) plus nOPV2 (10\^5.3 CCID₅₀) plus nOPV3 (10\^6.5 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
62123715|NCT01580319|EXPERIMENTAL|Exercise|Participants receive a physical exercise plan to play at home
62684135|NCT06137664|EXPERIMENTAL|Neonates: MD nOPV1 + LD nOPV2 + HD nOPV3|Newborns will receive nOPV1 (10\^6.0 CCID₅₀) plus nOPV2 (10\^5.3 CCID₅₀) plus nOPV3 (10\^6.5 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
62684136|NCT06137664|EXPERIMENTAL|Neonates: HD nOPV1+ LD nOPV2+ MD nOPV3|Newborns will receive nOPV1 (10\^6.5 CCID₅₀) plus nOPV2 (10\^5.3 CCID₅₀) plus nOPV3 (10\^6.0 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
61923601|NCT05235464|ACTIVE_COMPARATOR|Standard meal|
61923602|NCT05235464|EXPERIMENTAL|High animal protein meal|
61923603|NCT05235464|EXPERIMENTAL|High plant protein meal|
62123716|NCT06307223|EXPERIMENTAL|30% supramolecular salicylic acid combined with supramolecular active zinc treatment group|The patients received weekly application of 30% supramolecular salicylic acid in conjunction with daily application of topical supramolecular active zinc anti-dandruff lotion, for a duration of 8 weeks.
62123717|NCT03309488||Food allergic|Patients with a positive oral challenge to the food being studied.
62123718|NCT03309488||Non food allergic|Patients with a negative oral challenge to the food being studied.
62123719|NCT01042639|ACTIVE_COMPARATOR|physical activity once a day|
62478153|NCT01422291|ACTIVE_COMPARATOR|morphine|
62478154|NCT01422291|EXPERIMENTAL|Paracetamole, dexketoprofen|Paracetamole, dexketoprofen
62684137|NCT06137664|EXPERIMENTAL|Neonates: HD nOPV1 + HD nOPV2 + HD nOPV3|Newborns will receive nOPV1 (10\^6.5 CCID₅₀) plus nOPV2 (10\^5.6 CCID₅₀) plus nOPV3 (10\^6.5 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
62684138|NCT06137664|ACTIVE_COMPARATOR|Neonates: bOPV|Newborns will receive bivalent OPV (types 1 and 3) at birth, week 6, week 10 and week 14 of life. Each dose (2 drops = 0.1 mL) contains \>10\^6.0 infective units of type 1 and \>10\^5.8 of type 3.
61923604|NCT05235464|EXPERIMENTAL|High plant protein meal with additional leucine|
61923605|NCT01747018|EXPERIMENTAL|Platelet-rich Plasma|From all the patients who participated in the clinical trial, 27 ml of blood sample was collected with a 20-G needle from an antecubital vein so that the ratio of the blood and the anti-coagulant became 10:1. The collected blood samples were transferred to a prepared separation kit (Prosys PRP, Seoul, Korea) and underwent centrifugation at the speed of 3,000 RPM for three minutes. The buffy coat layer and the plasma of the upper portion of the layer were obtained and were transferred to a concentration kit (Prosys PRP, Seoul, Korea) using a 10-ml syringe. They again underwent centrifugation at the speed of 3,300 RPM for three minutes in order to obtain concentrated PRP. The injection area was sterilized aseptically and 3-4 cc of PRP were percutaneously injected into the knee joints.
62123720|NCT01042639|EXPERIMENTAL|physical activity twice a day|
62123721|NCT01042639|NO_INTERVENTION|control|
62123722|NCT06547151|EXPERIMENTAL|AMOR-1|AMOR-1, Amorphous Calcium Carbonate (ACC) oral tablet contains 250 mg elemental calcium.
61923606|NCT04008043|EXPERIMENTAL|Dexamethasone|Participants in this arm will take a 6mg dexamethasone tablet the day before surgery, a 6 mg tablet the day of surgery, a 4mg tablet the day after surgery and a 2mg tablet the second day after surgery. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
62123723|NCT06547151|ACTIVE_COMPARATOR|Active Comparator|Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
62123724|NCT04808778||Participants with sickle cell anemia identified with neurological morbidity|"1. Successful completion of screening procedures inclusive of 1.) Cerebral blood flow velocity greater than or equal to 200 cm/sec measured twice or 2.) At least one measurement greater than or equal to 220 cm/sec in the middle cerebral artery or 3.) Two TCD measurements above 190 cm/sec within a three-month interval;~2. MRI showing cerebral infarcts with or without (based on Silent Cerebral Infarct Trial (SIT) criteria) neurological deficits on standard neurological examination;~3. Informed consent from a participant (\> 18 years) or parent/legal guardian for participants (\< 18 years) and assent of the participant completed;~4. Acceptance of hydroxyurea therapy for one year as standard care. After one year of therapy, the participant will have the option to continue therapy with follow-up visits to monitor adherence to therapy with his or her care provider."
62313636|NCT02847611|EXPERIMENTAL|Jamar then Labin|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
62478155|NCT04605211|EXPERIMENTAL|Being Present (Supportive Care)|Patients and caregivers receive Being Present intervention consisting of online audio-based mindfulness meditation exercise over 15 minutes at least 5 times per week, daily meditation reminders, and online webinars over 30-60 minutes every week.
62684139|NCT06137664|EXPERIMENTAL|Neonates: MD nOPV1 + LD nOPV2|Newborns will receive nOPV1 (10\^6.0 CCID₅₀) plus nOPV2 (10\^5.3 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
62684140|NCT06137664|ACTIVE_COMPARATOR|Neonates: LD nOPV2|Newborns will receive nOPV2 (10\^5.3 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
62684141|NCT02372773||Frontotemporal Dementia - MAPT|Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation
62684142|NCT02372773||Frontotemporal Dementia - PGRN|Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation
62684143|NCT02372773||Frontotemporal Dementia - C9OR72|Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.
62684144|NCT02372773||Control|Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.
62478156|NCT04313751|EXPERIMENTAL|Education, Physical Activity, and Stress Management Program|Classes for the intervention group will be run by a bilingual interventionist and will last 120 minutes weekly for 12 weeks and then monthly for 3 months.
62684145|NCT06543758|EXPERIMENTAL|Wearable exoskeletal robot group|Patients with stroke receive home-based robotic-assisted gait rehabilitation using a wearable exoskeletal robot.
62684146|NCT03912987||Affected|Affected with ALS or a related disorder, including ALS-FTD, FTD, PLS, and PMA.
61923607|NCT04008043|ACTIVE_COMPARATOR|Vicodin|Participants in this arm will take a vicodin tablet every 4-6 hrs as needed to a maximum of 8 tablets after surgery. Each tablet has 300 mg acetaminophen and 5 mg hydrocodone. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
62123725|NCT04808778||Participants with sickle cell anemia identified to be without neurological morbidity|"1. Successful completion of screening procedures inclusive of cerebral blood flow velocity less than or equal to 199 cm/sec in the middle cerebral artery;~2. Normal MRI and MRA;~3. No focal neurological deficit on standard neurological examination;~4. Informed consent from a participant (\> 18 years), or parent/legal guardian for participants (\< 18 years) and assent from the participant;~5. Agreement to be followed for at least one year in the study."
62123726|NCT00158769|EXPERIMENTAL|Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment as defined by a Child-Pugh score of 7-9 will be included. Subjects will be given GR270773 as a loading infusion of 25 milligram per kilogram per hour (mg/kg/hr) for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours.
62684147|NCT03912987||Healthy Controls|Those never diagnosed with and not at particular risk for developing ALS or a related disorder.
62123727|NCT00158769|EXPERIMENTAL|Healthy subjects|Subjects will be matched as closely as possible to the group of moderate hepatic subjects for gender, age and body mass index (BMI). Subjects will be administered 25 mg/kg/hr GR270773 as a loading dose for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours. Following a washout period of 21 days, the subjects will then receive a loading dose of 75 mg/kg/hr for 2 hours followed by a maintenance dose of 12.5 mg/kg/hr of GR270773 for 70 hours.
62684148|NCT06688461|EXPERIMENTAL|T2D-HIIT|This arm will perform HIIT under supervision. This arm will be compared to an age and BMI matched, normoglycemic non-intervention group.
62684149|NCT06596772|EXPERIMENTAL|MB04 (proposed etanercept biosimilar)|MB04 50 mg/week via subcutaneous injection
62684150|NCT06596772|ACTIVE_COMPARATOR|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
62123728|NCT00557024|EXPERIMENTAL|1|radiotherapy after RFA
62123729|NCT00557024|ACTIVE_COMPARATOR|2|RFA alone
62684151|NCT05094102|EXPERIMENTAL|Axillary Surgery|Breast cancer patients undergoing SLN biopsy (n=0-20) or axillary lymph node dissection (n=0-15) will be enrolled to undergo standard of care axillary reverse mapping (ARM) using isosulfan blue dye. Participants will also receive ICG injection with visualization through the OnLume Imaging System to allow comparison of blue dye versus ICG lymphatic identification.
62684152|NCT06650098|EXPERIMENTAL|WEB based application|The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.
61923608|NCT02054468|ACTIVE_COMPARATOR|Single-shot-Propofol & Remifentanil|Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation
61923609|NCT02054468|EXPERIMENTAL|30min infusion Propofol & Remifentanil|Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask
61923610|NCT06168227||Observational Group|Patients receive RC48
61923611|NCT03506867|ACTIVE_COMPARATOR|Usual care arm|We will provide the participants in this arm with pamphlets and knowledge about available services in the city through partner agencies. The life skills, training, and work arm will be offered to the usual care arm participants after the first six months of study enrollment.
62697339|NCT06637969|EXPERIMENTAL|mindfulness-based|The experimental group was also provided with a total of 30 minutes of mindfulness training once a day for seven consecutive days. The content included mindful breathing awareness for 8 minutes while resting and lying in bed, 10 minutes of mindfulness meditation, 12 minutes of mindfulness body scanning, and 10 minutes of mindful walking and breathing. The control group The group received routine care, and a pre-test was conducted before the implementation of the interventional measures (from 7 pm to 9 pm the day before the operation), and a post-test was conducted after the seven-day intervention (from 7 pm to 9 pm on the seventh day of the interventional treatment). Comparison between the experimental group and the control group group differences
62313637|NCT02847611|EXPERIMENTAL|Labin then Jamar|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
62313638|NCT02752308|ACTIVE_COMPARATOR|General anesthesia + caudal block|Patients who receive general anesthesia plus caudal epidural block and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
62313639|NCT02752308|ACTIVE_COMPARATOR|General anesthesia only|Patients who receive only general anesthesia and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
62313640|NCT01635933|EXPERIMENTAL|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn in daily wear modality for 4 weeks. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
62313641|NCT01635933|ACTIVE_COMPARATOR|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn in daily wear modality for 4 weeks, with a replacement pair dispensed at 14 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
62313642|NCT06672211|EXPERIMENTAL|Experimental group|Group receiving standard stoma care training + video-supported training
62313643|NCT06672211|NO_INTERVENTION|control group|Group receiving standard stoma care training
62313644|NCT03133481|ACTIVE_COMPARATOR|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
62313645|NCT03133481|ACTIVE_COMPARATOR|Femoral Nerve Block|Participants will be randomized using block randomization.
62313646|NCT05658029|EXPERIMENTAL|Open label treatment group|
62313647|NCT06027320|EXPERIMENTAL|Brain Health Education Arm|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
62697340|NCT03000881|EXPERIMENTAL|Cohort 6|This is a sub-study testing the effect of real output applied under two adhesive strips after 8 hours.
61923612|NCT03506867|ACTIVE_COMPARATOR|Life skills, training, and work arm|Participants will receive life-skills workshops, training, education resources and access to small-paid or volunteering positions.
61923613|NCT02125643|ACTIVE_COMPARATOR|Caffeine Pill|The caffeine will be administered.
62123730|NCT04035668|EXPERIMENTAL|Remibrutinib 100 mg bid|Remibrutinib 100 mg twice daily (bid)
62123731|NCT04035668|EXPERIMENTAL|Remibrutinib 100 mg qd|Remibrutinib 100 mg once daily (qd)
62313648|NCT06027320|OTHER|Alzheimer Disease Education Arm|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
62313649|NCT02028572||Primary open angle glaucoma|Subjects diagnosed to have primary open angle glaucoma with intraocular pressure \> 21 mm Hg and characteristic glaucomatous damage to the optic nerve.
62313650|NCT04950985||Participants|Adults undergoing a CT scan to investigate possible NOE.
62313651|NCT00780000|EXPERIMENTAL|A1|
62313652|NCT02265211|EXPERIMENTAL|Self-Help App|Smartphone app designed to teach cognitive defusion.
62313653|NCT03947879|EXPERIMENTAL|L-glutamine|Treatment with L-glutamine for 3 months.
62313654|NCT03947879|EXPERIMENTAL|No L-glutamine|No L-glutamine for 3 months.
62313655|NCT06470958||Menstrual-related migraine without aura|Migraine patients
62313656|NCT06470958||Healthy volunteers|Control group
62313657|NCT00866294|EXPERIMENTAL|paroxetine CR group|controlled-release (CR) of paroxetine 12.5 to 50mg/day
62123732|NCT04035668|PLACEBO_COMPARATOR|Placebo|Placebo group
62313658|NCT00866294|OTHER|paroxetine IR group|Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm
62313659|NCT00866294|PLACEBO_COMPARATOR|placebo group|matched placebo to both paroxetine CR and paroxetine IR
62313660|NCT06673381||high sensitive c-reactive protein to albumin ratio (hs-CAR)|Group A ( patients with high hs-CAR) and group B ( patients with low hs-CAR)
62313661|NCT00695994|EXPERIMENTAL|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle.
62313662|NCT00695994|EXPERIMENTAL|Gemcitabine and carboplatin|Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
62697341|NCT04598425|EXPERIMENTAL|Cognitive behavioral therapy for insomnia (CBTi)|
62313663|NCT05032976||Tozinameran (BNT162b2)|Subjects aged 6 months and older who are scheduled for Tozinameran vaccination
62313664|NCT05032976||Riltozinameran (BNT162b2 OMI BA.1)|Subject aged 12 years and older who are scheduled for Riltozinameran vaccination
62313665|NCT05032976||Famtozinameran (BNT162b2 OMI BA.4-5)|Subject aged 5 years and older who are scheduled for Famtozinameran vaccination
62313666|NCT05032976||Raxtozinameran (BNT162b2 OMI XBB.1.5)|Subject aged 6 months to 4 years and 12 years and older who are scheduled for Raxtozinameran vaccination
62313667|NCT02368444|EXPERIMENTAL|Intervention Group|Cognitive Behavioral Therapy and Yoga
62313668|NCT04976075||Adults|Patients of 18 or more years old
62313669|NCT04976075||Pediatrics|Patients less than 18 years old
62313670|NCT01971879|SHAM_COMPARATOR|Control|
62313671|NCT01971879|ACTIVE_COMPARATOR|Remote preconditioning|
62123733|NCT01818830||SIRS group|(1) temperature \> 38oC or \< 36oC; (2) pulse rate \> 90 beats/min; (3) ventilation rate \> 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) \< 32 mmHg; (4) white blood cell (WBC) count \>1 2,000μL-1 or \< 4000 μL-1 , or \> 10% immature cells.
62123734|NCT01818830||sepsis|SIRS+infection
62123735|NCT01818830||normal control|For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
62313672|NCT05738213|ACTIVE_COMPARATOR|Migraine|Adolescents with a migraine diagnosis
62313673|NCT05738213|PLACEBO_COMPARATOR|Healthy control|Adolescents without a migraine diagnosis
62313674|NCT02613572|EXPERIMENTAL|alpha lipoic acid (ALA) 600mg once daily x 5 days|All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.
62313675|NCT02613572|EXPERIMENTAL|alpha lipoic acid 800mg|once daily with meal x 5 days
62313676|NCT02613572|EXPERIMENTAL|alpha lipoic acid 1200mg|once daily x 5 days
62697342|NCT01422382|EXPERIMENTAL|All Subjects|There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
61923614|NCT02125643|PLACEBO_COMPARATOR|Placebo/Flour Pill|The flour will be administered.
62313677|NCT02613572|PLACEBO_COMPARATOR|Placebo 600mg|All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the
62313678|NCT02613572|EXPERIMENTAL|ALA 600 mg|once daily with a meal for 2 weeks
62313679|NCT02613572|PLACEBO_COMPARATOR|Placebo 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
62697343|NCT06638151|ACTIVE_COMPARATOR|Aspirin Group|
62697344|NCT06638151|EXPERIMENTAL|Dual Antiplatelet Group|
62123736|NCT00744224|PLACEBO_COMPARATOR|1|
62313680|NCT02613572|EXPERIMENTAL|ALA 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
62697345|NCT05591365|EXPERIMENTAL|Structured In-patient and Home plan|Structured In-patient and Home plan
62697346|NCT05591365|PLACEBO_COMPARATOR|Conventional therapy|Conventional protocol as per guidelines
61923615|NCT03223636||Healthy Volunteers|Healthy Volunteers
61923616|NCT06515067|EXPERIMENTAL|study group|People in this group applied back massage
61923617|NCT06515067|OTHER|control group|People in this group did not apply back massage
62123737|NCT00744224|ACTIVE_COMPARATOR|2|
62123738|NCT00744224|ACTIVE_COMPARATOR|3|
62123739|NCT02904759|EXPERIMENTAL|Desmopressin 25 µg|Desmopressin ODT
62123740|NCT02904759|EXPERIMENTAL|Desmopressin 50 µg|Desmopressin ODT
62123741|NCT02904759|PLACEBO_COMPARATOR|Placebo|Placebo ODT
62123742|NCT01904071|EXPERIMENTAL|UFNB|Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
62313681|NCT06672510|EXPERIMENTAL|Patients with Acute Pulmonary Embolism|Patients undergoing mechanical thrombectomy for acute pulmonary embolism.
62313682|NCT04210973|EXPERIMENTAL|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
62313683|NCT04210973|PLACEBO_COMPARATOR|Placebo|Placebo,oral, twice per day
62313684|NCT00765869|EXPERIMENTAL|1|Bowel cancer screening decision aid, DVD and Question Prompt List (QPL)
62313685|NCT00765869|EXPERIMENTAL|2|Bowel cancer screening decision with DVD only
62313686|NCT00765869|ACTIVE_COMPARATOR|3|Australian Government Bowel Cancer Screening consumer information booklet
62313687|NCT01494038|EXPERIMENTAL|Arm A (Immediate INH Treatment)|Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
62313688|NCT01494038|EXPERIMENTAL|Arm B (Deferred INH Treatment)|Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
62684153|NCT06650098|EXPERIMENTAL|artificial intelligence-supported mobile application|It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
62684154|NCT06650098|NO_INTERVENTION|control group|No intervention will be applied to the control group, and they will receive routine clinical and outpatient training.
62684155|NCT06685016|EXPERIMENTAL|Control Group|Subjects will not receive any treatment
62123743|NCT01904071|EXPERIMENTAL|UFIB|Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
62123744|NCT01904071|ACTIVE_COMPARATOR|IVMS|IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg
62123745|NCT04825028||Internal Diagnostic Accuracy Cohort|Consecutive patients with available CZT-SPECT within 3 months of measuring FFR in the left anterior descending coronary artery. In these patients, correlation between angiography-derived IMR and hyperemic microvascular resistance will be assessed.
62123746|NCT04825028||External Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (J Nucl Cardiol. 2020 Sep 30. doi: 10.1007/s12350-020-02252-8.), INOCA patients and normal controls confirmed by CZT-SPECT and angiography will be included for the assessment of angiography-derived IMR in diagnosing microvascular dysfunction.
62123747|NCT04825028||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the target vessel after successful revascularization. Those patients have follow-up data after 2 years from index procedure.
62123748|NCT03648814|EXPERIMENTAL|Intracameral injection|Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
62123749|NCT03648814|EXPERIMENTAL|Intravitreal injection|Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
62123750|NCT02699385|EXPERIMENTAL|Oral Rehydration Therapy (ORT) + Domperidone|Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
62123751|NCT02699385|EXPERIMENTAL|Oral Rehydration Therapy + Placebo|Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.
62123752|NCT02824822||High SUDEP risk cohort|Patients with epilepsy who have a high SUDEP-7 risk score and/or a blood-relative with epilepsy, seizure, cardiac arrest, sudden death, drowning/near-drowning, syncope or arrhythmia.
62123753|NCT02824822||Low SUDEP risk cohort|Patients with epilepsy and a low SUDEP-7 score.
62123754|NCT04237155|OTHER|Healthy controls involved in step 1|30 healthy individuals will complete a verbal material scoring questionnaire
62123755|NCT04237155|OTHER|Patients with schizophrenia involved in step 1|30 patients with schizophrenia will complete a verbal material scoring questionnaire
62123756|NCT04237155|OTHER|Healthy controls involved in step 2|30 healthy individuals will complete the source-monitoring task which will be created from step 1 as well as the task of reference
62123757|NCT04237155|OTHER|Patients with schizophrenia involved in step 2|30 patients with schizophrenia will complete the source-monitoring task which will be created from step 1 as well as the task of reference
62123758|NCT02089217|ACTIVE_COMPARATOR|Carotid Endarterectomy (CEA)|Carotid Endarterectomy
62123759|NCT02089217|ACTIVE_COMPARATOR|Carotid Stenting (CAS)|Carotid Stenting
62123760|NCT02089217|EXPERIMENTAL|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
62123761|NCT02089217|EXPERIMENTAL|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
62123762|NCT00194714|EXPERIMENTAL|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once per month for 6 months in the absence of disease progression or unacceptable toxicity.
62123763|NCT05218044|OTHER|Cryoablation|Phase I, single-arm study to evaluate the ability of cryoablation to achieve complete ablation of DCIS in the cryoablation zone of necrosis as a potential alternative to surgery.
62123764|NCT05767294||Neonatal|
62123765|NCT05767294||1-3 months old|
62123766|NCT05767294||3-6 months old|
62123767|NCT05767294||6 months-1 year old|
62313689|NCT04251585|EXPERIMENTAL|Low Insulin|Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.
62123768|NCT05767294||1-2 years old|
62123769|NCT05767294||2-5 years old|
62123770|NCT04287478|EXPERIMENTAL|Intravenous (IV)|Phage administered via the intravenous route.
62123771|NCT04287478|EXPERIMENTAL|Intravesical (IVS)|Phage administered via the intravesical route.
62123772|NCT04287478|EXPERIMENTAL|Subcohort A|Selected phage for E. coli administered via selected route based on previous Arms.
62123773|NCT04287478|EXPERIMENTAL|Subcohort B|Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.
62123774|NCT04287478|EXPERIMENTAL|Subcohort C|Selected phage for E. coli administered via selected route based on previous Arms.
62123775|NCT04287478|EXPERIMENTAL|Subcohort D|Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.
62123776|NCT05599152||ticagrelor/prasugrel Group|Patients with acute myocardial infarction who underwent percutaneous coronary intervention and maintained aspirin and ticagrelor/prasugrel as standard therapy.
62313690|NCT04251585|EXPERIMENTAL|Medium Insulin|Regular insulin (Novolin-R) 40 international units (10 units) in each nostril twice daily for 21 days, 100 µl volume.
62684156|NCT06685016|EXPERIMENTAL|Laser Diode Group|Subjects treated with Laser Diode
62684157|NCT06685016|EXPERIMENTAL|Sodium Fluoride Group|Subjects with a sodium fluoride gel treatment.
62684158|NCT05867069||Ipsilateral knee pain group|Those FAI patients presenting with preoperative ipsilateral knee pain.
62684159|NCT05867069||No ipsilateral knee pain group|Those FAI patients presenting without preoperative ipsilateral knee pain.
62684160|NCT06688617|EXPERIMENTAL|Swedish hand massage|Swedish hand massage was applied to patients who were extubated after the first 4 hours after surgery, were not under the effect of pharmacological or non-pharmacological analgesia, and were in the intensive care period after the first expression of pain.
62313691|NCT04251585|EXPERIMENTAL|High Insulin|Regular insulin (Novolin-R) 80 international units (10 units) in each nostril twice daily for 21 days, 200 µl volume.
62684161|NCT06688617|NO_INTERVENTION|Control|Patients who were extubated within the first 4 hours after surgery, who were not under the effect of pharmacological or nonpharmacological analgesia, and who were admitted to the intensive care unit with the first pain symptom were followed up during the follow-up periods.
62684162|NCT02018679|EXPERIMENTAL|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
62684163|NCT02018679|ACTIVE_COMPARATOR|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
62684164|NCT00534586|ACTIVE_COMPARATOR|1|remifentanil
62684165|NCT00534586|ACTIVE_COMPARATOR|2|propofol
62123777|NCT05599152||clopidogrel Group|In patients with acute myocardial infarction who underwent percutaneous coronary intervention, discontinued ticagrelor/prasugrel and switched to clopidogrel
62123778|NCT01909167|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Patients randomized to the treatment as usual arm will follow advice by their GP(general practitioner), mental health midwife or perinatal psychiatric team concerning treatment.
62684166|NCT00534586|ACTIVE_COMPARATOR|3|sevoflurane
62684167|NCT00534586|ACTIVE_COMPARATOR|4|s-ketamine
62684168|NCT06535893|ACTIVE_COMPARATOR|JCOG2205-TN|KEYNOTE-522 regimen: Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
62684169|NCT06535893|EXPERIMENTAL|JCOG2205-TN-1|Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab
62684170|NCT05607849|EXPERIMENTAL|Decisional aid for organised cancer screening|Women will receive a leaflet that presents the tool. The leaflet includes a link to access the tool, and encourages the person to consult their GP to initiate the shared decision-making process. GPs will receive a letter presenting the study that includes: a) information about shared decision-making and how to implement it; b) the letter that is sent to their patients, and c) a recommendation to implement shared decision-making with their patients.
62684171|NCT05607849|NO_INTERVENTION|Standard organised cancer screening|Women and their GPs will continue to carry out usual screening.
62123779|NCT01909167|ACTIVE_COMPARATOR|Online Cognitive Behavioral Therapy|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
62123780|NCT03993704|EXPERIMENTAL|Active|450 mg, 1125 mg, or 2250 mg of LHF-535 given once daily for 14 days
62684172|NCT05875831|OTHER|Coughing|
62123781|NCT03993704|PLACEBO_COMPARATOR|Placebo|Placebo to match LHF-535 given once daily for 14 days
62123782|NCT05727241||The study cohort (total sample)|All women will undergo ultrasound examination for three-dimensional umbilical cord index.
62123783|NCT05834842|EXPERIMENTAL|Behavioral: Online Intervention Unisalud|Participants in this group will receive 9 sessions of a multi-component intervention focused on the reduction of the consumption of ultra processed foods, symptoms of anxiety, depression and stress and the increase of physical activity.
62123784|NCT05834842|NO_INTERVENTION|No Intervention: Waiting List group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 9 sessions will receive the intervention.
62313692|NCT04251585|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride in each nostril twice daily for 21 days, 100 µl volume.
62313693|NCT04876664|EXPERIMENTAL|Ambulatory monitoring solution|this study has only one arm
62123785|NCT01426269|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo during phase 2 (week 12 - week 52)
62123786|NCT01426269|OTHER|Doxycycline and Metronidazole|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
62123787|NCT01426269|ACTIVE_COMPARATOR|Doxycycline|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
62123788|NCT03238391|EXPERIMENTAL|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
62123789|NCT03238391|SHAM_COMPARATOR|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
62123790|NCT03706690|EXPERIMENTAL|Durvalumab Therapy|Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/deterioration or confirmed radiological progression)
62123791|NCT03706690|PLACEBO_COMPARATOR|Placebo Therapy|Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)
62123792|NCT01190007|EXPERIMENTAL|Caduet|
62123793|NCT06476860||patients suspected of sepsis or septic shock|
62123794|NCT05052450||Dementia with Alzheimer|Patients previously diagnosed with Alzheimer disease would be included
62313694|NCT00435539|EXPERIMENTAL|ocriplasmin 75µg single injection|Ocriplasmin 75µg single injection versus sham injection
62313695|NCT00435539|EXPERIMENTAL|ocriplasmin 125µg single injection|Ocriplasmin 125µg single injection versus sham injection
62313696|NCT00435539|EXPERIMENTAL|ocriplasmin 175µg single injection|Ocriplasmin 175µg single injection versus sham injection
62313697|NCT00435539|EXPERIMENTAL|ocriplasmin 125µg multiple injections|Ocriplasmin 125µg multiple injections. Subjects who did not achieve resolution of VMT by the day 28 visit (i.e. non-responders) were given an open-label injection of ocriplasmin 125µg. Subjects who still did not achieve resolution of VMT by the day 56 visit were given a second open-label injection of ocriplasmin 125µg.
62313698|NCT00435539|SHAM_COMPARATOR|sham injection|sham injection
62313699|NCT03312673||Asthma population|Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
62313700|NCT02749721|OTHER|Other - vortioxetine|Open-label vortioxetine
62313701|NCT05215210|EXPERIMENTAL|Bitter-gourd|dried bitter-gourd supplements
62478157|NCT04313751|ACTIVE_COMPARATOR|Wait-list Control|Data in the wait-list control group will be collected at the same time intervals as the intervention group. After Time 3 data collection, they will be offered the Phase I intervention (12 weekly sessions).
62123795|NCT05052450||Dementia with Lewy Body Dementia|Patients previously diagnosed with Lewy Body Dementia would be included
62123796|NCT05052450||Dementia with Fronto-Temporal Dementia|Patients previously diagnosed with Fronto-Temporal Dementia would be included
62123797|NCT05052450||Dementia with Vascular Disease|Patients previously diagnosed with Dementia with Vascular Disease would be included
62123798|NCT05052450||Dementia with Parkinson Disease|Patients previously diagnosed with Dementia with Parkinson Disease would be included
62123799|NCT01271517|ACTIVE_COMPARATOR|Insulatard|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars
62123800|NCT01271517|ACTIVE_COMPARATOR|Lantus|Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
62123801|NCT01271517|ACTIVE_COMPARATOR|Levemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
62123802|NCT01923012|EXPERIMENTAL|Vitamin K2|
62123803|NCT03378141|EXPERIMENTAL|A&T- intensive|A\&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
62123804|NCT03378141|NO_INTERVENTION|A&T-non intensive|A\&T-non intensive arm only receives standard MNCH services
62123805|NCT01747486|EXPERIMENTAL|Target dose of 1-5x10e8|Arm 1: Target dose of 1-5x10e8 CART-19 cells (calculated as range of 10-50% transduced cells in 1 x10e9 total cells)
62123806|NCT01747486|EXPERIMENTAL|Target dose of 1-5x10e7|Arm 2: Target dose of 1-5x10e7 CART-19 cells (calculated as the range of 10-50% transduced cells in 1 x10e8 total cells)
62313702|NCT05215210|ACTIVE_COMPARATOR|Cucumber|dried cucumber supplements
62313703|NCT01668238||malignant tumor|Inpatients with malignant tumors of thyroid and breast
62313704|NCT01668238||benign tumor|Inpatients with benign tumors of thyroid and breast
62313705|NCT01668238||Healthy volunteers|Volunteers without thyroid or breast tumors
62313706|NCT04483362|EXPERIMENTAL|Physical Activity|Behavioural change techniques to promote physical activity
62313707|NCT04522102|EXPERIMENTAL|Intervention|Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).
62313708|NCT04522102|NO_INTERVENTION|Comparator|Avoid antiplatelet therapy.
62684173|NCT05875831|EXPERIMENTAL|Active Cycle of Breathing|
62478158|NCT04715646|EXPERIMENTAL|Brivaracetam|LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day.
62478159|NCT06402799|EXPERIMENTAL|E-biking intervention|Home-based e-biking
62478160|NCT00170547|EXPERIMENTAL|Group 3|382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
62478161|NCT00170547|EXPERIMENTAL|Group 4|382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
62684174|NCT02502383|EXPERIMENTAL|ACTION PAC Behavioral Intervention|Students attending intervention schools will receive the ACTION PAC intervention and communication of BMI and other health results to parents via a letter.
62123807|NCT06501911|EXPERIMENTAL|Bicalutamide with brain re-irradiation|"Participants will take oral bicalutamide daily for six (6) months at a starting dose of 150 mg daily. Participants will be enrolled in cohorts of six (6) patients. The dose will be incrementally adjusted based on dose limiting toxicities seen in the previously enrolled cohort until the Maximum Tolerated Dose (MTD) is reached. The MTD is defined as the dose level below the dose at which at least two (2) of six (6) participants experienced a dose limiting toxicity.~Participants will also receive 10 fractions of brain re-irradiation beginning one week after the start of bicalutamide treatment."
62123808|NCT06131892||Successful defibrillation during extra corporeal life support (ECLS) rewarming|
62123809|NCT06131892||Non Successful defibrillation during extra corporeal life support (ECLS) rewarming|
62123810|NCT06131892||Successful defibrillation before rewarming or during non-ECLS rewarming|non- ECLS: non- extra corporeal life support
62123811|NCT06131892||Non- successful defibrillation before rewarming or during non-ECLS rewarming|non- ECLS: non- extra corporeal life support
62123812|NCT05142878|EXPERIMENTAL|Experimental: Static air support devices (Ultracore Repose®)|"Residents will be placed on a static air foam hybrid mattress during 14 days:~• Ultracore Repose® Mattress"
62123813|NCT04239586|EXPERIMENTAL|Sulfonylurea treatment group|Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.
62313709|NCT03189225|OTHER|Capillary And Venous Accuracy|All subjects provided blood sample(s) to be tested on three Blood Glucose Monitoring Systems ( OneTouch Ultra 2, OneTouch Verio (Rice), OneTouch SelectPlus), LifeScan reference instrument ( YSI 2300) and hospitals own biochemistry analysers.
62313710|NCT02179307|EXPERIMENTAL|Arm label 1-Set, 3-Set|12-week progressive strength training protocol of different volumes
62313711|NCT05032833|EXPERIMENTAL|5-MeO-DMT arm|
62313712|NCT05032833|PLACEBO_COMPARATOR|Placebo arm|
62478162|NCT00170547|EXPERIMENTAL|Group 1|382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
62478163|NCT00170547|EXPERIMENTAL|Group 2|382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
62478164|NCT06146374|EXPERIMENTAL|Group 2|600mg (6x 100mg capsules) of SLV213 (N=8) or placebo (N=4) administered orally every 12 hours for 7 days to healthy male and female participants 18-65 years of age.
62478165|NCT06146374|EXPERIMENTAL|Group 3|800mg (8x 100mg capsules) of SLV213 (N=8) or placebo (N=4) administered orally every 12 hours for 7 days to healthy male and female participants 18-65 years of age.
62684175|NCT02502383|ACTIVE_COMPARATOR|Comparison|Students attending comparison schools will receive communication of BMI and other health results to parents via a letter.
62123814|NCT04444258|EXPERIMENTAL|Experimental I Group|After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
62123815|NCT04444258|NO_INTERVENTION|Control Group|FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
62123816|NCT03704727|EXPERIMENTAL|probiotic treatment|Probiotic: VSL#3 is a probiotic formula containing a mixture of 9x10\^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10\^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10\^10 CFU/g Streptococcus thermophilus. Administred orally
62123817|NCT00532922||1|Chinese asthma patient prescribed Symbicort® Turbuhaler®
62123818|NCT05765370|EXPERIMENTAL|LDL-C Lower-Target Group (25mg/dL≤ LDL-C<70mg/dL)|"Participants randomized into the LDL-C lower-target arm will have a goal of 25mg/dL≤ LDL-C\<70mg/dL.~Prescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level."
62313713|NCT00870272|ACTIVE_COMPARATOR|1|400mcg sublingual misoprostol
62313714|NCT00870272|ACTIVE_COMPARATOR|2|400mcg buccal misoprostol
62313715|NCT05501444|EXPERIMENTAL|Effect of antiperspirant|Aluminium chloride 15 percent
62313716|NCT06671639|EXPERIMENTAL|Arm 1|Arm 1 includes procedures to be performed robotically that have an adult model or already established preclinical evidence including: Sleeve Gastrectomy, Cholecystectomy, Splenectomy, Hysterectomy, endometriosis, ureteral re-implant, and cervical and thoracic tracheoplasty, thymectomy, lobectomy/wedge lung resection, lung segmentectomy
62313717|NCT06671639|EXPERIMENTAL|Arm 2|Arm 2 will be performed after all patients in Arm 1 have completed their procedures and where additional preclinical performance testing is required, including: Bronchoplasty, Endoscopic Laryngeal/Pharyngeal Suturing, including: Vocal Feminization, Laryngeal Cleft Repair, Endolaryngeal Adjacent Tissue Transfer, Pharyngoplasty; Ileocolonic Resections; Laryngoplasty with or without Graft; Proctectomy with Ileal Pouch-Anal Anastomosis (IPAA)
62684176|NCT06686745|EXPERIMENTAL|SIM0508 mono dose escalation|Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.
62684177|NCT06686745|EXPERIMENTAL|SIM0508 combination dose escalation|Every 28 days is one cycle.Multiple dose levels of SIM0508 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
62684178|NCT06686745|EXPERIMENTAL|SIM0508 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0508 combination with olaparib established from SIM0508 combination dose escalation.
62478166|NCT06146374|EXPERIMENTAL|Group1|400mg (4x 100mg capsules) of SLV213 (N=8) or placebo (N=4) administered orally every 12 hours for 7 days to healthy male and female participants 18-65 years of age.
62478167|NCT01811758|EXPERIMENTAL|Culturally Specific CBT|Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
62478168|NCT01811758|ACTIVE_COMPARATOR|Standard CBT (control)|Standard cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes each. Up to 8-weeks of transdermal nicotine patches. Traditional CBT, with no focus on race: smoking and health, benefits of quitting, weight control, relapse prevention, coping skills.
62478169|NCT02208128|NO_INTERVENTION|Receptor-Tyrosinkinase-Inhibitor|Guidelines-oriented therapy with approved systemic medications for renal cell carcinoma individually for each patient (Receptor-Tyrosinkinase-Inhibitor) (e.g.Sunitinib, Pazopanib, Bevacizumab, Everolimus, Axitinib, Temsirolimus). With 1.progression turning to second line treatment with one of the upper mentioned medications. Third line therapy due to the individual molecular modifications for each patient.
62478170|NCT03991273|EXPERIMENTAL|Y-M2M©|a group-based M2M© program conducted onsite at a local YMCA
62123819|NCT05765370|ACTIVE_COMPARATOR|LDL-C Higher-Target Group (70mg/dL≤ LDL-C<100mg/dL)|"Participants randomized into the LDL-C lower-target arm will have a goal of 70mg/dL≤ LDL-C\<100mg/dL.~Prescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level."
62123820|NCT01626612|EXPERIMENTAL|a strategy based on de-escalation|
62123821|NCT01626612|ACTIVE_COMPARATOR|a conservative strategy|
62123822|NCT03101410|EXPERIMENTAL|gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
62123823|NCT03101410|EXPERIMENTAL|gluten fee|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
62123824|NCT04804046|EXPERIMENTAL|Synbiotic|Bifidobacterium longum spp. longum R0175, Bifidobacterium animalis spp. Lafti B94, Bifidobacterium bifidum R0071 at 3x10\^9 CFU/d plus resistant starch type 2, arabinoxylan, and galactooligosaccharide at 24 g/d will serve as the treatment.
62123825|NCT04804046|PLACEBO_COMPARATOR|Digestible Maltodextrin|Digestible maltodextrin will serve as the placebo.
62123826|NCT05685030|PLACEBO_COMPARATOR|Placebo|product vehicle (sunflower oil)
62123827|NCT05685030|EXPERIMENTAL|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ daY.
62123828|NCT05685030|EXPERIMENTAL|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Blend: Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day.
62123829|NCT01204346|EXPERIMENTAL|MBT group|mentalization based treatment program
62478171|NCT03991273|EXPERIMENTAL|B-M2M©|a blended program that provides Y-M2M© and a home-based M2M© via videoconferencing
62478172|NCT01370083|EXPERIMENTAL|Stroke: TPPT|Adults with dysphagia post stroke (within 4-16 weeks of onset) who have radiographically confirmed difficulties with thin liquid bolus control. Individuals will complete 24 sessions of tongue-pressure-profile training over 8-12 weeks.
62478173|NCT01370083|ACTIVE_COMPARATOR|Stroke: TPSAT Control|Individuals with dysphagia (within 4-16 weeks post stroke) who demonstrate difficulties with thin liquid control on videofluoroscopy. Individuals will complete 24 sessions of tongue-pressure strength-and-accuracy training over 8-12 weeks.
62684179|NCT04725071|EXPERIMENTAL|Immunonutrition|Participants will consume a 6oz immunonutrition drink 2 times daily for 7 days and then once a day for remaining hospital stay.
62684180|NCT04725071|ACTIVE_COMPARATOR|Conventional Supplement|Participants will consume a 6oz conventional supplement drink 3 times daily for 7 days and then once a day for remaining hospital stay.
62123830|NCT01204346|ACTIVE_COMPARATOR|Treatment as usual group|treatment as usual group
62123831|NCT04222686|ACTIVE_COMPARATOR|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
62478174|NCT04870320|EXPERIMENTAL|Arm I (Endeavor)|Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks.
62478175|NCT04870320|ACTIVE_COMPARATOR|Arm II (Words!)|Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
62478176|NCT03114748|EXPERIMENTAL|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
62478177|NCT03114748|EXPERIMENTAL|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
62478178|NCT04653363||1|study1 is the patients who will be assessed by first rater.
62478179|NCT04653363||2|study2 is the patients who will be assessed by second rater.
62684181|NCT06687096|EXPERIMENTAL|The booklet group|The research protocol was explained during the colonoscopy appointment, and patients, when they agreed to follow their diet according to the recipe booklet, were accepted as part of the patient intervention group.
62684182|NCT06687096|OTHER|Control|The control group consists of patients who prepared for colonoscopy with the standard low-residue diet list without being given a recipe booklet.
62684183|NCT05192031|EXPERIMENTAL|Smoking cessation support|
62478180|NCT04653363||3|Theh are healty peers control patients who will be assessed by first rater.
62478181|NCT04984902|EXPERIMENTAL|Treatment|Treatment with Microbind® Affinity Blood Filter
62478182|NCT04984902|NO_INTERVENTION|Control|Antibiotics
62684184|NCT05192031|NO_INTERVENTION|Usual care|
62478183|NCT00959153|EXPERIMENTAL|Kidney stones|Kidney stones
62478184|NCT02736721|EXPERIMENTAL|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
62478185|NCT03214952||Vonoprazan 20 mg|The usual adult dosage for oral use is 20 mg of vonoprazan administered orally once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use was administered for a total of 4 weeks of treatment, and if that dosing proved insufficient, the administration may have been extended, but for no longer than 8 weeks of treatment. Participants received vonoprazan as part of a routine medical care.
62684185|NCT04450901|EXPERIMENTAL|Cohort A1 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 0.5 mg/kg
62684186|NCT04450901|EXPERIMENTAL|Cohort A2 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 2 mg/kg
62684187|NCT04450901|EXPERIMENTAL|Cohort A3 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 5 mg/kg
62684188|NCT04450901|EXPERIMENTAL|Cohort A4 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 10 mg/kg
62684189|NCT04450901|EXPERIMENTAL|Cohort B1|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
62684190|NCT04450901|EXPERIMENTAL|Cohort B2|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 3 weeks (Q3W). Dose: 300 mg"
62684191|NCT04450901|EXPERIMENTAL|Cohort B2 reserve|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 300 mg"
62123832|NCT04222686|ACTIVE_COMPARATOR|Losartan Arm|100 mg Losartan tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
62123833|NCT05796739|EXPERIMENTAL|Routine stress testing|In this group, the preselected functional stress testing (exercise electrocardiography, stress echocardiography, nuclear imaging, or stress cardiac magnetic resonance imaging) will be performed within three months (± 2 months) according to the practice pattern of each participating center.
62123834|NCT05796739|ACTIVE_COMPARATOR|As-needed stress testing|In this group, optimal medical treatment will be performed by current guidelines without further testing. A stress test will be performed only when new symptoms (exertional chest pain or dyspnea) occur that may clinically suggest significant coronary artery disease.
62123835|NCT04010006|EXPERIMENTAL|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
62123836|NCT04010006|ACTIVE_COMPARATOR|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
62123837|NCT05968859|ACTIVE_COMPARATOR|Aerobic Training|Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo aerobic training for 12 weeks, and then repeat study assessments.
62478186|NCT04500015|EXPERIMENTAL|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
62478187|NCT04500015|PLACEBO_COMPARATOR|Placebo Comparator|3 tablet of placebo self-administered by the patient 12 hours before IUD insertion
62684192|NCT04450901|EXPERIMENTAL|Cohort B3|"Tumor type: Metastatic NSCLC (Non-small-cell lung carcinoma), unresectable or metastatic, MSI-H (microsatellite instability-high) or dMMR (Deficient MisMatch Repair), recurrent or metastatic HNSCC (Head and neck squamous cell carcinoma), non-clear cell RCC (renal cell carcinoma), aSCC (anal squamous cell carcinoma), uterine cervical cancer, cSCC (cutaneous squamous cell carcinoma of the skin), uterine endometrial carcinoma, TMB-H (high tumor mutation burden) tumors, epithelial tumor of the penis (squamous cell carcinoma or adenocarcinoma), neuroendocrine tumor (any origin, pancreatic or non-pancreatic), and nasopharyngeal cancer.~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
62123838|NCT05968859|EXPERIMENTAL|Leg Training|Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo leg training for 12 weeks, and then repeat study assessments.
62123839|NCT05968859|NO_INTERVENTION|Healthy Controls|Healthy controls will be enrolled to complete the baseline study assessments for generation of normal reference values for comparison. Healthy controls will not undergo randomized exercise training interventions or repeat assessments.
62123840|NCT01528306|EXPERIMENTAL|HP802-247|
62123841|NCT01528306|PLACEBO_COMPARATOR|Placebo (Vehicle)|
62684193|NCT06530303|EXPERIMENTAL|Biological Tumor Infiltrating Lymphocytes (TIL) Therapy with Immunotherapy|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and TILs IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62684194|NCT02477033|ACTIVE_COMPARATOR|Butyricicoccus pullicaecorum|Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.
62684195|NCT02477033|PLACEBO_COMPARATOR|Placebo (maltodextrin)|Lyophilized maltodextrin, encapsulated with a pH-resistent coating.
62684196|NCT05756556|EXPERIMENTAL|Phase 2a|T3011 given via intratumoral (IT) injection in combination with Cobimetinib via oral administration in patients with advanced melanoma.
62684197|NCT01093573|EXPERIMENTAL|Dose Level 1|Aza at 75 mg/m2 D1-7 \& Midostaurin 25 mg BID D 8-21
62684198|NCT01093573|EXPERIMENTAL|Dose Level 2|Aza at 75 mg/m2 D1-7 \& Midostaurin 50 mg BID D 8-21
62684199|NCT01093573|EXPERIMENTAL|Dose Level 3|Azacitidine 75 mg/m2 IV D1-7 \& Midostaurin 75 mg PO BID D 8-21
62684200|NCT06691113|EXPERIMENTAL|Itepekimab high dose|Subcutaneous (SC) administration of Itepekimab high dose for 24 weeks
62684201|NCT06691113|EXPERIMENTAL|Itepekimab low dose|SC administration of Itepekimab low dose for 24 weeks
62313718|NCT06304272|EXPERIMENTAL|Irrigating Traumatic Wound with Drinking Water|In drinking water arm, acute traumatic wound will be cleaned with drinking water. Bacteriological safety of the drinking water will be ensured by testing water.
62123842|NCT00087880|ACTIVE_COMPARATOR|Brief Treatment|Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
62684202|NCT06691113|PLACEBO_COMPARATOR|Placebo|SC administration of matching placebo for 24 weeks
62684203|NCT06256432|EXPERIMENTAL|Ambrisentan - Low Dose 1|Liquid solution for oral administration, dose \< 250 µg/day, up to 60 days
62684204|NCT06256432|EXPERIMENTAL|Ambrisentan - Low Dose 2|Liquid solution for oral administration, dose \< 250 µg/day, up to 60 days
62684205|NCT06256432|ACTIVE_COMPARATOR|Terlipressin|Sterile lyophilized powder, to be reconstituted for intravenous administration, at a dose indicated by the study investigator and administered for up to 14 days, considering the following recommendation: 1 mg terlipressin administered in 2-minute bolus every 6 hours for 3 days, and dose of terlipressin increased to 2 mg every 6 hours in the absence of a decrease of at least 30% in serum creatinine by day 4
62684206|NCT04062565|EXPERIMENTAL|Experimental|Treprostinil and Riociguat
62684207|NCT02594852|EXPERIMENTAL|Intervention (+ laser)|+ laser therapy
62684208|NCT02594852|PLACEBO_COMPARATOR|Non-intervention (- laser)|- laser
62684209|NCT02098473|EXPERIMENTAL|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
62123843|NCT00087880|ACTIVE_COMPARATOR|Extended Bupropion/Low Contact|Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
62684210|NCT02098473|EXPERIMENTAL|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
62684211|NCT02098473|PLACEBO_COMPARATOR|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
62684212|NCT04996394||NMBAs|
62684213|NCT02616952|EXPERIMENTAL|Chinese herbal therapy group|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks.
62684214|NCT02616952|OTHER|Pelvic floor muscle training group|Pelvic floor muscle training includes intensive exercises and home exercises. Intensive exercises are conducted in hospital once a week while home exercises are performed three times daily for 12 weeks.
62123844|NCT00087880|PLACEBO_COMPARATOR|Extended Placebo/Low Contact|Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
62684215|NCT00363363|EXPERIMENTAL|1|
62684216|NCT00363363|ACTIVE_COMPARATOR|2|
62684217|NCT06011824||Biopsy Negative|Female age 18 and above with negative breast biopsy
62684218|NCT06011824||Biopsy positive for carcinoma in situ (ductal, lobular, or other)|Females age 18 and above with any subtype of breast cancer (ductal, lobular, or other)
62684219|NCT06011824||Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)|Females age 18 and above with any subtype of breast cancer (HER2+, ER/PR, TNBC, BRCA1 +/-, other).
62684220|NCT06011824||Metastatic Stage IV|Females age 18 and above with any subtype of breast cancer, including metastases
62684221|NCT06570707|EXPERIMENTAL|Brighter Bites|This group will receive the Brighter Bites intervention throughout the study implementation. The intervention includes fruit and vegetable distributions of \~20lbs. for teachers and families, healthy recipe tastings, and nutrition education.
62684222|NCT06570707|NO_INTERVENTION|Control group|This delayed intervention group will receive the Brighter Bites intervention after concluding their participation in the study.
62684223|NCT03682146|OTHER|RARP|robot-assisted laparoscopic prostatectomy
62684224|NCT03682146|OTHER|LRP|conventional laparoscopic radical prostatectomy
62697347|NCT04275284||PCV10 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks and 9 months of age.
62684225|NCT04837222||Participants with CD30-positive Lymphoma|All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.
62684226|NCT01455090|EXPERIMENTAL|Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
62313719|NCT06304272|EXPERIMENTAL|Irrigating Traumatic Wound with Normal Saline|In normal saline arm, acute traumatic wound will be cleaned with normal saline.
62313720|NCT01276015|EXPERIMENTAL|botulinum toxin A|botulinum toxin A diffusion in cerebral palsy
62313721|NCT04710940|EXPERIMENTAL|Intervention - Diabetes BOOST|Intervention group participants will complete a baseline survey, receive a referral to DSMT from the research team, a mailed welcome letter and self-care education sent via a series of personalized patient portal secure messages, text messages, and video call. They will be sent text messages with information about one of the American Association of Diabetes Educators 7 self-care behaviors and will receive encouragement to author their own self-management behavioral goals. Participants will also complete a telehealth training video call with research staff and review the goals that the participant replied with. The participant will then be encouraged to send a patient portal message to their DSMT CDCES that includes their personalized goals prior to their scheduled DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
62313722|NCT04710940|ACTIVE_COMPARATOR|Usual Care|Comparison Group participants will complete a baseline survey, receive a DSMT referral request from research team to their primary care provider and a mailed welcome letter. The mailed letter will welcome the participant to the study and contain general information about diabetes self-care behaviors and goal setting. They will complete a DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
62313723|NCT06672705|EXPERIMENTAL|Treatment (epcoritamab)|Patients receive epcoritamab SC on days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 4-9, and day 1 of each subsequent cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR may continue to receive epcoritamab if disease progression occurs within 6 months. Patients with PR or SD continue to receive epcoritamab in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and blood sample collection throughout the study and may undergo biopsy during screening.
62313724|NCT03131297|EXPERIMENTAL|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
62684227|NCT01455090|EXPERIMENTAL|Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
62684228|NCT01455090|EXPERIMENTAL|Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"\* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
62313725|NCT00813956|EXPERIMENTAL|1|standard chemotherapy plus BSI-201
62313726|NCT00856752|EXPERIMENTAL|T1|Pre-treatment with rifampicin
62313727|NCT00856752|EXPERIMENTAL|T2|Pre-treatment with cyclosporin
62313728|NCT00856752|EXPERIMENTAL|Reference|Administration of NRL001 alone: no pre-treatment
62313729|NCT00827268|OTHER|Arm 1|Repeated probes every 8 hours of treatment (1/week)
62313730|NCT05392322|ACTIVE_COMPARATOR|Self-help skills|Effect of self-help skills on fine motor skills in children with down's syndrome
62313731|NCT05392322|EXPERIMENTAL|Virtual video reality gaming|Effects of virtual video reality gaming on fine motor skills in children with down's syndrome
62313732|NCT05885685|EXPERIMENTAL|Healthy Participants|Participants will be prescribed a 1 week daily oral dose of nabilone which will begin at 0.25 mg and work their way up to 2 mg over the course of 7 days.
62313733|NCT03829189|ACTIVE_COMPARATOR|inulin|
62313734|NCT03829189|PLACEBO_COMPARATOR|maltodextrin|
62313735|NCT02005523|EXPERIMENTAL|RNS60|
62313736|NCT02005523|PLACEBO_COMPARATOR|Saline|
62684229|NCT01455090|EXPERIMENTAL|Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"\* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
62684230|NCT01455090|EXPERIMENTAL|Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"\* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
62684231|NCT01455090|EXPERIMENTAL|Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"\* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
62684232|NCT01455090|EXPERIMENTAL|Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"\* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
62684233|NCT01455090|EXPERIMENTAL|Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"\* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
62684234|NCT01455090|EXPERIMENTAL|Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"\* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
62684235|NCT01455090|EXPERIMENTAL|Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"\* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
62684236|NCT01455090|EXPERIMENTAL|Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"\* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
62684237|NCT01455090|EXPERIMENTAL|Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"\* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
62684238|NCT01455090|EXPERIMENTAL|Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV|"\* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablets orally twice daily 12 weeks~BMS-790052 30 mg tablets orally twice daily 12 weeks~BMS-791325 75 mg tablets orally twice daily 12 weeks~Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks \[if subject is \< 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM\]"
61923618|NCT06329843||Term-born babies & preterm born babies|"We will collect 300 paired (serum bilirubin and Picterus Jaundice Pro) measurements on eligible neonates \>35 weeks' gestation admitted to a well-baby nursery. Of these, 150 paired measurements will be from neonates who have already received phototherapy (either on phototherapy or status/post phototherapy) and had a light-occlusive adhesive skin patch in place. Each subject \>35 weeks gestation can have up to 5 measurements during the study.~We will collect 200 paired (serum bilirubin and Picterus) measurements on eligible neonates \<35 weeks gestation. Of these, 100 paired measurements will be from neonates who have already received phototherapy (either on phototherapy or status/post phototherapy) and had a light-occlusive adhesive skin patch in place. Each subject \<35 weeks gestation can have up to 5 measurements during the study."
61923619|NCT04985370|EXPERIMENTAL|Pain neuroscience education plus exercise|Three sessions of pain neuroscience education plus exercise.
61923620|NCT04985370|ACTIVE_COMPARATOR|Exercise alone|Exercise alone without pain neuroscience education.
61923621|NCT03150667|ACTIVE_COMPARATOR|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
62123845|NCT00087880|ACTIVE_COMPARATOR|Extended Bupropion/High Contact|Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
62684239|NCT04303169|EXPERIMENTAL|Pembrolizumab + Vibostolimab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
62697348|NCT04275284||PCV13 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks and 9 months of age.
62123846|NCT00087880|PLACEBO_COMPARATOR|Extended Placebo/High Contact|Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
62123847|NCT04122937||Ovarian cancer|Patients affected by ovarian cancer will be stratified according to BRCA1 and BRCA2 mutational status.
62684240|NCT04303169|EXPERIMENTAL|Pembrolizumab + Gebasaxturev|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus gebasaxturev (V937) intratumorally (IT) at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
62684241|NCT04303169|EXPERIMENTAL|Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
62684242|NCT04303169|EXPERIMENTAL|Pembrolizumab + MK-4830|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus MK-4830 IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
62123848|NCT04122937||Colon cancer|Patients affected by colon cancer will be similarly stratified according to BRAF and KRAS mutational status and to the presence of low-grade or high-grade microsatellite instability (MSI).
62123849|NCT02755181||BPD|Borderline Personality Disorder as diagnosed by DSM-5
62123850|NCT02755181||normal volunteers|normal volunteers
62123851|NCT03403413|EXPERIMENTAL|Muscle Vibration|Test feasibility of muscle vibration of tibialis anterior, rectus femoris, short head of biceps and tensor fasciae latae bilaterally during walking for 1 hour 3 times per week for 12 weeks to improve walking speed through improved coordination of hip, knee and ankle flexion.
62123852|NCT03264443|ACTIVE_COMPARATOR|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
62123853|NCT03264443|EXPERIMENTAL|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
62123854|NCT03641703|EXPERIMENTAL|FLT180a|Participants who have received gene therapy vector (FLT180a)
61923622|NCT03150667|ACTIVE_COMPARATOR|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
62684243|NCT04303169|EXPERIMENTAL|Favezelimab + Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive MK-4280A (favezelimab and pembrolizumab administered as a co-formulation) IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
62123855|NCT06219642|EXPERIMENTAL|VR mindfulness intervention|The intervention consists of a total of 10 sessions each lasting 30 minutes. In each session, we fit participants with the VR headset with a smartphone running the Sites for VR app. The phone, placed in the viewing compartment of the headset, shows a nature scene of the participant's choosing. Once participants have acclimated to the scene and understand how to look around the VR scene (by moving their heads in different directions), we will read a mindfulness script with a guided body scan and instructions to engage participants through experiencing the virtual reality nature scene with all senses.
62123856|NCT06219642|NO_INTERVENTION|Phone call check-in|Investigators will call patients every week and ask how they are doing.
62123857|NCT02071836|EXPERIMENTAL|Right Turns web application|Right Turns web application
62313737|NCT04388735||Newly Diagnosed MM 1st Line and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~* Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~* Both patients with or without identified caregivers will complete a one time series of questionnaires.~  * The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete."
62313738|NCT04388735||MM receiving 1-3 prior lines of therapy and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~* Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~* Both patients with or without identified caregivers will complete a one time series of questionnaires.~  * The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
62313739|NCT04388735||MM patients receiving ≥ 4 lines of therapy and Cargivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~* Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~* Both patients with or without identified caregivers will complete a one time series of questionnaires.~  * The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
62313740|NCT06575621|EXPERIMENTAL|Intervention|Participants receive education, medical navigation and participate in a twice weekly exercise program
62684244|NCT04303169|EXPERIMENTAL|Pembrolizumab + all-trans retinoic acid (ATRA)|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
61923623|NCT03784365|ACTIVE_COMPARATOR|First group|This group will receive an intravenous antibiotic for three days. The first dose will be given within half hour before the POEM procedure.
61923624|NCT03784365|EXPERIMENTAL|Second group|This group will receive only one dose of intravenous antibiotic within half hour before the POEM procedure
61923625|NCT04698265|EXPERIMENTAL|Human amniotic suspension allograft (ASA), 40 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 1 uses 40 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
62123858|NCT02071836|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual
62123859|NCT01755065||Teenager laparoscopic patients|
62123860|NCT04369495||Cyclophosphamide|Patients with induction therapy for lupus nephritis with cyclophosphamide
62313741|NCT06575621|NO_INTERVENTION|Healthy control|Healthy controls who are not recommended any intervention.
62313742|NCT06575621|NO_INTERVENTION|Unhealthy control|Unhealthy controls who choose not to participate in the pre-surgery support program. Will receive recommended referrals only.
62313743|NCT06113666|EXPERIMENTAL|Digital cognitive behavioral therapy for insomnia|Behavioral: digital cognitive behavioral therapy (dCBT-I)
62313744|NCT06113666|ACTIVE_COMPARATOR|Patient Education about insomnia|Behavioral: Digital patient education about insomnia (PE)
62684245|NCT05730478||ASOCT and UBM parameters Comparison|comparison between ASOCT and UBM parameters in glaucoma ASSESMENT
62684246|NCT05691569|EXPERIMENTAL|doll therapy|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy"
62313745|NCT03461289|EXPERIMENTAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
62313746|NCT06408831|ACTIVE_COMPARATOR|Classroom Teaching University Students Intervention Group|A special username and password will be given to the intervention group, which is randomly assigned to the female students of the classroom teaching department, to log in to the website, and they will be given a special access to the website. Afterwards, training on cyber sexual violence will be given within the scope of the literature. The scales will be applied to the students again after 12 weeks in order to see the effect of the behavior.
62478188|NCT03831139|EXPERIMENTAL|Prevention|TIM\&SARA has a duration of 16 fifty-minute sessions and is organized in five modules. The first module (2 sessions) outlines the rationale for the program and establishes connections between group leaders and adolescents. The next module (2 sessions) focuses on helping adolescents to consider already existing goals, set new ones, and learn how to achieve goals to build up the motivation of the youth to learn and apply the material of the following modules. The third module (6 sessions) focuses on understanding the relations among cognitions, emotions, and behaviors, and teaching the participating youths how to identify and challenge negative cognitions. The forth module (5 sessions) trains the youth in assertive and social competent social behavior. Finally, the last session is a review session and includes a celebration. All parts of the program use illustrative, culturally relevant situations introduced by the participating adolescents.
62478189|NCT03831139|NO_INTERVENTION|Control|The youth participate in school as usual.
62684247|NCT05691569|OTHER|non anthropomorphic object|non- anthropomorphic soft object
61923626|NCT04698265|EXPERIMENTAL|Human amniotic suspension allograft (ASA), 20 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 2 uses 20 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
62123861|NCT04369495||Mycophenolate|Patients with induction therapy for lupus nephritis with mycophenolate
62123862|NCT00431704|EXPERIMENTAL|vinorelbine, carboplatin, trastuzumab|
62123863|NCT04971447|EXPERIMENTAL|Group: transgender men|
62123864|NCT04971447|NO_INTERVENTION|Groupe: control cis-gender women|
62123865|NCT04971447|EXPERIMENTAL|Group: transgender women|
62123866|NCT04971447|NO_INTERVENTION|Groupe: control cis-gender men|
62123867|NCT01278394|EXPERIMENTAL|Group 1|AN2690 Solution, 5.0%
62123868|NCT01489982|EXPERIMENTAL|Light therapy|For patients who have sleep maintenance insomnia light therapy will be administered daily. If patients suffer only from sleep onset insomnia, this light therapy will be given upon awakening in the morning. Light boxes will be provided by Litebook company. In the active therapy group, the intensity of the light will be set at 10,000 lux with a head-to-light distance of 20cm. Patients will be instructed to let the light shine indirectly on their eyes (i.e. they do not look directly at the light). Patients can be reading, eating, watching TV, etc., during the time of light therapy.
62123869|NCT01489982|EXPERIMENTAL|CBT and sleep hygiene training|This will involve education about sleep in general, giving techniques related to sleep and relaxation, tips on stress management, etc.. This will take place at the Lady Davis Institute of the Jewish General Hospital. There will be 6 weekly sessions totalling 90 minutes - most of the time this will be in a group setting, with a maximum of 6 patients per group. Light therapy will also be part of this treatment strategy. There will be separate gropus for English and French-speaking patients
62478190|NCT02526121|EXPERIMENTAL|Phlebotomy associated with dietary and lifestyle counseling|
62478191|NCT02526121|ACTIVE_COMPARATOR|Dietary and lifestyle counseling.|
62478192|NCT00787553|ACTIVE_COMPARATOR|cefazolin|
62478193|NCT00787553|ACTIVE_COMPARATOR|tinidazole|
62478194|NCT00787553|ACTIVE_COMPARATOR|cefazolin plus tinidazole|
62478195|NCT06216756|EXPERIMENTAL|Osteochondral transplant on the femoral condyle|Eligible and enrolled patients will receive one or more cryopreserved osteochondral allograft core as part of their osteochondral transplant procedure
62684248|NCT02757768|EXPERIMENTAL|Mirabegron|Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
62684249|NCT02757768|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study.
62684250|NCT05375266||Study Cohort|The study cohort consist of patients with newly diagnosed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, paranasal sinuses or larynx in stage UICC (Union internationale contre le cancer) II-IVB
62313747|NCT06408831|NO_INTERVENTION|Kindergarten Teaching University Students Control Group|Participant Introduction Form, Cyber Sexual Violence Scale, Sensitivity Scale for Cyber Bullying (SZBÖ) Young Adult Form, Ensuring Personal Cyber Security Scale will be applied to the control group of kindergarten teaching female students as a pre-test. The Participant Introduction Form, Cyber Sexual Violence Scale, Sensitivity Scale for Cyber Bullying (SZSS) Young Adult Form, and Ensuring Personal Cyber Security Scale will be applied to the control group again after an average of 8-10 weeks without any intervention. In accordance with ethical principles, after the final results of the control group are collected, the videos in the training content will be sent to the control group.
62478196|NCT02016274|EXPERIMENTAL|sequential treatment|paclitaxel/cisplatin treatment and radiotherapy
62478197|NCT03086460|EXPERIMENTAL|Treatment A|"Treatment A, CHF 1531 pMDI:~CHF 1531 pMDI 6 μg total daily dose (TDD):~1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
62123870|NCT01489982|EXPERIMENTAL|Insomnia medications|Pharmacologic treatment will be individualized depending on patient characteristics and initial response. It will consist of two potential treatments - Doxepin or Zopiclone. Both of these agents are currently used commonly in the general population and also in PD patients. The agents will be prescribed exactly as any other medical prescription (i.e. patients will fill their own prescriptions at their own pharmacy).The decision for which agent to use will be as follows: a)If patients suffer from sleep onset insomnia (with or without sleep maintenance insomnia), or if doxepin is contraindicated, Zopiclone will be prescribedb) or b)If patients suffer from sleep maintenance insomnia only (or if Zopiclone is contraindicated), Doxepin will be the first choice agent.
62478198|NCT03086460|EXPERIMENTAL|Treatment B|"Treatment B, CHF 1531 pMDI:~CHF 1531 pMDI 12 μg TDD:~1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
62684251|NCT05375266||Control Group|The control group consists of patients with no current diagnoses of cancer undergoing surgery at the participating medical center
62684252|NCT06523387|EXPERIMENTAL|Pivotal Response Treatment Online (PRT-O) Course|The PRT-O Online Course (PRT-O) will consist of 10 online lessons completed asynchronously through the Stanford LearnMed Online CANVAS Platform. Parents are expected to view the 10 lessons over the course of a 12-week study period, complete worksheets, and to practice PRT at home.
62684253|NCT06523387|NO_INTERVENTION|Delayed Treatment Group (DTG)|No intervention.
62123871|NCT01489982|PLACEBO_COMPARATOR|Placebo intervention of light therapy|The inactive/placebo intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles. This therefore functions as a placebo condition for the active light therapy protocol. Patients be informed that some forms of light therapy will be expected to be less active, but we will not disclose what type of condition is inactive.
62123872|NCT00441636|EXPERIMENTAL|CPAP treatment|Continuous Positive Airway Pressure (CPAP)for 4 weeks
62123873|NCT00441636|NO_INTERVENTION|No CPAP|routine psychiatric care for 4 weeks followed by CPAP titration and initiation after followup measures.
62123874|NCT00441636|NO_INTERVENTION|Control group|No obstructive sleep apnea detected.
62478199|NCT03086460|EXPERIMENTAL|Treatment C|"Treatment C, CHF 1531 pMDI:~CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID."
62684254|NCT01293955|EXPERIMENTAL|JOINS 200mg|One tablet of JOINS 200mg is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.
62684255|NCT01293955|PLACEBO_COMPARATOR|Placebo|One tablet of Placebo is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.
62684256|NCT02957903|EXPERIMENTAL|Treatment A|"Injection around the lateral femoral cutaneous nerve:~8 ml Ropivacaine 0.75 %."
62684257|NCT02957903|PLACEBO_COMPARATOR|Treatment B|"Injection around the lateral femoral cutaneous nerve:~8 ml isotonic Saline."
62684258|NCT02506439|EXPERIMENTAL|10 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 10 mcg \[400 IU\] daily
62684259|NCT02506439|EXPERIMENTAL|20 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 20 mcg \[800 IU\] daily
62684260|NCT02506439|PLACEBO_COMPARATOR|Placebo|White-skinned women will receive a Placebo supplement, identical in appearance and taste to the active product
62684261|NCT01345942|EXPERIMENTAL|A food|
62123875|NCT03833661|EXPERIMENTAL|M7824|
62123876|NCT04487431|EXPERIMENTAL|BAY1817080 Part A|Healthy male participants will receive BAY1817080 given as an oral solution (study Part A)
62684262|NCT01345942|EXPERIMENTAL|B without food|
62313748|NCT05740007|EXPERIMENTAL|IW-3300 100 µg|IW-3300 at 100 µg rectal foam administered daily for 12 weeks
62478200|NCT03086460|EXPERIMENTAL|Treatment D|"Treatment D, CHF 1531 pMDI~CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID."
62478201|NCT03086460|EXPERIMENTAL|Treatment E|"Treatment E, Matched placebo~Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID."
62478202|NCT03086460|ACTIVE_COMPARATOR|Treatment F|"Treatment F, Formoterol fumarate inhalation solution (IS)~Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID."
62478203|NCT03251807|EXPERIMENTAL|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
62123877|NCT04487431|EXPERIMENTAL|[14C]BAY1817080 Part B|Healthy male participants will receive BAY1817080 blended with \[14C\]BAY1817080 given as an oral solution (study Part B).
62123878|NCT02147678|EXPERIMENTAL|Group E|Etomidate/remifentanil group. Patients in group E will be given etomidate and remifentanil during the operation, the speeds are 10\~15 μg/kg/min and 0.2\~0.4 μg/kg/min, respectively.
62123879|NCT02147678|EXPERIMENTAL|Group P|Propofol/remifentanil group. Patients in group P will be given propofol and remifentanil during the operation, the speeds are 50\~75 μg/kg/min and 0.2\~0.4 μg/kg/min, respectively.
62313749|NCT05740007|EXPERIMENTAL|IW-3300 300 µg|IW-3300 at 300 µg rectal foam administered daily for 12 weeks
62313750|NCT05740007|PLACEBO_COMPARATOR|Placebo|Placebo rectal foam administered daily for 12 weeks
62478204|NCT03251807|EXPERIMENTAL|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
62478205|NCT03774680|ACTIVE_COMPARATOR|Cetuximab nanoparticles goup|A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
62684263|NCT02242903|EXPERIMENTAL|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
62684264|NCT02242903|PLACEBO_COMPARATOR|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
62684265|NCT00635466|EXPERIMENTAL|Lap, 1|Patients undergoing laparoscopic surgery for rectal carcinoma
62684266|NCT01097681|EXPERIMENTAL|Normal renal function group|oral
62684267|NCT01097681|EXPERIMENTAL|Mild renal impairment group|oral
62684268|NCT01097681|EXPERIMENTAL|Moderate renal impairment group|oral
62684269|NCT03996018||group 1(HIV Uninfected)|Participant is HIV negative per antibody screen conducted on premises and participant is enrolled on HPTN 083 study
62684270|NCT03996018||group 2 (HIV Infected)|Participant has initiated ART therapy as a patient at St Jude Children's Research Hospital, newly diagnosed HIV and prolonged HIV
62684271|NCT04729426|EXPERIMENTAL|Position Group|Position group
62123880|NCT01667796|EXPERIMENTAL|Vitamin D3|Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.
62123881|NCT02403024|EXPERIMENTAL|InterWalk|The intervention program will prescribe that patients performing 150 min of interval training per week.
62123882|NCT02403024|OTHER|Waiting list Control|Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
62478206|NCT03774680|PLACEBO_COMPARATOR|Oral approved anticancer drug|A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
62123883|NCT02367924||Yondelis|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
62123884|NCT01644513||Positive Responders|Have received at least one injection with no evidence of residual subretinal or intra-retinal fluid present on Spectral Domain Optical Coherence Tomography (SDOCT) one month (+/- 1 week) following most recent injection.
62123885|NCT01644513||Suboptimal Responders|Have received three or more injections in last six months with residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection; Have not demonstrated complete resolution of fluid following any of the injections in the last 6 months Show leakage on Fluorescein Angiography (FA) or Indocyanine Green (ICG) imaging at some time during last 12 months
62478207|NCT00680277|EXPERIMENTAL|1|
62684272|NCT04729426|NO_INTERVENTION|Control group|No Position group
62684273|NCT06351761|EXPERIMENTAL|Normal Sinus Rhythm|Simultaneous ECG recording of patient with Normal Sinus Rhythm with investigational and reference devices
62123886|NCT04206098||Sex|Male/Female
61923627|NCT04698265|EXPERIMENTAL|CellularMatrix (a combination of platelet-rich plasma and hyaluronic acid)|CellularMatrix (RegenLab SA, Switzerland) is composed of sterile and non-pyrogenic tubes allowing the mix of Platelet Rich Plasma (PRP) with Hyaluronic Acid (HA) in the same proportion (2mL of PRP for 2mL of HA).
62313751|NCT03083951|EXPERIMENTAL|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
62313752|NCT03083951|ACTIVE_COMPARATOR|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
62313753|NCT02116972|EXPERIMENTAL|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
62313754|NCT02116972|EXPERIMENTAL|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
62684274|NCT06351761|EXPERIMENTAL|Atrial Fibrillation|Simultaneous ECG recording of patient with Atrial Fibrillation with investigational and reference devices
62684275|NCT03688139|EXPERIMENTAL|Engage Therapy|Participants receive Engage therapy for 9 weeks.
62684276|NCT03688139|ACTIVE_COMPARATOR|Supportive Therapy|Participants receive supportive therapy for 9 weeks.
62684277|NCT01489826|EXPERIMENTAL|Dexanabinol 2 mg/kg|Dexanabinol 2 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684278|NCT01489826|EXPERIMENTAL|Dexanabinol 3 mg/kg|Dexanabinol 3 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684279|NCT01489826|EXPERIMENTAL|Dexanabinol 6 mg/kg|Dexanabinol 6 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684280|NCT01489826|EXPERIMENTAL|Dexanabinol 12 mg/kg|Dexanabinol 12 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684281|NCT01489826|EXPERIMENTAL|Dexanabinol 15 mg/kg|Dexanabinol 15 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62123887|NCT02197975|EXPERIMENTAL|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
62313755|NCT02116972|PLACEBO_COMPARATOR|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
61923628|NCT04698265|PLACEBO_COMPARATOR|Normal saline|4ml of normal saline
62123888|NCT02197975|EXPERIMENTAL|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
62313756|NCT03635190|EXPERIMENTAL|Interventional|Orbital Circumferential Atherectomy
62313757|NCT04144881|EXPERIMENTAL|coronary computed tomography|
62123889|NCT02197975|PLACEBO_COMPARATOR|Placebo MDI|Placebo MDI. Administered as 2 inhalations
62123890|NCT06674083||Healthy adults|Inclusion criteria for participants are as follows: being between the ages of 18 and 30, having no balance issues (such as vertigo) that could affect assessments, and having no health problems that would interfere with understanding the assessments.
62123891|NCT00296361|ACTIVE_COMPARATOR|1|
62123892|NCT00296361|EXPERIMENTAL|2|
62123893|NCT01939171|PLACEBO_COMPARATOR|Non treated|Cadaver donor is cared and treated as usual protocol
62313758|NCT04144881|NO_INTERVENTION|conservative (ischemia-guided) management|
62313759|NCT00887445|EXPERIMENTAL|A|
62313760|NCT00887445|PLACEBO_COMPARATOR|B|
62123894|NCT01939171|EXPERIMENTAL|TREATED|Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement.
62313761|NCT02292381||Glaucoma Patients|Patients with primary open angle glaucoma
62313762|NCT02292381||Healthy controls|age- and sex matched controls
62313763|NCT03453060|EXPERIMENTAL|E-WE Thrombin Dose 1|Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
62313764|NCT03453060|EXPERIMENTAL|E-WE Thrombin Dose 2|Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
62313765|NCT03453060|EXPERIMENTAL|E-WE Thrombin Dose 3|Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
62313766|NCT03453060|EXPERIMENTAL|E-WE Thrombin Dose 4|Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
62313767|NCT03453060|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intravenous dose of placebo.
62313768|NCT02185170|EXPERIMENTAL|Fluorescence assesment|"All patients undergo a transurethral resection.~There are four different steps in the study:~* the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,~* the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,~* the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,~* the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner."
62123895|NCT06111040|OTHER|Caregiver-child dyads|A cohort of 375 caregivers and 375 children aged 4-5 years at baseline will be recruited and followed longitudinally for 18 months.
62478208|NCT00680277|EXPERIMENTAL|2|
62123896|NCT02700191|NO_INTERVENTION|Control|For subjects in the Control arm, the parameters measured by the (µ-Cor) µ-Cor system will not be analysed or made available to the investigator.
62123897|NCT02700191|EXPERIMENTAL|uCor|For subjects in the Interventional arm, all of the parameters measured by the (µ-Cor) µ-Cor system will be available to the investigator and will remain blinded to the subjects. The investigator will use µ-Cor information to aid in therapy adjustment decisions during the study period.
62123898|NCT01367483|EXPERIMENTAL|Arm1|MNTX active treatment
62123899|NCT00925210|EXPERIMENTAL|Sequential pEBUS - ENB|
62123900|NCT05323266|EXPERIMENTAL|Nasal Continuous Positive Airway Pressure (nCPAP)|Nasal Continuous Positive Airway Pressure is the main mode of oxygen supply observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
62123901|NCT05323266|EXPERIMENTAL|High-Flow Nasal Cannula (HFNC)|NasalContinuousPositiveAirwayPressure is another oxygen supply mode mainly observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
62313769|NCT06248008|EXPERIMENTAL|ASC40 50mg|ASC40 50mg, up to 40 weeks of treatment.
62313770|NCT01950884|EXPERIMENTAL|Ezetimibe|Ezetimibe tablets plus lifestyle
62313771|NCT01950884|ACTIVE_COMPARATOR|lifestyle|lifestyle
62478209|NCT05491187|ACTIVE_COMPARATOR|Group B (bupivacaine group)|Drug used: 0.5% hyperbaric bupivacaine heavy (8%dextrose) dose -11mg with volume of 2.2ml single administration, no repetition of intervention
62123902|NCT01760109|EXPERIMENTAL|Piperacillin Sodium and Sulbactam Sodium|"Drug:xintemie 1.5-3.0g,iv,bid 7-14 days~serious infections 6.0-12.0g,iv,tid for 7-14 days"
62123903|NCT05684094|EXPERIMENTAL|"Sleep extension and advance Lark Routine"|Participants go to bed 90 minutes earlier than their typical average bedtime to extend sleep duration and advance sleep timing
62313772|NCT01631357|EXPERIMENTAL|Arm 1: CIK+CT|Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.
62313773|NCT01631357|ACTIVE_COMPARATOR|Arm 2: CT|Arm 2: We design chemotherapy alone as a control arm
62313774|NCT00318838|PLACEBO_COMPARATOR|1|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
62313775|NCT00318838|EXPERIMENTAL|2|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
62478210|NCT05491187|EXPERIMENTAL|Group BF(bupivacaine with fentanyl group)|Drug used:- 0.5% hyperbaric bupivacaine heavy (8%dextrose) dose -10mg, 2ml and fentanyl 10mg ,0.2ml with total volume of of 2.2ml single administration, no repetition of intervention
62478211|NCT03874143|EXPERIMENTAL|RCom equipped with a smartphone|
62478212|NCT03874143|NO_INTERVENTION|RCom with paper-based system|
62123904|NCT05684094|ACTIVE_COMPARATOR|"Regular sleep duration and timing Owl Routine"|Participants go to bed at their typical average bedtime
62123905|NCT03437850||South African cohort|
62123906|NCT03437850||Swedish Cohort|
62123907|NCT02229019|EXPERIMENTAL|Volunteer mealtime assistance|Trained volunteers will provide mealtime assistance to older hospital inpatients at one mealtime each weekday.
62313776|NCT04227977|EXPERIMENTAL|Treatment|JuxtaFlow
62313777|NCT03684083||Case|patients having received heterologous stem cell transplantation (HSCT)
62313778|NCT03684083||Control|patients without HSCT
62313779|NCT01118143|EXPERIMENTAL|intervention group|Tailored oral health literacy instruction
62313780|NCT01118143|NO_INTERVENTION|control group|Oral health instruction not tailored to oral health literacy level
62313781|NCT01562769||Standard precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
62478213|NCT05526183|EXPERIMENTAL|Low dose arm|Low dose (5x1010 VP, i.m.); CoVacHGMix (with equal amounts of CoVacHGA1320, CoVacHGB420, CoVacHGC720 and CoVacHGD1480 adenoviral vector mix, as 0.5 solution) Intramuscular injection, two injections 28 days apart
62478214|NCT05526183|EXPERIMENTAL|High dose arm|High dose (1x1011 VP, i.m.); CoVacHGMix (with equal amounts of CoVacHGB420, CoVacHGC720 and CoVacHGD1480 adenoviral vector mix, as 1.0 solution) Intramuscular injections, two injections 28 days apart
62478215|NCT05713058|EXPERIMENTAL|eTRC diet|
62478216|NCT05713058|ACTIVE_COMPARATOR|Control diet|
62478217|NCT06559358|EXPERIMENTAL|Group 1|This group will receive subthreshold stimulation
62478218|NCT06559358|EXPERIMENTAL|Group 2|This group will receive suprathreshold stimulation
62123908|NCT02667743|EXPERIMENTAL|Paclitaxel Micelles for Injection + Cisplatin|"In the First Period, 230 mg/m2 of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.~In the Second Period, 300 mg/㎡ of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device to patients whose minimum neutrophil ≥1.0 × 109 /L and minimum platelet count ≥80 × 109 /L and with no hematologic toxicity of grade II to IV occurred in the First Period. Then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment."
62123909|NCT02667743|ACTIVE_COMPARATOR|Paclitaxel Injection + Cisplatin|175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
62123910|NCT02747381|EXPERIMENTAL|intervention|receive Alfacalcidol 1 mcg daily for 4 months beside the conventional asthma medications
62123911|NCT02747381|NO_INTERVENTION|control|Asthmatic patients receiving conventional asthma medications
62313782|NCT01562769||contact precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
62684282|NCT01489826|EXPERIMENTAL|Dexanabinol 22 mg/kg|Dexanabinol 22 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684283|NCT01489826|EXPERIMENTAL|Dexanabinol 30 mg/kg|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684284|NCT01489826|EXPERIMENTAL|Dexanabinol 36 mg/kg|Dexanabinol 36 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684285|NCT01489826|EXPERIMENTAL|Dexanabinol Expansion Phase|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
62684286|NCT02224079|EXPERIMENTAL|BIIB 722 CL|
62684287|NCT02224079|PLACEBO_COMPARATOR|Placebo|
62684288|NCT06333158|EXPERIMENTAL|Cholesfytol NG|3 capsules daily (orally) with dinner containing in total 1000 mg of Amla dry extract, 100 mg of Walnut leaf dry extract, 67.2 mg of Red yeast rice powder (equivalent to 2.9 mg of monacolines), 50 mg of olive fruit dry extract (equivalent to 10 mg of hydroxytyrosol). Taken for 8 weeks
62684289|NCT06333158|PLACEBO_COMPARATOR|Placebo|3 capsules daily (orally) with dinner taken for 8 weeks. Placebo contains magensium stearate, microcrystalline cellulose, colloidal silica and talc
62684290|NCT02716246|EXPERIMENTAL|Cohort 1 Low Dose|Dose of 0.5 X 10\^13 vg/kg
62123912|NCT06552260|EXPERIMENTAL|Group A: Presurgical Troriluzole|"18 participants will be randomly assigned to this group and with complete:~* Baseline visit with assessments and MRI.~* Cycle 0:~  * Day -6 through Day 0: Predetermined dose of Troriluzole 2x daily.~ * Day 0: pre-op MRI~ * Day 0: standard of care surgical resection of tumor~ * Day 0: post-op MRI~* Cycle 1 through Cycle 3:~  --Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.~* Cycle 3 through End of Treatment:~  --Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.~* MRIs every 8 weeks while on treatment.~* End of study visit with MRI~* Follow up every 3 months for 1 year, and then every 6 months for the next 3 years."
62313783|NCT01938222||Short Stitch|Short stitch suture technique (6:1) for abdominal all closure stitch interval \< 0,5 cm and lateral 0,5-0,8 cm
62313784|NCT02465034|ACTIVE_COMPARATOR|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
62313785|NCT02465034|ACTIVE_COMPARATOR|Healthy Control|Healthy individuals will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
62313786|NCT03576677|ACTIVE_COMPARATOR|Levosimendan|Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.
62313787|NCT03576677|PLACEBO_COMPARATOR|Placebo|Study participants in this arm will receive a 6 hours infusion of placebo (sterile isotonic sodium chloride + 5% dextrose + vitamin B)
62313788|NCT06320197||Passed in situ assessment|This group passed their in situ assessment (summative assessment)
62684291|NCT02716246|EXPERIMENTAL|Cohort 2 Mid Dose|Dose of 1 X 10\^13 vg/kg
62684292|NCT02716246|EXPERIMENTAL|Cohort 3 High Dose|Dose of 3 X 10\^13 vg/kg
62684293|NCT06695013|EXPERIMENTAL|Immunotherapy bridging treatment|Zanubrutinib ± radiotherapy was used as the bridging therapy in the immunobridging treatment group, a Follow-up maintenance treatment was determined according to the efficacy of D28 in the two groups. Patients with complete response (CR) were given no maintenance treatment, while patients with partial response (PR) were given Zanubrutinib orally plus PD-1 inhibitor for 2 years. Patients with stable SD or progressive PD were excluded from this study
62684294|NCT06695013|ACTIVE_COMPARATOR|no bridging treatment|The control group will not receive bridging treatment. Maintenance treatment will be consistent with the experimental group.
62684295|NCT05843721|OTHER|KOS treatment|Treatment with intranasal kinetic oscillation stimulation (KOS)
62684296|NCT06612151|EXPERIMENTAL|YL201|Participants are randomized to receive YL201 monotherapy intravenously on Day 1 of each 3-week cycle at RP3D dose level, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent as specified in the protocol.
62123913|NCT06552260|EXPERIMENTAL|Group B: Surgery + Troriluzole|"9 participants will be randomly assigned to this group and with complete:~* Baseline visit with assessments and MRI~* Day 0: pre-op MRI~* Day 0: standard of care surgical resection of tumor~* Day 0: post-op MRI~* Cycle 1 through Cycle 3:~  --Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.~* Cycle 3 through End of Treatment:~  --Days 1 through 28 of 28 day cycle: Predetermined dose of Troriluzole 2x daily.~* MRIs every 8 weeks while on treatment.~* End of study visit with MRI~* Follow up every 3 months for 1 year, and then every 6 months for the next 3 years."
62684297|NCT06612151|ACTIVE_COMPARATOR|topotecan hydrochloride for injection|Participants are randomized to receive topotecan hydrochloride intravenously, on Days 1 to 5 of each 3-week cycle per prescribing information, until PD, unacceptable toxicity, or withdrawal of consent as specified in the protocol.
62684298|NCT06051617|EXPERIMENTAL|Seladelpar|
62684299|NCT06051617|PLACEBO_COMPARATOR|Placebo|
62684300|NCT06497686||Control human lung tissues (normal human lung tissues)|
62684301|NCT06497686||Cancerous human lung tissues|
62684302|NCT04248673|PLACEBO_COMPARATOR|carbohydrate rich bread|
62684303|NCT04248673|EXPERIMENTAL|carbohydrate reduced bread|
62684304|NCT06675708|EXPERIMENTAL|Experimental group|The creatine experimental group will receive 20g of creatine for 5 days, divided into 4 equal doses, followed by 5g/day as a single dose for the duration of the trial.
62684305|NCT06675708|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive 20g of dextrose for 5 days, divided into 4 equal doses, followed by 5g/day as a single dose for the duration of the trial
62684306|NCT04348058|NO_INTERVENTION|Control group|Invitation letter and reminder letter to screening colonoscopy
62684307|NCT04348058|EXPERIMENTAL|Call Center|Telephone recruitment by motivational conversation and colonoscopy appointment
62684308|NCT04348058|EXPERIMENTAL|Combined|Non responders to invitation and reminder letter will be recruited by telephone conversation
62684309|NCT02715856|ACTIVE_COMPARATOR|Group I (standard follow up, physical activity measurement)|Patients undergo standard face-to-face follow up visits at 2, 6, 12, and 24 weeks after surgery. Patients also undergo a physical activity assessment over 15 minutes.
62684310|NCT02715856|EXPERIMENTAL|Group II (mobile surveillance)|Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.
62123914|NCT01115959|ACTIVE_COMPARATOR|valproic acid|Valproic acid given orally 400mg twice daily
62123915|NCT01115959|PLACEBO_COMPARATOR|placebo|Placebo twice daily for one month
62684311|NCT01893814|ACTIVE_COMPARATOR|Probiotics|
62684312|NCT01893814|PLACEBO_COMPARATOR|Control|
62684313|NCT06375863|OTHER|spinal anesthesia|patients who scheduled lower abdominal or urological surgery under spinal anesthesia older than 65 years
62684314|NCT06375863|OTHER|general anesthesia|patients who scheduled lower abdominal or urological surgery under general anesthesia older than 65 years
62684315|NCT03689088|EXPERIMENTAL|Investigational device (Goldfish)|IOP will be monitored for 24 h in the Goldfish eye
62684316|NCT03689088|ACTIVE_COMPARATOR|Tonometry|IOP will be acquired by standard tonometry at specific times in the the fellow eye
62684317|NCT06687447|ACTIVE_COMPARATOR|Oxycotin Massage Group|The researcher will perform oxytocin massage to the fifth-sixth rib along the patient's spine.
62684318|NCT06687447|ACTIVE_COMPARATOR|Reflexology Group|The researcher will apply pressure in different ways to the reflex points on the patient's sole with her fingers.
62684319|NCT06687447|OTHER|Control Group|Patients in the control group will not undergo any intervention and will receive their routine care.
62123916|NCT01815008|EXPERIMENTAL|Clopidogrel|Clopidogrel 75 mg daily by mouth for 1 week then Clopidogrel 75 mg daily with aspirin 81 mg daily
62313789|NCT06320197||Failed in situ assessment|This group failed their in situ assessment (summative assessment)
62684320|NCT06467708|EXPERIMENTAL|Determine the effect of tAN on serum concentrations of inflammatory mediators in TBI patients|Subjects will receive treatment upon providing informed consent and will undergo transcutaneous auricular neurostimulation (tAN) once daily during their ICU stay, with the treatment duration not exceeding 10 days. Two blood samples will be collected daily: one before the tAN session and another two hours after the session. Participant data will be collected daily throughout the ICU stay. Additionally, surveys will be collected from registered nurses providing direct care to TBI patients enrolled in the tAN-TBI study to assess the compatibility of tAN with patient care processes in the ICU.
62684321|NCT02958072|EXPERIMENTAL|LeucoPatch|Treatment with usual ulcer care and LeucoPatch once weekly up til 24 weeks or until healing.
62684322|NCT02958072|ACTIVE_COMPARATOR|Usual care followed by LeucoPatch|Usual care weekly for 12 weeks, if the ulcer persist after the12 weeks LeucoPatch treatment will be started for up to 12 weeks or until healing.
62684323|NCT06687902|EXPERIMENTAL|Patients with breast lesions|
62684324|NCT05883748|EXPERIMENTAL|DISC-1459 Oral Dose Level 1|Oral dose, once a day
62684325|NCT05883748|EXPERIMENTAL|DISC-1459 Oral Dose Level 2|Oral dose, once a day
62684326|NCT06689514|EXPERIMENTAL|Control group|
62684327|NCT06689514|EXPERIMENTAL|Low dose group|
62684328|NCT06689514|EXPERIMENTAL|High dose group|
62684329|NCT00252148|ACTIVE_COMPARATOR|ADMVA|ADMVA dosage escalation
62684330|NCT00252148|PLACEBO_COMPARATOR|Placebo|Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7
62478219|NCT06559358|SHAM_COMPARATOR|Group 3|This group will receive no stimulation
62684331|NCT05095441|EXPERIMENTAL|Part 1: Dose Escalation|C5252 single agent dose escalation in participants with glioblastoma
62313790|NCT01676376|ACTIVE_COMPARATOR|eSVS Mesh treated saphenous vein graft|Each subject will be randomized to an eSVS Mesh treated SVG to the right or left coronary system.
62313791|NCT01676376|SHAM_COMPARATOR|Control saphenous vein graft|Each subject will be randomized to an untreated (no eSVS Mesh) SVG to the right or left coronary system.
62123917|NCT04792086||Inhabitants in Nord-Trøndelag 70 years of age and older|All inhabitants in Nord-Trøndelag 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
62684332|NCT05095441|EXPERIMENTAL|Part 2: Dose Expansion|Recommended dose of C5252 as determined in Part 1 Dose Escalation in participants with glioblastoma
62313792|NCT01676376|ACTIVE_COMPARATOR|Single Vessel Treatment|Each subject with receive one SVG with eSVS Mesh either to the right or left coronary system.
62313793|NCT04097717|EXPERIMENTAL|Decision Aid Arm|Participants will use the web-based decision aid plus usual medical care.
62123918|NCT04792086||Inhabitants in one area in Trondheim, 70 years of age and older|All inhabitants one area in Trondheim, 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
62123919|NCT01475123|ACTIVE_COMPARATOR|Nicorandil|Nicorandil was administered orally (15mg/day).
61923629|NCT02730208|EXPERIMENTAL|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.
62123920|NCT01475123|NO_INTERVENTION|Non-nicorandil|Nicorandil was not administered.
62313794|NCT04097717|OTHER|Usual Care Arm|Participants will receive usual medical care.
62478220|NCT05041855|EXPERIMENTAL|Community based childhood obesity intervention|A novel family-inclusive childhood obesity treatment program consisting of 12 family group sessions delivered in English and Spanish by health educators at community recreation centers, followed by three group booster sessions occurring every 6 months.
62123921|NCT02617069|EXPERIMENTAL|Group 1 (Cardiac surgery+botulinum toxin)|All patients underwent conventional cardiac surgery. After the main stage of the surgery botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
62313795|NCT04888221|EXPERIMENTAL|tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks|Tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks
62313796|NCT04888221|PLACEBO_COMPARATOR|placebo administered subcutaneously (SC) weekly during 24 weeks|Placebo administered subcutaneously (SC) weekly during 24 weeks
62313797|NCT03148171|NO_INTERVENTION|Routine PrEP Care|Routine PrEP Care at each clinical site.
62313798|NCT03148171|ACTIVE_COMPARATOR|WERK Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
62478221|NCT05041855|ACTIVE_COMPARATOR|Primary care based childhood obesity intervention|A healthy lifestyle counseling intervention delivered by trained primary care providers and health educators at visits occurring every 3 months.
62684333|NCT05520866|EXPERIMENTAL|PrehabPal Web app|Web app based initial geriatric assessment will be given followed by daily tailored prehabilitation activities in the domains of exercise, nutrition, anxiety reduction, home preparation, and advanced care planning. Each participant is paired with a central health coach who monitors engagement and provides support through the Web app portal.
62684334|NCT05520866|NO_INTERVENTION|Written Surgery Prehabilitation Instructions|Participants will be provided paper-based prehabilitation instructions that include information about exercise, nutrition, anxiety reduction, home preparation, and advanced care planning. A paper diary is provided to record any prehabilitation activities.
62478222|NCT01034358|EXPERIMENTAL|Human Papillomavirus Vaccine|The Gardasil HPV vaccine was administered in 3 doses: baseline, 2 months, and 6 months.
61923630|NCT02730208|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.
61923631|NCT06398795|EXPERIMENTAL|DTS group|Patients undergo Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS)
61923632|NCT06398795|ACTIVE_COMPARATOR|COT group|Patients undergo conventional open thyroidectomy (COT)
61923633|NCT04705038|EXPERIMENTAL|Educational Intervention|Participants in this arm undergo a short educational session about orchiectomy. They will also be asked to complete questionnaires.
61923634|NCT04705038|NO_INTERVENTION|No Intervention|"Participants that decline the education session will continue with routine care of their cancer.~They will also be asked to complete questionnaires."
62684335|NCT05691361|EXPERIMENTAL|PART A - Active ADX-324 administered to HV|For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
61923635|NCT02524977|ACTIVE_COMPARATOR|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
61923636|NCT02524977|EXPERIMENTAL|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
61923637|NCT06520202|EXPERIMENTAL|Treatment Group|
62313799|NCT03424109||Beneficiaries with a one-year mortality of at least 30%|The patient cohort will be extracted via the Centers for Medicare and Medicaid Services (CMS) Research Data Assistance Center (ResDAC) using a two-step process to maximize diversity, and minimize intentional or unintentional exclusions based on risk, age, health literacy, demographics, or expected adherence.
62313800|NCT06671990|OTHER|Vericiguat THEN Placebo|Oral vericiguat tablet (2.5, 5, and 10 mg) for first period.
62313801|NCT06671990|OTHER|Placebo THEN Vericiguat|Oral placebo tablet (2.5, 5, and 10 mg) for first period.
62313802|NCT02090582|OTHER|Structured Palliative Care|
62313803|NCT02090582|OTHER|Usual Care|
62313804|NCT05760937|EXPERIMENTAL|BMS-986447|
62313805|NCT05760937|PLACEBO_COMPARATOR|Placebo|
62313806|NCT03210077||Entropy Group|General Anesthesia using Entropy Monitoring
62313807|NCT03210077||Control Group|General Anesthesia without Entropy (Control Group)
61923638|NCT06520202|ACTIVE_COMPARATOR|Vehicle Group|
61923639|NCT06520202|EXPERIMENTAL|Crossover Group|
62684336|NCT05691361|PLACEBO_COMPARATOR|PART A- Placebo administered to HV|For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
62313808|NCT05077189||Study Group|Patients with CV-19 and not in the acute period. This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).
62313809|NCT05077189||Control Group|Patients without CV-19 This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).
62684337|NCT05691361|EXPERIMENTAL|PART B - ADX-324 administered to HAE participants|This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs. The treatment of HAE participants is an open-label study.
62684338|NCT00049283|EXPERIMENTAL|Treatment (erlotinib hydrochloride, docetaxel, and radiation)|Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
62684339|NCT04948268|EXPERIMENTAL|Adaptive digital mental health intervention without coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and timing to meet participant preferences.
62697349|NCT04275284||PCV10 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 14 weeks and 9 months of age.
61923640|NCT00458497|EXPERIMENTAL|1|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
61923641|NCT00458497|PLACEBO_COMPARATOR|2|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.
61923642|NCT05988697||Observation group|Primary IIIB-IV BRAF V600E mutated advanced non-small cell lung cancer in a population of patients with advanced lung cancer proposed to be treated with Trametinib， Dabrafenib and Asprin
61923643|NCT01091727|EXPERIMENTAL|Botulinum toxin A|Botulinum toxin A 300U diluted with sterile saline (1 ml per injection site) and injected into 30 sites of the bladder, sparing the trigone.
62313810|NCT02047877||Respiratory Illness|Previously healthy patients admitted with acute respiratory illness who are then intubated requiring mechanical ventilator support. Endotracheally intubated patients of age 37 weeks gestation through 17 years with an acute respiratory illness in the absence of existing cardiopulmonary disease, tracheostomy, or immunocompromised condition. Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated.
61923644|NCT01091727|PLACEBO_COMPARATOR|Placebo|Sterile saline 30 cc injected into 30 sites in the bladder, sparing the trigone.
62684340|NCT04948268|EXPERIMENTAL|Non-personalized digital Mental Health intervention without coaching|The non-personalized intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Messages and content will not be tailored based on participants profile or usage.
62684341|NCT04948268|EXPERIMENTAL|Adaptive digital mental health intervention with coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and timing to meet participant preferences. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
62684342|NCT04948268|EXPERIMENTAL|Non-personalized digital Mental Health intervention with coaching|The non-personalized intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Messages and content will not be tailored based on participants profile or usage. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
61923645|NCT00205829|EXPERIMENTAL|Active Therapy|Occipital nerve stimulation (ONS) therapy delivered to a subject implanted with a bion ONS device
62123922|NCT02617069|ACTIVE_COMPARATOR|Group 2 (Cardiac surgery+placebo)|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
62123923|NCT06198114|EXPERIMENTAL|Multi Sensory Integration|This group will be treated with activity based training In which place different( nuts, screws, bullets, coins, paper clips, coloring ,scissor cutting with different shapes , Simulated feeding (by collecting beans with a spoon and transferring them into a container),transfer light and heavy weight objects into empty box.
62123924|NCT06198114|ACTIVE_COMPARATOR|Conventional Therapy|This group will be treated with traditional therapy in which Place toys/objects inside and encourage the student to reach in and pull them out as well as put them back in. Give the student objects that can be put together and pulled apart. Encourage the students to use two hands in an organized manner to manipulate objects (e.g., grasp/release, twist/turn, rotate and examine, open/close, stack, nest).
62123925|NCT04302805|PLACEBO_COMPARATOR|PE/rATG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg).
62123926|NCT04302805|ACTIVE_COMPARATOR|PE/rATG/IVIG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg) and IVIG 0.5g/kg intravenous infusions, on 1st, 3rd and 5th postoperative day. This is a center standard of care regimen.
62313811|NCT02026271|EXPERIMENTAL|Ad-RTS-hIL-12+veledimex|varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).
62313812|NCT01346137|EXPERIMENTAL|meloxicam|15 mg versus 30 mg per day P.O for 15 days, during 3 menstrual cycles
62313813|NCT02852694|ACTIVE_COMPARATOR|High Risk Group|subcutaneous methotrexate versus subcutaneous adalimumab
62313814|NCT02852694|ACTIVE_COMPARATOR|Low risk group|subcutaneous methotrexate versus oral dose of azathioprine / 6 mercaptopurine
62313815|NCT02852694|OTHER|Ancillary|the ancillary study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).
62313816|NCT04929873|PLACEBO_COMPARATOR|routine treatment|routine nursing
62684343|NCT04948268|ACTIVE_COMPARATOR|Active control|The active control condition will provide brief text messages that include a URL link to psychoeducational content, but will not include the interactive messaging component described in experimental arms.
62697350|NCT04275284||PCV13 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 14 weeks and 9 months of age.
61923646|NCT02172170|EXPERIMENTAL|BI 10773 single rising dose|
61923647|NCT02172170|PLACEBO_COMPARATOR|Placebo|
62123927|NCT00505791|PLACEBO_COMPARATOR|Sugar pill|Lactose, NF (monohydrate)
62313817|NCT04929873|EXPERIMENTAL|Experimental group|Immediately after the establishment of the side branch cycle, the closed transdone is connected for real-time monitoring of pressure, and clinical nursing practice is guided by transdictor pressure.
62313818|NCT03232723|OTHER|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
62313819|NCT01183546||Wheelchair Users with Spinal Cord Injury|wheelchair users with spinal cord injury
62313820|NCT00891657|EXPERIMENTAL|SprayShield™|SprayShield™
62313821|NCT00891657|NO_INTERVENTION|Control|No adhesion barrier administered.
62313822|NCT04086134|EXPERIMENTAL|Intervention fruit products 1|Three servings of fruit products per day for 4 weeks.
62123928|NCT00505791|ACTIVE_COMPARATOR|Nesiritide|Natrecor (nesiritide) is a commercially available B-type natriuretic peptide which is indicated for intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
62123929|NCT05157724||PLASMA|This technique consists of an endoscopic intervention, through the natural route (urethra).
62123930|NCT05157724||HOLEP|"This is a recent and difficult technique of endoscopic prostate enucleation, requiring a greater learning curve for the operators compared to PLASMA. The principle remains the same technically as the PLASMA procedure, the energy used is not electrical energy, but a laser.~Once the adenoma has been enucleated, it can only be removed by a morcellator (additional material) which can lead to complications such as bladder perforation. This is a blade that rotates in a tube that has to cut the adenoma once it has been freed from the prostate when it is in the bladder and it can happen that this blade catches on the bladder wall and causes a bladder wound or even a perforation."
62313823|NCT04086134|EXPERIMENTAL|Intervention fruit products 2|Three servings of fruit products per day for 4 weeks.
62684344|NCT06422923|EXPERIMENTAL|Treatment Arm|This is an open-label study of the bilateral intrahippocampal administration of NRTX-1001 in a single dose cohort of up to 10 subjects with drug-resistant bilateral MTLE.
62313824|NCT04086134|PLACEBO_COMPARATOR|Control fruit products|Three servings of control fruit products per day for 4 weeks.
62684345|NCT04879940|EXPERIMENTAL|Prostatic Artery Embolization (PAE)|Participants who receive PAE with Merit Medical Embospheres.
62684346|NCT06571825|EXPERIMENTAL|VAA group|
62313825|NCT02951130|EXPERIMENTAL|Milrinone|Milrinone infusion at 0.33µg/kg/min. The dose of the study drug will be increased to 0.66 µg/kg/min if oxygenation index (OI) remains ≥ 10 without any evidence of hypotension (as defined by the protocol) two hours after initiation of study drug. Infusion will be continued until the OI decreases to \< 7. The maximum duration of study drug infusion is 72 hours.
62313826|NCT02951130|PLACEBO_COMPARATOR|5% dextrose (D5W)|An equivalent volume of 5% dextrose (D5W) will be used for infants randomized to the placebo arm.
62313827|NCT06201572||Observation group|
62313828|NCT06201572||Control group|
61923648|NCT02903212|EXPERIMENTAL|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
62313829|NCT06201572||Positive control group|
62313830|NCT05873140|EXPERIMENTAL|Study group|Continuously receiving education (video clips and infographics) via application LINE
62313831|NCT05873140|NO_INTERVENTION|Control group|No application LINE
62313832|NCT03953560|EXPERIMENTAL|Screening|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis"
62313833|NCT03596125|EXPERIMENTAL|N-acetylcysteine (NAC)|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
62684347|NCT06571825|ACTIVE_COMPARATOR|HSCT group|
61923649|NCT02398409|EXPERIMENTAL|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
61923650|NCT02398409|OTHER|Control|8 week telephone usual care with education with nurse case manager
62684348|NCT03445442||Group 1|Sacrocolpopexy (SCP)
62684349|NCT03445442||Group 2|Native tissue repair surgery (NTR)
62684350|NCT03445442||Group 3|Vaginal mesh repair surgery (VMR)
62684351|NCT03701334|EXPERIMENTAL|Ribociclib + Endocrine Therapy|Participants will receive ribociclib 400 mg once daily on days 1-21 of a 28-day cycle and endocrine therapy once daily continuously
62684352|NCT03701334|ACTIVE_COMPARATOR|Endocrine Therapy|Participants will receive endocrine therapy only once daily continuously
62684353|NCT05466799|ACTIVE_COMPARATOR|FOLFIRINOX Chemotherapy|Subjects in Arm A will receive up to 12 cycles of Standard Of Care FOLFIRINOX chemotherapy
62684354|NCT05466799|EXPERIMENTAL|OncoSil™ in addition to FOLFIRINOX Chemotherapy|Subjects in Arm B will be implanted with the OncoSil™ device in addition to up to 12 cycles of Standard Of Care FOLFIRINOX chemotherapy
62684355|NCT06688318|EXPERIMENTAL|OA Knee|Knee Intraarticular Conditioned Media Injection
62684356|NCT05151419|OTHER|bronchoscope ,forceps,cryo-biopsy|biopies were taken from the lung mass using forceps and cryo-biopsy to evalute diagnostic yield of cryo-biosy versus forceps in the diagnosis of lung cancer
62684357|NCT03599297|EXPERIMENTAL|Bilateral synchronous simultaneous stone surgery|Patients who will be operated for kidney stones at both their kidneys in a single surgery session will be included in the study. Patients will undergo percutaneous nephrolithotomy for one side and flexible ureteroscopy for the other side.
62684358|NCT06687577|EXPERIMENTAL|DBT|Standard behavioral cessation intervention adapted to incorporate DBT skills for emotion regulation.
62684359|NCT06687577|ACTIVE_COMPARATOR|TAU|Standard behavioral cessation intervention.
62684360|NCT04019704|EXPERIMENTAL|AXS-05|AXS-05 (bupropion and dextromethorphan) oral tablets
62684361|NCT04019704|PLACEBO_COMPARATOR|Placebo|Placebo oral tablets to match AXS-05
62313834|NCT03596125|PLACEBO_COMPARATOR|Placebo|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
62313835|NCT05847972|EXPERIMENTAL|Experimental Group|A will undergo MWM and have their moulds taken in phenolic foam immediately after the musculoskeletal manipulation.
62478223|NCT01652092|OTHER|Arm A: Fully Myeloablative regimen|For use in patients with diseases including Wiskott-Aldrich syndrome, MHC Class II deficiency, hypomorphic SCID, etc. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, cyclophosphamide 50 mg/kg IV plus MESNA on days -9 through -6, busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2 and stem cell infusion on day 0.
62313836|NCT05847972|PLACEBO_COMPARATOR|Control Group|Participants will undergo MWM and moulds will be taken one week after the musculoskeletal manipulation.
62313837|NCT06350162|EXPERIMENTAL|Serplulimab+Radiation Therapy|Patients receive Serplulimab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy QD on days 1-5 during weeks 1-3 only. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.
62313838|NCT06350162|ACTIVE_COMPARATOR|Serplulimab|Patients receive Serplulimab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.
62313839|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria~Clinical diagnosis of MCI made by a specialist\* in a patient who fulfils the established clinical consensus criteria for MCI \[NIA/AA 2011\] specifically:~* Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant~* Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.~* Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions~* Not demented"
62478224|NCT01652092|OTHER|Arm B: Reduced Toxicity Ablative Regimen|For use in patients with diseases including SCID, CGD, CHS and other CID. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m\^2 IV on days -5 through -2 and stem cell infusion on day 0.
62684362|NCT03737890|EXPERIMENTAL|Inspiratory muscle Training|4 weeks of inspiratory muscle training
62684363|NCT03737890|ACTIVE_COMPARATOR|Hold Relax Pectoral Stretch|4 weeks of hold relax pectoral stretch
62684364|NCT06684821|EXPERIMENTAL|Racz catheter group|Patients will undergo epidural neuroplasty using Racz catheter during lumber fixation.
62684365|NCT06684821|ACTIVE_COMPARATOR|Control group|Patients will undergo classic lumber fixation.
62684366|NCT06689033||Group 1: Patients sedated for ERCP, receiving nasal oxygen|Nasal Oxygen, preoxygenation with 100% oxygen for 3 min with an oxygen flow rate of 8 L.min-1 via a nasal cannula before induction and 100% oxygen with a flow rate of 5 L.min-1 throughout the procedure.
62684367|NCT06689033||Group 2: Patients sedated for ERCP receiving high flow nasal oxygen|High flow nasal oxygen, preoxygenation with 100% oxygen with a flow rate of 40 L.min-1 for 3 min before induction and received 50% oxygen with a flow rate of 50 L.min-1.
62684368|NCT00870324||1. Control|Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant
62684369|NCT00870324||2. Experimental|Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant
62684370|NCT06687811|ACTIVE_COMPARATOR|Carbohydrate loading (CHO) group|Patient received preoperative carbohydrate loading of 200 ml Maltodextrin 12.5%, given 2 hours before the operation
62684371|NCT06687811|PLACEBO_COMPARATOR|Control|Patient received preoperative regular drinking water of 200 ml with zero-calorie sweetener, given 2 hours before the operation
62684372|NCT05465408|EXPERIMENTAL|Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention|Participants will have two (2), 60 minute, individual sessions with a nurse practitioner via videoconferencing (in person or via telephone) and complete three (3) questionnaires at the time of enrollment, 1-month post-baseline, and 3-months post-baseline.
62684373|NCT01423084|EXPERIMENTAL|MenB Lot 1|MenB vaccine Lot 1: 2 doses administered 1 month apart
62684374|NCT01423084|ACTIVE_COMPARATOR|MenB Lot 2|MenB vaccine Lot 2: 2 doses administered 1 month apart
62684375|NCT05970497|EXPERIMENTAL|Dose escalation of KB707 by intratumoral (IT) injection in solid tumors|Dose escalation of single-agent KB707 in 3 cohorts to treat superficial solid tumors
62684376|NCT05970497|EXPERIMENTAL|Dose expansion: KB707 in Combination with Opdualag (in patients with advanced melanoma)|Dose expansion cohort: KB707 administered in combination with Opdualag in approximately 100 subjects with advanced melanoma.
62123931|NCT06417346|EXPERIMENTAL|Laparoscopic TEP Repair under General Anesthesia|A mini-incision was made at the umbilical margin, passing through the skin and subcutaneous tissue to expose the external sheath of the rectus muscle. The RS was incised, and the rectus muscle was laterally displaced. A 10-mm trocar was inserted into the preperitoneal space, and CO2 insufflation was performed with a pressure set at 12 mmHg. Two additional 5 mm trocars were inserted between the umbilicus and the symphysis pubis under laparoscopic guidance. Using laparoscopic dissectors and graspers, all steps of myopectineal orifice dissection were performed (16). A 15 × 10 cm prolene mesh was spread and secured to cover both direct and indirect hernia areas, extending approximately 2-3 cm beyond. Trocars were removed under camera surveillance after CO2 desufflation, and the skin was closed.
62313840|NCT03134963||Alzheimer disease|"NIA/AA criteria~* Meets the criteria for dementia~  o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains~* Insidious or gradual onset~* Clear history of worsening cognition by report or observation~* The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:~  * Amnestic: impaired learning and recall of recently learned information~ * Non amnestic: language/visuospatial/executive dysfunction"
62313841|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:~* Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.~* One or more of:~  * Onset of dementia within 3 months of a diagnosed stroke~ * Abrupt deterioration in cognitive function~ * Fluctuating, stepwise progression of cognitive deficits"
62313842|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria~1. No evidence of subjective or objective memory impairment on cognitive testing~2. No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
62313843|NCT05184764|EXPERIMENTAL|AP-SA02|Anti-staphylococcal bacteriophage
62313844|NCT05184764|PLACEBO_COMPARATOR|Placebo|Inactive isotonic solution
62313845|NCT06666296|ACTIVE_COMPARATOR|Intervention group|The following digital measures are used to provide employees in the intervention group with comprehensive information at various levels and to create a sense of belonging: A digital recipe collection, an email newsletter, digital/hybrid teaching kitchen events and digital cafés with expert input and discussion groups. In addition, participants are provided with interesting information via the hospital's Instagram account and are constantly reminded of the campaign. When selecting the digital media, emphasis was placed on integrating different learning methods. Through self-learning content, such as the email newsletter, participants can absorb the information at their own pace, make a connection and evaluate it. The topics are then explored and discussed in greater depth in digital events. Individual priorities can be set in group discussions. Through regular input, participants experience a growth phase.
62313846|NCT06666296|OTHER|Control group|The control group will have access to the digital prescription collection, which is being developed on the basis of the Planetary Health Diet. In addition, the control group can use information on the clinic's Instagram account. In addition to access to the above-mentioned recipes and information via the Instagram channel, the intervention group receives additional digital support.
62313847|NCT00537823|EXPERIMENTAL|Arm 1 - Wildtype|"Neoadjuvant therapy~Week 1~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV Cetuximab 400 mg/m2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2/day over 46 hours~Weeks 2, 4, 6, 8 \*Cetuximab 250 mg/m\^2 IV weekly~Weeks 3, 5, 7~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV Cetuximab 400 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2/day over 46 hours~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Week 1, 3, 5, 7, 9, 11, 13, 15~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV Cetuximab 400 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2/day over 46 hours~Weeks 2, 4, 6, 8, 10, 12, 16~\*Cetuximab 250 mg/m\^2 IV weekly"
62697351|NCT04275284||PCV10 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
61923651|NCT06130007|EXPERIMENTAL|Neoadjuvant Treatment with Trastuzumab in Combination with Platinum-Based Doublet|A first-line chemotherapy regimen for oral squamous cell carcinoma involves combining paclitaxel with platinum agents. PD-1 antibodies have shown promise in cases where the cancer has recurred, metastasized, or didn't respond to platinum-based treatments. Research is ongoing on using immune induction therapy with surgery or chemoradiotherapy for locally advanced, resectable oral squamous cell carcinoma. Trastuzumab, in combination with standard chemotherapy, is being explored as an induction treatment for patients needing mandibulectomy due to tumor proximity to the mandible. This study is a prospective, single-arm, single-center Phase II explora.
61923652|NCT00920907|EXPERIMENTAL|Ipilimumab (Process B)|Reference
61923653|NCT00920907|EXPERIMENTAL|Ipilimumab (Process C)|Test
61923654|NCT03918681|EXPERIMENTAL|Intervention Group|The experimental group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups experimental group participants will receive gait retraining cues to transition to a NRFS running pattern.
62123932|NCT06417346|ACTIVE_COMPARATOR|Open Technique (Lichtenstein) under Spinal Anesthesia|Following a classic inguinal incision of approximately 5-7 cm extending laterally from the pubic tubercle, the external oblique aponeurosis was opened, the external ring was disrupted, and the spermatic cord/round ligament was suspended. The hernia sac was isolated from surrounding tissues and the spermatic cord/round ligament, then either reduced or ligated. Subsequently, a polypropylene mesh measuring approximately 60x110 mm² was placed to completely cover the transverse fascia, and continuous sutures were used to secure it laterally along the transverse arch starting from the pubic tubercle. Hemostasis was achieved, and the layers and skin were anatomically closed.
62123933|NCT00439569|EXPERIMENTAL|Single Arm|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
62123934|NCT00531830||1|Preschool children with PDD
62123935|NCT00531830||2|Preschool children without PDD
62123936|NCT05081570|EXPERIMENTAL|Intervention group|The participants will receive two tertiary stroke care consultations provided by stroke nurses via telecare in 2 months.
62123937|NCT01043458|EXPERIMENTAL|1|ABT-126 Low Dose
62697352|NCT04275284||PCV13 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
62123938|NCT01043458|EXPERIMENTAL|2|ABT-126 High Dose
62697353|NCT04053504|EXPERIMENTAL|Intervention|Behavioral intervention delivered by parent peer leaders.
62123939|NCT01043458|EXPERIMENTAL|3|Placebo for ABT-126
62313848|NCT00537823|EXPERIMENTAL|Arm 2 K-Ras 12/13 codon mutation|"Neoadjuvant Therapy~Weeks 1, 3, 5~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* Bevacizumab 5 mg/kg IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2~Week 7~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Weeks 1, 3, 5, 9, 11, 13~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* Bevacizumab 5 mg/kg IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2~Week 7, 15~* Leucovorin 400 mg/m\^2 IV~* Oxaliplatin 85 mg/m\^2 IV~* 5FU bolus 400 mg/m\^2~* 5FU CIVI 1200 mg/m\^2"
62478225|NCT01652092|OTHER|Arm C: Reduced Intensity Conditioning|For use in patients with diseases including HLH. Receives Alemtuzumab 0.2 mg/kg intravenously (IV) on days -14 through -10, fludarabine phosphate 30 mg/m\^2 IV on days -8 through -4, melphalan 140 mg/m\^2 IV on day -3 and stem cell infusion on day 0.
62478226|NCT01652092|OTHER|Arm D: No Preparative Regimen|For use in patients with complete SCID phenotype with no evidence of maternal engraftment or residual immune function who will be receiving their stem cell transplantation from a genotypically matched donor.
62697354|NCT04053504|NO_INTERVENTION|Standard Care|Standard diabetes care
62313849|NCT00607828|EXPERIMENTAL|Hypofractionated stereotactic radiotherapy (SRT)|All patients who have had successful implantation of a liver marker will undergo a 4D CT scan for planning SRT. Following transfer to the treatment planning system, the CT scan may be correlated by imaging fusion with MRI for contouring integrated tumor volume (ITV). The planning target volume (PTV) will be defined as ITV plus individualized margins which are determined by a 4D CT scan. Novalis with 6MV photons will be used for imaging guided SRT. Cohorts of 3-6 patients will receive SRT at daily doses of 8, 10, 12, 14 Gy within 2 weeks. The starting daily dose level will be 10 Gy. The marker will be localized by orthogonal X-ray to ensure reproducibility. A continuous respiratory gating will be accomplished with ExacTrac Adaptive Gating system if the required planning target margin is larger than 1 cm based on the 4D CT data.
62313850|NCT05665985|EXPERIMENTAL|Moringa Oliefera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
62313851|NCT05665985|PLACEBO_COMPARATOR|Placebo|Capsules similar to moringa oliefera, which contain powder, have no pharmacological effect.
62313852|NCT04383977|EXPERIMENTAL|Apatinib-Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
62313853|NCT04383977|ACTIVE_COMPARATOR|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
62313854|NCT03176966|ACTIVE_COMPARATOR|Vitamin E then Ropinirole|Patients will be provided with vitamin E, 400 international units (IU), at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to Ropinirole. Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
62313855|NCT03176966|ACTIVE_COMPARATOR|Ropinirole then Vitamin E|Patients will be prescribed ropinirole at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to vitamin E, 400 international units (IU). Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
62313856|NCT04570891|EXPERIMENTAL|FICB|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
61923655|NCT03918681|NO_INTERVENTION|Control Group|The control group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups control group participants will not receive any gait retraining cues and will only be instructed on standard of care return to run metrics to include volume, load, and duration of running.
61923656|NCT02942589|EXPERIMENTAL|100% Portions|Meal portion size: 100%
62313857|NCT04570891|PLACEBO_COMPARATOR|Control|No regional block is provided at the end of surgery.
62313858|NCT01003587|EXPERIMENTAL|District health information package|
62313859|NCT01003587|NO_INTERVENTION|No Intervention|
62478227|NCT06321263|EXPERIMENTAL|Peripheral Muscle Training Group|Older individuals in this group will participate in group exercise training, including aerobic and resistance training, twice a week for ten weeks, each session supervised by a researcher physiotherapist and lasting one hour.
62478228|NCT06321263|EXPERIMENTAL|Inspiratory Muscle Training Group:|Older people in this group will perform aerobic and resistance training for 1 hour a day, twice a week for ten weeks, under the supervision of a researcher physiotherapist. As for Inspiratory Muscle Training, they will participate in training with 30 breathing cycles a day, six days a week, for ten weeks (two days in the clinic, four days at home).
62478229|NCT00620074|EXPERIMENTAL|combination 2|anidulafungin plus voriconazole
61923657|NCT02942589|EXPERIMENTAL|125% Portions|Meal portion size: 125%
61923658|NCT02942589|EXPERIMENTAL|150% Portions|Meal portion size: 150%
62313860|NCT00659685|EXPERIMENTAL|A|Subjects received Kali formulated products under fasting conditions
62313861|NCT00659685|ACTIVE_COMPARATOR|B|Subjects received GlaxoSmithKline formulated products under fasting conditions
62313862|NCT02292134|EXPERIMENTAL|earplug and sleep mask|
62313863|NCT02292134|NO_INTERVENTION|control|
62478230|NCT00620074|EXPERIMENTAL|combination 1|anidulafungin plus voriconazole
62313864|NCT03311178|EXPERIMENTAL|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
62478231|NCT01787565||painPREMIER cohort|
62478232|NCT01787565||Control cohort|
62478233|NCT01439451|EXPERIMENTAL|experimental|perturbation training during walking
62478234|NCT01439451|ACTIVE_COMPARATOR|controls|treadmill walking
62684377|NCT06688357|ACTIVE_COMPARATOR|Parkinson Group NIR|Transcranial Near Infrared Stimulation for Parkinson's Disease participants who will attend a total of 6 treatment sessions over a two-week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60-minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
62123940|NCT02568644|EXPERIMENTAL|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
62313865|NCT00987259||Post MI patients|Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
62313866|NCT03324256|ACTIVE_COMPARATOR|Energy drink and placebo gum|Commercially-available energy drink (16oz) + 2 pieces of placebo gum
62313867|NCT03324256|ACTIVE_COMPARATOR|Caffeinated drink and placebo gum|Commercially-available caffeinated drink (16oz) + 2 pieces of placebo gum
62313868|NCT03324256|ACTIVE_COMPARATOR|Control drink and energy gum|Control drink (16oz) + 2 pieces of energy gum
62313869|NCT03324256|PLACEBO_COMPARATOR|Control drink and placebo gum|Control drink (16oz) + 2 pieces of placebo gum
62313870|NCT03324256|ACTIVE_COMPARATOR|Energy drink and total sleep deprivation|Commercially-available energy drink (16oz) + 2 pieces of placebo gum following total sleep deprivation
62313871|NCT05788068|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive CBT-based digital smoking cessation intervention. The intervention is a set of smoking cessation methods based on the theoretical study of cognitive behavioral therapy for smoking cessation, and its effectiveness has been confirmed through our large sample of randomized controlled studies. This study plans to intervene smokers for 4 weeks after the start of smoking cessation.
62313872|NCT02606773|EXPERIMENTAL|600 mg Novo C plus|Single dose of oral 600 mg Novo C plus dietary supplement (contains 600 mg ascorbic acid in liposomal formulation)
62684378|NCT06688357|SHAM_COMPARATOR|Parkinson Group - Sham|Parkinson's Disease participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
62684379|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
62123941|NCT02568644|PLACEBO_COMPARATOR|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
62123942|NCT03098368|ACTIVE_COMPARATOR|Patient (active) group|"* Rotigotine titration up to 16 mg/24 hr~* Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose~* Duration up to 12 weeks~* The treatment was titrated until optimal dosage~  * (that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~ * (or patient can not tolerated the side effects such as dyskinesia)~* All previous dopaminergic medications were not allowed to adjusted during the study period."
62123943|NCT03098368|PLACEBO_COMPARATOR|Control (placebo) group|"Placebo transdermal patch were titration with the same protocol as active group.~Duration up to 12 weeks~* The treatment (placebo patch) was titrated until optimal dosage~  * (that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~ * (or patient can not tolerated the side effects such as dyskinesia)~* All previous dopaminergic medications were not allowed to adjusted during the study period."
62123944|NCT00632424|EXPERIMENTAL|1|
62123945|NCT01574807|EXPERIMENTAL|mepivacaine + lidocaine followed by lidocaine + lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine (3% mepivacaine/2% lidocaine with epinephrine - combination 1) and 2.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two seperate appointments spaced 2 weeks apart.
62123946|NCT01574807|EXPERIMENTAL|lidocaine + lidocaine followed by mepivacaine plus lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
62313873|NCT02606773|EXPERIMENTAL|900 mg Novo C Plus|Single dose of 900 mg oral Novo C plus dietary supplement (contains 900 mg ascorbic acid in liposomal formulation)
62313874|NCT02606773|ACTIVE_COMPARATOR|500 mg intravenous vitamin C|Single dose of 500 mg intravenous ascorbic acid (Vitamin C 100 mg/ml injection; EGIS)
62313875|NCT02606773|ACTIVE_COMPARATOR|500 mg oral vitamin C|Single dose of 500 mg oral ascorbic acid (Cetebe 500 mg retard capsules; GlaxoSmithKline Consumer Healthcare - GSK Export)
62313876|NCT04824872|EXPERIMENTAL|Sequence 1|Dasiglucagon high dose, followed by placebo, followed by dasiglucagon low dose
62313877|NCT04824872|EXPERIMENTAL|Sequence 2|Dasiglucagn low dose, followed by dasiglucagon high dose, followed by placebo
62313878|NCT04824872|EXPERIMENTAL|Sequence 3|Placebo, followed by dasiglucagon low dose, followed by dasiglucagon high dose
62313879|NCT04824872|EXPERIMENTAL|Sequence 4|Dasiglucagon high dose, followed by dasiglucagon low dose, followed by placebo
62478235|NCT03847688||Treatment resistant Major Depressive Disorder|
61923659|NCT02942589|EXPERIMENTAL|175% Portions|Meal portion size: 175%
61923660|NCT02306499|EXPERIMENTAL|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH VARICOCELE|ICSI cases using cryopreserved testicular sperm from infertile azoospermic men, with proven diagnosis of varicocele (clinical \& sonographic), which will be used for ICSI in an ART program
62313880|NCT04824872|EXPERIMENTAL|Sequence 5|Placebo, followed by dasiglucagon high dose, followed by dasiglucagn low dose
62313881|NCT04824872|EXPERIMENTAL|Sequence 6|Dasiglucagon low dose, followed by placebo, followed by dasiglucagon high dose
62313882|NCT03152864|EXPERIMENTAL|Full Package|
62313883|NCT03152864|NO_INTERVENTION|Sensing Only|
62313884|NCT06043323|EXPERIMENTAL|Axicabtagene Ciloleuce|Participants will first have a procedure to collect your white blood cells that will be used to make axicabtagene ciloleucel. Then participatns will receive radiation therapy, followed by conditioning chemotherapy and 1 infusion of axicabtagene ciloleucel.
62313885|NCT06385496|EXPERIMENTAL|Treatment (sapanisertib [MLN0128 (TAK-228)])|Patients receive sapanisertib (MLN0128 \[TAK-228\]) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
62313886|NCT00795626|EXPERIMENTAL|Lifestyle counseling|"Two groups:~* control - conventional care~* intervention - systematic education in the reduction of the risk estimate to cardiovascular events"
62313887|NCT05385705|EXPERIMENTAL|Experimental: NKs|Subjects will be treated with cyclophosphamide single dose between days -5 and -3 before the NK-cell infusion. On Day 1 single loading doses of trastuzumab (8mg/kg iv) and pertuzumab (840 mg iv) will be administered followed by maintenance doses of 6mg/kg and 420mg respectively, every three weeks. After that, NK infusion will be done on day 2 and that will be followed by administration of IL-2 on day 2, 4 and 6 as a subcutaneous dose of 5x105 UI/m2.
62313888|NCT03208192|EXPERIMENTAL|ErbeJet|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
62313889|NCT03208192|EXPERIMENTAL|Misonix|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)
62313890|NCT06012604|EXPERIMENTAL|allogeneic mesenchymal stromal stem cells|Application of allogeneic mesenchymal stromal stem cells (MSC, derived from umbilical cord tissue) under ultrasound guidance into both parotid and submandibular glands.
62313891|NCT06445335|OTHER|FibroScan|
62313892|NCT02430792|ACTIVE_COMPARATOR|Football|Recreational football 1-hour twice weekly in a local football club on a disease specific team
62313893|NCT02430792|NO_INTERVENTION|Control|A 15-30-minute guidance session upon group allocation to encourage engagement in the standard rehabilitation offered by the municipality
62313894|NCT05868967|EXPERIMENTAL|[14C]DWP14012|Type: \[14C\]DWP14012 suspension containing 40 mg/80 μCi Dosage: orally take the suspension
61923661|NCT02306499|EXPERIMENTAL|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH NO VARICOCELE|ICSI cases using cryopreserved testicular sperms from infertile azoospermic men due to etiologies other than varicocele
61923662|NCT06197425|EXPERIMENTAL|Chemotherapy by FOLFIRI|
62313895|NCT01452425|EXPERIMENTAL|Tourniquet|Inflation of a tourniquet
62684380|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
61923663|NCT06197425|EXPERIMENTAL|Chemotherapy by Trifluridine tipiracil|
61923664|NCT06197425|ACTIVE_COMPARATOR|Surveillance inside the trial/control arm|
61923665|NCT06197425|NO_INTERVENTION|Surveillance outside the trial|
61923666|NCT05611177||Derivation cohort|It will contain 700 patients (70% of 1000 ARDS patients)
61923667|NCT05611177||Validation cohort|It will contain 300 patients (30% of 1000 ARDS patients)
61923668|NCT05611177||Confirmatory cohort|It will contain 303 patients (for external validation)
62313896|NCT00685178|EXPERIMENTAL|1 topiramate + CR|topiramate and contingency reinforcement for urine sample confirming cocaine abstinence
62313897|NCT00685178|EXPERIMENTAL|2 topiramate + NonCR|Topiramate and random reinforcement irrespective of cocaine use
62313898|NCT00685178|PLACEBO_COMPARATOR|4 Placebo + NonCR|
62123947|NCT04966416|EXPERIMENTAL|Pyrophosphate|Disodium pyrophosphate
62123948|NCT04966416|PLACEBO_COMPARATOR|Placebo|Glucose
62123949|NCT01997944|EXPERIMENTAL|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.
62123950|NCT01997944|ACTIVE_COMPARATOR|Pegasys|Peginteferon 180 mcg multiple dose S.C.
62123951|NCT02490254||1|Any child (aged 0-16 years) with a new diagnosis of uni or bilateral uveitis.
62123952|NCT00819325|EXPERIMENTAL|Intensive glycemic control|Included routine use of pioglitazone (30 mg/d) for 6 months in addition to titration of their other oral hypoglycemic agents in order to get the HbA1c\<6%.
62123953|NCT00819325|ACTIVE_COMPARATOR|conservative glycemic control|Included titration of oral hypoglycemic agents to get HbA1c\<7% without the use of a thiazolidinedione.
62123954|NCT01582646|OTHER|first period with terbutaline and second period with placebo|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
62123955|NCT01582646|OTHER|first period with placebo and second period with terbutaline.|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
62123956|NCT05883475||Patients with shoulder pain|"Those who scored above 0 for shoulder pain on the Visual Analog Scale (VAS) were assigned to the group with shoulder pain"
62313899|NCT00685178|ACTIVE_COMPARATOR|3 Placebo + CR|Placebo and contingency reinforcement for urine sample confirming cocaine abstinence
62123957|NCT05883475||Patients without shoulder pain|"Those who scored 0 for shoulder pain on the Visual Analog Scale (VAS) were assigned to the group without shoulder pain"
62123958|NCT05386953||Balanced group|Patients who received balanced crystalloids of lactated Ringer's solution or plasma solution during liver transplantation surgery
62123959|NCT05386953||Saline group|Patients who received only normal saline during liver transplantation surgery
62123960|NCT00304135|ACTIVE_COMPARATOR|Radio-chimiothérapie|Radio-chimiothérapie
62123961|NCT00304135|EXPERIMENTAL|GEMOX|GEMOX
62123962|NCT04854395|ACTIVE_COMPARATOR|Group A: Active FTB + Active PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml for IFCN + 10 ml Marcain 5 mg/ml is used for PPB
62123963|NCT04854395|ACTIVE_COMPARATOR|Group B: Active FTB + Sham PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml is used for IFCN
62123964|NCT04854395|ACTIVE_COMPARATOR|Group C: Sham FTB + Sham PPB + Active ACB|Single shot bolus of 25 ml Marcain 5 mg/ml is used for ACB
62123965|NCT02502344|EXPERIMENTAL|medical intervention group|subjects in this group will accept healthy lifestyle changes such as food control and intensive exercise for 3 months first. Then their insulin resistance will be evaluated again . If their insulin resistance didn't improve, then they will take metformin 0.5g qd to reduce insulin resistance. If their insulin resistance improved, they will continued healthy lifestyle changes.
62123966|NCT02502344|NO_INTERVENTION|clinical observeral group|subjects in this group will not accept medical interventions
62123967|NCT02439827|EXPERIMENTAL|"Fortaleça sua Saúde program"|The intervention program was structured into four main components: (i) training and activities in general curriculum; (ii) training and activities in Physical Education classes; (iii) active opportunities in the school environment; (iv) health education in school community.
62123968|NCT02439827|NO_INTERVENTION|Control|Schools from the control group carried out one semester with the regular and conventional activities of a full-time school. In general, the control schools had two weekly Physical Education classes that include content and activities according to the perspective of their teachers. The conventional Programa Saúde na Escola were also performed in these schools.
62123969|NCT05678023|ACTIVE_COMPARATOR|Contrast media 2 hours|Patients will receive contrast media after 2 hours of nasogastric decompression
62123970|NCT05678023|ACTIVE_COMPARATOR|Contrast media 24 hours|Patients will receive contrast media after 24 hours of nasogastric decompression
62123971|NCT05017571|NO_INTERVENTION|Adults no obesity, insulin resistance, or inflammation|Adults without obesity, insulin resistance or inflammation
62123972|NCT05017571|NO_INTERVENTION|Adults with obesity, but no insulin resistance/inflammation|Adults with obesity, but without insulin resistance or inflammation
62123973|NCT05017571|EXPERIMENTAL|Colchicine - Adolescents|Adolescents given Colchicine 0.6 mg per day (1 capsule per day)
62313900|NCT02094079||L-T4 treated hypothyroid pregnant women|L-T4 treated pregnant women
62313901|NCT04773041||Patients with DLB|Patients diagnosed with DLB enrolled from the HealthPartners Neuroscience Center.
61923669|NCT05904990|EXPERIMENTAL|traditional exercise therapy only|This 50-minute program included a 10-minute warm-up phase (treadmill walking at a comfortable speed), 30 minutes of stretching exercises for (glutei, paraspinal muscles, hamstring, pectoralis, scalenus, intercostal muscles, and trapezius), and a 10-minute cool-down involving self-stretching and respiratory exercises.
61923670|NCT05904990|EXPERIMENTAL|HILT alongside traditional exercise therapy,|pulsed Nd: YAG laser device (HIRO 3.0; ASA Laser, Arcugnano, Italy). This equipment delivers pulsed laser light at a wavelength of 1,064 nm, with a very high peak power of 3 kW and energy density ranging from 360 to 1,780 mJ/cm2.
61923671|NCT01653028|EXPERIMENTAL|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61923672|NCT06004687|ACTIVE_COMPARATOR|By applying acetaminophen mannitol to patients with gastrointestinal tumors before surgery|Acetaminophen mannitol injection 50ml(500mg) intravenously pumped 30 minutes before surgery
62123974|NCT05017571|EXPERIMENTAL|Colchicine - Adults|Adults given Colchicine 0.6 mg per day (1 capsule per day)
62123975|NCT05017571|PLACEBO_COMPARATOR|Placebo - Adolescents|Adolescents given Placebo (1 capsule per day)
62123976|NCT05017571|PLACEBO_COMPARATOR|Placebo - Adults|Adults given Placebo (1 capsule per day)
62123977|NCT03389191|EXPERIMENTAL|Patients with Viral Uveitis|Oral acyclovir 100 mg three times a day (TID).
62123978|NCT00943358|ACTIVE_COMPARATOR|Vaccine|adjuvanted influenza vaccine
62313902|NCT04773041||Patients with Alzheimer's disease (AD)|Patients diagnosed with AD age and sex-matched, selected from the ADNI database.
62123979|NCT00943358|ACTIVE_COMPARATOR|Vaccine 2|non-adjuvanted vaccine
62123980|NCT01264679|EXPERIMENTAL|Ferumoxytol|When a participant has persistent or recurrent IDA (defined as hemoglobin \<12.0 grams \[g\]/deciliter \[dL\] and with either transferrin saturation \<40% or ferritin \<100 nanograms/milliliter), the participant will begin a 7-week treatment period. Participants will receive 2 IV injections of ferumoxytol 7.0 milligrams (mg) iron/kilogram (maximum of 510 mg/dose), the first dose administered on Day 1 and the second on Days 3 through 9 of the Treatment Period.
62123981|NCT05000216|EXPERIMENTAL|Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62313903|NCT04773041||Patients with normal cognition (CN)|Patients diagnosed with normal cognition age and sex-matched, selected from the ADNI database.
61923673|NCT06004687|PLACEBO_COMPARATOR|By applying normal saline to patients with gastrointestinal tumors before surgery|Normal saline injection 50ml intravenously pumped 30 minutes before surgery
61923674|NCT04838392|EXPERIMENTAL|CGM System|Blood draw and glucose challenge will be performed to evaluate the performance of the CGM system compared to reference measurements during the in in-clinic visits.
62123982|NCT05000216|EXPERIMENTAL|Cohort A, Arm A2: BNT162b2 + Continue IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62313904|NCT00517686|EXPERIMENTAL|1|The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
62313905|NCT00517686|NO_INTERVENTION|2|Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
62478236|NCT01293591|OTHER|Control|270 kcal White bread with 15 g margarine
62478237|NCT01293591|OTHER|Garlic Treatment|270 kcal white bread with 15 g margarine and 5 g crushed garlic
62123983|NCT05000216|EXPERIMENTAL|Cohort A, Arm A3: Ad26.COV2.S + Continue IS (MMF or MPA)|Arm closed, effective protocol version 3.0. Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62123984|NCT05000216|EXPERIMENTAL|Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
62123985|NCT05000216|EXPERIMENTAL|Cohort A, Arm A5: BNT162b2 + Withhold IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
62313906|NCT06249126|OTHER|Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)|Surgical fixation by joint fusion + Surgical fixation with plates and screws, plates, sutures, or rods are used to hold the broken bone together
62313907|NCT06249126|OTHER|Open Reduction Internal Fixation (ORIF) only|Surgical fixation with plates and screws, plates, sutures, or rods are used to hold the broken bone together
62313908|NCT03279237|EXPERIMENTAL|FOLFIRINOX + pre-operative radiation|"* FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle~  * Oxaliplatin is administered intravenously~ * Leucovorin is administered intravenously~ * Irinotecan is administered intravenously~ * 5-Fluorouracil is administered intravenously~* Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
62313909|NCT03528252|ACTIVE_COMPARATOR|LDL Cholesterol|Will receive dietary advice effective for reducing LDL cholesterol.
62313910|NCT03528252|SHAM_COMPARATOR|Triglycerides|Will not be aware that they are in fact Control Group. Will receive dietary advice effective for reducing Triglycerides, but neutral for LDL cholesterol.
62313911|NCT05762822|PLACEBO_COMPARATOR|Placebo|60 ml water (same taste as active comparator) at 10 pm the night before and 6 am on the day for blood sampling (8 am).
62313912|NCT05762822|ACTIVE_COMPARATOR|3-OHB|60 ml 3-OHB (30 g) at 10 pm the night before and 6 am on the day for blood sampling (8 am).
62313913|NCT01088815|EXPERIMENTAL|Gemcitabine, nab-paclitaxel, GDC-0449|Gemcitabine and nab-Paclitaxel in combination with GDC-0449 (Vismodegib)
62313914|NCT01539265|EXPERIMENTAL|silodosin, arm 1|
62313915|NCT01539265|EXPERIMENTAL|silodosin, arm 2|
62313916|NCT01539265|PLACEBO_COMPARATOR|placebo|
62313917|NCT02214979|EXPERIMENTAL|Telmisartan/Ramipril|
62313918|NCT02214979|ACTIVE_COMPARATOR|Telmisartan + Ramipril capsule|
62123986|NCT05000216|EXPERIMENTAL|Cohort A, Arm A6: Ad26.COV2.S + Withhold IS (MMF or MPA)|Arm closed, effective protocol version 3.0. Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
62313919|NCT02214979|ACTIVE_COMPARATOR|Telmisartam + Ramipril tablet|
62313920|NCT04308369|OTHER|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
62313921|NCT03398408|EXPERIMENTAL|Intervention|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Participants in the intervention group will then be provided with the Lumosity cognitive flexibility training module and complete daily training for a total of five weeks. 1-3 days after completion of their training, all patients will be invited to complete the computerized versions of the TMT A and B, Color Match, and NCPT tests again on their personal computers."
62313922|NCT03398408|NO_INTERVENTION|Control|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Patients in the control group will complete all tests upon enrollment and approximately five weeks after their initial testing, but will not participate in training."
62313923|NCT01067638|EXPERIMENTAL|tranexamic acid|Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft
62313924|NCT06649903|EXPERIMENTAL|Cervical Spinal Manipulation (CSM)|This arm includes participants who receive a single session of high-velocity, low-amplitude spinal manipulation aimed at reducing pain and improving cervical range of motion and muscle strength in individuals with mechanical neck pain. The intervention is administered by a qualified physiotherapist, following established protocols for cervical spinal manipulation.
62313925|NCT06649903|EXPERIMENTAL|Visceral Osteopathy|Participants in this arm undergo a single session of visceral osteopathy techniques focused on improving pain and functional outcomes in individuals with mechanical neck pain. The VO techniques are designed to enhance mobility and alleviate discomfort through manipulation of the viscera and associated structures, performed by a trained osteopath.
62684381|NCT02771145|EXPERIMENTAL|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
62684382|NCT02465814|EXPERIMENTAL|Arm 1 - BAY1002670 + BAY1002670|Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
62313926|NCT01301612|ACTIVE_COMPARATOR|Radiation therapy and Cisplatin|Cisplatin, 40 mg/m2, IV - Weekly doses for 6 weeks Pelvic radiation therapy, 45 Gy External, Fractions of 1.8 Gy per day, 5 days a week Dose boosts,15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week Brachytherapy (if indicaed), 40 Gy at spot A(low dose rate), Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A, (high dose rate) Intracavitary,4 fractions of 7.0 Gy once or twice a week.
62313927|NCT01301612|EXPERIMENTAL|Nimotuzumab and|"Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks.~Nimotuzumab, 200 mg, Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes, Weekly doses for 14 weeks.~Pelvic radiation therapy, 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts, 15 Gy ± 5%, External,Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week~Brachytherapy (In case there is indication, should it be performed, not to be longer than the expected 70 days for the entire radiation therapy), 40 Gy at spot A (low dose rate) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks 28 Gy at spot A (high dose rate), Intracavitary, 4 fractions of 7.0 Gy once or twice a week."
61923675|NCT06115031|EXPERIMENTAL|Remimazolam|General anesthesia using continuous infusion of intravenous remimazolam and remifentanil. Remimazolam will be used for maintenance of general anesthesia and adjusted between 0.6-2mg/kg/hr until the end of surgery.
62313928|NCT02194881||Ivacaftor 1|patients with CF who are homozygous or heterozygous for the G551D mutation and treated with Ivacaftor
62684383|NCT02465814|EXPERIMENTAL|Arm 2 - Placebo + BAY1002670|Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
62684384|NCT02465814|EXPERIMENTAL|Arm 3 - BAY1002670 + BAY1002670|Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)
62684385|NCT02465814|EXPERIMENTAL|Arm 4 - Placebo+BAY1002670|Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)
62684386|NCT02465814|ACTIVE_COMPARATOR|Arm 5 - Ulipristal + Ulipristal|Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
62684387|NCT02465814|ACTIVE_COMPARATOR|Arm 6- Placebo + Ulipristal|Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
62684388|NCT02465814|ACTIVE_COMPARATOR|Arm 7- Ulipristal + Placebo|Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)
62684389|NCT06679907|EXPERIMENTAL|WaveLinQ® device|One of the two CE-marked devices used in the Endovascular AVF arm.
62684390|NCT06679907|EXPERIMENTAL|Ellipsys® device|One of the two CE-marked devices used in the Endovascular AVF arm.
62684391|NCT06679907|ACTIVE_COMPARATOR|Open surgery|
62684392|NCT00938080|EXPERIMENTAL|AG013: one mouth rinse/day|
62684393|NCT00938080|EXPERIMENTAL|AG013: three mouth rinses/day|
62123987|NCT05000216|EXPERIMENTAL|Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62123988|NCT05000216|EXPERIMENTAL|Cohort B, Arm B2: BNT162b2 + Continue IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62684394|NCT00938080|EXPERIMENTAL|AG013: six mouth rinses/day|
62123989|NCT05000216|EXPERIMENTAL|Cohort B, Arm B3: Ad26.COV2.S + Continue IS (MTX)|Arm closed, effective protocol version 3.0. Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62684395|NCT00938080|PLACEBO_COMPARATOR|one mouth rinse/day|
62684396|NCT00938080|PLACEBO_COMPARATOR|three mouth rinses/day|
62684397|NCT00938080|PLACEBO_COMPARATOR|six mouth rinses/day|
62684398|NCT01627106|EXPERIMENTAL|Vernakalant|
62684399|NCT01627106|ACTIVE_COMPARATOR|Amiodarone|
62123990|NCT05000216|EXPERIMENTAL|Cohort B, Arm B4: Moderna mRNA-1273 + Withhold IS (MTX)|Adult Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
62123991|NCT05000216|EXPERIMENTAL|Cohort B, Arm B5: BNT162b2 + Withhold IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster, per protocol instruction.
62313929|NCT03514472|ACTIVE_COMPARATOR|Group A (Below 18 years)|Dried Moringa oleifera leaves (15g/recipe)
62313930|NCT03514472|ACTIVE_COMPARATOR|Group B (Above 18)|Dried Moringa oleifera leaves (15g/recipe)
62684400|NCT06687772|EXPERIMENTAL|Anthracycline-based induction chemotherapy + ASCT + Thiotepa + Carmustine|"* Patients should receive induction treatment with anthracycline-based chemotherapy regimen per standard of care (6 cycles). Management, dose delays, and dose modifications will be per standard of care and treating physician discretion; administration of anthracycline-based induction therapy is not dictated by the study. Patients who have a PR by PET criteria but whose residual abnormality on PET is unlikely to represent residual disease may proceed to ASCT.~* After confirmation of complete response (CR) following induction therapy, patients will begin conditioning with thiotepa (days -5 and -4) and carmustine (day -6), followed by ASCT on day 0."
62684401|NCT00827307|EXPERIMENTAL|Combination|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.
62684402|NCT00827307|ACTIVE_COMPARATOR|Conctrol|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
62684403|NCT06309433|ACTIVE_COMPARATOR|PS TKA|Patients with Posterior stabilized Total knee replacement
62684404|NCT06309433|ACTIVE_COMPARATOR|CR TKA|Patients with cruciate retaining Total knee replacement
62684405|NCT06019728|EXPERIMENTAL|agalsidase beta|agalsidase beta 1 mg/kg infusion once every other week
62684406|NCT06613685|EXPERIMENTAL|Phase 2: GS-1720 + GS-4182 (Treatment Group 1)|Participants will receive a 1-day loading dose of GS-1720 (1300 mg) and GS-4182 (600 mg) on Day 1.Thereafter, participants will take weekly doses of single agent GS-1720 (650 mg) and GS-4182 (300 mg) coadministered for at least 48 weeks.
62684407|NCT06613685|ACTIVE_COMPARATOR|Phase 2: B/F/TAF (Treatment Group 2)|Participants will receive B/F/TAF (50/200/25 mg) daily for at least 48 weeks.
61923676|NCT06115031|ACTIVE_COMPARATOR|Propofol|General anesthesia using target-controlled infusion of intravenous propofol and remifentanil. Propofol will be adjusted maintaining the BIS between 40-60 until the end of surgery.
62123992|NCT05000216|EXPERIMENTAL|Cohort B, Arm B6: Ad26.COV2.S + Withhold IS (MTX)|Arm closed, effective protocol version 3.0. Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
62123993|NCT05000216|EXPERIMENTAL|Cohort C, Arm C1: Moderna mRNA-1273 + Continue IS (B cell depletion therapy)|Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62123994|NCT05000216|EXPERIMENTAL|Cohort C, Arm C2: BNT162b2 + Continue IS (B cell depletion therapy)|Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62313931|NCT04494711|EXPERIMENTAL|Physical functional literacy|5 week physical literacy program for adults with multiple chronic conditions
62313932|NCT06667466||sTFL + Flexible Negative-Pressure UAS|Under general anesthesia, a guidewire is first inserted. Then, the Flexible Negative Pressure UAS is inserted along the guidewire to the stone site. A ureteroscope is inserted through the sheath to the stone site. The sTFL is used to fragment the stone with a power setting of 0.8J and a frequency of 12 - 20Hz. Simultaneously, the fragmented stones are removed by negative pressure suction.
62684408|NCT06613685|EXPERIMENTAL|Phase 2 Extension Phase: GS-1720/GS-4182 Fixed-dose Combination (FDC)|At the end of the randomized treatment, Phase 2 participants will be given the option to participate in the Extension Phase. Phase 2 Treatment Group 1 will switch to GS-1720/GS-4182 FDC (650/300 mg) weekly. Phase 2 Treatment Group 2 will receive a loading dose of GS-1720/GS-4182 FDC (1300 mg/600 mg) on Extension Phase Day 1, then GS-1720/GS-4182 FDC (650/300 mg) weekly. Participants who choose to enter the Extension Phase will receive GS-1720/GS-4182 FDC tablets until the product becomes available or until Gilead Sciences elects to discontinue the study, whichever occurs first.
61923677|NCT05843487||Carotid plaque length|Patients underwent carotid ultrasonography and first coronary angiography simultaneously
61923678|NCT01612728|EXPERIMENTAL|Women with Arthralgia|Women who develop joint pain on Aromatase Inhibitor therapy will be placed on the clinical algorithm, as specified in the protocol.
61923679|NCT01612728|OTHER|Women without Arthralgia|Women who do not develop arthralgia will continue to have their joint pain and strength measured, as well as their medication compliance. However, they will not be placed on the clinical algorithm which is meant for alleviation of joint pains.
61923680|NCT00003046|EXPERIMENTAL|Interleukin-12|
61923681|NCT06521099|EXPERIMENTAL|Evaluative conditioning group with positive stimuli|Participants will be exposed to social stimuli paired with positive stimuli across multiple sessions.
62313933|NCT06667466||sTFL + Conventional UAS|Under general anesthesia, the Conventional UAS is inserted to the upper ureter or the ureteropelvic junction. A ureteroscope is inserted through the sheath to the stone site. The sTFT is used to fragment the stone with a power setting of 0.8J and a frequency of 12 - 20Hz. After fragmentation, the stones are removed by a stone basket.
62478238|NCT05493735|PLACEBO_COMPARATOR|Control|Lubricating jelly (placebo) will be placed in the vagina to the level of the pessary, five minutes prior to pessary removal.
62478239|NCT05493735|EXPERIMENTAL|Experimental|Lidocaine jelly will be placed in the vagina to the level of the pessary, five minutes prior to the pessary removal.
62478240|NCT05651191|EXPERIMENTAL|Human CD19 Targeted DASH CAR-T Cells Injection|Single administration：0.5×10\^6 CAR+T, 1.0×10\^7 CAR+T, 2.0×10\^7 CAR+T
62684409|NCT06613685|EXPERIMENTAL|Phase 3: GS-1720/GS-4182 FDC + Placebo to Match (PTM) B/F/TAF (Treatment Group 1)|Participants will receive a 1-day loading dose of GS-1720/GS-4182 FDC on Day 1. Thereafter, participants will receive GS-1720/GS-4182 FDC tablets weekly + PTM B/F/TAF once daily. Participants will receive treatment for at least 96 weeks.
62478241|NCT06560060||MARVEL|5000 individuals with type 1 diabetes \> 18 years of age
62697355|NCT06435221|EXPERIMENTAL|Cytisinicline 3 mg TID|Cytisinicline 3 mg TID for 52 weeks.
61923682|NCT06521099|ACTIVE_COMPARATOR|Control group with neutral stimuli|Participants will be exposed to social stimuli paired with neutral stimuli across multiple sessions.
61923683|NCT03932968||Symptomatic pain|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry during 24 hours will be performed.
61923684|NCT03932968||Control|patients after a sleeve gastrectomy without symptomatic pain
61923685|NCT05656989||Stage 3 Grade C Periodontitis|Generalized S3GC periodontitis patients had PD ≥ 6 mm and interproximal CAL ≥ 5 mm and with radiographic alveolar bone loss extending at least to the middle third of the root at 30 % of the teeth or more. These patients showed no more than four teeth loss due to periodontitis. The percentage bone loss/age values in this group were \> 1.0
61923686|NCT05656989||Gingivitis|Gingivitis patients exhibited PD ≤ 3 mm and no interproximal CAL or radiographic bone loss. These patients had BOP ≥ 30% of probe sites.
62697356|NCT06529627|ACTIVE_COMPARATOR|Long agonist protocol - ICSI-ET|
61923687|NCT05656989||Periodontal health|Periodontally healthy controls had an intact periodontium or a reduced periodontium in a non-periodontitis patient (without interproximal CAL or radiographic bone loss). PD was ≤ 3 mm and BOP was \< 10 % in this group.
61923688|NCT01336569|EXPERIMENTAL|DuoTrav|Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks
61923689|NCT02122731|EXPERIMENTAL|Amiloride|This is a non-randomized and non-controlled study with only one treatment arm with amiloride.
62313934|NCT03254667||Brodalumad exposed|1500 subjects exposes to brodalumab
62313935|NCT03254667||Comparator Subjects|2000 comparator subjects
62478242|NCT01203267|EXPERIMENTAL|paclitaxel plus carboplatin (PCb) Arm|4 cycles of neoadjuvant paclitaxel plus carboplatin
62478243|NCT02163382|EXPERIMENTAL|Neurovent Monitor XIII|1 hour Ventilation with NAVA
62478244|NCT03009955||Group P|patients who received primary caesarean section
61923690|NCT03961373|ACTIVE_COMPARATOR|Standard Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy
61923691|NCT03961373|EXPERIMENTAL|Experimental Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy
61923692|NCT05587673|EXPERIMENTAL|Methylprednisolone|Participants who have failed first line therapy and are still experiencing flare symptoms.
62313936|NCT01713036|EXPERIMENTAL|Pimasertib|
62313937|NCT04877782||Healthy older participants|Healthy older participants receiving both stimulation conditions (experimental and placebo) randomized across scanning sessions.
62313938|NCT06671379|EXPERIMENTAL|SHR-A2009 monotherapy|
62313939|NCT06671379|ACTIVE_COMPARATOR|platinum-based dual-agent chemotherapy|
62313940|NCT01347684|ACTIVE_COMPARATOR|Standard care using current drugs|Standard care with drug intervention
62313941|NCT01347684|EXPERIMENTAL|Behavioral therapy, splint therapy and physical therapy|Using rehabilitation for comparing use of drug
62478245|NCT03009955||Group R|patients who received repeated caesarean section
62478246|NCT05472350|EXPERIMENTAL|Breztri Aerosphere Group|Participants will receive Breztri Aerosphere twice a day from 3 days before surgery to 14 days after surgery
62478247|NCT05472350|PLACEBO_COMPARATOR|Placebo Group|Participants will receive 0.9% normal saline twice a day from 3 days before surgery to 14 days after surgery
62478248|NCT01137591|EXPERIMENTAL|APAP and NAC combination|N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill
62313942|NCT05315310|EXPERIMENTAL|REAL Training|Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
62313943|NCT01332435||Early 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
62313944|NCT01332435||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)
62313945|NCT03699345||Edwards CENTERA THV|
62313946|NCT04089124|OTHER|repair using General anesthesia ( control group)|Surgery repair zone II under GA
62313947|NCT04089124|OTHER|repair using Walant|Surgery repair zone II under WALANT
62478249|NCT01137591|PLACEBO_COMPARATOR|APAP and Placebo combination|N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill
62313948|NCT01206595|ACTIVE_COMPARATOR|SKY0402|Low-dose (175 mg), low-mid dose( 225 mg), and mid-dose (350 mg)
62313949|NCT01206595|ACTIVE_COMPARATOR|Bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
61923693|NCT05214846|EXPERIMENTAL|Education and Counseling|"After obtaining written informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. Women were counseled for 6 weeks.~Anxiety-depression levels (post-test) were applied by phone call 6 weeks later.This education consisted of the definition and the purpose of pregnancy and pregnancy problems and nutrition during pregnancy, sexuality during pregnancy, number of fetal movements, preparation of the delivery bag, breast care, etc."
61923694|NCT05214846|NO_INTERVENTION|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed.The control group was called by phone at the end of 6 weeks and told that they would be retested and 6 weeks later, they were called by phone and their anxiety and depression levels (posttest) were applied. directed to continue
62684410|NCT06613685|ACTIVE_COMPARATOR|Phase 3: B/F/TAF + PTM GS-1720/GS-4182 FDC (Treatment Group 2)|Participants will receive oral B/F/TAF daily along with PTM GS-1720/GS-4182 FDC weekly for at least 96 weeks. Additionally, participants will receive a 1-day loading dose of PTM GS-1720/GS-4182 on Day 1.
62123995|NCT05000216|EXPERIMENTAL|Cohort C, Arm C3: Ad26.COV2.S + Continue IS (B cell depletion therapy)|Arm closed, effective protocol version 3.0. Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62123996|NCT05000216|EXPERIMENTAL|Cohort D, Arm D1: Ad26.COV2.S + Withhold IS (MMF or MPA)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
62313950|NCT03882840|EXPERIMENTAL|ITNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
62313951|NCT03882840|EXPERIMENTAL|CAR-ITNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells with CAR-engineered, will be administrated to kill tumor cells.
62313952|NCT03415074|ACTIVE_COMPARATOR|Supplemented low protein diet (sLPD)|Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
62313953|NCT03415074|ACTIVE_COMPARATOR|Mild protein restriction diet (MPD)|Mild restriction in dietary protein intake (0.8 g/kg-day)
62313954|NCT06369324|NO_INTERVENTION|Control group|Participants in the control group will not receive any intervention and will continue with their normal combat and flight exercise activities. They will be asked not to take medication or seek alternative treatments.
62313955|NCT06369324|EXPERIMENTAL|Intervention group|Participants in the intervention group will follow a programme of education in pain neuroscience, supervised therapeutic exercise, and an intervention based on manual therapy combined with electrical stimulation called electro-massage.
62478250|NCT00027053|EXPERIMENTAL|Trazodone|
62684411|NCT06613685|EXPERIMENTAL|Phase 3 Extension Phase: GS-1720/GS-4182 Fixed-dose Combination (FDC)|"After the end of blinded treatment, Phase 3 participants will be given the option to participate in the Extension Phase. Phase 3 Treatment Group 1 will continue to receive GS-1720/GS-4182 FDC weekly while PTM B/F/TAF will be discontinued. Phase 3 Treatment Group 2 will switch to receive GS-1720/GS-4182 FDC tablets weekly. Participants in Treatment Group 2 will also receive a 1-day loading dose of GS-1720/GS-4182 FDC on Extension Phase Day 1.~Participants who choose to enter the Phase 3 Extension Phase will receive GS-1720/GS-4182 FDC tablets until the product becomes available or until Gilead Sciences elects to discontinue the study, whichever occurs first."
62684412|NCT06081244|EXPERIMENTAL|Neoadjuvant treatment: 12 weeks (4 cycles) SG i.v.|"* Cohort 1a: In case of (near) cCR: end of treatment, followed by surgery~* Cohort 1b: In case of cPR after 12 weeks: further 6 weeks (2 cycles) SG i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment~* In case of pCR: no further systemic treatment~* In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12"
62684413|NCT06081244|EXPERIMENTAL|Neoadjuvant treatment: 12 weeks (4 cycles) SG+PEM i.v.|"* Cohort 2a: In case of (near) cCR: end of treatment, followed by surgery~* Cohort 2b: In case of cPR after 12 weeks: 6 weeks (2 cycles) SG+PEM i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment~* In case of pCR: no further systemic treatment~* In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12"
62684414|NCT06410131|EXPERIMENTAL|Arm 1 Part 1 Dose Escalation|Escalating doses of FTL008.16 depending on cohort at enrollment
62684415|NCT06410131|EXPERIMENTAL|Arm 1 Part 2 Dose Expansion|Two dose groups of FTL008.16 depending on data of Arm 1 Part 1
62684416|NCT06649721|EXPERIMENTAL|BDLL|6-month all-oral regimen, consisting of Bedaquiline (BDQ, B), Delamanid (DLM, D), Linezolid (LZD, L), Levofloxacin (LFX) or Clofazimine (CFZ, C), as known as BDLLfxC or BDLL regimen
62684417|NCT05852990|EXPERIMENTAL|Intervention diet|Astringent diet supplemented with one sachet containing 10 grams of glutamine plus 100 million Colony Forming Units (CFU) of Lactobacillus reueri every 12 hours, from baseline treatment up to 6 weeks or death.
61923695|NCT02909803|EXPERIMENTAL|Lentil Variety|Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits
61923696|NCT02909803|ACTIVE_COMPARATOR|White Bread|Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits
62123997|NCT05000216|EXPERIMENTAL|Cohort D, Arm D2: Alternative mRNA Vaccine + Withhold IS (MMF or MPA)|Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of an alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
62123998|NCT05000216|EXPERIMENTAL|Cohort D, Arm D3: Moderna mRNA-1273 + Withhold IS (MMF or MPA)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
62123999|NCT05000216|EXPERIMENTAL|Cohort E, Arm E1: Ad26.COV2.S + Withhold IS (MTX)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
62684418|NCT05852990|NO_INTERVENTION|Standard diet|Astringent diet from baseline treatment up to 6 weeks or death.
62313956|NCT06673407|ACTIVE_COMPARATOR|Exposure Only|Group exposure therapy for social anxiety and public speaking fears.
62313957|NCT06673407|EXPERIMENTAL|Compassion Enhanced|Group exposure therapy for social anxiety and public speaking fears plus self-compassion exercises aimed at inducing a sense of common humanity.
62313958|NCT06673407|EXPERIMENTAL|Peer enhanced|Group exposure therapy for social anxiety and public speaking fears facilitated by a pair of doctoral student and undergraduate student co-facilitators who will explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
62313959|NCT06673407|EXPERIMENTAL|Fully enhanced|Group exposure therapy for social anxiety and public speaking fears plus self-compassion exercises aimed at inducing a sense of common humanity, facilitated by a pair of doctoral student and undergraduate student co-facilitators who will explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
62313960|NCT03549624||Intervention group|"All adult (\>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.~Patients will be treated with an perioperative regime/protocol consisting of:~1. Early so called NEWS-monitoring (measuring of standard physiological parameters);~2. Early start of antibiotics;~3. Rapid (within 6 hours) start of operation;~4. Goal-directed fluid therapy;~5. Intensified post-operative monitoring;~6. The presence of both surgical and anesthesiological specialists in the early care of the patients."
62313961|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
62313962|NCT06014814||Pulsed Field Ablation - General Anaesthesia|Patients undergoing pulsed field ablation for atrial fibrillation under general anaesthetic.
62313963|NCT06014814||Pulsed Field Ablation - Mild Conscious Sedation|Patients undergoing pulsed field ablation for atrial fibrillation under mild conscious sedation.
62478251|NCT00027053|PLACEBO_COMPARATOR|Placebo|
62478252|NCT03348553|SHAM_COMPARATOR|control group|20 subjects do not receive any supplementation
62478253|NCT03348553|ACTIVE_COMPARATOR|Omega2|20 subjects receive an Omega-Fatty-acid Nutratceutical
62684419|NCT05378763|EXPERIMENTAL|Poziotinib 8 mg|Participants will receive poziotinib 8 mg, orally, BID, in 21 day cycles or until disease progression, death, intolerable adverse events (AEs), initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study.
61923697|NCT06330844|EXPERIMENTAL|Experimental: RBSEF-CCT-MCI|Participants will complete the newly developed RBSE-CCT-MCI training program.
61923698|NCT06330844|OTHER|Control Group: ME-CCT|Participants will complete the original, ME-CCT training program.
61923699|NCT03845049|EXPERIMENTAL|group aflibercept|
61923700|NCT03845049|PLACEBO_COMPARATOR|control group|
62124000|NCT05000216|EXPERIMENTAL|Cohort E, Arm E2: Alternative mRNA Vaccine + Withhold IS (MTX)|Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of an alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
62313964|NCT03660904|EXPERIMENTAL|Home made media|home made vitrification \& thawing kit
62684420|NCT05378763|ACTIVE_COMPARATOR|Docetaxel 75 mg/m^2|Participants will receive docetaxel 75 mg/m\^2, intravenously (IV) on Day 1 of each 21-day treatment cycle or until disease progression, death, intolerable AEs, initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study.
62684421|NCT00677300|EXPERIMENTAL|Group A|Will receive Raltegravir (400mg twice daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
62684422|NCT00677300|ACTIVE_COMPARATOR|Group B|Will receive Tenofovir (300mg once daily) + Emtricitabine (200mg once daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
62684423|NCT03307590|ACTIVE_COMPARATOR|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
62684424|NCT03307590|ACTIVE_COMPARATOR|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
62684425|NCT02133677|EXPERIMENTAL|temozolomide+WBRT|temozolomide: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks WBRT:30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week)
62684426|NCT05947890|EXPERIMENTAL|1.1a - Adolescents and adults without HIV and negative interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684427|NCT05947890|EXPERIMENTAL|1.1b - Adolescents and adults without HIV and negative interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684428|NCT05947890|EXPERIMENTAL|1.2a - Adolescents and adults without HIV and positive interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684429|NCT05947890|EXPERIMENTAL|1.2b - Adolescents and adults without HIV and positive interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684430|NCT05947890|EXPERIMENTAL|2.1 a- Adolescents and adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684431|NCT05947890|EXPERIMENTAL|2.1.b - Adolescents and adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684432|NCT05947890|EXPERIMENTAL|2.2 a- Adolescents and adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62124001|NCT05000216|EXPERIMENTAL|Cohort E, Arm E3: Moderna mRNA-1273 + Withhold IS (MTX)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
62313965|NCT03660904|ACTIVE_COMPARATOR|Commercial media|commercially available vitrification \& thawing kit
62313966|NCT05700240||Orthokeratology treatment|
62313967|NCT05700240||single-vision spectacle correction|
62313968|NCT04533763|EXPERIMENTAL|Mindful Living (ML)|Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.
62313969|NCT04533763|ACTIVE_COMPARATOR|Healthy Lifestyles (HL)|Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.
62313970|NCT05823506|ACTIVE_COMPARATOR|Medication group|PDE5 inhibitor tadalafil in dosage 5 mg daily by 1 month
62313971|NCT05823506|EXPERIMENTAL|Combination group|PDE5 inhibitor tadalafil in dosage 5 mg daily by 1 month plus Device BTL-6000 fSWT: 6 sessions with EFD 0,09 mJ/mm2 by 5000 impulses per session in 5 points in corpora cavernosa penis
62478254|NCT03348553|ACTIVE_COMPARATOR|Omega4|20 subjects receive an Omega-Fatty-acid Nutraceutical
62478255|NCT03348553|ACTIVE_COMPARATOR|Omega2+OGV|20 subjects receive an Omega-Fatty-acid Nutraceutical + encapsulated fruit, vegetable and berry-juice concentrate
62684433|NCT05947890|EXPERIMENTAL|2.2 b- Adolescents and adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684434|NCT05947890|EXPERIMENTAL|3.1 a- Adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684435|NCT05947890|EXPERIMENTAL|3.1 b- Adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684436|NCT05947890|EXPERIMENTAL|3.2 a- Adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684437|NCT05947890|EXPERIMENTAL|3.2 b- Adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
62684438|NCT03389100|EXPERIMENTAL|18F-MK6240 injection|intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
62684439|NCT05852470|EXPERIMENTAL|Clareon Vivity/Vivity Toric|Previous implantation in both eyes with Clareon Vivity/Vivity Toric Extended Vision IOL (intraocular lens), with previous implantation defined as 90-180 days post second eye implantation
61923701|NCT02028871|ACTIVE_COMPARATOR|Intranasal Insulin First|Intranasal Insulin First, Placebo Second
62684440|NCT05852470|ACTIVE_COMPARATOR|Clareon Monofocal/Clareon Toric|Previous implantation in both eyes with Clareon Monofocal/Clareon Toric IOL (intraocular lens), with previous implantation defined as 90-180 days post second eye implantation
62684441|NCT06687421||Non-metastatic high-risk prostate cancer|ISUP ≥4, T3-4, or regional lymph node positive
62684442|NCT06687421||Low risk prostate cancer|ISUP = 1, PSA \<10 µg/L, PSA-density \<0,15 µg/l/cm3
62684443|NCT06687421||Medium risk prostate cancer|ISUP 2-3, PSA 10-20 µg/L
62684444|NCT06687421||Metastatic prostate cancer|PSA \> 80 µg/L, clinically manifest metastases
62124002|NCT05000216|EXPERIMENTAL|Cohort F, Arm F1: Ad26.COV2.S + Withhold IS (B cell depletion therapy)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
62124003|NCT05000216|EXPERIMENTAL|Cohort F, Arm F2: Alternative mRNA Vaccine + Withhold IS (B cell depletion therapy)|Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
62684445|NCT06002698|OTHER|Root canal treatment (Control)|The procedure can be carried out in single or two visits. Variations in root canal treatment protocols however will make it difficult to compare with pulpotomy so the aim is to standardize the protocols for the following variables including use of rubber dam, Irrigation protocol with 2-2.5% sodium hypochlorite; working length with combined radiographs and apex locators, automated instrumentation to accompany hand instrumentation and preparation to apical size 2-3 larger than the initial binding file. Canal to be medicated with non-setting calcium hydroxide if done in two visits and root canal filling with gutta percha and traditional sealers (warm or cold lateral condensation) and good coronal seal.
62684446|NCT06002698|EXPERIMENTAL|Full pulpotomy|The clinical procedure will be completed over one or two visits. Following adequate anesthesia and isolation with rubber dam, access to the pulp will be gained following caries removal to de-roof the pulp chamber and excision of the entire coronal pulp. The pulp chamber is irrigated with 2% sodium hypochlorite solution and the resultant bleeding from the remaining pulp will be controlled with a cotton pellet soaked in 2% sodium hypochlorite solution. Following complete haemostasis, the pulp stump will then be covered with Biodentine (Septodont Ltd., Saint Maur des Fausse ́s, France) and the tooth permanently restored with a restoration if treatment is completed in single visit or temporized with glass ionomer cement for the final restoration to be placed in the 2nd visit if operator opted for 2-visit treatment.
62684447|NCT05370209|EXPERIMENTAL|Otinova® Ear Spray|Otinova® Ear Spray 1-2 sprays, twice daily for 7 days
62684448|NCT01628770|EXPERIMENTAL|parenteral iron|dose will be calculated according to Ganzoni's formula, and will be administered by intravenous infusion
62684449|NCT01628770|ACTIVE_COMPARATOR|oral iron|oral iron in form of ferrous sulphate 200 mg twice daily
62684450|NCT06105645|EXPERIMENTAL|Arm with fast-ripples information|Patients for whom 4-6 usual clinical macro-electrodes will be replaced by hybrid micro-macro electrodes and for whom fast-ripples will be assessed
62684451|NCT06105645|ACTIVE_COMPARATOR|Arm without fast-ripples information|Patients who will undergo an SEEG with the usual electrodes and for whom fast-ripples will not be assessed.
62684452|NCT05741372|EXPERIMENTAL|Group 1: Healthy participants|Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.
62684453|NCT05741372|EXPERIMENTAL|Group 2: F4 Child-Turcotte-Pugh class A (Child-Pugh A) subjects (compensated)|"Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.~Compensated=without any disease symptoms"
62684454|NCT05741372|EXPERIMENTAL|Group 3: F4 Child-Turcotte-Pugh class B (Child-Pugh B) subjects (decompensated)|"Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.~Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome"
62684455|NCT04544631|EXPERIMENTAL|Active VR|"Participants in the active VR group played a virtual reality game entitled Virtual River Cruise. In this game, an otter floats down a river on a boat and players activate snow-blowing statues along the shore by focusing on them. The statues will emit snow if they are correctly aimed at by the child, and a thermometer placed in the front of the boat shows decreased temperatures as more snowflakes are blown. As feedback to reinforce continued engagement, a scoreboard placed beside the thermometer will show children the number of statues he/she has activated. Additionally, as the temperature drops, snow and ice will start piling up on the boat and its surroundings, providing an enhanced cooling experience for pediatric burn patients. Children interact with the immersive virtual reality environment by tilting their head, minimizing potential interference with the dressing change procedure."
62478256|NCT06323239|EXPERIMENTAL|SBRT+LDRT+PD-1+Chemotherapy|Patients will receive SBRT and LDRT one day before the GP chemotherapy and PD-1 antibody (six cycles), then followed by PD-1 antibody until progressive disease, intolerable toxicity, withdrawal of consent or a maximum of 2 year treatment.
62684456|NCT04544631|EXPERIMENTAL|Passive VR|Participants in the passive VR group were immersed in the same virtual reality environment as the active VR group, without any interactions with the VR game.
61923702|NCT02028871|PLACEBO_COMPARATOR|Placebo First|Placebo First, Intranasal Insulin Second
62478257|NCT05726669|EXPERIMENTAL|Intervention group|Self-help intervention based on cognitive behavioural therapy for depression in pulmonary hypertension. There will be four booklets which will take four weeks for participants to work through in their own time at home.
62684457|NCT04544631|NO_INTERVENTION|Standard Care Control|Participants in the standard group received routinely used distraction tools provided in the clinical setting, such as iPads, music, books, and/or talking.
62478258|NCT05726669|NO_INTERVENTION|Wait list control group|The wait list control group will not receive the self-help intervention, and will be compared to the intervention group on the outcome measures. The wait-list control group will receive the intervention after study completion if it is found to be helpful (June 2024).
62313972|NCT01134887|EXPERIMENTAL|Arm 1: Intervention-Veterans|"Veterans enrolled in the Intervention-Veterans arm received a copy of the NIA guide for Talking with Your Doctor \[Informational Guide for Patients\]. Just prior to their next scheduled visit an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor \[Educational Coaching\]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management."
62478259|NCT06196515|EXPERIMENTAL|Nano calcium hydroxide in hydrogel form|nano calcium hydroxide in hydrogel form is placed in the dry root canals after complete cleaning and shaping procedure.The intracanal medication will be distributed to fill the canals up to the orifice level.
61923703|NCT05640102||Cohort 1: MYD88 L265P mutation|Arm A: Treatment-naïve (TN); Arm B: Relapsed/refractory (R/R)
61923704|NCT05640102||Cohort 2: Non-L265P MYD88 mutation(s) and MYD88 wildtype|Arm C: TN and R/R
61923705|NCT03037268||Patients undergoing dilated examination|"* examined in the Retina Service of Wills Eye Hospital~* with and without visually significant posterior retinal or optic nerve pathology~* imaged with a Lytro Plenoptic Camera and 28D lens"
61923706|NCT04816201|EXPERIMENTAL|Electroacupuncture|Participants in the electroacupuncture group received acupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36). After skin disinfection, sterile adhesive pads were placed on these acupoints, and acupuncture needles were inserted through the adhesive pads approximately 50 to 60 mm into the skin. Paired electrodes from the electroacupuncture apparatus were attached to the needle handles of Xuanji (CV21) and Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), bilateral Liangmen (ST21), and bilateral Zusanli (ST36). The electroacupuncture stimulation lasted for 30 minutes with an intermittent wave of 50 Hz and a current intensity of 1 to 5mA (preferably with the skin around the acupoints shivering mildly without pain). Participants received 1 treatment session per day until the success of ventilator weaning (up to 21 days).
62124004|NCT05000216|EXPERIMENTAL|Cohort F, Arm F3: Moderna mRNA-1273 + Withhold IS (B cell depletion therapy)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
62124005|NCT05000216|EXPERIMENTAL|Cohort D, Arm D4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (MMF or MPA)|Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction.
62124006|NCT05000216|EXPERIMENTAL|Cohort E, Arm E4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (MTX)|Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction.
62124007|NCT05000216|EXPERIMENTAL|Cohort F, Arm F4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (B cell depletion therapy)|Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction
62124008|NCT05000216|EXPERIMENTAL|Cohort A, Arm A1P: Moderna mRNA-1273, Bivalent + Continue IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62313973|NCT01134887|ACTIVE_COMPARATOR|Arm 2: Control-Veterans|"Veterans enrolled in the Control-Veterans arm received a copy of the NIA guide for Talking with Your Doctor \[Informational Guide for Patients\]. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
61923707|NCT04816201|SHAM_COMPARATOR|Sham electroacupuncture|Participants in the sham electroacupuncture group received sham electroacupuncture with a pragmatic placebo needle on sham acupoints. The sham Xuanji (CV21) point was 1 cun (≈20 mm) above to Xuanji (CV21), the sham Danzhong (CV27) point was 1 cun(≈20mm) above to Danzhong (CV27), the sham Qihai (CV06) point was 1 cun(≈20mm) above to Qihai (CV06), the sham Guanyuan (CV04) point was 1 cun(≈20mm) above to Guanyuan (CV04), the sham Liangmen (ST21) point was 1 cun(≈20mm) lateral to Liangmen (ST21), and the sham Zusanli (ST36) point was 1 cun(≈20mm) lateral to Zusanli (ST36). Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no skin penetration or electricity output.
61923708|NCT04797897|EXPERIMENTAL|CORI UKA|Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with CORI.
61923709|NCT04797897|ACTIVE_COMPARATOR|Conventional UKA|Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with conventional approach with conventional manual instrumentation.
61923710|NCT01607840|EXPERIMENTAL|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
62478260|NCT06196515|ACTIVE_COMPARATOR|Nano calcium hydroxide in paste form|nano calcium hydroxide in paste form is placed in the dry root canals after complete cleaning and shaping procedure. The intracanal medication will be distributed to fill the canals up to the orifice level.
61923711|NCT01607840|EXPERIMENTAL|Cathodal|transcranial direct current stimulation using cathodal stimulation over the brain area of interest
61923712|NCT01607840|SHAM_COMPARATOR|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without actually delivering tDCS
61923713|NCT01943708|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP) device.|Standard CPAP therapy
61923714|NCT01943708|EXPERIMENTAL|Auto-CPAP device (SPAP).|Novel Auto-CPAP algorithm
61923715|NCT03350984|EXPERIMENTAL|NPH insulin group|Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin
61923716|NCT03350984|ACTIVE_COMPARATOR|Glargine and Lispro insulin group|"Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro.~Intervention drug: Glargine and Lispro"
61923717|NCT03192878||Naive patients|Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
61923718|NCT03192878||Switch patients|Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
62124009|NCT05000216|EXPERIMENTAL|Cohort A, Arm A2P: BNT162b2, Bivalent + Continue IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62124010|NCT05000216|EXPERIMENTAL|Cohort A, Arm A4P: Moderna mRNA-1273, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
62313974|NCT01134887|EXPERIMENTAL|Arm 3: Intervention-Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians \[Monograph for Physicians\]. The Four Habits provided practical evidence-based advice for improving patient-physician communication. Second, physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients \[Video-Assisted Coaching\], but before seeing them for follow-ups. The main goal of this meeting was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management."
62124011|NCT05000216|EXPERIMENTAL|Cohort A, Arm A5P: BNT162b2, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
62124012|NCT05000216|EXPERIMENTAL|Cohort B, Arm B1P: Moderna mRNA-1273, Bivalent + Continue IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62313975|NCT01134887|ACTIVE_COMPARATOR|Arm 4: Control-Physicians|"Primary care providers randomly assigned to the Control-Physicians arm of the study did not receive coaching or additional resources, and conducted their primary care practice as usual \[Control\]."
62313976|NCT05134298||Study Kohort|As specified by study population, inclusion and exclusion criteria
62313977|NCT02901262||qEEG patients|All the patients with continuous EEG (\>24 hours) in the two study units
61923719|NCT06325475|ACTIVE_COMPARATOR|Group A|"Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route."
61923720|NCT06325475|ACTIVE_COMPARATOR|Group B|Pregnant women in Group A will not receive neuraxial labor analgesia. If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen if needed.
61923721|NCT01242397|OTHER|CRT ON|After implant, patients will be randomized to CRT pacing ON vs OFF in crossover fashion with 3 months in each period
61923722|NCT01242397|OTHER|CRT- OFF|After implant, patients will be randomized to CRT pacing OFF vs ON in crossover fashion with 3 months in each period
61923723|NCT06086626|EXPERIMENTAL|Single-Dose Cefiderocol|Participants will receive a single dose cefiderocol on Day 1, along with standard of care antibiotics
61923724|NCT06086626|EXPERIMENTAL|Multiple-Dose Cefiderocol|Participants will receive cefiderocol every 8 hours for 5 to 14 days, along with standard of care antibiotics
61923725|NCT03069118|EXPERIMENTAL|Treatment|Three-month intervention on the online Workit Health platform
61923726|NCT03069118|PLACEBO_COMPARATOR|Control|A list of online resources/waitlist
61923727|NCT05610085|EXPERIMENTAL|Dose escalation with LEV|Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage of the study).
62684458|NCT02091960|EXPERIMENTAL|Enzalutamide + Trastuzumab|Participants received 160 mg enzalutamide orally once daily and 6 mg/kg trastuzumab administered by intravenous infusion or subcutaneous injection every 21 days. Participants continued on treatment until disease progression, unacceptable toxicity or any other discontinuation criteria were met.
62124013|NCT05000216|EXPERIMENTAL|Cohort B, Arm B2P: BNT162b2, Bivalent + Continue IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62124014|NCT05000216|EXPERIMENTAL|Cohort B, Arm B4P: Moderna mRNA-1273, Bivalent + Withhold IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
62124015|NCT05000216|EXPERIMENTAL|Cohort B, Arm B5P: BNT162b2, Bivalent + Withhold IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster, per protocol instruction.
62124016|NCT05000216|EXPERIMENTAL|Cohort C, Arm C1P: Moderna mRNA-1273, Bivalent + Continue IS (B cell depletion therapy)|Pediatric participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62124017|NCT05000216|EXPERIMENTAL|Cohort C, Arm C2P: BNT162b2, Bivalent + Continue IS (B cell depletion therapy)|Pediatric participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
62124018|NCT05000216|EXPERIMENTAL|Cohort D, Arm D1P: BNT162b2, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
62124019|NCT05000216|EXPERIMENTAL|Cohort D, Arm D2P: Moderna mRNA-1273, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
62313978|NCT06671080|EXPERIMENTAL|Assessment Group|All of the tests planned to be used in the study will be applied to adolescent amateur soccer players who meet the inclusion criteria.
62313979|NCT06672653|EXPERIMENTAL|C14 arm|In this arm, particpants will received by vaginal syringe, 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13).
62684459|NCT06627595||Patients with no physical activity / low physical activity|Patients with low score according to the IPAQ questionnaire at baseline. This is the lowest level of physical activity.
62684460|NCT06627595||Patients with moderate to high physical activity|Patients with moderate or high score according to the IPAQ questionnaire at baseline.
62697357|NCT01889446|PLACEBO_COMPARATOR|Calcium propionate|Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.
61923728|NCT05610085|ACTIVE_COMPARATOR|Standard of care Phenobarbital|Treatment with Phenobarbital 20mg/kg IV and if needed a further 20mg/kg totalling 40mg/kg
61923729|NCT03264170|ACTIVE_COMPARATOR|Prediction of pregnancy outcome|Women will receive an individualised prediction score of the pregnancy being viable at the follow-up ultrasound generated from the prediction tool.
61923730|NCT03264170|NO_INTERVENTION|Control|Women will not receive the prediction score
61923731|NCT05769543|ACTIVE_COMPARATOR|WATSU application|
61923732|NCT05769543|PLACEBO_COMPARATOR|Control|
61923733|NCT02537574|EXPERIMENTAL|NTX/BUP|Oral naltrexone + sublingual buprenorphine
62697358|NCT01889446|PLACEBO_COMPARATOR|Placebo|Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.
61923734|NCT02537574|ACTIVE_COMPARATOR|NTX/PBO-B|Oral naltrexone + sublingual placebo
61923735|NCT02537574|PLACEBO_COMPARATOR|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
62313980|NCT06672653|PLACEBO_COMPARATOR|Control arm|In this arm, particpants will received by vaginal syringe, 5ml of distilled water, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13).
62124020|NCT05000216|EXPERIMENTAL|Cohort E, Arm E1P: BNT162b2, Bivalent + Withhold IS (MTX)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
62124021|NCT05000216|EXPERIMENTAL|Cohort E, Arm E2P: Moderna mRNA-1273, Bivalent + Withhold IS (MTX)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
62124022|NCT05000216|EXPERIMENTAL|Cohort F, Arm F1P: BNT162b2, Bivalent + Withhold IS (B cell depletion therapy)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
62124023|NCT05000216|EXPERIMENTAL|Cohort F, Arm F2P: Moderna mRNA-1273, Bivalent + Withhold IS (B cell depletion therapy)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
62124024|NCT05463432|EXPERIMENTAL|HR19024|Part 1: Dose escalation of HR19024 montherapy for advanced solid tumor Part 2：PK expansion of HR19024 montherapy for advanced solid tumor Part 3: Efficacy expansion of HR19024 montherapy for advanced solid tumor
62313981|NCT05314582||TURP patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic prostatectomy (TURP).
62313982|NCT05314582||TURP patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic prostatectomy (TURP).
62313983|NCT05314582||TUR-BT patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic bladder tumor resection (TUR-BT).
62313984|NCT05314582||TUR-BT patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic bladder tumor resection (TUR-BT).
62313985|NCT05314582||Open prostatectomy patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent open prostatectomy (OP).
61923736|NCT06166030|EXPERIMENTAL|Effects of ImmuneRecov on Lung Function and Immune Response|Effects of 30 days supplementation with ImmuneRecov on Lung Function and Immune Response of post-COVID-19 patients.
61923737|NCT06166030|EXPERIMENTAL|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength
62124025|NCT04583306||Healthy Subjects|40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event
62124026|NCT04583306||COVID-19 Positive|40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups
62124027|NCT04583306||COVID-19 Negative|40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups
62124028|NCT04412018|NO_INTERVENTION|Usual Care|Participants in this arm will continue with usual care
62124029|NCT04412018|EXPERIMENTAL|Icosapent Ethyl|Participants in this arm will take icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
62124030|NCT02810080|EXPERIMENTAL|Closed Loop Control Ventilation|automatic adjustment of the ZOLL 731 ventilator FiO2 by the closed loop control software
62124031|NCT02810080|ACTIVE_COMPARATOR|Manual Control Ventilation|manual adjustment of the ZOLL 731 ventilator FiO2 by the treatment team based on physician order
62684461|NCT04674306|EXPERIMENTAL|Treatment α-lactalbumin and zymosan|"Participants diagnosed with triple negative breast cancer will be treated with successively higher doses of α-lactalbumin and zymosan in a 3 + 3 trial design. Treatment will involve 3 vaccinations every 2 weeks. Participants will be enrolled into 1 of 5 different dose levels each comprised of cohorts of 1-6 participants until the MTD has been identified (intra-patient dose escalation not permitted), after which the MTD will be expanded to 6 participants. Successively lower doses will be expanded to 6 participants until the lowest DL associated with immune response has been expanded.~DL1: 10 mcg a-lactalbumin + 10 mcg Zymosan Original DL2:100 mcg a-lactalbumin + 100 mcg Zyomsan DL2: 100 mcg a-lactalbumin + 10 mcg Zyomsan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL1b: 50 mcg a-lactalbumin + 10 mcg Zymosan DL1e: 10 mcg a-lactalbumin + 20 mcg Zymosan DL1f: 20 mcg a-lactalbumin + 10 mcg Zymosan DL1g: 20 mcg a-lactalbumin + 10 mcg Zymosan (if DL1e is too toxic)"
62697359|NCT06640296||Patients at high risk of developing IFD|patients at high risk of developing IFD receiving chemotherapy for (1st line or relapse treatment) or allo-HSCT for which primary fungal prophylaxis with Liposomal amphotericin B has been administered between 01/01/2019 to 31/12/2023
61923738|NCT04584697|EXPERIMENTAL|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
61923739|NCT04584697|PLACEBO_COMPARATOR|Placebo|A single injection of placebo will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
61923740|NCT03745430|EXPERIMENTAL|Ramucirumab+Nab-paclitaxel+Gemcitabine|Nab-paclitaxel and Gemcitabine will be administered on days 1, 8 and 15 every 4 weeks for a maximum of 8 cycles.
62124032|NCT02947958|EXPERIMENTAL|Teleconsultation|Tele consultation (experimental) - after the randomization the patient is guided to seek primary care under teleconsultation supervision to keep his treatment. One year later the patient's symptoms are reassessed in a medical consultation.
62124033|NCT02947958|ACTIVE_COMPARATOR|Hospital|Hospital (control) - after the randomization the patient is guided to keep his treatment in the tertiary care as usual. One year later the patient's symptoms are reassessed in a medical consultation.
62124034|NCT02994173|ACTIVE_COMPARATOR|Placebo|Oxycodone 1 mg / ml alone
62124035|NCT02994173|ACTIVE_COMPARATOR|Ketamine 0.25|Oxycodone 1 mg / ml + S-ketamine 0.25 mg / ml (ratio 1:0.25)
62124036|NCT02994173|ACTIVE_COMPARATOR|Ketamine 0.5|Oxycodone 1 mg / ml + S-ketamine 0.5 mg / ml (ratio 1:0.5)
62124037|NCT02994173|ACTIVE_COMPARATOR|Ketamine 0.75|Oxycodone 1 mg / ml + S-ketamine 0.75 mg / ml (ratio 1:0.75)
61923741|NCT02711345|EXPERIMENTAL|Escalation|
61923742|NCT02711345|EXPERIMENTAL|Expansion Group 1|
62124038|NCT05425199|EXPERIMENTAL|habituation exercises|head and eye movements first slowly then rapidly, head and body movements e.g., picking object from the ground standing and rotation in standing
62124039|NCT05425199|EXPERIMENTAL|proprioceptive training|Single leg stance (right side) + Single leg stance (left side) Lifting of right knee as high as comfortable and then alternative knee Tandem walking ,Toe walking ,Heel walking
62124040|NCT05425199|ACTIVE_COMPARATOR|Conventional vestibular therapy|Epley's Manuever
62124041|NCT05407571|OTHER|Echogenic Amniotic Fluid|estimation the nature of echogenic amniotic fluid.to overcome unnecessary intervention due to turbid amniotic fluid, assessing the neonatal outcome and estimation the gestational age at time of delivery in patients with echogenic amniotic fluid.
62124042|NCT06335862|OTHER|PPT-group|Participants allocated to this study arm will undergo the primary posterior tracheopexy (PPT). This PPT is performed concurrently with the primary OA correction. Afterwards, all patients follow the (same) routine follow-up schedule. This treatment is currently used in some centres.
62124043|NCT06335862|OTHER|No-PPT-group|Participants allocated to this study arm will undergo the the primary OA correction, without a PPT. Afterwards, all patients follow the (same) routine follow-up schedule. This treatment is also used in some centres.
62124044|NCT00332917|EXPERIMENTAL|1|
62124045|NCT05956613|NO_INTERVENTION|Control: conventional root canal treatment|
62478261|NCT06196515|ACTIVE_COMPARATOR|Conventional calcium hydroxide in paste form|conventional calcium hydroxide in paste form is placed in the dry root canals after complete cleaning and shaping procedure.The intracanal medication will be distributed to fill the canals up to the orifice level.
61923743|NCT02711345|EXPERIMENTAL|Expansion Group 2|
61923744|NCT02711345|EXPERIMENTAL|Expansion Group 3|
61923745|NCT02711345|EXPERIMENTAL|Expansion Group 4|
61923746|NCT06059118|EXPERIMENTAL|Repeat Sequential DFMO and High dose Testosterone in Sequence with Enzalutamide|Eligible patients will receive 7 days of DFMO (1000 mg PO bid) (days 1-7 of cycle), followed by 56 days of combined testosterone (testosterone cypionate 400 mg IM on day 8 and day 36) and DFMO (1000 mg PO bid) (days 8-63 of cycle), followed by 56 days of enzalutamide (160 mg PO daily) (days 64-119).
61923747|NCT04639115|EXPERIMENTAL|Ozanimod in subjects with mild hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with mild hepatic impairment
61923748|NCT04639115|EXPERIMENTAL|Ozanimod in subjects with moderate hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with moderate hepatic impairment
62124046|NCT05956613|OTHER|Test: partial pulpotomy|Partial pulpotomy using bioceramic putty
62124047|NCT01860820|NO_INTERVENTION|Best Medical Therapy|Participants will follow standard post-transplant protocols with IPC
62124048|NCT01860820|ACTIVE_COMPARATOR|Geko device|Participants will be fitted with the device to ensure that it functions according to the manufacturer's instructions by a trained technician. This device will be changed every 24 hours. The device is worn on both legs and is worn for 24 hours a day. The device will first be put on the first day following the day of surgery and will then be changed the following day at the same time for a total of 7 days after surgery.
62124049|NCT04329364|EXPERIMENTAL|Laser Haemorrhoidoplasty (LAH)|treatment that we would like to study
62124050|NCT04329364|ACTIVE_COMPARATOR|Conventional Open Haemorrhoidectomy (COH)|gold standard treatment as comparator
62313986|NCT05314582||Open prostatectomy patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent open prostatectomy (OP).
62124051|NCT02407834|EXPERIMENTAL|S1 - 0.25% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.25% sodium hypochlorite during 20 minutes, once a day. This protocol was used during 7 days.
62313987|NCT02277210|PLACEBO_COMPARATOR|Non-flushing group|Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
62313988|NCT02277210|ACTIVE_COMPARATOR|Flushing group|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
62313989|NCT01616615|EXPERIMENTAL|ASPIRIN|150 mg milligram(s)/ day oral use
62313990|NCT01616615|PLACEBO_COMPARATOR|PLACEBO|
62478262|NCT01200810|PLACEBO_COMPARATOR|Arm I|"Patients receive oral placebo once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
62313991|NCT00844298|EXPERIMENTAL|Nilotinib+mVPD|Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
62313992|NCT00816972|ACTIVE_COMPARATOR|DL 2.5 mg|Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days
62313993|NCT00816972|ACTIVE_COMPARATOR|OXY 5 mg|Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
62313994|NCT00816972|EXPERIMENTAL|DL 2.5 mg + OXY 2.5 mg|Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
62697360|NCT06175832|EXPERIMENTAL|CFA/PPOS cycle|Interventional stimulation
61923749|NCT04639115|EXPERIMENTAL|Ozanimod in healthy subjects|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in healthy subjects
61923750|NCT01222403|EXPERIMENTAL|Fluad|Subjects aged \>65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
61923751|NCT01222403|EXPERIMENTAL|Vantaflu_aTIV|Subjects aged \>65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
62124052|NCT02407834|EXPERIMENTAL|S2 - 0.5% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.5% sodium hypochlorite during 20 minutes, once a day.This protocol was used during 7 days.
62313995|NCT00816972|EXPERIMENTAL|DL 2.5 mg + OXY 5 mg|Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
62313996|NCT00816972|PLACEBO_COMPARATOR|Placebo|Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
62313997|NCT04257461|NO_INTERVENTION|Group1 Arm A|Observation only
62697361|NCT06175832|ACTIVE_COMPARATOR|rFSH / GnRH antagonist cycle|Conventional stimulation
62697362|NCT03537794||Treatment Resistant Depression|Unmedicated Individuals with Treatment Resistant Depression
62124053|NCT02407834|EXPERIMENTAL|S3 - 10% Ricinus communis|Brushing with specific brush and neutral soap, three times a day. After, immesion in 10% Ricinus communis solution during 20 minutes, once a day. This protocol was used during 7 days.
62124054|NCT02407834|PLACEBO_COMPARATOR|S4 - saline solution|Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
62313998|NCT04257461|OTHER|Group 1 Arm B|Mono- or bichemotherapy: fluoropyrimidine with or without Oxaliplatin (choice by physician/patient or by randomisation)
62478263|NCT01200810|EXPERIMENTAL|Arm II|"Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
61923752|NCT04936464|EXPERIMENTAL|Intervention Group|30-minute treatments, twice weekly x12 weeks
61923753|NCT04936464|SHAM_COMPARATOR|Sham Group|30-minute treatments, twice weekly x12 weeks
62124055|NCT02725762|EXPERIMENTAL|Photobiomodulation Treatment|Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
62697363|NCT03537794||Major Depressive Disorder|Unmedicated Individuals with Major Depressive Disorder
62124056|NCT02725762|SHAM_COMPARATOR|Sham Treatment|Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
62124057|NCT03522454|EXPERIMENTAL|Intervention group|Intervention group: Combination of a protein-rich oral nutritional supplement consumed twice daily for 4 weeks pre-TAVR and 12 weeks after the patient is discharged home post-TAVR, and a home-based supervised exercise program that combines walking and weight-bearing exercises to build strength and balance performed for 12 weeks after the patient is discharged home post-TAVR.
62313999|NCT04257461|OTHER|Group 2 Arm C|Monochemotherapy: fluoropyrimidine
62314000|NCT04257461|OTHER|Group 2 ARM D|Bichemotherapy: fluoropyrimidine with oxaliplatin
62478264|NCT01804244|EXPERIMENTAL|TMC278|All participants will receive a single-dose of TMC278 (1 25-mg tablet \[27.5 mg as the hydrochloride salt\]) after an overnight fast (going without food) of at least 10 hours before eating a standard breakfast. Study drug will be taken within 10 minutes after completion of a standardized breakfast.
62314001|NCT04448249|EXPERIMENTAL|Interventional group|The interventional group keeps a traditional follow up (day hospitalization then consultation with a MD within two to twelve months) but also meets an APN between the day hospitalization and the MD consultation, within one to six months
62124058|NCT03522454|NO_INTERVENTION|Lifestyle counselling group|Lifestyle counselling group: Recommendation to perform moderate-intensity aerobic activity at least 30 minutes 5 days per week as tolerated and eat a balanced diet based on the AHA/ACC Guideline on Lifestyle Management.
62124059|NCT06127199|EXPERIMENTAL|Ovaprene|
62314002|NCT04448249|NO_INTERVENTION|Control group|The control group of patients keeps a traditional follow-up: day hospitalization then consultation with a MD within two to twelve months
62314003|NCT02947139|EXPERIMENTAL|Study effect of DWC20161 on DWC20155/DWC20156 PK|To study effect of DWC20161 on DWC20155/DWC20156 PK
62124060|NCT02399943|EXPERIMENTAL|Trametinib and Panitumumab|"Trametinib: 2 mg QD, orally, continuously.~Panitumumab: 6 mg/kg, intravenously, Q2W"
62124061|NCT02701036||sporadic adult onset ataxia|SAOA denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from multiple system atrophy (MSA). SAOA is a group of ataxia of unknown etiology characterized by a slowly progressive cerebellar syndrome starting around the age of 50 years. Possibly is accompanied by signs of mild autonomic dysfunction that do not meet the criteria of severe autonomic failure required for a diagnosis of MSA.
62314004|NCT02947139|EXPERIMENTAL|Study effect of DWC20155/DWC20156 on DWC20161 PK|To study effect of DWC20155/DWC20156 on DWC20161 PK
61923754|NCT00848575||Group 1 - Device|The principal Investigator and sub-investigators of this study will identify potential participants that attend the gynecologic oncology or gynecology clinics of UAMS. These subjects will have been scheduled for diagnostic or therapeutic laparoscopy. Based on the Inclusion Criteria and Exclusion Criteria of this study, women who are eligible for the study will be approached to participate.
62697364|NCT03537794||Healthy Control|healthy controls with no previous psychiatric disorders
62124062|NCT02701036||cerebellar multiple system atrophy|Multiple system atrophy of cerebellar type is a cerebellar syndrome with sporadic onset developing in midlife, with autonomic features of otherwise unexplained bladder dysfunction with or without erectile dysfunction in males, orthostatic hypotension and atrophy of the cerebellum, brainstem, and middle cerebellar peduncles.
62314005|NCT02316119||Control group|Post-ACS patients without history of IS/TIA previously to the acute coronary and taking aspirin
62314006|NCT02316119||Case group|Post ACS patients with history of IS/TIA previously to the acute coronary event and taking aspirin
62314007|NCT06403774|EXPERIMENTAL|Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)|Bowel preparation will be made using a laxative (Two bowel X-M Solution 250 ml.)
62314008|NCT06403774|EXPERIMENTAL|Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )|Bowel preparation will be made using enema (Two bowel E.S. Enema )
62314009|NCT01278628|EXPERIMENTAL|Lifestyle modification|
62314010|NCT03237845|EXPERIMENTAL|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
62478265|NCT03676946|EXPERIMENTAL|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
62478266|NCT03676946|EXPERIMENTAL|ZKAB001 10mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
62478267|NCT03676946|EXPERIMENTAL|ZKAB001 15mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
62697365|NCT06313359||Cancer treatment induced peripheral neuropathy|Individuals with a history of non CNS cancer with cancer treatment induced peripheral neuropathy symptoms.
62697366|NCT06313359||Control group|Age and gender matched individuals without peripheral neuropathy symptoms.
62124063|NCT03695536||ultrasound use during resuscitation|The group with ultrasound integrated into the resuscitation efforts.
62124064|NCT03695536||no ultrasound use during resuscitation|The group without ultrasound integrated into the resuscitation efforts.
62124065|NCT03418805|EXPERIMENTAL|Ibuprofen CR Tablet 600 mg-fasting|One tablet of IBUCR 600 mg under fasting condition
62124066|NCT03418805|EXPERIMENTAL|Ibuprofen CR Tablet 600 mg-fed|One tablet of IBUCR 600 mg under fed condition
62697367|NCT05259098|EXPERIMENTAL|Sufentanil Sublingual Tablet System|Group treated with Sufentanil Sublingual Tablet System
61923755|NCT05321160|EXPERIMENTAL|Group E|1ug· kg-1 dexmedetomidine and 0.01mg·kg-1 atropine was administered intravenously. 0.25mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
61923756|NCT05321160|ACTIVE_COMPARATOR|Group S|1ug· kg-1 dexmedetomidine and 0.01mg·kg-1 atropine was administered intravenously. 4% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anesthesia by mask inhalation and 2-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained.
62124067|NCT03418805|ACTIVE_COMPARATOR|Advil Ibuprofen table 200 mg-fasting|IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
62124068|NCT03418805|ACTIVE_COMPARATOR|Motrin IB Ibuprofen Tablets 200 mg-fasting|IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition
62697368|NCT05259098|EXPERIMENTAL|Intravenous Patient-Controlled Analgesia with Morphine|Group treated with intravenous Patient-Controlled Analgesia with Morphine
62697369|NCT05541718|EXPERIMENTAL|Reiki|
62697370|NCT05541718|SHAM_COMPARATOR|Sham Reiki|
62697371|NCT05541718|ACTIVE_COMPARATOR|Mindfulness Meditation|
62124069|NCT05573542||Patients with Parkinson's|Individuals with confirmed diagnosis of Parkinson's disease by neurologist.
62124070|NCT05573542||Patients with irritable bowel syndrome|Individuals with IBS according to ROME IV criterias
62314011|NCT03237845|PLACEBO_COMPARATOR|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
62314012|NCT02508714|ACTIVE_COMPARATOR|Orsiro DES (Biotronik)|The ORSIRO hybrid coating DES (Biotronik, Switzerland) is a device which includes a modern, highly flexible, thin-strut stent platform, eluting sirolimus from a thin biodegradable BIO-lute coating grom PLLA (poly(L-lactic acid)) which is located mainly on the abluminal side.
61923757|NCT04127812|EXPERIMENTAL|Savor the Flavor|"The Savor the Flavor curriculum is a series of five interactive lessons designed to teach children how to savor foods and slow down while eating by focusing on the sensory experience of eating. The intervention also teaches attention control techniques so that children are better able to delay consumption of high energy, low nutrition foods, when appropriate, as well as general mindfulness practices (e.g. breathing exercises). Lessons are delivered in the Head Start classroom by a nutrition educator."
62124071|NCT05573542||Healthy controls|Healthy individuals lacking both IBS and Parkinson's disease, in addition to other criteras stated in the Eligibility section.
62124072|NCT04042129||1|gynecologic operations with urologic complications
62124073|NCT05615116||Before ileocecal resection|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited，and the patients were admitted for right hemicolectomy
62124074|NCT05615116||After ileocecal resection|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited，and the patients underwent reversal of ileostoma after right hemicolectomy
62697372|NCT05541718|NO_INTERVENTION|Waitlist Control|
62124075|NCT06093243||"women of childbearing age group"|women of childbearing age with or without endometriosis
62314013|NCT02508714|ACTIVE_COMPARATOR|RESOLUTE ONYX DES (Medtronic)|The RESOLUTE ONYX is a permanent polymer DES that uses a novel highly flexible metallic stent backbone with increased radiographic visibility eluting the drug zotarolimus from the BioLinx durable polymer coating. The stent platform uses corewire technology that allows the stent to have a denser core metal surrounded by outer layer of cobalt-chromium.
62684462|NCT04674306|EXPERIMENTAL|Preventitive a-lactalbumin and zymosan|"Participants with a genetic risk for developing TNBC who plan to undergo prophylactic mastectomy will be treated with α-lactalbumin and zymosan at doses based on the TNBC cohort. Treatment will involve 3 vaccinations every 2 weeks. Participants enrolled in the prevention cohort will be enrolled at the dose level being used in the TNBC cohort if no DLTs above Grade 1 have been observed. If the TNBC cohort proceeds to the next dose level before another prevention cohort patient is enrolled, the next prevention patient will be enrolled on the next dose level along with the TNBC cohort.~DL1: 10 mcg a-lactalbumin + 10 mcg Zymosan Original DL2:100 mcg a-lactalbumin + 100 mcg Zyomsan DL2: 100 mcg a-lactalbumin + 10 mcg Zyomsan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL1b: 50 mcg a-lactalbumin + 10 mcg Zymosan DL1e: 10 mcg a-lactalbumin + 20 mcg Zymosan DL1f: 20 mcg a-lactalbumin + 10 mcg Zymosan DL1g: 20 mcg a-lactalbumin + 10 mcg Zymosan (if DL1e is too toxic)"
61923758|NCT05049733|EXPERIMENTAL|Arm 1|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 1 mg/kg and then switch to other doses after washout periods.
62124076|NCT01846936|EXPERIMENTAL|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
62124077|NCT01846936|ACTIVE_COMPARATOR|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
62124078|NCT01846936|ACTIVE_COMPARATOR|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
62124079|NCT02136407||Blood donors|N=540
62124080|NCT02136407||Thrombocyte donors|N=75
62124081|NCT06092697|EXPERIMENTAL|3D printed PEEK|Indirect dental restoration
62124082|NCT06092697|EXPERIMENTAL|Milled PEEK|Indirect dental restoration
62314014|NCT00865462|EXPERIMENTAL|A|Abrika Bupropion 150 mg XL Tablet, single dose
62124083|NCT06092697|ACTIVE_COMPARATOR|Hybird resin composite|Indirect dental restoration
62124084|NCT00534183|EXPERIMENTAL|1|Olanzapine
62124085|NCT00534183|ACTIVE_COMPARATOR|2|Risperidone
62124086|NCT00534183|ACTIVE_COMPARATOR|3|haloperidol
62124087|NCT06553365|EXPERIMENTAL|FCN-159|FCN-159 8mg qd po
62124088|NCT03212079|NO_INTERVENTION|Control|The participant will self motivate hi/herself to increase physical activities.
62124089|NCT03212079|EXPERIMENTAL|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
62124090|NCT03212079|EXPERIMENTAL|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
62124091|NCT02474238|EXPERIMENTAL|The sequential technique|By using the double frequency YAG laser to make the initial bore and the Nd:YAG laser to complete the perforation on iris.
62124092|NCT02474238|ACTIVE_COMPARATOR|The pure Nd:YAG laser technique|By using the pure Nd:YAG to make a complete perforation on iris.
62124093|NCT01013246|EXPERIMENTAL|Video game play|
62124094|NCT01514344|EXPERIMENTAL|intralesional rituximab|
62124095|NCT05493254|EXPERIMENTAL|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
62314015|NCT00865462|ACTIVE_COMPARATOR|B|Wellbutrin XL® 150 mg Tablet, single dose
62684463|NCT04674306|EXPERIMENTAL|Standard of Care with a-lactalbumin and zymosan|"Participants undergoing chemo-immunotherapy for operable triple-negative breast cancer will be treated with α-lactalbumin concurrently with standard of care adjuvant pembrolizumab after having completed all pre- and postoperative chemotherapy and radiation therapy, with the exception of Xeloda/capecitabine at provider discretion. Treatment will involve 3 vaccinations every 2 weeks. Participants enrolled in the Pembrolizumab cohort will be enrolled at the proper Optimal Immunologic Dose as defined by the TNBC and preventative cohorts and based on information available at the time of study entry.~DL1: 10 mcg a-lactalbumin + 10 mcg Zymosan Original DL2:100 mcg a-lactalbumin + 100 mcg Zyomsan DL2: 100 mcg a-lactalbumin + 10 mcg Zyomsan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL1b: 50 mcg a-lactalbumin + 10 mcg Zymosan DL1e: 10 mcg a-lactalbumin + 20 mcg Zymosan DL1f: 20 mcg a-lactalbumin + 10 mcg Zymosan DL1g: 20 mcg a-lactalbumin + 10 mcg Zymosan (if DL1e is too toxic)"
62684464|NCT06407427|EXPERIMENTAL|Enhanced Care|Post-operative usual care where patients will receive standard care plus the use of a tool.
62684465|NCT06407427|ACTIVE_COMPARATOR|Usual Care|Post-operative usual care where patients will receive standard care alone.
61923759|NCT05049733|EXPERIMENTAL|Arm 2|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 2 mg/kg and then switch to other doses after washout periods.
62314016|NCT04494009|EXPERIMENTAL|INCMGA00012 군|INCMGA00012 500 mg iv every 4 weeks for up to 12 months
62314017|NCT04494009|NO_INTERVENTION|Observation arm|followed up every 12 weeks for up to 12 months
62314018|NCT06519877|EXPERIMENTAL|Group 1|Soluble corn fiber 20g/day x 4 weeks, washout period for 4 weeks, and placebo (maltodextrin) x 4 weeks.
62314019|NCT06519877|EXPERIMENTAL|Group 2|Placebo (maltodextrin) 20g/day x 4 weeks, washout period for 4 weeks, and soluble corn fiber x 4 weeks.
61923760|NCT05049733|EXPERIMENTAL|Arm 3|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 4 mg/kg and then switch to other doses after washout periods.
61923761|NCT05049733|PLACEBO_COMPARATOR|Arm 4|Participants will begin with ingestion of placebo soft gel tablets that do not contain cannabinoids and then switch to other doses after washout periods.
61923762|NCT03663153||SEMA4C high value follow-up group|Postoperative SEMA4C value is higher than 5.00 ng/ml.
61923763|NCT03663153||SEMA4C low value follow-up group|Postoperative SEMA4C value is lower than 5.00 ng/ml.
61923764|NCT04590079|EXPERIMENTAL|First intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment and daily sessions with the medical device - 1 month of wash-out - 3 months of conventional pain treatment.
62314020|NCT05414123||Breast Cancer|Subjects with Breast Cancer of all subtypes and independent of Hormone status who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
62314021|NCT05414123||Non-Small Cell Lung Cancer|Subjects with Non-Small Cell Lung Cancer of all subtypes who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
62314022|NCT01184989|OTHER|Dabigatran etexilate|open label, once daily dose approved by EMEA and Health Canada
62314023|NCT03109951|OTHER|Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
62684466|NCT06308965|ACTIVE_COMPARATOR|Sacrificing vessels|
62684467|NCT06308965|EXPERIMENTAL|Sparing vessels|
62684468|NCT03555994|EXPERIMENTAL|MEDI0382 (Part A)|MEDI0382 administered subcutaneously (Part A)
62684469|NCT03555994|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo comparator administered subcutaneously (Part A)
62684470|NCT03555994|ACTIVE_COMPARATOR|Liraglutide (Part B)|Active comparator administered subcutaneously (Part B)
62684471|NCT03555994|EXPERIMENTAL|MEDI0382 (Part B)|MEDI0382 administered subcutaneously (Part B)
62684472|NCT03555994|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo comparator administered subcutaneously (Part B)
62124096|NCT05493254|ACTIVE_COMPARATOR|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
62124097|NCT04187664|EXPERIMENTAL|EXCARE Pathway Group|The proposed pathway comprises a range of actions that include individual patient-centered risk assessment by the SAMPE Risk Model (30-day probability of death), specialized care in Post-Anesthetic and Intensive Care Units, and also in the surgical wards performed by the nursing, anesthesia, clinic and surgery teams.
62478268|NCT01043952|ACTIVE_COMPARATOR|Control|"Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
62684473|NCT00600704|ACTIVE_COMPARATOR|RESTRICTED FLUIDS|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass
62684474|NCT00600704|ACTIVE_COMPARATOR|FREE FLUIDS|Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
62124098|NCT05688644||Neurogenic Patients|Patients with underlined relevant neurologic condition, with either neurogenic bladder or bowel, after advanced evaluation of InterStim II
62124099|NCT05688644||Idiopathic|Patients without underlined relevant neurologic condition, after advanced evaluation of InterStim II
62124100|NCT06013072|EXPERIMENTAL|Pre-probiotic|One sachet per day during breakfast
62684475|NCT01994005|PLACEBO_COMPARATOR|Standard + Pamphlet|Subjects receiving standard counseling + ACOG pamphlets
62684476|NCT01994005|ACTIVE_COMPARATOR|Group 2: standard + facebook|Subjects receiving standard counseling + facebook education Intervention is 30 mins of use of facebook page
62684477|NCT03150641|OTHER|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
62684478|NCT03150641|EXPERIMENTAL|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
62684479|NCT00892450|EXPERIMENTAL|Arm 1|crossover design
62684480|NCT02481141|ACTIVE_COMPARATOR|5-ALA-SFC|"Study product administration will be as follows:~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
62124101|NCT06013072|PLACEBO_COMPARATOR|Placebo|One sachet per day during breakfast
62124102|NCT03926442|EXPERIMENTAL|Active1|Italian Herb in active breakfast meal
62124103|NCT03926442|EXPERIMENTAL|Active2|Cinnamon in active breakfast meal
62124104|NCT03926442|EXPERIMENTAL|Active3|Pumpkin Spice Mix in active breakfast meal
62684481|NCT02481141|PLACEBO_COMPARATOR|Placebo|"Study matching placebo administration will be as follows:~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
62478269|NCT01043952|EXPERIMENTAL|Bispectral Index Monitor|"Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
62478270|NCT00926887|SHAM_COMPARATOR|Placebo Laser|Placebo Laser is an inactive light
62478271|NCT00926887|ACTIVE_COMPARATOR|Erchonia EML Laser|Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.
62684482|NCT02970812|EXPERIMENTAL|Electrical Muscle Stimulation|Electrical Muscle Stimulation (EMS) program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
61923765|NCT04590079|EXPERIMENTAL|Second intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment - 1 month of wash-out - 3 months of conventional pain treatment and daily sessions with the medical device.
62124105|NCT03926442|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Breakfast
62124106|NCT03009305|EXPERIMENTAL|Lower body negative pressure|Single-arm, lower body negative pressure, continuous positive airway pressure, positive expiratory pressure.
62314024|NCT03345212|NO_INTERVENTION|Control group|Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
62314025|NCT03345212|EXPERIMENTAL|Training group|"Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.~Patients will be informed about group allocation."
62314026|NCT05963698|EXPERIMENTAL|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
62314027|NCT05963698|NO_INTERVENTION|Standard Care|Participants will receive local, standard medical care
62314028|NCT05974189||HFrEF patients treated with at least one GDMT and with vericiguat|"This study will use anonymized real-world data from HealthVerity closed Medical and Pharmacy Claims.~Adult patients with a diagnosis of HFrEF and received vericiguat added to at least one guideline directed medical therapy (GDMT), from January 1, 2021 through June 30, 2023 will be included in this retrospective cohort analysis."
62314029|NCT05974189||HFrEF patients treated with at least one GDMT, without vericiguat|"This study will use anonymized real-world data from HealthVerity closed Medical and Pharmacy Claims.~Adult patients with a diagnosis of HFrEF and received at least one GDMT (without vericiguat), from January 1, 2021 through June 30, 2023 will be included in this retrospective cohort analysis."
62314030|NCT01663740|EXPERIMENTAL|Cohort A: Partcipants who Received Valganciclovir|Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
62478272|NCT01220635|EXPERIMENTAL|Skill Group Program|Positive Thoughts and Actions Program
62478273|NCT01220635|ACTIVE_COMPARATOR|Individual Support Program|Measure of Adolescent Potential for Suicide (MAPS) - modified
62478274|NCT00256230|EXPERIMENTAL|Disulfiram|
62478275|NCT05344053|EXPERIMENTAL|Community-based precise management|
62478276|NCT05344053|ACTIVE_COMPARATOR|Standard community-based management|
62684483|NCT02970812|PLACEBO_COMPARATOR|Transcutaneous Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
62124107|NCT05619861|EXPERIMENTAL|CAR-T|Autologous CAR-T cells, intravenous infusion, infusion dose 0.1-3 × 106CAR-T cells/kg
62314031|NCT01663740|NO_INTERVENTION|Cohort B: Untreated Participants|Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.
62314032|NCT03348631|EXPERIMENTAL|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans and MRI on study.
62314033|NCT05592223|ACTIVE_COMPARATOR|BCG Challenged-Isoniazid Treated|Will receive INH in the dose of 300 mg for three days post BCG injection.
62314034|NCT05592223|PLACEBO_COMPARATOR|BCG Challenged-Isoniazid Untreated|Will not receive any INH or RIF dose.
62314035|NCT05592223|ACTIVE_COMPARATOR|BCG Challenged-RIF Treated|Will receive RIF in the dose of 600 mg for seven days post BCG injection.
62314036|NCT05808088|EXPERIMENTAL|Group 1, sound-files from inclusion|
62314037|NCT05808088|ACTIVE_COMPARATOR|Group 2, sound-files after 7 days|
62478277|NCT06012435|EXPERIMENTAL|Experimental Arm|sigvotatug vedotin monotherapy
62478278|NCT06012435|ACTIVE_COMPARATOR|Control Arm|Docetaxel monotherapy
62478279|NCT01055795|EXPERIMENTAL|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds"
62478280|NCT04247945|NO_INTERVENTION|HSC|
62478281|NCT04247945|EXPERIMENTAL|MSC+HSC|
62478282|NCT04823169|EXPERIMENTAL|podobarometry|podobarometric measures at day7 and day 30
62478283|NCT03016650|ACTIVE_COMPARATOR|Paracetamol|Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
62478284|NCT03016650|ACTIVE_COMPARATOR|ibuprofen|Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
62684484|NCT06552130|EXPERIMENTAL|Intranasal insulin spray|160 Units of human insulin as nasal spray
62478285|NCT06163989|EXPERIMENTAL|TheaLoz Duo in first month, crossover to control condition in second month|The TheaLoz Duo eyedrop will be prescribed and used by the participant for 1 month. At the second visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle, and no eyedrops will be prescribed, and the participant monitored following 1 month. At the third and final visit 1 month later, the participant will return for a follow-up visit.
62684485|NCT06552130|PLACEBO_COMPARATOR|Placebo spray|Nasal spray containing placebo solution
62684486|NCT05715281|EXPERIMENTAL|Treatment (atezolizumab, tiragolumab)|Patients receive atezolizumab IV over 60 minutes and tiragolumab IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO at baseline, undergo biopsy at baseline and on study, and undergo CT and collection of blood samples throughout the study.
61923766|NCT04733443|EXPERIMENTAL|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 /45mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
61923767|NCT04733443|ACTIVE_COMPARATOR|SeQuent® Please Neo|paclitaxel released coronary balloon catheters Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
62124108|NCT02278627|EXPERIMENTAL|manual lymphatic drainage|We wish to complete the physiotherapist's support with manual lymphatic drainage (MLD) using a specific method based on pressure of finger splayed (PFS)
62314038|NCT00863629|NO_INTERVENTION|1|25 normoglycemic patients as control group
61923768|NCT01451268|EXPERIMENTAL|Panobinostat Arm A|
61923769|NCT01451268|EXPERIMENTAL|Panobinostat Arm B|
61923770|NCT00436930|EXPERIMENTAL|Arm I|Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
61923771|NCT00436930|EXPERIMENTAL|Arm II|Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
61923772|NCT00505882|ACTIVE_COMPARATOR|Insulin|
62314039|NCT00863629|ACTIVE_COMPARATOR|2|20 hyperglycemic patients (glucose \>140 mg/dl) randomized to conventional glycemic control by insulin (CGC group; glucose goal 180-200 mg/dl)
62314040|NCT00863629|EXPERIMENTAL|3|20 hyperglycemic patients (glucose \>140 mg/dl) were randomized to intensive glycemic control by insunin (IGC group; glucose goal 80-140 mg/dl)
62684487|NCT06687070|EXPERIMENTAL|APG -2449 Monotherapy|Part A: Monotherapy for advanced solid tumors.
62684488|NCT06687070|EXPERIMENTAL|APG -2449 combined with PLD|Part B: Dose exploration and expansion of APG-2449 combined PLD.
62684489|NCT01807741|EXPERIMENTAL|Asenapine Group|Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.
62684490|NCT01807741|ACTIVE_COMPARATOR|Placebo Group|Sublingual tablets similar to the asenapine tablets.
62684491|NCT06537180||The Female Group|Patients are categorized as females according to their apparent gender.
61923773|NCT00505882|EXPERIMENTAL|Pramlintide|
61923774|NCT01709578|PLACEBO_COMPARATOR|Placebo q2w|Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
62124109|NCT02278627|NO_INTERVENTION|Usual treatment|
62124110|NCT06426823|PLACEBO_COMPARATOR|Saline and oral water (SAL-WAT)|Saline infusion, oral water ingestion
62124111|NCT06426823|ACTIVE_COMPARATOR|Saline infusion and oral glucose ingestion (SAL-GLU)|Saline infusion, oral glucose ingestion
62124112|NCT06426823|EXPERIMENTAL|GIP(3-30)NH2 infusion and oral water ingestion (GIA-WAT)|GIPR antagonist infusion, oral water ingestion
62124113|NCT06426823|EXPERIMENTAL|GIP(3-30)NH2 infusion and oral glucose ingestion (GIA-GLU)|GIPR antagonist infusion, oral glucose ingestion
62124114|NCT00915239|ACTIVE_COMPARATOR|Pantoprazole|
62478286|NCT06163989|ACTIVE_COMPARATOR|Control condition in first month, crossover to TheaLoz Duo in second month|No eyedrops will be prescribed and the participant monitored for 1 month. At the second visit 1 month later, the participant will return and be prescribed TheaLoz Duo eyedrop and used by the participant for another 1 month. At the third and final visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle and complete the study visits.
62478287|NCT04723134|ACTIVE_COMPARATOR|Folic Acid Wound Treatment|Intervention - participants receiving 2.5% folinic acid wound treatment for daily treatment of chronic early stage diabetic foot ulcer wound. This will be applied daily to the study wound selected for monitoring.
62684492|NCT06537180||The Male Group|Patients are categorized as males according to their apparent gender.
62684493|NCT02365688|OTHER|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
62684494|NCT04634136|ACTIVE_COMPARATOR|Active Substance: Full-spectrum Medical Canabis Product (HemPhar)|For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.
62684495|NCT04634136|PLACEBO_COMPARATOR|Placebo|For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.
62314041|NCT02350829|ACTIVE_COMPARATOR|Cardiomyopathy|"Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy~Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
62684496|NCT05891782|EXPERIMENTAL|Intervention group|A HAPA-based multicomponent fall intervention will use group education, individualized plans and face-to-face interviews to develop health behaviors, such as fall emergency management, IC enhancement (exercise management, diet management, cognitive improvement, psychological regulation, vision protection), medication and disease management, environmental improvement, and fall self-efficacy enhancement.
62684497|NCT05891782|EXPERIMENTAL|Control Group|The control group will receive the same overall duration and frequency of interventions as the intervention group.
62684498|NCT02922712|EXPERIMENTAL|NISE 100mg|Nise 100mg given BD for 3 weeks
62684499|NCT06483217|NO_INTERVENTION|Standard of care|Standard 6 month post-operative follow up interval for repeat injection
62684500|NCT06483217|EXPERIMENTAL|Patient-directed follow up|Post-operative follow up interval for repeat injection decided by patient based on OAB symptomatology (3-12 months)
62697373|NCT05962736|NO_INTERVENTION|Control group|The control group consisted of patients who underwent thoracotomy and underwent routine rehabilitation in the post-surgical period. routine respiratory rehabilitation program; It consists of a) positioning, b) general body exercises, c) airway clearance techniques, d) breathing exercises, e) incentive spirometry and f) mobilization applications.
62124115|NCT00915239|PLACEBO_COMPARATOR|Placebo|
62314042|NCT02350829|ACTIVE_COMPARATOR|Congenital Heart Disease|"Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan~Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
62314043|NCT02350829|ACTIVE_COMPARATOR|Controls|Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
62478288|NCT04723134|PLACEBO_COMPARATOR|Placebo|Intervention - participants receiving Placebo (PluroGel Burn and Wound Dressing) for daily treatment of chronic early stage diabetic foot ulcer wound. This will be applied daily to the study wound selected for monitoring.
62478289|NCT05840796|EXPERIMENTAL|soy protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day."
62697374|NCT05962736|EXPERIMENTAL|Study group|The study group consisted of patients who would receive mirror therapy in addition to the routine rehabilitation program described above and applied to the control group in the post-thoracotomy period.
61923775|NCT01709578|EXPERIMENTAL|Sarilumab 150 mg q2w|Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
62478290|NCT05840796|OTHER|casein protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day."
62684501|NCT05965479|EXPERIMENTAL|Trastuzumab deruxtecan|"Participants in the study will be treated with trastuzumab deruxtecan at a dose of 6.4 mg/kg intravenously every 21 days for 8 cycles. If required, patients may dose reduce to level -1 or level -2:~* Dose level 0 is 6.4 mg/kg intravenously every 21 days~* Dose level -1 is 5.4 mg/kg intravenously every 21 days~* Dose level -2 is 4.4 mg/kg intravenously every 21 days~T-DXd will be administered using an IV bag containing 5% (w/v) Dextrose Injection infusion solution and delivered through an IV administration set with a 0.2 or 0.22 μm filter. The standard infusion time for T-DXd is approximately 90 minutes +/- 10 minutes for the first infusion. If the first infusion is well tolerated and the participant does not experience an infusion-related reaction, then the minimum infusion time for subsequent cycles is 30 minutes. However, if there are interruptions during the infusion, the total time must not exceed 3 hours at room temperature."
62684502|NCT03622515|EXPERIMENTAL|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
62684503|NCT03622515|NO_INTERVENTION|Group C|Bispectral index (BIS)/Sedline monitoring
62684504|NCT04473937|EXPERIMENTAL|Radiotherapy|"Participants must have received CAR-T infusion within the last 90 days prior to completing a study screening and enrollment process.~* Participants will be enrolled within 28 days after screening is complete and radiotherapy will occur within 14 days after study enrollment.~* Radiotherapy will be administered based on a dose and schedule pre-determined by the study doctor."
62684505|NCT04717739||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
62684506|NCT05795660|EXPERIMENTAL|Osteochondral lesions of the talus group|Patients will receive PRP injection.
62684507|NCT05795660|PLACEBO_COMPARATOR|Control group|Patients will receive saline injection.
62314044|NCT06068725|NO_INTERVENTION|No invention: Control Group|Data collection tools were applied to individuals in the control group on day 0 (Z0), day 30 (Z1) and day 90 (Z2) of follow-up. Data collection tools applied to the control group are as follows: Patient Introduction Form, Heart Failure Symptom Status Scale, Minnesota Living with Heart Failure Questionnaire,Michel Uncertainty in Illness Scale - Community Form.
62314045|NCT06068725|EXPERIMENTAL|Experimental: application group|Two 15-minute training videos (30 minutes in total) prepared for symptom management will be shared on the phones of the patients/relatives in the application group and the patients and their relatives will be informed by watching the training video.Data collection tools were applied to individuals in the application group on day 0 (Z0), day 30 (Z1) and day 90 (Z2) of follow-up. Data collection tools applied to the application group are as follows: Patient Introduction Form, Heart Failure Symptom Status Scale, Minnesota Living with Heart Failure Questionnaire,Michel Uncertainty in Illness Scale - Community Form.
62314046|NCT01277289|EXPERIMENTAL|Ery-dex|Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
62314047|NCT01277289|PLACEBO_COMPARATOR|Placebo|placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
62314048|NCT04988126||Patient Group|Patient with Covid 19 Pneumonia
62314049|NCT04913324|EXPERIMENTAL|Virtual Care|
62314050|NCT04913324|NO_INTERVENTION|Standard of Care|
62314051|NCT02077322|EXPERIMENTAL|Silastic Spacer|This study arm receives the experimental treatment, a Silastic spacer.
62314052|NCT02077322|ACTIVE_COMPARATOR|Merocel Spacer|Merocel spacers are actively being used as the standard of care.
62478291|NCT00247195|EXPERIMENTAL|Culturally congruent assessment and treatment|Outreach by phone to primary care patients interested in mental health referral. Engagement and evaluation approach conducted using the DSM-IV cultural formulation model. Same treatment choices as in control arm (medication, interpersonal psychotherapy, and combination treatment).
62478292|NCT00247195|ACTIVE_COMPARATOR|Usual referral and treatment|Usual referral procedure from primary care: PC clinician gives patient information on how to access mental health care at research site. Usual engagement and evaluation approach without using cultural formulation model. Same treatment choices (medication, interpersonal psychotherapy, and combination treatment) as in experimental arm.
62684508|NCT06034431|EXPERIMENTAL|Ride Share Participants|"Investigators will recruit Black men with intermediate or high-risk PC who are seeking definitive treatment at Mass General Brigham Prostate Cancer Outreach Clinic, as Black men are more likely to report travel burden when accessing care and, therefore, most likely to benefit from ridesharing services.~Investigators will implement a pre/post-evaluation design with matched historical controls to estimate the impact of rideshares on reducing missed appointments. Historical controls will be sampled from the pre-intervention period of April 2022 to September 2024 and the post-intervention period between October 2024 and November 2025, where October 2024 represents the initiation of the intervention. Participants who identify as Black, reside in a census tract in Massachusetts, and have been recognized as having a high travel burden based on results from Aim 1 will be eligible to receive the rideshare intervention"
62684509|NCT06521736|EXPERIMENTAL|Testing commercial readiness of an AAC-BCI device|Participants with severe movement disabilities will use the augmentative and alternative communication, brain-computer interface (AAC-BCI) device at least 10 hours a week in their homes receiving supported from a caregiver, speech language pathologist and consultant and rate the intervention on user satisfaction, performance, reliability, comfort and overall readiness for commercialization.
61923776|NCT01709578|EXPERIMENTAL|Sarilumab 200 mg q2w|Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
61923777|NCT05198700|EXPERIMENTAL|Experimental Group|Participants in this group will be randomized to receive the probiotic formulation for 4 weeks.
61923778|NCT05198700|PLACEBO_COMPARATOR|Control Group|Participants in this group will be randomized to receive the placebo for 4 weeks.
61923779|NCT01397318||Experimental Group|
61923780|NCT01397318||Control Group|
61923781|NCT01221038||group 1|young women not using OC
61923782|NCT01221038||group 2|young women using OC
62124116|NCT03194958|NO_INTERVENTION|Standard Quitline|Participants will receive standard Missouri quitline services
62124117|NCT03194958|EXPERIMENTAL|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
62124118|NCT03194958|EXPERIMENTAL|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
62124119|NCT03194958|EXPERIMENTAL|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
62124120|NCT01231568|EXPERIMENTAL|Cohort 1 Treatment Sequence 1|Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
62684510|NCT04839926|EXPERIMENTAL|0.5mg CY150112|single oral CY150112 while fasting on day 1.
62124121|NCT01231568|EXPERIMENTAL|Cohort 1 Treatment Sequence 2|Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
62124122|NCT01231568|EXPERIMENTAL|Cohort 2 Treatment Sequence 1|Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
62478293|NCT02149420|EXPERIMENTAL|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
61923783|NCT01221038||group 3|young men (database)
61923784|NCT04415060|EXPERIMENTAL|Inhaled - volatile anesthetic|The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
61923785|NCT04415060|NO_INTERVENTION|Standard Care|The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
61923786|NCT04415060|NO_INTERVENTION|Non-randomized|In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
62478294|NCT02149420|EXPERIMENTAL|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg
62478295|NCT02149420|PLACEBO_COMPARATOR|Placebo|single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
62478296|NCT05630586|ACTIVE_COMPARATOR|Semaglutide 0.5 mg|"Inj. Semaglutide 0.5 mg s.c., 0.5 mg per week for 4 weeks~+ standard care"
62478297|NCT05630586|OTHER|Control|Standard care
62478298|NCT06350955|EXPERIMENTAL|Patients with Roux-en-Y gastric bypass and iron deficiency 1|
62478299|NCT06350955|EXPERIMENTAL|Patients with Roux-en-Y gastric bypass and iron deficiency 2|
62478300|NCT02903407|ACTIVE_COMPARATOR|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
62478301|NCT02903407|ACTIVE_COMPARATOR|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
62478302|NCT02572713||Early PD|20 early PD not requiring dopamine replacement therapy have been enrolled.
62684511|NCT04839926|EXPERIMENTAL|1.5mg CY150112|single oral CY150112 while fasting on day 1.
62684512|NCT04839926|EXPERIMENTAL|4.5mg CY150112|single oral CY150112 while fasting on day 1.
62478303|NCT02572713||Moderate PD|20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.
62478304|NCT02572713||Advanced PD|21 advanced PD with motor fluctuations have been enrolled.
62684513|NCT04839926|EXPERIMENTAL|10mg CY150112|single oral CY150112 while fasting on day 1.
62478305|NCT02572713||Healthy Controls|21 healthy controls have been enrolled.
62478306|NCT05400694|EXPERIMENTAL|Chocolate milk|Chocolate milk with reduced added sugar
62478307|NCT05400694|EXPERIMENTAL|Chocolate milk with whey protein|Chocolate milk with reduced added sugar and added whey protein
62478308|NCT05400694|EXPERIMENTAL|Chocolate milk with casein|Chocolate milk with reduced added sugar and added casein
62684514|NCT04839926|EXPERIMENTAL|18mg CY150112|single oral CY150112 while fasting on day 1.
62684515|NCT04839926|EXPERIMENTAL|24mg CY150112|single oral CY150112 while fasting on day 1.
62684516|NCT04535661||non CRE|Children with a negative culture for CRE during their stay in PICU are defined as non CRE.
62684517|NCT04535661||CRE colonization|Children who have a positive culture for CRE during their stay in PICU but lack of clinical symptoms are defined as CRE colonization.
62684518|NCT04535661||CRE infection|Children who have a positive culture for CRE during their stay in PICU combined with clinical symptoms are defined as CRE infection.
62124123|NCT01231568|EXPERIMENTAL|Cohort 2 Treatment Sequence 2|Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
62124124|NCT03830658|EXPERIMENTAL|Structured Intervention on Self-care with AVF|The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.
62124125|NCT03830658|ACTIVE_COMPARATOR|Usual-Care Control|Educational training was given during HD sessions. The dialysis nurse provided information about arteriovenous fistula care and trained the patient when he/she felt it was required. The dialysis units had no documentation concerning the educational training given to patients and the moment to provide such information was not defined, either.
62124126|NCT02600520|ACTIVE_COMPARATOR|Rosuvastatin Group|SRP followed by RSV gel LDD
62478309|NCT05400694|EXPERIMENTAL|Chocolate milk with alpha-lactalbumin|Chocolate milk with reduced added sugar and added alpha-lactalbumin
62478310|NCT05400694|EXPERIMENTAL|Chocolate milk with glycomacropeptide|Chocolate milk with reduced added sugar and added glycomacropeptide
62684519|NCT05669352|EXPERIMENTAL|CA-4948 and Pembrolizumab|
62684520|NCT04314973|ACTIVE_COMPARATOR|Evaluation sessions|Patients will be evaluated while walking without wearing the robotic device, once before the intervention phase, once right after, and once a month after.
62684521|NCT04314973|EXPERIMENTAL|Intervention phase|Patients will walk with the robotic device, for 12 sessions of 10 min.
62684522|NCT05106374||Observational (questionnaire, assessment, biospecimen)|Patients complete questionnaires over 30-40 minutes about daily activity and feelings, complete thinking and walking tests over 10 minutes, and undergo collection of blood samples before the first dose of chemotherapy and 90, 180, and 365 days after first dose of chemotherapy. Patients with non-small lung cancer also undergo collection of stool sample.
62684523|NCT06630390|EXPERIMENTAL|Daridorexant|Oral daridorexant 50 mg (or 25 mg, if taking a moderate 3A4 inhibitor) each of the first three nights after heart surgery.
62684524|NCT06630390|PLACEBO_COMPARATOR|Placebo|Oral matching placebo each of the first three nights after heart surgery.
62684525|NCT05168592|EXPERIMENTAL|Imaginal extinction|Conditioned fear will be diminished using imaginal extinction.
62684526|NCT05125172|ACTIVE_COMPARATOR|Internal focus of attention group|"Participants will be given instructions that make them think about their body's movements.~Participants will complete the external focus group second in the cross over."
62684527|NCT05125172|EXPERIMENTAL|External focus of attention group|"Participants will be given instructions that make them think about an outside target or outcome.~Participants will complete the internal focus group second in the cross over."
62684528|NCT01518036|EXPERIMENTAL|Low dose|
62684529|NCT01518036|EXPERIMENTAL|High dose|
62684530|NCT05381753||Ava-mGSIT-P18|Unresectable or metastatic PDGFRA exon 18 GIST
62684531|NCT05381753||Ava-Perioperative|Perioperative PDGFRA exon 18 GIST
62684532|NCT05381753||Ava-mGIST-other|Unresectable or metastatic GIST without KIT exon 13，14，or PDGFRA exon 18 mutation
62684533|NCT05381753||TKI|Unresectable or metastatic PDGFRA exon 18 GIST
62684534|NCT06517511|EXPERIMENTAL|Selinexor in combination with R-CHOP|"Patients with TP53-mutated diffuse large B-cell lymphoma will receive selinexor in combination with R-CHOP regimen from the second cycle of R-CHOP (3 weeks per cycle).~After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted."
62684535|NCT06688695|NO_INTERVENTION|Controll group|Standard care
62684536|NCT06688695|OTHER|INSPIRE-intervention|Intervention group, recieving the INSPIRE-intervention
62124127|NCT02600520|ACTIVE_COMPARATOR|Atorvastatin Group|SRP followed by ATV gel LDD
62124128|NCT02600520|PLACEBO_COMPARATOR|Placebo group|SRP followed by placebo gel LDD
62478311|NCT04275479||SDS - without Diabetes diagnosis|SDS - without Diabetes diagnosis
62684537|NCT01414647|EXPERIMENTAL|SRC|Strawberry, raspberry and cloudberry intervention for 8 weeks
62684538|NCT01414647|EXPERIMENTAL|BB|Bilberry intervention for 8 weeks
61923787|NCT04735718|EXPERIMENTAL|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. The main objectives and clinical endpoints are the performance and the safety profile of the investigational device.
61923788|NCT06017544||T2DM patients with GLP-1 RA|T2DM patients hospitalized due to AMI as a primary diagnosis, both STEMI and NSTEMI, referred for PCI, and under GLP-1 RA.
62684539|NCT01414647|EXPERIMENTAL|C|Control diet with restricted berry consumption
62684540|NCT05148663||blood drawing and hemorrhagic events in CCM patients|planned for three blood drawing before surgery
62684541|NCT05148663||blood drawing for age/gender/ethnicity matched controls|Blood draw from Control patients with no inflammation
62684542|NCT03258229|EXPERIMENTAL|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
62684543|NCT03258229|PLACEBO_COMPARATOR|Placebo|Placebo for 8 weeks
62684544|NCT04957082|ACTIVE_COMPARATOR|White Flint Registry: General|"White participants receive general consumption video information about SARS-CoV-2 antibody testing."
62684545|NCT04957082|ACTIVE_COMPARATOR|African American Registry: General|"African American participants receive general consumption video information about SARS-CoV-2 antibody testing."
62684546|NCT04957082|EXPERIMENTAL|African American Registry: Culturally Targeted|African American participants receive culturally targeted video information about SARS-CoV-2 antibody testing.
62684547|NCT06500689|EXPERIMENTAL|Allisartan Isoproxil/Sustained-Release Indapamide Group|Patients will be treated with one Allisartan Isoproxil/Sustained-Release Indapamide (240 mg/1.5 mg) tablet and one placebo of Allisartan Isoproxil during the double-blind period (Week 1\~Week 12) and one Allisartan Isoproxil/Sustained-Release Indapamide (240 mg/1.5 mg) tablet during the open-label period (Week 13\~Week 52) once daily.
62684548|NCT06500689|ACTIVE_COMPARATOR|Allisartan Isoproxil Group|Patients will be treated with one Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Sustained-Release Indapamide (240 mg/1.5 mg) tablet during the double-blind period (Week 1\~Week 12) and one Allisartan Isoproxil/Sustained-Release Indapamide (240 mg/1.5 mg) tablet during the open-label period (Week 13\~Week 52) once daily.
62684549|NCT06670313|ACTIVE_COMPARATOR|Preop Erector spinae plane block|Patients who underwent erector spinae block before surgery
62684550|NCT06670313|ACTIVE_COMPARATOR|postop Erector spinae plane block|Patients who underwent erector spinae block without waking the patient at the end of surgery
62684551|NCT02301793|EXPERIMENTAL|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.~Intervention: Nurse education in contemporary format"
62124129|NCT02487927||Weaning success|patients pass SBT and weaning without any ventilation in 48 hours
62478312|NCT04275479||SDS with Diabetes Diagnosis|SDS with Diabetes Diagnosis
62478313|NCT04275479||Cystic Fibrosis (CF) patients data & lab results|De-identified data from age matched population norms, CF patients associated pancreatic insufficiency known or treated diabetes
62124130|NCT02487927||weaning failure|patients do not pass SBT or ventilation with any ventilation in 48 hours
62124131|NCT05623553|EXPERIMENTAL|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns, independent of skin color, using Picterus JP.
62124132|NCT00906529|ACTIVE_COMPARATOR|Conservative Blood Glucose Control|Goal Pre-prandial blood glucose \<180 mg/dl.
61923789|NCT06017544||T2DM patients with SGLT2-is|T2DM patients hospitalized due to AMI as a primary diagnosis, both STEMI and NSTEMI, referred for PCI, and under SGLT2-is.
62124133|NCT00906529|ACTIVE_COMPARATOR|Aggressive Blood Glucose Control|Pre-prandial goal blood glucose \<110 mg/dl
62124134|NCT02634541|ACTIVE_COMPARATOR|DMARD-naive|Sulfasalazine will be given as the initial therapy.
62124135|NCT02634541|EXPERIMENTAL|Post-sulfasalazine|Sulfasalazine contraindicated or not efficient, adalimumab will be given as the initial therapy.
62124136|NCT04947072|EXPERIMENTAL|Erector Spinae Plane Block|Patient will receive single-shot ultrasound-guided erector spinae plane block at the level of T9 on the side which will be operated on.
62124137|NCT04947072|ACTIVE_COMPARATOR|Spinal Anesthesia|Patient will receive spinal anesthesia at the level of L3-L4 or L4-L5
62124138|NCT04734132|EXPERIMENTAL|Moringa|Six Moringa oleifera capsules (400 mg dry leaf powder /capsule) consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
62124139|NCT04734132|PLACEBO_COMPARATOR|Placebo|Six placebo capsules containing microcrystalline cellulose consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
62314053|NCT02798081|EXPERIMENTAL|Single arm study|A minimum of 46 elderly, students of a informatics course, will participate in the study. Initially, the students will have 8 usual informatics classes in the institution where they were enrolled spontaneously. Then, during the next 8 classes (from class 9 to class 16) they will practice 10 minutes of virtual reality games, as part of the class.
62314054|NCT04583865||teleconsultation|Patient with teleconsultation of pre-anesthesia
62314055|NCT01666873||total knee prosthesis|Patients that undergo a total knee prosthesis.
62478314|NCT05452785|EXPERIMENTAL|DFD-29 under fasting condition|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
62314056|NCT03687177|OTHER|Control group|Nurses from intensive care informed on the prevention of VAP and without visual cue to estimate the angle of elevation of the head of intubated patients
62314057|NCT03687177|OTHER|Experimental group|Nurses from intensive care informed on the prevention of VAP with visual cue to estimate the angle of elevation of the head of intubated patients.
62478315|NCT05452785|EXPERIMENTAL|DFD-29 after high-fat meal|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
62314058|NCT00799097||Endoscopic Sinus Surgery|Subjects who have failed maximum medical management and have elected for endoscopic sinus surgery
61923790|NCT06017544||T2DM patients with GLP-1 RA plus SGLT2-is|T2DM patients hospitalized due to AMI as a primary diagnosis, both STEMI and NSTEMI, referred for PCI, and under GLP-1 RA plus SGLT2-is.
61923791|NCT02821910|EXPERIMENTAL|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
62314059|NCT06487494|EXPERIMENTAL|2-octyl cyanoacrylate glue with four interrupted sutures|In this arm the provider will use 2-octyl cyanoacrylate glue with four interrupted sutures for wound closing following circumcision.
62314060|NCT06487494|ACTIVE_COMPARATOR|Continuous suture|In this arm the provider will use continuous suturing for wound closing following circumcision.
62478316|NCT05452785|ACTIVE_COMPARATOR|Solodyn under fasting condition|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast
62684552|NCT02301793|ACTIVE_COMPARATOR|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.~Intervention: Nurse education in traditional format"
62684553|NCT05159739||Total Joint Arthroplasty (TJA)|Recruitment of families with an increased incidence of TJI with PJI.
62684554|NCT01704573||NMR by abstinence status|"This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2\* nAChR availability using 2-\[18F\]-fluro-3-\[2(S)-2-azethidinylmethoxy\]-pyridine (2-\[18F\]FA) PET imaging.~Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.~All participants who complete both PET scans will also complete an anatomical MRI scan."
62684555|NCT06569966|EXPERIMENTAL|Prehabilitation Group|The contents of the ileostomy were collected and placed in a wide mouth container, mixed with 500mL normal temperature saline, and placed in a funnel with double layer medical gauze. The filtrate of the ileal contents was collected and placed into an enema for use. The catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. The adverse reactions such as abdominal pain, abdominal distension and fever were observed. The number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded.
62684556|NCT06569966|NO_INTERVENTION|Perioperative management group|Perioperative management group
62684557|NCT06196320|EXPERIMENTAL|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg) within 24 hours ± thrombectomy at treating clinician's discretion
62478317|NCT01319162||Women with PCOS|All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
62478318|NCT01319162||Women without PCOS|All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
62478319|NCT02283463|ACTIVE_COMPARATOR|Standard Cervical Tenaculum|Single tooth tenaculum, pierces the tissue of the cervix to allow provider to stabilize and place traction on the cervical cal/uterus
62684558|NCT06196320|ACTIVE_COMPARATOR|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
62684559|NCT06671392|EXPERIMENTAL|DWC202405|
62684560|NCT06671392|EXPERIMENTAL|DWC202405, DWC202314 / DWC202313, DWC202314|
61923792|NCT02821910|EXPERIMENTAL|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
61923793|NCT02821910|EXPERIMENTAL|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
61923794|NCT04205097|PLACEBO_COMPARATOR|Moderate NMB group|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
62478320|NCT02283463|EXPERIMENTAL|Bioceptive Cervical Retraction Device|Suction based method for stabilizing the cervix and uterus. Achieves suction 360 degrees around cervical os creating a portal through which instruments can be passed into the cervical canal and uterus. Provider can still place traction on uterus with this device just as with tenaculum.
62684561|NCT06671392|PLACEBO_COMPARATOR|DWC202405, DWC202314P / DWC202313, DWC202314P|
62684562|NCT03884920||Group A Pre-diabetic placebo|Group of pre-diabetics receiving placebo BD for six weeks
62684563|NCT03884920||Group B Pre-diabetic test|Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks
61923795|NCT04205097|EXPERIMENTAL|Deep NMB group|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2\~4 mg/kg
62124140|NCT02058017|EXPERIMENTAL|Part I & Part II|"Part I - This is a lead-in dose-finding, open-label, non-randomised arm of the study: Using a starting dose of 10mg per week, an accelerated dose titration escalation followed by a 3+3 design will be employed until MTD and recommended weekly dose are determined.~Part II - This is a single-centre, open-label non-randomised phase II study evaluating OPB-51602 in stage III-IVB NPC conducted in the window period prior to definitive chemoradiotherapy. Eligible patients will receive OPB-51602 on a weekly basis (Day 1, 8, 15) at the recommended dose determined in part I for a total of 15 days prior to definitive chemoradiotherapy."
62124141|NCT02875938|EXPERIMENTAL|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
62478321|NCT06449053|EXPERIMENTAL|TAKE CARE|"* Use of a dedicated e-health application. In order to promote the implementation of DILH prevention measures, we will use an e-health application developed specifically for the study by PRESAGE in the areas where the intervention will take place. This innovative application will be used on admission for all patients included in the acute geriatric sectors in which the intervention will be deployed. It will first assess the risk of DILH individually for each of the 6 risk factors, and then scale the risk for the patient. Once the risk assessment has been carried out, the system will immediately produce a document setting out the personalized care plan for each patient, and disseminate knowledge through documents aimed at patients and caregivers.~* The use of portable, connected treadmills (Ezygain, CE marked)~* The installation of motion detector lighting in hospital rooms"
62478322|NCT06449053|NO_INTERVENTION|CURRENT CARE|soins usuels
62478323|NCT06447948|EXPERIMENTAL|Intervention|"Phase 1 (Acceptability Study) intervention arm. Phase 1 participants (n=10) will test the digital health / falls prevention exercise intervention components (e.g. PA via wearables, digital peer support and home exercise delivered via KOKU App) for 1 month.~Phase 2 (Feasibility Study). Intervention Arm. Phase 2 participants (n=30) will test the optimised digital health / falls prevention exercise intervention components for 6 months."
62684564|NCT03884920||Group C Diabetic test|Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks
62124142|NCT01316263|EXPERIMENTAL|PDGFRα mutation negative|Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
62124143|NCT01316263|EXPERIMENTAL|PDGFRα mutation positive|Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.
62124144|NCT04707729|NO_INTERVENTION|Standard of care|Patients will be intubated according to both the standard of care
62684565|NCT01018771|EXPERIMENTAL|Actifuse ABX|Actifuse ABX bone substitute
62478324|NCT01937143|PLACEBO_COMPARATOR|Control|General information about infant immunizations at birth of a newborn infant
62684566|NCT01018771|ACTIVE_COMPARATOR|INFUSE, plus Mastergraft granules|
62684567|NCT01473784|EXPERIMENTAL|Transoral robotic surgery (TORS)|Patients will undergo TORS for oral and laryngopharyngeal benign and malignant lesions using the Da Vinci Robotic Surgical System. After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
62684568|NCT00395447||Straight-forward Device Replacement|Subject with a straight-forward device replacement without lead revisions or additions.
62684569|NCT00395447||Device Replacement with Upgrade|Subjects with a device replacement and planned lead upgrade, revision, or addition.
62684570|NCT04767646|EXPERIMENTAL|C-BNP with intensive rehabilitation program|
62684571|NCT04560998|EXPERIMENTAL|Semaglutide|Semaglutide given in addition to standard-of-care treatment
62684572|NCT04560998|PLACEBO_COMPARATOR|Placebo (semaglutide)|Placebo given in addition to standard-of-care treatment
62684573|NCT06520553|EXPERIMENTAL|BI 1569912 (C-14) followed by BI 1569912 (C-13)|BI 1569912 (C-14) = \[test treatment, T\] BI 1569912 (C-13) = \[reference treatment, R\]
62684574|NCT02448173|EXPERIMENTAL|OncoVAX and Surgery|Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
62684575|NCT02448173|ACTIVE_COMPARATOR|Surgery|Surgical resection of Stage II colon cancer
62684576|NCT04710303|EXPERIMENTAL|Cohort 1 (n = 10): hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose|hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose on Days 1 and 22
62684577|NCT04710303|EXPERIMENTAL|Cohort 2 (n = 10): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose on Days 1 and 22
62684578|NCT04710303|EXPERIMENTAL|Cohort 3 (n = 10): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose (or 5 × 10e10 VP per dose if safety concerns identified at higher dose) on Day 1
62684579|NCT04710303|EXPERIMENTAL|Cohort 6 (n=10):hAd5-S-Fusion+N-ETSD at 4 × 10e10 VP per dose|hAd5-S-Fusion+N-ETSD at 2 × 10e10 VP per nostril (or 4 × 10e10 VP per dose) on Day 1
62684580|NCT04223687|EXPERIMENTAL|Sugar-Sweetened Beverage Warning Label|
62684581|NCT04223687|OTHER|Neutral label|
62684582|NCT04886063|EXPERIMENTAL|Treatment|Daily subcutaneous (SC) injection of ATH-1017 - 40mg Dosage
62684583|NCT05476848|EXPERIMENTAL|Covid-19 (+) Patients|Oral Examination, Radiography, oral (salivary) swap sample collection will be performed.
62684584|NCT05476848|ACTIVE_COMPARATOR|Healthy Individuals|Oral Examination, Radiography, oral (salivary) swap sample collection will be performed.
62684585|NCT05818007|EXPERIMENTAL|hyaluronic acid|The hyaluronic acid is a natural polysaccharide composed of D-glucuronic acid and N-acetyl-D-glucosamine and is synthesized as a linear polymer. The majority of the cells have a capacity to synthesize HA at a varying extent in the cell cycle.
62684586|NCT05818007|ACTIVE_COMPARATOR|sodium bicarbonate|
62684587|NCT01259531|EXPERIMENTAL|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
62684588|NCT05851365|EXPERIMENTAL|Pre-surgical participants with prostate cancer|The hyperpolarized 13C bicarbonate injection includes the administration of 35 mL injected intravenously (IV) at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second, followed by magnetic resonance (MR) imaging. The intervention will include routine and safety assessments 5 to 9 days after the injection.
62684589|NCT00698412|EXPERIMENTAL|1|Cane group
62684590|NCT00698412|NO_INTERVENTION|2|Control Group
62684591|NCT03428828|EXPERIMENTAL|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
62684592|NCT03428828|ACTIVE_COMPARATOR|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
62684593|NCT05660291|EXPERIMENTAL|Early time-restricted eating|Subjects window for eating would be between 08:00 AM - 4:00 PM
62684594|NCT05660291|EXPERIMENTAL|Late time-restricted eating|Subjects window for eating would be between 12:00 PM (noon) and 8:00 PM
62684595|NCT01154998||Cases|
62684596|NCT01154998||Controls|
62684597|NCT06687369|EXPERIMENTAL|MB12 (Proposed Pembrolizumab Biosimilar)|MB12 (Proposed Pembrolizumab Biosimilar) + Pemetrexed + Carboplatin/ Cisplatin
62684598|NCT06687369|ACTIVE_COMPARATOR|EU- sourced Keytruda®|EU- sourced Keytruda® + Pemetrexed + Carboplatin/ Cisplatin
62684599|NCT06687369|ACTIVE_COMPARATOR|US- sourced Keytruda®|US- sourced Keytruda® + Pemetrexed + Carboplatin/ Cisplatin
62684600|NCT01757496|EXPERIMENTAL|Cough Assist|These children will receive 2 Cough Assist sessions daily.
62684601|NCT01757496|NO_INTERVENTION|Control group|These children receive standard care but no physiotherapy.
62684602|NCT04518943|EXPERIMENTAL|F1M1P1R1|Financial Reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
62684603|NCT04518943|EXPERIMENTAL|N1M1P1R1|Non-financial reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
62684604|NCT04518943|EXPERIMENTAL|N1M1P1R0|Non-financial reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
62684605|NCT04518943|EXPERIMENTAL|N1M1P0R0|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
62684606|NCT04518943|EXPERIMENTAL|N1M1P0R1|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
62684607|NCT04518943|EXPERIMENTAL|N1L1P1R1|Non-financial reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
62684608|NCT04518943|EXPERIMENTAL|N1L1P1R0|Non-financial reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
62684609|NCT04518943|EXPERIMENTAL|N1L1P0R0|Non-financial reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
62684610|NCT04518943|EXPERIMENTAL|N1L1P0R1|Non-financial reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
62684611|NCT04518943|EXPERIMENTAL|F1M1P1R0|Financial Reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
62684612|NCT04518943|EXPERIMENTAL|F1M1P0R0|Financial Reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
62684613|NCT04518943|EXPERIMENTAL|F1M1P0R1|Financial Reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
62684614|NCT04518943|EXPERIMENTAL|F1L1P1R1|Financial Reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
62684615|NCT04518943|EXPERIMENTAL|F1L1P1R0|Financial Reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
62684616|NCT04518943|EXPERIMENTAL|F1L1P0R0|Financial Reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
62478325|NCT01937143|ACTIVE_COMPARATOR|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
62684617|NCT04518943|EXPERIMENTAL|F1L1P0R1|Financial Reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
62684618|NCT04245579|EXPERIMENTAL|Experimental Group|"The experimental group carried out a 30-session multi-factorial group memory training program (UMAM method), with a frequency of three weekly sessions of 90 minutes each. The training program consists of four modules: 1- Stimulation of cognitive processes; learning and practicing internal memory strategies and solving everyday forgetfulness; 2- Instruction in basic concepts about memory; 3- Intervention on daily living and forgetting experiences, using internal and external strategies to solve everyday memory failures; 4- Metacognition or metamemory: the subjects were to reflect about their cognitive failures by analyzing the causes and variables of those failures.~In addition, the experimental group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.)."
62684619|NCT04245579|NO_INTERVENTION|Control Group|The Control Group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.).
62684620|NCT02580006|EXPERIMENTAL|EPORON→EPREX|"EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
62684621|NCT02580006|EXPERIMENTAL|EPREX→EPORON|"EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
61923796|NCT01530347|EXPERIMENTAL|Easy Check versus reference glucometer and blood ketone meter|Collection of paired measurements of capillary blood glucose using reference method (approved glucometer)and blood beta Hydroxybutyrate (approved ketone meter) and data generated by the non invasive study device
62478326|NCT01937143|ACTIVE_COMPARATOR|High intensity intervention|Pamphlet and video with information about pain management during infant immunizations at birth of a newborn infant
62684622|NCT06550310||Medical treatment group|Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) starting a new advanced medical therapy (e.g. biologic or small molecule)
62684623|NCT06550310||Surgical treatment group|Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis or IBD-U) undergoing an IBD-related surgery
62684624|NCT05750004|EXPERIMENTAL|Computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents.
62124145|NCT04707729|EXPERIMENTAL|Standard of care + ROX algorithm|In the intervention arm, patients will be intubated according to both the standard of care and the ROX index, whichever are met first. If the patient has a ROX index below different thresholds after different time-point within the first 12 hours since randomization, the NHF support will be increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. Then, the ROX index will be recalculated in 30 minutes. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done, the ROX index will be recalculated after 30 minutes of full NHF support. Then: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 30 minutes; and 3) if the ΔROX is \>0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.
62124146|NCT03419442||Ra-223 therapy before chemotherapy|Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
62124147|NCT03419442||Ra-223 after chemotherapy|Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
62124148|NCT03812575||Active eosinophilic esophagitis|
62124149|NCT03812575||Eosinophilic esophagitis in remission|
62124150|NCT03812575||No eosinophilic esophagitis|
62684625|NCT02172651|EXPERIMENTAL|Vitamin D3 - Blinded Registration|One capsule of vitamin D3 10,000 IU orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative vitamin D3 for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
62684626|NCT02172651|PLACEBO_COMPARATOR|Placebo - Blinded Registration|One placebo capsule orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative placebo for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
62684627|NCT03138382|EXPERIMENTAL|Treatment then sham|20 subjects will be randomised to first receive active vestibular nerve stimulation during indirect calorimetry. Then 2 weeks later they will return for sham stimulation during indirect calorimetry.
62684628|NCT03138382|EXPERIMENTAL|Sham then treatment|20 subjects will be randomised to first receive sham stimulation during indirect calorimetry. Then 2 weeks later they will return for active vestibular nerve stimulation during indirect calorimetry.
62684629|NCT03594656|EXPERIMENTAL|Early-start Group|Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
62684630|NCT03594656|PLACEBO_COMPARATOR|Delayed-start Group|Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
62684631|NCT01003964|EXPERIMENTAL|GP group|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
62684632|NCT01003964|EXPERIMENTAL|IP group|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
62684633|NCT01443611||Infants with first episode of Febrile Convlusions|
62124151|NCT02576613|EXPERIMENTAL|MPP-S|at least 30 weekly sessions of modified psychodynamic psychotherapy
62124152|NCT02576613|EXPERIMENTAL|standard therapy (TAU)|clinical standard treatment, including supportive therapeutic contacts, pharmacotherapy, creative and occupational therapies, psychoeducation, group therapies, excluding structured individual or group psychotherapy
62124153|NCT01110759||Under Local Infiltration|
62124154|NCT01110759||Under Peripheral Nerve Block|
62124155|NCT04128358|EXPERIMENTAL|Group on high dose dexamethasone, cyclosporin and rituximab|Egyptian patients with idiopathic thrombocytopenic purpura on high dose dexamethasone together with cyclosporine and rituximab.
62684634|NCT02120248|NO_INTERVENTION|Control|Participants receive standard WIC breastfeeding support but do not have contact with a breastfeeding peer counselor
62684635|NCT02120248|OTHER|Low Intensity|Participants will receive four scheduled phone calls from a peer counselor. Two prenatal calls and 2 postpartum.
62684636|NCT02120248|ACTIVE_COMPARATOR|High Intensity|Participants will receive eight scheduled phone contacts from a peer counselor. Two are prenatal and 6 are postpartum.
62684637|NCT01272219|EXPERIMENTAL|Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)|
62684638|NCT01272219|EXPERIMENTAL|Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)|
62684639|NCT01272219|PLACEBO_COMPARATOR|Liraglutide Placebo, no Pre-diabetes|
62684640|NCT01272219|EXPERIMENTAL|Liraglutide 3.0mg, Pre-diabetes|
62684641|NCT01272219|PLACEBO_COMPARATOR|Liraglutide Placebo, Pre-diabetes|
62684642|NCT05430919|EXPERIMENTAL|REGN5713-5714-5715|3-mAb
62684643|NCT05430919|EXPERIMENTAL|REGN5713-5715|2-mAb
62314061|NCT05101291|EXPERIMENTAL|Fractional spinal anaesthesia|"After FIC block or femoral nerve block with ropivacaine 3.5mg/ml 20-40ml. The LiDCOplus was calibrated with 0.3-0.45 mmol lithium based on body weight. After calibration and baseline parameter registration, the LiDCOplus system provided cardiac output variables A dural puncture by a 18G Tuohy needle was performed either between the L2 - L3 or the L3 - L4 interspaces, preferably using a mid-line approach. A catheter 20G was then inserted 4-5 cm into the intrathecal space. A solution (10 ml) of 1.5 mg/ml bupivacaine and 10 µg/ml fentanyl was prepared. Intrathecal anaesthesia was induced by giving 1,5 ml (2.25 mg of bupivacaine and 15 µg of fentanyl) of the solution, followed by a second 1.5 ml injection after 25 min.~MAP was maintained with a norepinephrine to target a MAP \>65mmHg or to avoid a \> 30% decline in MAP from baseline. Invasive haemodynamic parameters were recorded every 5 min for 45 min after initial intrathecal dose was given."
62124156|NCT04128358|ACTIVE_COMPARATOR|Group on steroids only|Egyptian patients with idiopathic thrombocytopenic purpura on parenteral or oral steroids.
62314062|NCT02795767|EXPERIMENTAL|Cohort A: 1.5 mg/kg Emicizumab QW|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
62314063|NCT02795767|EXPERIMENTAL|Cohort B: 3 mg/kg Emicizumab Q2W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
62314064|NCT02795767|EXPERIMENTAL|Cohort C: 6 mg/kg Emicizumab Q4W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
62314065|NCT05335083|NO_INTERVENTION|CPAP off condition|Participants will be monitored for a two-week period prior to commencing CPAP.
62684644|NCT05430919|EXPERIMENTAL|REGN5715|1-mAb
62684645|NCT05430919|PLACEBO_COMPARATOR|Matching Placebo|
62684646|NCT06682832||COPD group|Consisted of 18 individuals over 40 years of age with chronic obstructive pulmonary disease.
62684647|NCT06682832||PRISm group|Consisted of 18 individuals over 40 years of age with preserved ratio impaired spirometry.
62684648|NCT06682832||Healthy group|Consisted of 18 healthy individuals over 40 years of age.
62684649|NCT01275677|ACTIVE_COMPARATOR|Arm I (chemotherapy)|"GROUP IA: Patients receive docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.~GROUP IB: Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-3 weeks after last dose of doxorubicin hydrochloride and cyclophosphamide, patients also receive paclitaxel IV over 60 minutes once weekly for 12 doses in the absence of disease progression or unacceptable toxicity."
62684650|NCT01275677|EXPERIMENTAL|Arm II (chemotherapy, trastuzumab)|"GROUP IIA: Patients receive docetaxel and cyclophosphamide as in Group IA. Patients also receive trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity.~GROUP IIB: Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in Group IB. Patients also receive trastuzumab IV over 30-90 minutes weekly for 12 doses and then every 3 weeks for subsequent doses. Treatment repeats every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity."
62124157|NCT04128358|PLACEBO_COMPARATOR|Placebo group|Egyptian normal healthy volunteers who share on the President Initiative (100 Million Health).
62124158|NCT05231408|EXPERIMENTAL|Training Group|Training group will receive high-intensity interval aerobic exercise training on treadmill accompanied by physiotherapist for 8 weeks.
62314066|NCT05335083|EXPERIMENTAL|CPAP on condition|Participants will be monitored for a two-week period at least four weeks following commencement of CPAP.
62314067|NCT02236585|ACTIVE_COMPARATOR|Patient-controlled epidural analgesia|Patient-controlled epidural analgesia
62314068|NCT02236585|PLACEBO_COMPARATOR|Continuous epidural analgesia|Continuous epidural analgesia
62684651|NCT04835597||Observational (movement assessment, medical data collection)|Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.
62684652|NCT01866735|NO_INTERVENTION|Usual Care|
62684653|NCT01866735|EXPERIMENTAL|Standardized Rehabilitation Therapy|"Standardized Rehabilitation Therapy (SRT):~Participants randomized to the Standardized Rehabilitation Therapy arm will receive three types of interventions - Passive Range of Motion (PROM), Physical Therapy (PT) and Progressive Resistance Exercise (PRE). The SRT protocol will be administered by the BICU Mobility Team within 80 hours of ventilation and contains four levels of activity therapy. This Protocol will be delivered 7 days a week. Patients will be assessed daily and if appropriate will receive 3 separate sessions of activity each day."
62684654|NCT06651060|PLACEBO_COMPARATOR|Control (QR) labels|"Labels placed beneath all menu items will contain QR codes with the text, scan here, without any mention of sustainability"
62684655|NCT06651060|EXPERIMENTAL|High Climate Impact labels|"Labels will be placed beneath menu items with a high climate impact using a predetermined threshold of estimated greenhouse gas emissions set at \>=9.2 kgCO2e. Labels will contain white text, High Climate Impact, on a red background with a globe icon"
62684656|NCT06651060|EXPERIMENTAL|High Climate Impact Warning labels|"Labels will be placed beneath menu items with a high climate impact using a predetermined threshold of estimated greenhouse gas emissions set at \>=9.2 kgCO2e. Labels will contain white text, Warning: High Climate Impact, on a red background with a globe icon"
62124159|NCT05231408|SHAM_COMPARATOR|Control Group|Breathing exercises will be given to control group as a home program for 8 weeks.
62124160|NCT03385681|EXPERIMENTAL|Intervention Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate. Tailored Educational Intervention is administered to this group.
62124161|NCT03385681|NO_INTERVENTION|Control Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate in the study.
62124162|NCT00404417|EXPERIMENTAL|1|Botox/Placebo
62124163|NCT00404417|EXPERIMENTAL|2|Botox/Botox
62124164|NCT00404417|EXPERIMENTAL|3|Placebo/Botox
62124165|NCT00404417|PLACEBO_COMPARATOR|4|Placebo/Placebo
62124166|NCT04129619|EXPERIMENTAL|ORP-101 50 mg|ORP-101 (50 mg) once daily
62124167|NCT04129619|EXPERIMENTAL|ORP-101 100 mg|ORP-101 (100 mg), once daily
62124168|NCT04129619|PLACEBO_COMPARATOR|Placebo|Matching placebo, once daily
62124169|NCT03996278||Patients in the Grafalon group|Patients in the Grafalon group (n=150) will be followed prospectively and data prospectively collected thanks to the Astre database
62314069|NCT06051695|EXPERIMENTAL|A2B694|Patients receive Preconditioning Lymphodepletion (PCLD) Regimen followed by a single dose of A2B694 intravenously on day 0
62314070|NCT02453412|NO_INTERVENTION|Control|Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
62314071|NCT02453412|EXPERIMENTAL|Simulation|Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
61923797|NCT00498056|EXPERIMENTAL|1|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP. Injections will occur at study entry and Weeks 4, 8, and 24.
62124170|NCT03996278||Patients in the Thymoglobulin group|Patients in the thymoglobulin group (n=150) will be selected and analyzed retrospectively from the Astre database
62124171|NCT04470401|PLACEBO_COMPARATOR|Placebo|Abobotulinumtoxina 400 IU in 2cc of saline solution
62124172|NCT04470401|EXPERIMENTAL|Abobotulinumtoxina - 400IU|placebo (2cc of saline solution)
62124173|NCT06382649|EXPERIMENTAL|Rivastigmine|Patients in the rivastigmine arm will receive rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for up to three doses.
62124174|NCT06382649|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive oral placebo by mouth once, followed by oral placebo every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for up to three doses.
62314072|NCT05115461||Radicular pain group|Patients presenting with lumbar radicular pain and MRI findings associated with radiculopathy
62314073|NCT05115461||Control group|Age- and sex-matched control subjects without pain.
62314074|NCT04469894||Niemann-Pick Type A|Also referred to as Infantile Neurovisceral ASMD
62314075|NCT04469894||Niemann-Pick Type A/B|Also referred to as Intermediate form or Chronic Neurovisceral ASMD
62314076|NCT04469894||Niemann-Pick Type B|Also referred to as Chronic Visceral ASMD
62314077|NCT04469894||Niemann-Pick Type C (Early Infantile)|Onset at less than 2 years of age
62314078|NCT04469894||Niemann-Pick Type C (Late Infantile)|Neurodegenerative form (late-infantile) onset at 2-6 years of age
62314079|NCT04469894||Niemann-Pick Type C (Juvenile)|Neurodegenerative form (juvenile) onset at 6-15 years of age
62684657|NCT06651060|EXPERIMENTAL|Climate Grade labels|"Labels will be placed beneath all menu items, using predetermined estimated greenhouse gas emission thresholds to assign one of five icon-plus-text labels which indicate a specific climate impact grade (A, B, C, D, and F). Thresholds are set in kgCO2e as follows: \[A\] \<1.7, \[B\] \>=1.7 \& \<2.6, \[C\] \>=2.6 \& \<9.2, \[D\] \>=9.2 \& \<28, \[F\] \>=28. Labels shown will contain white text, Climate Grade, on a black background with a globe icon. The labels will include a white letter in a colored box on the left side, A (dark green), B (light green), C (yellow), D (orange), or F (red)"
61923798|NCT00498056|PLACEBO_COMPARATOR|2|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP placebo followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP placebo. Injections will occur at study entry and Weeks 4, 8, and 24.
61923799|NCT04988828|ACTIVE_COMPARATOR|Control|"deep squat~1min\*6repetitions"
62124175|NCT01699152|EXPERIMENTAL|TG02 citrate|TG02 citrate capsules given orally.
62124176|NCT00000265||Low anxiety|
62124177|NCT00000265||Moderate anxiety|
62124178|NCT00000265||High anxiety|
62124179|NCT06020963|EXPERIMENTAL|Group-1|Low intensive shockwave therapy 1000 shocks on each acupoint (CV-4, and bilateral ST-28) once a week for 8 weeks.
62124180|NCT06020963|EXPERIMENTAL|Group-2|Low intensive shockwave therapy 1000 shocks on each acupoint (CV-4, and bilateral SP-6) once a week for 8 weeks.
61923800|NCT04988828|EXPERIMENTAL|Whole body vibration group|"deep squat on a whole body vibration platform with 30Hz and 4mm amplitude~1min\*6repetitions"
62124181|NCT06020963|ACTIVE_COMPARATOR|Group-3|Oral tamsulosin 0.2mg once daily for 8 weeks.
62124182|NCT04280497|EXPERIMENTAL|Biomarker CIRCI neg: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
62314080|NCT04469894||Niemann-Pick Type C (Adult)|Psychiatric neurodegenerative form (adult) onset at greater than 15 years of age
61923801|NCT05897970||ACLR patients with Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
61923802|NCT04096222||Active pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactive disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
62124183|NCT04280497|PLACEBO_COMPARATOR|Biomarker CIRCI neg: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
62124184|NCT04280497|EXPERIMENTAL|Biomarker endocan: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
62124185|NCT04280497|PLACEBO_COMPARATOR|Biomarker endocan: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
62124186|NCT04280497|EXPERIMENTAL|Biomarker GILZ: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
62124187|NCT04280497|PLACEBO_COMPARATOR|Biomarker GILZ: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
62124188|NCT04280497|EXPERIMENTAL|Biomarker CPD: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
62314081|NCT04491396|OTHER|GYYB|This is a single-arm pre-post design.
62314082|NCT03642795||Patients with rheumatoid polyarthritis|
62124189|NCT04280497|PLACEBO_COMPARATOR|Biomarker CPD: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
62124190|NCT04280497|EXPERIMENTAL|Biomarker Transcriptomic SRS: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
62124191|NCT04280497|PLACEBO_COMPARATOR|Biomarker Transcriptomic SRS: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
62124192|NCT04280497|EXPERIMENTAL|Biomarker Endotype B: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
62314083|NCT04933097|EXPERIMENTAL|Sarcopenia|Only one arm with the sarcopenia assessment.
62314084|NCT05213598||Adults with FALD|male and female subjects =18 years of age who historically underwent Fontan procedure due to a severe CHD and thus are at risk for FALD by virtue of their altered physiology
62478327|NCT03616405|EXPERIMENTAL|14-day modified sequential therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.~Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 10mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the firs 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
62478328|NCT05912127|ACTIVE_COMPARATOR|• Group 1 (control group)|patients who received All on 4 implant-supported fixed restoration. The patients received 2 inclined implants anterior to the mental foramina and 2 vertical implants in the lateral incisor/canine areas.
62697375|NCT05488483||Breast and Melanoma Cohort|Participants with a suspicious finding at breast ultrasonography (BI-RADS 4 suspicious abnormality; BI-RADS 5, highly suggestive for malignancy) who are scheduled for ultrasound-guided breast biopsy will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. We will evaluate MSOT in 10 patients from the Melanoma Surgical Oncology Clinics (Dr. Ariyan, Co-I) with pathologically confirmed ITM following physical exam and biopsy. We will also evaluate MSOT in five melanoma patients with pathologically confirmed IT metastases scheduled for neoadjuvant immunotherapy prior to surgical resection.
62124193|NCT04280497|PLACEBO_COMPARATOR|Biomarker Endotype B: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
62314085|NCT06457048|EXPERIMENTAL|Stroke Unit Arm|All participants in this study will be adults with stroke cared for in the recently implemented stroke unit at the University Teaching Hospital in Lusaka, Zambia. Of note, all adults with stroke admitted to the University Teaching Hospital during the study period will be cared for in the stroke unit regardless of participation participation in this study. However, only those who consent to study participation will have data collected.
62314086|NCT06457048|NO_INTERVENTION|Pre-Stroke Unit Arm|This arm will consist of a historical cohort of adults with stroke admitted to the University Teaching Hospital in Lusaka, Zambia for the implementation of a stroke unit.
62314087|NCT00396227|EXPERIMENTAL|1|Vildagliptin 100mg + Met
62314088|NCT00396227|ACTIVE_COMPARATOR|TZD|TZD + metformin
62314089|NCT04535570||Pre Transplant|All 20 patients will have the energy expenditure measured in the pre-transplantation in order to compare with post-transplant data.
62314090|NCT04535570||Post Transplant|All 20 patients will have the energy expenditure measured in the post transplantation in order to compare with the pre-transplant data.
62314091|NCT00022711|EXPERIMENTAL|Temozolomide|Temozolomide 150mg/m2/day daily. Repeat cycles every 28days for maximum of six months
62314092|NCT01965548||Splenic injury|All patients admitted at the University Hospital North Norway Tromsø with a splenic injury following trauma, are included in the study.
62478329|NCT05912127|ACTIVE_COMPARATOR|• Group 2 (test group);|patients who received All on 3 implant-supported fixed restoration. The patients received 2 inclined implants anterior to the mental foramina and 1 vertical implant in the midline of the mandible.
62478330|NCT04757298|OTHER|Navigation only|Participants are randomized to receive navigation services only.
62478331|NCT04757298|OTHER|Navigation + Brief Counseling|After initial randomization into NS, some participants are randomized to receive Brief Counseling (BC)
62314093|NCT03662022|NO_INTERVENTION|No PEP|No PEP will be distributed
62314094|NCT03662022|OTHER|Household PEP|PEP will be given to all household contacts of an incident leprosy patient
62124194|NCT03648346|EXPERIMENTAL|Cohort 1: HL217 Ophathalmic Solution BID|Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
62124195|NCT03648346|EXPERIMENTAL|Cohort 2: HL217 Ophathalmic Solution QID|High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
62124196|NCT03648346|PLACEBO_COMPARATOR|Placebo Ophathalmic Solution|Placebo: two drops of placebo in one eye twice a day or 4 times a day
62124197|NCT06490991|EXPERIMENTAL|Arm A: Medication regimen 1-2|
62124198|NCT06490991|EXPERIMENTAL|Arm B: Medication regimen 2-1|
62314095|NCT03662022|EXPERIMENTAL|PEP 100m|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
61923803|NCT04096222||Inactive pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactive disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
62314096|NCT03662022|OTHER|PEP 100m + positive for anti-PGL-I IgM Ab|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)
62314097|NCT01943630|ACTIVE_COMPARATOR|AS101|Topical 15% AS101 gel, once a day (overnight)
62314098|NCT01943630|PLACEBO_COMPARATOR|Vehicle|Vehicle, Once a day topical application (Overnight)
62314099|NCT02758145|ACTIVE_COMPARATOR|Influenza vaccine information (G1)|During the recruitment visit at the occupational medicine unit between the 04/29/16 and the 10/31/16, the workers in this group (G1) in addition to their recruitment visit, will benefit from a short intervention given by the nurse concerning the flu, the advantages of the flu vaccination, and how they can be vaccinated in the institution. The nurse also transmits an information sheet concerning the benefits of the vaccination. 2 weeks after the beginning of the next flu vaccination campaign, they will receive a reminder letter to encourage vaccination.
62314100|NCT02758145|NO_INTERVENTION|No information (G2)|Workers in the control group (G2) receive no intervention, only recruitment visit.
62314101|NCT04018170|EXPERIMENTAL|JW1601|tablet formulation
62478332|NCT04757298|OTHER|Navigation + Critical Dialogue|After initial randomization into NS, some participants are randomized to receive Critical Dialogue (CD)
62697376|NCT05482451|EXPERIMENTAL|Nivolumab + all-trans retinoic acid|"Nivolumab: 3mg/kg intravenously on day 1.~All-trans retinoic acid (Vesanoid) 45 mg/m2 on days 1-14. The dose of Vesanoid can be increased with addition of 15 mg/m2 in next course of treatment if there is no severe adverse effects. Therefore, the dose of Vesanoid could be 60 mg/m2 from the second course, 75 mg/m2 from the third course, till the maximal dose of 150 mg/m2 if patients tolerated the treatment. The decision of dose escalation is left to in-charge physician.~The treatment cycle will repeat every 2 weeks."
62697377|NCT00071032|EXPERIMENTAL|Liberal (10 g/dL) Transfusion Strategy|Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
62314102|NCT04018170|PLACEBO_COMPARATOR|Placebo|tablet formulation identified with JW1601
62478333|NCT04757298|OTHER|Brochure only|Participants are randomized to receive Brochure only.
62478334|NCT04757298|OTHER|Brochure + Brief Counseling|After initial randomization to receive a brochure, some participants are randomized to receive Brief Counseling (BC)
62478335|NCT04757298|OTHER|Brochure + Critical Dialogue|After initial randomization to receive a brochure, some participants are randomized to receive Critical Dialogue (CD)
62478336|NCT05150041|ACTIVE_COMPARATOR|iPRo2 only (Control group)|- The Control group will go through target lifestyle coaching including diet and exercise and they will undergo 24 weeks of follow-up period.
62478337|NCT05150041|EXPERIMENTAL|iPRo2 + RT-CGM 1 week treatment (Treatment group 1)|Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.
62124199|NCT03093298|EXPERIMENTAL|Obesity|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling
62314103|NCT06003816|EXPERIMENTAL|Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI|The CHoBI7 program is first delivered during group sessions by a health promoter to those residing in a ring around a cholera patient. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A cholera prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After the group session, households receive weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended WASH behaviors.
62314104|NCT06003816|ACTIVE_COMPARATOR|Standard Message Arm|Standard message given in the Bangladesh to diarrhea patients at health facility discharge on use of oral rehydration solution
62314105|NCT02076672|EXPERIMENTAL|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
62314106|NCT05112185|EXPERIMENTAL|Healthy Beverage Access and Promotion|Intervention group will receive BPA-free self-serve pitchers and cups for serving water at mealtimes, individualized education to help families set healthy drinks goals for their family, and a curricula focused on increasing intake of water and healthy beverages.
62314107|NCT05112185|NO_INTERVENTION|Control|Usual care.
62314108|NCT02229149|EXPERIMENTAL|Triple Therapy|"Physician's choice of chemotherapy plus trastuzumab plus pertuzumab~* trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~* physician's choice of chemotherapy:~  1. Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~ 2. Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~ 3. Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~ 4. Docetaxel 75 mg/m2 IV every 3 weeks; OR~ 5. Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.~* AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks."
62314109|NCT02229149|ACTIVE_COMPARATOR|Double Therapy|"Physician's choice of chemotherapy plus trastuzumab~* trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~* physician's choice of chemotherapy:~  1. Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~ 2. Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~ 3. Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~ 4. Docetaxel 75 mg/m2 IV every 3 weeks; OR~ 5. Capecitabine 1500 mg PO BID 14 days on and then 7 days off."
62314110|NCT01188798|EXPERIMENTAL|Transplant recipients receiving Methotrexate|Participants will be biologically stratified according to disease, donor, and KIR match. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
62314111|NCT01188798|EXPERIMENTAL|Transplant recipients receiving Pentostatin|Participants will be biologically stratified according to disease, donor, and KIR match.between donor and host.In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
62314112|NCT04095910|EXPERIMENTAL|Planet Nutrition program|multidisciplinary school- based program
62314113|NCT04095910|NO_INTERVENTION|Control Group|Normal curricular classes
62314114|NCT01294254|EXPERIMENTAL|experimantal: wound site will be treated with Oleogel-S10|"The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg~* Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)~* Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site"
62314115|NCT01294254|ACTIVE_COMPARATOR|Moist wound healing dressing alone|Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
62684658|NCT06651060|EXPERIMENTAL|Climate Grade label also displaying full range of possible grades|"Labels will be placed beneath all menu items, using predetermined estimated greenhouse gas emission thresholds to assign one of five icon-plus-text labels which indicate a specific climate impact grade (A, B, C, D, and F). Thresholds are set in kgCO2e as follows: \[A\] \<1.7, \[B\] \>=1.7 \& \<2.6, \[C\] \>=2.6 \& \<9.2, \[D\] \>=9.2 \& \<28, \[F\] \>=28. Labels shown will contain white text, Climate Grade, on a black background with a globe icon. The labels will include a white letter in a colored box on the left side, A (dark green), B (light green), C (yellow), D (orange), or F (red). This label will also include a small scale of each white letter and colored box option beneath the main white letter and colored box"
61923804|NCT04096222||Healthy subjects|Healthy subjects will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) Demographic data will be documented, 2) biometric data, 3) A 34 ml blood sample will be taken
61923805|NCT01199900|EXPERIMENTAL|(Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT|
62314116|NCT02432677|EXPERIMENTAL|Remifentanil + Active tDCS|"* tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~* Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
62314117|NCT02432677|OTHER|Placebo + Active tDCS|"* tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~* Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
62314118|NCT02432677|OTHER|Remifentanil + Sham tDCS|"* Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~* Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
62314119|NCT02432677|OTHER|Placebo + Sham tDCS|"* Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~* Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
62314120|NCT00399802|ACTIVE_COMPARATOR|Single IV infusion of ZA 4 mg|Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
61923806|NCT01199900|EXPERIMENTAL|(Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT|
61923807|NCT01199900|ACTIVE_COMPARATOR|(Part 1) 5 mg Prednisone|5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
61923808|NCT01199900|EXPERIMENTAL|(Part 2) 3 mg PF-04171327|
61923809|NCT01199900|EXPERIMENTAL|(Part 2) 10 mg PF-04171327|
62314121|NCT00399802|EXPERIMENTAL|Odanacatib 5 mg|Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.
62314122|NCT05327530|EXPERIMENTAL|Group A: Avelumab|
62314123|NCT05327530|EXPERIMENTAL|Group B: Avelumab + Sacituzumab Govitecan|
62684659|NCT06651060|EXPERIMENTAL|Estimated Environmental Cost labels|"Labels will be placed beneath all menu items, displaying the estimated dollar value associated with greenhouse gas emissions. Labels shown will contain white text, Environmental Cost, with a dollar value (i.e., +$10.90) on a black background with a globe icon"
62684660|NCT06549907||Exploratory group|Patients treated with dual blockade of PD1/PDL1 and CTLA4 in combination of anti-angiogenic treatment
61923810|NCT01199900|ACTIVE_COMPARATOR|(Part 2) 5 mg Prednisone|
62314124|NCT05327530|EXPERIMENTAL|Group C: Avelumab + M6223|
62314125|NCT05327530|EXPERIMENTAL|Group D: Avelumab + NKTR-255|
62478338|NCT05150041|EXPERIMENTAL|iPRo2 + RT-CGM 1 week on /3 weeks off (2cycles) (Treatment 2)|- Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
62478339|NCT03851354|OTHER|Ultrasound meal accomodation test|ultrasound guided gastric dynamics test for tolerance of enteral feeding, 500 ml of water with protein (glutamine or casseinate) wil be administrated
62314126|NCT01952015|EXPERIMENTAL|AIN457|"All subjects were assigned to receive 150 mg secukinumab (AIN457) by subcutaneous injections. AIN457 was administered at baseline, weeks 1, 2, 3, 4. Prior to receiving the week 8 dose, all subjects were assigned to the following treatment group based on clinical components of their Clinical Global Impression (CGI) evaluation at week 8.~* No up-titration group received 1 injection of 150 mg AIN457 at weeks 8, 12, and each visit from week 16 until week 48.~* Up-titration group received 2 injections of 150 mg AIN457 at weeks 8, 9, 12 and each visit from week 16 until week 48.~Subjects who received 150 mg AIN457 can be up-titrated to 300 mg AIN 457 at any visit starting at week 16 based on clinical components of their CGI evaluation and investigator's discretion."
62314127|NCT04172831|EXPERIMENTAL|TNX-102 SL Tablets, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
62314128|NCT04172831|PLACEBO_COMPARATOR|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
62478340|NCT05235581|EXPERIMENTAL|BCAD's arm|The 4 interventions are in the BCAD's order.
62478341|NCT05235581|EXPERIMENTAL|BACD's arm|The 4 interventions are in the BACD's order.
62478342|NCT05235581|EXPERIMENTAL|CABD's arm|The 4 interventions are in the CABD's order.
62478343|NCT05235581|EXPERIMENTAL|ACBD's arm|The 4 interventions are in the ACBD's order.
62478344|NCT01322880|OTHER|Control Arm|The project, administered by the International Rescue Committee (IRC), involved 25 village savings and loans association (VSLA) groups across the province. The VSLA groups initially formed through local members of the community designated as community based facilitators (CBF).
62314129|NCT01266148|EXPERIMENTAL|Everolimus|Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
62314130|NCT01266148|EXPERIMENTAL|Control|Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
62314131|NCT03264638|EXPERIMENTAL|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
62314132|NCT03264638|EXPERIMENTAL|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
62314133|NCT03264638|ACTIVE_COMPARATOR|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
62314134|NCT02226614|EXPERIMENTAL|head cooling|head cooling
62314135|NCT06512766||Lichen planopilaris|Patients in this group were diagnosed and treated for lichen planopilaris (LPP), a form of primary lymphocytic cicatricial alopecia. Treatment options included hydroxychloroquine (HCQ), methotrexate (MTX), cyclosporine A (CsA), and retinoids. The effectiveness of these treatments varied among patients. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments were not consistent.
62478345|NCT01322880|EXPERIMENTAL|Treatment Group|"Half of the VSLA participants were invited to participate in an additional set of discussion groups to be attended along with their spouse. All participants were informed that due to space constraints, only half of the members would be able to attend. In each VSLA, individuals drew numbers from a bag or hat, and those with winning slips were the ones who entered the discussion groups with spouses."
62478346|NCT06469671|EXPERIMENTAL|Artificial intelligence - assisted colonoscopy|"The decision making system based on artificial intelligence. Real - time artificial intelligence - assisted colonoscopy will be performed in this group.~Detection of polyps is based on real time fixing a frame on the screen."
62478347|NCT06469671|ACTIVE_COMPARATOR|Conventional colonoscopy|Conventional colonoscopy will be performed in this group
62478348|NCT05748990|EXPERIMENTAL|Schizophrenia Group|Insulin (160IU) or placebo is administered intranasally 15 minutes prior to the PET scan.
62478349|NCT05748990|EXPERIMENTAL|Healthy Control Group|Insulin (160 IU) or placebo is administered intranasally 15 minutes prior to the PET scan.
62478350|NCT01152827|EXPERIMENTAL|RAD001|RAD001 10 mg daily po medication
62478351|NCT00002880|EXPERIMENTAL|Etoposide|Oral etoposide for relapsed or refractory non-Hodgkin's lymphoma
62478352|NCT04371081||Amplatzer Piccolo Occluder|Amplatzer Piccolo Occluder device implant
62684661|NCT05898334|EXPERIMENTAL|Treatment|Active biophoton generators will be placed under the hotel bed to be used by the participant who is randomized to the Treatment Group and activities of daily living will be observed for 4 weeks.
62478353|NCT01471353|EXPERIMENTAL|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study.
62684662|NCT05898334|PLACEBO_COMPARATOR|Control|Placebo biophoton generators will be placed under the hotel bed to be used by the participant who is randomized to the Control Group and activities of daily living will be observed for 4 weeks.
62684663|NCT04437823|EXPERIMENTAL|Group 1 : Treatment|Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10\^5 UCMSCs per Kg body weight delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).
62314136|NCT06512766||Frontal fibrosing alopecia|Patients in this group were diagnosed and treated for frontal fibrosing alopecia (FFA), a form of primary lymphocytic cicatricial alopecia. Treatment options included hydroxychloroquine (HCQ), methotrexate (MTX), cyclosporine A (CsA), and retinoids. The effectiveness of these treatments varied among patients. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments were not consistent.
62478354|NCT03935880|ACTIVE_COMPARATOR|Cartiva Hemiarthroplasty|Cartiva implant
62684664|NCT04437823|NO_INTERVENTION|Group 2: standard care|Five (5) subjects will be treated under Standard of Care (SOC) .
62684665|NCT02322931|EXPERIMENTAL|Imaging interventions|Eligible patients who consent to participate in this study will undergo a combination of 4 different imaging interventions (based on the group they're in, as described in the protocol), intra-operatively, in addition to their standard LDR brachytherapy treatment.
62478355|NCT03935880|ACTIVE_COMPARATOR|Cheilectomy|Bone spur removal
62478356|NCT04584294|EXPERIMENTAL|Intervention (MyPath)|Patients scheduled to see providers randomized to this arm will receive a weblink to the decision tool via text message after study enrollment and prior to their scheduled visit.
62684666|NCT05481164||Screen for Spinal Muscular atrophy for newborns|Babies with an SMA screen-positive result
62684667|NCT02355509|PLACEBO_COMPARATOR|Placebo|A placebo drug is given for three months
62684668|NCT02355509|EXPERIMENTAL|Acarbose|Acarbose is given for three months
62684669|NCT01908699|EXPERIMENTAL|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.
62684670|NCT01908699|EXPERIMENTAL|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.
62684671|NCT06113198|EXPERIMENTAL|rMenB+OMV NZ Group|Participants received rMenB+OMV NZ on Day 1, Day 61, and any day between Day 241- Day 391.
62684672|NCT06432725|EXPERIMENTAL|JUNTOS|Participants in this group will get access to the JUNTOS Referral Network website/app through the 6-month follow up (HIV test counselors) and 3-month follow up (Latino MSM).
62684673|NCT06432725|ACTIVE_COMPARATOR|Referral Sheet - HIV test counselors|Participants in this group will get access to the referral sheet through the 6-month follow up (HIV test counselors) and 3-month follow up (Latino MSM).
62684674|NCT04939103||1|Those patients with rectal cancer after neoadjuvant treatment and completed the examination of TRUS-FNA, TRUS, CT, MR, enteroscopy and superficial biopsy
62684675|NCT04590963|EXPERIMENTAL|Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2|Participants will receive intravenous (IV) monalizumab 750 mg every two weeks (Q2W) and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 every one week (Q1W) until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
62684676|NCT04590963|ACTIVE_COMPARATOR|Placebo Q2W + Cetuximab 400 mg/m^2|Participants will receieve IV placebo matched to monalizumab Q2W and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
62684677|NCT06508502||Revised Atlanta classifiaction (RAC) I - mild|No local or systemic complication
62684678|NCT06508502||Revised Atlanta classifiaction (RAC) II - moderate severe|Local complications as necrosis or fluid collection or organ failure \< 48h
62684679|NCT06508502||Revised Atlanta classifiaction (RAC) III - severe|Organ failure \> 48h
62684680|NCT02344498||Urban|HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
62684681|NCT02344498||Rural|HBV patients in Adama, Afar, Jigjiga and Jimma. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
62684682|NCT05865886|EXPERIMENTAL|BI 1291583 group|
62478357|NCT04584294|NO_INTERVENTION|Usual Care|Patients scheduled to see providers randomized to the usual care arm will receive no intervention and will receive usual primary care.
62684683|NCT05865886|PLACEBO_COMPARATOR|Placebo group|
62684684|NCT04991597|EXPERIMENTAL|Left Forearm Injection Sites Cooled, Right Forearm Injection Sites at Room Temperature|Palmar aspect of participants left forearm will have a cold compress pack placed on it. The palmar aspect of the right forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
62684685|NCT04991597|EXPERIMENTAL|Right Forearm Injection Sites Cooled, Left Forearm Injection Sites at Room Temperature|Palmar aspect of participants right forearm will have a cold compress pack placed on it. The palmar aspect of the left forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
61923811|NCT01199900|ACTIVE_COMPARATOR|(Part 2) 20 mg Prednisone|
61923812|NCT00738192|ACTIVE_COMPARATOR|1|Fentanyl delivered for controlling awaking pain
61923813|NCT00738192|ACTIVE_COMPARATOR|2|Sufentanil delivered for controlling awaking pain
62314137|NCT01288378|ACTIVE_COMPARATOR|Empirical|Empirical approach (fever driven) for starting antifungal therapy
62478358|NCT05597982|EXPERIMENTAL|KTFT|
62478359|NCT05597982|EXPERIMENTAL|PN|
62478360|NCT01724294||Cohort|
62478361|NCT05806853|EXPERIMENTAL|Dual tracer PET/MRI|All patients undergo PET/MRI with 68Ga-PSMA and 68Ga-DOTA-RM2. 68Ga-PSMA dose: 160 +-50 MBq, route of administration: intravenous 68Ga-DOTA-RM2 dose: 140 +-50 MBq, route of administration: intravenous
62684686|NCT03997500|PLACEBO_COMPARATOR|Normal saline|Simultaneous with subarachnoid block, a bolus of normal saline was given followed by normal saline infusion
62684687|NCT03997500|EXPERIMENTAL|Norepinephrine|Simultaneous with subarachnoid block, a bolus of norepinephrine was given followed by norepinephrine infusion
62684688|NCT00683072||1|
62684689|NCT03493893||Affixus|To compare Affixus to PFNA and TFNA
62124200|NCT05328011||overactive bladder syndrome|female patients with overactive bladder syndrome
62314138|NCT01288378|EXPERIMENTAL|Pre-emptive|Pre-emptive approach (diagnostic driven) for starting antifungal therapy
62314139|NCT06673342|NO_INTERVENTION|Control|Visual assessment of DMFT, added sugar consumption calculation, frequency of snacking calculation.
62684690|NCT03493893||PFNA|To compare PFNA to Affixus and TFNA
62684691|NCT03493893||TFNA|To compare TFNA toPFNA and Affixus
62684692|NCT02940223|EXPERIMENTAL|Group I (ethyl icosapentate, physical activity)|Patients receive ethyl icosapentate PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally continue to receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks.
62684693|NCT02940223|EXPERIMENTAL|Group II (placebo, physical activity)|Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
62684694|NCT02940223|EXPERIMENTAL|Group III (placebo, stretching exercises)|Patients receive placebo PO BID for 8 weeks. Patients meet with an exercise specialist during the first week to learn different stretching exercises and complete the stretching exercises 3 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
61923814|NCT00738192|ACTIVE_COMPARATOR|3|Butorphanol delivered for controlling awaking pain
61923815|NCT01087866|EXPERIMENTAL|Metformin|
62124201|NCT05328011||controls|women without overactive bladder syndrome
62124202|NCT03315884|EXPERIMENTAL|Iliac segment recanalization and stenting Iliac segment CFA|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
62124203|NCT03315884|ACTIVE_COMPARATOR|Iliac segment recanalization, stenting and plastic CFA patch|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
62314140|NCT06673342|EXPERIMENTAL|Intervention|Visual assessment of DMFT, added sugar consumption calculation, frequency of snacking calculation, plus Stephan's Curve-based nutritional counseling.
62314141|NCT06067646|OTHER|Health care providers involved in care for people living with hiv|Semi-structured interviews with health care providers
62314142|NCT06067646|OTHER|People living with HIV with prior pregnancy or desire to have children|Semi-structured interviews with people living with HIV with prior pregnancy or desire to have children
62124204|NCT04134078|EXPERIMENTAL|inhaled nitric oxide|Inhaled Nitric Oxide at 40 ppm will be administered in adults who suffer in hospital cardiac arrest. The administration of inhaled nitric oxide at 40 ppm will be provided upto 24 hours once ROSC is achieved.
62124205|NCT01124734|EXPERIMENTAL|Course 1 Cycle 1 and Cycle 2|"Course 1 Cycle 1: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.~Course 1 Cycle 2: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days."
62124206|NCT06060652||Retrospective cohort|34 OMPC patients enrolled in the ADAPT-CTC trial
62124207|NCT06060652||Prospective cohort|A minimum sample size of 70 OMPC patients undergoing SBRT must be enrolled in this study to satisfy the study endpoints
62124208|NCT03226899|ACTIVE_COMPARATOR|Lesinurad + XOI|lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI
62124209|NCT03226899|PLACEBO_COMPARATOR|Placebo + XOI|placebo tablet QD plus a stable, medically appropriate dose of an XOI
62684695|NCT03207087|EXPERIMENTAL|WEB Aneurysm Embolization Device|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. Subjects will be screened for study eligibility after giving informed consent.
61923816|NCT01087866|ACTIVE_COMPARATOR|Insulin|
62684696|NCT06693947|EXPERIMENTAL|Alpine dairy products|Intake of 3 portions of alpine dairy products made from milk of cows grazing in subalpine to alpine regions in the Swiss alps in Val Müstair (GR) (one portion equals 2 dl milk, 150-200 g yoghurt, quark, cottage cheese, other dairy products, 30g hard cheese, 60g soft cheese) during the 6-week intervention period. Every dairy product intake will be reported into the participants' food log. Participants will be instructed not to change their diet (with the exception of dairy products), lifestyle and physical activity during the study.
62684697|NCT06693947|NO_INTERVENTION|Non-alpine dairy products|Intake of 3 portions of standard dairy products made from milk of cows grazing in lower altitudes, found in local food stores, thus avoiding alpine dairy products during the 6-week intervention period. There are no other restrictions, all dairy products are considered equivalent. Every dairy product intake will be reported into the participants' food log. The participants will be instructed not to change their diet (with the exception of dairy products), lifestyle and physical activity during the study.
62314143|NCT03403101|EXPERIMENTAL|SIRIOX regimen|5-FU and leucovorin in the FOLFIRINOX regimen were replaced with oral S-1, forming the SIRIOX regimen(S1 plus irinotecan and oxaliplatin)
62314144|NCT05476549|EXPERIMENTAL|Lemon verbena|
62684698|NCT04725188|EXPERIMENTAL|Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 via IV infusion Q3W. Each cycle will be 21 days.
62684699|NCT04725188|EXPERIMENTAL|Arm 2: Pembrolizumab/Vibostolimab coformulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle will be 21 days.
62684700|NCT04725188|ACTIVE_COMPARATOR|Arm 3: Placebo + Docetaxel|Participants receive normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 IV infusion Q3W. Each cycle will be 21 days.
62684701|NCT06685978|PLACEBO_COMPARATOR|:Xiangjurupining Capsule Placebo group|Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
62684702|NCT06685978|EXPERIMENTAL|Xiangjurupining Capsule Experimental group|Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
62684703|NCT01713322|EXPERIMENTAL|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
62684704|NCT01713322|OTHER|No pain management education|Control - parents receive general information about childhood immunization.
62684705|NCT06681012|EXPERIMENTAL|Gelsectan®|Gelsectan® is a class III CE-marked medical device under the Regulation (EU) 2017/745 (MDR), which has been present on the EU market since 2017. Gelsectan® medical device consists of non-sterile capsules containing film-forming compounds (Xyloglucan, Pea protein, grape seed extract, and Xylo-oligosaccharide) indicated for symptomatic relief and prevention of IBS symptoms.
62684706|NCT06681012|PLACEBO_COMPARATOR|Placebo|Placebo capsule, comparable in size, appearance and taste, packaging and labelling, as well as mode and schedule of administration to the IMD (i.e., Gelsectan®).
62684707|NCT05999721|ACTIVE_COMPARATOR|Treatment Arm|In addition to standard care, the treatment arm will receive an ultrasound-guided bilateral single-shot superficial parasternal intercostal plane block at two levels.
62684708|NCT05999721|ACTIVE_COMPARATOR|Control Arm|The control arm will receive standard care alone.
62684709|NCT02269774|OTHER|Pulmonary vein isolation|Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index \> 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
62684710|NCT02269774|NO_INTERVENTION|No intevention|Intra-thoracic pressure swings induced by breathing manoeuvres during ECG-monitoring. Only patients with an apnea-hypopnea index \< 5/h and no premature atrial beats during the Mueller manoeuvre will be assigned to the no intervention arm.
62684711|NCT04300790|EXPERIMENTAL|CohortA: Normoglycemic patients|"Alpelisib plus metformin and Endocrine Therapy (fulvestrant or Letrozole or Exemestane): During the first cycle, patients will receive Endocrine Therapy and metformin at least one-week prior alpelisib administration (D8).~Alpelisib (BYL719) 300 mg PO (two tablets of 150 mg once a day) on a continuous dosing schedule starting on Cycle 1.~Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.~Endocrine Therapy:~Fulvestrant 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles) or Letrozole 2,5 mg, once daily, orally or Exemestane 25 mg once daily, orally."
61923817|NCT01298193|EXPERIMENTAL|Aprepitant|"Observational phase (first cycle):~Day 0 (Dexamethasone 8mg) Day 1 (5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg) + Chemotherapy (Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 ).~Days 2 and 3 (Dexamethasone 16 mg).~If not complete response:~Efficacy phase (second cycle):~Day 0 (Dexamethasone 8mg) Day 1 (Aprepitant: 125 mg,5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2, Tropisetron: 5 mg, Dexamethasone 12 mg)+ Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 .~Days 2 and 3 (Aprepitant: 1 capsule of 80 mg daily, Dexamethasone 8 mg)."
62314145|NCT05476549|PLACEBO_COMPARATOR|Placebo|
62314146|NCT06447181||3DVT-FI Group|Patients with hepatolithiasis using 3D visualization combined with ICG fluorescence technique
62314147|NCT06447181||Conventional operation Group|Patients with hepatolithiasis using conventional operation
62314148|NCT00778999|ACTIVE_COMPARATOR|Oral Contraceptive|Use of oral contraceptive pills prior to controlled ovarian stimulation
62478362|NCT04505085|EXPERIMENTAL|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
62478363|NCT04505085|EXPERIMENTAL|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
62478364|NCT00859105|EXPERIMENTAL|Imiquimod 5%|Manufactured by Apotex
62478365|NCT00859105|ACTIVE_COMPARATOR|Adara 5 % Cream US|Manufactured by 3M, US.
62478366|NCT00859105|ACTIVE_COMPARATOR|Adara 5% Cream Canada|Manufactured by 3M, Canada
61923818|NCT02964403|EXPERIMENTAL|Cox-2|Cox-2 inhibitor ParecoxibNa 40mg pre-ERCP injection
62124210|NCT05102409|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|Single dose
62124211|NCT05102409|ACTIVE_COMPARATOR|Xiidra® (5% lifitegrast ophthalmic solution)|Single dose
62124212|NCT00506298|EXPERIMENTAL|A|CRx-401 (bezafibrate + diflunisal)
62124213|NCT00506298|ACTIVE_COMPARATOR|B|bezafibrate + placebo
62124214|NCT05088629|OTHER|One group|3-meter Walk Back Test, Proprioception, Trunk Control and Muscle Strength test
62314149|NCT00778999|NO_INTERVENTION|Non-Oral Contraceptive|No use of oral contraceptive pills prior to controlled ovarian stimulation
62314150|NCT03847337|EXPERIMENTAL|New to diagnosis|We will test two telemedicine tools with children who have not been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
62478367|NCT00859105|PLACEBO_COMPARATOR|Vehicle|Manufactured by Apotex
62478368|NCT02375386|EXPERIMENTAL|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
62697378|NCT00071032|ACTIVE_COMPARATOR|2|Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
62697379|NCT02516813|EXPERIMENTAL|Phase 1a (Arm A): M3814 Capsule (100 mg) + RT|Participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that was not amenable to surgical therapy, or with standard systemic therapy with an indication for palliative radiotherapy (RT) received 100 milligrams (mg) of M3814 as capsule orally once daily on fraction day (FD) 6 in combination with RT (3 Gray \[Gy\] x 10, 5 fractions per week \[F/W\]).
62314151|NCT03847337|EXPERIMENTAL|Previously diagnosed|We will test two telemedicine tools with children who have been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
62314152|NCT01927146||Resectable gastric cancer|No intervention
62314153|NCT00089180|EXPERIMENTAL|Arm I (liposomal T4N5 lotion)|Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
61923819|NCT02964403|ACTIVE_COMPARATOR|Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
62124215|NCT02986412|EXPERIMENTAL|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
62124216|NCT02284555|EXPERIMENTAL|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
62124217|NCT06196099|ACTIVE_COMPARATOR|rest-Blood Flow Restriction plus Neuromuscular Electrical Stimulation|
62124218|NCT06196099|ACTIVE_COMPARATOR|rest-Blood Flow Restriction|
62124219|NCT06196099|ACTIVE_COMPARATOR|Squat Exercise|
62124220|NCT04605016|EXPERIMENTAL|Hydrophilic surface implants|
62124221|NCT04605016|ACTIVE_COMPARATOR|Hydrophobic surface implants|
62124222|NCT02902471|EXPERIMENTAL|Group A|Patients with bronchiolitis obliterans syndrome after bone marrow transplantation
62124223|NCT06169735|EXPERIMENTAL|Parathyroid patients|patients who require parathyroid identification and preservation during parathyroid surgery maneuver
62124224|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr \[H\&Y\] scores 1-2) aged 35 to 80 years
61923820|NCT02772484|EXPERIMENTAL|HS-1000 recording|The recording session should be performed in a quiet environment with no disturbance to the patient for a total of up to 60 minutes.
62124225|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
62124226|NCT01906788|ACTIVE_COMPARATOR|Group 1|Active comparator: Artemether Lumefantrine 6 dose regime orally
62124227|NCT01906788|EXPERIMENTAL|Group 2|Experimental: Artemether Lumefantrine 6 dose regime Plus single dose Primaquine (0.75/kg) on day 0
62124228|NCT01906788|EXPERIMENTAL|Group 3|Experimental: Artemether Lumefantrine 6 dose regimen plus single dose of Primaquine (0.75/kg) on day 2
62124229|NCT02622672|EXPERIMENTAL|Placebo|glycerin.soy-lecithin, and water
62124230|NCT02622672|EXPERIMENTAL|Supplement|water-soluble Ubiquinol 100 mg/d
62684712|NCT04300790|EXPERIMENTAL|CohortB: Pre-diabetic patients|"Alpelisib plus metformin and Endocrine Therapy (fulvestrant or Letrozole or Exemestane): During the first cycle, patients will receive Endocrine Therapy and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (two tablets of 150 mg once a day) on a continuous dosing schedule starting on Cycle 1.~Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.~Endocrine Therapy:~Fulvestrant 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles) or Letrozole 2,5 mg, once daily, orally or Exemestane 25 mg once daily, orally."
62684713|NCT04300790|EXPERIMENTAL|CohortC: Insulin naïve type 2 diabetic mellitus patients|"Alpelisib plus metformin plus vildagliptin and Endocrine Therapy (fulvestrant or Letrozole or Exemestane or Tamoxifen): During the first cycle, patients will receive Endocrine Therapy, metformin and vildagliptin at least two-weeks prior alpelisib administration (D15).Alpelisib (BYL719) 300 mg PO (two tablets of 150 mg once a day) on a continuous dosing schedule starting on Cycle 1.~Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.~Endocrine Therapy:~Fulvestrant 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles) or Letrozole 2,5 mg, once daily, orally or Exemestane 25 mg once daily, orally or Tamoxifen 20 mg once daily, orally."
62684714|NCT06688045|EXPERIMENTAL|Period 1: Nemtabrutinib|Participants receive a single oral dose of nemtabrutinib followed by a protocol specified wash-out period.
62684715|NCT06688045|EXPERIMENTAL|Period 2: Nemtabrutinib + Itraconazole|Participants receive oral doses of itraconazole once daily on Days 1 to 13 with a single oral dose of nemtabrutinib given with itraconazole on Day 4.
62684716|NCT06115603|ACTIVE_COMPARATOR|Cannabigerol|1mL of 80mg of Cannabigerol. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant.
62684717|NCT06115603|PLACEBO_COMPARATOR|Placebo|1mL of Placebo. Placebo is made in the form of MCT oil.
62684718|NCT04473833|EXPERIMENTAL|Participants in the Kentucky Ovarian Cancer Screening Program|Participants from the Kentucky Ovarian Cancer Screening Program who choose to participate in this trial will undergo further serial transvaginal ultrasonography (TVS) screening.
62684719|NCT06569329|EXPERIMENTAL|GentleWave System Root Canal Therapy|Sterile paper points will be inserted into the root canal at 3 time points: (i) before instrumentation, (ii) after washing the canal with 10% sodium thiosulfate, and (iii) after the GentleWave System root canal therapy has been completed. The paper points will collect bacteria, which will be analyzed via real-time Polymerase Chain Reaction to assess bacterial counts.
62684720|NCT06569329|EXPERIMENTAL|EdgePro Laser Root Canal Therapy|Sterile paper points will be inserted into the root canal at 3 time points: (i) before instrumentation, (ii) after washing the canal with 10% sodium thiosulfate, and (iii) after the EdgePro Laser root canal therapy has been completed. The paper points will collect bacteria, which will be analyzed via real-time Polymerase Chain Reaction to assess bacterial counts.
61923821|NCT02806193||Cardiovascular Magnetic Resonance Imaging|Cardiovascular imaging techniques (other subsidiary techniques such as CT and ECG will also be followed)
61923822|NCT00312403|OTHER|1|Patients with primary open angle glaucoma
61923823|NCT00312403|OTHER|2|Age- and sex-matched control subjects
61923824|NCT02044328|EXPERIMENTAL|Icotinib|Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery.
61923825|NCT03418467||tachycardiomyopathy|Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.
62314154|NCT00089180|PLACEBO_COMPARATOR|Arm II (placebo)|Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
62314155|NCT06649747|ACTIVE_COMPARATOR|Low dose|Name: AFA-281; Doseage Form: 5 and 20mg; Dosage: 60mg daily three times a day for 28 consecutive days
61923826|NCT03418467||dilated cardiomyopathy|Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.
61923827|NCT06023524|EXPERIMENTAL|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points.
61923828|NCT06023524|SHAM_COMPARATOR|Sham Laser Acupuncture and Standard Medication|Sham Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
62124231|NCT02529995|EXPERIMENTAL|AZD9291 40 mg|Cohort 1: 40 mg once daily
62124232|NCT02529995|EXPERIMENTAL|AZD9291 80 mg|Cohort 2: 80 mg once daily
62124233|NCT02704936||Male donor|42 samples of semen from male donor attached to a donation program Normal sperm count as WHO 2010.
62124234|NCT02704936||IUI positive pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and have obtained positive pregnancy in any of the first 4 treatments IUI
62124235|NCT02704936||IUI unsuccessful pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and after undergoing maximum 4 cycles have unsuccessfully IUI indication of IVF / ICSI.
62314156|NCT06649747|PLACEBO_COMPARATOR|Placebo|Name: Placebo Dosage form: matching study drug Dosage: 0 mg Frequency: daily TID for 28 consecutive days
62124236|NCT03289962|EXPERIMENTAL|Phase 1a Flat Dose Escalation: Autogene Cevumeran|Participants will receive autogene cevumeran at escalated dosages.
62314157|NCT06649747|ACTIVE_COMPARATOR|Mid Dose|Name: AFA-281; Doseage Form: 5 and 20mg; Dosage: 90 mg daily three times a day for 28 consecutive days
62124237|NCT03289962|EXPERIMENTAL|Phase 1b Flat Dose Escalation: Autogene Cevumeran + Atezolizumab|Participants will receive autogene cevumeran at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg)
62124238|NCT03289962|EXPERIMENTAL|Phase Ib: Dose Exploration: Autogene Cevumeran + Atezolizumab|Non-small cell lung cancer (NSCLC) or melanoma cancer immunotherapy (CIT)-treated participants will receive autogene cevumeran (at dosage lower than maximum tolerated dose \[MTD\] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
62314158|NCT06649747|ACTIVE_COMPARATOR|High Dose|Name: AFA-281; Doseage Form: 5 and 20mg; Dosage: 150 mg daily three times a day for 28 consecutive days
62314159|NCT04073823|ACTIVE_COMPARATOR|Flexitouch Plus|
62124239|NCT03289962|EXPERIMENTAL|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab|Participants with different indications as per inclusion criteria will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
62124240|NCT03289962|EXPERIMENTAL|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab (Serial Biopsy)|CIT-naive patients with selected tumor types who consent to optional serial biopsies will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a dixed dose of 1200 mg.
62314160|NCT04073823|EXPERIMENTAL|Flexitouch Plus with SW|
62314161|NCT02310633|ACTIVE_COMPARATOR|Memory Strategy Training|This arm involves intervention that teaches participants to use active encoding strategies to learn and remember new information.
62314162|NCT02310633|ACTIVE_COMPARATOR|Errorless Learning|This arm involves intervention that enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase.
62314163|NCT02310633|ACTIVE_COMPARATOR|Retrieval Practice|This arm involves intervention that enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue.
62314164|NCT04275752|NO_INTERVENTION|Usual Care Group|Subjects will receive no formal exercise recommendations
62314165|NCT04275752|EXPERIMENTAL|Exercise Intervention Group|Subjects will complete an exercise program
62314166|NCT00713869||1|Patients between the ages of 21 and 35 undergoing in-vitro fertilization will be included in this study.
62314167|NCT00713869||2|Recipients using only frozen donor eggs
62314168|NCT04804956||Early-rectal cancer|The patients to be included in this group will be those with Stage I (initial tumor stage). The tumors classified in stage I will be tumors in which the invasion of the submucosa and / or the invasion of the muscularis propria occur. This group will include patients diagnosed preoperatively with tumor stage T1-T2 N0.
62478369|NCT02375386|SHAM_COMPARATOR|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
62124241|NCT03375151|EXPERIMENTAL|EEG based feedback|The therapist will give feedback to the participants during the exercise based on their performance.and use the feedback from the EEG analyzed data to direct cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
62124242|NCT03375151|OTHER|Standard practice based feedback|The therapist will give feedback to the participants during the exercise based on their performance.
62314169|NCT04804956||Advanced-rectal cancer|The patients to be included in this group will be those with Stages II and III, that is, advanced tumors at the time of preoperative diagnosis. Tumors included in this group invade the perirectal fat and / or the surface of the visceral peritoneum and / or invade or adhere to adjacent organs or structures. In addition, any tumor stage with lymph nodes without distant metastases will be included in this group.
62478370|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
61923829|NCT02284971|EXPERIMENTAL|Arm A: CDX1127 & SBRT Concurrent|"SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
61923830|NCT02284971|EXPERIMENTAL|Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
62124243|NCT03375151|OTHER|No feedback|The participants will perform the exercise without feedback during practice.
62124244|NCT00665444|EXPERIMENTAL|A|Aripiprazole
62124245|NCT03734692|EXPERIMENTAL|cisplatin + rintatolimod + pembrolizumab|Intraperitoneal (IP) cisplatin 50mg/m\^2 solution with IP rintatolimod 200 mg solution and IV pembrolizumab 200 mg solution.
62314170|NCT04804956||Synchronous metastasis -rectal cancer|The patients to be included in this group will be those with Stage IV (disseminated tumor stage) in the initial study of the disease. Patients with distant metastases in one organ or more than one organ will be included.
62478371|NCT03556813||Group Vik|women over the age of 18 with breast cancer or remission
62124246|NCT05663151|EXPERIMENTAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|15 participants who meet study inclusion/exclusion criteria will be individually administered a full course of PE during 10, 60 minute-sessions, with independent multimodal assessment batteries administered at pre-treatment, mid-treatment (post session 5), post-treatment, and a 1-month follow-up.
62124247|NCT06325111||Patients with T1D and optimal glycaemic control|Optimal glycaemic control will be defined as HbA1c values \<7%
62478372|NCT03556813||Group physicians|women over the age of 18 with breast cancer or remission
62478373|NCT06627140||Risk group|Risk for preterm birth, but no actual preterm birth
62124248|NCT06325111||Patients with T1D and poor glycaemic control|Poor glycemic control will be defined as HbA1c value ≥7%
62124249|NCT02925351|EXPERIMENTAL|Imaging (fluorine F 18 clofarabine, PET/CT)|Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
62124250|NCT00559286|EXPERIMENTAL|A|treatment with 80 mg Telmisartan per day for 30 days
62124251|NCT00559286|ACTIVE_COMPARATOR|B|treatment with 20mg Telmisartan per day for 30 days
62124252|NCT00874471||sarcoidosis|
62124253|NCT00874471||ankylosing spondylitis|
62124254|NCT00874471||Behcet's disease|
62124255|NCT00874471||toxoplasmosis|
62124256|NCT00874471||herpetic acute retinal necrosis|
62124257|NCT00874471||idiopathic uveitis|
62124258|NCT00874471||ankylosing spondylitis (no uveitis)|
62124259|NCT00874471||sarcoidosis (no uveitis)|
62124260|NCT00874471||Behcet's disease (no uveitis)|
62124261|NCT00874471||normal control|
62478374|NCT06627140||Preterm birth group|Risk for preterm birth and actual preterm birth
62124262|NCT03230786|PLACEBO_COMPARATOR|Placebo|Placebo QD for 12 weeks as add-on to metformin
62124263|NCT03230786|EXPERIMENTAL|15µg KBP-042 QD|Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin
62124264|NCT03230786|EXPERIMENTAL|30µg KBP-042 QD|Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin
62124265|NCT03230786|EXPERIMENTAL|50µg KBP-042 QD|Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin
62124266|NCT04434586|SHAM_COMPARATOR|angiography 2D|Control group: an arteriography will be performed on the entire treated segment to assess the quality of the result, the application or not an active balloon will be left to the discretion of the operator. In case of application of the active balloon, a new arteriography before decision or not the use of stenting will be practiced. In case of stenting, an arteriographic final is performed.
62314171|NCT01174914|EXPERIMENTAL|Naltrexone Low-dose 3mg capsule|Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
62124267|NCT04434586|EXPERIMENTAL|angiography 2D with OCT|Experimental group: an arteriography and OCT acquisition on the entire treated segment to ensure the quality of the result, the application or not of an active ball will be left. In case of application of the active balloon, a new arteriography and OCT acquisition before decision or not the use of stenting will be practiced. In case of stenting, a final arteriography and then OCT acquisition are performed.
62124268|NCT00465816|EXPERIMENTAL|Nimenrix + Twinrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
62124269|NCT00465816|ACTIVE_COMPARATOR|Nimenrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
62124270|NCT00465816|ACTIVE_COMPARATOR|Twinrix Group|Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
62124271|NCT06677359|PLACEBO_COMPARATOR|Control group|Participants will recieved placebo supplementation without multicomponent training intervention.
62124272|NCT06677359|EXPERIMENTAL|Creatine group|Participants will recieved micronized creatine monohydrate supplementation without multicomponent training intervention.
62314172|NCT01174914|ACTIVE_COMPARATOR|Naltrexone Low Dose + ARVs|In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
62314173|NCT01174914|PLACEBO_COMPARATOR|ARV's (continued,standard) plus Placebo|In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
62314174|NCT05504330||Patient Group|Asymptomatic intracranial stenosis patients who receive standard medical treatment without stenting
62314175|NCT05504330||Healthy Control|Healthy control are free from intracranial stenosis
62314176|NCT00576693|EXPERIMENTAL|intensive medical management plus stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).
62314177|NCT00576693|EXPERIMENTAL|intensive medical management alone|Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
61923831|NCT02284971|EXPERIMENTAL|Arm C: CDX1127 & SBRT Sequential; SBRT upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
62314178|NCT01448551|EXPERIMENTAL|Text Messaging|
61923832|NCT06424665|EXPERIMENTAL|FZ-AD005|
62124273|NCT06677359|ACTIVE_COMPARATOR|Control multicomponent training group|Participants will recieved placebo supplementation and multicomponent training intervention
62124274|NCT06677359|EXPERIMENTAL|Creatine multicomponent training group|Participants will recieved micronized creatine monohydrate supplementation and multicomponent training intervention.
62124275|NCT03452189|ACTIVE_COMPARATOR|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
62124276|NCT03452189|PLACEBO_COMPARATOR|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
62124277|NCT00595790|ACTIVE_COMPARATOR|IC51 2 x 6 mcg|2 x 6 mcg (microgram)
62124278|NCT00595790|ACTIVE_COMPARATOR|IC51 1 x 12 mcg|1 x 12 mcg (microgram)
62124279|NCT00595790|ACTIVE_COMPARATOR|IC51 1 x 6 mcg|1 x 6 mcg (microgram)
62124280|NCT00247208|ACTIVE_COMPARATOR|1|Express 2 bare metal stent
62124281|NCT00247208|EXPERIMENTAL|2|Taxus, paclitaxel-eluting stent
62684721|NCT06569329|EXPERIMENTAL|The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy|Sterile paper points will be inserted into the root canal at 3 time points: (i) before instrumentation, (ii) after washing the canal with 10% sodium thiosulfate, and (iii) after the ProUltra Piezo Ultrasonic with EndoUltra Tips root canal therapy has been completed. The paper points will collect bacteria, which will be analyzed via real-time Polymerase Chain Reaction to assess bacterial counts.
61923833|NCT02207660||Cisplatin,P-HDFL|The general principles for patients schedule for P-HDFL regimen treatment were as followings: patients must have had white cell count \> 3000/mm3, platelet count \> 100000/mm3, a normal serum creatinine (≦1.5 mg/dL) or a measured creatinine clearance (\[urine creatinine level (mg/dL) X 24-hr urine amount (mL)\]/\[serum creatinine level (mg/dL) X 1,440 min\]) of ≧ 40 mL/min \[12,15\], total bilirubin ≦ 2 mg/dL, and transaminase (≦3X the upper normal limits). Also, patients needed to have measurable disease by radiographic studies (plain X-ray, CT or MRI scans), no serious active underlying medical issues, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
62684722|NCT04850625||Pyrotinib Plus Vinorelbine|lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2)
62314179|NCT01448551|NO_INTERVENTION|Control|Participation in the MPOWER program without receiving tailored text messages
62124282|NCT00648349|EXPERIMENTAL|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
62684723|NCT04850625||Lapatinib Plus Capecitabine|pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days)
62684724|NCT01837953|OTHER|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
62124283|NCT00648349|ACTIVE_COMPARATOR|2|Aciphex® Delayed-Release Tablets 20 mg
62124284|NCT01326039|ACTIVE_COMPARATOR|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
62684725|NCT01837953|EXPERIMENTAL|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
62124285|NCT01326039|PLACEBO_COMPARATOR|saline|perineural isotonic saline 20 ml
62124286|NCT02633267|EXPERIMENTAL|Usual Vocational Services + CBT|This is the experimental intervention - Usual vocational services at a vocational services center plus additional cognitive behavioral therapy at vocational service center.
62124287|NCT02633267|ACTIVE_COMPARATOR|Usual Vocational Services|This is the care as usual intervention - Vocational services as usually delivered to service seeking clients
62124288|NCT06139315|EXPERIMENTAL|BI 765845 treatment group (Part A)|Part A
62124289|NCT06139315|EXPERIMENTAL|BI 765845 treatment group (Part B)|Part B
62124290|NCT06139315|PLACEBO_COMPARATOR|Placebo group|Part A and B
62684726|NCT02327780|OTHER|FODMAP diet|participants will be put on a low FODMAP diet.
62124291|NCT01985542|ACTIVE_COMPARATOR|subcutaneous immunotherapy|Starts with birch pollen subcutaneous immunotherapy
62124292|NCT01985542|NO_INTERVENTION|no immunotherapy|not starting with birch pollen subcutaneous immunotherapy
62124293|NCT05356689|EXPERIMENTAL|traditional physiotherapy|Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
62684727|NCT03047044|ACTIVE_COMPARATOR|Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
62684728|NCT03047044|EXPERIMENTAL|Optimizing B.I (New) PCA mode|(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
62124294|NCT05356689|EXPERIMENTAL|3- 2dimensional lumbar traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed.
62124295|NCT05747495|EXPERIMENTAL|Participants registered in the online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link \[https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/\]."
62314180|NCT05955027|EXPERIMENTAL|80mg group|D1, two 40mg tablets and two placebo tablets
62314181|NCT05955027|EXPERIMENTAL|160mg group|D1, four 40mg tablets
62314182|NCT05955027|PLACEBO_COMPARATOR|Placebo group|D1, 4 placebo tablets
62478375|NCT06627140||Control group|Term birth without risk for preterm birth
62124296|NCT05957406|OTHER|SMART TRENDS Cohort 1|Acumen HPI Smart Alerts and Smart Trends Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.
62124297|NCT05957406|OTHER|SMART TRENDS Cohort 2|Acumen HPI Smart Alerts and Smart Trends Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.
62124298|NCT01305252|ACTIVE_COMPARATOR|tadalafil alone|tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
62124299|NCT01305252|ACTIVE_COMPARATOR|tadalafil and treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.
62124300|NCT00539292|EXPERIMENTAL|1|Silastic Spring-Loaded Silo
62124301|NCT00539292|ACTIVE_COMPARATOR|2|Primary Closure of Abdomen
62124302|NCT02847702|EXPERIMENTAL|VM902A 200 mg|VM902A 200-mg Capsules
62124303|NCT02847702|EXPERIMENTAL|VM902A 400 mg|VM902A 400-mg Capsules (2 x 200-mg capsules)
62124304|NCT02847702|ACTIVE_COMPARATOR|Naproxen|Naproxen 500-mg Capsules
62124305|NCT02847702|PLACEBO_COMPARATOR|Placebo|Placebo
62124306|NCT01170962|EXPERIMENTAL|Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
62124307|NCT01170962|EXPERIMENTAL|Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
62124308|NCT01170962|EXPERIMENTAL|Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
62124309|NCT01170962|EXPERIMENTAL|Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
62124310|NCT01170962|EXPERIMENTAL|Arm 5: Placebo plus peginterferon alfa-2a and ribavirin|(prior partial responders only)
62124311|NCT01875250|EXPERIMENTAL|Arm A - Enzalutamide for 3 months|Enzalutamide for 3 months
62124312|NCT01875250|EXPERIMENTAL|Arm B - Enzalutamide for 3 months + PSA-TRICOM|Enzalutamide 3 months + PSA-TRICOM (Prostvac-V/F) on weeks 1, 3, 5, 9,13,17 and 21
62124313|NCT04712851|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 4 cycles (24 weeks).
62124314|NCT03381820|EXPERIMENTAL|music listening|Participants who were randomized into intervention group were assigned to listen to the music everyday (day 1st to day 30th), at anytime of day that was suitable with their lifestyles but not at the time of BP measurement. During day 31st -120th, participants did not listen to the music. Other treatment was the same as the control arm.
62124315|NCT03381820|NO_INTERVENTION|control|control arm received conventional hypertension treatment.
62124316|NCT06285786|EXPERIMENTAL|Nursing Student|The study involves 1 single arm. A single group of participants will experience all experimental conditions. From an ergonomic standpoint, it has been recognized that providing patient-handling ergonomics training is crucial to their safety. This project will compare the same group performing patient handling tasks without training versus training while utilizing both long term care beds.
62124317|NCT03865758|EXPERIMENTAL|IN2L enhanced therapy|The intervention to be delivered is the use of the IN2L computer system to deliver video, music, and exercises to patients receiving physical and occupational therapy. Therapists will select the specific IN2L that will be most appropriate given each person's rehabilitation goals and personal preferences.
62124318|NCT03865758|NO_INTERVENTION|Usual OT and PT services without IN2L|The intervention to be delivered is physical therapy and occupational therapy to improve functioning.
62124319|NCT03968354||Steatosis group - Experimental1|Steatosis group
62124320|NCT03968354||NASH group without fibrosis - Experimental 2|NASH group without fibrosis
62124321|NCT03968354||Moderate fibrosis - Experimental 3|Moderate fibrosis
62124322|NCT03968354||Advanced fibrosis - Experimental 4|Advanced fibrosis
62124323|NCT03968354||Control group - Active Comparator|Control group
62124324|NCT00779636|EXPERIMENTAL|Desloratadine 10 mg|
62124325|NCT00779636|PLACEBO_COMPARATOR|Placebo|
62124326|NCT03446859|EXPERIMENTAL|TENS|It consists of 25 subjects with primary dysmenorrhea which were put on TENS for 30 minutes, three for 3 days. The subject were placed in supine lying in a comfortable position as possible. The abdomen to the inguinal region were decently exposed and cleaned, after inspection of the area for cuts, skin infections or any abnormalities. A pair of electrodes ( inactive electrodes) will be placed a little below the umbilicus ( Right and Left) and the other pair(active electrode) along the inguinal region at the level of pubic symphysis ( Right and Left) according to (Akinbo et al 2000). A quadripolar method will be used for electrode placement.
62478376|NCT06324825|EXPERIMENTAL|Fuzhegn Nizeng Formula|
62478377|NCT06324825|ACTIVE_COMPARATOR|Moluodan patient medicine|
62478378|NCT04968405|OTHER|Single Arm|Intervention with a 510k cleared shoulder arthroplasty device
62478379|NCT05204979||Misopristol|Group A: vaginal misoprostol will be taken Group B: sublingual misoprostol will be taken
62478380|NCT04514939||Group A - Leg elevation|Patients will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
62478381|NCT04514939||Group B- Non Leg elevation|Patients will lie in their hospital bed without leg elevation
62684729|NCT05535855|EXPERIMENTAL|UCD19 CAR T Infusion|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T cells. Infusion is subject to a seven (7) day delay following chemotherapy completion if needed for resolution of clinical toxicities or to allow for product release.
62684730|NCT02496156|ACTIVE_COMPARATOR|Usual Clinical Practice (UCP)|UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study. The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population. Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
61923834|NCT02758977|EXPERIMENTAL|ALPPS|"ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS)~Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) is performed according to local practice in the respective centers. Preconditions to participation are experience with major liver resections and documentation of having performed at least 5 ALPPS cases prior to participation due to the learning curve with this quite complex procedure.~The amount of transsection (in-situ split/liver partition) in Step 1 is left to the participating center, no minimal % of transsection is specified."
62124327|NCT03446859|NO_INTERVENTION|Control|These are 25 subjects which were not in any intervention. These were subjects that were not placed on TENS and were not used to drug taken for the amelioration of the dysmenorrhea. They were educated on the purpose of research and their inform consent was obtained. Their pain intensity was measured firs, third and 5th days
62124328|NCT03631550|ACTIVE_COMPARATOR|Active|Relivion Active device
62124329|NCT03631550|SHAM_COMPARATOR|Sham|Relivion Sham device
62314183|NCT06151015|EXPERIMENTAL|Dietary nitrate plus caloric restriction|Participants will drink beetroot juice with a calorie-restricted diet for 28 days.
62124330|NCT06216470|EXPERIMENTAL|VIR-3434|VIR-3434 300 mg subcutaneous injection every 4 weeks\*48 weeks
62124331|NCT05561452|EXPERIMENTAL|Single PRP Injection + Exercise|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
62124332|NCT05561452|EXPERIMENTAL|Multiple PRP Injection+ Exercise|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
62124333|NCT05561452|SHAM_COMPARATOR|Saline Injection + Exercise|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
62124334|NCT01601041||urinary tract infection|urinary tract infection in male patients with neurogenic bladder dysfunction due to spinal cord injury managed by intermittent catheterization
62124335|NCT01601041||control group|less than three urinary tract infections / year
62314184|NCT06151015|ACTIVE_COMPARATOR|Dietary nitrate alone|Participants will drink beetroot juice with a weight-maintenance diet for 28 days.
62314185|NCT00882713|EXPERIMENTAL|C.E.R.A.|Eligible participants will be administered continuous erythropoietin receptor activator (C.E.R.A.\[Mircera\]) intravenously (IV) every 4 weeks for 44 weeks. The starting dose of 120, 200, or 360 micrograms (mcg) will be based on the dose of epoetin alfa or beta administered in the week preceding the switch to C.E.R.A. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin (Hb) within a range of +/- 1.0 grams per deciliter (g/dL) of the reference hemoglobin (Hb) concentration and between 10.50 and 12.50 g/dL.
62314186|NCT03796169|EXPERIMENTAL|Endoscopist|Intervention for personal notification, open notification and colonoscopy quality education by a GI faculty
62314187|NCT03766997|EXPERIMENTAL|local injection|Compound betamethasone injection (Each injection contains betamethasone dipropionate at 5 mg for betamethasone and betamethasone sodium phosphate at 2 mg for betamethasone) was local injected to the breast by the patient once a week for one to four times followed by Hydrocortisone butyrate cream(0.1%) topical use twice a day until the termination of treatment.
62684731|NCT02496156|EXPERIMENTAL|Shared Medical Decision Making (SMDM)|Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM). Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached. The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
62124336|NCT01865253|EXPERIMENTAL|Renal Denervation|Renal Denervation treatment
62314188|NCT03766997|ACTIVE_COMPARATOR|topical|Hydrocortisone butyrate 0.1% cream was applied to the breast by the patient twice a day until the termination of treatment.
62314189|NCT04363307||Adult participants|Adult participants ages 18 and older with AF
62684732|NCT02026154||A, B, C|Group A- 15 patients without symptoms of heart failure - control group Group B- 30 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
62684733|NCT03662529|EXPERIMENTAL|Mind Freedom Plan therapy sessions|The Four-Session Mind Freedom Plan (MFP) is cognitive behavioral therapy (CBT)-based, client-centered, manualized individual therapy that functions as part of intensive outpatient substance abuse treatment. The MFP model is based on efficacious brief interventions, with content and format driven from military veteran feedback. The four 60-minute MFP sessions were one-on-one private consultations with a therapist that were focused on identifying and changing unhealthy thinking and behavioral patterns as core elements of CBT, but with an emphasis on problem-solving, coping skills, goal setting, and psychosocial functioning. At each session, structured worksheets were utilized and homework was assigned to facilitate this CBT-based skill building.
62684734|NCT03662529|ACTIVE_COMPARATOR|Treatment as usual therapy|The four 50-minute TAU sessions were one-on-one individual therapy sessions. Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed. Veterans were also connected with community-level psychosocial supports as appropriate.
62684735|NCT01674361|EXPERIMENTAL|Bitopertin 30 mg|"Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
62684736|NCT01674361|EXPERIMENTAL|Bitopertin 10 mg|"Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
62684737|NCT01674361|PLACEBO_COMPARATOR|Placebo|Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.
61923835|NCT02758977|ACTIVE_COMPARATOR|TWO STAGE HEPATECTOMY|"TWO STAGE HEPATECTOMY (TSH)~Two-Stage Hepatectomy is defined as:~1. Partial resection + portal vein ligation (RES PVL)~2. Partial resection + secondary portal vein embolization (RES PVE). Followed by (extended) hemihepatectomy after an interval to induce hypertrophy of the liver.~Conventional Two- Stage Hepatectomies will be standard procedures of the centers participating in the study."
62124337|NCT00738699|ACTIVE_COMPARATOR|1|MORAb-003 (Farletuzumab) Plus Paclitaxel
62124338|NCT00738699|PLACEBO_COMPARATOR|2|Placebo Plus Paclitaxel
62124339|NCT02728349|EXPERIMENTAL|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
62124340|NCT03720236|EXPERIMENTAL|Full preparation|Group A: the complete milling protocol indicated by the manufacturer for the 3.75x10 mm BLX implant will be performed.
62124341|NCT03720236|EXPERIMENTAL|Partial preparation|Group B: the partial / under milling protocol for the 3.75x10 mm implant, indicated by the manufacturer, will be carried out.
62314190|NCT02561377|EXPERIMENTAL|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
62314191|NCT02561377|EXPERIMENTAL|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
61923836|NCT04908020||Follow up|"The group is made up by children and adolescents, aged from 9 to 17, who received a cancer diagnosis, who completed oncological treatment and who are included in a clinical follow-up program since less than 3 years.~Furthermore, the study involves one parent for each patient to collect demographics and clinical data."
62124342|NCT03720236|EXPERIMENTAL|Deferred loading|Code 2: for implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. Impressions will be taken at 6 weeks to place the provisional prosthesis at 8 weeks. At 6 months the final impressions will be taken for the definitive load.
62124343|NCT03720236|EXPERIMENTAL|Immediate load|The code 1: to the implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. The impression will be made in the same surgery and the placement of the provisional prosthesis before 7 days. At 6 months the final impressions will be taken for the definitive load.
62314192|NCT02561377|NO_INTERVENTION|standard care|standard care complied with the daily lifestyle.
62314193|NCT05297305|ACTIVE_COMPARATOR|Onlay Component-Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
62478382|NCT06382636|PLACEBO_COMPARATOR|Standard of care|This group will utilize standard care with respect to healthcare provider practices for education and counseling surrounding prenatal screening and diagnostic testing options.
62478383|NCT06382636|EXPERIMENTAL|Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot|This arm will utilize an artificial intelligence AI enabled healthcare chatbot that provides patients with personalized information and decision-making support at different stages of the prenatal screen and diagnostic testing pathways.
62478384|NCT03956784|EXPERIMENTAL|E-assessed follow up|Patients undergoing colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric, for whom an early discharge has been programmed, and followed by a connected application and a nursing logistics platform at home.
61923837|NCT00566501|EXPERIMENTAL|Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).
62124344|NCT05936333|EXPERIMENTAL|Patient with chronic histiocytic intervillositis|Patient with CHI, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
62124345|NCT05936333|ACTIVE_COMPARATOR|patients with anti-phospholipid syndromes (APS)|Patient with antiphospholipid syndrome, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
62314194|NCT05297305|ACTIVE_COMPARATOR|Inlay Component-Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
62314195|NCT04467541|EXPERIMENTAL|Inactivated enterovirus type 71 vaccine|Inactivated enterovirus type 71 vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
62314196|NCT05259046|EXPERIMENTAL|Intervention|Intervention treatment . Dietary supplementation with Menaquinone-7 (MK-7) tablet (333 µg/day). MK-7 (K2VITAL®DELTA) tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
62314197|NCT05259046|PLACEBO_COMPARATOR|Placebo|Placebo tablet (no active treatment). The placebo tablets will match the intervention treatment in both taste and appearance. Placebo tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
62314198|NCT02399878||Patients undergoing surgery|All non-cardiothoracic surgical patients aged 18 years or above receiving general anesthesia at Massachusetts General Hospital between January 2007 and August 2014.
62314199|NCT06257407||Adults Patients with Liver transplant|No intervention during this observational study. Patient who meet the inclusion criteria will be included
62314200|NCT02172612|EXPERIMENTAL|Arm 1 - Intervention|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
62314201|NCT02172612|NO_INTERVENTION|Arm 2 - Control|Those included in the control group will receive a generic brochure about medication safety and inappropriate medication use in the elderly.
62314202|NCT00164905|ACTIVE_COMPARATOR|Doppler ultrasound|
62124346|NCT05936333|PLACEBO_COMPARATOR|women with a third full-term pregnancy without growth retardation.|Patient with normal pregnancies, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
62314203|NCT00164905|NO_INTERVENTION|No Doppler ultrasound|
62314204|NCT05131321||Part 1: Fusion Group|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
62314205|NCT05131321||Part 2: IMFN|Intramedullary Fibular Nailing: Participants allocated to the IMFN group will receive a locked fibular nail using a previously described technique.
62314206|NCT05131321||Control Group: Internal Fixation|ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
62478385|NCT03956784|OTHER|Standard home follow-up care|Patients undergoing surgery for colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric surgery, for whom an early discharge has been programmed, and followed by usual way.
62478386|NCT01625858||Supreme / other pediatric SGA|pediatric patients undergoing general anesthesia being treated with LMA Supreme or another pediatric supraglottic airway device
62478387|NCT02767791|ACTIVE_COMPARATOR|Acupuncture|Acupuncture wrist 6
62478388|NCT02767791|ACTIVE_COMPARATOR|Auriculotherapy|Auriculotherapy
62478389|NCT02767791|EXPERIMENTAL|Auriculotherapy and acupuncture|Auriculotherapy and acupuncture
62478390|NCT02767791|NO_INTERVENTION|No treatment|No treatment
62478391|NCT05347719|EXPERIMENTAL|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions led by a trained healthcare provider. Post-intervention, the experimental group will receive treatment as usual.
62124347|NCT02550691|EXPERIMENTAL|Subject carrying 3 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
62124348|NCT02550691|OTHER|Subject carrying 2 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
62314207|NCT04638127|EXPERIMENTAL|PREEMIE PROGRESS|PREEMIE PROGRESS is an innovative, video-based intervention that applies evidence-based family management theories to better equip parents to meet the chronic, complex healthcare needs of their preterm infant.
62478392|NCT05347719|NO_INTERVENTION|Wait List Control|Participants will engage in treatment as usual during the baseline period. After the experimental group completes the MBCT intervention, the wait list control group will complete the MBCT intervention.
62124349|NCT02550691|OTHER|Subject carrying 3 copies of the SMN2 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
62124350|NCT01219205|ACTIVE_COMPARATOR|major branched retinal venous occlusion|
62478393|NCT04722458||Patients with Lower urinary tract sypmtoms|Patients with Lower urinary tract sypmtoms over 18 years old will be included to this study
62478394|NCT04367766|ACTIVE_COMPARATOR|Immediate Implant Placement|prosthetically driven immediate implant placement (TLC implant, Straumann) with bone substitute (BioOss Collagen, Geistlich) filling the gap between the buccal socket wall and the implant surface and a collagen matrix (Fibrogide, Geistlich) positioning at the vestibular aspect to increase soft tissue volume, with immediate (non occlusal loading) prosthetic provisionalization.
62124351|NCT01219205|ACTIVE_COMPARATOR|macular branched retinal venous occlusion|
62124352|NCT02847780|ACTIVE_COMPARATOR|C-Mac video laryngoscope.|Active Comparator: C-Mac Videolaryngoscope for vocal cord movement assessment.
62314208|NCT04638127|ACTIVE_COMPARATOR|Attention Control|"To maintain their attention, control parents will view Welcome Videos that explain hand hygiene, visitor IDs, parking, etc. on their mobile devices."
62478395|NCT04367766|ACTIVE_COMPARATOR|Alveolar Ridge Preservation (ARP) + Delayed Implant Placement:|ARP performed with bone substitute (BioOss Collagen, Geistlich) and a collagen matrix placed to seal the socket entrance (Mucograft Seal, Geistlich). After 4 months of healing a prosthetically driven implant (TLC implant, Straumann) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be \< 2 mm and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be \< 2mm
62124353|NCT02847780|EXPERIMENTAL|Airway Ultrasound|Experimental: Airway Ultrasound for vocal cord movement assessment.
62124354|NCT04113707|EXPERIMENTAL|Motor Lab|Group A will receive 20 minutes of motor lab intervention daily.
62124355|NCT04113707|NO_INTERVENTION|Standard of Care|Group B will receive standard of care which will be 20 minutes of reading per day.
62124356|NCT01524952|EXPERIMENTAL|Active|cTEMS
62124357|NCT01736891|EXPERIMENTAL|Rasagiline|Rasagiline 0.5 mg by mouth every day for 2 weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
62124358|NCT01736891|PLACEBO_COMPARATOR|Placebo|placebo 0.5 mg by mouth every day for two weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
62124359|NCT02363192|EXPERIMENTAL|Pharmacist Intervention Group|
62124360|NCT02363192|NO_INTERVENTION|Usual Care Group|
62124361|NCT05076799|ACTIVE_COMPARATOR|3 L Polyethylene glycol solution group|The participants were instructed to consume 3000 mL of PEG solution
62124362|NCT05076799|EXPERIMENTAL|100 ml lactulose combined with 1 L PEG group|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
62478396|NCT04367766|ACTIVE_COMPARATOR|Spontaneous Healing + Delayed Implant Placement|extraction socket will be left to heal spontaneously. After 4 months of healing a prosthetically driven implant (TLC implant, Straumann) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be \< 2 mm, and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be \< 2mm .
62478397|NCT03872128|ACTIVE_COMPARATOR|patients receiving 300mg PREG|Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
62478398|NCT03872128|ACTIVE_COMPARATOR|patients receiving 500mg PREG|Patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
62478399|NCT03872128|PLACEBO_COMPARATOR|placebo|Patients randomly assigned to receive a placebo daily.
62478400|NCT04712045|EXPERIMENTAL|New PPE|Use of Short sleeve gown and single pair of gloves
62314209|NCT06671314||Heart Failure Cohort|Adults hospitalized with heart failure from the Get With The Guidelines - Heart Failure (GWTG-HF) registry and enrolled in Medicare Fee-for-Service at the time of discharge. Patients had heart failure with preserved or mildly reduced ejection fraction.
62314210|NCT02504892|EXPERIMENTAL|Birt-Hogg-Dube Syndrome|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
62314211|NCT02504892|EXPERIMENTAL|Sporadic chromophobe renal tumors|Sporadic chromophobe renal tumors
61923838|NCT00566501|EXPERIMENTAL|Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).
61923839|NCT03899688|EXPERIMENTAL|test site|The space obtained underneath the sinus mucosa will be filled with the xenograft without protecting the antrostomy with a collagen membrane in the test sites. Bone to implant contact was measured at the turned and machined surface.
61923840|NCT03899688|ACTIVE_COMPARATOR|control site|The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites. Bone to implant contact was measured at the turned and machined surface.
61923841|NCT02278471|NO_INTERVENTION|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
62124363|NCT05076799|EXPERIMENTAL|100 ml lactulose combined with 2 L PEG group|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
62314212|NCT03942328|EXPERIMENTAL|Phase II(pheresis, EBRT, dendritic cells, Prevnar, atezo, bev)|Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV and bevacizumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
62314213|NCT03942328|EXPERIMENTAL|Pilot study (pheresis, EBRT, dendritic cells, Prevnar)|Patients with unresectable intrahepatic CCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
62314214|NCT01650779|EXPERIMENTAL|Agalsidase beta|
62314215|NCT01556633|EXPERIMENTAL|Volunteers on dialysis|
62314216|NCT01556633|EXPERIMENTAL|Volunteers with reduced creatinine clearance|
61923842|NCT02278471|EXPERIMENTAL|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily."
62124364|NCT05076799|EXPERIMENTAL|200 ml lactulose group|the participants were instructed to consume 200 ml lactulose
62314217|NCT05664685|EXPERIMENTAL|Intervention|The intervention group will be treated with Esomeprazole 40 mg every 8 hours, Amoxicillin 1 gr every 8 hours, Metronidazole 500 mg every 8 hours, Bismuth subsalicylate 369 mg every 8 hours.
62124365|NCT01456715|ACTIVE_COMPARATOR|Gardasil, Immunogenicity, Booster dose.|
62124366|NCT01456715|EXPERIMENTAL|Cervarix, Immunogenicity, Booster dose.|
62314218|NCT05664685|ACTIVE_COMPARATOR|Control|The control group will be treated with Omeprazole 20mg every 12 hours, Amoxicillin 1 gr every 12 hours, Clarithromycin 500 mg every 12 hours, Placebo identical to Bismuth Subsalicylate, 3 times daily.
62314219|NCT06008171|ACTIVE_COMPARATOR|Patient Decision Aid|Consult about treatment options for field-directed therapies for actinic keratosis by the dermatologist, with the use of a Patient Decision Aid.
62314220|NCT06008171|NO_INTERVENTION|Without Patient Decision Aid (conventional)|Conventional consult about treatment options for field-directed therapies for actinic keratosis by the dermatologist, without the use of a Patient Decision Aid.
62314221|NCT01707823|EXPERIMENTAL|Prevention (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO for 7 days.
62314222|NCT06672757|EXPERIMENTAL|Intervention with NIHSS certification and use of app|All paramedics who have been NIHSS certified wil be enrolled in this arm. Intervention
61923843|NCT02297282|EXPERIMENTAL|Behavioural Activation|Originally a component of Cognitive Therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
62124367|NCT04974450|EXPERIMENTAL|Trigona Honey|The intervention will be given by oral route in a form of liquid of 70-gram trigona honey once daily for 8 weeks
62124368|NCT04974450|ACTIVE_COMPARATOR|Control|The intervention will be given by oral route in a form of liquid of 70-gram artificial honey once daily for 8 weeks
62124369|NCT02273544|EXPERIMENTAL|Asasantin ER (new formulation - low)|
62314223|NCT06672757|NO_INTERVENTION|Control - standard operating procedure|Paramedics will remain in this arm until they have been NIHSS certified
62314224|NCT00636623|OTHER|2|Pilates exercises
62314225|NCT00636623|OTHER|1|Connective tissue massage
62697380|NCT02516813|EXPERIMENTAL|Phase 1a (Arm A): M3814 Capsule (200 mg) + RT|Participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that was not amenable to surgical therapy, or with standard systemic therapy with an indication for palliative RT received 200 mg of M3814 as capsule orally once daily on FD 6 in combination with RT (3 \[Gy\] x 10, 5 F/W).
62314226|NCT05783869||Patient with bronchiectasis and cardiovascular comorbidities|Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.
62314227|NCT05783869||Patients with bronchiectasis and without cardiovascular comorbidities|Patients with Bronchiectasis had no comorbidities.
62314228|NCT03969433|EXPERIMENTAL|Phase I|Data collections are performed with TMSi Porti system and CTG (reference)
62314229|NCT03969433|EXPERIMENTAL|Phases II-III-IV|Data collections are performed with the Bloomlife sensor and CTG (reference)
62314230|NCT06265558|ACTIVE_COMPARATOR|Standard care|Conventional post-operative care
62697381|NCT02516813|EXPERIMENTAL|Phase 1a (Arm A): M3814 Capsule (300 mg) + RT|Participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that was not amenable to surgical therapy, or with standard systemic therapy with an indication for palliative RT received 300 mg of M3814 as capsule orally once daily on FD 6 in combination with RT (3 \[Gy\] x 10, 5 F/W).
62124370|NCT02273544|EXPERIMENTAL|Asasantin ER (new formulation - medium)|
62314231|NCT06265558|EXPERIMENTAL|Negative pressure therapy (NPT)|Immediate post-operative negative pressure therapy
62314232|NCT04083144|ACTIVE_COMPARATOR|Deep rTMS active + Varenicline|Participants undergoing deep rTMS (active) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
62124371|NCT02273544|EXPERIMENTAL|Asasantin ER (new formulation- high)|
62124372|NCT02273544|ACTIVE_COMPARATOR|Asasantin ER - commercial formulation|
62124373|NCT01457612|PLACEBO_COMPARATOR|Placebo1|Placebo Beverage 1 without fiber
62124374|NCT01457612|ACTIVE_COMPARATOR|Strawberry|Strawberry Beverage 20g/BID
62124375|NCT01457612|PLACEBO_COMPARATOR|Placebo2|Placebo Beverage 2 with Fiber
62124376|NCT00731523|EXPERIMENTAL|1|
62124377|NCT00838253|EXPERIMENTAL|1|
62124378|NCT00838253|EXPERIMENTAL|2|
62124379|NCT00838253|EXPERIMENTAL|3|
62124380|NCT00838253|PLACEBO_COMPARATOR|4|
62124381|NCT02055794|ACTIVE_COMPARATOR|Suturing of the perineal skin|Suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
62124382|NCT02055794|ACTIVE_COMPARATOR|No suturing of the perineal skin|No suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
62314233|NCT04083144|SHAM_COMPARATOR|Deep rTMS sham + Varenicline|Participants undergoing deep rTMS (sham) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
62314234|NCT00418886|PLACEBO_COMPARATOR|1|Placebo Vandetanib + Pemetrexed
62478401|NCT04712045|ACTIVE_COMPARATOR|Old PPE|Use of Long sleeve gown and double pairs of gloves
62314235|NCT00418886|EXPERIMENTAL|2|Vandetanib + Pemetrexed
62314236|NCT05367960|OTHER|Study Drug (BPN14770)|25mg BID Study Drug BPN14770 (Adults) or 15mg BID Study Drug BPN14770 (Adolescents with body weight \<43 kg)
62314237|NCT03807765|EXPERIMENTAL|Nivolumab followed by stereotactic radiosurgery (SRS)|480 mg Nivolumab will be given intravenously every 4 weeks, followed by SRS the week after the initial dose of Nivolumab.
62124383|NCT02055794|ACTIVE_COMPARATOR|Closing perineal skin with surgical glue|Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
62124384|NCT00726544|PLACEBO_COMPARATOR|Placebo|
62124385|NCT00726544|ACTIVE_COMPARATOR|Low Dose|
62124386|NCT00726544|ACTIVE_COMPARATOR|Medium Dose|
62124387|NCT00726544|ACTIVE_COMPARATOR|High Dose|
62124388|NCT00407082|EXPERIMENTAL|Fluocinolone acetonide 0.59mg|Fluocinolone acetonide ocular implant 0.59mg
62124389|NCT00407082|EXPERIMENTAL|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
62124390|NCT00407082|NO_INTERVENTION|No intervention|Fellow eye
62124391|NCT03301025|ACTIVE_COMPARATOR|Pregabalin group|(n=53):
62124392|NCT03301025|PLACEBO_COMPARATOR|placebo group|(n=53):
62124393|NCT01519752|EXPERIMENTAL|Oxiconazole Nitrate Cream 1%|
62124394|NCT01519752|ACTIVE_COMPARATOR|Oxiconazole Nitrate Cream 1% (Oxistat®)|
62124395|NCT01519752|PLACEBO_COMPARATOR|Placebo|
62124396|NCT03842488|EXPERIMENTAL|RAL 1200 QD|Start treatment with Raltegravir (RAL) 1200mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
62124397|NCT03842488|ACTIVE_COMPARATOR|DRV/cb|Start treatment with Darunavir/Cobicistat (DRV/cb) 800-150mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
62124398|NCT06554756|OTHER|Active Comparator|Saliva, serum and GCF collection of patients and samples molecules analysis
62124399|NCT06554756|EXPERIMENTAL|Experimental|Salivary, serum and GCF ANXA1, ANXA2 and IL-1beta observation Saliva, serum and GCF samples obtained for each patient were used for cytokine analysis. Prepared samples were analyzed for ANXA1, ANXA2 and IL-1beta using commercial ELISA kits (Elabscience, Houston, Texas, USA and Bioaasay Technology Laboratory (BT-Lab), Shanghai, China, respectively) according to the manufacturer's instructions.
62124400|NCT05742126|EXPERIMENTAL|HSK36273|Multiple continuous IV infusion ascending doses in cohort 1-5
62124401|NCT05742126|PLACEBO_COMPARATOR|Placebo|5 cohorts with matching placebo to HSK36273
62124402|NCT05742126|ACTIVE_COMPARATOR|Heparin sodium injection|Cohort 1-2 with matching positive control to HSK36273
62124403|NCT01713946|EXPERIMENTAL|Everolimus LT target of 3 - 7 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.
62124404|NCT01713946|EXPERIMENTAL|Everolimus HT target of 9 -15 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.
62314238|NCT02727114||participants aged 8 weeks to 3 years|"Echographic measurement of skin thickness at the proximal forearm, the deltoid region and medial thigh (till age of 2 years) in participants aged 8 weeks to 3 years.~aimed number: 32 boys \& 32 girls / maximum number: 50 boys \& 50 girls"
62478402|NCT04260217|EXPERIMENTAL|APG2575 400 mg|APG2575 400mg ramp up arm
62478403|NCT04260217|EXPERIMENTAL|APG2575 600 mg|APG2575 600 mg ramp up arm
62478404|NCT04260217|EXPERIMENTAL|APG2575 800 mg arm|APG2575 800 mg arm ramp up
62478405|NCT01521715|EXPERIMENTAL|Pazopanib|800 mg (2x400mg) pazopanib per day
62478406|NCT05286047|EXPERIMENTAL|Bifidobacterium longum CCFM1029|
62478407|NCT05286047|PLACEBO_COMPARATOR|Placebo|
62478408|NCT04292873|NO_INTERVENTION|Control|
62697382|NCT02516813|EXPERIMENTAL|Phase 1a (Arm A): M3814 Capsule (400 mg) + RT|Participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that was not amenable to surgical therapy, or with standard systemic therapy with an indication for palliative RT received 400 mg of M3814 as capsule orally once daily on FD 6 in combination with RT (3 \[Gy\] x 10, 5 F/W).
62124405|NCT01713946|PLACEBO_COMPARATOR|Placebo|Participants received placebo plus 1 to 3 antiepileptic drugs.
62124406|NCT02759588|EXPERIMENTAL|GL-ONC1|
62314239|NCT02727114||participants aged 3 to 6 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 3 to 6 years.~aimed number: 32 boys \& 32 girls / maximum number: 50 boys \& 50 girls"
62314240|NCT02727114||participants aged 6 to 12 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 6 to 12 years.~aimed number: 32 boys \& 32 girls / maximum number: 50 boys \& 50 girls"
62314241|NCT02727114||participants aged 12 to 18 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 12 to 18 years.~aimed number: 32 boys \& 32 girls / maximum number: 50 boys \& 50 girls"
62314242|NCT01203462|EXPERIMENTAL|Bifidobacterium supplemented yogurt|Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
62314243|NCT01203462|PLACEBO_COMPARATOR|Placebo Yogurt|Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
62314244|NCT06672432|EXPERIMENTAL|CareMom group|The intervention program, CareMom, is a structured, 8-week digital intervention delivered through a WeChat mini-program in Chinese, developed by Shanghai Thoven Technology Co. Ltd., China, under the guidance of psychologists and psychiatrists. CareMom is designed to support perinatal mental health by providing daily challenges, educational content, and interactive exercises that target cognitive restructuring, behavioral activation, and worry management, key therapeutic components for alleviating symptoms of depression and anxiety. Participants in the intervention group will also receive standard perinatal care throughout the study. This includes routine prenatal check-ups, postpartum nursing care, and scheduled postnatal visits, ensuring that all participants receive the essential healthcare services typically provided during the perinatal period.
62478409|NCT04292873|EXPERIMENTAL|Vitamin D|Enteral supplement of 569,600 IU vitamin D
62124407|NCT03616535|ACTIVE_COMPARATOR|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
62478410|NCT01273350|OTHER|Single arm|"Single arm observational study looking at a low risk cohort of individuals with carotid stenosis"
62478411|NCT00830258|EXPERIMENTAL|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
62697383|NCT02516813|EXPERIMENTAL|Phase 1a (Arm A): M3814 Tablet (100 mg) + RT|Participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that was not amenable to surgical therapy, or with standard systemic therapy with an indication for palliative RT received 100 mg of M3814 as tablet orally once daily for 2 consecutive weeks in combination with RT (3 Gy x 10, 5 F/W).
62124408|NCT03616535|ACTIVE_COMPARATOR|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (\~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
62124409|NCT03616535|ACTIVE_COMPARATOR|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
62684738|NCT06468930|EXPERIMENTAL|ALLLT + IPL group|Participants will receive a session of IPL therapy followed by LLLT therapy, once weekly for 4 weeks (total 4 treatment sessions). The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim. The LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system.
62684739|NCT06468930|ACTIVE_COMPARATOR|IPL alone group|The IPL alone group will receive only a session of IPL therapy, once weekly for 4 weeks (total 4 treatment sessions). The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim, similar to the combined group. Additionally, the special facial mask will also be placed on the participant's face for 15 minutes with no light power applied.
62684740|NCT06690502||IndoVac COVID-19 Vaccine|Clinically healthy adults aged 18 years and above who received Booster IndoVac COVID-19 Vaccination
62314245|NCT06672432|ACTIVE_COMPARATOR|Control group|The control group in this study will participate in an attention-matched, 8-week online relaxation training program delivered through a mobile application. Participants in the control group will also continue to receive standard perinatal care. This standard care is not altered or influenced by participation in the study, ensuring that all participants receive the usual care necessary for perinatal health.
62478412|NCT00830258|ACTIVE_COMPARATOR|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
62684741|NCT05600257||Screening cohort|Women received mammography screening
61923844|NCT02297282|NO_INTERVENTION|Wait List (Control Group)|The Control group (waitlist) will receive treatment as usual while they are waiting to start the BA intervention at the end of the Intervention Group Therapy time (28 sessions over an 18 week period). In addition to usual care, the control group will be assessed by clinical staff that offers treatment as usual for mood symptoms and quality of life measures during the waiting time.
61923845|NCT00867477|EXPERIMENTAL|Cohort 1: Esophagus Cancer|Breathing Test + Respiratory Symptoms Questionnaire
62124410|NCT03616535|NO_INTERVENTION|Standard of Care|Participants in this arm will receive standard of care
62124411|NCT03107117|EXPERIMENTAL|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
62124412|NCT03107117|ACTIVE_COMPARATOR|Standard care|Standard care is typically referral to counseling for substance use
62124413|NCT02665988|EXPERIMENTAL|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
62478413|NCT05679024|ACTIVE_COMPARATOR|Apixaban 2.5 mg twice daily and standard of care|Apixaban 2.5 mg twice daily (low dose) and all other standard of care
62478414|NCT05679024|NO_INTERVENTION|Standard of care and no anticoagulation|All other Standard of care and no anticoagulation
62478415|NCT06563115|PLACEBO_COMPARATOR|Placebo_Single Ascending Dose|Participants received a single SC dose of placebo on Day 1
62684742|NCT05600257||Diagnostic cohort|Women received clinical breast examination
62684743|NCT06690320|NO_INTERVENTION|control group|No application will be made to the control group. After the research is completed, a planned training program can be applied to the experimental group upon request by the researcher within the framework of ethical responsibilities.
62684744|NCT06690320|EXPERIMENTAL|experiment group|A one-session planned training program will be applied to the experimental group.
62684745|NCT02423954|EXPERIMENTAL|Arm 1|Temsirolimus 25 mg every 14 days + nivolumab
62684746|NCT02423954|EXPERIMENTAL|Arm 2|Irinotecan 150 mg/m2 every 14 days + nivolumab
61923846|NCT00867477|EXPERIMENTAL|Cohort 2: Lung Cancer|Breathing Test + Respiratory Symptoms Questionnaire
62124414|NCT02665988|PLACEBO_COMPARATOR|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
62124415|NCT01595061|EXPERIMENTAL|Treatment (IMRT, gemcitabine, cisplatin, surgery)|Patients undergo IMRT 5 days a week for 6 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after completion of chemoradiation patients undergo local core biopsy to confirm response or surgical excision of gross residual disease in the vulva and/or inguinal-femoral lymph nodes.
62124416|NCT02265276|ACTIVE_COMPARATOR|Saroglitazar Group|Tab Saroglitazar 4 mg oral daily fixed dose for 24 weeks
62124417|NCT02265276|PLACEBO_COMPARATOR|Pioglitazone Group|Tab Pioglitazone 30 mg daily fixed dose for 24 weeks
62124418|NCT00194896|ACTIVE_COMPARATOR|rosiglitazone|Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
62124419|NCT00194896|ACTIVE_COMPARATOR|glyburide|Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.
62684747|NCT02423954|EXPERIMENTAL|Arm 3|Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period
62684748|NCT04519138|EXPERIMENTAL|Endodrill Model X|Three consecutive samples will be taken using the Endodrill Model X instrument.
62684749|NCT04519138|ACTIVE_COMPARATOR|Endoscopic ultrasound guided fine-needle aspiration/biopsy|Three consecutive samples will be taken using the the standard method fine-needle aspiration/biopsy.
62684750|NCT06543537|EXPERIMENTAL|Arm 1: CASI Intervention|"Enrolled patients and caregivers will complete:~* Audio recorded baseline visit~* CASI via mobile device, laptop, or desktop computer 1 week prior to CASI visit 1~* Audio recorded CASI visit 1~* CASI via mobile device, laptop, or desktop computer 1 week prior to CASI visit 2~* Audio recorded CASI visit 2~* CASI via mobile device, laptop, or desktop computer 1 week prior to CASI visit 3~* Audio recorded CASI visit 3~* End of study visit~For each enrolled patient, enrolled clinicians will complete:~* Audio recorded baseline visit~* Audio recorded CASI visit 1~* Audio recorded CASI visit 2~* Audio recorded CASI visit 3~Enrolled clinicians will also complete:~* Baseline visit, one time~* End of study visit, one time"
62684751|NCT06543537|NO_INTERVENTION|Arm 2: Control|"Enrolled patients and caregivers will complete:~* Audio recorded baseline visit~* Audio recorded visit 1 will proceed according to usual, oncology care~* Audio recorded visit 2 will proceed according to usual, oncology care~* Audio recorded visit 3 will proceed according to usual, oncology care~* End of study visit~For each enrolled patient, enrolled clinicians will complete:~* Audio recorded baseline visit~* Audio recorded visit 1 will proceed according to usual, oncology care~* Audio recorded visit 2 will proceed according to usual, oncology care~* Audio recorded visit 3 will proceed according to usual, oncology care~Enrolled clinicians will also complete:~* Baseline visit, one time~* End of study visit, one time"
62684752|NCT02594943|ACTIVE_COMPARATOR|Conventional Biopsy|"4 out of 8 biopsies taken with a Boston Scientific Large capacity with needle biopsy forceps from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
62684753|NCT02594943|ACTIVE_COMPARATOR|Endodrill Biopsy|"4 out of 8 biopsies taken with the Endodrill 1A instrument from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
62684754|NCT06691152|EXPERIMENTAL|CAR T cell treatment group|This trial was designed as an open, single-arm, multicenter, dose-increasing trial, three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) are set up, starting from the low dose group to explore the safe and effective dose.
62478416|NCT06563115|EXPERIMENTAL|Experimental (PEG)-BHD1028_Single Ascending Dose|Participants received a single escalated SC dose of (PEG)-BHD1028 on Day 1
62124420|NCT05813444||Main Cohort|Dental students on the university hospital of Nice
62124421|NCT04425629|EXPERIMENTAL|casirivimab+imdevimab low dose|Low dose or body-weight equivalent for those under 18 years of age.
62478417|NCT06563115|PLACEBO_COMPARATOR|Placebo_Multiple Ascending Dose|Participants received SC doses of placebo once a day for 28 days
62684755|NCT04898309|EXPERIMENTAL|Study stage 1: GNR-038, 50 МЕ/ kg|Recombinant C1 esterase inhibitor
62684756|NCT04898309|EXPERIMENTAL|Study stage 1: GNR-038, 100 МЕ/ kg|Recombinant C1 esterase inhibitor
62684757|NCT04898309|EXPERIMENTAL|Study stage 1: Berinert®, 20 МЕ/ kg|Human C1 esterase inhibitor
62684758|NCT04898309|EXPERIMENTAL|Study stage 1: Placebo|Placebo
62124422|NCT04213053|OTHER|Concomitant strabismus patients|Horizontal strabismus surgery
62684759|NCT04898309|EXPERIMENTAL|Study stage 2: GNR-038 in selected dose|Recombinant C1 esterase inhibitor
62684760|NCT04898309|EXPERIMENTAL|Study stage 2: Berinert®, 20 МЕ/ kg|Human C1 esterase inhibitor
62684761|NCT04969770|EXPERIMENTAL|Neuromuscular scoliosis|Minor patients with neuromuscular scoliosis and followed at Necker Hospital
62684762|NCT04969770|OTHER|Neuromuscular pathologies without instrumented scoliosis|Minor patients with neuromuscular pathology without instrumented scoliosis and followed at Necker Hospital
62684763|NCT04969770|OTHER|Controls|Minor patients without neuromuscular pathology or scoliosis and followed at Necker Hospital
62684764|NCT06688877||Controlgroup: No headphones, no music, no noise cancelling (no additional treatment)|Experimental group 1: headphones with activated noise cancelling
62684765|NCT06688877||Experimental group 2: headphones with activated noise cancelling and soft 60 bpm music|
61923847|NCT02845518|EXPERIMENTAL|no arms|"All patients included will undergo a cardiac Magnetic Resonance Imaging (cMRI) at the baseline visit (V1), at 3- or 6-month follow up visit (V2 or V3), at 24-month follow up visit and in case of clinical worsening during the first 24-month of follow up.~All patients will complete a questionnaire on the acceptability and tolerability of cMRI and right heart catheterization at V1, V2 or V3 and V9, right heart catheterization being performed as a routine test in pulmonary arterial hypertension.~Depending on patient agreement, 22 ml of peripheral venous blood will be taken at visits V1, V2 or V3 and V9. On one of these 3 visits a blood sample of 5 ml will be taken from the pulmonary artery during the right cardiac catheterization."
62684766|NCT06688877||Experimental group 1: headphones with activated noise cancelling|
62684767|NCT06687733|EXPERIMENTAL|NGGT002|Six to eighteen patients will be enrolled into three cohorts at three dose levels.
62684768|NCT01127204|ACTIVE_COMPARATOR|arm 1 (reference strategy)|AZT-3TC-LPV/r twice a day
62684769|NCT01127204|EXPERIMENTAL|arm 2 (simplification strategy)|ABC-3TC-EFV once a day
62684770|NCT06672939|EXPERIMENTAL|Orforglipron|Participants will receive orforglipron orally
62684771|NCT06672939|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally
62684772|NCT03280615|EXPERIMENTAL|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
62684773|NCT03280615|PLACEBO_COMPARATOR|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
62697384|NCT02516813|EXPERIMENTAL|Phase 1a (Arm A): M3814 Tablet (200 mg) + RT|Participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that was not amenable to surgical therapy, or with standard systemic therapy with an indication for palliative RT received 200 mg of M3814 as tablet orally once daily for 2 consecutive weeks in combination with RT (3 Gy x 10, 5 F/W).
62684774|NCT06689124|ACTIVE_COMPARATOR|Nebulized fentanyl 2 mcg/kg|The researcher prepared fentanyl (the researcher informed the in-charge nurse to open the medicine cabinet and double-checked the dosage with the in-charge nurse). The dosage was 2 micrograms per kilogram of body weight (calculated based on the patient's actual weight in kilograms). The medication was contained in a nebulizer. It was then mixed with normal saline (0.9% normal saline) to a total volume of 5 milliliters and administered via nebulization.
62684775|NCT06689124|ACTIVE_COMPARATOR|Nebulized fentanyl 3 mcg/kg|The researcher prepared fentanyl (the researcher informed the in-charge nurse to open the medicine cabinet and double-checked the dosage with the in-charge nurse). The dosage was 3 micrograms per kilogram of body weight (calculated based on the patient's actual weight in kilograms). The medication was contained in a nebulizer. It was then mixed with normal saline (0.9% normal saline) to a total volume of 5 milliliters and administered via nebulization.
62684776|NCT06689124|ACTIVE_COMPARATOR|Nebulized fentanyl 4 mcg/kg|The researcher prepared fentanyl (the researcher informed the in-charge nurse to open the medicine cabinet and double-checked the dosage with the in-charge nurse). The dosage was 4 micrograms per kilogram of body weight (calculated based on the patient's actual weight in kilograms). The medication was contained in a nebulizer. It was then mixed with normal saline (0.9% normal saline) to a total volume of 5 milliliters and administered via nebulization.
62684777|NCT03399747|EXPERIMENTAL|Abb-R-CHOP|
62124423|NCT05583110|EXPERIMENTAL|Trastuzumab-Vinorelbine-Tucatinib|Trastuzumab-Vinorelbine-Tucatinib
62478418|NCT06563115|EXPERIMENTAL|Experimental (PEG)-BHD1028_Multiple Ascending Dose|Participants received SC doses of (PEG)-BHD1028 once a day for 28 days
62124424|NCT05412199|EXPERIMENTAL|Percussion Massage Therapy Group|The group to which percussion massage therapy will be applied to the posterior leg muscles.
62684778|NCT06365853|EXPERIMENTAL|Primary Prophylactic Steroid Eye Drops|Prednisolone acetate ophthalmic suspension 1% 6 times daily on Days -1 to 4 and 4 times daily (QID) on Days 5 to 8 of each cycle; Lubricating eye drops QID throughout the entire cycle (doses should follow steroid dosing, when given, by approximately 15 minutes); MIRV 6 milligrams (mg)/kilogram (kg) adjusted ideal body weight (AIBW) every 3 weeks (Q3W) on Day 1 of each cycle. Each cycle length = 21 days.
62684779|NCT06365853|EXPERIMENTAL|Primary Prophylactic Vasoconstricting Eye Drops|Primary prophylactic brimonidine tartrate ophthalmic solution eye drops 3 times daily (TID) on Days 1 to 8 of each cycle (vasoconstricting drops should be started on the day of first infusion and should begin before the first infusion on Cycle 1 Day 1); Lubricating eye drops QID throughout the entire cycle (doses should follow brimonidine dosing, when given, by approximately 15 minutes); MIRV 6 mg/kg AIBW Q3W on Day 1 of each cycle. Each cycle length = 21 days.
62684780|NCT06455280|EXPERIMENTAL|Open Label|subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.
62684781|NCT03378635|EXPERIMENTAL|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
62684782|NCT03378635|PLACEBO_COMPARATOR|Placebo|Single fixed dose (s.c.injection) of placebo
62684783|NCT03378635|ACTIVE_COMPARATOR|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
62684784|NCT02197364||ILD, Other respiratory diseases, Healthy control group|"ILD: those with interstitial lung disease.~Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.~Healthy control group: those who is healthy."
62124425|NCT05412199|EXPERIMENTAL|Graston (IASTM) Group|The group in which instrument-assisted soft tissue mobilization will be applied to the posterior leg muscles.
62314246|NCT02958163|ACTIVE_COMPARATOR|Trans-Arterial Chemo-embolization (TACE)|"Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date."
62314247|NCT02958163|EXPERIMENTAL|TACE+Stereotactic Ablative Radiotherapy|"The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date."
62684785|NCT00866775|EXPERIMENTAL|Eslicarbazepine 1600 mg QD|"Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD (Day 0) to 1200 mg QD (Week 1) to 1600 mg QD (Weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
62684786|NCT00866775|EXPERIMENTAL|Eslicarbazepine 1200 mg QD|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day 0) to 800 mg QD (week 1) to 1200 mg QD (weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
62684787|NCT03405753|ACTIVE_COMPARATOR|Aroia|
62314248|NCT03047460||healthy|"healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses~Intervention: multimodal evoked potentials"
62314249|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:~* Aged 18 to 58 years old, inclusive, at the time of informed consent.~* Expanded Disability Status Scale (EDSS) 0.0 to 6.5.~* Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb~* Have no comorbid condition (ie neuropathy) that could affect testing.~Intervention: multimodal evoked potentials"
62314250|NCT04294784|EXPERIMENTAL|Nab-P/PD-1|Patients in this arm receive albumin-bound paclitaxel and SHR-1210 (PD-1 inhibitor) thepary.
62314251|NCT04294784|ACTIVE_COMPARATOR|Nab-P|Patients in this arm receive albumin-bound paclitaxel single-agent chemotherapy.
62314252|NCT03071406|ACTIVE_COMPARATOR|Arm A: Nivolumab + Ipilimumab|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.
62314253|NCT03071406|ACTIVE_COMPARATOR|Arm B: Nivolumab + Ipilimumab + SBRT|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.
62314254|NCT04542291|EXPERIMENTAL|Dapagliflozin|"* Dapagliflozin is an oral drug which will be administered on an outpatient basis. Dosing will start at 5 mg daily and will increase to 10 mg daily after 2 weeks (after consulation with a study endrocrinologist) if the patient is tolerating the 5 mg dose. Dapagliflozin will be given for a total of 8 weeks (2 weeks at 5 mg and 6 weeks at 10 mg)~* Treatment with dapagliflozin will be initiated on Cycle 1 Day 1 of standard of care chemotherapy.~* Participants will use the BIOSENSE meter once daily"
62314255|NCT02897635|EXPERIMENTAL|Integrative Medicine Intervention|Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
62314256|NCT06511856||FH ORTHO shoulder patients|Patients operated with FH ORTHO shoulder medical devices (arthroplasty and trauma)
62314257|NCT06128512|EXPERIMENTAL|AA|Auricular acupuncture (AA) 24 hours before the examination.
62684788|NCT03405753|PLACEBO_COMPARATOR|Placebo|
62684789|NCT03916419|EXPERIMENTAL|Safety lead-in: Chemoradiation + Durvalumab|"* The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.~* Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of treating physician) for up to 12 months."
62684790|NCT03916419|EXPERIMENTAL|Phase II: Chemoradiation + Durvalumab|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of the treating physician) for up to 12 months.
62314258|NCT06128512|SHAM_COMPARATOR|Sham-AA|Sham Auricular acupuncture (Sham-AA) 24 hours before the examination.
61923848|NCT02749669|OTHER|Qualitative research|Semi-structured interviews
62684791|NCT03898973|OTHER|Study Phase|Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)
62314259|NCT03199092|EXPERIMENTAL|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
61923849|NCT02749669|NO_INTERVENTION|Economic evaluation|Questionnaire
61923850|NCT00123968|EXPERIMENTAL|1A|Participants will receive a low dose of the adenovirus-vectored HIV vaccine or placebo at study entry
62314260|NCT03199092|EXPERIMENTAL|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
62314261|NCT03120403|ACTIVE_COMPARATOR|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
62684792|NCT03659721|EXPERIMENTAL|FACAM|Intervention participants are assigned a support person (health nurse or a family therapist) who will offer support to the family until the child starts school at age 6. Intensity is up to 37 hours the first year followed by up to 10 hours of support each of the following years. The support person will offer individualized support to the family depending on the needs of the family. The support person will attend midwife consultations and help the pregnant woman to attend consultations with e.g. GP, midwife, or social worker. All intervention participants will also receive either an individual or group-based (COS-P)attachment based intervention during pregnancy and the first months of the child's life.
61923851|NCT00123968|EXPERIMENTAL|1B|Participants will receive a higher dose of the adenovirus-vectored HIV vaccine or placebo at study entry
61923852|NCT00123968|EXPERIMENTAL|1C|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a low dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
61923853|NCT00123968|EXPERIMENTAL|1D|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a higher dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
61923854|NCT00123968|EXPERIMENTAL|2A|Participants will receive the DNA plasmid vaccine at study entry and Days 28 and 56. They will also receive a low dose of the adenovirus-vectored HIV vaccine at Day 168.
61923855|NCT00123968|EXPERIMENTAL|2B|Participants will receive the DNA plasmid vaccine placebo at study entry and Days 28 and 56. They will also receive a the adenovirus-vectored HIV vaccine placebo at Day 168.
62314262|NCT03120403|ACTIVE_COMPARATOR|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
62314263|NCT03120403|ACTIVE_COMPARATOR|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
62314264|NCT02355379|EXPERIMENTAL|GROUP1 -ARM A|LV5FU2 or capecitabine
62478419|NCT06407206|EXPERIMENTAL|Sub occipital muscle inhibition technique along with conventional therapy|Patient is in supine position Therapist sits near the head of the participant and places his hand below the head of the participant With the pads of hand therapist palpates the arch of atlas between the occipital protuberance and spinous process of axis and place the middle and ring finger over it by flexing the metacarpophalangeal joint in 90 degrees of flexion, base of skull will rest on hands Pressure is exerted in upward direction towards the therapist and is maintained for two minutes so that the muscle scan relax Participants are guided to keep their eyes close in order to avoid movement which affects the tone of sub occipital muscle
61923856|NCT03268148|EXPERIMENTAL|low level laser group|LaserPen is applied to the local point for 20 seconds where heel-lancing will be performed in the low level laser group.
62124426|NCT05412199|EXPERIMENTAL|Dynamic Stretching Group|The group to which dynamic stretching exercises will be applied to the posterior leg muscles.
62124427|NCT05289349|ACTIVE_COMPARATOR|group (P) for propofol|propofol 6 mg/kg/h in group P
62314265|NCT02355379|EXPERIMENTAL|GROUP1-ARMB|FOLFOX4 or XELOX
62314266|NCT02355379|EXPERIMENTAL|GROUP2- ARM C|Observation
61923857|NCT03268148|NO_INTERVENTION|breast milk group|Subjects in breast milk group are given 5ml expressed breast milk by mouth using a syringe tube inserted to the participant's oral cavity over a 2-minute period before heel-lancing.
61923858|NCT00477581|EXPERIMENTAL|Sequence A|
62314267|NCT02355379|EXPERIMENTAL|GROUP2-ARM D|LV5FU2 or capecitabine
62314268|NCT01070303|EXPERIMENTAL|Adalimumab 40 mg every other week or every week|
62314269|NCT03340493|ACTIVE_COMPARATOR|Assigned Interventions|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds).
62314270|NCT03340493|EXPERIMENTAL|Tenecteplase|Patients will receive intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over \~10 seconds).
61923859|NCT00477581|EXPERIMENTAL|Sequence B|
61923860|NCT03960554|ACTIVE_COMPARATOR|Active drug|Denosumab 60 mg subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
62124428|NCT05289349|ACTIVE_COMPARATOR|group (S) for sevoflurane.|sevoflurane 1.0-1.5 minimum alveolar concentration (MAC) in group S.
62684793|NCT03659721|ACTIVE_COMPARATOR|Care as Usual|Families in the control group receive the usual care that is offered to families in the target group. This includes consultations with e.g. a midwife, social worker, medical doctor, and health visitor. If needed, CAU families can receive e.g. extra home visits or family therapy.
62684794|NCT03377998|EXPERIMENTAL|vitiligo patients|lesional skin biopsy to measure ERDR1 level
62684795|NCT03377998|EXPERIMENTAL|controls|normal skin biopsy to measure ERDR1 level
62684796|NCT03236805|EXPERIMENTAL|Ketamine IV|
62684797|NCT03236805|ACTIVE_COMPARATOR|Morphine IV|
61923861|NCT03960554|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
61923862|NCT01237964|EXPERIMENTAL|Xiaflex ( Collagenase use)|all 10 patients will be selected from out burn's clinic pool and will be injected using collagenase
61923863|NCT02717845|EXPERIMENTAL|CT scan Ellipse|New medical device for high tibial osteotomy
62124429|NCT05861063|PLACEBO_COMPARATOR|control group|The patients were divided into 3 groups based on different dosages of Dezocine injection, with 35 patients in each group: Group 1: Dezocine low-dose group, Group 2: Dezocine high-dose group; Group 3: Blank control group (normal saline).
62314271|NCT06340737|EXPERIMENTAL|Cohort 1: Follicular lymphoma (FL)|18-34 participants with FL will be administered the RP2D of CD22CART
62314272|NCT06340737|EXPERIMENTAL|Cohort 2: Mantle cell lymphoma (MCL)|12-32 participants with MCL will be administered the RP2D of CD22CART.
62314273|NCT06340737|EXPERIMENTAL|Cohort 3: Other lymphomas|up to 30 participants with no more than 10 of any one type, including: Hairy cell leukemia, Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia), Burkitt lymphoma, and Marginal zone lymphoma.
62314274|NCT00611130|EXPERIMENTAL|1|3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks
62314275|NCT00611130|PLACEBO_COMPARATOR|2|3 Placebo Tablets, bid, for 9 weeks
62314276|NCT01388010|EXPERIMENTAL|1 = Test product|Arm 1 - Intervention 1 (probiotics)
62314277|NCT01388010|OTHER|2 = Control product|Arm 2 - Intervention 2 (control)
62314278|NCT01374581|EXPERIMENTAL|Artemether/Lumefantrine|Tablets 20 mg/120 of Artemether/Lumefantrine will be given to 124 trial patients
61923864|NCT02717845|ACTIVE_COMPARATOR|CT scan Tomofix|Established medical device for high tibial osteotomy
62314279|NCT01374581|EXPERIMENTAL|Artesunate/Amodiaquine|Tablets 25mg/67,5 mg of Artesunate/Amodiaquine will be given to 124 trial patients.
62684798|NCT05623514|EXPERIMENTAL|Candidates for vaginal natural orifice trans-luminal surgery approach|Candidates for benign gynecological surgery in the vaginal natural orifice trans-luminal surgery approach
62684799|NCT04077437|EXPERIMENTAL|Experimental: MDMA-assisted psychotherapy|Administration of 80 to 120 mg midomafetamine HCl in combination with manualized psychotherapy, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively.
62684800|NCT04077437|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Administration of inactive placebo in combination with manualized psychotherapy.
62684801|NCT01046669|SHAM_COMPARATOR|Control|Standard medical care for septic shock
62124430|NCT05861063|EXPERIMENTAL|Dezocine low dose group|The patients were divided into 3 groups based on different dosages of Dezocine injection, with 35 patients in each group: Group 1: Dezocine low-dose group, Group 2: Dezocine high-dose group; Group 3: Blank control group (normal saline).
62314280|NCT01374581|ACTIVE_COMPARATOR|Quinine + Clindamycin|Quinine tablet 125mg + Clindamycin syrup 75mg/5ml will be given to 60 children.
62684802|NCT01046669|EXPERIMENTAL|Treatment|Two (2) PMX cartridges will be administered approximately 24 hours apart plus standard medical care for septic shock
62124431|NCT05861063|EXPERIMENTAL|Dezocine high dose group|The patients were divided into 3 groups based on different dosages of Dezocine injection, with 35 patients in each group: Group 1: Dezocine low-dose group, Group 2: Dezocine high-dose group; Group 3: Blank control group (normal saline).
62684803|NCT04652999|EXPERIMENTAL|Muscle Relaxation with Guided Imagery|The participants in Experimental Group will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
62124432|NCT04747743||Egyptian dental practitioners|170 dental practitioners in Egypt (professionals both academic and nonacademic).
62124433|NCT06555653||Subjects received video-based multmedia information|
62124434|NCT06555653||Subjects received traditional written information|
62124435|NCT02095171|EXPERIMENTAL|PRX002|
62124436|NCT02095171|PLACEBO_COMPARATOR|Placebo|
62124437|NCT06242041|EXPERIMENTAL|Treatment group|Routine treatment, and on the non-dialysis day, sodium zirconate silicate is given four times a week, starting from 5g/ day each time, and the blood potassium before dialysis is maintained at 4.0-5.0mmol/L, which can be adjusted by 10g/ week each time, and the highest dose can be increased to 80g/ week.
62124438|NCT06242041|PLACEBO_COMPARATOR|Control group|Routine treatment.
62314281|NCT05132738|EXPERIMENTAL|Ripretinib treatment group|
62314282|NCT00339079|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions.
62314283|NCT00339079|PLACEBO_COMPARATOR|Placebo|Patients only received placebo pills accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
62478420|NCT06407206|OTHER|conventional therapy|Transcutaneous electrical nerve stimulation at lower back and hamstring muscles (pulse rate: 4Hertz, pulse duration: 150µs for 15mins) Hot pack ( 15mins),Ankle pumps (15 reps with 5 sec hold), Knee Range of motions (flexion and extension,10 reps),Quadriceps set (10 reps,5 sec hold),Vastus Medialis oblique (10 reps 5 sec hold),Gluteus sets (10 reps, 5 sec hold),Single knee to chest (10 reps with 10 sec hold) McKenzie exercises (10 reps with 10 sec hold and 10 sec rest),Stretching of calf and hamstring muscles (passive stretching,7 reps with 5 sec hold).
62684804|NCT04652999|PLACEBO_COMPARATOR|Active Control Group|Participants in the Active Control Group will receive four individual 45-minute sessions of neutral guided imagery placebo, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
62684805|NCT04652999|NO_INTERVENTION|Passive Control Group|The participants in the Passive Control Group will not receive any intervention nor placebo session.
62684806|NCT05900830|ACTIVE_COMPARATOR|common educational methods|this group will receive common educational methods
62124439|NCT02202395|ACTIVE_COMPARATOR|0.25mg|LTS 0.25mg,qd MTX qw
62124440|NCT02202395|ACTIVE_COMPARATOR|0.5mg|LTS 0.5mg, qd MTX qw
62684807|NCT05900830|EXPERIMENTAL|play based program|this group will get the combined selected physical and occupational therapy program
62124441|NCT02202395|ACTIVE_COMPARATOR|1.0mg|LTS 1.0mg,qd MTX qw
62314284|NCT00339079|EXPERIMENTAL|Fluoxetine|Patients only received the SSRI Fluoxetine. Medication was adminstered on a fixed-flexible dosing regimen, beginning at 10mg/day for 2 weeks, then 20 mg/day for 2 weeks, 40 mg/day for two weeks, 60 mg/day for 2 weeks, and 80 mg/day (the target dose) thereafter. This was accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
61923865|NCT04516044||Video game|Patients treated by physicians who were randomized to either play an adventure-based video game that used narrative engagement to recalibrate physician heuristics in trauma triage or a puzzle-based video game that used analogical encoding to recalibrate physician heuristics in trauma triage.
62124442|NCT02202395|PLACEBO_COMPARATOR|Placebo|Placebo qd MTX qw
62314285|NCT00339079|EXPERIMENTAL|Combined CBT and Fluoxetine|Patients in this arm received both CBT and the fluoxetine medication. Both interventions were administered in the same way as when adminstered alone in the other arms.
61923866|NCT04516044||Control|Patients treated by physicians who were randomized either to nothing at all or to a text-based educational program.
61923867|NCT03641885|EXPERIMENTAL|mother and adolescents|an intervention group in which mothers and adolescents receive the intervention and questionnaires via Telegram social media
61923868|NCT03641885|EXPERIMENTAL|adolescents|an intervention group in which adolescents receive the intervention and questionnaires via Telegram social media
61923869|NCT03641885|ACTIVE_COMPARATOR|active control|mothers and adolescents are in active control group and only receive the questionnaires
61923870|NCT01231308|ACTIVE_COMPARATOR|Lifestyle modification|Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
62314286|NCT03469193|ACTIVE_COMPARATOR|internal PUC implanted with mechanical ancillary|
62314287|NCT03469193|EXPERIMENTAL|Internal PUC implanted with robotic assistance|
62314288|NCT03153397|EXPERIMENTAL|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
62314289|NCT03153397|ACTIVE_COMPARATOR|Osmolite|non-prebiotic fiber containing formula (Osmolite)
61923871|NCT01231308|EXPERIMENTAL|Roux-en-Y-Gastric Bypass|A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
61923872|NCT06091787|EXPERIMENTAL|Study Arm|This group will recieve Tab Ursodeoxycholic acid 450mg twice daily from the day after donor hepatectomy till post operative day 10.
61923873|NCT06091787|ACTIVE_COMPARATOR|Control Arm|This group will receive standard medical therapy following donor hepatectomy.
61923874|NCT03526731|EXPERIMENTAL|Group A (original QLB-2):|Local anesthetic will be injected between the quadratus lumborum muscle and the latissimus dorsi muscle guided by ultrasound.
61923875|NCT03526731|EXPERIMENTAL|Group B (trans-muscular OLB-3)|Local anesthetic will be injected between quadratus lumborum and psoas major after passing through the quadratus lumborum muscle guided by ultrasound.
61923876|NCT01395862||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period
61923877|NCT04163679|EXPERIMENTAL|Vaginal Preparation|In addition to standard care, subjects will undergo vaginal preparation (VP). A VP kit includes sponge sticks and sponges soaked in a povidone-iodine 10% solution.
61923878|NCT04163679|SHAM_COMPARATOR|Standard Infection Procedures|The very staff will follow hospital protocols for the cesarean delivery. The subject and the infant will be provided care in accordance with current medical standards and be discharged at the discretion of the attending physician.
61923879|NCT04246255|PLACEBO_COMPARATOR|Group C|Serum Physiologic %0,9 ampules ; 0,3ml {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
61923880|NCT04246255|EXPERIMENTAL|Group L|xylocaine %10 pump spray ; 30mg lidocaine {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
61923881|NCT01645722|OTHER|Procedure/Surgery: Enriched Fat grafting|Enriched Fat grafting
61923882|NCT01522729|EXPERIMENTAL|Fentanyl|
61923883|NCT01522729|EXPERIMENTAL|Placebo|
61923884|NCT01148797|EXPERIMENTAL|Canakinumab|
62314290|NCT02260414|EXPERIMENTAL|Patients with multiple myeloma|Patient with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
62314291|NCT02260414|ACTIVE_COMPARATOR|Patients with agressive lymphoma|Patient hospitalized for aggressive lymphoma treated with chemotherapy treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
61923885|NCT00470158|EXPERIMENTAL|combined iron and zinc|Iron and zinc together
61923886|NCT00470158|EXPERIMENTAL|Separate iron and zinc|Iron and zinc on separate days
61923887|NCT00470158|EXPERIMENTAL|iron alone|Iron
61923888|NCT00470158|EXPERIMENTAL|zinc alone|Zinc
62314292|NCT02260414|ACTIVE_COMPARATOR|Patients with acute medical condition|Patient older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
62478421|NCT00620711|EXPERIMENTAL|1|Babies that meet criteria will be offered participation in feasibility trial, there are no other arms.
61923889|NCT00470158|PLACEBO_COMPARATOR|placebo|
61923890|NCT04440371|ACTIVE_COMPARATOR|Tacrolimus|Phototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
61923891|NCT04440371|ACTIVE_COMPARATOR|calcipotriol / betamethasone|Phototherapy NBUVB will be given 3 times per week and calcipotriol \& betamethasone containing cream will be applied once a day
61923892|NCT04040868|OTHER|robot-assisted technique|
61923893|NCT04040868|OTHER|conventional fluoroscopy-assisted technique|
61923894|NCT01426997||High inflammation group (CRP>3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level \>3 mg/L
62314293|NCT02016742|EXPERIMENTAL|RDC5 dose level 1|Single dose of RDC5
62314294|NCT02016742|EXPERIMENTAL|RDC5 dose level 2|Single dose of RDC5
62314295|NCT02016742|EXPERIMENTAL|RDC5 dose level 3|Single dose of RDC5
62684808|NCT02375711|EXPERIMENTAL|Chronic Renal Failure|Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.
61923895|NCT01426997||Medium inflammation group (CRP=1-3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level = 1-3 mg/L
61923896|NCT01426997||Low inflammation group (CRP<1 mg/L).|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level \<1 mg/L
61923897|NCT03574480|EXPERIMENTAL|Control|Advice on healthy diet and physical activity recommendations
61923898|NCT03574480|EXPERIMENTAL|Intervention|"* Advice on healthy diet and physical activity recommendations~* Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
61923899|NCT03621618|OTHER|dobutamine|Cardiac failure
61923900|NCT03621618|OTHER|norepinephrine|Sepsis
61923901|NCT01511185|EXPERIMENTAL|NNC 90-1170|
61923902|NCT01511185|PLACEBO_COMPARATOR|Placebo|
61923903|NCT01511185|NO_INTERVENTION|Healthy|
62314296|NCT02016742|EXPERIMENTAL|RDC5 dose level 4|Single dose of RDC5
62124443|NCT01591239|EXPERIMENTAL|Home-Based Intervention|Parents will receive a 1-session training on how to deliver a 3-session intervention across a 3-week period. The intervention program begins with a 3 and a half hour training session delivered by the staff Trainer to the participating parent. At the conclusion of training, the parent will be given the intervention manual and supplemental materials. The trainer will phone the parent shortly before session 1, in between each intervention session, and after the third intervention (four phone calls total) to review the objectives and tasks associated with that week's intervention session and to help prepare for the coming session. At the final phone call between the parent and trainer (after the third week), the trainer will deliver to the parent the follow-up resources.
62314297|NCT02575313|EXPERIMENTAL|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
62684809|NCT05431556|EXPERIMENTAL|Virtual mind-body group exercise classes (VMB)|Will be provided with the schedule and links to the web-based mind-body exercises offered by MSK in real-time via the Zoom video conferencing platform. Each session is led by a licensed clinician (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting.
62684810|NCT05431556|ACTIVE_COMPARATOR|Enhanced usual care (EUC)|Pre-recorded self-care videos.
62684811|NCT00117442|EXPERIMENTAL|Pegfilgrastim 18 mg|Pegfilgrastim 18 mg given once for mobilization
62684812|NCT00117442|ACTIVE_COMPARATOR|Filgrastim|Filgrastim given daily for mobilization
62684813|NCT00117442|EXPERIMENTAL|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for mobilization
62684814|NCT00117442|EXPERIMENTAL|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for mobilization
62684815|NCT02268305|EXPERIMENTAL|MSM 1000mg twice a day (6000 mgs)|Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen
62684816|NCT02268305|PLACEBO_COMPARATOR|Placebo capsules twice a day|Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen
62684817|NCT01594814||RFA of AVNRT of AVRT|
62684818|NCT06136819|EXPERIMENTAL|RT-310 Cohort 1|Combination Product: RT-310 implant Cohort 1
62684819|NCT06136819|EXPERIMENTAL|RT-310 Cohort 2|Combination Product: RT-310 Implant Cohort 2
62684820|NCT02674828|EXPERIMENTAL|Reinforcement treatment|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
62684821|NCT02674828|ACTIVE_COMPARATOR|Standard Treatment|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
62684822|NCT01407887|ACTIVE_COMPARATOR|artesunate, amodiaquine methylene blue|two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
62684823|NCT01407887|NO_INTERVENTION|artesunate amodiaquine|The control group will receive once daily a fixed dose AS-AQ over three days.
62684824|NCT02184442|EXPERIMENTAL|TAVR - SAPIEN XT|TAVR (transaortic valve replacement) with SAPIEN XT
62684825|NCT02184442|ACTIVE_COMPARATOR|TAVR - SAPIEN|TAVR (transaortic valve replacement) with SAPIEN is the control arm
62684826|NCT06434805|OTHER|Education workshop|This is a one-day workshop with four sessions.
62684827|NCT06676878|EXPERIMENTAL|Diabetes|The study group will consist exclusively of diabetics and they will undergo the described treadmill stress test to exhaustion.
62684828|NCT06676878|ACTIVE_COMPARATOR|Control|The control group will consist exclusively of healthy participants and they will undergo the described treadmill stress test to exhaustion (identical to the study group).
62684829|NCT00626665|PLACEBO_COMPARATOR|Placebo|One placebo tablet every alternate day for 6 weeks
62684830|NCT03931811|EXPERIMENTAL|Short wave diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.~SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device). Both groups took injections in the beginning of the therapy, 3rd week and 6th week, a total of 3 times. SWD or sham SWD therapy was given right after the injections, also for a total of 3 times."
62314298|NCT02400112|EXPERIMENTAL|Vancomycin Powder|If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
62314299|NCT02400112|NO_INTERVENTION|Standard Treatment|If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
62684831|NCT03931811|SHAM_COMPARATOR|Sham diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.~Sham SWD group took 20 minutes of SWD therapy with device not working(Enraf-Nonius, Curapuls 970 Short wave diathermy device)."
62124444|NCT01591239|ACTIVE_COMPARATOR|Educational Group|Parents will receive a 2-hour, education-only psychoeducational curriculum (no parent-led intervention with their teen will occur.
62124445|NCT01346982|EXPERIMENTAL|Silimarine|darunavir + ritonavir + silimarine
62124446|NCT00648726|ACTIVE_COMPARATOR|Arm 1|
62124447|NCT00648726|ACTIVE_COMPARATOR|Arm 2|
62124448|NCT00648726|ACTIVE_COMPARATOR|Arm 3|
62124449|NCT03947086|ACTIVE_COMPARATOR|Active TDCS Group|Participants will receive active Transcranial Direct Current Stimulation (TDCS) (1.5 mA). Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
62124450|NCT03947086|SHAM_COMPARATOR|Sham tDCS Group|Participants will receive sham TDCS. The protocol is identical for placebo stimulation, but the current will stop after 30 seconds from the start of stimulation. Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
62124451|NCT05303415|EXPERIMENTAL|LIFU, heat evoked fMRI signals|fMRI resting and heat evoked signals performed after LIFU application to known brain region of interest or active sham region (within participant all conditions tested).
62124452|NCT02990546|EXPERIMENTAL|Intervention|In the intervention arm 10 mg of midodrine will be given orally three times daily starting at the time of stable or decreasing intravenous vasopressor support
62124453|NCT02990546|OTHER|Control|The control arm will receive standard of care for septic shock with IV vasopressor support as needed to maintain MAP goal \> 65 mmHg
62314300|NCT03245632||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
62314301|NCT03245632||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
62478422|NCT03158727|EXPERIMENTAL|Cx611|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each.
62684832|NCT03167658|EXPERIMENTAL|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
62314302|NCT01516450|ACTIVE_COMPARATOR|GSK1550188 200mg for SC|Single SC dose of belimumab 200mg
62314303|NCT01516450|ACTIVE_COMPARATOR|GSK1550188 200mg for IV|Single IV dose of belimumab 200 mg
62314304|NCT05834959|EXPERIMENTAL|SOGH employees, taking part in the same education and training program.|Participants will be recruited from the Seven Oak General Hospital staff population and will complete a two-part education and practical program.
62314305|NCT06672367|EXPERIMENTAL|Balance Training Group|"It includes participants receiving balance training for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously."
62684833|NCT03167658|NO_INTERVENTION|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
62684834|NCT03167658|NO_INTERVENTION|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
62124454|NCT02011698|EXPERIMENTAL|absorbable sutures|mesh fixation with absorbable sutures in lichtenstein anterior inguinal herniorrhaphy
62478423|NCT03158727|PLACEBO_COMPARATOR|Placebo|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate.
62478424|NCT03110848|EXPERIMENTAL|Statins|Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
62684835|NCT03191032|EXPERIMENTAL|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
61923904|NCT03385083|EXPERIMENTAL|ACTIVITY TRACKER|Subjects in Cohort A will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Cohort A will then meet with researchers via telehealth at 2 weeks and 4 weeks with researchers to review step counts and reaffirm targets. Subjects in Cohorts A will be reassessed in person at the conclusion of the six week period.
62124455|NCT02011698|ACTIVE_COMPARATOR|non absorbable sutures|mesh fixation with non absorbable sutures in lichtenstein anterior inguinal herniorrhaphy. This is the method to be considered the standard of care thus far.
62314306|NCT06672367|EXPERIMENTAL|Balance Training Combined with Gaze Stability Exercises Group|"It includes participants receiving balance training combined with gaze stability exercises for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.~Gaze stability exercises~Visual tracking exercise"
62314307|NCT02617758|EXPERIMENTAL|Treatment AB|Participants will receive Treatment A (single application of DURAGESIC fentanyl transdermal system 100 microgram per hour (µg/h) dose) as Reference in Period 1; followed by Treatment B (single application of Fentanyl transdermal system \[JNJ-35685-AAA-G021\] 100 µg/h dose) as test in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
62314308|NCT02617758|EXPERIMENTAL|Treatment BA|Participants will receive Treatment B \[single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose\] as test in Period 1; followed by Treatment A (single application of DURAGESIC fentanyl transdermal system 100 µg/h dose) as Reference in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
62478425|NCT03110848|ACTIVE_COMPARATOR|No statins|Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
62478426|NCT05193461|EXPERIMENTAL|patients with radicular pain recieved pulsed mood radiofrequency|Investigation effect of neuroplasticity of patient on outcome of pulsed mood radiofrequency
62684836|NCT03191032|NO_INTERVENTION|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
61923905|NCT03385083|PLACEBO_COMPARATOR|Control|Subjects in Cohort B will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Subjects in Cohorts B will be reassessed in person at the conclusion of the six week period.
61923906|NCT04323605|EXPERIMENTAL|outpatient assistance program|
62124456|NCT02011698|EXPERIMENTAL|fibrin biological glue|mesh fixation with fibrin biological glue in lichtenstein anterior inguinal herniorrhaphy
62124457|NCT06006052|EXPERIMENTAL|study group DDM|Group I: 10 teeth will be treated with demineralized dentin matrix attached to collagen membrane as a scaffold in the regenerative endodontic procedure.
62314309|NCT04076072|ACTIVE_COMPARATOR|Alcon Advanced Ultravit High-Speed Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
62684837|NCT05814549||No previous history of diagnosed HPV-related head and neck cancer|Participants have no previous history of diagnosed HPV-related head and neck cancer
62314310|NCT04076072|ACTIVE_COMPARATOR|Alcon Non-Beveled Tip Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
62684838|NCT03351959||ypT0 rectal cancers|Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
62124458|NCT06006052|ACTIVE_COMPARATOR|Control group|Group II: 10 teeth will be treated with the conventional regenerative endodontic procedure (blood clot scaffold).
62124459|NCT06006052|ACTIVE_COMPARATOR|positive control|Group III: 10 teeth will be treated with collage membrane as a scaffold in the regenerative endodontic procedure
62684839|NCT02702999|ACTIVE_COMPARATOR|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
61923907|NCT05931588|EXPERIMENTAL|Pilates exercises, streching and breathing|the intervention Pilates exercises, streching and breathing exercises is administered under supervision
62124460|NCT05525364||Screening of diabetes|"Our investigations included patients receiving treatment protocols conferring a diabetogenic risk. These included total body, cranial and abdominal irradiation (respectively TBI, CI and AI), steroids and L-asparaginase. Our cohort was therefore composed of patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).~The patients were stratified according to the presence or absence of hyperglycemia during the treatment protocol and during clinical follow-up, which ended in August 2020. The groups were called the hyperglycaemia-positive ALL, NHL or HL and the hyperglycaemia-free ALL, NHL or HL."
62124461|NCT01093430|EXPERIMENTAL|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
62314311|NCT01742962||Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
62314312|NCT05196932||COVID Card|Enrolled patients will receive antibody testing using both: 1) point-of-care, semi-quantitative SARS-CoV-2 antibodies test, 2) SARS-CoV-2 central laboratory antibodies test
61923908|NCT05931588|EXPERIMENTAL|streching and breathing|home based exercise program which is streching and breathing.
61923909|NCT02363569||case-|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed to the Women ER 24 hours after bleeding or bleeding secretions due to intercourse."
61923910|NCT02363569||control|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed the women ER due to spontaneous bleeding or bleeding secretions"
61923911|NCT04148677||Protoves M1® syrup|A combination of two alkaloid, Protopine and Nuciferine
61923912|NCT04148677||No treatment|Patients will not receive a treatment
62314313|NCT01479049|EXPERIMENTAL|MP group|Hearts are arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L) during cardiac surgery.
62314314|NCT01479049|ACTIVE_COMPARATOR|HP group|Hearts were arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L) during cardiac operation
61923913|NCT00817583|EXPERIMENTAL|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.
61923914|NCT05314985|EXPERIMENTAL|Prehab Group / Intervention Group|4 to 8 weeks of preoperative physical therapy training and education intervention before total knee replacement surgery.
61923915|NCT05314985|NO_INTERVENTION|Control Group|Usual care / no treatment before total knee replacement surgery.
61923916|NCT02416310|EXPERIMENTAL|TEAS group|TEAS are performed by a specific investigator on the specially acupoint.
61923917|NCT02416310|SHAM_COMPARATOR|Sham group|TEAS are performed by a specific investigator on the non-acupoint.
62124462|NCT01093430|ACTIVE_COMPARATOR|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
62314315|NCT04067531|OTHER|treatment of BV|all patients be treated with first Deqularum then with clindamycin Cream,
61923918|NCT02416310|PLACEBO_COMPARATOR|Control group|Only place cutted electrodes but do not give any electrical stimulation.
61923919|NCT01957527||Ticagrelor discontinuation|
61923920|NCT05802875|EXPERIMENTAL|RASMUS Resilience Training|RASMUS is a systematic, behavior-oriented group training in which the following methods are used: mindfulness exercises, exercises in self-compassion/guided meditations, knowledge transfer by means of a teaching talk/lecture, working out the topics in individual and small group work, group exercises, group discussion and exchange, train coping strategies: somatic, cognitive, and emotional levels, independent reflection on what has been learned, homework, weekly protocols, transfer to everyday life, questionnaires on resilience factors, mindfulness, and self-compassion for self-control, linking the course topics with one another.
61923921|NCT05802875|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|As a relaxation method with scientifically proven effects, progressive muscle relaxation aims at the conscious, voluntary tension and relaxation of certain muscle groups, which can bring the body into a state of deep relaxation. The application is not only effective in patients with various diseases, but also in healthy people.
61923922|NCT04538196|EXPERIMENTAL|R Education|Invervention: Resident who receives education on documentation and coding at the beginning of the surgical rotation
62124463|NCT01561989|EXPERIMENTAL|Arm I (400 IU cholecalciferol and vaccine therapy)|Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
62314316|NCT00013039|OTHER|Arm 1|
62314317|NCT03425565|EXPERIMENTAL|Pembrolizumab|
62314318|NCT02123147||Sjogren's syndrome|Patients who are diagnosed with Sjogren's syndrome. Blood will be collected once every 3-6 months for up to 3 years.
62314319|NCT02123147||Healthy Control|Patients who are diagnosed with healthy control. Blood will be collected once every 6 months for up to 3 years.
62314320|NCT06673121||Traditional Chinese Medicine Group|Patients with pulmonary nodules treated with traditional Chinese medicine
62478427|NCT05388266|EXPERIMENTAL|Paratracheal pressure|After the induction of anesthesia, paratracheal pressure is applied during mask ventilation.
62478428|NCT05388266|ACTIVE_COMPARATOR|No pressure|After the induction of anesthesia, no pressure is applied during mask ventilation.
62684840|NCT02702999|EXPERIMENTAL|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
62684841|NCT06669156||Partuients experiencing conversion of regional to general anesthesia for cesarean section|All parturients undergoing emergency or elective cesarean section in a participating hospital, who experience insufficient regional anesthesia and conversion to general anesthesia during the 1 year inclusion period
62684842|NCT06136884|EXPERIMENTAL|Part 1: Dose Escalation|Participants will be assigned to dose levels.
62684843|NCT06136884|EXPERIMENTAL|Part 2: Dose Expansion|After doses are decided in Part 1, participants entering part 2 will be assigned to a dose level.
62684844|NCT06045754|EXPERIMENTAL|Part A, Cohort 1: Vedolizumab + Adalimumab|Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then every 8 weeks (Q8W) until Week 22 and adalimumab SC 160, 80, and 40 mg at Weeks 0, 2, and 4, respectively, then 40 mg every 2 weeks (Q2W) until Week 26.
62684845|NCT06045754|EXPERIMENTAL|Part A, Cohort 2: Vedolizumab + Ustekinumab|Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then Q8W until Week 22 and ustekinumab IV 520, 390, or 260 mg (weight-based), then SC 90 mg 8 weeks after initial IV dose, then Q8W until Week 24.
62478429|NCT05384769|EXPERIMENTAL|Cohort A (liquid biopsy, optional LDCT)|Participants undergo collection of blood sample (liquid biopsy), with option to undergo LDCT if liquid biopsy results are positive.
62684846|NCT06045754|EXPERIMENTAL|Part B: Vedolizumab Monotherapy|Participants who achieve clinical remission in Part A will receive vedolizumab IV 300 mg monotherapy, Q8W from Week 30 until Week 46.
62684847|NCT06229873|EXPERIMENTAL|App-Based Inspiratory Muscle Strength Training|Using a handheld device, participants will perform 30 breaths a day, six days a week, for six weeks. Training will be guided by a smartphone application.
62684848|NCT06229873|ACTIVE_COMPARATOR|Clinic-Based Inspiratory Muscle Strength Training|Using a handheld device, participants will perform 30 breaths a day, six days a week, for six weeks. Training will be guided by researchers.
62684849|NCT03357172|EXPERIMENTAL|Recipient|
62684850|NCT03357172|EXPERIMENTAL|Donor|
62684851|NCT06570031|EXPERIMENTAL|ONO-4578 + letrozole + palbociclib|
62314321|NCT06673121||Non-Traditional Chinese Medicine Treatment Group|Patients with pulmonary nodules have not received traditional Chinese medicine treatment
62314322|NCT05344092|EXPERIMENTAL|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period.
62314323|NCT04714463||Immediate breast reconstruction|Women undergoing immediate breast reconstruction due to breast cancer or a high risk for breast cancer
62478430|NCT05384769|EXPERIMENTAL|Cohort B (LDCT, optional liquid biopsy)|Participants undergo low dose CT with optional liquid biopsy on the same day as LDCT.
62478431|NCT05646251|EXPERIMENTAL|EC-LBBAP Participant|A heart ultrasound will be used during a pacemaker implant procedure
62478432|NCT05646251|NO_INTERVENTION|Control participant|A pacemaker will be implanted using routine protocol. This is retrospectively collected; patients are not actively enrolled in this arm.
62478433|NCT06181422|ACTIVE_COMPARATOR|Group1: Metformin|Group1: (Metformin, n=30) who will receive metformin 500 mg three times daily.
62684852|NCT06570031|EXPERIMENTAL|ONO-4578 + letrozole + abemaciclib|
62684853|NCT04980963|EXPERIMENTAL|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention. Taking into consideration available psychoeducational assessment data, functional assessments from other agencies, and the participant's self-report regarding the functional difficulties that result from his or her ASD-related cognitive impairments, Scherer's (2012) Matching Person and Technology (MPT) protocol will guide the CST assessment. For purposes of the CST component of this intervention, the technological platform for cognitive accommodations will be an iPad II that is provided to each intervention-group participant at no charge (including wireless access if needed). The interventionist will provide training in the use of the iPad if necessary.
62684854|NCT04980963|ACTIVE_COMPARATOR|Abbreviated Treatment|Steps of the Control Condition. Following an in-person session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
62684855|NCT04722679||Patient|Elderly (defined as the ≥75 years old) patients with NVAF that are treated with a NOAC.
62684856|NCT04722679||Physician|Geriatricians (hospital or office-based).
62684857|NCT05444088|EXPERIMENTAL|Adebrelimab in combination with Bevacizumab|
62684858|NCT05444088|EXPERIMENTAL|Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D1|
62684859|NCT05444088|EXPERIMENTAL|Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D2|
62684860|NCT01560559|EXPERIMENTAL|Single Arm|Peroral endoscopic myotomy
62684861|NCT03071302|ACTIVE_COMPARATOR|keratoconus|"Evaluation of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes. Keratoconus with fellow eye without topographic and tomographic keratoconous pattern.Evaluation of tomographic datas. Sometimes we picked up the sample of corneal epithelium, and peripheral blood sample from corneal cross linking surgeries, in that case of keratoconus progression.~Group A Keratoconus/ like sound cornea. Group C Keratoconus / Keratoconus~Group C Keratoconus / Keratoconus"
62684862|NCT03071302|PLACEBO_COMPARATOR|sound cornea|"Evaluation of VSX1, SOD1, and TIMP3 genes. To analyze tomographic aspects, we evaluated the patients that underwent to LASIK (Lasei in situ Keratomileusis) with 2 year with follow up without any sign of ectasia To analyze the genes we picked up the sample of corneal epithelium, and peripheral blood sample from PRK (PhotoRefractive Keratectomy) surgeries. These patients showed topographic and tomographic normal pattern.~Group B Sound Cornea / Sound Cornea"
62684863|NCT01789502|ACTIVE_COMPARATOR|Plastic stents|Plastic stents are inserted by ERCP
62684864|NCT01789502|EXPERIMENTAL|Fully covered metal stents|Fully covered metal stents are inserted by ERCP
62684865|NCT02554474|ACTIVE_COMPARATOR|Immediate Group|Time spent in Moderate/Vigorous Physical Activity (MVPA) was measured with a SenseWear Mini sensor over a 7-day period. The mean time was calculated in bouted MVPA per day. A bout is defined as \>= 10 consecutive minutes or more at the level of \>= 3 METs (i.e., the lower bound of MVPA), with allowance for interruption of up to two minutes below the threshold.
61923923|NCT04538196|NO_INTERVENTION|R no Education|Resident who does not receive information on documentation and coding at the beginning of the surgical rotation
62478434|NCT06181422|ACTIVE_COMPARATOR|Group 2 :Lactoferrin|Group 2 :(Lactoferrin, n=30) who will receive lactoferrin 100 mg three times daily
61923924|NCT00920231|EXPERIMENTAL|Arm 1 initial system|"8 blind subjects are asked to use a prototype computer vision system to determine the challenges facing computer vision based indoor navigation.~Subjects are asked to travel through the hallways of a large hospital from the front entrance to a side entrance. The pathway consists of 9 segments including corners, four-way intersections, and doorways, and the total length of the route was approximately 200 meters. This challenging route was designed to stress the capabilities of the navigation system. It is a route that even sighted persons may find difficult to follow without practice. Pedestrian traffic was present throughout the route and lighting conditions could change in two of the segments where there were windows and doors."
62124464|NCT01561989|EXPERIMENTAL|Arm II (4,000 IU cholecalciferol and vaccine therapy)|Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
62684866|NCT02554474|PLACEBO_COMPARATOR|Delay Group|Time spent in sedentary activity was measured with a SenseWear Mini sensor over a 7-day period. The mean daily time spent in sedentary activity was calculated with an energy expenditure of \<=1.5 METs, occurring in bouts of \>= 20 minutes during waking hours.
62684867|NCT06672081|ACTIVE_COMPARATOR|conventional care|Patients in the conventional care group will receive guideline directed therapy including reperfusion treatment. If no clinically relevant hemodynamic improvement occurs, catheter-interventional treatment may be used as stated in the current ESC-guidelines
62124465|NCT01925469|EXPERIMENTAL|Benzocaine|Benzocaine spray (14%), an FDA approved drug, will be used to assess whether this provides additional pain relief at time of hysterosalpingogram.
62124466|NCT01925469|PLACEBO_COMPARATOR|Saline spray|A saline placebo spray will be used in the placebo group.
62124467|NCT00382850|ACTIVE_COMPARATOR|open nissen fundoplication|open repair through surgical midline incision
62124468|NCT00382850|ACTIVE_COMPARATOR|laparoscopic nissen fundoplication|use of laparoscope to do repair
62697385|NCT02516813|EXPERIMENTAL|Phase 1a (Arm A): M3814 Tablet (300 mg) + RT|Participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that was not amenable to surgical therapy, or with standard systemic therapy with an indication for palliative RT received 300 mg of M3814 as tablet orally once daily for 2 consecutive weeks in combination with RT (3 Gy x 10, 5 F/W).
62124469|NCT02773303|ACTIVE_COMPARATOR|Active|Children receiving Mente Autism™ neurofeedback therapy to use at home for 40 minutes a day for 12 weeks
62124470|NCT02773303|SHAM_COMPARATOR|Control|Children not receiving neurofeedback based therapy, but receiving the Sham therapy
62314324|NCT04714463||Delayed breast reconstruction|Women undergoing delayed breast reconstruction due to breast cancer or a high risk for breast cancer
62314325|NCT02466269||the preauricular approach|A classic preauricular incision was used to treat diacapitular condylar fractures
62124471|NCT01982890||Normal human controls|"Observational study. Subjects are screened for the absence of severe illnesses and followed prospectively with sequential blood draws, noting the occurence of acute and chronic severe illnesses.~Subjects are matched by age groups and sex with patients of the prospective cohort EUPA including patients with recent-onset inflammatory polyarthritis."
62124472|NCT03989986|EXPERIMENTAL|iPeer2Peer Mentorship|In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
62124473|NCT03989986|NO_INTERVENTION|Waitlist Control Group|The control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.
62314326|NCT03558321|EXPERIMENTAL|post menopausal bleeding|women with postmenopausal bleeding and endometrial thickness more than 5 mm
62314327|NCT04880057|ACTIVE_COMPARATOR|Resistance+Aerobic training group|Resistance+Aerobic training group (RAeT) RAeT includes resistance training (RT) program and aerobic training (AeT) program.
62314328|NCT04880057|EXPERIMENTAL|Agility training group|Agility training
62314329|NCT04670653|EXPERIMENTAL|MAGNÓLIA|Two applications in each nostril, once a day.
62314330|NCT04670653|ACTIVE_COMPARATOR|MOMETASONE FUROATE|Two applications in each nostril, once a day.
62478435|NCT04594577|EXPERIMENTAL|Fluispotter|Fluispotter automated blood sampling system
62684868|NCT06672081|EXPERIMENTAL|Early Catheter-Interventional Treatment + conventional care|Patients in this group will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration, if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these. Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation. The choice of the catheter types and sizes will be left to the treating interventionalists' discretion.
62124474|NCT02738372||Chronic Shoulder Pain|"1. Men / women aged between 18 and 70 years.~2. Patients suffering from shoulder pain, defined as pain presented or exacerbated by movements in the shoulder, pain intensity ≥ 2 measured by a numerical scale with values from 0 to 10, meaning 0= no pain and 10= the worst pain, will be included in this study, among all these following shoulder pain conditions: (i) Rotator Cuff tendinopathy; (ii) Adhesive Capsulitis; (iii) glenohumeral instability; (iv) SLAP lesion; (v) and/or acromioclavicular pathology. Subjects will not be required to undergo diagnostic imaging (i.e. Magnetic Resonance Imaging) to diagnosis the pathology because of the recruitment will be carried out by clinical findings.~3. Duration of symptoms: greater than 3 months."
62314331|NCT01179763||Retinal layer thickness analysis|Optical coherence tomography will be conducted to analyze retinal layer thickness (safe examination)
62124475|NCT02390544|EXPERIMENTAL|Melphalan in Patients Receiving HSCT|"The investigators will recruit approximately 30 patients who are scheduled to undergo allogeneic transplant with reduced intensity conditioning that includes melphalan. Approximately 10 patients who will receive melphalan as part of their conditioning regimen for an autologous transplant will also be recruited.~A test dose of melphalan will be administered prior to the start of the HSCT preparative regimen. The test dose will equal 10% of the standard dose. Blood samples will be drawn for pharmacokinetic measurement prior to and after the administration of the test dose and again around the full standard dose of melphalan. Urine samples will also be collected around the test dose and full standard dose of melphalan to measure markers of kidney injury."
62124476|NCT03267966|EXPERIMENTAL|Group A|Leeds Pathology Protocol (LEEPP)
62124477|NCT03267966|NO_INTERVENTION|Group B|"Conventional method of pathological evaluation"
62314332|NCT01988038||No treatment|
62314333|NCT03407391||Picky eater|Identified as a very picky eater from parental questionnaire
62314334|NCT03407391||Not a picky eater|Identified as not a picky eater from parental questionnaire
62478436|NCT01083264|EXPERIMENTAL|Arm 1|
62314335|NCT03407391||Somewhat picky eater|Identified as a somewhat picky eater from parental questionnaire
62314336|NCT04912128||Anlotinib group|Patients in Anlotinib group took Anlotinib 1 week before the MRI-based simulation，12mg/d QD，day1\~14, 21d/cycle. All patients received SBRT for brain metastases.
62314337|NCT04912128||SBRT group|Patients in SBRT group took no anti-angiogenic drugs. All patients received SBRT for brain metastases.
62314338|NCT02796950|EXPERIMENTAL|Acipimox|Administration of acipimox 250 mg p.o.
62124478|NCT04776265||RR HL Who Receive Salvage Chemotherapy and ASCT|Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant
62314339|NCT02796950|NO_INTERVENTION|Control|No intervention.
62478437|NCT01083264|EXPERIMENTAL|Arm 2|
62314340|NCT01125891|EXPERIMENTAL|gemcitabine and ON 01910.Na|
62314341|NCT00092547|EXPERIMENTAL|qHPV Vaccine in Base Study|Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
62314342|NCT00092547|PLACEBO_COMPARATOR|Placebo in Base Study|Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
62478438|NCT01083264|EXPERIMENTAL|Arm 3|
62478439|NCT04989491|EXPERIMENTAL|Experimental group|Prophylactic treatment with Rituximab: one single dose of 375mg/m2 intravenous 7 days before transplantation in case of living donor or at time of transplantation (D0 or D1) in case of transplantation with a deceased donor.
62478440|NCT04989491|ACTIVE_COMPARATOR|control group|Immunosuppression treatment will be given according to the practice of the centers; use of Thymoglobuline is strongly discouraged because of EBV seronegativity and risk of lymphoma. Basiliximab is recommended for induction therapy. Recommended maintenance immunosuppression consists in a calcineurin inhibitor (tacrolimus or ciclosporine), MMF and Steroids
62314343|NCT00092547|EXPERIMENTAL|qHPV Vaccine in Extension Study|Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.
62314344|NCT02564822||Migraneurs - Visual stimulation|Patients will be recruited via advertisements on the university. Patients should have migraine diagnosis according to the International Classification of Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.
62478441|NCT01312844|EXPERIMENTAL|Scopolamine|Patients receiving IV scopolamine at ECT treatment
62478442|NCT01312844|PLACEBO_COMPARATOR|Placebo|Patients receiving IV placebo at ECT treatment
62684869|NCT06691581||All patients with established diagnosis will be enrolled.|All patients with established diagnosis of inherited number or function platelet disorder (IPN and IPD, respectively), on the basis of internationally established clinical, laboratory and genetic criteria will be enrolled.
62684870|NCT04021368|EXPERIMENTAL|RVU120(SEL120)|The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of RVU120(SEL120) to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with RVU120(SEL120) to support the evaluation of the RD.
62478443|NCT00354835|ACTIVE_COMPARATOR|Arm I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
62684871|NCT03090542|NO_INTERVENTION|Control|
62124479|NCT06019299|ACTIVE_COMPARATOR|Positive Control|The control experimental group received training on the utilization of mindfulness-based stress reduction breathing techniques. Participants were instructed to set a timer for 5 minutes in order to engage in mindfulness breathing. Comprehensive instructions were provided during the initial laboratory time, elucidating the method by which participants were to direct their attention towards their breath. Moreover, participants were encouraged to cultivate a non-judgmental attitude when confronted with potential distractions and to subsequently redirect their focus back to their breathing. Participants were advised to integrate this technique into their daily lives as a means to alleviate anxiety and stress.
62124480|NCT06019299|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy intervention|"The active experimental group received a mindfulness based cognitive therapy through the Sanvello smartphone application. Participants were encouraged to practice mindfulness daily through the application program Braving Anxiety, which consisted of 35 modules. The anxiety management program consists of 1) Watch, 2) Read, 3) Listen, 4) Plan, 5) Listen - Mindfulness practice."
62124481|NCT06106555||Individuals with BPD|Individuals with BPD, as defined by the DSM-V, and a recent history (past 12 months) of self-harming behaviour.
62124482|NCT01291446|SHAM_COMPARATOR|High flatulogenic diet|3-day diet containing fermentable residues
62124483|NCT03555214|EXPERIMENTAL|Manual Therapy based on soft tissue|
62124484|NCT03555214|PLACEBO_COMPARATOR|Control Group|
62124485|NCT03555214|EXPERIMENTAL|Manual Therapy based on structural techniques|
62124486|NCT03555214|EXPERIMENTAL|Manual Therapy based on soft tissue and structural techniques|
62124487|NCT05238480|ACTIVE_COMPARATOR|XC-XP-XP-XC Sequence|Use of the Xtreme Conventional mouthguard (XC) while playing rugby for first and fourth weeks and the Xtreme Pro mouthguard (XP) for the second and third weeks.
62124488|NCT05238480|ACTIVE_COMPARATOR|XP-XC-XC-XP Sequence|Use of the Xtreme Pro mouthguard (XP) while playing rugby for first and fourth weeks and the Xtreme Conventional mouthguard (XC) for the second and third weeks.
62124489|NCT01274299||Infants|Healthy 0-4 years of age both boys and girls
62124490|NCT03357289|EXPERIMENTAL|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62124491|NCT03357289|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62684872|NCT03090542|ACTIVE_COMPARATOR|Product|
62684873|NCT06570408|PLACEBO_COMPARATOR|Group A (placebo)|
62684874|NCT06570408|EXPERIMENTAL|Group B (Treatment)|
62684875|NCT06685900|EXPERIMENTAL|Early intervention group (EIG)|the trial group that begins treatment in the 3-week of the total 15-week study period
61923925|NCT00920231|EXPERIMENTAL|Arm 2 modified system|The system is redesigned in response to problems identified from the first phase of the study. The redesigned system is tested by a second set of 8 blind subjects in the same indoor path as used in Arm 1.
62124492|NCT05740657||KISPI 000|Patients of the group received one or multiple clinically approved opioids, namely; Fentanyl, Remifentanil, Sufentanil, Alfentanil, Oxycodone, Morphine, Nalbuphine, Hydromorphone and Methadon. The drugs were administered in the course of a surgery or for pain management.
62684876|NCT06685900|EXPERIMENTAL|Late intervention group (LIG)|the comparator group that begins treament in the 9-week of the total 15-week study period
62124493|NCT05910749|EXPERIMENTAL|QEEG-guided sLoreta Neurofeedback|Brainmaster Discovery 24 EEG amplifier and BrainAvatar software will be used to conduct the neurofeedback sessions
62314345|NCT02564822||Control - Visual stimulation|Healthy volunteers will be recruited via advertisements on the university. For control subjects the individuals should not have migraine diagnosis assessed according to IHCD-III criteria.
61923926|NCT04654884|ACTIVE_COMPARATOR|Group 1|The participants in group 1 will receive AA as an adjunctive therapy to TaU (i.e. individual counseling therapy, psycho therapy, pharmacological therapy) during 8 weeks.
61923927|NCT04654884|NO_INTERVENTION|Group 2|Group 2, the control group, will receive TaU and will, just like goup 1, have a follow-up after 8 weeks.
61923928|NCT01824212||ICD-patients|Patients to whom cardiac fibrillation will be induced during the implantation of an implantable cardioverter defibrillator (ICD) or patients with an already implanted ICD, which function needs to be revised and during the revision cardiac defibrillation will be induced.
62124494|NCT05111483|EXPERIMENTAL|Tupler's technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains"
62124495|NCT05111483|EXPERIMENTAL|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre"
62124496|NCT04836806|EXPERIMENTAL|cetirizine and famotidine|Participants testing positive for COVID-19 who are randomized to take cetirizine and famotidine for 10 days.
62124497|NCT04836806|PLACEBO_COMPARATOR|Placebo|Participants testing positive for COVID-19 who are randomized to take a placebo to match cetirizine and famotidine for 10 days.
62124498|NCT01394510|EXPERIMENTAL|N-acetylcysteine dose study|Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
62314346|NCT03531268|ACTIVE_COMPARATOR|PGx testing has clinical utility|These are subjects whose PGx testing is judged to have clinical utility and whose clinical care may be modified. Modifications may include altering doses or types of drugs given based on metabolic profile of the patient.
62314347|NCT03531268|NO_INTERVENTION|PGx testing has no clinical utility|"These are subjects whose PGx testing is judged to have no clinical utility. Care as usual is provided, and there are no changes in drug selection or dosing based on the results of PGx testing."
62314348|NCT06094712|EXPERIMENTAL|CORT125134|After an overnight fast, subjects will receive a single CORT125134 150-mg oral dose of the Phase 2 capsule formulation on Day 1.
62314349|NCT06434740|EXPERIMENTAL|experimental group|The enrolled subjects will receive SBRT treatment combined with Puterizumab.
62314350|NCT03463265|EXPERIMENTAL|Arm A, Cohort 1: nab-sirolimus in patients with recurrent high grade glioma|nab-Sirolimus (ABI-009, nab-rapamycin, albumin-bound rapamycin) was administered at 100 mg/m2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle.
62314351|NCT03463265|EXPERIMENTAL|Arm A, Cohort 2: nab-sirolimus + temozolomide (TMZ) in patients with recurrent high grade glioma|"nab-Sirolimus (60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle).~Temozolomide (PO at 50 mg/m2 daily)"
62314352|NCT03463265|EXPERIMENTAL|Arm A, Cohort 3: nab-sirolimus + bevacizumab in patients with recurrent high grade glioma|"nab-Sirolimus (IV 60 mg/m 2 as a 30-minute infusion on Days 1, 8, and 15 of every 28-day cycle).~Bevacizumab (IV at a fixed dose of 5 mg/kg on Days 1 and 15 of every 28-day cycle)."
62314353|NCT03463265|EXPERIMENTAL|Arm A, Cohort 4: nab-sirolimus + lomustine (CCNU) in patients with recurrent high grade glioma|"nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle.~CCNU was administered PO at 90 mg/m2 on Day 1 of each odd 21-day cycle (ie, every 6 weeks)."
62684877|NCT05248009|EXPERIMENTAL|Semi-Permanent Tattoo Ink|Semi-Permanent Tattoo Ink
62684878|NCT00707369|EXPERIMENTAL|test|Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
62684879|NCT00707369|PLACEBO_COMPARATOR|control|Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
62684880|NCT04739215|EXPERIMENTAL|Clinical Trial: Experimental Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Dapagliflozin (Forxiga) 10 mg, one capsule per day orally.
62684881|NCT04739215|PLACEBO_COMPARATOR|Clinical Trial: Placebo Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Placebo in a similar pattern.
61923929|NCT01578564|EXPERIMENTAL|SOR-C13|
61923930|NCT05899010|ACTIVE_COMPARATOR|Vaginal progesterone 600mg|Vaginal progesterone 600mg daily (200mg tid) will be started and maintained until 10 weeks of pregnancy or either up to menses or up to negative pregnancy test performed 10 days after ET
61923931|NCT05899010|EXPERIMENTAL|Vaginal progesterone 800mg|Vaginal progesterone 800mg daily (400mg bid) will be started and maintained until 10 weeks of pregnancy or either up to menses or up to negative pregnancy test performed 10 days after ET.
62124499|NCT04260906|ACTIVE_COMPARATOR|Vagus nerve stimulation|Patients were admitted to the treatment as day visitors. Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears . The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
62124500|NCT04260906|ACTIVE_COMPARATOR|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
62684882|NCT04739215|NO_INTERVENTION|Descriptive Study|Patients with heart failure with preserved ejection fraction but with no type 2 diabetes mellitus (n=10).
62684883|NCT03747757|EXPERIMENTAL|Supportive Care (CBT)|Patients undergo CBT consisting of 7 counseling sessions, up to 45 minutes each over the phone.
62124501|NCT00181753|EXPERIMENTAL|1|Burn Patients receiving at least 3 days of parenteral feeding on routine formula
62684884|NCT06613477|EXPERIMENTAL|Population specific PK model-derived digoxin dosing|"Digoxin elixir will be used to dose enterally every 12 hours.~The dosage will be determined by the protocol PK model. Dosing is to be administered based on weight, postnatal age, and estimated glomerular filtration rate~The duration of the participation could be up to 180 days. Day 1 to S2P or Day 180 (+/- 7)"
62684885|NCT05647252|EXPERIMENTAL|Decolonization|"This study will be performed with an existing set manufactured by Schülke \& Mayr GmbH. The distribution of octenisan® wash lotion and octenisan® nasal gel in the form of a set (octenisan® set) largely streamlines and facilitates the application and compliance.~The duration of pre-surgical decolonization is planned to be five days. However, when this pre-surgical time period is too short, the decolonization may also start at least 3 days before surgery and be contin-ued up to 2 days post-surgery.~During the post-surgery application, the patient will be washed with water and Octenisan® set by their treating nurses. The patient will also return the empty/used set and answer to a short questionnaire during their hospital stay. The study team will recuperate the questionnaire during hospitalization."
62684886|NCT05647252|NO_INTERVENTION|Non-Decolonization|No Decolonization preoperatively
62684887|NCT01515254|NO_INTERVENTION|No intervention- control group|Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken. The control group subjects will have the opportunity to receive the intervention at the end of the study
62684888|NCT01515254|EXPERIMENTAL|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
62684889|NCT01333826|EXPERIMENTAL|Unconditional cash transfers|Monthly cash transfers given to households with school aged girls with no strings attached. Transfer amounts randomized within this arm.
62684890|NCT01333826|EXPERIMENTAL|Conditional Cash Transfer|Monthly cash transfers given to households with school aged girls conditional on regular school attendance (80%). Transfer amounts randomized within this arm.
62684891|NCT01333826|NO_INTERVENTION|Control Group|No cash transfer program implemented in this group.
62684892|NCT06605027|EXPERIMENTAL|Therapeutic Ketogenic Diet (TKD) Study Arm|Participants in the TKD Study Arm will complete 14 weeks of therapeutic ketogenic diet (TKD), weekly weight and ketone measurements, weekly behavioral assessments, and meetings with the study doctor and dietician every week, and peer counseling sessions.
62684893|NCT06605027|NO_INTERVENTION|Treatment as Usual (TAU) Study Arm|Participants who consent to be in the Treatment as Usual Study Arm will complete weekly weight and ketone measurements and questionnaires for 14 weeks.
62684894|NCT06060041||IC-8 Apthera intraocular lens (IOL) Group|Patients previously implanted with the IC-8 Apthera intraocular lens (IOL) and who have developed posterior capsular opacification (PCO) which requires treatment with Nd:YAG laser capsulotomy.
62684895|NCT03008980||Community GI Group|Diagnostic Test
61923932|NCT01178073|ACTIVE_COMPARATOR|Combination ambrisentan + tadalafil|ambrisentan + tadalafil
62124502|NCT00181753|EXPERIMENTAL|2|Burn patients receiving at least 3 days on parenteral feeding on glutamine enriched formula.
62684896|NCT03008980||Academic GI Group|Diagnostic Test
62684897|NCT03008980||Academic Esophageal Dysplasia and Cancer|Diagnostic Test
62684898|NCT03008980||Community Barrett's Esophagus Screening|Diagnostic Test
62684899|NCT03008980||Community Esophageal Dysplasia|Diagnostic Test
62684900|NCT03008980||Post-Ablation BE and Esophagus Dysplasia|Diagnostic Test
62124503|NCT00181753|EXPERIMENTAL|3|Burn patients receiving at least 3 days of enteral feeding on routine formula.
62684901|NCT03008980||GERD, BE, and Esophageal Dysplasia|Diagnostic Test
62684902|NCT04562090|EXPERIMENTAL|Mirabegron 25 mg|Participants received single oral dose of Mirabegron 25 milligrams (mg) tablet once daily, at the same time after a meal for a duration of 12 weeks. Dose escalation to 50 mg was permitted at Visit 3 (Week 4) or Visit 4 (Week 8) at the discretion of investigator.
62684903|NCT04562090|EXPERIMENTAL|Mirabegron 50 mg|Participants received single oral dose of Mirabegron 50 mg tablet once daily, at the same time after a meal for a duration of 12 weeks.
62684904|NCT03767387|ACTIVE_COMPARATOR|Prehabilitation + standard care|Trimodal Prehabilitation consisting on motivation, personalisation and supervision of physical activity before major surgery
62684905|NCT03767387|NO_INTERVENTION|Standard care|Standard care before major surgery
62684906|NCT06687161|ACTIVE_COMPARATOR|One (1) TMS treatment per day plus CBT-I|One (1) daily treatment of intermittent theta-burst stimulation (iTBS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 10 days (2 weeks) followed by a 9-week Internet-delivered cognitive behavioral therapy for insomnia (CBT-I) program
61923933|NCT01178073|ACTIVE_COMPARATOR|Monotherapy ambrisentan|ambrisentan
61923934|NCT01178073|ACTIVE_COMPARATOR|Monotherapy tadalafil|tadalafil
61923935|NCT02016339|ACTIVE_COMPARATOR|Standard Care|24 hour consultation telephone line to the sleep nurses will be open for the patients. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy
62124504|NCT00181753|EXPERIMENTAL|4|Burn patients receiving at least 3 days of enteral feeding on glutamine-enriched formula.
62124505|NCT02976116|EXPERIMENTAL|Fruquintinib & Gefitinib|Drug: Fruquintinib and Gefitinib
62124506|NCT05833906|EXPERIMENTAL|CKR-051 SAD|Participants will be administrated a single dermal dose of CKR-051 at various ascending dose levels or matching placebo for 1 day.
62124507|NCT05833906|EXPERIMENTAL|CKR-051 MAD|Participants will be administrated a single dermal dose of CKR-051 at various ascending dose levels or matching placebo for 21 day.
62124508|NCT05955391|EXPERIMENTAL|Experimental: TGRX-326|Subjects to be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles.
61923936|NCT02016339|ACTIVE_COMPARATOR|Intensive care|"Standard group care plus:~Involvement of the patient's partner or family. Extra education on sleep apnea syndrome and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence."
62684907|NCT06687161|ACTIVE_COMPARATOR|Two (2) TMS treatments per day plus CBT-I|Two (2) daily treatments, spaced 1 hour apart, of intermittent theta-burst stimulation (iTBS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 10 days (2 weeks) followed by a 9-week Internet-delivered cognitive behavioral therapy for insomnia (CBT-I) program
62684908|NCT05447858|ACTIVE_COMPARATOR|Managerial support in using systematic work environment evaluation and adjustment (SWEA)|Managerial support in using SWEA and the Prehab guide to enhance employees' work situation. Individual work adaptations are adaptations to everyone´s ability in the physical, organisational, and social work environment that aim to enable an employee with reduced ability to perform the normal work, continue working, or plan for a sustainable return to work. The Prehab guide contains a self-assessment test for the employee based on the requirements of the work and one's own ability that can be used in the dialogue with the manager. It also contains suggestions for activities to create a healthier workplace, such as discovering early signals of stress or pain, creating a caring workplace culture and boundaries, regular contact with an employee that is on sick-leave, clear and established safety procedures and routines for the work environmental work, routines for cooperation with other parties, and to learn from one's own and colleague's experiences in an open, permissive climate.
62684909|NCT05447858|EXPERIMENTAL|Neck-specific exercise in addition to SWEA|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control \[15, 30\]. To ensure that the exercises are learned and performed correctly, the participant will meet with a physiotherapist a total of four times, once during weeks 2, 3, 4, and 7 (week 1=first visit for a clinical examination due to law) for instruction, guidance, and support. In addition to photos, videos, and text regarding the exercises, the digital support (web-based program at the support and treatment platform Inera via 1177 managed by the County Councils) also contains information about why it is important to exercise the neck muscles, factors that may cause neck pain, how relapses can be handled, ergonomic advice related to the neck, and an exercise diary.
62684910|NCT05648747||Complicated Pelvic Inflammatory Disease|The development of complicated Pelvic Inflammatory Disease diagnosed during laparoscopy or by pre-operative image study
61923937|NCT02186132|EXPERIMENTAL|Atropine 0.6 mg|Atropine 0.6 mg intravenous
62124509|NCT00703950|EXPERIMENTAL|A,1|Cup feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
62478444|NCT00354835|EXPERIMENTAL|Arm II (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
61923938|NCT02186132|ACTIVE_COMPARATOR|Atropine 1.2 mg intravenous|Atropine 1.2 mg intravenous
61923939|NCT05705414|EXPERIMENTAL|Treatment group Valine then EEA|Valine will be administered as two 4 gm packets administered on dialysis treatment day followed by a washout period and then EEA
61923940|NCT05705414|EXPERIMENTAL|Treatment group EEA then Valine|EAA will be administered as one 12.5 gm packet administered on dialysis treatment day followed by a washout and then Valine
62478445|NCT02220647|EXPERIMENTAL|Treatment A (FDC)|
62684911|NCT05648747||Non-Complicated Pelvic Inflammatory Disease|No development of complicated Pelvic Inflammatory Disease diagnosed during laparoscopy or by pre-operative image study
62684912|NCT00787800|ACTIVE_COMPARATOR|Dual Chamber ICD|Dual chamber Implantable Cardioverter-Defibrillator (ICD): Atrial therapies and minimized ventricular pacing will be programmed on along with Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation.
62684913|NCT00787800|ACTIVE_COMPARATOR|Single Chamber ICD|Single chamber Implantable Cardioverter-Defibrillator: Optimally programmed Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies will be programmed on including use of detection enhancements.
62684914|NCT06688773|EXPERIMENTAL|progressive relaxation exercises group|
62684915|NCT06688773|OTHER|Control group|Implementation of standart postoperative care in the clinical setting.
62684916|NCT04575688|ACTIVE_COMPARATOR|Periarticular Injection|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a periarticular injection by the surgeon using 10 milliliters of Exparel mixed with 10 milliliters of bupivicaine 0.5 percent at the end of the procedure.
62684917|NCT04575688|ACTIVE_COMPARATOR|Popliteal Block|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a popliteal block by the anesthesiologist using 30 milliliters of bupivicaine 0.5 percent in the pre-operative area, prior to surgery, using an ultrasound machine for guidance.
62684918|NCT06680375|EXPERIMENTAL|mRNA Flu/COVID-19 Dose 1 Group|Participants receive one dose of investigational Flu mRNA vaccine composition in combination with a Dose 1 of a COVID-19 component and 1 dose of placebo on Day 1.
62684919|NCT06680375|EXPERIMENTAL|mRNA Flu/COVID-19 Dose 2 Group|Participants receive one dose of investigational Flu mRNA vaccine composition in combination with a Dose 2 of a COVID-19 component and 1 dose of placebo on Day 1.
62684920|NCT06680375|ACTIVE_COMPARATOR|Flu+COVID-19 Group|Participants receive one dose of a licensed Flu Seasonal vaccine and a licensed mRNA COVID-19 vaccine on Day 1.
62684921|NCT06680375|ACTIVE_COMPARATOR|mRNA Flu Group|Participants receive one dose of an investigational mRNA Flu Seasonal vaccine and 1 dose of placebo on Day 1.
62684922|NCT06680375|ACTIVE_COMPARATOR|mRNA COVID-19 Dose 1 Group|Participants receive one dose of Dose 1 investigational mRNA COVID-19 vaccine and 1 dose of placebo on Day 1.
62684923|NCT06680375|ACTIVE_COMPARATOR|mRNA COVID-19 Dose 2 Group|Participants receive one dose of Dose 2 investigational mRNA COVID-19 vaccine and 1 dose of placebo on Day 1.
62684924|NCT06680375|EXPERIMENTAL|mRNA Flu/COVID-19 _YA Group|Younger adult (YA,18-64 years of age) participants receive one dose of a selected Investigational Flu Seasonal/SARS-CoV-2 mRNA dose level from study Phase 1 and 1 dose of placebo on Day 1.
62684925|NCT06680375|ACTIVE_COMPARATOR|Flu+COVID-19 _YA Group|YA participants receive one dose of a licensed Flu Seasonal vaccine and a licensed mRNA COVID-19 vaccine on Day 1.
62684926|NCT06680375|ACTIVE_COMPARATOR|mRNA Flu _YA Group|YA participants receive one dose of an investigational mRNA Flu Seasonal vaccine and 1 dose of placebo on Day 1.
61923941|NCT05368077|EXPERIMENTAL|35 Pediatric Obstructive Sleep Apnea|"The investigators will also determine whether brain tissue changes, reduced CBF, and altered neural responses to cognitive challenge reverse, and cognition and mood signs improve after standard surgical procedure adenotonsillectomy for breathing condition at 6 months in pediatric OSA."
61923942|NCT05443061|EXPERIMENTAL|Nitroglycerin|Nitroglycerin 5mcg/kg (in 0.5cc) is subcutaneously injected before radial artery cannulation and before removal of the radial arterial catheter.
61923943|NCT05443061|ACTIVE_COMPARATOR|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation and before removal of the radial arterial catheter.
62478446|NCT02220647|ACTIVE_COMPARATOR|Treatment B (single agents)|
62684927|NCT06680375|ACTIVE_COMPARATOR|mRNA COVID-19 _YA Group|YA participants receive one dose of a selected SARS-CoV-2 mRNA dose level from study Phase 1 and 1 dose of placebo on Day 1.
62684928|NCT06680375|EXPERIMENTAL|mRNA Flu/COVID-19 _OA Group|Older adult (OA; 65 years of age and older) participants receive one dose of a selected Investigational Flu Seasonal/SARS-CoV-2 mRNA dose level from study Phase 1 and 1 dose of placebo on Day 1.
62684929|NCT06680375|ACTIVE_COMPARATOR|Flu+COVID-19 _OA Group|OA participants receive one dose of a licensed Flu Seasonal vaccine and a licensed mRNA COVID-19 vaccine on Day 1.
62684930|NCT06680375|ACTIVE_COMPARATOR|mRNA Flu _OA Group|OA participants receive one dose of an investigational mRNA Flu Seasonal vaccine and 1 dose of placebo on Day 1.
62684931|NCT06680375|ACTIVE_COMPARATOR|mRNA COVID-19 _OA Group|OA participants receive one dose of a selected SARS-CoV-2 mRNA dose level from study Phase 1 together and 1 dose of placebo on Day 1.
62314354|NCT03463265|EXPERIMENTAL|Arm A, Cohort 5: nab-sirolimus + marizomib (MRZ) in patients with recurrent high grade glioma|"nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle.~MRZ was administered at 0.8 mg/m 2 as a 10-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle. MRZ was administered approximately 10 minutes after the end of the nab-sirolimus infusion."
62314355|NCT03463265|EXPERIMENTAL|Arm B: nab-sirolimus + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma|"Induction Treatment (4 weeks) with nab-sirolimus (60 mg/m2 IV weekly); followed by~Concomitant Treatment (standard of care; 2 cycles): nab-sirolimus (60 mg/m2 IV on Days 8 and 15 of every 21-day cycle) in combination with TMZ (75 mg/m2 PO daily for 6 weeks) + radiotherapy (30 × 200 cGy, 5 days/week); followed by~Adjuvant Treatment (6 cycles) starting 4 weeks after Concomitant Treatment, with nab-sirolimus(60 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle) in combination with TMZ (150 mg/m2 PO daily on Days 1-5 of every 28-day cycle)"
62314356|NCT02138110|EXPERIMENTAL|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
62314357|NCT05057312|ACTIVE_COMPARATOR|Group I (standard CDC information)|Participants receive standard CDC information about HPV vaccination.
62684932|NCT05062707||AYA cancer patients|Patients aged 18-39 years, with a first histological and/or cytological diagnosis of a haematological or solid malignancy, scheduled to start systemic therapy with curative intent.
62684933|NCT04843839|EXPERIMENTAL|Test Eye|These eyes will be given the Test drug, that is Nepafenac Eye Drops 0.1% w/v, at the dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
62684934|NCT04843839|PLACEBO_COMPARATOR|Control Eye|These eyes will be given the placebo, that is Carboxy-methylcellulose sodium lubricant eye drops 0.5%w/v, at the same dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
61923944|NCT00652197||Extraventricular Drainage|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
62314358|NCT05057312|EXPERIMENTAL|Group II (video narratives)|Participants receive video narratives about HPV vaccination.
62314359|NCT05057312|EXPERIMENTAL|Group III (written narratives)|Participants receive written narratives about HPV vaccination.
62314360|NCT05057312|EXPERIMENTAL|Group IV (enhanced access to vaccine, CDC information)|Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.
62314361|NCT05057312|EXPERIMENTAL|Group V (enhanced access to vaccine, video narratives)|Participants receive enhanced access to vaccination and video narratives about HPV vaccination.
62684935|NCT06566768|EXPERIMENTAL|Part A: Deucravacitinib|
61923945|NCT05645250||Negatives cases|
61923946|NCT05645250||Positive cases|
62684936|NCT06566768|EXPERIMENTAL|Part B: Deucravacitinib|
62684937|NCT05569252|EXPERIMENTAL|DS-1211b low dose|Participants who will be randomized to receive a DS-1211 tablet once daily for 12 weeks.
62684938|NCT05569252|EXPERIMENTAL|DS-1211b middle dose|Participants who will be randomized to receive a DS-1211b tablet once daily for 12 weeks.
62684939|NCT05569252|EXPERIMENTAL|DS-1211b high dose|Participants who will be randomized to receive a DS-1211b tablet once daily for 12 weeks.
62684940|NCT05569252|PLACEBO_COMPARATOR|Placebo|Participants who will be randomized to receive a placebo tablet once daily for 12 weeks.
62124510|NCT00703950|ACTIVE_COMPARATOR|A,2|bottle feeding - conventional method Bottle feeding is the conventional method to feed preterm infant before breastfeeding or to substitute breastfeeding. We are using this method in the control group.
62124511|NCT04484415|EXPERIMENTAL|Cevira® treatment|The Cevira® treatment is an integrated combination of drug and device
62478447|NCT04347018|EXPERIMENTAL|BRIUS|BRIUS orthodontic appliance (wire) will be used to treat the patients. BRIUS appliance will be engaged to regular orthodontic brackets intra-orally to initiate orthodontic treatment at the University at Buffalo Orthodontic Clinic.
62684941|NCT06689371|EXPERIMENTAL|Group A (Dry needling): The 15 patients will receive three dry needling sessions per week for four|
62314362|NCT05057312|EXPERIMENTAL|Group VI (enhanced access to vaccine, written narratives)|Participants receive enhanced access to vaccination and written narratives about HPV vaccination.
62478448|NCT04347018|ACTIVE_COMPARATOR|Preadjusted edgewise full fixed appliance|regular full fixed orthodontic appliance (FFA) appliances will be used to treat patients. These are regular orthodontic brackets with standard orthodontic wires used to treat patients at the University at Buffalo Department of Orthodontics
62478449|NCT00089011|EXPERIMENTAL|Arm I (nonmyeloablative conditioning with fludarabine and TBI)|Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
62684942|NCT06689371|EXPERIMENTAL|Group B (Dry cupping): The 15 patients will receive three dry cupping sessions per week for four we|
62684943|NCT06689371|ACTIVE_COMPARATOR|Group C (control): The 15 patients will receive standard exercise three sessions per week for four w|
62684944|NCT05062200|EXPERIMENTAL|Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])|Japanese participants will receive single oral dose 1 of JNJ-77242113 (immediate-release \[IR\] tablet) or matching placebo on Day 1 in Cohort 1 of Part 1.
61923947|NCT03962309||Patients in charge of the participating GPs|In the study will be included patients in charge of the participating GPs aged 40-70 years
62124512|NCT04484415|PLACEBO_COMPARATOR|Placebo ointment|The placebo ointment contains only vehicle, and is similar in appearance and consistence as the Cevira® ointment. The placebo device is identical in appearance as the Cevira® device, but does not provide light.
62124513|NCT00813449|EXPERIMENTAL|A|Experimental group : Endostar combined with dacarbazine
62124514|NCT00813449|PLACEBO_COMPARATOR|2|Control group : Dacarbazine combined with placebo
62124515|NCT02854813||Group 1|Patients with a OAB-V8 score ≥8
62124516|NCT02854813||Group 2|Patients with a OAB-V8 score \<8
62684945|NCT05062200|EXPERIMENTAL|Cohort 2: JNJ-77242113 or Placebo (SAD)|Japanese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 2 of Part 1.
62124517|NCT01348035||Water Load Group|Water load group: 2.5 \~ 3 L water intake daily for 12 months (50ml/Kg body weight/day). When large amount water intake is not sustainable, patients can reduce the amount of water intake to the levels as much as large he or she can sustain.
62124518|NCT01348035||Non-Water Loaded Group|Non-water load group: The patients are free to access water intake, as they like.
62124519|NCT05814328|NO_INTERVENTION|Standard Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2
61923948|NCT01182779|EXPERIMENTAL|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
62124520|NCT05814328|EXPERIMENTAL|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
62124521|NCT01352611|EXPERIMENTAL|baclofen, intrathecal|A single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
62124522|NCT02462499|EXPERIMENTAL|Treatment|Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.
62124523|NCT06155071|EXPERIMENTAL|Group A (Plyometric training)|
62124524|NCT06155071|OTHER|Group B (Conventional)|
61923949|NCT01182779|ACTIVE_COMPARATOR|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
61923950|NCT03505671|EXPERIMENTAL|Group 1 (acupuncture)|Participants undergo 8 45-minute acupuncture treatments over 10 weeks.
61923951|NCT03505671|ACTIVE_COMPARATOR|Group 2 (usual care)|Participants receive usual care.
62478450|NCT00089011|EXPERIMENTAL|Arm II (nonmyeloablative conditioning with TBI)|Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.
62684946|NCT05062200|EXPERIMENTAL|Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])|Chinese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 3 of Part 2.
62124525|NCT04062760|ACTIVE_COMPARATOR|Standard diuretic therapy (SDT)|Furosemide +/- spironolactone or potassium canrenoate
61923952|NCT04145479|EXPERIMENTAL|low-resistance|women will perform low-resistance physical activity
61923953|NCT04145479|EXPERIMENTAL|aerobic|women will perform aerobic physical activity
61923954|NCT03593161|EXPERIMENTAL|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
61923955|NCT03593161|NO_INTERVENTION|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
62124526|NCT04062760|EXPERIMENTAL|Early sequential nephron blockade (ESNB)|Furosemide + metolazone + acetazolamide +/- spironolactone or potassium canrenoate
62124527|NCT02296463|EXPERIMENTAL|Treatment Group A|Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant
62124528|NCT02296463|EXPERIMENTAL|Treatment Group B|Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine
62124529|NCT02296463|EXPERIMENTAL|Treatment Group C|Day 0: RSV F Vaccine, Day 28: RSV F Vaccine
62478451|NCT00489177|ACTIVE_COMPARATOR|A|QuickOpt
62478452|NCT00489177|PLACEBO_COMPARATOR|B|Usual care
62478453|NCT05221021|ACTIVE_COMPARATOR|Vaginal Estradiol with placebo oral pill|Patient will receive 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
62478454|NCT05221021|ACTIVE_COMPARATOR|Oral Mirabegron with placebo vaginal cream|Patient will receive 50 milligrams oral Mirabegron once daily and placebo vaginal cream (Medisca's VersaPro Cream Base) once nightly for two weeks then three times per week
62478455|NCT06505343||Parkinson's patients with freezing phenomenon|Parkinson's patients with freezing phenomenon
62684947|NCT05062200|EXPERIMENTAL|Cohort 4: JNJ-77242113 or Placebo (SD)|Japanese participants will receive single oral dose 3 of JNJ-77242113 (delayed-release \[DR\] tablet) with absorption enhancer (AbE) or matching placebo on Day 1 in Cohort 4 of Part 3.
62697386|NCT02516813|EXPERIMENTAL|Phase 1a (Arm B): M3814 Capsule (50 mg) + CRT|Participants with local/locally advanced squamous cell carcinoma of the head and neck (SCCHN) received 50 mg of M3814 as capsule orally once daily on FD 6 in combination with fractionated RT (2 Gy x 33 to 35 fractions; 5 F/W) and Cisplatin twice at a dose of 100 milligrams per square meter (mg/m\^2) or weekly at a dose of 40 (mg/m\^2).
62478456|NCT06505343||Parkinson's patients without freezing phenomenon|Parkinson's patients without freezing phenomenon
62124530|NCT02296463|EXPERIMENTAL|Treatment Group D|Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine
62124531|NCT02296463|PLACEBO_COMPARATOR|Treatment Group E|Day 0: Placebo, Day 28: Hepatitis A Vaccine
62124532|NCT00813059|EXPERIMENTAL|1|
62124533|NCT01372761|PLACEBO_COMPARATOR|Normal Saline|
62124534|NCT01372761|EXPERIMENTAL|ZGN-433|
62697387|NCT02516813|EXPERIMENTAL|Phase 1a (Arm B): M3814 Tablet (100 mg) + CRT|Participants with squamous cell carcinoma of the head and neck (SCCHN) received 100 mg of M3814 as tablet orally once daily for 7 consecutive weeks in combination with fractionated RT (2 Gy X 33 to 35 fractions; 5 F/W) and Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 (mg/m\^2).
62124535|NCT02738320|EXPERIMENTAL|Intervention|Intervention patients will receive access to NHCPlus when discharge to a nursing home from the hospital is expected.
62124536|NCT02738320|NO_INTERVENTION|Usual Care|Control patients will receive the usual care when discharge to a nursing home from the hospital is expected.
62124537|NCT05935527|PLACEBO_COMPARATOR|Placebo (Normal Saline)|Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive placebo (Normal Saline) with a volume of 120 microliters injection.
62124538|NCT05935527|EXPERIMENTAL|POLAT-001|Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive POLAT-001 with a volume of 120 microliters injection, at either 1 mg/mL or 2 mg/mL
62124539|NCT00891436|PLACEBO_COMPARATOR|Placebo nasal spray|
62124540|NCT00891436|ACTIVE_COMPARATOR|Fluticasone furoate nasal spray|
62124541|NCT00642980|ACTIVE_COMPARATOR|Clindamycin Cure 1|Arm 1
62124542|NCT00642980|ACTIVE_COMPARATOR|Clindamycin Cure 2|Arm 2
62478457|NCT06505343||Healthy|Healthy
62124543|NCT00642980|PLACEBO_COMPARATOR|Placebo|Arm placebo
62684948|NCT06316063|EXPERIMENTAL|Apnoeic oxygenation with High-flow nasal oxygen|In the apnoeic oxygenation group the HFNO is used for pre-oxygenation,100 % O2, 40 L/min during 3 min. Thereafter, anaesthesia is induced by intravenous Propofol and Remifentanil. Rocuronium for full neuromuscular blockade is administered and a jaw thrust is used to keep an open airway. The airway will be kept patent throughout the procedure using a suspension laryngoscope, placed by the ENT surgeon. During apnoea oxygen will be increased to 70 L/min, 100% O2. Apnoea will be discontinued if any of the criteria SpO2 \< 90%, PaCO2 \>11 kPa, pH \<7.15 or arrhythmias with haemodynamic effects occur.
62124544|NCT03429998|PLACEBO_COMPARATOR|LDL apheresis|LDL apheresis during at least one year
62314363|NCT06672692|OTHER|Blinded, Prospective Arm|"Clinical specimens shall be collected prospectively from patients with signs or symptoms of respiratory tract infection. Nasal swab in Copan universal transport media (UTM) 3 milliliters for comparator testing should be collected by a healthcare professional.~Where subjects are willing and able, up to 40% of nasal swab for the investigational device will be self-collected under the guidance and supervision of a healthcare professional.~Nasopharyngeal (NPS) specimens (optional) should only be collected by a healthcare professional. All specimens collected from children 13 years or younger should only be collected by a trained healthcare professional. Follow the Centers for Disease Control and Prevention guidelines for collecting NPS swabs, unless otherwise specified by the sponsor."
62314364|NCT06668363|EXPERIMENTAL|Treat4All|Treat4All will be based on Fleming's Project TrEAT, culturally adapted to the Malawi context, and enhanced to include content on HIV prevention and treatment activities (PrEP use for those at risk for HIV; ART adherence and viral suppression for PWH). The sessions will provide personalized feedback on alcohol use; a description of adverse effects of alcohol and its role in STI acquisition; a review of reasons to cut down or quit; risky situations, and how to handle them; and optional goal setting. Alcohol-related content of sessions will include reviewing drinking patterns, harmful effects of drinking, and alcohol use behavior change strategies. HIV prevention and treatment content of session will include strategies for increasing HIV care engagement, including ART initiation and adherence and PrEP use for those at risk for HIV. Each session will use cognitive problem solving, skills building, and goal setting to facilitate knowledge, motivation, and behavior to reduce heavy drinking
61923956|NCT04216914|EXPERIMENTAL|Use of hand outline for bone age xray|Where children and young people are having left hand X-rays for clinical purposes the radiographer will place a template under their hand. The plate is designed not to show up on the X-ray and to not interfere with the X-ray itself. They will be asked to match their hand to the hand outline on the template.
61923957|NCT01907438||non-carriers|Tissues from premenopausal women undergoing esthetic breast surgery with no family history of breast or ovarian cancers will be obtained.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
61923958|NCT01907438||BRCA1 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA1 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
61923959|NCT01907438||BRCA2 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA2 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
61923960|NCT02854410|EXPERIMENTAL|Sodium nitrate supplementation|Patients will receive Sodium nitrate supplementation from 7 days before radiotherapy to one month after the end of radiotherapy
61923961|NCT02854410|PLACEBO_COMPARATOR|Placebo Comparator(sodium chloride)|Patients will receive placebo from 7 days before radiotherapy to one month after the end of radiotherapy
62314365|NCT06668363|ACTIVE_COMPARATOR|Standard of care (control arm)|Participants in the control arm will receive usual care (UC). This includes sexual risk reduction counseling that integrates messaging on reducing alcohol use prior to sex and the recommendation to abstain from alcohol while on ART. Participants in this arm will continue to receive all STI or HIV-related services.
62684949|NCT06316063|ACTIVE_COMPARATOR|Mechanical ventilation|In the mechanical ventilation group pre-oxygenation is performed by a tight-fitting facemask, 100 % O2, for three minutes. After anaesthesia induction and full neuromuscular blockade, tracheal intubation is performed and mechanical ventilation is started.
62684950|NCT03945253|EXPERIMENTAL|ASP8374-dose A|Participants will receive dose A of ASP8374 solution intravenously on day 1 of every 3-week cycle.
62684951|NCT03945253|EXPERIMENTAL|ASP8374-dose B|Participants will receive dose B of ASP8374 solution intravenously on day 1 of every 3-week cycle.
61923962|NCT05596396|EXPERIMENTAL|LifeHack|Participants assigned to this arm will receive a 6-week guided e-health intervention to increase positive mental health and well-being.
61923963|NCT05596396|ACTIVE_COMPARATOR|LifeHack-C|Participants assigned to this arm will receive the same intervention, delivered over 2 to 6 weeks.
61923964|NCT03206073|EXPERIMENTAL|1/Arm A1 Pexa-Vec + Durvalumab|Pexa-Vec escalation dose levels + Durvalumab
61923965|NCT03206073|EXPERIMENTAL|2/Arm A2 Pexa-Vec +Durvalumab|Maximum tolerated dose (MTD) of Pexa-Vec after the MTD is established +Durvalumab
61923966|NCT03206073|EXPERIMENTAL|3/Arm B1 Pexa-Vec + Durvalumab +Tremelimumab|Pexa-Vec escalation dose levels + Durvalumab +Tremelimumab
61923967|NCT03206073|EXPERIMENTAL|4/Arm B2|MTD of Pexa-Vec after the MTD is established+Durvalumab + Tremelimumab
61923968|NCT04743518|ACTIVE_COMPARATOR|anti-TNF|
61923969|NCT04743518|ACTIVE_COMPARATOR|vedolizumab|
61923970|NCT04743518|ACTIVE_COMPARATOR|tofacitinib|
61923971|NCT01733849||Group Bulgaria|Subjects in this group include infants/children from Bulgaria, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
62124545|NCT03429998|ACTIVE_COMPARATOR|Evolocumab|140 mg evolocumab biweekly
62124546|NCT03429998|ACTIVE_COMPARATOR|LDL apheresis and evolocumab|LDL-apheresis monthly evolocumab 140 mg biweekly
62684952|NCT00265005|EXPERIMENTAL|All|All subjects receive active drug up to a total of 3 doses
62684953|NCT05912725|EXPERIMENTAL|Accuracy of Implant impression techniques|"Active comparative : digital implant impression Participants underwent intra-oral scanning digital impression~Experimental : conventional implant impression Participants underwent conventional impressions And right side of pt mouth received screw retained prosthesis constructed from conventional impression left side received screws retained prosthesis constructed from digital impression"
62684954|NCT06117813|EXPERIMENTAL|Nu.T|Nu.T, 5 times a week for 8 weeks.
62684955|NCT06117813|OTHER|No-treatment Control|No-treatment was administered during control period.
62684956|NCT05308641|ACTIVE_COMPARATOR|PreviousSurgery(PrevSurg)_YES/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 4000 pulse, 20 Hz
62684957|NCT05308641|ACTIVE_COMPARATOR|PrevSurg_YES/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 500 pulse, 2 Hz
62684958|NCT05308641|ACTIVE_COMPARATOR|PrevSurg_YES/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: no
62684959|NCT05308641|ACTIVE_COMPARATOR|PrevSurg_YES/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: denied
62684960|NCT05308641|ACTIVE_COMPARATOR|PrevSurg_NO/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 4000 pulse, 20 Hz
62684961|NCT05308641|ACTIVE_COMPARATOR|PrevSurg_NO/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 500 pulse, 2 Hz
62684962|NCT05308641|ACTIVE_COMPARATOR|PrevSurg_NO/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: no
62684963|NCT05308641|ACTIVE_COMPARATOR|PrevSurg_NO/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: denied
62684964|NCT06003790|EXPERIMENTAL|Intervention|Participants will receive MR-001 delivered to their home via mail. Participants will be asked to use the device for 24 sessions, 3 times a week for 8 weeks.
62684965|NCT04098783|EXPERIMENTAL|Nursing interventions (home visit and health education) group|Nursing interventions group: Home visit, health education At the Intervention group; the researcher made pretest (baseline measurements) before the nursing interventions at the first home visit. The researcher offered education and guide about prevention of lymphedema after the baseline measurements at the first home visit. Second and third home visits were made three and six months after the first visit. At the second and the third home visits, the measurements were repeated, and the nursing interventions were maintained in the direction of the patients' individual needs.
61923972|NCT01733849||Group Latvia|Subjects in this group include infants/children from Latvia, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
61923973|NCT01244698|OTHER|Antibiotics until Drain Removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
61923974|NCT01244698|EXPERIMENTAL|Early discontinuation of antibiotics|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
61923975|NCT01575886|EXPERIMENTAL|Smoking cessation intervention|This group receives the teachable moment communication process intervention focused on smoking cessation and contributes data at baseline (Time 1) and post intervention (Time 2).
61923976|NCT01575886|OTHER|Delayed intervention group|This group serves as the comparison group for the evaluation of the smoking cessation intervention at Time 1 and Time 2 data collection to complete the group randomized trial. This group of clinicians then has Time 3 data collection focused on weight management receives a revised intervention focused on teachable moment communication for weight management and has Time 4 data collected to evaluate the teachable moment for weight management training as a pre-post design.
62684966|NCT04098783|NO_INTERVENTION|No Nursing interventions group|No Nursing interventions group; the researcher administered the pretests at first home visit. The measurements were repeated in the third and sixth months after the first home visit. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
62684967|NCT06412055|EXPERIMENTAL|NEURO SWING AFO|Participants will be fitted with a new custom-made spring-hinged AFO with the NEURO SWING® system ankle joint. Following a previously developed algorithm, the stiffness will be individually selected from six different configurations tested during an optimization measurement directly after delivery of the new AFO. Thereafter, participants will use the optimized AFO with individualized stiffness at home for six weeks during the course of the study.
62684968|NCT03324412|ACTIVE_COMPARATOR|Treatment of MTX|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.
62684969|NCT03324412|EXPERIMENTAL|Treatment of MTX and TwHF|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF).
62684970|NCT00292903|EXPERIMENTAL|A|
62684971|NCT00292903|ACTIVE_COMPARATOR|B|
62684972|NCT00504556|EXPERIMENTAL|1|DU-176b 30mg tablet once daily
62684973|NCT00504556|EXPERIMENTAL|2|DU-176b 60mg once daily
62684974|NCT00504556|EXPERIMENTAL|3|DU-176b 30mg b.i.d.
62684975|NCT00504556|EXPERIMENTAL|4|DU-176b 60mg tablets two times a day
62684976|NCT00504556|ACTIVE_COMPARATOR|5|warfarin tablets
62684977|NCT04250766|OTHER|Single arm echo-guided uterine biopsy|
62684978|NCT03810365|EXPERIMENTAL|Behavioral: Brief behavioral treatment for insomnia|Brief behavioral treatment for insomnia includes 45 minute individual intervention with two follow up phone calls.
62684979|NCT03810365|ACTIVE_COMPARATOR|Behavioral: Healthy eating control|Healthy eating control involves a 45 minute individual session with two follow up phone calls.
62684980|NCT06456684||early-stage Parkinson's disease|
62684981|NCT06456684||prodromal Parkinson's disease|
61923977|NCT00046891|EXPERIMENTAL|Ginkgo Biloba|120 mg per day (60 mg BID)
61923978|NCT00046891|PLACEBO_COMPARATOR|Placebo|1 tablet BID
61923979|NCT04534803|EXPERIMENTAL|BCG Vaccine|Participants randomized to the BCG arm will receive BCG vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
62314366|NCT06425744|ACTIVE_COMPARATOR|experimental 1 group|The experimental 1 group perform self-myofascial release and Pilates exercises.
62684982|NCT03612414|EXPERIMENTAL|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
62684983|NCT03612414|PLACEBO_COMPARATOR|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
62684984|NCT03232892|EXPERIMENTAL|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
61923980|NCT04534803|PLACEBO_COMPARATOR|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm.
61923981|NCT05236153|OTHER|RV mapping|Participants will undergo a sinus rhythm electroanatomic RV substrate map prior to TPVR.
61923982|NCT05507827|EXPERIMENTAL|Dose escalation|Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells
62684985|NCT03733782|ACTIVE_COMPARATOR|Modular enteral protein - Prosource|Subjects are patients admitted to the surgical intensive care unit and identified by one of the investigators as being appropriate for protein supplementation. Guidelines required that patients were: 1. Deemed ready to start enteral nutritional support by the attending physician within 72 hours of admission to the intensive care unit, 2. No contraindications to full enteral support, 3. No history of chronic liver disease, 4. Serum creatinine \< 2.0 mg/dl.
62684986|NCT03733782|NO_INTERVENTION|Control group|The investigators used the electronic medical record to identify control subjects. These were patients admitted to the surgical intensive care unit who were in the ICU long enough to undergo testing of 24 hour urine nitrogen excretion from January to December 2016.8 As part of standard clinical practice, measurement of urine nitrogen excretion is performed in patients who are in the ICU and receiving nutritional support for more than one week.
62684987|NCT03743142||Patients with AAA|Patients with AAA are eligible for participation and study screening. They will receive, once included, an endovascular repair of the AAA
61923983|NCT05956184|ACTIVE_COMPARATOR|Convention Method Group|Women who have an IUD inserted by conventional method will be asked to rate the most severe pain they experience during the procedure according to the Visual Analogue Scale (VAS) (from 0 to 10).
61923984|NCT05956184|ACTIVE_COMPARATOR|Direct Method Group|Women who have an IUD inserted by direct method will be asked to rate the most severe pain they experience during the procedure according to the Visual Analogue Scale (VAS) (from 0 to 10).
61923985|NCT04572802||control group|Coronary heart disease population: after coronary angiography, Gensini score was used to evaluate the severity of coronary artery occlusion, and then compared with the population of type 2 diabetes complicated with coronary heart disease
62314367|NCT06425744|ACTIVE_COMPARATOR|experimental 2 group|The experimental 2 group perform pilates exercise using reformer.
61923986|NCT04572802||experimental group (course of disease <5 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).Retrospective examination of patients' data, recording patients' laboratory tests and drug use, taking blood to measure orphanin, and evaluating the severity of coronary artery occlusion with Gensini score.
61923987|NCT04572802||experimental group(course of disease 5-10 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).
62314368|NCT04239404||PMI|
62314369|NCT04239404||non-PMI|
62478458|NCT00222118|EXPERIMENTAL|1|intervention group
62478459|NCT00222118|OTHER|2|Attention control
62478460|NCT00222118|OTHER|3|Usual care
62684988|NCT03816137|ACTIVE_COMPARATOR|Group A: ConM SOSIP and Mosaic SOSIPs|"ConM SOSIP 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only"
62478461|NCT05967390||Neurocognitive disorder (NCD)|The NCD patients are defined with a chronological age over 60 years and a Montreal Cognitive Assessment (MoCA) total score between 22 and 26.
62478462|NCT05035056||CT Coronary Angiogram with quantitative characterization of plaque|Participants (102) from Intensive Medical Therapy \[IMT\] and 102 from the Usual Care \[UC\] group in the WARRIOR trial) will undergo CTA at the Year 3 follow-up visit (can be as early as 2 years from randomization) at their respective enrollment study sites. Quantitative characterization of plaque analysis will be conducted at Cedars-Sinai Medical Center using Autoplaque plaque analysis software.
62684989|NCT03816137|ACTIVE_COMPARATOR|Group B: EDC ConM SOSIP and Mosaic SOSIPs|"EDC ConM SOSIP 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only"
62684990|NCT03816137|ACTIVE_COMPARATOR|Group C: ConS UFO and Mosaic SOSIPs|"ConS UFO 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only"
62684991|NCT03816137|ACTIVE_COMPARATOR|Group D: EDC ConS UFO and Mosaic SOSIPs|"EDC ConS UFO 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only"
62124547|NCT04689061||Biocomposite FastThread Interference Screw|The absorbable Biocomposite Interference Screws combine the inherent degradation characteristics of a biocompatible polymer with the bioactivity of a ceramic. They are made of a combination of 70% poly (L-lactide-co-D, L-lactide) (PLDLA) and 30% biphasic calcium phosphate (BCP). The material has withstood the test of time with over a decade of clinical use and millions of implantations. It has been shown that the Biocomposite Interference Screw integrates well into the surrounding bone, produces little to no inflammatory response, and partially degrades 2 years after implantation
62124548|NCT02804425|EXPERIMENTAL|"actor-spectator group"|actor at least once during the immersive simulation session
62124549|NCT02804425|NO_INTERVENTION|"spectator-only group"|observer during the whole one-day session but participation in the debriefing part of the four scenarios
62124550|NCT04212195||Part 1|Genetic determinants (n=500)
62314370|NCT00856427|EXPERIMENTAL|Diagnostic|Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
62314371|NCT02768909|EXPERIMENTAL|Pulmonary TB|"This arm will enroll 100 patients older than 15 years old, from Caracas, with pulmonary TB, culture proved.~Intervention:~1. They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~2. Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~3. Chest X-ray.~4. Sputum samples for Ziehl Neelsen smear and Culture in L-J.~5. Follow Up 5 days after beginning of Tx~6. Follow Up 15 days after beginning of Tx~7. Follow Up 30 days after beginning of Tx~8. Follow Up 60 days after beginning of Tx"
62314372|NCT02768909|ACTIVE_COMPARATOR|Non - Pulmonary TB|"This arm will enroll 75 patients older than 15 years old, from Caracas, with non TB pulmonary infections, culture negative.~Intervention:~1. They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~2. Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~3. Chest X-ray.~4. Sputum samples for Ziehl Neelsen smear and Culture in L-J."
62478463|NCT02348463||treatment of bacterial vaginosis|women with bacterial vaginosis will be offered treatment with clindamycin-2-phosphate
62684992|NCT03816137|ACTIVE_COMPARATOR|Group E: ConS UFO and ConM SOSIP and Mosaic SOSIPs|"ConS UFO 100mcg Intramuscular injections into the left or right arm Administered at 0 and 3 months~ConM SOSIP 100mcg Intramuscular injection into the left or right arm Administered at 6 months~Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only"
62124551|NCT04212195||Part 2|Biomarker discovery (n=40)
62478464|NCT01502176||Atrial fibrillation patients|All patients discharged from hospital with a diagnose of atrial fibrillation
62124552|NCT00651105|EXPERIMENTAL|1|
62124553|NCT00651105|PLACEBO_COMPARATOR|2|
62124554|NCT03359889||patients administered with PraxbindTM|
62124555|NCT01733095|EXPERIMENTAL|ambrisentan|In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months.
62124556|NCT05263115|ACTIVE_COMPARATOR|Resistance exercise|12-week progressive power-oriented resistance exercise program on leg press machine
62124557|NCT05263115|EXPERIMENTAL|Functional stair and stepping-based exercise|12-week progressive functional weight-bearing stair and stepping-based exercise program
62124558|NCT03163212|EXPERIMENTAL|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
62124559|NCT03163212|EXPERIMENTAL|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
62314373|NCT02768909|ACTIVE_COMPARATOR|Healthy Individuals|"This arm will enroll 75 patients older than 15 years old, from Caracas, without any symptom or sign of lower track infection.~Intervention:~1. They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~2. Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~3. Chest X-ray.~4. Sputum samples for Ziehl Neelsen smear and Culture in L-J."
62314374|NCT03372954|EXPERIMENTAL|Bone marrow autologous cells concentrate (BMAC)|retrograde administration on non-selected BMAC via coronary sinus
62314375|NCT03372954|PLACEBO_COMPARATOR|Control|standard treatment o heart failure
62314376|NCT06274333|ACTIVE_COMPARATOR|DP group|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg
62314377|NCT06274333|ACTIVE_COMPARATOR|TP group|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
62314378|NCT03426215||Ten year follow-up group|No interventions will be administered (Magnetic Resonance Imaging (MRI) will be administered as an outcome measurement).
62314379|NCT03671863||Infants who are treated for clubfoot|Infants who are treated for clubfoot in the reference reeducation center
62314380|NCT04611464||Single-group cross-sectional cohort|"Patients who have previously received off-label prescriptions of misoprostol for lumbar spinal stenosis for any duration and who are willing to provide verbal and informed consent.~Once enrolled, patients will complete the Swiss Lumbar Spinal Stenosis Questionnaire (SSSQ) as well as the Oswestry Disability Index (ODI). The SSSQ will elicit patients' responses specifically related to their usage of misoprostol for lumbar spinal stenosis.~Then their walking tolerance will be assessed by having them walk along a measured walkway of up to 500 feet to determine the onset of their neurogenic claudication symptoms at a certain distance, their claudication distance.~Prescription information on dosage and frequency of misoprostol use, and any reported side effects with use of this medication, and any cessation or stoppage of use of this medication will all be recorded."
62124560|NCT03163212|EXPERIMENTAL|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
62314381|NCT06504550|EXPERIMENTAL|Schroth Exercise. Group A receive Schroth Exercises.|Group A: Schroth Group (SG). The patients in the Schroth exercise group will start their exercise program under physiotherapist supervision. Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks. These exercises include spinal elongation, de-rotation, de-flexion, stretching, strengthening to maintain vertebral alignment.The participants will be asked to combine these exercises with their daily living activities (ADLs).During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support.Exercises are progressed from lying, sitting, or standing positions and from most to least passive support per a review of the quality of the performance.Decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises will depend on the patient's improvement in exercise performance
62314382|NCT06504550|EXPERIMENTAL|Klapp Exercise. Group B receive Klapp Exercises.|Group B: Klapp group (KG). The patients in the Klapp exercise group will be treated with supervised klapp exercises.Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.In each session, a sequence of 8 postures of Klapp Exercises will be carried out.Each posture will be maintained for 4-5 minutes with rest breaks when needed.Positions that will be held are: 1) Lateral crawl, 2) Horizontal sliding, 3) Crawl posture near the ground, 4) Bunny hopping, 5) Arm turn, 6) Big arch, 7) Lateral crawl near the ground, 8) Big curve
62314383|NCT05441969||Current major depressive episode group|Adult individuals (18-65 yrs) diagnosed with current major depressive episode (MDE), under treatment or medication naif, starting a new antidperessant strategy (n≈30).
62314384|NCT05441969||Maintenance antidepressant treatment group|Adult individuals (18-65 yrs) previously diagnosed with major depressive episode (MDE) currently remitted under continuation or maintenance antidepressant treatment (n≈30).
62314385|NCT05441969||Healthy subjects group|Adult individuals (18-65 yrs) without current diagnosis of major neuropsychiatric disorders, inlcluding MDE, hence not under any antidepressant medication. The same exclusion criteria will be applied as in the two clincial groups.
62314386|NCT05437029|EXPERIMENTAL|Q-Griffithsin Group 1: 3.0 mg daily spray|In Group 1, up to 12 participants will receive a dose of 3.0 mg intranasal Q-GRFT administered once daily, as 2 sprays (100 µL/ spray) in each nostril, for 7 days.
62314387|NCT05437029|EXPERIMENTAL|Q-Griffithsin Group 2: two 3.0 mg sprays per day|In Group 2, up to 12 participants will be enrolled to receive a total of 6.0 mg intranasal Q-GRFT administered as 3.0 mg twice daily (3.0 mg BID), with 2 sprays (100 µL/ spray) in each nostril approximately every 12 hours, for 7 days.
62314388|NCT06352216||Patients with Haemophilia A|Patients with severe and moderate Haemophilia A (FVIII \&lt; 5 %, ≥ 18 years' old)
62314389|NCT05930873|EXPERIMENTAL|experimental group|treatment within an immersive room
62478465|NCT06560528|EXPERIMENTAL|combination with Disitamab Vedotin and with Tislelizumab and Capecitabine|"Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~Disitamab Vedotin：2.5 mg/kg，Q3W； Tislelizumab：200 mg，Q3W； Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W."
62478466|NCT02163837|EXPERIMENTAL|rifaximine|
62684993|NCT03816137|ACTIVE_COMPARATOR|Group F: Mosaic SOSIPs and ConM SOSIP and ConS UFO|"Mosaic SOSIP Mos3.1 100mcg Intramuscular injection into the left or right arm Administered at 0 months~Mosaic SOSIP Mos3.2 100mcg Intramuscular injection into the left or right arm Administered at 2 months~Mosaic SOSIP Mos3.3 100mcg Intramuscular injection into the left or right arm Administered at 4 months~ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months"
62124561|NCT03593213|EXPERIMENTAL|Cariprazine 4.5 mg/day (Open-label Treatment Period)|Cariprazine 1.5 mg capsules orally once daily at Week 1, titrated to 3.0 mg capsules orally once daily at Week 2 and then titrated to 4.5 mg orally once daily from Week 3 through Week 18 in the Open-label Treatment Period.
62124562|NCT03593213|PLACEBO_COMPARATOR|Placebo (Double-blind Treatment Period)|Cariprazine placebo-matching capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
62124563|NCT03593213|EXPERIMENTAL|Cariprazine 3.0 mg/day (Double-blind Treatment Period)|Cariprazine 3.0 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
62478467|NCT01168856||Cohort|
62124564|NCT03593213|EXPERIMENTAL|Cariprazine 4.5 mg/day (Double-blind Treatment Period)|Cariprazine 4.5 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
62124565|NCT02178111|EXPERIMENTAL|Never perform episiotomy|In this group the birth attendant will sought to avoid the use of episiotomy, and try not to carry out the procedure unless considered absolutely needed
62124566|NCT02178111|ACTIVE_COMPARATOR|Selective episiotomy|Patients will be subjected to the usual routine (selective episiotomy, ie, in the presence of indications described in the literature, according to the discretion of the physician or nurse assisting the birth)
62684994|NCT03816137|ACTIVE_COMPARATOR|Group G: Mosaic SOSIPs and ConM SOSIP and ConS UFO|"Mosaic SOSIP Mos3.2 100mcg Intramuscular injection into the left or right arm Administered at 0 months~Mosaic SOSIP Mos3.1 100mcg Intramuscular injection into the left or right arm Administered at 2 months~Mosaic SOSIP Mos3.3 100mcg Intramuscular injection into the left or right arm Administered at 4 months~ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months"
62124567|NCT06436144|EXPERIMENTAL|Osimertinib Combined With Etoposide Soft Capsule|
62314390|NCT05930873|PLACEBO_COMPARATOR|control group|Traditional Treatment by presenting image stimuli in a paper format
62314391|NCT06673173|EXPERIMENTAL|group 1 quadrilateral bar design|Quadrilateral Group: each participant received bar mandibular overdentures on 4 implants with quadrilateral distribution. A plastic ready-made bar was cast in cobalt chrome alloy.
62684995|NCT03816137|ACTIVE_COMPARATOR|Group H: Mosaic SOSIPs and ConM SOSIP and ConS UFO|"Mosaic SOSIP Mos3.3 100mcg Intramuscular injection into the left or right arm Administered at 0 months~Mosaic SOSIP Mos3.2 100mcg Intramuscular injection into the left or right arm Administered at 2 months~Mosaic SOSIP Mos3.1 100mcg Intramuscular injection into the left or right arm Administered at 4 months~ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months"
62124568|NCT06554041|EXPERIMENTAL|Dental Crown with Titanium-Abutment|Participants in this arm will receive dental implants and single crowns made from titanium. The impact of titanium on peri-implant soft tissue health will be evaluated by measuring inflammatory markers and clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
62684996|NCT03816137|ACTIVE_COMPARATOR|Group I: Mosaic SOSIPs and ConM SOSIP and ConS UFO|"Mosaic SOSIPs (Mos3.1 + Mos3.2 + Mos3.3) 100mcg (3x33mcg) Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months~ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months"
62684997|NCT03816137|ACTIVE_COMPARATOR|Group J: 763 SOSIP|763 SOSIP 100mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months
62684998|NCT03816137|ACTIVE_COMPARATOR|Group K: AMC011 SOSIP|AMC011 100mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months
62684999|NCT03816137|ACTIVE_COMPARATOR|Group L: 763 SOSIP and AMC011 SOSIP|763 SOSIP and AMC011 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months
62685000|NCT03816137|ACTIVE_COMPARATOR|Group M: 763 SOSIP and AMC011 SOSIP and ConM SOSIP and Mosaic SOSIPs|763 SOSIP and AMC011 SOSIP and ConM SOSIP and Mos3.1 and Mos3.2 SOSIPs each at 20mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months
62685001|NCT06344923|EXPERIMENTAL|modified preventive ileostomy|Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing
62685002|NCT06344923|ACTIVE_COMPARATOR|conventional preventive ileostomy|Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing
62685003|NCT02365064|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
62685004|NCT02365064|EXPERIMENTAL|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
62685005|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
62685006|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
62685007|NCT05984992|EXPERIMENTAL|SRN-001|
62685008|NCT05984992|PLACEBO_COMPARATOR|Placebo|
62124569|NCT06554041|EXPERIMENTAL|Dental Crown with PEEK (Polyetheretherketone)-Abutment|Participants in this arm will receive dental implants and single crowns made from PEEK. The study will assess the biocompatibility of PEEK by examining inflammatory responses and clinical outcomes, including bleeding on probing and pocket depth, at 3 and 6 months post-implantation.
62124570|NCT06554041|EXPERIMENTAL|Dental Crown with Zirconia-Abutment|Participants in this arm will receive dental implants and single crowns made from zirconia. The effects of zirconia on peri-implant soft tissue will be analyzed by measuring the levels of inflammatory markers and observing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
62124571|NCT06554041|EXPERIMENTAL|Dental Crown with Lithium-Disilicate-Abutment (e.max)|Participants in this arm will receive dental implants and single crowns made from lithium disilicate (e.max). The study will evaluate the biocompatibility of e.max by measuring inflammatory markers and clinical outcomes, including bleeding on probing and pocket depth, at 3 and 6 months post-implantation.
62124572|NCT06294275|EXPERIMENTAL|Cohort 1: LP-001 Dose 1 (Single)|Single dose administration of LP-001 with dose 1
62124573|NCT06294275|EXPERIMENTAL|Cohort 2: LP-001 Dose 2 (Single)|Single dose administration of LP-001 with dose 2
62124574|NCT06294275|EXPERIMENTAL|Cohort 3: LP-001 Dose 3 (Single)|Single dose administration of LP-001 with dose 3
62124575|NCT06294275|EXPERIMENTAL|Cohort 4: LP-001 Dose 4 (Single)|Single dose administration of LP-001 with dose 4
62124576|NCT06294275|EXPERIMENTAL|Cohort 5: LP-001 Dose 5 (Single)|Single dose administration of LP-001 with dose 5
62124577|NCT06294275|EXPERIMENTAL|Cohort 6: LP-001 Dose 6 (Single)|Single dose administration of LP-001 with dose 6
62314392|NCT06673173|EXPERIMENTAL|group2 : Bilateral linear bar|Bilateral linear Group: each participant received bar mandibular overdentures on 4 implant on bilateral configuration
62314393|NCT00576498|EXPERIMENTAL|1- Narrow Band Imaging|"NBI-AFI imaging - Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.~Autofluorescence Imaging (AFI)- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm)"
62685009|NCT02262663|EXPERIMENTAL|Vilaprisan [0.5mg]|0.5 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
62685010|NCT02262663|EXPERIMENTAL|Vilaprisan [1mg]|1 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
62685011|NCT02262663|EXPERIMENTAL|Vilaprisan [2mg]|2 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
62124578|NCT06294275|PLACEBO_COMPARATOR|Cohort 7: Placebo (Single)|Single dose administration of placebo drug
62685012|NCT02262663|EXPERIMENTAL|Vilaprisan [4mg]|4 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
62685013|NCT05815784|NO_INTERVENTION|Observation|No treatment.
62685014|NCT05815784|OTHER|Atropine|0.05% atropine. One drop per eye per day for 2 years.
62685015|NCT05815784|OTHER|MiSight contact lenses|MiSight contact lenses. Daily wear for 2 years.
62685016|NCT01793571|EXPERIMENTAL|TAP block|20 ml Levobupivacaine 0,5%
62685017|NCT01793571|ACTIVE_COMPARATOR|Local wound infiltration|20 ml levobupivacaine 0,5%
62314394|NCT00576498|OTHER|2-Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars
62478468|NCT06191094|EXPERIMENTAL|Faricimab injection|Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The 6-mg dose of faricimab will be administered by IVT at the study site to patients. A specified filter needle must be used for each dose preparation of faricimab according to the instructions provided in the Investigator's Brochure and package insert. No other material than specified should be used. Vials of faricimab drug product are for a single-dose only (one injection preparation per patient per eye). Vials used for one patient must not be used for any other patient. Partially used vials, remaining faricimab drug product, as well as administration material must not be reused.
62685018|NCT01103518|EXPERIMENTAL|Combination 1|Ethinyl Estradiol + Cyproterone acetate
61923988|NCT04572802||experimental group(course of disease10-20 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 10 -20years).Finally, the data were obtained to evaluate the relationship between the course of diabetes and the severity of coronary heart disease, as well as the relationship between the course of diabetes and OFQ in patients' blood.
62314395|NCT01597193|EXPERIMENTAL|enzalutamide (80-mg with increase to 160 mg)|enzalutamide be provided as two or four 40-mg capsules by mouth daily
62314396|NCT01597193|EXPERIMENTAL|enzalutamide and anastrozole|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
62314397|NCT01597193|EXPERIMENTAL|enzalutamide and exemestane 25 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
62124579|NCT06294275|EXPERIMENTAL|Cohort 8: LP-001 Dose 7 (Multiple)|LP-001 with dose 7 was administered 4 times in total
62478469|NCT06191094|SHAM_COMPARATOR|Sham injection|Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The sham procedure mimics an intravitreal injection of faricimab except that the blunt end of an empty syringe is pressed against an anesthetized eye instead of a needle attached to a faricimab-filled syringe.
62685019|NCT01103518|ACTIVE_COMPARATOR|Combination 2|Ethinyl Estradiol + Cyproterone acetate
62685020|NCT03958097|EXPERIMENTAL|NK cell combined with PD-L1 antibody|"Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16), total NK cells infused at least 3×10\^9 .~200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.~NK cells and PD-L1 antibody will be infused every 21 days until disease progression or unacceptable adverse events."
62124580|NCT06294275|EXPERIMENTAL|Cohort 9: LP-001 Dose 8 (Multiple)|LP-001 with dose 8 was administered 4 times in total
62685021|NCT04632342|EXPERIMENTAL|Experimental group 1|HL301 1,200mg/day
62685022|NCT04632342|EXPERIMENTAL|Experimental group 2|HL301 1,800mg/day
62685023|NCT04632342|PLACEBO_COMPARATOR|Control group|Placebo
61923989|NCT00925171|EXPERIMENTAL|Pulmonary Rehabilitation Group|Intervention with exercise management
62124581|NCT06294275|PLACEBO_COMPARATOR|Cohort 10: Placebo (Multiple)|Placebo drug was administered 4 times in total
62124582|NCT01275105|OTHER|Vehicle|
62124583|NCT01275105|ACTIVE_COMPARATOR|Brimonidine Tartrate 0.01%|
62124584|NCT01275105|ACTIVE_COMPARATOR|Oxymetazoline HCl 0.025%|
62124585|NCT01275105|ACTIVE_COMPARATOR|Brimonidine Tartrate 0.025%|
62124586|NCT02658370|EXPERIMENTAL|animated home-based exercises (Wii-fit)|using the Wii game console by Nintendo
62124587|NCT02658370|ACTIVE_COMPARATOR|conventional home-based exercise program|by using a compilation with 31 exercises especially for rheumatoid arthritis patients
62314398|NCT01597193|EXPERIMENTAL|enzalutamide and exemestane 50 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
62314399|NCT01597193|EXPERIMENTAL|enzalutamide and fulvestrant|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
62314400|NCT05829720|ACTIVE_COMPARATOR|a2 Full Cream Milk|a2 Full Cream Milk, 200ml/bag, per 100ml serving Nutrient Composition Energy: 250 kcal Protein:3.2g Fat:3.3g Carbohydrate:4.3g Sodium:40mg Calcium:104mg
62314401|NCT05829720|ACTIVE_COMPARATOR|Conventional Milk (Weidendorf)|Conventional Milk (Weidendorf), 200ml/bag,per 100ml serving Nutrient Composition Energy: 267 kcal Protein:3.3g Fat:3.5g Carbohydrate:4.8g Sodium:50mg Calcium:120mg
62314402|NCT01477632|EXPERIMENTAL|A|
62314403|NCT01477632|EXPERIMENTAL|B|
62314404|NCT01477632|ACTIVE_COMPARATOR|C|
62314405|NCT06544863||Cirrhosis or suspected cirrhosis and/or TH patient|Patients with a diagnosis or suspected diagnosis of cirrhosis and/or TH managed at Pitié Salpêtrière University Hospital
62478470|NCT05909085|ACTIVE_COMPARATOR|Handheld traditional ultrasound|Traditional US will be used to compare number of needle manipulations to the handheld US.
62478471|NCT05909085|OTHER|Handheld Automated ultrasound|Automated device provides automatic information pertaining to distance to epidural space distance and interspace location.
62478472|NCT05011695|ACTIVE_COMPARATOR|1. Group ESWT treatment|"6000 SWT Easy device will be used for ESWT treatment. The plantar fascia of the patients will be applied once a week for 3 weeks. In each application, 2400 beats, 2.0 bar pressure and 12 frequency doses of ESWT will be applied"
62124588|NCT04479969|OTHER|Intervention|This is a small study to assess the usability of video conferencing. A total of 10 patients will be enrolled, 5 of which will be Spanish speakers. All patients will test the video conferencing.
62478473|NCT05011695|ACTIVE_COMPARATOR|2. Group transverse friction massage|Transverse friction massage will be applied to the plantar fascia of the patients for 3 weeks, 3 days a week, on Mondays, Wednesdays, and Fridays, with a break for 1 day and 15 minutes each. Transverse friction massage, when the patient is in the supine semi-lying position, the big toe will be dorsiflexed and in this position, it will be applied in the direction that will be transverse to the plantar fascia.
62685024|NCT04467489||CA (non-CASH)|Cavernous Angioma (CA) without symptomatic hemorrhage cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
62685025|NCT04467489||CA (CASH)|Cavernous Angioma (CA) with Symptomatic Hemorrhage (SH) cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
62685026|NCT04467489||Young with seizure|Young (\<30 years old) healthy control cohorts with seizures in the prior year
61923990|NCT00925171|NO_INTERVENTION|Control Group|"Patients will receive the standard advice to undertake strength and endurance exercises at home and invitation to attend the Norwich Breath Easy Group~Patients will be stratified according to whether the initial programme took place in the outpatient hospital or community setting"
61923991|NCT02125474|EXPERIMENTAL|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
62124589|NCT06131385||Acute ischemic stroke treated with intravenous thrombolysis|All of acute ischemic stroke patients who treated with intravenous thrombolysis.
62124590|NCT01495663|OTHER|Single Group|I-131-CLR1404
62124591|NCT01866969|EXPERIMENTAL|Supportive care (quality of life questionnaire)|Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
62685027|NCT04467489||Young without seizure|Young (\<30 years old) healthy control cohorts without seizures in the prior year
62124592|NCT01850511|EXPERIMENTAL|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
62124593|NCT01998711|EXPERIMENTAL|Memory group|Memory training
62124594|NCT01998711|NO_INTERVENTION|Control|Standard care
62124595|NCT04367272|ACTIVE_COMPARATOR|First Knee|The first knee is the knee where the surgery will begin to be applied.
62124596|NCT04367272|EXPERIMENTAL|Second Knee|The second knee is the knee where the surgeon will apply secondly.
62124597|NCT01296191|ACTIVE_COMPARATOR|VIGAMOX|Subjects undergoing cataract surgery, randomized to the VIGAMOX group Generic name is moxifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
62124598|NCT01296191|ACTIVE_COMPARATOR|Besivance|Subjects scheduled for cataract surgery, randomized to the Besivance group Generic name is besifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
62685028|NCT04467489||Older with HMA|Older (\>50 years old) with hemorrhagic microangiopathy (HMA)
62685029|NCT04467489||Older without HMA|Older (\>50 years old) without hemorrhagic microangiopathy (HMA)
62685030|NCT00776412||HIV negative|Healthy Volunteer cohort
62685031|NCT00776412||HIV positive INR|HIV positive INR cohort
62685032|NCT00776412||HIV positive Standard|HIV positive Standard cohort
62685033|NCT05704634|EXPERIMENTAL|Cohort A : EGFR-mutant cohort|Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.
62478474|NCT05011695|ACTIVE_COMPARATOR|3. Group exercise group|Stretching the plantar fascia and gastrocsoleus muscles of the patients, towel picking exercises with the foot intrinsic muscles, heel drop exercises will be given. All stretching and exercises will be applied once a day, 5 days a week, for 3 weeks. Plantar fascia stretching exercises will be performed with a physiotherapist; While the patient is lying in the supine position, 30 seconds of stretching will be performed using the windlass (windlass) mechanism (toes are brought to dorsi flexion). This stretch will be repeated 3 times. Gastrocsoleus stretching exercises will be studied with a physiotherapist. In the supine position, the gastrocsoleus muscles will be stretched for 10 seconds and stretching will be performed with 10 repetitions. Towel collection exercises for the foot intrinsic muscles will be practiced in 3 sets, 15 repetitions per day. Heel drop exercise will be applied in 3 sets of 15 repetitions per day.
62314406|NCT06529185|EXPERIMENTAL|treatment group|This group include 20 patients with COPD and intermittent claudication. These patients can receive aerobic exercise (by applying treadmill exercise for 20 min) and inspiratory muscle training (by using The BREATHER device with Light/Medium resistance for 3-5 sets /session), for 4 weeks (3 sessions per week) and pursed lip breathing.
62314407|NCT06529185|ACTIVE_COMPARATOR|control group|This group include 20 patients with COPD and intermittent claudication. These patients can receive pursed lip breathing and aerobic exercise (by applying treadmill exercise for 20 min) with the usually pharmacological treatment, for 4 weeks (3 sessions per week).
62478475|NCT05025085|EXPERIMENTAL|Monotherapy with AGEN1777|3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days \[3 weeks\]).
62478476|NCT05025085|EXPERIMENTAL|AGEN1777 in combination with a PD-1 inhibitor|3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days.
62314408|NCT00593112|EXPERIMENTAL|OROS Methylphenidate|
62314409|NCT00593112|OTHER|Control|Healthy Volunteer Control group
62314410|NCT03704051||Breastfeeding First, then Bottle-feeding|Mother-infant dyads were observed while breastfeeding during their first visit to our laboratory and were observed while bottle-feeding expressed breast milk during their second visit to our laboratory.
62314411|NCT03704051||Bottle-feeding First, then Breastfeeding|Mother-infant dyads were observed while bottle-feeding expressed breast milk during their first visit to our laboratory and were observed while breastfeeding during their second visit to our laboratory.
62314412|NCT06556810|EXPERIMENTAL|IC14 (atibuclimab)|20 mg/kg intravenously once at baseline
62314413|NCT05215327|EXPERIMENTAL|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of HD-QIV (0.7 mL; 60µg of each influenza antigen) 28-42 days apart
62314414|NCT05215327|EXPERIMENTAL|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|receive two doses of SD-QIV (0.5 mL; 15µg of each influenza antigen) 28-42 days apart
62314415|NCT05174637|EXPERIMENTAL|FDA018-ADC A mg/kg|Subjects will receive FDA018-ADC A mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62478477|NCT04632550|ACTIVE_COMPARATOR|Circumferential pulmonary vein isolation(CPVI) group|
62478478|NCT04632550|EXPERIMENTAL|Posterior box isolation(POBI) group|
62478479|NCT04632550|EXPERIMENTAL|POBI+Anterior linear ablation(AL) group|
62478480|NCT02427763|ACTIVE_COMPARATOR|Retainer use|"The volunteer use a thermoplastic appliance (Essix) for 8hours~Interventions:~* hours of use~* collect biofilm~* collect saliva~* collect epithelium"
62478481|NCT02427763|ACTIVE_COMPARATOR|Aligner use|"The volunteer use thermoplastic appliance (Essix) for 22 hours~Interventions:~* hours of use~* collect biofilm~* collect saliva~* collect epithelium"
62478482|NCT01895335|EXPERIMENTAL|Teriflunomide|Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.
62478483|NCT04207437|EXPERIMENTAL|Vibration Therapy|Patients will hold a hand held vibrating device for 3 minutes on each hand daily for 4 weeks.
62314416|NCT05174637|EXPERIMENTAL|FDA018-ADC B mg/kg|Subjects will receive FDA018-ADC B mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62314417|NCT05174637|EXPERIMENTAL|FDA018-ADC C mg/kg|Subjects will receive FDA018-ADC C mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62314418|NCT05174637|EXPERIMENTAL|FDA018-ADC D mg/kg|Subjects will receive FDA018-ADC D mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62314419|NCT05174637|EXPERIMENTAL|FDA018-ADC E mg/kg|Subjects will receive FDA018-ADC E mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62314420|NCT05174637|EXPERIMENTAL|FDA018-ADC F mg/kg|Subjects will receive FDA018-ADC F mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62314421|NCT05174637|EXPERIMENTAL|FDA018-ADC G mg/kg|Subjects will receive FDA018-ADC G mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
62314422|NCT04995744|OTHER|Patients with closed Neer type 4 proximal humerus fractures|patients aged 50-75 years with closed Neer type 4 proximal humerus fractures
62314423|NCT02349230|EXPERIMENTAL|Astym treatment|Astym treatment is a manual therapy intervention applied by certified therapists with specialized instruments
62314424|NCT02349230|SHAM_COMPARATOR|Sham Astym|A sham Astym treatment applied with non-therapeutic pressure and
62314425|NCT02349230|NO_INTERVENTION|Control|12 minutes of rest
62314426|NCT02442999|NO_INTERVENTION|Usual care|
62314427|NCT02442999|EXPERIMENTAL|Screen for Sleep Apnea|Screen for sleep apnea, treat with continuous positive airway pressure (CPAP) if diagnosed with sleep apnea
62314428|NCT02487745|ACTIVE_COMPARATOR|IPS Only|IPS Only participants will receive the Individual Placement and Support (IPS) supported employment.
62314429|NCT02487745|EXPERIMENTAL|IPS Plus Wage Supplement|IPS Plus Abstinence-Contingent Wage Supplement participants will receive the Individual Placement and Support (IPS) supported employment intervention and abstinence-contingent wage supplements.
62314430|NCT06027086|EXPERIMENTAL|Durvalumab and DRP-104|
62314431|NCT02295891|EXPERIMENTAL|MiraDry ® treatment|"MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart."
62314432|NCT04979572|EXPERIMENTAL|Part A (single dose) : Step 1 to 4: TS-172 10 mg, 30 mg, 90 mg, 270 mg|Single dose of TS-172 or placebo before breakfast
62478484|NCT01613872|NO_INTERVENTION|Control|Wait List Control
62478485|NCT01613872|EXPERIMENTAL|Mindfulness Based Stress Reduction|An 8 week standardized protocol of stress reduction using gentle yoga and meditation
62685034|NCT05704634|EXPERIMENTAL|Cohort B: LKB1-mutant cohort|Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.
62314433|NCT04979572|EXPERIMENTAL|Part B (multiple dose) : Step 5: TS-172 90 mg|Multiple dose of TS-172 or placebo before breakfast and dinner
62478486|NCT00526188|EXPERIMENTAL|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
62314434|NCT02221076|EXPERIMENTAL|Confocal Laser Endomicroscopy (CLE)|The patient will undergo a 10 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs.
62314435|NCT03178461|NO_INTERVENTION|Room temperature parenteral fluids|"This group will receive IV room temperature fluids, which is the standard of care.~The composition of the fluids given will be normal saline with 5% dextrose."
62314436|NCT03178461|EXPERIMENTAL|Body temperature parenteral fluids|"This group will receive IV warmed fluids, body temperature, which is the experimental intervention.~The composition of the fluids given will be normal saline with 5% dextrose."
62314437|NCT05755867||PNH Patients|Individuals of any age with a confirmed diagnosis of PNH or diagnosis consistent with PNH are eligible for inclusion.
62314438|NCT03278730|ACTIVE_COMPARATOR|Para-Tyrosine intervention|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Tyrosine. Strength 500 mg. Oral dose form: hard capsule. Number of Dispensed at frequency of 3x2 g daily. Duration of administration: 4 to 7 days."
62314439|NCT03278730|PLACEBO_COMPARATOR|Placebo|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Placebo.. Strength N/A. Oral dose form: capsule matching to Tyrosine capsule. Number of Dispnsed an frequency 3x2 g daily. Duration of administration: 4 to 7 days."
62478487|NCT04537663|EXPERIMENTAL|Bacille Calmette-Guérin (BCG)|Intradermal injection of BCG-Vaccine SSI \[Statens Serum Institut\]) - Danish strain 1331.
62478488|NCT04537663|PLACEBO_COMPARATOR|Placebo|Intradermal injection of sterile 0.9% NaCl.
62478489|NCT05900713|EXPERIMENTAL|D. N.S|dynamic neuromuscular stabilization training methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
62478490|NCT05900713|EXPERIMENTAL|balance exercises plus diaphragmatic breathing|balance exercises plus diaphragmatic breathing The balance exercises is balance training while standing and walking and The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
62685035|NCT06674460|EXPERIMENTAL|sublingual edaravone dexborneol|One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.
62685036|NCT06674460|PLACEBO_COMPARATOR|Placebo|One placebo tablet, to be taken sublingually, twice daily.
62685037|NCT06296706|EXPERIMENTAL|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.
61923992|NCT01903525|PLACEBO_COMPARATOR|Placebo|The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
61923993|NCT01903525|EXPERIMENTAL|Docosahexaenoic Acid (DHA)|The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.
61923994|NCT01949454|EXPERIMENTAL|Fluorometholone 0.1% 1 gtt bid x4weeks|Fluorometholone 0.1% 1 drop two times daily for four weeks
61923995|NCT01949454|PLACEBO_COMPARATOR|Artificial Tears 1 gtt bid x4 weeks|
61923996|NCT01949454|EXPERIMENTAL|Fluorometholone 0.1% 1 gtt qid x 4 weeks|Fluorometholone 0.1% 1 drop four times daily for four weeks
61923997|NCT01949454|PLACEBO_COMPARATOR|Artificial Tears 1 gtt qid x4 weeks|
62314440|NCT00243776||Cardiac Tissue|Cardiac tissue and cells will be obtained from participants undergoing cardiac surgical repair
62314441|NCT00450866|EXPERIMENTAL|Epothilone B|
62685038|NCT06296706|ACTIVE_COMPARATOR|Taxotere (Docetaxel)|Taxotere will be administrated by intravenous infusion once every 3 weeks.
62685039|NCT04989218|EXPERIMENTAL|Novel combination of chemotherapy and immunotherapy|"This study has one arm. All enrolled patients will receive a combination of a platinum based chemotherapy regimen (gemcitabine and cisplatin) and a combination of two immune check point inhibitors, anti- CTLA4 (Tremelimumab) and anti PDL-1 (durvalumab).~Gemcitabine will be administered (gemzar) intravenously, 1000mg/m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles. Cisplatin (Platinol) will be administered intravenously, 25mg//m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles.~Tremelimumab will be administered intravenously, 300mg flat dose, on Day 1 of cycle 1 only. Durvalumab will be administered intravenously 1500mg on Day 1 of a 21 day cycle for 4 cycles."
61923998|NCT01949454|EXPERIMENTAL|Fluorometholone 0.1% 1 gtt qid x 8 weeks|Fluorometholone 0.1% 1 drop four times daily for eight weeks
61923999|NCT01949454|PLACEBO_COMPARATOR|Artificial Tears 1 gtt qid x8 weeks|
62685040|NCT06691737|EXPERIMENTAL|Generalized Joint Hypermobility|
62685041|NCT06691737|EXPERIMENTAL|Not Generalized Joint Hypermobility|
61924000|NCT05041530|EXPERIMENTAL|REBUILD|Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and undergo oncologic laparotomy per the standard of care. The abdominal wall will be closed with REBUILD Bioabsorbable and suture of the surgeon's choice.
62685042|NCT06694519|EXPERIMENTAL|Temperature after apply RF in capacitive electrical transfer mode (Capernergy® device model C500)|It is a device designed mainly to address dysfunctions in the urogynecological area, where the increase in tissue temperature is regulated by a temperature sensor, with 3 frequencies (0.8MHz, 1MHz and 1.2 MHz) that will allow different tissue depths to be addressed, and a power of 310w. This device consists of two electrodes: an active capacitive electrode to be placed in the vaginal area with a probe cover and water-soluble gel and another dispersive electrode or return plate to be positioned in the lumbosacral region.
61924001|NCT06636266||Chiropractors|Practising in Scotland at the time of the survey/study
61924002|NCT06636266||Chiropractic students|Enrolled in the Scotland College of Chiropractic at the time of the study
61924003|NCT01515540|ACTIVE_COMPARATOR|lidocaine|5% lidoderm patch
61924004|NCT01515540|PLACEBO_COMPARATOR|control|placebo patch
62314442|NCT00909090|ACTIVE_COMPARATOR|Intervention|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
62314443|NCT00909090|PLACEBO_COMPARATOR|Placebo|visually identical placebo
62314444|NCT00916721|ACTIVE_COMPARATOR|Propranolol|propranolol
62314445|NCT00916721|PLACEBO_COMPARATOR|Placebo|sugar pill
62314446|NCT05574504|EXPERIMENTAL|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|Phase II trial is designed to evaluate the combination of avelumab (800 mg IV every 2 weeks-(days 1,15, and 29 every 6 week cycle ) and lurbinectedin (3·2 mg/m2 lurbinectedin administered as a 1-h intravenous infusion once every 3 weeks-day 1 and 22 every 6 week cycle ) for those with stable or responding disease following 4-6 cycles of platinum-based firstline chemotherapy for mUC with stable or responding disease following 4-6 cycles of platinum-based firstline chemotherapy for mUC.
62478491|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 1)|Neratinib 120 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62314447|NCT05568043|EXPERIMENTAL|In-person intervention delivery with virtual mentoring|The implemented interventions will be in-person and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
62478492|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 2)|Neratinib 120 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62685043|NCT06694519|EXPERIMENTAL|PFMT|"The PFMT will consist of a targeted programme, with a protocol of CORE and pelvic floor exercises established based on the assessment of the patients' strength, endurance and fatigue, with a frequency of twice a week led by a physiotherapist and a duration of 45 minutes each day and a period of 16 weeks.It will be carried out in groups of 8 people and accompanied by a physiotherapist experienced in therapeutic exercise.~Each session will consist of exercises to activate the pelvic floor muscles in isolation and in association with the CORE muscles, both static and dynamic."
62685044|NCT02544763|EXPERIMENTAL|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
62685045|NCT02544763|EXPERIMENTAL|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
62685046|NCT02544763|PLACEBO_COMPARATOR|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
62685047|NCT02928822|EXPERIMENTAL|Experimental Group|Virtual reality based sensorimotor aphasia therapy.
62685048|NCT02928822|ACTIVE_COMPARATOR|Control Group|Conventional aphasia therapy.
62685049|NCT06677554|EXPERIMENTAL|ultrasound with contrast injection|Patients consulting the gynecological emergencies as part of the management of a strong suspicion of adnexal torsion (after the clinical examination and standard ultrasound)
62685050|NCT06677554|ACTIVE_COMPARATOR|Control|Patients consulting the gynecological emergencies as part of the management of a strong suspicion of adnexal torsion (after the clinical examination and standard ultrasound)
62685051|NCT03755154|EXPERIMENTAL|S65487 - initial scheme|
62685052|NCT03755154|EXPERIMENTAL|S65487 - alternative scheme|
62685053|NCT06542380||Patients undergoing TAVI at DHZC 2019-2021|
62685054|NCT03191331|EXPERIMENTAL|Intervention group|Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
62685055|NCT03191331|NO_INTERVENTION|Control group|The control group will receive written material on healthy diet during pregnancy, otherwise basic care and guidance at maternity care clinics.
62685056|NCT06691178|EXPERIMENTAL|CO2 Vaginal Laser treatment|Laser treatment with a Fractional/Pixel CO2 laser (Femilift, Alma Lasers) will be performed with the following settings and procedure: single pulse; first pass 50-100 millijoules/pixel of energy, and 50-100 millijoules/pixel for the second pass. The energy level will be adjusted within the range based on the subject's comfort level. The same procedures will be followed for the sham group but no pulse will be generated.
62685057|NCT06691178|SHAM_COMPARATOR|Sham - no vaginal laser treatment|The vaginal laser probe will be placed as usual but no energy will be delivered to the tissue.
62685058|NCT05428007|EXPERIMENTAL|Study Group|Participants receive sarilumab at 150 mg flat dose is administered subcutaneously every 2 weeks for 12 doses from day 1, cycle 1 in combination with a regimen of ipilimumab at 1 mg/kg every 8 weeks and fixed dose nivolumab at 480 mg and relatlimab at 160 mg flat dose every 4 weeks two times during the 8-week induction period, then the same regimen again up to week 16, and up to week 24 in maintenance. After week 24 the regimen will be ipilimumab at 1 mg/kg every 8 weeks and fixed dose nivolumab at 480 mg with relatlimab at 160 mg flat dose every 4 weeks for 8 week cycles for up to a total of 2 years in patients with unresectable Stage III/Stage IV melanoma.
62685059|NCT01266200|ACTIVE_COMPARATOR|Minimal-invasive treatment (Mantis)|Patients, who received a minimal-invasive surgery and the fracture was fixed by a system called Mantis
62314448|NCT05568043|EXPERIMENTAL|In-person intervention delivery with virtual mentoring and co-design|The implemented interventions will be in-person and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
62478493|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 3)|Neratinib 120 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
61924005|NCT03224546|NO_INTERVENTION|Control Group|This group will receive payment for providing urine samples throughout the trial.
61924006|NCT03224546|EXPERIMENTAL|Low Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
62124599|NCT04855903|EXPERIMENTAL|Arm 1 (early phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 3 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 5 weeks"
62124600|NCT04855903|EXPERIMENTAL|Arm 2 (mid phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 4 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 4 weeks"
62124601|NCT04855903|EXPERIMENTAL|Arm 3 (late phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 5 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 3 weeks"
62124602|NCT05126121|EXPERIMENTAL|14d concomitant therapy|Patients will receive a 14-day concomitant therapy consisting of vonoprazan and three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, clarithromycin,levofloxacin,tinidazole,metronidazole.
62124603|NCT04194749|EXPERIMENTAL|Digital Media Therapy|The digital media based group will receive a modified post immobilization protocol. This will include giving the patients a Universal Serial Bus (USB) drive loaded with a 12 week physical therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.
62124604|NCT04194749|ACTIVE_COMPARATOR|Traditional Therapy|The traditional group will have clinic-based physical therapy protocol.
62124605|NCT06332404||Obstructive sleep apnea (OSA) patients treated with hypoglossal nerve stimulation (HNS) therapy|OSA patients treated with HNS therapy will be asked to participate in the registry.
61924007|NCT03224546|EXPERIMENTAL|High Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
61924008|NCT06622889|EXPERIMENTAL|8-week intervention targeting self-perception of aging|Participants in this condition will receive an 8-week intervention targeting self-perception of aging. Group sessions will be held at community health service centers, with one session per week, each lasting 45 to 60 minutes. Additionally, homework assignments will be supplemented, and researchers will provide additional remote support via WeChat.
61924009|NCT06622889|NO_INTERVENTION|Controls|
61924010|NCT03577171|EXPERIMENTAL|ABI-H0731 + SOC ETV|Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
61924011|NCT03577171|EXPERIMENTAL|Placebo + SOC ETV|Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
61924012|NCT05453266|ACTIVE_COMPARATOR|TXA Group|Patients with rotator cuff tear, operated arthroscopically under intraarticularly applied tranexamic acid in arthroscopic irrigation solution.
62314449|NCT05568043|EXPERIMENTAL|Virtual intervention delivery with virtual mentoring|The implemented interventions will be virtual and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
62685060|NCT01266200|ACTIVE_COMPARATOR|Conventional technique (XIA)|Patients who received a surgical treatment including one long cut (conventional operation technique) and the fracture was fixed by a conventional system called XIA
62314450|NCT05568043|EXPERIMENTAL|Virtual intervention delivery with virtual mentoring with co-design|The implemented interventions will be virtual and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
62314451|NCT02641899|EXPERIMENTAL|Experimental Treatment|ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg
62685061|NCT06688448|EXPERIMENTAL|Aortic Valve Replacement - Dafodil Prosthesis|Patients indicated for surgical aortic valve replacement will be randomized to receive the Dafodil prosthesis.
62685062|NCT06688448|ACTIVE_COMPARATOR|Aortic Valve Replacement - Inspires Resilia prosthesis|Patients indicated for surgical aortic valve replacement will be randomized to receive Inspires Resilia prosthesis.
62685063|NCT06443593|ACTIVE_COMPARATOR|Arm 1: Only vitamin B12 supplements|Only vitamin B12 supplements 2.2 mcg OD for 24 weeks
62685064|NCT06443593|ACTIVE_COMPARATOR|Arm 2: Vitamin B12 and oral iron supplements|Vitamin B12 2.2 mcg OD daily and oral iron 25 mg OD daily for 24 weeks
62685065|NCT06443593|ACTIVE_COMPARATOR|Arm 3: Vitamin B12 and vitamin D3|Vitamin B12 2.2 mcg OD daily and vit D3 60,000 IU once in three months for 24 weeks
62685066|NCT05196503|ACTIVE_COMPARATOR|Experimental group|Surgery for disc herniation and intraoperative periradicular administration of PRF
62124606|NCT06522724|EXPERIMENTAL|Education program and Pulmonary rehabilitation|Conventional pulmonary rehabilitation coupled with original education program.
62124607|NCT06522724|OTHER|Pulmonary rehabilitation|Conventional pulmonary rehabilitation
62124608|NCT00766298|EXPERIMENTAL|1|Weight Loss
62124609|NCT00766298|EXPERIMENTAL|2|Exercise
61924013|NCT05453266|PLACEBO_COMPARATOR|Control group|Patients with rotator cuff tear, operated arthroscopically without intraarticularly applied tranexamic acid in arthroscopic irrigation solution.
62124610|NCT00766298|EXPERIMENTAL|3|Exercise and Weight Loss
62124611|NCT06514222|EXPERIMENTAL|study|patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
62124612|NCT06514222|ACTIVE_COMPARATOR|Control|The patient will receive 400mg of ibuprofen plus 1000mg of Paracetamol simultaneously every 8 hours for two days.
62124613|NCT01493310|EXPERIMENTAL|Arm A (hormone therapy, chemotherapy)|Patients will receive mifepristone and nab-paclitaxel in 28-day treatment cycles. Patients receive mifepristone once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Treatment cycles are repeated every 28 days in the absence of disease progression or unacceptable side effects.
62685067|NCT05196503|ACTIVE_COMPARATOR|Control group|Surgery for disc herniation alone (i.e. reference treatment).
62685068|NCT05810649|EXPERIMENTAL|HA35 local injection Group|This clinical study used the 35 kDa low molecular weight HA fragment HA35, which was freshly manufactured by mixing bovine testis-derived hyaluronidase PH20 injection (H31022111) with high-molecular-weight HA injection (H20174089) for 20 minutes at room temperature.
61924014|NCT05024318|ACTIVE_COMPARATOR|SABR plus nephrectomy|Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.
62314452|NCT05046210|EXPERIMENTAL|LHA group (EG)|"Behavioral: LHA intervention~Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day, whereas the participants in the EG also received 4 lessons from a LHA over 4 weeks."
62685069|NCT04868071|EXPERIMENTAL|High-Speed Resistance Training|Participants performed exercises 8 times (sets) with 3-5 repetitions at 70%-75% of the maximal strength.
62685070|NCT04868071|EXPERIMENTAL|Low-Speed Resistance Training|Participants performed exercises 4 times (sets) with 8-10 repetitions at 70%-75% of the maximal strength.
62685071|NCT04868071|NO_INTERVENTION|Control Group|No activities
61924015|NCT05024318|EXPERIMENTAL|Pembrolizumab followed by SABR after cycle 1 plus nephrectomy|Pembrolizumab 200 mg (flat dose) will be administered as a 30 minute IV infusion every 21 days for 3 cycles. Patients will receive 1 cycle of pembolizumab prior to SABR followed by an additional 2 cycles of pembrolizumab (1 cycle is 21 days). Patients will undergo nephrectomy 9-12 weeks after commencement of treatment.
61924016|NCT01617148|EXPERIMENTAL|Treatment with Aflibercept|Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
61924017|NCT06321627||Patients with HPV-related tumors|Patients with HPV-related tumors of the oropharynx, cervix, and anus
62314453|NCT05046210|PLACEBO_COMPARATOR|Leaflet group (CG)|"Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.~The participants in the CG received oral exercise intervention and leaflets only."
62314454|NCT06483633|EXPERIMENTAL|sleep disorder group|
62314455|NCT06483633|EXPERIMENTAL|Control group|
62314456|NCT00547937|SHAM_COMPARATOR|Sham-CPAP|The sham CPAP device consisted of a conventional CPAP device, in which the area of the exhalation port was amplified, thereby nearly cancelling nasal pressure; an orifice resistor was connected between the tubing and the CPAP unit that loads the blower with the same airflow resistance as in effective CPAP
62314457|NCT00547937|ACTIVE_COMPARATOR|CPAP|
62314458|NCT03321929|EXPERIMENTAL|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects undergo lumpectomy as standard of care and will have the study intervention, guidance by intraoperative imaging using the LUM Imaging Device
62314459|NCT01571674|EXPERIMENTAL|Manipulation + Exercise Group|The treatment received by the manipulation+exercise group will differ from the exercise group for the first week only (two treatment sessions). During the first two sessions, patients in the manipulation+exercise group will receive cervicothoracic spine manipulations and range of motion (ROM) exercises only. Beginning on the third session these patients will receive the same exercise program as the exercise group.
62314460|NCT01571674|ACTIVE_COMPARATOR|Exercise Group|The exercise group will be treated with a stretching and strengthening program.
62314461|NCT05905328|EXPERIMENTAL|CTO1681 30 μg Total Daily Dose|Participants receive 10 μg CTO1681 orally 3 times daily (total daily dose of 30 μg) for 15 days.
62314462|NCT05905328|EXPERIMENTAL|CTO1681 60 μg Total Daily Dose|Participants receive 20 μg CTO1681 orally 3 times daily (total daily dose of 60 μg) for 15 days.
62314463|NCT05905328|EXPERIMENTAL|CTO1681 90 μg Total Daily Dose|Participants receive 30 μg CTO1681 orally 3 times daily (total daily dose of 90 μg) for 15 days.
62314464|NCT06340555|EXPERIMENTAL|Enzo intervencion group|"The hospital 1 guide for care consists on a multidisciplinary team intervention on three moments related to the loss: diagnose, intrapartum, postpartum.~1. Diagnose: we aim to inform, prepare following procedures and support in the decision-making.~2. Intrapartum: we aim to reduce or even avoid trauma caused by the situation.~3. Postpartum: we aim to ensure mother and partner are able to say good-bye absolutely how they planned and/or desire at each time. Also, coordinate continuum of care after hospital discharge."
62314465|NCT06340555|ACTIVE_COMPARATOR|Control group|It is the usual care intervention which consists in: diagnosis given by the doctor, intrapartum routine care and follow up on discharge by gynaecologist team.
62314466|NCT04546256|EXPERIMENTAL|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
61924018|NCT02814032||PTC group 1|papillary thyroid carcinoma patients with cervical lymph node metastasis
61924019|NCT02814032||PTC group 2|papillary thyroid carcinoma patients without cervical lymph node metastasis
62314467|NCT04546256|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS® 500/50
62314468|NCT01056523|EXPERIMENTAL|Ribavirin-Cytarabine arabinoside|Ribavirin will be given orally bid according to a dose escalation scheme daily for 28 days of a 28 day cycle Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle
62314469|NCT06672978|EXPERIMENTAL|Cohort 1: Age 6 to < 12 years|"Participants will receive meropenem-vaborbactam via an intravenous (IV) infusion for a minimum of 3 days, for up to 14 days.~Participants with clinical improvement have the option to switch to an oral antibiotic after Day 3."
62314470|NCT06672978|EXPERIMENTAL|Cohort 2: Age 2 to < 6 years|"Participants will receive meropenem-vaborbactam IV infusion for a minimum of 3 days, for up to 14 days.~Participants with clinical improvement have the option to switch to an oral antibiotic after Day 3."
62314471|NCT06672978|EXPERIMENTAL|Cohort 3: Age 3 months to < 2 years|"Participants will receive meropenem-vaborbactam IV infusion for a minimum of 3 days, for up to 14 days.~Participants with clinical improvement have the option to switch to an oral antibiotic after Day 3."
62314472|NCT05187338|EXPERIMENTAL|3 drugs|Three antibodies combination against PD1, PDL1, and CTLA4.
61924020|NCT02814032||Positive control group|benign disease
61924021|NCT02814032||Negative control group|histologically normal
62314473|NCT06453551|EXPERIMENTAL|Single dose 1|TRN501 - Dose 1
62314474|NCT06453551|EXPERIMENTAL|Single dose 2|TRN501 - Dose 2
62314475|NCT06453551|EXPERIMENTAL|Single dose 3|TRN501 - Dose 3
62314476|NCT06453551|EXPERIMENTAL|Single dose 4|TRN501 - Dose 4
62314477|NCT06453551|EXPERIMENTAL|Single dose 5|TRN501 - Dose 5
62314478|NCT06453551|EXPERIMENTAL|Single dose 6|TRN501 - Dose 6
62314479|NCT06453551|EXPERIMENTAL|Single dose 7|TRN501 - Dose 7
62314480|NCT06453551|EXPERIMENTAL|Single dose 8|TRN501 - Dose 8
62314481|NCT06438276||Adolescents with mood disorders seeking help in student welfare services|"Intervention group receiving psychiatric outreach nurse services: adolescents (12-16 years old) who seek help from student welfare services due to mood disorders and have access to psychiatric outreach nurse's service.~Control group receiving TAU: adolescents (12-16 years old) who seek help from student welfare services due to mood disorders and have no access to psychiatric outreach nurse's service."
62314482|NCT04928365|OTHER|Advanced melanoma patients|
62314483|NCT04928365|OTHER|Stage III and IV melanoma patients after radical surgery|
62314484|NCT05111249|EXPERIMENTAL|Treatment Arm A|Branaplam 56 mg oral solution once weekly
62314485|NCT05111249|EXPERIMENTAL|Treatment Arm B|Branaplam 112 mg oral solution once weekly
62314486|NCT05111249|EXPERIMENTAL|Treatment Arm C or X or Y|(C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly
62314487|NCT05111249|PLACEBO_COMPARATOR|Placebo|Matching placebo oral solution once weekly
62314488|NCT00401583|EXPERIMENTAL|Pazopanib receivers|During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
62314489|NCT00602862|EXPERIMENTAL|1|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
62314490|NCT00602862|EXPERIMENTAL|2|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/10mg 111In-cG250. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
62124614|NCT01493310|ACTIVE_COMPARATOR|Arm B (chemotherapy)|"Patients will receive nab-paclitaxel and placebo for a 28-day treatment cycle (Cycle 1).~Patients receive placebo once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Patients then cross-over to Arm A after completion of the first treatment cycle."
62124615|NCT05721924|ACTIVE_COMPARATOR|Pericapsular nerve group (PENG) block|The pericapsular nerve group (PENG) block is an ultrasound-guided approach, first described by Giron-Arango et al. for the blockade of the articular branches of the femoral, obturator and accessory obturator nerves that provide sensory innervation to the anterior hip capsule.
62124616|NCT05721924|ACTIVE_COMPARATOR|Supra-inguinal fascia iliaca compartment (S-FICB) block|A supra-inguinal fascia iliaca compartment block (S-FICB), a 3 in 1 block involving femoral nerve , lateral femoral cutaneous nerve and obturator nerve.
62124617|NCT01296334|EXPERIMENTAL|morphine low dose|morphine infusion 10 mg over a 210 min period
62124618|NCT01296334|EXPERIMENTAL|morphine high dose|morphine infusion 20 mg over a 210 min period
62685072|NCT02691494|PLACEBO_COMPARATOR|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)
62314491|NCT00602862|ACTIVE_COMPARATOR|3|5 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Whole-body scintigraphic images are recorded 1 week after the injection to calculate tumor uptake. Hereafter, patients will undergo surgery.
62314492|NCT05790304|OTHER|Group 1|Matched-control healthy participants with normal hepatic function.
62314493|NCT05790304|OTHER|Group 2|Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).
62124619|NCT01296334|EXPERIMENTAL|buprenorphine low dose|buprenorphine infusion 0.3 mg over a 210 min period
62314494|NCT05790304|OTHER|Group 3|Participants with severe hepatic impairment (CP Class C, score of 10 to 15).
62314495|NCT06274489|EXPERIMENTAL|Setanaxib|"Patients will receive the following setanaxib doses according to age at the time of consent/assent:~* For patients aged 12 to 17 years 1200 mg/day: 2 tablets in the morning (800 mg) and 1 tablet in the evening (400 mg)~* For patients aged ≥18 years 1600 mg/day: 2 tablets in the morning (800 mg) and 2 tablets in the evening (800 mg)"
62314496|NCT06274489|PLACEBO_COMPARATOR|Setanaxib placebo|Matching placebo will be provided.
62314497|NCT01712438|EXPERIMENTAL|Human cl rhFVIII|
62314498|NCT04908137|EXPERIMENTAL|2-Octyl Cyanoacrylate (Dermabond) Group|2-Octyl Cyanoacrylate (Dermabond) 0.5ml/ sticks topical application around post-circumcision site subcoronal area immediately after the circumcision devise is removed and circumcision procedure was done
62314499|NCT04908137|NO_INTERVENTION|Control Group|will receive Vaseline cream application around the post-circumcision site immediately after circumcision
62314500|NCT01048125|EXPERIMENTAL|Study group|Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
62685073|NCT02691494|EXPERIMENTAL|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
62685074|NCT02691494|EXPERIMENTAL|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
62314501|NCT01048125|ACTIVE_COMPARATOR|Control|Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
62314502|NCT06256575|ACTIVE_COMPARATOR|Active|Vasculera 630 mg, tablet, two (2) times per day for eight (8) weeks
62685075|NCT04983238|EXPERIMENTAL|BYON5667 & SYD985|BYON5667 eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
62685076|NCT04983238|PLACEBO_COMPARATOR|Placebo & SYD985|Placebo eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
62685077|NCT06372366||24 children with vitamin deficiency|
62314503|NCT06256575|PLACEBO_COMPARATOR|Placebo|Cornstarch, one (1) capsule, two (2) times per day for eight (8)
62314504|NCT06005714|EXPERIMENTAL|The effects of clarithromycin on pharmacokinetics of deuterium hydrobromide ramidvir tablets|
62314505|NCT06005714|EXPERIMENTAL|The effects of cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets|
62685078|NCT06372366||24 children with sufficient vitamin level.|
62685079|NCT01313325|EXPERIMENTAL|Treatment group|Children between 5-17 years who have balance deficits related to any movement disorder (preferably neuromuscular)
61924022|NCT04066465||Proton Therapy|Patients receive proton Radio(chemo)therapy according to clinical standard. Proton Treatment is indicated BEFORE inclusion into the trial ans is not part of the trial. Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases. In addition to the treatment parameters of the radio(chemo)therapy protocol, further radiation doses to brain substructures and organs at risk are documented.
61924023|NCT04066465||No Radiotherapy - Surgical only group|"Patients are included AFTER surgery of their brain tumour and receive no radiotherapy due to their disease (i.e. according to clinical standard). This Treatment is not part of the trial, but stratifies the Patient in this second Group.~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
62314506|NCT03330691|EXPERIMENTAL|Patient-derived CD19- and CD22 specific CAR v1|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
62685080|NCT02011542|PLACEBO_COMPARATOR|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
62685081|NCT02011542|ACTIVE_COMPARATOR|VSL #3|VSL #3 (probiotic mixture) is given to this group
62685082|NCT04902482|EXPERIMENTAL|iCycle training|Participants will attend 3 training sessions per week at the RNOH. During these sessions, participants will tether their wheelchair (from under the seat) to the front of the iCycle, and their feet will be attached to the iCycle pedals. For training, participants will complete virtual reality cycle races displayed on a large screen in front of the iCycle: the more voluntary effort the participant contributes the greater the speed of the avatar. During cycling, a motor will control cycling speed, and muscle stimulation (FES) will be applied to the leg muscles (right and left gluteus, quadriceps and hamstrings) on alternative revolutions of the pedals. A dashboard screen will display controls for the stimulation, speed, brake, game switch and an emergency stop. Sessions will increase from 20 mins or the maximum achievable at the start (whichever is lower) up to at least 1 hour.
62685083|NCT05547854|ACTIVE_COMPARATOR|In-Person Therapist Training|
62685084|NCT05547854|EXPERIMENTAL|Online Therapist Training|
62685085|NCT06377592||Groups providing specimens for development of Gram Stain analysis AI|
62685086|NCT03485885||Maqui Berry Extract (MBE)|To be tested for the extracts bioavailability
62697388|NCT02516813|EXPERIMENTAL|Ancillary cPoP: M3814 Capsule (100 mg) + RT|Participants with at least 2 (sub)cutaneous tumor/metastases of any type (at least 2 centimeters \[cm\] apart) with an indication for single high dose-palliative RT were included and received single oral dose of M3814 capsule at a dose of 100 mg on Day 2, prior 1.5 hours start of RT and a single high dose of RT (10-25 Gy) on Lesion 1 on Day 1 and on Lesion 2 on Day 2.
62314507|NCT03330691|EXPERIMENTAL|Patient-derived CD19- and CD22 specific CAR v2|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
62314508|NCT02383329|EXPERIMENTAL|Oral Nutritional Supplement (ONS)|Diet consultation for the child/family + ONS
62314509|NCT02383329|NO_INTERVENTION|No Oran Nutritional Supplement (ONS)|Diet consultation for the child/family
62314510|NCT01059604||Pregnant women exposed to sumatriptan, naratriptan, or combo|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination treatment during pregnancy
62314511|NCT03988751|ACTIVE_COMPARATOR|Continuous Ambulation|The total distance will be 40 meters. Study team members will walk, support, and coach the subject to walk as slow as he/she wants
62314512|NCT03988751|ACTIVE_COMPARATOR|Interval Ambulation|The subject will walk a total distance of 40 meters. This distance will be divided into four intervals of 10 meters to equal the same measured distance as the continuous group. The subject will receive two minutes of rest between each interval and will be supported and coached to walk as fast as they can.
62314513|NCT03078985|EXPERIMENTAL|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
62314514|NCT01926379|EXPERIMENTAL|Combination Intervention Package (CIP)|Patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate Isoniazid Prevention Therapy (IPT) on or after study initiation on July 1, 2013 will receive the combination intervention components that is a part of the Combination Intervention Package (CIP).
62314515|NCT01926379|OTHER|Standard Of Care (IPT alone)|Patients are screened for tuberculosis (TB) at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Eligible patients will receive the standard of care intervention, Isoniazid Prevention Therapy (IPT), per national guidelines. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued.
62314516|NCT06480071|EXPERIMENTAL|Nasal decongestion during exercise|Nasal decongestion with oxymetazomin nasal spray 0.05% 2 sprays each nostril 10 minutes before the exercise test
62124620|NCT01296334|EXPERIMENTAL|buprenorphine high dose|buprenorphine infusion 0.6 mg over a 210 min period
62124621|NCT01296334|PLACEBO_COMPARATOR|placebo|placebo (normal saline) infusion 0.6 mg over a 210 min period
62124622|NCT01241916|EXPERIMENTAL|Static-progressive splint|
62124623|NCT01241916|EXPERIMENTAL|Dynamic Splint|
62314517|NCT01326598||T2DM patients with A1C<7.0%|
62314518|NCT06267001|EXPERIMENTAL|Atezolizumab + Tiragolumab|Participants will receive atezolizumab and tiragolumab intravenously (IV).
62314519|NCT06267001|PLACEBO_COMPARATOR|Atezolizumab + Placebo|Participants will receive atezolizumab and placebo IV.
62478494|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 4)|Neratinib 120 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62314520|NCT01612793||AlphaCore device|AlphaCore device group will consist of subjects enrolled into the study with chronic obstructive pulmonary disease and receive an electrical stimulation to the vagus nerve to help open the subjects airways during the subjects stay in the hospital.
62314521|NCT05308095|EXPERIMENTAL|Intervention group|
62314522|NCT05646771|EXPERIMENTAL|Partner-Supported|Dyads comprised of one Veteran and a cohabitating support person will participate in a behavioral weight management intervention.
62314523|NCT05546996|NO_INTERVENTION|Phase A:|Establish suitability of digital video recording system for quantifying CSF drainage into an EVD drainage system.
62314524|NCT05546996|OTHER|Phase B|Exploratory study to generate initial data on the correlation between FlowSense flow rate measurements (FlowSense Flow Rate) and: A) EVD drainage data, quantified via video recording; B) intracranial pressure (ICP) measurements
62697389|NCT02516813|EXPERIMENTAL|Ancillary cPOP: M3814 Capsule (200 mg) + RT|Participants with at least 2 (sub)cutaneous tumor/metastases of any type (at least 2 cm apart) with an indication for single high dose-palliative RT were included and received single oral dose of M3814 capsule at a dose of 200 mg on Day 2, prior 1.5 hours start of RT and a single high dose of RT (10-25 Gy) on Lesion 1 on Day 1 and on Lesion 2 on Day 2.
62314525|NCT02911363|ACTIVE_COMPARATOR|Capitvator Cassette|The EMR specimen will be processed using the Captivator Cassette.
62314526|NCT02911363|ACTIVE_COMPARATOR|Standard of Care Processing|The EMR specimen will be prepared per Standard of Care.
62314527|NCT05186558|EXPERIMENTAL|penpulimab, lenalidomide, rituximab, gemcitabine and oxaliplatin（Penpulimab-R2-GemOx)）|penpulimab: 200 mg q2w, iv, drip R2-GemOx: lenalidomide 10 mg，po; Rituximab 375mg/m2, iv, drip; Gemcitabine 1000mg, po; Oxaliplatin 100mg/m2, iv, drip;
62314528|NCT05774691|ACTIVE_COMPARATOR|Routine protamine administration|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin.
62314529|NCT05774691|ACTIVE_COMPARATOR|Selective protamine administration|Selective protamine administration, in case of (threatening) bleeding.
62478495|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 5)|Neratinib 160 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62124624|NCT02000167||Phelan-McDermid Syndrome only|Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited. 1-21 years of age
62124625|NCT02000167||Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder|1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
62124626|NCT02589340|EXPERIMENTAL|Buspirone|Two week titration up to 10 mg tablet/3 times a day for 7 days
62478496|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 6)|Neratinib 160 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62124627|NCT02589340|PLACEBO_COMPARATOR|Placebo|Two week titration up to 3 tablets/3 times a day for 7 days
62124628|NCT01719666|OTHER|isolated MPFL reconstruction|
62314530|NCT06382493|ACTIVE_COMPARATOR|Esomeprazole-containing sequential H. pylori eradication therapy (conventional method)|esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for initial 5 days, and then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for the remaining 5 days.
62478497|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 7)|Neratinib 160 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62478498|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 8)|Neratinib 160 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62478499|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 9)|Neratinib 200 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62478500|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 10)|Neratinib 200 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62124629|NCT01719666|EXPERIMENTAL|MPFL reconstruction and Lateral retinaculum release|
62124630|NCT05849311|EXPERIMENTAL|Envafolimab with new manufacturing process|80 healthy male subjects with Envafolimab with new manufacturing process
62314531|NCT06382493|EXPERIMENTAL|Tegoprazan-containing sequential H. pylori eradication therapy (experimental method)|tegoprazan (50 mg) plus amoxicillin (1000 mg) twice a day for initial 5 days, and then tegoprazan (50 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for the remaining 5 days.
62314532|NCT02168946|EXPERIMENTAL|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
62314533|NCT02168946|ACTIVE_COMPARATOR|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
62478501|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 11)|Neratinib 200 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62124631|NCT05849311|ACTIVE_COMPARATOR|Envafolimab with old manufacturing process|80 healthy male subjects with Envafolimab with old manufacturing process
62124632|NCT06007118|EXPERIMENTAL|APBI, accelerated partial breast irradiation|The APBI group will be irradiated with a dose of 30Gy in 5 fractions in 5 working days.
62124633|NCT06007118|ACTIVE_COMPARATOR|WBI, whole breast irradiation|The control group of patients will be irradiated with a standard accelerated mode within 20 working days.
62478502|NCT00838539|EXPERIMENTAL|Neratinib and Temsirolimus (Dose level 12)|Neratinib 240 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
62685087|NCT03147885|EXPERIMENTAL|Treatment (selinexor, RCHOP)|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. RCHOP will be given at standard dosing every 21 days. In the phase 1 part there is dose escalation for Selinexor in a 3+3 design. Treatment will be given for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or better will receive maintenance selinexor PO on days 1, 8, 15, and 22 every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62685088|NCT02685852|ACTIVE_COMPARATOR|Arm 1: Exenatide (5mcg) + Acarbose Placebo|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose placebo immediately prior to the high-carb meal
62685089|NCT02685852|ACTIVE_COMPARATOR|Arm 2: Exenatide (5mcg) + Acarbose (25mg)|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
62685090|NCT02685852|PLACEBO_COMPARATOR|Arm 3: Exenatide Placebo + Acarbose (25mg)|Exenatide placebo 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
62685091|NCT04567771|EXPERIMENTAL|Treatment (radiation therapy, questionnaires)|Patients undergo standard of care proton or intensity modulated radiation therapy. Patients also complete quality of life questionnaires and adverse event assessments over 10-15 minutes each at baseline, at the end of radiation therapy, and at 1 month, 1 year, and 3 years post-radiation therapy.
62685092|NCT02251470|EXPERIMENTAL|HBE Wii (EG)|Participants receive an introduction of using the Nintendo Wii by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (wii-fit balances games) at home (instruction: min. 3 times a week for each 30 minutes).
62685093|NCT02251470|ACTIVE_COMPARATOR|HBE Control (CG)|Participants receive an introduction for conventional/traditional balance exercise by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (exercises in standing and walking) at home (instruction: min. 3 times a week for each 30 minutes).
62685094|NCT00191698|EXPERIMENTAL|A|Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
62685095|NCT00191698|PLACEBO_COMPARATOR|B|Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
62124634|NCT01351493|ACTIVE_COMPARATOR|Nitric oxide gel|
62124635|NCT01351493|PLACEBO_COMPARATOR|placebo|
62124636|NCT00769275||1|Screening at start study with Adenosine vasodilator stress Tc-99m Sestamibi SPECT imaging
62124637|NCT00769275||2|No screening
61924024|NCT04066465||Control Group|"Healthy kids are recruited as Standard Group.~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
61924025|NCT00450775|OTHER|1|
61924026|NCT05893901||Consumers of cereal products|Caregivers with children under 5 years of age who are consumer of cereal products in the Maradi, Falwell and Tera areas in Niger.
61924027|NCT01778777|EXPERIMENTAL|UniverseReverse|Cohort get an universe reverse prosthesis
61924028|NCT02515812|EXPERIMENTAL|Adrenergic Function Explorations with CZT camera|I-123-MIBG and CZT Camera (D-SPECT)
61924029|NCT02515812|ACTIVE_COMPARATOR|Adrenergic Function Explorations with Anger camera|I-123-MIBG and Anger Camera
62124638|NCT02545036|EXPERIMENTAL|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
62124639|NCT02545036|NO_INTERVENTION|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
62314534|NCT04933812|OTHER|Group Social Support Meetings and Facebook Group|Facebook group where community doulas will be providing information on various pregnancy and support topics in addition to 8 possible group Zoom meetings that will include pregnancy-related/reflection topics.
62314535|NCT02228512|ACTIVE_COMPARATOR|1|Treatment naive PEL (main cohort)
62314536|NCT02228512|ACTIVE_COMPARATOR|2|Treatment na(SqrRoot) ve large cell lymphoma arising in KSHV-MCD
62685096|NCT03419624|EXPERIMENTAL|Dapagliflozin plus Exenatide|Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
61924030|NCT02187874|ACTIVE_COMPARATOR|early umbilical cord occlusion|Cord clamping will be performed before 30 seconds after delivery, annoting the exact time of clampage and initiating reanimation and postnatal care procedures as usual. 60 second after delivery of the new born, 10 IU of Oxytocin will be administered intramuscularly.
61924031|NCT02187874|EXPERIMENTAL|delayed umbilical cord occlusion|"One of the paediatricians will hold the newborn ( in vaginal deliveries between 20-30 cm under the mother, in C-sections between the legs of the mother) until clamping of the umbilical cord is indicated by a second paediatrician who will be controlling the time and overall state of the baby. The baby will be wrapped during this time in a thermal blanket in a flexed lateral decubitus position to minimise stress and heat loss. Time of clamping: after 30 to 60 seconds( preferably 60). If loss of the baby's wellbeing is suspected, the paediatrician will assess the newborn's heart rate , stopping the procedureif this falls under 100ppm, initiating at that moment the necessary reanimation procedures.~60 second after the delivery of the new born 10 IU of oxytocin will be administered intramuscularly."
61924032|NCT02285660|OTHER|Routine CT scan plus 4D PET-CT scan|
61924033|NCT02285660|OTHER|Routine CT scan|
62124640|NCT01763086|EXPERIMENTAL|Mesenchymal stem cells|Mesenchymal stem cells 1×10\^6 cells/kg, intravenously
62685097|NCT03419624|PLACEBO_COMPARATOR|Placebo plus Placebo|Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
62685098|NCT03419624|ACTIVE_COMPARATOR|Placebo plus Exenatide|Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy
62124641|NCT03262623|EXPERIMENTAL|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
62124642|NCT03262623|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo through radial nerve block
62314537|NCT02228512|ACTIVE_COMPARATOR|3|Previously treated KSHV-NHL
62314538|NCT06673433||the obesity group|Patients diagnosed with obesity (body mass index (BMI) ≥ 28kg/m2)
62314539|NCT06673433||the control group|Paticipants with nomal BMI （18.5 - 24 kg/m2)
62314540|NCT03634072|OTHER|PVR Arm|PVR arm will undergo PVR via catheter or surgery
62314541|NCT03634072|NO_INTERVENTION|No PVR|No PVR group will continue with medical management
62314542|NCT06430268|EXPERIMENTAL|Non-surgical decontamination with titanium curettes followed by explantation|Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implants without any flap elevation.
62314543|NCT06430268|EXPERIMENTAL|: Non-surgical decontamination with erythritol powder prior to implant removal|Without any flap elevation, the supramucosal implant surfaces will be cleaned with the Airflow handpiece, while for the submucosal areas, a Perioflow handpiece and nozzle for submucosal instrumentation will be used. The nozzle will be changed after cleaning each implant.
62314544|NCT06430268|EXPERIMENTAL|Surgical decontamination with titanium curettes prior to implant removal|Intra-sulcular and, if necessary, vertical releasing incisions will be performed. Full-thickness flaps will be elevated in the buccal and lingual aspects and the granulation tissue will be removed. Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implants
62685099|NCT00890656|EXPERIMENTAL|Augmented Hyper-CVAD|Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.
62685100|NCT05802849|EXPERIMENTAL|a group with the use of acetazolamide|acetazolamide is prescribed at a dose of 250 mg 3 times a day
62685101|NCT05802849|NO_INTERVENTION|a group of standart therapy|standart therapy includes main and additional medicine for treatment of chronic heart failure
62685102|NCT04511741||invasive mechanical ventilation|
62685103|NCT04511741||non invasive mechanical ventilation|
62685104|NCT02167685||CMX001|Subjects who have previously participated in CMX001-301 or other CMX001 study.
62685105|NCT00707304|EXPERIMENTAL|1|Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
62685106|NCT00707304|PLACEBO_COMPARATOR|2|Placebo contains the same phosphate-based buffer used as the diluent for the talactoferrin solution. In addition, the placebo will contain FD\&C/EU grade dyes suitable for oral use to mimic the color of the vialed drug product.
62685107|NCT02327143|EXPERIMENTAL|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
62685108|NCT02327143|EXPERIMENTAL|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
61924034|NCT00926588|EXPERIMENTAL|Stepped Care|Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
61924035|NCT00926588|NO_INTERVENTION|Usual Care|Patients receive usual care for pain from their primary care physician
61924036|NCT05588557|ACTIVE_COMPARATOR|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|Marcaine® at 150 mg in each cohort.
61924037|NCT05588557|EXPERIMENTAL|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|ND-340(90-320 mg) at dose escalations
61924038|NCT04232306|EXPERIMENTAL|Liposomal Bupivacaine + Bupivacaine HCL|Liposomal bupivacaine + bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
61924039|NCT04232306|ACTIVE_COMPARATOR|Bupivacaine HCl surgical-site incision infiltration|Bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
62124643|NCT03086161|ACTIVE_COMPARATOR|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
62124644|NCT03086161|EXPERIMENTAL|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
62124645|NCT06335654||colorectal lesion|
62124646|NCT02879695|EXPERIMENTAL|Treatment (blinatumomab, nivolumab, ipilimumab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year. Patients also undergo bone marrow aspiration and biopsy and blood sample collection throughout the study.
62124647|NCT03803605|EXPERIMENTAL|VRC07-523LS + Vorinostat (VOR)|Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.
62124648|NCT05919368|EXPERIMENTAL|Yam pill|It consists of sweet potato, white art and ginseng
62124649|NCT05919368|PLACEBO_COMPARATOR|placebo group|It consists of corn starch and dextrin
62124650|NCT02550067|ACTIVE_COMPARATOR|Depot medroxyprogesterone acetate (DMPA)|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
62124651|NCT02550067|ACTIVE_COMPARATOR|Levonorgestrel implant (LNG)|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
62124652|NCT02550067|ACTIVE_COMPARATOR|Copper T380a IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
62124653|NCT01677936|EXPERIMENTAL|Raisin|Subjects randomized to the raisin treatment arm will consume raisins three times a day, prior to meals, and with a glass of water or non-caloric beverages (i.e. tea). Subjects will consume the raisins over a 12 week period.
62124654|NCT01677936|ACTIVE_COMPARATOR|Snack Group|Subjects randomized to the snack group will consume 100 calorie snack packs three times a day, before meals, and with water or other non-caloric beverages (i.e. tea). Subjects will consume the snack packs over a 12 week period.
62124655|NCT06014827|EXPERIMENTAL|Treatment (BgRT/SBRT)|"Patients continue to receive osimertinib PO QD in the absence of unacceptable toxicity. Patients undergo BgRT/SBRT every other day for 5 treatments. Patients then continue to receive osimertinib and are monitored via imaging. If additional progression is found, patients may receive additional BgRT/SBRT therapy. Treatment continues in the absence of \> 5 sites of progression, unacceptable toxicity, or the stopping of osimertinib for more than 4 weeks.~Patients undergo CT scan or PET/CT scan and blood sample collection throughout the study."
62124656|NCT02355197|ACTIVE_COMPARATOR|antioxidant|1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery in addition to treatment for gestational diabetes mellitus in the form of diet and insulin
62685109|NCT06693141||ESP|ESP block was applied to patients in this group in the preoperative period.
62685110|NCT06693141||ITM|Intrathecal morphine was applied to patients in this group in the preoperative period.
62685111|NCT06693141||Control|Patients who did not undergo ESP block or ITM were included in this group.
62685112|NCT03878602|ACTIVE_COMPARATOR|Control Group|Newborns will be subjected to umbilical cord immediate clamping
62314545|NCT06430268|EXPERIMENTAL|Surgical decontamination with erythritol powder prior to implant removal|Intra-sulcular and, if necessary, vertical releasing incisions will be performed. Full-thickness flaps will be elevated in the buccal and lingual aspects and the granulation tissue will be removed.The Airflow handpiece will be moved in a horizontal direction along implant threads from an apical to a coronal position. The angulation of the handpiece and working distance will not be standardized as they may vary according to the area being cleaned.
62314546|NCT06430268|NO_INTERVENTION|No decontamination prior to implant removal|No decontamination will be performed on implants in this group.
62314547|NCT05174806|EXPERIMENTAL|Topical Pravibismane (MBN-101)|Topical pravibismane (MBN-101) at a dose of 2.5 mg/mL will be applied directly to the infected wound and covered with an appropriate non-antimicrobial dressing. Dosing will occur 3 times per week for the 12 weeks of treatment.
62314548|NCT05174806|OTHER|Standard of Care|Standard of care treatment without administration of any topical drugs.
62314549|NCT06671015|EXPERIMENTAL|Extubation to HFNC|Immediately after planned extubation, the patients assigned to the HFNC group will be continuously treated by HFNC at a flow at the maximally tolerated level for 24 hours.
62314550|NCT06671015|ACTIVE_COMPARATOR|Control: Extubation to NIV for 24hrs post-extubation.|The NIV will be immediately initiated after planned extubation using specific, predetermined ventilator settings for 24 hours.
62314551|NCT06439914|EXPERIMENTAL|[89Zr]Zr-DFO-emapalumab|Radiotracer \[89Zr\]Zr-DFO-emapalumab injection
62314552|NCT00336193|EXPERIMENTAL|Home visitation|In the intervention condition, nurse home visitors receive enhanced training to improve delivery of parenting interventions to mothers
62685113|NCT03878602|EXPERIMENTAL|Study Group|Newborns will be subjected to umbilical cord delayed clamping
62685114|NCT05206045||Patients with Sezary syndrome|Adult patient with Sezary syndrome diagnosed between 1998 and 2020
62124657|NCT02355197|NO_INTERVENTION|control|Only treatment for gestational diabetes mellitus in the form of diet and insulin
62124658|NCT03751891|EXPERIMENTAL|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
62124659|NCT03751891|ACTIVE_COMPARATOR|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_A which will be fitted to the participants individual Hearing loss.
62124660|NCT03751891|ACTIVE_COMPARATOR|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_B which will be fitted to the participants individual Hearing loss.
62314553|NCT00597558|EXPERIMENTAL|Egg white protein|Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
62314554|NCT02553603|PLACEBO_COMPARATOR|Mild Cognitive Impairment, Placebo|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
62314555|NCT02553603|PLACEBO_COMPARATOR|Non-cognitively impaired, Placebo|Subjects aged 55- 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
62314556|NCT02553603|EXPERIMENTAL|Mild Cognitive Impairment, GHRH|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
62685115|NCT01897896|EXPERIMENTAL|Rollover Cohort: SD-809 ER|Participants who completed study SD-809-C-15 (NCT01795859, including 1-week washout period and Week 13 evaluation), will receive 6 milligrams (mg) SD-809 ER tablet once daily as a starting dose in this study. Dose titration will be continued through Week 8 to optimize dose. Dose of SD-809 ER can be adjusted weekly in increments of 6 milligrams per day (mg/day) (6 or 12 mg/day after a total daily dose of 48 mg is reached) based on chorea control and adverse events. Daily doses of SD-809 ER 12 mg and higher will be administered twice daily. Maximum total daily dose of SD-809 ER will be 72 mg/day (36 mg twice daily), unless participant is receiving a strong CYP2D6 inhibitor(such as, paroxetine, buproprion, fluoxetine), in which case maximum total daily dose will be 42 mg (21 mg twice daily). Long-term treatment with SD-809 ER at a stable dose (further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
62124661|NCT02647268|NO_INTERVENTION|Control (no oxytocin) pretreatment|The myometrial samples are bathed in physiological saline solution (PSS).
62124662|NCT02647268|ACTIVE_COMPARATOR|Magnesium Sulphate|The myometrial samples are bathed in a 3.5mM magnesium sulphate solution.
62124663|NCT02647268|ACTIVE_COMPARATOR|Magnesium Sulphate + oxytocin|The myometrial samples are bathed in a 3.5mM magnesium sulphate plus 10-5M oxytocin solution.
62124664|NCT04479865|EXPERIMENTAL|Sequence 1|Period 1, Aricept 5mg → DA-5207 150mg; Period 2, Aricept 5mg → Aricept 10mg
62124665|NCT04479865|EXPERIMENTAL|Sequence 2|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 150mg
62124666|NCT04479865|EXPERIMENTAL|Sequence 3|Period 1, Aricept 5mg → DA-5207 170mg; Period 2, Aricept 5mg → Aricept 10mg
62124667|NCT04479865|EXPERIMENTAL|Sequence 4|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 170mg
62124668|NCT04781881||Entresto|Patients administered Entresto by prescription
62124669|NCT00700336|EXPERIMENTAL|Pemetrexed, Cisplatin, and CBP501: Phase 2|pemetrexed, cisplatin and CBP501
62314557|NCT02553603|EXPERIMENTAL|Non-cognitively impaired, GHRH|Subjects aged 55 - 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
62314558|NCT01818557|NO_INTERVENTION|Every day blood glucose testing|Patients will test their blood glucose values 4 times every day
62314559|NCT01818557|EXPERIMENTAL|Every other day blood glucose testing|Patients will test their blood glucose 4 times every other day
62314560|NCT06116591|EXPERIMENTAL|mPnC candidate|Participants will receive the mPnC candidate at Visit 1 and Visit 3 (approximately 8 weeks apart). PCV10 will also be given at Visit 1.
62314561|NCT06116591|ACTIVE_COMPARATOR|mPnC control|Participants will receive the mPnC control at Visit 1 and Visit 3 (approximately 8 weeks apart). PCV10 will also be given at Visit 1.
62314562|NCT02500030|EXPERIMENTAL|Air Stacking|Air Stacking was performed with the subject seated in his wheelchair using a manual resuscitation bag (LIFESAVER® model 5345, Hudson, Temecula, USA) connected to a corrugated tube with an internal diameter of 22 mm, a one-way valve and a pipette. The maximum capacity of the bag was 1600 mL. A chest physiotherapist insufflated the patient during the inspiratory phase, requesting that inspire as much air as possible
62314563|NCT02500030|EXPERIMENTAL|Glossopharyngeal Breathing|"Glossopharyngeal Breathing was also performed with the subject seated in his wheelchair and performing successive maneuvers of swallowing air until the maximum volume achieve was maintained. Then, the patient was instructed to breathe through ventilometer to register the MIC. Three measurements for each of the techniques were performed, and the highest reading was recorded. A difference of \<10% between the measurements was used as the repeatability criterion"
62124670|NCT00700336|ACTIVE_COMPARATOR|Pemetrexed and Cisplatin: Phase 2|pemetrexed and cisplatin
62124671|NCT00700336|EXPERIMENTAL|Pemetrexed, Cisplatin, and CBP501:Phase 1|MTD, which was equal to recommended dose for the Phase II part, was determined by 6 patients (3+3)
62124672|NCT04225403|EXPERIMENTAL|Telephone-based motivational interviewing|Experimental intervention consisted of a motivational intervention for smoking cessation through telephone every 3 months for one year, performed by IBD nurse
62124673|NCT04225403|NO_INTERVENTION|usual care|No intervention consisted of a single telephone contact one year after the star of the study
62124674|NCT01041417|EXPERIMENTAL|GM-CSF|Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
62124675|NCT01041417|PLACEBO_COMPARATOR|Placebo|Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
62124676|NCT05344326|EXPERIMENTAL|CAT-GSH|Participants, who provide informed consent, will be provided an assessment session, six fortnightly CAT-GSH sessions, and one follow-up session.
62124677|NCT00812877|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
62124678|NCT00812877|ACTIVE_COMPARATOR|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide used as a direct pulp cap
62124679|NCT02120911|EXPERIMENTAL|Pertuzumab, trastuzumab|Pertuzumab, trastuzumab
62124680|NCT06103630|SHAM_COMPARATOR|Control group|Mandibular advancement device
62124681|NCT06103630|EXPERIMENTAL|Intervention group|Participants will received 1-2 times a week, 12-week-intervention of Oropharyngeal Exercises and Mandibular advancement device.
62124682|NCT01600729||All Participants|Participants with facial lines. There was no intervention in this study.
62314564|NCT02601001|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).
62697390|NCT02516813|EXPERIMENTAL|Ancillary cPOP: M3814 Capsule (400 mg) + RT|Participants with at least 2 (sub)cutaneous tumor/metastases of any type (at least 2 cm apart) with an indication for single high dose-palliative RT were included and received single oral dose of M3814 capsule at a dose of 400 mg on Day 2, prior 1.5 hours start of RT and a single high dose of RT (10-25 Gy) on Lesion 1 on Day 1 and on Lesion 2 on Day 2
62124683|NCT00360698|OTHER|insulin glulisine+insulin glargine+metformin+glimepiride|Bolus arm
62124684|NCT00360698|OTHER|insulin glargine+metformin+glimepiride|Control arm
62124685|NCT03049969|EXPERIMENTAL|Cognitive Remediation|For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a pre/post treatment assessment measures will be completed.
62124686|NCT01211093|EXPERIMENTAL|High frequency whole body vibration|This group will receive a single 10-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
62124687|NCT01211093|ACTIVE_COMPARATOR|low frequency whole body vibration|This group will receive a single 10-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
62124688|NCT01211093|ACTIVE_COMPARATOR|Control|This group will stand on the same vibration platform for 10 minutes, but no vibration will be given.
62124689|NCT05640154|EXPERIMENTAL|Educational program|aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. they will receive the nursing educational program which will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).also they will receive health-promoting lifestyle that includes (spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility and stress management).
62124690|NCT05640154|NO_INTERVENTION|control group|aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. the will not receive educational program and life style promotion.
62124691|NCT03050814|ACTIVE_COMPARATOR|Standard of Care (SOC) - Arm A|Participants will receive leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX)- + bevacizumab + for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine until disease progression.
62124692|NCT03050814|EXPERIMENTAL|Standard of Care (SOC) - Arm B + Lead in|Participants will receive leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX)- + bevacizumab + avelumab + Ad-CEA vaccine (given weeks 0,2,4,8,12,16 and then every 12 weeks) for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine + avelumab + Ad-CEA vaccine (following the every 12-week dosing schedule) until disease progression.
62124693|NCT01304342|ACTIVE_COMPARATOR|Remifentanil|Remifentanil 1 microgram/kg/h along with propofol infusion
62124694|NCT01304342|ACTIVE_COMPARATOR|Fentanyl|Fentanyl 200 micrograms intranasally
62124695|NCT01304342|PLACEBO_COMPARATOR|Normal saline|Normal saline intravenously and intranasally
62314565|NCT02601001|EXPERIMENTAL|Omecamtiv mecarbil 25 mg / 37.5 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was \< 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
62314566|NCT02601001|EXPERIMENTAL|Omecamtiv mecarbil 25 mg / 50 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was \< 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
62314567|NCT06658899|EXPERIMENTAL|Dose 1|CRD-4730 Dose 1 Tablet
62124696|NCT01373346|EXPERIMENTAL|Long limb Roux-en Y reconstruction|Long limb Roux-en Y reconstruction means that the length of Roux limb and biliopancreatic limb are longer than conventional reconstruction method after gastrectomy.
62314568|NCT06658899|EXPERIMENTAL|Dose 2|CRD 4730 Dose 2 Tablet
62314569|NCT06658899|PLACEBO_COMPARATOR|Dose 3|Placebo tablet to match CRD-4730
62314570|NCT04174131|EXPERIMENTAL|Treatment A (right) B (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
62314571|NCT04174131|EXPERIMENTAL|Treatment B (right) A (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
62314572|NCT06435156|EXPERIMENTAL|Sotagliflozin|Sotagliflozin oral tablet, 200mg once per day for 16 weeks.
62314573|NCT06435156|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet, 200mg once per day for 16 weeks.
62314574|NCT01066416|PLACEBO_COMPARATOR|Medical therapy|Patients undergo surgery 6 months after randomization
62314575|NCT01066416|EXPERIMENTAL|Surgery|Patients undergo surgery at time of randomization
62124697|NCT03109795|EXPERIMENTAL|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
62314576|NCT03515538|EXPERIMENTAL|RRx-001 Pre-Treatment plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin
62314577|NCT03515538|EXPERIMENTAL|RRx-001 Pre-Treatment, 2 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration
62124698|NCT03109795|ACTIVE_COMPARATOR|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
62124699|NCT06439901|OTHER|Screening for primary prevention of bronchopulmonary cancer|Screening CTscan according to the NELSON trial schedule (at inclusion, 1 year, 3 years, 5.5 years),
62314578|NCT03515538|EXPERIMENTAL|RRx-001 Pre-Treatment, 6 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration
62314579|NCT03515538|ACTIVE_COMPARATOR|Standard of Care|No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
62314580|NCT01569204|ACTIVE_COMPARATOR|BrECAPP|modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
62314581|NCT01569204|ACTIVE_COMPARATOR|BrECADD|modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
62314582|NCT01747330|EXPERIMENTAL|Creon micro, minimicrospheres|
62314583|NCT03595215|EXPERIMENTAL|TENS Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
62314584|NCT00577330|EXPERIMENTAL|Myalgesin|Subjects receive Myalgesin twice daily
62314585|NCT00577330|ACTIVE_COMPARATOR|Acetaminophen|Subjects receive acetaminophen 1000 mg three times a day
62314586|NCT01013883||systolic dysfunction|patients having left ventricular systolic dysfunction on echocardiography
62314587|NCT01013883||distolic heart failure|patients with clinical heart failure and preserved LV systolic dysfunction
62314588|NCT01456832||Renal Transplant Patients with Post-operative Hypoatremia|All renal transplant recipients at the Mayo Clinic of Florida from 1/1/2010 through 8/19/2011 who received a kidney from either a living or cadaveric donor.
62314589|NCT05743543|EXPERIMENTAL|Active SPG block|The block will be performed using a topical aerosolized nasal spray followed by the administration of a local anesthetic.
62314590|NCT06394219|EXPERIMENTAL|Anterior Pyelotomy|"Traditional transperitoneal laparoscopic pyelolithotomy:~Patients who were randomized to receive classic transperitoneal laparoscopic pyelolithotomy"
62314591|NCT06394219|EXPERIMENTAL|Posterior Pyelotomy|"Modified transperitoneal laparoscopic pyelolithotomy:~Patients who were randomized to receive modified transperitoneal laparoscopic pyelolithotomy by applying posterior pyelotomy."
62314592|NCT06065956|EXPERIMENTAL|Morphine group|Half of participants will be comprising of morphine group
62314593|NCT06065956|EXPERIMENTAL|Esmolol group|Half of participants will be comprising of esmolol group
62314594|NCT00247390|EXPERIMENTAL|Ramelteon 8 mg QD|
62314595|NCT00247390|PLACEBO_COMPARATOR|Placebo QD|
62314596|NCT03337841|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
62314597|NCT00374907|EXPERIMENTAL|Saxagliptin (A)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
62314598|NCT00374907|PLACEBO_COMPARATOR|Placebo (ST) / Metformin (LT) (B)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
62314599|NCT06095284||All nursing home residents included in the 2009-2021 MDS|All nursing home residents included in the 2009-2021 MDS
62314600|NCT06095284||Nursing home and non-nursing home residents diagnosed with an AD/ADRD condition|Nursing home and non-nursing home residents diagnosed with an AD/ADRD condition
61924040|NCT02177578|EXPERIMENTAL|Temozolomide plus radiation therapy to the tumor and SVZ|"Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy of radiation therapy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series and FLAIR series, plus the bilateral subventricular zone Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed, areas of contrast enhancement on T1 post gadolinium series MRI plus the ipsilateral subventricular zone Will be prescribed to 14 Gy in 2 Gy fractions"
61924041|NCT02177578|ACTIVE_COMPARATOR|Temozolomide and neural progenitor cell sparing radiation|"Patients will receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI abnormalities based on T1 post gadolinium series and FLAIR series.~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series.~Will be prescribed to 14 Gy in 2 Gy fractions"
61924042|NCT06049680|OTHER|Single arm SMOFlipid® (lipid injectable emulsion)|Investigational drug: SMOFlipid® (lipid injectable emulsion).
62314601|NCT02894983|OTHER|Arm 1|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
62685116|NCT01897896|EXPERIMENTAL|Switch Cohort: SD-809 ER|Participants who were receiving an approved dosing regimen of tetrabenazine for at least 8 weeks prior to screening, will be converted overnight from their existing tetrabenazine regimen to SD-809 ER regimen to achieve targeted steady-state area under the curve (AUC) of total (alpha+beta)- Dihydrotetrabenazine (HTBZ) metabolites that is predicted to be comparable to that of participant's prior tetrabenazine regimen. Participants will remain on initial dose of SD-809 ER through Week 1. Dose adjustment will be continued through Week 4 to optimize the dose. Dose of SD-809 ER can be adjusted weekly (upward or downward) in increments of 6 mg per day (6 mg/day or 12 mg/day after a total daily dose of 48 mg is reached), based on chorea control and treatment regimen tolerability. Long-term treatment with SD-809 ER at a stable dose (although further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
62685117|NCT02156505|EXPERIMENTAL|DoubleBare stent|Placement of double bare stent
62314602|NCT02894983|OTHER|Arm 2|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
62314603|NCT01686204|ACTIVE_COMPARATOR|Non-obese individuals|Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.
62314604|NCT01686204|EXPERIMENTAL|Obese individuals|Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.
62685118|NCT06690047|ACTIVE_COMPARATOR|Ruconest|open-label Ruconest
62685119|NCT06690047|NO_INTERVENTION|No Ruconest|No Ruconest given
62685120|NCT05319015|EXPERIMENTAL|Treatment Arm|Patients receive neoadjuvant lenvatinib (20 mg PO daily) for 12 weeks and pembrolizumab (200 mg IV every 3 weeks for four doses) prior to surgical resection of locally advanced RCC with IVC tumor thrombus. Following surgery, patients will receive adjuvant pembrolizumab (200 mg IV every 3 weeks for up to thirteen doses).
62685121|NCT02239042|SHAM_COMPARATOR|Low-level laser therapy (LLLT) Sham|LLLT Sham on the palatal donor site of connective tissue graft
62685122|NCT02239042|EXPERIMENTAL|Low-level laser therapy (LLLT)|LLLT on the palatal donor site of connective tissue graft
62685123|NCT05307094|EXPERIMENTAL|Intervention first|Participants will first be randomly assigned to a parent-mediated social communication intervention. At month 3 participants' social communication will be evaluated. Participants who present with delayed social communication skills will be randomly assigned to 2 additional treatment options: continue, or add video feedback. Participants who do not present with social communication delays will reduce intervention to a weekly phone call.
62685124|NCT05307094|ACTIVE_COMPARATOR|Developmental monitoring first|Participants will first be assigned to receive monthly monitoring of social communication development. At month 3 participants' social communication will be evaluated. Participants who present with delayed social communication skills will be randomly assigned to 2 additional treatment options: continue, or add video feedback. Participants who do not present with social communication delays will continue to receive developmental monitoring.
62685125|NCT03124602|EXPERIMENTAL|Test Subject|All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
62685126|NCT06683170||Pregnant women|Pregnant women wearing the pregnancy monitoring belt for two hours. In addition, the hospital patient monitor will be used to measure mother ECG, heart rate, breathing rate, oxygen saturation, blood pressure, contractions and fetal heart rate and movements.
62685127|NCT06683170||Healthcare professionals|Healthcare professionals participating in the pregnancy care.
62685128|NCT06083311|EXPERIMENTAL|Probiotic|Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
62685129|NCT06083311|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
62685130|NCT05814614|ACTIVE_COMPARATOR|electrical stimulation small phase duration|phase duration 200 microseconds, frequency 20 Hertz, 20 minutes
62685131|NCT05814614|ACTIVE_COMPARATOR|electrical stimulation broad pulse duration|phase duration 1000 microseconds, frequency 8 Hertz, 20 minutes
62685132|NCT05814614|SHAM_COMPARATOR|electrical stimulation inactive 100Hz|phase duration 200 microseconds, frequency 100 Hertz, 2 seconds active 20 seconds no output, 20 minutes
62685133|NCT05747937|EXPERIMENTAL|Amyotrophic Lateral Sclerosis patients|Amyotrophic Lateral Sclerosis (ALS) patients within 18 months from symptoms onset will be recruited
62685134|NCT05747937|ACTIVE_COMPARATOR|Healthy controls|A population of healthy controls matched for sex and age will be enrolled
62314605|NCT04050904|EXPERIMENTAL|ExpHeart|The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment.
62314606|NCT03176186|NO_INTERVENTION|TH/TTM|Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
62685135|NCT03016702|EXPERIMENTAL|High Risk Alzheimer's Disease|This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.
62685136|NCT03016702|EXPERIMENTAL|Low Risk Alzheimer Disease|This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.
62685137|NCT06289062|EXPERIMENTAL|NACI in FIGO ⅠB1 Cervical Cancer|Neoadjuvant chemotherapy plus camrelizumab for ⅠB1 Cervical Cancer. Patients first received one cycle of platinum-based doublet priming chemotherapy. After 3 weeks, participants subsequently received two cycles of the PD-1 inhibitor camrelizumab combined with chemotherapy every 3 weeks. The study will be conducted in two stages: (1) Patients enrolled in the first stage with tumors ≤2 cm and no new lesions after completion of treatment will undergo cone biopsy + pelvic lymphadenectomy or SLN mapping. Those who meet ConCerv criteria will undergo a second TCT, human papillomavirus (HPV) and colposcope 3 months later, and those who do not meet ConCerV criteria will undergo radical cervical surgery. (2) Patients enrolled in the second stage with tumors ≤2 cm and no new lesions underwent cervical biopsy + pelvic lymphadenectomy or SLN mapping; patients with LSIL on biopsy underwent TCT, HPV, and colposcope 3 months later; if biopsy suggests HSIL and above, perform cone biopsy.
62685138|NCT06658067|EXPERIMENTAL|Poorly Controlled Type 2 Diabetes- CGM|Participants will have CGM sensor placed at first visit and will be worn for 12 weeks. Sensor must be scanned 3 times daily. Adjustments to medication regimen will be recommended at 6 weeks. Follow-up appointments will be at 12 weeks and 24 weeks.
62685139|NCT05985174|EXPERIMENTAL|cases|"Neonates of both sexes included in this study with any suspected case of neonatal sepsis with maternal risk factors , e.g., prolonged labor , premature rupture of membrane (PROM) , maternal intrapartum fever and chorioamnionitis , and neonates with sepsis-related clinical signs :temparature instability , apnea , need for supplemental oxygen , bradycardia , tachycardia , hypotension , hypo~perfusion , feeding intolerance , and abdominal distension ."
62685140|NCT06690723|ACTIVE_COMPARATOR|Lifestyle modification|Participants are taught about lifestyle modification including diet and exercise
62685141|NCT06690723|ACTIVE_COMPARATOR|Vitamin D3 (Cholecalciferol)|Participants are given vitamin D3 for 16 weeks on top of lifestyle modification advice
62685142|NCT06690723|ACTIVE_COMPARATOR|Dapagliflozin (Forxiga)|Participants are given Dapagliflozin 10mg daily for 16 weeks on top of lifestyle modification advice
62314607|NCT03176186|ACTIVE_COMPARATOR|TH/TTM plus Xenon|50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
62314608|NCT05636085||Eligible subjects|Subjects ≥45 years of age and at average risk of colorectal cancer.
62314609|NCT02404831|ACTIVE_COMPARATOR|Traditional hospital-based PR|Class based pulmonary rehabilitation
62685143|NCT06690723|ACTIVE_COMPARATOR|Vitamin D3 plus Dapagliflozin|Participants are given vitamin D3 plus Dapagliflozin 10mg daily for 16 weeks on top of lifestyle modification advice
62685144|NCT01916226|EXPERIMENTAL|FPNS arm|Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
62685145|NCT01916226|PLACEBO_COMPARATOR|FPNS Placebo arm|Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
62685146|NCT01916226|EXPERIMENTAL|Cetirizine arm|Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
62685147|NCT01916226|PLACEBO_COMPARATOR|Cetirizine Placebo arm|Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
62685148|NCT01885338|EXPERIMENTAL|N-acetylcysteine (NAC)|Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
62685149|NCT01885338|PLACEBO_COMPARATOR|Inactive placebo capsule|A placebo capsule is used that is identical to the active treatment but lacks NAC. The inactive ingredients in the placebo capsule are cellulose, L-leucine, and silica. Dose is 2 capsules by mouth twice daily for 8 weeks.
62314610|NCT02404831|EXPERIMENTAL|Web-based PR|web-based pulmonary rehab
62314611|NCT02232646|EXPERIMENTAL|BBI503|
62314612|NCT00184054|EXPERIMENTAL|Arsenic Trioxide (ATO) Plus Ascorbic acid|"Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period.~Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given"
62314613|NCT02251223|EXPERIMENTAL|TPV/r low dose|
62314614|NCT02251223|EXPERIMENTAL|TPV/r medium dose|
62314615|NCT02251223|EXPERIMENTAL|TPV/r high dose|
62314616|NCT00098345|EXPERIMENTAL|Caprelsa (vandetanib) 300 mg|Daily oral dose of Caprelsa (vandetanib) 300mg
62314617|NCT00974337||Shock|"Preterm VLBW infants with shock (BP \<3rd centile for gestation and birth weight with at least one of the following:~1. Prolonged capillary refill time (\>3sec)~2. Reduced urine output (\<1 mL/kg/hr)~3. Metabolic acidosis (Base deficit \>5)"
62314618|NCT00974337||No shock|Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
62478503|NCT06272266|ACTIVE_COMPARATOR|COVID-19 group|This group included 32 people aged 18-55 who had previously had COVID-19. Individuals' physical activity levels were measured with the IPAQ short form. Peripheral muscle strength (quadriceps muscle strength, triceps strength, hand grip strength) was measured. The exercise capacities of the individuals were evaluated with a standard exercise tolerance test using a bicycle ergometer. At the end of the test, Borg Scale, test duration, maximum heart rate, maximum work (W) and MET values were recorded. VO2peak levels and VO2peak prediction values were calculated. CPET was applied to 14 people in this group. At the end of the test, the individual's Respiratory Exchange Rate, Anaerobic Threshold, VO2peak, VO2AT (Maximum Oxygen Capacity at Respiratory Anaerobic Threshold), Carbon Dioxide Ventilation Equivalent, heart rate recovery, heart rate recovery in the 1st minute were measured. Aerobic exercise training was given to 14 people in this group. measurements were repeated.
62478504|NCT06272266|ACTIVE_COMPARATOR|control group|This group included 32 people aged 18-55 who had not previously had COVID-19. The physical activity levels of the individuals were measured with the IPAQ short form. Peripheral muscle strength (quadriceps muscle strength, triceps strength, hand grip strength) was measured. The exercise capacities of the individuals were evaluated with a standard exercise tolerance test using a bicycle ergometer. At the end of the test, Borg Scale, test duration, maximum heart rate, maximum work (W) and MET values were recorded. VO2peak levels and VO2peak prediction values were calculated. CPET was applied to 15 people in this group. At the end of the test, the individual's Respiratory Change Rate, Anaerobic Threshold, VO2peak, VO2AT (Maximum Oxygen Capacity at Respiratory Anaerobic Threshold), Carbon Dioxide Ventilation Equivalent, heart rate recovery, Heart rate recovery at 1 minute was measured.
62478505|NCT05041075|ACTIVE_COMPARATOR|WB:UC|Weighted Blanket 2nd infusion Usual Care 3rd infusion
62478506|NCT05041075|ACTIVE_COMPARATOR|UC:WB|Usual Care 2nd infusion Weighted Blanket 3rd infusion
62478507|NCT01610245|ACTIVE_COMPARATOR|Nitazoxanide|Two Nitazoxanide 300 mg tablets and one placebo capsule twice daily with food for 5 days
62478508|NCT01610245|ACTIVE_COMPARATOR|Oseltamivir|Two placebo tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
62478509|NCT01610245|ACTIVE_COMPARATOR|Nitazoxanide and Oseltamivir|Two nitazoxanide 300 mg tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
62478510|NCT01610245|PLACEBO_COMPARATOR|Placebo|Two placebo tablets and one placebo capsule with food twice daily for 5 days
62478511|NCT00418561|EXPERIMENTAL|Cohort 1|Metazym (Recombinant human arylsulfatase A (rhASA)): 25 U/kg as a single dose - hereafter 50 U/kg
62478512|NCT00418561|EXPERIMENTAL|Cohort 2|100 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
62478513|NCT00418561|EXPERIMENTAL|Cohort 3|200 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
62478514|NCT05357235||Treatment intervention group|NA (TDF or TAF) combined with PEG-IFN was used. PEG-IFN was injected subcutaneously once a week and a personalized course of 24 weeks was used.
62124700|NCT03009994|OTHER|Exteriorization group|After delivery of the fetus and placenta, the surgeon bring uterus yet out from peritoneal cavity by manual handling of the uterus uterus from fundus and extracted out of the abdominal cavity before starting to close it. After repair of the uterus , uterus returned to abdominal cavity and repair anterior abdominal wall as following.
62685150|NCT04420182|OTHER|COVID-19 Virtual Care at Home|"VIRTUES COVID-19 Care at Home Platform~The components of the platform will include:~1. Vital sign monitoring, including O2 saturation with a home-based pulse oximeter, temperature and respiratory rate performed three times per day (a notification to do this will be sent from the app), with the option of doing assessments more frequently if needed. Study patients will be provided monitoring devices to collect this data.~2. Symptom logs will be entered by the patients.~3. Feedback to the patient by the local COVID-19 care team for any action:~   1. Two-way communication between the patient and the COVID-19 care team~  2. Ability for team members to see all prior notes in order to have continuity of care~  3. Reports of these interactions are transmitted to the patient's health record~4. Current information on COVID-19 as per the Public Health Agency of Canada"
62685151|NCT03151603|EXPERIMENTAL|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)~and~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
62685152|NCT03151603|ACTIVE_COMPARATOR|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),~and~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
62685153|NCT00306098|EXPERIMENTAL|Islet transplantation|Subjects receiving intraportal Islet cell infusion (transplant)
62685154|NCT01046994|EXPERIMENTAL|surgery|biliopancreatic diversion
62478515|NCT05357235||Non therapeutic intervention observation group|patients do not receive treatment and are observed and followed up regularly.
62685155|NCT01046994|ACTIVE_COMPARATOR|standard medical care|patients treated according to the rules of good clinical practice
62685156|NCT00004856|EXPERIMENTAL|Treatment: Herceptin|Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
62124701|NCT03009994|OTHER|Non exteriorization group|Uterine incision will be repaired intra abdominally
62124702|NCT01903798|ACTIVE_COMPARATOR|Prednisolone (Lille <0.45)|At Day 8, after randomization, this participants will continue prednisolone 40 mg/day (current standard of care) for 21 days.
62314619|NCT01900275||Septic shock or major trauma|Patients admitted within 24 hours to ICU for septic shock or major trauma (ISS \> 15). Septic shock is defined by sepsis with hypotension requiring \>4 hours of vasopressor support over previous 24 hours.
62478516|NCT06560099|ACTIVE_COMPARATOR|Group A (standard oxytocin dose)|
62478517|NCT06560099|ACTIVE_COMPARATOR|Group B (high dose oxytocin)|
62478518|NCT02984098|EXPERIMENTAL|Dextrose gel 40%|before heel lance, 2 ml oral dextrose gel 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
62314620|NCT06070233|SHAM_COMPARATOR|Sham Treatment|No intervention but can crossover after 6 months
62314621|NCT06070233|ACTIVE_COMPARATOR|SRS Treatment|
62314622|NCT04798417|EXPERIMENTAL|Probiotic|
62124703|NCT01903798|EXPERIMENTAL|Prednisolone, rilonacept (Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive rilonacept (Arcalyst®) once a week for 21 days. After randomization at Day 8, study participants will be given 320 mg subcutaneously (two injections of 2.0 ml, 160 mg each). On Day 15 and Day 22, study participants will be given 160 mg subcutaneously (one injection of 160 mg).
62124704|NCT01903798|ACTIVE_COMPARATOR|Prednisolone (Lille >0.45)|Prednisolone (40 mg/day) for the first 7 days, after randomization at Day 8, they will stop all therapy.
62124705|NCT01903798|EXPERIMENTAL|Prednisolone, mycophenolate(Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days. After randomization at Day 8, they will receive CellCept® at a dose of 1000 mg per day for the first four days followed by 2000 mg per day (two 500 mg tablets bid) for the remaining 17 days.
62124706|NCT05836285||Medium risk patients undergoing surgery|Patients undergoing surgery designated as medium risk using NSQIP risk scores
62124707|NCT04831190|EXPERIMENTAL|Intervention|All participants will be involved in a tailored exercise intervention for 12 weeks.
62124708|NCT01869543|EXPERIMENTAL|Stand Alone Air Cleaner-True/Sham|The participant will have stand alone air cleaners placed in their home. They will have true filtration followed by sham filtration.
62124709|NCT01869543|EXPERIMENTAL|Stand Alone Air Cleaner-Sham/True|Participants will have stand alone air cleaners placed in their homes. They will begin with sham filtration.
62314623|NCT04798417|EXPERIMENTAL|Prebiotic|
62124710|NCT01869543|EXPERIMENTAL|HVAC modification-True/Sham|Participants will have their HVAC system modified to include high efficiency filtration. They will begin true filtration followed by sham filtration.
62124711|NCT01869543|EXPERIMENTAL|HVAC Modification-Sham/True|Participants will have their HVAC system modified to include high efficiency filtration. They will begin sham filtration.
62124712|NCT03039361|EXPERIMENTAL|Equine Assisted Psychotherapy|6 week Equine Assisted Psychotherapy program
62124713|NCT03039361|NO_INTERVENTION|Control|Standard of Care, Existing PTSD therapy
62314624|NCT04798417|PLACEBO_COMPARATOR|Maltodextrin|
62314625|NCT02556879|OTHER|Liver retransplantation|"* Donor specific antibodies :Additional samples for Donor specific at each visit~* Serum bank : Additional samples for serum bank at each visit if possible~* DNA banq : Additional sample for DNA banq at inclusion visit if possible~* Liver biopsy :Liver biopsy at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)~* Liver ultrasounds and Fibroscan : Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)"
62478519|NCT02984098|ACTIVE_COMPARATOR|Dextrose gel 25%|before heel lance, 2ml oral dextrose gel 25% was administered, and pain related intensity was evaluated with premature infant pain profile scale
62685157|NCT00124657|EXPERIMENTAL|Patients with High-Grade/Low-Grade Glioma|Patients with newly diagnosed high-grade glioma (excluding those originating in the brain stem) and unfavorable low-grade glioma who are ≥ 3 years and \<26 years of age. Patients receiving enzyme-inducing anticonvulsants (EIACs) are not eligible for this study. Patients with spinal cord tumors will be eligible for the Phase I and Phase II component of this study, but they will not be taken into consideration to estimate PFS in the Phase II component of this trial because of their notoriously worse prognosis. Patients receive erlotinib hydrochloride.
62685158|NCT06089746|EXPERIMENTAL|Feasibility|Patients with LSS will receive DME and training to support continuous maintenance of flexion posture during the 6 week trial. All participants will be asked to wear actigraphs and pedometers intermittently and to complete questionnaires and mobility assessments.
62685159|NCT05025605|EXPERIMENTAL|80 Micrograms|Sublingual film containing 80 micrograms Dexmedetomidine
62685160|NCT05025605|EXPERIMENTAL|120 Micrograms|Sublingual film containing 120 micrograms Dexmedetomidine
62685161|NCT05025605|PLACEBO_COMPARATOR|Placebo|Sublingual Placebo film
62685162|NCT05025605|EXPERIMENTAL|60 Micrograms|Sublingual film containing 60 micrograms Dexmedetomidine Europe Only
62124714|NCT00851396||Obese female adolescents|Obese adolescents will be screened for vitamin D deficiency through an existing study. Those found to be vitamin D deficient will be given standard treatment of vitamin D deficiency. In this study, patients who self report that they had taken the treatment for vitamin D will be screened for serum 25 OH D level and will undergo OGTT. The OGTT results as well as insulin resistance indices will be compared to their initial values.
62124715|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
62124716|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
62124717|NCT01841437||iStent|
62124718|NCT03428958|EXPERIMENTAL|NUC-3373 + leucovorin (LV) every other week|Arm 1a: NUC-3373 administered IV followed by a 2-week washout period. The next dose of NUC-3373 administered in combination with LV at 400 mg/m2. All subsequent doses of NUC-3373 administered in combination with LV every 2 weeks in 28-day cycles.
62124719|NCT03428958|EXPERIMENTAL|NUC-3373 every other week|Arm 1b: LV 400 mg/m2 administered IV over 2 hours prior to NUC-3373 infusion followed by a 2-week washout period. Then, NUC-3373 administered IV every 2 weeks without LV in 28-day cycles.
62124720|NCT03428958|EXPERIMENTAL|NUC-3373 + leucovorin (LV) weekly|Arm 1c: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV weekly on Days 1, 8, 15 and 22 of 28-day cycles.
62124721|NCT03428958|EXPERIMENTAL|NUC-3373 + leucovorin (LV); combination chemotherapy ineligible|Arm 1d: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV on Days 1, 8, 15 and 22 of 28-day cycles.
62478520|NCT01701063|EXPERIMENTAL|Treatment-Naive or Prior Partial/Null Response|telaprevir + Peginterferon alfa-2b + Ribavirin
61924043|NCT05892861|EXPERIMENTAL|multi domain dietary education as cognitive stimulation|video lifestyle education, board game, and 24-hour dietary recall record from 1st week to 10th week as cognitive stimulation.
62685163|NCT05917964|EXPERIMENTAL|Cohort A (fasted-fed)|Cohort A was administered once in Cycle 1 Day1 under fasted condition and once in Cycle 2 Day1 (i.e., Day8 after Cycle 1 administration) under fed condition for a total of 2 doses.
62685164|NCT05917964|EXPERIMENTAL|Cohort B (fed-fasted)|Cohort B was administered once in Cycle 1 Day 1 under fed condition and once in Cycle 2 Day 1 (i.e., D8 after Cycle 1 administration) under fasted conditions for a total of 2 doses.
62685165|NCT04988490||Daily cannabis users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report daily cannabis use
62685166|NCT04988490||Cannabis non-users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report no cannabis use
61924044|NCT05892861|EXPERIMENTAL|usual clinical treatment|usual treatment in clinic
62314626|NCT04624633|EXPERIMENTAL|Cohort 1-Relapsed Disease|"Participants with relapsed disease~* Treatment with Acalabrutinib \& Umbralisib beginning C1D1,~* Ublituximab beginning C7D1~* Assessment of treatment response~* Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
62685167|NCT05992740|ACTIVE_COMPARATOR|bronchial wash group|the patients will undergo bronchoscope then pre-biopsy bronchial wash, biopsy, post-biopsy bronchial wash will be obtained
62314627|NCT04624633|EXPERIMENTAL|Cohort 2-Treatment Naive|"Participants with previously untreated disease~* Treatment with Acalabrutinib \& Umbralisib beginning C1D1,~* Ublituximab beginning C7D1~* Assessment of treatment response~* Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
62314628|NCT06619990|ACTIVE_COMPARATOR|Part A: Active drug|Active XmAb942 to be administered to healthy volunteers (SAD). Participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered once via either subcutaneous injection or intravenous infusion. Each dose cohort will have 8 participants receiving the dose as a subcutaneous injection, and 8 participants receiving the dose as an IV infusion. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. After a safety evaluation period of the dose without clinically significant adverse events (AEs) then 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule. A Safety Review Committee (SRC) will review data prior to escalation to the next dose level.
62685168|NCT05992740|ACTIVE_COMPARATOR|bronchial brush|the patients will undergo bronchoscope then pre-biopsy bronchial brush, biopsy, post-biopsy bronchial brush will be obtained
62685169|NCT00801255|EXPERIMENTAL|Cohort A|
62685170|NCT00801255|EXPERIMENTAL|Cohort B|
62685171|NCT00801255|EXPERIMENTAL|Cohort C|
62685172|NCT00801255|EXPERIMENTAL|Cohort D|
62685173|NCT00801255|EXPERIMENTAL|Cohort E|
62685174|NCT00801255|EXPERIMENTAL|Cohort F|
62124722|NCT03428958|EXPERIMENTAL|NUC-3373 + oxaliplatin weekly|Arm 2a: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
62685175|NCT00801255|EXPERIMENTAL|Cohort G|
62685176|NCT00324857|PLACEBO_COMPARATOR|Arm 1/Attention Control|Subjects randomized to the attention control arm received a patient educational booklet about OA published by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This booklet provides a brief educational program that summarizes how to live with knee OA but does not specifically mention joint replacement
62685177|NCT00324857|ACTIVE_COMPARATOR|Arm 2/Decision Aid (DA)|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
62685178|NCT00324857|ACTIVE_COMPARATOR|Arm 3/ Motivational Interview (MI)|Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain
62685179|NCT00324857|ACTIVE_COMPARATOR|Arm 4/ DA and MI|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.~Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain"
62685180|NCT04431284||Obese patients with binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae \>= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
61924045|NCT04561427||Pediatric Patients with narcolepsy|"* Patients between 0 and 18 years old~* Patients diagnosed with primary or secondary narcolepsy~* From both gender"
62124723|NCT03428958|EXPERIMENTAL|NUC-3373 + irinotecan weekly|Arm 2b: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
61924046|NCT04522908|EXPERIMENTAL|Cabozantinib - Single Arm|Single Arm with Cabozantinib starting dose 40 mg for 4 weeks and dose escalation to 60 mg afterwards.
62314629|NCT06619990|PLACEBO_COMPARATOR|Part A: Placebo|Placebo Comparator to be administered to healthy volunteers (SAD). Participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered once via either subcutaneous injection or intravenous infusion. Each dose cohort will have 8 participants receiving the dose as a subcutaneous injection, and 8 participants receiving the dose as an IV infusion. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. After a safety evaluation period of the dose without clinically significant adverse events (AEs) then 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule. A Safety Review Committee (SRC) will review data prior to escalation to the next dose level.
62124724|NCT03428958|EXPERIMENTAL|NUC-3373 + oxaliplatin (NUFOX) expansion|Arm 2c: At the completion of Arm 2a, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
62124725|NCT03428958|EXPERIMENTAL|NUC-3373 + irinotecan (NUFIRI) expansion|Arm 2d: At the completion of Arm 2b, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
62314630|NCT06619990|ACTIVE_COMPARATOR|Part B: Active|Active XmAb942 to be administered to healthy volunteers. Participants will be randomized in a 3:1 ratio to active or placebo. Determination of route of administration will be performed by SRC prior to initiation of Part B. Each dose cohort will have 8 participants receiving the dose as a subcutaneous infusion, and 8 participants receiving the dose as an IV infusion. The SRC may review data for determination of the next dose cohort.
62685181|NCT04431284||Obese patients without binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae \>= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
62685182|NCT02783963|OTHER|MI with nonobstructive CAD at coronary angiography|MI with nonobstructive CAD investigated by means of OCT and CMR
62124726|NCT03428958|EXPERIMENTAL|NUFOX + bevacizumab weekly|Arm 3a: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2a will be combined with bevacizumab. NUC-3373+LV will be administered weekly, oxaliplatin and bevacizumab will be administered every other week.
62124727|NCT03428958|EXPERIMENTAL|NUFOX + bevacizumab every other week|Arm 3b: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2a will be combined with bevacizumab. NUC-3373+LV+oxaliplatin+bevacizumab will be administered every other week.
62124728|NCT03428958|EXPERIMENTAL|NUFIRI + bevacizumab weekly|Arm 3c: NUC-3373, LV and irinotecan at dose levels used in Arm 2b will be combined with bevacizumab. NUC-3373+LV will be administered weekly, irinotecan and bevacizumab will be administered every other week.
62124729|NCT03428958|EXPERIMENTAL|NUFIRI + bevacizumab every other week|Arm 3d: NUC-3373, LV and irinotecan at dose levels used in Arm 2b will be combined with bevacizumab. NUC-3373+LV+irinotecan+bevacizumab will be administered every other week.
62124730|NCT03428958|EXPERIMENTAL|NUC-3373 + LV + bevacizumab; maintenance patients|Arm 3e: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with bevacizumab (administered every other week).
62685183|NCT06402474||sunbed position|30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
62685184|NCT06402474||control|30° reverse trendelenburg
62685185|NCT06687499|EXPERIMENTAL|Bismuth-based susceptibility-guided treatment|Participants who have triple- or quadruple-drug resistant H. pylori infection are enrolled. Participants receive one of the four regimens based on susceptibility test.
62685186|NCT06674343|EXPERIMENTAL|Furmonertinib|Furmonertinib 160mg, once daily, orally
62685187|NCT02011529|ACTIVE_COMPARATOR|TEAMcare treatment of diabetes|
62685188|NCT02011529|NO_INTERVENTION|Treatment as usual|Participants randomized to treatment as usual will receive their usual mental health treatment and primary care treatment
62685189|NCT01830465|EXPERIMENTAL|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
62685190|NCT06689410|OTHER|ICA cases|Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and/or cerebral arteriography
62685191|NCT01755754|EXPERIMENTAL|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
62685192|NCT01755754|EXPERIMENTAL|Female Condom|This trial will test the performance of female condoms when used concurrently with a placebo vaginal ring
62124731|NCT03428958|EXPERIMENTAL|NUFOX + cetuximab|Arm 3f: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2a may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or every other week, oxaliplatin will be administered every other week and cetuximab will be administered weekly.
62124732|NCT03428958|EXPERIMENTAL|NUFIRI + cetuximab|Arm 3g: NUC-3373, LV and irinotecan at dose levels used in Arm 2b may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or every other week, irinotecan will be administered every other week and cetuximab will be administered weekly.
62124733|NCT00095667|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
62124734|NCT02906735||Study group|Patients with knee surgery undergo plantar foot pressure measurement pre- and postoperatively
62124735|NCT04189744|PLACEBO_COMPARATOR|IPTp-SP plus MTZ placebo (control)|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and metronidazole placebo administered as directly observed therapy.
62124736|NCT04189744|ACTIVE_COMPARATOR|IPTp-SP plus MTZ|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and 4 tablets each containing 500mg metronidazole administered as directly observed therapy .
62124737|NCT04189744|ACTIVE_COMPARATOR|IPTp-DP plus MTZ|3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine, first dose and will be administered as directly observed therapy with the remaining two doses on the next two consecutive days at home. 4 tablets each containing 500mg metronidazole administered as directly observed therapy.
62124738|NCT02834598|EXPERIMENTAL|Rocking movement|Participant is lying in a hammock with a rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
62314631|NCT06619990|PLACEBO_COMPARATOR|Part B: Placebo|"Placebo Comparator to be administered to healthy volunteers. Participants will be randomized in a 3:1 ratio to active or placebo. Determination of route of administration will be performed by SRC prior to initiation of Part B.~Each dose cohort will have 8 participants receiving the dose as a subcutaneous infusion, and 8 participants receiving the dose as an IV infusion. The SRC may review data for determination of the next dose cohort."
62314632|NCT06619990|ACTIVE_COMPARATOR|Part C: Active|Active XmAb942 to be administered to participants with Ulcerative Colitis. The SRC will provide recommendations on the doses in Part C based on emerging Part A and/or Part B data.
62314633|NCT06619990|PLACEBO_COMPARATOR|Part C: placebo|Placebo Comparator to be administered to participants with Ulcerative Colitis. The SRC will provide recommendations on the doses, frequency and route of administration to be assessed in Part C based on emerging Part A and/or Part B data
62314634|NCT04373980|ACTIVE_COMPARATOR|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
62314635|NCT04373980|ACTIVE_COMPARATOR|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
62314636|NCT04373980|NO_INTERVENTION|Control group|
62314637|NCT05227274||MFM-Play|Neuromuscular disease patients completed MFM using MFM-Play
61924047|NCT04707352|EXPERIMENTAL|Dapagliflozin|The baseline procedures will be performed on the same day of screening or within the next five working days. All the baseline procedures will be performed on the same day. The baseline procedures include biobank, clinical assessment and echocardiogram, on the same day. In the following 24 hours, the patient will initiate Dapagliflozin at the recommended dose of 10 mg daily during 6 months. Temporary discontinuation may be considered at investigator criteria as in cases of symptomatic hypotension or acute declines in renal function and after discarding other potential causes.
61924048|NCT05039827|EXPERIMENTAL|MWM GROUP|Mobilization with movement with wrist extension
61924049|NCT05039827|ACTIVE_COMPARATOR|SOFT TISSUE MOBILIZATION GROUP|Parallel and perpendicular soft tissue massage at common extensor origin
61924050|NCT04172662|EXPERIMENTAL|Music therapy group|Receive Music therapy in addition to standard treatment
62124739|NCT02834598|ACTIVE_COMPARATOR|Lying position|Participant is lying in a hammock with no rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
62124740|NCT02834598|ACTIVE_COMPARATOR|Seated position|Participant is sitting on a chair. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
62124741|NCT02617368||KC group|KC group included patients those were diagnosed and classified for moderate keratoconus according to the Amsler-Krumeich classification system
62124742|NCT02617368||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
62124743|NCT02617368||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
62124744|NCT04329793|EXPERIMENTAL|Intervention arm|Assisted gait training with Walkbot System and their usual Physical Therapy.
62314638|NCT00091390|EXPERIMENTAL|External Beam Radiotherapy and High Dose brachytherapy boost|
62124745|NCT04329793|ACTIVE_COMPARATOR|Control arm|Their usual Physical Therapy.
62314639|NCT05359627|EXPERIMENTAL|Arm 1|normal renal function group
62314640|NCT05359627|EXPERIMENTAL|Arm 2|mild renal insufficiency group
62314641|NCT05359627|EXPERIMENTAL|Arm 3|long-term IHD group
62314642|NCT03465475||Group 1|The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
62124746|NCT02751138||Isocitrate dehydrogenase - 1 mutated|Immunophenotype of Glioblastoma and correlation with outcome
62124747|NCT02751138||Isocitrate dehydrogenase - 1 wild type|Immunophenotype of Glioblastoma and correlation with outcome
62685193|NCT06143423|EXPERIMENTAL|AP026 (TQA2226) for injection Single administration dose (SAD)|AP026 (TQA2226) for injection, administered once.
62124748|NCT03663504|ACTIVE_COMPARATOR|No Preparation|No preparation before surgery
62314643|NCT03465475||Group 2|The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
62314644|NCT03465475||Group 3|The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia
62314645|NCT04618861||Control Group|"This cohort involved the volunteers who had no known acute, subacute or chronic disease history, who did not suffer from any infection in the last fortnight, who were not on a particular medication, who presented to the ED with reasons other than infectious complaints, and who gave their written consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
62685194|NCT06143423|PLACEBO_COMPARATOR|AP026 (TQA2226) for injection matching placebo Single administration dose (SAD)|AP026 (TQA2226) for injection matching placebo, administered once.
62685195|NCT06143423|EXPERIMENTAL|AP026 (TQA2226) for injection Multiple administration dose (MAD)|AP026 (TQA2226) for injection, administered 4 times.
62124749|NCT03663504|ACTIVE_COMPARATOR|Oral Antibiotics|Oral antibiotics (neomycin and flagyl), to be taken the day before the surgery
62124750|NCT01281163|EXPERIMENTAL|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD on days 1 and 15-28 of course 1 and on days 1-28 of subsequent courses. Patients also receive AKT inhibitor MK2206 PO QD on days 8, 15, and 22 of course 1 and on days 1, 8, 15, and 22 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62124751|NCT04944407|EXPERIMENTAL|LHP GROUP|patients recieved minimal invasive LHP procedure with diode laser
62124752|NCT04944407|ACTIVE_COMPARATOR|MM GROUP|patients received conventional MM hemorroidectomy
62124753|NCT04627493|NO_INTERVENTION|Waitlist (Control)|Usual care
62124754|NCT04627493|EXPERIMENTAL|Exercise|Online exercise program
62124755|NCT01149395|EXPERIMENTAL|Dexlansoprazole|
62124756|NCT00130117|EXPERIMENTAL|r-metHuLeptin|r-metHuLeptin administered subcutaneously.
62124757|NCT00130117|PLACEBO_COMPARATOR|Oral Contraceptive Pills (OCPs)|PLACEBO
62124758|NCT02797717|OTHER|"A-COPDAC-28"|"standard COPDAC-28 (chemotherapy cycle:Cyclophosphamide,Doxorubicin,Prednisone,Dacarbazine), chemotherapy and standard involved node radiotherapy.~drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15. Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3. Vincristine 15mg/m2 , I.V. , day1+day 8. Cyclophosphamide 500mg/m2,infusion,day 1+day 8."
62685196|NCT06143423|PLACEBO_COMPARATOR|AP026 (TQA2226) for injection matching placebo Multiple administration dose (MAD)|AP026 (TQA2226) for injection matching placebo, administered 4 times.
62685197|NCT05460169|ACTIVE_COMPARATOR|Immediate Renal Denervation Group (I-RDN-group)|Patients are randomized into (immediate) I-RDN-group and (delayed) D-RDN-group, respectively. All subjects in the I-RDN-group will undergo a diagnostic, renal angiogram immediately (based on clinical grounds to rule out renal artery stenosis), which should be per Institutional practice via femoral artery access. Renal Denervation procedure will be applied using the Paradise® Renal Denervation System. The Paradise® Renal Denervation System is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
62124759|NCT02797717|EXPERIMENTAL|"B- DECOPDAC-21"|"DECOPDAC-21(chemotherapy cycle:Dacarbazine,Etoposide,Doxorubicin,Cyclophosphamide,Prednisone,Vincristine) intensified chemotherapy and no RT or restricted fields of radiotherapy.~Drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15:~Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3 Vincristine 15mg/m2 , I.V. , day1+day 8 Cyclophosphamide 625mg/m2,infusion,day1+day2 Etoposide 100mg/m2/day,infusion,day 1- day 3 Doxorubicin 25mg/m2, infusion, day 1"
62124760|NCT03809312|ACTIVE_COMPARATOR|Clavulin group with polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
62124761|NCT03809312|PLACEBO_COMPARATOR|Placebo group with polyps|Group who will receive placebo after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
62124762|NCT03809312|ACTIVE_COMPARATOR|Clavulin group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
62124763|NCT03809312|PLACEBO_COMPARATOR|Placebo group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
62124764|NCT02692417|EXPERIMENTAL|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
62685198|NCT05460169|OTHER|Delayed Renal Denervation Group (D-RDN-group)|3 months after randomization, patients in the (delayed) D-RDN-group will undergo renal denervation procedure after undergoing a diagnostic, renal angiogram and will be followed for additional 36 months.
62685199|NCT05091450|EXPERIMENTAL|Couple-based I-BMS intervention for infertility|The I-BMS intervention will be conducted face-to-face and in group format. It comprises four 3-hour sessions within one month. Two registered social workers who are professionally trained on I-BMS intervention model will deliver the intervention.
62124765|NCT02692417|EXPERIMENTAL|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
62124766|NCT01830738|EXPERIMENTAL|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.~Intervention: Single-port, peri-umbilical hysterectomy"
61924051|NCT04172662|NO_INTERVENTION|Control group|Receive standard treatment
61924052|NCT05346432|EXPERIMENTAL|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
62124767|NCT01830738|ACTIVE_COMPARATOR|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.~Intervention: Multi-port hysterectomy"
62124768|NCT02365766|EXPERIMENTAL|Arm A - Phase 1b Dose Finding Cohort:|Cisplatin-eligible subjects will receive pembrolizumab at starting dose of 200mg (dose level 0), and/or 120mg (dose level -1) in combination with gemcitabine and cisplatin. The MTD will be the highest pembrolizumab dose level in combination with gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Once the MTD is established, this portion of the study will close and the phase II will open to cohorts I and II at the recommended phase II dose (RP2D).
62124769|NCT02365766|EXPERIMENTAL|Arm B - Phase II Cohort I:|Cisplatin-eligible subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days) . Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. Note: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
62124770|NCT02365766|EXPERIMENTAL|Arm C - Phase II Cohort II:|Cisplatin-ineligible subjects receive gemcitabine every week every 28 days for 3 cycles. Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every 3-week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
62124771|NCT00583817|EXPERIMENTAL|Ascending Aortic Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the ascending aorta.
62124772|NCT00583817|EXPERIMENTAL|Arch Branch Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the aortic arch.
62124773|NCT00583817|EXPERIMENTAL|Thoracoabdominal Aortic Arm|Investigational endovascular stent-graft implantation to exclude thoracoabdominal aortic pathology including aortic aneurysms, renal artery aneurysms, and superior mesenteric artery aneurysms.
62124774|NCT02317965||Pregnant Women|"Pregnant women who are scheduled to undergo an amniocentesis or chorionic villus sampling (CVS) procedure~Intervention: Single Maternal blood draw of 20mL"
62124775|NCT01471145|EXPERIMENTAL|Depot Naltrexone|
62685200|NCT05091450|OTHER|Waitlist control|Couples allocated in the waitlist control group will begin the I-BMS intervention (same as the intervention group) after completing the 1-month follow-up assessment.
62314646|NCT04618861||CT (+), PCR (-) Covid-19 Suspected Pneumonia Group|"This group consisted of patients who applied to the emergency department with symptoms of Covid-19, whose thorax CT according to RSNAEC criteria showed typical Covid-19 pneumonia findings, but whose RT-PCR test was negative in the swab sample taken in the emergency room.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
62314647|NCT04618861||CT (+), Covid-19 Pneumonia Group|"This cohort consisted of the patients (a) who applied to the emergency department with SARS-CoV-2 symptoms and was diagnosed with SARS-CoV-2 infection according to WHO guideline (13) (b) whose CT imagings were compatible with SARS-CoV-2 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria (14), (c) whose nasopharyngeal swab samples taken in the ED were positive for RT-PCR, and (d) who gave their informed consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
62478521|NCT03745963|EXPERIMENTAL|Skin-to-skin contact|"Infants will be placed in full ventral skin-to-skin with their mother at least fifteen minutes prior to heel lance to allow time to settle and recover following transfer. Positioning will be determined based on individual maternal preference in order to optimize comfort as well as facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Skin to skin contact will continue until the procedure is completed.~In addition, infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) during SSC. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
62478522|NCT03745963|ACTIVE_COMPARATOR|24% Oral sucrose|"Infants will be placed in a cot or in an incubator, depending on their gestational age, for the duration of the blood collection. Administration of 0.12mls (0.04mls per drop) of 24 percent oral sucrose will occur two minutes prior to the heel lance.~The infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
62478523|NCT03919435|EXPERIMENTAL|On Drug|
62478524|NCT02785887|EXPERIMENTAL|Oncological and geriatrician review|Routine oncological care plus geriatric intervention
62478525|NCT02785887|NO_INTERVENTION|Oncological care|Routine oncological care only
62478526|NCT02917525|EXPERIMENTAL|Vitamin K2|22 patients will receive 360ug Vitamin K2 daily during 18 months.
62685201|NCT01608308|EXPERIMENTAL|IV Acetaminophen|The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
62124776|NCT03106142|OTHER|Academic detailing visit arm|The GPs will receive an academic detailing visit by a medical visitor. GPs will receive information on the conservative evidence-based management of knee osteoarthritis with physiotherapy. The information will be summarized on a flyer for the GPs.
62124777|NCT03106142|NO_INTERVENTION|control group|The two case vignettes will also be presented to GP who did not received the intervention.
62124778|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
62478527|NCT02917525|PLACEBO_COMPARATOR|Placebo|22 patients will receive placebo during 18 months.
62478528|NCT06560814|EXPERIMENTAL|Cabergoline|Tab Cabergoline 0.5 mg twice weekly for 24 weeks, plus timed intercourse
62478529|NCT06560814|ACTIVE_COMPARATOR|Dydrogesterone|tab Dydrogesterone( 10 mg) twice daily from day 5 to day 25 of menstrual cycle for 24 weeks, plus timed intercourse
62478530|NCT05464394|EXPERIMENTAL|Tranexamic acid|1500mg Tranexamic acid
62478531|NCT05464394|PLACEBO_COMPARATOR|Placebo|sodium chloride
62478532|NCT06166277||Control group|Awaiting the intervention, medically managed patients will remain in the control group for analysis purposes
62478533|NCT06166277||Procedural group|After undergoing successful radiofrequency cardioneuroablation or permanent pacemaker procedures the patient will cross-over to the procedural group for analysis purposes
62478534|NCT00942968|EXPERIMENTAL|1|
62478535|NCT03469843||Patients|patients with transposition of the great arteries long after repair with the arterial switch operation
62478536|NCT01090687||Group I Microcalcifications|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary findings based on microcalcifications will be recruited to have a breast CT scan.
61924053|NCT05346432|EXPERIMENTAL|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
62124779|NCT03635151|EXPERIMENTAL|TASK III Group|The Telephone Assessment and Skill-Building Kit (TASK III) group
62124780|NCT03635151|ACTIVE_COMPARATOR|ISR Group|The Information, Support, and Referral (ISR) group
62124781|NCT02133404|EXPERIMENTAL|ASP7991 group|receiving ASP7991 and Cinacalcet-placebo
62124782|NCT02133404|ACTIVE_COMPARATOR|Cinacalcet group|receiving Cinacalcet and ASP7991-placebo
62124783|NCT05167877||Control group|Participants without CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices.
62124784|NCT05167877||Active group|Participants with CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices. Self-reported measures of pain and type of activity for 7 days using electronic dairy.
62124785|NCT04989387|EXPERIMENTAL|Treatment Group A Dose Escalation and Expansion|INCA00186 will be administered as monotherapy every 2 or every 4 weeks.
62314648|NCT04618861||CT (-), PCR (+) Covid-19 infection group|"This cohort included the patients (a) who presented to the Covid-19 outpatient polyclinic of the ED with pneumonia symptoms, (b) whose CT imaging's were compatible with Covid-19 pneumonia in accordance with the RSNAEC criteria and whose PCR tests were positive, (c) whose SARS-CoV-2 PCR tests were positive as a result of contact tracing, and (d) who presented to the ED for further examination.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
62314649|NCT00806780|NO_INTERVENTION|1|routine surgery with cholangiography
62685202|NCT01608308|PLACEBO_COMPARATOR|Control|The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
61924054|NCT05346432|PLACEBO_COMPARATOR|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
61924055|NCT04213521|EXPERIMENTAL|Multisensory balance training group|The participants in the multisensory balance training group were provided with multiple-sensory balance exercises using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system-postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
61924056|NCT04213521|ACTIVE_COMPARATOR|Conventional balance training group|The participants in the Conventional balance training group performed conventional balance exercises, such as static and dynamic standing balance without altered sensory inputs.
62124786|NCT04989387|EXPERIMENTAL|Treatment Group B1 Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab. INCA00186 will be administered every 2 or 4 weeks and retifanlimab will be administered every 4 weeks.
62124787|NCT04989387|EXPERIMENTAL|Treatment Group B2 Dose Escalation and Expansion|INCA00186 will be administered in combination with INCB106385. INCA00186 will be administered every 2 or 4 weeks and INCB106385 will be administered once or twice daily.
62124788|NCT04989387|EXPERIMENTAL|Treatment Group C Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab and INCB106385. INCA00186 will be administered every 2 to 4 weeks, retifanlimab every 4 weeks and INCB106385 once or twice daily.
62124789|NCT01116635|EXPERIMENTAL|50mg dose loading per vial of doxorubicin|
62124790|NCT01116635|EXPERIMENTAL|75mg dose loading per vial of doxorubicin|
62124791|NCT02525796|PLACEBO_COMPARATOR|Placebo + Cinacalcet|Patients with primary hyperparathyroidism will receive placebo for 4 weeks followed by the addition of cinacalcet for 2 weeks
62314650|NCT00806780|EXPERIMENTAL|2|routine cholangiography
62314651|NCT03494803||Control|
62314652|NCT03494803||Prostate Cancer|
62314653|NCT04874038|EXPERIMENTAL|Intervention|Intraoperative intravenous lidocaine/placebo infusion
62478537|NCT01090687||Group II Soft tissue findings|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary soft tissue findings, with or without associated microcalcifications, will be recruited to have a breast CT scan.
62685203|NCT05077111|EXPERIMENTAL|Group A|sole Thoracic Epidural Anesthesia
62685204|NCT05077111|ACTIVE_COMPARATOR|Group B|General Anesthesia with One Lung Ventilation
62685205|NCT00337454|EXPERIMENTAL|A1|
62685206|NCT00337454|EXPERIMENTAL|A2|
62685207|NCT00337454|EXPERIMENTAL|A3|
62124792|NCT02525796|ACTIVE_COMPARATOR|Amiloride + Cinacalcet|Patients with primary hyperparathyroidism will receive amiloride for 4 weeks followed by the addition of cinacalcet for 2 weeks
62124793|NCT02525796|EXPERIMENTAL|Eplerenone + Cinacalcet|Patients with primary hyperparathyroidism will receive eplerenone for 4 weeks followed by the addition of cinacalcet for 2 weeks
62124794|NCT04450199|ACTIVE_COMPARATOR|Vitamin D|12 over encapsulated 50,000 IU Vitamin D2
62124795|NCT04450199|PLACEBO_COMPARATOR|Placebo|12 over encapsulated placebo tablets
62124796|NCT01653834|EXPERIMENTAL|Lymphocyte harvesting & reinfusion|Patients with a newly diagnosed high grade glioma (Grade III or IV), have a post-operative treatment plan that includes standard radiation and temozolomide, and have normal bone marrow function with Hematocrit ≥ 30%, platelet ≥ 100K, ANC ≥ 1000, and absolute lymphocyte count ≥ 1000 prior entry to this study are eligible for enrollment.
62124797|NCT03119558|EXPERIMENTAL|18F-Florbetaben (Neuraceq®) PET/MRI|Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F-Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45-60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.
62124798|NCT05537155|EXPERIMENTAL|Buccal acupuncture|Buccal acupuncture will be performed in addition to routine care.
62124799|NCT05537155|ACTIVE_COMPARATOR|Routine care|Routine care will be provided.
62314654|NCT04874038|PLACEBO_COMPARATOR|Control|Intraoperative intravenous lidocaine/placebo infusion
62685208|NCT00337454|EXPERIMENTAL|B1|
62685209|NCT00337454|EXPERIMENTAL|B2|
62685210|NCT00337454|EXPERIMENTAL|B3|
62685211|NCT04130971||Patients without neoadjuvant treatment|
62685212|NCT04130971||Patients with short course radiotherapy|
62685213|NCT04130971||Patients with long course chemoradiotherapy|
62685214|NCT04130971||Patients with short course radiotherapy and deferred surgery|
62685215|NCT06643663|EXPERIMENTAL|Pt with apicomarginal defects & interproximal bone loss receiving GTR|Surgery performed using ACM membrane and PRF plug.
62685216|NCT06643663|ACTIVE_COMPARATOR|Pt with apicomarginal defects & interproximal bone loss without GTR|Surgery performed without ACM membrane and PRF plug.
62685217|NCT05875610|EXPERIMENTAL|Venlafaxine Arm|Patients receiving Taxanes (Docetaxel or Paclitaxel) or Oxaliplatin containing regimens.
62685218|NCT05875610|ACTIVE_COMPARATOR|Gabapentin Arm|Patients receiving Taxanes (Docetaxel or Paclitaxel) or Oxaliplatin containing regimens.
62314655|NCT04792996||Gilbert´s Syndrome|Subjects with mild hyperbilirubinaemia and a plasma level of unconjugated bilirubin of 17.1 µmol.
62314656|NCT04792996||Control group|Healthy controls with lower plasma level of unconjugated bilirubin of 17.1 µmol, aen and gender matched.
62124800|NCT02951013|EXPERIMENTAL|restrictive group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 6g/dL, with a target hemoglobin range of 7.5-8.0g/dL.
62314657|NCT02008240|EXPERIMENTAL|Needle aspiration of hydrosalpinx|Aspiration of hydrosalpingeal fluid under ultrasound guidance
62314658|NCT02008240|ACTIVE_COMPARATOR|salpingectomy|Surgical removal of hydrosalpinx
62314659|NCT01969175|EXPERIMENTAL|Intervention Diet|
62478538|NCT03734718|ACTIVE_COMPARATOR|Glucose-Dependent Insulinotropic Polypeptide|6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide
62697391|NCT03132987|EXPERIMENTAL|Progressive strengthening program|Subjects identified as having a clinically relevant strength deficit will be asked to participate in physical therapy sessions 3 times per week for 3 weeks. The strengthening program will consist of an individualized, progressive exercise program with an emphasis on increasing lower extremity strength, power, and biomechanics.
61924057|NCT05471700|EXPERIMENTAL|Azacitidine combined with Venetoclax|"Each course is 28 days long. Subjects with newly diagnosed AML receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. If concomitantly receiving azoles, the dose of Venetoclax will be adjusted according to the instructions. At the same time patients will receive Azacitidine 75mg/m2 subcutaneous on Days 1-7.The induction therapy includes 1-2 cycle until subjects get remission.~Once complete remission, subjects will receive consolidation. Azacitidine combined with Venetoclax or middle to high dose of arabinoside based chemotherapy would be given at the discretion of the physician."
62124801|NCT02951013|ACTIVE_COMPARATOR|liberal group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 8g/dL, with a target hemoglobin range of 9.5-10.0g/dL.
62124802|NCT00542789|PLACEBO_COMPARATOR|1|Placebo
62124803|NCT00542789|EXPERIMENTAL|2|Esomeprazole 20 mg
62314660|NCT01969175|PLACEBO_COMPARATOR|Control|
62697392|NCT01598155|EXPERIMENTAL|Supragingival biofilm control|
62124804|NCT00869258|EXPERIMENTAL|GTX and Radiation Therapy with Gemzar|"Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine:~A cycle of chemotherapy is made up of 21 days. During each cycle patients will take Xeloda® twice a day for 14 days followed by a rest period of 7 days. On day 4 and 11 (+/- 2 days) of each 21-day cycle patients will also receive Gemzar and Taxotere.~Weekly Radiation Therapy with Low-Dose Gemzar Chemotherapy:~After completing a total of 3 cycles of GTX chemotherapy each patient will receive 5 weeks of standard radiation therapy in combination with low-dose Gemzar chemotherapy."
62124805|NCT02152813|ACTIVE_COMPARATOR|1. Bilateral TENS (Bi-TENS) group|Subjects having bilateral electrical stimulation and task-orientated exercises
62124806|NCT02152813|PLACEBO_COMPARATOR|Unilateral TENS (Uni-TENS) group|Subjects having unilateral TENS over their affected lower limb only, and task-oriented exercises
62314661|NCT05868642|EXPERIMENTAL|T group|Subaracnhoid block levobupivacaine 0.5%, 10 mg (2 ml) via subarachnoid injection plus 1mg for each metameric level needed to achieve the T10 level sensory block (evaluation with pinprick test at 10 minute after the firts injection and at 4 minute from the second injection)
62314662|NCT05868642|ACTIVE_COMPARATOR|S group|levobupivacaine 0.5%, 15 mg (3 ml) via subarachnoid injection
62314663|NCT03138850|EXPERIMENTAL|Olympus standard bite block|Standard of care using standard bite block and nasal cannula
62314664|NCT03138850|EXPERIMENTAL|YX Mandibular advancement bite block|Mandibular advancement bite block group
62124807|NCT00009217|ACTIVE_COMPARATOR|Haloperidol-Haloperidol|Haloperidol for 20 weeks followed by haloperidol for 24 weeks
62314665|NCT03138850|EXPERIMENTAL|Optiflow High flow nasal cannula|High flow nasal cannula group
62314666|NCT05829577|EXPERIMENTAL|Executive function treatment|Patient will receive Individual DLS and SI/SP training combined with EF strategies
62314667|NCT05829577|ACTIVE_COMPARATOR|Treatment as usual|patient will receive Individual DLS and SI/SP training.
62314668|NCT06673303|EXPERIMENTAL|Dynamic perceptual discrimination task|The task featured two task conditions, each of which required the integration of information from both stimulus dimensions. In each condition, participants viewed a stimulus containing motion and color information and were required to specify one of two possible responses. Within each condition, rules and the response mapping changed occasionally, but always by changing on a fixed feature dimension (ie. rightward/purple, leftward/orange). These uncued intra-dimensional shifts involved translational shifts in the learning boundary, requiring them to adapt their decision making within a familiar dimension. These shifts compelled participants to continuously adjust their learning strategies by focusing on the most relevant feature dimension.
62314669|NCT06048016|EXPERIMENTAL|periodontitis patients|Periodontitis Patients participate to test level of ALP in saliva and GCF.
62314670|NCT06663046|EXPERIMENTAL|Off-the-shelf REVO-UWD-00B|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning, followed by a one-time injection of universal UWD-00B cells
62314671|NCT00389077|EXPERIMENTAL|Perifosine Daily Dose|Daily dose perifosine 50 mg.
62314672|NCT00389077|EXPERIMENTAL|Perifosine Twice Daily Dose|Twice daily dose perifosine 50 mg.
62314673|NCT02563873|NO_INTERVENTION|Standard pacemaker settings|Standard pacemaker settings will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange
62314674|NCT02563873|EXPERIMENTAL|Tailored pacemaker settings|The pacemaker settings will be altered to match optimal heart rate range with respect to cardiac contractility, as determined by echocardiography. This will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange.
62314675|NCT00898053||Correlative studies|Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
62478539|NCT03734718|PLACEBO_COMPARATOR|Placebo|Saline
62478540|NCT02056691|EXPERIMENTAL|Exercise programme|Exercise programme Muscle biopsies
62478541|NCT01842750|EXPERIMENTAL|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
62685219|NCT02446288|ACTIVE_COMPARATOR|TMJ Next Generation|The TMJ NextGeneration device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
62685220|NCT02446288|ACTIVE_COMPARATOR|DSG Relaxer|The occlusal splint to be used in this study will be the DSG Relaxer™. The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
62685221|NCT02292355|EXPERIMENTAL|Pilates|Intervention group will undergo Pilates sessions in addition to conventional treatment with occlusal splint
62685222|NCT02292355|NO_INTERVENTION|Occlusal splint|Control group who receive conventional treatment with occlusal splint
62685223|NCT03903341|OTHER|idiopathic blepharospasm (BSP) de novo|bold signal in visual pathway
62685224|NCT03903341|OTHER|Healthy subjects|bold signal in visual pathway
62685225|NCT03418363|ACTIVE_COMPARATOR|DHEA Oral Capsule|Subjects will take 100mg DHEA (dehydroepiandrosterone) daily
62685226|NCT03418363|PLACEBO_COMPARATOR|Placebo Oral Capsule|
62124808|NCT00009217|PLACEBO_COMPARATOR|Haloperidol-Placebo|Haloperidol for 20 weeks followed by placebo for 24 weeks
62124809|NCT02860286|EXPERIMENTAL|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
62124810|NCT04920812||Mitochondrial diseases|annalysing with methology of multi-OMICS integration we will determined which RNA-Seq data (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy.
62124811|NCT02449863||Low risk ultrasound|Patients with a low risk ultrasound
62124812|NCT02449863||High risk ultrasound|Patients with a high risk ultrasound
62124813|NCT02378337||Retrospective development cohort|A total of 85 18F-FDG-PET adult studies were gathered over a 3-month period and retrospectively evaluated.
62124814|NCT02378337||Prospective validation cohort|To verify the application of methodology in clinical routine, we conducted a second phase of the study prospectively in 250 subjects (phase 2) using inclusion and exclusion criteria of the retrospective study (phase 1).
62124815|NCT05591040|EXPERIMENTAL|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
62124816|NCT05591040|ACTIVE_COMPARATOR|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
62124817|NCT01981837|EXPERIMENTAL|ALN-TTRSC (revusiran)|
62124818|NCT05188118|EXPERIMENTAL|Patients with metastatic or unresectable clear cell renal cell carcinoma|Patients with metastatic or unresectable clear cell renal cell carcinoma to receive same sequential treatment strategy. (Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x4 over 12 weeks, then subsequent therapies depending on treatment response for another 12 weeks \[Nivolumab for CR/PR/SD, Cabozantinib or Lenvatinib/Everolimus for PROG\]).
62124819|NCT02889016||PANS group|500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
62124820|NCT02889016||Health Controls|100 healthy children age- and gender- matched to the PANS group will be recruited
62124821|NCT02378597|ACTIVE_COMPARATOR|Delayed Intervention: Control|Delayed intervention: Control was a a behavioral treatment for resiliency delivered in a single 4 hour session delivered in a delayed fashion (waitlist control)
62124822|NCT02378597|EXPERIMENTAL|Experimental: Intervention|Experimental: Intervention was a 4 hour behavioral resiliency intervention.
62124823|NCT02304952|ACTIVE_COMPARATOR|Eccentric exercise|Conservative treatment with eccentric exercise as self-training
62124824|NCT02304952|ACTIVE_COMPARATOR|Radiofrequency microtenotomy|A minimally invasive surgery (Topaz) and eccentric exercise as postoperative treatment
62124825|NCT00910767|EXPERIMENTAL|Closed loop (algorithm)|
62124826|NCT00910767|PLACEBO_COMPARATOR|Open loop|
62124827|NCT03349762||Observational 1|Radiotherapy or Chemotherapy
62124828|NCT03349762||Observational 2|Huaier Granule \& Radiotherapy or chemotherapy
62124829|NCT03349762||Observational 3|Huaier Granules
62124830|NCT02615769|EXPERIMENTAL|Invitation with focused information of spirometry|
62124831|NCT02615769|ACTIVE_COMPARATOR|Standard invitition|
62124832|NCT03737591||Healthy individuals|Healthy individuals
62124833|NCT03737591||Patients with Colorectal cancer|Stage I-IV colorectal cancer patients
62124834|NCT03737591||Patients with Colorectal Adenomas|Patients with Colorectal Adenomas
62314676|NCT04453267||Patient Arm.|"Consecutive patients undergoing elective percutaneous coronary intervention (PCI) or isolated coronary artery bypass grafting (CABG) for symptomatic stable angina (SA) despite optimal medical therapy at the University Hospital Southampton NHS Foundation Trust will be prospectively enrolled (n=86).~No interventions administered. 40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
62314677|NCT04453267||Age and gender matched controls|"Age and gender-matched patients being investigated for chest pain with unobstructed coronary arteries, defined as coronary stenosis ≤ 30% in any major epicardial vessel on CT or invasive coronary angiography, will also be recruited as controls (n=86).~40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
62685227|NCT03301415|EXPERIMENTAL|Confirmed congenital CMV without baseline SNHL|Valganciclovir 16 mg/kg/dose orally twice daily for four months, n=229
62124835|NCT04643340||active group 1|This group will train the insular cortex by real-time fMRI
62124836|NCT04643340||active group 2|This group will train the visual cortex by real-time fMRI
62124837|NCT04643340||sham|This group will only train the insula by a particular strategy
62124838|NCT01731041|EXPERIMENTAL|Ticagrelor 180mg|Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
62124839|NCT01731041|ACTIVE_COMPARATOR|Ticagrelor 90mg|Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).
62124840|NCT00668863|EXPERIMENTAL|1|
62124841|NCT06677073|EXPERIMENTAL|HIIT group|
62124842|NCT06677073|EXPERIMENTAL|FATmax group|
62124843|NCT04181255|EXPERIMENTAL|Curosurf|
62124844|NCT04181255|PLACEBO_COMPARATOR|Sham (air)|
62124845|NCT06105333||NIRS Group|Preterm neonates less than 32 weeks gestation were randomly assigned to standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
62124846|NCT06105333||Standard Care Group|Preterm neonates less than 32 weeks gestation were randomly assigned to standard care (control-group) with routine monitoring during immediate transition (first 15 minutes after birth) and resuscitation.
62124847|NCT02190578|EXPERIMENTAL|Diagnostic: Reveal G4|Subjects tested with investigational devices and approved comparator assay algorithms for HIV
62124848|NCT01047852|EXPERIMENTAL|NIV|
62124849|NCT01047852|NO_INTERVENTION|Control|
62124850|NCT04056039|ACTIVE_COMPARATOR|"Atorvastatin"|"-Changes of troponin I in rheumatoid arthritis with atorvastatin 40 mg orally every 24 hours for four weeks"
62314678|NCT05308485||Parkinson´s disease individuals|
62314679|NCT05308485||Individuals with recent-onset parkinsonism|
62314680|NCT05308485||Healthy individuals|
62314681|NCT01359826|EXPERIMENTAL|Milnacipran|Patients administered milnacipran will receive a dose escalation to 50 mg twice a day over 12 days and continued at this dose until week 6. If tolerated and a 15% improvement in fatigue from baseline is achieved by assessment on the FSS, then patients will continue taking 50 mg twice a day until the end of the study on day 98 (week 14). Otherwise, the dose of milnacipran will be titrated upward to 100 mg twice a day over 12 days and continued at this dose until day 98 (week 14).
62314682|NCT01359826|PLACEBO_COMPARATOR|Placebo|Placebo tablets administered orally twice a day for 14 weeks.
62478542|NCT03701594|EXPERIMENTAL|Yoga-based physical therapy group|The yoga-based physical therapy session will take place in an enclosed, quiet space to minimize outside noise or distraction. The lights will be dimmed, and light, instrumental, calming music will be played throughout. The group will consist of approximately 2-5 individuals depending on the physical capabilities and assistance levels required. The session will consist of an introduction to pranayama (foundational breath-based exercises) followed by asanas, or physical postures, that will be modified according to each individual's physical abilities. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
62478543|NCT03701594|ACTIVE_COMPARATOR|Seated rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
62697393|NCT01598155|EXPERIMENTAL|Supra- and subgingival biofilm control|
62124851|NCT04056039|ACTIVE_COMPARATOR|"Colchicine"|"Changes of troponin I in rheumatoid arthritis with colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks"
62124852|NCT01332058|EXPERIMENTAL|Motivational Interviewing (MI)|
62124853|NCT05028959|EXPERIMENTAL|Female athletes|highly trained subjects
62124854|NCT05028959|EXPERIMENTAL|Leisure sport women|recreational sportswomen practicing regular physical activity
62124855|NCT02398617|OTHER|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
62124856|NCT04117789|EXPERIMENTAL|Therapist-guided ICBT for depression|"Participants will receive internet-delivered CBT with therapist support. The treatment consists of 8 online chapters with interactive features as videos and illustrations, delivered over a maximum of 10 weeks. The treatment has the main focus on behavioral activation.~The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The parent program also consists of eight chapters, including psychoeducation about depression and how to support their adolescent in treatment.~The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support."
61924058|NCT05189457|EXPERIMENTAL|First Strike then Second Strike|"The first part of the study treatment or first strike involves 12-18 weeks of combined therapy with LHRH analog and one of the new hormonal agents (NHAs). Participants will complete the first strike at week 13 if their PSA has reduced \>90%; otherwise they will complete a total of 18 weeks of therapy. The second part of the treatment or second strike involves 4 cycles docetaxel and LHRH analog. The second strike will start immediately after the first strike. MRI guided prostate biopsy will be performed after second strike. For patients with positive prostate biopsy or detectable PSA, the second strike will be consolidated with 4-6 additional cycles of docetaxel plus 6 doses of tislelizumab at 200 mg, given IV once every 3 weeks. For patients with undetectable PSA at year 3 from study enrollment, LHRH analog can be discontinued."
62478544|NCT03701594|ACTIVE_COMPARATOR|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
61924059|NCT04885231|EXPERIMENTAL|Opioid-Limiting Perioperative Pain Management Education and Counseling|"Patients will be instructed to take oxycodone only as a last resort if the pain becomes unbearable. The goal should be to take as little oxycodone as possible."
61924060|NCT04885231|ACTIVE_COMPARATOR|Traditional Perioperative Pain Management Education and Counseling|"Patients will be instructed to take opioids as needed for severe pain to manage and stay ahead of the postoperative pain"
61924061|NCT00571376||1|Those exposed to health information technology or health information exchange
61924062|NCT00571376||2|Those not exposed to health information technology or health information exchange
62124857|NCT04117789|EXPERIMENTAL|Self-guided ICBT for depression|The self-guided ICBT for depression is identical to the therapist-guided ICBT intervention, however without the therapist support. To ensure patient-safety, there will be clear instructions to the patients and primary caregivers how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
62478545|NCT06626555|EXPERIMENTAL|Letermovir|Letermovir 480mg PO once daily
62339621|NCT02277899||Overweight school-age children|"Overweight 6-12 year-old children. Weight status will be measured and parents complete surveys at baseline and one year later. Pediatricians will complete surveys at baseline, and after index visit. Visits will be directly video-recorded.~The impact of pediatrician clinical practices and communication strategies on child's weight status will be evaluated at one year. Clinical practices (such as risk-factor screening) that occur during the 1-year interval between well-child visits also will be assessed. Specific clinical practice elements and communication strategies that will be examined include:~1. Communication regarding child's high weight status~2. Counseling regarding cardiovascular risk factor screening and assessment~3. Behavioral counseling~4. Interval follow-up to readdress weight, and~5. Patient-centeredness, scored as the ratio of patient to doctor-centered communication regarding weight topics."
61924063|NCT05162040||Experimental Group|Twenty participants joined the experimental group (15 males and 5 females, mean aged=61.10; SD=12.62) and provided written informed consent to be enrolled onto the study. Participants with neurological pathologies were diagnosed with (6) ischemic strokes, (1) hemorrhagic stroke, (1) thalamic stroke, (1) internal capsule stroke (3) traumatic brain injury (TBI), (1) Parkinson syndrome, (1) mixed axonal neuropathy with sensory demyelination, (1) progressive multifocal leukoencephalopathy, (1) secondary obstructive hydrocephalus, (1) angioma avernosus hemorrhage, (1) hemiprotuberancial hemorrhage - cavernoma, (1) ataxia and (1) cerebral artery aneurysm.
61924064|NCT04314310|ACTIVE_COMPARATOR|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
61924065|NCT04314310|PLACEBO_COMPARATOR|placebo|equal volume of normal saline
61924066|NCT04496310|EXPERIMENTAL|Telemedicine|"Baseline: in office clinical assessment of all patients (collection of seizure diary).~Followup: scheduled 6-month consultations through a telemedicine device providing remote outcome assessment, counselling and follow-up. If required, on call video consultations available by contacting a provider through telemedicine, 3-hr/week."
62478546|NCT06626555|NO_INTERVENTION|Standard of Care|Standard of care - No intervention
62478547|NCT00905528||A|Subjects with type 2 diabetes mellitus, eGFR \> 80, hypertension, no overt proteinuria
61924067|NCT04496310|NO_INTERVENTION|Usual care|"Baseline: in office clinical assessment of all patients (collection of seizure diary).~Followup: scheduled 6-month in-office consultations with outcome assessment, counselling and follow-up. On-call consultations are possible if needed by the patient, by contacting a clinician through an in-office phone call, 3-hr/week."
61924068|NCT04862286|EXPERIMENTAL|Risankizumab|Participants will receive risankizumab subcutaneous (SC) injection every 12 weeks for 204 weeks.
62124858|NCT04117789|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both. The content of TAU and the treatment techniques used, will be monitored.
62124859|NCT04476472|EXPERIMENTAL|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
62124860|NCT02379299|ACTIVE_COMPARATOR|Single-hormone closed-loop control|Closed-loop glucose control by use of insulin only by use of DiaCon single-hormone closed-loop glucose control algorithm
62339622|NCT01692353||Exclusive cigarette smokers (SMK)|Subject's usual brand (UB) of cigarettes
62339623|NCT01692353||Exclusive moist snuff consumers (MSC)|Subject's usual brand (UB) of moist snuff
62339624|NCT01692353||Non-tobacco consumers (NTC)|No use of tobacco or nicotine-containing products of any kind
62124861|NCT02379299|EXPERIMENTAL|Dual-hormone closed-loop control|Closed-loop glucose control by use of insulin and glucagon by use of DiaCon dual-hormone closed-loop glucose control algorithm
62339625|NCT05689138||PCA|pancreatic cancer patients
62339626|NCT05689138||NC|normal control
61924069|NCT06709274|EXPERIMENTAL|MRD-guided management|Patients who are MRD-positive after surgery in the MRD-guided management group receive adjuvant therapy. Patients who are MRD-negative in the MRD-guided management group are monitored through observation.
61924070|NCT06709274|NO_INTERVENTION|Standard of care|Adjuvant therapy is not recommended. However, if the physician and patient decide on adjuvant therapy, the treatment regimen and cycle must be documented. Researchers are strongly advised to follow the medication guidelines laid out in the Chinese Society of Clinical Oncology (CSCO) Clinical Practice Guidelines.
61924071|NCT03480867|EXPERIMENTAL|Pre-operative RT and TMZ|* Single Arm: Pre-operative Radiation +Temozolomide followed by Surgery plus six cycles of Temozolomide
61924072|NCT02130726|EXPERIMENTAL|Minimally-invasive Gastrectomy|Patients allocated to the 'Minimally-invasive Gastrectomy' group will undergo minimally-invasive/laparoscopic total gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
62124862|NCT04692909|ACTIVE_COMPARATOR|Active|Active dTMS
62124863|NCT04692909|PLACEBO_COMPARATOR|Placebo|Placebo dTMS
62339627|NCT01989234|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Comparator
62339628|NCT01989234|EXPERIMENTAL|YKP10811 High Dose|YKP10811 High Dose
62478548|NCT00905528||B|Subjects with type 2 diabetes mellitus, eGFR \> 80, hypertension, no overt proteinuria
62685228|NCT06134999|EXPERIMENTAL|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62124864|NCT00262730|EXPERIMENTAL|Treatment Arm|"RT + TMZ 6wks, followed by~poly ICLC, temozolomide, radiation: radiation therapy"
62124865|NCT01257555||Treatment Group|
62124866|NCT03977935|NO_INTERVENTION|The first-generation MCCG group|"The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the 360-degree automatic scanning mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the small-bowel mode. The magnetic steering time for passing through the pylorus was not allowed more than 15 min."
62124867|NCT03977935|EXPERIMENTAL|The second-generation MCCG group|All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.
62124868|NCT01069471|EXPERIMENTAL|HHD O1-EPA plus adjuvant|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
62314683|NCT04630340|ACTIVE_COMPARATOR|STEADES-2 (Intervention) arm|"Subjects in the intervention arm will fill up the questionnaire embedded in the STEADES app and be inducted to the use of STEADES-2 device by the CRC. The CRC will assist to download the STEADES app into the subject's smartphone; demonstrate the use of the app and the procedure for the serious games; and linkage to the virtual coach. The subject will use the STEADES-2 device to assess their smoking status and play the game according to the stipulations in the protocol. The STEADES-2 app provides a portal for the subject to interact with the assigned virtual coach and for motivation messages to be delivered to them. The primary outcome is total smoking cessation as measured by~1. exhaled breath carbon monoxide using the STEADES-2 device and~2. urine cotinine level which indicates the nicotine from the cigarette smoking The secondary outcome is the score using the System Usability Scale (SUS) to assess the use and experience in using the STEADES-2 system"
62314684|NCT04630340|NO_INTERVENTION|Usual Care|"In the control arm, the subjects will be enrolled into the existing smoking cessation program at the respective polyclinic, which covers smoking cessation advice, together with an exhaled breath analyzed using a commercially available eCO measurement device by a trained nurse counsellor. They will complete a questionnaire and their smoking status will be re-assessed at 12 weeks after their enrolment. The primary outcome is total smoking cessation at the end of the study:~1. as measured by the exhaled breath carbon monoxide level determined by the STEADES-2 device and~2. urine cotinine levels which is a marker of nicotine level from smoking"
62314685|NCT05377905|EXPERIMENTAL|Microneedle Array Doxorubicin (MNA-D)|Immunocompetent and immuno-incompetent subjects will receive the MNA-D patch on 4 subsequent visits for a 20 minute time period at each application and will include patients who have competent immune systems with cSCC meeting all other inclusion/exclusion criteria and patients considered immuno-incompetent post transplant with cSCC meeting all other inclusion/exclusion criteria.
61924073|NCT02130726|ACTIVE_COMPARATOR|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive total resection of the stomach via laparotomy. This group is considered the control group
61924074|NCT01203527||Tamiflu use during first trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
62124869|NCT01069471|EXPERIMENTAL|HHD O1-EPA|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
62124870|NCT01069471|EXPERIMENTAL|LHD O1-EPA adjuvanted|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
62124871|NCT01069471|EXPERIMENTAL|LHD O1-EPA|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
62124872|NCT00638963|EXPERIMENTAL|Temozolomide|
62124873|NCT00638963|NO_INTERVENTION|Observational|
62314686|NCT02234115|EXPERIMENTAL|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
62314687|NCT05154214||Adenotonsillectomy|Excision of the palatine tonsils and excision or ablation of the adenoids by each individual surgeon's preferred techniques.
62685229|NCT06134999|PLACEBO_COMPARATOR|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
62124874|NCT05215925|EXPERIMENTAL|A|
62124875|NCT05215925|EXPERIMENTAL|B|
62124876|NCT05215925|EXPERIMENTAL|C|
62124877|NCT04951492|EXPERIMENTAL|Treatment (Olaparib)|Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62124878|NCT06554418|EXPERIMENTAL|Communities Care|Districts in two regions of Somalia randomized to Communities Care violence prevention program with adults and adolescents
62124879|NCT06554418|NO_INTERVENTION|Control|Districts in two regions of Somalia randomized to control - usual programming related to prevention of violence
62124880|NCT04231721||Healthy controls|
62124881|NCT05692024|ACTIVE_COMPARATOR|Coffee|Participants in the active arm will take 15 capsules of coffee, each of which will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend (equivalent daily dose: three cups of coffee). Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
62314688|NCT05154214||Drug-induced sleep endoscopy directed surgery (DISE)|DISE will be performed by the surgeon performing the surgical intervention. The DISE Rating Scale assesses the degree of maximal closure or obstruction at six locations in the upper airway: the nose, nasopharynx (adenoids), velopharynx (soft palate), oropharynx (tonsils), tongue base (tongue, lingual tonsils), and larynx (epiglottis, arytenoids). The degree of obstruction is scored on a 3-point rating scale as none (0), partial (+1), or complete (+2) at each anatomic site. The rating at each anatomic level can be summed into a DISE Rating Scale total. The actual surgery performed will determine which established surgical treatments will be used based on the results of the DISE.
62314689|NCT00632034|EXPERIMENTAL|1|
62314690|NCT03384511|EXPERIMENTAL|Apatinib & RGD PET/CT|All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
62314691|NCT00038194|EXPERIMENTAL|Imatinib + Docetaxel|
62314692|NCT04164212|OTHER|open label|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
62314693|NCT06672029|EXPERIMENTAL|Patients with adolescent idiopathic scoliosis|"All patients receive a combination of therapy including the three listed below:~* The pattern-specific manual therapy~* The Schroth Best Practice exercises~* The Gensingen brace application"
62314694|NCT06344520|EXPERIMENTAL|Pectoralis minor stretching exercise group|They observed the effects of shoulder stabilization exercises and pectoralis minor stretching exercises on balance and maximal shoulder strength in their study on healthy young people with rounded shoulder posture. Based on this, the pectoralis minor stretching exercise to be performed in swimmers not only corrects the maldeveloped posture in children, but also increases maximal shoulder muscle strength. It is aimed to increase swimming performance by contributing to the increase in swimming performance.Volunteer athletes who agreed to participate in the thesis were initially administered tests measuring balance, posture, motor control and swimming speed. After the tests, in addition to their own training, 3 pectoralis minor stretching exercises with a total duration of 15 minutes, as specified by Mi-Kyoung et al. (2018), were applied for 8 weeks, at least 2 times a week.
62314695|NCT06344520|SHAM_COMPARATOR|Group in which the sham Pectoralis Minor stretching exercise|Volunteer athletes who agreed to participate in the thesis were initially administered tests measuring balance, posture, motor control and swimming speed. After the tests, in addition to their own training, 3 sham pectoralis minor stretching exercises with a total duration of 15 minutes, were applied for 8 weeks, at least 2 times a week.
62314696|NCT06344520|ACTIVE_COMPARATOR|The group in which Pectoralis Minor stretching exercise was not applied|Volunteer athletes who agreed to participate in the thesis were initially administered tests measuring balance, posture, motor control and swimming speed. After the tests,They continued to do their own training
62478549|NCT00462345|EXPERIMENTAL|Rituximab, Methotrexate|Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
62478550|NCT05096663|ACTIVE_COMPARATOR|Arm A (standard of care)|Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62124882|NCT05692024|PLACEBO_COMPARATOR|Placebo|Participants in the placebo arm will take 15 capsules of placebo. Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances. Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
62124883|NCT03045354|EXPERIMENTAL|Mashed potatoes|Eggs with a side of mashed potatoes
62124884|NCT03045354|EXPERIMENTAL|French fries|Eggs with a side of French fries
62124885|NCT03045354|EXPERIMENTAL|Beans|Eggs with a side of beans
62124886|NCT03045354|EXPERIMENTAL|Traditional breakfast|Cereal, milk, toast and jam
62124887|NCT03045354|EXPERIMENTAL|Breakfast skipping|No breakfast
62124888|NCT03688906||Cohort A|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
62124889|NCT03688906||Cohort B|"Blood and stool specimen collection.~Samples must be collected prior to performing bowel preparation for the colonoscopy."
61924075|NCT01203527||Tamiflu use during second trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the second trimester of their pregnancy.
62124890|NCT03688906||Cohort C|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
62478551|NCT05096663|EXPERIMENTAL|Arm B (pembrolizumab, nogapendekin alfa)|Patients receive pembrolizumab IV over 30 minutes and nogapendekin alfa SC on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients then receive nogapendekin alfa SC on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62478552|NCT05174741|ACTIVE_COMPARATOR|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT \*3 sets/session\*TD Walk (10-15 minutes) \* BD
62478553|NCT05174741|EXPERIMENTAL|Aerobic Training group|"Supervised Conventional chest physiotherapy+ Aerobic training Conventional chest physiotherapy supervised (1st week) Then non supervised for 2nd to 6th week Warm-up (5 minutes) Breathing exercise and stepping Diaphragmatic Breathing exercise \*15 Reps\* TD~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day Cool down (5 minutes) AROM +Body stretch"
62314697|NCT00722540|EXPERIMENTAL|A|
62314698|NCT00722540|EXPERIMENTAL|B|
62314699|NCT00722540|EXPERIMENTAL|C|
62314700|NCT00722540|EXPERIMENTAL|D|
62478554|NCT05270135|OTHER|ASAP Intervention|This is a pilot study of the ASAP intervention pharmacies to explore the preliminary impact of intervention components: the CEU training, coaching from research staff, ASAP materials and tracking for the sale of syringes. Staff of each enrolled pharmacy will complete surveys.
62314701|NCT00722540|EXPERIMENTAL|E|
62314702|NCT04375631|EXPERIMENTAL|Arm I (CLAG-M, TBI, HCT, GVHD prophylaxis)|See detailed description.
62685230|NCT05652218|EXPERIMENTAL|Sequence 1|LB-CRT - Left Bundle Cardiac Resynchronization Therapy, Participants will spend 3 months in this group
62685231|NCT05652218|EXPERIMENTAL|Sequence 2|BiV-CRT - Biventricular Pacing Cardiac Resynchronization Therapy. Participants will spend 3 months in this group
62685232|NCT05839821||PD patients|Patients with Parkinson's disease
61924076|NCT01203527||Tamiflu use during third trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
62124891|NCT00636207|EXPERIMENTAL|Montelukast 0.1 mg|"Participants receive Montelukast inhalation powder, 0.1 mg.~* Part I: Administered as a single dose followed by at least a 3-day washout period."
62124892|NCT00636207|EXPERIMENTAL|Montelukast 0.3 mg|"Participants receive Montelukast inhalation powder, 0.3 mg.~* Part I: Administered as a single dose followed by at least a 3-day washout period."
62314703|NCT04375631|EXPERIMENTAL|Arm II (FLAG-Ida, TBI, HCT, GVHD prophylaxis)|See detailed description.
62314704|NCT06671886|EXPERIMENTAL|E-trigger|The NCCP Intervention is made up of multiple components. The investigators will start by applying the e-trigger and assessing the FIB-4 score, and then will train and educate PACT personnel on managing patients with positive triggers, including making treatment recommendations in collaboration with an inter-professional team. The e-trigger will be generated every three months.
62314705|NCT06671886|NO_INTERVENTION|Usual care|The control group will receive no additional training or education. PACTs will provide usual care.
62339629|NCT01989234|EXPERIMENTAL|YKP10811 Mid Dose|YKP10811 Mid Dose
62339630|NCT01989234|EXPERIMENTAL|YKP10811 Low Dose|YKP10811 Low Dose
62339631|NCT05268315|EXPERIMENTAL|Brief Psychoeducational Intervention|Parents of children with cancer who complete the study participate in a brief, 1-session psychoeducational intervention.
62478555|NCT06209983|EXPERIMENTAL|Arm E|"1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting."
62314706|NCT04103372|NO_INTERVENTION|Control Arm Schedule|All sites will begin in the Control arm, with patients recruited to the Control Arm Schedule. Clinical investigations prior to treatment, during treatment, after surgery and during further treatment should be performed as per standard clinical practice and as clinically indicated. Each site will transition to the Intervention arm at a month prescribed by their randomised cluster, and from that point patients are recruited to the Intervention Arm Schedule . Patients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point.
62314707|NCT04103372|EXPERIMENTAL|Intervention Arm Schedule|"Each site will transition to the Intervention arm at a month prescribed by their randomised cluster, and from that point patients are recruited to the Intervention Arm Schedule . The transition period lasts one month during which recruitment is halted and two interventions implemented:~1. MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.~2. Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.~Patients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point."
62314708|NCT02979067|ACTIVE_COMPARATOR|High-flow 100% oxygen|Nasal oxygen flow
62314709|NCT02979067|ACTIVE_COMPARATOR|Low-flow 100% oxygen|Nasal oxygen flow
62314710|NCT02979067|ACTIVE_COMPARATOR|High-flow 30% oxygen|Nasal oxygen flow
62314711|NCT03964415|EXPERIMENTAL|Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine|Participants will receive adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) via intramuscular (IM) injection into the deltoid muscle at months 0 (Day 1) and 3 (preferably the deltoid of the non-dominant upper arm) and, Ad26.Mos4.HIV together with Clade C and Mosaic gp140 HIV bivalent vaccine IM into the deltoid muscle at Months 6 and 12 (different deltoid for each injection).
62314712|NCT03964415|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive placebo into the deltoid muscle on Months 0 (Day 1), 3 (1 injection), 6 and 12 (2 injections).
62314713|NCT01804361|EXPERIMENTAL|Haporine-S|Moderate to severe dry patients administered with with Haporine-S
62478556|NCT06209983|PLACEBO_COMPARATOR|Arm H|"1. Preoperative preparation: overnight fasting preparation, bowel preparation.~2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters."
62478557|NCT00881634|EXPERIMENTAL|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
62478558|NCT00881634|ACTIVE_COMPARATOR|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
62478559|NCT02753179|EXPERIMENTAL|Bilateral vestibular hypofunction|Patients suffering from chronic bilateral vestibular hypofunction.
62478560|NCT02115165|EXPERIMENTAL|Cabazitaxel|
62478561|NCT03302780|EXPERIMENTAL|Sham tDCS and BreEStim|This arm includes a 20-min sham tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
62478562|NCT03302780|EXPERIMENTAL|active tDCS (M1) and BreEStim|This arm includes a 20-min active tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
62124893|NCT00636207|EXPERIMENTAL|Montelukast 1 mg|"Participants receive Montelukast inhalation powder, 1 mg.~* Part I: Administered as a single dose followed by at least a 3-day washout period.~* Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period."
62124894|NCT00636207|EXPERIMENTAL|Montelukast 3 mg|"Participants receive Montelukast inhalation powder, 3 mg.~* Part I: Administered as a single dose followed by at least a 3-day washout period.~* Part II: Administered QD for 5 days followed by at least a 3-day washout period.~* Part III: Administered QD for 10 days followed by at least a 7-day washout period."
62685233|NCT05839821||Healthy controls|Healthy older adults
62697394|NCT05838287|ACTIVE_COMPARATOR|Pioglitazone Administration Group|Pioglitazone 15mg/day titrated to 30 mg/day at week 2 and to 45 mg/day at week 4
62697395|NCT05838287|PLACEBO_COMPARATOR|Placebo/Control Group|Placebo
62314714|NCT01804361|ACTIVE_COMPARATOR|Restasis, Cyclosporine 0.05%|Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)
62314715|NCT05384054||Low Erythroferron group|The lower concentration group will be Group1.
62314716|NCT05384054||High Erythroferron group|The higher concentration group will be Group2.
62314717|NCT00619541|EXPERIMENTAL|A|"* 5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days~* Sorafenib 400 mg bid orally continuously~* 5-FU will be administered for a maximum of 12 cycles.~* Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease."
62314718|NCT05589181|ACTIVE_COMPARATOR|Buprenorphine Standard Dose|The standard arm will receive an induction dose of 12mg of buprenorphine (BUP) split as 8mg at time=0 and 4mg at time=30-60 min.
62314719|NCT05589181|EXPERIMENTAL|Buprenorphine High Dose|The experimental arm tests the safety and tolerability of 32mg of BUP split as 16mg at time=0 and 16mg at time=30-60 min as an induction dose.
62314720|NCT01955174|EXPERIMENTAL|Botulinum toxin injection|Esophageal endoscopic injection of botulinum toxin
62314721|NCT01955174|SHAM_COMPARATOR|No injection|No injection of botulinum toxin
62124895|NCT00636207|EXPERIMENTAL|Montelukast 10 mg|"Participants receive Montelukast inhalation powder, 10 mg.~* Part I: Administered as a single dose followed by at least a 3-day washout period.~* Part II: Administered QD for 5 days followed by at least a 3-day washout period.~* Part III: Administered QD for 10 days followed by at least a 7-day washout period."
62124896|NCT00636207|PLACEBO_COMPARATOR|Placebo|"Participants receive Placebo to Montelukast inhalation powder.~* Part I: Administered as a single dose followed by at least a 3-day washout period.~* Part II: Administered QD for 5 days followed by at least a 3-day washout period.~* Part III: Administered QD for 10 days followed by at least a 7-day washout period."
62478563|NCT03274492|EXPERIMENTAL|R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8.
62478564|NCT03274492|PLACEBO_COMPARATOR|R-CHOP plus Polatuzumab Vedotin Placebo|Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\^2 IV, cyclophosphamide 750 mg/m\^2 IV, doxorubicin 50 mg/m\^2 IV, and vincristine 1.4 mg/m\^2 IV (maximum 2 milligrams per dose \[mg/dose\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8.
62478565|NCT03292458|EXPERIMENTAL|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
62478566|NCT03292458|EXPERIMENTAL|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
62478567|NCT01056861||Cervical dystonia (torticollis)|Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
62314722|NCT01950936|EXPERIMENTAL|Procalcitonin-guidance|Discontinuation of Antibiotics. Procalcitonin is measured on day 1/2, day 3, day 5 and day 7 (all days where the patient is still admitted to hospital and antibiotics are discontinued, whenever Procalcitonin is \<0.15 ng/ml and dis-encouraged whenever Procalcitonin is \<0.25 ng/ml
62314723|NCT01950936|NO_INTERVENTION|Control - Standard of Care|Antibiotics are administered according to current guidelines
62478568|NCT01056861||Control|age matched controls with out cervical dystonia (torticollis)
62478569|NCT02835573||Sepsis-induced myocardial injury group|Patients admitted to the hospital with the diagnosis of Sepsis-induced myocardial injury
62478570|NCT02835573||Blank control group|Patients admitted to the hospital without the diagnosis of Sepsis-induced myocardial injury
62478571|NCT02599558|EXPERIMENTAL|Cytosponge-directed food reintroduction|Subjects will follow the six-food elimination diet per clinical protocol. The cytosponge will be used to monitor the diet at certain timepoints during food reintroduction
62124897|NCT05187780||Group 1|Adolescents with Idiopathic Scoliosis who have 10⁰-24⁰ Cobb angles
62124898|NCT05187780||Group 2|Adolescents with Idiopathic Scoliosis who have 25⁰-40⁰ Cobb angles
62124899|NCT05187780||Group 3|Healthy adolescents without scoliosis as controls
62124900|NCT03156595|PLACEBO_COMPARATOR|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
62124901|NCT03156595|EXPERIMENTAL|Hypnosis session|Hypnosis sessions with nurses or psychologists, with deepening sessions to facilitate self-hypnosis learning.
62124902|NCT01645423|EXPERIMENTAL|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
62124903|NCT01645423|ACTIVE_COMPARATOR|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
62314724|NCT03015272|EXPERIMENTAL|Auditory-Motor Mapping Training (AMMT)|Auditory-Motor Mapping Training (AMMT) is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention.
62314725|NCT03015272|ACTIVE_COMPARATOR|Speech-Repetition Therapy (SRT)|Speech-Repetition-Therapy (SRT) is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT
62478572|NCT04216329|EXPERIMENTAL|1/Experimental Therapy - Selinexor with Temozolomide and Radiation|Selinexor with temozolomide and radiation
62478573|NCT05191550|EXPERIMENTAL|Neurosurgeons, fellows, residents and medical students|Neurosurgeons (14), neurosurgical fellows and neurosurgical residents (24) from Montreal Neurological Institute and Hospital along with medical students (12) who are enrolled in first to fourth year of McGill medical school.
62478574|NCT01756326|EXPERIMENTAL|PREOB® Implantation|Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.
62124904|NCT02034903|NO_INTERVENTION|Standard warming|Feeding warmed in water bath
62124905|NCT02034903|EXPERIMENTAL|Commercial warmer|Feedings warmed with a commercial warmer
62124906|NCT03611205|EXPERIMENTAL|Diagnostic (dPET/CT)|Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.
62124907|NCT04981158|PLACEBO_COMPARATOR|control group, group I|standard general anesthetic (GA) technique
62124908|NCT04981158|ACTIVE_COMPARATOR|Epidural /GA using TET group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using tolerable endotracheal tube (TET)
62124909|NCT00011531|OTHER|1|
62124910|NCT05253664|EXPERIMENTAL|Woman-Centered Care Group|Woman-centered care was given to the experimental group. At the time of the study, 6 women were discharged early, 4 women did not want to continue the study, and the babies of 1 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 109 women in the experimental group.
62685234|NCT06372041|EXPERIMENTAL|Active tACS combined with the training|The tACS will be applied for the first 20 minutes of the training, every day of the treatment. Before and the after of the stimulation, SpO2 and HR will be checked. After the stimulation participants will be asked to rate the sensations and possible side effects occurring during tACS. The intensive bimanual training will be administered by following the procedure described in the Detailed Description session, as for the Sham tACS combined with the training arm.
62685235|NCT06372041|SHAM_COMPARATOR|Sham tACS combined with the training|The sham-tACS will be applied for the first 20 minutes of the training, every day of the treatment. However, in this condition, after the initial 30 seconds of ramp-up phase of the current, the stimulation will be switched off. This procedure allows participants to feel the characteristic tingling sensations in the vicinity of the electrodes for a brief period of time, which enhanced the plausibility of the sham condition.Before and the after of the stimulation, SpO2 and HR will be checked. After 20 minutes from setting-up the stimulation, participants will be asked to report the sensations and possible side effects occurring during tACS and to rate their feeling on several visual analogue scales and Likert scales. The intensive bimanual training will be administered by following the procedure described in the Detailed Description session, as for the Sham tACS combined with the training arm.
62685236|NCT06374979|EXPERIMENTAL|Ixekizumab Group|Participants will receive an initial dose of 160 mg (two injections of 80 mg) Ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
62685237|NCT04304196|EXPERIMENTAL|TEMPO|These patients and caregivers will be able to access the TEMPO modules and will receive technical support to use it effectively. Patients will receive usual care throughout the study.
62685238|NCT04304196|ACTIVE_COMPARATOR|Control|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
62685239|NCT00382863|EXPERIMENTAL|Treatment|HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)
62685240|NCT00382863|ACTIVE_COMPARATOR|Control|Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)
62314726|NCT04263922|EXPERIMENTAL|Huaiqihuang group|Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
62314727|NCT04263922|ACTIVE_COMPARATOR|Valsartan Group|Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
62478575|NCT01756326|ACTIVE_COMPARATOR|Bone Autograft|Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.
62314728|NCT02160340||Vitreomacular adhesion|Male or female subjects aged over 40 years with vitreomacular adhesion
62314729|NCT04548661|EXPERIMENTAL|Povidone-iodine solution|
62314730|NCT04548661|PLACEBO_COMPARATOR|Saline|
62314731|NCT04548661|NO_INTERVENTION|No irrigation|Standard incision management
62314732|NCT05370248|EXPERIMENTAL|The six|The group who received tidal volume of 6 ml/kg from mechanical ventilation
62478576|NCT02891980|EXPERIMENTAL|Group 2|MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366
62478577|NCT02891980|EXPERIMENTAL|Group 3|Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366
62314733|NCT05370248|ACTIVE_COMPARATOR|The ten|The group who received tidal volume of 10 ml/kg from mechanical ventilation
62314734|NCT05014698|EXPERIMENTAL|WGS|"at inclusion visit :~- Blood collection for whole Genome sequencing will be performed~At final visit :~the results of the WGS will be delivered to patients"
62478578|NCT02891980|EXPERIMENTAL|Group 4|Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29
62478579|NCT02891980|EXPERIMENTAL|Group1|MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29
62478580|NCT06120465|ACTIVE_COMPARATOR|Yoga intervention group|12 week programme of yoga - encouraged to complete 1 live class and one pre-recorded class a week. Participants will continue with usual cystic fibrosis care.
62478581|NCT06120465|NO_INTERVENTION|Control group|Usual cystic fibrosis care.
62478582|NCT01158274|EXPERIMENTAL|Treatment|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62478583|NCT02157974|EXPERIMENTAL|PCOS, medication naive + Byetta|PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
62314735|NCT05416606|ACTIVE_COMPARATOR|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
62314736|NCT05416606|ACTIVE_COMPARATOR|open prostatectomy|open surgical transvesical prostatectomy
62314737|NCT05506371|EXPERIMENTAL|Az group|"Periodontitis patients, who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure and additionally received oral azithromycin (Health Pharmaceutical Company, Kharkiv, Ukraine) in a dose of 500 mg q.d. for 7 days, then 500 mg q.w. for the next 3 weeks"
62314738|NCT05506371|ACTIVE_COMPARATOR|SRP group|Periodontitis patients who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure.
62478584|NCT02157974|NO_INTERVENTION|Control|Up to 25 girls without PCOS
62685241|NCT01919476|ACTIVE_COMPARATOR|Control Meal: Bagel, cream cheese|Control meal consists of bagel with cream cheese and apple juice.
62314739|NCT05506371|OTHER|H group|Reference group. 25 healthy volunteers who underwent only diagnostics to confirm the clinical healthy state of the gingiva
62124911|NCT05253664|NO_INTERVENTION|Control Group|Standard care was given to the control group. At the time of the study, 2 women were discharged early, 7 women did not want to continue the study, and the babies of 2 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 218 mothers, with 109 women in the control group.
62124912|NCT01366898|EXPERIMENTAL|Chemotherapy|
62314740|NCT02270632|PLACEBO_COMPARATOR|Arm 1|Placebo
62314741|NCT02270632|EXPERIMENTAL|Arm 2|F8IL10, 30 μg/kg
62314742|NCT02270632|EXPERIMENTAL|Arm 3|F8IL10, 160 μg/kg
62685242|NCT01919476|EXPERIMENTAL|Almond Meal: Bagel, almond butter|Almond meal consists of bagel with almond butter and apple juice.
62685243|NCT05601063||Psychiatric patient group|"Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable.~* Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder~* Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder~* (Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder~* Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder~* Personality disorder - borderline personality disorder~* Attention-Deficit Hyperactivity Disorder"
62685244|NCT05601063||Healthy controls|Healthy comparison subjects with no known psychiatric diagnosis
62124913|NCT00995306|ACTIVE_COMPARATOR|1|Civamide Cream 0.075%
62124914|NCT00995306|ACTIVE_COMPARATOR|2|Civamide Cream 0.01%
62124915|NCT03802708|OTHER|control|control
62124916|NCT00587652||1|Intermediate Segment Barrett's (2-4cm)
62124917|NCT00587652||2|Long segment Barrett's (\>4 cm)
62124918|NCT02743078|EXPERIMENTAL|Bevacizumab and TTFields Therapy|Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.
62314743|NCT02004652|EXPERIMENTAL|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
62314744|NCT02004652|PLACEBO_COMPARATOR|Placebo|Vitamin C, 50mg, tablet
62314745|NCT03922399|OTHER|Laser and Surgery in patients with major burn scars|Evaluating patients with major burn scar after laser and surgical treatments Multiple-directions evaluation, including senior plastic resident, young resident, professional burn surgeons, senior nurse with burn scar, one non-medical patients(usually patients' family and friends)
62314746|NCT04889495||Participants receiving Zirabev|Participants receiving Zirabev
62314747|NCT00118170|EXPERIMENTAL|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib once on day 1 and then once daily, twice daily, or every other day beginning on day 8 and continuing for 3 months. Patients are re-evaluated at 3 months. Patients with responding disease may continue study treatment in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients (per treatment cohort) receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
62314748|NCT03291782|EXPERIMENTAL|D-0120 Dose 1|D-0120 Dose 1 Patients will get D-0120 single agent or placebo of matching size during dose escalation
62314749|NCT03291782|EXPERIMENTAL|D-0120 Dose 2|D-0120 Dose 2 Patients will get D-0120 single agent or placebo of matching size during dose escalation
62314750|NCT03291782|EXPERIMENTAL|D-0120 Dose 3|D-0120 Dose 3 Patients will get D-0120 single agent or placebo of matching size during dose escalation
62314751|NCT03291782|EXPERIMENTAL|D-0120 Dose 4|D-0120 Dose 4 Patients will get D-0120 single agent or placebo of matching size during dose escalation
62314752|NCT03291782|EXPERIMENTAL|D-0120 Dose 5|D-0120 Dose 5 Patients will get D-0120 single agent once in the fasted state and once in the fed state.
62339632|NCT02709993|EXPERIMENTAL|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
62339633|NCT01518426|EXPERIMENTAL|Extraction of P300 ERPs|Extract P300 ERPs with Emotiv EEG headset
62124919|NCT04981015||Women with lower urinary tract symptoms|Women with lower urinary tract symptoms without cystocele were included.
62124920|NCT01763970|EXPERIMENTAL|Hypofractionated SBRT|800 cGy delivered in 5 fractions every day to total dose of 4000 cGy
62124921|NCT00172224||osteoporosis|
62685245|NCT03933631|EXPERIMENTAL|Pilocarpine, Prednisolone acetate and Ofloxacin|This group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
62685246|NCT03933631|ACTIVE_COMPARATOR|Prednisolone acetate and Ofloxacin (standard of care)|This group will use only Prednisolone acetate and Ofloxacin, without pilocarpine.
62685247|NCT01746069|PLACEBO_COMPARATOR|health advice|clinical practice routine
62685248|NCT01746069|EXPERIMENTAL|Quit smoking combined cessation programme|Health advice and support sms messages to patient's mobile phone + clinical routine practice
62124922|NCT06399679|EXPERIMENTAL|Rivastigmine|Patients in the rivastigmine arm will receive rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for up to three doses.
62314753|NCT05565677||Patients with lung cancer|Patients with a presumptive diagnosis of lung cancer for whom surgical resection or sampling will be clinically indicated according to the standard practices of the Cardiothoracic Department of AHEPA University Hospital of Thessaloniki, will be enrolled in this prospective study once they give written informed consent for specimen imaging. Surgical resections will be performed per standard of care and there will be no difference in patients' clinical management depending on the acquisition or not of surgical specimens. Patients with altered mental status and those who are unable or unwilling to provide informed consent will be excluded from this study.
62314754|NCT00227877|NO_INTERVENTION|Control - New England, USA|"Control participants will receive care as usual from their provider"
62314755|NCT00227877|EXPERIMENTAL|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
62314756|NCT00227877|NO_INTERVENTION|Control - Prague, CZR|"Control participants will receive care as usual from their provider"
62314757|NCT00227877|EXPERIMENTAL|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
62314758|NCT02307305|EXPERIMENTAL|Duloxetin group|"1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)~plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)"
62314759|NCT02307305|ACTIVE_COMPARATOR|routine pain control group|"Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)~Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone"
62314760|NCT06135818|EXPERIMENTAL|Patients with suspected extrapulmonary tuberculosis|Patients with pleural, pericardial, or peritoneal effusions due to suspected extrapulmonary tuberculosis and those with suspected TB meningitis.
62314761|NCT05878444|EXPERIMENTAL|Normal weight|People with BMI between 20-25 will be enrolled in this group. They will take the probiotic capsule daily during 15 days. Dosis will be 10\^9-10.
62314762|NCT05878444|EXPERIMENTAL|Overweight/Obese|People with BMI \>25 will be enrolled in this group. They will take the probiotic capsule daily during 15 days. Dosis will be 10\^9-10.
62314763|NCT05161962|EXPERIMENTAL|One group received standard oral care.|
62314764|NCT05161962|PLACEBO_COMPARATOR|It was applied to the other group by aspiration.|
62339634|NCT04134585||People aged 60|People aged 60 and over who had refused to participate in fall prevention workshops will be included. They will have semi-structured interviews.
62685249|NCT02989025|EXPERIMENTAL|Experimental|To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
62685250|NCT02989025|NO_INTERVENTION|Control|To determine how close the molecular markers are with 17 OHPC added to the management protocol.
62685251|NCT06685887|EXPERIMENTAL|HIPEC combined with SOX and immune checkpoint inhibitors|The participants volunteering to take HIPEC combined with SOX and immune checkpoint inhibitors will be assigned to this group.
62685252|NCT04409769||Description of use of ceftaroline and ceftobiprole|description of patients and their PJI/BJI,conditions of use, adverse event
61924077|NCT01203527||Tamiflu use in non-pregnant women|This group will consist of twenty-five non-pregnant healthy female volunteers who are being treated with Oseltamivir.
62124923|NCT06399679|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive oral placebo by mouth once, followed by oral placebo every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for up to three doses.
62685253|NCT04928131||Anorectal|Patients presenting with anorectal pain.
62685254|NCT04928131||TMJ|Patients presenting with temporomandibular joint pain.
62685255|NCT04928131||Foot/Ankle|Patients presenting with foot and ankle pain.
62124924|NCT00855400|EXPERIMENTAL|Transplant|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
62478585|NCT02157974|NO_INTERVENTION|PCOS medication naive|Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.
62478586|NCT02157974|NO_INTERVENTION|PCOS on COCPs|Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.
62478587|NCT02157974|NO_INTERVENTION|PCOS on metformin|Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures
62478588|NCT05276635|OTHER|Control (EFT)|had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I)
62478589|NCT05276635|ACTIVE_COMPARATOR|Sleep Hygiene Education (SHE) intervention group|received a Sleep Hygiene Education (SHE) intervention
62478590|NCT02067611|EXPERIMENTAL|X0002|low dose, BID;middle dose, BID, or high dose, BID.
62478591|NCT02067611|PLACEBO_COMPARATOR|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
62478592|NCT06562647|EXPERIMENTAL|SY001 Targets Mesothelin positive solid tumors in a Dose-increasing Setting|Patients with mesothelin-positive ovarian cancer were treated with an SY001 injection in combination with an anti-PD-1 antibody. Patient 001 received 1109 SY001 CAR-pMACs via intravenous injection. Following a two-month period in which the treatment's safety was confirmed, this patient underwent another two does of 1109 SY001 cells on both day 1 and day 3. Prior to the CAR-pMACs infusion on day 1, a PD1 antibody Tislelizumab Injection was administered. In the case of the patient 002, SY001 treatment was delivered intravenously on three occasions: day 1, day 3, and day 5. The same as the first patient's protocol, Tislelizumab was given prior to the CAR-pMACs on day 1.
62478593|NCT03777826|OTHER|Open label (1 arm)|Open label use of study product (post-marketing): PKU Synergy
62685256|NCT06554899|EXPERIMENTAL|Intervention (delivering CIFeR)|At the patient's first follow-up appointment after anti-cancer treatment, oncologists will, in addition to the usual follow-up procedure, deliver a brief psychological intervention (CIFeR)
62685257|NCT06554899|NO_INTERVENTION|Control (treatment as usual)|At the patients first follow-up appointment after anti-cancer treatment, oncologists will deliver treatment as usual (the usual follow-up procedure)
62685258|NCT02511743||physicians|physicians taking care of patients with chronic Hepatitis B Virus infection
62685259|NCT05562856|EXPERIMENTAL|surface pre-reacted glass filler coating material|surface pre-reacted glass filler coating material used to remineralize WSLs
62685260|NCT05562856|ACTIVE_COMPARATOR|micro-invasive resin infiltration technique (Icon)|micro-invasive resin infiltration technique (Icon) in the ability to improve caries lesion state (LF scores) and making the WSLs
62685261|NCT05562856|EXPERIMENTAL|Permaseal resin|Permaseal composite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs
62685262|NCT05562856|EXPERIMENTAL|Optiguard resin|Optiguardcomposite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs
62685263|NCT03890107||Pediatric tympanostomy tube patients|Patients diagnosed with otitis media and scheduled for tympanostomy tube placement will be imaged with the OtoSight
62685264|NCT05169944|EXPERIMENTAL|Treatment (Magrolimab)|Each participant will receive magrolimab intravenously (IV) at a priming dose of 1 mg/kg during Cycle 0, followed by either 30 mg/kg or 45mg mg/kg dose weekly for eight weeks (Cycles 1 and 2), followed by either 30 mg/kg or 45 mg/kg dose every two weeks for the remainder of the study.
62685265|NCT03715829|EXPERIMENTAL|Cohort 1|Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
62685266|NCT03715829|EXPERIMENTAL|Cohort 2|Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
62685267|NCT03715829|EXPERIMENTAL|Cohort 3|Maintenance dose A given QD for 24 weeks
62685268|NCT03715829|EXPERIMENTAL|Cohort 4|Maintenance dose B given QD for 24 weeks
62685269|NCT03715829|EXPERIMENTAL|Cohort 5|Maintenance dose C given QD for 24 weeks
62685270|NCT03715829|PLACEBO_COMPARATOR|Cohort 6|Placebo given QD for 24 weeks
62685271|NCT03715829|EXPERIMENTAL|Extension Cohort 1|4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
62685272|NCT03715829|EXPERIMENTAL|Extension Cohort 2|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
62685273|NCT03715829|EXPERIMENTAL|Extension Cohort 3|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
62685274|NCT03715829|EXPERIMENTAL|Extension Cohort 4|Maintenance dose A given QD for 24 weeks
62478594|NCT04630834|ACTIVE_COMPARATOR|Intervention group|Intervention Group: ibuprofen 10 mg/kg (maximum 600mg) plus acetaminophen 15mg/kg (maximum 650mg)
62478595|NCT04630834|PLACEBO_COMPARATOR|Placebo Group|Placebo Group: Ibuprofen 10mg/kg (maximum 600 mg) plus placebo 15mg/kg (maximum 650mg)
62478596|NCT01942122|EXPERIMENTAL|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
62478597|NCT01942122|EXPERIMENTAL|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
62478598|NCT01942122|ACTIVE_COMPARATOR|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
62685275|NCT03715829|EXPERIMENTAL|Extension Cohort 5|Maintenance dose B given QD for 24 weeks
62685276|NCT03715829|NO_INTERVENTION|Extension Cohort 6|Observation period for 24 weeks
62685277|NCT06673771|EXPERIMENTAL|Vestibular Rehabiliation Therapy|VRT include head and body movemnt, eye movement, balance training
62685278|NCT06673771|ACTIVE_COMPARATOR|Conventional Treatment|conventional treatment include balance, walking, weight shifting and muscle strengthening training
62685279|NCT06577948|ACTIVE_COMPARATOR|Assigned Intervention 1|Single vision spectacle lens
62685280|NCT06577948|EXPERIMENTAL|Assigned Intervention 2|P.A.U.S.E. spectacle lens 1
62685281|NCT06577948|EXPERIMENTAL|Assigned Intervention 3|P.A.U.S.E. spectacle lens 2
62697396|NCT05044468|EXPERIMENTAL|Group A (liposomal bupivacaine)|Patients receive liposomal bupivacaine via injection into the intercostal nerve block.
62697397|NCT05044468|ACTIVE_COMPARATOR|Group B (lidocaine)|Patients receive lidocaine via injection into the pleuroscopy port incision sites and indwelling pleural catheter site.
62697398|NCT01712373|ACTIVE_COMPARATOR|Ginseng|Ginseng, tablet, 250 mg, twice, 3 months
62697399|NCT01712373|PLACEBO_COMPARATOR|Placebo|Placebo, tablet
62697400|NCT05168293||Entecavir group|
62314765|NCT04904042|EXPERIMENTAL|Use of plasma of neutral argon|Use of plasma of neutral argon in the eradication of tumor implants at the mesentery level, with different doses (established according to the percentage of energy used) and distances of application and time. It will also be compared in-vivo with control therapy of Monopolar electrofulguration at a power of 100 in cut mode with ball-tip terminal.
62314766|NCT05725148|EXPERIMENTAL|Participants whose SBP and DBP meet the ISO 81060-2:2018 requirements|Each set of blood pressure tests is performed simultaneously. A cuff is worn on the right (or left) arm to check the blood pressure by auscultation, while 'CART-I plus' is worn on the finger of the opposite arm to check the blood pressure. At this time, the blood pressure test using an auscultation method is performed by two investigators simultaneously, and the blood pressure test using 'CART-I plus' is performed by the participants themselves
62314767|NCT04977999|ACTIVE_COMPARATOR|Eccentric training|Eccentron (BTE Technologies, Inc.) training
62314768|NCT04977999|EXPERIMENTAL|Aquatic training|Hydroworks aquatic training
62314769|NCT01109706||patient treated by statines|
62314770|NCT01109706||patient without normolipidemic treatment|
62314771|NCT04565561||Neovas BRS group|Neovas BRS group, n=20
62314772|NCT04565561||DCB group|DCB group, n=20
62314773|NCT05405543|EXPERIMENTAL|Arm 1|
62314774|NCT05405543|EXPERIMENTAL|Arm 2|
62314775|NCT05405543|EXPERIMENTAL|Arm 3|
62314776|NCT05405543|EXPERIMENTAL|Arm 4|
62314777|NCT05694078|EXPERIMENTAL|Lumbrical Injured Climbers|6-weeks relative motion splinting protocol, while pain-free sport activities are permitted
62314778|NCT01277224|EXPERIMENTAL|Movi2 Program|
62314779|NCT01277224|NO_INTERVENTION|Control|
62314780|NCT05208983||70 years and Older|Persons aged 70 years and over receiving a first or second dose of an approved COVID-19 vaccine and is a resident of Ontario
62314781|NCT05208983||30 - 50 years of age|Persons aged 30 - 50 years receiving a first or second dose of an approved COVID-19 vaccine and a resident of Ontario
62314782|NCT05458232||5mg tadalafil once daily for 14 days|
62314783|NCT04507308|EXPERIMENTAL|Transdiagnostic Sleep and Circadian Intervention|All participants will undergo baseline assessment and then complete a brief, single-session sleep-focused intervention based on psychoeduation and handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth).
62314784|NCT04256746|PLACEBO_COMPARATOR|Boiled Rice|63 g of raw rice was cooked.
62314785|NCT04256746|EXPERIMENTAL|Boiled Rice+0.37 gr extract|63 g of raw rice was cooked and 0.37 gr mulberry fruit powdered extract added and mixed
62314786|NCT04256746|EXPERIMENTAL|Boiled Rice+0.75 gr extract|63 g of raw rice was cooked and 0.75 gr mulberry fruit powdered extract added and mixed
62314787|NCT04256746|EXPERIMENTAL|Boiled Rice+1.12 gr extract|63 g of raw rice was cooked and 1.12 gr mulberry fruit powdered extract added and mixed
62314788|NCT04256746|EXPERIMENTAL|Boiled Rice+1.50 gr extract|63 g of raw rice was cooked and 1.50 gr mulberry fruit powdered extract added and mixed
62314789|NCT04256746|PLACEBO_COMPARATOR|Rice porridge|60 g of rice porridge was rehydrated with 300 ml boiling hot water
62314790|NCT04256746|ACTIVE_COMPARATOR|Rice porridge+1.50 gr extract|60 g of rice porridge was rehydrated with 300 ml boiling hot water and 1.50 gr mulberry fruit powdered extract added and mixed
62314791|NCT05958303|EXPERIMENTAL|Antioxidant Cocktail|The first dose will be 500 mg vitamin C, 200 IU vitamin E, and 300 mg of alpha lipoic acid 120 minutes before MRI. The second dose will be 500 mg vitamin C, 400 IU vitamin E, and 300 mg of alpha lipoic acid 60 minutes before MRI.
62314792|NCT05958303|ACTIVE_COMPARATOR|Placebo|Placebo 120 minutes before MRI, followed by another dose of placebo 60 minutes before MRI.
62685282|NCT06689384|EXPERIMENTAL|Recording of the diagnostic 3D images|20 patients with adequate oral health who had daily routine appointments for treatment at Marmara University restorative dentistry department were included in the study. Exclusion criteria for the study were missing premolar and molar teeth (except wisdom teeth) or the presence of amalgam and ceramic restorations that could affect the scanning in the right hemi-arc of the mandible. Using of intra oral scanners was performed by a restorative dentist with 5 years of experience. were scanned with 4 different intraoral scanners (IOS) (Trios 3, 3Shape; Primescan, Dentsply; Element 5D, iTero; Lumina, iTero) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The digital scan had appropriate anatomic references to enable a proper matching with the digital scan taken after teeth preparation. The official scanning strategy and ambient scanning light conditions in the manufacturer's instructions were followed for all scanners.
62697401|NCT05168293||Tenofovir group|
62697402|NCT05987423|EXPERIMENTAL|Satralizumab|In the Part I period, participants will receive satralizumab every 4 weeks (q4w) followed by proptosis response-based individualized treatment in Part II of the study
62314793|NCT04355117|EXPERIMENTAL|Treatment: TEV-48125|
62314794|NCT06518863|EXPERIMENTAL|Ultra-processed foods|Participants are instructed to consume only ultra-processed foods for 3 days.
62314795|NCT06518863|EXPERIMENTAL|Unprocessed foods|Participants are instructed to consume only unprocessed foods for 3 days.
62314796|NCT06392789|EXPERIMENTAL|GROUP I (Cecebot intervention)|Patients receive sleep education SMS conversations and access to website content modules over 10 minutes 2-4 times per week, sleep compression SMS conversations QW, and wear activity tracker daily on weeks 1-6.
62314797|NCT06392789|EXPERIMENTAL|GROUP II (waitlist control, Cecebot intervention)|Patients receive sleep education SMS conversations and access to website content modules over 10 minutes 2-4 times per week, sleep compression SMS conversations QW, and wear activity tracker daily on weeks 7-12.
62314798|NCT00623012|EXPERIMENTAL|1|
62314799|NCT04431999|EXPERIMENTAL|Whole blood group|Damage control resuscitation for trauma care using whole blood.
62314800|NCT04431999|ACTIVE_COMPARATOR|Fractionated blood products group|Damage control resuscitation for trauma care using component therapy.
62314801|NCT03512223|EXPERIMENTAL|Group A (IV dexamethasone)|Perineural (30ml of 0.75% ropivacaine + 0.5 ml normal saline) and IV (9.0 ml normal saline + 1 ml of 10 mg/ml Dexamethasone)
62314802|NCT03512223|EXPERIMENTAL|Group B (IV + perineural dexamethasone)|(IV + perineural dexamethasone): Perineural (30ml of 0.75% ropivacaine + 0.5 ml of 10 mg/ml Dexamethasone) and IV (9.5 ml normal saline + 0.5 ml of 10 mg/ml Dexamethasone)
62314803|NCT03512223|NO_INTERVENTION|Group C (control with no adjuvant dexamethasone)|Perineural (30ml of 0.75 ropivacaine + 0.5 ml normal saline) and IV (10 ml normal saline)
62314804|NCT04509700|EXPERIMENTAL|parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
62314805|NCT04509700|EXPERIMENTAL|parsaclicib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
62314806|NCT04509700|EXPERIMENTAL|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
62314807|NCT04509700|EXPERIMENTAL|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
62314808|NCT06512311|EXPERIMENTAL|PDC-based drug screening|120 patients will be included in the intervention group and will receive PDC-based drug screening. The molecular tumor board will formulate a personalized treatment recommendation by incorporating the individual characteristics of the patients including age, co-morbidities, co-medication, and performance status in addition to the results of the PDC-based drug screening.
62314809|NCT06512311|NO_INTERVENTION|Standard group|120 patients will be included in the standard group and will not receive PDC-based drug screening. In line, no personalized treatment approach will be formulated by the molecular tumor board and patients will all receive the recommendation for standard treatment including temozolomide maintenance therapy for 6 cycles.
62314810|NCT06488326|EXPERIMENTAL|Mulberry leaf extract 6 mg capsule|Take one capsule of the sample one time.
62478599|NCT06547541|EXPERIMENTAL|Exercise|The exercise intervention is a four-week intervention and will consist of body weight strength training. All training sessions during hospitalization will be supervised and will be performed individually for 30 min/day. If the patient is discharged within the four-week training period, the training will continue from home and will be online-based with a live video connection to an instructor. The training program will be the same. The intervention group will ideally exercise post-prandially (within 60 min following the meal) following either breakfast or lunch. Exercise intensity will be monitored throughout the training (with a heart rate monitor) and patients will estimate the rigorousness of the training using the rate of perceived exertion (RPE)-scale. If possible, the goal is for the patients to reach a minimum of 5, corresponding to moderate intensity, but preferably 7+ on the 0-10 RPE scale in each set. The aim is to complete the training sessions five out of seven days/week.
62478600|NCT06547541|NO_INTERVENTION|Control|The Control group will be placed in a chair for 30 minutes, within 60 minutes following either breakfast or lunch daily during admission, depending on other workflows in the ward. This corresponds to the time spent on exercise by the intervention group. The control group will also be in daily contact with the instructor following discharge and will be asked the same daily questions and will be seated in a chair for 30 minutes as during hospitalization.
62478601|NCT04194476|EXPERIMENTAL|120 neonates less than 28 days old|Each neonate will be tested for blood glucose level twice on the same heel stick site using two glucose meters. additional 200-300 ul blood will be collected and centrifuged. Plasma will be tested blood glucose in the lab analyzer in the clinical laboratory.
62478602|NCT04995783||Ulcerative Colitis|
62124925|NCT01128075||naïve subjects|Cohort of RMS patients who initiate disease modifying treatment with Rebif®
62124926|NCT01128075||non-naïve subjects|Cohort of RMS patients who initiate treatment with Rebif® after having failed therapy with other disease modifying drugs on the basis of lack of efficacy, compliance, safety, tolerability or convenience, as per clinical judgment of study investigator
62124927|NCT04152317|EXPERIMENTAL|Misoprostol 200mcg|In this group, the participants will receive 200mcg of misoprostol, single dose, via the vaginal route.
62314811|NCT06488326|EXPERIMENTAL|Mulberry leaf extract 12 mg capsule|Take one capsule of the sample one time.
62314812|NCT06488326|EXPERIMENTAL|Mulberry leaf extract 18 mg capsule|Take one capsule of the sample one time.
62314813|NCT06488326|PLACEBO_COMPARATOR|Placebo capsule|Take one capsule of the sample one time.
62314814|NCT03216265|OTHER|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
62314815|NCT03216265|OTHER|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
62314816|NCT03216265|OTHER|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
62314817|NCT05218447|EXPERIMENTAL|Low Frequency|Subjects will receive 2 sessions of robotic gait training (RGT) per week for 12 weeks
62314818|NCT05218447|EXPERIMENTAL|Moderate Frequency|Subjects will receive 3 sessions of robotic gait training (RGT) per week for 8 weeks
62314819|NCT05218447|EXPERIMENTAL|High Frequency|Subjects will receive 4 sessions of robotic gait training (RGT) per week for 6 weeks
62314820|NCT05218447|ACTIVE_COMPARATOR|Control Group|Subjects will receive usual care gait training without robotic gait training
62314821|NCT03902405|ACTIVE_COMPARATOR|Active CEASAR Intervention|"Participants will be given the active CEASAR intervention where they will be trained to avoid cues associated with stimulant use and approach healthy cues based on the orientation of the images presented. Individuals will be asked to approach (pull in) portrait images and avoid (push away) landscape images. In the active condition, pushed pictures (landscape orientation) will exclusively be stimulant-use related pictures. Conversely, healthy images will be in the portrait orientation which will be pulled in."
62314822|NCT03902405|PLACEBO_COMPARATOR|Placebo CEASAR|In the control condition, stimulant use-related pictures will be randomized and equally divided into push (landscape) and pull (portrait) conditions.
62478603|NCT04995783||Crohn's Disease|
62478604|NCT04995783||Rheumatoid Arthritis|
62478605|NCT04995783||Psoriasis|
62478606|NCT04995783||Control|
62478607|NCT01492556|EXPERIMENTAL|Etoposide|Etoposide Capsules
62478608|NCT01385930|EXPERIMENTAL|Lifestyle counseling|Lifestyle counseling
62124928|NCT04152317|ACTIVE_COMPARATOR|Misoprostol 800mcg|In this group, the participants will receive 800mcg of misoprostol, single dose, via the vaginal route.
62478609|NCT01385930|NO_INTERVENTION|Control group|Control group
62478610|NCT06560658|EXPERIMENTAL|Microdosing only|
62124929|NCT00705588|EXPERIMENTAL|1|Patients treated with epoprostenol (Flolan) will be given tadalafil (Cialis).
62314823|NCT01882023||Eating disorder|Patients currently in treatment for eating disorders.
62314824|NCT01882023||Healthy Controls|Age- and gender matched healthy controls.
62314825|NCT02138578|EXPERIMENTAL|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
62478611|NCT06560658|EXPERIMENTAL|Microdosing plus meditation|
62478612|NCT04077723|EXPERIMENTAL|Part I|Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab up to seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).
62478613|NCT04077723|EXPERIMENTAL|Part II|Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
62478614|NCT04077723|EXPERIMENTAL|Part III|Dose-Expansion Stage: Participants with r/r diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), and DLBCL arising from FL (transformed FL) will receive englumafusp alfa administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
62478615|NCT05028608|EXPERIMENTAL|Period 1|Fixed treatment sequence starting with 2 single oral doses of midazolam and a single dose of elinzanetant.
62478616|NCT05028608|EXPERIMENTAL|Period 2|Up titration of carbamazepine over 4 days (dose 1, 2, 3) continued by fixed dose 3 of carbamazepine prior to administration of midazolam / elinzanetant, followed by carbamazepine administration.
62478617|NCT02358538|EXPERIMENTAL|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
62124930|NCT00705588|EXPERIMENTAL|2|Patients receiving iloprost (Ventavis) will receive vardenafil (Levitra)
62124931|NCT05339893|SHAM_COMPARATOR|Affected Limb|"Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.~Within subject. Sham controlled. Double blind, the patient will not know whether they are receiving taVNS, all patients feel a ramp up current but only the active group will receive timed stimulation bursts during the robotic protocol that engages the affected limb. '"
62124932|NCT05339893|NO_INTERVENTION|Unaffected limb|Patients will engage the robot first with their unaffected limb. This practice will ensure understanding and serve to activate the hemisphere ipsilateral to the impaired limb. Patients are likely to perform this activity quickly, there will not be any taVNS during this part of the procedure.
62124933|NCT06383117|EXPERIMENTAL|Placebo control, then calcium carbonate|At visit 1, participants will be instructed to consume 2 capsules (containing the placebo: vegetable based cellulose) immediately before consuming a standardized meal. Within 8 weeks, at visit 2, participants will be instructed to consume 2 capsules (containing the calcium carbonate, 1200 mg total) immediately before consuming a standardized meal.
62124934|NCT06383117|EXPERIMENTAL|Calcium carbonate, then placebo control|At visit 1, participants will be instructed to consume 2 capsules (containing the calcium carbonate, 1200 mg total) immediately before consuming a standardized meal. Within 8 weeks, at visit 2, participants will be instructed to consume 2 capsules (containing the placebo: vegetable based cellulose) immediately before consuming a standardized meal.
62478618|NCT04486066|EXPERIMENTAL|Mindfulness-Based Stress Reduction (MBSR)|In MBSR, participants meet for 2 hours per week for 8 weeks in a video group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
62478619|NCT04486066|EXPERIMENTAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 sessions in a video group format, while retaining all essential elements.
62478620|NCT04486066|OTHER|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
62124935|NCT01302236|EXPERIMENTAL|Eplerenone|
62314826|NCT02138578|ACTIVE_COMPARATOR|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
62314827|NCT02138578|ACTIVE_COMPARATOR|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
62314828|NCT00707018|EXPERIMENTAL|External rotation shoulder sling|External rotation shoulder sling
62314829|NCT00707018|ACTIVE_COMPARATOR|Internal rotation shoulder sling|Internal rotation shoulder sling
62314830|NCT04397133|EXPERIMENTAL|intervention 1|in this group patients will get 4 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
62314831|NCT04397133|EXPERIMENTAL|intervention 2|in this group patients will get 8 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
62478621|NCT03151798|EXPERIMENTAL|Phase I: Observational studies|Patients are eligible who are undergoing either bariatric surgery or a liver biopsy for the diagnosis of nonalcoholic fatty liver disease
62478622|NCT03151798|EXPERIMENTAL|Phase II: Lifestyle treatment|Subjects will undergo lifestyle modification to cause weight loss and improved fitness
62478623|NCT03151798|PLACEBO_COMPARATOR|Phase II: Control treatment|Subjects will be given dietary advice and a stretching program.
62478624|NCT06742385|EXPERIMENTAL|Active arm|Both arms are equipped with the application, data are collected via the application and telemonitoring with alerts to the care team are activated in the active telemonitoring arm.
62478625|NCT06742385|NO_INTERVENTION|Control arm|Both arms are equipped with the application, data are collected via the application and telemonitoring with alerts to the care team are inactivated in the active control arm.
62697403|NCT05987423|PLACEBO_COMPARATOR|Placebo|In the part I period, participants will receive placebo q4w followed by proptosis response-based individualized treatment in part II of the study
61924078|NCT02285283|PLACEBO_COMPARATOR|Placebo|2 capsules by mouth twice a day for 24 weeks
62124936|NCT01408849|EXPERIMENTAL|Maytenus|Tea of Martens ilicifolia leaves
62124937|NCT01408849|ACTIVE_COMPARATOR|Omeprazole|Omeprazole as active comparator
62124938|NCT03013452|ACTIVE_COMPARATOR|Autogenic drainage|Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
62124939|NCT03013452|ACTIVE_COMPARATOR|oPEP|Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
62124940|NCT00933400|ACTIVE_COMPARATOR|Traditional Strategy [Group A]|In the traditional-care arm (Group A:Standard of Care (SOC)), all management and disposition decisions will be made by the healthcare providers caring for the participant. Participants will receive disposition (admit to hospital, admit to cardiac diagnostic unit, or discharge to home), diagnostic testing (none, stress testing, or cardiac catheterization), and treatment according to the team caring for the participant.
62124941|NCT00933400|EXPERIMENTAL|CT Coronary Angiography (CTCA)[Group B]|"In the study CT coronary angiography-based rapid rule out arm (Group B), participants will receive initial cardiac troponin and creatinine tests. Upon return of normal laboratory values (including a calculated creatinine clearance), the participants will receive a CT coronary angiography an estimated 90 minutes or as soon as the CT scanner is available following the initial values assessment. Participants with negative test results will be discharged unless other indications for admission per standard of care and follow up will comprise telephone interviews 30 days and 1 year after triage/presentation. Participants with positive test results will be admitted to the hospital for further management as dictated by the admitting team."
62124942|NCT00214266|EXPERIMENTAL|Campath-1H Induction Therapy Combined With CellCept® Therapy|Campath-1H Induction Therapy Combined With CellCept® Therapy
62124943|NCT04346732|EXPERIMENTAL|Vapocoolant spray|Vapocoolant spray was applied to the donors in the vapocoolant spray group.
62124944|NCT04346732|NO_INTERVENTION|Control|The donors in the control group were not given any intervention during the blood collection process.
62124945|NCT03786991||Organ donors|Organ donors after neurologic death (NDD) of 18 years old and older for whom consent to organ donation has been obtained.
62124946|NCT03786991||Liver and kidney Recipients|Liver and kidney recipients of 18 years old and older.
62124947|NCT00382681|EXPERIMENTAL|FID 107027|Contact lens solution used as instructed for 90 days.
62124948|NCT00382681|ACTIVE_COMPARATOR|ReNu MultiPlus|Contact lens solution used as instructed for 90 days.
62124949|NCT01082809|NO_INTERVENTION|Sunitinib|Sunitinib, 37.5 mg orally once daily continuously, comprising a 4-week cycle
62124950|NCT01954797||Physical Fitness|Patients from this group underwent 4 weeks of aerobic fitness training additional to normal supportive care, 5 times a week, for 50 minutes
62124951|NCT01954797||Relaxation|Patients of this group received 4-weeks of relaxation sessions additional to normal supportive care, 5 times a week, for 50 minutes.
61924079|NCT02285283|ACTIVE_COMPARATOR|Itraconazole|Two 100mg capsules by mouth twice a day for 24 weeks
61924080|NCT06074601||Pregnant People|Enrolling any pregnant person over the age of 18 with a singleton pregnancy with their pregnancy having been effectively dated by first trimester ultrasound or last menstrual period
61924081|NCT03676985|EXPERIMENTAL|ZKAB001 5 mg/kg/time|Three or six patients will treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
62314832|NCT04397133|SHAM_COMPARATOR|control group|this group will get sham intervention with 0 to 5 cmH2O resistance
62314833|NCT06672497||Patients diagnosed with breast or gynecological cancer and undergoing neoadjuvant chemotherapy.|Females ages 20...
62314834|NCT01623778||Add on ADV|Patients with inadequate response to interferon at 24 weeks received interferon add on ADV optimized therapy
62314835|NCT01623778||Switch to LDT|Patients with inadequate response to interferon at 24 weeks received switching to LDT therapy
62339635|NCT04003077|EXPERIMENTAL|Laser meridian massage|They are treated with laser meridian massage on the back including Bladder meridian and Governor vessel three times a week for 4 weeks.
62697404|NCT05463419|EXPERIMENTAL|PIKA COVID-19 vaccine|One dose of the experimental vaccine should be administered on Study Day 0 in the deltoid muscle.
61924082|NCT03676985|EXPERIMENTAL|ZKAB001 10 mg/kg/time|Three or six patients will treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
61924083|NCT03676985|EXPERIMENTAL|ZKAB001 15 mg/kg/time|Three or six patients will treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
61924084|NCT01490788|EXPERIMENTAL|Treatment A|1 x TNX-102 2.4 mg gelcap under fasting conditions
61924085|NCT01490788|EXPERIMENTAL|Treatment B|1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions
61924086|NCT01490788|ACTIVE_COMPARATOR|Treatment C|1 x TNX-102 2.4 mg gelcap under fed conditions
61924087|NCT03193125|EXPERIMENTAL|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
62314836|NCT01947673|EXPERIMENTAL|Modified Mindfulness Based Stress Reduction (MBSR) Program|After individual instruction, participants in this arm will perform meditation by following a series of mindfulness meditation (MM) recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using a digital audio (MP3) player at home on non-dialysis days, and asked to keep a log of these sessions.
62314837|NCT01947673|PLACEBO_COMPARATOR|Health Education|Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
62314838|NCT04709276|EXPERIMENTAL|Neuroendocrine Prostate Cancer (NEPC) or Aggressive Variant Prostate Cancer (AVPC)|"Subjects with neuroendocrine prostate cancer (NEPC) or aggressive variant prostate cancer (AVPC) will receive a combination of nivolumab, ipilimumab, carboplatin and cabazitaxel for up to 10 cycles of 21 days each. After carboplatin and cabazitaxel are discontinued, a combination of nivolumab and ipilimumab will be administered.~Nivolumab will be administered intravenously at a dose of 360 mg every 3 weeks.~Ipilimumab will be administered intravenously at a dose of 1 mg/kg every 6 weeks.~Carboplatin will be administered intravenously at a dose of AUC 4 mg/ml per minute.~Cabazitaxel will be administered intravenously at a dose of 20 or 25 mg/m2."
62314839|NCT03761953|EXPERIMENTAL|Oritavancin|Single IV infusion of 1200mg of oritavancin
62314840|NCT00770185|EXPERIMENTAL|Ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
62314841|NCT01221298|EXPERIMENTAL|ABT-450/r and ABT-072, plus ribavirin (RBV)|ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.
62314842|NCT04660903|EXPERIMENTAL|Intervention|One arm study - the intervention arm is the only actual
62314843|NCT03546478|EXPERIMENTAL|99mTc-ABH2 SPECT/CT|The patients were injected with 370±54 MBq of 99mTc-ABH2 in one dose intravenously and underwent SPECT/CT scan 90-270 min later.
62314844|NCT03778255|EXPERIMENTAL|Undergoing sentinel lymph node biopsy|
62314845|NCT06673225||Single group|History of smoking and/or passive exposure and/or respiratory symptoms.
62314846|NCT05811572||With Non-Specific Low Back Pain|pelvic floor muscles measurement with perinometer
62314847|NCT05811572||Without Low Back Pain|pelvic floor muscles measurement with perinometer
62314848|NCT05509894||Participants receiving Ngenla|Participants receiving Ngenla according to label
62314849|NCT04275310|EXPERIMENTAL|Microeconomic intervention|
62314850|NCT04275310|NO_INTERVENTION|Waitlisted control|
62314851|NCT06671522||Obesity|
62697405|NCT05463419|ACTIVE_COMPARATOR|Inactivated Covid-19 vaccine|One dose of the control vaccine should be administered on Study Day 0 in the deltoid muscle.
62124952|NCT05176106|EXPERIMENTAL|Intervention-Randomized Parishes|Parishes will be randomized in Masindi District to receive the intervention (i.e., an incentives package). VHTs who are active in that parish will thereby receive the incentives intervention.
62124953|NCT05176106|NO_INTERVENTION|Control-Randomized Parishes|Non-intervention randomized parishes will be the control parishes. Active VHTs in the control parishes will not receive the incentives intervention.
62124954|NCT06235424|ACTIVE_COMPARATOR|del Nido cardioplegia group|A group of patients that received high potassium cardioplegic solution with the addition of lidocaine, mixed with the patient's blood in 4:1 ratio
62697406|NCT03610698|EXPERIMENTAL|Facilitated Intervention|Intervention arm facilitated by a trained team member, delivering the 8 positive emotion skills over 5 weeks.
62314852|NCT04222725|EXPERIMENTAL|TRS01 low dose|
62314853|NCT04222725|EXPERIMENTAL|TRS01 medium dose|
62314854|NCT04222725|EXPERIMENTAL|TRS01 high dose|
62124955|NCT06235424|ACTIVE_COMPARATOR|Bretschneider-HTK cardioplegia group|A group of patients that received low sodium cardioplegic solution with the addition of histidine, tryptophan and alpha-ketoglutarate
62314855|NCT04222725|PLACEBO_COMPARATOR|Placebo|
62314856|NCT05634512||Collect blood from patients with MPS-IH) undergoing laronidase therapy and stem cell transplant.|The primary aim is to characterize the PK of IV laronidase in individuals with MPS IH and identify patient specific covariates that impact drug exposure. The secondary aim is to identify key differences pre-and post-HCT leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH.
62314857|NCT02255591|EXPERIMENTAL|Shamrock|Use of the Shamrock technique to place a lumbar plexus block with injection of 20 mL 2% Lidocaine-adrenaline added gadolinium.
62314858|NCT02255591|ACTIVE_COMPARATOR|Lumbar Ultrasound Trident|Use of the Lumbar Ultrasound Trident technique to place a lumbar plexus block with injection of 20 mL 2% lidocaine-adrenaline added gadolinium.
62314859|NCT00163722|ACTIVE_COMPARATOR|Standard diagnostic strategy of culture and histology|The standard-diagnostic strategy was designed to be consistent with the 2002 guidelines for antimicrobial use in neutropenic patients with cancer. When an invasive fungal infection was suspected (e.g. persistent fevers) cultures of blood, urine, sputum (if available) and faeces (if clinically indicated), and HRCT scans of chest were performed. Bronchoscopy and biopsies were performed according to institutional protocols. Empiric antifungal therapy was recommended whilst undergoing these investigations and was continued, de-escalated to prophylaxis, or changed to treatment of invasive aspergillosis or other IFD according to test results.
62314860|NCT00163722|EXPERIMENTAL|Aspergillus galactomannan and PCR directed|Results of once to twice weekly testing with Aspergillus galactomannan and PCR directed the timing of CT scan performance and whether antifungal therapy was given
62314861|NCT00703807|EXPERIMENTAL|1|Daily oral RAD001 for 21 days in combination with oral topotecan on days 1-5 of a 21 day cycle
62314862|NCT00722345|PLACEBO_COMPARATOR|1|
62314863|NCT00722345|EXPERIMENTAL|2|
62314864|NCT02917486||ECMO piperacillin|patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
62314865|NCT02917486||without ECMO piperacillin|patients in intensive care without ECMO with antiinfective therapy : piperacillin
62314866|NCT01511146|EXPERIMENTAL|Mitomycin+Gemcitabine|Intrahepatic treatment, where all standard treatments have been used
62314867|NCT04859803|ACTIVE_COMPARATOR|RISS group|patients will receive rhomboid intercostal block under ultrasound guidance.
62314868|NCT04859803|ACTIVE_COMPARATOR|Control group|Patients will received the conventional intravenous analgesia
62314869|NCT01719081|EXPERIMENTAL|Ultrasound Guided SIJ Injection|Needle placement will be performed under US guidance. Fluoroscopy will be used to confirm needle placement prior to medication injection.
61924088|NCT03193125|PLACEBO_COMPARATOR|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
61924089|NCT05760118||Diabetes Mellitus Patients|Patients diagnosed with diabetes mellitus.
62314870|NCT01719081|ACTIVE_COMPARATOR|Xray Guided SIJ Injection|Needle placement will be performed under fluoroscopy.
62478626|NCT05331508|EXPERIMENTAL|Treatment group|Prior to commencement of the study, providers responsible for FP and ANC service provision will participate in a 3-day competency-based skills-building training activity on Caring for women subjected to violence: A WHO curriculum for training health-care providers and the ARCHES intervention. Following the training, providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
62685283|NCT06689384|EXPERIMENTAL|Rubberdam Isolation|The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth. A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology. In the procedure that simulated the final impression process under rubber dam isolation, the relevant tooth was marked on the initial scan along with the contact areas of the adjacent teeth. The marked area which the to be re-scanned, was trimmed away from the virtual casts. The diameter of the mesh holes was controlled by adjusting the settings of the automatic mesh hole generator in the software program of the IOS.
62685284|NCT06689384|EXPERIMENTAL|Selective Cutting on the Scanner|In the procedure that simulated the final impression process under rubber dam isolation, the relevant tooth was marked on the initial scan along with the contact areas of the adjacent teeth. The marked area which the to be re-scanned, was trimmed away from the virtual casts. The diameter of the mesh holes was controlled by adjusting the settings of the automatic mesh hole generator in the software program of the IOS.
62685285|NCT06689384|EXPERIMENTAL|Recording the Final 3D Image|Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar. The rescanning procedures ended with the lingual surfaces of the second molar, followed by the lingual surfaces of the first molar and second premolar. Following the second scan, the area was re-scanned in high-resolution mode, where higher mesh quality could be achieved. The software of the intraoral scanner automatically fused two different data sets obtained by initial/reference and preparation digital scans. Data about tooth positions, morphologies, rubber dam, and surrounding soft tissues was integrated simultaneously. The obtained final scan was exported as an STL file.
62685286|NCT06192160|ACTIVE_COMPARATOR|Arm 1: Standard of Care (SOC)|"* Weeks 1-8: INH 300 mg, RIF 600 mg, PZA weight-based, EMB weight-based~* Weeks 9-26: INH 300 mg, RIF 600 mg"
62685287|NCT06192160|EXPERIMENTAL|Arm 2: Bedaquiline (BDQ), Pretomanid (Pa), and Linezolid (LZD)|"* Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, LZD 600 mg~* Weeks 9-26: INH 300 mg, RIF 600 mg"
61924090|NCT05682248|EXPERIMENTAL|Real rTMS group|True rTMS stimulation: 10Hz, intensity: 90% RMT, duration: 10s, interval: 30s, stimulation cycle: 1 time/day, treatment duration: 10 days;
62478627|NCT05331508|NO_INTERVENTION|Control group|FP clients and ANC clients will receive standard care. For FP services, this includes standard contraceptive care provided by personnel who have completed training on contraceptive service delivery by the Nigerian Federal Ministry of Health and partners. For ANC services, the standard is a minimum of 8 visits with health personnel trained on ANC care during pregnancy. This includes identification of women and girls at increased risk of developing complications during labor and childbirth; prevention, detection, and management of pregnancy-related and concurrent conditions; health education and promotion; promotion of the use of skilled attendance at birth and healthy behaviors such as breastfeeding, early postnatal care, and planning for optimal pregnancy spacing, routine examinations, detection of complications, prevention of malaria in pregnancy and other infections; provision of holistic care to ensure normal progression of the baby and good health of the mother.
62478628|NCT04738448|EXPERIMENTAL|Art Therapy Group|
62478629|NCT06732674|NO_INTERVENTION|Usual care|Scheduled hospital visits every 6 months
62478630|NCT06732674|EXPERIMENTAL|Home monitoring|Home monitoring strategy with remote patient data observation twice a week
62478631|NCT05560698|OTHER|Control|Standard reporting method
62478632|NCT05560698|OTHER|Intervention|Web based motivation-enhancing app
61924091|NCT05682248|PLACEBO_COMPARATOR|Sham rTMS group|sham stimulation group : intensity :0; other parameters are the same as true rTMS stimulation
62124956|NCT04053816|EXPERIMENTAL|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below 3.6 mEq/L.
62124957|NCT04053816|ACTIVE_COMPARATOR|Tight control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
62124958|NCT04985136|EXPERIMENTAL|camrelizumab + Rivoceranib|
62124959|NCT04985136|ACTIVE_COMPARATOR|Rivoceranib|
62124960|NCT04985136|ACTIVE_COMPARATOR|Sorafenib|
62124961|NCT04985136|ACTIVE_COMPARATOR|Regorafenib|
62124962|NCT03511651|OTHER|FRC at clinical PEEP level|Measuring FRC at clinical PEEP level
62314871|NCT06395142||stroke participants|Stroke participants performe pedal walking and visual-deprivation walking successively.
62314872|NCT06242340|EXPERIMENTAL|Group 1|Preterm (between 32 0/7 and 36 6/7 weeks)
62314873|NCT06242340|EXPERIMENTAL|Group 2|Preterm (between 32 0/7 and 36 6/7 weeks)
62314874|NCT06242340|EXPERIMENTAL|Group 3|Early term (between 37 0/7 and 38 6/7 weeks)
62314875|NCT06242340|EXPERIMENTAL|Group 4|Early term (between 37 0/7 and 38 6/7 weeks)
62314876|NCT04151563|EXPERIMENTAL|Arm A: cabozantinib + nivolumab + ipilimumab|
62314877|NCT04151563|EXPERIMENTAL|Arm B: cabozantinib + nivolumab|
62314878|NCT04151563|EXPERIMENTAL|Arm C: nivolumab + ramucirumab + docetaxel|
62314879|NCT04151563|EXPERIMENTAL|Arm D: lucitanib + nivolumab|
62314880|NCT04151563|EXPERIMENTAL|Arm E: nivolumab + docetaxel|
62314881|NCT04151563|ACTIVE_COMPARATOR|Arm F: docetaxel|
62314882|NCT04925544|EXPERIMENTAL|VK-2019_arm|Dose escalation and expansion up to 31 additional patients at a maximum of 1800 mg twice daily. Cycles will be defined as 28 days of treatment, subjects will receive VK 2019 until progression or dose limiting toxicity, for up to 12 cycles.
62314883|NCT01187212|ACTIVE_COMPARATOR|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day (D) 1
62314884|NCT01187212|EXPERIMENTAL|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
62314885|NCT03321617|EXPERIMENTAL|POMA 40mg BID (80mg)|Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.
62314886|NCT03321617|EXPERIMENTAL|POMA 80mg BID (160 mg)|Subject will take 80 mg pomaglumetad methionil (POMA) twice a day for 14 days
62314887|NCT03321617|EXPERIMENTAL|POMA 120mg BID (240mg)|Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days
62314888|NCT03321617|EXPERIMENTAL|POMA 160 mg BID (320 mg)|Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days
62314889|NCT03085810|EXPERIMENTAL|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks (+/- 14 days) for a maximum of 8 doses throughout the 192 weeks treatment period.
62314890|NCT03085810|ACTIVE_COMPARATOR|Substudy Group 1|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 3.5 hours every 24 weeks for the remainder of the study duration
62339636|NCT04003077|NO_INTERVENTION|Control|A control group of participants without laser meridian massage treatment are matched by age.
62685288|NCT06192160|EXPERIMENTAL|Arm 3A: BDQ, Pa and TBI-223 (1200 mg)|"* Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 1200 mg~* Weeks 9-26: INH 300 mg, RIF 600 mg"
62685289|NCT06192160|EXPERIMENTAL|Arm 3B: BDQ, Pa and TBI-223 (2400 mg)|"* Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 2400 mg~* Weeks 9-26: INH 300 mg, RIF 600 mg"
62124963|NCT03511651|EXPERIMENTAL|FRC at clinical PEEP + 5cmH2O|Increasing PEEP to clinical PEEP + 5cmH2O
62124964|NCT02537483|EXPERIMENTAL|IDP-120 Gel|IDP-120 Gel, applied topically to the face once daily for 12 weeks.
62124965|NCT02537483|ACTIVE_COMPARATOR|IDP-120 Component A|IDP-120 Component A, applied topically to the face once daily for 12 weeks
62124966|NCT02537483|ACTIVE_COMPARATOR|IDP-120 Component B|IDP-120 Component B, applied topically to the face once daily for 12 weeks
62124967|NCT02537483|PLACEBO_COMPARATOR|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, applied topically to the face once daily for 12 weeks
62124968|NCT03174171|EXPERIMENTAL|Intervention|Everolimus 0.75 mg b.i.d. orally for 14 days.
62124969|NCT04723394|EXPERIMENTAL|AZD7442|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 1 (n=up to approximately 850) will receive a single dose (× 2 IM injections) of 600 mg of AZD7442.
62124970|NCT04723394|PLACEBO_COMPARATOR|Placebo|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 2 (n=up to approximately 850) will receive saline placebo.
62124971|NCT03883529|EXPERIMENTAL|Women reviewing birth experience|Women who had their antenatal care provided at a high-risk antenatal clinic, will be offered to write about and review their birth experience about 6 weeks post-partum with a known midwife from antenatal care.
62124972|NCT02287441|PLACEBO_COMPARATOR|Raw Group|Vegetables Prepared Raw (raw)
62124973|NCT02287441|EXPERIMENTAL|Tomato Group|Tomato Products (tomato)
62124974|NCT04125810|EXPERIMENTAL|Probiotic|Probiotic
62124975|NCT04125810|PLACEBO_COMPARATOR|Placebo|Placebo
62124976|NCT06354140|EXPERIMENTAL|S-1 Combined With Tislelizumab|tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
62124977|NCT04780035|EXPERIMENTAL|"Group Vaccine"|2,250 volunteers who will be vaccinated with the EpiVacCorona vaccine, twice intramuscularly at a dose of 0.5 ml.
62124978|NCT04780035|PLACEBO_COMPARATOR|"Control Group"|750 volunteers who will be vaccinated with a placebo, twice intramuscularly at a dose of 0.5 ml.
62124979|NCT03310112|EXPERIMENTAL|4-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.
62124980|NCT03310112|ACTIVE_COMPARATOR|2-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.
62124981|NCT03310112|NO_INTERVENTION|No training control (NTC)|Participants will receive no intervention but will be tested before and after a no-training interval.
62124982|NCT03801967|EXPERIMENTAL|AZD9977|Each participant will receive AZD9977 at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
62124983|NCT03801967|PLACEBO_COMPARATOR|Placebo|Each participant will receive placebo at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
62124984|NCT04975945|EXPERIMENTAL|Local|Participants will receive single-time intra-operative intra-dermal ceftriaxone (15-20mg/kg diluted in 10 ml normal saline)
62124985|NCT04975945|ACTIVE_COMPARATOR|Parenteral|Participants will receive parenteral ceftriaxone (15-20mg/kg) for prolonged duration as per local protocol
62124986|NCT03264261|EXPERIMENTAL|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
62124987|NCT03264261|ACTIVE_COMPARATOR|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
62314891|NCT03085810|EXPERIMENTAL|Substudy Group 2|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 2 hours followed by sodium chloride given as a slow infusion over the remaining 1.5 hours to mimic the standard-length infusion (3.5 hour) every 24 weeks for the remainder of the study duration
62314892|NCT06362408||the DEX group|used DEX (safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery
62314893|NCT06362408||the Non-DEX group|did not use DEX throughout the entire anesthesia process
62314894|NCT04806568|EXPERIMENTAL|PwMS-CCT|"Adult individuals with Multiple Sclerosis will follow a cognitive training intervention.~* Neurological assessment~  * History of Multiple Sclerosis~ * Expanded Disability Status Scale (EDSS)~* 2 types of high-density electroencephalographic recordings~  * at rest with eyes closed (15 minutes)~ * event potentials via a multisensory oddball paradigm (45 minutes)~* Neuropsychological assessment~  * MMSE~ * CDT~ * GVLT~ * BVMT~ * SDMT~ * Verbal Fluency: Phonemic \[ Chi-Sigma-Alpha\] and Semantic \[Animals-Fruits-Objects\]~ * Digit Span (For-Back-Seq)_WAIS-4GR~ * SNST~ * GAT~ * DASS21~ * MSIS-29~ * CRIq~ * MFIS~ * EQ-5D-5L~ * BDI-II~* Somatometric assessment~  * Timed 25-Foot Walk (T25-FW)~ * 3m backwards walk test~ * Hole Peg Test (9-HPT)~ * Handgrip Strength Test~ * Single Leg Stance (SLS)~ * Four Square Step Test (FSST)~* BrainHQ training~* Monitoring of daily activity"
62314895|NCT04806568|ACTIVE_COMPARATOR|PwMS-CON|"Adult individuals with Multiple Sclerosis serving as active controls.~* Neurological assessment~  * History of Multiple Sclerosis~ * Expanded Disability Status Scale (EDSS)~* 2 types of high-density electroencephalographic recordings~  * at rest with eyes closed (15 minutes)~ * event potentials via a multisensory oddball paradigm (45 minutes)~* Neuropsychological assessment~  * Mini Mental Status Examination (MMSE)~ * Clock Drawing Test (CDT)~ * Greek Verbal Learning Test (GVLT)~ * Brief Visuospatial Memory Test (BVMT)~ * Symbol Digit Modalities Test (SDMT)~ * Verbal Fluency: Phonemic \[ Chi-Sigma-Alpha\] and Semantic \[Animals-Fruits-Objects\]~ * Digit Span (For-Back-Seq)_WAIS-4GR~ * Stroop Neuropsychological Test (SNST)~ * The Greek Accentuation Test (GAT)~ * DASS-21~ * MSIS-29~ * CRIq~ * MFIS~ * EQ-5D-5L~ * BDI-II~* Somatometric assessment~  * T25-FW~ * 3m backwards walk test~ * 9-HPT~ * Handgrip Strength Test~ * SLS~ * FSST~* Monitoring of dailty activity"
62314896|NCT04806568|NO_INTERVENTION|HC|"Healthy adults serving as passive controls.~* 2 types of high-density electroencephalographic recordings~  * at rest with eyes closed (15 minutes)~ * event potentials via a multisensory oddball paradigm (45 minutes)~* Neuropsychological assessment~  * Mini Mental Status Examination (MMSE)~ * Greek Verbal Learning Test (GVLT)~ * Brief Visuospatial Memory Test (BVMT)~ * Symbol Digit Modalities Test (SDMT)~* Somatometric assessment~  * Timed 25-Foot Walk (T25-FW)~ * 3m backwards walk test~ * Hole Peg Test (9-HPT)~ * Handgrip Strength Test~ * Single Leg Stance (SLS)~ * Four Square Step Test (FSST)"
62314897|NCT02446652|EXPERIMENTAL|Hydralazine/Magnesium valproate + QT|This group will receive TRANSKRIP® (Hydralazine/Magnesium valproate) + Carboplatin plus Paclitaxel
62314898|NCT02446652|PLACEBO_COMPARATOR|placebo + QT|This group will receive placebo + Carboplatin plus Paclitaxel
62314899|NCT04449432|EXPERIMENTAL|GROWell (Interactive Obesity Treatment Approach)|With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four components: (1) personalized goal setting, (2) daily support and educational messages, (3) self-monitoring of behavior with tailored feedback, and (4) skills training. Each component aligns with the self- regulatory processes shown in previous studies to be necessary for behavior change. All interactions with participants are via text using a cell phone.
62314900|NCT04449432|ACTIVE_COMPARATOR|Attention Support Control|The attention control will be delivered using text messaging to reduce the potential placebo effect that interacting with our mHealth system may have on pregnancy weight gain and postpartum weight loss. Information will be provided to control group participants that is specific to pregnancy, labor, delivery, and early infancy, but not to diet. Texts are specific to the participant's partner, pregnancy, employment, and breastfeeding plans/status.
62478633|NCT06555458|EXPERIMENTAL|Dexmedetomidine|"Patients will receive the standardized pre-op meds and spinal anesthetic.~Once the patient's spinal is performed, patient will receive the following:~Start with bolus of 0.4 microgram/kg over 10 minutes, and then infusion of 0.4 microgram/kg/hr infusion will be stopped after the last staple or suture is performed on the incision.~Interventions:~Drug: Dexmedetomidine"
62685290|NCT06192160|EXPERIMENTAL|Arm 4A: BDQ, Pa and Sutezolid (SZD) (800 mg)|"* Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 800 mg~* Weeks 9-26: INH 300 mg, RIF 600 mg"
62685291|NCT06192160|EXPERIMENTAL|Arm 4B: BDQ, Pa and SZD (1600 mg)|"* Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 1600 mg~* Weeks 9-26: INH 300 mg, RIF 600 mg"
62685292|NCT06137092|EXPERIMENTAL|AryoGen Pharmed Co. rFVIII-Fc/Elocta® (Sobi Co. rFVIII-Fc)|AryoGen Pharmed Co. rFVIII-Fc, IV, 50 units/kg, single dose, then Elocta® (Sobi Co. rFVIII-Fc), IV, 50 units/kg, single dose (cross-over)
62685293|NCT06137092|EXPERIMENTAL|Elocta® (Sobi Co. rFVIII-Fc)/AryoGen Pharmed Co. rFVIII-Fc|Elocta® (Sobi Co. rFVIII-Fc), IV, 50 units/kg, single dose, then AryoGen Pharmed Co. rFVIII-Fc, IV, 50 units/kg, single dose (cross-over)
62685294|NCT05954312|EXPERIMENTAL|VVD-130037 Dose Escalation|Participants will receive ascending doses of VVD-130037, orally, once daily in 21-day treatment cycles.
62685295|NCT01292993|EXPERIMENTAL|Treatment A|400 mg LX4211
62685296|NCT01292993|EXPERIMENTAL|Treatment B|1000 mg metformin
62124988|NCT01377428|EXPERIMENTAL|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
62124989|NCT01377428|ACTIVE_COMPARATOR|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
62124990|NCT06014775|EXPERIMENTAL|Intervention（Anti-CD38 antibody）|10 enrolled subjects : once a week x 8 doses
62478634|NCT06555458|PLACEBO_COMPARATOR|Saline|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.~Interventions:~Drug: Normal Saline"
62478635|NCT05136703|EXPERIMENTAL|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|Participants randomized to receive CBT-AD immediately will complete up to 15 individual sessions (12 session with 3 booster sessions) focused on depression and one session of ART Adherence counseling during the four months following randomization.
62124991|NCT05346978|EXPERIMENTAL|Nasturtium (NT)|5g freeze-dried nasturtium leaf powder ; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
62685297|NCT01292993|EXPERIMENTAL|Treatment C|400 mg LX4211 + 1000 mg metformin
62685298|NCT04882605||Donor/recipient couple with Matched Sibling Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation~+ its 10/10 HLA-matched donor recruited among his siblings"
62685299|NCT04882605||Donor/recipient couple with Haploidentical Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation~+ its 5/10 HLA-matched donor recruited among his relatives"
62685300|NCT05802836||Inhibitor negative, FVIII on demand or regularly|Patients with severe hemophilia A receiving emicizumab therapy which are negative for factor VIII Inhibitor (including patients post ITI) and are receiving factor VIII therapy either on demand or regularly,
62124992|NCT05346978|PLACEBO_COMPARATOR|Placebo (PLC)|3g collagen colored with green pigment used in the food industry; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
62124993|NCT01256736|EXPERIMENTAL|Tocilizumab 8mg/kg + DMARDs|
62124994|NCT01541631|EXPERIMENTAL|HIV-1 co-infected with schistosoma mansoni|HIV-1 patients co-infected with Schistosoma mansoni
62124995|NCT01541631|NO_INTERVENTION|HIV-1 positive individuals with negative S. mansoni|HIV-1 positive individuals with negative Schistosoma mansoni
62478636|NCT05136703|EXPERIMENTAL|Wait-List Control (WLC)|Participants randomized to the WLC condition will receive one session of ART adherence counseling immediately following randomization. After six months, WLC participants will have the opportunity to receive 15 individually delivered CBT-AD sessions (12 sessions and 3 booster sessions) focused on depression.
62478637|NCT06152081|EXPERIMENTAL|All Participants|All participants enrolled in the study will have the two caries detecting devices used during each research visit.
62478638|NCT00090662||Healthy volunteer|Healthy volunteer
62478639|NCT06094023||Teenage girls between 13 and 19 years living in the Arba Minch Demographic and Surveillance site.|Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals
62478640|NCT00583453|ACTIVE_COMPARATOR|A|Celecoxib 200 mg tablets
62478641|NCT00583453|PLACEBO_COMPARATOR|B|Placebo with same dosing schedule as the active comparator arm
62478642|NCT05247723|EXPERIMENTAL|SIVCA|Aspirating testicular tissue using a standard IV cannula with applied negative pressure.
62478643|NCT05247723|ACTIVE_COMPARATOR|Micro-TESE|Extracting testicular tissue surgically
62478644|NCT06007690|EXPERIMENTAL|High dose bel-sar treatment arm & laser application|High dose of bel-sar + laser application
62478645|NCT06007690|EXPERIMENTAL|Low dose bel-sar treatment arm & laser application|Low dose of bel-sar + laser application
62478646|NCT06007690|SHAM_COMPARATOR|Sham control arm & sham laser|Sham injection + sham laser
62124996|NCT01541631|EXPERIMENTAL|Schistosoma mansoni positive but HIV-1 negative|Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals
62685301|NCT05802836||Inhibitor positive, FVIII therapy regularly (ITI)|Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving regularly factor VIII therapy (ITI)
62124997|NCT01541631|NO_INTERVENTION|HIV-1 and Schistosoma mansoni negative|Individuals with no HIV-1 and S. mansoni infections
62339637|NCT00434122|EXPERIMENTAL|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
62339638|NCT00434122|PLACEBO_COMPARATOR|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
62478647|NCT05377827|EXPERIMENTAL|Dose Escalation Cohort A: WU-CART-007 T-NHL|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
62478648|NCT05377827|EXPERIMENTAL|Dose Escalation Cohort B: WU-CART-007 leukemia|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
62478649|NCT05377827|EXPERIMENTAL|Dose Expansion Cohort A: WU-CART-007 T-NHL|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.
62685302|NCT05802836||Inhibitor positive, no FVIII therapy|Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving no factor VIII therapy
62685303|NCT06419907|ACTIVE_COMPARATOR|Group 1|100% of a face to face 6 hour structured diabetes self management education session
62685304|NCT06419907|EXPERIMENTAL|Group 2|60% of a face to face 6 hour structured diabetes self management education session. Total attendance will be 3 hours 36 minutes.
62685305|NCT06419907|EXPERIMENTAL|Group 3|10% of a face to face 6 hour structured diabetes self management education session. Total attendance will be 36 minutes.
62685306|NCT06419907|ACTIVE_COMPARATOR|Group 4|Will not attend a face to face 6 hour structured diabetes self management education session
62685307|NCT00772200||Observational (neuropsychological and behavioral tests)|Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
62685308|NCT04198337|EXPERIMENTAL|Endoscopic Full Thickness Resection|Resection of the gastric GIST by ESD techniques followed by endoscopic closure of defect with suturing or clips and loop
62685309|NCT06687213||1_Case group 2_control group|"1. Case group diabetic smokers which will be counseled to cessate smoking~2. Control group diabetic smokers which will refuse to cessate smoking"
62685310|NCT06687213||Case control group|Case group: diabetic smokers which will cessate smoking Control group: diabetic smokers which will refuse to cessate smoking
62685311|NCT00666614|OTHER|Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
62685312|NCT00666614|OTHER|Standard Care|Normal Hospital Environment
62685313|NCT05428670|EXPERIMENTAL|Zanubrutinib+Rituximab+Lenalidomide|"The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 2-21;~Lenalidomide, 10-20 mg qd, po, day 2-14;~Rituximab, 375 mg/m², ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 10-20 mg qd po during 1-21 days in every 28 days, for a maximum of 2 years."
62685314|NCT05428670|ACTIVE_COMPARATOR|RCHOP/RCDOP|"The RCHOP/RCDOP regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Rituximab, 375 mg/m², ivgtt, day 1;~Cyclophosphamide, 500-750 mg/m², ivgtt, day 2;~Doxorubicin, 50 mg/m², ivgtt day 2 (liposomal doxorubicin, 20-30 mg/m², ivgtt day 2 or Epirubicin, 50-60 mg/m², ivgtt day 2);~Vincristine, 1.4 mg/m², iv day 2 or vindesine, 3mg/m², iv day 2;~Prednisone, 100 mg qd, po day 2-6."
62685315|NCT06675617|EXPERIMENTAL|Allay Aortic Stent|A covered thoracic stent graft is first deployed in supraceliac position as per standard of care then followed by the implantation of the Allay® Aortic Stent deployed from within the stent graft, extending below the celiac trunk to the end of the dissected aorta, typically the aortoiliac bifurcation.
62685316|NCT04833907|EXPERIMENTAL|3.7 x 10^13 v.g. rAAV-Olig001-ASPA|3.7 x 10\^13 v.g. of rAAV-Olig001-ASPA administered as a single dose neurosurgically to the brain via 2 pre-defined intracerebroventricular sites
62685317|NCT00383565|EXPERIMENTAL|Arm I|Patients receive FR901228 IV over 4 hours on days 1, 8, and 15.
62685318|NCT05592379|EXPERIMENTAL|Group 1A: 2-minute IV Psilocybin+Clonidine / Saline in Asleep Participants|Participants will receive 10 mL of placebo (saline) over 2 minutes while asleep during their first overnight visit. Participants will receive 0.2 mg oral clonidine and either 2 mg of IV psilocybin or saline over 2 minutes while asleep during their second overnight visit.
62685319|NCT05592379|EXPERIMENTAL|Group 1B: 2-minute IV Psilocybin+Clonidine Infusion in Awake Participants|If Group 1A participants can sleep 1 hour post-dosing and/or have no memory of dosing, Group 1B moves forward and participants will receive 0.2 mg clonidine and 2 mg of IV psilocybin over 2 minutes while awake.
62685320|NCT05592379|EXPERIMENTAL|Group 2A: 2-minute IV Psilocybin+Clonidine / Saline in Asleep Participants|If Group 1A participants fail to sleep 1 hour post-dose, Group 2A moves forward. Participants will receive 10 mL of placebo (saline) over 10 minutes while asleep during their first overnight visit. Participants will receive 0.2 mg oral clonidine and either 2 mg of IV psilocybin or saline over 10 minutes while asleep during their second overnight visit.
62478650|NCT05377827|EXPERIMENTAL|Dose Expansion Cohort B: WU-CART-007 leukemia|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.
62478651|NCT06323408||Embryonal|Embryonal tumors, including medulloblastoma and ATRT
62478652|NCT06323408||Glioma, IDH-mutated|IDH-mutated gliomas, including WHO grades 2, 3 and 4
62685321|NCT05592379|EXPERIMENTAL|Group 2B: 10-minute IV Psilocybin+Clonidine in Awake Participants|If Group 2A participants can sleep 1 hour post-dosing and/or have no memory of dosing, Group 2B moves forward and participants will receive 0.2 mg clonidine and 2 mg of IV psilocybin over 10 minutes while awake.
62314901|NCT05582577|EXPERIMENTAL|Simultaneous intravitreal bevacizumab injection with subthreshold micropulse laser|"After the eye examination, the eyes will be randomly divided into 2 groups {group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser, and group B: intravitreal injection of Bevacizumab alone}. For both groups, 3 intravitreal injections of bevacizumab with a dose of 1.25 mg will be performed, in sterile conditions at 1-month intervals as a loading dose.~A subthreshold micropulse laser will be performed after the third injection in group A. Then, the intravitreal injection of Bevacizumab will be continued if the central thickness of the macula is equal to or greater than 300 microns.~The follow-up will be performed 2, 3, 4, 6, 8, 10, and 12 months after the first injection. In each follow-up (except for the first month), ophthalmological examinations and Optical Coherence Tomography will be performed."
62314902|NCT05582577|ACTIVE_COMPARATOR|Intravitreal bevacizumab injection alone|"After the eye examination, the eyes will be randomly divided into 2 groups {group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser, and group B: intravitreal injection of Bevacizumab alone}. For both groups, 3 intravitreal injections of bevacizumab with a dose of 1.25 mg will be performed, in sterile conditions at 1-month intervals as a loading dose.~A sham laser will be performed after the third injection in group B. Then, the intravitreal injection of Bevacizumab will be continued if the central thickness of the macula is equal to or greater than 300 microns.~The follow-up will be performed 2, 3, 4, 6, 8, 10, and 12 months after the first injection. In each follow-up (except for the first month), ophthalmological examinations and Optical Coherence Tomography will be performed."
62314903|NCT03238248|EXPERIMENTAL|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
62314904|NCT04359446|OTHER|Stent under-expansion with NC Balloon|
62314905|NCT04359446|OTHER|Stent under-expansion with Laser Excimer + NC Balloon|
62314906|NCT06331728|EXPERIMENTAL|IGNX001|Participants will receive IGNX001 given as a single subcutaneous dose on Day 1.
62314907|NCT06331728|PLACEBO_COMPARATOR|Placebo|Participants will receive IGNX001 placebo given as a single subcutaneous dose on Day 1.
62478653|NCT05747807|EXPERIMENTAL|Percutaneous intradiscal radiofrequency|"Standard monitoring ,prone position, sterile prepped and draped No sedation, Fentanyl 0.5-2 mcg/kg IV as needed ATB prophylaxis: ceftriaxone 1 g IV Performed by interventional pain physician, under fluoroscopic guidance 2% lidocaine 5 ml LA using Flextrode introducer kit, Boston Scientific Corporation Using an extrapedicular approach ipsilateral to the prolapse, the Flextrode cannula is advanced to the posterior disc.~The Flextrode electrode is inserted through the cannula. Sensory (50Hz) and motor (2Hz) stimulation, 3 Volts amplitude and 1msec pulse width. Confirm no sensory/motor response.~Lateral, AP, and oblique x-ray views are used to confirm the active tips are fully within the disc Thermal RF: temp 80 ◦C, 4 min Ceftriaxone 75 mg intradiscal injection via the cannula"
62478654|NCT01442558|ACTIVE_COMPARATOR|SCL|Supraclavicular ultrasound-guided brachial plexus block
61924092|NCT02310321|EXPERIMENTAL|Phase 1: Dose Evaluation (DEv)|"Induction period: Participants received 120 milligrams (mg) gilteritinib (3 tablets of 40 mg) orally, once daily from day 4 to 17 combined with chemotherapy (idarubicin: 12 mg per square meters per day \[mg/m\^2/day\] on days 1 to 3, cytarabine: 100 mg/m\^2/day on days 1 to 7) via intravenous (IV) infusion; in cycles (C) 1 and 2 (1 cycle= 42 days).~Consolidation period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from day 1 to 14 combined with chemotherapy (cytarabine: 1500 mg/m\^2, twice daily on days 1, 3, and 5) via IV infusion; in the consolidation period in C1 to 3 (1 cycle= 28 days).~Duration of infusion was determined by site clinical practice and local package insert in both induction and consolidation periods..~Maintenance period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 1 to 28 in the maintenance period in C1 to 26 or untill discontinuation criterion is met (1 cycle= 28 days)."
62314908|NCT02677701|ACTIVE_COMPARATOR|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
62314909|NCT02677701|PLACEBO_COMPARATOR|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
62314910|NCT01797432|EXPERIMENTAL|Combined IL Kenalog and Restylane|Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp
62314911|NCT00978575|ACTIVE_COMPARATOR|Intravenous iron|
62314912|NCT00978575|ACTIVE_COMPARATOR|Oral iron|
62314913|NCT00978575|PLACEBO_COMPARATOR|Isotonic Sodium and placebo tablets|
62314914|NCT02558699|ACTIVE_COMPARATOR|conventional group|Group operating the atrial fibrillation by physician's personal experience, not by virtual simulation.
62314915|NCT02558699|EXPERIMENTAL|3D atrial computer model|Group choosing choose the best effective rotor mapping by simulating 3D atrial computer model which consider patinet's heart size and shape.
62478655|NCT01442558|ACTIVE_COMPARATOR|ICL|Infraclavicular ultrasound-guided brachial plexus block
62478656|NCT01442558|ACTIVE_COMPARATOR|AX|Axillary ultrasound-guided brachial plexus block
62314916|NCT01479088|EXPERIMENTAL|cinacalcet tab or extemporaneous solution po added to SoC|"Subjects who meet all inclusion/exclusion criteria at baseline will be given cinacalcet 30mg film-coated tablet, for oral use added to phosphate binders and vitamin D analogue.~For subjects receiving a cinacalcet dose \<30mg, commercially available cinacalcet 30mg tab will be ground and diluted with a 5% dextrose solution. Then, an aliquot of this solution corresponding to the individually prescribed dose will be administered as indicated.~Initial dosing of cinacalcet will be 0.5-0.75mg/kg or 30 mg po once daily (OD) each evening with food.~During the cinacalcet dose-titration 6-month period for efficacy assessment, the dose will be increased on monthly basis by 0.5 mg/kg or by 30mg OD to achieve the target iPTH value \<180 pg/mL, as tolerated by the subject, up to maximum of 180mg OD in absence of signs of hypocalcemia, according to the current summary of product characteristics."
62478657|NCT05382715||Cohort 1|
62478658|NCT00555113||1|pseudoxanthoma elasticum
62685322|NCT05592379|ACTIVE_COMPARATOR|Group 1C: 2-minute IV Psilocybin Alone in Awake Participants|If Group 1A allows for sleep 1 hour post dose, Group 1C will move forward and participants will receive 2mg of IV psilocybin over 2 minutes while awake for comparison.
62685323|NCT05592379|ACTIVE_COMPARATOR|Group 2C: 10-minute IV Psilocybin Alone in Awake Participants|If Group 2A allows for sleep 1 hour post dose, Group 2C will move forward and participants will receive 2mg of IV psilocybin over 10 minutes while awake for comparison.
62685324|NCT05592379|EXPERIMENTAL|Initial Groups 1A and 2A|Participants will receive 2mg of IV psilocybin over 2 minutes or 10 minutes while asleep during an overnight visit and 10 mL of placebo (saline) over 2 minutes or 10 minutes while asleep during another overnight visit. The order of administration will be determined by the study protocol.
62685325|NCT06673641|EXPERIMENTAL|Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
62314917|NCT03721081|PLACEBO_COMPARATOR|Na Cl 0.9%/Epi 1:200000|Subcutaneous infiltration of Na Cl 0.9%/Epi 1:200000
62314918|NCT03721081|ACTIVE_COMPARATOR|Lidocaine 1%/Epi 1:200000|Subcutaneous infiltration of Lidocaine 1%/Epi 1:200000
62314919|NCT03645252|ACTIVE_COMPARATOR|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
62314920|NCT03645252|ACTIVE_COMPARATOR|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
62314921|NCT05176847|EXPERIMENTAL|Gamified mLIFE app group|Participants allocated to this group will be provided with elements of social gaming and healthy competition within the mLIFE app.
62685326|NCT06673641|ACTIVE_COMPARATOR|CABTREO Topical Gel|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
62685327|NCT06673641|PLACEBO_COMPARATOR|Placebo Control|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
62685328|NCT02891954|EXPERIMENTAL|Single arm|Healthy volunteers will receive canagliflozin to assess pharmacodynamic responses to drug.
62685329|NCT02290574|EXPERIMENTAL|Thermo-radio-chemotherapy arm|Hyperthermia with concurrent chemo-radiation therapy
62685330|NCT06596356|EXPERIMENTAL|[14C] TS-172|Participants will receive oral \[14C\] TS-172 under fasted conditions
62685331|NCT02915601|EXPERIMENTAL|Sodium Bicarbonate|Participants assigned to oral sodium bicarbonate will receive 0.5 mEq/kg-lean body weight (LBW)/day for the entire 12 months. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
62685332|NCT02915601|PLACEBO_COMPARATOR|Placebo|Subjects randomly assigned to placebo will take the same number of capsules as if they were assigned to receive 0.5 mEq/kg-LBW/day of sodium bicarbonate. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
62685333|NCT06687239|OTHER|Blinded|Blinded biometric measurements
62685334|NCT06687239|OTHER|Non-blinded|Non-blinded biometric measurements
62314922|NCT05176847|ACTIVE_COMPARATOR|standard mLIFE app|Participants in this group will receive the same intervention as the experimental group, but some features of the App will not facilitate gaming or competition.
62314923|NCT04791969|EXPERIMENTAL|Naltrexone with ecological momentary intervention|Naltrexone Hydrochloride, 50 mg., intermittent with ecological momentary assessment (EMA)
62314924|NCT04791969|PLACEBO_COMPARATOR|Placebo with ecological momentary intervention|Placebo, intermittent with ecological momentary assessment (EMA)
62478659|NCT06741436||Control|Controls who meet the same inclusion/exclusion criteria, except they do not have preeclampsia and do not have pre-existing diabetes or chronic hypertension.
62685335|NCT06304012|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding+Rehabilitation therapy|Both groups of patients were provided with routine treatments. Based on this, the patients were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
62685336|NCT06304012|ACTIVE_COMPARATOR|Nasogastric tube feeding+Rehabilitation therapy|Both groups of patients were provided with routine treatments The group was provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
62685337|NCT06569784|EXPERIMENTAL|40 mg/120 μCi[14C]HSK31858|\[14C\]HSK31858
62685338|NCT06003647|NO_INTERVENTION|Control|Receive normal care
62685339|NCT06003647|EXPERIMENTAL|Intervention|Educational intervention
62685340|NCT06475495|EXPERIMENTAL|KYV101|Participants in this arm will receive a single dose of KYV-101 i.v., an autologous fully-human anti-CD19 CAR T-cell immunotherapy.
62685341|NCT06475495|ACTIVE_COMPARATOR|Rituximab|"In the Comparator group patients will receive 2x1 g Rituximab i.v. (Day 0 and Day 14).~Retreatment of 1000 mg rituximab i.v. may be initiated at week 24 if residual disease activity remains, otherwise retreatment should be delayed until disease activity returns. A DAS-28-CRP \> 3.2 will be used as a non-binding guidance for the re-treatment decision."
62685342|NCT06553898|EXPERIMENTAL|CAR-T treatment group|The trial consists of two phases, Dose Exploration(Part A) and Dose Expansion (Part B). In Part A, three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) are set up, starting from the low dose group to explore the safe and effective dose. Each dose group will be enrolled in 3 cases.If the optimal effective dose is still not explored in the highest dose group, the dose can be increased according to the situation, and the highest dose is no more than 6×105/kg. Upon the completion of Part A, 1 optimal dose is selected by the comprehensive judgment of the investigator and the technical partner to enter into the Part B stage. The group will then be enrolled in 3\~6 cases to continue to validate the safety and efficacy.A total enrollment of 12-18 patients is expected in the whole process of the trial.
62685343|NCT03731455|EXPERIMENTAL|Investigational and Comparator devices|Investigational (WISE Cortical Strip, WCS) and comparator (Subdural Strip Electrode, Ad-Tech Medical Instruments Corporation) devices will be used together.
62685344|NCT02621853|OTHER|MRI+RAMAN|Patients will undergo an MRI for assessment of the fat content of the liver. Then during surgery, their livers will be illuminated (for a few seconds) by Raman spectroscope (the device in question) to see if MRI findings correlate well with Raman spectroscopy findings.
62124998|NCT05384496|EXPERIMENTAL|Axitinib and Nivolumab for the Treatment of Mucosal Melanoma|This is a single center trial enrolling up to 20 total evaluable patients with unresectable primary or advanced mucosal melanomas arising from the head and neck, gastrointestinal, or genitourinary tract to receive frontline therapy with nivolumab IV 480mg q4 weeks plus axitinib 5mg PO twice daily. A Simon 2-stage design will be utilized. Upon progression with good tolerance, addition of stereotactive body radiation therapy (SBRT) or CTLA-4 blockade to continued nivolumab plus axitinib will be offered to patients depending on the type of progression. For patients with local or oligometastatic progression, stereotactic body radiotherapy (SBRT) will be added; for patients with progression in a site of prior radiotherapy or with multifocal or distant progression not amenable to SBRT, ipilimumab 1mg/kg IV q3 weeks for up to 4 doses will be added.
62124999|NCT04338893|ACTIVE_COMPARATOR|ROSA Total Knee Robotic Instrumentation|Total knee arthroplasty performed with ROSA Total Knee Robotic instrumentation
62125000|NCT04338893|ACTIVE_COMPARATOR|Conventional TKA Instrumentation|Total knee arthroplasty performed with conventional instrumentation
62125001|NCT01496521|EXPERIMENTAL|Aspirin|
62125002|NCT01496521|EXPERIMENTAL|Tea Polyphenols|
62125003|NCT01496521|NO_INTERVENTION|Control|
62125004|NCT05758597|EXPERIMENTAL|Remazolam besylate group|The remimazolam besylate treatment group was given remimazolam besylate 0.1-1mg/kg/h to maintain the target RASS score.
62125005|NCT05758597|ACTIVE_COMPARATOR|Midazolam group|The midazolam treatment group was given midazolam 0.05-0.2 mg/kg/h to maintain the target RASS score.
62125006|NCT02903615|EXPERIMENTAL|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
62685345|NCT05365880|EXPERIMENTAL|Liquid Lidocaine|The investigational treatment is 1.5 mL of aqueous 2% lidocaine.
62685346|NCT05365880|PLACEBO_COMPARATOR|Sham Placebo|The placebo arm is 1.5mL of aqueous of saline.
62685347|NCT02653755|ACTIVE_COMPARATOR|Ineligible for omission of RT|Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.
62125007|NCT02903615|PLACEBO_COMPARATOR|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
62125008|NCT00749749|EXPERIMENTAL|Bupivacaine collagen sponge|Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.
62125009|NCT00749749|ACTIVE_COMPARATOR|ON-ON-Q PainBuster Post-op Pain relief SystemQ system|Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.
62125010|NCT02772263|EXPERIMENTAL|CHAP-EMS Intervention|Participants guided through a 15-20 minute defined risk assessment by a trained paramedic. Risk factors assessed were those related to cardiovascular and diabetes risk (blood pressure, diabetes-risk status, lifestyle factors), and potential for falls. Based on these, the paramedic provided education and developed an individualized action plan directing participants to use available community resources to assist them in addressing their risk factors. They were advised to return to CHAP-EMS sessions regularly for BP monitoring and follow-up. Each participant's information was faxed to his/her family physician once a month.
62125011|NCT04319874|SHAM_COMPARATOR|sham group|Treated with conventional chemotherapy drugs
62125012|NCT04319874|PLACEBO_COMPARATOR|NC group|Treated with conventional chemotherapy drugs and Placebo
62125013|NCT04319874|EXPERIMENTAL|experimental group|Treated with conventional chemotherapy drugs and Ganoderma lucidum
62314925|NCT04737122|EXPERIMENTAL|LM-061 single agent escalation|The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. The subject in single agent dose levels will be administered multiple oral doses of LM-061 once daily.
62314926|NCT04737122|EXPERIMENTAL|LM-061 combination escalation|The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. The subjects in combination dose levels will be administered multiple oral doses once daily of LM-061 and Toripalimab fixed dose injections every 3 weeks
62125014|NCT02259543|NO_INTERVENTION|G0|Root decontamination performed by scaling and root planing followed by rinsing with saline solution during the treatment of recession defects by subepithelial connective tissue graft (SCTG). Control group.
62125015|NCT02259543|ACTIVE_COMPARATOR|G90|Root conditioning with citric acid+tetracycline solution (1:1) for 90 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
62125016|NCT02259543|ACTIVE_COMPARATOR|G180|Root conditioning with citric acid+tetracycline solution (1:1) for 180 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
62125017|NCT02869022|EXPERIMENTAL|Custodiol-N|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
62478660|NCT06741436||PreE Px|Preeclamptic participants who meet the inclusion/exclusion criteria
62478661|NCT06562387|ACTIVE_COMPARATOR|1. tDCS active|Cognitive Stimulation + tDCS active in the Dorsolateral Prefrontal Cortex (Dorsolateral Prefrontal Cortex) to improve scores on tests of cognitive functioning (attention, memory, coordination, perception, reasoning and processing speed) and P300 cognitive evoked potentials.
62478662|NCT06562387|SHAM_COMPARATOR|2. sham tDCS|Cognitive Stimulation + sham tDCS in the Dorsolateral Prefrontal Cortex (Dorsolateral Prefrontal Cortex) to improve scores on cognitive functioning tests (attention, memory, coordination, perception, reasoning and processing speed), and evoked potentials P300
61924093|NCT02310321|EXPERIMENTAL|Phase 1: Dose Expansion (DEx)|"Induction period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once a day from days 4 to 17 in combination with chemotherapy (idarubicin: 12 mg/m\^2/day on days 1 to 3, cytarabine: 100 mg/m\^2/day on days 1 to 7) via IV infusion; in the induction period in C1 and 2 (1 cycle= 42 days).~Consolidation period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once a day from days 1 to 14 in combination with chemotherapy (cytarabine: 1500 mg/m\^2, twice daily on days 1, 3, and 5) via IV infusion; in the consolidation period in C1 to 3 (1 cycle= 28 days).~Duration of infusion was determined based on site clinical practice and the local package insert in both induction and consolidation periods.~Maintenance period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once a day from days 1 to 28 in the maintenance period in C1 to 26 or a discontinuation criterion is met (1 cycle= 28 days)."
62125018|NCT02869022|ACTIVE_COMPARATOR|Custodiol|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
62478663|NCT06742905|ACTIVE_COMPARATOR|Standard echo|Standard echo exam provided by a sonographer using a standard view template
62125019|NCT03036813|ACTIVE_COMPARATOR|Dose 1|voxelotor
62125020|NCT03036813|ACTIVE_COMPARATOR|Dose 2|voxelotor
62125021|NCT03036813|PLACEBO_COMPARATOR|Placebo|Placebo
62125022|NCT02534311||Tocilizumab|Participants will receive tocilizumab (162 milligrams \[mg\]) SC injection for 48 weeks.
62125023|NCT03411369|EXPERIMENTAL|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|Water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin.
62125024|NCT03411369|PLACEBO_COMPARATOR|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
62314927|NCT06673082|EXPERIMENTAL|interventional group|Oral Zinc will be supplemented to the interventional group on a dose of 30 mg elemental zinc/day.
62314928|NCT06673082|PLACEBO_COMPARATOR|control group|oral placebo identical to Zinc inappearance and packaging
62314929|NCT01863758|EXPERIMENTAL|Human-cl rhFVIII|Up to 60-80 IU/kg of intravenous Human-cl rhFVIII was administered at an individually determined dose and dose interval.
62314930|NCT03728127|EXPERIMENTAL|DicaBr group and nuts (DCBN)|Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
62314931|NCT03728127|ACTIVE_COMPARATOR|DicaBr group (DCB)|Brazilian cardioprotective diet
62478664|NCT06742905|EXPERIMENTAL|Robotic echo|Robotic echo exam provided by a sonographer using a standard view template
62478665|NCT01098591||Myocardial infarction|Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
62478666|NCT01098591||Ischemic cardiomyopathy|Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
62685348|NCT02653755|ACTIVE_COMPARATOR|Eligible for omission of RT|Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.
62685349|NCT02811419|ACTIVE_COMPARATOR|i-scan|Inspection with i-scan surface enhancement
62125025|NCT03957798|NO_INTERVENTION|Control (Treatment as Usual)|TAU consists of inpatient substance abuse treatment, followed by referral to outpatient treatment. For those who live within the outpatient geographic catchment area of the treatment center, patients are subsequently admitted to outpatient levels of care at treatment center. For the non-opioid population (primarily marijuana), this consists of the intensive outpatient program counseling sessions starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress with 12 wks target length of service. For the opioid population, this consists of a specialty youth opioid program with group and individual counseling, relapse prevention medications treatment, psychiatric assessment and treatment, also starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress, with indefinite target length of service. For those not within the outpatient geographic catchment area, patients are referred to local continuing care and outpatient levels of care convenient to their homes.
62314932|NCT06107062|EXPERIMENTAL|400mg Full Spectrum Cannabidiol (fsCBD)|
62314933|NCT06107062|EXPERIMENTAL|400mg Broad Spectrum Cannabidiol (bsCBD)|
62314934|NCT06107062|PLACEBO_COMPARATOR|Placebo|
62314935|NCT05678790|EXPERIMENTAL|Balance and Coordination|Since it is a case study, there will be only one group in the study.
62314936|NCT06555094|OTHER|Treatment as usual (TAU) + EMA|Participants will receive TAU and be prompted to complete 4x/day smartphone-based EMA surveys of negative emotion and STBs.
62314937|NCT06555094|EXPERIMENTAL|Experimental intervention + TAU|Participants will receive TAU plus 3 brief sessions of CBT skills, one discretionary post-discharge skills booster session, and 4x/day EMA and prompted EMI, which guides in-the-moment CBT skills practice.
62314938|NCT02575482|EXPERIMENTAL|Single and Multiple ascending dose|Single dose of SUVN-D4010 in healthy male subjects
62478667|NCT02488408|EXPERIMENTAL|Part A|Bemcentinib will be administered as monotherapy in participants with relapsed or refractory AML following previous treatment with cytotoxic chemotherapy (with or without hematopoietic stem cell transplantation) or a gene expression modulator, such as a demethylating agent.
62478668|NCT02488408|EXPERIMENTAL|Part B1|Single agent bemcentinib will be administered to participants with AML who are unsuitable for intensive chemotherapy as a result of advanced age and/or existing co-morbidities.
62478669|NCT02488408|EXPERIMENTAL|Part B2|Bemcentinib will be administered in combination with low dose cytarabine in participants with AML who are unsuitable for intensive chemotherapy as a result of advanced age or existing co-morbidities.
62478670|NCT02488408|EXPERIMENTAL|Part B3|Bemcentinib will be administered in combination with decitabine in participants with AML who are unsuitable for intensive chemotherapy as a result of advanced age or existing co-morbidities.
62478671|NCT02488408|EXPERIMENTAL|Part B4|Bemcentinib will be administered as a monotherapy to participants with previously treated MDS (including high risk and intermediate with the exception of deletion 5q MDS).
62685350|NCT02811419|ACTIVE_COMPARATOR|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
62314939|NCT02575482|PLACEBO_COMPARATOR|Placebo|Placebo in healthy male subjects
62125026|NCT03957798|EXPERIMENTAL|Intervention (Treatment as usual + game)|
62314940|NCT06512038|OTHER|ADDITIONAL DEXA SCAN|There is only 1 arm on this trial, if a participant agrees to take part they will have additional DEXA radiograph.
62314941|NCT05941182||Patient participants|"Participants who have been assigned to remote consultation follow up following a face-to-face appointment by their clinician.~Online Perceived Attributes of eHealth Technology online questionnaire before and after the remote consultation."
62314942|NCT05941182||Staff participants|Medical and administrative eye clinic staff at participating centres. Normalisation process (NOMAD) online questionnaire before and after the implementation period.
62314943|NCT01144689|EXPERIMENTAL|Mindfulness Training|
62314944|NCT01144689|ACTIVE_COMPARATOR|Smoking Cessation Therapy|
62314945|NCT00107107|ACTIVE_COMPARATOR|Pramlintide Acetate|Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
62314946|NCT03873129|EXPERIMENTAL|A-CHESS|participant will be using the A-CHESS mobile app for 12 months
62314947|NCT01563692||Paediatric health care workers|NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
62314948|NCT01563692||Non-paediatric health care workers|This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
62478672|NCT02488408|EXPERIMENTAL|Part B5|Bemcentinib will be administered in combination with low dose cytarabine in participants with relapsed or refractory who have received at least one prior treatment for. Participants must be unsuitable for intensive chemotherapy as a results of advanced age or existing co-morbidities.
62478673|NCT03390322|EXPERIMENTAL|Duodenal Glycemic Control™|
62685351|NCT03731000|EXPERIMENTAL|PHIL® device|Using device
62685352|NCT02320071||Patients with incisional hernia|Patients with one or more incisional hernias, combined horizontal fascial defect 3-8 cm, planned for laparoscopic mesh repair. Patients are examined before and one and three months postoperative in regard to abdominal wall function, pain, discomfort, hernia-related quality of life and physical activity level.
62685353|NCT02003898|EXPERIMENTAL|Medtronic MiniMed 530G Insulin Pump|All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
62685354|NCT06257875|EXPERIMENTAL|Induction Group 1|Participants will receive Dose 1 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Adalimumab placebo will be utilized to maintain the blind.
62685355|NCT06257875|EXPERIMENTAL|Induction Group 2|Participants will receive Dose 2 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind.
62685356|NCT06257875|EXPERIMENTAL|Induction Group 3|Participants will receive adalimumab per label throughout induction. Lutikizumab placebo will be utilized to maintain the blind.
62685357|NCT06257875|EXPERIMENTAL|Maintenance Group 1|Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Adalimumab placebo will be utilized to maintain the blind.
62314949|NCT03397485|EXPERIMENTAL|Growing Milk|"Experimental Fortified milk has energy from fatty acids, protein and carbohydrates. This milk has probiotics and essential micronutrients such as Zn, Fe, vitamins ( A, D, E, K, C and B complex), selenium and Copper among others.~Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend."
62478674|NCT04443907|EXPERIMENTAL|OTQ923|Single intravenous infusion of OTQ923 Part A - Adults treated with OTQ923; Part B - Children age 2-17 treated with OTQ923 based on review of data from Part A by Health agency after a formal interim analysis.
62685358|NCT06257875|EXPERIMENTAL|Maintenance Group 2|Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind.
62685359|NCT06257875|EXPERIMENTAL|Maintenance Adalimumab|Participants who respond to adalimumab induction group 3 will continue to receive adalimumab per label in the maintenance period. Lutikizumab placebo will be utilized to maintain the blind.
62685360|NCT06257875|EXPERIMENTAL|Maintenance Non-Responders|Participants who do not respond to study drug at the end of induction period will receive open label SC lutikizumab in the maintenance period.
62685361|NCT02362763|EXPERIMENTAL|Study group|Subjects received five acupuncture sessions designed to treat pain in the vulvar area
61924094|NCT02310321|EXPERIMENTAL|Phase 2: FLT3-mutated AML|"Induction period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 8 until blood recovery combined with chemotherapy (idarubicin: 12 mg/m\^2/day on days 1 to 3, cytarabine: 100 mg/m\^2/day on days 1 to 7) via IV infusion; in C1 and 2. Each cycle was extended until blood recovery was observed.~Consolidation period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 1 until blood recovery combined with chemotherapy (cytarabine: 1500 mg/m\^2, twice daily on days 1, 3, and 5) via IV infusion; in C1 to 3. Each cycle was extended until blood recovery was observed.~Duration of infusion was based on site clinical practice and the local package insert in both induction and consolidation periods.~Maintenance period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 1 to 28 in the maintenance period in C1 to 26 or a discontinuation criterion is met (1 cycle= 28 days)."
62685362|NCT02362763|ACTIVE_COMPARATOR|Controls|Controls received five acupuncture sessions designed for sedation
62685363|NCT01962753|EXPERIMENTAL|18FAV45|
62685364|NCT01309100|EXPERIMENTAL|Investigational Lens|Bausch \& Lomb investigational silicone hydrogel lens.
61924095|NCT02582762|EXPERIMENTAL|Nail gel|apply nail gel twice daily
61924096|NCT02794740|EXPERIMENTAL|X0002 First Dose|Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.
62685365|NCT01309100|ACTIVE_COMPARATOR|Acuvue Oasys Lens|Johnson \& Johnson Acuvue Oasys contact lens.
62685366|NCT01309100|ACTIVE_COMPARATOR|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens.
62685367|NCT06085638|EXPERIMENTAL|Arm1: Cohort 1: Azacitidine + Tamibarotene|Participants will receive azacitidine on Days 1-7 of each cycle and tamibarotene 2 times a day every day. Up to 20 participants will be enrolled in Cohort 1.
62314950|NCT03397485|ACTIVE_COMPARATOR|Fortified Milk|Fortified milk has no energy from fatty acids nor micronutrients such as vitamin B12, Selenium and Copper. This milk was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend.
62314951|NCT05141526|EXPERIMENTAL|Non-restrictive satiating intervention|The non-restrictive satiating intervention will include guidelines and recipes to prepare highly satiating meals that will be low in energy density and glycemic index and high in protein, polyunsaturated fats, vitamins and minerals (e.g. calcium), and certain constituents of spices (e.g. capsaicin).
62125027|NCT03062358|EXPERIMENTAL|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
62125028|NCT03062358|PLACEBO_COMPARATOR|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
62125029|NCT05157022|ACTIVE_COMPARATOR|Focus extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
62125030|NCT05157022|ACTIVE_COMPARATOR|Radial extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
62125031|NCT05157022|SHAM_COMPARATOR|Sham extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
62125032|NCT04641741||Control|Healthy adults
62125033|NCT04641741||Severe eosinophilic asthma|Severe uncontrolled asthma according to ERS/ATS criteria and persistent eosinophilia in blood (\>300 cells/μL)
62125034|NCT04456725|ACTIVE_COMPARATOR|Control|Usual care group
62125035|NCT04456725|EXPERIMENTAL|Intervention|Intensive management utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring.
62125036|NCT05858749||Patients with mRCC|Patients with mRCC in the IMDC
62125037|NCT03974763||Test Group|Patients with acute, unilateral, facial paralysis (Bell's Palsy)
62125038|NCT03974763||Control Group|A group of age- and sex-frequency matched 'normal' controls. Based on past research, gender and age are possible confounders of facial movement/function. Thus, the control group will be frequency-matched to the patient group on gender and age.
62125039|NCT03270124|ACTIVE_COMPARATOR|No Resistance Exercise and No Activity Goal Arm|Blinded use of Fitbit with no daily activity goal and no resistance exercises
62125040|NCT03270124|EXPERIMENTAL|Resistance Exercise and Activity Goal Arm|Unblinded use of Fitbit with a daily activity goal (steps per day) and resistance exercises
62125041|NCT05452759|EXPERIMENTAL|new type of tracheotomy high-flow oxygen therapy (NTHF)|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
62314952|NCT05141526|EXPERIMENTAL|Conventional restrictive intervention + non-restrictive satiating intervention|Conventional restrictive intervention consisting of a -500 kcal/d calorie deficit (P1) followed by a non-restrictive satiating intervention (P2)
62314953|NCT05141526|PLACEBO_COMPARATOR|Minimal healthy guidelines|Considering recommendations from the latest Canadian Obesity Guidelines, the control group will receive a minimal intervention based on the Canada's Food Guide for Healthy Eating
62314954|NCT06513793|EXPERIMENTAL|The Nature-based Intervention Condition: Roots and Shoots|The intervention condition, Roots and Shoots, consists of a printed, self-help guidebook that incorporates weekly, evidence-based activities with the aim to improve mental wellbeing. The intervention is a short, four week course for improving low wellbeing and is informed by psychological theory, clinical psychology therapeutic principles and environmental psychology.
62314955|NCT06513793|ACTIVE_COMPARATOR|Waiting list Control Condition|Participants in the waiting list control group will complete the assessments at the three time points: baseline (T0), at a 2-weeks (T1) and post-intervention (T2). At this point control condition participants will be offered the intervention and will receive a copy of the Roots and Shoots guidebook in the post and will be provided with full access to the additional online resources.
62314956|NCT02797366|OTHER|Proton radiotherapy|Proton radiation therapy daily (Monday through Friday) for 4-8 weeks. This is a single arm study.
62125042|NCT05452759|ACTIVE_COMPARATOR|Respiratory Humidification Treatment（ AIRVO TM 2）|Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
61924097|NCT02794740|EXPERIMENTAL|X0002 Second Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
61924098|NCT02794740|PLACEBO_COMPARATOR|Placebo Second Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
62314957|NCT06285162||Critically ill patients with continuous renal replacement therapy.|"The patients will be followed during the first 6 hours of the initiation of a net ultrafiltration (2-3 milliliters/kilograms/hour) with continuous monitoring (R-R interval, ANI, cardiac index, invasive arterial pressure, central venous pressure, peripheral perfusion index), and perfusion monitoring every 6 hours (arterial lactate, central venous oxygen saturation, capillary refill time, mottling score). Such a fluid removal strategy is part of an institutional protocol or an ongoing clinical trial.~In addition to the usual monitoring, the PhysioDoloris monitor will be connected to the patient's scope. The ANI and its parameters will be recorded continuously throughout the study."
62314958|NCT04634162|EXPERIMENTAL|Cangrelor|Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
62314959|NCT04634162|PLACEBO_COMPARATOR|Placebo|Ticagrelor loading dose followed after 1 hour by placebo infusion
62478675|NCT04854798|EXPERIMENTAL|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
62125043|NCT02728765|ACTIVE_COMPARATOR|auto CPAP|Each patient will be interviewed by the physician on duty and invited to participate in the overnight hospital based auto continuous positive airway pressure (CPAP) titration study for 1 night and then commencement of auto CPAP treatment for 6 months.
62125044|NCT02728765|PLACEBO_COMPARATOR|Subtherapeutic CPAP|Following detection of obstructive sleep apnea (OSA), each patient randomized to this arm will receive the same CPAP education, mask fitting and short auto CPAP trial for acclimatization but their auto CPAP device will be set at a subtherapeutic level of 4 cmH20 for use at home. The patients randomized to both arms will receive the same general education about OSA, sleep hygiene, avoidance of alcohol, and weight reduction if appropriate.
62125045|NCT02033148|EXPERIMENTAL|Treatment (icotinib hydrochloride)|Patients receive icotinib hydrochloride PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62125046|NCT03731624||SLK|
62125047|NCT03731624||GVHD|
62125048|NCT03731624||Dry eye|
62125049|NCT03731624||Control|
62125050|NCT04650386|NO_INTERVENTION|Treatment As Usual (TAU)|Participants assigned to the TAU condition will be scheduled for buprenorphine medication management appointments and will receive OBOT at the FQHC and adjunctive psychosocial treatment as typically provided at the FQHC. The team will continue to meet with the patient during subsequent MAT visits on a decreasing frequency, with some slight site-specific variation. The schedule of MAT visits generally includes 3 clinic visits during the week of induction, 1-2 visits per week until the patient is stabilized, and monthly thereafter. Behavioral health clinicians provide support to the patient, discuss UDS results, assist with strategic problem-solving around recovery and adjustment to sobriety, and monitor the patient's engagement in MAT.
62125051|NCT04650386|EXPERIMENTAL|Adaptive Intervention|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
62125052|NCT05463029||Healthy Controls|Healthy control participants will be recruited from the general population through the use of flyers and other means of advertising.
62314960|NCT00277472|EXPERIMENTAL|valsartan HCTZ|
62314961|NCT00277472|ACTIVE_COMPARATOR|HCTZ|
62314962|NCT05610891|EXPERIMENTAL|Pediatric High-Grade Glioma Patients|Two dosing cohorts will be explored; patients in the first arm will receive two doses, 20 mCi/m2 each, separated by 14 days for two cycles, with a third optional cycle. Patients in the second arm will receive two doses, 10 mCi/m2 each, separated by 14 days for three cycles with a fourth optional cycle.
62314963|NCT02203838|EXPERIMENTAL|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.
62314964|NCT05495399|EXPERIMENTAL|Spondylectomy with Conventional RT|Spondylectomy for involved spine level followed by conventional RT 20Gy in 5 fractions
62314965|NCT05495399|ACTIVE_COMPARATOR|Debulking surgery with Conventional RT|Debulking surgery for involved spine level followed by conventional RT 20Gy in 5 fractions
62314966|NCT05495399|EXPERIMENTAL|Debulking surgery with SBRT|Debulking surgery for involved spine level followed by SBRT 24Gy in 12 fractions
62314967|NCT00711451|ACTIVE_COMPARATOR|manual|Manual removal of placenta
62314968|NCT00711451|ACTIVE_COMPARATOR|expressed|expressed placental removal
62314969|NCT00918762|EXPERIMENTAL|daVinci® Robotic Surgical System|Participants will undergo a planned surgical procedures via the robotic approach.
62314970|NCT02547337||Type 1 diabetes|
62314971|NCT02547337||Healthy subjects|
62314972|NCT00759304||PROOF cohort|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.
62314973|NCT06670924|ACTIVE_COMPARATOR|Running suture (RS)|Running suture technique for vesico-urethral anastomosis in open radical prostatectomy
62478676|NCT04854798|NO_INTERVENTION|Control Group|Control Group
62478677|NCT04573023|EXPERIMENTAL|JR-141 2.0 mg/kg/week|
62478678|NCT04573023|OTHER|administered as the standard of care: idursulfase (ELAPRASE®)|standard of care-controlled study
62478679|NCT04573023|OTHER|Rescue arm|
62478680|NCT00500994|EXPERIMENTAL|fMRI study|subjects receiving MRI
62478681|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
62685368|NCT06085638|EXPERIMENTAL|Arm2: Cohort 2,3: Azacitidine + Tamibarotene + Venetoclax|"Participants will receive azacitidine on Days 1-7 of each cycle, tamibarotene 2 times a day every day, and venetoclax on either Days 1-7 or Days 1-14 of each cycle, depending on the dose level you are assigned at enrollment. Up to 12 participants will be enrolled in Cohort 2.~Once Cohort 2 is complete, Cohort 3 will begin. Participants in Cohort 3 will receive the recommended dosing schedule found in Cohort 2 (azacitidine on Days 1-7, tamibarotene 2 times a day every day, and venetoclax on either Days 1-7 or Days 1-14"
62125053|NCT05463029||Affected Patients|Research staff locate eligible patients in the hospital through real-time medical record review at the time of initial presentation to the NICU or request for neurology consultation for patients in the MICU or CCU. Once potential patients have been identified, research staff will approach their Legally Authorized Representative to introduce the study and initiate the informed consent process, if appropriate.
62125054|NCT02735291|EXPERIMENTAL|Single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
62125055|NCT03244046|ACTIVE_COMPARATOR|Physiotherapy (Phys)|12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
62125056|NCT03244046|EXPERIMENTAL|Somatic Experiencing + phys|12 sessions of psychotherapy (somatic experiencing) and 12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
62125057|NCT03559348|EXPERIMENTAL|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
62125058|NCT00430872||MDASI-Spine Tumor Module Survey|M. D. Anderson Symptom Inventory-Spine (survey) of patients with a tumor on the spine or spinal cord.
62125059|NCT05042024|ACTIVE_COMPARATOR|the SRP Group|Patients received conventional periodontal therapy including scaling and root planing as a full-mouth procedure, n=25.
62125060|NCT05042024|EXPERIMENTAL|the Arg Group|Patients received oral L-arginine aspartate (Yuria-Pharm, Ukraine) at a dose of 1 g t.i.d. for 10 days after conventional periodontal therapy, n=25.
62125061|NCT05042024|EXPERIMENTAL|the Orn Group|Patients received oral L-ornithine aspartate (Farmak, Ukraine) at a dose of 3 g t.i.d. for 15 days after conventional periodontal therapy, n=25.
62125062|NCT03647969|EXPERIMENTAL|mFOLFOX/Nivolumab/Ipilimumab A/A1|"Nivolumab 240mg Flatdose i.v. d1 over 30 min every 2 weeks followed by Ipilimumab 1mg/kg i.v. d1 over 30 min every 6 weeks followed by FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment."
62125063|NCT03647969|EXPERIMENTAL|mFOLFOX/Nivolumab/Ipilimumab sequential A2|"3 cycles of induction chemotherapy with FOLFOX: FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks followed by immunotherapy consisting of: 4 administrations of Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks and 2 administrations of Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks~Sequence as described may be repeated starting two weeks after last administration of immunotherapy once, or, if medically reasonable, for an unlimited number of repetitions upon investigator decision. After discontinuation of chemotherapy, immunotherapy will be continued consisting of:~Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks and Ipilimumab at 1mg/kg i.v. d1 every 6 weeks until disease progression or inacceptable toxicity or end of study treatment."
62125064|NCT03647969|ACTIVE_COMPARATOR|mFOLFOX B|FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment.
62314974|NCT06670924|ACTIVE_COMPARATOR|Interrupted suture (IS)|Interrupted suture technique for vesico-urethral anastomosis in open radical prostatectomy
62314975|NCT06338696||ATTR Cardiomyopathy|Patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy)
62685369|NCT01507103|EXPERIMENTAL|Chemoradiotherapy+tecemotide (L-BLP25)+CPA|
62685370|NCT01507103|EXPERIMENTAL|Chemoradiotherapy+tecemotide (L-BLP25)|
62314976|NCT01348178||developmental dysplasia of the hip, PAO|All patients who underwent periacetabular osteotomy from 1999-2007 at the University Hospital of Aarhus
62314977|NCT05310383|EXPERIMENTAL|Patients with recurrent cervical cancer|Patients with recurrent, metastatic and persistent advanced cervical cancer
62314978|NCT06313905|EXPERIMENTAL|EVADRY|90 Sjogren's syndrom patients with objective xerostomia receiving the EVADRY dietary supplement treatment.
62314979|NCT06313905|PLACEBO_COMPARATOR|PLACEBO|90 Sjogren's syndrom patients with objective xerostomia receiving a placebo.
62314980|NCT05275218|EXPERIMENTAL|Intervention Group|Implementation of the KDIGO bundle for at least 72 hours 1. Discontinuation of all nephrotoxic drugs when possible 2. Optimization of volume status and perfusion pressure. 3. Consideration of a functional hemodynamic monitoring. 4.Close monitoring of serum creatinine, and urinary output 5. Avoidance of hyperglycemia 6. Considerations of alternatives to radiocontrast agents 7. Non-invasive or invasive diagnostic workup 8. Nephrology consultation.
62314981|NCT05275218|NO_INTERVENTION|Control Group|"Patients in the control group will receive standard of care. According to best clinical practice, this includes the following targets (unless specific individual targets are chosen by treating physician):~* mean arterial pressure (MAP): ≥ 65 mmHg~* passive leg raising test (PLRT): increase of cardiac output (CO)\<10%"
62314982|NCT04871321||Gem/Cis/nab-P|Gemcitabine + Cisplatin + Nab-Paciltaxel
62314983|NCT02876224|EXPERIMENTAL|Cobimetinib + Bevacizumab + Atezolizumab (Stage 1: SRP)|Stage 1 Safety Run-in Phase (SRP): Approximately 12 participants will receive cobimetinib 60 milligrams (mg) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 milligrams per kilogram (mg/kg) administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to Stage 2: dose expansion phase. If the results from the safety run-in phase require dose reduction in cobimetinib, then an additional Stage 1 cohort will be opened. Treatment will continue until the participant has disease progression according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
62314984|NCT02876224|EXPERIMENTAL|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: BC)|Stage 2 Biopsy Cohort (BC): Approximately 7 evaluable participants in the biopsy cohort in expansion phase will receive bevacizumab 5 mg/kg IV on Cycle 1 Days 1 and 15 (tumor biopsy on Cycle 1 Day 8) and cobimetinib (at dose determined during safety run-in phase) orally on Cycle 1 Day 15 to Cycle 2 Day 14 (tumor biopsy on Cycle 1 Day 22). From Cycle 2 onwards, participants will follow the same treatment regimen for bevacizumab and atezolizumab (optional tumor biopsy on Cycle 2 Day 22) as those in the safety run-in phase and expansion cohort, and for cobimetinib cycles start at Day 15 and will continue 21 days to Day 7 of next cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Biopsies must be collected before the initiation of cobimetinib and atezolizumab. Treatment will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, decision to withdraw, or pregnancy, whichever occurs first.
62314985|NCT02876224|EXPERIMENTAL|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: EC)|Stage 2 Expansion Cohort (EC): Approximately 14 participants will receive cobimetinib (at dose determined during safety run-in phase) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 mg/kg administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Treatment will continue until the participant has disease progression according to RECIST v1.1, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
62314986|NCT02112604||Ventilated patients|Patients who have been extubated within 24 hours and have been mechanically ventilated for at least 24 hours. Alice PDx, pulmonary function tests, muscle strength tests, grip strength measurements, ventilator, Sedatives and muscle relaxants given in the ICU
62314987|NCT01332526||Patients with BMI> 30 and metabolic syndrome ( ATP III).|Patients with BMI\> 30 and metabolic syndrome ( ATP III).
62125065|NCT03647969|EXPERIMENTAL|FLOT/Nivolumab C|"Nivolumab 240mg Flatdose i.v. d1 every 2 weeks followed by FLOT: Docetaxel 50mg/², Oxaliplatin 85 mg/m², leucovorin 200 mg/m² on day 1 and fluorouracil 2600 mg/m² IV continuous infusion over 24 hours every 2 weeks until disease progression or inacceptable toxicity or end of study treatment. After completion or discontinuation of chemotherapy, immunotherapy may be continued consisting of: Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks Chemotherapy can also be administered per local standard."
62125066|NCT06379711|EXPERIMENTAL|Transcutaneous spinal cord stimulation (tSCS)|Exploring the mechanisms of SCS for improving cardiovascular function in individuals with chronic, motor-complete SCI by measuring vascular related endothelial biomarkers and plasma catecholamines
62314988|NCT01332526||Patient with BMI> 30 without metabolic syndrome.|Patient with BMI\> 30 without metabolic syndrome.
62314989|NCT01332526||Normal healthy control|healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI \< 25;normotensives ).
62314990|NCT01332526||Patients with CKD stage III and uric acid < 7 mg/dl|"Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid \< 7 mg/dl.~* without diabetes mellitus proteinuria \< 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( \< 140/90 mmHg)"
62478682|NCT06655545||FES-guided CDK4/6 inhibitor plus endocrine therapy cohort|The group guided with FES-PET using a CDK4/6 inhibitor plus ET.
62478683|NCT06655545||FES-guided chemotherapy cohort|The group guided with FES-PET using chemotherapy.
61924099|NCT02794740|EXPERIMENTAL|X0002 Third Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
62685371|NCT01507103|ACTIVE_COMPARATOR|Chemoradiotherapy|
61924100|NCT02794740|PLACEBO_COMPARATOR|Placebo Third Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
61924101|NCT02794740|EXPERIMENTAL|X0002 Fourth Dose|8 Subjects,Single Dose,Once,Double-Blind.
61924102|NCT02794740|PLACEBO_COMPARATOR|Placebo Fourth Dose|2 Subjects,Single Dose,Once,Double-Blind.
62314991|NCT01332526||Patients with CKD stage III and uric acid > 7 mg/dl|"Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid \> 7 mg/dl~* without diabetes mellitus proteinuria \< 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( \< 140/90 mmHg)"
62314992|NCT01332526||Patient with asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia, uric acid \> 7 mg/dl with normal renal function
62314993|NCT01332526||Hemodialysis patients|"Patient with asymptomatic hyperuricemia, uric acid \> 7 mg/dl with normal renal function Hemodialysis patients.~* CKD: nondiabetic nephropathy~* duration hemodialysis 3-48 months~* Hb-11-13 g/dl~* well controlled hypertension ( \< 140/90 mmHg)~* without ACEi, ARB, allopurinol treatment~* residual diuresis will be estimated for last 48 hours-between mid and next dialysis"
62314994|NCT02961647||Asymptomatic patients|Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.
61924103|NCT03590197|PLACEBO_COMPARATOR|Control Arm|The patients in Control Arm will receive placebo with valproate (20 mg/kg).
61924104|NCT03590197|EXPERIMENTAL|Melatonin Arm|The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.
61924105|NCT02637128|EXPERIMENTAL|artemether-lumefantrine (AL)|"20mg artemether/120 mg lumefantrine per tablet, Coartem-D™; Novartis, Basel, Switzerland administered following manufacturer's prescribed weight-based dosing, twice daily for 3 days.~5-14 kg: 1 tablet; 15-24: 2 tablets; 25-34 kg: 3 tablets; \>34 kg: 4 tablets per dose"
62685372|NCT05815199|EXPERIMENTAL|E-cigarettes (EC)|Adult cigarette smokers with a SMI diagnosis randomized to the EC arm will receive NRT including nicotine patches and lozenges. Participants will also receive telehealth motivational counseling during the intervention period of 8 weeks.
62685373|NCT05815199|ACTIVE_COMPARATOR|Nicotine Replacement Therapy (NRT)|Adult cigarette smokers with a SMI diagnosis randomized to the NRT arm will receive NRT including nicotine patches and lozenges gum. Participants will also receive telehealth motivational counseling during the intervention period of 8 weeks.
61924106|NCT02637128|EXPERIMENTAL|artesunate-amodiaquine (ASAQ)|25mg artesunate/67.5 mg amodiaquine or 50 mg artesunate/135mg amodiaquine per tablet, Coarsucam™; Sanofi-Aventis, Paris, France administered following manufacturer's prescribed weight-based dosing, once daily for 3 days 4.5-8.9 kg: 1 25mg/67.5 mg tablet; 9-17.9 kg: 1 50mg/135 mg tablet; 18-35.9 kg 2 50mg/135 tablets; \>36 kg: 4 50mg/135mg tablets per dose
61924107|NCT00744458|ACTIVE_COMPARATOR|1|
61924108|NCT00744458|ACTIVE_COMPARATOR|2|
61924109|NCT00744458|ACTIVE_COMPARATOR|3|
61924110|NCT01232218|ACTIVE_COMPARATOR|Current Standard Treatment|Current standard treatment for hemiplegic shoulder pain will be provided to this group.
61924111|NCT01232218|EXPERIMENTAL|Standard treatment + study technique|Participants will receive current standard treatment for hemiplegic shoulder pain PLUS an additional stretching/strengthening technique. Both groups will be allotted the same treatment time.
61924112|NCT03952754|EXPERIMENTAL|Group 2: Hip Hop Nutrition-Math Curriculum|The intervention group will receive an tailored program for ten weeks, meeting twice a week.
61924113|NCT03952754|ACTIVE_COMPARATOR|Group 1: Food Explorers Program|The control group will receive the usual care for nutrition program provided by the schools, called Food Explorers. The group will also be conducted ten weeks, meeting twice a week.
61924114|NCT03418571|EXPERIMENTAL|ALX-0171 1.5 mg/kg|
61924115|NCT03418571|PLACEBO_COMPARATOR|Placebo|
61924116|NCT06335290||Radiotherapy to thoracic region|Collection of data of patients receiving RT to thoracic region
61924117|NCT02452697|ACTIVE_COMPARATOR|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
61924118|NCT02452697|EXPERIMENTAL|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
61924119|NCT02452697|ACTIVE_COMPARATOR|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
61924120|NCT02452697|EXPERIMENTAL|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
61924121|NCT00768937|EXPERIMENTAL|Treatment arm|all patients will be treated with sorafenib
61924122|NCT05956379|EXPERIMENTAL|Exercise group|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, \>=3 cardio workouts per week.
61924123|NCT05956379|NO_INTERVENTION|Control group|No change in exercise habits and maintaining baseline physical activity.
61924124|NCT01689961|EXPERIMENTAL|Nutrition+Exercise Intervention|"Structured + monitored nutrition and exercise intervention:~The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence"
61924125|NCT01689961|NO_INTERVENTION|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health services. In addition, they will be asked to attend 2 focus group sessions exploring women's experiences with exercise, nutrition, and weight gain in pregnancy. Women will receive information about healthy pregnancy from Health Canada.
61924126|NCT06572228|EXPERIMENTAL|Dupilumab + ICS/LABA|Randomized 1:1
62314995|NCT02961647||Symptomatic patients|Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.
62685374|NCT01992081|EXPERIMENTAL|Telecoaching|Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care.
61924127|NCT06572228|PLACEBO_COMPARATOR|Placebo + ICS/LABA|Randomized 1:1
61924128|NCT00711724||MGH 1|Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
61924129|NCT05831631||Included patients|The study population will comprise 200 (two hundred) adult patients candidate to neurosurgical treatment for newly diagnosed malignant brain tumors, able to express an informed consent.
61924130|NCT03570879||Power morcellation|Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.
62125067|NCT02781766|OTHER|One arm: patients with severe haemophilia A on prophylaxis|Patients with severe haemophilia A (FVIII \< 1 IU/dl), currently on prophylactic therapy , having the same prophylaxis regimen in the last six months, aged between 2 (with a body weight ≥12.5 kg ) and 45 years , with adequate venous access, having patient's diary or equivalent regularly completed and able to give informed consent
62125068|NCT03332992|EXPERIMENTAL|Viral changes + General intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
62125069|NCT03332992|EXPERIMENTAL|Viral changes + Behavioral intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
62125070|NCT03332992|EXPERIMENTAL|Viral changes + Accountability|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
62314996|NCT00818038||TYSABRI|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
62685375|NCT01992081|OTHER|Control|Participants will receive the usual care but will NOT receive daily coaching by telehealth system.
62314997|NCT04751331|EXPERIMENTAL|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113) administered as an intravenous bolus.
62314998|NCT04751331|PLACEBO_COMPARATOR|Placebo|Placebo (same volume of 0.9% saline) administered as an intravenous bolus
62685376|NCT02812537||patients with conduct disorders|Girls and boys having less than 16 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
62685377|NCT06641817||petients diagnosed with Kawasaki disease|Diagnostic criteria: based on the American Heart Association(AHA) guideline
62685378|NCT05950360||rock climbers (healthy group)|Climbers without shoulder pain
62685379|NCT05950360||rock climbers (shoulder pain group)|Climbers with shoulder pain
62685380|NCT00392288|PLACEBO_COMPARATOR|Placebo MDI|double-blind
62685381|NCT00392288|EXPERIMENTAL|Ciclesonide MDI 40 µg BID|double-blind
62685382|NCT00392288|EXPERIMENTAL|Ciclesonide MDI 80 µg BID|double-blind
62697407|NCT03610698|EXPERIMENTAL|Self-Guided Intervention|Intervention arm that is self-guided on an online platform, delivering the 8 positive emotion skills over 5 weeks.
62697408|NCT03610698|ACTIVE_COMPARATOR|Emotion Reporting Control|Participants in the emotion reporting control condition will be reporting their emotions daily for the same length as the intervention.
61924131|NCT03570879||Transvaginal extraction|Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.
62314999|NCT02817542||STEMI TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention with TA
62315000|NCT02817542||STEMI without TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention without TA
61924132|NCT04073329||Plain x ray|measurement the accuracy of post operative reduction by Matta method
62315001|NCT04524975|EXPERIMENTAL|CD-008-0045 60 mg/day|Patients assigned to the CD-008-0045 60 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast, lunch, and dinner for 8 weeks
62315002|NCT04524975|EXPERIMENTAL|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner, and 1 placebo capsule before lunch for 8 weeks.
62315003|NCT04524975|PLACEBO_COMPARATOR|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, lunch, and dinner for 8 weeks.
62315004|NCT04988516|EXPERIMENTAL|Virtual Reality Distraction|Use of Virtual Reality (VR) before the MRI.
62315005|NCT04988516|ACTIVE_COMPARATOR|Standard Treatment|Standard Treatment used at the radiology department.
61924133|NCT04073329||CT|measure the accuracy of reduction by Verbeek method
62315006|NCT02150642||Neurological Injury|
61924134|NCT03206255||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
61924135|NCT03206255||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
61924136|NCT03206255||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
61924137|NCT05580510|ACTIVE_COMPARATOR|Conventional treatment of Heart failure and Sacubitril/Valsartan|"Patients will receive conventional treatment consisting of spironolactone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours) or eplerenone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours); beta-blockers: bisoprolol 1.5 mg orally every 24 hours (maximum dose 10 mg every 24 hours) or metoprolol succinate 12.5 mg every 24 hours orally (maximum dose 200 mg every 24 hours) or carvedilol 3125 mg every 24 hours (maximum dose 25 mg every 24 hours) or ivabradine 5 mg every 12 hours (maximum dose 7.5 mg every 12 hours); diuretics: furosemide 20 to 400 mg orally every 24 hours or bumetanide 1 to 15 mg orally every 24 hours and/or chlorthalidone 25 mg orally every 24 hours.~Additionally, patients will receive Sacubitril/Valsartan, with the intention to titrate up to 49 mg/51 mg orally every 12 hours."
61924138|NCT05580510|EXPERIMENTAL|Conventional treatment plus Empagliflozin and Sacubitril/valsartan|"Patients will receive conventional treatment consisting of spironolactone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours) or eplerenone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours); beta-blockers: bisoprolol 1.5 mg orally every 24 hours (maximum dose 10 mg every 24 hours) or metoprolol succinate 12.5 mg every 24 hours orally (maximum dose 200 mg every 24 hours) or carvedilol 3125 mg every 24 hours (maximum dose 25 mg every 24 hours) or ivabradine 5 mg every 12 hours (maximum dose 7.5 mg every 12 hours); diuretics: furosemide 20 to 400 mg orally every 24 hours or bumetanide 1 to 15 mg orally every 24 hours and/or chlorthalidone 25 mg orally every 24 hours.~Additionally, patients will use Sacubitril/Valsartan, with the intention to titrate up to 49 mg/51 mg orally every 12 hours and Empagliflozin 10 mg orally every 24 hours."
61924139|NCT05580510|EXPERIMENTAL|Conventional treatment plus Empagliflozin|"Patients will receive conventional treatment consisting of spironolactone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours) or eplerenone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours); beta-blockers: bisoprolol 1.5 mg orally every 24 hours (maximum dose 10 mg every 24 hours) or metoprolol succinate 12.5 mg every 24 hours orally (maximum dose 200 mg every 24 hours) or carvedilol 3125 mg every 24 hours (maximum dose 25 mg every 24 hours) or ivabradine 5 mg every 12 hours (maximum dose 7.5 mg every 12 hours); diuretics: furosemide 20 to 400 mg orally every 24 hours or bumetanide 1 to 15 mg orally every 24 hours and/or chlorthalidone 25 mg orally every 24 hours.~Additionally, patients will use Empagliflozin 10 mg orally every 24 hours."
61924140|NCT01863810|EXPERIMENTAL|KW21052|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.
61924141|NCT01863810|ACTIVE_COMPARATOR|LYRICA|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.
61924142|NCT03280095|EXPERIMENTAL|Treatment 1|One capsule of test product (co-codamol 15mg/500mg capsule) containing 15mg codeine phosphate hemihydrate and 500mg paracetamol.
62315007|NCT02150642||No Neurological Injury|
62315008|NCT02616029|EXPERIMENTAL|Part 1: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG)."
62478684|NCT06655545||Non-FES-guided CDK4/6 inhibitor plus endocrine therapy cohort|The group examined without FES-PET using a CDK4/6 inhibitor plus ET.
61924143|NCT03280095|EXPERIMENTAL|Treatment 2|Two capsules of test product (co-codamol 15mg/500mg capsule), each containing 15mg codeine phosphate hemihydrate and 500mg paracetamol (i.e. a total dose of 30mg codeine phosphate hemihydrate and 1000mg paracetamol).
61924144|NCT03280095|ACTIVE_COMPARATOR|Treatment 3|One tablet of reference product (co-codamol 30mg/500mg tablet) containing 30mg codeine phosphate hemihydrate and 500mg paracetamol.
61924145|NCT02651714|EXPERIMENTAL|Tradipitant|Oral
61924146|NCT02651714|PLACEBO_COMPARATOR|Placebo|Oral
61924147|NCT02068339|PLACEBO_COMPARATOR|Placebo|Placebo Comparator / Tid (total 0mg)
61924148|NCT02068339|EXPERIMENTAL|Oltipraz 1|Total 90mg, by mouth, tid
62125071|NCT03332992|EXPERIMENTAL|Protect others + General intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
62125072|NCT03332992|EXPERIMENTAL|Protect others + Behavioral intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
62125073|NCT03332992|EXPERIMENTAL|Protect others + Accountability|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
62125074|NCT05228054|EXPERIMENTAL|Laser 1940nm|Patients with hemorrhoidal deasease 2-3 st. who will be treated with laser 1940nm
62125075|NCT05228054|ACTIVE_COMPARATOR|sclerotherapy|Patients with hemorrhoidal deasease 2-3 st. who will be treated with sclerotherapy
62315009|NCT02616029|EXPERIMENTAL|Part 2: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG."
61924149|NCT02068339|EXPERIMENTAL|Oltipraz 2|Total 120mg, by mouth, tid
61924150|NCT01020539|EXPERIMENTAL|Matched Family Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from a related family donor using bone marrow or cord blood stem cells. Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression. Graft-versus-host-disease (GVHD) prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
62125076|NCT05992701|EXPERIMENTAL|Directional deep brain stimulation|
62125077|NCT05342818|EXPERIMENTAL|Group N|patients will receive an intravenous infusion of neostigmine in a dose of 2.5 mg in 100 ml of normal saline within 20 minutes once daily
62125078|NCT05342818|EXPERIMENTAL|Group O|patients will receive an intravenous infusion of 8 mg of ondansetron in 100 ml of normal saline once daily for 20 minutes
62125079|NCT05342818|EXPERIMENTAL|Group M|patients will receive metoclopramide in a dose of 10 mg in 100 ml of normal saline once daily for 20 minutes by infusion
62125080|NCT02620813|NO_INTERVENTION|No Acne|Healthy subjects without acne between the ages of 15-45
62125081|NCT02620813|EXPERIMENTAL|Acne Subjects on Topical Tretinoin Treatment|Subjects with acne before and after topical retinoid therapy
62125082|NCT02620813|EXPERIMENTAL|Acne Subjects on Systemic Isotretinoin Treatment|Subjects with acne before and after isotretinoin therapy
62125083|NCT03817060|ACTIVE_COMPARATOR|Cleavage|Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development
62125084|NCT03817060|ACTIVE_COMPARATOR|Blastocyst|Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)
62315010|NCT04001751|EXPERIMENTAL|Therapeutic educational postural yoga program|Daily 15-min yoga sessions at home during 12 weeks. One 90-min yoga-therapeutic education session/week (during 6 weeks).
62315011|NCT05673603|EXPERIMENTAL|Cohort 1 (Mild Impairment): Brensocatib|Participants with mild renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
62315012|NCT05673603|EXPERIMENTAL|Cohort 2 (Moderate Impairment): Brensocatib|Participants with moderate renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
62315013|NCT05673603|EXPERIMENTAL|Cohort 3 (Severe Impairment): Brensocatib|Participants with severe renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
62125085|NCT06583460|OTHER|Breast cancer treatment with oncosexology supporting care|Patient initially treated by surgery combined with any therapy (chemotherapy, radiotherapy, hormonal therapy etc.) and benefiting oncosexological care.
62315014|NCT05673603|EXPERIMENTAL|Cohort 4 (Normal): Brensocatib|Healthy participants with normal renal function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with renal impairment.
62315015|NCT03762252|EXPERIMENTAL|Dry needling|Patients will receive dry needling over active trigger points in the scalene muscles
62315016|NCT03762252|ACTIVE_COMPARATOR|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the scalene muscles
62478685|NCT06655545||Non-FES-guided chemotherapy cohort|The group examined without FES-PET using chemotherapy.
62478686|NCT06595706|EXPERIMENTAL|Lucid-21-302|Multiple ascending dose cohorts
62478687|NCT06595706|PLACEBO_COMPARATOR|Placebo|Multiple ascending dose cohorts
62478688|NCT05958537|EXPERIMENTAL|Intervention|In the intervention group, 50 L/min with 0.6 FiO2 will be administered through a high-flow nasal cannula.
62125086|NCT05832190|ACTIVE_COMPARATOR|Arm 1: patient with usual follow-up (standard of care)|receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
62125087|NCT05832190|EXPERIMENTAL|Arm 2: Same usual general dietary recommendations PLUS Biotin|Patients will receive the same usual general dietary recommendations PLUS 1 capsule per day of Biotin 450 µg per day during 3 months before the surgery.
62125088|NCT05832190|EXPERIMENTAL|Arm 3: Same usual general dietary recommendations PLUS Fiber|Patients will receive the same usual general dietary recommendations PLUS 3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
62125089|NCT05832190|EXPERIMENTAL|Arm 4: Same usual general dietary recommendations PLUS Fiber PLUS Biotin|Patients will receive the same usual general dietary recommendations PLUS 3 servings per day of PureLean® Fiber and Biotin 450 µg per day (1 capsule per day), during 3 months before the surgery.
62125090|NCT00106678||Infected through risk behaviors|
62478689|NCT05958537|NO_INTERVENTION|Control|In the control group, oxygen therapy will also be administered in all cases, using the usual procedure: oxygen therapy through a conventional nasal cannula and at a flow of 5 L/min
62478690|NCT06511349|EXPERIMENTAL|TOLT-203|
62478691|NCT06598930|EXPERIMENTAL|Intensive follow-up|
62478692|NCT06598930|ACTIVE_COMPARATOR|Routine follow-up|
62125091|NCT00106678||Infected perinatally or through blood/blood products.|
62125092|NCT03611972|EXPERIMENTAL|Sugar-sweetened beverage (SSB)|SSB provided at 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 2 weeks
62125093|NCT04107402|EXPERIMENTAL|Septic shock|Septic shock Patients admitted to the ICU
62125094|NCT04107402|OTHER|Control group|Patients recruited at the central lab of the hospital, with matched age, gender and comorbidities
62125095|NCT04107402|EXPERIMENTAL|Covid-19|Covid-19 patients admitted to the ICU for Acute Respiratory Distress Syndrom with PaO2/FiO2 \< 200
62315017|NCT03095534|EXPERIMENTAL|3-Step Workout for Life|Participants will exercise at the moderate intensity three times a week for 10 weeks. The total of 30 workout sessions will consist of 18 sessions of group single-joint resistance exercise, 6 sessions of one-on-one multiple-joint resistance exercise, and 6 sessions of one-on-one activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice daily tasks around the home. The community fitness staff will modify the task demand to increase the physical challenge of the task to each participant, for example, increasing travel distance.
62315018|NCT01696877|ACTIVE_COMPARATOR|Degarelix|Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg at 14 (±3) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by their urologists according to standard institutional practices, but will require prostate-specific antigen evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
62478693|NCT03882034|EXPERIMENTAL|1|Intervention arm, Patient received pegvisomant
62478694|NCT04061486||Experimental arm|One half of the oocyte cohort is microinjected with sperm selected by the Fertile technique, while the other half of the patient's oocyte cohort is microinjected with sperm selected by the MACS technique.
62125096|NCT04279548|ACTIVE_COMPARATOR|On DBS|Patients in the on mode DBS
62125097|NCT04279548|SHAM_COMPARATOR|Off DBS|Patients in the off mode DBS
62478695|NCT06465810||ATTR cardiomyopathy (ATTR-CM)|Patients with ATTR-CM at enrollment
62478696|NCT06465810||Hereditary polyneuropathy (ATTRv-PN)|Patients with ATTRv-PN at enrollment
62478697|NCT06465810||ATTR-Mixed|Patients with a mixed ATTR amyloidosis phenotype
62478698|NCT06602219|EXPERIMENTAL|LY4100511 Dose 1|Participants will receive LY4100511 orally.
62125098|NCT02952209|NO_INTERVENTION|No Treatment|Tooth extraction with no bone graft.
62478699|NCT06602219|EXPERIMENTAL|LY4100511 Dose 2|Participants will receive LY4100511 orally.
62478700|NCT06602219|EXPERIMENTAL|LY4100511 Dose 3|Participants will receive LY4100511 orally.
62478701|NCT06602219|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62478702|NCT04076059|EXPERIMENTAL|Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)|Participants received enzalutamide 160 mg capsules, orally once daily if tolerable, and continued ADT until radiographic disease progression was documented or until they started another investigational agent or new therapy for treatment of prostate cancer. Participants were to remain on study treatment until confirmed radiographic disease progression. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment.
62478703|NCT04076059|PLACEBO_COMPARATOR|Placebo Plus ADT (Double Blind Phase)|"Participants received enzalutamide-matching placebo capsules, orally once daily and continued ADT until radiographic disease progression was documented or until they started another investigational agent or new therapy for treatment of prostate cancer. Participants were to remain on study treatment until confirmed radiographic disease progression. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment."
62478704|NCT04076059|EXPERIMENTAL|Enzalutamide Plus ADT (Open-Label Phase)|Participants who received placebo in double-blind phase and remaind on study treatment until confirmed radiographic disease progression received enzalutamide and continued ADT in open-label phase. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment.
62478705|NCT06594354|EXPERIMENTAL|Intervention arm|Patients in this arm will receive oral cryotherapy.The patients in the intervention group will have ice applied to their mouths for three cycles (the first cycle they met with the researcher and the second and third cycles/an average of two months) when they come for treatment at the hospital with the researcher and at home on the days they do not come for treatment, within the scope of the oral cryotherapy application protocol, they will be monitored by phone and a reminder message will be sent. During chemotherapy, ice cubes will be applied to the patients in the first hour they start receiving chemotherapy and in the same time period, three consecutive ice cubes (each ice cube melts for an average of 1.5-2 minutes/total average of 4.5-6 minutes) and the same application will be repeated three hours later. The patients will be asked to apply ice cubes at home six times (an average of 27-36 minutes/day) at two or three hour intervals for seven days, including the day they receive che
62478706|NCT06594354|NO_INTERVENTION|Control arm|Patients who meet the study criteria and are included in the control group will receive routine treatment and care procedures in the unit when they come to receive chemotherapy (the first cycle encountered by the researcher) and the other two cycles that follow, and will not receive oral cryotherapy.
62478707|NCT06511245|OTHER|WEB|
62125099|NCT02952209|ACTIVE_COMPARATOR|Alveolar Ridge Preservation Treatment|Tooth extraction followed by alveolar ridge preservation using xenograft bone graft and covered by a resorbable collagen membrane.
62685383|NCT04941573|EXPERIMENTAL|Hyperpolarized Xenon MRI for lung transplant diagnosis|"All post lung transplant patients will undergo hyperpolarized 129-Xenon MRI and conventional proton MR imaging of the lung. Recent HRCT and spirometry measurements as part of clinical care will be available in the medical history for comparison. There will be multiple administered inhalation of HP Xenon during an imaging session. Maps of xenon ventilation (distribution) will be used for analyzing function of the lungs. These maps will be compared against 3D high-resolution CT images for regional correlations, and against spirometry as global measurements of lung health status. Additionally, xenon dissolved in lung parenchyma and blood, allows for measurement of gas exchange properties.~Each subject will have a secondary imaging session after six-months for evaluating potential changes in the lung function and early detection of lung transplant complications such as CLAD."
62478708|NCT06511245|OTHER|Other endovascular techniques|
62478709|NCT06669338|EXPERIMENTAL|music therapy group|The group that listened to music for 20 minutes before the colonoscopy
62478710|NCT06669338|EXPERIMENTAL|white noise group|The group that listened to white noise for 20 minutes before the colonoscopy
62478711|NCT06669338|PLACEBO_COMPARATOR|control group|The group that listened to recorded ambient sound for 20 minutes before the colonoscopy.
62478712|NCT05802615|EXPERIMENTAL|PARITY|Participants will take part in the Protective Assets Reinforced with Integrated care and TechnologY (PARITY) program which is community-based doula support, community resources, and a mobile technology platform that reinforces individual strengths through positive messaging and by promoting wellness (sleep, physical activity, nutrition, prenatal care adherence) in Black pregnant women.
62478713|NCT05802615|PLACEBO_COMPARATOR|Control|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
62478714|NCT02906540|EXPERIMENTAL|Transpubic symphysis reset therapy group|Transpubic symphysis reset therapy will be conducted once a day for 7 consecutive days.
62478715|NCT02906540|EXPERIMENTAL|Physiotherapy group|Physiotherapy and a sham reset treatment will be performed once a day for 7 consecutive days.
62685384|NCT01748214||Nasal CPAP|Infants received nasal CPAP as standard of care.
62685385|NCT01748214||High Flow Nasal Cannual|Infants received high flow nasal cannula as standard of care.
62685386|NCT06677996|EXPERIMENTAL|Treatment Arm|Period 1: varegacestat administration for PK followed by Period 2: itraconazole and varegacestat administration for PK and DDI
62685387|NCT03977298|SHAM_COMPARATOR|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine
62125100|NCT05673252||Cervical cancer patients|The population is represented by women being admitted to the Gynecology Ward who are affected by cervical cancer.
62125101|NCT06331611|EXPERIMENTAL|TOF Monitoring|Instrumental monitoring with electromyography (TOF Group)
62125102|NCT06331611|ACTIVE_COMPARATOR|Clinical monitoring (Standard Group)|Clinical monitoring
62125103|NCT00159783|EXPERIMENTAL|Asenapine|Asenapine 5-10 mg twice daily for 40 weeks
62125104|NCT00159783|ACTIVE_COMPARATOR|Olanzapine|Olanzapine 5-20 mg once daily for 40 weeks
62125105|NCT01502969|PLACEBO_COMPARATOR|Placebo|Children receiving placebo (cell culture medium in absence of virus)
62125106|NCT01502969|ACTIVE_COMPARATOR|Rotavirus vaccine|Rotavin-M1, 10e6.3ffu/dose, 2 doses
62125107|NCT05657730|EXPERIMENTAL|Active group|
62125108|NCT03988023|EXPERIMENTAL|AMPION™ 4 mL dose|4 mL injection of Ampion
62125109|NCT03988023|PLACEBO_COMPARATOR|Saline|4 mL injection of placebo
62125110|NCT00857649|EXPERIMENTAL|Memantine|
62125111|NCT00857649|PLACEBO_COMPARATOR|Placebo|
62125112|NCT03110965|EXPERIMENTAL|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
62685388|NCT03977298|OTHER|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
62315019|NCT01696877|EXPERIMENTAL|Cyclophosphamide, GVAX and Degarelix|Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intradermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (2.5 × 108 cells), for a total dose of 5 × 108 cells. On day 14, Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg.
62125113|NCT03811574|EXPERIMENTAL|Semaglutide 2.4 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue semaglutide 2.4 mg until week 68.
62125114|NCT03811574|PLACEBO_COMPARATOR|Placebo (semaglutide 2.4 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue placebo (semaglutide 2.4 mg) until week 68.
62315020|NCT01764178|EXPERIMENTAL|Livalo fixed combination drug|Livalo fixed combination drug(Pitavastatin + Valsartan)
62315021|NCT01764178|ACTIVE_COMPARATOR|Pitavastatin + Valsartan|Pitavastatin, Valsartan
62685389|NCT05333510||TEG group|Thromboelastography guided blood product administration in patients of liver cirrhosis with non variceal bleed
62685390|NCT05333510||ROTEM group|Throboelastometry guided blood product administration in patients of liver cirrhosis with non variceal bleed
62685391|NCT04338620|EXPERIMENTAL|A: Experimental Group|Participants receive totally 3 cycles of camrelizumab combined with albumin-bound paclitaxel and Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
62315022|NCT00443430|ACTIVE_COMPARATOR|Methotrexate Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone
61924151|NCT01020539|EXPERIMENTAL|Unrelated Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from an unrelated donor using matched bone marrow or cord blood stem cells.Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression and unrelated donor transplant recipients will additionally receive Anti-Thymocyte Globulin. GVHD prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
62125115|NCT03811574|EXPERIMENTAL|Semaglutide 1.7 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue semaglutide 1.7 mg until week 68.
62125116|NCT03811574|PLACEBO_COMPARATOR|Placebo (semaglutide 1.7 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue placebo (semaglutide 1.7) until week 68.
62125117|NCT01689844|ACTIVE_COMPARATOR|Behavioral, DASH Plus - Dietary advice|This group will receive DASH diet advice and guided ordering of fruits, vegetables, nuts and beans that are high in potassium from a local supermarket.
62125118|NCT01689844|OTHER|DASH - C|DASH C Group will receive brief DASH diet advice and will be able to make non- guided purchases of food products from the local supermarket.
62125119|NCT01638611|ACTIVE_COMPARATOR|HIP2B|Six subjects per dosing cohort will receive HIP2B
62125120|NCT01638611|PLACEBO_COMPARATOR|Placebo|Two subjects per dosing cohort will receive placebo.
62125121|NCT04304924|EXPERIMENTAL|Personalised telephone-based health education|"The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
62125122|NCT04304924|NO_INTERVENTION|Standard health educational program|
62685392|NCT04338620|ACTIVE_COMPARATOR|B: Control group|Participants receive totally 3 cycles of albumin-bound paclitaxel combined with Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
61924152|NCT00959335|ACTIVE_COMPARATOR|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
61924153|NCT00959335|EXPERIMENTAL|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
61924154|NCT00427960|ACTIVE_COMPARATOR|rosuvastatin|rosuvastatin 5 mg
61924155|NCT00427960|ACTIVE_COMPARATOR|atorvastatin|atorvastatin 10 mg
61924156|NCT01025765|NO_INTERVENTION|Standard care of CHC|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg) for 48 weeks.
61924157|NCT01025765|EXPERIMENTAL|Pioglitazone|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg) for 48 weeks.
61924158|NCT01025765|EXPERIMENTAL|Acarbose|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg) for 48 weeks.
61924159|NCT01025765|EXPERIMENTAL|Metformin|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg) for 48 weeks.
61924160|NCT05129891|EXPERIMENTAL|Part A: Oral semaglutide|Four different formulations of oral semaglutide are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days
61924161|NCT05129891|EXPERIMENTAL|Part B: NNC0385-0434|Four different formulations of NNC0385-0434 are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days
62478716|NCT02287961|OTHER|Subjects|"* Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~* High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~* Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy~* High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)"
61924162|NCT01711879|ACTIVE_COMPARATOR|Aflibercept with Laser|A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
61924163|NCT01711879|EXPERIMENTAL|Aflibercept|2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
61924164|NCT00306202|EXPERIMENTAL|Stratum 1 (Ph+ CP-CML)|Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
61924165|NCT00306202|EXPERIMENTAL|Stratum 2/3 (Ph+ ALL or AP/BP-CML)|Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
61924166|NCT00306202|EXPERIMENTAL|Stratum 4 (Ph- ALL/AML)|Participants with second or subsequent relapse of Ph- ALL or Ph- AML
61924167|NCT00321724|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61924168|NCT00803218||Cohort Group 1|Subjects number 1 to 26
61924169|NCT00803218||Cohort Group 2|Subjects number 27 to 56
61924170|NCT05917509|EXPERIMENTAL|Participants Receiving DTG/3TC Fixed Dose Combination (FDC)|
61924171|NCT05917509|EXPERIMENTAL|Participants Receiving CAB + RPV LA|
61924172|NCT03964844||CASE|Patients who had an episode of diarrhoea caused by C. difficile in an hematological unit (2003-2018)
61924173|NCT03964844||CONTROL|Patients who have had an episode of diarrhoea not caused by C. difficile in an hematological unit (2003-2018)
62125123|NCT05692778||1: Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool
62125124|NCT05692778||2: Patients being foot examined in traditional manner|Patients being foot examined in traditional manner
62478717|NCT01528696|PLACEBO_COMPARATOR|Standard Dressing|Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
62478718|NCT01528696|EXPERIMENTAL|Silverlon|Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing
61924174|NCT03964844||PROSPECTIVE COHORT|All patients diagnosed with an hematological/oncological disease or with any immunosuppressive condition, who have a positive detection of toxigenic Clostridium difficile in 2019.
61924175|NCT06482762|EXPERIMENTAL|Active transcranial focused ultrasound (tFUS)|
61924176|NCT02723253|EXPERIMENTAL|Radiotherapy plus Tom-Ox|Patients received concomitant boost RT (55 Gy/5 weeks) with concurrent Tom-Ox chemotherapy. The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
62478719|NCT06558890|EXPERIMENTAL|Transcranial Alternating Current Stimulation Intervention|Patients with refractory TLE recruited for the study will undergo a 6-week treatment with the tACS (transcranial alternating current stimulation) protocol, which involves a 2mA current at 10Hz for 20 minutes on both sides. The treatment schedule is 5 days of treatment followed by 2 days of rest, and then another 5 days of treatment, with a weekly reinforcement treatment, for a total of 14 sessions.
62478720|NCT02286050|EXPERIMENTAL|CF Nursing Intervention|
62478721|NCT01500447||Central Precious Puberty|CPP subjects
62125125|NCT03410446|EXPERIMENTAL|Ketamine|"Three doses of ketamine will be given intranasal:~* Dose 1 will be 50 mg on Day 1~* Dose 2 will be between 50-100 mg on Day 4~* Dose 3 will be between 50-150 mg on Day 7"
62125126|NCT06677437||single group of adult patients with chronic renal failure who are all awaiting a kidney transplant|"This study focuses on a single group of adult patients with chronic renal failure who are all awaiting a kidney transplant, whether or not they are treated by extra-renal purification.~These patients are contraindicated for transplantation due to their anatomical constraints: major arterial calcifications, iliac dissections, iliac stenoses and They can only receive the kidney transplant after arterial preparation."
62125127|NCT03670368|EXPERIMENTAL|Intervention (Mentor/Mentee)|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on social relationships, coping behaviors, and healthy lifestyles.
62125128|NCT03670368|ACTIVE_COMPARATOR|Comparison group - written materials|Youth in the comparator group will receive written versions of all materials covered in the mentoring sessions.
62125129|NCT05904340|EXPERIMENTAL|Test Group|The percutaneous nerve discharger (model GM350PP) of APEX low-frequency therapeutic device is used for transcutaneous electrical nerve stimulation of acupoints. The approved number of medical equipment license for this product is: Department of Health Medical Device No. 006696, and the use mode of intervention measures is P5 Disperse -Dense Modulation mode (discharge frequency 2Hz/wave width 260μs/duration 3sec and discharge frequency 100 Hz/wavewidth 140μs/continuation 3sec alternately, maximum discharge volume 80mA), stimulate Neiguan (PC6), Hegu (LI4), Sanyinjiao (SP6) and Taichong (LR3) points, twice a day, 30 minutes each time, for 4 weeks, the intensity is divided into 10-25 mA for hands and 25-40 mA for feet, depending on personal tolerance Adjust flexibly within the interval, and evaluate the severity of neuropathy symptoms of the test every week.
62125130|NCT05904340|NO_INTERVENTION|Control Group|4 weeks of usual care, including prescribe vitamin B6 or B12 and massage therapy. Assessing the severity of neuropathy symptoms every week.
62125131|NCT00534300|EXPERIMENTAL|A|
62125132|NCT00534300|PLACEBO_COMPARATOR|B|
62125133|NCT00044863|EXPERIMENTAL|1|Patients with metastatic EGFR-positive colorectal carcinoma
62478722|NCT01500447||Hypogonadotropic Hypogonadism|IHH, KS, GnRH Deficiency, BAM syndrome (arhinia), HA, CDP subjects
62478723|NCT05388305|EXPERIMENTAL|CAR--γδT|
61924177|NCT05442775|EXPERIMENTAL|Reldesemtiv 300 mg twice daily|Patients in this arm take 1 reldesemtiv 300 mg oral tablet twice a day for a 600 mg total daily dose (TDD). Participants who had been down titrated during the parent trail take 150 mg by mouth twice a day.
62125134|NCT01445158||1|bone marrow or stem cell donors ages 10 to 15
62125135|NCT01445158||2|bone marrow or stem cell donors ages 16 to 26
62125136|NCT05296148|EXPERIMENTAL|Treatment|Treatment with the CroíValve DUO Coaptation Valve System
62125137|NCT03565055|EXPERIMENTAL|IPCST|Intervention = Patients that participate in IPCST programme
62125138|NCT03565055|ACTIVE_COMPARATOR|E.A.S.Y|Treatment as usual = Patients of E.A.S.Y Programme in HK Kwai Chung Hospital
62125139|NCT03797924|ACTIVE_COMPARATOR|ICBN with ropivacaine|Participants will receive ICBN with ropivacaine. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
62478724|NCT05879107|EXPERIMENTAL|Co-ad Group|Participants receive both the RSVPreF3 OA investigational vaccine and the PCV20 vaccine on Day 1.
62478725|NCT05879107|ACTIVE_COMPARATOR|Control Group|Participants receive the PCV20 vaccine on Day 1 and the RSVPreF3 OA investigational vaccine on Day 31.
62478726|NCT06558942|EXPERIMENTAL|iNPWT group|The clinical data of 60 patients who met the inclusion and exclusion criteria were collected prospectively, including: gender, age, smoking, body mass index (BMI), hypertension, diabetes, aspirin and other antiplatelet drugs, anticoagulants, injured animals (dogs or cats), wound parameters (including wound site, wound length, wound depth, and time of subsequent diagnosis). Rinse the patient's wound with a weak alkaline disinfectant for 15 minutes, thoroughly clean the wound, and then suture it in one stage. Place the device of incisional negative pressure wound therapy (iNPWT) and evaluate the wound quality for 2-3 days. If necessary, extend the use of the iNPWT device. All patients received prophylactic use of antibiotics within one week.
62315023|NCT00443430|ACTIVE_COMPARATOR|Methotrexate-Etanercept-Prednisolone Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks
62315024|NCT06208709|EXPERIMENTAL|CASA Arm|Arm that will be given the test intervention device.
62315025|NCT06208709|ACTIVE_COMPARATOR|SOC Arm|Arm that is given a standard brace used for treating Carpal Tunnel Syndrome pain.
62315026|NCT03424330|EXPERIMENTAL|Arm1 - ReX first|Subjects begin with the ReX-C Intervention stage followed by Standard of Care stage.
62315027|NCT03424330|EXPERIMENTAL|Arm 2- Standard of Care first|Subjects start with Standard of Care stage followed by ReX-C Intervention.
62315028|NCT04036136|EXPERIMENTAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
62315029|NCT04036136|ACTIVE_COMPARATOR|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
62315030|NCT05409976|EXPERIMENTAL|GORE® VIAFORT Vascular Stent|GORE® VIAFORT Vascular Stent
62315031|NCT06671964|OTHER|students one-one|"1. During the intervention, 30-minute in person sessions and lectures are held on a one-on-one basis .~2. Lectures were conducted daily for five days during the first month of the intervention~3. The students were exposed to the school nutrition education curriculum, which may also be considered an intervention as it introduced students to new nutrition knowledge. The school nutrition education curriculum presented general information about nutrition in accordance with official guidelines issued by the UAE Ministry of Education. Topics covered included the dangers of obesity, the prevalence of obesity in the UAE, and potentially effective ways to prevent this problem, the information in this program was broad and did not provide practical recommendations to students except for a set of general suggestions.~4. The topics covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary"
62315032|NCT06671964|OTHER|Peers|"1. 30-minute in person sessions were introduced to all the school children, and 10-minute question-and-answer sections were held at the end of each lesson to support knowledge acquisition.~2. Lectures were conducted daily for five days in the first month of the study.~3. The students were exposed to the school nutrition education curriculum, which may also be considered an intervention as it introduced students to new nutrition knowledge. The school nutrition education curriculum presented general information about nutrition in accordance with official guidelines issued by the UAE Ministry of Education. Topics covered included the dangers of obesity, the prevalence of obesity in the UAE, and potentially effective ways to prevent this problem, the information in this program was broad and did not provide practical recommendations to students except for a set of general suggestions.~4. The topics covered included a healthy eating lifestyle,"
62315033|NCT06671964|NO_INTERVENTION|Control group|The students in the control group did not receive any nutrition intervention except for the usual school curriculum-based nutrition education program. Participants in the intervention and control groups were recruited from different sections of the same schools.
62315034|NCT06671964|OTHER|parents|"1. 30-minute in person sessions and 10-minute question-and-answer sections were held at the end of each lesson to support knowledge acquisition.~2. Lectures were conducted daily for five days in the first month of the study."
62315035|NCT02152423|OTHER|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
62315036|NCT02152423|ACTIVE_COMPARATOR|ENOXAMED|patients are given a curative dose of Enoxaparin (ENOXAMED)
62315037|NCT05334589|EXPERIMENTAL|Experimental: Intervention group|Patients in the intervention group will be prewarming with a hot air blowing system for 30 minutes before the operation. The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
62315038|NCT05334589|NO_INTERVENTION|Control group|The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
62315039|NCT04834986|EXPERIMENTAL|Tislelizumab combined with Lenvatinib|
62315040|NCT00320671|EXPERIMENTAL|Participants will take aripiprazole|Participants will take aripiprazole
62315041|NCT00320671|EXPERIMENTAL|Participants will take risperidone|Participants will take risperidone
62315042|NCT00719810|EXPERIMENTAL|1|
62315043|NCT00719810|EXPERIMENTAL|2|
62315044|NCT00719810|ACTIVE_COMPARATOR|3|
61924178|NCT02285556|NO_INTERVENTION|general information|use cross-sectional study to collect 1000 ATS abuse or dependence patients' general information and 5 ml blood,get their blood plasma and DNA sample in order to explore the possible addict mechanism.
62315045|NCT03069768|EXPERIMENTAL|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
62315046|NCT03069768|ACTIVE_COMPARATOR|Control|Smokers in this group will not be given the mSMART application.
62315047|NCT03851341|EXPERIMENTAL|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
62315048|NCT03851341|ACTIVE_COMPARATOR|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
62315049|NCT04663867|EXPERIMENTAL|AngioSafe Peripheral CTO Crossing System Procedure|Use of AngioSafe Peripheral CTO Crossing System to facilitate the intraluminal placement of guidewires beyond Chronic Total Occlusions (CTOs) in the peripheral vasculature.
62315050|NCT06004115|EXPERIMENTAL|Lorazepam|Participants will receive a single 1mg dose of Lorazepam, to be taken orally under registered nurse (RN) supervision
62315051|NCT06004115|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo, to be taken orally under RN supervision
62315052|NCT02037919|EXPERIMENTAL|Immediate Nexplanon Insertion|An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
62315053|NCT02037919|ACTIVE_COMPARATOR|Post-op Nexplanon Insertion|"Participants in the delayed placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment. At this time an etonogestrel rod will be placed in her arm using standard procedure."
62478727|NCT05363059||BS group|The group of bariatric surgery therapy in metabolic syndrome patients.
62478728|NCT05363059||MT group|The group of medical therapy in metabolic syndrome patients
62478729|NCT04410263||COVID-positive ICU patients|The collective of COVID-positive patients on the ICU
62478730|NCT05947591||control|healthy adults than gait over 1 hour,
61924179|NCT02285556|NO_INTERVENTION|ATS diagnosis and evaluation for abusers|Use cohort study design to establish ATS abuse induced craving experiment.Do the initial and follow-up assessment from start smoking to stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community . Thus compare with normal group to explore the possible psychological abuse mechanism.
62315054|NCT04470752|PLACEBO_COMPARATOR|Placebo|InOrpha solution/ml, three times daily with meals for the Treatment period, 7 or 30 days.
62315055|NCT04470752|EXPERIMENTAL|Capsaicin|InOrpha solution plus 1 mcg Capsaicin/ml, three times daily with meals for the Treatment period of 7 or 30 days.
62315056|NCT03023410||Partial Revision|"A partial revision will be indicated when only the tibial liner is changed or only the tibial liner with the tibial tray or only the tibial liner with the femoral component."
62315057|NCT03023410||Total Revision|"A total revision will be indicated when all components are completely removed and replaced (tibial tray, femoral component and tibial liner)."
62315058|NCT04223167|EXPERIMENTAL|Energy Drink 1|The participants in this group are caffeine naive and consumed 473 ml Red Bull Energy Drink
62315059|NCT04223167|EXPERIMENTAL|Energy Drink 2|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately 130 mg caffeine and consumed 473 ml Red Bull Energy Drink
62315060|NCT04223167|EXPERIMENTAL|Energy Drink 3|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately more than 200 mg caffeine and consumed 473 ml Red Bull Energy Drink
62315061|NCT04223167|PLACEBO_COMPARATOR|Control|The participants in this group are caffeine naive and consumed 473 ml water
62315062|NCT05187533|OTHER|Mild dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
62315063|NCT05187533|OTHER|Moderate dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
62315064|NCT05187533|OTHER|Severe dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
62315065|NCT01022853|EXPERIMENTAL|BIBF 1120 and BI 6727|Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
62315066|NCT01780389|EXPERIMENTAL|Milnacipran|Open-label flexibly dosed milnacipran
62315067|NCT00797927|EXPERIMENTAL|1. quetiapine|quetiapine would replace the original conventional antipsychotic agent
62478731|NCT05947591||experimental|healthy adults that run over 1 hour
62478732|NCT06587217|EXPERIMENTAL|Carbidopa Monotherapy and Carbidopa-Levodopa|Participants will begin by taking 25mg of Carbidopa monotherapy three times per day (TID) for 3 days. On day four, participants will begin taking 1 tablet of Carbidopa-Levodopa (25/100mg) TID in addition to the Carbidopa monotherapy. On day seven, participants will increase to 1.5 tablets of Carbidopa-Levodopa (25/100mg) TID while maintaining 25mg Carbidopa monotherapy TID. The intervention will end after ten days of supplementation.
62478733|NCT05983445|EXPERIMENTAL|Genakumab|Genakumab 200mg s.c
62478734|NCT05983445|ACTIVE_COMPARATOR|Diprospan|Diprospan 7mg im
62685393|NCT02203279|EXPERIMENTAL|Rebase II Fast|The direct chair-side relining materiel 'Rebase II Fast' will be used.
62685394|NCT02203279|EXPERIMENTAL|Flexacryl|The direct chair-side relining material Flexacryl will be used
62315068|NCT00797927|NO_INTERVENTION|2. conventional antipsychotics|
62315069|NCT00864292||HIV-infected, no dementia|Patients with HIV-infection but no dementia
62315070|NCT00864292||HIV-infected, dementia|Patients with HIV-infection and dementia
62478735|NCT02101788|ACTIVE_COMPARATOR|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
62478736|NCT02101788|EXPERIMENTAL|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62685395|NCT02203279|EXPERIMENTAL|Vertex|Vertex is a heat-cured resin material which is going to be used for indirect relining
62685396|NCT03778697|EXPERIMENTAL|Adolescent Endosleeve|Patients who will undergo endoscopic sleeve gastroplasty
62685397|NCT04264845||Provider Focus Group|All heart failure providers at the participating centers will be screened as potential participants.
62125140|NCT03797924|PLACEBO_COMPARATOR|No ICBN block|Participants will have the site prepped, but no ICBN block given. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
62125141|NCT01171625|OTHER|CEP Aortic Bioprothesis, model 3300TFX|
62685398|NCT04264845||Patient Interview Group|Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
62685399|NCT04264845||PROs/Clinical Data Integration Group|"Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.~This group includes a sub-study of patients providing blood samples."
62685400|NCT00919360||Controls|Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, mode of delivery, maternal age, and race.
62125142|NCT00137995|EXPERIMENTAL|R-ICE|R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
62125143|NCT00137995|EXPERIMENTAL|R-DHAP|R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
62315071|NCT04561817|ACTIVE_COMPARATOR|PI3K/AKT mutations (altered)|Participants with recurrent epithelial ovarian cancer with PI3K/AKT mutations (altered)
62315072|NCT04561817|ACTIVE_COMPARATOR|Without PI3K/AKT mutations (non-altered)|Participants with recurrent epithelial ovarian cancer without PI3K/AKT mutations (non-altered)
62315073|NCT02151539||Observational (medical chart review)|Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.
62125144|NCT02539108|EXPERIMENTAL|Study Group 1|Participants at 6 months to \< 36 months age at enrollment
62315074|NCT00974077|OTHER|Wait List Control|Patients do ot receive psychotherapy. The wait list control group will be assessed according to study protocol and offered MBCT after 6 month
62315075|NCT00974077|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|The published protocol of MBCT will be used. This is an eight week group program. Participants learn mindfulness techniques but also cognitive techniques to prevent new depressive episodes
62315076|NCT05404854||chronic low back pain patients|Physical Activity by wearing an accelerometer for 7 days before and after the rehabilitation program sedentarity by wearing an accelerometer for 7 days before and after the rehabilitation program Measurement of explicit motivation Measurement of implicit attitudes
62315077|NCT03201653|ACTIVE_COMPARATOR|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
62315078|NCT03201653|EXPERIMENTAL|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
62685401|NCT00919360||Preeclamptics|Gravidas at 32-42 weeks gestation, delivered by Caesarean Section, who have preeclampsia as defined by Sibai et al, 1997.
62685402|NCT01878474|EXPERIMENTAL|Single ascending dose in Caucasian men|
62125145|NCT02539108|EXPERIMENTAL|Study Group 2|Participants at 3 years to \< 9 years age at enrollment
62125146|NCT00006517|ACTIVE_COMPARATOR|bright light box|30 min exposure shortly after wake-up
62125147|NCT00006517|ACTIVE_COMPARATOR|high-output negative ion generator|90 min exposure prior to wake-up
62125148|NCT00006517|PLACEBO_COMPARATOR|low-output negative ion generator|90 min exposure prior to wake-up
62315079|NCT04388657||Covid Intensive arm|Patients included in intensive care admission by one of the principal investigators from the 3 selectioned centers.
62315080|NCT02406872|EXPERIMENTAL|Remimazolam Tosilate 1|IV pumping of Remimazolam Tosilate at 6mg/kg/h for anesthesia induction
62315081|NCT02406872|EXPERIMENTAL|Remimazolam Tosilate 2|intravenous pumping of Remimazolam Tosilate at 12mg/kg/h for anesthesia induction
62315082|NCT02406872|EXPERIMENTAL|Remimazolam Tosilate 3|intravenous pumping of Remimazolam Tosilate at 18mg/kg/h for anesthesia induction
62315083|NCT02406872|ACTIVE_COMPARATOR|Propofol|single IV bolus of Propofol at 2.0-2.5mg/kg for anesthesia induction
62125149|NCT00006517|ACTIVE_COMPARATOR|dawn simulator|naturalistic incremental light exposure 90 min prior to wake-up
62478737|NCT05415501|EXPERIMENTAL|Structural priming training|Participants will be enrolled in 3 sessions of structural priming training (for experiment 1-3) or up to 15 treatment sessions (for experiment 4). Each session will be about 2 hour long, consisting of a set of tasks, including repeating, making, and remembering various types of sentences. In experiment 1-3, each participant will receive two different experimental priming conditions that are being compared within each session. In experiment 4, participants will receive a structural priming treatment in a single-subject design.
62478738|NCT06636370|NO_INTERVENTION|Control|This group receives biennial mammography only within the current Dutch National Breast Cancer Screening program. This group will not be informed about the study (pre-randomisation design)
62125150|NCT00006517|EXPERIMENTAL|dawn light pulse|rectangular pulse light exposure 13 min before wake-up, matched for total illuminance with dawn signal
62125151|NCT02974634|ACTIVE_COMPARATOR|Ostomy Self management Training|Ostomy self-management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
62125152|NCT02974634|PLACEBO_COMPARATOR|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient
62125153|NCT03733522|ACTIVE_COMPARATOR|Rubber dam isolation|"Absolute isolation~* local anesthesia~* use of dental clamp and rubber dam~* restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
62125154|NCT03733522|EXPERIMENTAL|Relative isolation|"Relative isolation~* no local anesthesia~* use of cotton roll and saliva ejector~* restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
62125155|NCT01721434|EXPERIMENTAL|Levosimendan|Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.
62125156|NCT01721434|PLACEBO_COMPARATOR|Placebo|Similar coloured placebo intravenous for a single 7 hours
62125157|NCT00184041|EXPERIMENTAL|Intensified Post-Remission: MTX/LV/PEG-Asparaginase|Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 \& 15
62125158|NCT05652244|EXPERIMENTAL|Retraction with mini-implants|Mini-implants will be used as an anchor unit.
62125159|NCT05652244|ACTIVE_COMPARATOR|Retraction with transpalatal arches|Transpalatal arches will be used as an anchor unit.
62125160|NCT00946842|EXPERIMENTAL|Panel A: Treatment Sequence ABC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ABC with food and subsequent treatments will be separated by 4 weeks.
62125161|NCT00946842|EXPERIMENTAL|Panel A: Treatment Sequence ACB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ACB with food and subsequent treatments will be separated by 4 weeks.
62125162|NCT00946842|EXPERIMENTAL|Panel A: Treatment Sequence BAC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BAC with food and subsequent treatments will be separated by 4 weeks.
62125163|NCT00946842|EXPERIMENTAL|Panel A: Treatment Sequence BCA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BCA with food and subsequent treatments will be separated by 4 weeks.
62315084|NCT00170157|EXPERIMENTAL|Arm I|Patients receive either leuprolide acetate intramuscularly (IM) or goserelin subcutaneously (SC) on days 0, 28, and 56. Patients also receive oral flutamide three times daily or oral bicalutamide once daily. Treatment with antiandrogen (AA) therapy continues for 3 months (3-4 months for patients who initiated AA therapy \<= 21 days prior to enrollment) in the absence of disease progression or unacceptable toxicity. Patients receive ipilimumab IV over 90 minutes on day 7 (within 7-28 days post-initiation of AA therapy for patients who initiated AA therapy \<= 21 days prior to enrollment) of AA therapy.
62478739|NCT06636370|EXPERIMENTAL|Contrast-enhanced Mammography (CEM)|This group receives supplemental screening with CEM after a negative mammography result in the Dutch National Breast Cancer screening program
62478740|NCT06636370|EXPERIMENTAL|Abbreviated MRI (AB-MRI)|This group receives supplemental screening with AB-MRI after a negative mammography result in the Dutch National Breast Cancer Screening program
62315085|NCT00170157|ACTIVE_COMPARATOR|Arm II|Patients receive AA therapy as in arm I. Patients may crossover to arm II in the case of disease progression.
62315086|NCT00005592|EXPERIMENTAL|Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8|For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
62315087|NCT01081210||Ultrasound screening|Patients admitted to Department of medicine at local hospital. Randomized inclusion, informed consent obtained.
62315088|NCT01582724|EXPERIMENTAL|Self-care acupressure|1
62685403|NCT01878474|EXPERIMENTAL|Age-effect in Caucasian men|
62315089|NCT01582724|NO_INTERVENTION|Usual care|2
62315090|NCT04034979|NO_INTERVENTION|Phase I-Baseline evaluation|The first two months of the investigator's project will be a baseline evaluation of the current decision making process about goals-of-care in a local ICU setting (Levis, Quebec). A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) dyads of physicians and newly admitted elderly patients discussing goals-of-care.
62125164|NCT00946842|EXPERIMENTAL|Panel A: Treatment Sequence CBA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CBA with food and subsequent treatments will be separated by 4 weeks.
62315091|NCT04034979|EXPERIMENTAL|Phase II-Impact of the decision aid|The two following months will be an evaluation of the decision making process about goals-of-care in the same local ICU setting using only the decision aid without any training. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care, whether the physician chooses to use the context-adapted decision-aid or not.
62315092|NCT04034979|EXPERIMENTAL|Phase III- Impact of the decision aid and the|This phase will be an evaluation of the decision making process about goals-of-care in the same local ICU setting after intensivists complete the training program and using the DA. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care using the context-adapted decision aid and the new skills learned in the training program.
62315093|NCT05503134|EXPERIMENTAL|Treatment|"Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2000 mg/ m2/day (days -6 to day -2)~Six doses of universal donor IL-21 expanded NK cells (UD-NK) given thrice weekly for two weeks starting on day 0. Days may vary and NK cells can be given from days 0 to 21. Patients may receive up to 2 cycles of fludarabine/cytarabine (FLA) + NK cells (up to 12 NK cell infusions) if they do not achieve CR after cycle 1 or if necessary to bridge to transplant."
62315094|NCT06162026|OTHER|Intervention|Risk assessment and cognitive screening app that includes questions answered by the participant and completion of a working memory task and two speech tasks
62315095|NCT05016128|EXPERIMENTAL|S-ketamine|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
62315096|NCT05016128|PLACEBO_COMPARATOR|Saline|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
62315097|NCT01808703|EXPERIMENTAL|Scaling and root planing plus PerioPatch|"All subjects in this group will receive scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam). Thereafter, PeriZone PerioPatch will be dispensed to subjects per randomization for administration over the trial period. Subjects will apply study patches (i.e., BID on Days 1, 28 and 42; QD on Days 2-6; Days 14-20, 29-30 and 43-44) to designated treatment sites (i.e., measuring 6 mm or more in pocket depth at Baseline)."
62315098|NCT01808703|ACTIVE_COMPARATOR|Scaling and root planing alone|Subjects in this group will receive only scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam).
62315099|NCT02749370|EXPERIMENTAL|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
62315100|NCT00317070|ACTIVE_COMPARATOR|DMSO|Intravesical installation
62315101|NCT00317070|EXPERIMENTAL|Cocktail|
62478741|NCT05365308|EXPERIMENTAL|Intervention: Quality Improvement tools|Quality improvement tools including: computer-assisted identification of iron deficiency anemia patients with an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education.
62478742|NCT05365308|NO_INTERVENTION|Control: usual care|Physicians will be notified at the start of the study that 120 days after the study start they will receive access to the quality improvement tools available to the intervention group.
62478743|NCT02861300|EXPERIMENTAL|CB-839 + capecitabine|Patients will receive CB-839 orally twice daily for 21 days (continuous administration) and capecitabine orally twice daily for 14/21 days. In the phase I portion of the study, patients will receive escalating doses of CB-839 and capecitabine and will have day 15 blood samples drawn and archived for as needed assessment of CB-839 pharmacokinetics. In the phase II portion of the study, patients will receiving 800mg CB-839 and 1000mg/m\^2 capecitabine as were determined to be safe doses during the phase I portion of the study. They will also undergo pre-treatment and post-treatment blood samples and tissue biopsies for evaluation of pharmacodynamic biomarkers.
62478744|NCT05159388|EXPERIMENTAL|PRS-344/S095012|PRS-344/S095012
62478745|NCT00829530|EXPERIMENTAL|1|
62125165|NCT00946842|EXPERIMENTAL|Panel A: Treatment Sequence CAB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CAB with food and subsequent treatments will be separated by 4 weeks.
62125166|NCT00946842|EXPERIMENTAL|Panel B: Treatment Sequence DEF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DEF with food and subsequent treatments will be separated by 4 weeks.
62315102|NCT00620204|EXPERIMENTAL|A|Atorvastatin group
62315103|NCT00620204|NO_INTERVENTION|B|Control group
62478746|NCT00829530|ACTIVE_COMPARATOR|2|
62478747|NCT06476977|EXPERIMENTAL|Dorsal Webspace Approach|A dorsal approach involves passing the needle with a 1:1 triamcinolone and lidocaine mixture in the dorsal webspace skin aiming just palmar to the proximal phalanx bone such that the needle is directed into the flexor tendon sheath at the A1 annular pulley.
62478748|NCT06476977|ACTIVE_COMPARATOR|Palmar Approach|Standard approach for injecting the 1:1 triamcinolone and lidocaine mixture involves the needle passing through the cutaneous and subcutaneous layers of the palmar skin surface and into the flexor tendon sheath at the A1 annular pulley.
62685404|NCT01878474|EXPERIMENTAL|Gender-effect in Caucasian women|
62685405|NCT01878474|EXPERIMENTAL|Single ascending dose in Japanese men|
62685406|NCT01878474|PLACEBO_COMPARATOR|Placebo: Single ascending dose in Caucasian men|
62685407|NCT01878474|PLACEBO_COMPARATOR|Placebo: Age-effect in Caucasian men|
62478749|NCT01112761|EXPERIMENTAL|Healthy Subjects|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
61924180|NCT02285556|ACTIVE_COMPARATOR|psychological training intervention|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
61924181|NCT02285556|ACTIVE_COMPARATOR|brain stimulation intervention|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
61924182|NCT02285556|NO_INTERVENTION|ATS diagnosis and evaluation for normal people|Do the same initial and follow-up assessment as ATS abusers who stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community .
61924183|NCT02285556|ACTIVE_COMPARATOR|physical and neurological rehabilitation|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
62125167|NCT00946842|EXPERIMENTAL|Panel B: Treatment Sequence DFE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DFE with food and subsequent treatments will be separated by 4 weeks..
62125168|NCT00946842|EXPERIMENTAL|Panel B: Treatment Sequence EDF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EDF with food and subsequent treatments will be separated by 4 weeks.
62125169|NCT00946842|EXPERIMENTAL|Panel B: Treatment Sequence EFD|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EFD with food and subsequent treatments will be separated by 4 weeks.
62125170|NCT00946842|EXPERIMENTAL|Panel B: Treatment Sequence FDE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FDE with food and subsequent treatments will be separated by 4 weeks.
62125171|NCT00946842|EXPERIMENTAL|Panel B: Treatment Sequence FED|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FED with food and subsequent treatments will be separated by 4 weeks.
62125172|NCT02396316|EXPERIMENTAL|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
62125173|NCT02396316|SHAM_COMPARATOR|Sham Injection|Sham injection group
62125174|NCT05320666|EXPERIMENTAL|Yes You Can…Make Smart Choices! (YYC…MSC!) Program|The intervention/treatment participants in the treatment condition will be exposed to NJPAG's YYC...MSC! program. The program is designed to be delivered five days a week for two weeks and contains 11 lessons.
62125175|NCT05320666|NO_INTERVENTION|Control|"The control schools were randomly selected out of a list of eligible schools in the Newark Public School system. Control schools will receive their health class as business-as-usual with no additional programming. There is no other place that provides the YYC...MSC! program in which participants could receive programming or information. Also, there are no future plans to provide the control group with the intervention. To our knowledge, there is no other similar programming operating in the Newark Public School area."
62478750|NCT01112761|EXPERIMENTAL|Athletes with history of concussion|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
62478751|NCT04476160|EXPERIMENTAL|Cinnamon|In this group, children will receive an intervention with 3000mg / day cinnamon along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
62315104|NCT06242925|EXPERIMENTAL|ABCLO Group|The cohort (interventional) patients will receive the standard of care (Lahey bag, Ioban and closed suction drains) in addition to the study intervention (AbCLO Device).
62315105|NCT06242925|NO_INTERVENTION|Historical Controls|"The control group is retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.~At TMC, we have a previously collected data bank of all open abdomen managed at our center. This data bank is approved by IRB. This data bank has 170 patients in total. we will use 45 patients from the data bank to be matched to the interventional group (15 patients) to have a total of 60 patients from TMC.~As of LAC+USC Medical Center, they will provide historical controls from the trauma registry."
62315106|NCT02891746||Premature infants|premature infants ≤ 34 weeks of gestation
62315107|NCT02891746||Term infants|neonates ≥ 37 weeks gestation
62315108|NCT00318201|EXPERIMENTAL|1|Altered efficacy for drug to drug interaction of diltiazam with erythromycin
62315109|NCT06574269|EXPERIMENTAL|Part 1, Cohort 1|Bunionectomy: Increasing dose cohorts for TLC590
62315110|NCT06574269|EXPERIMENTAL|Part 1, Cohort 2|Laparoscopy-assisted Open Ventral Hernia: TLC590
62315111|NCT06574269|EXPERIMENTAL|Part 2, Cohort 3|Breast Augmentation: TLC590 or Ropivacaine
62315112|NCT06574269|EXPERIMENTAL|Part 2, Cohort 4|Breast Augmentation: TLC590 or Ropivacaine
62315113|NCT06574269|EXPERIMENTAL|Part 2, Cohort 5|Breast Augmentation: TLC590 with the SMC-suggested dose
62315114|NCT06574269|EXPERIMENTAL|Part 3, Cohort 6|Laparoscopy-assisted Open Ventral Hernia: The MTD of TLC590
62315115|NCT06574269|EXPERIMENTAL|Part 3, Cohort 7|Total Knee Arthroplasty: The MTD of TLC590
62315116|NCT06574269|EXPERIMENTAL|Part 3, Cohort 8|Abdominoplasty: The MTD of TLC590
62478752|NCT04476160|NO_INTERVENTION|Control|In this group, children will receive a placebo intervention along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
62478753|NCT01718873|EXPERIMENTAL|bevacizumab before chemotherapy|Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
62315117|NCT00471471|EXPERIMENTAL|Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil|"The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year)."
62315118|NCT05348850||Study Group|"Athletes with patellofemoral pain syndrome will be selected Muscle contractile properties and functional performance will be assessed for athletes with patellofemoral pain syndrome .~Data will be collected from all athletes regarding age, gender, training intensity running experience and previous injuries.~By the end of the assessment it will be detected if muscle contractile properties of vastus medialis and vastus lateralis is a determinant factor that influence functional performance in runners with patellofemoral pain syndrome."
62315119|NCT02273310|EXPERIMENTAL|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
62315120|NCT02273310|NO_INTERVENTION|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
62315121|NCT05114863|EXPERIMENTAL|Non-menthol smokers|Subjects will be randomized to one of ten product use sequences, such that one of the five IPs (A1,B,C,D,N) will be used in each of the five Test Sessions.
62315122|NCT05114863|EXPERIMENTAL|Menthol smokers|Subjects will be randomized to one of six product use sequences, such that one of the six IPs (A2,E,F,G,H,N) will be used in each of the six Test Sessions.
62315123|NCT04606511|OTHER|Breast cancer patients with lymphedema|
62315124|NCT04606511|OTHER|Breast cancer patients without lymphedema|
62685408|NCT01878474|PLACEBO_COMPARATOR|Placeo: Gender-effect in Caucasian women|
62125176|NCT01318382|EXPERIMENTAL|TOF-Watch SX®|Participants who have undergone elective open or laparoscopic abdominal surgery, received general anesthesia, received at least one dose of non-depolarizing neuromuscular blocker and had the extent of their recovery from NMB monitored by a TOF-Watch SX®.
62125177|NCT01503749|NO_INTERVENTION|Control|Three patients with liver cirrhosis of this arm will not receive any intervention regarding to peripheral blood mononucleated cells.
62478754|NCT01718873|ACTIVE_COMPARATOR|bevacizumab with chemotherapy|Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
62685409|NCT01878474|PLACEBO_COMPARATOR|Placebo: Single ascending dose in Japanese men|
62685410|NCT05373680|EXPERIMENTAL|Metformin treatment group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive metformin 1000 mg PO daily added to their usual therapy.
62685411|NCT05373680|EXPERIMENTAL|Empagliflozin treatment group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive empagliflozin 10 mg daily PO added to their usual therapy.
62685412|NCT05373680|OTHER|Control group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive their usual therapy.
62685413|NCT04158258||Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
62685414|NCT04158258||Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
62685415|NCT04158258||Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
62685416|NCT04158258||Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
62685417|NCT04158258||Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
62685418|NCT04158258||Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
62685419|NCT05048264||Diabetic patients receiving a corticosteroid injection of their shoulder, knee or hip joints.|There are no study-related interventions for this study.
62685420|NCT02046876|EXPERIMENTAL|Multimodal Physiotherapy Program for Chronic Neck Pain Suffers|
62685421|NCT05653011||Control group|Patients who are not diagnosed with inflammatory bowel disease and have colitis.
62685422|NCT05653011||TNF-alpha Inhibitor-naive IBD group|Patients who are diagnosed with inflammatory bowel disease but do not have a history of TNF-a inhibitor treatment.
62685423|NCT05653011||TNF-alpha Inhibitor-treated IBD group|Patients who are diagnosed with inflammatory bowel disease and have a history of TNF-a inhibitor treatment.
62685424|NCT03248661|EXPERIMENTAL|Intervention media condition|monthly social media contact will be used to keep people connected to the idea of completing a second screening test 12 months after their last one.
62685425|NCT03248661|NO_INTERVENTION|control condition|this group will receive only a standard reminder for the annual repeat test, one month before the test due date
62685426|NCT06407401|ACTIVE_COMPARATOR|Control arm (SoC)|Standard of care (SoC) including a booklet focused on healthy behaviors
62685427|NCT06407401|EXPERIMENTAL|Experimental arm SoC with duloxetine|Duloxetine 60 mg (1 pill a day) + SoC
62685428|NCT06407401|EXPERIMENTAL|Experimental arm SoC with Furosemide|Furosemide 40 mg (1 pill a day) + SoC
62685429|NCT06255626|EXPERIMENTAL|1-CD40.RBDv non adjuvanted or mRNA vaccine (5:1 ratio)|Low dose (LD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio). If randomized to receive LD CD40.RBDv vaccine non adjuvanted in part 1, the subject will be randomised a second time to receive LD CD40.RBDv vaccine non adjuvanted (1:1) in part 2.
62685430|NCT06255626|EXPERIMENTAL|2-CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio)|LD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive LD CD40.RBDv vaccine adjuvanted in part 1, the subject will be randomised a second time to receive LD CD40.RBDv vaccine adjuvanted (1:1) in part 2.
62685431|NCT06255626|EXPERIMENTAL|3-High dose (HD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio)|High dose (HD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive HD CD40.RBDv vaccine non adjuvanted in part 1, the subject will be randomised a second time to receive HD CD40.RBDv vaccine non adjuvanted (1:1) in part 2.
62685432|NCT06255626|EXPERIMENTAL|4-High dose (HD) CD40.RBDv vaccine adjuvanted or mRNA vaccine|HD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive HD CD40.RBDv vaccine adjuvanted in part 1, the subject will be randomised a second time to receive HD CD40.RBDv vaccine adjuvanted (1:1) in part 2.
62685433|NCT04559139|ACTIVE_COMPARATOR|Arm I (surgery, adjuvant therapy)|Within 4 weeks of randomization, patients undergo surgery to remove part of the liver, the lymph nodes around the liver, and possibly the bile ducts. Patients then receive gemcitabine IV over 30 minutes and cisplatin IV over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62125178|NCT01503749|ACTIVE_COMPARATOR|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm.
62315125|NCT06468774||Median arcuate ligament syndrome (MALS)|Patients with MALS Scheduled for laparoskopic decompression.
62478755|NCT04740632|NO_INTERVENTION|Mothers of children with food allergy diagnosed by a multidisciplinary team|Mothers of children with food allergy diagnosed by a multidisciplinary team (Group 1) already followed for at least 6 months by the Tertiary Center of Pediatric Allergology..
61924184|NCT02285556|PLACEBO_COMPARATOR|fake brain stimulation intervention|fake transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
61924185|NCT05990998|EXPERIMENTAL|Patients will undergo a 68Ga-FAPI PET/CT and 68Ga-DOTATATE PET/CT|NPC patients receive a single intravenous injection of 68Ga-FAPI PET/CT and 68Ga-DOTATATE PET/CT (2-4mCi) PET/CT,and undergo PET/CT scan at 40-60 min post-injection.
61924186|NCT03785288|ACTIVE_COMPARATOR|ARM A: 3 treatments of 7Gy|Arm A: accepted randomization to HDR vaginal brachytherapy in 3 treatments (fractions) of 7Gy for a total dose of 21gy
61924187|NCT03785288|ACTIVE_COMPARATOR|ARM B: 6 treatment of 4Gy|Arm B: accepted randomization to HDR vaginal brachytherapy 6 treatments (fractions) of 4Gy for a total does of 24gy
62125179|NCT01503749|EXPERIMENTAL|Infusion of the mobilized monocyte cells|"G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells~. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance."
62315126|NCT06468774||Chronic mesenteric ischemia (CMI)|Patients with CMI caused by atherosclerotic stenosis or occlusion of celiac artery, superior mesenteric artery ( one or both arteries ), and scheduled treatment with either PTA/stent or mesenteric bypass.
62478756|NCT04740632|EXPERIMENTAL|Mothers of children with food allergy diagnosed by a non-multidisciplinary team|Mothers of children with food allergy diagnosed by a non-multidisciplinary team who plan to visit for the first time the Tertiary Center of Pediatric Allergology.
61924188|NCT03785288|ACTIVE_COMPARATOR|ARM AB: 6 treatment of 4Gy|Arm AB: initially randomized to ARM A but wanted to switch to ARM B treatment of HDR vaginal brachytherapy 6 treatments (fractions) of 4Gy for a total does of 24gy
61924189|NCT03785288|ACTIVE_COMPARATOR|ARM BA: 3 treatments of 7Gy|initially randomized to ARM B but wanted to switch to ARM A of HDR vaginal brachytherapy in 3 treatments (fractions) of 7Gy for a total dose of 21gy
61924190|NCT04710277|EXPERIMENTAL|Novel multimodal protocol group|They will receive scheduled topical ice therapy for 24 hours after surgery. It will be applied over abdominal incisions for 20 minutes every 2-3 hours. Acetaminophen and an NSAID will be scheduled for 96 hours. While inpatient, they will receive acetaminophen 975 mg every 8 hours and IV Toradol 15-30 mg every 6 hours with change to ibuprofen 800 mg every 8 hours when tolerating oral intake. They may take oxycodone 5 mg every 4-6 hours as needed (PRN) for breakthrough pain and pain score \>6. They may use ice PRN after 24 hours. They will be prescribed acetaminophen 1000 mg every 8 hours and ibuprofen 800 mg every 8 hours for 96 hours postoperative. They may take them as needed after. If the participant used 0 narcotics in the first 24 hours, they will not be prescribed a narcotic. If up to 5 tablets were used, they will be prescribed 5 tablets of oxycodone 5 mg every 6 hours PRN. If more than 5 tablets were used, they will be prescribed 10 tablets of oxycodone 5 mg every 6 hours PRN.
62125180|NCT00621569|ACTIVE_COMPARATOR|1|Group intervention with no dietary focus
62125181|NCT00621569|EXPERIMENTAL|2|DASH diet intervention
62125182|NCT01404182|EXPERIMENTAL|Influenza vaccination|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
62125183|NCT01274871||lung cancer surgery|
62125184|NCT02784132|OTHER|Study Arm A|Right eye examined first with video diversion then left eye examined without video diversion
62125185|NCT02784132|OTHER|Study Arm B|Right eye examined first without video diversion then left eye examined with video diversion
62125186|NCT02784132|OTHER|Study Arm C|Left eye examined first with video diversion then right eye examined without video diversion
62125187|NCT02784132|OTHER|Study Arm D|Left eye examined first without video diversion then right eye examined with video diversion
62125188|NCT00974831|EXPERIMENTAL|AA Drink|Amino Acid Drink Mixture
62125189|NCT00974831|PLACEBO_COMPARATOR|Glucose drink|
62125190|NCT03366870|EXPERIMENTAL|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
62125191|NCT03366870|EXPERIMENTAL|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
62315127|NCT06468774||Morbus Crohn intestine|Patients with diagnosed Mb Crohn of intestine who does not have CMI or MALS excluded with duplex ultrasound.
62315128|NCT06468774||Cholilithiasis|Patients with diagnosed Cholilithiasis who is scheduled for operative chelecystectomy and does not have CMI or MALS, excluded with the help of duplex ultrasound.
62315129|NCT06468774||Blood donor (Young)|Healthy blood donor with a median age of 45 years, who does not have symptoms of mesenteric ischemia or MALS and has excluded these two conditions with the help of duplex ultrasound.
62315130|NCT06468774||Blood donor (Old)|Healthy blood donor with a median age of 70 years, who does not have symptoms of mesenteric ischemia or MALS and has excluded these two conditions with the help of duplex ultrasound.
62315131|NCT03279510|EXPERIMENTAL|Hearing aids|All study participants will be fit with hearing aids.
62478757|NCT05919810|EXPERIMENTAL|Probiotic|Daily consumption of probiotic
62478758|NCT05919810|EXPERIMENTAL|Oral herbal supplement|Daily consumption of oral herbal supplement powder
62478759|NCT06721351|NO_INTERVENTION|Usual care|The usual care group will complete the DR screening with an eye care provider on a different day and at a different location. The study staff will facilitate this process for participants in the usual care group by assisting them in scheduling appointments for their routine retinal screening.
62315132|NCT06672588|EXPERIMENTAL|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
62315133|NCT06672588|ACTIVE_COMPARATOR|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma.
62315134|NCT06274112|EXPERIMENTAL|TMS A|Active continuous thetaburst stimulation administered over right dorsolateral prefrontal cortex for 40 seconds (600 pulses total)
62315135|NCT06274112|SHAM_COMPARATOR|TMS B|Sham continuous thetaburst stimulation administered over right dorsolateral prefrontal cortex for 40 seconds (600 pulses total)
62315136|NCT04549038|EXPERIMENTAL|Cases|Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.
62315137|NCT04549038|NO_INTERVENTION|Controls|Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.
62315138|NCT01099826|EXPERIMENTAL|lifestyle counseling tailored|
62315139|NCT01099826|EXPERIMENTAL|lifestyle counseling motivational|
62315140|NCT01099826|NO_INTERVENTION|control|
62315141|NCT01426048||Patients operated on with the TVT|
62315142|NCT05535673|EXPERIMENTAL|ThisCART19A cell injection|In this study, allogeneic anti-CD19 CART cell (This CART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
62315143|NCT02133014|EXPERIMENTAL|surgical operation therapy|Using the method of laparoscopic-assisted percutaneous catheter drainage of SAP.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline.
62315144|NCT02133014|NO_INTERVENTION|conventional therapy|using the method of conventional conservative therapy without surgical management.
62478760|NCT06721351|EXPERIMENTAL|Diabetic Retinopathy Screening|The intervention group will complete the DR screening using a special camera and the AI system (EyeArt®), the same day of the study visit. Participants assigned to the intervention group will also receive a retinal screening without dilation using the EyeArt® AI system; the DR screening will be completed before their medical provider visits. The results will be available immediately after the screening, allowing participants to learn about and discuss their eye health with their care provider.
62478761|NCT06741761|ACTIVE_COMPARATOR|Continuous 24 hour feeding (CONT24).|24 hour tube feeding is the standard of care. They will receive tube feeding continuously over 24 hours daily.
62478762|NCT06741761|EXPERIMENTAL|12-hour time-restricted feeding (TRF12)|The 12-hour time-restricted feeding group will receive the same amount of nutrition in 12 hours as would be needed in 24 hours. The hourly feeding rate will double.
62478763|NCT03575910||Acute Rejection (AR)|Heart transplant patients diagnosed with an ISHLT grade 2R or 3R via endomyocardial biopsy.
62315145|NCT03633643|PLACEBO_COMPARATOR|Group A|Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) \& Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
62315146|NCT03633643|ACTIVE_COMPARATOR|Group B|3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
62478764|NCT03575910||Mild Rejection (MR)|Heart transplant patients diagnosed with an ISHLT grade 1R via endomyocardial biopsy.
62478765|NCT03575910||Non-Rejection (NR)|Heart transplant patients diagnosed with an ISHLT grade 0R via endomyocardial biopsy.
62478766|NCT06560645|EXPERIMENTAL|PRT7732|PRT7732 is administered as an oral capsule once daily. Dose escalation/de-escalation decisions will be guided by the BLRM method until the RDE is determined.
62315147|NCT01079793|EXPERIMENTAL|ixabepilone|Adjuvant therapy
62315148|NCT03094936|OTHER|Group A|This group own twenty patients who met all the inclusion criteria. These will be treated with APC.
62315149|NCT03094936|ACTIVE_COMPARATOR|Group B|This group own twenty patients who met all the inclusion criteria. These will be treated with APC plus Endoscopic Suture Technique (OverStitch TM).
62478767|NCT00909753|EXPERIMENTAL|Ursodiol (test) First|Ursodiol Tablets, 500 mg
62315150|NCT02153242||Supra Ventricular Tachycardia (SVT)|Patients undergoing SVT studies
62315151|NCT03345862|EXPERIMENTAL|Intervention|Non-pharmacological multicomponent intervention
62315152|NCT03345862|NO_INTERVENTION|Control|Not intervention, usual attention
62315153|NCT00734929|EXPERIMENTAL|1|Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
62315154|NCT00734929|ACTIVE_COMPARATOR|2|Ondansetron 4 mg within 30 min of the end of surgery + Dexamethasone 10 mg after induction of anesthesia
62315155|NCT01589120|NO_INTERVENTION|control group|Verbal description of goals of care reflecting usual care
62315156|NCT01589120|EXPERIMENTAL|Video Arm|Video intervention group
62478768|NCT00909753|ACTIVE_COMPARATOR|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg
62478769|NCT04396873|OTHER|Only one arm|All subjects receive the same tests
62315157|NCT04955743|EXPERIMENTAL|Cohort 1: Melanoma|Participants who are melanoma (PD-1/PD-L1-experienced)
62315158|NCT04955743|EXPERIMENTAL|Cohort 2: Renal Cell Carcinoma|Participants who are Renal Cell Carcinoma (PD-1/PD-L1 experienced).
62315159|NCT03809572|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support.
62315160|NCT03809572|NO_INTERVENTION|Treatment as usual (TAU)|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
62478770|NCT03635164|EXPERIMENTAL|Dose Escalation and Expansion|"Part 1 of this trial will use a traditional 3+3 design will be used for this trial (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level). Dose escalation will occur as long as there are minimal dose limiting toxicities.The expectation is that 9 patients will be enrolled to the trial during part 1.This is based on the expectation that all dose levels are safe (i.e. patients will not experience DLTs at all dose levels). The range of patients needed will be 6-12 patients.~Part 2 of this trial will be an expansion cohort. A total of 8 additional patients will be enrolled at the dose level determined to be the MTD in part 1 of the study. These 8 patients will be used to confirm that the MTD is a safe combination, as well as provide additional patients to investigate the efficacy for the treatment combination.~Note: Standard of care surgery will follow 3-6 weeks after medication and radiation treatment."
62478771|NCT02226289|EXPERIMENTAL|bevacizumab-containing|bevacizumab with the latest received cytotoxic regimen
62478772|NCT04042233|ACTIVE_COMPARATOR|IV administration of vancomycin|Standard IV vancomycin administration protocol.
62478773|NCT04042233|EXPERIMENTAL|IO Vancomycin 500mg in 250 mL NS|Experimental Intraosseous administration protocol.
62315161|NCT02369835|EXPERIMENTAL|Arm I (modified Dakin's solution)|Participants apply modified Dakin's solution (0.005% to 0.010%) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
62315162|NCT02369835|PLACEBO_COMPARATOR|Arm II (placebo)|Participants apply placebo solution (saline) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
62315163|NCT03110042||Observational Cohort|All patients will receive usual standard of care with the heart failure management including the routine supplemental oxygen therapy.
62315164|NCT04498858||Patient|
62315165|NCT03501355|ACTIVE_COMPARATOR|Strength training group|Intervention:Inspiratory muscle strength training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
62315166|NCT03501355|ACTIVE_COMPARATOR|Endurance training group|Intervention: Inspiratory muscle endurance training group received inspiratory muscle endurance training (IMT) using POWERbreathe Classic threshold loading device
62315167|NCT05477238|EXPERIMENTAL|Cerebrovascular Accident|Stroke patients will perform 2 walking tests indoors and outdoors wearing a gas exchange analyzer, an accelerometer and a heart rate monitor meter
62315168|NCT05477238|OTHER|healthy volunteer|Healthy volunteers patients will perform 2 walking tests indoors and outdoors wearing a gas exchange analyzer, an accelerometer and a heart rate monitor meter
62315169|NCT05348005|NO_INTERVENTION|No TENS unit use|All subjects will start with 3 months of no TENS use and diary tracking
62315170|NCT05348005|ACTIVE_COMPARATOR|TENS unit use|All subjects will then have 3 months of TENS use during episodes of endometriosis pain flare and diary tracking.
62315171|NCT01378390|EXPERIMENTAL|ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million cells in case of incomplete fistula closure following week 12 assessment.
62315172|NCT01378390|SHAM_COMPARATOR|Placebo|Instillation of saline solution into the fistulous tract, following identical tract preparation process as for the investigational treatment group.
62315173|NCT03401177|EXPERIMENTAL|Naproxen & Heavy resistance training|Naproxen: 500 mg x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
62478774|NCT03465839|EXPERIMENTAL|Bedside handover|Education for improving handovers quality + Education for improving bedside handovers
62478775|NCT03465839|ACTIVE_COMPARATOR|Control|Education for improving handovers quality
62478776|NCT02982577|EXPERIMENTAL|Pilocarpine|Spray with Pilocarpine
62478777|NCT02982577|PLACEBO_COMPARATOR|Placebo|Spray without Pilocarpine
62685434|NCT04559139|EXPERIMENTAL|Arm II (neoadjuvant therapy, surgery, adjuvant therapy)|Patients receive gemcitabine IV over 30 minutes and cisplatin over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Approximately 4-8 weeks after completion of chemotherapy, patients whose disease has not spread to other places in the body (metastasized), then undergo surgery as in Arm I. Patients with successful surgery then resume treatment with gemcitabine IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62685435|NCT02773823|ACTIVE_COMPARATOR|Intervention|"Lifestyle intervention includes diet instruction and exercise intervention:~1. Diet instruction: The children were asked to increase fruit/vegetables consumption, reduce high fat food, etc.~2. Exercise intervention: The children participated sports 60 min/day,5d/week for 8 months."
62685436|NCT02773823|NO_INTERVENTION|Control|"No intervention in the group with control."
62685437|NCT06686251|EXPERIMENTAL|App LuAna|feedback of the artificial intelligence after the inclusion image in app LuAna.
62685438|NCT02040012|ACTIVE_COMPARATOR|AZP-531|subcut administration once or twice daily
62478778|NCT05221229||Study Cohort|A total of 30 patients will be included in the study group after screening of inclusion and exclusion criteria. Patients will have upstream risk factors assessed at the clinic consultation and offered risk factor optimization advice. In addition, they will received daily Liraglutide injections for 13 weeks before and 52 weeks after ablation.
62685439|NCT02040012|PLACEBO_COMPARATOR|Mannitol|subcut administration once or twice daily
62685440|NCT02969226|ACTIVE_COMPARATOR|Once daily screening + PS SBTs|In this arm, RTs will screen patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS\> 0 and =\< 8 cm H2O with PEEP\> 0 and =\< 5 cm H2O.
62685441|NCT02969226|EXPERIMENTAL|At least twice daily screening + PS SBTs|In this arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team \[RTs and physicians\]. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS\>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O.
62685442|NCT02969226|ACTIVE_COMPARATOR|Once daily screening + T-piece SBTs|In this arm + PS SBT' arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
62685443|NCT02969226|ACTIVE_COMPARATOR|At least twice daily screening + T-piece SBTs|In this arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently In the 'at least twice daily + PS SBT' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hrs and 13:00 - 15:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
62685444|NCT04450212|EXPERIMENTAL|Phase I, Buccal Swab Collection for DNA Isolation|Approximately 200 healthy volunteers recruited. They complete a brief demographic survey and a undergo one-time buccal swab for collection of cheek cells for DNA analysis.
62685445|NCT04450212|EXPERIMENTAL|Phase II, Vitamin K (Vitacost) Supplementation|Subjects from Phase I with a homozygous CYP4F2\*1 (n=14) or CYP4F2\*3 carriers (n=14) are selected to receive daily vitamin K supplementation, for 10-days. Blood and urine samples are collected sequentially, at baseline, and during the supplementation period.
62685446|NCT01713829|EXPERIMENTAL|Cranberry Beverage|Cranberry Beverage is provided in an 8 oz daily beverage consumed once daily for 12 weeks
62685447|NCT01713829|PLACEBO_COMPARATOR|Placebo Beverage|The placebo beverage looks like the active arm and is given in the same way but contains no active ingredient.
62315174|NCT03401177|PLACEBO_COMPARATOR|Placebo & Heavy resistance training|Placebo oral tablet: pill manufactured to mimic naproxen tablet x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
62315175|NCT03390231|EXPERIMENTAL|Stem Cell Educator|"The Stem Cell Educator (SCE) technology involves a closed-loop system that circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns only the educated immune cells to the patient's circulation. Several mechanistic studies with clinical samples and animal models have been conducted to demonstrate the proof of concept and clinical safety of SCE therapy. They suggest that SCE therapy may function via CB-SC induction of immune tolerance in the autoimmune T cells and pathogenic monocytes/macrophages that are encountered through the action of the autoimmune regulator (AIRE) and other molecular mechanisms. Following induction of immune tolerance in the immune cells, the immune balance and homeostasis may be restored when treated cells are returned in vivo."
62478779|NCT05074472|EXPERIMENTAL|Active Treatment: ZB131|During the Dose Escalation Stage, patients will be treated with ZB131 at increasing dose levels, beginning with a starting dose level (DL0) of 3 mg/kg once weekly, up to a maximum dose level (DL3) of 15 mg/kg once weekly.
62315176|NCT04379518|EXPERIMENTAL|Arm I (rintatolimod, recombinant interferon alfa-2b)|Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on day 3 (or 4) in the absence of disease progression or unacceptable toxicity.
62315177|NCT04379518|ACTIVE_COMPARATOR|Arm II/IV (standard of care)|Patients receive standard of care.
62315178|NCT04379518|EXPERIMENTAL|Arm III (rintatolimod)|Patients receive rintatolimod IV over 2.5-3 hours once.
62315179|NCT06611631|EXPERIMENTAL|Hyaluronic Acid Pulpotmoy|"1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown."
62315180|NCT06611631|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|"1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown."
62315181|NCT05101213|EXPERIMENTAL|Treatment for viral infections (virus-specific CTLs)|Patients receive virus-specific CTLs intravenously (IV) over 30 minutes. Patients with partial response, stable disease, or progressive disease may receive up to 8 additional infusions of virus-specific CTL at least 2 weeks between each infusion.
62478780|NCT06052917|EXPERIMENTAL|DECIdE|General practitionners and pharmacists will propose to their patients, complaining of a common symptom for which a drug is usually prescribed or dispensed, to discuss this drug and the symptom in order to reach a shared decision, using DECIdE as a support, on whether to take it or choose another alternative.
62125192|NCT03964376|EXPERIMENTAL|Nasal High Flow Group|Nasal High-Flow oxygen delivery will be applied starting at airflow of minimum 20 Litre/minute. It will be titrated in 15Litre/minute increments to 35 Litre/minute and a maximum 50 Litre/minute as determined by patient comfort. O2 supplementation will be managed by the anesthesia and surgical health care team to maintain the oxygen saturation level in the blood between 92-95%. In the Nasal High-Flow group, when SPO2 is in the range of 92-95%, air will be given instead of oxygen for the 1st 3 nights and during the day, if required, till discharge, whichever is earlier.
62315182|NCT06005493|EXPERIMENTAL|Module 1: AZD5863 Monotherapy Intravenous (IV)|Module 1: AZD5863 Intravenous (IV) Monotherapy
62315183|NCT06005493|EXPERIMENTAL|Module 2: AZD5863 Monotherapy Subcutaneous (SC)|Module 2: AZD5863 Subcutaneous (SC) Monotherapy
62315184|NCT03997474|EXPERIMENTAL|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
62315185|NCT03997474|EXPERIMENTAL|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL-2.
62315186|NCT03997474|EXPERIMENTAL|Cohort C|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
62685448|NCT06675305|EXPERIMENTAL|Beetroot juice supplementation|140 mL of beetroot juice (12.8 mmol of NO3-, Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) made from concentrates of beetroot juice (98%) and lemon juice (2%) (nutritional information (per 100 mL), energy: 373 kJ; fat: 0 g; carbohydrates: 18 g \[sugars: 17 g\]; protein: 3.7 g; salt: 0.48 g)
62315187|NCT03538873|ACTIVE_COMPARATOR|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
62315188|NCT03538873|NO_INTERVENTION|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
62315189|NCT02077062||study (hepatectomy) group|patients undergoing hepatectomy for malignant neoplasm
62315190|NCT02077062||control (non hepatectomy) group|patients undergoing intestinal resections (not incluiding hepatectomy) for malignant neoplasm
62315191|NCT05574101|EXPERIMENTAL|Participants with locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC|Participants have locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC
62315192|NCT03320629|EXPERIMENTAL|apatinib and S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
62315193|NCT03320629|ACTIVE_COMPARATOR|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
62685449|NCT06675305|PLACEBO_COMPARATOR|Placebo supplementation|140 mL of beetroot juice placebo without nitrates (0.08 mmol of NO3-, Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) made from concentrates of beetroot juice (98%) and lemon juice (2%) (nutritional information (per 100 mL), energy: 373 kJ; fat: 0 g; carbohydrates: 18 g \[sugars: 17 g\]; protein: 3.7 g; salt: 0.48 g)
62125193|NCT03964376|OTHER|Usual Care Group|In the usual care, patients will receive oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via facemask titrated to keep SpO2 level in the range of 92-95%. When SpO2 level reaches in the range of 92-95%, oxygen delivery will be discontinued.
62125194|NCT04956575|EXPERIMENTAL|Phase 1/2: mRNA-1010 Dose Level A|Participants will receive mRNA-1010 at dose level A by intramuscular (IM) injection on Day 1.
62125195|NCT04956575|EXPERIMENTAL|Phase 1/2: mRNA-1010 Dose Level B|Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
62315194|NCT00564707|ACTIVE_COMPARATOR|1|Standard biofeedback therapy will be given for painful levator ani syndrome over a course of eight weeks.
62125196|NCT04956575|EXPERIMENTAL|Phase 1/2: mRNA-1010 Dose Level C|Participants will receive mRNA-1010 at dose level C by IM injection on Day 1.
62125197|NCT04956575|EXPERIMENTAL|Phase 1/2: Placebo|Participants will receive placebo matching to mRNA-1010 by IM injection on Day 1.
62685450|NCT02039206|EXPERIMENTAL|Treatment|Deep TMS
62125198|NCT04956575|ACTIVE_COMPARATOR|Phase 2 NH: Active Comparator Dose Level A|Participants will receive active comparator at dose level A by IM injection on Day 1.
62685451|NCT00185614|EXPERIMENTAL|Auto- then Allo-HCT|Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue \[ie, autologous hematopoietic cells transplant (Auto-HCT)\]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 \& Day 0, to a target of \> 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV \& diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.
61924191|NCT04710277|ACTIVE_COMPARATOR|Usual care protocol group|Participants randomly assigned to the usual care protocol will receive current standard of care: scheduled acetaminophen and an NSAID for 24 hours. They will take acetaminophen 975 mg every 8 hours. They will also receive IV toradol 15 to 30 mg every 6 hours then switch to ibuprofen 800 mg every 8 hours when tolerating oral intake. They can also take oxycodone 5 mg every 4 to 6 hours on an as needed (PRN) basis for breakthrough pain with a pain score \>6. Per our current standard of care, usual care participants will be allowed to use either topical heat or ice on an as needed basis during their recovery. On discharge home, they will be prescribed acetaminophen 1000 mg every 8 hours PRN and ibuprofen 800 mg every 8 hours PRN. They will also be prescribed 15 tablets of oxycodone 5 mg every 6 hours PRN.
61924192|NCT01181648||oropharynx cancer survivors|This study has two components. First, we will conduct a cross-sectional survey of 200 oropharynx cancer survivors, diagnosed with HPV+ tumors, who are at least 12 months from their last treatment. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis.
61924193|NCT06483451||Individuals with active HCV infection|Individuals with active HCV infection
61924194|NCT01094639|PLACEBO_COMPARATOR|Supragingival prophylaxis|Plaque removal
61924195|NCT01094639|ACTIVE_COMPARATOR|Scaling root planing|SRP+oral hygiene
61924196|NCT04804501|EXPERIMENTAL|Blue Light Glasses (experimental)|These subjects will wear the device (glasses) while performing a reading task.
61924197|NCT04804501|OTHER|No Glasses (control)|These subjects will not wear the device (glasses) while performing a reading task.
61924198|NCT00813033|OTHER|patient decision aid|
61924199|NCT01212133||A|
61924200|NCT00587977||1|Aortic aneurysm repair
61924201|NCT00587977||2|Aortic aneurysm growth
61924202|NCT00587977||3|Aortic aneurysm growth stable.
61924203|NCT03665831|EXPERIMENTAL|Active H1 Coil deep rTMS active treatment|
61924204|NCT01384279|EXPERIMENTAL|metformin, topiramate|
61924205|NCT01791010|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training for 8 weeks using a device that provides a linear resistance in the inspiratory phase. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was at 40% of Maximal Inspiratory Pressure.
61924206|NCT01791010|SHAM_COMPARATOR|Training sham|Training sham for 8 weeks using a device without provides resistance. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was canceled.
62315195|NCT00564707|ACTIVE_COMPARATOR|2|Botulinum toxin type A will be injected under EMG guidance into spastic and painful levator ani muscles. This may be repeated only twice on separate visits.
62315196|NCT04594694|ACTIVE_COMPARATOR|Treatment A: BZF 200 milligrams (mg) Immediate release (IR)|Participants will receive Bezafibrate (BZF) 200 mg IR + OCA Placebo + BZF 400 mg Placebo
62315197|NCT04594694|ACTIVE_COMPARATOR|Treatment B: BZF 400 mg SR|Participants will receive BZF 400 mg SR + OCA Placebo + BZF 200 mg Placebo
62315198|NCT04594694|EXPERIMENTAL|Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR|Participants will receive OCA 5 mg to 10 mg + BZF 200 mg IR + BZF 400 mg Placebo
62315199|NCT04594694|EXPERIMENTAL|Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR|Participants will receive OCA 5 mg to 10 mg + BZF 400 mg SR + BZF 200 mg Placebo
62315200|NCT04594694|EXPERIMENTAL|Long-term safety extension (LTSE) phase: OCA + BZF|Participants will continue the original treatment assignment allocated during the DB Period. The OCA and BZF dose may be optimized based on safety and efficacy during the DB period.
62315201|NCT06512220|EXPERIMENTAL|Risperidone (1 mg) + Psilocybin (25 mg)|o One capsule of risperidone 1 mg will be taken first followed 60 minutes later by one capsule of psilocybin 25 mg. Both capsules will be taken orally with a glass of water.
62315202|NCT06512220|EXPERIMENTAL|Psilocybin (25 mg)|One capsule of psilocybin 25 mg will be taken orally with a glass of water.
62315203|NCT03280550|EXPERIMENTAL|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
62315204|NCT03280550|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
62315205|NCT04300218|EXPERIMENTAL|iCBT-I + CAU|Participants of this arm will get access to the course of the online cognitive-behavioral therapy for insomnia (iCBT-I) for 2 months along with the treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment
62315206|NCT04300218|ACTIVE_COMPARATOR|CAU|Participants of this arm will get a treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment. Then provided completion of all the assessments and satisfying eligibility criteria participants of this arm will get tha access to the 2-month iCBT-I course followed by the post-treatment assessment
61924207|NCT00679055|EXPERIMENTAL|MK-0736|Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
62125199|NCT04956575|EXPERIMENTAL|Phase 2 NH: mRNA-1010 Dose Level D|Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.
62125200|NCT04956575|EXPERIMENTAL|Phase 2 NH: mRNA-1010 Dose Level A|Participants will receive mRNA-1010 at dose level A by IM injection on Day 1.
62315207|NCT02458612|OTHER|control group|We will apply only upper limbs exercises with traditional therapy.
62315208|NCT02458612|ACTIVE_COMPARATOR|intervention group|We will apply mirror therapy and progressive strength training for upper extremities.
62315209|NCT02571179|EXPERIMENTAL|Intranasal fentanyl 50 microg/dose|patient was given intranasal fentanyl 50 microg/dose up to 250 microg
62315210|NCT06673251||children with type 1 diabetes|
62315211|NCT06673251||Healthy children|
61924208|NCT00679055|PLACEBO_COMPARATOR|Placebo|Participants will be orally administered placebo once daily for 12 weeks.
61924209|NCT02445391|NO_INTERVENTION|Arm A (observation) (closed to accrual 05/16/2016)|Patients undergo observation.
62125201|NCT04956575|EXPERIMENTAL|Phase 2 NH: mRNA-1010 Dose Level B|Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
62125202|NCT04956575|ACTIVE_COMPARATOR|Phase 2 Extension: Active Comparator Dose Level A|Participants will receive active comparator at dose level A by IM injection on Day 1.
62125203|NCT04956575|EXPERIMENTAL|Phase 2 Extension: mRNA-1010 Dose Level D|Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.
62125204|NCT04956575|EXPERIMENTAL|Phase 2 Extension: mRNA-1010 Dose Level E|Participants will receive mRNA-1010 at dose level E by IM injection on Day 1.
62125205|NCT04956575|EXPERIMENTAL|Phase 2 Extension: mRNA-1010 Dose Level F|Participants will receive mRNA-1010 at dose level F by IM injection on Day 1.
62315212|NCT04962165|EXPERIMENTAL|Experimental group|The group of SCI people will use a mandibular advancement device for treatment of obstructive sleep apnea.
61924210|NCT02445391|EXPERIMENTAL|Arm B (cisplatin or carboplatin)|Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62478781|NCT06052917|NO_INTERVENTION|routine without decision aid|General practitionners and pharmacists will prescribe or dispense to their patients, complaining of a common symptom, the drug they usually use and advise them or discuss the benefits and risks as they are used to doing.
62478782|NCT06559735|EXPERIMENTAL|SCS Study Arm|Within subject observational arm measuring non-invasive cerebral oxygenation/flow before, during and after SCS.
61924211|NCT02445391|ACTIVE_COMPARATOR|Arm C (capecitabine)|Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61924212|NCT05464329|EXPERIMENTAL|Arm A: Mosunetuzumab + DHAX|"* 3 cycles (cycle=21 days) of mosunetuzumab with DHAX salvage chemotherapy (selected at the discretion of the treating physician).~* The first 3 patients in each arm will receive Dose Level 1 along with standard dosing of DHAX. The rate of dose-limiting toxicities will determine whether the subsequent 3 patients in each arm are enrolled at Dose Level 1, or alternatively at Dose Level -1.~* For patients tolerating Cycle 1 of treatment, Cycles 2 and 3 will consist of mosunetuzumab administered as a single dose on Day 1 along with DHAX. Patients will undergo PET-CT restaging prior to Cycle 3, and those achieving a CR (or PR, at their physician's discretion) will receive the Cycle 3 dose of mosunetuzumab and DHAX, followed by standard of care stem cell mobilization and autoSCT. Patients with SD or PD after restaging will discontinue study treatment."
62315213|NCT03482310|EXPERIMENTAL|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
62315214|NCT05781399|EXPERIMENTAL|JNT-517 SAD (Part A)|Single dose of JNT-517 or placebo in fasted state.
62315215|NCT05781399|EXPERIMENTAL|JNT-517 MAD (Part B)|JNT-517 or placebo once or twice daily for 14 days, with first daily dose given after an overnight fast.
62685452|NCT02169258|PLACEBO_COMPARATOR|Selective Strategy|non-invasive evaluation of possible myocardial ischemia by using DSE or dTS followed by coronary angiography if the test is positive for ischemia
62685453|NCT02169258|NO_INTERVENTION|Registry|Clinical decisions are reached by consensus of operators, patients and family as usual care
62685454|NCT02169258|ACTIVE_COMPARATOR|Systemic Strategy|Routine coronary angiography before PTA without a previous non-invasive stress test
62685455|NCT03919019|EXPERIMENTAL|Macuprev Group|patients taking oral supplementation (Macuprev) 2 capsules per day for 6 months
62685456|NCT03919019|PLACEBO_COMPARATOR|Placebo Group|patients taking oral placebo 2 capsules per day for 6 months
62685457|NCT04885530|EXPERIMENTAL|Arm A - Ivermectin 400|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
62685458|NCT04885530|PLACEBO_COMPARATOR|Arm A - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight, matched to active study drug dosing."
62315216|NCT05781399|EXPERIMENTAL|JNT-517 Suspension Then Tablet Fasted Then Tablet Fed (Part C)|Single dose of JNT-517 suspension, JNT-517 tablet in a fasted state, and JNT-517 tablet in a fed state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
62315217|NCT05781399|EXPERIMENTAL|JNT-517 Tablet Fasted Then Tablet Fed Then Suspension (Part C)|Single dose of JNT-517 tablet in a fasted state, JNT-517 tablet in a fed state, and JNT-517 suspension in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
62685459|NCT04885530|EXPERIMENTAL|Arm B - Fluvoxamine|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.
62685460|NCT04885530|PLACEBO_COMPARATOR|Arm B- Placebo|Placebo - appearance and size matched to active study drug. Placebo will be self-administered orally by each participant twice a day for 10 days.
62685461|NCT04885530|EXPERIMENTAL|Arm C - Fluticasone|Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.
62685462|NCT04885530|PLACEBO_COMPARATOR|Arm C - Placebo|Placebo is a self-administered by inhalation. Participants will self-administer 1 blister of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.
62685463|NCT04885530|EXPERIMENTAL|Arm D - Ivermectin 600|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight for a daily dose of approximately 400-600 µg/kg."
62685464|NCT04885530|PLACEBO_COMPARATOR|Arm D - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight, matched to active study drug dosing."
62125206|NCT00656721|EXPERIMENTAL|Flutter Valve|This a crossover study, so all subjects performed both, control and experimental interventions. In Flutter Valve intervention the subjects remained comfortably seated, breathing through the device for 15 minutes, starting off from the total pulmonary capacity, and being free to cough. Thereafter, a 5-min session of cough ensued. In the control intervention the subjects followed the same sequence of the Flutter Valve intervention, but the metallic sphere and the cover of the device were removed. Since the patients were not acquainted with the valve, they did not know its proper assembly. As in the Flutter Valve intervention, during 15 minutes the patients could expectorate spontaneously and return to the device. A 5-min coughing session took place.
62125207|NCT05293548|EXPERIMENTAL|NVSI-06-09 Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
62315218|NCT05781399|EXPERIMENTAL|JNT-517 Tablet Fed Then Suspension Then Tablet Fasted (Part C)|Single dose of JNT-517 tablet in a fed state, JNT-517 suspension, and JNT-517 tablet in a fasted state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
62315219|NCT05781399|EXPERIMENTAL|JNT-517 PKU (Part D)|JNT-517 or placebo daily for 4 weeks. Dose is based on data from Parts A, B, and C.
62339639|NCT02260856|ACTIVE_COMPARATOR|Percutaneous Drill Epiphysiodesis|A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.
62685465|NCT04885530|EXPERIMENTAL|Arm E - Fluvoxamine 100|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 1 day, followed by a dose of 100 mg twice a day for 12 days.
62685466|NCT04885530|PLACEBO_COMPARATOR|Arm E - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
62125208|NCT05293548|ACTIVE_COMPARATOR|Inactivated Vaccine Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
62125209|NCT05887063|EXPERIMENTAL|Dementia Awareness Course|Participants attended one half-day Dementia Awareness course as a part of a group, delivered online
62315220|NCT03065803|ACTIVE_COMPARATOR|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
62315221|NCT03065803|OTHER|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
62315222|NCT01963052|EXPERIMENTAL|Part A: AGS-15E Dose Escalation (Dose Levels 1-6)|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Additional subjects may be enrolled for expansion of these dose levels to further evaluate the safety and efficacy, as recommended by a data review team (DRT).
62315223|NCT01963052|EXPERIMENTAL|Part B: AGS-15E Cisplatin Therapy -ineligible Expansion|Urothelial subjects who have not received any prior lines of therapy an who are unfit for Cisplatin therapy (Cis-ineligible) will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will initially be dosed one dose level below the preliminary recommended phase 2 dose (RP2D).
62315224|NCT01963052|EXPERIMENTAL|Part C: AGS15E Immune Checkpoint Inhibitor Treated Expansion|Subjects previously treated with immune checkpoint inhibitors (CPI) in the metastatic setting will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will be dosed at the RP2D.
62315225|NCT01963052|EXPERIMENTAL|Part A: AGS15E Dose Expansion|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks.
62685467|NCT04885530|EXPERIMENTAL|Arm F - Montelukast|Montelukast will be self-administered orally by each participant at a dose of 10 mg once a day for 14 days.
62125210|NCT05887063|NO_INTERVENTION|Treatment as Usual|Participants did not receive any active treatment but were able to access their usual supports
62125211|NCT05481463|EXPERIMENTAL|surufatinib combined with TAS-102|Surufatinib 250mg,TAS-102 35mg/m2
62125212|NCT01000480|EXPERIMENTAL|Pemetrexed|Pemetrexed and cisplatin are given as induction therapy followed after by pemetrexed and cisplatin with concurrent radiotherapy.
62125213|NCT00269789|EXPERIMENTAL|001|OROS Methylphenidate HCl
62125214|NCT00269789|ACTIVE_COMPARATOR|002|Ritalin
62125215|NCT00269789|PLACEBO_COMPARATOR|003|Placebo
62315226|NCT05699460||Early Parkinson's disease|
62315227|NCT05699460||Possible or Probable MSA-P|
62315228|NCT03893929||Chinese patients with clinical suspicious of prostate cancer|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
62685468|NCT04885530|PLACEBO_COMPARATOR|Arm F - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
62125216|NCT00508924|EXPERIMENTAL|ARG250|
62125217|NCT00508924|EXPERIMENTAL|ARG300|
62125218|NCT00508924|EXPERIMENTAL|ARG350|
62125219|NCT00508924|PLACEBO_COMPARATOR|Heparin|
62125220|NCT04294329|EXPERIMENTAL|Group Quadratus lumborum block with bupivacaine|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine where a solution of 0.25% bupivacaine 0.2 ml /kg (lean body weight) is used on each side with care not to exceed the toxic dose.
62125221|NCT04294329|PLACEBO_COMPARATOR|Group Quadratus lumborum block with saline|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine.A volume of 0.2ml/kg normal saline will given for each side.
62125222|NCT04243980||Group 1|Patients after total hip arthroplasty with short femoral stem
62125223|NCT05515900|EXPERIMENTAL|Sodium active, HMB active|The subjects in this group will take sodium pills of 2,000 mg/day from baseline to week 8, and take HMB pills of 3 g/day from week 5 to week 8 while on reduced-sodium diet.
62125224|NCT05515900|EXPERIMENTAL|Sodium active, HMB placebo|The subjects in this group will take sodium pills of 2,000 mg/day from baseline to week 8, and take placebo pills of 3 g/day from week 5 to week 8 while on reduced-sodium diet.
62125225|NCT05515900|EXPERIMENTAL|Sodium placebo, HMB active|The subjects in this group will take placebo pills from baseline to week 8, and take HMB pills of 3 g/day from week 5 to week 8 while on reduced-sodium diet.
62125226|NCT05515900|PLACEBO_COMPARATOR|Sodium placebo, HMB placebo|The subjects in this group will take placebo pills from baseline to week 8 while on reduced-sodium diet.
62315229|NCT04284917|EXPERIMENTAL|Receive Carglumic Acid|Experimental Case_ Carglumic Acid
62315230|NCT06480929|ACTIVE_COMPARATOR|study group|The study group included all patients admitted on odd numbered days of the month that performed a contrast TTE,
62125227|NCT04088123||Healthy Patients|The study design will involve analysis of platelet splicing/activity before and after exposure to a single, 180 mg loading dose of ticagrelor. All subjects will be cardiovascular healthy.
62685469|NCT04885530|EXPERIMENTAL|Arm G - Metformin|"Metformin IR tablets will be self-administered orally according to the following dosing schedule:~* 500 mg on Day 1;~* 500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and~* 500 mg in the morning and 2 x 500 mg (a total of 1000 mg) in the evening on Day 6 through Day 14."
62685470|NCT04885530|PLACEBO_COMPARATOR|Arm G - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
62685471|NCT02770365|EXPERIMENTAL|Test Product|estradiol cream
62685472|NCT02770365|ACTIVE_COMPARATOR|Reference Product|estradiol cream
62685473|NCT02770365|PLACEBO_COMPARATOR|Placebo product|Placebo cream
62315231|NCT06480929|NO_INTERVENTION|control group|The control group included patients admitted on even numbered days and were submitted to a conventional
62315232|NCT06673134||enteral nutrition group|enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition
62685474|NCT05474859|EXPERIMENTAL|Cohort 1|XT-0528 250 mg administered once daily
62685475|NCT05474859|EXPERIMENTAL|Cohort 2|XT-0528 500 mg administered once daily
62685476|NCT05474859|EXPERIMENTAL|Cohort 3|XT-0528 1000 mg administered once daily
62685477|NCT05474859|EXPERIMENTAL|Cohort 4|XT-0528 1500 mg administered once daily
62685478|NCT05474859|EXPERIMENTAL|Cohort 5|XT-0528 2500 mg administered once daily
62685479|NCT05500846|EXPERIMENTAL|Cryoablation Arm|Minimally invasively trans-perineal puncture of both cryo-needles and temperature-needles will be placed under real-time image guidance to the targeted area of cancer lesion or temperature-monitoring sites, respectively. The targeted tissue surrounding the tip of cryo-needles will be freeze down to targeted temperature for killing the cancer cells, and other non-treated area will be left in the prostate for aiming of maintain QOL (quality-of-life). The Minimally invasive cryoablation surgery will be performed under general anesthesia within one and half hour for aiming to be provided total 50 patients. (The used device for this arm has been clinically approved for cryoablation of renal cancer in Japan.)
62685480|NCT02719574|EXPERIMENTAL|PH1 Dose Escalation & Expansion FT-2102 (olutasidenib)|
62685481|NCT02719574|EXPERIMENTAL|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine|
62685482|NCT02719574|EXPERIMENTAL|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine|
62685483|NCT02719574|EXPERIMENTAL|PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent|Relapsed or Refractory (R/R) AML
62685484|NCT02719574|EXPERIMENTAL|PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent|AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation
62685485|NCT02719574|EXPERIMENTAL|PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent|R/R AML/MDS, previously treated with FT-2102
62685486|NCT02719574|EXPERIMENTAL|PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy
62125228|NCT02275377|EXPERIMENTAL|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 8 weeks.
62125229|NCT02275377|PLACEBO_COMPARATOR|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
62315233|NCT06673134||Glucocorticoid group|Glucocorticoid therapy
62315234|NCT06673134||Immunosuppressive group|Immunosuppressive therapy
62315235|NCT06673134||Fecal Microbiota Transplantation group|Fecal Microbiota Transplantation therapy
62315236|NCT06673134||Biologics group|Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).
62315237|NCT06443281||Patients with spinal cord injury with neuropathic pain|
62315238|NCT06443281||Patients with spinal cord injury but without neuropathic pain|
62315239|NCT06443281||Patients with peripheral neuropathy|
62315240|NCT06443281||Healthy subjects|
62315241|NCT02777840|ACTIVE_COMPARATOR|Face mask group|Patients will be given oxygen via face mask as per routine practice, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
62315242|NCT02777840|ACTIVE_COMPARATOR|THRIVE group|Patients will be given oxygen via high flow oxygen in Optiflo, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
62315243|NCT01123304|EXPERIMENTAL|MORAb 028|
62315244|NCT03199911|EXPERIMENTAL|Topical Antibiotic Ointment|Intervention: 200 patients in the antibiotic arm will receive either erythromycin or bacitracin, based on allergies, surgeon preference, and antibiotic availability. If neither antibiotic is obtainable by the patient, bacitracin polymyxin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
62315245|NCT03199911|PLACEBO_COMPARATOR|Topical Non-Antibiotic Ointment|Intervention: 200 patients in the placebo group will receive mineral oil/petrolatum-based artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.
62315246|NCT01301911|EXPERIMENTAL|Cipatinib|Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.
62315247|NCT04072640|EXPERIMENTAL|voriconazole treatment|induction treatment with Voriconazole 200mg bid (IV) + 5FC (100mg/kg/d) for 14 days, consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
62315248|NCT04072640|ACTIVE_COMPARATOR|amphotericin treatment (0.7-1.0mg/kg/d)|Induction treatment with amphotericin B 0.7-1.0mg/kg/d + 5FC (100mg/kg/d) for 14 days,consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
62315249|NCT04072640|EXPERIMENTAL|amphotericin B treatment (0.4-0.5mg/kg/d)|Induction treatment with amphotericin B 0.4-0.5mg/kg/d + 5FC (100mg/kg/d) for 28 days, consolidation treatment with fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
62315250|NCT03991377|EXPERIMENTAL|EMDR therapy|Patients in the psychotherapy intervention will receive up to 20 individual sessions of EMDR, weekly sessions, of 60 minutes each, using the standard EMDR therapy protocol developed by Shapiro to treat both current and past trauma-related symptom.
62315251|NCT03991377|ACTIVE_COMPARATOR|Treatment as usual|Multidisciplinary approach that includes pharmacological treatment and psychological support.
62315252|NCT02397720|EXPERIMENTAL|Arm 1 A Lead-In (azacitidine, nivolumab)|Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62125230|NCT02275377|NO_INTERVENTION|Normotensive|The normotensive control group (healthy) will go through the same initial evaluation without performing inspiratory muscle training.
62125231|NCT05537298||Survivor|Patients (n = 206) surviving critical illness will be enrolled to longitudinal, observational study examining muscle strength, power, and fatigue as well as physical function at hospital discharge and repeated at 3-, 6-, and 12-month following. A subset of individuals (n =40) will undergo muscle biopsies and blood will be collected.
62125232|NCT05537298||Control|A group of healthy controls will be recruited to serve as comparator to measures of strength, power, physical function, and muscle tissue analyses. Controls will participate in a one-time assessment.
62125233|NCT01149369|ACTIVE_COMPARATOR|Aprepitant|Aprepitant 125 mg per day
62315253|NCT02397720|EXPERIMENTAL|Arm 2 A Lead-In (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62315254|NCT02397720|EXPERIMENTAL|Arm 1 B (azacitidine, nivolumab)|Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62315255|NCT02397720|EXPERIMENTAL|Arm 3 Lead-In (azacitidine, nivolumab, Venetoclax)|Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.
62315256|NCT02397720|EXPERIMENTAL|Arm 2 B (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62685487|NCT02719574|EXPERIMENTAL|PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy
62685488|NCT02719574|EXPERIMENTAL|PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have been previously treated with single-agent FT-2102 as their last therapy prior to study enrollment
62315257|NCT02397720|EXPERIMENTAL|Arm 3 (azacitidine, nivolumab, Venetoclax)|Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.
62685489|NCT02719574|EXPERIMENTAL|PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent|Treatment naïve AML for whom standard treatments are contraindicated
62685490|NCT02719574|EXPERIMENTAL|PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine|Treatment naïve AML who are candidates for azacitidine first line treatment
62685491|NCT02529488|EXPERIMENTAL|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
62685492|NCT05197374|EXPERIMENTAL|Group 1|Cases who received estradiol pretreatment then underwent ICSI.
62125234|NCT01149369|PLACEBO_COMPARATOR|Aprepitant-placebo|Placebo aprepitant 125mg per day
62125235|NCT02750072|ACTIVE_COMPARATOR|Infrapatellar approach|Infrapatellar approach using the surgeon's incision of choice (i.e., patellar tendon split, tendon retraction medial, tendon retraction lateral).
62315258|NCT02392546|EXPERIMENTAL|Elobixibat 10 mg|elobixibat
62685493|NCT05197374|NO_INTERVENTION|group 2|Cases who underwent ICSI directly without receiving any pretreatment
62685494|NCT03111108|EXPERIMENTAL|Arm 1: EBR/GZR for 8 Weeks|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
62685495|NCT03111108|EXPERIMENTAL|Arm 2: EBR/GZR for 12 Weeks|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
62685496|NCT02976844||Low PEEP group|The positive end-expiratory pressure was less than 10cmH2O
62125236|NCT02750072|EXPERIMENTAL|Semi-extended suprapatellar approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed suprapatellar percutaneous instrumentation (patellofemoral protection sleeve).
62315259|NCT02392546|EXPERIMENTAL|Elobixibat 15 mg|elobixibat
62685497|NCT02976844||High PEEP group|The positive end-expiratory pressure was higher or equal to 10cmH2O.
62685498|NCT04769778|EXPERIMENTAL|Valsartan|Treatment with valsartan
62685499|NCT04769778|NO_INTERVENTION|no treatment|no treatment received
62685500|NCT06501105||WOUNDCHEK Bacterial Status positive|Wounds positive for bacterial protease activity that may delay healing if untreated. Pre- and post-test treatment plan recorded.
62685501|NCT06501105||WOUNDCHEK Bacterial Status negative|Wounds negative for bacterial protease activity. Pre- and post-test treatment plan recorded.
62685502|NCT03777215|EXPERIMENTAL|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of angiotensin-(1-7). The doses are: 2, 4, and 8 ng/kg/min. Each dose will be maintained for 10 minutes, with the highest dose maintained for an additional 90 minutes. The total infusion period is 120 minutes.
62685503|NCT03777215|PLACEBO_COMPARATOR|Placebo|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7). The total infusion period is 120 minutes.
62685504|NCT03042975||Laryngeal Dystonia|Patients with laryngeal dystonia will undergo an MRI of the brain and a blood draw.
62315260|NCT02392546|EXPERIMENTAL|Elobixibat 20 mg|elobixibat
62685505|NCT03042975||Unaffected relatives of laryngeal dystonia patients|Unaffected relatives of patients with laryngeal dystonia will undergo an MRI of the brain and a blood draw.
62685506|NCT03042975||Voice tremor|Patients with voice tremor will undergo an MRI of the brain and a blood draw.
62685507|NCT03042975||Muscle tension dysphonia|Patients with muscle tension dysphonia will undergo an MRI of the brain and a blood draw.
62685508|NCT00484328|EXPERIMENTAL|1|
62685509|NCT00484328|EXPERIMENTAL|2|
62125237|NCT04162444||Cohort 1|We will study safety, clinical and hemodynamic efficacy of the method of the aortic valve reconstruction with autopericardium in children with aortic valve disease.
62125238|NCT05142202|EXPERIMENTAL|Doubly Accelerated Partial Breast Irradiation after Breast-Conserving Surgery|"All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.~The control group consists of standard adjuvant APBI with multicatheter interstitial brachytherapy technique 8 x 4 Gy in 5 consecutive days or 7 x 4,3 Gy in 4 consecutive days (6 hours minimum gap between the fractions)."
62125239|NCT04887675|ACTIVE_COMPARATOR|Patients switched from PI/EFV based ART to INSTI based ART|60 patients on PI/EFV based ART, stable on treatment (undetectable viral load for at least 6 months). At the beginning of the study they are switched to INSTI based regimen. The reasons for the switch will be side effects or long-term toxicities like hyperlipidemia, diarrhea, (PI), insomnia, headache (EFV), high Framingham score (PI/EFV)
62125240|NCT04887675|ACTIVE_COMPARATOR|Patients initially treated with INSTI based regimens|60 patients initially started on INSTI based ART (raltegravir and dolutegravir), stable on treatment (undetectable viral load for at least 6 months).
62125241|NCT03288753|EXPERIMENTAL|Adults and children above 14 years old|"Visit 1:~Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2"
62125242|NCT03288753|EXPERIMENTAL|children up to 14 years old|"Visit 1 Satisfaction questionnaire on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2~The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions."
62125243|NCT03339258|EXPERIMENTAL|Doxazosin Mesylate, Extended Release|Subjects will undergo a 4-week titration phase during which doxazosin may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study medication for a 4-week stable dose phase.
62315261|NCT02392546|PLACEBO_COMPARATOR|Placebo|placebo
62315262|NCT02828319|EXPERIMENTAL|Z-213|
62315263|NCT00790296|EXPERIMENTAL|Thyrotropin releasing hormone (TRH)|TRH
62315264|NCT00790296|PLACEBO_COMPARATOR|Saline|Placebo
62315265|NCT01834326|ACTIVE_COMPARATOR|Palatal Oral Mucosa (POM) Graft|Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
62315266|NCT01834326|EXPERIMENTAL|Ex vivo Produced Oral Mucosa Equivalent|Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area
62315267|NCT00552539|EXPERIMENTAL|1|pre test survey, educational video, post test survey
62685510|NCT05630365|EXPERIMENTAL|Nasal sampling/Testing (Professional Use)|operators will collect one mid-turbinate nasal swab sample from both nostrils from each subject. The collected mid-turbinate nasal swab will be tested with the Panbio™ Rapid Panel by an operator at the study site in a Near Patient Testing setting (e.g. GP centre or hospital clinic). After the mid-turbinate nasal sampling, the operators will collect one NP swab sample from one nostril of each subject.UTM samples will be shipped to the Core Laboratory for testing with RT-PCR protocols for Flu A, Flu B and SARS-CoV-2, as per the laboratory manual
62685511|NCT01584297|EXPERIMENTAL|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
62315268|NCT00552539|NO_INTERVENTION|2|no intervention
62315269|NCT00552539|EXPERIMENTAL|3|educational video and post test survey
62315270|NCT00552539|NO_INTERVENTION|4|post test survey
62315271|NCT06293898|EXPERIMENTAL|BL-M07D1 administered Day 1 of a 21-day cycle|
62315272|NCT04182191|EXPERIMENTAL|Interventional group|89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
62315273|NCT04697147|EXPERIMENTAL|Intervention Group|Immediately randomized to receive the intervention for 12 weeks.
62478783|NCT04988464|EXPERIMENTAL|Sleep Scholar|Sleep Scholar is a fully automated, single-session, self-guided, internet-based CBT-I intervention that participants will read from a web browser on their electronic device. Sleep Scholar's content was adapted from Ellis and colleague's, Morin's, and Perlis and colleague's protocols for therapist-guided CBT-I interventions. Sleep Scholar will be completed in approximately 30 minutes and consists of three successive text-based modules: Sleep Education, Initiating Sleep, and Enhancing Sleep Quality. New content (e.g., vignettes and quizzes) was created to tailor the intervention to college students. For example, after each module, short multiple choice and/or true-false question will be administered to assess participants' understanding of Sleep Scholar's strategies. Participants will be automatically provided feedback on their responses to ensure their understanding of Sleep Scholar's strategies.
62478784|NCT04988464|PLACEBO_COMPARATOR|Building Healthy Habits|Building Healthy Habits will be used as the control condition. It combines two modules being utilized as the control condition in an ongoing randomized controlled trial. It is a single-session, self-guided, internet-based intervention that participants will read from a web browser on their electronic device. Building Healthy Habits was piloted by undergraduate research assistants to ensure that it was approximately the same duration as Sleep Scholar (i.e., 30 minutes). It consists of two successive text-based modules focused on healthy movement and healthy eating.
62478785|NCT06025578|EXPERIMENTAL|BMS-986278 Dose 1|
62685512|NCT04854499|EXPERIMENTAL|Safety Run-in Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum|"Participants with untreated metastatic or unresectable, locally recurrent head and neck squamous cell carcinoma (HNSCC) regardless of programmed cell death ligand 1 (PD-L1) status will receive the following:~* magrolimab~* pembrolizumab 200 mg on Day 1 of each cycle~* 5-fluorouracil (5-FU) 1000 mg/m\^2/day Days 1-4 of each cycle (for up to 6 cycles)~* platinum chemotherapy (cisplatin 100 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC) 5 per investigator choice (for up to 6 cycles))~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the recommended Phase 2 dose (RP2D) is determined. Each cycle is 21 days."
62125244|NCT03339258|PLACEBO_COMPARATOR|Placebo|Subjects will undergo a 4-week titration phase during which the placebo may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study placebo for a 4-week stable dose phase.
62125245|NCT04337307||standard decontamination|incubators decontaminated with antiseptic molecules, healthcare workers involved in this decontamination, patients housed in these incubators
62125246|NCT04337307||steam pulverization|incubators decontaminated with steam pulverization, healthcare workers involved in this decontamination, patients housed in these incubators
62125247|NCT03284905|ACTIVE_COMPARATOR|Probiotics|
62125248|NCT03284905|PLACEBO_COMPARATOR|Placebo|
62125249|NCT05898074|ACTIVE_COMPARATOR|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site following endoscopic skull base surgery
62125250|NCT05898074|ACTIVE_COMPARATOR|Non-absorbable Packing (Silastic Splint)|Participant will have a silastic splint (Non-Absorbable Packing) applied to the nasoseptal flap harvest site following endoscopic skull base surgery with no additional packing or agent
62125251|NCT04065802|EXPERIMENTAL|Radioablation Treatment|Patients will receive radioablation to scar regions of the heart responsible for ventricular tachycardia
62125252|NCT06190522||Patients with acute renal failure|Patients receiving a clinical ultrasound by the on-site emergency physician trained in the technique
62125253|NCT02803801|EXPERIMENTAL|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
62125254|NCT02108236|NO_INTERVENTION|Blank control group|A control group of patients is put on a waiting list for no intervention and remaining unchanged lifestyle.
62125255|NCT02108236|ACTIVE_COMPARATOR|intervention group|An intervention group of patients is put on a waiting list for acupuncture treatment.
62125256|NCT00177086|EXPERIMENTAL|Alfuzosin|
62315274|NCT04697147|NO_INTERVENTION|Waitlist Control|Randomized to receive the intervention post-study.
62315275|NCT05646641|EXPERIMENTAL|Exercise|8 weeks of strength training.
62125257|NCT00177086|PLACEBO_COMPARATOR|Placebo|
62125258|NCT01403168|EXPERIMENTAL|osteopathy + conventional analgesic treatments|
62125259|NCT01403168|PLACEBO_COMPARATOR|conventional analgesic treatments|
62125260|NCT04834648|EXPERIMENTAL|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
62125261|NCT04834648|NO_INTERVENTION|Control Arm|General Counseling, which included saying you need to visit the hospital and you have involvement in the eyes due to diabetes, providing a health education leaflet.
62315276|NCT05646641|NO_INTERVENTION|Control|Maintain their usual medical treatment and daily routines
62315277|NCT05618080||LGMD Type R1/LGMD2A/CAPN3|No intervention will be administered.
62315278|NCT04967755|EXPERIMENTAL|Jing-Si-Herbal-Tea(JSHT)|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians.
62315279|NCT03397420|EXPERIMENTAL|FAM-CARE|"Two facility clusters (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring"
62315280|NCT03397420|ACTIVE_COMPARATOR|Control Standard of Care|"Two clusters (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family."
62315281|NCT06550050||Clinical and molecular features of oral premalignancy and oral cancer|
62315282|NCT04374903|EXPERIMENTAL|Study Arm A (HCQ & AZ)|Subjects will receive HCQ 600mg PO X 10 days and AZ PO 250mg DAILY X 10 days.
62685513|NCT04854499|EXPERIMENTAL|Safety Run-in Cohort 2, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive the following:~* magrolimab~* docetaxel 75 mg/m\^2 on Day 1 of each cycle~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
62125262|NCT04112069|ACTIVE_COMPARATOR|Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with continuous subcutaneous insulin infusion (pump therapy) for approximately 5 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM). If randomized to the usual care arm first, subjects crossed over to the bionic pancreas arm following a 2-day washout period.
62125263|NCT04112069|EXPERIMENTAL|iLet Bionic Pancreas with Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
62125264|NCT01480505||High myopic eye|Persons with high Myopia suffered from Rhegmatogenous Retinal detachment
62125265|NCT01151839|ACTIVE_COMPARATOR|Surgery Alone|
62125266|NCT01151839|ACTIVE_COMPARATOR|Neoadjuvant chemoradiation followed by surgery|
62125267|NCT00762879||No treatment|
62125268|NCT00666068|EXPERIMENTAL|1|"Patients with hypopituitarism~Cross over design: see interventions 1-2"
62125269|NCT00666068|PLACEBO_COMPARATOR|2|"Parallel design:~Healthy controls to be compared with placebo condition in patients with hypopituitarism"
62125270|NCT05171621||Macular holes|
62125271|NCT05171621||Epiretinal membranes|
62125272|NCT04217512|ACTIVE_COMPARATOR|Standard hydration alone|Cisplatin with standard hydration
62315283|NCT04374903|EXPERIMENTAL|Study Arm B (HCQ+SIR)|Subjects will receive HCQ 600mg PO X 10 days and SIR 4mg PO X 1 day then 2mg PO DAILY X 9 days
62339640|NCT02260856|EXPERIMENTAL|Percutaneous Screw Epiphysiodesis|In the distal femur, guide wires will be placed in an antegrade fashion, with an 8 mm skin incision proximal to the physis both medially and laterally. The guide wire will be placed with the medial wire crossing the physis at the junction of the middle and medial third of the physis. The lateral guide wire will cross the physis at the junction of the lateral and middle third of the physis. The wires will extend into the epiphysis, but will not enter the joint. The guide wires will be over drilled with a 5 mm drill, and 7.3 mm fully threaded cannulated screws will be placed across the growth plate. For tibias, screw placement will be retrograde, with 8 mm incisions made medially and laterally distal to the physis, with guide wires aiming proximally.
62339641|NCT05411640|EXPERIMENTAL|Aerobics with Blood flow restriction|This group will perform Aerobic exercises with Blood Flow Restriction training, patient education and dietary modifications will be given for pre diabetes
62339642|NCT05411640|ACTIVE_COMPARATOR|Aerobics without Blood flow restriction|This group will perform Aerobic exercises without Blood Flow Restriction training, patient education and dietary modifications will be given for pre diabetes.
62339643|NCT05411640|OTHER|Education and Dietary modifications|This group will only receive education and dietary modifications for Pre-diabetes.
62339644|NCT02979730|ACTIVE_COMPARATOR|Core Lab Testing Arm|For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.
62125273|NCT04217512|ACTIVE_COMPARATOR|Pantoprazole high dose|Cisplatin with standard hydration with pantoprazole 1.6 mg/kg
62125274|NCT04217512|ACTIVE_COMPARATOR|Pantoprazole Low dose|Cisplatin with standard hydration with pantoprazole 0.6 mg/kg
62125275|NCT05532345||Development group, retrospectively collecting|The training set includes 80% of the development dataset from Beijing Friendship Hospital (Retrospectively collecting DILI 649 cases and AIH 180 cases in total)
62125276|NCT05532345||Validation group, retrospectively collecting|"The internal validation group includes 20% of the development dataset from Beijing Friendship Hospital (Retrospectively collecting DILI 649 cases and AIH 180 cases in total).~External validation groups include Fifth Medical Center of Chinese PLA Medical Center(Retrospectively collecting DILI 585 cases and AIH 400 cases in total), Beijing You'an Hospital (Retrospectively collecting DILI 266 cases and AIH 100 cases in total) and additional seven tertiary hospitals throughout China (Retrospectively collecting DILI 182 cases and AIH 92 cases in total, including Tianjin Second People's Hospital, Heilongjiang Provincial Hospital, Affiliated Hospital of Qingdao University, the First Affiliated Hospital of Xiamen University, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, Lanzhou University Second Hospital, Qinghai Provincial People's Hospital)."
62685514|NCT04854499|EXPERIMENTAL|Pre-expansion Safety Run-in Cohort, Magrolimab + Pembrolizumab|"The pre-expansion safety run-in cohort may be conducted at the sponsor's discretion prior to the initiation of Phase 2 Cohort 2.~Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
62125277|NCT05532345||Real-World validation group, prospectively and retrospectively collecting|Real-World validation data will be prospectively and retrospectively collected from Beijing Friendship Hospital (78 cases for DILI and 51 cases for AIH)
62125278|NCT02511613|PLACEBO_COMPARATOR|Placebo|Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution
62315284|NCT00693134||Myocarditis Patients|Patients initially diagnosed with myocarditis.
62315285|NCT00693134||Control Patients|Patients with no known cardiomyopathies
62315286|NCT06099873|EXPERIMENTAL|ZX-7101A|"Before starting study treatment on day 1 (D1), eligible subjects were randomly assigned in a 1:1 ratio to receive either ZX-7101A (1 tablet，specification：40mg, single dose) or placebo (1 tablet, single dose).~A total of 360 subjects were planned to be enrolled in this study，in ZX-7101A group was planned to enroll about 180 subjects."
62315287|NCT06099873|PLACEBO_COMPARATOR|Placebo group|"Before starting study treatment on day 1 (D1), eligible subjects were randomly assigned in a 1:1 ratio to receive either ZX-7101A (1 tablet，specification：40mg, single dose) or placebo (1 tablet, single dose).~A total of 360 subjects were planned to be enrolled in this study，in placebo group was planned to enroll about 180 subjects."
62125279|NCT02511613|ACTIVE_COMPARATOR|Active|Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%
62315288|NCT01901133|EXPERIMENTAL|A: Mild hepatic impairment subjects + control|
62315289|NCT01901133|EXPERIMENTAL|B: Moderate hepatic impairment subjects + control|
62315290|NCT06672055|EXPERIMENTAL|VXA-CoV2-3.1|Participants previously immunized against COVID-19 infection will be randomized to receive VXA-CoV2-3.1 tablet oral vaccine.
62315291|NCT06672055|ACTIVE_COMPARATOR|COMIRNATY®|Participants previously immunized against COVID-19 infection will be randomized to receive COMIRNATY® injectable COVID-19 vaccine.
62315292|NCT04914130||Older HIV-positive cohort (n=500)|"* documented HIV infection~* age \>50 years at study entry~* Korean ethnicity~* likely route of HIV acquisition via sexual exposure by male to male exposure~* able to comprehend study patient information leaflet.~* Virologically suppressed subjects Subjects with primary HIV infection are eligible and investigators are encouraged to recruit such subjects. Our target population (those infected with HIV via sexual routes of men who have sex with men) has been chosen as this group represent the vast majority of older HIV-positive individuals attending for care in Korea; analyses of other groups (e.g. injection drug users, those infected through blood/blood products and transgender individuals), who may have very different needs and outcomes, would likely be under-powered."
62315293|NCT04914130||Younger HIV-positive cohort (n=250)|"* documented HIV infection~* age \<50 at study entry\*~* Korean ethnicity~* likely route of HIV acquisition via sexual exposure by male to male exposure~* able to comprehend study patient information leaflet \* this group will comprise of at least 70 subjects in each of the following age groups: 20-29, 30-39, 40-49 years. Recruitment will be monitored by the Study Monitoring Team"
62125280|NCT03697655|EXPERIMENTAL|PREDATOR-BR Cohort A|n=46, Daratumumab 20 MG/ML \[Darzalex\], 16 mg/kg body weight administered as an intravenous infusion
62125281|NCT03697655|NO_INTERVENTION|PREDATOR-BR Cohort B|n=46, Control Group, Observation (no treatment)
62125282|NCT03697655|EXPERIMENTAL|PREDATOR-MRD Cohort A|n=59, Daratumumab 20 MG/ML \[Darzalex\], 16 mg/kg body weight administered as an intravenous infusion
62478786|NCT06025578|EXPERIMENTAL|BMS-986278 Dose 2|
62478787|NCT06025578|PLACEBO_COMPARATOR|BMS-986278 Placebo|
62478788|NCT01130545||Volunteers|Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)
62478789|NCT06527742||Eligible patients|"Consecutive purposive sample of all patients with stroke, deconditioning, lung disease, or amputation admitted to the Changi General Hospital Rehabilitation Medicine unit~All patients transferred in for inpatient rehabilitation will undergo case note screening and physical examination as part of their routine post-transfer clerking. Patients fulfilling the inclusion and exclusion criteria will be approached for recruitment and enrolment within 48 work hours of transfer in to the unit. Baseline measurements will be collected, and they will undergo usual rehabilitation with our multidisciplinary team. Repeat measurements will also be collected upon discharge."
62125283|NCT03697655|NO_INTERVENTION|PREDATOR-MRD Cohort B|n=59, Control Group, Observation (no treatment)
62125284|NCT04481672|EXPERIMENTAL|Magnesium Sulfate|"Starting the night before surgery participants will receive intravenous infusion of magnesium over approximately 36 hours. Dosage amounts will vary among participants as the study is determining the highest dose of magnesium that can be administered safely without severe or unmanageable side effects. The first 5 participants of the study will all receive the same dose of magnesium. The decision to test other doses of magnesium in 5 additional participants will depend on magnesium levels and dose tolerance outcomes in the first 5 participants.~Participants will be followed for 4 days and undergo blood test to measure magnesium levels at the time of hospital admittance, the morning prior to the surgery, twice immediately after surgery, and twice a day for 3 days after the surgery."
62125285|NCT00697489|ACTIVE_COMPARATOR|1|unique surgery
62315294|NCT04914130||HIV-negative cohort (n=250)|"* documented negative HIV test at screening~* age \>50 years at study entry~* Korean ethnicity~* self reported sexual preferences of men who have sex with men~To enroll matched control, we will try to match age, sexual orientation, and participating clinic."
62315295|NCT04389801|EXPERIMENTAL|Desferal|An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours
62315296|NCT04389801|PLACEBO_COMPARATOR|control group|Will receive glucose 5% over 4 hrs infusion
62478790|NCT06358950|EXPERIMENTAL|4 mg ALKS 2680|
62478791|NCT06358950|EXPERIMENTAL|6 mg ALKS 2680|
62478792|NCT06358950|EXPERIMENTAL|8 mg ALKS 2680|
62478793|NCT06358950|PLACEBO_COMPARATOR|Placebo|
62125286|NCT00697489|ACTIVE_COMPARATOR|2|Double surgery
62125287|NCT01415349|EXPERIMENTAL|SSP-002358 alone|
62125288|NCT01415349|EXPERIMENTAL|SSP-002358 + omeprazole|SSP-002358 + omeprazole
62125289|NCT03718598||Carpal tunnel syndrome|Patients with mild and moderate carpal tunnel syndrome
62125290|NCT03718598||normal|Patients without mild and moderate carpal tunnel syndrome
62125291|NCT02092519|ACTIVE_COMPARATOR|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport (NA-220H-8022)
62125292|NCT02092519|ACTIVE_COMPARATOR|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport (NA-230H-8020)
62125293|NCT02700958|EXPERIMENTAL|Remote ischemic preconditioning|Remote Ischemic Preconditioning (RIPC) is performed by inflating blood pressure cuff for 5-minutes at 200 mmHg, or if patients systolic blood pressure is higher than 200 mmHg 20 mmHg above systolic pressure, alternated with 5-minute deflation for 4 times.
62125294|NCT02700958|SHAM_COMPARATOR|SHAM remote ischemic preconditioning|SHAM Remote Ischemic Preconditioning (RIPC-SHAM) is accomplished by alternating 4 cycles of 5-minute inflation with 5-minute deflation. Blood pressure cuff will be inflated to 10-20 mmHg. RIPC-SHAM is performed with standard blood pressure cuff on upper-arm.
62315297|NCT01065129|EXPERIMENTAL|Dose Level 1|"AMD3100 320 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
62315298|NCT01065129|EXPERIMENTAL|Dose Level 2|"AMD3100 440 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
62478794|NCT04779918|OTHER|OviTex Reinforced Tissue Matrix|This is a single-arm study. All study subjects will receive OviTex.
62478795|NCT04675372|EXPERIMENTAL|Group 1|Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)
62478796|NCT04675372|ACTIVE_COMPARATOR|Group 2|Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam
62478797|NCT01601158|EXPERIMENTAL|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
62478798|NCT01937234|ACTIVE_COMPARATOR|Metoclopramide|Intravenous injection of 10mg metoclopramide
62125295|NCT04982445|EXPERIMENTAL|Participants receiving CABENUVA|
62125296|NCT04167163|ACTIVE_COMPARATOR|Treatment group|"Those with clinical osteoporosis who elect ABL treatment.~ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay."
62125297|NCT04167163|NO_INTERVENTION|Comparator group|Those with clinical osteopenia who receive no treatment.
62125298|NCT03899324|EXPERIMENTAL|Group 1: Experimental Bumetanide|bumetanide with a titration period
62125299|NCT03899324|PLACEBO_COMPARATOR|Group 2: Placebo comparator|placebo intake identically to group 1
62125300|NCT00739141|EXPERIMENTAL|1|There are three chemotherapy drugs involved. They are called fludarabine (5 doses), cyclophosphamide (1 dose), and thiotepa (2 doses). Also two days of radiation therapy. This is called Total Body Irradiation or TBI. The TBI if given for two days before, the transplant. On transplant day, the cord blood cells will be given through a catheter. The immune suppressing drugs given are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through the catheter. Later they can be given as tablets.
62125301|NCT05533515||RP Treatment cohort|We will use participants who have been deemed eligible for radical prostatectomy based on the current European Urology Association classification system, and who have been scheduled for surgery to completely remove the cancer in the prostate gland.
62125302|NCT05920746|EXPERIMENTAL|Kinesiotherapy with Static Magnetic Field|Patients have kinesiotherapy of hand and static magnetic field. All patients without steroid anti-inflammatory drugs.
62125303|NCT05920746|EXPERIMENTAL|Kinesiotherapy with low-frequency pulsed magnetic field|Patients have kinesiotherapy of hand and low-frequency pulsed magnetic field. All patients without steroid anti-inflammatory drugs.
62315299|NCT01065129|EXPERIMENTAL|Dose Level 3|"AMD3100 560 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
62315300|NCT01065129|EXPERIMENTAL|Expanded DLT Cohort|After the MTD is determined, patients will be enrolled at the MTD dose of plerixafor. These patients will not receive G-CSF priming but will be treated with plerixafor and azacitidine for 2 cycles.
62315301|NCT02612090|ACTIVE_COMPARATOR|Active Treatment Beverage|Strawberry
62315302|NCT02612090|PLACEBO_COMPARATOR|Placebo Treatment Beverage|Placebo Beverage
62478799|NCT01937234|PLACEBO_COMPARATOR|Placebo|Intravenous injection of 0.9% sodium chloride
62478800|NCT01778504||Probands|Children, adolescents, and adults
62478801|NCT01778504||Relatives of Probands|1st, 2nd, and 3rd degree relatives
62478802|NCT02554877|PLACEBO_COMPARATOR|Placebo|
62478803|NCT02554877|EXPERIMENTAL|PF-06291874, 30 mg|
62478804|NCT02554877|EXPERIMENTAL|PF-06291874, 60 mg|
62478805|NCT02554877|EXPERIMENTAL|PF-06291874, 100 mg|
62315303|NCT05255562|ACTIVE_COMPARATOR|Combined Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anterior area to the superficial serratus anterior area above the serratus anterior muscle and injected 2 ml normal saline for hydrodissection. Finally, 15 ml of 0.25% bupivacaine will be injected for the superficial serratus anterior block into the interfacial area.
62478806|NCT06651099|EXPERIMENTAL|mhealth application (experimental group)|The mhealth intervention group will be instructed to perform the exercises twice a week for 8 weeks, lasting approximately 30 minutes per session. Participants will be instructed to watch the health education content (e.g., short videos, infographics) and exercise videos provided by the app, and to take breaks during each session. Guidance will be provided during the intervention and weekly monitoring by a physiotherapist by messaging or telephone calls. In the first week of the intervention there will be two face-to-face sessions supervised by the physiotherapist to familiarize the participants with the mobile application and provide instructions on the intervention. A further face-to-face session will take place half-way the intervention, to monitor the participants.
62125304|NCT00738023|ACTIVE_COMPARATOR|Diabetics|Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
62315304|NCT05255562|ACTIVE_COMPARATOR|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
62315305|NCT04160403|EXPERIMENTAL|factors ( SES,age, sex,severity) and progress|the relation between progress in gross motor functions
62478807|NCT06651099|ACTIVE_COMPARATOR|Conventional booklet exercise (comparator group)|After the assessment, all participants will receive a printed booklet containing a description and recommendations for carrying out the exercise program at home, which will be characterized by general exercises (i.e., strengthening, mobilization). The individuals will be instructed to perform the exercises twice a week for 8 weeks, following the same duration on the experimental group. Participants will be monitored and supervised by another physiotherapist via messaging app or telephone calls, following the same procedures reported in the experimental group. In the first week of the intervention there will be two face-to-face sessions supervised by a physiotherapist to familiarize the participants with the exercises and explain the booklet, and provide instructions on the intervention. A further face-to-face session will take place half-way the intervention, to monitor the participants.
62478808|NCT01101620|ACTIVE_COMPARATOR|Levosimendan|
62478809|NCT01101620|PLACEBO_COMPARATOR|Placebo|
62478810|NCT04739475|OTHER|Non surgical Periodontal Therapy NPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
62478811|NCT05407935|EXPERIMENTAL|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
62478812|NCT05407935|ACTIVE_COMPARATOR|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
62478813|NCT04645160|EXPERIMENTAL|1/ Phase I|Tivozanib, P.O. daily at 0.89 mg (given on Days 1-21 of every 28-day cycle) with intra-patient escalation to 1.34 mg daily (given on Days 1-21 of every 28-day cycle) and possible dose de-escalation to 0.89 mg every other day (without interruption for a 28-day cycle) if needed to determine RP2D
62478814|NCT04645160|EXPERIMENTAL|2/ Phase II|Tivozanib at the RP2D established in Phase I
62478815|NCT02334722|EXPERIMENTAL|1 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for one week.
62125305|NCT00738023|ACTIVE_COMPARATOR|Non-Diabetic|Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours
62125306|NCT03823196|EXPERIMENTAL|Verum900|The arm will receive 900 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
62125307|NCT03823196|EXPERIMENTAL|Verum1800|The arm will receive 1800 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
62315306|NCT02192710|ACTIVE_COMPARATOR|Hypnovel® (midazolam)|Midazolam oral intake before anesthesia
62125308|NCT01449422|EXPERIMENTAL|URGO 310 3082|
62125309|NCT01449422|ACTIVE_COMPARATOR|Aquacel|
62125310|NCT00835952|EXPERIMENTAL|ATX-101|
62125311|NCT01215344|EXPERIMENTAL|VRD|VELCADE, Lenalidomide, Dexamethasone
62125312|NCT01215344|EXPERIMENTAL|VDD|VELCADE, liposomal doxorubicin, dexamethasone
62125313|NCT00951704||Cardiac arrest|
62125314|NCT01937507|EXPERIMENTAL|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
62125315|NCT00203372|EXPERIMENTAL|Bevacizumab 7.5 and TAC|one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.
62125316|NCT00203372|PLACEBO_COMPARATOR|Placebo 7.5 and TAC|Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.
62125317|NCT00203372|EXPERIMENTAL|Bevacizumab 15 and TAC|one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.
62125318|NCT00203372|PLACEBO_COMPARATOR|Placebo 15 and TAC|Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.
62315307|NCT02192710|EXPERIMENTAL|Electronic tab|
62315308|NCT02832440|OTHER|Intradialytic exercise|Exercise during hemodialysis
62315309|NCT02832440|OTHER|Home-based exercise|Exercise at home
62315310|NCT03819946|EXPERIMENTAL|Study Group- esophgeal cooling|In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.
62125319|NCT02541565|EXPERIMENTAL|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62315311|NCT03819946|ACTIVE_COMPARATOR|Control group- esophgeal temperature probe|In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.
62315312|NCT05905822||Prospectively genotyped participants|These participants will be advertised to in the local area. They will be genotyped for their APOE genotype, and then the stool sample will be collected.
62315313|NCT05905822||Database participants|"Participants from the previously genotyped cohort Early sleep and circadian markers of Alzheimer's disease: the impact of APOE-ε4 on circadian rhythm and sleep-wake homeostasis in humans (Reference: 2017/18-135) who have consented to be contacted will be contacted to collect a stool sample."
62315314|NCT06095674|EXPERIMENTAL|PD-1 checkpoint inhibitor and CTLA-4 inhibitor|Both antibodies will be peritumorally administered in early-stage cervical cancer prior to surgery.
62315315|NCT01793181||CRVO patients|Patients with a newly diagnosed CRVO. Maximum duration 3 months.
62315316|NCT01793181||Control patients|Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
62315317|NCT06094777|EXPERIMENTAL|HY-0102|"Dose Escalation(Standard 3+3 Dose escalation) Cohort 1: 5 mg/kg Q2W HY-0102 ivgtt Duration: 24w,DLT observation period: 28 days.~Cohort 2: 10 mg/kg Q2W HY-0102 ivgtt Duration: 24w,DLT observation period: 28 days.~Cohort 3: 15 mg/kg Q2W HY-0102 ivgtt Duration: 24w,DLT observation period: 28 days.~Dose Expansion Within the MTD and sub-MTD dose groups, select 1-2 doses for dose expansion, including approximately 30-40 cases of tumor types that have demonstrated preliminary efficacy in the early escalation phase. Conduct safety, tolerability, and preliminary anti-tumor efficacy evaluations to provide a basis for the recommended phase II clinical dose (RP2D). PK studies will be conducted on 12 subjects in each dose group, including dose escalation trial cases."
62315318|NCT04830748|ACTIVE_COMPARATOR|Therapeutic exercises group|The first group will receive therapeutic exercises in the form of stretching and strengthening exercises of the knee.
62315319|NCT04830748|EXPERIMENTAL|Therapeutic exercises and mechanical traction group|The experimental group will receive the same exercise program of the first group preceded by continuous mechanical traction of the knee.
62315320|NCT06673056|EXPERIMENTAL|N-acetyl-L-leucine (IB1001)|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients will receive a total daily dose of 2-4 g/day based on weight-tiered doses.
62315321|NCT06673056|PLACEBO_COMPARATOR|Placebo comparator|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients will receive a total daily dose of 2-4 g/day based on weight-tiered doses.
62315322|NCT03879863|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) QID|
62315323|NCT03879863|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution QID|
62315324|NCT03879863|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) QID to BID|
62125320|NCT03849495|EXPERIMENTAL|Group A|"* Period 1: D745~* Period 2: CKD-370"
62125321|NCT03849495|EXPERIMENTAL|Group B|"* Period 1: CKD-370~* Period 2: D745"
62315325|NCT03879863|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution QID to BID|
62315326|NCT00906256|ACTIVE_COMPARATOR|AZD7295|AZD7295
62315327|NCT00906256|PLACEBO_COMPARATOR|Placebo capsule|Placebo
62315328|NCT06139380|ACTIVE_COMPARATOR|Intranasal ketamine|
62315329|NCT06139380|PLACEBO_COMPARATOR|Intranasal sterile water|
62315330|NCT06102460|ACTIVE_COMPARATOR|Casein Protein|Each participant will consume a serving of casein protein mix.
62315331|NCT06102460|ACTIVE_COMPARATOR|a-lactalbumin|Each participant will consume a serving of a-lactalbumin protein mix.
62315332|NCT06102460|ACTIVE_COMPARATOR|Carbohydrate|Each participant will consume a serving of carbohydrate mix.
62315333|NCT06102460|PLACEBO_COMPARATOR|Placebo|Each participant will consume a serving of a placebo mix.
62315334|NCT03100331|EXPERIMENTAL|Single Arm; all receive neuropsychological testing & follow-up|
62478816|NCT02334722|ACTIVE_COMPARATOR|6 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for six weeks.
62478817|NCT06430177|EXPERIMENTAL|Experimental|Su Jok will be done
62125322|NCT03320434|EXPERIMENTAL|PRT-2761 0.5%|
62315335|NCT02714634|EXPERIMENTAL|methotrexate + targeted therapy group|"Methotrexate or leflunomide +~targeted therapy chosen by investigator"
62315336|NCT02714634|ACTIVE_COMPARATOR|Triple therapy|Triple therapy using 3 conventional disease modifying drugs (DMARDs)
62315337|NCT02563184|ACTIVE_COMPARATOR|COPD|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
62315338|NCT02563184|ACTIVE_COMPARATOR|Control|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
62315339|NCT05174572|OTHER|IMR|IMR evaluation before and after Reducer implantation
62315340|NCT03477630|EXPERIMENTAL|Platelet Rich Plasma|Four intra-articular infiltration of autologous PRP every 15 days.
62315341|NCT03477630|ACTIVE_COMPARATOR|Hyaluronic Acid|One intra-articular infiltration of SYNVISC-ONE
62315342|NCT01183962|OTHER|Vitamin D|Subject receives daily dose of Vitamin D
62478818|NCT06430177|SHAM_COMPARATOR|Placebo|Su Jok will be done
62315343|NCT01183962|OTHER|No medicine|Subject does not receive medication
62315344|NCT00062738|EXPERIMENTAL|nortriptyline|drug
62315345|NCT00062738|EXPERIMENTAL|paroxetine|drug
62315346|NCT00062738|PLACEBO_COMPARATOR|placebo|placebo
62315347|NCT00394914|EXPERIMENTAL|Pleconaril|Participants will receive Pleconaril nasal spray 4 sprays per nostril twice daily (BID), 24 mg/day for 1 week during the Treatment Period for a total of 14 doses.
62315348|NCT00394914|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo nasal spray 4 sprays per nostril BID for 1 week during the Treatment Period for a total of 14 doses.
62315349|NCT00803244|EXPERIMENTAL|300 IR|300 IR grass pollen allergen extract tablet
62315350|NCT00803244|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62478819|NCT06430177|NO_INTERVENTION|Control|
62478820|NCT01552317|EXPERIMENTAL|Intervention|A package of advice and interventions to help participants reduce their salt intake.
62478821|NCT01552317|NO_INTERVENTION|Normal care|This group will receive the normal care that they would get anyway.
62125323|NCT03320434|EXPERIMENTAL|PRT-2761 1%|
62125324|NCT03320434|ACTIVE_COMPARATOR|Patanol|
62315351|NCT03531957|EXPERIMENTAL|ASN002 40 mg|40 mg ASN002
62315352|NCT03531957|EXPERIMENTAL|ASN002 60 mg|60 mg ASN002
62315353|NCT03531957|EXPERIMENTAL|ASN002 80 mg|80 mg ASN002
62315354|NCT03531957|EXPERIMENTAL|Placebo Oral Tablet|Matching placebo for ASN002 doses
62315355|NCT05456100|EXPERIMENTAL|Expressive Helping|Participants complete a 20-minute expressive writing session once per week for the first three weeks. During Week 4, participants complete a 20-minute peer support writing session.
62315356|NCT05456100|ACTIVE_COMPARATOR|Expressive Writing|Participants complete a 20-minute expressive writing session once per week for four weeks.
62315357|NCT05456100|ACTIVE_COMPARATOR|Factual Writing|Participants complete a 20-minute factual writing about their cancer diagnosis and treatment every week for four weeks.
62315358|NCT02119104||Prevenar (13v)|
62315359|NCT06249542|EXPERIMENTAL|Care Delivery Improvement Intervention|The care delivery improvement intervention consisted of a period of 4 months during which practice facilitators supported each clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for depression and unhealthy substance use and substance use disorders.
62315360|NCT06249542|NO_INTERVENTION|Usual Care|"Usual care consisted of care received in a study clinic after January 1, 2015 and prior to active implementation of the quality improvement intervention in that clinic. The usual care period included 1) a two-month pre-intervention preparatory period during which EHR tools designed to support the intervention had been activated in the EHR and were available to clinic staff but had not yet been actively promoted by practice facilitators (a condition the investigators refer to as passive access), and 2) a two-month preparation period during which practice facilitators, who were not members of the local clinic staff, engaged clinic staff in team building exercises and pretesting of the intervention."
62315361|NCT06664515||Patients affected by macular hole|
62315362|NCT02572206|OTHER|PET/SPECT and MRI scans|"PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.~30 minute structural MRI will be obtained to permit co-registration of PET images."
62315363|NCT00397228|EXPERIMENTAL|ALTROPANE®|ALTROPANE® dosing
62315364|NCT00890968|EXPERIMENTAL|Triamcinolone Acetonide (TAC) DuraPeel|
62315365|NCT00890968|PLACEBO_COMPARATOR|Placebo|
62315366|NCT03984760|EXPERIMENTAL|Ferric Citrate Capsule|Ferric Citrate Capsule, product specification: 500 mg/cap, manufactured by Panion \& BF Biotech Inc.
62315367|NCT03984760|ACTIVE_COMPARATOR|Sevelamer Carbonate Tablet|Sevelamer carbonate tablet group, product specification: 800 mg/tablet, manufactured by Genzyme Ireland Limited
62315368|NCT01595646|PLACEBO_COMPARATOR|Saline|Saline placebo taken twice per day via intranasal route.
62315369|NCT01595646|EXPERIMENTAL|Insulin Detemir|20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
62315370|NCT01595646|EXPERIMENTAL|Insulin|20IU Insulin, administered twice per day (40IU total per day) via intranasal route
62315371|NCT03029403|EXPERIMENTAL|Dose Escalation|Patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
62315372|NCT03029403|EXPERIMENTAL|Dose Expansion - Cohort A|Patients with platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
62315373|NCT03029403|EXPERIMENTAL|Dose Expansion - Cohort B|Patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
62315374|NCT03029403|EXPERIMENTAL|Dose Expansion - Cohort C|Patients with recurrent advanced epithelial ovarian, fallopian tube and primary peritoneal patients with uncommon tumor histologies, including clear cell, mucinous and low grade serous or low grade endometrioid ovarian subtypes.
62315375|NCT04902950|PLACEBO_COMPARATOR|Group 1|The solution of saline will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 1 will undergo application of three normal saline soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
62125325|NCT03320434|ACTIVE_COMPARATOR|Pred-forte|
62315376|NCT04902950|EXPERIMENTAL|Group 2|The solution of Tranexamic Acid (TXA) will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 2 will undergo application of three (TXA) soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
62315377|NCT05429684|EXPERIMENTAL|A. HER2 low expression|Phenotype was signatured by HER2 low expression.
62315378|NCT05429684|EXPERIMENTAL|B. HER2 amplified|Signatured by wild type HER2 amplified.
62478822|NCT05074745|EXPERIMENTAL|Buccal and nasopharyngeal swabs|One patient will have 3 swabs taken, 2 buccal for PCR and ELISA POCT, 1 nasopharyngeal for PCR
62478823|NCT06597396|EXPERIMENTAL|Arm 1: Abrocitinib 50 mg daily|Participants will take 50 mg of abrocitinib daily for 12 weeks
62478824|NCT06597396|EXPERIMENTAL|Arm 2: Abrocitinib 100 mg once daily|Participants will take 100mg of abrocitinib daily for 12 weeks
62125326|NCT03320434|PLACEBO_COMPARATOR|PRT-2761 0%|
62315379|NCT05429684|EXPERIMENTAL|C. HER2 mutation|Signatured by HER2 mutation.
62315380|NCT05429684|EXPERIMENTAL|D. HER2 downstream mutation|Signatured by HER2 downstream mutation of PI3KCA, TP53 or PTEN.
62315381|NCT05429684|EXPERIMENTAL|E. Hormone receptor pathway activation|Signatured by both ER and PR strongly expressed,or CCND1 amplified.
62125327|NCT06651294|EXPERIMENTAL|Neorenal Forte|Up to Day 10 after the endourological procedure - 2 tablets 2 times daily Followed by 80 days after end date of 2X2 dose - 1 tablet 2 times daily
62125328|NCT06651294|PLACEBO_COMPARATOR|Placebo|Up to Day 10 after the endourological procedure - 2 tablets 2 times daily Followed by 80 days after end date of 2X2 dose - 1 tablet 2 times daily
62125329|NCT01954407|NO_INTERVENTION|Control: No Smoking-Related Messages|Respondents will answer questions about smoking-related beliefs and intentions to smoke before receiving the treatment smoking-related messages (they will still receive them at the end to make the groups comparable and still expose them to anti-smoking messages).
62125330|NCT01954407|EXPERIMENTAL|Promising Smoking-Related Messages|Respondents will receive one of the possible sets of promising smoking-related messages and these should affect smoking-related intentions to a greater extent (make respondents less likely to smoke) than less-promising smoking-related messages.
62125331|NCT01954407|EXPERIMENTAL|Less-Promising Smoking-Related Messages|Respondents will receive one of the possible sets of less-promising smoking-related messages and these should affect their intentions to a lesser extent than the promising smoking-related messages.
62125332|NCT00124878|ACTIVE_COMPARATOR|Arm 1 Male circumcision|Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
62125333|NCT00124878|NO_INTERVENTION|Arm 2|Men wait for two years of follow up before being offered male circumcision
62125334|NCT05653583|ACTIVE_COMPARATOR|Wrist Device|Twice daily stimulation sessions during the 4-week treatment period
62315382|NCT05429684|EXPERIMENTAL|F. Immune activation|Signatured by high TMB or PD-L1 positively expressed.
62315383|NCT01133639|PLACEBO_COMPARATOR|Placebo|Placebo plus standard of care
62315384|NCT01133639|EXPERIMENTAL|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
62478825|NCT06597396|PLACEBO_COMPARATOR|Arm 3: Placebo|Participants will take placebo daily for 12 weeks
62478826|NCT06627569|EXPERIMENTAL|Exercise|"Participants will complete 4 aerobic exercise training sessions per week for 12 weeks. The exercise program will begin at 15 minutes per session and duration will be gradually increased by 5 minutes each week until you reach 45 minutes per session. Exercise will be performed at a moderate to vigorous intensity, which will be about 60-70% of your predicted maximal level. Participants will meet with study personnel once per week."
62478827|NCT06627569|NO_INTERVENTION|Usual activity|Participants will keep doing what they usually do for the 12-week intervention period. They will be asked not to change their usual physical activity levels during this period. They will meet with study personnel once per week
62478828|NCT00875524|EXPERIMENTAL|CYD Dengue Vaccine Group|Participants who received CYD dengue vaccine as first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections. Participants were followed for 4 years after the third injection.
62125335|NCT05653583|ACTIVE_COMPARATOR|Ear Device|Twice daily stimulation sessions during the 4-week treatment period
62125336|NCT05653583|SHAM_COMPARATOR|Sham Device|"Twice daily stimulation sessions during the 4-week treatment period"
62125337|NCT03573063|OTHER|Androgen metabolism after starvation|Metabolism changes after 48 hours starvation in healthy women
62315385|NCT03288974||Post Marketing Survey of MM patients treated with POMALYST®|As a method of POMALYST® PMS, Drug Use Examination (DUE) is planned and designed to comply with the regulatory requirement in consequence of approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which is conducted as a regulatory required procedure to evaluate product safety of a new drug treatment in clinical routine practice in Korea. And this DUE will be conducted in compliance with the local guideline \[standard for Re-examination of New Drugs, etc.\] as a post approval commitment.
62315386|NCT04471740|EXPERIMENTAL|Normal-pressure hydrocephalus only|Patients suffering from normal-pressure hydrocephalus with NO sleep apnea
62315387|NCT04471740|ACTIVE_COMPARATOR|Normal-pressure hydrocephalus with sleep apnea|Patients suffering from normal-pressure hydrocephalus with sleep apnea
62125338|NCT02751580|EXPERIMENTAL|Health services research (telehealth)|Patients undergo their first post-treatment visit as a virtual telehealth visit using the JeffConnect application downloaded onto their electronic device.
62125339|NCT02155010|EXPERIMENTAL|Dexmedetomidine|IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
62125340|NCT02155010|ACTIVE_COMPARATOR|Dexmedetomidine with heavy bupivacaine|IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
62125341|NCT00761709|EXPERIMENTAL|AL-39256|AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
62315388|NCT01016483|EXPERIMENTAL|Safety Run-in Part: Regimen 1|Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m\^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).
62315389|NCT01016483|EXPERIMENTAL|Safety Run-in Part: Regimen 2|Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m\^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).
62478829|NCT00875524|SHAM_COMPARATOR|Control Vaccine Group|Participants who received the Meningococcal Polysaccharide Vaccine A + C, placebo, and Typhoid Vi polysaccharide vaccine as the first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections, respectively. Participants were followed for 4 years after the third injection.
62685515|NCT04854499|EXPERIMENTAL|Phase 2 Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum (Arm A)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m\^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m\^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
62125342|NCT00761709|ACTIVE_COMPARATOR|XALATAN|Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks.
62315390|NCT01016483|ACTIVE_COMPARATOR|Phase II: Arm 1 (Gemcitabine + Placebo)|Subjects will receive gemcitabine 1000 mg/m\^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.
62315391|NCT01016483|EXPERIMENTAL|Phase II: Arm 2 (Gemcitabine + Pimasertib)|Subjects will receive gemcitabine 1000 mg/m\^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.
62478830|NCT05162222|EXPERIMENTAL|Danicamtiv, followed by itraconazole + danicamtiv|
62125343|NCT00761709|PLACEBO_COMPARATOR|Vehicle|Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
62125344|NCT01071408|EXPERIMENTAL|Stroke Prevention Program + Usual Care|Stroke Prevention Care Program + Usual Care. The Stroke prevention care program is in addition, not a substitute for usual care. Persons randomized to this arm are eligible to all care, including care by stroke specialists, while enrolled in the intervention.
62125345|NCT01071408|NO_INTERVENTION|Usual care|
62125346|NCT02434744|EXPERIMENTAL|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
62125347|NCT02434744|EXPERIMENTAL|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
62125348|NCT02434744|EXPERIMENTAL|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
62125349|NCT02434744|EXPERIMENTAL|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
62125350|NCT02434744|PLACEBO_COMPARATOR|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
62125351|NCT02434744|PLACEBO_COMPARATOR|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
62125352|NCT02434744|PLACEBO_COMPARATOR|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
62125353|NCT02434744|PLACEBO_COMPARATOR|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
62125354|NCT01820780|EXPERIMENTAL|intensive disease management|Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
62125355|NCT01820780|ACTIVE_COMPARATOR|usual disease management|usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
62125356|NCT01062087||Local anesthetic|Women who received local anesthetic during surgery in addition to general anesthesia
62125357|NCT01062087||No local anesthetic|Women who did not receive any local anesthetic during surgery, but did have general anesthesia
62478831|NCT05162222|EXPERIMENTAL|Danicamtiv, followed by diltiazem + danicamtiv|
62125358|NCT02034968|EXPERIMENTAL|Nimotuzumab & nab-paclitaxel & cisplatin|"Nimotuzumab: 200mg,IV once a week during chemotherapy.~Nab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle~Cisplatin: 75mg/m2,IV on 21 day cycle"
62125359|NCT05187975|EXPERIMENTAL|Integrated rehabilitation group|This group will include 101 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation .
62125360|NCT05187975|ACTIVE_COMPARATOR|Standard care group|The patients were recommended to take one oral tablet of paroxetine hydrochloride (20 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
62125361|NCT04152694|OTHER|Ceftaroline in CRRT|Ceftaroline levels measured in patients receiving continuous renal replacement therapy
62125362|NCT05199142|EXPERIMENTAL|SDI-118|SDI-118 capsule self-administered orally once daily (QD) for 17 days.
62125363|NCT05199142|PLACEBO_COMPARATOR|Placebo|Placebo capsule self-administered orally once daily (QD) for 17 days.
62125364|NCT02336438|NO_INTERVENTION|Baseline Phase (Control)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours."
62125365|NCT02336438|EXPERIMENTAL|Treatment Phase (Glucomannan)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals."
62125366|NCT03221478|ACTIVE_COMPARATOR|Kinesio Taping placebo and exercises|kinesio placebo and exercises
62125367|NCT03221478|EXPERIMENTAL|Kinesio Taping and exercises|kinesio with tension and exercises
62315392|NCT02253875|EXPERIMENTAL|TPV + RTV + Omeprazole|
62478832|NCT06648850|EXPERIMENTAL|DA-001|Phenylephrine + Alpha 1 Agonist + TAAR Agonist
62315393|NCT02574312|ACTIVE_COMPARATOR|TKA with RUI|44 Subjects will receive TKA with RUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Reusable instruments (RUI).
62315394|NCT02574312|EXPERIMENTAL|TKA with SUI|44 Subjects will receive TKA with SUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Single Use Instruments (SUI).
62315395|NCT02575794|EXPERIMENTAL|Treatment (terameprocol)|"Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study"
62315396|NCT00259805|EXPERIMENTAL|IV Infusion|
62315397|NCT04649710|EXPERIMENTAL|Cohort 1: Dose 1 or placebo|Chinese participants
62315398|NCT04649710|EXPERIMENTAL|Cohort 2: Dose 2 or placebo|Chinese participants
62315399|NCT04649710|EXPERIMENTAL|Cohort 3: Dose 1 or placebo|Korean participants
62315400|NCT04649710|EXPERIMENTAL|Cohort 4: Dose 2 or placebo|Korean participants
62315401|NCT05955859|EXPERIMENTAL|Patient with clinical suspicion of mycotic sinusitis|Patient with clinical suspicion of mycotic sinusitis will undergo an examination as listed in Detailed Description.
62315402|NCT02211495|ACTIVE_COMPARATOR|No device|Treated with best medical therapy
62315403|NCT02211495|EXPERIMENTAL|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
62315404|NCT01430221|EXPERIMENTAL|MB-PHP Group|Mindfulness-based Personalized Health Planning (MB-PHP)with health coaching. MB-PHP includes weekly small group meetings for 22-weeks and 10 bi-weekly telephonic health coaching.
62315405|NCT01430221|ACTIVE_COMPARATOR|SAGE Group|Structure \& Guided Education (SAGE) includes small group-education sessions once per week for 22 weeks. Subjects also participate in 10 bi-weekly telephone calls with education partners who use supportive listening techniques..
62315406|NCT06672744|ACTIVE_COMPARATOR|exercise|Lumbar muscles (especially quadratus lumborum) and thoracolumbar fascia stretching exercises and strengthening exercises for the lumbar and abdominal muscles were described by the physiotherapist. Participants were asked to perform the exercises three times a day, five days a week.
62685516|NCT04854499|ACTIVE_COMPARATOR|Phase 2 Cohort 1, Pembrolizumab + 5-FU + Platinum (Arm B)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m\^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m\^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
62125368|NCT03221478|EXPERIMENTAL|Kinesio Taping with tension|Kinesio Taping with tension
62315407|NCT06672744|EXPERIMENTAL|kinesiotaping|Kinesiotaping was performed by the same researcher (XX) for two sessions per week for four weeks with fascia correction technique. The procedure was performed with the participant lying in the prone position. The tape was glued just below the beginning of the iliac crista without stretching. Submaximal tension was continued on the skin in line with the lower fibres of the quadratus lumborum muscle and thorocolumbar fascia. It was terminated without tension at the lower costal fold. I band was applied perpendicular to the line of insertion of the quadratus lumborum and thorocolumbar fascia to the crista iliaca with 50% tension in the middle section without tension at the beginning and end.
62125369|NCT01854229|ACTIVE_COMPARATOR|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
62125370|NCT01854229|ACTIVE_COMPARATOR|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
62125371|NCT06407024|ACTIVE_COMPARATOR|27 patients assigned to laparoscopic transabdominal adrenalectomy|
62125372|NCT06407024|ACTIVE_COMPARATOR|27 patients assigned to robotic transabdominal adrenalectomy|
62125373|NCT01319617|EXPERIMENTAL|SENSIMED Triggerfish|
62315408|NCT06672744|EXPERIMENTAL|Myofascial release technique|Myofascial release technique was applied by the same researcher (YY) twice a week for four weeks. Ischaemic compression was applied to palpable trigger points on the quadratus lumborum muscle. One hand was placed on the inferior crista iliaca and the other hand on the superior inferior costal fold and waited for 3 minutes with minimal tension. The hand was made into a fist and minimal pressure was applied with the proximal phalanges over the quadratus lumborum and the participant was asked to contract and release the muscle for 3 minutes.
62315409|NCT05571150|EXPERIMENTAL|Experimental intervention group|The dyad-focused strategy training intervention will be delivered to the treatment group. The intervention protocols of the dyad-focused strategy training were developed based on the strategy training guideline outlined by Skidmore et al, Bodenmann's framework of dyadic coping, and the self-efficacy theory.
62339645|NCT02979730|EXPERIMENTAL|ED Point of Care Testing Arm|Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.
62315410|NCT05571150|ACTIVE_COMPARATOR|Control intervention group|Participants in the control group will receive a dose-matched stroke education provided by a trained research therapist as an attention-control intervention. The therapist will provide in-person education to the dyad using an illustrated manual developed based on the stroke rehabilitation guidelines suggested by the American Heart Association/American Stroke Association .
62315411|NCT05611463|EXPERIMENTAL|Camrelizumab Plus Docetaxel and Cisplatin|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus cisplatin 75 mg/m\^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum).
62315412|NCT06671613|ACTIVE_COMPARATOR|Regular Diet|Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6.
62315413|NCT06671613|EXPERIMENTAL|FMD|Plant based diet program.
62315414|NCT04137172|EXPERIMENTAL|group1|underwent laparoscopic IPOM hernioplasty without repair
62315415|NCT04137172|EXPERIMENTAL|group2|underwent laparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS
62478833|NCT06648850|PLACEBO_COMPARATOR|Placebo|Placebo
62478834|NCT06648850|EXPERIMENTAL|Phenylephrine|Phenylephrine
62478835|NCT06648850|EXPERIMENTAL|Intact5|Cosmetic formulation containing bitter orange extract
62478836|NCT04699630|EXPERIMENTAL|Part A|Participants will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 every 3 weeks. All participants will undergo pre-treatment biopsies. (An archival tissue sample taken within two months of treatment should be provided if it is not medically feasible to provide a pre-treatment biopsy). Up to 60 participants will be enrolled into this arm.
62478837|NCT04699630|EXPERIMENTAL|Part B|Participants will receive 5.6 mg/kg U3-1402 intravenously on day 1 every 3 weeks. Part B will enroll 20 participants with metastatic hormone-receptor positive (HR+) HER2-negative cancer and 20 participants with metastatic triple-negative breast cancer (mTNBC), regardless of HER3 expression.
62478838|NCT04699630|EXPERIMENTAL|Part Z|Participants will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 every 3 weeks. Part Z will enroll an additional 21 participants with HER2+ MBC.
62478839|NCT04561492|EXPERIMENTAL|[68Ga]Ga-PentixaFor|
62125374|NCT05173324|EXPERIMENTAL|3-doses HPV vaccination|Participants will receive three doses of HPV vaccine at 0, 2, and 6 months
62125375|NCT05173324|EXPERIMENTAL|1-dose HPV vaccination|Participants will receive HPV vaccine at entry, and placebo (HAV vaccine) at 2 and 6 months
62125376|NCT05173324|PLACEBO_COMPARATOR|Placebo|Participants will receive Hepatitis A (HAV) vaccine at 0, 2, and 6 months
62125377|NCT05317572|ACTIVE_COMPARATOR|Group 1|Group 1: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 80 mcg intrathecal morphine) + iv Fentanyl-PCA
62125378|NCT05317572|ACTIVE_COMPARATOR|Group 2|Group 2: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 120 mcg intrathecal morphine) + iv Fentanyl-PCA
62125379|NCT05317572|ACTIVE_COMPARATOR|Group 3|Group 3: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 160 mcg intrathecal morphine) + iv Fentanyl-PCA
62125380|NCT02217904|EXPERIMENTAL|Islatravir 1 mg|Single oral dose of islatravir 1 mg
62125381|NCT02217904|EXPERIMENTAL|Islatravir 2 mg|Single oral dose of islatravir 2 mg
62125382|NCT02217904|EXPERIMENTAL|Islatravir 10 mg|Single oral dose of islatravir 10 mg
62125383|NCT02217904|EXPERIMENTAL|Islatravir 30 mg|Single oral dose of islatravir 30 mg
62125384|NCT02217904|EXPERIMENTAL|Islatravir 0.5 mg|Single oral dose of islatravir 0.5 mg
62315416|NCT04137172|EXPERIMENTAL|group3|underwent laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0
62315417|NCT06166706||Neonates|"neonates up to 44 weeks postmenstrual age or up to 60 weeks post menstrual age if born premature (GA \<37 weeks) undergoing general anaesthesia with mechanical ventilation.~No intervention will be administered."
62315418|NCT06166706||Infants|Infants of 1 month to 1 year old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
62315419|NCT06166706||Toddlers|Toddlers of 1 to 3 years old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
62315420|NCT06166706||Preschool|Children of preschool age 3 to 6 years old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
62478840|NCT00883233|EXPERIMENTAL|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
62125385|NCT02217904|EXPERIMENTAL|Islatravir 0.25 mg|Single oral dose of islatravir 0.25 mg
62125386|NCT02217904|EXPERIMENTAL|Islatravir 30 mg Extended Observation|Single oral dose of 30 mg islatravir administered following \>8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
62125387|NCT00414544|EXPERIMENTAL|CosmetaLife|Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
62125388|NCT00414544|ACTIVE_COMPARATOR|Restylane|Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
62125389|NCT04160429||Device feasibility (Macroduct Sweat Collection System)|Patients undergo collection of sweat samples via Macroduct Sweat Collection System 3710S and saliva and blood samples within 24 hours after medication administrations. Patients also complete questionnaires over 5-10 minutes and have medical charts reviewed.
62315421|NCT06166706||School-aged and adolescents|School aged children and adolescents of 6 to17 years old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
62315422|NCT02175667|EXPERIMENTAL|Global Postural Reeducation|Participants receiving GPR treatment during 45 minutes to stretch muscular chains
62315423|NCT02175667|NO_INTERVENTION|Control|Participants not receiving GPR treatment
62315424|NCT01371838|EXPERIMENTAL|Ceftaroline|
62315425|NCT01371838|ACTIVE_COMPARATOR|Ceftriaxone plus placebo|
62339646|NCT03866252|EXPERIMENTAL|Treatment Arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
62339647|NCT03866252|ACTIVE_COMPARATOR|Control Arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
62478841|NCT00883233|EXPERIMENTAL|2|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
62685517|NCT04854499|EXPERIMENTAL|Phase 2 Cohort 1, Magrolimab + Zimberelimab + 5-FU + Platinum (Arm C)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, zimberelimab 360 mg on Day 1 of each cycle, 5-FU 1000 mg/m\^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m\^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Zimberelimab therapy will be administered up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
62125390|NCT03963336|ACTIVE_COMPARATOR|Group A|12 IIH patients for whom serum D-dimer was assessed by ELISA.They received acetazolamide and anticoagulant LMWH in the prophylactic dose for 2 weeks then continued on acetazolamide. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
62125391|NCT03963336|ACTIVE_COMPARATOR|Group B|12 IIH patients for whom serum D-dimer was assessed by ELISA. They received acetazolamide only. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
62125392|NCT03963336|NO_INTERVENTION|Control group|24 healthy subjects for whom serum D-dimer was assessed by ELISA.
62125393|NCT00566072|EXPERIMENTAL|1|instructions and coaching on the use and intake of ganciclovir
62125394|NCT00566072|NO_INTERVENTION|2|
62125395|NCT02549313||position changes of head with brain lesion|patient with position changes of the head: registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 °.
62125396|NCT06459063|OTHER|Safety run-in phase - Allocetra increasing dose|A dose escalation phase to characterize the safety of Allocetra injection to the 1st CMC joint in the target thumb in different doses and select the dose for the randomized phase.
62125397|NCT06459063|ACTIVE_COMPARATOR|Randomization phase - Allocetra|Injection of Allocetra to the 1st CMC joint in the target thumb.
62125398|NCT06459063|PLACEBO_COMPARATOR|Randomization phase - Placebo|Injection of placebo to the 1st CMC joint in the target thumb.
62125399|NCT04381975|EXPERIMENTAL|Move in Mind Program|The Move in Mind Program is a 6-week Rolfing®-based intervention program shortened from ten to six sessions and adapted to a group setting by Rolfing® instructor Monica Canducci.
62125400|NCT04381975|OTHER|6 Week Waitlist Control|Participants will be crossed over to the Move in Mind program following the 6-week waitlist control. Participants of the waitlist control group will be asked to complete follow-up questionnaires both at the same time as the intervention group (after week six) as well as after their own program.
62125401|NCT02873312|EXPERIMENTAL|StimRouter Treatment|The Treatment group will receive therapeutic level StimRouter electrical stimulation. At the end of the Month 3 visit the Treatment group will continue to receive therapeutic level StimRouter electrical stimulation for an additional 3 months.
62125402|NCT02873312|SHAM_COMPARATOR|StimRouter Control|The Control group will receive sham (sub-therapeutic level only) StimRouter stimulation. At the end of the Month 3 visit the Control group will be allowed to receive therapeutic level StimRouter electrical stimulation for 3 months.
62125403|NCT02012569|EXPERIMENTAL|TT.173|It is applied directly to the bleeding of the donor site
62125404|NCT02012569|PLACEBO_COMPARATOR|placebo|It is applied directly to the bleeding of the donor site
62125405|NCT00923871|EXPERIMENTAL|Cone Beam CT|
62315426|NCT06672874|EXPERIMENTAL|Fermented Papaya Preparation (FPP) Intervention Arm|Participants in this single-arm study will receive Fermented Papaya Preparation (FPP), administered as a 3-gram dose taken three times daily (morning, afternoon, and evening) for 8 weeks. Assessments will be conducted at three time points: baseline, within 24 hours after initial FPP administration (short-term), and after 8 weeks (long-term). This arm investigates the association between FPP and driving performance, focusing on cognitive and psychomotor functions such as attention, memory, reaction time, and executive function using a high-fidelity driving simulator.
62315427|NCT03551418|EXPERIMENTAL|Repetitive video watching|Repetitively watching a video of an adult with Down Syndrome washing his hands
62315428|NCT05585437||gastric cancer specialist training program|
62315429|NCT04646317|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine infusion four 50 ml syringes containing 1 microgram per ml dexmedetomidine
62315430|NCT04646317|PLACEBO_COMPARATOR|normaL SALINE 0.9%|Four 50 ml syringes of .9 % Normal SALINE
62315431|NCT00855530|EXPERIMENTAL|1|
62315432|NCT04701255|EXPERIMENTAL|aberration-free IOL|20 human eyes with aberration-free intraocular lens Implantation after phacoemulsification cataract surgery
62315433|NCT04701255|ACTIVE_COMPARATOR|negative spherical aberration IOL|20 human eyes with negative spherical aberration intraocular lens Implantation after phacoemulsification cataract surgery
62315434|NCT01518699|EXPERIMENTAL|HA44 Abametapir Lotion|Study drug plus positive-control placebo.
62315435|NCT01518699|PLACEBO_COMPARATOR|Placebo|Placebo plus positive-control placebo.
62315436|NCT01518699|ACTIVE_COMPARATOR|Moxifloxacin|Placebo plus positive control
62315437|NCT02177669||Normals without ocular disease|
62315438|NCT00680004||1|Preoperative patients planned for a CT prior to an endograft implantation procedure
62315439|NCT00680004||2|Patients who underwent a complicated endograft implant and/or with increased risk of complications
62315440|NCT00914628|EXPERIMENTAL|A|HSV-TK engineering donor Lymphocytes
62315441|NCT00914628|ACTIVE_COMPARATOR|B|T-cell depleted or T-cell replete strategies
62315442|NCT01362400|ACTIVE_COMPARATOR|ARM 1: IPI 504 + Docetaxel|Drug: IPI-504 plus Docetaxel
62315443|NCT01362400|PLACEBO_COMPARATOR|Placebo + Docetaxel|Placebo plus Docetaxel
62685518|NCT04854499|EXPERIMENTAL|Phase 2 Cohort 2, Magrolimab + Pembrolizumab|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab at the RP2D determined in the Safety run-in cohort 1 and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
62685519|NCT04854499|EXPERIMENTAL|Phase 2 Cohort 3, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and docetaxel 75 mg/m\^2 on Day 1 of each cycle. Each cycle is 21 days.~Magrolimab and docetaxel will be continued until loss of clinical benefit, unacceptable toxicity, or death."
62685520|NCT02278744|EXPERIMENTAL|single-fraction radiosurgery|
62685521|NCT03764033|EXPERIMENTAL|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
62685522|NCT03764033|ACTIVE_COMPARATOR|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
62315444|NCT01294345||personalized genomics|genetic/genomic syndromes
62315445|NCT05876572|OTHER|healthy volunteer adults|
62685523|NCT04743063||New users of angiotensin receptor neprilysin inhibitor|
62685524|NCT04743063||New users of angiotensin II receptor blockers|
62685525|NCT04118426||Radiotherapy group|Patients receiving radiotherapy after surgery for brain tumor
62685526|NCT04118426||No radiotherapy group|Patients NOT receiving radiotherapy after surgery for brain tumor
62315446|NCT05823558||Ostoporotic Patients Group|T value of -2.5 and below in DEXA measurement
62315447|NCT05823558||Osteopenic Patients Group|T value between -2.5 and -1 in DEXA measurement
62315448|NCT05823558||Healthy Group|T value of -1 and above in DEXA measurement
62315449|NCT04038775|EXPERIMENTAL|Volunteering|"The experimental arm will receive a volunteer prescription from their provider and assistance from a study team member to find a volunteer job."
62315450|NCT04038775|NO_INTERVENTION|Control|The control arm will not be recommended to volunteer or assisted in finding a volunteer activity. They will answer the same survey questions as the intervention subjects.
62315451|NCT01716260||Chloroquine and Primaquine|Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days
62315452|NCT03640897|EXPERIMENTAL|Liniderm|"Oleocalcareous liniment Liniderm:~The product will be applied on the diaper area by parents/ caregivers at each diaper change."
62315453|NCT03640897|ACTIVE_COMPARATOR|Wipes|Free-fragrance baby wipes The product will be used on the diaper area by parents/ caregivers at each diaper change.
62315454|NCT03640897|ACTIVE_COMPARATOR|Water|Water and cotton pads The product will be used on the diaper area by parents/ caregivers at each diaper change.
62685527|NCT06402721|EXPERIMENTAL|Group 1: Mild hepatic impairment|Participants with mild hepatic impairment.
62685528|NCT06402721|EXPERIMENTAL|Group 2: Moderate hepatic impairment|Participants with moderate hepatic impairment.
62685529|NCT06402721|EXPERIMENTAL|Group 3 and 4: Normal hepatic function (control group)|Control group(s) of age-, weight-, and gender-matched participants with normal hepatic function.
62685530|NCT06168669|OTHER|Singel arm|All patients will be treated with the investigational device.
62685531|NCT01621035||elderly (> 70 y)|
62685532|NCT05855278|EXPERIMENTAL|Integrated PET/MRI|The study patients receive 18F-FDG PET/MRI before and during chemoradiotherapy.
62685533|NCT01546987|ACTIVE_COMPARATOR|ADT + RT|Standard androgen deprivation therapy (ADT) beginning two months prior to radiation therapy (RT). ADT comprised of anti-androgen continuing for two years and GnRH agonist stopping at end of RT.
62315455|NCT05342974|EXPERIMENTAL|Experimental: Atorvastatin followed by misoprostol|Oral dose of atorvastatin (80 mg) to be taken daily for seven days followed by misoprostol (800 mcg) on day 8. A second dose of misoprostol will occur 24 hours after the first dose if no significant bleeding (more than a regular period) has occurred.
62315456|NCT01260181|EXPERIMENTAL|Erlotinib|Participants will receive erlotinib 150 millgrams (mg) orally daily until disease progression.
62315457|NCT00923910|OTHER|Donors|Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.
62315458|NCT00923910|EXPERIMENTAL|Recipients|Participants receive donor lymphocytes and vaccines prepared from donors.
62315459|NCT01332929|EXPERIMENTAL|Bevacizumab|first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
62315460|NCT01286844|EXPERIMENTAL|Cohort 1|Subjects ≥4 and\< 12 years. First 6 subjects included, ≥8 and\< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects \< 21kg receive 2 SD periods (10mg and 50mg), Subjects \> 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
62685534|NCT01546987|EXPERIMENTAL|TAK-700 + ADT + RT|TAK-700 and standard androgen deprivation therapy (ADT) beginning two months prior to radiation therapy (RT). ADT comprised of anti-androgen continuing for two years and GnRH agonist stopping at end of RT. TAK-700 continues for two years.
62685535|NCT03918408|EXPERIMENTAL|Pulsed, accelerated|18 mW, 5 sec, 5 sec off, 10 minutes of illumination
62685536|NCT03918408|ACTIVE_COMPARATOR|Conventional|9 mW, continuous 10 minutes of illumination
62685537|NCT02138188||T1D patients on CSII|Patients affected by Type 1 Diabetes on insulin pump therapy
62685538|NCT03692026|EXPERIMENTAL|Study group|Immediate implant placement in fresh extraction sockets with addition of Hyaluronic acid and Melatonin mixture to the implant surface, into the extraction socket and to the peri-implant area.
62685539|NCT03692026|ACTIVE_COMPARATOR|Control group|Immediate implant placement in fresh extraction sockets without adding any material.
62685540|NCT02113280|ACTIVE_COMPARATOR|Physiotherapy|Physiotherapy
62685541|NCT02113280|EXPERIMENTAL|Arthroscopy|Arthroscopy
62685542|NCT06687187||Group I|received neostigmine 1 mg
62685543|NCT06687187||Group II|received neostigmine 2 mg
62685544|NCT06687187||Group III|received normal saline
62685545|NCT03992482|EXPERIMENTAL|IVIG-Eye Drop|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
62685546|NCT03992482|PLACEBO_COMPARATOR|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl)
62685547|NCT01485367|ACTIVE_COMPARATOR|Adapalene gel 0.3%|All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
62685548|NCT01485367|ACTIVE_COMPARATOR|Adapalene gel 0.3 %|All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
62685549|NCT04228003|EXPERIMENTAL|Pendulum|Pendulum Glucose Control formulation for T2D will be taken twice daily - 1 capsule with the morning meal and 1 capsule with the evening meal for 8 weeks with an option of continuing up to 6 months.
62125406|NCT05906940|EXPERIMENTAL|Health Participants|Participants in this group will be measured heart rate variability before and after transcutaneous vagus nerve stimulation.
62315461|NCT01286844|EXPERIMENTAL|Cohort 2|Subjects ≥1 and\< 4 years, receive 2 SD (5mg and 25mg)
62685550|NCT03382171|EXPERIMENTAL|FoodforCare group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five to six small protein and energy enriched meals that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
62685551|NCT03382171|NO_INTERVENTION|Usual care group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
62125407|NCT04404686|EXPERIMENTAL|Indomethacin group|Group of patients receiving Indomethacin for preterm labor treatment.
62125408|NCT04404686|ACTIVE_COMPARATOR|Nifedipine group|Group of patients receiving Nifedipine for preterm labor treatment.
62125409|NCT04987021|EXPERIMENTAL|Nucleus Smart App with Remote Assist Custom Sound Pro 6.3|Remote Assist Custom Sound Pro 6.3 to enable clinicians to use the App to remotely to program the recipients sound processors.
62125410|NCT01947790|EXPERIMENTAL|Pioglitazone group|Pioglitazone 15 mg/day will be given in this group for 9 months
62315462|NCT01495546|EXPERIMENTAL|Early loading|
62685552|NCT04424251|EXPERIMENTAL|stage I：HSK21542 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg； intravenous injection
62685553|NCT04424251|EXPERIMENTAL|stage I：HSK21542 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg；intravenous injection
62685554|NCT04424251|EXPERIMENTAL|stage I：HSK21542 0.5μg/kg|Postoperative: 0.5μg/kg；intravenous injection
62315463|NCT01495546|ACTIVE_COMPARATOR|late loading|
62125411|NCT01947790|ACTIVE_COMPARATOR|Metformin group|Metformin 0.85 twice daily will be given in this group for 9 months as control.
62125412|NCT00253734|ACTIVE_COMPARATOR|4|31 subjects to receive 15 mcg of TIV administered intramuscularly.
62125413|NCT00253734|EXPERIMENTAL|2|31 subjects to receive 6 mcg of TIV administered intradermally.
62315464|NCT02976493||MM patients receiving elotuzumab|Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.
62315465|NCT01196910|ACTIVE_COMPARATOR|Stimulation over the left dorsolateral prefrontal cortex|Group A (fifteen subjects) - treatment by HLPFC coil high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC).
62315466|NCT01196910|ACTIVE_COMPARATOR|stimulation over the right DLPFC|Group B (fifteen subjects) - Treatment by HLPFC coil high-frequency stimulation over the right DLPFC.
62315467|NCT01196910|PLACEBO_COMPARATOR|Treatment with HLPFC coil simulator mode|Group C (fifteen subjects) - Treatment with HLPFC coil simulator mode (sham).
62315468|NCT06399705|OTHER|RECHARGE: Minorities - CABG|
62315469|NCT06399705|OTHER|RECHARGE: Minorities - PCI|
62315470|NCT00003530|EXPERIMENTAL|Antineoplaston Therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62315471|NCT01233219||Group A|Homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene
62315472|NCT01233219||Group B|Both homozygous and heterozygous patients for the less frequent allele of the polymorphism A118G of OPRM1 gene
62315473|NCT04807569|EXPERIMENTAL|Experimental group|"10 sessions of non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation."
62315474|NCT04807569|EXPERIMENTAL|Control group|one-month course of drug therapy with alpha-1-adrenoblocker according to the standard scheme
62315475|NCT01415622|EXPERIMENTAL|PlasmaDerm|Treatment of small to medium-sized Ulcera crurum with the PlasmaDerm VU-2010 device in addition to standard care.
62315476|NCT01415622|OTHER|standard care|standard care of Ulcera crurum
62315477|NCT02517112|OTHER|Cardiovascular parameters measurements|
62685555|NCT04424251|EXPERIMENTAL|stage I：HSK21542 1μg/kg|Postoperative: 1μg/kg；intravenous injection
62315478|NCT00401973|EXPERIMENTAL|Olanzapine|olanzapine plus behavioral information
62685556|NCT04424251|EXPERIMENTAL|stage II：HSK21542 0.5μg/kg|Postoperative: 0.5μg/kg；intravenous injection
62315479|NCT00401973|EXPERIMENTAL|Olanzapine + Amantadine|Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
62315480|NCT00401973|EXPERIMENTAL|Olanzapine + Metformin|Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
62315481|NCT02540174|EXPERIMENTAL|Arm A|integrated addiction treatment program
62315482|NCT02540174|OTHER|Arm B|standard of care
62315483|NCT04177654||Cambodia|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62315484|NCT04177654||Bangladesh|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62315485|NCT04177654||Vietnam|The group of school-aged children from Vietnam who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62315486|NCT04177654||Lao PDR|The group of school-aged children from Lao PDR who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62315487|NCT04177654||Ghana|The group of school-aged children from Ghana who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62315488|NCT04177654||Senegal|The group of school-aged children from Senegal who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62315489|NCT04177654||Rwanda|The group of school-aged children from Rwanda who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62315490|NCT04177654||Haiti|The group of school-aged children from Haiti who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
62339648|NCT06553443|EXPERIMENTAL|Drug-coated balloon|Ranger drug-coated balloon will be used for all peripheral AVF stenosis.
62685557|NCT04424251|EXPERIMENTAL|stage II：HSK21542 1μg/kg|Postoperative: 1μg/kg；intravenous injection
62685558|NCT04424251|PLACEBO_COMPARATOR|Postoperative: Placebo|Placebo；intravenous injection
62685559|NCT02880605||appropriate in appropriate indications|
62685560|NCT02880605||inappropriate in appropriate indications|
62685561|NCT02880605||appropriate in inappropriate indications|
62685562|NCT02880605||inappropriate in inappropriate indications|
62685563|NCT03841474|EXPERIMENTAL|Intervention I|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
62478842|NCT00883233|EXPERIMENTAL|3|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
62478843|NCT00883233|ACTIVE_COMPARATOR|4|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
62685564|NCT03841474|NO_INTERVENTION|Control|Cardiovascular patients after PCI without depressive symptoms and without the need for psychiatric intervention
62125414|NCT00253734|EXPERIMENTAL|1|31 subjects to receive 9 mcg of TIV administered intradermally.
62125415|NCT00253734|EXPERIMENTAL|3|31 subjects to receive 3 mcg of TIV administered intradermally.
62125416|NCT00253734|ACTIVE_COMPARATOR|5|31 subjects to receive 9 mcg of TIV administered intramuscularly.
62125417|NCT00253734|ACTIVE_COMPARATOR|7|31 subjects to receive 3 mcg of TIV administered intramuscularly.
62125418|NCT00253734|ACTIVE_COMPARATOR|6|31 subjects to receive 6 mcg of TIV administered intramuscularly.
62125419|NCT05089526|ACTIVE_COMPARATOR|ketamine-lidocaine-dexmedetomidine (KLD) group|combination of ketamine-lidocaine-dexmedetomidine in one syringe
62125420|NCT05089526|ACTIVE_COMPARATOR|fentanyl (control) group|syringe of fentanyl
62125421|NCT03664401|EXPERIMENTAL|Kerecis Oral™|The Fish Skin Graft will be is cut to shape of wound bed and placed directly on the appropriate prepared recipient wound bed. The Fish skin graft has the smooth side down and the scaly side facing out. The graft will be sutured in place at either coronal end with resorbable sutures and may be secured apically if needed. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.
62125422|NCT03664401|ACTIVE_COMPARATOR|Autogenous Free Gingival Graft|"The recipient bed will be prepared at the appropriate sequential time as described. The graft will be harvested from the same side that the Free Gingival Graft is to be placed. A measurement will be made to determine the size of the donor tissue needed to be placed at the recipient site. Local anesthetic will be administered. The donor tissue will be harvested using the usual techniques. The width will be 5 mm and the length will match the predetermined measurement. The graft will be thinned as is usual practice.~The harvested palatal graft will be centered on the study tooth and placed on the appropriately prepared recipient wound bed. The graft will be sutured with resorbable sutures on the mesial and distal aspects of the tooth. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed."
62125423|NCT06148831|EXPERIMENTAL|Infant Carrier|In the intervention group, in the prenatal period (\~37 weeks gestation) will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client in practicing using the carrier and will provide materials to support continued learning.
62125424|NCT06148831|NO_INTERVENTION|Infant Carrier Waitlist|Participants assigned to the waitlist control will receive home visitation care as usual. At 6-months postpartum they will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client in practicing using the carrier and will provide materials to support continued learning.
62125425|NCT05961462|ACTIVE_COMPARATOR|Exercise training group|Exercise training containing 12 sessions of a structured aerobic exercise training program over 4 weeks (3 times per week).
62125426|NCT05961462|NO_INTERVENTION|Attention control|Conventional care.
62125427|NCT02778828|EXPERIMENTAL|Patients with Multi-Resistant Tb|
62125428|NCT01922830|EXPERIMENTAL|Bio-25 (Supherb)|"Bio-25 (Supherb) once daily (2 capsules -50 billion bacteria) for 6 months (or 4 weeks for healthy participants).~The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines."
62125429|NCT01922830|PLACEBO_COMPARATOR|Placebo|"Identical placebo once daily (2 capsules) for 6 months (or 4 weeks for healthy participants).~The placebo supplementation is identical-looking to the Bio-25 supplement."
62125430|NCT02205853|OTHER|The patient-directed (PD) strategy|A single-faceted patient-directed (PD) strategy that will embed the change at patient level.
62125431|NCT02205853|OTHER|The multi-faceted (MF) strategy|A multi-faceted (MF) strategy that will embed the change at the patient, professional and organizational levels.
62685565|NCT03841474|EXPERIMENTAL|Intervention II|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
62125432|NCT03724578|SHAM_COMPARATOR|standard preventive measures|the participants will only follow standard preventive measure twice a day brushing with fluoride toothpaste and flossing once a day
62125433|NCT03724578|ACTIVE_COMPARATOR|antimicrobial and fluoride mouth wash|participants will use mouth wash contains both chlorhexidine and fluoride in addition to standard preventive measures
62125434|NCT03724578|EXPERIMENTAL|grape seeds extract mouth wash|the intervention is grape seeds extract mouth wash
62125435|NCT03204565|EXPERIMENTAL|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
62125436|NCT03204565|ACTIVE_COMPARATOR|CAF (control)|coronally advanced flap alone
62125437|NCT04306718|EXPERIMENTAL|studyarm|Hyalocytes from ERM and ILM are cultured in alphaMEM to examine their proliferation habits
62125438|NCT01820182|EXPERIMENTAL|capsocam capsula|capsocam capsula readings
62125439|NCT01576107|EXPERIMENTAL|Physical activity|Exercise counseling (behavior change techniques)
62125440|NCT01576107|EXPERIMENTAL|Stress-management|Stress-management training
62125441|NCT05217849|EXPERIMENTAL|Tai Chi|Participants will engage in 60-minute Tai Chi classes twice a week for 12 weeks. The classes will be live-streamed over the internet. Tai Chi is an ancient Chinese system of gentle physical exercise and stretching. It involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
62478844|NCT06121973|NO_INTERVENTION|control group|Pregnant women in the control group did not receive any intervention other than routine care.
62478845|NCT06121973|EXPERIMENTAL|Experimental group|Pregnant women in the intervention group received online video-assisted education which demonstrated first meeting of the mother-baby and first breastfeeding in addition to receiving counselling on breastfeeding.
62315491|NCT05028023|EXPERIMENTAL|Pediatric patients with tracheal stenosis undergoing tracheal balloon dilatation|Pediatric patients with severe to median acquired tracheal stenosis undergoing tracheal balloon dilatation, and the effects of apneic oxygenation on regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, and arterial oxygen partial pressure PaO2
62315492|NCT05111119|EXPERIMENTAL|Making PrEP Smart|The Making PrEP Smart intervention is a mobile-based application which provides PrEP adherence reminders and supports HIV-self and partner testing for cis- and transgender women.
62125442|NCT05217849|EXPERIMENTAL|Gentle, Mindful Movement|Participants will engage in a gentle, mindful movement class twice a week for 12 weeks. The classes will be one hour long and will be live-streamed over the internet. The mindful movement classes will combine elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
62315493|NCT01797029|EXPERIMENTAL|Vaccine|
62125443|NCT05217849|ACTIVE_COMPARATOR|Health and Wellness Education|Participants will engage in bi-weekly 60 minute sessions of Health and Wellness Education classes. The classes will be held on-line for 12 weeks.
62125444|NCT02918279|EXPERIMENTAL|Liraglutide|
62125445|NCT02918279|PLACEBO_COMPARATOR|Placebo|
62315494|NCT01797029|PLACEBO_COMPARATOR|Placebo|
62315495|NCT00590681|EXPERIMENTAL|one|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
62315496|NCT03699839|EXPERIMENTAL|High dose influenza vaccine|Administration of high-dose influenza vaccine
62315497|NCT03699839|EXPERIMENTAL|MF59-adjuvanted influenza vaccine|Administration of MF59-adjuvanted vaccine
62315498|NCT03699839|ACTIVE_COMPARATOR|Standard influenza vaccine|Administration of standard intramuscular influenza vaccine
62315499|NCT03898583|EXPERIMENTAL|Microarray patch A|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use
62315500|NCT03898583|EXPERIMENTAL|Microarray patch B|21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use
62315501|NCT03898583|PLACEBO_COMPARATOR|Vehicle|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance
62315502|NCT03898583|ACTIVE_COMPARATOR|Daivobet|21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use
62315503|NCT03078673|EXPERIMENTAL|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
62315504|NCT03078673|EXPERIMENTAL|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
62315505|NCT03078673|EXPERIMENTAL|Control group|Only regular training
62315506|NCT03975972|EXPERIMENTAL|Occupational Therapy Based Literacy Intervention|For the intervention group, the results from the Inventory of Reading Occupations will be utilized to determine a prescriptive weekly intervention for each participant in the intervention group that will be provided to teachers based on student interest and literacy need. For the intervention group, each participant will be provided with a list of 12 questions that will be used to inform the intervention plan based on the interests of each participant within the intervention group. Collectively, the information from the 12 questions and the results of the Inventory of Reading Occupations will be used to determine a 9-week intervention plan for each participant within the intervention group. The researchers will work with the subjects twice per week, 30 minutes per session in the classroom using the prescriptive intervention that was determined from the assessments utilized.
62315507|NCT03975972|NO_INTERVENTION|Standard Classroom Based Literacy Intervention|The control group will receive the standard reading instruction provided within the school. With the control group, the researchers will provide occupational therapy support to classroom teachers. But, will provide this support using the materials that are standardly provided within the classroom for literacy instruction. The researchers will provide support to the classroom teachers to students in the control group twice per week for 30 mintues per session in the classroom.
62315508|NCT06378073|EXPERIMENTAL|Incentive Spirometer|
62125446|NCT04193969|EXPERIMENTAL|Radiculopathy due to nerve root compression|"Participants with radicular leg pain due to lumbar disc herniation or to foraminal- or recess stenosis.~Baseline assessments of pain intensities are performed through questionnaires prior to protocol. Data regarding initial pain, function, age, gender, pain-duration, weight and height is retrieved from the clinical registry SpineData.~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit in the treatment program. The protocol is repeated at the last visit in the treatment program."
62315509|NCT06378073|OTHER|Numeric Pain Rating Scale|
62315510|NCT04385030|ACTIVE_COMPARATOR|ETCC Active associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
62315511|NCT04385030|SHAM_COMPARATOR|ETCC simulated associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
62315512|NCT00849693|PLACEBO_COMPARATOR|Placebo|
62478846|NCT02393885|EXPERIMENTAL|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
62478847|NCT05705180||A Retrospective samples|"Retrospective (samples already stored, CoVaKo study cohort): Retrospective samples were consecutively collected during March 2020 and March 2022 (n=420).~Group 1A: RZV 1-12 months before COVID-19 -mRNA vaccination Group 1B: no RZV (control arm)"
62478848|NCT05705180||B Prospective samples|"Prospective (samples to be recruited, CoVaKo study cohort): Prospective samples will be collected April 2022 to July 2022 (n=180).~Group 2A: RZV 1-12 months before COVID-19 -mRNA vaccination Group 2B: no RZV (control arm)"
62478849|NCT04185493||CCTA Cohort|Consecutive patients with suspected coronary artery disease and low/intermediate pre-test probability
62478850|NCT03767374||Main study group (HIV-negative)|"2000 HIV-negative individuals seeking care at the STI clinic of Saint-Antoine Hospital~* Inguinal swab sample~* Anal swab sample~* Fecal sample~* Risk factor assessment"
62478851|NCT03767374||Exposure-matched group (HIV-positive)|"500 HIV-positive men who have sex with men from the Infectious Diseases Unit of Saint- Antoine Hospital. These individuals will be compared to 500 HIV-negative MSM from the main study group, matching on age (+/-5 years).~* Inguinal swab sample~* Anal swab sample~* Fecal sample~* Risk factor assessment"
62478852|NCT02365363|EXPERIMENTAL|Bagel control|100% wheat flour
62478853|NCT02365363|EXPERIMENTAL|Bagel with pea flour|Pea flour (30%)
62315513|NCT00849693|ACTIVE_COMPARATOR|Fluoxetine|
62478854|NCT02365363|EXPERIMENTAL|Bagel with pea fibre|Pea fibre (11g)
62315514|NCT00849693|EXPERIMENTAL|Duloxetine 60 mg|
62478855|NCT02365363|EXPERIMENTAL|Bagel w/ pea flour + pea fibre|Pea flour (30%) + pea fibre (11g)
62478856|NCT02365363|EXPERIMENTAL|Bagel w/ pea flour + pea protein|Pea flour (30%) + pea protein (24g)
62478857|NCT02365363|EXPERIMENTAL|Bagel w/ pea flour + pea fibre + pea protein|Pea flour (30%) + pea fibre (11g) + pea protein (24g)
62478858|NCT04407403|EXPERIMENTAL|Tai Chi tailored for lowering blood pressure (PRESSURE)|During the 12-week Tai Chi intervention, participants in the PRESSURE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the PRESSURE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
62478859|NCT04407403|EXPERIMENTAL|Tai Chi tailored for improving balance (BALANCE)|During the 12-week Tai Chi intervention, participants in the BALANCE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the BALANCE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
62315515|NCT00849693|EXPERIMENTAL|Duloxetine 30 mg|
62125447|NCT04193969|EXPERIMENTAL|Healthy controls|"Healthy controls Healthy age and gender-matched controls. Gender, weight and height are registered on questionnaires prior to protocol.~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit. The tests are repeated at the next visit. The interval between the two sessions will be determined by the averaged interval between tests in the patient group."
62125448|NCT04731948|PLACEBO_COMPARATOR|Folic Acid + Placebo|400µg Folic Acid per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
62125449|NCT04731948|ACTIVE_COMPARATOR|Folic Acid + Vitamin B12 Dose 1|400µg Folic Acid + 2 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
62315516|NCT04608097|EXPERIMENTAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
62125450|NCT04731948|ACTIVE_COMPARATOR|Folic Acid + Vitamin B12 Dose 2|400µg Folic Acid + 10 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
62125451|NCT04731948|ACTIVE_COMPARATOR|Folic Acid + Vitamin B12 Dose 3|400µg Folic Acid + 50 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
62315517|NCT04608097|PLACEBO_COMPARATOR|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
62315518|NCT00416767|EXPERIMENTAL|FOLFIRI|
62315519|NCT05805969|EXPERIMENTAL|Accommodating variable-resistance training|Participants in this group received the Accommodating variable-resistance program in addition to the standard physical therapy.
62478860|NCT04407403|NO_INTERVENTION|control group (CONTROL)|During the 12-week Tai Chi intervention, participants in the CONTROL group performed their regular daily activities. In addition, participants in the CONTROL group were instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed. Of note, both PRESSURE and BALANCE were offered to participants assigned in the CONTROL group after data collection was completed.
62478861|NCT00004738||Family Members|At least 2 family members of a patient with a confirmed diagnosis of Chiari I malformation.
62125452|NCT05520294||Chronic Cannabinoid Users|Ib or II Melanoma patients who are chronic cannabinoid users
62125453|NCT05520294||Non-users|Ib or II Melanoma patients non cannabinoid users
62125454|NCT05468398|NO_INTERVENTION|Control|The control group will receive a genicular RFA with local anesthetic as per the standard-of-care
62125455|NCT05468398|EXPERIMENTAL|VR Intervention|The VR Intervention group will receive a genicular RFA with local anesthetic as per the standard-of-care and the use of the Soothe VR device.
62125456|NCT01574339|EXPERIMENTAL|Treatment Arm|
62125457|NCT01683149|EXPERIMENTAL|Combination Chemotherapy|"Combination Chemotherapy: Topotecan and Sorafenib. Participants will receive the treatment in cycles. Every cycle is 28 days long. For the first cycle participants will get the chemotherapy drugs:~* Topotecan PO (by mouth) once daily on days 1-5 and days 8-12~* Sorafenib PO (by mouth) twice daily (BID), continuously on days 2-28 of cycle one and days 1-28 on each additional cycle.~* Level -1: Topotecan 1.0 mg/m\^2: Sorafenib 100 mg/m\^2 BID~* Level -2: Topotecan 0.8 mg/m\^2: Sorafenib 100 mg/m\^2 BID~* Level 1: Topotecan 1.0 mg/m\^2: Sorafenib 150 mg/m\^2 BID~* Level 2: Topotecan 1.4 mg/m\^2: Sorafenib 150 mg/m\^2 BID~* Level 3: Topotecan 1.4 mg/m\^2: Sorafenib 200 mg/m\^2 BID~* Level 4: Topotecan 1.8 mg/m\^2: Sorafenib 200 mg/m\^2 BID"
62125458|NCT04277715|EXPERIMENTAL|Parent training|Parents of participating children with chronic symptoms will receive the intervention in a virtual group format. Groups will last 90-minutes and run for 6-8 weeks. Groups will be co-led by a clinical psychologist and pediatric physician with expertise in child behavioral interventions and medically unexplained symptoms.
62125459|NCT01831700|EXPERIMENTAL|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
62315520|NCT05805969|ACTIVE_COMPARATOR|Standard Physical Therapy|Participants in this group received the standard exercise program.
62315521|NCT03702257|OTHER|Bronchial fibroscopy|Bronchial fibroscopy with trans-bronchial biopsies
62315522|NCT06569537|EXPERIMENTAL|Left Side BLT|Subjects will receive topical BLT applied to the left side of the face and 4% Lidocaine applied to the right side of the face prior to treatment.
62315523|NCT06569537|EXPERIMENTAL|Left Side Lidocaine|Subjects will receive topical 4% Lidocaine applied to the left side of the face and 4% BLT applied to the right side of the face prior to treatment.
62315524|NCT00839098|NO_INTERVENTION|Control Group|Control Group
62315525|NCT00839098|EXPERIMENTAL|Instruction Group|Instruction Group
62315526|NCT00839098|EXPERIMENTAL|Instruction and Virtual Coach Group|Instruction and Virtual Coach Group
62315527|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
62315528|NCT01651260|OTHER|Endotracheal (ET) tube securement device|Single arm study evaluated an experimental ET tube securement device with a bite block.
62315529|NCT01511289|ACTIVE_COMPARATOR|Imatinib|Imatinib 400mg QD
62315530|NCT01511289|EXPERIMENTAL|Radotinib 600mg|Radotinib 300mg BID
62315531|NCT01511289|EXPERIMENTAL|Radotinib 800mg|Radotinib 400mg BID
62315532|NCT00956241|OTHER|j-pouch coloanal anastomosis|although a j-pouch coloanal anastomosis is a common type of anastomosis, a comparison with the side-to-end has not been made.
62315533|NCT00956241|OTHER|side-to-end coloanal anastomosis|in the Netherlands, the side-to-end anastomosis is the standard procedure to perform an anastomosis in case of rectal resection. therefore, the side-to-end group was our control group
62315534|NCT04860713|ACTIVE_COMPARATOR|AOK Group|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
62315535|NCT04860713|ACTIVE_COMPARATOR|Nurtec (Rimegepant) Group|Drug: 75 mg of ODT
62315536|NCT06341569|EXPERIMENTAL|Respiratory breathing techniques group|Subjects included in the intervention group will receive a 14 week breathing technique program that will include: different types of breathing techniques (diaphragmatic, pursed-lips, alternate nostril breathing, etc.); progressive muscle relaxation techniques; and medical education about breathing.
62315537|NCT06341569|NO_INTERVENTION|Control group|Second-year physical therapy students that do not want to participate in the breathing technique program and will complete only the questionnaires.
62315538|NCT01009385|ACTIVE_COMPARATOR|prone position|
62315539|NCT01009385|ACTIVE_COMPARATOR|sitting position|
62315540|NCT06339229||surgery patients|
62478862|NCT00004738||Patients|Patient with a confirmed diagnosis of Chiari I malformation who has a family member with syringomyelia or Chiari I malformation
62478863|NCT06741527|OTHER|Integrity Implant System|
62478864|NCT06524479|EXPERIMENTAL|SEEG recording and CCEP|SEEG recordings using cortico-cortical evoked potentials (CCEPs) are conducted both during daytime and sleep to assess functional connectivity and network dynamics within the brain. The process involves delivering electrical stimuli to specific cortical areas and recording the evoked responses in distant cortical regions. This method helps in understanding the brain's connectivity patterns, distinguishing between normal and pathological conditions, and identifying critical areas for surgical planning in epilepsy patients. The variations between daytime and sleep recordings can provide insights into how brain connectivity changes across different states.
62478865|NCT03861247|ACTIVE_COMPARATOR|Control group|
62478866|NCT03861247|EXPERIMENTAL|Intervention group|
62478867|NCT06627868|PLACEBO_COMPARATOR|Placebo|
62478868|NCT06627868|EXPERIMENTAL|Oral NAD+ precursor supplementation|
62478869|NCT04596891|EXPERIMENTAL|Intervention|Remotely delivered psychotherapy combining exposure therapy with mindfulness
62685566|NCT03115515|EXPERIMENTAL|Adjustment in number of doses of thyroid hormone per week|"Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below:~* TSH\>10mIU/L, increase by 3 doses/week~* TSH 5.0-9.9mIU/L, increase by 2 doses/week~* TSH 2.0-4.9mIU/L, increase by 1 dose/week~* TSH 0.4-1.9mIU/L, no change~* TSH\<0.4mIU/L, decrease by 1 dose/week~* TSH\<0.1mIU/L, decrease by 2 doses/week~* Thyroid hormone dose will NOT be decreased due to TSH\<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
62685567|NCT03115515|EXPERIMENTAL|Adjustment in micrograms per day of thyroid hormone|"Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below:~* TSH\>10mIU/L, increase dose by 50mcg/day if dose \<125mcg/day or increase by 75mcg/day if dose \>125mcg~* TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose \<125mcg/day or increase by 50mcg/day if dose \>125mcg~* TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose \<125mcg/day or increase by 25mcg/day if dose \>125mcg~* TSH 0.4-1.9mIU/L, no change~* TSH\<0.4mIU/L, decrease dose by 12.5mcg/day if dose \<125mcg/day or decrease by 25mcg/day if dose \>125mcg/day~* TSH\<0.1mIU/L, decrease dose by 25mcg/day if dose \<125mcg/day or decrease by 50mcg/day if dose \>125mcg/day~* Thyroid hormone dose will NOT be decreased due to TSH\<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
62685568|NCT06674512|EXPERIMENTAL|Clinical Pharmacist-led Pharmaceutical Services|In addition to usual care services, the intervention group was provided with pharmaceutical care by a clinical pharmacist.
62685569|NCT06674512|NO_INTERVENTION|Usual care|Usual care
62315541|NCT04818450|EXPERIMENTAL|Gabapentin|Start gabapentin 100 mg at 9.00 PM on the second night of ICU admission and titrate gabapentin dose as needed. Maximum gabapentin dose in this study is 300 mg/day.
62478870|NCT06570655|EXPERIMENTAL|experimental group|The same 12 subjects first received 0.2 mg single dose intravenously, then received intramuscular injection of single-dose 0.1 mg, followed by single-dose 0.2 mg, and finally single-dose 0.4 mg. A wash-out period of 7 days was applied between the doses.
62478871|NCT06486454||HistoSonics Edison System|
62315542|NCT04818450|NO_INTERVENTION|Standard care|Not receiving gabapentin.
62478872|NCT06655324|EXPERIMENTAL|V350A|Participants will receive V350A vaccinations on Day 1, Month 2, and Month 6.
62685570|NCT03410771||ICU patients on amoxicillin/clavulanic acid|
62685571|NCT03410771||ICU patients on piperacillin/tazobactam|
62685572|NCT03410771||ICU patients on meropenem|
62685573|NCT03410771||ICU patients on vancomycin|
62315543|NCT01210950|EXPERIMENTAL|cell and RPR recepients|mesenchymal cells and plasma reach protein are injected to the callus center of short limb
62315544|NCT01581112|EXPERIMENTAL|Heavy armpit odour|Subjects with heavy armpit odour.
62315545|NCT01581112|EXPERIMENTAL|Heavy foot odour|Subjects with heavy foot odour.
62315546|NCT04947566|EXPERIMENTAL|Naproxen|in this group patients were given Naproxen
62315547|NCT04947566|EXPERIMENTAL|Ibuprofen|in this group patients were given ibuprofen
62315548|NCT04083911|EXPERIMENTAL|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in elderly newly diagnosed AML patients.
62315549|NCT02417220|ACTIVE_COMPARATOR|Weight Watchers Online 2015|
62315550|NCT02417220|EXPERIMENTAL|Weight Watchers Online 2015 Enhanced|
62315551|NCT01086059||Cohort 1 - Exposure cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have used adalimumab in the first trimester of pregnancy for any length of time from the date of conception.
62315552|NCT01086059||Cohort 2 - Matched Diseased Comparison Cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have not used adalimumab or any TNF antagonist in pregnancy.
62478873|NCT06655324|EXPERIMENTAL|V350B|Participants will receive V350B vaccinations on Day 1, Month 2, and Month 6.
62478874|NCT06655324|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo vaccinations on Day 1, Month 2, and Month 6.
62685574|NCT05552339||Type 2 Diabetes Mellitus patients|MyTherapy App users with Self-reported Type 2 Diabetes Mellitus who had been prescribed drugs for their T2DM.
62315553|NCT01086059||Cohort 3-Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used adalimumab or any TNF antagonist at any time in pregnancy nor have they been exposed to any known human teratogen during pregnancy.
62685575|NCT03376529|EXPERIMENTAL|SPR741/Ceftazidime (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
62315554|NCT01086059||Cohort 4 - Registry Group|Pregnant women who have used adalimumab for any length of time following the first day of the last menstrual period until the end of pregnancy who do not meet Cohort 1 inclusionary criteria.
61924213|NCT05464329|EXPERIMENTAL|Arm B: Mosunetuzumab + ICE|"* 3 cycles (cycle=21 days) of mosunetuzumab with ICE salvage chemotherapy (selected at the discretion of the treating physician).~* The first 3 patients in each arm will receive Dose Level 1 along with standard dosing of ICE. The rate of dose-limiting toxicities will determine whether the subsequent 3 patients in each arm are enrolled at Dose Level 1, or alternatively at Dose Level -1.~* For patients tolerating Cycle 1 of treatment, Cycles 2 and 3 will consist of mosunetuzumab administered as a single dose on Day 1 along with ICE. Patients will undergo PET-CT restaging prior to Cycle 3, and those achieving a CR (or PR, at their physician's discretion) will receive the Cycle 3 dose of mosunetuzumab and ICE, followed by standard of care stem cell mobilization and autoSCT. Patients with SD or PD after restaging will discontinue study treatment."
62315555|NCT06672380|EXPERIMENTAL|Structured and remotely guided physical exercise program for women who are breast cancer survivors|Structured and remotely guided physical exercise program The participants in this group took part in a remote exercise program for 3 months, with three classes a week, each lasting 1 hour on alternate days. This group had a more active follow-up, with personalized instruction and ongoing support to improve their physical and emotional health.
62315556|NCT06672380|ACTIVE_COMPARATOR|Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance|Arm 2: Initial Consultation and Exercise Guidance via Ebook The participants in this group received an initial consultation, where they were presented with health guidelines and an eBook containing information and guidance on physical exercise. After 30 days, they were given additional encouragement via text message to reinforce physical activity through the eBook, but there was no ongoing direct interaction.
62315557|NCT06672380|PLACEBO_COMPARATOR|Initial Incentive for Eating Habits in Women Surviving Breast Cancer|Arm 3: The control group only received general guidance on the importance of regular physical activity. The recommendations followed health guidelines, suggesting between 150 and 300 minutes of moderate-intensity physical activity per week.
62315558|NCT05090150|NO_INTERVENTION|Best clinic practices|Participants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm)
62315559|NCT05090150|EXPERIMENTAL|Best clinic practices plus lottery incentives|Participants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm)
62685576|NCT03376529|EXPERIMENTAL|SPR741/Piperacillin/tazobactam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
62685577|NCT03376529|EXPERIMENTAL|SPR741/Aztreonam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
62125460|NCT01831700|ACTIVE_COMPARATOR|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
62125461|NCT01551953|EXPERIMENTAL|tai chi exercise|
62125462|NCT01551953|EXPERIMENTAL|mind-body breathing|
62315560|NCT05090150|EXPERIMENTAL|Randomized from best clinic practices to smart lockers|Second randomization into community ART through the use of smart lockers
62315561|NCT05090150|EXPERIMENTAL|Randomized from best clinic practices to home delivery|Second randomization into home ART delivery
62315562|NCT05090150|EXPERIMENTAL|Randomized from best clinic practices plus lottery incentives to smart lockers|Second randomization into community ART through the use of smart lockers
61924214|NCT05090462||Standard surgical dressings (Clearpore)|
61924215|NCT05090462||NPWT dressing (PICO)|
61924216|NCT01545843|ACTIVE_COMPARATOR|No sleep deprivation|Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks
61924217|NCT01545843|EXPERIMENTAL|Late bedtime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
61924218|NCT01545843|EXPERIMENTAL|Early risetime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.
62125463|NCT01551953|ACTIVE_COMPARATOR|education|
62125464|NCT02479906|SHAM_COMPARATOR|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
62315563|NCT05090150|EXPERIMENTAL|Randomized from best clinic practices plus lottery incentives to home delivery|Second randomization into home ART delivery
62315564|NCT02183298|EXPERIMENTAL|BI 1356 BS - single rising dose|
62315565|NCT02183298|PLACEBO_COMPARATOR|Placebo|
62315566|NCT06050434||Trabectedin Rechallenge in Soft sarcoma patients|Adult GISAR participants with Trabectedin-pretreated soft tissue sarcomas and rechallenge with at least one cycle of Trabectedin in any line of therapy, with the interval between Trabectedin interruption and Trabectedin rechallenge being at least 3 months.
62339649|NCT06553443|ACTIVE_COMPARATOR|Conventional balloon|Conventional balloon will be used for all peripheral AVF stenosis.
62315567|NCT03068026|EXPERIMENTAL|Continuous exercise|Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.
62315568|NCT03068026|EXPERIMENTAL|Interval exercise|Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.
62315569|NCT03622411|EXPERIMENTAL|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
62315570|NCT03622411|ACTIVE_COMPARATOR|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
62315571|NCT03622411|ACTIVE_COMPARATOR|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
62315572|NCT05911958|EXPERIMENTAL|SHR-A1811|SHR-A1811 group
62315573|NCT03938662|EXPERIMENTAL|S-Adenosyl methionine and choline|Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.
62315574|NCT03938662|PLACEBO_COMPARATOR|Placebo|Patients in will be administered with placebo once daily for 24 weeks.
62685578|NCT03844815|EXPERIMENTAL|Treatment|"Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21~Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21~During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21"
62685579|NCT03059888|EXPERIMENTAL|Abatacept|125mg abatacept in 1ml solution administered once per week by subcutaneous injection
62125465|NCT02479906|EXPERIMENTAL|Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The HAC Coil is designed to stimulate neuronal pathways in the medial prefrontal cortex or motor cortex, including the anterior cingulated cortex.
62125466|NCT05372588|EXPERIMENTAL|Group A (NVX-CoV2515 )|1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.
62125467|NCT05372588|EXPERIMENTAL|Group B (NVX-CoV2373 )|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.
62125468|NCT05372588|EXPERIMENTAL|Group C (NVX-CoV2515 )|1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.
62125469|NCT05372588|EXPERIMENTAL|Group D (NVX-CoV2373)|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.
62125470|NCT05372588|EXPERIMENTAL|Group E (BA.1 Bivalent Vaccine)|1 intramuscular (IM) injection of Bivalent Vaccine (NVX-CoV2373 + NVX-CoV2515) of 0.5 mL injection volume on Day 0.
62125471|NCT05372588|EXPERIMENTAL|Group F (NVX-CoV2540)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
62125472|NCT05372588|EXPERIMENTAL|Group G (NVX-CoV2373)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
62315575|NCT06649955|EXPERIMENTAL|Active MyoRegulator Treatment Arm|4 weeks of active MyoRegulator® device treatment three times per week then follow-up at 1 week, 1 month, 3 months, and optionally at 6 months following the end of treatment
62315576|NCT02100657|EXPERIMENTAL|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
62315577|NCT00341315||Cohort|A primarily African-American population living in the vicinity of a DDT production plant inAlabama.
62315578|NCT06132490|EXPERIMENTAL|Valveless 12|Patients scheduled for genitourinary or colorectal robotic surgery, valveless insufflators will be used with 12 mmHg intra-abdominal pressure.
62315579|NCT06132490|EXPERIMENTAL|Valveless 8|Patients scheduled for genitourinary or colorectal robotic surgery, valveless insufflators will be used with 8 mmHg intra-abdominal pressure.
62315580|NCT04199754|EXPERIMENTAL|Contrast Enhanced Cone Beam CT|60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.
62315581|NCT06671509|EXPERIMENTAL|Group A: Mild Hepatic Impairment|
62315582|NCT06671509|EXPERIMENTAL|Group B: Moderate Hepatic Impairment|
62685580|NCT05609058|EXPERIMENTAL|Breast cancer underwent scanning in the supine position|Breast cancer patients with T1-2N0M0 stage who underwent radiation therapy after conserving surgery were enrolled. Supine scan sets were acquired during free breathing for all patients. Target volumes and organs at risk (OARs) including heart, ipsilateral lung and bilateral breast were contoured by the same radiation oncologist. The tumor bed (TB) was determined based on surgical clips. The Clinical target volume (CTV)consisted of the whole breast. The planning target volume (PTV) was CTV plus 0.5cm. The boost of PTV (PTVboost) was TB plus 0.5cm.
62685581|NCT03709030|NO_INTERVENTION|Standard Care|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with abdominal ultrasound as first line imaging, as per standard care
62315583|NCT06671509|EXPERIMENTAL|Group C: Normal Hepatic Impairment|
62315584|NCT03533478|EXPERIMENTAL|Group I|32 patients with mild or moderate diabetic macular edema.
62478875|NCT05946031|EXPERIMENTAL|In-lab procedures|Exclusive cigarette smokers will be recruited and will experience all study procedures in the laboratory.
62315585|NCT03533478|PLACEBO_COMPARATOR|Group II|32 patients with mild or moderate diabetic macular edema
62315586|NCT02426242||ICU PATIENTS|Patients with brain-injury
62315587|NCT04319289|EXPERIMENTAL|Group (A)|"Included 15 patients who are participating in an aerobic interval training exercise program with vitamin D supplementation (cholecalciferol 400 IU/day).~The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks."
62315588|NCT04319289|EXPERIMENTAL|Group (B)|Included 15 patients who are receiving vitamin D supplementation only . One capsule containing (cholecalciferol 400 IU) was taken every day for 12 weeks
62315589|NCT04319289|EXPERIMENTAL|Group (c)|Included 15 patients who are participating in an aerobic interval training exercise program only. The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks.
62315590|NCT03125642|EXPERIMENTAL|BEAM: NHL & HL|BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
62315591|NCT03125642|EXPERIMENTAL|CBV: HL|Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
62315592|NCT03125642|EXPERIMENTAL|CY/TBI|Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
62315593|NCT02856789||Healthy volunteers (HV)|"HV without any known treatment, without any coagulation trouble and with normal hemostasis results.~FS and TEG will be processed to define the most relevant parameters for normal range and the correlation between both assays.~Tests performed on HV :~* Routine hemostasis tests~* Fibrin structure (FS)~* Thromboelastography (TEG)~* Specialized hemostasis tests"
62315594|NCT02856789||Patients without coagulation disorder|"Hospitalized patients without coagulation disorder or abnormal hemostasis and hematological results and witout ongoing treatment (mainly anticoagulant treatment). FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~* Routine hemostasis tests~* Fibrin structure (FS)~* Thromboelastography (TEG)"
62315595|NCT02856789||Patients with coagulation disorders|"Hospitalized patients with coagulation disorders, mainly trauma patients or abnormal hemostasis and hematological results, mainly decreased fibrinogen level . FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~* Routine hemostasis tests~* Fibrin structure (FS)~* Thromboelastography (TEG)"
62315596|NCT05541692|OTHER|Efficacy of a sleep hygiene toolkit in ARU|Pre/post of intervention group (no control)
62315597|NCT03708003|EXPERIMENTAL|venetoclax + ibrutinib|Ibrutinib lead-in followed by venetoclax plus ibrutinib administered until cycle 31. The combination treatment will be continued as maintenance treatment or stopped depending on MRD-neg CR/CRi status.
62315598|NCT03863444|ACTIVE_COMPARATOR|Control Group|Routine Care
62315599|NCT03863444|EXPERIMENTAL|Intervention Group|Routine Care + Prenatal Preparation Education
61924219|NCT06155643|OTHER|Eko Device|Patients with cardiac risk factors
61924220|NCT05023798||ATD Cohort 1|The first iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment.
62315600|NCT06475222|ACTIVE_COMPARATOR|Study 1: Facial serum with alpha albutin|Participants will be randomly applied with home-based program of facial serum producing from 2% alpha albutin (standard facial serum) on either right side or left side of their face daily for 12 weeks.
62478876|NCT05946031|EXPERIMENTAL|Remote procedures|Exclusive cigarette smokers will be recruited and will experience all study procedures remotely.
62478877|NCT06397560|EXPERIMENTAL|PRDR Radiotherapy|
62685582|NCT03709030|EXPERIMENTAL|Direct MRCP|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with magnetic resonance cholangiopancreatography (MRCP) as first-line imaging
61924221|NCT05023798||ATD Cohort 2|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
62315601|NCT06475222|EXPERIMENTAL|Study 1: Facial serum with Tubtim Chumpae rice extract|Participants will be randomly applied with home-based program of facial serum producing from Tubtim Chumpae rice extract on either right side or left side of their face daily for 12 weeks.
62315602|NCT06475222|EXPERIMENTAL|Study 2: Facial mask with Hom Pathum rice extract|Participants will receive home-based program of facial mask with Hom Pathum rice extract for 30 min/day, 2 days/week for 12 weeks.
62315603|NCT06475222|ACTIVE_COMPARATOR|Study 3: Control jelly|Participants will consume with control jelly at 3.5 g/kg body weight. Consumption will be taken at Burapha University.
62315604|NCT06475222|EXPERIMENTAL|Study 3: Jelly with Tubtim Chumpae rice|Participants will consume with Tubtim Chumpae rice jelly at 3.5 g/kg body weight. Consumption will be taken at Burapha University.
62315605|NCT06475222|EXPERIMENTAL|Study 3: Jelly with Hom Pathum rice|Participants will consume with Hom Pathum rice jelly at 3.5 g/kg body weight. Consumption will be taken at Burapha University.
62315606|NCT06662994|ACTIVE_COMPARATOR|Patients with previous vitrectomy and diabetic macular edema treated with high dose aflibercept|Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.
62315607|NCT02060396|EXPERIMENTAL|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
62315608|NCT01369693|ACTIVE_COMPARATOR|General Portion 1 g pouch|
62315609|NCT01369693|ACTIVE_COMPARATOR|Catch Licorice Portion 1 g pouch|
62315610|NCT01369693|ACTIVE_COMPARATOR|Catch Licorice Portion Mini 0.5 g pouch|
62315611|NCT01369693|ACTIVE_COMPARATOR|Catch Licorice Portion Dry Mini 0.3 g pouch|
62315612|NCT02267499|EXPERIMENTAL|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
62315613|NCT02267499|NO_INTERVENTION|Passive Control|Participants do not receive an intervention serving as passive controls
62315614|NCT03005782|EXPERIMENTAL|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
62315615|NCT03005782|EXPERIMENTAL|Combination Therapy (REGN3767+cemiplimab)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
62125473|NCT05372588|EXPERIMENTAL|Group H (NVX-CoV2373 + NVX-CoV2540)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
62315616|NCT02255786|EXPERIMENTAL|ACT Parent Group|Participants will complete a total of five Acceptance and Commitment Therapy - Parent Group Sessions First four are held weekly, last session held one month from 4th session.
62315617|NCT02255786|NO_INTERVENTION|Treatment as Usual|Treatment as usual-Control
62315618|NCT06671418|OTHER|Endoscopic biliary drainage (standard of care)|
62315619|NCT06671418|ACTIVE_COMPARATOR|Primary percutaneous stenting|
62315620|NCT03453463|EXPERIMENTAL|exercise and protein supplementation|Predominately resistance exercise training 2-3x week for 18 months; 1.5-1.7 g/kg/d total protein supplementation, Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
62315621|NCT03453463|NO_INTERVENTION|control|Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
62315622|NCT03664817|EXPERIMENTAL|social capital intervention|This group will receive intervention developed from Phase 1 study and based on photovoice project
62315623|NCT03664817|ACTIVE_COMPARATOR|group-based health promotion intervention|"The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)"
62315624|NCT04827056|EXPERIMENTAL|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
62315625|NCT04827056|EXPERIMENTAL|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
62315626|NCT04827056|PLACEBO_COMPARATOR|Placebo|Placebo and study drug will look exactly the same in order to maintain the double-blind; study drug and placebo are administered exactly the same.
62315627|NCT03935477||High risk surgery|those undergoing elective and emergency, high-risk surgery receiving arterial cannulation and urethral catheterisation as standard
62478878|NCT02927639|EXPERIMENTAL|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
62478879|NCT02927639|NO_INTERVENTION|Control|This group will receive the usual standard of care for 6 months.
62315628|NCT03935477||Critical Care|Emergency admissions to UCLH critical care unit receiving arterial cannulation and urethral catheterisation as standard
62315629|NCT04002453||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
62478880|NCT06632600|EXPERIMENTAL|LXE408 28 days|LXE408 administered by oral route
62478881|NCT06632600|EXPERIMENTAL|LXE408 14 days and Placebo 14 days|LXE408 administered by oral route, followed by Placebo administered by oral route
62125474|NCT02058875|EXPERIMENTAL|Treatment Group|Maximization of mycophenolicacid (MPA) derivative (to a total daily dosage of 1440mg of Myfortic®) and reduction of cyclosporine dosage (as defined by C2 monitoring) in 50 stable renal transplant patients previously on immunosuppressive therapy with cyclosporine, an MPA derivative and prednisone.
62315630|NCT01227915|EXPERIMENTAL|Test|tobramycin 0.3% + dexamethasone 1% - União Química Lab
62315631|NCT01227915|ACTIVE_COMPARATOR|Comparator|tobramycin 0.3% + dexamethasone 1% - Alcon Lab
62315632|NCT02590679|EXPERIMENTAL|PRAS|pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract
62478882|NCT06632600|PLACEBO_COMPARATOR|Placebo 28 days|Placebo administered by oral route
62478883|NCT06632600|ACTIVE_COMPARATOR|Benznidazole 60 days|Benznidazole administered by oral route
62478884|NCT01961947|EXPERIMENTAL|ASP7374 group|
62315633|NCT01370798|EXPERIMENTAL|promestriene|Children with severe hypospadias treated with promestriene 1%
61924222|NCT05023798||ATD Cohort 3|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
62125475|NCT02058875|ACTIVE_COMPARATOR|Control Group|25 patients continued on an mycophenolicacid (MPA) derivative, cyclosporine and prednisone.
62315634|NCT01370798|PLACEBO_COMPARATOR|Placebo|Control group, children with severe hypospadias treated with Placebo.
62315635|NCT04094506|EXPERIMENTAL|ASP1948 1200 mg|Participants received 1200 mg ASP1948 intravenously, on day 1 of cycle 1 and 2 followed by once every 2 weeks (Q2W) until discontinuation criteria or up to 2 years. Each cycle duration was 14 days.
62315636|NCT04094506|EXPERIMENTAL|ASP1948 2000 mg|Participants received 2000 mg ASP1948 intravenously, on day 1 of cycle 1 and 2 followed by once Q2W until discontinuation criteria or up to 2 years. Each cycle duration was 14 days.
62315637|NCT04094506|EXPERIMENTAL|ASP1948 3000 mg|Participants received 3000 mg ASP1948 intravenously, on day 1 of cycle 1 followed by once every 3 weeks until discontinuation criteria or up to 2 years. Each cycle duration was 21 days.
62315638|NCT00759512|ACTIVE_COMPARATOR|Arm 1|This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care
61924223|NCT05023798||ATD Cohort 4|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
62315639|NCT00759512|NO_INTERVENTION|Arm 2|Standard of Care
62315640|NCT05786261|EXPERIMENTAL|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
62315641|NCT05786261|ACTIVE_COMPARATOR|control group|EEG con task, Gait Analysis, fMRI, rTMS,
61924224|NCT05023798||ATD Cohort 5|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
62315642|NCT00568789|EXPERIMENTAL|Ramelteon 8 mg, zolpidem 10 mg and placebo|
62315643|NCT01748695|EXPERIMENTAL|Placebo followed by V158866|Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks
61924225|NCT05023798||ATD Cohort 6|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
61924226|NCT05023798||ATD Cohort 7|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
61924227|NCT05023798||ATD Cohort 8|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
61924228|NCT05023798||ATD Cohort 9|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
62315644|NCT01748695|EXPERIMENTAL|V158866 followed by Placebo|V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks
62315645|NCT00878046|EXPERIMENTAL|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
61924229|NCT05023798||ATD Cohort 10|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
62125476|NCT02058875|NO_INTERVENTION|Observation Group|25 patients continued on an mycophenolic acid (MPA) derivative, tacrolimus, and prednisone will be followed during the same recruitment period as an additional comparison, as this is the other Calcineurin Inhibitor (CNI), which is used in kidney transplantation.
62315646|NCT01469052|EXPERIMENTAL|Cohort 1|
62315647|NCT01469052|EXPERIMENTAL|Cohort 2|
61924230|NCT03642743|EXPERIMENTAL|Two and six week follow up|Patients will be assigned to routine two and six week postoperative follow up appointments
62125477|NCT05957653|EXPERIMENTAL|Lidocaine + sufentanil intervention group|
62125478|NCT05957653|PLACEBO_COMPARATOR|Saline control group|
62125479|NCT02380209|EXPERIMENTAL|Optimization|CEST MRI of the breast for estimation of tumor pH.
62125480|NCT03496103|OTHER|Allergic Subjects|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
62315648|NCT01469052|EXPERIMENTAL|Cohort 3|
62315649|NCT01469052|EXPERIMENTAL|Cohort 4|
62315650|NCT01469052|EXPERIMENTAL|Cohort 5|
62315651|NCT01469052|EXPERIMENTAL|Cohort 6|
62315652|NCT03751709|EXPERIMENTAL|Subjects|Blinatumomab+Haplo-Mismatched Cell Therapy (HMCT)
62339650|NCT01398033|ACTIVE_COMPARATOR|Drug-coated balloon|"1. pre-dilatation of the target lesion with a non-coated balloon.~2. treatment of the target lesion with the paclitaxel-coated balloon"
62315653|NCT03281226|ACTIVE_COMPARATOR|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
62315654|NCT03281226|EXPERIMENTAL|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
62315655|NCT04853667||Patients with hereditary epidermolysis bullosa|Minor patients with hereditary epidermolysis bullosa
62315656|NCT04853667||Parents|Parents of patients with hereditary epidermolysis bullosa
62125481|NCT03496103|OTHER|Healthy|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
62125482|NCT03427034|EXPERIMENTAL|Cystoscopic surveillance|Patients with previous history of bladder cancer undergoing flexible cystoscopy will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
62315657|NCT04726267|OTHER|Glaucoma patients who was scheduled for trabeculectomy|Wide-field OCT was performed 1-2 weeks before the trabeculectomy. The OCT was done postoperatively at 1 month, 3 months, 6 months and 12 months after surgery.
62315658|NCT05451121|EXPERIMENTAL|propofol|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol (hypnotic agent) using a syringe pump at the dose of 1-1.5 mg / kg / h
62315659|NCT05451121|EXPERIMENTAL|Dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. continuous infusion of Dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h
62685583|NCT04139902|EXPERIMENTAL|Dostarlimab (TSR-042) (singly)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
62315660|NCT05451121|EXPERIMENTAL|propofol and dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\\kg\\h
62315661|NCT06611605|EXPERIMENTAL|Intervention group = 34 children|34 children aged 7-10 who applied to Akdeniz University Hospital Children's Blood Collection Unit and were subjected to storytelling with metaphor toys
61924231|NCT03642743|EXPERIMENTAL|Six week follow up only|Patients will be assigned to a single six week postoperative follow up appointment
62478885|NCT01961947|ACTIVE_COMPARATOR|TIV group|
61924232|NCT03580304|EXPERIMENTAL|industrial-physical-cognitive|
61924233|NCT03580304|EXPERIMENTAL|industrial- cognitive-physical|
61924234|NCT03580304|EXPERIMENTAL|physical- industrial- cognitive|
61924235|NCT03580304|EXPERIMENTAL|physical-cognitive- industrial|
61924236|NCT03580304|EXPERIMENTAL|cognitive- industrial-physical|
61924237|NCT03580304|EXPERIMENTAL|cognitive-physical-industrial|
62125483|NCT03427034|EXPERIMENTAL|Haematuria group|Patients referred with haematuria to exclude bladder cancer will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
62478886|NCT06741852|EXPERIMENTAL|nCLE-TBMC via a tunnel|Participants will receive nCLE-TBMC to obtain the samples from mediastinal lesions.
62478887|NCT06741852|EXPERIMENTAL|TBMC via a tunnel|Participates will receive TBMC via a tunnel to obtain the samples from mediastinal lesions.
62478888|NCT03319108|OTHER|Low Comorbidity Index Score|CCI; 1-3 as Group 1
62478889|NCT03319108|OTHER|High Comorbidity Index Score|CCI; 4 and above as Group 2
61924238|NCT03778944|ACTIVE_COMPARATOR|M group|Mannitol infusion
61924239|NCT03778944|ACTIVE_COMPARATOR|D group|Dopamine infusion
62315662|NCT06611605|NO_INTERVENTION|Control group = 34|34 children aged 7-10 who applied to Akdeniz University Hospital Children's Blood Collection Unit
62315663|NCT04965012|EXPERIMENTAL|CBT with MET treatment group|Participants in this arm will be provided with an MET-therapist guided introduction, in addition to the online CBT treatment.
62315664|NCT04965012|EXPERIMENTAL|CBT without MET treatment group|Participants in this arm will be provided with a brief non-MET research assistant-led welcome to the program, in addition to the online CBT treatment.
62315665|NCT04965012|NO_INTERVENTION|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about cannabis and wellbeing.
62685584|NCT04139902|EXPERIMENTAL|Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg and Cobolimab TSR-022 300mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered."
62125484|NCT03427034|NO_INTERVENTION|Longitudinal group|Patient with Negative cystoscopy with a positive BladderLight® test will be followed for 12 months to see if they subsequently develop bladder cancer.
62125485|NCT00580112|EXPERIMENTAL|Group A|Participants with triple negative phenotype: estrogen receptor, progesterone receptor and human estrogen receptor-2 (HER-2) negative status for breast cancer (abnormal tissue that grows and spreads in the body until it kills) will receive trabectedin 1.3 milligram per meter square (mg/m\^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hours (hrs) every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72hrs after the start of study drug infusion from Day 1 to 3.
62315666|NCT05814575|ACTIVE_COMPARATOR|Comparator|Standardized non-diagnostic fetal ultrasound protocol without interactive intervention to control for time and attention.
62315667|NCT05814575|EXPERIMENTAL|NEXUS Intervention|Standardized non-diagnostic fetal ultrasound with motivational interviewing techniques, focused on maternal and fetal strengths.
62315668|NCT05348187|OTHER|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Colorectal Cancer (CRC) and Non-small Cell Lung Cancer (NSCLC) tissue. The therascreen KRAS RGQ PCR Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
62315669|NCT01628991|EXPERIMENTAL|behavioural intervention|Recieving interventional behavioural program
62315670|NCT01628991|EXPERIMENTAL|vaginal cone|intravaginal device insertion(vaginal cone)
62315671|NCT05209568|EXPERIMENTAL|Celiac Disease|Individuals with a confirmed diagnosis of celiac disease based on serology and/or histology
62315672|NCT05209568|EXPERIMENTAL|Healthy Controls|Individuals without a diagnosis of celiac disease
62315673|NCT04442048|EXPERIMENTAL|IMM-101|The treatment regimen with IMM-101 will be one 1.0 mg (= 0.1 mL) dose given on Day 0, followed by a second dose of 0.5 mg (= 0.05 mL) on Day 14 (-2/+5 days), and a third Dose of 0.5 mg (= 0.05 mL) on Day 45 (+/-14 days)
62315674|NCT04442048|ACTIVE_COMPARATOR|Observation|
62315675|NCT06672172|EXPERIMENTAL|Treatment group A: subjects will receive HRS-7535 tablet orally at dose 1|
62315676|NCT06672172|EXPERIMENTAL|Treatment group B: subjects will receive HRS-7535 tablet orally at dose 2|
62315677|NCT06672172|EXPERIMENTAL|Treatment group C: subjects will receive HRS-7535 tablet orally at dose 3|
62315678|NCT06672172|PLACEBO_COMPARATOR|Treatment group D: subjects will receive HRS-7535 placebo tablet orally.|
62315679|NCT00571272||1|Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
62685585|NCT01943084|EXPERIMENTAL|Norditropin®|
62315680|NCT00571272||2|Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
62315681|NCT00571272||3|Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
62315682|NCT00571272||4|A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
62315683|NCT00571272||5|Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
62315684|NCT02698592|ACTIVE_COMPARATOR|CelsiusTMDS® 8 mm catheter|50 patients underwent ablation with CelsiusTMDS® 8 mm catheter.
62685586|NCT01943084|ACTIVE_COMPARATOR|Genotropin®|
62315685|NCT02698592|ACTIVE_COMPARATOR|Thermocool® 3.5 mm irrigated catheter|50 patients underwent ablation with Thermocool® 3.5 mm catheter of irrigated tip.
62478890|NCT01663233|EXPERIMENTAL|LCZ696 and amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and \<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.
62478891|NCT01663233|ACTIVE_COMPARATOR|Amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and \<180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.
62478892|NCT06664502|EXPERIMENTAL|Part 1 MAD - Low Dose|
62685587|NCT01347086|EXPERIMENTAL|BI 207127 NA (low dose)|Single dose of BI 207127 NA
62685588|NCT01347086|PLACEBO_COMPARATOR|Matching placebo (low dose)|Single dose of matching placebo
62685589|NCT01347086|EXPERIMENTAL|BI 207127 NA (medium dose)|Single dose of BI 207127 NA
61924240|NCT03778944|ACTIVE_COMPARATOR|C group|Adequate hydration
62125486|NCT00580112|EXPERIMENTAL|Group B|Participants with overexpressing HER-2 breast cancer will receive trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
62125487|NCT00580112|EXPERIMENTAL|Group C|Participants with familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carriers cancer will receive trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 mg orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
62125488|NCT04380155|EXPERIMENTAL|Participants|All participants will perform three moderate intensity cycling trials of different duration (30, 60 and 120 min) in an energy replete state.
62125489|NCT01659216||patients improved by EPNS; follow-up|Ninety female UFS patients with ≥50% symptom improvement at the end of EPNS treatment (Jul. 2001 to Jun. 2005) were followed up by a telephone questionnaire for at least 5 years.
62125490|NCT01000077||Discarded Operating Room Tissue|The purpose of this research study is to use the discarded (tissue that would normally be thrown out) tissue from your surgery in order to obtain cells that can be grown in a laboratory to study how to use cells like these to fix sick and diseased organs. We will test if these cells can be used to build new and healthy tissues. This technique is called tissue engineering. In this study we will be comparing cells obtained from different individuals.
62125491|NCT01000077||Discarded Placenta|During a standard surgery or delivery of a baby unneeded tissue is usually discarded. We would like to explore the opportunity to grow the cells of these discarded tissues in the laboratory. The cells will be placed in special dishes and supplemented with a mixture of salts and nutrients that were designed to allow the cells to survive outside the body and grow. This procedure is called tissue culture of cells. We will attempt to isolate a population of cells from the tissue culture and study them in the laboratory.
62315686|NCT02698592|EXPERIMENTAL|Thermocool® SF catheter|50 patients underwent ablation with Thermocool® SF catheter.
62315687|NCT01764646|EXPERIMENTAL|9 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
62315688|NCT01764646|EXPERIMENTAL|28 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
62478893|NCT06664502|EXPERIMENTAL|Part 1 MAD - Low-Mid Dose|
62685590|NCT01347086|PLACEBO_COMPARATOR|Matching placebo (medium dose)|Single dose of matching placebo
62685591|NCT01347086|EXPERIMENTAL|BI 207127 NA (high dose)|Single dose of BI 207127 NA
62685592|NCT01347086|PLACEBO_COMPARATOR|Matching placebo (high dose)|Single dose of matching placebo
62685593|NCT05546372|EXPERIMENTAL|Endobiliary RFA + stent placement|
62685594|NCT05546372|ACTIVE_COMPARATOR|Stent placement only|
62315689|NCT01984593|NO_INTERVENTION|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention group.
62315690|NCT01984593|ACTIVE_COMPARATOR|yoga|Two yoga exercises to perform at home 15 minutes twice daily.
62315691|NCT01863563|EXPERIMENTAL|QuickClot|QuickClot sponge will be applied for one minute each site of tonsillectomy and Adenoidectomy.
62478894|NCT06664502|EXPERIMENTAL|Part 1 MAD - Mid-High Dose|
62478895|NCT06664502|EXPERIMENTAL|Part 1 MAD - High Dose|
62478896|NCT06664502|EXPERIMENTAL|Part 2: DME naïve or experienced participants - Dose 1|
62478897|NCT06664502|EXPERIMENTAL|Part 2: DME naïve or experienced participants -Dose 2|
62125492|NCT03684044|EXPERIMENTAL|Baloxavir Marboxil|"Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
61924241|NCT04246736|EXPERIMENTAL|Intervention group|"The intervention group received a Recovery programme including three group sessions."
62125493|NCT03684044|PLACEBO_COMPARATOR|Placebo|"Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
62125494|NCT01337635|ACTIVE_COMPARATOR|Standard dose vitamin D|Treatment with cholecalciferol 400 IU daily at home.
62125495|NCT01337635|ACTIVE_COMPARATOR|High dose vitamin D|Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
62315692|NCT05885256||Trauma Patients|Seeking all patients that meets trauma activation criteria for the amendment of our order set. The participants existing blood from the routine clinical care blood draws will be used to obtain samples.
62478898|NCT06664502|EXPERIMENTAL|Part 2: NVAMD naïve or experienced participants - Dose 1|
61924242|NCT04246736|NO_INTERVENTION|Control group|The control group was on a waiting list to receive the intervention after the last follow-up measure (six months after the intervention group's last group session).
62315693|NCT02687113|OTHER|CT/US fusion|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
62315694|NCT02318394|EXPERIMENTAL|Monotherapy Arm|MEDI0562 monotherapy
62478899|NCT06664502|EXPERIMENTAL|Part 2: NVAMD naïve or experienced participants - Dose 2|
62478900|NCT03032107|EXPERIMENTAL|Pembrolizumab Combine With Trastuzumab Emtansine|"* Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle~* Pembrolizumab will be administered prior to T-DM1 administration~* Pembrolizumab will be given at a predetermine dose~* T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle~* T-DM1 will be given at a predetermine dose"
62478901|NCT02069535|EXPERIMENTAL|AVANZ Cupressus|AVANZ Cupressus
62478902|NCT01419561|NO_INTERVENTION|1|Evaluation for Alternative Causes of KICS Symptoms (inactive)
62478903|NCT01419561|NO_INTERVENTION|2|Natural history/Observation arm (inactive)
62315695|NCT04304222|OTHER|Sequence A|To receive the conventionally made denture framework then the 3D printed denture framework.
62478904|NCT01419561|EXPERIMENTAL|3|High dose zidovudine + valganciclovir (inactive)
62478905|NCT01419561|EXPERIMENTAL|4|Rituximab with or without liposomal doxorubicin (inactive)
62478906|NCT01419561|OTHER|5|Standard and alternative rational therapies (inactive)
62478907|NCT01419561|OTHER|6|Natural history
61924243|NCT02194608|EXPERIMENTAL|Telemedicine system|Participants will self-test blood glucose level, weight, and blood pressure and results will be uploaded and transmitted directly via a hometelehealth system to a central location (HUB). Blood draws will be administered at baseline and follow-up visits.
62125496|NCT04144595||Low plasma glucose|This group will be formed by women with low plasma glucose: fasting plasma glucose (\<10th percentile, \<65 mg/dL), 1 or 2-hour low plasma glucose results after OGTT.
62125497|NCT04144595||Normal plasma glucose|This group will be formed by women with normal plasma glucose: fasting plasma glucose ( ≥10th percentile, ≥65 mg/dL but \< 92 mg/dL), 1 or 2-hour normal glucose (\< 180 mg/dL and 153 mg/dL, respectively) results after OGTT.
62125498|NCT02944188|EXPERIMENTAL|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
62315696|NCT04304222|OTHER|Sequence B|To receive the 3D printed denture framework then the conventionally made denture framework.
62315697|NCT03528044|EXPERIMENTAL|Patients undergoing bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
62315698|NCT03528044|NO_INTERVENTION|Control group|Healthy controls with normal BMI.
62125499|NCT02944188|ACTIVE_COMPARATOR|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
62125500|NCT03145155|EXPERIMENTAL|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
62125501|NCT03145155|PLACEBO_COMPARATOR|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
62315699|NCT01396408|ACTIVE_COMPARATOR|Sunitinib|
62315700|NCT01396408|ACTIVE_COMPARATOR|Temsirolimus|
62315701|NCT05217381||Cohort 1|Patients with an initial diagnostic of early breast cancer or locally advanced breast cancer or de novo metastatic breast cancer
62315702|NCT06411899|EXPERIMENTAL|sonelokimab|Subjects randomized to this arm will receive sonelokimab 120 mg Q2W from Weeks 0 to 6 then 120 mg Q4W starting at Week 8 up to Week 48.
62315703|NCT06411899|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo Q2W from Weeks 0 to 6 then Q4W starting at Week 8 up to Week 16. They will receive sonelokimab 120 mg Q2W for 4 doses from Weeks 16 to 22 then Q4W from Week 24 up to Week 48
62315704|NCT03835208|EXPERIMENTAL|Low-morning-carbohydrate|"Low morning intake and high evening intake of carbohydrates. This means a distribution of carbohydrate as follows:~10% morning, 40% lunch, 50% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
62315705|NCT03835208|EXPERIMENTAL|High-morning-carbohydrate|"High morning intake and low evening intake of carbohydrates.~This means a distribution of carbohydrate as follows:~50% morning, 40% lunch, 10% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
62315706|NCT00934531|EXPERIMENTAL|Donepezil|participants with MCI receiving donepezil
62315707|NCT00934531|PLACEBO_COMPARATOR|Placebo|Participants with MCI receiving placebo
62478908|NCT06742255||stellate ganglion block group|
62478909|NCT06742255||medical treatment group|
62478910|NCT03523377|EXPERIMENTAL|prolonged overnight fasting|Participants randomized to the fasting arm will be instructed on how to use the SMS texting app to indicate the beginning and end of the nightly fast. In the first 2-4 weeks following the first overnight fast, intervention participants will complete three phone calls with study staff trained in motivational interviewing. These calls will be used to reinforce the prolonged overnight fasting instructions, identify barriers to prolonged overnight fasting, and support successes where they have occurred.
62315708|NCT03434132|ACTIVE_COMPARATOR|Open Radical Cystectomy|Open Radical Cystectomy, pelvic lymph node dissection, urinary diversion (neobladder or ileal conduit)
62315709|NCT03434132|EXPERIMENTAL|Robot assisted radical cystectomy|Robot assisted radical cystectomy, pelvic lymph node dissection, intracorporeal urinary diversion (neobladder or ileal conduit)
62315710|NCT03559985|OTHER|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
62478911|NCT03523377|ACTIVE_COMPARATOR|usual care|Participants randomized to the usual care arm will be instructed to eat a heart-healthy diet and exercise for at least 30 minutes five days a week, which is usual counseling in our clinics.
62478912|NCT05966753||Patients with diabetic macula edema (DME)|Patients diagnosed with diabetic macula edema (DME) in at least one eye, at least 18 years old, with information on laterality and registered in the Vestrum health database between January 2015 and May 2023.
62315711|NCT03559985|OTHER|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
62685595|NCT06132308|ACTIVE_COMPARATOR|PENG Block with 0.25% bupivacaine (20 cc)|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 20cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
62685596|NCT06132308|EXPERIMENTAL|PENG Block with 0.25% bupivacaine (30 cc)|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 30cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
62685597|NCT06132308|EXPERIMENTAL|PENG Block with 0.25% bupivacaine (40 cc)|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 40cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
62685598|NCT02363426|OTHER|Medical Device: INVOcell Culture Device|5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
62685599|NCT02363426|ACTIVE_COMPARATOR|Medical Device: IVF Incubator|5 day oocyte incubation using traditional IVF incubation.
62685600|NCT01055119|ACTIVE_COMPARATOR|Omega-3 fatty acids|
62685601|NCT01055119|PLACEBO_COMPARATOR|Olive oil|
62685602|NCT04760236|EXPERIMENTAL|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 1)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 1) according to 0-2 week schedule.
62685603|NCT04760236|EXPERIMENTAL|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 2)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 2) according to 0-2 week schedule.
62685604|NCT04760236|EXPERIMENTAL|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 3)|Participants (n=935) aged 1-40 years old will received OCV-S (Lot 3) according to 0-2 week schedule.
62315712|NCT02278185|EXPERIMENTAL|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
62315713|NCT02278185|ACTIVE_COMPARATOR|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
62685605|NCT04760236|ACTIVE_COMPARATOR|Shanchol™ group|Participants (n=935) aged 1-40 years old will received Shanchol™ according to 0-2 week schedule.
62685606|NCT05274451|EXPERIMENTAL|Experimental LYL797|ROR1-targeted CAR T cells
62685607|NCT05240924|EXPERIMENTAL|Exposure and Response Prevention (ERP)|ERP will be based upon the Treatments That Work series, which contains both a provider manual and client workbook. Sessions will last 90 minutes and occur weekly for 16 sessions. All ERP treatment will be delivered via VTH. Participants will receive instructions on accessing the VTH platform and take part in a brief practice run connecting to the VTH appointment with guidance from an RA. ERP treatment content includes psychoeducation about OCD, assessment of OCD symptoms, the rationale for treatment, construction of a hierarchy or a list of feared or avoided situations, and in-session in-vivo and imaginal exposures. Weekly homework assignments will include self-monitoring, reading chapters about the treatment, and practicing exposures daily. All therapy sessions will be audio-recorded. Although sessions are expected to occur weekly, accounting for delays due to scheduling, holidays, and missed appointments, the investigators will allow up to 6 months to complete the treatment.
62125502|NCT04504786|EXPERIMENTAL|Vitality acupunch (VA)|The VA program took 40 minutes to complete and included three phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allowed the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands were used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group received the VA program led by the instructors, who were trained and certified by the PI, 3 times per week and 40 minutes per session for 6 months.
62315714|NCT03177876|EXPERIMENTAL|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles \[Nanostreams\] with simultaneous implant placement
62315715|NCT03177876|ACTIVE_COMPARATOR|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
62315716|NCT04207112|EXPERIMENTAL|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
62315717|NCT04207112|EXPERIMENTAL|Regimen 2: Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
62315718|NCT04207112|EXPERIMENTAL|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
62315719|NCT04207112|ACTIVE_COMPARATOR|Control regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB
62315720|NCT06672107||Right hemisphere stroke|Participants with a history of a unilateral stroke affecting the right cerebral hemisphere.
62315721|NCT06672107||Left hemisphere stroke|Participants with a history of a unilateral stroke affecting the left cerebral hemisphere.
62315722|NCT01221051|ACTIVE_COMPARATOR|oxytocin|early cord clamping, administration of oxytocin 10 IU i.v, controlled cord traction, uterine massage after placenta expulsion
62315723|NCT01221051|PLACEBO_COMPARATOR|saline solution|early cord clamping, wait for signs of placenta detachment, encourage the woman to push out placenta by her own effort, uterine massage after placenta expulsion
62315724|NCT05009472|EXPERIMENTAL|Cleft Lip and Palate Patient|Cleft patient with transverse maxillary constriction and anteroposterior deficiency
62315725|NCT00149825|EXPERIMENTAL|MED+CBTI|Escitalopram plus Cognitive Behavioral Therapy for Insomnia
62315726|NCT00149825|ACTIVE_COMPARATOR|MED+CTRL|Escitalopram plus Pseudo-desensitization Therapy for Insomnia
62315727|NCT06037538|EXPERIMENTAL|Subject glucometer measurement|Blood glucose measurement BGM for personal use
62315728|NCT01659944|EXPERIMENTAL|Metoprolol alone then eliglustat + metoprolol|In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
62315729|NCT02606877|EXPERIMENTAL|Treatment naïve|Treatment naïve to pirfenidone
62315730|NCT02606877|EXPERIMENTAL|Pirfenidone-treated|Treatment before with pirfenidone
62478913|NCT06169124|EXPERIMENTAL|Treatment (exemestane, darolutamide, leuprolide acetate)|Patients receive exemestane PO QD and darolutamide PO BID starting on days -14 to -7 prior to C1D1 and then on days 1-28 of each cycle. Patients receive leuprolide acetate IM on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo chest CT or chest x-ray and CT, MRI, or PET/CT as well as blood sample collection throughout the study. Patients undergo collection of archived tissue during screening.
62478914|NCT06544902|EXPERIMENTAL|VR-Stress Management Group|Participants in this group will receive VR intervention for up to 6 months
62315731|NCT04489524|EXPERIMENTAL|individualized counselor-led MI sessions and NRT|The intervention (4 individualized counselor-led MI sessions and nicotine replacement therapy \[NRT\]) consisted of four 60-min in-person sessions of AMI counseling and a packet of self-help smoking cessation materials. Participants were provided NRT packs and counseled on their use.
62315732|NCT04489524|ACTIVE_COMPARATOR|general health education, self-help materials, and NRT|Participants in this condition were provided with four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco. Strategies for quitting smoking were also provided to participants in this group as well as a supply of NRT and counseling on its use.
62315733|NCT06421246||Activity monitoring and validity of the Danish Version of the Acute Care Mobility Assessement|24- hour activity will be assessed by SENS motion acitivity monitors before (Cohort 1) and after the introduction (Cohort 2) of a screen-solution with staff-facing real time activity data and investigation of the implementation process and outcomes. Furthermore, the Acute Care mobility assessment will be validated by cognitive debriefing interviews in 5-10 patients in Cohort 1.
62315734|NCT06672315|EXPERIMENTAL|Performing TEE|In this group of patients, transesophageal echocardiography (TEE) will be performed to confirm optimal chest compression positioning while utilizing a mechanical chest compression device.
62315735|NCT06672315|NO_INTERVENTION|not performing TEE|In this group of patients, transesophageal echocardiography (TEE) will not be performed, and the mechanical chest compression device will be positioned at the intersection of the nipple line and the sternum.
62315736|NCT00598962|EXPERIMENTAL|azithromycin and rifabutin/rifampin|Azithromycin and rifabutin/rifampin administered three times weekly.
62315737|NCT04232501|EXPERIMENTAL|Cirvo Compression device post surgery|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
62315738|NCT04232501|NO_INTERVENTION|Standard of Care Post Surgery|Patients receive standard-issue SCDs (pneumatic compression) and wear in surgery and after surgery until they are discharged home.
62315739|NCT02940886|EXPERIMENTAL|Iron isomaltoside/ferric derisomaltose|Administered IV
62315740|NCT02940886|ACTIVE_COMPARATOR|Iron sucrose|Administered IV
62315741|NCT00612846|EXPERIMENTAL|A|
62315742|NCT00612846|EXPERIMENTAL|B|
62125503|NCT04504786|ACTIVE_COMPARATOR|Control|Participants in the control group continued with their daily activities as usual.
62478915|NCT06544902|ACTIVE_COMPARATOR|Education Control Group|Participants in this group will be exposed to standard care through educational materials for up to 6 months.
62315743|NCT06671847|EXPERIMENTAL|Chair-based resistance band training|
62315744|NCT05924360|OTHER|Control Group|The individuals in this group will undergo a conventional exercise program.
62315745|NCT05924360|EXPERIMENTAL|Mulligan Group|In addition to the conventional treatment program, individuals in this group will receive the mobilization with movement technique in the directions of flexion, abduction, and external rotation, twice a week.
62315746|NCT05924360|EXPERIMENTAL|Maitland Group|In addition to the conventional treatment program, The Maitland application will be administered in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be delivered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
62478916|NCT06337552|EXPERIMENTAL|FEED-FF|"Participants will be asked to pick up the fermented foods at the Research Kitchen at Moffitt. Participants will be asked to eat 3-6 servings of FFs per day, from 1 week prior to treatment start through 12 weeks after treatment start/until the restaging scope is completed.~At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic.~Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints.~After the dietary intervention, participants will be asked to complete an exit survey to provide feedback on the study and intervention."
62478917|NCT06337552|ACTIVE_COMPARATOR|Standard of Care (SUC)|"Participants will receive general healthy eating handouts similar to current usual care documents provided in clinic.~These handouts will detail typical healthy foods and the suggested level of intake, or servings per day.~At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic. Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints."
62478918|NCT00834561|EXPERIMENTAL|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
62478919|NCT00834561|ACTIVE_COMPARATOR|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
62478920|NCT03647293|ACTIVE_COMPARATOR|Control Group|Neonates who underwent a peripherally inserted central catheter
62478921|NCT03647293|ACTIVE_COMPARATOR|Intervention Group|Neonates who underwent an Ultrasound Guided Central Catheter Insertion
62478922|NCT06742164|ACTIVE_COMPARATOR|Patients received Ivabradine|
62478923|NCT06742164|SHAM_COMPARATOR|Patients didn't receive Ivabradine .|
62478924|NCT06588153|EXPERIMENTAL|Prolia®|Participants with glucocorticoid-induced osteoporosis (GIOP) will receive Prolia® every 6 months (Q6M).
62478925|NCT06616532|EXPERIMENTAL|PM8002+Paclitaxel|Subjects will be administered with PM8002 in combination with Paclitaxel via intravenously (IV) infusion.
62125504|NCT02726828|ACTIVE_COMPARATOR|group I: morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine in 1 ml volume intrathecally.
62125505|NCT02726828|ACTIVE_COMPARATOR|group II: ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
62478926|NCT06616532|ACTIVE_COMPARATOR|Chemotherapy|Subjects will be administered with Investigator's Choice(Topotecan or Paclitaxel) via intravenously (IV) infusion Q3W.
62478927|NCT01915511||Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry
62315747|NCT03251976|EXPERIMENTAL|Intervention|video decision aid
62315748|NCT03251976|ACTIVE_COMPARATOR|Usual care|
62315749|NCT06380517|EXPERIMENTAL|Luminopia Group|watching dichoptic movies/shows wearing the Luminopia headset prescribed 1 hour per day (treatment time can be split into shorter sessions totaling 1 hour each day) 6 days a week with optical correction, if needed.
62315750|NCT06380517|ACTIVE_COMPARATOR|Patching Group|patching of the fellow eye 2 hours per day (treatment time can be split into shorter sessions totaling 2 hours each day) 7 days per week with optical correction, if needed.
62315751|NCT05427682|EXPERIMENTAL|Group A (normal liver function)|Each subject will receive a single dose of rongliflozin on Day 1
62478928|NCT01915511||Subjects with a non-IPF ILD diagnosis|Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype
62125506|NCT02726828|ACTIVE_COMPARATOR|group III: morphine + ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
62125507|NCT02051491|ACTIVE_COMPARATOR|BP-NCPAP|Nasal BP-NCPAP will be delivered using the Infant Flow® SiPAP™ and either nasal prongs or mask interface. A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with transcutaneous carbon dioxide (TcCO2) monitor data (if available). Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm water (H2O) and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on fraction of inspired oxygen (FiO2) requirements.
62315752|NCT05427682|EXPERIMENTAL|Group B (mild liver damage)|Each subject will receive a single dose of rongliflozin on Day 1
62315753|NCT05427682|EXPERIMENTAL|Group C (normal liver function)|Each subject will receive a single dose of rongliflozin on Day 1
62315754|NCT05427682|EXPERIMENTAL|Group D (moderate liver damage)|Each subject will receive a single dose of rongliflozin on Day 1
62315755|NCT01175239|EXPERIMENTAL|Single infusion of autologous CD34+ cells|
62315756|NCT03964012|EXPERIMENTAL|NmCV-5|"Subjects in this arm will receive polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W \& X.~A single dose of 0.5 mL will be administered intramuscularly."
62315757|NCT03964012|ACTIVE_COMPARATOR|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, \& W viz. Menactra.~A single dose of 0.5 mL will be administered intramuscularly."
62315758|NCT03698162|EXPERIMENTAL|Cohort I (STAR DCE-MRI)|Participants with recurrent high-grade glioma undergo STAR DCE-MRI every 2 months, and just prior to and 4-6 weeks after starting bevacizumab treatment. Participants may undergo more frequent MRI if there is concern for tumor progression.
61924244|NCT02194608|NO_INTERVENTION|Usual care|Participants will self-record their blood glucose levels, blood pressure and weight in a diary. Blood draws will be administered at baseline and follow-up visits.
62125508|NCT02051491|EXPERIMENTAL|NIHFV|NIHFV will be provided using the Drager VN500, using either nasal prong or mask interfaces.A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with TcCO2 monitor data (if available). Initial settings for NIHFV arm will be MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
62125509|NCT04111328|EXPERIMENTAL|sufentanil administration intravenously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
62125510|NCT04111328|EXPERIMENTAL|sufentanil administration subcutaneously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
62125511|NCT04111328|EXPERIMENTAL|hydromorphone administration intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
62315759|NCT03698162|EXPERIMENTAL|Cohort II (STAR DCE-MRI)|Participants with melanoma brain metastases undergo STAR DCE-MRI at baseline and 4-6 weeks after therapy. Participants may undergo more frequent MRI if there is concern for tumor progression.
62315760|NCT04681287|EXPERIMENTAL|inetetamab and PD-1 inhibitor combined with chemotherapy.|
62315761|NCT02625519|EXPERIMENTAL|Urinary follicle-stimulating hormone|Controled Ovarian stimulation with urinary follicle-stimulating hormone
62315762|NCT02625519|EXPERIMENTAL|Recombinant follicle-stimulating hormone|Ovarian stimulation with recombinant follicle-stimulating hormone
62315763|NCT04652492|EXPERIMENTAL|Tislelizumab in combination with cTACE|Tislelizumab in combination with on-demanded cTACE
62315764|NCT04016493||Control group (CAF+CTG; N=20)|
62315765|NCT04016493||Test group (TUN+CTG; N=20)|
62315766|NCT00418262|EXPERIMENTAL|Atomoxetine HCL (Strattera)|Teatment of children with fetal alcohol syndrome and ADHD with Atomoxetine HCL (Strattera)
62339651|NCT01398033|PLACEBO_COMPARATOR|non-coated balloon|Treatment of the target lesion with plain balloon angioplasty.
62315767|NCT06287424|EXPERIMENTAL|A: 4 tablet per day|"• Group A: Daily use of Aged Garlic Extract product: Take two (2) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (2) tablets immediately after breakfast and (2) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
62315768|NCT06287424|EXPERIMENTAL|B: 6 tablet per day|"• Group B: Daily use of Aged Garlic Extract product: Take three (3) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (3) tablets immediately after breakfast and (3) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
62315769|NCT06287424|EXPERIMENTAL|C: 8 tablet per day|"• Group C: Daily use of Aged Garlic Extract product: Take four (4) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (4) tablets immediately after breakfast and (4) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
62339652|NCT04428684|EXPERIMENTAL|Pepti 3.6 treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
62685608|NCT05240924|OTHER|Control Condition|Participants randomized to the control condition will receive 16 weekly sessions of stress management training via video telehealth. This control condition was chosen because it is expected to provide the therapeutic alliance and common factors associated with therapy generally and some specific effects in anxiety reduction.
62315770|NCT06287424|PLACEBO_COMPARATOR|D: Placebo|"• Group C: Daily use of Aged Garlic Extract product: Take four (4) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (4) tablets immediately after breakfast and (4) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
62315771|NCT06672263|EXPERIMENTAL|TQB3911 tablets|Once a day for 28 days as a treatment cycle
62125512|NCT04111328|EXPERIMENTAL|hydromorphone administration subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
62125513|NCT04111328|EXPERIMENTAL|sufentanil and dexmedetomidine intravenously|The dose of sufentanil, dexmedetomidine,for patient-controlled analgesia is 3.0μg/Kg, dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
62685609|NCT01793454|ACTIVE_COMPARATOR|40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the surgery.
62315772|NCT05913557|EXPERIMENTAL|Treatment Group|Participants completed a baseline assessment, received 4 months of RO DBT therapy, then completed a follow-up assessment.
62315773|NCT05913557|NO_INTERVENTION|No Treatment Group|Participants completed baseline assessment but did not receive treatment. A small subset also completed a follow-up assessment.
62315774|NCT05913557|NO_INTERVENTION|Healthy Controls|Participants completed baseline assessment but did not receive treatment.
62315775|NCT02526615|PLACEBO_COMPARATOR|Placebo|placebo, 2 tablets per day
62315776|NCT02526615|ACTIVE_COMPARATOR|Metformin|500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
62315777|NCT02526615|ACTIVE_COMPARATOR|Rosiglitazone|2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day
62478929|NCT01915511||New Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.
62685610|NCT01793454|ACTIVE_COMPARATOR|80% oxygen|Patients in this group will be ventilated with a fraction of inspired oxygen 80% during the surgery.
62125514|NCT04111328|EXPERIMENTAL|sufentanil and dexmedetomidine subcutaneously|The dose of sufentanil ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
62315778|NCT00693381|EXPERIMENTAL|1|Tacrolimus/MMF/steroids throughout the study
62315779|NCT00693381|EXPERIMENTAL|2|Tacrolimus/MMF/steroids with MMF reduction from week 7 to 12 and MMF discontinuation at month 3
62315780|NCT04003155|PLACEBO_COMPARATOR|Double-blind Period: Placebo|Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, once daily (QD) up to week 12 during double-blind treatment period.
61924245|NCT02448342|EXPERIMENTAL|ReDS Guided Treatment|After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
62125515|NCT04111328|EXPERIMENTAL|hydromorphone and dexmedetomidine intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5ml/h, PCA dose 1ml, locking time 15 min.
62125516|NCT04111328|EXPERIMENTAL|hydromorphone and dexmedetomidine subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5ml/h, PCA dose 1 ml, locking time 15 min.
62125517|NCT05622396|EXPERIMENTAL|MBSR program adapted|8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews
62125518|NCT00667056|EXPERIMENTAL|1|
62685611|NCT02667561|EXPERIMENTAL|Testosterone gel 1% 2.2 mg|Testosterone gel 1% Topical use 2.2 mg (220 mg of gel) once daily duration of treatment: 28 days
62125519|NCT00667056|PLACEBO_COMPARATOR|2|
62125520|NCT06451185|NO_INTERVENTION|Standard Care Group|Following successful insertion of a central venous catheter into an internal jugular vein, the site will be covered with a standard care transparent dressing.
62125521|NCT06451185|EXPERIMENTAL|Haemostatic Powder Group|Following successful insertion of a central venous catheter into an internal jugular vein, the site will be covered with a haemostatic powder product beneath the standard care transparent dressing.
62125522|NCT01373697|ACTIVE_COMPARATOR|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
62125523|NCT01373697|ACTIVE_COMPARATOR|Ibuprofen|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
62125524|NCT06499714||Women in luteal MCP|Women being in their luteal MCP on the day of ascent to high altitude.
62125525|NCT06499714||Women in follicular MCP|Women being in their follicular MCP on the day of ascent to high altitude.
62125526|NCT02059382|ACTIVE_COMPARATOR|Control|ChiRunning training Weekly training log Blinded accelerometer
62125527|NCT02059382|EXPERIMENTAL|Technology support for behavior change|ChiRunning training unblinded accelerometer tracking structured exercise using mobile app participation in online social network participation in study website
62125528|NCT03311893|ACTIVE_COMPARATOR|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
62125529|NCT03311893|PLACEBO_COMPARATOR|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
62315781|NCT04003155|EXPERIMENTAL|Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg|Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 30 mg orally, QD from week 13 up to Week 52 during extension treatment period.
62315782|NCT04003155|EXPERIMENTAL|Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg|Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 45 mg orally, QD from week 13 up to Week 52 during extension treatment period.
62478930|NCT05755282|ACTIVE_COMPARATOR|A: spectrum first then Purell|Half of participants will apply Spectrum Advanced (#1) Hand Sanitizer Foam followed by Purell Advanced (#2) Hand Sanitizer Foam
62685612|NCT02667561|EXPERIMENTAL|Testosterone gel 1% 4.4 mg|Testosterone gel 1% Topical use 4.4 mg (440 mg of gel) once daily duration of treatment: 28 days
62685613|NCT02667561|EXPERIMENTAL|Testosterone gel 1% 8.8 mg|Testosterone gel 1% Topical use 8.8 mg (880 mg of gel) once daily duration of treatment: 28 days
61924246|NCT02448342|ACTIVE_COMPARATOR|Standard of Care- Control arm|After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
62125530|NCT04894565|EXPERIMENTAL|intervention|effect of rehabilitation program in the intervention arm
62685614|NCT02667561|PLACEBO_COMPARATOR|Placebo of Testosterone Gel 1%|Placebo of Testosterone Gel 1% Topical use Approximately 550 mg of gel Once daily duration of treatment: 28 days
62685615|NCT06679517||Patients with aortic stenosis undergoing TAVI|Patients with a diagnosis of severe aortic stenosis candidates to TAVI procedures.
62685616|NCT03063164|ACTIVE_COMPARATOR|Intralase IFS|Intralase IFS vs. Visumax
62125531|NCT04788641|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: tacrolimus alone (treatment A) followed by the combination treatment of tacrolimus and SZC (treatment B) or vice versa.
62125532|NCT04788641|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: cyclosporin alone (treatment C) followed by the combination treatment of cyclosporin and SZC (treatment D) or vice versa.
62125533|NCT04954638||sodium hypochlorite|group 1: control group with sodium hypochlorite desinfection
62125534|NCT04954638||hyperpure chlorine dioxide|group 2: study group with hyperpure chlorine dioxide desinfection
62125535|NCT03524534|ACTIVE_COMPARATOR|Telephone Follow-Up Intervention|
62125536|NCT03524534|ACTIVE_COMPARATOR|In-person follow-up intervention|
62125537|NCT05263609|EXPERIMENTAL|Arm A|"Arm A (CR/oPR on pembrolizumab monotherapy):~Patients will continue pembrolizumab monotherapy if CR/oPR on initial treatment with pembrolizumab monotherapy. If CR/oPR persists at 8 cycles (24 weeks) after assignment on arm A, pembrolizumab break will commence. Patients will be monitored for disease progression with imaging every 9 weeks (+/- 1 week). If patients develop progression, pembrolizumab will be resumed and continued until subsequent PD. At that point, axitinib may be added to pembrolizumab as part of the study or patients may discontinue study treatment per the treating investigator's discretion."
62125538|NCT05263609|EXPERIMENTAL|Arm B|"Arm B (sPR/SD/PD):~Patients with sPR, SD or PD after 6 cycles of pembrolizumab monotherapy will be started on axitinib in addition to continuing pembrolizumab. If patients develop subsequent PD, treatment will be discontinued. If the subsequent scans show SD/PR/CR, the combination treatment will be continued until PD or unacceptable toxicity."
62125539|NCT05763524||Adrenalectomy in patients operated for Adrenocortical Carcinoma|All adult (18 years old and older) patients registered in EUROCRINE® database that underwent surgery for adrenocortical carcinoma from 2015 till 2021 will be included
62125540|NCT05081999|OTHER|Continuation of Beta-Blockers|For patients already on β-blocker therapy, the treatment will be continued and titrated at the discretion of the patient's most responsible physician(s).
62125541|NCT05081999|OTHER|De-Adoption of Beta-Blockers|For patients on β-blocker therapy, medication will be tapered over 3-7 days to minimize the potential for withdrawal-related symptoms. A standardized angina treatment algorithm, which is independent of β-blocker use, will minimize any worsening of angina symptoms during drug withdrawal by utilizing other guideline recommended anti-anginal agents, such as calcium-channel blockers, long acting nitrates, or ivabradine. An anticipated 5% of patients allocated to this arm will not be able to tolerate discontinuation, however, patients will continue participation as per intention-to-treat principle. Background lifestyle measures and medical therapies will be recommended according to current Canadian guideline recommendations and individual patient profiles. Structured algorithms to achieve blood pressure goals that exclude the use of a β-blocker based on the Canadian Hypertension Education Program Guidelines will be provided.
62315783|NCT04003155|EXPERIMENTAL|Double-blind Period: Placebo /Extension Period: Fezolinetant 30 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 30 mg orally, QD from week 13 up to week 52 during extension treatment period.
62315784|NCT04003155|EXPERIMENTAL|Double-blind Period: Placebo /Extension Period: Fezolinetant 45 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 45 mg orally, QD from week 13 up to week 52 during extension treatment period.
62315785|NCT02481518|EXPERIMENTAL|Magnesium|Magnesium preloading group : Magnesium preloading for Cisplatin treatment
62315786|NCT02481518|ACTIVE_COMPARATOR|Control|Control group : Normal saline preloading for cisplatin treatment
62315787|NCT05292222|EXPERIMENTAL|Intermittent theta burst stimulation|All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 10-12 weeks.
62315788|NCT00081289|EXPERIMENTAL|Neoadjuvant chemoradiation with irinotecan|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1200mg/m\^2/day 5 days/week during RT, and irinotecan 50 mg/m\^2 IV for 1 hour days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m\^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 plus 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m\^2 IV over 2 hours Day 1) .
62685617|NCT03063164|ACTIVE_COMPARATOR|Visumax|Visumax vs. Intralase iFS
62685618|NCT05463887|NO_INTERVENTION|Usual care|Control arm: Participants will not receive individualized preventive care recommendations (decision tool).
62685619|NCT05463887|ACTIVE_COMPARATOR|Individualized preventive care recommendations (decision tool)|Intervention arm: Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making.
62315789|NCT00081289|EXPERIMENTAL|Neoadjuvant chemoradiation with oxaliplatin|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1650mg/m\^2/day 5 days/week during RT, and oxaliplatin 50 mg/m\^2 IV for 2 hours days 1, 8, 15, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m\^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 plus 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m\^2 IV over 2 hours Day 1) .
61924247|NCT00043121|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV on days 1 and 15. Patients also receive oral capecitabine every 8 hours on days 1-2 and 15-16. Leucovorin calcium and fluorouracil administration is held at dose level 4 and above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61924248|NCT04805827|EXPERIMENTAL|Gabapentin|1 tablet contains 600 mg Gabapentin
61924249|NCT04805827|ACTIVE_COMPARATOR|Neurontin|2 capsule contains 2\*300 = 600 mg Gabapentin
61924250|NCT06495866||cases of seronegative spondyloarthropathy with fibromyalgia|cases already diagnosed as seronegative spondyloarthropathy by application of ASAS classificatin criteria for axial SpA and have concomitant fibromyalgia according to 2016 ACR criteria.
62125542|NCT06516315|EXPERIMENTAL|qfr|"Patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6) :~* Preoperative ultrasound, performed the day before or the day of surgery~* Intraoperative angiography performed immediately prior to revascularization (routine care procedure whose duration is extended by research)~* Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software."
62125543|NCT06516861|EXPERIMENTAL|MgSO4 intravenous|Sample will be given MgSO4 30mg/Kg Intravenous as a premedication drugs before intubation for all patients who had craniotomy surgery
62125544|NCT06516861|EXPERIMENTAL|Lidocaine intravenous|Sample will be given Lidocain 1.5mg/Kg Intravenous as a premedication drugs before intubation for all patients who had craniotomy surgery
62315790|NCT01782183|EXPERIMENTAL|Thermal camera by Flir HM series|all patients in both study and control groups will undergo thermal camera photo of the tonsils by Flir HM series
62315791|NCT06082947|EXPERIMENTAL|HSCT using TCR αβ/CD19+ depleted grafts|Allogeneic HSCT using the TCR αβ/CD19+ depleted platform and grafts from alternative donors (MUD, MMUD and haploidentical)
62315792|NCT00121810|EXPERIMENTAL|1|
62315793|NCT00121810|ACTIVE_COMPARATOR|2|
62478931|NCT05755282|ACTIVE_COMPARATOR|B: Purell first then spectrum|Half of participants will apply hand Purell Advanced (#2) Hand Sanitizer Foam followed by Spectrum Advanced (#1) Hand Sanitizer
61924251|NCT06495866||cases of seronegative spondyloarthropathy without fibromyalgia|cases already diagnosed as seronegative spondyloarthropathy by application of ASAS classificatin criteria for axial SpA and do not match with 2016 ACR criteria for fibromyalgia.
62125545|NCT06516861|PLACEBO_COMPARATOR|NaCl 0,9% Intravenous|Sample will be given NaCl 0,9% Intravenous 20 ml as a premedication drugs before intubation for all patients who had craniotomy surgery
61924252|NCT06495866||controls|control individuals will be matched for sex, age, and level of schooling without history of inflammatory joint disorders or any systemic active disease.
61924253|NCT02815774|ACTIVE_COMPARATOR|health volunteers|this group patients were given SP2086 50mg only one time.
62125546|NCT05319457|PLACEBO_COMPARATOR|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
62315794|NCT06255977|PLACEBO_COMPARATOR|Placebo Control: placebo|Intravenous infusion with placebo（same volume of saline） every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of placebo（same volume of saline） will be administered as a slow IV bolus over 30 minutes.
62478932|NCT05703360|EXPERIMENTAL|Waitlist Group|Those randomly assigned to the waitlist group will complete initial inclusion tests and baseline tests at Visit 1. They will receive no intervention during Period 1 (week 1-6) and then repeat baseline tests at Visit 2. Next they will perform the VR audiovisual stimulation during Period 2 (week 7-12) and then repeat baseline tests post-intervention at Visit 3.
62478933|NCT05703360|EXPERIMENTAL|VR Intervention First|Those randomly assigned to the intervention-first group will complete initial inclusion tests and baseline tests at Visit 1. They will perform the VR audiovisual stimulation during Period 1 (week 1-6) and then repeat baseline tests at Visit 2. They will receive no intervention during Period 2 (week 7-12) and then repeat baseline tests at Visit 3.
62685620|NCT04122690|EXPERIMENTAL|Partnered Dance Aerobic Exercise|Partnered Dance-Aerobic Exercise (PDAE) is an adapted form of Argentine tango, aka Adapted tango. Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
61924254|NCT02815774|ACTIVE_COMPARATOR|mild renal insufficiency|this group patients were given SP2086 50mg only one time.
61924255|NCT02815774|ACTIVE_COMPARATOR|moderate renal insufficiency|this group patients were given SP2086 50mg only one time.
62125547|NCT05319457|EXPERIMENTAL|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA.
61924256|NCT02815774|ACTIVE_COMPARATOR|severe renal insufficiency|this group patients were given SP2086 50mg only one time.
61924257|NCT02815774|ACTIVE_COMPARATOR|end-stage renal insufficiency|this group patients were given SP2086 50mg only one time.
61924258|NCT04841746|EXPERIMENTAL|Cycling rehabilitation with functional electrical stimulation|
62125548|NCT01485653|EXPERIMENTAL|Mepivacaine, Ultrasound Axillary Block|Group 1) 20mL 1.5% mepivacaine Group 2) 30mL 1.5% mepivacaine
61924259|NCT04841746|ACTIVE_COMPARATOR|Cycling rehabilitation|
62125549|NCT03674814|EXPERIMENTAL|Dose Level|Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
62125550|NCT04164056|EXPERIMENTAL|stimulation on the hippocampus|deep brain stimulation on the hippocampus
62125551|NCT04164056|ACTIVE_COMPARATOR|stimulation on the anterior nucleus of the thalamus|deep brain stimulation on the anterior nucleus of the thalamus
62125552|NCT06162897|NO_INTERVENTION|Treatment as usual|Participants will be offered the current standard of care, Ryan White Non-Medical Case Management. Case management services are need focused and contact is client initiated.
62125553|NCT06162897|EXPERIMENTAL|Dyadic Case Management|Participants will receive dyadic case management, specifically they will have two case managers assigned to their case. Case management services will be goal focused and will utilize components from Appreciative Inquiry to orient work to future planning, goals, and financial stability.
61924260|NCT03210181|EXPERIMENTAL|Block|Patients will receive superficial cervical plexus block
61924261|NCT03210181|PLACEBO_COMPARATOR|Placebo|Patients will receive normal saline
61924262|NCT05819684|EXPERIMENTAL|Part 1: Dose escalation|
61924263|NCT05819684|EXPERIMENTAL|Part 2: PK expansion|
61924264|NCT05819684|EXPERIMENTAL|Part 3: efficacy expansion|
61924265|NCT02438306|EXPERIMENTAL|CardiAMP cell therapy|Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.
62125554|NCT01088659|EXPERIMENTAL|1|
62315795|NCT06255977|EXPERIMENTAL|Experimental: CN-105 peptide for injection 0.1 mg/kg|Intravenous infusion with 0.1 mg/kg CN-105 peptide for injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
62315796|NCT06255977|EXPERIMENTAL|Experimental:CN-105 peptide for injection 0.3 mg/kg|Intravenous infusion with 0.3 mg/kg CN-105 peptide for injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
62315797|NCT06255977|EXPERIMENTAL|Experimental: CN-105 peptide for injection 1.0 mg/kg|Intravenous infusion with 1.0 mg/kg CN-105 peptide for injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
62315798|NCT00915967|EXPERIMENTAL|Vancomycin|Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
62315799|NCT00915967|PLACEBO_COMPARATOR|Saline|Subjects in the saline group will receive a Saline injection directly into the wound pocket.
62315800|NCT03356847|EXPERIMENTAL|SISA implant|
62315801|NCT05595382|EXPERIMENTAL|Emotional Group|Participants will be randomly assigned to receive an emotional or rational appeal, stratified by sex.
62315802|NCT05595382|EXPERIMENTAL|Rational Group|Participants will be randomly assigned to receive an emotional or rational appeal, stratified by sex.
62315803|NCT03116529|EXPERIMENTAL|Treatment|Neoadjuvant Radiation plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab
62685621|NCT04122690|ACTIVE_COMPARATOR|Walking Aerobic Exercise|Walking Aerobic Exercise (WAE) Participants in WAE will receive equivalent dose, volume, frequency, intensity and duration of exercise to the PDAE group. The investigators will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The investigators will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention.
61924266|NCT02438306|SHAM_COMPARATOR|Sham Comparator|Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.
61924267|NCT00575250|ACTIVE_COMPARATOR|1|Osteoporosis Prevention and Self-Management Course (4 x 2 1/2 hours)
61924268|NCT00575250|ACTIVE_COMPARATOR|2|"One introductory osteoporosis education session (1 x 2 1/2 hours)"
61924269|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
62125555|NCT01088659|EXPERIMENTAL|2|
62125556|NCT01566968||Healthy Volunteers|Adults between ages of 18-75 inclusive who have never smoked and have no history of any respiratory disease for which they are on regular treatment.
62125557|NCT01566968||Asthma|Adults between the ages on 18-75 inclusive who have a physician diagnosis of asthma and have no smoking history or minimal smoking history (less than 10 pack years or in other words less than 20 cigarettes per day for 10 years).
62125558|NCT01566968||COPD|Adults between the ages of 18-75 inclusive who have previously been smokers (at least 20 pack years) and have physician diagnosis and spirometry evidence of COPD.
62125559|NCT01566968||Healthy smokers|Adults between the ages of 18-75 inclusive who are currently smokers (at least 10 pack years history)but have no history of any respiratory disease and no evidence of COPD on spirometry.
62125560|NCT01566968||Chronic cough|Adults between ages of 18-75 inclusive who have history of dry cough for at least 8 weeks and have a normal chest x ray and no smoking history or minimal smoking history (less than 10 pack years).
62125561|NCT02441881|ACTIVE_COMPARATOR|Venefit|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
62125562|NCT02441881|ACTIVE_COMPARATOR|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
62125563|NCT02441881|ACTIVE_COMPARATOR|Endovenous Radiofrequency|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
62125564|NCT01063972|EXPERIMENTAL|Experimental 1|Experimental: 1 Centralized disease management
62315804|NCT06671275|EXPERIMENTAL|Single arm cell therapy|"The study was designed according to the 3+3 principle, with a total of 3 dose levels and dose escalation.~Low-dose group: 5.0×107 cells/time; Medium-dose group: 1.5×108 cells/time; High-dose group: 5.0×108 cells/time. Subjects were sequentially placed in 3 different dose groups administered as a single peripheral intravenous dose.~According to the enrollment restriction design, a total of a minimum of 9 subjects are expected to be enrolled, and the final sample size depends on the number of DLT, the number of dose groups ascended before DLT is observed, and the MTD is determined."
62315805|NCT06672419|EXPERIMENTAL|AI-Guided Tele-rehabilitation|Participants in this arm will receive a 12-week tele-rehabilitation program guided by artificial intelligence (AI) and computer vision technology. The program includes three personalized exercise sessions per week, tailored to the participants' capabilities and progress, and delivered remotely. In addition to the exercise sessions, participants will receive weekly educational sessions focused on pain neuroscience. These sessions are designed to enhance their understanding of chronic pain mechanisms and improve their ability to manage pain. The intervention will be supervised by a trained therapist who will monitor participants' progress and provide real-time feedback through the platform
62315806|NCT06672419|ACTIVE_COMPARATOR|Usual Care for Fibromyalgia|Participants in this arm will receive the standard care for fibromyalgia, which includes pharmacological treatments such as pain relievers (e.g., paracetamol, tramadol), antidepressants (e.g., amitriptyline, duloxetine), and anticonvulsants (e.g., pregabalin, gabapentin). In addition to these medications, participants will be provided with general recommendations on physical activity and disease management, in line with current clinical guidelines for fibromyalgia treatment.
62315807|NCT04183257|EXPERIMENTAL|vitamin D|vitamin D arm will receive oral vitamin D in escalating dosage.
62315808|NCT04183257|NO_INTERVENTION|Conventional|This arm will receive conventional treatment only.
62315809|NCT01742221|EXPERIMENTAL|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
62315810|NCT01742221|PLACEBO_COMPARATOR|Placebo|Single subcutaneous dose
62339653|NCT04428684|ACTIVE_COMPARATOR|Zoladex 3.6 mg treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
62315811|NCT04296630|ACTIVE_COMPARATOR|Message #1|This arm will receive one of five social media messages that is preferred by our target population through focus groups that are being conducted as part of a previous study.
62315812|NCT04296630|ACTIVE_COMPARATOR|Message #2|This arm will receive the second social media message that is preferred by our target population as identified from our previous focus group study.
62315813|NCT04296630|ACTIVE_COMPARATOR|Message #3|This arm will receive the third social media message that is preferred by our target population as identified from our previous focus group study.
62685622|NCT06294431|PLACEBO_COMPARATOR|Placebo Control 1|Clarity Product Form 1 - control
61924270|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
62125565|NCT01063972|EXPERIMENTAL|Experimental 2|Experimental: 2 Counseling alone
62125566|NCT03489915||Patients with macular edema due to RVO|assessment of visual acuity using Landolt chart and follow up of macular edema using OCT
62125567|NCT00589667|EXPERIMENTAL|Treatment|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
62125568|NCT04730713||Admitted to the center ICU due to neurosurgery, brain dysfunction and other neurological reasons|Aneurysmal subarachnoid hemorrhage (aSAH), traumatic brain injury (TBI), acute deficiency Blood stroke (AIS), acute cerebral hemorrhage (ICH), hypoxic ischemic encephalopathy (HIE), Sepsis-associated encephalopathy (SAE), intracranial tumor surgery; older than 18 years old, \<85 Years old; patients who need lumbar puncture.
62125569|NCT00265200|EXPERIMENTAL|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
62125570|NCT00459745|ACTIVE_COMPARATOR|Pravastatin|Pravastatin 40 mg
62125571|NCT00459745|ACTIVE_COMPARATOR|Fenofibrate|Fenofibrate 160 mg
62125572|NCT00459745|EXPERIMENTAL|Pravafen (Parvastatin and Fenofibrate)|Combined Therapy of Pravastatin 40 mg and Fenofibrate 160 mg.
62125573|NCT01384201||Confocal Laser Endomicroscopy|OGD by Confocal Endomicroscopy
62125574|NCT01384201||White light endoscopy|OGD by whitelight endoscopy
62125575|NCT01499992|EXPERIMENTAL|aquatic physical therapy|aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focussing on the shoulder.
62125576|NCT01499992|NO_INTERVENTION|standard care|
62125577|NCT05298020|EXPERIMENTAL|Envafolimab and Endostar plus AG regimen|Envafolimab:400mg,sc,d1,Q4W; Endostar：210mg，CIV72h，d1-3，Q4W； Chemotherapy:AG (nab-paclitaxel:125mg/m2,iv,d1,d8,Q4W；gemcitabine：1000mg/m2, iv,d1,d8，Q4W).
62125578|NCT03475524|EXPERIMENTAL|study Metformin 1000 mg|
62125579|NCT03475524|EXPERIMENTAL|study Metformin 500 mg|
62125580|NCT03475524|PLACEBO_COMPARATOR|control group|
62125581|NCT06250413|EXPERIMENTAL|Intervention|The participants will be given 4 capsules containing fecal matter (Capsule 1) after treatment with antibiotics on day 7. Intervention group will be given placebo (Capsules 2) on day 28.
62125582|NCT06250413|PLACEBO_COMPARATOR|Control|"The participants will be given 4 placebo capsules (Capsule 2) after treatment with antibiotics on day 7.~Control group will be given FMT capsules (Capsules 1) as rescue therapy on day 28."
62125583|NCT00955825|EXPERIMENTAL|300 IR|300 IR grass pollen allergen extract tablet
62125584|NCT00955825|PLACEBO_COMPARATOR|Placebo|Pacebo tablet
62125585|NCT00117936|EXPERIMENTAL|1|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - high dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
62125586|NCT00117936|EXPERIMENTAL|2|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
62125587|NCT00117936|PLACEBO_COMPARATOR|3|Placebo solution void (not containing) Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141), given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
62315814|NCT04296630|ACTIVE_COMPARATOR|Arm #4|This arm will receive the fourth social media message that is preferred by our target population as identified from our previous focus group study.
62315815|NCT04296630|ACTIVE_COMPARATOR|Tailored Arm|This arm will receive social media messages that will be tailored by sex.
62315816|NCT04296630|NO_INTERVENTION|Control Arm|This arm will not receive any intervention.
62315817|NCT04755400|ACTIVE_COMPARATOR|Potassium Nitrate|4 days treatment with 24 mmol potassium nitrate capsules
62315818|NCT04755400|PLACEBO_COMPARATOR|Potassium Chloride|4 days treatment 24 mmol potassium chloride capsules
62315819|NCT06312007|EXPERIMENTAL|Semi-seated position|Semi seated position
62685623|NCT06294431|EXPERIMENTAL|Active Product 1.1|Clarity Product Form 1 - active product 1
62685624|NCT06294431|PLACEBO_COMPARATOR|Placebo Control 2|Clarity Product Form 2 - control
62685625|NCT06294431|EXPERIMENTAL|Active Product 2.1|Clarity Product Form 2 - active product 1
62315820|NCT06312007|EXPERIMENTAL|Side Lying position|Side lying position
62315821|NCT05365295|EXPERIMENTAL|ADHD|- ADHD children aged between 8 to 10 years old
62685626|NCT06294431|PLACEBO_COMPARATOR|Placebo Control 3|Clarity Product Form 3 - control
62125588|NCT04370418|OTHER|neoadjuvant chemo-radiation|"Short-course RT: 5 fractions of 5 Gy to a total dose of 25 Gy over 5 consecutive days. IMRT plans are generated with 6 MV photons.~Dose-escalated concurrent 5-FU: The 3 doses levels of 5-FU are 100, 150, and 200 mg/m2/d. 5-FU will be given by continuous infusion for 20 hours every day starting on the morning of radiation.~mFOLFOX: will be given 2 weeks after concurrent chemoradiation for a total of 4 cycles, with each cycle being 14 days. Surgery will be omitted in patients with complete pathological response and proceed to adjuvant chemotherapy. If patient develops progressive or metastatic disease, he/she will be omitted from the investigators study.~The surgery will be considered 4-8 weeks after end of therapy. Adjuvant mFOLFOX6: 6 cycles chemotherapy will begin between 4 weeks and 8 weeks after surgery.~Toxicities assessment: be using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0."
62125589|NCT02003469|EXPERIMENTAL|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
62125590|NCT01760564|EXPERIMENTAL|Miglustat|miglustat 200mg tid
62125591|NCT06061575|OTHER|Acetaminophen|Adult patients diagnosed with sepsis according to the latest current guidelines, who have agreed to participate in the study or have provided consent by their relatives, and received 1g of acetaminophen for fever management.
62125592|NCT06061575|OTHER|Ibuprofen|Adult patients diagnosed with sepsis according to the latest current guidelines, who have agreed to participate in the study or have provided consent by their relatives, and received 400 mg of ıbuprofen for fever management.
62315822|NCT01378754|EXPERIMENTAL|6.5 milligram per kilogram of Fospropofol (Lusedra®)|
62315823|NCT01378754|EXPERIMENTAL|10 milligram per kilogram of Fospropofol (Lusedra®)|
62315824|NCT01378754|EXPERIMENTAL|12 milligram per kilogram of Fospropofol (Lusedra®)|
62315825|NCT05330442|NO_INTERVENTION|CoCM alone|In the CoCM alone arm, participants will have access to treatment as usual from the CM.
62315826|NCT05330442|EXPERIMENTAL|CoCM+WET|In the CoCM+WET intervention arm, patients will be encouraged to receive WET.
62685627|NCT06294431|EXPERIMENTAL|Active Product 3.1|Clarity Product Form 3 - active product 1
62315827|NCT05496426|EXPERIMENTAL|KL130008 capsule High Dose|KL130008 capsule administered orally
62315828|NCT05496426|EXPERIMENTAL|KL130008 capsule Middle Dose|KL130008 capsule administered orally
62315829|NCT05496426|EXPERIMENTAL|KL130008 capsule Low Dose|KL130008 capsule administered orally
62685628|NCT06294431|EXPERIMENTAL|Active Product 3.2|Clarity Product Form 3 - active product 2
62685629|NCT06294431|PLACEBO_COMPARATOR|Placebo Control 4|Clarity Product Form 4 - control
62685630|NCT06294431|EXPERIMENTAL|Active Product 4.1|Clarity Product Form 4 - active product 1
62315830|NCT05496426|PLACEBO_COMPARATOR|Placebo|Placebo administered orally
62315831|NCT03897712|EXPERIMENTAL|Custom Samfilcon B Contact Lenses|Participants will wear Bausch + Lomb investigational custom samfilcon B contact lenses daily for 3 months. Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study. Participants will store their worn study lenses in a lens case filled with Biotrue multi-purpose solution (MPS).
62315832|NCT03897712|PLACEBO_COMPARATOR|Alden Optical HP Sphere contact lenses|Participants will wear Alden Optical HP Sphere contact lenses daily for 3 months. Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study. Participants will store worn study lenses in a lens case filled with Biotrue MPS.
62315833|NCT04515485||Patients undergoing laparoscopy|The participants are patients that have undergone the laparoscopic surgery.
62315834|NCT06550674|EXPERIMENTAL|constitutional genetic analysis|Constitutional genetic exome analysis will be performed on the blood sample. If necessary, an analysis on a second independent sample (jugal smear) will be carried out if a probably pathogenic or pathogenic variant in a hereditary cancer predisposition gene is identified.
62315835|NCT05757999|ACTIVE_COMPARATOR|MgSo4|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) 10 min. will be administered before induction of anesthesia
62685631|NCT06294431|PLACEBO_COMPARATOR|Placebo Control 5|Clarity Product Form 5 - control
62685632|NCT06294431|EXPERIMENTAL|Active Product 5.1|Clarity Product Form 5 - active product 1
62685633|NCT06294431|EXPERIMENTAL|Active Product 5.2|Clarity Product Form 5 - active product 2
62685634|NCT06294431|PLACEBO_COMPARATOR|Placebo Control 6|Clarity Product Form 6 - control
61924271|NCT05574166|EXPERIMENTAL|SP-8356 powder|Part1 will consist of escalating single doses in five sequential cohorts. Each dose level cohort will consist of 8 subjects: 6 subjects will receive SP-8356 and 2 subjects will receive placebo in fasted state according to the randomization schedule. Subjects in Cohort 3 will receive a single dose of SP-8356 or placebo in the fasted then fed state on separate dosing occasions.
62315836|NCT05757999|PLACEBO_COMPARATOR|Saline Placebo|an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min. will be administered before induction of anesthesia.
62315837|NCT04664660||Patients with previous histologic diagnosis of endometriosis|
62685635|NCT06294431|EXPERIMENTAL|Active Product 6.1|Clarity Product Form 6 - active product 1
62685636|NCT02471677|ACTIVE_COMPARATOR|Puregon|Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
62685637|NCT02471677|EXPERIMENTAL|Elonva|Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
62315838|NCT04664660||Patient without endometriosis|
62315839|NCT02665442|EXPERIMENTAL|Stylet|This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
62685638|NCT03725319||Epinephrin injection|Diluted Epinephrin (1:100) in small amounts from 1 to 5 ml is injected into apex of the papilla to stop post sphincterotomy-bleeding
62685639|NCT03725319||Plastic stent insertion|A plastic stent (diameter: 8-11,5F and length of 50 -100mm) is inserted into the common bile duct to stop post sphincterotomy-bleeding
62685640|NCT03275831|ACTIVE_COMPARATOR|Intrasite Gel|Intrasite Gel is an effective method for hydrating dry necrotic and sloughy wounds. It is an amorphous gel that contains 85% water, and gently increases the moisture level within the wound, encouraging moist wound healing through autolytic debridement.
62685641|NCT03275831|EXPERIMENTAL|PluroGel Burn and Wound Dressing|PluroGel contains a surfactant-based cleanser to assist wound debridement and cleansing
62685642|NCT05422157||Control|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
62685643|NCT05422157||Hemophilia|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
62685644|NCT05422157||FV Leiden|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
62685645|NCT05422157||Cirrhosis|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
61924272|NCT05574166|PLACEBO_COMPARATOR|Placebo|Part1 will consist of escalating single doses in five sequential cohorts. Each dose level cohort will consist of 8 subjects: 6 subjects will receive SP-8356 and 2 subjects will receive placebo in fasted state according to the randomization schedule. Subjects in Cohort 3 will receive a single dose of SP-8356 or placebo in the fasted then fed state on separate dosing occasions.
61924273|NCT05547022||Critical Limb ischemia patients with tissue loss|CLI patients with minor and major tissue loss who had endovascular revascularisation
62125593|NCT03195608|EXPERIMENTAL|Intervention|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
62685646|NCT05422157||Anticoagulation|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
61924274|NCT03931954||Study population|Patients completing the inclusión criteria
61924275|NCT04424524|OTHER|Direct-to-pharmacy oral PrEP refill visits|Intervention
62315840|NCT02665442|NO_INTERVENTION|Non-Stylet|This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
62315841|NCT03400670|ACTIVE_COMPARATOR|Ventilator NCPAP|neonatal ventilator (SLE; Specialised Laboratory Equipment, UK) PEEP: 5 cmH2O
62315842|NCT03400670|ACTIVE_COMPARATOR|Infant Flow-driver NCPAP|infant flow-driver device (Infant Flow System, Viasys Corp., USA) PEEP:5-8 cmH2O, This group receive variable flow
61924276|NCT04424524|NO_INTERVENTION|Usual care|Control
61924277|NCT06331676|EXPERIMENTAL|Endometriosis|Women with endometriosis who have an indication for gynaecological surgery
61924278|NCT06331676|ACTIVE_COMPARATOR|Control|Women with no endometrial pathology who have an indication for gynaecological surgery
62685647|NCT02094885|EXPERIMENTAL|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
62685648|NCT02094885|OTHER|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
62685649|NCT00532415|EXPERIMENTAL|Triamcinolone|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
62685650|NCT03288259|EXPERIMENTAL|Obese patients|Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.
62685651|NCT05223829|EXPERIMENTAL|Brexanaolone|In this single-arm study, participants will be administered brexanolone as a continuous IV infusion over 20 hours (titrated up to 90mcg/kg/hour).
62685652|NCT04535362|ACTIVE_COMPARATOR|menthol cigarettes|Will smoke only menthol cigarettes for two weeks
62685653|NCT04535362|ACTIVE_COMPARATOR|non menthol cigarettess|Will only smoke non menthol cigarettes for two weeks
62685654|NCT06673797|EXPERIMENTAL|Group A:The first intervention group would participate in Swiss ball exercises along with stretching|"Group A: The first intervention group would participate in Swiss ball exercises along with stretching as baseline treatment. The exercises would be performed 3 times per week for four weeks. (12)~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times. (11)~   1. Calf stretching~  2. Hamstring stretches~  3. Quad stretchings~2. 2. Swiss ball exercises~   1. Sitting on the Swiss ball with the trunk straight, arms by the sides, and eyes opened progressed towards eyes closed for 10 seconds, then rest~  2. Sitting on the Swiss ball with trunk straight and arm by the sides.~  3. Standing with gym ball in front.~  4. One leg weight bearing on a gym ball with the therapist behind the patient, gripping the patient's pelvis to provide support"
62685655|NCT06673797|EXPERIMENTAL|Group B: The second intervention group would participate in Frenkel Exercises along with stretching.|"1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times. (11)~   1. Calf stretching~  2. Hamstring stretches~  3. Quads stretching~2. Frenkel's lower limb exercises are the exercises listed below. The time of each session was set to be 10 minutes in the first week and then raised by 5 minutes every week. The patients were given 5 minutes to relax after 10 minutes of practice.~   a. Supine lying: i. with the head lifted; Hip abduction and adduction ii. with the head lifted, and one hip and knee extended iii. with the head lifted; and extending one leg to position the heel on the designated spot b. While sitting: i. stretch one leg to the side, bringing the heel to a spot where a mark has been made on the floor.~   ii. Stride sitting; Stand up from a seated position, then return to a seated position.~   c. Stride standing: i. weight transfer from foot to foot. ii. stepping sideways with feet on floor markings. iii. turn around. iv. walking and turning to avoid obstacles."
62685656|NCT01013870|EXPERIMENTAL|MTBI subjects randomized to drug|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the treatment arm of the phase II drug trial of atorvastatin. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for seven days and started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving a placebo.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
62685657|NCT01013870|PLACEBO_COMPARATOR|MTBI subjects randomized to placebo|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the placebo arm of the phase II drug trial of atorvastatin. These subjects will receive a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
62125594|NCT03195608|ACTIVE_COMPARATOR|Control|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, participants will drive the scenario and receive feedback from a trained evaluator regarding their live performance. No lane change assistance system will be utilized. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world.
62685658|NCT06674759|EXPERIMENTAL|Treatment of Tongren Dahuoluo Pills|
62125595|NCT05458817|EXPERIMENTAL|1. Digital diary|75 participants in the group
62125596|NCT05458817|ACTIVE_COMPARATOR|2. Paper diary|75 participants in the group
62125597|NCT05458817|EXPERIMENTAL|3. Digital: diary and headache nurse|75 participants in the group
62125598|NCT05458817|ACTIVE_COMPARATOR|4. Paper diary and conventional headache nurse|75 participants in the group
62125599|NCT05458817|EXPERIMENTAL|5. Digital: diary, headache nurse and clinal psychologist|75 participants in the group
62125600|NCT05458817|ACTIVE_COMPARATOR|6. Paper diary, conventional headache nurse and conventional clinical psychologist|75 participants in the group
62125601|NCT05458817|EXPERIMENTAL|7. Digital: diary, headache nurse, clinal psychologist and physiotherapist|75 participants in the group
62125602|NCT05458817|ACTIVE_COMPARATOR|8. Paper diary, conventional: headache nurse, clinal psychologist and physiotherapist|75 participants in the group
62125603|NCT05517564|EXPERIMENTAL|A (GM-60106)|Drug: GM-60106 Dosage: Part A: 2.5, 5, 10, 20, 40, 60, or 100 mg, Part B: 5, 10, 20 mg, Part C: 10, 20 mg Dosage Form: Bovine-gelatin capsules Route of Administration: Oral
62125604|NCT05517564|EXPERIMENTAL|B (Placebo)|Dosage Form: Bovine-gelatin capsules Route of Administration: Oral Matching placebo has an identical formulation to the GM-60106 drug product, prepared without the active pharmaceutical ingredient
62125605|NCT04901936|EXPERIMENTAL|Pegcetacoplan|
62125606|NCT04530747|EXPERIMENTAL|Metformin + PAP|"Subjects randomized to this arm will be orally given 2000 mg metformin daily. Metformin dosage will be slowly increased to improve tolerance.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
62125607|NCT04530747|PLACEBO_COMPARATOR|Placebo oral capsule + PAP|Subjects randomized to this arm will receive placebo matching study drug. Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
62125608|NCT05633719||Pediatric solid cancer|
62125609|NCT05221281|EXPERIMENTAL|Intervention: Multimodal intervention consisting of four core components.|"Core Component 1: Individualized Assessment~Core Component 2: Transition Facilitation with a Navigator~Core Component 3: Participant Skills-building~Core Component 4: Structured Educational eLearning Curriculum"
62125610|NCT05221281|OTHER|Control: Standard of care|Routine Care
62125611|NCT02662894|EXPERIMENTAL|Valsartan 160mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.
62125612|NCT02662894|EXPERIMENTAL|Valsartan 320mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.
62125613|NCT02662894|ACTIVE_COMPARATOR|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
62685659|NCT06674759|PLACEBO_COMPARATOR|Treatment of Tongren-Dahuoluo Bolus Placebo|
62685660|NCT03706066||PanOptix|Cataract surgery with implantation of Acrysof IQ PanOptix IOL
62125614|NCT02662894|ACTIVE_COMPARATOR|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
62125615|NCT01900834||All participants|
62125616|NCT02318134|EXPERIMENTAL|FMT group|In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.
62125617|NCT02318134|PLACEBO_COMPARATOR|Control group|In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.
62125618|NCT00766558||1 Disclosure|Traumatic writing prompts provided. Participant is assigned a potential stress-producing topic for written disclosure.
62125619|NCT00766558||2 control|Received nontraumatic writing prompts. Participant assigned a non-stressful writing condition
62125620|NCT00980473|ACTIVE_COMPARATOR|Iridoplasty|
62125621|NCT00980473|ACTIVE_COMPARATOR|Control (Medication)|
62125622|NCT05177601|ACTIVE_COMPARATOR|TMS+DCS|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
62125623|NCT05177601|ACTIVE_COMPARATOR|TMS+Placebo|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
62315843|NCT01422304|EXPERIMENTAL|Sugammadex|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive sugammadex and placebo to neostigmine, and participants assigned to planned spontaneous recovery will receive sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
62315844|NCT01422304|EXPERIMENTAL|Usual Care|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive neostigmine and placebo to sugammadex, and participants assigned to planned spontaneous recovery will receive placebo to sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
62315845|NCT05930925|EXPERIMENTAL|[phenyl-14C]ARV-471|\[phenyl-14C\]ARV-471 is administered as a single dose
62315846|NCT05930925|EXPERIMENTAL|[oxoisoindolin-14C]ARV-471|\[oxoisoindolin-14C\]ARV-471 is administered as a single dose
62315847|NCT00317941|EXPERIMENTAL|IFNB-1b 250 mcg (Betaseron) via Betaject|Interferon beta 1b (\[IFNB-1b\] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject
62315848|NCT00317941|EXPERIMENTAL|IFNB-1b 250 mcg (Betaseron) via Betaject light|Interferon beta 1b (\[IFNB-1b\] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject Light
62685661|NCT05645887|EXPERIMENTAL|Human Albumim (20%, 300mL, 60gr) in 180 min IV|Further doses of albumin (60g/l) will be administered daily from day 0 to day 7 in patients with serum albumin concentrations \<35 g/L.
62685662|NCT05645887|PLACEBO_COMPARATOR|Saline solution 0,9% (500mL) in 180 min IV|Saline solution will be given from day 0 to day 7.
62685663|NCT05951179|EXPERIMENTAL|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
62685664|NCT05596591|EXPERIMENTAL|Intervention|Participants will receive four sessions over four consecutive weeks (one per week) of focused extracorporeal shockwave therapy.
62685665|NCT05596591|NO_INTERVENTION|Control|Participants will receive the conventional treatment for bone marrow lesions, which includes avoidance of weight bearing and anti-inflammatory medications.
62685666|NCT04477837||direct oral anticoagulant (DOAC) No.1|Apixaban 5mg, oral, twice daily for at least four months
62685667|NCT04477837||direct oral anticoagulant (DOAC) No.2|Rivaroxaban 20mg, oral, once daily for at least four months
61924279|NCT01879527|ACTIVE_COMPARATOR|Amiloride hydrochlorothiazide|5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid. Trade name of the agent: Amilostad HCT 5/50mg tablets Manufacturer: Stada initial dose: 1 x 5/50mg once daily target dose: 2 x 5/50mg once daily Patients will be provided with capsules (size 00) containing one tablet of study medication and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication
62315849|NCT00317941|ACTIVE_COMPARATOR|IFNB-1a 44 mcg (Rebif) via Rebiject II|Interferon beta-1a (\[IFNB-1a\] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II
62315850|NCT00893594|PLACEBO_COMPARATOR|1|Placebo taken at onset of aura associated with migraine.
62685668|NCT04477837||direct oral anticoagulant (DOAC) No.3|Edoxaban 60mg, oral, once daily for at least four months
62315851|NCT00893594|ACTIVE_COMPARATOR|2|Sumatriptan with naprosyn taken at onset of aura associated with migraine.
62339654|NCT05175937||APP group|Patient wearing ICD with Bluetooth® technology and smartphone APP based remote monitoring
62339655|NCT05175937||Bedside transmitter group|Patient wearing ICD monitored remotely through a bedside transmitter
62685669|NCT04477837||direct oral anticoagulant (DOAC) No.4|Dabigatran 150mg, oral, twice daily for at least four months
62685670|NCT01730573|ACTIVE_COMPARATOR|Interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
62685671|NCT01730573|ACTIVE_COMPARATOR|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
62685672|NCT06391489|OTHER|PACS Participant With Cognitive and Memory Dysfunction|"Participants will receive the HOBSCOTCH-PACS intervention consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam or by phone)~1 educational session (on webcam) 6 HOBSCOTCH intervention sessions (webcam or phone)~1 wrap-up session (webcam or phone)"
62125624|NCT05177601|SHAM_COMPARATOR|shamTMS+DCS|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
62125625|NCT05177601|PLACEBO_COMPARATOR|shamTMS+placebo|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
62125626|NCT04169698|NO_INTERVENTION|Control group|Participants will receive daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
62125627|NCT04169698|EXPERIMENTAL|Denosumab group|Participants will receive a single 60 mg subcutaneous dose of denosumab (Prolia) every 6 months for 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
62315852|NCT02019381|OTHER|Endocrine Society UL Dosage Vitamin D|Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
62339656|NCT05691634|EXPERIMENTAL|Patient with tatoo|
62339657|NCT06516939|EXPERIMENTAL|The Application of Bovine Basic Fibroblast Growth Factor Gel|
61924280|NCT01879527|PLACEBO_COMPARATOR|Sugar pill|Patients will be provided with capsules (size 00) containing sugar and instructed to take these capsules once daily in the morning together with breakfast.
62125628|NCT04169698|EXPERIMENTAL|Alendronate group|Participants will receive an oral alendronate at a dose of 70 mg once every week for up to 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
62125629|NCT04026594|EXPERIMENTAL|Mindfulness Based Stress Reduction (MBSR)|"306 participants will be randomized in the MBSR program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a MBSR recall session will be offered six month after intervention.~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability.."
62478934|NCT06551090||CAMERA|Adult subjects with epilepsy will undergo noninvasive video Electroencephalography (EEG) and intracranial electrodes sampling the amygdala and hippocampus (unilateral or bilateral). A subset of subjects (n=10) will use the Context-Aware Multimodal Ecological Research and Assessment (CAMERA) platform for 2 weeks after discharge with a subset of modalities: physiologic wristband, smartphone phenotyping, ecological momentary assessment (EMA) surveys, and memory task. At unpredictable intervals, CAMERA will interrupt subjects with: (a) an audible alarm to elicit an acoustic startle response; (b) a self-reported anxiety state scale; and (c) a visuospatial memory task with threat interference. For example, participants will fill out a brief survey and play a video game several times each day and wear a wristband with sensors.
61924281|NCT03508531|ACTIVE_COMPARATOR|ESP Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
61924282|NCT03508531|ACTIVE_COMPARATOR|OSTAP Block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
61924283|NCT03508531|SHAM_COMPARATOR|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed. No block will be performed in this group.
62478935|NCT06558708|EXPERIMENTAL|GZR101 Injection|Participants will receive once daily GZR101 Injection with or without pre-dinner meal-time insulin, s.c, treat-to-target dose
61924284|NCT04756180|EXPERIMENTAL|Omacor|Omacor 2gm/day for first 4 week followed by 4gms/day for 8 weeks
61924285|NCT04756180|PLACEBO_COMPARATOR|Placebo|Omacor Placebo 2gm/day for first 4 week followed by 4gms/day for 8 weeks
61924286|NCT00901927|EXPERIMENTAL|Bendamustine + Mitoxantrone + Rituximab|Bendamustine starting dose 90 mg/m\^2 intravenously (IV) over 30-60 minutes on Days 1 and 2 of each 8-day cycle. Mitoxantrone 10 mg/m\^2 IV over 15 minutes on Day 2 of each cycle. Rituximab 375 mg/m\^2 IV over several hours on Day 1 of each cycle.
61924287|NCT05817071|ACTIVE_COMPARATOR|Arthroscopic massive Rotator Cuff Tears Repair without using long head of biceps tendon augmentation|Arthroscopic repair either complete or partial with medialization or not by anchors without using proximal part of long head of biceps tendon) ( single row or double row )(partial or complete anatomical)
62315853|NCT02019381|OTHER|Institute of Medicine Dosage Vitamin D|Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
62478936|NCT06558708|EXPERIMENTAL|GZR33-70 Injection|Participants will receive once daily GZR33-70 Injection with or without pre-dinner meal-time insulin, s.c., treat-to-target dose
62478937|NCT00781339|EXPERIMENTAL|Active|
62478938|NCT03221543|EXPERIMENTAL|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
62478939|NCT03631628|EXPERIMENTAL|MT+ Bilateral TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program: 30 minutes of MT+bilateral TENS and 1 hour conventional training of standardized upper limb training.
62315854|NCT02666911|EXPERIMENTAL|4D Ultrasound|4D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury. The same patients will be imaged with both 2D and 4D transducers.
62315855|NCT02666911|ACTIVE_COMPARATOR|2D ultrasound|2D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury.The same patients will be imaged with both 2D and 4D transducers.
62315856|NCT01025778|EXPERIMENTAL|Remission induction and haplo-SCT|Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.
62478940|NCT03631628|PLACEBO_COMPARATOR|sham-MT+ Bilateral TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program: 30 minutes of sham-MT+bilateral TENS and 1 hour conventional training of standardized upper limb training.
62478941|NCT00308152|NO_INTERVENTION|Control|Observation only
62478942|NCT00308152|ACTIVE_COMPARATOR|Active|Infusion of 1 liter normal saline before sedated colonoscopy
62478943|NCT02070458|EXPERIMENTAL|Treatment (ixazomib, MEC)|Patients receive ixazomib PO on days 1, 4, 8, and 11; they receive mitoxantrone hydrochloride IV, etoposide IV over 1 hour; the receive intermediate-dose cytarabine IV over 6 hours on days 1-6.
62478944|NCT05349513|EXPERIMENTAL|interventionnal arm|Administration of the experimental questionnaire ESSME in patient's environment.
62125630|NCT04026594|ACTIVE_COMPARATOR|Progressive Muscle Relaxation Training (PMRT)|"306 participants will be randomized in a relaxation program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a relaxation recall session will be offered six month after intervention.~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability"
62125631|NCT06233500|ACTIVE_COMPARATOR|Group A: eyes will be treated without ILM flap|Group A: Only wide ILM peeling up to the arcades well be done
62125632|NCT06233500|ACTIVE_COMPARATOR|Group B : eyes will be treated by ILM flap|Group B: ILM peeling with flap well be done
62125633|NCT06154668||Cohort #A|monotherapy anti-PD1 first line
62125634|NCT06154668||Cohort #B|monotherapy anti-PD1 second line
62125635|NCT06154668||Cohort #C|monotherapy anti-PD1 adjuvant
62125636|NCT06154668||Cohort #D|combotherapy anti-PD1/CTLA-4 first line
62125637|NCT06154668||Cohort #E|untreated stage I and II melanoma patient
62315857|NCT02384369|EXPERIMENTAL|SNC-102 sustained release tablet|SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
62315858|NCT02384369|PLACEBO_COMPARATOR|Placebo|Placebo tablet for oral administration, BID for 8 weeks
62315859|NCT06274346|ACTIVE_COMPARATOR|Multiangular Isometric exercise group:|Each patient was allowed to warm up for 10 minutes on the bicycle ergometer before each isometric exercise session. For this part of the study we position the patient on isokinetic device with the hip joint flexed at 90˚ the back supported with a backrest and the pelvis stabilized with a strap. The distal of the thigh was rested on a lifted support in the front of the seat and was wrapped with a strap. The center of rotation of the dynamometer was placed opposite the center of the femur lateral epicondyle. The lever arm of the dynamometer was set so that the load cell pad was comfortable against the lower part of the leg close to the lateral malleolus.
62315860|NCT06274346|EXPERIMENTAL|Retrograde walking group:|Each patient was allowed to warm up for 10 minutes on the bicycle ergometer before each retrograde walking session. The patients were instructed to walk backwards for 10 min on a flat surface for a distance of 30 m at a comfortable speed supervised by the physiotherapist. Patients were required to walk backwards without looking behind. Safety measures were taken to ensure patients' well-being during retro walking. The physiotherapist stood beside the patients, gave them moral support, and guided them through the walking path till the patients are confident to walk on their own. The patient is also encouraged to increase their speed throughout the 4 weeks of rehabilitation.
62315861|NCT06274346|OTHER|Pulsed short wave diathermy:|Patient is in supine lying, contra planer (transverse) method was used. The electrodes were placed over opposite aspects of the part i.e. knee. Timing: was applied for 20 minutes, 3 days/ week for duration of 4 weeks. After pulsed SWD, both groups were given static quadriceps exercise, dynamic quadriceps exercise, straight leg raise, prone knee bending, side lying hip abduction, prone hip extension for 10 repetitions with 5 seconds hold followed by 2 seconds rest for each exercise for a period of 3 days per week for duration of 4 weeks.
62339658|NCT06516939|PLACEBO_COMPARATOR|Bovine Basic Gel|
62339659|NCT03148431|EXPERIMENTAL|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
62339660|NCT03148431|PLACEBO_COMPARATOR|Placebo|Placebo administered IV once in healthy participants
62125638|NCT03554460|EXPERIMENTAL|dual-limb NIV|A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
62125639|NCT03588715|EXPERIMENTAL|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
62478945|NCT02361905|EXPERIMENTAL|Ulipristal acetate|women will be treated with an oral dose of ulipristal acetate 5 mg/day for 3 months
62478946|NCT02361905|ACTIVE_COMPARATOR|Leuprolile acetate|Women will be treated with an intramuscular (IM) injection of leuprolide acetate 11.25 mg in the luteal phase
62125640|NCT03588715|EXPERIMENTAL|bNAb only|bNAb (3BNC117 + 10-10-74) only
62125641|NCT05181592|EXPERIMENTAL|Luspatercept (single arm)|open-label, single-arm
62125642|NCT05183490|EXPERIMENTAL|Group A: Allogenic Stem Cell Transplant Recipient (SCT)|"Dose levels selected for Group A are based on previous experience with VST cells in HCT recipients and are lower than in Group B (SOT recipients), as donor-derived R-MVST cells are more likely to persist in recipients of HCT from the same donors. Thus, there is theoretically a higher risk for development of GVHD in this subset of patients. Each group will undergo independent dose escalation.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
62315862|NCT02734992|OTHER|Acceptance and Commitment therapy + MTAU|"The Acceptance and Commitment therapy + MTAU (active treatment) consists of an unpublished manual developed for the purposes of the Algea project (Vasiliou \& Karekla, 2015). The protocol specifies the following goals: (a) increase individuals' willingness to face uncomfortable internal experiences; b) promoting meaningful activities even in the present of head pain; (c) emphasizing acceptance as an alternative to avoidance in coping with headache; (d) clarifying individuals' values in important life domains; e) enhancing present moment-to-moment awareness.~Participants will be asked to remain stable on their pharmacotherapy during this study. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions.~Participants will complete questionnaires at pre-, post-treatment, and at 3-month follow-up. The WL group will enter treatment at the 3-month follow-up of the ACT-group."
62315863|NCT02734992|OTHER|MTAU/ Wait-list Control Gr|"The MTAU/ Wait-list Control Gr will follow their usual treatments, including any new treatments their GPs or Neurologists might prescribe (mostly prophylactic and abortive medication), during the study at the time. Following the completion of the active group follow up 3months, participants allocated to the control group will receive the active treatment. Participants will complete the same questionnaires at three different time points: pre-, post-treatment, and at 3-month follow-up.~Participants will be asked to remain stable on their pharmacotherapy during this study and inform the researchers of any changes. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions. Excluded participants will be referred to appropriate services."
62315864|NCT03787004|EXPERIMENTAL|Part 1 Cohort 1 (Single Dose)|Single 100 mg oral dose of CNTX-6970 (film-coated tablet or enteric-coated tablet)
62315865|NCT03787004|EXPERIMENTAL|Part 1 Cohort 2 (Single Dose)|Single 100 mg oral dose of CNTX-6970 film-coated tablet
62315866|NCT03787004|EXPERIMENTAL|Part 2 (Multiple Ascending Dose)|100 mg, 300 mg, and 600 mg CNTX-6970 oral tablet
62315867|NCT03787004|PLACEBO_COMPARATOR|Part 2 Placebo|Placebo oral tablet
62315868|NCT04056130|EXPERIMENTAL|Cohort SAD1|9 Subjects for SAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
62315869|NCT04056130|EXPERIMENTAL|Cohort SAD2|9 Subjects for SAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
62315870|NCT04056130|EXPERIMENTAL|Cohort MAD1|9 Subjects for MAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
62315871|NCT04056130|EXPERIMENTAL|Cohort MAD2|9 Subjects for MAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
62315872|NCT03982459|EXPERIMENTAL|Decision support tool|Patients in this single-arm study all receive training in use of a decision support tool by a trained coordinator.
62315873|NCT05603286|EXPERIMENTAL|Home-monitoring arm|After inclusion, participants will skip one regular 3-monthly control visit and instead complete an online EQ-5D-Y-5L and JAMAR questionnaire. 5-7 months after inclusion, participants will be followed-up at the hospital and complete a questionnaire about their experiences with home-monitoring.
62315874|NCT05198986||ECMO Prone Position|After baseline assessment in supine position, patients will be positioned in prone position to assess modification of lung mechanics, aeration and hemodynamics
62315875|NCT01795469|EXPERIMENTAL|Abdominal and LE compression|Zoex compression garment during tilt testing (all straps)
61924288|NCT05817071|EXPERIMENTAL|Arthroscopic Massive Rotator Cuff Tears Repair With biceps Augmentation|• Single or double row repair technique by Rotator Cuff(RC) anchors. Biceps augmentation will be done via release and mobilize the Long Head of Biceps Tendon from bicipital groove. then the proximal part of long head of biceps tendon will be lateralized towards greater tuberosity crossing the gap by passing 1 limb of the RC anchor using suture passer (scorpion or lasso loop) and the other limb of the same anchor was passed through torn cuff. a horizontal limb of distal part biceps tendon was interpositioned between the Rotator Cuff Tears And humeral head, aiding in biological healing and strengthening poor quality rotator cuff tendons
61924289|NCT06242483|NO_INTERVENTION|Usual care group|Patients randomized to usual care will receive standard care, in which hypertension treatment will be provided according to local practices and will not have access to the Elfie solution. Additionally, they will be requested not to access/use other mobile phone apps or participate in any kind of digital health intervention related to hypertension treatment during the trial.
61924290|NCT06242483|EXPERIMENTAL|Digital health intervention group (Elfie solution)|Patients randomized to digital health intervention group will receive standard care plus the Elfie solution. Participants randomized to the Elfie solution will be instructed to download the Elfie app and will receive training on how to register in the app and on how to use all the app features. Participants will be then instructed to use the app according to the monitoring plan created by the app for the following 6 months.
61924291|NCT02519387|EXPERIMENTAL|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
62737850|NCT01483235|EXPERIMENTAL|Reduced cardiac rehabilitation (rCRP)|The rCRP is the intervention group, compared to the standard cardiac rehabilitation program group (sCRP). The rCRP will have the core elements of the sCRP, that is, in-hospital exercise sessions, dietary counseling, educational sessions, follow-up with the cardiologist, dietician and exercise specialist. The only difference will be the number of in-hospital exercise sessions (10 sessions for the rCRP v/s 32 sessions for the sCRP). Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
62125643|NCT05183490|EXPERIMENTAL|Group B: Solid organ transplant recipients (SOT)|"In SOT recipients, the study will use higher doses of R-MVST cells, as the infused anti-viral T cells are less likely to persist long-term and cause GVHD, based on the safety profile of PyVST cells used for therapy of PML in non-HCT subjects.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
62315876|NCT01795469|EXPERIMENTAL|abdominal compression only|Zoex compression garment use during tilt table testing (straps 4 and 5 fastened around thighs and abdomen)
62315877|NCT01795469|EXPERIMENTAL|Lower extremity compression only|Zoex compression garment use during tilt table testing (straps 1-4, lower extremity and thighs, fastened)
62315878|NCT02881307|EXPERIMENTAL|Dietary Supplement|
62315879|NCT02881307|ACTIVE_COMPARATOR|Dietary Counseling|
62478947|NCT05022381|OTHER|Preoperative and Postoperative Pain Level|The preoperative pain level, hip function and quality of life of patients who underwent radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerve in chronic hip pain will be compared with the postoperative pain level, hip function and quality of life of these patients.
62125644|NCT02685189||0.75 mg/kg Previous exposure to stannsoporfin|Previous exposure 0.75 mg/kg
62125645|NCT02685189||1.5 mg/kg Previous exposure to stannsoporfin|Previous exposure 1.5 mg/kg
62125646|NCT01362153|EXPERIMENTAL|001|Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
62125647|NCT01362153|EXPERIMENTAL|002|Golimumab SC injection of 100 mg every 4 weeks through Week 20
62315880|NCT06520072|EXPERIMENTAL|Intervention Arm: Nutrition and wellness app|The parents/guardians in this study arm will use the Children Eating Well (CHEW) mobile app focused on child and family nutrition and wellness for the first 8 weeks of the study. This app is designed to help parents/guardians of preschool-aged children to improve nutrition, physical activity, sleep, feeding children at mealtimes, and related wellness topics.
62315881|NCT06520072|ACTIVE_COMPARATOR|Attention Control Arm: Reading app|The parents/guardians this study arm will use the Beanstack mobile app (or the Bookroo app, as an alternative) focused on parents reading to their children for the first 8 weeks of the study. This app may help parents/guardians to read more to their preschool children (and other children), which is good for child learning and development.
62478948|NCT05954650||Patients in a Minimally Conscious State|"Patients diagnosed as in a Minimally Conscious State Plus and Minus"
62478949|NCT06742307|ACTIVE_COMPARATOR|Faricimab treatment arm|A planned quarterly (every 12-16 weeks) aflibercept injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. The intervention faricimab is injected into the eyeball with a 30G needle.
62478950|NCT02817867|ACTIVE_COMPARATOR|tDCS|Patients who will be treated with Transcranial direct-current stimulation (tDCS) in the ipsilesional motor cortex.
62339661|NCT04949178||Critically ill cirrhotics with septic shock and AKI undergoing CRRT|Consecutive critically ill cirrhotics with septic shock and AKI who give written informed consent will be included in this prospective study
61924292|NCT00434343|PLACEBO_COMPARATOR|Global Therapeutic Massage (GTM)|Weekly massages consisting of full body Western massage for 1hour.
62478951|NCT02817867|ACTIVE_COMPARATOR|rTMS|Patients who will be treated with Magnetic brain stimulation (rTMS) in the contralesional motor cortex.
62478952|NCT02817867|EXPERIMENTAL|tDCS + rTMS|Patients who will be treated with the association between Transcranial direct-current stimulation (tDCS) and magnetic brain stimulation (rTMS), in the ipsilesional and contralesional motor cortex, respectively.
62478953|NCT00627016|EXPERIMENTAL|Dexlansoprazole 30 mg QD|
62685673|NCT00088881|EXPERIMENTAL|Treatment|"R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients with progressive disease go off study.~Zevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Radiation therapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy."
62685674|NCT01501500|ACTIVE_COMPARATOR|botulinum toxin type A. HV angle|intramuscular injection of BTA into target muscle
62685675|NCT01501500|PLACEBO_COMPARATOR|Normal saline, HV angle|intramuscular injection of normal saline into target muscle
62685676|NCT04555239|ACTIVE_COMPARATOR|Standard of Care, Upper Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
62685677|NCT04555239|ACTIVE_COMPARATOR|Standard of Care, Lower Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
62125648|NCT04487600|EXPERIMENTAL|Active Voiding Trial|At the completion of surgery, a Foley catheter was left in place. When the patient was determined to be ambulatory by the recovery room nurse, the bladder was backfilled with 300cc of sterile normal saline. Voiding 200cc or (2/3) of the backfill amount was considered passing.
62339662|NCT01682499|EXPERIMENTAL|Calcium and Magnesium Infusion|
62339663|NCT00610376|EXPERIMENTAL|1A|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home intervention component.
62685678|NCT04555239|EXPERIMENTAL|FDM, Upper Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
61924293|NCT00434343|ACTIVE_COMPARATOR|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
61924294|NCT01642654|ACTIVE_COMPARATOR|Control|
61924295|NCT01642654|EXPERIMENTAL|Treatment|
61924296|NCT05166889|EXPERIMENTAL|Tozorakimab Dose 1|Dosing subcutaneously tozorakimab Dose 1 and placebo
62339664|NCT00610376|ACTIVE_COMPARATOR|2|This group did not receive any special treatment during the study, but did receive the intervention at the close of the study
62339665|NCT00610376|EXPERIMENTAL|1B|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home control component.
62339666|NCT05525338|EXPERIMENTAL|TDM-guided dosing arm|
62685679|NCT04555239|EXPERIMENTAL|FDM, Lower Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
62315882|NCT06186336||DL-Based Vulnerable Plaque Detection and Assessment Tool|"Enrolled subjects will receive a clinically indicated CCTA and ICA with OCT within 10 days. At least two qualified CCTA radiologists will independently review and annotate the coronary plaques in the CCTA using their local post-processing tools. At least two trained OCT readers will review and annotate the coronary plaques in the ICA/OCT using their local post-processing tools.~The original de-identified CCTA data will be inputted into the Vulnerable Plaque Detection and Assessment Tool. The tool will perform the automatic identification of the plaque location and characteristics. These results will be compared to assess the algorithm's performance."
62315883|NCT05044169|EXPERIMENTAL|Broncho-Vaxom|Intervention
62315884|NCT02110108|EXPERIMENTAL|Revlite Laser System- Single Wavelength|Revlite Laser System- 1064nm wavelength will be used on half of the face.
62315885|NCT02110108|EXPERIMENTAL|Revlite Laser System- Dual Wavelength|Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.
62315886|NCT02018510|EXPERIMENTAL|Group 1A|"HIV-uninfected individuals~1 mg/kg, single dose IV administration of 3BNC117"
62315887|NCT02018510|EXPERIMENTAL|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
62685680|NCT00833729|EXPERIMENTAL|etanercept|Single armed study
62685681|NCT04402814||Arm A (positive for COVID-19)|"One or two samples of your blood that were previously collected for routine care will be obtained from the hospital laboratory and will be tested for the antibodies against COVID-19 virus.~* First blood sample obtained: 7 to 12 days following onset of symptoms; and/or~* Second blood sample obtained: 12 to 40 days following the onset of symptoms."
61924297|NCT05166889|EXPERIMENTAL|Tozorakimab Dose 2|Dosing subcutaneously tozorakimab Dose 2
61924298|NCT05166889|PLACEBO_COMPARATOR|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
61924299|NCT00568685|ACTIVE_COMPARATOR|Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)|
62685682|NCT04402814||Arm B (negative for COVID-19)|One sample of blood that was collected for routine care at any point during hospitalization will be obtained from the hospital laboratory and will be tested for the antibodies.
62315888|NCT02018510|EXPERIMENTAL|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
62315889|NCT02018510|EXPERIMENTAL|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
62315890|NCT02018510|EXPERIMENTAL|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
62315891|NCT02018510|EXPERIMENTAL|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
62315892|NCT02018510|EXPERIMENTAL|Group 2A|"HIV-infected individuals on or off ART~1 mg/kg, single dose IV administration of 3BNC117"
62315893|NCT02018510|EXPERIMENTAL|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
62315894|NCT02018510|EXPERIMENTAL|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
61924300|NCT00568685|ACTIVE_COMPARATOR|Atomoxetine 0.5 mg/kg/day|
61924301|NCT00568685|ACTIVE_COMPARATOR|Atomoxetine 1.2 mg/kg/day|
61924302|NCT04005989|PLACEBO_COMPARATOR|PLACEBO GROUP|injection of saline solution
62315895|NCT02018510|EXPERIMENTAL|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
62315896|NCT02018510|EXPERIMENTAL|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
62315897|NCT02018510|EXPERIMENTAL|Group 3|HIV-infected individuals off ART, VL \< 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
62315898|NCT02018510|EXPERIMENTAL|Group 4|HIV-infected individuals on ART, VL \< 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
62685683|NCT06679088||students of Paderborn University|18 years to 25 years (adult)
62685684|NCT02303483|PLACEBO_COMPARATOR|Placebo|lime tablets
62315899|NCT02018510|EXPERIMENTAL|Group 5A|HIV-infected individuals on ART, VL \< 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
62315900|NCT02018510|EXPERIMENTAL|Group 5B|HIV-infected individuals on ART, VL \< 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
62315901|NCT00053846|EXPERIMENTAL|buspirone hydrochloride|buspirone hydrochloride
62315902|NCT00053846|PLACEBO_COMPARATOR|Placebo|Placebo
62685685|NCT02303483|EXPERIMENTAL|Nicotinamide riboside (NR, Vit B3)|NIAGEN (ChromaDex) 1 g x 2 orally per day
62315903|NCT01562015|EXPERIMENTAL|Ganetespib|Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
62315904|NCT01347697|EXPERIMENTAL|Porcine collagen implant (biological mesh)|Reconstruction with an acellular porcine dermal collagen implant (biological mesh).
62315905|NCT01347697|ACTIVE_COMPARATOR|Gluteus maximus flap|Reconstruction with a gluteus maximus myocutaneous flap.
62685686|NCT05978128|EXPERIMENTAL|Screening (electronic patient portal, patient navigation)|Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.
62685687|NCT02634697|EXPERIMENTAL|3RP Intervention Group|"AF Patients will undergo the 3RP intervention which will comprise of the following:~i. One-one-one session: each subject will spend an hour with a clinician to set specific goals for the intervention. They will also answer questionnaires.~ii. ECG monitoring: Enrolled subjects may be monitored with an ECG at some point after the time of consent up to the day of the one-on-one session, and again after completing the 8 weeks.~iii. Weeks 1 - 8: subjects will meet with the clinician/staff member as a group once a week for 1.5 hours each where they will be taught a variety of techniques to elicit the relaxation response as well as other cognitive skills.~At the end of the 4th (mid-point) and 8th (last) weekly session, subjects will answer questionnaires.~iv. 6 month follow up: 3 months after the final 3RP session to answer questionnaires.~v. Subjects will be asked to keep track of their AF episodes during the course of the study."
62685688|NCT02634697|ACTIVE_COMPARATOR|3RP Waitlist Control Group|The Control Group will wait for 6 months (from the time the Intervention group starts the 3RP intervention) and then will undergo the same study procedures as the intervention group - except for the 6 month follow up.
62125649|NCT04487600|NO_INTERVENTION|Passive Voiding Trial|At the completion of surgery, a Foley catheter was removed in the operating room. Study participants were allowed six hours to void spontaneously, with 200cc being considered adequate consistent with institution standard practice. At the completion of six hours, if spontaneous voiding has not occurred, a bladder scan was performed and additional time was allowed based on bladder volume with criteria previously established as institution standards based on published practices.
62315906|NCT06671574|NO_INTERVENTION|Control Group|This group will not receive intervention, but will receive information sessions on general health and well-being topics, such as sleep hygiene, healthy lifestyle habits and practical tips to improve rest, in order to control for the placebo effect. These information sessions will be held at the beginning of the study and will be supported by brochures and educational material.
62315907|NCT06671574|EXPERIMENTAL|Experimental Group|This group will participate in a structured program that combines the development of emotional intelligence with relaxation techniques. It will last 12 weeks, with sessions twice a week, each lasting approximately 60 minutes. The sessions will be led by a mental health professional. During the sessions, exercises will be worked on to recognize, understand and regulate emotions, allowing participants to develop skills to better manage stress and anxiety. In addition, relaxation techniques such as deep breathing, guided meditation and visualization will be practiced, which have been shown to be effective in reducing muscle tension, lowering cortisol levels and promoting restful sleep.
62315908|NCT06284421|EXPERIMENTAL|Durometer|This is a single-arm trial in which a Shore durometer will be used to measure the hardness of the uterus after placental delivery during cesarean section.
62315909|NCT04936139|EXPERIMENTAL|Art Therapy|Patients assigned to the intervention group will participate in 12 weekly group therapy workshop sessions.
62315910|NCT04936139|NO_INTERVENTION|Control group|"Patients assigned to the control group will receive the usual follow-up care of each center provided for the cancer patient and will not perform art therapy workshops.~They will be offered the opportunity to participate in the workshops once they have completed their participation in the study, putting them on a waiting list."
62125650|NCT00418496|EXPERIMENTAL|Aldekleukin Plus Dose Escalation Sorafenib|Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
62125651|NCT05781347|ACTIVE_COMPARATOR|Obese patients receiving Stretta|
62315911|NCT03869073|EXPERIMENTAL|Low Dose|This treatment arm will receive the highest dose of evolocumab currently marketed and approved: 420mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
62315912|NCT03869073|EXPERIMENTAL|High Dose|This treatment arm will receive double the highest dose of evolocumab currently marketed and approved: 840mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
62315913|NCT03869073|PLACEBO_COMPARATOR|Placebo|This treatment arm will receive saline solution. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
62478954|NCT00627016|PLACEBO_COMPARATOR|Placebo|
61924303|NCT04005989|ACTIVE_COMPARATOR|Low dose group|hASC injection (1x10e6 / kg body weight)
61924304|NCT04005989|ACTIVE_COMPARATOR|Intermediate Dose|injection of hASC (2x10e6 / kg of body weight)
62125652|NCT05781347|NO_INTERVENTION|Obese patients receiving Conservative therapy/PPI|
62125653|NCT05781347|ACTIVE_COMPARATOR|Non-obese patients receiving Stretta|
62125654|NCT05781347|NO_INTERVENTION|Non-obese patients receiving Conservative treatment/PPI|
62125655|NCT00183352||1|Women with bipolar disorder
62125656|NCT00183352||2|Women who are healthy controls
62125657|NCT04746131|EXPERIMENTAL|IMM0306|IMM0306 Dose escalation: 0.1mg/kg, 0.2mg/kg, 0.4mg/kg, 0.8mg/kg,1.2mg/kg and 1.6mg/kg through intravenous administration weekly up to 52 weeks.
62125658|NCT03203538|EXPERIMENTAL|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
62125659|NCT03203538|ACTIVE_COMPARATOR|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
62125660|NCT03203538|EXPERIMENTAL|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
62125661|NCT03203538|ACTIVE_COMPARATOR|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
62315914|NCT01771679|EXPERIMENTAL|Allogeneic Mesenchymal Bone Marrow Cells|1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)
62315915|NCT03510143|NO_INTERVENTION|Control|No use of Neoveil in the neck node dissection area
61924305|NCT04005989|ACTIVE_COMPARATOR|High dose group|injection of hASC (4x10e6 / kg body weight)
61924306|NCT03491189|ACTIVE_COMPARATOR|Lag screw fixation|Lag screw fixation
61924307|NCT03491189|ACTIVE_COMPARATOR|Helical Blade fixation|Helical Blade fixation
62125662|NCT03203538|EXPERIMENTAL|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
62125663|NCT03203538|ACTIVE_COMPARATOR|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
62125664|NCT06263673|EXPERIMENTAL|Sitagliptin Group|Subjects will receive sitagliptin for the approximately 4-week treatment period.
62125665|NCT06263673|EXPERIMENTAL|Dapagliflozin Group|Subjects will receive dapagliflozin for the approximately 4-week treatment period.
62125666|NCT06263673|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo for the approximately 4-week treatment period.
62125667|NCT01517815|EXPERIMENTAL|No overweight patient|Patient with weight less than or equal to 120kg
62125668|NCT01517815|EXPERIMENTAL|Overweight patients|Patient with weight more than 120kg
62125669|NCT03995992|ACTIVE_COMPARATOR|multi sport|During 10 days, each morning, from 9 am to 12 pm, participants had sporting activities: mountain walking, mountain biking, climbing, canyoning and collective orienteering running. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
62125670|NCT03995992|EXPERIMENTAL|diving|During 10 days, each morning, from 9 am to 12 pm, participants had diving activities. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
62125671|NCT00941655|EXPERIMENTAL|Surgery + HIPEC + Systemic Chemotherapy|"Surgery -gastric resection, metastasectomy, and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes. Leucovorin 20 mg/m\^2 IV and Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Irinotecan 165 mg/m\^2 IV over 90 minutes, Oxaliplatin 85 mg/m\^2 over 120 minutes, Leucovorin 200 mg/m\^2 IV 120 minutes, 5FU 3200 mg/m\^2 continuous IV infusion over 48 hours."
62125672|NCT00941655|EXPERIMENTAL|Systemic Chemotherapy Alone|Irinotecan 165 mg/m\^2 IV over 90 minutes, Oxaliplatin 85 mg/m\^2 over 120 minutes, Leucovorin 200 mg/m\^2 IV 120 minutes, 5FU 3200 mg/m\^2 continuous IV infusion over 48 hours.
62125673|NCT00521755|EXPERIMENTAL|A|
62125674|NCT01542229|EXPERIMENTAL|Arm 1: PE + TAU|Prolonged Exposure Therapy +Treatment As Usual
62125675|NCT01542229|ACTIVE_COMPARATOR|Arm 2: Usual Treatment|Treatment As Usual
62125676|NCT05001529|EXPERIMENTAL|Group A|Subject with severe asthma, treated with anti IL5R antibodies
62125677|NCT05001529|NO_INTERVENTION|Group B|Subject with severe asthma, treated with conventional therapy
62125678|NCT05434624|EXPERIMENTAL|Group M|Bronchoscopy group in which only midazolam will be used
62125679|NCT05434624|EXPERIMENTAL|Group P|Bronchoscopy group in which midazolam and propofol will be used
61924308|NCT00413166|EXPERIMENTAL|Induction ATRA + ATO + Idarubicin|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATRA 45 mg/m2 daily by mouth beginning day 1; ATO 0.15 mg/kg by vein daily beginning on day 1; Idarubicin 12 mg/m2 x 1 dose; Methylprednisolone 50 mg daily for 5 days starting on day 1."
61924309|NCT00413166|EXPERIMENTAL|Maintenance|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATO 0.15 mg/kg by vein over 2 hours Monday-Friday for 4 weeks, then a 4-week break. ATRA 45 mg/m2 by mouth every day for 2 weeks, followed by 2 additional weeks of no study drug. Continue ATRA until treatment with ATO complete."
62125680|NCT05528146|EXPERIMENTAL|A|In a single-blind crossover trial (male or female), these groups will receive 3.5 g/day or 7 g/day of psyllium for 4 weeks. The trial will stop 1 week after the first phase and post-test. The two groups will then swap doses for 4 weeks. Post-tests will be recorded upon completion of this Phase 2 trial. After completing the trial, determine the dose effect.
62315916|NCT03510143|EXPERIMENTAL|Neoveil|Use of Neoveil in the neck node dissection area
62315917|NCT01447173|EXPERIMENTAL|2000 IU vitamin D Daily|
62125681|NCT05528146|EXPERIMENTAL|B|In a single-blind crossover trial (male or female), these groups will receive 3.5 g/day or 7 g/day of psyllium for 4 weeks. The trial will stop 1 week after the first phase and post-test. The two groups will then swap doses for 4 weeks. Post-tests will be recorded upon completion of this Phase 2 trial. After completing the trial, determine the dose effect.
62125682|NCT00520546|EXPERIMENTAL|1|Patients with prostate carcinoma confirmed by needle biopsy, age \>50 years, planned radical prostatectomy with lymph-node dissection, fasting for \>12 hours before FEC-PET and an interval between biopsy and PET \>3 weeks.
62125683|NCT00535145|EXPERIMENTAL|001|Treatment as usual (TAU), Paliperidone ERTreatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
62125684|NCT04307199|EXPERIMENTAL|Group A|Membrane sweep @ 39 weeks' gestation only
62125685|NCT04307199|EXPERIMENTAL|Group B|Membrane sweep @ 40 weeks' gestation only
62125686|NCT04307199|EXPERIMENTAL|Group C|Membrane sweep @ 39, 40 and 41 weeks' gestation or until onset of labour
62125687|NCT04307199|EXPERIMENTAL|Group D|Membrane sweep @ 40 and 41 weeks' gestation or until onset of labour
62125688|NCT04307199|NO_INTERVENTION|Control Group|Women in the control arm will not receive a membrane sweep and will receive usual care (as defined by local hospital protocols and vaginal examination to determine Bishop score only).
62125689|NCT02828943|ACTIVE_COMPARATOR|IMT with Low Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. For the comparator group, EMT will be set to 5 cm H2O, the lowest setting on the device. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with low resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training.
62125690|NCT02828943|EXPERIMENTAL|IMT with High Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. EMT training loads in the experimental group will be set to 30% of maximal expiratory pressure. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with high resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training. At two weeks, participants will have a follow-up office visit to monitor progress and those that have completed 80% of their training sessions will increase their training to 40% of maximum inspiratory and expiratory pressures as tolerated.
62125691|NCT04049435||horizontal deficiency anterior maxilla|Using the titanium sheet in augmentation of horizontally deficient anterior maxilla will be efficient, time saving, accurate reconstruction
62125692|NCT03037086||One single cohort|One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
62125693|NCT03407846|ACTIVE_COMPARATOR|Total laparscopic hystrectomy|
62125694|NCT03407846|EXPERIMENTAL|Total abdominal hystrectomy|
62125695|NCT03726424||mutation|patients carrying one or more specific pathogenic mutations
62125696|NCT03726424||control|patients not carrying the pathogenic mutation(s)
62125697|NCT04877067|ACTIVE_COMPARATOR|WJ-MSC combine witf rEMS|WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.
62125698|NCT04877067|ACTIVE_COMPARATOR|Only rEMS|rEMS applications were repeated 10 times with a 1-week interval.
62125699|NCT04877067|ACTIVE_COMPARATOR|Only WJ-MSC|WJ-MSC was applied only one time for both eyes.
62478955|NCT06540716|OTHER|Hypoglossal nerve stimulation|
62125700|NCT05971680|EXPERIMENTAL|Vitamin B 1|VITAMIN B1 (High Potency) 500mg
62125701|NCT05971680|OTHER|control|patient not subjected to treatment . only follow up
62125702|NCT03479034||Group 1|"* Ages 18-85~* Cognitively able to understand instructions and care for themselves~* Lives in the community (not institutionalised)~* Owner of a smartphone and able to use Apps~* On 3 or more chronic prescription medications~* Has had experience with prescriptions in Australia for at least 1 year~* Current patient attending Holdsworth House Medical Practice~Willing to use the ScalaMed ePrescription application"
62125703|NCT01024088||GBS PATIENT|
62125704|NCT01024088||CONTROL|
62125705|NCT00001277|NO_INTERVENTION|Primary hyperparathyroidism|Patients with confirmed or suspected primary hyperparathyroidism or complications
62125706|NCT00001277|EXPERIMENTAL|DOTATATE and F-DOPA|Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA
62125707|NCT04732260|EXPERIMENTAL|letermovir|Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP
62315918|NCT01447173|PLACEBO_COMPARATOR|400 IU Vitamin D pill|
62315919|NCT05260255|EXPERIMENTAL|vitamin D supplementation|add on vitamin D2 ( calciferol ) 40,000 IU/wk for 12 weeks
62315920|NCT05260255|PLACEBO_COMPARATOR|placebo|add on placebo for 12 weeks
62478956|NCT03964935|EXPERIMENTAL|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After scaling, root planing, and polishing (SRP), the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
62478957|NCT03964935|ACTIVE_COMPARATOR|Minocycline HCL|Minocycline HCL Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
62478958|NCT03964935|PLACEBO_COMPARATOR|Distilled water|Used to irrigate periodontal pockets after SRP
61924310|NCT00413166|EXPERIMENTAL|Induction ATRA + ATO + GO|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO)~ATRA 45 mg/m2 daily po (in 2 divided doses) beginning day 1; ATO 0.15 mg/kg IV daily beginning on day 1; GO 9 mg/m2 on day 1 Methylprednisolone 50 mg daily for 5 days followed by rapid taper starting on day 1.~Theophylline 100mg p.o. bid days 1-3, 200 mg p.o. bid days 4-6, and 300 mg p.o. bid thereafter during periods when patient is receiving ATRA or ATO. Theophylline administration continues until therapy with ATO and ATRA is completed."
62478959|NCT00829790|EXPERIMENTAL|1|Doxycycline Monohydrate
62478960|NCT00829790|ACTIVE_COMPARATOR|2|Vibramycin Monohydrate®
62125708|NCT05623163|EXPERIMENTAL|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
62125709|NCT05489536|EXPERIMENTAL|A Web/smartphone-based Lifestyle Program Intervention Group|As this study is designed specifically to isolate the effect of introducing the web/app into the existing care pathway, the intervention group will receive standard prenatal care provided by health clinics and the web/smartphone app.
62125710|NCT05489536|NO_INTERVENTION|Control Group|A standard usual prenatal care includes ten clinic visits for routine pregnancy checks (weight gain, iron status, blood pressure, fasting blood glucose etc.)
62478961|NCT05885971|OTHER|Group of pregnant women with eating disorder|
61924311|NCT02894632|EXPERIMENTAL|Healthy volunteers|Volunteers without cardiac, hepatic or renal pathology
62125711|NCT04399148|EXPERIMENTAL|Sequence 1|Desloratadine - Aprepitant - Ketotifen
62125712|NCT04399148|EXPERIMENTAL|Sequence 2|Aprepitant - Ketotifen - Desloratadine
62125713|NCT04399148|EXPERIMENTAL|Sequence 3|Ketotifen - Desloratadine - Aprepitant
62125714|NCT06345586|EXPERIMENTAL|Drospirenone|Participants received Drospirenone 4 mg tablet orally once daily for 21-28 days
62478962|NCT05885971|OTHER|Group of pregnant women with no eating disorder|
62478963|NCT01778010|PLACEBO_COMPARATOR|Modafinil 0mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.
62478964|NCT01778010|EXPERIMENTAL|Modafinil 200mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.
62478965|NCT01778010|EXPERIMENTAL|Modafinil 400mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.
62125715|NCT03038555||Disease group (subject to strategy)|Choose subjects that have ever got PE before as the diseases group.
62315921|NCT06671249|EXPERIMENTAL|Laparoscopic breast-conserving surgery|Subjects who is going to accept laparoscopic breast-conserving surgery.
62478966|NCT06138821|EXPERIMENTAL|ESG + lifestyle modification|Endoscopic sleeve gastroplasty weight loss procedure with a lifestyle modification program for 12 months.
62478967|NCT06138821|ACTIVE_COMPARATOR|Lifestyle modification|Lifestyle modification program for 12 months.
62478968|NCT03973268|EXPERIMENTAL|1|Individuals in Arm 1 will receive double-blinded perampanel and open-label ketamine on the first day, then double-blinded perampanel on the second day.
62478969|NCT03973268|EXPERIMENTAL|2|Individuals in Arm 2 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded perampanel on the second day.
62478970|NCT03973268|EXPERIMENTAL|3|Individuals in Arm 3 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded placebo on the second day.
62685689|NCT01670149|PLACEBO_COMPARATOR|Placebo|Identical looking tablet
62315922|NCT06671249|ACTIVE_COMPARATOR|Traditional open breast-conserving surgery|Subjects who is going to accept traditional open breast-conserving surgery.
62685690|NCT01670149|ACTIVE_COMPARATOR|Rifaximin , Xifaxanta™|2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),
62685691|NCT00742157|OTHER|UNMC Group|Compare the low and high dose effects of Growth Hormone from previously pooled patients (high dose) and UNMC patients (low dose).
62125716|NCT03038555||Control group|Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
62315923|NCT05197868|ACTIVE_COMPARATOR|Intubation with traditional laryngoscope|Participants will be required to intubate the manikin by using a traditional laryngoscope
62315924|NCT05197868|EXPERIMENTAL|Intubation with a straight blade video laryngoscope|Participants will be required to intubate the manikin by using a straight blade video laryngoscope
62315925|NCT05197868|EXPERIMENTAL|Intubation with hyper-angulated video laryngoscope|Participants will be required to intubate the manikin by using a hyper-angulated video laryngoscope
62315926|NCT06166069||A|Intraperitoneal Onlay Mesh(IPOM) Plus (GroupA) the laparoscopic closure of the hernia defect will be then performed with detached stitches, non-resorbable 1/0 suture with running intracorporeal suture or intra/extracorporeal interrupted suture
62685692|NCT05950997|EXPERIMENTAL|previously untreated chronic lymphocytic leukemia.|Previously untreated CLL patients with ≥1 of the IWCLL 2018 criteria for requiring treatment will be enrolled. Treatment with acalabrutinib may be continued until treatment for 24 months, or until an unacceptable drug-related toxicity occurs or until disease progression, whichever occurs first. Dose modification provisions are provided in the study protocol. Treatment with obinutuzumab or obinutuzumab/chlorambucil is up to 6 cycles per the obinutuzumab package insert.
62685693|NCT06548295|EXPERIMENTAL|modified constraint induced movement therapy (mCIMT)|
62315927|NCT06166069||B|Intraperitoneal Onlay Mesh(IPOM) standard (Group B) no defect closure will be performed.
62315928|NCT00744055|EXPERIMENTAL|Prazosin|prazosin (16mg/day)
62315929|NCT00744055|PLACEBO_COMPARATOR|Placebo|Placebo in identical looking capsule blister packs
62315930|NCT00122772|EXPERIMENTAL|EBR plus 2 HDBT fractions|External Beam Radiotherapy High Dose Brachytherapy (2 fractions of 9Gy)
62685694|NCT06548295|EXPERIMENTAL|conservative treatment|
62685695|NCT00215657|EXPERIMENTAL|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
62685696|NCT00215657|EXPERIMENTAL|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
61924312|NCT03401853|EXPERIMENTAL|Arm I (pembrolizumab, rituximab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity."
62125717|NCT03440034|EXPERIMENTAL|Pioglitazone|All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
62125718|NCT00026234|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
62125719|NCT04353934||Respondents|All adults aged 18 or older who elect to respond to the online survey
62685697|NCT00215657|EXPERIMENTAL|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
62685698|NCT00215657|EXPERIMENTAL|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
62685699|NCT00215657|EXPERIMENTAL|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
62685700|NCT00215657|EXPERIMENTAL|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
62685701|NCT00215657|EXPERIMENTAL|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
62685702|NCT00215657|EXPERIMENTAL|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
62125720|NCT06032117||Post infectious irritable bowel syndrome group|Participants will have post-infectious IBS (as identified via Rome IV criteria or previous physician diagnosis)
62125721|NCT06032117||Healthy control group|Participants will not have post-infectious IBS, matched on age group, sex, and race/ethnicity.
62125722|NCT01384240|EXPERIMENTAL|Proflavine Hemisulfate|
62125723|NCT05082935|EXPERIMENTAL|Partner-optimized venue placement strategy|The Phase II intervention involves outreach from community partners to attend testing at existing events organized by community partners, such as the Mexican Consulate. At the event, it includes the on-site Promotores de Salud psychoeducation related to SARS-CoV-2 health related behaviors.
62685703|NCT05639803|EXPERIMENTAL|PEGIFNα1b 1.5 μg/kg|8 randomized participants receive one dose PEGIFNα1b 1.5 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
62685704|NCT05639803|EXPERIMENTAL|PEGIFNα1b 3.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 3.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
62685705|NCT05639803|EXPERIMENTAL|PEGIFNα1b 5.0μg/kg|8 randomized participants receive one dose PEGIFNα1b 5.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
62685706|NCT05639803|EXPERIMENTAL|PEGIFNα1b 6.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 6.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
62685707|NCT05639803|EXPERIMENTAL|PEGIFNα1b 7.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 7.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
62685708|NCT05405257|PLACEBO_COMPARATOR|Placebo|Placebo infusion: IV 0.9% NaCl, rate is 200ml over 40 minutes. Total of three infusions in three consecutive days (one per day)
62685709|NCT05405257|ACTIVE_COMPARATOR|Oxytocin|Treatment infusion: IV 1IU Oxytocin in 200ml of 0.9% NaCl, rate is 200ml over 40 minutes. Total of three infusions in three consecutive days (one per day)
62315931|NCT00122772|ACTIVE_COMPARATOR|EBR plus 4 fractions HDBT|External Beam Radiotherapy High Dose Brachytherapy (4 fractions of 7Gy)
62685710|NCT00309946|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
62685711|NCT01880775|EXPERIMENTAL|prilocaine heavy 2%& fentanyl|prilocaine heavy 2% 30 mg and fentanyl 20 micgr ampoule intrathecal
62685712|NCT01880775|ACTIVE_COMPARATOR|bupivacaine heavy 0.5% & fentanyl|bupivacaine heavy 0.5% 7.5 mg and fentanyl 20 micg ampoule intrathecal
62315932|NCT00122772|EXPERIMENTAL|EBR/2 HDBT fractions/Chemotherapy|"External Beam Radiation~High Dose Brachytherapy (2 fractions of 9Gy)~Cisplatin"
62315933|NCT00122772|EXPERIMENTAL|EBR/4 fractions HDBT/chemotherapy|"External Beam Radiation~High Dose Brachytherapy (4 fractions of 7Gy)~Cisplatin"
62685713|NCT03060707|EXPERIMENTAL|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
62685714|NCT03060707|ACTIVE_COMPARATOR|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
62685715|NCT00370955|ACTIVE_COMPARATOR|High vacuum group|Those patients who underwent phacoemulsification using high hydrodynamic parameter: 400 mmHg vacuum and 40 ml/min flow rate.
62685716|NCT00370955|ACTIVE_COMPARATOR|Low vacuum group|Patients who underwent phacoemulsification using low hydrodynamic parameters: 200 mmHg vacuum and 20 ml/min flow rate.
62685717|NCT03794544|EXPERIMENTAL|Durvalumab 1500 mg|Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
62315934|NCT02892097|ACTIVE_COMPARATOR|Parietal tDCS plus RTP|Single session of bilateral parietal tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP).
62315935|NCT02892097|ACTIVE_COMPARATOR|Primary motor cortex tDCS plus RTP|Single session of bilateral primary motor cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
62315936|NCT02892097|SHAM_COMPARATOR|Sham tDCS plus RTP|Single session of sham tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
62685718|NCT03794544|EXPERIMENTAL|Durvalumab 1500 mg + Oleclumab 3000 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
62125724|NCT05082935|EXPERIMENTAL|Active Comparator, Residential density-located venue placement strategy|This is the Phase I intervention (Clinical Trial ID: NCT04793464). It includes the Phase I Promotores de Salud intervention, which consists of outreach to promote testing and vaccination at re-occurring testing events that have been selected for sites that have a high residential density of Latinx persons. At the testing events, it includes the on-site Promotores de Salud psychoeducation related to SARS-CoV-2 health related behaviors.
62315937|NCT00569920|PLACEBO_COMPARATOR|1|Placebo
62315938|NCT00569920|ACTIVE_COMPARATOR|2|"dexamethasone low-dose"
62315939|NCT00569920|ACTIVE_COMPARATOR|3|"Dexamethasone high-dose"
62315940|NCT06554496|EXPERIMENTAL|CPAP Treatment Group|Patients with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) who are eligible for Continuous Positive Airway Pressure (CPAP) therapy.
62315941|NCT06580119|EXPERIMENTAL|Group A: In-Person|Participants will be asked to participate in the 4 intervention classes in person. The pre-intervention and post-intervention assessments will require participants to complete a 20-25-minute online survey via Qualtrics and provide saliva samples.
62315942|NCT06580119|ACTIVE_COMPARATOR|Group B: Virtual|Participants will be asked to participate in the 4 intervention classes virtually. The pre-intervention and post-intervention assessments will require participants to complete a 20-25-minute online survey via Qualtrics and provide saliva samples.
62315943|NCT03854162|ACTIVE_COMPARATOR|FREEHAND|For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
62315944|NCT03854162|ACTIVE_COMPARATOR|PILOT|The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
62339667|NCT05525338|NO_INTERVENTION|Standard dose arm|Alectinib plasmaconcentration will be blinded untill the end of the trial. No intervention based on the alectinib plasmaconcentrion will be performed. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
62685719|NCT03794544|EXPERIMENTAL|Durvalumab 1500 mg + Monalizumab 750 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
61924313|NCT03401853|EXPERIMENTAL|Arm II (pembrolizumab, obinutuzumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better, who are experiencing clinical benefit in the judgment of the investigator, may receive obinutuzumab IV on day 1 of cycles 5, 9, 13, 17, 21, and 25."
61924314|NCT05087849|EXPERIMENTAL|Intralesional injection of nonavalent human papillomavirus vaccine|Single-arm, open-label study. Intervention consists of intralesional injection of nonavalent human papillomavirus vaccine at 0 and 4 weeks.
61924315|NCT04198506|EXPERIMENTAL|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.
62125725|NCT03608475|ACTIVE_COMPARATOR|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
62125726|NCT03608475|EXPERIMENTAL|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
62125727|NCT06087549|ACTIVE_COMPARATOR|Control group|regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine
62125728|NCT06087549|ACTIVE_COMPARATOR|Pericapsular nerve group block (PENG) group|regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + PENG block - 0.5mL/kg 0.2% ropivacaine, max. 20mL
62125729|NCT06087549|ACTIVE_COMPARATOR|Erector Spinae Plane Block (ESPB) group|regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + ESP block - 0.5mL/kg 0.2% ropivacaine, max. 20mL
62125730|NCT02655458|EXPERIMENTAL|autologous PBMC reconstitution, Elotuzumab, Lenalidomide|Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
62125731|NCT02882035|EXPERIMENTAL|OFA (opioid free anesthesia)|"All drugs were given IV. Induction in the opioid free group began with a loading dose of clonidine (0.2 mcg kg-1), a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1) (adapted according to hemodynamic stability).~Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups. A bolus of ketamine (0.2mg kg -1) was given if necessary in the opioid free group (up to three bolus max. were permitted).~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
62125732|NCT02882035|NO_INTERVENTION|OA (opioid anesthesia)|"All drugs were given IV. Induction in the opioid group began with remifentanil TCI, a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1). Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups.~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
62315945|NCT03854162|ACTIVE_COMPARATOR|PARTIAL GUIDE|The only non-guided step is implant insertion, that is, all drilling happens through the SMART Guide surgical template. After having prepared soft tissue access, the guide is placed, and all drillings are performed through it, according to the surgical protocol. Here the depth of the bony bed is also determined, as the sleeve does not allow the drill to move any deeper than planned. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
62315946|NCT03854162|ACTIVE_COMPARATOR|FULL GUIDE|"The SMART Guide surgical template is used for all steps of the operation, including the insertion of the implant. Apart from this, the procedure is exactly the same as described under partial guide."
61924316|NCT04198506|ACTIVE_COMPARATOR|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
62315947|NCT01245894|ACTIVE_COMPARATOR|Low-dose Rosuvastatin|5mg Rosuvastatin/day
62315948|NCT01245894|ACTIVE_COMPARATOR|High-dose Rosuvastatin|Rosuvastatin 40mg/day
62315949|NCT02749487||cured (c)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
62315950|NCT02749487||Died ( M)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
62315951|NCT02680301|OTHER|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
62315952|NCT02680301|OTHER|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
62315953|NCT02401178||Well baby|"For cross-sectional study design:~The dependent variables are LCPUFA composition from buccal. The independent variables are 17 SNP from FADS genes.~For extended cross-sectional study design:~The dependent variable is atopic dermatitis, while independent variables are:~17 SNP; LCPUFA and FLG gene mutation"
62478971|NCT02580279|EXPERIMENTAL|EGCG group|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution;The solution is sprayed three times a day at 0.05 ml/cm2 to the whole radiation field until two weeks after radiation completion; Patients who developed grade Ⅱ radiation-induced dermatitis have the option to either withdraw from the study or to continue with EGCG. Patients are follow general good skin care practices during radiation therapy, such as not applying water soaks to relieve itching or pain, not vigorously rubbing the irradiated area, or not erasing ink marks; patting the skin dry with a soft towel; avoiding exposure to the sun; and wearing loose and cotton clothes. They are advised not to use deodorant, lotion, cream, make up, perfume or any other product on the area during the course of radiation therapy.
62478972|NCT02580279|PLACEBO_COMPARATOR|placebo|The placebo is 0.9% saline solution.Patients are also to follow general good skin care practices which is same as the EGCG group.
62478973|NCT06560372|EXPERIMENTAL|Treatment or monitoring of a moderate or severe TBI presenting with SAH on initial cerebral CT scan|"Patients hospitalized at Martinique University Hospital for treatment or monitoring of a moderate or severe TBI (Glasgow Score less than or equal to 13 at initial treatment) presenting with SAH on initial cerebral CT scan.~Any head trauma patient with an altered level of consciousness must benefit, as part of routine care, from clinical monitoring and a CT imaging assessment, as well as the opinion of the doctor on duty in the resuscitation department.~If the patient has a traumatic SAH on the cerebral CT scan, he must benefit from an injected sequence exploring the supra-aortic trunks. If there is evidence of intracranial hypertension on cerebral CT or abnormal transcranial doppler, they will benefit, according to the service protocol, from the placement of a parenchymal intracranial pressure sensor. These patients also benefit from clinical monitoring in critical care, as well as a daily biological assessment."
62478974|NCT05884190|ACTIVE_COMPARATOR|Standard of Care (SoC)|Standard of Care for Postpartum Hypertension
62478975|NCT05884190|EXPERIMENTAL|Remote Medical Model (RMM)|Includes SoC plus RMM
62315954|NCT05326893|EXPERIMENTAL|Study Group|"Femoral nerve neurodynamic mobilization group~T1: Baseline measurements were made and blood samples were taken for biochemical analysis.~NM and placebo NM techniques were applied for three weeks, three times a week, and totaling nine visits. At the end of the third week, it was waited 3 days to eliminate the acute effect of NM.~T2: Baseline measurements and blood samples were repeated a second time.~The protocol for establishing the DOMS was applied on the same day.~T3: Following the protocol for inducing the DOMS, the baseline measurements were repeated for the third time without any interruption, and the blood sample was taken.~T4-T5-T6: The first measurements and blood sample collections were repeated for the fourth, fifth and sixth times, respectively, 24h, 48h, 72h after the DOMS protocol."
62315955|NCT05326893|PLACEBO_COMPARATOR|Placebo Group|"Femoral nerve placebo neurodynamic mobilization group~T1: Baseline measurements were made and blood samples were taken for biochemical analysis.~NM and placebo NM techniques were applied for three weeks, three times a week, and totaling nine visits. At the end of the third week, it was waited 3 days to eliminate the acute effect of NM.~T2: Baseline measurements and blood samples were repeated a second time.~The protocol for establishing the DOMS was applied on the same day.~T3: Following the protocol for inducing the DOMS, the baseline measurements were repeated for the third time without any interruption, and the blood sample was taken.~T4-T5-T6: The first measurements and blood sample collections were repeated for the fourth, fifth and sixth times, respectively, 24h, 48h, 72h after the DOMS protocol."
62478976|NCT05884190|EXPERIMENTAL|Community Health Model (CHM)|Includes SoC, RMM plus CHM
62478977|NCT03397251|EXPERIMENTAL|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
62478978|NCT04673721|ACTIVE_COMPARATOR|Fortified eggs + Intermittent fasting|Consume at least 12 fortified eggs per week with 16-hour fast and then an 8-hour nutritional window.
61924317|NCT03431311|EXPERIMENTAL|Adoptive Cell Therapy (ACT)|"The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.~Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point."
61924318|NCT01246531||Urolithiasis|Case arm: men above fifty years-old with urolithiasis
62315956|NCT02746679|EXPERIMENTAL|MBSR Group|The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
62315957|NCT02746679|NO_INTERVENTION|wait-list control group|The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.
62478979|NCT04673721|ACTIVE_COMPARATOR|Non-egg supplemented diet + Intermittent fasting|Maintain consumption of 2 or less eggs per week with 16-hour fast and then an 8-hour nutritional window.
61924319|NCT01246531||Control|Control arm: men above fifty years-old without urolithiasis
61924320|NCT02337348|EXPERIMENTAL|OCT guided coronary intervention|Coronary angiography and optical coherence tomography imaging
61924321|NCT02337348|ACTIVE_COMPARATOR|Conventional coronary intervention|Coronary angiography
62125733|NCT01491646||Pulmonary Hypertension|Previous diagnosis of PH by right heart catheterization
61924322|NCT00301821|EXPERIMENTAL|Epratuzumab + Rituximab + CHOP|One arm open label.
62125734|NCT01491646||Healthy Controls|Healthy controls without lung/heart conditions
62125735|NCT04993898|EXPERIMENTAL|Plyometric training with warm up and cool down|"Plyometric training will include following exercises.~* Squat to Squat Jump~* Lunge to Plyo Lunge~* Step Jack to Star Jumps~* Plank to Plyo Spider Lunge~* Plank to Frogger"
62125736|NCT04993898|ACTIVE_COMPARATOR|Conventional training with warm up & cool down|"Conventional training will include following exercises.~* Squats~* Single leg squat~* Cork hip lift~* Press ups"
62315958|NCT00828867|EXPERIMENTAL|Cohort 1|100mg
61924323|NCT04071587|EXPERIMENTAL|BCI training|Patients randomized to this group will receive up to12 (minimum 8) sessions of BCI training with the RecoveriX system (gtec, Austria). The system combines EEG driven functional electrical stimulation with visual feedback. BCI training is provided as a part of standard training of the impaired upper limb.
62315959|NCT00828867|EXPERIMENTAL|Cohort 2|200mg
62315960|NCT00828867|EXPERIMENTAL|Cohort 3|400mg
62315961|NCT00828867|EXPERIMENTAL|Cohort 4|800mg
62478980|NCT04673721|ACTIVE_COMPARATOR|Fortified eggs + Usual care diet|Consume at least 12 fortified eggs per week with consistency with current diet.
61924324|NCT04071587|ACTIVE_COMPARATOR|Control|Patients randomized to this control group will receive standard physiotherapy and occupational therapy for their impaired upper limb.
61924325|NCT02354482||Diverse, high-risk patient populations|
61924326|NCT05633225||Patient-group|Ninety adolescents, 13-17 years of age Diagnosed with Hypermobility Spectrum Disorder or hypermobile Ehlers Danlos Syndrome.
61924327|NCT05633225||Control-group|Ninety adolescents, 13-17 years of age. Participants have to be pain free at time of investigation (NRS score \<3/10)
61924328|NCT06003400|EXPERIMENTAL|Tri.O FITT|The study patients will undergo a screening period of upto 4 weeks, a traetment period of upto 12 weeks and a follow-up period of upto 12 additional weeks.
61924329|NCT00916214|EXPERIMENTAL|Intervention|
62315962|NCT00828867|EXPERIMENTAL|Cohort 5|1500mg
62478981|NCT04673721|PLACEBO_COMPARATOR|Non-egg supplemented diet + Usual care diet|Maintain consumption of 2 or less eggs per week with consistency with current diet.
61924330|NCT05143554|ACTIVE_COMPARATOR|Active percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
62478982|NCT02882282|ACTIVE_COMPARATOR|Arm A (observation)|Patients undergo observation.
62478983|NCT02882282|EXPERIMENTAL|Arm B (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62478984|NCT03011476|ACTIVE_COMPARATOR|Donepezil|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
62478985|NCT03011476|PLACEBO_COMPARATOR|Placebos|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
62125737|NCT04562844|EXPERIMENTAL|Social cognition|
62315963|NCT00828867|EXPERIMENTAL|Cohort 6|2000mg
62315964|NCT00828867|EXPERIMENTAL|Cohort 7|800mg with food
62315965|NCT00828867|EXPERIMENTAL|Cohort 8|3000mg
62315966|NCT00828867|EXPERIMENTAL|Cohort 9|4000mg
62315967|NCT04174885|OTHER|AF epicardial ablation|Patient with persistent AF will receive an epicardial ablation.
62315968|NCT05372575|OTHER|PCV13 group and non PCV13 group|This study plan to recruit those young patients who have or not have got PCV13 vaccine before study start
62125738|NCT05773313|EXPERIMENTAL|The Open Table Model|Subjects identified as having their health negatively impacted by Social Determinants of Health (SDOH) will meet with The Open Table members to determine their specific needs, decide on a plan for overcoming this need and following up to ensure resolution.
62125739|NCT04838496|EXPERIMENTAL|Single-arm study|All patients will receive induction chemotherapy consisting of 4-6 cycles of FOLFOXIRI. Restaging will be performed after 4 cycles with a pelvic MRI and a thoraco-abdominal CT-scan. In case of stable or responsive disease, the remaining 2 cycles of FOLFOXIRI will be provided. In case of progressive, but still resectable disease, chemoradiation will be provided immediately, without the remaining 2 cycles of FOLFOXIRI. Restaging will be performed after chemoradiation. In case of resectable disease, surgery is performed.
62125740|NCT03775785|EXPERIMENTAL|tailored enteral nutrition|Tailored Human milk fortification procedure Tailored milk fortification will be done twice a day (8 am and 8 pm) for each following 12 hour nursing shift. Standard fortification will be added first. The remainder amount of protein, lipids and carbohydrates required to meet the recommended by ESPGHAN doses will be acheived by adding single ingrediant nutrients.
62125741|NCT03775785|NO_INTERVENTION|standard enteral nutrition|Standard fortification will be added according to the unit protocol.
62125742|NCT03837600||Healthy Cohort|Participants who have smoked less than 5 pack-years, have quit smoking for more than 15 years and have no known lung diseases.
62125743|NCT03837600||High-risk Cohort|Participants who are at high risk for lung cancer including current smokers who have smoked for more than 30 pack-years and have not quit within 15 years.
62125744|NCT03837600||Cancer Cohort|Participants who have been diagnosed with lung cancer.
62125745|NCT05161429||DPP4|Patients receiving second line diabetes treatment with dipeptidyl peptidase-4 inhibitors (DPP4) following metformin
62125746|NCT05161429||GLP1-RA|Patients receiving second line diabetes treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) following metformin
62125747|NCT05161429||Basal insulin|Patients receiving second line diabetes treatment with basal insulin following metformin
62125748|NCT05161429||SLGT2|Patients receiving second line diabetes treatment with sodium-glucose cotransporter-2 inhibitors (SLGT2) following metformin
62315969|NCT00447213|EXPERIMENTAL|1|
62315970|NCT00447213|EXPERIMENTAL|2|
62315971|NCT02147938||1: early conversion from Prograf® to Advagraf®|patients converted during the first 6 months post-transplantation
62315972|NCT02147938||2: late conversion from Prograf® to Advagraf®|patients converted between 6 and 12 months post-transplantation
62478986|NCT00443651|EXPERIMENTAL|Rituximab 1000 mg (Stage I patients)|Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
62125749|NCT05161429||SU|Patients receiving second line diabetes treatment with sulfonylureas (SU) following metformin
62125750|NCT04759482||Patients with sleep apnea|We selected 150 patients recorded by polysomnography between january 2019 and june 2020 in the Center for Sleep Medecine and Research in Nancy.
62125751|NCT02024685|ACTIVE_COMPARATOR|Standard patient-physician counseling interaction|The control arm will receive counseling regarding treatment options using standard patient-physician interactions and nomogram-predicted probabilities of treatment outcome for the various treatment options and they will be unaware of the decision analysis recommendation.
62125752|NCT02024685|EXPERIMENTAL|Personalized treatment recommendations|The treatment arm would be provided with a personalized treatment recommendations based on the decision analysis model prior to treatment selection.
62125753|NCT01806116|EXPERIMENTAL|decitabine + transplantation|
62125754|NCT05369169|EXPERIMENTAL|Resonance paced breathing|Active resonance breathing task consisting of synchronizing breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
62125755|NCT05369169|ACTIVE_COMPARATOR|Low demand vanilla control|"A low-demand cognitive vanilla task wherein different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles"
62125756|NCT03432403||New LMA or Old LMA|newly designed LMA or older designed LMA
62125757|NCT00991107|EXPERIMENTAL|HE3286|HE3286 20 mg (10 mg BID)
61924331|NCT05143554|SHAM_COMPARATOR|Sham percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
61924332|NCT05541068|ACTIVE_COMPARATOR|Guided by bioimpedance analysis|These patients were discharged when dry-weight was achieved according to BIA measurements if there was none clinical condition which justified the hospitalization.
61924333|NCT05541068|ACTIVE_COMPARATOR|Control arm|In those patients, BIA parameters were not known by the physician responsible. These patients were discharged when they achieved the euvolemic state based in the criteria of their physician
61924334|NCT02024438|OTHER|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
62125758|NCT02180763|EXPERIMENTAL|Gammanorm® 165 mg/mL|
62125759|NCT01044303|EXPERIMENTAL|Myfortic Escalation|Participants EC-MPS dose was escalated to a minimum daily dose of 1440mg or equivalent, with the maximum dose never exceeding the manufacturer's recommendations.
62125760|NCT02035670||tradition diagnostic strategy|According to the current diagnistic procedures of FUO
62125761|NCT02035670||two-step diagnostic strategy|"First step is to differentiate FUO according to the onset of disease and invasive pathogens.~Second step is to further differentiate FUO according to trends of disease and inflammation scores."
62125762|NCT00134069|EXPERIMENTAL|Treatment (sorafenib, irinotecan, cetuximab)|Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.
62125763|NCT02497716|EXPERIMENTAL|Rivaroxaban|Single arm, open label study
62125764|NCT05800041|EXPERIMENTAL|Treatment group A|WTX221 low dose
61924335|NCT02024438|EXPERIMENTAL|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
61924336|NCT04437849|EXPERIMENTAL|Telemonitoring|
61924337|NCT04437849|NO_INTERVENTION|Usual Care|
61924338|NCT00558376|ACTIVE_COMPARATOR|1|Ingestion of 3L polyethylene Glycol
61924339|NCT00558376|ACTIVE_COMPARATOR|2|Ingestion of 2 doses of sodium phosphate 45 cc
62125765|NCT05800041|EXPERIMENTAL|Treatment group B|WTX221middle dose
62125766|NCT05800041|EXPERIMENTAL|Treatment group C|WTX221 high dose
62125767|NCT01079065|EXPERIMENTAL|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
61924340|NCT06087003||Basilliximab induction group|Basiliximab was administered intravenously 4 hours before kidney graft reperfusion and at day 4 after kidney transplantation. For pediatric patients weighing \> 30kg, the dose of Basiliximab was 20mg, otherwise was 10mg.
62685720|NCT03794544|EXPERIMENTAL|Durvalumab 1500 mg + Danvatirsen 200 mg|Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
62685721|NCT00989443|EXPERIMENTAL|Cidofovir|
62315973|NCT03372057|EXPERIMENTAL|Dose Optimization Phase: Cohort 1|Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
61924341|NCT06087003||rATG induction group|Rabbit antithymoglobulin (rATG) was administered intravenously during kidney transplantation (pre-reperfusion) and 1-2 days after transplantation. The dose was about 0.5-1 mg/kg per day.
62125768|NCT01079065|ACTIVE_COMPARATOR|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson \& Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
62125769|NCT05521061|EXPERIMENTAL|1.5 g/day 2-fucosyllactose|1.5 g/day of human milk oligosaccharides will be supplemented in the first intervention group.
62315974|NCT03372057|EXPERIMENTAL|Dose Optimization Phase: Cohort 2|Duvelisib 75 mg PO BID, administered in 28-day cycles.
62315975|NCT03372057|EXPERIMENTAL|Expansion Phase|Duvelisib PO BID at a starting dose of 75 mg for the first 2 cycles, followed by a mandatory reduction to 25 mg BID thereafter for those patients with complete response (CR), partial response (PR) or stable disease (SD), in 28-day cycles (dose determined in Optimization Phase).
62315976|NCT06338059||painDETECT questionnaire scores> 13 likely or possible neuropathic pain (group 1)|lipedema patients showing NP symptoms
62315977|NCT06338059||painDETECT questionnaire scores13 unlikely neuropathic pain(group 2)|lipedema patients showing no NP symptoms
62315978|NCT03569514||AIGIV|Anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
62339668|NCT02403830|EXPERIMENTAL|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
62478987|NCT00443651|EXPERIMENTAL|Rituximab 500 mg (Stage II patients)|Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
62685722|NCT01767311|EXPERIMENTAL|Core Study: Lecanemab 2.5 mg/kg biweekly|2.5 mg/kg biweekly
62685723|NCT01767311|EXPERIMENTAL|Core Study: Lecanemab 5.0 mg/kg biweekly|5.0 mg/kg biweekly
62685724|NCT01767311|EXPERIMENTAL|Core Study: Lecanemab 10 mg/kg biweekly|10 mg/kg biweekly
62685725|NCT01767311|EXPERIMENTAL|Core Study: Lecanemab 5.0 mg/kg monthly|5.0 mg/kg monthly
62685726|NCT01767311|EXPERIMENTAL|Core Study: Lecanemab 10 mg/kg monthly|10 mg/kg monthly
62685727|NCT01767311|PLACEBO_COMPARATOR|Core Study: Lecanemab-matched Placebo|Matching placebo biweekly
62315979|NCT06671600|EXPERIMENTAL|Treatment Group (OMT)|For the OMM treatment group, an osteopathic manipulative treatment protocol will be applied to the cranial, cervical, thoracic, and ribcage regions. OMM procedures performed on the treatment group willconsist of 1. suboccipital decompression/release, 2. base spread, 3. occipitoatlantal (OA) decompression, 4. venous sinus drainage, 5. compression of the fourth ventricle, 6. cervical myofascial (unilateralperpendicular stretch), 7. thoracic inlet release (direct or indirect), 8. Bilateral rib raising, 9. thoracoabdominal diaphragm doming (direct technique), and 10. pedal pump (Dalrymple lymphatic pump). All aforementioned techniques are based on the protocol from Foundations of Osteopathic Medicine.
62315980|NCT06671600|SHAM_COMPARATOR|Sham Group|The sham group will serve as the control group and will receive a light touch-control procedure based on prior study utilizing light touch
62315981|NCT03285009|OTHER|Training intervention|See information elsewhere
62315982|NCT00052429|EXPERIMENTAL|High-Dose Radiation Therapy Plus Chemotherapy|"Phase I~* Radiotherapy: Patients receive radiotherapy once daily 5 days a week for 6 weeks beginning on day 1.~* Concurrent chemotherapy: Patients receive cisplatin IV over 20-30 minutes on days 1-5 and 22-26.~* Adjuvant chemotherapy: Approximately 2-5 weeks after the completion of radiotherapy, patients receive fluorouracil IV continuously on days 1-4 and cisplatin IV over 20-30 minutes on days 1-5 and 22-26. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. In the absence of dose-limiting toxicity in 1 whole cohort of patients, study proceeds to phase II. Phase II~* Patients are treated as in phase I. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter."
62315983|NCT01202110|EXPERIMENTAL|Propranolol|Propranolol 1mg iv
62315984|NCT01202110|NO_INTERVENTION|Control|Routine care
62125770|NCT05521061|EXPERIMENTAL|3 g/day 2-fucosyllactose|3 g/day of human milk oligosaccharides will be supplemented in the second intervention group.
62125771|NCT05521061|PLACEBO_COMPARATOR|Maltodextrine|The placebo group will receive maltodextrin as a placebo at a dose with no effect on metabolic control.
62125772|NCT01671358||Isolation Rooms for MRSA|Rooms that currently have a patient in them that are in isolation status due to MRSA
62125773|NCT01671358||Non-isolation rooms|Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
62125774|NCT06335576||Gastric cancer patients receiving adjuvant chemotherapy|
62125775|NCT04537403|EXPERIMENTAL|Aim 1A|Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery
62125776|NCT04537403|EXPERIMENTAL|Aim 1B|Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery
62125777|NCT03858868|EXPERIMENTAL|Church and park-based intervention|Participants at intervention churches will be offered: texting intervention (messages about physical activity); peer leader training; walking groups; park-based fitness classes; sermons; participation in park advisory board; community advocacy.
62125778|NCT03858868|OTHER|Publicly available physical activity materials|Participants at control churches will be offered standard health educational materials (brochures, tip sheets, posters) about physical activity.
62125779|NCT05904925|NO_INTERVENTION|Usual care|Usual care group will perform the usual prenatal care indicated by the obstetrician and will receive an educational booklet.
62125780|NCT05904925|ACTIVE_COMPARATOR|Pilates|Pilates group will perform the usual prenatal care indicated by the obstetrician and will receive an educational booklet. Additionally, this group will receive an exercise program based on Pilates, twice a week, individually, throughout the gestational period.
62125781|NCT02544152|EXPERIMENTAL|Lubiprostone|Participants receive 8 mcg lubiprostone capsules twice daily (BID)
62125782|NCT02544152|PLACEBO_COMPARATOR|Placebo|Participants receive 0 mcg capsules BID
62125783|NCT04425668|ACTIVE_COMPARATOR|Control Group|
62125784|NCT04425668|EXPERIMENTAL|Academic detailing intervention|
62315985|NCT04249895||Main Cohort|All patients are undergoing radiotherapy in Tata Medical Center
62315986|NCT01753752|EXPERIMENTAL|Chitosan-N-acetylcystein|Instillation into the study eye
62315987|NCT01753752|PLACEBO_COMPARATOR|Placebo|Instillation into the fellow eye
62315988|NCT06314906|EXPERIMENTAL|True Acupuncture Combined with Antiemetic Therapy|Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz.
62125785|NCT04816799|EXPERIMENTAL|START|START (startle adjuvant rehabilitation therapy) will be applied.
62125786|NCT04816799|NO_INTERVENTION|Control|Subjects will train but without START
62125787|NCT00528944||Cohort A|Patients with obstructive defects and radiological evidence of emphysema
62315989|NCT06314906|PLACEBO_COMPARATOR|Antiemetic therapy|Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group. They will also receive the same antiemetic medications as the experimental group.
62125788|NCT00528944||Cohort B|Patients with obstructive ventilatory defects and no radiological evidence of emphysema
62125789|NCT00528944||Cohort C|Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
62125790|NCT03032913||Pancreatic ductal adenocarcinoma patients|Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC
62125791|NCT03032913||Non-cancer patients|Patients with no Cancer
62125792|NCT00701896|OTHER|Healthy Control - Non-smoking|Healthy Control arm with 51 subjects who are HIV negative and do not smoke
62125793|NCT00701896|OTHER|Healthy Control - Smoker|Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
62125794|NCT00701896|ACTIVE_COMPARATOR|HIV Smoking Cessation Arm|Includes up to 365 subjects who are HIV positive and initiate smoking cessation
62315990|NCT06049420|EXPERIMENTAL|Active|participants that have received a referral, and opt-in for the adjunctive treatment plan
62315991|NCT03567499|EXPERIMENTAL|Part A: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 200 milligrams (mg) in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
62315992|NCT03567499|EXPERIMENTAL|Part A:Sequence 2|Subjects in sequence 2 will receive GSK3039294 600 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
62315993|NCT03567499|EXPERIMENTAL|Part A: Sequence 3|Subjects in sequence 3 will receive GSK3039294 200 mg in period 1 followed by GSK3039294 600 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session
62685728|NCT01767311|EXPERIMENTAL|Extension Phase: Lecanemab 10 mg/kg|All participants who fulfill Extension Phase inclusion and exclusion criteria will have the option to participate in the Extension Phase to receive lecanemab 10 mg/kg biweekly for up to 60 months or until the benefit-to-risk ratio from treatment with lecanemab is no longer considered favorable, whichever comes first. Additionally, participants who have received Extension Phase treatment for at least 18 months may opt to enter the dosing regimen substudy during which they will receive either lecanemab 10 mg/kg once every 4 weeks (Q4W) or once every 3 months (Q3M).
61924342|NCT04054154|EXPERIMENTAL|Device Feasibility (Millar Mikro-tip catheter, elastography)|Patients scheduled for an ultrasound-guided tumor biopsy undergo stiffness assessment of the tumor with shear wave elastography over 2 minutes and pressure measurements of the tumor using a Millar Mikro-tip catheter before and after the biopsy is collected.
62125795|NCT00701896|EXPERIMENTAL|Motivational Intervention|Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
62125796|NCT01715636|OTHER|Eviplera|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
62125797|NCT01957124|EXPERIMENTAL|PRF application|
62125798|NCT02486835|EXPERIMENTAL|"Cough Syrup for adults and children"|Marked (authorized) medical device acting by protecting the oropharynx, in a non pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris.Dosage form: syrup Dosage: 5 ml three times a day. Frequency: the duration of the study for each patient is 4 nights, 3 days.
62125799|NCT02486835|PLACEBO_COMPARATOR|Placebo|The placebo intervention is a syrup of same taste and colour without the protective components. Dosage form: syrup. Dosage: 5 ml three times a day Frequency: the duration of the study for each patient is 4 nights, 3 days.
62125800|NCT01137708|EXPERIMENTAL|Treatment Sequence 1|
62125801|NCT01137708|EXPERIMENTAL|Treatment Sequence 2|
62315994|NCT03567499|EXPERIMENTAL|Part A: Sequence 4|Subjects in sequence 4 will receive GSK3039294 600 mg in period 1 followed by GSK3039294 200 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
62315995|NCT03567499|EXPERIMENTAL|Part A: Sequence 5|Subjects in sequence 5 will receive GSK3039294 200 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
62315996|NCT03567499|EXPERIMENTAL|Part A: Sequence 6|Subjects in sequence 6 will receive matching placebo in period 1 followed by GSK3039294 600 mg in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
62315997|NCT03567499|EXPERIMENTAL|Part B: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 (dose level to be decided on results of Part 1) in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
62315998|NCT03567499|EXPERIMENTAL|Part B: Sequence 2|Subjects in sequence 2 will receive GSK3039294 (dose level to be decided on results of Part 1) in period 1 followed by matching placebo in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing
62315999|NCT05477680|EXPERIMENTAL|Surgery|Removing different brain lesions using neuronavigation
62316000|NCT02133235|ACTIVE_COMPARATOR|conventional|insertion of endobronchial blocker and auscultation, fiberoptic confirmation and reposition
62316001|NCT02133235|EXPERIMENTAL|auscultation|insertion endobronchial blocker by auscultation without conventional bronchoscopic reposition
62316002|NCT02399475|EXPERIMENTAL|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
61924343|NCT01049399|PLACEBO_COMPARATOR|Placebo|once daily administration of powder for oral suspension.
62125802|NCT04877652||ADHF patients|Patients with acute decompensated heart failure (ADHF) having insufficient response to diuretic therapy following a dose escalation protocol in keeping with AHA guidelines for the management of heart failure.
62316003|NCT02399475|EXPERIMENTAL|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
62316004|NCT01322607|OTHER|Arm 1: High-Intensity Program|High-intensity treadmill-based exercise
62316005|NCT01322607|OTHER|Arm 2: Low-Intensity Program|Low-intensity lifestyle intervention (group exercise)
62339669|NCT02403830|PLACEBO_COMPARATOR|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
62125803|NCT02274142|EXPERIMENTAL|Restorations with Encapsulated material|Restorations performed with encapsulated glass ionomer cement (EQUIA - GC Corp). Capsules with glass ionomer will be activated and applied after selective carious tissue removal in primary molars.
62685729|NCT05681585|OTHER|Intervention arm|Clusters (medical/geriatric hospital units) in the intervention arm receives a comprehensive implementation support program during the trial period.
61924344|NCT01049399|EXPERIMENTAL|NP031112 800 mg|Group dosed with 800 mg once daily for 52 weeks
61924345|NCT01049399|EXPERIMENTAL|NP031112 600 mg|Group treated with 600 mg once daily for 52 weeks
61924346|NCT01159977|EXPERIMENTAL|Facilitated small group|Facilitated small groups.
61924347|NCT01159977|ACTIVE_COMPARATOR|Unstructured protected time|Same time provided as for facilitated small groups, but without structure.
61924348|NCT01159977|PLACEBO_COMPARATOR|Usual practice|No protected time.
61924349|NCT05048797|EXPERIMENTAL|Arm 1|Trastuzumab Deruxtecan (T-DXd)
61924350|NCT05048797|ACTIVE_COMPARATOR|Arm 2|Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)
61924351|NCT06709313|EXPERIMENTAL|chromium group|Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.
62316006|NCT05598996|EXPERIMENTAL|COT-Based Intervention|The COT-based intervention will include the following to improve both steps/day (move more), and improving minutes/week of MVPA (exercise): adaptive daily steps/day goal-setting plus feedback; positive reinforcement (i.e., points, which translate to gift cards), self-monitoring of both steps/day and min/week MVPA; education about MVPA sent via text message in both conditions; planning support for scheduling bouts of MVPA via SMS in both conditions; and motivational messages sent via SMS in both conditions, and the use of a self-experimentation tool (REFLECT), developed based on prior successful pilot efforts, focused on fostering effective self-regulatory capacities of individuals.
62339670|NCT03001154|EXPERIMENTAL|One-session VRET face-to-face|One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.
62125804|NCT02274142|ACTIVE_COMPARATOR|Restorations with Hand-Mixed material|Restorations will be performed with hand-mixed glass ionomer cement (Fuji IX - GC Corp) after selective carious tissue removal in primary molars.
62125805|NCT01945125|NO_INTERVENTION|THW Group|Patients under THW stimulation for RIT
61924352|NCT06709313|NO_INTERVENTION|Non chromium group|Participants will not receive chromium after sacroiliac joint injection.
62125806|NCT01945125|OTHER|rhTSH Group|Patients under rhTSH stimulation for RIT
62125807|NCT03882554|EXPERIMENTAL|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
62125808|NCT02601170|EXPERIMENTAL|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
62339671|NCT03001154|EXPERIMENTAL|Waiting-list, then Internet-administered VRET|4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.
62339672|NCT05672966|EXPERIMENTAL|1-BV601DP(Low dose HPV vaccine with adjuvant)|Subjects received low dose of BV601DP
62685730|NCT05681585|NO_INTERVENTION|Control arm|"Clusters (medical/geriatric hospital units) in the control arm receives no implementation support program during the trial period.~These units will receive the implementation support program after the trial period."
62685731|NCT01514279|EXPERIMENTAL|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
62125809|NCT02601170|ACTIVE_COMPARATOR|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
62125810|NCT05728008||subject treated with ustekinumab (anti-IL12-23)|subjects treated with ustekinumab (anti-IL12-23) and have a follow-up at 24 +/- 4 weeks from the start of the third line therapy
62125811|NCT05728008||subject treated withtofacitinib (pan JAK inhibitor)|subjects treated with tofacitinib (pan JAK inhibitor) and have a follow-up at 24 +/- 4 weeks from the start of the third line therapy.
62125812|NCT03206684|EXPERIMENTAL|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
62339673|NCT05672966|EXPERIMENTAL|1-BV601DPP(Low dose HPV vaccine without adjuvant)|Subjects received low dose of BV601DPP
62685732|NCT01514279|EXPERIMENTAL|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines
62685733|NCT01514279|NO_INTERVENTION|Tools4CHANGE|In contrast to the behavioral arms, youths with their parent(s)/guardian randomized to this group will have one 60-minute face-to-face meeting at initiation of the study with a dietitian who is also trained in recommendations for exercise and sedentary behavior.
62685734|NCT05516407|EXPERIMENTAL|FEN164|"Full-Spectrum Medicinal Cannabis Plant Extract with less than 0.08% THC (FEN164)~Stage 1: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each) Stage 2: 20mg/kg (8 weeks), 15mg/kg, 10mg/kg, 5mg/kg (1 week each)"
62125813|NCT03206684|ACTIVE_COMPARATOR|rhG-CSF|rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
62125814|NCT05793723||Cases|Infants with confirmed neonatal COVID-19 infection
62125815|NCT05793723||Controls|Infants born to mothers with no history of COVID-19 infection during pregnancy and no neonatal COVID-19 infection
62125816|NCT01897155|OTHER|SBP 20-30% under baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
62125817|NCT01897155|OTHER|SBP 20-30% over baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index(40-60). Patients received a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over baseline. The upper limit of SBP was 165 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
62125818|NCT06267131|OTHER|Enrolled patients|All enrolled patients will have brain pulse monitoring
62125819|NCT05395546|EXPERIMENTAL|dCBT-I treatment group|
62125820|NCT06175000|EXPERIMENTAL|Arm I (obinutuzumab|Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.
62125821|NCT06175000|ACTIVE_COMPARATOR|Arm II (observation)|Patients undergo observation for a total of 2 years.
62125822|NCT02093312|NO_INTERVENTION|Control group|The control group is not offered any home food-delivery service, but continues with their habitual diet
62125823|NCT02093312|EXPERIMENTAL|Intervention group|The intervention group is offered home food-delivery service
62125824|NCT05378828|OTHER|Use of an electric wheelchair with or without sensors|During 3 weeks, the electric weehlchair will not have sensors, then sensors will be put on the wheelchair for the next 3 weeks then removed for 3 other weeks.
62125825|NCT03665779|EXPERIMENTAL|isosorbide mono-nitrate group|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
62125826|NCT03665779|PLACEBO_COMPARATOR|placebo group|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.
62125827|NCT00376363|ACTIVE_COMPARATOR|Ahmed implant,1|Ahmed glaucoma drainage implant for intraocular pressure control
62125828|NCT00376363|ACTIVE_COMPARATOR|Baerveldt implant|Baerveldt glaucoma drainage implant for intraocular pressure control
62125829|NCT02159846||Test Group and Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
62125830|NCT02159846||Test Group & Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
62685735|NCT01333787|ACTIVE_COMPARATOR|Dietary Fiber Mixture|The dietary fiber mixture was composed of six different types of fibers. It was used for treatment of chronic constipation in children.
62685736|NCT01333787|PLACEBO_COMPARATOR|Maltodextrine|Blinded control group
62478988|NCT04132518|EXPERIMENTAL|Group A: Sculptra|Participants in Group A will receive up to 4 injections of Sculptra from Day 1 with 5 (±1) weeks (at least 4 weeks) intervals and will be followed up for 24 months.
62685737|NCT06329622|EXPERIMENTAL|Intervention|In the intervention group, low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day. The intervention will last for 6 months. Then,during the subsequent 3-month observation period, the patients maintain a low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
62685738|NCT06329622|ACTIVE_COMPARATOR|Control|In the control group, low-protein diet (0.6-0.8g protein/kg body weight/day) and the target energy intake of 25-30kcal/kg body weight/day will be prescribed for 9 months
62685739|NCT05889741|EXPERIMENTAL|Stellate Ganglion Block|One time administration of a stellate ganglion block
62685740|NCT05889741|PLACEBO_COMPARATOR|Sham SGB|One time administration
62685741|NCT06541080||Regular Sampling Group (RSG)|This group consists of all NEN patients who have measurable tumor burden on imaging (and who do not fulfill the criteria for the Intensive Sampling Group) and are willing to participate in the study.
62685742|NCT06541080||Intensive Sampling Group (ISG)|This group consists of patients who at baseline or during the course of the study patients in this group (i) have a histologically confirmed NEN of WHO 2019 grade 1-3 NET or NEC from pancreatic, colorectal, or small intestinal origin and (ii) are starting any kind of 1st line systemic treatment (e.g. somatostatin analogues, targeted therapy, chemotherapy, etc.).
62685743|NCT04562519|EXPERIMENTAL|diabetic HD group|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
61924353|NCT06418152|EXPERIMENTAL|Interventional Arm|Up to five individuals with PD and DBS will receive the DART intervention. The 16 DART sessions will be delivered over an 8-week period (but not more than 10-weeks). Each DART session will consist of approximately 30-minutes of dual-task activity and will be scheduled over a 1 hour period. A physical therapist or physical therapist assistant will oversee each session. Exercises will be progressed based on results from the DART platform, feedback from the participant, and the clinical expertise of the physical therapist or physical therapist assistant
62685744|NCT04562519|ACTIVE_COMPARATOR|Nondiabetic goup|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
62685745|NCT05746273|EXPERIMENTAL|Transdermal Nicotine Patch|Participants will be randomized to apply nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 7mg in the first 3 weeks. Doses can be optionally titrated to a maximum of 14mg over 12 weeks, based on tolerability and perceived benefit. After 12 weeks, the patch dose will be tapered over 2-3 weeks.
62685746|NCT05746273|PLACEBO_COMPARATOR|Transdermal Placebo Patch|Participants will be randomized to apply placebo transdermal patches during waking hours. Placebo patch titration will mirror the active arm, increasing the dose will titrate up from 3.5mg to 7mg in the first 3 weeks. Doses can be optionally titrated to a maximum of 14mg over 12 weeks, based on tolerability and perceived benefit. After 12 weeks, the patch dose will be tapered over 2-3 weeks.
62125831|NCT01689090|EXPERIMENTAL|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions at two examination days.
62125832|NCT01689090|EXPERIMENTAL|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions at two examination days.
62478989|NCT04132518|EXPERIMENTAL|Group B: Sculptra|Participants in Group B will receive up to 4 injections of Sculptra from Day 1 with 5 (±1) weeks (at least 4 weeks) intervals and will be followed up for 24 months.
62478990|NCT04132518|NO_INTERVENTION|Group B: Control|Participants in Group B will not receive any treatment and participants will be followed up for 12 months.
62685747|NCT03412552||severe preeclampsia without HELLP syndrome|severe preeclampsia if they met one or more of the following criteria of The American College of Obstetricians and Gynecologists (10): systolic blood pressure \>160 mm/ Hg or diastolic blood pressure \>110 mm/Hg, headache, epigastric or right-upper-quadrant pain, visual disturbances,pulmonary edema, and proteinuria (urinary protein level \>5 g/24 h).Women with severe preeclampsia selected for analysis also met all of the following laboratory criteria: platelet count ≥150,000/ mm3, serum lactate dehydrogenase \<600 IU /dL, serum total bilirubin \<1.2 mg/dL and serum aspartate aminotransferase \<70IU/L
62685748|NCT03412552||eclampsia without HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded
62125833|NCT05815797|EXPERIMENTAL|SDD Formula|Subjects will receive SDD Formula granules (37g twice daily) for 12 weeks.
62125834|NCT05815797|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo granules (37g twice daily) for 12 weeks.
62125835|NCT02663778|ACTIVE_COMPARATOR|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
62125836|NCT02663778|EXPERIMENTAL|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
62339674|NCT05672966|PLACEBO_COMPARATOR|1-Placebo|Subjects received placebo
62478991|NCT04099823|OTHER|MR brain|"Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.~Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.~Those who meet eligibility criteria for the study and have agreed to participate will be taken to the MRI suite when MR imaging of the brain will be performed."
62685749|NCT03412552||eclampsia with HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded.HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (\<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
62685750|NCT03412552||HELLP syndrome without eclampsia|HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (\<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
62478992|NCT04456881|EXPERIMENTAL|anatomical reconstruction group of Patellofemoral ligament|
62478993|NCT03710928|EXPERIMENTAL|very low carbohydrate diet|Dietary Intervention, food delivery
62478994|NCT03710928|ACTIVE_COMPARATOR|standard diet|Dietary Intervention, food delivery
62125837|NCT05357469|EXPERIMENTAL|Immediate St (Scrambler Therapy)|Participant will start ST (Scrambler Therapy) treatment right away.
62478995|NCT02510118|EXPERIMENTAL|conventional chemotherapy + placebo ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the placebo ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency.
62685751|NCT02452593|ACTIVE_COMPARATOR|"Tibial Nerve Stimulation"|"This group will do transcutaneous electrical stimulation of the tibial nerve at home.~Development of an innovative portable equipment, with domestic technology for home application of the posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Frequency: 20 Hz, Pulse width: 200 us; duration: 15min daily"
62685752|NCT02452593|ACTIVE_COMPARATOR|"Pelvic Floor Exercises"|This group will make pelvic muscle training 3 times a day . In decubit dorsal posture, legs flexed and abductee. Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and contractions keeping 4 seconds and relaxing 8 seconds for 10 times.
62685753|NCT02920047|EXPERIMENTAL|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 14 days between the each period."
62685754|NCT02920047|EXPERIMENTAL|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
62685755|NCT02920047|EXPERIMENTAL|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
62685756|NCT02189629|EXPERIMENTAL|CD5789 (trifarotene) cream|
62685757|NCT06045247|EXPERIMENTAL|R-miniCVP+ Epcoritamab|Starting on Day 1 of Cycle 2, you will also receive epcoritamab 1 time each week (Days 1, 8, 15, and 22 of each cycle). Epcoritamab is given as an injection under your skin, after you complete your dose of R-miniCVP. You may receive up to 6 cycles of R-miniCVP (Cycles 1-6) and up to 11 cycles of epcoritamab (Cycles 2-12), depending on how the disease responds to treatment.
62685758|NCT05773586|EXPERIMENTAL|Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)|Subjects will be randomized to receive a single dose of APG-5918 or placebo.
62685759|NCT05773586|EXPERIMENTAL|Multiple Ascending Dose (MAD) cohorts in Anemic Patients (Part B)|Subjects will receive once daily APG-5918 or for 28 days.
62685760|NCT06674954|ACTIVE_COMPARATOR|Regional anesthesia|After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block, superficial cervical block, and supraclavicular brachial plexus block will be applied to these patients under ultrasound guidance. Total of 40 ml of local anesthetic solution (20 ml %0.5 bupivacaine + 10 ml %2 lidocaine + 10 ml physiological saline) will be prepared; 15 ml will be used for interscalene brachial plexus block, 10 ml will be used for superficial cervical block, and 15 ml will be used for supraclavicular brachial plexus block.
62685761|NCT06674954|ACTIVE_COMPARATOR|General anesthesia|Anesthesia induction will be performed with 2.5 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl. Maintenance will be achieved with sevoflurane (MAC: 0.9-1.0) and remifentanil (0.05-0.2 mcg/kg/min). Remifentanil titration will be done according to basal heart rate and blood pressure.
62685762|NCT04562805|EXPERIMENTAL|DynamX Bioadaptor|Elixir Medical DynamX™ Sirolimus Eluting Coronary Bioadaptor
62685763|NCT04562805|ACTIVE_COMPARATOR|Medtronic Resolute Onyx Stent|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
62685764|NCT01908387|EXPERIMENTAL|Oral azacitidine|
62685765|NCT05938816|EXPERIMENTAL|Mindfulness-Based Stress Reduction|
62685766|NCT05938816|PLACEBO_COMPARATOR|Health and Wellness Education|
62685767|NCT04413708|EXPERIMENTAL|P3-T PrEP adherence app|"Intended app use includes, at a minimum, participant completion of selected app activities (medication tracking, daily quest, social wall post) each day for the 3 month intervention period.~Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit."
62685768|NCT04413708|NO_INTERVENTION|Standard of Care|Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit.
62685769|NCT04203771|EXPERIMENTAL|Probiotic|Orodispersible tablets containing AB-DENTALAC probiotic formula.
62685770|NCT04203771|PLACEBO_COMPARATOR|Control|Orodispersible tablets without probiotic strains (excipients only).
62737851|NCT01483235|ACTIVE_COMPARATOR|Standard cardiac rehabilitation (sCRP)|The standard cardiac rehabilitation (sCRP) follows the standard cardiac rehabilitation program model of a four-month period. Patients receive an initial intake evaluation by a cardiologist, nurse, exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counseling, medical care, psychological screening and smoking cessation if needed.
62737852|NCT04654169|EXPERIMENTAL|The IAI and SSNB group|Ultrasound-guided IAI and SSNB are planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
61924354|NCT06491914|EXPERIMENTAL|Aflibercept 8 mg|Participants previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications
61924355|NCT05472454|OTHER|Ready-to-eat meals|Pre-Post
61924356|NCT00440778|EXPERIMENTAL|Gr 1 - intracoronary + infusion|abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion
61924357|NCT00440778|EXPERIMENTAL|Gr 2 - intracoronary|100% abciximab bolus dose 0.3 mg/kg ic
62125838|NCT05357469|EXPERIMENTAL|Waitlist ST (Scrambler Therapy)|Participant will start ST (Scrambler Therapy) treatment about 4 weeks after your Baseline Visit.
62125839|NCT01267383|EXPERIMENTAL|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
62125840|NCT01267383|ACTIVE_COMPARATOR|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
62339675|NCT05672966|EXPERIMENTAL|2-BV601DP(High dose HPV vaccine with adjuvant)|Subjects received high dose of BV601DP
62737853|NCT04654169|ACTIVE_COMPARATOR|The only-IAI group|Ultrasound-guided IAI is planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
62685771|NCT06481813|OTHER|Cohort A|"Patients are prospectively enrolled the day before their surgery for lung cancer, following selection based on tumor size assessed by the latest CT scan. The lesion size must be ≥ 20 mm (to prioritize anatomopathological analyses performed as part of care). If patients receive adjuvant treatment, blood samples will be collected on the day of treatment initiation and during follow-up. Patients receiving neoadjuvant treatment will be enrolled at the time of their first consultation with the medical oncologist.~Patients in this cohort must meet the following criteria:~- Stage I / II / IIIA-B localized NSCLC (non-small-cell lung cancer) eligible for surgery and adjuvant or neoadjuvant therapy (15-20% of NSCLC)~Intervention : patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)"
62316007|NCT05598996|NO_INTERVENTION|Control|The non-COT approach was designed to be an equivalent to emerging standard of care options for digital health worksite wellness programs to increase PA (control) for a 12-month study period. Participants assigned to the non-COT-based (control) group will receive the latest Fitbit Versa smartwatch and will download the Fitbit smartphone app. Unlike the intervention group, the daily step goal and the accompanying number of points will be static (10,000 steps/day; 150 points/day, respectively). The goal will be delivered to participants via the standard Fitbit app features and points will be communicated via email. Participants will also receive a weekly PA goal (150 minutes of MVPA/per week) and the same accompanying motivational and informative texts that the intervention group receives. Control participants will not complete the physical activity and exercise reflection and planning exercise (Reflect).
62316008|NCT01624129||eosinophilic esophagitis|patients with histopathological defined eosinophilic esophagitis
62685772|NCT06481813|OTHER|Cohort B|"Patients are prospectively enrolled at the diagnosis of lung neoplasm, during the establishment of the therapeutic plan by the referring oncologist or pneumo-oncologist. Enrollment can also occur at the initiation of first-line treatment if it was not done at the time of the diagnostic consultation.~Patients in this cohort must meet the following criteria:~- metastatic NSCLC or SCLC (small-cell bronchial cancers), with drained or punctured pleural effusion and anatomopathological evidence of tumor cells~Intervention, the following volumes of blood will be drawn at each visit :~* 2\*8ml (EDTA tubes)~* 1\*8mL PBMC (only for patients receiving immunotherapy, collected before the 1st course of treatment, before the 2nd course of treatment, and at relapse)~* 1\*6mL Paxgene (only for patients with lung cancer of non-epidermoid histology, collected at 1st treatment, 2nd treatment and relapse)"
62685773|NCT06481813|OTHER|Cohort C|"Cohort C patients are recruited in the same way as for cohort B.~Patients in this cohort must meet the following criteria:~* Metastatic NSCLC receiving systemic chemotherapy, immunotherapy and/or targeted therapy~* Locally advanced stage III NSCLC treated with radio-chemotherapy +/- immunotherapy~* Extra-thoracic SCLC treated with chemotherapy +/- immunotherapy~* Intra-thoracic SCLC treated with radio-chemotherapy~Intervention, the following volumes of blood will be drawn at each visit :~* 2\*8ml (EDTA tubes)~* 1\*8mL PBMC (only for patients receiving immunotherapy, collected before the 1st course of treatment, before the 2nd course of treatment, and at relapse)~* 1\*6mL Paxgene (only for patients with lung cancer of non-epidermoid histology, collected at 1st treatment, 2nd treatment and relapse)"
62685774|NCT06481813|OTHER|Cohort BMB|"Patients are enrolled preoperatively, at the diagnosis of metastatic lung cancer at the cerebral level. The patient signs consent preoperatively (consent provided by the neurosurgeon). Subsequently, they are prospectively followed as part of their management in medical oncology, postoperatively.~Patients in this cohort must meet the following criteria:~- Patient operated on for brain metastasis as part of care, and diagnosed with lung cancer.~Intervention, the following volumes of blood will be drawn at each visit :~* 2\*8ml (EDTA tubes)~* 1\*8mL PBMC (only for patients receiving immunotherapy, collected before the 1st course of treatment, before the 2nd course of treatment, and at relapse)~* 1\*6mL Paxgene (only for patients with lung cancer of non-epidermoid histology, collected at 1st treatment, 2nd treatment and relapse)"
62737854|NCT02765815|ACTIVE_COMPARATOR|Exparel plus multi-drug cocktail|Liposomal bupivacaine, 266mg plus Bupivacaine 0.25% with Epinephrine, Ketorolac 30mg, and Morphine 10mg.
62125841|NCT02108210|EXPERIMENTAL|Anakinra|This therapy will consist of once daily subcutaneous injections (100mg/day) during a period of 4 weeks. Patients will be monitored at week 1 and week 4 after starting medication for development of side effects. Therapy will be stopped in case of severe side effects, interfering disease or pregnancy. During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards.
62316009|NCT02739698|EXPERIMENTAL|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
61924358|NCT00440778|ACTIVE_COMPARATOR|Gr 3 - intravenous|abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion
61924359|NCT00440778|EXPERIMENTAL|Gr 4 - intravenous|100% abciximab bolus dose 0.3 mg/kg iv
62316010|NCT02739698|EXPERIMENTAL|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
62316011|NCT03262493|EXPERIMENTAL|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
62316012|NCT03262493|NO_INTERVENTION|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
62685775|NCT06481813|OTHER|Healthy Controls :|"A population of healthy subjects will also be included. These healthy subjects will be either :~* Companions of patients with lung cancer who have come to the oncology clinic for their loved ones.~* Patients who have undergone atypical lung resection as part of their care for pneumothorax.~Intervention : Healthy subject will be sampled from 2 x 8 mL blood tubes (EDTA tubes)~In addition to blood samples from healthy subjects, healthy tissue remnants from atypical lung resections performed as part of care for pneumothorax management will be used to analyze the study objectives.~A maximum of 30 healthy subjects are expected in this population."
62685776|NCT06481813|OTHER|Ancillary study|"Patients included in the other arms of the cohort may also participate in the ancillary study if they meet the following conditions :~Being carriers of metastatic KRAS G12C mutated NSCLC with a treatment plan involving sotorasib, adagrasib, or another KRAS inhibitor, either alone or in combination with another treatment.~A target of 40 patients (among the 700 patients included in the cohort, excluding healthy subjects) is set for the ancillary study."
62685777|NCT00005775|EXPERIMENTAL|Glutamine|TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids) with L-glutamine added (20% of the total amount of amino acids)
62685778|NCT00005775|PLACEBO_COMPARATOR|Placebo|Standard TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids)
62685779|NCT05900349|EXPERIMENTAL|Carbohydrate mouth rinsing|Rinsing mineral water for 20 seconds
62685780|NCT05900349|EXPERIMENTAL|caffeine gum|placebo gum chewing for 10 min
62685781|NCT06413875|EXPERIMENTAL|enterprise group|The data collection form was sent online to the participants in the sample and they were asked to fill it out (pre-test). Two separate groups were opened on WhatsApp for the intervention and control groups. For this reason, in this study, the educational intervention included sending an informative video once a week and informative messages three days a week for four weeks.In the intervention part of the study, after all participants filled out the data collection form, the intervention group was informed about Menopause once a week on the first day of each week for four weeks. An information video prepared in line with the topics specified in the Symptom-Specific Training Booklet has been sent. Informative messages were sent via WhatsApp three days a week, in parallel with the training topic of each week (training intervention).After the training, a data collection form was sent to the intervention group via WhatsApp and the participants were asked to fill it out again (posttest).
62685782|NCT06413875|NO_INTERVENTION|control group|The data collection form was sent online to the participants in the sample and they were asked to fill it out (pre-test). No educational intervention was given to the control group. After the training, a data collection form was sent to the control group via WhatsApp and the participants were asked to fill it out again (posttest).
62685783|NCT00423865|EXPERIMENTAL|cisplatin & RAD001|This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid tumors
62685784|NCT05069740|EXPERIMENTAL|Salsalate|3000 mg/day salsalate (1500 mg twice daily) for 5 days
62685785|NCT05069740|PLACEBO_COMPARATOR|Placebo|1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days
62685786|NCT06655727||Parkinson disease group|Patients with Parkinson's disease
62685787|NCT06655727||Control group|Healthy volunteers
62685788|NCT02986438|ACTIVE_COMPARATOR|Active rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold.
62685789|NCT02986438|SHAM_COMPARATOR|Sham rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
62685790|NCT03982693|ACTIVE_COMPARATOR|Active|edetate disodium (EDTA)dff active infusion
62685791|NCT03982693|PLACEBO_COMPARATOR|Placebo|Placebo infusion
62685792|NCT02462629|EXPERIMENTAL|BLZ-100|
62685793|NCT04050436|EXPERIMENTAL|Cemiplimab in combination with RP1|Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks
62685794|NCT04050436|ACTIVE_COMPARATOR|Cemiplimab|Cemiplimab administered intravenously as a single therapy every 3 weeks
62685795|NCT06569615|EXPERIMENTAL|Group 1|shock wave Group
62685796|NCT06569615|EXPERIMENTAL|Group 2|LASER Group
62685797|NCT06569615|EXPERIMENTAL|Group 3|Cryotherapy Group
62685798|NCT01378273|PLACEBO_COMPARATOR|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
62685799|NCT01378273|EXPERIMENTAL|Epo 1000 U/kg followed by 400 U/kg|Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.
62685800|NCT06470919|EXPERIMENTAL|Next Generation digital vaccine card with SMS reminders for upcoming vaccination(s)|
62685801|NCT06470919|NO_INTERVENTION|Pre-intervention cohort|This group will be compared to the post-intervention group to assess the digital vaccine card.
62685802|NCT05532163|EXPERIMENTAL|Natalizumab|Participants will receive natalizumab 300 milligrams (mg) (2\*150 mg), SC injection, once every 4 weeks (Q4W) up to Week 24.
62685803|NCT02867423|OTHER|A - CK boost radiation|CK boost radiation
62685804|NCT02290951|EXPERIMENTAL|Part A|DLBCL post CAR-T
62685805|NCT02290951|EXPERIMENTAL|1N Part B|FL
62685806|NCT02290951|EXPERIMENTAL|2N Part B|DLBCL
62685807|NCT06674226|EXPERIMENTAL|Ciprofol group|"Interventions:~Drug:Ciprofol"
61924360|NCT01698632||benign-looking adnexal masses|
62316013|NCT02158143|EXPERIMENTAL|vitamin D3|
62685808|NCT06674226|ACTIVE_COMPARATOR|Propofol group|Drug:Propofol
62339676|NCT05672966|EXPERIMENTAL|2-BV601DPP(High dose HPV vaccine without adjuvant)|Subjects received high dose of BV601DPP
62339677|NCT05672966|PLACEBO_COMPARATOR|2-Placebo|Subjects received placebo
62685809|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
62685810|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
62685811|NCT05137626|EXPERIMENTAL|AT-527 + digoxin (simultaneous)|n=14
62685812|NCT05137626|EXPERIMENTAL|AT-527 + digoxin (staggered)|n=14
62685813|NCT06674941|EXPERIMENTAL|Cohort 1: Teprotumumab|Non-Japanese participants will receive SC injection of teprotumumab Dose A by a syringe pump.
62685814|NCT06674941|EXPERIMENTAL|Cohort 2: Teprotumumab|Japanese participants will receive SC injection of teprotumumab Dose A by a syringe pump.
62685815|NCT06674941|EXPERIMENTAL|Cohort 3: Teprotumumab|Non-Japanese participants will receive SC injection of teprotumumab Dose B by an injection device.
62316014|NCT02261480||Group A: Documented Prior History|"Pediatric and adult participants with sickle cell disease (SCD) with a documented prior history of parvovirus B19 infection (aplastic crisis).~Group A participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group A."
61924361|NCT00597701|ACTIVE_COMPARATOR|Baclofen|Standard benzodiazepine therapy plus baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
61924362|NCT00597701|PLACEBO_COMPARATOR|Placebo|Standard benzodiazepine therapy plus placebo every eight hous as inpatients for 72 hours or until discharge if less than 72 hours.
61924363|NCT04746716||Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who had a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
61924364|NCT04746716||No Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who hadn't a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
61924365|NCT04720157|EXPERIMENTAL|177Lu-PSMA-617|Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
61924366|NCT04720157|ACTIVE_COMPARATOR|Standard of Care|For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
61924367|NCT01596673|EXPERIMENTAL|BCAD Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet)."
61924368|NCT01596673|EXPERIMENTAL|CDBA Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet (matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet."
62316015|NCT02261480||Group B: No Prior History|"Pediatric and adult participants with SCD who have never had a documented parvovirus B19 infection (aplastic crisis).~Group B participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group B."
62685816|NCT06380504|NO_INTERVENTION|Standard of Care|"* Usual screening of wasting by health extension workers (HEW) using MUAC~* Previous introduction of Family-led MUAC (not maintained)~* Behavior Change Communication (BCC) offered by Health extension worker (low intensity)~* Treatment of SAM at health post or health center~* Follow-up of SAM OTP defaults through home visits by HEW (very low intensity)"
62316016|NCT02261480||Group C: Suspected and/or Confirmed|"Sickle cell disease patients with suspected and/or confirmed acute parvovirus B19 infection, the latter defined as febrile illness with anemia without adequate compensatory reticulocytosis.~Group C participants will have blood draw and nasopharyngeal wash on day 1, day 7±4 days, day 30±7 days, and day 120±14 days."
62685817|NCT06380504|EXPERIMENTAL|R-SWITCH integrated intervention package|"1. Monthly group meetings of AFD community groups~2. Introduction of weight-for-age Z-score \<-3 as an additional screening criterion~3. Promotion of Family-led MUAC screening and SAM awareness to fathers, community and religious leaders~4. Follow-up and counselling during home visits by AFD leaders~5. Strengthening communication between HEW and AFDs"
62316017|NCT03952923|EXPERIMENTAL|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
62316018|NCT01052012|EXPERIMENTAL|Active: SABER-Bupivacaine|SABER-Bupivacaine
62316019|NCT01052012|ACTIVE_COMPARATOR|Comparator: Bupivacaine HCl|Bupivacaine HCl
62316020|NCT01052012|PLACEBO_COMPARATOR|Placebo: SABER-Placebo|SABER-Placebo
62316021|NCT05378789|EXPERIMENTAL|20-min nap|"ICU nurses can take a 20-minute nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
62316022|NCT00477529|EXPERIMENTAL|ABI-008|
62339678|NCT00679731|EXPERIMENTAL|A|ABT-874
62316023|NCT02295930|EXPERIMENTAL|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
62316024|NCT02295930|EXPERIMENTAL|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
62316025|NCT04709861||Retrospective 6 week Weight-Bearing|Delayed weight-bearing 6 weeks after total ankle replacement
62316026|NCT04709861||Prospective 2 week Weight-Bearing|Early weight-bearing 2 weeks after total ankle replacement
62316027|NCT02229994||Adults patients with chronic respiratory diseases|"- 200 adult patients with chronic respiratory diseases will be studied longitudinally and transversely (follow-up: 6 months) in 12 centres.~1. Sample 1 (n=110 patients) with COPD~2. Sample 2 (n=30 patients) with Diffuse interstitial lung diseases~3. Sample 3 (n=30 patients) with Pulmonary Arterial Hypertension primary or secondary (post embolic .....).~4. Sample 4 (n=30 patients) Adult with Cystic fibrosis"
62316028|NCT04086303|EXPERIMENTAL|young handball players|The first group was named young players (n = 19; age = 18.05 ± 2.58 years, body mass index = 22.0 ± 2.21 kg, sport participation ≤ 10 years)
62316029|NCT04086303|ACTIVE_COMPARATOR|adult handball players|The second group was named old players (n =23; age = 28,91 ± 3.39 years, body mass index = 22.20 ± 2.75 kg, sport participation ≥ 11 years).
62316030|NCT05986539||Breastfeeding dyad|Women, and their infants, that intend to exclusively breastfeed or begin using formula as supplemental to breastmilk throughout the study.
62316031|NCT05986539||Formula feeding dyads|Women, and their infants, that intend to exclusively use formula from 6-18 weeks of life, the duration of the study,
62316032|NCT01272180|EXPERIMENTAL|ABCWY+OMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart."
62316033|NCT01272180|EXPERIMENTAL|ABCWY+qOMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart."
62316034|NCT01272180|ACTIVE_COMPARATOR|rMenB+OMV|"Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart."
62316035|NCT01272180|ACTIVE_COMPARATOR|MenACWY|"Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later."
62316036|NCT03884348||PAM-treated clarithromycin-resistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
62316037|NCT03884348||PAC-treated nonresistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
62316038|NCT05502848|EXPERIMENTAL|AD patients treated with ICBT|
62316039|NCT05502848|NO_INTERVENTION|AD patients receiving regular treatment|
62316040|NCT05502848|NO_INTERVENTION|Healthy Controls|
62339679|NCT00679731|ACTIVE_COMPARATOR|B|Methotrexate
62316041|NCT01126619||Anti-TNF|Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor (anti-TNF) agent prior to enrollment according to national approved indications and reimbursement guidelines.
62316042|NCT02463266||SUSTAIN Monitoring and Care Management|SUSTAIN program participants who complete an initial clinical assessment and, if indicated, agree to follow-up services including Monitoring and/or Care Management.
62316043|NCT01004146|PLACEBO_COMPARATOR|Control group|Patients assigned to the control group were educated on the proper technique of using the incentive spirometer and were instructed to use it for 3 breaths once per day to become able to use the device properly and consistently.
62316044|NCT01004146|EXPERIMENTAL|Experimental Group|Patients assigned to the experimental group were instructed to use the spirometer by inhaling as slowly and deeply as possible in a set of 10 times and to repeat the process at least 5 times every day until the day of surgery.
62316045|NCT02298517|NO_INTERVENTION|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
62316046|NCT02298517|EXPERIMENTAL|Incentive spirometry to flow|Was determined for this study that the flow of inspired air will be sufficient to raise up to three spheres. In addition to direct them to do explosive, fast and deep, lifting the ball explosively breaths. Every fifteen inspirations volunteers will be invited to rest for intervals of 30-60 seconds and repeat six times. The use of incentive spirometry was adapted from the recommendations of the American Association for Respiratory Care (1991).
62316047|NCT02298517|EXPERIMENTAL|incentive spirometry to volume|Use of this incentive spirometry will be done as follows: the participants will be instructed to inhale deeply through the mouthpiece, to total lung capacity, starting from functional residual capacity. Will be performed 6 sets of 15 breaths each (deep, slow and sustained) intervals with 30-60 seconds between each series.
62316048|NCT02298517|EXPERIMENTAL|inspiratory load equipment-Threshold|This group will use the device Threshold™. Where adjustment is considered 40% of PNSN achieved by the patient evaluation. The volunteer will be instructed to remain in a supine position with 45 ° fowler comfortably with arms and shoulders relaxed and perform an inspiration with enough force to overcome the linear load of the device, then make a normal expiration. This study was determined to carry six sets of 15 repetitions. The rest will be about one to two minutes in each intervention.
62316049|NCT02298517|EXPERIMENTAL|inspiratory load equipment-Power breathe|To exercise inspiratory muscle in this group will be used device Power breathe ® K2 have the same resistance setting, allowing us to tailor your level of inspiratory muscles. Such adjustment will be made considering 40% of PNSN achieved by the patient in the assessment sniff. For its implementation, the patient will be lying with a tilt of the head of the litter at 45 °, the patient will be asked to inspire to overcome the resistance of the linear unit and after performing a normal expiration. This group will also be achieved 6 series with 15 repetitions each, with an interval of one to two minutes between sets.
62316050|NCT00514449|EXPERIMENTAL|Valacyclovir|1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
62316051|NCT00514449|PLACEBO_COMPARATOR|Sugar pill|2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.
62125842|NCT02108210|PLACEBO_COMPARATOR|Placebo|"Patients in the placebo group will also receive once daily subcutaneous injection during a period of 4 weeks. Placebo injections will be identically in appearance compared to the Anakinra injections. Patients in the placebo group will have the same visits and monitoring for side effects as the patients randomized to the other treatment arm.~During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards."
62125843|NCT04469855||Ozempic®|Japanese people with type 2 diabetes being treated in normal clinical practice conditions
62125844|NCT05429034|EXPERIMENTAL|MIST-paradigm|Patients assigned to the MIST paradigm arm are exposed to psychosocial stress.
62125845|NCT05429034|SHAM_COMPARATOR|Sham-paradigm|Patients assigned to the sham paradigm are not exposed to psychosocial stress.
62125846|NCT04600440|EXPERIMENTAL|Plasma treatment|Convalescent plasma 200 ml daily during three days
62316052|NCT00554294|NO_INTERVENTION|Control group|Control schools had school curriculum as usual and did not receive environmental intervention.
62316053|NCT00554294|EXPERIMENTAL|Intervention group|Intervention schools received water dispensers, drinking bottles and lessons as intervention.
62316054|NCT02267512|EXPERIMENTAL|ATG-F single dosing group|Intravenous (IV)
62125847|NCT04600440|NO_INTERVENTION|No plasma|Best conventional treatment
62125848|NCT06437600|EXPERIMENTAL|The experimental group|Participants will receive immediate angioplasty (with or without stenting) for the culprit vessel and the target residual stenosis should be less than 30%. All participants will receive the best medical management (BMM).
62125849|NCT06437600|NO_INTERVENTION|The control group|Participants will receive BMM alone.
62125850|NCT04960072|EXPERIMENTAL|Tumor Infiltrating Lymphocytes|1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with relapsed/refractory malignant gastrointestinal tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
62125851|NCT00003432|EXPERIMENTAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed DC cancer vaccine
62316055|NCT02267512|EXPERIMENTAL|ATG-F continuous dosing group|Intravenous (IV)
62316056|NCT04982549|EXPERIMENTAL|Durvalumab + platinum-based chemotherapy and radiation|"All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide carboplatin/paclitaxel pemetrexed/cisplatin pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
62316057|NCT00541359|EXPERIMENTAL|Arm I|"PART I (completed as of 09/06/06; all patients enrolled in study after 09/06/06 are enrolled in part II): Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8 followed 6 hours later by bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive bortezomib IV on days 1, 4, 8, and 11 followed 6 hours later by escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~In both parts of the study, patients who achieve a response may receive additional courses of treatment."
62316058|NCT02405039|ACTIVE_COMPARATOR|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
62316059|NCT02405039|PLACEBO_COMPARATOR|Placebo or Vehicle control Comparator|One of two study arms: placebo or vehicle control topical administered 3 times per day
62316060|NCT06498102|EXPERIMENTAL|Time Restricted Feeding Group|Thirty-one healthy, young males (age: 27.5±6 years, body mass: 76.5±8.4 kg, and maximal oxygen uptake \[V̇O2max\]: 43.9±6.6 mL/kg/min) were randomly assigned to either TRF (n=14) or control group (n=17). TRF group followed an 16:8 intermittent fasting diet program for 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the diet program.
62316061|NCT06498102|NO_INTERVENTION|Control Group|Control group maintained their existing dietary habits during the 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the program.
62125852|NCT04356430|EXPERIMENTAL|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before robotic assisted radical prostatectomy
62125853|NCT04356430|EXPERIMENTAL|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robotic assisted radical prostatectomy. Goserelin 10.8 mg will be administered once per 12 weeks.
62125854|NCT00130156|EXPERIMENTAL|1|
62125855|NCT00130156|EXPERIMENTAL|2|
62125856|NCT02036307|EXPERIMENTAL|DHA-enriched|DHA-enriched supplement (DHA 3g + 600 mg EPA in 6 g of fish oil/day)
62125857|NCT02036307|EXPERIMENTAL|EPA-enriched|EPA-enriched supplement (EPA 2.4 g + DHA 600mg in 6 g of fish oil/day)
62125858|NCT01353001|EXPERIMENTAL|Diet Only|
62125859|NCT01353001|EXPERIMENTAL|Diet plus Aerobic Training|
62125860|NCT01353001|EXPERIMENTAL|Diet plus Resistance Training|
62316062|NCT03288584||Tocilizumab|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
62316063|NCT03288584||Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
62316064|NCT03288584||Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
62125861|NCT02015546|EXPERIMENTAL|Vilazodone 10mg|Vilazodone 10 mg/d arm (10mg/d initiation dose, titrated to 40 mg/d in 2 weeks, continued for 8 week trial)
62125862|NCT02015546|EXPERIMENTAL|Vilazodone 20mg|vilazodone 20 mg arm (20mg/d initiation dose, titrated to 40 mg/d in 1 week, continued for 8-week trial)
62125863|NCT02015546|EXPERIMENTAL|Vilazodone 40mg|vilazodone 40 mg/d arm (40 mg/d initiation and continuation dose for 8-week trial.
62125864|NCT05631210|NO_INTERVENTION|Normal privacy agreement|This group was the control. They were given a normal privacy agreement to read and interpret.
62125865|NCT05631210|EXPERIMENTAL|Pictogram privacy agreement|This group was given the same privacy agreement of the control group, but with the addition of pictograms that summarized the information.
62316065|NCT02571361|ACTIVE_COMPARATOR|Treatment A:|Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
62316066|NCT02571361|ACTIVE_COMPARATOR|Treatment B:|Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
62316067|NCT02571361|ACTIVE_COMPARATOR|Treatment C:|Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
62316068|NCT02571361|ACTIVE_COMPARATOR|Treatment D:|Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
62316069|NCT02887105||Patients with cerebrovascular accident|
62316070|NCT05299827||Children diagnosed with lower urinary system dysfunction (LUTD Group)|Children who are between the ages of 5-18 and diagnosed with lower urinary system dysfunction by pediatric urologist.
62316071|NCT05299827||Healty Group|Healthy participants in the same age group in the control group; The siblings or cousins of the cases who applied to Tuğtepe Pediatric Urology Center but did not meet the inclusion and exclusion criteria and/or the cases who applied to the outpatient clinic were determined to be healthy after being examined by the relevant physician, and consisted of girls and boys who volunteered to participate in the study. .
62316072|NCT02151500|EXPERIMENTAL|Stress and Health Interview|Stress and Health Interview is an experiential assessment technique
62125866|NCT06123871||Type 2 diabetes group|The group was based on the clinically confirmed diagnosis of type 2 diabetes
62125867|NCT06123871||Diabetic nephropathy group|The group was based on the clinically confirmed diagnosis of type 2 diabetes.The group was based on the clinically confirmed diagnosis of type 2 diabetes.Patients were re-screened strictly according to the following admission criteria: persistent albuminuria and/or decreased eGFR,while other causes of chronic kidney disease (CKD) were excluded. When diabetes mellitus is identified as the cause of kidney damage and other primary and secondary glomerular diseases and systemic diseases are excluded, at least one of the following conditions can be diagnosed as DKD: (1) Urinary Albumin/Creatinine Ratio(UACR)≥30 mg/g or Urinary albumin excretion rate (UAER)≥30 mg/24 h, The UACR or UAER was checked again within 3 to 6 months, and 2 out of 3 times reached or exceeded the critical value; Eliminate other interfering factors such as infection; (2) eGFR\&lt; 60 ml·min-1.(1.73 m2) -1 for more than 3 months;(3) Renal biopsy was consistent with DKD pathological changes.
62125868|NCT00334594|ACTIVE_COMPARATOR|No radiotherapy|
62125869|NCT00334594|EXPERIMENTAL|Radiotherapy|
62125870|NCT06191666|EXPERIMENTAL|Cancer Survivors|Cancer survivors with ow/ob who have completed active treatment will take part in a single-arm 12-week feasibility/acceptability/proof-of-concept study incorporating group nutrition education and discussion, skills development sessions and cooking demonstrations, and 1:1 counseling with a dietitian.
62125871|NCT00911521|ACTIVE_COMPARATOR|Vaccine arm|subjects receiving vaccination
62125872|NCT05624112|EXPERIMENTAL|AD patients|AD patients aged ≥12 and ≤ 65
62125873|NCT05624112|NO_INTERVENTION|Healthy volunteers|Non-treatment healthy volunteers
62125874|NCT05709899|OTHER|Group I : Bilateral erector spinae plane block at L1|"Ultrasound (US) will be used to identify the level of L1 after skin sterilization with the patient on the lateral position. A high frequency linear-array US transducer covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. 2-3 ml of 2% lidocaine depocaine HCL will be infiltrated.16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the US beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle. 20 ml of bupivacaine 0.25% sunnypivacaine will be injected in this potential space over five minutes. The injectate will be observed spreading underneath the ES muscle lifting the muscle of the transverse process. This will be repeated on the opposite side."
62316073|NCT02151500|NO_INTERVENTION|Wait-list Control|Standard medical care until the 6-week follow-up is completed
62316074|NCT01781026|EXPERIMENTAL|Vemurafenib Administration|Vemurafenib 960 mg orally, twice per day
62316075|NCT04806581|EXPERIMENTAL|Allogeneic Hepatocyte Cohort 1|"Participants will each be administered L dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: L"
62316076|NCT04806581|EXPERIMENTAL|Allogeneic Hepatocyte Cohort 2|"Participants will each be administered M dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: M"
62316077|NCT04806581|EXPERIMENTAL|Allogeneic Hepatocyte Cohort 3|"Participants will each be administered H dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: H"
62316078|NCT01105741||Active Crohn's disease - single arm|Active Crohn's disease, a decision is made to start treatment with adalimumab.
62316079|NCT05268094|EXPERIMENTAL|Ductal Artery Stent|Transcatheter ductal artery shunt will be placed by the interventional team. Drug-eluting coronary stent brand, length, and diameter are determined by the interventional team.
62737855|NCT02765815|ACTIVE_COMPARATOR|Multi-drug cocktail alone|Bupivacaine 0.5% with Epinephrine, Ketorolac 30mg, Morphine 10mg.
62316080|NCT05268094|EXPERIMENTAL|Systemic-to-Pulmonary Artery Shunt|Surgical systemic-to-pulmonary artery shunt performed by the interventional team. SPS diameter, length, and material will be determined by the surgeon performing the intervention.
62316081|NCT06003751|EXPERIMENTAL|Phase 2 Cohort A|Cohort A - Low Dose or Sham
62316082|NCT06003751|EXPERIMENTAL|Phase 2 Cohort B|Cohort B - High Dose or Sham
62685818|NCT02998125||before and after total knee arthroplasty|assess the functional outcome before and 6 months after total knee arthroplasty
61924369|NCT01596673|EXPERIMENTAL|DACB Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
62125875|NCT05709899|OTHER|Group II : Transmuscular quadratus lumborum block at L1|"Patient will be positioned in left lateral to obtain appropriate view of QL. Aseptic precautions will be taken by wearing sterile gown and sterile drapes. By using Ultrasound MacroMaxx™ with linear probe (HFL38_10-5 MHz) covered with sterile plastic sheath SiteRite placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this juncture the layers of abdominal layers will start to taper. When the probe will be placed in the posterior axillary line as per the posterior approach, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL noticed. At the junction of the tapered ends of abdominal muscles and QL, a 21 g 100 mm SonoPlexStimu cannula needle will be inserted in plane. Under ultrasound guidance, in that space 20 mL of 0.25% bupivacaine sunnypivacainewill be injected separating the fascia."
62125876|NCT02933944|EXPERIMENTAL|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
62125877|NCT03310866|ACTIVE_COMPARATOR|fiberoptic, airway|Classical fiberoptic intubation assisted by side fenestrated airway and head tilt- chin lift- jaw thrust by 2 anesthetist
62125878|NCT03310866|EXPERIMENTAL|fiberoptic, Machintosh|oral Fiberoptic bronchoscopic intubation assisted by Macintosh Laryngoscope, by 2 anesthetist
62125879|NCT03924037|ACTIVE_COMPARATOR|Zero Suicide|Participants randomly assigned to the Zero Suicide arm will also participate in a weekly support group until the final follow-up time point when they will be crossed-over into the intergenerational knowledge sharing group.
62125880|NCT03924037|EXPERIMENTAL|Zero Suicide plus KICKS|Participants randomly assigned to the Zero Suicide plus KICKS arm will participate in a weekly intergenerational knowledge sharing group.
62125881|NCT05800639||Children with emergence delirium|"Pediatric patients who develop emergence delirium in the post-anesthetic care unit (PACU).~Emergence delirium will be assessed using the Pediatric Assessment of Emergence Delirium (PAED) scale every 10 min until PACU discharge."
62125882|NCT05800639||Children without emergence delirium|"Pediatric patients who do not develop emergence delirium in the post-anesthetic care unit (PACU).~Emergence delirium will be assessed using the Pediatric Assessment of Emergence Delirium (PAED) scale every 10 min until PACU discharge."
62125883|NCT03436277|PLACEBO_COMPARATOR|Placebo|Sucralose 1,5 g
62125884|NCT03436277|EXPERIMENTAL|L-Carnitine|L- Carnitine 1,5 g
62125885|NCT04327167|OTHER|Digital intervention|
62125886|NCT04275245|EXPERIMENTAL|Meplazumab|10mg Meplazumab by intravenous infusion, every day for 2 days
62125887|NCT06198712|EXPERIMENTAL|Etavopivat|Participants will receive Etavopivat once daily (QD) orally.
62125888|NCT03090776|OTHER|unenriched|all eligible women for partial or total mastectomy intervention will be ketamine or placebo saline
62125889|NCT03090776|OTHER|enriched for PPMP risk|women at high risk for persistent pain after partial or total mastectomy intervention will be ketamine or placebo saline
62125890|NCT04691635||Group 1|Patients with Progressive Supranuclear Palsy
62316083|NCT01225393|EXPERIMENTAL|A|
62316084|NCT01225393|ACTIVE_COMPARATOR|B|
62316085|NCT01225393|PLACEBO_COMPARATOR|C|
62685819|NCT06684379|ACTIVE_COMPARATOR|Saline Solution 0,9% for injection|Participants will receive a single 10 mL dose Intravenous (IV) infusion of normal saline (0.9%)
62685820|NCT06684379|EXPERIMENTAL|PRS CK STORM - dose A|A sterile secretome derived from the co-culture of M2-type macrophages and ASC (adipose stromal cells) containing 116,059 pg/mL Tissue Inhibitor of Matrix Metalloproteinase- 1 (TIMP-1). Participants will receive a total dose of 1,160,585.366 pg of TIMP-1 via IV infusion
61924370|NCT01596673|EXPERIMENTAL|ABDC Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
62685821|NCT06684379|EXPERIMENTAL|PRS CK STORM - dose B|A sterile secretome derived from the co-culture of M2-type macrophages and ASC (adipose stromal cells) containing 232,017 pg/mL TIMP-1. Participants will receive a total dose of 1,160,585.366 pg of TIMP-1 via IV infusion.
61924371|NCT03486717|EXPERIMENTAL|Control|Study group that does not wear the virtual reality goggles. This group will serve as a control.
62685822|NCT04162158|EXPERIMENTAL|Targeted drug combined with allogeneic NK cell treatment group|In addition to traditional symptomatic supportive treatment, Sorafenib, regolfinib or levabinib will be administered in combination with allogeneic NK cells (3 cycles).
61924372|NCT03175432|EXPERIMENTAL|Arm I (atezolizumab, bevacizumab)|Participants receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
61924373|NCT03175432|EXPERIMENTAL|Arm II (atezolizumab, bevacizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62125891|NCT04691635||Group 2|Patients with Parkinson's disease
61924374|NCT03626571||Native valve infective endocarditis|Patients with infective endocarditis of native valves of the heart with no contraindications to MRI scanning.
61924375|NCT03626571||Prosthetic endocarditis|Patients with endocarditis of prosthetic heart valves or device-related infections.
61924376|NCT03626571||Non-infective post-operative|Patients who have recently undergone valve or device implantation with no evidence of post-operative infection.
61924377|NCT01397812||1|"Subjects will comprise of patients who are the recipients of a heart transplant within the previous 12 months and are scheduled for a routine endomyocardial biopsy.~Subjects will provide breath samples for the Heartsbreath test using the BreathScanner 1.0. Optionally subjects will provide breath samples using the BreathLink point of care system."
61924378|NCT05868668|EXPERIMENTAL|fSWT|Focused Shock wave treatments
61924379|NCT05868668|ACTIVE_COMPARATOR|rWT|Radial wave treatments
61924380|NCT05868668|SHAM_COMPARATOR|Sham|Sham treatments
61924381|NCT06282848|ACTIVE_COMPARATOR|Atropine 0.05%|Group receiving atropine treatment for 18 months after 6 months of monitoring without intervention
61924382|NCT06282848|EXPERIMENTAL|DIMS lens|Group receiving DIMS lens treatment for 18 months after 6 months of monitoring without intervention
61924383|NCT02610959|EXPERIMENTAL|Intervention group|Intervention with cod 200 grams two times the week for four months.
61924384|NCT02610959|EXPERIMENTAL|Control group|Control group which will continue to eat their habitual diet.
61924385|NCT00644748|EXPERIMENTAL|Gabapentin group|
61924386|NCT02250027|EXPERIMENTAL|experimental A (0.6g/day)|HL301 0.6g/day: 2 capsules at once, 3 times a day, for 7 days
62125892|NCT04691635||Group 3|Healthy controls
62125893|NCT01130727|ACTIVE_COMPARATOR|green tea extract|
62125894|NCT01130727|ACTIVE_COMPARATOR|Cocoa extract rich in polyphenols|
62125895|NCT01130727|PLACEBO_COMPARATOR|placebo|
62685823|NCT04162158|NO_INTERVENTION|Targeted drug treatment group|Sorafenib, regolfinib or levabinib will be administered in addition to traditional symptomatic supportive care.
62316086|NCT06483100|EXPERIMENTAL|Elranatamab|"Patients will receive at least 12 months of maintenance elranatamab therapy. Patients will have MRD testing within clonoSEQ every 6 months. If 2 consecutive tests are negative, elranatamab will be stopped and the patient will go on observation schedule.~Once a patient starts the observation schedule, standard disease monitoring will be performed every 3 months and bone marrow-based MRD will be performed every 6 months until MRD recurrence, disease progression or end of study period (patients' on-study status will be a maximum of 36 months for treatment and intensive observation combined). Patients who experience MRD recurrence will be re-treated per study protocol. A patient may move back to the observation schedule after treatment re-initiation provided the same criteria as above are met (2 consecutive negative MRD tests). Patients who are determined to have progressive disease per IMWG criteria (whether on treatment or observation schedule) will transition off study."
62685824|NCT00498966|EXPERIMENTAL|Group A|Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor.Intervention: Perifosine.
62685825|NCT00498966|EXPERIMENTAL|Group B|Patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Intervention: Perifosine.
62685826|NCT03105765|ACTIVE_COMPARATOR|Ketamine|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours."
62685827|NCT03105765|PLACEBO_COMPARATOR|Placebo|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Placebo (normal Saline) for 24 hours."
62685828|NCT03796221|ACTIVE_COMPARATOR|Control Group|Will receive standard pediatric obesity treatment
62685829|NCT03796221|EXPERIMENTAL|Intervention Group|Will receive standard pediatric obesity treatment and parenting videos
62685830|NCT01963832|EXPERIMENTAL|eCMIT and Fluoxetine|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)
62685831|NCT01963832|EXPERIMENTAL|eCIMT and placebo|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo
61924387|NCT02250027|EXPERIMENTAL|experimental B (1.2g/day)|HL301 1.2g/day: 2 capsules at once, 3 times a day, for 7 days
62125896|NCT01130727|PLACEBO_COMPARATOR|cocoa extract with low polyphenol|
62125897|NCT01361945|EXPERIMENTAL|AUY922|Single Arm
62125898|NCT06281808|EXPERIMENTAL|Photon Counting Detector CT|PCD CT
62125899|NCT02178098|EXPERIMENTAL|ETC-1002|ETC-1002 180 mg/day
62125900|NCT02178098|PLACEBO_COMPARATOR|Placebo|Placebo control
62685832|NCT01963832|EXPERIMENTAL|Usual care and fluoxetine|Ususal physical care combined with Fluoxetine (FLX)
61924388|NCT02250027|EXPERIMENTAL|experimental C (1.8g/day)|HL301 1.8g/day: 2 capsules at once, 3 times a day, for 7 days
61924389|NCT02250027|PLACEBO_COMPARATOR|Placebo|placebo: 2 capsules at once, 3 times a day, for 7 days
62685833|NCT01963832|EXPERIMENTAL|Usual care and placebo|Usual physical care combined with placebo
62685834|NCT06357000||Time between the dates of PCI and cancer surgery <12 months|Time between the dates of PCI and cancer surgery \<12 months
61924390|NCT04510974||Cervical SCI|Ages between 21-70 years old Injured between C1-T1 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
61924391|NCT04510974||Thoracic SCI|Ages between 21-70 Injured between T6-T12 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
61924392|NCT04510974||Able-bodied Control|Ages between 21-70
62125901|NCT02539225|EXPERIMENTAL|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
62685835|NCT06357000||time between the dates of PCI and cancer surgery ≥12 months|time between the dates of PCI and cancer surgery ≥12 months
62685836|NCT00167531|EXPERIMENTAL|Treadmill walking|30 minutes per day of treadmill walking with body weight support and assistance from one therapist
62685837|NCT00167531|ACTIVE_COMPARATOR|Overground walking|30 minutes per day of overground walking with assistance from one therapist
61924393|NCT00144027|NO_INTERVENTION|Control|The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
61924394|NCT00144027|EXPERIMENTAL|Antipsychotic adherence intervention|Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.
61924395|NCT03408002|NO_INTERVENTION|control group|no intervention
61924396|NCT03408002|EXPERIMENTAL|Psychological intervention|"Psychological intervention using the Four elements technique elaborated by Shapiro and reported in M. Luber (2009) during a psychological consultation conducted the day before surgery."
61924397|NCT06184399|PLACEBO_COMPARATOR|Arm A: IVM ODT Placebo|Placebo for ivermectin (oro-dispersible tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
61924398|NCT06184399|EXPERIMENTAL|Arm B: IVM ODT 100 µg/kg|Combination therapy of ivermectin (100 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
61924399|NCT06184399|EXPERIMENTAL|Arm C: IVM ODT 200 µg/kg|Combination therapy of ivermectin (200 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
61924400|NCT06184399|EXPERIMENTAL|Arm D: IVM ODT 300 µg/kg|Combination therapy of ivermectin (300 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
61924401|NCT06184399|EXPERIMENTAL|Arm E: IVM ODT 400 µg/kg|Combination therapy of ivermectin (400 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
62685838|NCT04592562|EXPERIMENTAL|GAE Arm|Patients who meet study eligibility will be scheduled to undergo the Genicular Artery Embolization procedure and will subsequent be followed for 12 months after their procedure.
61924402|NCT06184399|ACTIVE_COMPARATOR|Arm F: IVM standard tablets|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using tablets of 3 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
61924403|NCT05191979|ACTIVE_COMPARATOR|Blood volume interactions with cardiovascular adaptations|Individual differences in the time course and relationship between cardiovascular (central and peripheral) adaptations to long-term aerobic training and the concomitant blood volume changes.
61924404|NCT05191979|ACTIVE_COMPARATOR|Sex differences|Evaluate differences between genders and hormonal factors influencing individual differences (high vs. low responders) - hypothesizing that female have a blunted cardiovascular response to long-term aerobic training.
62316087|NCT01062399|EXPERIMENTAL|Ph I: RT + TMZ + RAD001 2.5 mg/day|Radiation therapy (RT), concurrent temozolomide (TMZ), and concurrent RAD001 2.5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
62316088|NCT01062399|EXPERIMENTAL|Ph I: RT + TMZ + RAD001 5 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
62316089|NCT01062399|EXPERIMENTAL|Ph I: RT + TMZ + RAD001 10 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
62316090|NCT01062399|ACTIVE_COMPARATOR|Ph II: RT + TMZ|Radiation therapy and concurrent temozolomide followed by post-radiation temozolomide
62316091|NCT01062399|EXPERIMENTAL|Ph II: RT + TMZ + RAD001|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
62316092|NCT01376739||Group 1|
62316093|NCT02729311|EXPERIMENTAL|Group 1|Paired PLIÉ Program, immediate start
62316094|NCT02729311|OTHER|Group 2|Paired PLIÉ Program, delayed start
62685839|NCT06296030|EXPERIMENTAL|Classic ACT program|Participants will engage in pre-test measures (anxiety, race-based stress, and psychological flexibility). Subjects will then participate in a 12-week telehealth group (once a week, 2 hours a week) with other group members where a classic Acceptance and Commitment Therapy protocol will be administered. After this, participants will engage in post-test measures.
62685840|NCT06296030|EXPERIMENTAL|POOF ACT program|Participants will engage in pre-test measures (anxiety, race-based stress, and psychological flexibility). Subjects will then participate in a 12-week telehealth group (once a week, 2 hours a week) with other group members where an Acceptance and Commitment Therapy protocol will be administered that has been culturally tailored to address African American racial trauma. After this, participants will engage in post-test measures.
61924405|NCT04000230|EXPERIMENTAL|TCIT|Teachers in the intervention group receive TCIT in the first half of the school year and booster coaching is provided throughout the second half of the school year as the Waitlist Control group is trained.
61924406|NCT04000230|ACTIVE_COMPARATOR|Waitlist Control|Waitlist Control teachers do not receive any intervention for the first half of the school year. They then receive the same TCIT training as the intervention group in the second half of the school year.
62316095|NCT05241171|EXPERIMENTAL|Fitbit plus Feedback Intervention|Participants who were randomized to the provider-feedback intervention arm received goal setting, and feedback graphs and charts,
62316096|NCT05241171|ACTIVE_COMPARATOR|Fitbit alone|Participants in self-managed control group were provided access to the Fitbit website or app but did not receive any feedback on their activity level from the study team.
62316097|NCT04181203|ACTIVE_COMPARATOR|SRT + 6 months of LHRHa|"* Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~* SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
62316098|NCT04181203|EXPERIMENTAL|SRT + 6 months of LHRHa + 6 months of Apalutamide|"* Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~* Treatment with apalutamide (240 mg PO daily) should start the same day as the first LHRHa administration, for 6 months.~* SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
62737856|NCT04117373||Cohort 1|Patients from the existing Optum insurance claimed database with a confirmed diagnosis of melanoma, basal cell carcinoma, or squamous cell carcinoma who have undergone skin cancer excision surgery followed by interpolated flap repair between the years 2001-2006.
62737857|NCT06191874||Surgery planning by SOC methods, then by HoloDBS|Standard-of-care (SOC) surgery plan is built before the HoloDBS hypothetical surgery plan
62316099|NCT01810367|EXPERIMENTAL|ABX Combined With Cisplatin|ABX，100mg/m2，d1、8、15，ivgtt,in 30 min，28day one cycle； cisplin 75mg/m2 d1 ivgtt
62316100|NCT01810367|ACTIVE_COMPARATOR|Gemcitabine Combined With Cisplatin|gemcitabine 1000mg/m2，d1、8；cisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle.
61924407|NCT05789108|OTHER|Biomarkers and long term complications in DVT patients|Patients with DVT will be enrolled in the study during their hospitalization at the ED. The enrolled patients will have 4 follow-up visits, 1) during the first 14 days after diagnosis, 2) after 3 months, 3) after 12 months and 4) 24 months after the time of diagnosis.
62316101|NCT05970055||PONV and Non PONV|PONV- patients who developed nausea and vomiting postoperatively Non PONV- patients who did not develop nausea and vomiting postoperatively
62316102|NCT04728971|EXPERIMENTAL|Micafungin Preventing Group|
62316103|NCT04728971|ACTIVE_COMPARATOR|Others Preventing Group|
62316104|NCT02508727|OTHER|Healthy volunteers|Healthy volunteers
62316105|NCT02508727|OTHER|Subjects with an anterior myocardial infarction sequela|Subjects with an anterior myocardial infarction sequela
62316106|NCT02508727|OTHER|Subjects with lower myocardial infarction sequelae|Subjects with lower myocardial infarction sequelae
62316107|NCT00805883|EXPERIMENTAL|1|
62316108|NCT04270851||Borderline Resectability|Patients with colorectal liver metastases where the decision-making on technical resectability is difficult, i.e. 'borderline resectable,' where a group of liver surgeons might reasonably be expected to find the decision whether to operate to be challenging. A group of up to 20 such patients will undergo pre-operative LiMAx test and HepaT1ca pre-operative scanning. Recruited participants' data will be used to create anonymised online case scenarios to be used in a survey, assessing whether liver surgeons find these pre-operative assessments helpful in their decision-making on technical resectability.
62316109|NCT06340204|EXPERIMENTAL|Pediatric|pediatric patients
62316110|NCT06340204|EXPERIMENTAL|Adults|Adult patients
62316111|NCT06119178||EX-PRESS P-50|EX-PRESS P-50 filtration device implanted in one or both eyes during glaucoma surgery
62316112|NCT06119178||EX-PRESS P-200|EX-PRESS P-200 filtration device implanted in one or both eyes during glaucoma surgery
62316113|NCT00973908|ACTIVE_COMPARATOR|VSL#3|Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
62478996|NCT02510118|EXPERIMENTAL|conventional chemotherapy + ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency, a herbal extract twice daily for 26 weeks for lower dosage.
61924408|NCT05260970||undergoing rectus muscle reapproximation|Primigravida Singleton Pregnancies Who Underwent Elective Cesarean Section with rectus muscle reapproximation procedure
62478997|NCT05014958|EXPERIMENTAL|40 hz frequency exercise group|Individuals in this study group will receive exercise training at 40 hz frequency on whole body vibration device.
62685841|NCT06103799|EXPERIMENTAL|IMB model-based continuity of care|"Intervention through the IMB model-based continuity of care was focused on three aspects:~1. Information intervention: (a) instructing patients to follow the official account of the dental implant department and introducing the instructions to use the application, (b) regularly updating the educational content and disseminating detailed knowledge about the prevention and treatment of oral diseases, especially for peri-implantitis.~2. Motivation intervention: (a) providing an online platform for patients to interact with nurses and doctors, where they can obtain professional answers. (b) assessing the risk factors related to peri-implantitis and diabetes and developing appropriate interventions~3. Behavioral skills intervention: (a) providing feedback on the correct use of tools and implants and cleaning of the overdentures by observing the cleaning videos that the patients were required to upload."
62316114|NCT00973908|PLACEBO_COMPARATOR|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
62316115|NCT00638066|EXPERIMENTAL|1|
62316116|NCT00638066|ACTIVE_COMPARATOR|2|
62316117|NCT01485679|EXPERIMENTAL|positrons emission tomography|
62316118|NCT03809065|EXPERIMENTAL|group N|Patients in this group will receive Nitroglycerin infusion for deliberate hypotension at a rate of 0.5-2 μg /kg/min .
62316119|NCT03809065|ACTIVE_COMPARATOR|group L|Patients in this group will receive Labetalol infusion for deliberate hypotension at a rate of be 0.5-2 mg/kg/h .
62316120|NCT03851679||pregnancy woman|woman who are submitted to elective Cesarean Section in spinal anesthesia
62316121|NCT01302041|EXPERIMENTAL|Enzalutamide|Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.
62316122|NCT04973228|EXPERIMENTAL|Roflumilast Foam 0.3%|Participants with seborrheic dermatitis apply roflumilast foam 0.3% once daily (QD) for 8 weeks.
62478998|NCT05014958|EXPERIMENTAL|25 hz frequency exercise group|Individuals in this study group will receive exercise training at 25 hz frequency on whole body vibration device.
61924409|NCT05260970||not undergoing rectus muscle reapproximation|Primigravida Singleton Pregnancies Who Underwent Elective Cesarean Section without rectus muscle reapproximation procedure
61924410|NCT00687232|EXPERIMENTAL|1|AZD4818
61924411|NCT00687232|PLACEBO_COMPARATOR|2|
62316123|NCT04973228|PLACEBO_COMPARATOR|Vehicle Foam|Participants with seborrheic dermatitis apply vehicle foam QD for 8 weeks.
62316124|NCT02166528||experiment group|patients with FPFD
62316125|NCT02166528||control group|patients without FPFD
62316126|NCT03334370||DM subjects in Hong Kong|
62316127|NCT06671223|EXPERIMENTAL|Corticoesteroid Infiltrations|In this group, participants will receive infiltrations directly into the affected plantar fascia. This intervention aims to reduce the inflammation and pain associated with plantar fasciopathy.
62316128|NCT06671223|PLACEBO_COMPARATOR|Conservative treatment|Participants in this group will receive conservative treatment that does not include infiltrations. This approach is based on non-invasive methods that are commonly used to manage plantar fasciopathy.
62316129|NCT03291197|EXPERIMENTAL|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
62316130|NCT05483543|EXPERIMENTAL|Pamiparib monoagent|Drug: Pamiparib 40mg bid orally
62316131|NCT05342831|EXPERIMENTAL|Experimental: experimental group|Biological Nutrition Technique
62316132|NCT05342831|NO_INTERVENTION|Assigned Interventions|standard care group
62316133|NCT00590083|EXPERIMENTAL|Virus Specific Cytoxic T lymphocytes|Virus Specific Cytoxic T lymphocytes
62316134|NCT02077049|EXPERIMENTAL|serious games self-training program|Serious games are played, using Kinect® and Fit Bit®. This program is performed during the 10 days of the intervention on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
62316135|NCT02077049|ACTIVE_COMPARATOR|Conventional self-training program|conventional physical exercises are performed during the 10 days of the intervention, on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
62478999|NCT05014958|ACTIVE_COMPARATOR|0 hz frequency exercise group|Individuals in this study group will receive exercise training at 0 hz frequency on whole body vibration device.
62316136|NCT05864157|ACTIVE_COMPARATOR|Control|Participants will perform walking practice on a treadmill and overground without the use of a metronome.
62316137|NCT05864157|EXPERIMENTAL|Targeted Rhythmic Auditory Cueing (TRAC)|Participants will perform walking practice on a treadmill (with a metronome set to 85% of typical cadence) and overground (with a metronome set to 115% of typical cadence).
62316138|NCT05864157|EXPERIMENTAL|Distorted Targeted Rhythmic Auditory Cueing (dTRAC)|Participants will perform walking practice on a treadmill (with a metronome set around 85% of typical cadence) and overground (with a metronome set around 115% of typical cadence).
62316139|NCT04132752|EXPERIMENTAL|Intervention|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
62316140|NCT04132752|NO_INTERVENTION|Control|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
62316141|NCT06671977|ACTIVE_COMPARATOR|10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes|Low dose DMT
62479000|NCT04070547|EXPERIMENTAL|Early tVNS|First 2 weeks this group will receive transcutaneous vagal nerve stimulation 4 hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28) without any intervention. Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
62685842|NCT06103799|NO_INTERVENTION|routine health education|For the control group, standard care was provided in the form of routine health education regarding various topics, such as proper brushing techniques, use of an oral irrigator, and other auxiliary tools. The patients were followed-up via telephonic interviews to monitor their condition, including usage of the implant and lifestyle changes; the interviews were conducted at 2 weeks, 1 month, 3 months, and 6 months after treatment. Data were collected about oral health, blood glucose control, lifestyle habits, and comorbidities by using the compliance questionnaire. Appropriated health education was provided if there were any concerns such as gingival swelling, plaque accumulation, and elevated blood glucose levels.
62316142|NCT06671977|ACTIVE_COMPARATOR|14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.|Medium Dose DMT
62479001|NCT04070547|EXPERIMENTAL|Early Sham|First 2 weeks this group will receive sham stimulation 4hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
61924412|NCT03548571|EXPERIMENTAL|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
62316143|NCT06671977|ACTIVE_COMPARATOR|0.5 mg over 5 minutes and then 2 mg over and 55 minutes|THC-Medium Dose
62316144|NCT06671977|PLACEBO_COMPARATOR|Placebo|
62316145|NCT06671977|ACTIVE_COMPARATOR|0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes|Low Dose THC
62316146|NCT01553539|EXPERIMENTAL|Treatment (antiangiogenesis therapy)|Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.
62316147|NCT00469014|ACTIVE_COMPARATOR|Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 30 mg/m\^2 intravenous (IV) Daily + Fludarabine 30 mg/m\^2 IV Daily; + Clofarabine 10 mg/m\^2 IV Daily; Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
62316148|NCT00469014|EXPERIMENTAL|Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 20 mg/m\^2 IV + Fludarabine 20 mg/m\^2 IV Daily + Clofarabine 20 mg/m\^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
62479002|NCT04070547|EXPERIMENTAL|Late tVNS|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive transcutaneous vagal nerve stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
62479003|NCT04070547|EXPERIMENTAL|Late Sham|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive sham stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
62685843|NCT02124005|EXPERIMENTAL|Femoral block, ultrasound, bupivacaine|
61924413|NCT03548571|ACTIVE_COMPARATOR|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
62316149|NCT00469014|EXPERIMENTAL|Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 10 mg/m\^2 IV Daily + Fludarabine 10 mg/m\^2 IV Daily + Clofarabine 30 mg/m\^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
62316150|NCT00469014|EXPERIMENTAL|Arm 4: Busulfan + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 40 mg/m\^2 IV Daily + Clofarabine 40 mg/m\^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
62316151|NCT02221739|EXPERIMENTAL|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
62316152|NCT01892969||HEART AND LUNG FAILURE|Patients with Heart failure or Respiratory Failure with Hyperglycemia
62316153|NCT04444700|EXPERIMENTAL|Therapeutic anticoagulation|Therapeutic anticoagulation with LMWH or UFH (high dose nomogram). The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Therapeutic anticoagulation will be administered until discharged from hospital, 28 days or death. If the patient is admitted to the ICU or requiring ventilatory support, we recommend continuation of the allocated treatment as long as the treating physician is in agreement.
62316154|NCT04444700|NO_INTERVENTION|Standard care|Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is considered standard care.
62685844|NCT03912753|EXPERIMENTAL|Comunică|Comunică is delivered over eight 60-min live chat sessions, delivered by trained psychologists, on our mHealth study platform compatible with any mobile device (laptops, smartphones).
62125902|NCT02539225|ACTIVE_COMPARATOR|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
62125903|NCT00785512|ACTIVE_COMPARATOR|1|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
62125904|NCT00785512|PLACEBO_COMPARATOR|2|Matching placebo tablets, oral administration
62125905|NCT03872362||Training dataset|No interventions
62125906|NCT03872362||External validation1|No interventions
62125907|NCT03872362||External validation2|No interventions
62479004|NCT03713086|ACTIVE_COMPARATOR|Rabipur®|Participants received 3 doses of Rabipur® intramuscular injection at Days 1, 8 and 29 according to the manufacturer's recommendations.
61924414|NCT03347708|EXPERIMENTAL|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells).
61924415|NCT03347708|EXPERIMENTAL|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
61924416|NCT03347708|PLACEBO_COMPARATOR|Saline|Single intradiscal injection with saline solution.
61924417|NCT03347708|PLACEBO_COMPARATOR|Sodium Hyaluronate Vehicle|Single intradiscal injection with Sodium Hyaluronate Vehicle.
62125908|NCT04251013|ACTIVE_COMPARATOR|Group A: RX Cytology brush, Boston Scientific FIRST|A first biliary brushing will be carried out during ERCP using a standard brush RX Cytology Brush, Boston Scientific, then a second brushing will be carried out using a brush INFINITY®, US Endoscopy
62125909|NCT04251013|ACTIVE_COMPARATOR|Group B: Infinity®, US Endoscopy FIRST|A first biliary brushing will be carried out during ERCP using an INFINITY® brush, US Endoscopy then a second brushing will be carried out using standard RX Cytology Brush, Boston Scientific
62125910|NCT02917343|EXPERIMENTAL|intervention arm|participants received 4 weeks of mirror therapy and repetitive task training
62125911|NCT01612169|NO_INTERVENTION|Treatment as Usual (TAU) Group|"Participants assigned to the TAU group will receive the standard treatment provided at each hospital for linking patients to HIV and substance use care.~During the formal site selection process, a thorough assessment will be conducted of each site's standard practice for linkage to HIV care and substance use treatment. Throughout the course of the trial, hospital sites will be monitored for any potential changes that might occur in standard practice around linkage to HIV care and substance use treatment."
62125912|NCT01612169|EXPERIMENTAL|Patient Navigation (PN) Group|"The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.~After the initial four meetings, patient navigators will meet with PN group participants ideally twice monthly during months 2 and 3 and once monthly during months 4 - 6."
62316155|NCT01391091|ACTIVE_COMPARATOR|Patients without history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
62316156|NCT01391091|ACTIVE_COMPARATOR|Patients with history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
62316157|NCT03693365||Patients undergoing surgeries|"Patients undergoing surgery with general anesthesia and controlled mechanical ventilation with indication of invasive arterial blood pressure.~Classification ASA 2-4"
62316158|NCT02967848||Patients with Cancers in Liver|Adult patients with primary liver cancer or liver metastases from any other histology who will be measured before and after Radiotherapy by '99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green and Liver Elasticity.
62316159|NCT01894516|PLACEBO_COMPARATOR|Placebo|Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
62339680|NCT05078099|EXPERIMENTAL|Study arm - Binocular CureSight|Using binocular treatment device 90 min a day 5 times a week for 12 weeks following by 90 min a day 3 times a week for additional 12 weeks
62316160|NCT01894516|EXPERIMENTAL|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
62125913|NCT01612169|EXPERIMENTAL|Patient Navigator Plus Contingency Management (PN+CM) Group|"Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM). Using the principles of contingency management, this combined intervention will incorporate viral load suppression as a target of reinforcement as well as several other behaviors (HIV clinical care, medication adherence, cessation or reduction of substance use) that are hypothesized to be moderators or mediators of the primary outcome.~For participants randomly assigned to the PN+CM study group, patient navigators will: 1) effectively communicate the incentive plan to the participant, 2) track each of the seven target behaviors that may earn participant incentives, 3) verify occurrence of the target behaviors, 4) deliver incentives according to the protocol, and 5) maintain a record of incentives delivered. PNs will use a computer-based tracking program to facilitate this work."
62125914|NCT05664477|EXPERIMENTAL|PhytoSERM group|PhytoSERM 50mg tablet composed of the phytoestrogens daidzein, genistein and S-equol, administered orally every day for 24 weeks.
62125915|NCT05664477|PLACEBO_COMPARATOR|Placebo group|Placebo product with identical shape, size and color with absence of daidzein, genistein, and S-equol. Administered orally every day for 24 weeks.
62125916|NCT05975749|EXPERIMENTAL|Adjuvant Treatment of Serplulimab and Trastuzuma and Chemotherapy|
62125917|NCT05975749|ACTIVE_COMPARATOR|Adjuvant Chemotherapy only|
62125918|NCT03887650|EXPERIMENTAL|Liposomal Bupivacaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
62125919|NCT03887650|ACTIVE_COMPARATOR|Bupivacaine 0.5% with Adjuncts|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
62125920|NCT02517450|EXPERIMENTAL|experimental group|The subjects had to participate an adventure-based training programme.
62125921|NCT02517450|PLACEBO_COMPARATOR|placebo control group|The subjects had to participate a placebo control programme
62125922|NCT01958866|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen administer 1000 mg every 4-6 hours when fever is presented
62125923|NCT01958866|EXPERIMENTAL|Tinospora Crispa-extract Product|Tinospora Crispa-extract tablet administer 500 mg every 4-6 hours when fever is presented
62479005|NCT03713086|EXPERIMENTAL|CV7202 1 mcg|Participants received messenger ribonucleic acid (mRNA) CV7202 1 microgram (mcg) intramuscular injection at Day 1, of whom half of the participants received a second dose of CV7202 1 mcg at Day 29.
62125924|NCT01958866|PLACEBO_COMPARATOR|Placebo|Placebo 2 tablets will be administered every 4 hours when fever is presented
62125925|NCT06513117|EXPERIMENTAL|Multimodal Intervention (Exercise, breathing retraining nutritional and behaviour change support)|"Participants with difficult asthma and multimorbidity (more than 2 additional long term health conditions alongside asthma) will be invited to take part in the study. Participants will undertake in a 6-month/ 24 week supervised multimodal health improvement programme (combining exercise training, behavioural change support, breathing retraining and dietary and emotional self-management support. This programme will run alongside usual treatment.~Participants will be asked to undergo some additional exercise-based tests, activity monitoring, assessment of nutritional wellbeing and complete some questionnaires before, after and during the intervention, with a total of 3 face to face study visits and 2 virtual visits at University Hospital Southampton."
62125926|NCT01123408|EXPERIMENTAL|clozapine|During the first 6 weeks clozapine was gradually increased to 500 mg/day and then continued. For the next period, it could vary from 200-800 mg/day;
61924418|NCT00891111|EXPERIMENTAL|Direct Payment|Direct Payment: Employees receive a $25 gift card upon completion of a Health Risk Assessment
62125927|NCT01123408|EXPERIMENTAL|Olanzapine|During the first 6 weeks olanzapine was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks olanzapine could vary from 10 to 30 mg/day
62479006|NCT03713086|EXPERIMENTAL|CV7202 2 mcg|Participants received mRNA CV7202 2 mcg intramuscular injection at Day 1, of whom half of the participants received a second dose of CV7202 2 mcg at Day 29.
62125928|NCT01123408|ACTIVE_COMPARATOR|Haloperidol|During the first 6 weeks haloperidol was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks the dose could vary from 10 to 30 mg/day
62125929|NCT05862610|EXPERIMENTAL|Trilaciclib plus chemotherapy (Trilaciclib+AC-T)|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
62125930|NCT05862610|EXPERIMENTAL|Chemotherapy (AC-T)|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
62316161|NCT01894516|EXPERIMENTAL|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
62479007|NCT03713086|EXPERIMENTAL|CV7202 5 mcg|Participants received mRNA CV7202 5 mcg intramuscular injection at Day 1.
62479008|NCT05954728|EXPERIMENTAL|CBT-AR|
62125931|NCT05186714|ACTIVE_COMPARATOR|Tai Chi|12 weeks of Tai Chi classes
62125932|NCT05186714|PLACEBO_COMPARATOR|Wellnes Education|12 weeks of Wellness Education classes
62316162|NCT01894516|EXPERIMENTAL|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
62316163|NCT05851846|EXPERIMENTAL|Intervention|Mind body intervention + Usual care: The intervention will be delivered virtually
62316164|NCT05851846|NO_INTERVENTION|Control arm|The participants in the comparator group will be wait listed for the intervention
62479009|NCT05954728|EXPERIMENTAL|Nutrition Counseling|
62125933|NCT00085436|EXPERIMENTAL|Vaccine, Aldesleukin-2, Interferon-a|All patients will be treated with autologous tumor cell vaccine administered into inguinal lymph nodes via ultrasound guidance in addition to systemic IL-2 and recombinant interferon alfa. Two cycles of induction IL-2/IFNα-2a followed by 3 cycles of maintenance IL-2 + IFNα-2a.
62685845|NCT03912753|ACTIVE_COMPARATOR|Education Attention Control (EAC)|"The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.Topics include 1) GBM identity, 2) HIV 101, 3) HIV/STI testing, 4) alcohol and the body, 5) the role of alcohol in HIV risk, 6) HIV-status disclosure and sexual health communication, 7) finding social supports, and 8) summary. EAC participants will receive five quiz questions after each module, with correct answers in a following screen."
62685846|NCT01027754|EXPERIMENTAL|Varenicline|Drug treatment in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
62685847|NCT01027754|PLACEBO_COMPARATOR|Placebo|Matched placebo capsules in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
62685848|NCT03996395||Infants|Infants, 4-4.5 months of age at enrollment
62685849|NCT05456399||Patients with cranial MRI|Axial sections of 5 mm thickness will be imaged. The thickness of the temporal muscle will be measured at the point where the floor of the temporal fossa is bounded most caudally by the zygomatic bone, sphenoid bone and temporal bone. After the MRI measurements are completed, the thickness of the muscle will be measured by ultrasound at the same location by two clinicians (a radiologist and a physiatrist) who are expertise in musculoskeletal ultrasonography.
62685850|NCT05456399||Patients with cranial CT|Axial sections of 5 mm thickness will be imaged. The thickness of the temporal muscle will be measured at the point where the floor of the temporal fossa is bounded most caudally by the zygomatic bone, sphenoid bone and temporal bone. After the MRI measurements are completed, the thickness of the muscle will be measured by ultrasound at the same location by two clinicians (a radiologist and a physiatrist) who are expertise in musculoskeletal ultrasonography.
62685851|NCT02264821|EXPERIMENTAL|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
62316165|NCT05913076|EXPERIMENTAL|Investigation of the Effects of Alt-RAMEC and Facemask 1 week Use in Class III Malocclusion|A sample of 40 patients, consisting of 18 males and 22 females with a mean age of 10.64 ± 0.98, who were in the growth and developmental stage, were divided into three treatment groups. The formation of groups was carried out with the aim of achieving a near-equal distribution of male and female participants within each group, as indicated in Table 1. The first group comprised 14 patients, while the second and third groups consisted of 13 patients each. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.
62479010|NCT02493283|ACTIVE_COMPARATOR|Treatment A|single-dose administration of 100 mg dapsone; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
62479011|NCT02493283|ACTIVE_COMPARATOR|Treatment B|multiple-dose administration of 100 mg dapsone s.i.d. for 7 days; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
62685852|NCT02264821|EXPERIMENTAL|rachi morphine|100 µg intrathecal morphine and saline infiltration
62685853|NCT02264821|PLACEBO_COMPARATOR|placebo|intrathecal saline and saline infiltration
62685854|NCT06549868|EXPERIMENTAL|Yoga|Participants will be asked to follow a yoga-based bedtime routine for 4 weeks
62685855|NCT06549868|OTHER|Story|Waitlist control arm. Participants will complete a 4-week control period upon randomization. After this control period is completed, they will crossover into the intervention group and follow the same 4 week intervention as the yoga group.
62685856|NCT04869514|ACTIVE_COMPARATOR|either lumbar manipulation (LMANIP)|LMANIP will consist of high velocity low amplitude (HVLA) SMT at the L4/L5 motion segment. LMANIP consists of two HVLA impulses, applied in side-posture on the right and left side (order pseudorandomized).
62685857|NCT04869514|ACTIVE_COMPARATOR|thoracic manipulation (TMANIP)|TMANIP will consist of high velocity low amplitude (HVLA) SMT at the T4/5 motion segment. TMANIP consists of supine SMT to the right and left (order pseudorandomized) using a thenar contact at facet joint level T4/5
62685858|NCT04869514|SHAM_COMPARATOR|lumbar mobilisation (LMOB)|LMOB will be applied with the same positioning as in the LMANIP procedure, but instead of a thrust, a slow, a slow, passive mobilization without impulse will be applied
62685859|NCT04869514|NO_INTERVENTION|No intervention|A natural history arm will serve to further control for potential specific and non-specific effects of TMANIP and LMOB. Subject will rest in side-lying position for the same duration as during the active interventions.
62685860|NCT06074406|EXPERIMENTAL|Portable MRI Arm|All subjects enrolled with be assigned to Arm 1
62685861|NCT06175065|EXPERIMENTAL|RLS-0071|Doses of RLS-0071, will be administered Q8H, three times a day, for at least 3 days and up to 5 days
62685862|NCT06175065|PLACEBO_COMPARATOR|Placebo|Doses of Placebo for RLS-0071, will be administered Q8H, three times a day, for at least 3 days and up to 5 days
62685863|NCT05627492|EXPERIMENTAL|Youth with and/or at familial risk for bipolar disorder|120 youth aged 14 to 26 with bipolar disorder (type I, type II, not otherwise specified/NOS via KSADS-PL or SCID-5-RV) OR at high-risk for bipolar disorder (parent or sibling with bipolar disorder type I or II via KSADS-PL or SCID-5-RV) will be enrolled in the dialectical behavioral therapy booster session intervention.
62685864|NCT06690177|ACTIVE_COMPARATOR|EscharEx (EX-03)|"EX-03 is the code name of the third generation of EscharEx investigational medicinal product (IMP) formulation. A sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb ), the active pharmaceutical ingredient (API), that is blended with excipients.~EX-03 5% powder, should be diluted with Water for Injection (WFI) prior usage"
62685865|NCT06690177|PLACEBO_COMPARATOR|Placebo|"Placebo (Gel Vehicle, hydrogel) contains the same excipients as in EX-03, without the API.~A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area Placebo powder, should be diluted with Water for Injection (WFI) prior usage"
62685866|NCT06690177|OTHER|Collagenase|Non-surgical standard of care treatment arm
62685867|NCT00002656|EXPERIMENTAL|Pyrazoloacridine|Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
62685868|NCT05350267|EXPERIMENTAL|Treatment|HALO is a mixed-delivery intervention (online learning, digital technologies, telehealth visits) co-designed with mothers that (a) uniquely tailors intervention content to integrate post-bariatric surgery guidelines to recommendations to reduce child obesity risk, (b) teaches mothers evidence-based parenting behaviors to support intergenerational lifestyle and home food environment changes, and (c) addresses unique barriers to family-level change identified by mothers post-bariatric surgery.
62685869|NCT05350267|ACTIVE_COMPARATOR|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
62737858|NCT06191874||Surgery planning by HoloDBS, then by SOC methods|HoloDBS hypothetical surgery plan is built before the standard-of-care (SOC) surgery plan
62737859|NCT01168830|EXPERIMENTAL|Investigational device|
62737860|NCT03824873|ACTIVE_COMPARATOR|internal iliac artery ligation + cesarean hysterectomy|
62737861|NCT03824873|ACTIVE_COMPARATOR|cesarean hysterectomy|
62125934|NCT03454646|EXPERIMENTAL|Group randomized for continuing treatment|"Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.~All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
62125935|NCT03454646|NO_INTERVENTION|Group randomized for stopping treatment|Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
62125936|NCT04597203|EXPERIMENTAL|split face - left side|
62125937|NCT04597203|ACTIVE_COMPARATOR|split face - right side|
62316166|NCT05913076|EXPERIMENTAL|Investigation of the Effects of Alt-RAMEC and Facemask 3 week Use in Class III Malocclusion|The second group comprised 13 patients who were in the growth and developmental stage. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.
62339681|NCT06553183|EXPERIMENTAL|study group|the patients will receive eight sessions of Immersive virtual reality based exercise, 2 sessions per week for 4 weeks besides the traditional physical therapy.
62479012|NCT02220985|EXPERIMENTAL|Arm A (MRD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
62479013|NCT02220985|EXPERIMENTAL|Arm B (MRD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
62737862|NCT02810288||Expert|Anaesthesiologist with large paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
62125938|NCT03878199|EXPERIMENTAL|Treatment (CPX-351, ruxolitinib, allogeneic SCT)|See Detailed Description.
62125939|NCT00150176|EXPERIMENTAL|asenapine|
62125940|NCT00150176|PLACEBO_COMPARATOR|placebo|
62125941|NCT01213303||Blood donors|Evaluation of cardiovascular risk factors, oxidative stress and fatty acid metabolism in a cohort of blood donors
62125942|NCT04022616||Immediate Surgery|Adult patients with breast malignancy.
62316167|NCT05913076|EXPERIMENTAL|Investigation of the Effects of Alt-RAMEC and Facemask 5 week Use in Class III Malocclusion|The third group comprised 13 patients who were in the growth and developmental stage. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.
62316168|NCT05006807||Twitch Monitoring|Patients undergoing surgery with general anesthesia requiring neuromuscular blockade.
62316169|NCT04559906|EXPERIMENTAL|Group A|Spray and Stretch technique Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
62316170|NCT04559906|ACTIVE_COMPARATOR|Group B|Sustain pressure release Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
62316171|NCT02028689|EXPERIMENTAL|Lesinurad and Metformin|"Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg~Sequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
62479014|NCT02220985|EXPERIMENTAL|Arm C (MUD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
62737863|NCT02810288||Non-experts|Anaesthesiologist with little paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
62737864|NCT05683405|EXPERIMENTAL|Mechanical debridement|
62737865|NCT05683405|EXPERIMENTAL|Air polishing|
62737866|NCT06000475|ACTIVE_COMPARATOR|Cognitive Processing Therapy (CPT)|Standard CPT as described in the treatment manual
62125943|NCT04022616||Neo-adjuvant Chemotherapy|Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.
62125944|NCT04022616||Lymph Node Tissue|Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.
62125945|NCT04022616||Metastatic Breast Cancer|Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).
62125946|NCT04446078|EXPERIMENTAL|PEEK - All-on-4|Patients rehabilitated with a PEEK-acrylic resin prosthesis supported by immediate function dental implants inserted through the All-on-4 concept
62125947|NCT05084612|PLACEBO_COMPARATOR|control group (S)|LMA will be placed using the standard Brain's insertion technique.
62125948|NCT05084612|ACTIVE_COMPARATOR|Rotational group (R)|LMA will be placed using a two Person Insertion with lateral rotation technique.
62125949|NCT03454529|EXPERIMENTAL|Treatment (simvastatin)|Patients receive simvastatin PO daily for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
62316172|NCT02028689|EXPERIMENTAL|Lesinurad and Furosemide|"Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg~Sequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
62316173|NCT01847144|ACTIVE_COMPARATOR|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
62316174|NCT01847144|ACTIVE_COMPARATOR|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
62316175|NCT02169635|EXPERIMENTAL|Macula buckle|Macular buckle: perform episcleral macular buckle surgery using a three-armed silicone capsule to support the posterior staphyloma in high myopia.
62316176|NCT01696409||Arm A|400 IU vitamin D3 once a day for 2 months
62316177|NCT01696409||Arm B|2000 IU Vitamin D3 once/day for 2 months
62316178|NCT05419154|EXPERIMENTAL|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
62316179|NCT02602873||good efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can reach effective outcome.
62316180|NCT02602873||poor efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can not reach effective outcome.
62316181|NCT01072279|EXPERIMENTAL|Burundi: T24|
62316182|NCT01072279|EXPERIMENTAL|Burundi: TNFP|
62316183|NCT01072279|EXPERIMENTAL|Burundi: T18|
62316184|NCT01072279|NO_INTERVENTION|Burundi: Control|
62125950|NCT03687892|EXPERIMENTAL|continuous Theta Burst Stimulation|The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
62125951|NCT03687892|EXPERIMENTAL|intermittent Theta Burst Stimulation|The investigators will perform two applications of 40s of intermittent Theta Burst Stimulation (iTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
62316185|NCT01072279|EXPERIMENTAL|Guatemala: PROCOMIDA|
62316186|NCT01072279|EXPERIMENTAL|Guatemala: no family ration|
62685870|NCT06674369||15 patients between the ages of 22-70 (m=52.0 year) with homonymous hemianopsia|Homonymous hemianopia (HH) patients due to long-standing post-chiasmatic lesions between 2017 and 2020 were included in the study . To eliminate spontaneous neuronal recovery only the patients with hemianopia, diagnosed at least six months before the initial examination and who had undergone full clinical MRI evaluation were included. Initially all patients were applied peripheral field expander 40 D horizontal Peli prisms. In the initial and follow-up examinations, in addition to neurological history, a complete ophthalmologic examination was performed, followed by computerized visual field examination using Estermann binocular field program and Swedish Interactive treshold algorithm program (SITA 30-2) (Zeiss Humphrey3-850). Ganglion cell layer thickness was measured by OCT (Zeiss Cirrus HD Oct) and compared with the normal retinal image.
62685871|NCT04768478|ACTIVE_COMPARATOR|Cannabidiol (CBD)|
62685872|NCT04768478|PLACEBO_COMPARATOR|Control|
62737867|NCT06000475|EXPERIMENTAL|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
62316187|NCT01072279|EXPERIMENTAL|Guatemala: LNS|
62316188|NCT01072279|EXPERIMENTAL|Guatemala: Sprinkles|
62316189|NCT01072279|EXPERIMENTAL|Guatemala: reduced family ration|
62316190|NCT01072279|NO_INTERVENTION|Guatemala: control|
62316191|NCT04487847|EXPERIMENTAL|PIRADS 1-2|25 patients with PIRADS 1-2 (probably benign) on mpMRI
62316192|NCT04487847|EXPERIMENTAL|PIRADS 3|25 patients with PIRADS 3 (equivocal scan) on mpMRI
62316193|NCT04487847|EXPERIMENTAL|PIRADS 4-5|25 patients with PIRADS 4-5 (probably malignant) on mpMRI
62316194|NCT01827540|EXPERIMENTAL|Cenicriviroc + Midazolam, and CVC + DTG|Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 \& w/ CVC 150mg on Day 9.
62479015|NCT02220985|EXPERIMENTAL|Arm D (MUD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
62479016|NCT03714594|ACTIVE_COMPARATOR|Dapagliflozin 10mg|Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.
62316195|NCT01827540|EXPERIMENTAL|Dolutegravir , and DTG + CVC|Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.
62479017|NCT03714594|ACTIVE_COMPARATOR|Saxagliptin 5mg|Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
62316196|NCT03918642|EXPERIMENTAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
62316197|NCT03918642|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
62316198|NCT05734781||1|Interviewees: terminally ill patients, families and healthcare providers of such patients
62316199|NCT04329923|ACTIVE_COMPARATOR|Cohort 1 HCQ|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with hydroxychloroquine 400 mg twice a day for up to 14 days
62316200|NCT04329923|PLACEBO_COMPARATOR|Cohort 1 Placebo|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with placebo twice a day for up to 14 days. Crossover is allowed if symptoms worsen after 7 days of treatment.
62479018|NCT03714594|ACTIVE_COMPARATOR|Saxagliptin 5 mg + dapagliflozin 10 mg|Please see Arm 1 and 2
62479019|NCT00723047|EXPERIMENTAL|1|
62737868|NCT00889603||1|
62316201|NCT04329923|EXPERIMENTAL|Cohort 2 HCQ high dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg twice a day for up to 14 days
62316202|NCT04329923|ACTIVE_COMPARATOR|Cohort 2 HCQ low dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for up to 7 days
62737869|NCT02905799|EXPERIMENTAL|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
62316203|NCT04329923|EXPERIMENTAL|Cohort 3 HCQ|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for 2 months
62316204|NCT04329923|PLACEBO_COMPARATOR|Cohort 3 Placebo|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with placebo for 2 month. Crossover is allowed if subject becomes SARS-CoV2 positive.
62316205|NCT01878006|EXPERIMENTAL|Morphine|Morphine injection 10 mg/70kg
62316206|NCT01878006|PLACEBO_COMPARATOR|Placebo|Saline injection
62316207|NCT00434460||1|Patients receiving invasive mechanical ventilation \> 48 hours.
62316208|NCT02204540|EXPERIMENTAL|Monitoring by webcam|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming food) while being recorded and monitored by webcam.
62737870|NCT02905799|PLACEBO_COMPARATOR|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
62737871|NCT00526747||Epo-resistant|Patients with CKD (estimated GFR \< 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
62737872|NCT00526747||Epo-responsive|Patients with CKD (estimated GFR \< 60cc/min) not on hemodialysis who are requiring \<100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
62737873|NCT06290466|EXPERIMENTAL|FCN-437c capsule|fasting oral, single dose.Specification :100mg
62737874|NCT06290466|PLACEBO_COMPARATOR|FCN-437c capsule Placebo|fasting oral,single dose.Specification :100mg
61924419|NCT00891111|EXPERIMENTAL|Regret Lottery|Regret Lottery: Employees are divided into work units of about 5 employees. Employees in the lottery-linked incentive condition will be eligible for a weekly lottery drawing only if they have already completed their health risk assessment. The lotteries will work as follows. Participants will be assigned to work units of about 10 people. Each week, one work group is drawn at random. If a participants group was drawn and that participant already completed the health risk assessment, then that person will win a $100 cash prize. If all of the members of his or her work group also filled out the health risk assessment, then the prize will be boosted.
61924420|NCT06437990|EXPERIMENTAL|Arteriovenous loop graft|A saphenous vein graft was used to create an arteriovenous loop from the common carotid artery to the external jugular vein, providing vascular supply for a free functional gracilis muscle flap in patients with late-onset brachial plexus injury.
61924421|NCT03809923|EXPERIMENTAL|Dexmedetomidine Combined With Lidocaine Infusion Affect PONV|
61924422|NCT03809923|EXPERIMENTAL|Effect of infusion saline on PONV|
61924423|NCT03809923|EXPERIMENTAL|Effect of infusion lidocaine on PONV|
61924424|NCT03809923|EXPERIMENTAL|Effect of infusion dexmedetomidine on PONV|
61924425|NCT01464723|EXPERIMENTAL|Lucentis|Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
61924426|NCT06515249|EXPERIMENTAL|Integrative medicine|Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient's and staff's choice
61924427|NCT06515249|NO_INTERVENTION|Control|
62685873|NCT06159582|ACTIVE_COMPARATOR|eSTEP Treatment Group|Treatment group participants will be given access to eSTEP (Electronic Support to Engage with PrEP), an mHealth intervention to promote engagement on the full PrEP care continuum tailored to the unique needs of transgender women (TW) and gay, bisexual, and other men who have sex with men (GBMSM), in addition to the usual HIV testing and PrEP clinical care.
62685874|NCT06159582|PLACEBO_COMPARATOR|Control Arm|Usual HIV testing and PrEP clinical care
62685875|NCT05497245|EXPERIMENTAL|intervention group|mobile app-based breastfeeding education
62316209|NCT02204540|ACTIVE_COMPARATOR|In-person monitoring|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming good) while being monitored in-person.
62685876|NCT05497245|NO_INTERVENTION|control group|rutin health care
62685877|NCT06689709|OTHER|Serum Alp Levels In Healthy Turkish Children|This study has been proceeded on children, who have no history for a chronic diseasse or medication and attending to the Keçiören Education and Research Hospital Pediatric Policlinic for routine control between September 2012-September 2013
61924428|NCT02029339|EXPERIMENTAL|triple-tube group|The patients were treated with continuous topical triple-tube irrigation and suction
61924429|NCT02029339|ACTIVE_COMPARATOR|SOC group|The patients were treated with standard of care (SOC) without topical irrigation
61924430|NCT04688879||According to the degree of occlusion, 13 patients were divided into complete and incomplete groups.|Seven patients were complete occlusion and 6 patients were incomplete occlusion and all underwent thrombolysis with intra-arterial urokinase and the outcome was analysed..
61924431|NCT01005043|EXPERIMENTAL|heavy ion radiotherapy|Heavy ion radiotherapy of osteosarcoma with 60 to 66 GyE (20-22 days). Before and after radiotherapy, but not during radiotherapy, chemotherapy is recommended to standard therapy protocols like EURAMOS 1 which is not part of this study.
61924432|NCT01176344|EXPERIMENTAL|Vitamin D supplementation|Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly
61924433|NCT01176344|PLACEBO_COMPARATOR|Placebo|The control arm will receive identical inert placebo capsules given once monthly.
62316210|NCT04940598|EXPERIMENTAL|High intensity interval exercise|High intensity interval arm crank exercise
62316211|NCT04940598|OTHER|No-Exercise Control|No-exercise control group
62316212|NCT02948231|EXPERIMENTAL|Mistral|
62316213|NCT03556722|ACTIVE_COMPARATOR|repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.
62685878|NCT06685874||Patients with exacerbation of fibrotic interstitial lung disease|Patients with exacerbation of fibrotic interstitial lung disease as per inclusion and exclusion criteria
62685879|NCT05103111||FHP group (study group)|it will be consisted of 50 women, suffering from FHP (CVA is less than 48°)
62685880|NCT05103111||control group (without FHP)|it will be consisted of 50 women, not having FHP (CVA is more than 48°).
62685881|NCT04052126|EXPERIMENTAL|Individualized physical activity program|
62316214|NCT03556722|SHAM_COMPARATOR|Sham repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.
62316215|NCT06497725|EXPERIMENTAL|Teleguidance-facilitated Airway Management|The airway expert able to remotely access to videolaryngoscopy monitor will provide verbal feedback during the endotracheal intubation.
62685882|NCT02372357|EXPERIMENTAL|Posaconazole 120mg/m² tid|"Pediatric patients admitted to receive chemotherapy or hematopoietic stem cell transplantation for the treatment of a hematological malignancy are receiving Posaconazole prophylaxis 120 mg/m² tid.~At steady state, blood sampling will be performed: 9 blood samples will be taken during 1 dosing interval to evaluate the pharmacokinetics of posaconazole."
62125952|NCT02570568|ACTIVE_COMPARATOR|Conventional Venepuncture|Veins will be identified by a combination of visualization and palpation. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
62125953|NCT02570568|EXPERIMENTAL|Veinlite|Placing Veinlite onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
62316216|NCT06497725|NO_INTERVENTION|Standard Airway Management|Operator will use standard videolaryngoscopy without expert feedback during the endotracheal intubation.
62316217|NCT01972477|EXPERIMENTAL|DLBS1449, 1x75 mg|DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
62316218|NCT01972477|EXPERIMENTAL|DLBS1449, 1x150 mg|DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
62316219|NCT01972477|PLACEBO_COMPARATOR|Placebo|Placebo once daily, taken every day along the study period
62316220|NCT01198444||Group 1|
62316221|NCT04385901|NO_INTERVENTION|Standard of Care|These are patients who were diagnosed with COVID19 and recovered with usual care prior to implementation of the rehabilitation program developed by MUHC therapists. These patients will be selected in such a way as to match the approximate demographics that exist within the treatment group. These patients received education and supportive care only.
62316222|NCT04385901|EXPERIMENTAL|Rehabilitation Group|These are patients who were diagnosed with COVID19 and participated in the physical and pulmonary rehabilitation program developed at MU Healthcare as described in the study design.
62316223|NCT06169748|EXPERIMENTAL|Real UHCDS a-TDCS + Therapeutic Exercise|Real unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise.
62316224|NCT06169748|SHAM_COMPARATOR|Sham UHCDS a-TDCS + Therapeutic Exercise|Sham unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise.
62316225|NCT06169748|ACTIVE_COMPARATOR|Therapeutic Exercise|Therapeutic Exercise.
62737875|NCT06305299|EXPERIMENTAL|Chimeric Antigen Receptors|blood will be collected to prepare the iC9-CAR.B7-H3 T cells. Disease-fighting T cells will be isolated and modified to prepare the iC9-CAR.B7-H3 T cells. In part 2, the iC9-CAR.B7-H3 T cells are given by infusion after completion of lymphodepletion chemotherapy.
62737876|NCT02724579|EXPERIMENTAL|Treatment (reduced radiation therapy and chemotherapy)|"RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks.~MAINTENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients also undergo MRI throughout the trial."
62737877|NCT02031991|EXPERIMENTAL|A = PF-06439535|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
62737878|NCT02031991|ACTIVE_COMPARATOR|B = Bevacizumab-EU|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
62737879|NCT02031991|ACTIVE_COMPARATOR|C = Bevacizumab-US|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
62738570|NCT06147128||Experimental: PBP for Technical emergency undocking skills|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge on TS before continuing to the robotic surgical training element. The trainees knowledge will be assessed in a formative and summative fashion. After the trainees initial assessment, procedure-specific and validated procedure metrics will be used to teach them the steps of the emergency undocking procedure, as well as the correct (and incorrect) way to perform it. The metrics will be used to give to the trainees performance feedback with specific advice on how they might improve their performance, in the regards of technical skills.
62125954|NCT02570568|EXPERIMENTAL|Pen-torch Transillumination|The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
62125955|NCT03817476|EXPERIMENTAL|T1-T2-R|
62125956|NCT03817476|EXPERIMENTAL|T1-R-T2|
62125957|NCT03817476|EXPERIMENTAL|T2-T1-R|
62125958|NCT03817476|EXPERIMENTAL|T2-R-T1|
62685883|NCT03630510|EXPERIMENTAL|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
62685884|NCT03630510|NO_INTERVENTION|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
62685885|NCT06640192|ACTIVE_COMPARATOR|Control|Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor
62685886|NCT06640192|EXPERIMENTAL|Intervention|High doses of triple therapy antiretroviral drugs: dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h.
62685887|NCT05633056|NO_INTERVENTION|Enhanced standard of care|"* Care from trained and supported physicians, nurses, and social workers who have received repeated trainings from study staff on medical and behavioral aspects of DR-TB HIV care, which will be documented in terms of date, attendance, and content~* All participants who receive care as inpatients will receive an orientation to DR-TB treatment in form of a group session designed to impart key behavioral information and health knowledge about the disease, treatment, and skills to obtain optimal outcome.~* Discharge counselling session will be conducted prior to discharge.~* Study participants will complete study assessments at baseline (enrollment) and monthly for the first six months."
62685888|NCT05633056|OTHER|Psychosocial support|"* In addition to Arm 1~* Participants will participate in individual counseling aligned with their monthly clinic visit.~* Individual counseling will use motivational interviewing (MI) techniques, based on the 4-part engaging, focusing, evoking and planning approach for each participant.~* Home visits will be conducted (if warranted/consented for by the participant) by the same trained counselors known to patients.~* Adherence support groups will be facilitated by counselors trained in group facilitation methods; group curriculum will include 6 sessions (monthly, gender specific, structured adherence support groups) that focus on practical topics.~* Discharge planning (if inpatient)~* Community treatment planning (if outpatient)"
62685889|NCT05633056|OTHER|mHealth|"* In addition to Arm 1~* Participants will receive x 2 portable Wisepill devices. (x1 for MDR-TB treatment and x1 for ART).~A Wisepill device is an RT2000 cellular-enabled electronic pill boxes using 2G/3G cellular network.~* Participants will select a text message reminder from a guided menu of choices and receive a weekly text message encouraging adherence.~* Participants will receive a study call to support regular adherence. Participants will be assessed weekly. Less than 85% observed/expected doses will be considered at risk for non-adherence and the intervention will be increased."
62685890|NCT05633056|OTHER|mHealth and Psychosocial support|Combination of Arm 2 and Arm 3.
62125959|NCT03817476|EXPERIMENTAL|R-T1-T2|
62125960|NCT03817476|EXPERIMENTAL|R-T2-T1|
62125961|NCT03718546||Sibling pediatric donors|Donors who are donating to a sibling
62125962|NCT03718546||Sibling recipients and caregivers|Recipients who are receiving a transplant from a sibling
62125963|NCT03718546||Non-donor sibling|From the donor-recipient families
62125964|NCT03718546||Non-donor siblings|Of patients receiving unrelated transplants
62125965|NCT03718546||Healthy comparison|A matched sample
62125966|NCT03718546||Parents|Parent/caregiver of study participating donor.
62125967|NCT02825368|EXPERIMENTAL|Homeopathic vaccine group|"* Diphtheria (Diphtherinum®), pertussis (Pertussinum®), tetanus (Tetanotxicum®), measles (Morbilinum®) and mumps (Ourlianum®) nosodes.~* Two sterile saline injections (0.5ml each, intramuscular and subcutaneous) as placebo."
62125968|NCT02825368|ACTIVE_COMPARATOR|Conventional vaccine group|"* One intramuscular dose of Tdap (tetanus, diphtheria, acellular pertussis)~* One subcutaneous dose of MMR (measles, mumps, rubella)~* Sugar pellets as placebo."
62125969|NCT02825368|PLACEBO_COMPARATOR|Control group|"* Sugar pellets oral dose~* Two sterile saline injections (0.5 ml each, intramuscular and subcutaneous) as placebo"
62125970|NCT06041373||Paroxysmal Atrial Fibrillation Patients|
62125971|NCT04937842|EXPERIMENTAL|MST|standard chemotherapy with microtransplantation
61924434|NCT03860883|EXPERIMENTAL|Arm A (Wide Local Excision = 1cm Margin)|1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
61924435|NCT03860883|ACTIVE_COMPARATOR|Arm B (Wide Local Excision = 2cm Margin)|2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
62316226|NCT06671821|EXPERIMENTAL|Group A|Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
62316227|NCT06671821|EXPERIMENTAL|Group B|Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
62316228|NCT06671821|EXPERIMENTAL|Group C|Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
62125972|NCT04937842|NO_INTERVENTION|CT|standard chemotherapy only, without microtransplantation
62125973|NCT01460446|EXPERIMENTAL|Aviva Expert blood glucose meter|Participants used the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
62125974|NCT01460446|ACTIVE_COMPARATOR|Aviva Nano blood glucose meter|Participants used the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
62125975|NCT00945607|EXPERIMENTAL|Guided Relaxation Training|"Eligible subjects who have been randomized to the intervention arm will be scheduled for GRT introduction and training with a research staff member. The GRT sessions will consist of six weekly on-site sessions in which the subject is provided instructions and then allowed to listen to the GRT CD. Subjects will be instructed to conduct independent GRT sessions at home, twice daily, at least four hours apart, for the duration of the study. Subjects will also be instructed that on the days of one-on-one sessions with a research staff member at TCCC, that they will only be required to perform the independent session once at home.~Subjects will be provided with a diary to record the date and time of each independent GRT session performed at home. Subjects will be instructed to bring their completed diary with them at each subsequent visit."
62125976|NCT00945607|NO_INTERVENTION|Standard of Care(SOC)|Eligible subjects who are randomized to the SOC arm will not receive the GRT sessions. During the six week treatment phase, these subjects will only receive SOC provided to all subjects newly diagnosed with breast cancer at TCCC. This consists of an education session with the nurse or nurse practitioner. In addition, they will also be provided with supportive care and symptom management as needed. This arm will also be provided with a diary to record their stress level at least twice daily.
62125977|NCT04426890|EXPERIMENTAL|Arm 1|300 mg of CT-P39 as SC injections via PFS
62316229|NCT06671821|EXPERIMENTAL|Group D|Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
62316230|NCT00592150|EXPERIMENTAL|1|Fenoldopam infusion
62316231|NCT00592150|PLACEBO_COMPARATOR|2|Placebo infusion
62316232|NCT00739297|PLACEBO_COMPARATOR|1|montelukast Placebo
62316233|NCT00739297|EXPERIMENTAL|2|montelukast
62125978|NCT04426890|ACTIVE_COMPARATOR|Arm 2|300 mg of EU-approved Xolair as SC injections via PFS
62125979|NCT04426890|EXPERIMENTAL|Arm 2-1|300 mg of CT-P39 as SC injections via PFS
62316234|NCT00739297|EXPERIMENTAL|3|montelukast
62316235|NCT00739297|EXPERIMENTAL|4|montelukast
62316236|NCT06597955||Healthcare system leadership, providers, and staff|Leadership, providers, and staff at the project team's affiliated healthcare system
62316237|NCT06597955||Patients due for colorectal cancer screening|Patients who are considered due for colorectal cancer screening prior to a scheduled appointment with a primary care provider at the project team's affiliated healthcare system and completed the appointment.
62316238|NCT02495077|EXPERIMENTAL|Experimental|rATG is co-administered with anti-TNFa (infliximab/Remicade®) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
62316239|NCT02495077|ACTIVE_COMPARATOR|Control|Rabbit anti-thymocyte globulin (rATG/Thymoglobulin®) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
62316240|NCT02974946|EXPERIMENTAL|Study group|Patients will receive the RenalGuard system
62316241|NCT02974946|NO_INTERVENTION|Control group|Standard practice will be performed with no RenalGuard system
62316242|NCT06336824|EXPERIMENTAL|Early Oral Switch Therapy (EOS)|"Patients will switch from IV therapy to oral antibiotics for 7 to 11 days to achieve a total 14 days of definitive antimicrobial therapy for SAB.~First choice oral antibiotics for MSSA and MRSA: Tab. Trimethoprim-sulfamethoxazole (TMP 10mg/kg/day)~Alternative oral antibiotics for MSSA: Tab. Clindamycin 600mg TDS, Tab. Cephalexin 1gm QID, Tab Linezolid 600mg BD~Alternative oral antibiotics for MRSA: Tab. Linezolid 600mg BD"
62316243|NCT06336824|ACTIVE_COMPARATOR|Standard IV therapy (SIV)|"Patients will continue with IV therapy for 7 to 11 days to achieve a total 14 days of definitive antimicrobial therapy for SAB.~First choice IV antibiotics for MSSA: IV Cloxacillin 2g every 4 or 6 hours~Alternative IV antibiotics for MSSA: IV Cefazolin 2g TDS~First choice IV antibiotics for MRSA: IV Vancomycin 15-20mg/kg BD~Alternative IV antibiotics for MRSA: IV Ceftaroline 600mg TDS"
62339682|NCT06553183|ACTIVE_COMPARATOR|control group|the patients will receive eight sessions of the traditional physical therapy, 2 sessions per week for 4 weeks.
62339683|NCT02047630|EXPERIMENTAL|Generic latanoprost|1 eye drop hs
61924436|NCT03101267|EXPERIMENTAL|ASP4070 4 mg|Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.
61924437|NCT03101267|EXPERIMENTAL|ASP4070 1 mg|Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.
61924438|NCT03101267|PLACEBO_COMPARATOR|Placebo|Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.
62479020|NCT05554406|ACTIVE_COMPARATOR|Arm I (cytarabine, daunorubicin)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62685891|NCT04512625|NO_INTERVENTION|Control group|Sensitivity level scores were evaluated on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation.
62685892|NCT04512625|EXPERIMENTAL|Group GL (Gluma desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
62685893|NCT04512625|EXPERIMENTAL|Group SF (SheildForce desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
62685894|NCT04512625|EXPERIMENTAL|Group TS (Telio CS desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
62685895|NCT02815254|ACTIVE_COMPARATOR|Low dose exercise intervention|
62685896|NCT02815254|EXPERIMENTAL|High dose exercise intervention|
62685897|NCT05472987|ACTIVE_COMPARATOR|Open Ventral Hernia Repair|These patients will undergo open retromuscular ventral hernia repairs
62685898|NCT05472987|ACTIVE_COMPARATOR|Robotic Ventral Hernia Repair|These patients will undergo robotic retromuscular ventral hernia repairs.
62685899|NCT05388825|EXPERIMENTAL|Sequence 1|N=14 subjects receive 2.5 mg TPN171H and 10 mg Placebo for Period 1; 5 mg TPN171H and 10 mg Placebo for Period 2 ; 10 mg Placebo and 5 mg Placebo for Period 3.
62316244|NCT04109443|EXPERIMENTAL|Young Men & Media Program group|Participants randomized to the Young Men and Media Program group will have access to the online sexual health media literacy materials. They will also complete three assessments at baseline, post-intervention, and a 3 month follow-up.
62685900|NCT05388825|EXPERIMENTAL|Sequence 2|N=14 subjects receive 5 mg TPN171H and 10 mg Placebo for Period 1; 10 mg Placebo and 5 mg Placebo for Period 2 ; 2.5 mg TPN171H and 10 mg Placebo for Period 3.
62685901|NCT05388825|EXPERIMENTAL|Sequence 3|N=14 subjects receive 10 mg Placebo and 5 mg Placebo for Period 1; 2.5 mg TPN171H and 10 mg Placebo for Period 2; 5 mg TPN171H and 10 mg Placebo for Period 3.
62316245|NCT04109443|ACTIVE_COMPARATOR|Control group|Participants randomized to the control group will have access to available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections including HIV. They will complete three assessments at baseline, post-intervention, and a 3 month follow-up.
62339684|NCT02047630|ACTIVE_COMPARATOR|Brand-name latanoprost|1 eye drop hs
62339685|NCT02211976|EXPERIMENTAL|Bisacodyl|
61924439|NCT01361854|EXPERIMENTAL|polysomnography for suspicion of SDB|adults, suspects of suffering from sleep disordered-breathing, who must undergo a diagnostic polysomnography
62125980|NCT04426890|ACTIVE_COMPARATOR|Arm 2-2|300 mg of EU-approved Xolair as SC injections via PFS
62685902|NCT05388825|EXPERIMENTAL|Sequence 4|N=14 subjects receive 5 mg TPN171H and 10 mg Placebo for Period 1; 10 mg TPN171H and 5 mg Placebo for Period 2; 10 mg Placebo and 5 mg Placebo for Period 3.
62685903|NCT05388825|EXPERIMENTAL|Sequence 5|N=14 subjects receive 10 mg TPN171H and 5 mg Placebo for Period 1; 10 mg Placebo and 5 mg Placebo for Period 2; 5 mg TPN171H and 10 mg Placebo for Period 3.
62125981|NCT04426890|EXPERIMENTAL|Arm 3|"1. Treatment period 1: 150 mg of CT-P39~2. Treatment period 2: 300 mg of CT-P39"
62125982|NCT04426890|ACTIVE_COMPARATOR|Arm 4|"1. Treatment period 1: 150 mg of EU-approved Xolair~2. Treatment period 2: 300 mg of EU-approved Xolair"
62125983|NCT04014634|PLACEBO_COMPARATOR|Placebo|Injection of NaCl
62125984|NCT04014634|EXPERIMENTAL|Verum|
62125985|NCT00591500||Control|The control group comprises patients with a first primary melanoma diagnosed in a twelve-month period.
62125986|NCT00591500||Cases|Cases are patients diagnosed with a second or higher order primary in a six-year period.
62125987|NCT02753192|OTHER|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.
62125988|NCT04750044|EXPERIMENTAL|early refeeding group|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.
62125989|NCT04750044|ACTIVE_COMPARATOR|delayed refeeding group|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2.
62125990|NCT05330234|OTHER|Therapists|Single arm study. Participants are members of the therapy team at Imperial College Healthcare NHS Trust's stroke wards.
62125991|NCT00964730|EXPERIMENTAL|Talampanel|
62125992|NCT00964730|PLACEBO_COMPARATOR|Placebo|
62125993|NCT00964730|OTHER|Moxifloxacin|
62125994|NCT03947684|EXPERIMENTAL|TMS|Paired-pulse transcranial magnetic stimulation during active contraction to determine the influence of sex hormone fluctuations on cortical excitability in naturally cycling women.
62125995|NCT06460688|EXPERIMENTAL|Mother Rehabilitative Aid Education Program|Participants in group A will be educate thoroughly about treatment plan which includes routine neuro physical therapy aiming (Gross Motor Function \& Balance) A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.
62685904|NCT05388825|EXPERIMENTAL|Sequence 6|N=14 subjects receive 10 mg Placebo and 5 mg Placebo for Period 1; 5 mg TPN171H and 10 mg Placebo for Period 2; 10 mg TPN171H and 5 mg Placebo for Period 3.
62125996|NCT06460688|ACTIVE_COMPARATOR|Neuro physical Therapy.|Routine neuro physical therapy will be given(1) for 45 minutes, 5 days a week for 8 weeks. Participants in group B will not be educated about treatment plan. Routine home plan was given in this group once in a week, for 8 weeks.
62125997|NCT01673555|EXPERIMENTAL|GSK1278863 5mg|GSK1278863 5mg
62125998|NCT01673555|EXPERIMENTAL|GSK1278863 100mg|GSK1278863 100mg
62125999|NCT01673555|PLACEBO_COMPARATOR|Placebo|Placebo
62126000|NCT05677061|EXPERIMENTAL|HA-coated|Hydroxyapatite coating on Screw thread of DHS
62126001|NCT05677061|ACTIVE_COMPARATOR|NON-coated|No coating on Screw thread of DHS
62126002|NCT02515838|PLACEBO_COMPARATOR|Placebo|Placebo infusion
62126003|NCT02515838|EXPERIMENTAL|Sevuparin|Sevuparin infusion
62126004|NCT03690596|EXPERIMENTAL|NRT + QuitBuddy|This smartphone app will identify high-risk situations through real-time EMA data collected before and during a quit attempt. One week of pre-quit smoking behaviors will be integrated with passively sensed GPS data to create hotspot maps. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
62126005|NCT03690596|EXPERIMENTAL|NRT + QuitBuddy-Recall|This smartphone app will identify high-risk situations through retrospective recall of locations where the patient typically smoked. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
62126006|NCT03690596|ACTIVE_COMPARATOR|NRT Control (treatment as usual)|Standard Care Control is intended to approximate the real-world experience where smokers obtain over-the-counter NRT and, after brief instructions at the outset (\~1 lozenge per hour, during cravings, and \<20 per day), determine usage for themselves.
62126007|NCT00003612|EXPERIMENTAL|Schedule A: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
62126008|NCT00003612|EXPERIMENTAL|Schedule B: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
62126009|NCT02645149|EXPERIMENTAL|A1. Non-V600 BRAF, BRAF wildtype, NRAS wildtype. Actionable gene mutation, matched drug available|Patients will receive targeted drug matched to the actionable gene mutation detected on NGS testing. If a patient cannot receive the matched targeted therapy because of the existence of one or more drug specific exclusion criteria, an alternative matched therapy may be assigned, or trametinib, or clinical trials if available.
62685905|NCT06688110|EXPERIMENTAL|Gixam followed by standard of care colonoscopy|All enrolled participants will undergo the Gixam test followed by a standard of care colonoscopy
62685906|NCT03859856||women with Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus
62685907|NCT03859856||women without Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control
62126010|NCT02645149|EXPERIMENTAL|A2. Non-V600 BRAF, BRAF wildtype, NRAS wildtype. Actionable gene mutation, no matched drug available|Patients may have an actionable aberration for which there is no current study-specific drug supply available. In this scenario, access will be sought for compassionate use of the relevant approved targeted therapy.
62126011|NCT02645149|EXPERIMENTAL|A3. Non-V600 BRAF, BRAF wild type and NRAS wild type melanoma - no actionable genetic aberration|Patients for whom there is no actionable genetic aberration will receive trametinib, based upon the known MAPK excess activity in the majority of melanomas that may be inhibited by a MEK inhibitor
62126012|NCT02645149|EXPERIMENTAL|B. Mucosal melanoma|Patients will receive combined trametinib and ribociclib based on evidence to suggest that combined MEK inhibition and CDK4/6 inhibition may be effective. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.
62126013|NCT02645149|EXPERIMENTAL|C. NRAS mutant melanoma|Patients with an NRAS mutation detected on standard gene testing only will receive combined trametinib and ribociclib based on evidence that combining MEK inhibition and CDK4/6 inhibition is a viable treatment option.
62126014|NCT02645149|OTHER|D. BRAF V600 mutant melanoma|Patients will receive standard of care treatment only.
62126015|NCT02743195|OTHER|Polyphenol/prebiotic blend|Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
62126016|NCT06453798|EXPERIMENTAL|cervical spine exercises|Cervical spine exercise training, patients received the intervention, once a day, 6 times a week, 2 weeks as a course of intervention, a total of 2 courses of intervention
62126017|NCT06453798|EXPERIMENTAL|Neuromobilization|Neuromobilization, patients received this intervention, once a day, 6 times a week, 2 weeks as a course of intervention, a total of 2 courses of intervention
62126018|NCT06453798|EXPERIMENTAL|cervical spine exercises combined with nerve mobilization|cervical spine exercises combined with nerve mobilization，patients received this intervention, once a day, 6 times a week, 2 weeks as a course of intervention, a total of 2 courses of intervention
62126019|NCT03703336|EXPERIMENTAL|ROTAVIN Liquid Formulation|Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
62126020|NCT03703336|ACTIVE_COMPARATOR|ROTAVIN-M1 Frozen Formulation|Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
62126021|NCT00727922|EXPERIMENTAL|1|
62126022|NCT04676334|EXPERIMENTAL|Rucaparib|Rucaparib administered at dose and schedule last taken in parent study, or per investigator decision.
62126023|NCT04676334|NO_INTERVENTION|Long-term Follow-up|Participants discontinued rucaparib treatment and were in long-term follow-up in the parent study.
62126024|NCT03639558|ACTIVE_COMPARATOR|Haloperidol + Promethazine + Chlorpromazine|Haloperidol + Promethazine + Chlorpromazine are all psychiatric drugs that have been well tested. The combination of these 3 drugs, however, have never been randomised.
62126025|NCT03639558|EXPERIMENTAL|Haloperidol + Promethazine|Haloperidol + Promethazine are both psychiatric drugs with antipsychotic and calming properties.
62126026|NCT00002842|EXPERIMENTAL|Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin|Patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks
62126027|NCT02238210|EXPERIMENTAL|Atrovent® - common cold group|Treatment duration for common cold group - three time daily for 4 days
62126028|NCT02238210|EXPERIMENTAL|Experimental: Atrovent® - allergy group|Treatment duration for allergy group - three time daily for 14 days
61924440|NCT04968054|ACTIVE_COMPARATOR|Propofol group|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively
61924441|NCT04968054|EXPERIMENTAL|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
62126029|NCT04324333|EXPERIMENTAL|Using Digital wearable system for fall detection|Digital wearable system (Owlytics Healthcare's app) enables a 24/7 health-tracking service, collecting personal health data from wearable wristbands and insoles. The data is analyzed by machine-learning algorithms that can detect abnormal physiological patterns. This allows the prediction and prevention of potentially harmful health events (such as falls).
62126030|NCT02301208|ACTIVE_COMPARATOR|Low dose cisplatin arm|concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
62126031|NCT02301208|ACTIVE_COMPARATOR|High dose cisplatin arm|concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
62685908|NCT06418698||Patients with acute ischemic stroke due to large or medium vessel occlusion|Patients with acute ischemic stroke due to large or medium vessel occlusion meeting inclusion criteria, must accept mechanical thrombectomy and have CT images which can get the IAC Agatston score.
62685909|NCT05150561||Cohort I - Patients newly diagnosed with malignant lymphoma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
62685910|NCT05150561||Cohort II - Patients newly diagnosed with acute leukaemia (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
62685911|NCT05150561||Cohort III - Patients newly diagnosed with multiple myeloma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
62685912|NCT01832298|EXPERIMENTAL|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
62685913|NCT05539352|EXPERIMENTAL|Active treatment plus EUC|All caregivers are assigned to this condition and receive the treatment plus EUC.
62685914|NCT03521609|EXPERIMENTAL|Emotional Intelligence Intervention|Patient's emotional abilities will be stimulated by means of a brief intervention in a group format (nine sessions). In these sessions we will use both projective and guided-fantasy techniques for the emotional diagnosis, as well as psychoeducational workshops of both emotional education and emotional intelligence development.
62685915|NCT06164600|EXPERIMENTAL|Bovine Colostrum group|Thirty Patients will receive oral bovine colostrum sachets daily for one month in a dose of 1 sachet per day for children less than 2 years and 2 sachets per day for children older than 2 years.They will be instructed to take each sachet on an empty stomach at least 30 min before meals after being added to 50 ml of neutral (previously boiled) water with continuous mixing until being dissolved.
62685916|NCT06164600|PLACEBO_COMPARATOR|Control group|Thirty Patients will receive oral placebo sachets daily in a similar dose for the same duration. They will be instructed to receive it similarly to the experimental group.
62685917|NCT06688526|ACTIVE_COMPARATOR|Auditory Stimulation|Quiet sounds are played during sleep
62685918|NCT06688526|SHAM_COMPARATOR|Sham Stimulation|Volume is set to zero.
62685919|NCT01444924|EXPERIMENTAL|Bupivicaine|TAP block with bupivicaine/epinephrine placed prior to surgery.
62685920|NCT01444924|PLACEBO_COMPARATOR|Placebo|TAP block with placebo placed prior to surgery
61924442|NCT03099070|NO_INTERVENTION|Control, Not-Fasting|Participants will experience the control intervention and will not fast prior to the lab visit.
62339686|NCT02211976|EXPERIMENTAL|Simeticone|
62685921|NCT05633355|EXPERIMENTAL|Rocatinlimab|Rocatinlimab will be administered subcutaneously every 4 weeks (Q4W) for 52 weeks with one additional dose at Week 2.
62685922|NCT06306976|OTHER|Control Group 1|"Control group 1 patients will have no incisional hernia or prior laparotomy.~Imaging:~Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points"
62685923|NCT06306976|OTHER|Control Group 2|"Control group 2 patients will have no hernia and will be undergoing elective midline laparotomy.~Imaging:~Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points .~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral~Tensiometry For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure."
62685924|NCT06430684|EXPERIMENTAL|Treatment|Empagliflozin 10mg daily for 3 months (n=20)
62685925|NCT06430684|NO_INTERVENTION|Standard of Care|Participants will not take empagliflozin (n=20)
62685926|NCT01392066||Breast cancer patients and their partners|Patients with breast cancer and their cohabiting partners/spouses
62685927|NCT06683898|EXPERIMENTAL|External Focused Pilates|Pilates training was implemented with an external focus (EF).
62685928|NCT06683898|EXPERIMENTAL|Internal Focused Pilates|Pilates training was implemented with an internal focus (IF).
62685929|NCT05860868|EXPERIMENTAL|2 cycles|2 cycles induction + concurrent chemoradiotherapy
62685930|NCT05860868|ACTIVE_COMPARATOR|3 cycles|3 cycles induction + concurrent chemoradiotherapy
62339687|NCT02211976|EXPERIMENTAL|Bisacodyl and simeticone|
62685931|NCT06641258|OTHER|Control Group (Standard Procedure)|"Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application."
62126032|NCT02301208|EXPERIMENTAL|Low dose nedaplatin arm|concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
62126033|NCT02301208|EXPERIMENTAL|High dose nedaplatin arm|concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
62126034|NCT06300424|EXPERIMENTAL|Almonertinib and Chemo-immunotherapy|6 weeks of almonertinib followed by 3 cycles of neoadjuvant adebrelimab (1200mg every 3 weeks) with nab-paclitaxel and carboplatin (nab-paclitaxel 135 mg/m2, d1 and d8, and carboplatin AUC 5, d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including EGFR-TKIs up to 3 years or immunotherapy for up to 1 year or till disease progression or unacceptable toxicity.
62126035|NCT04414995|EXPERIMENTAL|Paracetamol+Ibuprofen|Patients in Group 1 will receive a combination of 1000 mg IV paracetamol and 800 mg IV ibuprofen at the end of operation following by 1000 mg IV paracetamol and 800 mg IV ibuprofen every 6 hours up to 72 hours.
62126036|NCT04414995|EXPERIMENTAL|Paracetamol+normal saline|Patients in Group 2 will receive 1000 mg IV paracetamol and 100 ml IV normal salines at the end of operation following by 1000 mg IV paracetamol and 100 ml IV normal salines every 6 hours up to 72 hours.
62126037|NCT04414995|EXPERIMENTAL|Ibuprofen+normal saline|Patients in Group 3 will receive 800 mg IV ibuprofen and 100 ml IV normal salines at the end of operation following by 800 mg IV ibuprofen and 100 ml IV normal salines every 6 hours up to 72 hours.
62126038|NCT01599117|PLACEBO_COMPARATOR|Placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
62126039|NCT01599117|ACTIVE_COMPARATOR|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
62126040|NCT03084744|EXPERIMENTAL|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
62126041|NCT03084744|PLACEBO_COMPARATOR|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
62126042|NCT02858882||Swimmers|Screening of elite athletes
62126043|NCT01625013|EXPERIMENTAL|Synvisc-One|
62126044|NCT02014129|EXPERIMENTAL|Cohort 1 - 100 mg Abemaciclib|100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
61924443|NCT03099070|EXPERIMENTAL|Control, Fasting|Participants will experience the control intervention and will fast prior to the lab visit.
61924444|NCT03099070|EXPERIMENTAL|Stress, Not-Fasting|Participants will experience the stress intervention and will not fast prior to the lab visit.
61924445|NCT03099070|EXPERIMENTAL|Stress, Fasting|Participants will experience the stress intervention and will fast prior to the lab visit.
62126045|NCT02014129|EXPERIMENTAL|Cohort 2 - 150 mg Abemaciclib|150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
62126046|NCT02014129|EXPERIMENTAL|Cohort 3 - 200 mg Abemaciclib|200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
62339688|NCT02626572|EXPERIMENTAL|S47445 5mg|
62685932|NCT06641258|EXPERIMENTAL|Experimental Group|"Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied"
62685933|NCT01687595|EXPERIMENTAL|HerpV 240 μg + QS-21 50 μg|Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1. At Week 24, participants who completed treatment period 1 will receive a booster dose of combination of HerpV 240 μg and QS-21 50 μg in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
62126047|NCT02383472|EXPERIMENTAL|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
62316246|NCT03855917|EXPERIMENTAL|Sof plus G/P|Four weeks of sofosbuvir (400mg) plus glecaprevir-pibrentasvir (300mg/120mg) will be administered, followed by immediate retreatment of virological relapse with glecepravir/pibrentasvir (300mg/120mg) for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
62339689|NCT02626572|EXPERIMENTAL|S47445 15mg|
62339690|NCT02626572|EXPERIMENTAL|S47445 50mg|
62339691|NCT02626572|PLACEBO_COMPARATOR|Placebo|
62339692|NCT02214316|EXPERIMENTAL|Interventional 1|Interventional experimental arm with hypertonic saline
62316247|NCT05011422|EXPERIMENTAL|ex vivo αβ-TCR/CD19 depleted haplo-hematopoietic stem cell infusion (HSCT)|"* Patients will undergo standard of care conditioning regiment prior to HSCT~* On Day 0, patients will undergo infusion of the ex vivo αβ-TCR/CD19 depleted haplo-HSCT from a stimulated peripheral stem cell source per institutional standard of care. Patients whose graft has a residual CD20+ count \> 1.0 x 10\^5 may receive a single infusion of rituximab on Day +1 at a dose of 375 mg/m\^2 at provider's discretion."
62316248|NCT04756089|EXPERIMENTAL|Breast stimulation|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
62126048|NCT02383472|PLACEBO_COMPARATOR|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
62316249|NCT04756089|ACTIVE_COMPARATOR|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
62479021|NCT05554406|EXPERIMENTAL|Arm II (cytarabine, daunorubicin, venetoclax)|Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62126049|NCT03680417|ACTIVE_COMPARATOR|Safety Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
62316250|NCT00991172|PLACEBO_COMPARATOR|placebo injection|
62316251|NCT00991172|EXPERIMENTAL|active|subcutaneous injection of REGN475
62316252|NCT00991172|EXPERIMENTAL|active 2|subcutaneous injection of REGN475
62479022|NCT05554406|EXPERIMENTAL|Arm III (azacitidine, venetoclax)|Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62126050|NCT03680417|ACTIVE_COMPARATOR|Sub Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
62126051|NCT00168519|ACTIVE_COMPARATOR|1|
62316253|NCT04376346|EXPERIMENTAL|Intervention Arm|Participants in the intervention arm will complete the AIY-C curriculum that has been translated for mHealth delivery. This includes completing various activities such as completing their own risk assessment when it comes to AEP and setting goals for themselves.
62316254|NCT04376346|NO_INTERVENTION|Control Arm|Participants in the control arm will complete activities that are carefully designed under different topics than the intervention arm. In this regard, participants will complete various activities such as quizzes, interactive games and videos. The investigators will ensure that participants in both arms will spend similar time on completing the activities.
62316255|NCT02868502||Trabeculectomy|Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.
62316256|NCT02868502||Ahmed Glaucoma Valve implantation|Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.
62316257|NCT02868502||Cyclophotocoagulation|Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.
62316258|NCT02868502||Ocular hypotensive eye drops|"Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments.~IOP measurement in different positions."
62316259|NCT02868502||Ocular Hypertension|"Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg..~IOP measurement in different positions."
62685934|NCT01687595|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1 and at Week 24 in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
62126052|NCT06677177|EXPERIMENTAL|Patients with LUTS due to BPH/ nano-water|Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia receiving nano-water combined with tamsulosin and Dutasteride
62126053|NCT06677177|ACTIVE_COMPARATOR|Patients with LUTS due to BPH/regular water|Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia receiving regular water combined with tamsulosin and Dutasteride
62316260|NCT02868502||Control|"Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia.~IOP measurement in different positions."
62316261|NCT01438710|EXPERIMENTAL|LCP-Tacro|LCP Tacro tables for once daily oral administration
62316262|NCT01438710|EXPERIMENTAL|Prograf|Tacrolimus capsules for twice daily oral administration
62685935|NCT06673238|EXPERIMENTAL|Part 1: Group 1|Participants will receive a single dose of either ABBV-722 Dose A or placebo.
62126054|NCT05732649|EXPERIMENTAL|Experiment 1|Participants will take part in three different sessions. In each session, network communication at visual areas will be coupled with the intensity of a sound, of a tactile stimulation, or both.
62479023|NCT05554406|EXPERIMENTAL|Arm IV (daunorubicin and cytarabine liposome)|Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62126055|NCT05732649|EXPERIMENTAL|Experiment 2 (Group A)|Participants undergo neurofeedback training of network communication between the target brain area (i.e., the left superior parietal area) and the rest of the brain during about 20 minutes (the precise duration will be defined with the experience of Experiment 1), using the sensory feedback modality defined in Experiment 1. Then, they perform the mirror-drawing task.
62126056|NCT05732649|ACTIVE_COMPARATOR|Experiment 2 (Group B)|Participants will use neurofeedback to train network communication of a control brain area in the other (right) hemisphere which is not directly linked to visuo-motor processing or learning, using otherwise the same duration and feedback setup. This control condition allows to obtain a similar feedback experience and hence a true blinding. Moreover, it enables an evaluation of the spatial specificity of the feedback training. After neurofeedback, they perform the mirror-drawing task.
62126057|NCT05732649|NO_INTERVENTION|Experiment 2 (Group C)|Participants will not receive neurofeedback, but directly train the mirror-drawing task.
62126058|NCT01833923|EXPERIMENTAL|anlotinib|dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week
62126059|NCT00567333|OTHER|1|
62479024|NCT05554406|EXPERIMENTAL|Arm V (daunorubicin and cytarabine liposome, venetoclax)|Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62479025|NCT06521021|OTHER|WW + Home modification and grocery delivery (AVOID)|"WW + modification of home food environment + online grocery shopping and delivery~Arm assignment is selected by participant."
62479026|NCT06521021|OTHER|WW + Inhibitory control training (RESIST)|"WW + daily gamified inhibitory control training~Arm assignment is selected by participant."
62126060|NCT00567333|OTHER|2|
62479027|NCT02199873|EXPERIMENTAL|BIIX 1 XX - single rising dose|
62479028|NCT02199873|PLACEBO_COMPARATOR|Placebo|
62126061|NCT01061671|ACTIVE_COMPARATOR|simvastatin|40 mgms of simvastatin daily
62126062|NCT01061671|PLACEBO_COMPARATOR|placebo|Matched placebo pill daily
62685936|NCT06673238|EXPERIMENTAL|Part 1: Group 2|Participants will receive a single dose of either ABBV-722 Dose B or placebo.
62685937|NCT06673238|EXPERIMENTAL|Part 1: Group 3|Participants will receive a single dose of either ABBV-722 Dose C or placebo.
62685938|NCT06673238|EXPERIMENTAL|Part 1: Group 4|Participants will receive a single dose of either ABBV-722 Dose D or placebo.
62126063|NCT01068743|OTHER|Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.
62126064|NCT01068743|OTHER|Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.
62316263|NCT02807116|EXPERIMENTAL|Pacritinib and Rifampin|On Day 1, subjects received a single oral 400-mg dose of pacritinib. On Days 8 through 17, following a 7-day washout period, 600-mg oral doses of rifampin were administered QD. It was anticipated that steady-state concentrations of rifampin would be achieved by Day 17. On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
62316264|NCT06671925|EXPERIMENTAL|SCOOP Intervention Group|SCOOP is a 7-week intervention, delivered primarily over the telephone by community health workers, to support chronic pain self-management and social connectedness.
62316265|NCT06671925|NO_INTERVENTION|Control group|Control group participants receive usual care between the baseline and 8-week follow-up survey. After completing the follow-up survey, control participants will be invited to take part in an educational workshop about pain and loneliness and will receive all intervention materials.
62316266|NCT00717353||1|Lung cancer
62316267|NCT04674852|OTHER|Marking cN+ nodes|These patients have already undergone neoadjuvant chemotherapy for locally advanced breast cancer with metastasis to the axillary lymph nodes. During standard of care needle-directed I-125 seed localization, the research marker will also be deployed through the same needle. Ultrasound detection of the marker will be compared to conventional biopsy markers and the I-25 seed.
62685939|NCT06673238|EXPERIMENTAL|Part 1: Group 5|Participants will receive a single dose of either ABBV-722 Dose E or placebo.
62126065|NCT01068743|OTHER|Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.
62126066|NCT01068743|OTHER|Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.
62126067|NCT01437332||Diabetes|
62126068|NCT01437332||Nerve injury|
62126069|NCT01437332||Other|
62126070|NCT03265886|EXPERIMENTAL|Warm bupivacaine at (37°c)|Warmed bupivacaine at body temperature will be administered
62126071|NCT03265886|ACTIVE_COMPARATOR|Bupivacaine at operating room temperature (23°c)|Bupivacaine at temperature of 23°C will be administered
62126072|NCT04261465|EXPERIMENTAL|Paclitaxel Carboplatin Olaparib|"Subjects will receive weekly therapy with paclitaxel 60 mg/m2 IV and carboplatin AUC 2 IV for 3 weeks out of 4, and olaparib tablets at the dose of 150 mg bid administered orally for 3 consecutive days (D1-D3), every week for each cycle.~After 3 cycles patients will be evaluated for interval debulking surgery. After surgery they will receive consolidation treatment with paclitaxel and carboplatin according to Investigator's choice"
62126073|NCT02190643|EXPERIMENTAL|Adherence condition|Brief smoking cessation counseling session (based on 5 A's approach) that includes a module focused on improving adherence to using the nicotine patch, plus 8-week supply of nicotine patches.
62126074|NCT02190643|ACTIVE_COMPARATOR|Standard condition|Brief smoking cessation counseling session (based on 5 A's approach) that does not include a module focused on improving nicotine patch adherence, plus 8-week supply of nicotine patches.
62126075|NCT04435236|ACTIVE_COMPARATOR|Cervical ESP block group|Cervical ESP block will be performed as described by Elsharkawy at al. (7).
62126076|NCT04435236|SHAM_COMPARATOR|ISB Block group|ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
62316268|NCT00430781|EXPERIMENTAL|Combination arm|Pazopanib plus lapatinib
62316269|NCT00430781|ACTIVE_COMPARATOR|Lapatinib monotherapy|Lapatinib
62316270|NCT00430781|ACTIVE_COMPARATOR|Pazopanib monotherapy|Pazopanib
62126077|NCT01032486||Azilect|Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
62126078|NCT01565148|EXPERIMENTAL|Group 1|"Drug: iCo-007 350 mcg~iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4"
62126079|NCT01565148|EXPERIMENTAL|Group 2|"Drug: iCo-007 700 mcg~iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4"
62126080|NCT01565148|EXPERIMENTAL|Group 3|"Drug: iCo-007 350 mcg and Laser~iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation"
62126081|NCT01565148|EXPERIMENTAL|Group 4|"Drug: Ranibizumab and iCo-007 350 mcg~Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later"
62126082|NCT01339234|EXPERIMENTAL|Body-weight supported treadmill training|
62126083|NCT02455297|EXPERIMENTAL|Copanlisib|Copanlisib (BAY80-6946) solution for IV infusion
62126084|NCT05374681|OTHER|Medical treatment alone|Medical treatment without embolization of the MMA.
62126085|NCT05374681|OTHER|Surgical treatment alone|Surgical treatment without embolization of the MMA.
62316271|NCT02257814|NO_INTERVENTION|Control Group|Control group
62316272|NCT02257814|EXPERIMENTAL|Incredible Years|incredible years intervention
62316273|NCT02257814|EXPERIMENTAL|Preschool PATHS|Preschool PATHS (Promoting Alternative Thinking Strategies)
62316274|NCT02257814|EXPERIMENTAL|Tools of the Mind|Tools of the Mind
62479029|NCT04019015|EXPERIMENTAL|Kcentra|"A single dose of Kcentra based on estimated body weight~* 2000 U for patients with an estimated body weight ≤ 75kg~* 3000 U for patients with an estimated body weight \> 75kg"
61924446|NCT02732080|EXPERIMENTAL|Deferred coronary stenting|In this arm, after establishing TIMI -3 flow in infarct related artery with balloon angioplasty, patients will undergo stent implantation when coronary autoregulatory function was recovered (initial hyperemic flow was subsided and baseline resistance was increased). Recovery of the auto regulatory function will be determined by measuring microvascular flow and resistance. After stenting microvascular flow / resistance will continue to be monitored using pressure/flow sensor tipped guide wire until the completion of 1 hour follow up period.
62316275|NCT03488810|ACTIVE_COMPARATOR|Arm A: ADT + radiation therapy|"Patient will receive 2 injections of a three-monthly LHRH agonist depot plus non-steroidal anti-androgen (rescue treatment) (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
62685940|NCT06673238|EXPERIMENTAL|Part 2: Group 6|Participants who are Han Chinese will receive a single dose of ABBV-722 Dose C.
62685941|NCT06673238|EXPERIMENTAL|Part 2: Group 7|Participants who are Japanese will receive a single dose of ABBV-722 Dose C.
62685942|NCT06673238|EXPERIMENTAL|Part 3: Group 8|Participants will receive either ABBV-722 Dose B or placebo for 14 days.
62685943|NCT06673238|EXPERIMENTAL|Part 3: Group 9|Participants will receive either ABBV-722 Dose C or placebo for 14 days.
62685944|NCT06673238|EXPERIMENTAL|Part 3: Group 10|Participants will receive either ABBV-722 Dose D or placebo for 14 days.
62685945|NCT06673238|EXPERIMENTAL|Part 3: Group 11|Participants will receive either ABBV-722 Dose E or placebo for 14 days.
62685946|NCT04098913|EXPERIMENTAL|Reduced screen-based media use|Reducing recreational screen-based media use for a period of 2 weeks.
62685947|NCT04098913|NO_INTERVENTION|Control group|Participants are asked to continue their habitual screen-based media use.
61924447|NCT02732080|ACTIVE_COMPARATOR|Immediate stenting|In this arm, patients will undergo stenting immediately after balloon angioplasty. After stent implantation, microvascular flow / resistance values will be continuously monitored using pressure/flow sensor tipped guide wire until the end of 1 hour follow up period.
61924448|NCT05751616|ACTIVE_COMPARATOR|Conventional sintering|
61924449|NCT05751616|EXPERIMENTAL|Speed sintering|
61924450|NCT05121493|ACTIVE_COMPARATOR|Platelet Poor Plasma Tear|
61924451|NCT05121493|EXPERIMENTAL|Platelet Rich Plasma Tears|
62479030|NCT04019015|PLACEBO_COMPARATOR|Placebo|A single infusion of volume matched placebo solution (Normal Saline)
62479031|NCT01744587|PLACEBO_COMPARATOR|Placebo|Placebo qd (2# bid) for 3 years
62685948|NCT05356429||experimental group|In the experimental group, LCDM was added to the general mature culture medium.
62685949|NCT05356429||control group|In the control group, he culture medium was general mature culture medium.
62685950|NCT06570135|EXPERIMENTAL|premature ejaculation group|
62685951|NCT06570135|EXPERIMENTAL|Non-premature ejaculation group|
62685952|NCT06689527|EXPERIMENTAL|Vamorolone/Midazolam|both Test Drug and Reference Drug are administered in this arm
62685953|NCT02976688|EXPERIMENTAL|Sodium propionate|Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.
62685954|NCT01627093||Observational (questionnaire, medical chart review)|Patients complete questionnaires over 30 minutes before treatment begins, at each visit during treatment, and again at all follow-up visits related to treatment. Patients also have their medical records reviewed.
62685955|NCT04943068|EXPERIMENTAL|Bremelanotide|Bremelanotide (BMT) subcutaneously (SC) via auto-injector for 8-weeks double-Blind period
62685956|NCT04943068|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneously (SC) via auto-injector for 4-weeks single-Blind period and for 8-weeks double-Blind period
62685957|NCT01265147|ACTIVE_COMPARATOR|Cisplatin|cisplatin combine with IMRT
62685958|NCT01265147|EXPERIMENTAL|Nedaplatin|Nedaplatin combine with IMRT
62685959|NCT05378425|EXPERIMENTAL|Part 1 - Dose Escalation Phase (Monotherapy)|NTX-1088 administered as a 60-minute IV infusion at escalating doses as a monotherapy. NTX-1088 will be administered on Day 1 of a 21-day cycle.
62685960|NCT05378425|EXPERIMENTAL|Part 1 - Dose Escalation Phase (Combination Therapy)|"NTX-1088 administered as a 60-minute IV infusion in escalating doses in combination with pembrolizumab. NTX-1088 will be administered on Day 1 of a 21-day cycle.~Pembrolizumab will be administered as a 30-minute IV infusion, within 2 hours prior to NTX-1088 administration, at a dose of 200 mg on Day 1 of every 21-day cycle."
62685961|NCT05378425|EXPERIMENTAL|Part 2 - Dose Expansion (Monotherapy)|NTX-1088 administered at the RP2D as a 60-minute IV infusion as a monotherapy.
62685962|NCT05378425|EXPERIMENTAL|Part 2 - Dose Expansion (Combination Therapy)|NTX-1088 administered at the RP2D as a 60-minute IV infusion in combination with pembrolizumab at the standard labeled dose.
61924452|NCT03503851|ACTIVE_COMPARATOR|One CLIP|Implantation of single MitraClip
62126086|NCT05374681|EXPERIMENTAL|Medical treatment associated with an embolization of the MMA|Medical treatment + embolization under local anesthesia or conscious sedation. The embolization will be carried out by femoral or radial arterial guided by pre-embolization cervical CTA. The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
62126087|NCT05374681|EXPERIMENTAL|Surgical treatment associated with an embolization of the MMA|Surgical treatment + embolization under local anesthesia or conscious sedation. The embolization will be carried out by femoral or radial arterial guided by pre-embolization cervical CTA. The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
62126088|NCT05701397|EXPERIMENTAL|Study group|Patients undergoing surgery for lumbar spinal stenosis. Patients will have a biopsy taken from the ligamentum flavum and test for the presence of amyloid. Patients with amyloid in the ligamentum flavum will be referred for a DPD scintigraphy.
62126089|NCT00309907|EXPERIMENTAL|Etanercept and corticosteroid therapy|Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.
62126090|NCT02107339|EXPERIMENTAL|methadone group|Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
62126091|NCT02107339|ACTIVE_COMPARATOR|Hydromorphone group|Patients will receive hydromorphone 2 mg at the end of the surgical procedure
62126092|NCT02093715||RSV|Infant with acute bronchiolitis due to RSV
62126093|NCT02093715||Co- Infection|Infant with acute bronchiolitis due to RSV and other respiratory virus
62126094|NCT02093715||Other|Infant with acute bronchiolitis due to non-RSV respiratory virus
62126095|NCT02093715||Unknown|Infant with acute bronchiolitis with negative PCR results for respiratory viruses
62126096|NCT02093715||Control|Healthy infants
62126097|NCT01198275|ACTIVE_COMPARATOR|n-3 PUFAs|
62126098|NCT01198275|PLACEBO_COMPARATOR|placebo|
62126099|NCT04490252|NO_INTERVENTION|Free diet|Free diet
62126100|NCT04490252|EXPERIMENTAL|FMD|Fasting mimetic diet for 5 days, next cycle after 25 days of free diet
62126101|NCT02242695|EXPERIMENTAL|Fluomizin vaginal tablets|Fluomizin vaginal tablets containing 10mg dequalinium chloride once daily for 6 days and one placebo vaginal tablet on day 7
62126102|NCT02242695|ACTIVE_COMPARATOR|Canesten vaginal tablets|Canesten vaginal tablets containing 100mg clotrimazole once daily for 7 days
61924453|NCT03503851|ACTIVE_COMPARATOR|Two CLIPs|Implantation of second MitraClip (after successful Implantation of single MitraClip)
61924454|NCT05821101|EXPERIMENTAL|Mini-Monovision Arm|Bilateral implantation of Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision.
61924455|NCT04335799|EXPERIMENTAL|Weight Loss Plus Stress Management|Diabetes Prevention Program Intensive Lifestyle Intervention augmented with stress management training
62126103|NCT04521530|EXPERIMENTAL|immediate functional loading with temporary crowns|patients were rehabilitated with immediate functionally loaded implants.
62479032|NCT01744587|EXPERIMENTAL|Epigallocatechin Gallate (EGCG)|EGCG 600 mg qd (2# bid) for 3 years
62685963|NCT06416982|EXPERIMENTAL|Perineal massage before pessary examination|"Participant will undergo 2 minutes of perineal massage with water-based gel prior to the pessary examination.~This consists of 2 minutes of perineal massage at the external perineum and sides of the vaginal vestibule, as well as internal massage with the thumb, gliding from 4 to 8 o'clock, then tissue stretching technique with one intracavitary finger and other external finger at the 4 o'clock and 8 o'clock positions three times. The massage will be done by trained doctors who are not performing the pessary check."
62126104|NCT04521530|EXPERIMENTAL|immediate non functional loading with temporary crowns|patients were rehabilitated with immediate non-functionally loaded implants.
62126105|NCT00332241|EXPERIMENTAL|A1|Active Abilify
62126106|NCT00332241|PLACEBO_COMPARATOR|A2|
62126107|NCT03596853|EXPERIMENTAL|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
62126108|NCT03596853|SHAM_COMPARATOR|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
62126109|NCT04826445||Patients included in PENTOCLO protocol|We perform a prospective study with inclusions of all consecutive patients with osteoradionecrosis eligible for PENTOCLO.
62126110|NCT05208242|EXPERIMENTAL|Hyperoncotic albumin|Hyperoncotic albumin for all fluid resuscitation and also as a daily supplement, guided by daily serum albumin values, for up to 7 days.
62126111|NCT05208242|ACTIVE_COMPARATOR|Buffered crystalloids|Buffered crystalloid solutions for all fluid resuscitation and maintenance purposes. Participants in this arms will NOT receive any albumin during their participation.
62126112|NCT05572060|ACTIVE_COMPARATOR|Group C: (n=25) control.|patients will receive standardized protocol without receiving metformin.
62126113|NCT05572060|ACTIVE_COMPARATOR|Group D: (n=25) diabetic patients.|diabetic patients will receive standardized protocol and receiving metformin 500 mg every 8 hours since admission regardless of their random blood sugar with measurement of random blood sugar every hour and dextrose 25% infusion will be used if needed and also insulin infusion will be used when appropriate with target random blood sugar 140-180 in diabetic patients.
62685964|NCT06416982|NO_INTERVENTION|No perineal massage before pessary examination|Participant will not undergo 2 minutes of perineal massage, but will have water-based gel applied to the vaginal introitus and perineum prior to the pessary check.
62685965|NCT06127810||3T Contrast Enhanced Images First|
62685966|NCT06127810||0.064 Contrast Enhanced Images First|
62685967|NCT00588198||1|Melanoma patients
62316276|NCT03488810|EXPERIMENTAL|Arm B: ADT + radiation therapy + Apalutamide|"Patients will receive 2 injections of a three-monthly LHRH agonist depot. Apalutamide treatment: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
62316277|NCT00693212|EXPERIMENTAL|a|This arm was only open to subjects entering the second, open-label phase. All subjects were given open-label methylphenidate. Dosing was flexible.
62685968|NCT02956863|ACTIVE_COMPARATOR|Exercises|Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
62685969|NCT02956863|EXPERIMENTAL|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and the participants will receive treatments during 4 weeks, 1 treatments per week associated with Osteopathic Manipulative Treatment (OMT)
62685970|NCT03370835|EXPERIMENTAL|Sequence 1|"Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10~Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18"
62685971|NCT03370835|ACTIVE_COMPARATOR|Sequence 2|"Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10~Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18"
62126114|NCT05572060|ACTIVE_COMPARATOR|Group ND: (n=25) non-diabetic patients.|patients will receive standardized protocol and receiving metformin 500 mg every 8 hours since admission regardless of their random blood sugar with measurement of random blood sugar every hour and dextrose 25% infusion will be used if needed and also insulin infusion will be used when appropriate with target random blood sugar 100-140 in non diabetic patients.
62126115|NCT03238313|EXPERIMENTAL|Plan A|Plan A is the treatment condition. It is a 23-minute video that is designed to promote effective contraceptive use, use of dual methods of protection (condom use and prescription birth control use), and HIV/STI testing in African/American and Latina young women.
62126116|NCT03238313|ACTIVE_COMPARATOR|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a 17-minute video, but contains no information about reproductive health. Instead, the video teaches about the harms of cigarettes.
62126117|NCT01134237|ACTIVE_COMPARATOR|Urokinase|arm of interest
62126118|NCT01134237|PLACEBO_COMPARATOR|Control|Normal saline as a placebo for control arm
62738093|NCT01775163||Low Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 8 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
61924456|NCT04335799|ACTIVE_COMPARATOR|Weight Loss Only|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics
61924457|NCT03000270|ACTIVE_COMPARATOR|Prolonged unloading prior to PPCI|Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention
62126119|NCT03051165|OTHER|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
62316278|NCT00693212|EXPERIMENTAL|MPH|This is the active treatment arm of the double-blind placebo controlled phase. Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
62316279|NCT00693212|PLACEBO_COMPARATOR|PBO|This 2 week arm is the placebo part of the crossover design. Subjects receive placebo in a manner similar to the MPH arm. It lasts 2 weeks.
62316280|NCT00153634|EXPERIMENTAL|1|Antibiotic regimen assignment based on biofilm susceptibility test results
62316281|NCT00153634|ACTIVE_COMPARATOR|2|Antibiotic regimen assignment based on conventional susceptibility test results
62316282|NCT04051567|EXPERIMENTAL|LDA group|
62316283|NCT04051567|NO_INTERVENTION|NC group|
62316284|NCT01856946|EXPERIMENTAL|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
62316285|NCT03550716|ACTIVE_COMPARATOR|mTESE|Patients randomized to mTESE
62316286|NCT03550716|ACTIVE_COMPARATOR|TESA|Patients randomized to TESA
62126120|NCT03787966|EXPERIMENTAL|ATOPE-B|An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
62126121|NCT03787966|ACTIVE_COMPARATOR|ATOPE-I|An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
62126122|NCT01393002||INABBRA|Participating hospitals in the INABBRA alliance.
62126123|NCT01122901|EXPERIMENTAL|Group A (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62126124|NCT01122901|EXPERIMENTAL|Group B (gamma-secretase inhibitor RO4929097, surgery)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days -6 to -1. Patients undergo surgical resection on day 0. Within 30 days after surgical resection, patients receive gamma-secretase inhibitor RO4929097 as in group A.
62126125|NCT00816751|ACTIVE_COMPARATOR|1|
62126126|NCT00816751|EXPERIMENTAL|2|
62126127|NCT02297061||TEG group|200 consecutive hip fracture patients, Thrombelastography is performed on admission.
62126128|NCT02519517|EXPERIMENTAL|permissive hypercapnia|during one lung ventilation, right ventricular function was assessed by TEE and the effect of rising PCO2 appreciated
62126129|NCT05076058|EXPERIMENTAL|Treatment group|"Tablet name: tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza;~Dosage: 1g/tablet, 3 tablets/time；~Frequency: 2 times/day;~Duration: 6 months"
62316287|NCT00616239|ACTIVE_COMPARATOR|A|Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
62126130|NCT05076058|PLACEBO_COMPARATOR|Control group|"Tablet name: Placebo;~Dosage: 1g/tablet, 3 tablets/time；~Frequency: 2 times/day;~Duration: 6 months"
62126131|NCT04834219||On-pump CABG|Patients with an on-pump indication by the cardiovascular surgery department will be included in the study.
62126132|NCT04834219||Off-pump CABG|Patients with an off-pump indication by the cardiovascular surgery department will be included in the study.
62126133|NCT00743444|EXPERIMENTAL|1|AZD3355
62126134|NCT00743444|PLACEBO_COMPARATOR|2|
62316288|NCT00616239|ACTIVE_COMPARATOR|B|Subjects randomized to have the left side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
62316289|NCT04135261|EXPERIMENTAL|Part 1: Dose escalation|"QW - up to 4 (28 day) cycles of treatment (treatment administered 1x weekly) or Q3W - up to 6 (21 day) cycles of treatment (treatment administered 1x q3w)~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee."
62316290|NCT04135261|EXPERIMENTAL|Part 2: Dose expansion|Treatment administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) established in Part 1, in specific tumor cohorts - Melanoma, HCC and RCC.
62316291|NCT05801523|ACTIVE_COMPARATOR|laparoscopic ethanol sclerotherapy|
62316292|NCT05801523|ACTIVE_COMPARATOR|laparoscopic cystectomy|
62316293|NCT06585670|EXPERIMENTAL|Digital Mindfulness Intervention Arm|Participants in the intervention arm will be asked to engage with the digital meditation and mindfulness modules administered through the Calm Health platform for at least 10 minutes per day for 8 weeks.
62316294|NCT06585670|NO_INTERVENTION|Non-Intervention Arm|Participants in the non-intervention arm will not have access to the invite-only Calm Health mobile application for the first 8 weeks of the study. They will be instructed not to use any other digital mindfulness or meditation platform over the course of the study. They will be granted access to the mobile application after 8 weeks since their enrollment have elapsed.
62316295|NCT01437631|EXPERIMENTAL|endoclip|The group of patients who undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(\>1cm).
62316296|NCT01437631|NO_INTERVENTION|no endoclip|The group of patients who do not undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(\>1cm).
62316297|NCT03090191|EXPERIMENTAL|Clostridium difficile vaccine|
62316298|NCT03090191|PLACEBO_COMPARATOR|Placebo|
62316299|NCT05207436|EXPERIMENTAL|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Oxytocin|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (B-CBCT) weekly. Prior to each session, the Veteran participant will self-administer intranasal oxytocin. The estimated length of treatment participation is 8 to 15 weeks. All procedures take place in the Veterans home via home-based clinical video teleconferencing (CVT).
62316300|NCT04792138||Men suspected of Prostate Cancer|
62316301|NCT01139723|EXPERIMENTAL|A|
62126135|NCT03792204||PD patients with wearing-off effect|"people who have been clinically diagnosed with Parkinson's disease (PD) and have received anti PD therapy would be recruited into the study. The anti -PD treatment would not be changed in the population of the participants.~We would use the tool of 'Wearing-off 9 questionnaire' to determine the prevalence of Wearing-off phenomenon in Parkinson's patients in Shanghai"
62126136|NCT02267967|EXPERIMENTAL|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
62126137|NCT05167656|EXPERIMENTAL|Intraoral Manual Therapy plus exercise and education.|Six sessions of intraoral manual therapy plus exercise and counselling.
62126138|NCT05167656|EXPERIMENTAL|Extraoral Manual Therapy plus exercise and education.|Six sessions of extraoral manual therapy plus exercise and counselling.
62316302|NCT01139723|EXPERIMENTAL|B|
62316303|NCT00530712|EXPERIMENTAL|PTA and Stenting with EverFlex device|Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System
62316304|NCT00370149|ACTIVE_COMPARATOR|Antibiotic-impregnated Catheters (M/R)|Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
62685972|NCT06641947||benign and malignant|"Benign Lesion Group: This cohort includes patients diagnosed with benign pancreatic lesions, such as pancreatic cysts or neuroendocrine tumors. These patients typically do not require aggressive treatments like surgery or chemotherapy and are managed with regular monitoring and non-invasive interventions. Histopathological confirmation or stability over a minimum of one year of follow-up without progression is used to classify lesions as benign.~Malignant Lesion Group: This cohort comprises patients diagnosed with malignant pancreatic lesions, such as pancreatic ductal adenocarcinoma (PDAC). These patients often require more aggressive treatment options, including surgery, chemotherapy, and radiotherapy. The malignancy of the lesions is confirmed through histopathological analysis, and the cohort focuses on cases with clear evidence of tumor growth and progression."
62126139|NCT05167656|ACTIVE_COMPARATOR|Exercise and education.|Exercise and counselling alone without any manual therapy treatment.
62126140|NCT01084707|EXPERIMENTAL|Oral Nicotine 24-SA|2 Self-administrations of Experimental Nicotine once every hour
62126141|NCT01084707|EXPERIMENTAL|Oral Nicotine 24|2 administrations of Experimental Nicotine by study personnel once every hour
62126142|NCT01084707|EXPERIMENTAL|Oral Nicotine 48|2 administrations of Experimental Nicotine by study personnel once every 30 minutes
62126143|NCT01084707|ACTIVE_COMPARATOR|NiQuitin™ Lozenge 4 mg|1 NiQuitin™ lozenge, administered by study personnel once every hour
62126144|NCT01084707|ACTIVE_COMPARATOR|Nicorette® Gum 4 mg|1 piece Nicorette® gum, chewed for 30 minutes once every hour
62316305|NCT00370149|PLACEBO_COMPARATOR|Non-impregnated Catheter (C/S)|Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
62316306|NCT05154747|ACTIVE_COMPARATOR|Continuous Therapy (CT) Control Group|The control group is a continuous daily oral combination ART consisting of dolutegravir (DTG), with a tenofovir (TFV) and lamivudine(3TC)/emtricitabine(FTC) backbone
62126145|NCT03069313|EXPERIMENTAL|Arm I|Oral Vitamin B12
62126146|NCT01641198|ACTIVE_COMPARATOR|Configuration 1|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at two sites, SC (Screw-Vent) at one site
62126147|NCT01641198|EXPERIMENTAL|Configuration 2|Device placement: B (Brånemark) at one site, SW (Swede-Vent) at two sites, SC (Screw-Vent) at two sites
62126148|NCT01641198|EXPERIMENTAL|Configuration 3|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at one site, SC (Screw-Vent) at two sites
62126149|NCT01016522|EXPERIMENTAL|KetoCal|KetoCal tube feeding formula
62126150|NCT03195075|ACTIVE_COMPARATOR|Group 1|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography guided biliary drainage
62316307|NCT05154747|EXPERIMENTAL|Long Acting (LA) Injectable Group|The intervention group is a long-acting injectable, cabotegravir (CAB) LA and rilpivirine (RPV) LA given every 8-weeks after an optional 4-week oral lead-in period with oral cabotegravir and rilpivirine, and two loading doses separated by 4 weeks.
62316308|NCT06119698|EXPERIMENTAL|GetActive+|A mind-body program focused on increasing physical and emotional function in older adults with chronic musculoskeletal pain
62126151|NCT03195075|ACTIVE_COMPARATOR|Group 2|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to percutaneous trans-hepatic biliary drainage.
62126152|NCT02270710||Healthy Subjects|Overall in good health Provide informed consent Male and females, age 18 years and older Nonsmokers
62126153|NCT02270710||SLE Subjects|Enrolled by Hospital for Special Surgery Diagnosed with Systemic Lupus Erythematosus
62126154|NCT00306397|ACTIVE_COMPARATOR|A|Rapamycin - MMF after 3 months
62316309|NCT06119698|NO_INTERVENTION|Treatment as usual|Treatment as Usual (TAU) includes traditional primary care management of chronic pain.
62316310|NCT00644540|EXPERIMENTAL|1|
62316311|NCT00644540|ACTIVE_COMPARATOR|2|
62316312|NCT01601392|EXPERIMENTAL|Anodal tDCS|
62316313|NCT01601392|ACTIVE_COMPARATOR|Cathodal tDCS|
62685973|NCT02066259||healthy_0|healthy, people with normal (negative) colonoscopy results.
61924458|NCT03000270|ACTIVE_COMPARATOR|Immediate unloading prior to PPCI|Activation of Impella CP immediately prior to primary percutaneous coronary intervention
61924459|NCT04774120||Young Patients (Patients aged 18 to 65 years.)|Propofol infusion rate will be started at 20-25 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
62126155|NCT00306397|ACTIVE_COMPARATOR|B|Low dose tacrolimus - MMF - Rapamycin after 3 months
62126156|NCT01499199|EXPERIMENTAL|Dolutegravir 50mg Once Daily|All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
62126157|NCT06196788|EXPERIMENTAL|gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1 (venous injection), 8 (venous injection), and 15 (transcatheter arterial infusion) every 4 weeks.
62126158|NCT02761239|OTHER|Cricopharyngeal muscle innervation|The recurrent laryngeal nerve (RLN), vagus nerve, external branch of the superior laryngeal nerve (EBSLN) and pharyngeal plexus were stimulated intraoperatively by the NIM 3.0 Nerve Monitoring System (Medtronic Xomed, Jacksonville, FL, USA). Responses were evaluated by visual observation of the cricopharyngeal muscle and electromyographies via needle electrodes inserted into the cricopharyngeal muscle.
62126159|NCT03318484|ACTIVE_COMPARATOR|Optimal Medical Care|Optimal medical care (OMC) only is administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
62126160|NCT03318484|EXPERIMENTAL|Optimal Medical Care and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
62685974|NCT02066259||patient_1|people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ
62685975|NCT02066259||benign_2|people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia
62126161|NCT01336946|EXPERIMENTAL|health promotion program|Psycho education and behavioural group sessions and supervised walking sessions will be performed.
62126162|NCT01336946|NO_INTERVENTION|Control group|No intervention will be performed in this control group.
62316314|NCT01601392|SHAM_COMPARATOR|Sham|
62316315|NCT04904146||Patients with Mycosis fungoides and Sézary syndrome|
62316316|NCT04904146||Healthy volontaires|
62316317|NCT04221451|EXPERIMENTAL|GZ402671|"Primary population: participant will receive venglustat dose once daily during the primary analysis period (104 weeks) and the open-label extension period (104 weeks).~Secondary population: participant will receive venglustat at various doses once daily during the primary analysis period open-label (104 weeks) and the open-label extension period (104 weeks)."
62316318|NCT04221451|PLACEBO_COMPARATOR|Placebo|Primary population: participants will receive placebo once daily during the primary analysis period (104 weeks) and will receive venglustat dose once daily during the open-label extension period (104 weeks).
62316319|NCT00942877|EXPERIMENTAL|Cediranib (AZD2171) Treatment|"Adult participants will be treated with 30 mg by mouth once a day for 28 days (28-day cycles).~Pediatric participants (\<16 years old) will be treated with 12 mg/m\^2/day once a day for 28 days (28-day cycles)."
62126163|NCT06167213|EXPERIMENTAL|TMVR in failing mitral surgical bioprosthetic valve|Transcatheter Mitral Valve Replacement (TMVR) in subjects with a failing mitral surgical bioprosthetic valve.
62479033|NCT04145622|EXPERIMENTAL|Dose escalation|Participants with advanced solid tumors who received I-DXd IV Q3W monotherapy during dose escalation phase. Enrollment to this phase is currently closed.
62126164|NCT06167213|EXPERIMENTAL|TMVR in failing native mitral valve with an annuloplasty ring|Transcatheter Mitral Valve Replacement (TMVR) in subjects with a failing native mitral valve with an annuloplasty ring.
62126165|NCT01301716|EXPERIMENTAL|A|
62126166|NCT01301716|EXPERIMENTAL|B|
62126167|NCT01301716|EXPERIMENTAL|C|
62316320|NCT04341844|EXPERIMENTAL|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
62316321|NCT04341844|PLACEBO_COMPARATOR|Control|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
62316322|NCT04604730|EXPERIMENTAL|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
62316323|NCT04604730|ACTIVE_COMPARATOR|Anastomosis with protective stoma|Anastomosis with protective stoma
62479034|NCT04145622|EXPERIMENTAL|Dose expansion|Currently enrolling participants with advanced solid tumors who will receive I-DXd IV Q3W monotherapy at the recommended dose for expansion.
62479035|NCT06421337|EXPERIMENTAL|Study group|Subjects presenting at emergency departments of participating hospitals with suspected acute stroke within 24 hours from symptom onset with or without stroke code activation
62126168|NCT06187246|EXPERIMENTAL|Avatar-based Intervention Group|Treatment was based on the CBT approach and previous literature about FOD. It consisted of 12 weekly online individual sessions, which were administered once a week (total duration = 3 months) and lasted about 60 minutes each.
62126169|NCT06187246|ACTIVE_COMPARATOR|Minimal support control group|It consisted in individual informative talks, during which they were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
62126170|NCT01895023|EXPERIMENTAL|Dexmedetomidine group|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
62685976|NCT05739162|EXPERIMENTAL|Endoscopic Sleeve Gastroplasty (ESG)|Participants undergo Endoscopic Sleeve Gastroplasty (ESG). Following the 6-week transitional diet after undergoing the ESG procedure, participants will start the lifestyle intervention.
62685977|NCT02510274|EXPERIMENTAL|Part1, ASP3325 Tablet A|ASP3325 tablets A will be orally administered with 150 mL of water in fasting condition on non-dialysis day in Day 1
62126171|NCT01895023|ACTIVE_COMPARATOR|Midazolam group|The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
62126172|NCT01895023|PLACEBO_COMPARATOR|Placebo Group|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
62316324|NCT06477016||Group A-OsciPulse System|Patients admitted to the neuro intensive care unit or intermediate neurological care unit with a diagnosis of ischemic stroke randomly assigned to Group A.
62316325|NCT06477016||Group B- Standard Reference Therapy|Patients admitted to the neuro intensive care unit or intermediate neurological care unit with a diagnosis of ischemic stroke randomly assigned to Group B.
62316326|NCT04356105|ACTIVE_COMPARATOR|Minimal Stimulation Group|Minimal dose stimulation ovarian induction protocol given to poor responders, involving letrozole, low dose recombinant FSH and GnRH antagonist
62316327|NCT04356105|ACTIVE_COMPARATOR|Microflare Group|Microflare ovarian induction protocol given to poor responders, involving OCP, GnRH agonist, high dose recombinant FSH
62685978|NCT02510274|EXPERIMENTAL|Part2, ASP3325 Tablet B group 1|ASP3325 tablets B will be orally administered t.i.d. 30 minutes before each meal for 2 weeks
62685979|NCT02510274|EXPERIMENTAL|Part2, ASP3325 Tablet B group 2|ASP3325 tablets B will be orally administered t.i.d. 30 minutes just after each meal for 2 weeks
62316328|NCT05116982|EXPERIMENTAL|ORGONO Living Silica Acacia Gum-MMST Powder|ORGONO Living Silica Acacia gum-MMST Power. In capsules. One capsule a day for 7 days.
62316329|NCT05116982|EXPERIMENTAL|ORGONO Living Silica Malto-OSA Powder|ORGONO Living Silica Malto-OSA Powder. In capsules. One capsule a day for 7 days.
62126173|NCT01758328|EXPERIMENTAL|Pts with Mutiple myeloma|Patients will undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor. Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. The administration of WT1-specific cytotoxic T cells (WT1 CTLs) post transplantation is integrated to induce complete remissions in patients with residual disease and to decrease the rate of relapse following the allogeneic transplant.
62126174|NCT01587053||AVK|patient with AVK treatment
62126175|NCT04968756|EXPERIMENTAL|Treatment with the SPECTRALIS CENTAURUS device|"In Stage 1, two laser pattern will be applied in areas of the retina that require ablative laser photocoagulation.~In Stage 2, a laser pattern will be applied along and on the outside of the arcades. Furthermore, a treatment pattern will be applied to an area temporal to the fovea affected by intermediary age-related macular degeneration (AMD) and confluent soft drusen."
62126176|NCT03701386|ACTIVE_COMPARATOR|cesarean hysterectomy|Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
62126177|NCT03701386|EXPERIMENTAL|N&H sandwich technique|In the N\&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade was performed
62126178|NCT01210820|EXPERIMENTAL|Natural Astigmatism|Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
62126179|NCT01210820|EXPERIMENTAL|Post cataract with residual astigmatism|Subjects who have had cataract removal surgery but have residual astigmatism.
62126180|NCT02614625||Normal subjects|Patient with healthy, normal eyes
62126181|NCT02614625||Eyes with corneal disease|"Subjects that have any of the following conditions~* Corneal dystrophy or degeneration~* Corneal scarring~* Corneal ulcer~* Corneal injury~* Keratoconus~* Patients who had undergone corneal surgery~* Patients with other corneal disease"
62316330|NCT05116982|EXPERIMENTAL|ORGONO Living Silica Collagen Booster|ORGONO Living Silica Collagen Booster. Liquid. One bottle a day for 7 days.
62685980|NCT01084135|EXPERIMENTAL|Rivastigmine- Liquid form|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
61924460|NCT04774120||Elderly patients (Patients aged 65 to 85 years. )|Propofol infusion rate will be started at 15-20 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
61924461|NCT05905796|EXPERIMENTAL|Brain Health Intervention|Calculate eRADAR scores using EHR data to identify eligible individuals Invite eligible individuals for brain health assessment visit Enter results of brain health assessment visit into EHR Provide summary of results and recommended next steps to the Primary Care Physician and participant
61924462|NCT05905796|NO_INTERVENTION|Usual Care|Usual care Individuals who meet eligibility criteria will receive usual care.
62126182|NCT02614625||Eyes with retinal disease|"Subjects that have any of the following conditions:~* Diabetic macular edema~* Cystoid macular edema~* Age related macular degeneration~* Retinal vascular disorders (e.g. retinal artery occlusion)~* Epiretinal membrane~* Choroidal nevus~* Macular hole~* Patients who had undergone retinal surgery~* Patients with other retinal disease"
62316331|NCT05116982|PLACEBO_COMPARATOR|Placebo|Placebo. In capsules and liquid. One capsule and one bottle a day for 7 days.
62316332|NCT04175197||Study Cohort|Subjects with symptoms of intermittent claudication and/or critical limb ischemia (Rutherford Class 2-3-4-5-6) with angiographic evidence of femoropopliteal-below-the-knee arterial occlusion or stenosis
62316333|NCT01605305|EXPERIMENTAL|FOLFOX6|
62316334|NCT04578717|EXPERIMENTAL|Air-abrasion + Etch & rinse adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by etch\&rinse adhesive application using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
62316335|NCT04578717|EXPERIMENTAL|Air-abrasion + Self-etch adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by self-etch adhesive application which was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
62479036|NCT00764712|ACTIVE_COMPARATOR|Matias protocol|A protocol based on the absolute glucose value - Matias protocol (Matias)
62479037|NCT00764712|ACTIVE_COMPARATOR|Bath protocol|A protocol based on the relative glucose change - Bath protocol (Bath)
62479038|NCT00764712|ACTIVE_COMPARATOR|eMPC|a computer-based model predictive control algorithm with variable sampling rate (eMPC)
62479039|NCT03938246|EXPERIMENTAL|TVB-2640 25 mg (US)|Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).
62479040|NCT03938246|EXPERIMENTAL|TVB-2640 50 mg (US)|Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).
62479041|NCT03938246|PLACEBO_COMPARATOR|Placebo (US)|Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.
62479042|NCT03938246|EXPERIMENTAL|TVB-2640 50 mg (China)|Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).
62479043|NCT03938246|PLACEBO_COMPARATOR|Placebo (China)|Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.
62126183|NCT02614625||Eyes with glaucoma|Eyes diagnosed with glaucoma of any type and any stage
61924463|NCT02041442|EXPERIMENTAL|All subjects|Electrical mapping of the urinary bladder
61924464|NCT04812080|EXPERIMENTAL|EXPLORER PET/CT Imaging|Study participants will be injected with 10 +/- 2 mCi of 18F-FDG using and IV line and a 60 minute PET scan will begin on EXPLORER. Prior to the PET scan, an ultra-low-dose CT scan (less than 1 minute ) will be acquired for attenuation correction purposes only. Ninety (90) minutes after being injected with FDG, participants will have another ultra-low dose CT scan (less than 1 minute) which will be acquired for attenuation correction purposes only. This will be followed by a 20 minute PET scan on EXPLORER. One-hundred and twenty (120) minutes after being injected with FDG, participants will be positioned supine on the scanner table for the last time. At this time, a low dose CT scan (less than 1 minute) will be acquired once again for attenuation correction purposes. This will be followed by one last 20 minute PET scan on EXPLORER. The IV line will be removed after completion of the study.
62316336|NCT04578717|EXPERIMENTAL|Etch & rinse adhesive|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
62316337|NCT04578717|EXPERIMENTAL|Self-etch adhesive|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
62316338|NCT02901717|ACTIVE_COMPARATOR|Standard of Care|Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.
62479044|NCT03938246|EXPERIMENTAL|TVB-2640 75 mg (US)|After completion of Cohorts 1 and 2, and if no stopping criteria are met upon review by the Independent SRC, an additional TVB-2640 75 mg open-label Cohort 3 will open in the US
62685981|NCT01084135|PLACEBO_COMPARATOR|Liquid placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
62685982|NCT05983250|PLACEBO_COMPARATOR|Placebo|Placebo
62685983|NCT05983250|ACTIVE_COMPARATOR|TNX-103|oral levosimendan
62685984|NCT05692323|EXPERIMENTAL|Supervised Prehabilitation Exercise Program|
62685985|NCT06674668|EXPERIMENTAL|Intervention group|The intervention includes traditional physiotherapy and vibrotactile device use.
62126184|NCT03175172|EXPERIMENTAL|Experimental|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units \[CFU\]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
62126185|NCT02153541|PLACEBO_COMPARATOR|Glycerin with Oxyquinoline Sulfate|For those participants who receive glycerin with oxyquinoline sulfate placebo, we do not anticipate any change in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
62126186|NCT02153541|ACTIVE_COMPARATOR|Antipyrine-benzocaine otic solution|Will be used on 50% of participants, we anticipate reduction in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
62126187|NCT02206269||Alair System|This is a single arm study with Alair system used.
62126188|NCT03222323|EXPERIMENTAL|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
62126189|NCT03222323|ACTIVE_COMPARATOR|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
62126190|NCT03222323|PLACEBO_COMPARATOR|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
62126191|NCT03222323|ACTIVE_COMPARATOR|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
62126192|NCT03791892|EXPERIMENTAL|Shoulder mobilization Group|Kaltenborn mobilization will be applied to patient in experimental group only.
62126193|NCT03791892|ACTIVE_COMPARATOR|Conventional treatment Group|Application of conventional treatment that includes stretching and strengthening exercises of shoulder.
62126194|NCT02967458|EXPERIMENTAL|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
62126195|NCT01665092|PLACEBO_COMPARATOR|Control|Normal saline
62685986|NCT06674668|ACTIVE_COMPARATOR|Control group|For traditional physiotherapy, passive stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity.
62685987|NCT05194072|EXPERIMENTAL|SGN-B7H4V (Parts A, B, and C)|SGN-B7H4V monotherapy
62685988|NCT05194072|EXPERIMENTAL|SGN-B7H4V and Pembrolizumab (Parts D and E)|SGN-B7H4V in combination with Pembrolizumab.
62685989|NCT06688162|PLACEBO_COMPARATOR|Usual Care|Usual Care
62685990|NCT06688162|EXPERIMENTAL|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation(scMIS)
62685991|NCT06037083||20 extremely low birth weight infants|In addition to the standard care, all participants will be monitored using an extra oxygen saturation probe, two near infrared spectroscopy sensors, and an electrical impedance tomography belt. Data will be continuously collected from extubation to 168 hours postextubation
62685992|NCT02914483|OTHER|Enhanced Usual Care (EUC)|
62685993|NCT02914483|OTHER|Stress Management|
62126196|NCT01665092|EXPERIMENTAL|Carnitine Low|Levo-Carnitine 6g
62126197|NCT01665092|EXPERIMENTAL|Carnitine Medium|Levo-Carnitine 12 g
62126198|NCT01665092|EXPERIMENTAL|Carnitine High|Levo-Carnitine 18 g
62685994|NCT05478213|EXPERIMENTAL|Monophasic Action Potential (MAP) Catheter|Participants undergoing ventricular tachycardia ablation per standard of care will also have cellular action potential of the ventricular myocardium assessed with the MAP catheter.
62685995|NCT04867629|EXPERIMENTAL|Rapeseed oil|Participants asked to consume 20mL of rapeseed oil raw every day for 12 weeks
62685996|NCT04867629|ACTIVE_COMPARATOR|Sunflower oil|Participants asked to consume 20mL of sunflower oil raw every day for 12 weeks
61924465|NCT04376892||Group 1|Exercise capacity under 149 meter
62126199|NCT06217874||Observational|Patients undergo blood sample collection, tumor biopsy (during clinically scheduled biopsy), and have their medical records reviewed on study.
62126200|NCT01388881|EXPERIMENTAL|Music Education|Music education classes take place three times a week, 50 minutes each. These interventional classrooms will make available keyboard and blockflute.
62126201|NCT01388881|NO_INTERVENTION|Non-intervention|In this arm, children will be not encourage practicing musical activities and will not have musical classes.
62126202|NCT05597280|EXPERIMENTAL|BE-PEP|"Intervention arm in which BE-PEP will be provided to all persons residing within 100 meters of an index case, to be repeated after four weeks for household contacts.~BE-PEP: bedaquiline (400 or 800 mg depending on weight band) combined with rifampicin (10 mg/kg) will be provided as post-exposure prophylaxis~Both arms will target anyone living within 100 meters of an index case or the entire village if more than 50% are eligible. The dosage form of rifampicine is 150 mg and 300 mg, for bedaquiline it's 20 mg or 100 mg."
62126203|NCT05597280|ACTIVE_COMPARATOR|SDR PEP|"WHO recommended standard PEP will be provided, i.e. 10 mg/kg of rifampicin in a single dose. In both arms anyone living within 100 meters of an index case will be targeted or the entire village if more than 50% are eligible.~The dosage form of rifampicine is 150 mg and 300 mg."
62126204|NCT02993744||Case Group|75 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, threatening preterm delivery, application of Betamethasone
62126205|NCT02993744||Control Group|65 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, no threatening preterm delivery
62126206|NCT02698228|SHAM_COMPARATOR|Standard of Care|Intravenous injection of 0.1mg/kg of morphine. Injection of 5cc of 0.9% normal saline into the subcutaneous tissue of the thigh.
62126207|NCT02698228|ACTIVE_COMPARATOR|Femoral nerve block|Intravenous injection of 0.1mg/kg of morphine. Injection of 20cc of 0.5% bupivacaine into the fascia iliaca space using standard anatomic landmarks.
62316339|NCT02901717|EXPERIMENTAL|Mino-Lok Therapy (MLT)|Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
62126208|NCT02698228|ACTIVE_COMPARATOR|Ultra-sound guided femoral nerve block|Intravenous injection of 0.1mg/kg of morphine.Injection of 20cc of 0.5% bupivacaine around their femoral nerve under direct ultrasound guidance
62126209|NCT04877496||Immunocompetent controls|Participants aged at least 18 years, no history of COVID19, no history of anti-CD20 treatment
62316340|NCT06056739|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Alio platform.
62316341|NCT06056739|NO_INTERVENTION|Control Subject|All subjects who are enrolled into the control group and participate in data collection will not receive the noninvasive Alio platform.
62316342|NCT05799144|EXPERIMENTAL|Treatment (pBI-11, TA-HPV, pembrolizumab)|Patients receive pBI-11 vaccine IM, TA-HPV vaccine IM, and pembrolizumab IV on study. Patients undergo CT or MRI and blood sample collection during screening and on study. Patients may undergo tumor biopsy during screening and on study.
62316343|NCT01894282|ACTIVE_COMPARATOR|Manual Therapy|Spinal Manipulative therapy (SMT) for the purpose of this study we will allow the use of other types of MT, including non-thrust spinal mobilization and flexion-distraction technique.
62479045|NCT06005610|EXPERIMENTAL|Group 1: BIC-treated|Participants taking bictegravir (BIC) + tenofovir alafenamide (TAF) + emtricitabine (FTC)
62479046|NCT06005610|EXPERIMENTAL|Group 2: DTG-treated|Participants taking dolutegravir (DTG) once daily + tenofovir disoproxil fumarate (TDF) + (FTC or lamivudine \[3TC\])
61924466|NCT04376892||Group 2|Exercise capacity between 150 and 249 meter
61924467|NCT04376892||Group 3|Exercise capacity between 250 and 349 meter
61924468|NCT04376892||Group 4|Exercise capacity above 340
62126210|NCT04877496||Patients with a treatment history of rituximab|Participants aged at least 18 years, no history of COVID19, history of at least 1 dose of anti-CD20 treatment received since 01/01/2010
61924469|NCT01120834|EXPERIMENTAL|all subjects|
61924470|NCT00997438|EXPERIMENTAL|MS - Secondary Progressive|1200 mg of Lipoic acid supplement
61924471|NCT00997438|EXPERIMENTAL|MS - Relapsing Remitting|1200mg of Lipoic acid supplement
61924472|NCT00997438|EXPERIMENTAL|Healthy Controls|1200 mg of Lipoic acid supplement
62685997|NCT04867629|NO_INTERVENTION|Habitual diet|Participants asked to maintain their habitual diet for 12 weeks
61924473|NCT04541160||Suspected community-acquired pneumonia patients|Suspected community-acquired pneumonia patients that will be evaluated by an imaging method
61924474|NCT02992210|EXPERIMENTAL|effectiveness of 4SCAR-GD2 T cells|The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
61924475|NCT00560885|EXPERIMENTAL|AtriCure Bipolar System|The AtriCure Synergy Bipolar Ablation system is used to create lesions outlined in the Maze IV procedure during a concomitant open cardiac surgical procedure.
61924476|NCT01740843|ACTIVE_COMPARATOR|Low intensity anodal tDCS|tDCS will be administered for 10 min at 1mA
62685998|NCT00606099|EXPERIMENTAL|1|telbivudine
62685999|NCT00606099|ACTIVE_COMPARATOR|2|adefovir dipivoxil
62686000|NCT04265118|EXPERIMENTAL|Sideward Tilt of Bed|During sleep, while lying in supine position, the participant will be tilted sidewards by the bed. In practice, the experimenter activates the bed at timepoints during the night where the participant is lying in supine position. Activating the bed results in one half of the bed lifting 10 to 40 Degrees sidewards.
61924477|NCT01740843|EXPERIMENTAL|High intensity anodal tDCS|tDCS will be administered for 10 min at 2.5mA
61924478|NCT01740843|SHAM_COMPARATOR|Sham tDCS|Sham will be administered for 10 min at 0 mA
61924479|NCT05266027|EXPERIMENTAL|Experimental Group|Nalbuphine Sebacate (Naldebain) intramuscular injection
61924480|NCT05266027|PLACEBO_COMPARATOR|Placebo Group|Placebo medication intramuscular injection
62126211|NCT01150383|ACTIVE_COMPARATOR|group RO (Room air / Oxygen)|RO (Room air / Oxygen): First 6 weeks of exercise training under normoxic conditions (Room air), followed by 6 weeks of exercise training with oxygen supplementation.
62126212|NCT01150383|ACTIVE_COMPARATOR|group OR (Oxygen / Room air)|OR (Oxygen / Room air): First 6 weeks of exercise training with oxygen supplementation, followed by 6 weeks of exercise training under normoxic conditions (room air).
62686001|NCT02921282||Genotype dopamine|Genotyping will be conducted at the conclusion of the study
62686002|NCT02921282||Genotype cannabinoids|Genotyping will be conducted at the conclusion of the study
62686003|NCT03940157|EXPERIMENTAL|Oh Happy Day Class - Still I Rise|The Oh Happy Day Class-Still I Rise (OHDC-SIR) is a one-time, 4-hour class focused on awareness of depression and healthy self-management strategies ( a workbook is created with the class content). The class is offered in non clinical setting, but will be delivered in a classroom setting at the University. The class will be taught by the PI Dr. Ward, who is an associate professor and licensed psychologist, and Dr. Ward's research program manager, Lucretia Sullivan-Wade.
62686004|NCT06484543|EXPERIMENTAL|Maslinic Acid|MA (an extract from olive fruit). Each participant will be instructed to take 3 tablets (60 mg or equivalent) daily after breakfast for 12 weeks.
62686005|NCT06484543|PLACEBO_COMPARATOR|Placebo|Each subject will be instructed to take 3 matching placebo tablets (or equivalent) daily after breakfast for 12 weeks.
62686006|NCT06673979||Painfull: patients with Numeric Rating Score equal or higher than 4|"The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain), and patients with NRS equal or higher than 4 are defined as painfull."
61924481|NCT00910468||Robot Assisted Laparoscopic Myomectomy|
61924482|NCT00910468||Myomectomy via Laparotomy|
61924483|NCT01371370|EXPERIMENTAL|Resistance exercise training|Lower-body exercises 3 times per wk for 12 wk
61924484|NCT01371370|EXPERIMENTAL|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
61924485|NCT01371370|EXPERIMENTAL|Resistance exercise training & diet|Lower-body exercise training and diet
61924486|NCT01371370|NO_INTERVENTION|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
61924487|NCT01418027|EXPERIMENTAL|Intensive exercise|The subjects receive an intensive exercise for 6 months and a subsequent conventional exercise for another 6 months.
62686007|NCT06673979||Pain-free: patients with Numeric Rating Score lower than 4|"The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain), and patients with NRS lower than 4 are defined as pain-free."
62126213|NCT01387906|EXPERIMENTAL|Topical bimatoprost for eyebrows|Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
62126214|NCT06045845|EXPERIMENTAL|Standard Beet Juice First|First Test: Beet Juice / Second Test: Placebo
61924488|NCT01418027|NO_INTERVENTION|Lifestyle counseling|Subjects receive a general lifestyle counseling for 12 months
61924489|NCT01418027|EXPERIMENTAL|Regular exercise|Subjects receive conventional exercise for 12 months
61924490|NCT06381973|ACTIVE_COMPARATOR|ELTGOL_Physio|ELTGOL + Manual pressure of the physiotherapist
61924491|NCT06381973|ACTIVE_COMPARATOR|ELTGOL_Auto|ELTGOL performed autonomously
61924492|NCT06381973|ACTIVE_COMPARATOR|PEP|Positive expiratory pressure (PEP)
61924493|NCT06381973|ACTIVE_COMPARATOR|1L-Tidal-Breathing|Tidal-breathing of 1 liter per breath
61924494|NCT06381973|ACTIVE_COMPARATOR|Spontaneous Breathing|
62126215|NCT06045845|EXPERIMENTAL|Placebo Beet Juice First|First Test: Placebo / Second Test: Beet Juice
62126216|NCT02892903|NO_INTERVENTION|Conventional angiography|Routine angiography will be performed according to local best practice
61924495|NCT02602977|EXPERIMENTAL|multiple-dose RIPC|Multiple-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive 4 cycles of remote ischemic preconditioning of the upper limb per day in the 7 consecutive days before the endotoxemia experiment. The last dose will be applied 40 minutes before LPS administration.
62479047|NCT06005610|EXPERIMENTAL|Group 3: Boosted DRV-treated|Participants taking any regimen containing darunavir plus cobicistat (DRV/c)
62479048|NCT02648997|EXPERIMENTAL|Cohort 1 (original cohort): Nivolumab Monotherapy|Nivolumab monotherapy (240 mg every 2 weeks)
62479049|NCT02648997|EXPERIMENTAL|Cohort 2: Nivolumab in Combination with Ipilimumab|"* External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy)~* Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks)~* Followed by Nivolumab monotherapy (480 mg every 4 weeks)."
62479050|NCT00001254||Patients|Patients will Zollinger-Ellison Syndrome
61924496|NCT02602977|EXPERIMENTAL|single-dose RIPC|Single-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive a single RIPC dose, starting 40 minutes before LPS administration.
62126217|NCT02892903|EXPERIMENTAL|Routine Measurement of FFR|Additional investigation with the measurement of FFR in all major vessels
62126218|NCT02320877|EXPERIMENTAL|Mandibular Advancement Device|Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.
61924497|NCT02602977|ACTIVE_COMPARATOR|control group|Only LPS infusion. A group of 10 subjects that will be administered LPS without RIPC.
62126219|NCT05486897||cerebral amyloid angiopathy|Patient with cerebral amyloid angiopathy
62126220|NCT05486897||Hypertensive arteriopathy|Patients with hypertensive arteriopathy
62126221|NCT05253612|OTHER|ISPOCD test battery|The participants will be randomized to start with ISPOCD test battery followed by Mindmore digitalized cognitive test battery with 2 weeks passing between the cognitive testing for both groups
62126222|NCT05253612|OTHER|Mindmore digitalized cognitive test battery|Strating with Mindmore digitalized cognitive test battery followed by ISPOCD test battery, with 2 weeks passing between the cognitive testing for both groups
62126223|NCT02500264|ACTIVE_COMPARATOR|Protocol #1|interventions: 1.6Hz, Rampdown 0.4S, electrodes position - both L.Rectus Abdominis, 5cmX5cm Size, on inspirium
62126224|NCT02500264|ACTIVE_COMPARATOR|Protocol #2|1Hz, Rampdown 0.6S, electrodes position - both Rectus Abdominis, 5cmX5cm Size, on inspirium
62126225|NCT02500264|ACTIVE_COMPARATOR|Protocol #3|1.6Hz, Rampdown 0.4S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium Oblique
62126226|NCT02500264|ACTIVE_COMPARATOR|Protocol #4|1Hz, Rampdown 0.6S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium
62126227|NCT02206750|SHAM_COMPARATOR|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
62126228|NCT02206750|EXPERIMENTAL|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
62316344|NCT01894282|EXPERIMENTAL|Mind Body Intervention (MBI)|"Mind Body Intervention will consist of a combination of the previously described manual therapy and Cognitive Behavioral Therapy for pain (CBT-p). Cognitive Behavioral Therapy for pain management has three basic components. The treatment rationale, coping skills training and application and maintenance of learned coping skills."
62316345|NCT06671769|EXPERIMENTAL|Natural Heart Health Dietary Supplement in Chocolate Powder Form|a natural heart-health dietary supplement in chocolate powder form designed to be taken daily.
62316346|NCT05242588|EXPERIMENTAL|JS005 150 mg|30 patients will be enrolled in this arm.
62316347|NCT05242588|PLACEBO_COMPARATOR|Placebo 150 mg|10 patients will be enrolled in this arm.
62316348|NCT05242588|EXPERIMENTAL|JS005 300 mg|30 patients will be enrolled in this arm.
62316349|NCT05242588|PLACEBO_COMPARATOR|Placebo 300 mg|10 patients will be enrolled in this arm.
62316350|NCT05242588|EXPERIMENTAL|JS005 450 mg|30 patients will be enrolled in this arm.
62316351|NCT05242588|PLACEBO_COMPARATOR|Placebo 450|10 patients will be enrolled in this arm.
62316352|NCT01854567|EXPERIMENTAL|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
62316353|NCT01854567|ACTIVE_COMPARATOR|Control|Infusion of two unexpanded cord blood units.
62316354|NCT01891747|EXPERIMENTAL|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab \& temozolomide.
62316355|NCT00690937|EXPERIMENTAL|1 ECS|Low dose treatment
62316356|NCT00690937|EXPERIMENTAL|2 ECS|High dose treatment
62316357|NCT00690937|ACTIVE_COMPARATOR|3 Colesevelam|Active control treatment
62316358|NCT00690937|PLACEBO_COMPARATOR|4 Placebo|Placebo matched to low dose treatment
62316359|NCT00690937|PLACEBO_COMPARATOR|5 Placebo|Placebo matched to high dose treatment
62316360|NCT04412603|EXPERIMENTAL|Conventional Mirror Therapy group|"Therapy:~-With the affected upper limb into the mirror box, perform the exercise with the non-affected extremity which is reflected in the mirror box. -The affected side must perform the corresponding movement within its possibilities, according to the exercise that is being performed with the healthy arm. - It is very important to look at the mirror at all times, which reflects the non-affected side while doing the exercises."
62479051|NCT04708431||Female subjects relatives who are carriers of the AR gene difference|We will enroll 50 female subjects relatives AIS subjects who are carriers of the AR gene difference
62479052|NCT04708431||Female subjects relatives who are not carriers of the AR gene|We will enroll 50 female subjects relatives of AIS subjects who are not carriers of the AR gene.
62316361|NCT04412603|EXPERIMENTAL|Mirror Therapy Virtual Reality group|"Therapy:~-Perform the exercises with the non-affected limb, which must be watched constantly with virtual reality glasses, to interpret that this limb corresponds to the affected side. - The affected side accompanies the movement within its possibilities (out of sight of the patient, it can be covered with a handkerchief). - It is very important to look at the non-affected side. The affected side should be out of the visual field to avoid confusion."
62479053|NCT04708431||Healthy male subjects relatives|We will enroll 50 healthy male subjects of AIS relative subjects
62479054|NCT04708431||Subjects with androgen receptor mutations|500 Subjects with confirmed androgen receptor mutations
62479055|NCT03730168|EXPERIMENTAL|study group and control group|"Two groups; study group included 30 diabetic male patients who where trained by circuit weight training program in the form of sets of resistance exercises (in the form of dumbbells and sand bags) for the muscles of lower limb and upper limb .The training sessions were performed 3 days per week for a period of 12 weeks. All patient were on their prescribed routine medications .~The control group were on there prescribed medications only ."
62479056|NCT05201469|EXPERIMENTAL|VIB4920|"Participants will receive VIB4920 1500 mg intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24.~Participants will also receive methylprednisolone 1000 mg at Week 0 and will begin MMF 2-3 g per day and prednisone 25 mg per day, tapered to ≤ 5 mg per day from Week 8."
62126229|NCT05806255|EXPERIMENTAL|RELIEF Intervention Group|"The RELIEF App will be implemented according to a standardized procedure at the six following sites, with 100 patients recruited at each site:~1. Home and Community Care Support Services Central West~2. Home and Community Care Support Services Central~3. Home and Community Care Support Services Champlain~4. Home and Community Care Support Services North East~5. Curve Lake First Nation (CLFN)~6. St. Mary's Hospital"
62126230|NCT06206824|EXPERIMENTAL|Part 1 : Single Ascending Doses in Healthy Volunteers|A total of 48 healthy male volunteers will be randomized into six consecutive single ascending dose cohorts of 8 subjects, 6 receiving one dose of Leucettinib-21 and 2 receiving placebo.
62126231|NCT06206824|EXPERIMENTAL|Part 2 : Food-Effect in Healthy Volunteers|A total of 12 healthy male volunteers will be randomly assigned to one of two sequences in this cross over study part. All subjects will receive the same one dose of Leucettinib-21 in each sequence.
62479057|NCT05201469|PLACEBO_COMPARATOR|VIB4920 Placebo|"Participants will receive VIB4920 placebo intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24.~Participants will also receive methylprednisolone 1000 mg at Week 0 and will begin MMF 2-3 g per day and prednisone 25 mg per day, tapered to ≤ 5 mg per day from Week 8."
62479058|NCT01818024|EXPERIMENTAL|Part 1: Cohort 1a|Single IV dose of GSK2862277 as a continuous infusion over 2 hours.
62126232|NCT06206824|EXPERIMENTAL|Part 3 : Multiple Ascending Doses over 14 days in Healthy Volunteers|A total of 36 healthy male volunteers will be randomized into three consecutive multiple ascending doses cohorts of 12 subjects, 9 receiving one dose of Leucettinib-21 and 3 receiving placebo everyday for 14 days.
62316362|NCT00858767|ACTIVE_COMPARATOR|1|2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
62479059|NCT01818024|EXPERIMENTAL|Part 1: Cohort 1b|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
62479060|NCT01818024|EXPERIMENTAL|Part 1: Cohort 1c|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
61924498|NCT01936727|OTHER|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
62126233|NCT06206824|EXPERIMENTAL|Part 4 : Single Dose in People with Down Syndrome and Alzheimer's Disease|A total of 12 people with Down Syndrome and 12 people with Alzheimer's Disease will receive the same one dose of Leucettinib-21.
62126234|NCT03674034||term|50 CTscan and MRI images of children aged at term
62126235|NCT03674034||one month|50 CTscan and MRI images of children aged one month
62126236|NCT03674034||two months|50 CTscan and MRI images of children aged two months
62316363|NCT00858767|ACTIVE_COMPARATOR|2|2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
62316364|NCT00858767|ACTIVE_COMPARATOR|3|2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
62479061|NCT01818024|EXPERIMENTAL|Part 2: Cohort 2a GSK2862277|Single IV dose of GSK2862277 as a continuous infusion over 1 hour.
62479062|NCT01818024|EXPERIMENTAL|Part 2: Cohort 2a Placebo|Matching placebo will be administered as a continuous IV infusion over 1 hour.
62479063|NCT01818024|EXPERIMENTAL|Part 2: Cohort 2b GSK2862277|Single IH dose of GSK2862277.
62479064|NCT01818024|EXPERIMENTAL|Part 2: Cohort 2b Placebo|Matching placebo will be administered.
62479065|NCT01818024|EXPERIMENTAL|Part 3: Cohort 3a GSK2862277|IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.
62479066|NCT01818024|EXPERIMENTAL|Part 3: Cohort 3a Placebo|Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.
62479067|NCT01818024|EXPERIMENTAL|Part 3: Cohort 3b GSK2862277|Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.
62479068|NCT01818024|EXPERIMENTAL|Part 3: Cohort 3b Placebo|Matching placebo will be administered as IH daily for 5 days.
62479069|NCT05718700||Bulevirtide (previously participated in Study MYR-Reg-2)|Participants who are currently receiving bulevirtide (BLV) according to the approved label and have participated in Study MYR-Reg-02.
62479070|NCT05718700||Bulevirtide|Participants who are scheduled to receive BLV according to the approved label.
62316365|NCT04953637|EXPERIMENTAL|Physiotherapy group|Participants assigned to the physiotherapy group will receive physiotherapy treatment at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks. They will begin to receive the physiotherapy treatment at 4 months following their surgery and once their DBS settings are optimized.
62316366|NCT04953637|NO_INTERVENTION|Control group|Participants assigned to the control group will not receive any additional intervention and will be precluded from starting formal physiotherapy for the duration of the study. However, they will be encouraged to keep an active lifestyle. In order to stay active, they will be recommended to do simple home exercises following a home exercise video that will be presented to them. They will be asked to do it 3 times/week for 8 weeks and keep an exercise log to help them stay on track.
62316367|NCT01182129|ACTIVE_COMPARATOR|Swedish Snus Type 1|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
62479071|NCT06463587|PLACEBO_COMPARATOR|Placebo|"DBPC Period: Participants will be administered with Placebo, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.~BE Period: Participants initially randomized to placebo matched to cladribine in DBPC period will receive cladribine Low Dose or High Dose, orally as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated if clinically justified with placebo matched to cladribine.~RT Period: Participants requiring retreatment with cladribine Low Dose or High Dose or retreated with cladribine supplemental dose if clinically justified."
62479072|NCT06463587|EXPERIMENTAL|Cladribine Low Dose|"DBPC Period: Participants will be administered with cladribine Low Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.~BE Period: Participants initially randomized to cladribine Low Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified.~RT Period: Participants requiring retreatment with cladribine Low Dose regimen and/or supplemental dose will receive the selected dose of cladribine if clinically justified."
62479073|NCT06463587|EXPERIMENTAL|Cladribine High Dose|"DBPC Period: Participants will be administered cladribine High Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.~BE Period: Participants initially randomized to cladribine High Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified.~RT Period: Participants requiring retreatment with cladribine High Dose regimen and/or supplemental dose will receive the selected dose of cladribine if clinically justified."
62126237|NCT01944306||Low birth-weight, obese|
62126238|NCT01944306||Low birth-weight, normal body weight|
62126239|NCT01944306||Normal birth-weight, obese|
62126240|NCT01944306||Normal birth-weight, normal body weight|
62126241|NCT03132922|EXPERIMENTAL|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
62126242|NCT03132922|EXPERIMENTAL|Radiation Sub-Study: Autologous genetically modified MAGE-A4c1|
62126243|NCT00761605|EXPERIMENTAL|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
62126244|NCT06411834|EXPERIMENTAL|Decision Navigation Tool|Patients will be asked to complete a decision navigation tool that helps them identify and rank key decision criteria. Then we will use a predictive model to inform patients which initial treatment options similar patients have made, and which choices lead to high satisfaction and low regret.
62126245|NCT06411834|NO_INTERVENTION|Usual care|Patients will undergo usual care
62479074|NCT05677321||Participants with AUD|Drink regularly (i.e., 2 or more drinks per day for at least 3 days per week in the past 12 months)
62686008|NCT06673849|EXPERIMENTAL|Rhythmic Stabilization group|The CP child will positions his/her upper extremity anywhere in its available range of motion and holds an isometric contraction. The physiotherapist will provide enough resistance to cause the child to react, but not enough to break the isometric contraction. As the child progresses, length of time of rhythmic stabilization increases, the therapist's resistance increases, and amount of contact area between therapist's hands and child's upper extremity decreases. The exercise program consisted of 30-minute sessions per week for six weeks
62686009|NCT06673849|EXPERIMENTAL|Ball Balancing group|Have the child balance on his/her hands on a 48-inch Gymnastic ball, first with eyes open, then closed. Progress from both hands on one large ball to each hand on separate balls and then to the weaker arm on one ball. Also, progress through the four body positions. With his/her eyes open, then closed. If he/she misses the position, he/she opens his/her eyes and actively moves to the desired position. Use a spotter, especially when doing this exercise for the first time or changing body positions, since the patient may fall off the Gymnastic ball. Start with one repetition of 10 seconds and progress to three to five repetitions of 60 seconds each and this will be done till 6 weeks
62686010|NCT01740518||PEG + ascorbic acid|Those who taken PEG 2L + ascorbic acid
62686011|NCT01740518||PEG 4L|Those who taken PEG 4L alone
62316368|NCT01182129|ACTIVE_COMPARATOR|Swedish Snus Type 2|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
62479075|NCT05677321||Participants without AUD|Does not drink regularly (less than 2 drinks per day for at least 3 days per week in the past 12 months)
62479076|NCT06576037|EXPERIMENTAL|Part 1A: Dose Escalation CBP-1019 + FOLFOX|Participants will be administered the study treatments on an outpatient basis.
62686012|NCT04422834|EXPERIMENTAL|Health Professional Students|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
62686013|NCT06688864|EXPERIMENTAL|Black adults with chronic pain|
62686014|NCT06688864|EXPERIMENTAL|LGBTQIA+ adults with chronic pain|
62316369|NCT01182129|ACTIVE_COMPARATOR|4 mg Nicorette chewing gum|Nicorette is chewed according to instructions in package insert over 30 minutes.
62316370|NCT01224353|PLACEBO_COMPARATOR|Thioctacid Oral Placebo Tablet|
62479077|NCT06576037|EXPERIMENTAL|Part 1B: Dose Escalation CBP-1019 + FOLFOX + Bevacizumab|Participants will be administered the study treatments on an outpatient basis.
62479078|NCT06576037|EXPERIMENTAL|Part 1C: Dose Escalation CBP-1019 + Pembrolizumab|Participants will be administered the study treatments on an outpatient basis.
62686015|NCT04645030||Patients suspected of pneumonia|Patients suspected for pneumonia after initial evaluation by the treating physician.
62479079|NCT06576037|EXPERIMENTAL|Part 1D: Dose Escalation CBP-1019 + Enzalutamide|Participants will be administered the study treatments on an outpatient basis.
62479080|NCT06576037|EXPERIMENTAL|Part 2A: Pancreatic CBP-1019 + FOLFOX|Participants will be administered the study treatments on an outpatient basis.
62479081|NCT06576037|EXPERIMENTAL|Part 2B: Colorectal CBP-1019 + FOLFOX + Bevacizumab|Participants will be administered the study treatments on an outpatient basis.
62479082|NCT06576037|EXPERIMENTAL|Part 2C: Epithelial Origin CBP-1019 + Pembrolizumab|Participants will be administered the study treatments on an outpatient basis.
62479083|NCT06576037|EXPERIMENTAL|Part 2D: CRPC CBP-1019 + Enzalutamide|Participants will be administered the study treatments on an outpatient basis.
62479084|NCT02257658|EXPERIMENTAL|Doxycycline|Subjects in the doxycycyline arm will receive Doxycycline, oral, 100 mg, once daily for 36 weeks.
62686016|NCT00674843|EXPERIMENTAL|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
62686017|NCT06362889|EXPERIMENTAL|Microneedling with CBD oil|All subjects will receive microneedling with CBD oil.At the baseline visit, the subject will undergo treatment by the principal investigator or subinvestigator. 3 days from the treatment visit, a phone call visit will be placed to assess any safety events and adherence to protocol guidelines. Day 21 visit, several assessments will be recorded and if no adverse events are reported related to the study device and/or procedure, a second treatment will be performed. After 3 days from the treatment visit, a phone call will be placed to assess any safety events. Subjects will have subjective assessments and photographs taken at all visits. At day 42, the subject will return for a third treatment if no adverse events related to the study device and/or procedure are reported. After 3 days from the treatment visit, a phone call will be placed to assess any safety events. On day 63,no treatment to be performed, only a safety assessment, standardized assessments/questionnaires and photography.
62686018|NCT05904379|EXPERIMENTAL|AK112, AK104 dose 1 plus carboplatin and paclitaxel|
62479085|NCT02257658|ACTIVE_COMPARATOR|Incentive|Subjects in the incentive arm will receive escalating payments for remaining STI free at Weeks 12, 24 and 36.
62686019|NCT05904379|EXPERIMENTAL|AK112, AK104 dose 1 plus carboplatin and pemetrexed|
62126246|NCT02176772||Tuberculosis, no HIV and severe anemia|
62316371|NCT01224353|ACTIVE_COMPARATOR|Thioctacid Oral Tablet|
62316372|NCT06238999|EXPERIMENTAL|Test goup TM Flow|The newly developed flowable composite TM Flow will be used for the restoration of NCCLs in the test group. The treatment workflow is very similar to other flowable composites.
62479086|NCT05184894|EXPERIMENTAL|AKI in Care Transitions (ACT) Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will participate in the ACT program which provides standardized education and assists with coordination of follow up care after hospital stay.
62126247|NCT01112033||chronic HCV infection|The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
62316373|NCT06238999|ACTIVE_COMPARATOR|Control group Tetric EvoFlow|The well-established Tetric EvoFlow will be used for the restorations of NCCLs in the control group.
62126248|NCT05340114|EXPERIMENTAL|Subjects examined by the operations with CEREBO®|CEREBO® - A portable non-invasive device to detect intracranial haemorrhage Frequency - The operator will scan at least 10 patients Duration - 40 seconds per subject No adverse effect or contraindications
62126249|NCT03036644|EXPERIMENTAL|e-cigarette nic_O LT|e-cigarette (without nicotine; low temperature)
62316374|NCT03568006|EXPERIMENTAL|Intervention|"Intervention will consist of passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint.~Besides, participants will receive a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene."
62316375|NCT03568006|ACTIVE_COMPARATOR|Control|Control treatment will consist of a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene.
62479087|NCT05184894|NO_INTERVENTION|Usual Care Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will receive standard of care from their inpatient and outpatient care teams.
62686020|NCT05904379|EXPERIMENTAL|AK112, AK104 dose 2 plus carboplatin and paclitaxel|
62686021|NCT05904379|EXPERIMENTAL|AK112, AK104 dose 2 plus carboplatin and pemetrexed|
61924499|NCT01936727|OTHER|infusion asissted easyTip|The phacoemulsifications tip used was an infusion assisted easyTip 2.2mm (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
61924500|NCT02351986|EXPERIMENTAL|Subacromial Impingement Syndrome|Subjects between 18 to 45 years, with Subacromial Impingement Syndrome at least one week.
62126250|NCT03036644|EXPERIMENTAL|e-cigarette Nic_1 LT|e-cigarette (with nicotine; low temperature)
62126251|NCT03036644|EXPERIMENTAL|e-cigarette Nic_0 HT|e-cigarette (without nicotine; high temperature)
62126252|NCT03036644|EXPERIMENTAL|e-cigarette NIC_1 HT|e-cigarette (with nicotine; high temperature)
62316376|NCT01140542|ACTIVE_COMPARATOR|Roflumilast|500µg, once daily
62316377|NCT01140542|PLACEBO_COMPARATOR|Placebo|
62316378|NCT01188018|ACTIVE_COMPARATOR|Brief Advice|
62316379|NCT01188018|EXPERIMENTAL|Motivational Interviewing|
62126253|NCT03036644|ACTIVE_COMPARATOR|Tobacco cigarette|Tobacco cigarette
62316380|NCT01188018|ACTIVE_COMPARATOR|Health Education|
62479088|NCT06251180|EXPERIMENTAL|Dose Escalation|Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP
62316381|NCT04813679||Neutropenic Enterocolite patients assessed with bed side ultrasound sonography|"From March 2007 through the entire study period all patients admitted eighter in our chemotherapy-ward or BMT-ward to receive intensive chemotherapy (chemo) for any hematological malignancies, or chemotherapy (CHT) for both auto transplant (ASTC) and allogeneic transplant (AlloTx), were prospectively enrolled in the study. When the patient received more than one chemo cycle, each ward access was considered a new observational period.~Patients who received CHT and experienced CHT-induced neutropenia (CHTNP) were enrolled in the study. We defined one observational period each admission on the ward to receive CHT, in which CHT and length of stay could vary from the previous admission. One observational period ended with the discharge of the pts form the ward. If a pts experienced a new chemo related NECe during another admission, it was considered as e new NECe."
62316382|NCT04813679||Neutropenic Enterocolite negative patients assessed with bed side ultrasound sonography|NEC negative patients received bed-side ultrasound sonography after three days of neutropenia.
62479089|NCT06251180|EXPERIMENTAL|Dose Expansion [non-GCB DLBCL]|Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP
62126254|NCT03036644|PLACEBO_COMPARATOR|Placebo|No E-cigarettes, Nor tobocco cigarettes
61924501|NCT02351986|NO_INTERVENTION|Control|Healthy subjects between 18 to 45 years.
61924502|NCT02753218|EXPERIMENTAL|Midazolam and LEO 32731|
61924503|NCT00881478|ACTIVE_COMPARATOR|Nutrition counselling alone|Nutrition counseling session with registered dietician
62126255|NCT02464293|EXPERIMENTAL|mindfulness-based cognitive therapy|
62126256|NCT00482729|EXPERIMENTAL|1|Arm 1: drug
62126257|NCT00482729|ACTIVE_COMPARATOR|2|Arm 2: active comparator
62126258|NCT02272816|EXPERIMENTAL|Carboplatin AUC-10|
62126259|NCT04652583|ACTIVE_COMPARATOR|Active Stimulation 20 minutes|Intramuscular stimulation
62126260|NCT04652583|ACTIVE_COMPARATOR|Active Stimulation 60 minutes|Intramuscular stimulation
62126261|NCT04652583|SHAM_COMPARATOR|Sham Stimulation 20 minutes|Muscle-free-zone stimulation
62479090|NCT06251180|EXPERIMENTAL|Dose Expansion [MCL]|Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP
62479091|NCT06251180|EXPERIMENTAL|Dose Expansion [MZL]|Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP
62479092|NCT03199963|EXPERIMENTAL|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
62126262|NCT00253110|ACTIVE_COMPARATOR|risperidone|
62316383|NCT02225223|OTHER|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
62316384|NCT02225223|OTHER|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
62316385|NCT02659345|EXPERIMENTAL|Art Therapy|The art therapy intervention will be executed by an art therapist at the Cancer Center. The same art therapy practices that are utilized in daily practice will be employed in this study. The intervention will include assessment of patient's needs and goals in addition to utilization of various art modalities. Sessions will conclude with processing of the art and supportive counseling as appropriate. Pilot testing of the intervention has been performed informally at Maroone Cancer Center with positive feedback provided by patients and their support systems to the physicians, nurses, and art therapist. Change in pain, emotional distress, depression, adn anxiety will be measured by the emotions thermometer.
62686022|NCT05904379|EXPERIMENTAL|AK112 plus AK104|
62686023|NCT05904379|EXPERIMENTAL|AK112, AK104 plus docetaxel|
62686024|NCT05904379|ACTIVE_COMPARATOR|docetaxel|
62686025|NCT02044146|EXPERIMENTAL|Personalized Therapy|"A point-of-care bedside genetic test for CYP2C19\*2 and CYP2C19\*3 using a buccal swab will be conducted.2 P2Y12 inhibitory drug therapy will be then be directed based on a risk algorithm (integrating genotyping and clinical variables). Patients with high ischemic risk are defined as having (\*2 or \*3) and/or diabetes and/or (having age\>65 AND BMI\>=28). High-risk patients will be switched to prasugrel at 10mg daily, while low ischemic risk patients be kept on clopidogrel 75 daily. For patients \>age 75 or wt \< 60 kg, prasugrel will be reduced to 5mg daily."
62686026|NCT02044146|ACTIVE_COMPARATOR|Ticagrelor|Patients will be treated with a 90mg twice daily regimen of Ticagrelor
62686027|NCT02044146|OTHER|Clopidogrel registry arm|A concurrent registry of patients (not randomized) who are receiving clopidogrel only (as decided by treating physician) will be followed as a comparator group.
62686028|NCT06605534|EXPERIMENTAL|LungTalk Group|LungTalk is a novel theoretically grounded health educational tool that will be delivered via iPad and is an interactive computer-based program that includes audio, video and animation segments with scripts presented from a master content library in consideration of different ways people like to learn. Informed by our prior research, LungTalk tailors its content based on smoking status and perceived barriers. In prior work, LungTalk more than doubled Lung Cancer Screening (LCS) knowledge and health beliefs (p \< 0.01), and was associated with a significant increase in deciding to screen for lung cancer compared to control group; OR 1.99; 95% CI, 1.03, 3.85, p = 0.03.
62686029|NCT06605534|ACTIVE_COMPARATOR|Non-tailored Lung Screening Pamphlet Group|Non-tailored Lung Screening Pamphlet is a non-tailored educational brochure, What is Lung Cancer Screening from the GO2 Foundation that will be emailed to the patient. This widely used educational standard of care is a 2-page reader-friendly non-tailored electronic brochure about risk and screening for lung cancer used in clinical and community settings.
62686030|NCT04589468|EXPERIMENTAL|Dose-Finding/Escalation|Fifty (n=50) post-treatment patients with colorectal cancer or breast cancer, deemed high-risk of relapse. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial.
62686031|NCT04589468|EXPERIMENTAL|Dose Expansion|An independent cohort of 30 post-treatment patients with colorectal (n=15) or breast (n=15) cancer deemed high-risk of relapse. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D.
62686032|NCT06690554|NO_INTERVENTION|Placebo group|"* Information about the research will be provided.~* Written consent will be obtained.~* Personal Information Form, Fertility Awareness, Preconceptional Knowledge and Attitude will be applied to women who accept to participate in the research.~* Five days after the first interview, women will be reached and the scales will be applied.~* Three months after the first interview, women will be reached, invited to the institution and the scales will be applied again."
62686033|NCT06690554|EXPERIMENTAL|Education Group|"Women will be given a five-day training in line with the health promotion model.~* Information will be provided to women who apply to the hospital.~* Written consent documents will be obtained from women who agree to participate in the study.~* Women assigned to the intervention group will attend classes in groups of 8-10.~* Women will be given a 60-minute training once a day for five days.~* The total training duration is five hours.~* Scales will be applied to women who complete the training at the end of the fifth day.~* Women who have completed the training will be contacted by phone at the end of the first and second months, reminded of health promotion behaviors and their questions will be answered and follow-ups will be carried out.~* At the end of the third month, women who have received training will be invited to the institution and the Fertility Awareness, Preconceptional Knowledge and Attitude will be filled out face-to-face for the final test."
62686034|NCT05506631|EXPERIMENTAL|Outpatient cervical ripening|Placement of transcervical Foley balloon for cervical ripening in outpatient setting
61924504|NCT00881478|EXPERIMENTAL|Nutrition counselling + portion control|Nutrition counseling with registered dietician in addition to teaching about use of a portion control tool
62126263|NCT00253110|ACTIVE_COMPARATOR|haloperidol|
62126264|NCT03819816|EXPERIMENTAL|DEA-App|The intervention (DEA) group will receive the newly developed app.
62126265|NCT03819816|OTHER|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
62126266|NCT04738058|EXPERIMENTAL|Preterm infants diagnosed as feeding intolerance will receive bovine lactoferrin|they will receive bovine lactoferrin 100mg/day with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
62316386|NCT05942534||mask type assessment|The mask type assessment will compare a cloth mask, child and adult medical mask, child and adult KN95 respirator, and N95 respirator.
62126267|NCT04738058|PLACEBO_COMPARATOR|Preterm infants diagnosed with feeding intolerance will receive placebo|they will receive the placebo with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
62686035|NCT05506631|ACTIVE_COMPARATOR|Inpatient cervical ripening|Placement of transcervical Foley balloon for cervical ripening in inpatient setting
62316387|NCT05942534||mask modification assessment|The mask modification assessment will compare a child medical mask, adult medical mask with and without modifications (tuck and tie, twisted ear loops), and child and adult N95 respirator.
62686036|NCT06686407|EXPERIMENTAL|Group 1|
62686037|NCT06686407|EXPERIMENTAL|Group 2|
62686038|NCT05967455|EXPERIMENTAL|Cohort 1 Naive DENV1|Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), two doses (0.5 mL of 6.5 x 10\^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 181.
62686039|NCT05967455|EXPERIMENTAL|Cohort 2 Naive DENV3|Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), two doses (0.5 mL of 1.4 x 10\^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 181.
62686040|NCT05967455|EXPERIMENTAL|Cohort 3 Returning DENV1|Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), single dose (0.5 mL of 6.5 x 10\^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.
62686041|NCT05967455|EXPERIMENTAL|Cohort 4 Returning DENV3|Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), single dose (0.5 mL of 1.4 x 10\^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.
62686042|NCT05692557|EXPERIMENTAL|Virtual reality distraction and chest physiotherapy|"Virtual reality distraction: The Oculus Rift's Fujii - Mystical Journey was a game played by the Virtual reality distraction group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations. The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there. Before beginning the chest physical therapy, the patients had 15 minutes to play this computer game"
62686043|NCT05692557|ACTIVE_COMPARATOR|Progressive relaxation exercise and chest physiotherapy|Progressive muscle relaxation: The patients of the control group performed the Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds, the process was repeated for a period of 15 minutes
62126268|NCT05997966|ACTIVE_COMPARATOR|Progressive Resistance Exercises Group|In the exercise group, a home-based exercise program will be applied in addition to a 30-minute walking request twice a week, and will consist of stretching exercises for the lower extremities, isometric exercises and progressive resistance strengthening exercises (IDE) of the hip, knee and ankle. The 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days). Resistance bands will be used for resistance in the IDE program. In addition, the exercise intensity in the IDE program will be questioned with the perceived difficulty level (AZD). The AZD scale shows the perceived intensity and pulse rate change during exercise between 6-20. All exercises will be performed without resistance for the first 4 weeks, with AZD levels at 40% of 1 maximum repetition at week 5 to 8, AZD 13-15 (somewhat difficult), and after week 8 to AZD 15-16 (difficult). Progress will be achieved by increasing the number of repetitions.
62126269|NCT05997966|SHAM_COMPARATOR|Control Group|In the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made. Individuals in the control group will be called every week by phone for gait follow-up.
62316388|NCT06132763|EXPERIMENTAL|Hydration Intervention|Students and staff at the intervention school will receive a school-based hydration intervention that includes a student-developed marketing campaign and incentivizes water bottles in school.
62479093|NCT03199963|PLACEBO_COMPARATOR|Matching Placebo Gel|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
62686044|NCT05758142|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive 1, 2, or 3 inert placebo tablets twice daily (i.e., 2, 4, or 6 tablets per day) for 12 weeks.
62686045|NCT05758142|ACTIVE_COMPARATOR|Potassium Chloride 30 mmol per day|Participants randomized to the 30 mmol per day group will receive 1 potassium chloride tablet (15 mmol strength) twice daily (i.e., 2 tablets per day) for 12 weeks.
62686046|NCT05758142|ACTIVE_COMPARATOR|Potassium Chloride 60 mmol per day|Participants randomized to the 60 mmol per day group will receive 2 potassium chloride tablets (15 mmol strength) twice daily (i.e., 4 tablets per day) for 12 weeks.
62686047|NCT05758142|ACTIVE_COMPARATOR|Potassium Chloride 90 mmol per day|Participants randomized to the 90 mmol per day group will receive 3 potassium chloride tablets (15 mmol strength) twice daily (i.e., 6 tablets per day) for 12 weeks.
62479094|NCT00114647||1|Healthy Volunteers
62479095|NCT00114647||2|HIV
62479096|NCT01885572|OTHER|TiLOOP Bra|Treatment with TiLOOP Bra
62126270|NCT00111085|EXPERIMENTAL|Clazosentan 1 mg/h|intravenous clazosentan at 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
62479097|NCT03579303|ACTIVE_COMPARATOR|Homoeopathic remedies in PCOS|Homoeopathic treatment for menstrual disorders in females with PCOS
62316389|NCT06132763|PLACEBO_COMPARATOR|Control|Students and staff at the control school will participate in assessments only.
62316390|NCT06036108|EXPERIMENTAL|Fasting-state administration group|Brexpiprazole QW formulation in a fasting-state administration
62479098|NCT03579303|ACTIVE_COMPARATOR|Homoeopathic remedies and yoga in PCOS|Homoeopathic treatment integrated with yoga therapy for menstrual disorders in females with PCOS
62479099|NCT06447922||Conventional TKA with Cutting Guides|Patients undergoing a conventional total knee arthroplasty with cutting guides (no robot-assistance).
62686048|NCT06686485||Treatment Subjects|A subject is considered enrolled once an approved informed consent form has been signed and dated. Enrolled Subjects will undergo AF ablation procedure with the FARAPULSE PFA System, followed by WATCHMAN implant during the same procedure.
62686049|NCT02868879||Schizophrenia|
61924505|NCT03301974|EXPERIMENTAL|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
61924506|NCT03301974|EXPERIMENTAL|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
62126271|NCT00111085|EXPERIMENTAL|Clazosentan 5 mg/h|intravenous clazosentan at 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
62126272|NCT00111085|EXPERIMENTAL|Clazosentan 15 mg/h|intravenous clazosentan at of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
62126273|NCT00111085|PLACEBO_COMPARATOR|Placebo|intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
62126274|NCT06210334|EXPERIMENTAL|HAIC combined with Tislelizumab and Lenvatinib (HAI-TIS-LEN) group|HAIC with modified FOLFOX (oxaliplatin, 85 mg/ m2, leucovorin 400 mg/ m2, 5-fluorouracil bolus 400 mg/m2 on day 1; and 5-fluorouracil infusion 2400 mg/ m2 for 46 h) on day1-2 every 3 weeks. Tislelizumab injection intravenously after 24h of HAIC every 3 week. Lenvatinib 12/8 mg (weight ≥ 60 kg/\< 60 kg) orally once daily starting 1-3 days after HAIC.
62126275|NCT02328963|EXPERIMENTAL|Everolimus|Everolimus + reduced dose of cyclosporine A
62126276|NCT02328963|ACTIVE_COMPARATOR|mycophenolic acid|mycophenolic acid + standard dose of cyclosporin A
62126277|NCT01291381|ACTIVE_COMPARATOR|Dermatophagoides pteronyssinus extract|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
62126278|NCT01291381|ACTIVE_COMPARATOR|Pharmacotherapy|Persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
62126279|NCT06411743|EXPERIMENTAL|Treatment group1|Recombinant Human Albumin Injection,10g/day, once daily for 14 days
62316391|NCT06036108|EXPERIMENTAL|Fed-state administration group|Brexpiprazole QW formulation in a fed-state administration
62316392|NCT03561285||Stroke with antiphospholipid|
62316393|NCT03561285||stroke without antiphospholipid|
62316394|NCT03418662|NO_INTERVENTION|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
62686050|NCT02868879||Normal controls.|
62686051|NCT06304896|ACTIVE_COMPARATOR|The Cardioprotective Group (CPG)|50 patients will receive a low-dose Beta-blockers in the form of Carvedilol 6.25 mg PO twice daily, a low-dose ACE inhibitors in the form of Ramipril 2.5 mg PO once daily, and a statin in the form of rosuvastatin 20 mg oral tablets.
62686052|NCT06304896|ACTIVE_COMPARATOR|The Immunomodulatory Group (IMG)|50 patients will receive Colchicine 0.6 PO once daily.
62686053|NCT06304896|PLACEBO_COMPARATOR|The Placebo Control Group (PCG)|50 patients will receive a placebo as a control group.
62686054|NCT06689189||Healthy control group|Individuals who are physically healthy with no underlying diseases and have not been hospitalized within the past two years. Recruitment for healthy volunteers will be conducted through notices and online media.
61924507|NCT03301974|EXPERIMENTAL|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
61924508|NCT02992080|OTHER|Cystic fibrosis Patients|
61924509|NCT02992080|OTHER|Patients without fibrosis cystic|
61924510|NCT02992080|OTHER|Cystic fibrosis Patients (secondary use of samples)|
62126280|NCT06411743|EXPERIMENTAL|Treatment group2|Recombinant Human Albumin Injection,20g/day ,once daily for 7 days
62126281|NCT06411743|ACTIVE_COMPARATOR|Control group1|Human Albumin,10g/day, once daily for 14 days
62126282|NCT06411743|ACTIVE_COMPARATOR|Control group2|Human Albumin,20g/day, once daily for 7 days
62126283|NCT00939432||Gender|male/female
62316395|NCT03418662|EXPERIMENTAL|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
62316396|NCT00203645|EXPERIMENTAL|Brief self-directed treatment|self-help workbook plus motivational telephone intervention
62479100|NCT06447922||Robot-Assisted TKA|Patients undergoing a robot-assisted total knee arthroplasty.
62479101|NCT06218394|EXPERIMENTAL|microneedling|
62479102|NCT06218394|EXPERIMENTAL|autologous concentrated growth factor|
62479103|NCT06218394|ACTIVE_COMPARATOR|5% minoxidil|
62479104|NCT06489223|EXPERIMENTAL|Use of an Orofacial Myofunctional Rehabilitation Pacifier|The device will be offered to the child during waking periods during three tests which will be programmed remotely or not from a bottle. Each of this tests will last 15 minutes. Tests taking place near a meal must take place within 20 minutes before or after the bottle. The last test will be offered at bedtime with the aim of the child falling asleep with the device.
62479105|NCT04830462|OTHER|LTBI and DM|Participants with LTBI and DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
62479106|NCT04830462|OTHER|LTBI without DM|Participants with LTBI without DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
62479107|NCT06675331|EXPERIMENTAL|Meal delivery program|Patients will receive 2 meals daily (14 meals weekly) of medically-tailored meals incorporating traditional Navajo foods, followed by a cooking class at the end of the meal program (meals provided for 4 weeks)
62126284|NCT00939432||Age|18-100 years
62126285|NCT00939432||Educational level|primary school, secondary school, university
62316397|NCT00203645|EXPERIMENTAL|Self-directed plus telephone support|Self-help workbook, motivational telephone intervention plus telephone booster calls
62316398|NCT00203645|ACTIVE_COMPARATOR|Workbook only|Workbook only
62479108|NCT00827463|EXPERIMENTAL|NFS and iron in the first quater|first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery.
62479109|NCT00827463|EXPERIMENTAL|No NFS and iron in the first quater|second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy
62479110|NCT04175977|EXPERIMENTAL|Wave 1: Usual Care for Months 1-7, Transition for Months 8-9, Intervention for Months 10-26|PWD at the hospice sites randomized to Wave 1 will receive usual care for 7 months, followed by the 2-month-long transition to the intervention over months 8 and 9, followed by the QAPI intervention for 16 Months from Month 10-26.
62126286|NCT04431297|OTHER|Health Care Workers|Voluntary participation in the virtual presentations
62126287|NCT04366908|ACTIVE_COMPARATOR|Control - best available therapy|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
62316399|NCT00203645|NO_INTERVENTION|Waitlist|Six week waitlist
62316400|NCT04156646|EXPERIMENTAL|Treatment sequence ABC|In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
62316401|NCT04156646|EXPERIMENTAL|Treatment sequence BAC|In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
62316402|NCT02690467|EXPERIMENTAL|Insupen G34x3,5mm|Needle for insulin pen 3,5 mm long and with a diameter of 34 gauge
62126288|NCT04366908|EXPERIMENTAL|Treatment|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~* Start: 2 capsules~* Days 3, 7, 14, 21, 28: 1 capsule"
62316403|NCT02690467|ACTIVE_COMPARATOR|Insupen G32x4mm|Needle for insulin pen 4 mm long and with a diameter of 32 gauge
62479111|NCT04175977|EXPERIMENTAL|Wave 2: Usual Care for Months 1-8, Transition for Months 9-10, Intervention for Months 11-26|PWD at the hospice sites randomized to Wave 2 will receive usual care for 8 months, followed by the 2-month-long transition to the intervention over months 9 and 10, followed by the QAPI intervention for 15 months from Month 11-26.
62479112|NCT04175977|EXPERIMENTAL|Wave 3: Usual Care for Months 1-9, Transition for Months 10-11, Intervention for Months 12-26|PWD at the hospice sites randomized to Wave 3 will receive usual care for 9 months, followed by the 2-month-long transition to the intervention during months 10 and 11, followed by the QAPI intervention for 14 months from Months 12-26.
62479113|NCT04175977|EXPERIMENTAL|Wave 4: Usual Care for Months 1-10, Transition for Months 11-12, Intervention for Months 13-26|PWD at the hospice sites randomized to Wave 4 will receive usual care for 10 months, followed by the 2-month-long transition to the intervention during months 11 and 12, followed by the QAPI intervention for 13 months from Months 13-26.
62316404|NCT05496803|OTHER|study group|parents receiving routine education plus digital video disk before catheterization:pre-catheterization educational videos plus routine education
62316405|NCT05496803|OTHER|control group|parents receiving routine education: pre-catheterization routine education
62316406|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
62316407|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
62479114|NCT04175977|EXPERIMENTAL|Wave 5: Usual Care for Months 1-11, Transition for Months 12-13, Intervention for Months 14-26|PWD at the hospice sites randomized to Wave 5 will receive usual care for 11 months, followed by the 2-month-long transition to the intervention during months 12 and 13, followed by the QAPI intervention for 12 months from Months 14-26.
62479115|NCT04175977|EXPERIMENTAL|Wave 6: Usual Care for Months 1-12, Transition for Months 13-14, Intervention for Months 15-26|PWD at the hospice sites randomized to Wave 6 will receive usual care for 12 months, followed by the 2-month-long transition to the intervention during months 13 and 14, followed by the QAPI intervention for 11 months from Months 15-26.
62479116|NCT04175977|EXPERIMENTAL|Wave 7: Usual Care for Months 1-13, Transition for Months 14-15, Intervention for Months 16-26|PWD at the hospice sites randomized to Wave 7 will receive usual care for 13 months, followed by the 2-month-long transition to the intervention during months 14 and 15, followed by the QAPI intervention for 10 months from Months 16-26.
62479117|NCT04175977|EXPERIMENTAL|Wave 8: Usual Care for Months 1-14, Transition for Months 15-16, Intervention for Months 17-26|PWD at the hospice sites randomized to Wave 7 will receive usual care for 14 months, followed by the 2-month-long transition to the intervention during months 15 and 16, followed by the QAPI intervention for 9 months from Months 17-26.
62479118|NCT05944510|EXPERIMENTAL|Add-on Dextromethorphan|Dextromethorphan 30mg once daily will be administered along with clozapine (as standard of care) in Treatment-resistant schizophrenia.
62479119|NCT05944510|PLACEBO_COMPARATOR|Add-on Placebo|Matched Placebo will be administered along with clozapine (as standard of care) in Treatment resistant schizophrenia.
62479120|NCT04184167|ACTIVE_COMPARATOR|intermittent fasting|intermittent fasting before ICSI
62479121|NCT04184167|PLACEBO_COMPARATOR|No intermittent fasting|Usual diet
62686055|NCT06689189||Infected Non-Sepsis Patient Group|Patients with infections and a SOFA score of 1 will be screened and confirmed by a physician to meet the inclusion criteria. After obtaining informed consent, a nurse will collect a 4 cc blood sample within 24 hours of qualification. Within 7 days of ICU admission, physicians will assess whether patients with non-sepsis infections progress to sepsis. If so, these patients will be categorized into the sepsis patient group. One week post-discharge and on the 28th day post-diagnosis, a nurse will follow up to inquire about their health status.
62126289|NCT04329130|EXPERIMENTAL|Chidamide combined Lenalidomide|"Chidamide, 20 mg, twice per week; lenalidomide, 25 mg, d1-21, and rest for 7 days.~one treatment cycle per 28 days.For patients with limited lesions and good drug response, local radiotherapy may be assessed by the investigator."
62126290|NCT05261997|EXPERIMENTAL|Endoscopic group|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 48h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary. Conservative treatments similar to patients in the control group were given in endoscopic group according to patients' condition.
62316408|NCT03290300||Long-Term Study Subjects|This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.
62316409|NCT06622109||20-valent Pneumococcal Conjugate Vaccine|Infants aged 2 months, inclusive to 7 months, exclusive who have been vaccinated with PREVENAR 20 for the first time.
62479122|NCT05078970|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants in this group will be studied as they proceed through treatment in the acute care setting and follow the intervention plan laid out in the discharge summary, per usual protocols at each facility. In both settings, the elements of typical care include crisis prevention planning, which outlines potential triggers, skills to use, and people and places to call in crisis, as well as referral to ongoing behavioral health treatment. We will not alter usual care but track recommendations, contacts and care through questionnaires the family completes as well as medical record review in order to understand the impact of the experimental conditions in relation to typical services.
62686056|NCT06689189||Vasopressorin treated sepsis group|Patients with confirmed infections, having qSOFA ≥ 2 and SOFA ≥ 2, accepted with vasopressor therapy, will be screened and confirmed by a physician to meet the inclusion criteria. After physician confirmation that the inclusion criteria are met, patients will be informed and asked to sign an informed consent form. Blood samples (4 cc) will be collected within 24 hours before and after hospitalization entry and within 24h after transferred out of the ICU.
62686057|NCT06689189||No vasopressor theapy sepsis group|Group/Cohort Description: Patients with confirmed infections, having qSOFA ≥ 2 and SOFA ≥ 2, without vasopressor therapy, will be screened and confirmed by a physician to meet the inclusion criteria. After physician confirmation that the inclusion criteria are met, patients will be informed and asked to sign an informed consent form. Blood samples (4 cc) will be collected within 24 hours before and after hospitalization entry.
62686058|NCT03818971|EXPERIMENTAL|alcohol consumption with alcohol use disorder (AUD)|subjects with regular alcohol consumption with AUD according to the DSM 5 without any other substance use disorder (except alcohol) without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
62686059|NCT03818971|OTHER|alcohol consumption without alcohol use disorder|subjects with regular alcohol consumption without AUD according to the DSM 5 without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
62686060|NCT03818971|OTHER|no alcohol consumption|subjects without alcohol consumption without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
62686061|NCT01663363|EXPERIMENTAL|wavefront-guided LASIK|LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System.
62686062|NCT05122143|EXPERIMENTAL|Sequence 1|Treatment sequence for the 3 treatment exposure visits is ABC.
62686063|NCT05122143|EXPERIMENTAL|Sequence 2|Treatment sequence for the 3 treatment exposure visits is BCA.
62686064|NCT05122143|EXPERIMENTAL|Sequence 3|Treatment sequence for the 3 treatment exposure visits is CAB.
62686065|NCT05122143|EXPERIMENTAL|Sequence 4|Treatment sequence for the 3 treatment exposure visits is ACB.
62686066|NCT05122143|EXPERIMENTAL|Sequence 5|Treatment sequence for the 3 treatment exposure visits is BAC.
62686067|NCT05122143|EXPERIMENTAL|Sequence 6|Treatment sequence for the 3 treatment exposure visits is CBA.
62686068|NCT04906187|EXPERIMENTAL|Arm A : Experimental group with intraoperative ANI monitoring of nociception|
62686069|NCT04906187|OTHER|Arm B : Control group without ANI intraoperative monitoring of nociception|
62686070|NCT03169374|EXPERIMENTAL|Virtual Reality Technology|Virtual Reality Therapy
62126291|NCT05261997|OTHER|Conservative group|Patients will have pancreatic enzymes (Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table) to control symptoms of exocrine pancreatic insufficiency. The recommended initial dose for adults is (25 000-40 000) IU lipase per meal (40 000 IU for meals and 20 000 IU for snacks), which can be increased until the PEI is relieved. The maximum recommended dose is (75 000-80 000) IU lipase per meal. Actions including drugs(Acarbose Tablets, Glucophage, Glimepirde Tablets) or insulin(Biosynthetic Human Insulin Injection, Tresiba or both) would also be taken for control of diabetes according to patients' glucose levels.
62126292|NCT05881317|EXPERIMENTAL|ArtiAid® Plus group|Each pre-filled syringe contains 15 mg/ml (1.5%) sodium hyaluronate, subjects received one injection per week for three weeks.
62126293|NCT02147054|ACTIVE_COMPARATOR|Rocuronium with >95% inhibition|"IV Rocuronium to be given:~* Bolus dose of Rocuronium 0.3 mg/kg to achieve \>95% inhibition as indicated by Train of Four monitoring~* Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~* To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
62126294|NCT02147054|ACTIVE_COMPARATOR|Rocuronium with 50% inhibition|"IV Rocuronium to be given:~* Bolus dose of Rocuronium 0.3 mg/kg to achieve 50% inhibition as indicated by Train of Four monitoring~* Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~* To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
62126295|NCT02147054|NO_INTERVENTION|No Rocuronium|No Rocuronium will be given
62316410|NCT06498063|EXPERIMENTAL|Glucagon|Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
62686071|NCT02993666|EXPERIMENTAL|upper body|warming with upper body blankets
62686072|NCT02993666|EXPERIMENTAL|lower body|warming with lower body blankets
62686073|NCT06209450|EXPERIMENTAL|Ventral hernia repair|
62686074|NCT02973152|ACTIVE_COMPARATOR|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
62316411|NCT06498063|EXPERIMENTAL|Glucagon+Exendin9-39|Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
61924511|NCT01225536|EXPERIMENTAL|ARQ 736|
62316412|NCT06498063|PLACEBO_COMPARATOR|Sodium chloride (Placebo comparator)|NaCl (0.9%)
62316413|NCT02046564|EXPERIMENTAL|ASC-01|The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
62479123|NCT05078970|ACTIVE_COMPARATOR|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
62479124|NCT05078970|ACTIVE_COMPARATOR|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and a maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
62479125|NCT06045546|EXPERIMENTAL|5-5-5-8 group|In this group, the new 5-5-5-8 technique of laparoscopic cholecystectomy will be done.
62479126|NCT06045546|ACTIVE_COMPARATOR|Control|In this group, the 10-10-5-5 technique of laparoscopic cholecystectomy will be done.
62479127|NCT05487989||optic neuritis patients|Patients suffering from an acute episode of optic neuritis will be included. There will be only one group of patients prospectively followed-up.
62479128|NCT03316963|EXPERIMENTAL|Drug-induced sleep endoscopy (DISE) with Neostigmine|Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
62479129|NCT06731803|EXPERIMENTAL|NeoART-001|Trastuzumab-deruxtecan 5.4 mg/kg i.v., on day 1, Q3W plus 5-FU/LV: leucovorin 200 mg/m2 i.v., followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion on day 1, Q2W. Patients will receive three cycles of neoadjuvant T-DXd combined with four cycles 5-FU/LV followed by surgery.
62686075|NCT02973152|ACTIVE_COMPARATOR|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
62686076|NCT06687850|EXPERIMENTAL|A therapy/service canine was used during therapy sessions|The canine was included during therapy sessions and the effect of the canine on children with varying verbality was examined both during and after sessions
62686077|NCT06034262|EXPERIMENTAL|SclerFIX-IP|Treated, devitalised and sterile graft of umbilical cord amniotic membrane
62686078|NCT06696053|EXPERIMENTAL|Patients with Tuberculosis|
61924512|NCT02208700|EXPERIMENTAL|Oxepa|Other: Therapeutic nutrition with EPA, GLA and antioxidants.
61924513|NCT02208700|ACTIVE_COMPARATOR|Jevity 1.5|Other: Jevity 1.5 Complete Balanced Nutrition with Fiber .
62316414|NCT02046564|PLACEBO_COMPARATOR|Placebo|The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
62316415|NCT03078725|ACTIVE_COMPARATOR|Glyburide|hypoglycemic agent approved for treatment of GDMA2
62316416|NCT03078725|ACTIVE_COMPARATOR|Metformin|hypoglycemic agent approved for treatment of GDMA2
62316417|NCT05820295|EXPERIMENTAL|Intervention|The intervention group will assign care coordinators to individuals based on perceived need for assistance with care coordination. Perceived need will be measured through a proxy's responses to a previously validated telephone survey on perceptions of care coordination.
62316418|NCT05820295|ACTIVE_COMPARATOR|Control|Usual care assigns patients to care coordinators in response to a discharge from a hospital or a direct referral from a physician.
62316419|NCT00723840||Crohn's Disease Participants|"Participants with Crohn's Disease for at least 6 months, who have a Crohn's Disease Activity Index (CDAI) score \>= 150. The CDAI score evaluates Crohn's disease symptoms - a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.~These participants have active disease despite drug therapy."
62316420|NCT02927171|NO_INTERVENTION|Usual Care|Skilled nursing facility rehabilitation therapists provide all patients with usual standard of care.
62316421|NCT02927171|EXPERIMENTAL|I-STRONGER|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER) Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities. Skilled nursing facility rehabilitation therapists will be trained in I-STRONGER intervention and will implement to all eligible patients as new standard of care.
62316422|NCT02952547|EXPERIMENTAL|Test / Reference Drug|DWJ1366 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
62316423|NCT02952547|EXPERIMENTAL|Reference / Test Drug|Co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1366 Tab.
62316424|NCT06326229||Musculoskeletal patients|Patients suffering from musculoskeletal problems referred by a family physician for management in primary care physiotherapy services.
62316425|NCT00791128|EXPERIMENTAL|EndoBarrier GI Liner|22 patients were implanted with the GI Liner for a 52-week duration. Assessments were performed during the 6 months post-explant period.
62316426|NCT03822403|ACTIVE_COMPARATOR|EQUIA|EQUIA Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
62316427|NCT03822403|ACTIVE_COMPARATOR|Gradia Direct Posterior|Gradia Direct Posterior The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
62316428|NCT06672068|EXPERIMENTAL|Cohort 1|TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
62316429|NCT06672068|EXPERIMENTAL|Cohort 2|TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
62316430|NCT03493503|EXPERIMENTAL|Salbutamol loading dose|Salbutamol loading dose of 15 mcg/kg in 10 minutes, with a maximum of 750 mcg.
62316431|NCT03493503|PLACEBO_COMPARATOR|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes.
62316432|NCT04036058|EXPERIMENTAL|Intervention|Enact universal gloving practices
62479130|NCT06731803|EXPERIMENTAL|NeoART-002|Trastuzumab-deruxtecan 5.4 mg/kg i.v., on day 1, Q3W plus FLO: oxaliplatin 85 mg/m2 \& leucovorin 200 mg/m2, each as an i.v. infusion followed by 5-FU 2600 mg/ m2 as a 24-h continuous infusion on day 1, Q2W. Patients will receive three cycles of neoadjuvant T-DXd combined with four cycles 5-FU/LV followed by surgery.
62479131|NCT01340495|EXPERIMENTAL|Proton Radiation|Radiation therapy with proton beam
62479132|NCT00597805||1|Patients scheduled for a total, anterior or posterior pelvic exenteration
62479133|NCT06495684|EXPERIMENTAL|Anodal tDCS + Social Learning|In this arm, participants will undergo 5 sessions of 30 minutes anodal tDCS combined with social learning tasks on consecutive weekdays.
62316433|NCT04036058|NO_INTERVENTION|Control|Continue standard of care gloving practices
62479134|NCT06495684|SHAM_COMPARATOR|Placebo anodal tDCS + Social Learning|In this arm, participants will undergo 5 sessions of 30 minutes placebo anodal tDCS combined with social learning tasks on consecutive weekdays.
62316434|NCT05209243|EXPERIMENTAL|Interventional arm|STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
62316435|NCT05209243|ACTIVE_COMPARATOR|Control arm|STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
62316436|NCT01732263|EXPERIMENTAL|SSP-004184 (Child-Pugh A Liver Impaired)|The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
62479135|NCT06558617||Thai community-dwelling older adults|
62479136|NCT05315999|EXPERIMENTAL|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
62479137|NCT05315999|PLACEBO_COMPARATOR|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
62479138|NCT03083574|EXPERIMENTAL|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
62316437|NCT01732263|EXPERIMENTAL|SSP-004184 (Child-Pugh B Liver Impaired)|
62316438|NCT01732263|EXPERIMENTAL|SSP-004184 (Child-Pugh C Liver Impaired)|
62316439|NCT01732263|EXPERIMENTAL|SSP-004184 (Matched Healthy Subjects)|
62316440|NCT03435029|EXPERIMENTAL|Cognitive Remediation Program (REHACOP)|The cognitive rehabilitation program (REHACOP) is a 5 month intervention that allows both individual and group intervention. For the purpose of this study, we included intervention in several domains: attention, language, memory, processing speed, and executive functioning for 3 months, 3 times per week, in 60 minute per session.
62316441|NCT03435029|ACTIVE_COMPARATOR|Occupational Therapy|The control group performed of occupational group activities (memory tasks, reading the newspaper, drawing, singing or doing crafts). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
62316442|NCT04523792|EXPERIMENTAL|Opioid withdrawal patients|Subjects with opioid use disorder seeking treatment and/or experiencing symptoms of opioid withdrawal receive acute administration of SUBOXONE sublingual film followed by SUBLOCADE administration in the 1) ED, 2) Clinical Decision Unit or 3) Inpatient unit combined with 6 months of treatment with SUBLOCADE in the outpatient treatment clinic.
62316443|NCT06253559||ovarian cancer patients|all ovarian cancer patients that meet the criteria of the study
62316444|NCT04128592|OTHER|Wheezing|
62316445|NCT04128592|OTHER|Rattling|
62316446|NCT03808714|ACTIVE_COMPARATOR|Intervention|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session (delivered by a trained Community Health Worker) plus pharmacological consultation(s) via telemedicine, but this will be determined during pretesting.
62316447|NCT03808714|ACTIVE_COMPARATOR|Control|"Alabama Tobacco Quitline, which is considered the standard-of-care for smoking cessation in Alabama."
62316448|NCT03446170|EXPERIMENTAL|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
62686079|NCT05360602|EXPERIMENTAL|Control group|35 STEMI patients undergoing PCI who will receive standard of care that will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
62126296|NCT06177106|OTHER|Cohort A - history of > 2 Cutaneous squamous cell carcinoma (cSCC)|Participants who have a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability. Subjects from each cohort will be matched based on age and gender.
62126297|NCT06177106|OTHER|Cohort B - no history of cSCC|Participants without a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability.
62126298|NCT06107894|EXPERIMENTAL|Cohort 1|Autologous Tumor-infiltrating lymphocytes
62126299|NCT06107894|EXPERIMENTAL|Cohort 2|Autologous Tumor-infiltrating lymphocytes, Low dose IL-2
62126300|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
62126301|NCT01652417|NO_INTERVENTION|oral prednisone|Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
62126302|NCT01652417|EXPERIMENTAL|methylprednisolone bolus|methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
62126303|NCT04848233|OTHER|Drink intervention|Placebo and two drinks containing a blend of five amino acids and chromium picolinate, are included with every main meal and served in a standardized, non-randomised order.
62126304|NCT03068078|NO_INTERVENTION|Control-group|The control group will be eating a regular diabetes diet according to the Danish National Recommendations
62126305|NCT03068078|EXPERIMENTAL|Intervention-group|Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats
62126306|NCT00492271|EXPERIMENTAL|1|Experimental arm with increasing dosage
62316449|NCT03446170|EXPERIMENTAL|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
62316450|NCT03446170|EXPERIMENTAL|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
62316451|NCT03446170|EXPERIMENTAL|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
62686080|NCT05360602|EXPERIMENTAL|Test group|35 STEMI patients undergoing PCI who will receive the standard of care in addition to IV Alpha Lipoic Acid 600 mg before PCI then 600 mg orally for 28 days after PCI
62686081|NCT06559176|EXPERIMENTAL|PM359|PM359 is an autologous CD34+ hematopoietic stem cell (HSC) suspension that is Prime Edited at the NCF1 locus resulting in expression of the p47phox protein.
62686082|NCT05447663|EXPERIMENTAL|Siremadlin (HDM201)|Participants with AML post allogeneic stem cell transplantation (allo-SCT) will receive siremadlin monotherapy in part 1 and siremadlin monotherapy as well as in combination with donor lymphocyte infusion in part 2
62686083|NCT06689436|EXPERIMENTAL|5 mg Apixaban Oral Dissolving Film (fasting)|Treatment T1: Subject will receive a single dose of 5 mg Apixaban Oral Dissolving Film under fasting condition
62686084|NCT06689436|EXPERIMENTAL|5 mg Apixaban Oral Dissolving Film (fed)|Treatment T2: Subject will receive a single dose of 5 mg Apixaban Oral Dissolving Film under fed condition.
62686085|NCT06689436|ACTIVE_COMPARATOR|5 mg Apixaban Oral Tablet (US RS/RLD)|Treatment R1: Subject will receive a single dose of 5 mg Apixaban Oral Tablet (US RS/RLD) under fasting condition.
62316452|NCT03446170|NO_INTERVENTION|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
62316453|NCT03486535||Diabetic patients|Diabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
62316454|NCT03486535||Non-diabetic patients|Nondiabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
62686086|NCT06689436|ACTIVE_COMPARATOR|5 mg Apixaban Oral Tablet (EU product)|Treatment R2: Subject will receive a single dose of 5 mg Apixaban Oral Tablet (EU product)) under fasting condition.
62126307|NCT05554185|EXPERIMENTAL|group A|aspirin 100mg and probiotics 1 bag
62126308|NCT05554185|PLACEBO_COMPARATOR|group B|aspirin 100mg and placebo1 bag
62126309|NCT06461871|EXPERIMENTAL|moderate intensity aerobic exercises with balance training|A received moderate intensity aerobic exercises which include walking, cycling, with each session lasting 15 minutes for 3-5 days per week in combination with balance training which include heel raise
62126310|NCT06461871|EXPERIMENTAL|moderate intensity resistance exercises with balance training|Group B receive moderate intensity resistance exercises which include biceps curls, triceps curls , with each session lasting 10 repetitions for 3-5 days per week in combination with balance training which include heel raise
62126311|NCT06250569||first group|women with with adenomyosis
62126312|NCT06250569||second group|women without adenomyosis
62479139|NCT03771469|EXPERIMENTAL|Questionnaires and sleep studies|Caregivers of patients meeting eligibility criteria will be invited to participate. If they agree to participate, baseline SRBD-PSQ, OSA-18, and PedsQL questionnaires along with written informed consent forms will be mailed to them along with their standard scheduling paperwork. Caregivers will be asked to review the consent form and complete the questionnaires and bring the paperwork to clinic on the day of their visit. Sleep study testing will also be ordered prior to their visit so that it can be scheduled within a month of the initial clinic visit and again three months later.
62479140|NCT05143801|ACTIVE_COMPARATOR|No mask temperate|Participant exercised in room temperature environment not wearing a surgical face mask
61924514|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI \<28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
61924515|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI \<28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
62126313|NCT03762291|EXPERIMENTAL|CVD908ssb-TXSVN|"3 different dosing schedules will be studied (3+3 design). At the beginning, patients will start on the lowest dose (1 of 3 different levels) of TXSVN. Once that dose schedule proves safe, the next group of patients will be started at a higher dose. This process will continue until all 3 dose levels are studied. If the side-effects are too severe, the dose will be lowered or the TXSVN administrations will be stopped. Each patient will receive 2 vaccinations at the same dose, 2 weeks apart, according to the following dosing schedules: The administration will be oral.~Dose Level 1~Day 0: 2 x 10\^5 cfu~Day 14: 2 x 10\^5 cfu~Dose Level 2~Day 0: 2 x 10\^6 cfu~Day 14: 2 x 10\^6 cfu~Dose Level 3~Day 0: 2 x 10\^7 cfu~Day 14: 2 x 10\^7 cfu"
62316455|NCT05334784|EXPERIMENTAL|Impella ECP Device|Subjects receiving the Impella ECP.
62316456|NCT05216211|ACTIVE_COMPARATOR|Group Caudal|Caudal block with 1 ml / kg, % 0.25 bupivacaine
62316457|NCT05216211|NO_INTERVENTION|Group Control|No intervention
62316458|NCT05407298||CBD users|
62479141|NCT05143801|EXPERIMENTAL|Mask temperate|Participant exercised in room temperature environment while wearing a surgical face mask
62686087|NCT03907579|EXPERIMENTAL|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.
62686088|NCT06500936|EXPERIMENTAL|Intervention (SMS)|The intervention included two series of SMS messages. First, women of IG received one weekly SMS messages for 2 weeks. Those women that did not register a mammography in SITAM 45 days after the 2nd message, received the second series, consisting of one weekly SMS message over two weeks. The intervention assumed an average of 30 days to obtain appointments and perform the mammography, plus 15 days until the report was uploaded in SITAM and available for delivery. Messages stopped if a mammography was registered in SITAM.
62686089|NCT06500936|NO_INTERVENTION|Usual care|The women in the control group received standard care, which in this context is opportunistic screening. Women in the control group had the possibility of asking for an appointment for mammography, if they wanted to do so. To ask for the appointment, women must complete different steps: 1) women have to ask for an appointment with a health professional in a primary health center; 2) a health professional has to prescribe a mammography, 3) then women ask for the appointment at the administrative office in the health center.
62686090|NCT06370663|EXPERIMENTAL|Radiotherapy plus HAIC|Radiotherapy + Hepatic Arterial Infusion Chemotherapy (Gesitabine) + Chemotherapy (GEMOX)
62686091|NCT06685991|EXPERIMENTAL|Dexamethasone pre-induction|Participants in this group will receive a single dose of dexamethasone administered intravenously before fentanyl administration during anesthesia induction. This arm assesses the impact of pre-fentanyl dexamethasone on postoperative outcomes, including nausea, pain, glycemic control, and hemodynamic stability.
62686092|NCT06685991|EXPERIMENTAL|Dexamethasone post-induction|Participants in this group will receive a single dose of dexamethasone administered intravenously after the muscle relaxant during anesthesia induction. This arm examines the effects of administering dexamethasone post-muscle relaxant on postoperative outcomes, including nausea, pain, glycemic control, and hemodynamic stability.
62686093|NCT06685991|PLACEBO_COMPARATOR|No Dexamethasone (Control)|Participants in this control group will not receive dexamethasone during anesthesia induction. This group serves as a baseline to compare the outcomes with those receiving dexamethasone at different timing points.
62686094|NCT02240914||Vascular USG and IVUS imaging diagnosis|
61924516|NCT05561010|EXPERIMENTAL|Intra-articular injection of bupivacaine|5 ml of bupivacaine (0.25% w/v)
62316459|NCT05407298||CBD non-users|
62316460|NCT01209208|EXPERIMENTAL|A|Budesonide
62479142|NCT05143801|ACTIVE_COMPARATOR|No mask hot|Participant exercised in a hot environmental temperature not wearing a surgical face mask
62479143|NCT05143801|EXPERIMENTAL|Mask hot|Participant exercised in a hot environmental temperature while wearing a surgical face mask
62479144|NCT03958396|ACTIVE_COMPARATOR|OSA Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea
62479145|NCT03958396|ACTIVE_COMPARATOR|Control (non-OSA) Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) no known obstructive sleep apnea presenting for any procedure requiring general anesthetic
62479146|NCT04084080|EXPERIMENTAL|Exchange transfusion plus standard of care|Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months.
62316461|NCT01209208|EXPERIMENTAL|B|Mesalazine
62316462|NCT01209208|PLACEBO_COMPARATOR|C|
62316463|NCT04340830|EXPERIMENTAL|smoker|Those consuming at least 10 cigarette a day for ten years were included in smoker group.
62316464|NCT04340830|ACTIVE_COMPARATOR|non-smoker|Patients who never smoke were included in non-smoker group. Patients who quit smoking were not included in this group.
62316465|NCT05354284||Sexual gender minority people|People self defining Lesbian, Bi-sexual, Transgender, Quer or other are recruited and asked to fill in a questionnaire during pregnancy, three months postpartum and one year later.
62316466|NCT03662152|EXPERIMENTAL|Foam roller|Non-Vibration Foam Rolling (NVFR) Group: subjects performed the FR protocol using a custom-made foam roller composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long).
62316467|NCT03662152|EXPERIMENTAL|vibration foam roller|Vibration Foam Rolling (VFR) Group: subjects performed the same protocol using a foam roller with vibration (frequency: 18 Hz) composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long) (Hyperice ®).
62479147|NCT04084080|ACTIVE_COMPARATOR|Standard of care|Randomized to standard of care
62686095|NCT04619745|EXPERIMENTAL|Intervention Group|All children enrolled in the study will complete five study visits. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity. The intervention group will complete individualized, parent-led, home and play-based activity plans for 6 months, beginning as soon as the child returns to the inpatient unit. The activities in the plan will be tailored to each phase of treatment (in hospital, discharge to week 7, week 8 to 6 months), follow a standardized format and provide content individualized to each child's age and previous visit assessments.
62686096|NCT04619745|EXPERIMENTAL|Wait List Control Group|All children enrolled in the study will complete five study visits. After the first visit is complete, children will be randomized to either the intervention or wait-list control study group. Control participants will follow the same schedule of assessments at each visit, but the intervention will be provided between the 12-month and 16-month assessments. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity.
62686097|NCT06417788|EXPERIMENTAL|Test group or Dynamic guided group|in this arm, the position and angulation of the implant in the patient's mouth will be guided by a dynamic guided system.
62686098|NCT06417788|ACTIVE_COMPARATOR|Control group or Static guided group|In this arm, the position and angulation of the implant in the patient's mouth will be guided by a stereolitographic pilot drill guide.
62686099|NCT03133377|EXPERIMENTAL|Early activity and Mobilisation intervention|Patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
62686100|NCT03133377|NO_INTERVENTION|Standard of care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
62686101|NCT06661915|EXPERIMENTAL|Arm I (ASTX727)|Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at cycle 1 day 0 and blood sample collection and bone marrow aspiration and biopsy throughout the study.
62686102|NCT06661915|EXPERIMENTAL|Arm II (ASTX727, iadademstat)|Patients receive ASTX727 PO QD on days 1-5 and iadademstat PO QD on days 1-5, 8-12, and 15-19 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at cycle 1 day 0 and blood sample collection and bone marrow aspiration and biopsy throughout the study.
62316468|NCT05462587|EXPERIMENTAL|AVTX-803|Approximately 4 subjects will receive AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day for 8 weeks.
61924517|NCT05561010|PLACEBO_COMPARATOR|Intra-articular injection of sodium chloride|5 ml of sodium chloride (9mg/ml, 0.9% solution for injection)
62316469|NCT05462587|NO_INTERVENTION|Withdrawal|Subject will be in withdrawal for 8 weeks.
62316470|NCT04023812||Cohort 1|Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
62316471|NCT04023812||Cohort 2|Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
62686103|NCT00637156|EXPERIMENTAL|PRESTIGE LP Device|
62686104|NCT00637156|OTHER|ATLANTIS Cervical Plate System|
62686105|NCT04178863|ACTIVE_COMPARATOR|lataprost|latanoprost use
62686106|NCT04178863|ACTIVE_COMPARATOR|timolol|timolol group
62316472|NCT04291300|EXPERIMENTAL|Lutetium treatment|Drug: Lutetium-177-PSMA-I\&T, 4 cycles of 7.4 GBq intravenously, every 6 weeks.
62316473|NCT05797350|ACTIVE_COMPARATOR|Paul Glaucoma Implant|"The Paul glaucoma implant (PGI) will be used as an active comparator group to compare its effectiveness and safety with the Ahmed glaucoma valve in the treatment of childhood glaucoma. The PGI works by diverting excess fluid from the eye to a plate placed under the conjunctiva, which allows the fluid to drain away from the eye and be absorbed. This helps to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.~The PGI has a smaller internal and external tube diameter than the Ahmed glaucoma valve, which reduces the contact area between the tube and the corneal endothelium. This theoretically reduces the rate of endothelial cell loss, which can be a complication of GDDs. Additionally, the extraocular portion of the PGI is smaller, which may reduce the long-term risk of tube erosion and exposure.~The smaller lumen may theoretically reduce the risk of postoperative hypotony as well."
61924518|NCT02567552|EXPERIMENTAL|Prolutex|Subcutaneous progesterone
61924519|NCT02567552|ACTIVE_COMPARATOR|Prontogest|Intramuscular progesterone
61924520|NCT01857310|EXPERIMENTAL|Folic acid and zinc supplementation|5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
61924521|NCT01857310|PLACEBO_COMPARATOR|Placebo|Matching placebo, taken orally daily for 6 months.
62316474|NCT05797350|ACTIVE_COMPARATOR|Ahmed Glaucoma valve|"The Ahmed glaucoma valve (AGV) arm of the study is the active comparator group and is intended to be directly compared to the Paul glaucoma implant (PGI) in treating childhood glaucoma. The AGV is a type of glaucoma drainage device that is designed to lower intraocular pressure in patients with refractory glaucoma. It is made of a rigid plastic material and consists of a small drainage tube that is inserted into the eye and a valve mechanism that helps regulate the flow of aqueous humor from the eye to the external drainage tube.~The AGV is implanted during a surgical procedure, and its design allows it to be placed in a variety of locations in the eye. The valve mechanism helps to regulate the flow of aqueous humor, and the device is designed to be long-lasting with a low risk of complications. The AGV is a well-established treatment option for patients with refractory glaucoma and has been used for many years in clinical practice."
62686107|NCT06690450|EXPERIMENTAL|Venofer® 200 mg|A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes.
62686108|NCT06690450|ACTIVE_COMPARATOR|Venofer® 100 mg|A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose
62686109|NCT03509480|ACTIVE_COMPARATOR|Curettage with Vitoss|ultraporous beta-tricalcium phosphate mixed with autologous bone marrow aspirate for patients undergoing surgical curettage for benign bone lesions
62316475|NCT00381316|ACTIVE_COMPARATOR|1|Thallous Chloride T1-201
62316476|NCT00381316|ACTIVE_COMPARATOR|2|Technetium Tc99m Tetrofosmin injections
62316477|NCT01221233|EXPERIMENTAL|NMES AND Stabilization Exercises|Neuromuscular Electrical Stimulation and Lumbar Stabilization Exercises
62316478|NCT01221233|ACTIVE_COMPARATOR|Moist Heat AND Stabilization Exercises|Moist Heat and Lumbar Stabilization Exercises
62316479|NCT02890771|ACTIVE_COMPARATOR|Tooth Brushing|Tooth brushing with dentifrice
62316480|NCT02890771|EXPERIMENTAL|Turmeric massaging|Tooth Brushing,massaging with whole turmeric powder
62316481|NCT02890771|EXPERIMENTAL|SRP with turmeric massaging|SRP with turmeric massaging on half arch
62686110|NCT03509480|ACTIVE_COMPARATOR|Curettage with Prodense|ultraporous beta-tricalcium phosphate mixed with calcium sulfate for patients undergoing surgical curettage for benign bone lesions
62686111|NCT03416387|OTHER|OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION|
62316482|NCT00552825||1|all were in a single group
62316483|NCT02064218||Hypertensive patients|Hypertensive patients naive to hypertensive treatment
62316484|NCT02064218||healthy subjects|healthy subjects
62316485|NCT05032157|EXPERIMENTAL|LOU064 25mg b.i.d.|LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open- label) taken orally b.i.d. for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
62316486|NCT05032157|PLACEBO_COMPARATOR|Placebo|LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
62316487|NCT05159583|EXPERIMENTAL|In-Home Technology System|"The full system \[(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors\] will be self-installed by rural caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
62686112|NCT01548885|EXPERIMENTAL|Study Staff Test BGMSs|All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
62686113|NCT06688630|EXPERIMENTAL|Intervention Group|The laser acupuncture and artificial tears therapy
62686114|NCT06688630|SHAM_COMPARATOR|Control Group|The sham laser acupuncture and artificial tears therapy
62686115|NCT01659151|EXPERIMENTAL|Combination Therapy|Combination Chemotherapy and Immunotherapy. The combination of vemurafenib followed by lymphodepletion with chemotherapy, Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) infusion, and High Dose Interleukin-2 (IL-2).
62686116|NCT04565353|NO_INTERVENTION|Holdout control|Participants will only receive the standard appointment reminders from their providers.
62686117|NCT04565353|EXPERIMENTAL|Default Reservations Opt-Out Condition|"The day before their scheduled appointment, participants receive a text reading: A flu shot has been reserved for you to receive at your appointment tomorrow. Reply Y if you want this shot held for you, N if you don't. The text will include a picture of a vial that says Your Flu Shot on it."
62686118|NCT04565353|EXPERIMENTAL|Default Reservations Opt-In Condition|"The day before their scheduled appointment, participants receive a text reading: Reply Y if you would like to receive a flu shot at your appointment tomorrow, N if not. The text will include a picture of vial with no text on it."
62686119|NCT04565353|EXPERIMENTAL|Intergroup Competition Treatment Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind another region in flu shot rate last year (your region and another region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
62686120|NCT04565353|EXPERIMENTAL|Intergroup Competition Control Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind the target flu shot rate of 70% last year (your region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
62316488|NCT05159583|SHAM_COMPARATOR|Limited In-Home Technology System|"The full system \[(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors\] will be self-installed by rural caregivers (N=60) in their homes. Only monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm."
62316489|NCT01380496|ACTIVE_COMPARATOR|B|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
62316490|NCT01380496|ACTIVE_COMPARATOR|C|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
62316491|NCT01380496|EXPERIMENTAL|A|Subjects received the Par formulated product
62316492|NCT05588492|EXPERIMENTAL|Rifamycin containing regimen|Rifamycin containing regimen
62316493|NCT05588492|EXPERIMENTAL|Rifamycin-free regimen|Rifamycin-free regimen
62316494|NCT02392208|OTHER|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
62316495|NCT02392208|OTHER|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
62316496|NCT01073072|EXPERIMENTAL|Tutomesh|Technique of abdominal wall reconstruction strengthened by Tutomesh®
62479148|NCT02378857||Patient group|Adolescents (15-18 years of age) With univentricular heart defects and Fontan type palliation.
62479149|NCT02378857||Control group|Age- and gender-matched healthy individuals
62479150|NCT05081934|ACTIVE_COMPARATOR|Treatment as usual, TAU|TAU: Interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial.
62479151|NCT05081934|EXPERIMENTAL|TAU + A-CRA|"Behavioral: A-CRA, a 12-14 weekly sessions long behavioral treatment for youth (ages 12-25) suffering from substance use disorder and co-occurring problems, i.e. criminal behavior. The aim is to increase constructive behavior that reduces the need of substances and creates a context where it is rewarding to stay sober. Individual functional analyses, goals and needs guides treatment planning and interventions.~TAU: interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial."
62126314|NCT03066115|EXPERIMENTAL|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
62126315|NCT03066115|EXPERIMENTAL|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
62126316|NCT06222918|NO_INTERVENTION|Supragingival margins|
62126317|NCT06222918|ACTIVE_COMPARATOR|Subgingival margins (G-ænial Universal Injectable)|"Matrix: Methacrylate monomer %31. Fillers: Silica, Barium Glass %69~G-ænial Universal injectable is a light-cured, radiopaque universal high-strength composite that can be used for all restorative indications while offering excellent viscosity and perfect direct syringe application. It has enhanced thixotropic properties that allow you to create the most beautiful \& durable restorations with a minimum of manipulation."
62126318|NCT06514027|EXPERIMENTAL|Dose group A of BEBT-109 combined with investigator-selected chemotherapy|"BEBT-109 Capsules: Administration and Dosage: Oral administration, 180mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle.~Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.~Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.~Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles."
62316497|NCT01073072|ACTIVE_COMPARATOR|conventional repair|Conventional technique to repair incisional or abdominal wall hernias
62686121|NCT04565353|EXPERIMENTAL|Flu Shot for You Symbolic Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity to dedicate getting the flu shot to someone by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
62686122|NCT04565353|EXPERIMENTAL|Flu Shot for You Herd Immunity Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity of getting the flu shot to protect a vulnerable loved one by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
62316498|NCT03509753|EXPERIMENTAL|High Fiber|Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
62316499|NCT03509753|ACTIVE_COMPARATOR|Low Fiber|Per 10 ounces of feed: 0 g fiber, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
62316500|NCT05019183|EXPERIMENTAL|Experimental arm|Patients in the experimental arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) during which they will be able to move freely in a virtual environment.
62316501|NCT05019183|OTHER|Control arm|Patients in the control arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) without being exposed to a virtual environment.
62316502|NCT05064345|ACTIVE_COMPARATOR|HB0034 dose group 1|HB0034 single dose
62316503|NCT05064345|ACTIVE_COMPARATOR|HB0034 dose group 2|HB0034 single dose
62316504|NCT05064345|ACTIVE_COMPARATOR|HB0034 dose group 3|HB0034 single dose
62316505|NCT05064345|ACTIVE_COMPARATOR|HB0034 dose group 4|HB0034 single dose
62686123|NCT04565353|EXPERIMENTAL|Flu Shot for You Control Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also receive a reminder message on the day of the appointment. They will not receive any further information, nor will they be asked to respond with initials of an individual.
62686124|NCT04565353|EXPERIMENTAL|Prosocial Condition|The day before their scheduled appointment, participants will receive a message describing the pro-social benefits of getting a flu shot, and a reminder to ask for their flu shot. The described pro-social benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting loved ones from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting loved ones from serious complications from the flu). Participants will also receive a reminder message on the day of the appointment.
62686125|NCT04565353|EXPERIMENTAL|Self-Oriented Condition|The day before their scheduled appointment, participants will receive a message describing the self-oriented benefits of getting a flu shot, and a reminder to ask for their flu shot. The described self-oriented benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting oneself from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting oneself from serious complications from the flu).
62316506|NCT05064345|ACTIVE_COMPARATOR|HB0034 dose group 5|HB0034 single dose
62316507|NCT05064345|ACTIVE_COMPARATOR|HB0034 dose group 6|HB0034 single dose
62316508|NCT05064345|ACTIVE_COMPARATOR|HB0034 dose group 7|HB0034 single dose
62316509|NCT05064345|PLACEBO_COMPARATOR|Matching placebo for each dose group|placebo, single dose
62686126|NCT04565353|EXPERIMENTAL|Information Vivid Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain vivid information about getting the flu. Participants will also receive a reminder message the day before the appointment.
62316510|NCT03903029||Low-dose (10mg) rosuvastatin|Four statin benefit groups per 2013 ACC/AHA guideline in Korea
62316511|NCT05221294|EXPERIMENTAL|MDN group|will receive modified Del Nido cardioplegia solution
62316512|NCT05221294|EXPERIMENTAL|C group|will receive Custodiol cardioplegia
62316513|NCT03197675|SHAM_COMPARATOR|Control group|Participants who are randomized to the control group will not receive any acupuncture. Participants will however be assessed weekly to obtain the same data on their pain scale and other outcome measures as the treatment group. Participants will be evaluated in person during their standard of care clinical follow up appointments at the three month and six month points for in person interviews and data collection .
62316514|NCT03197675|ACTIVE_COMPARATOR|treatment group|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
62316515|NCT06427681|EXPERIMENTAL|BH006 for injection|150 mg fosaprepitant/0.25 mg palonosetron intravenously 30 minutes (±1 minute)
62316516|NCT06427681|ACTIVE_COMPARATOR|Fosaprepitant for injection+Palonosetron hydrochloride injection|Fosaprepitant for injection：150 mg fosaprepitant intravenously 30 minutes (±1 minute) ; Palonosetron hydrochloride injection： 0.25 mg palonosetron in 5 mL (0.05 mg/mL) infusion time is 30 seconds (﹢5seconds) .
62316517|NCT04064684|EXPERIMENTAL|Budesonide administered by nebulizer|
62316518|NCT04064684|PLACEBO_COMPARATOR|Placebo administered by nebulizer|
62126319|NCT06514027|EXPERIMENTAL|Dose group B of BEBT-109 combined with investigator-selected chemotherapy|"BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg; Frequency and Duration of Administration: Twice a day,and 21 days as a treatment cycle.~Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.~Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.~Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles."
62126320|NCT06514027|EXPERIMENTAL|Dose group C of BEBT-109 combined with investigator-selected chemotherapy|"BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle.~Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.~Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.~Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles."
62126321|NCT06514027|EXPERIMENTAL|BEBT-109 monotherapy|BEBT-109 Capsules: Administration and Dosage: Oral administration, 180mg; Frequency and Duration of Administration: Once a day,and 21 days as a treatment cycle.
62126322|NCT00413257|EXPERIMENTAL|1|nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
62126323|NCT00413257|EXPERIMENTAL|2|nefopam administration will start at the end of the surgery and will be continued until postoperative H48
62126324|NCT00413257|PLACEBO_COMPARATOR|3|control group that will receive a placebo from the induction time of anesthesia until H48
62126325|NCT06326632|EXPERIMENTAL|CL-AE group|The CL-AE group received a 12-week constant-load aerobic training besides the respiratory retraining program.
62126326|NCT06326632|EXPERIMENTAL|G-AE group|The G-AE group received a 12-week intensity- and duration-graded aerobic training in addition to the respiratory re-training.
62126327|NCT06326632|ACTIVE_COMPARATOR|Control group|The control group received the respiratory re-training only for 12 consecutive weeks.
62126328|NCT00781378|ACTIVE_COMPARATOR|Group 1|rt-PA 100 mg continuous intravenous infusion for 2 hours
62126329|NCT00781378|EXPERIMENTAL|group 2|rt-PA 50 mg continuous intravenous infusion for 2 hours
62316519|NCT06184919||Patients and caregivers|Patients attending the Perioperative Optimization of Senior Health (POSH) clinic
62316520|NCT06184919||Healthcare providers|Healthcare providers referring to or working in the Perioperative Optimization of Senior Health (POSH) clinic
62316521|NCT01376830||COPD patients|
62316522|NCT04384640||Patients seated after Intra-Tympanic injection|
62316523|NCT04918940|EXPERIMENTAL|Post-vaccination immunity|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
62316524|NCT00598533|EXPERIMENTAL|Dual-DES|Rapamycin + Probucol-eluting stent
62316525|NCT00598533|ACTIVE_COMPARATOR|ZES|Polymer based Zotarolimus-eluting stent
62316526|NCT02444637|EXPERIMENTAL|Rivastigmine (Exelon) Patch|For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.
62316527|NCT05023486|EXPERIMENTAL|NP-G2-044 Monotherapy - Capsule/Tablet|NP-G2-044 capsule/tablet PO QD for each 28-day cycle
62316528|NCT05023486|EXPERIMENTAL|NP-G2-044 Combination Therapy With Anti-PD-1 Therapy|NP-G2-044 capsules PO QD for each 28-day cycle, Anti-PD-1 Therapy per standard of care, at a dose and frequency in accordance with the package insert
62316529|NCT03731416|PLACEBO_COMPARATOR|GBR by xenograft|"* Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~* Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* • The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
62316530|NCT03731416|ACTIVE_COMPARATOR|GBR by xenograft ,autogenous bone|Intervention In the control group:first crestal incision then two vertical incisions by blade 15c,full thickness flap reflection, bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area(atrophic maxilla) then covered by a native collagen membrane which will be stabilized by tacks.Then The flap will then be closed using interrupted 4/0 resorbable sutures.
62316531|NCT02225067|EXPERIMENTAL|C13-CAC|
62339693|NCT06349733|EXPERIMENTAL|Injection 1 U / 0.1ml BTXA|Botulinum toxin type A (BTXA) was injected into both sides of the knife edge immediately after operation, the injection volume was 1U/0.1ml per point, the interval between the injection points on the same side of the knife edge was 1cm, and the distance of each injection point from the knife edge was 0.5cm. It was injected only once immediately after operation.
62479152|NCT00984022|ACTIVE_COMPARATOR|Iodoform dressing|Iodoform dressing for cutaneous abscess
62316532|NCT05173272|EXPERIMENTAL|Experimental: Neoadjuvant Therapy+CCRT|Patients will be treated with 2 cycles of neoadjuvant chemotherapy (Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21) combined with serplulimab （300mg d1 q21）. After that, weekly cisplatin 30mg/m\^2 for 4 or 5 weeks is administered concomitant with external beam radiotherapy (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes. The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors. All radiotherapy should be completed within eight weeks.
62316533|NCT05173272|EXPERIMENTAL|Experimental: CCRT alone|weekly cisplatin 40mg/m\^2 for 4 or 5 weeks is administered concomitant with external beam radiotherapy (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes. The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors. All radiotherapy should be completed within eight weeks.
62316534|NCT03524365|ACTIVE_COMPARATOR|RYGB plus LM counselling|96 subjects with NASH
62316535|NCT03524365|ACTIVE_COMPARATOR|SG plus LM counselling|96 subjects with NASH
62316536|NCT03524365|SHAM_COMPARATOR|ILM|96 subjects with NASH
62479153|NCT00984022|ACTIVE_COMPARATOR|Aquacel dressing|Aquacel dressing for cutaneous abscess
62686127|NCT04565353|EXPERIMENTAL|Information Basic Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain basic information about getting the flu. Participants will also receive a reminder message the day before the appointment.
62686128|NCT04565353|EXPERIMENTAL|Information Control Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain information about exercising. Participants will also receive a reminder message the day before the appointment.
62686129|NCT04565353|EXPERIMENTAL|Sharing Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
62126330|NCT05861193|EXPERIMENTAL|Cases|Patients belonging to the intervention group presented abfraction lesions in upper and/or lower premolars. These abfraction lesions consist of a loss of dental hard tissue at the cervical level of more than 1 mm, and are associated with type 1 gingival recession of the Cairo classification.
62126331|NCT02468297|EXPERIMENTAL|Electronic Acupuncture Shoe|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week."
62126332|NCT02468297|PLACEBO_COMPARATOR|Control group|Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
62126333|NCT02968225|EXPERIMENTAL|Computer Game|"All Computer Game participants will complete:~* online screening~* Diagnostic and eye-tracking pre-testing~* 2 month intervention~* Eye-tracking post-testing"
62479154|NCT01857934|EXPERIMENTAL|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.~Cells for infusion are prepared using the CliniMACS System."
62479155|NCT05456360|OTHER|Intervention group|Participants will receive sleep enhancement intervention and will wear the ViSi Mobile device.
62686130|NCT04565353|EXPERIMENTAL|No Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot.
62686131|NCT04565353|EXPERIMENTAL|Healthy Habits Easy Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of easy health behaviors (e.g., whether they walked 500 feet yesterday, at least two serving of fruits and vegetables in the last week, and slept at least 6 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
62126334|NCT02968225|NO_INTERVENTION|Waitlist control|"All Treatment as usual control participants will complete:~* online screening~* Diagnostic and eye-tracking pre-testing~* Eye-tracking post-testing"
62126335|NCT03908671|EXPERIMENTAL|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with advanced esophageal and non-small cell lung cancers
62126336|NCT05907473|EXPERIMENTAL|Conventional Rehabilitation Group|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
62126337|NCT05907473|EXPERIMENTAL|Virtual Reality Therapy Group|The patients in this group will be able to play balance-based games with the Virtual Reality System for 20 minutes, 3 days a week, together with the conventional rehabilitation program.
62126338|NCT00687167|EXPERIMENTAL|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
62126339|NCT00687167|EXPERIMENTAL|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
61924522|NCT03551353||Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
61924523|NCT03551353||Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
62316537|NCT01810146|NO_INTERVENTION|Digestive functions investigations|Results from digestive functions investigations will be compared between patients eligible for bariatric surgery (BMI\>40kg/m2) and volunteers (BMI between 20 and 25kg/m2).
62686132|NCT04565353|EXPERIMENTAL|Healthy Habits Difficult Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of difficult health behaviors (e.g., whether they walked 3 miles yesterday, ate 4-6 servings of fruits and vegetables yesterday, and slept at least 9 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
62686133|NCT04565353|EXPERIMENTAL|Healthy Habits Control Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot.
62686134|NCT04565353|EXPERIMENTAL|Just-In-Time Reminders 24-Hour Condition|Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 24 hours before their appointment.
62686135|NCT04565353|EXPERIMENTAL|Just-In-Time Reminders 15-Minute Condition|Just-In-Time Reminders 15-Minute Condition: Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 15 minutes before their appointment.
62686136|NCT01522274|ACTIVE_COMPARATOR|Moderate intensity exercise|Brisk walk on treadmill for 56 minutes 3x per week.
62686137|NCT01522274|ACTIVE_COMPARATOR|Health education|Attend health education sessions 3x per week.
62686138|NCT01714063||Age 5-6.5|Group 1 will consist of 16 children aged 5-6.5 years
62686139|NCT01714063||Aged 6.6- 8 years|Group 2 will consist of 16 children aged 6.6- 8 years
62686140|NCT00000437|EXPERIMENTAL|Naltrexone Tablet and Nicotine Patch|
62686141|NCT00000437|ACTIVE_COMPARATOR|Naltrexone Tablet and Placebo Patch|
61924524|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
61924525|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
61924526|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
61924527|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
62686142|NCT00000437|ACTIVE_COMPARATOR|Placebo Tablet and Nicotine Patch|
62316538|NCT05382676||Visual Function|automated vision measured by EyeSwift®Pro-ESP100
62316539|NCT01977534||Absorb BVS|Subjects receiving Absorb BVS
62316540|NCT02865044|ACTIVE_COMPARATOR|Wax Ester Marine Oil|Active: Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules)
62686143|NCT00000437|PLACEBO_COMPARATOR|Placebo Tablet and Placebo Patch|
62686144|NCT04196920||Cohort with TNF combination therapy|Cohort with TNF combination therapy (infiximab/adalimumab) with azathiorpine
61924528|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 5|Participants will self-administer an e-cigarette e-liquid.
61924529|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 6|Participants will self-administer an e-cigarette e-liquid.
61924530|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 7|Participants will self-administer an e-cigarette e-liquid.
62316541|NCT02865044|OTHER|Ethyl Ester Marine Oil|Control: Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule)
62316542|NCT06287125||systemic sclerosis patients|"Adult (aged above 18 years) SSc patients who fulfilled the 2013 European League Against Rheumatism/American College of Rheumatology (EULAR / ACR) for SSC and 1980 ACR criteria.~-SSc patients will be subjected to 2017 European Scleroderma Trials and Research group (EUSTAR) activity index"
62316543|NCT06287125||systemic lupus erythematosus patients|"Adult SLE Patients who fulfilled the 2019 EULAR / ACR classification criteria for systemic lupus erythematosus.~-SLE patients will be subjected to SLE Disease Activity Score (SLE-DAS)."
62316544|NCT06287125||Healthy controls|Apparently healthy subjects
62686145|NCT04196920||Cohort with anti-TNF combination therapy|Cohort with anti-TNF combination therapy (infiximab/adalimumab) with methotrexate
62686146|NCT03621215|EXPERIMENTAL|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK) diluted with 220 mL of water once per day (250 mL total volume per day). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries per day.
62686147|NCT03621215|PLACEBO_COMPARATOR|Fruit-flavoured placebo drink|"Matched for sensory characteristics and energy (with the addition of glucose).~once per day (250 mL total volume per day)"
62686148|NCT06358508|EXPERIMENTAL|Sapphire 3 Coronary Dilatation Catheter|Single arm with investigational Sapphire 3 Coronary Dilatation Catheters
62479156|NCT05456360|OTHER|Control group|Participants will receive sleep enhancement intervention only. Participants in the control group will not wear the ViSi Mobile device.
62686149|NCT00561821|EXPERIMENTAL|Esmirtazapine 0.5 mg|one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
62686150|NCT00561821|EXPERIMENTAL|Esmirtazapine 1.5 mg|one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
62126340|NCT01926678|EXPERIMENTAL|Swedish massage therapy|Swedish massage therapy once per week for 6 weeks
62126341|NCT01926678|ACTIVE_COMPARATOR|Light touch therapy|Light touch therapy once per week for 6 weeks
62126342|NCT01926678|OTHER|Wait list|A 6 week wait list, followed by randomization to massage therapy or light touch therapy once per week for 6 weeks
62316545|NCT03925428|EXPERIMENTAL|Treatment (entinostat, molibresib)|Patients receive entinostat PO on days 1, 8, 15, and 22 and molibresib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62316546|NCT01898546|EXPERIMENTAL|Primary angioplasty and postconditioning|Primary angioplasty followed by postconditioning
62316547|NCT01898546|ACTIVE_COMPARATOR|Primary angioplasty|Primary angioplasty alone
62479157|NCT03606174|EXPERIMENTAL|Cohort 1|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
61924531|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 8|Participants will self-administer an e-cigarette e-liquid.
62126343|NCT01112670|EXPERIMENTAL|ABCB1 Group 1|ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
62316548|NCT04122768|EXPERIMENTAL|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
62316549|NCT04122768|SHAM_COMPARATOR|Sham coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application.
62316550|NCT03609229|EXPERIMENTAL|Study group|Abdominal Sacrocolpopexy with burch technique
62316551|NCT03609229|ACTIVE_COMPARATOR|control group|Abdominal Sacrocolpopexy without burch technique
62316552|NCT01892254|EXPERIMENTAL|Metformin-Placebo|Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo
62316553|NCT01892254|PLACEBO_COMPARATOR|Placebo-metformin|Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet
62479158|NCT03606174|EXPERIMENTAL|Cohort 2|Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
62686151|NCT00561821|EXPERIMENTAL|Esmirtazapine 3.0 mg|one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
62686152|NCT00561821|PLACEBO_COMPARATOR|Placebo|one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days
62686153|NCT03871504|EXPERIMENTAL|submaximal isometric exercise.|submaximal isometric exercise will be performed.
62686154|NCT03871504|NO_INTERVENTION|Quiet rest.|Subject will rest in seating position for a period that mimics the exercise time.
62686155|NCT06596135|EXPERIMENTAL|Setelanotide (Open-label)|Once daily (QD) subcutaneous injection of setmelanotide
62686156|NCT06135324||Prevalence of Cognitive impairment and impaired manual dexterity|Determine the prevalence of both cognitive impairment and impaired manual dexterity in stable out-patients with COPD
62126344|NCT01112670|EXPERIMENTAL|ABCB1 Group 2|ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
62126345|NCT01112670|EXPERIMENTAL|ABCB1 Group 3|ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
62126346|NCT05583539|NO_INTERVENTION|Usual Care|Patients will receive usual care at the discretion of their providers.
62126347|NCT05583539|EXPERIMENTAL|Thromboelastography guided resuscitation|Patients will undergo thromboelastography testing that will be used by primary providers to guide blood product resuscitation.
62126348|NCT02077426|EXPERIMENTAL|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises
61924532|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 9|Participants will self-administer an e-cigarette e-liquid.
61924533|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 10|Participants will self-administer an e-cigarette e-liquid.
61924534|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 11|Participants will self-administer an e-cigarette e-liquid.
61924535|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 12|Participants will self-administer an e-cigarette e-liquid.
61924536|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 13|Participants will self-administer an e-cigarette e-liquid.
61924537|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 14|Participants will self-administer an e-cigarette e-liquid.
62126349|NCT04536519|ACTIVE_COMPARATOR|Lateral Heel Wedged Insole Alone with physical therapy|"the lateral heel wedged insole (19) comprised non-custom, high density based on insoles of ethyl-vinyl acetate distributed bilaterally, preferably, covered in leather, were used in the study. The insole were equipped with a lateral wedge of 50 to 60.~In the case of unilateral knee osteoarthritis, the non-wedge insole were used to compensate for possible leg length discrepancy in the contra-lateral leg. Shoes used was based on gymnast type to keep wedge insole in place. This further finalized individual to individual with unanimous decisions of Cordwainers, orthotics, and principal researcher, physiotherapist."
62126350|NCT04536519|ACTIVE_COMPARATOR|Lateral aand medial Heel Wedged Insole with physiotherapy|medial arch support part were combine with aforementioned lateral heel wedged support, full length support. There is a debate, however, 4 to 6 mm of full length support is considered to be effective for required alteration in mechanics
62126351|NCT02000349|EXPERIMENTAL|Frozen Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (\*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by NGS, and will have one or two euploid embryo(s) thawed and transferred on a FET cycle, before noon. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (\*).
61924538|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 15|Participants will self-administer an e-cigarette e-liquid.
61924539|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 16|Participants will self-administer an e-cigarette e-liquid.
61924540|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 17|Participants will self-administer an e-cigarette e-liquid.
61924541|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 18|Participants will self-administer an e-cigarette e-liquid.
61924542|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 19|Participants will self-administer an e-cigarette e-liquid.
61924543|NCT04399031|EXPERIMENTAL|E-cigarette e-liquid 20|Participants will self-administer an e-cigarette e-liquid.
62126352|NCT02000349|EXPERIMENTAL|Fresh Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (\*) biopsied on day 5, analyzed by NGS, and will have one or two euploid embryo transferred on day 6, in the am. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (\*). Any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
62316554|NCT03465852|EXPERIMENTAL|Intervention arm|"Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, and will receive the Spanish language ChiCAS intervention shortly after being randomized and will complete a follow-up assessment 6 months after completing the intervention.~."
61924544|NCT04208581|EXPERIMENTAL|Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive Yiqi Huoxue Huatan granule in addition to Western medicine.
61924545|NCT04208581|PLACEBO_COMPARATOR|Placebo Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive placebo Yiqi Huoxue Huatan granule in addition to Western medicine.
61924546|NCT01323842||rule in renal colic|ED patients with abdominal/flank pain where a diagnosis of renal colic is being considered and undergoing formal imaging while in the ED
61924547|NCT02707809|NO_INTERVENTION|Control|Routine anesthesia care for kidney transplant
62479159|NCT03606174|EXPERIMENTAL|Cohort 3|Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
61924548|NCT02707809|EXPERIMENTAL|Dexmedetomidine|Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine
62316555|NCT03465852|OTHER|Wait list comparison (control) arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, but will not receive the Spanish language ChiCAS intervention until they complete a follow-up assessment 6 months after completing the baseline assessment.
62316556|NCT05436808|EXPERIMENTAL|Radiation Treatment|
62316557|NCT03207828|EXPERIMENTAL|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
62126353|NCT03426878|ACTIVE_COMPARATOR|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
62126354|NCT03426878|EXPERIMENTAL|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
62126355|NCT00865436|EXPERIMENTAL|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
62126356|NCT00865436|ACTIVE_COMPARATOR|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
62316558|NCT03207828|OTHER|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
62316559|NCT03805295|EXPERIMENTAL|Spring 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Winter-Spring 2018. They will serve as the control group in Fall 2018.
62316560|NCT03805295|EXPERIMENTAL|Fall 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Fall 2018.
62316561|NCT01288040|EXPERIMENTAL|Treadmill exercise|Split-belt treadmill training
62316562|NCT06173752|EXPERIMENTAL|Exposure therapy|"Participants will complete exposure therapy for up to 12 weeks, and each coached exposure session will be approximately 50 minutes. Exposure plans will be developed collaboratively between participants and their clinician at the beginning of treatment, and refined iteratively as clinically appropriate. In each coached exposure, participants will:~1. Complete an Exposure Feedback Form~2. Wear a wristwatch that provides psychophysiological data~The intervention will occur across two study sites (McLean Hospital, San Diego State University). Sites will differ on level of care. At McLean Hospital, participants will be recruited from the OCD Institute and will receive exposure therapy via partial hospital or residential setting as part of their standard care, regardless of participation in the study. At San Diego State University, participants will be recruited to receive exposure therapy via outpatient setting."
62316563|NCT00950352|EXPERIMENTAL|Citicoline|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
62316564|NCT00950352|PLACEBO_COMPARATOR|Placebo|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
62316565|NCT00767195||1. Control group|Patients in the intensive care unit who have no pulmonary edema
62126357|NCT02047981|ACTIVE_COMPARATOR|Biannual mass oral azithromycin|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.~In Niger during year 3, all communities will be offered azithroymcin."
62126358|NCT02047981|PLACEBO_COMPARATOR|Biannual mass oral placebo|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~In Niger during year 3, all communities will be offered azithroymcin."
62126359|NCT00677391|ACTIVE_COMPARATOR|1|
62126360|NCT00677391|PLACEBO_COMPARATOR|2|
62126361|NCT00540748|EXPERIMENTAL|A1|
62126362|NCT00540748|NO_INTERVENTION|A2|
62126363|NCT01655888|EXPERIMENTAL|single arm with Tremelimumab|Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity
62126364|NCT04066725|EXPERIMENTAL|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 60 days
62126365|NCT04066725|EXPERIMENTAL|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 60 days.
62126366|NCT04066725|PLACEBO_COMPARATOR|Placebo|Participants will be given a placebo orally once daily for a total of 60 days.
62126367|NCT05798273|OTHER|intra-arterial injection of [68Ga]Ga-PSMA-11|eligible for intra-arterial injection (age \>18 years) with enhancing glioma or brain metastases eligible for (re-)resection.
62316566|NCT00767195||2. Study group 1|Patients with cardiogenic pulmonary edema in the intensive care unit
62316567|NCT00767195||3. Study group 2|Patients with non-cardiogenic pulmonary edema in the intensive care unit
62126368|NCT01778283|EXPERIMENTAL|Acetate-free solution first|Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
62126369|NCT01778283|ACTIVE_COMPARATOR|Acetate-based solution first|Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
62126370|NCT05868772||Active Sentry Handpiece|At low IOP settings
62126371|NCT05868772||Ozil Handpiece|At high IOP settings
62126372|NCT05289258|ACTIVE_COMPARATOR|Neuropsychological treatment|Combination of different neuropsychological rehabilitation programs
62126373|NCT05289258|EXPERIMENTAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED).
62126374|NCT05289258|OTHER|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
62126375|NCT02240446|EXPERIMENTAL|Active tDCS|Active tDCS
62126376|NCT02240446|PLACEBO_COMPARATOR|Sham tDCS|Sham tDCS
62126377|NCT05075941||Shelters Paris/93|
62126378|NCT05075941||Workers' hostels Paris/93|
62126379|NCT05075941||travelling community IDF(77/93/95)|
62126380|NCT05075941||Street/Camps Paris/93|
62316568|NCT04952389|EXPERIMENTAL|Acupuncture Therapy Group|Subjects will undergo ten sessions of acupuncture therapy with a licensed acupuncturist in addition to the standard of care.
62316569|NCT04952389|ACTIVE_COMPARATOR|Standard of Care|Subjects will be treated with two times daily budesonide rinses and olfactory (sense of smell) training. This is considered the current standard of care in the treatment of olfactory dysfunction.
62316570|NCT02502877|OTHER|Midazolam Group|"In the midazolam group the investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after."
61924549|NCT02525315|EXPERIMENTAL|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
61924550|NCT02745067|OTHER|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
62126381|NCT05075941||Covid Homeless and migrants Marseille|
62126382|NCT05075941||Hostel Paris/93|
62126383|NCT05536830||Participant dyads: Caregivers and Care Recipients|Participants will be recruited in pairs as caregivers and care recipients. All data collected is observational in nature.
62126384|NCT03946007||Patients with melanoma or NSCLC|Patients (age ≥18 years) with melanoma or NSCLC ≥2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG.
62126385|NCT03133039|ACTIVE_COMPARATOR|bioabsorbable screw|
62126386|NCT03133039|ACTIVE_COMPARATOR|titanium screw|
62126387|NCT01533870|EXPERIMENTAL|NKTR-118|Single dose NKTR-118 25 mg on Day 1 only
62126388|NCT01533870|ACTIVE_COMPARATOR|Rifampin|Rifampin 600 mg once daily on Days 4 to 12
62126389|NCT01533870|ACTIVE_COMPARATOR|Rifampin/ NKTR-118|Rifampin 600 mg plus NKTR-118 25 mg on Day 13
62126390|NCT04701879|ACTIVE_COMPARATOR|Spine decompression with core stability exercises|Interventions in experimental group includes Hot pack, Spinal decompression therapy and core stability exercises
62316571|NCT02502877|ACTIVE_COMPARATOR|Propofol group|"In the propofol group the investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery."
62316572|NCT06080113|EXPERIMENTAL|Treatment group|Curative targeted focal brachytherapy treatment for localized unifocal prostate-cancer
62316573|NCT06096233|NO_INTERVENTION|Control|The participants will not perform any exercise.
62316574|NCT06096233|EXPERIMENTAL|Short Exercise|The participants will run on the treadmill for 10 minutes.
62316575|NCT06096233|EXPERIMENTAL|Prolonged Exercise|The participants will run on the treadmill for 30 minutes.
62126391|NCT04701879|EXPERIMENTAL|Spine decompression|Intervention includesHot pack and spinal decompression therapy ..
62126392|NCT01368198|ACTIVE_COMPARATOR|Ocular Emulsion|An Ocular Emulsion
62126393|NCT01368198|ACTIVE_COMPARATOR|OPTIVE™|An OPTIVE™
62126394|NCT00944333|EXPERIMENTAL|Clopidogrel 6|6 month dual antiplatelet therapies in patients after second generation DES implantation
62126395|NCT00944333|EXPERIMENTAL|Clopidogrel 12|12 month dual antiplatelet therapies in patients after second generation DES implantation
62126396|NCT00643929||Observational|Subjects who have participated in a prior eltrombopag study, receiving either placebo or eltrombopag
62126397|NCT06314763|EXPERIMENTAL|Single dose rivaroxaban 20 mg and steady-state sotorasib 960 mg|To assess the pharmacokinetics of single dose rivaroxaban in presence and absence of 960 mg sotorasib at pharmacokinetic steady-state. Samples will be taken pre-dose (t=0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 hours post ingestion.
62686157|NCT06135324||Assess relationship of impairments with patient errors using pMDI, SMI, and/or DPIs|assess the relationships of cognitive impairment and impaired manual dexterity with patient errors using their prescribed, current pMDIs, SMIs, and/or DPIs.
62316576|NCT03037320|EXPERIMENTAL|group A|root coverage to be performed by semilunar vestibular incision technique
62126398|NCT01839526|OTHER|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
62126399|NCT04753580|EXPERIMENTAL|group 1|healthy adult 20-35 years old
62126400|NCT04753580|EXPERIMENTAL|group 2|healthy elderly 65+ years old
62126401|NCT04753580|EXPERIMENTAL|group 3|Frail elderly 65+ years old
62126402|NCT05386498|EXPERIMENTAL|Precure composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
62126403|NCT05386498|EXPERIMENTAL|Contact Making Instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
62126404|NCT05386498|ACTIVE_COMPARATOR|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
62126405|NCT05110105|EXPERIMENTAL|Intervention|Participants will receive interactive board game health education.
62126406|NCT05110105|ACTIVE_COMPARATOR|Control|Participants will receive conventional health education.
62126407|NCT02015520|EXPERIMENTAL|Arm 1: Clazakizumab (Dose # A) (Double-Blind)|Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
62126408|NCT02015520|EXPERIMENTAL|Arm 2: Clazakizumab (Dose # B) (Double-Blind)|Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
62126409|NCT02015520|EXPERIMENTAL|Arm 3: Clazakizumab (Dose # C) (Double-Blind)|Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
62126410|NCT02015520|EXPERIMENTAL|Arm 4: Placebo matching with Clazakizumab (Double-Blind)|Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
62316577|NCT03037320|OTHER|group B|root coverage by coronally advanced flap
62316578|NCT00650429|EXPERIMENTAL|Arm A|
62316579|NCT03690258|EXPERIMENTAL|Variable load exercise|"Variable load intervention (The nHANCE-squat ultimate - iso-inertial load, with power output in watts performed 3 x per week) will being performed to determine whether this training approach is an effective countermeasure to attenuate for rapid declines in muscle power, function, contractile capacity that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in seniors.~Data available at: http://nhance.se/"
62126411|NCT03472755|OTHER|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
62339694|NCT06349733|EXPERIMENTAL|Injection 2.5U / 0.1ml BTXA|Botulinum toxin type A (BTXA) was injected into both sides of the knife edge immediately after operation, the injection volume was 2.5U/0.1ml per point, the interval between the injection points on the same side of the knife edge was 1cm, and the distance of each injection point from the knife edge was 0.5cm. It was injected only once immediately after operation.
62479160|NCT03606174|EXPERIMENTAL|Cohort 4|Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
62686158|NCT01635530|ACTIVE_COMPARATOR|Ceftriaxone|Treatment of intravenous ceftriaxone (2 g/day), three weeks
62686159|NCT01635530|EXPERIMENTAL|Doxycycline|Treatment with oral doxycycline (200mg / day), four weeks
62686160|NCT04628052|EXPERIMENTAL|Music|
62686161|NCT04628052|NO_INTERVENTION|No-Music|
62686162|NCT05836220|EXPERIMENTAL|Double-Blind Phase PLS240|
62686163|NCT05836220|PLACEBO_COMPARATOR|Double-Blind Phase Placebo|
62316580|NCT03690258|EXPERIMENTAL|Variable load intervention|"This study is being conducted to determine whether this variable load (The nHANC dead lift - eccentric overload performed 3 x per week for 4-6 weeks) intervention is an effective countermeasure to modulate blood pressure in seniors. Since age-related incline in resting blood pressure (hypertension) is accelerated already after short bouts of physical inactivity, any attempt to counteract age-related and disuse-related decline have high clinical significance. In addition, we aim to examine endothelial function via non-invasive flow mediated dilatation (FMD) technique.~Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in this specific population. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system, especially for reducing economic burden."
62316581|NCT05986344||Copper intrauterine contraceptive device|Women will have the copper T-380 IUD (silverline, imported by DKT Egypt LLC-Egypt) ® IUD.
62316582|NCT05986344||Levonorgestrel Intrauterine System|Women will recieve the LNG-IUS (Mirena, Bayer HealthCare, Berlin, Germany)® IUD .
62479161|NCT03606174|EXPERIMENTAL|Cohort 5|Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
62126412|NCT03472755|OTHER|Direct anterior techniques.|. In the direct anterior technique, patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached.
62126413|NCT01323231|EXPERIMENTAL|Communities in Schools Services|Communities in Schools services include case management, mental health services, mentorship services, after school programs, and academic assistance.
62126414|NCT05075083|EXPERIMENTAL|Experimental Group|A total 400 subjects receive two doses inactivated COVID-19 vaccine with the interval of 21 days
62126415|NCT05384210|ACTIVE_COMPARATOR|Milnacipran|Patients will receive Milnacipran as a mono-therapy will be administered in increment doses for 3 months
62126416|NCT05384210|ACTIVE_COMPARATOR|Gabapentin|patients will receive Gabapentin as a mono-therapy will be administered in increment doses for 3 months
62126417|NCT05384210|ACTIVE_COMPARATOR|Combined gabapentin/milnacipran|Patients will receive combined gabapentin and milnacipran as a combination therapy will be administered in increment doses for 3 months
62126418|NCT05403567|EXPERIMENTAL|Bootle Blast Intervention|Children will play the Bootle Blast game at home for 8 continuous weeks.
62126419|NCT05598580|EXPERIMENTAL|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy. After that, participants will be monitored for another 24 weeks.
62126420|NCT05598580|EXPERIMENTAL|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy. After that, participants will be monitored for another 24 weeks.
62126421|NCT05598580|NO_INTERVENTION|Control|Participants will continue to receive antiretroviral therapy without other intervention and be monitored for 48 weeks.
62126422|NCT06451913|EXPERIMENTAL|Amoxicillin + Saccharomyces boulardii CNCM I-745|The patients will received oral Amoxicillin (1000 mg capsules bid) for 14 days and oral Saccharomyces boulardii CNCM I-745 (®) 250 mg x 2 capsules twice a day for 21 days.
62479162|NCT03606174|EXPERIMENTAL|Cohort 6|Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
62479163|NCT03606174|EXPERIMENTAL|Cohort 7|Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
62126423|NCT06451913|PLACEBO_COMPARATOR|Amoxicillin + Placebo|The patients will received oral Amoxicillin (1000 mg capsules bid) for 14 days + oral Placebo capsules for 21 days.
62126424|NCT01993160|EXPERIMENTAL|18F-FCH PET MR|Integrated whole body PET-MR or PET-CT and separate whole body MRI with use of 18F-FCH as the molecular probe
62126425|NCT06394271|EXPERIMENTAL|Early EVAR|Endovascular aneurysm repair within 2 months of randomisation using any licensed infrarenal aortic endograft within the manufacturer's instructions for use.
62126426|NCT06394271|NO_INTERVENTION|Surveillance|Regular imaging surveillance (ultrasound or CT) of aneurysm diameter until the diameter reaches 5.5 cm, develops symptoms of impending rupture or ruptures. The delayed repair may be by any method.
62126427|NCT03731377|EXPERIMENTAL|Intubated group|Patient in this group will receive general anesthesia with endotracheal tube intubation to perform one lung ventilation. Patient will be paralyzed and controlled ventilation will be implied.
62126428|NCT03731377|EXPERIMENTAL|Non-intubated group|Patient in this group will receive general anesthesia with laryngeal mask insertion. Patients in this group will not be paralyzed and keep spontaneous breathing to maintain one lung ventilation.
62316583|NCT05882162|ACTIVE_COMPARATOR|Control Group|A scalpel number 15 was used to raise a triangular or envelope-shaped full-thickness mucoperiosteal flap. The bone in the buccal cavity of the third molar was removed with steel rounds and fissure burs to reach the cementum-enamel boundary. 3/4 of the tooth was cut bucco-lingually from 1-2 mm apical to the enamel cement border with the help of a high-speed surgical handpiece with a fissure steel bur. The root surface was positioned 2-3 mm apically from the surrounding alveolar bone level with the help of a steel round bur. The remaining enamel tissue and pulpal tissue in the coronal part were completely removed. Calcium silicate material was not used for pulp capping of the root pulp. During the procedure, the mandibular second molar's surface was curetted, and the surgical area was rinsed with saline solution to remove any potential surgical debris. The required number of simple sutures were used to close the surgical field without tension.
62339695|NCT06349733|EXPERIMENTAL|Injection 5U / 0.1ml BTXA|Botulinum toxin type A (BTXA) was injected into both sides of the knife edge immediately after operation, the injection volume was 5U/0.1ml per point, the interval between the injection points on the same side of the knife edge was 1cm, and the distance of each injection point from the knife edge was 0.5cm. It was injected only once immediately after operation.
62686164|NCT05836220|EXPERIMENTAL|Open-Label Extension Phase PLS240|After completion of the Double-Blind Phase, all participants will have the opportunity to enroll in the 26 week Open-Label extension, where they will receive PLS240.
62686165|NCT02257021|EXPERIMENTAL|Tipranavir and high dose of ritonavir plus BILR 355 BS|
62686166|NCT02257021|EXPERIMENTAL|BILR 355 BS with low dose of ritonavir|
62686167|NCT01066299|EXPERIMENTAL|oxitocin nasal spray|oxytocin nasal spray
62686168|NCT01066299|PLACEBO_COMPARATOR|placebo|inactive nasal spray
62686169|NCT06439329|ACTIVE_COMPARATOR|Standard Patient Navigation (PN)|"PNs are near-peer professionals who have shared lived experiences with participants and help them overcome barriers to accessing and engaging in quality care. PNs are trained and linked to PrEP/ART and SUD services. This manualized PN approach provides appointment scheduling to brick and mortar services only, and not to MHU or telehealth services."
62686170|NCT06439329|EXPERIMENTAL|PN + Patient Choice (PC) (PN+PC)|PNs working in the PN + PC arm will be trained to engage participants in selecting from the menu of options developed in the pilot. This menu of SUD and HIV prevention and treatment service delivery options will be created through bolstering and working with our CAB.
62686171|NCT06026332||ADSTILADRIN|
62686172|NCT05012618|EXPERIMENTAL|Dose escalation part (Part A)|Patients will receive LUNA18 capsule(s) at escalated doses
62686173|NCT05012618|EXPERIMENTAL|Biomarker part (Part B)|Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A
62686174|NCT05012618|EXPERIMENTAL|Cohort expansion part (Part C)|Patients will receive LUNA18 capsule(s) at the recommended dose
62686175|NCT05012618|EXPERIMENTAL|Backfill part (Part AA)|Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A
61924551|NCT04639037|ACTIVE_COMPARATOR|Manual adjustment of vasopressor|Fluid and vasopressor will be managed as standard practice guided by the EV1000 monitoring device (manually infusion of both fluid and vasopressors) Objective being to maintain MAP within a target MAP range of 80-90 mmHg (fluid will be optimized and stroke volume index will be maintained within normal values)
62686176|NCT05012618|EXPERIMENTAL|Dose finding part (Part D)|Patients will receive LUNA18 capsule(s) in combination with cetuximab at finding doses
62686177|NCT05012618|EXPERIMENTAL|Cohort expansion part (Part E)|Patients will receive LUNA18 capsule(s) in combination with cetuximab at the recommended dose
62686178|NCT06114641|EXPERIMENTAL|Control|Enoxaparin will be given for 3 to 8 days or until clinically stable as per its current approval for use in UA and NSTEMI. The minimum duration of therapy will be 3 days; however, catheterization and PCI can be scheduled earlier than this time as indicated. Initial 30 mg IV loading dose is administered and followed by 1 mg/kg subcutaneously every 12 hours
62686179|NCT06114641|ACTIVE_COMPARATOR|Comparator|Originitaro Enoxaparin will be given for 3 to 8 days or until clinically stable as per its current approval for use in UA and NSTEMI. Initial 30 mg IV loading dose is administered and followed by 1 mg/kg subcutaneously every 12 hours
62126429|NCT03107546|OTHER|Skin graft|full thickness skin graft
62126430|NCT03107546|EXPERIMENTAL|Hyalomatrix|skin graft substitute
62126431|NCT06552728|EXPERIMENTAL|Fibromyalgia participants - Energy Healing Intervention|
62126432|NCT05948592|EXPERIMENTAL|TP-102|Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.
62126433|NCT05948592|PLACEBO_COMPARATOR|Placebo|Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.
62686180|NCT01872208|EXPERIMENTAL|Human Acellular Vessel (HAV)|HAV implantation to study participants.
62686181|NCT06144658|EXPERIMENTAL|Augmented Reality Headset Usability|In this arm, participants tested the functionality and usability of the headset (a Microsoft Hololens 2 or a Varjor XR3)
62686182|NCT05007860||No active therapy|Age ≥18 years and CLL/SLL (WHO criteria). We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, active therapy, treating physician intent to initiate CLL/SLL therapy within ≤2 months, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
62126434|NCT03062332||Bipolar disorder,mania|The group includes subjects who are diagnosed to mania episode of bipolar disorder.
62686183|NCT05007860||BTK inhibitor therapy (continued)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is continued through vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
62686184|NCT05007860||BTK inhibitor therapy (interrupted)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is interrupted at time of vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
62686185|NCT00310843||All study population|
62686186|NCT05690204|EXPERIMENTAL|Placebo versus SAP-001|Placebo arm
62126435|NCT03062332||Bipolar disorder,depressive|The group includes subjects who are diagnosed to depression episode of bipolar disorder.
62126436|NCT03062332||Bipolar disorder,mixed|The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
62126437|NCT03062332||First episode major depression|The group includes subjects who are diagnosed to first episode of major depression.
62126438|NCT03062332||major depression，recurrent|The group includes subjects who are diagnosed to recurrent episode of major depression.
62126439|NCT03062332||Healthy control|The group includes subjects who are Healthy control.
62126440|NCT01844492|ACTIVE_COMPARATOR|ICU Usual Care Control|described below
62126441|NCT01844492|EXPERIMENTAL|The PARTNER Intervention|described below
62126442|NCT02639910|EXPERIMENTAL|Cohort A|tafasitamab (MOR208) in combination with idelalisib
62126443|NCT02639910|EXPERIMENTAL|Cohort B|tafasitamab (MOR208) in combination with venetoclax
62126444|NCT05448846|ACTIVE_COMPARATOR|Control|Usual care (i.e., 'Enhanced Recovery After Surgery' (ERAS) protocol)
62126445|NCT05448846|EXPERIMENTAL|Home-based multicomponent exercise program|Complete a home-based multicomponent exercise program from diagnosis to 3 months after surgery in addition to ERAS protocol.
62126446|NCT05951309|EXPERIMENTAL|Myoinositol+D-chiroinositol+folic acid group|This group is given myoinositol+d-chiro inositol+folic acid once a day (inofolic combi, ITF company, Italy) (myoinositol 550 miligram+ d-chiroinositol 13,8 miligram+folic acid 200 micrograms)
62126447|NCT05951309|EXPERIMENTAL|Metformin group|This group is given metformin 500 miligram three times a day (glucophage 500mg, Merck company, Turkey) (total dose of metformin 1500 miligram a day)
62126448|NCT01771731|EXPERIMENTAL|Cannabis|Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
62126449|NCT01771731|PLACEBO_COMPARATOR|Placebo|Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
62126450|NCT03160599|EXPERIMENTAL|Restricted Calorie Ketogenic Diet|"Calorie restriction: The basis of dietary design is 70-85% of individual's total calories. The total calorie is based on patient's activity level and their basal metabolism values, which is obtained from indirect calorimetry or harris-benedict formula.~Treatment will consist of ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard."
62316584|NCT05882162|EXPERIMENTAL|Test Group|A scalpel number 15 was used to raise a triangular or envelope-shaped full-thickness mucoperiosteal flap. The bone in the buccal cavity of the third molar was removed with steel rounds and fissure burs to reach the cementum-enamel boundary. 3/4 of the tooth was cut bucco-lingually from 1-2 mm apical to the enamel cement border with the help of a high-speed surgical handpiece with a fissure steel bur. The root surface was positioned 2-3 mm apically from the surrounding alveolar bone level with the help of a steel round bur. The remaining enamel tissue and pulpal tissue in the coronal part were completely removed. Calcium silicate material was used for pulp capping of the root pulp. During the procedure, the mandibular second molar's surface was curetted, and the surgical area was rinsed with saline solution to remove any potential surgical debris. The required number of simple sutures were used to close the surgical field without tension.
62316585|NCT02157272|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 20mg qd, Rivaroxaban 15mg qd if creatinine clearance between 30-49 ml/min (calculated by Cockroft-Gault equation)
62316586|NCT02157272|ACTIVE_COMPARATOR|Warfarin|To Keep an INR between 2.0 and 3.0
62316587|NCT05024838||Spinal anesthesia|The investigators retrospectively collected the electronic medical record of patients receiving spinal anesthesia from July 1, 2018, to Dec 31, 2018. Patients less than 18 years old were excluded from this study.
62479164|NCT03606174|EXPERIMENTAL|Cohort 8|Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
62686187|NCT05690204|EXPERIMENTAL|SAP-001 low dose|SAP-001 low dose
62686188|NCT05690204|EXPERIMENTAL|SAP-001 middle dose|SAP-001 middle dose
62686189|NCT05690204|EXPERIMENTAL|SAP-001 high dose|SAP-001 high dose
62686190|NCT02105012|EXPERIMENTAL|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
62686191|NCT02105012|EXPERIMENTAL|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
62686192|NCT02105012|EXPERIMENTAL|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
62686193|NCT02105012|EXPERIMENTAL|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
62686194|NCT02105012|PLACEBO_COMPARATOR|Placebo MDI|Placebo MDI administered as 2 inhalations BID
62686195|NCT02489617|EXPERIMENTAL|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).~-- Pathologic evaluation of excised tissue"
62126451|NCT06155877|EXPERIMENTAL|LAMAP intervention|"Teachers receive two sets of activities, accompanied by a tutorial. Both sets of activities also include evaluation tools that teachers can use to clarify the objectives of the lesson and to assess the pupils' learning progress. The estimated length of each set is 5 hours.The activities and the tutorials were created by pedagogical experts of the Fondation La Main à la pâte, an NGO whose goal is to foster science education. Activities and tutorials are now freely available on the La Main a la pâte website. Teachers were free to choose whether to present the first or the second set of activities, and to choose how many of the activities to conduct. The actual length of the intervention thus varied from one classroom to another, which mimics ecological conditions. Teachers were asked to devote at least one hour to the activities.~LAMAP activities are available on the experiment's OSF repository"
62316588|NCT03851744|ACTIVE_COMPARATOR|Sea Level|Carbohydrate metabolism measured at SL
62686196|NCT06691555||Group 1 that includes Primary Open-Angle Glaucoma and Pseudoexfoliative Glaucoma Patients|This cohort includes patients diagnosed with primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) who have undergone suprachoroidal silicone tube (SST) shunt implantation. The study focuses on assessing the long-term safety and efficacy of the SST shunt, monitoring intraocular pressure (IOP) control, endothelial cell count (ECC) changes, and any adverse events over an extended follow-up period. This observational cohort includes patients aged 41-88 years, treated with the SST shunt either alone or in combination with cataract surgery, and meeting the inclusion criteria from a prior retrospective study.
62686197|NCT01019174|ACTIVE_COMPARATOR|oral application|oral application Cyclophosphamide
62686198|NCT01019174|ACTIVE_COMPARATOR|intravenous application|intravenous application Cyclophosphamide
62686199|NCT06220253|OTHER|Vaginal Hysterectomy by bipolar coagulation technique|The surgery will take place according to the canonical times of vaginal hysterectomy, after incision of the portio, detachment of the bladder-vaginal fascia and vaginal rectum, opening of the anterior and posterior peritoneum, taking, section and ligament of the ligaments uterus-sacral ligaments, and subsequent coagulation by bipolar instrument of the other structures of the uterus and their section, in particular of the uterine arteries, tubes, uterine-ovarian ligaments and round ligament bilaterally.
62686200|NCT06220253|OTHER|Vaginal hysterectomy by traditional technique with reabsorbable stitches|The surgery will take place according to the canonical times of vaginal hysterectomy, after incision of the port, detachment of the bladder-vaginal fascia and vaginal rectum, opening of the anterior and posterior peritoneum, taking and suturing with absorbable threads of all the support structures of the uterus, in particular uterus-sacral ligaments, uterine arteries, tubes, uterine-ovarian ligaments and round ligament bilaterally.
62686201|NCT01821846||Liraglutide|
62686202|NCT03889015|ACTIVE_COMPARATOR|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
62686203|NCT03889015|EXPERIMENTAL|probiotic yogurt|Probiotics are live microorganisms that confer oral health benefits by adhering to the oral mucosa and surface of teeth as a part of the biofilm thus preventing the adhesion, colonization, and proliferation of cariogenic bacteria inhibiting the formation of pathogenic plaque
62686204|NCT06307366||(Future) parents with (a partner with) mental illness in the mood-psychosis spectrum|"The following participants will be included: (Future) parents with (a partner with) mental illness in the mood-psychosis spectrum (psychotic disorder, bipolar disorder, severe depression); ≥ 18 years old.~If including (future) parents with mental illness and their partners will turn out to be difficult given our timeframe, we will mitigate this by additionally including family members of people with mental illness, e.g. siblings or grandparents."
62686205|NCT04341012||Normal|No known medical conditions
62686206|NCT04341012||Liver Cirrhosis|Clinically diagnosed with cirrhosis
62686207|NCT04341012||COVID-19 tested|Persons with known test results for COVID-19 RNA
62686208|NCT04341012||Other|Persons with other medical diagnosis, no known liver disease, negative for COVID-19
62686209|NCT02091128||Females with classic galactosemia and POI|
62686210|NCT02532907||Patients who will have their second Liver biopsy at week 4|The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
62686211|NCT02532907||Patients who will have their second Liver biopsy at week 12|Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
62686212|NCT05541666||The Emotional Freedom Technique Group|"After the patients in the case group are determined, the scales will be introduced. The patient information form, State-Trait Anxiety Inventory and Visual Analog Scale will be filled. After that, the emotional freedom technique will be explained.~On the postoperative 1st and 2nd days, firstly pain and anxiety levels will be measured with the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales. And then one session of emotional freedom technique that is approximately 30 minutes, will be applied. And after all, the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales will be applied again."
62686213|NCT05541666||Control Group|The patient in the control group will be interviewed on the preoperative 1sy day and the scales will be introduced, The patient information form, State-Trait Anxiety Inventory and Visual Analog Scale will be filled. On the postoperative 1st and 2nd days, no application will be made other than the clinical protocols and the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales will be applied to the patient.
62686214|NCT03220256|EXPERIMENTAL|Lamotrigine tolerance|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks.
62686215|NCT03829683|ACTIVE_COMPARATOR|Vitamin C infusion (ascorbic acid)|Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)
62686216|NCT03829683|PLACEBO_COMPARATOR|Placebo|Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours
62686217|NCT05579288|EXPERIMENTAL|Study Arm|Patients will receive inhaled N2O/O2 (70% N2O and 30% O2). A sterile bivalve speculum will be placed. Laminaria will be inserted. Inhaled N2O/O2 will be stopped after speculum removal.
62686218|NCT05579288|PLACEBO_COMPARATOR|Control Arm|"Patients will receive inhaled O2 (100% O2). A sterile bivalve speculum will be placed. Laminaria will be inserted. Inhaled O2 will be stopped after speculum removal.~Patients will receive inhaled O2 (100% O2) throughout the procedure until speculum removal."
62686219|NCT00718731|EXPERIMENTAL|1|Subject on active drug
62126452|NCT06155877|EXPERIMENTAL|Chatbot intervention|Teachers, and then pupils, receive a link to a chatbot. This chatbot is a basic conversational agent that can answer the most common questions about vaccination. The chatbot is entirely scripted, providing users with a limited choice of questions at each stage. These questions are the most commonly raised questions about vaccination in adolescents, based on existing literature, and on focus groups conducted by our team. In this intervention, teachers will be asked to supervise the use of the chatbot in class. Pupils will use the chatbot either individually or in groups depending on the number of computers available. Teachers will be encouraged to conclude the intervention by a class discussion. Teachers will be asked to devote about one hour to this intervention (use of the chatbot and class discussion). The full chatbot text is available on the experiment's OSF repository
62316589|NCT03851744|EXPERIMENTAL|High Altitude|Carbohydrate metabolism measured at HA
62316590|NCT01978912|EXPERIMENTAL|Cohort 1|one time 5 μg/disc dose of KTP-001 by intradiscal injection
62316591|NCT01978912|EXPERIMENTAL|Cohort 2|one time 15 μg/disc dose of KTP-001 by intradiscal injection
62686220|NCT00718731|PLACEBO_COMPARATOR|2|Subject on placebo
62686221|NCT00966446|EXPERIMENTAL|Unsupervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided.
62686222|NCT00966446|EXPERIMENTAL|Supervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Study staff is in contact with household members during this intervention to ensure compliance.
62686223|NCT00966446|NO_INTERVENTION|No Intervention|Households do not undergo active MRSA decolonization protocol
61924552|NCT04639037|EXPERIMENTAL|Automated adjustment of vasopressor|Fluid will be managed using the EV1000 monitoring in order to optimize stroke volume index and vasopressor will be automatically deliver by a closed-loop system to maintain the MAP within the target range of 80-90 mmHg
62316592|NCT01978912|EXPERIMENTAL|Cohort 3|one time 50 μg/disc dose of KTP-001 by intradiscal injection
62316593|NCT01978912|EXPERIMENTAL|Cohort 4|one time 150 μg/disc dose of KTP-001 by intradiscal injection
62316594|NCT03723564|EXPERIMENTAL|Amnioinfusion|Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
62686224|NCT05235828|EXPERIMENTAL|Active intervention (ACT) group|8-12 participants will meet for 3-hour sessions for the first 5 days of the intervention. This is followed by five weeks of 1-hour sessions twice per week. In total, the intervention will be 15 sessions that run for a total of 25 hours over 6-weeks. Experienced and licensed SKY instructors from the International Association for Human Values (IAHV) and Art of Living Foundation (AOLF) will provide the intervention through video calls. Instructors will guide participants through the v-SKY intervention through visual demonstrations and verbal guidance. All sessions will be delivered virtually using Zoom. Sessions will not be recorded.
62686225|NCT05235828|NO_INTERVENTION|Waitlist control (WLC) group|8-12 participants will not receive the intervention for 6-weeks. The 6-weeks will line up with the v-SKY intervention that the ACT group receives. After the waitlist period, the WLC group will receive the same v-SKY intervention as the ACT group. According to our earlier estimates, a high number of veterans with PTSD may not be actively receiving treatment for their illness. For these reasons, a waitlist control design may better reflect the current treatment environment for veterans with PTSD.
62686226|NCT06674200|ACTIVE_COMPARATOR|Regular|"The stoma surgery is performed using conventional non-molding suturing techniques. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Perform routine suturing around the stoma without additional mesentery shaping. Form the stoma, ensuring a tight fit of the surrounding tissues."
62686227|NCT06674200|EXPERIMENTAL|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery is shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Separate the mesentery around the stoma and shape it into a sturdy support structure.~Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
62686228|NCT05041699|EXPERIMENTAL|IPM Ring-105|Ring-105 (xx mg dapivirine + xxx mg levonorgestrel)
62686229|NCT05041699|ACTIVE_COMPARATOR|IPM Ring-106.|Ring-106 (xx mg dapivirine + xxx mg levonorgestrel)
62686230|NCT05187988|ACTIVE_COMPARATOR|Supraclavicular approach group|probe placed firmly over the supraclavicular fossa, parallel to the clavicle to obtain a short-axis view of the divisions of the brachial plexus and the subclavian artery, lying on the first rib After skin infiltration with lidocaine 2% a 23-gauge 70mm block needle inserted in-plane with the ultrasound beam, in a lateral-to-medial direction, until the needle tip's positioned at the junction of the first rib and subclavian artery
62686231|NCT05187988|ACTIVE_COMPARATOR|Retroclavicular approach group|the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will be then inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip is constantly seen, until it is positioned posterior to the axillary artery
62686232|NCT01609400||Breast enhancement|
62686233|NCT04138277|EXPERIMENTAL|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
62686234|NCT02946411||Patients|The glucose of 48 patients will be measured during 5 days after cardiac surgery.
62686235|NCT00449787|ACTIVE_COMPARATOR|Sumatriptan|Sumatriptan 100 mg tablet
62686236|NCT00449787|ACTIVE_COMPARATOR|Naproxen|Naproxen 500 mg tablet
62686237|NCT06678568|NO_INTERVENTION|The standard follow-up protocol|follow-up and film every week at hospital
62686238|NCT06678568|EXPERIMENTAL|The optimized follow-up protocol|follow-up and film every week at hospital except the 3rd week is telemedicine follow-up
62686239|NCT04037397|ACTIVE_COMPARATOR|Antiarrhythmic Medications|Patients randomized to the antiarrhythmic drug group are administered medications approved for treatment of AF by the regulatory bodies of each participating country. The selection of antiarrhythmic drugs and dosages is left to the discretion of the investigator, and will follow the AHA/ACC/HRS general guidelines
62686240|NCT04037397|ACTIVE_COMPARATOR|Radio Frequency Catheter Ablation|Patients randomized to radiofrequency catheter ablation will undergo isolation of the pulmonary veins with confirmation of entrance block into each vein. The CARTO TM(Biosense Webster, CA) system will be used to reconstruct the atrial geometry and assist for mapping and ablation. Ablation will be performed using approved ablation devices (Biosense Webster, CA).
62316595|NCT03445039|EXPERIMENTAL|TSFE using osteotomes with bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute is placed in this group.The interventions in the arm are bone grafting and the TSFE will be performed by osteotomes.
62316596|NCT03445039|EXPERIMENTAL|TSFE using osteotomes without bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by osteotomes.
62126453|NCT06155877|NO_INTERVENTION|Control|In the control group, teachers were not sent any extra materials, and pupils were exposed to the standard curriculum. Teachers in the control group received the material after the end of the intervention. French teachers most commonly offer the course on vaccination during the last year of middle school (the equivalent of 9th grade). Time spent on this course varies and can be quite small.
62316597|NCT03445039|EXPERIMENTAL|modified TSFE with bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute is placed before the implant placement.Interventions in the arm are bone grafting and the TSFE will be performed by dask drills.
62316598|NCT03445039|EXPERIMENTAL|modified TSFE without bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by dask drills.
62316599|NCT03713723||Patients undergoing IVF treatment with hemodynamic monitoring|Fifty health women aged 18-45 undergoing their first, second or third cycle of IVF treatment will be monitored with the non invasive NICaS bioimpedance
62316600|NCT00916604|EXPERIMENTAL|A|3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
62316601|NCT00916604|PLACEBO_COMPARATOR|B|Placebo oral suspension given to 3 groups (2 on placebo in each group)
62316602|NCT03271827|EXPERIMENTAL|Apnoeic oxygenation group|Standard airway management + 3 L/min of oxygen by nasal cannula
62316603|NCT03271827|NO_INTERVENTION|Standard care group|Standard airway management
62479165|NCT03606174|EXPERIMENTAL|Cohort 9|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
62126454|NCT04867902|EXPERIMENTAL|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
62316604|NCT01411397|ACTIVE_COMPARATOR|mesh repair|MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION
62479166|NCT06603077|EXPERIMENTAL|AVTX-009 Regimen 1|Patients will receive AVTX-009 regimen 1.
62479167|NCT06603077|EXPERIMENTAL|AVTX-009 Regimen 2|Patients will receive AVTX-009 regimen 2.
62316605|NCT01411397|ACTIVE_COMPARATOR|mesh repair without intestinal resection|mesh repair of strangulated hernia without resection
62316606|NCT01673048|ACTIVE_COMPARATOR|Femoral fracture, ESIN|"Prospectively all patients treated with the 3-nail-configuration for dislocated femoral shaft fractures were enrolled; 25 patients are planned, 18 could be enrolled Comparison will be with own previous data of patients treated with the classical 2-C-shaped ESIN-osteosynthesis"
62479168|NCT06603077|PLACEBO_COMPARATOR|Placebo|Patients will receive matching placebo.
62479169|NCT01447017|EXPERIMENTAL|DPK-060 2% ear drops|DPK-060 2% ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
62479170|NCT01447017|PLACEBO_COMPARATOR|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
62479171|NCT06571747|EXPERIMENTAL|CV Nudge/CV Nudge|Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the cardiovascular-focused nudge communication at 2 different timepoints during the influenza season.
62126455|NCT01976312|EXPERIMENTAL|Ranibizumab 0.5 mg|PRN intravitreal injection
62316607|NCT01413178|EXPERIMENTAL|Busulfan + Melphalan|Busulfan test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
62316608|NCT01413178|EXPERIMENTAL|Melphalan|High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.
62126456|NCT01976312|SHAM_COMPARATOR|Sham injection|As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
62686241|NCT04691115|EXPERIMENTAL|Part A, Group 1: AM1476 1 mg|Part A, Group 1: AM1476 1 mg capsule, orally once on Day 1 in fasted state
62126457|NCT03298724|EXPERIMENTAL|TAPP Intervention|The Teachers and Partners intervention will be provided
62126458|NCT04666857|NO_INTERVENTION|standard care|Control subject will receive standard care of treatment
62126459|NCT04666857|EXPERIMENTAL|intervention group|intervention group will receive early intervention
62126460|NCT02364349|ACTIVE_COMPARATOR|Bee Venom (BV) group|All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
62126461|NCT02364349|EXPERIMENTAL|essential Bee Venom (eBV) group|All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
62126462|NCT00924807|EXPERIMENTAL|Androgen Depr, Radiotherapy, Sorafenib|Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
62126463|NCT06075472|EXPERIMENTAL|Treatment Group|IMT: Inspiratory Muscle Training. Five days per week, 30 minutes per day.
62126464|NCT06075472|ACTIVE_COMPARATOR|Control Group|Balance exercises: It has been specially designed for the patient.
62126465|NCT05843708|EXPERIMENTAL|Fasting condition / Low-fat meal|A single oral dose of 1×40 mg vorasidenib tablet administered under fasted conditions or following a low-fat meal.
62126466|NCT05843708|EXPERIMENTAL|Low-fat meal / Fasted condition|A single oral dose of 1×40 mg vorasidenib tablet administered following a low-fat meal or under fasted conditions.
62126467|NCT05843708|EXPERIMENTAL|Vorasidenib|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1.
62126468|NCT05843708|EXPERIMENTAL|Vorasidenib and ciprofloxacin|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 and twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14.
62126469|NCT05273788|ACTIVE_COMPARATOR|1Hz Arm|ThorS-MagNT treatment intervention with 2400 total stimulations at 1Hz with the magnetic coil.
62126470|NCT05273788|ACTIVE_COMPARATOR|10Hz Arm|ThorS-MagNT treatment intervention with 2400 total stimulations at 10Hz with the magnetic coil.
62126471|NCT05273788|SHAM_COMPARATOR|Sham Arm|Sham intervention with 2400 total sham stimulations with the magnetic coil.
62126472|NCT00975039|EXPERIMENTAL|WST11|Treatment with WST11-mediated VTP
62126473|NCT06218303|EXPERIMENTAL|MUC1 vaccine + adjuvant Hiltonol + Aromatase Inhibitor|MUC1 peptide vaccine with poly-ICLC adjuvant Hiltonol administered subcutaneously (SQ) Anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg by mouth daily
62126474|NCT06218303|ACTIVE_COMPARATOR|Aromatase Inhibitor|Anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg by mouth daily
62126475|NCT06281054||Revascularized Group|Cancer patients with diagnosis of acute myocardial infarction that was treated with PCI or CABG
62126476|NCT06281054||Medical Group|Cancer patients with diagnosis of acute myocardial infarction that was treated with medical treatment only
62126477|NCT01186198||MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Patients requiring initial balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis will be included.
62126478|NCT03281616|ACTIVE_COMPARATOR|Diet and Physical Activity Recording|
62126479|NCT03281616|ACTIVE_COMPARATOR|Diet and No Physical Activity Recording|
62126480|NCT05350475|EXPERIMENTAL|Proton therapy|"Radiation: Proton Therapy 78 Gray (Gy) in 39 fractions with 56 Gy to the Pelvic Lymph Nodes (LN), 5 days a week.~Androgen Deprivation Therapy (ADT) for three years, starting 3 months before Proton Therapy."
62126481|NCT05350475|ACTIVE_COMPARATOR|Photon Therapy|Radiation: Photon Therapy 78 Gy in 39 fractions with 56 Gy to the pelvic LN, 5 days a week. ADT for three years, starting 3 months before Photon Therapy.
62126482|NCT02285413|EXPERIMENTAL|DC vaccination|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase
62126483|NCT02285413|EXPERIMENTAL|DC vaccination with cisplatinum|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase. each DC vaccine will be preceded by cisplatin infusion: 50 mg/m2, 1-2h before DC injection.
62126484|NCT04065113|EXPERIMENTAL|Embolization Only|Medically managed patient receives middle meningeal artery embolization
62686242|NCT04691115|EXPERIMENTAL|Part A, Group 2: AM1476 5 mg|Part A, Group 2: AM1476 5 mg capsule, orally once on Days 1 in fasted state
62126485|NCT04065113|EXPERIMENTAL|Embolization + Evacuation|Participant receives standard of care evacuation and then undergoes MMA embolization
62686243|NCT04691115|EXPERIMENTAL|Part A, Group 3: AM1476 25 mg|Part A, Group 3: AM1476 25 mg capsule, orally once on Days 1 in fasted state
62686244|NCT04691115|EXPERIMENTAL|Part A, Group 4: AM1476 125 mg|Part A, Group 4: AM1476 125 mg capsule, orally once on Days 1 in fasted state
62686245|NCT04691115|EXPERIMENTAL|Part A, Group 5: AM1476 375 mg|Part A, Group 5: AM1476 375 mg capsule, orally once on Days 1 in fasted state
62126486|NCT04065113|NO_INTERVENTION|Medical Management|Historical control of medically managed patients
62126487|NCT04065113|ACTIVE_COMPARATOR|Surgical Patients|Historical control of patients receiving standard surgery alone
62686246|NCT04691115|EXPERIMENTAL|Part A, Group 6: AM1476 650 mg|Part A, Group 6: AM1476 650 mg capsule, orally once on Days 1 in fasted state
62686247|NCT04691115|EXPERIMENTAL|Part A, Group 7: AM1476 950 mg|Part A, Group 7: AM1476 950 mg capsule, orally once on Days 1 in fasted state
62686248|NCT04691115|EXPERIMENTAL|Part A, Group 8: AM1476 1500 mg|Part A, Group 8: AM1476 1500 mg capsule, orally once on Days 1 in fasted state
62126488|NCT01716936||MAGEC Implant|All patients implanted with the MAGEC System will be reviewed for inclusion into this retrospective study.
62126489|NCT02997917|EXPERIMENTAL|Education|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the real education group, solutions at suprathreshold concentration for detection will be given with a subsequent comment on the flavor and an explanation of the components and preparation of the soup (low temperature cooking to preserve flavors).
62316609|NCT00802165|EXPERIMENTAL|Electroacupuncture Treatment Group|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
62316610|NCT00802165|SHAM_COMPARATOR|Sham Treatment Group|Sham electroacupuncture treatment gives comparison to the experimental group
62126490|NCT02997917|SHAM_COMPARATOR|Sham|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the sham education group solutions at subthreshold concentration for detection with no explanation will be provided.
62126491|NCT00447733|EXPERIMENTAL|Integrated treatment|Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
62316611|NCT01105403|EXPERIMENTAL|CD34+ mobilisation for transplantation|
62316612|NCT00692705|OTHER|1|Alzheimer's Disease (AD) patients
62316613|NCT00692705|OTHER|2|Healthy volunteers
62316614|NCT03587909|ACTIVE_COMPARATOR|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
62316615|NCT03587909|ACTIVE_COMPARATOR|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
62316616|NCT05336227|EXPERIMENTAL|Immediate Start - Virtual Reality Exergaming|12 weeks of virtual reality active video gaming using immersive commercially available equipment, with adapted games for people to play in the seated position. Maintain normal eating/nutritional behaviors.
62479172|NCT06571747|EXPERIMENTAL|CV Nudge/Usual Care|Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the cardiovascular-focused nudge communication at first timepoint and then usual care communication at the second timepoint during the influenza season.
62686249|NCT04691115|EXPERIMENTAL|Part A, Group 9: AM1476 2400 mg|Part A, Group 9: AM1476 2400 mg capsule, orally once on Days 1 in fasted state
62126492|NCT00447733|ACTIVE_COMPARATOR|Treatment as usual|Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
62126493|NCT05119764|NO_INTERVENTION|Control Group|Standard pre- and postoperative physical therapy without manual lymphatic drainage.
62126494|NCT05119764|EXPERIMENTAL|Manual lymphatic drainage before and after knee replacement|Manual lymphatic drainage before and after knee replacement
62126495|NCT05119764|EXPERIMENTAL|Manual lymphatic drainage after knee replacement|Manual lymphatic drainage after knee replacement
62126496|NCT04218110|EXPERIMENTAL|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
62126497|NCT04218110|EXPERIMENTAL|Project X 10.5ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
62126498|NCT04218110|EXPERIMENTAL|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
62316617|NCT05336227|NO_INTERVENTION|Wait-list Control|Maintain habitual physical activity levels for 12 weeks, before receiving the same intervention. Maintain normal eating/nutritional behaviors.
62316618|NCT05174689|OTHER|EIA wih house dust mite|Patients with EIA and house-dust mite allergy and an eNO \> 30 ppb
62316619|NCT05174689|OTHER|EIA without sensitization|Patients with EIA without allergic sensitization and an eNO \< 20 ppb
62316620|NCT05174689|OTHER|Healthy controls|Healthy controls without allergic sensitization or known asthma
62316621|NCT01512368|EXPERIMENTAL|Supervised exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.
62316622|NCT00492401|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62316623|NCT06494904|EXPERIMENTAL|High Dose SL-BUP|Participants will receive three 5.7 mg Zubsolv pills; all will be active medication.
62316624|NCT06494904|ACTIVE_COMPARATOR|Standard SL-BUP|Participants will receive three pills; one 5.7 mg Zubsolv pill with active medication and two placebo pills.
62316625|NCT01731691|EXPERIMENTAL|α1 Proteinase Inhibitor in HIV disease|α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
62316626|NCT01731691|PLACEBO_COMPARATOR|Placebo in HIV disease|Placebos weekly for 8 weeks
62316627|NCT01731691|NO_INTERVENTION|Uninfected controls|Blood collection only for 8 weeks
62316628|NCT02760407|EXPERIMENTAL|Arm 1: Olokizumab q4w|Olokizumab 64 mg subcutaneous q4w +placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
62316629|NCT02760407|EXPERIMENTAL|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
62316630|NCT02760407|ACTIVE_COMPARATOR|Arm 3: Adalimumab q2w|"Adalimumab 40mg q2w subcutaneous + Methotrexate~Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
62686250|NCT04691115|PLACEBO_COMPARATOR|Part A, Groups 1 to 9: Placebo|Part A, Groups 1 to 9: AM1476 placebo-matching capsule, orally once on Days 1 in fasted state
62479173|NCT06571747|EXPERIMENTAL|Usual Care/CV Nudge|Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the usual care communication at first timepoint and then cardiovascular-focused nudge communication at the second timepoint during the influenza season.
62479174|NCT06571747|NO_INTERVENTION|Usual Care/Usual Care|The usual care arm will receive standard-of-care communication encouraging vaccination at both timepoints during the influenza season.
62686251|NCT04691115|EXPERIMENTAL|Part B, Group 1: AM1476 100 mg QD (once daily)|Part B, Group 1: AM1476 100 mg capsule, orally once on Days 1-10 in fasted state
62686252|NCT04691115|EXPERIMENTAL|Part B, Group 2: AM1476 375 mg BID (twice daily)|Part B, Group 2: AM1476 375 mg capsule, orally twice on Days 1-9 and once on Days 10 in fasted state
62686253|NCT04691115|EXPERIMENTAL|Part B, Group 3: AM1476 500 mg BID|Part B, Group 3: AM1476 500 mg capsule, orally twice on Days 1-9 and once on Days 10 in fasted state
62479175|NCT06680869|EXPERIMENTAL|Early Amiodarone Protocol|Amiodarone administration after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine.
62479176|NCT06680869|ACTIVE_COMPARATOR|Usual Care Protocol|Amiodarone administration after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine.
62479177|NCT05377242|EXPERIMENTAL|Gulf War Veterans, Curcumin|"All GWI Veterans will undergo the same screening and experimental procedures. Participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. This trial tests three interventions, which are all tested independently. Participants will receive only one of the three interventions. The curcumin, resveratrol, and stinging nettle trials all follow the same design and procedures.~Participants will complete one month of baseline, eight months of capsules, and one month of endline measurements."
62686254|NCT04691115|PLACEBO_COMPARATOR|Part B, Groups 1 to 3: Placebo|Part B, Groups 1 to 3: AM1476 placebo-matching capsule, orally once or twice on Days 1-10 in fasted state
62686255|NCT06063720||AI group|AI monitoring of effective withdrawal time
62686256|NCT00952562|ACTIVE_COMPARATOR|cholecalciferol|3000 IU cholecalciferol per day for 16 weeks
62686257|NCT00952562|PLACEBO_COMPARATOR|placebo|
62686258|NCT04298333|EXPERIMENTAL|BP-C1|BP-C1 will be used as supportive care
62686259|NCT04747431|EXPERIMENTAL|Cohort 1|"Drug: PBFT02 Dose 1: 3.3 x 10\^10 GC/g\* Single dose of PBFT02, via intra cisterna magna~\*GC/g: gene copy per gram of estimated brain weight"
62686260|NCT04747431|EXPERIMENTAL|Cohort 2|"Drug: PBFT02 Dose 2: 1.1 x 10\^11 GC/g\* Single dose of PBFT02, via intra cisterna magna~\*GC/g: gene copy per gram of estimated brain weight"
62686261|NCT04747431|EXPERIMENTAL|Optional Cohort 3|"Drug: PBFT02 Dose 3: 2.2 x 10\^11 GC/g\* Single dose of PBFT02, via intra cisterna magna~\*GC/g: gene copy per gram of estimated brain weight"
62316631|NCT02760407|PLACEBO_COMPARATOR|Arm 4: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
62316632|NCT00751101|EXPERIMENTAL|Arm A: Prior to initiation of capecitabine|Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
62126499|NCT04218110|ACTIVE_COMPARATOR|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.
62126500|NCT03653169|EXPERIMENTAL|Open-Label Active TMS|All subjects will receive open-label treatment with active Transcranial Magnetic Stimulation (TMS)
62126501|NCT02772471|EXPERIMENTAL|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and invasive ICP monitoring. HS-1000 ICP monitoring intervals will last at least 30 minutes, continuously depending on the patient's clinical condition.
62316633|NCT00751101|EXPERIMENTAL|Arm B: After hand-foot syndrome symptoms appear|Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
62126502|NCT03299322|PLACEBO_COMPARATOR|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
62316634|NCT05827146|EXPERIMENTAL|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 4 week
62316635|NCT05827146|EXPERIMENTAL|Hepalatide 4.2mg|4.2 mg/day subcutaneously (s.c.) for 4 week
62686262|NCT06691594|EXPERIMENTAL|neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy|"Eligible participants will receive neoadjuvant treatment consisting of:~SBRT: One session of 10Gy radiation to the primary tumor, followed by a 150mg subcutaneous injection of pembrolizumab (PD-1 inhibitor).~Chemotherapy and Immunotherapy: One week after SBRT, participants will undergo 6 cycles of pembrolizumab (400mg), albumin-bound paclitaxel (250mg/m²), and carboplatin (AUC=5).~Surgery: Surgery will be performed 21 days after the last chemotherapy cycle, with either breast-conserving surgery or modified radical mastectomy. Pathological evaluation will assess the treatment response.~Adjuvant Immunotherapy: Four weeks post-surgery, patients will receive pembrolizumab every 3 weeks for up to 1 year."
62686263|NCT03616093|EXPERIMENTAL|Test Beet shot|Active supplement containing 6.2 mmol nitrate
62126503|NCT03299322|EXPERIMENTAL|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
62316636|NCT05827146|EXPERIMENTAL|Hepalatide 6.3mg|6.3 mg/day subcutaneously (s.c.) for 4 week
62316637|NCT05827146|PLACEBO_COMPARATOR|Placebo 2.1mg/4.2mg/6.3mg|Placebo 2.1 mg/4.2mg/6.3mg, once a day subcutaneously (s.c.) for 4 week
62686264|NCT03616093|PLACEBO_COMPARATOR|Placebo beverage|Placebo supplement containing negligible nitrate
62686265|NCT06094738|EXPERIMENTAL|Relacorilant under fasted conditions|Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
62686266|NCT06094738|EXPERIMENTAL|Relacorilant after a high-fat meal|Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
62686267|NCT06094738|EXPERIMENTAL|Relacorilant after a low-fat meal|Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
62686268|NCT01080547|ACTIVE_COMPARATOR|Conventional Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
62686269|NCT01080547|ACTIVE_COMPARATOR|FTMD Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
62126504|NCT03299322|EXPERIMENTAL|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
62686270|NCT01080547|ACTIVE_COMPARATOR|Conventional Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
62686271|NCT01080547|ACTIVE_COMPARATOR|FTMD Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.
62686272|NCT06566716||Malignant|Patients with an adnexal mass that is surgically diagnosed as malignant
62126505|NCT04447209||Child Health Clinic (CHC)|"Children attending CHC for routine vaccinations and follow-up in a tertiary center Parents will be counselled on food groups based on Infant and Young Children feeding practices.~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
62686273|NCT06566716||Non-Malignant|Patients with an adnexal mass that is surgically diagnosed as benign
62686274|NCT03570385|EXPERIMENTAL|Patient with Optic Neuritis|
62686275|NCT00023023||Adults and children subjects|The NIH and SH components will enroll and follow only adult (age \>=18) blood donor or recipient subjects. CNMC will enroll and follow children between the ages of 6 months and 18 years.
62316638|NCT05360615|EXPERIMENTAL|Empagliflozin|
62316639|NCT05360615|PLACEBO_COMPARATOR|Placebo|
62316640|NCT00003210|EXPERIMENTAL|Treatment (interleukin-12)|Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
62316641|NCT04239235|EXPERIMENTAL|Intervention|Community Reinforcement Approach and Family Training is a 10-session rolling group for the support person.
62316642|NCT04239235|NO_INTERVENTION|Control|This condition is for support persons who do not receive CRAFT. They will receive no intervention or usual care services available at the clinic.
62316643|NCT05253352||Healthy volunteers|Healthy female volunteers with no history of lymphedema. Physical therapy examination, ICG lymphography, venous ultrasound and lymphoscintigraphy with SPECT/CT imaging
62316644|NCT05253352||Women with breast cancer who did not develop lymphedema|Women who have had an axillary lymph node dissection (ALND) and did not develop lymphedema. Physical therapy examination, ICG lymphography, venous ultrasound and lymphoscintigraphy with SPECT/CT imaging
62316645|NCT01852864|EXPERIMENTAL|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
62316646|NCT06567106|EXPERIMENTAL|Ultrasound application at minimal intensity|Apply minimal-intensity ultrasound to the participant. The intensity is below 2 W/cm².
62316647|NCT06567106|EXPERIMENTAL|Ultrasound application at mild intensity|Apply mild-intensity ultrasound to the participant. The intensity is below 3 W/cm².
62316648|NCT06567106|SHAM_COMPARATOR|Ultrasound application at medium intensity|Apply medium-intensity ultrasound to the participant. The intensity is below 5 W/cm².
62316649|NCT06567106|SHAM_COMPARATOR|No ultrasound application|No ultrasound application to the participant.
62316650|NCT04829643|EXPERIMENTAL|PET/MRI|Patients with early breast cancer up to 3 cm without overt nodal involvement who are candidates to upfront surgery
62316651|NCT02983981|EXPERIMENTAL|open label|Topicort topical spray
62316652|NCT06343207|EXPERIMENTAL|CAI PT|Chronic ankle instability patient + percussive therapy intervention
62126506|NCT04447209||Community Children|"Children of urban poor families living in low-cost flats around Kuala Lumpur. Parents will be counselled on food groups based on Infant and Young Children feeding practices.~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
62126507|NCT03100513|ACTIVE_COMPARATOR|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
62126508|NCT03100513|ACTIVE_COMPARATOR|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient \<75Kg over 3 hours or 4 sachets if patient \>75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
62126509|NCT05355623|ACTIVE_COMPARATOR|amniotic membrane graft|patients in which the surgical vaginal repair will be done with the application of a sterilized (gamma irradiated) amniotic membrane.
62126510|NCT05355623|ACTIVE_COMPARATOR|surgical vaginal repair|patients in which the surgical vaginal repair will be done without any graft.
62126511|NCT04732338|EXPERIMENTAL|Study arm - Osteopathic Manipulative Therapy|"Standard of care including physical therapy, occupational therapy and over the counter medication AND OMT as described below:~1. Musculoskeletal examination of the cervical spine. Testing will be comprised of :~   1. Range of motion testing involving cervical rotation, lateral side bending, flexion and extension.~  2. Muscular palpation of the cervical paraspinals for hypertonicity of the muscles and/or tenderness.~2. Patient placed supine on the examination table.~3. Treatment sessions lasting 5-10 minutes each. OMT techniques: cervical muscle energy, myofascial release of the cervical paraspinals and a suboccipital release.~Assessment with Headache Impact Test (HIT-6) at baseline and follow-up visit and change in pain scores between baseline and post treatment."
62126512|NCT04732338|NO_INTERVENTION|Control - Standard of care|Standard of care including physical therapy, occupational therapy and over the counter medication.
62316653|NCT06343207|NO_INTERVENTION|CAI NOPT|Chronic ankle instability patient + NO percussive therapy intervention (control)
62316654|NCT06343207|EXPERIMENTAL|CON PT|Healthy subjects + percussive therapy intervention
62126513|NCT05933551|EXPERIMENTAL|After the training, the knowledge levels and skills of the nurses about the Z technique|
62126514|NCT04447482|EXPERIMENTAL|Treatment Group|4D electromagnetic navigation bronchoscopy (4D-ENB) for lung biopsy. Guidance based on tip tracked surgical tools and images calculated from CT.
62126515|NCT04447482|ACTIVE_COMPARATOR|Control Group|Bronchoscopic lung biopsy taken while using X-ray fluoroscopy.
62126516|NCT02242487|EXPERIMENTAL|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
62126517|NCT02242487|EXPERIMENTAL|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
62316655|NCT06343207|NO_INTERVENTION|CON NOPT|Healthy subjects + NO percussive therapy intervention
62316656|NCT02740153||Urea Cycle Disorder with Liver Transplant|"* Age 18 and under~* Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~* History of liver transplant"
62316657|NCT02740153||Urea Cycle Disorder without Transplant|"* Age 18 and under~* Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~* No history of liver transplant, managed medically"
62126518|NCT04395378||Flying pilots|Flying pilots holding class 1 and class 2 certificates
62126519|NCT01522742||Healthy control subjects|Healthy control subjects matched to psoriasis patients on traditional cardiovascular risk factors will be studied at baseline.
62126520|NCT01522742||Psoriasis patients starting etanercept|Patients with moderate to severe psoriasis with or without arthritis who are about to be started on etanercept (enbrel) by their treating clinicians will be studied at baseline and 3 months after etanercept therapy.
62126521|NCT04943419||Colorectal cancer|Patients with colorectal cancer qualified for elective operations.
62126522|NCT02988037|EXPERIMENTAL|A-DBT-A|Began Adapted Dialectical Behaviour Therapy for Adolescents
62126523|NCT06408493|EXPERIMENTAL|Intervention|Participants will attend the 8-weeks MYCardio-PEER program with their peer leaders, supplemented with face-to-face components.
62126524|NCT06408493|NO_INTERVENTION|Control|Participants will receive printed documents with standard tips on dietary and lifestyle management for CVD.
62316658|NCT06007430|PLACEBO_COMPARATOR|Group 1 (Healthy Control)|24 Patients receiving Placebo Capsule per oral once daily for 60 days.
62316659|NCT06007430|ACTIVE_COMPARATOR|Group 2 (Healthy control)|26 Patients receiving Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA), one capsule per oral once daily for 60 days.
62316660|NCT06007430|PLACEBO_COMPARATOR|Group 3 (Diabetes Type 2)|23 Patients receiving Placebo Capsule per oral once daily for 60 days.
62316661|NCT06007430|ACTIVE_COMPARATOR|Group 4 (Diabetes Type 2)|27 Patients Receiving Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA), one capsule per oral once daily for 60 days.
62316662|NCT01654562|EXPERIMENTAL|CHM|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
62316663|NCT01654562|ACTIVE_COMPARATOR|Age-matched controls|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
62316664|NCT04990544|EXPERIMENTAL|Adult Group 2a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
62316665|NCT04990544|EXPERIMENTAL|Adult Group 2b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
61924553|NCT01806727|ACTIVE_COMPARATOR|Diabetes Self Management (DSM)|Diabetes Self Management education, delivered in the clinics, using group-based visits and targeting improved control of hemoglobin A1c and related risk factors.
61924554|NCT01806727|EXPERIMENTAL|Community Lifestyle Weight Loss (LWL)|Participants with type 2 diabetes will be enrolled in a 12 month lifestyle intervention designed to achieve a mean \>7% weight loss induced through caloric restriction and increased physical activity. The intervention will be delivered via supervised Community Health Workers (CHWs). Most meetings will be at a community location.
61924555|NCT04672330|EXPERIMENTAL|Neoadjuvant arm|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) prior to surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation） Drug: Tislelizumab 200 mg per cycle, IV on day 1 of every 3-week cycle, for 2-4 cycles prior to surgery
62126525|NCT00925886|EXPERIMENTAL|Acrysof Toric intraocular lens|A One piece, acrylic intraocular lens is implanted in the lens bag.
62126526|NCT01837472|EXPERIMENTAL|Probiotic|
62316666|NCT04990544|EXPERIMENTAL|Adult Group 2c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28.
61924556|NCT04640181|ACTIVE_COMPARATOR|Adaptive Dosing: Enoxaparin|"* Low 40mg subcutaneous (SQ) daily, or~* Intermediate 40mg SQ q12 hours, or~* Therapeutic 1mg/kg SQ q12 hours"
61924557|NCT04640181|ACTIVE_COMPARATOR|Adaptive Dosing: Rivaroxaban|"* Low 10mg po daily~* Intermediate 10mg po daily~* Therapeutic 20mg po daily"
61924558|NCT00882973|EXPERIMENTAL|Cohort 1|Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
61924559|NCT00882973|EXPERIMENTAL|Cohort 2|Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
62126527|NCT01837472|PLACEBO_COMPARATOR|Placebo|
62126528|NCT04377815||General Public cohort|General Public
62126529|NCT04377815||Hospital cohort|Medical records of patients hospitalised due to COVID-19
62126530|NCT00174382|EXPERIMENTAL|1|
62126531|NCT06484855|EXPERIMENTAL|IBI355 7.5mg/kg|IBI355 7.5mg/kg and placebo will be given to the subjects every 4 weeks (8:2)
62126532|NCT06484855|EXPERIMENTAL|IBI355 15mg/kg|IBI355 15mg/kg and placebo will be given to the subjects every 4 weeks (8:2)
62126533|NCT06484855|EXPERIMENTAL|IBI355 30mg/kg|IBI355 30mg/kg and placebo will be given to the subjects every 4 weeks (8:2)
62686276|NCT04883554|EXPERIMENTAL|Olfactory therapy group|"The therapeutic group takes place in specific stages on a weekly basis and lasts approximately 45 minutes. The group consists of a maximum of 6 patients of approximately the same age. The therapists leading the therapeutic group choose in advance the smells that will be offered to patients, based on one odor for each of the following categories: food and woody / flowery. The odors circulate between the participants of the group (patients and therapists), on wipes of blotting paper soaked in the bottles and soaked in the odors. The first step of the therapeutic group is olfactory perception: this is the moment when the odors selected for the session are presented to the patients. Each scent goes around the patients and therapists, three times and without verbalization. Therefore, patients can express their feelings through drawing or writing on distributed sheets. .~In a second step, called rendering, patients are asked to express what they think of the smell presented."
62686277|NCT04883554|ACTIVE_COMPARATOR|Body therapy group|"The therapeutic group takes place according to very specific stages at a weekly frequency and lasts 1 hour. The group is made up of a maximum of 6 patients.~This workshop includes three times divided equally over a period of 1 hour:~Kinesic time or time to set the body in motion (20 min):~These techniques involve lying on the floor on a mat and approaching the movement slowly. The movements are suggested by the patients and then imitated by the rest of the group.~Kinesthetic time: time of slow movements (20 min):~During this time, the patient is asked to find a period of calm close to immobility without imposing the instruction. They are asked to touch the different parts of the body as slowly as possible in isolation, starting and ending in the center of the body.~Talk time (20 min):~Patients are invited to verbalize what they felt bodily"
62126534|NCT03496194||Head of Post Anaesthesia Care Unit|The chief physician of PACUs at all Danish Anaesthesia departments will receive electronic survey on postoperative pain treatment
62126535|NCT04489498||Children with stiff cerebral palsy|Children with stiff cerebral palsy, aged 1 to 13 years
62686278|NCT04875533|EXPERIMENTAL|20vPnC/Saline|20vPnC and saline
62686279|NCT04875533|ACTIVE_COMPARATOR|13vPnC/PPSV23|13vPnC and PPSV23
62686280|NCT00730600|EXPERIMENTAL|1|1= THAI traditional massage
62686281|NCT06291727|ACTIVE_COMPARATOR|Mepivacaine|Standard dose of mepivacaine anesthesia (1.5% or 2%) for total knee arthroplasty procedure
62686282|NCT06291727|ACTIVE_COMPARATOR|Bupivacaine|Standard dose of hyperbaric bupivacaine anesthesia (0.75%) for total knee arthroplasty procedure
62686283|NCT06570642|EXPERIMENTAL|Affect (no enhancements) > Intensity|Participants receive affect-based goals for the first 8-weeks, then cross-over to receive intensity-based goals for the second 8-weeks. No enhancements are added to the standard mHealth intervention.
62686284|NCT06570642|EXPERIMENTAL|Intensity > Affect (no enhancements)|Participants receive intensity-based goals for the first 8-weeks, then cross-over to receive affect-based goals for the second 8-weeks. No enhancements are added to the standard mHealth intervention.
62686285|NCT06570642|ACTIVE_COMPARATOR|Affect (+ SAVOR + TYPE/CONTEXT) > Intensity|Participants receive affect-based goals for the first 8-weeks. In addition to the standard mHealth intervention, participants engage in both SAVOR and TYPE/CONTEXT enhancements to augment the treatment effects of the affect-based goals condition. Participants then cross-over to receive intensity-based goals for the second 8-weeks.
62686286|NCT06570642|ACTIVE_COMPARATOR|Intensity > Affect (+ SAVOR + TYPE/CONTEXT)|Participants receive intensity-based goals for the first 8-weeks, then cross-over to receive affect-based goals for the second 8-weeks. In addition to the standard mHealth intervention, participants engage in both SAVOR and TYPE/CONTEXT enhancements to augment the treatment effects of the affect-based goals condition.
62126536|NCT04489498||Normal children|Normal children, aged 1 to 13 years
62126537|NCT04562259||patients with Kimmerle's anomaly|patients who have a complete or incomplete bony bridge over the posterior arch of the first cervical vertebra
62126538|NCT03484065||Afibrinogenemia|
62126539|NCT02882204||First Episode Patients|First episode patients new to the PEPP program.
62126540|NCT02882204||Chronic Patients|Existing patients who have been enrolled in the PEPP program for \>3 years
62126541|NCT02882204||Healthy Controls|Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
62316667|NCT04990544|PLACEBO_COMPARATOR|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
62316668|NCT04990544|EXPERIMENTAL|Elderly Group 2d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
62316669|NCT04990544|EXPERIMENTAL|Elderly Group 2e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
61924560|NCT00882973|EXPERIMENTAL|Cohort 3|Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
62126542|NCT02882204||Cliniucal High Risk patients|Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
62126543|NCT01684150|EXPERIMENTAL|EPZ-5676 Extension cohort|
62126544|NCT02125695||Healthy Volunteers|Skin taping; blood sampling; optional biopsy
62126545|NCT02125695||Cutaneous lupus erythematosus|This group consists of participants affected with lupus (DLE, SCLE). Skin taping; blood sampling; optional skin biopsy (DLE participants); required skin biopsy (SCLE participants)
62126546|NCT02125695||Atopic dermatitis|Skin taping; blood sampling; optional skin biopsy
62126547|NCT05150067|EXPERIMENTAL|Experimental group|The participants in the experimental group received a blended learning programme with face-to-face training and an online module on handover practice.
62126548|NCT05150067|ACTIVE_COMPARATOR|waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed.
62316670|NCT04990544|EXPERIMENTAL|Elderly Group 2f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
61924561|NCT02697097||Control Arm Group|Participants aged 18-30, Male and Female (10 participants each). Control group must have normal range of movement and no evidence of femoro-acetabular impingement (FAI) on clinical examination (negative impingement test, no symptoms). Other exclusions for Control Group include previous surgery to hip joint/s, history of arthritis, family history of FAI, patients who have had symptoms of hip pain in the preceding 1 year or may have other conditions which may affect the hip joint or hip muscle strength including neurological conditions or muscular dystrophy.
61924562|NCT02697097||FAI Arm Comparison Group|Participants aged 18-30, Male and Female (10 participants each). Participants with femoro-acetabular impingement as diagnosed clinically and on radiological imaging for the comparison group (MRI).
62126549|NCT06223048|EXPERIMENTAL|AMDX-2011P 50 mg|AMDX2011P mg 50 (2ml) single bolus injection intravenous for diagnostic review
62126550|NCT06223048|EXPERIMENTAL|AMDX-2011P 100 mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
62126551|NCT05993351||Concussion|Individuals who have recently sustained a concussion within the past 2-weeks.
62126552|NCT05993351||Healthy Control|Individuals who have limited to no concussion history, and have not recently sustained a concussion.
62126553|NCT05989035|ACTIVE_COMPARATOR|Younger without MetAP2 inhibition|Participants between 18 and 30 years old without MetAP2 inhibition in conditioned media
62126554|NCT05989035|ACTIVE_COMPARATOR|Older without MetAP2 inhibition|Participants 65 years old and without MetAP2 inhibition in conditioned media
62316671|NCT04990544|PLACEBO_COMPARATOR|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
62316672|NCT00911664|PLACEBO_COMPARATOR|1|
62316673|NCT00911664|EXPERIMENTAL|2|
62126555|NCT05989035|EXPERIMENTAL|Younger with MetAP2 inhibition|Participants between 18 and 30 years old with MetAP2 inhibition in conditioned media
62126556|NCT05989035|EXPERIMENTAL|Older with MetAP2 inhibition|Participants 65 years old with MetAP2 inhibition in conditioned media
62126557|NCT04882553|EXPERIMENTAL|Incremental inspiratory effort|"Every participant will be subjected to a stepwise incremental inspiratory effort:~1. Ventilated~2. Baseline spontaneous breathing with deep anesthesia (minimal alveolar concentration 1.5)~3. Spontaneous breathing with PEEP 10 and deep anesthesia (minimal alveolar concentration 1.5)~4. Spontaneous breathing with PEEP 0 and deep anesthesia (minimal alveolar concentration 1.5)~5. Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0)~6. Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +7cmH2O~7. Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +15cmH2O"
62316674|NCT00911664|EXPERIMENTAL|3|
62316675|NCT04761497|EXPERIMENTAL|active music therapy|Each session consisted of: song of welcome (patients had to greet and introduce themselves), rhythmic exercise (three songs were used; therapist and patients kept rhythm by clapping their hands), dance exercises (three songs were used; patients should make free body movements in response to music), game of recognition of songs and interpreters (four songs were used) and song of goodbye.
62316676|NCT04761497|EXPERIMENTAL|passive music therapy|The therapist and the patients were seat listening to the music recorded in a CD. The therapist told patients which the name and the interpreter of each song of the list.
62316677|NCT04761497|PLACEBO_COMPARATOR|control|Patients were watching nature videos for the same duration than the interventions. A therapist was with them facilitating the activity.
62316678|NCT03474718|EXPERIMENTAL|Group A|At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
62316679|NCT03474718|EXPERIMENTAL|Group B|At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
62316680|NCT01236222|NO_INTERVENTION|Control group|
62316681|NCT01236222|EXPERIMENTAL|Cycling to school|
62316682|NCT05062317|EXPERIMENTAL|ctDNA (Low Risk)|Will receive less intense chemotherapy, such as capecitabine or 5-fluorouracil.
62316683|NCT05062317|EXPERIMENTAL|ctDNA (High Risk)|Will receive more intense chemotherapy. This may include resuming the chemotherapy you received before surgery (for example, FOLFOX \[5-fluorouracil, leucovorin and oxaliplatin\] or FOLFIRI \[5-fluorouracil, leucovorin and irinotecan\] with or without bevacizumab)
62316684|NCT04652687||VIA Disc NP|Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment
62316685|NCT04311476|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride infusion within 24 hours after birth
62316686|NCT04311476|EXPERIMENTAL|ACBMNC|Autologous Umbilical Cord Blood Mononuclear Cells intravenously within 24 hours after birth,dose is 5×107cells/kg ,
62316687|NCT00299884||1|Lipitor 20 mg
62316688|NCT00299884||2|Lipidil Supra 160 mg and Ezetrol 10 mg
62686287|NCT06570642|ACTIVE_COMPARATOR|Affect (+SAVOR) > Intensity|Participants receive affect-based goals for the first 8-weeks. In addition to the standard mHealth intervention, participants engage in the SAVOR enhancement to augment the treatment effects of the affect-based goals condition. Participants then cross-over to receive intensity-based goals for the second 8-weeks.
62686288|NCT06570642|ACTIVE_COMPARATOR|Intensity > Affect (+SAVOR)|Participants receive intensity-based goals for the first 8-weeks, then cross-over to receive affect-based goals for the second 8-weeks. In addition to the standard mHealth intervention, participants engage in the SAVOR enhancement to augment the treatment effects of the affect-based goals condition.
62686289|NCT06570642|ACTIVE_COMPARATOR|Affect (+TYPE/CONTEXT) > Intensity|Participants receive affect-based goals for the first 8-weeks. In addition to the standard mHealth intervention, participants engage in the TYPE/CONTEXT enhancement to augment the treatment effects of the affect-based goals condition. Participants then cross-over to receive intensity-based goals for the second 8-weeks.
62686290|NCT06570642|ACTIVE_COMPARATOR|Intensity > Affect (+TYPE/CONTEXT)|Participants receive intensity-based goals for the first 8-weeks, then cross-over to receive affect-based goals for the second 8-weeks. In addition to the standard mHealth intervention, participants engage in the TYPE/CONTEXT enhancement to augment the treatment effects of the affect-based goals condition.
62686291|NCT03902210|EXPERIMENTAL|Online Yoga|The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes (6 manufactured specifically for the cancer-afflicted patients instructed by Udaya yoga therapist, Jules Mitchell, MS). Patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes. Participants will be instructed to view a safety handout (see yoga safety \& modifications handout) before gaining access to the Udaya video library. Yoga therapist, Jules Mitchell and PIs Huberty and Palmer will pre-approve Udaya videos that are appropriate for this population.
62686292|NCT03902210|PLACEBO_COMPARATOR|Podcast|The podcast control group will be asked to view 60 minutes per week of online podcast videos. The podcast videos will contain general cancer-related health education material. To match the online yoga group for time and attention, 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a daily log (see podcast group weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.
62686293|NCT00720083|ACTIVE_COMPARATOR|RT + Cisplatin|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
62686294|NCT00720083|EXPERIMENTAL|RT + Cisplatin + Vandetanib|Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
61924563|NCT02670343|EXPERIMENTAL|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
62316689|NCT02199522|EXPERIMENTAL|titration induction of propofol|titration induction of propofol by Fresenius pump at the speed of 1 mg•kg-1•min-1
62316690|NCT02199522|NO_INTERVENTION|convention induction of propofol|propofol 2mg•kg-1 intravenously by Fresenius pump at the speed of 250mg•min-1
62316691|NCT03330743|NO_INTERVENTION|Usual care|
62316692|NCT03330743|PLACEBO_COMPARATOR|Parent Mentor|
62316693|NCT03330743|ACTIVE_COMPARATOR|Parent Mentor with Positive Deviance|
62316694|NCT06591819|EXPERIMENTAL|Treatment|The standard treatment for patients with prostate cancer is to receive brachytherapy boost and then radiation therapy in 25 fractions. This research study is being conducted to see how safe and effective delivering brachytherapy boost and then whole pelvis proton radiation therapy in 5 fractions (with each fraction having a higher dose than each fraction in the standard treatment) is in treating patients with prostate cancer. Subjects will also be asked to complete quality of life questionnaires for this study.
62316695|NCT00751881|EXPERIMENTAL|Teriflunomide 7 mg / 14 mg|Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
62316696|NCT00751881|EXPERIMENTAL|Teriflunomide 14 mg / 14 mg|Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
62316697|NCT00751881|PLACEBO_COMPARATOR|Placebo / Teriflunomide 14 mg|Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.
62316698|NCT00546819|EXPERIMENTAL|ZOSTAVAX™|Participants administered ZOSTAVAX™ on Day 1.
62316699|NCT00546819|PLACEBO_COMPARATOR|Placebo|Participants administered Placebo on Day 1.
62316700|NCT04632329|EXPERIMENTAL|Negative Pressure|
62686295|NCT00100750|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, tipifarnib)|Patients receive tipifarnib PO BID on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61924564|NCT06033508|ACTIVE_COMPARATOR|T2DM with neuropathy + WBV|Patients with type 2 Diabetes mellitus with neuropathy who will be trained by whole body vibration
62686296|NCT05384223|EXPERIMENTAL|RRFT (Risk Reduction through Family Therapy)|
61924565|NCT06033508|ACTIVE_COMPARATOR|T2DM without neuropathy + WBV|Patients with type 2 Diabetes mellitus without neuropathy who will be trained by whole body vibration
61924566|NCT06033508|PLACEBO_COMPARATOR|T2DM without neuropathy + land exercise|Patients with type 2 Diabetes mellitus without neuropathy who will be trained on land
61924567|NCT01129570|EXPERIMENTAL|Siliphos - dose escalation|
61924568|NCT06271174|EXPERIMENTAL|Loco-Regional Analgesia|"Patients will receive Loco-Regional Analgesia during General Anesthesia, and systemic analgesia if necessary~* Carbocaine"
61924569|NCT06271174|ACTIVE_COMPARATOR|Systemic Analgesia Only|"Patients will just receive General Anesthesia and systemic analgesia.~_ Profofol and/or Suxaméthonium and/or Sévoflurane"
61924570|NCT03841838|EXPERIMENTAL|Energy drink|Two 12 oz bottles of energy drink
61924571|NCT03841838|PLACEBO_COMPARATOR|Placebo|Two 12 oz bottles of placebo drink
62316701|NCT04632329|NO_INTERVENTION|Control Eye|
62686297|NCT05384223|ACTIVE_COMPARATOR|Treatment as Usual (TAU): Encompass|
62316702|NCT00777465||KDIGO 0|Patients with no acute kidney injury after cardiac surgery
62686298|NCT06221046|PLACEBO_COMPARATOR|Control|Patients will be treated with a standard of care for MASD.
62686299|NCT06221046|EXPERIMENTAL|Cream D|Patients will be treated with Cream D.
62686300|NCT02844712|OTHER|Evaluation of reexposure to a negatively tested betalactam|
62686301|NCT06671548|EXPERIMENTAL|Relugolix plus megestrol acetate/medroxyprogesterone acetate (the treatment group)|Relugolix 40 mg co-administered with megestrol acetate 1 mg and medroxyprogesterone acetate 2 mg for 12 weeks followed by 12 weeks of daily oral relugolix 40 mg co-administered with megestrol acetate 1 mg and medroxyprogesterone acetate 2 mg..
62686302|NCT06671548|PLACEBO_COMPARATOR|Placebo (the placebo group)|Relugolix 40 mg placebo co-administered with megestrol acetate 1 mg placebo and medroxyprogesterone acetate 2 mg placebo for 12 weeks followed by 12 weeks of daily oral relugolix 40 mg co-administered with megestrol acetate 1 mg and medroxyprogesterone acetate 2 mg.
62686303|NCT00558480|ACTIVE_COMPARATOR|1|Vitamin A
62686304|NCT00558480|PLACEBO_COMPARATOR|2|Vitamin A placebo
62686305|NCT04938531|EXPERIMENTAL|Exercise|Exercise, passive
62686306|NCT06691542|EXPERIMENTAL|Intralesional injection of Metformin|Group 1: will include 36 patients with multiple common, plantar and/or plane warts. They will be treated by intralesional injection of metformin using insulin syringe every 2-weeks until complete clearance or for a maximum of 6 sessions.
61924572|NCT02812303||Population Health Coordinator Support|"8 practices received the support of central population health coordinators (PHCs). PHCs utilized a population health management (PHM) information technology (IT) tool and performed administrative tasks including appointment scheduling, ordering overdue laboratory testing, chart reviews, and obtaining outside tests/labs. In addition, PHCs regularly met with physicians to review those patients who required clinical intervention to develop an action plan.~The network did not have sufficient resources to implement a PHC in all of the 18 network practices. So PHCs were allocated by responses from the practice leader, baseline quality scores, size of the practice, nature of the practice (health center vs not), and location of the practice. These decisions were made in a way that sought to equitably distribute available PHC resources within the practice network as a way to get network buy-in and maximize the impact of the program, both for practices with and without PHCs."
61924573|NCT02812303||No Population Health Coordinator Support|Ten practices without PHC support were provided training on how to use the PHM IT tool. The staff in these practices remained primarily responsible for managing administrative tasks.
61924574|NCT04827121|ACTIVE_COMPARATOR|Fascial iliac compartment block group|Patients in this group will recieve supra-inguinal fascial iliac compartment block after anesthesia induction.
61924575|NCT04827121|ACTIVE_COMPARATOR|Quadratus lumborum block group|Patients in this group will recieve quadratus lumborum block after anesthesia induction.
61924576|NCT00744471|EXPERIMENTAL|Tanezumab 10 mg|Tanezumab 10 mg IV every 8 weeks
61924577|NCT00744471|EXPERIMENTAL|Tanezumab 5 mg|Tanezumab 5mg IV every 8 weeks
61924578|NCT00744471|EXPERIMENTAL|Tanezumab 2.5 mg|Tanezumab 2.5 mg IV every 8 weeks.
61924579|NCT00744471|EXPERIMENTAL|Placebo|Placebo
62316703|NCT00777465||KDIGO 1|Patients with acute kidney injury KDIGO stage 1 after cardiac surgery (Increase in SCr by ≥ 0.3 mg/dL (≥ 26.5 lmol/L) or 1.5 to 1.9 times baseline)
62686307|NCT06691542|EXPERIMENTAL|Intralesional injection of platelet- rich plasma|Group 2: will include 36 patients with multiple common, plantar and/or plane warts. They will be treated by intralesional injection of platelet- rich plasma into the warts by an insulin syringe every 2 weeks until complete clearance or for a maximum of 6 sessions
62686308|NCT06691542|EXPERIMENTAL|Cryotherapy|Group 3: will include 36 patients with multiple common, plantar and/or plane warts. They will receive cryotherapy sessions every two weeks until complete clearance or for a maximum of 6 sessions.
62316704|NCT00777465||KDIGO 2|Patients with acute kidney injury KDIGO stage 2 after cardiac surgery (2.0 to 2.9 times baseline SCr)
62316705|NCT00777465||KDIGO 3|Patients with acute kidney injury KDIGO stage 3 after cardiac surgery (3.0 times baseline or more; or increase in SCr to ≥ 4.0 mg/dL; or initiation of renal replacement therapy)
62316706|NCT01461577|EXPERIMENTAL|insulin glargine|Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day. Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
62316707|NCT01257126|EXPERIMENTAL|diclofenac potassium|
62316708|NCT01257126|ACTIVE_COMPARATOR|nimesulide|
62316709|NCT01832311|EXPERIMENTAL|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
62316710|NCT01832311|EXPERIMENTAL|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
62316711|NCT01832311|NO_INTERVENTION|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
62316712|NCT01832311|NO_INTERVENTION|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
62686309|NCT03434886|EXPERIMENTAL|CF View|
62686310|NCT03434886|ACTIVE_COMPARATOR|CF Educational videos|
62686311|NCT03434886|ACTIVE_COMPARATOR|CF View and videos|
62686312|NCT03434886|NO_INTERVENTION|Usual standard of care|
62686313|NCT00910130||End Stage Renal Disease|Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes
62686314|NCT00910130||Control|"Healthy people, with normal Renal Function and without Diabetes, matched with ESRD group for age, gender, BMI"
62686315|NCT06573242|EXPERIMENTAL|DK:REACH-HF|12 weeks of homebased cardiac rehabilitation for patients with heart failure and their caregivers
62686316|NCT06570109||Frail|Defined by Fried Frailty Criteria
62686317|NCT06570109||Non-Frail/pre-frail|Defined by Fried Frailty Criteria
62686318|NCT06056544|EXPERIMENTAL|Intervention Group|C4 is a longitudinal intervention which provides individualized client-centered HIV prevention and support services designed to address health and psychosocial needs that impact the success of PrEP use and adherence (i.e., co-morbidities, substance use, mental health, housing, etc.).
62686319|NCT06056544|NO_INTERVENTION|Control Group|Individuals in the control group will receive standard of care for PrEP use at each clinic. The standard of care is PrEP clinical care includes identifying and engaging patients in need of PrEP, conducting necessary exams and lab tests and prescribing PrEP for the patients, as well as ongoing patient monitoring with follow-up visits and prescriptions-for as long as the patient needs PrEP.
62686320|NCT06690697|ACTIVE_COMPARATOR|TLS-negative patients with standard second-line treatment (sorafenib or axitinib)|Recurrent or metastatic clear cell renal cell carcinoma patients confirmed to be TLS-negative by HE/IHC assay will be treated with standard second-line treatment (sorafenib or axitinib).
62686321|NCT06690697|ACTIVE_COMPARATOR|TLS-positive patients treated with standard second-line treatment (sorafenib or axitinib)|Recurrent or metastatic clear cell renal cell carcinoma patients confirmed to be TLS- positive by HE/IHC assay will be treated with standard second-line treatment (sorafenib or axitinib).
62686322|NCT06690697|EXPERIMENTAL|TLS-negative patients treated with toripalimab and JS004|Recurrent or metastatic clear cell renal cell carcinoma patients confirmed to be TLS-negative by HE/IHC assay will be treated with toripalimab and JS004.
62686323|NCT06690697|EXPERIMENTAL|TLS-positive patients treated with toripalimab and JS004|Recurrent or metastatic clear cell renal cell carcinoma patients confirmed to be TLS- positive by HE/IHC assay will be treated with toripalimab and JS004.
62686324|NCT04572269||Subjects with OSA|Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI \>5)
62316713|NCT02163408||Healthy Volunteers|100 healthy volunteers will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality and image contrast will be compared between the two protocols.
62316714|NCT02163408||Patients with Carotid Artery Disease|40 patients will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality, image contrast, and composition analysis will be compared between the protocols.
62316715|NCT02963077|EXPERIMENTAL|Cohort 1 SAD - 0.1 mg A4250|Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
62316716|NCT02963077|EXPERIMENTAL|Cohort 2 SAD - 0.3 mg A4250|Dose: 0.3 mg of A4250.
62316717|NCT02963077|EXPERIMENTAL|Cohort 3 SAD - 1 mg A4250|Dose: 1 mg A4250.
62686325|NCT02098486|ACTIVE_COMPARATOR|Ceftraxone|ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)
62686326|NCT02098486|ACTIVE_COMPARATOR|Moxifloxacin|Intravenous moxifloxacin (400 mg/day, infused more than 60 min)
62316718|NCT02963077|EXPERIMENTAL|Cohort 4 SAD - 3 mg A4250|Dose: 3 mg A4250.
62316719|NCT02963077|EXPERIMENTAL|Cohort 5 SAD - 10 mg A4250|Dose: 10 mg A4250.
62316720|NCT02963077|PLACEBO_COMPARATOR|Cohort 1 SAD placebo|Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
62316721|NCT02963077|PLACEBO_COMPARATOR|Cohort 2 SAD placebo|Dose: 0.3 mg A4250 matching placebo.
62316722|NCT02963077|PLACEBO_COMPARATOR|Cohort 3 SAD placebo|Dose: 1 mg A4250 matching placebo.
62316723|NCT02963077|PLACEBO_COMPARATOR|Cohort 4 SAD placebo|Dose: 3 mg A4250 matching placebo.
62686327|NCT00963885|PLACEBO_COMPARATOR|Part 1: Placebo|Placebo in combination with standard doses of Pegasys and Copegus.
62686328|NCT00963885|EXPERIMENTAL|Part 1: RO5190591 300mg po|RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
62686329|NCT00963885|EXPERIMENTAL|Part 1: RO5190591 600mg po|RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
62686330|NCT00963885|EXPERIMENTAL|Part 1: RO5190591 900mg po|RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
62686331|NCT00963885|PLACEBO_COMPARATOR|Part 2: Placebo|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
62686332|NCT00963885|EXPERIMENTAL|Part 2: RO5190591 300mg po|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
62686333|NCT05118529|ACTIVE_COMPARATOR|Sitting in bed|Sitting in bed with 60 degrees elevated back-rest during 20 minutes
62686334|NCT05118529|EXPERIMENTAL|Sitting in chair|Sitting in chair during 20 minutes
62686335|NCT02042144||Group 1|
61924580|NCT02179775|ACTIVE_COMPARATOR|propranolol|
62126558|NCT05628493||The non-SALD group|The patient did not meet the SALD diagnosis during the study observation period. SALD was diagnosed when the level of serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1000IU/L, or total bilirubin (TBIL) level \>3mg/dL during hospitalization.
62126559|NCT05628493||The SALD group|The patient's maximum values of ALT, AST, or TBIL during hospitalization reached any of the SALD criteria.
62126560|NCT00566514|ACTIVE_COMPARATOR|1|D-ribose 5 grams TID orally
62126561|NCT00566514|PLACEBO_COMPARATOR|2|Dextrose 5 grams TID
62126562|NCT06238752|EXPERIMENTAL|first-line treatment with the combination of apatinib, immune checkpoint inhibitor and chemotherapy|Patients received 8 cycles of apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks, with a maintenance therapy with apatinib plus tislelizumab for a maximum of 1 year. Homogeneous patients receiving ICIs combined with chemotherapy at the same time were deemed as the control group for efficacy.
62316724|NCT02963077|PLACEBO_COMPARATOR|Cohort 5 SAD placebo|Dose: 10 mg A4250 matching placebo.
62686336|NCT01817946||Genetic testing|All participants determined eligible for the study will be placed into genetic testing arm.
62126563|NCT03678558|EXPERIMENTAL|Cytochalasin B supplemented vitrification medium|
62126564|NCT03678558|NO_INTERVENTION|Vitrification medium with no supplementation|
62126565|NCT02191319||Viramune®|Patients switching from protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) containing antiretroviral regimen to Viramune®
62316725|NCT02963077|EXPERIMENTAL|Cohort 1 MAD - 1 mg A4250 qd|Dose: 1 mg A4250 qd for 7 days.
62316726|NCT02963077|PLACEBO_COMPARATOR|Cohort 1 MAD placebo|Dose: 1 mg A4250 matching placebo qd for 7 days.
62316727|NCT02963077|EXPERIMENTAL|Cohort 2 MAD - 3 mg A4250|Dose: 3 mg A4250 qd for 7 days
62316728|NCT02963077|PLACEBO_COMPARATOR|Cohort 2 MAD placebo|Dose: 3 mg A4250 matching placebo qd for 7 days.
61924581|NCT02179775|ACTIVE_COMPARATOR|Quince's oxymel|
61924582|NCT02179775|PLACEBO_COMPARATOR|placebo|
61924583|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
61924584|NCT02563132|EXPERIMENTAL|Carbon dioxide insufflation colonoscopy (CO2)|Carbon dioxide during both insertion and withdrawal phase of the colonoscopy.
61924585|NCT02563132|NO_INTERVENTION|Air insufflation colonoscopy (AI)|Air insufflation during both insertion and withdrawal phase of the colonoscopy.
62126566|NCT04410458|EXPERIMENTAL|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic.
62316729|NCT02963077|EXPERIMENTAL|Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.|Dose: 1.5 mg A4250 b.i.d. for 7 days.
62316730|NCT02963077|PLACEBO_COMPARATOR|Cohort 3 MAD placebo|Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
62686337|NCT01855503||Metastatic Breast Cancer|
62316731|NCT02963077|EXPERIMENTAL|Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d|Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
62316732|NCT02963077|ACTIVE_COMPARATOR|Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d|Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
62686338|NCT01407614|ACTIVE_COMPARATOR|external lumbar drainage|Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
62126567|NCT04410458|EXPERIMENTAL|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
62126568|NCT04410458|EXPERIMENTAL|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
62126569|NCT04410458|PLACEBO_COMPARATOR|SMS with thank-you note|SMS content in this group will be thank-you note for their previous donation(s) .
62126570|NCT03504423|EXPERIMENTAL|CPI-613, mFolfirinox|"CPI-613, mFolfirinox~CPI-613 at 500 mg/m2 IV infusion at a rate of 4mL/min via a central venous port on day 1 and 3 of a 14-day cycle.~mFolfirinox (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 140mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
62126571|NCT03504423|ACTIVE_COMPARATOR|Folfirinox|"Folfirinox~Folfirinox: Oxaliplatin (Eloxatin) at 85 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 180mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
62316733|NCT02963077|EXPERIMENTAL|Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
62316734|NCT02963077|PLACEBO_COMPARATOR|Cohort 5 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
62316735|NCT02963077|ACTIVE_COMPARATOR|Cohort 6 MAD - 1 g CRC|Dose: 1 g CRC b.i.d
62316736|NCT02963077|PLACEBO_COMPARATOR|Cohort 6 MAD CRC placebo|Dose: 1 g CRC matching placebo b.i.d.
62316737|NCT02963077|EXPERIMENTAL|Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d
62316738|NCT02963077|PLACEBO_COMPARATOR|Cohort 7 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
62686339|NCT01407614|NO_INTERVENTION|No intervention|In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage
62686340|NCT05474716|EXPERIMENTAL|Topical Brimonidine 0.2% bid ophthalmic solution|Topical Brimonidine tartrate 0.2% ophthalmic solution used twice daily. It is a selective alpha 2 adrenergic agonist that is used as an ocular hypotensive in glaucoma and ocular hypertension patients and has proposed neuroprotective effect.
62686341|NCT03413449||Resections|Frailty model for patients undergoing esophagectomy and pneumonectomy/lobectomy for cancer
62316739|NCT05164276|ACTIVE_COMPARATOR|Sniffing group|Before intubation, the patient's shoulder is supported by a 5cm pillow to make neck flexion with extension of atlanto-occipital joint, confirming that the external auditory meatus and sternal notch plane are horizontal and aligned. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
62316740|NCT05164276|EXPERIMENTAL|Neutral group|Before intubation, the patient's head is placed without a pillow on the bed. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
62316741|NCT05164276|EXPERIMENTAL|Flexed group|Before intubation, the patient's neck is flexed with pads until the chin touches the chest. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
62316742|NCT03472534|OTHER|study in healthy volunteers|diacerein 1% ointment
62686342|NCT03069924|ACTIVE_COMPARATOR|Unframed Messaging|Unframed smoking cessation materials
62686343|NCT03069924|EXPERIMENTAL|Gain-framed Messaging|Gain-framed messaging
62686344|NCT04831619|EXPERIMENTAL|PET scanner in addition to MRI|
62686345|NCT02842242|EXPERIMENTAL|Open Label|MYK-461
62126572|NCT02423291|EXPERIMENTAL|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
62316743|NCT04879446|EXPERIMENTAL|A-PRF Test Group|Advanced Platelet Rich Fibrin liquid applied into the implant cavity and implant surface. That is the only difference between A-PRF control group and A-PRF test group.
62686346|NCT04212442|EXPERIMENTAL|Immediate Intervention|Upon enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
62126573|NCT01472146|EXPERIMENTAL|Zometa neoadjuvant HER2 breast cancer|"Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.~Drug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid"
62126574|NCT06295913|EXPERIMENTAL|Capsule of an olive extract with a high content of hydroxytytorosol (Hytolive®). Group 1|Intake of one capsule (Hytolive®)/day containing 15 mg of hydroxytyrosol before breakfast for 16 weeks.
62126575|NCT06295913|ACTIVE_COMPARATOR|Capsule of placebo. Group 2|Intake of one capsule placebo/day without hydroxytyrosol before breakfast for 16 weeks.
62126576|NCT03595852|EXPERIMENTAL|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing \>120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
62126577|NCT03595852|PLACEBO_COMPARATOR|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
62126578|NCT01828775|EXPERIMENTAL|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
62126579|NCT01828775|EXPERIMENTAL|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
62316744|NCT04879446|EXPERIMENTAL|CGF Test Group|Concentrated growth factor liquid applied into the implant cavity and implant surface. That is the only difference between CGF control group and CGF test group.
62316745|NCT04879446|EXPERIMENTAL|A-PRF Control Group|Dental implant applications were made with traditional methods.
62316746|NCT04879446|EXPERIMENTAL|CGF Control Group|Dental implant applications were made with traditional methods.
62316747|NCT05582122|NO_INTERVENTION|Standard follow-up monitoring (16 visits over 5 years)|"Patients enrolled in the control arm will be monitored according to SFORL guidelines. Physical Examination (PE) will be carried out:~- every 2 months the 1st year, every 3 months the 2nd year, every 4 months the 3rd year, every 6 months at 4 and 5 years.~Annual chest CT scan will be performed for current smokers \& for those who have quit smoking less than 15 years ago."
62316748|NCT05582122|EXPERIMENTAL|Lightened follow-up visits frequency (9 visits over 5 years), with HPV16 Ct-DNA dosing|"Physical Examinations (with HPV16 Ct-DNA dosing) planned at Months 4,8,12,18,24,30,36,48,60 post treatment.~Annual chest CT scan will be performed for current smokers \& for those who have quit smoking less than 15 years ago.~Any patient with a normal PE but positive HPV16 ct-DNA test during follow-up period will require a confirmation test \~1-2 months later.~If HPV16 ct-DNA positivity is confirmed, an H\&N MRI /PET-CT will be performed. Then:~* If MRI and PET-CT are negative, the patient will be examined every 2 months (PE and HPV16 Ct-DNA dosing) and MRI/PET-CT will be repeated every 4-6 months, until HPV16 Ct-DNA becomes undetectable.~* If MRI and/or PET-CT is positive, the patient will get a biopsy to confirm disease recurrence. Once confirmed, the patient will have the necessary care, as per local practices, but will continue to be followed up within this study up to 5 years after treatment."
62316749|NCT00380484|EXPERIMENTAL|1|Budesonide
62316750|NCT00380484|ACTIVE_COMPARATOR|2|Montelukast
62316751|NCT01943279|ACTIVE_COMPARATOR|Standard Follow-up (SFU)|Women selecting SFU at either site (BCBC or CIHC) will schedule their in-person follow-up appointment before leaving the BCBC clinic on Study Day 1, when they receive their medication. In-person follow-up appointment will be scheduled for Study Day 15 (± 3 days)where, as per usual care, includes a history and a Post-abortion Checklist, transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
62686347|NCT04212442|EXPERIMENTAL|Wait-list Control|Two months after study enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
62339696|NCT06349733|OTHER|Injection 0.9%Nacl|Immediately after operation 0.9%Nacl was injected on both sides of the knife edge, the injection volume per point was 0.1ml, the interval between each injection point on the same side of the knife edge was 1cm, and each injection point was away from the knife edge 0.5cm. It was injected only once immediately after operation.
62126580|NCT04916145|NO_INTERVENTION|No any treatment|Participants randomly assigned to this group will maintain a routine life without any treatments (no use of SAT-008).
62126581|NCT04916145|EXPERIMENTAL|Use of SAT-008|Participants randomly assigned to this group will be treated by SAT-008 during the study.
62316752|NCT01943279|EXPERIMENTAL|Remote Follow-up (RFU)|On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
62316753|NCT00987051|EXPERIMENTAL|1|Patients with endometrial cancer
62479178|NCT05377242|EXPERIMENTAL|Gulf War Veterans, Resveratrol|"All GWI Veterans will undergo the same screening and experimental procedures. Participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. This trial tests three interventions, which are all tested independently. Participants will receive only one of the three interventions. The curcumin, resveratrol, and stinging nettle trials all follow the same design and procedures.~Participants will complete one month of baseline, eight months of capsules, and one month of endline measurements."
62686348|NCT03127163|OTHER|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
62686349|NCT05327543|EXPERIMENTAL|Iyengar yoga|Intervention group 1 receives an Iyengar yoga intervention in a group setting, based on the internationally renowned yoga school of B.K.S. Iyengar, which in the context of this study primarily includes physical and relaxation exercises.
62686350|NCT05327543|EXPERIMENTAL|Meditative yoga|Intervention group 2 receives an Integrative yoga intervention including physical and meditation exercises as well as ideologically neutral explanations of the ethical aspects of Yoga.
62126582|NCT03169244|ACTIVE_COMPARATOR|Bupropion|Bupropion extended release
62316754|NCT02039271|NO_INTERVENTION|Standard of Care|Subjects will receive standard post-operative care after total knee replacment surgery
62316755|NCT02039271|EXPERIMENTAL|Music Therapy|Subjects will receive music therapy in addition to standard post-operative therapy.
62126583|NCT03169244|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet
62126584|NCT04348617|EXPERIMENTAL|Exercise-Rest|This group will perform the exercise condition at least 1 week after the preliminary visit and will perform the resting condition a minimum of 15 days and a maximum of 2 months after the exercise condition.
62126585|NCT04348617|EXPERIMENTAL|Rest-Exercise|This group will perform the resting condition at least 1 week after the preliminary visit and will perform the exercise condition a minimum of 15 days and a maximum of 2 months after the resting condition.
62316756|NCT02231216|EXPERIMENTAL|Rhinoseptoplasty and turbinectomy|Patients submitted to rhinoseptoplasty associated to Endoscopic partial turbinectomy.
62316757|NCT02231216|ACTIVE_COMPARATOR|Rhinoseptoplasty|Patients submitted only to rhinoseptoplasty, without turbinectomy procedure.
62316758|NCT00562510|EXPERIMENTAL|Raltegravir|
62316759|NCT00562510|PLACEBO_COMPARATOR|Raltegravir matching placebo|
62686351|NCT05327543|NO_INTERVENTION|Waitlist Control Group|Group 3 consists of a waitlist control group. Participants will be offered the opportunity to attend a yoga intervention after 4 months. The patients in this waiting list control group are allowed to choose the yoga course after 4 months.
62686352|NCT02853214|EXPERIMENTAL|Identification of genetic factors in dysglobulinemia cases|
62686353|NCT02591407|ACTIVE_COMPARATOR|TAP Block- Exparel|Transversus abdominis plane block utilizing the medication Exparel®
62686354|NCT02591407|ACTIVE_COMPARATOR|Continuous Epidural Analgesia|Continuous Epidural Analgesia
62126586|NCT01054924||U.S. CRC screening population|
62126587|NCT01751958|EXPERIMENTAL|Epidural Steroid injection|Group-Epidural Steroid injection (Intermittent)
62126588|NCT01751958|EXPERIMENTAL|Epidural Steroid Injection2|Group-injection under angiography (continuous)
62126589|NCT04622722|ACTIVE_COMPARATOR|Group A|Group A: Drinking Nutren Diabetes provides energy at 360 kcal per 360 ml
62126590|NCT04622722|PLACEBO_COMPARATOR|Group B|Group B: Having Isocaloric diet provide 360 kcal.
62126591|NCT01102231|EXPERIMENTAL|A|Chemoradiotherapy
62339697|NCT04640207|EXPERIMENTAL|Facial skin treatment|Facial skin treatment using the Alma Hybrid system.
62126592|NCT03757572|EXPERIMENTAL|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Alginate dressings with silver and high-G cellulose, which combine increased absorption properties, antimicrobial action and high coherence will be used. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials for latent breathing of the skin with dressing dimensions based on the wound size, will be also placed.~Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
62316760|NCT05090540||Transcatheter Edge to Edge Repair|TEER procedure is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of MV. If the use of one MitraClip device does not result in sufficient reduction in mitral regurgitation, a second MitraClip device may be used to reduce MR optimizing the procedure.
62479179|NCT05377242|EXPERIMENTAL|Gulf War Veterans, Stinging Nettle|"All GWI Veterans will undergo the same screening and experimental procedures. Participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. This trial tests three interventions, which are all tested independently. Participants will receive only one of the three interventions. The curcumin, resveratrol, and stinging nettle trials all follow the same design and procedures.~Participants will complete one month of baseline, eight months of capsules, and one month of endline measurements."
62479180|NCT03781622|EXPERIMENTAL|WOLF Thrombectomy Device Arm|Patients enrolled in the study who received the treatment and who met all Inclusion and Exclusion Criteria
62479181|NCT01315990|EXPERIMENTAL|FOLFIRI + Cetuximab|
62686355|NCT04343833|ACTIVE_COMPARATOR|Control with Standard dental implant|Patients were treated with implants Inhex Ticare Standard (Mozo Grau, Ticare, Valladolid, Spain). The implants presented a surface treated with Reabsorbable Blast Media (RBM), conical macro-design with non-aggressive threads, internal connection, and platform switching. On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
62686356|NCT04343833|EXPERIMENTAL|Test with the new implant design|Patients were treated with Implants Inhex Quattro Ticare (Mozo Grau, Ticare, Valladolid, Spain). The implants also presented a surface treated with RBM, conical macro-design with expanded micro threads, internal connection, and platform switching.On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
62686357|NCT06504966|EXPERIMENTAL|MAB-22|Single subcutaneous dose at Day 1 (baseline), 6 months (Week 26) and Visit 12 (Week 52)
62686358|NCT06504966|EXPERIMENTAL|Prolia® and MAB-22|Single subcutaneous dose of Prolia® at Day 1 (baseline), 6 months (Week 26) and single subcutaneous dose of MAB-22 (switching) or Prolia ® (non-switching) at Visit 12 (Week 52)
62686359|NCT04077086|EXPERIMENTAL|Intervention|Children at Intervention schools will receive free spectacles of a design they select, based on the child's measured refractive power and dispensed at school by the study optometrist. Additionally, teachers (but not children) in eligible classes will be informed that if 80% spectacle compliance as measured across three separate unannounced inspections was achieved, they will be given an incentive of an conditional cash transfer. The cash transfer will be deposited into the teacher's bank accounts directly.
62686360|NCT04077086|NO_INTERVENTION|Control|Children at Control schools will receive a glasses prescription and letter to the parents informing them of the refractive status of their child, with free glasses provided only at the end of the trial. No teacher incentive will be offered. Service offered to the Control group exceeds standard care, in that no school-based programs of vision screening and refraction currently exist in the study area, or in most of rural China.
62686361|NCT05347797|OTHER|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue. The KRAS Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
62686362|NCT03635879|ACTIVE_COMPARATOR|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
62686363|NCT03635879|ACTIVE_COMPARATOR|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
62686364|NCT03635879|ACTIVE_COMPARATOR|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
62686365|NCT03635879|ACTIVE_COMPARATOR|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
62686366|NCT03635879|ACTIVE_COMPARATOR|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
62686367|NCT03635879|EXPERIMENTAL|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
62686368|NCT05899959||Patients receiving an EKG holter|patients receiving an EKG holter at the outpatient clinic for 24-48 hours of remote monitoring
62686369|NCT05899959||Patients receiving an automatic blood pressure cuff|patients receiving an automatic blood pressure cuff at the outpatient clinic for 24 hours of remote monitoring
62479182|NCT00574847|EXPERIMENTAL|Escitalopram|Escitalopram treatment
62479183|NCT00574847|PLACEBO_COMPARATOR|Placebo|Placebo
62479184|NCT02006212|OTHER|cadiac surgical patient; One arm|All patients undergoing first or redo cardiac surgery with or without cardiopulmonary bypass necessitating general and/or local anesthesia. If they present any EEG abnormality intraoperatively an immediate cerebral CT scan will be performed and the necessary measures will be taken to reduce the neurologic damage.
62479185|NCT05686395|ACTIVE_COMPARATOR|group 1 Ultrasound-guided Interscalene Block group|In this group, ultrasound-guided ISB will be done using 10 ml of bupivacaine 0.25%.
62126593|NCT03757572|ACTIVE_COMPARATOR|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Wound care will be performed with the application of simple gauze dressings. Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
62479186|NCT05686395|ACTIVE_COMPARATOR|group 2 Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|, ultrasound-guided SHAC block will be done using 10 ml of bupivacaine 0.25% injected in the interfacial plane between deltoid and subscapular muscle and 10 ml of bupivacaine 0.25% injected in the pericapsular space. Ultrasound-guided SSN block will be done using 10 ml of bupivacaine 0.25% injected at sub omohyoid space.
62479187|NCT01734369||Healthy Control Subjects|Military service members active duty or no longer in duty, military contractors, and civilians working for the military. Controls should be without a recognized autoimmune or chronic muscle disease.
62686370|NCT03066518|PLACEBO_COMPARATOR|Melatonin|Melatonin 5 mg, daily, eight weeks
62686371|NCT03066518|PLACEBO_COMPARATOR|placebo|Placebo, daily, eight weeks
62686372|NCT05528445||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE) and Montreal-Cognitive-Assessment-Test(MoCA)
62686373|NCT06481072|EXPERIMENTAL|Intervention level 1 - patient education treatment.|Participants who are randomized to experimental condition arm 1 will be offered patient education for functional abdominal pain disorder (FAPD).
62686374|NCT06481072|EXPERIMENTAL|Intervention level 2 - patient education and iCBT|Participants who are randomized to experimental condition arm 2 will be offered patient education treatment and internet delivered cognitive behavior therapy (iCBT) treatment.
62686375|NCT04078516||Type 1 diabetes and painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
62686376|NCT04078516||Type 1 diabetes and non-painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
62126594|NCT03830086|OTHER|Group A: general anesthesia|Patients undergoing gynecological laparoscopic surgery under general anesthesia, using the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium, Sevoflurane
62686377|NCT04078516||Type 1 diabetes and no neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
62686378|NCT04078516||Matched controls without diabetes|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
62686379|NCT01918020|EXPERIMENTAL|Go Wild with Fruits and Veggies!|This group will receive nutrition education to learn about fruits and vegetables and physical activities right from the start of the experiment.
62686380|NCT01918020|OTHER|Go Wild with Fruits and Veggies! delayed|This group will only receive nutrition education about 4 months after the experiment starts.
62686381|NCT04210076|EXPERIMENTAL|Mindfulness-Based Attention Training for Teams (MBAT-T)|Teams randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
62686382|NCT04210076|ACTIVE_COMPARATOR|Mindfulness-Based Attention Training for Individuals (MBAT-I)|Individuals randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
62686383|NCT04210076|NO_INTERVENTION|No-training|Teams will not engage in any mindfulness training
62686384|NCT06690372|EXPERIMENTAL|Preliminary clinical efficacy and feasibility of 12-week home-based VR-Move exercise program|Following baseline (week 0) assessments participants will be instructed to maintain their daily activities as usual for four weeks. Following the 4-week control phase, and the pre-intervention data collection session participants will be provided with instructions on set-up and use of the VR exercise platform, clinical dashboard and mobile app. Participants will be issued a wireless heart rate monitor (Polar Electro Oy, Model 190027141, Kemple, Finland) to wear on their wrist during each exercise session, tracking heart rate. Participants will be asked to use the VR-Move platform independently following system prompts (as with any virtual exercise product). Over the 12-weeks, participants will be instructed to exercise with the VR-Move 3x/week for 30 minutes for 12-weeks total, with modules presented in a prescribed weekly sequence to provide novel and re-enforcement of modules, while ensuring all modules are performed. Further, participants will be provided the opportunity of a 30 m
62686385|NCT02901561|EXPERIMENTAL|misoprostol 200|misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
62479188|NCT01734369||Myositis Subjects|Diagnosis of myositis during military service or service as a military contractor or civilian working for the military with polymyositis, dermatomyositis, or inclusion body myositis.
62479189|NCT00841542|EXPERIMENTAL|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
62479190|NCT00841542|ACTIVE_COMPARATOR|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
62479191|NCT06485804|EXPERIMENTAL|Intervention group|Participants in the intervention group will use a smartphone application which will provide an individualized exercises program.
62479192|NCT06485804|NO_INTERVENTION|Control group|Participants in the control group will receive a rehabilitation program delivered on a paper sheet containing pictures of exercises with written explanations in French, including the number of sets and repetitions
62479193|NCT01163435|EXPERIMENTAL|high dose dual therapy|group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
62686386|NCT02901561|ACTIVE_COMPARATOR|misoprostol 400|misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
62126595|NCT03830086|OTHER|Group B: regional anesthesia|Patients undergoing gynecological laparoscopic surgery under regional anesthesia, using the following drugs: Sufentanil, Bupivacaine
62126596|NCT01566916|ACTIVE_COMPARATOR|Total Hip Arthroplasty performed via direct anterior approach|
62126597|NCT01566916|ACTIVE_COMPARATOR|Total Hip Arthroplasty using anterolateral approach|
62126598|NCT05511766|PLACEBO_COMPARATOR|PLACEBO|Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
62126599|NCT05511766|ACTIVE_COMPARATOR|Allopurinol|Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months
62126600|NCT05511766|ACTIVE_COMPARATOR|Simvastatin|Group 3: (atorvastatin n=50) who will receive oral atorvastatin 20 mg daily for 6 months
62126601|NCT03837431||CL suspicion|Individuals presenting with clinical suspicion of CL
62126602|NCT04157426|EXPERIMENTAL|Ultrasound-guided percutaneous electrolysis|
62126603|NCT04157426|ACTIVE_COMPARATOR|ultrasound-guided dry needling|
62479194|NCT01163435|EXPERIMENTAL|sequential therapy|group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
62479195|NCT01163435|ACTIVE_COMPARATOR|clarithromycin-based triple therapy|group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
62479196|NCT01163435|ACTIVE_COMPARATOR|levofloxacin-based triple therapy|group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)
62479197|NCT05569512|EXPERIMENTAL|Uproleselan with pre-transplant conditioning|"Participants will receive IV uproleselan on day -8 prior to stem cell transplant. Uproleselan will be administered IV twice daily from day -7 through day -2.~Participants will also receive a standard pre-transplant conditioning regimen with fludarabine, clofarabine and busulfan. Each of these 3 drugs will be administered IV once daily from day -7 through day -4."
62686387|NCT06571071|EXPERIMENTAL|De-Stress and Chill Gummies-U001|
62126604|NCT04446598|EXPERIMENTAL|Laser group|In the laser group, the patients received two sessions of Er:YAG intraurethral laser in non-ablative SMOOTH™ mode, with 1 month interval between sessions.
62126605|NCT04446598|ACTIVE_COMPARATOR|Tadalafil group|The tadalafil group was treated with daily oral administration of tadalafil, at a dose of 5 mg/day, which lasted consecutively for two months.
62126606|NCT00536341|EXPERIMENTAL|lenalidomide, fludarabine, rituximab|"Phase I Non-stratified, dose-escalation: \>=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed.~Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation."
62479198|NCT03122535|ACTIVE_COMPARATOR|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
62126607|NCT03424499|ACTIVE_COMPARATOR|Single-use catheter|"Participants will use a sterile single-use catheter of polyvinyl chloride (PVC) for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique, each PVC catheter will be sterile and used only once for each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
62316761|NCT05090540||Mitral Valve Replacement|Mitral-valve replacement includes complete preservation of the subvalvular apparatus to avoid dilation of the left ventricle over time. The technique of preservation, type of prosthetic valve implanted, and technique of suture placement has been chosen according to the preference of the surgeons. In SMR due to ischemic cardiomyopathy, CABG operation(Revascularization) is required
62126608|NCT03424499|EXPERIMENTAL|Reused catheter with 0.5% benzalkonium chloride|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soap after each catheterization and stored in a container with 0.5% benzalkonium chloride.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
62316762|NCT05090540||Restrictive Mitral Annuloplasty|RMA may be performed with the use of complete rigid or semi-rigid annuloplasty ring which has been downsized for the annulus diameter. Since patients who received RMA have coronary artery lesions, a CABG operation is useful to ensure favorable remodeling of the left ventricle.
62316763|NCT05090540||Restrictive Mitral Annuloplastie Plus Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SVR). The SVR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation. In patients who received SVR due to ischemic cardiomyopathy CABG operation is required
62316764|NCT05844527|EXPERIMENTAL|MRG-001|MRG-001 will be administered subcutaneously at 0.01 mL/kg bodyweight 3 times per week for 3 weeks.
62316765|NCT05844527|PLACEBO_COMPARATOR|Saline|Placebo will be administered subcutaneously at 0.01 mL/kg bodyweight 3 times per week for 3 weeks.
62316766|NCT02279329|OTHER|COPD and Bronchiectasis Patients|All enrolled COPD and Bronchiectasis patients will undergo Pulmonary Function Tests, Hyperpolarized Helium MRI, chest CT, 6-Minute Walk Test, and complete questionnaires at up to 8 visits over 2-3 years.
62479199|NCT03122535|ACTIVE_COMPARATOR|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
62479200|NCT06562621|EXPERIMENTAL|ON-01/ONF|ON-01: 1ml intratumoral injection of ON-01. ONF: 100 mg/kg/day orally after operation for 20 consecutive days.
62479201|NCT06034483|EXPERIMENTAL|Pelvic Floor Exercise Training|progressive pelvic floor muscle training for 8 weeks
62479202|NCT06034483|ACTIVE_COMPARATOR|Patient/Individual Education|Individual/patient education includes menopause, sexual health, pelvic floor health and lifestyle issues.
62479203|NCT06272942||Post intensive care unit (ICU) morbidity|All adult patients in Optum Claims data from January 1, 2016 until October 1, 2022.
62479204|NCT03324646||controls|healthy subjects
62686388|NCT06571071|EXPERIMENTAL|De-Stress and Chill Gummies-I001|
62126609|NCT03424499|EXPERIMENTAL|Reused catheter with soap and water|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soap after each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
62126610|NCT04433078|EXPERIMENTAL|Doxycycline|Participants receive 100 MG BID for 21 days
62316767|NCT01123447|ACTIVE_COMPARATOR|Surgery|Isolated ulnar shaft fractures will be treated with open reduction and internal fixation using a limited contact dynamic compression (LC-DC) plate with screws. These will remain at the fracture site for the lifetime of the patient.
62479205|NCT03138863|EXPERIMENTAL|FETO Group|Participants undergoing fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
62126611|NCT04433078|PLACEBO_COMPARATOR|Placebo|Participants receive Placebo BID for 21 days
62126612|NCT05264870|ACTIVE_COMPARATOR|Group A|combined spinal epidural anesthesia (CSE) with 7,5mg hyperbaric Marcaine and 2,5mcg Sufentanil
62126613|NCT05264870|ACTIVE_COMPARATOR|Group B|combined spinal epidural anesthesia (CSE) anesthesia with 10mg hyperbaric Marcaine and 2,5mcg Sufentanil
62126614|NCT00824135|EXPERIMENTAL|1|
62126615|NCT03379051|EXPERIMENTAL|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
62126616|NCT03379051|EXPERIMENTAL|Ublituximab + Umbralisib + Lenalidomide|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions; Umbralisib and Lenalidomide both administered days 1 - 21 of every 28 days
62126617|NCT01198028|EXPERIMENTAL|Treatment (erlotinib)|Participants receive erlotinib PO QD in the absence of disease progression or unacceptable toxicity.
62126618|NCT03667911|NO_INTERVENTION|Control Group|Only routine patient education on bowel preparation of colonoscopy. Give oral instructions on bowel preparation(including definition, significance, correct steps as well as dietary limitations) by a well-trained nurses or doctors. Written instructions are offered, which have the some contents.
62316768|NCT01123447|ACTIVE_COMPARATOR|Short arm cast|Those individuals randomized to the non-operative treatment group will be treated with a closed reduction and short-arm (below-elbow) cast.
62316769|NCT00003369|EXPERIMENTAL|tirapazamine/cisplatin|tirapazamine and cisplatin given Day 1 of each 21-day treatment cycle
62479206|NCT03367702|ACTIVE_COMPARATOR|Intensity-Modulated Radiation Therapy (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy (IMRT) once daily 5 fractions per week for 28 fractions over less than 32 business days.
62479207|NCT03367702|EXPERIMENTAL|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.
62479208|NCT06690333|ACTIVE_COMPARATOR|Left bundle area pacing|Transvenous pacemaker with left bundle area pacing
62479209|NCT06690333|ACTIVE_COMPARATOR|MICRA AV|Transcatheter pacemaker with MICRA AV
62479210|NCT05187481|EXPERIMENTAL|Experimental Group|The experimental group will take Jianpi Huatan dispensing granule while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
62686389|NCT06571071|PLACEBO_COMPARATOR|Placebo Gummies-001|
62126619|NCT03667911|EXPERIMENTAL|Virtual-reality Group|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
62126620|NCT02759913||Amyotrophic lateral sclerosis|Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
62126621|NCT02759913||ALS mimics|Other motorneuron disorders, isolated upper and lower motoneuron disorders Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection
62126622|NCT05744258|OTHER|IBS patients|
62316770|NCT04346823|EXPERIMENTAL|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3 minutes. Then, parturients breath 1% of sevoflurane in mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min. Values of inspired (FI) and end-tidal (FET) concentrations of sevoflurane, oxygen and respiratory rate (RR) measured by end-tidal carbon dioxide (EtC02) were monitored continuously and recorded at 30 seconds intervals by a gas analyzer.~30 seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure. HR, FI and FET concentration of sevoflurane, Sp02 and EtC02 will be recorded at 30-s interval during ECV. Non-invasive BP will be recorded every one minute. Duration of ECV in addition to level of difficulty estimated by obstetrician will be recorded.~ECV considered successful when a cephalic presentation, confirmed by ultrasound scan, achieved."
62316771|NCT04346823|NO_INTERVENTION|No sevoflurane|If the parturient is assigned to the control (nonintervention) group, the participants will not receive any medications neither tocolytics nor analgesics as the routine care in our hospital. However, the participants will be monitored throughout the procedure for vital signs and for pain scores as in the intervention group.
62316772|NCT03061968|EXPERIMENTAL|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
62316773|NCT03061968|NO_INTERVENTION|control group|The control group only receive routine care in sick baby room unite.
62316774|NCT01713400|EXPERIMENTAL|Ustekinumab|Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
62126623|NCT05744258|OTHER|Healthy volunteers|
62126624|NCT02709304|PLACEBO_COMPARATOR|Standard Gel|Standard gel not containing local anesthetic used to insert urinary catheters.
62126625|NCT02709304|EXPERIMENTAL|Lidocaine Gel|lidocaine containing gel uses to insert urinary catheters
62126626|NCT00373373|PLACEBO_COMPARATOR|A|Chemotherapy + Placebo
62126627|NCT00373373|ACTIVE_COMPARATOR|B|Chemotherapy + Sorafenib
62126628|NCT04232371|ACTIVE_COMPARATOR|New Ablation Technique|Will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
62126629|NCT04232371|ACTIVE_COMPARATOR|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
62126630|NCT00875160|EXPERIMENTAL|AT2101|
62126631|NCT05830942|ACTIVE_COMPARATOR|Walking Exercise plus active tDCS|The walking exercise will focus on use of complex walking tasks such as obstacle crossing, accurate foot placement, and walking on compliant surfaces. Each session will consist of 30 minutes of walking. Active tDCS will be delivered over prefrontal cortex.
62126632|NCT05830942|SHAM_COMPARATOR|Walking Exercise plus sham tDCS|The walking exercise will focus on use of complex walking tasks such as obstacle crossing, accurate foot placement, and walking on compliant surfaces. Each session will consist of 30 minutes of walking. Sham tDCS will be delivered over prefrontal cortex.
62126633|NCT00388661|ACTIVE_COMPARATOR|Melatonin|melatonin 3mg
62126634|NCT00388661|PLACEBO_COMPARATOR|Placebo|
62126635|NCT00296036|EXPERIMENTAL|Arm I (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
62126636|NCT00296036|EXPERIMENTAL|Arm II (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
62126637|NCT00296036|EXPERIMENTAL|Arm III (closed to accrual as of 10/24/2007)|Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
61924586|NCT04801316|OTHER|Part 1: Video training|"Participants will undergo the following procedures:~Community instructors (involved in the training itself):~* Attend a video-facilitated training~* Be assessed for competency level of class execution before and after the video-facilitated training~* Might need to conduct or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)~* Might need to participate in one interview/discussion which will last up to 2 hours~Community-dwelling older adult or community providers (individuals involved in the programme implementation but not the training itself):~* Attend or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)~* Participate in one interview/discussion which will last up to 2 hours"
61924587|NCT04801316|EXPERIMENTAL|Part 2: Exercise Intervention|"Participants will participate in 6 months of exercises, and be provided with education and advice on how to reduce their risk of falls.~The exercises are divided into 2 phases:~1. The Steady Feet (SF) exercise programme phase. A twice-weekly tailored structured group exercise class will be conducted for 3 months with community instructors and exercise video.~2. A 3 months maintenance exercise phase. A once-weekly structured community group exercise class."
61924588|NCT04801316|NO_INTERVENTION|Part 2: Control|Participants will be provided with the usual education and advice on how to reduce their risk of falls.
61924589|NCT01165333|EXPERIMENTAL|Dose escalation|In the first part of the trial, a dose-ranging study in ca. 18-21 patients will be done. A standard dose escalation strategy will be used including 3 to 6 patients at each dose level, the first cohort of patients being treated at dose level one Interventions : Cilengitide dose escalation ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
61924590|NCT01165333|EXPERIMENTAL|Cohort extension|An additional 20 patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations Interventions : Cilengitide ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
62316775|NCT01713400|PLACEBO_COMPARATOR|Placebo|Placebo, Tacrolimus, and Sirolimus. Placebo: Identical volume to that of ustekinumab. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
62316776|NCT06173492|EXPERIMENTAL|Socket ridge preservation with PRF|40 ml of blood is drawn and collected in plastic tubes of 10 ml. The tubes are placed in a centrifuge at 2700 rpm for 12 minutes to get the clot of fibrin. After extraction, the clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
62316777|NCT06173492|ACTIVE_COMPARATOR|Spontaneous healing|No treatment is applied. The socket is made to heal spontaneously.
62316778|NCT05113823|ACTIVE_COMPARATOR|High Fidelity Simulator|Subjects will receive training using high fidelity simulator
62316779|NCT05113823|ACTIVE_COMPARATOR|Low Fidelity Simulator|Subjects will receive training using low fidelity simulator
62316780|NCT06043310||AMAB + continuous estrogen|Identify as assigned male at birth (AMAB) who have had continuous estrogen treatment for a minimum of 1 year.
62316781|NCT06043310||AMAB - continuous estrogen|Identify as assigned male at birth (AMAB) who have not had continuous estrogen treatment for a minimum of 1 year.
62339698|NCT06017583|EXPERIMENTAL|Experimental arm|The experimental group will receive concurrent simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) and concurrent capecitabine chemotherapy, and complete 2 \~ 4 cycles of XELOX chemotherapy, while receiving full tislelizumab treatment for at least 4 cycles (21 days per cycle).
62316782|NCT04981340|EXPERIMENTAL|Standard urotherapy + Diaphragmatic breathing exercises+ pelvic floor exercises|Diaphragmatic breathing exercises will be demonstrated by a qualified physiotherapist. Exercises will be done in lying and sitting positions respectively. In supine, with the lower extremities supported over a pillow and hands positioned on the abdominal muscles, children will be asked to inhale the air through the nose, bulge the abdomen outwards as much as possible, hold their breath for a few seconds, and then exhale slowly through pursed lips. The same exercise will be then performed in both side-lying positions and in a sitting position in front of the mirror. Children will be instructed to watch the anterior abdominal wall movement during inspiration and to repeat the same action while seated on the toilet to initiate voiding. They will be asked to perform the diaphragmatic breathing exercises daily at home.
62316783|NCT04981340|ACTIVE_COMPARATOR|Standard urotherapy|Standard urotherapy will start with the education of the children and their parents about the normal function of the bladder and external urinary sphincter and the nature of their voiding disorder. The importance of regular fluid intake (200 ml 5-6 times per day) and regular voiding will be explained. Special voiding and defecation diaries that a child has to fill out at home will be provided. An optimal voiding posture will be demonstrated in front of a mirror: a sitting position, with feet supported, hips abducted and abdominal muscles relaxed.
62316784|NCT05819632|EXPERIMENTAL|curcumin gel|the denuded palatal area will be superficially covered with a continuous thin layer of curcumin gel 2% one time immediately after the surgery (curcumin gel will be prepared in 2% concentration on a carbapol base)according to (Bhatia et al., 2014)
62316785|NCT05819632|ACTIVE_COMPARATOR|gelatine sponge|"absorbable gelatin sponge will be cut to the palatal wound size and applied. Following manual compression of the wound area, both agents will be secured in place using compressive palatal sling sutures.~commercial name (CUTANPLAST)"
62316786|NCT01950078||surgical patients|grouped by receiving surgery
62316787|NCT01950078||Healthy volunteers group|grouped by healthy college students
62316788|NCT06237842||Healthy participants|Participants from 3 to 18 years old, from both genders and with no sleep disorders
62316789|NCT06237842||Participants with sleep disorders|Participantes with one sleep disorder or complaint.
62316790|NCT03464097|EXPERIMENTAL|Ozanimod|
62316791|NCT03464097|PLACEBO_COMPARATOR|Placebo|
62316792|NCT00224107|EXPERIMENTAL|Silodosin|Silodosin 8 mg once daily with food
62316793|NCT00224107|PLACEBO_COMPARATOR|placebo|Matching Placebo capsule once daily with food
62479211|NCT05187481|PLACEBO_COMPARATOR|Control Group|The experimental group will take Placebo granule (containing 1/10 of the formula dose of Jianpi Huatan Granule) while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
62479212|NCT03036748|EXPERIMENTAL|TX control|Kidney transplant recipients with urinary albumin/creatinin-ratio \< 30mg/g
62479213|NCT03036748|EXPERIMENTAL|TX Proteinuria|Kidney transplant recipients with urinary albumin/creatinin-ratio \> 300mg/g
62316794|NCT05078567|EXPERIMENTAL|Single arm open label study|Topical used natural lactic acid-enriched cream twice daily.
62316795|NCT01810159|EXPERIMENTAL|ICC|Integrated collaborative care
62316796|NCT01810159|ACTIVE_COMPARATOR|E&R|Education and Resources--enhanced usual care
62316797|NCT05347914|EXPERIMENTAL|Mindfulness|
62316798|NCT02573805||erectile dysfunction group|International Index of Erectile Function (IIEF-5) questionnaire≥22 Rigiscan test are performed for two nights
62316799|NCT02573805||control group|International Index of Erectile Function (IIEF-5) questionnaire\<22 Rigiscan test are performed for two nights
61924591|NCT03005938|EXPERIMENTAL|Spinal manipulation|Spinal manipulation
62316800|NCT01508078||Asthmatics|Otherwise healthy asthmatic subjects
62316801|NCT01508078||Healthy controls|Healthy individuals without evidence of pulmonary disease.
62316802|NCT04364672|EXPERIMENTAL|Women with stage 1-4 newly diagnosed breast cancer|
62316803|NCT04905914|EXPERIMENTAL|50mg ATRN-119|Once daily oral administration.
62316804|NCT04905914|EXPERIMENTAL|100mg ATRN-119|Once daily oral administration.
62316805|NCT04905914|EXPERIMENTAL|200mg ATRN-119|Once daily oral administration.
62316806|NCT04905914|EXPERIMENTAL|350mg ATRN-119|Once daily oral administration.
62316807|NCT04905914|EXPERIMENTAL|400mg ATRN-119|Twice daily oral administration.
62316808|NCT04905914|EXPERIMENTAL|1100mg ATRN-119|Once daily oral administration
62316809|NCT04905914|EXPERIMENTAL|1300mg ATRN-119|Once daily oral administration
62316810|NCT04905914|EXPERIMENTAL|1500mg ATRN-119|Once daily oral administration
62316811|NCT04905914|EXPERIMENTAL|650mg ATRN-119|Twice daily oral administration.
62316812|NCT04905914|EXPERIMENTAL|750mg ATRN-119|Twice daily oral administration.
62316813|NCT04905914|EXPERIMENTAL|550mg ATRN-119|Once or twice daily oral administration
62316814|NCT01176851|EXPERIMENTAL|Glyco pMDI|Glyco pMDI 100 µg
62479214|NCT05156983|EXPERIMENTAL|TAK-330 25 IU/kg|Participants will receive TAK-330, 25 international unit per kilogram (IU/kg) single intravenous infusion on Day 1 (prior to surgery) as an initial dose and an additional dose of 25 IU/kg TAK-330 can be administered during the surgery if deemed necessary by the surgeon. The total dose of TAK-330 administered to the participant should not exceed 50 IU/kg or 5,000 IU, whichever is smaller.
62479215|NCT05156983|ACTIVE_COMPARATOR|SOC 4F-PCC|Participants will receive 4F-PCC (excluding Prothromplex Total and activated 4F-PCC) as standard of care (SOC) on Day 1 (prior to surgery). The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
62479216|NCT04165252||Term Birth|Delivery between 37-41 weeks of gestation
62479217|NCT04165252||Preterm birth|Delivery between 24-37 weeks of gestation
62479218|NCT06044090|EXPERIMENTAL|Placebo followed by Minocycline|In this arm, participants will take a 5-day course of placebo-control pills and then a 5-day course of 200 mg of minocycline. Sessions will be separated by a minimum washout period of 14 days.
61924592|NCT03005938|SHAM_COMPARATOR|Imitation of the spinal manipulation|Imitation of the spinal manipulation
62316815|NCT01176851|EXPERIMENTAL|Glyco pMDI Charcoal|Glyco pMDI 100 µg + charcoal block
62479219|NCT06044090|EXPERIMENTAL|Minocycline followed by Placebo|In this arm, participants will take a 5-day course of 200 mg of minocycline and then a 5-day course of placebo-control pills. Sessions will be separated by a minimum washout period of 14 days.
62686390|NCT06691360|EXPERIMENTAL|AK137|Each subject will receive a single dose of AK137 every 3-week cycle (Q3W) or every 2-week cycle (Q2W). Participants may continue on study drug until unacceptable toxicity, or other withdrawal criteria is met.
62686391|NCT06446323|ACTIVE_COMPARATOR|Group I: Neonates receiving a 0.2 ml dose of sucrose solution|Participants in this arm receive a 0.2 ml dose of sucrose solution. Care providers administer the specified dose of sucrose solution to neonates who have undergone minor procedures and are experiencing post-procedural pain. The dose is administered orally, following standardized protocols. Participants in this group are monitored for pain intensity using the Premature Infant Pain Profile (PIPP) by investigators who are masked to the treatment allocation. Data on pain scores and any adverse events are recorded and analyzed as part of the study.
62686392|NCT06446323|ACTIVE_COMPARATOR|Group II: Neonates receiving a 0.5 ml dose of sucrose solution.|Participants in this arm receive a 0.5 ml dose of sucrose solution. Similar to Arm 1, care providers administer the specified dose orally to neonates following minor procedures. The administration is conducted according to standardized protocols. Pain intensity in this group is also monitored using the Premature Infant Pain Profile (PIPP) by investigators who remain masked to the treatment allocation. Data collected includes pain scores and any adverse events experienced by participants.
61924593|NCT03734744|EXPERIMENTAL|Adults with Cystic Fibrosis|CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
62126638|NCT00296036|PLACEBO_COMPARATOR|Arm IV (closed to accrual as of 10/24/2007)|Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
62126639|NCT00296036|EXPERIMENTAL|Arm V|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
62126640|NCT00296036|PLACEBO_COMPARATOR|Arm VI|Patients receive placebo cream applied to palms and soles twice daily on days 1-21.
62316816|NCT01176851|ACTIVE_COMPARATOR|Glyco IV injection|Glyco solution for injection 100 µg
62339699|NCT06017583|PLACEBO_COMPARATOR|Control arm|The control group received intensity-modulated radiotherapy (IMRT) without tirellizumab, and the other treatment regiments were consistent with the experimental group.
62479220|NCT01678222||SNP|individuals who are homozygous for either the major or minor variant of both SNPs
62479221|NCT01180322|ACTIVE_COMPARATOR|Arm A|Standard Therapy
62479222|NCT01180322|EXPERIMENTAL|Arm B|"Investigational Therapy Azacitidine Prior"
62479223|NCT01180322|EXPERIMENTAL|Arm C|"Investigational Therapy Azacitidine Concurrent"
62479224|NCT01180322|EXPERIMENTAL|Arm D|"Investigational Therapy Azacitidine After"
62479225|NCT05636735||midwife students group|midwife students in France
62479226|NCT02311361|EXPERIMENTAL|Durvalumab + 8 Gray (Gy) in 1 fraction|Cohort 1/Dose Level A1 Durvalumab + 8 Gray (Gy) in 1 fraction
62479227|NCT02311361|EXPERIMENTAL|Durvalumab +5 Gy in 5 fractions|Cohort 2/Dose Level A2 Durvalumab +5 Gy in 5 fractions
62316817|NCT01544595|PLACEBO_COMPARATOR|PASI 75 Responders|"PASI 75 responders participated in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen."
62316818|NCT01544595|EXPERIMENTAL|Partial responders|Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.
62316819|NCT03074175|EXPERIMENTAL|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
62316820|NCT03074175|EXPERIMENTAL|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion \>5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
62479228|NCT02311361|EXPERIMENTAL|Tremelimumab + 8 Gy in 1 fraction|Cohort 3/Dose Level B1 (was removed with Amendment A) Tremelimumab + 8 Gy in 1 fraction
62316821|NCT04016363|EXPERIMENTAL|ProbeFix arm|The echocardiography probe is fixated on the patient's thorax using the ProbeFix
62479229|NCT02311361|EXPERIMENTAL|Tremelimumab + 5 Gy in 5 fractions|Cohort 4/Dose Level B2 (was removed with Amendment A) Tremelimumab + 5 Gy in 5 fractions
62479230|NCT02311361|EXPERIMENTAL|Durvalumab +Tremelimumab + 8 Gy in 1 fraction|Cohort C/ Dose Level C1 Durvalumab +Tremelimumab + 8 Gy in 1 fraction
62479231|NCT02311361|EXPERIMENTAL|Durvalumab +Tremelimumab +5 Gy in 5 fractions|Cohort C/Dose Level C2 Durvalumab +Tremelimumab +5 Gy in 5 fractions
61924594|NCT03734744|EXPERIMENTAL|Non-CF Controls with Low vitamin D|Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
62126641|NCT02509637|ACTIVE_COMPARATOR|Flutter Intervention|After initial evaluation, the subjects will perform breathing exercises with quiet inspiration and prolonged expiration on the device for thirty minutes, with breaks of one minute every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
62479232|NCT03948503|EXPERIMENTAL|Mobilization with movement (MWM) group|Application of the Mulligan concept
62479233|NCT03948503|PLACEBO_COMPARATOR|Sham group|Sham treatment
62479234|NCT06167122||Craniofacial fibrous dysplasia|Fibro-osseous lesions within the affected bones based on image, and surgical intervention based on 4 different anatomical zones.
62479235|NCT06660368|EXPERIMENTAL|CLAG-based therapy with venetoclax|Study participants will receive CLAG-M (cladribine, cytarabine, G-CSF, mitoxantrone) and Venetoclax
61924595|NCT04165811|EXPERIMENTAL|Aerobic Dance based Exercise|The exercise program will be administered 60 minutes, 2 days a week for 8 weeks. The exercise program will be created by physiotherapists as a group exercise program.
61924596|NCT04165811|EXPERIMENTAL|Counseling of physical activity|Physical activity counseling is aimed at increasing the physical activity levels of the individuals who are waiting for bariatric surgery in the preoperative period.
61924597|NCT03660631|EXPERIMENTAL|CVRS Early Intervention|Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
62479236|NCT06660368|ACTIVE_COMPARATOR|CLAG-based therapy without venetoclax|Study participants will receive CLAG-M (cladribine, cytarabine, G-CSF, mitoxantrone)
62479237|NCT00649987|EXPERIMENTAL|1|Albuterol Sulfate Extended-Release Tablets 8 mg
62479238|NCT00649987|ACTIVE_COMPARATOR|2|VoSpire® ER Tablets 8 mg
62479239|NCT03757845|NO_INTERVENTION|Control diet|
62479240|NCT03757845|EXPERIMENTAL|Mediterranean diet|
62479241|NCT02588339|EXPERIMENTAL|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
62479242|NCT06052267|EXPERIMENTAL|TEV-56248 Low Dose|Inhalation powder via multidose dry powder inhaler with integrated electronic module (eMDPI) with a dosing frequency of 2 inhalations as needed to control asthma symptoms.
62686393|NCT03720808|EXPERIMENTAL|Balloon Blowing|Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
62479243|NCT06052267|EXPERIMENTAL|TEV-56248 High Dose|Inhalation powder via multidose dry powder inhaler with integrated electronic module (eMDPI) with a dosing frequency of 2 inhalations as needed to control asthma symptoms.
62479244|NCT06052267|ACTIVE_COMPARATOR|Albuterol sulfate|Inhalation powder via multidose dry powder inhaler with integrated electronic module (eMDPI) with a dosing frequency of 2 inhalations as needed to control asthma symptoms.
62479245|NCT05801315|EXPERIMENTAL|Full mouth ultrasonic debridement plus glycine powder air polishing|Plaque and calculus are firstly removed through full mouth ultrasonic debridement (FMUD) in all sites (both dental and implant). After this procedure an air polishing device (Air-flow Master Piezon®) is used as additional therapy to further debride peri-implant trans-mucosal tract.
62316822|NCT04016363|ACTIVE_COMPARATOR|Controll arm|The sonographer manually holds the probe on the patient's thorax
62316823|NCT05914272||trement group|Patient has used osmotic drugs within 72 hours of admission.
62316824|NCT05914272||control group|Patient has not used osmotic drugs within 72 hours of admission.
62316825|NCT01264991|EXPERIMENTAL|APM group|
62316826|NCT01264991|PLACEBO_COMPARATOR|Sham group|
62316827|NCT00991627|ACTIVE_COMPARATOR|Pharmacological|Patients in this group will receive a basal infusion of ephedrine. Hypotension will be treated for a reduction in systolic blood pressure 20% below baseline values.
62479246|NCT05801315|ACTIVE_COMPARATOR|Full mouth ultrasonic debridement|Plaque and calculus are removed through full mouth ultrasonic debridement (FMUD) in all sites (both dental and implant).
62479247|NCT05337540|EXPERIMENTAL|EVI-01 - low dose|4 mL, one single EVI-01 intra-articular injection
62479248|NCT05337540|EXPERIMENTAL|EVI-01 - high dose|6 mL, one single EVI-01 intra-articular injection
62126642|NCT02509637|ACTIVE_COMPARATOR|Chest Compression Intervention|After initial evaluation, the subjects will be instructed to perform deep breaths between three quiet inspiration brought, and expiration will be accompanied by bilateral compression with the therapist's hands on the lower ribs during thirty minutes with one minute intervals of rest every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
62126643|NCT02509637|ACTIVE_COMPARATOR|Crontrol Intervention|After initial evaluation, patients will be remain seated quiet breathing without any guidance for thirty minutes. Immediately after this time will be held reassessment with Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied to acceptance and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for wight, adhesiveness and purulence.
62126644|NCT01618643||Acetic acid chromoendoscopy|"* Patients with known Barrett's metaplasia under surveillance~* Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia~* Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion"
62126645|NCT02794194|NO_INTERVENTION|Control group|No intervention
62126646|NCT02794194|EXPERIMENTAL|Vibration group|Proprioceptive training on a whole body vibration platform. Participants in the Vibration group trained with a BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
62126647|NCT02794194|EXPERIMENTAL|Non-vibration group|Proprioceptive training with the BOSU® on the floor. Participants in the Non-Vibration group trained with a BOSU® on the floor.
62126648|NCT00823225|OTHER|A: Standard therapy|
62126649|NCT00823225|EXPERIMENTAL|B: Urokinase|
62126650|NCT06478992|OTHER|the thickness of the thickest uterine myometrium ≥30mm|
62126651|NCT06478992|OTHER|the thickness of the thickest uterine myometrium <30mm|
62126652|NCT02382328|EXPERIMENTAL|alpha lipoic acid|600mg/24 oral pills alpha lipoic acid 28 days before and 120 days after carpal tunnel release.
62126653|NCT02382328|PLACEBO_COMPARATOR|Placebo|Oral pills of mangensium inactivated 28 days before and 120 days after carpal tunnel release.
62479249|NCT05337540|ACTIVE_COMPARATOR|Synvisc-One|6 mL, one single intra-articular injection
62479250|NCT06155721|EXPERIMENTAL|Virtual Reality Cognitive Stimulation Program|"Participants with MCI undergo 8 VR sessions, using Oculus Quest 2 headsets for immersive cognitive exercises. Activities include a Supermarket Shopping Task for memory, a Payment Task for cognitive flexibility, and a Recipe Sequencing Task for problem-solving. Additionally, 360-degree videos with visuo-verbal stimulation are used to engage attention and episodic memory, monitored by therapists.~The investigators employ Oculus Quest 2 VR headsets with hand tracking technology to provide a seamless and immersive experience, especially beneficial for participants with Mild Cognitive Impairment (MCI)."
62479251|NCT06561841|EXPERIMENTAL|Treatment group A|
62479252|NCT06561841|EXPERIMENTAL|Treatment group B|
62479253|NCT06561841|EXPERIMENTAL|Treatment group C|
62479254|NCT05453422|EXPERIMENTAL|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
61924598|NCT03660631|OTHER|CVRS Delayed Intervention|Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
62126654|NCT03364595||Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the radial head fracture will be carried out
62126655|NCT03364595||Replacement|The operating surgeon will determine the positioning of the patient for surgery. During the surgery, they take out the the comminuted radial head and proceed replacement using artificial.
62126656|NCT04585412|EXPERIMENTAL|Palonosetron (Stothu®)|Stothu® Solution for Injection 0.25 mg/5 mL
62126657|NCT04585412|ACTIVE_COMPARATOR|Palonosetron (Aloxi®)|Aloxi® Solution for Injection 0.25 mg/5mL
62126658|NCT05712993|EXPERIMENTAL|transcoronoid|participants are TN patients complain TN without secondary causes of trigeminal neuralgia underwent V2 targeting through coronoid notch
62126659|NCT05712993|EXPERIMENTAL|infrazygomatic anterior out of plane|participants are TN patients complain TN without secondary causes of trigeminal neuralgia underwent V2 targeting through infrazygomatic anterior out of plane
62126660|NCT00726596|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine - 400 mg (cohort A) Hydroxychloroquine - 600 mg (cohort B)
62126661|NCT00335049|EXPERIMENTAL|PAL|Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
62126662|NCT00335049|ACTIVE_COMPARATOR|SVL|Single Vision Lenses (SVLs) worn both years of the study.
62126663|NCT06554743|EXPERIMENTAL|Default Veg|Received a plant-based meal as the default option on the event RSVP form that required participants to pre-select their meal choice
62126664|NCT06554743|ACTIVE_COMPARATOR|Default Meat|Received a meal with meat as the default option on the event RSVP form that required participants to pre-select their meal choice
61924599|NCT02195284|EXPERIMENTAL|Sub-study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler
62316828|NCT00991627|EXPERIMENTAL|Non-Pharmacological|Patients in this group will undergo uterine lateral displacement through the use of a wedge-shaped cushion placed under their right hip. Hypotension will be treated for a reduction in systolic blood pressure 40% below baseline values.
62316829|NCT01563588|EXPERIMENTAL|dietary and physical training|12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
62316830|NCT01563588|NO_INTERVENTION|control|dietary counseling by a dietetician in the anticancer hospital
62316831|NCT06275165|EXPERIMENTAL|acupressure|Participants received routine care and acupressure.
62316832|NCT06275165|NO_INTERVENTION|no intervision|received routine care
62316833|NCT03777956|ACTIVE_COMPARATOR|Lacosamide|Lacosamide (50 mg) are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
62686394|NCT03720808|EXPERIMENTAL|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
61924600|NCT02195284|EXPERIMENTAL|Sub-study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI (metered-dose inhaler) or use MDI first and then ELLIPTA inahler
62126665|NCT01765543|EXPERIMENTAL|Vemurafenib + Rifampin|There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
62316834|NCT03777956|PLACEBO_COMPARATOR|Placebo|Placebo are given as capsules, same as lacosamide, and taken orally twice a day, without active ingredient.
62316835|NCT05938881||self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10\*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
62316836|NCT05938881||mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
62316837|NCT04462848|EXPERIMENTAL|anti-SARS-CoV-2 human convalescent plasma|single transfusion of human convalescent plasma
62316838|NCT06673186|EXPERIMENTAL|Group I (bar locator): Patients were given overdentures with bar locator attachments|Group I received mandibular overdentures with a bar locator attachment , specially designed milled bar with parallel walls was built for this group, and two holes were drilled in the top surface of the bar using a 1.7 mm bar drill to create the threaded site in the waxed bar, followed by a 2.0 mm bar tap. The locator female component was then connected to the corresponding site using a customised rider.
62316839|NCT06673186|EXPERIMENTAL|group2, Patients were given overdentures with bar clip attachment.|bar clip attachment. Patients received mandibular overdentures with bar clip attachments. A plastic prefabricated bar was cast in cobalt-chrome alloy. Group II patients received mandibular overdentures with bar clip attachments. A plastic prefabricated bar was cast in cobalt-chrome alloy.
62339700|NCT04872335|EXPERIMENTAL|Gong's Mobilization|Subjects received gong's mobilization three times in a week for 4 weeks.
62339701|NCT04872335|EXPERIMENTAL|Gradually Graded Exercise Therapy|Subjects received gradually graded exercise therapy three times in a week for 4 weeks.
62479255|NCT05453422|NO_INTERVENTION|Control group|Routine maintenance will be applied.
61924601|NCT02195284|EXPERIMENTAL|Sub-study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA inhaler
61924602|NCT01425775|ACTIVE_COMPARATOR|Vitamin D|
61924603|NCT01425775|PLACEBO_COMPARATOR|Placebo|
61924604|NCT01350518|PLACEBO_COMPARATOR|Study prepared meals and placebo|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will not receive any fiber (Benefiber) supplementation in their TrueLemon mixture.
62126666|NCT06335472|ACTIVE_COMPARATOR|three nerves pulsed radiofrequency with hydrodissection|suprascapular nerve ,axillary nerve, lateral pectoral nerve pulsed radiofrequency combined with hydrodissection in adesive capsultis
62126667|NCT06335472|ACTIVE_COMPARATOR|suprascapular nerve pulsed radiofrequency with hydrodissection|suprascapular nerve pulsed radiofrequency combined with hydrodissection
62316840|NCT05144295|EXPERIMENTAL|Investigational Arm|"* Patients will receive lubiprostone capsules (Amiprostone 8 and 24 mcg, or Lubicont 8 mcg)~* Patients weighing \<50 kg will be given lubiprostone at doses of 8 mcg/8 hours.~* Patients weighing ≥ 50 kg will be given lubiprostone at doses of 24 mcg BID.~* Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and a large volume of fluid."
62686395|NCT03720808|EXPERIMENTAL|Coughing|Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
62686396|NCT03720808|EXPERIMENTAL|Control|No intervention was performed to reduce pain and fear in the control group.
62686397|NCT05783271||mpMRI and biparametric MRI|Multiparametric MRI of the bladder consists of :conventional (T1 weighted imaging and high resolution T2 weighted imaging) and functional sequences (diffusion-weighted imaging ,dynamic), biparametric MRI consists of (T2,Dws)all data will be regrouped to evaluate the accuracy and validity of each separate group and in distinguishing non-muscle invasive from muscle-invasive tumors, with VI-RADS score application and comparison with pathological findings, then interobserver agreement for detection of muscle invasion according to mp-MRI and VI-RADS scoring system findings will be calculated.
62686398|NCT03574389|EXPERIMENTAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|"1. Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.~2. Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).~3. Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.~4. Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age."
62686399|NCT03574389|ACTIVE_COMPARATOR|Haemophilus influenzae type b (Hib)|"1. No participants in cohort 1 will receive Hib vaccine.~2. Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.~3. Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age."
62686400|NCT06685822|EXPERIMENTAL|Children participate in eye-tracking activity|Children enrolled in the HEAL-R Autism at MTRH study will be enrolled into the study. Research participation includes a one-time eye-tracking activity in which the child will view a series of different pictures and movies while their eye movements and pupil diameter are tracked and recorded.
62686401|NCT02363894||Subjects enrolled in DEFINITIVE AR|
62686402|NCT01955265|EXPERIMENTAL|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
62686403|NCT01955265|ACTIVE_COMPARATOR|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
62316841|NCT05144295|ACTIVE_COMPARATOR|Control Arm|"Subjects will receive the conventional therapy (one or a combination of the following):~* Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day),~* Bisacodyl tablets  Bisacodyl 5 mg/tablet in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years, or~* Sodium Picosulfate 0.75% drops (Picolax drops) in a daily dose of 2.5-20 mg/day."
62316842|NCT02989077||Group A|Having combined coronary and cerebral ischemia.
62316843|NCT02989077||Group B|Having only coronary ischemia
62479256|NCT03346902|PLACEBO_COMPARATOR|Placebo|"Drug: : Placebo: 0.9% Sodium Chloride Injection~Injection of Placebo into area of scarring (forehead)"
62316844|NCT02989077||group C|Having only cerebral ischemia
62316845|NCT02796404|EXPERIMENTAL|Homebased cardiac rehabilitation program|Homebased Cardiac rehabilitation program with monitoring vest and mixed surveillance.
62316846|NCT02796404|OTHER|Traditional cardiac rehabilitation|Multidisciplinary program in a cardiac rehabilitation gym. Routine clinical practice
62316847|NCT03344497|OTHER|VC (Conventional Consultation/Video) Group|Subjects will receive conventional consultation and watch an animated video.
62479257|NCT03346902|ACTIVE_COMPARATOR|EB001|Drug: EB-001 Injection of EB-001 into area of scarring (forehead)
62479258|NCT05889546||Active SCLC Diagnosis|
62686404|NCT01934231|EXPERIMENTAL|Single arm|Each participant will take Potassium Clavulanate (CVA)/ Amoxicillin (AMPC) corresponding 6.4/90 mg/kg/day in two divided doses (every 12 hours) just before lactation or meal for 7 days depending on his/her body weight at the start of treatment (Day 1). The actual daily dose depends on the body weight of the participant.
62316848|NCT03344497|NO_INTERVENTION|CC (Conventional Consultation) Group|Subjects will receive conventional consultation only. Subjects will cross-over to receive animated video at the end.
62686405|NCT01122680|EXPERIMENTAL|Treatment A|patients inhale 2 puffs (dose of 1.25 mcg) once daily in the evening via Respimat inhaler
62686406|NCT01122680|EXPERIMENTAL|Treatment C|patients inhale 2 puffs (dose of 5 mcg) once daily in the evening via Respimat inhaler
62686407|NCT01122680|PLACEBO_COMPARATOR|Placebo|patients inhale 2 puffs of placebo matching tiotropium once daily in the evening via Respimat inhaler
62126668|NCT06011109|EXPERIMENTAL|APG-157|"The participants will receive APG-157 daily by taking two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth.~The participants will continue to receive Bevacizumab as standard of care."
62126669|NCT03107767|ACTIVE_COMPARATOR|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
62126670|NCT03107767|NO_INTERVENTION|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
62126671|NCT02729506|ACTIVE_COMPARATOR|Arm A|"Intervention:~Yttrium-90 Transarterial Radioembolization~* Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~* The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~* Patients must not be less than 18 and not more than 80 and can be either gender.~* Patients must have a performance status of ECOG score equal to or less than 2.~* Child-Pugh's A or Early B, score 8 and above"
62126672|NCT02729506|ACTIVE_COMPARATOR|Arm B|"Intervention:~Trans-arterial chemo-embolization using Drug-eluting beads~* Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~* The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~* Patients must not be less than 18 and not more than 80 and can be either gender.~* Patients must have a performance status of ECOG score equal to or less than 2.~* Child-Pugh's A or Early B, score 8 and above"
62316849|NCT00909285|EXPERIMENTAL|Treatment Group (#1)|
62686408|NCT01122680|EXPERIMENTAL|Treatment B|patients inhale 2 puffs (dose of 2.5 mcg) once daily in the evening via Respimat inhaler
62686409|NCT04822558|OTHER|Ankle and hindfoot reconstruction surgery|Patients who underwent an ankle- or hindfoot reconstruction surgery
62686410|NCT00397046|EXPERIMENTAL|Neratinib 80 mg|
62316850|NCT00909285|SHAM_COMPARATOR|Control group (#2)|
62316851|NCT01823796||Healthy women.|35 healthy women. Control group.
62126673|NCT05132478|ACTIVE_COMPARATOR|Standard Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITHOUT emotionally supportive statements
62126674|NCT05132478|EXPERIMENTAL|Emotionally Supportive Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITH emotionally supportive statements
62126675|NCT05103358|EXPERIMENTAL|Arm A: Pathogenic inactivating TSC1 alterations|Patients with pathogenic inactivating TSC1 alterations.
62316852|NCT01823796||Fibromyalgia women group|35 women with fibromyalgia were measured at baseline of the observational study.
62126676|NCT05103358|EXPERIMENTAL|Arm B: Pathogenic inactivating TSC2 alterations|Patients with pathogenic inactivating TSC2 alterations.
62686411|NCT00397046|EXPERIMENTAL|Neratinib 160 mg|
62686412|NCT00397046|EXPERIMENTAL|Neratinib 240 mg|
62686413|NCT00397046|EXPERIMENTAL|Neratinib 320 mg|
62686414|NCT04026958|EXPERIMENTAL|Clarithromycin|Participants in this study arm will receive clarithromycin for 14 days.
62686415|NCT04026958|PLACEBO_COMPARATOR|Placebo|Participants in this study arm will receive a placebo to match clarithromycin for 14 days.
62686416|NCT04523519|EXPERIMENTAL|Video directly observed therapy with contingency management|Video directly observed therapy with contingency management, in addition to Integrated Next-Step Counseling.
62686417|NCT04523519|PLACEBO_COMPARATOR|Integrated Next-Step Counseling|
62686418|NCT02542280|EXPERIMENTAL|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
62686419|NCT02542280|ACTIVE_COMPARATOR|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
62686420|NCT00601185||1|Patients undergoing a shave biopsy and confocal microscopy.
62686421|NCT06231472|ACTIVE_COMPARATOR|Group A with preoperative fluid infusion|Group A patients received fluid infusion calculated according to hourly weight before surgery.
61924605|NCT01350518|ACTIVE_COMPARATOR|Nutritional Counseling with fiber|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions will focus on knowledge, self-regulation, motivation, experience and environment. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture .
61924606|NCT01350518|PLACEBO_COMPARATOR|Nutrition counseling and placebo|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions (interventions) will focus on knowledge, self-regulation, motivation, experience and environment.Participants will receive no fiber supplementation in their TrueLemon mixture .
62316853|NCT04599816|ACTIVE_COMPARATOR|levosimendan administration at a dose of 3 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 3 mcg/kg after anesthesia induction
61924607|NCT01350518|ACTIVE_COMPARATOR|Study prepared meals and fiber|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture.
61924608|NCT04843852|EXPERIMENTAL|Intervention - vaccination|"HEPLISAV-B is available in pre-filled, single-dose 0.5 mL vials. Each dose contains 20 μg of HBsAg and 3,000 μg of 1018 adjuvant. HEPLISAV-B is administered as an intramuscular injection in the deltoid region.~Study subjects randomized to the vaccine group will receive a total of 2 injections, each administered at least 4 weeks apart - the same dosing schedule recommended for hepatitis B prevention.~Once enrolled, participants will have study visits on days 0 (first injection), 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196."
61924609|NCT04843852|NO_INTERVENTION|No vaccination|Participants randomized to the control group will have study visits on days 0, 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196.
61924610|NCT00589485||1|
61924611|NCT00589485||2|
62126677|NCT03332758||RD treated with vitrectomy|Vitreous fluid from retinal detachment treated with pars plana vitrectomy
62126678|NCT03332758||RD treated with external drainage|Subretinal fluid from retinal detachment treated with external drainage.
62316854|NCT04599816|ACTIVE_COMPARATOR|levosimendan administration at a dose of 6 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 6 mcg/kg after anesthesia induction
62316855|NCT04599816|ACTIVE_COMPARATOR|levosimendan administration at a dose of 12 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 12 mcg/kg after anesthesia induction
62316856|NCT01541592|ACTIVE_COMPARATOR|Saturated fat|Palm oil (rich in the saturated fat palmitate)
61924612|NCT00542971|EXPERIMENTAL|Sorafenib + Idarubicin + Ara-C|Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m\^2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m\^2 IV over 24 hours daily (days 1-4)
62126679|NCT03332758||Macular holes treated with vitrectomy|Vitreous fluid from patients treated for macular hole
62126680|NCT03332758||ERM treated with vitrectomy|Vitreous fluid from patients treated for epiretinal membrane
62126681|NCT01896310||pCLE examination|patients will be prospectively recruited and examined first with high-definition endoscopy (EG-2990i, Pentax, Japan) followed by probe-based confocal laser endomicroscopy
62126682|NCT01123421||With osteoporotic fracture|Approximately 100 postmenopausal women that have been enrolled in a population-based case-control study that have experienced a clinically-diagnosed fracture of thoracolumbar spine or distal forearm due to minimal or moderate trauma based on review on their inpatient and outpatient medical records will be enrolled.
62686422|NCT06231472|NO_INTERVENTION|Group B without preoperative fluid infusion|No intervention was made to patients in group B.
62316857|NCT01541592|ACTIVE_COMPARATOR|Monounsaturated fat|Olive oil (rich in the monounsaturated fat oleate)
62316858|NCT01541592|ACTIVE_COMPARATOR|Polyunsaturated fat|Safflower oil (rich in the polyunsaturated fat linoleate)
62316859|NCT00615706||1|Asthmatics
62686423|NCT00521352|ACTIVE_COMPARATOR|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
62316860|NCT00615706||2|Healthy volunteers (without asthma)
62316861|NCT02980835|EXPERIMENTAL|Intervention|Patients who receive injections of A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) at the beginning of surgery and second set of injections containing a mixture of B (contains 10 mL of 0.9% normal saline) and C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) prior to the closure
62316862|NCT02980835|ACTIVE_COMPARATOR|Control|Participants who receive injection of B (contains 10 mL of 0.9% normal saline) at the beginning of surgery and injectate A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) and injectate C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) at the end of procedure prior to the closure (which mimics standard care) is the control group
62316863|NCT04790006|EXPERIMENTAL|TG103|TG103 will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
62316864|NCT04790006|PLACEBO_COMPARATOR|Placebo|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
62316865|NCT01475292|EXPERIMENTAL|RV568 treatment group low dose|
62316866|NCT01475292|EXPERIMENTAL|RV568 treatment group high dose|
62316867|NCT01475292|PLACEBO_COMPARATOR|Placebo treatment group|
62316868|NCT04795804|PLACEBO_COMPARATOR|Placebo|11.43 g (3 x 3.81 g) maltodextrin the day before the clinical investigation day
62316869|NCT04795804|ACTIVE_COMPARATOR|Human milk-like oligosaccharide alone|12 g (3 x 4 g) of the human milk-like oligosaccharide the day before the clinical investigation day
62316870|NCT04795804|EXPERIMENTAL|Human milk-like oligosaccharide and resistant starch|12 g (3 x 4 g) of the human milk-like oligosaccharide and 7.5g resistant starch (3 x 2.5 g) the day before the clinical investigation day
61924613|NCT04926727||Pregnant women|"600 Pregnant women between the 18th and 22nd week.~* 200 from Northern Italy;~* 200 from Central Italy;~* 200 from Southern Italy and the Islands."
62126683|NCT01123421||Without osteoporotic fracture|Approximately 100 control women will have no history of a prior spine, hip, or wrist fracture.
62316871|NCT06497647|ACTIVE_COMPARATOR|group A|this group will receive imipramine alone
62316872|NCT06497647|ACTIVE_COMPARATOR|group B|this group will receive sulbutiamine alone
62316873|NCT06497647|ACTIVE_COMPARATOR|group C|this group will receive sulbutiamine plus imipramine
62316874|NCT01361529|EXPERIMENTAL|safty test|FLP,dose escalation,MTD
62316875|NCT05468086|EXPERIMENTAL|Solace VR|This arm will include software that provides immersive distraction based content for pain reduction.
62316876|NCT06672965|PLACEBO_COMPARATOR|Placebo|Placebo was prepared as a capsule composed of excipients only (stearic acid and natural caramel color to match the mg weight of the combination supplement capsule). Take two (2) capsules daily with water.
62316877|NCT06672965|ACTIVE_COMPARATOR|Calming supplement|The combination supplement was prepared to deliver 600 mg of Lemon Balm extract, 100 mg of Magnolia Bark extract (containing 40 mg of honokiol) and 200 mg L-theanine daily in 2 capsules with water.
62316878|NCT03991624|OTHER|Alzheimer's patients (lack of executive functions)|
62316879|NCT03991624|OTHER|control (lack of executive functions)|
62316880|NCT03991624|OTHER|Alzheimer's patients (lack of working memory)|
62316881|NCT03991624|OTHER|control (lack of working memory)|
62316882|NCT03991624|OTHER|Alzheimer's patients (lack of episodic memory)|
62316883|NCT03991624|OTHER|control (lack of episodic memory)|
62316884|NCT02093975|EXPERIMENTAL|Video consultation|Patients in this arm receive video consultation from physician in doctor manned rapid response vehicle.
62316885|NCT02093975|ACTIVE_COMPARATOR|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician in rapid response vehicle.
62316886|NCT04281212||CTO|Period of 1 month in the participating centers, during which all the patients with CTO and responding to all selection criteria may be included in the study, in order to describe which therapeutic choices have been chosen for this type of patient.
62316887|NCT04281212||CTO with attempted angioplasty|Period of 2 months in the participating centers, during which all the patients for whom an angioplasty has been attempted after a CTO, and responding to all selection criteria, may be included in the study, in order to evaluate the success of the procedure
62316888|NCT03698240|EXPERIMENTAL|Mindfulness-based program|Children and parents receive the program
62316889|NCT03698240|NO_INTERVENTION|Waiting-list|Children and parents receive no-interventions.
62316890|NCT01073592||CNV patiens|
62479259|NCT00001276||Patients with hypoglycemia|Patients with hypoglycemia due to diverse etiologies.
61924614|NCT03707184|EXPERIMENTAL|Diagnostic (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 intravenously (IV) over 30 seconds and undergo PET/CT scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy.
61924615|NCT02097537|EXPERIMENTAL|Methacholine Chloride|children with bronchial asthma
61924616|NCT02861989||Osteoporotic women|women over 50 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
62316891|NCT05121597|EXPERIMENTAL|Videolaryngoscope Group|The group that we will use a videolaryngoscope for nasotracheal intubation.
62316892|NCT05121597|ACTIVE_COMPARATOR|Control Group|The group that we will use a direct laryngoscope for nasotracheal intubation.
62316893|NCT01968044|EXPERIMENTAL|Gemigliptin|Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
62479260|NCT06378099|NO_INTERVENTION|Control Group|"Patients will receive usual care. This group will have three activities: 1. Voluntary selection of OTC medication, 2. Health education on what responsible self-medication entails, 3. Identification of ADRs associated with the use of OTC medications or worsening of the MA, and referral to a physician.~For each MA, the Pharmacist will request the patient's signature on Annex 1, proceed with Activity 1, fill in the instrument included in Annex 4, and continue with Activity 2.~On days 3, 5, 7, and 10 post-care, patients will be contacted via a chatbot or a phone call to answer Annex 5. On days 5, 6, 10, and 12, the Pharmacist will review the responses received to carry out follow-up on Activity 3, and refer to a physician if necessary."
62686424|NCT00521352|SHAM_COMPARATOR|Sham rTMS|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
62686425|NCT06055569|EXPERIMENTAL|Action Observation Therapy (AOT) associated with Neuromuscular Electrical Stimulation (NMES)|The group will receive 5 consecutive days a week, for 3 weeks, 60 minutes-long sessions of action observation therapy (AOT) associated with a synchronous neuromuscular stimulation of motor synergies (NMES). After AOT-NMES, subjects will be asked to repeat the observed movement.
61924617|NCT02861989||At risk women|women over 50 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
61924618|NCT02861989||Osteoporotic men|Men over 60 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
61924619|NCT02861989||At-risk men|Men over 60 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
61924620|NCT02861989||General practitioners|General practitioners from the Rhône area, France
62316894|NCT01968044|OTHER|Placebo to linagliptin|Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
62339702|NCT01023412|ACTIVE_COMPARATOR|Nutritional product|Oral nutritional supplement containing immuno nutrients
62339703|NCT01023412|PLACEBO_COMPARATOR|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
62339704|NCT02382341||Observational|BIOSURE™ HEALICOIL™ PK Interference Screw
62316895|NCT05111834|EXPERIMENTAL|Supervised resistance training plus nutritional endorsement|"The study participants receive a progressive moderate-to-high-intensity resistance training program (a 60 minutes twice a week for a period of 24- weeks) plus nutritional endorsement. The training will take place at the NCT Heidelberg, in regional qualified facility centers or online under supervision and guidance of experienced exercise therapists.~The progressive resistance program for participants who train at facility centers comprises of 6 machine-based exercises, each performed 2 sets,12 repetitions of 60%-80% of 1 RM. For participants who train online, the training load will be defined during the introductory training session with the aim of choosing a load which to perform two times 12 repetitions. The program targets major upper and lower body muscle groups (with emphasis on the lower extremities). In addition, patients receive nutritional advice/diet modification, depending on their individual requirements and/or changes in general condition."
62316896|NCT05111834|ACTIVE_COMPARATOR|Nutritional endorsement only|Patients receive nutritional advice/diet modification, depending on their individual requirements and/or changes in general condition.
62316897|NCT03717324||First evaluation group (survey_1)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA)
62316898|NCT03717324||Co-creation group|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA) who want to participate in the co-creation workshop
62316899|NCT03717324||Second evaluation group (survey_2)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA), after improvements are made
62126684|NCT03634280|PLACEBO_COMPARATOR|Splinting|Splinting was applied to the patients' ankle in the second group(n=120). Splint were kept on the patients for 5 days for 23 hours a day. In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
62316900|NCT03253198|ACTIVE_COMPARATOR|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
62316901|NCT03253198|ACTIVE_COMPARATOR|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
62316902|NCT01825044|ACTIVE_COMPARATOR|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
62316903|NCT01825044|ACTIVE_COMPARATOR|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
62316904|NCT05553379||Children 7 to 17|Children with asthma
62316905|NCT05553379||Adults 18 to 80|Adults with asthma
62316906|NCT01300780|ACTIVE_COMPARATOR|Experimental|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
62316907|NCT01300780|PLACEBO_COMPARATOR|placebo group|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
62316908|NCT03746574|EXPERIMENTAL|Intervention Clinics|Participants in the intervention clinics experienced a 12 session compassion curriculum intevention offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
62316909|NCT03746574|NO_INTERVENTION|Control Clinics|Completed baseline, end of curriculum, and 6 month follow up survey. Otherwise no intervention
62316910|NCT01873664|EXPERIMENTAL|Jaw tapping|All subjects performed the jaw-tapping for 4 weeks at home.
62126685|NCT03634280|EXPERIMENTAL|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm\*5m) is used. 120 participants were taped for a lateral ankle sprain. 50-mm wide and 0.5-mm thick KT was applied to the tendinomuscular meridian around the ankle with three I-shaped tapes. Initially, one I-shaped tape was applied along the course of the tibialis anterior muscle, and another I-shaped tape was then applied to the peroneus longus and brevis muscles. The third I-shaped tape was applied from the abductor digiti minimi muscle and wrapped around the ankle in a figure-of-eight shape to the abductor hallucis muscle, surrounding the ankle over the medial and lateral malleoli. The tape was applied to the skin by applying zero tension, and skin problems were avoided.
62316911|NCT00611793|EXPERIMENTAL|1|PTK787/ZK222584 and Bevacizumab
62316912|NCT05914311|ACTIVE_COMPARATOR|Suture Group|secure one of the 2 trial leads with suture only-randomized to left or right
62316913|NCT05914311|EXPERIMENTAL|Dermabond|secure one of the 2 trial leads to be secured with both dermabond and suture-randomized to left or right
62316914|NCT02457897|EXPERIMENTAL|Patients with insulin receptor mutation|
62316915|NCT01187420||EEG and Cerebral Vasospasm|Cerebral Vasospasm and role of BIS vista monitor in Subarachnoid Hemorrhage (SAH) patients
62316916|NCT06272253|EXPERIMENTAL|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 μg|Study product are provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given 1 dose (0.5 ml) once.
62316917|NCT01283581|EXPERIMENTAL|Delafloxacin|300 mg IV (intravenous) every 12 hours for 5-14 days
62316918|NCT01283581|ACTIVE_COMPARATOR|Vancomycin|15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
62316919|NCT01283581|ACTIVE_COMPARATOR|Linezolid|600 mg IV every 12 hours for 5-14 days
62316920|NCT06111573|EXPERIMENTAL|Vitamin D + Occlusal Splint|Vitamin D is a fat-soluble secosteroid. Vitamin D is very important in muscle and bone metabolism. Vitamin D is a vitamin with some anti-inflammatory and immune-modulating properties.
62316921|NCT06111573|ACTIVE_COMPARATOR|Diclofenac Sodium + Occlusal Splint|Diclofenac Sodium is a type of NSAID which has been found effective both as an analgesic and in reducing inflammation and is classified as weak and preferentially COX-2 selective.
62479261|NCT06378099|EXPERIMENTAL|Intervention Group|"Patients will be guided and followed by the pharmacist. This group will have four activities: 1. Classification and presence of the MA, 2. Referral to a physician for the presence of a non-MA, 3. Patient guidance on pharmacological measures in case an OTC medication is required 4. Identification of ADRs associated with the use of OTC medications or worsening of the MA and referral to a physician.~For each MA, the Pharmacist will request the patient's Informed Consent, apply what is described in Activities 1, 2, and 3, and fill in the instrument included in Annex 4.~Days 3, 5, 6, 7, 10, and 12 will be followed as described for control group."
62479262|NCT04150913|EXPERIMENTAL|Anakinra and Axicabtagene Ciloleucel|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.~* Screening~* Enrollment/Leukapheresis period~* Bridging therapy (if applicable)~* Lymphodepleting chemotherapy period~* Investigational Product (IP) treatment period~  * Anakinra~ * Axicabtagene Ciloleucel~* Post treatment assessment period~* Long term follow-up period"
62479263|NCT06663813|EXPERIMENTAL|Intervention Arm|Participants in the intervention arm will receive Type 2 Diabetes Mellitus educational materials that includes information regarding Type 2 Diabetes symptoms, risk factors, and resources for further follow-up care alongside standard Emergency Medicine care, which includes discharge instructions provided by ED practitioners along with verbal explanations from their assigned ED nurse.
62479264|NCT00353158|ACTIVE_COMPARATOR|A|Subjects currently on or previously on chronic voriconazole or subjects who are scheduled to begin voriconazole
62316922|NCT05061888|ACTIVE_COMPARATOR|Food Waste Intervention Group|This group will receive an intervention on food waste management and fruit and vegetable replacement to increase diet quality while avoiding an increase in calories. Both groups will obtain free fruit and vegetable boxes and will use the FoodImage app to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
62316923|NCT05061888|PLACEBO_COMPARATOR|Stress Management Control Group|This group will receive an intervention on Stress Management and will be intensity matched to the treatment group. Both groups will obtain free fruit and vegetable boxes and will use FoodImage to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
62316924|NCT01380405|NO_INTERVENTION|without health education|the normal practices without specific intervention
62479265|NCT00353158|EXPERIMENTAL|B|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
62686426|NCT06055569|ACTIVE_COMPARATOR|Action Observation Therapy (AOT)|The group will receive 5 consecutive days a week, for 3 weeks, 60 minutes-long sessions of action observation therapy (AOT). The neuromuscular electrical stimulator will be placed on the subjects' arm without synchronous stimulation. After AOT, subjects will be asked to repeat the observed movement.
61924621|NCT06518902|EXPERIMENTAL|MSCs group|mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks.
62126686|NCT01947088|EXPERIMENTAL|Music Therapy Arm|Music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.) Pre-study and post-study scores from the neuropsychological assessments will be compared to determine if music therapy has a significant effect on the child's cognitive recovery. Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for music therapy (treatment group) for about 45 minutes, twice per week, for Weeks 1-8. CThe Music Therapy group will partake in interventions such as singing and playing musical instruments.
62126687|NCT01947088|ACTIVE_COMPARATOR|Unstructured Play Arm|Child life programs provide children with opportunities to engage in normal play and recreational activities that promote growth, development and feelings of success and fulfillment.All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). This is the standard of care for all brain surgery patients. The results of this assessment and will be used in this research study. In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
62126688|NCT03101930|EXPERIMENTAL|liraglutide|Subjects in the liraglutide group will receive subcutaneous liraglutide (0.6 mg/d for one week, 1.2 mg/d for one week, and then 1.8 mg/d for 12 weeks) and oral placebo.
62126689|NCT03101930|ACTIVE_COMPARATOR|sitagliptin|Subjects in the sitagliptin group will receive subcutaneous placebo daily and sitagliptin 100 mg/d orally for 14 weeks.
62316925|NCT01380405|EXPERIMENTAL|individual health education|"The study intervention is an individual education in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. The lesson included inhalation devices, explanatory leaflets"
62316926|NCT01380405|EXPERIMENTAL|health education group|"The study intervention is education in group in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. In addition to the necessary furniture and teaching material that will be required (slide projector, over-head-projector, projection screen, video, etc.), the physical space given over to this purpose should consist of an area in which material can be left which will be used to complete the teaching and patient information (inhalation devices, explanatory leaflets, small monographs, slides, etc.)."
61924622|NCT04627662|OTHER|Care Partners|Based on previous work, we will recruit up to 75 Care Partners and their 75 care recipients with dementia. This allows for 20% attrition. We will recruit participants from Alzheimer's Disease Research Centers (ADRCs) and other national locations.
62126690|NCT03101930|ACTIVE_COMPARATOR|hypocaloric diet|Subjects in the hypocaloric diet group will be given a caloric goal designed to achieve a weight loss similar to that expected in the liraglutide treatment arm based on his or her resting energy expenditure. Subjects will be provided counseling and written instructions on how to achieve their daily caloric goal, including use of their own mobile phone applications to monitor caloric intake. To assure compliance with the prescribed caloric goal, subjects will meet with the study dietitian every other week for problem solving and review of diet intake logs.
62126691|NCT06059560|EXPERIMENTAL|interventian group|Intensive nutritional interventions based on real-world treatments
62479266|NCT01444053||Wearers of contact lenses without UV Protection|Subjects who have worn a soft contact lens without UV protection for the past five years or more.
62479267|NCT01444053||Wearers of contact lenses with UV Protection|Subjects who have worn a soft contact lens with UV protection for the last 5 years or more.
62479268|NCT05466942|OTHER|Controled Hypoxia - Healthy volunteer|Male and female subjects, ranging in pigmentation from light to dark
62479269|NCT00702377|EXPERIMENTAL|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops
62479270|NCT00702377|ACTIVE_COMPARATOR|OPTIVE|OPTIVE Lubricant Eye Drops
62479271|NCT06421636|EXPERIMENTAL|Part A High Dose|Randomized 2:2:1
62479272|NCT06421636|EXPERIMENTAL|Part A Low Dose|Randomized 2:2:1
62479273|NCT06421636|PLACEBO_COMPARATOR|Part A Placebo|Randomized 2:2:1
62479274|NCT06421636|EXPERIMENTAL|Part B High Dose|Randomized 2:2:1
62126692|NCT06059560|EXPERIMENTAL|control group|Nutritional guidance and education based on real world treatments
62126693|NCT00811278||step1|asthma patients on step 1 therapy
62126694|NCT00811278||step 2|asthma patients on step 2 therapy
62126695|NCT00811278||healthy|non-asthmatics
62126696|NCT04730362|ACTIVE_COMPARATOR|Control group|20 patients in which a Guedel oral airway will be inserted for airway management and to conduct inhalational anesthetic through face mask fixed with harness to the head and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
62126697|NCT04730362|ACTIVE_COMPARATOR|supraglottic group|20 patients in which supraglottic airway laryngeal mask airway (LMA) will be used and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
62126698|NCT05467319|EXPERIMENTAL|Ferric derisomaltose|1000mg of intravenous Ferric derisomaltose/Iron isomaltoside in 100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
62316927|NCT03115801|ACTIVE_COMPARATOR|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64."
62126699|NCT05467319|PLACEBO_COMPARATOR|Placebo|100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
62479275|NCT06421636|EXPERIMENTAL|Part B Low Dose|Randomized 2:2:1
62479276|NCT06421636|PLACEBO_COMPARATOR|Part B Placebo|Randomized 2:2:1
62479277|NCT00675142|EXPERIMENTAL|1|IUI 36 hours after ovulation induction
62316928|NCT03115801|ACTIVE_COMPARATOR|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
62316929|NCT05547555||INVASIVE PGT-A|Women who proceed to embryo transfer after invasive PGT-A embryo selection.
62316930|NCT05547555||NON INVASIVE PGT-A|Women who proceed to embryo transfer after non- invasive PGT-A embryo selection.
62479278|NCT00675142|EXPERIMENTAL|2|IUI 42 hours after ovulation induction
62479279|NCT00675142|EXPERIMENTAL|3|IUI 48 hours after ovulation induction
62479280|NCT02937948|EXPERIMENTAL|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
62479281|NCT04303884|EXPERIMENTAL|Experimental: Pembrolizumab|Chemo-resistant gestational trophoblastic neoplasias treated with pembrolizumab
62479282|NCT06239064||Participants suspected to genetic obesity|Participants suspected to genetic obesity
62126700|NCT05341869|PLACEBO_COMPARATOR|Control|Prior to starting surgery after general anesthesia, the 10 mL of normal saline was performed by the primary surgeon. The syringe was injected with 5 mL on each side into the cervical stroma at 3 and 9 o'clock with a depth of 2 to 3 cm.
62316931|NCT04277572||Aortic valve replacement|using different ways of aortic valve replacement either by prosthetic valves or by ozaki technique
62316932|NCT06342297|NO_INTERVENTION|No dermatoscopy|Dermatoscopy not used in decision of surgical margin
62316933|NCT06342297|EXPERIMENTAL|Dermatoscopy|Dermatoscopy is used in decision of surgical margin
62126701|NCT05341869|EXPERIMENTAL|Study|Prior to starting surgery after general anesthesia, thE 10 mL of 0.5% bupivacaine with epinephrine was performed by the primary surgeon. The syringe was injected with 5 mL on each side into the cervical stroma at 3 and 9 o'clock with a depth of 2 to 3 cm.
62126702|NCT01117519|ACTIVE_COMPARATOR|unbalanced infusion solution|
62126703|NCT01117519|ACTIVE_COMPARATOR|balanced infusion solution compound|
62316934|NCT04283032||Multiparametric magnetic resonance + transrectal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transrectal biopsy (BPTE)
62479283|NCT00463684|EXPERIMENTAL|All subjects|Healthy infants 9 months of age (plus or minus 2 weeks) that met the eligibility criteria. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV) and one dose of live, attenuated measles vaccine.
62479284|NCT00398983|EXPERIMENTAL|Decitabine 20 mg/m^2|20 mg/m\^2 intravenous (IV) daily for 5 days
62126704|NCT04578392|ACTIVE_COMPARATOR|high ligation of ileocolic artery|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
62479285|NCT00398983|NO_INTERVENTION|No Study Drug|Continue current therapy.
62479286|NCT01788800|EXPERIMENTAL|Exercise training|"Cognitive Behavioural Therapy (CBT)~+ Exercise training 3 times/week, 30 minutes on a treadmill, 70% maximal oxygen uptake (VO2max), 8 weeks"
62479287|NCT01788800|ACTIVE_COMPARATOR|Movements|"Cognitive Behavioural Therapy (CBT)~+ Low intensity physical activity without cardiovascular activation, 3 times/week, 30 minutes, 8 weeks"
62686427|NCT06055569|PLACEBO_COMPARATOR|Observation of motor-neutral stimuli (MNO)|The group will receive 5 consecutive days a week, for 3 weeks, 60 minutes-long sessions of motor-neutral observation (MNO). The neuromuscular electrical stimulator will be placed on the subjects' arm without synchronous stimulation. After MNO, subjects will be asked to execute movements.
62479288|NCT06588283|EXPERIMENTAL|Ixekizumab|Ixekizumab administered subcutaneous (SC).
62479289|NCT06588283|EXPERIMENTAL|Ixekizumab and Tirzepatide|Ixekizumab concomitantly administered with tirzepatide SC.
62479290|NCT06482658|EXPERIMENTAL|Transrectal perilesional/regional systematic biopsy (PB/RSB) group|For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra) through transrectal prostate biopsy. The location of these nine cores depended on the shape and location of the suspicious lesion.
62479291|NCT06482658|EXPERIMENTAL|Combination of transrectal systematic biopsy and targeted biopsy (TB+SB) group|For patients in the TB+SB group, three to five transrectal targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core transrectal prostate biopsy.
61924623|NCT05562947|EXPERIMENTAL|Implant arm|Participants will have the implant (pre-filled intraoperatively with ranibizumab 100 mg/mL) surgically inserted on Day 1. After Day 1, patients in the implant arm will attend monthly study visits, and receive implant refill-exchanges with ranibizumab 100 mg/mL at Week 24 and Week 48. At the Week 48 study visit, patients will move to the long term extension phase of the study and continue receiving refill-exchanges Q24W until the end of study. Patients will attend monthly visits up to Week 96 and bi-monthly visits, thereafter
61924624|NCT05562947|EXPERIMENTAL|Intravitreal arm|Participants will receive intravitreal ranibizumab 0.5 mg injections starting on Day 1. Patients will receive intravitreal ranibizumab 0.5 mg Q4W until Week 44. At the Week 48 study visit, patients will receive the PDS implant (pre-filled intraoperatively with ranibizumab 100 mg/mL), move to the long-term extension phase of the study and receive Q24W refill exchanges until the end of study. If patients are unable to attend the Week 48 visit due to extenuating circumstances, they should return no later than the next scheduled visit (Week 52), when they will receive the PDS implant. Patients will attend monthly visits up to Week 96 and bi-monthly visits, thereafter.
61924625|NCT01600742|ACTIVE_COMPARATOR|WBRT, placebo|
62126705|NCT04578392|ACTIVE_COMPARATOR|mesenteric sparing for a primary ileocolic resection|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
62479292|NCT00912769||subvastus approach/ midvastus approach|subvastus: vastus medialis oblique was not cut during operation midvastus: vastus medialis oblique was cut during operation
62479293|NCT00912769||Cybex|Knee extension/ flexion isometric and isokinetic performance of all cases were tested using Cybex
62479294|NCT05007470|EXPERIMENTAL|Probiotic|VSL#3
62479295|NCT05007470|PLACEBO_COMPARATOR|Pacebo|
62479296|NCT03347487|EXPERIMENTAL|Deep Brain Stimulation of Bilateral Habenula|
62479297|NCT00001205||1|Male and female participants with NCC (arms 1-5) or epidemiology consistent with the potential for prior exposure to neurocysticercosis (arm 6)
62479298|NCT06533553|EXPERIMENTAL|150 mg dexpramipexole BID|150 mg dexpramipexole oral tablet taken twice a day
62479299|NCT04547192|NO_INTERVENTION|Pre TIF introduction|Emergency Health Service prior to introduction of TIF.
62479300|NCT04547192|EXPERIMENTAL|Post introduction of TIF|Emergency Health Service after introduction of TIF.
62686428|NCT04774562|EXPERIMENTAL|Video-Assisted Discharge Education (VADE) Group|VADE group received video-assisted discharge education in addition to the physiotherapy program given to the PT group on the same day by the same physiotherapist. The VADE program included information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities, home settings. VADE was prepared as a presentation of written information and videos which is shown this information by a professional model. Video shoots were done by a physiotherapist experienced in the field of physiotherapy and rehabilitation after THR surgery. The presentation was stopped when participants have questions or have points were not understood and the necessary explanations were shown verbally and practically. Along with the physiotherapy booklet, the participants were given an educational booklet containing written and visual information prepared in the same content as VADE.
62686429|NCT04774562|EXPERIMENTAL|Physiotherapy (PT) Group|The physiotherapy program given to the PT group after THR surgery. The physiotherapy program included breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation. The whole program was taught verbally and practically to participants and their relatives. Information was given about the exercises to be added at the end of the first week and in the 4th week. A physiotherapy booklet prepared with the same content was given to the participants. The booklet was examined by the patient and relatives, and the questions they asked were answered by the same physiotherapist. The participants were informed that they should continue the exercises for 12 weeks.
62316935|NCT04283032||Multiparametric magnetic resonance + transperineal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transperineal biopsy (BPTP)
62316936|NCT04283032||Transrectal biopsy|The patient underwent a transrectal biopsy (BPTE)
62316937|NCT04283032||Transperineal biopsy|The patient underwent a transperineal biopsy (BPTP)
62479301|NCT00429416|EXPERIMENTAL|LLME to Decrease GVHD Following HSC T|To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
62126706|NCT03421678||Japanese American|Two parents of Japanese descent
62479302|NCT06580197||Surgical control group (Group A)|Patients who received ear acupuncture treatment (≥ 1 time) due to perioperative anxiety, pain, prevention/treatment of DGF, or other indications for ear acupuncture treatment in actual diagnosis and treatment were divided into two groups based on exposure factors. Patients who received ear acupuncture treatment were included in the surgical observation group (Group B), while other patients were included in the surgical control group (Group A). Both groups of patients were from the basic surgical ward of Peking Union Medical College Hospital and were planning to undergo abdominal surgeries such as Whipple, pancreaticoidectomy, and subtotal gastrectomy;
62126707|NCT03421678||Non-Hispanic Whites|Two parents of non-Hispanic white descent
62126708|NCT03421678||Native Hawaiians|At least one parent of Hawaiian descent
62126709|NCT03020979|EXPERIMENTAL|500mg apatinib|Patients will receive 500mg of apatinib tablet orally, once daily.
62126710|NCT00529516|EXPERIMENTAL|FluAS25 Group|Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.
62126711|NCT00529516|ACTIVE_COMPARATOR|Fluarix ≥ 65 years age Group|Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
62126712|NCT00529516|ACTIVE_COMPARATOR|Fluarix 18-40 years age Group|Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
62126713|NCT02087345||Dental erosions|
62126714|NCT04114786|EXPERIMENTAL|3D-printed mask|Patients will undergo the standard CT SIM, and MR SIM necessary for radiation therapy, creating the masks from the MRIs. Prior to the start of their treatment, patients will have an additional CT scan with the 3D printed mask to confirm safety and treatment accuracy. Patients will then proceed with their standard radiation therapy, immobilized with the mask.The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
62126715|NCT04114786|ACTIVE_COMPARATOR|Control group|Control group that will be treated with the standard thermoplastic mask, as a comparison measure. The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
62126716|NCT00068601|ACTIVE_COMPARATOR|Standard Chemotherapy|Patients receive cyclophosphamide-containing chemotherapy alone.
62316938|NCT02414321||Fontan group|"Right heart catheterization:~* pulmonary artery OCT analysis~* dobutamine stress test~* pulmonary vascular response test (nitric oxide)~* trans-thoracic echocardiography"
62316939|NCT02414321||Control group|"Right heart catheterization:~- pulmonary artery OCT analysis"
62316940|NCT02414321||PAH group|"Right heart catheterization:~- pulmonary artery OCT analysis"
62316941|NCT01008930|EXPERIMENTAL|PEM Scan|HR PEM images (High Resolution PEMFlex Solo II scan images)
62316942|NCT01455571|EXPERIMENTAL|HM781-36B|Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
62316943|NCT04461847|EXPERIMENTAL|patients underwent ESM|
62316944|NCT04461847|ACTIVE_COMPARATOR|patients underwent SM|
62316945|NCT03080922|EXPERIMENTAL|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
62316946|NCT05782218|EXPERIMENTAL|Almond arm|Almonds will be provided to increase the gut content in mono and poly-unsaturated fatty acids.
61924626|NCT01600742|EXPERIMENTAL|WBRT and concurrent vorinostat|
61924627|NCT03368963|EXPERIMENTAL|Treatment (Nal-IRI, TAS-102)|Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Cycles repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
62126717|NCT00068601|EXPERIMENTAL|Chemotherapy Plus Goserelin|Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
62126718|NCT01359592|ACTIVE_COMPARATOR|PET Negative: R-CHOP|R-CHOP x 3 Cycles
62316947|NCT05782218|EXPERIMENTAL|Coconut arm|This snack is isocaloric and almost perfectly matches the macronutrient profile of the almonds. However, despite being in the same quantity, almost all provided fatty acids will be saturated fatty acids.
62316948|NCT05606822||Anastomotic leakage after gastrointestinal surgery|No interventions will be administered, as this is an observational study.
62316949|NCT05606822||Esophageal perforation (Boerhaave syndrome, iatrogenic, trauma, other)|No interventions will be administered, as this is an observational study.
62316950|NCT04575662|EXPERIMENTAL|STAR Treatment|Patients performing STAR treatment
62316951|NCT01142323|EXPERIMENTAL|Fenofibrate|fenofibrate 160 mg po daily
62126719|NCT01359592|EXPERIMENTAL|PET Positive: IFRT +Zevalin|Standard IFRT+ Zevalin IV per ABW
62316952|NCT06286930|EXPERIMENTAL|anodal tDCS, then cathodal tDCS|Participants receive 1, 20-minute anodal tDCS stimulation. After a washout period of 2-3 weeks, then receive 1, 20-minute cathodal tDCS stimulation.
62479303|NCT06580197||Surgical observation group (Group B)|Patients who received ear acupuncture treatment (≥ 1 time) due to perioperative anxiety, pain, prevention/treatment of DGF, or other indications for ear acupuncture treatment in actual diagnosis and treatment were divided into two groups based on exposure factors. Patients who received ear acupuncture treatment were included in the surgical observation group (Group B), while other patients were included in the surgical control group (Group A). Both groups of patients were from the basic surgical ward of Peking Union Medical College Hospital and were planning to undergo abdominal surgeries such as Whipple, pancreaticoidectomy, and subtotal gastrectomy;
61924628|NCT06168760||Healthy|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
62316953|NCT06286930|EXPERIMENTAL|cathodal tDCS, then andoal tDCS|Participants receive 1, 20-minute cathodal tDCS stimulation. After a washout period of 2-3 weeks, then receive 1, 20-minute anodal tDCS stimulation.
62316954|NCT01918215|OTHER|Device Implantation|A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR
62316955|NCT01918215|NO_INTERVENTION|Observational Registry|A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR
62316956|NCT02050854||Observation|Subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal adherence and are currently on treatment with oral aripiprazole
62686430|NCT01861275||Nasal CPAP|We want to study the nasal-cpap treatment and it's compliance in sleep apnea patients with ischaemic stroke.
62126720|NCT04802148|NO_INTERVENTION|control (natural healing)|Extraction socket is naturally healed
62126721|NCT04802148|EXPERIMENTAL|Test 1 (membrane guided regeneration)|Extraction socket is filled with graft (FDBA) and covered with collagen membrane
62126722|NCT04802148|ACTIVE_COMPARATOR|Test 2 (collagen plug)|Extraction socket is filled with a collagen plug
62126723|NCT06672718|EXPERIMENTAL|SAD Cohorts, Experimental Arm|Participants will receive a single dose of SPY002-091 in a dose escalation format
62126724|NCT06672718|PLACEBO_COMPARATOR|SAD Cohorts, Placebo Arm|Participants will receive a single dose of placebo
62126725|NCT04247074|EXPERIMENTAL|QM1114-DP in the LCL + Placebo in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
62316957|NCT06151756|OTHER|Video mobile application supported education|In order to ensure standardization in the expression of all skills, a video flow plan was prepared and recordings were conducted in accordance with this plan. The videos were organized in a way that the practitioner narrates all the steps of the procedure, with being visible and audible. Before the application, each video was watched repeatedly by the research team and necessary arrangements were performed. Then, the videos created about the applications were uploaded to the mobile application-based web system. After the systematic preparations were completed, trainings on the system and usage were provided to the instructors in charge of the skill practices. In addition, all students were trained on research, the system, and usage, and were provided with the opportunity to download the mobile application to their phones.
62339705|NCT02445144||SCA Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
62339706|NCT02445144||Control Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
62686431|NCT01861275||no Nasal CPAP|No nasal-cpap in sleep apnea patients with ischaemic stroke.
62126726|NCT04247074|PLACEBO_COMPARATOR|Placebo in the LCL and GL|"A buffered solution; Mode of administration:~intramuscular injection"
62126727|NCT04247074|EXPERIMENTAL|Placebo in the LCL + QM1114-DP in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
62126728|NCT04247074|EXPERIMENTAL|QM1114-DP in the LCL + GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
62126729|NCT03544736|EXPERIMENTAL|Cohort A|"Subjects having palliative radiotherapy towards esophageal tumor will receive concomitant therapy With Nivolumab i.v. 240mg Q2W: first 6 patients, 360mg Q3W: Next 6 patients or 480mg Q4W: Last 6 patients, treatment to progression or up to 2 years of treatment.~Radiotherapy: 2 Gy / day, (5 fx/week) to a total of 20 - 50 Gy in 25fx (2-4Gy/fx) at the decision of the responsible physician."
62126730|NCT03544736|EXPERIMENTAL|Cohort B|"Subjects receiving definitive chemoradiotherapy for esophageal cancer will receive concomitant therapy with Nivolumab 240mg Q2W, during RT, and continued with 480mg Q4W, treatment to progression or up to 1 year after completion of radiotherapy. 6 patients in total.~Chemotherapy: Paclitaxel i.v. 175mg/m2 and Carboplatin AUC5, then after 21 days Radiotherapy 1,8 Gy / day (5 fx/week) up to 50,4 Gy in 28fx and concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Nivolumab as described above."
62316958|NCT06151756|NO_INTERVENTION|Control|"The students in the control group, on the other hand, were subjected to standardized training in the skills laboratory without watching any videos after the theoretical information provided in the course. While the students were practicing, they were evaluated by the relevant instructors according to the process steps in the Basic Nursing Skills Learning Guide. In both groups, students were informed about the research and evaluated in terms of inclusion criteria. Prior to the start of the intervention, all students were asked to fill the student introduction form, the Problem Solving Inventory and the California Critical Thinking Disposition Scale."
62316959|NCT00427388|EXPERIMENTAL|Treatment|500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
62316960|NCT00427388|PLACEBO_COMPARATOR|Placebo|500 mg of matching placebo (normal saline solution) divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
62316961|NCT03121352|EXPERIMENTAL|Carboplatin + Nab-paclitaxel + Pembrolizumab|Combination therapy of Carboplatin, Nab-paclitaxel, and Pembrolizumab
62126731|NCT03544736|EXPERIMENTAL|Cohort C|"Subjects with operable esophageal cancer eligible for neoadjuvant chemoradiotherapy will receive Nivolumab 240mg Q2W, concomitantly with RT Then surgery 4-12 weeks after RT. Within 6-12 months after surgery: Adjuvant Nivolumab 480mg Q4W, for 12 months. 6 patients in total.~Neoadjuvant chemotherapy: Concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Radiotherapy: 41,4 Gy in 23 fractions."
61924629|NCT04115540|EXPERIMENTAL|TENS penile nerve stimulation group|"The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to prime their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use)."
62126732|NCT05210257|OTHER|Conventional physiotherapy|Conventional physiotherapy program consists of neck isometric exercises, neck isotonic exercises, stabilization exercises, stretching exercises and posture exercises and physiotherapy agents.
62479304|NCT06580197||Healthy control group (Group C)|According to the surgical observation group (Group B), the healthy control group (Group C) consisted of healthy volunteers from the same period at the Beijing Union Medical College Hospital Health Examination Center.
62686432|NCT05073731|EXPERIMENTAL|Synchronized Telerehabilitation|Physical activity training aiming to increase hand/arm function and fine motor function will be applied via videoconference for 8 weeks, 2 days a week, in 45-60 minute sessions.
62316962|NCT04303585||SAP block|This group includes patients who receive preoperative Serratus Anterior Plane block
62316963|NCT04303585||ESP block|This group includes patients who receive preoperative Erector Spinae Plane block
62479305|NCT06667700|EXPERIMENTAL|Molnupiravir|Participants will receive 800 mg molnupiravir orally every 12 hours for 5 days (a total of 10 consecutive doses)
62479306|NCT06667700|PLACEBO_COMPARATOR|Placebo|Participants will receive molnupiravir-matching placebo orally every 12 hours for 5 days (a total of 10 consecutive doses)
62686433|NCT05073731|ACTIVE_COMPARATOR|Asynchronous Telerehabilitation|Exercise videos and exercise tracking form will be sent.
62686434|NCT00671242||I|L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
62686435|NCT00671242||Nuclear|
62686436|NCT04157582|EXPERIMENTAL|Study group|will consist of 20 hemiparetic patients and will receive Pilates training in addition to conventional physical therapy program consists of (manual stretching exercises, Strengthening Exercises and Wobble board training ) for 18 sessions every other day for one and half month , 3 sessions /week ,each session for 1.30 hours (40 minutes for pilates then 10 minutes rest then 40 minutes conventional physical therapy).
62686437|NCT04157582|EXPERIMENTAL|Control group|will consist of 20 hemiparetic patients and will receive conventional physical therapy program only same as group I for 18 sessions every other day for one and half month, 3 sessions /week, each session for (40 minutes ).
62686438|NCT04954989|EXPERIMENTAL|Test rHuEpo in a single subcutaneous application.|Group T: Test rHuEepo shall be administered subcutaneosly to study participants
62126733|NCT05210257|ACTIVE_COMPARATOR|Neuroscience education|Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.
62126734|NCT01740531|EXPERIMENTAL|S-303 Treated Red Blood Cells (RBC)|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
62126735|NCT01740531|ACTIVE_COMPARATOR|Conventional, untreated Red Blood Cells|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
62126736|NCT03017183|OTHER|EBUS-TBNA - Endobrochial Forceps Biopsy|In this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
62126737|NCT03017183|OTHER|Forceps - EBUS-TBNA|In this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
62686439|NCT04954989|ACTIVE_COMPARATOR|Reference rHuEpo in a single subcutaneous application.|Group T: Reference rHuEepo shall be administered subcutaneosly to study participants
62686440|NCT05978310||Group P|Patients operated in the prone position
62126738|NCT04306705||Tocilizumab|Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no less than 60 minutes. Tocilizumab was administered according to the local label.
62126739|NCT04306705||Continuous Renal Replacement Therapy|Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive 3 times or more.
62126740|NCT04306705||Standard care|Standard of care therapy per local written policies or guidelines.
62126741|NCT02793154|EXPERIMENTAL|Part A: Exenatide|Part A is a single arm design and all subjects will receive 10 mcg subcutaneous injection (SC) of exenatide twice daily for 5 days
62126742|NCT02793154|EXPERIMENTAL|Part B: Albiglutide|In Part B, half of the subjects will be randomized to receive albiglutide: On Day 1: Once weekly SC injection at 30 mg for 4 weeks From Week 5, Day 1: Dose will be increased to 50 mg once weekly SC injection for 4 weeks
62126743|NCT02793154|ACTIVE_COMPARATOR|Part B: Exenatide|"In Part B, half of the subjects will be randomized to receive exenatide: On Day 1: Twice daily SC injection at 5 mcg for 4 weeks.~From Week 5, Day 1: Dose will be uptitrated to 10 mcg twice daily SC injection for 4 weeks"
62126744|NCT00721565|EXPERIMENTAL|1|behavior change intervention
62686441|NCT05978310||Group S|Patients operated in the supine position
62686442|NCT05978310||Group L|Patients operated in the lateral position
62686443|NCT01342042|ACTIVE_COMPARATOR|Metformin|
62686444|NCT01342042|ACTIVE_COMPARATOR|exenatide-4|
62686445|NCT00855166|EXPERIMENTAL|A|Dapagliflozin 10 mg plus Metformin
62126745|NCT00721565|NO_INTERVENTION|2|written materials
62126746|NCT02309034|EXPERIMENTAL|Jump exercise|rebound exercises.
62479307|NCT06243913||Intervention arm|Use of vitrified donor semen for Intrauterine Artificial Insemination
62479308|NCT06733025|EXPERIMENTAL|BoNT injection|The participants will first receive BoNT injection for their upper limb spasticity. Earliest three months after the injection they will undergo surgery.
62479309|NCT06733025|EXPERIMENTAL|Surgery|
62686446|NCT00855166|PLACEBO_COMPARATOR|B|Placebo plus Metformin
62686447|NCT04717479|OTHER|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
62686448|NCT04717479|OTHER|Wait-list Control|Participants will wait 8 weeks and then they will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
62686449|NCT01901757|EXPERIMENTAL|HCP1201, Fasted followed by fed|HCP1201 dosing in the fasted state followed by fed dosing
62479310|NCT03891784|EXPERIMENTAL|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62686450|NCT01901757|EXPERIMENTAL|HCP1201, Fed followed by fasted|HCP1201 dosing in the fed state followed by fasted dosing
62686451|NCT05817344|EXPERIMENTAL|3-Week Baseline|Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy - Integrated (WET-I) followed by a 4-week follow-up phase with repeated weekly assessments.
62686452|NCT05817344|EXPERIMENTAL|5-Week Baseline|Participants in this arm are randomized to a 5-week baseline period with repeated weekly assessment after the initial intake. Following the 5-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy - Integrated (WET-I) followed by a 4-week follow-up phase with repeated weekly assessments.
62686453|NCT02115243|OTHER|Ipi/ILI|Patients will receive ipilimumab followed by ILI.
62686454|NCT06289283||Bladder carcinoma of non muscle invasive bladder cancer and muscle invasive bladder cancer.|"Group I: Non-muscle invasive bladder cancer,16 patients, 16 for bladder tissue, and 16 for urine samples. Total 32 samples. (The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample ( one samble). Recent research showed that microbiota is detecred in the urothelium of normal undividuals and patients with bladder cancer, this microbiota would differ from urine( liquid) microbiota.(References: ) Group II: Muscle invasive bladder cancer, 11 patients. 22 samples 11 for bladder tissue and 11 for urine samples obtained from the same patients. Group III: 11 Normal adults: urine samples from serves as control group of the study.~Total number of participant is 38 individual"
62686455|NCT06674590|EXPERIMENTAL|Experimental group A|It includes participants receiving proprioceptive neuromuscular facilitation physical therapy for chronic stroke patient's for balance and gait parameter for a period of 6 weeks.
62686456|NCT06674590|EXPERIMENTAL|Experimental group B|It includes participants receiving motor relearning program physical therapy for chronic stroke patient's for balance and gait parameter for a period of 6 weeks.
62686457|NCT06348147|EXPERIMENTAL|Daratumumab, lenalidomide, bortezomib, and dexamethasone|Subjects with newly diagnosed multiple myeloma (NDMM) are eligible for standard-of-care autologous stem cell transplantation (ASCT) and receive daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd).
62686458|NCT06687382|EXPERIMENTAL|MBK-01 with no maintenance dose|Participants will receive MBK-01 capsules of intestinal microbiota coming from healthy donors. They will receive an initial dose of 4 capsules the first day, followed by a single daily capsule during 16 days.
62686459|NCT06687382|EXPERIMENTAL|MBK-01 with maintenance dose|Participants will receive MBK-01 capsules of intestinal microbiota coming from healthy donors. They will receive an initial dose of 4 capsules the first day, followed by a single daily capsule during 16 days. 3 months after the ending of the initial dose they will receive a maintenance dose, administered the same as the initial dose.
62686460|NCT06687382|NO_INTERVENTION|No intervention|Participants will not receive any intervention.
62686461|NCT06690944|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation Group|The Proprioceptive Neuromuscular Facilitation group (PNFG) intervention consisted of applying PNF concept exercises and techniques related to facilitating sitting and walking, carried out by a therapist with basic IPNFA® (International Proprioceptive Neuromuscular Facilitation Association) instruction. The PNF intervention was divided into two stages: Stage 1: which consisted of facilitating stability and controlled mobility of the initial position and phases 1, 2, 3, of the sit-up. At the initial position, we applied PNF stabilizing reversals technique for 2 minutes, to stimulate stability in the upright sitting position. In phase 1, we applied PNF to stimulate controlled mobility of the anterior inclination of the erect trunk. In Phase 2, to improve the concentric and eccentric control of lower limb extensor muscles and, in Phase 3 to improve the stability in an upright position again. Stage 2: consists of facilitating activities related to gait.
62686462|NCT06690944|ACTIVE_COMPARATOR|Physical exercise without proprioceptive neuromuscular facilitation control group|The physical exercise without proprioceptive neuromuscular facilitation control group (CG) Intervention consisted of the same activities carried out in the proprioceptive neuromuscular facilitation group (PNFG) during Stages 1 and 2, during the same amount of minutes, sessions, and weeks; however, CG intervention did not include specific techniques and basic principles (i.e. approximation and optimal resistance) and procedures of the PNF concept. The activities were instructed and supervised by a trained professional through verbal command. The professional was at stand-by assistant position to prevent accidents.
62686463|NCT03474601||Acromegaly|Patients diagnosed with acromegaly
62686464|NCT03474601||Cushing's disease|Patients diagnosed with Cushing's disease
62479311|NCT04879719|EXPERIMENTAL|Ego-depletion group|Participants in this condition are asked to suppress their emotion while watching an emotional video of a surgery. Suppressing the natural emotional reaction to such a video demands cognitive resources and thus can induce a state of ego-depletion.
62686465|NCT03474601||Hyperprolactinemia/prolactinomas|Patients diagnosed with hyperprolactinemia/prolactinoma
62126747|NCT02309034|EXPERIMENTAL|Aquatic exercise|Hydrogimnastic.
62316964|NCT02377310||All patients|All patients will undergo coronary physiological study with measurement of resting Pd/Pa, iFR™, hyperaemic iFR and FFR.
61924630|NCT02443779||Early Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
61924631|NCT02443779||Advanced Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
61924632|NCT05631288||Cases|Periodontally compromised patients attending the Periodontology Department during periodontal diagnosis appointments at the point of first diagnosis.
61924633|NCT05631288||Controls|Periodontally healthy patients attending the remaining specialty departments ath the same clinic at the point of first diagnosis.
61924634|NCT05550610|EXPERIMENTAL|Mindfulness and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Yoga was delivered 6 days/week, 30 minutes per day.
62126748|NCT02309034|ACTIVE_COMPARATOR|Nutritional guidance|Nutritional counseling classes.
62126749|NCT02102841|EXPERIMENTAL|Skin biopsy|5mm skin punch biopsy on forearm
62316965|NCT01494961|EXPERIMENTAL|Couple-oriented post-test HIV counseling|Women received couple-oriented post-test HIV counseling
61924635|NCT05550610|NO_INTERVENTION|Training as Usual|Training as usual included standard exercises 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
61924636|NCT05718050|EXPERIMENTAL|Flexure|Dentate patients, 18 years of age or older, in good health and, in need of implant treatment
61924637|NCT02931591|ACTIVE_COMPARATOR|GH+Metformin|The children will be given both Growth Hormone and Metformin for 6 months
61924638|NCT02931591|PLACEBO_COMPARATOR|GH+Placebo|Children will be given both GH and Placebo for 6 months
61924639|NCT00570479|ACTIVE_COMPARATOR|1|50 mgs of anecortave acetate (0.5 ml of a 10% suspension)
62126750|NCT02102841|EXPERIMENTAL|Skin suction blister|Skin suction blister induced on forearm
62126751|NCT02102841|EXPERIMENTAL|Mantoux, skin biopsy, suction blister|0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
62316966|NCT01494961|NO_INTERVENTION|Standard post-test HIV counseling|Women received post-test HIV counseling as per standard site protocol
62316967|NCT02461732|ACTIVE_COMPARATOR|CBT for Substance Dependence|Standard CBT for substance use disorders
62479312|NCT04879719|ACTIVE_COMPARATOR|Control group|Participants in the control group are asked to watch the same emotional video. However, they are required to simply watch the video without suppressing any emotions.
62126752|NCT03489187||VTTS as standard of care|VTTS as standard of care.
62316968|NCT02461732|EXPERIMENTAL|Integrated CBT for PTSD and Substance Dependence|Integrated CBT for PTSD and substance use disorders, combining elements of cognitive processing therapy for PTSD with coping skills and relapse prevention for substance use disorders
61924640|NCT00570479|ACTIVE_COMPARATOR|2|Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension)
62686466|NCT03474601||Pituitary stalk lesions|Patients diagnosed with pituitary stalk lesions
61924641|NCT00570479|ACTIVE_COMPARATOR|3|Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension)
61924642|NCT00570479|ACTIVE_COMPARATOR|4|Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension)
62316969|NCT01735110|ACTIVE_COMPARATOR|Femoral approach group|PCI through Femoral approach
62316970|NCT01735110|EXPERIMENTAL|radial approach group|PCI through radial approach
62316971|NCT02772497|EXPERIMENTAL|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks
62479313|NCT06506903|EXPERIMENTAL|Avalus Ultra|Avalus Ultra bioprosthesis: sizes 19mm, 21mm, 23mm, 25mm, 27mm, and 29mm
62479314|NCT01791751|EXPERIMENTAL|Clomifene Citrate|Clomifene Citrate 50 mg
61924643|NCT03486704|EXPERIMENTAL|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
61924644|NCT03486704|ACTIVE_COMPARATOR|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
61924645|NCT03486704|ACTIVE_COMPARATOR|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
62126753|NCT01620034|ACTIVE_COMPARATOR|11 Day Arm|
62126754|NCT01620034|EXPERIMENTAL|4 Day Arm|
62126755|NCT02897882|EXPERIMENTAL|Lung transplant|Pain evaluation
62316972|NCT04258553||Cervix cancer|Cervix cancer n=62
62316973|NCT04258553||Healthy controls|Healthy volunteers n=61
62316974|NCT05217979|ACTIVE_COMPARATOR|Transcutaneous pulsed radiofrequency|After signing informed consent, patients assigned to the intervention group by randomization will receive a single treatment with transcutaneous pulsed radiofrequency.
62339707|NCT00809458|EXPERIMENTAL|Arm 1 (Vitamin E)|Vitamin E
62339708|NCT00809458|PLACEBO_COMPARATOR|Arm 2|Placebo (same vehicle as used for vitamin E)
62479315|NCT01791751|NO_INTERVENTION|Control|No intervention
62686467|NCT03474601||Nonfunctioning pituitary adenomas|Patients diagnosed with nonfunctioning pituitary adenomas
62126756|NCT02313363|EXPERIMENTAL|PSDCS|using the patient-centered smartphone-based diabetes care system (PSDCS) for 12 weeks
62686468|NCT03474601||Central diabetes insipidus|Patients diagnosed with central diabetes insipidus
62686469|NCT03474601||Craniopharyngioma|Patients diagnosed with craniopharyngiomas
62686470|NCT03474601||Others|Patients diagnosed with other suprasellar/parasellar lesions
62686471|NCT06608732|EXPERIMENTAL|Inaticabtagene autoleucel Combined with Autologous Hematopoietic Stem Cell Transplantation|
62686472|NCT00773461|EXPERIMENTAL|1|
62686473|NCT00773461|PLACEBO_COMPARATOR|2|
61924646|NCT03486704|EXPERIMENTAL|Face to Face VRRS plus active tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
62316975|NCT05217979|SHAM_COMPARATOR|Sham|After signing informed consent, patients assigned to the sham group by randomization will receive a single treatment with sham, which is indistinguishable from the active treatment. This is achieved by putting the device in demo mode, which gives all the same audiovisual signals as the active mode, but no treatment. Given that the treatment is not felt by patients, this ensures blinding.
62316976|NCT01312792|EXPERIMENTAL|Modified IMCI guideline|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
62316977|NCT01312792|ACTIVE_COMPARATOR|Current IMCI guideline|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
62479316|NCT02339571|EXPERIMENTAL|Arm A (nivolumab, ipilimumab, sargramostim)|"INDUCTION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, ipilimumab IV over 30 minutes on day 1 of each cycle, and sargramostim SC on days 1-14 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive nivolumab and sargramostim as in Induction therapy. Patients with PR, SC, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT scan, and blood sample collection throughout the study. Patients may also undergo a MUGA during screening, as well as an ECHO throughout the trial as clinically indicated."
62126757|NCT02972944|EXPERIMENTAL|Cholecystectomy group|Cholecystectomy group will undergo laparoscopic cholecystectomy within 48 hrs after randomization.
62686474|NCT00190528|ACTIVE_COMPARATOR|Surgery|
62686475|NCT00190528|EXPERIMENTAL|Chemotherapy + Surgery|
62316978|NCT04838444|EXPERIMENTAL|VLA1553|
62316979|NCT04789746|EXPERIMENTAL|Running group|Participants that will join the running program.
61924647|NCT03486704|ACTIVE_COMPARATOR|Face to Face VRRS plus placebo tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
62316980|NCT06232122|EXPERIMENTAL|68Ga-FAPI ,PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62316981|NCT01636869|EXPERIMENTAL|bupicavaine|
62479317|NCT02339571|EXPERIMENTAL|Arm B (nivolumab, ipilimumab)|"INDUCTION THERAPY: Patients receive nivolumab and ipilimumab as in Arm I. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive nivolumab as in Induction therapy. Patients with PR, SD, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT scan, and blood sample collection throughout the study. Patients may also undergo a MUGA during screening, as well as an ECHO throughout the trial as clinically indicated."
62479318|NCT03512925|EXPERIMENTAL|Standardized post-coercion review|Intervention: Standardized post-coercion review session. Patients allocated to this arm receive a standardized post-coercion review of the coercive measure they experienced using the developed guidelines.
62479319|NCT03512925|NO_INTERVENTION|Control group|Patients allocated to this arm are treated following usual standards and routine. This might include some form of post-coercion review that doesn't follow the developed standardized guidelines.
62479320|NCT06228066|EXPERIMENTAL|Arm 1|Treatment with lurbinectedin
62479321|NCT06228066|EXPERIMENTAL|Arm 2|Treatment with lurbinectedin and avelumab
62479322|NCT05935605||LHD with no PH|Subjects with Left Heart Disease (LHD) and no Pulmonary Hypertension (PH; mean pulmonary artery (PA) pressure ≤20 mmHg) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
62479323|NCT05935605||LHD with isolated PVH|Subjects with Left Heart Disease (LHD) and isolated Pulmonary Venous Hypertension (PVH; mean PA pressure\>20 mmHg and PVR\<3 WU) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
61924648|NCT03680430|EXPERIMENTAL|limb soft tissue sarcoma|
61924649|NCT04877106|ACTIVE_COMPARATOR|Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®)|JANUMET®, 50mg/850mg, batch no. M047893, manufactured by MSD Pharma (Singapore) Pte.Ltd
62126758|NCT02972944|ACTIVE_COMPARATOR|Non-operative group|Patients of non-operative group will be treated conservatively with intravenous antibiotics (cefuroxime) at surgical ward. Elective cholecystectomy will not be arranged.
62479324|NCT05935605||LHD with vasoactive PVD|Subjects with Left Heart Disease (LHD) and vasoactive Pulmonary Vascular Disease (PVD; mean PA pressure\>20 mmHg and PVR≥3 WU with ≥20% reduction in PVR with inhaled nitric oxide) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
62479325|NCT05935605||LHD with fixed PVD|Subjects with Left Heart Disease (LHD) and fixed Pulmonary Vascular Disease (PVD; mean PA pressure\>20 mmHg, PVR≥3 WU, and PVR reduction of \<20% with inhaled nitric oxide) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
62479326|NCT06472167|NO_INTERVENTION|Chronic airway diseases treated by medication|Chronic airway diseases treated by medication without breathing exercises
61924650|NCT04877106|EXPERIMENTAL|Sitagliptin Phosphate/metformin Hydrochloride Tablets|50mg/850mg, batch no. 161006, manufactured by Tonghua Dongbao Pharmaceutical Co., Ltd.
62126759|NCT02415140||COPD|Spirometry confirmed COPD patients
62316982|NCT04323709||levosimendan group|All patients undergoing VA-ECMO from January 2012 to December 2018 and treated with levosimendan were eligible.
62316983|NCT04323709||group control|All patients undergoing VA-ECMO from January 2012 to December 2018 but not treated with levosimendan were eligible.
62316984|NCT01678807|EXPERIMENTAL|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days
61924651|NCT03361579|OTHER|Placebo education group|Prior to the intervention during the Placebo is given, the volunteer receives a detailed information about the effect and the strength of an open-label placebo. This education is performed via a slide show and a news report video. The important terms for Placebo analgesia: positive expectations, conditioning, communication are discussed
61924652|NCT03361579|OTHER|Placebo non education group|No detailed Information about open-label placebo prior to the intervention. The volunteer is told about the possible strength of the Placebo effect on pain directly before the application.
62126760|NCT02415140||Control|normal geriatric patients without lung disease
62316985|NCT01678807|EXPERIMENTAL|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days
62316986|NCT01678807|PLACEBO_COMPARATOR|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily for 28 days
62316987|NCT03151525|EXPERIMENTAL|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
62316988|NCT03151525|ACTIVE_COMPARATOR|Infliximab|Infliximab 5 mg/kg every 8 weeks
62316989|NCT06570954|ACTIVE_COMPARATOR|No waiting period|At the end of the baseline visit, participants will be randomized to receive Retraining and Control Therapy (ReACT) with no waiting period.
62316990|NCT06570954|ACTIVE_COMPARATOR|3-month waiting period|At the end of the baseline visit, participants will be randomized to receive Retraining and Control Therapy (ReACT) after a waiting period of 3 months.
61924653|NCT04020575|EXPERIMENTAL|Dose Escalation|"Dose escalation or de-escalation is tested in cohorts of 3 patients each using standard 3+3 dose-finding."
61924654|NCT04020575|EXPERIMENTAL|Luminal|Dose Expansion - 15 patients will be enrolled with luminal (hormone receptor positive, HER2 negative) metastatic breast cancer.
61924655|NCT04020575|EXPERIMENTAL|HER2+|Dose Expansion - 15 patients will be enrolled with HER2+ metastatic breast cancer.
61924656|NCT04020575|EXPERIMENTAL|Triple Negative|Dose Expansion - 15 patients will be enrolled with triple negative metastatic breast cancer.
61924657|NCT01323738|NO_INTERVENTION|Treatment as Ususal|Patients participate in the Treatment as Usual including a non-specific information group.
61924658|NCT01323738|EXPERIMENTAL|Psychoeducation|Intervention group
61924659|NCT01386112|EXPERIMENTAL|EUR-1100 1.5 mg|
61924660|NCT01386112|EXPERIMENTAL|EUR-1100 3.0 mg|
61924661|NCT01386112|PLACEBO_COMPARATOR|placebo|
62316991|NCT06570954|ACTIVE_COMPARATOR|6-month waiting period|At the end of the baseline visit, participants will be randomized to receive Retraining and Control Therapy (ReACT) after a waiting period of 6 months.
62316992|NCT06250153|NO_INTERVENTION|Treatment as Usual|This group will receive routine substance use screening questions during their in-person primary care visit as part of standard of care.
62316993|NCT06250153|EXPERIMENTAL|m-SBIRT (mobile-Screening, Brief Intervention, and Referral to Treatment)|This group will receive a mobile phone text message based substance use screening (questions used in standard of care) with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to substance use disorder (SUD) treatment.
62316994|NCT01558089||etanercept + methotrexate|
62316995|NCT02492750|EXPERIMENTAL|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
62316996|NCT02492750|ACTIVE_COMPARATOR|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62316997|NCT03465735|OTHER|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
61924662|NCT02376829|EXPERIMENTAL|The Invisalign System|Class II correction of malocclusions
61924663|NCT01504568|OTHER|Prophylactic Antibotics|Amoxicillin/clavulanic acid
61924664|NCT01504568|NO_INTERVENTION|Non Treatment|Subjects will be followed without the use of antibiotics.
61924665|NCT04411524|EXPERIMENTAL|Treatment Arm|A total of 50 MSI-H LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
61924666|NCT06366022|EXPERIMENTAL|Multiple adjacent recessions coverage with sCTG with inner side of the graft|"Experimental: Multiple adjacent recessions coverage with subepithelial connective tissue graft..~A modified microsurgical tunnel technique. Initial sulcular incisions with a microsurgical blade are followed by a full-thickness buccal flap preparations till muco-gingival junction using the tunneling knives. Subsequently, the split-thickness preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted the inner side into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures."
62126761|NCT05377567|EXPERIMENTAL|TAU + FIBRO-On|FIBRO-On is a virtual multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
62126762|NCT05377567|ACTIVE_COMPARATOR|TAU + FIBRO-Out|FIBRO-Out is a outdoor multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
62316998|NCT03465735|OTHER|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
62316999|NCT00428727|EXPERIMENTAL|1|Nitric oxide patches
62317000|NCT00428727|PLACEBO_COMPARATOR|2|Placebo patches
62317001|NCT03468023|EXPERIMENTAL|Short arm cast|Patient treated with below-elbow cast
62317002|NCT03468023|ACTIVE_COMPARATOR|Long arm cast|Patients treated with above-elbow cast
62317003|NCT02844504|EXPERIMENTAL|Low Intensity Exercise Training 1|Cancer survivors will receive low intensity handgrip exercise training.
62317004|NCT02844504|EXPERIMENTAL|Low Intensity Exercise Training 2|Cancer survivors will receive low intensity handgrip exercise training different than other arm.
62317005|NCT02844504|NO_INTERVENTION|Control|This group will receive no training.
62686476|NCT05658276||With LV Unloading|"Adults (18+) who are in cardiogenic shock and being treated with mechanical circulatory support (veno-arterial ECMO) inserted peripherally. The patients in this group will also have an additional device, such as an Impella or an intra-aortic balloon pump (IABP) for left ventricular unloading. The decision whether or not to unload the patient will be purely clinical.~Data will be collected from the patient's chart and entered into a secure database. A standard complete transthoracic echocardiogram will be completed at enrollment and then again 7 days from enrollment (+/- 2 days). Additional blood tests will be ordered for the 7 days after enrollment. All tests will be ordered on Day 1 (patient on ECMO, prior to any LV unloading) and additionally as follows:~* Troponin: Daily for 7 days~* NT-proBNP: Daily for 7 days~* PCO2 gap (in blood gas analysis): Every 6 hours for 3 days~* Lactate (in blood gas analysis): Every 12 hours for 3 days~* cBIN1: Twice in 7 days"
61924667|NCT06366022|ACTIVE_COMPARATOR|Multiple adjacent recessions coverage with sCTG with outer side of the graft|"Multiple adjacent recessions coverage with subepithelial connective tissue graft..~A modified microsurgical tunnel technique. Initial sulcular incisions with a microsurgical blade are followed by a full-thickness buccal flap preparations till muco-gingival junction using the tunneling knives. Subsequently, the split-thickness preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted the outer side into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures."
61924668|NCT03531034|EXPERIMENTAL|Hypertensive Women|Group of hypertensive and controlled women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
61924669|NCT03531034|ACTIVE_COMPARATOR|Normotensive Women|Group of normotensive women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities.
62126763|NCT05377567|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
62317006|NCT04864977|EXPERIMENTAL|LY2963016|Participants with type 2 diabetes will be started on insulin glargine and dose will be titrated. Insulin glargine will be delivered via insulin pen each evening subcutaneously (SC). They will also check fasting blood glucose values on a study meter and prior to treating hypoglycemia. Participants will be asked to report the time and dose of their last administration.
61924670|NCT03052764|ACTIVE_COMPARATOR|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
61924671|NCT03052764|PLACEBO_COMPARATOR|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
61924672|NCT04028245|EXPERIMENTAL|Spartalizumab and Canakinumab|Subjects with renal cell carcinoma will receive study treatment Q4 weeks x 2 doses prior to radical nephrectomy.
61924673|NCT01728948||Group 1|
62126764|NCT02301559|EXPERIMENTAL|Pilates Group|Pilates Group, Pilates exercises, 20 sessions, lasting 40 minutes each, 3 times per week. Soil and ball exercises, with emphasis on the pelvic region. The program began with the work of breathing and postural correction, with warm-up exercises or preparatory, followed by the framework of classical movements of the method.
62317007|NCT03267095|EXPERIMENTAL|Study|.Patient in stduy Arm will receive music therapy sessions
61924674|NCT02886156|EXPERIMENTAL|CPAP plus BSC|Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center.
62126765|NCT00957411|ACTIVE_COMPARATOR|Arm I|Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
62317008|NCT03267095|NO_INTERVENTION|Control|Patient in control Arm will have cosuling for mother and follow up
62697409|NCT05997901|EXPERIMENTAL|Varenicline healthbot|While the exact healthbot features will be based on results from the rapid review, interviews and Wizard of OZ testing, the investigators know from the existing literature on medication adherence, and behaviour change interventions, that the healthbot will provide: 1) reminders for varenicline dosing and schedule; 2) information and suggestions on managing known side effects (the most frequently cited reason for varenicline non-adherence is experiencing side effects); 3) answers to questions about medication use (e.g., what to do if a dose is missed); and 4) support to increase participants' motivation to continue their quit attempts. During the next 12 weeks, participants will be reminded by the healthbot to take their varenicline at the appropriate times, and will be able to interact with the healthbot when they want.
62126766|NCT00957411|EXPERIMENTAL|Arm II|Patients receive cisplatin and undergo radiotherapy as in arm I. Patients also receive cetuximab IV over 1 hour once weekly during weeks 1-6.
62317009|NCT00784784|EXPERIMENTAL|Influenza vaccine|Influenza vaccine, using Fluviral trivalent split virus vaccine
62479327|NCT06472167|ACTIVE_COMPARATOR|Chronic airway diseases treated by medication with breathing exercises|Chronic airway diseases treated by medication and breathing exercises
62479328|NCT05746455|EXPERIMENTAL|Motivation Skills Training (MST)|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline as well as a satisfaction survey.
62479329|NCT05617872|PLACEBO_COMPARATOR|Normal Saline Group|Inject 20ml normal saline solution into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
62126767|NCT02843217|EXPERIMENTAL|Text Messaging|
62126768|NCT05346523|EXPERIMENTAL|Usual Care + CDDS usage|Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual but with support of the CDDS.
62479330|NCT05617872|EXPERIMENTAL|Vinegar 20ml Group|Inject 20ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
62479331|NCT05617872|ACTIVE_COMPARATOR|Vinegar 40ml Group|Inject 40ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
62479332|NCT06441682|EXPERIMENTAL|ARGX-119 - Dose 1|Participants will receive first dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period
62479333|NCT06441682|EXPERIMENTAL|ARGX-119 - Dose 2|Participants will receive second dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period
62479334|NCT06441682|EXPERIMENTAL|ARGX-119 - Dose 3|Participants will receive third dosage level of ARGX-119 intravenously during the double blinded treatment period followed by ARGX-119 in active treatment extension period
61924675|NCT02886156|ACTIVE_COMPARATOR|BSC intervention|Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
62126769|NCT05346523|NO_INTERVENTION|Usual Care|Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual without support of the CDDS.
62126770|NCT06327386||After neoadjuvant therapy for gastric cancer|"* Diagnosed primary gastric adenocarcinoma patients (cT2N+non-surgical treatment, cT3NanyMany and above staging)~* Staging of MRI enhanced examination before neoadjuvant therapy~* Restaging of preoperative 18F-FAPI and 18F-FDG PET/MRI examination~* Postoperative resection was performed after neoadjuvant therapy, with postoperative pathology, regression grading, and related immunohistochemistry~* Patient age ≥ 18 years old~* The patient voluntarily participates and signs an informed consent form."
62317010|NCT00784784|EXPERIMENTAL|Antiviral prophylaxis|Zanamivir antiviral prophylaxis
62317011|NCT02021123|EXPERIMENTAL|Anidulafungin 100 mg single dose|100 mg single dose anidulafungin pre-surgery (gastric bypass)
62317012|NCT06031467|ACTIVE_COMPARATOR|Non-surgical mechanical therapy|Titanium curettes were used for non-surgical mechanical therapy in both groups under local anesthesia. The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt. The control group received mechanical therapy alone.
62317013|NCT06031467|ACTIVE_COMPARATOR|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|Titanium curettes were used for non-surgical mechanical therapy in both groups under local anesthesia. The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt. The laser group received mechanical therapy followed by Er;Cr;YSGG laser.
62686477|NCT05658276||Without LV Unloading|"Adults (18+) who are in cardiogenic shock and being treated with mechanical circulatory support (veno-arterial ECMO) inserted peripherally. The patients in this group will not have any LV unloading device in addition to the ECMO support. The decision not to do LV unloading will be purely clinical.~Data will be collected from the patient's chart and entered into a secure database. A standard complete transthoracic echocardiogram will be completed at enrollment and then again 7 days from enrollment (+/- 2 days). Additional blood tests will be ordered for the 7 days after enrollment. All tests will be ordered on Day 1 (patient on ECMO, prior to any LV unloading) and additionally as follows:~* Troponin: Daily for 7 days~* NT-proBNP: Daily for 7 days~* PCO2 gap (in blood gas analysis): Every 6 hours for 3 days~* Lactate (in blood gas analysis): Every 12 hours for 3 days~* cBIN1: Twice in 7 days"
62686478|NCT01744626|EXPERIMENTAL|CC-292 with Rituximab|Dose Escalation
62479335|NCT06441682|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo intravenously during the double-blinded treatment period followed by ARGX-119 in active treatment extension period
62686479|NCT06464367|EXPERIMENTAL|Migraine psilocybin|Migraine participants randomized to receive 10 mg psilocybin (oral)
62686480|NCT06464367|PLACEBO_COMPARATOR|Migraine placebo|Migraine participants randomized to receive 2.5 mg THC (oral)
62686481|NCT06464367|EXPERIMENTAL|Healthy control psilocybin|Healthy control participants randomized to receive 10 mg psilocybin (oral)
62686482|NCT06464367|PLACEBO_COMPARATOR|Healthy control placebo|Healthy control participants randomized to receive 2.5 mg THC
62126771|NCT04011631|EXPERIMENTAL|Patients with cardiac surgery|All patients undergoing cardiac surgery at the Ziekenhuis Oost-Limburg, meeting all inclusion and no exclusion criteria, are asked to participate in the investigation.
62126772|NCT01611831|EXPERIMENTAL|ACT in group|Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
62126773|NCT01611831|ACTIVE_COMPARATOR|Improved Treatment as usual by General practitioner|Patients assigned to this arm will receive treatment as usual by their General Practitioner in the Primary Care center. To enhance treatment, investigators participating in the trial will receive the Guidelines for fibromyalgia treatment in Primary Care handed by Health Service in Aragón.
62126774|NCT02531113|EXPERIMENTAL|RPC1063 (Ozanimod)|
62317014|NCT01588574|ACTIVE_COMPARATOR|BOTOX (registered trade mark)|
62317015|NCT01588574|EXPERIMENTAL|MT10109|
62317016|NCT01256619|ACTIVE_COMPARATOR|marvelon|
62317017|NCT01162369||Group 1 - Non-Delirius Patients|
62686483|NCT06465641|ACTIVE_COMPARATOR|Methylphenidate|Methylphenidate hydrochloride in capsules
62686484|NCT06465641|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose in capsules
62686485|NCT03622905|EXPERIMENTAL|DBS On|DBS system On
62686486|NCT03622905|SHAM_COMPARATOR|DBS Off|DBS System Off
62686487|NCT05145816|EXPERIMENTAL|Cohort (DL 0) for Part 1|Cohort (DL 0) for Starting Dose : 1.9 mg/kg Belantamab mafodotin intravenously every 8 weeks
62686488|NCT05145816|EXPERIMENTAL|Cohort (DL +1) for Part 1|Cohort (DL +1) for Dose Escalation: 2.5 mg/kg Belantamab mafodotin intravenously every 8 weeks
62686489|NCT05145816|EXPERIMENTAL|Cohort (DL -1) for Part 1|Cohort (DL -1) for Dose De-escalation : 1.9 mg/kg Belantamab mafodotin intravenously every 12 weeks
62126775|NCT03372473|EXPERIMENTAL|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg one dose a day
62126776|NCT03372473|ACTIVE_COMPARATOR|Montelukast|Montelukast 5mg one dose per day
62126777|NCT00572286||1|heart transplant patient ( pre or post)
62126778|NCT05421364|EXPERIMENTAL|Endometrial cell composition|The cell composition and their quantities will be compared before and after intrauterine administration of PBMC in the endometrial biopsies.
62126779|NCT01647438|OTHER|Print Health Education|Participants receive print health education materials
62126780|NCT01647438|EXPERIMENTAL|Lifestyle Intervention|Six weekly health education classes and phone counseling.
62126781|NCT05762159||erector spinae block|Patients receiving erector spinae block for pain management of spinal osteosynthesis. Pupillometer will be realized during analgesia (usual practice).
62126782|NCT02073578|OTHER|Treatment|Peroral Endoscopic Myotomy (POEM)
62126783|NCT02967536||Mild OSA|Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) \>5 events/hour and \<10 events/hour with Epworth Sleepiness Score (ESS)\>9.
62126784|NCT02967536||Severe OSA|Untreated OSA patients. AHI \>30 events/hour, with excessive sleepiness (ESS \>9).
62126785|NCT02967536||Healthy control|Healthy control. AHI \<5 events/hour.
62126786|NCT00176839|EXPERIMENTAL|Treatment Arm|Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0.
62317018|NCT01162369||Group 2 - Delirious Patients|
62317019|NCT00005398||1; no experimental groups in this study|Observational cohort study
62317020|NCT00968578|ACTIVE_COMPARATOR|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
62317021|NCT00968578|PLACEBO_COMPARATOR|Saline|Saline iv pre-operatively in equivalent volume (placebo)
62317022|NCT06598007|EXPERIMENTAL|CT3001 50mg|Participants will be administered CT3001 oral solution after a meal (within 15 minutes) at Cycle 0 Day 1 and repeated daily dosing for 21 days in ongoing cycles.
62317023|NCT06598007|EXPERIMENTAL|CT3001 100mg|Participants will be administered CT3001 oral solution after a meal (within 15 minutes) at Cycle 0 Day 1 and repeated daily dosing for 21 days in ongoing cycles.
62317024|NCT06598007|EXPERIMENTAL|CT3001 200mg|Participants will be administered CT3001 oral solution after a meal (within 15 minutes) at Cycle 0 Day 1 and repeated daily dosing for 21 days in ongoing cycles.
62479336|NCT06623409|ACTIVE_COMPARATOR|GARDASIL®9 (G9)|Participants will receive vaccinations with G9.
62317025|NCT06598007|EXPERIMENTAL|CT3001 300mg|Participants will be administered CT3001 oral solution after a meal (within 15 minutes) at Cycle 0 Day 1 and repeated daily dosing for 21 days in ongoing cycles.
62317026|NCT06598007|EXPERIMENTAL|CT3001 500mg|Participants will be administered CT3001 oral solution after a meal (within 15 minutes) at Cycle 0 Day 1 and repeated daily dosing for 21 days in ongoing cycles.
62317027|NCT06598007|EXPERIMENTAL|CT3001 700mg|Participants will be administered CT3001 oral solution after a meal (within 15 minutes) at Cycle 0 Day 1 and repeated daily dosing for 21 days in ongoing cycles.
62317028|NCT01951482|EXPERIMENTAL|Bevacizumab and Pemetrexed/cisplatin|Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d
62317029|NCT01951482|ACTIVE_COMPARATOR|Pemetrexed/cisplatin|Pemetrexed/cisplatin q21d
62317030|NCT06671340|EXPERIMENTAL|IH/T2D|partipiants with intermediate hyperglycemia (IH) n=15 or T2D (n=15)
62479337|NCT06623409|EXPERIMENTAL|V540B|Participants will receive vaccinations with V540B.
62479338|NCT06116617|EXPERIMENTAL|SRSD107|SRSD107 for subcutaneous (s.c.) injection Group A1, 15mg, single dose Group A2, 45mg, single dose Group A3, 120mg, single dose Group A4, 240mg, single dose Group A5, 450mg, single dose
62479339|NCT06116617|PLACEBO_COMPARATOR|Placebo|Sodium chloride for subcutaneous (s.c.) injection
62126787|NCT01257932||Diagnostic Tool|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
62126788|NCT05362110|EXPERIMENTAL|Experimental|HCP1803-3
62126789|NCT05362110|ACTIVE_COMPARATOR|Active Comparator|RLD2002
62126790|NCT02903199|EXPERIMENTAL|Whey Protein|Whey protein (18g) experimental supplement
62126791|NCT02903199|EXPERIMENTAL|Hydrolysed Protein|Hydrolysed whey protein (19.1g) experimental supplement
62126792|NCT02903199|PLACEBO_COMPARATOR|Placebo|Water placebo supplement
62126793|NCT05579899|EXPERIMENTAL|EVO101 Cream|Active Treatment, BID, 8 weeks
62126794|NCT05579899|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Treatment, BID, 8 weeks
62126795|NCT02324010|EXPERIMENTAL|Sitaglipltin (100mg)|Active drug (sitagliptin)
62317031|NCT05839990|ACTIVE_COMPARATOR|Surgery|Patients with ascending aortic aneurysm and dlatation who undergo surgical tretment
62317032|NCT05839990|NO_INTERVENTION|Non-surgery|Patients with ascending aortic dlatation who undergo surveillance
62317033|NCT04897412|EXPERIMENTAL|CBL-514 Injection|Participant will receive CBL-514 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
62317034|NCT04897412|PLACEBO_COMPARATOR|Placebo: 0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
62317035|NCT01752517||refractory SCLC|NI group vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days; every 3 weeks; up to the maximum cycles (total:6);
62317036|NCT03141307|ACTIVE_COMPARATOR|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
62317037|NCT03141307|PLACEBO_COMPARATOR|Control|This group will receive the standard of care currently used (paper-based brochure)
62339709|NCT02678663|EXPERIMENTAL|Injection-assisted cold snare polypectomy (I-CSP)|Polyps in this group will be resected with the cold snare technique after pre-lift of the lesion with a submucosal injection of methylene blue-tinted normal saline solution. The polyp and a small rim of normal tissue will be then snared closely and removed in a single piece without the use of electrocautery.
62126796|NCT02324010|PLACEBO_COMPARATOR|Placebo (sugar pill)|Inactive drug (placebo)
62339710|NCT02678663|ACTIVE_COMPARATOR|Endoscopic mucosal resection (EMR).|"Polyps in this group will be removed in a single piece by using an inject-and-cut EMR technique. Methylene blue-tinted normal saline solution will be injected into the submucosal space followed by the application of snare cautery for lesion resection."
62479340|NCT06127095||Participants with RRMS|Participants who receive natalizumab intravenously (IV) or subcutaneously (SC) or ocrelizumab, or ofatumumab, as per the standard local prescribing procedures will be enrolled to collect data. Participants will complete an online one-shot questionnaire combining closed and open-ended questions.
62479341|NCT02435160|EXPERIMENTAL|Ulcerative Colitis|
62686490|NCT05145816|EXPERIMENTAL|Cohort (DL -2) for Part 1|Cohort (DL -2) for Dose De-escalation: 1.4 mg/kg Belantamab mafodotin intravenously every 12 weeks
62126797|NCT02652689|EXPERIMENTAL|Diagnostic ultrasound|Recording Doppler ultrasound signals noninvasively from the right chest wall
62126798|NCT01126918|ACTIVE_COMPARATOR|Brochure Condition|Participants in this condition receive an educational brochure about healthy body image via post-mail.
62126799|NCT01126918|EXPERIMENTAL|Group Condition|Participants in this condition attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
62126800|NCT01231802|EXPERIMENTAL|Arm 1: Eniluracil/5-FU/Leucovorin|Arm 1: (weekly, 28-day cycle): Approximately eighty subjects will orally self-administer eniluracil approximately 13 hr (range of 11-16 hr) before receiving 5 FU and leucovorin. The next day they will orally self-administer 5-FU and leucovorin. On the third day, they will orally self-administer leucovorin. The regimen is taken once per week for three consecutive weeks followed by one-week off-treatment.
62126801|NCT01231802|ACTIVE_COMPARATOR|Arm 2: Capecitabine|Arm 2: (bid daily, 21-day cycle): Approximately sixty subjects will self-administer oral capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
62126802|NCT04951362|ACTIVE_COMPARATOR|intranasal Ivermectin group|49 pateints with anosmia received ivermectin nanosuspension nasal spray
62126803|NCT04951362|PLACEBO_COMPARATOR|saline nasal spray|47 pateints with anosmia received saline nasal spray
62126804|NCT02214550|NO_INTERVENTION|D+COS-no OC|Ten participants in the Dysmenorrhea + COS group will not receive an OC intervention. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
62126805|NCT02214550|ACTIVE_COMPARATOR|D+COS-cyclic microgestin 1/20|26 participants in the Dysmenorrhea + COS group will receive cyclic OC. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
62317038|NCT06321484|EXPERIMENTAL|Dose Level 0|"Participants will be enrolled in a staggered fashion into a 3+3 dose de-escalation per protocol to establish a maximum tolerated dose (MTD). Dosage will start at dose level 0.~* Baseline visit.~* MRIs, PET scans, and/or CT scans every 8 weeks.~* Cycle 0:~  * Day -7 of 8 day cycle: Apheresis for autologous NK cell collection.~ * Days -6 through -2 of 8 day cycle: Predetermined dose of lymphodepleting chemotherapy per protocol.~ * Days -5 through -4 of 8 day cycle:~    * Predetermined dose of lymphodepleting chemotherapy per protocol.~   * Predetermined dose of premedication per institutional standards.~ * Day 0 of 8 day cycle:~    * Predetermined dose of CIML NK cells once~   * Subcutaneous low-dose IL-2 once~* Cycle 1:~  - Days 2-8: Subcutaneous low-dose IL-2 every other day for 4 additional doses~* Off-Treatment:~  * Long-term follow up for 5 years after last CIML NK cell infusion."
62317039|NCT06321484|EXPERIMENTAL|Dose Level -1|"3+3 de-escalation to dose level -1 per protocol if DLTs occur in Cohort 1 dose Level 0.~* Baseline visit.~* MRIs, PET scans, and/or CT scans every 8 weeks.~* Cycle 0:~  * Day -7 of 8 day cycle: Apheresis for autologous NK cell collection.~ * Days -6 through -2 of 8 day cycle: Predetermined dose of lymphodepleting chemotherapy per protocol.~ * Days -5 through -4 of 8 day cycle:~    * Predetermined dose of lymphodepleting chemotherapy per protocol.~   * Predetermined dose of premedication per institutional standards.~ * Day 0 of 8 day cycle:~    * Predetermined dose of CIML NK cells once~   * Subcutaneous low-dose IL-2 once~* Cycle 1:~  - Days 2-8: Subcutaneous low-dose IL-2 every other day for 4 additional doses~* Off-Treatment:~  * Long-term follow up for 5 years after last CIML NK cell infusion."
62317040|NCT03742492|EXPERIMENTAL|Canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
62317041|NCT03742492|PLACEBO_COMPARATOR|Canned tuna + soybean oil|Meal containing canned tuna + soybean oil
62317042|NCT02596347||Beryllium Sensitization (BeS)|Blood draw
62479342|NCT02561611|NO_INTERVENTION|Control Group|"* Usual Working Condition Group (UWC)~* The no-intervention control condition will be asked to maintain their usual work and lifestyle throughout the study. Participants may be contacted by Pennington Biomedical staff during the intervention."
62479343|NCT02561611|EXPERIMENTAL|Intervention Group|"* Combined Intervention (Walk More and Pedal Desk; WMPD)~* Participants in the WMPD condition will engage in both step-counting (Walk More, WM) and pedal desk (PD) intervention components."
62317043|NCT02596347||Chronic Beryllium Disease(CBD)|blood draw BAL
62317044|NCT03662334|EXPERIMENTAL|Hylenex recombinant|Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).
62126806|NCT02214550|ACTIVE_COMPARATOR|D+COS-continuous microgestin 1/20|26 participants in the Dysmenorrhea + COS group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
62317045|NCT03662334|SHAM_COMPARATOR|Sham Injection|Comparing the preadministration of a sham injection in the setting of CSII.
62317046|NCT01949493|OTHER|Care as usual|The patient will receive the usual care provided by the neurologists at VieCuri Medical Center. This may include an expectant strategy, a wrist splint, corticosteroid injection or carpal tunnel release surgery.
62126807|NCT02214550|ACTIVE_COMPARATOR|PBS-continuous microgestin 1/20|26 participants in the Painful Bladder Syndrome group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
62317047|NCT01949493|EXPERIMENTAL|Mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus.
62317048|NCT01170377||Mental Retardation|Patients receiving valproate or not
62317049|NCT05641376|ACTIVE_COMPARATOR|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia.
62317050|NCT05641376|ACTIVE_COMPARATOR|Intravenous Dexmedetomidine|Children will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
62317051|NCT02025972|EXPERIMENTAL|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
62317052|NCT06667557||sTFL Group|Kidney stones and/or upper ureteral stones are treated with a superpulsed thulium fiber laser (sTFL)
62317053|NCT06667557||Ho:YAG Group|Kidney stones and/or upper ureteral stones are treated with a holmium :YAG laser (Ho:YAG)
62339711|NCT06085261|EXPERIMENTAL|home-based telerehabilitation|Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises.
62339712|NCT06085261|ACTIVE_COMPARATOR|center-based traditional rehabilitation|Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.
62339713|NCT06062407||Stroke subjects without fall risk|The patient was diagnosed with a stroke with a berg score of not less than 40.
62479344|NCT02517554||Remote cancer genetic services by videoconference|
62479345|NCT02517554||Remote cancer genetic services by telephone|
62479346|NCT02517554||Usual Care|
62479347|NCT02010463|OTHER|Exercise Intervention|9-month exercise program involving four exercise education sessions
62479348|NCT02100917|EXPERIMENTAL|DMB-3111|6 mg/kg is once given in intravenous drip infusion taking 90 min
62479349|NCT02100917|ACTIVE_COMPARATOR|trastuzumab|6 mg/kg is once given in intravenous drip infusion taking 90 min
62479350|NCT00835666|EXPERIMENTAL|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
62317054|NCT05283083|EXPERIMENTAL|Dexmedetomidine|"Patients will receive dexmedetomidine infusion according to the protocol plus the usual care.~We will evaluate patients for inclusion in the study after 6 hours on NE infusion, given stabilization of the MAP \> 65 mmHg. In the DEX group, we will commence DEX infusion at the rate of 0.2 mcg.kg-1.h-1 without a loading dose, then titrate DEX infusion to maintain the HR from 60 to 90 bpm.~Titration of the DEX infusion rate will not be more than 0.1 mcg.kg-1.h-1 every 30 minutes at any time. The maximum DEX infusion rate will be 0.7 mcg.kg-1.h-1.~We aim to continue DEX infusion for 48 hours. After 48 hours of DEX infusion, we will taper the DEX infusion over one hour.~According to our protocol, DEX infusion would trigger either STOP events or hemodynamic assessment events:"
62317055|NCT05283083|NO_INTERVENTION|Usual care without dexmedetomidine infusion|The patients in this group will receive the usual care.
62479351|NCT00835666|ACTIVE_COMPARATOR|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
62479352|NCT02956525|EXPERIMENTAL|Dexibuprofen 200 mg - Fed|Fed condition
62479353|NCT02956525|EXPERIMENTAL|Dexibuprofen 200 mg - Fasting|Fasting condition
62479354|NCT05824481|EXPERIMENTAL|Cadonilimab + Lenvatinib|"Safety run-in stage. A dose de-escalation schedule is used in this phase. Dose Level 1: cadonilimab 10 mg/kg administered intravenously on day 1 and lenvatinib 16 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a DLT, we will de-escalate to Dose Level 2: cadonilimab 10 mg/kg administered intravenously on day 1 and lenvatinib 12 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in the safety run-in phase.~Expansion stage. The expansion stage will begin once the RP2D of lenvatinib have been determined in the safety run-in phase in order to assess antitumor activity of cadonilimab and lenvatinib combination. In expansion stage, cadonilimab 10 mg/kg and lenvatinib PR2D will be administered."
62479355|NCT05266313|EXPERIMENTAL|Oncosexology program|Several workshops before and after the radical prostatectomy
62479356|NCT05266313|NO_INTERVENTION|Usual care|Usual care of the urology department for patients with prostate cancer
62479357|NCT01564238|EXPERIMENTAL|High calcium diets (1300 mg or higher)|
62479358|NCT01564238|EXPERIMENTAL|Low calcium diet (800 mg/d)|
62686491|NCT05145816|EXPERIMENTAL|Cohort Dose Expansion for Part 2|Cohort Dose expansion for Part 2: Belantamab mafodotin Dose from1.0 mg/kg to 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks, or 12 weeks as determined by Part 1 recommended dosage calculations.
62686492|NCT05145816|EXPERIMENTAL|Cohort (DL -3) for Part 1|Cohort (DL -3) for Dose De-escalation: 1.0 mg/kg Belantamab mafodotin intravenously every 12 weeks
62686493|NCT05560880|EXPERIMENTAL|High Intensity Interval gait training|subjects will receive 3x/week high intensity interval training for 20 minutes over a 4 week period
62686494|NCT05560880|ACTIVE_COMPARATOR|Moderate intensity continuous gait training|subjects will receive 3x/week moderate intensity continuous gait training for 20 minutes over a 4 week period
62126808|NCT02214550|NO_INTERVENTION|No Intervention: Pain Discovery Aim|"255 Reproductive-age women (18-45) will be identified and divided into 5 groups~Healthy Controls Chronic Pain (Positive Controls) Dysmenorrhea (D) Dysmenorrhea with Cross Organ Sensitization (D+COS) Painful bladder syndrome (PBS)/interstitial cystitis (IC) After a screening, dysmenorrhea with COS and PBS participants will be compared with controls. Daily Diaries will be completed for 1-3 months. During the luteal phase of the participants' menstrual cycle or a predetermined time, participants will complete aim #1 testing consisting of a battery of questionnaires, bladder sensitivity testing, quantitative sensory testing (QST), a blood draw and EEG testing. All participants will also complete a yearly follow-up questionnaire for 5 years."
62126809|NCT05104294||mild Primary Open Angle Glaucoma group (Group I)|28 eyes of 16 patients with mild primary open angle glaucoma as group I.
62317056|NCT02778880|EXPERIMENTAL|Ketamine|Ketamine 1.5 mg/kg intranasally for one dose
62317057|NCT02778880|ACTIVE_COMPARATOR|Fentanyl|Fentanyl 2 mcg/kg intranasally for one dose
62317058|NCT06172257|EXPERIMENTAL|OCS-01|dexamethasone ophthalmic suspension,1.5% \[15 mg/mL\]
62686495|NCT02787174|NO_INTERVENTION|Control|Participants will receive routine clinical treatment care.
62317059|NCT06172257|PLACEBO_COMPARATOR|Vehicle ophthalmic suspension|Vehicle of OCS-01
62479359|NCT06366113|OTHER|Morning group|Endurance and muscular exercise can be performed in the morning, either at 9:00am or 9:45am, or vice versa.
62686496|NCT02787174|EXPERIMENTAL|Intervention|Participants will receive interactive tailored asthma medication adherence education on an iPad.
62686497|NCT06295471|EXPERIMENTAL|Treatment|23 healthy subjects with treatment of the DFG and CO2 laser
62686498|NCT06695234|EXPERIMENTAL|MAT RCT study|MAT vs Treatment-as- usual RCT
62686499|NCT06695234|NO_INTERVENTION|Qualitative follow-up|Qualitative follow up of a sub-sample of those within the intervention group
62686500|NCT06560879|EXPERIMENTAL|Lactobacillus casei|Oral administration of 1 capsule with Lactobacillus casei (2.5 billion CFU + microcrystalline cellulose) before breakfast and another capsule before lunch, for a total dose of 5 billion CFU/day.
62479360|NCT06366113|OTHER|Afternoon group|Endurance and muscular exercise can be performed in the afternoon, from 3:00 pm to 3:45 pm, or vice versa.
62479361|NCT03566017|EXPERIMENTAL|Experimental open label|pegunigalsidase alfa
62479362|NCT06656338|EXPERIMENTAL|Arm 1: Higher HEI-2020 diet followed by lower HEI-2020 diet|
62479363|NCT06656338|EXPERIMENTAL|Arm 2: Lower HEI-2020 diet followed by higher HEI-2020 diet|
62479364|NCT02973867||Cohort called Elodie|Obese patients
62686501|NCT06560879|EXPERIMENTAL|Lactobacillus rhamnosus|Oral administration of 1 capsule with Lactobacillus rhamnosus (2.5 billion CFU + microcrystalline cellulose) before breakfast and another capsule before lunch, for a total dose of 5 billion CFU/day.
62686502|NCT06560879|EXPERIMENTAL|Bifidobacterium bifidum|Oral administration of 1 capsule with Bifidobacterium bifidum (1 billion CFU + microcrystalline cellulose) before breakfast and another capsule before lunch, for a total dose of 2 billion CFU/day.
62686503|NCT06560879|PLACEBO_COMPARATOR|Placebo|Oral administration of 1 capsule of 300 mg of microcrystalline cellulose before breakfast and another before lunch (600 mg/day).
62686504|NCT06044714|EXPERIMENTAL|Manual Standardized Stress Acupuncture (MSSA) and Mindfulness-Based Stress Reduction (MBSR)|
61924676|NCT04957095|EXPERIMENTAL|Parkinson's disease patients|This group consists of Parkinson's disease patients who are undergoing deep brain stimulation surgery for treatment of their movement disorder. Participants will complete behavioral assessments while receiving subcortical DBS stimulation and / or inhaled levodopa medication, Inbrija. Stimulation will be applied at the previously determined therapeutic frequency. Two capsules (84 mg) of Inbrija will be administered.
62686505|NCT06044714|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction (MBSR)|
61924677|NCT00674778|EXPERIMENTAL|1|Radial approach
62126810|NCT05104294||moderate to severe Primary Open Angle Glaucoma group (Group II)|44 eyes of 24 patients with moderate to severe primary open angle glaucoma as group II.
62317060|NCT01114711||Frovatriptan|All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
62686506|NCT01623427|EXPERIMENTAL|Vacuum|the group of patients assigned to application of vacuum to the wound dressing
62686507|NCT01623427|ACTIVE_COMPARATOR|Control|The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.
62686508|NCT03538808|ACTIVE_COMPARATOR|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
62686509|NCT03538808|PLACEBO_COMPARATOR|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
62686510|NCT03538808|ACTIVE_COMPARATOR|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
62686511|NCT03538808|PLACEBO_COMPARATOR|Low Dose Placebo Deception|told low dose medication + received placebo
62686512|NCT00945880|EXPERIMENTAL|Experimental Group|clemizole hydrochloride, 100mg, BID
62686513|NCT06686108|EXPERIMENTAL|combination therapy|There is only 1 arm. Combination therapy arm included venetoclax combined with hypomethylating agents such as azacitidine or decitabine. 1. venetoclax: 400mg/d, po, days 1-7 of each 28-day cycle. 2.For patients without TP53 mutation, azacitidine was administered: 32mg/m2/d, ih, days 1-5 of each 28-day cycle; for patients with TP53 mutation, decitabine was administered: 5mg/m2/d, iv, days 1-5 of each 28-day cycle.
62686514|NCT03463460|EXPERIMENTAL|Treatment (pembrolizumab, sunitinib malate)|Participants receive pembrolizumab IV over 30 minutes on day 1 and sunitinib malate PO daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
62686515|NCT04850443||trial group|tocilizumab siltuximab
62686516|NCT04850443||control group|conventional treatment
61924678|NCT00674778|ACTIVE_COMPARATOR|2|Femoral approach
62686517|NCT05102461|PLACEBO_COMPARATOR|Placebo|Subjects randomized in the Placebo Arm will take one placebo capsule daily. Each capsule will also contain 32 mg of riboflavin as a tracer substance for tracking compliance.
61924679|NCT05832827|EXPERIMENTAL|MK-3475(Pembrolizumab), Lenvatinib, carboplatin, and paclitaxel|Intervention: Carboplatin + paclitaxel + pembrolizumab + lenvatinib for 3 weeks (21 days) as 1 cycle, up to a maximum of 4 cycles in the induction phase. Then, maintenance therapy with pembrolizumab and lenvatinib will be continued until progression or unacceptable adverse events up to 31 cycles.
61924680|NCT05293509|EXPERIMENTAL|Phase I: Sequential Pharmacological PTIS|
61924681|NCT05293509|EXPERIMENTAL|Phase II: RTC Regimen and GVHD Prophylaxis Based on Post-Cy|
61924682|NCT02247947||dead|Patients dead until day 20 (primary outcome measure)
61924683|NCT02247947||survivors|patients alive after day 20 (primary outcome measure)
61924684|NCT03839927||Evaluation Group|Survey Application
62126811|NCT05104294||Control Group|80 eyes of 40 healthy subjects as control group.
61924685|NCT01950910||subjects w/ non-motor neurodegenerative disease|subjects with ALS or with non-motor neurodegenerative disease
62126812|NCT04992364||Positive Clinical Performances|Subjects show positive clinical performances regarding burnout syndrome
62126813|NCT04992364||Negative Clinical Performances|Subjects show negative clinical performances regarding burnout syndrome
62317061|NCT01369719|EXPERIMENTAL|Osveral|20 mg/kg oral osveral daily
62317062|NCT01369719|ACTIVE_COMPARATOR|desferal|40mg/kg desferal for 6 nights in a week subcutaneously
62317063|NCT04523285|EXPERIMENTAL|TQB3728 tablets|TQB3728 tablets administered orally, once a week in 28-day cycle.
62317064|NCT01116245|EXPERIMENTAL|Low Dose|5x10\^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
62317065|NCT01116245|EXPERIMENTAL|Middle Dose|3.3x10\^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
62686518|NCT05102461|ACTIVE_COMPARATOR|Treatment|Subjects randomized in the Treatment Arm will take one placebo capsule daily. One Florajen Digestion capsule contains 15 billion live cultures of Lactobacillus acidophilus (7.5 billion), Bifodobacterium lactis (6.0 billion), and Bifidobacterium longum (1.5 billion). Each capsule will also contain 32 mg of riboflavin as a tracer substance for tracking compliance.
62686519|NCT01436890|EXPERIMENTAL|Low dose|Low dose revamilast
62686520|NCT01436890|EXPERIMENTAL|Medium dose|Medium dose Revamilast
62686521|NCT01436890|EXPERIMENTAL|High dose|High dose Revamilast
62686522|NCT01436890|PLACEBO_COMPARATOR|Placebo|Matching placebo in triple dummy format
62686523|NCT01903720|EXPERIMENTAL|OZURDEX®|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
62686524|NCT02101853|ACTIVE_COMPARATOR|Arm A (HR and IR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT. Closed effective September 18, 2019.
62686525|NCT02101853|EXPERIMENTAL|Arm B (HR and IR blinatumomab)|Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT.
62686526|NCT02101853|ACTIVE_COMPARATOR|Arm C (LR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance.
62479365|NCT06395324|EXPERIMENTAL|Pre, during and post high arabinose foods intake|All individuals will enter a lead-in period consisting of a low arabinose diet, then they will consume a high arabinose diet and then back to the low arabinose diet.
62479366|NCT01564394|EXPERIMENTAL|Qigong|Qigong originated in China hundreds of years ago and has been practiced for centuries. It consists of a sequence of slow, flowing physical movements with concentration on the breath and awareness and may promote physical and mental relaxation and energy balance.
62479367|NCT01564394|SHAM_COMPARATOR|Stretching control|The non-aerobic stretching will serve as an attention control group to control for non-specific factors; dose of attention and to mimic being in a group setting.
62479368|NCT02257528|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
62317066|NCT01116245|EXPERIMENTAL|High Dose|1x10\^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
62317067|NCT01116245|PLACEBO_COMPARATOR|Placebo|normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
62479369|NCT05093153||Waldenström's macroglobulinemia cohort patient|Adult patients diagnosed with Waldenström's Macroglobulinemia
62479370|NCT06531421|OTHER|Intervention|Distribution of Equity Report Cards
62686527|NCT02101853|EXPERIMENTAL|Arm D (LR blinatumomab)|Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance.
62317068|NCT06286852||Experimental group|Subjects meeting a diagnosis of nutrition and eating disorder
62126814|NCT04210180|EXPERIMENTAL|Varenicline plus e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. The FDA approved starter kit of varenicline will be provided to participants at V3 (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) along with additional G6 cartomizers. After the first week of varenicline, participants will receive the FDA-approved standard dose of varenicline (1 mg twice daily) and will continue to receive enough G6 cartomizers for the next 11 weeks.
62126815|NCT04101968||GBA-PD|People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
62126816|NCT04101968||Asymptomatic GBA|Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.
62126817|NCT04773327|EXPERIMENTAL|PEG-rhG-CSF prevention|Mecapegfilgrastim subcutaneous injection, 6mg, 24-48h after the end of antitumor drug administration in each chemotherapy cycle,
62126818|NCT04773327|NO_INTERVENTION|non-prevention|Only close monitoring after chemotherapy
62126819|NCT06522880||Children|Children up to and including 36 months in large group childcare centers in the study network
62126820|NCT06522880||Staff|All staff members in large group childcare centers attended by children participants
62317069|NCT06286852||Control group|children - adolescents from various schools in the Florence area, chosen through statistical criteria based on age, gender, ethnicity
62317070|NCT01302769|EXPERIMENTAL|battlefield auricular acupuncture|battlefield auricular acupuncture
62317071|NCT01302769|NO_INTERVENTION|placebo|
62686528|NCT02842385|ACTIVE_COMPARATOR|Nonsubmerged thick group|Nonsubmerged type of implants placed with thick (\>3 mm) soft tissue
62686529|NCT02842385|ACTIVE_COMPARATOR|Nonsubmerged thin group|Nonsubmerged type of implants placed with thin (\<3 mm) soft tissue
62686530|NCT02842385|ACTIVE_COMPARATOR|Submerged thick group|Submerged type of implants placed with thick (\>3 mm) soft tissue
62686531|NCT02842385|ACTIVE_COMPARATOR|Submerged thin group|Submerged type of implants placed with thin (\<3 mm) soft tissue
62686532|NCT06689488||Microwave ablation|Patients with a malignant lung nodule who are candidates for surgical resection.
62126821|NCT05976295|EXPERIMENTAL|Therapy group|
62126822|NCT05976295|PLACEBO_COMPARATOR|Control group|
62126823|NCT01456013|ACTIVE_COMPARATOR|Standard Therapy|Standard of care for patients at risk of CIN
62126824|NCT01456013|EXPERIMENTAL|RenalGuard Therapy|Induced Diuresis with Matched Replacement
62126825|NCT03023800|EXPERIMENTAL|Buckle|Macular buckling and intraocular gas (C3F8) injection.
62317072|NCT00772512|EXPERIMENTAL|A|
62126826|NCT03023800|ACTIVE_COMPARATOR|Vitrectomy|Vitrectomy, internal limiting membrane peeling, and gas tamponade (C3F8).
62317073|NCT00772512|EXPERIMENTAL|B|
62317074|NCT00772512|PLACEBO_COMPARATOR|C|
62339714|NCT06062407||Stroke subjects with fall risk|The patient was diagnosed with a stroke with a berg score of less than 40.
62339715|NCT06062407||Healthy subjects|No history of stroke with normal lower limb motor function and balance
62126827|NCT02810184||CBCT arm|all participating patients receive an additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
62126828|NCT02167984||at term newborns|Infant with GE \>=37w
61924686|NCT01950910||subjects w/out motorneuron degenerative dis|subjects without motorneuron degenerative disease
61924687|NCT05035641|EXPERIMENTAL|AND017 Dose A|AND017 will be administrated orally at dose A
62126829|NCT02167984||preterm newborns|Infant with GE \<37w
62339716|NCT04195659||Top Surgery|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, and who are undergoing mastectomy and chest masculinization in one of three plastic surgery practices in Chicago.
61924688|NCT05035641|EXPERIMENTAL|AND017 Dose B|AND017 will be administrated orally at dose B
61924689|NCT05035641|EXPERIMENTAL|AND017 Dose C|AND017 will be administrated orally at dose C
61924690|NCT05035641|PLACEBO_COMPARATOR|Placebo|Placebo will be administrated orally
62126830|NCT03861364|ACTIVE_COMPARATOR|High Propofol|High Propofol induction dose
62686533|NCT02456883|EXPERIMENTAL|gilteritinib and 14C-labeled gilteritinib|Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.
62686534|NCT06674265|ACTIVE_COMPARATOR|Intervention Group|Patients with refractory/recurrent neuroblastoma will receive 3 to 5 systemic injections of allogeneic NK cells during the intervals between their chemotherapy courses
62686535|NCT06674265|NO_INTERVENTION|Control Group|Patients in the control group will receive no cells and just conventional treatments will be administered to them.
62686536|NCT06479707|OTHER|Pilot|
62686537|NCT03396575|EXPERIMENTAL|Group A|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) during cycles of Dose-intensified TMZ
62686538|NCT03396575|EXPERIMENTAL|Group B|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) with Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
62317075|NCT02484573|EXPERIMENTAL|Propanolol|Patients will take the non-selective beta blocker propranolol for approximately 4 weeks starting immediately after endoscopy for esophageal variceal ligation. Patients will be initiated on a dose of 20mg by mouth every 12 hrs before titration to maximum tolerated dose. Patients will undergo testing before and after treatment for the variables listed in the outcomes section below.
62126831|NCT03861364|ACTIVE_COMPARATOR|Low Propofol|Low Propofol induction dose
62126832|NCT00994097|EXPERIMENTAL|A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed|NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology
62126833|NCT00994097|ACTIVE_COMPARATOR|B: cisplatin/gemcitabine or cisplatin/pemetrexed|Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology
62126834|NCT04153747|ACTIVE_COMPARATOR|Conventional ablation|"Point-by-point catheter-based pulmonary veins isolation using convencional radiofrequency parameters.~* Anterior aspect of pulmonary veins: 40 W, temperature limit 45 ºC, irrigation 17-30 ml/min; objective LSI\>=6 or Ablation index \>=500.~* Posterior aspect of pulmonary veins: 20-40 W, temperature limit 45 ºC, irrigation 17-3 ml/min; objective LSI\>=5 or Ablation index \>=350."
62317076|NCT05022992|EXPERIMENTAL|Resistance Training Session|Resistance training. Heavy resistance training. 10 reps x 3 set of upper- and lower-body resistance exercises
62317077|NCT05022992|NO_INTERVENTION|Control|Control activity. None-exercising. 30 min of rest
61924691|NCT00882700|EXPERIMENTAL|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
61924692|NCT00882700|ACTIVE_COMPARATOR|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
62126835|NCT04153747|EXPERIMENTAL|High-power and short-duration ablation|Point-by-point catheter-based pulmonary veins isolation using high-power and short duration radiofrequency: 70 W, duration per application 9-10 s (initial ramp 2-3 s according to the technical characterictics of radiofrequency sources), temperature limit 45 ºC, irrigation 17 ml/min, contac-force \> 5 g.
62317078|NCT01675921|NO_INTERVENTION|Control|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to this study website at the start and at the end of the study."
62317079|NCT01675921|EXPERIMENTAL|Facebook group|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to the study website at all times throughout the study.~Participants will have access to the secret study group on Facebook for 12 months.~Participants will take the ACT survey once a month for 12 months."
62317080|NCT00929578|PLACEBO_COMPARATOR|Placebo|The sterile placebo: Bacteriostatic Sodium Chloride for Injection.
62686539|NCT03163329|EXPERIMENTAL|TAVR group|
62686540|NCT03163329|ACTIVE_COMPARATOR|SAVR group|
62686541|NCT05835596|ACTIVE_COMPARATOR|Access to MumCare app|"Women will be randomized prospectively (before or after delivery) after they consent to participate in the study. These women are at increased risk of longterm cardiovascular disease due to hypertensive or gestational diabetes pregnancy complication. This group is randomized to have access to the MumCare app will, in addition to standard care, have access to the app for 14-18 months following giving birth. The MumCare app has 3 main parts (1. an educational part, 2. The patient's own health data (entered by the user herself) that represent modifiable risk factors for cardiovascular disease), and 3. The app will send push reminders for the woman to book a visit at her general practitioner according to recommended guidelines (that are usually not followed-up today).~All women in the study will be invited to a cardiovascular health evaluation at 14-18 months postpartum."
62697410|NCT02499237|ACTIVE_COMPARATOR|Denosumab|Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year
61924693|NCT05223335|EXPERIMENTAL|Genotype-Guided Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYP2C19\*2 or\*3 LOF allele carrier will be given prasugrel or ticagrelor monotherapy.
61924694|NCT05223335|ACTIVE_COMPARATOR|Conventional Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYp2C19\*2 or\*3 LOF allele non-carriers will continue with clopidogrel monotherapy.
62479371|NCT06479096|EXPERIMENTAL|Brush / Espresso Mild Prototype|All subjects will receive a marketed fluoride-containing dentifrice and a soft flat trimmed bristled toothbrush to use for the one week wash out period and throughout the study. Subjects will be required to record their daily product use times on a subject diary. After the one week wash out period, subjects subjects will use their assigned mouthwash for the first time at the site under supervision. Subjects will brush their teeth at the site after all assessments are complete. That evening, subjects will brush their teeth and rinse a second time unsupervised. All other twice daily brushing/rinsing will occur unsupervised at home. Subjects will be required to record their daily product use times (brushing and rinsing) on their subject diary.
61924695|NCT02783846|PLACEBO_COMPARATOR|Group control|24 eligible patients are received equal volumes of saline intravenously for 10 minutes
62317081|NCT00929578|ACTIVE_COMPARATOR|Fluphenazine|This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
62479372|NCT06479096|EXPERIMENTAL|Brush / Espresso Intense Prototype|All subjects will receive a marketed fluoride-containing dentifrice and a soft flat trimmed bristled toothbrush to use for the one week wash out period and throughout the study. Subjects will be required to record their daily product use times on a subject diary. After the one week wash out period, subjects subjects will use their assigned mouthwash for the first time at the site under supervision. Subjects will brush their teeth at the site after all assessments are complete. That evening, subjects will brush their teeth and rinse a second time unsupervised. All other twice daily brushing/rinsing will occur unsupervised at home. Subjects will be required to record their daily product use times (brushing and rinsing) on their subject diary.
62479373|NCT06479096|ACTIVE_COMPARATOR|Brush / Fresh Breath Oral Rinse|All subjects will receive a marketed fluoride-containing dentifrice and a soft flat trimmed bristled toothbrush to use for the one week wash out period and throughout the study. Subjects will be required to record their daily product use times on a subject diary. After the one week wash out period, subjects subjects will use their assigned mouthwash for the first time at the site under supervision. Subjects will brush their teeth at the site after all assessments are complete. That evening, subjects will brush their teeth and rinse a second time unsupervised. All other twice daily brushing/rinsing will occur unsupervised at home. Subjects will be required to record their daily product use times (brushing and rinsing) on their subject diary.
62686542|NCT05835596|NO_INTERVENTION|No access to MumCare app|"Women will be prosepctively randomized (before or after delivery) after they consent to participate in the study. These women are at increased risk of longterm cardiovascular disease due to hypertensive or gestational diabetes pregnancy complication. Women randomized to NOT have access to the MumCare app will receive standard care, which includes being provided oral and written information according to delivery ward routines.~All women in the study will be invited to a cardiovascular health evaluation at 14-18 months postpartum."
62686543|NCT03851666|PLACEBO_COMPARATOR|12 weeks daily administration Placebo|Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
62686544|NCT03851666|EXPERIMENTAL|12 weeks daily administration Cereal 1|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 1).~The daily dose administrated is 15 grams."
61924696|NCT02783846|ACTIVE_COMPARATOR|Group dexmedetomidine 0.5 µg/kg|24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
61924697|NCT02783846|ACTIVE_COMPARATOR|Group dexmedetomidine 1.0 µg/kg|25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes
61924698|NCT02129660|EXPERIMENTAL|Dose 1 of glycopyrrolate, 2.0% QD|glycopyrrolate Topical Wipes
62317082|NCT06378658|EXPERIMENTAL|Intervention A - Intervention B - Intervention C|"Intervention A: BAY2927088 is administered under fasted status. Intervention B: BAY2927088 is administered under fed status (light low-fat meal).~Intervention C: BAY2927088 is administered under fed status (high fat, high calorie meal).~Each participant will subsequently undergo a fourth intervention period that includes dosing with BAY2927088 and esomeprazole."
62317083|NCT06378658|EXPERIMENTAL|Intervention B - Intervention C- Intervention A|"Intervention A: BAY2927088 is administered under fasted status. Intervention B: BAY2927088 is administered under fed status (light low-fat meal).~Intervention C: BAY2927088 is administered under fed status (high fat, high calorie meal).~Each participant will subsequently undergo a fourth intervention period that includes dosing with BAY2927088 and esomeprazole."
62317084|NCT06378658|EXPERIMENTAL|Intervention C - Intervention A - Intervention B|"Intervention A: BAY2927088 is administered under fasted status. Intervention B: BAY2927088 is administered under fed status (light low-fat meal).~Intervention C: BAY2927088 is administered under fed status (high fat, high calorie meal).~Each participant will subsequently undergo a fourth intervention period that includes dosing with BAY2927088 and esomeprazole."
62686545|NCT03851666|ACTIVE_COMPARATOR|12 weeks daily administration Cereal 2|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 2).~The daily dose administrated is 15 grams."
61924699|NCT02129660|EXPERIMENTAL|Dose 2 of glycopyrrolate, 3.0% QD|glycopyrrolate Topical Wipes
62479374|NCT06479096|PLACEBO_COMPARATOR|Brush / Hydroalcohol|All subjects will receive a marketed fluoride-containing dentifrice and a soft flat trimmed bristled toothbrush to use for the one week wash out period and throughout the study. Subjects will be required to record their daily product use times on a subject diary. After the one week wash out period, subjects subjects will use their assigned mouthwash for the first time at the site under supervision. Subjects will brush their teeth at the site after all assessments are complete. That evening, subjects will brush their teeth and rinse a second time unsupervised. All other twice daily brushing/rinsing will occur unsupervised at home. Subjects will be required to record their daily product use times (brushing and rinsing) on their subject diary.
61924700|NCT02129660|ACTIVE_COMPARATOR|Dose 1 of glycopyrronium, 2.5% QD|glycopyrronium Topical Wipes
61924701|NCT02129660|ACTIVE_COMPARATOR|Dose 2 of glycopyrronium, 3.75% QD|glycopyrronium Topical Wipes
62126836|NCT03561064|EXPERIMENTAL|Receiving CBT-I|This is a single arm study. All participants will receive CBT-I (cognitive behavioral therapy for insomnia).
62126837|NCT06412445|ACTIVE_COMPARATOR|Patients with unilateral inguinal hernia undergoing TAPP repair and mesh fixation with tissue glue|Patients aged from 18 to 60 years with unilateral direct or indirect inguinal hernia who will undergo laparoscopic TAPP inguinal hernia repair having there mesh fixated with tissue glue. Glubran 2® surgical glue is a medical device Class III CE marked for internal and external use. It is a synthetic biodegradable cyanoacrylate basis glue, modified by the addition of a monomer synthesized by the manufacturer GEM. It is ready for use. It has high adhesive and haemostatic properties and once it is polymerised it creates an efficient antiseptic barrier against the most diffused infective or pathogenic agents during the surgical intervention. It polymerizes quickly in contact with live tissue and wet environment creating a thin and elastic film having high tensile properties which guarantee strong adhesion to the tissues. This film naturally conforms with the tissues on which it is applied; it is not permeable to liquids and is not altered by blood or organic liquids
62317085|NCT05707845|PLACEBO_COMPARATOR|control group (A)|Group A: (control group): 20 participants Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs)
62317086|NCT05707845|EXPERIMENTAL|study group (B)|"Group B: (Study group): 20 participants~* Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).~* Physical therapy program weight reduction by diet program in the form of caloric restriction, in combination to aerobic exercise in the form of using treadmill 30 minutes /3 times a week for 12 weeks."
62317087|NCT05035186|EXPERIMENTAL|Group 1|Clarithromycin based
62479375|NCT06523634|ACTIVE_COMPARATOR|Control|Standard of care radiotherapy
62126838|NCT06412445|ACTIVE_COMPARATOR|Patients with unilateral inguinal hernia undergoing TAPP repair with self fixating mesh|Patients aged from 18 to 60 years with unilateral direct or indirect inguinal hernia who will undergo laparoscopic TAPP inguinal hernia repair with self fixating mesh. Covidien ProGrip mesh is a self-gripping polyester mesh, 15x15 cm in size, it is equipped with resorbable microgrip technology which provides immediate fixation of the entire mesh surface for a secure repair and even distribution of tension for patient comfort. The resorbable polylactic acid (PLA) microgrips enable surgeons to position and place the mesh in under 60 seconds, without the use of additional fixation. Surgeons and patients can depend on a secure repair with the potential for greater patient comfort. According to the manufacturer, the time for degradation of the quickly absorbing layer is \< 1 day and that for the layer with microgrips \> 18 months
62126839|NCT02622984|EXPERIMENTAL|RBIRT|Telehealth model or the remote administration of SBIRT, a short term, brief intervention and referral to treatment for alcohol abuse.
62317088|NCT05035186|EXPERIMENTAL|Group 2|Levofloxacin based
62317089|NCT05895175||DONATED GAMETE GROUP|couples who got pregnant through egg donation (with their own semen)
62317090|NCT05895175||OWN GAMETE GROUP|couples who got pregnant through standard IVF treatment, with their own gametes
62317091|NCT01903239|OTHER|Low-Risk BCC Excisional Margins|This is a study investigating the efficiency of 1-2 mm margins for the excision of low-risk basal cell carcinoma.
62317092|NCT02595060|EXPERIMENTAL|150 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
62317093|NCT02595060|EXPERIMENTAL|450 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
62317094|NCT02595060|PLACEBO_COMPARATOR|inhaled placebo|once daily inhaled placebo for 3 days
62317095|NCT06203678|ACTIVE_COMPARATOR|Kinesio taping+exercise|"Kinesio taping will be applied to the bilateral upper trapezius and sternocleidomastoid muscles by an experienced practitioner, once a week for 4 weeks.~Cervical stretching and strengthening exercises home program"
62479376|NCT06523634|EXPERIMENTAL|SBRT|SBRT: 5 fractions
61924702|NCT02129660|PLACEBO_COMPARATOR|Vehicle|Vehicle Topical Wipes
61924703|NCT00495131|ACTIVE_COMPARATOR|Peginterfron and ribavirin (24 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
61924704|NCT00495131|ACTIVE_COMPARATOR|Peginterferon and ribavirin (48 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
62126840|NCT02622984|ACTIVE_COMPARATOR|SBIRT|Face-to-face intervention and referral to treatment for alcohol abuse.
62317096|NCT06203678|PLACEBO_COMPARATOR|Sham taping+exercise|"Sham taping will be applied to the bilateral upper trapezius and sternocleidomastoid muscles once a week for 4 weeks, using patch tape of the same color as kinesio tape.~Cervical stretching and strengthening exercises home program"
62317097|NCT06203678|OTHER|Exercise|Cervical stretching and strengthening exercises home program
62317098|NCT04110249|EXPERIMENTAL|Diagnostic (PAI, ALTENS)|"PART I: Patients undergo PAI before the start of chemoradiation therapy, weekly during 7 weeks of chemoradiation, and again 3-4 months after completion of chemoradiation therapy.~PART II (CANCER-FREE WITH XEROSTOMIA): Patients undergo PAI at baseline, up to twice during acupuncture-like transcutaneous nerve stimulation (ALTENS) therapy, once after ALTENS, and at 3-6 months follow up."
62317099|NCT05106972|EXPERIMENTAL|UC-MSC infusion|UC-MSC infusion by intravenus, 1\*10\^8 cells/dose, 2 doses (apart from 24weeks)
62479377|NCT01087346|ACTIVE_COMPARATOR|Control|Information about child health
62126841|NCT00203216|EXPERIMENTAL|Levatiracetam|Subject titrated open-label study drug to maximally tolerated dose: maximum: 3000 mg. per date. (minimum allowed daily dose to remain in study: 1000)
62126842|NCT04418999|EXPERIMENTAL|Dexamethasone insert|Per participant, one eye will be randomized to receive the intracanalicular dexamethasone insert at the baseline visit (study eye). DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus at the day 1 visit by pulling the lower lid taught and using a forceps to insert the medication into the lower canaliculus through the lower punctum.
62126843|NCT04418999|ACTIVE_COMPARATOR|Loteprednol etabonate ophthalmic gel 0.38%|Per participant, one eye will be randomized to receive the standard of care topical lotemax etabonate ophthalmic gel 0.38% (control eye). Patients will be prescribed a loteprednol etabonate ophthalmic gel 0.38% and will instill one drop into the eye following a 4x/day,3x/day,2x/day,1/xday weekly taper
62126844|NCT00773370|EXPERIMENTAL|APA-Stroke|The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
62126845|NCT00773370|ACTIVE_COMPARATOR|Sittercise|Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.
62126846|NCT00761189|EXPERIMENTAL|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
62126847|NCT01061151|ACTIVE_COMPARATOR|Antepartum Arm A|Mothers received ZDV + sdNVP + TRV Tail
62126848|NCT01061151|EXPERIMENTAL|Antepartum Arm B|Mothers received Triple ARV (3TC-ZDV + LPV-RTV)
62126849|NCT01061151|EXPERIMENTAL|Antepartum Arm C|Mothers received Triple ARV (TRV + LPV-RTV)
62126850|NCT01061151|OTHER|Late Presenters|Registration to facilitate a structure to screen women and infants for randomization in the Postpartum Component.
62479378|NCT01087346|EXPERIMENTAL|Family Environment Information|Information about family environment factors in children's obesity risk
62126851|NCT01061151|EXPERIMENTAL|Postpartum Arm A (Maternal Prophylaxis)|Mothers received prophylaxis \[preferred regimen: TRV + LPV-RTV\]. Infants received short-course NVP.
62317100|NCT03415464|EXPERIMENTAL|Functional training|15 weeks of structured exercise intervention in the form of functional training. We have divided 15 weeks into 5 cycles each cycle lasting 3 weeks. Intervention will be administered twice per week, and each session will last 45 minutes.Each 45 minutes will be further divided into 10 minutes of functional warm-up, 30 minutes of neuromuscular training (strength, agility, balance, coordination) and 5 minutes of cool down. During the 3 week period the intensity of exercise will be increased with different form of same exercise, different number of repetitions and exercise duration.
62317101|NCT03415464|NO_INTERVENTION|Regular army training|Regular military training.
62317102|NCT01809990|EXPERIMENTAL|internet-delivered cognitive behavior therapy|Participants will be assigned to a 12 weeks internet-delivered cognitive behavior therapy program including therapist contact via an internet platform and telephone.
62317103|NCT01032785||Healthy term newborn|Any healthy term newborn born in Wolfson Medical Center
62317104|NCT05895279|EXPERIMENTAL|MiCaP Research Digest Video Group|Participants watch MiCaP Research Digest video on study. Participants complete a survey throughout the trial.
62479379|NCT01087346|EXPERIMENTAL|Gene times Family Environment Information|Information about interactions between genetic and family environment factors in children's obesity risk
62126852|NCT01061151|EXPERIMENTAL|Postpartum Arm B (Infant Prophylaxis)|Infants received extended NVP.
62126853|NCT01061151|EXPERIMENTAL|Maternal Health Arm A (Continue triple ARVs)|Mothers continued receiving triple ARV regimen \[preferred regimen: TRV + LPV-RTV\].
62126854|NCT01061151|ACTIVE_COMPARATOR|Maternal Health Arm B (Discontinue triple ARVs)|Mothers discontinued triple ARV regimen.
62686546|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI \<25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
62686547|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI \<25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
62686548|NCT05054907||Wearable devices + Smartphone|The only arm in the study.
62686549|NCT05181696||COVID-19 pneumonia patients|Patients treated at the University Hospital Osijek Respiratory Center with pneumonia caused by SARS-CoV-2
62686550|NCT03371225|EXPERIMENTAL|Active tDCS and Active Exercise|Active tDCS for 20 min Active exercise (60-70% max HR) for 30 min
62686551|NCT03371225|ACTIVE_COMPARATOR|Sham tDCS and Active Exercise|Sham tDCS for 20 min Active exercise (60-70% max HR) for 30 min
62686552|NCT03371225|ACTIVE_COMPARATOR|Active tDCS and Sham Exercise|Active tDCS for 20 min Sham exercise (within 10% baseline HR) for 30 min
62686553|NCT03371225|SHAM_COMPARATOR|Sham TDCS and Sham Exercise|Sham tDCS for 20 min Sham exercise (within 10% baseline HR) for 30 min
62686554|NCT05982379|EXPERIMENTAL|Intervention|This study was carried out with two groups. Technology Based Motivation Program were used for the intervention group.
62686555|NCT05982379|NO_INTERVENTION|Control|No application was made to the control group, standard procedure was followed.
62686556|NCT04919473|EXPERIMENTAL|vMCO-I High dose|Participants received 3.5E11vg/eye of vMCO-I
62317105|NCT05895279|ACTIVE_COMPARATOR|Alternate Video Group|Participants watch an alternative video on study. Participants complete a survey throughout the trial.
62317106|NCT06671197||PVI-only|
62317107|NCT06671197||PVI + LAPWI|posterior left atrial wall line
62317108|NCT06671197||PVI + PWI + SVCI|posterior left atrial wall isolation and superior vena cava isolation
62317109|NCT01754688||Jaundice infants|Bilirubin Induced Neurologic Dysfunction II score
62479380|NCT01087346|EXPERIMENTAL|Genetic Information|Information about genetic factors in child obesity risk
62686557|NCT04919473|EXPERIMENTAL|vMCO-I Low Dose|Participants received 1.75E11vg/eye of vMCO-I
62317110|NCT02530944||Lupus patients|People diagnosed with Systemic Lupus Erythematosus by a physician
62317111|NCT06672731|EXPERIMENTAL|Children with cerebral palsy|50 children with cerebral palsy in whom the intervention is intended as the application of already validated movement sensors, namely actigraphs.
62479381|NCT00663481|EXPERIMENTAL|1|CoFactor
62686558|NCT05407766|EXPERIMENTAL|100M of OSSM-001|Single injection of mesenchymal stem cells at dose of 100M
62686559|NCT05407766|EXPERIMENTAL|300M of OSSM-001|Single injection of mesenchymal stem cells at dose of 300M
62686560|NCT05407766|PLACEBO_COMPARATOR|Placebo|Single injection of normal saline
62686561|NCT06431633|ACTIVE_COMPARATOR|ARM 1: Observation-investigator decision|Patients randomized in this arm will be in observation for 10 months. It is allowed to administer adjuvant treatment according to investigator criteria. Immunotherapy is not allowed in this arm, only chemotherapy treatment is allowed.
62686562|NCT06431633|EXPERIMENTAL|ARM 2: Immunotherapy. Zimberelimab treatment for 13 cycles|"Adjuvant treatment with Zimberelimab will start between the 3rd to the 10th week from surgery. 13 cycles will be administered in total. Cycles will be administered in 21-day intervals (Q3W).~Zimberelimab: day 1 360 mg IV Q3W (13 cycles)"
62686563|NCT06431633|EXPERIMENTAL|ARM 3: Sacituzumab Govitecan + Zimberelimab for 8 cycles + Zimberelimab for 5 cycles|"Sacituzumab Govitecan: day 1 and 8; 10mg/Kg IV Q3W Zimberelimab: day 1 360 mg IV Q3W~Treatment sequence:~Adjuvant treatment will start between the 3rd to the 10th week from surgery. 13 cycles will be administered in total. Cycles will be administered in 21-day intervals (Q3W).~Patients will receive 8 cycles of Sacituzumab Govitecan + Zimberelimab and 5 cycles of Zimberelimab monotherapy."
62697411|NCT02499237|EXPERIMENTAL|Denosumab plus zoledronic acid|Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year
61924705|NCT01889940|NO_INTERVENTION|Pre-intervention group.|"The initial assessment includes pre-intervention measures (baseline) for the patient, his/her relative (or main caregiver) and the rehabilitation staff.~Patients are assessed during the first week (or ≥ 10 days of SCI Unit admission) and at discharge (an expected average of 8 weeks). At the time of each patient's discharge, their family or main caregiver is also surveyed.~Lastly, rehabilitation team members are also assessed across the pre-intervention phase."
61924706|NCT01889940|OTHER|Post-intervention group.|Once intervention and coaching period for professionals has ended, post-intervention sample (patients, family and professionals) is assessed with the same time criteria than the pre-intervention sample.
62317112|NCT06672731|ACTIVE_COMPARATOR|Typically developing children|50 healthy children, evaluated c/o AOUP for the exclusion of other diseases, in whom for intervention is intended the application of already validated movement sensors.
62317113|NCT00829166|EXPERIMENTAL|Trastuzumab emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
62317114|NCT00829166|ACTIVE_COMPARATOR|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m\^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
61924707|NCT04143061|EXPERIMENTAL|Group 1|MenACYW conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
61924708|NCT04143061|ACTIVE_COMPARATOR|Group 2|Menactra® conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
62686564|NCT05844319|EXPERIMENTAL|intervention|"Following the completion of the evaluations of the cases, the following 6-step program will be applied to cope with the pain:~1. Informative education about the disease~2. Teaching relaxation positions for pain management~3. Relaxation exercises with breathing exercises~4. Training on ergonomic approaches in daily life (correct sitting, lying, working, carrying, etc.)~5. Education of principles of joint protection~6. Creating and training a personalized physical activity and exercise plan"
62686565|NCT04917939||epilepsy with HS|
62686566|NCT04917939||epilepsy without HS|
62686567|NCT01379937|EXPERIMENTAL|GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
61924709|NCT04143061|EXPERIMENTAL|Group 3|MenACYW conjugate vaccine, 1 vaccination, adults in India aged ≥ 56 years
61924710|NCT04143061|ACTIVE_COMPARATOR|Group 4|Quadri Meningo™, 1 vaccination, adults in India aged ≥ 56 years
61924711|NCT04143061|EXPERIMENTAL|Group 5|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in India aged 2 to 17 years
61924712|NCT04143061|ACTIVE_COMPARATOR|Group 6|Menactra®, 1 vaccination, children and adolescents in India aged 2 to 17 years
61924713|NCT04143061|EXPERIMENTAL|Group 7|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
61924714|NCT04143061|ACTIVE_COMPARATOR|Group 8|Menactra®, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
62126855|NCT03983681|EXPERIMENTAL|Experimental|The experimental group will receive memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
62126856|NCT03983681|PLACEBO_COMPARATOR|Control group|The control group will receive placebo memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
61924715|NCT04143061|EXPERIMENTAL|Group 9|MenACYW conjugate vaccine and age-recommended routine pediatric vaccine(s), toddlers aged 12 to 23 months in India
61924716|NCT04143061|ACTIVE_COMPARATOR|Group 10|Age-recommended routine pediatric vaccine(s) (RPV) only, toddlers aged 12 to 23 months in India
62126857|NCT00765271|ACTIVE_COMPARATOR|Group 2|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Raltegravir 400 mg (2 x 200mg tablets) twice daily from days 2 to 15 Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 16 to day 29)
62126858|NCT00765271|ACTIVE_COMPARATOR|Group 1|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 2 to day 15) Raltegravir 400 mg (2 x 200mg tablets) twice daily from day 16 to 29
62126859|NCT05640869|EXPERIMENTAL|Modified DPP|Participants in this arm will participate in the modified Diabetes Prevention Program curriculum.
61924717|NCT05086939|EXPERIMENTAL|Autologous Mesenchymal Stromal Cells (MSC)|Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.
62126860|NCT06038799|ACTIVE_COMPARATOR|Remote staff training|Staff will receive 15 hours of remote training followed by 12 weeks of remote supervision (one hour per week).
62126861|NCT06038799|ACTIVE_COMPARATOR|Face to face staff training|Staff will receive 15 hours of face to face training followed by 12 weeks of face to face supervision (one hour per week).
62126862|NCT00609310|EXPERIMENTAL|I|Flavonoid treatment
62126863|NCT01897870|EXPERIMENTAL|HomeCoMe-program group|the arm receiving the pharmacist home visit
62126864|NCT06001190|ACTIVE_COMPARATOR|probiotic intervention|probiotic group with daily treatment
62126865|NCT06001190|PLACEBO_COMPARATOR|placebo|placebo-controlled with daily treatment
62686568|NCT01379937|EXPERIMENTAL|GSK1562902A Formulation 1 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
61924718|NCT05086939|EXPERIMENTAL|Allogenic Mesenchymal Stromal Cells (MSC)|Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.
62126866|NCT02781623||MRI|An MRI will be conducted pre-operatively, 3 months post-operatively, and 1 year post-operatively.
62126867|NCT03200626||Cytokine alone or JIT plerixafor based mobilization|
62126868|NCT03200626||Routine plerixafor based mobilization|
62126869|NCT03200626||Chemomobilization|
62317115|NCT04802356|EXPERIMENTAL|Multiple Myeloma experimental arm|Combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone)
62686569|NCT01379937|ACTIVE_COMPARATOR|GSK1562902A Formulation 2 - Havrix / Havrix Jr Group|Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
61924719|NCT05086939|ACTIVE_COMPARATOR|Active Control|Hyaluronic Acid 60mg/3ml administered intra-articularly.
62126870|NCT01169454||Monitor then drain|Subjects who are treated with intermittent CSF drainage
62126871|NCT01169454||Drain then monitor|Subjects who are treated with continuous CSF drainage at set pressure thresholds
62126872|NCT00879463|ACTIVE_COMPARATOR|GROUP A|Brain tissue oxygen saturation monitoring
62126873|NCT00879463|ACTIVE_COMPARATOR|GROUP B|CONTROL GROUP
62126874|NCT04238429|EXPERIMENTAL|Toothpaste containing effective ingredients|Use the toothpaste containing 10% high cleaning silica base,0.5% sodium phytate and 0.5% sodium pyrophosphate to brush teeth twice daily for 8 weeks
62126875|NCT04238429|PLACEBO_COMPARATOR|Negative control toothpaste|Use the negative control dentifrice to brush teeth twice daily for 8 weeks
62317116|NCT03752853|EXPERIMENTAL|iCBT for depression - behavioral activation first (BAF)|internet-based intervention for mild to moderate depression: patients receive behavioral activation first, followed by cognitive restructuring
62317117|NCT03752853|EXPERIMENTAL|iCBT for depression - cognitive restructuring first (CRF)|internet-based intervention for mild to moderate depression: patients receive cognitive restructuring first, followed by behavioral activation
62317118|NCT00546858||Survey|Patients with interstitial cystitis
62317119|NCT02711748|EXPERIMENTAL|Bradycardia|Treatment In case of bradycardia. The patient unconscious, breathing preserved in ECG - bradycardia 40 / min with pulse.
62317120|NCT02711748|EXPERIMENTAL|PEA|In case of bradycardia. The patient unconscious, not breathing, the ECG - bradycardia 30 / min - no pulse. Pulseless electrical activity
62317121|NCT00001259|PLACEBO_COMPARATOR|Study 1, Phase 1, Assignment 1 - Placebo|As part of double Blind randomized trial, participants in Assignment 1 were randomized to 8 weeks of placebo (P) injections (1 injection per month). These participants then continued on to Study 2 after completion of 8 weeks of placebo injections.
62317122|NCT00001259|EXPERIMENTAL|Study 1, Phase 1, Assignment 2 - GnRH agonist injections (Lupron-L only)|As part of double Blind randomized trial, participants in Assignment 2 were randomized to 8 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Those who exhibited a remission of symptoms after 8 weeks continued on to receive one more month of GnRH agonist treatment (12 weeks total) and then entered Study 1, Phase 2.
62317123|NCT00001259|EXPERIMENTAL|Study 1, Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
62317124|NCT00001259|EXPERIMENTAL|Study 1, Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
62317125|NCT00001259|EXPERIMENTAL|Study 2, Phase 1 - GnRH agonist injections (Lupron-L only)|Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
62317126|NCT00001259|EXPERIMENTAL|Study 2, Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
62317127|NCT00001259|EXPERIMENTAL|Study 2, Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
62317128|NCT03112837|EXPERIMENTAL|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
62317129|NCT03112837|NO_INTERVENTION|non-drug group|only receiving radiotherapy and chemotherapy
62317130|NCT03112837|NO_INTERVENTION|healthy control group|
62317131|NCT01527604|ACTIVE_COMPARATOR|Avenanthramide-enriched oat muffin|
62479382|NCT00663481|EXPERIMENTAL|2|CoFactor
62479383|NCT00663481|ACTIVE_COMPARATOR|3|Leucovorin
62479384|NCT01180361||Active SLE patients|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
62479385|NCT01180361||Psoriatic arthritis|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Diagnosed according to criteria described by McGonagle et al (McGonagle, D., Conaghan, P.G., and Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.)
62479386|NCT01180361||Normal controls|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Healthy volunteers. Not on corticosteroids.
62479387|NCT01180361||Active RA patients|Age 18-65, male and female, no methotrexate or statin therapy in prior 3 months. Not on biological therapies. satisfy at least 4 of the 7 revised criteria (1987) for the classification of RA
62479388|NCT04728828||In-center adult haemodialysis patients eligible and voluntary for COVID19 vaccination|
62317132|NCT01527604|PLACEBO_COMPARATOR|Refined flour muffin|
62339717|NCT04195659||Control|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, were seen in a gender development clinic in Chicago, and who are not planning to undergo top surgery. Controls will be matched with top surgery patients on age and number of months of testosterone.
62339718|NCT02622100||Bioresorbable Vascular Scaffold|
62339719|NCT01902953|EXPERIMENTAL|Lymphoseek and VBD SLN dissection|Ex-Vivo Lymphoseek and VBD SLN dissection
62339720|NCT04773899|OTHER|Cohort C1|COVID19 (+) ICU patients with COVID19 pneumonia.
62339721|NCT04773899|OTHER|Cohort C2|COVID19 (-) matched ICU patients
62479389|NCT03651739||TKR Patients|Any patient undergoing total knee arthroplasty and will use the Knee Connect during their knee classes at the Holland Centre
62479390|NCT01767974||Non-Small Cell Lung Cancer|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
62479391|NCT03744585||Cohort 1|Subjects who received at least one dose of cabozantinib during the Authorization for Use (ATU) period (12/09/2016 to 09/12/2016) for the treatment of advanced Renal Cell Carcinoma (RCC).
62479392|NCT03744585||Cohort 2|Subjects who received at least one dose of cabozantinib during the first six months after the ATU period (10/12/2016 to 16/02/2018).
62479393|NCT03090789||Study Participant|Study participants can be individuals with either a clinical diagnosis or genetic confirmation of Friedreich ataxia. In addition, this study enrolls Friedreich ataxia carriers and unaffected controls.
62479394|NCT02151981|EXPERIMENTAL|Osimertinib|Osimertinib 80 mg, orally, once daily
62479395|NCT02151981|ACTIVE_COMPARATOR|Platinum-based doublet chemotherapy|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2
62317133|NCT03553238|EXPERIMENTAL|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
62317134|NCT00782808||1 HIV DNA will be stratified by high|
62686570|NCT01379937|ACTIVE_COMPARATOR|Havrix / Havrix Jr Group|Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
62317135|NCT00782808||2 HIV DNA will be stratified by low|
62317136|NCT02831491|EXPERIMENTAL|Ramucirumab + Docetaxel|Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.
62317137|NCT06672393|EXPERIMENTAL|HS-10374|Subjects will receive HS-10374 from Week 0 through Week 52.
62317138|NCT06672393|PLACEBO_COMPARATOR|Placebo|Subjects will receive HS-10374 matching placebo from Week 0 through Week 16, and HS-10374 from Week 16 through Week 52.
62317139|NCT05619211|EXPERIMENTAL|Movement-to-Music|12 weeks of sprint-intensity interval training while following along with YouTube videos that include arm-based routines, with coaching through telecommunications. Participants are instructed to maintain their habitual diet and nutrition patterns
62339722|NCT04773899|OTHER|Cohort C3|COVID19 (-) ASA 1 non-hospitalized patients
62126876|NCT05125029|NO_INTERVENTION|Placebo|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
62317140|NCT05619211|NO_INTERVENTION|Wait-list Control|12 weeks of maintaining habitual physical activity, diet, and nutrition patterns, until receiving 12 weeks of Movement-to-Music
62317141|NCT01600131|EXPERIMENTAL|Caregiver education and support|problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.cidrr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
62686571|NCT05454007|EXPERIMENTAL|Individuals with Stroke|In this single group, proof-of-principle design, all eligible participants will be assigned to a single group. These are individuals with stroke who meet inclusion and exclusion criteria. They will each undergo the same assessments and participate in a single walking training session.
62686572|NCT05704699|EXPERIMENTAL|eTRE|participants allocated to this group are required to consume food during 0800h and 1600h.
61924720|NCT05788796|EXPERIMENTAL|Experimental: Experimental group|Experimental:Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid.
61924721|NCT05788796|NO_INTERVENTION|Assigned Interventions|No Intervention: Control group Pregnant women in the control group will be asked not to make any lifestyle changes and to continue their routine daily lives.
62686573|NCT05704699|ACTIVE_COMPARATOR|eTRE with BISC|participants allocated to this group are required to consume food during 0800h and 1600h as well as complete 3 sessions of BISC per week.
61924722|NCT04211571|EXPERIMENTAL|MCO group|Hemodialysis using Theranova 400 dialyzer
61924723|NCT04211571|ACTIVE_COMPARATOR|High-flux group|Hemodialysis using high-flux dialyzer (Fx CorDiax 80; Fresenius Medical Care)
61924724|NCT03791827||Corticosteroid|Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid
61924725|NCT03791827||Corticosteroid and cyclophosphamide|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide
61924726|NCT03791827||Corticosteroid and mycophenolate mofetil|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil
61924727|NCT03791827||Corticosteroid and azathioprine|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine
61924728|NCT03791827||Corticosteroid and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus
62317142|NCT01600131|OTHER|Standard Care|Caregivers receiving standard of care
62317143|NCT04239560|EXPERIMENTAL|Boron-based Gel|During each radiation therapy session, 15 minutes before radiotherapy, 3% sodium pentahydrate panteurate will be used.
62317144|NCT04239560|PLACEBO_COMPARATOR|Radiation Traumatic Dermatitis Treated with Placebo|During each radiotherapy session, 15 minutes before radiotherapy, the gel will be free of any chemical treatments
62317145|NCT01019590|EXPERIMENTAL|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
61924729|NCT03791827||Corticosteroid and cyclosporine A|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A
62126877|NCT05125029|ACTIVE_COMPARATOR|10 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
62126878|NCT05125029|ACTIVE_COMPARATOR|20 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
62126879|NCT06048835||MBC|Patients diagnosed with metastatic breast cancer
62126880|NCT06048835||EBC|Patients diagnosed with primary early-breast cancer candidate for surgery
62317146|NCT01019590|ACTIVE_COMPARATOR|2|Benicar HCT ® Tablets 40 mg/25 mg
62317147|NCT04191278|ACTIVE_COMPARATOR|Varenicline|An α4β2 nicotinic acetylcholine receptor partial agonist
62686574|NCT02900404||NVAF Patients|Adult female and male patients with non-valvular atrial fibrillation (NVAF) treated with rivaroxaban before and after surgery
61924730|NCT03791827||Corticosteroid, mycophenolate mofetil and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus
61924731|NCT03791827||Retuximab|An option for refractory lupus nephritis
61924732|NCT03026088|EXPERIMENTAL|Bisoprolol|
61924733|NCT04455984||Neoadjuvant chemoradiotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemoradiotherapy followed by curative-intent surgery
61924734|NCT04455984||Neoadjuvant chemotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemotherapy followed by curative-intent surgery
62317148|NCT04191278|EXPERIMENTAL|Varenicline + mobile app|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications
62317149|NCT04191278|EXPERIMENTAL|Varenicline + mobile app + contingency management|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications + monetary reinforcers for being adherent to medication
62317150|NCT02144220|EXPERIMENTAL|Virtual care visit|One-time virtual care visit for Parkinson disease.
62686575|NCT02900404||VTE/PE Patients|Adult female and male patients with venous thromboembolism/pulmonary embolism (VTE/PE) treated with rivaroxaban before and after surgery
62126881|NCT06048835||HC|Control group of sex and age matched healthy volunteers, not affected by any neoplastic disease
62126882|NCT00592410|EXPERIMENTAL|1|
62317151|NCT03177837|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
62317152|NCT03177837|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
62126883|NCT01127373|EXPERIMENTAL|radiation therapy via multi-beam IMRT|This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.
62126884|NCT04900636|EXPERIMENTAL|Telemedicine Arm|Use of a telemedicine platform combined with face-to-face visits according to protocol
62317153|NCT06361745|EXPERIMENTAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject
62317154|NCT04059133|EXPERIMENTAL|LiESWT arm|"1. For SUI: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.~2. For OAB: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°, and the applicator was gently placed on suprapubic skin area over the bladder dome and bilateral bladder walls with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually."
62686576|NCT02565459|EXPERIMENTAL|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation.
62686577|NCT02565459|NO_INTERVENTION|No intervention|
62686578|NCT05630118|EXPERIMENTAL|SHUTi Intervention|Adult heavy drinkers with insomnia
62686579|NCT05630118|ACTIVE_COMPARATOR|Web-Based Insomnia Education Program|Adult heavy drinkers with insomnia
62317155|NCT04059133|SHAM_COMPARATOR|Sham arm|"1. For SUI: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.~2. For OAB: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). The applicator was gently placed on the suprapubic skin area over the bladder dome (1000 pulses) and bilateral bladder walls (each side 1000 pulses). The probe was placed on the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°."
62479396|NCT02143245|OTHER|Revision Population|"The study population is both men and women who have had previous shoulder surgery with symptoms suggestive of deep infection. These include the presence of pain, stiffness, and radiologic signs of infection including implant lucencies or migration.~Patients in this population will undergo a synovial biopsy, in addition to undergoing an open tissue biopsy at the time of their procedure. Diagnostic accuracy will be compared, and all participants will be tracked over time."
61924735|NCT06371508|EXPERIMENTAL|Experimental group|Women in the experimental group of the research will be given training content prepared by the researcher. The training presentation content will include information about breast cancer, breast cancer screening programs and breast self-examination.
62126885|NCT04900636|NO_INTERVENTION|Control Arm|conventional follow-up according to routine clinical practice.
62126886|NCT02990949|EXPERIMENTAL|Testing group|Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
61924736|NCT06371508|NO_INTERVENTION|Control group|Women in the control group will not be given any training and only their current information will be determined. Additionally, their awareness on this issue will be raised as they participate in the study.
62479397|NCT06575686|EXPERIMENTAL|Treatment (epcoritamab, tazemetostat)|Patients receive tazemetostat PO BID on days 1-28 of each cycle. Patients also receive epcoritamab SC on days 1, 8, 15, and 22 of cycles 2-4 then on day 1 of remaining cycles. Cycles repeat every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples on study and undergo bone marrow biopsy and CT or PET/CT throughout the study.
62126887|NCT02990949|NO_INTERVENTION|Control group|
62126888|NCT05033314|EXPERIMENTAL|Rivaroxaban thromboprophylaxis|
62126889|NCT05033314|PLACEBO_COMPARATOR|Placebo|
62126890|NCT00637936|ACTIVE_COMPARATOR|1|Group 1 is given 30% oxygen during and 2 hours after surgery
62126891|NCT00637936|ACTIVE_COMPARATOR|2|Group 2 is given 80% during and 2 hours after surgery.
62126892|NCT02759016|EXPERIMENTAL|BI 836826|BI 836826 administered in combination with Standard of Care Ibrutinib
62126893|NCT04630535||Obstructive Sleep Apnea|Pacient with OSA (AHI≥5) undergoing aorto-bifemoral bypass
62126894|NCT04630535||Without Obstructive Sleep Apnea|Patinets without OSA undergoing aorto-bifemoral bypass
62126895|NCT04618757|EXPERIMENTAL|Hedonic Reward|Participants' reward for meeting monthly step targets is in the form of reimbursements of up to $50 for expenses on hedonic activities of their choice
61924737|NCT00084838|EXPERIMENTAL|Multi-agent Intrathecal and Systemic CT with RT (mod IRS III)|"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)~Induction Chemotherapy: CT backbone of the IRS-III regimen \[vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)\] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.~Radiation Therapy: Pts w/ M0 dz OR M+ dz aged \<3y received focal RT (3D conformal or intensity-modulated delivery). Pts \>3y w/ M+ dz rcvd craniospinal irradiation.~Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively."
61924738|NCT05568706|EXPERIMENTAL|EDP-938|EDP-938 800 mg, once daily
61924739|NCT05568706|PLACEBO_COMPARATOR|Placebo|Matching placebo, once daily
61924740|NCT05708027|EXPERIMENTAL|AtriCure|Group of patients to whom was applied AtriCure device during thoracoscopic ablation.
61924741|NCT05708027|ACTIVE_COMPARATOR|Medtronic|Group of patients to whom was applied Medtronic device during thoracoscopic ablation.
61924742|NCT04996823|EXPERIMENTAL|Ipilimumab + Axtinib|Participants will receive treatment with ipilimumab 3 mg/kg IV q3 weeks x 4 doses and axitinib at 5 mg by mouth twice daily. Each cycle is 3 weeks/21 days
61924743|NCT06640569||US Adult Kratom Extract Consumers|Participants who regularly consume commercial kratom extracts will orally self-administer a single serving of their commercial kratom extract product under direct observation in order to evaluate acute physiological, subjective, and cognitive effects and determine pharmacokinetics. Participants will undergo direct observation and assessment for acute self-administration and for a period following the peak effects (i.e., a period of short abstinence). Physiological, subjective, and cognitive effects will be measured in an inpatient unit where the participant will reside for 2 days and 1 night (consecutive).
61924744|NCT00190515|ACTIVE_COMPARATOR|1|5-FU/l-LV
61924745|NCT00190515|EXPERIMENTAL|2|UFT/LV
61924746|NCT05091502|OTHER|Healthy volunteers|
61924747|NCT06655870|EXPERIMENTAL|Single Ascending Dose (SAD): mRNA-0184|Participants will receive a single subcutaneous (SC) injection of a fixed dose of mRNA-0184 on Day 1.
61924748|NCT06655870|EXPERIMENTAL|Multiple Ascending Dose (MAD): mRNA-0184|Participants will receive up to 2 SC injections of a fixed dose of mRNA-0184 on Days 1 and 15.
62126896|NCT04618757|EXPERIMENTAL|Cash Reward|Participants' reward for meeting monthly step targets is in the form of $50 cash disbursements
62317156|NCT02769260|NO_INTERVENTION|No toothbrushing during experiment and Pyrosequencing|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope) and 16S DNA pyrosequencing.
62479398|NCT04979910|EXPERIMENTAL|Ixekizumab|Ixekizumab 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2 and 4 via subcutaneous route.
62686580|NCT02196727||Patients undergoing Bascom operation|
62479399|NCT06562283|EXPERIMENTAL|Ambulatory patients (SMA-AMB)|"The patient is said to be ambulant if he or she is able to walk and perform a muscle contraction test with the quadriceps."
62686581|NCT06438250|EXPERIMENTAL|dynamic PET scans|PET imaging will begin at 3 minutes, 15 minutes, 30min minutes, 60 minutes and 150 minutes after injection
62686582|NCT04295928|EXPERIMENTAL|Intervention|Implementation of a personalized pharmaceutical plan with a view to increasing the patient's therapeutic education in the hospital and in the community (entrance and discharge reconciliation, 3 pharmaceutical interviews in the hospital, strengthening of the community-hospital link , 3 outpatient pharmaceutical consultations)
62686583|NCT04295928|NO_INTERVENTION|Usual care period|No changes to usual center practices
62686584|NCT01873508|EXPERIMENTAL|Fast release MR capsule|
62126897|NCT05075213|EXPERIMENTAL|QuitBet|"QuitBet is a quit smoking game delivered via a smartphone application that lasts 28 days and includes contingency management in the form of a deposit contract, integrated exhaled breath carbon monoxide (CO) testing, a social feed on which players can post and respond to messages, and a leaderboard that displays players' status (i.e., whether they are still eligible to win). A game host will post educational information about smoking cessation and serve as a discussion moderator. Participants will deposit (bet) $30 of their own money at the start of the game. Participants who submit a CO test that is 6ppm or lower (indicating no smoking) on at least 24 of the 26 days between day 3-28 will be declared winners and will split the pot of money that was deposited. All participants who submit at least 21 CO tests during the 28 day game, regardless of the CO test result, will be entered into a lottery to win a prize worth $75."
62126898|NCT05075213|ACTIVE_COMPARATOR|QuitBet-NS (no social elements)|QuitBet-NS will include the deposit contract and integrated CO testing with identical rules to QuitBet for being a winner, the $75 raffle for submitting at least 21 CO tests, a display of the participant's daily CO test results that is updated in real time, and a game feed on which only the game host has the ability to post. Players will not be able to post on this feed or respond to the host's posts. At the beginning of the game, the host will post limited information, including a list of smoking cessation resources. QuitBet-NS will NOT include the social feed, leaderboard, or any other social features.
62126899|NCT01443845|EXPERIMENTAL|1|Roflumilast
62126900|NCT01443845|PLACEBO_COMPARATOR|2|Placebo
62126901|NCT03882502|EXPERIMENTAL|stimulation group|
62126902|NCT03882502|SHAM_COMPARATOR|sham stimulation|
62126903|NCT02014142|EXPERIMENTAL|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
62126904|NCT02014142|EXPERIMENTAL|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
62126905|NCT00731497|ACTIVE_COMPARATOR|1|children in households/villages using Solar Water Disinfection (SODIS) method of disinfecting household drinking water
62126906|NCT00731497|NO_INTERVENTION|2|children in households/villages where Solar Water Disinfection (SODIS) has not been implemented
62126907|NCT04153058|EXPERIMENTAL|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
62126908|NCT04153058|ACTIVE_COMPARATOR|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
62126909|NCT02504086|EXPERIMENTAL|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
62126910|NCT04743310|EXPERIMENTAL|Tozuleristide with Canvas imaging system|
62126911|NCT02186769|ACTIVE_COMPARATOR|Risperdal® Consta®|25 Mg or 50 mg
62126912|NCT02186769|EXPERIMENTAL|L03004|25 mg or 50 mg
62126913|NCT03997682|EXPERIMENTAL|Hands-Up Program|Participants will be guided through a 45 minutes exercise program, set up as a group exercise class, with program modifications being made for each individual participant. In order to meet the requisite number of participants there will be approximately 4 cohorts of 10 participants. Immediately after the exercise class participants will attend a 30-minute educational session. The educational sessions will cover bone health principles, nutrition for bone health, osteoporosis practice guidelines, ways to self-monitor balance and lower extremity strength, impacts of physical activity, home hazard detection, hazards at work and in the community, postural effects on bone loading and fracture risk, and integrating physical activity in daily life. Nutritional education will emphasize the importance of calcium and vitamin D, sources of both diary and dairy free calcium, vitamin D supplements, the importance of protein, and meat and meat-free sources of protein.
62126914|NCT03997682|NO_INTERVENTION|Standard Care|The control group will receive usual care after a distal radius fracture. The standard care for a distal radius fracture will receive an assessment related to whether casting or surgery is necessary. The participant may be in a cast for 6 weeks with routine check up and x-rays to monitor the healing, at 3 months, 6 months and 12 months. The participant should receive some physical therapy related to restoring function of the hand and wrist.
62317157|NCT02769260|NO_INTERVENTION|No toothbrushing during experiment|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
62317158|NCT02769260|ACTIVE_COMPARATOR|Toothbrushing during experiment|48hours-Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
62317159|NCT06351215|PLACEBO_COMPARATOR|Control|placebo sugar pill and standard intraoperative pain control using short-acting opioids, with drug choice and dosing at the practitioner's discretion
62317160|NCT06351215|EXPERIMENTAL|Interventional|5mg PO methadone for participants \<50kg or 10mg PO methadone for participants \>50kg
62686585|NCT01873508|EXPERIMENTAL|Slow release MR capsule|
62686586|NCT01873508|EXPERIMENTAL|Target release MR capsule|
62686587|NCT01269437|EXPERIMENTAL|Budesonide, Novolizer|Budesonide Dry Powder Inhaler
62686588|NCT01269437|ACTIVE_COMPARATOR|BudesonideTurbuhaler|Budesonide Dry Powder Inhaler
62126915|NCT01542593|EXPERIMENTAL|Ureteral catheterization|"During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
62126916|NCT02658240|ACTIVE_COMPARATOR|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
62126917|NCT02658240|ACTIVE_COMPARATOR|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
62126918|NCT02202772|EXPERIMENTAL|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
62126919|NCT02202772|EXPERIMENTAL|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
62317161|NCT03290638|EXPERIMENTAL|Dehydrated Human Amnion Chorion Membrane|This membrane was investigated to evaluate its use as an open barrier for guided bone regeneration (GBR) after tooth extraction and to determine whether intentional exposure of this membrane to the oral environment compromises ridge dimensions and bone vitality for implant placement.
62479400|NCT06562283|EXPERIMENTAL|Non-ambulatory patients capable of effective grasping (SMA-PRE)|"The patient is said to be non-ambulant, with the ability to grasp the hand."
62126920|NCT02202772|EXPERIMENTAL|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
62317162|NCT03290638|ACTIVE_COMPARATOR|Type I Bovine Collagen Membrane|This membrane has been tested as an open barrier for GBR after tooth extraction. The intentional use of this membrane to the oral environment did not compromise ridge dimensions and bone vitality for implant placement.
62479401|NCT06562283|EXPERIMENTAL|Non-ambulatory patients without grasping ability (SMA-POU)|"The patient is said to be non-ambulant, with the ability to contract the thumb, but without the ability to grasp the hand."
62479402|NCT06133972|EXPERIMENTAL|Ianalumab monthly|Ianalumab s.c. monthly
62479403|NCT06133972|EXPERIMENTAL|Ianalumab quarterly|Ianalumab s.c. quarterly
62686589|NCT03583710|EXPERIMENTAL|Arm A (mitotane)|Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
62317163|NCT05555030|EXPERIMENTAL|At least 30 children between 2 and 13 years of age|Participants 2-13 years of age will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the iCura SARS-CoV-2 Antigen Rapid Home Test. The parent or legal guardian of the child will collect an anterior nasal swab sample from the child and perform the iCura SARS-CoV-2 Antigen Rapid Home Test.
62479404|NCT06133972|PLACEBO_COMPARATOR|Placebo monthly|Placebo s.c. monthly
62126921|NCT02202772|EXPERIMENTAL|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
62126922|NCT02202772|EXPERIMENTAL|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
61924749|NCT00586729|EXPERIMENTAL|Vashe|Vashe Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
62126923|NCT03677349|EXPERIMENTAL|Resensitized group|Patients with resensitized free flap by neurorrhaphy
62126924|NCT03677349|EXPERIMENTAL|Non Resensitized group|Patients without resensitized free flap by neurorrhaphy.
62126925|NCT00861029|EXPERIMENTAL|Pazopanib|Subjects will receive pazopanib during study
62126926|NCT00861029|OTHER|Placebo|Placebo as a comparator to pazopanib
62126927|NCT06451471||Active Comparator: Group 1|PATIENT GROUP DIAGNOSED WITH FMF
62126928|NCT06451471||Active Comparator: Group 2|HEALTHY CONTROL GROUP
62126929|NCT04421924|EXPERIMENTAL|Thrombelastogram (TEG)|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.
62126930|NCT04421924|EXPERIMENTAL|Standard of Care (SOC)|In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
62479405|NCT05996185|EXPERIMENTAL|Mogamulizumab + DA-EPOCH|"All subjects are scheduled to receive six cycles of DA-EPOCH + Mogamulizumab~Cycle 1: Mogamulizumab on days 1,8,15, of a 21-day cycle with DA-EPOCH on day 1.~Cycle 2 onwards: Mogamulizumab on day 1 with DA-EPOCH~Mogamulizumab will be administered modified to a 21-day cycle in combination with chemotherapy. Subjects will receive 1.0 mg/kg of mogamulizumab as an IV infusion over at least 1 hour on Days 1, 8, 15 of the first cycle and Day 1 for the subsequent cycles. This dosing regimen will ensure the first 4 doses are given weekly at a dose of 1 mg/kg. Subsequent dosing will occur on a 21-day schedule to coincide with the frequency of administration of DA-EPOCH to allow for simpler co-administration of the study drugs."
62479406|NCT01131637|EXPERIMENTAL|rhNRG-1|recombinant human neuregulin-1
62479407|NCT01131637|PLACEBO_COMPARATOR|placebo|placebo
62479408|NCT06561646|EXPERIMENTAL|single-port robotic-assisted breast surgery|the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer; single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection
62479409|NCT06061562||DS group|A cohort of participants (child, teenager, or adult), with or without sleep disorders
62317164|NCT05555030|EXPERIMENTAL|Subject 14-65+ years of age|Participants will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the iCura SARS-CoV-2 Antigen Rapid Home Test. The participant will then self-collect or, if both are over 18, collect from another study participant an anterior nasal swab sample and test using the iCura SARS-CoV-2 Antigen Rapid Home Test.
62317165|NCT00795067||Carotid atherosclerosis group|Patients who undergo carotid ultrasound examination for carotid atherosclerosis screening
62317166|NCT05762939|EXPERIMENTAL|Chatbot|Intervention using a pre-release version of Fido (https://fido.aid.pl), Polish AI-based therapy chatbot.
62317167|NCT05762939|ACTIVE_COMPARATOR|Control (book)|Intervention using self-help materials - chapters from a popular book on cognitive therapy, including worksheets.
62317168|NCT03392519||Chronic stroke|More than 3 months post-stroke Ischemic or hemorrhagic stroke
62317169|NCT00416351|EXPERIMENTAL|Clofarabine|Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.
62317170|NCT06024330||Positive VAN scale|"Motor Function: Check for arm drift with arms extended, palms up, and eyes closed for 10 seconds. If present, proceed to the VAN criteria.~V (Visual): Assess for reported double vision, field cut, or vision loss, or difficulty seeing fingers in a quadrant. If any visual disturbances are found, the patient is VAN positive.~A (Aphasia): Identify difficulties forming words, repeating a short sentence, recognizing two objects, or following simple commands. If any aphasia symptoms are observed, the patient is VAN positive.~N (Neglect): Check for forced gaze, inability to track a pen to one side, or lack of sensation in limbs. If any neglect signs are detected, the patient is VAN positive."
62317171|NCT06024330||Negative VAN scale|"A negative VAN scale indicates that a potential stroke patient does not exhibit the primary signs associated with a large vessel occlusion (LVO). Specifically, the patient demonstrated no arm drift during the initial motor function test. If the motor assessment is proceeded to the VAN criteria, the patient shows no visual disturbances like double vision or field cuts (V), no aphasia symptoms such as difficulty forming words or repeating sentences (A), and no signs of neglect, like forced gaze or lack of sensation in limbs (N)"
62317172|NCT06024330||Positive VES scale|"Eye Deviation: Scored as 1 if there's a forced deviation of both eyes to any side; otherwise, scored as 0.~Aphasia: Scored as 1 if the patient is awake and exhibits one or more of the following:~Inability to repeat a sentence. Inability to name an object. Talking incoherently or not obeying commands. Being mute. Otherwise, scored as 0. Neglect: Scored as 1 if the patient can perceive touch on both sides individually but fails to feel it on one side when stimulated simultaneously. Otherwise, scored as 0.~Obtundation: Scored as 1 if the patient cannot maintain wakefulness during a conversation; otherwise, scored as 0.~The VES can range from 0 to 4. A score of 1 or higher suggests a positive likelihood for ELVO. Additionally, if a patient tests positive for aphasia, neglect can be deduced by noting if the patient disregards the examiner on one side but is responsive when the examiner switches sides."
62317173|NCT06024330||Negative VES scale|"Eye Deviation: No forced deviation of both eyes is observed. Aphasia: The patient, while awake, can repeat sentences, name objects, speaks coherently, follows commands, and is not mute.~Neglect: The patient can perceive touch both when sides are stimulated individually and simultaneously.~Obtundation: The patient remains awake and alert during conversation. A total score of 0 on the VES scale represents a VES negative outcome."
62317174|NCT06024330||Positive LARIO scale|"Facial Palsy: The presence of facial muscle weakness or paralysis scores 1, while a normal facial expression scores 0.~Arm Weakness: A score of 1 is given for arm drift, no effort against gravity, or no movement at all. No drift is scored 0.~Grip Strength: Reduced or absent grip strength scores 1, while a normal grip scores 0.~Language: Changes in speech, global aphasia, or the patient being mute results in a score of 1. Normal language is scored 0.~Neglect: A score of 1 is given if the patient exhibits extinction to bilateral simultaneous stimulation in one or more sensory modality, doesn't recognize their own hand, or consistently orients only to one side of the body. The absence of these signs scores 0.~A cumulative score exceeding 3 on the LARIO Stroke Scale categorizes the patient as LARIO positive,"
62317175|NCT06024330||Negative LARIO scale|"Facial Palsy: No observable facial muscle weakness or paralysis. Arm Weakness: The arm remains steady without drift and exhibits normal effort against gravity.~Grip Strength: The patient displays normal grip strength. Language: The patient speaks normally, without aphasia or muteness. Neglect: No signs of sensory extinction upon bilateral simultaneous stimulation, proper recognition of their own hand, and balanced orientation to both sides of the body.~A cumulative score of 3 or less on the LARIO Stroke Scale classifies the patient as LARIO negative,"
62317176|NCT03540368|EXPERIMENTAL|Tranexamic acid injection|Group with tranexamic acid injection
62317177|NCT03540368|PLACEBO_COMPARATOR|Placebo|Group with Placebo
62317178|NCT01571882|EXPERIMENTAL|1 = Tested product 1|
62317179|NCT01571882|EXPERIMENTAL|2 = tested product 2|
62686590|NCT03583710|EXPERIMENTAL|Arm B (mitotane, etoposide, cisplatin)|Patients receive mitotane as in Arm A. Patients also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
61924750|NCT00586729|ACTIVE_COMPARATOR|5% Mafenide Acetate|5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
61924751|NCT06589687||Unexpected cesarean delivery under neuraxial anesthesia|Patients who have an unexpected cesarean delivery under neuraxial anesthesia.
61924752|NCT06466486|PLACEBO_COMPARATOR|Placebo|Follitropin delta and FE 999302 placebo
62126931|NCT06235294|EXPERIMENTAL|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene)
62126932|NCT06235294|PLACEBO_COMPARATOR|Placebo|Daily capsule of 400 mcg folic acid.
62126933|NCT04791592|ACTIVE_COMPARATOR|Group PIFB|PIF block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
62126934|NCT04791592|ACTIVE_COMPARATOR|Group TTMPB|TTMP block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
62126935|NCT01611246||Anesthetization|Anesthetization
62126936|NCT02599545||Maternal/VLBW Infant Pairs|One-hundred-fifty mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final sample size of 120 pairs.
62126937|NCT00405535|EXPERIMENTAL|A|glycine powder
62126938|NCT00405535|PLACEBO_COMPARATOR|B|placebo powder
62126939|NCT01431586|EXPERIMENTAL|Single dose JDTic 1 mg, 3 mg, or 10 mg|
62126940|NCT01875848|EXPERIMENTAL|buprenorphine/naloxone|induction onto buprenorphine/naloxone from opioid treatment
61924753|NCT06466486|ACTIVE_COMPARATOR|FE999302 and Placebo Every 2nd Day Group|Follitropin delta and FE 999302 every 2nd day and FE 999302 placebo every 2nd day
61924754|NCT06466486|ACTIVE_COMPARATOR|FE999302 Dose Group 1|Follitropin delta and FE 999302
61924755|NCT06466486|ACTIVE_COMPARATOR|FE999302 Dose Group 2|Follitropin delta and FE 999302
61924756|NCT06466486|PLACEBO_COMPARATOR|Placebo Group 2|Follitropin delta and FE 999302 placebo
61924757|NCT06466486|ACTIVE_COMPARATOR|FE999302 Dose Group 3|Follitropin delta and FE 999302
62126941|NCT01875848|ACTIVE_COMPARATOR|opioid dose escalation|increase of up to 25% of current opioid dose
62126942|NCT05133375|EXPERIMENTAL|GROUP A|Macintosh laryngoscope was used for endotracheal intubation.
62126943|NCT05133375|EXPERIMENTAL|GROUP B|McCoy laryngoscope was used for endotracheal intubation.
62126944|NCT01852071|EXPERIMENTAL|Gene Therapy|Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells
62126945|NCT00098553|EXPERIMENTAL|everolimus|"Patients receive oral everolimus once daily for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months until disease progression and then every 4 months for up to 5 years after registration."
62126946|NCT01430338||BAT|brown adipose tissue detected, undetected
62126947|NCT04902378|EXPERIMENTAL|Tandem t:slim X2 insulin pump with Control IQ technology plus CGM|Participants randomized to the intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology and Dexcom G6 Continuous Glucose Monitor.
62317180|NCT01571882|ACTIVE_COMPARATOR|3 = Active control product|
62317181|NCT04678167|EXPERIMENTAL|Boarding ring glasses|"Realization of the following examinations WITH Boarding ring glasses :~* caloric tests,~* measurement of the speed of Nystagmus,~* angle of deviation in Fukuda,~* Alexander's degree of nystagmus,~* EHTEV and EEV questionnaires,~* anxiety VAS"
62317182|NCT04678167|PLACEBO_COMPARATOR|Placebo glasses|"Realization of the following examinations WITH Placebo glasses :~* caloric tests,~* measurement of the speed of Nystagmus,~* angle of deviation in Fukuda,~* Alexander's degree of nystagmus,~* EHTEV and EEV questionnaires,~* anxiety VAS"
62317183|NCT04678167|OTHER|No glasses|"Realization of the following examinations WITHOUT glasses :~* caloric tests,~* measurement of the speed of Nystagmus,~* angle of deviation in Fukuda,~* Alexander's degree of nystagmus,~* EHTEV and EEV questionnaires,~* anxiety VAS"
62317184|NCT03304483|EXPERIMENTAL|Athletes|246-km running
62317185|NCT04372693|EXPERIMENTAL|group of students who are learning by Online Distance|"The following principals implemented while online learning will be processing;~1. Address and consider the students' differences in online learning application as a new experience.~2. Allow for Individual Locus of Control.~3. Motivate the student:~4. Avoid information overload,~5. Create A real-life context,~6. Encourage social interaction,~7. Provide hands-on activities,~8. Encourage student reflection."
62317186|NCT04372693|NO_INTERVENTION|students who were learned by Traditional Classroom-Based|
62317187|NCT01284179|EXPERIMENTAL|Hypnotherapy|Participants will be randomized to either the home hypnotherapy or educational group. The HHT protocol will consist of sequences of two different types of sessions, longer biweekly sessions (LS), each approximately 30-40 minutes in length, and shorter daily sessions (SS), approximately 12 minutes in length. On the first day of each sequence, the patient will listen to the appropriate LS. The patients will listen to the SS on a daily basis in between each LS. Every 2 weeks a new sequence will begin, for a total of 12 weeks of treatment.
62317188|NCT01284179|OTHER|Educational|Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
62317189|NCT04501653|EXPERIMENTAL|Psilocybin first|Participants will receive 25 mg of psilocybin at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the control drug (methylphenidate) at their second drug exposure neuroimaging session.
62317190|NCT04501653|ACTIVE_COMPARATOR|Methylphenidate first|Participants in this group will be randomized to receive 40 mg of methylphenidate at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the active comparator (psilocybin) at their second drug exposure neuroimaging session.
62479410|NCT04003272||Comprehensive Reverse Versa-Dial Titanium Glenosphere|Patients who have an allergy to typical cobalt chrome or other metal allergies had surgery to repair shoulder malfunction/disease.
62686591|NCT01952262||critically ill ICU patients|critically ill intensive care unit patients
62317191|NCT01432314|EXPERIMENTAL|Treatment group|Child A Hepatocellular carcinoma patients with unilobar portal vein invasion.
62317192|NCT00509873|EXPERIMENTAL|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
62317193|NCT00509873|PLACEBO_COMPARATOR|Placebo Eye Drops|Placebo Eye Drops
62317194|NCT02818153|EXPERIMENTAL|questionnaire for allergic rhinitis control|Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
62317195|NCT05026658|EXPERIMENTAL|Visibly Digital Acuity Product|
62317196|NCT05026658|EXPERIMENTAL|ETDRS Visual Acuity Lane Test|
62317197|NCT01784510|ACTIVE_COMPARATOR|2 cm|
62317198|NCT01784510|EXPERIMENTAL|6 cm|
62317199|NCT05563532||anxious group|Children with a score ≥4 on the venham picture test were included.
62479411|NCT03304704||DSF Cohort|Accrual/Screening up to 1800 will include volunteers between the ages of 5 and 17 years and will be enrolled for genotyping and monthly blood sampling
62479412|NCT03304704||Genotype Cohort|Accrual/Screening up to 1500 will complete a single visit with blood draw for genotyping for future fidelity assessments with blood-fed, spray wild-caught mosquitoes.
62317200|NCT05563532||non-anxious group|Children with a score \<4 on the venham picture test were included.
62317201|NCT02385695||Posterior Dynamic Stabilization|Surgical treatment with posterior dynamic stabilization
62479413|NCT03304704||Parasite Surveillance Cohort|Accrual/Screening up to 1500 will be enrolled for genotyping and a minimum of six monthly blood sampling and mosquito wild catches wild-caught mosquitoes within their compound
62686592|NCT04411199|EXPERIMENTAL|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
62686593|NCT04411199|OTHER|Standard of Care|The SoC for prophylactic antibiotic treatment is based on international guidelines
62686594|NCT03897270|EXPERIMENTAL|Diagnostic (photoacoustic imaging of the breast)|Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.
62686595|NCT01366274|ACTIVE_COMPARATOR|Usual method of MHI|
62686596|NCT01366274|EXPERIMENTAL|Protective MHI|
62317202|NCT02385695||Internal Fixation and Fusion|Surgical treatment with internal fixation and fusion
62317203|NCT00417612|EXPERIMENTAL|1|Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
62317204|NCT00417612|PLACEBO_COMPARATOR|2|Participants given placebo capsule to match for comparison
62686597|NCT05516472|EXPERIMENTAL|Hyperoxaluric group|Treatment group based on 24 hour urine analysis showing oxalate \>40 mg/day.
62686598|NCT05516472|EXPERIMENTAL|Hypercalciuric Group|Treatment group based on 24 hour urine analysis showing urinary calcium \>225 mg/day.
62126948|NCT04902378|NO_INTERVENTION|Standard insulin delivery (multiple daily injections (MDI) or pump) and CGM|Participants randomized to the control group will be fitted with the Dexcom G6 Continuous Glucose Monitor. They will continue to use standard insulin delivery (MDI or pump) and CGM.
62126949|NCT01109524|EXPERIMENTAL|Cetuximab + Cisplatin + Vinorelbine|
62126950|NCT06075394||psoriasis patients|Patients with psoriasis in the Department of Dermatology, Xijing Hospital of Air Force Medical University from December 2012 to December 2022 were consecutively collected. Inclusion criteria: (1) age ≥18 years; (2) Clear diagnosis of psoriasis. Exclusion criteria: (1) age \<18; (2) Hypertension caused by conditions such as primary hypertension, hyperthyroidism, chronic renal insufficiency, or Cushing's syndrome, which are severe endocrine system diseases; (3) Patients with autoimmune diseases, severe cardiovascular, hepatic, renal, or other major organ disorders, as well as blood disorders and endocrine system diseases.
62126951|NCT06075394||Healthy individuals|Healthy individuals being randomly selected healthy individuals from a medical examination center.
62126952|NCT03117023|EXPERIMENTAL|dexmedetomidine group|sufentanil + dexmedetomidine
62126953|NCT03117023|NO_INTERVENTION|control group|sufentanil + saline
62126954|NCT01024881|ACTIVE_COMPARATOR|group 1|neutral shoulder position during infraclavicular subclavian catheterization
62126955|NCT01024881|EXPERIMENTAL|group 2|lowered shoulder position during infraclavicular subclavian catheterization
62126956|NCT04434677|ACTIVE_COMPARATOR|Hypofractionation|Control arm:patients who will receive standard 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
62126957|NCT04434677|EXPERIMENTAL|Ultrahypofractionation|Experimental arm: Patients who will receive 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
62126958|NCT04282824|EXPERIMENTAL|Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
62126959|NCT04282824|EXPERIMENTAL|Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
62317205|NCT05754827||1-CKD patients without cardiovascular complications|
62317206|NCT05754827||2-CKD patients with cardiovascular complications|
62686599|NCT05516472|PLACEBO_COMPARATOR|Control group Hyperoxaluria|Control group enrolling patients with hyperoxaluria
62126960|NCT06118827|EXPERIMENTAL|HS-10518 Dose 1|Dose level 1 of HS-10518, QD, orally, 7 days
62126961|NCT06118827|PLACEBO_COMPARATOR|Placebo Dose 1|Dose level 1 of matching placebo, QD, orally, 7 days
62126962|NCT06118827|EXPERIMENTAL|HS-10518 Dose 2|Dose level 2 of HS-10518, QD, orally, 7 days
62126963|NCT06118827|PLACEBO_COMPARATOR|Placebo Dose 2|Dose level 2 of matching placebo, QD, orally, 7 days
62126964|NCT06118827|EXPERIMENTAL|HS-10518 Dose 3|Dose level 3 of HS-10518, QD, orally, 7 days
62126965|NCT06118827|PLACEBO_COMPARATOR|Placebo Dose 3|Dose level 3 of matching placebo,QD, orally, 7 days
62126966|NCT06118827|EXPERIMENTAL|HS-10518 Dose 4|Dose level 4 of HS-10518, QD, orally, 7 days
62126967|NCT06118827|PLACEBO_COMPARATOR|Placebo Dose 4|Dose level 4 of matching placebo, QD, orally, 7 days
62126968|NCT03586817|ACTIVE_COMPARATOR|Palonosetrona|Palonosetron 75 mcg during the anesthesia
62317207|NCT00599430|PLACEBO_COMPARATOR|1|Placebo
62317208|NCT00599430|ACTIVE_COMPARATOR|Active 1|One probiotic strain
62317209|NCT00599430|ACTIVE_COMPARATOR|Active 2|Blend of two strains
62317210|NCT00818142||eating disorder, type 1 diabetes|Individuals diagnosed with type 1 diabetes and an eating disorder who withhold their insulin.
62317211|NCT04645797|EXPERIMENTAL|APR003 Dose Escalation|This portion of the study will evaluate the safety and pharmacokinetics of a range of APR003 doses administered once a week for 21 days in subjects with advance colorectal cancer (CRC) with metastases to the liver and to determine the RP2D.
62317212|NCT01721369||Transient Loss of Consciousness (T-LOC)|Transient Loss of Consciousness (T-LOC). Treatment according to normal clinical practice.
62126969|NCT03586817|ACTIVE_COMPARATOR|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
62317213|NCT00719732|EXPERIMENTAL|ReSTOR Aspheric +3|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
62317214|NCT03053089|EXPERIMENTAL|Stage 1 (adult)|AGT-181
62317215|NCT03053089|EXPERIMENTAL|Stage 2 (children)|AGT-181
62317216|NCT05070949|EXPERIMENTAL|Mindful Self-Compassion|Participants will meet every 2 weeks via zoom application or equivalent online meeting platforms, for 12 weeks. The sessions will be led by a clinical psychologist. The curriculum will follow mindful compassion program by Neff KD
62317217|NCT05070949|NO_INTERVENTION|Wait List Control|Wait list control group will not participate in the MSC program during the first 12 weeks of the protocol but will be given an opportunity to participate after 12 weeks, using the same curriculum.
62317218|NCT05782413|EXPERIMENTAL|Group A|The child will receive a design exercise program. The therapy was based on the principles of NDTBobath neurodevelopmental therapy.
62686600|NCT05516472|PLACEBO_COMPARATOR|Control group Hypercalciuria|Control group enrolling patients with hypercalciuria
62686601|NCT00742690|ACTIVE_COMPARATOR|1|35 patients with cirrhosis and type 1 HRS
62317219|NCT05782413|EXPERIMENTAL|Group B|The child will receive a design exercise program for 45 min then mechanical vestibular exercise for 15 mins.
62317220|NCT05807022|EXPERIMENTAL|Percutaneous or transbronchial argon-helium cryoablation|
62317221|NCT02468089|EXPERIMENTAL|Carbepenem+albumin+GMCSF.|
62686602|NCT00742690|EXPERIMENTAL|2|35 patients with cirrhosis and type 1 HRS
62686603|NCT04665895|EXPERIMENTAL|Test Product|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
61924758|NCT06138288||acupressure group|Women who are in acupressure will apply the application after cesarean section 2nd hour after applying the data collection forms (descriptive features formula, VAS, WHO). For women on acupressure, the application will be applied manually to the SP6, P6 and L14 points in the order indicated by the drawing with the index or middle finger, 1-1.5 cm depth for 5 seconds, pressing for 5 seconds, resting for 2 seconds and continuing for 2 minutes to go. will be with you. VAS will be filled again after the application.
61924759|NCT06138288||control group|
61924760|NCT04702854|EXPERIMENTAL|Experimental|Measure of cutaneous melanomas by ultrasound biomicroscopy
62126970|NCT04092231||1|Thirty children were between two and five years of age at the time of implantation. All were congenital pre-linguistically bilateral profound sensorineural hearing loss. Reports about basic audiological evaluation which included air and bone conduction thresholds, speech audiometry for all the study group before the implantation were obtained. They had limited benefit from consistent use of hearing aid amplification and enrolled in a rehabilitation program focused on oral communication. they underwent unilateral CI with CI experience ranged from 6 months and above.
62126971|NCT03961906|ACTIVE_COMPARATOR|Tübingen physiotherapy concept|Will receive our therapy concept and perform self-trainings on a regular basis.
61924761|NCT00815516|EXPERIMENTAL|Micafungin|Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
61924762|NCT00815516|ACTIVE_COMPARATOR|Amphotericin B deoxycholate|Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
61924763|NCT01536288|ACTIVE_COMPARATOR|Rhodiola crenulata-placebo sequence|Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
61924764|NCT01536288|ACTIVE_COMPARATOR|Placebo-Rhodiola crenulata sequence|Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
61924765|NCT06182709|EXPERIMENTAL|online modeled exposure + mental retrieval cue group exposure|online modeled exposure training followed by group exposure training, including mental retrieval cue with five standardized exposure steps
61924766|NCT06182709|ACTIVE_COMPARATOR|live modeled exposure + mental retrieval cue group exposure|live modeled exposure training followed by group exposure training, including mental retrieval cue with five standardized exposure steps
62126972|NCT03961906|NO_INTERVENTION|controls|Will receive standard-care which includes their regular physiotherapy as provided by the local therapist and can include self-trainings as well.
62126973|NCT00716859|ACTIVE_COMPARATOR|Timolol|
62317222|NCT02468089|ACTIVE_COMPARATOR|Carbepenem+albumin|
62126974|NCT00716859|EXPERIMENTAL|latanoprost|
62126975|NCT01493778|EXPERIMENTAL|turoctocog alfa|
62126976|NCT03960398||Patients concerned by iatrogenic diseases|Patients living in the South-East of France and consulting in the emergency department of Toulon La Seyne sur Mer hospital for iatrogenic diseases
62126977|NCT04575740|EXPERIMENTAL|Positive Airway Pressure Device|All participants will receive PAP therapy
62317223|NCT06024005|ACTIVE_COMPARATOR|Device Group|Transcutaneous device group with Urostim 2
62317224|NCT06024005|ACTIVE_COMPARATOR|Drug Group|Drug Group with Kinzy 5 mg
62317225|NCT03880227|EXPERIMENTAL|Anodal followed by sham stimulation tDCS to rTPJ|cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.
62317226|NCT03880227|ACTIVE_COMPARATOR|Anodal followed by sham stimulation tDCS to dmPFC|cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.
62686604|NCT04665895|ACTIVE_COMPARATOR|Reference Product|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
62686605|NCT04665895|PLACEBO_COMPARATOR|Placebo|Placebo
62686606|NCT06674213||Grup I-İlioinguinal/İliohipogastrik Nerve Block|Ilioinguinal/Iliohypogastric nerve block will be applied under ultrasound guidance. Pain measurements were evaluated 24 hours after surgery. Pain measurement will be evaluated according to the VAS scale.
62686607|NCT06674213||Grup II-Erektör Spine Nerve Block|Erector spine plane block will be applied under ultrasound guidance. Pain measurements were evaluated 24 hours after surgery. Pain measurement will be evaluated according to the VAS scale.
62126978|NCT04593914|EXPERIMENTAL|Cavilon Advanced Skin Protectant|"Cavilon Advanced Skin Protectant forms a film barrier intended to protect intact or damaged skin. It is effective in conditions where skin is frequently or continuously exposed to moisture and caustic irritants such as feces, digestive fluids, wound drainage and urine. Cavilon Advanced Skin Protectant also can be used in areas exposed to friction and shear from bedding, clothing, shoes or any other material that would rub against the skin.~The skin barrier protectant will be applied on the irradiated skin from the third week of radiotherapy until 1 week after the final radiotherapy session."
62317227|NCT03880227|EXPERIMENTAL|Sham followed by anodal stimulation tDCS to rTPJ|cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.
62317228|NCT03880227|ACTIVE_COMPARATOR|Sham followed by anodal stimulation tDCS to dmPFC|cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.
62686608|NCT06674213||Grup III-Retrolaminer Nerve Block|Retrolaminar block will be applied under ultrasound guidance. Pain measurements were evaluated 24 hours after surgery. Pain measurement will be evaluated according to the VAS scale.
62317229|NCT01073748|ACTIVE_COMPARATOR|asthmatic subjects|Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
62317230|NCT01073748|OTHER|Healthy children|Children with no asthma as control group.
62686609|NCT01566565|ACTIVE_COMPARATOR|Theophylline|
61924767|NCT06182709|ACTIVE_COMPARATOR|online modeled exposure + standardized group exposure|online modeled exposure training followed by group exposure training with five standardized exposure steps
62317231|NCT04497246||Elderly patients|Elderly patients (over 65 years old) hospitalized for COVID-19 within the CHU Brugmann Hospital
62317232|NCT04497246||Health Care professionals|Health Care professionals working within the CHU Brugmann Hospital
61924768|NCT06182709|ACTIVE_COMPARATOR|live modeled exposure + standardized group exposure|live modeled exposure training followed by group exposure training with five standardized exposure steps
62686610|NCT01566565|ACTIVE_COMPARATOR|Bambuterol|
62686611|NCT06332755|EXPERIMENTAL|Dose Escalation|
62686612|NCT01048359|EXPERIMENTAL|Brief Intervention|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
62317233|NCT01201369|ACTIVE_COMPARATOR|Cypher™ Stent|Participants in the Cypher arm will be randomised to receive a Cypher™ (Cordis, Miami Lake, USA) coronary stent
62317234|NCT01201369|ACTIVE_COMPARATOR|Xience™ Stent|Patients in the Xience™ arm will receive a Xience™ Stent(Abbott Vascular, Santa Clara, USA.
62479414|NCT01899755|EXPERIMENTAL|GSK2800528 Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
62479415|NCT01899755|PLACEBO_COMPARATOR|Placebo Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
62686613|NCT01048359|ACTIVE_COMPARATOR|Brief advice|This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
62686614|NCT01048359|EXPERIMENTAL|Brief Intervention plus Booster|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.
62686615|NCT05143515|EXPERIMENTAL|PACE Label group|This group used the PACE label plus calorie label to help participants to know about the number of minutes of walking or running required to burn off the calories in food and drinks.
62686616|NCT05143515|NO_INTERVENTION|Calorie Label group|This group used only calorie labels to show the number of calories in food and drinks.
62686617|NCT02594579|ACTIVE_COMPARATOR|Vitamin D|Dietary Supplement: Vitamin D3
62686618|NCT02594579|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo
62686619|NCT06687083|EXPERIMENTAL|nasal high frequency|"Preterm neonates who will be allocated will start nHFOV. nHFOV will be provided via binasal prongs (Size: small, medium, large; Diameter according to its chart.~The initial parameters will be mean airway pressure (MAP) of 6 cm H2O (range 6-10), frequency of 8 Hz (range 8-12) and amplitude will be adjusted until infant's chest showed slight oscillations and amplitude will be 7 (range 7-10).~The fraction of inspired oxygen (FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter"
62686620|NCT06687083|ACTIVE_COMPARATOR|nasal CPAP|Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter.
62686621|NCT04020913||Short Stature Boys|Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency (defined as peak GH responses to pharmacologic stimuli \<10ng/ml) or idiopathic short stature (i.e., no identifiable pathology) will be studied pre and post 12 months of GH therapy.
62686622|NCT04020913||Normally Statured Boys|A group of 15 healthy, normally statured (between 10th- 90th %), age-matched boys not on Growth Hormone replacement, preferably siblings (although not exclusively), will be recruited to serve as healthy controls.
62686623|NCT02735642|EXPERIMENTAL|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
62686624|NCT02735642|EXPERIMENTAL|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
62686625|NCT02735642|EXPERIMENTAL|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
62686626|NCT02735642|EXPERIMENTAL|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
62686627|NCT02735642|OTHER|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
62686628|NCT02735642|OTHER|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
62686629|NCT02368873|ACTIVE_COMPARATOR|Intervention group|Patients with IPOM Dynamesh mesh around the straight permanent colostomy.
62686630|NCT02368873|NO_INTERVENTION|Control group|Patients with the straight permanent colostomy without a mesh.
61924769|NCT04050371|EXPERIMENTAL|TRUVADA DOT|one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days
62317235|NCT01780558|OTHER|group NC-A|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the natural cycles.
62339723|NCT04995328|EXPERIMENTAL|Radiation Care Gel application|Radiation Care® gel is instructed to use on the target skin area accepted radiation therapy twice daily.
62479416|NCT01899755|ACTIVE_COMPARATOR|Adalimumab Arm|In Cohort 4, all subjects will receive adalimumab 40 mg (0.8 mL solution) as subcutaneous injection
62479417|NCT05143177|PLACEBO_COMPARATOR|Placebo|
62479418|NCT05143177|ACTIVE_COMPARATOR|DA-1229 5mg|
62479419|NCT05143177|ACTIVE_COMPARATOR|DA-1229 10 mg|
62686631|NCT04606849|OTHER|Physician Survey|A modified version of a previously validated REDCap questionnaire will be administered to Instacare clinicians in the cluster where ePNa-CheXED was deployed via email at 6 months after ePNa-CheXED implementation. Our questionnaire includes questions on respondent demographics and Likert-style questions about respondents' experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components
62317236|NCT01780558|OTHER|group HRT-B|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospitalwill be recruited , who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
62317237|NCT06396156|ACTIVE_COMPARATOR|anterior chamber iris-claw lens|Eyes that receive Artisan IOL that is fixed anterior to the iris
62317238|NCT06396156|ACTIVE_COMPARATOR|Retro-pupillary Iris- Claw lens|Eyes that receive Artisan IOL that is fixed posterior to the iris
62317239|NCT04408521|EXPERIMENTAL|NEUROFEEDBACK|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. Self-regulation of alpha rhythm is reflected in the dynamically varying opacity of the video replay window, i.e. the window would turn lighter/darker and reveal/obscure video content during episodes of low/high alpha amplitude, respectively.
62317240|NCT04408521|PLACEBO_COMPARATOR|CONTROL|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. The recording is passive without real-time EEG neurofeedback (i.e. constant brightness and volume).
62317241|NCT02674607|EXPERIMENTAL|patients|thirty children with beta thalassemia major will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
62126979|NCT06147167|EXPERIMENTAL|indvidualized iTBS|In this arm of the study, participants undergo individualized intermittent theta burst stimulation (iTBS) subsequent to encephalography (EEG) testing. Three electrodes are strategically positioned on the first dorsal interosseous (FDI) hotspot to record the resting theta frequency, which is subsequently utilized as the theta frequency for theta burst stimulation (TBS). The participants receive this treatment regimen once daily, five times a week, over a total duration of three weeks.
62126980|NCT06147167|ACTIVE_COMPARATOR|standard iTBS|In this particular arm of the study, participants also undergo an initial electroencephalography (EEG) procedure. Subsequently, intermittent theta burst stimulation (iTBS) is administered using the standard theta burst stimulation frequency of 5Hz. The participants receive this treatment once daily, five times a week, over a total duration of three weeks.
62126981|NCT06147167|SHAM_COMPARATOR|sham iTBS|In this arm, the treatment procedure is similar to the standard iTBS unless the coil is perpendicular to the scalp.
62126982|NCT03348917|ACTIVE_COMPARATOR|Treatment sequence Group 1|"Treatment Sequence Group 1 = A -\> B -\> C~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)"
62126983|NCT03348917|ACTIVE_COMPARATOR|Treatment sequence Group 2|"Treatment Sequence Group 2 = B -\> C -\> A~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)"
62126984|NCT03348917|ACTIVE_COMPARATOR|Treatment sequence Group 3|"Treatment Sequence Group 3 = C -\> A -\>B~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)"
62126985|NCT04600752|EXPERIMENTAL|Participants receiving Augmentin (ES)-600|Eligible participants will receive Augmentin (ES)-600 at 90/6.4 mg/kg/day administered in two divided doses, every 12 hours with food for 10 days.
62126986|NCT01376089|OTHER|Arm 1-Iodixanol|
62317242|NCT02674607|NO_INTERVENTION|controls|thirty healthy children of matched age and sex
62317243|NCT03215888||Obese|Obese individuals undergoing bariatric surgery
62317244|NCT03215888||controls|matched non-obese controls
62317245|NCT04758117||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for psoriatic arthritis (PsA).
62317246|NCT02559232||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fibrillation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
62126987|NCT01376089|ACTIVE_COMPARATOR|Arm 2-Iopamidol|
62126988|NCT04597658|ACTIVE_COMPARATOR|Conventional rehabilitation|
62317247|NCT01615003|EXPERIMENTAL|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
62317248|NCT01615003|PLACEBO_COMPARATOR|control group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
62317249|NCT00830427|EXPERIMENTAL|PF-00610355|
62317250|NCT00830427|EXPERIMENTAL|PF - 00610355|
62317251|NCT00830427|PLACEBO_COMPARATOR|Placebo|
62317252|NCT02345369|ACTIVE_COMPARATOR|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
62126989|NCT04597658|EXPERIMENTAL|Body weightsupported treadmill training|
62317253|NCT02345369|ACTIVE_COMPARATOR|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
62479420|NCT06265727|EXPERIMENTAL|Part A Dose Escalation - CRB-701 Dose Level 1|CRB-701 Dose level 1, intravenous infusion over 30 mins, Dose schedule 1
62317254|NCT06077058|EXPERIMENTAL|Intervention group|Factorial design with four components/factors: 1) SEE versus none; 2) NRTS versus none; 3) CBIM versus none; and 4) chatbot for smoking cessation versus none, and to 2 x 2 x 2 x 2=16 trial groups. All participants will be randomly and evenly assigned to these 16 intervention groups.
62317255|NCT06077058|NO_INTERVENTION|Control group|The control group will only provide simple smoking cessation advice with no intervention after recruitment
62317256|NCT00815165||Protocol 04-039 subjects|At least 50 and maximum of 100 healthy adolescent female subjects aged 12-17 years who were vaccinated in protocol 04-039 will be enrolled.
62479421|NCT06265727|EXPERIMENTAL|Part A Dose Escalation - CRB-701 Dose Level 2|CRB-701 Dose Level 2, intravenous infusion over 30 mins, Dose schedule 1
62479422|NCT06265727|EXPERIMENTAL|Part A Dose Escalation - CRB-701 Dose Level 3|CRB-701 Dose Level 3, intravenous infusion over 30 mins, dose schedule 1
62479423|NCT06265727|EXPERIMENTAL|Part A Dose Escalation - CRB-701 Dose Level 4|CRB-701 Dose Level 4, intravenous infusion over 30 mins, dose schedule 1
62479424|NCT06265727|EXPERIMENTAL|Part B Dose Optimization: CRB-701 High dose|Selected high dose of CRB-701, intravenous infusion over 30 mins, dose schedule 1
62479425|NCT06265727|EXPERIMENTAL|Part B Dose Optimization: CRB-701 low dose|Selected Low dose of CRB-701, intravenous infusion over 30 mins, once every three weeks
62479426|NCT06265727|EXPERIMENTAL|Part C Dose Expansion - Cohort 1|Recommended Phase 2 dose and schedule of CRB-701, intravenous infusion over 30 mins
62317257|NCT00815165||Positive and Negative Controls|Approximately 100 screened subjects will be enrolled to serve as positive and negative controls.
62317258|NCT02025699||LRTI|
62479427|NCT06265727|EXPERIMENTAL|Part C Dose Expansion - Cohort 2|Recommended Phase 2 dose and schedule of CRB-701, intravenous infusion over 30 mins
62479428|NCT06265727|EXPERIMENTAL|Part C Dose Expansion - Cohort 3|Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
62479429|NCT06265727|EXPERIMENTAL|Part C Dose Expansion - Cohort 4|Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
62317259|NCT02025699||Sepsis|
62317260|NCT02025699||Non-Infectious disease group|
62317261|NCT03949582|EXPERIMENTAL|Mycoprotein as in Soup|24 will be randomised to soup (12 caucasian and 12 south asian) in order to test raw mycoprotein. Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
62317262|NCT03949582|EXPERIMENTAL|Mycoprotein as in Mince|24 will be randomised to mince (12 caucasian and 12 south asian) in order to test processed mycoprotein (Quorn). Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
62317263|NCT04761380||stable COPD subjects|
62317264|NCT04761380||age-matched control subjects subjects who did not have any pulmonary disease|
62317265|NCT00500149|EXPERIMENTAL|1|
62317266|NCT00500149|PLACEBO_COMPARATOR|2|
62317267|NCT02293434||All Children (1 month to 18 years)|All children (1 month to 18 years) admitted to all PICUs in France during three one-week periods (February, June, October) in the course of a year
62479430|NCT06265727|EXPERIMENTAL|Part C Dose Expansion - Cohort 5|Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
62479431|NCT04364581|ACTIVE_COMPARATOR|Letrozole group|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
62479432|NCT04364581|PLACEBO_COMPARATOR|Placebo group|Women will be treated with placebo for 10 days before hysteroscopic intervention
62479433|NCT05262530|EXPERIMENTAL|BNT142|
62479434|NCT02102815|EXPERIMENTAL|Dexamethasone|Preoperative dexamethasone 0.15mg/Kg mixed with NSS to 50 mL IV slowly push over 5 minutes
62317268|NCT02815631|EXPERIMENTAL|Cardiogoniometry (CGM)|"Every patient involved in the study will undergo a series of CGM recordings whilst having their FFR procedure. These recordings will all be done whilst they are in the catheterisation laboratory and will be taking at the following points during the procedure.~1. First baseline recording - taken when the patient first enters the catheterisation laboratory and is prepped for their procedure.~2. Second baseline recording - taken when the FFR guide wire is in place in the coronary artery being assessed.~3. Maximal hyperaemia recording - this will be taken when the patient is at maximal hyperaemia during their adenosine infusion for their FFR procedure.~The patients involvement will then be finished in the study and will be cared for as per clinical practice.~If the CGM records a result of anything less than 0, it will be regarded as a positive result."
62479435|NCT02102815|PLACEBO_COMPARATOR|Placebo|Preoperative intravenous normal saline 50 mL slowly push over 5 minutes
62479436|NCT03264339|EXPERIMENTAL|Smal step|Small Step Program, comprising 3 treatment focus areas (Hand use, Mobility, Communication)
62479437|NCT00471133|EXPERIMENTAL|Xenogeneic Tyrosinase|
62686632|NCT04606849|OTHER|Adapt ePNa-CheXED for InstaCares|"Adapt ePNa-CheXED for Instacares and after in silico testing, pilot it among super user clinicians during Instacare shifts and assess its usability. ePNa needs adaptation for more limited patient data available in Instacare clinics, calibration of severity measures for lower observed mortality, and a chest imaging prompt in patients with pneumonia signs and symptoms. ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion)."
62339724|NCT01822691|EXPERIMENTAL|INCB024360 Treatment|Participants were treated with 600 mg orally, twice a day for 16 weeks, unless clear evidence of disease progression or toxicity was evident.
62686633|NCT01729429|ACTIVE_COMPARATOR|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
62686634|NCT01729429|EXPERIMENTAL|HPV brochure, recall, reminders|"* HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
62686635|NCT03844035|EXPERIMENTAL|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator(oxytet oral irrigatör).All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual).PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites.Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
62686636|NCT03844035|EXPERIMENTAL|Interdental brush group|Fifteen patients using toothbrush and interdental brush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
61924770|NCT02912988|EXPERIMENTAL|Letrozole group|"Letrozole + standard treatment:~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
61924771|NCT02912988|NO_INTERVENTION|Control group|"Standard treatment:~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
61924772|NCT05684523|EXPERIMENTAL|Redormin® 500|fixed combination of valerian and hops dry extract, 500 mg, once daily for 21 days
61924773|NCT05684523|PLACEBO_COMPARATOR|Placebo|matching placebo, once daily for 21 days
61924774|NCT05961644|EXPERIMENTAL|Experimental|Drug: Cladribine at a dose of 1.8 mg/kg of body weight. Cladribine will be given subcutaneously over 6 visits every 5-6 weeks.
61924775|NCT05961644|PLACEBO_COMPARATOR|Control|Comparator: Placebo matched to the subcutaneous injection of cladribine.
62339725|NCT01691352|ACTIVE_COMPARATOR|Wick|Patients with wick placed in their wound at the time of ostomy reversal
61924776|NCT05894239|OTHER|Induction Therapy: Phesgo plus Taxane-Based Chemotherapy|Participants will be administered the treatments as outlined in the interventions section.
61924777|NCT05894239|EXPERIMENTAL|Maintenance Therapy: Inavolisib plus Phesgo|Participants will be administered the treatments as outlined in the interventions section.
62339726|NCT01691352|SHAM_COMPARATOR|No wick|patients with non-wicked dressing placed on their wound
62479438|NCT05281744|EXPERIMENTAL|Dementia Care Consultation program|The Dementia Care Consultation program provides an in-depth, personalized service for individuals and families facing ADRD.
62479439|NCT05281744|NO_INTERVENTION|Routine Care|Members randomized into the control group will receive routine care.
62479440|NCT02341846||Patients with cancer pain|Qualitative semi-structured interviews with patients who have experienced cancer pain
62479441|NCT02341846||Caregivers for those with cancer pain|Qualitative semi-structured interviews with caregivers who have cared for those who have experienced cancer pain.
62479442|NCT02341846||Healthcare professionals|Healthcare professionals whose role involves the management of cancer pain.
62479443|NCT05826327|EXPERIMENTAL|Esketamine Group|The epidural analgesic drug mix for labour analgesia is ropivacaine 0.08mg/mL compounded with esketamine 0.3mg/mL.
62479444|NCT05826327|PLACEBO_COMPARATOR|Control Group|The epidural analgesic drug mix for labour analgesia is ropivacaine 0.08mg/mL compounded with sufentanil 0.3ug/mL.
62686637|NCT03844035|ACTIVE_COMPARATOR|Control group|Fifteen patients using only toothbrush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
62317269|NCT02815631|ACTIVE_COMPARATOR|Fractional flow reserve (FFR)|"Every patient involved in the study will undergo an FFR assessment of their coronary arteries. These recordings will all be done whilst they are in the catheterisation laboratory. They will have the following recordings:~1. A baseline FFR will be recorded once the pressure wire has been advanced down the coronary artery being assessed.~2. Maximal hyperaemia FFR will be recorded during adenosine infusion.~An FFR ratio of \<0.80 will be regarded as a positive result."
62697412|NCT01657188||Heart failure, sleep-disordered breathing|Patients with stable heart failure NYHA ≥ II, EF ≤ 45% with or without central sleep apnea (apnea-hypopnea index ≥ 15/h) with or without adaptive servoventilation
62317270|NCT04476537|EXPERIMENTAL|Intervention Arm|Individuals who meet the eligibility criteria based on their provided tissue sample will be followed by the investigators to obtain medical information every 4 weeks. This follow-up will consist of a review of medical records, contact with the participant's treating physician, or personal contact between the participant and the investigators at Columbia University Irving Medical Center (CUIMC). During the study, their tumor tissue will be evaluated to identify medications that may help treat the cancer. The results of these tests will be reviewed by experts on a Precision Medicine Tumor Board (PMTB) and these experts may recommend a specific treatment to the participant or participant's physician.These participants will continue to be followed until death or withdrawal of consent from the study.
62317271|NCT04476537|NO_INTERVENTION|Observation Arm|Individuals who do not meet the eligibility criteria based on their provided tissue sample will be provided follow-up with their treating physicians up to every 4 weeks to gather clinical information related to their disease.
62317272|NCT02088216|ACTIVE_COMPARATOR|N-Acetylcysteine group|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
62317273|NCT02088216|OTHER|Control group|Participants received as-needed therapy.
62317274|NCT01198418|EXPERIMENTAL|Internet-based counseling|Completes surveys monthly about their sexual and drug use behaviors as well as receives information designed to help reduce the chances of getting an STI.
62317275|NCT01198418|NO_INTERVENTION|Survey Alone|Completes surveys monthly about their sexual and drug use behaviors
62317276|NCT05616949|ACTIVE_COMPARATOR|Arm 1 Title: Treatment as Usual (TAU)|Arm 1: Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
62317277|NCT05616949|EXPERIMENTAL|Arm 2 Title: Peer Recovery Support Services (PRSS) + TAU|Arm 2: Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services (TAU+PRSS) vs. an active comparator composed of treatment as usual services without the PRSS intervention (i.e., TAU-alone). Follow ups will be conducted at weeks 2, 4, 8, 12, 16, 20, 24 (end of intervention), 36, and 52 to collect data on the primary outcome of MOUD retention and other outcomes.
62317278|NCT05920850|OTHER|Single Arm|"1. A culturally tailored video that provides education about the process of low-dose helical computed tomography (LDCT) lung cancer screening~2. A culturally tailored shared decision-making tool that educates participants about the shared decision-making process~3. The use of a flip chart that reinforces the information provided in the video and shared decision-making tool~4. Navigation support for participants who express interest in LDCT and quitting smoking"
62317279|NCT02239094|OTHER|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
62317280|NCT03819244|EXPERIMENTAL|Diode laser|Soft tissue incision with 940 nm Gallium Aluminum Arsenide diode laser, at implant recovery settings (2.5 W output power, average power: 1.25 W, pulse length : 1.00 ms, pulse interval: 1.00 ms) in second-stage implant surgery.
62317281|NCT03819244|EXPERIMENTAL|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz, H mode, 10% water and 10% air) in second-stage implant surgery.
61924778|NCT05894239|ACTIVE_COMPARATOR|Maintenance Therapy: Placebo plus Phesgo|Participants will be administered the treatments as outlined in the interventions section.
62126990|NCT05198531|EXPERIMENTAL|TQB2858 Injection combining with other drugs|"Combination 1 is TQB2858 Injection and Anlotinib Hydrochloride Capsules. Combination 2 is TQB2858 Injection, Gemcitabine Hydrochloride Injection and Cisplatin Injection for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment.~Combination 3 is TQB2858 Injection, Gemcitabine Hydrochloride Injection, Cisplatin Injection and Anlotinib Hydrochloride Capsules for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment."
62126991|NCT05420090|EXPERIMENTAL|eating banana for 6 weeks before bedtime|Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime.
62126992|NCT05420090|EXPERIMENTAL|drinking milk for 6 weeks before bedtime|Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime.
62126993|NCT05420090|EXPERIMENTAL|Control|Not making any changes in diet
62126994|NCT02878772|ACTIVE_COMPARATOR|vinpocetine group|Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
62126995|NCT02878772|PLACEBO_COMPARATOR|Control group|Patients will receive aspirin only.
62126996|NCT00666445||1|Patients diagnosed with Alzheimer's Disease
62126997|NCT00666445||2|Aged-matched normal controls
62317282|NCT02241850|OTHER|High intensity training|9 weeks of supervised training
61924779|NCT01982058|EXPERIMENTAL|Intimacy-Enhancing Couples|Patients and their partners receive communication and intimacy-enhancing intervention (IEC) once a week comprising the following five 90-minute sessions: Orientation and Stories of the Cancer Experience; Communication and Listening to Partner's concerns; Communication and Coping with Cancer Issues as a Team; Being Supportive to Solve Concerns; and Reflecting on Changes and Future Adaptation.
62126998|NCT03231722|ACTIVE_COMPARATOR|mFOLFOX6 + Panitumab|"* Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~* Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with~* L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~* 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by~* 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
62317283|NCT04522427|EXPERIMENTAL|Multifocal and Extended Depth-of-Focus intraocular lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
62317284|NCT04522427|ACTIVE_COMPARATOR|Monofocal intraocular Lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
62317285|NCT02985125|EXPERIMENTAL|Phase I - Dose Level 1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 250mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
62317286|NCT02985125|EXPERIMENTAL|Phase I - Dose Level 2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 300mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
62317287|NCT02985125|EXPERIMENTAL|Phase I - Dose Level -1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 200mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
62317288|NCT02985125|EXPERIMENTAL|Phase I - Dose Level -2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 150mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
62686638|NCT06686914|ACTIVE_COMPARATOR|Cannabidiol (CBD) Oil 300mg|Cannabidiol (CBD) Oil, 300mg, 1 dose, 120 minutes prior to testing. After consumption of the respective treatment drug, the participant will be given a standardized meal and wait for 120 minutes to allow for drug absorption and for CBD to begin taking effect; this time frame was chosen based on the pharmacokinetics of CBD along with the consideration of participant burden (max absorption 2-5 hours; average half-life 17 hours).
62686639|NCT06686914|ACTIVE_COMPARATOR|Cannabidiol (CBD) Oil 150mg|Cannabidiol (CBD) Oil, 150mg, 1 dose, 120 minutes prior to testing. After consumption of the respective treatment drug, the participant will be given a standardized meal and wait for 120 minutes to allow for drug absorption and for CBD to begin taking effect; this time frame was chosen based on the pharmacokinetics of CBD along with the consideration of participant burden (max absorption 2-5 hours; average half-life 17 hours).
62697413|NCT05996120|ACTIVE_COMPARATOR|Hypothermic Cardiopulmonary Bypass|Patients allocated to this arm will undergo standard care for coronary artery bypass grafting and/or valve surgery with mild hypothermia during CPB.
62317289|NCT02985125|EXPERIMENTAL|Phase II - Dose|"Treatment cycles are 28 days long.~LEE011 (taken orally) - the recommended phase II dose Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
62317290|NCT03955848|EXPERIMENTAL|ARM 1|NK cell infusion
62317291|NCT03955848|NO_INTERVENTION|ARM 2|Follow up without treatment
62317292|NCT05074095||1|Patients with urogenital injuries
62317293|NCT05074095||2|Patients without urogenital injuries
62317294|NCT04497220|PLACEBO_COMPARATOR|Nocebo Group|Participants in this group will receive the control treatment
62317295|NCT04497220|EXPERIMENTAL|Positive Connotation Group|Participants in this group will receive the experimental treatment.
62317296|NCT05933291||COVID-19 with steroid|COVID-19 ARDS patients with steroid treatment
62317297|NCT05933291||COVID-19 without steroid|COVID-19 ARDS patients without steroid treatment
62317298|NCT05933291||non-COVID-19 with steroid|non-COVID-19 ARDS patients with steroid treatment
62317299|NCT05933291||non-COVID-19 without steroid|non-COVID-19 ARDS patients without steroid treatment
62686640|NCT06686914|PLACEBO_COMPARATOR|Placebo Oil|Placebo Oil 1 dose 120 minutes prior to testing. After consumption of the respective treatment drug/placebo, the participant will be given a standardized meal and wait for 120 minutes to allow for drug absorption and for CBD to begin taking effect; this time frame was chosen based on the pharmacokinetics of CBD along with the consideration of participant burden (max absorption 2-5 hours; average half-life 17 hours).
62686641|NCT03893916|EXPERIMENTAL|cohort|MEG - EEG HR
62686642|NCT06199830||cough variant asthma|(1) chronic cough (≥8 weeks) as the sore or predominant symptom; (2) variable airway limitation evaluated by BHR test; (3) a positive response to anti-asthma therapy; (4) No other causes of chronic cough.
62126999|NCT03231722|EXPERIMENTAL|mFOLFOXIRI + Panitumumab|"* Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~* Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by~* Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with~* L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~* 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
62127000|NCT06075069|EXPERIMENTAL|Feeding appliance immediately after birth|
62127001|NCT06075069|EXPERIMENTAL|Feeding appliance after 1-3 months|
62127002|NCT06075069|EXPERIMENTAL|Feeding appliance after 4 -12 months|
61924780|NCT01982058|ACTIVE_COMPARATOR|General Health and Wellness|Patients and their partners receive a General Health and Wellness intervention focusing on nutrition and physical activity once a week comprising of five 90-minute sessions: Introduction and Nutrition Basics; Nutrition and Prevention of Recurrence; Nutritional Review and Introduction to Relaxation; Physical Activity Basics; Aerobics and Resistance Exercises and Wrap up.
61924781|NCT01982058|OTHER|Usual Care|Patients and their partners receive standard psychological and emotional care (usual care \[UC\]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
61924782|NCT03902106|ACTIVE_COMPARATOR|beta2-agonist and exercise|Subjects undergo exercise training with administration of salbutamol (800 microgram in 12 hours x 2)
61924783|NCT03902106|SHAM_COMPARATOR|placebo and exercise|Subjects undergo exercise training with administration of sham placebo
62127003|NCT01871675|EXPERIMENTAL|Arm 1: IPI-145 plus Rituximab|"IPI-145 will be administered orally, twice daily, in 28-day (4-week) cycles, on a continuous basis at the maximum tolerated dose of 25 mg twice-daily (BID), as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
62127004|NCT01871675|EXPERIMENTAL|Arm 2: IPI-145 plus Rituximab/Bendamustine|"IPI-145 will be administered orally, twice daily, in 28 day cycles, on a continuous basis, until disease progression, unacceptable toxicity or patient refusal. The maximum tolerated dose of IPI-145 will be 25 mg twice-daily (BID) as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given. Bendamustine 90 mg/m2 IV will be administered on Days 1 and 2, of each 28 day cycle. Rituximab should be administered prior to bendamustine."
62127005|NCT04688866||Pregnant women with cervical insufficiency (Cases)|Pregnant women with a shortened (\<25 mm) or dilated cervix in the second trimester (or late first trimester)
62127006|NCT04688866||Pregnant women without cervical insufficiency (Controls)|Pregnant women with a normal-length (\>= 25 mm) and closed cervix in the second trimester (or late first trimester)
62127007|NCT00103324|EXPERIMENTAL|Treatment|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62127008|NCT04065334|EXPERIMENTAL|low dose training|
62127009|NCT04065334|ACTIVE_COMPARATOR|high dose training|
62127010|NCT05263336|ACTIVE_COMPARATOR|Intervention|Intraoperative verdye green iv administration to visualize blood supply to the anastomosis
62127011|NCT05263336|NO_INTERVENTION|Control|No administration of verdye green intraoperatively
62127012|NCT05195775|EXPERIMENTAL|Tadalafil plus BOLD-MRI (Schedule A)|The intervention is the same as in Schedule B; this arm will use BOLD-MRI as the technique to monitor drug impact on skeletal muscle.
62479445|NCT06355752|EXPERIMENTAL|Real dry needling|Subjects included in this group will receive a session with dry needling in the quadratus lumborum muscle.
62686643|NCT06199830||chronic cough|(1) chronic cough (≥8 weeks) as the sore or predominant symptom; (2) without radiographic evidence of lung disease; (3) with no fever, blood-stained sputum or other active respiratory injection;
62686644|NCT05288751|NO_INTERVENTION|Treatment as usual (TAU)|These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months.
62697414|NCT05996120|ACTIVE_COMPARATOR|Normothermic Cardiopulmonary Bypass|Patients allocated to this arm will undergo intervention care for coronary artery bypass grafting and/or valve surgery with normothermia hypothermia during CPB.
62686645|NCT05288751|EXPERIMENTAL|Attendance-only CM|Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments.
62686646|NCT05288751|EXPERIMENTAL|Attendance + abstinence CM|Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program.
62686647|NCT03355092|EXPERIMENTAL|vBloc Therapy + Usual Care for Type 2 Diabetes|
62127013|NCT05195775|EXPERIMENTAL|Tadalafil plus Doppler ultrasound (Schedule B)|The intervention is the same as in Schedule A; this arm will use Doppler ultrasound as the technique to monitor drug impact on skeletal muscle.
62686648|NCT03355092|NO_INTERVENTION|Usual Care for Type 2 Diabetes|
62686649|NCT04526457|OTHER|Standard of Care|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH and randomized to standard of care with lipid testing only.
61924784|NCT04128332|OTHER|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) delivering 35Gy in five fractions (7Gy/fraction) over 5 days.
61924785|NCT03176875|EXPERIMENTAL|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
61924786|NCT03176875|ACTIVE_COMPARATOR|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
62127014|NCT04178226|NO_INTERVENTION|Control|conventional therapy (NSAIDs and OCP)
62127015|NCT04178226|EXPERIMENTAL|Manual Acupuncture|manual acupuncture therpy
62127016|NCT04178226|EXPERIMENTAL|Laser Acupuncture|laser acupuncture therapy
62127017|NCT04581733|EXPERIMENTAL|Single Arm|Male and female Participants \<18 years
62686650|NCT04526457|OTHER|Genetic Testing|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH randomized to genetic testing
62686651|NCT04840186|ACTIVE_COMPARATOR|2nd line chhemotherapy|Patients in this arm will be receiving the standard care which is 2nd line chemotherapy. Type of chemotherapy determined by treating oncologist.
62697415|NCT04021745|EXPERIMENTAL|App-based mindful eating|The intervention will be delivered through a mindful eating smartphone application using the latest evidence-based mindful eating methods and behavior change theory.
62686652|NCT04840186|ACTIVE_COMPARATOR|2nd line chemotherapy + resection|Patients in this arm will be treated with liver resection and/or ablation at Oslo University Hospital followed by adjuvant 2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist.
61924787|NCT02236481|EXPERIMENTAL|Anakinra|100 mg of anakinra once daily by subcutaneous injection for 24 months
61924788|NCT02236481|ACTIVE_COMPARATOR|TNF alpha inhibitors|treatment with TNF-alpha inhibitors according to the relative summary of product charateristics
62127018|NCT04295993|EXPERIMENTAL|methylene blue group|The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.
62127019|NCT04295993|ACTIVE_COMPARATOR|Norepinephrine group|The patients in this group will receive norepinephrine infusion.
62127020|NCT06497855||Cases|Patients who, during general anaesthesia, will hear the 20 words and will be tested form implicit memory formation.
62127021|NCT06497855||Controls|Patients who, during general anaesthesia, will not hear the 20 words and will be tested form implicit memory formation to assess the role of chance on the tests adopted
62127022|NCT05074069||Neovaginal reconstruction|Neovaginal reconstruction post-vulvovaginal resection
62127023|NCT05074069||Flap Reconstruction|Flap closure of perineal defect post-gynaecological organ resection
62127024|NCT05074069||No reconstruction/Primary closure|Primary closure of defect post-multivisceral, gynaecological organ-involving, resection
62127025|NCT02725086|EXPERIMENTAL|Part 1; Filgrastim 5 ㎍/kg|Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
62127026|NCT02725086|EXPERIMENTAL|Part 2; Filgrastim 10 ㎍/kg|Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
61924789|NCT02467335|ACTIVE_COMPARATOR|Healthy Subjects|Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.
61924790|NCT02467335|ACTIVE_COMPARATOR|Hepatic Impaired Subjects - Mild Rating|Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
61924791|NCT02467335|ACTIVE_COMPARATOR|Hepatic Impaired Subjects - Moderate Rating|Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
62127027|NCT05989542|EXPERIMENTAL|PLB1001|Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
62127028|NCT05425992||Patients treated in CCBD|Patients who are currently receiving therapy at the Center for Cancer and Blood Disorders
62127029|NCT03014947|EXPERIMENTAL|MSB11022|
62127030|NCT03014947|ACTIVE_COMPARATOR|US-licensed Humira|
62127031|NCT03014947|ACTIVE_COMPARATOR|EU-approved Humira|
62127032|NCT05328271|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62127033|NCT05328271|ACTIVE_COMPARATOR|1500 mg L-Valine|1500 mg L-Valine
62127034|NCT05328271|EXPERIMENTAL|250 mg Beta-Aminoisobutryic Acid|250 mg Beta-Aminoisobutryic Acid
62127035|NCT05328271|EXPERIMENTAL|500 mg Beta-Aminoisobutryic Acid|500 mg Beta-Aminoisobutryic Acid
62127036|NCT05328271|EXPERIMENTAL|1500 mg Beta-Aminoisobutryic Acid|1500 mg Beta-Aminoisobutryic Acid
62127037|NCT01865149||both optic nerve sheath diameter|
62697416|NCT05326295||Breast cancer patients|
62317300|NCT03686202|EXPERIMENTAL|Group A: Safety Cohort|Subjects with advanced solid tumors already on ICI will receive treatment with MET-4 in addition to SOC ICI. MET-4 is administered orally as an initial daily loading dose (5g) of MET-4 over 2 days followed by a daily maintenance dose (1.5g) of MET-4 and will be continued until unacceptable toxicity, progression of disease
62317301|NCT03686202|EXPERIMENTAL|Group B|Eligible subjects with advanced solid tumors starting ICI will be randomised in a 3:1 ratio stratifying for prior IO exposure, to receive MET-4 together with any approved PD-1/PD-L1 inhibitor as per SOC or control group. There will be a run-in period for subjects in the MET-4 treatment group. Following the run-in period of ICI therapy, subjects will be administered the same MET-4 dose as subjects in group A.
62317302|NCT03686202|EXPERIMENTAL|Group C|In group C, eligible subjects with advanced solid tumors whom are already on ICI with first unconfirmed PD on evaluation scans per investigator's assessment, will be randomised in a 1:1 ratio to receive MET-4 in addition to the PD-1/PD-L1 inhibitor as per SOC or control group. These subjects must be clinically stable and are to be continued on ICI at the discretion of the investigator. There will be no run-in period for this cohort. Subjects will be administered the same MET-4 dose as subjects in groups A and B.
62317303|NCT03686202|EXPERIMENTAL|Group D|In group D, eligible subjects with stage III or resected stage IV melanoma who are to start adjuvant ICI, will be randomized in a 1:1 ratio to receive MET-4 in addition to anti-PD1 antibody +/- anti-CTLA4 antibody as per SOC or control group. Patients will be stratified per BRAF mutation status. Subjects will be administered the same MET-4 dose as subjects in groups A, B and C. MET-4 will be initiated as run-in for a minimum of 1 week, and maximum of 2 weeks before ICI administration. MET-4 will be continued until unacceptable toxicity, confirmed PD by RECIST v1.1 or completion of 1 year of ICI, whichever occurs earlier. Subjects in the control arms of groups B, C and D will be treated with ICI therapy as per institution standard of care without MET-4.
62317304|NCT05135975|EXPERIMENTAL|Cabozantinib|Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day, to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
62317305|NCT00843622|EXPERIMENTAL|1|Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants
62686653|NCT06391086|EXPERIMENTAL|Treatment with tFUS|Treatment with tFUS
62686654|NCT04392570||Fasting group|patients with type 2 diabetes who prefer to fast during Ramadan
61924792|NCT02467335|ACTIVE_COMPARATOR|Hepatic Impaired Subjects - Severe Rating|Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
62127038|NCT03573518|EXPERIMENTAL|BTX 1503 5% BID|BTX 1503 5% CBD (w/w) solution twice daily
62127039|NCT03573518|EXPERIMENTAL|BTX 1503 5% QD|BTX 1503 5% CBD (w/w) solution once daily
62127040|NCT03573518|EXPERIMENTAL|BTX 1503 2.5% QD|BTX 1503 2.5% CBD (w/w) solution once daily
62127041|NCT03573518|PLACEBO_COMPARATOR|Vehicle BID|Vehicle twice daily
62127042|NCT03573518|PLACEBO_COMPARATOR|Vehicle QD|Vehicle once daily
62127043|NCT01028118|OTHER|Therapy for Women reporting violence|Asking about life experience with violence and Cognitive Behavior Therapy.
62127044|NCT00226018|ACTIVE_COMPARATOR|1|Acceleromyography with Hand Adapter on dominant arm
62127045|NCT00226018|ACTIVE_COMPARATOR|2|Acceleromyography with Hand Adapter on non-dominant arm
62127046|NCT00226018|PLACEBO_COMPARATOR|3|Acceleromyography without Hand Adapter on dominant arm
62127047|NCT00226018|PLACEBO_COMPARATOR|4|Acceleromygraphy without Hand Adapter on non-dominant arm
62127048|NCT01608347|EXPERIMENTAL|LMWH + Folic acid group|Daily 40 mg of enoxaparin (LMWH) (Clexane, Sanofi Aventis, Paris, France)subconsciously started once positive pregnancy test. Treatment will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tab once/daily until 13 weeks' of gestation.
62479446|NCT06355752|SHAM_COMPARATOR|Sham dry needling|Subjects included in this group will receive a session with sham dry needling in the quadratus lumborum muscle.
62686655|NCT04392570||Non-fasting group|patients with type 2 diabetes who are otherwise healthy and have no contraindications for fasting but prefer not to fast
62686656|NCT01485198|ACTIVE_COMPARATOR|Control|Patients treated with Acetaminophen
62127049|NCT01608347|ACTIVE_COMPARATOR|Folic acid|500 microgram folic acid tab/day started once positive pregnancy test and will be continued until 13 weeks' of gestation.
62127050|NCT06518668|EXPERIMENTAL|NKX019 infusion|Subjects with SLE will receive cyclophosphamide LD followed by NKX019.
62127051|NCT05107024|ACTIVE_COMPARATOR|Traditional balloon dilation group|The optimal size of the semi-compliant balloon (balloon to vessel ratio 1.0) was determined by the surgeon according to angiography, and sufficient predilation was performed to achieve residual stenosis. 30% vascular anatomy criteria, and then a 1:1 DCB was selected for drug release
61924793|NCT06468969|EXPERIMENTAL|Enhanced Follow-up Group|"Participants in this group will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment: Comprehensive evaluation of symptoms. Nutritional Assessment: Using internationally recognized tools such as NRS 2002 and PG-SGA.~Psychological Assessment: Utilizing tools such as the Distress Thermometer (DT), Generalized Anxiety Disorder 7-item scale (GAD-7), Fear of Cancer Recurrence 7-item scale (FCR-7), Insomnia Severity Index (ISI), and the Patient Health Questionnaire 9-item depression scale (PHQ-9)."
61924794|NCT06468969|ACTIVE_COMPARATOR|Standard Follow-up Group|Participants in this group will receive standard postoperative follow-up care, which includes medical examinations and treatments as necessary. Nutritional and psychological assessments will only be conducted if deemed necessary by the patient or the healthcare provider. This group will serve as the control group for comparison with the enhanced follow-up group.
61924795|NCT05468385|EXPERIMENTAL|Tragus stimulation|Vagus nerve stimulation via tragus
61924796|NCT05468385|SHAM_COMPARATOR|Sham stimulation|Sham stimulation via earlobe
61924797|NCT03509467|EXPERIMENTAL|Intervention Group A|"Intervention Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
62479447|NCT02231840||Not treatment-seeking participants|Individuals who meet current or past DSM 5 criteria for AUD but are not seeking treatment. Healthy volunteers and other volunteers.
61924798|NCT03509467|EXPERIMENTAL|Intervention Group B|"Intervention Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
61924799|NCT03509467|PLACEBO_COMPARATOR|Control Group A|"Control Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
62479448|NCT02231840||Treatment-seeking Patients|Individuals who meet current DSM 5 criteria for AUD and are seeking treatment for it.
62686657|NCT01485198|EXPERIMENTAL|Experimental|Patients who underwent a BMASC extraction and joint infusion
62686658|NCT03686982|EXPERIMENTAL|Active Nitrate Bar|include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
61924800|NCT03509467|PLACEBO_COMPARATOR|Control Group B|"Control Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
61924801|NCT04549324||Sleep Apnea (AHI ≥ 15 per hour)|Patients with moderate/severe sleep apnea (Apnea/hypopnea-index ≥ 15 per hour).
61924802|NCT04549324||Non-Sleep Apnea (AHI < 5 per hour)|Patients without sleep apnea (Apnea/hypopnea-index \< 5 per hour).
62479449|NCT03249454|EXPERIMENTAL|Anode, then Cathode, then Anode, then Sham, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479450|NCT03249454|EXPERIMENTAL|Sham, then Cathode, then Anode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62686659|NCT03686982|PLACEBO_COMPARATOR|Placebo Bar|Containing no active ingredients
62686660|NCT01827306|ACTIVE_COMPARATOR|Biofreeze|Apply 5 minutes before therapy by applying a small coin sized amount to the painful area. Subjects will then complete a standard shoulder therapy program.
62686661|NCT01827306|NO_INTERVENTION|Control|Subjects in this arm will complete a standard shoulder therapy program as normal, with no intervention.
62686662|NCT04682691|SHAM_COMPARATOR|Group (C)|will be receive flavored water in total volume 15 ml
62317306|NCT00843622|PLACEBO_COMPARATOR|2|Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants
62317307|NCT02033980|OTHER|colorectal lesions|All lesions will be observed with NBI and removed endoscopically or surgically for histological diagnosis.
62317308|NCT03605134||study group|level of cardiac troponin and diastolic function assessment by means of transthoracic echocardiography
62317309|NCT05181917|EXPERIMENTAL|Intervention|Patients assigned to the intervention group will receive the STUDIA application on their mobile device, which has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
62317310|NCT05181917|ACTIVE_COMPARATOR|Control|The patients assigned to the control group will also receive the STUDIA application on their mobile devices. The insulin dose calculation process is the same as that described for the intervention group. However, the simulation results will be kept hidden from the patient.
62479451|NCT03249454|EXPERIMENTAL|Anode, then Cathode, then Sham, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479452|NCT03249454|EXPERIMENTAL|Cathode, then Anode, then Cathode, then Anode, then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479453|NCT03249454|EXPERIMENTAL|Anode, then Anode, then Sham, then Cathode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479454|NCT03249454|EXPERIMENTAL|Sham, then Anode, then Cathode, then Cathode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479455|NCT03249454|EXPERIMENTAL|Cathode, then Anode, then Cathode, then Sham, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479456|NCT03249454|EXPERIMENTAL|Sham, then Anode, then Cathode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479457|NCT03249454|EXPERIMENTAL|Cathode, then Cathode, then Sham, then Anode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479458|NCT03249454|EXPERIMENTAL|Anode, Then Cathode, Then Anode, Then Cathode Then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62127052|NCT05107024|EXPERIMENTAL|RFR-guided step by step balloon dilation group|Balloon dilation start with 2.0mm compliant balloon. After 8atm pressure expansion, the RFR value was measured. If RFR≥0.93, the pre-expansion was stopped. Otherwise, RFR value is measured after pressure expansion of 16atm, if RFR value is still less than 0.93, then a 2.5mm compliant or non-compliant balloon was used to expand the pressure of 8ATM, and the balloon diameter and expansion pressure were continuously increased until RFR≥0.93. Then a DCB with the same diameter as the pre-expanded balloon was selected for drug release.
62127053|NCT00566124|ACTIVE_COMPARATOR|1|Insulin detemir
62686663|NCT04682691|ACTIVE_COMPARATOR|Group (M)|will be receive 10 ml of oral metoclopramide (10mg)
61924803|NCT02808091|EXPERIMENTAL|Early stage (IB or bulky disease - II)|who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
62127054|NCT00566124|ACTIVE_COMPARATOR|2|Insulin glargine
62686664|NCT04682691|ACTIVE_COMPARATOR|Group (E)|will be receive 10 ml of oral Erythromycin (400mg)
61924804|NCT02808091|EXPERIMENTAL|Advanced stage (III - IV)|will receive only chemotherapy alone
62127055|NCT00566124|ACTIVE_COMPARATOR|3|NPH insulin
62127056|NCT04508348|ACTIVE_COMPARATOR|Exclusive Human Milk|Group One will receive an exclusive human milk diet throughout the 28-day feeding period or until hospital discharge
62127057|NCT04508348|OTHER|Maternal human milk or Formula|Group Two (Control Group) will receive maternal human milk or formula (per standard of care).
62127058|NCT03926936|EXPERIMENTAL|Low-grade uterine sarcoma|Participants with low-grade uterine sarcoma
62127059|NCT03926936|EXPERIMENTAL|low-grade endometrial carcinoma|Participants with low-grade endometrial carcinoma
62127060|NCT03926936|EXPERIMENTAL|sex cord stromal tumors|Participants with sex cord stromal tumors
62317311|NCT02124720|EXPERIMENTAL|Mobile application|Use of the iSTIM mobile application 2 to 4 times per week over approximately 8 to 16 weeks
62317312|NCT04846153|OTHER|Human-based Quantification|No intervention. No support tool will be used for quantifying airway stenosis from the bronchoscopic images collected previously.
62317313|NCT04846153|ACTIVE_COMPARATOR|Computer-based Quantifiction|Computer based support tool will quantifying airway stenosis from the bronchoscopic images collected previously.
62317314|NCT02615106|EXPERIMENTAL|Endostar Combined With Radiotherapy|Drug: Endostar Endostar 7.5 mg/m2/day, day 1-14 Radiation: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
62317315|NCT03887637||Danoprevir Sodium triple therapy|"DNV(Danoprevir Sodium)/PegIFNα(Peginterferon α-2a)/RBV(Ribavirin) : (1) DNV : 100mg (one tablet) orally twice daily for 12 weeks. (2) PegIFNα: 180ug subcutaneous infection on abdomen or thigh once a week for 12 weeks. (3) RBV: 500mg (5 tablets) orally twice daily for 12 weeks in patients weighing less than 75kg; 600mg (6 tablets) orally twice daily for 12 weeks in patients weighing ≥75kg.~Dosing time: In the morning, participants will be instructed to take DNV and RBV with food or one hour after food. The drugs are not allowed to be cut or divided. The interval between DNV and RBV dosing time should be 12±2 hours."
62317316|NCT03887637||Sofosbuvir/ Velpatasvir therapy|Sofosbuvir/ Velpatasvir :500mg (two drugs in one tablet) orally once daily for 12 weeks.
62317317|NCT03887637||Ombitasvir/Paritaprevir therapy|Ombitasvir/Paritaprevir: Ombitasvir two tablets orally once daily for 12 weeks; Paritaprevir one tablet orally twice daily for 12 weeks.
62317318|NCT03887637||Grazoprevir/elbasvir therapy|Grazoprevir/elbasvir: 150mg (two drugs in one tablet) orally once daily for 12 weeks.
62317319|NCT03887637||Daclatasvir/Asunaprevir therapy|Daclatasvir (60mg)one tablet once daily and Asunaprevir (100mg)one tablet twice daily for 24weeks
62317320|NCT03887637||Danoprevir Sodium/Sofosbuvir therapy|Danoprevir Sodium: 100mg (one tablet) orally twice daily for 12 weeks;Sofosbuvir:400mg (one tablet) orally once daily for 12 weeks.
62317321|NCT01816646|EXPERIMENTAL|Cidofovir|Patients receive a single dose of 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours. Probenecid 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
62317322|NCT00716729||Pateints with longstanding hip and/groin pain|
62317323|NCT05649124|EXPERIMENTAL|Acupressure group|"* Participants in this group will be interviewed at postpartum 3rd and 5th hours. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS and McGill Pain Questionnaire, which will be applied to evaluate perineal pain at the 3rd and 5th hours of the postpartum period, will be filled in by the participant.~* In a total application where SP6, ST36 and LI4 points will be applied for 2 minutes, the total time will be 12 minutes.~* After the application, the VAS and McGill Pain Questionnaire Evaluating Perineal Pain will be filled in by the participant.~* The participant will be informed that the study has been completed."
62317324|NCT05649124|NO_INTERVENTION|Control group|"* Participants in this group will be interviewed at postpartum 3rd and 5th hours. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* 3. VAS (Visual analog scale) and McGill Pain Questionnaire for Evaluating Perineal Pain will be required at 5th and 5th hours.~* No application will be made other than routine applications."
62317325|NCT01272271||Children|
62317326|NCT01272271||Adults|
62317327|NCT05099757|EXPERIMENTAL|20 µg at month 0, months 0, 1 or 0, 1, and 6|20 µg recombinant hepatitis B vaccine with one, two or three injections at month 0, months 0, 1 or 0, 1, and 6
62479459|NCT03249454|EXPERIMENTAL|Sham, Then Anode, Then Anode, Then Cathode, Then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
62479460|NCT03285594|PLACEBO_COMPARATOR|Placebo|Following a 4-week run-in period, participants were randomized to matching placebo to sotagliflozin 200 milligrams (mg) administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
62127061|NCT03926936|EXPERIMENTAL|low-grade serous ovarian cancer|Participants with low-grade serous ovarian cancer
62127062|NCT05344924|EXPERIMENTAL|Cohort I（TACE-A-A Cohort）|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
62127063|NCT05344924|EXPERIMENTAL|Cohort II (A-A Cohort)|Patients will receive penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
62127064|NCT06502275|EXPERIMENTAL|Nutrition combined with exercise group|Provide mobile health interventions that combine nutrition and exercise
62317328|NCT05064995||Patients|Patients with the Diagnosis of a Bipolar Disorder
62317329|NCT05064995||Healthy Controls|Individuals with no diagnosis of Bipolar Disorder
62317330|NCT05061225|EXPERIMENTAL|Intervention|Participants invited to the private Facebook group
62317331|NCT05061225|NO_INTERVENTION|Waiting list|Waiting list. Will be invited to Facebook group after finalising the study and will receive same intervention.
62697417|NCT05681481|EXPERIMENTAL|efgartigimod PH20 SC|participants receiving efgartigimod PH20 SC on top of Prednisone
62697418|NCT00977444|EXPERIMENTAL|kondrium|intraarticular injections once month
62127065|NCT06502275|NO_INTERVENTION|routine care group|Provide routine care
62317332|NCT06014905|EXPERIMENTAL|Hyperpolarized 13C pyruvate, Magnetic Resonance Imaging|Participants will receive a single research MR imaging using HP 13C pyruvate, intravenously injected at a rate of 5 ml/second followed by a 20-ml saline flush at 5 ml/second. Safety monitoring, including vital signs and symptom monitoring will be performed for 30 minutes after dosing is completed, 1 to 3 days after dosing, and up to 30 days post scanning procedure. During the follow-up period, study personnel will obtain clinical data from the participants' medical records.
62317333|NCT06672770|EXPERIMENTAL|Functional Inspiratory Muscle Training Group|The functional inspiratory muscle training (FIMT) group (n=21) will receive basic inspiratory muscle training (IMT) with a device capable of delivering threshold pressure loading (POWERbreathe) for the first four weeks. The first, middle and last sessions of the week will be supervised (face-to-face) and other sessions will be unsupervised (at home, twice a day, totaling 30 minutes). The intensity of inspiratory muscle training will be adjusted to 50-60% of maximal inspiratory pressure and these measurements will be repeated at the beginning of each week and weekly pressure increases will be adjusted. After the first four weeks are completed, then inspiratory muscle training will be combined with exercises at the beginning of the fifth week, and participants will perform supervised in-person FIMT three days per week for four weeks and unsupervised home IMT on the remaining days.
62127066|NCT06103149|EXPERIMENTAL|MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems
62317334|NCT06672770|EXPERIMENTAL|Basic Inspiratory Muscle Training Group|Basic inspiratory muscle training (IMT) group (n=21) will be given IMT with a device capable of performing threshold pressure loading (POWERbreathe Classic Light Resistance, PowerBreath, IMT Technologies Ltd, Birmingham, UK) for eight weeks. The first day of the week, the middle of the week and the last session will be supervised (face-to-face), and the other sessions will be unsupervised (at home, twice a day, 30 minutes in total). The intensity of inspiratory muscle training will be adjusted to be 50-60% of the maximal inspiratory pressure, and these measurements will be repeated at the beginning of each week and weekly pressure increases will be adjusted.
62317335|NCT06672770|NO_INTERVENTION|Control Group|"Participants in the control group (n=21) will be informed about the benefits of at least 150-300 minutes of moderate intensity or 75-150 minutes of vigorous intensity aerobic physical activity and breathing exercises per week and exercise recommendations will be given. Both daily physical activities and breathing exercises will be monitored with a pre-prepared exercise tracking form. Participants will be called to the laboratory for clinical measurements at the beginning and end of the study.~Participants in the control group will be taught to do diaphragmatic breathing, thoracic expansion, pursed lip breathing and breath control breathing exercises for 20 minutes a day and will be given as home exercises without supervision, with 1-2 minutes of rest between each exercise."
62317336|NCT04895059|EXPERIMENTAL|Group A: Rosuvastatin / Ezetimibe fixed dose|In fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg / 10 mg Administration way: oral
62479461|NCT03285594|EXPERIMENTAL|Sotagliflozin 200 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
62479462|NCT03285594|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
62686665|NCT04349371|EXPERIMENTAL|CQ group|Participants will receive CQ supply for 3 months. Patients will receive a supply of 36 -- 250 mg tabs or placebo that will last 3 months (enough for taking two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
62686666|NCT04349371|PLACEBO_COMPARATOR|Placebo group|Participants will receive placebo supply for 3 months. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
62686667|NCT06225037|EXPERIMENTAL|Group 1: EEG Monitoring|EEG sensor placed with the EEG monitored.
61924805|NCT05965297|EXPERIMENTAL|DeltaFil|Class II restorations are placed in primary molars after conventional cavity preparation.
61924806|NCT05965297|ACTIVE_COMPARATOR|Riva Self Cure HV|Class II restorations are placed in primary molars after conventional cavity preparation.
61924807|NCT02424214|EXPERIMENTAL|Ca Ionophore group|Artificial Oocyte activation with Ca Ionophore for 20 min after Intracytoplasmic Sperm Injection
62127067|NCT06103149|NO_INTERVENTION|Waitlist control group|
62317337|NCT04895059|ACTIVE_COMPARATOR|Group B: Rosuvastatin (Crestor®)|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
62317338|NCT04895059|ACTIVE_COMPARATOR|Group C: Ezetimibe (Ezetrol®)|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration wat: Oral
62317339|NCT04648878|EXPERIMENTAL|Group A - Hybrid combination|Group A (n=12) will receive 18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks.
62479463|NCT02642042|EXPERIMENTAL|Treatment (trametinib, docetaxel)|Patients receive trametinib PO on days 1-21. Patients also receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62479464|NCT00350389|EXPERIMENTAL|1|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
61924808|NCT02424214|EXPERIMENTAL|Strontium Chloride group|Artificial Oocyte activation with Strontium Chloride for 60 min after Intracytoplasmic Sperm Injection
61924809|NCT02424214|NO_INTERVENTION|Only Intracytoplasmic Sperm Injection|after Intracytoplasmic Sperm Injection Oocytes will cultured and incubated
62317340|NCT04648878|EXPERIMENTAL|Group B - Powered Exoskeleton only|Group B (n=12) will receive 18 visits of powered exoskeleton only, three times a week for approximately 6 weeks.
62479465|NCT00350389|NO_INTERVENTION|2|Usual care, updated multifocal glasses if required
62479466|NCT06517719||Lutetium (177Lu) vipivotide tetraxetan|Patients with mCRPC initiating lutetium (177Lu) vipivotide tetraxetan
61924810|NCT04087928|EXPERIMENTAL|Group Flexors (A)|Group A was treated by applying FMV to the flexor muscles of the upper limb (brachial biceps and carpal flexors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
62479467|NCT00840866|EXPERIMENTAL|1|
62686668|NCT06225037|ACTIVE_COMPARATOR|Group 2: Standard Care|EEG sensor placed with the output concealed.
62697419|NCT00977444|EXPERIMENTAL|kondrium f|
62697420|NCT00977444|ACTIVE_COMPARATOR|corticosteroid|intraarticular injections once month
62317341|NCT04648878|EXPERIMENTAL|Group C - Physical Therapy only|Group C (n=12) will receive 18 visits of physical therapy, three times a week for approximately 6 weeks. Upon completion of the data collection portion of the study, group C will receive 9 sessions, three times a week for approximately three weeks of powered exoskeleton therapy. Data will not be collected or reported during this phase, but but may be retained for future approved use.
62317342|NCT06097936||HPV Patients|
62317343|NCT06565338||group A|dexmedetomidine 0.4 mic/kg loading dose then 0.25 mic/kg/hr for 5 days
62317344|NCT06565338||group B|vitamin D 100.000 IU given IM once
62317345|NCT04281537||Patient with Fabry Disease on Enzyme Replacement Therapy (ERT)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase alfa or agalsidase beta)
62317346|NCT04281537||Caregiver|Caregiver of patient with Fabry Disease on Enzyme Replacement Therapy (ERT)
62317347|NCT05331664|ACTIVE_COMPARATOR|Group 1|"* Subconjunctival antibiotic (cefazolin 50 mg/0.5 mL, moxifloxacin 0.5 mg/0.1 mL, or vancomycin 1 mg/0.1 mL) and subconjunctival dexamethasone (4 mg/mL) at the time of surgery~* Topical atropine 1% and antibiotic-steroid ointment (neomycin-polymyxin B-dexamethasone) at the time of surgery~* Topical moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin; 4 times per day for 1 week after surgery.~* Topical prednisolone 1% 1 drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper)~* Topical atropine 1% daily for 1 week"
62479468|NCT00840866|ACTIVE_COMPARATOR|2|
61924811|NCT04087928|EXPERIMENTAL|Group Extensors (B)|Group b was treated by applying FMV to the extensors muscles of the upper limb (triceps brachial and carpus extensors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
62127068|NCT05382104|EXPERIMENTAL|Sequence 1: Treatment A + Treatment B + Treatment C|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 under fasting condition (Treatment A), followed by maribavir single 400 mg tablet, on Day 1 of Period 2. administered with a low fat/low calorie meal (Treatment B), and further followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of minimum of 72 hours between each ID dosing.
62127069|NCT05382104|EXPERIMENTAL|Sequence 2: Treatment A + Treatment C + Treatment B|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 under fasting condition (Treatment A), followed by maribavir single 400 mg tablet on Day 1 of Period 2 administered with a high fat/high calorie meal (Treatment C), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a low fat/low calorie meal (Treatment B). There will be a washout period of minimum of 72 hours between each ID dosing.
62127070|NCT05382104|EXPERIMENTAL|Sequence 3: Treatment B + Treatment A + Treatment C|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a low fat/low calorie meal (Treatment B), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 under fasting condition (Treatment A), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of minimum of 72 hours between each ID dosing.
62127071|NCT05382104|EXPERIMENTAL|Sequence 4: Treatment B + Treatment C + Treatment A|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a low fat/low calorie meal (Treatment B), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 administered with a high fat/high calorie meal (Treatment C), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 under fasting condition (Treatment A). There will be a washout period of minimum of 72 hours between each ID dosing.
62317348|NCT05331664|ACTIVE_COMPARATOR|Group 2|"* Subtenon triamcinolone acetonide (40 mg/1mLl) at the time of surgery~* Subconjunctival antibiotic (cefazolin 50 mg/0.5 mL, moxifloxacin 0.5 mg/0.1 mL, or vancomycin 1 mg/0.1 mL) and subconjunctival dexamethasone (4 mg/mL) at the time of surgery~* Topical atropine 1% and antibiotic-steroid ointment (neomycin-polymyxin B-dexamethasone) at the time of surgery~* No postoperative eye drops"
62317349|NCT02572661|OTHER|Squamous Head and Neck Cancer|radiation
62317350|NCT06511869|EXPERIMENTAL|AZD4205 treatment|"Cohort 1: Participants achieving a CR as assessed by the investigator according to Lugano criteria following the first-line systemic therapy.~Cohort 2: Participants achieving a PR as assessed by the investigator according to Lugano criteria following the first-line systemic therapy."
62317351|NCT06337851|ACTIVE_COMPARATOR|Simultaneous burr hole craniostomy (Group-1)|Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
62479469|NCT06307431|EXPERIMENTAL|V940 + Pembrolizumab|Participants will receive V940 1 mg via intramuscular (IM) injection every 3 weeks (Q3W) for up to 9 doses plus Pembrolizumab 400 mg via an intravenous (IV) infusion every 6 weeks (Q6W) for 9 cycles (up to \~54 weeks). Each cycle is 6 weeks.
62479470|NCT06307431|ACTIVE_COMPARATOR|Placebo + Pembrolizumab|Participants will receive placebo as an IM injection Q3W for up to 9 doses plus Pembrolizumab 400 mg via an IV infusion Q6W for 9 cycles (up to \~54 weeks). Each cycle is 6 weeks.
62479471|NCT02632864|EXPERIMENTAL|Proton arm|Proton beam therapy
62479472|NCT05239585|EXPERIMENTAL|Remote EEG monitoring|All subjects will pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
62686669|NCT06286072|EXPERIMENTAL|Training and Message Group|"Patients in this group were given training for 3 consecutive days during their stay in the hospital.~Day 1: general information about the disease, medication use Day 2: Physiology of fatigue, factors causing fatigue, and the relationship between COPD and fatigue.~Day 3 Strategies to cope with fatigue (Breathing exercises, good thinking, etc.)~Patients were messaged twice a week after they were discharged. Message sent for 8 weeks. Short, motivating and reminder messages were used. For example;~* When I can control my shortness of breath, my fatigue level decreases significantly.~* Excessive thinking and stress lead to more fatigue. That's why I stay away from negative thoughts.~At the baseline and 8th weeks, the patients were interviewed again and their dyspnea and fatigue levels were measured again."
62686670|NCT06286072|EXPERIMENTAL|Training Group|"Patients in this group were given training for 3 consecutive days during their stay in the hospital.~Day 1: general information about the disease, medication use Day 2: Physiology of fatigue, factors causing fatigue, and the relationship between COPD and fatigue.~Day 3 Strategies to cope with fatigue (Breathing exercises, good thinking, etc.)~No other treatment was performed on these patients.~At the baseline and end of 8 weeks, the patients were interviewed again and their dyspnea and fatigue levels were measured again."
62686671|NCT06286072|ACTIVE_COMPARATOR|Routine Treatment and Care Group|"These patients received routine treatment and care in the clinic. No training was given. Message not sent.~At the baseline and 8th weeks, the patients were interviewed again and their dyspnea and fatigue levels were measured again."
62686672|NCT01722643|EXPERIMENTAL|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
62686673|NCT01722643|ACTIVE_COMPARATOR|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
62686674|NCT06679127||Newborn|Newborn is sleeping in the bed monitoring device for two hours
62686675|NCT06679127||Parents|Parents of the newborns participating in the study.
62686676|NCT06679127||Healthcare professionals|Healthcare professionals participating in newborn care.
62686677|NCT01564329|EXPERIMENTAL|endostar2|CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
62686678|NCT01564329|EXPERIMENTAL|endostar1|CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
62686679|NCT06663969|EXPERIMENTAL|Temporal Interference|The investigators performed temporal interference (TI) stimulation to patients with drug-resistant epilepsy undergoing SEEG monitoring. They observed electrophysiological activity and clinical manifestations before, during, and after stimulation to investigate the electrophysiological mechanisms of TI.
62686680|NCT04063462|EXPERIMENTAL|Cohort 1|Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC
62686681|NCT04063462|EXPERIMENTAL|Cohort 2|Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC
62686682|NCT05518162|EXPERIMENTAL|women receiving InBloom app|
62686683|NCT05518162|ACTIVE_COMPARATOR|women receiving ROSE as usual|
62686684|NCT05518162|NO_INTERVENTION|historical controls- no treatment|We will capitalize on data from a large ROSE trial which consists of a demographically similar sample by comparing depression diagnosis outcomes for Inbloom and ROSE to the 96 participants in the care as usual group (an educational pamphlet on PPD).
62686685|NCT05518162|NO_INTERVENTION|electronic health record utilization data|We will leverage EHR utilization data by retrospectively identifying 152 people from the same clinics who did not receive ROSE or InBloom and matched for eligibility criteria, demographics and PPD risk factors using propensity scores, and comparing their utilization to those in the ROSE and InBloom groups.
61924812|NCT06084728||Pregnant women|30 pregnant women.
61924813|NCT06084728||Non-pregnant women|30 non pregnant women as control group
62479473|NCT03909607|ACTIVE_COMPARATOR|SDK 0.75 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 0.75mg/k
61924814|NCT06404424||Baseline therapy|Patients of group one received standard treatment according to Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021, without the use of blood purification methods.
62479474|NCT03909607|ACTIVE_COMPARATOR|SDK 1.0 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.0mg/k
62686686|NCT01689688||EES-XIENCE V|Groups who were treated with XIENCE V® everolimus eluting stent
62686687|NCT06637670|EXPERIMENTAL|The experimental group|This group was applied 'Y shaped' kinesiology taping on quadriceps femoris muscle, based on facilitation technique with 25-50% stretching.
62686688|NCT06637670|PLACEBO_COMPARATOR|The placebo group|This group was applied a tape without tension, perpendicular to the quadriceps femoris muscle
62686689|NCT02067598|EXPERIMENTAL|Scapular exercise|The participants will receive thirty minutes session of scapular exercise for 12 sessions
62686690|NCT02067598|NO_INTERVENTION|Control|
62686691|NCT06691230||Flat-panel detector computed tomography perfusion imaging, FDCTP|Potential clinical use of FDCTP acquired during or shortly after the endovascular stroke treatment
62686692|NCT02695771|EXPERIMENTAL|Mitomycin C|Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
62686693|NCT02695771|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
62686694|NCT02695771|NO_INTERVENTION|No intervention|Patients randomized to this arm will receive no intervention intravesicular immediately following TURBT one time.
62686695|NCT05198661|OTHER|Paraneoplastic neurological syndrome patients and autoimmune encephalitis patient|patients with diagnosis of paraneoplastic neurological syndrome or autoimmune encephalitis
62686696|NCT03318393|ACTIVE_COMPARATOR|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
62686697|NCT03318393|EXPERIMENTAL|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
62686698|NCT02478749|EXPERIMENTAL|Infant|patients aged younger than 1year
62686699|NCT02478749|EXPERIMENTAL|Child|patients aged 1year to 5years
62686700|NCT02478749|EXPERIMENTAL|Adult|adult patients
62686701|NCT04095026||Patients|Patients age \>18 years and \<= 65 years enrolled in 11-N-0051 Epilepsy Surgery
62686702|NCT00389480|EXPERIMENTAL|I|Dose escalating
62127072|NCT05382104|EXPERIMENTAL|Sequence 5: Treatment C + Treatment A + Treatment B|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 under fasting condition (Treatment A), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a low fat/low calorie meal (Treatment B). There will be a washout period of minimum of 72 hours between each ID dosing.
62479475|NCT03909607|ACTIVE_COMPARATOR|SDK 1.5 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.5mg/k
62479476|NCT01505933|ACTIVE_COMPARATOR|dexmedetomidine|
62686703|NCT04190446|EXPERIMENTAL|Arm I (proton beam radiation therapy)|Patients undergo proton beam radiation therapy 5 days a week over 3 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study.
62686704|NCT04190446|EXPERIMENTAL|Arm II (IMRT)|Patients undergo IMRT 5 days a week over 5 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study.
62686705|NCT01103115|PLACEBO_COMPARATOR|Placebo|Subjects in this group will take the placebo tablets
62686706|NCT01103115|ACTIVE_COMPARATOR|Ca600mg+VitD400IU|subjects receive a daily dose of 600 mg elemental calcium and 400 IU vitamin D3
62479477|NCT01505933|ACTIVE_COMPARATOR|propofol|
62686707|NCT01103115|ACTIVE_COMPARATOR|Ca600mg+VitD800IU|subjects receive a daily dose of 600 mg elemental calcium and 800 IU vitamin D3
62686708|NCT02644057|ACTIVE_COMPARATOR|M-group|Will be given milrinone as an intravenous infusion at 0.2-0.6 mcg/kg/min for a maximum period of 72 hours and adjusted based on creatinine clearance measured by cockcroft-gault equation. It would be titrated based on hemodynamic response , urine output and at the discretion of the treating physician
62686709|NCT02644057|ACTIVE_COMPARATOR|D-group|Will be given dobutamine as an intravenous infusion at a maximum rate of 20 mcg/kg/min depending on patient tolerance and would adjusted based on hemodynamic response, urine output and at the discretion of treating physician
62686710|NCT03457415||Healthy Cohort|Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
62686711|NCT03457415||High-risk Cohort|High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
62686712|NCT03457415||Cancer Cohort|Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
62686713|NCT06029166|OTHER|Hematologic malignancy patients requiring a treatment by Bruton's tyrosine kinase inhibitor|Consecutive adult patients with a definite diagnosis of hematologic malignancy requiring a treatment by Bruton's tyrosine kinase (BTK) inhibitor (ibrutinib, acalabrutinib, zanubrutinib) during at least 12 months will be included to receive an insertable subcutaneous cardiac monitor (ISCM).
62686714|NCT03340935|EXPERIMENTAL|Fasting mimicking diet|Fasting mimicking diet (FMD)
62686715|NCT05823441|PLACEBO_COMPARATOR|OS group|Half an hour after the volunteers inhaled 24 units of oxytocin spray, they watched the pre recorded video (attached with pictures and introductions of strangers) and underwent a pain test.
62686716|NCT05823441|PLACEBO_COMPARATOR|PS group|Half an hour after the volunteers inhaled the same amount of saline spray, they watched the pre recorded video (with pictures and introductions of strangers attached) and received a pain test.
62317352|NCT06337851|ACTIVE_COMPARATOR|Consecutive burr hole craniostomy (Group-2)|In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated.
62317353|NCT04982614|EXPERIMENTAL|2-dose regimen group|Boys and girls (aged 9-14 years) and young women (aged 15-26 years) living with HIV will receive a two-dose regimen of the HPV vaccine at baseline (Month 0) and Month 6.
62317354|NCT04982614|ACTIVE_COMPARATOR|3-dose regimen group (SOC)|HIV-uninfected young women (aged 15-26 years) will receive the standard of care three-dose regimen of the HPV vaccine at baseline (Month 0), Month 2 and Month 6.
62317355|NCT01937208|EXPERIMENTAL|high-dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
62317356|NCT01937208|ACTIVE_COMPARATOR|standard dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
62317357|NCT04457726|EXPERIMENTAL|Recipients with severe COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have severe COVID-19.
62317358|NCT04457726|EXPERIMENTAL|Recipients with mild to moderate COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have mild to moderate COVID-19.
62317359|NCT03332004|EXPERIMENTAL|Indocyanine Green arm|All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged
62317360|NCT05262595|EXPERIMENTAL|Arm 1|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
62317361|NCT05262595|EXPERIMENTAL|Arm 2|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
62317362|NCT05262595|EXPERIMENTAL|Arm 3|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
62686717|NCT05823441|EXPERIMENTAL|OA group|Half an hour after the volunteers inhaled 24 units of oxytocin spray, they watched the pre recorded video (attached with pictures and introductions of acquaintances) and underwent a pain test.
62127073|NCT05382104|EXPERIMENTAL|Sequence 6: Treatment C + Treatment B + Treatment A|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 administered with a low fat/low calorie meal (Treatment B), and followed by maribavir single 400 mg tablet on Day 1 of Period 3 under fasting condition (Treatment A). There will be a washout period of minimum of 72 hours between each ID dosing.
62317363|NCT05262595|ACTIVE_COMPARATOR|Arm 4|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
62317364|NCT05638711||Before group|"* Patient: ICU patients received CVVH between 2019/01/01 - 2020/10/01 (before utilization of built-in calculator)~* received regular protocol of ICU patient care (same in two groups)"
62317365|NCT05638711||After group|"* Patient: ICU patients received CVVH between 2020/10/01 - 2021/12/31 (after utilization of built-in calculator)~* received regular protocol of ICU patient care (same in two groups)"
62479478|NCT02540603|EXPERIMENTAL|Full Face Mask|F\&P Jupiter Full Face Mask with Headgear
62686718|NCT05823441|PLACEBO_COMPARATOR|PA group|Half an hour after the volunteers received the same dose of saline, they watched the pre recorded video (attached with pictures and introductions of acquaintances) and received the pain test.
62686719|NCT05751226|EXPERIMENTAL|BI 1820237 treatment group|
62686720|NCT05751226|PLACEBO_COMPARATOR|Placebo group|
62317366|NCT03856073|EXPERIMENTAL|Novice|Anesthesiologists without experiment of manufacturing bronchoscopy.
62317367|NCT06512467|EXPERIMENTAL|Donafenib combined with Sintilimab and HAIC|Donafenib:200mg bid; Sintilimab:200mg Q3D; HAIC:Q3W.
62317368|NCT02213198|EXPERIMENTAL|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
62317369|NCT02213198|ACTIVE_COMPARATOR|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
62317370|NCT05590949||Post- menopausal breast cancer patients|Participants are post- menopausal with a breast cancer diagnosis who received at least 2 doses of denosumab, and then discontinued therapy, and discontinued Aromatase Inhibitors/AI prior to or within 6 months of stopping denosumab
62317371|NCT02948777|EXPERIMENTAL|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
62317372|NCT03395340|EXPERIMENTAL|Ruxolitinib cream|Investigational cream to 1 location; vehicle cream to 2nd location
62317373|NCT03395340|PLACEBO_COMPARATOR|Vehicle cream|Investigational cream to 1 location; vehicle cream to 2nd location
62479479|NCT06330584|PLACEBO_COMPARATOR|Placebo|Total dose of midazolam = 0 mg (no active compound)
62479480|NCT06330584|ACTIVE_COMPARATOR|Standard of Care (SOC)|Total dose of midazolam = 0.9 mg
62686721|NCT05751226|EXPERIMENTAL|BI 1820237 + semaglutide treatment group|
62686722|NCT05751226|ACTIVE_COMPARATOR|placebo + semaglutide group|
62686723|NCT05751226|EXPERIMENTAL|BI 1820237 + BI 456906 treatment group|
62686724|NCT05751226|ACTIVE_COMPARATOR|placebo + BI 456906 group|
62479481|NCT06330584|ACTIVE_COMPARATOR|Double Dose of Standard of Care (2xSOC)|Total dose of midazolam = 1.8 mg
62686725|NCT02376855|NO_INTERVENTION|Control|Providers in the Control group followed standard care protocols. If they deemed a patient was in need of cardiology consultation, a referral was created using the standard process. The referral was processed by a referral coordinator and transmitted to an appropriate cardiologist. An appointment was then scheduled for the patient to have an in-person consultation with a cardiologist.
62686726|NCT02376855|EXPERIMENTAL|eConsult|"The intervention consisted of an eConsult pathway and standardized protocol for PCPs to obtain cardiology consults using a secure messaging peer to peer (P2P) module embedded within the EHR. Intervention providers were asked to send all cardiology referrals for their adult patients through the eConsult system. Providers could bypass the eConsult pathway for patients with established relationships with a cardiologist or for whom providers felt a consult was urgent (required a face-to-face visit within a week or less). eConsults contain reason for consult, relevant test results, records or reports but are sent electronically to a Cardiology Consultant for review. eConsults were responded to within two business days. Responses were case-specific and generally contained recommendations for management, additional testing, or a face-to-face cardiology visit. The PCP was responsible for considering/acting upon recommendations and determining when an eConsult was complete."
62686727|NCT06391333|ACTIVE_COMPARATOR|laryngeal mask airway|In this group, patients use a laryngeal mask airway for intraoperative mechanical ventilation.
62686728|NCT06391333|PLACEBO_COMPARATOR|endotracheal intubation|In this group, patients use a endotracheal tube for intraoperative mechanical ventilation.
62686729|NCT01380132|EXPERIMENTAL|Anal injection of Nasha Dx|
62686730|NCT01664715|ACTIVE_COMPARATOR|150 Minutes per Week|Performs 150 minutes of physical activity per week.
62686731|NCT01664715|ACTIVE_COMPARATOR|225 Minutes per Week|Performs 225 minutes of physical activity per week.
62686732|NCT01664715|ACTIVE_COMPARATOR|300 Minutes per Week|Performs 300 minutes of physical activity per week.
62686733|NCT04755231|EXPERIMENTAL|PanOptix IOL|AcrySof IQ PanOptix Presbyopia Correcting IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery
62686734|NCT06689748||Experts|Airway management experts The Steering Committee selected Experts from across the globe based on pre-defined criteria and will conduct iterative Delphi rounds to generate consensus among the experts.
62686735|NCT06499961|EXPERIMENTAL|digital version of Holistic Healthy Life Education (e2HLE)|
62686736|NCT06499961|OTHER|Waitlist-control|
62686737|NCT05308719|NO_INTERVENTION|Standard Oxygen Therapy|Standard oxygen therapy arm patients will be given 30-40% inspired O2 and flow 2-6 l/min via nasal prongs or non-rebreathing mask (not humidified and not heated) post extubation. Monitoring of saturations, respiratory rate and arterial gases will happen 15 minutes post extubation and then as per local policy thereafter. If saturations \< 93% then FiO2 will be increased as per respiratory escalation protocol. Standard oxygen therapy will be given for a minimum of 16 hours post extubation.
62686738|NCT05308719|OTHER|High-Flow Nasal Therapy|High-flow nasal therapy arm patients will be given AIVRO 2 high flow oxygen therapy machines post extubation, start at 30-40% inspired O2 and flow 30 l/min then up to 50 l/min over 5-10 min. Monitoring of saturations, respiratory rate and arterial gases will happen after 15 minutes post extubation and then as per local policy thereafter. If saturations \< 93% then increase FiO2 as per respiratory escalation protocol. High flow nasal therapy will be given for a minimum of 16 hours post extubation.
62686739|NCT02665650|EXPERIMENTAL|AFM13 + Pembrolizumab|Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.
62317374|NCT04292119|EXPERIMENTAL|Lorlatinib and Crizotinib|"* The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~* Phase 1 (the dose-finding portion of the study) will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~  * Lorlatinib will be administered orally once daily at a predetermined dose for 28 days~ * Crizotinib will be administered orally twice daily at a predetermined dose for 28 days~* Phase II patients will be treated with Lorlatinib and Crizotinib at a dose recommended based on the phase I study."
62686740|NCT05632601|EXPERIMENTAL|Sex-Specific Risk HDP Subgroup Factor Group and Age-Matched Control Group|"* Blood sample~* Questionnaires~* Arterial stiffness assessment~* Transthoracic Echocardiogram~* Coronary Computed Tomography Angiography (CTA)~* Cardiac Positron Emission Tomography (PET)"
62686741|NCT05632601|NO_INTERVENTION|Sex-Specific Risk factor group and Age-Matched Control Group|"* Blood sample~* Questionnaires~* Arterial stiffness assessment"
62686742|NCT06066099|EXPERIMENTAL|Part A: Single Ascending Doses|"Participants will be randomized to receive a single oral dose of AP31969 or matching placebo in 1 of 5 groups.~Participants in an additional food effect assessment group will be randomized to receive 2 single oral doses of AP31969 or matching placebo; 1 dose in fasted and 1 dose in fed state in a 2-period, fixed-sequence design (first fasted, then fed with at least 1 week washout between periods)."
62686743|NCT06066099|EXPERIMENTAL|Part B: Multiple Ascending Doses|Participants will be randomized to receive multiple oral doses of AP31969 or matching placebo for 10 days in 1 of 4 groups.
62686744|NCT06642688|EXPERIMENTAL|Sacroiliac Joint Manipulation Group|Sacroiliac joint manipulation was performed on this group in the lateral decubitus position.
62686745|NCT06642688|EXPERIMENTAL|Cervical Joint Manipulation Group|Cervical joint manipulation was performed on this group in the supine position.
62686746|NCT06642688|NO_INTERVENTION|Control Group|This group did not undergo any interventions.
62686747|NCT02369939|ACTIVE_COMPARATOR|control arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m\^2/d on d1 and 29; 5-Fluorouracil 1000mg/m\^2/d on d1-5, 29-33
62686748|NCT02369939|EXPERIMENTAL|Experimental arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m\^2/d on d1 and 29; 5-Fluorouracil 1000mg/m\^2/d on d1-5, 29-33 Hyperthermia: 6
62686749|NCT06196203|EXPERIMENTAL|AK117 (dose 1) in combination with azacitidine|Subjects receive AK117 (dose 1) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously
62127074|NCT01407198|EXPERIMENTAL|Nilotinib/XRT|Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
62479482|NCT04075864|EXPERIMENTAL|behavioral intervention to improve physical activity|"The proposed study is prospective single-arm feasibility clinical trial that will enroll 12 hospitalized patients with CF in accordance with consensus criteria.~Standard care for an acute CF exacerbation includes i.v. antibiotics and airway clearance therapies for 10-14 days. Routine care following hospitalization is an outpatient CF clinic visit 2-4 weeks after discharge, and then regular follow up every 2-3 months.~In addition, to standard care in the hospital, study participants will receive a 1) tailored exercise prescription, 2) daily, individual, supervised, aerobic and strength/power training, as well as 3) daily behavioral counseling focused on topics related to long-term adherence to exercise (details below)."
62479483|NCT03135301|EXPERIMENTAL|letrozole plus metformin|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued
62479484|NCT03135301|ACTIVE_COMPARATOR|letrozole|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding
62127075|NCT06145867|EXPERIMENTAL|PBM therapy|All participants will use the 670 nm lamp for 2 minutes each morning for 14 days.
62127076|NCT03592069|ACTIVE_COMPARATOR|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
62127077|NCT03592069|ACTIVE_COMPARATOR|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
62127078|NCT00151567|EXPERIMENTAL|1|Tamsulosin
62127079|NCT00151567|PLACEBO_COMPARATOR|2|Placebo
62127080|NCT03303651|EXPERIMENTAL|PPI (Pain Pupillary Index)|Opioid administration guided by Pain Pupillary Index (PPI) derived from Videopupillometry performed with the device AlgiScan manufactured by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following an electric nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 milliampere depending on the degree of PRD and afterwards displays the PPI. The numerical index ranges from 0 to 10. A low PPI score indicates a deep analgesia, a high PPI score indicates an insufficient or light analgesia. A PPI score of 2 or 3 is supposed to represent an optimal level of analgesia according to the manufacturer. 5 µg sufentanil will be administered every 5 minutes if PPI score is calculated more than 3.
62127081|NCT03303651|EXPERIMENTAL|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electrics) Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide analgesics (15 - 17). 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
62317375|NCT04292119|EXPERIMENTAL|Lorlatinib and Binimetinib|"* The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~* The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~  * Lorlatinib will be administered orally once daily at a predetermined dose for 28 days~ * Binimetinib will be administered orally twice daily at a predetermined dose for 28 days.~* Phase II patients will be treated with Lorlatinib + Binimetinib at a dose recommended based on the phase I study."
62479485|NCT03343535|EXPERIMENTAL|OCS Preservation|
62479486|NCT02889380||Cetrotide|This study will retrospectively collect the data from the subjects who had been treated with 0.25 milligram (mg) of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available assisted reproductive technology (ART) outcome.
62479487|NCT04523168|EXPERIMENTAL|Chronic Refractory Angina|Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.
62479488|NCT04811235|EXPERIMENTAL|Arm 1|NIRS monitoring of spinal cord oxygenation and hemodynamics
62479489|NCT04842123|OTHER|Atrial fibrillation (AF)|Patients with a known history of AF who are in AF at the time of study screening.
62479490|NCT04842123|OTHER|Normal Sinus Rhythm (SR)|Patients with no known diagnosis of AF or other arrhythmia
62686750|NCT06196203|EXPERIMENTAL|AK117 (dose 2) in combination with azacitidine|Subjects receive AK117 (dose 2) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously
62686751|NCT06196203|PLACEBO_COMPARATOR|Placebo in combination with azacitidine|Subjects receive placebo intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously
62479491|NCT01444378|EXPERIMENTAL|Absolute Pro® and Pro LL® Peripheral Stent Systems|
62686752|NCT06267014|EXPERIMENTAL|Virtual Reality sessions|
62686753|NCT04309266|EXPERIMENTAL|Robot Assisted Therapy with Metacognitive Skills Training|All participants will be enrolled in the single arm of this study, where they will receive robot assisted therapy combined with metacognitive skills training.
62686754|NCT06675474||Periodontitis|These patients had at least two interdental sites (at two non-adjacent teeth) with interproximal CAL ≥5 mm, along with PD ≥6 mm and RBL extending to the mid-third of the root or beyond. CAL was not originated from endodontic lesions draining through the marginal periodontium, dental caries extending into the cervical areas of the teeth, trauma-related gingival recession or distal bone loss in 2nd molars owing to extractions of 3rd molars. They had ≤4 teeth lost due to periodontitis.
62686755|NCT03638180|EXPERIMENTAL|Single Ascending Doses|Single ascending doses, 6 dose levels
62686756|NCT03638180|EXPERIMENTAL|Multiple Ascending Doses|Multiple ascending doses, 3 dose levels
62686757|NCT06675409|ACTIVE_COMPARATOR|Expert Guided Group|The expert-guided group will participate in virtual patient sessions consisting of 12 patient scenarios under the guidance of an expert. These patient scenarios are selected clinical cases designed to enhance critical decision-making skills in emergency patient management. Throughout the training, students will receive verbal feedback from experts on their performance
62686758|NCT06675409|EXPERIMENTAL|Self Learning Group|The self-learning group will also participate in training with the same 12 patient scenarios as the other group, but instead of expert guidance, the students in this group will engage with the virtual patient scenarios independently and manage the process without instructor guidance. In this group, feedback on students' performance will be provided in written form by the computer-based virtual patient simulator.
62686759|NCT03854435|EXPERIMENTAL|Heart rate assessed by using a stethoscope (auscultation)|Heart rate will be assessed by using a stethoscope (auscultation) in newborn infants immediately after birth
62686760|NCT03854435|ACTIVE_COMPARATOR|Heart rate assessed by palpation of the umbilical cord|Heart rate will be assessed by palpation of the umbilical in newborn infants immediately after birth
62686761|NCT05075473|EXPERIMENTAL|Segmental Stabilization|Segmental control over the primary stabilizers (TrA, deep multifidus, pelvic floor and diaphram) is maintained. Weight of body is minimized by using drawing in maneuver. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
62686762|NCT05075473|ACTIVE_COMPARATOR|General lumber stabilization exercises|It includes exercises in closed chain with low velocity as well as low load. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for about 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
62686763|NCT03186183|EXPERIMENTAL|GPS program|"The individual GPS motivational interviewing counseling program has 4-6 sessions.~Week 1: information on sexually transmitted infections and HIV disclosure laws is reviewed. Participants are introduced to the sex diary, stress exercise, and stages of change model.~Week 2: a decisional balance exercise about the participant's current sexual behavior is completed and a behavioral goal is chosen.~Week 3: participants explore their greatest fears and hopes about the goal, and the importance of and their confidence in achieving it.~Week 4: the facilitator and participant identify triggers, automatic thoughts, counters, strategies, supports, and rewards pertaining to the pursuit of the goal and role play the new goal.~1-2 supplemental sessions may be added as needed."
62686764|NCT02569008|EXPERIMENTAL|1 ml / Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes
62686765|NCT02569008|EXPERIMENTAL|2 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes
62686766|NCT02569008|EXPERIMENTAL|3 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes
62686767|NCT02569008|EXPERIMENTAL|4 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes
62479492|NCT04277403|EXPERIMENTAL|HA-WBRT+SIB|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis
62479493|NCT04277403|ACTIVE_COMPARATOR|SRS|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases
62686768|NCT01326572||female, male, HIV, lung disease|All participants in the University of Pittsburgh Multicenter AIDS Cohort Study are eligible for this protocol. All participants in the UCSF Women's HIV study are eligible and all Men from the UCLA men's HIV study are eligible
62686769|NCT02808611|ACTIVE_COMPARATOR|Propranolol|Propranolol is a beta-blocker
62686770|NCT02808611|PLACEBO_COMPARATOR|Placebo|Placebo
62686771|NCT02196974|EXPERIMENTAL|cryobiopsy|
62686772|NCT02766478|EXPERIMENTAL|Genistein|Participants with and without diabetes will receive 60 mg/day oral genistein (30 mg taken twice daily) for 12 weeks.
62686773|NCT02766478|PLACEBO_COMPARATOR|Placebo|Participants with and without diabetes will receive placebo taken twice daily for 12 weeks.
62686774|NCT00628615||2|male patients with lower urinary tract symptoms
62686775|NCT00628615||1|Female patients with overactive bladder syndrome
62317376|NCT04292119|EXPERIMENTAL|Lorlatinib and TNO155|"* The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~* The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~  * Lorlatinib will be administered orally once daily at a predetermined dose for 21 days~ * TNO155 will be administered orally once daily at a predetermined dose for 14 out of 21 days.~* Phase II patients will be treated with Lorlatinib + TNO155 at a dose recommended based on the phase I study."
62686776|NCT01284738|ACTIVE_COMPARATOR|TM patients|thalassemia major (TM) Need transfusion for survive
62686777|NCT01284738|ACTIVE_COMPARATOR|TI patients|thalassemia intermedia (TI) Patients with TI have a milder clinical phenotype than those with TM
62686778|NCT06215157|ACTIVE_COMPARATOR|Flotrac Group|In this group,an arterial catheter was inserted preoperatively. An indwelling radial artery catheter was connected to the hemodynamic monitoring system (EV1000; Edward Lifesciences Corp., Irvine, CA, USA) via FloTrac™ (Edwards Lifesciences Corp.) sensors.
62686779|NCT06215157|EXPERIMENTAL|BioZ Group|In this group,haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™) monitoring.
62686780|NCT05109559|EXPERIMENTAL|Ad26.COV2.S given at the interval ≥ 90 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A1, a total of 360 adult volunteers aged 18 years or older, will receive the full-dose (5x10\^10 vp) of the study product, at later (90 days or more) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
62686781|NCT05109559|EXPERIMENTAL|Ad26.COV2.S given at 45-75 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A2, a total of 110 adult volunteers aged 18 years or older, will receive the full-dose (5x10\^10 vp) of the study product, at early (45-75 days) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
62686782|NCT05109559|EXPERIMENTAL|Half dose of Ad26.COV2.S given ≥ 90 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A3, a total of 110 adult volunteers aged 18 years or older, will receive the half-dose (2.5x10\^10 vp) of the study product, at later (90 days or more) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
62317377|NCT05319951|EXPERIMENTAL|Oral Rehydration Salts Power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
62317378|NCT05319951|EXPERIMENTAL|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
62317379|NCT05319951|PLACEBO_COMPARATOR|recommended water intake|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
62686783|NCT05109559|EXPERIMENTAL|Ad26.COV2.S given 28 days after receiving 1 dose of either Sinovac or Sinopharm|Study Part B is a prospective, multi-center, open-label Phase 1/2 heterologous prime-boost study to assess the Ad26.COV2.S (full dose 5x10\^10 vp) as the 2nd vaccination in subjects who are documented to all have received the 1st dose of Sinovac or all received the 1st dose of Sinopharm COVID-19 vaccine, with an interval of 28 days +/- 3 days, followed from Visit 1 (V1) to Visit 7 (V7) at 336 days.
62686784|NCT06642961|EXPERIMENTAL|GR1802 300mg Q2W|GR1802 is injected subcutaneously (SC) with a loading dose of 600 mg at the first dose, and then 300 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
62317380|NCT06306638|EXPERIMENTAL|Phase I cohort 1 (I-PDT, EBUS)|Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 3 treatment sessions. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
62479494|NCT05640115|EXPERIMENTAL|Group A (Ureteral Stenting)|Group A: Participants in this group will receive a standard of care ureteral stenting performed by a urologist.
61924815|NCT06404424||Baseline therapy + High-volume plasma exchange (HVPE) + Efferon CT hemoperfusion|Patients of second group received standart treatment, like first group and also high volume plasma exschange procedure and hemoperfusion procedure using Efferon CT device.
62317381|NCT06306638|EXPERIMENTAL|Phase I cohort 2 (I-PDT, EBUS, palliative radiation therapy)|Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
62317382|NCT06306638|EXPERIMENTAL|Phase II (I-PDT, EBUS, palliative radiation therapy)|Phase II: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
62479495|NCT05640115|EXPERIMENTAL|Group B (Percutaneous Nephrostomy)|Participants in this group will receive a standard of care percutaneous nephrostomy tube placement performed by an interventional radiologist.
61924816|NCT06404424||Baseline therapy + High-volume plasma exchange (HVPE) + Efferon LPS hemoperfusion|Patients of third group received standart treatment, like first group and also high volume plasma exschange procedure and hemoperfusion procedure using Efferon LPS device.
61924817|NCT04587180||Patients with cutting-through|Patients who had cutting-through during the lateral knotless anchor fixation.
61924818|NCT04587180||Patients without cutting-through|Patients who didn't have cutting-through during the lateral knotless anchor fixation.
61924819|NCT00723203|EXPERIMENTAL|Treatment (panobinostat)|"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle"
62127082|NCT03303651|EXPERIMENTAL|NOL (Nociception Level)|Opioid administration (sufentanil) guided by Nociception Level (NOL) derived from finger photoplethysmography performed with the analgesia monitoring device PMD200 manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature and finger motion. The composite algorithm of the device analyses the data and the numerical index NOL is presented on a scale from 0 (no pain) to 100 (extreme pain) (18). A NOL score between 10 and 25 has been proposed as the target range to guide analgesics. 5 µg Sufentanil will be administered every 5 minutes if NOL score is calculated more than 25.
62127083|NCT03303651|ACTIVE_COMPARATOR|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
62127084|NCT04436614|EXPERIMENTAL|Aloe Vera and Crocus|50 patients Aloe Vera and Crocus (saffron) 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle Intervention: Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle 1L, per 15 days.
62127085|NCT04436614|PLACEBO_COMPARATOR|Aloe Vera|50 patients Aloe Vera (simple) in a glass bottle 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera (simple) in a glass bottle Intervention: Dietary Supplement: Aloe Vera (simple) in a glass bottle in a glass bottle 1L, per 15 days.
62127086|NCT04436614|OTHER|Mediterranean Diet|50 patients Mediterranean dietary protocol Intervention:mediterranean diet
62317383|NCT02379910|EXPERIMENTAL|SAD 1|AM1030-CREAM
62317384|NCT02379910|EXPERIMENTAL|SAD 2|AM1030-CREAM
62317385|NCT02379910|EXPERIMENTAL|SAD 3|AM1030-CREAM
62317386|NCT02379910|EXPERIMENTAL|MAD 1|AM1030-CREAM
62317387|NCT02379910|EXPERIMENTAL|MAD 2|AM1030-CREAM
61924820|NCT04630639|EXPERIMENTAL|Validation Arm|Participants will wear the Sparkle device (test device) while instrumented with an esophageal manometry catheter (reference standard) to record respiratory effort.
61924821|NCT03750422|ACTIVE_COMPARATOR|Stratacel|medical grade silicone gel following Picoway Laser treatment
61924822|NCT03750422|SHAM_COMPARATOR|Vehicle|Clear ultrasound gel following Picoway Laser treatment
61924823|NCT04682873|EXPERIMENTAL|Enisamium iodide|Hospitalized patients who were randomized in to this treatment group will receive enisamium iodide containing capsules (Amizon® Max).
61924824|NCT04682873|PLACEBO_COMPARATOR|Placebo|Hospitalized patients who were randomized in to this treatment group will receive placebo containing capsules.
61924825|NCT00198796|EXPERIMENTAL|H10407|H10407
61924826|NCT00869843|OTHER|Single group|
62127087|NCT05632471|EXPERIMENTAL|web-based training for parents in the intervention group|"Parents were given I know digital games training with 10 videos from the website."
62317388|NCT00691197|EXPERIMENTAL|Carboxymethylcellulose sodium and Glycerin|Carboxymethylcellulose sodium and Glycerin based rewetting drop
62317389|NCT00691197|ACTIVE_COMPARATOR|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium based rewetting drop
62479496|NCT03110627|EXPERIMENTAL|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
62479497|NCT03110627|ACTIVE_COMPARATOR|VVI ICD|VVI ICD - Single chamber ICD system - Control group
62317390|NCT04803708|EXPERIMENTAL|Part A- Cohort 1|8 eligible subjects with non-infected DFU will be enrolled (Cohort 1) and receive IP three times weekly (TIW) every other day for up to one week. Of these 8 enrolled subjects, 6 subjects will be randomized to TP-102 and 2 to placebo. Subjects will be followed-up for 7 days.
62479498|NCT00834275|EXPERIMENTAL|1|
62479499|NCT00834275|ACTIVE_COMPARATOR|2|
62479500|NCT06485089||women using tirzepatide for weight loss|Women attending the University of Kansas Medical Center (KUMC) Weight Management Clinic
62127088|NCT05632471|OTHER|parents in the control group|No intervention was applied to the parents in the control group.
62127089|NCT05049434|EXPERIMENTAL|Medicurtain®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
62127090|NCT05049434|ACTIVE_COMPARATOR|GUARDIX-SG®|Treat Medicurtain® 5ml prefilled syringe after surgery
62127091|NCT03532906|ACTIVE_COMPARATOR|TAP block|Patients receive the injection of local anaesthetic into the right abdominal wall (TAP block) together with the injection of local anaesthetic into the surgical wounds.
62127092|NCT03532906|OTHER|Control|Patients receive the injection of local anaesthetic into the surgical wounds only.
62127093|NCT00970658|EXPERIMENTAL|Salonsip|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
62127094|NCT00970658|ACTIVE_COMPARATOR|Sabiá|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
62127095|NCT01182571||heart transplantation|
62127096|NCT05447507|ACTIVE_COMPARATOR|Remimazolam|
62127097|NCT05447507|ACTIVE_COMPARATOR|Dexmedetomidine|
62127098|NCT00477308|OTHER|salvage therapy|Children with drug resistance were treated using the drug resistant profile
62127099|NCT00262301|EXPERIMENTAL|"100 IU/kg rhC1INH"|100 IU/kg recombinant human C1 inhibitor
62127100|NCT00262301|PLACEBO_COMPARATOR|Saline|Saline solution
62127101|NCT01479647|EXPERIMENTAL|PH-797804 1 mg Fasted|Subjects will receive a single 1 mg dose in the fasted state
62127102|NCT01479647|EXPERIMENTAL|PH-797804 1 mg Fed|Subjects will receive a single 1 mg dose following a high-fat meal
62127103|NCT01479647|EXPERIMENTAL|PH-797804 10 mg Fasted|Subjects will receive a single 10 mg dose in the fasted state
62317391|NCT04803708|EXPERIMENTAL|Part B- Cohort 2|"18 subjects with a DFU with a grade 2 or 3 infection, as per PEDIS classification, and at least one bacterial strain susceptible to bacteriophage cocktail will be included in Cohort 2. Subjects will receive IP TIW, every other day, up to four weeks and will be randomized at a 2:1 randomization rate to either:~* TP-102 q.d 3x weekly up to four weeks (n=12)~* Placebo q.d. 3x weekly up to four weeks (n=6)~Subjects will be followed-up for 7 days."
62479501|NCT02825160||Ventavis|Ventavis treatment group
62479502|NCT05974267|EXPERIMENTAL|Cohort 1: M5717 (60 mg) + Pyronaridine|Participants will receive single oral dose of M5717 60 milligram (mg) plus pyronaridine tetraphosphate (pyronaridine) 720 mg (Participants \>= 65 kilogram \[kg\]) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
62479503|NCT05974267|EXPERIMENTAL|Cohort 2: M5717 (200 mg) + Pyronaridine|Participants will receive single oral dose of M5717 200 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
62479504|NCT05974267|EXPERIMENTAL|Cohort 3: M5717 (660 mg)+ Pyronaridine|Participants will receive single oral dose of M5717 660 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
62127104|NCT01479647|EXPERIMENTAL|PH-797804 10 mg Fed|Subjects will receive a single 10 mg dose following a high-fat meal
62127105|NCT01479647|EXPERIMENTAL|PH-797804 24 mg Fed|Subjects will receive a single 24 mg dose following a high-fat meal
62127106|NCT05454228||Delirium|
62127107|NCT05454228||Non-delirium|
62127108|NCT01551355|EXPERIMENTAL|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
62127109|NCT01551355|NO_INTERVENTION|children - control group|The control preschool facilities continued with their usual preschool curriculum
62127110|NCT05266066|EXPERIMENTAL|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care and no antibiotic therapy for VAT. Antibiotics will be prescribed if other infections and/or organ dysfunction ensues (especially shock) or there is progression to pneumonia
62127111|NCT05266066|ACTIVE_COMPARATOR|7 day antibiotic course for VAT|Patients will receive standard care and 7 day course of antibiotic therapy for VAT.
62686785|NCT06642961|EXPERIMENTAL|GR1802 150mg Q2W|GR1802 is injected subcutaneously (SC) with a loading dose of 300 mg at the first dose, and then 150 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
61924827|NCT02876640|EXPERIMENTAL|Treatment (retinoid 9cUAB30)|Patients receive retinoid 9cUAB30 PO QD for 14 to 28 days. Patients then undergo tumor resection surgery. Patients undergo blood and urine sample collection throughout the study.
62317392|NCT01459107|EXPERIMENTAL|Treatment (Transplantation)|Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
62479505|NCT05974267|EXPERIMENTAL|Cohort 4: Atovaquone-proguanil|Participants will receive orally 3 doses of Malarone (fixed-dose combination of atovaquone-proguanil) once daily in a 3-day treatment regimen.
61924828|NCT01557894|EXPERIMENTAL|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for Social Phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
62127112|NCT01544855|EXPERIMENTAL|APOE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
62127113|NCT02271854|EXPERIMENTAL|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
62479506|NCT03089515|ACTIVE_COMPARATOR|Healthy Controls|
62686786|NCT06642961|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 12 doses
62127114|NCT02271854|PLACEBO_COMPARATOR|Placebo|Placebo gel applied four times daily
62127115|NCT02725294||COPD patients|Veterans with COPD who are cared for at VA Puget Sound Health Care System (Seattle, WA) or VA Eastern Colorado (Denver, CO) who are at high risk for a COPD exacerbation based on an exacerbation treated with prednisone or antibiotics in the year preceding enrollment.
62127116|NCT02725294||Informal Caregiver for COPD patients|Informal caregiver (ie. family member, friend, etc.) for the patient with COPD who is participating in the COPD patients cohort.
62127117|NCT00919594|EXPERIMENTAL|Interpersonal Psychotherapy for Mothers|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
62479507|NCT03089515|EXPERIMENTAL|Survivors|
62479508|NCT00598052|ACTIVE_COMPARATOR|A|Escitalopram + cognitive-behavior treatment
62479509|NCT00598052|PLACEBO_COMPARATOR|B|Placebo + cognitive-behavior therapy
62317393|NCT00698126||A|
62317394|NCT00698126||B|
62317395|NCT02527876|EXPERIMENTAL|High Intensity Interval Training/FitBit Flex|Meet with personal trainer once per week for 20-minute exercise session
62479510|NCT05477589|ACTIVE_COMPARATOR|BuCyMel|a combination of busulfan, cyclophosphamide and melphalan, conditioning regimen
62479511|NCT05477589|EXPERIMENTAL|CloFluBu|a combination of clofarabine, fludarabine and busulfan conditioning regimen
62479512|NCT03677141|EXPERIMENTAL|Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding|Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
61924829|NCT01557894|NO_INTERVENTION|Waitlist control group|Waitlist control group
61924830|NCT03977454|EXPERIMENTAL|Group 1 patients will receive nerve block per standard of care|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI."
62479513|NCT03677141|EXPERIMENTAL|Phase Ib: M-CHP-Pola Dose-Finding|Participants will receive M-CHP-Pola up to the RP2D.
62479514|NCT03677141|EXPERIMENTAL|Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort|Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
62686787|NCT06673706|NO_INTERVENTION|No-label Control|Participants will see packaged food-and-beverage items with no front-of-package labels (other than any posted by the manufacturer).
62686788|NCT06673706|EXPERIMENTAL|High-In with color|"Participants will see packaged food-and-beverage items displaying front-of-package labels that say, High In \[nutrient\] (nutrients: saturated fat, sodium, or added sugar) if the item contains 20% or more of the daily recommended limit per serving for each nutrient. The nutrients will be highlighted in red.~If the item is not high in 1 or 2 of the nutrients, the nutrient(s) will not be on the label. If the item is not high in any of the 3 nutrients, the product will not display this label."
62317396|NCT02527876|EXPERIMENTAL|Moderate Intensity/FitBit Flex|Meet with personal trainer once per week for 30-minute exercise session and exercise two times a week outside of personal trainer
62317397|NCT02527876|PLACEBO_COMPARATOR|Delayed Control/FtBit Flex|No exercise offered
62317398|NCT02806765|EXPERIMENTAL|Dietary Supplement|This experimental arm reflects administration of a softgel capsule containing a dose of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol below the upper tolerable limit
62317399|NCT02806765|EXPERIMENTAL|Control|This experimental arm reflects administration of placebo in softgel capsule
62317400|NCT01024465|EXPERIMENTAL|ReShape Duo Balloon|Patients seeking weight loss with a starting BMI in the 30-40 range, received the ReShape Duo Balloon
62317401|NCT04367337||Poland|Adults, general population, N = 400
62317402|NCT04367337||Australia|Adults, general population, N = 400
62317403|NCT04367337||Canada|Adults, general population, N = 400
62317404|NCT04367337||China|Adults, general population, N = 400
62317405|NCT04367337||France|Adults, general population, N = 400
62317406|NCT04367337||Gambia|Adults, general population, N = 400
62317407|NCT04367337||Germany|Adults, general population, N = 400
62317408|NCT04367337||Israel|Adults, general population, N = 400
62127118|NCT00919594|ACTIVE_COMPARATOR|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
62127119|NCT02273986|EXPERIMENTAL|Digoxin|Digoxin
62127120|NCT02273986|EXPERIMENTAL|Digoxin with K-877|Digoxin with K-877
62127121|NCT03714815|EXPERIMENTAL|Open-label treatment period|oral administration of 10 mg macitentan once daily
62127122|NCT00609336|EXPERIMENTAL|Treatment (chemotherapy, radiation, pancreaticoduodenectomy)|See Detailed Description
62127123|NCT01912131|EXPERIMENTAL|First 24 patients Cognitive interviewing|Part 1 - This first study phase will involve interviewing 24 patients to ask for their feedback on the appropriateness of questions being developed for use in the narrative interviewing in part 2 of the study. The cognitive interview will be audio-recorded. Demographics and ECOG performance status will be recorded prior to the cognitive interview.
62317409|NCT04367337||Italy|Adults, general population, N = 400
62317410|NCT04367337||Malaysia|Adults, general population, N = 400
62317411|NCT04367337||Portugal|Adults, general population, N = 400
62317412|NCT04367337||Romania|Adults, general population, N = 400
62317413|NCT04367337||Singapore|Adults, general population, N = 400
62317414|NCT04367337||Switzerland|Adults, general population, N = 400
62317415|NCT06667284|ACTIVE_COMPARATOR|Group a|Roux en y procedure
62317416|NCT06667284|ACTIVE_COMPARATOR|Group b|Omega Brown anastomosis
62317417|NCT03058458|EXPERIMENTAL|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
62317418|NCT03058458|EXPERIMENTAL|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
62317419|NCT03058458|EXPERIMENTAL|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
62317420|NCT03058458|EXPERIMENTAL|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
62317421|NCT05189015|EXPERIMENTAL|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
62317422|NCT05189015|ACTIVE_COMPARATOR|Amlodipine|- Comparator group: Amlodipine, 5 (10) mg once a day, oral administration
62317423|NCT04030403||Microbial Keratitis participants|151 participants presenting with clinically suspected microbial keratitis will be recruited from St Paul's Eye Unit, Royal Liverpool University Hospital.
62317424|NCT04030403||Healthy control participants|20 participants with no history of microbial keratitis who use no eye drop medication will be recruited.
62317425|NCT04030403||Contact-lens wearers|20 participants with no history of microbial keratitis who are contact-lens wearers will be recruited.
62317426|NCT04030403||Glaucoma eye drop users|20 participants who have no history of microbial keratitis but are on eye drop treatment for glaucoma. This group has been included to assess for changes in the corneal microbiome that could be secondary to drop treatment.
62317427|NCT04030403||Keratoconus participants|30 participants with keratoconus who are undergoing cross-linking will be recruited. These participants as part of the routine cross-linking procedure will have their corneal epithelium removed. This removed epithelium from an otherwise healthy corneal surface will allow for a direct comparison between the corneal microbiome characterised from the corneal impression membrane and that characterised directly from the epithelium.
62317428|NCT01841008|EXPERIMENTAL|Tacrolimus ointment 0.1%|
62317429|NCT01841008|PLACEBO_COMPARATOR|Group Placebo|
62317430|NCT06524882|EXPERIMENTAL|Luminopia Group|dichoptic movies/shows wearing the Luminopia headset prescribed 1 hour per day (treatment time can be split into shorter sessions totaling 1 hour each day) 6 days a week with current optical correction if needed
62479515|NCT03677141|EXPERIMENTAL|Phase II: M-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
62686789|NCT06673706|EXPERIMENTAL|High-In black and white|"Participants will see packaged food-and-beverage items displaying front-of-package labels that say, High In \[nutrient\] (nutrients: saturated fat, sodium, or added sugar) if the item contains 20% or more of the daily recommended limit per serving for each nutrient. The label will have a white background and black text.~If the item is not high in 1 or 2 of the nutrients, the nutrient(s) will not be on the label. If the item is not high in any of the 3 nutrients, the product will not display this label."
62127124|NCT01912131|ACTIVE_COMPARATOR|usual care|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will neither be shown the goals-of-care (GOC) video nor undergo the narrative interview process - they will be contacted as per re-assessment.
62127125|NCT01912131|EXPERIMENTAL|video-only arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
62127126|NCT01912131|EXPERIMENTAL|combined narrative and video (P-COCC) arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences.
62127127|NCT04141150|EXPERIMENTAL|[18F]APN-1607|Subjects will undergo PET imaging using \[18F\]APN-1607.
62686790|NCT06673706|EXPERIMENTAL|Nutrition Info with color|"Participants will see packaged food-and-beverage items displaying front-of-package labels that list high, medium, or low for saturated fat, sodium, and added sugars. High is defined as 20% or more of the daily recommended limit per serving, medium as 6-19%, and low as 5% or less. The word high will be highlighted red; the word medium will be highlighted yellow; and the word low will be highlighted green."
62686791|NCT06673706|EXPERIMENTAL|Nutrition Info black and white|"Participants will see packaged food-and-beverage items displaying front-of-package labels that list high, medium, or low for saturated fat, sodium, and added sugars. High is defined as 20% or more of the daily recommended limit per serving, medium as 6-19%, and low as 5% or less. The label will have a white background and black text."
62697421|NCT05640427|PLACEBO_COMPARATOR|Group C|Group C received general anesthesia with intravenous normal saline. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
62127128|NCT01234363|EXPERIMENTAL|Magnetic Resonance Elastography, Supersonic Shear Imaging|Magnetic Resonance Elastography and Supersonic Shear Imaging
62127129|NCT05728060||chronic radiation enteritis|Non-surgically treated cervical cancer patients develop chronic radiation enteritis after radiation therapy.
62127130|NCT05728060||No chronic radiation enteritis after radiotherapy|Patients with non-surgical cervical cancer do not develop chronic radiation enteritis after radiation therapy.
61924831|NCT03977454|ACTIVE_COMPARATOR|Group 2 will NOT receive any nerve blocks.|Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.
61924832|NCT06417073|EXPERIMENTAL|Face-to-Face Interventions|
62317431|NCT06524882|EXPERIMENTAL|Vivid Vision Group|dichoptic games using the Vivid Vision headset, prescribed approximately 25 minutes per day (treatment time to complete the day's sessions can be split into shorter sessions totaling about 25 minutes each day) 6 days per week with current optical correction if needed
62317432|NCT06524882|ACTIVE_COMPARATOR|Continued Optical Correction Group|continued full-time optical correction alone if needed
62479516|NCT03677141|ACTIVE_COMPARATOR|Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
62317433|NCT01148056|EXPERIMENTAL|Short course IMRT|Patients will receive short course IMRT (Intensity Modulated Radiation Therapy) prior to surgery. Dose will be 5 Gy x 5, followed by surgery the week after
62317434|NCT01380756|EXPERIMENTAL|Arm 1- Dose Escalation|The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
62127131|NCT05728060||Patients with cervical cancer|Patients with cervical cancer did not undergo any treatment.
62127132|NCT02727296|ACTIVE_COMPARATOR|propofol|Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.
62127133|NCT02727296|ACTIVE_COMPARATOR|sevoflurane|Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.
62127134|NCT01381471||COPD|Patients with a diagnosis code of COPD
62127135|NCT06081049|EXPERIMENTAL|Colchicine|Colchicine 0.5 mg once daily
62127136|NCT06081049|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62127137|NCT02847689|EXPERIMENTAL|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
62127138|NCT02847689|SHAM_COMPARATOR|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
62127139|NCT01434862|EXPERIMENTAL|Closed loop with pramlintide|Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
62127140|NCT01434862|EXPERIMENTAL|Closed loop without pramlintide|This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
62127141|NCT01434862|EXPERIMENTAL|Open loop with pramlintide|The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.
62317435|NCT01380756|EXPERIMENTAL|Arm 2- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
62317436|NCT02295098|ACTIVE_COMPARATOR|Thoracic epidural catheter|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
62317437|NCT02295098|ACTIVE_COMPARATOR|Paracostal catheter|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
62317438|NCT01869244||hand resting splint|Patients with hand resting splint treatment
62317439|NCT04083742||Eyes with Open Angle|3 repeat measurements on each of the 3 investigational and reference devices
62317440|NCT04083742||Eyes with Narrow Angle|3 repeat measurements on each of the 3 investigational and reference devices
62127142|NCT04526834|EXPERIMENTAL|CD30 positive NHL subtypes|"(ALCL, PTCL-NOS, ENKTCL, DLBCL-NOS, PMBCL)~Dose Level 1~Dose Level 2~Dose Level 3"
62127143|NCT05051449|EXPERIMENTAL|Ketamine|
62127144|NCT02120430|ACTIVE_COMPARATOR|Early administration of the video|Video delivered at one month of child's life
62127145|NCT02120430|EXPERIMENTAL|Late administration of the video|Video delivered at seven months of child's life
62127146|NCT06397144|ACTIVE_COMPARATOR|Paxlovid commercial tablets A (Low Dose)|Single oral dose of nirmatrelvir/ ritonavir 150 (1 × 150)/100 mg commercial tablets under fasted conditions (Reference 1)
62317441|NCT01382589|EXPERIMENTAL|Arm A: Afamelanotide + NB-UVB|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 6 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total)
62317442|NCT01382589|ACTIVE_COMPARATOR|Arm B: NB-UVB alone|Subjects in this arm B will receive NB-UVB light only (administered thrice weekly, 72 treatments in total)
62317443|NCT02101606|EXPERIMENTAL|Tenecteplase|
61924833|NCT06417073|EXPERIMENTAL|Tele-Rehabilitation|
61924834|NCT06417073|EXPERIMENTAL|Home-Based Training|
61924835|NCT04163718|EXPERIMENTAL|Treatment with Umbralisib|
62127147|NCT06397144|ACTIVE_COMPARATOR|Paxlovid commercial tablets B (High Dose)|Single oral dose of nirmatrelvir/ ritonavir 300 (2 × 150)/100 mg commercial tablets under fasted conditions (Reference 2)
62127148|NCT06397144|EXPERIMENTAL|Nirmatrelvir/ritonavir FDC tablets Test formulation 1|Single oral dose of nirmatrelvir /ritonavir 150/100 mg (2 × \[75/50 mg\]) FDC tablets Test formulation 1 (Test 1)
62127149|NCT06397144|EXPERIMENTAL|Nirmatrelvir/ritonavir FDC tablets Test formulation 2|Single oral dose of nirmatrelvir/ ritonavir 300/100 mg (2 × \[150/50 mg\]) FDC tablets Test formulation 2 (Test 2)
62127150|NCT02904642|NO_INTERVENTION|Control|"All enrolled caregivers will receive a congratulatory text message at enrollment which indicates who is conducting the study and which also includes a general-health related saying, The greatest wealth is health. No additional text messages or travel subsidies will be sent to caregivers randomized to the control arm."
62317444|NCT05874245|EXPERIMENTAL|Group D; oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia.
62317445|NCT05874245|EXPERIMENTAL|Group K; oral ketamine group|will receive 6 mg/kg oral Ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia.
62317446|NCT05874245|EXPERIMENTAL|Group M; oral Midazolam group|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia.
62317447|NCT03647943|EXPERIMENTAL|Active tDCS|Participants will receive 10 sessions of active tDCS + cognitive training.
62317448|NCT03647943|SHAM_COMPARATOR|Sham tDCS|Participants will receive 10 sessions of sham tDCS + cognitive training.
62317449|NCT04069767|EXPERIMENTAL|ICoreDIST|The intervention starts with an assessment by the physiotherapist to identify the patient's movement problems in order to choose among the 48 exercises in the intervention. Each session lasts for 60 minutes + exercises 5-10 minutes outside of therapy and is performed 5-6 days/per week in the rehabilitation units, and 3 sessions/week + home exercises 30 minutes 3 days per week in home based or outpatient treatment during the 12 weeks period.To allow for individualisation, each exercise contains five levels of difficulty. All exercises demand enhancement of dynamic trunk stability and functional movements.
62317450|NCT04069767|ACTIVE_COMPARATOR|Standard Care|Consists of standard inpatient rehabilitation, home-based and outpatient-based physiotherapy with the same dose as the intervention group.
62317451|NCT04493619|EXPERIMENTAL|Phase 2a PLX2853 Monotherapy (80 mg)|Subjects with ARID1A mutation-positive advanced gynecological malignancies
62317452|NCT04493619|EXPERIMENTAL|Phase 1b PLX2853 (40 mg) + Carboplatin Combination Therapy|Subjects with platinum-resistant EOC
62317453|NCT04493619|EXPERIMENTAL|Phase 2a PLX2853 (80 mg) + Carboplatin Combination Therapy|Subjects with platinum-resistant EOC
62317454|NCT04493619|EXPERIMENTAL|Phase 1b PLX2853 (80 mg) + Carboplatin Combination Therapy|Subjects with platinum-resistant EOC
62317455|NCT03948204||Prostate cancer|Men diagnosed with prostate cancer
62686792|NCT06673706|EXPERIMENTAL|Nutrition Info without color, with percent Daily Value|"Participants will see packaged food-and-beverage items displaying front-of-package labels that list high, medium, or low for saturated fat, sodium, and added sugars. High is defined as 20% or more of the daily recommended limit per serving, medium as 6-19%, and low as 5% or less. The label will also list the exact percent of the daily recommended limit (i.e., daily value) for each nutrient per serving. The label will have a white background and black text."
62686793|NCT02364271||Not low risk for MACE in 30 days|"Patients with not low risk of major adverse cardiac events within 30 days Patients with TIMI\>0 or mHEART\>2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
62686794|NCT02364271||Low risk for MACE in 30 days|"Patients with low risk of major adverse cardiac events within 30 days~Patients with TIMI=0 and mHEART\<=2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
62686795|NCT05420337|ACTIVE_COMPARATOR|Group Intramuscular|Transversus Abdominis Plane Block will administer with 20 ml of % 0.25 bupivacaine and 0.1 mg/kg morphine intramuscular
62686796|NCT05420337|ACTIVE_COMPARATOR|Group TAP|Transversus Abdominis Plane Block will administer with 20 ml of % 0.25 bupivacaine and 0.1 mg/kg morphine
62317456|NCT03948204||Men without prostate cancer|Men without prostate cancer matched for age and county
61924836|NCT03741127|OTHER|P-BCMA-101 treated|Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
61924837|NCT00883584|ACTIVE_COMPARATOR|1|IMD-1041
61924838|NCT00883584|PLACEBO_COMPARATOR|2|
62686797|NCT03791424|EXPERIMENTAL|Midazolam|Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
62686798|NCT03791424|PLACEBO_COMPARATOR|Control|Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
62686799|NCT06571903|NO_INTERVENTION|Control|Teaching with tutor
62317457|NCT01524211|EXPERIMENTAL|Single Treatment Arm-Zenith t-Branch Cohort|Zenith t-Branch Cohort:Those subjects eligible for enrollment will receive endovascular treatment with the investigational Zenith t-Branch Endovascular Graft.
62686800|NCT06571903|EXPERIMENTAL|Intervention|Teaching from videos for independent study
62686801|NCT04478734|EXPERIMENTAL|Moderate doses|moderate doses of combination therapy applying the minimum average dosage of thiamine and biotin used in patients with BTBGD
62686802|NCT04478734|EXPERIMENTAL|High doses|high doses of the combination therapy applying the average standard dosage of thiamine and biotin used in patients with BTBGD.
62686803|NCT06136299|NO_INTERVENTION|Control - Standard warm-up|This group performed a standard warm-up protocol during their soccer practice sessions.
62686804|NCT06136299|EXPERIMENTAL|Intervention - NMT|This group performed a specific Neuromuscular Training (NMT) warm-up program known as FIFA 11+ Kids during their soccer practice sessions
62686805|NCT03768050|ACTIVE_COMPARATOR|Advanced care for frail elderly|Integrated care program for frail elderly covering Home Hospitalization/Early Discharge; geriatric residences and; home-based case management done by dedicated teams specialised in geriatric medicine
62686806|NCT03768050|NO_INTERVENTION|Standard care|Usual care at the community and geriatric residences by primary care physicians
62686807|NCT06572150|EXPERIMENTAL|Minimal Intraoperative Electrophysiology|Participants undergoing DBS for the diagnosis of Parkinson's disease
62317458|NCT01524211|EXPERIMENTAL|Single Treatment Arm-Terumo Arch Branch Cohort|Terumo Arch Branch Cohort:Those subjects eligible for enrollment will receive endovascular treatment with the investigational Terumo Arch Branch Endovascular Graft.
62686808|NCT06572150|OTHER|Standard Intraoperative Electrophysiology|Participants who previously underwent DBS surgery for the diagnosis of Parkinson's disease
62686809|NCT06689267|EXPERIMENTAL|Initial CT perfusion|Patients enrolled in the Initial CT perfusion group will first undergo CTA and CTP examinations. Based on the results of these tests, the treatment team will then decide whether to proceed with conservative medical therapy or perform coronary angiography.
62317459|NCT05652868|EXPERIMENTAL|Part 1 Dose Escalation|Part 1 patients will receive MYTX-011.
62317460|NCT05652868|EXPERIMENTAL|Part 2 Cohort A|Part 2 Cohort A patients will be randomized to two different dose levels of MYTX-011. Doses to be determined after completion of Part 1.
62317461|NCT05652868|EXPERIMENTAL|Part 2 Cohort B|Part 2 Cohort B patients will receive MYTX-011 at the recommended phase 2 dose.
62317462|NCT05652868|EXPERIMENTAL|Part 2 Cohort C|Part 2 Cohort C patients will receive MYTX-011 at the recommended phase 2 dose.
62686810|NCT06689267|ACTIVE_COMPARATOR|Invasive Coronary Angiography|Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed. Based on the results of these tests, the treatment team will then decide whether to proceed with conservative medical therapy or interventional treatment (including stent implantation or balloon angioplasty).
62686811|NCT05289908|EXPERIMENTAL|Phase I study|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg.... A minimum of three patients and a maximum of six are enrolled in each cohort. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
61924839|NCT03217981||2015|2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
61924840|NCT03217981||2016|2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
61924841|NCT00399672|ACTIVE_COMPARATOR|1|The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
62317463|NCT05652868|EXPERIMENTAL|Part 2 Cohort D|Part 2 Cohort D patients will receive MYTX-011 at the recommended phase 2 dose.
62317464|NCT05652868|EXPERIMENTAL|Part 2 Cohort E|Part 2 Cohort E patients will receive MYTX-011 at the recommended phase 2 dose.
62317465|NCT05652868|EXPERIMENTAL|Part 2 Cohort B2|Part 2 Cohort B2 patients will be randomized to two different dose levels of MYTX-011. Doses to be determined after completion of Part 1
62127151|NCT02904642|EXPERIMENTAL|SMS reminder|At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
62317466|NCT05652868|EXPERIMENTAL|Part 2 Cohort E2|Part 2 Cohort E2 patients will be randomized to two different dose levels of MYTX-011. Doses to be determined after completion of Part 1
62317467|NCT01401088|EXPERIMENTAL|Artificial drainage implant|Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
62317468|NCT01089868||Group A|Patients who suffer from a suspected GBM and will undergo a microsurgical procedure for diagnosis verification. MRI and Positron Emission Tomography (PET) scans are scheduled prior to microsurgery, post microsurgery and after having completed radiochemotherapy and an additional scan after TMZ chemotherapy.
62317469|NCT01089868||Group B|Patients enrolled in Group B suffer from a suspected GBM which cannot be accessed microsurgically either due to a an eloquent location of the tumor, or patient's refusal to undergo surgery. In these patients, diagnosis will be obtained by means of stereotactic surgery. After an initial PET and MRI scan prior to biopsy, patients will be monitored by post radiochemotherapy as well as post 3-months chemotherapy MRI/PET scans.
62317470|NCT01039649||Lung Radiation|Patients with tumors in the lung that require radiation therapy
62317471|NCT04644575|EXPERIMENTAL|Arm A: Previously treated in BIVV001 study|This arm includes participants who have completed study EFC16293 or study EFC16295, participants who have completed Arm B or Arm C of this study (LTS16294) and roll over into Arm A, and participants who have completed any other potential BIVV001 study. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
62317472|NCT04644575|EXPERIMENTAL|Arm B: Newly initiated (China Only) in BIVV001|This arm includes Chinese participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) for 52 weeks. After 52 weeks of treatment in this arm B, participants will be able to roll over into arm A.
62317473|NCT04644575|EXPERIMENTAL|Arm C: Newly initiated in BIVV001 with planned major surgery|This arm includes participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) and will undergo planned major surgery after at least 6 initial EDs with BIVV001, and within 26 weeks from Day 1. After 52 weeks of treatment in arm C, participants will be able to roll into arm A.
62317474|NCT00064662|OTHER|Burch|The Burch colposuspension
62317475|NCT00064662|OTHER|Sling|Pubovaginal sling, using autologous rectus fascia
62479517|NCT03677141|EXPERIMENTAL|Phase II: M-CHOP 1L DLBCL|"Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.~NOTE: No participants were enrolled to this arm."
62127152|NCT02904642|EXPERIMENTAL|SMS reminder + Unconditional Incentive|Participants will receive SMS reminders as described in the SMS reminder arm. Additionally, participants will be sent a 150 Kenyan Shillings (KES) incentive to the mobile phone number they provided at enrollment. The incentive will be delivered three days before the child turns nine months (i.e. sent on the same day as the first SMS reminder). Caregivers will receive the mobile-money incentive unconditionally. The intent of the incentive is to help offset the costs associated with transportation to the clinic. The transaction costs associated with mobile-money transactions will be borne by the study such that mothers will receive the full 150 KES.
62317476|NCT03141801|EXPERIMENTAL|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
62479518|NCT06689956||Observational|Patients undergo tissue sample collection and have their medical records reviewed on study.
62686812|NCT05289908|EXPERIMENTAL|Phase II study|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 4 weeks. The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
62686813|NCT02231580|EXPERIMENTAL|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
62686814|NCT02231580|PLACEBO_COMPARATOR|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
62686815|NCT06642233||Women and men aged 18-75|People with a medical diagnosis of unspecific pain in the cervical spine - acute and chronic pain, regardless of when it began.
62686816|NCT05187910|ACTIVE_COMPARATOR|Patients with Voice Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
62686817|NCT05187910|ACTIVE_COMPARATOR|Patients with Swallowing Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
62127153|NCT06311617||Healthy Pregnant Patients|Health pregnancies
62127154|NCT06311617||Pregnant Patients with Pre-Existing Diabetes|Patients with pre-existing diabetes who are pregnant
62127155|NCT06311617||Pregnant Patients with Vascular Disease or Risk Factors for Vascular Disease|"1. Multiple gestations~2. Preeclampsia or eclampsia~3. Gestational diabetes~4. Hypercoagulable state such as disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome."
62127156|NCT01537419|ACTIVE_COMPARATOR|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
62127157|NCT01537419|EXPERIMENTAL|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
62127158|NCT03532243|EXPERIMENTAL|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the threshold loading device with incremental inspiratory load.
62127159|NCT03532243|EXPERIMENTAL|normal respiratory muscle|Patients with normal respiratory muscle are performing the threshold loading device with incremental inspiratory load.
62127160|NCT04413812|EXPERIMENTAL|Experimental Group|The experimental group will participate in a 3-months training programme focusing on health competence related outcomes.
62127161|NCT04413812|NO_INTERVENTION|Control Group|The control group does not participate in the exercise programme but undergoes identical outcome assessments.
62127162|NCT03886402|EXPERIMENTAL|Treatment|Each subject will receive a single injection of autologous adipose-derived stromal vascular fraction (SVF) and will be monitored for 6 months
62127163|NCT05967429||Hepatocellular carcinoma receiving sorafenib|Patient with advanced stage HCC receiving sorafenib
62127164|NCT02070666|EXPERIMENTAL|Protective ventilation arm|"* Low tidal volumes (from 4 to 6 milliliters(mL)/kilogram (kg) of predicted body weight (PBW)~* Plateau pressure less than 25 centimeter of water (cmH2O)~* Minimum PEEP of 5 cmH2O."
62127165|NCT02070666|ACTIVE_COMPARATOR|Control group|"Traditional-sized tidal volumes (from 8 to 10 mL/kg PBW)~* Plateau pressure less than 25 cmH2O~* Minimum PEEP of 5 cmH2O."
62127166|NCT00825630|ACTIVE_COMPARATOR|Lansoprazole (Lanton)|Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning
62127167|NCT00825630|ACTIVE_COMPARATOR|Omeprazole (Losec)|Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning
62127168|NCT00825630|ACTIVE_COMPARATOR|Pantoprazole (Controloc)|Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning
62127169|NCT00825630|ACTIVE_COMPARATOR|Esomeprazole(Nexium)|Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning
62127170|NCT04775992||preemptive group|patients in this group will receive preoperative gabapentoids
62127171|NCT04775992||control group|patients in this group will not receive gabapentoids
62127172|NCT06152939||1|patients with acute anterior ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention .
62686818|NCT05187910|ACTIVE_COMPARATOR|Patients with Upper Airway Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
62686819|NCT00295503|EXPERIMENTAL|1|cisplatin, pemetrexed, and bevacizumab
62127173|NCT06152939||2|patients with acute anterior ST segment elevation myocardial infarction have thrombolytic therapy .
62317477|NCT03141801|EXPERIMENTAL|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
62479519|NCT05672186|SHAM_COMPARATOR|Waitlist control|Participants in low-income neighborhoods and/or adjacent to low-income housing randomized to the control group will be placed on a waitlist to receive market service after follow- up data collection is complete.
62127174|NCT00538122||Thioridazine Group|Patients must have been treated with (Mellaril) thioridazine at least three months at time of enrollment.
62127175|NCT02436213|EXPERIMENTAL|Healthy control|A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
62317478|NCT03141801|ACTIVE_COMPARATOR|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
62317479|NCT03141801|ACTIVE_COMPARATOR|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
62317480|NCT00688493|EXPERIMENTAL|20 mg single dose of dapagliflozin|20 mg dapagliflozin
62317481|NCT00688493|EXPERIMENTAL|150 mg single dose of dapagliflozin2|150 mg dapagliflozin
62317482|NCT00688493|ACTIVE_COMPARATOR|400 mg single dose of moxifloxacin|Moxifloxacin
62479520|NCT05672186|EXPERIMENTAL|Experimental group|Participants in low-income neighborhoods and/or adjacent to low-income housing randomized to the intervention group will receive the full-service market intervention following randomization.
62479521|NCT05615974|EXPERIMENTAL|LM101 Dose Escalation|
62479522|NCT05615974|EXPERIMENTAL|LM101 combination therapy exploratory|
62479523|NCT05615974|EXPERIMENTAL|LM101 combination expansion|
62479524|NCT00429962|EXPERIMENTAL|A|intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
62479525|NCT00429962|ACTIVE_COMPARATOR|B|intravitreal ranibizumab
62479526|NCT01344863|EXPERIMENTAL|1|
62479527|NCT01344863|ACTIVE_COMPARATOR|2|
62479528|NCT02718326|EXPERIMENTAL|Dosing regimen 1|Participants will receive IVT aflibercept dosing regimen 1
62479529|NCT02718326|EXPERIMENTAL|Dosing regimen 2|Participants will receive IVT aflibercept dosing regimen 2
62479530|NCT02718326|SHAM_COMPARATOR|Dosing regimen 3|Participants will receive matching sham injections
62686820|NCT01558505|ACTIVE_COMPARATOR|standard PTA|conventional balloon angioplasty
62127176|NCT02436213|EXPERIMENTAL|Pulmonary AVM|A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.
62127177|NCT02436213|EXPERIMENTAL|HHT but no pulmonary AVM|Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
62127178|NCT02650544|EXPERIMENTAL|mirtazapine|Mirtazapine arm will be orally administered with mirtazapine 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
62686821|NCT01558505|EXPERIMENTAL|Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty
62686822|NCT01848457|EXPERIMENTAL|Cycles 1 & 2: HDMTX 4 h, PTZ+C; Cycles 3 & 4: HDMTX 12 h, C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 12-hour infusion and cisplatin is administered alone
62686823|NCT01848457|EXPERIMENTAL|Cycles 1 & 2: HDMTX 4 h, C; Cycles 3 & 4: HDMTX 12 h, PTZ + C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin
62686824|NCT01848457|EXPERIMENTAL|Cycles 1 & 2: HDMTX 12 h, PTZ+C; Cycles 3 & 4: HDMTX 4 h, C|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 4-hour infusion and cisplatin is administered alone
62686825|NCT01848457|EXPERIMENTAL|Cycles 1 & 2: HDMTX 12 h, C; Cycles 3 & 4: HDMTX 4 h, C + PTZ|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin
62686826|NCT03302429|EXPERIMENTAL|PRF/ BCP|"Biphasic calcium phosphate (BCP)bioceramic bone substitute combined with platelet rich fibrin PRF"
62686827|NCT03302429|ACTIVE_COMPARATOR|autogenous bone graft|Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft
62686828|NCT06645145|NO_INTERVENTION|Verb learning with only visual and auditory support|"This is gold standard learning scenario for young children."
62686829|NCT06645145|EXPERIMENTAL|Verb learning with auditory, visual, and text support|Participants receive the added support of text to determine if this additional support helps them learn novel words with higher accuracy.
62686830|NCT03907891|EXPERIMENTAL|Motivational social support (MSS) from a nurse alone|Participants will receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse. The nurse will apply motivational interviewing techniques to explore the patient's thoughts about making a behavior change to attain adequate physical activity (PA). Patients will be encouraged to exercise based on instructions provided by the hospital staff. The patient's ability to take their radial pulse before and after PA will be assessed, and patients will be provided written instructions on the correct manner to take a radial pulse. Patients will receive daily motivational text messages from the nurse for 6 weeks. The texts will be sent via the REDCap automated system. The automated system confirms that texts were sent. The motivational interviewer nurse will confirm by phone that the patient receives her/his first text from the REDCap system.
62686831|NCT03907891|EXPERIMENTAL|MSS from nurse with additional significant other support (SOS)|Participants will also receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse and text messages from a nurse for 6 weeks, as described in arm 1. In addition, patients will receive daily text messages from their significant other for 6 weeks. Researchers developed the 42 significant other text messages. The motivational interviewing nurse will provide the text messages to the significant other in writing. The order of texts sent from the significant other will be randomized so that we can determine their effectiveness in general. The significant other will be asked to type and send the text message listed for each date to the patient. Study staff will confirm by phone that the patient received the first text from the significant other. Patients will be asked to track the number of text messages from the significant other that they read over the 6-week period using the log provided.
62686832|NCT03907891|ACTIVE_COMPARATOR|Attention control (AC)|Participants in the AC group will receive a 60-minutes session with a nurse via videoconference or telephone (at participant discretion) viewing of American Heart Association educational videos and and documents regarding IHD. The nurse will additionally provide a written copy of the hospital physical activity instructions, will assess the patient's ability to take their pulse, and provide written instructions on the correct manner to take a radial pulse.
62686833|NCT04008069|EXPERIMENTAL|Open-Label Sarilumab (pre-randomization)|On entering the study, all participants receive open-label sarilumab every two weeks for 16 weeks.
62127179|NCT02650544|PLACEBO_COMPARATOR|Placebo|Placebo arm will be orally administered with placebo 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
62127180|NCT03201861|EXPERIMENTAL|paclitaxel and cisplatin|Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.
62127181|NCT03201861|ACTIVE_COMPARATOR|epirubicin and cyclophosphamide|"Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel~Investigators will declare one of the following regimens:~Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.~Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles."
62127182|NCT01153880||Age <9 months definitive|Age at time of prescription was \<9 months
62127183|NCT01153880||Age <9 months uncertain|Age at time of prescription was uncertain for \<9 months
62127184|NCT01153880||9 months to 6 years|Age at time of prescription was 9 months to 6 years
62127185|NCT01153880||7 to 18 years|Age at time of prescription was 7 to 18 years
62127186|NCT01153880||19 to 65 years|Age at time of prescription was 19 to 65 years
62127187|NCT01153880||66 years and older|Age at time of prescription was 66 years and older
62127188|NCT02706717|ACTIVE_COMPARATOR|Visbiome Extra Strength|
62127189|NCT02706717|PLACEBO_COMPARATOR|Placebo for Visbiome Extra Strength|
62127190|NCT05731999|EXPERIMENTAL|Single application of phenethylamines (D1)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of phenethylamines.
62479531|NCT05910164||A) administration starting with prefilled syringe|"- Group A = Phase 1 then phases 2, 3, 4~The study protocol consists of 4 different stages~* Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE)~* Phase 2: pen injection guided (thanks to the detailed information) by the IDE~* Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase~* Phase 4: injection by pen in complete autonomy, patient alone"
62479532|NCT05910164||B) administration starting with prefilled pen|"- Group B = Phase 2, 3, 4 then phase 1~The study protocol consists of 4 different stages~* Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE)~* Phase 2: pen injection guided (thanks to the detailed information) by the IDE~* Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase~* Phase 4: injection by pen in complete autonomy, patient alone"
62479533|NCT02534233|EXPERIMENTAL|CryoBalloon ablation|Patients having ablation of dysplastic tissue in esophagus.
62479534|NCT04258735|OTHER|Metastatic breast cancer cohort|Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
62686834|NCT04008069|EXPERIMENTAL|Double-Blind Sarilumab (post-randomization)|After completing the open-label period, participants are randomized in blinded fashion to receive sarilumab every two weeks for 12 weeks.
62127191|NCT05731999|EXPERIMENTAL|Single application of benzodiazepines (D2)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of benzodiazepines.
62127192|NCT05731999|EXPERIMENTAL|Single application of cannabinoids (D3)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of cannabinoids.
62127193|NCT05731999|EXPERIMENTAL|Single application of opioids (D4)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of opioids.
62127194|NCT02466516|EXPERIMENTAL|SEL 6 mg|Selonsertib (SEL) 6 mg for 24 weeks.
62127195|NCT02466516|EXPERIMENTAL|SEL 18 mg|SEL 18 mg for 24 weeks.
62127196|NCT02466516|EXPERIMENTAL|SEL 6 mg+SIM 125 mg|SEL 6 mg plus SIM 125 mg for 24 weeks.
62127197|NCT02466516|EXPERIMENTAL|SEL 18 mg+SIM 125 mg|SEL 18 mg plus SIM 125 mg for 24 weeks.
62127198|NCT02466516|EXPERIMENTAL|SIM 125 mg|SIM 125 mg for 24 weeks.
62127199|NCT06515301|EXPERIMENTAL|Structured nurse-led telephone call reminders plus standard care.|Participants in this arm will receive proactive telephone call reminders from nurses for their scheduled follow-up visits. Reminders will be administered initially at 4 months post-recruitment and then every 4 months for a year for HIV-negative women. For women living with HIV, reminders will be administered every 2 months for 6 months after recruitment.
62127200|NCT06515301|EXPERIMENTAL|Home-visit reminders by health extension workers plus standard care.|Health Extension Workers (HEWs) will conduct home visits to remind participants of their scheduled follow-up appointments. Scheduled initially at 4 months post-recruitment for HIV-negative women and 2 months for HIV-positive women, followed by visits every 2 months for 6 months for HIV-positive individuals and every 4 months for 12 months for HIV-negative individuals.
62317483|NCT00688493|PLACEBO_COMPARATOR|Placebo|Placebo
62127201|NCT06515301|EXPERIMENTAL|Application-based automated SMS text reminders plus standard care.|Participants will receive automated SMS text reminders via a mobile application for their follow-up visits. SMS reminders will be sent initially at 4 months and 2 months post-recruitment for HIV-negative and HIV-positive women, respectively. Subsequent reminders will be sent every 2 months for 6 months for HIV-positive women and every 4 months for 12 months for HIV-negative women.
62127202|NCT06515301|ACTIVE_COMPARATOR|Standard care only|Participants in the control group will receive standard follow-up care according to the guidelines outlined by the Ethiopian Ministry of Health and current clinical practices of the country.These women will be orally informed of their follow-up appointment dates and will receive a post-treatment follow-up card at the baseline. Apart from this information and routine care, no additional interventions will be provided.
62317484|NCT06339996|EXPERIMENTAL|Male dietary supplement|Patients received male supplements for a three-month treatment period
62479535|NCT04016415|EXPERIMENTAL|Mindfulness Based Stress Reduction|
62479536|NCT04016415|ACTIVE_COMPARATOR|Stress Management Education|
62479537|NCT06193200|EXPERIMENTAL|Dexamethasone sodium phosphate|IV infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)
62479538|NCT06193200|PLACEBO_COMPARATOR|Placebo|IV infusion of placebo encapsulated in autologous erythrocytes using the EryDex System (EDS)
62479539|NCT06510504|EXPERIMENTAL|225 mg BNC210|
62479540|NCT06510504|PLACEBO_COMPARATOR|Placebo|
62479541|NCT06107634|ACTIVE_COMPARATOR|Standard paraesophageal hernia repair|Standard paraesophageal hernia repair (crural suturing and a total (Nissen) fundoplication)
62686835|NCT04008069|PLACEBO_COMPARATOR|Double-Blind Placebo (post-randomization)|After completing the open-label period, participants are randomized in blinded fashion to receive placebo every two weeks for 12 weeks.
62686836|NCT01251211|ACTIVE_COMPARATOR|botulinum toxin type A|botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)
62686837|NCT01251211|PLACEBO_COMPARATOR|sodium chloride 9 %|sodium chloride 9 % will be used as a neutral placebo
62686838|NCT04065841|EXPERIMENTAL|Arm A: combination therapy|Combination therapy arm: tropifexor 140 mcg capsule + licogliflozin 30 mg tablet, once daily orally
62686839|NCT04065841|EXPERIMENTAL|Arm B: tropifexor monotherapy|Tropifexor monotherapy arm: tropifexor 140 mcg capsule (+ placebo matching licogliflozin tablet), once daily orally
62686840|NCT04065841|EXPERIMENTAL|Arm C: licogliflozin monotherapy|Licogliflozin monotherapy arm: licogliflozin 30 mg tablet (+ placebo matching tropifexor capsule), once daily orally
62686841|NCT04065841|PLACEBO_COMPARATOR|Arm D: Placebo|Placebo arm: placebo matching tropifexor capsule + placebo matching licogliflozin tablet, once daily
62686842|NCT00892866|OTHER|Ancillary-Correlative (biomarkers in cervical cancer)|Patients undergo liquid-based cytology specimen sample collection for analysis of CA-IX, p16, Ki-67, and MCM2 expression via IHC and for the presence of high risk HPV DNA and HPV genotyping.
62686843|NCT06230679|EXPERIMENTAL|Non-invasive Neuromodulation|Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62686844|NCT06230679|PLACEBO_COMPARATOR|Placebo Non-invasive Neuromodulation|Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62686845|NCT02281864|OTHER|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
62686846|NCT02281864|EXPERIMENTAL|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
62686847|NCT06571006|EXPERIMENTAL|experiment group|"The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB."
62686848|NCT06571006|NO_INTERVENTION|control group|no intervention
62317485|NCT02991950|EXPERIMENTAL|parnaparin sodium|"Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI"
62686849|NCT05459779|EXPERIMENTAL|Electric wheelchair with activated assistance module|This condition will be achieved in a standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance, in a random order established upstream.
61924842|NCT00399672|ACTIVE_COMPARATOR|2|The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
62317486|NCT02991950|NO_INTERVENTION|no treatment|Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.
62317487|NCT06667089|EXPERIMENTAL|Povidone-Iodine Group|The povidone-iodine group will receive applications of 10% povidone-iodine solution or gel directly on the wound area involving a gentle cleaning of the wound followed by the application of povidone-iodine left on for a brief period to maximize its antimicrobial action with treatment applied according to protocol frequency, such as twice daily or as clinically indicated, with close monitoring for any adverse reactions or signs of infection
62317488|NCT06667089|EXPERIMENTAL|Chlorhexidine Group|The chlorhexidine group will receive applications of chlorhexidine solution, typically at a concentration of 0.5% to 2%, also following a gentle cleaning of the wound area before applying chlorhexidine, which will remain on the wound according to protocol guidelines with a similar frequency and monitoring approach to assess for antimicrobial effectiveness, wound healing progress, and potential skin irritation
62479542|NCT06107634|EXPERIMENTAL|Standard paraesophageal hernia repair + gastropexy|Standard paraesophageal hernia repair with the addition of a three point gastropexy (posterior, left anterolateral and anterior gastropexy)
62479543|NCT04677075||mastectomy group|patients with breast cancer and eligible for mastectomy
62479544|NCT00001392||Study Cohort|Subjects with known or suspected forms of sclerosing glomerular or chronic, fibrosing tubulointerstitial kidney diseases
62479545|NCT05456191|EXPERIMENTAL|Asciminib|Participants will receive asciminib 80 mg QD
62479546|NCT05456191|ACTIVE_COMPARATOR|Nilotinib|Participants will receive nilotinib 300 mg BID
62479547|NCT05454683|EXPERIMENTAL|Melatonin plus Zinc|"Dietary Supplement:~53 patients treated with melatonin 1 mg plus Zinc 10 mg"
62479548|NCT05454683|PLACEBO_COMPARATOR|Placebo|53 patients treated with isomaltose and magnesium stearate (excipients)
62479549|NCT06623643||1|Evaluation of Melatonin and Cortisol Levels in Individuals with Bruxism
62127203|NCT05925140|ACTIVE_COMPARATOR|LUSZ Control group: Corticosteroid Therapy-enhanced Standard Care (CTSC) alone.|The control group receives the standard care treatment with corticosteroid therapy.
62317489|NCT03327922|EXPERIMENTAL|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
62317490|NCT03327922|EXPERIMENTAL|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
62479550|NCT06623643||2|Evaluation of Melatonin and Cortisol Levels in Individuals without Bruxism
62479551|NCT04987554|EXPERIMENTAL|AM3 supplementation group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
62479552|NCT04987554|PLACEBO_COMPARATOR|Control Group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
62479553|NCT06377605|ACTIVE_COMPARATOR|Erector Spinae block .|"the block will be performed preoperatively with 1mg midazolam administration intravenous , and 5 cm lidocaine 1% infiltration at each side prior to the block .~the patient will be placed in the lateral or sitting position . The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) \[16\] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected , the distribution will be better."
62479554|NCT06377605|ACTIVE_COMPARATOR|local anaesthetic infiltration|: the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
62479555|NCT05609617|EXPERIMENTAL|Face and neck injection|"NCTF135HA intradermal injection on face and neck. 3 injections spaced out by two weeks; injection points are spaced every 1-1.5 cm with a quantity of 0.05 ml on each point.~Application of Hydra Filler cream twice daily on the face and neck."
62127204|NCT05925140|EXPERIMENTAL|LUSZ Antivirals Group: CTSC + Remdesivir or Lopinavir/Ritonavir.|The Antivirals group receives the standard care treatment with corticosteroid therapy in combination with antiviral (Remdesivir) or antiretroviral (Lopinavir/Ritonavir) medications.
62479556|NCT05609617|EXPERIMENTAL|Face and upper chest/décolleté injection|"NCTF135HA intradermal injection on face and décolleté. 3 injections spaced out by two weeks; injection points are spaced every 1-1.5 cm with a quantity of 0.05 ml on each point.~Application of Hydra Filler cream twice daily on the face and décolleté."
62479557|NCT05609617|ACTIVE_COMPARATOR|Face and neck controle|Application of Hydra Filler cream twice daily on the face and neck.
62479558|NCT05609617|ACTIVE_COMPARATOR|Face and upper chest/décolleté controle|Application of Hydra Filler cream twice daily on the face and décolleté.
62479559|NCT03839719|EXPERIMENTAL|Group OC|"Ocimum sanctum (OC) is a natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is also listed by the U.S. FDA as an herb Generally Recognized As Safe (GRAS) for its intended use as a therapeutic herb. Pharmacological constitutes present in the extract are eugenol, Urosolic acid, Carvacrol, linalool , limatrol, caryophyllene, and methyl carvicol. The literature showed that Ocimum sanctum extract has significant anti-gingivitis and anti-inflammatory effect as mouthrinse.~Other Names:~Tulsi Holy Basil"
62686850|NCT05459779|OTHER|Electric wheelchair with assistance module not activated|This condition will be achieved in a standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activated assistance, in a random order established upstream.
62127205|NCT05925140|EXPERIMENTAL|LUSZ Immunosuppressive Group: CTSC + IL-6 receptor antagonist (Tocilizumab).|The Immunosuppressive group receives the standard care treatment with corticosteroid therapy in combination with Tocilizumab, an IL-6 receptor antagonist.
62127206|NCT03618524|EXPERIMENTAL|Experimental|Lower limb hot water immersion
62317491|NCT06573814|EXPERIMENTAL|Bio Gelee Royale Forte|Participants will be instructed to take two capsules of study product in the morning on empty stomach once per day for 98 days. If there is an incidence of URTI between enrollment and Day-14, participant will be instructed to start study product intake three days after symptom resolution. If a dose is missed participants are instructed to take the dose approximately two hours after a meal. Participants will be advised not to exceed two capsules daily.
62317492|NCT06573814|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take two capsules of study product in the morning on empty stomach once per day for 98 days. If there is an incidence of URTI between enrollment and Day-14, participant will be instructed to start study product intake three days after symptom resolution. If a dose is missed participants are instructed to take the dose approximately two hours after a meal. Participants will be advised not to exceed two capsules daily.
62317493|NCT05743023|EXPERIMENTAL|Consciousness-based Ayurvedic lifestyle Intervention|In the intervention group, each participant will receive a structured education and be asked to follow a 12-week personalized diet and daily routine protocol based on the assessment of their current Ayurvedic mind-body state. Participants will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week.
62317494|NCT05743023|ACTIVE_COMPARATOR|Waitlist control|Participants in the waitlist control group will not receive any intervention. They will continue usual care and will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week. Participants n this group receive their personalized protocol at the end of 12 weeks after completing all the data collection.
62479560|NCT03839719|ACTIVE_COMPARATOR|Group CHX|"Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in a variety of oral disorders in various formulations.~As an antimicrobial agent, chlorhexidine is effective in vitro against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes and yeasts and fungi. The digluconate of chlorhexidine (1:6Di 4' chlorophenyl-diguani-dohexane) is a synthetic antimicrobial drug which has been widely used as a broad spectrum antiseptic.~Other Names:~Chlorhexidine"
62317495|NCT05337267|EXPERIMENTAL|sintilimab (after the change)|
62317496|NCT05337267|ACTIVE_COMPARATOR|sintilimab (before the change)|
62317497|NCT02408146|EXPERIMENTAL|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia.
61924843|NCT01828515|EXPERIMENTAL|Vilazodone and Hydrocortisone, then Placebo and Hydrocortisone|Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment. After a 23 day medication washout the procedure will be repeated using placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment.
62317498|NCT02408146|EXPERIMENTAL|parecoxib|The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.
62317499|NCT02408146|EXPERIMENTAL|new intravenous infusion pump|The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.
62479561|NCT03839719|PLACEBO_COMPARATOR|Group PI|"Group PI: Placebo (Distilled water) as the mouthrinse.~Placebo (Distilled water) 10 ml is used as mouthrinse. Distilled water is commonly used as an excipient in a variety of drugs and it is also widely used as a placebo.~Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.~Treatment was carried out by placing 03 sterile agar plates uncovered at pre-designated sites to collect samples of aerosolized bacteria."
62479562|NCT03480230|EXPERIMENTAL|Treatment arm|"1. Non-squamous histology:~   * Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.~  * Compound 565994 500 mg/m2 administered over 10 minutes, and~  * Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.~  * Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.~2. Squamous histology:~   * Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.~  * Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.~  * Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.~  * Platinum and Compound 343782 will be given for 3 cycles."
62479563|NCT03556618|EXPERIMENTAL|Whole Person Care (WPC) Reentry Program - Post-Release|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated transition age youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Whole Person Care (WPC) Reentry Program will consist of community health workers (i.e. network coaches) who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved transition age youth pre- and post-release to increase youths' engagement in community SUD and mental health services. Participants in this branch will include youth exiting the adult justice system (ages 18-24) who receive PRE- and POST-release WPC services."
62686851|NCT02102802||MDMA-assisted therapy|Participants undergoing MDMA-assisted therapy in the main study, MP-8 (NCT#01211405)
62686852|NCT00233168|EXPERIMENTAL|1|Peer medication adherence counseling
62127207|NCT01075113|EXPERIMENTAL|Arm A|Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally. Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
62317500|NCT03388177|EXPERIMENTAL|Treatment as usual + Yoga-based therapy|The yoga-based therapy (YBT) group will receive YBT in addition to treatment-as-usual (TAU). YBT will be administered with a manualized protocol and delivered in a group format consisting of nine weekly sessions of 1,5 hours. Group sessions consist of hatha yoga practices of physical postures, breathing practices, and meditation. Each session has a different theme. The practices will primarily consist of yoga exercises (80%) and meditation (e.g., breathing practices) (20%). Between sessions, participants complete an online module with additional psychoeducation and a practice video to encourage home practice for 30-45 minutes a day. YBT will be delivered by a psychologist who is also a trained yoga teacher.
62317501|NCT03388177|OTHER|Treatment as usual|The treatment as usual (TAU)-only condition will consist of interventions recommended by the Dutch guidelines for depression. These include the combination of pharmacotherapy (antidepressant medications) and psychotherapy (e.g., cognitive behavioral therapy \[CBT\], interpersonal psychotherapy). Lentis mental health clinicians will administer TAU. In order to improve ability to interpret study results, the investigators will record frequency, content (e.g., cognitive restructuring), format (group versus individual), and intensity of contact within TAU. Such quantification of TAU will allow us to address alternative explanations (e.g., contact time) in the case of positive results for YBT.
62317502|NCT01379443|ACTIVE_COMPARATOR|Parental reports of their children|Parental report of family-centered processes of care (MPOC) Parent mental health Parent perceived social support
62317503|NCT01379443|NO_INTERVENTION|Integration of service provider teams|Network co-alition teams were measured using the Integration of Human Services Measure, the Partnership Synergy Measure and a Network Capacity Measure were employed at the CEO level.
62317504|NCT03870581|EXPERIMENTAL|AI-SMART group|Participants' warfarin therapy were guided by an AI-based miniprogram embedded in the Wechat social software.
62317505|NCT03870581|ACTIVE_COMPARATOR|Human-SMART group|Participants' warfarin therapy were guided by an human-based miniprogram embedded in the Wechat social software.
62317506|NCT02549677|EXPERIMENTAL|EC regimen|Epirubicin, cyclophosphamide
62317507|NCT02549677|ACTIVE_COMPARATOR|TC regimen|docetaxel, cyclophosphamide
62317508|NCT00631722|EXPERIMENTAL|A|
62317509|NCT00631722|ACTIVE_COMPARATOR|B|
62317510|NCT00716404||1|All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.
61924844|NCT01828515|EXPERIMENTAL|Placebo and Hydrocortisone, then Vilazodone and Hydrocortisone|Placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment. After a 23 day medication washout the procedure will be repeated using Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment.
62317511|NCT05498753||Control|Healthy infants
62317512|NCT05498753||Experimental|Preterm Infants
62317513|NCT00915811|EXPERIMENTAL|FBATG|Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
62317514|NCT04942418|ACTIVE_COMPARATOR|Multicolor feldspathic ceramic laminate veneers|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
62317515|NCT04942418|EXPERIMENTAL|Multicolor hybrid ceramic laminate veneers.|Multi-shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
62317516|NCT05033444|EXPERIMENTAL|PRV-002|PRV-002 active formulation
62317517|NCT05033444|PLACEBO_COMPARATOR|Placebo comparator|Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
62317518|NCT02925221||ADPKD patients on tolvaptan|ADPKD patients who are newly prescribed with JINARC™ (tolvaptan) or already treated with JINARC™ (tolvaptan) will be eligible.
62317519|NCT03807999|ACTIVE_COMPARATOR|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel 125 mg/m2 as 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) once weekly for 3 weeks followed by a week of rest. plus Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) once weekly for 3 weeks followed by a week of rest.
62479564|NCT03556618|NO_INTERVENTION|Control|Participants in the control arm will receive PRE-release services only from Whole Person Care. They will not receive the POST-release WPC community health worker intervention. Participants in this branch will include youth exiting the adult jail system (ages 18-24).
62317520|NCT03807999|EXPERIMENTAL|Gemcitabine|Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
62317521|NCT05632939|EXPERIMENTAL|ASKB589 +CAPOX+Sintilimab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
62317522|NCT06313281|ACTIVE_COMPARATOR|Group 1|External 0.9% NaCl nasal preparation
62317523|NCT06313281|ACTIVE_COMPARATOR|Group 2|External nasal preparation with antisepsis by CHG 0.05%
62479565|NCT05843864|EXPERIMENTAL|Standard Physical Therapy and Photobiomodulation Therapy|61 Participants will be randomized to this group and will receive Photobiomodulation Therapy (PBMT) in addition to standard physical therapy.
62686853|NCT00233168|ACTIVE_COMPARATOR|2|Peer life skills counseling
62317524|NCT06313281|ACTIVE_COMPARATOR|Group 3|Intranasal irrigation with 80 mg of gentamicin added to 1000 ml of 0.9% NaCl plus external nasal preparation with antisepsis by CHG 0.05%
62317525|NCT02101411||clopidogrel|treated with cloopidogrel
62317526|NCT02101411||ticagrelor|treated with ticagrelor
62479566|NCT05843864|SHAM_COMPARATOR|Standard Physical Therapy and Sham Photobiomodulation Therapy|61 Participants will be randomized to this group and will receive sham Photobiomodulation Therapy (PBMT) in addition to standard physical therapy.
62317527|NCT02101411||cilostazol|treated with clopidogrel+cilostazol
62479567|NCT00956579||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study"
62479568|NCT00956579||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
62479569|NCT06550076|EXPERIMENTAL|Part A (De Novo Cohort) + Part B (Open Label Extension): TAK-279|"Part A: Participants will receive TAK-279, oral tablet once daily (QD) for up to 52 weeks.~Part B: Participants who completed the treatment period of parent studies (TAK-279-3001 \[NCT06088043\] or TAK-279-3002 \[NCT06108544\]) or who completed Part A will receive TAK-279, oral tablet QD for up to 156 weeks."
62479570|NCT04639219|EXPERIMENTAL|T-DXd|T-DXd monotherapy
62479571|NCT05761652||Modeling group|
62479572|NCT05761652||Validation group|
62127208|NCT01075113|EXPERIMENTAL|Arm B CLOSED|Reduced Dose 200mg Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally). Cohort B has been closed. Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib. The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
62127209|NCT03950622|EXPERIMENTAL|V114|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
62127210|NCT03950622|ACTIVE_COMPARATOR|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
62127211|NCT01247831|OTHER|glaucoma patients|All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
62317528|NCT01051388|ACTIVE_COMPARATOR|Group I|Low-dose PPI (Rabeprazole sodium 10 mg)
62479573|NCT06552780|EXPERIMENTAL|high intensity laser , TENs and ultrasound and isometric exercise|Group A ( study group )will receive high intensity laser ,TENs , ultrasound therapy , and isometric exercise.
62479574|NCT06552780|EXPERIMENTAL|ischemic compression ,TENs , ultrasound and isometric exercise|Group B ( study group) will receive ischemic compression ,TENs and ultrasound therapy and isometric exercise.
62127212|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
62127213|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
62317529|NCT01051388|ACTIVE_COMPARATOR|Group II|High-dose PPI (Rabeprazole sodium 20 mg)
62317530|NCT01051388|ACTIVE_COMPARATOR|Group III|Non-PPI (Gefarnate)
62479575|NCT06552780|EXPERIMENTAL|TENs , ultrasound and isometric exercise|Group C (control group ) will receive TENs and ultrasound therapy and isometric exercise only.
62479576|NCT05877261||Prior Cementless Knee Replacement Cohort|Patients who received a cementless knee replacement in 2017-2018 and participated in a prior study measuring the first year of implant migration.
62127214|NCT03562884|EXPERIMENTAL|BLI800|BLI800 given orally as a split-dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m.- 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
62127215|NCT03562884|ACTIVE_COMPARATOR|Fortrans®|Fortrans® given orally as a split dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m - 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
62127216|NCT05209581||Study Group|Adult refugees/immigrants living in accommodation structures
62127217|NCT05631405|PLACEBO_COMPARATOR|Placebo|
62127218|NCT05631405|EXPERIMENTAL|Intervention|
62317531|NCT05091801|EXPERIMENTAL|Control + Intervention|We will explore our hypothesis using a fixed-order within-subjects study design in a group of healthy participants. Each participant will have one week of normal dietary habits and one week of increased chewing time. We will collect stool samples three times per week in order to measure microbial abundance and metabolism.
62317532|NCT03059563|EXPERIMENTAL|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
62686854|NCT04426357|EXPERIMENTAL|Group 1 (Participants with Renal impairment): JNJ-64417184|Participants with varying degrees of impaired renal impairment function (moderate renal impairment \[optional\], severe renal impairment, and end stage renal disease \[ESRD\] not requiring hemodialysis) will be enrolled and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
62686855|NCT04426357|ACTIVE_COMPARATOR|Group 2 (Healthy Participants): Control Group|Participants with normal renal function will be enrolled in controlled group and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
62127219|NCT01897272||Splinting After Surgery|This group will be fitted for a splint and given instructions on wearing their splint after their short-incision Carpal Tunnel Release
62127220|NCT01897272||No Splinting After Surgery|This group will not be splinted after the short-incision carpal tunnel release
62127221|NCT00171184|EXPERIMENTAL|1|Darifenacin
62127222|NCT00171184|PLACEBO_COMPARATOR|2|Placebo
62127223|NCT00646035|PLACEBO_COMPARATOR|A|
62127224|NCT00646035|PLACEBO_COMPARATOR|B|
62127225|NCT01723631|OTHER|Relapsing Multiple Sclerosis- group 1|Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
62127226|NCT01723631|OTHER|Relapsing Multiple Sclerosis- group 2|Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
62127227|NCT01723631|OTHER|secondary progressive multiple sclerosis- Group 3|Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
62317533|NCT03059563|PLACEBO_COMPARATOR|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
62317534|NCT00716937|EXPERIMENTAL|1|Excision of the cyst and Karydakis flap
62127228|NCT01723631|OTHER|primary progressive multiple sclerosis- group 4|Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
62317535|NCT00716937|EXPERIMENTAL|2|Excision of the cyst and laying open
62127229|NCT01723631|OTHER|control 1|healthy volunteers
62127230|NCT01723631|OTHER|Control 2|Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
62127231|NCT01723631|OTHER|Control 3|Patients having an autoimmune pathology
62127232|NCT03000842|EXPERIMENTAL|Healthy Subjects|transcutaneous vagal nerve stimulation
62317536|NCT03729869|EXPERIMENTAL|Progesterone Males|35 men will take 400 mg of progesterone a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
62317537|NCT03729869|PLACEBO_COMPARATOR|Placebo Males|35 men will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
62317538|NCT03729869|EXPERIMENTAL|Progesterone Female|35 women will take 200 mg of progesterone twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
62317539|NCT03729869|PLACEBO_COMPARATOR|Placebo Females|35 women will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
62317540|NCT01083290|EXPERIMENTAL|Order of strenghts; 25 mg, 50 mg, 100 mg|
62317541|NCT01083290|EXPERIMENTAL|Order of strenghts; 50 mg, 100 mg, 25 mg|
62317542|NCT01083290|EXPERIMENTAL|Order of strenghts; 100 mg, 25 mg, 50 mg|
62686856|NCT06408441||unifocal disease|Primary, localized, single lesion
62127233|NCT03000842|EXPERIMENTAL|Hypertensive Subjects|transcutaneous vagal nerve stimulation
62127234|NCT01855334|EXPERIMENTAL|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
62127235|NCT01855334|PLACEBO_COMPARATOR|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
62127236|NCT01855334|EXPERIMENTAL|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
62127237|NCT01855334|EXPERIMENTAL|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
62686857|NCT06408441||Loco-regional disease|multifocal single-organ involvement
62686858|NCT06408441||Systemic metastases|multi-organ involvement and/or loco-regional lymph-node involvement
62686859|NCT06679504||Fibrin glue group|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue
62686860|NCT06679504||Tack fixation group|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue Versus Tack Mesh Fixation
62127238|NCT06553053|EXPERIMENTAL|Experimental Group|"Receiving acupuncture with the function of harmonizing Shaoyang, nourishing spleen and kidney with warmth"
62127239|NCT06553053|ACTIVE_COMPARATOR|Control group|"Receiving acupuncture group with the function of nourishing spleen and kidney with warmth"
62127240|NCT06242782|ACTIVE_COMPARATOR|Positive Control|VRA using Ti-Reinforced d-PTFE membrane
62127241|NCT06242782|EXPERIMENTAL|Test 1|VRA using Ti-Reinforced e-PTFE membrane
62127242|NCT06242782|EXPERIMENTAL|Test 2|VRA using 3D printed Titanium mesh
62127243|NCT06242782|EXPERIMENTAL|Test 3|VRA using Reinforced PTFE mesh
62127244|NCT03109223|ACTIVE_COMPARATOR|Commercially availabel infant formula|
62127245|NCT03109223|EXPERIMENTAL|Test formula with 2-FL|
62127246|NCT03109223|ACTIVE_COMPARATOR|Breast Fed|
62686861|NCT01258699|EXPERIMENTAL|3|BK-C-0701 480mg
62686862|NCT01258699|EXPERIMENTAL|2|BK-C-0701 320mg
62317543|NCT02379416|EXPERIMENTAL|treatment|The starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
62686863|NCT01258699|ACTIVE_COMPARATOR|1|Thioctacid HR tab 600mg
62686864|NCT02510742|ACTIVE_COMPARATOR|SPG neurostimulation|SPG neurostimulation of frequency 20 Hz
62686865|NCT02510742|SHAM_COMPARATOR|Control|Sham neurostimulation of amplitude=0
62686866|NCT05388968||Nuchal translucency with no genetic abnormalities|Pregnant women between 11 and 14 weeks with a fetus showing a nuchal translucency \> 3.5 mm and no genetic abnormalities with array CGH.
62686867|NCT05388968||Nuchal translucency with genetic abnormalities|Pregnant women between 11 and 14 weeks with a fetus showing a nuchal translucency \> 3.5 mm and a genetic abnormalities at array CGH.
62686868|NCT05388968||Genetic abnormalities|Pregnant women between 11 and 14 weeks with a fetus showing a nuchal translucency \< 3.5 mm and a suspicion of genetic abnormalities
62317544|NCT03013751|EXPERIMENTAL|Drug|Udenafil administered for 52 weeks
62317545|NCT01340287|ACTIVE_COMPARATOR|1 = Tested product|
62317546|NCT01340287|SHAM_COMPARATOR|2 = Control product|
62686869|NCT02784496|EXPERIMENTAL|Treatment (ruxolitinib, follow-up)|Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
62686870|NCT05995561||atrial fibrillation|cases presenting with atrial fibrillation at the emegency department.
62686871|NCT06690671|EXPERIMENTAL|Golidocitinib in combination with anti-PD-1|Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.
62686872|NCT04504812|ACTIVE_COMPARATOR|Phase 1: Best Practices + Duloxetine|"Participants will receive Duloxetine and a prescription for guideline-recommended treatments for knee osteoarthritis, i.e., Best Practices. Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.~Phase 1 ended enrollment on April 12, 2024."
62686873|NCT04504812|ACTIVE_COMPARATOR|Phase 1: Best Practices + Duloxetine + Pain coping skills|"Participants will receive Duloxetine, pain coping skills training, and a prescription for guideline-recommended treatments for knee osteoarthritis, i.e., Best Practices. Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.~Phase 1 ended enrollment on April 12, 2024."
62317547|NCT01627756|EXPERIMENTAL|Ventilation Group|Volume controlled ventilation was done during the whole surgery.
62317548|NCT01627756|ACTIVE_COMPARATOR|Non-ventilation Group|In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
62317549|NCT05632133|EXPERIMENTAL|lacosamide group|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
62317550|NCT05632133|EXPERIMENTAL|control group|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
62317551|NCT02692053|EXPERIMENTAL|Patients with septic shock|
62686874|NCT04504812|ACTIVE_COMPARATOR|Phase 2: Intra-Articular Injection (HA+)|"Participants will receive an intra-articular injection of hyaluronic acid mixed with steroid and bupivacaine.~Phase 2 ended enrollment on October 24, 2024."
62686875|NCT04504812|ACTIVE_COMPARATOR|Phase 2: Nerve Procedure: Long Acting Blocks|"Participants will receive a nerve blocking procedure, long-acting local anesthetic, and steroid injection.~Phase 2 ended enrollment on October 24, 2024."
62686876|NCT04504812|ACTIVE_COMPARATOR|Phase 2: Nerve Procedure: Nerve Ablation|"Participants will receive a nerve ablation procedure and steroid injection.~Phase 2 ended enrollment on October 24, 2024."
62686877|NCT04504812|ACTIVE_COMPARATOR|Phase 1: Best Practices|"Participants will receive a prescription for guideline-recommended treatments for knee osteoarthritis, i.e., Best Practices. Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.~Based on the pre-specified stopping rules described in Protocol section 13.2, the DSMB advised ceasing enrollment into Arm 1A (Best Practices). This recommendation was accepted by the sponsor and study investigators. Arm 1A (Best Practices) was closed on 11/29/2023."
62686878|NCT03373669|ACTIVE_COMPARATOR|Shanchol Dose-interval Group 1|Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
62686879|NCT03373669|EXPERIMENTAL|Shanchol Dose-Interval Group 2|Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
62686880|NCT01941342|ACTIVE_COMPARATOR|Pancreatoduodenectomy|Instant pancreatoduodenectomy within one week after diagnosis including: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract.
62686881|NCT01941342|EXPERIMENTAL|ENBD and Pancreatoduodenectomy|"Consistent ENBD (Endoscopic Nasobiliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
62686882|NCT01941342|EXPERIMENTAL|EBD and Pancreatoduodenectomy|"Consistent EBD (Endoscopic Biliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
62686883|NCT01941342|EXPERIMENTAL|PTCD and Pancreatoduodenectomy|"Consistent PTCD (Percutaneous Transhepatic Cholangial Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
62686884|NCT00879619|EXPERIMENTAL|Chemotherapy and enzyme inhibitor|Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
62686885|NCT01310751|EXPERIMENTAL|iloprost nebuliser solusion|50 ng/kg/min
62686886|NCT01310751|PLACEBO_COMPARATOR|distilled water|2ml
62686887|NCT06075537|EXPERIMENTAL|Cohort A2|Participants with nMPS II, aged ≥5 to ≤10 years
62686888|NCT06075537|EXPERIMENTAL|Cohort B2|Participants with nMPS II or nnMPS II, aged ≥1 to ≤18 years
62686889|NCT06075537|EXPERIMENTAL|Cohort C2|Participants with nMPS II, aged \<4 years
62317552|NCT02692053|OTHER|Blood samples from a historical cohort of healthy volunteers|
62317553|NCT02778776|EXPERIMENTAL|Agave inulin + Metfomin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
62317554|NCT02778776|ACTIVE_COMPARATOR|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
62686890|NCT06075537|EXPERIMENTAL|Cohort D2|Participants with nMPS II or nnMPS II, aged ≤18 years with preexisting hepatomegaly who have never taken standard-of-care ERT
61924845|NCT06115148|EXPERIMENTAL|Feeding|Participants will be instructed to consume study beverages to provide \>1.2 grams of protein per kilogram bodyweight and \>120% of total energy needs. Energy needs will be estimated by the Mifflin-St Jeor equation multiplied by an activity factor of 1.5. Study beverages will be a mix of meal replacement shakes e.g., Ensure (Abbott Laboratories, Chicago, IL, USA) products to accommodate protein and energy needs. Study beverages will be consumed every \~3 hours to induce a perpetually fed state. Feeding will occur during waking hours, typically between 7a-11p. Breath will be collected before, during and after the intervention.
61924846|NCT06115148|EXPERIMENTAL|Fasting|Participants will be instructed to consume only water during the duration of the Fasting Protocol. Regardless of the randomization sequence, participants will have consumed their last meal or study beverage by 11p the night prior. Breath will be collected before, during and after the intervention.
61924847|NCT05704296|EXPERIMENTAL|Y-composite grafting|The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
61924848|NCT05704296|ACTIVE_COMPARATOR|Aortocoronary grafting|The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
61924849|NCT04805944||DTG treated (A)|80 HIV-infected adults treated with dolutegravir (as a component of their usual provider-prescribed antiretroviral regimen)
61924850|NCT04805944||BIC treated (B)|30 HIV-infected adults treated with bictegravir (as a component of their usual provider-prescribed antiretroviral regimen)
61924851|NCT04805944||DTG discontinued due to neuropsychiatric adverse event (C)|50 HIV-infected adults having stopped dolutegravir due to neuropsychiatric adverse effects (insomnia, depression, anxiety)
61924852|NCT04805944||Shifting to DTG (D)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing dolutegravir
61924853|NCT04805944||Shifting to BIC (E)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing bictegravir
61924854|NCT05641675||right heart catheterization cohort|The study investigators will screen up to 50 Veterans undergoing right heart catheterization for clinical indications with the intention to consent up to 20 Veterans. Veterans will be screened by study investigators. Veterans who decline to consent and vulnerable populations (pregnant, incapacitated, incarcerated) will be excluded from the study.
61924855|NCT05151601|EXPERIMENTAL|HMOs + Probiotics|"Dosing: A total daily dose of 2 x sachets (6g/day)~Product Comprised of:~1. 2.5g of a proprietary blend of human milk oligosaccharides combined with~2. 20 billion CFUs of a mixture of Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium animalis spp. lactis, and Bifidobacterium longum.~Mode of administration: oral."
62686891|NCT06075537|EXPERIMENTAL|Cohort E2|Participants with nMPS II, aged ≥6 years; participants with nnMPS II, aged \<6 or ≥17 years; or participants with nMPS II, aged ≥1 to ≤18 years, with a history of prior HSCT or gene therapy and have completed at least 48 weeks in Study DNLI-E-0001
61924856|NCT05151601|PLACEBO_COMPARATOR|Placebo|Dosing: A total daily dose of 2 x sachets (6g/day)u (8 weeks of phase 1A). Product: powdered maltodextrin. Mode of administration: oral.
61924857|NCT02052570||Children post-HSCT|Children post-HSCT age 10-16 yrs of age who had allogeneic transplant who are within 5 years of transplant and returned to school in past 12-24 months after previously attending school pre-transplant
61924858|NCT02052570||Parents of children post-HSCT|Parents of children post-HSCT (children in focus group) will participate in focus group with other parents to discuss the challenges and successes of their child returning to school following HSCT.
61924859|NCT02052570||Teachers of children post-HSCT|Teachers of children post- HSCT (children in focus group) will participate in focus group with other teachers to discuss the challenges and successes of children returning to school post HSCT
61924860|NCT02052570||PBMT provider of child post-HSCT|PBMT provider of child-post HSCT (child in focus group) will participate in in focus group with other PBMT providers to discuss the successes and challenges of coordinating school reentry in child post-HSCT
61924861|NCT05303272|EXPERIMENTAL|Abatacept|Subject received subcutaneous administration of abatacept 125 mg once every week through the 52 week double blind period.
61924862|NCT05303272|ACTIVE_COMPARATOR|Mycophenolate mofetil|Subject received subcutaneous administration of matching placebo of abatacept once a weeks through the 24 week double blind period. A washout period of MMF for 4 weeks (24 th-28th week) is used to ensure data integrity. Subsequently,subject were administered subcutaneous administration of abatacept 125 mg once every week through the 28-52 week open label period.
61924863|NCT06336161|ACTIVE_COMPARATOR|Group A ( Erector Spinae Plane Block)|About 40 patients who will be subjected to Ultrasound-Guided Erector Spinae Plane Block.for Postoperative Pain Management
61924864|NCT06336161|ACTIVE_COMPARATOR|Group B (Caudal Injection)|About 40 patients who will be subjected to Ultrasound-Guided Caudal Injection in Lumbosacral Spine Surgeries for Postoperative Pain Management
61924865|NCT03320603|OTHER|Phase 1|Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.
61924866|NCT03320603|OTHER|Phase 2|Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.
62317555|NCT02778776|ACTIVE_COMPARATOR|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
62686892|NCT06075537|EXPERIMENTAL|Cohort A7|Participants with nMPS II, aged ≥2 to \<6 years
61924867|NCT01960387|EXPERIMENTAL|Clofarabine and Cytarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
61924868|NCT01727908|NO_INTERVENTION|Endoscopy without staining of the mucosa|
61924869|NCT01727908|EXPERIMENTAL|Endoscopy with staining of the mucosa.|
61924870|NCT01099800||Mexican/Mexican American families|Parents and children who self-identify as being of Mexican heritage whether US-born or Mexican-born
61924871|NCT01099800||Puerto Rican families|Parents and children who self-identify as Puerto Rican whether US-born or island-born.
61924872|NCT04099251|EXPERIMENTAL|Nivolumab|
61924873|NCT04099251|PLACEBO_COMPARATOR|Placebo|
61924874|NCT06156540|NO_INTERVENTION|Control group|No intervention was made to the control group. The posttest was administered four weeks after the pretest.As a result, caregivers' care burden and psychological well-being will be measured.
61924875|NCT06156540|EXPERIMENTAL|Virtual Reality Group|A pretest was administered to the experimental group. Then, 360-degree VR videos (nature walks, trips, etc.) were watched three days a week for four weeks. Then, the final test was administered.As a result, caregivers' care burden and psychological well-being will be measured.
61924876|NCT02845830||Participants in early stage of dementia|Subjects with any type of dementia at an early phase diagnosed in the last 12 months with MMSE score 20-25 points
61924877|NCT02845830||Participants without dementia|Subjects without dementia with MMSE score 26-30 points
61924878|NCT00320164||Group A: Leukapheresis|Subject's peripheral blood mononuclear cells are collected via leukapheresis.
62317556|NCT02778776|PLACEBO_COMPARATOR|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
62317557|NCT04545112|EXPERIMENTAL|XABG|
61924879|NCT00320164||Group B: Buffy Coats Collection|Subject's peripheral blood mononuclear cells are collected via the buffy coats from blood.
61924880|NCT04041739||diabetic foot osteomyelitis|"Patients will be subjected to:~1-History taking including duration of diabetes and ulcer . 2 Clinical examination of ulcer , including diagnosis of osteomyelitis 3- Venous blood will be withdrawn to do the following laboratory tests :~* HbA1c~* erythrocyte sedimentation rate(ESR)~* C reactive protein(CRP)~* Complete blood culture~* Serum urea and creatinine 4-culture and sensitivity test 5-Bone fragments and tissue biopsy from infected ulcers 6-Fundus examination"
62317558|NCT01270646|EXPERIMENTAL|Intraventricular Electrical Activation|
61924881|NCT04092569|ACTIVE_COMPARATOR|Intervention group|Pre-medical consultation structured diabetes self-care education programme
61924882|NCT04092569|NO_INTERVENTION|Control group|Usual care
61924883|NCT05333783|EXPERIMENTAL|Augmented Reality Exposure Therapy Based on ExposXR software|The intervention arm will receive the assigned intervention in one session. Participants will be called for 2 times for post-assessment.
61924884|NCT05333783|NO_INTERVENTION|Treatment as Usual|The control arm has no intervention. However, the participants are not given any instruction limiting their encounters with the phobic stimuli. The participants in the control arm will receive the intervention after the post-assessments are completed.
61924885|NCT02906969|EXPERIMENTAL|Colonoscopy educational Video|Brief educational video of colonoscopy to determine comprehension and quality of bowel preparation.
61924886|NCT02906969|PLACEBO_COMPARATOR|Control|Non-colonoscopy video as a control.
62127247|NCT03125863|EXPERIMENTAL|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
62317559|NCT03008590|OTHER|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
62317560|NCT03008590|OTHER|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
61924887|NCT01058265|EXPERIMENTAL|Integrative|Integrative Medical care is defined as a comprehensive medical evaluation that emphasizes wellness and healing of the whole person as major goals above and beyond suppression of a specific somatic disease. The patient is viewed as a whole person with mind and spirit as well as body and these dimensions are incorporated into diagnosis and treatment plans. An integrative medicine evaluation includes four aspects of health: physical, emotional, mental and spiritual health. Maximum improvement in health is achieved by addressing each aspect through an integrated treatment plan. The evaluation generally takes 90-120 minutes.
61924888|NCT01058265|ACTIVE_COMPARATOR|Standard|Standard general medical evaluation.
61924889|NCT04488107|EXPERIMENTAL|Dose escalation cohort of FCN-437c|"* This study plans to start escalating from 50 mg QD, through 100 mg, 200 mg, 300 mg, 450 mg, to 600 mg.~* Participants will receive FCN-437c in sequential 28-day cycles which are made up of monotherapy QD for 21 days followed by a 7 day rest period.~* Participants must be histologically or cytologically diagnosed with ER+/ HER2- advanced breast cancer."
61924890|NCT04488107|EXPERIMENTAL|Dose expansion cohort of FCN-437c + letrozole|"* The dose expansion stage will be initiated after escalating to MTD.~* Six patients will be treated with FCN-437c combined with letrozole.~* DLT assessment and PK blood collection will be completed in the first 28-day cycle.~* If DLT does not occur in the first three patients, 15 additional patients were enrolled to complete the expansion study of MTD group.~* If one DLT occurs in the first three patients, three additional patients will be enrolled onal patients were enrolled and completed the MTD group.~* Patients will be evaluated every 8 weeks until disease progression, intolerable toxicity, death, investigator's decision or patient's voluntary withdrawal from the study."
61924891|NCT05122676|EXPERIMENTAL|MI-CARE program|Those automatically identified as eligible and randomized to the MI-CARE arm are outreached by a study nurse care manager and offered the 12-month long virtual Collaborative Care program by telephone or video visits. Individuals are free to accept or decline the offer (e.g., stop/restart, not accept right away) during the 12 months after their randomization date.
61924892|NCT05122676|NO_INTERVENTION|Usual care|Those identified as eligible and randomized to the usual care arm have no contact with the study. All outcome data for both study arms are collected from secondary, electronic sources.
61924893|NCT02433327|ACTIVE_COMPARATOR|PEWS - trigger tool|"Paediatric Early Warning Score:~Children randomized to PEWS - trigger tool"
61924894|NCT02433327|ACTIVE_COMPARATOR|RM - trigger tool|"Paediatric Early Warning Score:~Children randomized to Central Denmark Region (RM)- trigger tool"
62317561|NCT06361277|OTHER|Group 1|"Treatment A: Co-administration of 2 tablets of C2205 and JW0201 Treatment B: Co-administration of 2 tablets of JW0202 and C2202~Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration"
62317562|NCT06361277|OTHER|Group 2|"Treatment A: Co-administration of 2 tablets of C2205 and JW0201 Treatment B: Co-administration of 2 tablets of JW0202 and C2202~Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration"
62317563|NCT06660212|SHAM_COMPARATOR|Sham laser|15 treatments will be provided over a 12 week period but at an intensity of 1% output for all sites and at all stages. Each treatment will last approximately 20 minutes. At each visit, the array will be applied to the surface of the perineum (red and infrared light), followed by treatment at specific painful sites using the red light probe.
62686893|NCT06075537|EXPERIMENTAL|Cohort B7|Participants with nnMPS II, aged ≥6 to \<17 years
61924895|NCT02380820|EXPERIMENTAL|AirsoftDuo first|"Patients randomized to this arm will be placed on the Airsoft Duo mattress, and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Softform Premium mattress (in static mode). The patient will then continue his/her stay with the Softform Premium mattress (in static mode) for 1 month.~Intervention: Airsoft Duo mattress Intervention: Softform Premier mattress (in static mode)"
62127248|NCT01691690|EXPERIMENTAL|IV Acetaminophen|Patients will receive pre-medication with oral midazolam Participants of this experimental arm of the study will receive Acetaminophen IV to evaluate opioid-sparing effect and pain score reduction..
62127249|NCT01691690|PLACEBO_COMPARATOR|Saline placebo infused intraoperatively|For this arm Morphine will be administered to manage pain.
62317564|NCT06660212|ACTIVE_COMPARATOR|Real laser|15 treatments will be provided over a 12 week period. Each treatment will last approximately 20 minutes and will include the laser array first being applied to the surface of the perineum (red and infrared light) and the focal probe will be applied to painful sites on the perineum. All the stages will involve use of the same array and probe placement, but at each stage the dosage will be increased according to the BioFlex protocol.
62686894|NCT06599320||Partial edentulous patients rehabilitated with at least one dental implant|Partial edentulous patients rehabilitated with at least one dental implant in function for at least 20-years
62479577|NCT06491420|EXPERIMENTAL|Patients with pipin 1 fractures fixed with arthroscopy|"Accurate portal placement was essential for optimal visualization and safe access to the hip joint.~* The anterolateral, anterior, and distal lateral accessory portals were utilized for arthroscopic labral repair.~* The anterolateral portal was placed approximately 1-2 cm superior to the tip of the greater trochanter and 1-2 cm anterior, at an angle of 15° to 20° relative to the floor.~* The anterior portal was established for visualization of the posterior-superior capsule, posterior-superior labrum, posterior recess, femoral head, ligamentum teres, and other structures.~* The distal lateral accessory portal was placed after traction was released and the operative knee was flexed to 45°.~After reducing the fracture under arthroscopic guidance, a guidewire fixed the fracture a cannulated screw was passed over the wire to fix the fracture."
62697422|NCT05640427|EXPERIMENTAL|Group D1|groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
62479578|NCT03659994|EXPERIMENTAL|Vitabeard High Dose|3 capsules of multivitamin Vitabeard
62479579|NCT03659994|EXPERIMENTAL|Vitabeard Mid-Dose|2 Capsules of multivitamin Vitabeard, 1 Capsule of Placebo
62479580|NCT03659994|EXPERIMENTAL|Vitabeard Low-Dose|1 Capsule of multivitamin Vitabeard, 2 Capsules of Placebo
62479581|NCT03659994|PLACEBO_COMPARATOR|Placebo|3 Capsules of Placebo
62479582|NCT00702533||Healthy volunteers|Healthy volunteers between 18 and 60 years of age
62479583|NCT00702533||patients with gastric acid secretory disorders|18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.
62479584|NCT05232786||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
62127250|NCT04921293|ACTIVE_COMPARATOR|Standard Diet|Standard diet incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with bitter taste placebo.
62317565|NCT06660212|ACTIVE_COMPARATOR|Sham laser + multi-modal physiotherapy|Over 12 weeks, participants will receive 10 physiotherapy sessions and 15 sham laser sessions, lasting a total of 50 minutes. Laser and physiotherapy treatments will be delivered within the same visit where possible. For the physiotherapy, the therapist will start with education, followed by progressive relaxation exercises and deep breathing. Participants will practice graded pelvic floor muscle (PFM) contractions, manual stretching techniques with external palpation, and gradually progressing to the insertion of one or two fingers into the vagina. Finally, vaginal dilators will be used to stretch the vaginal opening and PFMs. The participant will use relaxation breathing and contraction/relaxation cycles to facilitate insertion, progressing to larger dilators as tolerated. For the sham laser, the same protocol will be followed as described in previous arms.
62317566|NCT06660212|EXPERIMENTAL|Laser + multi-modal physiotherapy|This treatment group will receive a combination therapy (i.e., both laser and physiotherapy), with each session lasting up to 50 minutes over a 12 week period. Laser and physiotherapy treatments will be delivered within the same visit where possible. Laser and physiotherapy protocols will be delivered as described in the previous arms.
62317567|NCT04985773|EXPERIMENTAL|Lacrosse NSE ALPHA percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) in which at least one Lacrosse NSE ALPHA device is used.
62317568|NCT02682888|EXPERIMENTAL|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
62127251|NCT04921293|EXPERIMENTAL|Endogenous Ketosis|Ketogenic diet incorporating current recommendations for heart failure (\<50gr of carbohydrates, low sodium, and liquids) for 10 days.
62317569|NCT02682888|EXPERIMENTAL|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
62317570|NCT02682888|EXPERIMENTAL|oxytocin group|experiment 2: intranasal administration of oxytocin
62317571|NCT02682888|PLACEBO_COMPARATOR|placebo control group|experiment 2: intranasal administration of placebo
62317572|NCT02458651||Tier 1 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
62317573|NCT02458651||Tier 1 and South|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
62479585|NCT05232786||Health Care Professionals (HCPs)|HCPs treating people who have obesity
62479586|NCT03142568|EXPERIMENTAL|Sildenafil cohort 1|Within cohort 1 infants will be randomized using a 3:1 scheme to receive sildenafil or placebo. Infants randomized to sildenafil will receive 0.125 mg/kg daily every 8 hours intravenously (IV), or 0.25 mg/kg daily every 8 hours enterally for 28 days.
62479587|NCT03142568|PLACEBO_COMPARATOR|Placebo cohort 1|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
62127252|NCT04921293|EXPERIMENTAL|Exogenous ketosis|Standard incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with exogenous ketones (ketone monoester) for 10 days.
62127253|NCT03348371|EXPERIMENTAL|Oral day|Participant receive ethanol orally
62127254|NCT03348371|EXPERIMENTAL|i.v. infusion day|Participant receive ethanol in an i.v. infusion
62127255|NCT03230942|EXPERIMENTAL|Patient education program|Pre-operative education and pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
62127256|NCT03230942|ACTIVE_COMPARATOR|Control - only pos-op rehabilitation|Pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
62127257|NCT05669170|ACTIVE_COMPARATOR|Treatment|Methylphenidate 20 mg
62127258|NCT05669170|PLACEBO_COMPARATOR|Placebo|Placebo
62127259|NCT04459897||diagnosed or treated for granulomatous hepatitis fol|The cohort is composed by patient diagnosed or treated for granulomatous hepatitis followed in the internal medicine and / or Hepato-gastroenterology departments (Croix-Rousse Hospital, Edouard-Herriot Hospital, Lyon Sud Hospital Center).
62127260|NCT01941758|EXPERIMENTAL|Basic science (trivalent influenza vaccine)|Patients receive trivalent influenza vaccine on day 1.
62317574|NCT02458651||Tier 2 and Middle|Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
62317575|NCT02458651||Tier 2 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
62317576|NCT02458651||Tier 2 and South Eastern|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
62317577|NCT02458651||Tier 2 and South Western|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
62317578|NCT03611309|EXPERIMENTAL|Surgeon-palliative care team co-management|In the Surgeon-palliative care team co-management arm, all patients receive the surgical care of surgeon alone management, which includes surgeon and the surgical team. In addition to this surgeon alone care, palliative care will also be provided by a specialist team. For patients in this arm, patients and/or family members will be seen by the palliative care team: (1) in an outpatient setting prior to surgery, (2) in the hospital within 72 hours of their initial surgery and as needed afterwards, and (3) via phone on in-clinic (per patient preference) on an at least monthly basis and/or as needed for 12 weeks following surgery.
62317579|NCT03611309|OTHER|Surgeon alone management|The surgeon and surgical team will manage symptoms, psychosocial support, and prognostic related communication. The surgeon and surgical team care for the patient and their family both prior to and following surgery. The surgeon team is given guidelines published by the National Cancer Coalition Network as to when palliative care specialist consultation is recommended
62127261|NCT02976532|OTHER|EMT Arm|The study is performed with a single arm, as the system is an additional tool for derotation measurement and the surgical procedure itself and its technique is not changed.
62686895|NCT04402073|OTHER|standard arms|"Criteria: Adult SHH (p53wt) M0-1, adult WNT M0-1, adult Group 4 M0-1.~Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.~Criteria: Post pubertal \< 18 y SHH (p53wt) M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy."
62686896|NCT04402073|EXPERIMENTAL|experimental arms|"Radiotherapy Criteria: Adult and post-pubertal SHH (p53wt) M0; adult WNT M0, adult Group 4 M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy.~SMO-inhibitor Criteria: Adult and post-pubertal SHH (p53wt) M0.~Sonidegib 200 mg/day (daily) from first day of radio-chemotherapy until end of maintenance chemotherapy, including 6w chemotherapy break."
62686897|NCT02241031|EXPERIMENTAL|MPs|MPs will be intravenously infused within 48 hours after chemotherapy. During the study period, patients can receive platelet infusion but can not receive platelet stimulating factors.
62686898|NCT02241031|ACTIVE_COMPARATOR|Non-MPs|Patients can receive platelet infusion but can not receive platelet stimulating factors.
62317580|NCT01526187||Sub-Saharan Africa|
62317581|NCT01526187||Asia|
62686899|NCT05544344|EXPERIMENTAL|Intervention|Subjects receive an intervention with 4 components: establishing a working alliance with a health coach, completing an online inventory to assess personal wellness in eight life areas, developing a Restart plan that includes personalized life goals, and follow-along with a health coach to address barriers to goal attainment and to reinforce achievement.
62686900|NCT05544344|ACTIVE_COMPARATOR|Services as Usual|Subjects receive mental health services as usual.
62686901|NCT03320083|ACTIVE_COMPARATOR|Educational care derived from POSSUMS|Intervention group were offered a sleep education session using behavioral change counseling communication skills, derived from the POSSUMS approach developed by Douglas P and Whittingham K. However we could not use Acceptance and Commitment Therapy (ACT), because none of the investigators had sufficient training on ACT at the time the study was conducted.
62686902|NCT03320083|NO_INTERVENTION|Usual Care|General anticipatory guidance given
62317582|NCT01526187||Latin America|
62686903|NCT01456403||Carotid endarterectomy patients|Patients scheduled for clinically indicated carotid endarterectomy
62686904|NCT06528184|ACTIVE_COMPARATOR|Usual care arm|Participants will only be offered clinician-sampling for HPV DNA testing to determine if they are agreeable to undergo screening.
62686905|NCT06528184|EXPERIMENTAL|Intervention arm|Participants will be offered clinician-sampling or self-sampling for HPV DNA testing to determine if they are agreeable to undergo screening using either modality.
62317583|NCT02135601|NO_INTERVENTION|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
62317584|NCT02135601|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
62686906|NCT02346812|EXPERIMENTAL|Brassica|Brassica vegetables will be consumed daily as part of a controlled diet.
62127262|NCT02143739||Newly diagnosed asthma patients|The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD(chronic obstructive pulmonary diseases) history, or asthma exacerbation.
62317585|NCT03799003|EXPERIMENTAL|ASP1951 0.07 mg Monotherapy|Participants have received ASP1951 0.07 mg intravenously on day 1 of every 3-week cycle.
62317586|NCT03799003|EXPERIMENTAL|ASP1951 0.7 mg Monotherapy|Participants have received ASP1951 0.7 mg intravenously on day 1 of every 3-week cycle.
62686907|NCT02346812|OTHER|Control|Typical American diet will be consumed, without any Brassica vegetables.
62317587|NCT03799003|EXPERIMENTAL|ASP1951 5 mg Monotherapy|Participants have received ASP1951 5 mg intravenously on day 1 of every 3-week cycle.
62686908|NCT01767857|EXPERIMENTAL|Xilonix|MABp1 administered IV every two weeks, plus best supportive care
62686909|NCT01767857|PLACEBO_COMPARATOR|Placebo|Placebo administered IV every two weeks, plus best supportive care
62686910|NCT01514422|EXPERIMENTAL|Minocycline|All subjects will be given minocycline over 8 weeks
62127263|NCT03366636|NO_INTERVENTION|Control|"The control/comparison group will be receiving only their usual services which are offered at the agencies they frequent, including mental health services, case management, job training, educational services, and, in specific venue contexts, may receive HIV risk reduction or other sex education interventions such as Street Smart. These same services are also open to the intervention group. Usage of these services varies by site (residential vs drop-in; city (San Diego vs Los Angeles) and type of service (case management, mental health, health care, etc.)."
62127264|NCT03366636|EXPERIMENTAL|Project Legacy|The experimental/intervention arm will receive the Project Legacy intervention
62127265|NCT00757133|EXPERIMENTAL|1|Conventional laparotomy closure
62127266|NCT00757133|ACTIVE_COMPARATOR|2|Laparotomy closure with mesh augmentation
62127267|NCT03832894|ACTIVE_COMPARATOR|Group receiving oestradiol tablets in addition to progesterone|"Group A :Will receive 400mg progesterone in the form of vaginal or rectal suppositories in addition to estradiol valerate oral tablets in a dose of 4mg/day(2x2), for luteal phase support. Starting from the day of ovum pickup and for 14 days after embryo transfer.~Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer."
62127268|NCT03832894|PLACEBO_COMPARATOR|Group not receiving oestradiol tablets.|Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer
62127269|NCT01885793||Cuffed endotracheal tube|Surgical patients who require endotracheal intubation with a cuffed endotracheal tube (ETT).
62127270|NCT01070069|ACTIVE_COMPARATOR|Standard EVAR (IntuiTrak)|EVAR using standard vascular exposure for access
62317588|NCT03799003|EXPERIMENTAL|ASP1951 20 mg Monotherapy|Participants have received ASP1951 20 mg intravenously on day 1 of every 3-week cycle.
62317589|NCT03799003|EXPERIMENTAL|ASP1951 70 mg Monotherapy|Participants have received ASP1951 70 mg intravenously on day 1 of every 3-week cycle.
62317590|NCT03799003|EXPERIMENTAL|ASP1951 200 mg Monotherapy|Participants have received ASP1951 200 mg intravenously on day 1 of every 3-week cycle.
62317591|NCT03799003|EXPERIMENTAL|ASP1951 700 mg Monotherapy|Participants have received ASP1951 700 mg intravenously on day 1 of every 3-week cycle.
62317592|NCT03799003|EXPERIMENTAL|ASP1951 1400 mg Monotherapy|Participants have received ASP1951 1400 mg intravenously on day 1 of every 3-week cycle.
62317593|NCT03799003|EXPERIMENTAL|ASP1951 20 mg + pembrolizumab 200 mg Combination Therapy|Participants have received ASP1951 20 mg intravenously on day 1 of every 3-week cycle in combination with pembrolizumab 200 mg administered on day 1 of every 3-week cycle, at least 30 minutes after the end of infusion of ASP1951.
62317594|NCT03799003|EXPERIMENTAL|ASP1951 700 mg + pembrolizumab 200 mg Combination Therapy|Participants have received ASP1951 700 mg intravenously on day 1 of every 3-week cycle in combination with pembrolizumab 200 mg administered on day 1 of every 3-week cycle, at least 30 minutes after the end of infusion of ASP1951.
62686911|NCT02242656|EXPERIMENTAL|Group 1|Assigned to receive Treatment A (Period 1), Treatment B (Period 2), Treatment C (Period 3)
62686912|NCT02242656|EXPERIMENTAL|Group 2|Assigned to receive Treatment B (Period 1), Treatment A (Period 2), Treatment C (Period 3)
62686913|NCT04351672|EXPERIMENTAL|Early Time-Restricted Feeding|
62686914|NCT04351672|EXPERIMENTAL|Late Time-Restricted Feeding|
62127271|NCT01070069|EXPERIMENTAL|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
62127272|NCT01070069|EXPERIMENTAL|PEVAR (ProstarXL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
62127273|NCT01154985|PLACEBO_COMPARATOR|Placebo|3x placebo capsules TID
62127274|NCT01154985|EXPERIMENTAL|EPA-E 1800 mg/day|2x EPA-E 300 mg capsules + 1placebo capsule TID
62686915|NCT01517178|ACTIVE_COMPARATOR|Standard Care base plate|Standard care are the participants own product and can have several manufacture and brand names
62686916|NCT01517178|EXPERIMENTAL|New ostomy base plate (SS)|SS = New ostomy base plate. Due to company confidentiality the product is called SS and this is not short for any name
62686917|NCT05586685|EXPERIMENTAL|GroupA diaphragmatic release + conventional|"Group A: diaphragmatic release +conventional The patients will be positioned in the supine position. The therapist stood at the head of the patient contact thoracic cage and ask the patient to take inspiration and move laterally then ask the patient to expire.~conventional Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks: Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch the pectoral area from the supine lying position"
62686918|NCT05586685|EXPERIMENTAL|Group B: conventional|Group B: conventional posture correction exercises Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position
62686919|NCT02034266|EXPERIMENTAL|Omega-3 supplementation|Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.
62686920|NCT05451329|ACTIVE_COMPARATOR|VVN539 Ophthalmic Solution 0.02%|VVN539 Ophthalmic Solution 0.02%
62686921|NCT05451329|ACTIVE_COMPARATOR|VVN539 Ophthalmic Solution 0.04%|VVN539 Ophthalmic Solution 0.04%
62686922|NCT05451329|PLACEBO_COMPARATOR|VVN539 Ophthalmic Solution Vehicle|VVN539 Ophthalmic Solution Vehicle
62686923|NCT02395627|EXPERIMENTAL|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
62686924|NCT02395627|EXPERIMENTAL|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
62686925|NCT02395627|EXPERIMENTAL|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
62686926|NCT03906955|EXPERIMENTAL|Efficacy for Lifestyle PA|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for lifestyle physical activity.
62686927|NCT03906955|ACTIVE_COMPARATOR|Efficacy for Work-life Balance|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for work-life balance.
62686928|NCT01100580|ACTIVE_COMPARATOR|water therapy|"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
62127275|NCT01154985|EXPERIMENTAL|EPA-E 2700 mg/day|3x EPA-E 300 mg capsules TID
62686929|NCT01100580|EXPERIMENTAL|low salt diet + water therapy|low salt diet refers to a salt intake of 4 g/day
62127276|NCT02668250|EXPERIMENTAL|Experimental group : OPTI-AGED|The OPTI-AGED group will receive a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia.
62127277|NCT02668250|ACTIVE_COMPARATOR|Control Group :|The control group will not benefit from the OPTI-AGED intervention but patients will receive the usual care.
62127278|NCT05961020|EXPERIMENTAL|20 women was treated by moderate restricted diet for 3 months.|
62317595|NCT03799003|EXPERIMENTAL|ASP1951 1400 mg + pembrolizumab 200 mg Combination Therapy|Participants have received ASP1951 1400 mg intravenously on day 1 of every 3-week cycle in combination with pembrolizumab 200 mg administered on day 1 of every 3-week cycle, at least 30 minutes after the end of infusion of ASP1951.
62317596|NCT03388983|EXPERIMENTAL|6-week prehabilitation group|6-week prehabilitation
62127279|NCT05961020|EXPERIMENTAL|20 women treated by whole body vibration.|
62317597|NCT03388983|NO_INTERVENTION|Control group|Patients will receive standard preoperative care (including information about the surgery from an orthopedic surgeon, and a pamphlet summarizing tips of maintaining proper posture and staying active). The usual postoperative care does not include routine rehabilitation program though a short course of rehabilitation may be given based on orthopedic surgeons' discretion.
62317598|NCT03399539|EXPERIMENTAL|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62317599|NCT04316572|EXPERIMENTAL|mental health specialist video consultation|"The intervention group will receive five video consultations with psychotherapists directly in the GP's practice.~The consultations will be carried out via the web portal of a certified video service provider (arztkonsultation ak GmbH). The patient will be located in the GP's practice and the psychotherapist in his practice or another suitable room. Patients are scheduled for five sessions of 50 minutes."
62317600|NCT04316572|NO_INTERVENTION|treatment as usual by the GP|Routine treatment by the GP, which may or may not include conversations about psychosocial problems and/or referral to specialised services (e.g., inpatient therapy, counseling, self-help).
62127280|NCT05105126|EXPERIMENTAL|Active tDCS first|"\[Active stimulation first, then crossover to Sham stimulation\]~Each participant will receive BOTH sham or active tDCS but the order of each will be randomized. The active tDCS and sham are procedurally identical. Participants in both arms will have the initial tingling sensation and the active tDCS stimulation will CONTINUE for 20 minutes at 1 mA (milliamps). All tDCS sessions will occur during ABA therapy."
62317601|NCT01025245|EXPERIMENTAL|remifentanil, MgSO4|Experimental 1 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and MgSO4 30 mg/kg IV at the induction followed by intraoperative infusion at 10 mg/kg/hr Drug : remifentanil, MgSO4 Experimental 2 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and normal saline Drug : remifentanil Active comparator : Intraoperative remifentanil infusion at 0.05 ㎍/㎏/min and normal saline Drug : remifentanil
62479588|NCT03142568|EXPERIMENTAL|Sildenafil cohort 2|Cohort 2 infants will receive sildenafil 0.5 mg/kg daily every 8 hours intravenously (IV) or 1 mg/kg daily every 8 hours enterally for 28 days.
62127281|NCT05105126|SHAM_COMPARATOR|Sham tDCS first|"\[Sham stimulation first, then crossover to Active stimulation\]~Each participant will receive BOTH sham or active tDCS but the order of each will be randomized. The active tDCS and sham are procedurally identical. Participants in both arms will have the initial tingling sensation, except in sham stimulation, the current will be DISCONTINUED after 30 seconds while the power indicator remains on for the remainder of 20 minutes at 0 mA (milliamps). All tDCS sessions will occur during ABA therapy."
62127282|NCT01579916|EXPERIMENTAL|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
62127283|NCT01579916|PLACEBO_COMPARATOR|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
62127284|NCT00879060|EXPERIMENTAL|Spironolactone|Experimental group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to experimental group will be initiated on 25mg of spironolactone. If at week 4, serum potassium is \<5.5 mmol/L and serum creatinine-baseline creatinine is \<0.5 mg/dl, the study drug will be increased to the target dose of 50mg once daily.
62127285|NCT00879060|PLACEBO_COMPARATOR|Placebo Control|Placebo group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to placebo group will be initiated on an inactive placebo pill.
62127286|NCT06232577|EXPERIMENTAL|5x-Multiplier Model|In this group, you will be given 5 times the amount of opioid medication you needed on your last day in the hospital. You would then use this supply plus standard non-narcotic pain medications.
62127287|NCT06232577|EXPERIMENTAL|3-Tier Model|The total amount of opioid medication you needed on your last day in the hospital to set a maximum number of opioid medications at discharge (up to 30).
62317602|NCT06138847||Group I|Group I consisted of children with epilepsy who were only taking one type of ASMs, either levetiracetam or carbamazepine
62317603|NCT06138847||Group II|Group II comprised forty-one age and sex-matched healthy children as a control group.
62686930|NCT02918630|ACTIVE_COMPARATOR|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
62127288|NCT05724420|EXPERIMENTAL|STRIVE Group|"STRIVE is comprised of a 4-hour formal education session where participants are provided knowledge, skills, and resources specific to self-assessment for mental wellness and effective mindfulness strategies.~High-fidelity simulation sessions are utilised to reinforce and apply mindfulness techniques learned in the formal session. Clinical scenarios are designed to be challenging and stressful."
62317604|NCT05934799|OTHER|Sequence TR|30 subjects assigned to the sequence TR will receive a single 75 mg dose of the test product Clopidogrel (1 x 75 mg film-coated tablet), marked as T in the sequence, in Period 1 and Period 3, and a single 75 mg dose of the reference product Plavix® (1 x 75 mg film-coated tablet), marked as R in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62317605|NCT05934799|OTHER|Sequence RT|30 subjects assigned to the sequence RT will receive a single 75 mg dose of the reference product Plavix® (1 x 75 mg tablet), marked as R in the sequence, in Period 1 and Period 3 and a single 75 mg dose of the test product Clopidogrel (1 x 75 mg tablet), marked as T in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62317606|NCT04134104||Bowel, Bladder, and Sexual Dysfunction group|Out of 38 patients included for surgery 12 were excluded due to poor follow up and those patients who underwent upfront surgery. Only 26 patients were included in the study. There were 20 (76.9%) males and 6 (23.1%) females respectively. The mean age of the patient was 43.577yrs (26-75) and mean BMI was 20.78. The number of patients that underwent LAR was 24 (92.30%) and those who underwent APR were 2( 7.6%) after neoadjuvant chemoradiotherapy respectively.
62686931|NCT02918630|EXPERIMENTAL|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
62686932|NCT05081271|ACTIVE_COMPARATOR|Homologous booster vaccine group|A single dose booster of the same type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
62686933|NCT05081271|ACTIVE_COMPARATOR|Heterologous booster vaccine group|A single dose booster of the opposite type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
62479589|NCT03142568|PLACEBO_COMPARATOR|Placebo cohort 2|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
62317607|NCT04713358|EXPERIMENTAL|Nalmefene group|for the nalmefene group, immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
62479590|NCT03142568|EXPERIMENTAL|Sildenafil cohort 3|Cohort 3 infants will receive sildenafil 1 mg/kg daily every 8 hours intravenously (IV) or 2 mg/kg daily every 8 hours enterally for 28 days.
62479591|NCT03142568|PLACEBO_COMPARATOR|Placebo cohort 3|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
62127289|NCT05724420|NO_INTERVENTION|Control|Residents randomized to the control group will receive information regarding resilience development as per the usual standard of communication. All new residents will receive contact details of physician wellness services available at Schulich School of Medicine \& Dentistry.
62317608|NCT04713358|PLACEBO_COMPARATOR|Control group|Intravenous injection of normal saline 1ml immediately after surgery
62317609|NCT02813330|EXPERIMENTAL|Sterile Water injection|Subcutenous injection at low back portion during labor pain
62317610|NCT02813330|EXPERIMENTAL|saline injection|Subcutenous injection at low back portion during labor pain
62317611|NCT02517047|EXPERIMENTAL|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
62317612|NCT04644419||Control group of the LCCC1848|Patients in the control arm will receive standard of care.
62317613|NCT02413398|EXPERIMENTAL|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
62317614|NCT02413398|PLACEBO_COMPARATOR|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
62317615|NCT04020237|NO_INTERVENTION|Observational arm|General counselling to particulate matter practice score.
62317616|NCT04020237|OTHER|Interventional arm|Active education and feedback on the particulate matter practice score that affects real life.
62317617|NCT01369810||1|All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
62317618|NCT03920852|EXPERIMENTAL|Ruxolitinib cream|
62479592|NCT05521984|EXPERIMENTAL|Brain Cancer: Dapagliflozin + Standard of Care Chemotherapy (Ages 6-10)|"* Dapagliflozin will be initiated by mouth once daily at the same time as standard of care chemotherapy (carmustine).~* Dapagliflozin 5 mg by mouth once daily on days 1-84 (duration of study)~* All patients will stop taking dapagliflozin after 12 weeks of treatment."
61924896|NCT02380820|EXPERIMENTAL|Softform Premium first|"Patients randomized to this arm will be placed on the Softform Premium mattress (in static mode), and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Airsoft Duo mattress. The patient will then continue his/her stay with the Airsoft Duo mattress for 1 month.~Intervention: Softform Premier mattress (in static mode) Intervention: Airsoft Duo mattress"
61924897|NCT00281073|ACTIVE_COMPARATOR|TEE and ICE|Serial use of TEE and ICE for comparative analysis
61924898|NCT00281073|ACTIVE_COMPARATOR|ICE or TEE|
62479593|NCT05521984|EXPERIMENTAL|Brain Cancer: Dapagliflozin + Standard of Care Chemotherapy (Ages 11-21)|"* Dapagliflozin will be initiated by mouth once daily at the same time as standard of care chemotherapy (carmustine).~* Dapagliflozin will be initiated at 5 mg by mouth once daily, days 1-4 (2 weeks)~* Dapagliflozin will be escalated to 10 mg by mouth once daily for the remaining 10 weeks (after consultation with study endocrinologist)~* All patients will stop taking dapagliflozin after 12 weeks of treatment."
62686934|NCT05952375|EXPERIMENTAL|XKDCT086 treatment for patients with Claudin18.2 target positivity|"Drug: XKDCT086 (chimeric antigen receptor T cell preparation targeting Claudin18.2)~Dosage form: Cell suspension~Dose: 30-50mL/bag~Medication method: intravenous drip~Frequency: Once"
61924899|NCT04633460|EXPERIMENTAL|Ketone ester|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a ketone ester
62127290|NCT04454151|EXPERIMENTAL|Azithromycin|1x250
62127291|NCT00853918|EXPERIMENTAL|$20 Cash|
62127292|NCT00853918|EXPERIMENTAL|$50 Cash|
62317619|NCT03102775|EXPERIMENTAL|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
62317620|NCT03102775|ACTIVE_COMPARATOR|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
62317621|NCT05706519||Control Group|Six hundred volunteers. This group has to be without any type of cardiovascular Disease.
62317622|NCT05706519||Case Group|Six hundred volunteers. In this group, participants must present a diagnosis of ischemic heart disease at least 1 year but less than 5 years from recruitment
62317623|NCT05163561|EXPERIMENTAL|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A
62317624|NCT05163561|EXPERIMENTAL|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B
62127293|NCT00853918|EXPERIMENTAL|$50 Check|
62127294|NCT00853918|EXPERIMENTAL|$100 Check|
62317625|NCT05163561|EXPERIMENTAL|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C
62317626|NCT05163561|ACTIVE_COMPARATOR|Sii Licensed IPV|Sii Licensed IPV
62127295|NCT05035303|ACTIVE_COMPARATOR|Nor-Epinephrine (NE)-Group|The PCNL tract is infiltrated by Nor-Epinephrine before its dilatation.
62686935|NCT03995472|EXPERIMENTAL|SHR-1501 and SHR-1316 dose escalation|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
62127296|NCT05035303|PLACEBO_COMPARATOR|S-Group|The PCNL tract is infiltrated by Normal Saline before its dilatation.
62127297|NCT01698125||Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
62127298|NCT03273777|EXPERIMENTAL|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
61924900|NCT04633460|PLACEBO_COMPARATOR|Placebo|KE-free solution
62127299|NCT03273777|NO_INTERVENTION|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
62686936|NCT03995472|EXPERIMENTAL|SHR-1501 and SHR-1316 dose expansion|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
62686937|NCT03995472|EXPERIMENTAL|SHR-1501 and SHR-1316 Indication expansion|SHR-1501 given subcutaneously with a recommended dose. SHR-1316 given intravenously.
62317627|NCT01024673||patients with H1N1|patients who are clinical found to be positive for H1N1 will be enrolled
62479594|NCT05521984|EXPERIMENTAL|Solid Tumor Cancer: Dapagliflozin + Standard of Care Chemotherapy (Ages 6-10)|"* Dapagliflozin will be initiated by mouth once daily at the same time as standard of care chemotherapy (topotecan + cyclophosphamide).~* Dapagliflozin 5 mg by mouth once daily on days 1-84 (duration of study)~* All patients will stop taking dapagliflozin after 12 weeks of treatment.~* Each cycle is 21 days."
62127300|NCT03661957|ACTIVE_COMPARATOR|Non grafted maxillary sinus floor elevation with implant pacem|
62127301|NCT03661957|EXPERIMENTAL|using short dental implants for posterior atrophic maxilla|
62127302|NCT01714960|EXPERIMENTAL|Healthy volunteers low dose|MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.
62127303|NCT01714960|EXPERIMENTAL|Healthy volunteers high dose|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
62127304|NCT01714960|EXPERIMENTAL|Glaucoma patients|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
62127305|NCT01714960|PLACEBO_COMPARATOR|Placebo|Placebo eye drops, 1-3 drops three times per day, duration: 16 days.
62127306|NCT00411216|EXPERIMENTAL|exercises for gaze stabilization|Experimental group performed vestibular adaptation and substitution exercises
62127307|NCT00411216|PLACEBO_COMPARATOR|Control exercises|Saccadic eye movements against a Ganzfeld to prevent retinal slip error signal; no head movements
62127308|NCT03260140|EXPERIMENTAL|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
62127309|NCT03260140|NO_INTERVENTION|usual care control|participant in this arm will continue with usual care
62127310|NCT05445440|EXPERIMENTAL|Part 1|
62127311|NCT05445440|EXPERIMENTAL|Part 2|
62127312|NCT02722473|ACTIVE_COMPARATOR|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5°C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5°C for 24 hours.
62127313|NCT02722473|PLACEBO_COMPARATOR|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5°C for 48 hours
62127314|NCT01339130|OTHER|behavioral and physiological tests|Computerized tests and Electrophysiological measurements
62127315|NCT00525486|EXPERIMENTAL|A|The treated group of pregnant women, after having successful treatment for PTL
62127316|NCT00525486|NO_INTERVENTION|B|The no treatment arm of women treated with tocolysis for PTL.
62127317|NCT01546753|EXPERIMENTAL|Walnut Protein Powder|38 weeks on active walnut powder on blinded treatment phase
62127318|NCT01546753|PLACEBO_COMPARATOR|Oat Powder|38 weeks on placebo (oat) powder during blinded treatment phase
62686938|NCT06675448||Moderate MR|Patients who present with moderate MR and remain in this state will be re-evaluated at 6 months by a phone call and EMR review for ConComitant Cardiac Medication Review, NYHA Class and Adverse Event Evaluation. At 12 months a follow-up evaluation that will include a review of medications, NYHA class, KCCQ, 6MWT, BNP, Adverse Event review and TTE.
62127319|NCT01546753|OTHER|Open-label Walnut Protein Powder|Open-label treatment with walnut protein powder up to week 298 of total treatment
62127320|NCT03427346|ACTIVE_COMPARATOR|EMR|Endoscopic mucosal resection
62127321|NCT03427346|ACTIVE_COMPARATOR|ESD|Endoscopic submucosal dissection
62127322|NCT00595413|EXPERIMENTAL|Atacicept 150 mg with loading dose|
62127323|NCT00595413|EXPERIMENTAL|Atacicept 150 mg without loading dose|
62127324|NCT00595413|ACTIVE_COMPARATOR|Adalimumab|
62127325|NCT00595413|PLACEBO_COMPARATOR|Placebo|
62127326|NCT04207294|EXPERIMENTAL|Vitamin D-enriched pork|One portion of Vitamin D-enriched pork
62127327|NCT04207294|PLACEBO_COMPARATOR|Control pork|One portion of control pork
62127328|NCT04207294|ACTIVE_COMPARATOR|Vitamin D supplement|Equivocal dose of Vitamin D supplement
62127329|NCT04207294|EXPERIMENTAL|Vitamin D-enriched chicken|One portion of Vitamin D-enriched chicken
62127330|NCT04207294|PLACEBO_COMPARATOR|Control chicken|One portion of control chicken
62127331|NCT01039948|EXPERIMENTAL|Phase 2: AV-299 + gefitinib|Phase 2: AV-299 (formerly SCH 900105) administered IV at RP2D (as determined by Phase 1b portion) in combination with gefitinib 250 mg/day orally.
62127332|NCT01039948|ACTIVE_COMPARATOR|Phase 2: Gefitinib|Phase 2: Gefitinib 250 mg/day, orally.
62127333|NCT04263519|ACTIVE_COMPARATOR|Low Serum Level|Stable Blood Tacrolimus of 2-5 ng/ml.
62127334|NCT04263519|ACTIVE_COMPARATOR|High Serum Level|Stable Blood Tacrolimus of 5.1-10 ng/ml.
62127335|NCT02359188|ACTIVE_COMPARATOR|tVNS|Transcutaneous vagal nerve stimulation with 25 Hz
62127336|NCT02359188|SHAM_COMPARATOR|Sham-tVNS|Sham transcutaneous vagal nerve stimulation with 1 Hz
62317628|NCT04389606|EXPERIMENTAL|Study Formula (SF)|New infant formula for term infants
62317629|NCT04389606|ACTIVE_COMPARATOR|Comparator Formula (CF)|Commercially available infant formula for term infants
62317630|NCT04389606|NO_INTERVENTION|Human Milk Reference Group|Human milk
62479595|NCT05521984|EXPERIMENTAL|Solid Tumor Cancer: Dapagliflozin + Standard of Care Chemotherapy (Ages 11-21)|"* Dapagliflozin will be initiated by mouth once daily at the same time as standard of care chemotherapy (topotecan + cyclophosphamide).~* Dapagliflozin will be initiated at 5 mg by mouth once daily, days 1-4 (2 weeks)~* Dapagliflozin will be escalated to 10 mg by mouth once daily for the remaining 10 weeks (after consultation with study endocrinologist)~* All patients will stop taking dapagliflozin after 12 weeks of treatment.~* Each cycle is 21 days."
62479596|NCT01354626|EXPERIMENTAL|High fat diets|High-fat-Low-protein or High-fat-high-protein
62127337|NCT01708798|PLACEBO_COMPARATOR|Placebo|"One tablet by mouth daily. If serum potassium level is \<5.0 mmol/L at four weeks, increase to two tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is \<5.0 mmol/L at four weeks, increase to one tablet by mouth daily."
62127338|NCT01708798|EXPERIMENTAL|Eplerenone|"Eplerenone 25 mg tablet by mouth daily. If serum potassium level is \<5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is \<5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily."
62127339|NCT00099086|EXPERIMENTAL|Experimental Arm|
62127340|NCT03429972|EXPERIMENTAL|Paclitaxel and Elasto-Gel™ Cryotherapy|Cryotherapy will be applied using Elasto-Gel™ hypothermia mitts and slippers for 15 minutes before, during and 15 minutes after each paclitaxel infusion.
62127341|NCT03429972|OTHER|Paclitaxel alone|Paclitaxel will be administered without cryotherapy.
62127342|NCT03240978|EXPERIMENTAL|High intensity intervention|Exercise intervention at 70 to 80% of estimated heart rate maximum for 12 weeks.
62127343|NCT03240978|EXPERIMENTAL|Moderate intensity intervention|Exercise intervention at 50 to 70% of estimated heart rate maximum for 12 weeks.
62127344|NCT03240978|NO_INTERVENTION|non-exercise group|Participants will not receive any type of exercise training.
62127345|NCT02971943|OTHER|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
62127346|NCT05434273|EXPERIMENTAL|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
62127347|NCT05434273|SHAM_COMPARATOR|Control|Receive usual care
62127348|NCT06070337|EXPERIMENTAL|H-Guard|Participants receiving H-Guard Intervention.
62127349|NCT03663036|EXPERIMENTAL|FL-ASCR|Magnetic Resonance Imaging of the shoulder Radiograph of the shoulder
62127350|NCT01366677|EXPERIMENTAL|Yoga Therapy|
62127351|NCT00242359|OTHER|omalizumab|open-label
62127352|NCT01638026|EXPERIMENTAL|Gnrh agonist , hcg|Gnrh agonist for final oocyte maturation, hcg for luteal support
62127353|NCT02336386|EXPERIMENTAL|CDD Plus Bortezomib|Patients will receive Bortezomib (1.3mg/m2) Subcutaneous injection on Days 1, 4,8,11 and plus dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, Liposome doxorubicin 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity.
62127354|NCT02336386|ACTIVE_COMPARATOR|CDD|Dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, doxorubicin Dexamethasone 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity
62127355|NCT02722551|EXPERIMENTAL|Treatment|Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)
62479597|NCT01354626|OTHER|Control group|Low-protein-low-fat (according to healthy eating guidelines)
62686939|NCT06675448||Mitraclip|For patient who undergo Mitraclip, the safety and effectiveness of the procedure will be evaluated and all peri-procedural complications recorded using the same definitions for procedural success and complications used in the COAPT trial
62127356|NCT04586309|EXPERIMENTAL|Early TM Training|This group will receive training in Transcendental Meditation and will complete assessments at baseline, 1 month and 3 months.(3 assessments in total).
62127357|NCT04586309|ACTIVE_COMPARATOR|Delayed TM training|This arm will complete the baseline, 1 month and 3 month assessments and then will receive the TM training, followed by additional 1 month and 3 month post-training assessments (5 in total)
62127358|NCT06217692|EXPERIMENTAL|experimental group|experimental group
62127359|NCT06217692|NO_INTERVENTION|control group|control group
62317631|NCT04076449||Cerebral Cavernous Malformation with Epilepsy|Patients with cerebral cavernous malformation and associated with epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
62686940|NCT00304148||CRIC Cohort|
62686941|NCT00304148||CRIC Subcohort|
62686942|NCT01346917|EXPERIMENTAL|Lidocaine|
62127360|NCT01674699||EXCOR|Pediatric candidates age 0 - 21 with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR® Pediatric.
62127361|NCT00779870||1|healthy volunteers
62127362|NCT00779870||2|mild asthmatics
62127363|NCT00779870||3|moderately-severe asthmatics
62127364|NCT00779870||4|severe asthmatics
62127365|NCT01411592|ACTIVE_COMPARATOR|Multilink|RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system \[A/B primer and Multilink-Automix\] with Metal/Zirconia primer)
62686943|NCT01346917|PLACEBO_COMPARATOR|Placebo|
62686944|NCT05106062|EXPERIMENTAL|Remote Monitoring follow up|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
62317632|NCT04076449||Cerebral Cavernous Malformation without Epilepsy|Patients with cerebral cavernous malformation but without epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
62317633|NCT02703116|EXPERIMENTAL|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
62317634|NCT02703116|ACTIVE_COMPARATOR|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
62317635|NCT04146584|EXPERIMENTAL|Sofwave Treatment|In this arm (single) patients would be treated twice with Sofwave on the face and/or submental and neck.
62317636|NCT06300619|ACTIVE_COMPARATOR|Pilates|Standard Pilates Protocol with no hip/shoulder cuff cuing. Delivered from a seated position.
62127366|NCT01411592|ACTIVE_COMPARATOR|Panavia 21 TC|RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
62317637|NCT06300619|EXPERIMENTAL|Pilates+4|Pilates protocol that involves hip and shoulder cuff activation and stabilization exercises and cues to augment the Pilates exercise.
62317638|NCT02110121|EXPERIMENTAL|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
62317639|NCT02110121|EXPERIMENTAL|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
62127367|NCT01877343|EXPERIMENTAL|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
62317640|NCT01946048|EXPERIMENTAL|mesenchymal stem cells|Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
62127368|NCT04821219|EXPERIMENTAL|Tumoroid generation|Single arm, including all the patients enrolled to generate tumor models
62127369|NCT03569982|NO_INTERVENTION|Control|Patients receiving best supportive care
62317641|NCT06146218|EXPERIMENTAL|Contemplative-Based Resilience Training (CBRT)|The intervention group will undergo a 10-week program addressing mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing.
62317642|NCT01588197|EXPERIMENTAL|ACC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy.~The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the rACC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
62317643|NCT01588197|EXPERIMENTAL|PFC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy. The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the PFC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
62317644|NCT00921505|ACTIVE_COMPARATOR|Ibuprofen 400 mg|Ibuprofen oral single dose
62317645|NCT00921505|ACTIVE_COMPARATOR|Ibuprofen 1200 mg|Ibuprofen oral single dose
62317646|NCT00921505|ACTIVE_COMPARATOR|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) oral single dose
62317647|NCT00921505|ACTIVE_COMPARATOR|Ibuprofen 400 mg + paracetamol 1000 mg|Paracetamol (acetaminophen) + ibuprofen oral single dose
62317648|NCT01095250|EXPERIMENTAL|AIN457 300mg s.c every 2 weeks|AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks.
62317649|NCT01095250|EXPERIMENTAL|AIN457 300mg s.c. every 4 weeks|AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks.
62317650|NCT01095250|EXPERIMENTAL|AIN457 150mg s.c every 4 weeks|AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks
62317651|NCT01095250|PLACEBO_COMPARATOR|Placebo s.c every 2 weeks|Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks
62317652|NCT00849303|EXPERIMENTAL|earlier gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
62686945|NCT05106062|NO_INTERVENTION|Conventional Follow up|This group will not turn on remote monitoring function of defibrillator. Patient should be seen at clinic according to center's custom but no longer than 6 months between each visit
62686946|NCT05686720|EXPERIMENTAL|SZ011 CAR-NK|
62686947|NCT06674876|NO_INTERVENTION|Control group|This group only filled pre and post surveys at baseline, 4 and 6 weeks
62686948|NCT06674876|OTHER|IG 1-Blog writing|This group were asked to write 2blogs a week for four weeks based on SOPHIE framework
62127370|NCT03569982|EXPERIMENTAL|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
62127371|NCT01409252||Hemorrhagic stroke patients|
62127372|NCT01860612|EXPERIMENTAL|PMA Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
62317653|NCT00849303|ACTIVE_COMPARATOR|later gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
62479598|NCT04521218|EXPERIMENTAL|Thrust joint Manipulation|Thrust joint Manipulation, heat application, Strengthening exercise and home plan
62479599|NCT04521218|ACTIVE_COMPARATOR|Reverse Sustained Natural apophyseal glides|Reverse Sustained Natural apophyseal glides (SNAG), heat application, Strengthening exercise and home plan.
62479600|NCT04636034|EXPERIMENTAL|Ropivacaine-Lidocaine|
62479601|NCT04636034|PLACEBO_COMPARATOR|Placebo|
62479602|NCT04636034|SHAM_COMPARATOR|"Sham-block with Placebo"|
62479603|NCT05323916|ACTIVE_COMPARATOR|"Neuroproprioceptive facilitation, inhibition"|"According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, participants undergoes one hour a day of individual physiotherapy on a neurophysiological basis - neuroproprioceptive facilitation, inhibition, which, by combining appropriate stimuli in a suitable time sequence, maintains optimal motor pathway function and optimal irritability of control or regulation structures."
62686949|NCT06674876|OTHER|IG2-Blog writing and workshop|This group was asked to write 2bolgs a week for four weeks and then attend a 4hour wellness workshop
62317654|NCT00279903|ACTIVE_COMPARATOR|Cortisone|
62317655|NCT00279903|EXPERIMENTAL|Low Dose Btx-A|
62317656|NCT00279903|EXPERIMENTAL|High Dose Btx-A|
62317657|NCT02075255|EXPERIMENTAL|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
62686950|NCT06054061|EXPERIMENTAL|TAU + Wellbeing promotion group (Think and Cope Positively) Intervention|In addition to their usual treatment, participants form the experimental arm will receive 15 weekly intervention sessions, where aspects related to subjective wellbeing, life plans, alliance with the therapist or family and social relationships will be worked on.
61924901|NCT04022343|EXPERIMENTAL|Treatment (cabozantinib)|Patients receive cabozantinib orally once daily for 12 weeks in the absence of disease progression or unacceptable toxicity. The assigned starting dose for cabozantinib is 60 mg/day. Two dose reduction levels of cabozantinib are permitted
61924902|NCT04336644|EXPERIMENTAL|Continuous patch monitoring system|-Participants will receive standard of care treatment with either arsenic trioxide, ribociclib, or capecitabine. They will have continuous patch monitor system (BodyGuardian Mini Plus) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment.
62127373|NCT01860612|EXPERIMENTAL|Compassionate Use Cohort|Study participants that do not meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
62127374|NCT01860612|EXPERIMENTAL|Continued Access Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the Continued Access cohort, after enrollment in the PMA cohort is complete.The fellow eye can be treated 1 month after the primary eye.
62317658|NCT02075255|EXPERIMENTAL|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
62479604|NCT05323916|ACTIVE_COMPARATOR|Technology based physical therapy|According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, they will undergo physiotherapy for an hour a day using the implementation of modern technologies based on the principles of sensorimotor learning, i.e. repeating specific and targeted functions in different environments / conditions in order to strengthen the memory footprint and initiate structural changes in the central nervous system. According to the indication, participants will be offered one of the robotic systems using an exoskeleton (Gloreha, Erigo and Meditutor, Lokomat and Ekso) or a therapy using virtual environment.
61924903|NCT02641483|EXPERIMENTAL|Colonic Motility|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
61924904|NCT01732003|EXPERIMENTAL|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
61924905|NCT01732003|PLACEBO_COMPARATOR|Placebo Pill|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
62317659|NCT02075255|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously every 4 weeks
62317660|NCT02143518|EXPERIMENTAL|100 µg Na-GST-1/Alhydrogel|High Dose Na-GST-1/Alhydrogel® Only
62317661|NCT02143518|EXPERIMENTAL|30 µg Na-GST-1/Alhydrogel + CpG 10104|Low Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
62317662|NCT02143518|EXPERIMENTAL|100 µg Na-GST-1/Alhydrogel + CpG 10104|High Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
62317663|NCT02662686|ACTIVE_COMPARATOR|Control|Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).
62317664|NCT02662686|EXPERIMENTAL|MitoScore|Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.
61924906|NCT00775385|ACTIVE_COMPARATOR|A|Standard chemotherapy
61924907|NCT00775385|EXPERIMENTAL|B|Customized treatment
61924908|NCT02435069|NO_INTERVENTION|Pre-operative Baseline Phase|Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
61924909|NCT02435069|EXPERIMENTAL|Dose Response - NS and USP Glycerin - First Intervention|Initial flush used NS or USP Glycerin randomized to treatment sequence. The starting volume and administration frequency for NS was 10mL/kg and glycerin 20 mL administered every other day. The NS dose was titrated in 10 mL increments to achieve continence so as not to exceed 500 mL daily for a child under five years of age and 1000 mL daily for a child over 5 years of age. USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, NS was decreased by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. USP Glycerin was decreased in 5 mL increments to the lowest dose of 5 mL daily. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was be trialed on the alternate therapy and then dropped from the study.
61924910|NCT02435069|EXPERIMENTAL|NS and USP Glycerin - Effectiveness - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they achieved continence on optimal dosing with minimal side effects.This arm evaluated the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
61924911|NCT05805202|EXPERIMENTAL|aHUS Patient|The study will include 110 patients consenting adult and pediatric patients with a diagnosis of atypical hemolytic uremic syndrome and carrying mutations in the MCP or DGKE genes. New patients will be selected through clinical and genetic screening of the inhabitants of a small island of South Italy (Linosa) with high incidence of patients affected by DGKE mutations and characterized by a high rate of endogamy
62317665|NCT01842893|EXPERIMENTAL|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
62479605|NCT05323916|EXPERIMENTAL|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|The concept of therapy implementing the ICF model is based on a comprehensive, so-called biopsychosocial approach to the patient and his/her disease (four hours). The key is to set individual goals of the therapy together with the rehabilitator and with the use of so-called ICF core sets, which individually take into account the given situation of the rehabilitated person. This approach includes interdisciplinary diagnosis of the current condition, i.e. not only based on the diagnosis, but also on the functional status and activities performed, it also takes into account the socio-psychological background of the patient.
62479606|NCT05323916|PLACEBO_COMPARATOR|Control group|Participants will undergo standard care.
62479607|NCT06588296|EXPERIMENTAL|Ixekizumab|Ixekizumab administered subcutaneous (SC).
62686951|NCT06054061|OTHER|TAU + waiting list|The control group will continue to receive the treatment as usual in their intervention resources. At the end of the 15-week control period they will receive the intervention.
62686952|NCT06290037|OTHER|Elderly drivers|Individuals over the age of 65 who are currently driving
61924912|NCT05805202|OTHER|Healthy volunteer|2 healthy subjects will undergo urine analysis (multistick) and only subjects with normal parameters will be enrolled as controls.
62127375|NCT04159493|PLACEBO_COMPARATOR|Placebo|"Subjects will be randomized to placebo.~Placebo, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
62127376|NCT04159493|ACTIVE_COMPARATOR|Ovestin|"Subjects will be randomized or assigned to varying doses of Ovestin (500, 50, 25, 12.5, 10, 5, 2.5, 0.5, 0.25 mcg) as determined by the dose de-escalation constraints specified in the protocol.~Active, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
62127377|NCT05639777|EXPERIMENTAL|Intranasal|That will receive intranasal dexmedetomidine (1.5mcg/kg)
62686953|NCT02189967|ACTIVE_COMPARATOR|conventional fractionation|radiotherapy with conventional fractionation (5 x 2Gy per week)
62317666|NCT03718104||Naltrexone|Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
62479608|NCT06588296|EXPERIMENTAL|Ixekizumab and Tirzepatide|Ixekizumab concomitantly administered with tirzepatide SC.
62686954|NCT02189967|ACTIVE_COMPARATOR|accelerated fraction|radiotherapy with accelerated fraction (7 x 2 Gy per week)
62686955|NCT03194529|EXPERIMENTAL|FMT in children with disease remission|All children (with Crohn's disease in remission) will receive the equivalent of 50 g of stools from a healthy donor (FMT) into the jejunum through upper endoscopy.
62686956|NCT06241430|EXPERIMENTAL|CardioMems|Participants randomized to this arm will receive hemodynamic-guided GDMT titration with CardioMems.
62686957|NCT06241430|NO_INTERVENTION|Usual Care|Participants randomized to this arm will receive usual care involving GDMT.
62686958|NCT06688981||Patients|ADPKD patients
62686959|NCT01079390|EXPERIMENTAL|High dose acupuncture|six needle applied during acupuncture
62686960|NCT01079390|EXPERIMENTAL|Low dose acupuncture|two needles will be applied.
62686961|NCT01079390|PLACEBO_COMPARATOR|placebo acupuncture|sham acupuncture treatment will be applied
62686962|NCT04507269|EXPERIMENTAL|VIR-2218|Drug: VIR-2218 VIR-2218 given by subcutaneous injection
62686963|NCT04507269|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Saline given by subcutaneous injection
62686964|NCT06482853|EXPERIMENTAL|Angiotensin-(1-7)|Participants will receive intravenous angiotensin-(1-7) at one study visit for a total of 120 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following this 30 minute dose escalation period, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 90 minutes. Infusion rates will be calculated for each patient based on body mass.
62686965|NCT06482853|PLACEBO_COMPARATOR|Saline|Participants receive intravenous saline at one study visit for a total of 120 minutes. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass.
62127378|NCT05639777|PLACEBO_COMPARATOR|control group|That will receive the same volume of 2 ml of intranasal normal saline
62127379|NCT06522711|EXPERIMENTAL|Virtual reality|Patients assigned to use a virtual reality headset during their surgery.
62127380|NCT06522711|ACTIVE_COMPARATOR|Control|Standard of care group.
62127381|NCT05993507|EXPERIMENTAL|Problem Management Plus (PM+)|As an open trial single group pre-post design, all participants in the study will receive PM+.
62127382|NCT06162858|OTHER|Healthy participants|no shoulder pain no shoulder diagnosis 60 years and older
62127383|NCT06162858|OTHER|RSA participants|primary reverse shoulder arthroplasty 60 years and older
62127384|NCT02764944|EXPERIMENTAL|Intervention|simple non-exposure EFTR group (single arm study)
62127385|NCT00495885|EXPERIMENTAL|Volinanserin|Volinanserin 2 mg for a maximum of 87 days
62127386|NCT00495885|PLACEBO_COMPARATOR|Placebo|Placebo for volinanserin for a maximum of 106 days
62127387|NCT06498544||Women in luteal MCP|Women being in their luteal MCP on the day of ascent to high altitude.
62127388|NCT06498544||Women in follicular MCP|Women being in their follicular MCP on the day of ascent to high altitude.
62127389|NCT02467946|EXPERIMENTAL|Adcetris-Levact (BV-Be) Association|Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles
62127390|NCT01739907|EXPERIMENTAL|Iron-fortified dairy product|Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet
62127391|NCT01739907|EXPERIMENTAL|Iron and vitamin D dairy product|Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet
62127392|NCT03427216|ACTIVE_COMPARATOR|Vaginal Baclofen/diazepam supp|Insert vaginal suppository once daily
62127393|NCT03427216|PLACEBO_COMPARATOR|Vaginal Placebo supp|Insert vaginal suppository once daily
62127394|NCT04917224|EXPERIMENTAL|Cohort A: Central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from a lobar bronchus
62127395|NCT04917224|EXPERIMENTAL|Cohort B: Ultra-central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from the mainstem bronchus, trachea, or esophagus
62127396|NCT02886286|EXPERIMENTAL|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be \>2 and \<10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
62127397|NCT02886286|ACTIVE_COMPARATOR|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be \>2 and \<10.
62127398|NCT04805996|EXPERIMENTAL|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|This study has only one arm and no comparator.
62127399|NCT00739739|EXPERIMENTAL|PD 0299685 15mg|
62127400|NCT00739739|EXPERIMENTAL|PD 0299685 30mg|
62127401|NCT00739739|PLACEBO_COMPARATOR|Placebo|
62127402|NCT02414412|ACTIVE_COMPARATOR|Ulmus|Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
62127403|NCT02414412|PLACEBO_COMPARATOR|Placebo|placebo 250mg orally 2 times a day for 4 weeks
62127404|NCT01041612|ACTIVE_COMPARATOR|Group A: C-SEMS, inserted above SO|-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.
62127405|NCT01041612|ACTIVE_COMPARATOR|Group B: C-SEMS, inserted across SO|-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.
62127406|NCT02079844|EXPERIMENTAL|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
62127407|NCT02079844|EXPERIMENTAL|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
62317667|NCT03718104||Buprenorphine/Naloxone|Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
62686966|NCT06548113|ACTIVE_COMPARATOR|Standard TMS|A series of standard TMS protocols will be delivered to determine target engagement compared to seTMS. TMS will be delivered using neuro-navigation based on participant's own MRI images. Intensity will be set to 120% of the participant's motor threshold. Participants will be monitored during the session for adverse events and/or side effects.
62686967|NCT06548113|ACTIVE_COMPARATOR|Sensory-entrained TMS (seTMS)|Sensory entrained TMS (seTMS) is a combination of music and TMS to align brain oscillations and enhance the effects of TMS. seTMS will be delivered to determine target engagement to noninvasive seTMS brain stimulation compared to standard TMS. TMS will be delivered using neuro-navigation based on participant's own MRI images. Intensity will be set to 120% of the participant's motor threshold. Participants will be monitored during the session for adverse events and/or side effects.
62686968|NCT05363215|EXPERIMENTAL|S-217622: Group A|Participants with mild renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
62686969|NCT05363215|EXPERIMENTAL|S-217622: Group B|Participants with moderate renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
62686970|NCT05363215|EXPERIMENTAL|S-217622: Group C|Participants with severe renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
62686971|NCT05363215|EXPERIMENTAL|S-217622: Group D|Participants with normal renal function will receive a single dose of S-217622 on Day 1, in a fasted state.
62686972|NCT02999997|EXPERIMENTAL|Ronnie Gardiner Method (RGM)|Exercising two times/week according to the RGM program in groups of 15 participants (2 groups).
62686973|NCT02999997|NO_INTERVENTION|Control group|Participants in the control group are instructed to live their ordinary life.
62686974|NCT03614832|EXPERIMENTAL|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
62686975|NCT03614832|ACTIVE_COMPARATOR|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
62686976|NCT04391608|ACTIVE_COMPARATOR|Tenofovir Alafenamide|Tenofovir Alafenamide 25 mg/day
62686977|NCT04391608|NO_INTERVENTION|TDF dose reduction|TDF dose reduction
62686978|NCT06687759|EXPERIMENTAL|Carbon-14 radiolabeled [14C] MK-1084|Participants receive single oral dose of MK-1084 on Day 1.
62686979|NCT02338557|EXPERIMENTAL|GROUP A|Subjects in Group A received MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects.
62686980|NCT02338557|ACTIVE_COMPARATOR|GROUP B|Group B received Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
62686981|NCT04858997|EXPERIMENTAL|Palbociclib-AI|ER(+)/HER2(-) patients with histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease receive palbociclib PO daily on days 1-21, combined with AI as first-line treatment Disease assessments measured by CT imaging will be performed at first 4 weeks, 8weeks, then every 8weeks (± 7 days) from the date of randomization until radiographic/clinical documentation of progressive disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
62686982|NCT05391958|SHAM_COMPARATOR|Normal Real group|the medication group was given according to the actual weight of normal weight patients
62686983|NCT05391958|ACTIVE_COMPARATOR|Normal Lean group|For normal weight patients, the medication group was given according to the lean body mass
62686984|NCT05391958|SHAM_COMPARATOR|Obese Real group|the medication group was given according to the actual weight of obese weight patients
62686985|NCT05391958|EXPERIMENTAL|Obese Lean group|the medication group was given according to the lean body mass of obese weight patients
62317668|NCT03718104||Naltrexone - alcohol use disorder|Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
62317669|NCT04822363|EXPERIMENTAL|Group A: Healthy|Low Dose Aspirin - 81mg daily for 7 days
62686986|NCT04180462|EXPERIMENTAL|Intervention Group|Practices randomly assigned to this arm will receive the multi-component intervention.
62686987|NCT04180462|NO_INTERVENTION|Wait list control group|Practices randomly assigned to this arm will be placed on a waiting list to receive the intervention in the last two years of the study.
62686988|NCT06689072|ACTIVE_COMPARATOR|Opioid Group|Participants diagnosed with Opioid use disorder
61924913|NCT05373940|EXPERIMENTAL|Heart failure optimal therapy alone (HFOT)|Heart failure Optimal therapy without implantable cardioverter defibrillator. This group will not undergo an ICD implantation. They will be treated according to the HFOT recommended in the latest guidelines.
62317670|NCT04822363|EXPERIMENTAL|Group B: Healthy|High Dose Aspirin - 325mg daily for 7 days
62317671|NCT04822363|EXPERIMENTAL|Group C: Healthy|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
62127408|NCT02079844|EXPERIMENTAL|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
62317672|NCT04822363|EXPERIMENTAL|Group D: Obese|Low Dose Aspirin - 81mg daily for 7 days
62317673|NCT04822363|EXPERIMENTAL|Group E: Obese|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
62317674|NCT02625662||iFSHD group|First recruitment group
62686989|NCT06689072|SHAM_COMPARATOR|Control Group|Participants who do not have Opioid use disoder
62686990|NCT06033859||Implants with BOP score 0|Implants with no BOP according to the modified bleeding index at baseline.
61924914|NCT05373940|ACTIVE_COMPARATOR|Heart failure optimal therapy (HFOT) + Implantable cardioverter defibrillator (ICD)|Optimal medical therapy + implantable cardioverter defibrillator (HFOT+ICD). This group will undergo an ICD implantation (standard of care), any brand, CE marked, implantable (lifelong), available and reimbursed in the French market (the type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.
61924915|NCT03258177|EXPERIMENTAL|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
61924916|NCT03258177|NO_INTERVENTION|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
61924917|NCT01916967|EXPERIMENTAL|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
62317675|NCT02645305|EXPERIMENTAL|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients.
62317676|NCT03516799|EXPERIMENTAL|Acupuncture (ACU) Group|The group of participants who opt in to acupuncture
62317677|NCT03516799|NO_INTERVENTION|Treatment-as-Usual (TAU) Group|The group of participants who enroll in the study but opt out of acupuncture (treatment-as-usual)
62686991|NCT06033859||Implants with BOP score 1|Implants with a bleeding dot at baseline.
62686992|NCT06033859||Implants with BOP score 2|Implants with a continuous line of blood that fills the sulcus at baseline.
62686993|NCT06033859||Implants with BOP score 3|Implants with a profuse bleeding and/or hemorrhage drip at baseline.
62686994|NCT02683798|ACTIVE_COMPARATOR|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
62686995|NCT02683798|EXPERIMENTAL|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
62317678|NCT03744169||Children with acute respiratory failure|Point-of-care lung ultrasound on admission to the PICU to determine the cause of respiratory failure.
62317679|NCT02082067|EXPERIMENTAL|Adductor canal|All patients in the arm will receive continuous adductor canal block under ultrasound guidance. 10ml of Ropivacaine 0,75%, BBraun, Germany, will be injected to dilate adductor canal. After catheter insertion 10ml of Ropivacaine 0,75% will be injected.
62317680|NCT02082067|ACTIVE_COMPARATOR|Femoral|All patients in the arm will receive continuous femoral nerve block under ultrasound guidance. Correct position of catheter will be check with injection of 20ml Ropivacaine 0,75% BBraun, Germany medial to femoral nerve.
62317681|NCT02082067|PLACEBO_COMPARATOR|Controls|No patients of this arm receive continuous nerve block. Intravenous opioids analgesia will be administered.
62317682|NCT04205591|ACTIVE_COMPARATOR|Autologous cortical plate|Thin autologous cortical plates that allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
62317683|NCT04205591|EXPERIMENTAL|Porcine cortical plate|Thin porcine cortical platesthat allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
62317684|NCT01165801|NO_INTERVENTION|Control Group (CO)|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
62317685|NCT00161304|ACTIVE_COMPARATOR|Testosterone Enanthate|Testosterone
62317686|NCT00161304|PLACEBO_COMPARATOR|Placebo|Placebo
62317687|NCT05875935|EXPERIMENTAL|Subject with a non-recurrent glial lesion requiring surgery in vigilance|
62317688|NCT06029816|EXPERIMENTAL|Arm1-Exon 18|Exon 18 G719X, E709X, etc，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，
62317689|NCT06029816|EXPERIMENTAL|Arm2-Exon 20|S768I in exon 20，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，
62317690|NCT06029816|EXPERIMENTAL|Arm3-Exon 21|L861Q of exon 21，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，
62686996|NCT04677361|EXPERIMENTAL|MILs™ in Combination with Pembrolizumab|"Each patient will have their bone marrow collected, MILs produced, and the patient will be dosed with all of the MILs produced for that individual patient. The minimum requirement for treatment is 2 x 108 cells. The MILs™ must be administered via a central catheter which could either be a PICC line, port or central line.~Subjects will be treated with MILs™ and pembrolizumab (200 mg Q3W) combination. MILs™ will be administered on Day 0 and pembrolizumab administered on Day 1. Pembrolizumab will be administered as a 30 minute IV infusion with a window of -5 minutes and +10 minutes is permitted."
62686997|NCT00562198|EXPERIMENTAL|1|Investigational drug Stalevo 200
62317691|NCT01518192|ACTIVE_COMPARATOR|1Doxycycline|
62317692|NCT01518192|ACTIVE_COMPARATOR|2 Cefuroxime axetil|
62317693|NCT05655546|OTHER|Intervention Arm|Participants in this group will complete the baseline study activities, as described above. Additionally, participants will be instructed to create a Cue Health account and download the Cue Health App. Using the app and the 10 Cue Health COVID-19 molecular tests that are provided (or Cue Health Flu+COVID molecular tests if available and FDA authorized), the participant will perform tests after exposure or if symptoms arise. Participants can also use the test for close contacts who are exposed to COVID-19 and/or have symptoms. If COVID-19 infection occurs, participants will have access to telemedicine to discuss further with a healthcare professional. When clinically indicated, medication for the treatment of COVID-19 (and/or Influenza in case of Cue Health Flu+COVID test availability) will be prescribed and delivered to the participants' delivery address. Participants can also seek care through other healthcare providers or not seek care, at their discretion.
62317694|NCT05655546|NO_INTERVENTION|Control Arm|Participants in the control group will complete the baseline study activities, as described above. If symptoms arise or COVID-19 infection occurs, participants will test and seek care as they normally would.
62317695|NCT01625728||Experimental group.|Participants are either student teachers or practicing teachers.
62686998|NCT01978015|EXPERIMENTAL|latanoprost and timolol maleate fixed combination|Latanoprost 0.005% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
62686999|NCT01978015|EXPERIMENTAL|bimatoprost and timolol maleate fixed combination|bimatoprost 0.03% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
62687000|NCT01978015|PLACEBO_COMPARATOR|dextran and hypromellose|A control group of patients with POAG and pseudophakic after trabeculectomy without medication. These patients received a lubricant drop twice daily at 8 a.m. and 8 p.m. for 6 months
62687001|NCT01978015|EXPERIMENTAL|travoprost and timolol maleate fixed combination|Travoprost 0.004% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
61924918|NCT01916967|EXPERIMENTAL|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
61924919|NCT01916967|PLACEBO_COMPARATOR|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
61924920|NCT03764488|EXPERIMENTAL|BIIB067 High Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).
62127409|NCT04706052||Superficial Parotidectomy Patient|All the patients with pleomorphic adenoma irrespective of age and gender who underwent Superficial parotidectomy
62317696|NCT01625728||Control Group.|Participants are no students teachers or practicing teachers.
62317697|NCT00216021|EXPERIMENTAL|Single Group Assignment|Capecitabine + Oxaliplatin
62317698|NCT02002078|NO_INTERVENTION|Methylprednisolone, caustic burns|
62317699|NCT05945485|EXPERIMENTAL|Arm 1|Healthy adults, 18 to 49 years of age will receive 10 mcg of DCVC H1 HA mRNA Vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
62317700|NCT05945485|EXPERIMENTAL|Arm 2|Healthy adults, 18 to 49 years of age will receive 25 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
62317701|NCT05945485|EXPERIMENTAL|Arm 3|Healthy adults, 18 to 49 years of age will receive 50 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A safety evaluation will occur to ensure the safety data support proceeding to the optimal dose group. N = 20
62317702|NCT05945485|ACTIVE_COMPARATOR|Arm 4|Healthy adults, 18 to 49 years of age will receive 60 mcg of Licensed quadrivalent inactivated influenza vaccine (IIV4), Fluzone Quadrivalent, administered intramuscularly to the upper arm/deltoid once. N = 10
62317703|NCT01254604|EXPERIMENTAL|Tafluprost|One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
62479609|NCT04161885|EXPERIMENTAL|Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care|Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)
62479610|NCT04161885|EXPERIMENTAL|Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC|Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
62479611|NCT04161885|EXPERIMENTAL|Part 2: Arm B - Best Supportive Care (BSC)|Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)
62479612|NCT06594926|EXPERIMENTAL|Testosterone enthanate|Participants will receive continuous androgen deprivation therapy with LHRH agonists/antagonists. The study intervention will be IM testosterone enthanate, injected on day 1 of each 56-day cycle (+3 days) except for cycle 1. Concurrent darolutamide will be taken at a dose of 600mg BD on days 29-56 of each cycle. Both LHRH and agonist/antagonist and darolutamide are supplied through the PBS as standard of care medications.
62479613|NCT01180634|EXPERIMENTAL|Aeroquin 240 mg|Participants received 240 milligrams (mg) of Aeroquin by inhalation route twice daily (BID) for a period of 28 days.
62127410|NCT05032794|EXPERIMENTAL|Unrestricted diet|The participant is not instructed to follow any dietary recommendation before colonoscopy. But only the restriction and fasting required for sedation.
62127411|NCT05032794|ACTIVE_COMPARATOR|One day low residue diet|"The participant is instructed to follow a low residue diet the day before the colonoscopy.~It will be given a informative document and educated by a nurse."
62127412|NCT05006586||RVF|All patients having undergone repair for rectovaginal fistula
62127413|NCT06284642|ACTIVE_COMPARATOR|lumbar drainage combined with intrathecal urokinase injection|lumbar drainage combined with intrathecal urokinase injection
62127414|NCT06284642|PLACEBO_COMPARATOR|lumbar drainage|lumbar drainage combined with intrathecal placebo saline injection
62127415|NCT05012241||Czech patients with multiple sclerosis|Czech patients with multiple sclerosis will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test. Video of their performance will be obtained.
62127416|NCT00661869|ACTIVE_COMPARATOR|Wellness Group|
62127417|NCT03279861|ACTIVE_COMPARATOR|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
62127418|NCT03279861|ACTIVE_COMPARATOR|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
62127419|NCT06268990|ACTIVE_COMPARATOR|RYGB-FMT intervention group|morbidly obese patients randomized for FMT from patients successfully treated with RYGB surgery
62317704|NCT01254604|ACTIVE_COMPARATOR|Timolol|One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
62317705|NCT01943539|EXPERIMENTAL|EVO Game Play|Neuro-typical controls and ADHD will receive EVO game play.
62127420|NCT06268990|ACTIVE_COMPARATOR|LEAN-FMT intervention group|morbidly obese patients randomized for FMT from normal weight (lean) volonteers
62127421|NCT06268990|SHAM_COMPARATOR|M-FMT intervention group|morbidly obese patients randomized for autologous FMT
62127422|NCT05638308|OTHER|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
62127423|NCT04933526|ACTIVE_COMPARATOR|Flumatinib|600mg QD orally form 1 to 12 months
62127424|NCT04933526|PLACEBO_COMPARATOR|Dasatinib|100mg QD orally form 1 to 12 months
62127425|NCT04071756|EXPERIMENTAL|Topical Tazarotene 0.1% Gel Plus BPS|"* Pharmacy teaching call~* DFCI approved teaching sheets will be provided~* 20% urea applied to the palms and soles in the morning + tazarotene 0.1% gel, applied to the palms and soles nightly"
62127426|NCT04071756|PLACEBO_COMPARATOR|Placebo Gel Plus BPS|"* A substance that has no therapeutic effect, used as a control in testing new drugs~* Pharmacy teaching call~* DFCI approved teaching sheets will be provided~* 20% urea applied to the palms and soles in the morning with placebo gel applied in the evening."
62127427|NCT01224015|OTHER|onabotulinumtoxinA 24U|24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
62317706|NCT03750110|ACTIVE_COMPARATOR|Usual Care|Smoking Cessation NICE PH48 Guidelines
62317707|NCT03750110|ACTIVE_COMPARATOR|Intervention|Smoking Cessation NICE PH48 Guidelines plus personalised feedback from Lung Scan
62317708|NCT04718519||Migrant Workers|
62317709|NCT00907140|OTHER|Chemoradiation therapy|
62479614|NCT01180634|PLACEBO_COMPARATOR|Placebo|Participants placebo matching Aeroquin by inhalation route, BID for a period of 28 days.
62687002|NCT02708368||Patients on dialysis|16 patients on dialysis with a sex ratio 1:1; 8 patients on hemodialysis and 8 patients on hemodiafiltration
62317710|NCT00607646|EXPERIMENTAL|1|Hyperinsulinemic (high dose insulin) hypoglycemic clamp studies with oral administration of DHEA or placebo prior to each clamp x 2 on day 1. Day 2 hyperinsulinemic hypoglycemia. Participant randomized to either DHEA or placebo for baseline trial (arm 1) and 6 weeks treatment.
62317711|NCT00607646|EXPERIMENTAL|2|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
62317712|NCT00607646|EXPERIMENTAL|Arm 3 (optional)|Individuals will be asked to return after at least 2 months and repeat the trial they did not complete (for example, placebo if they were in the DHEA trial before). Again Day 1 would consist of two hyperinsulinemic clamps with placebo or DHEA given orally. Day 2 hyperinsulinemic hypoglycemic clamp with oral administration of placebo or DHEA.
62317713|NCT00607646|EXPERIMENTAL|Arm 4|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
62317714|NCT03952312|EXPERIMENTAL|"OncoTool Intervention"|
62317715|NCT03952312|ACTIVE_COMPARATOR|"Oncotool Control"|
62317716|NCT04196842|EXPERIMENTAL|Telemonitoring|Blood pressure and heart rate monitoring, scale, activity tracker.
62687003|NCT02708368||Healthy Subjects|16 healthy subjects with a sex ratio 1:1
62127428|NCT01224015|PLACEBO_COMPARATOR|placebo (normal saline)|Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
62127429|NCT01224015|EXPERIMENTAL|onabotulinumtoxinA 44U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
62127430|NCT05672888|EXPERIMENTAL|Jaktinib|Jaktinib 100mg BID
62127431|NCT05672888|PLACEBO_COMPARATOR|Placebo|placebo
62127432|NCT00687856||LVAD Recipients|Participants who have had or are about to have a left ventricular assist device (LVAD) implanted
62127433|NCT01947634|EXPERIMENTAL|ResMed Apnea Link plus|Overnight respiratory polygraphy is performed in Fabry patients
62127434|NCT01450228|PLACEBO_COMPARATOR|Placebo KI1001|
62127435|NCT01450228|EXPERIMENTAL|KI1001|
62127436|NCT02224924|ACTIVE_COMPARATOR|autologous blood patch injection (ABPI)|
62127437|NCT02224924|EXPERIMENTAL|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|
62317717|NCT04196842|NO_INTERVENTION|No intervention|No intervention.
62317718|NCT01654497|EXPERIMENTAL|Dexanabinol|
62317719|NCT02698761|NO_INTERVENTION|Standard of Care|Patient will receive standard of care. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be aware of study presence but will not receive any specific instruction for the patient.
62317720|NCT02698761|EXPERIMENTAL|Comprehensive Care Plan|Patient will abide by the comprehensive care plan and sign an agreement stating compliance. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be notified of study and support patient's compliance with study procedures.
62687004|NCT06695429|EXPERIMENTAL|Beetroot juice supplementation|"Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.~(In addition to usual treatment with hydration and statins to prevent contrast induced nephropathy)"
62317721|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
62317722|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
62479615|NCT06602674||Pulmonary lymphoma|(1) Adult patients (≥18 years). (2) Patients with primary or recurrent lymphoma, ≥6 months from last treatment. (3) Baseline assessment at hospital revealed PET-positive pulmonary lesions, CT-measured maximum diameter ≥3mm, visible across ≥2 image layers. (4) Pathological results within 3 months of exam date, confirmed lung lesion types via tracheoscopy, lung puncture, or surgery. Or baseline pulmonary lesions of lymphoma diagnosed by lymph node and external lung puncture, remains considered to be pulmonary lymphoma based on follow-up clinical and imaging evaluation.
62479616|NCT06602674||Lung cancer|(1) Adult patients (≥18 years). (2) Patients with primary lung cancer patients without prior malignancy (3) Baseline assessment at hospital revealed PET-positive pulmonary lesions, CT-measured maximum diameter ≥3mm, visible across ≥2 image layers. (4) Pathological results within 3 months of exam date, confirmed lung lesion types via tracheoscopy, lung puncture, or surgery.
62687005|NCT06695429|NO_INTERVENTION|Usual care|Usual treatment with hydration and statins to prevent contrast induced nephropathy
62687006|NCT03179709||Intervention|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the active treatment arm of ROSE.
62687007|NCT03179709||Control|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the control treatment arm of ROSE.
62127438|NCT06434441|ACTIVE_COMPARATOR|Study group:|The patients will receive calverial grafts, to reconstruct the deficient maxillary ridge
62127439|NCT06434441|ACTIVE_COMPARATOR|Control group:|The patients will receive iliac crestgrafts, to reconstruct the deficient maxillary ridge
62317723|NCT02159092|EXPERIMENTAL|Contingency Management|Monetary incentives are given for submitting negative saliva cotinine tests.
62317724|NCT02159092|NO_INTERVENTION|Fixed Rate Control|Fixed amounts of payments are provided for submitting saliva samples
62317725|NCT04463160|EXPERIMENTAL|"prevention program for prediabetes Say No to Diabetes"|
62317726|NCT04463160|NO_INTERVENTION|No prevention program|
62317727|NCT04705597|EXPERIMENTAL|BGE-175|BGE-175 tablet to be taken by mouth once a day for 14 days
62317728|NCT04705597|PLACEBO_COMPARATOR|Placebo|Placebo tablet to be taken by mouth once a day for 14 days
62317729|NCT06182033|EXPERIMENTAL|Peer-mediated pivotal response intervention|"Facilitators hold four 15-minute training sessions with the peer group to engage the target child. The facilitator explicitly identifies the buddy and asks the children to use four strategies to play with the child during center time: (a) offer your buddy some play options; (b) show and talk about how to play with your buddy; (c) compliment your buddy; and (d) show your buddy how to take turns. At each training session the facilitator will describe one strategy, provide examples, and practice the strategy through role play. After trainings, the facilitator provides ongoing support during center time to implement the strategies over 12 weeks during months 3-6 of the 9 months of study participation."
62317730|NCT06182033|NO_INTERVENTION|Control|Business as usual
62317731|NCT00726323|EXPERIMENTAL|5/9 dosing|240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
62687008|NCT03179709||Refusal|The investigators will interview physicians who have refused to allow their patients to be enrolled in ROSE.
62687009|NCT00653705|ACTIVE_COMPARATOR|Probiotic|Children given probiotic BB12 enriched yogurt drink.
62127440|NCT03796936|EXPERIMENTAL|3MDR With Eye Movement Component (EM+)|All participants will complete 10 treatment sessions (3 preparatory, 6 3MDR and 1 concluding), led by a trained therapist, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component. For those in the EM+ intervention group, the EM component starts after the participant has thoroughly discussed a picture with the therapist; a red ball starts at one edge of the screen, moves rapidly back and forth across it, and upon reaching either edge, a 2-digit number appears superimposed in white on the ball. The number changes every time the ball meets either edge. The participant is asked to track the ball and call out the displayed numbers.
62127441|NCT03796936|ACTIVE_COMPARATOR|3MDR Without Eye Movement Component (EM-)|All participants will complete 10 treatment sessions (three preparatory sessions, six 3MDR sessions and one concluding session; see Table 1), led by a therapist who has been completed training in the conduct of this form of therapy, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component.There will be no exposure to the distractor stimulus (red ball) for those in the EM- intervention group.
62127442|NCT05772923|EXPERIMENTAL|Contact x-ray brachytherapy|Contact x-ray brachytherapy will be given applied after randomisation with a maximum interval of 14 weeks after finishing the neoadjuvant (chemo)radiation. Contact x-ray brachytherapy consists of three fractions of 30Gy per fraction applied to the tumour, with a 2 week interval between each boost. Response evaluation takes place every 3 months thereafter. Patients in whom a clinical complete response is detected during follow-up are offered a watch-and-wait approach; patients in whom an incomplete response or disease progression is noted, completion or salvage TME-surgery is advised.
62127443|NCT05772923|EXPERIMENTAL|Extending the waiting interval, with or without local excision|The waiting interval will be extended with 6-8 more weeks after the first response evaluation, followed by a second (or third in case of ongoing response) re-assessment. Patients with a clinical complete response at the time of the second (or third) response evaluation will be offered a watch-and-wait approach without any surgical treatment. Patients with a remaining small lesion will be offered transanal local excision. Depending on the final pathological staging after local excision, patients are categorized as low-risk or high-risk, and will be offered a watch-and-wait strategy or completion TME-surgery, respectively.
62127444|NCT06498336||Critically ill adult septic patients without acute kidney injury|The patients in this group will be screened clinically and by standard laboratory biochemical methods to determine sepsis diagnosis according to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
62127445|NCT06498336||Critically ill adult septic patients with acute kidney injury|The patients will be screened clinically and by standard laboratory biochemical methods to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to KDIGO 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
62127446|NCT06498336||Healthy volunteers|The blood samples for miRNA and biochemical parameters will be collected once, after randomization.
62127447|NCT03292120|EXPERIMENTAL|patients with septic shock|
62317732|NCT00726323|EXPERIMENTAL|daily dosing|80 mg foretinib on a daily dosing regimen
62317733|NCT03919890|EXPERIMENTAL|ONO-7684 Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
62687010|NCT00653705|PLACEBO_COMPARATOR|Control|Children given dairy drink.
62687011|NCT06675838|EXPERIMENTAL|Nursing students|Pre-Test and Post-Test Single Group Study
62317734|NCT03919890|PLACEBO_COMPARATOR|ONO-7684 Placebo Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
62317735|NCT03919890|EXPERIMENTAL|ONO-7684 Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
62317736|NCT03919890|PLACEBO_COMPARATOR|ONO-7684 Placebo Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
62317737|NCT03919890|EXPERIMENTAL|ONO-7684 Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
62317738|NCT03919890|PLACEBO_COMPARATOR|ONO-7684 Placebo Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
62479617|NCT06602674||Benign|(1) Adult patients (≥18 years). (2) Patients with benign solid lung lesions, without prior malignancy. (3) Baseline assessment at hospital revealed PET-positive pulmonary lesions, CT-measured maximum diameter ≥3mm, visible across ≥2 image layers. (4) Pathological results within 3 months of exam date, confirmed lung lesion types via tracheoscopy, lung puncture, or surgery.
62687012|NCT03829514|EXPERIMENTAL|Fenofibrate|Single arm. Participants will take study medication
62687013|NCT06400121|EXPERIMENTAL|Apimostinel + Cognitive Training|
62687014|NCT06400121|SHAM_COMPARATOR|Apimostinel + Sham Training|
62687015|NCT06400121|PLACEBO_COMPARATOR|Placebo + Cognitive Training|
62687016|NCT00752219|EXPERIMENTAL|NXL104/CAZ/MTZ|NXL104/ceftazidime + metronidazole
62687017|NCT00752219|ACTIVE_COMPARATOR|Meropenem|
61924921|NCT03764488|EXPERIMENTAL|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 mL aCSF.
61924922|NCT03764488|EXPERIMENTAL|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 5 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 5 mL aCSF.
61924923|NCT03764488|EXPERIMENTAL|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in up to 20 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in up to 20 mL aCSF.
61924924|NCT04914507|OTHER|Anterior Vertebral Body Tethering|The subject is will receive anterior vertebral body tethering surgery, as clinically indicated, after all pre-operative assessments are complete.
62127448|NCT04050969|ACTIVE_COMPARATOR|Atrial Fibrillation (AF) Catheter Ablation-Group A|Participants will undergo catheter ablation using either radiofrequency or cryo-ablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extra-pulmonary sites at the physician's discretion.
62479618|NCT06602674||Metastasis|(1) Adult patients (≥18 years). (2) Pulmonary metastatic patients, untreated with lung radiotherapy or particle implantation. (3) Baseline assessment at hospital revealed PET-positive pulmonary lesions, CT-measured maximum diameter ≥3mm, visible across ≥2 image layers. (4) Pathological results within 3 months of exam date, confirmed lung lesion types via tracheoscopy, lung puncture, or surgery. Or baseline pulmonary lesions of metastases diagnosed by lymph node and external lung puncture, remains considered to be pulmonary metastases based on follow-up clinical and imaging evaluation.
62479619|NCT06320171|EXPERIMENTAL|Experimental|"The intervention in the study involves a unique application of 20min of NESA microcurrents~During the intervention, patients were seated comfortably on (19)a sofa with their backs supported. NESA, a portable, noninvasive neuromodulation device, delivered low-frequency (1.3-14.28 Hz), low-intensity (0.1-0.9 mA), low-voltage (±3 V) microcurrents through 24 electrodes placed on the distal nerve endings of the wrists and ankles (six electrodes per limb). Direct stimulation of the autonomic nervous system was achieved using program 7 of the device with a directional electrode placed at the level of the C7 spinous process. This configuration established a circulating bioelectric circuit within the body, stimulating the autonomic nervous system below the patient's sensory threshold"
62317739|NCT02205385|ACTIVE_COMPARATOR|Traditional Traction Neurectomy|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the current standard of care surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). In the active comparator arm, gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally. It may be buried in healthy muscle to further pad the nerve ending. The intention is to place the inevitable recurrent end-neuroma away from superficial locations in which it is likely to become mechanically irritated."
62127449|NCT04050969|EXPERIMENTAL|Bariatric surgery prior to AF Catheter Ablation-Group B|"Participants will undergo either a Roux-en-Y gastric bypass or a laparoscopic sleeve gastrectomy. The choice of the procedure will be based on numerous factors including current practice, the surgeon's and participant's choice, BMI, and the presence of certain comorbidities and their severity such as GERD, kidney stones, and past surgical history. Participants will undergo standard preoperative evaluation including dietary consultation and psychological evaluation during the eligibility process.~After bariatric surgery, in addition to routine post-surgical management, patients will follow up with cardiologist prior to AF catheter ablation."
62127450|NCT03990285|OTHER|[18F]Fluciclovine in glioblastoma|Axumin is a positron emitting radiopharmaceutical that has been studied in vivo in humans in a number of tumor types with positron emission tomography (PET/CT). 18F-Fluciclovine is a fluorine-18 labeled synthetic amino acid analog that is FDA approved as a PET imaging agent for prostate cancer recurrence, however, it has also been tested in other tumors. Investigators will use a typical dose of 18F-fluciclovine that is used for clinical studies in glioblastoma. This will be 5 mCi (approximate range for most studies is anticipated to be 5 mCi +/- 20%), but a lesser dose may be injected if, in the opinion of a Nuclear Medicine Authorized User, complete imaging data could be generated.
62127451|NCT03430258|PLACEBO_COMPARATOR|conventional oxygen therapy|oxygen was delivered by a nasal cannula or nonrebreather mask
62127452|NCT03430258|ACTIVE_COMPARATOR|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
62127453|NCT05309733||Observational Cohort 1|All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
62317740|NCT02205385|EXPERIMENTAL|Targeted Muscle Reinnervation|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the experimental surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle."
62479620|NCT06320171|PLACEBO_COMPARATOR|Placebo|The placebo group (n = 20) followed the same procedure, the device was set to deliver a low-intensity current below the sensory threshold, effectively rendering it inactive from the participants' perspective. .
62479621|NCT04363554|OTHER|Urine dilution test|Urine dilution test
62479622|NCT04363554|OTHER|Urine concentration test|Urine concentration test
62317741|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI \>=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
62317742|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
62317743|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
62317744|NCT06442709|EXPERIMENTAL|Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients|"Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients."
62127454|NCT01681381|ACTIVE_COMPARATOR|Firebird2® DES|Device:Firebird2® DES The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length.
62127455|NCT01681381|EXPERIMENTAL|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length.
62317745|NCT06442709|PLACEBO_COMPARATOR|Receive placebo in Advanced NPC Patients|Placebo replaces tocilizumab and asprin in advanced NPC patients.
62317746|NCT04788199||Non-closure group|Group in which mesenteric defects were not closed after laparoscopic Roux-en-Y gastric bypass.
62317747|NCT04788199||Closure group|Group in which mesenteric defects were closed using cyano-acrylate glue after laparoscopic Roux-en-Y gastric bypass.
62317748|NCT01844700|ACTIVE_COMPARATOR|Ziprasidone|(20-160mg/d, bid) for 12 weeks
62317749|NCT01844700|ACTIVE_COMPARATOR|Aripiprazole, quetiapine, risperidone|Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks
62317750|NCT04655677|EXPERIMENTAL|Autologous EXP039 administered by intravenous (IV) infusion|Autologous EXP039 administered by intravenous (IV) infusion
62317751|NCT06192446||Women with hormone-sensitive early breast cancer|"Women older than 18 years of age who have suffered from hormonally dependent breast cancer stages 0-III (from in situ to locally advanced breast cancer) according to the American Joint Committee on Cancer (AJCC) classification and have been undergoing adjuvant endocrine therapy for more than 3 months."
62127456|NCT03356223|EXPERIMENTAL|Abemaciclib|
62317752|NCT04676139|EXPERIMENTAL|Fluoxetine|patients will undergo maintenance therapy selective serotonin reuptake inhibitors, fluoxetine, 10 mg capsules once daily for 12 weeks
62317753|NCT04676139|PLACEBO_COMPARATOR|Placebo|patients will undergo maintenance therapy Placebo for 12 weeks
62317754|NCT06190912|EXPERIMENTAL|Bryostatin 1|Participants in this arm will receive treatment with Bryostatin 1
62317755|NCT01271478|EXPERIMENTAL|Telmisartan plus Captopril|captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)
62317756|NCT01271478|EXPERIMENTAL|Telmisartan plus Placebo|telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day
62317757|NCT01271478|EXPERIMENTAL|Captopril plus Placebo|patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
62317758|NCT01271478|PLACEBO_COMPARATOR|Placebo|2 tablets of placebo orally twice a day
62317759|NCT02805907|EXPERIMENTAL|Intervention Group (IG)|Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
62317760|NCT02805907|PLACEBO_COMPARATOR|Control Group (CG)|Placebo in a presentation with an identical appearance taken weekly by the oral route
62317761|NCT05892185|EXPERIMENTAL|GELA|Participants underwent at least one preoperative visit and had GELA implantation on Day 0 (The day of surgery)
62317762|NCT05892185|ACTIVE_COMPARATOR|XEN|Participants underwent at least one preoperative visit and had XEN gel stent implantation on Day 0 (The day of surgery).
62317763|NCT02735317|EXPERIMENTAL|FORRAD group|"This group of patients will receive Oral Ulcer Gargle (FORRAD®) during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the experimental group."
62317764|NCT02735317|ACTIVE_COMPARATOR|Quadruple mixture group|"This group of patients will receive quadruple mixture, which is composed of dexamethasone, gentamicin, vitamin B12, and procaine, during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the active comparator group."
62317765|NCT06439719||T2DM with microvascular complications|T2DM with microvascular complications
62317766|NCT06439719||T2DM without microvascular complications|T2DM without microvascular complications
62317767|NCT03611400|EXPERIMENTAL|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10\^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10\^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
62317768|NCT03611400|PLACEBO_COMPARATOR|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
61924925|NCT04260490||Cases|"Cases will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected.~Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
61924926|NCT04260490||Controls|"Controls selected after stratification on department of residence, sex and age of the cases and who give a written informed consent to participate.~Controls will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses in both cases and controls. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected. Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
62317769|NCT02125929|EXPERIMENTAL|robotic arm|robotic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
62479623|NCT01442155||Capecitabine + Oxaliplatin|Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.
62687018|NCT06498180|EXPERIMENTAL|Experimental group|"In the experimental group, subjects will undergo periodontal initial treatment under local anesthesia combined with glucocorticoid local blockade therapy (such as triamcinolone acetonide injection), local use of triamcinolone acetonide ointment, and 1% sodium bicarbonate rinse (avoiding systemic use during visits) after baseline examination, while receiving the following professional oral hygiene guidance:~Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes A periodontist with rich clinical experience will perform periodontal initial treatment under local anesthesia."
62687019|NCT06498180|ACTIVE_COMPARATOR|Control group|"In the control group, participants will undergo routine glucocorticoid local blockade therapy (such as triamcinolone acetonide injection), local administration of triamcinolone acetonide ointment, and 1% sodium bicarbonate rinse (avoiding systemic medication during visits) after baseline examination, while receiving the following professional oral hygiene guidance:~Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes Based on ethical considerations, all participants will receive full mouth periodontal initial treatment at the end of the trial."
61924927|NCT03858231|ACTIVE_COMPARATOR|Opioid|
62317770|NCT02125929|EXPERIMENTAL|Laparoscopic surgery|laparoscopic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
62317771|NCT02125929|EXPERIMENTAL|Open surgery|Open surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 100
62479624|NCT02915198|EXPERIMENTAL|Metformin|Participants receive initial treatment with metformin XR 500 mg 1 tablet daily, with stepwise titration to a maximum dose of 2000 mg (4 tablets) daily.
61924928|NCT03858231|ACTIVE_COMPARATOR|Non-opioid|
61924929|NCT05143190|EXPERIMENTAL|PTR-01|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg once monthly for a total of 5 doses.
62317772|NCT02971696|EXPERIMENTAL|HCC patients (Group 1)|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
62317773|NCT02971696|ACTIVE_COMPARATOR|HCC patients (Group 2)|Patient will take best supportive care
62317774|NCT04740593|EXPERIMENTAL|Group 1 - High refractive error: Intervention|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the intervention group
62687020|NCT06688604|EXPERIMENTAL|vaginal birth|
62687021|NCT06688604|EXPERIMENTAL|Childbirth with spinal and epidural anesthesia|
62687022|NCT06688604|NO_INTERVENTION|Cesarean section under general anesthesia|
62687023|NCT02261610|EXPERIMENTAL|clinical group|In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
61924930|NCT03671993|EXPERIMENTAL|EPNS group|Electrical pudendal nerve stimulation (EPNS) is a type of conservative treatment which can directly modulate the pudendal nerve and produce a regulation effects on both the sensory fibers and the motor fibers of pudendal nerve.
62317775|NCT04740593|OTHER|Group 2 - High refractive error: Control|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the control group
62479625|NCT02915198|PLACEBO_COMPARATOR|Placebo|Participants receive initial treatment with 1 tablet daily of placebo (for metformin XR), with stepwise titration to a maximum of 4 tablets daily.
62479626|NCT03289923|EXPERIMENTAL|Active TMS+ Cognitive Therapy|active
62479627|NCT03289923|SHAM_COMPARATOR|Sham TMS + Cognitive Therapy|inactive
62479628|NCT04360252|EXPERIMENTAL|Gracie Diet|Patients will have a nutritional consultation and will follow the Gracie diet for a month.
61924931|NCT03671993|ACTIVE_COMPARATOR|II group|Intravesical instillation (II) are mixture solution administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects.
62127457|NCT00826657|PLACEBO_COMPARATOR|placebo|Receive placebo (sugar pill) during the intervention. Received a 1000 mg vitamin B12 injection at the end of the study.
62127458|NCT00826657|ACTIVE_COMPARATOR|Vitamin B12|Received 500 micrograms vitamin B12 per day during the study Received a 1000 mg vitamin B12 injection at the start of the study
62127459|NCT03335748|ACTIVE_COMPARATOR|active control group|The program for the active control group is the same as for the experimental group, except that the degree of difficulty of the exercises remains low and invariable across trials, with three items needing to be recalled throughout.
62127460|NCT03335748|EXPERIMENTAL|the Cogmed program|12 exercises proposed in the Cogmed program. Eight of these target visuospatial WM and four target verbal WM. Eight exercises are preprogrammed for each session, for a total of 90 trials (Pearsons, 2014). The degree of difficulty of the trials increases as a function of the participant's performance. For each trial, the participant receives feedback on their performance.
62127461|NCT06015399|EXPERIMENTAL|Closed insufflation technique group|Closed insufflation technique is characterized by ligation in the proximal portion of targeted bronchus and gas injection in the distal portion. Closed insufflation technique group includes patients undergoing segmentectomy using closed insufflation technique.
62479629|NCT01449383|ACTIVE_COMPARATOR|low meat high fibre (lmhf)|consumption of less than 30g red meat per day and at least 40g dietary fibre per day
62479630|NCT01449383|ACTIVE_COMPARATOR|high meat low fibre (hmlf)|consumption of 200g red meat and not more than 20g dietary fibre per day
62479631|NCT05598047|EXPERIMENTAL|Executive Functioning Training|BrainHQ (POSIT Science Inc.) computerized cognitive training modules will be used as in our other studies; but these will focus on executive functioning training. These programs have gaming components that encourage adherence. BrainHQ cognitive training products are tested and endorsed by the scientific community. A meta-analysis of computerized cognitive training in older adults found optimal therapeutic effects occurred when training sessions last at most 60 minutes and are administered 1-3 times per week - dosage parameters already incorporated in our study. This self-administered program uses touch-screen technology with tablets which allows computer novices to engage with the training exercises.
62479632|NCT05598047|NO_INTERVENTION|No-Contact Control Group|These participants will not receive any intervention.
62479633|NCT01788423|EXPERIMENTAL|Audiologist-Based|Audiologist selects hearing aid for patient
62317776|NCT04740593|OTHER|Group 3 - Mild or no refractive error|Children with mild or no refractive error (i.e. not exceeding the AAPOS 2003 criteria) at age one
62479634|NCT01788423|EXPERIMENTAL|Consumer Decides|Consumer selects hearing aid
62479635|NCT01788423|PLACEBO_COMPARATOR|Placebo|Patient fitted with hearing aid that is acoustically transparent.
62479636|NCT04609878|EXPERIMENTAL|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
62479637|NCT04609878|EXPERIMENTAL|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
62127462|NCT06015399|ACTIVE_COMPARATOR|Dilatation and collapse technique|Dilatation and collapse technique is characterized by pure oxygen dilatation and subsequent collapse after the division of targeted bronchus. Dilatation and collapse technique group includes patients undergoing segmentectomy using Dilatation and collapse technique.
62127463|NCT02780440||Control Group|Subjects will participate in standard occupational therapy rehabilitation protocol plus a traditional home based exercise program.
62127464|NCT02780440||Experimental Group 1|Subjects will participate in standard rehabilitation protocol plus unimanual home based mirror therapy program
62127465|NCT02780440||Experimental Group 2|Subjects will participate in standard rehabilitation protocol plus bimanual home based mirror therapy program.
62317777|NCT01671436|EXPERIMENTAL|Central Meditation and Imagery Therapy|Intervention involved Central Meditation, may be characterized by a voluntary, regulated attentional set towards a specific stimulus or set of stimuli and visualization exercises utilized within CMIT, which primarily involves two types of thought experiments: 1) creating mental models of how a person fits into the larger world and universe according to evolutionary biology and modern cosmology, in order to gain a larger perspective on emotions and thought patterns, and 2) backcasting, the generation of a desirable future coupled with mental time travel back to the present to determine how to create that future with present-day actions.
62127466|NCT01837966|ACTIVE_COMPARATOR|Lavender oil|Lavender oil aromatherapy
62317778|NCT05005559|EXPERIMENTAL|Vaccine candidate|
62317779|NCT05005559|PLACEBO_COMPARATOR|Saline placebo|
62317780|NCT01520324|EXPERIMENTAL|Patients with UC undergoing colonoscopy|
61924932|NCT04461249||Latanoprost group|Latanoprost 0.005 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
61924933|NCT04461249||Travoprost group|Travoprost 0.004 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
62127467|NCT01837966|PLACEBO_COMPARATOR|Placebo|Placebo -- unscented oil aromatherapy
62127468|NCT01748110|NO_INTERVENTION|Local Control Group|This arm is for patients in the District of Columbia (DC), (Maryland) MD, (Virginia) VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
62127469|NCT01748110|EXPERIMENTAL|Local TRIMM Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
62127470|NCT01748110|EXPERIMENTAL|Local Intensive Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to undergo intensive in-person fitness interventions according to the Look AHEAD model. This will involve attendance at weekly support group meetings and personal monthly meetings with a health care provider/
62317781|NCT05876650|EXPERIMENTAL|Pilates exercise Group|6 Pilates exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow.
61924934|NCT04461249||Tafluprost group|Tafluprost 0.0015 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
62127471|NCT01748110|NO_INTERVENTION|Distant Control Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
62317782|NCT05876650|EXPERIMENTAL|Yoga Group|6 Yoga poses: Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow pose.
62317783|NCT00763685|ACTIVE_COMPARATOR|etoricoxib 120 mg|active control
62317784|NCT00763685|PLACEBO_COMPARATOR|2|Placebo
62317785|NCT00763685|ACTIVE_COMPARATOR|3|Paracetamol 1 g and etoricoxib 120 mg
62317786|NCT01299597|EXPERIMENTAL|Cohort 1: Atorvastatin|single dose session with Atorvastatin with PK samples collected up to 72h post dose, then 14 days repeat dose session with SB649868 with Atorvastatin single dose co-administered on day 8 (same time as SB649868) and on day 12 (2 hours before SB649868).
62479638|NCT04609878|ACTIVE_COMPARATOR|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
62479639|NCT04609878|ACTIVE_COMPARATOR|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
62479640|NCT01528163|EXPERIMENTAL|Cabazitaxel|Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel
61924935|NCT02793466|EXPERIMENTAL|Durvalumab; MEDI4736|Open label
62317787|NCT01299597|EXPERIMENTAL|Cohort 2: Simvastatin|single dose session with Simvastatin with PK samples collected up to 24h post dose, then 14 days repeat dose session with SB649868 with Simvastatin single dose co-administered on day 12 (same time as SB649868) and on day 14 (2 hours before SB649868).
62479641|NCT01528163|ACTIVE_COMPARATOR|Methotrexate|"Methotrexate is the historical control and has been widely used in SCCHN for palliation.~This medication is an antimetabolite and antifolate drug. It acts by inhibiting the metabolism of folic acid."
62317788|NCT00077623|EXPERIMENTAL|RO0503821 (1x/2 Weeks)|Eligible participants received RO0503821 (Mircera \[methoxy polyethylene glycol-epoetin beta\]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of\<8000, 8000-16000, or \>16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
62317789|NCT00077623|EXPERIMENTAL|RO0503821 (1x/4 Weeks)|Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of\<8000, 8000-16000, or \>16000 IU/week administered during the week preceding the switch to the study drug.
62317790|NCT00077623|ACTIVE_COMPARATOR|Epoetin Reference|Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .
62317791|NCT02975869|ACTIVE_COMPARATOR|Standard Leukemia Care|Standard Leukemia care
62317792|NCT02975869|EXPERIMENTAL|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
62317793|NCT02092415|EXPERIMENTAL|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
62687024|NCT02261610|OTHER|PCT group|In the second group, the use of antibiotics will be guided by the algorithm (PCT group).
62479642|NCT02558491|EXPERIMENTAL|Decision Support System|Blinded continuous glucose monitor (CGM) data will be collected prior to the Experimental Admission and analyzed by the study team to determine the optimal insulin therapy parameters for each insulin pump and multiple daily injections (MDI) participant. These optimized parameters will be used during the Experimental Admission.
62479643|NCT02558491|ACTIVE_COMPARATOR|Usual Care|Insulin pump and MDI participants will use their own insulin parameters, including basal rate, correction factor and carbohydrate-insulin ratio, and determine their own insulin usage during the Control Admission.
62687025|NCT05160441|EXPERIMENTAL|Platelet Rich Plasma Injection Group|Minimum 2cc Leukocyte Poor Platelet Rich Plasma
62479644|NCT01160666|EXPERIMENTAL|1: Belilumab|
62687026|NCT05160441|ACTIVE_COMPARATOR|Corticosteroid Injection Group|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
62687027|NCT05160441|EXPERIMENTAL|Delayed Platelet Rich Plasma Injection Group upon Corticosteroid Injection Failure|If a participant does not have any benefit from the corticosteroid injection by the six-week follow-up time point, then that participant will be eligible for a platelet rich plasma injection.
62317794|NCT05480137|OTHER|plain balloon|plain balloon is used in BPA
62317795|NCT05480137|OTHER|NSE scoring balloon|NSE scoring balloon is used in BPA
62317796|NCT05938088|EXPERIMENTAL|mirogabalin group|perioperative mirogabalin
62317797|NCT05938088|SHAM_COMPARATOR|placebo group|placebo
62687028|NCT01016041|EXPERIMENTAL|everolimus stent|
62317798|NCT01888354|EXPERIMENTAL|Acthar Gel 80 IU x 14 days|Acthar Gel 80 IU SQ x 14 days
62317799|NCT01888354|EXPERIMENTAL|Acthar Gel 80 IU x 5 days|Acthar Gel 80 IU SQ x 5 days
62317800|NCT02004054||optic neurotis|measure of pupil diameter
62317801|NCT05921916|EXPERIMENTAL|MBF-118 100mg oral single dose|Drug: MBF-118 100mg oral capsules single dose Hard gelatin capsules
62687029|NCT01016041|ACTIVE_COMPARATOR|paclitaxel eluting|
62687030|NCT00236197|EXPERIMENTAL|1|
62687031|NCT00236197|PLACEBO_COMPARATOR|2|
62687032|NCT00831155|ACTIVE_COMPARATOR|1|Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
62687033|NCT00831155|NO_INTERVENTION|2|Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
62687034|NCT01071785|NO_INTERVENTION|usual diet|no dietary or drug intervention. Patients followed their usual diet.
62687035|NCT01071785|EXPERIMENTAL|guar gum|guar gum
62687036|NCT06617364|EXPERIMENTAL|pediatric patients with suspected lactose intolerance|On the one hand the patients will undergo the hydrogen breath test and on the other their gastrointestinal transit time will be measured using MSOT and ICG contrast agent.
62317802|NCT05921916|EXPERIMENTAL|MBF-118 200 mg oral single dose|Drug: MBF-118 200mg oral capsules single dose Hard gelatin capsules
62317803|NCT05921916|EXPERIMENTAL|MBF-118 400 mg oral single dose|Drug: MBF-118 400mg oral capsules single dose Hard gelatin capsules
62317804|NCT05921916|EXPERIMENTAL|MBF-118 100 mg oral multiple dose|"Drug: MBF-118 100mg oral capsules multiple dose. One single daily dose during five days.~Hard gelatin capsules"
62317805|NCT05921916|EXPERIMENTAL|MBF-118 200 mg oral multiple dose|"Drug: MBF-118 200mg oral capsules multiple dose. One single daily dose during five days.~Hard gelatin capsules"
62687037|NCT06690164|EXPERIMENTAL|Intervention arm 1|Atorvastatin 40mg once a day + Omeprazole 20mg once a day, both drugs to be taken for 30 days.
62687038|NCT06690164|ACTIVE_COMPARATOR|Control arm 2|Atorvastatin 40mg once a day to be taken for 30 days.
62687039|NCT02498795|ACTIVE_COMPARATOR|Group of Dry Needling|"They will receive a treatment of dry needling with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. The punction will be realized using the technique of entry - Hong's rapid exit. Three punction will realize in the disabled zone of 3 seconds of duration."
62687040|NCT02498795|ACTIVE_COMPARATOR|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. An intensity of 3 milliampere will be in use, during 3 seconds and one will repeat 3 times."
62687041|NCT02498795|PLACEBO_COMPARATOR|Control Group|They will receive a treatment of punction placebo with ultrasound scan together with a treatment in the one that will realize eccentric exercise's program that the patient will have to realize in his domicile.
62127472|NCT01748110|EXPERIMENTAL|Distant TRIMM Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
62127473|NCT02628678|OTHER|Fructooligosaccharide (FOS)|Subjects will be required to take 8 grams of FOS per day for a total of 10 days.
62127474|NCT01406223|ACTIVE_COMPARATOR|varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
62317806|NCT05921916|EXPERIMENTAL|MBF-118 400 mg oral multiple dose|"Drug: MBF-118 400mg oral capsules multiple dose. One single daily dose during five days.~Hard gelatin capsules"
62317807|NCT05921916|PLACEBO_COMPARATOR|Placebo oral single dose|Placebo: Hard gelatin capsules single dose
62317808|NCT05921916|PLACEBO_COMPARATOR|Placebo oral multiple dose|Placebo: Hard gelatin capsules. One single daily dose during five days.
62317809|NCT05921916|EXPERIMENTAL|MBF-118 600 mg oral single dose|Drug: MBF-118 600mg oral capsules single dose Hard gelatin capsules
62479645|NCT06510361|EXPERIMENTAL|Epcoritamab|"35 participants will be enrolled and will complete study procedures as follows:~* Baseline visit with imaging (CT, MRI or PET scan) and bone marrow biopsy.~* Imaging after Cycles 3 and 6 only.~* Cycles 1-3:~  --Days 1, 8, 15 and 22 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily~* Cycles 4-9:~  --Days 1 and 15 of 28 day cycle: Predetermined dose of Epcoritamab 1x daily~* Cycles 10-12:~  --Day 1 of 28 day cycles: Predetermined dose of Epcoritamab 1x daily~* End of Treatment visit with imaging and bone marrow biopsy.~* Follow up: every 3 months for 2 years or until disease worsens.~* Off study visit with imaging."
62687042|NCT05853952|EXPERIMENTAL|Non-invasive Neuromodulation|The non-invasive neuromodulation experimental group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
62687043|NCT05853952|PLACEBO_COMPARATOR|Placebo Non-invasive Neuromodulation|The non-invasive neuromodulation placebo group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
62687044|NCT04545892|EXPERIMENTAL|Capsaicin|From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate.
62687045|NCT01579877|EXPERIMENTAL|Yukmijihwang-tang|Yukmijihwang-tang: Real herbal extract granule
62127475|NCT01406223|ACTIVE_COMPARATOR|NRT (nicotine patches only)|21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
62317810|NCT02393599|EXPERIMENTAL|Lorcaserin|Lorcaserin (10mg) will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
62317811|NCT02393599|PLACEBO_COMPARATOR|Placebo|Placebo will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
62317812|NCT00221845|ACTIVE_COMPARATOR|Conventional BP Control|Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
62317813|NCT00221845|EXPERIMENTAL|Intensified BP Control|Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
62317814|NCT02688114|EXPERIMENTAL|Barrett's Esophagus Treatment|All participants are in the treatment arm. Patients with Barrett's esophagus will undergo baseline surveillance endoscopy, be treated with radiofrequency ablation, and undergo follow up endoscopy 1, follow up endoscopy 2, and follow up endoscopy 3.
62317815|NCT00733512||ReSTOR|AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL)
62479646|NCT04948658||Adolescents with DOR|Adolescents with diminished ovarian reserve (DOR) who respond poorly to ovarian stimulation for egg freezing
61924936|NCT03277521|ACTIVE_COMPARATOR|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
61924937|NCT03277521|ACTIVE_COMPARATOR|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
61924938|NCT03277521|ACTIVE_COMPARATOR|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
61924939|NCT02622750|EXPERIMENTAL|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
61924940|NCT02622750|ACTIVE_COMPARATOR|four-branched Dacron graft|"A four-branched Dacron graft (Boston Scientific Inc, Boston, MA) and a stent graft (MicroPort Medical Co Ltd, Shanghai, China) were used in total arch replacement combined with stented elephant trunk (SET) implantation.The SET was inserted into the true lumen of the descending aorta.The proximal edge of the residual aorta was trimmed to match the proximal end of the stent graft.The anastomosis between the four-branched prosthetic graft and the distal aorta containing the intraluminal stented graft was carried out using open aortic technique."
61924941|NCT04533958|EXPERIMENTAL|HypnoVR Arm|During each Docetaxel infusion, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
61924942|NCT04533958|NO_INTERVENTION|Control Arm|Patients receive the docetaxel infusions under standard conditions (no medical hypnosis in virtual reality intervention)
61924943|NCT02843308|EXPERIMENTAL|Immediate Treatment|Facilitated group therapy with behavioral practice; 18 weeks
61924944|NCT02843308|EXPERIMENTAL|Delayed Treatment|Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
61924945|NCT02843308|NO_INTERVENTION|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment.
61924946|NCT06476964|EXPERIMENTAL|patients with actinic keratosis(AK)|
61924947|NCT06476964|EXPERIMENTAL|patients with squamous cell carcinoma in situ (in situ cSCC)|
62687046|NCT01579877|PLACEBO_COMPARATOR|Yukmijihwang-tang_Placebo|Yukmijihwang-tang_Placebo: Placebo herbal extract granule
61924948|NCT06476964|EXPERIMENTAL|patients with squamous cell carcinomas infiltrative (infiltrative cSCC)|
61924949|NCT06476964|EXPERIMENTAL|patient with invasive metastases (cSCC with cutaneous metastases)|
62127476|NCT01406223|ACTIVE_COMPARATOR|varenicline + bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus bupropion at a dose of 150mg once per day. Subsequently, the dose of varenicline will be 1 mg twice per day and the dose of bupropion will be 150 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline and bupropion, smokers in this group will also receive placebo patches.
62127477|NCT01406223|PLACEBO_COMPARATOR|Post-quit NRT|Nicotine patches at 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
62127478|NCT04313205|ACTIVE_COMPARATOR|Capsule|JKB-122 capsule on period 1 followed by JKB-122 Tablet on period 2
62687047|NCT04416490||Patients|Patients with high-risk stage II or stage III primary colon cancer who have received curative resection
62687048|NCT02513251||Case group|Chronic pain patient
62687049|NCT05584137|EXPERIMENTAL|Dose cohort 1 of the first stage (escalation stage)|"In this cohort, HLX26 500 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
61924950|NCT01834482|ACTIVE_COMPARATOR|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
61924951|NCT01834482|ACTIVE_COMPARATOR|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
61924952|NCT00823342|PLACEBO_COMPARATOR|Group A|CLEVUDINE 30 mg qd + TENOFOVIR Placebo
61924953|NCT00823342|ACTIVE_COMPARATOR|Group B|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
61924954|NCT00823342|PLACEBO_COMPARATOR|Group C|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
61924955|NCT04586361|EXPERIMENTAL|Experimental group 1|Intraoperative1 kit of Platelet-rich plasma(PRP) injection into knee joint after anterior cruciate ligament (ACL) reconstruction.
62127479|NCT04313205|ACTIVE_COMPARATOR|Tablet|JKB-122 tablet on period 1 followed by JKB-122 capsule on period 2
62317816|NCT04936672|EXPERIMENTAL|Brisk walking group|"Type of exercise is brisk walking. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time."
61924956|NCT04586361|EXPERIMENTAL|Experimental group 2|Intraoperative1 kit of PRP+Hyaluronic acid(HA) injection into knee joint after ACL reconstruction.
61924957|NCT04586361|PLACEBO_COMPARATOR|Experimental group 3|Intraoperative 20 ml normal saline injection into knee joint after ACL reconstruction.
61924958|NCT02878824||HK-Children|This is a group of typically-developing children ages 7-12 years old who are of Chinese ethnicity, born and raised in Hong Kong (n=32).
61924959|NCT02878824||FHK-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity; either born, migrated and/or raised in Hong Kong (n=32).
61924960|NCT02878824||FU-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in an urban area in the Philippines (n=32).
61924961|NCT02878824||FR-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in a rural area in the Philippines (n=32).
61924962|NCT01637987|ACTIVE_COMPARATOR|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during peripheral intravenous line (PIV) insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
61924963|NCT01637987|ACTIVE_COMPARATOR|Wee Sight Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device assists in vein identification by being held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. This will be used to identify veins during peripheral intravenous line (PIV) insertion procedures.
61924964|NCT01637987|ACTIVE_COMPARATOR|Near Infra-red light (VeinViewer)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. This will be used to identify veins during peripheral intravenous line (PIV) insertion procedures.
62127480|NCT04204993|EXPERIMENTAL|Experimental: Influenza A|Participants will be inoculated with Influenza A/Belgium/4217/2015 at a dose of 5x105 TCID50 in a volume of 0,5mL via intranasal drops or spray. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood, respiratory tract sampling, and sensor monitoring. Following discharge, they will be followed up for up to 6 months post-inoculation.
62479647|NCT04948658||Adolescents with POI|Adolescent females up to age 21 years old, who have undergone menarche and are subsequently diagnosed with POI and their last menstrual period occurred within 2 years of presentation.
62317817|NCT04936672|EXPERIMENTAL|Tai Chi Chuan|"Type of exercise is Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate."
61924965|NCT00398333|EXPERIMENTAL|Eicosapentaenoic acid enriched nutritional supplement|
61924966|NCT00398333|NO_INTERVENTION|No supplementation|
61924967|NCT05838235|EXPERIMENTAL|6 month adapted physical activity|"The various assessments will be carried out during 2 visits at 6 months interval as part of the usual follow-up at the Toulouse University Hospital. Standard cardiopulmonary exercise test assessment will be coupled with an assessment by an APA coach on the same day.~The APA program built from the initial assessment will be returned to the child and his family during a videoconference.~In addition, a regular reassessment and adjustment of this program will be made every 15 days during phone calls by the APA coach."
61924968|NCT05616806|EXPERIMENTAL|distress tolerance skills training|technology delivered distress tolerance skills training
61924969|NCT02233062|EXPERIMENTAL|Semen quality|
61924970|NCT05320302|EXPERIMENTAL|[11C]-Lu AF88370|Participants will receive \[11C\]-Lu AF88370 via an intravenous cannula on Day 1.
61924971|NCT00318227|ACTIVE_COMPARATOR|Liberal Red cell transfusion arm|Transfusion if Hgb \<100g/L
62317818|NCT04936672|EXPERIMENTAL|Brisk walking combined with Tai Chi Chuan|"Type of exercise is brisk walking combine with Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity of brisk walking is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time.~The intensity of Tai Chi Chuan is 50%-70% of the individual's maximum heart rate."
62317819|NCT04936672|NO_INTERVENTION|Control Group|Keeping their daily life.
62687050|NCT05584137|EXPERIMENTAL|Dose cohort 2 of the first stage (escalation stage)|"In this cohort, HLX26 800 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
61924972|NCT00318227|ACTIVE_COMPARATOR|Restrictive Red Cell transfusion|Transfusion if Hgb \<70g/L
61924973|NCT05334511|EXPERIMENTAL|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
61924974|NCT01606254|EXPERIMENTAL|Paliperidone palmitate 50 mg|Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
62687051|NCT05584137|EXPERIMENTAL|Dose cohort 3 of the first stage (escalation stage)|"In this cohort, HLX26 1600 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
62687052|NCT05584137|EXPERIMENTAL|Dose cohort 1 of the second stage (expansion stage)|"In this cohort, HLX26 800 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 20 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
62687053|NCT05584137|EXPERIMENTAL|Dose cohort 2 of the second stage (expansion stage)|"In this cohort, HLX26 1600 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 20 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
62687054|NCT06033209|EXPERIMENTAL|Part A Intramuscular (IM) safety with dose finding - Group 1|
61924975|NCT01606254|EXPERIMENTAL|Paliperidone palmitate 100 mg|Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
61924976|NCT01606254|EXPERIMENTAL|Paliperidone palmitate 150 mg|Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
61924977|NCT01606254|EXPERIMENTAL|Paliperidone palmitate 150/ 50 mg|Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
61924978|NCT01912963|EXPERIMENTAL|Phase I: Dose Level 1 (D1)|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (D1)~Cycle duration=21 days~The Phase I run-in potentially evaluates 2 dose levels of eribulin in combination with pertuzumab and trastuzumab. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
62687055|NCT06033209|EXPERIMENTAL|Part A IM safety with dose finding - Group 2|
62687056|NCT06033209|EXPERIMENTAL|Part A IM safety with dose finding - Group 3|
62687057|NCT06033209|EXPERIMENTAL|Part A IM safety with dose finding - Group 4|
62687058|NCT06033209|EXPERIMENTAL|Part A IM safety with dose finding - Group 5|
62687059|NCT06033209|EXPERIMENTAL|Part A IM safety with dose finding - Group 6|
62687060|NCT06033209|EXPERIMENTAL|Part A Subcutaneous (SC) safety with dose finding - Group 7|
62687061|NCT06033209|EXPERIMENTAL|Part A SC safety with dose finding - Group 8|
62687062|NCT06033209|EXPERIMENTAL|Part A SC safety with dose finding - Group 9|
62479648|NCT04948658||Individuals with variations in sex characteristics (or differences in sex development, DSD)|Individuals with variations in sex characteristics (or differences in sex development, DSD) who undergo gonadectomy for clinical indications.
62687063|NCT06033209|EXPERIMENTAL|Part A SC safety with dose finding - Group 10|
62127481|NCT06552819||Children with cerebral palsy, obesity and neuromuscular disease, parents and therapists|
62127482|NCT02020252||Touchscreen Participants|New lung, gastric and pancreatic cancer patients presenting to the University of Chicago outpatient oncology clinics, a large research institution located on Chicago's Southside, were identified for study accrual, using the electronic scheduling system.
62687064|NCT06033209|EXPERIMENTAL|Part A SC safety with dose finding - Group 11|
62687065|NCT06033209|EXPERIMENTAL|Part A SC safety with dose finding - Group 12|
62687066|NCT06033209|EXPERIMENTAL|Part B IM Immunogenicity - Group 13|
62687067|NCT06033209|EXPERIMENTAL|Part B SC Immunogenicity - Group 14|
62687068|NCT06033209|EXPERIMENTAL|Part B Immunogenicity - Group 15|Group 15 N332-GT5 gp140 with SMNP dose and route (SC or IM) is To Be Determined (TBD) based on groups 6 and 12 (Part A).
62687069|NCT01229202|ACTIVE_COMPARATOR|standard of care|standard of care for trabeculectomy surgery
62687070|NCT01229202|ACTIVE_COMPARATOR|bevacizumab arm|
62687071|NCT01084759|EXPERIMENTAL|Etoposide and Testosterone|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.
62687072|NCT06549920|EXPERIMENTAL|Internal mammary node irradiation|Patients with right-sided breast cancer tumors were allocated to internal mammary node irradiation.
62687073|NCT06549920|NO_INTERVENTION|No internal mammary node irradiation|Patients with left-sided breast cancer tumors were allocated to no internal mammary node irradiation.
62687074|NCT06314152|EXPERIMENTAL|3-point fixation group|During laparoscopic transabdominal preperitoneal inguinal hernia repair, lightweight Mesh Fixation with 3-point Fixation. First fixation is in cooper ligament. Second fixation is in the back of rectus abdominis. Third fixation is in the later of tractus iliopubicus.
62687075|NCT06314152|ACTIVE_COMPARATOR|1-point fixation group|During laparoscopic transabdominal preperitoneal inguinal hernia repair, lightweight Mesh Fixation with 1-point Fixation in the back of rectus abdominis.
62687076|NCT01520103|EXPERIMENTAL|Vinorelbin and Everolimus|
62687077|NCT01520103|OTHER|standard therapy|Vinorelbin
62687078|NCT04491708|EXPERIMENTAL|Apparatus Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
62687079|NCT04491708|EXPERIMENTAL|Mat Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
62687080|NCT06673784||Evaluation of post-traumatic endophthalmitis|"1. conception~2. acquisition of data~3. analysis of data"
62687081|NCT04389463||Cardiac or thoracic surgery in COVID-19 positive patients|
62127483|NCT06014216|EXPERIMENTAL|Patients allocated ice lollies to treat post-operative thirst|Ice lollies consisted of a flavoured ice popsicle (blackcurrant) provided through hospital catering. Participants were allocated a single ice popsicle with thirst scores recored pre and post intervention.
62127484|NCT06014216|OTHER|Patients allocated water as control comparison|Water is a routine treatment for post-operative thirst and therefore used a control to compare our intervention against.
62127485|NCT02063425|ACTIVE_COMPARATOR|Fluoxetine|
62127486|NCT02063425|PLACEBO_COMPARATOR|Placebo|
62479649|NCT04948658||Turner Syndrome and galactosemia|Individuals with Turner Syndrome and galactosemia prior to menarche aged 4 years to 12 years who have not demonstrated signs of premature ovarian insufficiency (one FSH\>25 IU/L)
62479650|NCT04948658||Turner Syndrome with Y material|Children and adolescents who have Turner syndrome with Y material and undergo prophylactic gonadectomy.
62317820|NCT01790438|EXPERIMENTAL|LY2605541|Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications \[OAM(s)\] whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks.
62687082|NCT04389463||Cardiac/thoracic surgery in COVID-19 negative patients|
62687083|NCT00103701|EXPERIMENTAL|1|
62687084|NCT01647880|EXPERIMENTAL|Fingolimod (Gilenya®)|0,5 mg once a day in the morning, oral
62687085|NCT01647880|ACTIVE_COMPARATOR|Interferon beta-1b (Extavia®)|every second day, s.c.
62687086|NCT05179005||RibFix Advantage|Underwent surgical stabilization of rib fractures
62479651|NCT06394089||DS Group|Patients with degenerative spondylolisthesis Meyerding grade Ⅰ (slippage \>3 mm but \<25%) will be identified as having lumbar spinal stenosis combined with degenerative spondylolisthesis and will be allocated to the DS group.
62687087|NCT04231565|ACTIVE_COMPARATOR|TAF group|100 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long unless the patient achieves HBsAg loss.
62687088|NCT04231565|NO_INTERVENTION|Observation group|100 patients would not receive treatment from baseline to life-long.
62687089|NCT06566300|EXPERIMENTAL|injection of autologous nanofat grafting|Two separate scars with similar properties or splitting of one large post-burn atrophic scar. One (part of the) scar will be treated by injection of autologous nanofat grafting and the other (part of the) scar will be treated by microneedling with autologous nanofat graft.
62687090|NCT06566300|EXPERIMENTAL|microneedling with autologous nanofat graft|Two separate scars with similar properties or splitting of one large post-burn atrophic scar. One (part of the) scar will be treated by injection of autologous nanofat grafting and the other (part of the) scar will be treated by microneedling with autologous nanofat graft.
62687091|NCT03818074|EXPERIMENTAL|Boston Wavewriter (1000Hz) spinal cord stimulation|To investigate the response to high frequency (1000Hz) in patients who are due to have spinal cord stimulation for neuropathic back pain.
62687092|NCT02219100|EXPERIMENTAL|Home administration of mifepristone|This arm consisted of women who chose home administration of 200 mg mifepristone.
62687093|NCT02219100|NO_INTERVENTION|Clinic administration of mifepristone|This arm consisted of women who underwent clinic administration of 200 mg mifepristone.
62479652|NCT06394089||Non-DS Group|Patients not with degenerative spondylolisthesis will be identified as having lumbar spinal stenosis only and will be allocated to the Non-DS group.
62479653|NCT04936581||Open Total Mesorectal Excision|Patients undergoing open low anterior resection
62479654|NCT04936581||Laparoscopic Total Mesorectal Excision|Patients undergoing laparoscopic low anterior resection
62479655|NCT04936581||Robotic Total Mesorectal Excision|Patients undergoing robotic low anterior resection
62687094|NCT04985110|EXPERIMENTAL|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
62687095|NCT04985110|PLACEBO_COMPARATOR|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
62687096|NCT02364895|EXPERIMENTAL|Male arm|Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
62687097|NCT02364895|EXPERIMENTAL|Female arm|Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
62687098|NCT04903093|EXPERIMENTAL|Part A: Abrocitinib Tablet|
62687099|NCT04903093|EXPERIMENTAL|Part A: Abrocitinib Suspension F1|
62687100|NCT04903093|EXPERIMENTAL|Part A: Abrocitinib Tablet + Famotidine|
62687101|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F1|
62687102|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F2|
62687103|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F3|
62687104|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F4|
62687105|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F5|
62687106|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F6|
62687107|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F1 + Famotidine|
62127487|NCT05780528|EXPERIMENTAL|mulligan mobilization|the patients will receive mulligan mobilization three times a week for four weeks
62317821|NCT01790438|ACTIVE_COMPARATOR|Human Insulin NPH|Administered by SC injection once daily at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on FBG. Human insulin NPH will be used alone or in combination with up to 3 pre-study OAM(s) whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks. Some participants who are unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may be asked to add a second injection prior to the morning meal.
62317822|NCT06066918|EXPERIMENTAL|Pregabalin|Pregabalin 75 mg X2
62317823|NCT06066918|NO_INTERVENTION|No treatment|no treatment
62317824|NCT04355338||0-9 years|Participants aging 0-9 years
62317825|NCT04355338||10-19 years|Participants aging 10-19 years
62317826|NCT04355338||20-29 years|Participants aging 20-29 years
62317827|NCT04355338||30-39 years|Participants aging 30-39 years
62127488|NCT05780528|EXPERIMENTAL|instrumented assisted soft tissue mobilization|the patients will receive instrumented assisted soft tissue mobilization three times a week for four weeks
62687108|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F2 + Famotidine|
62317828|NCT04355338||40-49 years|Participants aging 40-49 years
62317829|NCT04355338||50-59 years|Participants aging 50-59 years
62479656|NCT04936581||Transanal Total Mesorectal Excision|Patients undergoing transanal Total Mesorectal Excision (taTME)
62479657|NCT02388971|EXPERIMENTAL|MLN1202 Dose|MLN1202 Dose, intravenously (IV), once on Days 1, 29 and 57.
62317830|NCT04355338||60-69 years|Participants aging 60-69 years
62317831|NCT04355338||70-79 tears|Participants aging 70-79 years
62317832|NCT04355338||80+ years|Participants aging 80 years or more
62317833|NCT00163553|EXPERIMENTAL|P|Epidural pethidine group
62317834|NCT00163553|PLACEBO_COMPARATOR|N|placebo group
62317835|NCT04487860|EXPERIMENTAL|AS012 dose regimen I|Oral
62317836|NCT04487860|EXPERIMENTAL|AS012 dose regimen II|Oral
62479658|NCT02388971|EXPERIMENTAL|MLN1202 Placebo|MLN1202 placebo, intravenously (IV), once on Days 1, 29 and 57.
62479659|NCT02243579|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
62479660|NCT06743438|EXPERIMENTAL|TMF treatment group|
62687109|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F3 + Famotidine|
62127489|NCT05780528|ACTIVE_COMPARATOR|conventional treatment|the patients will receive conventional treatment three times a week for four weeks
62127490|NCT01088113||Tai Chi|Healthy subjects with Tai Chi practice
62127491|NCT01088113||Qigong|Healthy subjects with Qigong practice
62127492|NCT00391846|OTHER|Guided by NT-proBNP|Treatment guided by clinical symptoms and signs + NTproBNP
62127493|NCT00391846|OTHER|Not Guided by NT-proBNP|Treatment guided by clinical symptoms and signs
62317837|NCT04487860|EXPERIMENTAL|AS012 dose regimen III|Oral
62317838|NCT04487860|EXPERIMENTAL|AS012 dose regimen IV|Oral
62317839|NCT04487860|PLACEBO_COMPARATOR|Placebo|Oral
62317840|NCT04269512|ACTIVE_COMPARATOR|extended lymph node dissection|Patients randomized to arm A undergo bilateral lymph node dissection in the pelvic area as part of prostatectomy. At least 10 lymph nodes must be removed.
62317841|NCT04269512|NO_INTERVENTION|standard without lymph node dissection|Application of standardized surgical technique without extensive lymph node dissection. If, contrary to expectation, intraoperative suspicion of lymphogenic metastasis results, a lymph node dissection is performed and the patient is excluded from the study (freedom of the surgeon).
62317842|NCT05602597|EXPERIMENTAL|Part A - Itraconazole|"Period 1 -- Participants to receive 10mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 200mg Itraconazole by mouth twice daily beginning on Day 3 through Day 10. On Day 7 200 mg Itraconazole and 10 mg HMPL-689 will be simultaneously administered."
62317843|NCT05602597|EXPERIMENTAL|Part B - Fluconazole|"Period 1 -- Participants to receive 10mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 400mg Fluconazole by mouth daily on Day 3, then 200 mg Fluconazole by mouth daily Day 4 through Day 10. On Day 7 200 mg Fluconazole and 10 mg HMPL-689 will be simultaneously administered."
62317844|NCT05602597|EXPERIMENTAL|Part C - Rimfampin|"Period 1 -- Participants to receive 30mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 600mg Rifampin by mouth daily beginning on Day 3 through Day 11. On Day 10 600mg Rifampin will be administered by mouth approximately 1 hour before the start of breakfast and 30mg HMPL-689 will be administered by mouth approximately 30 minutes after the start of breakfast."
62317845|NCT05602597|EXPERIMENTAL|Part D - Rabeprazole|"Period 1 -- Participants to receive 30mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 40mg Rabeprazole by mouth daily beginning on Day 3 through Day 9. On Day 9 40mb Rabeprazole will be administered by mouth approximately 1 hour before the start of breakfast and 30mg HMPL-689 will be administered by mouth approximately 30 minutes after the start of breakfast."
62479661|NCT06206291|ACTIVE_COMPARATOR|Methadone CBD|CBD capsules (BSPG Laboratories) in two dosing periods for a total of 8 weeks.
62479662|NCT06206291|PLACEBO_COMPARATOR|Methadone Placebo|Matching placebo.in first dosing period and CBD 400mg in second dosing period
62479663|NCT06206291|ACTIVE_COMPARATOR|Buprenorphine CBD|CBD capsules (BSPG Laboratories) in two dosing periods for a total of 8 weeks.
62479664|NCT06206291|PLACEBO_COMPARATOR|Buprenorphine Placebo|Matching placebo.in first dosing period and CBD 400mg in second dosing period
62479665|NCT01534819||Protocol B, abdominal arm, revision group|AAA subjects with previously implanted commercial endografts for the treatment of graft migration and/or Type Ia endoleak
62687110|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F4 + Famotidine|
62687111|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F5 + Famotidine|
62687112|NCT04903093|EXPERIMENTAL|Part B: Abrocitinib Suspension F6 + Famotidine|
62127494|NCT05725135||Males|Propofol total intravenous anaesthesia (TIVA) will be used for both induction and maintenance of anaesthesia. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using automated closed-loop anesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
62127495|NCT05725135||Females|Propofol total intravenous anaesthesia (TIVA) will be used for both induction and maintenance of anaesthesia. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using automated closed-loop anesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesi
62317846|NCT03714386|EXPERIMENTAL|expanded hemodialysis (HDx)|HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
62317847|NCT03714386|ACTIVE_COMPARATOR|online hemodiafiltration (HDF-OL)|OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
62317848|NCT04239274|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|
62479666|NCT01534819||Protocol B, abdominal arm, primary group|AAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type Ia endoleak, or to treat Type Ia endoleak evident at the time of implantation.
62127496|NCT01896349|EXPERIMENTAL|IPT+antidepressant drugs|"Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
62127497|NCT01896349|ACTIVE_COMPARATOR|Antidepressant Drugs|"Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
62127498|NCT01853410|EXPERIMENTAL|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
62127499|NCT04837976||Individuals with Parkinson's Disease|
62127500|NCT04837976||Supportive individuals|For example carers, family members or any other individual providing regular support or care to the person with Parkinson's.
62127501|NCT04837976||Healthcare Professionals|
62127502|NCT03516240|EXPERIMENTAL|Experimental|Participants receive the topical analgesic, Biofreeze.
62127503|NCT03516240|PLACEBO_COMPARATOR|Placebo|Participants receive a placebo cream.
62127504|NCT01248936|EXPERIMENTAL|Overall Trial|Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor
62127505|NCT04050644|EXPERIMENTAL|Preservative-free dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preservative-free dexamethasone 0.1% and diclofenac 0.1% eye drops.
62317849|NCT04239274|EXPERIMENTAL|Transcranial Pulsed Stimulation tPCS|
62317850|NCT04239274|SHAM_COMPARATOR|No Stimulation|
62317851|NCT00474630|EXPERIMENTAL|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy
62317852|NCT00474630|PLACEBO_COMPARATOR|Placebo|Placebo with ancillary therapy
62127506|NCT04050644|ACTIVE_COMPARATOR|Preserved dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preserved dexamethasone 0.1% and diclofenac 0.1% eye drops.
62317853|NCT03627455||Male, with DM|
62317854|NCT03627455||Male, without DM|
62317855|NCT03627455||Female, with DM|
62317856|NCT03627455||Female, without DM|
62317857|NCT04590937|EXPERIMENTAL|Cocktail/ Cocktail + BI 730357|Cocktail treatment will be followed by the Test treatment in a fixed sequence. The treatment periods are separated by a wash-out phase of at least 14 days between the two cocktail administrations.
62317858|NCT04360330|EXPERIMENTAL|Preoperative SABER|"* Experimental: Preoperative Stereotactic Ablative Breast Radiotherapy (SABER). Phase I study testing up to 4 dose levels.~* Non-experimental: Participants will undergo standard partial mastectomy and axillary surgery as per discretion of treating physician 4 to 6 weeks (+ at most 1 week delay) after preoperative SABER is completed."
62317859|NCT05055661|NO_INTERVENTION|The control group|Patients randomized to the control group will receive health education, audiovisual educational meterial regarding the use of inhalers and inhalators spacers and be contacted throughout the six months to collect the study variables, by telephone contact.
62687113|NCT05560763|EXPERIMENTAL|Completed Cases|
62317860|NCT05055661|EXPERIMENTAL|The intervention group|Patients randomized to the intervention grop will receive the same health education as the control group at the reference Basic Health Unit and also will be carried, once a month, the pharmaceutical teleconsultation during six months, by video call. The study variables will be collected in the same periods as the control group patients, by telephone contact.
62127507|NCT02282267|EXPERIMENTAL|Gefitinib|Patients with EGFR mutation in plasma detected by droplet digital PCR could receive Gefitinib 250mg every day until disease progression.
62127508|NCT00373386|EXPERIMENTAL|Growth Hormone|Growth hormone treatment 0.3 mg/kg/min
62127509|NCT05032534|ACTIVE_COMPARATOR|Newly developed cone for 6 weeks the currently used cone for 6 weeks|Starts off with treatment with the newly developed cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
62317861|NCT01430429|EXPERIMENTAL|NI-0801|
62479667|NCT01534819||Protocol B, thoracic arm, revision group|TAA subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
62479668|NCT01534819||Protocol B, thoracic arm, primary group|TAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation
62479669|NCT01534819||Protocol B, advanced disease arm, revision group|Advanced disease subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
62479670|NCT01534819||Protocol B, advanced disease arm, primary group|Advanced disease subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation.
62479671|NCT01534819||Protocol C, abdominal arm, short neck, primary group|Planned use of Heli-FX™ in conjunction with the Endurant II/IIs endograft in AAA subjects with short proximal necks (≥ 4 mm and \< 10 mm) in primary group.
62127510|NCT05032534|ACTIVE_COMPARATOR|Currently used cone for 6 weeks the newly developed cone for 6 weeks|Starts off with treatment with the currently used cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
62127511|NCT06124066|ACTIVE_COMPARATOR|Mirabegron|The participants were given mirabegron 50 mirabegron/day started 3 days before DJ stent insertion and until 6 weeks after the DJ stent insertion and filled in USSQ every week until 6 weeks after the DJ stent insertion(filled in directly when the patient arrived or by telephone)
62127512|NCT06124066|ACTIVE_COMPARATOR|Tamsulosin|The participants were given tamsulosin 0.4 mg that was started 3 days before DJ stent insertion and until 6 weeks after the DJ stent insertion and filled in USSQ every week until 6 weeks after the DJ stent insertion(filled in directly when the patient arrived or by telephone)
62127513|NCT06124066|PLACEBO_COMPARATOR|Placebo|The participants were given a placebo that was started 3 days before DJ stent insertion and until 6 weeks after the DJ stent insertion and filled in USSQ every week until 6 weeks after the DJ stent insertion(filled in directly when the patient arrives or by telephone)
62317862|NCT05801926|EXPERIMENTAL|Immediate assignment|Within this block, half are assigned to receive the sensor right away.
62317863|NCT05801926|ACTIVE_COMPARATOR|Delayed assignment|Within this block, half are assigned to receive the sensor after a delay of 3 to 4 weeks
62317864|NCT03893903|EXPERIMENTAL|IDH1 peptide vaccine|IDH1R132H peptide vaccine alone
62479672|NCT02307994|EXPERIMENTAL|75IU uFSH|75IU uFSH (Livzon Pharm Group Inc., China) being injected into severe oligospermia patients or azoospermia patients every 3 days for 6 months
62479673|NCT05388214|EXPERIMENTAL|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
62479674|NCT05345509|ACTIVE_COMPARATOR|Aricept Tablet|Aricept Tablet, QD, PO
62479675|NCT05345509|EXPERIMENTAL|IVL3003 (A mg)|SC, Single Dose
62479676|NCT05345509|EXPERIMENTAL|IVL3003 (B mg)|SC, Single Dose
62479677|NCT05345509|EXPERIMENTAL|IVL3003 (C mg)|SC, Single Dose
62479678|NCT05345509|EXPERIMENTAL|IVL3003 (Dmg)|Intramuscular
62127514|NCT05965388||Chronic hepatitis B patients treated with nucleoside analogues or interferon|Chronic hepatitis B patients treated with nucleoside analogues or interferon
62317865|NCT03893903|EXPERIMENTAL|combination|IDH1R132H peptide vaccine and Avelumab
62317866|NCT03893903|EXPERIMENTAL|Avelumab|Avelumab alone
62317867|NCT04743414|EXPERIMENTAL|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of itraconazole on Day 4 through Day 8, with a single oral dose of CTP-543 being co-administered on Day 7.
62479679|NCT05345509|EXPERIMENTAL|IVL3003 (Emg)|Intramuscular
62479680|NCT04022954||Inquiry™ AFocusII™ Double Loop|The Inquiry™ AFocus™ catheters are for recording intracardiac signals and cardiac stimulation during diagnostic electrophysiological studies. The Inquiry™ AFocus™ catheters are for use in mapping atrial regions of the heart.
62479681|NCT04022954||Advisor™ HD Grid, Sensor Enabled™|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart with recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
62317868|NCT04942483||Preschool children with a history of wheeze, aged 1 to 5 years old|"This is a pragmatic, observational study involving preschool children with wheeze aged one to five years old. All treatment and routine monitoring decisions will be at the discretion of their treating general practitioner (GP) or paediatrician (as per usual clinical practice), blinded to the study measurements.~The following three biomarker tests will be performed a) atopic sensitisation, b) blood eosinophil count and c) FeNO (off-line method)."
62317869|NCT01135485||Study group I|Study group I will include children who have undergone stage I palliation employing allograft material for left ventricular outflow tract reconstruction at CHOP during infancy (\<1 year of age). Stage I palliation is defined as an operation in which augmentation of the native ascending aorta and aortic arch is performed to bypass atresia or critical obstruction of the left heart structures.
62317870|NCT01135485||Study Group II|Study group II who have undergone stage II palliation in which allograft material is used, but have not undergone antecedent stage I palliation. Stage II palliation is defined as a superior cavopulmonary anastomosis in which the superior vena cava is anastomosed to the ipsilateral pulmonary artery via either the bidirectional Glenn or hemi-Fontan procedures.
62317871|NCT01135485||Control Group|The control group who have undergone palliative or corrective surgery for congenital heart disease during infancy (\<1 year of age) not requiring allograft material.
62317872|NCT04080115|EXPERIMENTAL|Attention Training Technique (ATT)|
62317873|NCT04080115|ACTIVE_COMPARATOR|Sham intervention control condition|
62317874|NCT01000064|ACTIVE_COMPARATOR|Vyvanse|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
62317875|NCT01000064|PLACEBO_COMPARATOR|Placebo|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
62317876|NCT03455881||NICU TED Genetic Cohort|This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
62317877|NCT03455881||NICU TED MRI Cohort|This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.
62317878|NCT03455881||TED Genetic Cohort|This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
62687114|NCT01810172|ACTIVE_COMPARATOR|Dry suction pleural drainage system|The control group will have their chest tube connected to a dry suction pleural drainage system The intervention will be the dry suction pleural drainage system
62479682|NCT06603103|EXPERIMENTAL|total knee arthroplasty with kinematic alignment and SPHERIKA prosthesis|
62687115|NCT01810172|EXPERIMENTAL|Digital pleural drainage system|The experimental group will have their chest tube connected to a digital pleural drainage. The intervention will be the digital pleural drainage system.
62127515|NCT05554614|EXPERIMENTAL|BTW app with reward-based feedback|Teens will install the BTW app with reward-based feedback. This tracks driving performance while providing individualized driving feedback using gamification concepts.
62317879|NCT03455881||NICU Control MRI Cohort|This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.
62317880|NCT04367701||Thalassemia group|"16 pediatric patients with thalassemia major undergoing surgery for repair of congenital heart disease.~Authors measure hemolysis by free plasma hemoglobin concentration."
62317881|NCT04367701||Control group|"25 pediatric patients with demographic data related to those in thalassemia group, undergoing surgery for repair of congenital heart disease.~Authors measure hemolysis by free plasma hemoglobin concentration"
62317882|NCT05117710|ACTIVE_COMPARATOR|Ebselen|The intervention will be 7-10 days administration of ebselen 600 mg twice daily taken orally. Ebselen has been manufactured to Good Manufacturing Practice (GMP) standards and will be provided by Sound Pharmaceuticals Inc. in 200 mg capsules.
62317883|NCT05117710|PLACEBO_COMPARATOR|Placebo|The intervention will be 7-10 days administration of placebo 600 mg twice daily taken orally.Identical placebo capsules have been manufactured and formulated in the same facilities as the active treatment.
62479683|NCT06603103|EXPERIMENTAL|total knee arthroplasty with kinematic alignment and ORIGIN prosthesis|
62127516|NCT05554614|EXPERIMENTAL|BTW app with situational supervised driving practice|Teens will install the BTW app the same as the app with reward-based feedback in conjunction with a situational supervised driving practice intervention for teen-parent dyads.
62127517|NCT05554614|SHAM_COMPARATOR|Sham BTW app|Teens will install the sham BTW app with driving performance tracking only.
62127518|NCT04643899|NO_INTERVENTION|Control group|Patients benefiting only from the usual nutritional rehabilitation program G1a: diabetic patients G1b: non-diabetic patients
62127519|NCT04643899|EXPERIMENTAL|Electrostimulation group|Patients benefiting from the usual program AND muscle electrostimulation sessions G2a: diabetic patients G2b: non-diabetic patients
62317884|NCT04760314|EXPERIMENTAL|Lebrikizumab 250 mg Every 4 weeks (Q4W)|Participants received 500 mg of Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections as a loading dose at Baseline followed by 250 mg of Lebrikizumab administered SC Q4W from Week 4 until Week 12, in combination with topical corticosteroid. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
62317885|NCT04760314|EXPERIMENTAL|Lebrikizumab 250 mg Every 2 weeks (Q2W)|Participants received 500 mg of Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 followed by 250 mg of Lebrikizumab administered SC Q2W from Week 4 until Week 14, in combination with topical corticosteroid. Week 16 responders entered maintenance period and were randomly allocated to receive 250 mg lebrikizumab Q2W or 250 mg lebrikizumab Q4W, in a 1:1 ratio. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
62317886|NCT04760314|PLACEBO_COMPARATOR|Placebo|Participants received two SC injections of Placebo as a loading dose at Baseline in combination with topical corticosteroid and Week 2 followed by a single injection Q2W from Week 4 until Week 14. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
62317887|NCT01344811|EXPERIMENTAL|Telemonitoring group|"* A Smartphone, body composition analyzer and Pedometer will be provided~* transmitting the results to the Smart Care Server via Smartphone~* At Smart care Center,care manager will provide remote body weight and activity monitoring and individual obesity case management"
62687116|NCT04286776|EXPERIMENTAL|Direct Electrical Stimulation|Stimulation will be applied concurrently with the task, if applicable, and stimulation trials will be interleaved with sham trials, where no stimulation is delivered.
62687117|NCT05438771|ACTIVE_COMPARATOR|Bicarbonate|"1.Correct method of brush Platelet value suitable for tooth brushing Feature of toothbrush (soft, nylon bristled, rounded tip, standard size) Fluoride toothpaste, its amount and use in dry brushes In toothbrush 45 degree, the contact of the bristles with the gums, 4 times contact with the inner, outer, chewing surface, tongue cleaning The benefits of correct brushing (preventing dental plaque and gingival recession, etc.) Importance of brushing teeth twice a day (breakfast and after dinner) Preparation of mouth wash Boiled and cooled water at 100°C Putting 5 measures of boiled and cooled water in a teacup with the 20 ml measuring cup provided.~Adding 1 teaspoon (6 g) of sodium bicarbonate to water Making a mouthwash Teaching how to gargle with 20 ml of bicarbonate 4 times a day at 6-hour intervals and being asked to spit it out without swallowing,"
62687118|NCT05438771|EXPERIMENTAL|Ankaferd Blood Stopper|"Correct method of brush Preparation of the mouthwash Boiled and cooled water at 100°C Putting 4 ml of water in the 5 ml measuring cup given to the patient Putting Ankaferd Blood Stopper on the remaining 1 ml portion of the 5 ml beaker Giving information about making and using mouthwash Use on an empty stomach 2 hours before meals in the morning and at least 2 hours after dinner After rinsing your mouth thoroughly with a mouthwash containing 5 ml of Ankaferd Blood Stopper prepared 2 times a day, you can swallow the solution in your mouth.~It is said that there is a solution-related discoloration in the mouth and teeth, but that it will return to its original state after tooth brushing."
62687119|NCT03989479|ACTIVE_COMPARATOR|Conventional Toothbrush|Brushing with conventional Kid's Soft Toothbrush, Colgate (5-9-year-old)
61924979|NCT01912963|EXPERIMENTAL|Phase II Cohort A: Without Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
62127520|NCT05184361|EXPERIMENTAL|Intermittent energy restriction (IER)|"Initially participants will undergo 2-weeks of neutral energy balance (EB). After this, the IER will consist of: 2-weeks of energy restriction interspersed with 1-week in neutral EB (total of 23-week period).~At the end, 8-weeks in neutral EB will be required."
62317888|NCT01344811|OTHER|Control group|"* A weighing scale and Pedometer will be provided~* recording in a self diary of body weight and the number of steps"
62479684|NCT01286545||Ankylosing spondylitis, long term treatment with infliximab|Patients with ankylosing spondylitis under long term treatment with infliximab within the open label clinical trials EASIC and DIKAS are now followed up in a registration study. No intervention is planned. Patients will be followed up for clinical outcome parameters and for radiographic progression.
62479685|NCT03322267|EXPERIMENTAL|Pembrolizumab|Adjuvant cisplatin-chemoradiotherapy followed by pembrolizumab
62479686|NCT00830414|EXPERIMENTAL|1|
62687120|NCT03989479|EXPERIMENTAL|T-shaped Toothbrush|Brushing with T-shaped toothbrush (Denson™, Malaysia)
62687121|NCT02688166||Breast Cancer|Breast cancer patients who are undergoing internal mammary lymph node radiation
62687122|NCT02688166||Lung Cancer, thymic cancer or mesothelioma|"Non-surgical Stage III non-small cell lung cancer patients undergoing mediastinal nodal irradiation with curative intent using concurrent chemotherapy~Any lung cancer, thymic cancer or mesothelioma patient getting either chemoradiation or radiation alone wherein heart gets radiation exposure"
62687123|NCT01294930||hip fracture|Patients operated for hip fracture, giving informed consent
62687124|NCT06501339|EXPERIMENTAL|Maintenance ECT|
62687125|NCT06501339|ACTIVE_COMPARATOR|Aripiprazole|
62687126|NCT02451007|EXPERIMENTAL|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
62687127|NCT03401879|EXPERIMENTAL|Patients with MS|Patients with Multiple Sclerosis
62127521|NCT05184361|ACTIVE_COMPARATOR|Continuous energy restriction (CER)|Similarly to IER, CER participants will undergo 2-weeks of neutral EB. After this, the CER will consist of: 16-weeks of continuous energy restriction. At the end, 8-weeks in neutral EB will be required.
62479687|NCT00830414|ACTIVE_COMPARATOR|2|DEPO-PROVERA®
62127522|NCT03669913|EXPERIMENTAL|Intervention|Intervention arm will receive a pre evaluation survey, 11 lessons on CSE sequentially in a period of one year and a post evaluation survey
62127523|NCT03669913|NO_INTERVENTION|Control arm|This is a control arm that receives no intervention but will have and pre and post evaluation in one year
62127524|NCT03416712|NO_INTERVENTION|Control|"To obtain baseline socioeconomic data on all children (intervention and control), study participants will utilize the Children's HealthWatch Survey (www.childrenshealthwatch.org), which is a standardized, validated survey designed to collect demographics and information on child health and development, parental health, and socioeconomic factors income, education level, financial literacy, childcare, and government assistance).~The control group will not complete the WE CARE HOUSTON survey and will not receive any referrals to community resources from the study team at the time of enrollment (they may be referred to resources by their medical/clinical team as per standard of care during their hospitalization at Texas Children's Hospital). The study investigators will offer control participants information on community resources at the end of the study. Study participants will be called for a 6 month follow up structure telephone survey."
62127525|NCT03416712|EXPERIMENTAL|Intervention|The intervention group will complete a short survey called the WE CARE HOUSTON survey. The WE CARE HOUSTON survey has been designed to quickly assess patient need for local services that address the social determinants of health. The WE CARE HOUSTON survey will be administered on paper or verbally if family is not able to read. Based on the parent's responses to the screening survey, the study investigators will use an algorithm to direct families to appropriate services and community resources. Families who screen positive for social needs will receive a handout on resources. For the families that screen positive for depression/ mental health needs, domestic violence, or alcohol and drug abuse, the study investigators will notify the medical/clinical team and recommend an inpatient social work prior to discharge. Intervention participants will be called 1 week-2 months after enrollment to follow up on resources and will be called for a 6 month follow up structured telephone survey.
62317889|NCT04018287||HPP-Group|"1. genetical verified hypophosphatasia~2. age \>18 years~3. written informed consent~4. complete serological and radiological examinations"
62317890|NCT04018287||Control-Group|"1. healthy men and women without any history of musculoskeletal diseases~2. Alkaline phosphatase (AP) in reference range~3. written informed consent~4. complete serological and radiological examinations"
62687128|NCT03401879|EXPERIMENTAL|Healthy control subjects|Healthy age- and sex- matched control subjects
62687129|NCT02176759|EXPERIMENTAL|Regular FePP|Rice (50g dry weight) fortified with 4mg regular FePP
62687130|NCT02176759|EXPERIMENTAL|Regular FePP with citrate added during extrusion|Rice (50g dry weight) fortified with 4mg regular FePP and citrate added during the extrusion process
62127526|NCT01369498|EXPERIMENTAL|Simtuzumab 200 mg|Participants in Stage 1 of study will receive simtuzumab 200 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
62317891|NCT05283915|EXPERIMENTAL|Mild hepatic impairment group|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
62317892|NCT05283915|EXPERIMENTAL|Normal hepatic function group|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
62317893|NCT01902797|EXPERIMENTAL|Household|In each camp, the camp residences are divided into different sections (as clusters for sampling) by camp registration. In the first stage, sections are selected using Population-proportion-to size (PPS) method. In the second stage, households are randomly selected from the household list in each section provided by NGO and local committee. When a household is not responding, a nearest household on the north will be used as replacement. All family members and overnight guests aged above 5 years in the selected household will be invited for venous blood sample (2 ml); for children aged 1-5 years old, the blood sample (100 microL) will be obtained by finger prick; children younger than 1 year old are excluded. The head of household will be invited for a short questionnaire.
62479688|NCT06102044|EXPERIMENTAL|Zinc Supplementation|14-day regimen of twice-daily 5 mg elemental zinc supplements to be taken orally or by enteral feeding tube
62479689|NCT06102044|PLACEBO_COMPARATOR|Placebo|14-day regimen of twice-daily oral placebo supplements to be taken orally or by enteral feeding tube
62687131|NCT02176759|EXPERIMENTAL|Regular FePP with citrated added at consumption|Rice (50g dry weight) fortified with 4mg regular FePP and citrate shortly added before consumption
62687132|NCT02176759|ACTIVE_COMPARATOR|Ferrous sulphate|Rice (50g dry weight) fortified with 4mg ferrous sulphate
62317894|NCT04922125|EXPERIMENTAL|Pulse flour|Puree produced from pulse flours and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
62317895|NCT04922125|EXPERIMENTAL|Pre-processed pulse flour|Puree produced from pre-processed pulse flour with different structural aspects and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
62317896|NCT04479501||Asthma group|Patients with asthma
62317897|NCT05452161|ACTIVE_COMPARATOR|Standard care|Control group receives the standard care in place in the service, a group information session about knee/hip arthroplasty surgery.
62317898|NCT05452161|EXPERIMENTAL|Standard care + individualized patient-centered preparation and education session|Intervention group A receives, in addition to standard care, an individualized patient-centered preparation and education session
62317899|NCT05452161|EXPERIMENTAL|Standard care + individualized patient-centered preparation and education session + remote follow-up|Intervention group B receives, in addition to standard care and an individualized patient-centered preparation and education session, a remote postoperative follow-up
62317900|NCT05922852||SGLT2i+ARNI|patients in this group received SGLT2i combined with ARNI medication。
62317901|NCT05922852||SGLT2i only|patients in this group received SGLT2i medication only。
62479690|NCT03873272|ACTIVE_COMPARATOR|Cryotherapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
62697423|NCT05640427|EXPERIMENTAL|Group D2|groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
62697424|NCT05536791||Pediatric patients eligible for Dabigatran Etexilate (DE) VTE treatment and secondary VTE prevention|
62127527|NCT01369498|EXPERIMENTAL|Simtuzumab 700 mg|Participants in Stage 1 of study will receive simtuzumab 700 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
62127528|NCT01369498|EXPERIMENTAL|Simtuzumab 200 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
62127529|NCT01369498|EXPERIMENTAL|Simtuzumab 700 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
62127530|NCT01066026|EXPERIMENTAL|Metallic cannula|Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool
62127531|NCT01066026|ACTIVE_COMPARATOR|Standard needle|Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.
62127532|NCT06666829|EXPERIMENTAL|Multidomain treatment group|Participant will undergo a Multidomain rehabilitation treatment using the combination of two or more innovative technological and robotic devices.This will also be associated with the conventional rehabilitation
62127533|NCT06666829|ACTIVE_COMPARATOR|Single domain treatment group|Participant will undergo a Single domain rehabilitation treatment using only one innovative technological or robotic device.This will also be associated with the conventional rehabilitation
62127534|NCT00973115|EXPERIMENTAL|Simvastatin CR 20mg- morning administration|
62127535|NCT00973115|ACTIVE_COMPARATOR|Simvastatin CR 20mg- evening administration|
62317902|NCT05922852||ARNI only|patients in this group received ARNI medication only。
62317903|NCT05922852||control|patients in this group received neither SGLT2i nor ARNI。
62317904|NCT00349791|PLACEBO_COMPARATOR|1|placebo patch replaced twice a week for two years
62317905|NCT00349791|EXPERIMENTAL|2|testosterone patch replaced twice a week for two years
62317906|NCT00592358|EXPERIMENTAL|1|
62317907|NCT06164795||Romo-Zol group|Postmenopausal women treated with romosozumab for 12 months will receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose
62317908|NCT06164795||Romo-Dmab group|Postmenopausal women treated with romosozumab for 12 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months starting at 1 month after the last romosozumab dose
62317909|NCT06164795||Romo-TPTD group|Postmenopausal women treated with romosozumab for 12 months will receive daily injections of teriparatide 20μg for 12 months starting at 1 month after the last romosozumab dose
62317910|NCT06164795||TPTD-Zol group|Postmenopausal women treated with teriparatide for 24 months will receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose
62317911|NCT06164795||TPTD-Dmab group|Postmenopausal women treated with teriparatide for 24 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months
62317912|NCT06164795||TPTD-Romo group|Postmenopausal women treated with teriparatide for 24 months will receive month injections of romosozumab for 12 months
62127536|NCT03366701||Patient during rehabilitation program|Patient performing a 5 weeks inpatient pulmonary rehabilitation program
62479691|NCT03873272|ACTIVE_COMPARATOR|Compression Therapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
62697425|NCT02889874|NO_INTERVENTION|A: Radiation Therapy & endocrine therapy|Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
62127537|NCT03366701||Patient after the rehabilitation program|Patient in their domicile after the 5 weeks program
62127538|NCT04571606|ACTIVE_COMPARATOR|Liposomal Bupivacaine|Pre-operative ultrasound guided interscalene nerve block with 10 mL 1.3% liposomal bupivacaine (Exparel) and 10 mL 0.5% bupivacaine
62127539|NCT04571606|ACTIVE_COMPARATOR|Peripheral Nerve Catheter|Pre-operative ultrasound guided interscalene nerve block with 20 mL of 0.25% bupivacaine and placement of peripheral nerve catheter with 10 mL/hr 0.2% bupivacaine infusion via OnQ pump.
62127540|NCT06143371|EXPERIMENTAL|CAN10 single ascending dose|A single dose of CAN10 will be administered intravenously (IV) to healthy subjects.
62127541|NCT06143371|PLACEBO_COMPARATOR|CAN10 single ascending dose - placebo|A single dose of matching placebo will be administered intravenously (IV) to healthy subjects.
62127542|NCT06143371|EXPERIMENTAL|CAN10 multiple ascending dose|Multiple doses of CAN10 will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis
62127543|NCT06143371|PLACEBO_COMPARATOR|CAN10 multiple ascending dose - placebo|Multiple doses of matching placebo will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis
62127544|NCT05344014|EXPERIMENTAL|Photobiomodulation group|In the experimental group, before local infiltration anesthesia was administered, PBMT (a diode laser: 940 nm; continuous mode; 0.5W; 78 J/cm2) was applied perpendicular to the root surface at buccal and palatal area for 60 sec each).
62127545|NCT05344014|PLACEBO_COMPARATOR|Placebo Group|In the control group, the laser probe was directed to the mucosa for (buccal and palatal area), but not activated.
62127546|NCT05765019|EXPERIMENTAL|Spinal mobilization group|
62127547|NCT05765019|ACTIVE_COMPARATOR|Core stabilization exercise group|
62127548|NCT02720965|EXPERIMENTAL|Electronic pump|Continuous nerve blocks Remote-controlled perineural local anesthetics delivery
62127549|NCT02720965|NO_INTERVENTION|single injection|single injection
62127550|NCT01042197|ACTIVE_COMPARATOR|2|Body surface area: 12 %
62479692|NCT03873272|PLACEBO_COMPARATOR|Control arm (Loose glove/sock)|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
62479693|NCT00841191|EXPERIMENTAL|Siltuximab 2.8 mg/kg (Cohort 1)|
62479694|NCT00841191|EXPERIMENTAL|Siltuximab 5.5 mg/kg (Cohort 2)|
62127551|NCT01042197|ACTIVE_COMPARATOR|1|Body surface area: 6 %
62127552|NCT01042197|ACTIVE_COMPARATOR|3|Body surface area: 24 %
62127553|NCT01042197|ACTIVE_COMPARATOR|4|Body surface area: 6 %
62127554|NCT01042197|ACTIVE_COMPARATOR|5|Body surface area: 12 %
62127555|NCT01042197|ACTIVE_COMPARATOR|6|Body surface area: 24 %
62127556|NCT01042197|ACTIVE_COMPARATOR|7|Body surface area: 6 %
62127557|NCT01042197|ACTIVE_COMPARATOR|8|Body surface area: 12 %
62127558|NCT01042197|ACTIVE_COMPARATOR|9|Body surface area: 24 %
62127559|NCT06524973|EXPERIMENTAL|Arm A (telehealth self-management coaching sessions)|Patients and FCGs attend telehealth self-management coaching sessions over 40-60 minutes every other week for 6 sessions over 3 months.
62127560|NCT06524973|ACTIVE_COMPARATOR|Arm B (standard of care)|Patients and FCGs receive standard of care on study.
62479695|NCT00841191|EXPERIMENTAL|Siltuximab 11 mg/kg (Cohort 3)|
62479696|NCT00841191|EXPERIMENTAL|Siltuximab 15 mg/kg (Cohort 4)|
62479697|NCT00841191|EXPERIMENTAL|Siltuximab 15 mg/kg (Expansion Cohort 5)|
62479698|NCT00841191|EXPERIMENTAL|Siltuximab 15 mg/kg (Ovarian Cancer Cohort 6)|
62697426|NCT02889874|EXPERIMENTAL|B: No Radiation Therapy (ET only)|Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
62697427|NCT00643656|EXPERIMENTAL|A|Mixture of 50% nitrous oxide and 50% oxygen
62127561|NCT06307301|EXPERIMENTAL|Phase I Study in ALS with Abatacept & IL-2|"Primary Objective:~1. To assess the safety and the tolerability of abatacept followed by IL-2 administration in ALS patients~Secondary Objectives:~1. To investigate the immunomodulatory effects of abatacept followed by IL-2, by monitoring the change in the number of Tregs~2. To investigate the immunomodulatory effects of abatacept followed by IL-2, by monitoring the change in the suppressive activity of Tregs on T effector proliferation.~3. To investigate the immunomodulatory effects of abatacept followed by IL-2, by monitoring in the level of cytokines secreted by PBMCs throughout the course of the study~Exploratory Objective:~1. To characterize the effects of abatacept followed by IL-2 on clinical outcome measures of ALS, including the Appel ALS Rating Scale (AALS) and ALS Functional Rating Scale-Revised (ALSFRS-R) scores, and the forced vital capacity (FVC) and maximum inspiratory pressure (MIP)."
62127562|NCT02111889|EXPERIMENTAL|one|
62127563|NCT06497959|EXPERIMENTAL|Non-growth restriction group (control group)|Fetuses not affected by growth pathology, defined by an estimated weight greater than the 10th percentile at ultrasound
62127564|NCT06497959|EXPERIMENTAL|Severe growth restriction group|Severe growth restriction defined by an estimated fetal weight below the 3rd percentile on ultrasound
62127565|NCT01499381||Routine prostate biopsy patients|
62127566|NCT02073370||health subjects; outpatients aged over 65|The research subjects will be culled from outpatients aged over 65 at NTUH; 1000 Taiwanese subjects aged 20-40 equally divided in both genders will be recruited in order to establish the norm of Taiwanese's skeletal muscle index.
62127567|NCT02711059|ACTIVE_COMPARATOR|parathyroidectomy|change in insulin resistance
62127568|NCT02711059|NO_INTERVENTION|control|the study participant will be examined parallel with the active comparator
62479699|NCT00841191|EXPERIMENTAL|Siltuximab 15 mg/kg (KRAS Mutant Tumors Cohort 7)|
62479700|NCT01660945|PLACEBO_COMPARATOR|placebo|placebo
62479701|NCT01660945|ACTIVE_COMPARATOR|vytorin 10|vytorin 10 mg
62697428|NCT00643656|PLACEBO_COMPARATOR|B|Mixture of 50% oxygen and 50% nitrogen
61924980|NCT01912963|EXPERIMENTAL|Phase II Cohort B: With Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
61924981|NCT01543373|EXPERIMENTAL|CRE8 arm|
61924982|NCT01543373|ACTIVE_COMPARATOR|Vision/Multilik8 arm|
62127569|NCT00933426|EXPERIMENTAL|Lenalidomide and Paclitaxel|"Phase I: Up to 5 differing doses of Lenalidomide tested plus fixed dose of Paclitaxel.~Phase II: Lenalidomide at highest tolerated dose from Phase I plus Paclitaxel."
62127570|NCT03173105|ACTIVE_COMPARATOR|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
62479702|NCT01660945|ACTIVE_COMPARATOR|vytorin 20|vytorin 20 mg
61924983|NCT05768958|EXPERIMENTAL|Morning exercise|Study visit performed in the morning with 45 min exercise.
61924984|NCT05768958|EXPERIMENTAL|Morning control|Study visit performed in the morning with 45 min rest period.
61924985|NCT05768958|EXPERIMENTAL|Evening exercise|Study visit performed in the evening with 45 min exercise.
61924986|NCT05768958|EXPERIMENTAL|Evening control|Study visit performed in the evening with 45 min rest period.
61924987|NCT01278303|OTHER|Treatment of Aortic Wall Injury|Repair of aortic wall injury with covered CP Stents
61924988|NCT01479985|EXPERIMENTAL|CDM Tool|participants will be randomized to completing the CDM tool
61924989|NCT01479985|NO_INTERVENTION|Control|Participants will fill out a computer survey similar to CDM tool without the decisive factors and computer print out
62127571|NCT03173105|SHAM_COMPARATOR|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
62127572|NCT03173105|ACTIVE_COMPARATOR|Group 3 (G3)|active tDCS + static proprioceptive exercises
62127573|NCT03173105|SHAM_COMPARATOR|Group 4 (4)|sham tDCS + static proprioceptive exercises
62127574|NCT04110223||non-smell cell lung cancer (NSCLC)|Advanced NSCLC patients receiving radiotherapy or chemo-radiotherapy
62127575|NCT04110223||Rectal cancer|Rectal cancer patients receiving neoadjuvant radiotherapy or chemo-radiotherapy
62479703|NCT05289648|EXPERIMENTAL|Preoperative Niraparib|Single arm. Following the initial assessment and endometrial biopsy the participants will receive niraparib for 28 days. After the treatment period the patients will be surgically staged. All participants will receive the standard of care.
62479704|NCT02842853|EXPERIMENTAL|MenACYW Conjugate Vaccine Lot 1|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 1a) and adults aged 18 to 55 years (Group 1b) received a single dose of MenACYW conjugate vaccine from lot 1 on Day 0.
62127576|NCT04110223||Smell cell lung cancer (SCLC)|SCLC patients receiving radiotherapy or chemo-radiotherapy
62127577|NCT04110223||Esophageal cancer|Esophageal cancer patients receiving radiotherapy or chemo-radiotherapy
62127578|NCT04110223||Cervical cancer|Cervical cancer patients receiving radiotherapy or chemo-radiotherapy
62127579|NCT04110223||Liver cancer|Liver cancer atients receiving radiotherapy or chemo-radiotherapy
62479705|NCT02842853|EXPERIMENTAL|MenACYW Conjugate Vaccine Lot 2|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 2a) and adults aged 18 to 55 years (Group 2b) received a single dose of MenACYW conjugate vaccine from lot 2 on Day 0.
62479706|NCT02842853|EXPERIMENTAL|MenACYW Conjugate Vaccine Lot 3|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 3a) and adults aged 18 to 55 years (Group 3b) received a single dose of MenACYW conjugate vaccine from lot 3 on Day 0.
62127580|NCT01429350|ACTIVE_COMPARATOR|IV rtPA|IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
62127581|NCT01429350|EXPERIMENTAL|IV rtPA and IA Penumbra System|Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
62479707|NCT02842853|ACTIVE_COMPARATOR|Menactra®|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 4a) and adults aged 18 to 55 years (Group 4b) received a single dose of Menactra® on Day 0.
62479708|NCT06072768|EXPERIMENTAL|15-day taper prednisone|This will be for 30 days. Participants will be allocated to the 15-day strategy preferentially until enrollment goals have been met; once completing the 15-day strategy, many participants will also be eligible to complete the 150-day strategy, and may subsequently enroll in it if they wish. Participants that are not eligible for the 15-day strategy, but are eligible for the 150-day strategy, will be enrolled in the 150-day strategy.
62127582|NCT01724242|EXPERIMENTAL|Vaginal DHEA|Vaginal DHEA 0.5%(6.5mg)inserted nightly
62127583|NCT01724242|PLACEBO_COMPARATOR|Placebo|
62127584|NCT03999034|EXPERIMENTAL|Patients|experimental, cognitive test, no treatment investigated. 140 patients (90 relasping remitting and 50 progressive multiple sclerosis)
62127585|NCT03999034|EXPERIMENTAL|Healthy controls|experimental, cognitive test, no treatment investigated. 400 healthy controls divided into 20 groups, due to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not).
62127586|NCT06168149||Neonates with respiratory distress syndrome|A total of 80 patients with no systemic maternal disease findings and diagnoses, without chronic drug use, who were measured at least 24 hours after antenatal corticosteroids were administered during pregnancy, and whose delivery occurred within a maximum of 72 hours, will be included in our study as two case groups with and without RDS diagnosis in neonatal follow-up.
62127587|NCT06168149||Neonates who do not develop respiratory distress syndrome|A total of 80 patients with no systemic maternal disease findings and diagnoses, without chronic drug use, who were measured at least 24 hours after antenatal corticosteroids were administered during pregnancy, and whose delivery occurred within a maximum of 72 hours, will be included in our study as two case groups with and without RDS diagnosis in neonatal follow-up.
62127588|NCT04103723||patients with premedication|Patients receiving preoperative premedication with midazolam before surgery.
62127589|NCT04103723||patients without premedication|Patients without preoperative premedication before surgery.
62127590|NCT05511428|EXPERIMENTAL|Treatment (daratumumab and hyaluronidase-fihj)|Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
62127591|NCT02382744|EXPERIMENTAL|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
62317913|NCT02627846|ACTIVE_COMPARATOR|EndoVenous Laser Ablation|EndoVenous Laser Ablation (EVLA) involves the delivery of laser light through a glass fibre placed into the lumen of a refluxing vein. This energy is converted into heat inducing a permanent, non-thrombotic occlusion.
62479709|NCT06072768|EXPERIMENTAL|150-day taper prednisone|This will be for 180 days. Participants who are not eligible for the 15-day strategy, but are eligible for the 150-day strategy, will be enrolled in the 150-day strategy.
62127592|NCT02382744|EXPERIMENTAL|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
62127593|NCT04153110|EXPERIMENTAL|Real tDCS - Real tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
62127594|NCT04153110|SHAM_COMPARATOR|Sham tDCS - Real tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks).
62317914|NCT02627846|ACTIVE_COMPARATOR|MechanoChemical Ablation (ClariVein®)|Mechanochemical ablation (MOCA) is performed by a device called ClariVein® which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip.
62317915|NCT05057949|EXPERIMENTAL|Part A, Treatment Sequence(Larotinib-Larotinib/Rifampin)|Larotinib , capsules (150mg\*2+50mg\*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to 26, participants received rifampin 600 mg as capsules, orally, once daily (QD) and Larotinib 350 mg as capsules, orally was coadministered on Day 20. There was a washout period of 13 days between the two treatments.
62479710|NCT01498939|EXPERIMENTAL|IDet 0.2 U/kg|
62479711|NCT01498939|EXPERIMENTAL|IDet 0.4 U/kg|
62127595|NCT01547546|EXPERIMENTAL|Single Arm|
62127596|NCT02239913|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and phentermine during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62127597|NCT02239913|EXPERIMENTAL|Topiramate Dose 1|Subjects will be maintained on the low topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the low dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62479712|NCT01498939|EXPERIMENTAL|IDet 0.8 U/kg|
62479713|NCT05842473|ACTIVE_COMPARATOR|TMS active + language therapy|TMS (active) using theta burst protocol over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by one session per week during 6 months. Each TMS session is followed by language training.
62317916|NCT05057949|EXPERIMENTAL|Part B, Treatment Sequence(Larotinib-Larotinib/itraconazole)|Larotinib , capsules (150mg\*2+50mg\*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to Day 25, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 15 to Day 25 and a single oral dose of Larotinib 350 mg as capsule was coadministered on Day 19 (Treatment B). There was a washout period of 13 days between the two treatments.
62127598|NCT02239913|EXPERIMENTAL|Topiramate Dose 2|Subjects will be maintained on the high topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the high dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62127599|NCT04970446|ACTIVE_COMPARATOR|FMT arm|Anaerobically prepared, freeze-thawed faecal microbiota transplantation
62127600|NCT04970446|PLACEBO_COMPARATOR|Placebo arm|Placebo liquid formulation (normal saline, glycerol, food colorant)
62127601|NCT04997616|EXPERIMENTAL|25 mg/day dose of Happy Lane CBD (Lower Dose)|One 25 mg Happy Lane CBD gel capsule per day (25 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days.
62127602|NCT04997616|EXPERIMENTAL|50 mg/day dose of Happy Lane CBD (Larger Dose)|Two 25 mg Happy Lane CBD gel capsules per day (50 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days. Both capsules will be taken at the same time as each other.
62127603|NCT02060669|EXPERIMENTAL|Arm 1|xeloda maintaenance
62127604|NCT02060669|NO_INTERVENTION|Arm 2|best supprotive care
62127605|NCT02598596|EXPERIMENTAL|Pegloticase regimen <120 kg - Main Study|Subjects weighing \<120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
62127606|NCT02598596|EXPERIMENTAL|Pegloticase regimen ≥120kg|Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
62127607|NCT02598596|EXPERIMENTAL|Pegloticase PK Sub-Study|Subjects weighing \<120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
62127608|NCT02598596|EXPERIMENTAL|Pegloticase Imaging Sub-Study|A subset of subjects participating in the Main Study and weighing \<120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
62127609|NCT02598596|EXPERIMENTAL|Pegloticase FDG-PET-CT Sub-Study|A subset of subjects participating in the Main Study and weighing \<120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
62127610|NCT02598596|EXPERIMENTAL|Pegloticase and Azathioprine|Subjects weighing \<120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
62127611|NCT05506436|EXPERIMENTAL|Implementation group|Four sessions are conducted with the nurses of the center assigned to the intervention group to agree on the implementation strategy together with the professionals. Once the strategy is defined, the implementation of the intervention will be launched in this group for 6 months. After this period, the final evaluation will be carried out, as well as a qualitative evaluation through a focus group.
62127612|NCT05506436|ACTIVE_COMPARATOR|Control group|A single session will be scheduled to introduce the nurses of the center assigned to this group to the EVIDENT 3 intervention, and access and downloading will be allowed for free use in their practice.
62317917|NCT02491658|EXPERIMENTAL|Treat Psoriasis Vulgaris with UC-MSCs|Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg) within 8 weeks.
62317918|NCT03105154|EXPERIMENTAL|Prevena Dressing|Groin dressed with Prevena
62317919|NCT03105154|ACTIVE_COMPARATOR|Conventional Dressing|Groin dressed with conventional bandage
62479714|NCT05842473|SHAM_COMPARATOR|TMS sham + language therapy|TMS (sham) using theta burst protocol over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by one session per week during 6 months. Each TMS session is followed by language training.
62127613|NCT04456322|EXPERIMENTAL|RT plus Nimotuzumab|Patients with pretreatment plasma EBV DNA\<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy ( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
62317920|NCT05547373|EXPERIMENTAL|Intervention|The investigators will select HCWs from the selected departments at the national hospitals, provincial hospitals, and district referral hospitals to participate in the pilot intervention. The participants will also include representatives from the Communicable Disease Control Department and the Department of Hospital Services of the Ministry of Health, the provincial hospitals, and the district referral hospitals in Cambodia and Lao PDR.
62317921|NCT01486316|OTHER|Control arm|Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
62317922|NCT01486316|EXPERIMENTAL|Risk Status Guided|Study doctors will have access to the experimental IDENTIFY-HF Risk Status for subjects in the Guided arm between months 6 and 18. At all times during the study, study doctors will also be able to use the standard device diagnostics in the office using the programmer, or by data transmission from the patient's home (or another remote location).
62317923|NCT00205504|ACTIVE_COMPARATOR|Obese women with metabolic syndrome|
62317924|NCT00205504|ACTIVE_COMPARATOR|Obese women without metabolic syndrome|
62317925|NCT00205504|ACTIVE_COMPARATOR|lean women without metabolic syndrome|
62317926|NCT01829789|EXPERIMENTAL|G-CRT|Group Community Reinforcement Training for parents
62317927|NCT01829789|ACTIVE_COMPARATOR|I-CRT|Individual Community Reinforcement Training for parents
62317928|NCT00872833||age 18-29|People age groups 18-29 with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
62479715|NCT02193724||Retinoblastoma|Participants identified with heritable retinoblastoma will undergo a skin biopsy or blood draw to collect cells for processing and analysis.
62479716|NCT03893487|EXPERIMENTAL|Treatment (fimepinostat, tumor resection)|"Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.~MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor."
62687133|NCT06687538|EXPERIMENTAL|Mobile application group|"When the executive (EP) goes to the patient for the procedure, he/she will fill out the Informed Consent Form, open the envelope and find out which group the patient is in. Introductory Information Form, 'State Anxiety Scale', 'Hemodynamic Variables Monitoring Form' and 'Surgical Fear Scale' will be completed for all patients undergoing TURP. Patients in the study group will be introduced to the training to be given with the mobile application and downloaded to their phones/tablets. According to randomization, patients in the study group will receive training with the mobile application and patients in the control group will receive routine care. In the postoperative period, Hemodynamic Variables Monitoring Form, Visual Analog Scale and Discharge Training Satisfaction Scale will be completed for all patients."
62687134|NCT06687538|NO_INTERVENTION|Control group|"When the executive (EP) goes to the patient for the procedure, he/she will fill out the Informed Consent Form, open the envelope and find out which group the patient is in. Introductory Information Form, 'State Anxiety Scale', 'Hemodynamic Variables Monitoring Form' and 'Surgical Fear Scale' will be filled out for all patients who will undergo TURP. Patients in the control group will receive routine care. In the postoperative period, Hemodynamic Variables Monitoring Form, Visual Analog Scale and Discharge Training Satisfaction Scale will be completed for all patients."
62317929|NCT00872833||age 30+|People age groups 30+ years with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
62317930|NCT06270797||normal intubation|during general anesthesia, normal intubation without any difficult airway or difficult intubation were recorded in the note.
62317931|NCT06270797||difficult airway or difficult intubation|during general anesthesia, any type of difficult airway or difficult intubation were recorded in the note.
62317932|NCT06203145|EXPERIMENTAL|BCD-KPD-AutoHSCT|BCD-KPD-AutoHSCT/BCD-AutoHSCT
62317933|NCT03159754|EXPERIMENTAL|Early Appendectomy|
62317934|NCT03159754|EXPERIMENTAL|Interval Appendectomy|
62317935|NCT03159754|EXPERIMENTAL|No Appendectomy|
62317936|NCT02874794|EXPERIMENTAL|LCZ696 (sacubitril/valsartan)|minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
62317937|NCT02874794|ACTIVE_COMPARATOR|Enalapril|minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
62317938|NCT01347918||control|Healthy controls
62317939|NCT01347918||IBS|Patients that fulfil the Rome III criteria for irritable bowel syndrome (IBS)
62127614|NCT04456322|ACTIVE_COMPARATOR|RT plus Cisplatin|Patients with pretreatment plasma EBV DNA\<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
62127615|NCT05383859|EXPERIMENTAL|Intervention Group (IG)|"1. Completing the consent and the pre-intervention questionnaires, anthropometric and HbA1c measurements.~2. Dietary and/ or physical activity: face to face plus written material~3. 3 months later: motivational phone call."
62127616|NCT05383859|NO_INTERVENTION|Control group (CG)|"1. Completing the consent and the pre-intervention questionnaires, anthropometric and HbA1c measurements.~2. Usual care"
62127617|NCT06109220|EXPERIMENTAL|Stage of arthritis|Patients with unilateral or bilateral knee degenerative inflammation (KOA) with Kellgren-lawrence rating of level 3 or lower
62127618|NCT04072653|EXPERIMENTAL|Observation group( SLNB is spared)|In the second stage, sentinel lymph node biopsy will be spared in the patients with negative preoperative axillary assessment.
62127619|NCT02346526|EXPERIMENTAL|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.~* Blood Tests~* CT scan~* Bone scan~* FACBC PET/MRI in a subset of participants"
62317940|NCT00973830|EXPERIMENTAL|Carve-In|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling with a nurse or medical assistant from their clinic. Counseling focuses on behavioral changes patients can make to improve their diabetes.
62317941|NCT00973830|EXPERIMENTAL|Carve-Out|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling over-the-phone with a diabetes health educator stationed in Chicago, IL. Counseling focuses on behavioral changes patients can make to improve their diabetes.
62479717|NCT05686122|EXPERIMENTAL|PainPac|4 behavioral cancer pain intervention sessions delivered by mobile application. Patient-focused intervention. PainPac uses Social Cognitive Theory to promote behaviors to improve pain, self-efficacy for pain management, and pain-related quality of life indices. It also uses real-time data to personalize the intervention and messaging to participants. The app also has interactive components to improve coping skills engagement.
62687135|NCT05398692|ACTIVE_COMPARATOR|+ PEM|Patients who experience Post Exertional Malaise (PEM) will receive 10 weeks of virtual rehabilitation.
62687136|NCT05398692|EXPERIMENTAL|No PEM|Patients who do not experience Post Exertional Malaise (PEM) will receive 10 weeks of traditional pulmonary rehabilitation.
62687137|NCT05336357|EXPERIMENTAL|Goal-Directed Therapy Group|Patients allocated to the Goal-Directed Therapy group will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours after randomization, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously.
62127620|NCT03253731||Healthy Volunteers|15 healthy volunteers
62127621|NCT05088954|ACTIVE_COMPARATOR|Patients diagnosed with metabolic syndrome|
62127622|NCT05088954|ACTIVE_COMPARATOR|Patients without a diagnosis with metabolic syndrome|
62127623|NCT02752503|EXPERIMENTAL|Nalmafene|
62127624|NCT00654316|EXPERIMENTAL|1|BCG delivered intradermally into the deltoid region in volunteers who have received BCG 10 - 20 years previously.
62127625|NCT03915340|OTHER|Sequence ABAB|16 subjects assigned to the sequence ABAB will receive a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in Periods 1 and 3 and a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62127626|NCT03915340|OTHER|Sequence BABA|16 subjects assigned to the sequence BABA will receive a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in Periods 1 and 3 and a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62127627|NCT03015896|EXPERIMENTAL|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 60 minutes on days 1 and 15 of courses 1-4 and on day 1 of courses 5-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62127628|NCT03586258|EXPERIMENTAL|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
62127629|NCT03586258|SHAM_COMPARATOR|Healthy Volunteers|Healthy Controls
62127630|NCT03966846|EXPERIMENTAL|Kefir Group|Kefir group received one bottle of kefir (180 ml) daily for 12 weeks. Microbial composition of the kefir included Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris, Lactococcus lactis ssp. diacetylactis, Leuconostoc mesenteroides ssp. cremoris, Lactobacillus kefyr, Kliyveromyces marxianus, and Saccharomyces unisporus.
62127631|NCT03966846|PLACEBO_COMPARATOR|Control Group|Control group received one bottle of milk (180 ml) daily for 12 weeks.
62317942|NCT00973830|NO_INTERVENTION|Control|Patients in this arm receive standard care. They receive no Diabetes Guide or brief counseling sessions
62317943|NCT03237260|EXPERIMENTAL|Vedolizumab 300mg|vedolizumab open label
62127632|NCT05327049|EXPERIMENTAL|no intervention|No Intervention: conventional selective caries removal without treatment After taking the first sample of dentin, the cavity will be restored
62127633|NCT05327049|EXPERIMENTAL|diode laser treatment|After selective caries removal the cavity was irradiated in contact mode with continuous wave of radiation through a 400µm flexible fiber that was inserted inside the cavity with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. Irradiation time was 15 seconds and repeated three times for 15 seconds interval with contact, pulsed mode and the output power was adjusted at 1.30 Watt.
62317944|NCT03531372|EXPERIMENTAL|Mipolixin®|Mipolixin® (Advanced Natural Antacid - AdNA)
62317945|NCT03531372|ACTIVE_COMPARATOR|Poliprotect®|Poliprotect® (Neobianacid)
62317946|NCT01976533||Advanced therapy, Heart-lung transplantation, dead|
62127634|NCT05327049|EXPERIMENTAL|Aloe Vera treatment|After selective caries removal the lesions were treated with aloe Vera paste which was prepared by mixing aloe Vera powder by distilled water until a thick paste is formed. the paste was applied to the prepared floor by condenser to cover the remaining carious lesion
62127635|NCT05459259||Patients participants|Adults who have undergone elective knee arthroplasty with post-operative arthrofibrosis/stiffness who have undergone MUA in the previous 24 months or are currently listed for a MUA.
62127636|NCT05459259||Healthcare Professionals|Physiotherapists/Occupational Therapist/ Nurses and Orthopedic surgeons with clinical experience in the management of patients with arthrofibrosis following knee joint arthroplasty
62127637|NCT05908669||GBM patients, IDH-wt|
62127638|NCT03216213|NO_INTERVENTION|Control|Vignette contains no extra information
62127639|NCT03216213|EXPERIMENTAL|Frame|Vignette is framed in a particular manner
62127640|NCT03216213|EXPERIMENTAL|Norms|Vignette contains extra information about norms
62687138|NCT05336357|NO_INTERVENTION|Conventional Therapy Group|Patients allocated to the Conventional Therapy Group will be treated according to the assistant team of the Emergency Unit, where will be measured the following parameters: invasive or non-invasive blood pressure (decided by the assistant team), peripheral oximetry, heart and respiratory rate, urinary output, in association with clinical history, complete physical examination and laboratory and imaging tests.
62127641|NCT03216213|EXPERIMENTAL|All|Vignette contains extra information about norms and is framed in a particular manner.
62127642|NCT05384691|OTHER|Luspatercept|Single-arm design: All patients are treated with 1.75 mg Luspatercept per kg body weight subcutaneously on day 1 of each 21 day cycle for up to 24 weeks and in case of response for up to 1.5 years.
62127643|NCT03407131|EXPERIMENTAL|Joint replacement|Intertrochanteric fracture patients were treated with joint replacement surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
62317947|NCT01751646|EXPERIMENTAL|Group A: Vitamin D3 50,000 IU|Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
62127644|NCT03407131|ACTIVE_COMPARATOR|Intramedullary nail fixation|Intertrochanteric fracture patients were treated with intramedullary nail fixation surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
62317948|NCT01751646|PLACEBO_COMPARATOR|Group B: Vitamin D3 placebo|Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
62317949|NCT05964725|EXPERIMENTAL|Receive traditional medical therapy and transcranial direct current stimulation|intravenous methylprednisolone infusion (dose of 1 mg/kg/day, maximum 60 mg/day) for 5 to 10 days. Patients included in this study were routinely examined and tested for audiometry, including otoscopy, pure tone audiometry, acoustic impedance, brainstem evoked potential, and tinnitus detection. After completion, the 32-guide EEG collector from Bricon was used to collect changes in neural activity in all subjects.
62317950|NCT05964725|SHAM_COMPARATOR|Receive traditional medical therapy and sham stimulation|Similarly, intravenous methylprednisolone infusion (dose of 1 mg/kg/day, maximum 60 mg/day) for 5 to 10 days. By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
62317951|NCT01442129|EXPERIMENTAL|MPC Intramyocardial injection|Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
62479718|NCT05686122|NO_INTERVENTION|PCST-Video|4 behavioral cancer pain intervention sessions delivered by videoconferencing by a pain therapist in the medical center to the patient in their natural environment (e.g., home). Sessions will be scheduled weekly for 45-60 min and mimic in person sessions. PCST-Video session content is matches the PainPac skills modules. PCST-Video participants will complete assessments at the same intervals as PainPac participants.
62687139|NCT03595124|EXPERIMENTAL|Arm A (axitinib, nivolumab)|Patients receive axitinib PO BID on days 1-28 and nivolumab intravenously (IV) over 30 minutes, or per institutional guidelines, on days 1 and 15 (if \< 18 years old) or on day 1 (if \>= 18 years old). Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
62127645|NCT04455633|EXPERIMENTAL|LX9211 low dose|LX9211, once daily
62127646|NCT04455633|EXPERIMENTAL|LX9211 high dose|LX9211, once daily
62127647|NCT04455633|PLACEBO_COMPARATOR|Placebo|Placebo, once daily
62127648|NCT04372004|ACTIVE_COMPARATOR|Viral RNA test using nasopharyngeal swab|
62127649|NCT04372004|ACTIVE_COMPARATOR|Viral RNA test using sputum|
62687140|NCT03595124|EXPERIMENTAL|Arm B (axitinib)|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AS OF 1/23/2020 - PROSPECTIVE PATIENTS ARE RANDOMLY ASSIGNED TO ARMS A OR C)
62127650|NCT04372004|ACTIVE_COMPARATOR|Serology test using blood|
62127651|NCT00957242|ACTIVE_COMPARATOR|warfarin|Oral warfarin titrated to an international normalization ratio (INR) of 2-3
62317952|NCT01442129|SHAM_COMPARATOR|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
62127652|NCT00957242|PLACEBO_COMPARATOR|placebo|Oral placebo (1mg or 2.5mg)
62127653|NCT00617331|EXPERIMENTAL|Dose 7.5 mcg|7.5 micrograms of vaccine administered on Day 0 and Day 28.
62127654|NCT00617331|EXPERIMENTAL|Dose 30 mcg|30 micrograms of vaccine administered on Day 0 and Day 28.
62127655|NCT03423277|EXPERIMENTAL|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 8 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
62479719|NCT06644300|EXPERIMENTAL|Monotherapy BM230 Dose Escalation|Patients will be treated with BM230 subcutaneous (s.c.) injection once every 1 week (Q1W) for 3 weeks in the 1st cycle and thereafter once every 2 weeks (Q2W) with 4 weeks as a cycle.
62127656|NCT05911581|ACTIVE_COMPARATOR|room temperature washing solution|İntra-arterial flushing with heparinized fluid kept in room air
62127657|NCT05911581|ACTIVE_COMPARATOR|washing solution at patient temperature|Intra-arterial flushing with heparinized fluid at patient body temperature
62479720|NCT06644300|EXPERIMENTAL|Monotherapy BM230 Safety/PK/PD Expansion|Expansion cohorts of monotherapy BM230 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
62479721|NCT02617966||Affected|Participants with retinal disease
62479722|NCT02617966||Unaffected|Healthy volunteers
62687141|NCT03595124|EXPERIMENTAL|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes, or per institutional guidelines, on days 1 and 15 (if \< 18 years old) or on day 1 (if \>= 18 years old). Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
62317953|NCT03896399|EXPERIMENTAL|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
62317954|NCT01674543|EXPERIMENTAL|Resistance training|
62317955|NCT01674543|EXPERIMENTAL|Concurrent training|
62317956|NCT01674543|SHAM_COMPARATOR|Control Group|
62317957|NCT05883267|EXPERIMENTAL|Virtual reality|"The VR glasses will be PICO model neo 2. The visual and vocal data content include both calming, affective imagery and interactive gaming, supplied by XR-Health Israel Ltd. The vocal-guided affective imagery during the procedure will be identical to the vocal guide in the VR glasses."
62317958|NCT05883267|ACTIVE_COMPARATOR|Audio|The vocal-guided affective imagery during the procedure will be identical to the vocal guide in the VR glasses.
62317959|NCT04797013|ACTIVE_COMPARATOR|rhTNK-tPA (0.25mg/kg)|rhTNK-tPA (0.25mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.
62317960|NCT04797013|ACTIVE_COMPARATOR|rt-PA (0.9mg/kg)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the remainder in 1 hour. Maximum dose 90mg.
62317961|NCT02401256|EXPERIMENTAL|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.~Included drugs:~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
62317962|NCT02839746||Dabigatran|Patients switched from vitamin K antagonist (VKA) to dabigatran
62317963|NCT01573208|EXPERIMENTAL|Register|Register
62317964|NCT03625219|ACTIVE_COMPARATOR|Prednisone|Cohort B only: Subjects will take 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
62687142|NCT03117621||Patients initiating Blinatumomab|Patients initiating Blinatumomab after Country-Specific Reimbursement approval in routine clinical practice.
62687143|NCT00764426|ACTIVE_COMPARATOR|non-alcoholic beverages|dealcoholised red wine, de-alcoholised beer, water
62687144|NCT00764426|ACTIVE_COMPARATOR|alcoholic beverages|red wine, beer, ethanol
62687145|NCT03094377|EXPERIMENTAL|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
62687146|NCT03094377|ACTIVE_COMPARATOR|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
62687147|NCT01825863|ACTIVE_COMPARATOR|Active abdominal wall block|60ml ropivacaine 0.375% single shot
62317965|NCT03625219|PLACEBO_COMPARATOR|Placebo|Cohort B only: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
62317966|NCT03490669|EXPERIMENTAL|Dose Escalation|Multiple dose levels of MSC-1 treatment once every 3 weeks
62317967|NCT03490669|EXPERIMENTAL|Dose Expansion|MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
62317968|NCT01168804|EXPERIMENTAL|single arm bendamustine bortezomib dexamethasone|single arm combination regimen: bendamustine - bortezomib- dexamethasone
62479723|NCT06443151||Spinal Cord Injury|Men and women of all races, ethnic backgrounds, over the age of 18 years: adults with chronic (\>12 months), motor complete (AIS A/B) SCI with paraplegia (neurological level of injury \[NLI\] at T2 or below).
62479724|NCT06443151||Control (Non-Spinal Cord Injury)|Non-injured men and women of all races, ethnic backgrounds, over the age of 18 years.
62479725|NCT06470425|ACTIVE_COMPARATOR|Control Group|
62479726|NCT06470425|EXPERIMENTAL|AI-Guided Group|
62479727|NCT04571021|EXPERIMENTAL|I-DEPT|Novel triage. The triage nurse can adjust the triage category one level of urgency down or one or two levels up.
62479728|NCT04571021|ACTIVE_COMPARATOR|DEPT|Existing triage algorithm
62479729|NCT06561997||Robot-assisted group|received percutaneous pedicle screw fixation (PPSF) with robotic assistance
62687148|NCT01825863|PLACEBO_COMPARATOR|Placebo abdominal wall block|60ml saline 9% single shot
62479730|NCT06561997||Free-hand group|received percutaneous pedicle screw fixation (PPSF) without robotic assistance
62479731|NCT04974684|EXPERIMENTAL|Interventional group|This study group will contain 30 patients that will be stratified further by 1:1 randomization to 2 groups of 15 patients - one group will be given only apixaban 5mg twice a day, the second group will be given apixaban 5mg twice a day and aspirin 100mg per day.
62687149|NCT06686433|EXPERIMENTAL|Test|Novel infant formula
62317969|NCT03132246||Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group went on to develop an infection."
62479732|NCT04974684|NO_INTERVENTION|Control group|This study group will contain 15 patients that will by treated following standard anticoagulation protocol (Warfarin INR 2-3 + aspirin 100mg/day).
62479733|NCT03587493|EXPERIMENTAL|EXPERIMENTAL GROUP|"110 adults, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included.~Blood sample analysis will be performed"
62127658|NCT03344536|EXPERIMENTAL|fulvestrant and Debio 1347|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter. Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated. The dosage in the phase 2 portion will be the MTD/RP2D determined in the phase 1b portion.
62127659|NCT00846326|EXPERIMENTAL|Oxymetazoline-Fluticasone Propionate|Combination nasal spray with oxymetazoline 0.05% and fluticasone propionate 0.05%
62127660|NCT00846326|PLACEBO_COMPARATOR|Oxymetazoline-placebo|oxymetazoline 0.05% w/v and placebo fluticasone propionate
62127661|NCT06412770|EXPERIMENTAL|Tai Chi intervention group|Tai Chi intervention group
62127662|NCT06412770|PLACEBO_COMPARATOR|Tai Chi Imagery Intervention Group|Tai Chi Imagery Intervention Group
62127663|NCT06412770|OTHER|Control group|no intervention
62127664|NCT02779998|ACTIVE_COMPARATOR|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute in order to maintain peripheral oxygen saturation (SpO2) above 94% during electrophysiology procedure under light sedation.
62127665|NCT02779998|EXPERIMENTAL|non invasive ventilation|non invasive ventilation (NIV) which associated positive end expiratory pressure (PEEP: 5 to 10 cmH2O) and pressure support ventilation (PSV: 5 to 15 cmH2O, to achieve total Pressure bellow 20cmH2O) will be delivered during electrophysiology procedure under light sedation. The patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
62127666|NCT02424071|ACTIVE_COMPARATOR|Melatonin group|Patients will receive a pill containing 5mg of melatonin on the evening before the surgery. Patients will receive another pill containing 5mg of melatonin two hours prior to surgery.
62127667|NCT02424071|PLACEBO_COMPARATOR|Placebo group|Patients will receive a pill containing placebo on the evening before the surgery. Patients will receive another pill containing placebo two hours prior to surgery.
62127668|NCT05241041|EXPERIMENTAL|[1st year]Auricular Acupressure Experimental Group 1|auricular acupressure
62479734|NCT05675423||25 subjects with a history of TBI but no history of TMI|25 subjects with a history of TBI but no history of TMI.
62479735|NCT05675423||25 subjects with a history of TMI|25 subjects with a history of TMI.
62687150|NCT06686433|ACTIVE_COMPARATOR|Control|Standard infant formula
62127669|NCT05241041|NO_INTERVENTION|[1st year]Control Group 1|education material
62687151|NCT06686433|NO_INTERVENTION|Reference|Breastfeeding
62687152|NCT06690567||Patient with cardiogenic shock or patients undergoing complex PCI, with Impella implantation|Impella implantation as only intervention needed
62687153|NCT02489045|EXPERIMENTAL|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
62127670|NCT05241041|NO_INTERVENTION|[1st year]Normal Group|Non-gamblers
62127671|NCT05241041|EXPERIMENTAL|[2nd&3rd year]Auricular Acupressure Experimental Group 2|auricular acupressure + group counseling
62127672|NCT05241041|PLACEBO_COMPARATOR|[2nd&3rd year]Placebo Group|placebo acupressure + group counseling
62127673|NCT05241041|NO_INTERVENTION|[2nd&3rd year]Control Group 2|education material
62687154|NCT03637816|EXPERIMENTAL|Arm I (anamorelin hydrochloride)|Patients receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
62687155|NCT03637816|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
62127674|NCT00584246|EXPERIMENTAL|1|Pregabalin (Lyrica)
62127675|NCT00584246|PLACEBO_COMPARATOR|2|Placebo
62127676|NCT01255670|ACTIVE_COMPARATOR|penicillin and metronidazole|After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess
62127677|NCT01255670|PLACEBO_COMPARATOR|penicillin and placebo|After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess
62479736|NCT05675423||35 healthy controls|35 healthy controls.
62479737|NCT03612271|EXPERIMENTAL|mGlide Intervention|Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
62317970|NCT03132246||Not Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group did not go on to develop an infection."
62687156|NCT05846919|ACTIVE_COMPARATOR|Pediatric patients indicated for RSI and face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
61924990|NCT06688851||Management of the odontogenic cyst using a Patient Specific Implant (PSI)|Patients diagnosed with odontogenic cysts are included in this study. Cone Beam Computed Tomography (CBCT) and Intraoral Scans are performed and registered in a software for the design of Patient Specific Implants (PSI). A customized implant is designed and manufactured using Selective Laser Melting (SLM). Under local anesthesia, cystostomy is performed, and the wall of the cyst is sampled for histological diagnosis. The PSI is anchored subperiosteally on the bone using osteosynthesis screws. After a 6-month-long decompression period a CBCT scan is performed to determine whether enucleation of the cyst is feasible. Enucleation of the cyst is performed and the remaining cyst lining is sent for histopathological examination.
61924991|NCT04365062|EXPERIMENTAL|Intervention: Excimer laser and drug coated balloon|Intervention: Excimer laser and drug coated balloon group
61924992|NCT04365062|ACTIVE_COMPARATOR|Excimer laser and plain balloon|Excimer laser and plain balloon group
61924993|NCT04365062|ACTIVE_COMPARATOR|plain balloon and drug coated balloon|plain balloon and drug coated balloon group
61924994|NCT05183893|EXPERIMENTAL|Experimental: L-Citrulline|5 g of L-citruline + 5 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the product, which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
62127678|NCT04266912|EXPERIMENTAL|Treatment (avelumab, M6620)|Patients receive avelumab IV over 60 minutes on days 1 and 15, and M6620 IV over 60 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62127679|NCT03372746||1|Participants across multiple sites with AMD from the original cohort of study participants enrolled in the AREDS2
62127680|NCT05783739||Tendo Achilles Lengthening (TAL), percutaneous|Percutaneous lengthening of the achilles tendon.
62127681|NCT05783739||Tendo Achilles Lengthening (TAL), open|Open surgery with lengthening of the achilles tendon.
62127682|NCT05783739||Gastrocsoleus lengthening in zone 1 and 2|Lengthening of the gasrocnemius or its aponeurosis.
62127683|NCT04504708|EXPERIMENTAL|ZX-101A Dose Level 1|Starting dose (SD) of ZX-101A administered orally once daily in a 28-day cycle
62127684|NCT04504708|EXPERIMENTAL|ZX-101A Dose Level 2|2-times the SD of ZX-101A administered orally once daily in a 28-day cycle
62127685|NCT04504708|EXPERIMENTAL|ZX-101A Dose Level 3|3-times the SD of ZX-101A administered orally once daily in a 28-day cycle
62127686|NCT04504708|EXPERIMENTAL|ZX-101A Dose Level 4|4-times the SD of ZX-101A administered orally once daily in a 28-day cycle
62127687|NCT04504708|EXPERIMENTAL|ZX-101A Dose Level 5|5-times the SD of ZX-101A administered orally once daily in a 28-day cycle
62317971|NCT03679481|EXPERIMENTAL|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
62317972|NCT03679481|PLACEBO_COMPARATOR|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
62317973|NCT06559137|ACTIVE_COMPARATOR|Peripheral Nerve Block (PNB) group|"* Patients will receive a purple surgical marker dot at the decided site of injection~* A 20 mL Adductor PNB will be injected intraoperatively at the point of the purple dot~* Patient will receive 0.2% plain Ropivacaine (perineural injection) regardless of weight"
62317974|NCT06559137|NO_INTERVENTION|No Peripheral Nerve Block (PNB) group|"* Patients will receive a purple surgical marker dot at a point where a PNB would be injected, if they were randomized to the no peripheral nerve block group~* A bandage will be placed over the purple dot and wrapped with the standard gauze/bandage from the surgery"
62127688|NCT02214160|EXPERIMENTAL|UX007|Participants previously treated with UX007 or treatment-naive participants will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
62127689|NCT01628419|EXPERIMENTAL|Health intervention program|Health promotion intervention program will be implemented at each workplace and will include: exercise program, nutritional counseling for the kitchen service, lectures on different topics (physical activity, nutrition, sleeping behaviour etc.).
62127690|NCT00713063|EXPERIMENTAL|1|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
62127691|NCT00713063|ACTIVE_COMPARATOR|2|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
62127692|NCT05822063|ACTIVE_COMPARATOR|Lidocaine group|the skin site will be prepped first and then two puffs of lidocaine (20 mg) will be sprayed by the researcher from a 5-cm distance on the dermal surface near the needle insertion point. Five minutes after spraying, the skin surface at the site of arterial needle insertion will be disinfected with 70% alcohol-soaked cotton pads and the specific hemodialysis needles will be inserted into the vessels of the fistula area by the ward nurse
62687157|NCT05846919|ACTIVE_COMPARATOR|Pediatric patients indicated for RSI and HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
62687158|NCT05846919|EXPERIMENTAL|Pediatric patients indicated for RSI and HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
62687159|NCT06690736|EXPERIMENTAL|CXCR4 PET/CT Imaging|Intravenous injection of one dose of 2-5 mCi 68Ga/18F-Pentixafor/Pentixather. Tracer doses of radiotracers will be used to image lesions by PET/CT
62687160|NCT03241160||Children with cerebral palsy|Children with a diagnosis of spastic cerebral palsy aged between 2 to 12 years who will be referred by pediatric neurologists will be included. Children under the age of 24 months, and used any medicine and/or oral appliances that could affect the chewing performance, will be excluded. Chewing evaluation will be performed.
62687161|NCT03189927|EXPERIMENTAL|BD-Covered stent|Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae
61924995|NCT05183893|EXPERIMENTAL|Experimental: Citrulline-malate|8g of citrulline-malate + 2 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the products which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
62127693|NCT05822063|ACTIVE_COMPARATOR|cold packs|In the ice pack method, 5 pieces of ice measuring 5\*5 will be placed in latex gloves and covered with material cover. They were placed after the passage of 2 min on the hand at the site of fistula 5 min before making the puncture. Next, specific hemodialysis needles will be inserted in the vessels of fistula area by the ward nurse after disinfecting the fistula area with 70% alcohol-soaked cotton pads.
62127694|NCT05822063|ACTIVE_COMPARATOR|flash lights|the patient's face will be photographed. The photograph will be taken with a camera \[(Sony HVLHFL1 with luminance intensity approximately 100 cd, lighting distance approximately 11 Lux, flash shooting distance (1-5 m)\].
62127695|NCT05822063|NO_INTERVENTION|control|no intervention
62127696|NCT02945098|NO_INTERVENTION|Control group|No intervention. Remained five minutes at rest.
62127697|NCT02945098|PLACEBO_COMPARATOR|Placebo group|Apply Kinesio Taping without tension.
61924996|NCT05183893|PLACEBO_COMPARATOR|Placebo|10g of maltodextrin plus additives (Lifepro®).
62127698|NCT02945098|EXPERIMENTAL|KT group|Apply Kinesio Taping application with tension.
62127699|NCT05486052|OTHER|Evaluation of reliability, repeatability and validity of devices among healthy subjects|Evaluation of the reliability, repeatability and credibility of biofeedback-based devices such as Biometrics, Luna EMG, Vectis, Rotor and nIRS among healthy individuals
62127700|NCT05486052|OTHER|Biofeedback method and Health-resort based rehabilitation|Health-resort based treatments supplemented with biofeedback training
62127701|NCT05486052|OTHER|Health-resort based rehabilitation|Control group - health-resort based treatments, without biofeedback training.
62127702|NCT02270645|EXPERIMENTAL|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
62127703|NCT02270645|NO_INTERVENTION|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
62317975|NCT04576351||1|"Sub cohort 1:~Participants in the WHO NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS CoV-2 infected patients.~Eligibility: consenting adults (age ≥18) hospitalized with definite COVID-19 included in the WHO COVID-19 Study. Participants invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected."
62687162|NCT03015948|EXPERIMENTAL|2.5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)
62687163|NCT03015948|EXPERIMENTAL|10mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.
62687164|NCT03015948|EXPERIMENTAL|20mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .
62687165|NCT03015948|EXPERIMENTAL|Placebo|For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)
62479738|NCT03612271|NO_INTERVENTION|Clinical Care Comparison|Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
62687166|NCT03015948|EXPERIMENTAL|5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)
62687167|NCT02397369|EXPERIMENTAL|Tobacco users: Self Help|Self-help intervention is defined as any manual or programme to be used by individuals to assist a quit attempt not aided by counsellors or group support.They include written materials on the health effects of tobacco, audio-or video tape or computer programmes.
62687168|NCT02397369|EXPERIMENTAL|Tobacco users:Telephonic counseling|Telephone counseling is a way of providing individual counseling via telephone conversation or telephone hotlines. It can be proactive or reactive.
62127704|NCT02719600|EXPERIMENTAL|Down Syndrome Group|Group with Down Syndrome
62127705|NCT02719600|ACTIVE_COMPARATOR|Typical Development Group|Control group with typical development
62317976|NCT04576351||2|"Sub cohort 2:~Patients with COVID-19 and neurological symptoms related to COVID-19 admitted to the Norwegian Departments of Neurology or other relevant Departments (both hospitalized and outpatient visits) and persons with neurological symptoms participating in other COVID-19 studies and not already participating in the WHO NOR Solidarity multicenter trial."
62687169|NCT02397369|EXPERIMENTAL|Tobacco users:Behavioural therapy Only|Behavioural therapy includes multiple sessions of Focus Group Discussion (FGD) and individual tobacco cessation counseling sessions. The participants in this group will be given advice to quit tobacco via multisession formal cognitive-behavioural therapy as per the Tobacco Cessation Clinic (TCC) guidelines.
62317977|NCT06175312|EXPERIMENTAL|Manipulations of graded feature salience (Expt 1.1)|Participants will view stimuli made salient based on feature contrast in one feature dimensions (color or motion direction; or checkerboard luminance contrast). The degree to which a location is salient will be manipulated based on the feature contrast across multiple values
62317978|NCT01481571|EXPERIMENTAL|Vitrification media and device|Vitrification medium oocyte, warming medium oocyte and Rapid-i
62317979|NCT01680224|ACTIVE_COMPARATOR|Healthy Weight|The main goal of the Healthy Weight intervention is to make small, sustainable changes to input and output on a weekly basis to achieve a balance between caloric intake and output. All sessions begin with a brief review of what was covered in the previous session, presentation of educational handouts, careful review of previous behavior change goals, and the development of healthy behavior change plans for the next session. Home exercises for all sessions consist of following individualized diet and exercise goals, and keeping a food and exercise log to determine areas for future healthy changes.
62317980|NCT01680224|EXPERIMENTAL|Project Health|Project Health adds dissonance-inducing activities, discussions, and homework activities to the Healthy Weight basic intervention. Each session begins with a verbal commitment to participate (to underscore the voluntary nature of participation), includes discussions of completed home practice assignments and in-session writing/sharing exercises (to create accountability), and concludes with home exercises (to increase level of effort). Completed home assignments are videotaped in subsequent sessions to increase accountability.
62687170|NCT02397369|EXPERIMENTAL|Tobacco users:Pharmacologic|Pharmacotherapy in the form of Nicotine Replacement Therapy based on individual need assessment to relieve withdrawal symptoms in tobacco users when trying to quit.
62687171|NCT06671496|EXPERIMENTAL|Zasocitinib Dose A|Participants will receive zasocitinib Dose A, tablets, orally, once daily (QD) for up to Week 52.
62687172|NCT06671496|EXPERIMENTAL|Zasocitinib Dose B|Participants will receive zasocitinib Dose B, tablets, orally, QD for up to Week 52.
62127706|NCT01350024|ACTIVE_COMPARATOR|Frontal Nerve Block|Patients will receive a frontal nerve block for anesthesia
62127707|NCT01350024|ACTIVE_COMPARATOR|Subconjucntival Injection|Patients will receive a subconjunctival injection for anesthesia
62127708|NCT06518876|EXPERIMENTAL|Phase 1a: Low dose group|Infusion of KQ-2003 CAR T-cells by single dose of 0.5×10\^6 CAR-T cells/kg
62127709|NCT06518876|EXPERIMENTAL|Phase 1a: Medium dose group|Infusion of KQ-2003 CAR T-cells by single dose of 1.0×10\^6 CAR-T cells/kg
62127710|NCT06518876|EXPERIMENTAL|Phase 1a: High dose group|Infusion of KQ-2003 CAR T-cells by single dose of 2.0×10\^6 CAR-T cells/kg
62127711|NCT06518876|EXPERIMENTAL|Phase 1b: RP2D|After all subjects in the Phase 1a dose-escalation study completed DLT observation, RP2D was determined based on the analysis results for the phase 1b expansion study.
62127712|NCT00232180|ACTIVE_COMPARATOR|Eplerenone arm|Eplerenone administered on top of background standard heart failure therapy
62687173|NCT06671496|EXPERIMENTAL|Placebo + Zasoctinib|Participants will receive placebo, orally, QD for up to Week 16, followed by zasoctinib Dose A or Dose B, orally, QD, from Week 16 up to Week 52.
62127713|NCT06196177|EXPERIMENTAL|Levosimontane group|name：Levosimendan injection dose：12.5mg；once；24h
62127714|NCT06196177|NO_INTERVENTION|control group|blank control
62687174|NCT03784729|EXPERIMENTAL|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted."
62127715|NCT02365779|EXPERIMENTAL|bilateral laparoscopic salpingectomy|
62127716|NCT05900765|EXPERIMENTAL|Zimberelimab combined with or without AVD sequential radiotherapy|"1. Combination therapy： Subjects received Zimberelimab 240mg Q3W 2 cycle.~   According to the results of PET/CT evaluation:~   CR: Additional 2 cycles of Zimberelimab (4 cycles of Zimberelimab monotherapy in total); PR: 2 cycles of Zimberelimab+ AVD therapy (only PR patients combined with AVD). Subjects who did not achieve a Partial Response (PR) or Complete Response (CR) in their initial or subsequent efficacy evaluations, and whose potential for benefit was deemed unlikely by the investigator, were discontinued from the study.~2. Radiotherapy treatment period (patients with CR/PR): Sequentially radiation therapy 20-30Gy."
62127717|NCT02771899|EXPERIMENTAL|EOS + spineEOS software in adults|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
62127718|NCT02771899|ACTIVE_COMPARATOR|EOS in adults|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
62127719|NCT02771899|EXPERIMENTAL|EOS + spineEOS software in children|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
62127720|NCT02771899|ACTIVE_COMPARATOR|EOS in children|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
62687175|NCT03784729|SHAM_COMPARATOR|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm.
62687176|NCT06688253|EXPERIMENTAL|Interventional group with Efgartigimod|Efgartigimod will be given to patients with MG CRISIS
62687177|NCT06688253|NO_INTERVENTION|Historical PLEX group|this group is the retrospective arm
62687178|NCT06310694|EXPERIMENTAL|Intervention Group (Elastane circular dressing on sterile transparent dressing)|"A peripheral intravenous catheter was placed by following all the steps applied to the control group. A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter. There is no need to remove additional circular dressings during intravenous therapy.~The peripheral intravenous catheter was monitored for 72 hours with 8-hour observations. Peripheral intravenous catheter was evaluated for infiltration, phlebitis, pain, obstruction, dressing stability, and leakage."
62687179|NCT06310694|NO_INTERVENTION|Control group (fixation of PIVC with a sterile transparent dressing)|"Peripheral intravenous catheter application was performed by the researcher in accordance with all steps. In the study, only patients who received a 20-gauge peripheral intravenous catheter were followed. The patient's peripheral intravenous catheter was fixed by the researcher with a sterile transparent dressing.~The peripheral intravenous catheter was monitored for 72 hours with 8-hour observations. Peripheral intravenous catheter was evaluated for infiltration, phlebitis, pain, obstruction, dressing stability, and leakage."
62687180|NCT00694928|EXPERIMENTAL|1|clindamycin phosphate/butoconazole nitrate
62687181|NCT00694928|ACTIVE_COMPARATOR|2|butoconazole nitrate
62127721|NCT04310358|EXPERIMENTAL|PLM group 1|Participants will do a pretest (Test 1), the 4 short PLMs, an immediate post-test (Test 2) and a remote post-test (Test 1).
62127722|NCT04310358|EXPERIMENTAL|PLM group 2|Participants will do a pretest (Test 2), the 4 short PLMs, an immediate post-test (Test 1) and a remote post-test (Test 2).
62127723|NCT06033118|EXPERIMENTAL|Gemox combined with Anlotinib and Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
62127724|NCT04056611|EXPERIMENTAL|Adult cohort: JNJ-53718678 or Placebo|Participants greater than or equal to (\>=) 18 to less than or equal to (\<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
62127725|NCT04056611|EXPERIMENTAL|Adolescent cohort: JNJ-53718678 or Placebo|Participants \>=13 to \<18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
62127726|NCT00371787|EXPERIMENTAL|soft contact lens|
62127727|NCT00371787|NO_INTERVENTION|non-lens wear|control group
62127728|NCT01000831|ACTIVE_COMPARATOR|Adjuvanted Arepanrix 2 doses|Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart
62127729|NCT03425734|EXPERIMENTAL|D group|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
62127730|NCT03425734|EXPERIMENTAL|S group|50 ml saline
62127731|NCT06439732|EXPERIMENTAL|Intervention|In this group we will use a continuous non-invasive hemodynamic monitoring system (Acumen IQ cuff)
62127732|NCT06439732|NO_INTERVENTION|Control|In this group we will use the oscillometric non-invasive blood pressure monitoring system
62317981|NCT01680224|PLACEBO_COMPARATOR|Control|"Some participants will be randomized to control condition whereby they will be given an psychoeducational video (Weight of the World)to view."
62127733|NCT04386356|NO_INTERVENTION|Orotracheal intubation with macintosh laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Macintosh laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
62479739|NCT02465060|EXPERIMENTAL|Subprotocol A (EGFR activating mutation)|Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients may also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
62479740|NCT02465060|EXPERIMENTAL|Subprotocol B (HER2 activating mutation)|Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62317982|NCT03043365|EXPERIMENTAL|Arm 1: Control Fish Oil first, then Saury Oil|Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm
62317983|NCT03043365|EXPERIMENTAL|Arm 2: Saury Oil first, then Control Fish Oil|Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm
62317984|NCT03043365|NO_INTERVENTION|Washout Period|8 week washout period to occur between week 8 and week 16. No study supplement taken by subject at this time.
62317985|NCT00886821|EXPERIMENTAL|1|
62479741|NCT02465060|EXPERIMENTAL|Subprotocol C1 (MET amplification)|Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
62479742|NCT02465060|EXPERIMENTAL|Subprotocol C2 (MET exon 14 deletion/mutation)|Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
62479743|NCT02465060|EXPERIMENTAL|Subprotocol E (EGFR T790M or rare activating mutation)|Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
62317986|NCT03907722||Genotypic variants|AA, AG and GG genotype
62317987|NCT01797783|EXPERIMENTAL|DAILIES® AquaComfort Plus® Multifocal|Nelfilcon A multifocal contact lens with comfort additive worn for 30 days on a daily wear, daily disposable basis
62317988|NCT01797783|ACTIVE_COMPARATOR|Focus® DAILIES® Progressives|Nelfilcon A multifocal contact lens worn for 30 days on a daily wear, daily disposable basis
62317989|NCT04296136||High risk of mortality|Adult patients admitted to the hospital medicine service with a high risk of mortality
62317990|NCT04296136||High risk of mortality (pre-implementation)|Adult patients admitted to the hospital medicine service with a high risk of mortality
62317991|NCT04072237|EXPERIMENTAL|Study Population|MarzAA (Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)
62317992|NCT00309777|EXPERIMENTAL|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
62317993|NCT00309777|ACTIVE_COMPARATOR|Simvastatin 20 mg|Simvastatin 20 mg once daily
62317994|NCT00309777|EXPERIMENTAL|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
62317995|NCT00309777|ACTIVE_COMPARATOR|Simvastatin 40 mg|Simvastatn 40 mg once daily
62317996|NCT03412630|EXPERIMENTAL|Diagnostic (computed tomography perfusion imaging)|Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
62317997|NCT00410280|OTHER|1|
62317998|NCT03041376|EXPERIMENTAL|Walking intervention|
62317999|NCT03041376|NO_INTERVENTION|Control|
62318000|NCT02723162|EXPERIMENTAL|VRN+ NAC|Titrated VRN up to 1mg BID with NAC at 1200mg BID for 28 days
62318001|NCT02723162|ACTIVE_COMPARATOR|NAC+ PBO|1200mg BID for 28 days plus VRN placebo for 28 days
62318002|NCT02723162|ACTIVE_COMPARATOR|VRN+ PBO|Titrated VRN up to 1mg BID with NAC placebo for 28 days
62318003|NCT02723162|PLACEBO_COMPARATOR|PBO+PBO|Double placebo taken for 28 days
62318004|NCT00864227|EXPERIMENTAL|Umbilical Cord Blood Transplantation|Participants will receive a double unit Hematopoietic Umbilical Cord Blood Stem Cell Transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
62318005|NCT01892527|EXPERIMENTAL|Tivantinib plus Cetuximab|Single arm
62318006|NCT04272905||Maternity patients|"* \> 18 years~* Post-natal following any form of delivery~* Between 4 and 48 hours after delivery~* Able to understand English adequately to give consent and complete the questionnaire"
62318007|NCT04272905||Maternity Unit Staff|"* Doctors, midwives and other staff~* Work on labour ward"
62687182|NCT06689995|EXPERIMENTAL|Bio-immune Capsule|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg
62687183|NCT06689995|PLACEBO_COMPARATOR|Placebo Capsule|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg
62687184|NCT03708809|EXPERIMENTAL|Immediate insertion|The intrauterine system will be inserted immediately after surgical termination of pregnancy, before awakening from anesthesia
62687185|NCT03708809|EXPERIMENTAL|Delayed insertion|The intrauterine system will be inserted on the first menstruation after termination of pregnancy. Women allocated to this arm will be asked to contact the study coordinator in order to visit the hospital on the proper timing for IUD insertion.
62687186|NCT03708809|OTHER|Control|Women who refuse to actively participate in the intervention groups will be offered consultation on other options for contraception during gynecological clinic visit after fist menstruation from termination of pregnancy.
62687187|NCT05197270|EXPERIMENTAL|4D-150 Dose Escalation up to 4 dose levels|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62687188|NCT05197270|EXPERIMENTAL|4D-150 Dose Expansion Dose 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62687189|NCT05197270|EXPERIMENTAL|4D-150 Dose Expansion Dose 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62687190|NCT05197270|ACTIVE_COMPARATOR|4D-150 Dose Expansion Control|Aflibercept at a fixed regimen will be administered.
62687191|NCT05197270|EXPERIMENTAL|4D-150 Steroid Optimization|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62687192|NCT05197270|EXPERIMENTAL|4D-150 Population Extension Dose 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62687193|NCT05197270|EXPERIMENTAL|4D-150 Population Extension Dose 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62687194|NCT05197270|EXPERIMENTAL|4D-150 Population Extension Dose 3|4D-150 will be administered at the assigned dose
62687195|NCT06606275||Apixaban arm|Patient who were receiving warfarin while on dialysis
62687196|NCT06606275||Warfarin arm|Patient who were receiving warfarin while on dialysis
62687197|NCT06686576|EXPERIMENTAL|Experimental group|Phase Ib/Ⅲ Participants will receive QL1706 pre and post surgery
62687198|NCT06686576|ACTIVE_COMPARATOR|Phase III Control group|Participants will receive SOC (CAPEOX) or undergo expectant observation post surgery.
62687199|NCT04020263|EXPERIMENTAL|Levosimendan|Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.
62687200|NCT04020263|PLACEBO_COMPARATOR|Placebo|Control group: Patients with cardiogenic shock treated with placebo (Cernevit/Soluvit) in addition to the conventional strategy.
62687201|NCT06537466|ACTIVE_COMPARATOR|Mediterranean Diet|This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
62687202|NCT06537466|EXPERIMENTAL|Very Low Ketogenic Diet|The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
62479744|NCT02465060|EXPERIMENTAL|Subprotocol F (ALK translocation)|Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687203|NCT06284564|EXPERIMENTAL|Evolocumab + Nivolumab|If you are found to be eligible to take part in this study, you will receive evolocumab and nivolumab on Day 1 of each cycle (every 4 weeks). Evolocumab will be given as an injection under the skin. Nivolumab will be given by vein over about 60 minutes.
62687204|NCT05023902|ACTIVE_COMPARATOR|Pilates|The Pilates Mat exercise group followed an eight-week exercise program. The exercise protocol of this study was designed by the researchers (Table I). According to previous reports, 6 to 8 weeks of Pilates training has positive effects on physical and psychological health (Akbas, Unver, 2021; Bavli \& Koybasi, 2016; Pourvaghar, Bahram, Sharif \& Sayyah, 2014; Rogers \& Gibson, 2009). As the program advanced, 20-cm diameter mini soft balls, Pilates rings, 65 cm diameter soft gymnastic balls, and rubber bands were used in this order as materials in Pilates exercises. After an initial warm-up exercises at a slow pace for 10 minutes, Pilates exercises with and without equipment were performed for 40 minutes. The exercises ended with a 10- minute recovery and stretching exercises for relaxation of all muscle groups
62479745|NCT02465060|EXPERIMENTAL|Subprotocol G (ROS1 translocation or inversion)|Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687205|NCT05023902|EXPERIMENTAL|NIA Dance|NIA includes nine basic movement forms, 13 principles, and 52 basic moves. The nine movement forms were derived from martial arts, dance arts, and the healing arts of the Alexander Technique, Feldenkrais Method, and Yoga (Rosas \& Rosas, 2004). The 13 principles specify areas related to fitness, personal growth, and lifestyle. Centered on the joy of movement, they focus on, for example, being sensitive to personal rhythms, making the correct movement choices, and experiencing positive changes in daily life. The moves of NIA are used to engage all body areas, improve fitness, and facilitate self-healing.
62687206|NCT06689670|EXPERIMENTAL|INT001 Treatment|Patients with liver tumors enrolled in the study will receive INT001
62687207|NCT05905198|EXPERIMENTAL|HFS-VFS|This arm will experience HFS first during the crossover, and then VFS.
62687208|NCT05905198|EXPERIMENTAL|VFS-HFS|This arm will experience VFS first during the crossover, and then HFS.
62687209|NCT05385523|EXPERIMENTAL|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
62687210|NCT05385523|EXPERIMENTAL|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
62687211|NCT05385523|EXPERIMENTAL|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
62687212|NCT04194697|EXPERIMENTAL|Exercise group|Participants will conduct exercise programs provided by the app 3 times a week for 12 weeks. Except for the exercise program provided by the app, the amount of activity and exercise in daily life will not change from before the study.
62687213|NCT04194697|OTHER|Non-exercise group|Participants will not change the amount of activity or exercise in daily life from before the study.
62687214|NCT03833583|EXPERIMENTAL|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
62687215|NCT03833583|SHAM_COMPARATOR|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
62687216|NCT01627197|ACTIVE_COMPARATOR|Intraaterial chemotherapy|"This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms~Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended)."
62479746|NCT02465060|EXPERIMENTAL|Subprotocol H (BRAF V600E/R/K/D mutation)|Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479747|NCT02465060|EXPERIMENTAL|Subprotocol I (PIK3CA mutation)|Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687217|NCT01627197|NO_INTERVENTION|Watchful waiting|Arm 2 (control): No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
62687218|NCT00993473|EXPERIMENTAL|Lantus (insulin glargine)|Lantus given as basal insulin once a day in the morning by subcutaneous injection
62687219|NCT00993473|ACTIVE_COMPARATOR|NPH insulin|Neutral Protamine Hagedorn (NPH) human insulin given as basal insulin either once or twice per day generally in the morning and /or at bedtime by subcutaneous injection
62687220|NCT02191995|EXPERIMENTAL|body awareness yoga|body awareness yoga session prior to breakfast meal
62479748|NCT02465060|EXPERIMENTAL|Subprotocol J (HER2 amplification >= 7 copy numbers)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
62479749|NCT02465060|EXPERIMENTAL|Subprotocol K1 (FGFR amplification)|Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
62687221|NCT02191995|NO_INTERVENTION|Control Arm|No intervention
62687222|NCT01337505|EXPERIMENTAL|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 doxorubicin equivalents of 165, 260, and 325 mg/m2)will be administered as a 30 minute IVI on Day 1 of each cycle.
62687223|NCT03538821|EXPERIMENTAL|Intact cod protein from fillet|Dietary supplement: intact cod protein from fillet, 8 g protein daily for 8 weeks
62687224|NCT03538821|EXPERIMENTAL|Intact cod protein from residual material|Dietary supplement: intact cod protein from residual material, 8 g protein daily for 8 weeks
62687225|NCT03538821|EXPERIMENTAL|Control|Control group receive tablet containing fillers and no proteins
62687226|NCT04870554|NO_INTERVENTION|Continuous Feeding|Enteric feeding will be given continuously.
62687227|NCT04870554|EXPERIMENTAL|Timed Feeding|Enteric feeding will be given four times per day, approximating breakfast, lunch, a snack, and dinner.
62127734|NCT04386356|ACTIVE_COMPARATOR|Orotracheal intubation with Airtraq Video Laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
62127735|NCT00342407||Cohort|Female flight attendants
62318008|NCT01445743|EXPERIMENTAL|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention women will receive a blinded dose of Tdap vaccine (ADACEL)
62318009|NCT01445743|PLACEBO_COMPARATOR|Placebo Comparator: Physiologic Saline solution|Administration of Tdap vaccine or placebo as a single 0.5 mL of Saline (0.9% NaCl) solution
62687228|NCT04202094|EXPERIMENTAL|Biopsy group|Young adult men (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment during childhood and who have chosen to undergo a testicular biopsy procedure at a young age as a fertility preservation strategy.
62318010|NCT04525222|EXPERIMENTAL|Arm I (Actify, text notifications)|Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
62687229|NCT04202094|EXPERIMENTAL|No biopsy group|Young adult men (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment during childhood and who have refused to undergo a testicular biopsy procedure at a young age as a fertility preservation strategy.
62318011|NCT04525222|ACTIVE_COMPARATOR|Arm II (Current Standard Care, text notifications)|Participants use app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
62318012|NCT00972998|EXPERIMENTAL|Healthy individuals|
62318013|NCT00664274|OTHER|CRT Group|
62318014|NCT01254396|ACTIVE_COMPARATOR|Sildenafil ODT tablet 50 mg, Fasted|Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
62318015|NCT01254396|EXPERIMENTAL|Sildenafil ODT tablet 50 mg, Fed|Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
62479750|NCT02465060|EXPERIMENTAL|Subprotocol K2 (FGFR mutation or fusion)|Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
62687230|NCT04202094|NO_INTERVENTION|Control group|Spontaneously conceived young adults whose data on reproductive health have already been published (Belva F et al., 2016/2017/2019).
62687231|NCT04873193|OTHER|Oscillometry + Pneumotach Procedure with Leo Device measurements|"All patients will undergo oscillometry procedure, followed by pneumotach procedure to measure tidal volume in different sitting positions. The Leo device will be worn throughout both procedures to measure the chest electrical impedance and compare against pneumotach measurements.~Oscillometry and pneumotach are part of standard of care."
62687232|NCT04003389|EXPERIMENTAL|Fezolinetant 30 mg|Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, once daily (QD) for a period of 52 Weeks.
62687233|NCT04003389|EXPERIMENTAL|Fezolinetant 45 mg|Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD for a period of 52 Weeks.
62687234|NCT04003389|PLACEBO_COMPARATOR|Placebo|Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, QD for a of period of 52 Weeks.
62687235|NCT05918146|EXPERIMENTAL|Intervention group|Dextrose injection, one time
62687236|NCT05918146|PLACEBO_COMPARATOR|Control group|Normal saline injection, one time
62687237|NCT05579522|EXPERIMENTAL|injectable fat graft|Injection of fat graft from the buccal pad of fat into the interdental papilla
62687238|NCT05579522|ACTIVE_COMPARATOR|hyaluronic acid filler|injection of hyaluronic acid filler in the interdental papilla
62687239|NCT05544396|EXPERIMENTAL|probiotic group|Routine eradicate treatment H. pylori, and probiotics (2 packs per day) for 6 months.
62687240|NCT05544396|PLACEBO_COMPARATOR|control group|Only routine eradicate treatment H. pylori.
62687241|NCT03487458|NO_INTERVENTION|Control|participants receive no surgical treatment
62687242|NCT03487458|EXPERIMENTAL|Rib Fixation Surgery|participants receive surgical treatment
62687243|NCT06689332|EXPERIMENTAL|Single arm pilot study. Intervention: Comprehensive geriatric assessment.|Comprehensive geriatric assessment (CGA) is performed by a geriatrician and a geriatric nurse. CGA in this study includes: Assessment of coexisting diseases and treatments. Review of medications and adjustments as needed. Assessment of symptoms and health related issues including screening for depression, dementia, delirium, nutritional problems, falls, polypharmacy and fatigue. Objective examination including blood tests and electrocardiogram. Assessment of activities of daily living and instrumental activities of daily living through standardized questionnaires. Assessment of domestic conditions, including need for assistance from community-based health care services. Assessment of physical function through history and physical tests. Based on the CGA findings, the geriatrician will initiate relevant interventions (including investigations or treatments) and follow-up as required.
62687244|NCT02529956|EXPERIMENTAL|UCB4940 8 mg|Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.
62687245|NCT02529956|EXPERIMENTAL|UCB4940 40 mg|Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.
62687246|NCT02529956|EXPERIMENTAL|UCB4940 160 mg|Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.
62687247|NCT02529956|EXPERIMENTAL|UCB4940 480 mg|Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.
62127736|NCT04565418|EXPERIMENTAL|Exercise training|12 week high-intensity interval training (3 sessions per week): Before and after exercise, subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws and indirect calorimetry.
62479751|NCT02465060|EXPERIMENTAL|Subprotocol L (mTOR mutation)|Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62687248|NCT02529956|EXPERIMENTAL|UCB4940 640 mg|Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.
62687249|NCT02529956|PLACEBO_COMPARATOR|Placebo|Single intravenous (iv) infusion of Placebo over at least 60 minutes.
62687250|NCT06687863|EXPERIMENTAL|OSA training group|The training group will be analised compared the effects of exercise on vascular function in different polimorphic aleles.
62687251|NCT06673953|EXPERIMENTAL|Respiratory training (study) group.|Thirty patients (n=30) receiving respiratory muscles training and traditional physical therapy program for six weeks (three sessions/ week) for 40-60 minutes.
61924997|NCT05075057|EXPERIMENTAL|Experimental Group|A total 400 subjects aged ≥60 years with chronic bronchitis and COPD receive three doses inactivated COVID-19 vaccine on Day 0, Day 21, Day 111, respectively.
61924998|NCT02568982||patient with Cushing's disease|
61924999|NCT04631302|EXPERIMENTAL|Mindfulness|
61925000|NCT04631302|ACTIVE_COMPARATOR|Light Physical Exercise|
62127737|NCT04960644|EXPERIMENTAL|MTX and corticosteroid|perimental: MTX and corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response MTX (5-6mg/m\^2/day,Maximum dose 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
62318016|NCT02209597|EXPERIMENTAL|StudyArm|"Subjects will be studied for 28 weeks in a sequential cross-over study: a~Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
61925001|NCT00234910|EXPERIMENTAL|A|2 drug arm
62479752|NCT02465060|EXPERIMENTAL|Subprotocol M (TSC1 or TSC2 mutation)|Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
61925002|NCT00234910|ACTIVE_COMPARATOR|B|3 drug arm, SOC
61925003|NCT01435317|EXPERIMENTAL|standard|Standard treatment with the ANM T30 CR®-System
61925004|NCT00072176|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61925005|NCT04910282||Eye Disease Patients|Patients with eye diseases age 65 and above will be included. Patients from the Ivey Eye Institute, St. Joseph's Health Care London, ON will be recruited in-person, based on inclusion and exclusion criteria.
61925006|NCT02477267|EXPERIMENTAL|Test-Reference Sequence|SL spray, followed by SL film
61925007|NCT02477267|EXPERIMENTAL|Reference-Test Sequence|SL film followed by SL spray
61925008|NCT04348890|EXPERIMENTAL|Treatment Arm|
61925009|NCT03668366|EXPERIMENTAL|S-1 arm|The patients in the S-1 arm will receive IMRT (66-70.4Gy to GTV, 57-60.8Gy to CTV1, 54-56Gy to CTV2, given in 30-32 fractions). During the IMRT course, S-1 will be administered orally according to body surface area (BSA\<1.25m2, 30mg; BSA: 1.25-1.5m2, 40mg; BSA\>1.5m2, 50mg) twice per day for 30-32 days. The dose modifications of S-1 will not be permitted during concurrent chemotherapy unless progression of the disease, toxicities of grade 4 or patient's refusal.
62127738|NCT04960644|ACTIVE_COMPARATOR|corticosteroid|perimental: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response
62318017|NCT06671405|EXPERIMENTAL|Itraconazole Cohort|"* All participants will receive 2 single doses of dose 1 of AZD0780 and 14 doses of itraconazole, under fed conditions.~* This part will consist of Period 1 (AZD0780 administration only), Period 2 (itraconazole administration only), and Period 3 (AZD0780 + itraconazole administration)."
62687252|NCT06673953|ACTIVE_COMPARATOR|Traditional (control) group|Thirty patients (n=30) receiving the traditional physical therapy program for six weeks (three sessions/ week) for 40-60 minutes.
62127739|NCT00352976|EXPERIMENTAL|Treatment with TBI|Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.
62127740|NCT01275287|ACTIVE_COMPARATOR|Standard of care|Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here.
62127741|NCT01275287|EXPERIMENTAL|Eculizumab arm|"Standard of care for ANCA vasculitis + eculizumab treatment~Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here."
62127742|NCT02201043|ACTIVE_COMPARATOR|Thalidomide 150mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd.po.to the end
62127743|NCT02201043|ACTIVE_COMPARATOR|Thalidomide 100mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end
62127744|NCT02201043|PLACEBO_COMPARATOR|Placebo|Placebo po.
62687253|NCT06691789|EXPERIMENTAL|Intervention|This arm had intervention
62687254|NCT06691789|NO_INTERVENTION|Control|This arm had no intervention
62127745|NCT02284412|ACTIVE_COMPARATOR|neostigmine|Neostigmine will be dosed as 60 μg/kg, and glycopyrrolate 12 μg/kg (commercially available 5:1 co-formulation), as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
62127746|NCT02284412|EXPERIMENTAL|Sugammadex|Sugammadex will be dosed 15 mg/kg, as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
62127747|NCT02284412|PLACEBO_COMPARATOR|Water for injection|Water will be dosed arbitrarily as a 1 mL single iv bolus administered over 10sec.
62127748|NCT05293431|EXPERIMENTAL|Active Stimulation Group|This group will receive real tACS non-invasive brain stimulation
62127749|NCT05293431|SHAM_COMPARATOR|Sham Control Group|This group will receive Sham tACS non-invasive brain stimulation
62127750|NCT00096915|EXPERIMENTAL|darbepoetin alfa|
62127751|NCT02979808|EXPERIMENTAL|Navina Smart|Navina Smart will be used during 12 months for transanal irrigation (TAI).
62127752|NCT04787653|ACTIVE_COMPARATOR|Otoband efficacy on Tinnitus|"Participants will wear the Otoband on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Each participant will select his/her preferred stimulation level. The OtoBand will be programmed to operate at one of three power levels that are thought to be effective. The OtoBand will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
62687255|NCT06524648||Infertile women with medical recommendation of niPGT-A|"Patients will not undergo any additional intervention apart from those already scheduled for their ART. The only study specific procedures are the culture of the embryos in a timelapse system and the collection of the embryo's culture media, which is usually discarded. Both procedures will be performed following the stardard practice.~No drugs will be administered as per the study."
62687256|NCT02333474|ACTIVE_COMPARATOR|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line Version 2.2014.
62127753|NCT04787653|PLACEBO_COMPARATOR|Placebo device efficacy on Tinnitus|"The placebo device will use the same case, headband and battery as the OtoBand. The transducer in the OtoBand will be rotated 90 degrees, so that the placebo device will vibrate in a direction ineffectual at providing bone conducted vibrations. The vibrations will be in the horizontal plane, parallel to the skull, and will not have their energy penetrating the skull all the way to the vestibular system. Each participant will select his/her preferred stimulation level. The placebo devices will be made to vibrate at one of three power levels, none of which are thought to be effective. The placebo will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
62127754|NCT00214240|EXPERIMENTAL|1|Cytogam in addition to standard of care (IV ganciclovir therapy)
62127755|NCT00214240|NO_INTERVENTION|2|Receive standard of care therapy (IV ganciclovir)
62127756|NCT06335719|EXPERIMENTAL|Treatment Group|Treatment group undergoes nerve biopsies during surgery. In addition, patients in the treatment group receive brief electrical stimulation therapy for approximately 10 minutes during the first stage cross-face nerve graft surgery.
62127757|NCT06335719|EXPERIMENTAL|Control Group|Control group undergoes only nerve biopsies during surgery - no brief electrical stimulation.
62127758|NCT06320912|EXPERIMENTAL|Group(A)|
62127759|NCT06320912|ACTIVE_COMPARATOR|Group(B)|
62127760|NCT01634516|EXPERIMENTAL|Dietary support|Face to face intervention plus subsequent telephone support
62127761|NCT01634516|PLACEBO_COMPARATOR|No dietary support|No face to face intervention plus subsequent telephone support
62127762|NCT03245580|OTHER|Arm 1 -modified wet suction|Intervention:Procedure Core Liver Biopsy Technique: Modified Wet Suction
62127763|NCT03245580|OTHER|Arm 2- Slow Pull|Intervention: Procedure Core Liver Biopsy Technique: Slow Pull
62127764|NCT01304355||Controls|Healthy Control Subjects
62127765|NCT01304355||IBS Group|Subjects diagnosed with IBS
62127766|NCT01610297|EXPERIMENTAL|ICL670|Oral dose of ICL670 at 10 mg/kg daily
62127767|NCT03135184|EXPERIMENTAL|HDL Therapeutics PDS-2™ System|Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
62127768|NCT06244615|EXPERIMENTAL|Verum mouth and throat rinse|Formulation containing WO 6607 for oral administration (rinse and gargle).
61925010|NCT04744038|EXPERIMENTAL|Investigational Device|Participants will then be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device. Participants will use their own mask with the investigational device for the duration of this study.
62127769|NCT06244615|PLACEBO_COMPARATOR|Placebo mouth and throat rinse|Formulation containing WO 6608 for oral administration (rinse and gargle).
62318018|NCT06671405|EXPERIMENTAL|Carbamazepine Cohort|"* All participants will receive 2 single doses of dose 1 of AZD0780 and 6 doses of 100 mg, 6 doses of 200 mg, and 40 doses of 300 mg carbamazepine, under fed conditions.~* This part will consist of Period 1 (AZD0780 administration only), Period 2 (carbamazepine administration only), and Period 3 (AZD0780 + carbamazepine administration)"
62127770|NCT06153810|EXPERIMENTAL|Early stimulation|Biofeedback treatment is started after two weeks of observation
62127771|NCT06153810|EXPERIMENTAL|Delayed stimulation|Biofeedback treatment is started after three weeks of observation
62127772|NCT00908505|EXPERIMENTAL|physiotherapy|
62127773|NCT06235619||Non aneurysm patients|CT anatomical characteristics of the aortic arch in subjects without aneurysms requiring treatment.
62127774|NCT06235619||Aneurysm patients|CT anatomical characteristics of the aortic arch in subjects withaneurysms requiring treatment.
62127775|NCT05083702|ACTIVE_COMPARATOR|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|fluroscopy guided superior hypogastric plexus block transdiscal approach for chronic pain treatment in cancer bladder VAS score and morphine consumption are measured before and after 1 day , 1 month , 3 monthes
62127776|NCT05083702|ACTIVE_COMPARATOR|ultrasound-guided superior hypogastric plexus block|ultrasound guided superior hypogastric plexus block in treatment of chronic pain in cancer badder VAS score and morphine consumption are measured before and after 1 day , 1 month , 3 monthes
62127777|NCT05053568|EXPERIMENTAL|Intervention group|Live visualised, fluoroscopy-fused, image-guided, left ventricular lead placement on the basis of avoiding scar and targeting late mechanically activated segments.
62479753|NCT02465060|EXPERIMENTAL|Subprotocol N (PTEN mutation or deletion and PTEN expression)|Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61925011|NCT05242523|NO_INTERVENTION|Control|No exposure to smells.
62687257|NCT02333474|EXPERIMENTAL|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line Version 2.2014 and simultaneous injection of mix vaccine (MV). MV will be given
62687258|NCT06421454|EXPERIMENTAL|Melatonin|Ulcers will be treated daily with melatonin cream for 8 weeks
62687259|NCT06421454|ACTIVE_COMPARATOR|Control|Ulcers will be treated daily with hydrogel for 8 weeks
62687260|NCT01641055|EXPERIMENTAL|Salmon protein hydrolysate|
62687261|NCT01641055|EXPERIMENTAL|Herring protein hydrolysate|
62687262|NCT01641055|SHAM_COMPARATOR|Cod protein|
62687263|NCT01641055|PLACEBO_COMPARATOR|Milk protein|
62687264|NCT06642779||877PAY (monofocal)|26 patients (52 eyes) binocularly implanted with the 877PAY monofocal IOL model
62687265|NCT06642779||877PEY (extended depth of focus)|38 patients (76 eyes) binocularly implanted with the 877PEY extended depth of focus IOL model
62687266|NCT05014126|EXPERIMENTAL|Pain, Stress, & Emotions Class|No active or placebo comparator will be used. This is a single-arm study design.
62687267|NCT02430714||Arm 1|A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
62687268|NCT04412239|EXPERIMENTAL|Telephone Consultation in TB Patients|The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective.
62687269|NCT04245605||Early angiography|Patients admitted to hospital with acute heart failure undergoing coronary angiography within 14 days of hospital admission
62687270|NCT04245605||Control|Patients admitted to hospital with acute heart failure not undergoing coronary angiography within 14 days
62687271|NCT04482621|ACTIVE_COMPARATOR|Decitabine + Standard of Care (SOC)|Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
62687272|NCT04482621|PLACEBO_COMPARATOR|Standard of Care (SOC) + Placebo|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
62687273|NCT05973656|EXPERIMENTAL|Group I (alcohol consumption)|Participants who consume alcohol receive a standard drink or an alcohol dose that will result in a 0.03% BAC PO on study. Participants also undergo collection of saliva and breathalyzer testing throughout the trial.
62687274|NCT05973656|ACTIVE_COMPARATOR|Group II (biospecimen collection)|Participants who do not drink alcohol undergo collection of saliva, mouthwash, and cheek brush samples throughout the trial.
62687275|NCT02800746|EXPERIMENTAL|Experimental group|Ferric carboxymaltose
62687276|NCT02800746|PLACEBO_COMPARATOR|Control Group|Placebo
62687277|NCT00311831|ACTIVE_COMPARATOR|1|
62687278|NCT00311831|EXPERIMENTAL|2|
62687279|NCT00636337|EXPERIMENTAL|1|Participants meeting inclusion criteria will be provided with a laptop computer outfitted with a wireless card for the duration of the intervention and will be trained in the use of RoboMemo in the clinic by study personnel. Although many participants may have ready access to home computers, we decided that all participants will be required to use laptops provided by the study for two reasons: 1) to ensure that coaches and participants are blind to treatment condition (as described above), and 2) to ensure that participants will always have access to the intervention program (i.e., they will not compete with other family members for computer time). Once trained, children will complete the intervention at home. The intervention will consist of four 30- to 45-minute sessions per week for 8 weeks (total = 32 sessions). This intervention schedule is similar to the schedule employed by Klingberg and colleagues in their home-based CT trials with ADHD children.
62318019|NCT06321744|EXPERIMENTAL|Adapted physical activity program (APA Program)|"An intervention (APA program) will be offered to patients hospitalized in the conventional hospitalization department of the medical oncology department.~At entry, after presenting the study and obtaining non-opposition from patients, an initial assessment will be carried out before the APA program.~At the end of the initial assessment, an APA program supervised (individually and in a room) by an APA teacher will be offered to patients. The sessions will be offered daily to patients (maximum 5 times/week). They will last on average 20 minutes each depending on the fatigue, pain and fitness of the patients. The objectives pursued are mainly an improvement in functional independence and mobility."
62318020|NCT02133378|EXPERIMENTAL|Hemopatch|Use of Hemopatch on bleeding spot
62318021|NCT02133378|SHAM_COMPARATOR|Control|Traditional techniques hemostasis (dry or wet gauze compression or similar)
62318022|NCT01140516|ACTIVE_COMPARATOR|Trimethoprim|Prophylactic Antibiotics
62687280|NCT00636337|PLACEBO_COMPARATOR|2|The design will be a double-blind, placebo-controlled trial in which half of the participants will be randomized to the intervention condition and half will receive a comparison computer program. Specifically, participants assigned to the comparison (placebo) condition will complete a modified version of the CT at home. The treatment and comparison CT programs begin identically, at the lowest difficulty level. Those in the treatment condition will complete activities of increasing difficulty over the intervention period. Those in the placebo condition, in contrast, will complete the same basic tasks during each session of the intervention, regardless of performance. In this way, a true estimate can be obtained of the efficacy of the treatment program.
62687281|NCT05211960|EXPERIMENTAL|Treatment|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness. Participants will receive a premium account for 1 year; the current study will evaluate outcomes over 3 months. The intervention will be delivered concurrently with treatment as usual which includes standard psychosocial care as participants are referred to their respective programs.
62687282|NCT03376412|EXPERIMENTAL|Single Arm Treatment.|All patients will be unilaterally implanted in the non-dominant eye with the Raindrop Near Vision Inlay for the compensation of presbyopia.
62687283|NCT05281653|EXPERIMENTAL|Neuromuscular Training Group|Athletes in this group will receive progressive neuromuscular exercise training in addition to routine 2 weekly training sessions.
62687284|NCT05281653|EXPERIMENTAL|Control Group|The routine will continue with 2 workouts per week.
62127778|NCT05053568|NO_INTERVENTION|Control group|Empirical standard-of-care left ventricular lead placement, in line with current CRT implantation guidelines with electrical guiding on the basis of Q-LV sense.
62318023|NCT01140516|PLACEBO_COMPARATOR|Simple syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
62318024|NCT00120796|ACTIVE_COMPARATOR|1|Lamivudine alone
62318025|NCT00120796|EXPERIMENTAL|2|Lamivudine + Vaccine
62127779|NCT05792280|EXPERIMENTAL|AI-assisted group|Subjects will undergo EUS examination with the assistance of AI system.
62318026|NCT06671834|EXPERIMENTAL|PF-07905428 Low Strength|Participants may receive 0.08% PF-07905428 QD. Area of application will be increased as the study proceeds from one cohort to the next.
62318027|NCT06671834|EXPERIMENTAL|PF-07905428 High Strength|Participants may receive 0.24% PF-07905428 QD. Area of application will be increased as the study proceeds from one cohort to the next.
62318028|NCT06671834|PLACEBO_COMPARATOR|Placebo|All participants will receive Placebo QD. Area of application will be increased as the study proceeds from one cohort to the next.
62318029|NCT00815984||Schoolchildren with asthma.|Schoolchildren with asthma.
62318030|NCT01568905|EXPERIMENTAL|Arm 1 Low Level Nicotine Cigarette|(0.4 mg/g)
62318031|NCT01568905|EXPERIMENTAL|Arm 2 Intermediate Nicotine Level Cigarette|(5.7-5.8 mg/g)
62318032|NCT01568905|EXPERIMENTAL|Arm 3 High Level Nicotine Cigarette|(11.4-12.8 mg/g)
62127780|NCT05792280|NO_INTERVENTION|non-assisted group|Subjects will undergo EUS examination without the assistance of AI system
62127781|NCT05559281|EXPERIMENTAL|Group A|
62318033|NCT06175507|EXPERIMENTAL|Naltrexone|Naltrexone 50mg orally once daily will give for 12 weeks
62318034|NCT06175507|ACTIVE_COMPARATOR|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
62318035|NCT06416839|EXPERIMENTAL|VR Exercise|This arm will use a VR exercise game that increases in frequency, intensity and duration with each week of the intervention.
62318036|NCT06247540|EXPERIMENTAL|Treatment (venetoclax, rituximab, nivolumab)|Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.
62318037|NCT03792269|EXPERIMENTAL|Multi-channel chemotherapy|Patients will receive intraperitoneal irinotecan (50mg, d1, q2w).
62318038|NCT03792269|ACTIVE_COMPARATOR|Control Group|Patients will receive intravenous oxaliplatin (130mg/m\^2, d1, q3w), and oral capecitabine (1.0g, d1-14, q3w).
62318039|NCT06375330|EXPERIMENTAL|Treatment|10 mg/ml Polynucleotides + 10 mg/ml Hyaluronic Acid in 2 mL prefilled syringe injections
62318040|NCT06375330|NO_INTERVENTION|Physiotherapy|Physiotherapy
62127782|NCT05559281|ACTIVE_COMPARATOR|Group B|
62318041|NCT06457763||Ultrasound|While the patients were in the supine position on the operating room table, the external tracheal diameter, measured just above the sternoclavicular junction, was measured by ultrasound. Appropriately sized tube size was selected in accordance with previous studies and cadaver studies.
62318042|NCT06457763||conventional|For female patients, a 37 fr left double lumen tube was chosen for patients taller than 160 cm, and a 35 fr left double lumen tube was chosen for patients shorter than 160 cm. For male patients, a 41 fr left double lumen tube was selected for patients taller than 170 cm and a 39 fr tube was chosen for men shorter than 170 cm.
62318043|NCT04516616|EXPERIMENTAL|Study group|Patients receive 1 cycle of cisplatin and albumin-bound paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of PD-1 antibody combined neoadjuvant chemotherapy.
62318044|NCT00073593|EXPERIMENTAL|bivalirudin|250mg vial given as 0.75mg/kg intravenous (IV) bolus and 1.75 mg/kg/hr IV infusion for the duration of the procedure with the option to increase or decrease the infusion in 0.25 mg/kg/hr increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an ACT\>300 seconds.
62127783|NCT03675581|EXPERIMENTAL|All subjects|
62127784|NCT01836133||Erlotinib 150 mg|Participants received 150 mg erlotinib once daily, orally, as tablets, until disease progression or unacceptable toxicity, up to 3 years.
62127785|NCT02250118|EXPERIMENTAL|Bevacizumab|Intrapleural use: range 0.5 - 5 mg/kg
62127786|NCT00373529|EXPERIMENTAL|Clofarabine|Participants received an induction cycle of clofarabine 30 mg/m\^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day intravenous infusion for 5 consecutive days.
62127787|NCT01001936|EXPERIMENTAL|1|
62127788|NCT01604161||Somatropin|
62318045|NCT00073593|ACTIVE_COMPARATOR|heparin/protamine|1.5-3.5 mg/kg (200-400 U/kg) intravenous (IV) bolus to target an ACT \>300 seconds followed by weight-adjusted boluses as needed during the procedure to achieve/maintain the target ACT. Protamine as needed
62318046|NCT03996538|EXPERIMENTAL|Metformin Hydrochloride Extended Release Tablets|Patients will consume 3 tablets of 500mg metformin hydrochloride extended-release tablets daily (1500mg/day (after 3 week dose gradation)).
62318047|NCT03996538|PLACEBO_COMPARATOR|Placebo|Patients will consume 3 identical placebo tablets (after similar 3 week dose gradation).
62318048|NCT02242149|PLACEBO_COMPARATOR|Placebo|All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
62318049|NCT02242149|EXPERIMENTAL|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
62318050|NCT02046915|EXPERIMENTAL|Pomalidomide, Dexamethasone, Cyclophosphamide|"1. Pomalidomide administered orally at the starting dose of 4 mg/day on Days 1-21 of a 28-day cycle~2. Low-dose Dexamethasone administered orally at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle~3. Cyclophosphamide administered intravenously 500 mg/m² on Days 1 and 15 of a 28-day cycle"
62318051|NCT00042185|EXPERIMENTAL|Dissonance intervention|
62127789|NCT01893970|EXPERIMENTAL|SWIFT: Acute Social Work Intervention in the ED and Follow Up|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
62127790|NCT01893970|ACTIVE_COMPARATOR|SWIFT-Acute Only: Acute social work intervention in the ED|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
62127791|NCT01285986|EXPERIMENTAL|Vein collar at distal anastomosis|Vein collar at the distal anastomosis
62127792|NCT01285986|EXPERIMENTAL|No vein collar at the distal anastomosis|No vein collar at the distal anastomosis
62127793|NCT01277614|EXPERIMENTAL|Lifestyle counseling|This is a 6-month intervention in which participants with 2 or more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
62127794|NCT01277614|PLACEBO_COMPARATOR|Health Literature|
62127795|NCT01188369|EXPERIMENTAL|levosimendan|infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation
62127796|NCT01188369|PLACEBO_COMPARATOR|Placebo|Identical placebo
62127797|NCT02450344|EXPERIMENTAL|Internet intervention|Interactive health promotion
62127798|NCT02450344|ACTIVE_COMPARATOR|Conventional intervention|Passive health promotion
62127799|NCT00188890||1|prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
62127800|NCT02965846|EXPERIMENTAL|AGN-195263|
62127801|NCT02965846|PLACEBO_COMPARATOR|Vehicle|
62127802|NCT03806088||patients of chronic kidney disease|no interventions
62127803|NCT02150967|EXPERIMENTAL|BGJ398 (infigratinib)|To estimate the anti-tumor activity of BGJ398 (infigratinib)
62127804|NCT05291104|NO_INTERVENTION|Placebo|Interventions are not received any treatments.
62127805|NCT05291104|EXPERIMENTAL|Intervention|Interventions are received folic acid or choline
62127806|NCT00440011|EXPERIMENTAL|1|
62127807|NCT00440011|ACTIVE_COMPARATOR|2|
62127808|NCT04954196|EXPERIMENTAL|Amlodipine arm|Single dose per os Amlodipine 5mg administration per day
62127809|NCT04954196|PLACEBO_COMPARATOR|Placebo arm|Single dose per os placebo (microcrystalline cellulose) administration per day
62318052|NCT00042185|ACTIVE_COMPARATOR|Healthy Weight Intervention|
62127810|NCT04297371||CTD with RVH|The diagnosis of CTD was made based on the clinical classification criteria. The RVH patient was diagnosed by an echocardiography demonstration (later confirmed by CMR) of a hypertrophic RV (maximal end-diastole RV wall thickness \>4 mm) due to CTD.
62127811|NCT04297371||CTD without RVH|The diagnosis of CTD was made based on the clinical classification criteria.The subjects were enrolled as having non-RVH if their RV wall thickness was ≤ 4 mm (later confirmed by CMR).
62127812|NCT04297371||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
62127813|NCT06029387||Retrospective cohort|"The retrospective cohort will include 2500 patients who underwent a clinically indicated cCTA examination for CAD evaluation.~Duration of enrollment: enrollment of patients via a telephone call will last 15 months starting from the beginning of the study (month 0).~Duration of total follow-up: no follow-up is planned. Duration of total study period: total retrospective study duration will be 30 months"
62127814|NCT06029387||Prospective cohort|"The prospective cohort will include 500 patients undergoing a clinically indicated cCTA for CAD evaluation.~Duration of enrollment: enrollment of patients at the time of cCTA examination will last 12 months.~Duration of total follow-up: each patient will be followed up for 36 months from the date of the cCTA.~Duration of total study period: total prospective study duration will be 54 months (last patient enrolled at month 12 + 36 months of follow-up + 6 months for data analysis)."
62127815|NCT05868161||Retrospective|All subjects in whom the Pounce Thrombectomy System was attempted will be included.
62127816|NCT01285635|ACTIVE_COMPARATOR|Docetaxel Alone|
62318053|NCT00042185|ACTIVE_COMPARATOR|Expressive writing control intervention|
62127817|NCT01285635|EXPERIMENTAL|Pulse Dose AT-101 Arm|
62127818|NCT01285635|EXPERIMENTAL|Metronomic AT-101 Arm|
62127819|NCT00683696|EXPERIMENTAL|CRT=ON|Cardiac Resynchronization Therapy activated.
62127820|NCT00683696|ACTIVE_COMPARATOR|CRT=OFF|Cardiac Resynchronization Therapy deactivated.
62127821|NCT04544904|NO_INTERVENTION|Usual Care|Patients will receive the usual care.
62127822|NCT04544904|EXPERIMENTAL|PAARx|Patients will be prescribed technology-based physical activity programming.
62127823|NCT04544904|EXPERIMENTAL|PAARx and JM|Patients will be prescribed technology-based physical activity programming and be referred to a web-based resource for evidence-based joint management.
62127824|NCT04860401|EXPERIMENTAL|precision and accuracy study|precision and accuracy of Oxyprem are studied
62127825|NCT02363452|EXPERIMENTAL|AGS|Reverse transcriptase inhibitors
62127826|NCT04580771|EXPERIMENTAL|Treatment (radiation therapy, cisplatin, PDS0101)|Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin IV over 4 hours QW during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity. Patients also receive PDS0101 SC on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
62318054|NCT00042185|NO_INTERVENTION|Assessment-only control condition|
62127827|NCT06079931|EXPERIMENTAL|Babaodan combined with standard concurrent chemoradiotherapy treatment group|60-66Gy/30-33F radiotherapy, 2Gy/dose; During radiation therapy, concurrent chemotherapy including paclitaxel 45 mg/m2 and carboplatin (AUC 2) was administered once a week on the first day. From the start of radiation therapy to the completion of concurrent chemoradiotherapy (CCRT) for 2 months, the patient took 2 capsules of Babaodan orally every day, tid (1.8 g/day). Systemic corticosteroids can be used in patients with acute radiation pneumonia with G ≥ 2.
62127828|NCT05661994|EXPERIMENTAL|Omega-3 Group|While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group.
62697429|NCT03684980|EXPERIMENTAL|Arm A - Rituximab + MTX + Glucarpidase|Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m\^2. (Cohort A) will receive MTX 3 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
62127829|NCT05661994|NO_INTERVENTION|Control Group|While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group.
62127830|NCT04383730||Usual practice of intravenous sedation|The choice of the intravenous sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center
62127831|NCT04383730||Usual practice of inhaled sedation|The choice of the inhaled sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center.
62127832|NCT03930121|EXPERIMENTAL|Experimental group|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
62318055|NCT02967120||p16 hydroxymethylation status|patients with p16 hydroxymethylation
62318056|NCT06295510||healthy group (HG)|"Participants were grouped according to their basic conditions without any intervention.~no intervention It's only observational study. No interventions."
62127833|NCT03930121|SHAM_COMPARATOR|Control group|Placebo stimulation (using sham-tDCS) combined with SLT
62318057|NCT06295510||case group（PG）|"Participants were grouped according to their basic conditions without any intervention.~no intervention It's only observational study. No interventions."
62318058|NCT03077945|EXPERIMENTAL|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
62318059|NCT03077945|PLACEBO_COMPARATOR|Control Condition|This group will complete control tasks, including viewing neutral videos.
62318060|NCT04964921||Impaired Fasting Glucose Individuals|The group contains subjects with various stages of impaired fasting glucose tolerance levels and diabetes (with or without complications). All subjects will be considered in one group since the heart rate variability and vital signs are monitored in a single visit.
62127834|NCT01675258||Control|Healthy adults above the age of 18 years
62127835|NCT01675258||Study|Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
62127836|NCT05589441|EXPERIMENTAL|Nebulized inhalation of salbutamol group|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
62127837|NCT05589441|EXPERIMENTAL|Insulin complex glucose group|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
62127838|NCT05918614|EXPERIMENTAL|KD025|500 mg KD025 administered orally twice daily (BID) for 28 days
62127839|NCT05918614|PLACEBO_COMPARATOR|Placebo|Placebo administered orally BID for 28 days
62127840|NCT00493649|EXPERIMENTAL|TC+H|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.
62318061|NCT06530628||Adult patients resident in Pavillon C of the Pierre Garraud Hospital|
62318062|NCT01949064|ACTIVE_COMPARATOR|Michigan-type occlusal splint|Occlusal splint, Michigan-type
62318063|NCT01949064|ACTIVE_COMPARATOR|Grindcare|Biofeedback device
62318064|NCT00724035|EXPERIMENTAL|Infraclavicular|This group will receive an ultrasound-guided infraclavicular brachial plexus block.
62318065|NCT00724035|ACTIVE_COMPARATOR|Axillary|This group will receive an ultrasound-guided axillary brachial plexus block.
62318066|NCT03292627||mid age|mid age: 50-70 years old
62318067|NCT03292627||old age|old age: age older than 70 years old
62318068|NCT05040178||Male and Female Adult and Pediatric Participants|Patients treated with Carbaglu for the treatment for hyperammonemia due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
62318069|NCT03634215||Multiple Trauma patients|
62318070|NCT05441150|ACTIVE_COMPARATOR|Ketamine Group|Patients who received low-dose ketamine infusion
62318071|NCT05441150|SHAM_COMPARATOR|Control group|Patients who received 0.9% Sodium Chloride Solution, Intravenous, (NaCl) infusion
62318072|NCT00478972|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily in addition to diet and exercise
62318073|NCT00478972|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily in addition to diet and exercise
62318074|NCT01883245|ACTIVE_COMPARATOR|sham tDCS|This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
62318075|NCT01883245|EXPERIMENTAL|real tDCS|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
62318076|NCT01853124|EXPERIMENTAL|Lacidofil|Lacidofil sachet containing active ingredients
62318077|NCT01853124|PLACEBO_COMPARATOR|Placebo|Placebo sachet containing inactive ingredients
62318078|NCT04436510|EXPERIMENTAL|Verdiperstat|Verdiperstat is administered twice daily p.o. for 24 weeks.
62318079|NCT04436510|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo is administered twice daily p.o. for 24 weeks.
62318080|NCT00592501|EXPERIMENTAL|Proton/Photon Radiotherapy, Cisplatin, Fluorouracil|
62127841|NCT02423798|OTHER|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
62127842|NCT05848531|NO_INTERVENTION|Morphine|Standard Morphine PCIA
62318081|NCT00764842||CLP Hip|
62318082|NCT05995522|EXPERIMENTAL|Supplementation arm|Vitamin K2
62318083|NCT05995522|PLACEBO_COMPARATOR|Placebo arm|Cornstarch
62318084|NCT02467452|EXPERIMENTAL|BDP/FF/GB|Drug: BDP/FF/GB Other name: CHF 5993 pMDI 100/6/12 mcg
62318085|NCT02467452|ACTIVE_COMPARATOR|FlF/VI + Tiotropium|FlF/VI + Tiotropium Other name: Relvar DPI 100/25 mcg + Spiriva 18 mcg capsule
62318086|NCT01455077||Obese patients|BMI \> 35
62318087|NCT00126542|EXPERIMENTAL|Treatment (bevacizumab, erlotinib hydrochloride)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to 1 of the study drugs may continue treatment with the remaining study drug alone in the absence of disease progression or unacceptable toxicity.
62318088|NCT00775775||TBI|Patients with moderate to severe TBI
62318089|NCT02109003|EXPERIMENTAL|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Pressure easy® device for 24h, followed by discontinuous control (every 4 hours) with a manual manometer for 24 h.
62318090|NCT02109003|ACTIVE_COMPARATOR|Manual control of Pcuff followed by continuous control.|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
62318091|NCT02175563|NO_INTERVENTION|Without feedback|Participants compress the chest of the manikin without smartphone based feedback app.
62127843|NCT05848531|EXPERIMENTAL|Clonidine and Morphine|Morphine Associated with Clonidine PCIA
62697430|NCT03684980|EXPERIMENTAL|Arm B - Rituximab + MTX + Glucarpidase|Patients will receive up to 8 cycles of treatment consisting of rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m\^2. (Cohort B) will receive MTX 8 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
62318092|NCT02175563|EXPERIMENTAL|With feedback|Participants compress the chest of the manikin with a smartphone based feedback app.
62127844|NCT01996605|EXPERIMENTAL|Oxytocin 15 mcg|Oxytocin 15 mcg injected spinally
62127845|NCT01996605|EXPERIMENTAL|Oxytocin 150 mcg|Oxytocin 150 mcg injected spinally
62127846|NCT01996605|ACTIVE_COMPARATOR|Placebo|Preservative free normal saline injected spinally
62318093|NCT02409420|EXPERIMENTAL|PACT|PACT: a brief physiotherapy intervention based on ACT principles optimised to promote self-management. ACT aims to promote the acceptance of pain, the belief that it is not always necessary to change pain to move forward and the understanding that focusing on pain avoidance.
62318094|NCT02409420|NO_INTERVENTION|Control|Usual care
62318095|NCT04370028||Divaza|Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.
62318096|NCT04536415|EXPERIMENTAL|Oseltamivir Phosphate 75 mg capsules (Yangtze River)|During the study session, healthy participants will be administered a single dose of Oseltamivir Phosphate capsules 75 mg of Yangtze River Pharmaceutical (Group) Co., Ltd., China under Fed condition.
62318097|NCT04536415|ACTIVE_COMPARATOR|Tamiflu capsules 75 mg (Genentech, Inc.)|During the study session, healthy participants will be administered a single dose of Tamiflu capsules 75 mg of Genentech, Inc. under Fed condition.
62318098|NCT03545152|NO_INTERVENTION|comparison group|No procedure conducted between the pre- and the post-test evaluations, and they received an abridged version of the training after the post-test session.
61925012|NCT05242523|EXPERIMENTAL|Olfactory Condition - 1|Participants in this condition will be exposed to the smell of natural wood scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
61925013|NCT05242523|EXPERIMENTAL|Olfactory Condition - 2|Participants in this condition will be exposed to the smell of Bergamot scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
61925014|NCT03795610|EXPERIMENTAL|Arm A: IPI-549 40 mg PO qdaily|Patients enrolled in Arm A will receive IPI-549 40 mg by mouth daily for at least 14 days
62127847|NCT06480942||Positive PLR test (PLR +)|"* Patient over 18 years old.~* Hospitalized in intensive care.~* For which the clinician in charge of the patient will need to predict the response to fluids and decide on a possible infusion of fluids, because of:~  * Acute circulatory failure with mean arterial pressure \< 65mmHg or \< 30mmHg of its baseline value for hypertensive patients.~ * And/or other signs of hemodynamic instability (tachycardia, mottling, oliguria, hyperlactatemia) :~* In spontaneous ventilation and without ventilatory assistance.~* Previously equipped with an arterial catheter."
62127848|NCT06480942||Negative PLR test (PLR-)|"* Patient over 18 years old.~* Hospitalized in intensive care.~* For which the clinician in charge of the patient will need to predict the response to fluids and decide on a possible infusion of fluids, because of:~  * Acute circulatory failure with mean arterial pressure \< 65mmHg or \< 30mmHg of its baseline value for hypertensive patients.~ * And/or other signs of hemodynamic instability (tachycardia, mottling, oliguria, hyperlactatemia) :~* In spontaneous ventilation and without ventilatory assistance.~* Previously equipped with an arterial catheter."
62127849|NCT01827917|EXPERIMENTAL|rabies vaccine|When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die
62127850|NCT02060955|EXPERIMENTAL|Alecsat|"The experimental product is an autologous product based on the individual patients blood. Blood donation are performed in study weeks 0, 6, 11, 23 and 43.~The patient receives treatment as bolus injection at study weeks 4, 9, 14, 26 and 46."
62127851|NCT02060955|ACTIVE_COMPARATOR|bevacizumab/irinotecan|Patients allocated to the comparator arm will be treated in accordance with standard practice in Denmark for relapsed glioblastoma multiforme, up to 16 treatment cycles with 4 weeks duration
62127852|NCT01761552|EXPERIMENTAL|Sugammadex (tradename Bridion)|
62479754|NCT02465060|EXPERIMENTAL|Subprotocol P (PTEN loss)|Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479755|NCT02465060|EXPERIMENTAL|Subprotocol Q (HER2 amplification)|Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61925015|NCT01565837|EXPERIMENTAL|Ipilimumab + SART|Patients with oligometastatic but unresectable malignant melanoma will receive induction ipilimumab plus concurrent SART followed by maintenance ipilimumab.
62127853|NCT01761552|ACTIVE_COMPARATOR|Traditional reversal or spontaneous recovery:|Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade.
62479756|NCT02465060|EXPERIMENTAL|Subprotocol R (BRAF fusion or BRAF non-V600 mutation)|Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479757|NCT02465060|EXPERIMENTAL|Subprotocol S1 (NF1 mutation)|Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61925016|NCT02034071|EXPERIMENTAL|DCCR Open Label - DCCR Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to continue DCCR, at the same dose as they received on Day 69, in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
62127854|NCT02650791|NO_INTERVENTION|Prophylactic Platelet Transfusions|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 10\^9/L.
62687285|NCT02115672|EXPERIMENTAL|BL-8040|Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).
62687286|NCT06005636||with post-stroke delirium|ischemic stroke patients with post-stroke delirium
62687287|NCT06005636||without post-stroke delirium|ischemic stroke patients without post-stroke delirium
62687288|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
62687289|NCT06569433|ACTIVE_COMPARATOR|Therapeutic exercise|In the interventions, the control group performing therapeutic exercise only, will perform a specific exercise programme for knee tendinitis under the supervision of a physiotherapist,
62687290|NCT06569433|ACTIVE_COMPARATOR|Femoral nerve movilization|will receive therapeutic exercise sessions and femoral nerve mobilisations performed by a trained physiotherapist.
62687291|NCT02862262|EXPERIMENTAL|Blinded, Prospective Arm (1)|Clinical performance of the ARIES Bordetella Assay for the detection of B. pertussis and B. parapertussis will be evaluated in prospectively collected, de-identified, left-over, clinical specimens.
62687292|NCT02862262|EXPERIMENTAL|Blinded, Pre-selected Arm (2)|In the event that an insufficient number of positive specimens are acquired for B. pertussis / B. parapertussis in Arm 1, clinical performance of the ARIES Bordetella Assay will be tested using banked, pre-selected, positive clinical specimens.
62127855|NCT02650791|EXPERIMENTAL|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral dose of Tranexamic Acid 1 gram three times daily. Tranexamic Acid will start when Platelet count is less than 50 x 10\^9/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions
62479758|NCT02465060|EXPERIMENTAL|Subprotocol S2 (GNAQ or GNA11 mutation)|Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687293|NCT02862262|EXPERIMENTAL|Blinded, Contrived Arm (3)|Contrived specimens will be tested using the ARIES Bordetella Assay to evaluate detection of B. parapertussis in the event that an insufficient number of positive specimens are acquired in Arm 2.
62687294|NCT01906138|OTHER|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
62687295|NCT00151073|EXPERIMENTAL|Zoledronate Alone|Zoledronate is given alone for the first cycle. All subsequent cycles consist of Docetaxel (70mg/m\^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
62687296|NCT00151073|EXPERIMENTAL|Docetaxel and Estramustine|Docetaxel and Estramustine are given for the first cycle of therapy. All subsequent cycles consist of Docetaxel (70mg/m\^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
62687297|NCT05957094|PLACEBO_COMPARATOR|Placebo visit|Participants will then undergo pre-intervention testing, with at least 20 minutes of rest between each. Once these tests are complete, the participant will ingest a placebo (sugar pill) that is identical in appearance to the drug condition. Three hours after placebo ingestion all tests will be conducted again. Participants will remain in the lab and will be free to read or work during this resting 3 hour period. This will conclude this experimental visit.
62687298|NCT05957094|ACTIVE_COMPARATOR|SSRI visit|Participants will then undergo pre-intervention testing, with at least 20 minutes of rest between each. Once these tests are complete, the participant will ingest citalopram (40 mg) Then three hours later all tests will be conducted again. Participants will remain in the lab and will be free to read or work during this resting 3 hour period. This will conclude this experimental visit.
62687299|NCT04602598|EXPERIMENTAL|Zanubrutinib|Zanubrutinib orally at a dose of 80mg BID for 24 weeks
62687300|NCT03510533|EXPERIMENTAL|Eating disorders patients|first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V
62687301|NCT03510533|OTHER|healthy volunteers|Volunteers with negative SCOFF test (No active or history of eating disorders)
62127856|NCT00301652|EXPERIMENTAL|mycophenolate mofetil|
62479759|NCT02465060|EXPERIMENTAL|Subprotocol T (SMO or PTCH1 mutation)|Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or nuclear study during screening, tumor biopsy on study and CT scan, MRI and blood sample collection throughout the study.
62479760|NCT02465060|EXPERIMENTAL|Subprotocol U (NF2 inactivating mutation)|Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479761|NCT02465060|EXPERIMENTAL|Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)|Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib PO QD on days 1-28 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO or nuclear study throughout the trial as clinically necessary. Patients undergo biopsies and blood sample collection on study.
62479762|NCT02465060|EXPERIMENTAL|Subprotocol W (FGFR pathway aberrations)|Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479763|NCT02465060|EXPERIMENTAL|Subprotocol X (DDR2 S768R, I638F, or L239R mutation)|Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479764|NCT02465060|EXPERIMENTAL|Subprotocol Y (Akt mutation)|Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479765|NCT02465060|EXPERIMENTAL|Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)|Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687302|NCT06465966|EXPERIMENTAL|iRAI data collection|Radiation therapists will position the participant on the treatment table. After the participant is setup, a water bag will be placed on his abdomen and a 2D transducer is placed on top of the water bag. The 2D transducer is held in place by an articulated arm attached to the treatment table. The water bag serves as a path for the photo acoustic waves created during treatment to be detected by the 2D transducer and captured for data collection.
62687303|NCT05996653|OTHER|ST-MRI scans|All patients will undergo Saturation Transfer (ST)-MRI during their standard of care imaging visits (or within 14 days of their standard MRI).
62687304|NCT05209295|EXPERIMENTAL|Group 1|
62127857|NCT02909439|ACTIVE_COMPARATOR|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
62127858|NCT02909439|ACTIVE_COMPARATOR|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
62479766|NCT02465060|EXPERIMENTAL|Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)|Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479767|NCT02465060|EXPERIMENTAL|Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)|Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687305|NCT05209295|EXPERIMENTAL|Group 2|
62687306|NCT05209295|OTHER|Group 3|Control - participants with normal hepatic function
62479768|NCT02465060|EXPERIMENTAL|Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)|Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687307|NCT06689423||Symptomatic Cohort|Subjects displaying signs and/or symptoms of respiratory tract infections
62687308|NCT04968600|EXPERIMENTAL|Posterior-cruciate-ligament-retaining (CR)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
62687309|NCT04968600|EXPERIMENTAL|posterior-cruciate-ligament-stabilized (PS)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
62687310|NCT06527872||All Participants cohort|Participants with active LN who initiated belimumab as per local label alongside standard therapy/ies under routine care conditions.
62687311|NCT06216262|ACTIVE_COMPARATOR|Control group|1450 ppm fluoride toothpaste
62127859|NCT05674136|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00061 sensor
62127860|NCT03213327|OTHER|Case management|Case management program Utilization of the StayOk web application
62127861|NCT03576833|EXPERIMENTAL|Balloon|
62318099|NCT03545152|EXPERIMENTAL|exercise group|The exercise program will include instructions on how to read the program, complete the activities, record their sessions, and exercise safely at first day. To promote incorporating exercising in their daily life routine during the 24-week period, we provided 2 group-based (5-8 participants with 2 instructors at community centers, 60' each) and one home-based (with the exercise program VCD and manual to bring home, 30') exercise program.
62318100|NCT03545152|EXPERIMENTAL|cognitive training group|Consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
62318101|NCT03808272|EXPERIMENTAL|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System
62318102|NCT02279589|ACTIVE_COMPARATOR|Group A|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
62318103|NCT02279589|ACTIVE_COMPARATOR|Group B|"Description 15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
62687312|NCT06216262|ACTIVE_COMPARATOR|Arginine|toothpaste containing arginine
62687313|NCT06216262|ACTIVE_COMPARATOR|Novamin|toothpaste containing novamin
62687314|NCT06216262|ACTIVE_COMPARATOR|Propolis|toothpaste containing propolis
62127862|NCT06459024||Patients with relapsed or refractory acute myeloid leukemia|All patients with relapsed or refractory acute myeloid leukemia
62687315|NCT06216262|ACTIVE_COMPARATOR|Casein Phosphopeptide Amorphous Calcium Phosphate|Dental cream containing casein phosphopeptide amorphous calcium phosphate
62687316|NCT06216262|ACTIVE_COMPARATOR|Potassium Nitrate|mouthwash containing potassium nitrate
62127863|NCT00825084|EXPERIMENTAL|single dose cohort-Japanese group|Japanese healthy subjects
62127864|NCT00825084|EXPERIMENTAL|single dose cohort-Western group|Western healthy subjects
62127865|NCT00825084|EXPERIMENTAL|multiple dose cohort-Japanese group|Japanese healthy subjects
62318104|NCT02279589|ACTIVE_COMPARATOR|Group C|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
62687317|NCT04859231|ACTIVE_COMPARATOR|Control|
62127866|NCT00825084|EXPERIMENTAL|multiple dose cohort-Western group|Western healthy subjects
62127867|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
62127868|NCT03482635|EXPERIMENTAL|Group 1- Placebo Group|
62127869|NCT03482635|EXPERIMENTAL|Group 2- Small Dose Group|
62127870|NCT03482635|EXPERIMENTAL|Group 3- Medium Dose Group|
62127871|NCT03482635|EXPERIMENTAL|Group 4 - High Dose Group|
62127872|NCT03875963|EXPERIMENTAL|Antibiotic loaded bone filler|Patients will undergo irrigation and debridement, surgical stabilization as required, and defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\]. The concurrent use of antibiotics is at the discretion of the treating physician.
62318105|NCT02279589|ACTIVE_COMPARATOR|Group D|"Description:~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
62318106|NCT02538146|EXPERIMENTAL|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
62318107|NCT00985881|EXPERIMENTAL|Arm 1: stochastic resonance|Mechanical stochastic resonance
62318108|NCT00985881|OTHER|Arm 2: current clinical practice|Current clinical practice
62318109|NCT02693353||Study Group|Patients with diagnosed epiretinal membrane undergoing cataract surgery.
62318110|NCT02693353||Control Group|Patients without epiretinal membrane undergoing cataract surgery.
62318111|NCT02027688|ACTIVE_COMPARATOR|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
62318112|NCT02027688|ACTIVE_COMPARATOR|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
62687318|NCT04859231|EXPERIMENTAL|Investigational|
62687319|NCT04859231|NO_INTERVENTION|Mother's-own Breast Milk|
62687320|NCT04348630|EXPERIMENTAL|HOT condition|Participants are exposed to 36°C and 45% relative humidity for 8 hours. These conditions were chosen to represent an extreme heat condition (i.e., heatwave) and are similar to peak domicile conditions measured in low-income high-rise apartment complexes during heatwaves.
61925017|NCT02034071|EXPERIMENTAL|DCCR Open Label - Placebo Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to receive placebo equivalent to the DCCR dose received on Day 69 in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
61925018|NCT02747173||RCC patients with bone metastases|Patients will receive the standard TKI treatment for first line treatment naive metastatic RCC. Sunitinib or pazopanib as decided by the investigator.
61925019|NCT02597634|EXPERIMENTAL|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
61925020|NCT02597634|PLACEBO_COMPARATOR|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
61925021|NCT06638268|EXPERIMENTAL|Acute TAVI|Acute TAVI within 12 hours.
61925022|NCT06638268|ACTIVE_COMPARATOR|Standard treatment|TAVI no earlier than 72 hours.
61925023|NCT04414514|EXPERIMENTAL|Open-label|Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks
61925024|NCT01272284|OTHER|Altis® SIS|Subjects enrolled with Altis® SIS
61925025|NCT06248411|EXPERIMENTAL|KK2260 (Dosing regimen 1)|
61925026|NCT06248411|EXPERIMENTAL|KK2260 (Dosing regimen 2)|
61925027|NCT05671328||Patients with suspected ventilator-associated pneumonia|
61925028|NCT01144871||Male Parent/Guardians|Male Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
61925029|NCT01144871||Female Parent/Guardian|Female Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
61925030|NCT04005170|EXPERIMENTAL|PD-1 group|All patients will receive standard fractionation radiation therapy (RT) scheme: 50.4 Gy in 28 fractions over 5-6 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 and 2 cycles of toripalimab 240 mg on days 1, 22 followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
61925031|NCT03609151|ACTIVE_COMPARATOR|group A|laparoscopic hepatectomy (surgery)
61925032|NCT03609151|EXPERIMENTAL|group B|stereotactic body radiotherapy (SBRT)
61925033|NCT02890290|ACTIVE_COMPARATOR|Intervention|Marine protein hydrolysate pills (3000mg)
61925034|NCT02890290|PLACEBO_COMPARATOR|Control|Placebo pills (gum arabicum)
61925035|NCT04849325|EXPERIMENTAL|IBS Titan|
62127873|NCT03875963|NO_INTERVENTION|Standard of care|Current standard of care treatment for infected tibial defects or infected tibial nonunions includes treatment with irrigation and debridement, surgical stabilization as required, and defect management as required including placement of a polymethyl methacrylate spacer with or without antibiotics. A second procedure may or may not occur 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. Concurrent use of antibiotics is at the discretion of the treating physician.
61925036|NCT04849325|ACTIVE_COMPARATOR|Percutaneous Transluminal Angioplasty (PTA)|
61925037|NCT02374086|EXPERIMENTAL|Exercise Training|Subjects will exercise for 8 weeks
61925038|NCT05807633||Novosyn®|Novosyn® used in patients undergoing uterus closure in cesarean section
62127874|NCT03495713|EXPERIMENTAL|Single Arm|Subjects will receive initial treatment with the immunomodulatory agent, nivolumab, followed by low-dose (4 Gy x 2) involved-site radiotherapy in subjects with less than an anatomic CR after the first restaging scan. Patients with anatomic CR will continue nivolumab alone without radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease, and must be eligible for treatment with nivolumab.
61925039|NCT02942420|EXPERIMENTAL|Dose Group A|Bucillamine 300 mg/day
61925040|NCT02942420|EXPERIMENTAL|Dose Group B|Bucillamine 600 mg/day
62127875|NCT01407393|EXPERIMENTAL|Glucosanol|Glucosanol
62318113|NCT03799315|EXPERIMENTAL|Jail-Based Use of Smoking Cessation Treatment (JUST)|Participants will receive guidline-based smoking cessation counseling while in jail and phone-based smoking cessation counseling sessions and nicotine lozenges after release from jail.
62318114|NCT03799315|NO_INTERVENTION|Enhanced Treatment As Usual (TAU)|Participants will receive the usual, limited smoking cessation treatment while in jail, plus an additional health and wellness education session in jail. Nicotine lozenges will be offered at the end of the study to those who did not quit smoking.
62318115|NCT05182502|EXPERIMENTAL|Tixel treatment arm|subjects will receive 3 monthly treatments with the Tixel device
62318116|NCT06162676|EXPERIMENTAL|HPV game group|Parent-child dyads receive a HPV game intervention
62318117|NCT06162676|NO_INTERVENTION|Usual care|Parent-child dyads receive child's usual care
62318118|NCT00151411|EXPERIMENTAL|Metformin|Metformin
62318119|NCT00151411|PLACEBO_COMPARATOR|Placebo|Placebo
62318120|NCT06671743|EXPERIMENTAL|trypsin-chymotrypsin|
62318121|NCT06671743|ACTIVE_COMPARATOR|Ibuprofen|
62318122|NCT06671743|ACTIVE_COMPARATOR|paracetamol|
62318123|NCT06671743|PLACEBO_COMPARATOR|placebo|
62318124|NCT02314208|ACTIVE_COMPARATOR|Xenbilox|Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months
62318125|NCT02314208|ACTIVE_COMPARATOR|Resveratrol|Resveratrol 80mg capsule by mouth every day for 2 months
62318126|NCT02314208|ACTIVE_COMPARATOR|Tahor|Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months
62318127|NCT02004405|EXPERIMENTAL|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
62687321|NCT04348630|EXPERIMENTAL|WARM Condition|Participants are exposed to 31°C and 45% relative humidity for 8 hours. These conditions are similar to mean domicile conditions measured in a variety of domicile types during heat waves complexes during heatwaves and are consistent with the World Heath Organization recommendation for maximal indoor temperatures.
62318128|NCT02004405|ACTIVE_COMPARATOR|Flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
62318129|NCT04450355|EXPERIMENTAL|Nefopam group|At the end of induction, the nefopam group will receive intravenous nefopam 20mg mixed with 50ml of normal saline, and at the end of surgery, this group will receive intravenous nefopam 60mg mixed with 50ml of normal saline at a rate of 2ml/hr.
62318130|NCT04450355|PLACEBO_COMPARATOR|Control group|The control group will receive intravenous normal saline 50ml at the end of induction and receive intravenous normal saline 50ml at a rate of 2ml/hr at the end of surgery.
62687322|NCT04348630|EXPERIMENTAL|TEMPERATE Condition|Participants are exposed to 26°C and 45% relative humidity for 8 hours. These conditions are consistent with Toronto Public Health recommendation for maximal indoor temperatures, which are based on the increase in mortality associated with increases in outdoor temperature above these limits.
62687323|NCT04348630|EXPERIMENTAL|COOL Condition|Participants are exposed to 22°C and 45% relative humidity for 8 hours. These conditions are consistent with actively cooled (air-conditioned) domicile.
62687324|NCT00417287|ACTIVE_COMPARATOR|High dose|128 mg/m2
62687325|NCT00417287|ACTIVE_COMPARATOR|Low dose|54 mg/m2
62318131|NCT05321797|EXPERIMENTAL|Aerobic Training Group|Cycling exercise group along with Conventional therapy
62127876|NCT01407393|PLACEBO_COMPARATOR|Placebo|Placebo
62127877|NCT00547352|ACTIVE_COMPARATOR|1|sildenafil treatment for at least 10 weeks prior to a 1 week wash out
62127878|NCT00547352|ACTIVE_COMPARATOR|2|Tadalafil treatment for 8 weeks following the 1 week washout period.
62127879|NCT01254188|EXPERIMENTAL|Nilotinib|300 mg BID
62127880|NCT06113770|EXPERIMENTAL|ready made zirconia|the selected tooth will receive ready made zirconia crown
62127881|NCT06113770|EXPERIMENTAL|pmma crown|the selected tooth will receive cad cam custom made pmma crown
62127882|NCT03855007|EXPERIMENTAL|Iguratimod|The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
62127883|NCT04257071|ACTIVE_COMPARATOR|Usual Care|Participants randomized to the usual care study arm will receive the usual care for their MS.
62318132|NCT05321797|ACTIVE_COMPARATOR|Conventional Physiotherapy|Strectching with ROM and gait training
62318133|NCT04347811|EXPERIMENTAL|Death Cafe Arm|Participants undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
62318134|NCT04347811|NO_INTERVENTION|Control Arm|Participants do not undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
62318135|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
62318136|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
62318137|NCT02971644|EXPERIMENTAL|cobalt alloy pedicle screw implantation|The spinal tuberculosis patients with severe kyphosis deformity who will undergo cobalt alloy pedicle screw implantation.
62687326|NCT06476392|EXPERIMENTAL|Melatonin|2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
62687327|NCT06476392|PLACEBO_COMPARATOR|Placebo|2 identical appearing placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
62479769|NCT02465060|EXPERIMENTAL|Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)|Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib (LOXO-101) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
62479770|NCT02465060|EXPERIMENTAL|Subprotocol Z1F (PIK3CA mutation)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
62687328|NCT04693377|ACTIVE_COMPARATOR|Arm A (SBRT)|Patients undergo stereotactic body radiation therapy for 1 fraction.
62687329|NCT04693377|EXPERIMENTAL|Arm B (cryoablation, SBRT)|"Patients undergo cryoablation. Within 10 days after cryoablation, patients undergo stereotactic body radiation therapy for 1 fraction. Alternatively, patients may receive stereotactic body radiation therapy initially, followed by cryoablation."
62687330|NCT05253651|EXPERIMENTAL|Tucatinib Arm|Tucatinib + trastuzumab + mFOLFOX6
62127884|NCT04257071|EXPERIMENTAL|OOP Cost Communication and Optimization|Participants in this study arm in addition to usual care, will receive a personalized discussion of their OOP cost estimates for treatment obtained through an online price transparency tool, personalized analysis of expenses by financial counselor, and enrollment in any cost optimization opportunities for which they are eligible using a comprehensive financial navigation program.
62127885|NCT05746754|EXPERIMENTAL|Craniospinal proton radiotherapy|30 Gy in 10 fractions to CNS
62127886|NCT04080336|EXPERIMENTAL|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
62127887|NCT04080336|ACTIVE_COMPARATOR|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
62127888|NCT04080336|PLACEBO_COMPARATOR|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
62127889|NCT02308319|ACTIVE_COMPARATOR|PROMPT|Prompt therapy with Tenofovir disoproxil fumarate (Viread(R)) 300mg p.o
62127890|NCT02308319|OTHER|Watchful monitoring|Wait and treat with Tenofovir disoproxil fumarate (Viread(R)) when active liver disease is present \[defined as HBV DNA \>2,000 IU/ml and abnormal ALT (\>40 IU/ml)\]
62127891|NCT01198145|EXPERIMENTAL|Arm I: Sulfasalazine|Patients receive oral sulfasalazine twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
62127892|NCT01198145|PLACEBO_COMPARATOR|Arm II: Placebo|Patients receive oral placebo twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
62127893|NCT05103423|EXPERIMENTAL|Treatment group 1|
62127894|NCT05103423|EXPERIMENTAL|Treatment group 2|
62127895|NCT05103423|PLACEBO_COMPARATOR|Placebo|
62127896|NCT01148134||Bcr-Abl positive ALL|
62127897|NCT01148134||Bcr-Abl negative ALL|
62127898|NCT01105117|ACTIVE_COMPARATOR|1|ACT-385781A (Actelion Epoprostenol)
62127899|NCT01105117|ACTIVE_COMPARATOR|2|Flolan®
62127900|NCT05757583||Patients with asthma, obesity and metabolic dysfunction|"Otherwise healthy asthmatic subjects with:~1. Body Mass Index (BMI) ≥ 30; and~2. Metabolic dysfunction evidenced by at least one of the following:~   * high plasma IL-6 (\> 3.0 pg/mL)~  * insulin resistance (HOMA-IR \> 3 mass units)"
62127901|NCT05757583||Patients with asthma, obesity and no metabolic dysfunction|"Otherwise healthy asthmatic subjects with:~1. Body Mass Index (BMI) ≥ 30; and~2. No evidence of metabolic dysfunction"
62127902|NCT05757583||Patients with severe asthma and mucus plugs|"Otherwise healthy asthmatic subjects:~1. Requiring treatment with high dose inhaled corticosteroids plus a second controller, systemic corticosteroid, or biologic therapy; and~2. Evidence of mucus plugs as defined by a mucus plug score ≥ 4"
62127903|NCT05757583||Patients with severe asthma and no mucus plugs|"Otherwise healthy asthmatic subjects:~1. Requiring treatment with high dose inhaled corticosteroids plus a second controller, systemic corticosteroid, or biologic therapy; and~2. No evidence of mucus plugs as defined by a mucus plug score \< 4"
62127904|NCT01739270|ACTIVE_COMPARATOR|dexamethasone with levobupivacaine|25ml 0.5% levobupivacaine plus 4mg Dexamethasone are given for supraclavicular brachial plexus block for upper extremity surgery
62127905|NCT01739270|ACTIVE_COMPARATOR|levobupivacaine|25ml 0.5% levobupivacaine plus 1ml 0.9% saline are given for supraclavicular brachial plexus block for upper extremity surgery
62127906|NCT06421259||HIV infected patients under injectable ART|HIV infected patients under injectable ART
62687331|NCT05253651|ACTIVE_COMPARATOR|Standard of Care Arm|mFOLFOX6 + (bevacizumab OR cetuximab). Either (1) mFOLFOX6, (2) mFOLFOX6 and bevacizumab, or (3) mFOLFOX6 and cetuximab
62687332|NCT00488293|EXPERIMENTAL|Arm 1|Store and forward teledermatology consult process
62687333|NCT00488293|NO_INTERVENTION|Arm 2|Conventional consult process
62127907|NCT02023710|EXPERIMENTAL|BEV plus Chemotherapy|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle
62687334|NCT00842803|NO_INTERVENTION|Control Group|Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
62687335|NCT00842803|EXPERIMENTAL|Albumin group|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
62687336|NCT05870657||Overall cohort|Patients receiving inclisiran
62687337|NCT06652490||Group A (control group): ( n=25 )|CVL insertion in the right internal jugular vein using ultrasound. The US probe is placed perpendicular to the venous anatomy in the SAX approach.
62687338|NCT06652490||Group B (comparative group): ( n=25 )|CVL insertion in the right internal jugular vein using ultrasound. The US probe is aligned at 45° angulation clockwise with the venous anatomy in the OAX approach.
62687339|NCT03263390||Bariatric Surgery|Subjects that have demonstrated extreme response to bariatric surgery.
62687340|NCT03263390||Anti Obesity Medications|Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.
62687341|NCT06125301|EXPERIMENTAL|Intervention group|Care as usual + weekly self-monitoring during one year follow-up and discussing app results with caregivers.
62687342|NCT06125301|NO_INTERVENTION|Control group|Care as usual.
62687343|NCT05489458||Exploratory Surgery with Resection|Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and had their tumors resected.
62127908|NCT02023710|ACTIVE_COMPARATOR|Chemotherapy alone|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle
62127909|NCT02708108|EXPERIMENTAL|Obesity Intervention|Personalized 28-day Dietary Intervention and Activity and Exercise Intervention with the goal to reduce fat gain and lean muscle loss while inducing an overall negative energy balance.
62127910|NCT01144468||MAP3 Participants|study participants in the MAP.3 study are randomly assigned to either placebo or 25 mg exemestane daily for 5 years. Allocation is blinded. We are following 354 of these study participants and are blinded to treatment allocation.
62127911|NCT02376530|NO_INTERVENTION|Usual shopping|No change in condition.
62127912|NCT02376530|EXPERIMENTAL|Nutrient profiling|Nutrient profiling system will be present during shopping session.
62127913|NCT02376530|EXPERIMENTAL|Price change|Price changes will be present during shopping session.
62318138|NCT02014532|ACTIVE_COMPARATOR|Montelukast|Patients in Test Group were given Leukotriene receptor antagonist, Montelukast 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
62127914|NCT02376530|EXPERIMENTAL|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
62127915|NCT06105125|EXPERIMENTAL|Autologous micrograft from the palate|Modified papilla preservation technique with a combined approach using a bone substitute soaked with autologous micrografts from the palate.
62127916|NCT06105125|ACTIVE_COMPARATOR|Control group|Modified papilla preservation technique with a combined approach using a bone substitute.
62127917|NCT05527912|EXPERIMENTAL|Arm I (RCZ WITH CHOP)|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy
62127918|NCT01777750|ACTIVE_COMPARATOR|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of \<35°C prior to revascularization.
62127919|NCT01777750|NO_INTERVENTION|Standard treatment|Standard treatment
62127920|NCT01149512||LAGB patients in Weight Wise Program|All patients seen within the Weight Wise program and selected for surgical management, who have undergone LAGB will be included in this analysis.
62127921|NCT01058499|EXPERIMENTAL|MBSR|
62127922|NCT06170073||Poor sleepers|With a total score of Pittsburgh Sleep Quality Index (PSQI) \> 5.
62318139|NCT02014532|PLACEBO_COMPARATOR|Placebo|Patients in Control Group were given placebo drug 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
62318140|NCT05675280||Iron deficiency at diagnosis|
62318141|NCT05675280||No iron deficiency at diagnosis|
62318142|NCT01428102||RapidTEG|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent RapidTEG.
62318143|NCT01428102||Kaolin|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent Kaolin.
62687344|NCT05489458||Exploratory Surgery without Resection|Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and did not have their tumors resected.
62687345|NCT03850301|EXPERIMENTAL|Etifoxine then XBD173|
62687346|NCT03850301|EXPERIMENTAL|XBD173 then Etifoxine|
62687347|NCT05825001|EXPERIMENTAL|Arm 1 (active EFT)|Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
62687348|NCT05825001|ACTIVE_COMPARATOR|Arm II (control EFT)|Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
62687349|NCT03813121|EXPERIMENTAL|midazolam intravenous infusion|single midazolam infusion (0.02 mg/kg over 20 minutes)
62687350|NCT03813121|PLACEBO_COMPARATOR|placebo intravenous infusion|single placebo infusion (saline over 20 minutes)
62687351|NCT03813121|EXPERIMENTAL|ketamine intravenous infusion|single ketamine infusion (0.5 mg/kg over 20 minutes)
62687352|NCT06641440|EXPERIMENTAL|prednisone plus levothyroxine|25 mg of predisone plus 75 microgram levothyroxine daily for 3 months
62687353|NCT06641440|ACTIVE_COMPARATOR|levothyroxine only|75 micrograms of levothyroxine only daily for three months
62687354|NCT02392728|EXPERIMENTAL|Intervention VE|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
62687355|NCT02392728|ACTIVE_COMPARATOR|Intervention GI|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
62687356|NCT03752372||HSCT cohort|IL10RA-deficient patients who received hematopoietic stem cell transplantation
62687357|NCT00489476|EXPERIMENTAL|1.25 mg Staccato Loxapine|1.25 mg ADASUVE, single dose
62687358|NCT00489476|EXPERIMENTAL|2.5 mg Staccato Loxapine|2.5 mg ADASUVE, single dose
62479771|NCT02465060|EXPERIMENTAL|Subprotocol Z1G (PTEN loss)|Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479772|NCT02465060|EXPERIMENTAL|Subprotocol Z1H (PTEN mutation)|Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62127923|NCT06170073||Good sleepers|With a total score of Pittsburgh Sleep Quality Index (PSQI) ≤ 5.
62318144|NCT02788916||Cohort 1|Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.
62318145|NCT04738045|PLACEBO_COMPARATOR|control|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily for 5 days.
62318146|NCT04738045|EXPERIMENTAL|interventional|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
62318147|NCT05360186|EXPERIMENTAL|Intervention group (Group A): NCH gel after USG-MVA|In the intervention group (Group A), a 15 cm sterile delivery cannula will be inserted through the internal os and a syringe of NCH gel (5ml) will be applied to the uterine cavity after cleansing the cervix with an antiseptic solution.
62318148|NCT05360186|NO_INTERVENTION|Controlled group (Group B): No NCH gel after USG-MVA|In the control group (Group B), as the patient is conscious during the procedure, an empty 5ml syringe will be inserted into the internal os and held for 1 minute as a sham procedure.
62318149|NCT00854932|EXPERIMENTAL|PCT group|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.
62479773|NCT02465060|EXPERIMENTAL|Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)|Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62479774|NCT02465060|EXPERIMENTAL|Subprotocol Z1K (AKT mutation)|Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479775|NCT02465060|EXPERIMENTAL|Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)|Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62687359|NCT00489476|EXPERIMENTAL|5 mg Staccato Loxapine|5 mg ADASUVE, single dose
62687360|NCT00489476|EXPERIMENTAL|Staccato Placebo|Staccato Placebo, 0 mg
62127924|NCT01253031||Group 1|young normal hearing
62127925|NCT01253031||Group 2|older normal hearing
62687361|NCT03564067|OTHER|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
62687362|NCT04332770||Hypothyroid group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to withdraw their levothyroxine for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
62127926|NCT01253031||Group 3|older hearing impaired
62127927|NCT00978042|EXPERIMENTAL|VOLUMA® XC Treatment Arm|Participants treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs) at study start. Participants were eligible for re-treatment if applicable.
62127928|NCT00978042|OTHER|Control Arm_No Treatment then VOLUMA® XC|No treatment for 6 months, then participants were treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs). Participants were eligible for re-treatment if applicable.
62318150|NCT00854932|NO_INTERVENTION|Standard group|The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.
62318151|NCT05564598|EXPERIMENTAL|Cohort 1 Safety Run-in|The first 3 patients enrolled will receive both anti-viral medication and CMV CTLs, and treatment will be staggered every 28 days from the last dose of CMV CTLs from the prior patient.
62318152|NCT05564598|EXPERIMENTAL|Cohort 2 Antiviral medication + CMV CTLs|Patients will receive both anti-viral medication and CMV CTLs
62318153|NCT05564598|ACTIVE_COMPARATOR|Cohort 2 Antiviral medication only|Patients will only receive anti-viral therapy
62318154|NCT05279794|EXPERIMENTAL|Jones Group (Strain Counterstrain)|Jones Group consist in 90 seconds in a ralease positioning of no pain in muscle acortation
62318155|NCT05279794|ACTIVE_COMPARATOR|Myofascial Induction Group|Myofascial Induction Group consist in 15 minutes of superficial and deep lumbar fascia maneuvers
62318156|NCT05279794|PLACEBO_COMPARATOR|Placebo Group|Placebo Group only have to mantain no pain positioning for 3 minutes
62318157|NCT03749993|OTHER|Screening Arm|Screening
61925041|NCT04061382||Randomised selection of population - Group 1|Group 1 will be focusing on COVID-19, diphtheria and group C invasive meningococcal disease. The investigators are aiming to recruit around 2300 individuals and the investigators are aiming to ensure that sample is broadly representative of the region according to IMD (Index of Multiple Deprivation scores). PHE have generated a list of all postcodes in recruiting regions and determining the quintiles of IMD within that region. Participants interested in taking part in the study will contact sites to arrange a visit. Basic demographic characteristics will be collected by questionnaire and/ or case report form (CRF) and will include: DOB, gender, GP details, Ethnic group, association with communities of special interest, household income and vaccination history.The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
62687363|NCT04332770||Control group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to get rhTSH (not to withdraw their levothyroxine) for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
62687364|NCT01688791|EXPERIMENTAL|Part A: Vintafolide BIW|Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m\^2, administered on Day 1 of each 21-day cycle
61925042|NCT04061382||Group 2|"Group two will focus on 0-19 year olds only. They will not be restricted to the post code sampling. Instead this will include standard recruitment methods such as social media advertisements within the normal recruiting regions for each site. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients. The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.~A proportion of participants from this group from selected sites will also provide up to a maximum of three blood samples for separation of peripheral blood mononuclear cells (PBMCs) to evaluate T cell responses. These participants can be either seronegative or seropositive at their Visit 1."
62127929|NCT04646902||HTN_OSA|"Patients with hypertension\* with obstructive sleep apnea\*\*~\* Hypertension will be defined as: i) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or ii) in untreated patients: office systolic blood pressure values \>= 140 mmHg and/ or diastolic blood pressure values \>= 90 mmHg.~\*\* OSA will be defined with a polysomnography level 1, 2 or 3 performed within the previous twelve months with:~* an apnea-hypopnea index \> 5 events per hour (with more than 50% of obstructive events) associated with symptoms (associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory disturbance or observed apnea) or medical/psychiatric disorder (hypertension, coronary artery disease, atrial fibrillation, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder), OR~* an apnea-hypopnea index \> 15 events per hour, AND~* no significant changes in health, medications, or lifestyle since the polysomnography."
62127930|NCT04646902||HTN_NoOSA|Patients with hypertension without obstructive sleep apnea
62127931|NCT04646902||NoHTN_OSA|Patients without hypertension with obstructive sleep apnea
62127932|NCT04646902||NoHTN_NoOSA|Patients without hypertension without obstructive sleep apnea (healthy controls)
62127933|NCT03608202|EXPERIMENTAL|POCUS protocol group|"POCUS protocol group~It will be submitted to an ultrasound protocol which consists in performing the following ultrasound studies in each patient:~Measurement of the diameter of the optic nerve. Neck. Pulmonary ultrasound (LUS score). Echocardiogram (function and volemia). Abdomen. Femoral vascular package. Eco-guided interventionism. Central venous accesses (controlling positioning with saline injection under ultrasound), arterial, pleural or abdominal drainage and percutaneous tracheotomy will be performed under ultrasound."
62127934|NCT03608202|ACTIVE_COMPARATOR|Control group|The usual handling will be followed. The studies will only be performed if the medical team-treating team considers it, requesting a radiologist specialist the same, as is done routinely.
62318158|NCT02291315||Test meal ingestion|On the morning of the absorption study, fasted women received 2 mg of 42Ca intravenously (in 5 ml of isotonic saline) over 5 minutes before being randomly assigned to receive either the milk or cassia meal first for breakfast and the milk or cassia meal second for lunch. The milk meal consisted of approximately 100 mg of fresh ultrahigh temperature (UHT) milk to which 2 mg of 44Ca was added and allowed to equilibrate for 12 h prior to ingestion and the cassia meal consisted of 142 g of cooked cassia to which 1 mg of 43Ca was extrinsically added.
62318159|NCT05152147|ACTIVE_COMPARATOR|Arm A|Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
62479776|NCT02465060|EXPERIMENTAL|Subprotocol Z1M (LAG-3 expression >= 1%)|Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479777|NCT05659381|EXPERIMENTAL|HIPEC|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cisplatin 100 mg/m2 IP over 90 minutes at 42 degrees C
62479778|NCT05659381|ACTIVE_COMPARATOR|No HIPEC|No treatment
62318160|NCT05152147|EXPERIMENTAL|Arm B|Zanidatamab plus physician's choice of CAPOX or FP
62318161|NCT05152147|EXPERIMENTAL|Arm C|Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP
62318162|NCT00758303|ACTIVE_COMPARATOR|1|Low Dose TRIA-662
62318163|NCT00758303|ACTIVE_COMPARATOR|2|High Dose TRIA-662
62318164|NCT00758303|PLACEBO_COMPARATOR|3|Matching Placebo for TRIA-662
62318165|NCT05203133|EXPERIMENTAL|Baseline Assessment (Days -5 to -1)|Participants will complete a a 5-day baseline assessment in which habitual energy intake (remote food photography method) and exercise energy expenditure will be monitored.
62479779|NCT06087289|EXPERIMENTAL|Part 1: Dose escalation to determine Recommended Phase II Dose (RPIID)|"Part 1 of the study will include escalating doses of KAND567 administered in combination with carboplatin (according to standard of care) to approximately 10 subjects in total (may range from 6 to 24 subjects depending on DLTs). Carboplatin will be given on Day 1 of the 21-day cycle at a dose of AUC 5 according to standard of care. KAND567 will be orally administered during the first 2 weeks (Days 2 to 14) of each 21-day carboplatin cycle for up to 6 treatment cycles (or until unacceptable toxicity or disease progression).~KAND567 dose escalation will apply for the first week (Days 2 to 7) of the treatment cycle. During the second week of the treatment cycle (Days 8 to 14), KAND567 will be administered at a fixed dose of 250 mg BID to all subjects. Doses of KAND567 will be escalated according to an adaptive, intra-individual dose escalation design."
62318166|NCT05203133|EXPERIMENTAL|Energy Balance (Days 1 to 5)|Participants will be provided with all food intake for five days, to provide an energy intake of 54 kcal/kg FFM/day. On days 1, 3 and 5, participants will complete aerobic (cycling) exercise at \~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy balance (energy availability = 45 kcal/kg of FFM/day, required for weight maintenance.
62318167|NCT05203133|EXPERIMENTAL|Energy Deficit (Days 6-11)|Participants will be provided with all food intake for five days, to provide an energy intake of 19 kcal/kg FFM/day. On days 6, 8 and 10, participants will complete aerobic (cycling) exercise at \~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy deficit (energy availability = 10 kcal/kg of FFM/day) resulting in \~2.5 kg of weight-loss.
62318168|NCT03832868|EXPERIMENTAL|Pre-visit decision aid|Patients receiving the decision aid pre-visit will be given a paper copy of the decision aid in the waiting room and will have a minimum of 15 minutes to review it - either in the waiting room or in the exam room while waiting for the electrophysiologist.
62318169|NCT03832868|EXPERIMENTAL|Post-visit decision aid|Patients receiving the decision aid after the encounter will meet with the electrophysiologist first and receive the aid afterward.
62318170|NCT01240993|ACTIVE_COMPARATOR|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study.
62318171|NCT01240993|EXPERIMENTAL|Mothers and Toddlers Program|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
62318172|NCT02406781|EXPERIMENTAL|Treatment strategy A|Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.
62479780|NCT06087289|EXPERIMENTAL|Part 2: Expansion cohort to evaluate RPIID|"An expansion cohort will be enrolled in Part 2 of the study to further evaluate the RPIID (approximately 20 subjects; may range from 6 to 24 subjects, depending on Part 1). If the number of subjects with confirmed CX3CR1 expression in tumor cells is below 50%, an additional 15 subjects may be included in Part 2 of the study.~Carboplatin will be given on Day 1 of the 21-day cycle at a dose of AUC 5 according to standard of care. For KAND567, the RPIID will be orally administered to the cohort during the first week of each carboplatin cycle (Days 2 to 7). During the second week of the treatment cycle (Days 8 to 14), KAND567 will be administered at 250 mg BID. Up to 6 treatment cycles will be given (or until unacceptable toxicity or disease progression)."
62479781|NCT02137330|EXPERIMENTAL|Obalon Arm|Children swalowed up to 3 intragastric balloons
62479782|NCT02137330|NO_INTERVENTION|Dietary and lifestyle changes Arm|
62479783|NCT00611364|EXPERIMENTAL|Study group|
62127935|NCT01924676|EXPERIMENTAL|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62127936|NCT01924676|EXPERIMENTAL|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62479784|NCT00611364|ACTIVE_COMPARATOR|Control group|
62687365|NCT01688791|EXPERIMENTAL|Part A: Vintafolide TIW|Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m\^2, administered on Day 1 of each 21-day cycle
62127937|NCT01924676|EXPERIMENTAL|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62127938|NCT02995655|EXPERIMENTAL|CX-01 + Azacitidine|"* CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.~* Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.~* Up to 6 cycles of treatment allowed"
62687366|NCT01688791|EXPERIMENTAL|Parts B & C: Vintafolide Single Dose & Weekly (QW)|Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
62687367|NCT06468943|EXPERIMENTAL|Patients receiving Pola+ZR-CHP treatment|
62687368|NCT06570265|EXPERIMENTAL|Interventional arm|
62687369|NCT04774549||Patients with inflammatory cardiomyopathy|Patients referred to CMR for suspected/known inflammatory cardiomyopathy and/or diagnosed inflammatory cardiomyopathy from CMR findings
62687370|NCT02187263||hereditary DCM|
62687371|NCT02187263||inflammatory DCM|
62127939|NCT04134273|EXPERIMENTAL|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
62127940|NCT04134273|ACTIVE_COMPARATOR|Clindamycin Phosphate Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
62127941|NCT04134273|PLACEBO_COMPARATOR|Vehicle of the test product|Placebo (vehicle of the test product), applied to the face twice a day for 84 days.
62127942|NCT06521723|EXPERIMENTAL|AIH + Walking Training with transcutaneous spinal stimulation (WALKtSTIM)|Acute Intermittent Hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
62127943|NCT06521723|SHAM_COMPARATOR|Sham + WALKtSTIM|Sham acute intermittent hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
62127944|NCT04718688|EXPERIMENTAL|CO-OP intervention|CO-OP intervention
61925043|NCT04061382||Group 3|Group three will consist of up to 300 participants aged 0-19 from the Black, Asian and Minority ethnic population aged 0-19 years. They will not be restricted to the post code sampling and will be recruited at a sub-set of sites depending on capacity and the demographic profile of the local population. Recruitment will be by multiple approaches, including mail outs, radio and advertising in community (e.g. community centres, religious establishments) or Pharmacies and GP practices where we have ethics approval for them to act as PICs. These can vary according to each site's experience and their contacts within their local community on how is best to approach the BAME community. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients.
61925044|NCT00558779|EXPERIMENTAL|1|
61925045|NCT00558779|ACTIVE_COMPARATOR|2|
62479785|NCT05111574|EXPERIMENTAL|Arm 1 (nivolumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients undergo bone scans and blood and tissue sample collection throughout the trial.
61925046|NCT02822391||Stroke-group|Screened and recruited from the Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospital and University of Geneva, Geneva, Switzerland by a senior consultant neurologist (BL). Patients were included if they were hospitalized for stroke rehabilitation, were able to undergo psychophysical testing and presented with a facial impairment according to the House-Brackmann criteria ≥2 15. They were excluded if they presented with acute pain in the oro-facial sphere (nominal question) or an additional neuro-muscular disease.
61925047|NCT02822391||Control-group|Similar to stroke group in regard to age, gender and dental state. no stroke
61925048|NCT04063098|OTHER|All participants|Participants scheduled for endoscopic sleeve gastroplasty
61925049|NCT04689815|EXPERIMENTAL|Oral arsenic trioxide-Azacitidine|12 monthly cycles of oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle).
61925050|NCT02065115|EXPERIMENTAL|Cryotherapy|Cryotherapy: 12 ounces of crushed ice place in a plastic bag applied to the radial artery puncture area for 3 minutes
61925051|NCT02065115|NO_INTERVENTION|Control|Cryotherapy is not applied to the radial artery puncture area
61925052|NCT04653532|EXPERIMENTAL|mHealth Technology|Participants in this group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
61925053|NCT04653532|ACTIVE_COMPARATOR|Exercise Counselling|Participants in this group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular contact with an exercise specialist.
61925054|NCT00560378|EXPERIMENTAL|Tacrolimus Ointment 0.1%|
61925055|NCT04223648|EXPERIMENTAL|Treatment|"Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
61925056|NCT02829983|ACTIVE_COMPARATOR|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
61925057|NCT02829983|PLACEBO_COMPARATOR|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
61925058|NCT03945292|EXPERIMENTAL|Fazirsiran (also referred to as TAK-999 or ARO-AAT)|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses."
61925059|NCT03945292|PLACEBO_COMPARATOR|Placebo|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses."
62127945|NCT03743506|EXPERIMENTAL|Volunteers without motor abnormalities.|The test was performed in a single, 30-minute session. The test is divided into two phases, with feedback and no feedback from the system. The order of phases was randomized. In each phase the volunteer will remain balanced on the wobble board for 15 seconds under the conditions of the phase. This test is repeated 3 times with a 30 seconds rest between them, then the next phase is performed. With feedback the volunteer can observe the system responses. Without feedback the volunteer can not observe the response of the system.
62687372|NCT02187263||LVNC|
62127946|NCT01644916|OTHER|Usual control|Usual control will be provided with usual standard management of COPD and psychiatric comorbidities.
62127947|NCT01644916|OTHER|Integrated care|Integrated care will be provided with integrated care management.
62687373|NCT02187263||HCM|
62687374|NCT02187263||ARVC|
62687375|NCT02187263||acute myocarditis|
62687376|NCT03019263|EXPERIMENTAL|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
62687377|NCT03019263|ACTIVE_COMPARATOR|Control|Nutritional counseling
61925060|NCT03945292|EXPERIMENTAL|Open-Label Fazisiran (also referred to as TAK-999 or ARO-AAT)|After all enrolled participants completed the Week 16 visit, an interim analysis was performed to select a single dose level (25, 100 or 200 mg) for the open-label phase of the study. Fazirsiran 200 mg was the selected dose and all participants with fibrosis at Screening who completed the post-dose liver biopsy at Week 48 (or Week 72 or 96) receive this dose every 12 weeks for the duration of the study (open-label phase).
61925061|NCT01043328||GROUP OSCC|"The study group is composed by patients with a condition that requires a procedure/surgery for oral squamous cell carcinoma treatment.~INTERVENTIONS: Collect blood, saliva and oral tissue."
61925062|NCT01043328||CONTROL GROUP|"Group without oral squamous cell carcinoma but with a condition that requires prosthetic procedure/surgery.~INTERVENTIONS: Collect blood, saliva and oral tissue."
62127948|NCT02529839|EXPERIMENTAL|Experimental|"Fludarabine 30mg/m2 for 4 days, Cyclophosphamide 50mg/kg for 2 days, Alemtuzumab administered subcutaneously 24mg total dose.~Autologous bone marrow transplantation"
62127949|NCT00490802|EXPERIMENTAL|Intranasal Oxytocin|Subjects were given 24 IU intranasal oxytocin twice daily, in the morning and afternoon for 6 weeks.
61925063|NCT03024437|EXPERIMENTAL|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
62127950|NCT00490802|PLACEBO_COMPARATOR|Placebo|Subjects were given placebo twice daily, in the morning and afternoon for 6 weeks.
62127951|NCT06031012|EXPERIMENTAL|glutamine combined with thalidomide|"L-Glutamine: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take three times a day, two tablets each time; once in the morning, once in the afternoon, and once in the evening.~Thalidomide: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take orally at 100mg, once every evening."
62127952|NCT06031012|ACTIVE_COMPARATOR|glutamine alone|L-Glutamine: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take three times a day, two tablets each time; once in the morning, once in the afternoon, and once in the evening.
62127953|NCT06473090|EXPERIMENTAL|Video group|"Participants will watch a 15-minute educational video at the beginning of the session before their involvement in the 2 high-fidelity simulation scenarios.~The educational video used was developed by experts (in Human Factors and Obstetric Anesthesia) and validated by SFAR and CARO. It depicts poor use of NTS (including CLC) during a maternal cardiac arrest anesthesia scenario and then proper use of NTS during the same scenario."
62318173|NCT02406781|EXPERIMENTAL|Treatment strategy B|Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.
62687378|NCT06675682|EXPERIMENTAL|Beetroot juice supplementation|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 2.5 h before initiating the testing session.
61925064|NCT03024437|EXPERIMENTAL|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
62479786|NCT05111574|ACTIVE_COMPARATOR|Arm 2 (nivolumab, placebo)|Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients undergo bone scans and blood and tissue sample collection throughout the trial.
62687379|NCT06675682|PLACEBO_COMPARATOR|Placebo supplementation|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 2.5 h before initiating the testing session.
61925065|NCT03024437|EXPERIMENTAL|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 or PDL1 inhibitor.~Patients in Cohort B will be treated with the same combination therapy as in Cohort A."
62127954|NCT06473090|ACTIVE_COMPARATOR|Text group|"Participants will read a text-type educational support for 15 minutes at the beginning of the session before their involvement in 2 high-fidelity crisis simulation scenarios.~The text-type educational support, written in French by the same team of experts, covers all the NTS mentioned in the video and has already been used in a previous study"
62127955|NCT03010813|EXPERIMENTAL|Novel single port robotic system|A single port innovation designed to deliver an articulating 3D high definition camera and three fully articulating instruments through a single 25-mm cannula
62479787|NCT05111574|EXPERIMENTAL|Arm 3 (nivolumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycle in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients undergo bone scans and blood and tissue sample collection throughout the trial.
62687380|NCT06687590||Subjects|The study population will consist of subjects with claudication or ischemic rest pain, with de novo or restenotic lesions in the iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistulae.
62127956|NCT05998252|EXPERIMENTAL|Alveo balloon dilatation catheter|Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and undergo a planned percutaneous coronary intervention with Alveo balloon dilatation catheter.
62127957|NCT02940951|OTHER|Usual home care provided by clinicians|Usual care provided by the home health clinicians. This may or may not include use of some standardized forms of quality of life assessment that were in place prior to the study beginning.
62127958|NCT02940951|EXPERIMENTAL|Use of QPSS by home health clinicians|Usual home care plus the use of the Quality of Life Assessment and Practice Support System (QPSS) to document, monitor and address the quality of life concerns of patients and family caregivers.
62127959|NCT01643616|ACTIVE_COMPARATOR|group US|"Ultrasound guided block :~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
62127960|NCT01643616|ACTIVE_COMPARATOR|group NS|"Nerve stimulation technique:~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
62479788|NCT00001467||Blood relatives|blood related family members of proband
62687381|NCT05069415|ACTIVE_COMPARATOR|Emmetropia|The target refraction for both eyes will be emmetropia (± 0.25 D).
62127961|NCT03999671|EXPERIMENTAL|INSTRUMENT SF 36|Instrument SF36 Spanish version, validated in Spain, translated in several languages and applied to multiple studios in Mexico. The 36 items explore 8 dimensions: the state of physical health, physical function, physical role, body pain, general health, vitality, social function, emotional role and mental health: considering depression, anxiety, self-control, and general well-being.
62127962|NCT03999671|ACTIVE_COMPARATOR|Checklist|Verify that the interventions of both groups were carried out
62127963|NCT05603013|EXPERIMENTAL|Vinorelbine Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
62318174|NCT04708145|EXPERIMENTAL|Group 1|"Study eyes without PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if DRSS level is 47 or worse as determined by the treating investigator.~Subjects may be evaluated every 8 weeks if a 2-step DRSS level worsening compared to the last protocol-scheduled 16-week visit occurs, the DRSS level is 53 or worse, or if a subject has active PDR. Visits can continue every 8 weeks until there is no active PDR, and the DRSS improves to the level observed at the visit before the subject began being seen at 8-week intervals. Thereafter, visits will continue at 16 week intervals."
62318175|NCT04708145|EXPERIMENTAL|Group 2|"Study eyes with PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if the neovascular disease process is active and stable (not new or worse) as determined by the treating investigator. If the neovascular disease is inactive, no treatment will be given.~If new or worsening neovascularization develops, subjects may be seen and treated every 8 weeks until the neovascular disease is stable or inactive, at which time the interval between visits will increase to 16 weeks."
62318176|NCT03718494||Menopausal Hormone Therapy (mHT) Group|Women that participated in and completed the KEEPS study (NCT00154180) that were randomized to receive menopausal hormone therapy (mHT) will have a follow up brain Positron Emission Tomography (PET) imaging (F-18 Florbetapir PET or F-18 AV-1451 PET) and cognitive function testing.
62687382|NCT05069415|EXPERIMENTAL|Mini monovision|The target refraction for the dominant eye will be plano (± 0.25 D) and for the non-dominant eye between -0.75D ±0.15.
62687383|NCT04802005|EXPERIMENTAL|Aerobic interval|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure (target expenditure \~450-500kcal/session). Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity at 70-85% of predicted HRmax, and for the second period the intensity will be reduced to 60-65% of predicted HRmax for 2 minutes. The training sessions will be carried out outdoors at the trails located on campus. The activity will consist of walking and/or light jogging. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion (RPE) as needed. The RPE for the first period range will be 13-17 (15-17 at the end of the period) and 10-12 for the second period.
62687384|NCT04802005|NO_INTERVENTION|Control group|Participants in the control group will not participate in the training programs.
62687385|NCT02970058|ACTIVE_COMPARATOR|Platelet-rich Plasma|30 patients will receive platelet-rich plasma post-spinal anesthesia
62687386|NCT02970058|PLACEBO_COMPARATOR|Control|30 patients will receive sterile saline post-spinal anesthesia
62687387|NCT00100893|EXPERIMENTAL|Dietary Supplement: grape seed proanthocyanidin extract|Administered orally.
62687388|NCT00434941|EXPERIMENTAL|Radiotherapy + Capecitabine|Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
62127964|NCT03712306|NO_INTERVENTION|Control group|No intervention. Participants will only receive a brochure on general healthy eating habits.
62127965|NCT03712306|EXPERIMENTAL|Dietary advice|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products.
62127966|NCT03712306|EXPERIMENTAL|Dietary advice and advice on timing|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products, as well as advice regarding the consumption of protein rich food products in close proximity of usual physical activity.
62127967|NCT00011986|ACTIVE_COMPARATOR|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
62127968|NCT00011986|EXPERIMENTAL|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
62127969|NCT00011986|EXPERIMENTAL|Arm III|Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
62318177|NCT03718494||Placebo Group|Women that participated in and completed the KEEPS study (NCT00154180) that were randomized to receive placebo treatment will have a follow up brain Positron Emission Tomography (PET) imaging (F-18 Florbetapir PET or F-18 AV-1451 PET) and cognitive function testing.
62318178|NCT02160977|EXPERIMENTAL|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
62318179|NCT02160977|ACTIVE_COMPARATOR|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
62318180|NCT03616769||quantiles of serum uric acid level|quantiles according to the patient's serum uric acid level
62318181|NCT03207256|EXPERIMENTAL|TGR-1202|Oral TGR-1202 Daily
62318182|NCT03207256|EXPERIMENTAL|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
62479789|NCT00001467||Proband|person initially ill/studied/diagnosed
62687389|NCT02608086|OTHER|Control|"Flyer What can I do facing a crisis?"
62687390|NCT02608086|EXPERIMENTAL|Psychological First Aid|"Psychological First Aid according to an adapted protocol based on the WHO PFA Operation Guide 2012 Brochure Network and Services Flyer What can I do facing a crisis?."
62127970|NCT00011986|EXPERIMENTAL|Arm IV|Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.
62127971|NCT00011986|EXPERIMENTAL|Arm V|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
62127972|NCT00847834|EXPERIMENTAL|1|"4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:~* If DBP\<85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg~* If DBP≥85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet of Irbesartan 150mg"
62687391|NCT00814736|EXPERIMENTAL|UK369,003 + Placebo or sildenafil|All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo
62687392|NCT01251757|NO_INTERVENTION|Usual Care (UC)|Participants in this arm received their usual care with no restrictions.
62127973|NCT00847834|EXPERIMENTAL|2|"2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:~* If DBP\<85mmHg: 4 weeks of of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg~* If DBP≥85mmHg: 4 weeks of two tablets Irbesartan 150mg / Hydrochlorothiazide 12.5mg"
62127974|NCT02555449|EXPERIMENTAL|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
62127975|NCT00424645|EXPERIMENTAL|Voraxaze|Voraxaze administered 50 units/kg intravenously (IV) repeated a maximum of 2 times in a given cycle of chemotherapy.
62127976|NCT00424645|PLACEBO_COMPARATOR|Placebo|Placebo administered IV following Voraxaze arm.
62127977|NCT01130246|EXPERIMENTAL|A-002 500 mg|Once daily oral administration
62318183|NCT03239808|EXPERIMENTAL|Experimental group|76 patients who start RRT with the incremental HD regimen.
62318184|NCT03239808|ACTIVE_COMPARATOR|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
62318185|NCT02857023|EXPERIMENTAL|Cogmed intervention|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
62318186|NCT02857023|EXPERIMENTAL|Cogmed-waitlist control|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
62318187|NCT04927988|OTHER|Arm 1.|Using of Ringer's Lactated
62687393|NCT01251757|ACTIVE_COMPARATOR|Interactive Voice Recognition (IVR)|automated phone calls
62687394|NCT01251757|ACTIVE_COMPARATOR|Enhanced IVR (IVR+)|automated phone calls \& Educational mailings and follow-up for nonadherence
62687395|NCT04105257|OTHER|All patients|All patients seen at emergency with acute neurological deficit will be assessed if eligible to CTP/MRI
62127978|NCT01130246|PLACEBO_COMPARATOR|Matched Placebo|Once daily oral administration
62127979|NCT05705505|EXPERIMENTAL|Escalating daily doses of narazaciclib in combination with letrozole (2.5mg day)|"Phase 1: Initiating at 160mg per day of narazaciclib, patients will receive escalating doses of narazaciclib (oral tablets/once daily) in combination with 2.5mg of letrozole (oral tablet/once daily).~Phase 2: All patients will receive the recommended phase 2 dose (RP2D) of the combination of narazaciclib (oral tablets) and letrozole (oral tablet/QD)"
62318188|NCT01873742|EXPERIMENTAL|The use of STIC feedback system|This will constitute the experimental condition, using of STIC feedback system.
62318189|NCT01873742|EXPERIMENTAL|Treatment as usual|This condition will not include the use of the STIC feedback system.
62687396|NCT02457598|EXPERIMENTAL|Tirabrutinib + Idelalisib (Combination I)|"Dose Escalation:~Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib 20 mg + idelalisib 50 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 20 mg + idelalisib 50 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + idelalisib up to 100 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib for an additional 6 years from the date of Protocol Amendment 8."
62127980|NCT05752175|EXPERIMENTAL|WPV01|
62318190|NCT02974257|EXPERIMENTAL|Thiamine|Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
62318191|NCT02974257|PLACEBO_COMPARATOR|Placebo|Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
62318192|NCT00641043|EXPERIMENTAL|BI 1356 (5 mg)|BI 1356 5mg in initial combination therapy with pioglitazone 30 mg
62318193|NCT00641043|PLACEBO_COMPARATOR|Placebo matching BI 1356 5 mg|Placebo in initial combination therapy with pioglitazone 30 mg
62318194|NCT00123357||Group 1|
62318195|NCT05872425|EXPERIMENTAL|Treatment with DingKunDan(GuangYuYuan) combined with compound oral contraceptives|This arm is treated with DingKunDan plus compound oral contraceptives: Drospirenone and Ethinylestradiol Tablets (Ⅱ).
62127981|NCT05752175|PLACEBO_COMPARATOR|Placebo|
62127982|NCT00394407|ACTIVE_COMPARATOR|sliding scale regular insulin|sliding scale insulin given acqhs
62127983|NCT00394407|ACTIVE_COMPARATOR|glargine insulin and glulisine insulin|glargine basal insulin once a day with prandial glulisine insulin tid
62127984|NCT05123742||DHCW Subjects|Dental Health Care Workers
62127985|NCT05123742||Patient Subjects|Dental patients
62127986|NCT03084549|EXPERIMENTAL|Ropivacaïne|
62127987|NCT03084549|PLACEBO_COMPARATOR|Placebo|
62127988|NCT02582086|EXPERIMENTAL|BOR15001L7 Cream|BOR15001L7 Cream with 5% 15019L0
62127989|NCT02582086|PLACEBO_COMPARATOR|Placebo Cream|Placebo Cream
62127990|NCT02621632|OTHER|Healthy subjects and patients|To done a novel compression system. 20 healthy subjects and 20 patients done a novel compression system termed Socknleg and a compression class III stocking as a comparator.The Socknleg compression system was developed by the investigator and produced by Sigvaris AG, St. Gallen, Switzerland.
62127991|NCT03700294|EXPERIMENTAL|ADCT-601|
62127992|NCT04064866|EXPERIMENTAL|PRP/Hemocyte Autograft Intervention Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to active condition will have exactly 3 cc of hemocyte autograft placed in a 3 cc syringe. The syringe barrels and tubing were covered with opaque tape so that the injector was blinded to the contents. 1-2 cc of PRP was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
62127993|NCT04064866|PLACEBO_COMPARATOR|Placebo Control Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to placebo condition will have exactly 3 cc of saline placed in a 3 cc syringe. 1-2 cc of saline was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
62127994|NCT04477330|EXPERIMENTAL|Priming+HIISTT|Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training
62127995|NCT04477330|SHAM_COMPARATOR|Sham+HIISTT|Sham tDCS before high intensity interval speed based treadmill training
62127996|NCT05757388|EXPERIMENTAL|Group P|Receives the parecoxib 40 mg iv slowly push plus paracetamol 1 gm (100 mL) infusion drip in 30 min after induction.
62127997|NCT05757388|PLACEBO_COMPARATOR|Group C|Receives normal saline in the same process.
62127998|NCT00821184|ACTIVE_COMPARATOR|Vesicare|Vesicare alone
62127999|NCT00821184|ACTIVE_COMPARATOR|Vesicare/behavioral modification|Vesicare plus behavioral modification
62128000|NCT03277534|EXPERIMENTAL|Electrical stimulation|
62128001|NCT03277534|SHAM_COMPARATOR|Control|
62128002|NCT00694447|EXPERIMENTAL|Real acupuncture|Real acupuncture
62128003|NCT00694447|SHAM_COMPARATOR|Sham acupuncture|Sham acupuncture
62128004|NCT03278769|EXPERIMENTAL|Ventilator setting|Positive end-expiratory pressure , Tidal volume
62128005|NCT05588115||Concussion|Patients presenting to the ED who are diagnosed with concussion according to the ICD-10 criteria and absent of comorbidities.
62128006|NCT05588115||MSK|Patients presenting to the ED who are diagnosed with a muscle or skeletal injury (MSK; soft tissue damage or inflammation, fractured bone, etc.) and absent of comorbidities.
62128007|NCT02788604|EXPERIMENTAL|Experimental Group|Participants in this arm will have a summary of their family's psychosocial risk factors provided to the treatment team. This will occur twice: once shortly after diagnosis (within 2-4 weeks) and once approximately 6 months following diagnosis.
61925066|NCT03294473|EXPERIMENTAL|Autodial R/R|R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
61925067|NCT03294473|EXPERIMENTAL|Text Message R/R|R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
61925068|NCT03294473|EXPERIMENTAL|Postcard R/R|R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
62687397|NCT02457598|EXPERIMENTAL|Tirabrutinib + Entospletinib (Combination II)|"Dose Escalation:~Participants will receive a single dose of tirabrutinib 40 mg on Day 1 of Cycle 1 and tirabrutinib 40 mg + entospletinib 200 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 40 mg + entospletinib 200 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + entospletinib up to 400 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + entospletinib for an additional 6 years from the date of Protocol Amendment 8."
62687398|NCT02457598|EXPERIMENTAL|Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)|"Dose escalation:~Participants will receive tirabrutinib + idelalisib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and idelalisib doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
61925069|NCT03294473|NO_INTERVENTION|Standard of Care Control|Participants in this group will not receive any influenza vaccination reminders
62687399|NCT02457598|EXPERIMENTAL|Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)|"Dose escalation:~Participants will receive tirabrutinib + entospletinib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and entospletinib doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
62687400|NCT02457598|EXPERIMENTAL|Single Agent Tirabrutinib (Combination V)|Participants with relapsed or refractory chronic lymphocytic leukemia (CLL) may be enrolled to receive tirabrutinib 80 mg once daily.
62687401|NCT03918291|EXPERIMENTAL|Addition of whole-body vibration to squat training|The addition of whole-body vibration to squat training (for 12 weeks, 3x/week). The mechanical stimulation parameters of the vibration consisted of the following: frequency of 35 to 40 Hz, amplitude of 4 mm and acceleration that ranged from 2.78 to 3.26 G
62687402|NCT03918291|OTHER|Squat training|Squatting exercises for 12 weeks, 3x/week
62687403|NCT05667558||Study grup|
61925070|NCT02800954|EXPERIMENTAL|multiple myeloma group|case group = patients with multiple myeloma
61925071|NCT02800954|EXPERIMENTAL|MGUS group|monoclonal gammopathy of undetermined significance
61925072|NCT02800954|OTHER|healthy control group|control group = healthy subjects
61925073|NCT06386731|ACTIVE_COMPARATOR|intermittent phototherapy group|In the intermittent phototherapy group, phototherapy will be applied for 1 hour, phototherapy will be turned off for 2 hours, and time will be left for cleansing from the skin. The 3-hour cycle is completed twice and the 6-hour session is completed, and at the end, the total bilirubin will be measured and the hourly bilirubin decrease rate will be calculated.
62318196|NCT05872425|ACTIVE_COMPARATOR|Treatment with compound oral contraceptives|This arm is only treated with compound oral contraceptives: Drospirenone and Ethinylestradiol Tablets (Ⅱ).
62318197|NCT05694819|EXPERIMENTAL|Darolutamide monotherapy|Targeted patients: 24
61925074|NCT06386731|OTHER|continuous phototherapy group|In the continuous phototherapy group, total bilirubin will be measured at the end of 6 hours of uninterrupted phototherapy and the hourly bilirubin decrease rate will be calculated.
61925075|NCT03949907|OTHER|Nutritional counseling alone|Nutritional counseling consists of a personalized dietary prescription with regular consultation by a registered dietitian and telephone interviews, as well as of the use of oral nutritional supplements, when necessary.
61925076|NCT03949907|EXPERIMENTAL|Supplemental parenteral nutrition plus nutritional counseling|Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.
61925077|NCT06706726|EXPERIMENTAL|Group A: Single-port robotic-assisted breast surgery including sentinel lymph node biopsy|Single-port robotic-assisted（Endoscopic Instrument Control System SP1000）subcutaneous gland resection and sentinel lymph node biopsy combined with immediate breast reconstruction in the management of breast cancer
62318198|NCT05694819|EXPERIMENTAL|Darolutamide plus Goserelin|Targeted patients: 32
61925078|NCT06706726|EXPERIMENTAL|Group B: Single-port robotic-assisted breast surgery including axillary lymph node dissection|Single-port robotic-assisted（Endoscopic Instrument Control System SP1000）subcutaneous gland resection and axillary lymph node dissection combined with immediate breast reconstruction in the management of breast cancer
62318199|NCT01319929|EXPERIMENTAL|LY2828360 then Placebo|80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
62318200|NCT01319929|EXPERIMENTAL|Placebo then LY2828360|Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
62318201|NCT01499238|ACTIVE_COMPARATOR|nasal SIMV|rate: 30-50/min, PIP: 16, PEEP: 4-6, fİO2: 40%
62687404|NCT04951544|EXPERIMENTAL|Intervention Group|This arm will start the intervention using LetSync app v1.0 from T1 to T4, baseline/Month 0 to Month 14.
62687405|NCT04951544|ACTIVE_COMPARATOR|Waitlist-Control Group|This arm will wait to begin the intervention using the LetSync app v2.0 from T3 to T4, Month 8 to Month 14.
62687406|NCT06433245|ACTIVE_COMPARATOR|Control: 3% sodium hypochlorite|After partial pulpotomy procedure, pulp wound will be irrigated with 3% sodium hypochlorite and haemostasis will be achieved by placing the cotton pellet soaked with 3% sodium hypochlorite on the amputated pulp.
62687407|NCT06433245|EXPERIMENTAL|Test: 5% sodium hypochlorite|After partial pulpotomy procedure, pulp wound will be irrigated with 5% sodium hypochlorite and haemostasis will be achieved by placing the cotton pellet soaked with 5% sodium hypochlorite on the amputated pulp.
62687408|NCT01440751|EXPERIMENTAL|ologen Collagen Matrix|When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva
62687409|NCT01440751|ACTIVE_COMPARATOR|Mitomycin-C (MMC)|When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva
62687410|NCT06501573|EXPERIMENTAL|SGB-9768|a single dose of SGB-9768 by subcutaneous (sc) injection
62687411|NCT06501573|PLACEBO_COMPARATOR|Placebo|placebo calculated volume to match active treatment by sc injection
62687412|NCT03098706|OTHER|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
62687413|NCT03098706|EXPERIMENTAL|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
62687414|NCT01917032|ACTIVE_COMPARATOR|Sprinkles|Micronutrient Powder Sprinkles 1 gram orally on weekdays during 11 weeks
62687415|NCT01917032|PLACEBO_COMPARATOR|Placebo|Maltodextrin 1 gram orally on weekdays during 11 weeks
62687416|NCT04494737|ACTIVE_COMPARATOR|Active Comparator: Program 1|Mindfulness Training program is based on mindfulness based stress reduction developed by Kabat-Zinn, but the didactic content is focused on attention training and meta-awareness. Participants will be taught formal open awareness meditation, gentle yoga, and a 'body scan' meditation during weekly classes. Importantly, there is no retreat day included in the program.
62687417|NCT04494737|ACTIVE_COMPARATOR|Active Comparator: Program 2|Stress Management Education (SME) is designed to control for non-specific factors such as contact hours, stress education, and gentle exercise. Stress education classes will consist of teaching about the effects of stress on health and optimizing one's personal health care, understanding positive coping behavior, optimizing nutrition to decrease stress, and exercise and strength training.
62687418|NCT01968278|EXPERIMENTAL|Baked milk group|BM (baked milk)
62687419|NCT01968278|NO_INTERVENTION|Control|IgE-cow's milk allergic patients not treated with OIT
62687420|NCT04812015|OTHER|Dose Group 1|
62687421|NCT04812015|OTHER|Dose Group 2|
62687422|NCT04812015|OTHER|Dose Group 3|
62318202|NCT01499238|ACTIVE_COMPARATOR|nasal CPAP|PEEP: 4-6 mmHg, Fio2: 40%
62318203|NCT03722680|EXPERIMENTAL|Riluzole|The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
62687423|NCT04812015|OTHER|Dose Group 4|
62318204|NCT03722680|PLACEBO_COMPARATOR|Placebo|Posology, administration and duration of treatment will be equivalent to riluzole group.
62687424|NCT04812015|OTHER|Dose Group 5|
62687425|NCT04812015|OTHER|Dose Group 6|
62687426|NCT04614662|EXPERIMENTAL|Intervention|"Participants enrolled at intervention sites will be prompted to complete symptom screening three times weekly via SPARK with corresponding feedback and links to symptom management care pathways sent to their healthcare providers.~Symptom screening using SPARK can be performed at any time and as often as desired, but screening will be prompted three times weekly for eight weeks.~Each day the participant completes symptom screening and has at least one severely bothersome symptom, the primary healthcare team will receive an email summarizing the symptom report and highlighting symptoms that are a lot or extremely bothersome.~Upon study activation, we will work with each of the 10 intervention sites to develop site-specific, adapted care pathways that consider relevant work flows, institutional culture and available resources."
61925079|NCT00446589|EXPERIMENTAL|F|HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide
62318205|NCT00787332|EXPERIMENTAL|Desirudin|Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
62687427|NCT04614662|NO_INTERVENTION|Control|At control sites, usual care will be provided, which may or may not include symptom screening, access to CPGs or care pathways. Participants will complete SSPedi to obtain the primary outcome at weeks 0, 4 and 8 but the scores will not be revealed to providers and will not be linked to care pathways.
62687428|NCT05314075|ACTIVE_COMPARATOR|Upper Body|
62687429|NCT05314075|ACTIVE_COMPARATOR|Under body|
62687430|NCT02704377|EXPERIMENTAL|Supportive care (quality of life, supportive care preferences)|Participants complete questionnaires about quality of life and preferences for supportive care treatment, wear accelerometerundergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week, and undergo a single Dual X-ray Absorptiometry (iDXA) scan over 10 minutes. Other interventions include: Laboratory Biomarker Analysis, Quality-of-Life Assessments, and othe Questionnaire Administration.
62687431|NCT06564688||Dysphagia in the oral phase after stroke|The swallowing function was assessed by swallowing related scale and the Videofluoroscopic Swallowing Study, and then functional magnetic resonance imaging was performed.
62687432|NCT06564688||Without dysphagia after stroke|First, the swallowing function related scale was evaluated, and then the functional magnetic resonance imaging (fMRI) scan was performed.
62687433|NCT06564688||Healthy controls|First, the swallowing function related scale was evaluated, and then the functional magnetic resonance imaging (fMRI) scan was performed.
62687434|NCT06673732|EXPERIMENTAL|Group A|Group A (n=14) will receive Muscle Energy Technique (MET) combined with stationary Cycling. In the first three days, an initial assessment will be conducted, including Visual Gait Analysis, the Observational Gait Scale, and the Foot Posture Index. From Week 1 to 4, MET will involve the patient contracting for 5-10 seconds while the therapist resists, followed by a rapid 10-second stretch (3-5 repetitions), along with stationary Cycling for 5-10 minutes. A follow-up assessment will occur in Week 4. From Week 5 to 8, the same protocol will continue with 5-8 repetitions and cycling for 10-20 minutes, concluding with a final assessment in Week 8.
62687435|NCT06673732|EXPERIMENTAL|Group B|Group B (n=14) will undergo Muscle Energy Technique without stationary cycling. In the first 3 days, an initial assessment, including Visual Gait Analysis, Observational Gait Scale, and Foot Posture Index, will be conducted. From Week 1 to 4, the technique involves the patient contracting for 5-10 seconds while the therapist resists, followed by a rapid 10-second stretch (3-5 repetitions). A follow-up assessment will occur in Week 4. From Week 5 to 8, the same process continues with 5-8 repetitions, ending with a final assessment in Week 8.
62687436|NCT06568393|EXPERIMENTAL|Calisthenic|In this group, calisthenic exercises were performed by a therapist with face to face and it was taken for 8 weeks.
62687437|NCT06568393|ACTIVE_COMPARATOR|Home exercise|In this group, a home exercise programme of calisthenic exercises was prepared and shown to the participants with visuals and they were asked to perform this exercise programme for 8 weeks.
62128008|NCT02788604|ACTIVE_COMPARATOR|Control Group|Participants in this arm will NOT have a summary of their family's psychosocial risk factors provided to the treatment team shortly after diagnosis. However, the risk factors will be distributed to the treatment team 6 months following diagnosis.
62128009|NCT04761146|EXPERIMENTAL|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT Diffusing Alpha-emitters Radiation Therapy using the DaRT applicator and seeds, inserted for 14 days prior to removal.
62128010|NCT00480077|EXPERIMENTAL|Access Arm|HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report
62128011|NCT00480077|ACTIVE_COMPARATOR|Control arm|HF subjects managed with standard clinical assessment
62128012|NCT01781585||sustained low-efficiency dialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
62128013|NCT01781585||continuous veno-venous hemofiltration|Patients were randomized to receive CVVH or SLED and the next day on the other.
62128014|NCT06492070|EXPERIMENTAL|Arm 2 (cryocompression)|Patients receive paclitaxel infusions QD and receive cryocompression therapy with cooling compression wraps TID for 15 minutes before, during, and after receiving paclitaxel infusions on day 1 of each cycle. Treatment with paclitaxel continues up to 6-9 cycles in the absence of disease progression or unacceptable toxicity.
62687438|NCT01122745||Catheter Group|Patient will have continuous interscalene block for pain relief placed preoperatively. They will go home with the portable pump. Pain score will be tracked via phone and compared with the control or single short group.
62128015|NCT06492070|EXPERIMENTAL|Arm A (cryocompression and cilostazol)|Patients receive paclitaxel infusion QD and receive cryocompression therapy with cooling compression wraps TID over 15 minutes before, during, and after receiving paclitaxel infusion on day 1 of each cycle. Patients also receive cilostazol PO BID beginning with their first paclitaxel infusion continuing until 2 weeks after the final paclitaxel infusion. Treatment with paclitaxel continues for up to 6-9 cycles in the absence of disease progression or unacceptable toxicity.
62128016|NCT06492070|ACTIVE_COMPARATOR|Arm C (standard of care)|Patients undergo standard of care throughout the study.
62318206|NCT00787332|ACTIVE_COMPARATOR|Argatroban®|Patients randomized to IV Argatroban®
62318207|NCT06200467|EXPERIMENTAL|Arm A: R1 then R3 then T then R|Arm A: BI 456906-placebo (reference treatment 1 (R1)) then moxifloxacin-placebo (reference treatment 3 (R3)) then BI 456906 (Test Treatment (T)) then moxifloxacin-placebo (R3)
62687439|NCT01122745||Single shot group|Patient will have single shot interscalene block and will go home. Pain will be tracked using phone. Pain will be compared with the catheter group.
62687440|NCT03199651|ACTIVE_COMPARATOR|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
62687441|NCT03199651|EXPERIMENTAL|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
62687442|NCT05051059|OTHER|Soft tissue sarcoma of the thigh|Patients who underwent surgical resection of a deep intramuscular soft tissue sarcoma of the thigh
62687443|NCT05051059|NO_INTERVENTION|Control group|A group of healthy age-matched individuals will be identified out of an available gait lab database to compare the gait pattern with tha of the patient group
62687444|NCT05051059|OTHER|Bone or soft tissue sarcoma of the lower extremity|Patients who underwent surgical resection of a bone or soft tissue sarcoma of the lower extremity
61925080|NCT00446589|EXPERIMENTAL|I|Hemodialysis pts suffering from osteoporosis who received iv ibandronate
61925081|NCT00346944|EXPERIMENTAL|Treatment group|
61925082|NCT00346944|NO_INTERVENTION|Reference group|
61925083|NCT02896374|EXPERIMENTAL|Patients|Treated or hospitalized patients for schizophrenia.
61925084|NCT02896374|EXPERIMENTAL|Control|No schizophrenic participants, comparable to schizophrenia patients in age, gender, education level and socio premorbid verbal IQ.
61925085|NCT05751096|ACTIVE_COMPARATOR|LIFU - CRPS|Real LIFU application for CRPS cohort.
61925086|NCT05751096|SHAM_COMPARATOR|SHAM - CRPS|Sham LIFU application for CRPS cohort.
61925087|NCT05751096|ACTIVE_COMPARATOR|LIFU - FM|Real LIFU application for FM cohort.
61925088|NCT05751096|SHAM_COMPARATOR|SHAM - FM|Sham LIFU application for FM cohort.
61925089|NCT05844709||Control group|The infants will be divided into 200 in the control group. Eligible hospitalized preterm infants that met the inclusion criteria from January 2017 to December 2019 were selected for the control group by retrospective cohort.
61925090|NCT05844709||Experimental group|The infants will be divided into 30 in the experimental group.
61925091|NCT01041729|EXPERIMENTAL|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
61925092|NCT01041729|ACTIVE_COMPARATOR|Control|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment"
61925093|NCT04544969||Chemotherapy|Patients treated with palliative chemotherapy
62687445|NCT06686615||Triple therapy|Adult patients who have been diagnosed with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia treated with bempedoic acid in combination with ezetimibe and either rosuvastatin or atorvastatin (ie, triple therapy) and will be followed for up to 1 year after initiation of triple therapy.
62687446|NCT05931497|EXPERIMENTAL|verum whole body hyperthermia|WBH will be completed with a Clearlight Sauna Dome and ancillary equipment to monitor core body temperature. For the verum WBH, participants will be brought to a core body temperature of 101.3°F.
61925094|NCT02009007|EXPERIMENTAL|dopamine|dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
61925095|NCT02009007|EXPERIMENTAL|phenylephrine|Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
62687447|NCT05931497|SHAM_COMPARATOR|sham whole body hyperthermia|The sham condition will be identical to the active WBH condition. Time and other procedures will be consistent. Mild heat will be used to mimic an active WBH session.
62687448|NCT02273427|ACTIVE_COMPARATOR|BIIL 284 BS fasted|
61925096|NCT04777838|ACTIVE_COMPARATOR|Citalopram|Citalopram 10mg
61925097|NCT04777838|ACTIVE_COMPARATOR|Amitriptyline|Amitritptyline 25 mg
61925098|NCT04777838|ACTIVE_COMPARATOR|Bite Splint|Michigan Splint, nocturnal use
61925099|NCT03676335|EXPERIMENTAL|0.3 g: 0.15 mg（1)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
61925100|NCT03676335|EXPERIMENTAL|0.3 g: 0.15mg（2)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
61925101|NCT03676335|EXPERIMENTAL|0.3 g: 0.3 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
61925102|NCT03676335|ACTIVE_COMPARATOR|0.4 ml: 0.2 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
61925103|NCT02135939|ACTIVE_COMPARATOR|American Heart Association diet|Participants randomized into this arm will follow an American Heart Association diet plan for 8 weeks.
61925104|NCT02135939|EXPERIMENTAL|Whole-food plant-based vegan diet|Participants randomized into this arm will be asked to follow a whole-food plant-based vegan diet plan for 8 weeks.
62687449|NCT02273427|EXPERIMENTAL|BIIL 284 BS with high fat meal|
62687450|NCT02273427|EXPERIMENTAL|BIIL 284 BS with low fat meal|
62687451|NCT03975179|EXPERIMENTAL|Frozen section omission|Intraoperative frozen section biopsy of resection margin will not be performed
62687452|NCT03975179|ACTIVE_COMPARATOR|Frozen section|Intraoperative frozen section biopsy of resection margin will be performed. Margin evaluation of superior, medial, lateral, inferior margin is recommended but will follow surgeon's discretion.
62687453|NCT00107614|EXPERIMENTAL|DT PACE/auto transplant/maint therapy|
61925105|NCT02909179|EXPERIMENTAL|mCARE-II|mCARE-II supported service provision through existing community health workforce.
61925106|NCT02909179|NO_INTERVENTION|Comparison|Standard of care, paper-based service provision through existing community health workforce.
61925107|NCT03582644|EXPERIMENTAL|CRYOTHERAPY INTERVENTION|Patients with end stage knee osteoarthritis, both sexes, 60 years or higher
61925108|NCT00289718|EXPERIMENTAL|Twinrix Group|"Subjects who received 2 doses of Twinrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the long term follow-up."
61925109|NCT00963677|EXPERIMENTAL|Intubation without difficulty|The patients are not predicted for difficult intubation
61925110|NCT00963677|EXPERIMENTAL|Difficult intubation|The patients will be anticipated for difficult intubation without difficult ventilation
61925111|NCT01918722|EXPERIMENTAL|ICH-1|herbal medicine with Hirudo, Tabanus,8 herbals, promote blood circulation function
62128017|NCT06034522|EXPERIMENTAL|Face correction with Investigational device|Subjects will be injected with the investigational device in the face.
62128018|NCT04866238|ACTIVE_COMPARATOR|Vestibular fixed appliances|Adult patients in this group will be treated using fixed appliances.
62318208|NCT06200467|PLACEBO_COMPARATOR|Arm B: R1 then R2 then R1 then R3|Arm B: BI 456906-placebo (R1) then moxifloxacin (Reference Treatment 2 (R2)) then BI 456906-placebo (R1) then moxifloxacin-placebo (R3)
62318209|NCT06200467|PLACEBO_COMPARATOR|Arm C: R1 then R3 then R1 then R2|Arm C: BI 456906-placebo (R1) then moxifloxacin-placebo (R3) then BI 456906-placebo (R1) then moxifloxacin (R2)
62318210|NCT05703828||chronic ankle sprain group|
62318211|NCT05703828||health subjects group|
62318212|NCT01907529|EXPERIMENTAL|Chemo plus Endostar|Docetaxel, epirubicin and cyclophosphamide plus endostar
62687454|NCT05434598|EXPERIMENTAL|Patients: ChromSeq|ChromoSeq will be performed on bone marrow or peripheral blood DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
62687455|NCT05434598|NO_INTERVENTION|Stakeholders (Treating Physicians)|Stakeholders (treating physicians) will complete surveys/questionnaires
62318213|NCT01907529|ACTIVE_COMPARATOR|Chemo only|docetaxel, epirubicin and cyclophosphamide
62128019|NCT04866238|EXPERIMENTAL|Clear aligners|Adult patients in this group will be treated using clear aligners.
62128020|NCT05073562|EXPERIMENTAL|Nutrition+ Intervention|This group will receive a structured nutrition education package provided by Community Health Assistants (CHAs) based on a handbook on nutrition education developed by UNICEF with collaboration from the Liberia Ministry of Health. The structured nutrition education package will focus on four key areas: causes and prevention of anemia, healthy eating and food choices, hand washing, and physical exercise. Participants in the intervention group will also receive IFA supplementation on a weekly basis for the duration of the study, and a one-time oral deworming treatment (mebendazole), which will be administered once at the beginning of the study.
62128021|NCT05073562|ACTIVE_COMPARATOR|Control group - standard services only|This group will receive only the current package of basic nutrition services provided at the health facility and at community level by health workers and CHAs, respectively.
62318214|NCT02805088|EXPERIMENTAL|Bipolar Disorder patients|
62318215|NCT02805088|EXPERIMENTAL|Schizophrenia patients|
62318216|NCT02805088|EXPERIMENTAL|Healthy Volunteers|
62318217|NCT05165329|ACTIVE_COMPARATOR|Probiotic and Peanut Oral Immunotherapy (PPOIT)|Probiotic and peanut oral immunotherapy taken daily for 18 months
62318218|NCT05165329|ACTIVE_COMPARATOR|Placebo Probiotic and Peanut Oral Immunotherapy|Placebo probiotic and peanut oral immunotherapy taken daily for 18 months
62318219|NCT05165329|PLACEBO_COMPARATOR|Placebo Probiotic and Placebo Oral Immunotherapy|Placebo probiotic and placebo oral immunotherapy taken daily for 18 months
62318220|NCT02158858|EXPERIMENTAL|Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm (MF patients treated with pelabresib alone)|"* Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi (pelabresib alone)~* Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)"
62479790|NCT04684186||Endovascular fiducial marker insertion|Fiducial markers are inserted and released near the tumor through femoral puncture. A catheter is led through the venous system to the right heart and from there through the heart into the pulmonary arteries.
62687456|NCT06571578|EXPERIMENTAL|exoerimental Group|Thirty subjects will receive combined program containing interval inspiratory muscle training and conventional exercise program for FHP 12 weeks (3 sessions/ week).
62128022|NCT02944760|EXPERIMENTAL|Low-Level Light Therapy Group|The patient was placed supine on a stretcher and the application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. Six points in quadriceps and four points in gastrocnemius, were irradiated, bilaterally, by 30 seconds.
62128023|NCT02944760|PLACEBO_COMPARATOR|Placebo Group|The patient was placed supine on a stretcher and the application of laser therapy occured with apparatus off.
62128024|NCT04750850|EXPERIMENTAL|Core stability exercises group|30 minutes of core stability exercises program at a light intensity and take a rest breaks if is necessary. They will be instructed in the use of the 4-5 points of the Borg 10 Rating of Perceived Exertion for self-monitoring of exercise intensity. The exercises will performed twice a day for 5 days a week during 5 weeks. A physiotherapist conducted an initial home visit to ensure correct execution of the exercises. He or she will teach the exercises and then the patient will perform them alone in your home. Once a week the physiotherapist will phone the patient and will ask her/him for doubts.
62128025|NCT04750850|ACTIVE_COMPARATOR|Control group|The patients to continue as normal and not change their routine in terms of exercise and physical activity during the period of study.
62128026|NCT03113617|EXPERIMENTAL|Diagnostic (68Ga-RM2 PET/CT)|Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.
62128027|NCT04292132|ACTIVE_COMPARATOR|Conventional loading|Loading of 4 interforaminal implants three months after surgery.
62128028|NCT04292132|EXPERIMENTAL|Immediate Loading|Loading of 4 interforaminal implants immediately after surgery.
62128029|NCT03631953|EXPERIMENTAL|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
62128030|NCT02139696||MS patients initiating fingolimod|Patients will be imaged using PET and MRI at baseline, and twice during treatment.
62128031|NCT01437605|ACTIVE_COMPARATOR|A: recMAGE-A3 + AS15|ASCI injections without Poly IC:LC
62128032|NCT01437605|ACTIVE_COMPARATOR|B: recMAGE-A3 + AS15 + Poly IC:LC|ASCI injections with Poly IC:LC
62128033|NCT00774852|EXPERIMENTAL|Treatment|Abatacept plus Euro-lupus regimen
62128034|NCT00774852|PLACEBO_COMPARATOR|Control|Abatacept placebo plus Euro-lupus regimen
62128035|NCT02648503|EXPERIMENTAL|Deep neuromuscular block|PTC=1-2
62128036|NCT02648503|ACTIVE_COMPARATOR|Moderate neuromuscular block|TOF=1-2
62128037|NCT03324945|EXPERIMENTAL|Neurocognitive Assessment +/- FMRI|All participants receive pre- and post-chemotherapy neurocognitive assessments. A sequentially-assigned subset also receive pre- and post-chemotherapy Functional Magnetic Resonance Imaging (FMRI) procedures.
62128038|NCT02830906|EXPERIMENTAL|ramosetron group|Patients received 0.3 mg of intravenous ramosetron before spinal anesthesia and intrathecal morphine
62128039|NCT02830906|ACTIVE_COMPARATOR|ondansetron group|Patients received 8 mg of intravenous ondansetron before spinal anesthesia and intrathecal morphine
62128040|NCT02045459|EXPERIMENTAL|Exercise Program and Medical Therapy|All subjects randomized to this arm will be given intensive medical therapy including - Isosorbide mononitrate, Lisinopril, Carvedilol, and Simvastatin. After 8 weeks of ONLY medication therapy, the subjects will begin a intensive exercise program. This will be supervised on site at UVA. Also, on days that the subject is not being supervised, they will be required to keep a journal of their exercise at home.
62128041|NCT01571596|EXPERIMENTAL|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)
62687457|NCT06571578|OTHER|Control Group|control group Thirty subjects will receive a conventional exercise program for FHP for 12 weeks (3 sessions/ week).
61925112|NCT01918722|ACTIVE_COMPARATOR|ICH-2|herbal medicine without Hirudo, Tabanus,Only 6 herbals
62479791|NCT04684186||Bronchoscopic fiducial marker insertion|Fiducial markers are inserted and released near the tumor into the bronchi using an endoscopic route
62687458|NCT05613179|EXPERIMENTAL|Group1 (lever positioning manipulation)|Patients with lumbar disc herniation treated by lever positioning manipulation
61925113|NCT01918722|PLACEBO_COMPARATOR|placebo herbal medicine|Placebo ：granula，dose twice a day by Oral or nasogastric tube for 10 days
61925114|NCT04671173|EXPERIMENTAL|Experimental arm (only one arm)|Only one arm, the participants will all received the device to measure Intra-compartmental pressure after consenting to study participation.
61925115|NCT03601000|EXPERIMENTAL|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
62687459|NCT05613179|ACTIVE_COMPARATOR|Group2 (placebo group)|Patients with lumbar disc herniation treated by sham lever positioning manipulation
62687460|NCT05613179|NO_INTERVENTION|Group3 (healthy controls)|Healthy control group without any intervention.
62128042|NCT02600052|EXPERIMENTAL|GPNF|Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
62128043|NCT02600052|ACTIVE_COMPARATOR|GCONTROL|Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
62128044|NCT05598684||Cohort|Adult patients who agreed to initiate treatment with a biosimilar (adalimumab FK) or to replace the reference adalimumab with the adalimumab FK biosimilar
62128045|NCT05906875|EXPERIMENTAL|Decrease fear of falling|
62318221|NCT02158858|EXPERIMENTAL|Arm 2: Prior JAKi Combination Arm|"* Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib (pelabresib + Ruxolitinib)~* Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)"
62318222|NCT02158858|EXPERIMENTAL|Arm 3: JAKi Naïve Combination Arm|Open to patients with MF who have not previously received a JAKi (pelabresib + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
62318223|NCT02158858|EXPERIMENTAL|Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm|Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)
62318224|NCT05323552||Hernia repair with laparoscopic TEP approach without curare and without orotracheal intubation.|Patients will undergo laparsocopic TEP hernia repair without curare and without orotracheal intubation.
62318225|NCT02816762|EXPERIMENTAL|CPAP treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
62479792|NCT04739800|ACTIVE_COMPARATOR|Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
62128046|NCT05906875|EXPERIMENTAL|Decrease the number of fall risk factors|
62128047|NCT05906875|EXPERIMENTAL|Increase balance confidence|
62128048|NCT05906875|EXPERIMENTAL|prove feasible to integrate into an existing community group exercise program|
62318226|NCT02816762|ACTIVE_COMPARATOR|Control treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
62318227|NCT06532461|ACTIVE_COMPARATOR|Starting 3-days infusion set and Novorapid|Start first 3-days infusion set for 4 months then cross-over to 7-days infusions set for 4 months - allocated to Novorapid
62318228|NCT06532461|ACTIVE_COMPARATOR|Starting 3-days infusion set and Humalog|Start first 3-days infusion set for 4 months then cross-over to 7-days infusions set for 4 months - allocated to Humalog
62318229|NCT06532461|ACTIVE_COMPARATOR|Starting 7-days infusion set and Novorapid|Start first 7-days infusion set for 4 months then cross-over to 3-days infusions set for 4 months - allocated to Novorapid
62318230|NCT06532461|ACTIVE_COMPARATOR|Starting 7-days infusion set and Humalog|Start first 7-days infusion set for 4 months then cross-over to 3-days infusions set for 4 months - allocated to Humalog
62318231|NCT05741164|EXPERIMENTAL|Treatment (propranolol and pembrolizumab)|Patients receive propranolol PO and pembrolizumab IV while on study. Patients undergo CT scan, blood sample collection and may undergo tumor biopsy during screening and on study.
62318232|NCT02345434|NO_INTERVENTION|No informative letter|This is the control arm and it involves no contact with the prescriber
62318233|NCT02345434|EXPERIMENTAL|Informative letter|This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)
62318234|NCT02948192||Preterm Delivery|African american women who present for prenatal care who experience spontaneous preterm birth
62318235|NCT02948192||Term delivery|African american women who present for prenatal care who experience term birth
62687461|NCT00266032|EXPERIMENTAL|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
62318236|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
62318237|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
62687462|NCT00266032|EXPERIMENTAL|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
62687463|NCT00266032|ACTIVE_COMPARATOR|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
62687464|NCT00449852|EXPERIMENTAL|Interactive Voice Response Group|
62687465|NCT00449852|NO_INTERVENTION|Usual Care Group|
62687466|NCT04472403||PFLL Group|"Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/m2) on day 1 and day 28, every 60 days.~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
62318238|NCT03471429||Dog|Patient sees therapy dog for 15 minutes, which is standard of care at this hospital.
61925116|NCT03601000|PLACEBO_COMPARATOR|Placebo|Placebo given three times every day for 16 weeks.
62318239|NCT03471429||No Dog|Patient receives standard of care
62318240|NCT04665258||COVID-19 vaccine group|Participants scheduled to receive the COVID-19 vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
62318241|NCT03321292|EXPERIMENTAL|L-arginine and Acetylesalicylic acid|L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
62318242|NCT03321292|ACTIVE_COMPARATOR|Acetylesalicylic acid75mg|acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
62318243|NCT02630277|EXPERIMENTAL|Arm 1|1:1 Intravitreal Aflibercept Injection once every 4 weeks
62318244|NCT02630277|EXPERIMENTAL|Arm 2|Intravitreal of Aflibercept once every 4 weeks for 4 months then as needed (PRN)
62318245|NCT05941884||Schistosoma haematobium cystitis.|patient has symptoms suggestive of Schistosoma haematobium infection like terminal hematuria and burning micturition
62318246|NCT05941884||Healthy personnel.|as control group
62318247|NCT05941884||Schistosomal bladder cancer.|from patient undergone diagnostic cystoscopy and sampling and confirmed pathologically as Schistosomal bladder cancer.
62318248|NCT05941884||non Schistosomal bladder cancer.|from patient undergone diagnostic cystoscopy and sampling and confirmed pathologically as non Schistosomal bladder cancer.
62318249|NCT05941884||Schistosomal cystitis patients.|from patient undergone diagnostic cystoscopy and sampling and confirmed pathologically as Schistosomal cystitis
62318250|NCT05941884||healthy bladder tissue from tissue biopsy patient with benign prostatic hyperplasia.|as control group
62318251|NCT05591443||Heart failure patients|Patients with CHF will be considered for inclusion in the study based on their verified medical record, indicating that they are diagnosed with CHF and are using guideline-directed medical therapy (GDMT). Diagnostic criteria, as laid out in the latest 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and management of chronic and acute heart failure, will be followed.
62318252|NCT01595256|EXPERIMENTAL|walking group|
62318253|NCT01595256|NO_INTERVENTION|usual care|
62318254|NCT01789073|EXPERIMENTAL|Oral Impact, Nestlé Health Science|Oral Impact-arm receives the intervention the last 7 days prior to surgery
62318255|NCT01789073|NO_INTERVENTION|Control|The control-arm receives no intervention but is treated according to the standard procedures
62318256|NCT02533960||NOAC|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).~Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs)."
62318257|NCT02533960||VKA|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).~Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)"
62128049|NCT01058785|EXPERIMENTAL|Lucanix|Patients will receive injections of Lucanix for each dose cohort.
62318258|NCT02533960||Without OAC|"Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.~Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation."
62697431|NCT03684980|EXPERIMENTAL|Arm C - HD-MTX (Arm Outpatient MTX Therapy in times of COVID-19)|MTX ≤ 3.5 g/m2 will be administered on Day 1, along with pre- and post- hydration. Patients will return on Day 2 for continued hydration and glucarpidase 2000 units. Glucarpidase rapidly and sustainably reduces serum MTX levels \>95% without crossing the blood brain barrier, effectively resulting in systemic MTX clearance. Patients will return for bloodwork on Day 3 to document MTX clearance. Arm Outpatient MTX Therapy in times of COVID-19 will only be a single-institution arm, only open at Memorial Sloan Kettering Cancer Center.
62128050|NCT03475316|EXPERIMENTAL|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
62128051|NCT03475316|ACTIVE_COMPARATOR|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
62128052|NCT02086097|EXPERIMENTAL|dexketoprofen trometamol|Administration of 25mg of Dexketoprofen Trometamol, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
62128053|NCT02086097|ACTIVE_COMPARATOR|IBUPROFEN|Administration of 600mg of Ibuprofen, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
62128054|NCT02086097|PLACEBO_COMPARATOR|PLACEBO|4 doses of sugar pills, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
62128055|NCT01609075||Cohort|
62318259|NCT04848363|EXPERIMENTAL|Study group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before the operation, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.
62318260|NCT04848363|PLACEBO_COMPARATOR|Control group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before surgery, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of saline.
62318261|NCT06671470|EXPERIMENTAL|Group A|
61925117|NCT01704898|OTHER|Efavirenz 600 Test-Stocrin 600 Reference|Efavirenz 600 mg will be randomly assigned.
61925118|NCT01704898|OTHER|Stocrin 600 Reference-Efavirenz 600 Test|Stocrin 600 mg will be randomly assigned.
61925119|NCT00787995||MPS IVA|Subjects with mucopolysaccharidosis IVA (Morquio Syndrome)
61925120|NCT03516981|EXPERIMENTAL|GEP low TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the Recommended Phase 2 Dose (\[RP2D\], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
61925121|NCT03516981|EXPERIMENTAL|GEP low TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
62128056|NCT02253537||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
62128057|NCT05748015|ACTIVE_COMPARATOR|relapsing-remitting multiple sclerosis|Patients with relapsing-remitting multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.
62128058|NCT05748015|ACTIVE_COMPARATOR|primary progressive multiple sclerosis|Patients with primary progressive multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.
62318262|NCT03103269|EXPERIMENTAL|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
62318263|NCT03103269|EXPERIMENTAL|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
62687467|NCT04472403||Non-PFLL Group|"Patients were treated with other platinum-based chemotherapy every 21 days including:~PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.~GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.~TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1.~TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5.~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
61925122|NCT03516981|EXPERIMENTAL|GEP low TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
61925123|NCT03516981|EXPERIMENTAL|GEP low TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
61925124|NCT03516981|EXPERIMENTAL|GEP low TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
62128059|NCT00041548|EXPERIMENTAL|1|Nitric Oxide for Inhalation
62128060|NCT00041548|PLACEBO_COMPARATOR|2|oxygen
62479793|NCT04739800|EXPERIMENTAL|Arm II (durvalumab, cediranib maleate, olaparib)|Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
62479794|NCT04739800|EXPERIMENTAL|Arm III (durvalumab, cediranib maleate)|Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
62479795|NCT04739800|EXPERIMENTAL|Arm IV (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
62479796|NCT02322593|EXPERIMENTAL|TAS-118/Oxaliplatin|TAS-118 plus Oxaliplatin
62479797|NCT02322593|ACTIVE_COMPARATOR|S-1/Cisplatin|S-1 plus Cisplatin
62128061|NCT06514937|NO_INTERVENTION|Patients with dual pathology without social cognition damage|Patients with dual pathology without damage without intervention
62687468|NCT05024214|EXPERIMENTAL|Phase Ib arm|Subjects with advanced or metastatic solid tumor (excluding hepatocellular carcinoma and thyroid cancer) with disease progression or intolerance or no effective treatment after standard therapy
62687469|NCT05024214|EXPERIMENTAL|Phase II cohort1-NSCLC|Subjects with non-small cell lung cancer, resistant after previous treatment with PD-(L)1 inhibitors
61925125|NCT03516981|EXPERIMENTAL|GEP low TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
61925126|NCT03516981|EXPERIMENTAL|GEP hi TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
62128062|NCT06514937|NO_INTERVENTION|Patients with dual pathology with Social Cognition damage control|Patients with dual pathology with social cognition damage with regular therapy in the centre
62128063|NCT06514937|EXPERIMENTAL|Patients with dual pathology with social cognition with Emotional Training|Patients with dual pathology with social cognition damage with Emotional Training therapy in the centre
62128064|NCT02616900|EXPERIMENTAL|eSight Eyewear|Main arm
62128065|NCT05401474|ACTIVE_COMPARATOR|30 L/min|HFNC at 30L/min. FiO2 adjusted to reach SpO2 95%
62687470|NCT05024214|EXPERIMENTAL|II Phase cohort1-RCC|Subjects with renal cell carcinoma, resistant after previous treatment with PD-(L)1 inhibitors
62687471|NCT05024214|EXPERIMENTAL|Phase II cohort1-HCC|Subjects with hepatocellular carcinoma, resistant after previous treatment with PD-(L)1 inhibitors
62687472|NCT05024214|EXPERIMENTAL|Phase II cohor2-experiment group|Subjects with renal cell carcinoma, no previous systemic treatment for advanced disease
62687473|NCT05024214|EXPERIMENTAL|Phase II cohort2-control group|Subjects with renal cell carcinoma, no previous systemic treatment for advanced disease
62479798|NCT00191815|EXPERIMENTAL|Gemcitabine + Cisplatin|
62687474|NCT06674681|OTHER|HPV Self-Collection|Patients at partnering clinics who are enrolled in the clinics' HPV self-collection program(s). The requirements for being enrolled in the program are based off of the American Cancer Society's recommendation for cervical cancer screening.
62128066|NCT05401474|EXPERIMENTAL|45 L/min|HFNC at 45L/min. FiO2 adjusted to reach SpO2 95%
61925127|NCT03516981|EXPERIMENTAL|GEP hi TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
62128067|NCT05401474|EXPERIMENTAL|60 L/min|HFNC at 60L/min. FiO2 adjusted to reach SpO2 95%
62128068|NCT01919450|ACTIVE_COMPARATOR|10 Second Delay|A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
62687475|NCT02262325|EXPERIMENTAL|Treatment (hypofractionated radiation boost, chemoradiation)|Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
61925128|NCT03516981|EXPERIMENTAL|GEP hi TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
62128069|NCT01919450|ACTIVE_COMPARATOR|2 Minute Delay|A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
61925129|NCT03516981|EXPERIMENTAL|GEP hi TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
62128070|NCT01919450|ACTIVE_COMPARATOR|4 Minute Delay|A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
62128071|NCT01919450|ACTIVE_COMPARATOR|1 Minute Delay|A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
62128072|NCT04255940||After outbreak|
62479799|NCT05642923|ACTIVE_COMPARATOR|Synthetic Vitamin B1|Synthetic Vitamin B1, 400 mg per day
62479800|NCT05642923|NO_INTERVENTION|No intervention|No intervention
62479801|NCT06591598|EXPERIMENTAL|Regimen 1|15 participants will be assigned to Regimen 1. Regimen 1 participants will be administered 8 mg aflibercept injections according to the Regimen 1 dosing schedule.
62687476|NCT04283279|EXPERIMENTAL|Virtual reality exercise|20 participants will be randomised to this arm
62128073|NCT04255940||Past 3 months|
62128074|NCT04255940||Last year|
62128075|NCT01504659|ACTIVE_COMPARATOR|Bipolar-Ketalar|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of intranasal ketalar
62128076|NCT01504659|PLACEBO_COMPARATOR|Bipolar-Placebo|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of placebo
62128077|NCT02881203|EXPERIMENTAL|Breathe Well + RPM|Participants will receive Breathe Well audiovisual feedback in addition to the RPM system
62128078|NCT02881203|ACTIVE_COMPARATOR|RPM|Varian's RPM system is the current standard of care at Royal North Shore Hospital where this trial is to be run.
62128079|NCT04748575|EXPERIMENTAL|Acai smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the acai smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the placebo smoothie.
62128080|NCT04748575|EXPERIMENTAL|Placebo smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the placebo smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the acai smoothie.
62479802|NCT06591598|EXPERIMENTAL|Regimen 2|Up to 15 participants will be assigned to Regimen 2. Regimen 2 participants will be administered 8 mg aflibercept injections according to the Regimen 2 dosing schedule.
62479803|NCT06591598|EXPERIMENTAL|Regimen 3|Up to 15 participants will be assigned to Regimen 3. Regimen 3 participants will be administered 8 mg aflibercept injections according to the Regimen 3 dosing schedule.
62479804|NCT00473863|EXPERIMENTAL|intervention|Receives CCTA
61925130|NCT03516981|EXPERIMENTAL|GEP hi TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
61925131|NCT03516981|EXPERIMENTAL|GEP hi TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
61925132|NCT01571297|ACTIVE_COMPARATOR|RM-131|
61925133|NCT01571297|PLACEBO_COMPARATOR|Placebo|
61925134|NCT04581135||COVID-19 Lung|COVID-19 survivors in Switzerland
61925135|NCT03912896|EXPERIMENTAL|Children with autism spectrum disorder|
61925136|NCT01216995|ACTIVE_COMPARATOR|Dose A|Dose A
61925137|NCT01216995|PLACEBO_COMPARATOR|Placebo|Placebo
61925138|NCT04263454|OTHER|Healthy Control|All healthy control participants will undergo the same screening and experimental procedures. Healthy controls must report no other medical conditions ( including fibromyalgia) to be considered for inclusion. All healthy controls will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
61925139|NCT04263454|EXPERIMENTAL|Fibromyalgia|All fibromyalgia participants will undergo the same screening and experimental procedures. However, fibromyalgia participants will need to meet 2010 American College of Rheumatology diagnostic criteria for fibromyalgia. All fibromyalgia participants will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
61925140|NCT05696080|EXPERIMENTAL|V116|Participants will receive a single intramuscular (IM) dose of V116 on Day 1, and single IM dose of placebo for PCV15 + PPSV23 on Week 8
61925141|NCT05696080|ACTIVE_COMPARATOR|PCV15 + PPSV23|Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
62128081|NCT05204394|EXPERIMENTAL|VM-1500A-LAI 600mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 600mg i / m Q4W injections with the background of oral 2NRTIs QD.
62687477|NCT04283279|EXPERIMENTAL|Vestibular rehabilitation exercise|20 participants will be randomised to this arm
61925142|NCT02770469|ACTIVE_COMPARATOR|Standard Intervention|The standard intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship.
61925143|NCT02770469|EXPERIMENTAL|Enhanced Intervention|The enhanced intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship as well as cognitive-behavioral stress management.
61925144|NCT02366598|EXPERIMENTAL|20g Hemp protein shake|Hemp protein shake, 20 grams, given once at beginning of acute trial
61925145|NCT02366598|EXPERIMENTAL|40 g hemp protein shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial
61925146|NCT02366598|ACTIVE_COMPARATOR|20 g Soybean protein shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial
61925147|NCT02366598|EXPERIMENTAL|40 g Soybean protein shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial
61925148|NCT02366598|PLACEBO_COMPARATOR|Control shake|non-protein control shake, given once, at beginning of acute trial
61925149|NCT02901639|EXPERIMENTAL|counseling group|will receive counseling about contraceptive methods using illustrations through postpartum interview with the study
61925150|NCT02901639|NO_INTERVENTION|NO counseling|will not receive any counseling about contraceptive methods
61925151|NCT03415100|EXPERIMENTAL|CAR-NK cells targeting NKG2D ligands|
61925152|NCT01861171|PLACEBO_COMPARATOR|Placebo|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
62128082|NCT05204394|EXPERIMENTAL|VM-1500A-LAI 900mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 900mg i / m Q4W injections with the background of oral 2NRTIs QD.
62128083|NCT05204394|OTHER|Standard or Care|Any approved 1st line oral HIV treatment regimen
62479805|NCT00473863|NO_INTERVENTION|Control|
62687478|NCT04283279|OTHER|Control|20 participants will be randomised to this arm
62687479|NCT01834378|NO_INTERVENTION|No intervention|
62687480|NCT01834378|EXPERIMENTAL|Low intensity intervention|
62687481|NCT01834378|EXPERIMENTAL|High intensity intervention|
62687482|NCT06570083|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive three months of personalized support via WeChat, including tailored exercise recommendations, motivational messages, and educational content.
61925153|NCT01861171|ACTIVE_COMPARATOR|Green Tea|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
61925154|NCT04941781|EXPERIMENTAL|PIPE-307|Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of \[11C\] PIPE- 307.
62479806|NCT05996198|EXPERIMENTAL|Patients with History of Stroke|"Individuals with history of stroke more than 6 months prior to enrollment.~Participants will complete 3 blocks of 54 trials in a single session. Block 1 is a baseline phase where subjects will perform reaches without any loads applied via the exoskeleton devices. Block 2 is the intervention block where bilateral exoskeletons apply gravity assistance to the impaired arm for stroke survivors and gravity resistance to the non-impaired arm. Block 3 is a retention block, where tested procedures are identical to block 1."
61925155|NCT02301585|EXPERIMENTAL|Passive Leg Raising|Before decision on fluid administration a passive leg raising test is performed. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
62128084|NCT04353102|EXPERIMENTAL|YH002|All subject will receive YH002 intravenously as single agent every three weeks (Q3W) for up to 2 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first. Subjects who remain on treatment in the absence of disease progression for more than 2 years may continue to receive study drug through a single patient IND.
62479807|NCT05996198|EXPERIMENTAL|Healthy Controls|"Healthy age and gender-matched control participants.~Participants will complete 3 blocks of 54 trials in a single session. Block 1 is a baseline phase where subjects will perform reaches without any loads applied via the exoskeleton devices. Block 2 is the intervention block where bilateral exoskeletons apply gravity assistance to the non-dominant arm and resistance is applied to the dominant arm in healthy controls. Block 3 is a retention block, where tested procedures are identical to block 1."
62479808|NCT03934281|ACTIVE_COMPARATOR|HAS dressing|"Patients included in the HAS dressing arm will receive the best available dressing according to the HAS recommendations. HAS is the french National Authority for Health (HAS) ."
62479809|NCT03934281|EXPERIMENTAL|Honey dressing|"the honey used in this study is the Melectis G dressing. This is a combination of thyme honey (99.8%) and hyaluronic acid (0.2%).~The patient will benefit from the honey dressing until complete healing and/or until the end of the study (maximum 12 months)."
62479810|NCT06558825|EXPERIMENTAL|Integrated Intervention to Promote PrEP Uptake|
61925156|NCT02301585|ACTIVE_COMPARATOR|Standard of care|Patients are treated according to Surviving Sepsis Guidelines. Fluid is administered according to the choice of the clinician.
62128085|NCT04358939|EXPERIMENTAL|Prone decubitus group|Prone positioning of patients on nasal high-flow oxygen therapy with usual care
62128086|NCT04358939|NO_INTERVENTION|Control group|Patients on nasal high-flow oxygen therapy with usual care and positioned in supine
62128087|NCT01620684|ACTIVE_COMPARATOR|metyrapone|Overnight metyrapone treatment (total dose of 30 mg/kg)
62128088|NCT01620684|PLACEBO_COMPARATOR|sugar pill|Overnight treatment with placebo capsules
62128089|NCT05865145|EXPERIMENTAL|Group A|will receive High Intensity Interval Training program
62479811|NCT06558825|ACTIVE_COMPARATOR|Standard Treatment Condition|
62479812|NCT01725958|EXPERIMENTAL|Dietary Supplement|"Treatment Regimen~-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake."
62479813|NCT05776277|EXPERIMENTAL|Iltamiocel|
62128090|NCT05865145|EXPERIMENTAL|Group B|will receive Low Intensity Interval Training program
62128091|NCT05702775|NO_INTERVENTION|Non-endoscopic treatment group (Group NE)|Antibiotic treatment will start from the moment of diagnosis in both arms of the study. Following the recommendations of the Clinical Practice Guideline for the Management of Acute Cholecystitis of Tokyo 2018, CAL will be classified into three groups according to severity (I,II,III) and empirical antibiotic treatment will be started according to the recommendations of said guideline
61925157|NCT01402895|ACTIVE_COMPARATOR|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
62128092|NCT05702775|EXPERIMENTAL|Endoscopic treatment group (EUS-GBD Group)|The procedure will be performed after at least 6 hours of fasting The placement of the drain will be performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy.
62128093|NCT05202912|OTHER|Cohort A(Food effect)|
62128094|NCT05202912|OTHER|Cohort B(Single dose)|
62479814|NCT05776277|PLACEBO_COMPARATOR|Placebo|
62128095|NCT00462358|EXPERIMENTAL|ARRY-520|
62128096|NCT00462358|EXPERIMENTAL|ARRY-520 + G-CSF support|
62128097|NCT01942018|EXPERIMENTAL|EGOO|Patients presenting with symptomatic gastroesophageal junction outflow obstruction (EGOO)who will be treated with Per oral endoscopic myotomy (POEM)
62128098|NCT04958343||reconstruction group|Patients will receive pelvic reconstruction following radical cystectomy during the operation.
62479815|NCT04496349|EXPERIMENTAL|APG-115 monotherapy part|APG-115 will be given alone
62687483|NCT06570083|ACTIVE_COMPARATOR|Control group|Participants in the control group will receive a self-help booklet designed to promote physical activity among the elderly.
62687484|NCT03725527|ACTIVE_COMPARATOR|Rectus sheath block|Patients will receive ultrasound-guided rectus sheath block' performed after induction of general anesthesia and before surgery.
62687485|NCT03725527|NO_INTERVENTION|control|Patients will receive general anesthesia .
62687486|NCT05438576|EXPERIMENTAL|Intervention|Participants will have ECGs analyzed with artificial intelligence for cardiomyopathy detection.
62687487|NCT05438576|NO_INTERVENTION|Control|Participants will have standard clinical ECGs acquired.
62687488|NCT05406531|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|MBCT-Ca uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
62687489|NCT05406531|EXPERIMENTAL|Positive Psychology - online|Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
62687490|NCT05406531|EXPERIMENTAL|Autogenic Training - online|Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
62687491|NCT05406531|NO_INTERVENTION|Waiting list|No intervention.
62128099|NCT04958343||non-reconstruction group|Patients will not receive pelvic reconstruction following radical cystectomy during the operation.
62128100|NCT01519037|ACTIVE_COMPARATOR|calcimimetic agent (cinacalcet)|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or the placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
62318264|NCT03103269|EXPERIMENTAL|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.~This group does not receive the Challenge! Small Group Intervention.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
62318265|NCT03103269|NO_INTERVENTION|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
62318266|NCT02778048||fecal incontinence patients (m/f)|patients suffering from fecal incontinence (m/f) are going to be assessed via MRI, US, FLIP, and HRAM
62318267|NCT06171880|EXPERIMENTAL|Treatment(Experimental): JLP-1901|Group I(Peroid I-Comparator\[JLP-2008\], Peroid II-Treatment\[JC-001\], Period III-Comparator\[JLP-2008\], Peroid IV-Treatment\[JC-001\]), Group II(Peroid I-Treatment\[JC-001\]Comparator\[JLP-2008\], Peroid II-Comparator\[JLP-2008\], Period III-Treatment\[JC-001\], Peroid IV-Comparator\[JLP-2008\])
62318268|NCT06171880|ACTIVE_COMPARATOR|Control(Active Comparator): JC-001|Group I(Peroid I-Comparator\[JLP-2008\], Peroid II-Treatment\[JC-001\], Period III-Comparator\[JLP-2008\], Peroid IV-Treatment\[JC-001\]), Group II(Peroid I-Treatment\[JC-001\]Comparator\[JLP-2008\], Peroid II-Comparator\[JLP-2008\], Period III-Treatment\[JC-001\], Peroid IV-Comparator\[JLP-2008\])
62318269|NCT03102736|PLACEBO_COMPARATOR|Placebo and Ketamine|Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes
62687492|NCT04859686|EXPERIMENTAL|Treatment|Participants underwent intervention.
62687493|NCT04859686|NO_INTERVENTION|Waitlist|Participants received no intervention.
62687494|NCT06023498|EXPERIMENTAL|Manual Therapy and Exercise (MTE)|"Participants will be asked to attend 10 sessions of manual therapy that will be administered by a chiropractic physician and will consist of movements designed to enhance flexibility and muscle health. Session will last \~ 20 minutes.~The home exercise program (HEP) will consist of a light aerobic program (either walking with the lumbar spine in slight flexion while supported by a wheeled walker, going up and down a flight of stairs, using a treadmill, or using an exercise bicycle), neural mobilization self-stretches, individualized muscular stretches and core strengthening exercises. Participants will be encouraged to do the HEP 1-2 times per day, starting with 5 minutes and working up to 30 minutes.~During the subsequent 6 months, there will be no additional treatment administered. Participants will be asked to continue their HEP."
62687495|NCT06023498|EXPERIMENTAL|MTE Plus MTE Boosters|"Participants will be asked to attend 10 sessions of manual therapy that will be administered by a chiropractic physician and will consist of movements designed to enhance flexibility and muscle health. Session will last \~ 20 minutes.~The home exercise program (HEP) will consist of a light aerobic program (either walking with the lumbar spine in slight flexion while supported by a wheeled walker, going up and down a flight of stairs, using a treadmill, or using an exercise bicycle), neural mobilization self-stretches, individualized muscular stretches and core strengthening exercises. Participants will be encouraged to do the HEP 1-2 times per day, starting with 5 minutes and working up to 30 minutes.~During the subsequent 6 months, participants will be asked to return for monthly MTE booster sessions, and they will be asked to continue their HEP."
62128101|NCT01519037|PLACEBO_COMPARATOR|Placebo|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
62687496|NCT06023498|EXPERIMENTAL|MTE and Intramuscular Electroacupuncture (IMEA) Plus MTE and IM Boosters|"Participants will be asked to attend 10 sessions of manual therapy that will be administered by a chiropractic physician and will consist of movements designed to enhance flexibility and muscle health. Session will last \~ 20 minutes.~Participants also will be asked to attend weekly intramuscular electroacupuncture (IMEA) sessions administered by a licensed acupuncturist. 30-gauge acupuncture needles will be placed in the muscles of the lower back and buttocks and gentle pulsing electrical stimulation will be delivered for 20 minutes.~The home exercise program (HEP) will be identical to that in the MTE and the MTE + Boosters groups.~During the subsequent 6 months, participants will be asked to return for monthly MTE and IMEA boosters. Participants also will be asked to continue their HEP."
62687497|NCT06638593|EXPERIMENTAL|Arm 1: MIRRORS-FROZEN Protocol.|Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.
62687498|NCT06638593|ACTIVE_COMPARATOR|Arm 2 : Standard open surgery.|A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
61925158|NCT01402895|ACTIVE_COMPARATOR|Exercise|The physiotherapist will teach the participant how to tighten the transversus abdominus muscle. The participant will be asked to do a series of these exercises.
61925159|NCT06260761|EXPERIMENTAL|MIPO|isolated close fracture of distal end radius
62128102|NCT03844269|EXPERIMENTAL|AKL-T01|
62128103|NCT03433586|PLACEBO_COMPARATOR|Placebo|Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days
62128104|NCT03433586|ACTIVE_COMPARATOR|Aspirin|Aspirin (81mg) will be taken orally daily for 10-14 days.
62318270|NCT03102736|EXPERIMENTAL|Nitroprusside and Ketamine|0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)
61925160|NCT06260761|ACTIVE_COMPARATOR|Conventional|isolated close fracture of distal end radius
61925161|NCT04658173|EXPERIMENTAL|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
62318271|NCT04305093||Precision Analytical patients|Individuals who had laboratory work completed at Precision Analytical and completed the associated questionnaire on symptoms and comorbidities.
62687499|NCT03854149||Adults with CHD & non-valvular atrial arrhythmias|Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)
62687500|NCT02719730|EXPERIMENTAL|Reimbursement arm|Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
62687501|NCT02719730|NO_INTERVENTION|Control arm|Participating caregivers will mail in receipts from grocery store purchases. Participants in the control arm will also be given the same guidance about preferred whole grain foods and whole grain products but will have no specific financial incentive related to purchases of whole grain foods during the 12-week study period.
62687502|NCT03442972|EXPERIMENTAL|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
61925162|NCT04658173|ACTIVE_COMPARATOR|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1.5 to 2mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
62687503|NCT03442972|PLACEBO_COMPARATOR|Placebo|Placebo, subcutaneous, single dose
62687504|NCT01260311||Patients prescribed with Fesoterodine|Patients diagnosed with Over-active bladder and prescribed with fesoterodine.
62687505|NCT00506311|EXPERIMENTAL|Fibrin Sealant|
62687506|NCT00506311|NO_INTERVENTION|No Fibrin Sealant|
62687507|NCT04231019||Dental practitioners (general, specialists or students)|Two self-administered questionnaires will be used in the study one to general practitioners and specialists and another one with a plain language describing the study will be distributed to the fifth year dental students in Egypt with total 1000 dentist to assess their knowledge, awareness and perception regarding MIH.
62318272|NCT00604448|EXPERIMENTAL|Pulse group|a group receiving a meal with pulses (5 cups/week) for 8 weeks
62318273|NCT00604448|EXPERIMENTAL|Energy-restricted group|a group with a diet restriction of 500 kcal/day for 8 weeks
62318274|NCT05891743||Epoxy_Group|Workers who are exposed to epoxy handling procedures, specifically filling and lamination tasks performed by production workers, mainly in finishing areas.
62318275|NCT05891743||Non_exposed|Workers from other areas unrelated to epoxy handling procedures, that will be included in the study as the non-exposed control group.
62318276|NCT05673135|OTHER|Non-obese hypertensive pregnant women|
62318277|NCT05673135|OTHER|Obese hypertensive pregnant women|
62128105|NCT04357951|EXPERIMENTAL|Behavior Therapy + DCS|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the d-cycloserine pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
62128106|NCT04357951|ACTIVE_COMPARATOR|Behavior Therapy + Placebo|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the placebo pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
62128107|NCT03482011|EXPERIMENTAL|Mirikizumab|"Induction Period:~Participants received 250 milligrams (mg) mirikizumab administered subcutaneously (SC) every 4 weeks (Q4W).~Maintenance Period:~Participants received one of the four options below:~Placebo administered SC every 8 weeks (Q8W) for responders (≥PASI 90).~125 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for non-responders (\<PASI 90)."
62687508|NCT06197802||Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group|Subjects would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli)
62687509|NCT06197802||Gardasil®9 group|Subjects would receive 3 doses of 270μg/0.5ml Gardasil®9
62687510|NCT03386058|EXPERIMENTAL|Intervention|Temporary device deactivation
62687511|NCT02356653|EXPERIMENTAL|Expanded access to CliniMACs device for T cell depletion|access for patients who lack a fully HLA matched sibling, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-open protocols that utilize CliniMACs technology for T depletion. Subjects will undergo transplant of stem cells with CD3+/CD19+ depletion.
62687512|NCT01177358|EXPERIMENTAL|Botulinum Toxin A injection|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 Units (0.1 mL) of Botulinum Toxin A will be injected at three sites along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy."
62128108|NCT03482011|PLACEBO_COMPARATOR|Placebo|"Induction Period: Participants received placebo administered SC Q4W.~Maintenance Period:~Participants received one of the two options below:~Placebo administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q4W during week 16 to week 32 and Q8W during week 40 and 48 for non-responders (\< PASI 90)."
62128109|NCT04630600|OTHER|Control|Normal waiting room
62128110|NCT04630600|EXPERIMENTAL|Intervention#1|Waiting room with partially-equipped aquarium (without fish)
62128111|NCT04630600|EXPERIMENTAL|Intervention#2|Waiting room with fully-equipped aquarium (with fish)
62479816|NCT04496349|EXPERIMENTAL|APG-115 + APG-2575 combination dose escalation part|APG-115 is given in combination with APG-2575
62687513|NCT01177358|PLACEBO_COMPARATOR|Saline|0.1 mL of normal saline in a placebo vial containing 2 mL of normal saline will be injected along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy.
62687514|NCT05555693||Patients in the control group were followed up without POCD postoperatively.|If the MOCA or MMSE assessment all show a negative resluts at all time point.
62128112|NCT02304055|ACTIVE_COMPARATOR|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
62128113|NCT02304055|ACTIVE_COMPARATOR|Oxytocin|100 women with atonic PPH will receive oxytocin 5IU slowly iv.
62318278|NCT06440590|ACTIVE_COMPARATOR|supra-pectineal quadrilateral buttress plating|Patients treated by supra-pectineal quadrilateral buttress plating through anterior intrapelvic approach
62479817|NCT04496349|EXPERIMENTAL|APG-115 + APG-2575 combination dose expansion part|APG-115 is given in combination with APG-2575
62687515|NCT05555693||Patients in the case group were followed up with POCD postoperatively.|If the MOCA assessment is positive at any time point after surgery, and there is a positive MMSE at any time point after surgery(no need for both MOCA and MMSE to be positive at the same time
62687516|NCT06241014|EXPERIMENTAL|Group A: Group A will be treated with mulligan mobilizations and Sling exercises.|Group A: In this group, Subjects will be treated with Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times, having two sessions per week for 3 weeks. The sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day.
62687517|NCT06241014|ACTIVE_COMPARATOR|Group B: Group B will be treated with mulligan mobilizations alone.|Group B: In this group, Subjects will be treated with Mulligan mobilizations and sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated a total of six times, having two sessions per week for 3 weeks.
62687518|NCT00371163||Contact Dermatitis|Males or females with contact dermatitis
62687519|NCT00371163||Psoriasis|Males or females with psoriasis
62687520|NCT00371163||No skin disease|Males or females with no skin diseases
62687521|NCT00371163||Atopic Dermatitis|Males of females with atopic dermatitis
62687522|NCT06611813|EXPERIMENTAL|Neoadjuvant Chemotherapy in Combination with Toripalimab|"Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide+ 240 mg Toripalimab, starting from the first day of the week, for a total of 12 weeks.~Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks + 240 mg Toripalimab for a total of the following 12 weeks."
62687523|NCT03882801|EXPERIMENTAL|Sequence 1: Placebo -> Gefapixant|In Period 1, participants receive a single oral dose of placebo matching gefapixant (MK-7264) every night at bedtime (QHS), for 7 days. In Period 2, participants receive a single oral dose of gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
62687524|NCT03882801|EXPERIMENTAL|Sequence 2: Gefapixant -> Placebo|In Period 1, participants receive a single oral dose of gefapixant (MK-7264) QHS for 7 days. In Period 2, participants receive a single oral dose of placebo matching gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
62687525|NCT03288935|ACTIVE_COMPARATOR|Group 1 (TICM only)|Assigned to TICM group after reception \& placement.
62687526|NCT03288935|ACTIVE_COMPARATOR|Group 2 (TICO only)|Assigned to TICO group after reception \& placement.
62687527|NCT03288935|ACTIVE_COMPARATOR|Group 3 (TICM & TICO)|Assigned to both TICM and TICO group after reception \& placement.
62687528|NCT03288935|NO_INTERVENTION|Group 4 (None)|No additional intervention after reception \& placement
62687529|NCT05169957|EXPERIMENTAL|Ipilimumab + Nivolumab + Stereotactic Body Radiation Therapy (SBRT)|Liver SBRT following the second cycle of ipilimumab + nivolumab, which will then be continued up to 4 total cycles prior to subsequent maintenance nivolumab for duration of clinical benefit and tolerance (standard of care systemic therapy)
62687530|NCT04488887||Diabetic retinopathy Group|Patients with non-proliferative and proliferative diabetic retinopathy with clear media will be recruited.
62687531|NCT04488887||Myopia Group|Patients with different grades of myopia, with accurate segmentation will be recruited
62128114|NCT01078116||Patients with Rheumatoid Arthritis|Eligible rheumatoid arthritis patients treated with adalimumab according to the approved Summary of Product Characteristics (SmPC) in European Union
62128115|NCT01420549|EXPERIMENTAL|Rosuvastatin + Ezetimibe|Participants received Rosuvastatin 10 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was \<100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Rosuvastatin 20 mg+ Ezetimibe 10mg tablet orally once daily for more 4 weeks.
62479818|NCT06601933|PLACEBO_COMPARATOR|Control|"This sample will receive health education. The participant will read chapters from the book, Living a Healthy Life with chronic conditions, 5th edition, by K Lorig, D Laurent, V Gonzalez, D Sobel, M Minor and M Gecht-Silver, and review chapters with the unblinded study coordinator."
62687532|NCT04488887||Choroidal neovascularization group|Patients with active choroidal vascularization without scarring will be recruited
62687533|NCT04488887||Healthy controls|Healthy individuals without retinal disorders will be included for comaprison
62687534|NCT02349477|EXPERIMENTAL|Gabapentin|Gabapentin up to 1200 mg per day in 3 divided doses
62687535|NCT02349477|PLACEBO_COMPARATOR|placebo|matching placebo
62687536|NCT02618811||Group 1|not sarcopenic
62687537|NCT02618811||Group 2|sarcopenic
62687538|NCT02618811||Group 3|not myosteatotic
62687539|NCT02618811||Group 4|myosteatotic
62318279|NCT06440590|ACTIVE_COMPARATOR|Infrapectineal plating|Patients treated by infra-pectineal conventional plating applied on the medial wall through anterior intrapelvic approach
62687540|NCT00680914|EXPERIMENTAL|Synflorix Group|Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
62687541|NCT00680914|ACTIVE_COMPARATOR|Prevenar Group|Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
62687542|NCT06682273|EXPERIMENTAL|TEA + AA|Thread-embedding acupuncture (TEA) every week in 4 weeks (4 sessions). Combined with auricular acupuncture (AA) every week in 4 weeks (4 sessions).
62318280|NCT04944979|EXPERIMENTAL|Experimental: Kedrion IVIG 10%|Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
62318281|NCT00593086|ACTIVE_COMPARATOR|A|Standard of care pain management
62318282|NCT00593086|EXPERIMENTAL|B|SnoWorld Virtual Reality Game
62318283|NCT05470582|EXPERIMENTAL|Flu-M, children aged 3-9 years|
62318284|NCT05470582|ACTIVE_COMPARATOR|Vaxigrip, children aged 3-9 years|
62318285|NCT05470582|EXPERIMENTAL|Flu-M, children aged 6-35 months|
62318286|NCT05470582|ACTIVE_COMPARATOR|Vaxigrip, children aged 6-35 months|
62318287|NCT06157697|NO_INTERVENTION|Control Group|Only educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided.
62318288|NCT06157697|EXPERIMENTAL|Intervention Group 1 - Non-Conditional Social Transfer|"Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice - which is meant to show our appreciation and support for their efforts in breastfeeding.~Intervention: Behavioral: Social Transfer"
62318289|NCT06157697|EXPERIMENTAL|Intervention Group 2 - Conditional Social Transfer|"Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice if they are still exclusively breastfeeding.~Intervention: Behavioral: Social Transfer"
62318290|NCT02296840|EXPERIMENTAL|Ibuprofen|After undergoing adenotonsillectomy, patients who are randomized into the test intervention arm will receive ibuprofen (10mg/kg/day every 6-8 hours) after surgery.
62318291|NCT02296840|ACTIVE_COMPARATOR|Hydrocodone-acetaminophen (Control)|After undergoing adenotonsillectomy, patients who are randomized into the control intervention will receive hydrocodone-acetaminophen (0.15mg/kg/day every 4-6 hours).
62318292|NCT03962998|ACTIVE_COMPARATOR|Lactulose/Rhamnose|1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution
62318293|NCT03962998|EXPERIMENTAL|MB-102|4 μmol of MB-102/kg body weight administered orally as a solution
62318294|NCT05715086|ACTIVE_COMPARATOR|Group A (Upfront ureteroscopy)|
62318295|NCT05715086|NO_INTERVENTION|Group B (Observation/delayed ureteroscopy)|
62318296|NCT04673409||Suspected myocarditis of undefined aetiology|Patients with signs and symptoms of acute myocarditis (as defined by the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases).
62318297|NCT04673409||Suspected myocarditis with autoimmune rheumatic disease|Patients with suspected myocarditis due to an underlying AIRD.
62687543|NCT06682273|ACTIVE_COMPARATOR|TEA + sham AA|Thread-embedding acupuncture (TEA) every week in 4 weeks (4 sessions). Combined with sham auricular acupuncture (sham AA) every week in 4 weeks (4 sessions).
62318298|NCT06224543|ACTIVE_COMPARATOR|Group A (10% dose GV)|Each participant will receive a Standard dose gadobutrol (0.1 mmol/kg) in Period 1 and 10% dose gadobutrol (0.01 mmol/kg) in Period 2. During study Period 1, each participant will receive gadobutrol as a single intravenous (IV) administration at the standard dose for contrast-enhanced MRI followed by study Period 2 where a single IV low dose (10% dose) of gadobutrol will be administered. There will be a washout period of at least 72 hours but less than 15 days between the two periods. The individual study duration will therefore range from 4 to 15 days.
62318299|NCT06224543|ACTIVE_COMPARATOR|Group B (25% dose GV)|Each participant will receive a Standard dose gadobutrol (0.1 mmol/kg) in Period 1 and Study Period 2: 25% dose gadobutrol (0.025 mmol/kg) in Period 2. During study Period 1, each participant will receive gadobutrol as a single intravenous (IV) administration at the standard dose for contrast-enhanced MRI followed by study Period 2 where a single IV low dose (25% dose) of gadobutrol will be administered. There will be a washout period of at least 72 hours but less than 15 days between the two periods. The individual study duration will therefore range from 4 to 15 days.
62318300|NCT01157858|ACTIVE_COMPARATOR|Everolimus + octreotide LAR|Octreotide LAR combined with everolimus
62318301|NCT01157858|ACTIVE_COMPARATOR|Octreotide LAR|Octreotide LAR monotherapy
62318302|NCT02091622|OTHER|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
62318303|NCT02091622|NO_INTERVENTION|No intervention|No intervention.
62318304|NCT05224622|EXPERIMENTAL|Drive In|Drive In attendees will undergo one breath sampling.
62318305|NCT05224622|EXPERIMENTAL|Healthy|Healthy attendees will undergo two successive breath sampling.
62318306|NCT05224622|EXPERIMENTAL|Corona Department|Healthy attendees will undergo five successive breath sampling.
62318307|NCT02033551|EXPERIMENTAL|Arm A - Veliparib Monotherapy|Subjects in this arm will be dosed with Veliparib continuous dosing.
62687544|NCT06682273|ACTIVE_COMPARATOR|AA + sham TEA|Auricular acupuncture (AA) every week in 4 weeks (4 sessions). Combined with sham thread-embedding acupuncture (sham TEA) every week in 4 weeks (4 sessions).
62687545|NCT06682273|SHAM_COMPARATOR|Sham both|Sham thread-embedding acupuncture (sham TEA) every week in 4 weeks (4 sessions). Combined with sham auricular acupuncture (sham AA) every week in 4 weeks (4 sessions).
62687546|NCT03707340||Breast Cancer Pts with hyposexual desire disorder/HSDD|
62687547|NCT06467058|OTHER|Adults|"In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package."
62687548|NCT03662373||carbon ions radiation therapy|the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
62687549|NCT03662373||protons radiation therapy|the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
62687550|NCT00004228|EXPERIMENTAL|A0 (localized disease Stg I/II) Modified CCG BFM|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Doxorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Methotrexate, Intrathecal Methotrexate)
62479819|NCT06601933|ACTIVE_COMPARATOR|Low Dose Crossword|This sample will receive low dose crossword training with one crossword puzzle per week during the first 12 weeks on the Cognifit web-based platform. Subsequent booster sessions will occur at 20, 32, 42, 52, 64 and 78 weeks.
62479820|NCT06601933|ACTIVE_COMPARATOR|High Dose Crossword|This sample will receive high dose crossword training. This sample will receive high dose crossword training with four crossword puzzles per week during the first 12 weeks on the Cognifit web-based platform, followed by booster sessions at 20, 32, 42, 52, 64 and 78 weeks.
62479821|NCT05449743|EXPERIMENTAL|patient treated with a phlebology-oriented spa therapy|Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
62687551|NCT00004228|EXPERIMENTAL|A1 (Disseminated, No CNS - CCG mod BFM w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, prednisone, Methotrexate, Intrathecal Methotrexate)
62687552|NCT00004228|EXPERIMENTAL|A2 (Disseminated, No CNS - CCG mod BFM w/ intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
62128116|NCT01420549|ACTIVE_COMPARATOR|Simvastatin + Ezetimibe|Participants received Simvastatin 20 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was \<100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Simvastatin 40 mg + Ezetimibe 10mg tablet orally once daily for more 4 weeks.
62479822|NCT06004895|EXPERIMENTAL|Actual IPL and LLLT|IPL and LLLT will be administered using the Espansione Group Ltd Eye-light unit. Five pulses of IPL will be administered along the lower lid region of the eye after the Pult meiboscore and Fitzpatrick skin grading has been entered into the unit. LLLT consisting of a wearable facial mask with red LEDs is then administered for 15 minutes.
62479823|NCT06004895|SHAM_COMPARATOR|Sham IPL and LLLT|Sham IPL will be administered by placing a separate empty IPL cartridge on the lower eyelid regions of the patient's other eye while a working IPL cartridge (Espansione Group Ltd Eye-light unit) simulates a light pulse pointed away from the patient's face, after entering the Pult meiboscore and Fitzpatrick skin grading into the unit. Five simulated pulses will be administered. LLLT consisting of a wearable facial mask with red LEDs is then administered for 15 minutes.
62128117|NCT03643939|EXPERIMENTAL|High Flow Nasal Catheter|The HFNC (AIRVO2 Fisher \& Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
62479824|NCT06674577|EXPERIMENTAL|Atacicept 150mg once weekly subcutaneous (SC) injection|"Other Names:~VT-001"
62479825|NCT04625205|EXPERIMENTAL|Part 1 dose finding phase: NEO-PTC-01 Dose 1|Monotherapy - Dose 1
62479826|NCT04625205|EXPERIMENTAL|Part 1 dose finding phase: NEO-PTC-01 Dose 2|Monotherapy - Dose 2
62479827|NCT04625205|EXPERIMENTAL|Part 1 dose finding phase: NEO-PTC-01 plus IL-2|NEO-PTC-01 in combination with a fixed dose of IL-2 (cohort will only be open in countries where IL-2 is approved)
62479828|NCT04625205|EXPERIMENTAL|Part 1 dose finding phase: NEO-PTC-01 plus PD-1 inhibitor|The PD-1 inhibitor therapy will be introduced, beginning 1 to 2 weeks post NEO-PTC-01, to patients who failed PD-1/PD-L1 inhibitor therapy prior to enrollment to the NTC-001 study
62687553|NCT00004228|EXPERIMENTAL|B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
62479829|NCT04625205|EXPERIMENTAL|Part 2 dose expansion phase: NEO-PTC-01|Patients currently receiving PD-1/PD-L1 inhibitors (as single agent or in combination with CTLA4 inhibitors) as therapy for metastatic melanoma
62687554|NCT00004228|EXPERIMENTAL|B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
62687555|NCT00004228|EXPERIMENTAL|B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
62128118|NCT03643939|ACTIVE_COMPARATOR|Non-invasive positive pressure ventilation|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.
62128119|NCT01295697|EXPERIMENTAL|EZN-2208|Cytotoxic Agent
62128120|NCT04773678|EXPERIMENTAL|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
62128121|NCT04773678|EXPERIMENTAL|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
62128122|NCT04773678|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous (SC) injection.
62128123|NCT03278379|EXPERIMENTAL|Intervention Arm|Treatment with Avelumab
62128124|NCT03143842|OTHER|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
62128125|NCT02833506|ACTIVE_COMPARATOR|Cohort I (NY-ESO-1 protein with MIS416)|Patients receive NY-ESO-1 protein with MIS416 vaccine SC on days 1, 15, 29, 57, 85, and 113 in the absence of disease progression or toxicity.
62128126|NCT02833506|EXPERIMENTAL|Cohort II (NY-ESO-1 protein with MIS416, sirolimus)|Patients receive NY-ESO-1 protein with MIS416 vaccine as in Cohort I. Patients also receive sirolimus PO daily for 2 weeks followed by 2 weeks off starting on days 1, 29, 57, and 85.
62128127|NCT04115683|EXPERIMENTAL|Intervention Group|
62479830|NCT03292484|EXPERIMENTAL|AR101|Eligible participants who participated in a prior AR101 study received or continued initial dose escalation, up-dosing, and maintenance of AR101 at 300 milligrams (mg) per day until discontinuation criteria was met (maximum exposure: 4.8 years).
62128128|NCT04115683|ACTIVE_COMPARATOR|Control Group|
62128129|NCT02935998|EXPERIMENTAL|ziprasidone|The injection mesylate ziprasidone used in this study have been marketed, manufactured by Pfizer and provided study drug for research purposes.Strength:Each vial contains Ziprasidone 30 mg, Sulfobutyl betadex sodium 441 mg. When reconstituted as directed the solution for injection contains the equivalent of 20 mg per mL of Ziprasidone.The initial dosage of ziprasidone injection：Most patients are suggested with 20mg i.m. Those with first-episode, lower age, emaciated body, or BARS score at 5 are suggest with 10mg i.m. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
62128130|NCT03462823|ACTIVE_COMPARATOR|Control treatment|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
62128131|NCT03462823|EXPERIMENTAL|Experimental treatment|ACL-reconstruction using hamstring autograft with hybrid fixation combined with the osteoconductive device under study.
62128132|NCT05707624|EXPERIMENTAL|experimental|"During the process; Phone numbers were obtained and recorded at the first meeting with the parents. The link of the first two training videos was sent to the smartphones of the participants at the same time. Parents are explained how to access the videos from the link. Afterwards, other training videos, prepared once a week and as 2 videos, were sent to the parents' smartphones on a regular basis.~After the procedure; Participants were contacted by phone 2 weeks after the last videos were watched. They were asked to fill out and send the questionnaire and scale online sent to their phones."
62318308|NCT02033551|EXPERIMENTAL|Arm B - Veliparib in Combination with Carboplatin & Paclitaxel|Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy.
61925163|NCT05959603|NO_INTERVENTION|Standard of care|2 g of IV cefazolin will be administered within 60 minutes before surgical incision (3 g for pts weighing ≥120 kg), repeated dose in the operating room every four hours (allergic patients will receive 900 mg of clindamycin within 60 minutes which will be repeated every six hours or 15 mg/kg of vancomycin once within two hours before incision).
61925164|NCT05959603|EXPERIMENTAL|Intervention group: 500 mg vancomycin|Patients will receive 500 mg of powdered vancomycin to the surgical site in addition to standard of care IV prophylaxis
61925165|NCT05959603|EXPERIMENTAL|Intervention group: 1 g vancomycin|Patients will receive one gram of powdered vancomycin to the surgical site in addition to standard of care IV prophylaxis
61925166|NCT00218725|OTHER|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
61925167|NCT00218725|OTHER|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
61925168|NCT04623385|ACTIVE_COMPARATOR|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
61925169|NCT04623385|SHAM_COMPARATOR|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
61925170|NCT01898494|EXPERIMENTAL|Arm S (Surgery) then Arm A (Low risk, observation)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, low risk patients are under observation.
61925171|NCT01898494|EXPERIMENTAL|Arm S (Surgery) then Arm B (Intermediate risk, low-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive low-dose IMRT (50 Gy) QD five days a week for 5 weeks.
61925172|NCT01898494|EXPERIMENTAL|Arm S (Surgery) then Arm C (Intermediate risk, standard-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive standard-dose IMRT (60 Gy) QD five days a week for 6 weeks.
61925173|NCT01898494|EXPERIMENTAL|Arm S (Surgery) then Arm D (High risk, IMRT, chemotherapy)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, high risk patients then receive IMRT (66Gy) QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
61925174|NCT00430651|EXPERIMENTAL|1|Docetaxel + Carboplatin
61925175|NCT00430651|EXPERIMENTAL|2|Docetaxel
61925176|NCT01455467|ACTIVE_COMPARATOR|One iStent|Implantation of one iStent in conjunction with cataract surgery
61925177|NCT01455467|ACTIVE_COMPARATOR|Two iStent|Implantation of two iStent devices in conjunction with cataract surgery
62738094|NCT01775163||High Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 20 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
61925178|NCT01991106|EXPERIMENTAL|High intensity interval training|10-minute warm up at 60-70% of maximal heart rate (HRmax). Then walking, running or cycling at 85-95% of maximal heart rate at intervals of 4 x 4 minutes, with 3 minute active breaks (50-70% of HRmax) between intervals. A 5-minute cool down period.
61925179|NCT01991106|EXPERIMENTAL|Moderate intensity continuous training|walking, running or cycling continuously at 60-70% HRmax for 44 minutes.
62318309|NCT02033551|EXPERIMENTAL|Arm C Veliparib in Combination with Modified FOLFIRI|Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy.
62318310|NCT03378401|EXPERIMENTAL|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
62318311|NCT03378401|PLACEBO_COMPARATOR|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
62318312|NCT05164952|EXPERIMENTAL|Delayed use of zoledronic acid arm|delayed-ZOL patients will receive ZOL only if their T-score fall below -2.0, after a nontraumatic clinical fracture, or if an asymptomatic fracture will be detected by spinal X-ray at the 3- monthly assessment.
62318313|NCT05164952|EXPERIMENTAL|Immediate use of zoledronic acid arm|Immediate-ZOL patients will receive ZOL immediately after randomization
62318314|NCT06255990||NovoSorb® BTM and STSG|Full thickness skin defect qualifying for coverage with the dermal substitute NovoSorb® BTM before transplantation with a split-thickness skin graft (STSG) according to clinical routine
62128133|NCT05707624|PLACEBO_COMPARATOR|Control group|"During the process; The phone number obtained from the parents was recorded and no other application was made other than the routine procedure of the clinic. Parents were not contacted in the following weeks.~After the procedure; The control group was also reached via telephone 2 weeks after the video submission to the intervention group was completed. They were asked to fill out and send the questionnaire and scale online sent to their phones."
62128134|NCT05004597|EXPERIMENTAL|infants longitudinally received three dimensional photo|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months
62318315|NCT06255990||STSG alone|Full thickness skin defect qualifying for coverage with split-thickness skin graft (STSG) alone according to clinical routine
62318316|NCT06254469|OTHER|Part A - Lead in|Part A plans to enroll 50 participants (approximately 20 participants with mild cognitive impairment \[MCI\] due to suspected CTE, 20 participants with MCI due to suspected AD, and 10 age-matched healthy volunteers, whose age is within 3 years of any participants with MCI due to suspected CTE or AD in Part A).
62128135|NCT02740400|EXPERIMENTAL|CT-TTNB|patients receive CT-TTNB to diagnose PPLs.
62128136|NCT02740400|EXPERIMENTAL|EBUS-GS|patients receive EBUS-GS to diagnose PPLs.
62318317|NCT06254469|EXPERIMENTAL|Part B - AD|Part B plans to enroll 90 participants with MCI due to suspected AD for primary accuracy assessments of F-18 FNT-PET imaging.
62318318|NCT06254469|EXPERIMENTAL|Part B - CTE|Part B plans to enroll 90 participants with MCI due to suspected CTE from concussive and percussive injuries in approximately 1:1 ratio for primary accuracy assessments of F-18 FNT-PET imaging.
62318319|NCT02275026|EXPERIMENTAL|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
62318320|NCT02137434|PLACEBO_COMPARATOR|Low calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 40 mg of calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
62738095|NCT01766804|EXPERIMENTAL|Bovine colostrum|A daily supplement of bovine colostrum powder.
62738096|NCT01766804|PLACEBO_COMPARATOR|Placebo|A daily placebo supplement consisting of whole milk powder and whey protein.
62738097|NCT06463743|EXPERIMENTAL|metformin|metformin
62738098|NCT06463743|PLACEBO_COMPARATOR|placebo|placebo
62738099|NCT02088879|EXPERIMENTAL|Group1|"* first : chest compression with kneeling position~* second : chst compression with standing position"
62738100|NCT02088879|EXPERIMENTAL|Group2|"* first : chest compression with standing position~* second : chst compression with kneeling position"
62738101|NCT00512850|OTHER|Folic acid|Folic acid supplement 1g/day
62318321|NCT02137434|EXPERIMENTAL|High dietary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of skimmed milk containing 540 mg of dietary calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
62479831|NCT05461768|EXPERIMENTAL|Study treatment|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62687556|NCT00004228|EXPERIMENTAL|B1 (Disseminated CNS-) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
62687557|NCT01442571|EXPERIMENTAL|Hyaluronic Acid Injection, pain, function|
62687558|NCT01442571|PLACEBO_COMPARATOR|Saline Injection|
62687559|NCT06439927|EXPERIMENTAL|Polycaprolactone nasal mesh|
62687560|NCT02831335||Group 1|normal 21-35 years old participants
62687561|NCT02831335||Group 2|normal 36-50 years old participants
62687562|NCT02831335||Group 3|normal 51-65 years old participants
62687563|NCT02831335||Group 4|normal 66- 80 years old participants
62687564|NCT05554731|EXPERIMENTAL|New balloon catheter for Endotracheal hemostasis + Traditional Therapy|"1. Haemoptysis clinic for regular haemoptysis after treatment and life safety safeguard measures;~2. Balloon closure after informed consent (it can be blocked in emergency);~3. CTA (can be performed as an emergency prior to balloon blockage);~4. Artery interventional therapy (if necessary);~5. Surgery (if needed)."
62687565|NCT05554731|ACTIVE_COMPARATOR|Traditional Therapy|"1. Haemoptysis clinic for regular haemoptysis after treatment and life safety safeguard measures;~2. CTA (can be performed as an emergency prior to balloon blockage);~3. Artery interventional therapy (if necessary);~4. Surgery (if needed)."
62687566|NCT03615274|EXPERIMENTAL|Experimental|Children in the training group must complete home-based executive function training by iPad. At the same time, they are asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
62687567|NCT03615274|ACTIVE_COMPARATOR|Placebo non-adaptive training|Children in the control group must complete cognitive control tasks. They are also asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
62687568|NCT01110512|EXPERIMENTAL|Flavonid|
62687569|NCT01110512|ACTIVE_COMPARATOR|Daflon|
62687570|NCT05848843|EXPERIMENTAL|Dose Confirmation Cohort|
62687571|NCT05848843|EXPERIMENTAL|Dose Expansion Cohort|
61925180|NCT01991106|ACTIVE_COMPARATOR|nutritional advice|10 individual nutrition consultations with an accredited dietitian over the 12 month period. Content of consultations will include healthy food choices, portion sizes and regular mealtimes.
62318322|NCT02137434|EXPERIMENTAL|High supplementary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 540 mg of supplementary calcium from calcium carbonate, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
62479832|NCT03878121|EXPERIMENTAL|A1|Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
62479833|NCT03878121|EXPERIMENTAL|A2|Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
62479834|NCT03878121|EXPERIMENTAL|B1 (exploratory)|Previously vaccinated; Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
62479835|NCT03878121|EXPERIMENTAL|B2 (exploratory)|Previously vaccinated; Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
62687572|NCT01585207|EXPERIMENTAL|Vigabatrin|3 tablets, bid for 8 weeks
62687573|NCT04903769|OTHER|Parkinson's Patients and Caregivers|Will participate in the 8-session SMART-PD program as a participant with Parkinson's disease or as a caregiver of a participant with Parkinson's disease
62687574|NCT01724814|EXPERIMENTAL|Cohort S1|HM12460A Dose 1 (1.2 nmol/kg) or placebo
62687575|NCT01724814|EXPERIMENTAL|Cohort S2|HM12460A Dose 2 (2.4 nmol/kg) or Placebo
62687576|NCT01724814|EXPERIMENTAL|Cohort S3|HM12460A Dose 3 (4.8 nmol/kg) or Placebo
62687577|NCT01724814|EXPERIMENTAL|Cohort S4|HM12460A Dose 4 (9.6 nmol/kg) or Placebo
62687578|NCT01724814|EXPERIMENTAL|Cohort S5|HM12460A Dose 5 (14.4 nmol/kg) or Placebo
62479836|NCT00644137|EXPERIMENTAL|A|pregabalin 300mg/day given in conjunction with smoking cigarettes.
62479837|NCT00644137|EXPERIMENTAL|2|cigarettes given in conjunction with pregabalin
62128137|NCT06024824|EXPERIMENTAL|Radiation; IMRT|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT. Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose\* Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions\* Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions~\* Progression to the next dose in successive cohorts depends on the number of patients experiencing DLTs within 4 weeks post-RT treatment in each patient cohort."
62318323|NCT06044753|NO_INTERVENTION|Control Arm( Arm1)|"Arm1 which is standard care/control group (as per usual practice). May use the distraction, Parental presence, or with musics, soft prep talks, distractions with toys, as per anaesthetist's usual practice.~Patients will receive 100% oxygen of 6 L/min flow for 30 seconds. Nitrous oxide of 2 L/min will be added with ratio oxygen and nitrous oxide of 3:1. Sevoflurane inhalation will be initiated with 4% concentration for 30 seconds, followed by 8%. The induction will be proceeded in usual manner"
62318324|NCT06044753|EXPERIMENTAL|VR ( Virtual Reality) ( Arm2)|"Group 2 patients will choose one of the three YouTube videos, either Frozen theme song, SpongeBob or Minions according to their preference. The selected video will be played on the doctor's handphone and slotted into the VR headset.A handphone playing YouTube videos (either Frozen or SpongeBob or Minions VR cartoons) will be slotted into the VR headset prior to applying on the patient. They will have mask on first followed by the VR headset.~Patients will receive 100% oxygen of 6 L/min flow for 30 seconds. Nitrous oxide of 2 L/min will be added with ratio oxygen and nitrous oxide of 3:1. Sevoflurane inhalation will be initiated with 4% concentration for 30 seconds, followed by 8%. The induction will be proceeded in usual manner"
62318325|NCT01208662|EXPERIMENTAL|RVD Alone|"All participants received one cycle of Lenalidomide (R), bortezomib (V) and dexamethasone (D) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD Alone participants received five additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study. After finishing protocol-specified treatment, off-study salvage transplantation was recommended but not mandated for RVD Alone participants at relapse.~RVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12"
62318326|NCT01208662|ACTIVE_COMPARATOR|RVD plus ASCT|"All participants received one cycle of Lenalidomide (R), bortezomib (V) and dexamethasone (d) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD plus autologous stem cell transplant (ASCT) participants received high-dose melphalan (200 mg/m2, adjusted for ideal body weight) ASCT and, upon recovery (\~day 60), two additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study.~After finishing protocol-specified treatment, RVD plus ASCT participants could undergo a second transplant.~RVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12"
62479838|NCT02082808|EXPERIMENTAL|Sequence 1|Participants will receive the study Treatment A for 5 days (DTG 50mg q24h) in Period 1 followed by a washout period (\>=7days) and Treatment B for 5 days (DCV 60mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
62318327|NCT00657761|PLACEBO_COMPARATOR|Placebo|Saline solution 0.9% sc/12h for 7 days
62479839|NCT02082808|EXPERIMENTAL|Sequence 2|Participants will receive the study Treatment B for 5 days (DCV 60mg q24h) in Period 1 followed by a washout period (\>=7days) and Treatment A for 5 days (DTG 50mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
62318328|NCT00657761|EXPERIMENTAL|Enfuvirtide|Enfuvirtide 90 mg/12h sc for 7 days
62479840|NCT06332430|EXPERIMENTAL|CAN2109|CAN2109 IT injection every three weeks (Q3W)
61925181|NCT01991106|NO_INTERVENTION|non-obese children|100 healthy non-obese children aged 7-16 (controls)
62479841|NCT05942066||Healthy donors|Participants who are in good health and willing to provide a blood sample
62479842|NCT06438315||SuperSaturated Oxygen (SSO2) Therapy|Treated with SSO2
62687579|NCT01724814|EXPERIMENTAL|Cohort S6|HM12460A Dose 6 (19.2 nmol/kg) or Placebo
62128138|NCT04948801||genotype 3a HCV|genotype 3a hepatitis C
62128139|NCT04948801||genotype 6 HCV|genotype 6 hepatitis C
62128140|NCT04948801||genotype 3b HCV|genotype 3b hepatitis C
62318329|NCT02349906|EXPERIMENTAL|Treosulfan|"One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.~The dose has to be calculated as follows:~If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.~If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.~If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day."
62128141|NCT03766971|EXPERIMENTAL|Early-onset Cigarette Smokers|Participants who began smoking cigarettes earlier in life (\<16 years old) will be randomized to 7 or 21 days of tobacco cessation.
62318330|NCT02349906|ACTIVE_COMPARATOR|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
62318331|NCT01618981|EXPERIMENTAL|first active|
62318332|NCT01618981|EXPERIMENTAL|first inactive|
62128142|NCT03766971|EXPERIMENTAL|Late-onset Cigarette Smokers|Participants who began smoking cigarettes later in life (\>16 years old) will be randomized to 7 or 21 days of tobacco cessation.
62128143|NCT04580316|EXPERIMENTAL|Experimental group|75 children were managed during intervention using Parental Active Presence.
62128144|NCT04580316|PLACEBO_COMPARATOR|control group|75 children were managed with passive parent presence.
62318333|NCT00087204|EXPERIMENTAL|Treatment (becatecarin)|Patients receive rebeccamycin analogue (XL119) IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 1 additional course beyond CR. Patients achieving a PR or HI receive 2 additional courses beyond PR or HI. Cohorts of 3-6 patients receive escalating doses of XL119 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
62318334|NCT02062151|EXPERIMENTAL|NAS babies|Acupuncture for NAS
62128145|NCT03565315|EXPERIMENTAL|Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group|10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)
62318335|NCT03313271||a cohort of patients with lymphoma in China|establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time
62318336|NCT01646008||respiratory|
62318337|NCT05312905|ACTIVE_COMPARATOR|Mirror Therapy|Exercises including mirror therapy will be applied to the participants in the Mirror Therapy group. The mirror will be placed in such a way that the affected extremity of the patient could not be seen behind the mirror and the healthy extremity would be in front of his eyes, the patient will perform the exercises indicated by the physiotherapist with his intact extremity, looking into the mirror. The exercises will be performed in sessions lasting 60 minutes, 3 days a week, over 8 weeks.
62128146|NCT03565315|EXPERIMENTAL|Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12\*, Week 24\*)~\*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
62128147|NCT03565315|EXPERIMENTAL|Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group|10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)
62128148|NCT03565315|EXPERIMENTAL|Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12\*, Week 24\*)~\*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
62128149|NCT05518253|EXPERIMENTAL|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
62318338|NCT05312905|EXPERIMENTAL|Mirror+Cognitive Therapy|The participants in the Mirror+Cognitive Therapy will be given a cognitive task with the application of mirror therapy. Cognitive tasks with mirror therapy will be applied in sessions lasting 60 minutes, 3 days a week, over 8 weeks.
62318339|NCT01914445|EXPERIMENTAL|Indigo Carmine|Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
62318340|NCT01157871|EXPERIMENTAL|placebo|4 administrations at 2-week interval of placebo solution
62318341|NCT01157871|EXPERIMENTAL|NV1FGF 16 mg|4 administrations at 2-week interval of 4mg at each administration
62318342|NCT01157871|EXPERIMENTAL|NV1FGF 32 mg|4 administrations at 2-week interval of 8mg at each administration
62318343|NCT03196050|EXPERIMENTAL|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
61925182|NCT02906371|ACTIVE_COMPARATOR|Tocilizumab high tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
62128150|NCT05518253|EXPERIMENTAL|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
62128151|NCT02290067|ACTIVE_COMPARATOR|Omnitest 3|Blood glucose monitoring system
62128152|NCT02290067|EXPERIMENTAL|Omnitest 5|Blood glucose monitoring system
62128153|NCT02290067|EXPERIMENTAL|Omnitest 5D|Blood glucose monitoring system
62128154|NCT01084031|EXPERIMENTAL|propofol|
62128155|NCT04133298|ACTIVE_COMPARATOR|Tunneling with laser de-epithelized gingival graft.|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
61925183|NCT02906371|ACTIVE_COMPARATOR|Tocilizumab low tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
61925184|NCT03903653|ACTIVE_COMPARATOR|Chemodenervation + Serial Casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection and weekly serial casting Intervention = Weekly Serial Casting AND Botulinum Toxin A injection (350-400 units per treated limb)
61925185|NCT03903653|ACTIVE_COMPARATOR|Chemodenervation without serial casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection. Intervention = Botulinum Toxin A injection (350-400 units per treated limb) alone.
61925186|NCT01920555|ACTIVE_COMPARATOR|Ketamine 0.1mg|Patients in this arm will receive 0.1 mg/kg of Ketamine - one single infusion
61925187|NCT01920555|ACTIVE_COMPARATOR|Ketamine 0.2mg|Patients in this arm will receive 0.2 mg/kg of Ketamine - one single infusion
61925188|NCT01920555|ACTIVE_COMPARATOR|Ketamine 0.5mg|Patients in this arm will receive 0.5 mg/kg of Ketamine - one single infusion
61925189|NCT01920555|ACTIVE_COMPARATOR|Ketamine 1.0mg|Patients in this arm will receive 1.0 mg/kg of Ketamine - one single infusion
61925190|NCT01920555|PLACEBO_COMPARATOR|Midazolam (Active Placebo)|Patients in this arm will receive 0.045 mg/kg of midazolam - one single infusion
62128156|NCT04133298|ACTIVE_COMPARATOR|Tunnelingwith subepithelial connective tissue graft.|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid.
62128157|NCT02064959|EXPERIMENTAL|Hypothermia|Hypothermia to 33°C
62128158|NCT02064959|ACTIVE_COMPARATOR|Normothermia|standard care - normothermia (37°C)
62128159|NCT01227278|PLACEBO_COMPARATOR|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
62128160|NCT01227278|EXPERIMENTAL|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
62318344|NCT02860468|EXPERIMENTAL|Cranberry juice consumption|participants in this arm will be provided cranberry juice to consume for 21 days in total
62318345|NCT02860468|PLACEBO_COMPARATOR|Placebo juice consumption|participants in this arm will be provided placebo juice to consume for 21 days in total
62318346|NCT02339025||Tricare Participants|From WRNMC
62318347|NCT04907604|OTHER|First intervention group|Clusters 1 and 2 (group 1) will start the intervention at month 1, immediately after completing the baseline assessment. After 7 weeks of using the app and having access to the EMPOWER website (with material related to the anti-stigma campaign and recommendations for employees to deal with psychosocial risk factors), they will answer a post-treatment assessment protocol through the app.
62318348|NCT04907604|OTHER|Second intervention group|Clusters 3 and 4 (group 2) that serve as control group of cluster 1 and 2 (group 1), will also complete the assessment at T1. Clusters 3 and 4 (group 2) will start the intervention in step 2, after completing the second assessment.
62318349|NCT04907604|OTHER|Third intervention group|Clusters 5 and 6 (group 3), that serve as control group of group 1 and 2, will also complete the assessment at T2. Clusters 5 and 6 (group 3) will start the intervention in step 3. All clusters will answer a total of five assessments
62318350|NCT02619240||patients suspected of TB|patients suspected of TB requiring to undergo bronchoscopy as part of the investigation
62318351|NCT02286011|EXPERIMENTAL|MNC (Mononuclear cells)|"All patients included in the clinical trial will receive an intramuscular infusion of autologous mononuclear cells (MNC) of Bone Marrow (BM) in TA muscle of one of the lower limb (experimental group). The lower limb on the CMN infuse autologous BM will be determined randomly.~The average dose is 550 millions of cells (100-1200 million) diluted in 2 ml. saline"
62318352|NCT02286011|PLACEBO_COMPARATOR|Saline|All patients included in the clinical trial will receive an intramuscular infusion of 2 mL of saline (placebo) in the TA muscle of the contralateral limb (group control).
62318353|NCT06671327|EXPERIMENTAL|Dexmedetomidine group|The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.
62318354|NCT06671327|PLACEBO_COMPARATOR|Placebo group|the Placebo group was infused with equal amounts of isochronous Sodium Chloride 0.9%
62128161|NCT04421261||Air-Q Self Pressurized Airway Device with Blocker|
62128162|NCT04421261||Proseal Laryngeal Mask Airway|
62128163|NCT02701257|ACTIVE_COMPARATOR|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
62128164|NCT02701257|EXPERIMENTAL|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
62128165|NCT02701257|EXPERIMENTAL|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
62128166|NCT02701257|EXPERIMENTAL|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
62128167|NCT02701257|ACTIVE_COMPARATOR|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
62128168|NCT05710575|EXPERIMENTAL|probiotic group|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
62128169|NCT05710575|EXPERIMENTAL|placebo group|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
62687580|NCT06687304|ACTIVE_COMPARATOR|Enhanced light environment|
62687581|NCT06687304|NO_INTERVENTION|Non-enhanced light environment|
62687582|NCT00903344|EXPERIMENTAL|Vitamin D|4000IU Vitamin D3 in tablet taken daily with multivitamin
62687583|NCT00903344|ACTIVE_COMPARATOR|Multivitamin|Multivitamin with 400IU vitamin D tablet
62687584|NCT06673836|EXPERIMENTAL|dynamic cycling|one group will perform dynamic cycling for 6 consecutive weeks,3 days a week for 30 minutes per session.
62318355|NCT05716607|EXPERIMENTAL|Once-daily dual-release hydrocortisone|
62318356|NCT05716607|ACTIVE_COMPARATOR|Thrice-daily conventional immediate-release hydrocortisone|
62318357|NCT04338022|EXPERIMENTAL|Evobrutinib + Teriflunomide matched Placebo: DB Period|
62318358|NCT04338022|ACTIVE_COMPARATOR|Teriflunomide + Evobrutinib matched Placebo: DB Period|
62318359|NCT01729364|EXPERIMENTAL|crystalloid|crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes
62318360|NCT01729364|EXPERIMENTAL|colloid|colloidal fluids administration, HES 6% (130/0,4) 7ml/kg under 30 minutes
62318361|NCT00832715|EXPERIMENTAL|EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA)
62318362|NCT04303390|ACTIVE_COMPARATOR|24 hour Cefuroxime arm|25% of the entire study participants are assigned to 24 hours and second generation cephalosporin
62687585|NCT06673836|EXPERIMENTAL|inclined treadmill|one group will perform treadmil for 3 days a week with 10 degree inclination for 6 six consecutive weeks.
62687586|NCT05284071|EXPERIMENTAL|Experimental: Single-Arm|This is a prospective, single-arm, post-market study to verify clinical performance, treatment satisfaction and adherence, and safety of Actiste 1.0 (Actiste) and the Companion app with TBL Backend when used as intended by subjects diagnosed with T1DM or T2DM.
62687587|NCT06675240|EXPERIMENTAL|MediNF|Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
62687588|NCT04670315||Single Group|Scale validation in stroke patients
62687589|NCT01922895|PLACEBO_COMPARATOR|Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
62687590|NCT01922895|ACTIVE_COMPARATOR|Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
62687591|NCT04938843|EXPERIMENTAL|F. prausnitzii and D. piger|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
62687592|NCT04938843|PLACEBO_COMPARATOR|Placebo|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
62687593|NCT00997659|EXPERIMENTAL|chromium picolinate|
62687594|NCT03791060|EXPERIMENTAL|Secukinumab Subcutaneous Injection|"300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks.~Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks."
62687595|NCT05702489|EXPERIMENTAL|ZX-7101A low dose group|40 mg, tablet, single oral administration when the subject screened successfully
62687596|NCT05702489|EXPERIMENTAL|ZX-7101A high dose group|80 mg, tablet, single oral adminitration when the subject screened successfully
62687597|NCT05702489|PLACEBO_COMPARATOR|Placebo control|Analog tablet with no active ingredient, single oral administration when the subject screened successfully
62687598|NCT04702607||contrast enhanced 4DCT|
62687599|NCT02925143|EXPERIMENTAL|E-learning course|
62687600|NCT06570928|PLACEBO_COMPARATOR|Placebo arm|Patients will receive a liquid solution only with vehicle and no cannabinoid.
62687601|NCT06570928|EXPERIMENTAL|Experimental arm|Patients will receive the dose of 0,2 ml of a compound contain CBD:THC (50 mg:5 mg).
62687602|NCT02029612|OTHER|Group 1 - Phone Call Support|Smoking cessation telephone hotline phone number provided to participants, along with a 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participant receives 11 phone calls from study staff over a 6-month period. Breath test performed at 3 month and 6 month visit.
62687603|NCT02029612|OTHER|Group 2 - Text Messaging Support|Participants receive 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participants receive text messages for support about quitting smoking over a 6 month period. Breath test performed at 3 month and 6 month visit.
62687604|NCT04214444|ACTIVE_COMPARATOR|Single-dose before treatment|12 patients will receive a single-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection
62687605|NCT04214444|ACTIVE_COMPARATOR|Single-dose after treatment|12 patients will receive a singe-dose of prevenar three weeks after the beginning of the immunochemotherapy (R-CHOP) following two months later by pneumovax injection
62687606|NCT04214444|EXPERIMENTAL|Double-dose before treatment|12 patients will receive a double-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection.
62687607|NCT03800901|ACTIVE_COMPARATOR|Control|The Control arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will not be offered Continuing Medical Education (CME) or American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
62687608|NCT03800901|EXPERIMENTAL|CME|The CME arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will be offered Continuing Medical Education (CME) and American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
62687609|NCT02411045|ACTIVE_COMPARATOR|Group 1: Control|Ask participants to take a picture of themselves
62687610|NCT02411045|EXPERIMENTAL|Group 2: Dress for Success|Ask participants to take a picture of themselves while wearing their workout gear
62687611|NCT02411045|EXPERIMENTAL|Group 3: Exercise for Success|Ask participants to take a picture of themselves while wearing their workout gear and complete a 30-minute workout
62687612|NCT05476731||case|
62687613|NCT05476731||control|
62687614|NCT05035628|EXPERIMENTAL|Cardiopulmonary exercise training group|Cardiopulmonary exercise intervention will include aerobic exercise, resistance and respiratory exercises, three sessions per week for 2 months
62687615|NCT05035628|NO_INTERVENTION|control group|Control group with no intervention.
62687616|NCT01557569|ACTIVE_COMPARATOR|Atomoxetine|Group receiving atomoxetine
62687617|NCT01557569|PLACEBO_COMPARATOR|Placebo|Group will receive placebo instead of atomoxetine
62687618|NCT00332566|EXPERIMENTAL|Group A|
62687619|NCT00332566|ACTIVE_COMPARATOR|Group B|
62687620|NCT06673680||colposcopic evaluation|do colposcopy and cervical punch biopsy then compare between findings
62687621|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
62687622|NCT06464913|EXPERIMENTAL|No Chest Wall RT|This group will have chest wall RT omitted and will only receive RT to the supraclavicular and infraclavicular lymphatic drainage areas.
62687623|NCT06464913|ACTIVE_COMPARATOR|Traditional RT|This group will receive standard RT to the chest wall and supraclavicular and infraclavicular lymphatic drainage areas.
62318363|NCT04303390|ACTIVE_COMPARATOR|24 hour Cefazolin arm|25% of the entire study participants are assigned to 24 hours and first generation cephalosporin
62318364|NCT04303390|ACTIVE_COMPARATOR|48 hour Cefuroxime arm|25% of the entire study participants are assigned to 48 hours and second generation cephalosporin
62318365|NCT04303390|ACTIVE_COMPARATOR|48 hour Cefazolin arm|25% of the entire study participants are assigned to 48 hours and first generation cephalosporin
62687624|NCT06662513||oesophagectomy|patients who underwent oesophagectomy within the specified time frame
62687625|NCT00635050|EXPERIMENTAL|Doxil, Paclitaxel, Cyclophosphamide + Avastin|Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, in patients with locally advanced invasive breast cancer.
62128170|NCT03452085|ACTIVE_COMPARATOR|artificial saliva spray (AS)|"The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment."
62128171|NCT03452085|PLACEBO_COMPARATOR|maritime throat spray (TT)|"The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment."
62128172|NCT01405807|EXPERIMENTAL|Alemtuzumab - high dose (60mg)|Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months
62687626|NCT02570425|PLACEBO_COMPARATOR|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
62687627|NCT02570425|PLACEBO_COMPARATOR|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
62687628|NCT05281458|EXPERIMENTAL|Early endoscopic interventions for AP|Participants in the intervention group will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
62687629|NCT05281458|NO_INTERVENTION|Standard endoscopic interventions for AP|Participants in the control group will have postponed drainage, preferably until AP progress to the walled-off necrosis stage.
62687630|NCT00257933|ACTIVE_COMPARATOR|1|High dose prednisolone
62687631|NCT00257933|EXPERIMENTAL|2|Lower dose prednisolone alternating with placebo
62687632|NCT04704700|ACTIVE_COMPARATOR|patient with inspace device|
62687633|NCT04704700|PLACEBO_COMPARATOR|patient without inspace device|
62687634|NCT06683677|EXPERIMENTAL|High-flow-nasal-cannula|Extremely preterm infants receive High-Flow Nasal Cannula therapy immediately after birth. The intervention includes placental transfusion, followed by administering High-Flow Nasal Cannula at a flow rate of 8 l/min along with intermittent tactile stimulation. Criteria for switching to Continuous Positive Airway Pressure or Positive Pressure Ventilation are established for cases of persistent bradycardia or low Saturation of oxygen (SpO2).
62687635|NCT06675201|EXPERIMENTAL|NeoDC-Vac + ICIs|"Experimental Group: NeoDC-Vac combined with ICIs NeoDC-Vac: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause."
62687636|NCT06675201|ACTIVE_COMPARATOR|ICIs|ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.
62687637|NCT01893099|EXPERIMENTAL|Sorafenib- Cohort 1|Sorafenib 400 mg BID will be started 14 days after the administration of SIRT with SIR-Sphere®.
62687638|NCT01893099|EXPERIMENTAL|Sorafenib- Cohort 2|Sorafenib 400 mg BID will be started 11 days after the administration of SIRT with SIR-Sphere®.
62687639|NCT01893099|EXPERIMENTAL|Sorafenib- Cohort 3|Sorafenib 400 mg BID will be started 3 days after the administration of radioembolization with SIR-Sphere®.
62687640|NCT01893099|EXPERIMENTAL|Sorafenib- Cohort 4|Sorafenib 400 mg BID will be started 7 days prior to the administration of radioembolization with SIR-Spheres® and be given continuously, without drug holidays.
62687641|NCT06658236|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation Group|Group A will perform PNF exercises using a yellow Thera-Band with a flexion-abduction-external rotation pattern, followed by extension-adduction-internal rotation, all with the elbow extended. The protocol includes three sets of 10 reps, with 60-second rest intervals conducted thrice a week for 12 weeks.
62128173|NCT01405807|EXPERIMENTAL|Alemtuzumab - low dose (30mg)|Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months
62128174|NCT04771351|EXPERIMENTAL|COVI-AMG 100 mg|A single injection of 100 mg of COVI-AMG will be administered.
62687642|NCT06658236|EXPERIMENTAL|Chest Expansion Exercise Group|Group B was instructed to 1) breathe normally at rest; 2) perform upper extremity flexion, abduction, and external rotation with inhalation, followed by extension, adduction, and internal rotation with exhalation using a yellow Thera-Band. Subjects completed three sets of 10 repetitions with a 1-minute rest between sets thrice a week for 12 weeks.
62687643|NCT03177798|EXPERIMENTAL|Icatibant then Placebo|"Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
62687644|NCT03177798|EXPERIMENTAL|Placebo then Icatibant|"Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
62687645|NCT02890160|EXPERIMENTAL|Firesorb|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
62128175|NCT04771351|EXPERIMENTAL|COVI-AMG 200 mg|A single injection of 200 mg of COVI-AMG will be administered.
62128176|NCT04771351|PLACEBO_COMPARATOR|Placebo|A single injection of placebo will be administered.
62479843|NCT06438315||Control|Not treated with SSO2
62128177|NCT01706354|ACTIVE_COMPARATOR|Local anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
62128178|NCT01706354|EXPERIMENTAL|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
62128179|NCT01068756|OTHER|Dapagliflozin/Rifampin|
62128180|NCT01613716|EXPERIMENTAL|Ozurdex|Subjects will receive Ozurdex injections and will be monitored for macular edema.
62318366|NCT03334578|EXPERIMENTAL|Drug: Gastrografin|"Patient will receive 30ml of Gastrografin (diluted at 1:3 ratio with water) as recommended by the manufacturer for a single dose in our population. The dose will be given via the nasogastric tube, which will then be clamped for 1 hour. Gastrografin will only be given if there is evidence of a bowel obstruction. Additionally, Gastrografin will only be given when the patient is hemodynamically stable, not receiving any inotropes, and off of invasive respiratory support. Once administered the patient will receive an x-ray at 48 hours. If Gastrografin can be viewed past the obstruction than another dose of Gastrografin (30ml at 1:3 dilution ratio with water via NG tube) can be given. If gastrografin is not viewed past the obstruction than another dose will not be given.~Generic name: Diatrizoate Meglumine, Diatrizoate Sodium"
62318367|NCT03334578|NO_INTERVENTION|Control: Standard care|This group will be recruited from an ongoing observational study at our centre. The patients in this group have all received the standard care for treating gastroschisis and any potentially associated bowel obstruction. They have not received Gastrografin. They will be recruited between May 2010 and May 2019.
62687646|NCT02890160|ACTIVE_COMPARATOR|XIENCE|Implantation of the XIENCE Everolimus Eluting Coronary Stent System
62687647|NCT05855993|EXPERIMENTAL|Nerve Glide Exercise with Ultra Sound|
62687648|NCT05855993|ACTIVE_COMPARATOR|Nerve Glide Exercise without Ultra Sound|
62687649|NCT04642079|EXPERIMENTAL|Cohort 1: =>15 through 23 months of age|20vPnC
62687650|NCT04642079|EXPERIMENTAL|Cohort 2: 2 through 4 years of age|20vPnC
62687651|NCT04642079|EXPERIMENTAL|Cohort 3: 5 through 9 years of age|20vPnC
62687652|NCT04642079|EXPERIMENTAL|Cohort 4: 10 through 17 years of age|20vPnC
62687653|NCT06570876||Radical surgery|Total cystopericystectomy and anatomical liver resections are considered RS (i.e., segmentectomy, bisegmentectomy, left lateral segmentectomy, left hepatectomy, right hepatectomy, right trisectionectomy, and liver transplantation).
62687654|NCT06570876||Conservative surgery|Partial cystopericystectomy and the Lagrot technique are considered CS.
62128181|NCT03260010|EXPERIMENTAL|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
62128182|NCT05953870|EXPERIMENTAL|MUSIC AND COMFORT THERAPY|"The intervention group will be exposed pre- and postoperatively to relaxing music, which is defined as a slower tempo music that can quiet mind and make patients feel soothed."
62128183|NCT05953870|NO_INTERVENTION|CONTROL GROUP|These patients will follow the standard surgical pathways as per daily routine.
62687655|NCT00934388|EXPERIMENTAL|Mesh placed in pre peritoneal plane|
62687656|NCT00934388|ACTIVE_COMPARATOR|No mesh placed|
62687657|NCT02056951|ACTIVE_COMPARATOR|Multidisciplinary rehabilitation|The central objective of inpatient multidisciplinary orthopedic rehabilitation (MOR) is to improve functional health with the main focus on restoring and improving work ability. A MOR lasts on average 23 days with a total extent of therapy of 48 hours on average. MOR is provided by a multiprofessional team consisting of physicians, psychologists, sport therapists, physiotherapists, occupational therapists, masseurs, social workers, dieticians and nurses. The interventions are carried out mainly in open groups.
62687658|NCT02056951|EXPERIMENTAL|Interprofessional rehabilitation|The central objective of the interprofessional rehabilitation (PASTOR) is the development of active self-management of chronic non-specific low back pain. PASTOR is matched to the MOR with respect to the total duration and total extent of therapy, the included professions and the interventions dimensions (physical, psychological). The differences between PASTOR and MOR are characterized by, a) an integrative combination of profession related modules within a comprehensive and consistent treatment approach, b) an interprofessional and collaborative teamwork based on profession related modules, c) the use of standardized methods, media and materials by all professions in the therapeutic team d) a highly structured and detailed manual for the entire treatment process. The interventions are carried in fixed groups with eight to twelve participants.
62687659|NCT01883375|EXPERIMENTAL|Dignity Talk dyad completers|Those dyads where both patient and family member co-participant complete the protocol using the Dignity Talk Communication Topics
62128184|NCT02459782|OTHER|US Guided Dual Quadrant Peribulbar block|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
62318368|NCT02199977|OTHER|test only (free)|The participant is entitled to a free malaria rapid diagnostic test, but no ACT voucher.
62687660|NCT01883375|EXPERIMENTAL|Dignity Talk non-completers|Those dyads where patient and family member co-participant either do not complete the protocol or do not use the Dignity Talk Communication Topics (November 2016 - the investigators have not as yet enrolled any participants who have not completed the study without using the Dignity Talk Topics. However some participants have withdrawn from the study without completing.
62128185|NCT05574452|EXPERIMENTAL|Pilot group|Pilot group undergoing ACL reconstruction using the SONAR Femoral Aimer PSI
62128186|NCT02067949|NO_INTERVENTION|broad spectrum AB +fluids|Control group :50 patients will be treated according to SURVIVING SEPSIS CAMPAIGN BUNDLES
62128187|NCT02067949|ACTIVE_COMPARATOR|simvastatin|50 patients will be treated according SSCG plus simvastatin as single oral tablet 40 mg / day begin with inclusion in the study and continue until hospital discharge .If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube. (White R, Bradnam V, 2013)
62128188|NCT03388281||Patients with implanted pacemaker|Patients with implanted cardiac pacemaker registered in pacemaker database of the Department of Cardiology at the Medical University Vienna were included.
62318369|NCT02199977|OTHER|test (free) & conditional ACT voucher|The participant is entitled to a free malaria rapid diagnostic test, and an ACT voucher conditional on a positive test result.
62318370|NCT02199977|OTHER|test only (not free)|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), but no ACT voucher.
62318371|NCT02199977|OTHER|test (not free) & conditional ACT voucher|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), and an ACT voucher conditional on a positive test result.
62318372|NCT03664986|EXPERIMENTAL|Exparel pudendal block|This group will have intra-operative pudendal block performed with Liposomal Bupivacaine (EXPAREL) solution.
62318373|NCT03664986|NO_INTERVENTION|Comparison group|This group will be those to receive current standard treatment with no pudendal block performed.
62318374|NCT04011436|EXPERIMENTAL|Core, Hip and knee.|Physical Exercises to strengthen the core, hip and knee.
62318375|NCT04011436|SHAM_COMPARATOR|Hip and Knee|Physical Exercises to strengthen the hip and knee.
62479844|NCT04705935||Term pregnant women without labor contractions or rupture of membranes|Term pregnant women \> 37 weeks gestation with a normal pregnancy. One blood sample before a scheduled caesarean section.
61925191|NCT03200665|EXPERIMENTAL|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
61925192|NCT03200665|NO_INTERVENTION|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
62128189|NCT04336059|OTHER|group 1|will receive sham PENG block with normal saline in total volume of 20 ml.
62128190|NCT04336059|EXPERIMENTAL|group 2|will receive real PENG block with bupivacaine (0.25%) in total volume of 20 ml.
62318376|NCT02747043|EXPERIMENTAL|ABP 798|ABP 798 was administered at a dose of 375 mg/m\^2 as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
62318377|NCT02747043|ACTIVE_COMPARATOR|Rituximab|Rituximab was administered at a dose of 375 mg/m\^2 as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
61925193|NCT06235242|EXPERIMENTAL|GT201 treatment group|
61925194|NCT03144024|EXPERIMENTAL|band|
61925195|NCT03144024|ACTIVE_COMPARATOR|Rigid ring|
61925196|NCT04733378|EXPERIMENTAL|Peri-operative neurological monitoring|
61925197|NCT03777735||human bone graft screw|The patients will receive human bone graft screws surgically.
61925198|NCT02025517|NO_INTERVENTION|Without Cognitive Tasks|Gait training on treadmill during 20 minutes.
62128191|NCT05035004|EXPERIMENTAL|Post exercise hot water immersion|Moderate intensity cycling for 30 minutes, followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion.
62128192|NCT05035004|ACTIVE_COMPARATOR|Exercise|Moderate intensity cycling for 30 minutes.
62318378|NCT02131467|EXPERIMENTAL|Perampanel|Perampanel 2 mg tablets will be initiated once daily at bedtime. The dose will be titrated over 6 weeks starting at 2 mg OD at baseline visit for 1 week, followed by 2mg increases every 1 week to a maximum of 12 mg/day. If side effects occur then patients will be decreased to previous dose level. If unable to tolerate increases, patients will enter the maintenance phase at previously tolerated dose, for minimum 4 weeks. Patients reaching 12 mg (maximal dose) will be maintained at that dose for 4 weeks. Taper will be over 2 weeks 1 tablet every 2 days from a maximum of 6 tablets per day to stop.
62318379|NCT01072864|EXPERIMENTAL|5 g of walnuts|
62318380|NCT01072864|EXPERIMENTAL|20 g of walnuts|
62318381|NCT01072864|EXPERIMENTAL|30 g of walnuts|
62318382|NCT01072864|EXPERIMENTAL|40 g of walnuts|
62318383|NCT01477216|EXPERIMENTAL|Measuring method|To compare glycemic responses and GI values from capillary and venous blood and to compare glucose solution with white bread as the reference food and to study the effect of the number of reference tests on GI values.
62318384|NCT01477216|EXPERIMENTAL|Mixed meals|To examine the glycaemic and insulinaemic responses of a mashed potato-based meal when a high fat food (rapeseed oil) or a high protein food (chicken breast) or fat, protein and salad together were added to the meal. Furthermore, we studied how the predicted and measured GI values of the mixed meal differed from each other.
62479845|NCT04705935||Term pregnant women with labor contractions|Term pregnant women \> 37 weeks gestation with a normal pregnancy. One blood sample when labor contractions, but before spontaneous rupture of membranes.
62479846|NCT04705935||Term pregnant women with spontaneous rupture of membranes|Term pregnant women \> 37 weeks gestation with a normal pregnancy. One blood sample after spontaneous rupture of membranes, but without labor contractions.
62687661|NCT03373513|ACTIVE_COMPARATOR|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
61925199|NCT02025517|EXPERIMENTAL|Cognitive Tasks|Treadmill training plus cognitive verbal fluency, memory and spatial planning tasks, during 20 minutes.
61925200|NCT03557554|EXPERIMENTAL|Massage Therapy|Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.
61925201|NCT01859585|EXPERIMENTAL|Parecoxib|Parecoxib
62318385|NCT01477216|EXPERIMENTAL|Coffee|To examine the effects of two different coffee portions with glucose and caffeine-containing soft drinks on postprandial glucose and insulin responses. Further objectives were to study how coffee and different accompaniments affect glucose and insulin responses.
62687662|NCT03373513|ACTIVE_COMPARATOR|Multiport Laparoscopy|Multiport Laparoscopic hysterectomy is performed in this other arm
62687663|NCT03104920|EXPERIMENTAL|ERAS program|We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.
62687664|NCT03104920|ACTIVE_COMPARATOR|Traditional treatment|We give routine clinic practices for the treatment of HCC.
62687665|NCT00987935|EXPERIMENTAL|Nintedanib (BIBF 1120)|Phase I dose escalation and phase II using dose determined in phase I
61925202|NCT01859585|EXPERIMENTAL|Ketorolac|Ketorolac
62128193|NCT05035004|ACTIVE_COMPARATOR|Hot water immersion|Whole-body hot water immersion for 30 minutes, followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion.
62128194|NCT05855291|EXPERIMENTAL|Integrated PET/MRI|The study patients receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
62128195|NCT02436317|EXPERIMENTAL|Study group|"All patients included in intervention group will be examined with an ultrasound machine with cardiac probe and vascular probe \[Saote/ Mylab 5/ Italy\] using both 2 dimensional and color Doppler imaging modalities according to our local point of care ultrasonography protocol.~Including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator."
62687666|NCT00987935|ACTIVE_COMPARATOR|Sorafenib|Twice daily dosing in phase II
62687667|NCT01620047|EXPERIMENTAL|Femoral Nerve Fentanyl|Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
62687668|NCT01620047|ACTIVE_COMPARATOR|Femoral Nerve Ropivacaine|Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
62687669|NCT01620047|PLACEBO_COMPARATOR|Intravenous Fentanyl with placebo|Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
62687670|NCT06640699|EXPERIMENTAL|NFT Group|NFT group will receive Phase I cardiac rehabilitation and neurophysiological facilitation techniques.
61925203|NCT01859585|NO_INTERVENTION|No medication|No medication
62687671|NCT06640699|ACTIVE_COMPARATOR|Control Group|Control group will receive Phase I cardiac rehabilitation alone.
62687672|NCT04787016|EXPERIMENTAL|Pilate training|The participants of this group perform pilate training along with conventional cricket training.
62687673|NCT04787016|NO_INTERVENTION|Conventional training|The participants perform only conventional cricket training.
62687674|NCT00458705|EXPERIMENTAL|Combination therapy|Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.
62687675|NCT06643208||Combination therapy group|Patients with unresectable cholangiocarcinoma were treated with D-TACE-HAIC (GEMOX regimen) combined with envafolimab and lenvatinib
61925204|NCT00002664|EXPERIMENTAL|Treatment|
61925205|NCT00494065|EXPERIMENTAL|1|Chiropractic Spinal Manipulative Therapy + Home exercise
62738102|NCT00512850|OTHER|Placebo|Placebo pill once per day
61925206|NCT00494065|ACTIVE_COMPARATOR|2|Home exercise
61925207|NCT04405427|EXPERIMENTAL|head acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the head
61925208|NCT04405427|ACTIVE_COMPARATOR|body acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the body
61925209|NCT01374711|PLACEBO_COMPARATOR|placebo|LPS will be administered twice on days 1 and 7. In between placebo will be administered on days 2, 4 and 6 subcutaneously.
61925210|NCT01374711|ACTIVE_COMPARATOR|GM-CSF|LPS will be administered twice on days 1 and 7. In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
62128196|NCT02436317|NO_INTERVENTION|Control group|All patients included in the control group won't be examined with an ultrasound machine. Participation including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator.
62128197|NCT02461264|ACTIVE_COMPARATOR|ARM A|Two packed red blood cells will be transfused in patient with anemia defined as a hemoglobin level below 8 g / dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is \<8 g / dL, two new packed red blood cells are transfused and so on.
62128198|NCT02461264|EXPERIMENTAL|ARM B|Single red blood packed cells Transfusion will be administered in patient with anemia defined as a hemoglobin level below 8 g/dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is \<8 g / dL, a single unit is transfused and so on.
62318386|NCT01477216|EXPERIMENTAL|Snacks|To measure GI and II values for Finnish snack foods
62318387|NCT01477216|EXPERIMENTAL|Berries|To study the effects of berries on glycemic and insulinemic responses
61925211|NCT01374711|ACTIVE_COMPARATOR|IFN-y|LPS will be administered twice on days 1 and 7. In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
61925212|NCT02602847||Patients with alcoholic or hepatitis C virus related disease|cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV
62318388|NCT01477216|EXPERIMENTAL|GIs of low-carbs|To measure glycemic and insulinemic responses to low-carbohydrates foods
62318389|NCT01477216|EXPERIMENTAL|Glucose metabolism and BMI|To examine the effects of overweight and glucose tolerance on the glucose, insulin and lipid responses to an HGI meal and an LGI meal. Furthermore, the second aim was to study the effect of BMI and glucose tolerance on the GI measured.
62479847|NCT04705935||Preterm labor contractions (PLC)|One blood sample when labor contractions before 34 weeks gestation without rupture of membranes.
61925213|NCT02602847||Hepatitis B core antibody positive donors|cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors
62318390|NCT01477216|EXPERIMENTAL|Insulin measurement|To compare how methodological choices affect measured insulin values
62318391|NCT01477216|EXPERIMENTAL|Alcohol|To investigate the effect of alcohol on postprandial glucose and insulin responses, and to determine glycemic and insulinemic indices values for beer and non-alcoholic beer.
62318392|NCT01454089|EXPERIMENTAL|OGX-427 600 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)
62687676|NCT06688656|OTHER|Arm 1|Resectable EGFR-Mutant Stage II-IIIB Non-Squamous Non-Small Cell Lung Cancer Patients. Eligible subjects who meet the inclusion criteria and have signed the informed consent will receive sintilimab in combination with chemotherapy, with a treatment cycle of 3 weeks. A tumor assessment will be conducted before the start of the third cycle of treatment, and surgery will be performed within 3-6 weeks after the last cycle of neoadjuvant therapy, with a tumor assessment conducted 7 days prior to surgery. After completing local treatment (surgery), researchers will offer optional adjuvant therapy to patients, including EGFR-TKI.
61925214|NCT02602847||HBV patients|cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication
62128199|NCT03654235|EXPERIMENTAL|PNE and PE program|Pain neuroscience education (Health education) and Physical exercise program.
62128200|NCT03654235|ACTIVE_COMPARATOR|Usual care in Primary Care Physiotherapy|Usual care in Primary Care Physiotherapy Units
62128201|NCT00541333|ACTIVE_COMPARATOR|Copaxone|
62128202|NCT00541333|SHAM_COMPARATOR|Sham|
62128203|NCT05316246|EXPERIMENTAL|CD30-positive Relapsed/Refractory NK/T-cell Lymphoma|Brentuximab vedotin will be administered as 1.8 mg/kg IV infusion on Day 1 of each 3-week cycle. PD-1 inhibitor tislelizumab will be administered as 200 mg on Day 1 of each 3-week cycle. Patients will receive maximum of 8 cycles if they do not meet the criteria for removal from the study. Patients will be assessed for overall response using the Revised Response Criteria for Malignant Lymphoma (Lugano 2014). Dedicated computed tomography (CT) scans (neck, chest, abdomen, and pelvis) will be performed at Baseline and at Cycles 2, 4 and 8, and positron emission tomography (PET) scans will be performed at Baseline and at Cycles 4 and 8.
62128204|NCT05617742|EXPERIMENTAL|68Ga-FAPI-46 PET Scan|A single-center prospective interventional single-arm clinical trial. All patients will undergo whole-body 68Ga-FAPI-46 PET scan within two weeks before or after 18F-FDG-PET. Injected activity of 68Ga-FAPI-46 is limited to 100-250 MBq per examination.
62479848|NCT04705935||Preterm Prelabor Rupture of the Fetal Membranes (PPROM)|One blood sample when rupture of the fetal membranes before 34 weeks gestation without labor contractions.
62318393|NCT01454089|EXPERIMENTAL|OGX-427 1000 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)
62687677|NCT00638391||1|all patients treated with Anastrozole
62128205|NCT00609908|ACTIVE_COMPARATOR|A1|Acute Burn Wounds: Wound debridement and split skin grafting
62318394|NCT01454089|ACTIVE_COMPARATOR|Placebo|Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo
62318395|NCT05468450|ACTIVE_COMPARATOR|Ultrasound-guided-foam sclerotherapy (UGFS)|Injection of Polidocanol foam into SSV
62318396|NCT05468450|ACTIVE_COMPARATOR|Endovenous Laser Ablation (EVLA)|Ablation of SSV using laser energy
62318397|NCT02145767|EXPERIMENTAL|Progesterone|Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.
62318398|NCT02145767|PLACEBO_COMPARATOR|Placebo|Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.
62318399|NCT04197297|OTHER|CT and MRI Scans|Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
62318400|NCT05351086|EXPERIMENTAL|Inhaled placebo and IV D.H.E. 45 1 mg|
62318401|NCT05351086|EXPERIMENTAL|Inhaled PUR3100 0.5 mg and IV placebo|
62318402|NCT05351086|EXPERIMENTAL|Inhaled PUR3100 1.0 mg and IV placebo|
62318403|NCT05351086|EXPERIMENTAL|Inhaled PUR3100 1.5 mg and IV placebo|
62479849|NCT04705935||Control group|Women with normal pregnancies. One blood sample in gestation week 25+0 to 37 matched as controls for PLC and PPROM cases.
62479850|NCT04705935||Longitudinal cohort during pregnancy|Women with normal pregnancies, where blood samples will be collected at week 12, 20, 28, 34 and 36, as well as at labor.
62479851|NCT04705935||Longitudinal cohort post partum|Women with normal pregnancies, where blood samples will be collected at labor, as well as 2 days, and 4, 8 and 12 weeks after birth.
62128206|NCT00609908|EXPERIMENTAL|A2|Acute Burn Wounds: excision of the burn wound and primary closure, using a skin stretching device
62128207|NCT00609908|ACTIVE_COMPARATOR|B1|Scar reconstruction: serial excision
62128208|NCT00609908|EXPERIMENTAL|B2|Scar reconstruction: primary closure, using skin stretching device
62318404|NCT01193790|EXPERIMENTAL|Coblation|
62318405|NCT05031325|EXPERIMENTAL|Endoscopic submucosal dissection with Purastat|To compare of the risk of bleeding after endoscopic submucosal dissection, after ESD, application of Purastat gel (not a drug but a device with CE mark) with a catheter of a gel on the resected area to cover the whole surface of mucosal resection.
61925215|NCT02142114|ACTIVE_COMPARATOR|Eye injection by 30 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size (may be that day or within 1 week of the 1st injection). When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
61925216|NCT02142114|ACTIVE_COMPARATOR|Eye injection by 32 gauge needle|
62128209|NCT02299752|EXPERIMENTAL|Catheterization|Blood vessel Catheterization during resuscitation with single and double - gloving system. Catheterization was performed using simulation mannikin
62318406|NCT05031325|NO_INTERVENTION|Comparative arm without Purastat|After endoscopic submucosal dissection (ESD) and hemostasis, if the patient is randomized in the comparative group, no gel will be applied on the resected area that will remain like this without intervention (common practice)
62318407|NCT06442917|EXPERIMENTAL|Breathing Exercise Group|32 the Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth was completed before the pregnancy intervention and the VAS was measured.
62318408|NCT06442917|EXPERIMENTAL|Affirmation Method Group|32 pregnant women who were admitted to the hospital for childbirth and were in the latent phase (0-3 cm) filled out the pre-intervention Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth, and the VAS was measured.
62318409|NCT06442917|EXPERIMENTAL|Breathing Exercise and Affirmation Method Group|During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained and the application was made with breathing exercise training.
62318410|NCT06442917|NO_INTERVENTION|control group|Routine midwifery care was applied during the trauma.
62318411|NCT04185610|EXPERIMENTAL|Qi Gong|Weekly QiGong for Chemotherapy-Induced Neuropathy classes for 10 weeks
62738103|NCT03072394|EXPERIMENTAL|EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse.
62318412|NCT01641315|EXPERIMENTAL|Rabies vaccine, IM day 0,3,7,28 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 28 with equine rabies immunoglobulin 40 IU/Kg on day 0.
61925217|NCT01701427||1|1. Healthy, un-operated, groin-hernia free, pain-free and medicinal free males
61925218|NCT00883844|EXPERIMENTAL|1|Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
61925219|NCT00883844|ACTIVE_COMPARATOR|2|Continuation of Nucleos(t)ide analogue mono-therapy
61925220|NCT06423989|EXPERIMENTAL|male fertility|
61925221|NCT04699253||Consenting participants|Patients meeting the eligibility criteria and are using the SanaCoach heart failure during the study period.
61925222|NCT04699253||Consenting non-participants|Patients meeting the eligibility criteria but do not wish to use the SanaCoach heart failure and only fill-in an anonymized questionnaire once, without any follow-up.
61925223|NCT01755273|NO_INTERVENTION|Standard pancreaticoduodenectomy|Cases receiving pancreaticoduodenectomy with standard enteral bypass
62318413|NCT01641315|EXPERIMENTAL|Rabies vaccine, IM day 0,3,7,14 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 14 with equine rabies immunoglobulin 40 IU/Kg on day 0.
62318414|NCT01641315|ACTIVE_COMPARATOR|Rabies vaccine, IM Day 0,3,7,14,28 with RIG|Rabies exposed victims receive rabies vaccination intramuscularly on Day 0,3,7,14,28 with equine rabies immunoglobulin 40 IU/Kg on day 0
62318415|NCT02299908|EXPERIMENTAL|TAP block with Bupivacaine at 0.25%|Intervention: Injection of local anesthetics in the transverses abdominal plane
61925224|NCT01771575|EXPERIMENTAL|Treatment Arm|PoNS™ device
62687678|NCT06142422|EXPERIMENTAL|experimental group with intermittent Theta Burst Stimulation|The procedure under study is the use of a stimulation device to perform intermittent Theta Burst Stimulation treatment on the precuneus to treat resistant schizophrenia. Targeting requires a neuronavigation device.
61925225|NCT01771575|PLACEBO_COMPARATOR|Placebo Arm|placebo device
61925226|NCT03385161|ACTIVE_COMPARATOR|botulinum toxin A|"Intraprostatic injection of botulinum toxin A (onabotulinumtoxinA; 100 IU) through transrectal ultrasonography.~One vial (100 IU) is dissolved in 10 ml saline and injected in the transition zone of each lobe of the prostate in 3 sites; basal, middle and apical.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle was introduced to the prostate."
62128210|NCT03873337|EXPERIMENTAL|NRT + Persistence Targeted Smoking Cessation in SMI|Participants will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of task persistence focused cessation counseling delivered via telehealth.
62128211|NCT01340417|EXPERIMENTAL|one label|Measurements of melatonin levels in urine, blood, milk.
62128212|NCT06149819|EXPERIMENTAL|Intervention (paramedical)|"The patients will be cared for by one of the specially trained nurses based on a previously established allocation per day. A nurse will be able to take in charge several patients successively included on the same day, in accordance with the actual practice of organized intra-hospital sector and according to the standardized algorithm based on the recommendations.~The DSMB will analyzed the compliance and safety of the management in this group at 20, 50 and 50% of enrollment and at the request of the sponsor if necessary.~An adjudication committee will determine compliance with diagnostic management in the two groups."
62128213|NCT06149819|NO_INTERVENTION|Control (medical)|"In this group the patients will received usual medical care over the same period in the emergency department and meeting eligibility criteria. Patients will be included prospectively after obtaining their consent, with a 1:1 ratio with sex and age correspondence +/- 5 years).~An adjudication committee will determine compliance with diagnostic management in the two groups."
62128214|NCT01011946|EXPERIMENTAL|Positron Emission Mammography|
62128215|NCT04593251|EXPERIMENTAL|CALY-002|
62128216|NCT04593251|PLACEBO_COMPARATOR|Placebo|
62128217|NCT01347892||DeNovo NT Subject|Subjects who have received or who are scheduled to receive a DeNovo NT Graft for repair of a cartilage lesion in the ankle.
62128218|NCT06435637|EXPERIMENTAL|Collagen protein|100 g of collagen peptides (in boluses) with vitamin C
62318416|NCT02299908|PLACEBO_COMPARATOR|Placebo saline solution|Placebo: Injection of saline solution in the transverses abdominal plane
62318417|NCT00573326|EXPERIMENTAL|1|Imatinib 200 mg p.o. once a day for 6 months
62318418|NCT04550546|EXPERIMENTAL|Nystatin treatment|Participants will be given 1-week supply of nystatin suspension (6ml 600,000 U/mL) and be instructed to rinse the mouth with nystatin for 1 minute and spit out the suspension, at a frequency of four times a day, for a duration of 1 week. Participants will be instructed to spit the suspension after the oral rinse and do not swallow the suspension, and they will be instructed to avoid eating, drinking and brushing their teeth for 30 minutes.
62318419|NCT01775046||DTA patients|160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.
61925227|NCT03385161|ACTIVE_COMPARATOR|Ethanol|"Intraprostatic injection of dehydrated ethanol through transrectal ultrasonography.~An amount equal to 25% of prostate volume was injected distributed over 6-8 sites among both prostatic lobes with an average of 2 ml per site.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle introduced to the prostate."
61925228|NCT04428775|EXPERIMENTAL|Group I (Low Dose)|Group I (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 17.1 mg/twice a day (bid) (total of 34.2 mg/day)
61925229|NCT04428775|EXPERIMENTAL|Group II (High Dose)|Group II (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 34.2 mg/bid (total of 68.4 mg/day)
62128219|NCT06435637|PLACEBO_COMPARATOR|Placebo|Non-caloric placebo (flavoured water) drinks, with vitamin C.
62128220|NCT04143204||very preterm infants cohort|A prospective cohort of very preterm or very low birth weight infants from birth to corrected age 18 months.
62128221|NCT05575622||Patients with hepatocellular carcinoma receiving immunotherapy|
61925230|NCT00107952|EXPERIMENTAL|Telavancin|
61925231|NCT00107952|ACTIVE_COMPARATOR|Vancomycin|
61925232|NCT02803762|EXPERIMENTAL|Investigational: [14C] Pacritinib|All enrolled subjects are checked in the day before drug administration. Following at least a 10-hour fast (not including water), each subject will receive an oral dose of 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity).
62128222|NCT06521801||Patients with Renal Disease or Cardiology Disease|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with renal disease and cardiac disease.
62128223|NCT03029598|EXPERIMENTAL|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62128224|NCT04962477||Pregnant|
62128225|NCT04962477||Non-pregnant|
62318420|NCT02183545|EXPERIMENTAL|BI 1060469|single rising doses given as tablet
62318421|NCT02183545|PLACEBO_COMPARATOR|Placebo|given as tablet (matching placebo of BI 1060469)
61925233|NCT02922491|EXPERIMENTAL|Group 1|"400 mg Vitamin E of synthetic source~1 once daily during 2 months"
62318422|NCT01565629|NO_INTERVENTION|Waitlist Condition|Children in this condition will withhold from any type of intervention for a period of 12 weeks.
62318423|NCT01565629|EXPERIMENTAL|Computer Assisted CBT|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
62318424|NCT06535399|EXPERIMENTAL|Group A: BMS-986369 Moderate Hepatic Impairment|
62318425|NCT06535399|EXPERIMENTAL|Group B: BMS-986369 Severe Hepatic Impairment|
62318426|NCT06535399|EXPERIMENTAL|Group C: BMS-986369 Normal Hepatic Function|
62318427|NCT03789773|EXPERIMENTAL|Diagnostic (holographic mm-wave imaging)|Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial CT simulation.
62318428|NCT01193725|ACTIVE_COMPARATOR|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
62318429|NCT01193725|EXPERIMENTAL|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
62318430|NCT01193725|PLACEBO_COMPARATOR|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
62128226|NCT05948644|EXPERIMENTAL|TPN171H|TPN171H is received 2.5mg QD for 2 consecutive weeks, then 5 mg QD for 14 consecutive weeks. If the dose is well-tolerated,TPN171H is up-titrated to 10mg QD , which will last for up to 2 years.
62318431|NCT00723112||Affected Group|Adult subjects with the diagnosis of MDS based on the French-American-British classification system.
62318432|NCT00723112||Healthy Controls|Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected
62318433|NCT05280015|ACTIVE_COMPARATOR|Microbiotherapy in addition of venlafaxin|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the microbiotherapy during 12 weeks. The microbiotherapy is GynMDD devlopped by Gynov and which is composed by a probiotic associated to polyphenol and an amino acid.
62318434|NCT05280015|PLACEBO_COMPARATOR|calibration arm|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the placebo therapy during 12 weeks.
62318435|NCT05967234|EXPERIMENTAL|Telehealth solution|Telehealth solution offered for breastfeeding education.
62318436|NCT03925441||Pediatric participants with chronic severe plaque psoriasis|Participants with chronic severe plaque psoriasis receiving adalimumab in routine clinical practice
61925234|NCT02922491|EXPERIMENTAL|Group 2|"400 mg Vitamin E of natural source~1 once daily during 2 months"
62128227|NCT01284075|EXPERIMENTAL|Guided Imagery and Music therapy group (GIMT)|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
62128228|NCT01284075|ACTIVE_COMPARATOR|White Noise Group (WN)|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
62128229|NCT01284075|ACTIVE_COMPARATOR|No Interventions Group (CP)|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
62128230|NCT01925339|EXPERIMENTAL|Test (immediate restoration)|Test (immediate restoration): immediate restoration will be placed on immediately placed implants.
62128231|NCT01925339|EXPERIMENTAL|Control: delayed restoration|Control: delayed restoration: immediate placed implants will be restored at 4 months.
61925235|NCT02922491|PLACEBO_COMPARATOR|Group control|"400 mg of starch~1 once daily during 2 months"
61925236|NCT02922491|NO_INTERVENTION|No intervention|Without intervention
61925237|NCT02925325|EXPERIMENTAL|Music Therapy|Music therapy 8 weekly sessions
61925238|NCT02925325|ACTIVE_COMPARATOR|Usual Treatment|It is the usual medical treatment.
62128232|NCT05801367|ACTIVE_COMPARATOR|Formocresol (Control-Gold standard-Group A)|Premade Formocresol (Tricresol \& Formalin) will be used in this research. Composition was Tricresol 35%, Formaldehyde (40%) 19%, excipient additive 100% (PD, Switzerland, ISO9001/ISO9001_2000/ ISO13485/CE_MARK), (Universal Dental Pvt, Ltd)
62318437|NCT00328263|EXPERIMENTAL|1|Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.
62318438|NCT00328263|PLACEBO_COMPARATOR|2|placebo devoid of bacteria
62318439|NCT02518178|ACTIVE_COMPARATOR|NFC Sticker|Participants will receive an NFC (Near Field Communication) sticker, placed on their existing immunization (MAMTA) card. This will serve as a comparator to the NFC necklace while still allowing for patient data to be digitized and utilized by the health service provider, Seva Mandir.
62318440|NCT02518178|EXPERIMENTAL|NFC Necklace|Participants will receive a necklace with an NFC pendant, which interfaces with the Khushi Baby mobile application to digitize the data. This arm will allow for the assessment of peer influence effects of the necklace as a social symbol.
62318441|NCT02518178|EXPERIMENTAL|NFC Necklace + Voice Reminder|In addition to the NFC necklace, mothers of the participants in this arm will receive dialect-specific voice call reminders, informing them about the next camp and the importance of vaccinations.
62318442|NCT02385032|EXPERIMENTAL|AB|Ursodiol followed by URSO Forte
62318443|NCT02385032|EXPERIMENTAL|BA|URSO Forte followed by Ursodiol
62318444|NCT02636764|ACTIVE_COMPARATOR|exercise group|An exercise protocol drawn up with the objective will be held to strengthen the musculature: flexor and extensor of the knee; extension, abduction, hip side rotator, using the weight and the elastic band.
62318445|NCT02636764|PLACEBO_COMPARATOR|exercise group + Ultrasound therapy|Apart from intervening in the exercise group, an ultrasound device is used .
62318446|NCT02636764|EXPERIMENTAL|exercise group + interferential current|Besides the intervention of the exercise group after the exercises will be applied to interferential current through the device. Will be positioned 4 electrodes (8x5 cm), two upper and two lower (forming a square) around the center of the knee.
62687679|NCT06142422|PLACEBO_COMPARATOR|control group with placebo stimulation|"In the control group, stimulation is simulated using a Sham or placebo coil. The stimulation device is the same as for the experimental group, only the coil differs."
62128233|NCT05801367|EXPERIMENTAL|Allium sativum oil (Experimental-Group B)|Premade Allium sativum oil (Garlic oil) (Mohammad and Baroudi, 2015b) will be used in this research (SAC group of companies-9001:2015 certified; Registration # PAK17.1724-U; NTN # 0299739-8, Karachi, Pakistan
62128234|NCT02009215|EXPERIMENTAL|Intermittent preventive treatment (IPT)|Dihydroartemisinin-piperaquine (DP)
62128235|NCT02009215|NO_INTERVENTION|Control|No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.
62128236|NCT05794568|ACTIVE_COMPARATOR|OITcontrol group|
62128237|NCT05794568|NO_INTERVENTION|paperPRO group|
62128238|NCT04553523|EXPERIMENTAL|Hydrus Microstent|Hydrus Microstent implanted in the eye immediately following cataract surgery and placement of a monofocal intraocular lens (IOL)
62128239|NCT02983669|EXPERIMENTAL|Thyme|Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
62128240|NCT02983669|PLACEBO_COMPARATOR|Placebo|Wheat powder capsule 350 mg twice daily for 3 months
62318447|NCT02636764|EXPERIMENTAL|exercise group + short-wave diathermy|Besides the intervention of the exercise group after the exercises will be applied diathermies short wave in continuous mode. For that will be used apparatus, 27.12 megahertz, by means of vulcanized rubber electrodes (12x17 cm) with gentle warming for 30 minutes.
62318448|NCT02636764|EXPERIMENTAL|exercise group + Low level laser therapy|Apart from intervening in the exercise group, will be applied to Low level laser therapy, through the laser unit, Class 3b, gallium-aluminum-arsenide, continuous mode, wavelength: 830 nanometer, power: 30 watts.
62318449|NCT00004154|EXPERIMENTAL|Fenretinide|Fenretinide (4-HPR) 200 mg orally every day for 12 months taken 25 out of every 28 days.
62318450|NCT00004154|PLACEBO_COMPARATOR|Placebo|Placebo orally every day for 12 months, taken 25 out of every 28 days.
62318451|NCT03849469|EXPERIMENTAL|Arm 1|Arm 1: XmAb®22841 Monotherapy
62318452|NCT03849469|EXPERIMENTAL|Arm 2|Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)
62318453|NCT01785953||1|
62318454|NCT03633578|EXPERIMENTAL|Interventional group|Patients are asked to walk ont a treadmill in four conditions: with and without distraction (virtual environment) and at different speed (comfortable vs high).
62687680|NCT05597605|EXPERIMENTAL|The SHINE SYSTEM|
62687681|NCT06048497||Preload|Patients with baseline FTc \< 327 ms were assigned to the preload group, and Ringer Lactate (RL) preload fluid administration to these patients was continued until FTc \> 327 ms.
62128241|NCT03149991|ACTIVE_COMPARATOR|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
62128242|NCT03149991|PLACEBO_COMPARATOR|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
62128243|NCT01901081|EXPERIMENTAL|Prosthetic Training with IMES prosthesis|
62128244|NCT02250235|EXPERIMENTAL|Self-affirmation|In the self-affirmation arm, the patients completed a 10 item questionnaire about their past acts of kindness (self-affirmation) prior to reading the health risk information.
62128245|NCT02250235|NO_INTERVENTION|Control|Control patients completed 10 matched control questions with no self-affirming properties, prior to reading the health risk information.
62318455|NCT02328573|EXPERIMENTAL|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
62318456|NCT02328573|NO_INTERVENTION|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
62128246|NCT05456126||Term infants|The inclusion criteria for term infants are: gestational age 37-42 weeks, birth weight \>2,500 grams, aged 2-4 months, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
62128247|NCT05456126||Preterm infants|The inclusion criteria for preterm infants are: gestational age \<37 weeks, birth weight \<2,500 grams, aged 2-4 months (corrected for prematurity), and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
62128248|NCT02389907||Total Hip Replacement Group|Adults who have undergone a total hip replacement
62128249|NCT02389907||Hysterectomy Group|Adults who have undergone a hysterectomy
62128250|NCT03419572||Second line therapy|Data collection
62128251|NCT03419572||Third and later line therapy|Data collection
62318457|NCT04691596|ACTIVE_COMPARATOR|Control Group|One fourth of participants were assigned to the Control Group, and received a basic training with the StepUp app and were asked to contact the study team with any problems or questions they encountered during the eight-week study period. No other intervention tools or app reminders were provided to the Control Group.
62687682|NCT06048497||Non-preload|Patients with baseline FTc \> 327 ms were assigned to the non-preload group, and preload fluid was not administered to these patients
62687683|NCT00662038|EXPERIMENTAL|Treatment|pirfenidone
62687684|NCT02673060|EXPERIMENTAL|dose escalation of MBC-11|MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)
62318458|NCT04691596|EXPERIMENTAL|Treatment Group 1|Additionally eligible to receive weekly $5 Amazon gift cards over the first four weeks of the study for performing a ≥10-minute walk (i.e. non-cue-contingent incentives)
62318459|NCT04691596|EXPERIMENTAL|Treatment Group 2|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were similarly eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any time of day (i.e. non-cue-contingent incentives)
62687685|NCT05281575|ACTIVE_COMPARATOR|Treatment as Usual BFS (TAU BFS)|Continuation of existing Baby Friendly Spaces program activities in integrated nutrition centers, which are not manualized and without re-training have naturally drifted in fidelity to the intervention and supervision approach due to time since initial training.
62687686|NCT05281575|EXPERIMENTAL|Enhanced BFS|The implementation-enhanced BFS intervention includes re-training using newly developed training materials that focus on building core therapeutic engagement skills. Ongoing supports include brief guidance sheets for each of the most commonly delivered BFS activities, as well as newly established group supervision focused on BFS, discussion facilitation, activities and self-care.
62687687|NCT03733535|EXPERIMENTAL|Treatment|Benralizumab 30mg subcutaneous injection on study days 0, 28 and 56 and 1.0 L 129-Xenon/4-Helium mixture, twice per visit, on days 0, 14, 28 and 112.
62687688|NCT06564051||Observational|Patients undergo blood sample collection and have medical records reviewed throughout study.
62687689|NCT04080531|EXPERIMENTAL|Arm I (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
62687690|NCT04080531|EXPERIMENTAL|Arm II (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
62687691|NCT04050566||Mothers|900 mothers recruited during pregnancy
62318460|NCT04691596|EXPERIMENTAL|Treatment Group 3|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any the pre-specified time of their chosen contextual cue (i.e. cue-contingent incentives)
62687692|NCT04050566||Children|900 children born to the recruited mothers
62687693|NCT05207943|EXPERIMENTAL|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and and in the popliteal fossa.
62318461|NCT01467739|ACTIVE_COMPARATOR|Ambu ® aScope®|
62687694|NCT05207943|SHAM_COMPARATOR|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and in the popliteal fossa.
62687695|NCT05207943|NO_INTERVENTION|Control|Participant will maintain the conventional rehabilitation treatment
62687696|NCT02757963|OTHER|BPE/BPO screening and IPSS screening tool|Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS \>=8 and/or BPE/BPO questionnaire \>=3 with a PSA \>=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
62687697|NCT03194932|EXPERIMENTAL|Treatment|"In Part 1, venetoclax with cytarabine will initially be given at dose level 1 and escalated based on tolerability. Idarubicin will be given only at dose level 4.~Note: Part 1 has been completed.~Two expansion cohorts will be enrolled:~* Cohort A will be a group of 12 participants receiving the recommended phase 2 doses (RP2D) of venetoclax plus cytarabine.~* Cohort B will be a group of 12 participants receiving the RP2D of venetoclax plus cytarabine and idarubicin.~Intrathecal Triple Therapy (ITMHA) will be given prior to cycle 1. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA beginning on day 8 until the cerebrospinal fluid becomes free of leukemia.~Cohort C: Participants will receive venetoclax PO on days 1-21, azacitidine IV on days 1-7, and cytarabine Q12H on days 8-11."
62687698|NCT04823052|PLACEBO_COMPARATOR|Placebo|One capsule, twice a day
62687699|NCT04823052|ACTIVE_COMPARATOR|Sulindac (HLX-0201), dose strength 1|One capsule, twice a day
62687700|NCT04823052|ACTIVE_COMPARATOR|Sulindac (HLX-0201), dose strength 2|One capsule, twice a day
62687701|NCT04823052|ACTIVE_COMPARATOR|Gaboxadol (HLX-0206)|One capsule, twice a day
62687702|NCT06673667|ACTIVE_COMPARATOR|KT-621|Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-621.
62687703|NCT06673667|PLACEBO_COMPARATOR|Placebo|Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.
62687704|NCT05862584|EXPERIMENTAL|Main Cohort|Cohort of patients with inflammatory rheumatism (rheumatoid arthritis or spondyloarthritis diagnosed according to ACR/EULAR 2010 or ASAS), over 18 years of age, and with stable chronic inflammatory rheumatism under biological treatment
62687705|NCT06686862|EXPERIMENTAL|Ibuprofen|Ibuprofen tapering schedule during 3 weeks.
62687706|NCT06686862|NO_INTERVENTION|Acetaminophen|Acetaminophen or metamizole in case of allergy until pain resolution, according to routine clinical practice.
62687707|NCT02096926|PLACEBO_COMPARATOR|Placebo|placebo
62687708|NCT02096926|ACTIVE_COMPARATOR|Ibuprofen|400 mg PO
62687709|NCT04600414|ACTIVE_COMPARATOR|Collaborative Care for Mental Health Disorders|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for mental health disorders.
62687710|NCT04600414|EXPERIMENTAL|Collaborative Care for Opioid Use Disorder|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for opioid use disorder.
62687711|NCT02459600|EXPERIMENTAL|All participants|"The measurement will be done at all the participants. the results will the divides in the following way:~1. Refraction measurements under general anesthesia without cycloplegic eye drops.~2. Refraction measurements under general anesthesia with cycloplegic eye drops."
62687712|NCT06641115|EXPERIMENTAL|HOPE Therapy|Helping Opioid Use and PTSD with Exposure (HOPE) therapy is an integrated 10-12 week treatment for opioid use disorder and trauma/posttraumatic stress disorder
62687713|NCT06641115|NO_INTERVENTION|Treatment as Usual|Participants take medications as prescribed and attend standard community substance use treatment services
62687714|NCT06168448||Group 1 : Patients with oral and written information|"Group made up of patients hospitalized at that time in the infectious diseases department who met the eligibility criteria set out in the protocol.~This group of patients will receive the legal oral and written information concerning the additional examination prescribed, as usually delivered by their doctor."
62687715|NCT06168448||Group 2 : Patients with oral and written information + video information|"Group made up of patients hospitalized at that time in the infectious diseases department who met the eligibility criteria set out in the protocol.~This group of patients will receive the legal oral and written information concerning the additional examination prescribed, as usually delivered by their physician, and in addition the video tool will be applied to them."
62687716|NCT06168448||Group 3 : Caregivers|"Nurses and physicians working in the infectious and tropical diseases department.~This group of caregivers will assess the impact of the intervention on their practice."
62128252|NCT03485950|EXPERIMENTAL|Group I (ceftolozane-tazobactam)|Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.
62318462|NCT01467739|ACTIVE_COMPARATOR|a conventional reusable fiberscope.|
62318463|NCT01801046|EXPERIMENTAL|Treatment (chemotherapy, G-PBSC)|INDUCTION CHEMOTHERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-3 and cytarabine IV on days 1-7. HMMACT: Patients receive G-PBSC on day 9.
62318464|NCT06098885||extraction treatment|patients treated with bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
62687717|NCT06682598|EXPERIMENTAL|Multicomponent Training|The subjects will perform multicomponent training sessions every day until hospital discharge day. It is composed of strength, power, balance, and walking exercises. The intervention is based on the VIVIFRAIL program, adapted for the participant's functional level.
62687718|NCT06682598|NO_INTERVENTION|Control|Subjects will receive the usual care of the hospital
62687719|NCT00832026||Sleep apnea|Patients with diagnosed obstructive sleep apnea
62687720|NCT02980900|PLACEBO_COMPARATOR|Placebo supplement|Post exercise placebo supplement Pre bed placebo supplement
62687721|NCT02980900|ACTIVE_COMPARATOR|Post exercise supplement|Post exercise protein-polyphenol supplement Pre bed placebo supplement
62318465|NCT06098885||distalization treatment|patients treated by distalization orthodontic treatment.
62318466|NCT03943667|EXPERIMENTAL|GEMPAX|Gemcitabine + Paclitaxel until progression
62318467|NCT03943667|ACTIVE_COMPARATOR|Control|Gemcitabine alone until progression
62687722|NCT02980900|ACTIVE_COMPARATOR|Pre bed supplement|Post exercise placebo supplement Pre bed protein-polyphenol supplement
62687723|NCT02980900|ACTIVE_COMPARATOR|Post exercise + pre bed supplement|Post exercise protein-polyphenol supplement Pre bed protein-polyphenol supplement
62687724|NCT04205916|EXPERIMENTAL|Experimental Group|A total of 50 study subjects (50 eyes) will receive Dextenza dexamethasone intracanalicular insert placed in the lower punctum of their scheduled surgical eye at the time of surgery and will receive intracameral ketorolac during the procedure and 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure.
62687725|NCT04205916|ACTIVE_COMPARATOR|Control Group|A total of 50 study subjects (50 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, ketorolac 0.5% qid 1 day prior to surgery and for 1 month postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
62687726|NCT05768672||Cases|Right-handed Individuals diagnosed with obesity will be recruited at the beginning of a rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).
62687727|NCT05768672||Controls|Age-matched, right-handed, individuals with a healthy weight recruited outside the hospital through personal contacts of the researchers and word-of-mouth
62687728|NCT05350774|EXPERIMENTAL|IVIg arm|IVIg arm IV immunoglobulin 0.4g/kg/day for 5 days
62687729|NCT05350774|PLACEBO_COMPARATOR|Placebo arm|equivalent volume of Normal Saline for 5 days
62687730|NCT01251861|ACTIVE_COMPARATOR|Arm A (observation and bicalutamide)|Patients undergo observation on weeks 1-12. Patients then receive bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of \>= 50% may continue on bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
62318468|NCT03628469|EXPERIMENTAL|Proactive Health Support|The purpose of the intervention is to enhance patients' self-management strategies and thereby enable patients to cope with illness at home and prevent the development of those conditions, that are sensitive to preventive efforts.The intervention includes active listening, coaching and counselling and elements from case management such as assessing the need for healthcare services. Emphasis is on supporting and empowering the patient to make the necessary contacts to healthcare professionals.
62687731|NCT01251861|EXPERIMENTAL|Arm B (Akt inhibitor MK2206 and bicalutamide)|Patients receive Akt inhibitor MK2206 PO once per week on weeks 1-44 and bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of \>= 50% may continue on Akt inhibitor MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
62687732|NCT05919030|EXPERIMENTAL|Chemoradiation + Tislelizumab|"Intensity-modulated radiotherapy (IMRT):~Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy~During concurrent radiation therapy:~Drug: Tislelizumab 200 mg IV Q3W Drug: Nab Paclitaxel 75 mg/m² IV QW Drug: Cisplatin 25 mg/m² IV QW~During consolidation therapy:~Drug: Tislelizumab 200 mg IV Q3W Drug: Nab Paclitaxel 220 mg/m² IV Q3W Drug: Cisplatin 75 mg/m² IV Q3W"
62687733|NCT05919030|ACTIVE_COMPARATOR|Chemotherapy + Tislelizumab|Drug: Tislelizumab 200 mg IV Q3W Drug: Nab Paclitaxel 220 mg/m² IV Q3W Drug: Cisplatin 75 mg/m² IV Q3W
62687734|NCT03493880||naCT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
62687735|NCT03493880||naCRT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
62318469|NCT03628469|NO_INTERVENTION|Usual care|Usual care
62687736|NCT05890755||Healthy participants between 18 and 40 years of age|
62687737|NCT05890755||Healthy participants between 60 and 80 years of age|
62687738|NCT02510248|EXPERIMENTAL|Study Drug|Study drug will be AL-704 once or twice daily for up to 7 days in dosages ranging from 100 mg to 1500 mg.
62687739|NCT02510248|PLACEBO_COMPARATOR|Placebo|Placebo to match study drug dosing.
62687740|NCT01005979|EXPERIMENTAL|A|
62687741|NCT06047587|EXPERIMENTAL|VR-TrAC|Participants assigned to the VR-TrAC group will follow the training: Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each. The treatment protocol used in this training is based on the Virtual Reality Aggression Prevention Training (VRAPT), developed by Klein Tuente et al. (2020). The first four sessions focus on the early stages of information processing (what is happening and what does it mean). Session five through eight focus on the late information processing stages (what goals am I trying to achieve, what options do I have to react, what am I going to do, and what is the reaction or behavior). Session 10 through 15 combines the early and late stages, as all newly learned behavior will be incorporated in the interactive scenarios. To train the aforementioned stages, different aggressive-inducing situations are practiced in VR.
62128253|NCT03485950|ACTIVE_COMPARATOR|Group II (standard of care antibiotic treatment)|Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.
61925239|NCT01643603|EXPERIMENTAL|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. Patients who are day 100-180 post transplant will be eligible. The treatment will be started as close to day 100 as possible. The range of days is provided to ensure that patients have recovered from toxicities associated with ASCT and are not deemed ineligible if they were recovering from any toxicity associated with ASCT at day 100.The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months.
62128254|NCT01766154|EXPERIMENTAL|Subjects with normal renal function given tirofiban|Subjects with normal renal function (CrCl \>90 mL/min)
62128255|NCT01766154|EXPERIMENTAL|Subjects with moderate renal insufficiency given tirofiban|Subjects with moderate renal insufficiency (CrCl 30-59 mL/min)
62128256|NCT01766154|EXPERIMENTAL|Subjects with severe renal insufficiency given tirofiban|Subjects with severe renal insufficiency (CrCl \<30 mL/min).
62318470|NCT03393845|EXPERIMENTAL|Pembrolizumab + Fulvestrant|Pembrolizumab 200m IV q3W + Fulvestrant. Loading dose 500mg IV IM q2W x3 followed by 500mg IM q4W
62318471|NCT01010841|ACTIVE_COMPARATOR|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
62479852|NCT06662786|EXPERIMENTAL|Arm A: Amivantamab in Combination With Chemotherapy|Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
62479853|NCT06662786|ACTIVE_COMPARATOR|Arm B: Cetuximab in Combination With Chemotherapy|Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
61925240|NCT01759888|EXPERIMENTAL|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 60 PD patients, including 20 LRRK2 G2385R, 20 PARK6, and 20 idiopathic PD. Subjects will be evaluated sequentially with 18F-DTBZ during a 36 month period. 18F-DTBZ PET scans will be performed twice, at baseline, and 24 (21\~27) months following the start of their participation in the study.
62128257|NCT06020885|EXPERIMENTAL|Experiment group|"This is a prospective, single-arm, phase 1 trial. A total of 18 unresectable LA-ESCC patients are required to be enrolled.~1. Induction chemo-immunotherapy All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.~2. Hypo-CCRT Evaluation will be performed three weeks after the induction chemo-immunotherapy, LA-ESCC patients without disease progression will continue the split-course hypo-CCRT treatment.~Split-course hypo-CCRT is administered at the following three dose levels:~* Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~* Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~* Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
62128258|NCT05106075|EXPERIMENTAL|biologic sample collection|Blood samples or gingival exsudat collection
62128259|NCT01845259|EXPERIMENTAL|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
62318472|NCT01010841|EXPERIMENTAL|Low-glycemic-load diet + medical food|Modified Mediterranean-style, low-glycemic-load diet + medical food
62318473|NCT01287234|OTHER|All Patients|All patients will have an echocardiogram and SonR sensor readings completed.
62318474|NCT05638386||Patients who underwent a robotic-assisted total knee arthroplasty with the use of bone plugs|
62318475|NCT05638386||Patients who underwent a robotic-assisted total knee arthroplasty without the use of bone plugs|
62318476|NCT05837312|EXPERIMENTAL|Reconnecting to Internal Sensations and Experiences|The interoceptive training consists of four 25-30 minute modules (plus 15-minutes worth of optional weekly practice) that focus on multiple aspects of interoception including: body awareness, body sensations and movement, eating, health and selfcare, emotional awareness, and understanding the self in relation to others. These modules are delivered weekly.
62318477|NCT03952546|EXPERIMENTAL|Treatment Arm|Saline-coupled bipolar sealer
62318478|NCT03952546|ACTIVE_COMPARATOR|Control Arm|Unipolar electrocautery
62318479|NCT06392984||Participants aged 10-18 years who were diagnosed with pectus deformity|Pectus deformity study form consisting of clinical and radiological measurements of participants aged 10-18 years who were diagnosed with pectus deformity and applied to the scoliosis outpatient clinic will be filled in detail.
62318480|NCT06392984||Control group|Pectus deformity study form consisting of clinical and radiological measurements of participants aged 10-18 years who were diagnosed with normal and applied to the scoliosis outpatient clinic will be filled in detail.
62318481|NCT05898503|EXPERIMENTAL|Combined training group|
62318482|NCT05898503|EXPERIMENTAL|Resistance training group|
62318483|NCT05898503|EXPERIMENTAL|Walking exercise group|
62318484|NCT05898503|ACTIVE_COMPARATOR|Positive control group|
62318485|NCT05898503|SHAM_COMPARATOR|Negative control group|
62318486|NCT01219244|EXPERIMENTAL|Caloric restriction|
62318487|NCT01219244|EXPERIMENTAL|omega-3 supplementation|
62318488|NCT01219244|EXPERIMENTAL|resveratrol supplementation|
62318489|NCT01219244|PLACEBO_COMPARATOR|placebo|
62479854|NCT06488716|EXPERIMENTAL|Phase Ia: Dose Escalation|
62479855|NCT06488716|EXPERIMENTAL|Phase Ia: Expansion|
62479856|NCT06488716|EXPERIMENTAL|Phase Ib: Dose Escalation|
62479857|NCT06488716|EXPERIMENTAL|Phase Ib: Expansion|
62318490|NCT01219244|EXPERIMENTAL|2nd step: intervention + physical /cognitive training|most effective dietary intervention plus physical and cognitive training
62318491|NCT01219244|PLACEBO_COMPARATOR|2nd step: most effective dietary intervention plus control|most effective dietary intervention plus control
62479858|NCT01171898|EXPERIMENTAL|Dose Escalation Cohort (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
62479859|NCT01171898|EXPERIMENTAL|Non-metastatic CRPC (Phase 2)|Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
62128260|NCT01845259|PLACEBO_COMPARATOR|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
62318492|NCT01382186||Purposive Sampling|Purposive sampling was used to identify a sample of 33 Veterans who have been Personally Authenticated for the SM feature on MHV. Participants were recruited from each site (Tampa, Boston). Women were purposively recruited to ensure females were represented in data findings.
62318493|NCT01382186||Random Sampling|Random sampling was used to conduct a quantitative survey with 819 veterans to explore their experiences using secure messaging.
62318494|NCT01936649|EXPERIMENTAL|AdreView (Iobenguane I 123 Injection)|Two administrations of single intravenous (i.v) injection of Iobenguane I 123 10 millicuries (mCi) (370 MBq) over 1 to 2 minutes within an interval of 5 to 14 days.
62318495|NCT01776099|ACTIVE_COMPARATOR|pure galactose|5 grams of galactose, three times a day with the main meals, duration: 4 weeks
62318496|NCT01776099|PLACEBO_COMPARATOR|pure palatinose|5 grams of palatinose, three times a day with the main meals, duration: 4 weeks
62318497|NCT01776099|PLACEBO_COMPARATOR|soluble non-fermentable fibers|5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks
62479860|NCT01171898|EXPERIMENTAL|Treatment-naive metastatic CRPC (Phase 2)|Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
62128261|NCT05546359|EXPERIMENTAL|Stage 1 - Group 1: IV amisulpride 0.035 mg/kg + IV dexamethasone|Stage 1 - Group 1: IV amisulpride 0.035 mg/kg + IV dexamethasone
62128262|NCT05546359|EXPERIMENTAL|Stage 1 - Group 2: IV amisulpride 0.07 mg/kg + IV dexamethasone|Stage 1 - Group 2: IV amisulpride 0.07 mg/kg + IV dexamethasone
62128263|NCT03903822|EXPERIMENTAL|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
62128264|NCT03903822|EXPERIMENTAL|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
62128265|NCT03903822|EXPERIMENTAL|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
62128266|NCT03903822|EXPERIMENTAL|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
62128267|NCT03903822|EXPERIMENTAL|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
62128268|NCT03903822|EXPERIMENTAL|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
62128269|NCT03903822|PLACEBO_COMPARATOR|Vehicle cream QD|Vehicle cream applied once daily (QD)
62128270|NCT03903822|PLACEBO_COMPARATOR|Vehicle cream BID|Vehicle cream applied twice daily (BID)
62479861|NCT01171898|EXPERIMENTAL|Post-abiraterone metastatic CRPC (Phase 2)|Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
61925241|NCT01180530||A|
62128271|NCT02617771|ACTIVE_COMPARATOR|Vit D|Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
62128272|NCT02617771|NO_INTERVENTION|Control|
62128273|NCT01348594||Vitamin D deficient|
62128274|NCT01348594||Vitamin D sufficient|
62128275|NCT06181695|EXPERIMENTAL|Sufentanil IN + Morphine IV|Intranasal Sufentanil + IV morphine:
62128276|NCT06181695|PLACEBO_COMPARATOR|Placebo IN + Morphine IV|Placebo of Sufentanil administered intranasally (IN) . One single administration +IV morphine similar to the experimental arm:
62479862|NCT01805869||Healthy volunteers|Male or female ages 16-50
62128277|NCT05191810|EXPERIMENTAL|Study Group|Macrogol (PEG 3350, PEG 4000), standard dosage Educational intervention: Recommendation of adequate for age fluid intake plus standard information about non-pharmacological supporting treatment
62128278|NCT05191810|NO_INTERVENTION|Control Group|Macrogol (PEG 3350, PEG 4000), standard dosage Standard educational information about non-pharmacological supporting treatment
62128279|NCT04565834||Suicidal patients|Patients who have made at least one attempt to commit suicide.
62128280|NCT04565834||Control group|"This group will consist of two types of people:~* 75 healthy subjects (i.e. those who have no mental disorders and have never attempted to commit suicide) and~* 150 patients suffering from depression but have never attempted to commit suicide."
62128281|NCT04033107|EXPERIMENTAL|Treatment arm|Vitamin C combined with metformin
62128282|NCT03906435|NO_INTERVENTION|Control Arm|Standard of care information given by NICU staff and Follow up Clinic staff, including information about health care, diagnosis, medications, daily cares, anticipatory guidance, and discharge prep information.
62128283|NCT03906435|EXPERIMENTAL|Intervention CBT Arm|In addition to Standard of care information that the control arm receives, this arm will also receive 5 CBT sessions focusing on past NICU trauma, emotional coping, parental perceptions of child vulnerability, and helpful parenting and emotional coping skills.
62318498|NCT01776099|ACTIVE_COMPARATOR|non-soluble non-fermentable fibers|5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks
62318499|NCT03280732|EXPERIMENTAL|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
62318500|NCT02288975||CytoSorb|Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
62318501|NCT02288975||Control|Patients with septic shock will get routine ICU care.
62318502|NCT01315015|EXPERIMENTAL|Contrast enhanced breast MRI|The additional MRI will take place biennially after the regular screening mammogram for a study period of 6 years.
62318503|NCT01315015|NO_INTERVENTION|Regular breast cancer screening|No further follow-up until next scheduled screening examination two years later (according to the current Dutch guideline).
62318504|NCT04710589||CTV 3mm|CTV is expanded by 3mm on the basis of GTV.
62318505|NCT04710589||CTV 6mm|CTV is expanded by 6mm on the basis of GTV.
62128284|NCT05146440|EXPERIMENTAL|PM14 in monotherapy and in combination with radiotherapy in STS and other solid tumors|"Cohort A : Phase I. PM14 24-h IV 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort B: Phase I. PM14 3-h IV infusion 3 d 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort E: PM14 at RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort F: PM14 at the RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort C: Phase I: PM14 at the RP2D, 21-d cycles in combination with radiotherapy, up to PD or toxicity. Dexamethasone recommended. Radiation therapy 3Gy/f 10 d. Phase II: PM14 at RP2D with radiation therapy.~Cohort D: Phase I: PM14 at the RP2D, 3 x 21-d cycles in neoadjuvant setting, in combination with radiotherapy. Dexamethasone recommended. Radiation therapy 1.8Gy/f 25 d. Phase II: PM14 at RP2D with radiation therapy."
62318506|NCT02421120|EXPERIMENTAL|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
62687742|NCT06047587|OTHER|Care as Usual|Participants receive Care As Usual (CAU) when necessary. CAU in prison consists of treatment with the main focus to stabilize a disrupted psychological state (such as pharmacological treatment, supportive contact or a transfer to a Penitentiary Psychiatric Centre where necessary interventions are applied to stabilize the disorder).
62318507|NCT04534062|EXPERIMENTAL|Group A|Participants in Group A will perform PNF D2 flexion and extension with free weights (PNF D2 FW) The intensity of exercise will be determined for each individual by using maximum repetition test (1 repetition maximum 1-RM). The intensity will be kept 50 % of the maximal load. 3 sets of PNF D2 FW Flexion (flexion-abduction and external rotation) and PNF D2 FW Extension (extension-adduction-internal rotation) respectively will be performed on each upper limb with 10 repetitions per set. All exercises will be performed with a rest interval of 30 seconds to 1 minute between the sets.
62687743|NCT06036264||Exposed subject group|Patients, starting dialysis, eligible for arteriovenous fistula (AVF) creation and/or renal transplantation who received pre-Advanced Practice Nurse (APN) intervention in their care pathway will be included Datas will be collected of medical record.
62479863|NCT05192720|EXPERIMENTAL|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 100 ml/day orally for 1 month. The intervention solution is given in a neutral plastic container
62687744|NCT06036264||Comparable unexposed subject group|"All patients starting dialysis sessions eligible for arteriovenous fistula (AVF) creation and/or renal transplantation will be included.~Datas will be collected of medical record."
62687745|NCT06036264||professional working with the pre-Advanced Practice Nurse (APN)|"professional working with the pre-Advanced Practice Nurse (APN) will be included.~Semi-structured interview will be performed."
62128285|NCT03197571|EXPERIMENTAL|Nant Urothelial Cancer Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
62687746|NCT05490472|EXPERIMENTAL|JAB-2485 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-2485 will be administered as monotherapy to determine the MTD and RP2D.
62687747|NCT05490472|EXPERIMENTAL|JAB-2485 monotherapy, Phase 2a, Dose Expansion|JAB-2485 will be administered as monotherapy in patients with specific tumor types to evaluate the preliminary antitumor activity.
62687748|NCT05566769|EXPERIMENTAL|NMOSDCopilot|Performance of digital tests and standard test in clinic at D0 and M6 Use of NMOSDCopilot at-home in between visits during 12 months
62318508|NCT04534062|EXPERIMENTAL|Group B|Participants in this group will perform 3 sets of PNF D2 flexion (flexion-abduction and external rotation) and extension (extension-adduction-internal rotation) respectively with elastic bands after assessing the 1-RM test starting with a lightest resistance and gradually progressing to the higher level. Subsequently, 71% to 86% of 1-RM will be taken as a target range of the resistance for the training that will be applied through Elastic Resistance Band in accordance with values that are provided on the Thera-Band website. Moreover, each set will consist of 10 repetitions for both D2 flexion and Extension and a resting interval of 60 seconds between two consecutive sets. The procedure will be repeated for both limbs.
62318509|NCT04534062|EXPERIMENTAL|Group C|The participants in the Group C or control group will perform the PNF D2 flexion and extension without any resistance. Three sets consist of 10 repetitions of each pattern for both upper limbs will be performed with an interval of 60 seconds between two consecutive sets.
62318510|NCT03005847|EXPERIMENTAL|FPP arm|active treatment with fermented papaya preparation
62318511|NCT04196036|ACTIVE_COMPARATOR|Day 3 vitrification|Day of vitrification of supernumerary embryos is day 3
62318512|NCT04196036|ACTIVE_COMPARATOR|Day 5 vitrification|Day of vitrification of supernumerary embryos is day5
62128286|NCT03199209|EXPERIMENTAL|Group I (home visit, information about healthy lifestyles)|Participants and their family member meet with a community health worker in their home over 90 minutes to learn about physical activity, healthy eating, and to set goals, once a month for 6 months. Participants also receive 2-5 text messages per week that contain health tips related to healthy lifestyles and information about local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
62128287|NCT03199209|EXPERIMENTAL|Group II (home visit, information about healthy homes)|Participants and their family member meet with a community health worker in their home over 90 minutes to receive information on how to be safe and healthy at home and information about indoor air quality, home safety, CPR/first aid, how to prepare for emergencies, and keeping pests away, once a month for 6 months. Participants also receive 2-5 text messages per week that contain information about healthy homes and local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
62128288|NCT00653276|ACTIVE_COMPARATOR|Treatment A|Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
62128289|NCT00653276|ACTIVE_COMPARATOR|Treatment B|Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
62128290|NCT01673516|ACTIVE_COMPARATOR|group Co|"group Co receives intensive medical therapy utilizing integrated hemodynamic management calculated by impedance cardiography of The HOTMAN® System"
62128291|NCT01673516|ACTIVE_COMPARATOR|group RDN|"For patients who will be randomly assigned to undergo renal denervation by The SymplicityTM Renal Denervation System, the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Symplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm."
62128292|NCT03010631|ACTIVE_COMPARATOR|Cohort 1 (Treatment Sequence AB)|Cohort 1: Treatment A. Capsule Fasted (7-day Washout) then Treatment B. Sprinkle Formulation, Fasted
62128293|NCT03010631|EXPERIMENTAL|Cohort 1 (Treatment Sequence BA)|Cohort 1: Treatment B. Sprinkle Formulation, Fasted (7-day Washout) then Treatment A. Capsule Fasted
62128294|NCT03010631|EXPERIMENTAL|Cohort 2 (Treatment Sequence CD)|Cohort 2: Treatment C: Sprinkle Formulation, Fed (7-day Washout) then Treatment D: Sprinkle Formulation, Fasted
62128295|NCT03010631|EXPERIMENTAL|Cohort 2 (Treatment Sequence DC)|Cohort 2: Treatment D: Sprinkle Formulation, Fasted (7-day Washout) then Treatment C. Sprinkle Formulation, Fed
62128296|NCT03762668|OTHER|MDACL, then DACL|Modified delefilcon A contact lenses (MDACL) worn first, followed by delefilcon A contact lenses (DACL), as randomized. Each product worn bilaterally (in both eyes) for approximately 1 week in a daily disposable modality.
62128297|NCT03762668|OTHER|DACL, then MDACL|DACL worn first, followed by MDACL, as randomized. Each product worn bilaterally for approximately 1 week in a daily disposable modality.
62128298|NCT05936177|OTHER|Education Group|The Education Group arm will involve participants who receive the osteoporosis education intervention, which includes a concise educational session delivered by a physiatrist, covering various topics related to osteoporosis. Participants in this arm will have the opportunity to enhance their knowledge and awareness of osteoporosis through the provided educational materials and interactive discussions.
62128299|NCT01992692||PD group|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
62128300|NCT01992692||non-PD group|Non-Parkinsonian patients undergoing intracranial surgery
62128301|NCT02429570|EXPERIMENTAL|Meclofenamate|All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
62318513|NCT01641016|ACTIVE_COMPARATOR|Continuous Therapy|Continue with current antiretroviral therapy regime as per standard care
62128302|NCT02820116|EXPERIMENTAL|Icotinib|Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.
62318514|NCT01641016|EXPERIMENTAL|Short Cycle Therapy|Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
62318515|NCT06032676||Infants with necrotising enterocolitis reviewed by a surgeon|Infant with suspected or confirmed NEC undergoing review by surgeon, regardless of outcome of that review (i.e. surgery indicated or not)
62318516|NCT02222727|ACTIVE_COMPARATOR|Donepezil|Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
62318517|NCT02222727|NO_INTERVENTION|Control|Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.
62318518|NCT02378428|EXPERIMENTAL|MIBG|Research participants with MIBG avid tumors
62479864|NCT05192720|PLACEBO_COMPARATOR|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 100 ml/day orally for 1 month. The placebo solution is given in a neutral plastic container (same as for intervention/experimental solution).
62479865|NCT03037554|EXPERIMENTAL|Lateralized Thermal Sleepwear|For two consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics
62128303|NCT03386539|EXPERIMENTAL|Everolimus/Low-Dose Tacrolimus|"Everolimus approximately 0.6 mg/m2/dose taken by mouth every 12 hours for 30 months. Everolimus dose will be adjusted to achieve a trough concentration of 3-8 ng/ml.~Tacrolimus 0.0125 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 3-5 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 2.5-4.5 ng/mL.)"
62128304|NCT03386539|ACTIVE_COMPARATOR|Tacrolimus/Mycophenolate Mofetil|"Tacrolimus 0.05 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 7-10 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 5-8 ng/mL.)~Mycophenolate mofetil 600 mg/m2/dose by mouth every 12 hours for 30 months."
62128305|NCT04439747||Control|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, neutrophil- gelatinase assosiated lipocalin-2 (NGAL), adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, antibodies to thyroid peroxidase (Ab-TPO), Ab--R-TSH, Ab-Tg, parathyroid hormone (PTH), vitamin D, osteocalcin, b-cross-laps, prolactin)
62128306|NCT04439747||CKD 1-2|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps, prolactin)
62128307|NCT04439747||CKD 3-5|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps,prolactin)
62128308|NCT04410367|EXPERIMENTAL|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
62128309|NCT04790604|EXPERIMENTAL|Intervention|Community health navigator program for six months.
62128310|NCT04790604|OTHER|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program.
62128311|NCT02395978|EXPERIMENTAL|Part I: 1 PDC-1421 Capsule|1 PDC-1421 Capsule TID, p.o. after meal for 28 days
62128312|NCT02395978|EXPERIMENTAL|Part I: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
62128313|NCT02395978|EXPERIMENTAL|Part II: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 42 days
62128314|NCT02395978|EXPERIMENTAL|Part II: 1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
62128315|NCT02395978|PLACEBO_COMPARATOR|Part II: 2 placebo|2 placebo TID, p.o. after meal for 42 days
62128316|NCT03038581||Self-inflicted wrist injury|Wrist injury by self-infliction
62318519|NCT01893593|OTHER|Control|Usual care
62318520|NCT01893593|ACTIVE_COMPARATOR|Intervention|Multifaceted intervention to improve clinical systems
62318521|NCT03760380|EXPERIMENTAL|Phase 1 Short Term|Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
62318522|NCT03760380|EXPERIMENTAL|Phase 2 Long Term|Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
62479866|NCT03037554|SHAM_COMPARATOR|Sham-Lateralized Sleepwear|For two consecutive nights subjects will wear Sham-Lateralized Sleepwear
62479867|NCT03832361|EXPERIMENTAL|IMGN853|IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
62128317|NCT03038581||Traumatic wrist injury|Wrist injury by not self-inflicted trauma
62128318|NCT01759186||None interventional|
62128319|NCT04377698|ACTIVE_COMPARATOR|Platelet Rich Fibrin group(PRF)|Following apicoectomy PRF gel was prepared and placed in the osseous defect followed by placement of PRF membrane
62128320|NCT04377698|ACTIVE_COMPARATOR|Freezed Dried Bone Allograft group(FDBA)|Following apicoectomy FDBA graft were prepared and placed in the osseous defect followed by placement of PRF membrane
62318523|NCT05604612|EXPERIMENTAL|Experimental|
62318524|NCT05604612|NO_INTERVENTION|Active Comparator|
62318525|NCT01652378||Cocaine-Addicted Participants|Group of participants diagnosed with cocaine dependence
62318526|NCT01652378||Control Participants|healthy control volunteers
62318527|NCT05544825|EXPERIMENTAL|Ice plant group|This group takes ice plant extract for 12 weeks.
62318528|NCT05544825|PLACEBO_COMPARATOR|Placebo group|This group takes a placebo for 12 weeks.
62479868|NCT06679309|EXPERIMENTAL|Integrated care pathway supported by the integrated care lead|"Enrolled patients in the ICP will then undergo more assessment by the Integrated Care Lead to develop a preliminary inventory of their needs for transitioning back to their health home. Patients will then be assigned an Integrated Care Lead with expertise in managing their particular needs. This will result in the development of a complex care plan that is co-designed with a patient's acute and community care team (eg: primary care, home care, community services, hospital medical team etc). This plan will be documented in Connect Care and incorporated into the discharge summary at the time of hospital discharge. (see Appendix 2)~Calgary Zone Integrated Care Program will then provide:~* Continuity of care with the assigned ICP team member(s) throughout their hospitalization and connection with community resources and services in the process of complex discharge planning.~* Efficient use of healthcare resources by reducing duplication of services and systematically screening for unmet"
62128321|NCT00212134|ACTIVE_COMPARATOR|aphakic contact lens|"Contact lens correction of aphakia~INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly."
62318529|NCT02470013|EXPERIMENTAL|Intervention Group|Nutrition counselling and balanced, energy dense, moderate protein sip feed ('Fortimel Compact, Nutricia GmbH) for 3 months
62687749|NCT06464510|EXPERIMENTAL|Early Vasopressin|After randomization, vasopressin will be initiated and titrated up to 0.04U/min to maintain the target mean arterial pressure (MAP). Concurrently, norepinephrine will be reduced, with the goal of using the maximum dose of vasopressin and minimizing or eliminating the use of norepinephrine, while still maintaining the target MAP.
62687750|NCT06464510|ACTIVE_COMPARATOR|Norepinephrine plus vasopressin for rescue|After randomization, norepinephrine will be titrated to maintain the target MAP. Vasopressin will be introduced as a rescue strategy only if the norepinephrine dose exceeds 0.5 μg/kg/min. Once vasopressin is initiated, it can be titrated up to 0.04U/min to help maintain the target MAP if the norepinephrine dose remains above 0.5 μg/kg/min.
62687751|NCT06308926|EXPERIMENTAL|MRG-001 (Low-dose)|MRG-001 will be administered subcutaneously at 0.007 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
62687752|NCT06308926|EXPERIMENTAL|MRG-001 (High-dose)|MRG-001 will be administered subcutaneously at 0.01 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
62687753|NCT06308926|PLACEBO_COMPARATOR|Placebo|Sterile injectable saline will be administered subcutaneously at 0.01 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
61925242|NCT04956770|EXPERIMENTAL|Rehabilitation supported by TESS|"Patient will be asked to come to the hospital for three types of patient sessions:~* Stimulation configuration sessions: TESS protocols will be setup and optimized during this phase.~Duration: minimum 4 sessions over 2 weeks, maximum 20 sessions over a month. In addition, some sessions at a free frequency as needed during rehabilitation will be programed (maximum once a week).~* TESS-supported rehabilitation sessions: Patients will undergo an in-clinic rehabilitation training regime supported by TESS.~Duration: 24 sessions spread over minimum three months and maximum five months~* Pre- and post-rehabilitation evaluation sessions: four clinical evaluation sessions will take place focusing on assessment of locomotion, balance and PD related deficits."
61925243|NCT02923427|ACTIVE_COMPARATOR|Laryngeal mask Supreme|"Insertion of the Laryngeal mask Supreme and evaluation of its clinical performance"
61925244|NCT02923427|EXPERIMENTAL|i-gel|"Insertion of the i-gel and evaluation of its clinical performance"
62128322|NCT00212134|EXPERIMENTAL|aphakic intraocular lens|"Intraocular lens implantation~INTERVENTION: At the time of surgery to remove the cataractous natural lens, an intraocular lens was implanted to correct the large hyperopic refractive error induced by the cataract surgery."
62128323|NCT03648762|OTHER|Aerobic Exercise Intervention|12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
62128324|NCT03648762|OTHER|Combined Aerobic and Strength Exercise Intervention|12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
62128325|NCT03648762|OTHER|Inspiratory Muscle Training Exercise Intervention|12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
62128326|NCT02002052|ACTIVE_COMPARATOR|Standard Arm|Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
62128327|NCT02002052|EXPERIMENTAL|Experimental Arm|Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy
62128328|NCT02672722|EXPERIMENTAL|Healthy Test Subjects|We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.
62128329|NCT05563168|EXPERIMENTAL|Standard Of Care (SOC) + diltiazem|Patients will receive the standard of care at the time of their inclusion in the trial and will also receive diltiazem (60mg 3 times a day) for 7 days.
62318530|NCT02470013|NO_INTERVENTION|Control Group|Nutrition counselling upon hospital discharge (usual care)
62318531|NCT00341952||Cases|individuals diagnosed with incident, first primary non-Hodgkin lymphoma
62318532|NCT00341952||Controls|individuals identified in the same geographical areas without non-Hodgkin lymphoma or othercancers
62318533|NCT03303339|EXPERIMENTAL|Phase 1b: Onvansertib + low-dose cytarabine|Onvansertib, administered in escalating doses orally Day 1 through Day 5 every 28 days (1 cycle) in combination with cytarabine, which will be administered in all cohorts as 20 mg/m\^2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle). Onvansertib administration, in combination with cytarabine, will be initiated at a starting dose of 12 mg/m\^2 orally, daily for 5 days. Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
62318534|NCT03303339|EXPERIMENTAL|Phase 1b: Onvansertib + decitabine|Onvansertib will be administered in escalating doses orally, Day 1 through Day 5 every 28 days (1 cycle) in combination with decitabine, administered consistently in all cohorts as 20 mg/m\^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle). Onvansertib administration, in combination with decitabine, will be initiated at a starting dose of 12 mg/m\^2 orally, daily for 5 days (Day 1 through Day 5). Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
62687754|NCT00493285|ACTIVE_COMPARATOR|1|MEDI-534 at 10\^4 TCID50 at 0, 2, and 4 months (Nasal spray)
62687755|NCT00493285|ACTIVE_COMPARATOR|2|MEDI-534 at 10\^5 TCID50 at 0, 2, and 4 months (Nasal Spray)
62128330|NCT05563168|PLACEBO_COMPARATOR|SOC + placebo|Patients will receive the standard of care at the time of their inclusion in the trial and will also receive a diltiazem placebo (3 times a day) for 7 days
62128331|NCT00203411|EXPERIMENTAL|Bevacizumab Plus Capecitabine|Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m\^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.
62128332|NCT02120222|EXPERIMENTAL|Treatment (selinexor)|Patients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
62128333|NCT02703701||Usual Care|Group enrolled during normal emergency department operating procedures (without a physician present at triage).
62318535|NCT03303339|EXPERIMENTAL|Phase 2: Onvansertib + decitabine|Onvansertib recommended phase 2 dose, orally Day 1 through Day 5 every 28 days (1 cycle) and decitabine, administered consistently as 20 mg/m\^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle), with treatment modifications or delays based on return of hematopoietic function to baseline or Grade ≤1 toxicity for optimal subject management.
62318536|NCT06554613|EXPERIMENTAL|Olanzapine in Combination with Immune Checkpoint Inhibitors Treatment Group|Receiving first-line treatment with a PD-1/PD-L1 inhibitor as a single agent or in combination with chemotherapy (according to the instructions manual)，Medication is administered on the first day of each cycle, with one cycle every 3 weeks. A continuous 21-day treatment constitutes one treatment cycle.Then receive olanzapine orally at a dose of 5mg once daily (qd), with continuous administration for 6-8 weeks.
62318537|NCT06554613|ACTIVE_COMPARATOR|Group Without Olanzapine|Receiving first-line treatment with a PD-1/PD-L1 inhibitor as a single agent or in combination with chemotherapy (according to the instructions manual)，Medication is administered on the first day of each cycle, with one cycle every 3 weeks. A continuous 21-day treatment constitutes one treatment cycle..
62128334|NCT02703701||Physician at Triage|Group enrolled while a physician is present at triage.
62479869|NCT03587311|EXPERIMENTAL|GROUP I (anetumab ravtansine, bevacizumab)|Patients receive anetumab ravtansine IV over 1 hour on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479870|NCT03587311|EXPERIMENTAL|GROUP II (paclitaxel, bevacizumab)|Patients receive paclitaxel on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62479871|NCT05911321|EXPERIMENTAL|Single Arm|Subjects with relapsed or refractory multiple myeloma receiving the study treatment.
62479872|NCT03520647|EXPERIMENTAL|Treatment Arm|G-CSF mobilized peripheral stem cells and post haplo-identical transplantation cyclophosphamide
62479873|NCT06587464||HAE Participants (Type I or II)|"Participants with HAE type I or II who are prescribed icatibant, enrolled in the patient support program (PSP), and registered in the MyHAE Story mobile app will be included and their data will be collected retrospectively from the first documented date of app until the date of the last recorded attack, participant withdrawal, loss to follow-up, or the end of the study, whichever occurs first."
62479874|NCT04455841|EXPERIMENTAL|Treatment Group A (TGA)|INCB000928 will be administered once daily (QD).
62479875|NCT04455841|EXPERIMENTAL|Treatment Group B (TGB)|INCB000928 will be administered in combination with ruxolitinib.
62479876|NCT04455841|EXPERIMENTAL|Treatment Group C (TGC)|INCB000928 will be administered in combination with ruxolitinib.
62479877|NCT05043038||General Anesthesia Night Float|The residents will be followed over a three week period - one week prior to night float (baseline), the week of night float, and one week after night float (recovery). Participants will be asked to fill out PROMIS surveys weekly.
62479878|NCT05043038||Obstetric Anesthesia Rotation|The residents will be followed and asked to wear the fitbit over a four week period during their rotation. Participants will complete three PROMIS surveys over the four week rotation, and as well as a follow-up PROMIS survey one week after the study period has completed
62479879|NCT04789655|EXPERIMENTAL|CC-96191|CC-96191 will be administered intravenously on a 28-day Cycle
62128335|NCT00925899|EXPERIMENTAL|Melatonin|20 mg
62128336|NCT00925899|PLACEBO_COMPARATOR|Placebo|
62479880|NCT06660173|EXPERIMENTAL|Maridebart Cafraglutide|Participants will be randomized to receive maridebart cafraglutide at varying dose levels, or placebo, for up to 24 weeks. Participants who complete the 24-week main treatment period and meet specific criteria will have the option to begin an exploratory part 2 portion where they will be re-randomized to receive maridebart cafraglutide for an additional 24 weeks.
62128337|NCT00125645|EXPERIMENTAL|Irbesartan|Tablet Irbesartan 150 mg once daily
62128338|NCT04771793||Group A- before implentation of physical restraint protocols|
62128339|NCT04771793||Group B- after implentation of physical restraint protocols|
62128340|NCT05622123|EXPERIMENTAL|Patients with type 1 diabetes who have completed the ENCAPSULATE-DM1 or FMT preserve-DM1 trial|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4 to quantify beta cell mass
62128341|NCT01634893|EXPERIMENTAL|Sorafenib plus Hydroxychloroquine|"Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
62128342|NCT05893459|EXPERIMENTAL|Debrief|Following exposure to a laboratory stressor, participants in this arm will debrief their experience with a friend for 5 minutes while their psychophysiological reactivity is recorded using an electrocardiogram (ECG). Their interaction will be audio and video recorded for later observational coding of their friend's validating and invalidating behaviors during the conversation.
62318538|NCT00854529|EXPERIMENTAL|1|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery
62479881|NCT06660173|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive maridebart cafraglutide at varying dose levels, or placebo, for up to 24 weeks. Participants who complete the 24-week main treatment period and meet specific criteria will have the option to begin an exploratory part 2 period where they will receive maridebart cafraglutide for an additional 24 weeks.
62479882|NCT04410796|EXPERIMENTAL|Osimertinib alone|All patients will receive osimertinib 80mg orally daily. Subjects randomized to Arm A may be dispensed osimertinib for 2 cycles from Cycle 4 onward. Patients will be required to complete a pill diary beginning at Cycle 4.
62479883|NCT04410796|EXPERIMENTAL|Osimertinib plus Carboplatin and Pemetrexed|All patients will receive osimertinib 80mg orally daily. Patients receive Carboplatin (AUC 5 IV q 3 weeks) and Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles followed by pemetrexed maintenance from cycle 8 onwards. Patients will be required to complete a pill diary beginning at Cycle 4.
62479884|NCT00302146||Asymptomatic|Unaffected at-risk individuals with or without a first degree family member with parkinsonism, GD with and without a family history of PD, Gaucher carriers with and without a family history of PD.
62687756|NCT00493285|ACTIVE_COMPARATOR|3|MEDI-534 at 10\^6 TCID50 at 0, 2, and 4 months (Nasal Spray)
62128343|NCT05893459|NO_INTERVENTION|No Debrief|Following exposure to a laboratory stressor, participants in this arm will sit by themselves while their psychophysiological reactivity is recorded using an electrocardiogram (ECG).
62128344|NCT03310645|EXPERIMENTAL|Dose 1 of BAY1817080|"Study Part 1:~Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
62128345|NCT03310645|EXPERIMENTAL|Dose 2 of BAY1817080|"Study Part 1:~Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
62479885|NCT00302146||Control|Controls will include subjects without GBA mutations, with sporadic PD and healthy volunteers who do not have a family history of parkinsonism or Gaucher disease.
62479886|NCT00302146||PD|Subjects with parkinsonism to better characterize the parkinsonian phenotype (e.g.,GD/PD, Sporadic PD, Gaucher carrier PD).
62479887|NCT04408586|ACTIVE_COMPARATOR|Phentermine - Topiramate Extended Release group|
62479888|NCT04408586|PLACEBO_COMPARATOR|Placebo Group|
62479889|NCT04013802|EXPERIMENTAL|HLA-matched VSTs|"Partially HLA-matched VSTs will be thawed and given by intravenous injection. Patients will receive 2 x 10\^7 or 4 x 10\^7 partially HLA-matched MVSTs, depending on their body surface area, as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused with agreement of the principal investigator, patient and/or guardian and the treatment team~Additional doses may be from the same donor or a different donor based on available cell lines and patient/disease factors. Decision to switch to a different donor can be made by the principal investigator based on factors that include sequential treatment of different viral infections, concerns for immune escape of the targeted virus and/or availability of a better matched or otherwise superior VST line. Additional treatments will only be given following the agreement of the patient, treating physician, and investigator. This process can be repeated as needed."
62479890|NCT04931342|EXPERIMENTAL|Ipatasertib + Paclitaxel (PIK3CA/AKT1/PTEN-altered tumors)|Participants in the Ipatasertib + Paclitaxel arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62318539|NCT00854529|ACTIVE_COMPARATOR|2|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery
62479891|NCT04931342|EXPERIMENTAL|Cobimetinib (BRAF/NRAS/KRAS/NF1-altered tumors)|Participants in the Cobimetinib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62479892|NCT04931342|EXPERIMENTAL|Trastuzumab Emtansine (ERBB2-amplified/mutant tumors)|Participants in the Trastuzumab Emtansine arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62479893|NCT04931342|EXPERIMENTAL|Atezolizumab + Bevacizumab (Non-matched)|Participants in the Atezolizumab + Bevacizumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62128346|NCT03310645|EXPERIMENTAL|Dose 3 of BAY1817080|"Study Part 1:~Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
62128347|NCT03310645|EXPERIMENTAL|Dose 4 of BAY1817080|"Study Part 1:~Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
62128348|NCT03310645|PLACEBO_COMPARATOR|Placebo|"Study Part 1:~Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1"
62128349|NCT03310645|EXPERIMENTAL|Placebo+BAY1817080|"Study Part 2:~Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080"
62128350|NCT03310645|EXPERIMENTAL|BAY1817080+Placebo|"Study Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo"
62128351|NCT02928224|EXPERIMENTAL|Safety Lead-in, Triplet Arm|Encorafenib + binimetinib + cetuximab.
62128352|NCT02928224|EXPERIMENTAL|Doublet Arm|Encorafenib + cetuximab.
62128353|NCT02928224|ACTIVE_COMPARATOR|Control Arm|Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
62128354|NCT04241354|ACTIVE_COMPARATOR|Intra-articular LP-PRP Injection|A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.
62128355|NCT04241354|EXPERIMENTAL|Intra- and extra- articular LP-PRP Injection|A single injection of LP-PRP will be administered to the intra- articular space and the extra- articular structures under ultrasound guidance at the first visit.
62128356|NCT02768545|EXPERIMENTAL|Liver transplant candidates|Ezetimibe in a dose of 10 mg/d for 12 weeks.
62128357|NCT05454410|EXPERIMENTAL|MIJ821 - low dose|Single subcutaneous administration of low dose of MIJ821 on Day 1
62128358|NCT05454410|EXPERIMENTAL|MIJ821 - medium dose|Single subcutaneous administration of medium dose of MIJ821 on Day 1
62128359|NCT05454410|EXPERIMENTAL|MIJ821 - high dose|Single subcutaneous administration of high dose of MIJ821 on Day 1
62128360|NCT05454410|PLACEBO_COMPARATOR|Placebo|Single subcutaneous administration of 0.9% sodium chloride on Day 1
62128361|NCT05015010|EXPERIMENTAL|Alectinib|The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 96 weeks. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
62128362|NCT02708927|EXPERIMENTAL|patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
62128363|NCT02708927|EXPERIMENTAL|Control|healthy subject
62128364|NCT00585052|EXPERIMENTAL|Paclitaxel and lovastatin|Paclitaxel given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly. Lovastatin self-administered at 80mg daily.
62318540|NCT00854529|NO_INTERVENTION|3|20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.
62318541|NCT01177150|EXPERIMENTAL|001|JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
62318542|NCT01177150|EXPERIMENTAL|002|JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
62318543|NCT06499090|ACTIVE_COMPARATOR|Mirtazapine group|patients will receive orally the night before surgery the study medication and daily up to two weeks after: Mirtazapine group: Mirtazapine 30 mg tablet
62479894|NCT04931342|EXPERIMENTAL|Giredestrant + Abemaciclib (ER+ tumors)|Participants in the Giredestrant + Abemaciclib arm will receive treatment until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
62479895|NCT04931342|EXPERIMENTAL|Inavolisib + Palbociclib (PIK3CA-altered tumors)|Participants in the Inavolisib + Palbociclib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62479896|NCT04931342|EXPERIMENTAL|Inavolisib + Palbociclib + Letrozole (ER+ and PIK3CA-altered tumors)|Participants in the Inavolisib + Palbociclib + Letrozole arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62479897|NCT04931342|EXPERIMENTAL|Inavolisib + Olaparib (Non-matched)|Participants in the Inavolisib + Olaparib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62128365|NCT01714869|OTHER|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
62318544|NCT06499090|PLACEBO_COMPARATOR|placebo group|"patients will receive orally the night before surgery the study medication and daily up to two weeks after:~placebo tablet"
62318545|NCT05640232|EXPERIMENTAL|Experimental|CDE100 The patient must take 1 pill of CDE100 association and placebo of Buscopan® Composto association, if pain, until three times a day.
62687757|NCT05425355|EXPERIMENTAL|Intravenous (IV) acetaminophen plus oral placebo|In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
61925245|NCT03722173|EXPERIMENTAL|BI 894416 alone (R) / BI 894416+Itraconazole (T)|"Participants were administered 3 milligram (mg) BI 894416 tablet (1 mg X 3 tablets) orally on Day 1 alone in treatment period 1 (R), and along with 20 milliliter (mL) of 10 mg/ mL Itraconazole oral solution in treatment period 2 (T).~In period 2 (T), participants received 200 mg ((20 milliliter (mL)) of Itraconazole oral solution once daily for 5 days, from Day -3 to Day 2. On Day 1 participants received additionally after the Itraconazole dosing, 3 mg BI 894416 tablet (1 mg X 3 tablets) orally in treatment period 2 (T). Both treatment periods were separated by a washout period of at least 6 days between BI 894416 administrations. In both treatments, BI 894416 was administered to subjects in the fasting state."
62128366|NCT06261606|EXPERIMENTAL|Hybrid strategy|"A hybrid strategy inclusive of:~1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131."
62128367|NCT06261606|NO_INTERVENTION|Usual care|No active strategy (usual care) without any clear recommendations related to air pollution. A control card will be shared with the patients randomized to the control group
62128368|NCT01935544|EXPERIMENTAL|botulinum toxin injections|The main objective is to compare the efficiency of botulinum toxin injections depending on the localization technique: ultrasound vs. electrical stimulation.
62128369|NCT01935544|OTHER|ultrasound guidance|The secondary objective is to demonstrate less painful localization associated to ultrasound-guidance
62128370|NCT00041938|ACTIVE_COMPARATOR|aspirin|Aspirin: 325 mg per day
62128371|NCT00041938|ACTIVE_COMPARATOR|warfarin|Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75
62128372|NCT03868397|EXPERIMENTAL|Liver MRI|In this study, MRI refers to phase-contrast 4D flow sequence.
62318546|NCT05640232|ACTIVE_COMPARATOR|Control|"Buscopan® Composto association.~The patient must take 1 pill of Buscopan® Composto association and placebo of CDE100 association, if pain, until three times a day."
62318547|NCT02416687|ACTIVE_COMPARATOR|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
62318548|NCT02416687|NO_INTERVENTION|Control group|Postpartum women who used no contraceptive method in the first six weeks after delivery
62318549|NCT01463852|EXPERIMENTAL|Vincrisitne 2mg|Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.
62318550|NCT01236729||Knee replacement recipients|Patients (aged 75 years or over) with late-stage arthritis who have undergone or are undergoing primary knee replacement
62318551|NCT00734409|EXPERIMENTAL|RASS plus (BIS)|Participants in this arm will receive sedation assessment with the RASS scale augmented with Bispectral Index (BIS) Monitor
62318552|NCT00734409|NO_INTERVENTION|RASS only|Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution
62318553|NCT01225263|EXPERIMENTAL|Simvastatin and vitamin D|Participants in this arm will receive simvastatin + vitamin D.
61925246|NCT04656275|EXPERIMENTAL|BI 1323495 treatment group (part 1)|Part 1
61925247|NCT04656275|EXPERIMENTAL|BI 1323495 treatment group (part 2)|Part 2
62318554|NCT01225263|PLACEBO_COMPARATOR|"Placebo Sugar Pill"|"Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill."
62318555|NCT03026504|EXPERIMENTAL|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
62318556|NCT02565823|EXPERIMENTAL|Exercise intervention|Subjects will undergo an acute bout of exercise for 45 mins at 75% of peak aerobic capacity
62318557|NCT00426751|ACTIVE_COMPARATOR|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
62687758|NCT05425355|ACTIVE_COMPARATOR|Intravenous (IV) placebo plus oral acetaminophen|In this group the IV study drug will be normal saline and the pill will be acetaminophen
62687759|NCT01783808|EXPERIMENTAL|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
62128373|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
62128374|NCT05283447|EXPERIMENTAL|Intervention|Specific manual therapy for GERD and hiatal hernia
62318558|NCT00426751|EXPERIMENTAL|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
62318559|NCT00807547|ACTIVE_COMPARATOR|Allergy vaccination|Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals
62318560|NCT00807547|PLACEBO_COMPARATOR|Subcutaneous injections|Placebo injections
62318561|NCT03492450|NO_INTERVENTION|Control Group|All subjects continue participating in their normal daily and physical activities.
62479898|NCT04931342|EXPERIMENTAL|Inavolisib + Giredestrant (ER+ and PIK3CA-altered tumors)|Participants in the Inavolisib + Giredestrant arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62687760|NCT01783808|NO_INTERVENTION|Control group|The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.
62687761|NCT02007980||Patients with indwelling ureteral stent|Patients with existing indwelling ureteral stent, no additional treatment
61925248|NCT04656275|PLACEBO_COMPARATOR|Placebo group|Placebo
62128375|NCT05283447|PLACEBO_COMPARATOR|Control|Manual therapy unrelated to GERD and hiatal hernia
62128376|NCT04326192|EXPERIMENTAL|All subjects|All subjects will have two PET/CT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET/CT) or with SCS during PET/CT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.
62128377|NCT06266845|OTHER|Knowledge Test|
62128378|NCT06266845|OTHER|Knowledge Test Satisfaction and Self-Confidence Scale|
62318562|NCT03492450|EXPERIMENTAL|Treadmill training Group|16 sessions (2 sessions/week for 8 weeks) of treadmill training as recommended in a review on this subject (Langeskov-Christensen, 2015) aimed at the reduction/stabilization of gait and balance disturbances.
62318563|NCT04523779|EXPERIMENTAL|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
62479899|NCT04931342|EXPERIMENTAL|Inavolisib + Bevacizumab (PIK3CA-altered tumors)|Participants in the Inavolisib + Bevacizumab arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
62479900|NCT04931342|EXPERIMENTAL|Atezolizumab + Bevacizumab + Cyclophosphamide (Non-matched)|Participants in the Atezolizumab + Bevacizumab + Cyclophosphamide arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
62479901|NCT06046430||Frozen Shoulder Group|The sample of the study will consist of patients who applied to Harran University Hospital and were diagnosed with frozen shoulder.
62479902|NCT06046430||Healthy Group|Healthy volunteers similar to the patient group in gender and age factors.
62687762|NCT02319915|EXPERIMENTAL|Tranexamic acid|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection.
62687763|NCT02319915|ACTIVE_COMPARATOR|Tranexamic acid + adrenalin|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.
62687764|NCT03390686|EXPERIMENTAL|HD204 (Bevacizumab biosimilar)|HD204 + Carboplatin/Paclitaxel
62687765|NCT03390686|ACTIVE_COMPARATOR|Avastin (Bevacizumab)|Avastin® + Carboplatin/Paclitaxel
62479903|NCT05685498|OTHER|Peer-led HIV self-testing among male fisherfolk in Uganda|Men aged 15 years or older, who self-report a HIV-negative or unknown HIV status at enrolment and last tested for HIV three or more months are enrolled into the study. Enrolled men receive two HIV self-test kits from a trained community-based distributor (or peer-leader). Peer-leaders are selected from existing social networks and are trained in HIV self-testing procedures prior to distributing HIV self-test kits. The goal of the study is to assess if distribution of HIV self-test kits to men through trained local peer-leaders is feasible and acceptable in a fishing community context, and whether this approach can help to improve access to HIV testing services and, by implication, improve HIV testing uptake and subsequent linkage to appropriate HIV prevention, care and treatment services. Men are interviewed at baseline will be followed up at 1, 6 and 12 months post-baseline to determine HIV testing uptake, linkage to and retention in HIV care.
62479904|NCT04086108|EXPERIMENTAL|Tomato|Single oral administration
62128379|NCT06266845|OTHER|Perceived Gains Scale and DASS-21 (Depression, Anxiety, and Stress Scale-21)|
62128380|NCT04192916||MPN patients treated with DOACs|
62318564|NCT04523779|NO_INTERVENTION|Enhanced Usual Care|EUC participants will receive anxiety education materials, a note in their medical record indicating the presence of elevated anxiety symptoms, and 4 brief monthly check-in calls with project staff. The primary outcome, anxiety symptoms, will be evaluated at 4-, 8- and 12-month follow-ups. Due to ethical concerns of withholding needed treatment, EUC participants will NOT be restricted from receiving mental health services including psychotherapy during the study period. The investigators fully expect that EUC participants may receive anxiety treatments (e.g., antianxiety and antidepressant medications or psychotherapy).
62318565|NCT05366933|EXPERIMENTAL|Supplemented with B-Complex|Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station
62318566|NCT04250493|EXPERIMENTAL|MSA patient|Patients will be recruited at the French Reference Center for MSA.
62318567|NCT04250493|OTHER|Control|Healthy volunteer matched for age (+/- 5years) and sex with MSA patient.
62318568|NCT02096939||Primary aldosteronism|Patients with primary aldosteronism, who undergo surgery or will be started on antihypertensive medication, including mineralocorticoid receptor antagonists
62318569|NCT02096939||Essential hypertension|Patients with essential hypertension who will be started on antihypertensive medication
62318570|NCT06353971|EXPERIMENTAL|Briquilimab|Cohort 1: Participants will be treated at the trial site with 40 mg briquilimab (Subcutaneous Injection) Cohort 2: Participants will be treated at the trial site with 120 mg briquilimab (Subcutaneous Injection) Cohort 3: Participants will be treated at the trial site with 180 mg briqulimab (Subcutaneous Injection)
62318571|NCT00303342|EXPERIMENTAL|mind body treatment|regulation of attention, respiration and posture
62128381|NCT04082611|ACTIVE_COMPARATOR|Group 1 - Data-driven clinical recommendations (CR)|Data-driven clinical recommendations (CR)
62128382|NCT04082611|EXPERIMENTAL|Group 2 - Data-driven coached multi-modal intervention (MMIC)|Data-driven coached multi-modal intervention (MMIC)
62318572|NCT00303342|ACTIVE_COMPARATOR|desensitization|mentation on insomnia behaviors and cognitive activity
62318573|NCT06190002||invasive fungal infection group and non-invasive fungal infection group|According to the presence or absence of invasive fungal infection, the patients were divided into invasive fungal infection group and non-invasive fungal infection group
62687766|NCT01907646|EXPERIMENTAL|Bladder training group|The patients of this group were submitted to passive vesical gymnastic during the second and third postoperative days, throughout the closure of the catheter for 3 h and open it for 15 min all day long.
62128383|NCT02769858|EXPERIMENTAL|Light Therapy|Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.
62479905|NCT04086108|EXPERIMENTAL|GABA supplement|Single oral administration
62479906|NCT04086108|EXPERIMENTAL|Glutamate supplement|Single oral administration
62479907|NCT04086108|NO_INTERVENTION|Placebo|Single oral administration, same volume of water that is distributed in the other arms
62479908|NCT05479643|EXPERIMENTAL|Patients with Aphonia or Dysphonia|Participants with Aphonia or Dysphonia will be asked to recite phrases with sEMG attached to articulatory muscles.
62479909|NCT05479643|PLACEBO_COMPARATOR|Healthy Volunteers|Healthy Volunteer will be asked to recite phrases with sEMG attached to articulatory muscles.
62128384|NCT00969137|ACTIVE_COMPARATOR|Nicotine|Intravenous Nicotine
62128385|NCT00969137|PLACEBO_COMPARATOR|Saline|Saline infusion
62128386|NCT03557411|EXPERIMENTAL|SHR-1210 +Hypofraction radiotherapy|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
62128387|NCT01424670|EXPERIMENTAL|Delamanid + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive 100 mg delamanid orally BID (morning and evening) + OBR for 2 months, followed by 200 mg delamanid QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
62128388|NCT01424670|PLACEBO_COMPARATOR|Placebo + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive placebo orally BID (morning and evening) + OBR for 2 months followed by placebo QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
62318574|NCT03671759|EXPERIMENTAL|Experimental: N-of-1|"Participants will be randomized in two-day blocks to consume then avoid caffeine (Start: On Caffeine) or avoid then consume caffeine (Start: Off Caffeine). Using an N-of-1 strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, participants will receive instructions and answer questions to help us understand the relationship between caffeine and heart rhythm."
62318575|NCT00088010|EXPERIMENTAL|1|
62318576|NCT00088010|PLACEBO_COMPARATOR|2|
62318577|NCT05137522|EXPERIMENTAL|Assigned Interventions|Chidamide combines with VP-16 and methylprednisolone
62479910|NCT00835692|EXPERIMENTAL|Clarithromycin Tablets|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
62128389|NCT03086369|EXPERIMENTAL|Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine|Participants received intravenous (IV) infusions of olaratumab 15 milligrams per kilogram (mg/kg), nab-paclitaxel 125 milligrams per meter square (mg/m\^2) and gemcitabine 1000 mg/m\^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
62128390|NCT03086369|EXPERIMENTAL|Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of olaratumab 20 mg/kg, nab-paclitaxel 125 mg/m\^2 and gemcitabine 1000 mg/m\^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
62128391|NCT03086369|EXPERIMENTAL|Phase1b (cohort expansion): Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine|"Following a protocol amendment, cohort expansion arm was added in phase 1b with new participants enrolled to confirm the safety of the olaratumab 20 mg/kg dose prior to opening the Phase 2. Participants received intravenous infusions of olaratumab 20 mg/kg, nab-paclitaxel 125 mg/m\^2 and gemcitabine 1000 mg/m\^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met."
62128392|NCT03086369|EXPERIMENTAL|Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of olaratumab 20 mg/kg loading dose on days 1, 8, 15 of cycle 1 followed by 15 mg/kg on days 1, 8, 15 of all subsequent cycles, in combination with nab-paclitaxel 125 mg/m\^2 and gemcitabine 1000 mg/m\^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
62479911|NCT00835692|ACTIVE_COMPARATOR|Biaxin® Tablets|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
62479912|NCT01553214|OTHER|Donors|volunteer healthy donors willing to receive G-CSF and dexamethasone and undergo leukapheresis
62479913|NCT03869892|EXPERIMENTAL|S95005 + Bevacizumab|
62479914|NCT03869892|ACTIVE_COMPARATOR|Capecitabine + Bevacizumab|
62687767|NCT01907646|EXPERIMENTAL|No bladder training group|The patients of this group were not submitted to passive vesical gymnastic during the second and third postoperative days
62128393|NCT03086369|PLACEBO_COMPARATOR|Phase 2: Placebo + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of placebo, nab-paclitaxel 125 mg/m\^2 and gemcitabine 1000 mg/m\^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
62128394|NCT02838199|EXPERIMENTAL|TAVR|Transcatheter aortic valve replacement with SAPIEN 3
62128395|NCT02838199|ACTIVE_COMPARATOR|SAVR|Surgical aortic valve replacement
62128396|NCT01969461|EXPERIMENTAL|Healthy Choices: MET CHW Clinic|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the CLINIC by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
62128397|NCT01969461|ACTIVE_COMPARATOR|Healthy Choices: MET CHW Home|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the HOME by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
62128398|NCT00243529|ACTIVE_COMPARATOR|MHC Class I restricted epitopes|HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase
62128399|NCT00243529|EXPERIMENTAL|MHC Class I and II restricted epitopes|HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase
62128400|NCT00243529|EXPERIMENTAL|mRNA transfected DC|HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase
62128401|NCT06215092||Developmental learning disorder|Children above 5 years old, with formal diagnosis of Developmental learning disorder.
62318578|NCT01479790|NO_INTERVENTION|Visante AS-OCT and Cirrus AS-OCT|The tear meniscus is the thin concave strip of the tear film near the eyelid margins. During the acquisition the participants place their chins on a chin rest and look at a fixation light/target. This whole procedure should not take more than 5 minutes. The patients are allowed to blink freely except for during the acquisition time of less than 5 seconds. The procedure will be repeated for the upper and lower tear meniscus of both eyes.
62318579|NCT01479790|EXPERIMENTAL|Thermography measurement|"In total, four pairs of thermographic sequences on the ocluar surface temperature from volunteers will be taken.~1. A thermographic sequence will be captured from each eye.~2. After 20 minutes, a second pair of thermographic sequences will be captured.~3. An eye mask with a temperature of not more than 40 deg C (will be worn by the volunteer for 5 minutes and a third pair of thermographic sequences will be captured immediately after mask removal.~4. A fourth pair of thermographic sequences will be captured 1 hour after mask removal."
62318580|NCT01748448|ACTIVE_COMPARATOR|Vitamin D|Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs
62318581|NCT01748448|PLACEBO_COMPARATOR|arachides oleum raffinatum|Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs
62318582|NCT05952219|EXPERIMENTAL|Sequence 1|Period 1: Reference drug(D759+D745+D029+D150) Period 2: Test drug(CKD-379)
62128402|NCT06215092||Disorder of intellectual development, mild|Children above 5 years old, with formal diagnosis of Disorder of intellectual development, mild.
62318583|NCT05952219|EXPERIMENTAL|Sequence 2|Period 1: Test drug(CKD-379) Period 2: Reference drug(D759+D745+D029+D150)
62318584|NCT04195074|EXPERIMENTAL|ETV group|100 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
62318585|NCT04195074|EXPERIMENTAL|TDF group|100 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
62479915|NCT05159700|EXPERIMENTAL|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
62479916|NCT05194982|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62479917|NCT05945290||Observational (Biospecimen collection, medical record)|Patients undergo blood sample collection throughout the study. Patients also undergo collection of leftover tissue samples from SOC procedures and have medical records reviewed.
24092535|NCT06416423|EXPERIMENTAL|Experimental: Intervention|Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic \& Advanced Parent Training Program. It consists of twelve (12) 2-hour online workshops led by Aviril Sepulveda, a certified peer coach in the Incredible Years Parent Training Series.
24092536|NCT06416423|OTHER|Control|Parents assigned to the control arm will be emailed and mailed written parent education materials from the American Academy of Pediatrics called the Bright Futures handouts. The control group is offered the Incredible Years® School Age Basic \& Advanced Parent Training Program after a 3-month wait list period.
62479918|NCT06685445|ACTIVE_COMPARATOR|Group EPSB (Continue Erector Spinae Plane Block)|Following induction of anesthesia, ESPB will be performed with 30 ml of 0.25% bupivacaine (Marcaine®) and a catheter will be placed before the start of surgery. 15 ml of 0.125% bupivacaine solution will be administered through the ESPB catheter at 12-hour intervals following the end of surgery. All participants will be attached to a patient-controlled analgesia (PCA) device prepared with 5 mg/ml tramadol (Contramal®) as soon as they are admitted to the recovery room. PCA will be non-infusion, with a lockout period of 20 minutes and a bolus dose of 10 mg. In the postoperative period, 1 g paracetamol (Parol®) will be administered intravenously every 8 hours, 75 mg diclofenac (Dikloron®) intramuscularly if NRS≥4 and 0.5 mg/kg meperidine (Aldolan®) intravenously if NRS≥4 is still present after 2 hours.
62687768|NCT00552279|EXPERIMENTAL|Cervarix-12 Group|Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule
62687769|NCT00552279|ACTIVE_COMPARATOR|Cervarix-6 Group|Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.
62128403|NCT06215092||Attention deficit hyperactivity disorder|Children above 5 years old, with formal diagnosis of Attention deficit hyperactivity disorder (ADHD).
62128404|NCT06215092||Autism spectrum disorder|Children above 5 years old, with formal diagnosis of Autism spectrum disorder (ASD).
62318586|NCT04195074|EXPERIMENTAL|TAF group|100 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
62128405|NCT06215092||Learning difficulties|Children above 5 years old, with difficulties in reading and/or writing without formal diagnosis of Developmental learning disorder.
62128406|NCT06215092||Control group|Children above 5 years old without formal diagnosis of neurodevelopmental disorders.
62128407|NCT01811706|EXPERIMENTAL|Dalfampridine and then placebo|Participant first receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks. After a washout period of 2 weeks, they then receive Placebo tablet orally every 12 hours, for a 4 weeks period.
62318587|NCT04272619|EXPERIMENTAL|Liver Cancer Education|
62318588|NCT03249896|EXPERIMENTAL|Intervention|Patients in the intervention arm will receive standard medical care and in addition to that, be given the Aina or Aina Mini device for self-monitoring of blood glucose (SMBG), the Habits-GDM mobile app, and a weighing scale.
62318589|NCT03249896|NO_INTERVENTION|Control|"Patients in the control arm will receive standard medical care and only be given the Aina or Aina Mini device for SMBG.~Standard medical care involves one session of face-to-face education by a diabetes nurse educator and a dietician. Patients are initiated on capillary glucose monitoring. Subsequently, standard clinical care is provided by their obstetrician. Participation in this study will not increase the frequency of clinic visits. The frequency of SMBG will be as clinically indicated and not increased as a result of participation in this study. Should the obstetrician feels that insulin is required, it will be initiated and if necessary the patient will be referred to the endocrinology service for management of insulin therapy. In some patients, the clinician may decide to prescribe metformin."
62128408|NCT01811706|EXPERIMENTAL|Placebo, Then Dalfampridine|Participant first receive Placebo tablet orally every 12 hours, for a 4 weeks period. After a washout period of 2 weeks, they then receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks.
62128409|NCT05300542|EXPERIMENTAL|Skin UVB irradiated 1.25MED|
62128410|NCT05300542|EXPERIMENTAL|Skin UVB irradiated 1.6MED|
62318590|NCT06490965|ACTIVE_COMPARATOR|Arm A|Standard of care rTMS protocol, i.e., daily frequency of repetitive excitatory TMS at 20 Hz of the medial prefrontal cortex - approximate duration of each session between 40-60 minutes.
62318591|NCT06490965|EXPERIMENTAL|Arm B|Standard of care rTMS protocol, i.e., daily frequency of repetitive excitatory TMS at 20 Hz with adjustment of the stimulation site to primarily target the bilateral medial orbitofrontal cortex.
62318592|NCT04938141||Acalabrutinib|CLL patients initiating acalabrutinib alone or in combination with an anti-CD20 mAb
62318593|NCT04938141||Ibrutinib|CLL patients receiving ibrutinib alone or in combination with an anti-CD20 mAb
62687770|NCT05512819|EXPERIMENTAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (20vPnC)
62128411|NCT05300542|NO_INTERVENTION|Untreated Skin|
62128412|NCT00799396|EXPERIMENTAL|Overall Study|Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
62128413|NCT05531708|EXPERIMENTAL|Anti-mesothelin CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, anti-mesothelin CAR-T cells.
62128414|NCT01227876|EXPERIMENTAL|Test|Ster ® (prednisolone 1% ophthalmic suspension - União Química)
62128415|NCT01227876|ACTIVE_COMPARATOR|Comparator|Pred Fort ® (prednisolone 1% ophthalmic suspension - Allergan)
62128416|NCT01697059|EXPERIMENTAL|Piperacillin + Amoxicillin|Piperacillin/Tazobactam (Zosyn®) 100 mg/kg, up to adult dose of 3 g, i.v. q 6 hours x 2 doses, followed by Ampicillin/Clavulanate (Augmentin®) 50 mg/kg/d p.o. in 3 divided doses for 1 week.
61925249|NCT02675101|ACTIVE_COMPARATOR|Whole nuts|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume a combination of whole almonds and walnut pieces, a total of 110 g per day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Walnuts and almonds will be provided to participants for the duration of the study.
61925250|NCT02675101|EXPERIMENTAL|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 18 g olestra/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Fat free Pringles will be provided to participants for the duration of the study.
62687771|NCT05512819|ACTIVE_COMPARATOR|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (13vPnC)
62687772|NCT04945330||Gastrointestinal (GI)|Participants with GI cancer.
61925251|NCT02675101|PLACEBO_COMPARATOR|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 17.4 g oil/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Original Pringles will be provided to participants for the duration of the study.
61925252|NCT00939757|EXPERIMENTAL|1. mirabegron, lower dose|
61925253|NCT00939757|EXPERIMENTAL|2. mirabegron, higher dose|
61925254|NCT03555773|EXPERIMENTAL|Lipogems|Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract
61925255|NCT03824028||Clareon IOL AutonoMe|Prior implantation with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system
61925256|NCT03967678|PLACEBO_COMPARATOR|Beef from standard supply|
61925257|NCT03967678|EXPERIMENTAL|n-3 enriched beef from dietary supplement finished cattle|
61925258|NCT03967678|ACTIVE_COMPARATOR|n-3 enriched beef from grass finished cattle|
61925259|NCT01683227|EXPERIMENTAL|Screening/motivational drug intervention|Screening and brief intervention counseling matched to patient's risk level delivered in the ER
61925260|NCT01683227|PLACEBO_COMPARATOR|Motivational placebo intervention|Screening and brief intervention for driving and traffic safety
61925261|NCT05158387|EXPERIMENTAL|Tozorakimab Dose 1|Dosing subcutaneously tozorakimab Dose 1 and placebo
61925262|NCT05158387|EXPERIMENTAL|Tozorakimab Dose 2|Dosing subcutaneously tozorakimab Dose 2
62687773|NCT04945330||Head and neck (H&N)|Participants with H\&N cancer.
62687774|NCT04945330||Lung|Participants with lung cancer.
62687775|NCT04945330||Soft tissue sarcoma (STS)|Participants with STS cancer.
61925263|NCT05158387|PLACEBO_COMPARATOR|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
61925264|NCT01070862|EXPERIMENTAL|thalidomide + dexamethasone|Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
61925265|NCT01070862|ACTIVE_COMPARATOR|Vincristin, Adriamycin, Dexamethasone|
62318594|NCT03312140|OTHER|Choline Chloride|Patients receive choline chloride (1g Choline) three times a day for 12.6 weeks as a food supply
62318595|NCT03271008|ACTIVE_COMPARATOR|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
62318596|NCT03271008|ACTIVE_COMPARATOR|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
61925266|NCT01070862|EXPERIMENTAL|thalidomide, melphalan, endoxan, dexamethasone|
61925267|NCT01070862|ACTIVE_COMPARATOR|melphalan, endoxan, dexamethasone (MCDex)|
61925268|NCT01070862|EXPERIMENTAL|Thalidomide, Dexamethasone|
61925269|NCT01070862|NO_INTERVENTION|watch and wait|
61925270|NCT02307786||Beta-Thalassemiall -Transplantation|
61925271|NCT02307786||Beta-Thalassemia Supportive Care|
62318597|NCT03271008|ACTIVE_COMPARATOR|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
62318598|NCT03454048|EXPERIMENTAL|Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 1 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg).
62318599|NCT03454048|EXPERIMENTAL|Group 2 (Cohort A) LD-PIP/LD-PIP2/SP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 2(LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
62318600|NCT03454048|EXPERIMENTAL|Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP|Cohort B will be subjected to a standard blood stage challenge with \~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 3 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg)
62479919|NCT06685445|ACTIVE_COMPARATOR|Group ESPB+SAPB (Continue Erector Spinae Plane Block + Serratus Anterior Plane Block)|Following induction of anesthesia, ESPB with 30 ml of 0.25% bupivacaine (Marcaine®) will be performed and the catheter will be placed before the surgery starts. After the end of surgery, SAPB with 30 ml of 0.25% bupivacaine will be performed before extubation. Following the end of the surgery, 15 ml of 0.125% bupivacaine solution will be administered through the ESPB catheter at 12-hour intervals. All participants will be attached to a patient-controlled analgesia device prepared with 5 mg/ml tramadol (Contramal®) as soon as they are admitted to the recovery room. There will be no infusion in PCA, 20 minutes lock time, 10 mg bolus dose. In the postoperative period, 1 g paracetamol (Parol®) will be administered intravenously every 8 hours, 75 mg intramuscular diclofenac (Dikloron®) if NRS≥ 4 and 0.5 mg/kg meperidine (Aldolan®) intravenously if NRS≥ 4 is still present after 2 hours.
62479920|NCT03605342|ACTIVE_COMPARATOR|Buprenorphine + CPT-C|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then CPT-C for 12 weeks.
61925272|NCT04108676|EXPERIMENTAL|single arm|Drug: Fluzoparib Drug: Omeprazole
61925273|NCT03310827|EXPERIMENTAL|Personalized Nutrition|Participant receives gene test results with diet plan (personalized nutrition)
61925274|NCT03310827|PLACEBO_COMPARATOR|Gene Test Report Only|Participant receives standard diet plan
62128417|NCT04296227|EXPERIMENTAL|ISO 81060-2:2018.|The intended purpose of the test is to evaluate the Vital Detect blood pressure monitor to ISO 81060-2:2018. The intended use for these products are manual and automatic Non-Invasive Blood Pressure monitoring on adults age 18 and older.
62128418|NCT04018859|EXPERIMENTAL|Platelet-Rich Plasma|Participants will receive intradermal injections of 2-3mL autologous PRP to eyebrows.Three treatments will be performed 1 month apart.
62687776|NCT04945330||Primary central nervous system (CNS)|Participants with CNS cancer.
61925275|NCT05503316|EXPERIMENTAL|GRAIL group|"Participants will receive 5 weeks of training on the GRAIL device, which is focused on training balance during walking.~Therapy frequency: 2\*30 minutes per week."
61925276|NCT05503316|ACTIVE_COMPARATOR|Traditional gait rehabilitation|"Participant will receiver traditional gait rehabilitation which also includes training balance during walking.~Therapy frequency in both groups is equal."
61925277|NCT03649867|OTHER|Semi-structured interview|Each female patient who attended the Survive \& Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
62128419|NCT04018859|PLACEBO_COMPARATOR|Placebo (sterile saline)|Participants will receive intradermal injections of 2-3mL sterile saline to eyebrows.Three treatments will be performed 1 month apart.
62128420|NCT05233007||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
62128421|NCT02467166|EXPERIMENTAL|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
62128422|NCT03764475|OTHER|Long-term Safety of Roflumilast|Participants applied roflumilast (ARQ-151) cream 0.3% once daily for 52 weeks
62128423|NCT05498818|EXPERIMENTAL|Synaquell Male Group|Male youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
62687777|NCT04945330||Melanoma|Participants with Melanoma cancer.
62687778|NCT04945330||Pediatrics|
61925278|NCT04596553|ACTIVE_COMPARATOR|Essential Amino Acid|Participants will consume 1 dose of: 15 g crystalline essential amino acid supplement (Pure Encapsulation Essential Aminos 180) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
62318601|NCT03454048|EXPERIMENTAL|Group 4 (Cohort B) LD-PIP/LD-PIP2/SP|Cohort B will be subjected to a standard blood stage challenge with \~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 4 (LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
62318602|NCT05989620||LGMD, DM2, LOPD|
61925279|NCT04596553|ACTIVE_COMPARATOR|Collagen Peptide|Participants will consume 1 dose of: 15g collagen peptide (Gelita TENDOFORTE) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
61925280|NCT04596553|PLACEBO_COMPARATOR|Maltodextrin Placebo|Participants will consume 1 dose of:15 g maltodextrin (Canadian Protein Maltodextrin) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
62128424|NCT05498818|PLACEBO_COMPARATOR|Placebo Male Group|Male youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
62128425|NCT05498818|EXPERIMENTAL|Synaquell Female Group|Female youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
62128426|NCT05498818|PLACEBO_COMPARATOR|Placebo Female Group|Female youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
62479921|NCT03605342|ACTIVE_COMPARATOR|Buprenorphine + IDC|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then IDC for 12 weeks
62687779|NCT04945330||Others|
62687780|NCT06569225|EXPERIMENTAL|Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig|
62687781|NCT06563674|ACTIVE_COMPARATOR|Control|Participants will receive the acceptance-based healthy lifestyles program between week 8-14.
62128427|NCT00316953|EXPERIMENTAL|Stratum 1 (solid tumors)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62128428|NCT00316953|EXPERIMENTAL|Stratum 2 (leukemia)|Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.
62128429|NCT00214773||Observational|No intervention. This is an observational program.
62479922|NCT02077894||Affected participants|Participants with an eye disease.
62687782|NCT06563674|EXPERIMENTAL|Intervention|Participants will receive the acceptance-based healthy lifestyles program between week 1-6.
62738104|NCT03072394|ACTIVE_COMPARATOR|Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
62479923|NCT02077894||Unaffected family members|Unaffected family members.
62738105|NCT04589234|EXPERIMENTAL|Saltikva with FOLFIRINOX|30 patients will be enrolled to receive standard of care FOLFIRINOX with oral Salmonella-IL2 (Dose 10-9) every 2 weeks for 2 years
62738106|NCT04589234|EXPERIMENTAL|Saltikva with Gemcitabine/Abraxane|30 patients will be enrolled to receive standard of care Gemcitabine/Abraxane with oral Salmonella-IL2 (Dose: 10-9) every 3 weeks for 2 years
62738107|NCT01553682|NO_INTERVENTION|Enhanced Standard-Of-Care|Participants will watch a video about how to prevent STIs and HIV, then do question and answer session. This group will be last 1 hour. It will be led by one African American health educator, and have about 4-8 other young women participants. Participants will be asked to rate the workshop anonymously.
62738108|NCT01553682|ACTIVE_COMPARATOR|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
62738109|NCT01553682|EXPERIMENTAL|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
62738110|NCT06659601||Training Cohort|Patients in this cohort diagnosed with stage IA invasive lung adenocarcinoma who underwent sub-lobar resection. This cohort is used to train the 3D deep learning model to predict recurrence risk.
62738111|NCT06659601||Validation Cohort|Patients in this cohort with stage IA ILADC. It is used to validate the model performance internally and assess its generalization within the same institution。
62738112|NCT06659601||Testing Cohort|Patients in this cohort from other institution. It is used to test the generalizability of the model in predicting recurrence risk in an independent dataset.
62738113|NCT04683146|ACTIVE_COMPARATOR|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propranolol- 1 60% as control.
62128430|NCT01898741|EXPERIMENTAL|irradiation|24 Gy in 3 fractions
62128431|NCT02768467|EXPERIMENTAL|Tissue Matrix Graft Placement|After the buccal mucosa is removed during reconstructive surgery, the wound is covered with an acellular tissue collagen matrix
62738114|NCT04683146|ACTIVE_COMPARATOR|Hand antisepsis with solution of alcohol, chlorhexidine digluconate and potassium sorbate|Effectiveness of pre-surgical hand washing in reducing bacterial load using a solution of alcohol, chlorhexidine digluconate and potassium sorbate
62687783|NCT06674291||MDR-END regimen treatment group|"1. Treatment Regimen~   Delamanid 100 mg twice daily Linezolid 600 mg once daily for the first 2 months, 300 mg once daily afterward Levofloxacin (body weight ≤ 50 kg) 750 mg once daily (body weight \> 50 kg) 1000 mg once daily Pyrazinamide (body weight \< 50 kg) 1000 mg once daily (body weight 50 to 70 kg) 1500 mg once daily (body weight \> 70 kg) 2000 mg once daily~2. Treatment period : 9 month (40 weeks) If the sputum test results show conversion within 3-6 months after the start of treatment, the overall treatment period is extended by 3 months for a total of 12 months (52 weeks)."
62687784|NCT01977976|EXPERIMENTAL|Endometrial Aspirate (EA) group|Endometrial aspirate by pipelle
62687785|NCT01977976|NO_INTERVENTION|Control group|No intervention prior to scheduled IVF
62687786|NCT06067893|EXPERIMENTAL|Dexmedetomidine|Patient receives low dose dexmedetomidine infusion in addition to normal post-operative pain management protocol
62687787|NCT06067893|PLACEBO_COMPARATOR|Control|Patient receives normal saline infusion in addition to normal post-operative pain management protocol
62687788|NCT01798654||Antithrombotic agents|
62687789|NCT05625867|EXPERIMENTAL|Post-resuscitation interdisciplinary consultation at 4/5 months after discharge from the ICU|
62687790|NCT05625867|ACTIVE_COMPARATOR|Patient managed under standard practice conditions|
62128432|NCT02768467|ACTIVE_COMPARATOR|Without stitches|After the buccal mucosa is removed during reconstructive surgery, no stitches will be used for the wound to heal.
62128433|NCT01424397|EXPERIMENTAL|SB-705498|Experimental
62128434|NCT01424397|ACTIVE_COMPARATOR|Fluticasone Propionate|Active Comparator
62128435|NCT01424397|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62128436|NCT01424397|EXPERIMENTAL|SB-705498+FP|Experimental
62128437|NCT02840006|ACTIVE_COMPARATOR|General anesthesia only|Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1
62128438|NCT02840006|ACTIVE_COMPARATOR|General anesthesia associated spinal anesthesia|spinal anesthesia using bupivacaine 0,5% hyperbaric 20 mg, morphine 200 mcg, set trendeleburg for 10 minutes, sensitive test in T1. Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1.
62128439|NCT04722588|NO_INTERVENTION|Control period|The control period is represented by standard care procedures, which are similar in all three EDs: Patients cared for in the EDs receive treatment from ED physicians and nurses, and no pharmacists are involved in any of the EDs.
62128440|NCT04722588|EXPERIMENTAL|Intervention period|"During the intervention period, clinical pharmacists will be present in the EDs from 08.00 - 19.00 Monday to Friday.~The ED pharmacists will collaborate with the interdisciplinary team and perform the following tasks as appropriately as possible and by prioritized need; medication history taking, medication reconciliation, medication review, drug therapy recommendations, guidance on drug administration, medication information and counseling to patients/next of kin and health care personnel and communication about medications and changes in medication regimes. Standardized procedures, like the integrated medicines management (IMM) methodology, will be applied where possible. How, when and which task will be performed for each patient cannot be predetermined, but must be performed according to patient's needs and eventual time constraints."
62128441|NCT03289468||Group1|Endometrial Benign Disease
62128442|NCT03289468||Group2|Endometrial Cancer and Precancerous Lesions
62128443|NCT01574794|EXPERIMENTAL|Strengthening Exercises|Recreational older runners recruited from local community
62128444|NCT01574794|EXPERIMENTAL|Stretching Exercises|Recreational older runners recruited from local community
62128445|NCT01574794|NO_INTERVENTION|Control Group|Recreational older runners recruited from local community
62128446|NCT01555099|EXPERIMENTAL|AZD5423|New study drug
62128447|NCT01555099|ACTIVE_COMPARATOR|Budesonide|Comparator to which the new study drug will be compared
62128448|NCT01555099|PLACEBO_COMPARATOR|Placebo|No drug to which both other arms will be compared
62479924|NCT04334941|ACTIVE_COMPARATOR|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.
62687791|NCT02683473||Infants|Infants aged 1-3 months
62687792|NCT06160778|EXPERIMENTAL|Ketorolac Tromethamine|Ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available in Canada for use to treat acute pain in the emergency department.
62687793|NCT06160778|ACTIVE_COMPARATOR|Morphine Sulfate|An intravenous opioid that is commonly used as part of usual care for treament of pain in patients with acute abdominal pain and suspected appendicitis.
62687794|NCT06312254|ACTIVE_COMPARATOR|Pharmacological modulation with lidocaine 5%|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
62687795|NCT06312254|ACTIVE_COMPARATOR|Pharmacological modulation with Phenytoin 10%|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
62687796|NCT06312254|ACTIVE_COMPARATOR|Pharmacological modulation with Mepyramine 2%|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
62738115|NCT03400865|EXPERIMENTAL|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.
62128449|NCT03467386|EXPERIMENTAL|Treatment (TMLI, cyclophosphamide)|Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm\^3 for 3 consecutive days.
62128450|NCT02370758|ACTIVE_COMPARATOR|Low CMV CMI|Patients that show low levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) continued for an additional 2 months at half dose.
62128451|NCT02370758|NO_INTERVENTION|High CMV CMI|Patients that show high levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) stopped.
62128452|NCT02655588|EXPERIMENTAL|ImbPST|"ImbPST Arm: Participants in this arm will interact with imbPST program which provides a simulated therapy session based on the Problem Solving Treatment-Primary Care (PST-PC) treatment manual used in depression clinical trials . imbPST via a virtual therapist (presented via audio and video) provides programmed instructions on the steps and skills of problem solving, emotional support, and tailored feedback to the user's input."
62128453|NCT02655588|NO_INTERVENTION|Control Group|Control Arm: Participants in this group will not receive any treatment for their depression and their depressive symptoms will be monitored for 6 to 9 weeks
62128454|NCT04995718|EXPERIMENTAL|IPET: Intelligent physical exercise training during working hours|Workplace physical exercise
62128455|NCT01827345|EXPERIMENTAL|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
62128456|NCT06012617||UCP group|children with hemiplegia due to stroke
62128457|NCT00963625|EXPERIMENTAL|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
62128458|NCT00963625|ACTIVE_COMPARATOR|Fresh blastocyst transfer.|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
62128459|NCT00711581|EXPERIMENTAL|A|Subjects will undergo a laparoscopic cholecystectomy. The gallbladder will be retracted using the Endograb retractor.
62128460|NCT01726842||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
62128461|NCT01726842||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~* VA \<20/40 and 2 logMAR lines difference in normal eye~* Mild amblyopia (\>20/40)~* Moderate amblyopia (20/40 and \<20/100)~* Severe amblyopia (≥20/100 or worse)~* Bilateral amblyopia: \>4 years age VA\<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~* Constant: \>2 PD at near and or distance.~* Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~* 'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~* 'hypermetropia' (≥3.5 D),~* 'myopia' (≥-4.0 D),~* 'astigmatism' (≥1.5 D).~* 'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
62128462|NCT01726842||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
62128463|NCT04470375|EXPERIMENTAL|VR pain education|Students receiving the 45 minute pain education through Virtual Reality
62128464|NCT06172673||Community dwelling participants|Individuals between the ages of 19 and 45 in South Korea.
62128465|NCT03372070|EXPERIMENTAL|cNEP|silicone collar applied to anterior neck
62128466|NCT00088413|EXPERIMENTAL|All Cohorts: Colorectal, Non-Colorectal, Breast, and Ovarian|All cohorts receive the same intervention (Cohort 1: Colorectal arm, non-colorectal cancers; Cohort 2: breast cancer; Cohort 3: ovarian cancers)
62128467|NCT03789955|EXPERIMENTAL|Fluoroscopic-guided TEB|After assessment of the epidural space using the loss of resistance technique with air under fluoroscopic guidance, six fluoroscopic views will be obtained: true anteroposterior, contralateral oblique (CLO) at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral for comparison CLO view with lateral view.
62128468|NCT03632759|EXPERIMENTAL|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
62128469|NCT03632759|EXPERIMENTAL|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
62128470|NCT00925977|ACTIVE_COMPARATOR|insulin Glargine + insulin Apidra|insulin Glargine + insulin Apidra
62128471|NCT00925977|ACTIVE_COMPARATOR|Insulin NPH + Insulin Apidra|12 weeks treatment with Insulin NPH + Insulin Apidra
62128472|NCT02703246|ACTIVE_COMPARATOR|abdominal morcellation|Women randomized to this group will undergo abdominal morcellation.
62128473|NCT02703246|ACTIVE_COMPARATOR|vaginal morcellation|Women randomized to this group will undergo vaginal morcellation.
62738116|NCT03581149|ACTIVE_COMPARATOR|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
62128474|NCT01381406||COPD patients|Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
62128475|NCT04804930||patients with systemic scleroderma|
62128476|NCT04804930||healthy subject|healthy subject without systemic scleroderma or known hair or scalp disease
62687797|NCT06312254|PLACEBO_COMPARATOR|Control|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
62687798|NCT06675162|EXPERIMENTAL|Pilates Reformer Training (OW)|A group of women with overweight/obesity in this arm will participate in a 60-minute muscle-strengthening training session with Pilates Reformer equipment.
62687799|NCT06675162|EXPERIMENTAL|Pilates Reformer Training (NW)|A group of women with normal weight in this arm will participate in a 60-minute muscle-strengthening training session with Pilates Reformer equipment.
62687800|NCT06314048||Standard of Care - CGM and RPM|1. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
62687801|NCT04467853|EXPERIMENTAL|LCAR-C18S Cells|Each subject will receive LCAR-C18S Cells
62687802|NCT04275869|EXPERIMENTAL|Experimental Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
62687803|NCT04275869|NO_INTERVENTION|Control Group|Control group will receive the standard treatment which consists of regular gynaecological visits; the Reproduction Service gynaecologists will recommend healthy lifestyle habits and give the patients a document detailing a specific diet they should follow for weight loss.
62687804|NCT03379584|EXPERIMENTAL|SGN-CD48A|SGN-CD48A
62687805|NCT04101331|EXPERIMENTAL|Cohort A|Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).
62687806|NCT03570515|EXPERIMENTAL|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days.
62687807|NCT03570515|ACTIVE_COMPARATOR|Educational Film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
62687808|NCT01189721|ACTIVE_COMPARATOR|sevoflurane|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients who are in this group will be infused propofol intraoperatively.
62687809|NCT01189721|EXPERIMENTAL|propofol|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients included this group will be inhaled sevoflurane intraoperatively.
62687810|NCT00803855|EXPERIMENTAL|AZD1446 Oral or placebo|Single oral administration of AZD1446 or placebo
62687811|NCT00803855|EXPERIMENTAL|AZD1446 Oral, with or without food|Single oral administration of AZD1446 with or without food
62687812|NCT04297774|EXPERIMENTAL|virtual reality group|18 sessions of standard treatment plus virtual reality treatment.
62687813|NCT04297774|ACTIVE_COMPARATOR|standard treatment group|18 sessions of standard treatment plus balance training.
62687814|NCT04801901|EXPERIMENTAL|Distal transradial access (dTRA)|Subjects randomized to the experimental arm will undergo left heart catheterization using distal transradial access (dTRA) to facilitate coronary angiography and/or percutaneous coronary intervention.
62128477|NCT06258824||Pancreatic Cancer (PDAC)|A clinical diagnosis of PDAC was defined by results of a multidisciplinary team meeting consisting of at least a consultant hepatopancreaticobiliary surgeon, consultant hepatopancreaticobiliary physician, consultant histopathologist and consultant radiologist. ERCP findings, endoscopic ultrasound findings, biliary brushing cytology, and fine needle aspiration cytology were anonymised and recorded. The combination of a pancreatic mass on radiographic imaging without acute cholangiopathy, and clinical or radiographic progression after ≥12 months of follow-up, or death clinically and radiographically determined to be due to pancreatic cancer. For surgical resection and biopsy specimens, diagnoses and staging were rendered based on standard histo-morphological criteria. For the purposes of analysis, pathological staging was used in preference to clinical staging where possible.
62687815|NCT04801901|ACTIVE_COMPARATOR|Forearm radial access (fTRA)|Cardiac catheterization to facilitate coronary angiography and/or percutaneous coronary intervention using the standard forearm radial artery which is the current standard of care in interventional cardiology.
62687816|NCT03001739|EXPERIMENTAL|Intensive BP control (<120mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to \< 120 mm Hg
62687817|NCT03001739|ACTIVE_COMPARATOR|Conventional BP control (120-140mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg
62687818|NCT06572033||Respiratory Therapists|This cohort consists of respiratory therapists (RTs) who are actively involved in both simulation-based training sessions and actual neonatal deliveries. Participants will have varying levels of experience, from newly qualified to seasoned professionals. During the study, RTs will perform positive pressure ventilation (PPV) on both neonatal mannequins in the simulation lab and on newborns in the delivery room. Their performance will be measured using a respiratory function monitor (RFM), focusing on parameters such as mask leak, peak inspiratory pressure (PIP), positive end-expiratory pressure (PEEP), and exhaled tidal volume (eVT). The goal is to assess the transferability of their skills from simulation to real-life scenarios.
62738117|NCT03581149|ACTIVE_COMPARATOR|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
62738118|NCT05306834|ACTIVE_COMPARATOR|Minimal cSVD patient group|little or no white matter hyperintensities
62738119|NCT05306834|ACTIVE_COMPARATOR|Extensive cSVD patient group|moderate to severe white matter hyperintensities
62738120|NCT02859727|EXPERIMENTAL|CDZ173|140mg/day
62738121|NCT00211354|EXPERIMENTAL|anecortave acetate|anecortave acetate 15 mg. juxtascleral injection every 6 months for 24 months
62687819|NCT06572033||Newborn Infants|This cohort consists of respiratory therapists (RTs) who are actively involved in both simulation-based training sessions and actual neonatal deliveries. Participants will have varying levels of experience, from newly qualified to seasoned professionals. During the study, RTs will perform positive pressure ventilation (PPV) on both neonatal mannequins in the simulation lab and on newborns in the delivery room. Their performance will be measured using a respiratory function monitor (RFM), focusing on parameters such as mask leak, peak inspiratory pressure (PIP), positive end-expiratory pressure (PEEP), and exhaled tidal volume (eVT). The goal is to assess the transferability of their skills from simulation to real-life scenarios.
62687820|NCT06644482|OTHER|Exercise group in a hospital|Participants will take part in an exercise group delivered once a week in a hospital setting for 16 weeks
62687821|NCT06543862|OTHER|All participants|The endoscopist will make an optical diagnosis (OD) prediction for all small polyps (up to 10 mm) in white light (WL). Then, the endoscopist will make another OD prediction using image enhanced endoscopy (IEE) modes. After that, CADx will be activated in the IEE mode and a CADx prediction will be documented. Finally, after seeing the CADx prediction, the endoscopist will make a final prediction, which can agree or disagree with the autonomous CADx one. Polyps will be resected and sent to a pathology lab, where a pathologic diagnosis (blinded to the endoscopist's predictions) will be rendered.
62687822|NCT06256939|EXPERIMENTAL|Intervention Group|The Therapy BRIDGE program is a prospective, longitudinal, non-randomized pilot study for infants diagnosed with IVH and their caregivers. The Therapy BRIDGE program will begin as the infant is nearing discharge from the NICU and continue as the infant transitions to home. It will use a hybrid model including both in-person and telehealth sessions.
62687823|NCT06256939|NO_INTERVENTION|Control Group|In the instance that a patient is deemed eligible to participate in the Therapy BRIDGE program and the caregiver chooses not to participate, the caregiver will be offered the opportunity to be enrolled in the control arm of our study as part of a monitoring group. This group of patients will continue to receive usual care while admitted to the NICU and any outpatient recommendations will be deferred to the primary NICU therapists caring for the infant based on the patient's individualized needs.
62687824|NCT04655976|EXPERIMENTAL|Participants receiving cobolimab+ dostarlimab+ docetaxel|
62687825|NCT04655976|EXPERIMENTAL|Participants receiving dostarlimab+ docetaxel|
62687826|NCT04655976|ACTIVE_COMPARATOR|Participants receiving docetaxel|
62687827|NCT06690476|EXPERIMENTAL|Dose escalation(IPM514 monotherapy)|Drug：IPM514 Intramuscular Injection A total of 7 administrations, including 2 cycles of vaccination with each cycle at QW × 3 doses; there is a 2-weeks interval between the two cycles, then followed by a boost dose 3 weeks after the 2'nd cycle.
62687828|NCT06690476|EXPERIMENTAL|Dose expansion (IPM514 combined with tislelizumab)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration The usage and dosage of the tislelizumab will be based on the drug instructions. IPM514 administration is planned to be concomitant with PD-1 antibody and to be stopped after 9 doses of treatment, while the PD-1 antibody will be continuously administered for a maximum of 1 year.
62738122|NCT01332591|ACTIVE_COMPARATOR|Complete revascularization|"Percutaneous coronary intervention of non-infarct coronary arteries"
62738123|NCT01332591|NO_INTERVENTION|Conservative management|standard guideline-based medical therapy
62738124|NCT06552936|EXPERIMENTAL|Low level laser therapy (LLLT)|The LLLT phase will be done with an uninitiated 300-micron tip at 0.5 W in a CW. For this phase, the tip will be kept apart from the targeted tissue by 1mm in the scanning motion.
62479925|NCT04334941|EXPERIMENTAL|Arm II (atezolizumab, talazoparib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and talazoparib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.
62479926|NCT06217822|EXPERIMENTAL|Dose escalation of BAY3563254|Participants with advanced mCRPC will receive increased 225Ac-PSMA-Trillium doses in a planned stepwise fashion.
62479927|NCT06217822|EXPERIMENTAL|Dose expansion group A of BAY3563254|Participants with advanced mCRPC treated with 225Ac-PSMA-Trillium, who must have received at least 1 but no more than 2 prior taxane-based chemotherapy regimens. Prior radiopharmaceutical treatment is not permitted.
62318603|NCT04471103|EXPERIMENTAL|Real-Time Delphi Method|The Real-Time Delphi Method involves a single-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant once they have rated an outcome. They can then modify how they rated the outcome based on this feedback if they wish. Participants can also re-visit and re-rate outcomes as many times as they wish when the survey is live. Duration will span approximately 5 weeks.
62687829|NCT06690476|EXPERIMENTAL|Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
62687830|NCT02496754|EXPERIMENTAL|New protocol group|Use long term GnRH-a 3.75mg at day 2 of menstrual cycle. Around 30 days later, controlled ovarian hyperstimulation using gonadotropins is initiated.
62687831|NCT02496754|ACTIVE_COMPARATOR|Standard GnRH-a long protocol|Use short GnRH-a 0.1mg at luteal phase of last menstrual cycle for 10 days and 0.05mg for another 4 days. Once pituitary down regulation is achieved,controlled ovarian hyperstimulation using gonadotropins is initiated. During ovarian stimulation, short GnRH-a is used daily at the dose of 0.05mg until human chorionic gonadotrophin (HCG) trigger.
62687832|NCT05700422|EXPERIMENTAL|OC-01 (varenicline solution) 0.03 mg nasal spray|
62687833|NCT02712216|OTHER|Trocar Insertion Sites|Insertion of a 21-gauge 3.5inch spinal needle perpendicular to the abdominal wall at each possible trocar site. The needle will be placed after the abdomen is insufflated under direct visualization with the laparoscopic camera. The needle will be inserted to the level of the peritoneum and a hemostat will be place on the needle at the level of the epidermis.
62687834|NCT05293262||Patients who underwent endourological surgery for urolithiasis during COVID19|Endourological surgery (including ureteral stent insertion, ureteroscopy, retrograde intrarenal surgery)
62687835|NCT01946646|EXPERIMENTAL|S-1-CCRT|There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT
62687836|NCT03765983|EXPERIMENTAL|Cohort A: single-arm, two stage, phase II cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter
62687837|NCT03765983|EXPERIMENTAL|Cohort B: a pre-surgical window cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter Surgical brain metastasis resection
62687838|NCT06563713|EXPERIMENTAL|lowest dose group|8 subjects will be randomized to receive lowest dose of STSP-0902 subcutaneous injection or dose-matched placebo (First cohort)
62687839|NCT06563713|EXPERIMENTAL|low dose group|8 subjects will be randomized to receive low dose of STSP-0902 subcutaneous injection or dose-matched placebo (Second cohort)
62687840|NCT06563713|EXPERIMENTAL|middle dose group|8 subjects will be randomized to receive middle dose of STSP-0902 subcutaneous injection or dose-matched placebo (Third cohort)
62479928|NCT06217822|EXPERIMENTAL|Dose expansion group B of BAY3563254|Participants with advanced mCRPC treated with 225Ac-PSMA-Trillium, who must not have received taxane-based chemotherapy since becoming castration resistant. Prior radiopharmaceutical treatment is not permitted.
62687841|NCT06563713|EXPERIMENTAL|high dose group|Experimental: 8 subjects will be randomized to receive high dose of STSP-0902 subcutaneous injection or dose-matched placebo (Fourth cohort)
62687842|NCT06563713|EXPERIMENTAL|highest dose group|Experimental: 8 subjects will be randomized to receive highest dose of STSP-0902 subcutaneous injection or dose-matched placebo (Fifth cohort)
62687843|NCT04241432|ACTIVE_COMPARATOR|Platform type 1|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
62687844|NCT04241432|ACTIVE_COMPARATOR|Platform type 2|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
62687845|NCT02704000|NO_INTERVENTION|Control|No interventions - only baseline and endline assessments to be conducted at children's home.
62479929|NCT06217822|EXPERIMENTAL|Dose expansion group C of BAY3563254|Participants with advanced mCRPC treated with 225Ac-PSMA-Trillium, who must have had prior treatment with 177Lu-PSMA more than 6 weeks before the start of study treatment and at least 1 but no more than 2 taxane regimens (or been deemed ineligible for or refused taxane therapy on consultation with their physician).
62687846|NCT02704000|EXPERIMENTAL|Home visits by CDAs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained child development agents (CDAs). CDAs will implement the Jamaica curriculum intervention during the home visits..
62687847|NCT02704000|EXPERIMENTAL|Home visits by CHWs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained community health workers (CHWs) trained on delivering the intervention. CHWs will implement the Jamaica curriculum intervention during the home visits..
62687848|NCT06026644||Quality of life assessment|Quality of life questionnaires
62687849|NCT01335685|EXPERIMENTAL|Arm A: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m\^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle for up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles \[34 months\]).
62687850|NCT01335685|EXPERIMENTAL|Arm A: Ixazomib 3.7 mg|Ixazomib 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m\^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally on Days 1 to 4 in 42-day cycle for up 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 10 maintenance cycles; overall up to 19 cycles \[21 months\]).
62687851|NCT01335685|EXPERIMENTAL|Arm B: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m\^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 15 maintenance cycles; overall up to 27 cycles \[25 months\]).
62318604|NCT04471103|ACTIVE_COMPARATOR|Multi-round Delphi Method|The Multi-Round Delphi Method involves a three-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant at the end of Round 1 and the end of Round 2. Participants can then modify how they rated the outcome based on feedback, in Rounds 2 and 3, if they wish. Each survey Round will run for 3 weeks approximately. In between survey Rounds, there will be a downtime of approximately 10 days before providing feedback and a further 7 days before starting the next round. Duration will span approximately 14 weeks.
62318605|NCT01016405||Severity of dry eye in patients undergoing cataract surgery|
62318606|NCT03855306|EXPERIMENTAL|A Test|Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide
62318607|NCT03855306|ACTIVE_COMPARATOR|B Reference|Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide
62318608|NCT06533644|EXPERIMENTAL|Part 1 - Dose Escalation, Cohort 1: Partial Oncolysis + SV-102|Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 1.
62318609|NCT06533644|EXPERIMENTAL|Part 1 - Dose Escalation, Cohort 2: Partial Oncolysis + SV-102|Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 2.
62318610|NCT06533644|EXPERIMENTAL|Part 1 - Dose Escalation, Cohort 3: Partial Oncolysis + SV-102|Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 3.
62479930|NCT06217822|EXPERIMENTAL|225Ac-PSMA-Trillium Imaging and Dosimetry|The 225Ac-PSMA-Trillium Imaging and Dosimetry Substudy will enroll throughout both dose escalation and dose expansion, starting with the first dose level in dose escalation. The substudy will generally be available at all study sites to participants in the main study.
62318611|NCT06533644|EXPERIMENTAL|Experimental: Part 2 - Dose Expansion: Partial Oncolysis + SV-102|Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, dose based on data from Part 1.
62318612|NCT04795713|EXPERIMENTAL|PD-L1 Positive NSCLC|Subjects with PD-L1 Positive Lung Carcinoma (NSCLC) who received prior PD-1/PD-L1 treatment
62318613|NCT04795713|EXPERIMENTAL|PD-L1 Positive SCCHN|Subjects with PD-L1 Positive Squamous Cell Carcinoma of the head and neck (SCCHN), refractory to or ineligible for platinum-based therapy, who received prior PD-1/PD-L1 treatment
62318614|NCT04795713|EXPERIMENTAL|Other relapsed/refractory PD-L1 positive solid tumors|Subjects with any other relapsed or refractory PD-L1 positive solid tumor who received PD-1/PD-L1 treatment.
62318615|NCT04795713|EXPERIMENTAL|PD-L1 positive advanced cancer|Subjects with PD-L1 positive advanced cancer (solid tumors)
62318616|NCT00515463|EXPERIMENTAL|Denosumab - Vial|Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
62318617|NCT00515463|EXPERIMENTAL|Denosumab - Prefilled syringe|Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
62318618|NCT02517944||Familial hypercholesterolemia patients|"* clinical data~* biological data~* cardiac and aortic RMI with gadolinium"
62128478|NCT06258824||Cholangiocarcinoma (CCA)|A clinical diagnosis of CCA was defined by radiological criteria according to results of a multidisciplinary team meeting consisting of at least a consultant hepatopancreaticobiliary surgeon, consultant hepatopancreaticobiliary physician, consultant histopathologist and consultant radiologist. ERCP findings, endoscopic ultrasound findings, biliary brushing cytology, and fine needle aspiration cytology were anonymised and recorded. This was also determined based on clinical or radiographic progression after ≥12 months of follow-up, or death clinically and radiographically determined to be due to cancer. For surgical resection and biopsy specimens, diagnoses and staging were rendered based on standard histo-morphological criteria. For the purposes of analysis, pathological staging was used in preference to clinical staging where possible.
62128479|NCT06258824||Benign|A clinical diagnosis of benign disease was defined by assessment at ERCP as well as results of a multidisciplinary team meeting consisting of at least a consultant hepatopancreaticobiliary surgeon, consultant hepatopancreaticobiliary physician, consultant histopathologist and consultant radiologist. Any patients with a benign aetiology were either clinically determined on the basis of no further progression after ≥12 months follow-up with either documented resolution or stability of prior ductal abnormalities or no further intervention as documented in electronic hospital records at 12 months.
62128480|NCT02190981||Ultrasound for Small Bowel Obstruction|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected small bowel obstruction
62128481|NCT05079646|NO_INTERVENTION|Group 1, subgroup A (blue color coded)|Normal teeth with no cavity preparation and no endodontic procedure.
62128482|NCT05079646|EXPERIMENTAL|Group 1, subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu).
62318619|NCT02517944||Control group|"* clinical data~* biological data~* cardiac and aortic RMI with gadolinium"
62318620|NCT05828446|EXPERIMENTAL|HCC screening population according to European Association for the Study of the Liver recommendation|
62318621|NCT03894904|EXPERIMENTAL|Papaverine plus heparin during procedure, with rescue papaverine as needed|1 mL bolus of papaverine (0.12 mg/mL) plus heparin (2 units/mL) in saline (NaCl 0.9%) will be administered as soon as the arterial catheter is placed and secured, and a 1 mL bolus of papaverine (0.12 mg/mL) plus heparin (2 units/mL) in saline (NaCl 0.9%) will be administered one hour after initial bolus. If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second bolus, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
62479931|NCT06217822|EXPERIMENTAL|HPGe or NaI Whole Body Radioactivity Measurement of 225Ac-PSMA-Trillium|HPGe or NaI measurements of whole-body radioactivity of 225Ac and its daughters as a function of time will be conducted on an optional basis during dose escalation and dose expansion at selected sites to evaluate the clearance of total radioactivity from the body over time. Participants in the 111In-PSMA-Trillium and Tris-POC Imaging Substudy will not be eligible for this HPGe or NaI Whole Body Radioactivity Measurement of 225Ac-PSMA-Trillium Substudy.
62687852|NCT01335685|EXPERIMENTAL|Arm B: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 cycle plus melphalan 6 mg/m\^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles \[58 months\]).
62128483|NCT05079646|EXPERIMENTAL|Group 1, subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent)
62128484|NCT05079646|ACTIVE_COMPARATOR|Group 1, subgroup D (black color coded) positive control group|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson)
62128485|NCT05079646|NO_INTERVENTION|Group 2, Subgroup A (Blue color coded) negative control group|Normal teeth with no cavity preparation and no endodontic procedure.
62318622|NCT03894904|ACTIVE_COMPARATOR|Heparin during procedure, with rescue papaverine as needed|1 mL bolus of heparin (2 units/mL) in saline (NaCl 0.9%) will be administered as soon as the arterial catheter is placed and secured, and a 1 mL bolus of heparin (2 units/mL) in saline (NaCl 0.9%) will be administered one hour after initial bolus. If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second bolus, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
62318623|NCT02058355|EXPERIMENTAL|Personalized Normative Feedback|This group receive the complete Personalized Normative Feedback (with normative information and a list of consequences)
62318624|NCT02058355|EXPERIMENTAL|Normative Feedback|This group receive a feedback only with normative informations (without a list of consequences)
62318625|NCT02058355|EXPERIMENTAL|Consequences List Feedback|This group receive a list of consequences without normative informations
62479932|NCT06563336|EXPERIMENTAL|EMG-driven hand robot training|"Robot rehabilitation program was applied with Hand of Hope®(Rehab-Robotics Company, Hong Kong), and EMG-driven exoskeleton. The biggest advantage of this system is that it measures the residual muscle activity values with surface EMG(sEMG) sensors. The residual muscles activity is used by giving feedback to the patient.~Participants in the experimental group and the control group received 60 sessions of hand rehabilitation programs delivered 5 times a week over 12 weeks. Experimental group performed robotic rehabilitation for 30 minutes and conventional occupational treatment for 30 minutes a day."
62128486|NCT05079646|EXPERIMENTAL|Group 2, Subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu) by using tofflemire retainer and matrix band.
62128487|NCT05079646|EXPERIMENTAL|Group 2, Subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent) by using tofflemire retainer and matrix band.
62128488|NCT05079646|ACTIVE_COMPARATOR|Group 2, Subgroup D (black color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson) by using tofflemire retainer and matrix band.
62128489|NCT02831712|OTHER|Iron supplement|Ferrous Fumarate tablet 200 mg
62128490|NCT03740009|EXPERIMENTAL|Perimenopausal women, depressed|Participants will take Bazedoxifene/Conjugated Estrogen orally for 3 weeks
62128491|NCT02438904|EXPERIMENTAL|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
62128492|NCT02613546|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
62128493|NCT02613546|OTHER|Control|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
62128494|NCT02764242|OTHER|insect sting allergy|"Skin prick tests to local and imported insect sting allergen with different concentration are performed.~sIgE Measurement (to insect and the recombinant venom)"
62128495|NCT01603758|NO_INTERVENTION|Observational Arm|Cholesterol metabolic parameters will be measured in 100 subjects in an observational study. Results will be related to circulating biomarkers and carotid intima-media thickness.
62128496|NCT01603758|PLACEBO_COMPARATOR|Ezetimibe Interventional Arm|Cholesterol metabolic parameters will be measured before and after ezetimibe or placebo intervention. Changes due to ezetimibe will be determined
62128497|NCT05700630|EXPERIMENTAL|Determine the safety and feasibility of administering FT538 monotherapy|Administering FT538 monotherapy as an intravenous infusion once every 14 days for 4 consecutive doses and in combination with twice weekly vorinostat for the reduction of the HIV reservoir.
62128498|NCT05700630|EXPERIMENTAL|Characterize the toxicities and impact of FT538 and vorinostat|To characterize the toxicities associated with FT538 monotherapy and with vorinostat in this patient population. To determine the impact of FT538 on the persistence of low-level HIV viremia, defined as detectable HIV-1 RNA of ≤200 copies/mL despite good ART adherence.
62128499|NCT03508518|EXPERIMENTAL|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
62128500|NCT03508518|ACTIVE_COMPARATOR|Care as usual|"Patient will have usual care :~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
62128501|NCT02989103||Hyperthyroidism Follow-up Cohort Study|Hyperthyroid patients enrolled and treated between 1946 and 1964 in 25 U.S. and 1 UK site
62128502|NCT00807937|EXPERIMENTAL|A|AZD7325 5mg twice daily
62128503|NCT00807937|EXPERIMENTAL|B|AZD7325 15mg twice daily
62128504|NCT00807937|ACTIVE_COMPARATOR|C|Lorazepam 2mg twice daily
62128505|NCT00807937|PLACEBO_COMPARATOR|D|Placebo
62128506|NCT04498663|EXPERIMENTAL|Therapeutic Interview Condition|The therapeutic interview for chronic pain will be a one-session interview lasting approximately 90 minutes. The goals of the therapeutic interview are to promote awareness of the role of trauma and interpersonal stress in pain, to encourage experience of emotions associated with interpersonal stressors and conflicts, and to encourage more adaptive interpersonal communication in current relationships.
62128507|NCT04498663|NO_INTERVENTION|Waitlist Control Condition|Participants in the waitlist control condition will receive a delayed interview (after 6-week follow-up assessment), if they choose to do so.
62128508|NCT03649113|EXPERIMENTAL|sclerotherapy arm|Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
62128509|NCT02578589|ACTIVE_COMPARATOR|surgery|
62128510|NCT02578589|ACTIVE_COMPARATOR|Conservative treatment|
62128511|NCT00422006|EXPERIMENTAL|1|Non diabetic non dyslipidemic patient
62128512|NCT00422006|EXPERIMENTAL|2|Patient with metabolic syndrome
62479933|NCT06563336|ACTIVE_COMPARATOR|conventioanl training|The control group performed 30-minutes conventional occupational treatment twice a day. In both groups, the hand rehabilitation program was carried out at the same time and interval for 60 minutes a day.
62128513|NCT00422006|EXPERIMENTAL|3|Patients with type II diabetes
62479934|NCT02422875||Healthy Controls|Subjects are healthy persons without any autoimmune conditions or infectious diseases
62128514|NCT00422006|EXPERIMENTAL|4|Patient with a single lipidic anomaly
62128515|NCT06275035|EXPERIMENTAL|Experimental arm|Participants in the experimental arm (memantine) will be started on memantine. The starting dose of memantine will be 5mg once daily at bedtime for 1 week, followed by 5mg twice daily for 1 week, and finally increased to the full dose of 10 mg twice daily for 6 months.
62128516|NCT06275035|NO_INTERVENTION|Standard arm|Participants in the standard arm will continue the standard treatment as planned.
62479935|NCT02422875||Autoimmune Disease|Subjects diagnosed with autoimmune disease including but not limited to: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome (SS), Scleroderma, Myositis, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), inflammatory arthritis, undifferentiated connective tissue disease, idiopathic thrombocytopenic purpura (ITP), Graft vs Host Disease (GVHD), Autoimmune Lymphoproliferative Syndrome (ALPS) and IgG4-related disease
62318626|NCT06274138|EXPERIMENTAL|haptonomy|Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
61925281|NCT04570722|OTHER|Single arm study|Patients with a history of axillary surgical lymph node procedures (SLNP) presenting for routine radiographic scan will complete baseline measures: bilateral volumetric measurements and self-reported symptoms. Patients will undergo SOC contralateral arm intravenous access attempt. After one failed attempt, ipsilateral intravenous access instead of pedal or neck access will be offered per research protocol. Nursing documentation will reflect the failed venipuncture and categorize a reason for the failed attempt.
61925282|NCT02780609|EXPERIMENTAL|Selinexor Plus HDM HCT|The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.
61925283|NCT05938179|EXPERIMENTAL|HS-10353 Capsules|
62128517|NCT04055246|EXPERIMENTAL|Prebiotic|Participants receive prebiotics containing fiber bar to consume 2x daily for 1 week.
62479936|NCT02422875||Infectious Disease|Subjects diagnosed with an infectious disease including but not limited to: Hepatitis C, Epstein Barr Virus (infectious mononucleosis - EBV), Sepsis, Guillain-Barre syndrome (GBS), Mycoplasma pneumoniae or Human Immunodeficiency Virus (HIV)
62479937|NCT02422875||Autoimmune - Family|Subjects have a brother, sister, mother, father, or child with an autoimmune disease
62479938|NCT02422875||Vaccination|Subjects have received or will receive a vaccination as part of regular standard of care from their healthcare provider or other outside source
62479939|NCT00001355||Healthy Volunteer|Healthy Volunteer to serve as controls
62479940|NCT00001355||Patient|Patients known to have or suspected of having an immune defect significantly or primarily involving the phagocytes
62479941|NCT00001355||Patient Relatives|blood relatives of patients
62479942|NCT05260957|EXPERIMENTAL|Combination CAR-T Cell Therapy, Mosunetuzumab + Polatuzumab|"Participants will receive study treatment in three phases: Induction Phase, CAR-T Treatment Phase and Consolidation Phase.~During the Induction Phase (Days -42, through -6), participants will receive Mosunetuzumab on Days -42, -35, -28, and -7; and Polatuzumab on Day -28. On Day -6, participants will be evaluated in clinic.~During the CAR-T Treatment Phase (Days -5, through Day 0), participants will receive lymphodepleting chemotherapy for three consecutive days beginning on Day -5, followed by CAR-T Cell therapy via infusion on Day 0.~During the Consolidation Phase (Days +1 through +90), participants will receive Mosunetuzumab on Day +14; and combination Mosunetuzumab and Polatuzumab on Days +35, +56 and +77."
62479943|NCT02760927|EXPERIMENTAL|Endotracheal Tube Fastener|The intervention administered is a revised commercially available endotracheal tube holder with a tract to accommodate a subglottic suction lumen of an oral endotracheal tube.
62479944|NCT04717349||Family Members of PAG patients|Clinical evaluation of family members that would provide clinical information related to the diagnosis of a proband in future research.
62479945|NCT04717349||PAG patient|Pediatric and adolescent patients with gynecologic conditions.
62479946|NCT06462196||Bipolar Disorder|Individuals with Bipolar Disorder
62479947|NCT06462196||Major Depressive Disorder|Individuals with Major Depressive Disorder
62479948|NCT06462196||Suicide Risk|Individuals at an elevated suicide risk
62687853|NCT01335685|EXPERIMENTAL|Arm B: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m\^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 24 cycles \[24 months\]).
62687854|NCT01335685|EXPERIMENTAL|Arm C: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m\^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles \[40 months\]).
61925284|NCT05938179|EXPERIMENTAL|HS-10353 matched-placebo oral capsules|
62128518|NCT04055246|PLACEBO_COMPARATOR|Placebo|Participants receive placebo bar containing no added prebiotics to consume 2x daily for 1 week.
62128519|NCT03319797|OTHER|Treatment with NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte transplantation)
61925285|NCT04119154|EXPERIMENTAL|Standard diagnosis and CEM platform|Participants will receive standard diagnostic approach and assessment by CEM platform
61925286|NCT04955964||All Participants|Participants with diagnosis of HAE who have received at least one dose of lanadelumab according to currently approved indications in routine clinical practice settings in Argentina will be observed in this study.
61925287|NCT00769574|EXPERIMENTAL|1|Patients with coronary syndrome
62128520|NCT02118675||Age 5-17 years|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
62318627|NCT06274138|NO_INTERVENTION|control|Explanation of the purpose of the study will be provided to pregnant women and their partners, obtaining verbal and written consent. Pregnant women in the control group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
62318628|NCT02088944||exposed to IFX|
62318629|NCT01214616|EXPERIMENTAL|afatinib and vinorelbine IV|patient to receive 20mg or 40mg of po daily afatinib in combination with vinorelbine IV
62318630|NCT01766427||morning electroacupuncture with pills|
62318631|NCT01766427||afternoon EA with pills|
62318632|NCT01766427||no EA group with pills|
62318633|NCT06283095|EXPERIMENTAL|study group|we will do expansion palatoplasty
62128521|NCT02118675||Age 18-80 years|Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
62128522|NCT00640549|PLACEBO_COMPARATOR|2|
62128523|NCT00640549|ACTIVE_COMPARATOR|1|
62128524|NCT00770757|EXPERIMENTAL|CC-4047 Arm|CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).
62128525|NCT05007665||Chronic Liver Diseases Patients/Healthy People|Chronic hepatitis (B OR C) , autoimmune hepatitis, liver cirrhosis, primary hepatocellular carcinoma
62128526|NCT01157663|EXPERIMENTAL|Adapted Balance Training group|
62128527|NCT01157663|ACTIVE_COMPARATOR|Standard Balance training group|Balance training with unipedal standing during 8 weeks
62128528|NCT02928354|EXPERIMENTAL|Treatment A - AZD7594|Treatment A - AZD7594 inhalation powder Particle size Large
62128529|NCT02928354|EXPERIMENTAL|Treatment B - AZD7594|Treatment B - AZD7594 inhalation powder Particle size Medium
62128530|NCT02928354|EXPERIMENTAL|Treatment C - AZD7594|Treatment C - AZD7594 inhalation powder Particle size Small
62318634|NCT05464485||ACL hamstring reconstructions using semitendinosus (ST) tendon only|
62318635|NCT05464485||ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|
62318636|NCT01682369|OTHER|Group 1 a - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
62318637|NCT01682369|OTHER|Group 1 b - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
62318638|NCT01682369|OTHER|Group 1 c - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Aggripal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Aggripal)~V3-(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
62687855|NCT01335685|EXPERIMENTAL|Arm C: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m\^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 21 cycles \[24 months\]).
62738125|NCT06552936|EXPERIMENTAL|High intensity laser therapy (HILT)|HILT will be done directly after extraction when the extraction socket is filled with blood (without oozing). It will be conducted with the help of an un-initiated 300-micron tip running at the 2-watt (W) power output. It will be in a continuous emission mode (CW).
62738126|NCT06552936|EXPERIMENTAL|Low level laser therapy+ high intensity laser therapy|The patient will receive a combination of LLLT and HILT.
62738127|NCT06552936|SHAM_COMPARATOR|Control|The patient will have the identical treatment as the experimental group but with the laser device in the non-activated phase.
62318639|NCT01682369|OTHER|Group 2 a - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
62318640|NCT01682369|OTHER|Group 2 b - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
62738128|NCT04367155|ACTIVE_COMPARATOR|tranexamic acid local|tranexamic acid inside the irrigation fluid
62738129|NCT04367155|ACTIVE_COMPARATOR|tranexamic acid IV|tranexamic acid injection
62128531|NCT01444417|EXPERIMENTAL|Romiplostim|Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.
62128532|NCT01444417|PLACEBO_COMPARATOR|Placebo|Participants received weekly subcutaneous placebo for 24 weeks.
62128533|NCT01736215||Participants with cancer related anemia|Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.
62128534|NCT03872635|EXPERIMENTAL|CHO Drinking Grope|receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
62128535|NCT03872635|NO_INTERVENTION|Traditional fast Grope|fast on standard hospital protocol (8 hour fasting for solid and 4 hour fasting for clear liquid
62128536|NCT04865146||TRIGEN™ INTERTAN™|Confirmed femoral fracture subjects who are scheduled for repair using INTERTAN 10S Nail
62687856|NCT01335685|EXPERIMENTAL|Arm D: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m\^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m\^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles \[38 months\]).
62687857|NCT03903042||Group 1|Center 1: Traditional camera(Canon) vs Aurora camera
62687858|NCT03903042||Group 2|Center 2: Traditional camera(Zeiss) vs Aurora camera
62687859|NCT03903042||Group 3|Center 3: Traditional camera(Topcon) vs Aurora camera
62687860|NCT01027351|EXPERIMENTAL|5rMenB|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
62687861|NCT01027351|EXPERIMENTAL|5rMenB+OMV NZ|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
62318641|NCT01682369|OTHER|Group 2 c - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
62687862|NCT01027351|EXPERIMENTAL|3rMenB|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
62687863|NCT01027351|EXPERIMENTAL|3rMenB+OMV NZ|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
62687864|NCT01027351|EXPERIMENTAL|Naive_4042|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
62687865|NCT01027351|EXPERIMENTAL|Naive_6062|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.
62318642|NCT04037358|EXPERIMENTAL|Radium-223 and SABR|First radium-223 infusion will be within two weeks of SABR
62318643|NCT04037358|ACTIVE_COMPARATOR|SABR|SABR(1-5 fractions) will be administered for all men
62318644|NCT04579068|EXPERIMENTAL|Screening and Brief Intervention of Problematic Alcohol Use|We plan to test the feasibility and effectiveness of the delivery of the peer-based SBIRT using the RAPS4-QF screening tool with CDU students. Furthermore, we will compare delivery by AAPLs' race/ethnicity, drinking status (abstainer vs. non-abstainer), and adverse life experiences. Following the screening by AAPLs, we expect a 30% detection of problematic alcohol use (i.e. high episodic drinking \[HED\] or AUD) and at-risk alcohol use. Participants that screen positive will receive brief motivational interviewing and referral to treatment and will be contacted 6 months following the SBIRT to assess their drinking behaviors. We expect that participants will decrease their alcohol consumption or drinking risk at the 6-month follow up.
62318645|NCT00445055|EXPERIMENTAL|1|Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
62318646|NCT00445055|EXPERIMENTAL|2|Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
62318647|NCT00445055|PLACEBO_COMPARATOR|3|Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
62318648|NCT00192517|ACTIVE_COMPARATOR|1|MEDI-522
62318649|NCT00192517|PLACEBO_COMPARATOR|2|Placebo
62687866|NCT02137278|ACTIVE_COMPARATOR|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment
62687867|NCT02137278|EXPERIMENTAL|Vasoactive drug therapy|Continue current vasoactive therapy
62687868|NCT03670433||Patients admitted in the Polyvalent Internal Medical Unit|"Patients over 65 years old admitted in the Polyvalent Internal Medical Unit (UMIP) of Rennes University Hospital between 09/04/2017 and 10/31/2017 or going back home or to a rehabilitation service during the same period.~Cost analysis of medication reconciliation."
62687869|NCT02672605|NO_INTERVENTION|Control|Participant completes a survey measuring abortion stigma prior to receiving the mandatory Pennsylvania State consent for their abortion.
62687870|NCT02672605|EXPERIMENTAL|Investigational|Participant completes a survey measuring abortion stigma after receiving the mandatory Pennsylvania State consent for their abortion.
62738130|NCT06388148|EXPERIMENTAL|Endovascular thrombectomy|Patients in this group will be treated with medical management plus endovascular thrombectomy
61925288|NCT00769574|OTHER|2|Subjects without coronary syndrome
62479949|NCT06429007|EXPERIMENTAL|Metformin Intervention|Participants will complete a pre-study visit with baseline bloodwork including a complete blood count (CBC), liver and renal function, basic chemistry, glucose, and lactate. At this visit, parents will be taught how to administer metformin and given a 6-week supply of metformin at 50% of the target dose to minimize potential gastrointestinal upset. Parents will be educated on adverse effects and receive a diary to log dose administration and noted side effects. After six weeks, participants will return for a study visit with repeat labs. Bloodwork at this visit will include plasma metformin levels for measurement of pharmacokinetics. Study staff will also review diary completion for adverse effects and to ensure there have been no missed doses. Parents will then receive a 6-week supply of metformin 25mg/kg for 6 weeks. A final study visit will then occur following 12-weeks of metformin therapy, with repeat labs including plasma metformin levels.
62128537|NCT04425616|EXPERIMENTAL|Universal Interventions|"The delivery of nutrition, exercise and psychological interventions delivered in the following structure:~* Month 1: Up to three times per week~* Months 2-3: Once per week~* Months 4 - 6: One session per month for the last 3 months"
62479950|NCT06042738|ACTIVE_COMPARATOR|Group 1|group receiving antioxidant support
62479951|NCT06042738|NO_INTERVENTION|Group 2|group that did not receive antioxidant support
62479952|NCT06508710|EXPERIMENTAL|Ketamine Group|The patient will receive 3 doses of intravenous ketamine (0,50mg/kg) in addition to the usual venlafaxine treatment
62479953|NCT06508710|PLACEBO_COMPARATOR|Placebo group|The patient will receive 3 doses of intravenous placebo (50mL of NaCl 9‰) in addition to the usual venlafaxine treatment
62479954|NCT02993159|EXPERIMENTAL|Arm I (afimoxifene, placebo)|Patients apply afimoxifene gel to both breasts and receive placebo PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
62479955|NCT02993159|ACTIVE_COMPARATOR|Arm II (placebo, tamoxifen citrate)|Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
62479956|NCT00455312|EXPERIMENTAL|Patients with DC|Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
62128538|NCT01330147||Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
62128539|NCT05096806|ACTIVE_COMPARATOR|Usual care plus TENS|"Participants in this group will receive transcutaneous electrical nerve stimulation (TENS) and usual care.~TENS treatment will perform in the region of the knee and the extensor muscles for 20 minutes, 2 times a week. 4 electrodes will be placed, 2 on the proximal region of the internal and external vastus, and the other 2 on the distal region of the motor plate.~Usual care will consist in home exercises with toning exercises of the extensor apparatus, pelvic region and musculoskeletal stretching exercises of 2 weekly sessions, the recommendation of daily activity of walking for 1 hour daily as an active lifestyle and the recommendation of the reduction of body weight in the case of being above normal weight. There will be a total of 6 face-to-face sessions at the rate of 2 weekly sessions"
62479957|NCT00455312|EXPERIMENTAL|Patients with SAA|Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
62479958|NCT05286229|EXPERIMENTAL|Cohort 1 (ABBV-383 Dose A)|Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive ABBV-383 dose A in 21-day cycles.
61925289|NCT01732731|EXPERIMENTAL|treadmill training|children will receive home-based treadmill training with supervision from a physical therapist
61925290|NCT01732731|NO_INTERVENTION|no treadmill training|children will not receive treadmill training
61925291|NCT01247038|EXPERIMENTAL|Metal on ceramic articulation|The arm consists of patients with Ceramic femoral heads articulating with metal acetabular cups
61925292|NCT01247038|ACTIVE_COMPARATOR|Metal-on-metal|The arm consists of patients with Metal femoral heads articulating with metal acetabular cups
62318650|NCT03136211|EXPERIMENTAL|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
62318651|NCT03136211|NO_INTERVENTION|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
62318652|NCT00202410|PLACEBO_COMPARATOR|physiologic solution|subcutaneous administration of physiologic solution
62318653|NCT00202410|EXPERIMENTAL|Bacille Calmette-Guèrin (BCG) Vaccine|Anti-Tubercular Vaccination
62479959|NCT05286229|EXPERIMENTAL|Cohort 2 (ABBV-383 Dose B)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 dose B in 21-day cycles.
62479960|NCT01010503|EXPERIMENTAL|Single Arm|
62479961|NCT05138250|EXPERIMENTAL|Treatment arm (all participants, not randomised)|All participants will be treated with mepolizumab, a 100mg dose every 4 weeks for 1 year (13 doses)
62687871|NCT06111742|EXPERIMENTAL|Interactive Gaming Group|Subjects will utilize an interactive gaming platform via the Bedside Entertainment and Relaxation Theater (BERT) directly prior to and during induction of anesthesia.
62687872|NCT06111742|NO_INTERVENTION|Standard of Care|Subjects will be offered standard of care interventions to improve preoperative anxiety. The interactive gaming system under investigation will not be available to this group.
62687873|NCT03494842|ACTIVE_COMPARATOR|the active TENS group|Transcutaneous nerve stimulation (TENS)
62687874|NCT03494842|PLACEBO_COMPARATOR|the placebo TENS group|Placebo Transcutaneous nerve stimulation (TENS)
62687875|NCT00594997|EXPERIMENTAL|Education|Students who receive an educational intervention which consists of a 45 minute interactive presentation as well as a 30 minute health education entertainment by a juggler.
62318654|NCT02553720|EXPERIMENTAL|Aquatic Group|Conventional management plus aquatic exercise At least 15 minutes of walking 3 times/week for 3 months
62318655|NCT02553720|OTHER|Control Group|Conventional management without aquatic exercise
62318656|NCT01001533||Children sedated by DEX|All pediatric patients (1 month to 18 years of age) eligible for Radiology Sedation Service for CT scan and Nuclear Medicine Scan procedure.
62318657|NCT04220047|EXPERIMENTAL|Left Atrial Appendage Resection|
62318658|NCT04220047|NO_INTERVENTION|off-pump coronary artery bypass|
62687876|NCT00594997|ACTIVE_COMPARATOR|Control|Students who fill out pre and post surveys and receive the intervention after the post-survey
62687877|NCT01050218|OTHER|DVS SR Open Label|Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level.
62687878|NCT06686121|EXPERIMENTAL|Home based exercise + nitrate rich beetroot juice|This group will be participating in home based exercise and drinking nitrate rich beetroot juice for six months.
62687879|NCT06686121|PLACEBO_COMPARATOR|Home-based exercise + placebo|This group will be participating in home based exercise and drinking placebo beetroot juice with nitrate removed for six months.
62318659|NCT00890630|ACTIVE_COMPARATOR|Oxytocin|Induction of Labour with Oxytocin Alone
62318660|NCT00890630|EXPERIMENTAL|Intracervical Catheter|Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.
62318661|NCT00352781|EXPERIMENTAL|Nicotine Replacement + Behaviour Therapy|Nicotine Replacement Therapy as per monograph \& behavioural intervention
62318662|NCT02658162|EXPERIMENTAL|SANGUINATE|Two (2) infusions of SANGUINATE
62318663|NCT02658162|PLACEBO_COMPARATOR|Normal Saline|Two (2) infusions of Normal Saline
62318664|NCT05082571|EXPERIMENTAL|Vadadustat|Cohort 1: participants with ≥12 years to \<17 years; Cohort 2: participants with ≥6 years to \<12 years; Cohort 3(a): participants with ≥2 years to \<6 years; and Cohort 3(b): participants with ≥4 months to \<2 years
62318665|NCT01588301|EXPERIMENTAL|Group 1 : Further invitation by mail|Further invitation to attend for cervical cytology
62479962|NCT02595944|EXPERIMENTAL|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET/CT throughout the trial and blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.
62479963|NCT02595944|ACTIVE_COMPARATOR|Arm II (observation)|Patients are followed serially with CT and/or PET/CT imaging for up to 1 year and then during follow-up. Patients also undergo blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.
62479964|NCT01815320|EXPERIMENTAL|Contrast-enhanced ultrasound (CE-US)|Ce-US is performed by contrast agent infusion SonoVue. The acquisition protocol will consist of two different administrations of SonoVue, performed 10 minutes apart. In the first session, SonoVue microbubbles will be administered as a fast 1.5 ml bolus immediately followed by 5 ml saline solution. In the second session, max 2 vials (9.6 ml) of SonoVue will be infused at an infusion rate between 0.5 and 1.0 ml/min.
62479965|NCT05292365|EXPERIMENTAL|RE-PACT Intervention|Intervention participants receive respiratory illness action plans and weekly mobile health (mHealth) confidence surveillance. At times of low confidence or hospitalization, just-in-time action planning and coaching activities are conducted.
62687880|NCT06686121|EXPERIMENTAL|Attention control + nitrate-rich beetroot juice|This group will be participating in attention control and drinking nitrate rich beetroot juice for six months.
62687881|NCT06686121|PLACEBO_COMPARATOR|Attention control + placebo|This group will be participating in attention control and drinking placebo beetroot juice with nitrate removed for six months.
62687882|NCT04628494|EXPERIMENTAL|Epcoritamab (GEN3013; DuoBody®CD3xCD20)|Epcoritamab will be administered in Cycles of 28 days until any of the discontinuation criteria is met
62738131|NCT06388148|ACTIVE_COMPARATOR|Medical management|Patients in this group will be treated with medical management alone
62318666|NCT01588301|EXPERIMENTAL|Group 2 : Kit for Self-collected vaginal sample|Kit for Self-collected vaginal sample sent at home and then test for Human Papillomavirus (HPV)
62318667|NCT01588301|NO_INTERVENTION|Group 3: Control|
62318668|NCT03839433|ACTIVE_COMPARATOR|ciclesonide positive|"Half of the Mannitol positive patients were given ciclesonide. Half of the Mannitol negative patients were given ciclesonide. All patients in the ciclesonide positive arm received ciclesonide."
62318669|NCT03839433|PLACEBO_COMPARATOR|Placebo|"Half of the Mannitol positive patients were given a placebo. Half of the Mannitol negative patients were given a placebo. All patients in the placebo arm received placebo."
62318670|NCT04357093|EXPERIMENTAL|Grape seed extract mouthwash|Grape seed extract mouth wash 15% concentration
62318671|NCT04357093|ACTIVE_COMPARATOR|Sodium fluoride mouthwash|Sodium fluoride mouthwash 1000 ppm
62318672|NCT06110234|EXPERIMENTAL|Episodic Specificity Induction|In each of the six training sessions, participants practice the ESI first under supervision and then unsupervised (self-administered). Self-administration is performed on a laptop. During each practice of the ESI, participants perform a detailed recall of a new 1-minute video clip of a complex scene - a skit of the famous English comedian Mr. Bean. Each session lasts for 90 minutes.
62318673|NCT06110234|ACTIVE_COMPARATOR|Associative Memory|In each of the six training sessions, participants recall pairs of words and pictures (e.g., names of women and rings). These pairs are presented successively after a fictitious scenario is presented to motivate memorization. There are 12 scenarios, each with 5 different word/picture pairs. Simple additions and subtractions separate the encoding phase from the recall phase. This training is adapted from Bellander et al, (2017). A general knowledge quiz is also administered at the end of the session. The training is performed on a laptop. Each session lasts for 90 minutes.
62318674|NCT02335450|EXPERIMENTAL|Single Arm|All five participants in the study will receive this intervention. The participants will be visited in their homes by a physical therapist once a week. The physical therapist will use a coaching technique called motivational interviewing to help the participant develop personal physical activity goals. The participant will discuss their physical activity challenges, and with the help of the physical therapist the participant will set up personal physical activity goals for the following week. The participant will be given a wristband physical activity monitor to wear during the day for four weeks to track their progress in meeting their activity goals.
62318675|NCT01818791|ACTIVE_COMPARATOR|Making Proud Choices alone|These sites will be trained in Making Proud Choices.
62479966|NCT05292365|NO_INTERVENTION|Active Control (AC)|AC subjects will receive usual comprehensive medical care and coordination.
62479967|NCT06335082||Acute Arm|Data will be collected at pre-ablation/baseline and at time of the ablation procedure. Sites should follow the subjects per their standard of care and at a minimum report any acute onset procedure or device-related complications through 30-days post procedure. Data collection will include procedural workflow, procedural outcomes, and acute onset procedure or device-related complications through 30 days.
62687883|NCT04628494|ACTIVE_COMPARATOR|Investigator's choice of chemotherapy|"R-GemOx will be administrated in Cycles of 28 days until maximum cycles completion or any of the discontinuation criteria is met~BR will be administrated in Cycles of 21 days until maximum cycles completion or any of the discontinuation criteria is met"
62687884|NCT06673537|EXPERIMENTAL|Manip|Manip: Connective Tissue Massage (CTM) + Spinal Manipulation (SM) Participants in the CTM+SM group will be applied three times a week, starting from the predicted day of ovulation (cycle length minus 14 days) until the onset of the next menstrual period. This will include treatment of the pelvic regions, specifically the sacral, lumbar, lower thoracic, and anterior pelvic areas. In addition to the CTM, spinal manipulation will be performed. The manipulation will follow the CTM and will involve the application of high-velocity, low-amplitude (HVLA) force bilaterally to all clinically relevant vertebral levels from T10 to L5, as well as to the sacroiliac joints, accompanied by an audible release from one or more joints. Treatment will be administered three times a week, with each session lasting 20 minutes. This regimen will continue for a duration of six weeks.
62687885|NCT06673537|SHAM_COMPARATOR|Sham Manip|Sham Manip: Connective Tissue Massage (CTM) + Sham Spinal Manipulation (Sham SM) The intervention will be applied three times a week, starting from the predicted day of ovulation (cycle length minus 14 days) until the onset of the next menstrual period. This will include treatment of the pelvic regions, specifically the sacral, lumbar, lower thoracic, and anterior pelvic areas. In addition to the CTM, sham spinal manipulation will be performed three times a week. This will involve the application of low-amplitude force bilaterally to all clinically relevant vertebral levels from T10 to L5 and to the sacroiliac joints, without producing any audible release. Treatment will be administered three times a week, with each session lasting 20 minutes. This regimen will continue for a duration of six weeks.
62687886|NCT06673537|NO_INTERVENTION|Control Group|Participants in this group will undergo an initial assessment during which general information about the study will be provided. They will be informed about the importance of refraining from taking any medications throughout the six-week study period. All participants will be re-evaluated after the completion of the six weeks.
62687887|NCT06674434|EXPERIMENTAL|Group A|The group will engage in traditional tennis elbow exercises and mobilization through movement.
62687888|NCT06674434|ACTIVE_COMPARATOR|Group B|The group will be given a prolonged stretch along with conventional tennis elbow exercises.
62738132|NCT02950155|EXPERIMENTAL|Rituximab|A single infusion at a dose of 500 mg of Mabthera/Rituximab.
61925293|NCT05674552|EXPERIMENTAL|Study group|Children receiving exogenous ketone esters + standard of care
62318676|NCT01818791|EXPERIMENTAL|Making Proud Choices+Getting To Outcomes|These sites will receive training in Making Proud Choices and receive the Getting To Outcomes intervention.
62318677|NCT02546856|ACTIVE_COMPARATOR|Heart Failure (HF) cardiologist up-titration|Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
62318678|NCT02546856|EXPERIMENTAL|HF nurse up-titration|Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.
62318679|NCT03753568|EXPERIMENTAL|Study group|The participants use either direct oral anticoagulants or oral diabetic medication.
62318680|NCT05605327|EXPERIMENTAL|EUS-guided gastroenterostomy|
62479968|NCT06335082||Symptomatic Monitoring Only Arm (SMO)|Data will be collected at pre-ablation/baseline, the ablation procedure, a 3-Month post-ablation office visit and 12-Months post-ablation (monitoring is triggered for symptomatic recurrences only). Data collection will include procedural workflow, procedural outcomes, acute, mid, and late onset procedure or device related complications, and symptomatic recurrence.
62479969|NCT06335082||Full Monitoring Arm (FM)|Data will be collected at pre-ablation/baseline, the ablation procedure, a 3-Month post-ablation office visit, interim continuous monitoring for asymptomatic arrhythmia recurrence at 6- and 12-Months post-ablation as well as monitoring as needed for symptomatic recurrences, and a 12-Month post-ablation office visit. Data collection will include procedural workflow, procedural outcomes, acute, mid, and late onset procedure or device related complications, symptomatic recurrence as well as asymptomatic recurrence.
62479970|NCT05187923||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
62479971|NCT05187923||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
62479972|NCT01619241||advanced non-small cell lung cancer|
62479973|NCT05373615|EXPERIMENTAL|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on effluent rate
62128540|NCT05096806|EXPERIMENTAL|Usual care plus Acupuncture|"Participants in this group will receive acupuncture treatment and usual care.~Acupuncture treatment will consist in 20-minute semi-standardized acupuncture sessions, 2 times a week. The intervention will consist of the insertion of 8 needles: 4 in points located in the knee (points St34, St35, XiYan and Sp10) and 4 more sensitive to palpation points located between the knee and the ankle. Stimulation will be performed to obtain local spasm response, the needles will be left for 20 minutes and then removed. The needles will be sterile disposable silicone needles of 0.20x20mm and 0.20x40mm.~Usual care will be the same described in the Usual care plus TENS group"
62128541|NCT05496777|OTHER|Intervention arm|Patients planned for pancreatic resection will be included for a home-based prehabilitation program.
62479974|NCT05706909||Genex with ABMC|Injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the Core decompression procedure
62479975|NCT01030328|ACTIVE_COMPARATOR|TriLipix + Atorvastatin|Two tables of TriLipix + Atorvastatin taken once a day by mouth.
62479976|NCT01030328|PLACEBO_COMPARATOR|2|2 sugar pills
62128542|NCT02146716|NO_INTERVENTION|Control|
62128543|NCT02146716|EXPERIMENTAL|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.
62128544|NCT06322316|ACTIVE_COMPARATOR|The Ultrasound-guided Retrolaminar Block (RLB) Group|Received a preoperative ultrasound-guided retrolaminar block using 20 ml levobupivacaine 0.25% Ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.
62128545|NCT06322316|ACTIVE_COMPARATOR|The Ultrasound-guided Erector Spinae Plane Block (ESPB) Group|"Received a preoperative ultrasound-guided erector spinae plane block using 20 ml levobupivacaine 0.25%.~ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process."
62128546|NCT02685969||18F-Flutemetamol & 18F-FDG PET scans|All study participants will be assessed by PET scan with 18F-Flutemetamol \& 18F-FDG PET scans.
62128547|NCT03379740|EXPERIMENTAL|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
62318681|NCT05605327|ACTIVE_COMPARATOR|Laparoscopic gastroenterostomy|
62318682|NCT04708964|ACTIVE_COMPARATOR|Flurbiprofen|5 ml of flurbiprofen solution 0.25% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
62479977|NCT03649633|EXPERIMENTAL|Steroids/Vitamin C group|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
62738133|NCT02950155|SHAM_COMPARATOR|Sodium Chloride solution|A single infusion with sodium chloride solution.
62318683|NCT04708964|PLACEBO_COMPARATOR|Placebo|5 ml of saline solution 0.9% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
62318684|NCT05611684|EXPERIMENTAL|Polyethylene Glycol Losenatide|Trearment for 12 weeks
62318685|NCT05228912||BNT162b2 mRNA|Group of patients of any age, any sex, that will receive a complete scheme of approved BNT162b2 mRNA vaccination , assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
61925294|NCT05674552|NO_INTERVENTION|Control group|Children receiving only standard of care
62128548|NCT03379740|EXPERIMENTAL|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
62318686|NCT05228912||mRNA-1273|Group of patients of any age, any sex, that will receive a complete scheme of approved mRNA-1273 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
62318687|NCT05228912||ChAdOx1-S|Group of patients of any age, any sex, that will receive a complete scheme of approved ChAdOx1-S vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
62318688|NCT05228912||Ad26.COV2|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad26.COV2 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
62479978|NCT03649633|PLACEBO_COMPARATOR|Control group|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
62687889|NCT06675006||Bowen Therapy with Cryotherapy Group|This group consists of participants receiving Bowen therapy combined with cryotherapy for the treatment acute ankle sprain. Each session includes a 30-minute Bowen therapy treatment, focusing on gentle, non-invasive movements designed to stimulate the body's healing processes. Cryotherapy involves the application of ice to the affected area to reduce inflammation and pain. Participants in this group will undergo three treatment sessions on days 1, 8, and 15 of the study, with assessments of pain intensity and functional capacity conducted before and after the intervention.
62687890|NCT06675006||Medical Massage and Cryotherapy Group|This group consists of participants who receive traditional medical massage for the treatment of acute ankle sprain. Interventions are conducted over three sessions, occurring on days 1, 8, and 15, with each session lasting 30 minutes. The medical massage aims to alleviate pain, improve muscle relaxation, and enhance overall functionality in daily activities. Participants' pain levels and functional capacity are assessed using the VAS pain scale and Roland-Morris questionnaire at both the beginning and end of the study period.
62687891|NCT06637865|EXPERIMENTAL|IMP761 Part A|Single dose IMP761, randomized in 3:2 (IMP761:placebo) Cohort 1: 5 subjects
62687892|NCT06637865|PLACEBO_COMPARATOR|Placebo Part A|Single dose placebo, randomized in 3:2 (IMP761:placebo) Cohort 1: 5 subjects
62687893|NCT06637865|EXPERIMENTAL|IMP761 Part B KLH challenge|"Single dose IMP761, randomized in 4:1 (IMP761:placebo). KLH immunization followed by IMP761 on Day 1 and dermal rechallenge on day 2 (Cohorts 2-3) or on days 2, 9 and 23 (Cohorts 4-5)~Cohort 2: 5 subjects Cohort 3: 5 subjects Cohort 4: 10 subjects Cohort 5: 10 subjects"
62687894|NCT06637865|PLACEBO_COMPARATOR|Placebo Part B KLH challenge|"Single dose Placebo, randomized in 4:1 (IMP761:placebo). KLH immunization followed by placebo on Day 1 and dermal rechallenge on day 2 (Cohorts 2-3) or on days 2, 9 and 23 (Cohorts 4-5)~Cohort 2: 5 subjects Cohort 3: 5 subjects Cohort 4: 10 subjects Cohort 5: 10 subjects"
62687895|NCT06637865|EXPERIMENTAL|IMP761 Part C|"Multiple ascending dose IMP761, randomized 5:2 (IMP761:placebo) every 28 days, 3 times.~Cohort 6: 7 subjects Cohort 7: 7 subjects"
62479979|NCT00342654||1|Participants from two large, nutritional intervention trials that were conducted in Linxian, China between 1985-1991.
62479980|NCT04747535|NO_INTERVENTION|Control|Regular treatment
62479981|NCT04747535|EXPERIMENTAL|Auto CPAP|Auto CPAP, AirSense 10 AutoSet, ResMed Inc, max pressure 10 cm water, min pressure 5 cm water
62479982|NCT04747535|OTHER|CPAP since before|Patients with CPAP since before will all continue using CPAP. They will not attend the randomization process. They will be regarded as a separate group.
62479983|NCT00051857||1/Healthy Controls|Subjects 5 years old and up with musculoskeletal impairment, pathology, or variant.
62128549|NCT03311737|EXPERIMENTAL|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
62128550|NCT03311737|ACTIVE_COMPARATOR|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
62128551|NCT03828240|OTHER|Enhanced rehabilitation|
62318689|NCT05228912||Ad5-nCoV|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad5-nCoV vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
62318690|NCT05228912||Gam-COVID-Vac|Group of patients of any age, any sex, that will receive a complete scheme of approved Gam-COVID-Vac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
62318691|NCT05228912||Coronavac|Group of patients of any age, any sex, that will receive a complete scheme of approved Coronavac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
62479984|NCT00051857||2/Healthy Volunteers|Subjects 5 years old and up without musculoskeletal impairment, pathology, or variant.
62318692|NCT03578354|EXPERIMENTAL|4-AP|15 mg 4-aminopyridine twice daily
62318693|NCT03578354|EXPERIMENTAL|Atenolol|25 mg atenolol twice daily
62318694|NCT03578354|PLACEBO_COMPARATOR|Placebo|Masked placebo twice daily
62318695|NCT04866667||antidiabetic drugs including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs including GLP-1 RAs
62318696|NCT04866667||antidiabetic drugs not including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs not including GLP-1 RAs，such as metformin，insulin
62687896|NCT06637865|PLACEBO_COMPARATOR|Placebo Part C|Multiple dose placebo, randomized 5:2 (IMP761:placebo) every 28 days, 3 times. Cohort 6: 7 subjects Cohort 7: 7 subjects
62687897|NCT04304287|EXPERIMENTAL|Experimental|Preoperative blood donations 14 day before total hip replacement procedure Donation of one dose of autologous blood 14 day before total hip replacement procedure
62687898|NCT04304287|ACTIVE_COMPARATOR|Active comparator|Preoperative blood donation 72 hours before total hip replacement procedure Donation of one dose of autologous blood 72 hours before total hip replacement procedure
62687899|NCT04304287|OTHER|Other|Without preoperative blood donation
62687900|NCT05215236|EXPERIMENTAL|Opiate Sparing|Standard icing and elevation therapy Acetaminophen 1000 milligrams by mouth every 8 hours for five days then as needed every 8 hours for pain control Gabapentin 100 milligrams by mouth three times per day for 14 days Celecoxib 100 milligrams by mouth two times per day for 5 days Esomeprazole 20 milligrams by mouth once per day for 14 days Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone Oxycodone 5 milligrams by mouth every 6 hours as needed for pain control unresponsive to other medications
62687901|NCT05215236|ACTIVE_COMPARATOR|Opiate Based|Standard icing and elevation therapy Oxycodone 5-10 milligrams by mouth every 4 to 6 hours as needed for pain control Acetaminophen 1000 milligrams by mouth every 8 hours as needed for pain control Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone
62687902|NCT01390519||Afinitor|Afinitor
62687903|NCT06631053|ACTIVE_COMPARATOR|No Exercise|Participants will undergo a 30d Unilateral Lower Limb Suspension (ULLS) without exercise
62687904|NCT06631053|EXPERIMENTAL|velocity-based FIT (VBFIT)|Participants will undergo a 30d Unilateral Lower Limb Suspension (ULLS) with exercise
62687905|NCT01267136|EXPERIMENTAL|Capital® with Codeine Suspension|
62687906|NCT01267136|ACTIVE_COMPARATOR|Tramadol suspension|
62738134|NCT00913887|EXPERIMENTAL|1|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
62738135|NCT00913887|EXPERIMENTAL|2|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
62738136|NCT00913887|ACTIVE_COMPARATOR|3|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
62738137|NCT06412835|EXPERIMENTAL|Students' course success|Knowledge level of nursing students
62128552|NCT04426916||normal lumbar spine|Patient without spondylolisthesis or significant spinal anatomic deformity. (ex\> severe spondylosis, spinal stenosis, scoliosis, etc..)
62479985|NCT04902352|EXPERIMENTAL|Periadventitial dissection|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process."
62128553|NCT04426916||spondylolisthesis|Spondylolisthesis patients, with whom the deformity is at just one level. The patients should not have any other significant spinal deformity. (ex\> severe spondylosis, spinal stenosis, scoliosis, etc..)
62128554|NCT04048668|ACTIVE_COMPARATOR|Anodal tDCS|2mA for 20 minutes
62128555|NCT04048668|SHAM_COMPARATOR|Sham tDCS|30 second ramp-up / ramp-down for 20 minutes
62128556|NCT05592925||N0|gastric cancer patients with no lymph node metastasis
62128557|NCT05592925||N+|gastric cancer patients with lymph node metastasis, including patients with N1, N2 and N3 stage cancer
62128558|NCT04701866|EXPERIMENTAL|Music|Music will be provided for participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks).
62128559|NCT04701866|NO_INTERVENTION|Usual Care|Participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks) will be administered as per usual care. That is, without music provided or permitted. Contact time with clinicians before, during, and after ketamine treatments will be matched.
62318697|NCT01830452|EXPERIMENTAL|Parietex Progrip mesh|Ventral hernioplasty using a (self gripping / self adhering / self fixating) Progrip mesh not needing fixation devices
62738138|NCT06412835|EXPERIMENTAL|self-directed learning|self-directed learning
62738139|NCT01132950|ACTIVE_COMPARATOR|Didactic Educational Counseling|
62738140|NCT01132950|EXPERIMENTAL|Motivation Interviewing|Participant will receive two sessions of personalized motivational interviewing.
62738141|NCT02026674|EXPERIMENTAL|FloRite|LUTS patients that used FloRite for home urine flow diagnostics.
62738142|NCT05611255|EXPERIMENTAL|Systematic Intermittent Catheterization (SIC)|A bladder catheter will be placed in the operating room, at the end of the operation, in a patient still under general anesthesia. Once the urine has been drained and quantified, the bladder catheter will be removed before the patient is discharged and extubated.
62738143|NCT05611255|ACTIVE_COMPARATOR|Bladder Scan Guided Catheterization (BSGC)|No systematic catheterization will be performed, the indication for catheterization will be guided by bladder-scan volume monitoring.
62738144|NCT06659484||Community-dwelling older adults assessed without mobility disability risk factors following initial|"Community-dwelling older adults aged of \>70y, screened at risk of mobility disability risk factors and assessed without any mobility disability risk factors. This group is not included for intervention and received lifestyle counselling to maintain habits. No follow-up is conducted in this group.~Or community-dwelling older adults aged of \>70y, screened with medical contraindication. This group is not included for intervention and oriented to other medical practitioners. No follow-up is conducted in this group."
62738145|NCT06659484||Community-dwelling older adults assessed with mobility disability risk factors following initial ass|Community-dwelling older adults aged of \>70y, screened at risk of mobility disability risk factors and assessed with at least 1 mobility disability risk factor. This group is included for 3 months exercise intervention. Follow-up is conducted at 3 months (T3) and from T3 at 6 months (phone call) and 12 months.
62738146|NCT00837421||sepsis|sepsis survivors
62738147|NCT00929435||MRSA surveillance|Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.
62738148|NCT01918891|NO_INTERVENTION|Usual Home Care|Regardless of study arm, all patients will receive usual home health services: a physician-ordered plan of care; skilled nursing and/or therapy services as prescribed by the MD; patient education, monitoring and hands-on care; and home health aide services depending on functional deficits and availability of unpaid caregivers.
62738149|NCT01918891|EXPERIMENTAL|Nurse Practitioner + Health Coach|The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
62128560|NCT03451721|EXPERIMENTAL|ImageReady™ MR Conditional Defibrillation System|"1. Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology~2. Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
62128561|NCT06166225|EXPERIMENTAL|Internet-based weight loss program + Iyengar yoga|Participants randomized to this group will receive a 12-month automated weight loss program which is delivered via the Internet and will also receive a 9-month Iyengar yoga intervention (delivered during months 4-12). Yoga classes will be delivered live (via Zoom) and participants will be instructed to attend two classes per week for the first 14 weeks and one class per week thereafter. They will also be asked to do self-guided yoga practice on their own and report their yoga practice on the study website.
62128562|NCT06166225|ACTIVE_COMPARATOR|Internet-based weight loss program + health and wellness classes|Participants randomized to this group will receive a 12-month automated weight loss program which is delivered via the Internet and will also receive a 9-month health and wellness intervention (delivered during months 4-12). Health and wellness classes will be delivered live (via Zoom) and participants will be instructed to attend two classes per week for the first 14 weeks and one class per week thereafter. Classes will consist of lectures, videos, and discussions and will provide education around a variety of lifestyle topics.
62318698|NCT01830452|ACTIVE_COMPARATOR|Parietex Mesh|Ventral hernioplasty using a polyester mesh fixed with non absorbable sutures as described by Lichtenstein/Amid
62318699|NCT02134704|EXPERIMENTAL|Scoliosis Group|
62318700|NCT02134704|EXPERIMENTAL|Healthy Volunteers Group|
62318701|NCT03135028|EXPERIMENTAL|ENTO monotherapy (Group A)|Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
62318702|NCT03135028|EXPERIMENTAL|ENTO + cytarabine + daunorubicin (Group B)|"Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission \[CR\] or morphologic complete remission with incomplete blood count recovery \[CRi\] and do not require or cannot proceed to allogeneic stem cell transplantation \[SCT\] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles."
62318703|NCT04724486|ACTIVE_COMPARATOR|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
62318704|NCT04724486|EXPERIMENTAL|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
62479986|NCT04902352|ACTIVE_COMPARATOR|NO periadventitial dissection|For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
62479987|NCT01272037|EXPERIMENTAL|Arm I (chemotherapy and endocrine therapy)|Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
62318705|NCT04962321|EXPERIMENTAL|PsychoEd|These participants are enrolled to participate in the 8-session education sessions.
62318706|NCT01311206|EXPERIMENTAL|PBFR|Partial Blood Flow Restriction (PBFR) during Low-Intensity Exercise.
62318707|NCT01311206|ACTIVE_COMPARATOR|PBFR control|Low-Intensity Exercise without partial blood flow restriction.
62318708|NCT02325505||Tuberous sclerosis complex|All patients with TSC, LAM or AML followed at Hospital das Clínicas, University of São Paulo Medical School will be included in the proposed study. Patients of all ages will participate in the study.
62318709|NCT05713305|EXPERIMENTAL|Intervention group|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists. In-depth interviews are conducted both before and after the experiment to explore the feasibility of the intervention
62128563|NCT01484353|EXPERIMENTAL|Intervention group|This is the only arm in the study. They will be compared before and after
62128564|NCT04818931|EXPERIMENTAL|Antibiotics|Cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
62128565|NCT04818931|NO_INTERVENTION|No antibiotics|
61925295|NCT01754909|ACTIVE_COMPARATOR|enalapril|Use of enalapril in subjects undergoing radiotherapy for lung cancer.
62318710|NCT05713305|PLACEBO_COMPARATOR|Control group|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news. In-depth interviews are conducted both before and after the experiment to explore the feasibility of the intervention
62318711|NCT06115577||endometrial polyp|pathology according to histological examination
62318712|NCT06115577||endometrial hyperplasia without atypia|pathology according to histological examination
62318713|NCT06115577||atypical endometrial hyperplasia|pathology according to histological examination
62318714|NCT06115577||endometrial cancer|pathology according to histological examination
62318715|NCT02645448|OTHER|Resistance Exercise Low intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
62318716|NCT02645448|OTHER|Resistance Exercise High intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
62479988|NCT01272037|EXPERIMENTAL|Arm II (endocrine therapy)|Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
62318717|NCT01147731|EXPERIMENTAL|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
62128566|NCT02298452|OTHER|Hearing aid|172 subjects with a mild hearing loss. 140 subjects with a moderate hearing loss. 70 subjects with a severe/ profound hearing loss.
62318718|NCT01792986|OTHER|water-only 24-hour fasting once per week for 6 weeks|
62318719|NCT05453370|EXPERIMENTAL|CALMA app|the arm will receive CALMA app and continue with the usual treatment in a mental health service of a public hospital during the 3 months of the study. In the first interview, the CALMA application will be downloaded to the participant's smartphone. In each follow-up interview (30-days and 60-days), the use of the app will be reinforced.
62318720|NCT05453370|OTHER|Treatment As Usual (TAU)|the arm will not receive the app and will continue with the usual treatment in a mental health service of a public hospital during the 3 months of the study.
61925296|NCT01754909|PLACEBO_COMPARATOR|placebo|Use of placebo in subjects undergoing radiotherapy for lung cancer
62128567|NCT01432613|OTHER|MRI-oriented muscle biopsy|Muscle sample will be done following the usual care.
62128568|NCT02094807|OTHER|Conservative management|Not operated. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
62128569|NCT02094807|ACTIVE_COMPARATOR|Operative management|Operative fixation of rib fractures. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
62128570|NCT01717820|EXPERIMENTAL|Freeze-dried whole-grape powder|Freeze-dried whole-grape powder (46g/day)will be provided to participants for 12 weeks.
62128571|NCT06555588|EXPERIMENTAL|ENGAGE|Behavioral symptom management focused on values identification and skills training.
62128572|NCT06555588|ACTIVE_COMPARATOR|Supportive Care|Education, support, and resources focused on common cancer-related concerns.
62128573|NCT03380234|EXPERIMENTAL|Intervention|8 worksheets and around 15 online quizzes and 30 WhatsApp messages.
62128574|NCT03380234|OTHER|Control|Control students will receive the following minimal intervention to reduce their intention to smoke and SHS - a leaflet on smoking and SHS published by the Department of Health.
62128575|NCT02756377|ACTIVE_COMPARATOR|cetylpyridinium chloride|mouthwash (cetylpyridinium chloride)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
62318721|NCT06329362|ACTIVE_COMPARATOR|Minimal Invasive Implant ridge splitting|Using minimally invasive implant placement in atrophied ridge without mucoperiosteal flap, and specially designed implant shaped expanders.
62318722|NCT06329362|ACTIVE_COMPARATOR|conventional open flap ridge splitting implantation.|Using the conventional open flap technique with mucoperiosteal elevation to expose the ridge with the use of conventional bone expanders and chisels.
62318723|NCT05182229|ACTIVE_COMPARATOR|Clinic-Based Lymphedema Therapy|
62318724|NCT05182229|ACTIVE_COMPARATOR|Home-Based (a hybrid model) Lymphedema Therapy|
62318725|NCT03444363|EXPERIMENTAL|Study group|SRP plus diode laser (810 nm wavelength, 1 W power)
62318726|NCT03444363|ACTIVE_COMPARATOR|Control group|SRP plus placebo
62318727|NCT02190435|EXPERIMENTAL|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
62128576|NCT02756377|ACTIVE_COMPARATOR|Chlorhexidine mouthwash|mouthwash ( Alcohol-free chlorhexidine)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
62128577|NCT06009536|EXPERIMENTAL|Resistance training protocol|Participants in this group will complete a 12-week ankle dorsiflexion resistance training protocol according to Silbernagel. It is a series of heel rise exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
62318728|NCT02190435|ACTIVE_COMPARATOR|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
62128578|NCT06009536|NO_INTERVENTION|Participants with healthy tendons|"Participants in this group are considered healthy based on subjective judgment followed by clinical and ultrasound examination of the Achilles tendon.~In this group, no specific treatment will be performed, only Achilles tendon will be monitored through time."
62128579|NCT01577836||Robotic assistance, Nîmes|The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.
62128580|NCT01577836||Laparotomy, Marseilles|The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.
62128581|NCT02721134|OTHER|additional blood tubes|
62128582|NCT06362278||cases group|In-patients from cardiology department of The First Affiliated Hospital with Nanjing Medical University will be screened using inclusion/exclusion criteria for patients. Among the patients who meet the criteria and willing to give an informed consent, 30 patients with youngest CAD-diagnosed-age will be enrolled as cases.
62128583|NCT06362278||matching controls group|In-patients from cardiology department of The First Affiliated Hospital with Nanjing Medical University will be screened using inclusion/exclusion criteria for controls. 30 controls matched in gender and age will be enrolled as matching controls.
62318729|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
62318730|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
62318731|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
62318732|NCT04969393|EXPERIMENTAL|Group A (High Intensity Laser therapy + Conventional Physical Therapy)|Patients in group (A) received conventional physical therapy program along with HILT. Patients received pulsed Nd: YAG laser treatment, produced by EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2).
62479989|NCT06074328|NO_INTERVENTION|No-VR Group|
61925297|NCT00145678|EXPERIMENTAL|dynamic deconstructive psychotherapy|weekly individual psychotherapy of 50 minute duration lasting 12-18 months
61925298|NCT00145678|ACTIVE_COMPARATOR|optimized community care|eclectic weekly individual and group psychotherapy, as well as drug and alcohol rehabilitation
61925299|NCT02495103|EXPERIMENTAL|Phase I Component - Vandetanib|Phase I Component
61925300|NCT02495103|EXPERIMENTAL|Phase II Component- Vandetanib/Metformin|Phase II Component
61925301|NCT03005171|ACTIVE_COMPARATOR|Epidural|"Epidural catheters will be placed in the 9th or 10th thoracic intervertebral space prior to induction of anesthesia.Through the thoracic epidural catheter 0.125% bupivacaine at a rate of 5 mL/h will be infused.~The infusion continues for 24h"
61925302|NCT03005171|ACTIVE_COMPARATOR|Lidocaine|"Intravenous lidocaine infusion will typically start in the operating room prior to induction of anesthesia at a rate of 2 to 3 mg/min. Postoperatively, the rate will be decreased to 0.5 to 1 mg/min.~The infusion continues for 24h"
61925303|NCT03261180|EXPERIMENTAL|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
61925304|NCT03261180|ACTIVE_COMPARATOR|Group II (regular diet)|Patients receive regular diet.
62479990|NCT06074328|EXPERIMENTAL|VR-Group|
61925305|NCT06008834|EXPERIMENTAL|Interventional group|Patients who undergo a minimal invasive colorectal surgery and are included in the first-day discharge protocol with domiciliary follow-up
61925306|NCT05562271|SHAM_COMPARATOR|sham radiation therapy|sham radiation therapy
61925307|NCT05562271|EXPERIMENTAL|low-dose radiation therapy, 30 cGy/6 fx (experimental 1)|low-dose radiation therapy, 30 cGy/6 fx
61925308|NCT05562271|EXPERIMENTAL|low-dose radiation therapy, 300 cGy/6 fx (experimental 2)|low-dose radiation therapy, 300 cGy/6 fx
61925309|NCT00015938|EXPERIMENTAL|treatment|docetaxel and vinorelbine with filgrastim support
61925310|NCT00023244|EXPERIMENTAL|Corticosteroid (steroid) withdrawal|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
62128584|NCT06362278||verification group|In-patients from cardiology departments of all 3 centers will be screened using inclusion/exclusion criteria. Other than previous 60 participants, about another 100 patients and controls in total who meet the criteria and willing to give an informed consent will be enrolled as verification group.
62479991|NCT03410784|OTHER|First-line chemotherapy with pembrolizumab|"* Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles~* Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~* Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
62128585|NCT01675895|EXPERIMENTAL|Group Levobupivacaine lidocaine|Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine
62479992|NCT00024804||1|Subjects with known or suspected bone disease and disorder of mineral metabolism.
62318733|NCT04969393|ACTIVE_COMPARATOR|Group B (Conventional Physical Therapy)|Patients in this group received the conventional physical therapy program in the form of splinting, tendon and neural gliding exercises. Patients were instructed to wear a neutral custom volar splint at night and while performing strenuous activities during the day for 5 weeks.Also, the patients performed nerve-and tendon-gliding exercise under direct supervision of the therapist during the treatment sessions. Each exercise was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
62479993|NCT04170894|EXPERIMENTAL|Apnea|Patients will undergo an atrial fibrillation ablation and will have induced periods of apnea throughout the procedure.
62479994|NCT04170894|ACTIVE_COMPARATOR|Control|Patients who choose not to participate in the apnea arm will have the opportunity to consent to the control arm. These patients will undergo an atrial fibrillation ablation per standard of care without periods of apnea throughout the procedure. This data will be collected to use as a comparator to the apnea arm.
62479995|NCT02476045|ACTIVE_COMPARATOR|ARM A|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with 5-FU/LV (De Gramont regimen) plus panitumumab given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
62479996|NCT02476045|EXPERIMENTAL|ARM B|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with panitumumab alone given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
62479997|NCT03668041|ACTIVE_COMPARATOR|Trazodone|Participants who are assigned to take trazodone, an active study medication.
62479998|NCT03668041|ACTIVE_COMPARATOR|Eszopiclone|Participants who are assigned to take eszopiclone, an active study medication.
62687907|NCT06045286|EXPERIMENTAL|High- and Low-dose radiotherapy combined with immunotherapy.|All eligible patients will receive high-dose radiotherapy, followed by low-dose radiotherapy combined with PD-1 inhibitor therapy starting within 7 days after completion. The single dose of high-dose radiotherapy will be 6-8 Gy for 3-7 consecutive exposures, and the single dose of low-dose radiotherapy will be 0.5-1.4 Gy for 3-7 consecutive exposures.The PD-1 inhibitor (Zimberelimab) will be administered at the dose recommended in the specification every 3 weeks until disease progression, unacceptable toxicity, and withdrawal of informed consent by the patient.
62687908|NCT03981055|EXPERIMENTAL|Active tDCS and Active TUS|Active tDCS and Active TUS for 20 min
62687909|NCT03981055|SHAM_COMPARATOR|Sham TDCS and Sham TUS|Sham TDCS and Sham TUS for 20 min
62687910|NCT04148755||Elastography guided FNA|Those patients are going to have EUS elastography guided FNA
62687911|NCT04148755||EUS. FNA|From records we are going to compare them with patients who had EUS without elastography guided FNA
62687912|NCT05142319|ACTIVE_COMPARATOR|Homologous mRNA booster vaccine|BNT162b2 + BNT162b2 + BNT162b2 or mRNA-1273 + mRNA-1273 + mRNA-1273
62687913|NCT05142319|EXPERIMENTAL|Heterologous mRNA booster vaccine|BNT162b2 + BNT162b2 + mRNA-1273 or mRNA-1273 + mRNA-1273 + BNT162b2
62687914|NCT05142319|EXPERIMENTAL|COVAXIN|BNT162b2 + BNT162b2 + COVAXIN or mRNA-1273 + mRNA-1273 + COVAXIN
62687915|NCT05142319|EXPERIMENTAL|Nuvaxovid|BNT162b2 + BNT162b2 + Nuvaxovid or mRNA-1273 + mRNA-1273 + Nuvaxovid
62687916|NCT00563316|EXPERIMENTAL|Panitumumab + Irinotecan|Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.
62687917|NCT06509984|EXPERIMENTAL|apremilast treatment|treatment by apremilast in two phases of challenge
62687918|NCT04901715|ACTIVE_COMPARATOR|Genotypes associated mild phenotype|Subjects with 2 confirmed mutations in RSPH1, Radial Spoke Head Component 9 (RSPH9), Radial Spoke Head Component 4A (RSPH4a), or Dynein Axonemal Heavy Chain 11 (DNAH11). This group may also include subjects with mutations in newly identified genes that are associated with a milder clinical phenotype.
62687919|NCT04901715|ACTIVE_COMPARATOR|Genotypes associated with severe phenotype|Subjects with 2 confirmed mutations in DNAH5, Dynein Axonemal Intermediate Chain 1 (DNAI1), Coiled-Coil Domain Containing 39 (CCDC39), or Coiled-Coil Domain Containing 40 (CCDC40). This group may also include subjects with mutations in newly identified genes that are associated with a more severe clinical phenotype.
62687920|NCT04901715|ACTIVE_COMPARATOR|Healthy Control|Healthy subjects with no pre-existing lung disease.
62687921|NCT04279093||Pregnant/postpartum women and their partners|"The investigators aim to recruit 20 women in late pregnancy from the Antenatal Assessment Unit and the Antenatal Clinic at St Mary's Hospital. Their partners will be invited to participate where applicable.~Inclusion and exclusion criteria for pregnant women are as follows:~* Inclusion: after 36 weeks gestation, aged over 18 years and fluent in English, under the care of Manchester University NHS Foundation Trust~* Exclusion: current stillbirth (women experiencing a stillbirth during the study will be withdrawn from the study), fetal abnormality, or multiple pregnancy~Inclusion criteria for partners: male or female partners of a mum participating in the study, aged over 18 and fluent in English."
62687922|NCT04100603||Patients with CDI|Patients who are infected with C. diff
62687923|NCT02214212|ACTIVE_COMPARATOR|Red Light (RL)|"Intervention/Device:~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
62687924|NCT02214212|EXPERIMENTAL|Bright White Light (BWL)|"Intervention/Device:~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
62687925|NCT04130425|EXPERIMENTAL|Healthy Individuals|Subject will be measured for forearm rotation while wearing the custom orthoses Hely \& Weber MTC Fracture Brace, thermoplastic orthosis, and delta cast orthosis.
62687926|NCT04824287|EXPERIMENTAL|Experimental|pelvic floor exercise
62687927|NCT04824287|NO_INTERVENTION|control group|no intervention
61925311|NCT00023244|ACTIVE_COMPARATOR|Control Treatment|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.
61925312|NCT06169397|EXPERIMENTAL|XTMAB-16 Treatment|Dose to be established in the XTMAB-16-201 Study.
61925313|NCT02579928|EXPERIMENTAL|Ketamine|Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
61925314|NCT02579928|EXPERIMENTAL|Midazolam|Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),
61925315|NCT01337271|ACTIVE_COMPARATOR|PSV|
61925316|NCT01337271|EXPERIMENTAL|NAVA|
62687928|NCT02798003||Cachectic cancer patients|Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
62687929|NCT02798003||Non-cachectic cancer patients|Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
61925317|NCT04328350||AYA who are on treatment 2-12 months post -diagnosis|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (30 on-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
61925318|NCT04328350||AYA who are off -therapy 1 to 4 years|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (20 off-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
61925319|NCT00633620|EXPERIMENTAL|colonoscopy|Non-NBI HDTV colonoscopy
61925320|NCT05469685|EXPERIMENTAL|10-day treatment group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 10 days
62128586|NCT01675895|ACTIVE_COMPARATOR|Group Control|Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline
61925321|NCT05469685|ACTIVE_COMPARATOR|14-day treatment group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days
61925322|NCT05611125|EXPERIMENTAL|Intervention|Individuals in the intervention group will undergo a series of two telehealth video visits and a series of survey assessments at baseline, 3, and 6 months.
61925323|NCT05611125|NO_INTERVENTION|Control|Individuals in the control group will continue with their usual standard of care and undergo a series of survey assessments at baseline, 3, and 6 months.
62128587|NCT04502901|EXPERIMENTAL|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects once a day for 14 days. The applied dosage cohorts are 2.5mg, 5mg, 10mg and 20mg.
62479999|NCT03668041|PLACEBO_COMPARATOR|Placebo|Participants who are assigned to take a placebo, a non-active study medication.
62687930|NCT02798003||Cachectic COPD patients|Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
61925324|NCT06240780|ACTIVE_COMPARATOR|ACL Arthroscopic Active Participants|After the surgery, the patient will be placed in the study provided semiconductor element interwoven Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
61925325|NCT06240780|PLACEBO_COMPARATOR|ACL Arthroscopic Placebo Participants|After the surgery, the patient will be placed in the study provided plain fabric Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
62128588|NCT04502901|PLACEBO_COMPARATOR|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects once a day for 14 days.
62128589|NCT05282472|EXPERIMENTAL|with surgical mask|all participants who were applied CPET with surgical mask
62128590|NCT05282472|ACTIVE_COMPARATOR|without surgical mask|all participants who were applied CPET without surgical mask
62128591|NCT02178423|EXPERIMENTAL|Ultrasound|Ultrasound for diagnosis of CVC position in children
62480000|NCT04049760|EXPERIMENTAL|migalastat HCl 150 mg|One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.
62318734|NCT04289103|EXPERIMENTAL|Inolimomab/Leukotac|"* Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion"
62318735|NCT02532868|EXPERIMENTAL|MK-0457|Participants received MK-0457 at assigned dose as a continuous intravenous infusion (CIV) over 24 hours; one group of participants also received MK-0457 100 mg capsules, orally, prior to the CIV.
62318736|NCT04222127|EXPERIMENTAL|EUS-guided injection of CYA of GVs|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle
61925326|NCT06240780|NO_INTERVENTION|ACL Arthroscopic Stand of Care Participants|After the surgery, the patient will be placed in thigh high compression hose, bilaterally, worn 23 hours per day for 31 days.
61925327|NCT06240780|ACTIVE_COMPARATOR|ACL + MCL Arthroscopic Active Participants|After the surgery, the patient will be placed in the study provided semiconductor element interwoven Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
62318737|NCT04222127|EXPERIMENTAL|Direct endoscopic injection of CYA of GVs|Direct endoscopic injection of CYA of the gastric varix using standard endoscopy
62318738|NCT04908189|EXPERIMENTAL|Deucravacitinib|
62318739|NCT04908189|PLACEBO_COMPARATOR|Placebo|
62318740|NCT04908189|OTHER|Apremilast|
62318741|NCT05857202||Operated laryngeal cancer patients treated with non narcotic|Operated laryngeal cancer patients who were administered non narcotic drugs postoperative for pain management
62128592|NCT03434652|ACTIVE_COMPARATOR|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
62128593|NCT03434652|SHAM_COMPARATOR|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
62128594|NCT03297281|EXPERIMENTAL|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
62128595|NCT03297281|ACTIVE_COMPARATOR|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
62128596|NCT03848910|EXPERIMENTAL|Investigational device - Sound Processor|
62128597|NCT04263675||GDM+|Women with history of gestational diabetes
62128598|NCT04263675||GDM-|Women without history of gestational diabetes
62128599|NCT02234128|EXPERIMENTAL|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
62318742|NCT05857202||Operated laryngeal cancer patients treated with non narcotic and opioids|Operated laryngeal cancer patients who were administered non narcotic and opioids postoperative for pain management
62318743|NCT05857202||Operated laryngeal cancer patients treated with opioids|Operated laryngeal cancer patients who were administered opioids postoperative for pain management
62318744|NCT06693726|EXPERIMENTAL|Angiotensin II Infusion|
62318745|NCT02089386|EXPERIMENTAL|Tamoxifen|Tamoxifen 20 mg daily for 12 weeks
62318746|NCT03475407|EXPERIMENTAL|Treatment Group|Ozurdex intravitreal injection
62480001|NCT01386437||Fungal infections|Patients with or without inherited or acquired abnormalities of immune function manifesting mucocutaneous and/or invasive fungal infections
62128600|NCT02234128|EXPERIMENTAL|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
62318747|NCT00328198|EXPERIMENTAL|Dose escalation|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
62318748|NCT00328198|EXPERIMENTAL|No escalation|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
62128601|NCT02234128|NO_INTERVENTION|Control Group|Those patients receiving a single or double lung via conventional transplant.
62128602|NCT06048172|NO_INTERVENTION|Waiting control group|The patients in the treatment-as-usual control group remain on the waiting list for 14 weeks after the baseline measurement. After 14 weeks, they participate in the study diagnostics post-treatment at time point.
62128603|NCT06048172|EXPERIMENTAL|Intervention group|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
62128604|NCT05382936|EXPERIMENTAL|QD Regimen|Patients in the QD regimen will take study medication once daily.
62128605|NCT05382936|EXPERIMENTAL|BID Regimen|Patients in the BID regimen will take study medication twice daily.
62128606|NCT05972213||Longitudinal group|"25 patients anticipated. Patients with :~* Uncontrolled asthma: ACT score \< 20 and/or at least one exacerbation in the last 6 months~* Naïve biotherapy~* Indication for initiation of biotherapy according to the referring pulmonologist (omalizumab, mepolizumab, benralizumab, dupilumab)"
62318749|NCT05815121|EXPERIMENTAL|Acupressing group|"Patients benefit from one session of acupressing with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.~They will also be asked to regularly and gently massage the treated points"
62318750|NCT05815121|SHAM_COMPARATOR|SHAM group|Patients treated according to the same scheme as the experimental group, but with stickers only on the points, and the points should not be massaged.
62318751|NCT05524272|EXPERIMENTAL|THE EFFECTS OF COLOUR BY NUMBER MANDALA|This study was conducted to find out the effects of colour by number mandala in decreasing the stress of hospitalized children with chronic disease. A randomized controlled study.This study was conducted with 120 children between the ages of 8 and 11. 60 children formed the experimental group, while 60 children formed the control group. Descriptive Information Form and Perceived Stress Scale were used in data collection.
61925328|NCT06240780|PLACEBO_COMPARATOR|ACL + MCL Arthroscopic Placebo Participants|After the surgery, the patient will be placed in the study provided plain fabric Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
62128607|NCT05972213||Cross-sectional group|"80 patients anticipated.~* Patient on biotherapy (omalizumab, mepolizumab, benralizumab, dupilumab) for at least 6 months.~* Controlled asthma (ACT \> 20 and no exacerbation for 6 months) or uncontrolled asthma (ACT \< 20 and/or at least 1 exacerbation for 6 months)."
62128608|NCT03447249|PLACEBO_COMPARATOR|Placebo|Participants who received placebo matched to VX-659/TEZ/IVA for 24 weeks in the TC treatment period.
62318752|NCT02238405|EXPERIMENTAL|Counseling|Intensive anti-smoking counseling
62318753|NCT02238405|NO_INTERVENTION|Standard Care|Control group will receive current standard of care.
62480002|NCT06439836|EXPERIMENTAL|Treatment (CA-4948, pembrolizumab)|Patients receive CA-4948 orally PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, CT, MRI, or PET throughout the study. Additionally, patients may undergo a tumor biopsy on study.
61925329|NCT06240780|NO_INTERVENTION|ACL + MCL Arthroscopic Stand of Care Participants|After the surgery, the patient will be placed in thigh high compression hose, bilaterally, worn 23 hours per day for 31 days.
62128609|NCT03447249|EXPERIMENTAL|VX-659/TEZ/IVA TC|Participants who received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
62128610|NCT05032638|EXPERIMENTAL|Experimental Group|Subjects with motor impairment will work closely with an occupational therapist to identify a goal and select activities that they will work on at home to improve the function of their affected arm.
62128611|NCT02861846|OTHER|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
62128612|NCT01943916|EXPERIMENTAL|Imagio OA/US (US and OA/US)|Imagio OA/US (gray scale and opto-acoustic)
62128613|NCT01943916|EXPERIMENTAL|Imagio gray scale ultrasound|Imagio gray scale ultrasound alone
62128614|NCT06403956|EXPERIMENTAL|video group|The population of the study consisted of 123 students who were first-year students in the Home Patient Care Program. Video group (n=29)
62128615|NCT06403956|EXPERIMENTAL|Paint group|The population of the study consisted of 123 students who were first-year students in the Home Patient Care Program. Paint group (n=29)
62318754|NCT04686734||SARS-CoV-2 positive|
62318755|NCT04686734||SARS-CoV-2 negative|
62318756|NCT04093323|EXPERIMENTAL|Treatment (IFNA2, rintatolimod, celecoxib, alphaDC1 cell based treatment)|Patients receive recombinant interferon alpha-2 IV over 30 minutes, rintatolimod IV over 2.5 hours, and celecoxib PO BID on days 1-3. Beginning cycle 2, patients also receive alpha-type-1 polarized dendritic cells ID on day 1. Treatment repeats every 3 weeks up to 4 cycles in the absence of disease progression or unacceptable toxicity. At 12 weeks, patients with progressive disease may switch to ipilimumab with or without a PD-1/PD-L1 inhibitor and patients with a complete response CR, PR, or stable disease SD may switch to a PD-1/PD-L1 inhibitor or best alternative care.
62318757|NCT02719418||Tinzaparin|Hospitalized patients with chronic renal insufficiency (eGFR ≤ 30 mL/min/1.73 m2) at risk of VTE secondary to non-surgical reasons and receiving thromboprophylactic doses of tinzaparin 3500 or 4500 unit sub-cutaneous once daily.
62318758|NCT05873413|ACTIVE_COMPARATOR|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
62318759|NCT05873413|EXPERIMENTAL|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
62687931|NCT02798003||Non-cachectic COPD patients|Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
61925330|NCT01875003|EXPERIMENTAL|Lebrikizumab High|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms \[mcg\] of fluticasone propionate dry powder inhaler \[DPI\] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
62318760|NCT05873413|PLACEBO_COMPARATOR|Attention-only control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
62318761|NCT02243527|EXPERIMENTAL|Inspiratory Muscle Training|
62318762|NCT02243527|SHAM_COMPARATOR|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
62318763|NCT05065944||Pre-Anesthesia Evaluation: Telemedicine|Pre-Anesthesia evaluation conducted remotely via video conferencing
61925331|NCT01875003|EXPERIMENTAL|Lebrikizumab Low|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
61925332|NCT01875003|PLACEBO_COMPARATOR|Placebo|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
62128616|NCT06403956|NO_INTERVENTION|Control group|The population of the study consisted of 123 students who were first-year students in the Home Patient Care Program. Control group (n=29)
62128617|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
62687932|NCT00050011|EXPERIMENTAL|Zoledronic Acid upfront|Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
62687933|NCT00050011|EXPERIMENTAL|Zoledronate delayed-start|In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
62687934|NCT04525469|EXPERIMENTAL|Narrative Exposure Therapy|NET is a fully-manualized evidence-based treatment for PTSD. Participants will receive 6 weekly 60-minute individual sessions of NET.
62687935|NCT05678127|EXPERIMENTAL|Patients with unilateral ACNES|
62687936|NCT02075697||New drugs|Cohort exposed to biologic therapy, apremilast or fumarates
62687937|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
62128618|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
62128619|NCT00490100|EXPERIMENTAL|Treatment|Treatment
62687938|NCT02118246|EXPERIMENTAL|Dry Needling|The taut band of trigger point in vastus lateralis muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
62687939|NCT02118246|EXPERIMENTAL|Kinesio Tape|Y technique with 25% tension on the tails was applied. Direction of the technique was insertion to origin of the muscle and zone of the trigger point was placed at the center of Y strip.
62687940|NCT02062255|ACTIVE_COMPARATOR|Aspirin|Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day.
62687941|NCT02062255|ACTIVE_COMPARATOR|Omega-3 Free Fatty Acids|Three hundred thirty-six gelatin coated 450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).
62687942|NCT02062255|ACTIVE_COMPARATOR|Aspirin & Omega-3 FFAs|Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily.
62687943|NCT03822715|EXPERIMENTAL|Dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day) + standard of care aromatase inhibitors
62318764|NCT05065944||Pre-Anesthesia Evaluation: In person|Pre-Anesthesia evaluation conducted in person
62480003|NCT06690411|EXPERIMENTAL|Myofascial Release Group|Twenty participants who will be randomized into the myofascial release group will undergo the myofascial release technique by an experienced physiotherapist 3 times a week for 4 weeks.
62687944|NCT06672822|EXPERIMENTAL|Sodium thiosulfate (STS)|Open label, single-arm, receiving 1-5ml of STS (250mg/ml) sodium thiosulfate (STS) injections to calcinosis lesions.
62687945|NCT01156467|ACTIVE_COMPARATOR|Control|Infants randomised to this arm will receive a regular nasogastric tube, and the ventilatory care is given as routinely is done.
62687946|NCT01156467|ACTIVE_COMPARATOR|NAVA|Infants randomised to this arm will receive and Edi-catheter as an oro-/nasogastric tube and the Edi-signal will be monitored and when possible NAVA-ventilation used.
62687947|NCT02344927|ACTIVE_COMPARATOR|Non-Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~* Continuance of oral intake (if appropriate)~* Regular (4 hourly) mouth care~* Standard management of pain and other symptoms in the terminal phase."
62687948|NCT02344927|ACTIVE_COMPARATOR|Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~* Continuance of oral intake (if appropriate)~* Regular (4 hourly) mouth care~* Clinically-assisted hydration~* Standard management of pain and other symptoms in the terminal phase"
62687949|NCT03004183|EXPERIMENTAL|Single arm|"ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.~SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.~Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
62480004|NCT06690411|EXPERIMENTAL|Mulligan SNAG group|Twenty participants who will be randomized into the Mulligan SNAG group will undergo the Mulligan SNAG technique by an experienced physiotherapist 3 times a week for 4 weeks.
62480005|NCT06615752|EXPERIMENTAL|green tea and quercetin|Green tea and quercetin capsules will be administered in combination with docetaxel treatment.
62687950|NCT05792462|EXPERIMENTAL|Baricitinib|Baricitinib will be taken orally with a dose of 2mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
62128620|NCT02390570|EXPERIMENTAL|Implementation Arm|
62128621|NCT00003375|NO_INTERVENTION|Observation|Observation only.
62128622|NCT00003375|EXPERIMENTAL|Radiation therapy|Radiation therapy only.
62128623|NCT00003375|EXPERIMENTAL|Radiation plus PCV chemotherapy|Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy
62128624|NCT02219724|EXPERIMENTAL|MOXR0916: Dose Escalation Stage|Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days.
62318765|NCT03119038|ACTIVE_COMPARATOR|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
62318766|NCT03119038|ACTIVE_COMPARATOR|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
62128625|NCT02219724|EXPERIMENTAL|MOXR0916: Expansion Stage|Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years).
62128626|NCT04277221|EXPERIMENTAL|Standard therapy with ADCTA vaccine (study group)|"- ADCTA vaccine as study treatment~Dose(s): Ten doses, including 2\~4×10\^7 cells for the 1st dose (double doses), and 1\~2×10\^7cells for the 2nd to 10th doses.~Administrative route: The ADCTA vaccine will be injected in axillar or inguinal regions close to lymphnodes subcutaneously at clinic.~Frequency: The primary immunization inoculation is followed by 3 vaccines bi-weekly and then 6 vaccines monthly inoculation, for a total of 10 doses.~- Bevacizumab as standard therapy"
62128627|NCT04277221|ACTIVE_COMPARATOR|Standard therapy (control group)|"* No study treatment~* Bevacizumab as standard therapy"
62318767|NCT04195451|EXPERIMENTAL|Live Video-Supervised Exercise Intervention Arm|Patients randomized to exercise intervention at baseline will participate in live-video-supervised exercise sessions x3/week for 3 months, and then will follow a maintenance regimen for 6 months. During maintenance, patients will continue live-video-supervised exercise sessions, only x1/week, and will be instructed to exercise on their own x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
62318768|NCT04195451|EXPERIMENTAL|Live-Video-Supervised Exercise Control Arm|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the 3-month exercise intervention of live-video-supervised exercise sessions x3/week for 3 months.
62318769|NCT01930734|PLACEBO_COMPARATOR|Normal Saline|"Normal Saline Placebo infusion containing Normal Saline NaCl 0.9% twice a week for a total duration of 6 months.~Placebo will be given at the same rate as the Dobutamine infusion, under the same measures."
62318770|NCT01930734|EXPERIMENTAL|Dobutamine|Twice weekly, IV Dobutamine infusion up to 5mcg/Kg/min infusion, for the duration of 6 months. Medication will be administered under medical supervision and continues ECG and vital sign monitoring. Routine electrolyte and renal function testing will be performed and electrolytes corrected as indicated.
62318771|NCT02829346|EXPERIMENTAL|Peri-articular group|Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.
62318772|NCT02829346|ACTIVE_COMPARATOR|Intravenous group|Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.
62318773|NCT06300970|ACTIVE_COMPARATOR|Artesunate+Amodiaquine (ASAQ)|"Amodiaquine-artesunate (ASAQ) dose based on weight, given once daily for three days.~ASAQ has three formulations, with the dose depending on the weight of the child according to the following.~4.5-8.9 kg = 1 tablet 25 mg AS/67.5 mg AQ 9-17.9kg = 1 tablet 50 mg AS/135 mg AQ 18.0-35.9kg = 1 tablet 100 mg AS/270 mg AQ~≥36.0kg = 2 tablets 100 mg AS/270 mg AQ"
62128628|NCT01711905|EXPERIMENTAL|Vitamin D3|cholecalciferol 20 µg per day for 12 weeks
62128629|NCT01711905|NO_INTERVENTION|Placebo|Placebo for 12 weeks
62128630|NCT02962817|EXPERIMENTAL|Educational intervention through a web platform|"This group will have access to our web platform where they will find information related to nonspecific chronic low back pain. This information will be presented through dynamic explanatory 3D videos made by the author.~The aim of this intervention is to change and modify wrong beliefs and attitudes about chronic low back pain of physicians and nurses working in primary care settings, using a web-based educational tool with the additional result of increasing knowledge on pain neurophysiology and reducing fear-avoidance beliefs."
62128631|NCT02962817|ACTIVE_COMPARATOR|Clinical practice guidelines on low back pain|Control group: They will have access to a video where medical staff and primary care nurses explain the content of the clinical practice guideline for addressing back pain.
62128632|NCT00244959|EXPERIMENTAL|Anastrozole|Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer
62128633|NCT00718848||1|These are patients treated with conventional hemodialysis (4 hours/session, 3 sessions/week) who convert to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week).
62128634|NCT00718848||2|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elect to remain on this dialysis schedule and agree to the study-related investigations at baseline and one year thereafter.
62480006|NCT06615752|PLACEBO_COMPARATOR|placebo|Placebo capsules will be administered in combination with docetaxel treatment as comparison.
62480007|NCT06067438|EXPERIMENTAL|Arm I (amiodarone hydrochloride)|Patients receive amiodarone hydrochloride IV for 4 days and then via a feeding tube for 3 days on study.
62480008|NCT06067438|PLACEBO_COMPARATOR|Arm II (normal saline)|Patients receive normal saline IV for 4 days on study.
62480009|NCT00835575|EXPERIMENTAL|1|
62480010|NCT00835575|ACTIVE_COMPARATOR|2|
61925333|NCT03859206|EXPERIMENTAL|empyema patients having medical thoracoscopy|"patients having empyema will undergo medical thoracoscopy as follow :~With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.~the intervention : is breaking the septation within the loculated empyema"
62128635|NCT01678872|OTHER|Long Term Follow up|Long Term follow up of patients who received RetinoStat in a previous study.
62318774|NCT06300970|ACTIVE_COMPARATOR|Artemether+Lumefantrine (AL)|"Artemether+Lumefantrine (AL) dose is based on weight and given twice daily for three days. AL has one formulation, with pills containing 20 mg artemether and 120 mg lumefantrine. The number of tablets per dose depends on the weight of the child according to the following:~5 -14.9 kg = 1 tablet per dose 15 -24.9 kg = 2 tablets per dose 25 -34.9 kg = 3 tablets per dose~≥35 kg = 4 tablets per dose~1 tablet contains 20 mg artemether and 120 mg lumefantrine"
62480011|NCT06308861|EXPERIMENTAL|Single administration Amg dose Group|
62480012|NCT06308861|EXPERIMENTAL|Single administration Bmg dose Group|
62480013|NCT06308861|EXPERIMENTAL|Single administration Cmg dose Group|
62480014|NCT06308861|EXPERIMENTAL|Single administration Dmg dose Group|
62480015|NCT06308861|EXPERIMENTAL|Single administration Emg dose Group|
62318775|NCT03142997||group S|anesthetized children on spontaneous ventilation.
62480016|NCT06308861|PLACEBO_COMPARATOR|Single administration Amg dose Group-Placebo|
62480017|NCT06308861|PLACEBO_COMPARATOR|Single administration Bmg dose Group-Placebo|
62480018|NCT06308861|PLACEBO_COMPARATOR|Single administration Cmg dose Group-Placebo|
62480019|NCT06308861|PLACEBO_COMPARATOR|Single administration Dmg dose Group-Placebo|
61925334|NCT03859206|NO_INTERVENTION|tube thoracostomy in patients with empyema|after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.
61925335|NCT04867031|EXPERIMENTAL|White fish (cod)|Participants will consume 1 portion (\~130g) of white fish (Bird's Eye Inspirations Cod Fillets with Tomato \& Rosemary), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
62128636|NCT04356820|EXPERIMENTAL|acupressure|
62128637|NCT04356820|EXPERIMENTAL|music|
62128638|NCT04356820|NO_INTERVENTION|control|
62128639|NCT05872724|EXPERIMENTAL|Arm A|Eligible subjects were assigned to high-risk or medium-risk groups based on Peter's criteria and Sedlis criteria. Patients with a high-risk classification or MRDc0 (+) status received a treatment consisting of conventional pelvic concurrent chemoradiotherapy, adjuvant chemotherapy, four courses of immunotherapy, continued immunotherapy with MRDIn(+), and follow-up monitoring with MRDIn(-)
62128640|NCT05872724|EXPERIMENTAL|Arm B|Patients deemed intermediate risk and with MRDc0 (-) status received concurrent chemoradiotherapy in the small pelvic target volume, four courses of immunotherapy, continued immunotherapy with MRDIn(+), and follow-up monitoring with MRDIn(-)
62128641|NCT04382404|EXPERIMENTAL|Sofosbuvir-Velpatasvir|Sofosbuvir-Velpatasvir
62128642|NCT04421469|EXPERIMENTAL|Comprehensive treatment|Patients with multiple metastatic NPC were given Triprilimab(JS001) and chemotherapy combined with local treatment.
62318776|NCT03142997||group C|anesthetized children on controlled ventilation.
62318777|NCT04961801|EXPERIMENTAL|Acalabrutinib in combination with tacrolimus and methotrexate|"1. Phase I: To determine the maximum tolerated dose (MTD) of Acalabrutinib in combination with tacrolimus and methotrexate for Phase II.~2. Phase II: To determine if acalabrutinib in combination with tacrolimus and methotrexate is safe and effective in reducing acute GVHD rate."
62480020|NCT06308861|PLACEBO_COMPARATOR|Single administration Emg dose Group-Placebo|
62480021|NCT06308861|EXPERIMENTAL|Multiple administration Amg dose group|
62480022|NCT06308861|EXPERIMENTAL|Multiple administration Bmg dose group|
62480023|NCT06308861|EXPERIMENTAL|Multiple administration Cmg dose group|
62480024|NCT06308861|EXPERIMENTAL|Multiple administration Dmg dose group|
62480025|NCT06308861|EXPERIMENTAL|Multiple administration Emg dose group|
62480026|NCT06308861|PLACEBO_COMPARATOR|Multiple administration Amg dose group - Placebo|
62480027|NCT06308861|PLACEBO_COMPARATOR|Multiple administration Bmg dose group - Placebo|
62480028|NCT06308861|PLACEBO_COMPARATOR|Multiple administration Cmg dose group - Placebo|
62480029|NCT06308861|PLACEBO_COMPARATOR|Multiple administration Dmg dose group - Placebo|
62480030|NCT06308861|PLACEBO_COMPARATOR|Multiple administration Emg dose group - Placebo|
61925336|NCT04867031|EXPERIMENTAL|Semi-skimmed milk|Participants will consume 1 portion (\~450mL) of milk (Tesco UHT Semi-Skimmed), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
61925337|NCT04867031|EXPERIMENTAL|Dried seaweed sheets|Participants will consume 1 portion (\~6g) of dried seaweed sheets (Itsu Crispy Seaweed Thins), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
61925338|NCT01616511||Pathway CH-1 Subjects|
61925339|NCT02775201|ACTIVE_COMPARATOR|Plantaris release under ultrasound guidance|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris released under ultrasound guidance by a consultant radiologist
61925340|NCT02775201|ACTIVE_COMPARATOR|Plantaris excision surgically|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris excised in surgery by a consultant orthopaedic surgeon
61925341|NCT01063712|OTHER|Nit-Occlud PDA-R|Interventional, prospective clinical study, non randomized.
61925342|NCT03915522|EXPERIMENTAL|Adductor Canal Block|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a single adductor canal block wiht 20cc of 0.5% Ropivacaine using ultrasound guidance .
61925343|NCT03915522|PLACEBO_COMPARATOR|Placebo Comparator|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a sham adductor canal block with 2ml of 1% subcutaneous lidocaine at the level of the adductor canal using ultrasound guidance.
61925344|NCT05333081|OTHER|Evaluation of the glycemic index|
62128643|NCT04525651|EXPERIMENTAL|Digital Acupuncture Instrument Group|The needles will be stimulated manually to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness) and then paired electrodes from the digital acupuncture instrument will be attached to the needle handles and another two adjunct acupoints by the research assistant. The electric current will be increased until the needles begin to vibrate slightly.
62318778|NCT04027465|NO_INTERVENTION|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
62318779|NCT04027465|EXPERIMENTAL|Treatment|Following randomization, participants in this group will receive escalating doses of egg protein, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
62318780|NCT05316077||Vectorio® kit|
61925345|NCT02547714|EXPERIMENTAL|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
61925346|NCT04601337||Brachial plexus and/or nerve transfer surgery patients|Patients set to undergo brachial plexus reconstruction or nerve transfer surgery that are 18 years or older.
62318781|NCT05159232|ACTIVE_COMPARATOR|laparoscopic trans abdominal preperitoneal repair|length of hospital stay
62318782|NCT05159232|ACTIVE_COMPARATOR|open mesh repair of inguinal hernia|length of hospital stay
62318783|NCT00992446|EXPERIMENTAL|Treatment (chemotherapy, ASCT, bortezomib, vorinostat))|All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
62318784|NCT03335631|EXPERIMENTAL|Group-supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
62318785|NCT03335631|EXPERIMENTAL|Home-based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
62318786|NCT03010423|EXPERIMENTAL|Nicorandil|
62318787|NCT02950662|ACTIVE_COMPARATOR|Metal housing|metal housing of ball and socket attachment the intervention will be overdenture
61925347|NCT01852357|SHAM_COMPARATOR|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
61925348|NCT01852357|EXPERIMENTAL|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
61925349|NCT04528771|EXPERIMENTAL|SNO|12 patients in the S-nitrosylation arm will receive SNO (six-hour treatment with a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr).
62128644|NCT04525651|ACTIVE_COMPARATOR|Manual Acupuncture Group|Patients in the MA group will undergo similar procedures as the EA group except that no current will be output from the instrument.
62128645|NCT04525651|SHAM_COMPARATOR|Sham Acupuncture Group|Patients in the SA group will receive non-invasive acupuncture to avoid de qi.
62128646|NCT04046536|ACTIVE_COMPARATOR|Active rTMS at the LDLPFC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left dorsolateral prefrontal cortex (LDLPFC).
62318788|NCT02950662|ACTIVE_COMPARATOR|Peek housing|Peek housing of ball and socket attachment the intervention will be overdenture
62318789|NCT06664450||Patients with severe OSA treated with CPAP for at least 3 months.|The group consists of patients diagnosed with severe Obstructive Sleep Apnea (OSA) who have been treated with Continuous Positive Airway Pressure (CPAP) therapy for a minimum of 3 months.
62318790|NCT06664450||Patients with severe OSA in new access and therefore not yet subjected to CPAP treatment.|"This group comprises patients recently diagnosed with severe Obstructive Sleep Apnea (OSA) who have not yet started treatment with Continuous Positive Airway Pressure (CPAP). This cohort will be compared to a group of patients who have been undergoing CPAP therapy for at least 3 months. The primary objective is to assess the presence and severity of cognitive symptoms, commonly referred to as Brain Fog, which includes impairments in memory, attention, and concentration. Participants in this group will complete a one-time assessment, which will involve various scales to evaluate cognitive function, sleep quality, daytime sleepiness, and fatigue levels. This study aims to provide insights into the cognitive impacts of untreated severe OSA, thereby highlighting the potential benefits of initiating CPAP therapy."
62480031|NCT05450107|EXPERIMENTAL|Intervention|The intervention group is offered surgical treatment of the shaft fracture of the fifth metatarsal bone with ORIF. Depending on the type of shaft fracture this will be either lag screw fixation or plate fixation. After surgery a period of cast immobilisation with gradual increase of weight bearing will commence
62480032|NCT05450107|ACTIVE_COMPARATOR|Control|The control group (conservative treatment), will receive a period of cast immobilisation, with a gradual increase in weight bearing by protocol.
62318791|NCT00740025||QD|Women who received their meds as QD administration
62480033|NCT01791686|EXPERIMENTAL|Dense Deposit Disease|"► Induction Period~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.~► Maintenance Period~The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks."
62480034|NCT06376331|EXPERIMENTAL|Washed microbiota transplantation|WMT
62318792|NCT00740025||BID|Women who received their gonadotropins as a BID dose
62318793|NCT05911009|EXPERIMENTAL|1350mg BC 007 solution for infusion for 75-minutes intravenous infusion|
62128647|NCT04046536|SHAM_COMPARATOR|Sham rTMS at the LDLPFC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LDLPFC.
62128648|NCT04046536|ACTIVE_COMPARATOR|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
62128649|NCT04046536|SHAM_COMPARATOR|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
62318794|NCT05911009|PLACEBO_COMPARATOR|0.9% NaCl solution for infusion for 75-minutes intravenous infusion|
62318795|NCT05911009|EXPERIMENTAL|1900mg BC 007 solution for infusion for 105-minutes intravenous infusion|
62318796|NCT05911009|PLACEBO_COMPARATOR|0.9% NaCl solution for infusion for 105-minutes intravenous infusion|
62318797|NCT00436215|EXPERIMENTAL|BAY 43-9006 + Bevacizumab|BAY 43-9006 (sorafenib) + Bevacizumab
62128650|NCT02190097|EXPERIMENTAL|paleolithic diet|subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
62128651|NCT02190097|ACTIVE_COMPARATOR|American Diabetes Association diet|subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
62687951|NCT03885206|EXPERIMENTAL|Hospital|Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
62318798|NCT00085540|EXPERIMENTAL|Phase 1 Dose Escalation - Romidepsin|"Patients receive FR901228 (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation two dose levels:~Romidepsin (depsipeptide): 13.3mg/m2 and 17.7mg/m2~Pharmacokinetics"
62318799|NCT00085540|EXPERIMENTAL|Phase 2 Dose from Phase 1 - Romidepsin|"Patients receive FR901228 (romidepsin) as in phase I at dose level 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity~Romidepsin (depsipeptide): 13.3mg/m2"
62318800|NCT02480075||Chronic pain|Observational ; Adult patients seeking medical treatment that have been diagnosed with chronic pain.
62318801|NCT05979090|EXPERIMENTAL|Mastery Learning Group|
62318802|NCT05979090|NO_INTERVENTION|Standard of Care Group|
62318803|NCT05762744|OTHER|Homozygous for major alleles of GCGR and GIPR|"Based on data in a genotype database, these individuals were homozygous for the wild type major alleles of both GCGR and GIPR."
62480035|NCT06119464|NO_INTERVENTION|Unexposed to intervention (control period)|This is the time period of the study where hospital clusters are not receiving the intervention
62318804|NCT05762744|OTHER|Homozygous for missense variant in GIPR|Based on data in a genotype database, these individuals were homozygous for rs1800437 a missense variant (p.E354Q) in the GIP receptor gene (GIPR).
62318805|NCT05762744|OTHER|Homozygous for missense variant in GCGR|Based on data in a genotype database, these individuals were homozygous for rs1801483a missense variant (p.G40S) in the glucagon receptor gene (GCGR).
62318806|NCT03677089|EXPERIMENTAL|ECHO Cohort|Sites undergo 12 ECHO Autism telehealth clinics. Clusters of two sites each will initiate intervention with 3 months between the start of each cluster.
62480036|NCT06119464|EXPERIMENTAL|Exposed to intervention (intervention period)|This is the time period of the study where hospital clusters are receiving the multimodal intervention.
62687952|NCT03885206|NO_INTERVENTION|Municipal acute ward|Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
61925350|NCT04528771|PLACEBO_COMPARATOR|Placebo|12 patients in the placebo arm will receive nitrogen gas (six-hour treatment).
61925351|NCT03247478||invasive breast cancer|Patients with invasive breast cancer who underwent computed tomography (CT) reconstruction of axillary lymph node for assessment of lymph node response after NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis.
61925352|NCT01600508|ACTIVE_COMPARATOR|Traditional stoma care|Being discharged from a hospital with a stoma is a challenge to the patient's quality of life in many aspects. Optimal stoma function and care is essential to keep quality of life best possible. Videoconference can be a useful tool to help patients cope with stoma problems without travelling long distances to a surgical outpatient clinic.
61925353|NCT01600508|EXPERIMENTAL|Videoconference Stoma Consultations|Videoconference Stoma Consultations
61925354|NCT03051646|EXPERIMENTAL|Acetylsalicylic acid first, placebo second|Participant is administered acetylsalicylic acid one hour prior to exercise.
61925355|NCT03051646|PLACEBO_COMPARATOR|Placebo oral capsule first, ASA second|Participant is administered placebo one hour prior to exercise.
61925356|NCT05473182|OTHER|Single arm: All participants receive the intervention|All participants receive power wheelchair skills training using the IndieTrainer system.
61925357|NCT04927000|NO_INTERVENTION|control group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)\].~All subjects were treated with Glucocorticoid (10-15mg)/Days)."
61925358|NCT04927000|EXPERIMENTAL|Tofacitinib treatment group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)\].~All subjects were treated with Glucocorticoid (10-15mg)/Days). All subjects were treated with Tofacitinib 5mg/BID."
62128652|NCT02554786|EXPERIMENTAL|QMF149 150/160 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered once daily (o.d) via Concept1 inhaler in the evening.
62318807|NCT02654106|EXPERIMENTAL|Refractory Brain Metastases|Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases
62318808|NCT02354170|EXPERIMENTAL|Cohort 1 (m300)|One (1) 300-mg mifepristone tablet, taken once daily for 4 weeks
61925359|NCT00898378||Colorectal Cancer Patients|Patients with stages I/II, III and IV colorectal cancer
61925360|NCT00898378||Colorectal Polyps Patients|Patients with adenomatous polyp(s) after colonoscopy.
61925361|NCT00898378||Healthy Controls|No abnormalities after colonoscopy.
61925362|NCT02914847|EXPERIMENTAL|Immediate Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery training (FIT) immediately.
61925363|NCT02914847|NO_INTERVENTION|Delayed Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery Training (FIT) after a 3 month delay.
61925364|NCT00286611||Amifostine|Those individuals enrolled who have received amifostine as part of standard care.
61925365|NCT04026581||Assessment|A comprehensive AAC assessment collecting clinical and personal data required to select a speech-generating device (SGD) is conducted along with a trial of three AAC technology solutions, followed by a trial for BCI access to an AAC system.
61925366|NCT04026581||Training and Treatment|AAC training and treatment services will be provided and communication performance outcomes monitored over the course of studying clinical treatment services. At monthly home visits the SLP gathers clinical and personal data on communication performance outcomes and user satisfaction of their AAC system and any alternative access methods.
61925367|NCT05803980|EXPERIMENTAL|FMT from healthy donor|Subjects receiving a single infusion FMT via colonoscopy from healthy donor
61925368|NCT05803980|PLACEBO_COMPARATOR|Autologous FMT|Subjects receiving a single infusion autologous FMT via colonoscopy
62128653|NCT02554786|EXPERIMENTAL|QMF149 150/320 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening.
62318809|NCT02354170|EXPERIMENTAL|Cohort 2 (m900)|Three (3) 300-mg mifepristone tablets (900-mg dose), taken once daily for 4 weeks
62318810|NCT02354170|PLACEBO_COMPARATOR|Cohort 3 (Placebo)|Placebo taken once daily for 4 weeks
62318811|NCT04892862|ACTIVE_COMPARATOR|dorsal surgical approach|dorsal surgical approach
62128654|NCT02554786|ACTIVE_COMPARATOR|MF 400 µg|Mometasone furoate (MF) 400 μg was delivered o.d via Twisthaler® in the evening
62128655|NCT02554786|ACTIVE_COMPARATOR|Salmeterol /fluticasone 50/500 μg|Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.
62128656|NCT02554786|ACTIVE_COMPARATOR|MF 800 μg|MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.
62128657|NCT04370314|EXPERIMENTAL|Zirconia implant-supported crown|Full zirconia implant-supported crown
62318812|NCT04892862|ACTIVE_COMPARATOR|volar surgical approach|volar surgical approach
62318813|NCT00231985|PLACEBO_COMPARATOR|1|Participants will receive supportive psychotherapy.
62318814|NCT00231985|ACTIVE_COMPARATOR|2|Participants will receive habit reversal therapy.
62318815|NCT03381092||invasive breast cancer|Patients with invasive breast cancer who have clinically negative axilla and receive neoadjuvant treatment followed by sentinel lymph node biopsy are eligible for this study.
62480037|NCT05640765|ACTIVE_COMPARATOR|Arm 1: (Standard of care + Educational material)|CGs receive the standard of care services assigned by the care team for their patient. Participants also receive additional educational and supportive material for health and wellness.
62687953|NCT06570057|EXPERIMENTAL|Intervention Group|Community mobilization will be done via male and female community groups using a PLA Cycle whereby groups themselves identify and priorities problems associated with diabetes and the risk of developing diabetes. Next this study will plan strategies to address the problems identified in the community, put these strategies into practice and, finally, evaluate the effectiveness of these strategies. Lay facilitators will convene the groups monthly over a period of 18 months, with one meeting per month.
62687954|NCT06570057|NO_INTERVENTION|Control Group|The Control Group will not receive the PLA (Participatory Learning and Action) intervention. However, they will still benefit from the study in several ways. Information about the trial and guidance on who to contact in case of hyperglycemia or intermediate hyperglycemia will be provided. The disease burden in the control area will be monitored, and findings will be included in national and international advocacy and dissemination efforts
62318816|NCT05257577||Study group|Breast conserving surgery
62687955|NCT01254539|EXPERIMENTAL|Autologous bone marrow stem cells intraspinal transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
62687956|NCT01254539|EXPERIMENTAL|Intrathecal infusion of autologous bone marrow stem cells|Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
62687957|NCT01254539|PLACEBO_COMPARATOR|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
62687958|NCT06639815||Group 1|with molar incisor hypomineralization
62687959|NCT06639815||Group 2|without molar incisor hypomineralization
62687960|NCT06413069|ACTIVE_COMPARATOR|Almond treatment|Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks.
62687961|NCT06413069|NO_INTERVENTION|Control condition|Patients of the no-nut group will receive 6,7 kgs of almonds after completing 16 weeks of waiting time, supporting their compliance as untreated group.
62687962|NCT06671899||CIMT in a clinical setting|Those who underwent modified constraint-induced movement therapy in a clinical setting in Sweden during the years 2000-2018.
62687963|NCT06671210||Self-comparison|
62687964|NCT00698165||Patients|1200 adults with mild to severe Alzheimer's disease
62687965|NCT00698165||Caregivers|1200 informal caregivers
62687966|NCT02006615|EXPERIMENTAL|High frequency rTMS plus fNIRS|rTMS with neuroimage assessment of functional near infrared spectroscopy
62687967|NCT02006615|SHAM_COMPARATOR|Sham rTMS|Sham stimulation
62687968|NCT02006615|EXPERIMENTAL|High frequency rTMS|High frequency rTMS to modulate brain areas
62687969|NCT02682251|EXPERIMENTAL|Heart Failure Patients with CRT-CIED|PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)
62687970|NCT04961580||Ceftazidime avitbatan sodiumt group|Children treated with ceftazidime avitbatan sodium in the pediatric intensive care unit will be enrolled in this group. Blood sample will be retained at various time intervals for pharmacokinetics.
62687971|NCT02886364|OTHER|Women delivered at AAC Hospital|The intervention is only being implemented at the Ángel Albino Corzo Hospital due to limited funding. The site was selected by the Ministry of Health in Chiapas as a hospital that would benefit from improved quality of care around childbirth. There are no other arms in this study.
62687972|NCT02416479|EXPERIMENTAL|SystemCHANGE|SystemCHANGE supports patient-designed, interventionist-guided, small experiments to: 1) assess individual systems (including important others who shape medication taking) and the system's impact on medication taking and propose individual system solutions to improve MA, 2) implement the proposed individual systems' solutions to improve MA, 3) track MA data, and 4) evaluate MA data.
62687973|NCT02416479|ACTIVE_COMPARATOR|Patient-education attention-control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
62687974|NCT05791630|NO_INTERVENTION|WHO partograph|all study sites use the WHO partograph as standard care in the first step of the trial
62318817|NCT03626753|ACTIVE_COMPARATOR|Oral Group|"received in post operative period oral analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
62318818|NCT03626753|ACTIVE_COMPARATOR|Intravenous group|"received in post operative period intravenous analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
62318819|NCT00876980|ACTIVE_COMPARATOR|1|nasal Continuous Positive Airway Pressure treatment for 3 months
62318820|NCT00876980|NO_INTERVENTION|2|controls have no treatment, being observed for 3 months
62318821|NCT01941368|NO_INTERVENTION|Control|Individuals assigned to Control Group will undergo baseline testing and then be asked to continue their normal exercise routine for 4 weeks and will undergo post-testing (visits 16 and 17) after this time period.
62318822|NCT01941368|PLACEBO_COMPARATOR|Placebo + High-Intesnity Interval Training (HIIT)|On training days, individuals will consume 1 gram of placebo 30 min prior to training, 1gram placebo 1 hour post training, and 1gram placebo 3 hours post training. On non-training days, individuals will consume placebo 3 times per day (8am, 12pm and 4pm).
62687975|NCT05791630|EXPERIMENTAL|WHO labour care guide|All study sites will cross over to the intervention according to randomization and use the LCG for assessing labour progression and wellbeing in labour
62687976|NCT01716637|ACTIVE_COMPARATOR|Etanercept|25 mg administered weekly for 6 weeks
61925369|NCT03364907||HIPEC patients|Patients with a diagnosis of peritoneal carcinomatosis who undergo HIPEC treatment with oxaliplatin.
62318823|NCT01941368|ACTIVE_COMPARATOR|HMB-FA + HIIT|On training days, individuals will consume 1 gram HMB-FA 30 min prior to training, 1gram HMB-FA 1 hour post training, and 1gram HMB-FA 3 hours post training. On non-training days, individuals will consume HMB-FA 3 times per day (8am, 12pm and 4pm).
62480038|NCT05640765|EXPERIMENTAL|Arm 2: (Standard of care + BeWell360-CG)|CGs receive the standard of care services assigned by the care team for their patient and participate in the BeWell360-CG coaching sessions on study.
62480039|NCT06136546|EXPERIMENTAL|Infliximab|Participants in this arm will receive 5 mg/kg of infliximab via an in-dwelling catheter.
62480040|NCT06136546|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive saline as placebo via an in-dwelling catheter.
62687977|NCT01716637|ACTIVE_COMPARATOR|Nutritional Supplements|Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
62687978|NCT04921306|EXPERIMENTAL|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 28 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
62687979|NCT04921306|PLACEBO_COMPARATOR|Placebo|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 28 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
62687980|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
62687981|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
62687982|NCT05882565|EXPERIMENTAL|Mindfuness training group|This is a group that will receive mindfulness intervention for 14 days. Participants in this group will also be asked baseline, daily and post questions, as well as follow up questions (3 months after the intervention). During the intervention, they can fill out an optional daily journal.
62687983|NCT05882565|ACTIVE_COMPARATOR|Psychoeducation group|This is a group that will receive psychoeducation intervention for 14 days. Participants in this group will also be asked baseline, daily and post questions, as well as follow up questions (3months after the intervention). During the intervention, they can fill out an optional daily journal.
62687984|NCT05882565|NO_INTERVENTION|Waitlist control group|This is a group that will not receive any training, however, this group will be asked several questions (baseline, daily and post questions, as well as follow up questions (3-months later)). They can also fill out an optional daily journal.
62687985|NCT02542371||HIV infected with known subclinical atherosclerosis|
62687986|NCT02542371||HIV infected without known subclinical atherosclerosis|
62687987|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
62687988|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
62687989|NCT06673927|EXPERIMENTAL|YZJ-1139 Single-dose Group|Subjects will be randomized into two groups： the experimental group will receive YZJ-1139; the control group will receive placebo.
62687990|NCT06673927|EXPERIMENTAL|YZJ-1139 multiple-dose Group|Subjects will be randomized into two groups；the experimental group will receive YZJ-1139; the control group will receive placebo once a day, 7 days.
62687991|NCT01723839|OTHER|FCR with Lenalidomide|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity. If there are at least 5 CRs after 4 cycles of FCR plus lenalidomide the study will accrue an additional 35 subjects.
62687992|NCT01065805|EXPERIMENTAL|1|18F-FLT PET
62687993|NCT06691828|EXPERIMENTAL|Active Treatment Arm IV and Oral|This single Arm will include a single dose by IV and a single dose given by mouth for all 8 subjects.
62687994|NCT02458027|EXPERIMENTAL|20g Hemp Protein Shake|Hemp protein shake, 20 grams, given once at beginning of acute trial.
62687995|NCT02458027|EXPERIMENTAL|40 g Hemp Protein|Hemp protein shake, 40 grams, given once, at beginning of acute trial.
62687996|NCT02458027|ACTIVE_COMPARATOR|20 g Soybean Protein Shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial.
62687997|NCT02458027|EXPERIMENTAL|40 g Soybean Protein|Soybean protein shake, 40 grams, given once, at beginning of acute trial.
62687998|NCT02458027|PLACEBO_COMPARATOR|Control Shake|Non-protein control shake, given once, at beginning of acute trial.
62687999|NCT02615275|EXPERIMENTAL|Supportive Care (bioelectrical impedance analysis, RT)|Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.
61925370|NCT04107259||Patient with diabetes|60 newly diagnosed type 2 diabetes
62688000|NCT04204902|EXPERIMENTAL|Test Treatment then Reference Treatment|Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in treatment period 1 followed by a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in treatment period 2. The treatment periods were separated by 21 day washout period.
62318824|NCT04884620||Cross-sectional cohort|Healthy children and adolescents from twenty-five selected schools in the metropolitan area
61925371|NCT04107259||Control|60 non-diabetic control subjects
61925372|NCT03823378|EXPERIMENTAL|ABBV-599 in M16-063/ABBV-599 in M16-763|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
61925373|NCT03823378|EXPERIMENTAL|ABBV-105 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
61925374|NCT03823378|EXPERIMENTAL|ABBV-105 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
61925375|NCT03823378|EXPERIMENTAL|ABBV-105 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
61925376|NCT03823378|EXPERIMENTAL|UPA 15 mg/ABBV-105 placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
61925377|NCT03823378|EXPERIMENTAL|Placebo in M16-063/ABBV-599 in M16-763|Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
61925378|NCT03679585|EXPERIMENTAL|Supportive Care (social media intervention)|Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
61925379|NCT00315354|EXPERIMENTAL|1|Low glycemic index diet
61925380|NCT00315354|ACTIVE_COMPARATOR|2|Low fat diet
61925381|NCT00315354|ACTIVE_COMPARATOR|3|Very low carbohydrate diet
62128658|NCT06322797|EXPERIMENTAL|rTMS over the M1 cortex of the injured hemisphere localized by motor action potential|Experimental A group : rTMS was administered by trained physicians over the M1 cortex of the injured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb.
62128659|NCT06322797|EXPERIMENTAL|rTMS over the specific site of the injured hemisphere localized by fMRI|Experimental B group : rTMS was administered by trained physicians over the specific site which is after checking the brain site activated during finger tapping during fMRI imaging, target coordinates are set based on the 10-20 EEG system coordinate system in the taken MRI image.
61925382|NCT00851760|EXPERIMENTAL|1 Combined Surgery|
61925383|NCT00851760|ACTIVE_COMPARATOR|2 consecutive surgery|
61925384|NCT04300374||Sevoflurane only|inhalation of sevoflurane during general anesthesia
61925385|NCT04300374||Remifentanil and Sevoflurane|remifentanil infusion and inhalation of sevoflurane during general anesthesia
61925386|NCT00894127|EXPERIMENTAL|CyPath Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from two cohorts, including (1) high-risk control group comprised of individuals not diagnosed but at high risk for lung cancer (n=102) and, (2) cancer group comprised of individuals with confirmed lung cancer diagnosis (n=26), was labeled in exact manner with TCPP and evaluated to detect red fluorescent \[ie, cancer\] cells (RFCs) from deep-lung sputum samples.
61925387|NCT05929755|PLACEBO_COMPARATOR|Control group (standard care)|1 cc gel foam powder mixed with thrombin
62128660|NCT06322797|SHAM_COMPARATOR|Sham group|Sham group: shame rTMS( sound mode) is applied over the M1 cortex of the injured hemisphere which is the site that caused the largest visible twitch in the participant's thumb when stimulation is applied
62128661|NCT03041584|EXPERIMENTAL|Materialise Universal®/ mucosa (Mat Mu)|
61925388|NCT05929755|EXPERIMENTAL|Test group (standard care + study intervention)|1 cc of gel foam powder mixed with thrombin and 80mg Depo-Medrol
61925389|NCT04224883|ACTIVE_COMPARATOR|24-hours group|"The critical patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
61925390|NCT04224883|EXPERIMENTAL|16-hours group|"The critical patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
61925391|NCT04224883|EXPERIMENTAL|intermittent group|The critical patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60min or 120min through stomach tube.Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days
61925392|NCT04171427|OTHER|Lithium liposome and placebo A|• Group A : 4 patients; Lithium liposome 1 application / day (evening) on target lesions on one side of the body, placebo 1 application / day (evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
61925393|NCT04171427|OTHER|Lithium liposome and placebo B|Group B : 4 patients; Liposomal Lithium 2 applications / day (morning and evening) on target lesions on one side of the body, placebo 2 applications / day (morning and evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
61925394|NCT04171427|OTHER|Lithium liposome and placebo C|Groupe C : 4 patients; Lithium liposome 2 applications / day (morning and evening) on one side, placebo 2 applications / day (morning and evening) on contralateral target lesions.
61925395|NCT04840576|PLACEBO_COMPARATOR|Conventional Dressing|waterproof sterile dressing OPSITE Post-Op Visible, Smith \& Nephew, UK
61925396|NCT04840576|EXPERIMENTAL|Prophylactic negative wound pressure dressing|PICO-7, Smith \& Nephew, UK
62128662|NCT03041584|EXPERIMENTAL|Materialise Universal®/ bone (Mat Bo)|
62128663|NCT03041584|EXPERIMENTAL|FacilitateTM/ mucosa (Fac Mu)|
62128664|NCT03041584|EXPERIMENTAL|FacilitateTM/ bone (Fac Bo)|
62128665|NCT03041584|ACTIVE_COMPARATOR|mental navigation (Mental)|
62128666|NCT03041584|ACTIVE_COMPARATOR|pilot-drill template (Templ)|
62128667|NCT00151424|EXPERIMENTAL|1|asenapine 5-10mg BID
62128668|NCT00151424|PLACEBO_COMPARATOR|2|Placebo
62128669|NCT00151424|ACTIVE_COMPARATOR|3|olanzapine 10-20 mg QD
62128670|NCT01007396|OTHER|new healthcare workers|doctors and nurses who were newly hired in 2008 at the Samsung Medical Center
62688001|NCT04204902|EXPERIMENTAL|Reference Treatment then Test Treatment|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in treatment period 1 followed by a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in treatment period 2. The treatment periods were separated by 21 day washout period.
62688002|NCT01509404|ACTIVE_COMPARATOR|Valcyte|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
62688003|NCT01509404|ACTIVE_COMPARATOR|Valcyte then Cytogam|valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
62688004|NCT04317742|ACTIVE_COMPARATOR|Sleep Healthy Using the Internet (SHUTi) Intervention Group|Participants will receive a direct link to access the SHUTi program (per randomization) from the study team.
62688005|NCT04317742|ACTIVE_COMPARATOR|Online Patient Education (PE) Control Group|Participants will receive a direct link to access online patient education (per randomization) from the study team.
62688006|NCT06672133|EXPERIMENTAL|Arm Combined Radiotherapy|"After randomization，patients receive adebrelimab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy QD on days 1-5 during weeks 1-5 only.~Patients undergo CT, MRI or PET/CT scan,throughout the trial. Patients also undergo blood and tissue collection throughout the trial."
62688007|NCT06672133|ACTIVE_COMPARATOR|Arm Non-radiotherapy|"After randomization，patients receive adebrelimab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients undergo CT, MRI or PET/CT scan,throughout the trial. Patients also undergo blood and tissue collection throughout the trial."
62688008|NCT06536855|EXPERIMENTAL|Gardasil 9 Arm|The study is open label with only one arm that will receive the vaccine
62688009|NCT04505787|EXPERIMENTAL|Esflurbiprofen hydrogel patch|"Esflurbiprofen hydrogel patch 165 mg (EFHP) (Teikoku Seiyaku Co.), transdermal patch containing 165 mg S-flurbiprofen, once daily consecutive application over 14 days; each patch to be applied for 24 h, application site: outer ankle (same site and position for all applied patches)"
62688010|NCT04505787|ACTIVE_COMPARATOR|Froben|"Froben 100 mg comprimidos revestidos (Abbott Laboratórios, Lda., Portugal), immediate release tablets containing 100 mg flurbiprofen, oral multiple dose administration of 1 tablet three times daily (TID) over 4 consecutive days after a light meal"
62688011|NCT00803374|EXPERIMENTAL|0.1 mg/kg|
62688012|NCT00803374|EXPERIMENTAL|0.3 mg/kg|
62688013|NCT00803374|EXPERIMENTAL|1.0 mg/kg|
62688014|NCT00803374|EXPERIMENTAL|3.0 mg/kg|
62688015|NCT00803374|EXPERIMENTAL|10 mg/kg|
62688016|NCT01788774|OTHER|Risperidone ISM 50mg|Three different single doses will be evaluated
62128671|NCT05391464|ACTIVE_COMPARATOR|Peripheral Nerve Block|Participants will receive an ultrasound-guided, single shot PNB using 30ml 0.5% bupivacaine with 10mg dexamethasone. The anatomic location of the block will be determined by the anesthesiologist and will vary according to fracture location and anticipated surgical approaches. Intraoperative sedation will be used at the discretion of the anesthetic team.
62128672|NCT05391464|ACTIVE_COMPARATOR|General Anesthesia +/- PNB|GA will be administered in the operating room by a nurse anesthetist, with support from the anesthesiologist. GA will be induced with propofol and fentanyl and maintained with sevoflurane or desflurane and fentanyl. Doses will be determined by the anesthesiology team.
62318825|NCT04884620||Longitudinal cohort|Cases with first-time diagnoses of extremely early puberty within the period 1995-2019 in the National Patient Registry and five randomly selected references drawn from the general background population in the Danish Civil registry (CPR) matched on age and sex for each case
62688017|NCT01788774|OTHER|Risperidone ISM 75mg|Three different single doses will be evaluated
62688018|NCT01788774|OTHER|Risperidone ISM 100mg|Three different single doses will be evaluated
62688019|NCT04078568|ACTIVE_COMPARATOR|the standard group|"1. IVIG 2g/kg once, given within 12 to 24 hours;~2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
62688020|NCT04078568|EXPERIMENTAL|the standard+prednisolone group|"1. IVIG 2g/kg once, given within 12 to 24 hours;~2. Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~3. Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued."
62688021|NCT03004495|EXPERIMENTAL|CHF5259 and CHF6001|(T): CHF6001 + CHF5259 b.i.d. for 14 days
62688022|NCT03004495|ACTIVE_COMPARATOR|CHF5259 + placebo|(R1): CHF5259 25µg b.i.d. for 14 days
62688023|NCT03004495|ACTIVE_COMPARATOR|CHF6001 + placebo|(R2): CHF6001 b.i.d. for 14 days
62688024|NCT02012777|ACTIVE_COMPARATOR|cohort 1 10mg propranolol|"first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings."
62318826|NCT02389946|EXPERIMENTAL|Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
62318827|NCT02389946|ACTIVE_COMPARATOR|Xience everolimus coronary stent system|Intervention with a Xience DES.
62318828|NCT03551145|EXPERIMENTAL|Acellular collagen matrix|In a test group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Acellular collagen matrix will be adapted and suture to the vascular bed.
62688025|NCT02012777|ACTIVE_COMPARATOR|cohort 2 20mg propranolol|This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
62688026|NCT02012777|ACTIVE_COMPARATOR|cohort 3 40mg propranolol|This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.
62688027|NCT06688396|EXPERIMENTAL|DCM Screening|"Participants with dilated cardiomyopathy will invite their first-degree relatives to participate in DCM screening to examine the impact of an Artificial Intelligent (AI) enhanced 6lead (6L) mobile EKG in encouraging first degree relatives (FDR) of probands with a dilated cardiomyopathy (DCM) to obtain appropriate cardiac screening."
62688028|NCT06214325|EXPERIMENTAL|Music Therapy|Participants will receive 2 in-person music therapy sessions during hospital admission and 2 virtual music therapy sessions post-discharge.
62688029|NCT03988439|EXPERIMENTAL|IDP-118 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 4 to 11 years 11 months) will apply IDP-118 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
62688030|NCT05333588|EXPERIMENTAL|Tumor infiltrating lymphocyte|1x10\^9-5x10\^10 of autologous TILs will be adoptive transfer to patients.
62688031|NCT01118637|EXPERIMENTAL|Immediate|Assigned immediately after baseline assessment to receive step 1 treatment (web-based self-help)
62688032|NCT01118637|NO_INTERVENTION|Wait list|Assigned to wait list for 10 weeks before receiving step 1 treatment.
62688033|NCT03038919|EXPERIMENTAL|Anabolic patients|Intramuscular injection of testosterone cypionate 200mg every 15 days in addition to standard nutrition and physical therapy at ICU.
62688034|NCT03038919|OTHER|Control|Standard nutrition and physical therapy at ICU without administration of testosterone cypionate
62688035|NCT05499819|EXPERIMENTAL|Black beans|Canned black beans, drained and rinsed
62688036|NCT05499819|EXPERIMENTAL|Red kidney beans|Canned red kidney beans, drained and rinsed
62688037|NCT05499819|EXPERIMENTAL|Extra-lean ground beef|Extra-lean ground beef, pan-fried
62688038|NCT04665843|EXPERIMENTAL|Atezolizumab + Tiragolumab|Participants will receive atezolizumab followed by tiragolumab every three weeks (Q3W) on Day 1 of each 21-day cycle.
62688039|NCT04665843|PLACEBO_COMPARATOR|Atezolizumab + Placebo|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle.
62688040|NCT01421459|EXPERIMENTAL|LY2963016 + OAMs|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) \[alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)\] administered per standard of care for 24 weeks
62688041|NCT01421459|ACTIVE_COMPARATOR|Lantus + OAMs|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
62688042|NCT06675604||Subset 1|Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology
62688043|NCT06675604||Subset 2|Other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc...)
62688044|NCT06675604||Subset 3|Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis
62128673|NCT01336543|EXPERIMENTAL|Active Treatment|"ACTIVE TREATMENT intervention below:~1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 60 mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
62128674|NCT03772652||Peri-implantitis|Subjects who were diagnosed with peri-implantitis and received treatment at least five years ago at the Graduate Periodontics Clinic at University of Michigan with sufficient baseline data. Soft tissue measurements (observation) of the implant will be completed.
62128675|NCT02887898|ACTIVE_COMPARATOR|Carb counting and bolus calculator|Education in carb counting and the use of an automated bolus calculator
62688045|NCT06679543|NO_INTERVENTION|Normal sleep|During this arm, participants will be asked to come to the lab for testing after a night of normal sleep. Normal sleep will be defined as participants habitual sleep-wake timing.
62688046|NCT06679543|EXPERIMENTAL|Partial sleep deprivation|During this arm, participants will be asked to come to the lab for testing after a night of partial sleep deprivation. Participants will be asked to fall asleep at their habitual bedtime but wake up early (\~40% of normal sleep duration).
62128676|NCT02887898|PLACEBO_COMPARATOR|Carb counting|Education in carb counting and manual calculation of insulin bolus
62128677|NCT05334199|EXPERIMENTAL|Biodegradable stent treatment group|Biodegradable stent treatment group
62128678|NCT01154439|EXPERIMENTAL|Everolimus|Everolimus mice-regimen
62128679|NCT06449170|OTHER|Mango Ataulfo|150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino) plus 15ml of sunflower seed oil
62128680|NCT06449170|OTHER|Avocado Hass|120g of avocado hass plus 150ml of control beverage (Supportan® Drink Cappuccino)
62128681|NCT06449170|OTHER|Boiled Nopal|300g of boiled nopal plus 150 ml of control beverage (Supportan® Drink Cappuccino) plus 18ml of sunflower seed oil
62688047|NCT04269785|ACTIVE_COMPARATOR|Radiofrequency ablation|These patients will receive ablation by radiofrequency catheter, guided by of 3-dimensional electro-anatomic mapping technology
62128682|NCT06449170|OTHER|Corn Tortilla|3 pieces of corn tortilla plus 150 ml of control beverage (Supportan® Drink Cappuccino) plus 2ml of sunflower seed oil
62128683|NCT06449170|OTHER|Guava|3 pieces of guava plus 150 ml of control beverage (Supportan® Drink Cappuccino) plus 16ml of sunflower seed oil
62688048|NCT04269785|ACTIVE_COMPARATOR|Cryoballoon ablation|These patients will receive ablation by cryoballoon catheter, guided by X-ray fluoroscopy
62688049|NCT05250180|EXPERIMENTAL|Intervention|animal assisted therapy
62688050|NCT05250180|ACTIVE_COMPARATOR|Control|Treatment as usual
62688051|NCT03199534|EXPERIMENTAL|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
62688052|NCT03199534|EXPERIMENTAL|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
62688053|NCT03199534|EXPERIMENTAL|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
62688054|NCT04074837|PLACEBO_COMPARATOR|Placebo|Placebo liquid suspension.
62688055|NCT04074837|ACTIVE_COMPARATOR|NNI-362, 10 mg|NNI-362 at 10 mg in liquid suspension
62688056|NCT04074837|ACTIVE_COMPARATOR|NNI-362, 20 mg|NNI-362 at 20 mg in liquid suspension
61925397|NCT04907461|EXPERIMENTAL|Laparoscopic guided TAP block|"The surgeon uses a laparoscopic technique to visualise the peritoneum from the inside of the abdomen and guides the hypodermic needle through the abdominal wall from the outside. When the needle point is visible through the peritoneum and almost enters the abdominal cavity, the surgeon retracts the needle around 5 mm. Then by deploying a test dose of the local anaesthetics a so called Doyle's bulge sign can confirm the right position in the nervous plane. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin."
62128684|NCT06449170|OTHER|Amaranth|1/2 cup of amaranth plus 150 ml of control beverage (Supportan® Drink Cappuccino) plus 35ml of sunflower seed oil
62128685|NCT06449170|OTHER|Supportan® DKN Cappuccino|290ml of control beverage (Supportan® Drink Cappuccino)
62128686|NCT02692469|ACTIVE_COMPARATOR|Duodenal Switch Surgical Intervention|a DS procedure involves creating a sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel
62128687|NCT02692469|EXPERIMENTAL|Single Anastomosis Duodenal-Ileal Bypass|The SADI defers from the DS in that after the duodenum is separated from the stomach, preserving the pylorus, a loop of bowel 200 cm from the ileo-cecal valve is anastomosed with the pylorus, thus requiring only one anastomosis
62128688|NCT01317836||Patients having pancreatic cystic lesion|
62128689|NCT02106182|EXPERIMENTAL|Silodosin|Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks
62128690|NCT02355275|EXPERIMENTAL|Home Exercise Program|
62128691|NCT03976570|EXPERIMENTAL|Occupational Therapy|Occupational Therapy
62318829|NCT03551145|ACTIVE_COMPARATOR|Autogenous free gingival graft|In a control group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Free gingival graft will be harvested from the zone of the posterior palate, and then adapted and sutured to the vascular bed.
62318830|NCT05431582|EXPERIMENTAL|Regimen A|ZN-c3 in combination with bevacizumab
62318831|NCT05431582|EXPERIMENTAL|Regimen B|ZN-c3 in combination with bevacizumab and pembrolizumab
62688057|NCT04074837|ACTIVE_COMPARATOR|NNI-362, 60 mg|NNI-362 at 60 mg in liquid suspension
62688058|NCT04074837|ACTIVE_COMPARATOR|NNI-362, 120 mg|NNI-362 at 120 mg in liquid suspension
62688059|NCT04074837|ACTIVE_COMPARATOR|NNI-362, 240 mg|NNI-362 at 240 mg in liquid suspension
62688060|NCT00537797|EXPERIMENTAL|Arm 1|"18-FDG-PET exam with SUV determination~Thyroid operation to remove nodule~Pathologic confirmation of nodule histology~Determine sensitivity and specificity of FDG-PET, correlative studies"
62128692|NCT01393067|ACTIVE_COMPARATOR|study group NEPS|implantation of multiple non-expandable plastic stents
62318832|NCT05927389|EXPERIMENTAL|Experimental group: 6 months APA program|"The various assessments will be carried out during 2 visits at 6 months interval as part of the usual follow-up at the Constitutional Bone Diseases unit at the Toulouse University Hospital.~The APA program built from the initial assessment will be returned to the child and his family during a videoconference.~In addition, a regular reassessment and adjustment of this program will be made every 15 days during phone calls by the APA coach."
62318833|NCT06403384|NO_INTERVENTION|Control|no intervention was applied for the control group
62318834|NCT06403384|EXPERIMENTAL|Vibration|Vibration was applied for the vibration group
62688061|NCT02981160|NO_INTERVENTION|Standard Care Group|The participants assigned to this group will follow a standard weight loss program for 12-months. This patients will be instructed by the Weight loss program registered dietitian/diet tech in clinic in terms of nutrition regimen, daily intake and calories.Patients will be followed up monthly as per clinic protocol. All visits will include physical measurements including body mass index (BMI) based on height and weight, blood pressure, and body composition (fat percentage). Body composition will be assessed during clinic visits by bio-impedance. Waist circumference (cm) will be measured at the umbilicus.
62688062|NCT02981160|EXPERIMENTAL|Mobile Device Assistant Group|"This group will follow the same weight loss protocol, monitoring, and clinic visits as the standard weight loss group described above, but will also use the mobile health tool (Breezing) to track REE every visit. This data will be loaded onto an accompanying electronic pad using the Breezing app and will be transmitted electronically to the study investigators who will use the information to adjust dietary and physical activity recommendations and targets. The test will be performed at initial visit, 2 weeks, 1, 3, 6 and 12 months after started."
62688063|NCT06641401||Endoscopic Flexor Hallucis Longus Transfer Group|28 Patients with acute Achilles tendon rupture treated with Endoscopic Flexor Hallucis Longus transfer by a single surgeon in a single hospital (General Hospital of Naousa, Greece). All patients followed the same postoperative rehabilitation program.
62688064|NCT03801109|EXPERIMENTAL|Hyperbaric group|
62688065|NCT03801109|EXPERIMENTAL|Magnetic group|
62688066|NCT03801109|ACTIVE_COMPARATOR|Physical group|
62688067|NCT03801109|NO_INTERVENTION|Baseline group|
62688068|NCT00529815|EXPERIMENTAL|1CGM and SBGM|Intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
62688069|NCT00529815|ACTIVE_COMPARATOR|2 SBGM|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
62688070|NCT03060265|ACTIVE_COMPARATOR|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
62688071|NCT03060265|PLACEBO_COMPARATOR|Placebo|100ml normal saline, one dose IV
62318835|NCT03566537||Cases|Patients who are going to undergo a thyroid surgery due to symptomatic non-toxic multinodular goiter, uncontrolled thyrotoxicosis or suspicious FNA
62480041|NCT02849496|EXPERIMENTAL|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II. Patients undergo an x-ray, CT scan, MRI, bone scan, and/or PET scan as well as a biopsy and blood sample collection throughout the trial. Patients may also undergo a bone marrow aspiration and biopsy on study.
62480042|NCT02849496|EXPERIMENTAL|Arm II (olaparib, atezolizumab)|Patients receive olaparib as in Arm I and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, bone scan, and/or PET scan as well as a biopsy and blood sample collection throughout the trial. Patients may also undergo a bone marrow aspiration and biopsy on study.
62688072|NCT01950598|ACTIVE_COMPARATOR|Fresh carrier graft for KPro|KPro implanted using fresh cornea, preserved in optisol GS
62688073|NCT01950598|EXPERIMENTAL|Frozen carrier graft for KPro|KPro implanted using frozen cornea, which was supplied as a whole globe cryopreserved at -80°C in gramicidin 0.025 mg/mL and polymyxin B sulfate 10 000 U/mL ophthalmic solution.
62688074|NCT01917370||ICC patients|patients with intrahepatic cholangiocarcinoma treated by surgical treatment
62688075|NCT04884074|EXPERIMENTAL|The study group|The procedure done to this group is Sleeve Gastrectomy with Anterior Crural Repair (ACR)
62688076|NCT04884074|OTHER|The control group|The procedure done to this group is the Standard Sleeve Gastrectomy (SSG)
62688077|NCT03424980||Tyrosine kinase inhibitors|Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
62688078|NCT02483910|EXPERIMENTAL|DI-LL via telehealth|Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks). Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
62688079|NCT02483910|ACTIVE_COMPARATOR|Standard of care delivered via telehealth|"Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks.~NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks."
62688080|NCT04083079|EXPERIMENTAL|PEG-rhG-CSF cohort|"PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once.~Dosage: 6mg for weight ≥45kg，3mg for weight \<45kg, subcutaneous injection"
62318836|NCT03566537||Controls|Patients with benign thyroid disease, not undergoing thyroidectomy
62318837|NCT01604486||MI without ischaemic preconditioning|Myocardial infarction unheralded by any previous cardiovascular disease diagnosis and without symptoms of chest pain in the previous 90 days.
62688081|NCT04083079|EXPERIMENTAL|rhG-CSF cohort|"rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10\^9/L.~rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10\^9/L.~Dosage: 5μg/kg/d, subcutaneous injection"
62688082|NCT06686160|EXPERIMENTAL|Plyometric Training|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise, Plyometrics are primarily used by athletes to improve performance and are used in the fitness field to a much lesser degree. This training focuses on learning to move from a muscle extension to a contraction in a explosive way, for example repeated jumping.
62688083|NCT06686160|EXPERIMENTAL|Theraband Resistance Exercise|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise Therabands is a Set of bands which are primarily use for resistance Training for strength and Power.
61925398|NCT04907461|ACTIVE_COMPARATOR|Ultrasound guided TAP block|The anaesthesiologist uses ultrasound to identify the nervous plane in-between the external and transverse abdominal muscles. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin.
61925399|NCT00046111|EXPERIMENTAL|Primary Group|40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
61925400|NCT00006389|EXPERIMENTAL|Treatment|Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1 hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
62128693|NCT01393067|ACTIVE_COMPARATOR|group cSEMS|implantation of a self-expandable metal stent (cSEMS)
62318838|NCT01604486||MI with longstanding disease|Patients with myocardial infarction who have had diagnosed atherosclerotic disease for longer than 90 days preceding infarct.
62318839|NCT01604486||MI with only chest pain|Patients with chest pain in the 90 days preceding MI, but with no prior atherosclerotic disease diagnoses.
62318840|NCT01604486||MI with disease and chest pain|Myocardial infarction occurring with previously diagnosed atherosclerotic disease of longer than 90 days' duration, but with chest pain in 90 days preceding infarct.
62318841|NCT06536985|ACTIVE_COMPARATOR|Contral group|
62318842|NCT06536985|EXPERIMENTAL|Treatment group|
62318843|NCT01149278|ACTIVE_COMPARATOR|high pressure|
62318844|NCT01149278|PLACEBO_COMPARATOR|normal pressure|
62688084|NCT01954511|NO_INTERVENTION|Manual therapy|Upper cervical flexion mobilization, C5 central posterior-anterior mobilization, Pressure biofeedback device
61925401|NCT01880047|ACTIVE_COMPARATOR|Eltrombopag|Subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status. Randomization will be performed at the time of informed consent with a computer generated randomization table. Subjects and investigators will be blinded to assignment and treatment in this phase.
61925402|NCT01880047|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly allocated in a two to one ratio to receive treatment or placebo. All subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status.
61925403|NCT03316534|PLACEBO_COMPARATOR|Placebo|Placebo
61925404|NCT03316534|ACTIVE_COMPARATOR|Aspirin|Aspirin (100 mg/daily)
61925405|NCT04350346|ACTIVE_COMPARATOR|The patient group who taken Motilitone|
61925406|NCT04350346|ACTIVE_COMPARATOR|The patient group who taken Gasmotin|
62688085|NCT04872946|EXPERIMENTAL|InnerCalm+skin care|An oral supplement and topical agent will be assigned.
62688086|NCT04872946|EXPERIMENTAL|InnerCalm only|An oral supplement will be assigned.
62688087|NCT04872946|EXPERIMENTAL|Skincare Only|A topical agent only will be assigned.
62688088|NCT01793233||Ancillary-Correlative (menstrual diary, biomarker analysis)|Patients complete a menstrual diary to document vaginal bleeding and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment.
62128694|NCT03405714|EXPERIMENTAL|Brivaracetam|Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects \>=12 to \<16 years; Cohort 2: Subjects \>=6 to \<12 years; Cohort 3: Subjects \>=2 to \<6 years; Cohort 4: Subjects 1 month to \<2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
62688089|NCT04787341|ACTIVE_COMPARATOR|Panitumumab followed by Regorafenib|
62688090|NCT04787341|EXPERIMENTAL|Regorafenib followed by Panitumumab|
62688091|NCT05524792||COVID-19|no interventional study
62688092|NCT05524792||Control I: No COVID-19|no interventional study
62688093|NCT05524792||Control II: Influenza 2018|no interventional study
62128695|NCT03570437|ACTIVE_COMPARATOR|Arm 1: Paclitaxel|Paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles.
62318845|NCT04008862|EXPERIMENTAL|Partnership-based care|Each patient will serve as his/her own control
62318846|NCT05283538|EXPERIMENTAL|Coronary Artery Calcification Evaluation|
62688094|NCT05524792||Control III: Historical 2018|no interventional study
62688095|NCT05885750|EXPERIMENTAL|Diet 1|Unprocessed or minimally processed plant-based protein-rich food products
62688096|NCT05885750|EXPERIMENTAL|Diet 2|Mildly processed plant-based protein-rich food products
62688097|NCT05885750|EXPERIMENTAL|Diet 3|Heavily refined plant-based protein-rich food products
62688098|NCT02595437|EXPERIMENTAL|Triferic via IV and Hemodialysate|On study Day 1, patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment. On study Day 3, Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
62688099|NCT06513312|EXPERIMENTAL|Randomized Phase: Lenacapavir (LEN) Group|Participants will receive subcutaneous (SC) LEN 927 mg on Day 1 and 26 weeks and oral LEN 600 mg on Day 1 and 2.
62688100|NCT06513312|EXPERIMENTAL|Randomized Phase: F/TDF|Participants will receive daily F/TDF (200/300 mg) fixed dose combination (FDC) tablets for up to 52 weeks.
62688101|NCT06513312|EXPERIMENTAL|LEN Open Label Extension (OLE) Phase|Participants in the F/TDF group will transition to get LEN and participants in the LEN group will continue to get LEN. All participants will get SC LEN on Day 1 and week 26 of the OLE phase.
62688102|NCT06513312|EXPERIMENTAL|Pharmacokinetic (PK) Tail Phase: F/TDF|After completion of the LEN OLE Phase or upon discontinuation from the Randomized Phase for those receiving LEN, participants will be transitioned to receive F/TDF in the PK Tail Phase. Participants will receive once daily F/TDF for 78 weeks, beginning 26 weeks after the last LEN injection
62128696|NCT03570437|EXPERIMENTAL|Arm 2: Cediranib and paclitaxel|Cediranib 20 mg once daily for 28 days given with weekly paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue cediranib once daily until disease progression.
62128697|NCT03570437|EXPERIMENTAL|Arm 3: Cediranib and olaparib|Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue with olaparib and cediranib until disease progression.
62128698|NCT03191981|EXPERIMENTAL|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
62128699|NCT05973578|OTHER|Stereotactic body radiotherapy|Patients will be treated with a stereotactic body radiotherapy technique as a single fraction treatment up to a dose of 25 Gy delivered to the VT substrate
62128700|NCT00640250|EXPERIMENTAL|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
62128701|NCT00812461|PLACEBO_COMPARATOR|Placebo|
62128702|NCT00812461|EXPERIMENTAL|Nalmefene|
62128703|NCT03292913|EXPERIMENTAL|Intervention Group|Receives the Positive Health Check intervention plus standard of care
62128704|NCT03292913|OTHER|Control Group|Receives standard of care
62318847|NCT02146807|EXPERIMENTAL|Picosecond Laser System|
62128705|NCT00598377|ACTIVE_COMPARATOR|1|Patients with autosomal dominant polycystic kidney disease
62128706|NCT00598377|ACTIVE_COMPARATOR|2|Healthy subjects
62318848|NCT02791789|OTHER|Autism Spectrum Disorder|clinical exam, speech and language therapy and neuropsychological evaluations, Training to the SEMATIC serious game
62318849|NCT04339946||Patients with suspicious of rectosigmoid endometriosis|
62318850|NCT02322723||Moderately to severely active RA patients|Moderately to severely active RA patients aged 18 years or older, both male and female
62318851|NCT02247661||Direct lateral approach|Total or hemiarthroplasty operated with direct-lateral approach.
62318852|NCT02247661||Postero-lateral approach|Total or hemiarthroplasty operated with postero-lateral approach.
62318853|NCT02794831||patient|Adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery.
62318854|NCT02794831||control|Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site
62318855|NCT03520023|NO_INTERVENTION|Standard Care|Standard care with consultant discretion regarding consult of palliative care medicine
61925407|NCT00340288||Premenopausal fibroid cases|Premenopausal women (18 years or older) with at least one uterine leiomyoma diagnosis confirmed by ultrasound
61925408|NCT01083927|ACTIVE_COMPARATOR|Rotational Narrow Strip Graft|Technique of surgery
61925409|NCT01083927|ACTIVE_COMPARATOR|Full Graft|Surgical technique
61925410|NCT04551391||Case|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI determined as:~* Previous (within 3 years) eGFR \>45 mL/min/1.73m2 OR no history of kidney disease if no recent (within 3 years) blood results available AND~* Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value AND~* Increasing creatinine \>= 27μmol/L above index value within 48 hours"
61925411|NCT04551391||Control|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to hospital without AKI: (eGFR \> 60).~This group will be recruited contemporaneously with, and matched to, AKI participants by:~1. Age (± 5 years)~2. Sex~3. AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not AND/OR (ii) History of cardiovascular disease or not"
61925412|NCT06632769||term neonates|term neonates after Cesarean section
61925413|NCT05323565|ACTIVE_COMPARATOR|Group A (n=15): (Dexamethasone group)|Patients will receive 20 ml 0.25% bupivacaine plus 4 mg dexamethasone on each side TAB bock.
61925414|NCT05323565|ACTIVE_COMPARATOR|Group B (n=15): (Dexmedetomidine group)|Patients will receive 20 ml 0.25% bupivacaine plus 0.5 mcg/kg of dexmedetomidine on each side TAB block.
61925415|NCT05323565|SHAM_COMPARATOR|Group C (n=15): (control group)|Patients will receive 20 ml 0.25% bupivacaine on each side TAB block.
61925416|NCT04935437|ACTIVE_COMPARATOR|Intervention|The patients in this arm will be enrolled in a 2 months supervised rehabilitation program. Evaluation will take place at recruitment time and at the end of the program (2 months).
62688103|NCT01130428|EXPERIMENTAL|Intervention group|As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.
62688104|NCT01773889|EXPERIMENTAL|Denileukin Diftitox/SC Pegylated IFNα-2A|Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A
61925417|NCT04935437|NO_INTERVENTION|Control|The patients in this arm will not be enrolled in a supervised rehabilitation program. Evaluation will take place at recruitment and at 2 months.
61925418|NCT04735575|EXPERIMENTAL|EMB-06|"In Phase I part: participants enrolled at different time will receive EMB-06 by IV infusion at different ascending dose levels.~In Phase II part: participants will receive EMB-06 by IV infusion at previously defined RP2D."
61925419|NCT05396703||TOETVA|All patients who underwent a transoral endoscopic thyroidectomy via vestibular approach (TOETVA) at the investigators' center.
62318856|NCT03520023|EXPERIMENTAL|Experimental|Early palliative care consult based upon meeting study inclusion criteria
61925420|NCT04472091|EXPERIMENTAL|Genicular artery embolization|"Participants will undergo the genicular artery embolization (GAE) procedure for the treatment of moderate to severe knee osteoarthritis. A total of 30 patients will be enrolled in the single treatment arm of the study.~The study will involve a screening period in which patient eligibility is determined. Once eligibility is confirmed, patients will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ). Following treatment, patients will undergo follow-up at 1, 6, 12, and 24 months post GAE."
61925421|NCT01111409|EXPERIMENTAL|VFIX|
61925422|NCT04830644|EXPERIMENTAL|Iguratimod 1|orally 25mg twice a day
61925423|NCT04830644|EXPERIMENTAL|Iguratimod 2|orally 20mg twice a day
61925424|NCT04830644|EXPERIMENTAL|Iguratimod 3|orally 10mg twice a day
61925425|NCT04830644|PLACEBO_COMPARATOR|Placebo|orally twice a day
61925426|NCT02059005|EXPERIMENTAL|Specialized Community Disease Management|Specialized Community Disease Management
62318857|NCT00524745|ACTIVE_COMPARATOR|0,2,6 month vaccination schedule|
62318858|NCT00524745|ACTIVE_COMPARATOR|0,3,9 month vaccination schedule|
62688105|NCT02584738|EXPERIMENTAL|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4.~Intravenous methylprednisolone or oral prednisolone"
62688106|NCT02584738|PLACEBO_COMPARATOR|Nebulized isotonic saline|Nebulized salbutamol and ipratropium bromide with 2.5 ml of isotonic saline. Intravenous methylprednisolone or oral prednisolone
62688107|NCT06674057|EXPERIMENTAL|experimental group|It includes participants receiving kinesio taping in addition to conservational physical therapy for subacute stroke patient's upper limb ROM/spasticity/function. for a period of 6 weeks.
61925427|NCT02059005|ACTIVE_COMPARATOR|Treatment As Usual|Treatment as Usual: standard post-hospital discharge with medical monitoring.
61925428|NCT01016561|EXPERIMENTAL|Arm I|Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
61925429|NCT01410552|OTHER|ICD or CRT-D with PARAD+|only 1 arm is the study: all patients implanted with ICD or CRT-D with PARAD+ enabled, no comparator
61925430|NCT00526877|EXPERIMENTAL|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
62318859|NCT00524745|ACTIVE_COMPARATOR|0,6,12 month vaccination schedule|
62318860|NCT00524745|ACTIVE_COMPARATOR|0,12,24 month vaccination schedule|
62318861|NCT03819283|OTHER|Hepatic evaluation|
62688108|NCT06674057|ACTIVE_COMPARATOR|control group|It includes participants receiving conservational physical therapy for subacute stroke patient's upper limb ROM/spasticity/function. for a period of 6 weeks.
62688109|NCT06642844|EXPERIMENTAL|Experimental: Group A|Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.
62688110|NCT06642844|ACTIVE_COMPARATOR|Active comparator: Group B|Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.
62688111|NCT04975165|EXPERIMENTAL|Staged total knee arthroplasty|Staged replacement of both knees in two separate surgeries.
62688112|NCT04975165|EXPERIMENTAL|Simultaneous total knee arthroplasty|Simultaneous replacement of both knees in a single surgery.
62688113|NCT01800110|EXPERIMENTAL|2|label I- 200 cc pomegranate juice once daily for 6 weeks post partum. label II- control group, no placebo is givening.
62128707|NCT02258815|EXPERIMENTAL|ch14.18|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
62128708|NCT03922061|EXPERIMENTAL|fIPV-dmLT|fractional-dose inactivated polio vaccine (fIPV) given intradermally with double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant
62128709|NCT03922061|ACTIVE_COMPARATOR|fIPV|fractional-dose inactivated polio vaccine (fIPV) given intradermally
62318862|NCT05243550|EXPERIMENTAL|UGN-102|Patients will receive 6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).
62318863|NCT06472505|EXPERIMENTAL|Using polyglycolic acid mesh|
62128710|NCT03300492|EXPERIMENTAL|NK-DLI|"Preemptive immunotherapy with ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses following haplo-HSCT."
62128711|NCT02410018|EXPERIMENTAL|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
62128712|NCT02410018|EXPERIMENTAL|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
62128713|NCT00886756|EXPERIMENTAL|1|
62128714|NCT00886756|PLACEBO_COMPARATOR|2|
62318864|NCT00907478|EXPERIMENTAL|Romiplostim|"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years.~The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L."
62318865|NCT03701165|OTHER|Snoring cohort.|Subjects will undergo two nights of polysomnography. The first night will be a baseline recording. The next night subjects will use the DryMouth Shield during the polysomnography.
62688114|NCT04361331|OTHER|Toripalimab combined with lenvatinib|"1. Toripalimab: 240 mg, intravenous infusion, Q3W;~2. Lenvatinib: 8mg (body weight \<60kg) or 12mg (body weight ≥60kg), qd;"
62688115|NCT04361331|OTHER|Lenvatinib combined with gemox|"1. Lenvatinib: 8mg (body weight \<60kg) or 12mg (body weight ≥60kg), qd~2. Gemox chemotherapy D1: Oxaliplatin 85mg / m2, Gemcitabine 1g / m2 D8: Gemcitabine 1g / m2 Three weeks are a course, a total of 6-8 courses"
62688116|NCT02235688|EXPERIMENTAL|aldoxorubicin|
62688117|NCT00421967|EXPERIMENTAL|1|
62688118|NCT00421967|ACTIVE_COMPARATOR|2|
62688119|NCT06355284||Overcontrol|Trauma-exposed veterans with PTSD symptoms and average rigidity, emotional overcontrol, and maladaptive perfectionism subscale scores on the Pathological Obsessive Compulsive Personality Scale greater than or equal to 4.
62688120|NCT05584631|EXPERIMENTAL|Intravenous immune globulin G|Subjects will receive there current intravenous immune globulin dose.
62688121|NCT05584631|EXPERIMENTAL|Subcutaneous immune globulin G|The dosage will be converted from the subject's current intravenous immune globulin G dosage 1:1 (gm per gm).
62128715|NCT03053024||Cohort 1: Relapse/refractory MCL (rrMCL ) Participants|Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma \[rrMCL\]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
62128716|NCT03053024||Cohort 2: Newly Diagnosed MCL Participants|Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
62128717|NCT01486524||DrotAA Treatment Group|Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
62318866|NCT06474741|EXPERIMENTAL|intervention|in-app twice-weekly parent notification about torticollis and head turn asymmetries
62318867|NCT06474741|NO_INTERVENTION|control|in-app twice-weekly parent notification about general infant development
62318868|NCT04618497|EXPERIMENTAL|Inhalational methoxyflurane (Penthrox)|
62318869|NCT04618497|ACTIVE_COMPARATOR|Intramuscular ketorolac|
62318870|NCT03306069|EXPERIMENTAL|Control|Nutritional therapy / no exercise
62318871|NCT03306069|EXPERIMENTAL|HIIT|High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy
62318872|NCT03306069|EXPERIMENTAL|MIIT-HR|Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy
62688122|NCT06674408|EXPERIMENTAL|Prioprioceptive exercises|Hot packs, mobilization, stretching and strengthening, closed and open chain kinetic exercises, hand function exercises, hand eye coordination exercises
62688123|NCT06674408|ACTIVE_COMPARATOR|Conventional|Hot packs, mobilization, stretching and strengthening, finger ladder exercise, Codman's pendulum exercise, towel stretch exercise and wand exercises
62688124|NCT04321031|PLACEBO_COMPARATOR|Placebo|participants will receive medication for 48 weeks
62128718|NCT01486524||Control Group (non-DrotAA treated)|Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).
62480043|NCT05470348|EXPERIMENTAL|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62480044|NCT01434953|EXPERIMENTAL|Labeled|
62128719|NCT05393804|EXPERIMENTAL|Cohort 1|Participants with relapsed/refractory MM who had an autologous hematopoietic stem cell transplant (AHCT). In an AHCT, their own blood-forming stem cells are collected. Participants are then treated with high doses of chemotherapy which kills the cancer cells, but it also gets rid of the blood-producing cells that are left in the bone marrow. Afterward, the collected stem cells are put back into the bloodstream, allowing the bone marrow to produce new blood cells.
62480045|NCT01434953|ACTIVE_COMPARATOR|Unlabeled|
62480046|NCT06346483|ACTIVE_COMPARATOR|Moses 2.0 arm|"Ureteroscopy with high powered holmium laser lithotripsy with Moses 2.0 pulse modulation.~Ureteral dusting settings: 0.2-0.3x60 Hz (not to exceed 20 W) Renal dusting settings: 0.2-0.3 J x 120 Hz (not to exceed 40 W)"
62480047|NCT06346483|ACTIVE_COMPARATOR|Standard High-powered arm|"Ureteroscopy with high powered holmium laser lithotripsy without Moses 2.0 pulse modulation.~Ureteral dusting settings: 0.2-0.3 x 60 Hz (not to exceed 20 W) Renal dusting settings: 0.2-0.5 J x 80 Hz standard (not to exceed 40 W)"
61925431|NCT01278160|EXPERIMENTAL|BIAsp 30 (2:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 2/3 and 1/3 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
62128720|NCT05393804|EXPERIMENTAL|Cohort 2|Participants with relapsed/refractory MM who had an allogeneic hematopoietic cell transplant (alloHCT). In an alloHCT, a person's stem cells are replaced with new, healthy stem cells from a donor.
62128721|NCT02594631|ACTIVE_COMPARATOR|ESWL Group|Patients in this arm will receive ESWL as treatment for acute calcular urinary retention
62318873|NCT03306069|EXPERIMENTAL|MIIT-LT|Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding \~70-75% HRmax) combined with Nutritional therapy
62318874|NCT05518344|EXPERIMENTAL|single arm|"* Release ISL from Inserter~* Remove Inserter.~* Tack the haptics under the iris in 4 locations~* Verify that ISL is centered~* Remove lid speculum and drape from subject's eye and face.~* Move the subject to a slit lamp and verify ISL centration."
62318875|NCT04157660|EXPERIMENTAL|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
62318876|NCT04157660|SHAM_COMPARATOR|Sham room air|Room air will be applied similarly to oxygen
62318877|NCT04458038|EXPERIMENTAL|intervention arm|
62480048|NCT04387552|EXPERIMENTAL|Prenatal SS/Postnatal BF|Prenatal Safe Sleep/Postnatal Breastfeeding Mobile Health Messages
62480049|NCT04387552|EXPERIMENTAL|Prenatal BF/Postnatal SS|Prenatal Breastfeeding/Postnatal Safe Sleep Mobile Health Messages
62480050|NCT04387552|EXPERIMENTAL|Prenatal SS/Postnatal SS|Prenatal Safe Sleep/Postnatal Safe Sleep Mobile Health Messages
62128722|NCT02594631|ACTIVE_COMPARATOR|Endoscopy group|Patients in this arm will receive endoscopic treatment for acute calcular urinary retention
62480051|NCT04387552|EXPERIMENTAL|Prenatal BF/Postnatal BF|Prenatal Breastfeeding/Postnatal Breastfeeding Mobile Health Messages
62480052|NCT06685835|EXPERIMENTAL|Brensocatib 10 mg|Participants will receive brensocatib 10 mg tablet, once daily (QD), orally for 52 weeks.
62128723|NCT04875624||Hypoglycemic neonates|Preterm or small for gestational age neonates at risk for hypoglycemia who were found to be hypoglycemic during the screening for hypoglycemia
62128724|NCT04875624||Normoglycemic neonates|Preterm or small for gestational age neonates who were found to be normoglycemic during the screening for hypoglycemia
62128725|NCT03481816|EXPERIMENTAL|Arm 1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts.
62318878|NCT01707212|EXPERIMENTAL|Pain management education|Education about pain management during infant immunization
62318879|NCT01707212|OTHER|No pain management education|Control - general information about immunization only
62128726|NCT03481816|EXPERIMENTAL|Arm 2/Dose expansion|Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.
62318880|NCT02660424|EXPERIMENTAL|VX-150, placebo|Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
62318881|NCT02660424|EXPERIMENTAL|placebo, VX-150|Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
62480053|NCT06685835|EXPERIMENTAL|Brensocatib 40 mg|Participants will receive brensocatib 40 mg tablet, QD, orally for 52 weeks.
62128727|NCT04065958|EXPERIMENTAL|Yoga-mindfulness|Yoga-mindfulness program consisting of movements/postures (asanas), breathing practices, relaxation practices and meditation practices, together with brief talks on yoga-based coping strategies. The intervention starts with a introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks, with home assignments for about 30 minutes per day, four days per week.
62688125|NCT04321031|EXPERIMENTAL|PF-06865571 25 milligrams (mg) twice daily (BID)|participants will receive medication for 48 weeks
62318882|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
62318883|NCT02847936|ACTIVE_COMPARATOR|VICRYL PLUS|triclosan-coated sutures
62318884|NCT02847936|ACTIVE_COMPARATOR|VICRYL|non antibacterial coated sutures
62318885|NCT04215081|EXPERIMENTAL|ExoAtlet II Safety and Efficacy|20 participants with paraplegia from SCI will participate in gait training using ExoAtlet II powered exoskeleton.
62318886|NCT01950481|EXPERIMENTAL|Normal Hepatic Function|Subjects with normal hepatic function
62318887|NCT01950481|EXPERIMENTAL|Mild Hepatic Impairment|Subjects with mild hepatic impairment
62318888|NCT01950481|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment
62128728|NCT04065958|ACTIVE_COMPARATOR|Patient education and physiotherapy|Patient education program consisting of lectures on topics related to inflammatory arthritis and pain together with mild physiotherapy. The interventions starts with an introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks. Each session consists of a lecture and a program of instructed physiotherapy. Besides the weekly sessions, home assignments consisting of 30 minutes of walking, are performed four days per week.
62128729|NCT04764006|EXPERIMENTAL|Surufatinib plus Sintilimab|Drug: Surufatinib plus Sintilimab Surufatinib will be given orally. Sintilimab will be given intravenously
62318889|NCT01950481|EXPERIMENTAL|Severe Hepatic Impairment|Subjects with severe hepatic impairment
62318890|NCT05506332|EXPERIMENTAL|Venetoclax and 6-mercaptopurine|Single arm study with venetoclax and 6-mercaptopurine administered in two to six cycles of 28 days. Venetoclax is given at a dosage of 600mg with dose reduction in case of interaction with a moderate or strong CYP3A4 inhibitor. 6-mercaptopurine is given at a dosage of 100mg.
62318891|NCT01988012|EXPERIMENTAL|Tocilizumab|Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.
62318892|NCT00282165|PLACEBO_COMPARATOR|placebo|four week double blind placebo treatment phase
62318893|NCT00282165|ACTIVE_COMPARATOR|naratriptan|four week double blind experimental treatment using daily naratriptan tablets
62318894|NCT01044277|EXPERIMENTAL|Group A|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
62318895|NCT01044277|EXPERIMENTAL|Group B|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
62318896|NCT01044277|PLACEBO_COMPARATOR|Group C|Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
62318897|NCT03921281|EXPERIMENTAL|treatment group|The treatment group (n=38) will receive scalp acupuncture combined with rehabilitation treatment for 3 times per week for 12 weeks.
62318898|NCT03921281|OTHER|control group|The control group (n=38) will receive rehabilitation treatment for 3 times per week for 12 weeks.
62318899|NCT05527704|ACTIVE_COMPARATOR|CPAP+Salbutamol|All patients will receive nCPAP at 5-6 cm H2O pressure with an oxygen concentration of 21% or more to maintain preductal saturation between 90% and 95%. Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulised salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
62318900|NCT05527704|PLACEBO_COMPARATOR|CPAP+Placebo|Patients in the placebo group will also receive nCPAP at 5-6 cm H2O pressure with an oxygen concentration of 21% or more to maintain preductal saturation between 90% and 95%. In addition, patients will receive 3 mL nebulised 0.9% NaCl administered for 30 min. as a placebo
62318901|NCT05606354|EXPERIMENTAL|Intervention group (Group A)|"STRECHING EXERCISES:~A. HAMSTRING MUSCLE STRECHING.~B. CALF MUSCLE STRECHING:~2. STRENGTHENING EXCERCISES: 2 exercises will be performed on targeted muscle group Quadriceps. A. QUADRICEP MUSCLE (with ankle weight). B. QUADRICEP MUSCLE (straight leg raise).~3. KNEE RANGE OF MOTION EXERCISES: (FLEXION AND EXTENSION)~4. FUNCTIONAL EXERCISES:~A. SIT TO STAND:~B. CLIMBING STAIRS:~KINESIO TAPING The following KT application techniques will be used for intervention group after identifying the goal. Goal - A: Proprioception Stimulation and Mechanical Correction Tape Technique-A: (Strip Cutting Shape: One Y-shaped + two I-shaped strips).~Goal B: Lymphatic Correction and Muscle Correction Tape Technique-B: (Strip Cutting Shape: Two Y-shaped + two I-shaped strips)."
62318902|NCT05606354|OTHER|control group (Group.B)|GROUP.B - (CONTROL) - EXERCISES ONLY WITHOUT KINESIO TAPE The exercise types and dosage will be exactly the same for control group (as in experimental group (as mentioned above) But no kinesio tape will be given to this group.
62128730|NCT03435666|EXPERIMENTAL|Capecitabine|Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.
62318903|NCT04061798|EXPERIMENTAL|ACT guided heparinization|Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
62318904|NCT04061798|ACTIVE_COMPARATOR|5 000 IU of heparin|A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Depending on that ACT value near the end of surgery, the local protamine can be given to neutralize the effect of heparin. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.
62128731|NCT03435666|ACTIVE_COMPARATOR|XELODA|XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.
62128732|NCT04290572|EXPERIMENTAL|Isotretinoin 10 mg/day|One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.
62688126|NCT04321031|EXPERIMENTAL|PF-06865571 75 mg BID|participants will receive medication for 48 weeks
62128733|NCT04290572|EXPERIMENTAL|Isotretinoin 20 mg/day|One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.
62128734|NCT04290572|ACTIVE_COMPARATOR|Isotretinoin 30 mg/day|One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.
62128735|NCT06077110|EXPERIMENTAL|P-OMICs-flow patients|
62128736|NCT02065024|ACTIVE_COMPARATOR|b-cryptoxanthin plus phytosterols|Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols
62318905|NCT00006386|EXPERIMENTAL|External beam radiotherapy with stereotactic boost|External beam radiotherapy (EBXRT): 50 Gy in 25 daily fractions of 2 Gy. Stereotactic radiotherapy (SRT) boost: 4 treatments of 5 or 7 Gy, once per week during weeks 3-6. Patients will not receive EBXRT on the SRT treatment days.
62480054|NCT06685835|PLACEBO_COMPARATOR|Placebo Followed by Brensocatib 10 mg|Participants will receive brensocatib-matching placebo tablet, QD, orally for 16 weeks, and then Brensocatib 10 mg tablet, QD, orally for 36 weeks.
61925432|NCT01278160|EXPERIMENTAL|BIAsp 30 (1:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 1/2 and 1/2 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
62128737|NCT02065024|PLACEBO_COMPARATOR|control|Fruit and milk based beverage not enriched
62128738|NCT04766034|SHAM_COMPARATOR|Control|The grocery shopping simulation will not include any discounts or bundles
62128739|NCT04766034|ACTIVE_COMPARATOR|Discount|The grocery shopping simulation will include discount on eligible fruits and vegetables
62128740|NCT04766034|ACTIVE_COMPARATOR|Bundles|The grocery shopping simulation will include healthy bundle defaults with no discount
62128741|NCT04766034|ACTIVE_COMPARATOR|Bundles and Discount|The grocery shopping simulation will include healthy bundle defaults plus a discount
62128742|NCT04295915||Specimens that meet inclusion criteria|
62128743|NCT04727840|OTHER|Intervention|All 20 CKD patients will be receiving a potassium binder while consuming a tailored diet of non-potassium restricted foods
62128744|NCT05583253|ACTIVE_COMPARATOR|Vitrectomy group with previous refractive surgery|Cases with primary retinal detachment that are prepared for pars-plana vitrectomy with previous history of refractive surgery.
62128745|NCT05583253|ACTIVE_COMPARATOR|Vitrectomy group with no previous intraocular surgery|Subjects with primary retinal detachment that are prepared for pars-plana vitrectomy with no previous history of intraocular surgery.
62128746|NCT03071081|EXPERIMENTAL|TOP1288 200mg BID|1 day dosing
62128747|NCT03071081|PLACEBO_COMPARATOR|Placebo to TOP1288 200mg BID|1 day dosing
62128748|NCT03071081|EXPERIMENTAL|TOP1288 1g BID|1 day dosing
62128749|NCT03071081|PLACEBO_COMPARATOR|Placebo to TOP1288 1g BID|1 day dosing
62128750|NCT03071081|EXPERIMENTAL|TOP1288 Xg (where X is <=1g) BID|7 days dosing
62128751|NCT03071081|PLACEBO_COMPARATOR|Placebo to TOP1288 Xg|7 days dosing
62128752|NCT00714714|EXPERIMENTAL|Tretinoin and Adapalene gels|Adapalene facial gel and tretinoin facial gel applied daily for two weeks on opposite sides of the face (in a split-face model)
62318906|NCT04579055|EXPERIMENTAL|1-min STS test: chair seat height adjusted to 90° knee flexion|In this experimental condition, the patient performs the 1-minute sit to stand test on an individually adjusted seat height of 90° knee joint flexion.
62480055|NCT06685835|PLACEBO_COMPARATOR|Placebo Followed by Brensocatib 40 mg|Participants will receive brensocatib-matching placebo tablet, QD, orally for 16 weeks, and then Brensocatib 40 mg tablet, QD, orally for 36 weeks.
62480056|NCT04229225|EXPERIMENTAL|UBX0101 single dose (SD)|"Cohort 1 (n=18): UBX0101 8.0 mg or placebo IA at Week 0~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
62688127|NCT04321031|EXPERIMENTAL|PF-06865571 150 mg BID|participants will receive medication for 48 weeks
61925433|NCT03012022||Healthy Volunteers|Volunteers without known cardiomyopathy or heart failure
62128753|NCT02755116|EXPERIMENTAL|Olanzapine|10mg pill
62128754|NCT02755116|PLACEBO_COMPARATOR|Placebo|
62128755|NCT04771780|EXPERIMENTAL|KHK7791|"During the dosing period, subjects administer KHK7791 twice daily just before meals.Subjects will be underwent tests at scheduled visits at least weekly until Week 12, at least once every 2 weeks after completion of Week 12 test.~KHK7791 and phosphate binders are adjusted with the goal of controlling serum phosphorus concentration within a certain range based on the dose adjustment criteria described in the study protocol.It should be considered that phosphorus adsorbent should be switched to KHK7791 whenever feasible."
62128756|NCT02990754|EXPERIMENTAL|Intervention Group|Individuals attending one or more fearless physical activity events
62128757|NCT04372316|ACTIVE_COMPARATOR|methylcobalamin injection|
62128758|NCT04372316|ACTIVE_COMPARATOR|methylcobalamin tablet|
62318907|NCT04579055|ACTIVE_COMPARATOR|1-min STS test: chair seat height standardized of 46cm|In this experimental condition, the patient performs the 1-minute sit to stand test on a standard height chair of 46cm.
62318908|NCT00962065|EXPERIMENTAL|Low Dose|A low dose of LX4211; daily oral intake for 28 days
62318909|NCT00962065|EXPERIMENTAL|High Dose|A high dose of LX4211; daily oral intake for 28 days
62318910|NCT00962065|PLACEBO_COMPARATOR|Placebo|Matching placebo dosing with daily oral intake for 28 days
62480057|NCT04229225|EXPERIMENTAL|UBX0101 repeat dose (RD)|"Cohort 2 (n=18): UBX0101 4.0 mg or placebo IA at Weeks 0 and 4~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
62480058|NCT04923763||Tongue_examination|The general public will be invited for tongue examination. The data will be used to establish the automatic tongue video analysis system.
62318911|NCT04333433||MicroShunt treatment group|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 were implanted with the device
62318912|NCT04333433||Trabeculectomy control arm|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 underwent trabeculectomy procedure
62318913|NCT04716439||magnesium sulfate effect on IONM reading in spine surgery|one group receives magnesium other do not
62480059|NCT01246258||Test group|Standard tests of balance function
61925434|NCT04445116|EXPERIMENTAL|Endeavor™ Action Video Game Treatment|25 participants will fill out questionnaires and complete a neuropsychological evaluation. During study participation, participants will target using Endeavor™ action video game to complete 25-30 minutes at-home sessions 5 days a week for a total of 8 weeks via an iOS application.
62318914|NCT02058199|EXPERIMENTAL|normal subjects|A single dose of 10 mg of rivaroxaban will be administered
62128759|NCT04925336|EXPERIMENTAL|Experimental|Nociceptive intervention arm
62128760|NCT01932203|ACTIVE_COMPARATOR|aspirin|aspirin 100mg by mouth once a day for 104 weeks
62128761|NCT01932203|EXPERIMENTAL|Cilostazol|Pletaal SR 200mg by mouth once a day for 104 weeks
62128762|NCT03083067|EXPERIMENTAL|Salvational intervention(SI) group|Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.
62318915|NCT02058199|EXPERIMENTAL|Obese non bypassed|A single dose of rivaroxaban will be administered
62318916|NCT02058199|EXPERIMENTAL|obese bypassed|A single dose of rivaroxaban will be administered
62480060|NCT02081105|OTHER|PEEP 5|level of PEEP of 5 cm H2O randomly applied to the patient
62318917|NCT02058199|EXPERIMENTAL|pre and post bypassed subject|A single dose of rivaroxaban will be administered prior to gastric bypass. Subjects will be restudied 12 to 24 weeks following bypass
62318918|NCT00701740|ACTIVE_COMPARATOR|A|A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
62318919|NCT00701740|ACTIVE_COMPARATOR|B|11 subjects received only the same moisturizer/sunscreen
62318920|NCT05616065|EXPERIMENTAL|Blinded|Interviewers will be assigned a candidate to interview. They will be asked not to review the medical school transcripts or standardized test scores (USMLE, COMLEX). They will be permitted to review personal statements, letters or recommendation, and other personal information in the application.
62480061|NCT02081105|OTHER|PEEP 15|level of PEEP of 15 cm H2O randomly applied to the patient
62480062|NCT04243538|NO_INTERVENTION|Control arm|Standard of care.
62480063|NCT04243538|EXPERIMENTAL|I-HoME intervention|Weekly televisits with a nurse practitioner that will implement the I-HoME intervention.
62688128|NCT04321031|EXPERIMENTAL|PF-06865571 300 mg BID|participants will receive medication for 48 weeks
62688129|NCT04321031|EXPERIMENTAL|PF-06865571 (150 mg BID) + PF-05221304 (5 mg BID)|participants will receive medication for 48 weeks
61925435|NCT06077708|ACTIVE_COMPARATOR|D3K2 with periodontal therapy|Individuals given D3K2 with periodontal therapy were included in the test group.All serum and gingival crevicular fluid samples from individuals who underwent non-surgical periodontal treatment were taken again at 3rd and 6th months, and clinical periodontal measurements were recorded. Glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), 25(OH)D3, parathyroid hormone (PTH), calcium (Ca) and magnesium (Mg) values were determined in serum samples. GCF and serum IL-1ß and IL-10 values were analyzed by enzyme-linked immunosorbent analysis (ELISA).
61925436|NCT06077708|PLACEBO_COMPARATOR|Placebo with periodontal therapy|Individuals given placebo with periodontal therapy were included in the control group.All serum and gingival crevicular fluid samples from individuals who underwent non-surgical periodontal treatment were taken again at 3rd and 6th months, and clinical periodontal measurements were recorded. Glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), 25(OH)D3, parathyroid hormone (PTH), calcium (Ca) and magnesium (Mg) values were determined in serum samples. GCF and serum IL-1ß and IL-10 values were analyzed by enzyme-linked immunosorbent analysis (ELISA).
61925437|NCT00433654|ACTIVE_COMPARATOR|MRI group|The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
61925438|NCT00433654|OTHER|Control group|The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.
61925439|NCT04714359|EXPERIMENTAL|MDMA-assisted therapy|Three open-label sessions of MDMA-assisted therapy, each scheduled approximately 1 month apart, with initial dose of midomafetamine HCl of 80 or 120 mg and optional supplemental dose half that of initial dose (40 or 60 mg) 1.5 to 2 hours later
61925440|NCT01210287|NO_INTERVENTION|Observation|Observation of the HBV reactivation in HBsAg negative/HBcAg positive patients receiving RCHOP without prophylactic anti-HBV treatment.
61925441|NCT05403333|EXPERIMENTAL|Utidelone|Drug: utidelone Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
62128763|NCT03083067|ACTIVE_COMPARATOR|Control(CT) group|CT group maintain the original treatment
62128764|NCT06516328||healthy (H)|Periodontally and systemically healthy individuals
62128765|NCT06516328||Periodontitis (P)|Patients with periodontitis without diabetes
62128766|NCT06516328||Diabetic Periodontitis (DP) group|Periodontitis patients with diabetes under control (Glycosylated hemoglobin (HbA1c) value ≤ 6.5% and fasting blood sugar levels \<200 mg/dl.)
62128767|NCT06516328||Poorly controlled Diabetic Periodontitis group (PDP)|Periodontitis patients with uncontrolled diabetes HbA1c value \> 6.5% and fasting blood sugar levels \> 200 mg/dl.
62318921|NCT05616065|ACTIVE_COMPARATOR|Unblinded|Interviewers will be assigned a candidate to interview. They will be given full permission to review the full application of their candidate as per their normal interview protocol.
62318922|NCT06020859|EXPERIMENTAL|NaviEC-2000Pro Gastro Scan|NaviEC-2000Pro Gastro Scan is a new mode of NaviEC-2000Pro
62318923|NCT06020859|EXPERIMENTAL|NaviEC-2000Pro Routine gastric examination|NaviEC-2000Pro Routine gastric examination is a mode of NaviEC-2000Pro
62318924|NCT06020859|ACTIVE_COMPARATOR|NaviEC-1000 Routine gastric examination|NaviEC-1000 Routine gastric examination is a mode of NaviEC-1000
61925442|NCT01571024|EXPERIMENTAL|BKM120 + mFOLFOX6|BKM120 + mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.
61925443|NCT02531243|EXPERIMENTAL|CALMS|12 session family therapy using multi-user biofeedback games
61925444|NCT05716503|EXPERIMENTAL|Study group (A)|Study group (A): Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
61925445|NCT05716503|EXPERIMENTAL|Control group (B)|Control group (B): Will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
61925446|NCT02240290|EXPERIMENTAL|tozadenant|A single dose of 240 mg tozadenant (four 60 mg tablets) and a 74 kBq (2 μCi) 14C-labeled tozadenant capsule will be administered with 240 mL of water.
62128768|NCT04534400||Patients with SARS-CoV-2 infection|
62128769|NCT04534400||Patients with Postoperative hypoxemic respiratory failure|
62128770|NCT01525277||left subclavian vein|CVC implanted in the left subclavian vein
62128771|NCT01525277||right subclavian vein|CVC implanted in the right subclavian vein
62128772|NCT01239758|EXPERIMENTAL|ACE-031 (Extension of cohort 1 from core study, A031-03)|
62128773|NCT01239758|EXPERIMENTAL|ACE-031 (Extension of cohort 2 from core study, A031-03)|
62128774|NCT01239758|EXPERIMENTAL|ACE-031 (Extension of cohort 3 from core study, A031-03)|
62318925|NCT00273858||etanercept|Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC).
62318926|NCT03042013|EXPERIMENTAL|ASP8273|Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
62318927|NCT02706093|OTHER|High Intensity Interval Training #1|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
62318928|NCT02706093|OTHER|Moderate intensity continuous training|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
62318929|NCT02706093|OTHER|High Intensity Interval Training #2|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
62318930|NCT02706093|OTHER|High Intensity Interval Training #3|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
62688130|NCT04321031|EXPERIMENTAL|PF-06865771 (300 mg BID) + PF-05221304 (10 mg BID)|participants will receive medication for 48 weeks
62688131|NCT00983801|EXPERIMENTAL|Ixabepilone|
62318931|NCT02209233|NO_INTERVENTION|Control|If randomized to the control group, patients will not be receiving massage therapy.
62128775|NCT03380611|EXPERIMENTAL|Wakame|Subjects will receive capsules containing wakame
62128776|NCT03380611|EXPERIMENTAL|Spirulina|Subjects will receive capsules containing spirulina
62318932|NCT02209233|EXPERIMENTAL|Massage Therapy|If randomized to the intervention group, patients will receive massage therapy of the hand, arm, shoulder, and neck by the licensed massage therapist on duty. The massage will be given in a manner that is congruent with standard of care practices by the Heart and Surgical Hospital and the licensed massage therapist.
62318933|NCT00950612|EXPERIMENTAL|Group A|
62318934|NCT00950612|PLACEBO_COMPARATOR|Group B|
62318935|NCT04408092|EXPERIMENTAL|GM-CSF treatment at second-look surgery arm|Newly diagnosed patients with EPN who have a subtotal resection at initial presentation and are without evidence of metastatic tumor will be enrolled in this stratum. Total patient population in this stratum will be 10 patients. It should be noted that prior experience suggests that about 1/3 of newly presenting patients still have residual tumor after the initial surgery
62318936|NCT04408092|EXPERIMENTAL|GM-CSF treatment at recurrence arm.|"EPN patients with a first regional relapse and without evidence of metastatic tumor will be enrolled in this stratum. Total patient population will be 10 patients.~Patients with a first recurrence will have the recurrence confirmed by the local institutional neuro-radiologists. They will have the entire neuro-axis scanned and a spinal tap performed (where safe) to exclude metastatic tumor. They will then receive 5 days of GM-CSF and then proceed to surgery if deemed clinically indicated by the treating physician"
62480064|NCT05594693||Patients Referred by the Pain Service or Palliative Care Service|"Any CHCO patient referred for integrative interventions by the Pain Service or the Palliative Care Service.~Patients at CHCO include premature infants through young adults. Any of these patients could benefit from integrative treatments. The treatments will only be offered after medical team approval and parental consent. All treatments will be provided by credentialed and licensed providers and will follow CHCO approved policies and procedures."
62480065|NCT01811953|EXPERIMENTAL|1 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
62480066|NCT01811953|EXPERIMENTAL|2 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
62480067|NCT01811953|EXPERIMENTAL|3 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fasted conditions
62688132|NCT05757167|EXPERIMENTAL|HS-RDT screening/AL treatment|Pregnant women will be screened with a malaria HS-RDT and, if positive, treated with artemether-lumefantrine
62128777|NCT03380611|PLACEBO_COMPARATOR|Control|Subjects will receive capsules containing microcrystalline cellulose
62128778|NCT00741546||A|Patients referred for cardiac surgery intervention
62128779|NCT04225949|EXPERIMENTAL|line graph|
62128780|NCT04225949|ACTIVE_COMPARATOR|bar graph|
62128781|NCT03113266|EXPERIMENTAL|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
62128782|NCT06159569|EXPERIMENTAL|Population treated with LACRIACT|20 patients affected by dry eye who met the inclusion and exclusion criteria.. It is optional for the Investigator to recruit a sub-group of patients (maximum number 10 of 20 recruited patients) with regular soft contact lens that will be analysed separately.
62128783|NCT01858831|EXPERIMENTAL|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
62128784|NCT01858831|ACTIVE_COMPARATOR|Atovaquone 750 mg|Atovaquone 750 mg
62128785|NCT01858831|ACTIVE_COMPARATOR|Atovaquone 1500 mg|Atovaquone 1500 mg
62128786|NCT05492409|EXPERIMENTAL|GNR-069|Weekly subcutaneous injections of GNR-069 in the individually titrated dose.
62480068|NCT01811953|EXPERIMENTAL|4 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
62480069|NCT01811953|EXPERIMENTAL|5 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
62480070|NCT01811953|EXPERIMENTAL|6 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
62688133|NCT05757167|NO_INTERVENTION|Usual antenatal care|Pregnant women will receive usual antenatal care
61925447|NCT05551572||septic samples|patients undergoing revision surgery for prosthetic joint infection
62128787|NCT02742519|EXPERIMENTAL|Part 1-Sequence 1|ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
62128788|NCT02742519|EXPERIMENTAL|Part 1 - Sequence 2|placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
62128789|NCT02742519|EXPERIMENTAL|Part 2: ivacaftor|open label period
62128790|NCT06450496|EXPERIMENTAL|Bienestar Program|On-line positive parenting program
62128791|NCT06450496|NO_INTERVENTION|Control|Control group
62128792|NCT03336515|OTHER|Group A-General Recommendation|General recommendation not sleeping in supine position without the postural device
62318937|NCT00467909|EXPERIMENTAL|Hgh micronutrients, high n-3 fatty acid treatment Arm|High micronutrients, high n-3 fatty acid treatment The high micronutrient treatment provided 100% of the RDA of iodine, iron, riboflavin, vitamin B-6, vitamin B-12, folate, and vitamin A for children 7-9 y of age (25) (Table 1). To optimize the bioavailability of iron, zinc was provided at 92% of the RDA based on a molar ratio of 2 (iron) to 1 (zinc), vitamin C was provided at 650% of the RDA based on a molar ratio of 4 (vitamin C) to 1 (iron) and, calcium was provided at 33% of the RDA to minimize possible inhibition of iron absorption (26., 27., 28.).
62128793|NCT03336515|PLACEBO_COMPARATOR|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
62128794|NCT03336515|EXPERIMENTAL|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
62128795|NCT00254657|PLACEBO_COMPARATOR|Placebo|
62128796|NCT00254657|EXPERIMENTAL|Levetiracetam|
62128797|NCT00111813|EXPERIMENTAL|vorinostat 200 mg + bortezomib 0.7 mg/m^2|Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
62128798|NCT00111813|EXPERIMENTAL|vorinostat 200 mg + bortezomib 0.9 mg/m^2|Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
62128799|NCT00111813|EXPERIMENTAL|vorinostat 300 mg + bortezomib 1.3 mg/m^2|Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
62128800|NCT00111813|EXPERIMENTAL|vorinostat 400 mg + bortezomib 0.9 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
62128801|NCT00111813|EXPERIMENTAL|vorinostat 400 mg + bortezomib 1.1 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
62128802|NCT00111813|EXPERIMENTAL|vorinostat 400 mg + bortezomib 1.3 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
62128803|NCT03427632||percutaneous Vertebroplasty|patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)
62128804|NCT03754959|EXPERIMENTAL|Dose Group 1|
62128805|NCT03754959|EXPERIMENTAL|Dose Group 2|
62128806|NCT03754959|EXPERIMENTAL|Dose Group 3|
62318938|NCT00467909|EXPERIMENTAL|low micronutrients, high n-3 fatty acid treatment|low micronutrients, high n-3 fatty acid treatment The low micronutrient treatment delivered micronutrients per kcal proportional to that consumed by the children in their habitual diet (S Muthayya, 2006, unpublished observations). This amounted to 15% of the RDA provided in 420 kcal. The high n-3 treatment provided 900 mg ALA, which is 50% of the recommended intake of ALA for children aged 2-12 y (29), and 100 mg DHA, which corresponds with ≈50% of the recommended fish intake for children
62318939|NCT00467909|EXPERIMENTAL|low micronutrients, low n-3 fatty acid treatment.|low micronutrients, low n-3 fatty acid treatment. The low micronutrient treatment delivered micronutrients per kcal proportional to that consumed by the children in their habitual diet (S Muthayya, 2006, unpublished observations). This amounted to 15% of the RDA provided in 420 kcal. The high n-3 treatment provided 900 mg ALA, which is 50% of the recommended intake of ALA for children aged 2-12 y (29), and 100 mg DHA, which corresponds with ≈50% of the recommended fish intake for children
62480071|NCT05434364|EXPERIMENTAL|Facilitated Tucking|giving facilitated tucking before, during and after the procedure
62480072|NCT05434364|EXPERIMENTAL|Swaddling|giving swaddling before, during and after the procedure
62480073|NCT05434364|EXPERIMENTAL|Prone position|giving prone position before, during and after the procedure
62128807|NCT03754959|EXPERIMENTAL|Dose Group 4|
62128808|NCT03754959|EXPERIMENTAL|Dose Group 5|
62128809|NCT00529100|EXPERIMENTAL|Pemetrexed/Cisplatin/Radiation Phase 1|Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m\^2) IV through 500 mg/m\^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m\^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m\^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m\^2 IV and cisplatin 75 mg/m\^2 IV.
62128810|NCT00529100|EXPERIMENTAL|Pemetrexed/Cisplatin/Radiation Phase 2|Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m\^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m\^2 IV and cisplatin 75 mg/m\^2 IV.
61925448|NCT05551572||aseptic samples|patients undergoing revision surgery for prosthetic replacement without infection
61925449|NCT00882219|EXPERIMENTAL|Xience V®|
62480074|NCT05434364|NO_INTERVENTION|control|Rutin care in the neonatal intensive care unit
62688134|NCT01681849|EXPERIMENTAL|Paroxetine Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive paroxetine for a three month period followed by an open label phase of three months.
62128811|NCT00544752|EXPERIMENTAL|16|indoor temperature of 16 degrees celcius
62128812|NCT00544752|EXPERIMENTAL|20|indoor temperature 20 degrees celcius
62128813|NCT00544752|EXPERIMENTAL|24|indoor temperature of 24 degrees celcius
62318940|NCT00467909|EXPERIMENTAL|high micronutrients, low n-3 fatty acid treatment|high micronutrients, low n-3 fatty acid treatment The high micronutrient treatment provided 100% of the RDA of iodine, iron, riboflavin, vitamin B-6, vitamin B-12, folate, and vitamin A for children 7-9 y of age (25) (Table 1). To optimize the bioavailability of iron, zinc was provided at 92% of the RDA based on a molar ratio of 2 (iron) to 1 (zinc), vitamin C was provided at 650% of the RDA based on a molar ratio of 4 (vitamin C) to 1 (iron) and, calcium was provided at 33% of the RDA to minimize possible inhibition of iron absorption (26., 27., 28.).
62688135|NCT01681849|PLACEBO_COMPARATOR|Placebo Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive placebo for a three month period followed by an open label phase of paroxetine for three months.
62688136|NCT01681849|OTHER|PTSD Negative|Women who have experienced early childhood abuse and do not have PTSD will serve as a control group and complete baseline assessments. They do not undergo intervention therefore they are assessed at baseline only.
62688137|NCT02748174|EXPERIMENTAL|Episodic Migraine group|100 patients with chronic or episodic migraine
62688138|NCT02748174|EXPERIMENTAL|Chronic Migraine Group|100 patients with chronic or episodic migraine
62688139|NCT02748174|EXPERIMENTAL|Post concussive Headache Group|75 patients
62688140|NCT04854317|ACTIVE_COMPARATOR|Patients undergoing Endoscopic Sleeve Gastroplasty|Obese patients with I, II, and III grade of obesity (BMI 30-44.99 kg/m2) and previous failed attempts of diet.
62688141|NCT04854317|ACTIVE_COMPARATOR|Patients undergoing Endoluminal Vertical Gastroplasty|Obese patients with I, II, and III grade of obesity (BMI 30-44.99 kg/m2) and previous failed attempts of diet.
62688142|NCT04854317|ACTIVE_COMPARATOR|Patients undergoing Primary Obesity Surgical Endolumenal 2|Obese patients with I, II, and III grade of obesity (BMI 30-44.99 kg/m2) and previous failed attempts of diet.
62688143|NCT00982579|EXPERIMENTAL|Vaccinees|Vaccinated at 20 weeks of age (n=24)
62688144|NCT00982579|NO_INTERVENTION|Controls|No experimental vaccine (n=24)
62688145|NCT06639555|ACTIVE_COMPARATOR|PRP alone|
62688146|NCT06639555|ACTIVE_COMPARATOR|EMD Alone|
62688147|NCT06639555|ACTIVE_COMPARATOR|GTR (barrier membrane)|
62688148|NCT06639555|ACTIVE_COMPARATOR|GTR(barrier membrane and PRP)|
62688149|NCT02486770|EXPERIMENTAL|Group 1|Aerucin 2.0mg/kg
62688150|NCT02486770|EXPERIMENTAL|Group 2|Aerucin 8.0mg/kg
62688151|NCT02486770|EXPERIMENTAL|Group 3|Aerucin 20.0mg/kg
62688152|NCT04147169||Dying patients|Dying patients admitted to the Intensive Care Unit who are approaching end-of-life.
62688153|NCT06399692|OTHER|RECHARGE:Women - CABG|
62128814|NCT03795194|OTHER|8-day|8-day course of ampicillin clavulanate antibiotic
62128815|NCT03795194|OTHER|4-day|4--day course of ampicillin clavulanate antibiotic
62128816|NCT01622868|EXPERIMENTAL|Arm A (WBRT or SRS)|Patients undergo WBRT 5 days a week for 3 weeks for a total of 15 treatments, or SRS for 1 treatment.
62128817|NCT01622868|EXPERIMENTAL|Arm B (lapatinib ditosylate, WBRT or SRS)|Patients undergo WBRT or SRS as in Arm A. Patients also receive lapatinib ditosylate PO QD for 6 weeks.
62688154|NCT06399692|OTHER|RECHARGE:Women - PCI|
62688155|NCT03607500|EXPERIMENTAL|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
62688156|NCT03607500|NO_INTERVENTION|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
62688157|NCT02980185||Laparoscopic primary cytoreduction|Patients in whom primary cytoreduction was performed using a laparoscopic approach
62688158|NCT02980185||Abdominal primary cytoreduction|Patients in whom primary cytoreduction was performed using an open abdominal approach
62688159|NCT04804033|ACTIVE_COMPARATOR|BHV-3500 200mg|Zavegepant 200mg oral soft gel capsule.
62688160|NCT04804033|PLACEBO_COMPARATOR|Placebo 200mg|Matching placebo 200mg oral soft gel capsule.
62688161|NCT04804033|ACTIVE_COMPARATOR|BHV-3500 100mg|Zavegepant 100mg oral soft gel capsule.
62688162|NCT04804033|PLACEBO_COMPARATOR|Placebo 100mg|Matching placebo 100mg oral soft gel capsule.
62688163|NCT05274698|EXPERIMENTAL|Group A (Experimental group):|This group includes 30 patients with adhesive capsulitis who will receive muscle energy techniques 1 session per day, 5 days a week for 8 weeks in addition to their conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises).
62688164|NCT05274698|OTHER|Group B (Control group):|This group includes 30 patients with adhesive capsulitis who will receive their conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.
62688165|NCT06683248|EXPERIMENTAL|Sleep deprivation|All participants will undergo an 8-hour sleep opportunity, immediately followed by a night of total sleep deprivation.
62688166|NCT02688335|EXPERIMENTAL|Cloud9 Snoring Treatment|Snoring participants will be instructed to use the device as much as possible for 2 weeks.
62128818|NCT06347575|EXPERIMENTAL|Implantation of the caverStim device|Implantation of caverStim in SCI patients
62688167|NCT06570915|EXPERIMENTAL|Daratumumab|Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 dosing patterns) in one cycle. Patients with conditions may use up to two cycles of treatment.
62318941|NCT05915819|EXPERIMENTAL|Plyometric Training|"This group will trained with Plyometric training This training of this group will be Plyometric in which many exercises of both region upper extremity and lower extremity guided to weightlifter for assessment of functional performance. Before starting the plyometric training the trainer will perform a traditional exercise like push-ups or cycling for warmup, 5-10minutes. In plyometric training the exercise we will focus all over the body fitness, The exercise prescription according to weeks, sets and repetition.~sessions will be 6 days a week 6 weeks training sessions"
62318942|NCT05915819|EXPERIMENTAL|Eccentric Training|"This group will Trained with Eccentric muscle training Before starting the eccentric heavy load exercise trainers will perform warm up exercise then we will continue training.~Sessions will be 6 days a week 6 weeks training sessions"
62318943|NCT02110134|EXPERIMENTAL|Revlite Laser System with Topical|Revlite Laser System for the Treatment of Melasma and hydroquinone skin care regimen
62318944|NCT02110134|ACTIVE_COMPARATOR|Topical|Hydroquinone skin care regimen
62318945|NCT02434315|ACTIVE_COMPARATOR|Group A - Control|FreeStyle Libre Pro 3 sensor wears
62318946|NCT02434315|EXPERIMENTAL|Group B - Intervention|FreeStyle Libre Pro 4 sensor wears, 2 with reviews
62318947|NCT02434315|EXPERIMENTAL|Group C - Intervention|FreeStyle Libre Pro 6 sensor wears, 4 with reviews
62688168|NCT04010838|NO_INTERVENTION|Conventional treatment|
62318948|NCT03025191|EXPERIMENTAL|Prison Connect|
62318949|NCT04349995||Amplatzer PFO Occluder|Percutaneous PFO Closure using Amplatzer PFO occluder
62318950|NCT05090410|EXPERIMENTAL|Filgotinib monotherapy|The administration of filgotinib 200mg/day switched from MTX ± other csDMARDs throughout the study period.
62318951|NCT05090410|ACTIVE_COMPARATOR|Tocilizumab monotherapy|The administration of subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
62318952|NCT02625142|EXPERIMENTAL|Family-centered rounds checklist|"During the post-intervention period, health care team members on two pediatric inpatient services received the Family-centered Rounds Checklist tool, as well as training in how to use the checklist in the delivery of effective family-centered rounds"
62688169|NCT04010838|EXPERIMENTAL|Spinal cord stimulation and conventional treatment|
62688170|NCT05802537|EXPERIMENTAL|Experimental group|Participants in the experimental group engaged in a home-based exergame program for 50 minutes per session, three times per week, for eight weeks. The program focused on enhancing lower extremity strength and balance.
62688171|NCT05802537|ACTIVE_COMPARATOR|Control group|The control group participated in weekly online education sessions for 50 minutes over an eight-week period. The topics covered included fall prevention, musculoskeletal health, aging, and fracture risks. No physical exercise intervention was given.
62688172|NCT06669208|EXPERIMENTAL|Low Dose|20 subjects will receive 2.5 mcg intramuscularly (IM) of HydroVax-005 CHIKV on Days 1 and 29
62688173|NCT06669208|EXPERIMENTAL|High Dose|20 subjects will receive 8 mcg intramuscularly (IM) of HydroVax-005 CHIKV on Days 1 and 29
62688174|NCT06669208|PLACEBO_COMPARATOR|Placebo|8 subjects will receive normal saline placebo intramuscularly (IM) on Days 1 and 29
62688175|NCT02096380||one cycle induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
62688176|NCT02096380||three cycles induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
62688177|NCT02197065|EXPERIMENTAL|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
62688178|NCT02197065|PLACEBO_COMPARATOR|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
62688179|NCT06686992|EXPERIMENTAL|distraction|The researcher will fill in the questionnaire and scales 5 minutes before the vaccination. During the procedure, the child will be played with roll-and-draw. The scales will be filled in again 5 minutes after the procedure. It will take an average of 5-10 minutes to fill out the forms.
62318953|NCT02625142|NO_INTERVENTION|Usual care|Two pediatric inpatient services were not provided the Family-centered rounds checklist tool, and delivered morning rounds in their usual manner. These services served as a control.
62318954|NCT04547244||T2DM patients with CRTd with automatic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an automatic optimization of CRTd.
62318955|NCT04547244||T2DM patients with CRTd with echocardiographic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an echocardiography guided optimization of CRTd.
62688180|NCT06686992|NO_INTERVENTION|control|Questionnaires and scales will be filled out by the researcher 5 minutes before vaccination. Only routine applications will be made. The scales will be filled again 5 minutes after vaccination.
62688181|NCT00885898|ACTIVE_COMPARATOR|1|"Non-invasive ventilation"
62688182|NCT00885898|ACTIVE_COMPARATOR|2|"Conventional"
62688183|NCT06590428|OTHER|Therapeutic Drug Monitoring (TDM)|Participants in the TDM arm will have their linezolid dose reduced if their trough concentration is greater than 2.5 mg/L
62318956|NCT04138524|EXPERIMENTAL|interventional|All the participants will received the full SAFIR. SAFIR is composed with 5 core components: 1) assessment of the family, 2) emotional support, 3) information, 4) family engagement, 5) care coordination. Each family will participate in 3 structured family meetings, with a follow-up at 30 days. During each meeting, every core component will be delivered but their dose will be adapted following the priorities of the families.
62128819|NCT04350541|EXPERIMENTAL|Interval training|Interval training will consist of 10 minutes of warm-up between 40-50% of the peak oxygen consumption (VO2peak), followed by four to six repetitions of three-minute intervals between 80-90% of VO2peak and three minutes between 40-50% VO2peak and finally, five minutes of cooling down between 30-40% of VO2peak.
62128820|NCT04350541|ACTIVE_COMPARATOR|Continuous training|The continuous aerobic training will consist of 10 minutes of warm-up with intensity between 40 and 50% of VO2peak, 20 minutes of conditioning between 60 and 70% of VO2peak and 5 minutes of cooling down between 30 and 40% of VO2peak.
62128821|NCT04556539|EXPERIMENTAL|SC10914 group|
62318957|NCT02538666|EXPERIMENTAL|Nivolumab monotherapy|Nivolumab intravenous fusion
62318958|NCT02538666|EXPERIMENTAL|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
61925450|NCT02615925|OTHER|Psychiatry Consultation|Psychiatry Consultation, it is proposed by one of the investigators, patients that clinical data from this psychiatric examination, conducted as part of their usual care, are recorded as part of the research that their is proposed and explained. An information note is then distributed and not collected their opposition
61925451|NCT05946265|EXPERIMENTAL|Intervention group|Intervention Group - RAR + FBM (n=56): The researcher responsible for FBM will remove the randomization envelope and apply Laser Therapy XP. All dosimetric parameters, details of sessions, and the number of FBM applications are presented in the project.
61925452|NCT05946265|PLACEBO_COMPARATOR|Control Group|Control Group - RAR + FBM simulation (n=56): Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention. The study flowchart presents the details of the project
61925453|NCT03719768|EXPERIMENTAL|Avelumab and Whole Brain Radiotherapy|Avelumab 800 mg intravenously (IV) and 3000 centriGray units (cGy) Whole Brain Radiotherapy once every 2 weeks
61925454|NCT04129502|EXPERIMENTAL|TAK-788 Group (Arm A)|TAK-788 160 milligram (mg) with or without food, capsules, orally, once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
61925455|NCT04129502|ACTIVE_COMPARATOR|Platinum-based Chemotherapy Group (Arm B)|Pemetrexed 500 milligram per meter square (mg/m\^2) plus cisplatin 75 mg/m\^2, infusion, IV, once on Day 1 of 21-day cycle pemetrexed 500 mg/m\^2 plus carboplatin, infusion, IV, once at a dose calculated to produce area under curve (AUC) of 5 milligram\*minute per milliliter (mg\*min/mL) on Day 1 of 21-day cycle until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria. Pemetrexed/cisplatin or pemetrexed/carboplatin will be repeated every 3 weeks for 4 cycles, followed by maintenance treatment with pemetrexed 500 mg/m\^2, on Day 1 of a 21-day cycle thereafter.
61925456|NCT05328115|ACTIVE_COMPARATOR|ALZ-101 125 μg|Intramuscular injection of 125 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
61925457|NCT05328115|ACTIVE_COMPARATOR|ALZ-101 250 μg|Intramuscular injection of 250 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
61925458|NCT05328115|PLACEBO_COMPARATOR|Placebo|Intamuscular Saline solution mixed adjuvant and dosed once a month at four doses
61925459|NCT05328115|ACTIVE_COMPARATOR|ALZ-101 400 μg|Intramuscular injection of 400 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
61925460|NCT06481176|EXPERIMENTAL|Exercise|Participants will complete a 12-week, RLS specific exercise program including strength training, cardiovascular exercise, and stretching.
61925461|NCT06481176|NO_INTERVENTION|Non-Exercise|Participants will have no intervention or interaction for 12 weeks.
62128822|NCT00802464|EXPERIMENTAL|GSK1437173A formulation 1 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
62128823|NCT00802464|EXPERIMENTAL|GSK1437173A formulation 2 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
62128824|NCT00802464|EXPERIMENTAL|GSK1437173A formulation 3 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
62128825|NCT00802464|PLACEBO_COMPARATOR|Control Group|Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
62318959|NCT02538666|PLACEBO_COMPARATOR|Placebo|Placebo
61925462|NCT05440708|EXPERIMENTAL|Cohort A: TTI-101 as a Single Agent|"Cohort A Phase 1b: Participants will receive various dose levels of TTI-101 as a single agent to determine the RP2D.~Cohort A Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 as a single agent."
61925463|NCT05440708|EXPERIMENTAL|Cohort B: TTI-101 in Combination with Pembrolizumab|"Cohort B Phase 1b: Participants will receive various dose levels of TTI-101 in combination with pembrolizumab to determine the RP2D.~Cohort B Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 in combination with pembrolizumab."
62480075|NCT06361407|EXPERIMENTAL|effect of trajectory perturbation|All participants will run the task consisting in 2 squares moving towards each other. On each trial they will answer whether the squares touch or do not touch. All participants are tested with all experimental conditions. The rate of 'touch' responses will be compared when there is a trajectory perturbation without rebound vs. a trajectory with perturbation with rebound vs. a trajectory without perturbation and without rebound vs. a trajectory without perturbation and with rebound.
62480076|NCT00919113|EXPERIMENTAL|8 weekly bladder instillations of Uracyst|20 mL Uracyst (2% sodium chondroitin sulfate) per instillation; 8 instillations over a 7-week period
62128826|NCT05938166|EXPERIMENTAL|experimental group (EG)|Behavioral: The EG will receive augmented reality (AR) simulation training intervention with traditional classroom oral health education.
62128827|NCT05938166|NO_INTERVENTION|Control group (CG)|The CG only receive traditional classroom oral health education.
62128828|NCT02574455|EXPERIMENTAL|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable adverse events (AEs).
61925464|NCT05440708|EXPERIMENTAL|Cohort C: TTI-101 in Combination with Atezolizumab and Bevacizumab|"Cohort C Phase 1b: Participants will receive various dose levels of TTI-101 in combination with atezolizumab and bevacizumab to determine the RP2D.~Cohort C Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 in combination with atezolizumab and bevacizumab."
61925465|NCT00364130|ACTIVE_COMPARATOR|Active Low Magnitude Mechanical Stimulus|Active Low Magnitude Mechanical Stimulus
61925466|NCT00364130|PLACEBO_COMPARATOR|Inactive Low Magnitude mechanical Stimulus|Inactive, or placebo low magnitude mechanical stimulus
61925467|NCT01604759|OTHER|Polarized probe measurement.|All patients belong under this arm as all will be measured by the polarized probe and the data will be compared to the biopsy site's pathology results.
61925468|NCT01668927|EXPERIMENTAL|tetracycline/furazolidone|one of the four empirical rescue therapies
61925469|NCT01668927|EXPERIMENTAL|amoxicillin/tetracycline|one of the four empirical rescue therapies
61925470|NCT01668927|EXPERIMENTAL|amoxicillin/furazolidone|one of the four empirical rescue therapies
61925471|NCT01668927|ACTIVE_COMPARATOR|tetracycline /metronidazole|Classical rescue therapy
62318960|NCT05663086|EXPERIMENTAL|Low-dose vaccine|30μg LYB001 is to be used in the clinical trial. The number of each arm is 60.
62480077|NCT00919113|PLACEBO_COMPARATOR|8 weekly bladder instillations of inactive control|20 mL inactive control buffer (phosphate-buffered saline); 8 instillations over a 7-week period
62480078|NCT03547271|EXPERIMENTAL|Group 1|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and measles, mumps, and rubella \[MMR\] vaccine) at 2, 4 and 12 to 18 months of age
62688184|NCT06590428|NO_INTERVENTION|Standard of Care (SOC)|Participants in the SOC arm will have their linezolid adjusted or held if they develop clinical adverse events.
62128829|NCT02574455|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.
62128830|NCT04368312||Health care providers/hospital staff|The targeted group are doctors and nurses (hospital stuff) of a large university hospital directly confronted with patients with Cov-19
62128831|NCT02317874|EXPERIMENTAL|Schedule A (7-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-7, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
62480079|NCT03547271|ACTIVE_COMPARATOR|Group 2|Licensed meningococcal vaccine (Nimenrix®), 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV- HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
62480080|NCT03547271|EXPERIMENTAL|Group 3|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
62480081|NCT03547271|EXPERIMENTAL|Group 4|MenACYW conjugate vaccine, 4 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4, and 12 to 18 months of age and administered alone at 6 months of age
62480082|NCT05634369|EXPERIMENTAL|Treatment|"Part 1: Enrollment of 5 patients in each cohort (osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and non-rhabdomyosarcoma).~Part 2: Enrollment of 2 cohorts in 2 stages for a total of 40 patients."
62480083|NCT04290546|EXPERIMENTAL|Cohort I without Ipilimumab Lead in|"Haploidentical donor derived CIML NK cell infusion with subcutaneous N-803 for eligible patients with platinum-refractory and immune checkpoint blockade-refractory, advanced head and neck squamous cell carcinoma (Cohort 1)~* CIML NK cell infusion (Dose 0 or -1) infused on Day 0.~* Interleukin-15 Superagonist dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles)."
62318961|NCT05663086|EXPERIMENTAL|High-dose vaccine|60μg LYB001 is to be used in the clinical trial. The number of each arm is 60.
62318962|NCT05663086|ACTIVE_COMPARATOR|Positive control|Positive-controlled vaccine is to be used in the clinical trial. The number of each arm is 60.
62318963|NCT03074448|ACTIVE_COMPARATOR|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
62318964|NCT03074448|EXPERIMENTAL|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
62318965|NCT05953740|EXPERIMENTAL|Panel A|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 at a specified Dose 1 or a dose matched placebo (Period 2).
62318966|NCT05953740|EXPERIMENTAL|Panel B|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 2 or a dose matched placebo (Period 2).
62318967|NCT05953740|EXPERIMENTAL|Panel C|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 3 or a dose matched placebo (Period 2).
62318968|NCT05953740|EXPERIMENTAL|Panel D|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 4 or a dose matched placebo (Period 2).
62318969|NCT05953740|EXPERIMENTAL|Panel E|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 5 or a dose matched placebo (Period 2).
62318970|NCT05953740|EXPERIMENTAL|Panel F|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 6 or a dose matched placebo (Period 2).
62318971|NCT03579875|EXPERIMENTAL|Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP in patients with Fanconi Anemia|"Given to:~* Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR~* Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia"
62318972|NCT03579875|EXPERIMENTAL|Treatment Plan 2: CY, FLU and MP in patients with Fanconi Anemia|"Given to:~• HLA-identical sibling donor recipients with aplastic anemia"
62318973|NCT03579875|EXPERIMENTAL|Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia|"Given to:~* Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI~* Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia who cannot tolerate TBI~* Per treating physician preference"
62318974|NCT03579875|EXPERIMENTAL|Treatment Plan 4: CY, FLU, and alemtuzumab|"given to TBD patients with:~* Bone marrow failure AND~* Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 3 patients would be treated per year. Statistical outcomes will be descriptive."
62318975|NCT03579875|EXPERIMENTAL|Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab.|"given to TBD patients with:~* Early MDS features (with or without cytogenetic abnormalities) AND~* Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 2 patients would be treated per year. Statistical outcomes will be descriptive."
62318976|NCT00798967|EXPERIMENTAL|Teduglutide|0.05 mg/kg/day sc dose of teduglutide
62480084|NCT04290546|EXPERIMENTAL|Cohort 2 with Ipilimumab Lead In|"Cohort 2 treated with an ipilimumab lead-in prior to CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone.~* Participants in the ipilimumab subgroup (Cohort 2) will receive a single dose of lead-in ipilimumab via iv per protocol determined dose followed by lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.~* CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0~* Interleukin-15 Superagonist (N-803) Administration~  -- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~* Cohort 2 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
62318977|NCT00798967|PLACEBO_COMPARATOR|Placebo|Matching subcutaneous dose of placebo to teduglutide
62318978|NCT02551367|EXPERIMENTAL|letrozole|patients receive letrozole 2.5 mg twice daily from day 2 to day 6 of the cycle , for 3 consecutive cycles, hcg hormone10.000 iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound.
62318979|NCT02551367|ACTIVE_COMPARATOR|clomiphene citrate|patients will receive clomiphene citrate 50 mg twice daily from day 2 to day 6 of the cycle for 3 consecutive cycles , hcg 10.000 hormone iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound .
62318980|NCT05296421|EXPERIMENTAL|Basic science (uniformly-labeled [13C]glucose)|Patients receive uniformly-labeled \[13C\]glucose IV over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care.
62318981|NCT03690622|SHAM_COMPARATOR|BSS|Balanced salt solution
62318982|NCT03690622|ACTIVE_COMPARATOR|Dexmedetomidine|dexmedetomidine (0.0055%)
62318983|NCT05443958||Seizure free group|
62318984|NCT05443958||Not seizure free group|
62318985|NCT05650450||Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)|
62688185|NCT00548691|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
62688186|NCT00548691|ACTIVE_COMPARATOR|Standard Medical Care (SMC)|SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
62688187|NCT02769481|ACTIVE_COMPARATOR|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
62318986|NCT05715541|OTHER|Comparison of INR Control and Drug Compliance Values by Groups|"Follow-up of the patients in the control group continued in the outpatient clinic.~This application includes an interface where patients can enter drug treatment information such as INR values, disease diagnosis, how many times a day and how many mg they take, and a chat box section where they can communicate with their physicians, including emergencies. The doctor reviewed the patient's INR findings once they were relayed by the patient, then told them to adjust the patient's warfarin dosage and schedule the next INR check. The application sent notifications to the patients every day about when and how many mg of the drug they would take"
62318987|NCT03158649|EXPERIMENTAL|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
62318988|NCT03158649|NO_INTERVENTION|Waiting List condition|Waiting List control condition
62318989|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
62480085|NCT04290546|EXPERIMENTAL|Cohort 3 with Cetuximab Infusions|"Cohort 3 treated with CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone, followed by cetuximab infusions.~* - Participants in cetuximab subgroup (Cohort 3) will receive lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.~* CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0~* Interleukin-15 Superagonist (N-803) Administration~  -- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~* Cetuximab Administration~  --dosed at 500mg/m2 IV over 120 minutes for the first dose, then over 60 minutes for subsequent doses. This will be infused every 14 days for 8 doses started on day +15.~* Cohort 3 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
62318990|NCT01220310|EXPERIMENTAL|Intervention|Online diabetes workshop observation and learning sessions
62688188|NCT02769481|ACTIVE_COMPARATOR|Glimepiride|Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
62318991|NCT03684161||Surgically closed VSDs|Patients born with a ventricular septal defect, which have been closed in early childhood.
62318992|NCT03684161||Small, persistent VSDs|Patients born with a small, hemodynamically insignificant ventricular septal defect.
62688189|NCT01171079|EXPERIMENTAL|Interceed|
62688190|NCT04187404|EXPERIMENTAL|5-cohort study design|"Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.~Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401in combination with nivolumab in 33 patients with adrenal carcinoma.~Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 combination with nivolumab in 20 patients (globally for both Cohorts 3A and 3B) with progressive malignant pheochromocytoma/ paraganglioma."
61925472|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
62318993|NCT03684161||Healthy controls|Healthy control subjects.
62480086|NCT05722184||CNHU-HKM|BactInsight system compared to BacT/ALERT® 3D
62480087|NCT05722184||Hôpital Saint Jean de Dieu, Boko|BactInsight system compared to manual blood culture system (visual inspection)
62480088|NCT05722184||Centre Hospitalier Universitaire Yalgado Ouédraogo|BactInsight system compared to BacTec FX40
62480089|NCT05628545|EXPERIMENTAL|GDKM-100 injection|"In this trial, the patients will receive multiple high-activity γδ T cell immunotherapies.The trial is divided into two parts: Part 1 is a multiple-dose escalation trial consisting of 3 dose groups (2×10\^8 cells/person, 5×10\^8 cells/person, 10×10\^8 cells/person at 1-3 infusion, 4-6 infusion and 7-9 infusion), with 9 patients planned to be enrolled. Part 2 is a single dose trial in which doctor and the PI evaluates whether to give the rest patients to receive the 10×10\^8 cells/person infusions based on available safety data.~The check indexes are CT scan，intestinal flora detection and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62480090|NCT05108948||Spinal deformity operated patients|
62480091|NCT01463423|EXPERIMENTAL|Limited Primary Non-small Cell Lung Cancer (NSCLC)|Participants with limited primary NSCLCs (graded as T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0)
62480092|NCT01463423|EXPERIMENTAL|History of NSCLC|Participants with prior history of NSCLC and new limited primary NSCLC lesion(s)
62480093|NCT01463423|EXPERIMENTAL|Advanced Lung Cancer Including Metastatic Lung Cancer|Participants with more advanced lung cancer or lung metastases from a variety of different cancers.
62480094|NCT05450692|EXPERIMENTAL|Group A: Ceralasertib plus durvalumab combination therapy|Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.
62480095|NCT05450692|ACTIVE_COMPARATOR|Group B: Docetaxel monotherapy|Participants will be administered docetaxel (standard of care) administered intravenously.
62480096|NCT06561659|ACTIVE_COMPARATOR|Exercise Condition|For participants randomized to the exercise intervention, they will complete 30 minutes of brisk walking around the campus. They will be asked to maintain at least a moderate level of exercise intensity throughout the 30-minute walk.
62480097|NCT06561659|OTHER|Relaxation Control Condition|For participants randomized to the control group, they will sit in the testing room and watch informational videos about animals.
62480098|NCT06730919||Systemic autoimmune disease|Women with systemic autoimmune diseases who underwent cesarean delivery.
62480099|NCT06730919||Non-systemic autoimmune disease|Women without systemic autoimmune diseases who underwent cesarean delivery.
62688191|NCT04187404|EXPERIMENTAL|randomized extension of Cohort 2A (3 arms): C2A-I|Randomized extension of Cohort 2A (65 patients using a 4:1:1 ratio): 43 patients belonging to this extension of Cohort 2A will be treated by EO2401 and nivolumab in combination.
61925473|NCT05279053||Male|
62318994|NCT06111326|EXPERIMENTAL|BC3402+Durvalumab|Subjects will receive BC3402 and Durvalumab in a treatment cycle.
62318995|NCT01594476|EXPERIMENTAL|Levonorgestrel IUS insertion at 3 weeks|IUD placement at 3 weeks after delivery.
62318996|NCT01594476|EXPERIMENTAL|Levonorgestrel IUS insertion at 6 weeks|IUD placement at 6 weeks after delivery.
62318997|NCT00403117|PLACEBO_COMPARATOR|Placebo, Marijuana (0% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62318998|NCT00403117|EXPERIMENTAL|Placebo, Marijuana (3.27% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62318999|NCT00403117|EXPERIMENTAL|Naltrexone (12mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62319000|NCT00403117|EXPERIMENTAL|Naltrexone (12mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62319001|NCT00403117|EXPERIMENTAL|Naltrexone (25mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62319002|NCT00403117|EXPERIMENTAL|Naltrexone (25mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62480100|NCT06273124|EXPERIMENTAL|SteadiSet Extended Wear Infusion Set|Each participant will be asked to wear the Investigational Extended Wear Infusion Set for up to 168 hours for 12 consecutive wear periods with the Tandem t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 or G7 sensor.
61925474|NCT05279053||Female|
61925475|NCT00688727|EXPERIMENTAL|1|Cognitive behavioural Therapy
61925476|NCT00688727|ACTIVE_COMPARATOR|2|Standard Care
61925477|NCT06463678|EXPERIMENTAL|IVIEW-1201|
61925478|NCT06463678|ACTIVE_COMPARATOR|NATACYN®|
62319003|NCT00403117|EXPERIMENTAL|Naltrexone (50mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62319004|NCT00403117|EXPERIMENTAL|Naltrexone (50mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62319005|NCT00403117|EXPERIMENTAL|Naltrexone (100mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62319006|NCT00403117|EXPERIMENTAL|Naltrexone (100mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
62319007|NCT03610971|EXPERIMENTAL|Combination Therapy + Remission Phase|"Combination therapy followed by treatment free remission (TFR) phase.~Combination Therapy: Ruxolitinib plus BCR-ABL Tyrosine Kinase Inhibitors (TKIs).~All eligible patients will begin ruxolitinib in combination with their BCR-ABL TKI on cycle 1 day 1 of the combination phase. For cycle 2 and beyond, if day 1 of a cycle is delayed, day 1 procedures should be repeated if out of the specified window and day 1 of the cycle is considered the day study drug is restarted. They will continue combination therapy for a total of 12 cycles. Each cycle will be approximately 28 days.~At the end of 12 cycles ruxolitinib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, participants will discontinue their BCR-ABL TKI and be monitored off treatment."
62480101|NCT03490864|EXPERIMENTAL|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
62480102|NCT03490864|EXPERIMENTAL|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
62688192|NCT04187404|EXPERIMENTAL|randomized extension of Cohort 2A (3 arms): C2A-II|11 patients belonging to this extension of Cohort 2A will be treated by EO2401 alone.
62688193|NCT04187404|ACTIVE_COMPARATOR|randomized extension of Cohort 2A (3 arms): C2A-III|11 patients belonging to this extension of Cohort 2A who will be treated by nivolumab alone.
62688194|NCT02624479|EXPERIMENTAL|Fast first|Sodium thiosulfate fast release formulation first, followed by medium and slow
62688195|NCT02624479|EXPERIMENTAL|Medium first|Sodium thiosulfate medium release formulation first, followed by slow and fast
62688196|NCT02624479|EXPERIMENTAL|Slow first|Sodium thiosulfate slow release formulation first, followed by fast and medium
62688197|NCT04390009|OTHER|Siemens Biograph Vision PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
62688198|NCT04390009|OTHER|United Imaging uEXPLORER PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
62688199|NCT00476723||1|HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
62688200|NCT03115463|EXPERIMENTAL|OX25|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 10th to 25th percentile saturations observed in healthy term newborns.
62688201|NCT03115463|NO_INTERVENTION|OX50|Resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines
62688202|NCT03115463|ACTIVE_COMPARATOR|OX75|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 75th percentile saturations observed in healthy term newborns.
62688203|NCT00912509|ACTIVE_COMPARATOR|30 minute light duration|30 minute treatment with UVX light
62688204|NCT00912509|ACTIVE_COMPARATOR|45 minute light duration|45 minute treatment with UVX light
62688205|NCT06232590|EXPERIMENTAL|Control Lens, then Test Lens|Participants will wear the Control Lens for 1 month, then the Test Lens for 1 month
62688206|NCT06232590|EXPERIMENTAL|Test Lens, then Control Lens|Participants will wear the Test Lens for 1 month, then the Control Lens for 1 month
62688207|NCT02229682|EXPERIMENTAL|Mild-dose IMRT|"Experimental: Mild-dose of 46Gy with IMRT~Drug:~gemcitabine：1250mg/m2 (iv drip) on days 1, oxaliplatin: 85 mg/m2 (iv drip) on day 1, and pegaspargase: 2500 IU/m2 (intramuscular injection) on day 1. Cycle is repeated every 14 days~IMRT： IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions."
62688208|NCT06570811|EXPERIMENTAL|Placebo Comparator|Placebo Group: 20 patients will receive 80 mg/m2 of paclitaxel chemotherapy weekly for 12 weeks after receiving 4 cycles of AC protocol (Adriamycin and cyclophosphamide)
62688209|NCT06570811|EXPERIMENTAL|Active Comparator|Coenzyme Q10 Group : 20 patients will receive paclitaxel weekly for 12 weeks after receiving 4 cycles of AC protocol (Adriamycin and cyclophosphamide) in addition to oral 200 mg Coenzyme Q10 twice daily for 3 months.
62688210|NCT00318136|EXPERIMENTAL|Treated with Bevacizumab|
61925479|NCT06109285|EXPERIMENTAL|Reader Study|Vascular Severity Score Provided on second reading
62319008|NCT04393181||recipients of hearts with impaired function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with impaired function
62480103|NCT03490864|EXPERIMENTAL|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
62688211|NCT05646173|ACTIVE_COMPARATOR|grup 1|"Grup 1: Participants will be treated with ultrasound (5 min), TENS with a hot pack for (20 minutes). Home exercises will be given. The home exercises will be given consist of isometric waist, hip flexor stretching, hamstring stretching, self-mobilization exercise, waist and abdominal concentric strength exercises.~1.5w/cm² continuous ultrasound wiil applied with Chattanooga Intelect Mobile Ultrasound device.TENS: It will be applied to the lumbar region with a COMPEX brand stim device, together with a hot pack.The current intensity was opened by questioning according to the sensory threshold of the people.~Home based exercise program:In the first week of the exercise program; isometric exercises, stretching and mobilization exercises were given. Second week; additional bridging exercise; In the third week, additional isotonic, active abdominal and back strengthening exercises were included in all exercises.~The application will be done in 15 sessions, 5 days a week"
62688212|NCT05646173|EXPERIMENTAL|grup 2|"Grup 2: Participants will be given auricular vagus stimulation (25 min). Home exercises will be given. The home exercises will be given consist of isometric waist, hip flexor stretching, hamstring stretching, self-mobilization exercise, waist and abdominal concentric strength exercises.~Vagus stimulation: A specially manufactured earphone that can be selected according to the size of the ear placed in the outer ear will be applied from the vagustim device (frequency 10 Hz, pulse duration less than 500 microseconds, in modulated TENS mode and biphasic asymmetric waveform) connected to it.~Home based exercise program: In the first week of the exercise program; isometric exercises, stretching and mobilization exercises were given. Second week; additional bridging exercise; In the third week, additional isotonic, active abdominal and back strengthening exercises were included in all exercises.~The application will be done in 15 sessions, 5 days a week."
62688213|NCT01689649|EXPERIMENTAL|Topiramate|For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
62688214|NCT06640803|EXPERIMENTAL|Cognitive Behavioral Case Management|Once youths are identified with a clinical high risk for psychosis (CHRp) syndrome they will begin a 2-year, 6 step intervention. They will be assessed every 6 months. If youths continue to meet CHRp criteria they will move into the next step. If they no longer meet criteria they exit the study and resume standard care. If they develop psychosis or reach the end of the 2-year intervention they can move to EDAPT, a psychosis specialty clinic or work with personnel to find a more appropriate clinical service.
62688215|NCT06510621|EXPERIMENTAL|Socket-Shield Technique|Cut the tooth crown; divided along the long axis; trim the socket shield. Finally, the socket-shield was removed by minimally invasive forceps when the adjacent tooth moved proximate to the shield during the process of closing orthodontic gap.
62480104|NCT03490864|PLACEBO_COMPARATOR|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
62480105|NCT00005917||Chediak-Higashi Syndrome|Confirmed or suspected patients with Chediak-Higashi Syndrome.
62480106|NCT06532877|EXPERIMENTAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions and a booster session, advanced gastrointestinal cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that the team developed to guide mindfulness practices.
62128832|NCT02317874|EXPERIMENTAL|Schedule B (3-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-3, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
62128833|NCT01338675|EXPERIMENTAL|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
62319009|NCT04393181||recipients of hearts with normal function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with normal function
62319010|NCT04238663|EXPERIMENTAL|MB02 (Bevacizumab Biosimilar)|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62319011|NCT04238663|ACTIVE_COMPARATOR|EU approved Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62319012|NCT04238663|ACTIVE_COMPARATOR|US licenced Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
62319013|NCT00679159|EXPERIMENTAL|1|24 children (5 x 10\^7pfu)
62319014|NCT00679159|EXPERIMENTAL|2|36 infants (2.5 x 10\^7pfu)
62319015|NCT00679159|EXPERIMENTAL|3|36 infants (5 x 10\^7 pfu)
62319016|NCT00679159|EXPERIMENTAL|4|36 infants (1 x 10\^8pfu)
62319017|NCT00679159|PLACEBO_COMPARATOR|5|36 infants (Prevenar vaccine)
62319018|NCT03702205|EXPERIMENTAL|Betaine supplementation|The experimental procedure for each athlete includes a 3-week betaine supplementation either 2.5 g or 5 g daily. Betaine will be administered in the form of capsules containing either 0.5 or 1 g betaine. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 5 betaine capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
62319019|NCT03702205|EXPERIMENTAL|Placebo treatment|The experimental procedure for each athlete included a 3-week placebo administration. Placebo will be capsules with starch. Placebo will be ingested with at least 250 mL of water. Each athlete will ingest 5 placebo capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
62480107|NCT06532877|ACTIVE_COMPARATOR|Education/Support|Across six weekly 50-minute sessions and a booster session, advanced gastrointestinal cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
62480108|NCT02468518|EXPERIMENTAL|Patients|Vitamin E capsule 200 IU bd x 12 weeks
62480109|NCT02468518|ACTIVE_COMPARATOR|Arsenic exposed controls|Vitamin E capsule 200 IU bd x 12 weeks
62480110|NCT02468518|ACTIVE_COMPARATOR|Healthy volunteers|Vitamin E capsule 200 IU bd x 12 weeks
62480111|NCT05119296|EXPERIMENTAL|Pembrolizumab 200 mg|Participants will receive pembrolizumab (Keytruda) 200 mg administered by IV infusion every 3 weeks. Participants will remain on study and receive pembrolizumab for the nominal duration of treatment (35 cycles, approximately 2 years) or until there is evidence of disease progression by RECIST, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason.
62480112|NCT01887522|EXPERIMENTAL|VINILO|"VINILO-arm: Vinblastine and nilotinib given in combination at the RD defined in the Phase I part:~* Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~* Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28 Recommended doses of the drug combination will be reconsidered at an interim stage of the phase II trial after the analysis of the delayed toxicity encountered in the first 20 patients treated at the initial RD (adaptive design)."
62480113|NCT01887522|ACTIVE_COMPARATOR|Control Vinblastine only|"Control Vinblastine only arm:~· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Each 28-day cycle is repeated on Day 29/Day 1.~In both treatment groups, dose reductions and/or administration delays will be performed in case of severe hematological and/or non hematological toxicities while on treatment.~Vinblastine will be temporarily stopped in case of neutropenia \<1 x109/L or thrombopenia \<75 x 109/L. It could be re-started at a reduced dose after complete recovery.~Patients benefiting from study treatment may continue up to 12 cycles as long as the toxicity-benefit ratio is adequate."
62480114|NCT04678856|EXPERIMENTAL|Part A and B: Dupilumab|Participants received dupilumab 300 milligrams (mg) via SC injection q2w for up to 53.1 weeks.
62480115|NCT04678856|PLACEBO_COMPARATOR|Part A and B: Matching placebo|Participants received matching placebo via SC injection q2w for up to 53.2 weeks.
62688216|NCT06510621|NO_INTERVENTION|non-Socket-Shield Technique|A high-speed turbine was used to cut the tooth crown 1.5-2 mm from the buccal gingival margin. The tooth was then divided along the long axis, approximately 2 mm from the buccal side. The palatal roots were removed using minimally invasive elevation and extraction forceps. Next, the buccal socket-shield was trimmed to approximately 4-6 mm in height (1 mm from the buccal gingival margin), 3-4 mm in width, and 1-1.5 mm in thickness. The trimming process required with clear visualization of the shield and calibration by periodontal probe. Finally, the socket-shield was removed immediately
62688217|NCT06474962|EXPERIMENTAL|Pause|Individuals will attempt to halt e-cigarette consumption for 7 days
62688218|NCT06474962|NO_INTERVENTION|Control|Individuals will continue habits as usual
61925480|NCT04891731||leuprorelin 3M plus AIs|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year AIs: anastrozole 1mg /letrozole 2.5mg/exemestane 25mg daily for 1 year
62688219|NCT06457997|EXPERIMENTAL|Phase 1a and Phase 1b|PHN-010 is administered intravenously.
62128834|NCT02561702|EXPERIMENTAL|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
62128835|NCT02561702|EXPERIMENTAL|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
62128836|NCT05882617|EXPERIMENTAL|experimental|single impalnts supported overdenture
62128837|NCT05882617|ACTIVE_COMPARATOR|active comparator|two implants supported overdenture
62128838|NCT05882617|OTHER|others|four implants supported overdenture
61925481|NCT04891731||leuprorelin 3M plus TAM|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year TAM: daily for 1 year
61925482|NCT05508724||Critically-ill mechanically ventilated patients|Intensive Care patients receiving mechanical ventilation due to respiratory failure
61925483|NCT05331027|EXPERIMENTAL|Desflurane Group|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
62128839|NCT00920738||Cancer Survivors|Subjects who are cancer survivors must have survived childhood cancer (diagnosed \< or = 18 years) for a minimum of 5 years and be in remission.
62128840|NCT00920738||Healthy Siblings of Cancer Survivor|Healthy populations similar in age and gender distribution, derived from a frequency matched control population of 350 healthy siblings.
62480116|NCT06203938|EXPERIMENTAL|TILS-treated|Transcranial infrared light stimulation (TILS) will be administered via light-emitting diodes (LEDs), which are a safe and non-invasive form of transcranial photobiomodulation.
62688220|NCT05226195|EXPERIMENTAL|Group 1: Sterile Kinesio tape application|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
62688221|NCT05226195|NO_INTERVENTION|Group 2: Control group|The standard post-surgical protocol applied in our clinic will be applied to Group 2. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
62688222|NCT03734055|EXPERIMENTAL|Peer Mentoring|The program will consist of 12 sessions of peer mentoring that will include one standard educational session by telephone or video for approximately 60 minutes every 2 weeks. Additional interaction will be discouraged, but mentees and mentors will be asked to report any additional social interaction should it occur. The bi-weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. 60-minute calls are necessary for the delivery of educational content and mentors and mentees to be able to discuss their own experiences and potential solutions.
62688223|NCT03734055|ACTIVE_COMPARATOR|Social Support Group|Mentees randomized to the social support control group will be enrolled in a lupus support group designed specifically for this project.
62319020|NCT02445378|EXPERIMENTAL|Group I (aromatherapy and essential oils week 1)|Patients select between 3 scented essential oils: peppermint, lavender, or chamomile which is diffused in the hospital room from approximately 9 PM in the evening until morning during week 1 and placebo intervention using rose water during week 2.
62688224|NCT01091883|EXPERIMENTAL|Exablate treatment|Exablate 2000
62688225|NCT01091883|ACTIVE_COMPARATOR|Radiation|External Beam Radiation
62688226|NCT03039751|EXPERIMENTAL|AdvVEGF-D|Intramyocardial AdVEGF-D
62688227|NCT03039751|PLACEBO_COMPARATOR|Control|Intramyocardial placebo (buffer solution without gene)
62688228|NCT06636812|EXPERIMENTAL|losartan|single-dose losartan potassium (Cozaar; weight-adjusted 25mg or 50mg)
62688229|NCT06636812|PLACEBO_COMPARATOR|Placebo|Microcellulose placebo in identical capsule
62688230|NCT01550887|NO_INTERVENTION|Impulsivity evaluation|
62688231|NCT03773562|OTHER|Erenumab|All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
62319021|NCT02445378|EXPERIMENTAL|Group II (aromatherapy and essential oils week 3)|Patients undergo placebo intervention using rose water during week 1 and aromatherapy and essential oils as in Group I during week 2.
62480117|NCT06203938|SHAM_COMPARATOR|Sham|The sham control group undergoes the same procedure as the treatment group, but without the LEDs turned on.
62688232|NCT05226338|EXPERIMENTAL|Sequence 1|3 period, 3 dose level
62688233|NCT05226338|EXPERIMENTAL|Sequence 2|3 period, 3 dose level
62319022|NCT03143582|EXPERIMENTAL|Running group|13 week, bi-weekly running group
62319023|NCT05393583|EXPERIMENTAL|Outpatient|Discharge on the day of hysterectomy
62688234|NCT05226338|EXPERIMENTAL|Sequence 3|3 period, 3 dose level
62688235|NCT05226338|EXPERIMENTAL|Sequence 4|3 period, 3 dose level
62319024|NCT05393583|ACTIVE_COMPARATOR|Inpatient|Discharge after 1 night stay in the hospital
62319025|NCT02561416|EXPERIMENTAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) The MBSR consists in eight 2-h group sessions and an all-day mindfulness retreat, and offers intensive and structured training in mindfulness meditation to help patients to relate to their physical and psychological conditions in more accepting and nonjudgmental ways. Participants will be encouraged to engage in home mindfulness practices. Sessions will be lead by 4 MBSR accredited instructors.
62319026|NCT02561416|ACTIVE_COMPARATOR|Psycho-educational Program|Psycho-educational Program (FibroQol) It consists of eight 2-h group sessions including information about FMS (4 sessions) based on a consensus document of the Health Department of Catalonia + autogenic relaxation (4 sessions).
62319027|NCT02561416|OTHER|Treatment As Usual|Treatment As Usual.
62480118|NCT00741780||G-CSF plus plerixafor|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
62480119|NCT00741780||G-CSF plus placebo|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
62480120|NCT06742138|EXPERIMENTAL|Pomalidomide Plus(+) QL2109 + Dexamethasone|
62688236|NCT05226338|EXPERIMENTAL|Sequence 5|3 period, 3 dose level
62688237|NCT05226338|EXPERIMENTAL|Sequence 6|3 period, 3 dose level
62688238|NCT04964752|OTHER|the upper arm group on Day 2|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 2.
62688239|NCT04964752|OTHER|the upper arm group on Day 15±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 15±1 day.
62688240|NCT04964752|OTHER|the upper arm group on Day 29±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 29±1 day.
62688241|NCT04964752|OTHER|the abdomen group on Day 2|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 2.
62688242|NCT04964752|OTHER|the abdomen group on Day 15±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 15±1.
62688243|NCT04964752|OTHER|the abdomen group on Day 29±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 29±1.
62319028|NCT01429012|EXPERIMENTAL|Mesenchymal Stem Cells|"2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.~MSC will be injected even if the number of available cells is lower than 40 X 10E6.~The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist."
62319029|NCT01429012|PLACEBO_COMPARATOR|Culture medium without MSC.|Culture medium used to resuspend the Mesenchymal Stem Cells.
62319030|NCT05513612|EXPERIMENTAL|Autologous CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CAR-T cells. CAR-T cells targeted CD19/BCMA/CD123/CD7 are autologous genetically modified T cells.
62319031|NCT04791397|EXPERIMENTAL|Group trial|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
62319032|NCT04791397|EXPERIMENTAL|Group control|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
62319033|NCT05318625|EXPERIMENTAL|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
62319034|NCT02183467|EXPERIMENTAL|BI 1356, low dose|
62319035|NCT02183467|EXPERIMENTAL|BI 1356, high dose|
62319036|NCT02183467|PLACEBO_COMPARATOR|Placebo|
62319037|NCT02183467|ACTIVE_COMPARATOR|Moxifloxacin|
62319038|NCT06149312|EXPERIMENTAL|Advance Care Planning Intervention|Patients from experimental arm will benefit from a Standardized Advance Care Planning interview alone or in the presence of relatives within 3 days after randomization.
62319039|NCT06149312|NO_INTERVENTION|Standard cares|Patients from control arm will be treated without specific intervention, which does not exclude the possibility of resorting to non standardized advance care planning interviews with an oncologist or a physician specialized in palliative care.
62319040|NCT05836012|EXPERIMENTAL|Experimental|HIL-214 (1 dose at 4 months of age and 1 dose at 6 months of age) and routine childhood vaccines according to schedule.
62319041|NCT05836012|PLACEBO_COMPARATOR|Placebo|Placebo (1 dose at 4 months of age and 1 dose at 6 months of age) and routine childhood vaccines according to schedule.
62319042|NCT03189576|OTHER|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
62319043|NCT06672536|EXPERIMENTAL|SCT520FF dose level 1 treatment|SCT520FF dose level 1(0.625mg),IVI,injection once every 4 weeks,three times continuously
62319044|NCT06672536|EXPERIMENTAL|SCT520FF dose level 2 treatment|SCT520FF dose level 2(1.25mg),IVI,injection once every 4 weeks,three times continuously
62319045|NCT06672536|EXPERIMENTAL|SCT520FF dose level 3 treatment|SCT520FF dose level 3(2.5mg),IVI,injection once every 4 weeks,three times continuously
62319046|NCT01660841|EXPERIMENTAL|Arm 1|
62688244|NCT05313958|EXPERIMENTAL|treatment arm|"The patients in this arm will receive SCCLG-M5 2022 regimen for newly dignosed acute monocytic leukemia (M5) ,including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period and followed by three courses(HA1M, HA2E, HA3) in consolidation therapy prescribed as the NOPHO-AML 2004 protocol.~The targeted drugs sorafenib 200mg/m2/day orally is used for FLT3 positive acute monocytic leukemia until molecular biology remission for 2 years."
62319047|NCT00292292|EXPERIMENTAL|Kineflex Lumbar Artificial Disc|Treatment arm
62319048|NCT00292292|ACTIVE_COMPARATOR|Charite|
62319049|NCT05416229|EXPERIMENTAL|Psilocybin-assisted therapy|45 patients will receive a single administration of 25mg psilocybin given in a protocol of psychological support before, during and after dosing.
62319050|NCT05416229|PLACEBO_COMPARATOR|Placebo-assisted therapy|45 patients will receive a single administration of placebo (lactose) given in a protocol of psychological support before, during and after dosing.
62319051|NCT06129994||Study Group|Participants will complete the observational study over the 15 day study period
62319052|NCT01576861|EXPERIMENTAL|GH replacement|Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy
62319053|NCT01576861|NO_INTERVENTION|Control CHF patients under optimized CHF therapy|
62319054|NCT03336398|EXPERIMENTAL|Tinnitus Distressed Patients|Tinnitus distressed patients are patients who experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
62319055|NCT03336398|EXPERIMENTAL|Tinnitus Patients|Tinnitus patients are patients who do not experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
62319056|NCT00619931|EXPERIMENTAL|1|APD791 or placebo
62319057|NCT00619931|EXPERIMENTAL|2|APD791 or placebo
62319058|NCT00619931|EXPERIMENTAL|3|APD791 or placebo
62319059|NCT00619931|EXPERIMENTAL|4|APD791 or placebo
62319060|NCT00619931|EXPERIMENTAL|5|APD791 or placebo
62319061|NCT01670851||Strattice|eLAPE
62319062|NCT02284906|EXPERIMENTAL|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
62319063|NCT02284906|PLACEBO_COMPARATOR|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
62319064|NCT01392989|EXPERIMENTAL|Allogeneic Cytokine-induced Killer Cells (CIK)|Target dose of ≥ 5 x 10e6 CD34+ cells/kg of recipient body weight plus an additional 2 x10e9 mononuclear cells.
62319065|NCT05232591||1|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
62319066|NCT05232591||2|GCF samples will be taken from the collateral teeth (healthy teeth) of the teeth diagnosed with chronic apical periodontitis.
62480121|NCT06742138|ACTIVE_COMPARATOR|Pomalidomide + DARZALEX FASPRO® + Dexamethasone|
62480122|NCT01421901|EXPERIMENTAL|Ertapenem|
62480123|NCT01421901|ACTIVE_COMPARATOR|appendectomy|Appendectomy is compared to Ertapenem
62480124|NCT05146076|EXPERIMENTAL|telemedicine supervised group|physical training supervised by telemonitoring
62480125|NCT05146076|ACTIVE_COMPARATOR|institutional training|institutional training supervised by physiotherapist
62480126|NCT04855279|PLACEBO_COMPARATOR|Control|
62480127|NCT04855279|ACTIVE_COMPARATOR|Topical neutral sodium fluoride|
62480128|NCT04855279|ACTIVE_COMPARATOR|ACP-CCP gel|
62480129|NCT04855279|ACTIVE_COMPARATOR|nano-hydroxyapatite solution|
62688245|NCT05026736|EXPERIMENTAL|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue to receive treatment at the discretion of the treating physician.
62688246|NCT05216380|EXPERIMENTAL|ActivityLink|ActivityLink will be a clinic implementation program delivered to clinic staff.
62688247|NCT04053426||"Population before"|Patient included before implementation of care algorithm.
61925484|NCT05331027|ACTIVE_COMPARATOR|Sevoflurane Group|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
62319067|NCT06279585|EXPERIMENTAL|Experimental group|Participants from both groups will undergo the three assessments and receive standard medical care.The patients in the experimental group will participate, at Time T1 (week 1 to 12), in a 12-week physiotherapy treatment program consisting of a total of 38 sessions: 2 health education sessions, 24 supervised combined exercise sessions, and 12 self-administered complementary exercise sessions.
62688248|NCT04053426||"Population after"|Patients included after the implementation of care algorithm and training of health professionnals
62688249|NCT06571084||suspected PA|Patients with a high risk for PA who were willing to participate in the study were recruited. The inclusion criteria1 were as follows: persistent hypertension (BP \>150/100 mm Hg), or drug-resistant hypertension; newly diagnosed hypertension; hypertension and spontaneous or diuretic-induced hypokalemia; hypertension with adrenal incidentaloma; hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (\<40 years); or status as a hypertensive first-degree relative of patients with PA; patients with hypertension and obstructive sleep apnea.
62128841|NCT03169894|EXPERIMENTAL|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
62319068|NCT06279585|NO_INTERVENTION|Control group|"Participants from both groups will undergo the three assessments and receive standard medical care.~The Control Group (GC), externally to the trial itself, for ethical reasons, considering potential benefits without risks, and as a strategy for blinding the study itself, will carry out the physiotherapy treatment program following the final assessment of the study, becoming a hybrid program under the same protocol."
62319069|NCT04841629|EXPERIMENTAL|PreBioGyn Gel|Topical administration to forearm
62319070|NCT04841629|ACTIVE_COMPARATOR|Trimosan Gel|Topical administration to forearm
62319071|NCT04841629|ACTIVE_COMPARATOR|RepHresh Gel|Topical administration to forearm
62319072|NCT03505697|EXPERIMENTAL|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
62319073|NCT03505697|EXPERIMENTAL|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
62319074|NCT04003506|EXPERIMENTAL|Group LB|local infiltration of analgesia (LIA) with adductor canal block (ACB) will be given using 10ml of 1.33% liposomal bupivacaine with 10ml 0.5% standard bupivacaine
62319075|NCT04003506|ACTIVE_COMPARATOR|group SB|LIA with ACB will be given using 20ml 0.5%standard bupivacaine
62319076|NCT03255525|ACTIVE_COMPARATOR|Deep friction massage P50|In this group it was applied a pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
62319077|NCT03255525|EXPERIMENTAL|Deep friction massage P25|In this group it was applied the percentile 25, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
62688250|NCT06640348||healthy control|By analyzing the Raman signals of peripheral serum from normal controls, unique signal characteristics specific to ovarian cancer patients are identified through comparative analysis with the control group.
62688251|NCT06640348||Ovarian cancer group|Extract information from blood samples of ovarian cancer patients, specifically identifying cancer and non-cancer signals to construct a statistical algorithm model for the early diagnosis of ovarian cancer.
62688252|NCT01059279||FMF patients|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
62688253|NCT01059279||healthy people|Healthy individuals, that participated in the study of Heller Institute of Medical Research.
62688254|NCT06689241|ACTIVE_COMPARATOR|group E|81 patients will receive subcutaneous enoxaparin 40 mg every 24 hours starting 12 hours after bariatric surgery for 14 days.
62688255|NCT06689241|EXPERIMENTAL|group R|81 patients will receive oral rivaroxaban 10 mg once daily starting 24 hours after bariatric surgery for 14 days.
62688256|NCT01993680|EXPERIMENTAL|Pyridostigmine bromide|14 days of active treatment followed by 21 days wash out
62688257|NCT01993680|ACTIVE_COMPARATOR|fludrocortisone|14 days of fludrocortisone treatment; 21 days wash out
61925485|NCT02793193|EXPERIMENTAL|Active (rifaximin/B.longum 1714)|
61925486|NCT02793193|EXPERIMENTAL|Placebo|
61925487|NCT02001025||Absorb scaffold|Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years
62319078|NCT03255525|EXPERIMENTAL|Deep friction massage P75|In this group it was applied the percentile 75, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
62480130|NCT06423339|EXPERIMENTAL|Group A|Group A will receive genicular nerve block combined with interspace between the popliteal artery and the capsule of the posterior knee block(IPACK)
62688258|NCT00846482|EXPERIMENTAL|Resected or metastatic CRC|All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin
62688259|NCT05377814|NO_INTERVENTION|Passive control|The (passive) control condition includes the same questionnaire as the experimental group, however participants are not presented with the intervention.
61925488|NCT02001025||Xience stent|Second generation drug-eluting stent to treat coronary artery lesions
62128842|NCT01236001||Vimpat® treatment|Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.
62688260|NCT05377814|EXPERIMENTAL|Intervention (volitional help sheet)|"Participants in the intervention group will be asked to form implementation intentions with respect to wearing face coverings. Participants will be presented with the stem If I am tempted not to wear a face covering consistently... and given 10 options with which to complete as many if-then plans as they like. These ten options have been taken from the literature and have been shown to be effective with respect to changing numerous behaviours, including self-harm, smoking, alcohol consumption and physical activity."
62688261|NCT04484428|EXPERIMENTAL|Treatment Arm A|K-285
62319079|NCT03344159|EXPERIMENTAL|Spironolactone|Participants with chronic right-sided heart failure will receive spironolactone 12.5mg daily up to a maximum dose of 50 mg daily for a total duration of 12 weeks.
62128843|NCT05816902||validation set 1|The validation set 1 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College.
62128844|NCT05816902||validation set 2|The validation set 2 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Second Affiliated Hospital of Harbin Medical University.
62128845|NCT01183936|ACTIVE_COMPARATOR|2 cm margin of excision|Patients with CMM \>2 mm treated with an excision of 2-cm.
62128846|NCT01183936|ACTIVE_COMPARATOR|4 cm margin of excision|Patients with CMM \>2 mm treated with an excision of 4-cm.
62128847|NCT05779215||acute ischemic stroke with large- or medium-vessel occlusion|acute ischemic stroke patients with large- or medium-vessel occlusion including all treatments.
62128848|NCT02290613|EXPERIMENTAL|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
62128849|NCT02290613|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62128850|NCT04452539||Paediatric cardiac surgery patients|All patients undergoing paediatric cardiac surgery
62319080|NCT03344159|PLACEBO_COMPARATOR|Placebo|Participants with chronic right-sided heart failure will receive placebo daily for a total duration of 12 weeks.
62128851|NCT01448512|OTHER|Usual Care|Participation in 4 time matched sessions on health education topics
62128852|NCT01448512|EXPERIMENTAL|PartnerPlus intervention|Four group counseling sessions focused on prevention of mother to child transmission (PMTCT) sexual risk reduction \& adherence.
62128853|NCT06355492|PLACEBO_COMPARATOR|Control group|Patients will take buccal infiltration anesthesia using (regular screen).
62128854|NCT06355492|EXPERIMENTAL|VR group|Patients will take buccal infiltration anesthesia using (Virtual reality goggles).
62319081|NCT04365816||Prospective cohort University Hospital, Grenoble|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
62688262|NCT04484428|ACTIVE_COMPARATOR|Treatment Arm B|Menthol
62128855|NCT00084552|ACTIVE_COMPARATOR|Arm I|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
62319082|NCT04365816||Prospective cohort University Hospital, Toulouse|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
62128856|NCT00084552|EXPERIMENTAL|Arm II|Patients undergo IMRT with dose restriction to erectile tissue once daily 5 days a week for approximately 7.5 weeks.
62128857|NCT04079400||Tb group|Subjects who underwent bronchoscopy for suspicious endobronchial pulmonary tuberculosis (Tb) observed on chest computed tomography
62128858|NCT04079400||NTM-PD group|Subjects who underwent bronchoscopy for suspicious non-tuberculous mycobacterial pulmonary disease (NTM-PD) observed on chest computed tomography
62128859|NCT04079400||LC group|Subjects who underwent bronchoscopy for suspicious endobronchial lung cancer (LC) observed on chest computed tomography
62128860|NCT04079400||HM group|Subjects who underwent bronchoscopy for hemoptysis
62128861|NCT04079400||Control group|Subjects who underwent bronchoscopy to rule out endobronchial lesion observed on chest computed tomography. Endbronchial lesion should not be typical for any category of respiratory diseases including tuberculosis, NTM-TB and lung cancer.
62128862|NCT02030158||Early Goal-Directed Therapy (EGDT)|Protocolised resuscitation (termed Early Goal-Directed Therapy - EGDT)
62128863|NCT02030158||Usual resuscitation|Usual resuscitation
62128864|NCT00940043||Rupture of fetal membranes|women with rupture of fetal membranes before onset of labor
62128865|NCT06521944||Exposed|Participants who receive RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation
62128866|NCT06521944||Unexposed|Participants who do not receive RSV vaccine during pregnancy
62128867|NCT01202136||Pancreatic cysts|patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts
62319083|NCT04365816||Prospective cohort University Hospital, Nancy|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
62480131|NCT06423339|EXPERIMENTAL|Group B|Group B will receive ultrasound guided sub-sartorial Adductor canal block (ACB)
62688263|NCT02837952|ACTIVE_COMPARATOR|Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
62688264|NCT02837952|PLACEBO_COMPARATOR|Placebo|Placebo
62688265|NCT04791020|ACTIVE_COMPARATOR|Lidocaine + paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
62688266|NCT04791020|EXPERIMENTAL|Lidocaine|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied.
62128868|NCT02186743|EXPERIMENTAL|Intervention Diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
62128869|NCT02186743|ACTIVE_COMPARATOR|Active control diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
62128870|NCT01298934|EXPERIMENTAL|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
62319084|NCT04365816||Prospective cohort University Hospital, Rennes|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
62319085|NCT04365816||Prospective cohort Hospices Civils de Lyon|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
62319086|NCT04365816||Prospective cohort Assistance Publique Hôpitaux de Paris|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
62319087|NCT04365816||Prospective cohort University Hospital, Rouen|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
62319088|NCT04704882|EXPERIMENTAL|omental patchwork group|
62319089|NCT04704882|NO_INTERVENTION|non-omental patchwork group|
62319090|NCT00958568|EXPERIMENTAL|Olanzapine and Fluoxetine combination (OFC)|
62319091|NCT00958568|ACTIVE_COMPARATOR|Fluoxetine|
62480132|NCT06604026|EXPERIMENTAL|Treatment arm|use of the BD PosiFlush™ SafeScrub device
62128871|NCT06116708|EXPERIMENTAL|22 Healthy Volunteers|Each of the 22 volunteers will participate in a trial with both of the seat cushions. The test order is randomized.
62128872|NCT05799742|ACTIVE_COMPARATOR|Lichtenstein|Conventional approach
62128873|NCT05799742|EXPERIMENTAL|Laparoscopy|Experimental approach
62128874|NCT01915459|EXPERIMENTAL|Botulinum toxin type A(Botulax®)|Botulinum toxin type A
62319092|NCT03981575||Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months
62319093|NCT04844047|ACTIVE_COMPARATOR|FAST|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in the community. Participants attended a 30-minute fall prevention education session once per week. FAST followed the same principles as Standard, with the addition of the following goals: 1) Increase UE strength (shoulder girdle/arm) utilizing both concentric and eccentric contractions, 2) Improve trunk and neck postural control during slow and fast body motions, 3) Optimize forward descent strategies via practice of quick response reaching, landing and controlled descent with hands on the wall or on the floor as able. Training progression for strength and body control included increasing the distance standing from the wall, progressing to one arm descents, increasing reps and speed and moving to greater gravity and body weight resistance such as hands and knees position on the floor as able. Quick movement practice targeted unexpected reaching activities, balloon and ball toss
62319094|NCT04844047|PLACEBO_COMPARATOR|Standard|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in a community site (assisted living residence). Participants also attended a 3o minute fall prevention education session once per week. The Standard intervention consisted of a fall prevention exercise program designed for community-dwelling older adults. Exercises focussed on balance, leg strength, walking and mobility exercises designed to decrease fall risk.
62319095|NCT04376268|ACTIVE_COMPARATOR|Chlorhexidine gluconate|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects.
62319096|NCT04376268|ACTIVE_COMPARATOR|Chlorhexidine mouthwash with boric acid (0.1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
62319097|NCT04376268|ACTIVE_COMPARATOR|Chlorhexidine mouthwash with boric acid (0.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
62480133|NCT06604026|ACTIVE_COMPARATOR|Control Arm|pre-filled saline syringe (BD PosiFlush™ SP Syringe) and alcohol pad
62480134|NCT06310668|EXPERIMENTAL|CBT intervention arm|patients with substance use disorder in the inpatient department of the addiction unit in Mansoura University Hospital who will receive group CBT sessions
62480135|NCT06310668|NO_INTERVENTION|NON-CBT control arm|age and gender-matched patients with substance use disorder in the outpatient clinics of the addiction unit in Mansoura University Hospital who will not receive group CBT sessions
62480136|NCT03734705|EXPERIMENTAL|Imaginal Exposure Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about their worst-case scenario regarding discarding a possession (i.e., imaginal exposure).
62480137|NCT03734705|SHAM_COMPARATOR|Neutral Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about what they would do if they had a day off work or school.
62480138|NCT06354894||Patients affected by proximal humeral fracture|
62480139|NCT02348281|EXPERIMENTAL|bicalutamide|150mg, po, qd, d1-28
62128875|NCT01915459|ACTIVE_COMPARATOR|Botulinum toxin type A(Botox®)|Botulinum toxin type A
62128876|NCT01203995|NO_INTERVENTION|Usual Care|
62128877|NCT01203995|EXPERIMENTAL|brief nutrition education|
62128878|NCT01203995|ACTIVE_COMPARATOR|In Center training|
62128879|NCT01203995|EXPERIMENTAL|Video Conference training|
62480140|NCT03528187||Patient Cohort 1|"* Age 18 or over~* BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)~* Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications \[dietary change, behavioural therapy, increased physical activity\], surgical intervention or pharmacological treatment) as part of their usual clinical care~* Informed written consent~* Able to tolerate MRI"
62319098|NCT04376268|ACTIVE_COMPARATOR|Chlorhexidine mouthwash with boric acid (1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
62319099|NCT04376268|ACTIVE_COMPARATOR|Chlorhexidine mouthwash with boric acid (1.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
62319100|NCT04376268|ACTIVE_COMPARATOR|Chlorhexidine mouthwash with boric acid (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
62319101|NCT04376268|ACTIVE_COMPARATOR|Chlorhexidine mouthwash with boric acid (2.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
62480141|NCT03528187||Patient Cohort 2|"* Age 18 or over~* Attending weight management service at UCLH~* Informed written consent~* Able to tolerate MRI"
62480142|NCT03528187||Controls|"* Age 18 or over~* BMI less than 25~* Informed written consent~* Able to tolerate MRI"
62480143|NCT05486156|EXPERIMENTAL|Intervention A Time with e-Nature Group (Multicomponent Nature-Based Intervention - MNBI)|After signing the Free and Informed Consent Term, participants will be directed to a multicomponent intervention based on the experience of aesthetic, emotional and multisensory appreciation, knowledge, environmental education/interpretation and active involvement. At the end of the activity, the participants will fill in the post-intervention questionnaires, which will be applied immediately and 30 days after the intervention.
62480144|NCT05486156|ACTIVE_COMPARATOR|Control Group|The group will do an activity made up of contact with nature during a light walk with attention directed to the senses (classical forest bathing). The trail will be accompanied by a guide who will not make any type of intervention other than offering the questionnaires to be filled in at the end of the activity and driving in the section foreseen for the activity.
62480145|NCT00924547|EXPERIMENTAL|Docosahexanoic Acid Supplement|In this arm, participants took two different doses of a DHA supplement. Each dose of the DHA supplement was taken for 4 weeks.
62480146|NCT00924547|PLACEBO_COMPARATOR|Placebo|In this arm, participants took a placebo pill that did not contain any DHA.
62480147|NCT03934476|EXPERIMENTAL|Ketogenic diet|"Ketogenic diet:~* \< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~* protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~* fat type intake recommendation:~* natural fats~* trans-FA reduction"
62480148|NCT03934476|EXPERIMENTAL|Exercise HIIT (High-Intensity Interval Training)|"Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~* week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~* week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~* week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~* week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~* week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~* week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
62480149|NCT03934476|EXPERIMENTAL|Ketogenic diet + Exercise HIIT|"Ketogenic diet:~* \< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~* protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~* fat type intake recommendation:~* natural fats~* trans-FA reduction~Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~* week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~* week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~* week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~* week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~* week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~* week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
62480150|NCT03934476|NO_INTERVENTION|Control Group|The study subjects in this arm will undergo no dietary changes and no exercise intervention.
62480151|NCT02622867|EXPERIMENTAL|Lactobacillus plantarum 3547|1 capsule/daily during 12 weeks with Lactobacillus plantarum 3547 (10x109 cfu/d). The capsule contains 77 mg probiotic Lp3547 and 390 mg maltodextrin
62480152|NCT02622867|PLACEBO_COMPARATOR|Maltodextrin|1 daily capsule of maltodextrin (425 mg) during 12 weeks
62480153|NCT06560762|OTHER|Dose arm (3 cohorts; 3 doses)|Up to 18 participants will be enrolled (Up to 6 participants, for 5 completers per cohort). Each successive cohort of participants will receive STM-01 at the following doses: 50.0 x 106 neonatal mesenchymal stem cells (nMSCs), 100.0 x 106 nMSCs, and 200.0 x 106 nMSCs.
62688267|NCT06673940|ACTIVE_COMPARATOR|Intervention arm|TENS applied to acupuncture points in addition to physical therapy program
62319102|NCT04376268|ACTIVE_COMPARATOR|Boric acid mouthwash (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
62319103|NCT04833075|OTHER|Single arm|additional blood sampling (single arm)
62128880|NCT04048382|EXPERIMENTAL|Patient Navigation (PN)|This intervention consists of standardized health educational materials and manualized sessions that can be implemented based on a participant's stage in the PrEP continuum. The intervention will utilize bilingual peer lay navigators and also consist of barrier reduction strategies to assist individuals with implementing HIV prevention, including the use of PrEP.
62128881|NCT04048382|OTHER|Usual Care (UC)|Participants in this condition will receive the CDC's 2-page PrEP Information Sheet in the participant's preferred language (either English or Spanish).
62319104|NCT01753115|EXPERIMENTAL|BioThrax + Ciprofloxacin PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
62319105|NCT01753115|EXPERIMENTAL|BioThrax + Ciprofloxacin no PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
62319106|NCT01753115|EXPERIMENTAL|BioThrax only|BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
62319107|NCT01128972|EXPERIMENTAL|Test Dentifrice + Test Mouth Rinse (MR)|Test fluoride dentifrice and test fluoride MR
62319108|NCT01128972|EXPERIMENTAL|Test Dentifrice + Sterile Water Rinse|Test fluoride dentifrice and sterile water rinse
62319109|NCT01128972|EXPERIMENTAL|Placebo Dentifrice + Test MR|Placebo dentifrice and test fluoride rinse
62319110|NCT01128972|ACTIVE_COMPARATOR|Reference Dentifrice + Sterile Water Rinse|Marketed fluoride dentifrice with sterile water rinse
62319111|NCT01128972|PLACEBO_COMPARATOR|Placebo Dentifrice + Sterile Water Rinse|Placebo dentifrice and sterile water rinse
62480154|NCT01222234|EXPERIMENTAL|Group 1: Cholecalciferol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
62128882|NCT06285149|EXPERIMENTAL|80 patients with advanced HCC in Child-Pugh B who had not been systematically|Icaritin will be divided into the first dose group (200mg bid orally) using 3+3 dosage. The second dose group will be 400mg bid orally; And the third dose group, 600mg bid, taken orally. It is taken within 1 hour after a meal, and Icaritin will be administered continuously during interventional therapy.
62319112|NCT03333785|EXPERIMENTAL|Intervention group|Primary care providers whose patients have been randomized to the intervention group will receive an invitation from their patient's cancer specialist provider to communicate using eOncoNote. Primary care providers and cancer specialist providers will use eOncoNote in addition to usual methods of communication.
62688268|NCT06673940|ACTIVE_COMPARATOR|control arm|only physical therapy program
62688269|NCT06542341|EXPERIMENTAL|Active Light treatment Arm|Treatment with red and near infra red light 5 x week for 6 weeks
62319113|NCT03333785|NO_INTERVENTION|Control group|Primary care providers whose patients have been randomized to the control group will receive usual care (i.e. their primary care providers will not access eOncoNote to communicate with the cancer specialist providers and vice versa) and will be able to contact each other via telephone, fax, and mail consultation letters and progress notes, as per usual care.
62319114|NCT00872716|EXPERIMENTAL|Quetiapine XR|100 mg single-dose Quetiapine XR
62319115|NCT00872716|PLACEBO_COMPARATOR|Placebo|
62480155|NCT01222234|EXPERIMENTAL|Group 2: Calcitriol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.
62480156|NCT01222234|EXPERIMENTAL|Group 3: Cholecalciferol - non-CKD|Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
62480157|NCT03816345|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.
62688270|NCT02869009|EXPERIMENTAL|clopidogrel plus aspirin group|the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
62688271|NCT02869009|EXPERIMENTAL|aspirin group|the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.
62319116|NCT06286280|EXPERIMENTAL|Cytosorb group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
62128883|NCT05100589|EXPERIMENTAL|PeakATP|PeakATP formula dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.
62128884|NCT05100589|PLACEBO_COMPARATOR|Placebo|Placebo formula (same as experimental with no PeakATP) dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.
62319117|NCT06286280|NO_INTERVENTION|Control group|Participants undergoing cardiac surgery will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
62319118|NCT06077630||Attended appointments|An appointment scheduled by a patient that was attended
62319119|NCT06077630||Not-attended appointments|An appointment scheduled by a patient that was not-attended, regardless of the cause
62319120|NCT00538382|EXPERIMENTAL|Case|Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
62319121|NCT00538382|ACTIVE_COMPARATOR|Non-pregnant Control|Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
62319122|NCT00538382|ACTIVE_COMPARATOR|Internal Control|Internal controls are defined as the same women(cases)at three months postpartum.
62319123|NCT01639859|EXPERIMENTAL|Elastography|
62480158|NCT06562764|NO_INTERVENTION|Controlled|The control group is the set of subjects that do not receive the intervention in a study.
62480159|NCT06562764|EXPERIMENTAL|Counselling by the Trained Pharmacist|"The intervention group 1 is the set of subjects that receive the counseling intervention in a study."
62480160|NCT06562764|EXPERIMENTAL|Counselling and Pictograms|"Intervention group 2 consists of the subjects who receive the counseling and pictogram intervention in a study."
62480161|NCT04914351|EXPERIMENTAL|Dose Escalation|"Cohort 1: 0.03 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 2: 0.3 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 3: 1 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 4: 2 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 5: 4 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 6: 10 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort."
62128885|NCT05106946|EXPERIMENTAL|ThisCART22 cells injections|In this study, allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
62128886|NCT06186492|EXPERIMENTAL|Experimental WVE-006 (Dose A) or placebo|
62319124|NCT06214949|EXPERIMENTAL|Personalized Repetitive Transcranial Magnetic Stimulation|
62319125|NCT06214949|EXPERIMENTAL|Sham Personalized Repetitive Transcranial Magnetic Stimulation|
62319126|NCT01496573||Basic science (biomarker analysis)|Archived tumor tissue samples are analyzed for CRKL expression.
62319127|NCT01531218|ACTIVE_COMPARATOR|azithromycin|azithromycin 500mg
62319128|NCT01531218|PLACEBO_COMPARATOR|placebo|placebo 500mg
62319129|NCT04221074|ACTIVE_COMPARATOR|Modified Pectoral Plane (PECSII ) block (P)|done after induction of general anaesthesia in supine position of the patient with his arm of the side of the operation abducted 90 degree with the probe with frequency L4-12t (Logiq e machine) at the midclavicular level and angled infero-laterally,the axillary artery and vein and the second rib identified the probe moved laterally until the pectoralis minor and serratus anterior are identified,the local anesthetic was injected at two points using (echoplext guge20 length 50 mm ) needle:the first injection of 10 ml of 0.25% Bupivacaine and 4 mg dexamethasone injected between the pectoralis major and minor muscles,and the second injection of 20 ml of 0.25% Bupivacaine and 4 mg dexamethasone between the pectoralis minor and serratus anterior muscles .
62319130|NCT04221074|ACTIVE_COMPARATOR|Erector Spinae Plane ( ESP )block (E)|after induction of general anaesthesia in lateral position of the patient where the surgical side up and at T4 level the probe with frequency L4-12t (Logiq e machine) placed lateral to the spine by 3 cm in parasagittal plane the needle (echoplext guge20 length 50 mm ) advanced between the transverse process and the erector spinae muscle at that level 20 ml of 0.25% Bupivacaine and 8 mg dexamethasone injected.
62319131|NCT04734756|EXPERIMENTAL|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
62128887|NCT06186492|EXPERIMENTAL|Experimental WVE-006 (Dose B) or placebo|
62319132|NCT06532383|EXPERIMENTAL|PF-07940369 and Placebo (Cohort 1)|Single dose administration of PF-07940369 and placebo; Within a cohort, participants will receive up to 4 oral doses of PF-07940369 and up to 2 doses of placebo.
62319133|NCT06532383|PLACEBO_COMPARATOR|PF-07940369 and Placebo (Cohort 2)|Single dose administration of PF-07940369 and placebo; Within a cohort, participants will receive up to 4 oral doses of PF-07940369 and up to 2 doses of placebo.
62480162|NCT05015751||Hydrocephalus Patients|Hydrocephalus patients with an existing ventriculoperitoneal shunt and symptoms of a shunt malfunction.
62480163|NCT03769896|ACTIVE_COMPARATOR|Treatment Group|Nabilone 0.25 mg
62128888|NCT06186492|EXPERIMENTAL|Experimental WVE-006 (Dose C) or placebo|
62128889|NCT06186492|EXPERIMENTAL|Experimental WVE-006 (Dose D) or placebo|
62128890|NCT06186492|EXPERIMENTAL|Experimental WVE-006 (Dose E) or placebo|
62480164|NCT03769896|PLACEBO_COMPARATOR|Placebo Group|Placebo (corn starch)
62480165|NCT03221530|EXPERIMENTAL|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
62480166|NCT03221530|ACTIVE_COMPARATOR|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
62480167|NCT00679081|EXPERIMENTAL|CelTx|CelTx
62128891|NCT06186492|EXPERIMENTAL|Experimental WVE-006 (Dose F) or placebo|
62128892|NCT06186492|EXPERIMENTAL|Experimental WVE-006 (Dose G) or placebo|
62480168|NCT00679081|ACTIVE_COMPARATOR|Autologous CTG|Autologous sub-epithelial connective tissue graft
62480169|NCT05990907|OTHER|Tilting table without and with RIC|The experimental setup consists of two separate measurements. In the first measurement, the subject is ortho-statically stressed by changing the position (lying to upright) on a tilting table (similar to the established tilting table test). 24 hours after the first measurement, the ischemic preconditioning will be carried out in three cycles with a directly subsequent tilting table test.
62128893|NCT06251570||Patients with Lung Cancer|Patients with Lung Cancer
62480170|NCT03664063|ACTIVE_COMPARATOR|Azithromycin for Yaws|Patients will receive standard treatment for yaws alone
62480171|NCT03664063|ACTIVE_COMPARATOR|IDA for Lymphatic Filariasis|Patients will receive standard IDA (Ivermectin \& Diethylcarbamazine \& Albendazole) treatment for Lymphatic Filariasis alone
62480172|NCT03664063|EXPERIMENTAL|Combination Therapy of Azithromycin for Yaws and IDA for LF|Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.
62128894|NCT06251570||Control Group|Control Group
62128895|NCT00613782|ACTIVE_COMPARATOR|1|Reandron 100 treatment
62128896|NCT00613782|PLACEBO_COMPARATOR|2|Placebo
62319134|NCT05908383|EXPERIMENTAL|GMDTC for injection|The subjects assigned to the treatment group will receive once medication at 8:00 am on the second day after admission.
62319135|NCT05908383|PLACEBO_COMPARATOR|Normal saline group|The subjects assigned to the placebo group will receive once medication at 8:00 am on the second day after admission.
62319136|NCT04004507|EXPERIMENTAL|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye (QD) for one day.
62128897|NCT03340857|EXPERIMENTAL|Intelligent electric bicycle (VELIS) sessions|Intelligent electric bicycle (VELIS) sessions with an instructor, twice a week for 6 weeks
62128898|NCT01522924|EXPERIMENTAL|Counseling practice sessions|Dental students will be administered the first questionnaire before receiving a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients, and debriefing session.
62128899|NCT01522924|NO_INTERVENTION|Lecture only|Students will receive the first questionnaire before the lecture and the second questionnaire after the lecture
62128900|NCT00575614|ACTIVE_COMPARATOR|1|
62128901|NCT00575614|PLACEBO_COMPARATOR|2|
62128902|NCT01184326|EXPERIMENTAL|Dose Level 0: Everolimus 5mg + Pazopanib 600 mg|Everolimus 5mg + Pazopanib 600 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
62128903|NCT01184326|EXPERIMENTAL|Dose Level -1: Everolimus 5mg + Pazopanib 400 mg|Everolimus 5mg + Pazopanib 400 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
62319137|NCT04004507|PLACEBO_COMPARATOR|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye (QD) for one day.
62128904|NCT01184326|EXPERIMENTAL|All Phase I Dose Expansion Participants|All phase I dose expansion participants received Everolimus 5mg and Pazopanib at the maximum tolerated dose established in the dose finding part of the study.
62128905|NCT01184326|EXPERIMENTAL|All Phase I Participants|All phase I participants received Everolimus 5mg and Pazopanib according to the established dose escalation schedule or the maximum tolerated dose established in the dose finding part of the study.
62128906|NCT02617927||Vedolizumab Cohort|"* Group 1a Mothers exposed to Vedolizumab at any time during pregnancy (and up to 3 months prior to last menstrual period \[LMP\], if this information is available).~* Group 1b Infants born to Group 1a patients."
62128907|NCT02617927||Anti-TNF Agents Cohort|"* Group 2a Patients with IBD who were exposed to anti-TNFs at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~* Group 2b Infants born to Group 2a patients."
62128908|NCT02617927||Conventional therapy only Cohort|"Patients with IBD who were exposed to conventional therapy only any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~• Group 3b Infants born to Group 3a patients."
62128909|NCT01873313||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.
62319138|NCT05037903|EXPERIMENTAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy, including behavioral exercises and homework assignments.
62319139|NCT05900414|EXPERIMENTAL|Intervention|Receives web-based information and access to patient decision aid before clinic visit
62319140|NCT05900414|ACTIVE_COMPARATOR|Control|Receives web-based information only before clinic visit
62319141|NCT03716063|EXPERIMENTAL|test group|The test group will oral Jianpi Huatan dispensing granule , once a day in the morning and evening, once a month for a course of treatment, a total of three courses.
62319142|NCT03716063|PLACEBO_COMPARATOR|control group|The control group will oral drug:low-dose control granules (containing 1/10 of the dose of the experimental group) , once a day in the morning and evening, once a month for a course of treatment, a total of three courses
62319143|NCT02083250|EXPERIMENTAL|Treatment (vorinostat, chemotherapy, SCT)|"CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.~TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0."
62319144|NCT01901471|EXPERIMENTAL|CsA Group|
62319145|NCT01901471|PLACEBO_COMPARATOR|Placebo group|
62319146|NCT05420467|ACTIVE_COMPARATOR|TCbHP|HER2-positive breast cancer
62319147|NCT05420467|EXPERIMENTAL|nPCbHP|HER2-positive breast cancer
62319148|NCT05420467|ACTIVE_COMPARATOR|EC-T|Luminal breast cancer (HER2-, more than 4 lymph node metastases), and triple negative breast cancer
62319149|NCT05420467|EXPERIMENTAL|ddEC-wnP|Luminal breast cancer (HER2-, more than 4 lymph node metastases), and triple negative breast cancer
62319150|NCT05420467|ACTIVE_COMPARATOR|TC|Luminal breast cancer (HER2-, with 1-3 lymph nodes)
62319151|NCT05420467|EXPERIMENTAL|nPC|Luminal breast cancer (HER2-, with 1-3 lymph nodes)
62319152|NCT04555655|EXPERIMENTAL|Chicken extract supplement|
62319153|NCT04555655|EXPERIMENTAL|Peptides supplement|
62319154|NCT04555655|PLACEBO_COMPARATOR|Placebo|
62319155|NCT00434850|EXPERIMENTAL|Allogeneic Pancreatic Islet Cells|Participants in this study can receive up to three separate islet transplants. They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant. Participants will continue taking sirolimus for the duration of the study. On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus. The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant. Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant. Etanercept will also be administered on Days 3, 7, and 10 post-transplant. Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
62319156|NCT00672542|EXPERIMENTAL|A|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from untreated monocytes
62319157|NCT00672542|EXPERIMENTAL|B|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with control siRNA
62128910|NCT00522951|EXPERIMENTAL|Gadobutrol 0.1 mmol/kg bw|Participants received first injection (intravenous \[i.v.\]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
62128911|NCT00522951|EXPERIMENTAL|Gadobutrol 0.2 mmol/kg bw|Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
62688272|NCT02005926|EXPERIMENTAL|negative FNA result of abnormal node|Axillary ultrasound examination was undergone for all breast cancer patients before sentinel lymph node biopsy (SLNB). If abnormal axillary lymph node was found, ultrasound-guided FNA cytology of these nodes were performed. The abnormal nodes were defined as completely hypoechoic node, asymmetric focal hypoechoic node, cortical lobulation and cortical thickness \>3mm. Patients with negative results of FNA would undergo SLNB. Technetium-99m-labeled Rituximab was used for lymphatic mapping. Before the SLNB operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
62128912|NCT00522951|EXPERIMENTAL|Gadoteridol (ProHance)|Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
62319158|NCT00672542|EXPERIMENTAL|C|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with siRNA targeting the three inducible immunoproteasome subunits
62319159|NCT03502759|NO_INTERVENTION|Pre-intervention|Seizure patients receive usual care.
62688273|NCT06674239|EXPERIMENTAL|Education|"In the experimental phase of the study, an informed consent form, patient information form, healthy lifestyle behaviors scale, patient follow-up and evaluation form and education booklet were used.~Patient Information Form: This form was developed by the researchers. Healthy Lifestyle Behaviors Scale: The scale, which measures the health-promoting behaviors associated with the individual's healthy lifestyle, consists of a total of 52 items.~Patient Follow-up and Evaluation Form: Metabolic value tests are routinely requested in the institution.~Education Booklet: An education booklet was created based on the literature and the opinions of three experts.~Data collection method: Individualized education was given to the experimental group. Then, the Patient Information Form and the Healthy Lifestyle Behaviors Scale were applied as pre-test and post-test. The laboratory values of the patients were examined and recorded in the Patient Follow-up and Evaluation Form."
62688274|NCT06674239|NO_INTERVENTION|Observation|"Data collection method: Face-to-face interviews were used to inform the patients in the control group about the study and the interview lasted approximately 10-15 minutes. The patients in the control group signed an informed consent form. The Patient Information Form and the Healthy Lifestyle Behaviors Scale were applied as pre-test and post-test in the control group. The laboratory values of the patients were examined and recorded in the Patient Follow-up and Evaluation Form."
62688275|NCT06675149|EXPERIMENTAL|Group B|This group includes 30 patients who will receive 4 weeks(3times/week) DiacutaneusFibrolysis in addition to post-surgical traditional physiotherapy .
62688276|NCT06675149|PLACEBO_COMPARATOR|Group A|This group will includes 30 patients who will receive 4 weeks (3times/week) post-surgical traditional physiotherapy (TENS , massage , ROM exersice ) .
62688277|NCT05504746|EXPERIMENTAL|SHEN26 capsule (SAD and FE part)|SHEN26 capsule 50mg, 200mg, 400mg, 800mg, and 1200mg dose groups
62688278|NCT05504746|EXPERIMENTAL|SHEN26 capsule (MAD part)|SHEN26 capsule 200mg, 400mg, and 600mg dose groups
61925489|NCT04432337|EXPERIMENTAL|Type 2 diabetes patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for TD2 patients after cardiac surgery with extracorporeal circulation .
61925490|NCT04432337|ACTIVE_COMPARATOR|Non-diabetic type 2 patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for non-diabetic type 2 patients after cardiac surgery with extracorporeal circulation
62128913|NCT05708144|EXPERIMENTAL|Indocyanine green-Sacituzumab govitecan-hziy (ICG-SG)|The fresh excision breast cancer tissues were completely soaked in the ICG-SG incubation solution for about 10 minutes, followed by 5 minutes of rinsing with PBS buffer and drying with the use of absorbent paper. Then fluorescence imaging was performed with the DPM NIR-II system. And the result was analyzed to identify the tumor area and distinguish the tumor boundary.
62319160|NCT03502759|EXPERIMENTAL|Post-intervention|Physicians provide care enhanced by computer based clinical decision support about SUDEP.
62319161|NCT03435653|ACTIVE_COMPARATOR|Control group|Control group OFD with DFDBA
62319162|NCT03435653|EXPERIMENTAL|Test group|Test group OFD with decortication and DFDBA
62319163|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
62319164|NCT03092687||substance disorders|decedents with and without substance use disorders
62319165|NCT03014661||Single group study|Single Group study investigating retrospectively the Quality of life of patients with pollinosis under or after specific immunotherapy with Pollinex quattro
62319166|NCT02926573|ACTIVE_COMPARATOR|Gabapentin|Gabapentin liquid by mouth or Per Tube 300mg twice a day
62319167|NCT02926573|PLACEBO_COMPARATOR|Placebo|Placebo liquid by mouth or Per Tube twice a day
62319168|NCT05975567||Diseased cadaveric coronary arteries from individuals with sudden cardiac death|Cadaveric coronary artery segments (5-15 mm) will be excised at necropsy (post mortem) from 10 individuals with SCD likely to have advanced coronary atherosclerosis.
62319169|NCT05975567||Aspirated thrombotic specimens from patients with ST-elevated myocardial infarction|Thrombotic samples will be aspirated from 30 patients with STEMI admitted to the Hippokrateion Hospital of Thessaloniki, Greece and undergoing primary PCI and routine thrombus aspiration per standardized procedures.
62319170|NCT05975567||Calcific aortic valves surgically resected from patients with calcific aortic valve disease|Calcific aortic valves will be surgically removed from 30 patients with CAVD undergoing cardiac surgery for aortic valve replacement.
62319171|NCT02022423|ACTIVE_COMPARATOR|Telephone Counseling|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs
62319172|NCT02022423|EXPERIMENTAL|Internet-based walking program|Weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
62319173|NCT02022423|EXPERIMENTAL|Telephone counseling and Internet-based walking program|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs plus weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
62319174|NCT02022423|NO_INTERVENTION|Usual Care|Subjects will continue with their health care as usual
62319175|NCT03999567|EXPERIMENTAL|Pen and Paper vs. Mobile Digit Symbol Substitution Test|This validation study will assess the convergent validity of the mobile DSST application with the pencil version of the DSST. Correlations between performance on app-based version of the DSST and paper-based version of DSST will be measured.
62319176|NCT00615940|EXPERIMENTAL|1|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with WX-671 once daily by mouth, Days 1-21 inclusive.
62688279|NCT05504746|PLACEBO_COMPARATOR|SHEN26 placebo (SAD and FE part)|SHEN26 placebo 50mg, 200mg, 400mg, 800mg, and 1200mg dose groups
62128914|NCT05265481|NO_INTERVENTION|Baseline|In this phase, the investigators will not apply any venodilation method.
62128915|NCT05265481|ACTIVE_COMPARATOR|Tourniquet applied|The investigators will apply a blood pressure cuff tourniquet inflated to 60 mmHg pressure.
62128916|NCT05265481|ACTIVE_COMPARATOR|Tourniquet plus manual tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein manually.
62128917|NCT05265481|EXPERIMENTAL|Tourniquet plus device tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein with a massage device.
62128918|NCT05036408|EXPERIMENTAL|Supportive care (cancer pain rehabilitation program)|Patients participate in the cancer pain rehabilitation program for 6 weeks, including educational sessions over 2 hours once weekly, group psychological interventions, group physical therapy, and 1:1 physical and occupational therapy treatment per the patient's treatment plan. Patients may also undergo osteopathic manual treatments per physical and occupational therapy assessments.
62128919|NCT04339348|EXPERIMENTAL|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus vaginal inert placebo cream at the time of IUD insertion
62128920|NCT04339348|ACTIVE_COMPARATOR|lidocaine prilocaine cream|Lidocaine-prilocaine anesthetic cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo will be given 3 hours before LNG-IUD insertion
62128921|NCT04339348|PLACEBO_COMPARATOR|placebo|inert vaginal placebo cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours before LNG-IUD insertion
62128922|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
62128923|NCT05045534|EXPERIMENTAL|Cohort 1 Single Dose SD1 (first dose)|Group SD1 a first single dose of TB-840(n=6) or placebo(n=2)
62128924|NCT05045534|EXPERIMENTAL|Cohort 2 Single Dose SD2 (second dose)|Group SD2 a first single dose of TB-840(n=6) or placebo(n=2)
62128925|NCT05045534|EXPERIMENTAL|Cohort 3 Single Dose SD3 (third dose)|Group SD3 a first single dose of TB-840(n=6) or placebo(n=2)
62319177|NCT00615940|EXPERIMENTAL|2|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with placebo once daily by mouth, Days 1-21 inclusive.
62319178|NCT06419036||Patients with COPD|The study population for this research consists of individuals diagnosed with COPD (Chronic Obstructive Pulmonary Disease) who have a history of exacerbation-induced hospitalization within the one-year period preceding recruitment.
62319179|NCT01423240|EXPERIMENTAL|Lurasidone 20 mg|
62319180|NCT01423240|EXPERIMENTAL|Lurasidone 60 mg|
62319181|NCT01423240|PLACEBO_COMPARATOR|Placebo|
62319182|NCT06651697|ACTIVE_COMPARATOR|Full bladder|Full bladder protocol for participants undergoing radiation therapy to pelvis for common malignancies.
62128926|NCT05045534|EXPERIMENTAL|Cohort 4 Single Dose SD4 (fourth dose)|Group SD4 a first single dose of TB-840(n=6) or placebo(n=2)
62128927|NCT05045534|EXPERIMENTAL|Cohort 5 Single Dose SD5 (fifth dose)|Group SD5 a first single dose of TB-840(n=6) or placebo(n=2)
62128928|NCT05045534|EXPERIMENTAL|Cohort 6 Single Dose SD6 (sixth dose)|Group SD6 a first single dose of TB-840(n=6) or placebo(n=2)
62128929|NCT05045534|EXPERIMENTAL|Cohort 7 Single Dose SD7 (seventh dose)|Group SD7 a first single dose of TB-840(n=6) or placebo(n=2)
62319183|NCT06651697|EXPERIMENTAL|Empty bladder|Empty bladder protocol for participants undergoing radiation therapy to pelvis for common malignancies.
62319184|NCT01420640|ACTIVE_COMPARATOR|Tai Chi|
62319185|NCT01420640|ACTIVE_COMPARATOR|Aerobic Exercise Training|
62319186|NCT00976768|EXPERIMENTAL|FOLFIRI arm|Patients receiving FOLFIRI
62688280|NCT05504746|PLACEBO_COMPARATOR|SHEN26 placebo (MAD part)|SHEN26 placebo 200mg, 400mg, and 600mg dose groups
62319187|NCT05215392|EXPERIMENTAL|Smartphone Application|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app.
62319188|NCT05215392|ACTIVE_COMPARATOR|Treatment As Usual|Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
62480173|NCT04236596|EXPERIMENTAL|Study participants|Study participants received an implanted neurostimulator at their pudendal nerve as part of normal clinical care. This was not an intervention study as clinical care was not modified based on study participation. Participants consented to undergo in the research study steps towards mapping of the pudendal nerve.
62480174|NCT06741683|EXPERIMENTAL|Cohort 1: TDV 0.5 mL|Participants with the age group 18 to 60 years will receive TDV, 0.5 milliliter (mL) subcutaneous (SC) injections, on Day 1 and Day 90.
62480175|NCT06741683|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants with the age group 18 to 60 years will receive placebo (normal saline), 0.5 mL SC injections, on Day 1 and Day 90.
62480176|NCT06741683|EXPERIMENTAL|Cohort 2: TDV 0.5 mL|Participants with the age group 4 to 17 years will receive TDV, 0.5 mL SC injections, on Day 1 and Day 90.
62480177|NCT04831580|ACTIVE_COMPARATOR|Open radical or simple hysterectomy|
62480178|NCT04831580|EXPERIMENTAL|Robotic radical or simple hysterectomy|
62480179|NCT06421935|EXPERIMENTAL|M9466 plus Tuvusertib|
62319189|NCT02725073|EXPERIMENTAL|photodynamic therapy|Photodynamic therapy with a novel photosensitizer and flexible laser catheter
62480180|NCT06421935|EXPERIMENTAL|M9466 Monotherapy|
62480181|NCT06421935|EXPERIMENTAL|M9466 with AA-P(abiraterone acetate and prednisone or prednisolone)|
62688281|NCT06640049|EXPERIMENTAL|Dostarlimab monotherapy|Participants will receive dostarlimab as monotherapy.
62688282|NCT03673930|ACTIVE_COMPARATOR|Zanthozylum armatum|fruit extract
62688283|NCT03673930|PLACEBO_COMPARATOR|Placebo|placebo
62688284|NCT06303752|EXPERIMENTAL|Autologous ADRC|Allocated patients will be treated for the fistula by combined surgical debridement of the fistula tract, closure of the internal orifice and injection of 30 ml lipoaspirate around the entire length of the fistula tract. Lipoaspirate will be harvested from the anterior abdominal wall under the same operation. Two hours later, the patient will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
62688285|NCT06303752|EXPERIMENTAL|allogenic ADRC001|Allocated patients will be treated for the fistula by combined surgical debridement of the fistula tract, closure of the internal orifice and injection of 30 ml lipoaspirate around the entire length of the fistula tract. Lipoaspirate will be harvested from the anterior abdominal wall under the same operation. Two hours later, the patient will receive injection of 5 ml suspension including 30 million cultured allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
62319190|NCT04014504||study group|The results of the hearing screening test of the beats of the patients who have undergone pethidine in the active phase of labor will be examined. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at.
62688286|NCT00341874||1|Subjects with hearing loss consisting of both nonsyndromic and syndromic forms of deafness of genetic etiology
62688287|NCT04986137||Group 1|Acute kidney injury due to acute tubular necrosis
62688288|NCT04986137||Group 2|Acute kidney injury due to prerenal azotemia
62688289|NCT04986137||Group 3|Acute kidney injury due to hepatorenal syndrome type 1
62688290|NCT02534623|ACTIVE_COMPARATOR|Spinal anesthesia|Transurethral resection of the bladder performed under spinal anesthesia.
62688291|NCT02534623|ACTIVE_COMPARATOR|General anesthesia|Transurethral resection of the bladder performed under general anesthesia.
62319191|NCT04014504||control group|In the active phase of labor, hearing screening test results of beats of pediatric patients will be evaluated. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at. control group.
62319192|NCT02389413|EXPERIMENTAL|PQ912 oral|PQ912 will be administered orally twice daily for 12 weeks.
62319193|NCT02389413|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally twice daily for 12 weeks.
62319194|NCT02009137|EXPERIMENTAL|EVERA|EVERA- korean ESTES system, apply for 12 weeks
62319195|NCT02009137|ACTIVE_COMPARATOR|ESTES|ESTES apply for 12 weeks
62480182|NCT05365451|EXPERIMENTAL|Arm 1A: metformin alone (baseline)|Arm 1A will consist of administration of a single dose of metformin (50 mg) by mouth as a liquid to 16 subjects (8 males, 8 females). Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 2A and 2B. A washout of at least 7 days will occur between Arm 1A and Arm 1B.
62480183|NCT05365451|EXPERIMENTAL|Arm 1B: metformin + cimetidine|Arm 1B will consist of administration of a single oral dose of cimetidine (400 mg) with water by mouth. One hour later, metformin (50 mg) will be administered by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 2A and 2B. A washout of at least 7 days will occur between Arm 1B and Arm 2A.
62480184|NCT05365451|EXPERIMENTAL|Arm 2A: furosemide alone (baseline)|Arm 2A will consist of administration of a single dose of furosemide (5 mg) by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. A washout of at least 7 days will occur between Arm 2A and Arm 2B.
62480185|NCT05365451|EXPERIMENTAL|Arm 2B: furosemide + probenecid|Arm 2B will consist of administration of a single oral dose of probenecid (1,000 mg) with water by mouth. One hour later, furosemide (5 mg) will be administered by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 1A and 1B. A washout of at least 7 days will occur between Arm 2B and Arm 1A.
62688292|NCT00608790|EXPERIMENTAL|1|
62688293|NCT06398574|EXPERIMENTAL|Real dry needling|With the subject lying supine, a dry needling technique will be applied to the infraspinatus muscle.
62688294|NCT06398574|SHAM_COMPARATOR|Sham dry needling|With the subject lying supine, a sham dry needling technique will be applied to the infraspinatus muscle, simulating the real procedure.
62688295|NCT05772156|EXPERIMENTAL|Prophylactic methylergonovine|Prophylactic methylergonovine 200mcg IM
62688296|NCT05772156|PLACEBO_COMPARATOR|Control group/placebo|Matching placebo
61925491|NCT01171664|PLACEBO_COMPARATOR|Placebo|Placebo containing no active pharmaceutical ingredients
62128930|NCT05045534|EXPERIMENTAL|Cohort 8 Single Dose SD8 (eighth dose)|Group SD8 a first single dose of TB-840(n=6) or placebo(n=2)
62480186|NCT04410731|EXPERIMENTAL|BM-MSC injections for low back pain|Single bilateral intra-articular injections of allogeneic BM-MSCs for lumbar facet joint arthropathy
61925492|NCT01171664|EXPERIMENTAL|STAHIST|STAHIST tablet for the symptomatic treatment of Seasonal Allergic Rhinitis
62128931|NCT05045534|EXPERIMENTAL|Cohort 9 : Mutiple Dose MD1|Group MD1 a first multiple dose of TB-840(n=6) or placebo(n=2)
62128932|NCT05045534|EXPERIMENTAL|Cohort 10 : Mutiple Dose MD2|Group MD2 a first multiple dose of TB-840(n=6) or placebo(n=2)
62480187|NCT05747469|OTHER|Adipose Allograft Matrix (AAM)|Using fluoroscopic guidance (X-ray), a needle will be injected into the joint space. 1 cc of Leneva (adipose allograft matrix, MTF Biologics) will be injected into the joint.
62480188|NCT03379883|PLACEBO_COMPARATOR|Pulsed radiofrequency (P-RF)|Patients will receive both intra articular RF and genicular nerve RF ablation
62480189|NCT03379883|EXPERIMENTAL|Platelet rich plasma (PRP)|Patients will receive intra-articular platelet rich plasma (PRP)
62480190|NCT04380181||Dobutamine|Weaning from cardiopulmonary bypass using dobutamine as inotrope.
62480191|NCT04380181||Milrinone-epinephrine|Weaning from cardiopulmonary bypass using milrinone and epinephrine as inotropes.
62480192|NCT05187208|EXPERIMENTAL|Experimental|BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients (high-grade serous or high-grade endoemtrioid)
62480193|NCT06627270|EXPERIMENTAL|10 days of metronidazole and chlorhexidine|Participants will receive metronidazole (500 mg t.i.d. x 10 days) and chlorhexidine (10 ml t.i.d. x 10 days) prior to surgical resection.
62480194|NCT05579535|ACTIVE_COMPARATOR|group A|classical gait training
62480195|NCT05579535|EXPERIMENTAL|group B|gait training while using weight around ankle
62480196|NCT00004847|EXPERIMENTAL|Adults or children with suspected PHEO/PGL|Patients are adults or children of any age with known, sporadic or familial PHEO/PGL
62480197|NCT00570635|EXPERIMENTAL|A|
62480198|NCT00570635|EXPERIMENTAL|B|
62480199|NCT06572111|EXPERIMENTAL|Part A: BI 1839100 (C-14) formulation 1|BI 1839100 (C-14) = BI 1839100 Carbon 14 Radiolabelled
61925493|NCT05325437|EXPERIMENTAL|Experimental Group|Laparoscopic splenectomy and azygoportal disconnection
62480200|NCT06572111|EXPERIMENTAL|Part B: BI 1839100 followed by BI 1839100 (C-14) formulation 2|
62480201|NCT00326482||Prior Liver Biopsy|HIV+ historical liver biopsy history
62480202|NCT00326482||Prospective Liver Biopsy with ARV|HIV+ taking c/ARV medications
62480203|NCT00326482||Prospective Liver Biopsy without ARV|HIV+ not taking c/ARV medications
62480204|NCT05574270|EXPERIMENTAL|IC-8 IOL Group|A monofocal or monofocal toric IOL implanted in the first eye of a subject and the IC-8 IOL implanted in the second eye.
62480205|NCT02635750|EXPERIMENTAL|Part 1: 25 mg BI 409306 (R1) / 25 mg BI 409306 + 10 mg donepezil (T1)|Subjects received treatment in a fixed sequence. First BI 409306 as reference treatment (R1)), then BI 409306 + donepezil as test treatment (T1)).
61925494|NCT06134609|EXPERIMENTAL|Assigned to intercourse|The study group is subjected to perform intercourse without using a condom at the evening/night after the embryo transfer
61925495|NCT06134609|NO_INTERVENTION|Assigned to abstain|The control group is assigned to abstain from coitus the next 48 hours after the embryo transfer.
61925496|NCT00739492|ACTIVE_COMPARATOR|1|deposit based incentive
61925497|NCT00739492|ACTIVE_COMPARATOR|2|"deposit based incentive framed with maintenance period"
61925498|NCT00739492|NO_INTERVENTION|3|Control arm, no financial incentive
61925499|NCT01232205|ACTIVE_COMPARATOR|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
61925500|NCT01232205|PLACEBO_COMPARATOR|Control|
61925501|NCT06326489|EXPERIMENTAL|780G|Patients in this arm will receive a 780G for three months.
62128933|NCT05045534|EXPERIMENTAL|Cohort 11 : Mutiple Dose MD3|Group MD3 a first multiple dose of TB-840(n=6) or placebo(n=2)
62128934|NCT00585156|EXPERIMENTAL|Arm #1|Celebrex treatment group
62128935|NCT01064336||Pregnant women on eltrombopag|Any women with eltrombopag exposure during pregnancy that is reported prior to or after knowledge of the pregnancy outcome, substantiated by health care provider, and meeting the enrollment criteria: documentation that eltrombopag is being taken during pregnancy; timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to Eltrombopag for stratification and reporting purposes ); sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered; whether the outcome of pregnancy was known at the time of the report; source of the report (i.e. health care professional, patient); full provider contact information to allow for follow-up (name, address, etc.)
62128936|NCT01064336||Infants|Infants through the first year of life whose mothers were exposed to eltrombopag during pregnancy.
62128937|NCT00859794|EXPERIMENTAL|Cognitive and Behavioral Testing|Participants will participate in cognitive tasks where brain recordings and task performance will be monitored and recorded.
62480206|NCT02635750|EXPERIMENTAL|Part 2: 5 mg donepezil (R2) / 5 mg donepezil + 100 mg BI 409306 (T2)|Subjects received first the reference treatment (R2) followed by a washout period, followed by the test treatment (T2).
62480207|NCT02635750|EXPERIMENTAL|Part 2: 5 mg donepezil + 100 mg BI 409306 (T2) / 5 mg donepezil (R2)|Subjects received first the test treatment 2 (T2) followed by a washout period, followed by the reference treatment 2 (R2)).
62480208|NCT01426633|EXPERIMENTAL|Gemcitabine + Trabectedin|
62480209|NCT05393193|OTHER|HIV-exposed neonates|Point-of-care HIV testing at birth
62480210|NCT05393193|OTHER|HIV-positive infants identified through birth HIV screening|Early antiretroviral treatment per standard of care, including dolutegravir-based regimen beginning at 4 weeks of age for infants weighing at least 3.0kg.
62480211|NCT01966666|EXPERIMENTAL|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
62480212|NCT01966666|EXPERIMENTAL|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
62688297|NCT06639490|EXPERIMENTAL|Experimental Group A|Robot-assisted gastrectomy will be performed using RUS GA
62128938|NCT04961021|ACTIVE_COMPARATOR|Medial rectus advancement with resection|Surgery will be done to strengthen the medial rectus muscle with resection and anterior displacement again to the original insertion site 5 mm from limbus
62128939|NCT04961021|ACTIVE_COMPARATOR|Medial rectus advancement with lateral rectus recession|Surgery will be done to strengthen the medial rectus muscle with anterior displacement again to the original insertion site 4- 5 mm from limbus with weakening procedure to the lateral rectus muscle at the same time
62128940|NCT02657733|OTHER|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and Nellcor Bedside Respiratory Patient Monitoring System
62128941|NCT04853706|OTHER|Delirium|
62128942|NCT02395744|EXPERIMENTAL|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 2mm to 4mm in diameter. Following the achievement of optimal interventional results (≤ 30 percent residual stenosis without stenting and without flow-limiting dissection) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment.
62128943|NCT06020313|EXPERIMENTAL|Experimental Resveratrol|Resveratrol capsules (100mg) will be used from 7am to 7pm, de 3 em 3h. That is, at 7 am, 10 am, 1 pm, 4 pm and 7 pm for 7 days.
62128944|NCT06020313|PLACEBO_COMPARATOR|Placebo|After 48h washout, placebo capsules (100mg) will be used from 7am to 7pm, de 3 em 3h. That is, at 7 am, 10 am, 1 pm, 4 pm and 7 pm for 7 days.
62128945|NCT05339113|EXPERIMENTAL|68Ga-FAPI-46 PET/CT + 18-FDG PET/CT|18FDG PET/CT scan is followed by \[68Ga\]FAPI-46 PET/CT within 2-3 days.
62128946|NCT03609008|ACTIVE_COMPARATOR|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
62128947|NCT03609008|PLACEBO_COMPARATOR|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
62688298|NCT06639490|ACTIVE_COMPARATOR|Active Comparator Group B (standard treatment)|Robot-assisted gastrectomy will be performed using without software RUS GA. Only
62128948|NCT01991301|EXPERIMENTAL|carfilzumib|Carfilzomib at a dose of 20mg/m2 I.V. will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no \> grade II toxicity\* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no \> grade II toxicity\* the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.
62480213|NCT01966666|EXPERIMENTAL|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
62128949|NCT05457049||Undetectable MRD|Stage IB-IIIA NSCLC patients who after complete resection. And patients who maintain MRD negativity in two-round MRD landmark test (first in 3-7 days after surgery, second in 1 months ±7 days after surgery) will be enrolled. And patients will be under close dynamic monitoring at least two years.
62128950|NCT04218266|EXPERIMENTAL|BAY2433334 50mg+Apixaban matching placebo|
62128951|NCT04218266|EXPERIMENTAL|BAY2433334 20mg+Apixaban matching placebo|
62128952|NCT04218266|ACTIVE_COMPARATOR|BAY2433334 matching placebo+Apixaban|Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
62128953|NCT04820686|EXPERIMENTAL|VBR + AB-729 + SOC NrtI|Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up.
62480214|NCT01966666|PLACEBO_COMPARATOR|Placebo|
62480215|NCT06560346||FRDA, genetically confirmed|individuals with FRDA, genetically confirmed, aged 4-21yrs
62480216|NCT06560346||Matched healthy controls|Participants in the control group (Group 2) will be aged 4-21 years at enrollment and fulfill group matching criteria to an enrolled participant with FRDA (age, sex)
62688299|NCT00376558|ACTIVE_COMPARATOR|Contingency Management w/ CRA|Cocaine users: Contingency management w/ Community Reinforcement Approach
62688300|NCT00376558|NO_INTERVENTION|Healthy Control|A group of healthy matched comparison subjects with no DSM-IV axis I Disorder was included; they were matched for cigarette smoking, gender, and ethnicity.
62128954|NCT04820686|OTHER|VBR + SOC NrtI|Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment was used as a reference regimen.
62128955|NCT04820686|OTHER|AB-729 + SOC NrtI|Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment was used as a reference regimen.
62128956|NCT03101371|ACTIVE_COMPARATOR|Standard of care catheter insertion|Standard of care catheter insertion in which catheter is inserted right out of package/non-treated catheter.
62480217|NCT05305690||Penetrating cerebrovascular injury, managed nonoperatively|PCVI from penetrating trauma without upfront operation
62688301|NCT06579144|ACTIVE_COMPARATOR|Damactocog alfa pegol|Patients treated with damactocog alfa pegol at the time of screening will receive one single injection with 50 IU/kg at visit 1, then one single dose 50 IU/kg with efanesoctocog alfa at visit 8.
61925502|NCT02015702|EXPERIMENTAL|One-on-one physician training|One-on-one physician training Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
62480218|NCT05305690||Penetrating cerebrovascular injury, managed operatively|
62688302|NCT06579144|ACTIVE_COMPARATOR|Turoctocog alfa pegol|Patients treated with turoctocog alfa pegol at the time of screening will receive one single injection with 50 IU/kg at visit 1, then one single dose 50 IU/kg with efanesoctocog alfa at visit 8.
62128957|NCT03101371|EXPERIMENTAL|Aseptic protocol for catheter insertion|Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter
62128958|NCT03761472|ACTIVE_COMPARATOR|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2 ml solution, once initially.
62480219|NCT02476838|OTHER|traumatic amputation of the hand|may be male or female patients between the ages of 18 and 60 who are missing all or part of one or both hands and forearms
62688303|NCT04802109|PLACEBO_COMPARATOR|CPR with level D PPE|The participant doing CPR for 5 minutes with wearing level D personal protective equipment with surgical face mask
62688304|NCT04802109|EXPERIMENTAL|CPR with level C PPE|The participant doing CPR for 5 minutes with Level C personal protective equipment with N-95 face mask
62688305|NCT04802109|EXPERIMENTAL|CPR with Level C PPE + PAPR|The participant doing CPR for 5 minutes with Level C personal protective equipment with Powered Air-Purifying Respiratory.
62128959|NCT03761472|ACTIVE_COMPARATOR|Platelet-rich plasma injection|Platelet-rich plasma 5 ml, once initially
62128960|NCT03761472|NO_INTERVENTION|Unaffected side Hyaluronic acid|Unaffected sides of the patients will be controls for hyaluronic acid group, no intervention.
62128961|NCT03761472|NO_INTERVENTION|Unaffected side Platelet-rich plasma|Unaffected sides of the patients will be controls for Platelet-rich plasma group, no intervention.
62480220|NCT05362344||NICE-CF Cohort|Adults with CF ages 18 - 75 years who are due for a routine screening or surveillance colonoscopy for colon cancer.
61925503|NCT02015702|ACTIVE_COMPARATOR|Usual training|Usual training. This group will get the usual specified training for learning to use our electronic health record. Both groups received 12 hours of EPIC classroom training, exposure to the EPIC e-learning modules, user acceptability testing classes, and unlimited time on the EPIC 'playground', a site to practice on virtual patients. All had 90 days of elbow support with an EPIC-training non-physician technician, who were visible and available on all inpatient wards, as well as access to a physician-only support line available at all hours.
62688306|NCT05894655|PLACEBO_COMPARATOR|San Ysidro Health Center - Main Clinic|At the main clinic all 3 strategies will be available: walk-up testing, vending machine, and Community Health Worker (CHW) providing education.
62688307|NCT05894655|EXPERIMENTAL|San Ysidro Health Center - Logan Heights|A vending machine and Community Health Worker (CHW) providing education will be available at Logan Heights
62688308|NCT05894655|EXPERIMENTAL|San Ysidro Health Center - Lincoln Park|A vending machine and Community Health Worker (CHW) providing education will be available at Lincoln Park
61925504|NCT00599781|EXPERIMENTAL|PBL/HSC|
61925505|NCT02686528|EXPERIMENTAL|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
61925506|NCT02686528|ACTIVE_COMPARATOR|Hip Precautions|Patients will receive the following hip precautions: no hip flexion past 90º, no crossing the legs, and no twisting at the waist for the first six weeks after surgery.
62128962|NCT05855655|EXPERIMENTAL|Mindfulness-Based Queer Resilience (MBQR)|MBQR is an online, Zoom-based mindfulness course that meets 2.5 hour per week for ten weeks, facilitated by queer mindfulness teachers, with weekly home practice and additional reflection and reading activities that can be completed by participants independently via study website portal. In addition to the 10 weekly sessions there is an all-day retreat (6hrs) that takes place around week 6. The participants also meet one-on-one with the instructor(s) at the beginning and middle of class for a 30-minute welcome call and check in.
62688309|NCT05894655|EXPERIMENTAL|San Ysidro Health Center - Chula Vista|A vending machine and Community Health Worker (CHW) providing education will be available at Chula Vista
62688310|NCT00854737|ACTIVE_COMPARATOR|1|Omega-3 fatty acid and cytidine supplementation
62688311|NCT00854737|ACTIVE_COMPARATOR|2|omega-3 fatty acid supplementation
62688312|NCT00854737|PLACEBO_COMPARATOR|placebo|placeno or sugar pill
62688313|NCT02098603|NO_INTERVENTION|Testing Only|
62688314|NCT02098603|EXPERIMENTAL|Testing & Intervention|
62319196|NCT01583192|ACTIVE_COMPARATOR|chloride-hexidine soluted in alcohol|"patients will have skin preparation with chloride-hexidine soluted in alcohol prior to their forefoot surgery.~Skin swabs will be taken prior to skin preparation, after skin preparation and after skin closure at the end of the operation"
62319197|NCT01583192|ACTIVE_COMPARATOR|povidine-jodine soluted in alcohol|skin perparation will be done with povidine-jodine soluted in alcohol prior to forefoot surgery.
62319198|NCT02471131|EXPERIMENTAL|WATCHMAN Implantation|
62319199|NCT01360164|EXPERIMENTAL|Human umbilical cord mesenchymal stem cells transplantation|Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.
62319200|NCT04621123|EXPERIMENTAL|Experimental group|Subjects randomized to convalescent anti-SARS-CoV-2 MBT plasma plus SMT will receive one infusion of 200 to 300 ml of ABO-compatible convalescent plasma obtained from a convalescent donor.
62319201|NCT04621123|PLACEBO_COMPARATOR|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300 ml of sterile saline solution 0.9%.
62319202|NCT05782556||Patients allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|Patients allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) due to cirrhotic and non-cirrhotic portal hypertension
61925507|NCT04856865|EXPERIMENTAL|Low dose ADP101|Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period. ADP101: Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.
62128963|NCT05855655|ACTIVE_COMPARATOR|Health Education|"The online Health Education course is a self-paced program that can be largely completed independently (no group meeting, no all-day) by control group participants. The ten weekly modules are estimated to take around 30 to 90 minutes each to complete and consist of readings, videos, infographics, and other related activities (e.g., reflections, quizzes).~Participants randomized to the control will be offered an optional MBQR-hybrid course after the 6-month follow-up assessment is complete. MBQR-hybrid is an online-based mindfulness course asynchronously facilitated by queer mindfulness teachers, with weekly home practice and additional reflection and reading activities that can be completed by participants independently via study website portal. Participants will also have the option of participating in weekly live 1-hour sessions. MBQR-hybrid is designed to be completed within a 3-months time frame (10 modules that can be paced to complete in a 10-14 weeks time frame)."
62688315|NCT06510075|EXPERIMENTAL|Digital Health Intervention (DHI)|This group will receive routine prenatal care services. Additionally, those randomized to this arm will receive a DHI intervention. A modified DHI will be utilized that was developed by Memora Health in conjunction with EQUATE partners at UPenn and feedback from the POPPY Study Team and Community Advisory Board. All content is designed for 7th grade Flesch-Kincaid level or lower.
62128964|NCT01970319||Diabetic with nephropathy|
62688316|NCT06510075|EXPERIMENTAL|Community health worker (CHW)|"Individuals randomized to this group will receive routine prenatal care services. Additionally, they will receive a CHW intervention. The CHW intervention will be adapted from an ongoing CHW program in Jefferson County, AL called From Day One (FDO), a comprehensive patient-centered program designed to educate and provide non-clinical, psychosocial, emotional support to expectant mothers from the 1st trimester of pregnancy through 12 weeks postpartum. The intervention has been modified by the POPPY Study Team and Community Advisory Board"
62128965|NCT01970319||Diabetics without nephropathy|
62128966|NCT05439395||STEELEX|Steelex® Sternum Set for sternal closure
62128967|NCT05134324|EXPERIMENTAL|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. The patient received robotic therapy for upper extremity just after each active TMS sessions
62128968|NCT05134324|SHAM_COMPARATOR|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil. The patient received robotic therapy for upper extremity just after each sham TMS sessions
62128969|NCT05134324|EXPERIMENTAL|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions. The patient received robotic therapy for upper extremity just after each active tDCS sessions
62128970|NCT05134324|SHAM_COMPARATOR|sham tDCS|Participants recevied sham stimulation. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
62319203|NCT02965534|EXPERIMENTAL|Night Spectacle Correction|Refraction for this glasses was obtained at low luminance.
62319204|NCT02965534|ACTIVE_COMPARATOR|Spectacle Correction for photopic light conditions|Refraction for this glasses was obtained at high luminance level.
62688317|NCT06510075|EXPERIMENTAL|DHI Plus CHW|This group will receive routine prenatal care services. Additionally, this group will receive both DHI and CHW interventions.
62688318|NCT06510075|NO_INTERVENTION|Usual Care|This group will receive routine prenatal care services.
62688319|NCT01607008|OTHER|MRI imaging|Use of MRI imaging in conjunction with standard radiation treatment
62319205|NCT06247592|EXPERIMENTAL|Radiofrequency group|Pulse radiofrequency will be applied at 42 degrees for 240 seconds with a channel placed near the greater occipital nerve.
62688320|NCT05505786|ACTIVE_COMPARATOR|Normal stance width|Those assigned to this group will complete their pre-season training as normal i.e. when performing their squat exercises they will do so using their habitual (self-selected) stance width.
62128971|NCT05510895|EXPERIMENTAL|neoadjuvant and adjuvant triplet combination of encorafenib, binimetinib and cetuximab|"Neoadjuvant treatment with encorafenib, binimetinib and cetuximab for up to 8 weeks (4 biweekly cycles). In Week 10-12 surgery of the tumor followed by central determination of tumor regression grade (TRG).~TRG0-1: insufficient response to neoadjuvant triplet. Standard chemotherapy with fluoropyrimidines and oxaliplatin should be applied. TRG2-4: 4-8 weeks after surgery adjuvant treatment with encorafenib, binimetinib and cetuximab continues for up to 16 Weeks (8 biweekly cycles)."
62688321|NCT05505786|EXPERIMENTAL|Wide stance width|Those assigned to this (i.e. experimental) group will also complete their pre-season training as normal, the only exception will be that when performing their squat exercises they will increase their stance width by 20% compared to their self-selected stance width.
62688322|NCT06311734|EXPERIMENTAL|Part A: SAD in healthy participants|Part A: Single ascending doses of up to 800 mg LW231 tablets in healthy participants.
62688323|NCT06311734|EXPERIMENTAL|Part b: MAD in healthy participants|Part B: Multiple ascending doses of up to 400 mg LW231 tablets in healthy participants. Dosages will be determined from data collected from Part A.
62688324|NCT06311734|EXPERIMENTAL|Part c: MAD in CHB participants (optional)|Part C: Multiple ascending doses of up to 400 mg LW231 tablets in CHB participants. Dosages will be determined from data collected from Part A and Part B.
61925508|NCT04856865|EXPERIMENTAL|High dose ADP101|Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period. ADP101: Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.
62128972|NCT03381781|EXPERIMENTAL|Experimental group|Patients with p53 mutations will be treated with Decitabine,Arsenic Trioxide and Cytarabine.
62688325|NCT06685770||total intravenous anesthesia groups|In this study, neurological evaluation tests will be performed before and after surgery for patients who will undergo surgery for breast cancer. All patients will be followed during the perioperative period according to the standards specified in the American Society of Anesthesia guideline. Neurological evaluations will be performed at the 24th hour before surgery, on the day of surgery, and on the 1st, 3rd and 5th days after surgery. Those who underwent total intravenous anesthesia after peroperative anesthesia management will constitute this group. The total amounts of propofol and remifentanil consumed in this group will be recorded.
62688326|NCT06685770||inhaled anesthesia groups|In this study, neurological evaluation tests will be performed before and after surgery for patients who will undergo surgery for breast cancer. All patients will be followed during the perioperative period according to the standards specified in the American Society of Anesthesia guideline. Neurological evaluations will be performed at the 24th hour before surgery, on the day of surgery, and on the 1st, 3rd and 5th days after surgery. Those who received inhaler anesthesia after peroperative anesthesia management will constitute this group. In this group, Minimal alveolar concentration levels of sevoflurane and total amounts of remifentanil will be recorded.
62688327|NCT01764932|OTHER|Thoracic epidural catheter insertion|Fluoroscopic imaging. For patients undergoing thoracic epidural analgesia (TEA) with catheter placement for pain associated with thoracic or upper abdominal surgery
62688328|NCT05259605||Gliomas, glioneuronal tumors, and neuronal tumors|
62688329|NCT05259605||Choroid plexus tumors|
62688330|NCT05259605||Embryonal tumors|
62688331|NCT05259605||Cranial and paraspinal nerve tumors|
62688332|NCT05259605||Mesenchymal, non-meningothelial tumors|
62688333|NCT05259605||Melanocytic tumors|
62688334|NCT05259605||Germ cell tumors|
62128973|NCT02231983||Severe Combined Immunodeficiency|Case histories were analyzed to grasp important characteristics of the diseases. Distribution of lymphocyte subsets from peripheral blood were examined by flow cytometry. Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
62688335|NCT05259605||Tumors of the sellar region|
62688336|NCT05259605||Diffuse midline glioma, H3 K27M-mutant|
62688337|NCT05259605||Diffuse hemispheric glioma, H3 G34-mutant|
62688338|NCT05259605||Gliomas and glioneuronal tumors driven by MAPK pathway alterations|
62688339|NCT05259605||Gliomas with MYB/MBL1 alterations|
62688340|NCT05259605||Ependymoma|
62688341|NCT05259605||Pineal tumors|
62688342|NCT05259605||Meningioma with specific driver mutations|
62319206|NCT06247592|ACTIVE_COMPARATOR|Block group|Nerve blockade will be applied to the greater occipital nerve with 5 cc 2% prilocaine.
62688343|NCT05259605||Hemangiopericytoma (Solitary fibrous tumor)|
62688344|NCT05259605||Hemangioblastoma|
62688345|NCT05259605||Genetic tumor syndromes|
62688346|NCT04290897|EXPERIMENTAL|Supportive care (anhydrous enol-oxaloacetate)|Patients receive anhydrous enol-oxaloacetate PO BID for 8 weeks in the absence of worsening symptoms or unacceptable toxicity.
62688347|NCT06083571|EXPERIMENTAL|Intranasal Patients|Intranasal ketorolac (1 spray (15.75mg) if 15kg-29.9kg and 2 sprays (31.5mg) if 30kg or heavier and oral adjuncts oral Prochlorperazine (Between 15-25 kg: dose of 2.5 mg; 26-50 kg: dose of 5 mg; \> 50 kg: dose of 10 mg, single maximum dose 10 mg) and oral Diphenhydramine (Between 15-25 kg: dose of 12.5 mg; 26-50 kg: dose of 25 mg; \> 50 kg: dose of 50 mg, single maximum dose 50mg)
62688348|NCT06083571|ACTIVE_COMPARATOR|Intravenous Patients|IV ketorolac (0.5 mg/kg, maximum single dose of 30 mg) with oral adjuncts oral Prochlorperazine (Between 15-25 kg: dose of 2.5 mg; 26-50 kg: dose of 5 mg; \> 50 kg: dose of 10 mg, single maximum dose 10 mg) and oral Diphenhydramine (Between 15-25 kg: dose of 12.5 mg; 26-50 kg: dose of 25 mg; \> 50 kg: dose of 50 mg, single maximum dose 50mg)
62688349|NCT01964209||No treatment|This is a psychometric study of a screening tool for ADHD, so we will not be administering any treatments or interventions.
62688350|NCT06380907|ACTIVE_COMPARATOR|Arm 1|ZL-1102
62688351|NCT06380907|ACTIVE_COMPARATOR|Arm 2|ZL-1102
62128974|NCT01388777|EXPERIMENTAL|Cryoablation|Cryoablation therapy followed by re-imaging then complete surgical resection.
62688352|NCT06380907|ACTIVE_COMPARATOR|Arm 3|ZL-1102
62688353|NCT06380907|PLACEBO_COMPARATOR|Arm 4|Vehicle
62688354|NCT06380907|PLACEBO_COMPARATOR|Arm 5|Vehicle
62688355|NCT00091897|EXPERIMENTAL|Rituximab or placebo|Rituximab or placebo is administered through intravenous access on day 1 and again on day 15 (+/- 2 days)
62688356|NCT01744366|EXPERIMENTAL|Degarelix|Degarelix 240/80 mg
62688357|NCT01744366|ACTIVE_COMPARATOR|Goserelin|Goserelin 3.6 mg
62688358|NCT06642766|EXPERIMENTAL|Fiber supplemenmt|
62688359|NCT05339425||Osteoporotic fracture|No additional intervention will be administered.
62688360|NCT06640634|EXPERIMENTAL|therapeutic a-tDCS (Th-tDCS)|In patients diagnosed with PDPH, three consecutive days of active a-tDCS intervention are performed starting from the day of diagnosis.
62688361|NCT06640634|SHAM_COMPARATOR|sham in therapeutic t-DCS (Th-tDCS)|In patients diagnosed with PDPH, three consecutive days of sham a-tDCS are performed starting from the day of diagnosis
62688362|NCT06640634|EXPERIMENTAL|preventive a-tDCS (Pr-tDCS)|Patients undergoing a lumbar puncture for diagnostic purposes receive an active a-tDCS intervention for three consecutive days.
62688363|NCT06640634|SHAM_COMPARATOR|sham in preventive tDCS (Pr-tDCS)|Patients undergoing a lumbar puncture for diagnostic purposes receive an sham tDCS for three consecutive days.
62688364|NCT01660373|EXPERIMENTAL|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
62688365|NCT01660373|ACTIVE_COMPARATOR|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
62688366|NCT00896844|EXPERIMENTAL|emotional disclosure|writing about emotional events from the past
62688367|NCT00896844|PLACEBO_COMPARATOR|placebo writing|writing about how they spent their time the previous day
62688368|NCT05872516|EXPERIMENTAL|Software diagnosis|Software diagnosis with gold standard of 3 doctors' consensus.
62688369|NCT04133038||Children consulting|Children consulting in the expert center for food difficulties.
61925509|NCT04856865|EXPERIMENTAL|Pooled Placebo|Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period. Placebo: Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.
62128975|NCT03081611|EXPERIMENTAL|Ram cannula|NIPPV VIA Ram cannula
62319207|NCT03695523|EXPERIMENTAL|PLAY (PhysicaL ActivitY) Policy Intervention|The childcare physical activity policy will be adopted for 8 weeks within participating toddler and preschool classrooms of facilities allocated to the experimental group.
62319208|NCT03695523|NO_INTERVENTION|Control group|Childcare centres will maintain their typical daily programming and standard of care for the duration of the 8-week intervention period.
62688370|NCT04133038||Pierre Robin sequence|Children with Pierre Robin sequence following for food difficulties.
62688371|NCT04133038||Cardiac malformations|Children with cardiac malformations followed for food difficulties.
62688372|NCT04133038||Oesophageal atresia|Children with oesophageal atresia followed for food difficulties.
62688373|NCT04133038||Cleft lip and palate|Children with cleft lip and palate followed for food difficulties.
62688374|NCT04133038||Autism spectrum disorders|Children followed for congenital pathology that cause food difficulties.
62688375|NCT04133038||Ex-prematurity < 32 AG|Children born premature followed for food difficulties.
62688376|NCT04133038||Chromosomal anomalies|Children with chromosomal anomalies followed for food difficulties.
62688377|NCT00022854|PLACEBO_COMPARATOR|1|
62128976|NCT03081611|ACTIVE_COMPARATOR|Short nasal prongs|NIPPV VIA short nasal prongs
62688378|NCT00022854|EXPERIMENTAL|2|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
62688379|NCT00022854|EXPERIMENTAL|3|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
62128977|NCT02283242|EXPERIMENTAL|Galantamine|"* 8 mg of Galantamine for 4 weeks~* 16 mg Galantamine for 8 weeks"
62128978|NCT02283242|PLACEBO_COMPARATOR|Placebo|"* 8 mg of placebo for 4 weeks~* 16 mg placebo for 8 weeks"
62128979|NCT05308056||ECT-patients|Patients receiving routine ECT.
62128980|NCT00797017||001|
62128981|NCT00797017||002|
62128982|NCT00797017||003|
62128983|NCT00797017||004|
62128984|NCT00797017||005|
62128985|NCT00797017||006|
62128986|NCT00797017||007|
62128987|NCT05235906|EXPERIMENTAL|Surufatinib + Sintilimab|
62319209|NCT04766424|EXPERIMENTAL|Behavioral sleep extension group|Participants in the sleep extension group will receive a fitbit, weekly coaching calls and educational materials for 8 weeks. In months 3-6, they will receive educational materials and an email from the coach each month.
62688380|NCT05193383|EXPERIMENTAL|Imaginal exposure|Exposure to mental imagery including a fearful stimulus (spider) and corresponding scenes including a neutral stimulus (leaf)
62128988|NCT06107101|EXPERIMENTAL|Treatment|20 subjects with CRSwNP and asthma that will start Mepolizumab treatment
62128989|NCT06107101|NO_INTERVENTION|Disease control group|10 subjects with CRSsNP without asthma that will not start Mepolizumab and will continue their standard of care treatment.
62128990|NCT06107101|NO_INTERVENTION|Control group|10 healthy subjects without any sinuses disease
62128991|NCT02996669||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
62128992|NCT02996669||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
62319210|NCT04766424|OTHER|Health education|Participants in the health education group will receive 8 weekly health education emails and telephone calls to confirm their receipt and clarify any concepts from the materials. In months 3-6, they will receive monthly health education materials.
62319211|NCT02834403|EXPERIMENTAL|L-NMMA 7.5 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 7.5 mg/kg (starting dose) will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
62688381|NCT05193383|EXPERIMENTAL|In vivo exposure|Exposure to video clips including a fearful stimulus (spider) and corresponding clips including a neutral stimulus (leaf)
62128993|NCT02084849||Group 1|Group 1 will consist of 300 ADPKD individuals who are early in the course of their disease and demonstrate risk factors for progression to ESRD.
62128994|NCT02084849||Group 2|Group 2 will consist of ADPKD subjects who have progressed to a more advanced stage of their renal disease. There is no limit with regard to the number of subjects to be recruited into this group.
62128995|NCT05616754|EXPERIMENTAL|Test group|People more than 4 months after completing basic immunization with recombinant novel coronavirus protein vaccine (CHO cells)
62128996|NCT05616754|ACTIVE_COMPARATOR|control group|People more than 4 months after completing basic immunization with recombinant novel coronavirus protein vaccine (CHO cells)
62128997|NCT05616754|EXPERIMENTAL|Observation group|People over 4 months after completing basic immunization with COVID-19 mRNA vaccine
62128998|NCT06247046|EXPERIMENTAL|Live SK08 powder|Live SK08 powder, (1-25)×10\^9 CFU, oral, twice daily for up to 52 weeks period.
62128999|NCT06247046|PLACEBO_COMPARATOR|Placebo|SK08 placebo matching powder, oral, twice daily for up to 52 weeks period.
62319212|NCT02834403|EXPERIMENTAL|L-NMMA 10 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 10 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
62688382|NCT06645262||Experimental Group|In this group, the intervention will consist of cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
62129000|NCT01558986|ACTIVE_COMPARATOR|Treatment Arm|Patients to receive intravenous cefazolin 1 gram within 30 minutes prior to skin incision
62129001|NCT01558986|PLACEBO_COMPARATOR|Placebo Arm|Patients to receive sterile water only within 30 minutes prior to skin incision
62129002|NCT05127681|EXPERIMENTAL|severe hemophilia A or B patients|30 patients with severe hemophilia A or B (Factor (F)VIII or Factor IX (FIX)≤ 1%) aged 20 to 60 years will be included in this study.
62129003|NCT05127681|OTHER|healthy men|"Data of healthy men, matching in age- height-weight-ethnicity and smoking-matched with patient will be collected. These data are already available at the Institut national de la santé et de la recherche médicale (INSERM) research unit associated."
62129004|NCT05464316|EXPERIMENTAL|Adjustable Transobturator Male System|
62129005|NCT05464316|ACTIVE_COMPARATOR|Artificial Urinary Sphincter|
62129006|NCT00972075|EXPERIMENTAL|Circadin|Circadin is 2 mg of prolonged release melatonin
62129007|NCT00972075|PLACEBO_COMPARATOR|Placebo|
62129008|NCT02619786|EXPERIMENTAL|inhaled colistin|Inhaled colistin 75 mg mixed with normal saline up to 4 ml every 12 hours at least 5 days
62129009|NCT02192242|EXPERIMENTAL|Acute ischemic pain|acute ischemic pain was induced by treadmill testing in all patients investigated
62129010|NCT03015311|EXPERIMENTAL|Intensive BP control|SBP within 110 - \<130 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 110 - \<130 mm Hg.
62129011|NCT03015311|ACTIVE_COMPARATOR|Standard BP control|SBP within 130 - \<150 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 130 - \<150 mm Hg.
62129012|NCT03811587|EXPERIMENTAL|Treatment group|Diabetes type 2 patients will take a fasting mimicking diet of 5 consecutive days a month, for a duration of 12 months. Besides this, they will receive usual diabetes care from the general practitioner.
62129013|NCT03811587|NO_INTERVENTION|Control group|Diabetes type 2 Patients will have no intervention, they will receive usual diabetes care from the general practitioner.
62129014|NCT01290185|EXPERIMENTAL|Coiled Catheter|Placement of the coiled catheter for continuous infusion of local anesthetics close to the femoral nerve: To place coiled catheters ab 18-gauge Tuohy needle (Sonoline Curl Catheter Set, Pajunk® Medizintechnologie GmbH, Geisingen, Germany) of 8 cm length is placed adjacent to the nerve by ultrasound guidance and nerve stimulator control. At this position and after injection of 5 ml dextrose 5% in water to dilate the space the coiled catheter is blindly advanced 2 cm through the needle and the final position verified with ultrasound.
62319213|NCT02834403|EXPERIMENTAL|L-NMMA 12.5 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 12.5 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
62688383|NCT06645262||Control Group|In this group, the intervention will consist of cryotherapy, therapeutic exercises, the use of braces, and manual massage.
62129015|NCT01290185|ACTIVE_COMPARATOR|Conventional stimulating Catheter|For the control group a conventional stimulating catheter is placed adjacent to the femoral nerve as follows: To place the simulating catheter an 18-gauge Tuhoy needle s placed adjacenit to the nerve by ultrasound guidance. At this position a stimulation catheter is introduced through the needle and stimulated with a decreasing current from 1 mA to 0.4 mA, with a pulse width 0.1ms to verify the appropriate motor response of the quadriceps muscle. The catheter is slowly advanced 3 cm beyond the needle tip under continuous electric stimulation using a current that is subsequently adapted according to the motor response achieved. If muscles twitches disappear during catheter placement at a current above 1 mA, either the catheter or the needle are manipulated until muscle twitches reappear.
62129016|NCT05085067|NO_INTERVENTION|Group A: no auto-cross linked hyaluronic acid gel|no auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
62129017|NCT05085067|EXPERIMENTAL|Group B: infusing auto-cross linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
62480221|NCT04709081|EXPERIMENTAL|Part 1: ACH-0145228, Midazolam, and Digoxin|"Period 1: Participants received single doses of midazolam and digoxin.~Period 2: Participants received ACH-0145228 twice daily, in addition to coadministration with single doses of midazolam and digoxin.~Scheduled pharmacokinetics (PK) blood and urine samples were collected, with a washout period of at least 7 days between collection of the last PK blood sample in Period 1 and the first dose of ACH-0145228 in Period 2."
62319214|NCT02834403|EXPERIMENTAL|L-NMMA 15 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 15 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
62319215|NCT02834403|EXPERIMENTAL|L-NMMA 17.5 mg/kg and Docetaxel 100 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 17.5 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 100 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
62319216|NCT02834403|EXPERIMENTAL|L-NMMA 20 mg/kg and Docetaxel 100 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 20 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 100 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
62319217|NCT02834403|EXPERIMENTAL|Phase II: RP2D determined in the Phase Ib|Phase II: L-NMMA starting dose will be the RP2D determined in the Phase Ib portion of the study.
62319218|NCT03710785|EXPERIMENTAL|forward neck posture syndrome patients|Patients diagnosed with forward neck posture syndrome in cervical plain X-ray have a cervical spine extension exercise for 4 weeks
62319219|NCT00890812||Factors VIII, IX and XI levels measured|Case group
62319220|NCT00890812||Non Stroke patients|This is the control group. This group represents patients who were initially evaluated for stroke.
62319221|NCT05896982|NO_INTERVENTION|Care as usual|Patients in this group will not receive any additional information materials or support on top of care as usual, but information videos will be made available after completion of the MPI procedures.
62319222|NCT05896982|EXPERIMENTAL|Care as usual with information support|Patients in this group will primarily receive additional information on the diagnostic process that they will go through with the use of video materials. Supportive coaching will not be provided in this group.
62480222|NCT04709081|EXPERIMENTAL|Part 2: ACH-0145228 and Itraconazole|"Period 1: Participants received a single dose of ACH-0145228.~Period 2: Participants received itraconazole once daily, in addition to coadministration with a single dose of ACH-0145228.~Scheduled PK blood samples were collected, with a washout period of at least 2 days between collection of the last PK blood sample in Period 1 and the first dose of itraconazole in Period 2."
62688384|NCT02858778|EXPERIMENTAL|Interventional group (Ig)|The interventional group (Ig) will have an early palliative care consultation ordered during their stay in the emergency department.
62688385|NCT02858778|NO_INTERVENTION|Control group (Cg)|The control group will be treated as standard of care. Palliative care consultations may or may not be ordered at the attending physician's discretion.
62319223|NCT05896982|EXPERIMENTAL|Care as usual with supportive coaching|Patients in this group will receive supportive coaching throughout their clinic visit. The coach is available for questions as well as specific support for each patient. Information support using video materials will not be supplied to the patients during the diagnostic process in this group, but will be made available after completion of the MPI procedures.
62688386|NCT00078195|EXPERIMENTAL|Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT|Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
62129018|NCT03338868||Patients with MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
62129019|NCT03338868||Patients without MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
62129020|NCT01615393|ACTIVE_COMPARATOR|Ribavirin capsule arm|
62129021|NCT01615393|EXPERIMENTAL|Ribavirin tablet arm|
62129022|NCT04385680|EXPERIMENTAL|Chlorhexidine vaginal prep.arm|"Women in labor who will receive vaginal cleaning immediately before cesarean section using 50 ml of chlorhexidine gluconate 0.05% solution and standard abdominal scrub with chlorhexidine gluconate 4%. This concentration is indicated within the British National Formulary for swabbing in obstetrics. A swab soaked in the antiseptic will be used to clean the vagina for 30 seconds prior to CS at the time of urinary catheter insertion by long forceps.~After the CS procedure, the vagina is always cleaned of excess blood as with a dry swab."
62129023|NCT04385680|NO_INTERVENTION|No vaginal antiseptic arm|Women in labor who will receive abdominal scrub with chlorhexidine gluconate 4% only. Vaginal preparation is not including antiseptic or using normal saline only.
62129024|NCT02343029|EXPERIMENTAL|Intervention|Participants in the Intervention group exercise three times a week for 30 minutes on a bicycle ergometer (optibike med, ergoline GmbH, Bitz, Germany) in the integrated gym hall of one of the participating residencies. Training is individualised as respective performance is adapted to the power at the first ventilator threshold (assessed during cardiopulmonary exercise test).
62129025|NCT02343029|ACTIVE_COMPARATOR|Waiting Control|Participants of Waiting Control continue their regular physical activity behaviour for 12 weeks. They will start the same exercise intervention after a reassessment at week 12 for the next upcoming 12 weeks. (13-24)
62129026|NCT02374307|EXPERIMENTAL|Exercise and education|This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
62129027|NCT02374307|NO_INTERVENTION|Control|The control group performs activities as usual.
62129028|NCT04133337|EXPERIMENTAL|Apatinib Combined With SHR-1210 Injection|"* Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery.~* Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion.~* Surgery:~The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose."
62319224|NCT05896982|EXPERIMENTAL|Care as usual with information support and supportive coaching|Patients in this group will receive both information support as well as supportive coaching during their diagnostic clinic visit.
62319225|NCT03591796|EXPERIMENTAL|HFOV|Ventilated infants were randomized to HFOV.
62688387|NCT00078195|EXPERIMENTAL|Omalizumab pre-treatment, omalizumab|Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
62129029|NCT03681054|EXPERIMENTAL|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
62129030|NCT03681054|EXPERIMENTAL|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
62319226|NCT03591796|ACTIVE_COMPARATOR|CMV|Ventilated infants were randomized to CMV.
62319227|NCT01187797|EXPERIMENTAL|Intervention|
62319228|NCT02407574|EXPERIMENTAL|Spontaneous rhythm first|Stepwise preload increase by repeated administration of 100 mL of fluid during spontaneous rhythm and then stepwise preload reduction by repeated drainage of 100 mL of fluid during atrial pacing.
62319229|NCT02407574|EXPERIMENTAL|Atrial pacing first|Stepwise preload increase by repeated administration of 100 mL of fluid during atrial pacing and then stepwise preload reduction by repeated drainage of 100 mL of fluid during spontaneous rhythm.
62319230|NCT02474017|EXPERIMENTAL|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
62319231|NCT00337298|EXPERIMENTAL|1|Crossover design. Arm is same all the way
62319232|NCT01070550||Cohort|Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.
62319233|NCT03395171|EXPERIMENTAL|Treatment: Cholecalciferol (Vitamin D3)|Athletes with Vitamin D levels lower than 30ng/mL will be treated with the supplement for eight weeks.
62319234|NCT03395171|NO_INTERVENTION|Prospective Control Group|Athletes with Vitamin D levels higher than 30ng/mL were enrolled and compared but not treated.
62319235|NCT00227279|EXPERIMENTAL|1|
62319236|NCT00227279|PLACEBO_COMPARATOR|2|
62319237|NCT02241512|EXPERIMENTAL|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
62319238|NCT02241512|PLACEBO_COMPARATOR|Placebo|Single dose IV normal saline
62688388|NCT00078195|ACTIVE_COMPARATOR|Ragweed RIT, ragweed IT|Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
62688389|NCT00078195|PLACEBO_COMPARATOR|Placebo|Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
62688390|NCT05286112|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT delivered over the course of 10, \~60 minute sessions
62688391|NCT05286112|ACTIVE_COMPARATOR|Health Education|Health education sessions delivered over the course of 10, \~60 minute sessions
62688392|NCT04869384|EXPERIMENTAL|Intervention|Subjects will receive reminders and feedback to improve their adherence via a sensor attached to Easyhaler inhaler and mobile application
62688393|NCT04869384|ACTIVE_COMPARATOR|Usual care|Subjects do not receive reminders and feedback, but receive treatment as usual.
62688394|NCT06597344|EXPERIMENTAL|Gepotidacin|Single Arm
62688395|NCT04816903|EXPERIMENTAL|Symptomatic vaginitis patients|All participants will be enrolled according to their complaints, All will be tested by the Gyni system, Only in the second group the physician will be unblinded to the Gyni results.
62688396|NCT06639360|EXPERIMENTAL|Active-cTBS group|Patients assigned to the Active-cTBS group will be treated with cTBS and usual medical treatment after endovascular treatment
62688397|NCT06639360|SHAM_COMPARATOR|Sham-cTBS group|Patients assigned to the Sham-cTBS group will be treated with sham-cTBS and usual medical treatment after endovascular treatment
62688398|NCT05867888|ACTIVE_COMPARATOR|Control group|conventional physical therapy program (Instructions, Ice application, Deep tissue massage, Stretching exercises, Joint mobilization and isometric exercises).
62688399|NCT05867888|EXPERIMENTAL|Experimental group 1|Shock wave therapy + Conventional physical therapy.
62688400|NCT05867888|EXPERIMENTAL|Experimental group 2|Low level laser therapy + Conventional physical therapy.
62688401|NCT00663260|ACTIVE_COMPARATOR|Dapagliflozin (10 mg)|
62688402|NCT00663260|ACTIVE_COMPARATOR|Dapagliflozin (5 mg)|
62688403|NCT00663260|PLACEBO_COMPARATOR|Placebo|
62688404|NCT05746637||Study population|The entire study population
62688405|NCT06168006|EXPERIMENTAL|Exercise intervention|The subjects randomized to this group will perform three app-based training sessions per week for 12 weeks, each session lasting a maximum of 40 minutes.
62688406|NCT06168006|SHAM_COMPARATOR|Control intervention|This group will receive a booklet with exercise instructions, and will be recommended the same frequency and duration of exercise as the experimental group
62688407|NCT04315922||Severe Ischemic Stroke|Severe Stroke as defined by inclusion criteria
62688408|NCT04315922||Mild Ischemic Stroke|Mild Stroke as defined by inclusion criteria
62688409|NCT04315922||Transient Ischemic Attack|Transient Ischemic Attack as defined by inclusion criteria
62319239|NCT02793908|EXPERIMENTAL|Pleyris|Subcutaneous progesterone will be administered 25 mg a day from the day following the ovulation for 14 days
62319240|NCT02793908|ACTIVE_COMPARATOR|Crinone8|Vaginal progesterone will be administered 90 mg a day from the day following the ovulation for 14 days
62319241|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
62319242|NCT00931892|EXPERIMENTAL|Low gluten group|Subjects will eat 3g of gluten per day
62319243|NCT00931892|EXPERIMENTAL|High gluten group|Subjects will eat 10g of gluten per day
62319244|NCT05186181||group RISEN STAR|Patients with Stanford B-type aortic dissection will be treated with endovascular repair with in situ needle fenestration of left subclavian artery.
62688410|NCT05792345|OTHER|Control|Infiltration will be performed by surgeon at the site of sternotomy
62688411|NCT05792345|ACTIVE_COMPARATOR|With TTMPB|Regional anesthesia is performed with direct view of the nerves and vascular position
62688412|NCT01258426||Normal, IGT, T2DM|
62319245|NCT03081325|EXPERIMENTAL|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
62688413|NCT05422573|NO_INTERVENTION|Standard of care|Pre-test genetic counseling appointment with results returned by phone or EHR. Post-test appointment available upon request.
62688414|NCT05422573|EXPERIMENTAL|Efficiency|Pre-test genetics education by educational video with an OPTIONAL call with a genetic counselor to address questions. Pre-test appointment available by request. Post-test genetic counseling appointment.
62688415|NCT05422573|EXPERIMENTAL|Flipped|Pre-test genetics education by educational video with a REQUIRED call with a genetic counselor to address questions. Pre-test appointment available by request. Post-test genetic counseling appointment.
62319246|NCT01750476||Depo-Provera|Women who choose to initiate Depo-Provera
62319247|NCT01750476||Mirena|Women who choose to initiate Mirena (intrauterine device)
62319248|NCT01750476||Oral contraception|Women who choose to initiate oral contraception
62688416|NCT06636331|EXPERIMENTAL|Treatment S-FICB Arm|S-FICB with PCRA using Ropivacaine 0.2% continuous 2ml/hr, demand dose 5ml as needed.
62688417|NCT06636331|EXPERIMENTAL|Treatment Epidural Arm|Epidural with PCEA using Ropivacaine 0.2% continuous 2ml/hr, demand dose 5ml as needed.
62688418|NCT04847037|EXPERIMENTAL|Connected Tools|For the experimental group, the postoperative procedure requires the use of personal connected tools: a smartphone, a digital tablet or a computer with internet connection. A scale and a connected watch will also be loaned to patients so that they can take the necessary measures. Before returning home, patients must be trained to take correct measures and inform them on the dedicated platform.
62688419|NCT04847037|NO_INTERVENTION|No Connected Tools|Patients randomized to the control group will be operated according to the same protocol as the experimental group. For them, there will be no home follow-up, so no special procedure to follow.
62688420|NCT06690840|EXPERIMENTAL|Atezolizumab plus Cyclophosphamide and Vinorelbine|Atezolizumab 840 mg intravenous (IV) on Days 1 and 15 of every 28-day cycle in combination with Cyclophosphamide 300 mg/m2 IV on Days 1 ,8,15, 21 of every 28-day cycle and Vinorelbine 30 mg per os (PO) on Days 1, 3, 5 every week of every 28-day cycle
62688421|NCT05682677|EXPERIMENTAL|PACT+iTBS|Personalized, Augmented Cognitive Training (PACT; 6 sessions over 4 weeks) + intermittent theta burst stimulation (iTBS; 20 sessions over 4 weeks)
62688422|NCT05682677|SHAM_COMPARATOR|PACT+sham iTBS|Personalized, Augmented Cognitive Training (PACT; 6 sessions over 4 weeks) + sham intermittent theta burst stimulation (sham iTBS; 20 sessions over 4 weeks)
62688423|NCT04679987||paroxysmal Af|
62319249|NCT01708083||Type 2 Diabetes and BMI>35|Patients with type 2 diabetes and body mass index 35 or more.
62319250|NCT01708083||BMI>35|Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
62688424|NCT04679987||no paroxysmal Af|
62319251|NCT01708083||BMI 18-27|Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
62319252|NCT01165203|EXPERIMENTAL|GSK1437173A Group|Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
62319253|NCT01165203|PLACEBO_COMPARATOR|Placebo Group|Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
62319254|NCT03421990||Group A|General anesthesia technique
61925510|NCT06255210|EXPERIMENTAL|Induction chemotherapy in different subtypes of olfactory neuroblastoma|"Induction chemotherapy based on pathological molecular subtypes of olfactory neuroblastoma.~① According to the immunohistochemical results of the pathological report, patients with Ki-67 index ≥ 25% were treated with two weeks of gemcitabine+platinum based chemotherapy regimen;~② According to the immunohistochemical results of the pathological report, patients with Ki-67 index \<25% were treated with a basic chemotherapy regimen of cyclophosphamide+etoposide+cisplatin (CEP regimen);~According to the progression of the patient's disease, the combination of other chemotherapy/small molecule drugs/targeted drugs can be considered;"
62319255|NCT03421990||Group B|Regional anesthesia technique
62319256|NCT04618393|EXPERIMENTAL|EMB-02|"In Phase I part: participants enrolled in the different time will receive EMB-02 once weekly (IV) at different ascending dose levels.~In Phase II part: participants will receive EMB-02 once weekly (IV) at previously defined RP2D."
62319257|NCT05085548|EXPERIMENTAL|Dose Escalation|Participants will receive ProAgio in escalating doses.
62319258|NCT05085548|EXPERIMENTAL|Expansion Biopsy Arm|Pre- and post-treatment tumor biopsy is optional for participants enrolled in the standard arm, but mandatory for participants enrolled in the biopsy arm.
61925511|NCT05882071||Patients initiating treatment with SGLT2i|
61925512|NCT05882071||Type 2 diabetes mellitus patients initiating SGLT2i|
62319259|NCT05085548|EXPERIMENTAL|Standard Arm|Participants will receive ProAgio at the RP2D and may elect to receive concurrent gemcitabine beginning with the start of Cycle 2.
62319260|NCT01564290|PLACEBO_COMPARATOR|probiotic|Probiotic product with Sacharomices Boulardii
62319261|NCT01564290|ACTIVE_COMPARATOR|probiotic yogurt|Yogurt with Lactobacilus Rhamnonsus strain spp
62319262|NCT01671488|EXPERIMENTAL|Treatment|"The first dose will be given 10-14 days prior to the initiation of chemoradiation.~Patient will then receive 5-FU: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days and Mitomycin: 10 mg/m2, day 1 and 29 with IMRT radiation: 54 Gy in 30 fractions at 1.8 Gy per fraction.~The 2-4th dosages of ADXS11-001 will not be until after completion of all chemoradiation. The second dosage of ADXS11-001 will not be administered until a minimum of 10 days after completion of chemoradiation. The subsequent third and fourth treatment with of ADXS11 will be administered at 28 day intervals."
62319263|NCT05222906|EXPERIMENTAL|Venglustat|Venglustat
62319264|NCT05222906|ACTIVE_COMPARATOR|Cerezyme|Cerezyme
62688425|NCT02274233|EXPERIMENTAL|1.5 mg/kg|1.5 mg/kg SP-420 once daily for 14 days
62688426|NCT02274233|EXPERIMENTAL|3 mg/kg|3 mg/kg SP-420 once daily for 14 days
62688427|NCT02274233|EXPERIMENTAL|6 mg/kg|6 mg/kg SP-420 once daily for 14 days
61925513|NCT02417844|ACTIVE_COMPARATOR|Tamsulosin HCl|
61925514|NCT02417844|ACTIVE_COMPARATOR|Tamsulosin|
61925515|NCT01125501|ACTIVE_COMPARATOR|Protandim|one capsule a day for 30 days of protandim given, followed by a wash out period.
61925516|NCT01125501|PLACEBO_COMPARATOR|Placebo|one capsule a day for 30 days will be given followed by a washout period.
62319265|NCT01132573|EXPERIMENTAL|Treatment (entinostat and clofarabine)|"Patients receive entinostat PO on days 1 and 8 and clofarabine IV over 2 hours on days 3-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity (only for patients \>= 60 years of age with newly diagnosed ALL or ABL who are unable or unwilling to tolerate standard multi-agent chemotherapy and patients with relapsed or refractory ALL or ABL).~Patients 40-59 years of age with newly diagnosed ALL receive standard multi-agent induction chemotherapy beginning on day 11. Patients \>= 21 years of age in their first relapse with sensitive disease begin initiation of allogeneic transplant after one course of entinostat and clofarabine."
62319266|NCT02206711|EXPERIMENTAL|Single oral dose of [14C] BMS 955176|A single 180 mg oral dose of \[14C\] BMS-955176 containing approximately 80 microcurie of total radioactivity.
62319267|NCT02206711|EXPERIMENTAL|Nasoduodenal (ND) Tube Cohort|A single dose of \[14C\] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.
62319268|NCT05305638|EXPERIMENTAL|Experimental Group|
62688428|NCT02274233|EXPERIMENTAL|12 mg/kg|12 mg/kg SP-420 once daily for 14 days
62688429|NCT02274233|EXPERIMENTAL|24 mg/kg|24 mg/kg SP-420 once daily for 28 days
62688430|NCT02274233|EXPERIMENTAL|9 mg/kg|9 mg/kg SP-420 twice daily for 28 days
62319269|NCT05305638|EXPERIMENTAL|Control Group|
62319270|NCT05463679|ACTIVE_COMPARATOR|Enzastaurin 500 mg QD|Receive 500 mg enzastaurin QD plus background standard of care.
62319271|NCT05463679|PLACEBO_COMPARATOR|Placebo QD|Matching placebo QD plus background standard of care.
62319272|NCT03621969|EXPERIMENTAL|Group 1|"Group 1 will receive:~1. Medical History and Brief Physical Exam~2. Diagnostic Assessments~3. Patient Instruction and use of RePlay Device~4. two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,~5. then will rest for 2 weeks (weeks 3-4),~6. then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment."
62319273|NCT03621969|EXPERIMENTAL|Group 2|"Group 2 will receive:~1. Medical History and Brief Physical Exam~2. Diagnostic Assessments~3. Patient Instruction and use of RePlay Device~4. two weeks of RePlay device therapy daily at home (they will take the RePlay devices and tablets home) (weeks 1-2), followed by re-assessment,~5. then will rest for 2 weeks (weeks 3-4),~6. then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."
62319274|NCT01185535|ACTIVE_COMPARATOR|2 times topical anesthesia for glottis|
62319275|NCT01185535|ACTIVE_COMPARATOR|3 times topical anesthesia for glottis|
62319276|NCT01185535|ACTIVE_COMPARATOR|4 times topical anesthesia for glottis|
62319277|NCT01837147|EXPERIMENTAL|Web-based Tracking Group|Technology-Based Physical Activity Promotion
62129031|NCT02991534|OTHER|Arm 1|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
62319278|NCT01837147|ACTIVE_COMPARATOR|Pedometer Group|Participants assigned to this group will receive a pedometer.
62319279|NCT06247696|PLACEBO_COMPARATOR|Placebo Pillow|
62319280|NCT06247696|ACTIVE_COMPARATOR|Control Pillow|
62319281|NCT06247696|EXPERIMENTAL|Vata Pillow|
62319282|NCT06247696|EXPERIMENTAL|Pitta Pillow|
62319283|NCT06247696|EXPERIMENTAL|Kapha Pillow|
62319284|NCT02055027||Adherent Patients|Comparison between groups
61925517|NCT06081517||Black patients with advanced cancer|
61925518|NCT06081517||Non Black patients with advanced cancer|
61925519|NCT03733340|EXPERIMENTAL|Imipenem prophylaxis group|Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT
61925520|NCT03733340|NO_INTERVENTION|Blank control group|Without antibacterial prophylaxis at the onset of condition of all-HSCT
62319285|NCT02055027||Non-adherent patients|Comparison between groups
62319286|NCT03961919|EXPERIMENTAL|FLAT-Auto|Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT
62319287|NCT02438436|EXPERIMENTAL|simo decoction|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection until flatus.
62319288|NCT02438436|ACTIVE_COMPARATOR|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
62319289|NCT02438436|NO_INTERVENTION|empty control|
62319290|NCT01629667|EXPERIMENTAL|Tralokinumab 400 milligram (mg)|Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
62319291|NCT01629667|EXPERIMENTAL|Tralokinumab 800 mg|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
62319292|NCT01629667|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
62319293|NCT02270398|EXPERIMENTAL|Dual-task training group|Participants in this group will receive dual-task balance and gait training for half hour and relaxation exercise for another half hour in each session. There will be 3 sessions per week for 8 weeks.
62319294|NCT02270398|ACTIVE_COMPARATOR|Single-task training group|This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
62319295|NCT02270398|ACTIVE_COMPARATOR|Flexibility and strength training group|The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
62319296|NCT05667428|EXPERIMENTAL|Leprorelin group|Leprorelin was given subcutaneously before each cycle of chemotherapy.
62319297|NCT05667428|PLACEBO_COMPARATOR|Control group|Normal salinewas given subcutaneously before each cycle of chemotherapy.
62319298|NCT06415578|ACTIVE_COMPARATOR|control|Only ergonomics training will be given
62319299|NCT06415578|EXPERIMENTAL|exercise|Exercise training will be provided along with ergonomics training.
62688431|NCT04289402|EXPERIMENTAL|Personalized tDCS|Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minutes session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
62688432|NCT04289402|SHAM_COMPARATOR|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
62688433|NCT00605657|EXPERIMENTAL|Valproic acid|Single arm study involving oral administration of valproic acid and monitoring of its efficacy by CT scans done before and after the intervention. Blood samples were also obtained to monitor safety labs and biomarkers.
61925521|NCT02799979||Case|Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months
61925522|NCT02799979||Control|Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline
61925523|NCT05305027||IVF patients: first serum βHCG|IVF patients who undergo βHCG after fresh or frozen embryo transfer
62129032|NCT06004505|OTHER|Vestibular Rehabilitation Group|Vestibular rehabilitation program; Gaze consisted of stabilization, adaptation, neck and balance exercises.
62129033|NCT05582044|EXPERIMENTAL|Heart Failure with Preserved Ejection Fraction (40 Participants)|Lower-body negative pressure (-15 and -25 mmHg) and neutral pressure (0 mmHg)
62129034|NCT05582044|ACTIVE_COMPARATOR|Healthy Controls (20 Participants)|Lower-body negative pressure (-15 and -25 mmHg) and neutral pressure (0 mmHg)
62129035|NCT01868958||CSM subjects|Subjects with clinical indications of cervical spondylotic myelopathy (CSM).
62129036|NCT01868958||Control group|Aged matched to the CSM group but with no signs of CSM
62129037|NCT02789215|EXPERIMENTAL|Intervention|Receive new CACFP menu pattern
62129038|NCT02789215|NO_INTERVENTION|Control|Follow existing CACFP menu pattern
62129039|NCT00147485|EXPERIMENTAL|1|
62688434|NCT06675422|EXPERIMENTAL|JY231 injection for the treatment of active systemic lupus erythematosus|
62129040|NCT06051175|EXPERIMENTAL|Sensory attributes perception - bitter taste|"During the experiment individuals will be exposed to caffeine solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
62319300|NCT05447130|EXPERIMENTAL|Corneal Endothelial Evaluation after Phacoemulsification in Eyes with Pseudoexfoliation Syndrome|
61925524|NCT03325699|EXPERIMENTAL|Intervention|Participants assigned to the intervention group will have access to the SMART4MD health application and participate in clinical visits every 6 months
62319301|NCT05447130|EXPERIMENTAL|Corneal Endothelial Evaluation after Phacoemulsification in Eyes without Pseudoexfoliation|
61925525|NCT03325699|NO_INTERVENTION|Control|Participants assigned to the intervention group will NOT have access to the SMART4MD health application and participate in clinical visits every 6 months
61925526|NCT06364774|EXPERIMENTAL|beta thalassemia|This arm will evaluate the safety and efficacy of infusing autologous hematopoietic stem and progenitor cells (HSPC) transduced with the novel lentiviral vector ALS20 that encodes the human βA-T87Q-globin gene, following myeloablative conditioning with busulfan.
62319302|NCT04302883|EXPERIMENTAL|Intervention group|TEE FEES
62319303|NCT04302883|ACTIVE_COMPARATOR|Control group|FEES
62319304|NCT04116632|EXPERIMENTAL|BMS-963272 or Placebo once daily (QD)|
62319305|NCT04116632|EXPERIMENTAL|BMS-963272 or Placebo every 12 hours (Q12H)|
62319306|NCT04116632|EXPERIMENTAL|BMS-963272 or Placebo every 8 hours (Q8H)|
62688435|NCT03109769|EXPERIMENTAL|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
62688436|NCT03109769|ACTIVE_COMPARATOR|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
61925527|NCT05592522|EXPERIMENTAL|EOI group|Ultrasound-guided bilateral external oblique intercostal (EOI) using 30 ml of 0.25% bupivacaine hydrochloride and oblique subcostal transverse abdominis plane (OSTAP) block using Placebo (NSS 0.9%) 30 ml combined with bilateral posterior rectus sheath block with 15 ml bupivacaine 0.25%.
61925528|NCT05592522|EXPERIMENTAL|OSTAP group|Ultrasound-guided bilateral oblique subcostal transverse abdominis plane (OSTAP) block using 30 ml of 0.25% bupivacaine hydrochloride and external oblique intercostal (EOI) using Placebo (NSS 0.9%) 30 ml combined with bilateral posterior rectus sheath block with 15 ml bupivacaine 0.25%.
62688437|NCT04373551|EXPERIMENTAL|Cultural adaptation of a patient-provider communication tool|Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.
61925529|NCT00637871|EXPERIMENTAL|1|
62319307|NCT05929027|ACTIVE_COMPARATOR|Treatment Arm G1|The interventions will consist of 5 daily sessions over 3 weeks. Because the interventions are self-administered, the sessions are unsupervised in the sense that the sessions do not include synchronous therapy provided by a clinician or a therapist. Instead, during each week, the intervention will include 2 short (less than 15 minutes) telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.
62688438|NCT06232993|EXPERIMENTAL|occlusal splint|A 0.5 mm thick hard thermoplastic acrylic plate was adapted to the model in the laboratory and prepared to cover the occlusal, buccal, and lingual surfaces of the teeth
62688439|NCT06232993|EXPERIMENTAL|kinesio taping|The tape was cut into 2 pieces of an 'I' shape, approximately 5 cm long and 2.5 cm wide, according to the instructions in the manual.
62688440|NCT06232993|EXPERIMENTAL|exercises|Participants in the EG group performed the exercises twice a day, with 10 repetitions and 3 sets for 5 weeks.
61925530|NCT00637871|ACTIVE_COMPARATOR|2|
61925531|NCT05350176|EXPERIMENTAL|Experimental group|Probiotic intake containing 10 billions of Colony Forming Units of Lactobacillus plantarum (1 capsule per day)
61925532|NCT05350176|PLACEBO_COMPARATOR|Placebo group|Placebo intake. Placebo capsules will contain dextrose (1 capsule per day)
61925533|NCT03194503|ACTIVE_COMPARATOR|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
61925534|NCT03194503|NO_INTERVENTION|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
61925535|NCT01764035|ACTIVE_COMPARATOR|Brief Supportive Psychotherapy (SP)|30 people will be randomized to receive Brief Supportive Psychotherapy.
61925536|NCT01764035|EXPERIMENTAL|Body Scan (BS) Meditation Intervention|30 people will be randomized receive the Body Scan Meditation Intervention.
61925537|NCT04113031|EXPERIMENTAL|Flywheel group|The players allocated to the flywheel group will perform six weeks of squat resistance exercise using a flywheel device.
61925538|NCT04113031|EXPERIMENTAL|Barbell free weight group|The players allocated to the barbell free weight group will perform six weeks of squat resistance exercise using a an olympic barbell and free weight of high loads.
61925539|NCT04113031|ACTIVE_COMPARATOR|Control|All players in all three groups (including control group) will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match).
61925540|NCT06390137|EXPERIMENTAL|FSM Treatment Group|Participants receiving the 40 hertz/97 hertz alternating sharp square wave 200 uamp microcurrent treatment (machine is turned on and placed in an opaque bag to cover the screen; the machine is silent and therefore will be indistinguishable form placebo)
62339727|NCT04109235|ACTIVE_COMPARATOR|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
62688441|NCT06356545||Case|Congenital diarrhea and enteropathy (CODE) patients
62688442|NCT06356545||Control|Healthy children
62688443|NCT05333965|EXPERIMENTAL|Lens A, Then Lens B|Participants wore Lens A for one month and then crossed over to wear Lens B for one month.
62688444|NCT05333965|EXPERIMENTAL|Lens B, Then Lens A|Participants wore Lens B for one month and then crossed over to wear Lens A for one month.
62688445|NCT06010563|EXPERIMENTAL|TPVI|
62688446|NCT05044039|EXPERIMENTAL|Dose Escalation Stage: Duvelisib|"* Duvelisib is an oral medication taken on a once or twice daily basis on all dosing days. Doses being explored in this study are 15 mg BID (starting dose), 25 mg BID, and 15 mg QD. In the dose escalation stage, patients will receive duvelisib from Day -2 through Day 28.~* CAR T-cells will be given per standard of care."
62688447|NCT05044039|EXPERIMENTAL|Cohort A Dose Expansion Stage: Duvelisib|"* Patients in Cohort A will receive duvelisib from Day -2 to Day 28. The dose that will be given will be determined in the dose escalation stage (the maximum tolerated dose).~* CAR T-cells will be given per standard of care."
62129041|NCT06051175|EXPERIMENTAL|Sensory attributes perception - salty taste|"Individuals will be exposed to sodium chloride solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
62129042|NCT06051175|EXPERIMENTAL|Sensory attributes perception - sweet taste|"Individuals will be exposed to sucrose solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
62319308|NCT05929027|EXPERIMENTAL|Treatment Arm G2|The intervention will consist of 5 daily sessions over 3 weeks. Because the interventions are self-administered, the sessions are unsupervised in the sense that the sessions do not include synchronous therapy provided by a clinician or a therapist. Instead, during each week, the intervention will include 2 short (less than 15 minutes) telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. In this treatment arm, participants will use a knob-like computer interface connected to a tablet. The tablet features a series of game-like tasks to be carried out by moving the interface with the fingers. The target intervention is scheduled for 1.5 hours per day, which is typically divided into two sessions of 40 minutes with a 10-minute break in between.
62319309|NCT05929027|NO_INTERVENTION|Control Group (CG)|Unlike G1 and G2, the CG will remain in the standard of care treatment plan but will not receive any additional therapy. That is to say, participants will follow standard therapy plans as dictated by normal post-stroke hospital discharge planning. The only difference from the standard of care will be that participants in CG will still receive identical check-in appointments with follow-up questions concerning recovery and activities.
62319310|NCT03247907|ACTIVE_COMPARATOR|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
62319311|NCT03247907|ACTIVE_COMPARATOR|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
62319312|NCT03247907|ACTIVE_COMPARATOR|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
62319313|NCT03247907|ACTIVE_COMPARATOR|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
62319314|NCT03247907|ACTIVE_COMPARATOR|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
62319315|NCT03247907|ACTIVE_COMPARATOR|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
62688448|NCT05044039|EXPERIMENTAL|Cohort B Dose Expansion Stage: Duvelisib|"* Patients in Cohort B will receive duvelisib from Day -2 to Day 180 as follows:~  * Cycle 1 dosing begins on Day -2 and continues through Day 28 followed by 2 weeks off therapy~ * Cycles 2-6 are 28 days long and consist of dosing on Days 1 through 14, with 2 weeks off therapy.~* CAR T-cells will be given per standard of care."
62319316|NCT03247907|ACTIVE_COMPARATOR|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
62319317|NCT03247907|ACTIVE_COMPARATOR|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
62319318|NCT03384849||MRI patients|Up to 200 patients of different age, weight and sex, which undergo MRI examinations.
62319319|NCT05433298|EXPERIMENTAL|Treatment|Patient: Intravenous infusion of single-dose of Mesenchymal stem cells (MSCs)
62480223|NCT04521426||Lung Fibrosis|"1. probable or confirmed diagnosis of interstitial pulmonary fibrosis (IPF) or other fibrotic lung disease of unknown origin.~2. being listed for lung transplantation"
62688449|NCT01209494||Invasive EP Study Group|200 patients are studied before clinically indicated (according to AHA/ACC/ESC guidelines) first ICD implantation or ICD exchange. Invasive EP study is performed to test inducibility of malignant arrhythmia. In addition MAP recordings are performed for measurements of restitution properties. Pacing is done for 12-lead ECG and MAP recordings for analysis of BVR and TWA, if applicable.
62688450|NCT01209494||Noninvasive EP Study Group|"The assignment of patients to the invasive and noninvasive EP groups does not occur by randomization or for intervention.~In the noninvasive EP study group, 500 patients with chronically implanted ICD (\>3 month after implantation) are investigated using non-invasive EP study via ICD programmer. Programmed electrical stimulation is performed to test for inducibility of malignant arrhythmia. In addition pacing is done for measurements of BVR from the 12-lead ECG."
62688451|NCT05696522|EXPERIMENTAL|Treatment arm|Treatment with stereotactic ablative radiotherapy
62688452|NCT01686321|EXPERIMENTAL|Bendamustine and subcutaneous Rituximab|single-arm non randomized
62688453|NCT03400787|SHAM_COMPARATOR|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
62688454|NCT03400787|EXPERIMENTAL|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
62688455|NCT06675045|EXPERIMENTAL|Respiratory Variability Monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
62688456|NCT06569628|EXPERIMENTAL|Intervention group in Long-term Care Centres for old adults|This group participates directly in the incorporation of narrative care through the implementation of life stories and biographies (Envita Stories Methodology) in the long-term care centres for old adults in where they reside, through the specific workshops and by preparing their own life stories
62688457|NCT06569628|ACTIVE_COMPARATOR|Contact group in long-term care Centres for old adults|This group participates indirectly, through the implementation of the Envita Stories Methodology in the long-term care centres for old adults in which they reside but not in them directly
62688458|NCT06569628|NO_INTERVENTION|Control group in Long-term care centres for old adults|This Group resides in a long-term care centres for old adults in which the methodology is not being implemented, although it will be implemented throughout the project process
62688459|NCT03975946|ACTIVE_COMPARATOR|the rheopheresis group|
62688460|NCT03975946|PLACEBO_COMPARATOR|the shamapheresis group|
62688461|NCT01390103||Assessment following the hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
62688462|NCT05795881|NO_INTERVENTION|Control group|continuous enteral nutrition: 24 hours a day (standard of care)
62688463|NCT05795881|EXPERIMENTAL|Intervention group|cyclic daytime enteral nutrition: between 8 a.m. and 8 p.m. (same amount of nutrition as control group)
62319320|NCT05433298|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of single-dose of Ringer's lactate, albumin and heparin solution
62688464|NCT01205412||Assessed Cohort|Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
62688465|NCT01177306|EXPERIMENTAL|Extended Release Guanfacine|pre and post testing of working memory in subjects whose ADHD has responded to extended release guanfacine. Subjects will be tested before starting study drug and after 6-8 weeks on a stable dose of the study drug.
62688466|NCT04773457||Spine Surgery|Pediatric patients presenting for elective spine fusion surgery at Boston Children's Hospital
62688467|NCT04773457||Abdominal Surgery|Pediatric patients presenting for elective abdominal surgery at Boston Children's Hospital
62688468|NCT06637592|EXPERIMENTAL|Calcaneal taping|Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.
62688469|NCT06637592|EXPERIMENTAL|Windlass taping|Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
62319321|NCT00271440|EXPERIMENTAL|CHX 1.0%|1.0% CHX wiping
62319322|NCT00271440|EXPERIMENTAL|CHX 0.5%|0.5% Chlorhexidine
62480224|NCT04521426||COPD standard therapy|"1. COPD: GOLD stage III or IV~2. being listed for lung transplantation~3. did not underwent LVR surgery or endoscopic LVR~4. not being treated with chronic NIV"
62319323|NCT00271440|EXPERIMENTAL|CHX 0.25%|chlorhexidine cleansing with pre-soaked pre-sealed wipe
62480225|NCT04521426||COPD with long-term NIV|"1. COPD: GOLD stage III or IV~2. being listed for lung transplantation~3. did not underwent LVR surgery or endoscopic LVR~4. being treated with chronic NIV before lung transplantation (at least 1 months, at least 4 hours per day)."
62480226|NCT06331910|EXPERIMENTAL|insulin eye drop|
62480227|NCT06742489|EXPERIMENTAL|Treatment group|Participants in this group will receive T-PTNS three times a week for 30 minutes every time.
62688470|NCT01111552|ACTIVE_COMPARATOR|Phase B: Single-blind Prospective Treatment Phase|Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the end of Week 1 based upon tolerability profile, plus one matching placebo capsule, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
62688471|NCT01111552|ACTIVE_COMPARATOR|Phase B+: Single-blind Phase B Responders|Participants with response at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B plus one matching placebo capsule, for an additional 6 weeks, in Phase B+.
62688472|NCT01111552|ACTIVE_COMPARATOR|Phase C: Escitalopram Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
62688473|NCT01111552|ACTIVE_COMPARATOR|Phase C: Aripiprazole Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any week, based upon tolerability.
62688474|NCT01111552|ACTIVE_COMPARATOR|Phase C: Aripiprazole/Escitalopram Combination Therapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
62129043|NCT06051175|EXPERIMENTAL|Sensory attributes perception - acid taste|"Individuals will be exposed to citric acid solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
62129044|NCT06051175|EXPERIMENTAL|Sensory attributes perception - umami taste|"Individuals will be exposed to sodium glutamate monohydrate solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
62319324|NCT02237495|PLACEBO_COMPARATOR|Saline|Normal saline as placebo is continuously infused right after anesthesia induction and lasts for 12 hrs with the same infusion rate as the comparator dexmedetomidine
62319325|NCT02237495|EXPERIMENTAL|dexmedetomidine|dexmedetomidine intravenous infusion starts right after anesthesia induction in the operating room and last for 12 hours into ICU with a infusion dose of 0.4 ug/kg/h. To avoid potential cause of bradycardia, no dexmedetomidine bolus is given.
62480228|NCT06742489|SHAM_COMPARATOR|Sham group|The sham group will use the same device without therapeutic effect as a blank control.
62688475|NCT06556173|EXPERIMENTAL|VTX3232 Dose A|
62688476|NCT03987685|EXPERIMENTAL|Oratopo|To determine the Maximum Tolerated Dose (MTD) of oral topotecan with HM30181A administered once daily for 5 consecutive days every 21 days.
61925541|NCT06390137|PLACEBO_COMPARATOR|Placebo Group (Sham)|Participants receiving sham microcurrent treatment (machine is turned off and placed in an opaque bag to cover the screen)
61925542|NCT06183190||Autoimmune Liver Disease|Autoimmune Liver Disease
62129045|NCT03116620|EXPERIMENTAL|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
62129046|NCT00686855|EXPERIMENTAL|Tacrolimus|Tacrolimus Arm Closed to Accrual as of January 2012
62129047|NCT00686855|EXPERIMENTAL|Dexamethasone|
62319326|NCT04961840||Cohort 1: Pregnant Women Exposed to Prucalopride|Pregnant women with clinically diagnosis of constipation who have been exposed to prucalopride during pregnancy will be observed.
62129048|NCT04961749|EXPERIMENTAL|Vibration group|This group will receive vibration stimulation while standing on a side-alternating vibration platform. Vibration sessions will occur three times per week over four-weeks. Each session will include three-minutes of vibration followed by three-minutes rest, completing this sequence three times per session
62129049|NCT04961749|NO_INTERVENTION|Control group|This group will not receive vibration, but will rather hear a recording of the vibration, while still standing on the vibration platform. Still, this group will receive this training three times per week over four-weeks with a similar three-minute rotation as the vibration group.
62129050|NCT00808106||Albinism|Patients with albinism
62129051|NCT02208869||Patients diagnosed with FH|"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.~Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c \>8%) or hypothyroidism (thyroid-stimulating hormone \>1.5 upper normal limit), renal failure (creatinine clearance \<30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study."
62129052|NCT05965141|EXPERIMENTAL|Aribulin in combination with carboplatin and bevacizumab|This is a one-arm study without randomization. There was only one trial group of Aribulin combined with carboplatin and bevacizumab.
62319327|NCT04961840||Cohort 2: Pregnant Women Not Exposed to Prucalopride|Pregnant women with clinical diagnosis of constipation who have been exposed to other laxative and not prucalopride constipation drugs during pregnancy will be observed.
62319328|NCT04961840||Cohort 3: Untreated Pregnant Women|Pregnant women with clinical diagnosis of constipation with no recorded prescription dispensed for any constipation drugs during pregnancy will be observed.
62129053|NCT06515951||STANDING group|Consecutive adult patients who access the emergency room due to vertigo / imbalance will be considered eligible for the study. in this group patients will be evaluated by STANDING protocol
62129054|NCT06515951||Control group|Consecutive adult patients who access the emergency room due to vertigo / imbalance will be considered eligible for the study. in this group patients will be evaluated by standard of care
62129055|NCT01824420|EXPERIMENTAL|Study group|Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
62129056|NCT01824420|EXPERIMENTAL|Control group|Tolterodine (Detrusitol) 4mg QD
62319329|NCT02644525|PLACEBO_COMPARATOR|Placebo|Subjects given vitamin placebo
62319330|NCT02644525|EXPERIMENTAL|Imatinib 200mg|Subjects given a single dose of imatinib 200mg PO
62319331|NCT02644525|EXPERIMENTAL|Imatinib 400mg|Subjects given a single dose of imatinib 400mg PO
62319332|NCT02644525|EXPERIMENTAL|Imatinib 600mg|Subjects given a single dose of imatinib 600mg PO
62319333|NCT04364074|EXPERIMENTAL|GoodBelly Probiotic|Subjects randomized to this arm consume one serving of the Goodbelly lactobacillus plantarum 299v probiotic
62319334|NCT04364074|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm consume one serving of the Goodbelly that does not contain lactobacillus plantarum 299v
62319335|NCT06347822|EXPERIMENTAL|Single-Session Therapy Visit|Subjects will have a single-session therapy visit with an Integrated Behavioral Health (IBH) clinician.
62319336|NCT02832726|ACTIVE_COMPARATOR|cyano-hydroxo B12|Absorption of 3 doses of 9 ug cyano-B12 and 9 ug hydroxo-B12 for two days (the CobaSorb test). No drugs given.
62319337|NCT02832726|ACTIVE_COMPARATOR|Cyano-B12 doses|Absorption of 3 doses of 3 ug, 6 ug, and 9 ug cyano-B12 for two days (the CobaSorb test). No drugs given.
62319338|NCT06532019|NO_INTERVENTION|usual care group|Patients in this group will receive usual medical care for heart failure.
62480229|NCT00707330|EXPERIMENTAL|1|Subjects randomised to this arm will first be treated with Clarithromycin for a week, then have a 2-week washout, and finally one week of no treatment
62480230|NCT00707330|ACTIVE_COMPARATOR|2|Subjects randomised to this arm will first receive one week of no treatment, then have a 2-week washout, and finally be treated with Clarithromycin for a week
62480231|NCT06736691|EXPERIMENTAL|Emodepside|
62480232|NCT06736691|ACTIVE_COMPARATOR|Mebendazole|
61925543|NCT06183190||Wilsons Disease|Wilsons Disease
61925544|NCT06183190||Healthy Control|Healthy Control
61925545|NCT03354975|EXPERIMENTAL|Experiential Training|
61925546|NCT03354975|ACTIVE_COMPARATOR|Training-as-usual|
61925547|NCT05028738|ACTIVE_COMPARATOR|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
61925548|NCT05028738|ACTIVE_COMPARATOR|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
61925549|NCT05192122|OTHER|Bone marrow MRD-negative VGPR or CR|Discontinue maintenance therapy after at least three years
61925550|NCT05192122|OTHER|Bone marrow MRD-positive VGPR or CR|Continue maintenance therapy as per SOC
61925551|NCT06425159|ACTIVE_COMPARATOR|BHV-7000 75 mg|
61925552|NCT06425159|PLACEBO_COMPARATOR|Placebo|
61925553|NCT03508427|EXPERIMENTAL|Toi Même plus treatment as usual|"One-Arm study Intervention: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.~Tool: Toi Même mobile app"
61925554|NCT02594332|EXPERIMENTAL|Mepolizumab|100 mg SC every 4 weeks for 13 injections
61925555|NCT02594332|EXPERIMENTAL|Placebo|Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
62129057|NCT03435770|EXPERIMENTAL|EUSRA RFA needle|This procedure is very similar to the standard technique of EUS-guided fine needle aspiration. All patients would undergo EUS with a linear array or therapeutic echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the EUSRA RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue.
62688477|NCT03624556|EXPERIMENTAL|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
62688478|NCT03624556|PLACEBO_COMPARATOR|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
61925556|NCT01900639|ACTIVE_COMPARATOR|aspirin on awakening|intake of 80 acetylsalicylic acid on awakening for 2 weeks
61925557|NCT01900639|EXPERIMENTAL|aspirin at bedtime|intake of 80mg acetylsalicylic acis at bedtime
61925558|NCT04383899||Case patient|Patients from the cohort with severe coronavirus infection necessitating intensive care (artificial ventilation) with ulterior recovery or fatal outcome.
62129058|NCT02698813|EXPERIMENTAL|UCMSCs-HA|Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).
62688479|NCT03960346|OTHER|Esophageal Effects|To determine the correlation between rate of temperature decline and nadir cryoballoon temperatures rate of temperature decline and nadir esophageal temperatures during pulmonary vein isolation. Esophageal temperature probe is used during cryoablation to measure temperatures and then a 4-7 days post procedure esophagoscopy is performed to evaluate the physical effects on the esophagus.
62129059|NCT02698813|ACTIVE_COMPARATOR|Control|Procedure: Transdermal injection of hyaluronic acid only.
61925559|NCT04383899||Control patient|All patients from the cohort with non-severe coronavirus infection, who were not admitted to hospital or who were admitted to hospital but without the need for intensive care, and who recovered.
61925560|NCT03473249|NO_INTERVENTION|Retrospective Review|Comparison of CT and CEUS results from retrospective chart review of children who have had a CEUS for trauma at the Children's Hospital of Philadelphia (CHOP).
62319339|NCT06532019|EXPERIMENTAL|targeted intervention group|Patients in this group, besides usal medical care for heart failure, will receive targeted therapy: correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower NT-proBNP, CRP, NYHA Classification, to add diuretics for patients with higher RADs, multidiscipline intervention for patients complicating COPD, and actively reperfusion for ischemic HFpEF patients.
62688480|NCT02941029||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
62688481|NCT02002715|ACTIVE_COMPARATOR|Inhaled budesonide for 4 weeks|inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
61925561|NCT03473249|NO_INTERVENTION|Prospective Observation|Prospective observation of comparison of CT and CEUS results among children who are undergoing a CEUS and abdominal CT as part of clinical care.
62688482|NCT02002715|ACTIVE_COMPARATOR|Inhaled budesonide for 8 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
62688483|NCT02002715|ACTIVE_COMPARATOR|Inhaled budesonide for 16 weeks|inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
61925562|NCT03473249|OTHER|Contrast-Enhanced Ultrasound using Lumason|Prospective intervention using contrast enhanced ultrasound with IV contrast Lumason.
61925563|NCT06088381|EXPERIMENTAL|Intermediate Risk Experimental Observation|"Requires the following criteria:~1. Pathological T1-3 N1-2 with negative surgical margins~2. Absent or microscopic extracapsular extension(ECE) (≤1mm)~3. ctDNA positive pre-operatively and negative post-operatively~This group will undergo observation on the experimental arm of the study. They will be monitored for toxicity, Quality of Life (QoL) and outcomes evaluation. Suspected locoregional recurrence (LRR) based on physical examination, imaging or increasing ctDNA will undergo completion of workup at the discretion of the University of Maryland Head and Neck tumor board. LRR will be offered salvage treatment based on recommendations from multi-disciplinary discussion. Salvage therapy could include surgical resection (with or without adjuvant treatment), and definitive RT (with or without chemotherapy)."
61925564|NCT02779465|EXPERIMENTAL|Vitamin D|Drug: Vitamin D3 800 IU daily besides the anti-virus treatment with nucleos(t)ide medicine
61925565|NCT02779465|NO_INTERVENTION|Control|chronic hepatitis B patients with long term anti-virus therapy
61925566|NCT05350735|EXPERIMENTAL|Intervention arm: SMS text reminders and medical card|Participants in this intervention arm will receive the routine medical card indicating return date for the subsequent doses of anti-rabies vaccine and SMS reminders sent a day before each dose until the scheduled date of the last dose of anti-rabies vaccine.
61925567|NCT05350735|NO_INTERVENTION|Control arm: Medical card|Participants in the control arm will receive the routine medical card indicating return date for the subsequent doses of anti-rabies vaccine. No SMS text reminders will be sent to this group.
62319340|NCT03593304|ACTIVE_COMPARATOR|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
62688484|NCT05688111|ACTIVE_COMPARATOR|Tranexamic acid group|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
62688485|NCT05688111|PLACEBO_COMPARATOR|Glucose water group|Participants will receive 30 mL of 5% glucose water slowly intravenously immediately during the attack of the bleeding, twice daily for 48 hours. Accompanied with the usual expectant management care.
61925568|NCT02521103|OTHER|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
62129060|NCT04478851|EXPERIMENTAL|Intervention|All participants will be involved in group exercise classes, twice a week for 12 weeks.
62129061|NCT05640180||External control arm (ECA)|ECA built from patients from Optum® Electronic Health Records (EHR) real world data (RWD) that closely match Sodium/glucose cotransporter-2 inhibitors (SGLT2i) subgroups from the randomized clinical trials (RCTs).
62129062|NCT05640180||Internal control arm (ICA)|ICA built from participants from two RCTs called FIDELIO-DKD and FIGARO-DKD pooled for the FIDELITY analyses. FIDELIO-DKD/FIGARO-DKD placebo controls treated with SGLT2is at baseline.
62129063|NCT02677129|EXPERIMENTAL|home-based exercise intervention|"home-based exercise intervention:~Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems."
62688486|NCT05510167|ACTIVE_COMPARATOR|Study|Complete abstinence or ≤2 drinks/week in group 1 during the study period
62129064|NCT02677129|NO_INTERVENTION|Waiting control group|The wait list control group receives usual care over the study period. Usual care depends on the hospital guidelines as well as oncologists' and physicians' consideration.
62129065|NCT05537675||20 patients with meningioma|20 meningioma patients will be included in this study, 10 of whom will have been treated with Lutathera®.
62129066|NCT05537675||10 patients will have been treated with Lutathera®.|10 patients of the 20 will have been treated with Lutathera®.
62319341|NCT03593304|PLACEBO_COMPARATOR|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
62688487|NCT05510167|ACTIVE_COMPARATOR|Control|Allowed to continue their pre-ablation drinking habit
62688488|NCT06638970|EXPERIMENTAL|Secretome Injection|patient will receive 4 times secretome injection every two weeks for two months
62688489|NCT06638970|NO_INTERVENTION|Best Treatment Practice|patient will receive standart therapy for four months
62688490|NCT06673576|EXPERIMENTAL|Patients assigned for esthetic crown leghthening|
62688491|NCT02254460|EXPERIMENTAL|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
61925569|NCT04713657|ACTIVE_COMPARATOR|Propranolol|The target dose of Propranolol hydrochloride for this study target dose for this study will be 4 mg/kg/day divided in 4 doses. The concentration of propranolol solution is 20 mg/5 mL. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with propranolol will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
62129067|NCT06357234|EXPERIMENTAL|Aprepitant|Two doses of 40mg (2ml) Aprepitant
62319342|NCT01531491|EXPERIMENTAL|Hypercapnia group|Respiratory rate will be 10/min and the rebreathing tube will be connected between the y-piece of corrugated tube and the tracheal tube to maintain the partial pressure of the end-tidal carbon dioxide at around 50 mmHg during emergence after propofol anesthesia.
62688492|NCT02254460|PLACEBO_COMPARATOR|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
61925570|NCT04713657|PLACEBO_COMPARATOR|Placebo|Placebo will be given in a volume that corresponds to the patient's weight. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age. There is no current standard of care for pharmacologic therapy for infants with ToF. As such, there are no alternative treatments, and the placebo group is standard of care.
61925571|NCT04493879|EXPERIMENTAL|Bioptron Light Therapy (BLT) group|Received Bioptron Light Therapy (BLT) ten minutes every day for one month plus the routine medical treatment of oral mucositis(Analgesics, anti-inflammatory medication and antimicrobial therapy for any new mouth infections
61925572|NCT04493879|EXPERIMENTAL|Routine medical care group|Received only the routine medical care of oral mucositis for one month this consists of analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections
62129068|NCT06357234|PLACEBO_COMPARATOR|Dextrose|Two doses of dextrose (2ml)
62129069|NCT01923480|EXPERIMENTAL|15% CLINISOL 0.04 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
62129070|NCT01923480|EXPERIMENTAL|15% CLINISOL 0.08 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
62319343|NCT01531491|EXPERIMENTAL|Hypocapnia group|No rebreathing tube (Nothing) will be connected. Respiratory rate will be 10/min and the tidal volume will be modulated to maintain the partial pressure of the end-tidal carbon dioxide at around 30 mmHg during emergence after propofol anesthesia.
62688493|NCT04726956||case cohort|Pancreatic ductal adenocarcinoma patients (140)
62688494|NCT04726956||control cohort|healthy donors (140)
62688495|NCT04726956||Benign cohort|patients with Intraductal papillary mucinous tumor of the pancreas (IPMN), mucinous cystadenoma, or pancreatic cyst (30)
62129071|NCT01923480|EXPERIMENTAL|15% CLINISOL 0.13 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
62688496|NCT06674278||Patients with changes in ECG repolarization parameters and arrhythmias during acute COVID-19|
62688497|NCT06674278||Patients without changes in ECG repolarization parameters and arrhythmias during acute COVID-19|
62688498|NCT06642623|EXPERIMENTAL|Enavogliflozin Group|Subjects will take Enavogliflozin according to the investigator's judgment.
62688499|NCT06642623|ACTIVE_COMPARATOR|Dapagliflozin, Empagliflozin Group|Subjects will take Dapagliflozin or Empagliflozin according to the investigator's judgment.
62688500|NCT06285357|NO_INTERVENTION|control|
62688501|NCT06285357|EXPERIMENTAL|treatment|
62688502|NCT06289049|EXPERIMENTAL|Exercise Group|The exercise intervention will consist of 24 supervised, heavy lifting strength training exercise sessions over a 12 week period. The exercise frequency will be two times per week. Main exercises will consist of barbell back squat, bench press, and dead lift.
62688503|NCT06289049|NO_INTERVENTION|Usual Care Group|Participants randomized to the usual care group will be asked to continue will their typical daily routine during the 12 week study period, and not begin any new exercise program to increase their exercise levels from baseline. They will not receive any information or education regarding exercise. After the postintervention assessments, participants in the usual care group will be offered a 4-week introduction to heavy lifting strength training program and/or referred to a community-based exercise program
62688504|NCT02795962|ACTIVE_COMPARATOR|Transfer to an Endovascular Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center.
62688505|NCT02795962|NO_INTERVENTION|Transfer to the Local Stroke Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol.
62688506|NCT00779610|EXPERIMENTAL|Active|Vibration with forearm flexion (active contraction)
62688507|NCT00779610|SHAM_COMPARATOR|Passive|Vibration without forearm flexion (passive)
62319344|NCT02268565|PLACEBO_COMPARATOR|Insomnia symptom induction/placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
62688508|NCT05894083|ACTIVE_COMPARATOR|Surgery|Surgery followed by risk-adjusted adjuvant treatment (observation, radiation, or chemoradiation).
61925573|NCT05773157|OTHER|Receive Online Modules|All participants receiving the same online modules intervention.
62688509|NCT05894083|EXPERIMENTAL|Definitive CRT|Risk-adjusted definitive chemoradiation.
62688510|NCT01808170|ACTIVE_COMPARATOR|laparoscopic ovarian cystectomy|laparoscopic ovarian cystectomy will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
62688511|NCT01808170|ACTIVE_COMPARATOR|laparoscopic cyst deroofing|laparoscopic cyst deroofing will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
62688512|NCT03201094|NO_INTERVENTION|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
62688513|NCT03201094|EXPERIMENTAL|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
62688514|NCT03201094|EXPERIMENTAL|NMES only|Patients will undergo two 30 minute NMES sessions per day during study period.
62688515|NCT03201094|EXPERIMENTAL|HPRO only|Patients will receive HPRO three times daily during study period
62688516|NCT00693511|EXPERIMENTAL|Circuit Training|Participants received CT exercise training two times per week for approximately 60-90 min per session for 16 wk
62688517|NCT00693511|EXPERIMENTAL|Circuit training + motivational interviewing|Participants in the CT + MI group received the same CT classes but also received four individual MI and four group MI sessions throughout the 16-wk program by two trained research staff
62129072|NCT02200523|EXPERIMENTAL|SARA electrode|new electrode
62688518|NCT00693511|NO_INTERVENTION|Control|No intervention
62129073|NCT02200523|ACTIVE_COMPARATOR|Gold cup|gold standard
62129074|NCT01045252||congenital heart disease|Neonates that are enrolled in the NICU and are confirmed of congenital heart diseases.
62129075|NCT01045252||sepsis|Neonates that are enrolled in the NICU and are diagnosed as sepsis.
62319345|NCT02268565|EXPERIMENTAL|Insomnia symptom induction/aspirin|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
62319346|NCT06322823|EXPERIMENTAL|direct thawing|
62319347|NCT06322823|ACTIVE_COMPARATOR|commercially available vitrification thawing|
62688519|NCT04922879|EXPERIMENTAL|Individualized lung rehabilitation programme|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
62319348|NCT01765764|EXPERIMENTAL|Bimatoprost Solution BID|Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.
62129076|NCT01045252||Health|Neonates that are enrolled in the NICU and have no congenital heart diseases and sepsis.
62129077|NCT01625104|EXPERIMENTAL|Group 1: Aggressive Intervention Strategy|"Hospitals were randomized to an aggressive intervention strategy or to business as usual. The hospitals randomized to the aggressive intervention strategy underwent the following:~1. Grand Rounds conducted by physician and nurse from the Coordinating Center. This included a formal presentation on the evidence supporting rapid time to treatment in STEMI patients and evidence based strategies for reducing treatment delays.~2. Discussion with staff regarding perceived barriers to treatment and suggestions/ideas for strategies to overcome these barriers~3. Follow-up monthly phone conferences to continue to discuss strategies and ideas sharing~4. Written plan from sites detailing plans to change processes of care."
62129078|NCT01625104|PLACEBO_COMPARATOR|Group 2: Control Strategy|"Hospitals randomized to the control group were instructed to conduct business as usual."
62129079|NCT05876143||Fixed cementless UKP|Patient implanted with a fixed cementless Unicompartmental prosthesis
62129080|NCT05876143||Fixed cemented UKP|Patient implanted with a fixed cemented Unicompartmental prosthesis
62129081|NCT05876143||Mobile Cementless UKP|Patient implanted with a mobile cementless Unicompartmental prosthesis
62319349|NCT01765764|EXPERIMENTAL|Bimatoprost Solution QD|Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.
62319350|NCT01765764|PLACEBO_COMPARATOR|Vehicle to Bimatoprost Solution BID|Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.
62319351|NCT03070457|EXPERIMENTAL|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
62319352|NCT03070457|ACTIVE_COMPARATOR|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
61925574|NCT06744634||Romania Group|The structured questionnaire was performed by older adults from Romania
62129082|NCT05876143||Mobile Cemented UKP|Patient implanted with a mobile cemented Unicompartmental prosthesis
62129083|NCT05876143||Fixed Cementless UKP (TIT coating)|"Patient implanted with a fixed cementless Unicompartmental prosthesis coating with TIT"
62129084|NCT02906891|EXPERIMENTAL|Usual Care Patients on MDI or CSII|Usual Care Patients on MDI or CSII Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
62129085|NCT04187599|EXPERIMENTAL|Paragon CRT®100 Contact Lens|participants will wear the Paragon CRT®100 lens with a follow up for no less than 12 months.
62129086|NCT04982536|EXPERIMENTAL|VMCore Biopsy System|The VMCore biopsy needle will used to collect up to 10 tissue samples.
62129087|NCT04982536|ACTIVE_COMPARATOR|Standard of Care Biopsy Needle|The urologist will use his/her standard biopsy needle to collect up to 15 tissue samples.
62129088|NCT02034773|EXPERIMENTAL|CC-220 0.3mg x 14 days|
62319353|NCT02816710|EXPERIMENTAL|IVC Preoperative group|Conbercept injection before vitrectomy
62319354|NCT02816710|EXPERIMENTAL|IVC Postoperative group|Conbercept injection at the end of vitrectomy
62319355|NCT02816710|EXPERIMENTAL|IVC Pre- and Post-operative group|First conbercept injection before vitrectomy and second at the end of operation.
62319356|NCT01312428|OTHER|Pelvic Alignment Level (PAL)|Pelvic Alignment Level Instrument Used
62319357|NCT01312428|OTHER|No Pelvic Alignment Level (PAL)|No Pelvic Alignment Level Instrument Used
62319358|NCT01327339||Subjects eligible for REQUIP prescription|Male and female subjects who were considered appropriate to be prescribed REQUIP according to the prescribing information will be included in this study.
61925575|NCT06744634||Turkey Group|The structured questionnaire was performed by older adults from Turkey
62129089|NCT02034773|EXPERIMENTAL|CC-220 1mg x 28 days|
62129090|NCT02034773|EXPERIMENTAL|CC-220 0.3mg x 28 days|
62129091|NCT02034773|EXPERIMENTAL|CC-220 1mg x a total of 14 days|
62129092|NCT02034773|EXPERIMENTAL|Placebo|
62129093|NCT02034773|EXPERIMENTAL|CC-220 0.3mg (once every 3 days for 14 days)|
62129094|NCT02034773|EXPERIMENTAL|CC-220 1mg (once every 7 days for 28 days)|
62129095|NCT02034773|EXPERIMENTAL|CC-220 1mg (formulated and reference capsules)|
62129096|NCT01736514|EXPERIMENTAL|febuxostat group|oral
62129097|NCT01736514|ACTIVE_COMPARATOR|allopurinol group|oral
62319359|NCT02242071|EXPERIMENTAL|Stem Cell|bone marrow mononuclear cell transplantation
62319360|NCT04282473||with mesh|Placement of lightweight (\<50g/m2) monofilament mesh during colostomy formation
62319361|NCT04282473||no mesh|colostomy without mesh placement
62319362|NCT01283191|EXPERIMENTAL|Behavioral Incentives|Vouchers for complying with target behavior
62319363|NCT01283191|PLACEBO_COMPARATOR|Education Control|Education class
62319364|NCT02832804|EXPERIMENTAL|anodal stimulation|10 person The patients treated by anodal stimulation (2mA) for 20 minutes
62319365|NCT02832804|ACTIVE_COMPARATOR|cathodal stimulation|10 person The patients treated by cathodal stimulation (1-2mA) for 20 minutes
62319366|NCT02832804|SHAM_COMPARATOR|sham stimulation|10 person The patients treated by anodal stimulation (1-2mA) for 15 seconds
62319367|NCT04558762||Women who had a MUS inserted.|Women who underwent surgery with insertion of a MUS due to SUI 2006-2010 in Sweden with the MUS coming out retropubic (TVT) or through foramen obturatorium (TOT).
61925576|NCT06744634||Croatia Group|The structured questionnaire was performed by older adults from Croatia
62319368|NCT04558762||Controls|Women who have not had a MUS inserted due to stress urinary incontinence. Matched in age.
62319369|NCT01783626|SHAM_COMPARATOR|Evodial|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
62319370|NCT01783626|EXPERIMENTAL|Evodial+ Condition B1|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
61925577|NCT04557748||Prospective Observational Cohort Study|Men and women with lower urinary tract symptoms.
62129098|NCT00166283|EXPERIMENTAL|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
62129099|NCT00166283|PLACEBO_COMPARATOR|placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
62129100|NCT04680520|EXPERIMENTAL|Best practice skin care advice booklet plus emollient (Doublebase Gel® or Diprobase Cream®)|Use of emollient (Doublebase Gel® or Diprobase Cream®) plus best practice skin care advice. The advice is given in the form of a booklet containing advice on skin care. This will contain information on avoiding soap etc. It will also explain how to apply the emollient i.e. in the direction of the hair, all over the child's skin daily for the first year of life. Intervention group will receive both emollients and parents are asked to choose their preferred.
62319371|NCT01783626|EXPERIMENTAL|Evodial+ Condition B2|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
62319372|NCT01783626|EXPERIMENTAL|Evodial+ Condition C|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
61925578|NCT04557748||Prospective Observational Cohort Study Controls|Men and women who do not have urinary dysfunction.
61925579|NCT04557748||Central Sensitization Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
61925580|NCT04557748||Central Sensitization Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
61925581|NCT04557748||Physical Activity and Sleep Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
62688520|NCT05273736|EXPERIMENTAL|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase medication adherence by 20% between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined by the modified Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous subjects.
62688521|NCT03593278|EXPERIMENTAL|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
62688522|NCT01726608|ACTIVE_COMPARATOR|Radiofrequency neurotomy|Active Radiofrequency Neurotomy
62688523|NCT01726608|PLACEBO_COMPARATOR|Sham|Sham radiofrequency neurotomy
62688524|NCT01149460|EXPERIMENTAL|Valacyclovir|Test 1000 mg Tablet
62688525|NCT01149460|ACTIVE_COMPARATOR|Valtrex|Reference Listed Valacyclovir 1000 mg Tablet
62688526|NCT01882829|EXPERIMENTAL|Nuedexta (dextromethorphan/quinidine)|45/10 mg every 12 hours x 8 weeks
62688527|NCT06637618|ACTIVE_COMPARATOR|standard care|standard care, with physicians choice of the sequence and up-titration of heart failure medications (ACE-inhibitor, beta-blocker, mineralocorticoid receptor antagonist, SGLT2-inhibitor)
62688528|NCT06637618|EXPERIMENTAL|Up-front prescription of mineralocorticoid receptor antagonist, no later than the first ambulatory v|Up-front prescription of mineralocorticoid receptor antagonist, no later than the first ambulatory visit to the heart failure clinic. Earlier use during initial hospitalization is encouraged, but not mandatory
62688529|NCT06447480|EXPERIMENTAL|Drug group|Patients will be followed every month for 6 months in the group isotretinoin. Patients will start at the dose of 0.5 mg/kg/d. If tolerance is poor, the dose could be decrease to 0.25mg/d. After 3 months, following the recommendations the dose could be increase up to 1mg/kg/d depending on the efficacy.
62129101|NCT04680520|ACTIVE_COMPARATOR|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
62688530|NCT06447480|ACTIVE_COMPARATOR|Doxycycline|"Patients will be followed at 3 and 6 months in the group standard of care. They will be prescribed topical tretinoin or adapalene once daily (every other day if irritation) with doxycycline or lymecycline 100 mg/d."
62688531|NCT02985138|EXPERIMENTAL|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
62688532|NCT02985138|ACTIVE_COMPARATOR|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
62688533|NCT01629563|EXPERIMENTAL|Ulipristal acetate (PGL4001) 5mg|All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
62688534|NCT01629563|EXPERIMENTAL|Ulipristal acetate (PGL4001) 10mg|All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
62688535|NCT04403685|EXPERIMENTAL|Tocilizumab|Single-dose tocilizumab of 8 mg/kg (maximum dose of 800mg). Best supportive care.
62129102|NCT04427800||CKD G4|Chronic kidney disease stage (G4). (eGFR \< 30 mL/min/1.73m2)
62129103|NCT04427800||CKD G5|Chronic kidney disease stage (G5). (eGFR \< 15 mL/min/1.73m2) with imminent initiation of RRT
62129104|NCT04427800||ESRD on ICHD|End stage renal disease on in centre haemodialysis
62129105|NCT04427800||ESRD on HHD|End stage renal disease on home haemodialysis
62688536|NCT04403685|NO_INTERVENTION|Control arm|Best supportive care.
62688537|NCT03139721||Primary cohort|Subjects requiring aortic or mitral valve replacement
62688538|NCT03449147|PLACEBO_COMPARATOR|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and the 28-week extension period.
62688539|NCT03449147|EXPERIMENTAL|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and the 28-week extension period.
62129106|NCT04427800||ESRD on PD|End stage renal disease on peritoneal dialysis
62129107|NCT04427800||Post-transplant|Participants post-transplant
62129108|NCT01647724||control 1|standard recall letter to perform HPV test at the clinic
62129109|NCT01647724||Intervention 1|direct mailing of the self sampling device at home
62129110|NCT01647724||intervention 2|invitation to retire the self sampling device in local pharmacy
62129111|NCT03764787|EXPERIMENTAL|Radiation+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
62129112|NCT02563080||First attack of acute pancreatitis|50 patients with first attack of moderately severe or severe acute pancreatitis treated in Helsinki University Hospital.
62129113|NCT05178225|ACTIVE_COMPARATOR|patients with post-COVID-19 syndrome with Mountain spa rehabilitation|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 15 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, for 16 to 18 days
62688540|NCT03449147|EXPERIMENTAL|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and during the 28-week extension period.
62319373|NCT02429596|EXPERIMENTAL|Experimental Treatment|AED(s) currently taken (CBZ, VPA, TPM, OXC, LEV, LTG) will be substituted, starting with the morning dose on day 2, with an equivalent formulation available in the market. Namely, a brand product will be switched to a generic, randomly chosen among those available in the market, while maintaining unaltered the dosing regimen and times of administration.Likewise, a generic product will be switched to the brand or another generic.
62129114|NCT05178225|ACTIVE_COMPARATOR|patients with post-COVID-19 syndrome with Mountain spa rehabilitation + supplementation coenzyme Q10|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 22 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, 22 patients who will be on spa rehabilitation and at the same time on supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg, for 16 to 18 days
62129115|NCT05178225|PLACEBO_COMPARATOR|healthy control|15 healthy control volunteers (no Covid-19 or other pathologies)
62319374|NCT02429596|NO_INTERVENTION|No Experimental Treatment|When the randomized allocation requires continuation on the same product (control), the AED product(s) currently taken will be continued unaltered, with the same dosing regimen and times of administration.
62319375|NCT06498427||Child ACTT - Experimental|"Excerpt from the Partners Child ACTT service definition in North Carolina (Revised 5-23-19):~Program Requirements: Child ACTT (Assertive Community Treatment Team) is a team-based multi-disciplinary approach to serve children in their homes, kinships placements, foster homes ... The team will have daily meetings to prioritize activities, share information, and discuss individual members. The team will be available to respond 24/7 for crisis de-escalation and assessment, inclusive of availability by phone within 15 minutes and face to face within no more than 2 hours. This will include face-to-face assessment by a clinician, or nurse if this is determined to be needed for the individual. The psychiatric provider will be available minimally by phone 24/7 for consultation and treatment recommendations. The team will assess the overall needs of the family to ensure that all necessary treatment and supports are in place for entire family system."
62319376|NCT06498427||PRTF - Treatment as Usual|Psychiatric Residential Treatment Facilities (PRTFs) are non-hospital facilities intended to provide inpatient services to Medicaid-eligible individuals who are under the age of 21. A PRTF's mission is to either improve residents' condition or prevent further regression to ultimately remove the need for such services. PRTFs provide a range of comprehensive services intended to treat residents' psychiatric conditions under the supervision and direction of a psychiatrist. The core components in a PRTF program include at least weekly medication management, 24 hours nursing services, high staff-to-client ratio with awake staff during night hours, individual, group, and family therapy, intensive psychoeducation, behavioral model of care designed to teach new functional skills, and comprehensive assessments as needed.
62129116|NCT03320746|EXPERIMENTAL|Activity trackers|The participants were requested to wear a commercial wrist-worn activity tracker (Polar Loop 2, Polar, Kempele, Finland) every day and night for 12 months.
62319377|NCT00114114|EXPERIMENTAL|Group 1: 0 g/day|Zoladex plus Placebo Testosterone (T) gel
62319378|NCT00114114|EXPERIMENTAL|Group 2: 1.25 g/day|Zoladex plus 1.25 g/day T gel
62319379|NCT00114114|EXPERIMENTAL|Group 3: 2.5 g/day|Zoladex plus 2.5 g/day T gel
62319380|NCT00114114|EXPERIMENTAL|Group 4: 5 g/day|Zoladex plus 5 g/day T gel
62688541|NCT05225584|EXPERIMENTAL|Phase 1a Dose Escalation Lymphomas|KT-333 dosed IV weekly in 28 day cycles
62688542|NCT05225584|EXPERIMENTAL|Phase 1a Dose Escalation Solid Tumors|KT-333 dosed IV weekly in 28 day cycles
62688543|NCT05225584|EXPERIMENTAL|Phase 1b Dose Expansion PTCL|KT-333 dosed IV weekly in 28 day cycles
62129117|NCT03320746|NO_INTERVENTION|No activity trackers|Control group members were requested to abstain from the use of any type of activity trackers and they were informed that they will receive the activity trackers and guidance for using them after the follow-up.
62129118|NCT01259167||BACK group|training with a traditional protocol of Therapeutic Physical Exercise
62129119|NCT01259167||"Group C."|Control group with sedentary people undergoing usual care.
62129120|NCT01259167||JOBA group|training with JOBA® Core Trainer
62129121|NCT04728919||COVID-19 positive cases|Subjects with acute respiratory infection and positive COVID-19 test, who are well enough to be treated at home.
62319381|NCT00114114|EXPERIMENTAL|Group 5: 10* g/day|Zoladex plus 10\* g/day T gel. \*Note that the 10 g/day dose was reduced to 7.5 g/day part-way through the trial
62688544|NCT05225584|EXPERIMENTAL|Phase 1b Dose Expansion CTCL|KT-333 dosed IV weekly in 28 day cycles
62688545|NCT05225584|EXPERIMENTAL|Phase 1b Dose Expansion LGL-L|KT-333 dosed IV weekly in 28 day cycles
62688546|NCT05225584|EXPERIMENTAL|Phase 1b Dose Expansion Solid Tumor|KT-333 dosed IV weekly in 28 day cycles
62688547|NCT05225584|EXPERIMENTAL|Phase 1a Dose Escalation LGL-L|KT-333 dosed IV weekly in 28 day cycles
62688548|NCT05225584|EXPERIMENTAL|Phase 1a Dose Escalation T-PLL|KT-333 dosed IV weekly in 28 day cycles
62688549|NCT04740346|EXPERIMENTAL|3 months follow-up|Patients will be follow-up every 3 months after gastrectomy.
62688550|NCT04740346|ACTIVE_COMPARATOR|6 months follow-up|Patients will be follow-up every 6 months after gastrectomy.
61925582|NCT04557748||Physical Activity and Sleep Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
61925583|NCT04557748||Organ-Based Study|Women enrolled in the Prospective Observational Cohort Study with urinary urgency, with and without urgency incontinence.
61925584|NCT04557748||Organ-Based Study Controls|Women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency pr urgency incontinence.
61925585|NCT04557748||Qualitative Assessment of Patients with Urinary Urgency Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency who have treatment plans prescribed at the baseline visit.
61925586|NCT02801344|EXPERIMENTAL|Normal protein intake|participants will receive the controlled-diet containing 0.8 g protein /kg/day and the test drink containing 0.14 g protein/kg/d.
61925587|NCT02801344|EXPERIMENTAL|Moderate protein intake|participants will receive the controlled-diet containing 1.20 g protein /kg/day and the test drink containing 0.40 g protein/kg/d.
61925588|NCT02801344|EXPERIMENTAL|High protein intake|participants will receive the controlled-diet containing 1.83 g protein /kg/day and the test drink containing 1.03 g protein/kg/d.
61925589|NCT06699056||Cohort Breakdown to Power Accuracy Assessments|"The study will enroll up to 1,500 participants across Subprotocol A and B, with a predictive total cohort of at least 660 unique participants. Each participant must provide at least one valid paired data point, defined as ECHO results paired with at least 30 minutes of Peerbridge COR™ ECG data, acquired concurrently or within 60 minutes of ECHO completion. Enrollment will occur at a minimum of 3 trial sites, with data collection ensuring at least 165 valid paired points per EF Severity category, as determined by the reference ECHO, from different participants.~A paired data point is considered invalid if all 5-minute sitting windows during a 15-minute session yield Not Analyzable outputs. Participants who do not comply with the protocol or do not yield valid paired data points will be excluded from analysis and study statistics. Trial site investigators may use institutional EMR databases to identify, qualify, and recruit participants from their community patient populations."
62688551|NCT02272985|OTHER|CBF change during hemodialysis|\[15O\]H2O PET-CT scan and NIRS (Invos)
62688552|NCT02214628|EXPERIMENTAL|Fovista® plus anti-VEGF Simultaneous|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Simultaneous regimen followed by quarterly administration."
61925590|NCT06674018|PLACEBO_COMPARATOR|Placebo|Placebo
61925591|NCT06674018|EXPERIMENTAL|50 mg IPA|50 mg indole-3-propionic acid
61925592|NCT06674018|EXPERIMENTAL|120 mg IPA|120 mg indole-3-propionic acid
61925593|NCT06674018|EXPERIMENTAL|500 mg IPA|500 mg indole-3-propionic acid
61925594|NCT06703190||Participants testing positive for COVID-19 (i.e., cases)|Participants testing positive for SARS-CoV-2 infection by RAT at a CVS MinuteClinic and reporting at least one COVID-19 symptom
61925595|NCT06703190||Participants testing negative for COVID-19 (i.e. negative controls)|Participants testing negative for SARS-CoV-2 by RAT at a CVS MinuteClinic and reporting at least one COVID-19 symptom
62319382|NCT00114114|EXPERIMENTAL|Group 6: Placebo/Placebo (PBO/PBO)|Placebo Zoladex plus Placebo T gel (controls)
61925596|NCT06728228|EXPERIMENTAL|Amnioinfusion|Those in this experimental arm, Amnioinfusion, will undergo serial amnioinfusion in addition to routine care as deemed appropriate by the study doctor.
61925597|NCT06728228|NO_INTERVENTION|Comfort Care/Expectant Management|The non-experimental arm, Comfort Care/Expectant Management, will undergo comfort care as elected by the participant.
62319383|NCT03336138|ACTIVE_COMPARATOR|AMA group|Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
62688553|NCT02214628|EXPERIMENTAL|Fovista® plus anti-VEGF Pre-Treatment|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment regimen followed by quarterly administration."
62688554|NCT01772693|EXPERIMENTAL|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR guided Focused Ultrasound
62688555|NCT01772693|SHAM_COMPARATOR|Sham ExAblate Transcranial MRgFUS|Sham treatment with ExAblate MR guided Focused Ultrasound
62688556|NCT03523663||Control|healthy children without ADHD or other mental health issues
62688557|NCT03523663||ADHD|children diagnosed with ADHD
61925598|NCT05201924|EXPERIMENTAL|Bedtime routine|A bedtime routine intervention handbook and check list, including bedtime brushing, limited sugar consumption around bedtime, reading books instead of using screen devices before bed, setting a regular bedtime, turning off the light, and reaching a 9 to 11-hour sleep duration
61925599|NCT05201924|ACTIVE_COMPARATOR|control group|healthy lifestyle checklist
61925600|NCT02929251|ACTIVE_COMPARATOR|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
61925601|NCT02929251|EXPERIMENTAL|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
61925602|NCT02929251|EXPERIMENTAL|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
62319384|NCT03336138|NO_INTERVENTION|Control group|Patient with standard follow-up with no specific assistance for ambulatory patients
62319385|NCT01706445|NO_INTERVENTION|Control|
62319386|NCT01706445|OTHER|intervention|Exercise training
62319387|NCT06693479|EXPERIMENTAL|Device + Education|Education session at week 2 and feedback from SWL during week 2 and week 3
62688558|NCT03647137||Parkinson's disease without FoG|Subjects with Parkinson's disease that do not have freezing of gait observed during motor assessment while both on or off dopaminergic medication who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
62688559|NCT03647137||Parkinson's disease with FoG only while off-meds|Subjects with Parkinson's disease that have freezing of gait observed during motor assessment only while off dopaminergic medication who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
62688560|NCT03647137||Parkinson's disease with FoG worse while off-meds|Subjects with Parkinson's disease that have freezing of gait observed during motor assessment while both on and off dopaminergic medication, but greater severity of FoG under off-med, who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
62688561|NCT03647137||Parkinson's disease with FoG equivalent between on and off meds|Subjects with Parkinson's disease that have freezing of gait observed during motor assessment while both on and off dopaminergic medication, with no apparent effect of dopaminergic medication on FoG, who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
62688562|NCT03851952|OTHER|Optilume DCB|Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
62688563|NCT05870111|EXPERIMENTAL|Citicoline|2000mg/day citicoline for 4 weeks, administered orally
62688564|NCT05870111|PLACEBO_COMPARATOR|Placebo|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
62688565|NCT06382207|OTHER|Digital Stethoscopes to measure neonatal tachyarrhythmias|Parental caregivers of infant research subjects are trained to use technology (digital stethoscopes) to decrease stress and unnecessary trips to the emergency room.
62688566|NCT05593770|EXPERIMENTAL|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
61925603|NCT03624296|EXPERIMENTAL|patient with multiple sclerosis (MS)|
61925604|NCT02666534|EXPERIMENTAL|AFL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
61925605|NCT02666534|ACTIVE_COMPARATOR|MAL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
61925606|NCT04468321|EXPERIMENTAL|Apple Watch|Patients will be provided with the Apple Watch Series 6 with Irregular Rhythm Detection and ECG capabilities.
61925607|NCT04468321|PLACEBO_COMPARATOR|Withings Move|Patients will be provided with the Withings Move with activity tracking.
61925608|NCT06238817|EXPERIMENTAL|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
61925609|NCT06238817|PLACEBO_COMPARATOR|VC Period: Vehicle Cream BID|Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
62129122|NCT04728919||COVID-19 negative controls|Subjects with acute respiratory infection and negative COVID-19 test, who are well enough to be treated at home.
62319388|NCT06693479|ACTIVE_COMPARATOR|Education|Education session at week 2.
62319389|NCT02337504|NO_INTERVENTION|clinic-based care|Will receive HIV care at the clinic from the nurses and clinical officer on their regular schedule
62319390|NCT02337504|ACTIVE_COMPARATOR|Community-based care|Will receive HIV care in their community from a community health worker every month as part of a group of 6-10 people
62319391|NCT01323673|ACTIVE_COMPARATOR|Clobetasol Propionate 0.05%|
62319392|NCT01323673|PLACEBO_COMPARATOR|Vehicle|
62129123|NCT03671252|EXPERIMENTAL|Experimental: Group 1|Patient will receive FOLFOXIRI regimen every two weeks for 4-6 cycles within 2-3 months.Two weeks after completing 3 and 6 cycles of FOLFOXIRI regimen,patients will have two efficacy evaluations according to RECIST criteria and toxicity evaluation .If the tumor is defined as no progression without severe toxicity at the first efficacy evaluation, the rest of 3 cycles of FOLFOXIRI regimen will be performed.If it is defined as progression of primary tumor or it is defined as progression of primary tumor and MRF(+)at the second efficacy evaluation,patients are assigned into active comparator group. If distant metastasis occurred during chemotherapy, patients are treated according to the guidelines for metastatic colorectal cancer.Chemotherapy is initiated at 3-4 weeks after R0 resection. XELOX regimen is performed post-operatively (about 4-6 cycles). If postoperative pathology confirmed as positive margin, postoperative chemoradiotherapy was given.
62129124|NCT03671252|ACTIVE_COMPARATOR|Active Comparator:Group 2|The patients are scheduled to receive chemoradiotherapy. After 5 weeks from the end of chemoradiotherapy, patients will have a efficacy evaluation according to RECIST criteria. If the tumor is defined as CR、PR or SD, and the TME operation is conducted within 5-10 weeks after chemoradiotherapy completion. If tumor is defined as progressive disease with the possibility of R0 resection, the operation was also conducted within 5-10 weeks after chemoradiotherapy . If tumor is defined as progressive disease without possibility of R0 resection, the palliative chemotherapy was performed . If distant metastasis occurred during chemoradiotherapy, patients are treated according to the guidelines for metastatic colorectal cancer. Adjuvant chemotherapy of XELOX is performed post-operatively (about 4-6 cycles).
62319393|NCT02186327|NO_INTERVENTION|Standard care|The control arm will continue to receive standard care as they did prior to enrollment.
62480233|NCT06742411|EXPERIMENTAL|XELOX+Sintilimab+HBOT|"Patients will receive the XELOX regimen, consisting of oxaliplatin (130 mg/m² IV on Day 1) and capecitabine (1000 mg/m² orally twice daily for 14 days, repeated every 3 weeks), combined with sintilimab (200 mg IV on Day 1 every 3 weeks) and hyperbaric oxygen therapy (HBOT) administered alongside the XELOX regimen. Treatment will be administered for 4 to 6 cycles.~Following the initial treatment phase, patients will be evaluated for response. If disease progression is observed, patients will exit the study and receive subsequent treatments as deemed appropriate. For patients with stable disease or a response to therapy, maintenance treatment with capecitabine and sintilimab will continue until the occurrence of a study endpoint or other specified criteria."
62480234|NCT06319495|EXPERIMENTAL|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
62480235|NCT06319495|PLACEBO_COMPARATOR|Rehabilitation therapy+placebo|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
62480236|NCT06146972|EXPERIMENTAL|RF positive group|Iguratimod (25mg per tablet) 25mg twice daily plus tofacitinib (5mg per tablet) 5mg twice daily for 24 weeks.
62480237|NCT06146972|EXPERIMENTAL|RF negative group|Iguratimod (25mg per tablet) 25mg twice daily plus tofacitinib (5mg per tablet) 5mg twice daily for 24 weeks.
62480238|NCT05382858|EXPERIMENTAL|PSA-STN|Participants randomized in this arm will receive bilateral PSA stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral STN stimulation for another two months.
62480239|NCT05382858|EXPERIMENTAL|STN-PSA|Participants randomized in this arm will receive bilateral STN stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral PSA stimulation for another two months.
62129125|NCT02318407|EXPERIMENTAL|AMG 403|AMG 403 administered as subcutaneous doses
62129126|NCT02318407|PLACEBO_COMPARATOR|Placebo|No active drug
62319394|NCT02186327|EXPERIMENTAL|Integrative health coaching|Subjects in this arm will receive 6 sessions of integrative health coaching over a 3 month period, in addition to standard care.
62319395|NCT04323397|EXPERIMENTAL|nasal high frequency oscillatory ventilation|"nHFO: flow 8-10 L/minute, frequency 10 Hz, MAP = MAP (before extubation) + 2 or 8 (preterm), 10 (term) cmH2O, dP = 2-3 times of MAP with visible chest oscillations or 25-35 cmH2O, I:E = 1:1, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%"
62688567|NCT05593770|PLACEBO_COMPARATOR|Placebo|"Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
62688568|NCT02755883|EXPERIMENTAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
62319396|NCT04323397|EXPERIMENTAL|nasal synchronized intermittent positive pressure ventilation|"nSIPPV: flow 8-10 L/minute, rate 60/minute, PIP = PIP (before extubation) + 2-5 or 20 (preterm), 25 (term) cmH2O, PEEP = 5 cmH2O, IT = 0.5 s, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%. The highest trigger sensitivity avoiding auto triggering was selected."
62319397|NCT04389476||Medical staff in high contact with patients|
62319398|NCT04389476||Other personnel in low contact with patients|
62319399|NCT04389476||Patients|
62688569|NCT02755883|ACTIVE_COMPARATOR|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
62319400|NCT04389476||Community residents|
62319401|NCT05566197|EXPERIMENTAL|Intervention|This group will receive dietary adjustment and nutrition counseling.
62129127|NCT04110054|EXPERIMENTAL|S-600918 50 mg|Participants will receive 50 mg S-600918 orally once a day for 28 days.
62129128|NCT04110054|EXPERIMENTAL|S-600918 150 mg|Participants will receive 150 mg S-600918 orally once a day for 28 days.
62129129|NCT04110054|EXPERIMENTAL|S-600918 300 mg|Participants will receive 300 mg S-600918 orally once a day for 28 days.
62129130|NCT04110054|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to S-600918 orally once a day for 28 days.
62129131|NCT05952895||Stage III, Grade C Periodontitis|Conventional quadrant-wise scaling and root planing (SRP)
62129132|NCT05419570||Patients Undergoing Pancreaticoduodenectomy|
62129133|NCT03046810|EXPERIMENTAL|Wellness toileting system|This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
62129134|NCT01332045|SHAM_COMPARATOR|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
62129135|NCT01332045|ACTIVE_COMPARATOR|Continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
62129136|NCT02745340|ACTIVE_COMPARATOR|Acetate|
62129137|NCT02745340|EXPERIMENTAL|Citrate|
62129138|NCT01886729|ACTIVE_COMPARATOR|tDCS simultaneously with hyperbaric oxygen therapy|
62129139|NCT01886729|ACTIVE_COMPARATOR|tDCS 3 weeks after start tinnitus|
62129140|NCT04113798|EXPERIMENTAL|Moderate Intensity Exercise|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction
62129141|NCT04113798|ACTIVE_COMPARATOR|Control|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction
62129142|NCT05871112||Patella positioning after TKR + FUZION|Patients who underwent TKR - femoral component rotation established with a use of a dynamic tensioner (FUZION)
62129143|NCT05871112||Patella positioning after standard TKR|Patients who underwent standard TKR performed with measured resection technique
62129144|NCT00421070|NO_INTERVENTION|Treatment as usual|Observational component
62319402|NCT05566197|ACTIVE_COMPARATOR|Control|This group will receive standard diet and nutrition counseling.
62319403|NCT01729598|EXPERIMENTAL|Valproic Acid|Valproic acid 250 mg or 500mg by mouth twice daily.
62129145|NCT00421070|ACTIVE_COMPARATOR|Intervention|Massage therapy adjunct comparator
62129146|NCT03898024|EXPERIMENTAL|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
62129147|NCT03898024|EXPERIMENTAL|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
62129148|NCT03898024|EXPERIMENTAL|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
62129149|NCT03898024|EXPERIMENTAL|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
62129150|NCT03898024|EXPERIMENTAL|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
62129151|NCT01869946||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
62129152|NCT05950542||Group A|Vitiligo lesions on the face will be treated with cream (Olumiant)2mg twice daily and excimer light308nm DEKA, Florence,Italy twice weekly for 12 weeks.
62129153|NCT05950542||Group B|Vitiligo lesions on the face will be treated with excimer light308nm (DEKA,F lorence,Italy) only twice weekly for 12 weeks.
62129154|NCT05865834|EXPERIMENTAL|intervention arm|"One public and one private school will be randomly placed into intervention arm. Students from grade 6th - grade 10th will be recruited on their willingness to participant.~A smartphone application will be installed on the personal gadgets of the students in the interventional arm at baseline. For assessing the effectiveness of this app, the first follow-up will be done at one month after the intervention and the second follow up after 3 months to evaluate whether the application had an impact on their depressive and anxiety symptom using PHQ-A, GAD-7 and WHO-5 scales."
62129155|NCT05865834|ACTIVE_COMPARATOR|control arm|"one public and one private school will be randomly allocated to control arm. Students from grade 6th - grade 10th will be recruited on their willingness to participant.~the control group will receive self-reading educational leaflets. the first follow-up will be done at one month after the intervention and the second follow up after 3 months to evaluated whether the application had an impact on their depressive and anxiety symptom using PHQ-A, GAD-7 and WHO-5 scales."
62129156|NCT03531840|EXPERIMENTAL|Arm 1/Olaparib|Twice daily oral olaparib
62129157|NCT05552924|EXPERIMENTAL|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
62319404|NCT01729598|PLACEBO_COMPARATOR|Placebo|Placebo capsule by mouth twice daily.
62319405|NCT03990766|EXPERIMENTAL|Theophylline saline irrigation|Theophylline 12 mg capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
61925610|NCT06238817|EXPERIMENTAL|VC Extension Period/Escape Arm: Ruxolitinib 1.5% Cream BID|Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 24 during the Vehicle Control Extension (VCE) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62319406|NCT03990766|PLACEBO_COMPARATOR|Placebo saline irrigation|Identical-appearing lactose monohydrate capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
62480240|NCT05012254|EXPERIMENTAL|Induction treatment + Maintenance|"Induction: 2 cycles of platinum-based chemotherapy plus (Nivolumab + Ipilimumab):~- Non-squamous NSCLC patients: Pemetrexed: 500 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6 or Cisplatin: 75 mg/m2 IV, Q3W Nivolumab: 360 mg IV Q3W Ipilimumab: 1mg/kg IV Q6W~2 cycles will be administered at 21-day intervals (Q3W) for Pemetrexed, Carboplatin/Cisplatin and Nivolumab. Ipilimumab will be administered at 42 days interval (Q6W).~- Squamous NSCLC patients: Paclitaxel: 200 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6, Q3W Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W~Maintenance: following two cycles of chemo-immunotherapy the patients will receive:~Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W~Immunotherapy will be administered until disease progression, unacceptable toxicity, loss of clinical benefit or up to a maximum of 2 years of treatment."
61925611|NCT06238817|PLACEBO_COMPARATOR|VC Extension Period/Escape Arm: Vehicle Cream BID|Participants who applied vehicle cream during the VC Period, continued applying vehicle cream as a thin film twice daily (BID) from Weeks 8 to 24 during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved. Participants will be eligible to enter the ruxolitinib 1.5% cream open-label escape arm as defined in the protocol.
62129158|NCT05552924|NO_INTERVENTION|Control group|Routine maintenance will be applied.
62129159|NCT01131780|EXPERIMENTAL|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
62129160|NCT01131780|ACTIVE_COMPARATOR|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
62129161|NCT03807661|EXPERIMENTAL|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
62319407|NCT04971044|EXPERIMENTAL|COACH Intervention|COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for 4-6 year old children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
62480241|NCT04889716|EXPERIMENTAL|Cohort 1|Participants receive mosunetuzumab 60 mg for cycles 1 and 2 (although fractionated for cycle 1), and 30 mg for all subsequent cycles after standard-of-care therapy with CD19-directed CAR T-cells
62480242|NCT04889716|EXPERIMENTAL|Cohort 2|Participants receive obinutuzumab (1000 mg for each subject) and glofitamab after standard-of-care therapy with CD19-directed CAR T-cells. The dose of glofitamab for each subject will be 30 mg, other than for cycle 1, which will be 12.5 mg glofitamab fractionated over two weeks.
62688570|NCT05007158||pocket infection|Patients with isolated pocket infection were diagnosed in the presence of local signs of inflammation (one or more of erythema, pain, warmth, swelling, induration, tenderness, or fluctuation), wound dehiscence, hardware protrusion or pus discharge at the pocket in the absence of systemic findings.
62688571|NCT05007158||CIED systemic infection|Patient s with a CIED systemic infection, diagnosed as the presence of pocket infection accompanied by bacteraemia or echocardiographic finding suggestive of infective endocarditis, but not fulfilling the Duke criteria.
62688572|NCT05007158||Lead-associated infective endocarditis|Patients with infective endocarditis, diagnosed according to modified Duke criteria
62688573|NCT05007158||control group|CIED Patients presenting for elective device exchange or planned lead revision between without local or systemic infections were selected as controls
62688574|NCT04775979|EXPERIMENTAL|Diphenylcyclopropenone (DPCP)|Applying DPCP topically
62688575|NCT06496100|ACTIVE_COMPARATOR|Triticum aestivum|A group of 19 patients with a diagnosis of obesity without pharmacological or surgical treatment, who will receive 500 mg of triticum aestivum orally every 12 hours for 120 days.
62688576|NCT06496100|PLACEBO_COMPARATOR|Placebo (calcined magnesia)|A group of 19 patients with a diagnosis of obesity without pharmacological or surgical treatment, who will receive 500 mg of calcined magnesia orally every 12 hours for 120 days.
62129162|NCT02531737|EXPERIMENTAL|traitment|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1
62129163|NCT05447975|EXPERIMENTAL|Tai Chi group|
62129164|NCT05447975|NO_INTERVENTION|Control|
62688577|NCT06421285|EXPERIMENTAL|Intervention group|Individually tailored exercise consisting of aerobic, strength, and flexibility exercises is prescribed, self-exercise compliance monitoring through an application, and diet management education through nutritional counseling.
62688578|NCT06421285|NO_INTERVENTION|Control group|One session of flexibility exercise education, diet management education through nutritional counseling
62688579|NCT03508440|ACTIVE_COMPARATOR|Standard of Care|Oral steroids (prednisone or prednisolone) 60mg per day for 10 days or 60mg/day for 5 days followed by a 5 day taper
62129165|NCT02252042|EXPERIMENTAL|Pembroliziumab|Participants will receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to approximately 24 months. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to approximately 1 additional year at the investigator's discretion.
62129166|NCT02252042|ACTIVE_COMPARATOR|Standard Treatment|Participants will receive standard treatment of either methotrexate 40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m\^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
62129167|NCT01186549|ACTIVE_COMPARATOR|ephedrine 30 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
62480243|NCT03919071|EXPERIMENTAL|Treatment (radiation therapy, dabrafenib, trametinib)|Patients undergo standardized local RT 5 days a week (Monday-Friday) for 6-7 weeks. Four weeks after completion of RT, patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI at baseline, on day 1 of cycles 1, 3, 5, 7, 11, 14, 17, 20, and 23 while on treatment, then at time of relapse, every 3 months for year 1, every 4 months for year 2, every 6 months for year 3, and annually for years 4-5. Patients may also undergo lumbar puncture for CSF testing during treatment. Patients also undergo collection of blood on study.
62688580|NCT03508440|EXPERIMENTAL|SOC + injection|Oral steroids as described above + intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks.
62688581|NCT03508440|OTHER|Injection only|Only Intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks
62688582|NCT06638736|OTHER|Suture group|1/2 of the total number of patients will be randomized into the suture group (excision wound will be closed with suture), the intervention is the method of closure (sutures or staples)
62688583|NCT06638736|OTHER|Staples group|1/2 of the total number of patients will be randomized into the staples group (excision wound will be closed with staples), the intervention is the method of closure (sutures or staples)
62688584|NCT01676545||Chronic Periodontitis|
62688585|NCT01676545||Control|
62688586|NCT05734807|ACTIVE_COMPARATOR|NrtIs|
62688587|NCT05734807|EXPERIMENTAL|HH-003+NrtIs|
62688588|NCT05734807|EXPERIMENTAL|HH-003+NrtIs+PEG-IFN-α|
62688589|NCT02931227|EXPERIMENTAL|Brain-injured group|
62688590|NCT02931227|EXPERIMENTAL|Hypothermia group|
62688591|NCT02931227|EXPERIMENTAL|Hyperthermia group|
61925612|NCT06238817|EXPERIMENTAL|VC Extension Period: Ruxolitinib 1.5% cream open-label escape arm|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
61925613|NCT06274801|EXPERIMENTAL|Seralutinib 90 mg|Seralutinib inhaled orally twice per day (BID)
61925614|NCT06322537||Cardiac Surgery Patients|Adult (≥18 years old) patients who have undergone cardiac surgery.
61925615|NCT02301611|EXPERIMENTAL|Treatment|autologous TLPLDC (active vaccine)
61925616|NCT02301611|PLACEBO_COMPARATOR|Placebo|unloaded YCWP + autologous DC (control)
61925617|NCT00253500|EXPERIMENTAL|Epirubicin|
61925618|NCT06507722|OTHER|Cohort A - Late Chronotype first, then alternate|Sleep onset after 2am
62688592|NCT02931227|EXPERIMENTAL|PICCO group|
62688593|NCT06250426|ACTIVE_COMPARATOR|Active|Pre-thickened oral nutritional supplement with a cooling sensation flavour
62688594|NCT06250426|PLACEBO_COMPARATOR|Control|Pre-thickened oral nutritional supplement without a cooling sensation flavour
62688595|NCT00908141|EXPERIMENTAL|Arm I: sargramostim (days1-14)|Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62688596|NCT00908141|EXPERIMENTAL|Arm II: sargramostim (3xweek)|Patients receive GM-CSF SC three times weekly for 4 weeks. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62688597|NCT04796805|EXPERIMENTAL|Essential oil application group|The experimental group received 20% black pepper essential oil in a base of aloe vera gel applied topically to the forearm using a rollerball 10 min before venipuncture. Twelve swipes were applied using the rollerball applicator. The maximum dose of the black pepper/aloe vera gel mixture was 3 mL. Sphygmomanometer cuff was placed on the right arm, and the cuff was inflated until it reached the patient's diastolic blood pressure level. When the pointer reached the desired value, the period was commenced by the researcher. The nurse determined the right vein. After selecting the right vein, the period was ended as the nurse successfully placed a catheter.
61925619|NCT06507722|OTHER|Cohort B - Non-late Chronotype first, then alternate|Sleep onset before 11pm
61925620|NCT05250752|OTHER|On treatment|Assigned to oral treatment with dapagliflozin 10 mg for three consecutive days.
61925621|NCT06694701|PLACEBO_COMPARATOR|Placebo|Standard-of-care (SoC) treatment and placebo drug.
61925622|NCT06694701|ACTIVE_COMPARATOR|Emapalumab Group 1|SoC treatment and a low dose of emapalumab.
61925623|NCT06694701|ACTIVE_COMPARATOR|Emapalumab Group 2|SoC treatment and a high dose of emapalumab.
61925624|NCT05718544|EXPERIMENTAL|Combined supplement|Patient-controlled analgesia is established with esketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
61925625|NCT05718544|PLACEBO_COMPARATOR|Placebo|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
61925626|NCT04059185|EXPERIMENTAL|Program 1|Triple P-Level 2 (TPL2), parenting education and consultation
61925627|NCT04059185|EXPERIMENTAL|Program 2|Play Nicely (PN), multimedia, computer-based parenting education
61925628|NCT04059185|PLACEBO_COMPARATOR|Control|"Our usual care control group participants receive a resource and referral list for local social services"
61925629|NCT03508271||Elderly individuals with NVAF and HF who are taking OAC's|
62129168|NCT01186549|ACTIVE_COMPARATOR|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
62129169|NCT01186549|ACTIVE_COMPARATOR|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
62319408|NCT04971044|ACTIVE_COMPARATOR|Educational Control|The control arm will consist of a school readiness intervention developed by education and literacy experts on our team and implemented at local libraries. It will include 1) child lessons from Puente de Cuentos, a systematic, language-based curriculum focused on dual language storytelling (narrative language), and 2) parent sessions designed to improve parents' knowledge and skills related to improving children's language production and storytelling skills, to ultimately support school readiness.
62319409|NCT03828838|EXPERIMENTAL|Lu-177 PSMA-617|Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)
62319410|NCT05272163|EXPERIMENTAL|Main Experiment|This is a single arm study where all participants are tested on 1-2 hours of visual search.
62319411|NCT04217902||People living with diabetes in Grenoble and Lyon areas|Eligible patients with type 1 or type 2 diabetes 1) during or after hospitalization for decompensation, ketoacidosis, or other emergency or elective interventions such as insulin pump installation, 2) followed in routine care in specialized diabetes services, 3) participating in patient associations.
62319412|NCT04217902||Health care professionals working in diabetes care in Grenoble|Health care professionals working with diabetes care in specialized services or ambulatory care.
62319413|NCT02107391|EXPERIMENTAL|DCVAC/PCA added Standard Hormone Therapy|Combination therapy with Dendritic Cells DCVAC/PCa added on to a Standard of Care Hormone Therapy
62319414|NCT02107391|ACTIVE_COMPARATOR|Standard of Care Hormone Therapy|Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate
62688598|NCT04796805|NO_INTERVENTION|Control group|Diastolic blood pressure and body temperature of the patients in the control group were measured. A sphygmomanometer cuff was placed on the arm that was not actively used by the patient. Until the cuff's pointer reached the diastolic blood pressure level of the patient, it was inflated. When the tip came to the desired value, the period was noted by the researcher. Without any extra attempts being made, the catheter was placed by the nurse. The period ended with the successful catheter placement by the nurse. Period of appropriate vein selection, the period of placing the catheter successfully, patient and nurse satisfaction were recorded.
62688599|NCT06133270|EXPERIMENTAL|NNC0560-0004|"The study will be conducted in 3 parts.~Participants will be randomized to receive NNC0560-0004 in Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD)~No randomisation - only active treatment in Part C: Single dose"
62688600|NCT06133270|PLACEBO_COMPARATOR|Placebo (NNC0560-0004)|"Participant will be randomized to receive placebo in:~Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD)"
62688601|NCT06639581|ACTIVE_COMPARATOR|3mm lifting stimulus|Respiratory volume measures, vital signs and respiratory mechanics will be evaluated in 10 healthy preterm, by dorsal stimulation causing a displacement of 3 mm , performed by 2 operators .
62688602|NCT06639581|ACTIVE_COMPARATOR|5mm lifting stimulus|Respiratory volume measures, vital signs and respiratory mechanics will be evaluated in 10 healthy preterm, by dorsal stimulation causing a displacement of 5 mm , performed by 2 operators .
62688603|NCT06639581|ACTIVE_COMPARATOR|8mm lifting stimulus|Respiratory volume measures, vital signs and respiratory mechanics will be evaluated in 10 healthy preterm, by dorsal stimulation causing a displacement of 8 mm , performed by 2 operators .
62129170|NCT01186549|ACTIVE_COMPARATOR|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
62319415|NCT02022683|EXPERIMENTAL|Endoscopic Lung Volume Reduction|Patients are implanted with Zephyr Valves
62319416|NCT02022683|NO_INTERVENTION|Standard of Care|Patients are given Standard Medical Care
62319417|NCT01285921|EXPERIMENTAL|hippocampal surgery|"Vestibular test before and after hippocampal surgery~Principal criterion:~Research for an asymmetry of the vestibular responses (Caloric test, Vestibular Evoked Myogenic potentials: VEMp, Head Impulse Test: HIT, Eye Rotational Test: ERI). Investigator performs a blind vestibular test (single blind)"
62319418|NCT01219946||1|Patients with Chronic Obstructive Pulmonary Disease
62319419|NCT03747016|EXPERIMENTAL|High energy 2|In the second step, the experimental group (Group E2) was given high energy digestible food 300ml before the time of gastric emptying found in the first step before surgery.
62319420|NCT03747016|ACTIVE_COMPARATOR|Glucose 2|In the second step, Group G2 is given 5% glucose injection 300ml before the time of gastric emptying found in the first step before surgery.
62319421|NCT03747016|PLACEBO_COMPARATOR|Normal saline 2|In the second step, Group N2 is given normal saline 300ml before the time of gastric emptying found in the first step before surgery.
62319422|NCT03747016|NO_INTERVENTION|Control 2|In the second step, the control group (Group C2) was not given any diet before surgery.
62319423|NCT03747016|EXPERIMENTAL|High energy 1|In the first step,The experimental group (Group E1) is treated with high energy digestible food 300ml.
62319424|NCT03747016|ACTIVE_COMPARATOR|Glucose1|In the first step, Group G1 is given 5% glucose injection 300ml
62319425|NCT03747016|PLACEBO_COMPARATOR|Normal saline 1|In the first step, Group N1 is given normal saline 300ml.
62480244|NCT05037461|EXPERIMENTAL|High-dose-high precision MR-guided radiotherapy|"Radiotherapy for pancreatic NET will be delivered in an image-guided, hypofractionated scheme of 5 fractions of 8 Gy, prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days 2 or 3 times a week with a maximum overall treatment time of 14 days on the 1.5T MR-Linac (Elekta Unity MR-Linac).~The Gross Tumor Volume (GTV) is defines as the pNET visible on pre-treatment CT and MRI scan. No clinical target volume (CTV) is used. The PTV is made by adding a 3mm margin to the GTV.~The treatment plan is a 9-14 field intensity modulated radiotherapy (IMRT) plan with dose prescribed to 95% of the PTV. While respecting the dose constraints to adjacent tissues"
62319426|NCT03869138|EXPERIMENTAL|Virtual-reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
62688604|NCT06639581|NO_INTERVENTION|Basal|Respiratory volume measures, vital signs and respiratory mechanics will be evaluated in 10 healthy preterm basal- without stimulation- performed by 2 operators .
62688605|NCT06641869|EXPERIMENTAL|PCC1 Group|Dosage Form: Oral dietary supplement. Dosage: 2.5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.
62688606|NCT06641869|EXPERIMENTAL|Cellumiva Group|Dosage Form: Oral dietary supplement. Dosage: Blend containing Procyanidin C1, Pterostilbene, and Spermidine. Frequency: Administered once daily. Duration: 12 weeks.
62688607|NCT06641869|PLACEBO_COMPARATOR|Placebo|Dosage Form: Oral placebo supplement. Dosage: Administered once daily. Duration: 12 weeks.
62688608|NCT03110510|EXPERIMENTAL|FOLFIRI|D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Until disease progression, patient's refusal or unacceptable toxicities
62688609|NCT02904265|ACTIVE_COMPARATOR|Diazepam|Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
62688610|NCT02904265|EXPERIMENTAL|Acetazolamide|Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
61925630|NCT02732717||abnormal ultrasound index|twin pregnancy with abnormal ultrasound index
61925631|NCT02732717||normal ultrasound index|twin pregnancy with normal ultrasound index
62319427|NCT02940054||Patents with suspected Crohn's disease|"Adult patients showing at least one of the following symptoms, from at least 4 weeks:~* diarrhea~* nocturnal diarrhea~* body weight loss (\>5%)~* abdominal pain~* perianal lesions."
62688611|NCT06086873|EXPERIMENTAL|NGA Implant|NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)
61925632|NCT05988515|EXPERIMENTAL|CONCURRENT treatment order|"* 5 speech lessons with a human speech-language clinician: 1 time per week for 5 weeks.~* 15 speech lessons with an AI clinician (supervised by the caregiver), 3 times per week DURING the same 5 weeks as the human clinician sessions."
62688612|NCT06086873|EXPERIMENTAL|BLX implant (BLX) modSLA Surface|BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)
62319428|NCT02983903|EXPERIMENTAL|Single intervention arm - transbronchial biopsy|Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy
62319429|NCT02157831|EXPERIMENTAL|Subjects from UPCC 10903|
62688613|NCT06086873|EXPERIMENTAL|TLX implant (TLX) modSLA Surface|TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland).
62688614|NCT05384483|EXPERIMENTAL|Cariprazine|Cariprazine 1.5 to 3 mg per day
62129171|NCT01186549|PLACEBO_COMPARATOR|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
62129172|NCT05073159|ACTIVE_COMPARATOR|0 degree Head-of-Bed (HOB) position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
62319430|NCT01959308||Immunosuppressive therapy|Liver Transplant recipients who are receiving various doses and types of immunosuppressive therapy
62319431|NCT02909166|ACTIVE_COMPARATOR|aliskiren|Aliskiren 300 once a day (q.d)
62319432|NCT02909166|PLACEBO_COMPARATOR|placebo|Placebo once a day (q.d)
62688615|NCT05384483|PLACEBO_COMPARATOR|Placebo|Matching placebo
62688616|NCT05080478||Group A|patients receiving ticagrelor 90mg bid
62688617|NCT05080478||Group B|patients receiving clopidogrel 75mg qd
62129173|NCT05073159|ACTIVE_COMPARATOR|Elevated (30-degree or more) head-of-bed|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
62319433|NCT01943123|EXPERIMENTAL|probiotic drink|experimental group (30 subjects) were given 50 ml of probiotic drink for 6 months on daily basis
62319434|NCT01943123|PLACEBO_COMPARATOR|plain, unsweetend, unflavored pasturised milk|control group/ placebo group (30 subjects) were given pasteurized milk (50 ml) for 6 months on regular basis
62688618|NCT06240728|EXPERIMENTAL|NPX887 Treatment|Participants will receive NPX887 by IV infusion every 3 weeks.
62688619|NCT03749018|EXPERIMENTAL|Treatment (nivolumab, DA-REPOCH)|Patients receive rituximab IV and nivolumab IV over 60 minutes on day 1. Patients also receive etoposide, vincristine sulfate and doxorubicin hydrochloride IV continuously over 96 hours, cyclophosphamide IV bolus, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After course 6, patients receive nivolumab IV over 60 minutes on day 1 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62688620|NCT06640400|EXPERIMENTAL|Intervention group|The intervention group received cardiovascular ultrasound plus conventional drug therapy.
62688621|NCT06640400|NO_INTERVENTION|Control group|The control group received conventional drug treatment.
62688622|NCT04581577||Adult patients with neuromuscular or neurological disorders|Telephone questionnaires administered directly to patients over 16 years of age with neuromuscular or neurological disorders
62688623|NCT04581577||Parents of paediatric patients with neuromuscular or neurological disorders|Telephone questionnaires administered to the parents of patients over 16 years of age with neuromuscular or neurological disorders
62688624|NCT03913286|EXPERIMENTAL|Intervention|The participant will be implanted with the Blackrock Microsystems MultiPort system.
62688625|NCT03729141|EXPERIMENTAL|Added Cholesterol|
62688626|NCT03729141|ACTIVE_COMPARATOR|No Added Cholesterol|
62688627|NCT04377776||Transplanted patients|Transplanted Kidney, Pancreas or Pancreatic Islet patients at MedicineTransplant Unit - San Raffaele Scientific Istitute
62688628|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
62319435|NCT04833933||Control group|"Initially in DISCO trial : no intervention, usual care~In DISCO-SET trial : survey (the same in the 4 groups)"
62319436|NCT04833933||Questionnaire|"Initially in DISCO trial : Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.~In DISCO-SET trial : survey (the same in the 4 groups)"
62319437|NCT04833933||Coordination|"Initially in DISCO trial : Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).~In DISCO-SET trial : survey (the same in the 4 groups)"
62319438|NCT04833933||Questionnaire + Coordination|"Initially in DISCO trial :~* Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.~* Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).~In DISCO-SET trial : survey (the same in the 4 groups)"
62319439|NCT04180436|EXPERIMENTAL|morbidly obese patients with BMI ≥ 40|Morbidly obese patients with BMI ≥ 40
62319440|NCT04180436|EXPERIMENTAL|Patients operated by gastric bypass|Patients operated by gastric bypass for over a year and with stable weight
62319441|NCT04180436|EXPERIMENTAL|Patients operated by sleeve gastrectomy|Patients operated by sleeve gastrectomy for over a year and with stable weight
62688629|NCT06373718|EXPERIMENTAL|Immediate Treatment|Participants randomized to the Immediate Treatment group will receive CBT-I treatment immediately after randomization.
62129174|NCT06518538|EXPERIMENTAL|CPI-613+mFFX|"Day 1: Devimistat at 500 mg/m2 IV infusion over 2 hours mFFX (given immediately after devimistat administration):~* Oxaliplatin at 60 mg/m2 given as a 2-hr IV infusion~* Folinic acid at 400 mg/m2 given as 30- 90 min infusion immediately after oxaliplatin, and concurrently with Irinotecan at 120 mg/m2 given as a 90-min ( IV infusion via a Y-connector.~* Fluorouracil (5-FU) 42-48-hr infusion at 2,200 mg/m2, starting immediately after completion of folinic acid and irinotecan~Day 2:~mFFX:~▪ Completing the remaining of the 5-FU 42-48-hr infusion starting on day 1~Day3:~mFFX: ▪ Completing the remaining of the 5-FU 42-48-hr infusion starting on day 1, 2 and disconnect the 5-FU pump~Devimistat:~▪ Devimistat (500 mg/m2), IV infusion over 2 hours via a central venous catheter after completion of 5-FU infusion.~Day 8:~Devimistat (500 mg/m2), IV infusion over 2 hours via a central venous catheter"
62319442|NCT04180436|EXPERIMENTAL|Control group: non-operated subjects|Control group: non-operated subjects but with an age and a BMI corresponding to those of the patients of the 2 operated groups.
62688630|NCT06373718|OTHER|Enhanced Sleep Hygiene|Participants randomized to the Enhanced Sleep Hygiene (ESH) group will be offered the same CBT-I described above approximately 7 months after being randomized. We will also provide a list of referrals for treatment upon completion of their end of treatment visit (approx. week 11) should they choose to seek treatment sooner. In the interim, they will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms.
62688631|NCT05292287|EXPERIMENTAL|Home-based Watch Intervention|The home-based watch group will receive an exercise consultation with an exercise physiologist followed by check-in sessions at 1-month, 3-months, 6-months, and 12-months post-randomisation to set and review exercise and physical activity goals. They will wear a Polar Ignite wearable activity monitor which will help to monitor and guide their exercise sessions. Text-message feedback will be provided by an exercise physiologist based on information gathered from exercise sessions recorded on the watch by the participant.
62688632|NCT05292287|NO_INTERVENTION|Best Practice Usual Care Control|No intervention will be administered. Best practice usual care and activity.
62129175|NCT06006949|EXPERIMENTAL|roxadustat and luspatercept|"Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg.~Roxadustat (150mgqod) was administered for at least 6 months to evaluate efficacy.~Hemoglobin ≥120g/L can be discontinued, and hemoglobin \<120g/L can continue to use. Those who are effective will continue to be given the combination therapy until ineffective or intolerant."
62129176|NCT06006949|EXPERIMENTAL|luspatercept|"Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg.~Luspatercept was given for at least 6 months to evaluate the efficacy. Hemoglobin ≥120g/L can be discontinued, and hemoglobin \<120g/L can continue to use. Those who are effective will continue to be given the therapy until it is ineffective or intolerant"
62129177|NCT01671267|EXPERIMENTAL|Strength training|Strength training of the shoulder, arm and hand muscles for 3 x 10 minutes a week.
62129178|NCT01671267|ACTIVE_COMPARATOR|Ergonomic|Receives counseling on workstation adjustment and optimal use of the work tools.
62129179|NCT04134793||Sinus group|Six-month follow-up, by holter ECG record，the patients keep normal sinus after atrial fibrillation radiofrequency ablation.
62129180|NCT04134793||atrial fibrillation recurrence group|Six-month follow-up, by holter ECG record，the patients again suffer from atrial fibrillation after atrial fibrillation radiofrequency ablation.
62129181|NCT04626180|ACTIVE_COMPARATOR|Regular Extubation|
62129182|NCT04626180|EXPERIMENTAL|Pre Extubation Manual Hyperinflation|
62129183|NCT02010944|EXPERIMENTAL|1: FDC-SET-SET|Fixed Dose Combination followed by two periods of the Single Entity Tablets
62129184|NCT02010944|EXPERIMENTAL|2: SET-FDC-FDC|Single Entity Tablets followed by two periods of Fixed Dose Combination
62129185|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
62129186|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
62129187|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
62129188|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
62129189|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
62129190|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
62129191|NCT01782170|ACTIVE_COMPARATOR|Iocide Oral Rinse|Iocide Oral Rinse once daily 30 second rinse for 24 weeks
62129192|NCT01782170|PLACEBO_COMPARATOR|Placebo Control|Once daily 30 second rinse for 24 weeks
62129193|NCT00710775|OTHER|1|Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
62129194|NCT01052259|EXPERIMENTAL|Deoxyspergualin, Treatment,|
62129195|NCT03165175|EXPERIMENTAL|App + treatment as usual|The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
62129196|NCT03165175|NO_INTERVENTION|Treatment as usual|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
62319443|NCT06671041|EXPERIMENTAL|Preservative-free eye drop|Participants were assigned to use a preservative-free eye drop 4X a day
62319444|NCT00440128|ACTIVE_COMPARATOR|Docetaxel|Docetaxel
62129197|NCT01888848|EXPERIMENTAL|blueberry|Participants randomized into this arm of the study consume freeze-dried blueberry.
62129198|NCT01888848|PLACEBO_COMPARATOR|placebo|Participants randomized into this arm of the study consume a blueberry placebo.
62319445|NCT00440128|EXPERIMENTAL|Docetaxel/Casopitant|Docetaxel/Casopitant
62319446|NCT03896867|EXPERIMENTAL|Anapod™ Humi-Therm Heated Humidification System|Patient warming will be provided via the Anapod™ Humi-Therm Heated Humidification System Breathing Circuit.
62319447|NCT03896867|ACTIVE_COMPARATOR|Bair Hugger™ Warming Blanket|Patient warming will be provided via the Bair Hugger™ Warming Blanket.
62319448|NCT00653796|EXPERIMENTAL|Ezetimibe + Atorvastatin|
62319449|NCT00653796|ACTIVE_COMPARATOR|Atorvastatin|
62319450|NCT00396188||Normals|"1. Patients seeking initial laser vision correction that were screened to be good candidates for the procedure.~2. No history of refractive or other ocular surgery.~3. No corneal pathologies.~4. Normal corneal topography.~5. Contact lens wearers should discontinue use at least 2 weeks for hard contacts, and 3 days for soft lenses prior to imaging."
62688633|NCT01503177|EXPERIMENTAL|Treatment (viral therapy)|Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
62688634|NCT06644027|OTHER|Molicare Premium Bed Mat|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
62688635|NCT06644027|EXPERIMENTAL|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
62688636|NCT06435858|EXPERIMENTAL|Intervention|Empagliflozin 10mg
62688637|NCT06435858|PLACEBO_COMPARATOR|Control|Placebo
62688638|NCT00879372|PLACEBO_COMPARATOR|1|Placebo
62688639|NCT00879372|ACTIVE_COMPARATOR|2|Tianeptine
62688640|NCT02437526|EXPERIMENTAL|Treatment interruption|Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.
62688641|NCT03629717|EXPERIMENTAL|Denosumab|An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.
62688642|NCT05984862|EXPERIMENTAL|Experimental: Treatment left|"A randomized side of the scalp will be covered with bandage, the other side with no bandage.~Intervention: Device: Treatment - Bandage"
62688643|NCT05984862|EXPERIMENTAL|Experimental: Treatment right|"A randomized side of the scalp will be covered with bandage, the other side with no bandage.~Intervention: Device: Treatment - Bandage"
62688644|NCT01006486|EXPERIMENTAL|Anticoagulation clinic|Anticoagulation clinic, including all procedures related to a standardized use of coumarins.
62688645|NCT01006486|ACTIVE_COMPARATOR|Standard care|Standard use of coumarins, as prescribed by their physicians.
62319451|NCT00396188||Keratoconus|"1. An irregular cornea determined by distorted keratometry mires, distortion of the retinoscopic, or ophthalmoscopic red reflex (or a combination of these)~2. At least one of the following biomicroscopic signs: Vogt's striae, Fleischer's ring of \>2 mm arc, or corneal scarring consistent with keratoconus.~3. Contact lens wearers should discontinue use preferably 1 day or at least half an hour prior to imaging."
62129199|NCT02309996|EXPERIMENTAL|Supervisor Training Program|All supervisors from work units randomized to the intervention will receive a supervisor training program, the Supervisor/Manager Accommodation Recognition \& Training (SMART) Program. This training program is modeled on a program developed by Shaw and colleagues of the Liberty Mutual Research Institute for Safety (LMRIS). The aim of the training program is to prevent/reduce work disability by improving supervisor communication, response to workplace injury, and problem solving mechanisms. The training program is designed to be administered by two facilitators to groups of 10 to 12 supervisors, during one 4-hour session or two 2-hour sessions. The training program delivery mode includes PowerPoint presentation with supplementary audio or video segments, case studies, and group discussion.
62129200|NCT02309996|NO_INTERVENTION|No Supervisor Training Program|All supervisors from work units randomized to the control group will not receive the supervisor training program.
62319452|NCT00396188||Myopic Laser Vision Correction|"Patients who have undergone myopic:~1. LASIK~2. PRK~3. LASEK"
62319453|NCT00396188||Hyperopic Laser Vision Correction|"Patients who have undergone hyperopic:~1. LASIK~2. PRK~3. LASEK"
62319454|NCT00396188||Orthokeratology|1. Patients using specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error.
62319455|NCT00396188||Others|1. Corneal conditions (diseases/ pathologies/surgeries) that can potentially affect the corneal surface that are not listed above (e.g. pellucid marginal degeneration; postoperative corneal transplant, intra-corneal ring segments, refractive keratotomy, conductive keratoplasty; peripheral ulcerative keratitis, Terrien's marginal degeneration; etc.).
62319456|NCT04863287|EXPERIMENTAL|0.5 mg/kg of 2217LS|Single dose subcutaneous injection
62319457|NCT04863287|EXPERIMENTAL|1.5 mg/kg of 2217LS|Single dose subcutaneous injection
62480245|NCT05862545||COPD patients|Patients with COPD that start BGF treatment (The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guideline)
62480246|NCT05647005|EXPERIMENTAL|Experiment 1: Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. The sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
62688646|NCT04588558|EXPERIMENTAL|Flywheel exercise|The term isoinertial is derived from the words iso (same) and inertial (resistance), which define the primary concept of the isoinertial system in a terminology or that expresses both the concentric and eccentric phases of the same muscle contraction. Isoinertial refers to resistance used in exercise training, maintaining a constant inertia throughout the range of motion, a constant resistance in all respects, and facilitating maximum muscle strength. All participants received home exercise for 8 weeks.
62129201|NCT03859869|EXPERIMENTAL|Resected Participants Receiving Low Dose (12,000/6,000 units lipase) Pancrelipase|Resected participants (surgery to remove pancreatic cancer) will first be given low dose pancrelipase. Low dose is defined as 12,000 USP units (lipase) with meals and 6000 U with snacks. At Weeks 1, 5, or 9, participants will be evaluated, and those who meet criteria for dose increase will be given high dose pancrelipase. High dose is defined as 72,000 U with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding.
62129202|NCT03859869|EXPERIMENTAL|Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase|Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding.
62129203|NCT03859869|EXPERIMENTAL|Non-Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase|Non-resected participants (those who did not have surgery to remove pancreatic cancer) will receive high dose pancrelipase throughout the study in an open-label cohort. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks.
62129204|NCT01792934|ACTIVE_COMPARATOR|XELOX or FOLFOX regimen|XELOX or FOLFOX regimen
62319458|NCT04863287|EXPERIMENTAL|5 mg/kg of 2217LS|Single dose subcutaneous injection
62319459|NCT04863287|EXPERIMENTAL|10 mg/kg of 2217LS|Single dose subcutaneous injection
62319460|NCT04863287|PLACEBO_COMPARATOR|0.9% Sodium Chloride (NaCl)|Single dose subcutaneous injection
62319461|NCT05242276||uterine manipulator cohort|Patients with early-stage endometrial cancer who have performed a hysterectomy with a uterine manipulator to mobilize the uterus during the surgery.
62319462|NCT05242276||no uterine manipulator cohort|Patients with early-stage endometrial cancer who have performed a hysterectomy without a uterine manipulator to mobilize the uterus during the surgery.
62319463|NCT05782101||Bronchopulmonary Dysplasia/Retinopathy of prematurity|Preterm neonates whith Bronchopulmonary dysplasia and/or Retinopathy of prematurity
62319464|NCT05782101||No Bronchopulmonary Dysplasia/Retinopathy of prematurity|Preterm neonates without Bronchopulmonary Dysplasia and/or Retinopathy of prematurity
62319465|NCT02773758|EXPERIMENTAL|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
62319466|NCT02773758|OTHER|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
62319467|NCT01924897|EXPERIMENTAL|Exercise Training Arm|"Patients randomised to exercise training will be offered three sessions of aerobic interval exercise per week over the subsequent 4 weeks prior to their procedure. Each session will comprise 6 x 5 min repetitions at 60-80% peak VO2, with 2.5 min rest intervals. The aim will be to quickly progress patients to exercise intensities that correspond to and exceed the individual AT. Heart rate, clinical signs, blood pressure and perceived exertion will be recorded regularly throughout exercise.~Repeat CPET testing will then take place 4 weeks from the baseline test in the exercise laboratory (on the day prior to surgery) to determine changes (if any) in AT, VO2, VE/VCO2."
62480247|NCT05647005|EXPERIMENTAL|Experiment 2: Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
62480248|NCT05647005|NO_INTERVENTION|Control|Premature babies in this group will not be interfered with by the newborn nurses for 30 minutes after feeding without any voice intervention.
62480249|NCT06648655|EXPERIMENTAL|TMP-301|Daily (QD) x 14 weeks.
62688647|NCT04588558|ACTIVE_COMPARATOR|Electrotherapy modality|"Electrotherapy modalities especially transcutaneous electrical nerve stimulation (TENS) and ultrasound is used to treat OA.~All participants received home exercise for 8 weeks."
62319468|NCT01924897|NO_INTERVENTION|No Exercise Training Arm|The patients in the non-exercise arm of the study will not undergo any exercise intervention but will be CPET tested in the exercise laboratory at the same time points as the exercise arm patients.
62319469|NCT06201195|ACTIVE_COMPARATOR|Adductor canal block|Usg guidance adductor canal block with %0.25 Bupivacaine 20 ml
62480250|NCT06648655|PLACEBO_COMPARATOR|Placebo|Daily (QD) x 14 weeks.
62688648|NCT04588558|ACTIVE_COMPARATOR|Home exercise|All participants received home exercise three times a week for 8 weeks. Home exercises are structured with squats. The exercise program includes stretching exercises and strengthening (isometric and isotonic) exercises.
62129205|NCT01792934|EXPERIMENTAL|XELOX or FOLFOX regimen and maximal tumor debulking|XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).
62129206|NCT02226822||Adult patients with documented T2DM|Adult patients with documented history of type 2 diabetes mellitus who are initiating their second line oral or parenteral anti-diabetics medication after first line oral diabetic therapy
62129207|NCT01093820|EXPERIMENTAL|Epopoetinum beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
62129208|NCT03241017|EXPERIMENTAL|Durvalumab|Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).
62129209|NCT01150916|ACTIVE_COMPARATOR|Heart failure|Patients must fulfill Framingham and/or Boston criteria for heart failure and have systolic or diastolic disfunction in rest echocardiography.
62319470|NCT06201195|ACTIVE_COMPARATOR|Distal adductor canal block with anterior cutaneus nerve block|Usg guidance distal adductor canal block (%0.25 Bupivacaine 20 ml) with anterior cutaneus nerve block (%0.25 Bupivacaine 10 ml)
62319471|NCT00515008|EXPERIMENTAL|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi 18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
62319472|NCT00515008|PLACEBO_COMPARATOR|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
62129210|NCT01150916|ACTIVE_COMPARATOR|Liver Cirrhosis|Patients must have a biopsy proven diagnosis of liver cirrhosis or the diagnosis established on clinical basis in cases of known etiology of liver disease, peripheral signs of chronic liver disease, esophageal varices at endoscopy and an imaging method with evidence of cirrhosis.
62129211|NCT01150916|ACTIVE_COMPARATOR|Other causes of ascites|Patients must fulfill stringent diagnostic criteria for the cause of ascites, by clinical criteria, laboratory and imaging tests and histology when appropriate.
62129212|NCT01150916|ACTIVE_COMPARATOR|Concurrent heart failure and cirrhosis|Patients must fulfill the aforementioned criteria for both conditions.
62129213|NCT02974465|EXPERIMENTAL|Experimental Group|protocol of Biofeedback Electromyography plus conventional physical therapy treatment
62129214|NCT02974465|SHAM_COMPARATOR|Control Group|consisted of Sham- Biofeedback Electromyography plus conventional physical therapy treatment
62129215|NCT04249713|EXPERIMENTAL|Brodalumab|Brodalumab 210mg subcutaneously every week for 24 weeks
62129216|NCT00737035|EXPERIMENTAL|1-Intervention|For 16 weeks, participants will have access to an interactive healthcare communication application (IHCA).
62319473|NCT05688267|EXPERIMENTAL|Experimental group|The continuous mobility training adopted grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists. The five stages are half-lying on the bed, sitting at the bedside, sitting on the chair, standing and marching on spot.
62319474|NCT05688267|PLACEBO_COMPARATOR|Control group|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training. The physicians assessed the participants and appropriately adjusted the settings of the mechanical ventilation modules to gradually reduce the participants' dependence on mechanical ventilation. Hand bicycle training was conducted by nurse practitioners once a day. The participants' bedhead was raised, and the participants held the cycle ergometer with both hands once they could tolerate upright positions for 15-20 minutes. Training intensity was targeted at the level of symptom limitation, on the basis of a modified Borg scale rating of 3-5. Intermittent and short-term periods of rest were allowed for participants to achieve the goal of a total of 15-20 minutes exercise session.
62319475|NCT05573594|EXPERIMENTAL|MET Group|"the participants in the study group were under 8 sessions of MET, 2 times a week, in addition to the conventional physiotherapy program.~In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes."
62319476|NCT05573594|EXPERIMENTAL|Control Group|"In this study, the participants in the control group were under conventional physiotherapy program for 5 times a week, a total of 10 sessions~In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes"
62319477|NCT03692910|EXPERIMENTAL|Part A (Open-label): SAGE-217|Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD), in the evening, from Day 1 to Day 14.
62319478|NCT03692910|EXPERIMENTAL|Part B (Double-blind): SAGE-217|Participants were to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
62319479|NCT03692910|PLACEBO_COMPARATOR|Part B (Double-blind): Placebo|Participants were to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
62319480|NCT04490668||Human albumin support|Patients who received intravenous human albumin after gastric cancer surgery
62319481|NCT04490668||No human albumin support|Patients who did not receive intravenous human albumin after gastric cancer surgery
62319482|NCT02456116|EXPERIMENTAL|acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
61925633|NCT05988515|EXPERIMENTAL|SEQUENTIAL treatment order|"* 5 speech lessons with a human speech-language clinician: 1 time per week for 5 weeks.~* 15 speech lessons with an AI clinician (supervised by the caregiver), 3 times per week for the 5 weeks AFTER the human clinician sessions end."
61925634|NCT05315856||ChAdOx1 vaccine group|AstraZeneca vaccine (chimpanzee adenovirus-vectored vaccine, 0.5 mL \[5 × 1010 viral particles\] per dose)
61925635|NCT05315856||BNT162b2 vaccine group|Pfizer-BioNTech vaccine (mRNA vaccine; 0.3 mL \[30 μg\] per dose)
61925636|NCT00400946|ACTIVE_COMPARATOR|Intramuscular native E coli L-asparaginase (IM-EC)|Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
61925637|NCT00400946|EXPERIMENTAL|Intravenous PEG-asparaginase (IV-PEG)|Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
62129217|NCT00737035|ACTIVE_COMPARATOR|2- Control|For 16 weeks, participants will have access to generally available Internet-based information about parenting, trauma, and child development.
62129218|NCT01470508|EXPERIMENTAL|Family Enhancement|PAS is a 27-week program consisting of 25 sessions, 50 minutes in length, between an individual and a therapist. During six (6) family sessions, a family member will accompany the individual to therapy and will take an active role during the session. In this program, individuals and their family members will learn about ways to communicate about their relationship in the context of experiencing an eating disorder. PAS focuses on family-specific skills such as communication skills and problem solving skills while also incorporating eating disorders psychoeducation.
62129219|NCT01470508|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Individuals meet their therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy.
62129220|NCT05237453|EXPERIMENTAL|MR-guided adaptive radiotherapy|Patients receive Photon radiotheray as an MR-guided adaptive radiotherapy
62129221|NCT04073199|ACTIVE_COMPARATOR|Long Lever Group|This arm receive the protocolized treatment along with the long passive stretch of the Teres Major in Long Lever with the patient in supine position.
62129222|NCT04073199|ACTIVE_COMPARATOR|Short Lever Group|This arm receive the protocolized treatment along with the short lever stretch according to the Orthopaedic Manual Therapy of the Teres Major.
62129223|NCT04073199|NO_INTERVENTION|Control Group|only receive the protocolized physiotherapy treatment for the Subacromial syndrome that is applied in the Rehabilitation Service, without the addition of any additional stretch technique.
62129224|NCT03167034|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
62129225|NCT03167034|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
62129226|NCT00089544|EXPERIMENTAL|Cohort A (chemotherapy, radiation, thalidomide, surgery)|Patients receive doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients receive G-CSF subcutaneously beginning on days 4, 25, and 46 and continuing until blood counts recover. Patients undergo radiotherapy once daily on days 7-11, 14-18, 21, 28-32, 35-39, and 42. Patients receive oral thalidomide once daily on days 7-21 and 26-42. Patients undergo surgical resection between days 84 and 98. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 12 months in the absence of unacceptable toxicity.
62129227|NCT00089544|EXPERIMENTAL|Cohort B (thalidomide, radiation, surgery)|Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity.
62688649|NCT01550965|EXPERIMENTAL|Participants Receiving Adalimumab|Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.
61925638|NCT06743763|EXPERIMENTAL|fNIRS-NFT with VR|The experimental group will receive 16 sessions of training, 1 hour each, conducted twice per week over a period of 8 weeks. A classroom setting will be stimulated using VR and participants will be asked to complete some academic-related tasks during the stimulated lessons. The sensor on the neurofeedback device worn by the participants will detect changes in the blood oxy-hemoglobin level in brain cortical tissue and feedback to the participants via visual images or auditory sounds from the computer. Through practice, participants will learn to manipulate their attention, presumably by altering brain activities.
62129228|NCT06177444||Postoperative prophylactics|Patients receiving postoperative prophylactic antibiotic treatment
62129229|NCT06177444||non-postoperative prophylactics|Patients NOT receiving postoperative prophylactic antibiotic treatment
62129230|NCT02036424|ACTIVE_COMPARATOR|Bevacizumab|1.25 mg intravitreal injection given monthly during a 6 month period
62129231|NCT02036424|ACTIVE_COMPARATOR|Ozurdex|Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections
62319483|NCT02456116|SHAM_COMPARATOR|sham acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear sham-acupuncture needles bitten once (day 0-5)~2. Body sham-acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
62738150|NCT01918891|EXPERIMENTAL|Nurse Practitioner Only|The NP only program will provide a 30 day intervention via in-home and telephone encounters for patients randomized to this group. In the first 30 days post-enrollment the NP will focus on medical case management and coordination with primary care providers and specialists, provide self-management coaching, and intervene if gaps in care are identified - all with a focus on BP reduction and preparing the patient for ongoing BP maintenance.
62738151|NCT00708591|EXPERIMENTAL|1|
62738152|NCT06348251|OTHER|Behavioral intervention|
62129232|NCT05066958|EXPERIMENTAL|boost anti-viral immunity after T-cell depleted HSCT|
62129233|NCT00809939|ACTIVE_COMPARATOR|1|previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
62738153|NCT01067118|ACTIVE_COMPARATOR|Humalog U-100 Insulin|
62738154|NCT01067118|EXPERIMENTAL|LINjeta U-100|
62738155|NCT02333825|OTHER|Surgical Intervention|The surgical intervention to be studied in this arm is medial patellofemoral ligament reconstruction surgery using hamstring tendon. The tendon used will generally consist of autograft semitendinosus. If the hamstrings have been previously harvested or injured (i.e. in the setting of anterior cruciate ligament reconstruction or proximal tibial surgery), or if the patient/his or her family prefers to minimize donor site morbidity, allograft may be used.
62738156|NCT02333825|OTHER|Conservative treatment|The intervention to be studied in this arm is a rehabilitation program directed by physical therapists. If patients in this arm are found to have a small loose body, a simple arthroscopy will be performed to remove the loose body, but no stabilization of the patellofemoral joint will be performed. The rehabilitation program will be compiled into a booklet and distributed for use by the physical therapist chosen by the patient.
62738157|NCT03171519|ACTIVE_COMPARATOR|Exercise|
62738158|NCT03171519|EXPERIMENTAL|Exercise + acupuncture|
62738159|NCT01765036|EXPERIMENTAL|SonoVue®|"Non randomised study~Sonovue 4,8 ml intravenous administration, in 1 bolus, during the EUS examination"
62738160|NCT06134648|EXPERIMENTAL|Sentinel Cohort: RSV/hMPV Group 0 (Dose L)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
62738161|NCT06134648|EXPERIMENTAL|Sentinel Cohort: RSV/hMPV Group 1 (Dose A)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
62738162|NCT06134648|EXPERIMENTAL|Sentinel Cohort: RSV/hMPV Group 2 (Dose B)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
62738163|NCT06134648|PLACEBO_COMPARATOR|Sentinel Cohort: Placebo-Group 3|Participants will be randomized to receive a single IM injection of placebo
62738164|NCT06134648|EXPERIMENTAL|Main Cohort: RSV/hMPV Group 1 (Dose A)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
62738165|NCT06134648|EXPERIMENTAL|Main Cohort: RSV/hMPV Group 2 (Dose B)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
62319484|NCT02456116|OTHER|PCA/NSAID|minimal intervention (included in every arm) standard boli of morphine by pressing a button of PCA availability in the postoperative period (day 0-4) readout once a day NSAID (non-steroid antiinflammatory drug) 2x i.v. (75mg diclofenac-sodium, 30 mg orphenadrine citrate) (day 0-4)
62319485|NCT01761955|EXPERIMENTAL|High Dairy|Consuming four or more servings of dairy per day.
62738166|NCT06134648|PLACEBO_COMPARATOR|Main Cohort: Placebo-Group 3|Participants will be randomized to receive a single IM injection of placebo
62738167|NCT06134648|EXPERIMENTAL|Booster Cohort-RSV/hMPV|Participants will be randomized to receive a determined dose of single IM injection of RSV/hMPV vaccine candidate from a subset of Main cohort
62738168|NCT06134648|PLACEBO_COMPARATOR|Booster Cohort-Placebo|Participants will be randomized to receive of single IM injection of placebo from a subset of Main cohort
62738169|NCT06421519|EXPERIMENTAL|Pre-term infants requiring primary respiratory support before intubation|Infants \<34 weeks gestational age who require non-invasive respiratory support who may go on to require invasive ventilation.
62738170|NCT06421519|EXPERIMENTAL|Pre-term infants requiring respiratory support after extubation|Infants \<34 weeks gestational age who were previously invasively ventilated and are currently being weaned onto non-invasive respiratory support and eventually into self-ventilating in room air.
62738171|NCT06421519|EXPERIMENTAL|Pre-term infants requiring respiratory support after seven days|Infants \<34 weeks gestational age who have an ongoing need for non-invasive respiratory support after seven days of life and are likely to develop bronchopulmonary dysplasia.
62738172|NCT05913713|EXPERIMENTAL|High Intensity Interval Training (HIIT)|Supervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
62738173|NCT05913713|EXPERIMENTAL|Moderate Intensity Continuous Training (MICT)|Supervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
62738174|NCT05913713|OTHER|Usual Care (UC)|Research participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise).
62738175|NCT06112080||Normal Breath Sound Cohort|"32 patients ages 4-10, 16 patients ages 11-17)~* Admitted for a non-respiratory complaint~* Normal breath sounds on screening examination"
62738176|NCT06112080||Wheeze Cohort|"(106 patients ages 4-10, 53 patients ages 11-17)~* Admitted for pathologic process that may lead to wheezing (e.g., asthma)~* Presence of wheeze on screening examination"
62738177|NCT03332173|EXPERIMENTAL|Zanubrutinib|Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity
62738178|NCT04539964|EXPERIMENTAL|Treatment|Active stimulation for 1 min once per day
62738179|NCT04539964|SHAM_COMPARATOR|Control|Non-active stimulation for 1 min once per day
62738180|NCT04723355|EXPERIMENTAL|Holter device|In this single arm of the study, the participant will use 2 Holter systems simultaneously for 24 hours, an innovative 3-lead wireless water resistant device and a conventional device.
62738181|NCT03076216|OTHER|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of Care chemotherapy either gemcitabine or gemcitabine + Abraxane
62738182|NCT06662305|EXPERIMENTAL|ACTIVE|Participants in the active group will be given access to the Kick-Nic! app to use for vaping cessation.
62738183|NCT06662305|ACTIVE_COMPARATOR|CONTROL|Participants in the control group will be referred to the NCI Quit Vaping website.
62738184|NCT04870463|ACTIVE_COMPARATOR|Gold Standard Group|Patients treated with multi-braces fixed appliances and a conventional sequence of aligning and levelling arches (Ni-Ti arches with the same force in all sections)
62738185|NCT04870463|EXPERIMENTAL|Intervention Group|Patients treated with multi-braces fixed appliances and a different sequence of aligning and levelling arches (some arches provide individual forces for each group of teeth (incisors, premolars and molars))
62738186|NCT01099748|ACTIVE_COMPARATOR|Methadone|Dose of methadone must not change from 1 week prior to study start and through the duration of the study.
62738187|NCT01099748|EXPERIMENTAL|Lersivirine + Methadone|
62738188|NCT04207411|EXPERIMENTAL|Bupivacaine|The dose received at each injection will be 5 mg. One injection per week will be carried out over 4 consecutive weeks
62738189|NCT04207411|SHAM_COMPARATOR|Lidocaine|The dose received at each injection will be 1.25mg. An injection unique per week will be carried out over 4 consecutive weeks.
62738190|NCT01278238|ACTIVE_COMPARATOR|Phenylephrine|
62738191|NCT01278238|ACTIVE_COMPARATOR|Lower limb compression|
62738192|NCT01278238|PLACEBO_COMPARATOR|Placebo|
62738193|NCT03652766|OTHER|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
62738194|NCT00479128|EXPERIMENTAL|Bortezomib + Gemcitabine + Doxorubicin|Starting dose of Bortezomib 0.8 mg/m\^2 IV Over 3-5 Seconds. Starting dose of Gemcitabine 225 mg/m\^2 IV Up to 90 Minutes. Starting dose of Doxorubicin 12.5 mg/m\^2 IV Over 15-30 minutes.
62129234|NCT00809939|ACTIVE_COMPARATOR|2|previous preterm delivery, treatment with daily vaginal natural progesterone
62319486|NCT01761955|PLACEBO_COMPARATOR|Control, Low Dairy|Participants consumed less than 2 servings of low fat dairy per day.
62319487|NCT05325138||Parents|Parents of girls aged 9-14 years old
62319488|NCT04013581|EXPERIMENTAL|TZD group|Pioglitazone added to Metformin, DPP-4 inhibitors, Sulfonylurea
62319489|NCT04013581|ACTIVE_COMPARATOR|SGLT-2 inhibitor group|Empagliflozin added to Metformin, DPP-4 inhibitors, Sulfonylurea
62319490|NCT03601338|ACTIVE_COMPARATOR|Bemiparin group|"Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery~Other Name: Hibor; Laboratories Rovi pharmaceuticals"
62319491|NCT03601338|PLACEBO_COMPARATOR|control group|Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
62688650|NCT04850963|ACTIVE_COMPARATOR|Group 1 - anodal tDCS|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 1 (anodic tDCS) the anodic electrode (5x5 cm) will be applied to the primary motor area (C3/C4) ipsilateral to the lesion and the reference electrode (6x9 cm) to the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
62129235|NCT00809939|ACTIVE_COMPARATOR|3|short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
62319492|NCT02286115|EXPERIMENTAL|Life-Stress Interview|The Life-Stress Interview is an experiential assessment technique
62319493|NCT02286115|NO_INTERVENTION|Wait-list Control|Wait-list Control
62319494|NCT03230175|EXPERIMENTAL|TTAX01 plus standard care|Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. A six week course of systemic antibiotics will be used to resolve baseline infection. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary.
62319495|NCT03843658||Rheumatoid Arthritis|Clinician diagnosed rheumatoid arthritis
62319496|NCT03843658||Spondyloarthropathy|Ankylosing spondylitis and psoriatic arthritis
62319497|NCT03843658||Crystalline arthritis|Gout and Pseudo gout
62319498|NCT03843658||Connective Tissue Disease|Lupus, myositis, scleroderma, and sjogren's
62319499|NCT03843658||Non-Inflammatory arthritis|E.g. Osteoarthritis and Fibromyalgia
62319500|NCT01464047||Patients with CML or Ph+ ALL|
62319501|NCT01943864|EXPERIMENTAL|Trametinib (single tablet)|Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
62319502|NCT01943864|EXPERIMENTAL|Trametinib PK study (multiple tablet)|Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
62319503|NCT01943864|EXPERIMENTAL|Trametinib PK study (single tablet)|Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
62688651|NCT04850963|ACTIVE_COMPARATOR|Group 2 - tDCS dualsite|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. In group 2 (dualsite tDCS) two active electrodes (5x5 cm) will be used, which will be positioned over the primary motor area (C3/C4) and over the dorsolateral prefrontal cortex (F3 or F4) in the ipsilateral hemisphere. For this stimulation modality, two active electrodes (anodic) and a reference electrode (6x9 cm) will be used on the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
62688652|NCT04850963|PLACEBO_COMPARATOR|Group 3 - tDCS sham|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 3 (simulated tDCS) the positioning of the electrodes will be the same as for group 1, however the device will be configured in sham mode in which the current will cease 30 seconds after the start of stimulation.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
62688653|NCT02114944||NIV|Patients with acute respiratory failure or dyspnea and DNI order treated with noninvasive ventilation
62688654|NCT02114944||CPAP|Patients with dyspnea or acute respiratory failure and DNI order treated with continuous positive airways pressure (CPAP)
61925639|NCT06743763|ACTIVE_COMPARATOR|fNIRS-NFT without VR|The fNIRS-NFT without VR (NFT-2D group) will receive 16 sessions of training, 1 hour each, conducted twice per week over a period of 8 weeks. A classroom setting will be stimulated via a computer screen and participants will be asked to complete some academic-related tasks during the stimulated lessons by pressing a remote controller provided. The sensor on the neurofeedback device worn by the participants will detect changes in the blood oxy-hemoglobin level in brain cortical tissue and feedback to the participants via visual images or auditory sounds from the computer. Through practice, participants hopefully will learn to manipulate their attention, presumably by altering brain activities.
61925640|NCT06743763|ACTIVE_COMPARATOR|VR without fNIRS-NFT|In the VR without fNIRS-NFT Training, we have designed a virtual reality classroom scenario modeled and children are asked to complete academic tasks in the VR setting but no neurofeedback will be provided.
61925641|NCT06568783|EXPERIMENTAL|[18F]-FAPI-74 PET/ MRI|Participant receive \[18F\]-FAPI-74 injection and approximately 45-60 minutes later receive a MRI scan from vertex to legs, followed by a static PET emission scan over the same area.
61925642|NCT04494815|EXPERIMENTAL|Treatment A|Treatment A: Single 20 mg oral suspension dose of SR419 + single active control placebo capsule.
62319504|NCT03402867|EXPERIMENTAL|Intervention|Deep dry needling applied on active myofascial trigger points in the shoulder and neck regions
61925643|NCT04494815|ACTIVE_COMPARATOR|Treatment B|Treatment B: Single SR419 placebo oral suspension + single 300 mg oral capsule of active control.
61925644|NCT04494815|PLACEBO_COMPARATOR|Treatment C|Treatment C: Single SR419 placebo oral suspension + single active control placebo capsule.
61925645|NCT05868382|EXPERIMENTAL|mRNA-1010 Dose C|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
61925646|NCT05868382|EXPERIMENTAL|mRNA-1010.4 Dose B|Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.
61925647|NCT05868382|EXPERIMENTAL|mRNA-1010.4 Dose C|Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.
61925648|NCT05868382|EXPERIMENTAL|mRNA-1010.6 Dose A|Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
61925649|NCT05868382|EXPERIMENTAL|mRNA-1010.6 Dose B|Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
61925650|NCT05868382|EXPERIMENTAL|mRNA-1010.6 Dose C|Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
62129236|NCT00809939|ACTIVE_COMPARATOR|4|short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
62688655|NCT02114944||Standard oxygen|Patients with dyspnea and/or acute respiratory failure and DNI order, treated with standard oxygen therapy either via face mask or nasal cannula
61925651|NCT04995796|EXPERIMENTAL|Enrolled Participants|Study participation will involve 2 visits. The first visit will take approximately 90 minutes, but may be longer if participant desires longer interaction with the DSI/DA. The second visit will take approximately 5 minutes.
61925652|NCT03353389||No AKI|Adult admissions without Acute Kidney Injury during their stay
61925653|NCT03353389||CA-AKI|Adult admissions with Acute Kidney Injury diagnosed within 48 hours during their stay (Community-acquired Acute Kidney Injury)
61925654|NCT03353389||HA-AKI|Adult admissions with Acute Kidney Injury diagnosed after 48 hours during their stay (Hospital-acquired Acute Kidney Injury)
61925655|NCT06571409|EXPERIMENTAL|Coriander Seed Oil - Dose 1|Dietary supplement - Coriander Seed Oil dose 1
61925656|NCT06571409|EXPERIMENTAL|Coriander Seed Oil - Dose 2|Dietary supplement - Coriander Seed Oil dose 2
61925657|NCT06571409|PLACEBO_COMPARATOR|Placebo|Dietary supplement - Placebo
61925658|NCT05967416|EXPERIMENTAL|SIRPant-M (90×10^6 cells)|SIRPant-M Monotherapy (Single Agent)
61925659|NCT05967416|EXPERIMENTAL|SIRPant-M (90×10^6 cells) with focal XRT|SIRPant-M coupled with 2.5 Gy of focal XRT administered within 24 hours after the first ITI and within 3 hours before to 24 hours after the second and third ITI
61925660|NCT05967416|EXPERIMENTAL|SIRPant-M (300×10^6 cells)|SIRPant-M Monotherapy (Single Agent)
62129237|NCT02444858|EXPERIMENTAL|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous injection
62129238|NCT02444858|OTHER|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
62129239|NCT01973075||premature ovarian Insufficiency|4ml whole blood sample is going to collect from premature ovarian Insufficiency group for the assessment of genetic abnormalities
62319505|NCT01243606|EXPERIMENTAL|Single Diagnosis Treatment Protocols|Four disorder-specific cognitive-behavioral treatments will be conducted in accordance with treatment manuals of demonstrated efficacy. SDPs will be matched to the principal anxiety disorder diagnosis.
62480251|NCT06434753|EXPERIMENTAL|Zinc Acexamate|The experimental group will receive ACZ at a daily dose of 600 mg, equivalent to 100mg of elemental zinc (one hard gelatin capsule of 300 mg of ACZ twice a day). Treatment will be stopped when the patient presents any of the events that define the main endpoint of the study.
61925661|NCT05967416|EXPERIMENTAL|SIRPant-M (300×10^6 cells) with focal XRT|SIRPant-M coupled with 2.5 Gy of focal XRT administered within 24 hours after the first ITI and within 3 hours before to 24 hours after the second and third ITI
62129240|NCT01973075||healthy control group|4 ml of whole blood is going to taken from healthy control group
61925662|NCT05967416|EXPERIMENTAL|SIRPant-M (600×10^6 cells) with focal XRT, alternate Day 1, 3, 5 IT-dosing|SIRPant-M coupled with 2.5 Gy of focal XRT administered within 24 hours after the first ITI and within 3 hours before to 24 hours after the second and third ITI
62129241|NCT05608213|EXPERIMENTAL|Len-I|
62129242|NCT05608213|ACTIVE_COMPARATOR|Len|
62129243|NCT04850768||Periodontitis|Individuals with Periodontitis
62129244|NCT04850768||Gingivitis|Individuals with Gingival Inflammation
62129245|NCT04850768||Healthy|Individuals with Periodontally Healthy
62129246|NCT01074567|EXPERIMENTAL|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
62319506|NCT01243606|EXPERIMENTAL|Unified Protocol|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders will be individually administered in accordance with a treatment protocol.
62319507|NCT01243606|NO_INTERVENTION|Waitlist Control|Waitlist participants will not receive treatment during a 16-week waitlist period, but will receive the treatment of their choice immediately following the 16 week waiting period.
62319508|NCT06689735|EXPERIMENTAL|Schroth|3D corrective scoliosis exercises
62319509|NCT06689735|EXPERIMENTAL|Pilates|Pilates exercises
62480252|NCT06434753|PLACEBO_COMPARATOR|Placebo|The control group will receive twice a day orally hard gelatin capsules, identical to those of ACZ, in color, weight and nature, but containing an inert preparation (isomaltose).
62319510|NCT03206034|EXPERIMENTAL|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
62319511|NCT03206034|PLACEBO_COMPARATOR|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
62319512|NCT02003742|EXPERIMENTAL|NX-1207|Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a placebo QD oral treatment for 12 months.
62319513|NCT02003742|ACTIVE_COMPARATOR|Comparator|Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months
62480253|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
62480254|NCT06609343|EXPERIMENTAL|Hemodialysis Group|Fixed dose bupropion hydrochloride 150 mg extended-release tablets will be administered orally thrice a week during routine dialysis sessions for consecutive 8 weeks.
62480255|NCT01169558|EXPERIMENTAL|Bevacizumab|Bevacizumab will be administered in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum until disease progression or study completion.
62480256|NCT01013649|ACTIVE_COMPARATOR|Arm I (gemcitabine hydrochloride or combination chemotherapy)|Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.
62129247|NCT04997213|EXPERIMENTAL|Interventional group|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and were individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
62129248|NCT04997213|ACTIVE_COMPARATOR|Control group|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first were commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
62129249|NCT06176391|OTHER|single|Subjects are their own control
62129250|NCT00224445|EXPERIMENTAL|Truvada + Ritonavir-boosted Atazanavir|All participants received Truvada plus ritonavir-boosted atazanavir
62129251|NCT03827369||ICU patient|Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time.
62129252|NCT02612844|EXPERIMENTAL|NNC0143-0406|
62129253|NCT02612844|ACTIVE_COMPARATOR|Insulin Aspart|
62129254|NCT05573334|NO_INTERVENTION|Routine Care|The Routine Care arm is a control group receiving no study intervention. They receive whatever routine care is standard for the study PI's treatment of usual recurrent UTI patients, including antibiotics for active infections, estrogen and supplements for prevention of infection.
62129255|NCT05573334|EXPERIMENTAL|Flourish HEC|"The experimental (or intervention) arm uses 3 products in a vaginal hygiene system in addition to any routine care they would normally receive. These 3 products are a vulvar wash (for external use), a vaginal moisturizing gel (BioNourish), and a vaginal homeopathic suppository with probiotics.~The vulvar wash is used daily or as often as a participant bathes/showers. The vaginal moisturizing gel, which is formulated to match healthy vaginal secretions for pH, osmolality, and lactic acid levels, is used every day before bed.~The vaginal homeopathic suppository with probiotics is used every 3rd day before bed. This suppository contains native vaginal probiotic species associated with healthy vaginal microbiomes."
62129256|NCT03892564|EXPERIMENTAL|MC2-01 Cream, irradiation|One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation
62319514|NCT05776186||Before spinal anesthesia|Before spinal anesthesia with heavy bupivacaine 12.5 mg is administrated.
62319515|NCT05776186||After spinal anesthesia|After spinal anesthesia with heavy bupivacaine 12.5 mg is administrated.
62319516|NCT04534426|ACTIVE_COMPARATOR|Postoperative topical arnica montana cream|In this arm, Arnica group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
62688656|NCT02114944||HFNC|Patients with dyspnea and/or acute respiratory failure and DNI order treated with high-flow nasal cannula (HFNC).
62688657|NCT00803049|EXPERIMENTAL|Placebo/Teriflunomide 7 mg|Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.
61925663|NCT05967416|EXPERIMENTAL|SIRPant-M (600×10^6 cells) coupled with focal XRT, weekly (W1, 2, 3) IT-dosing|SIRPant-M coupled with 2.5 Gy of focal XRT administered within 24 hours after the first ITI and within 3 hours before to 24 hours after the second and third ITI
61925664|NCT06701578|EXPERIMENTAL|Safe and Sound Protocol Group|The intervention involves listening to specially designed filtered and modulated music that is tailored to enhance the individual's auditory system's ability to process and respond to auditory stimuli.
61925665|NCT06701578|PLACEBO_COMPARATOR|Control Group|The control condition involves listening to music that is not filtered and modulated.
62480257|NCT01013649|EXPERIMENTAL|Arm II (gemcitabine hydrochloride, erlotinib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes once a week for 3 weeks then off 1 week and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline. (closed to accrual 4/2/14)
61925666|NCT01669564|ACTIVE_COMPARATOR|Activated Patients|Will use HIT patient feedback to activate patients.
62480258|NCT01013649|EXPERIMENTAL|Arm III (chemotherapy)|Patients receive the same treatment as in arm I for 1 month. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.
62480259|NCT01013649|EXPERIMENTAL|Arm IV (chemotherapy, chemoradiotherapy)|Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.
62129257|NCT03892564|EXPERIMENTAL|MC2-01 Cream, no irradiation|One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
62129258|NCT03892564|EXPERIMENTAL|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
62129259|NCT03892564|EXPERIMENTAL|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
62129260|NCT03892564|EXPERIMENTAL|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
62129261|NCT04805216||Immunocompromised patients (study group)|People who are likely to have a suppressed immunity due to their haematological disorder or its treatment
62129262|NCT04805216||Immunocompetent volunteers (control group)|People without suppressed immunity
62129263|NCT03762434|ACTIVE_COMPARATOR|mobile app|Mobile app: The participants will receive a Life style Modification Program with the support of mobile application (MetS app). The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area of the Mets app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the app installment and briefing.
62129264|NCT03762434|ACTIVE_COMPARATOR|booklet|The participants will receive the Life Style Modification programme with the support of a Hong Kong version Metabolic Syndrome (MetS) booklet to take home and use for 3 months. The booklet had been modified from a booklet of a Life Style Intervention Programme (LIP) in China and the principal investigator of this proposal was the core team members of the previous project . The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management . The major component of the booklet for the change is the language translated from simplified Chinese to traditional Chinese and slight adjustment about the advice on vegetable choice due to difference in type of available vegetables in Hong Kong.
62129265|NCT03094182|EXPERIMENTAL|iron group|Patients in the iron group are given Intravenous iron isomaltoside during operation.
62129266|NCT03094182|PLACEBO_COMPARATOR|control group|Patients in the control group receive the same volume of normal saline during operation.
62129267|NCT06081075||Acutely ill neonates with suspected genetic condition, without a clear non-genetic aetiology|
62480260|NCT05501886|EXPERIMENTAL|Arm A - Patients Lacking PIK3CA Mutations (WT)|Gedatolisib + Palbociclib + Fulvestrant
62688658|NCT00803049|EXPERIMENTAL|Teriflunomide 7 mg/7 mg|Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
62688659|NCT00803049|EXPERIMENTAL|Placebo/Teriflunomide 14 mg|Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
62688660|NCT00803049|EXPERIMENTAL|Teriflunomide 14 mg/14 mg|Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
62688661|NCT01258985|ACTIVE_COMPARATOR|Tai Chi|12 weeks of Tai Chi classes
62688662|NCT01258985|ACTIVE_COMPARATOR|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of Supervised Home Exercise
62688663|NCT01706315|EXPERIMENTAL|Cohort 1 - GSK2140944 400 mg|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days
62688664|NCT01706315|PLACEBO_COMPARATOR|Cohort 1 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
62688665|NCT01706315|EXPERIMENTAL|Cohort 2 - GSK2140944 800 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1
62688666|NCT01706315|PLACEBO_COMPARATOR|Cohort 2 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
61925667|NCT01669564|OTHER|Control patients|Patients will not receive HIT patient feedback.
61925668|NCT01669564|OTHER|Intervention Physicians|Will use HIT patient feedback to activate patients.
61925669|NCT01669564|OTHER|Control Physicians|Patients will not receive HIT patient feedback.
62129268|NCT06009458|OTHER|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|For the orthokeratology treatment the subjects will be instructed to wear the study lenses each night during the hours of sleep (for a minimum of 6 hours) and remove the lenses during the waking hours. The subject will be examined at 1 day, 1 week, 1 month, 3 months, 6 months, 9 months and 12 months after dispensing to evaluate the ocular physiology and the treatment effect. The target refractive error (sphere) will be plano for all subjects. All subjects enrolled at two of the investigational sites (targeted total of 40 subjects) will be evaluated for the stability of UCVA and manifest refraction throughout a single day on or following the 3 month, 6 month, or 9 month follow up visits. A post-treatment follow-up visit will be scheduled 1 month following discontinuation of the study lens. When it has been determined that no additional follow up visits are required, the subject will be discharged from the study.
62319517|NCT04534426|ACTIVE_COMPARATOR|Postoperative topical mucopolysaccharide polysulfate cream|In this arm, Mucopolysaccharide polysulfate group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
62319518|NCT04534426|OTHER|Control group|In this arm control group consisted of 20 patients who were treated with only standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
61925670|NCT03599401|ACTIVE_COMPARATOR|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
62129269|NCT05834270|ACTIVE_COMPARATOR|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
62129270|NCT05834270|ACTIVE_COMPARATOR|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
62129271|NCT00687713|ACTIVE_COMPARATOR|Bupropion|Subjects will receive bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
62129272|NCT00687713|PLACEBO_COMPARATOR|Placebo|Subjects will receive a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
62129273|NCT04385056|EXPERIMENTAL|Low Dose MSCTC-0010|Participants will receive low-dose cell administration
62129274|NCT04385056|EXPERIMENTAL|Medium Dose MSCTC-0010|Participants will receive medium-dose cell administration
62129275|NCT04385056|EXPERIMENTAL|High Dose MSCTC-0010|Participants will receive high-dose cell administration
62129276|NCT04004819|EXPERIMENTAL|Rituximab group|Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
62129277|NCT04004819|NO_INTERVENTION|Control group|Patients will receive usual care and drug use.
62129278|NCT05899270|EXPERIMENTAL|3D group|In 3D group, the investigator will intubate using DLT chosen by an automatic comparison software for 3D reconstruction based on CT data (3DRACS).
62129279|NCT05899270|PLACEBO_COMPARATOR|control group|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
62129280|NCT05992298|EXPERIMENTAL|7 T MRI|
62129281|NCT01599104|EXPERIMENTAL|LCZ696 200 mg|LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
62129282|NCT01599104|EXPERIMENTAL|LCZ696 400 mg|LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
62129283|NCT01599104|ACTIVE_COMPARATOR|Olmesartan 20 mg|Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks
62129284|NCT05580380|ACTIVE_COMPARATOR|Limited Patient-Clinician Relationship Group|
62129285|NCT05580380|EXPERIMENTAL|Enhanced Patient-Clinician Relationship Group|
62129286|NCT04114422|EXPERIMENTAL|Seven-day preoperative exercise training program|All patients will undergo to seven-day preoperative exercise training program that includes aerobic and resistance exercises
62319519|NCT03339648|EXPERIMENTAL|Professional Development Enhancement|"During the measurement period, this group will receive the intervention, described below:~Content using three of UF Lastinger Center's innovations for cost-effective teaching and learning - e-Content Clinics, Coaching, and Communities of Practice. Elements of the professional development model are as follows:~1. E-Content Clinics- Content Clinics are offered online using digital video technology.~2. Coaching- Coaching develops strong cadres of leaders that have profound expertise and substantial success in advancing teaching and learning outcomes. This approach uses existing personnel to reinforce and deepen learning through online professional development by embedding it in day-to-day activities.~3. Online Community of Practice- This scalable online platform allows users to create virtual communities of practice designed to strengthen the learning and collaboration network."
62319520|NCT03339648|ACTIVE_COMPARATOR|Control- Delayed Intervention|This arm will continue business as usual during the measurement period. They will receive the exact same intervention described above once data collection is complete.
62319521|NCT03658330|EXPERIMENTAL|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
62319522|NCT04082767|ACTIVE_COMPARATOR|Dexmedetomidine|
62480261|NCT05501886|EXPERIMENTAL|Arm B - Patients Lacking PIK3CA Mutations (WT)|Gedatolisib + Fulvestrant
62480262|NCT05501886|ACTIVE_COMPARATOR|Arm C - Patients Lacking PIK3CA Mutations (WT)|Fulvestrant
62480263|NCT05501886|EXPERIMENTAL|Arm D - Patients with PIK3CA Mutation (MT)|Gedatolisib + Palbociclib + Fulvestrant
62319523|NCT04082767|ACTIVE_COMPARATOR|Midazolam|
62480264|NCT05501886|ACTIVE_COMPARATOR|Arm E - Patients with PIK3CA Mutation (MT)|Alpelisib + Fulvestrant
62480265|NCT05501886|EXPERIMENTAL|Arm F - Patients with PIK3CA Mutation (MT)|Gedatolisib + Fulvestrant
62480266|NCT02005419|PLACEBO_COMPARATOR|gemcitabine + placebo|gemcitabine at 1000 mg/m\^2 on days 1, 8, and 15; placebo at 2 g on days 1-28
61925671|NCT03599401|ACTIVE_COMPARATOR|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
62319524|NCT06435195||Pituitary Complex and Rare Diseases|The Pituitary Complex and Rare Diseases cohort consists of patients diagnosed with various pituitary disorders, including but not limited to pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, sellar region germ cell tumors, cavernous sinus syndrome, and other diseases. Patients requiring surgical resection or biopsy of pituitary pathologies will undergo transsphenoidal surgery or craniotomy.
62480267|NCT02005419|EXPERIMENTAL|gemcitabine + metformin|gemcitabine at 1000 mg/m\^2 on days 1, 8, and 15; metformin at 2 g on days 1-28
61925672|NCT03599401|PLACEBO_COMPARATOR|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
61925673|NCT04679298||Apixaban|N=20
61925674|NCT04679298||Edoxaban|N=20
61925675|NCT04679298||Dabigatran|N=20
61925676|NCT04679298||Rivaroxaban|N=20
61925677|NCT01373307|EXPERIMENTAL|Early Intervention|Participants are nested in churches which were randomly assigned to receive the intervention first.
61925678|NCT01373307|NO_INTERVENTION|Delayed Intervention|Wait-list control group. Participants are nested in churches which were randomly assigned to receive the intervention at a later date. Delayed Intervention participants receive an educational luncheon addressing stress reduction during the window of no intervention.
61925679|NCT05533476|EXPERIMENTAL|Multi Sensory Stimulation And Priming|8 weeks, 30 minutes per day home based MuSSAP training.
61925680|NCT05533476|EXPERIMENTAL|Intensive Usual Care (Upper Limb)|8 weeks, 30 minutes per day home based Intensive Usual Care (Upper Limb).
61925681|NCT06704295|OTHER|Control ad: Dark gray product with tobacco flavor name|
61925682|NCT06704295|EXPERIMENTAL|Dark gray product with strawberry flavor name|
61925683|NCT06704295|EXPERIMENTAL|Colorful (strawberry color) product with strawberry flavor name|
62129287|NCT04085094||1. Healthy and pre-menopausal women without CKD|"A total of 45 healthy and pre-menopausal women (\<50 years old) will be recruited. Thirty of them are not on oral anticonception; 15 will be examined at each visit during their follicular phase, 15 during their luteal phase. Fifteen are on oral contraception.~Three visits will take place:~* V1: after 5 days of a high salt diet (adding 6g of salt/day on top of regular diet), patients will undergo renal ultrasound (Doppler and CEUS), renal functional MRI (BOLD and phase contrast) and Na23 muscle and skin MRI.~* V2: after 5 days of low salt diet (dietary instructions), the same exams mentioned above will be repeated~* V3: renal CEUS will be performed before and after an oral protein load (1g/kg) or after SL nitroglycerin (0.2mg).~The day before each visit, a 24h urine collection will be performed in order to measure renal salt excretion."
62480268|NCT02942563|EXPERIMENTAL|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
62129288|NCT04085094||2. Pre-menopausal women with CKD|A total of 30 women with CKD will be recruited and undergo the same visits as outlined above
61925684|NCT06704295|EXPERIMENTAL|Colorful (strawberry color) product with strawberry flavor name and strawberry image|
61925685|NCT06704295|EXPERIMENTAL|Colorful (strawberry color) product with strawberry flavor features|Colorful (strawberry color) product with strawberry flavor name + strawberry image + strawberry flavor sensation descriptor
61925686|NCT06704295|EXPERIMENTAL|Colorful (strawberry color) product with strawberry flavor features and choice claim|Colorful (strawberry color) product with strawberry flavor name + strawberry image + strawberry flavor sensation descriptor + flavor choice claim
61925687|NCT05372536|EXPERIMENTAL|parent-led home-administered low-dose Cytarabine|Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
62129289|NCT04085094||3. Post-menopausal women without CKD|Fifteen post-menopausal women will undergo the same exams as outlined above
61925688|NCT05006794|EXPERIMENTAL|Part A: zamzetoclax Dose-Escalation|Patients will receive escalating doses of zamzetoclax to estimate MTD.
61925689|NCT05006794|EXPERIMENTAL|Part A: zamzetoclax Dose-Expansion|Patients will receive ≤ MTD of zamzetoclax.
61925690|NCT05006794|EXPERIMENTAL|Part B (Cohort B1): Zamzetoclax + docetaxel|Patients will receive escalating doses of zamzetoclax in combination with docetaxel.
62319525|NCT02354391|EXPERIMENTAL|Ingenol mebutate and MAL PDT|Participants will recieve Ingenol mebutate 0.015% topical gel treatment applied day 2,3 and 4 to quadrant 1. Patients will recieve ingenol mebutate 0.015% applied on day 1 followed by methyl aminolevulate and photodyamnic therapy on day 5 to quadrant 2. Particpants will recieve methyl aminolevulate and photodynamic therapy on day 5 to quadrant 3, and quadrant 4 will act as the control, with no treatment.
62129290|NCT04085094||4. Healthy men|A total of thirty age-and sex-matched men (15 below and 15 above 50 years old) will undergo the same exams as above.
62129291|NCT04085094||5.Men with CKD|Fifteen men with CKD will undergo the same exams as outlined above
62129292|NCT06117332|EXPERIMENTAL|Perception resulting from AI-powered artificial vision|The investigators will produce visual percepts in visual prosthesis patients either by directly stimulating electrodes (using FDA-approved pulse trains), or by asking them to view a computer or projector screen and using standard stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Informed by psychophysical data and computational models, the investigators will test the ability of different stimulus encoding methods to support simple perceptual and behavioral tasks (e.g., object recognition, navigation). These encoding methods may include computer vision and machine learning methods to highlight important objects in the scene or to highlight nearby obstacles and may be tailored to each individual patient.
62129293|NCT00903851|EXPERIMENTAL|(1) Lidoderm|(1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain
62129294|NCT03262935|EXPERIMENTAL|(vic-)trastuzumab duocarmazine|SYD985, every 3 weeks (Q3W)
62319526|NCT04788303|ACTIVE_COMPARATOR|Full intervention|Full intervention: school meal, garden, education, and community workshops
62319527|NCT04788303|ACTIVE_COMPARATOR|Partial intervention|Partial intervention: garden, education, and community workshops
62319528|NCT04788303|NO_INTERVENTION|Control|Control: standard of care
62319529|NCT03739944|ACTIVE_COMPARATOR|Laparotomic radical hysterectomy|
62480269|NCT05181969||Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Apheresis therapy
62480270|NCT05181969||Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Apheresis therapy
62129295|NCT03262935|ACTIVE_COMPARATOR|Physician's choice|"1. Lap/Cap~2. T/Cap~3. T/Vino~4. T/Eri"
62129296|NCT04257409|EXPERIMENTAL|DF patient active|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
62129297|NCT04257409|ACTIVE_COMPARATOR|DF patient control|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
62319530|NCT03739944|ACTIVE_COMPARATOR|Laparotomic radical trachelectomy|
62480271|NCT05181969||Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Apheresis therapy
62480272|NCT05181969||Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Apheresis therapy
62129298|NCT04257409|EXPERIMENTAL|Diabetic patient with mild neuropathy|Patients with Type 2 diabetes mellitus with mild form of peripheral sensory neuropathy
62129299|NCT04257409|EXPERIMENTAL|Diabetic patient with severe neuropathy|Patients with Type 2 diabetes mellitus with severe form of peripheral sensory neuropathy
62319531|NCT03739944|ACTIVE_COMPARATOR|Laparoscopic radical hysterectomy|
62319532|NCT03739944|ACTIVE_COMPARATOR|Laparoscopic radical trachelectomy|
62319533|NCT00504166|ACTIVE_COMPARATOR|alendronate sodium|alendronate sodium 70 mg tablet once a week for 24 months
62319534|NCT00504166|PLACEBO_COMPARATOR|placebo|placebo to match alendronate sodium
62319535|NCT05212194|OTHER|Post spinal puncture headache|the patients who developed post spinal puncture headache
62319536|NCT00783705|EXPERIMENTAL|Arm I (inositol)|Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
62319537|NCT00783705|EXPERIMENTAL|Arm II (placebo)|Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
62319538|NCT04237207|OTHER|Aidable Residual Hearing (ARH) Cohort|Control Device followed by experimental Device.
62480273|NCT03660826|EXPERIMENTAL|Arm I (cediranib maleate)|Patients receive cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
62480274|NCT03660826|EXPERIMENTAL|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
62129300|NCT03733119|EXPERIMENTAL|Akt/ERK inhibitor ONC201|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62129301|NCT03733119|EXPERIMENTAL|Akt/ERK inhibitor ONC201, methionine-restricted diet|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Participants also receive methionine-restricted diet PO on days 1-5, 8-12, and 15-19. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62129302|NCT01599793|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
62319539|NCT04237207|OTHER|Electric Only (EO) Cohort|Control Device followed by experimental Device.
62319540|NCT00674336|EXPERIMENTAL|Shellfish with Norovirus|We dosed shellfish with Norovirus and challenged human volunteers with Shellfish that had norovirus
62319541|NCT02228278|EXPERIMENTAL|Group A|Group A will receive the typical clinic visits plus daily text messages
62319542|NCT02228278|OTHER|Group B|Group B will act as the control and will receive the typical clinic visits.
62319543|NCT04459299||STEMI patients with clinical indication for primary PCI|Subjects with a clinical indication of STEMI.
62319544|NCT03153111|ACTIVE_COMPARATOR|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
62319545|NCT03153111|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks.
62688667|NCT01706315|EXPERIMENTAL|Cohort 3 - GSK2140944 1500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2
62129303|NCT05451095|EXPERIMENTAL|Treatment sequence T1-T2-R|T1: Lower dose of BI 474121 and higher dose of placebo followed by intravenous ketamine infusion T2: Higher dose of BI 474121 and lower dose of placebo followed by intravenous ketamine infusion R: Lower dose of placebo and higher dose of placebo followed by intravenous ketamine infusion
62129304|NCT05451095|EXPERIMENTAL|Treatment sequence T2-T1-R|
62129305|NCT05451095|EXPERIMENTAL|Treatment sequence T1-R-T2|
62129306|NCT05451095|EXPERIMENTAL|Treatment sequence T2-R-T1|
62129307|NCT05451095|EXPERIMENTAL|Treatment sequence R-T1-T2|
62129308|NCT05451095|EXPERIMENTAL|Treatment sequence R-T2-T1|
62129309|NCT03760354|EXPERIMENTAL|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
62129310|NCT03760354|PLACEBO_COMPARATOR|Placebo (no corticosteroid treatment)|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
62129311|NCT05673434|EXPERIMENTAL|Experimental: TM4SF1 positive CAR-T cells for digestive tumors|"The present study is proposed to study advanced malignant digestive tumors in adults, and the four escalating doses, namely, 0.5\~1.0.,1.0\~2.0,2.0\~3.0 and 3.0\~10.0 (×10 \^6/kg), will be given.~Intervention: Biological: TM4SF1-positive chimeric antigen receptor T-cell therapy"
62129312|NCT04441008|EXPERIMENTAL|aiTBS arm|aiTBS treatment as lead-in phase to ECT standard of care treatment.
62319546|NCT03814317|EXPERIMENTAL|Study Group|"Sarcoidosis patients with interstitial lung disease and precapillary pulmonary hypertension based on right heart catheterization (RHC).~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
62319547|NCT01703819|EXPERIMENTAL|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
62319548|NCT01703819|PLACEBO_COMPARATOR|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
62319549|NCT02952066|EXPERIMENTAL|TRP1 Density|Bronchial Biopsy: During the biopsy procedure the investigator will collect five bronchial specimens (1-2 cubic millimeters) each the major, lobar and segmental bronchi.
62319550|NCT01143597|ACTIVE_COMPARATOR|Somatosensory stimulation (SS)|Participants in the SS group receive median nerve electrical stimulation applied to the skin of the wrists.
62319551|NCT01143597|ACTIVE_COMPARATOR|Massed practice + somatosensory stimulation (MP+SS)|Participants in the MP+SS group receive a combined intervention consisting of SS and a skill-based exercise protocol
62319552|NCT01143597|ACTIVE_COMPARATOR|Conventional resistance training (CRT)|Participants in the CRT group will participate in a weight-based exercise program
62688668|NCT01706315|PLACEBO_COMPARATOR|Cohort 3 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
62129313|NCT04441008|ACTIVE_COMPARATOR|ECT arm|ECT as clinically indicated.
62319553|NCT03532555|ACTIVE_COMPARATOR|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
62480275|NCT03660826|EXPERIMENTAL|Arm III (cediranib maleate, olaparib)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
62480276|NCT03660826|EXPERIMENTAL|Arm IV (olaparib, capivasertib)|Patients receive olaparib PO BID on days 1-28 and capivasertib PO BID on days 1-4 each week. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
62480277|NCT03660826|EXPERIMENTAL|Arm V (olaparib, durvalumab)|Patients receive olaparib PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
62129314|NCT01845428|OTHER|pravastatin|All participants will receive pravastatin 20mg daily
62129315|NCT02931175|EXPERIMENTAL|Group 1|Mandatory twice a week (Mondays and Thursdays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
62129316|NCT02931175|EXPERIMENTAL|Group 2|Mandatory thrice a week (Mondays, Wednesdays, and Fridays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
62129317|NCT01414738|EXPERIMENTAL|Radiation|Whole-Brain Radiotherapy
62319554|NCT03532555|PLACEBO_COMPARATOR|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
62480278|NCT03660826|EXPERIMENTAL|Arm VI (cediranib maleate, durvalumab)|Patients receive cediranib maleate PO QD on days 1-5 each week and durvalumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
62480279|NCT04821375|EXPERIMENTAL|Bazedoxifene plus conjugated estrogens immediately|Immediate receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
62319555|NCT01856634|EXPERIMENTAL|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
62319556|NCT01856634|EXPERIMENTAL|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
62319557|NCT01856634|EXPERIMENTAL|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
62480280|NCT04821375|OTHER|Bazedoxifene plus conjugated estrogens wait list|After a 6-month waiting period, receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
62480281|NCT01585792|EXPERIMENTAL|TAK-875 25 mg|
62480282|NCT01585792|EXPERIMENTAL|TAK-875 50 mg|
62480283|NCT01585792|ACTIVE_COMPARATOR|Glimepiride|
62129318|NCT06366399|EXPERIMENTAL|AM Resistance Exercise|Resistance Exercise intervention taking place in the AM
62129319|NCT06366399|EXPERIMENTAL|PM Resistance Exercise|Resistance Exercise intervention taking place in the PM
62129320|NCT04861233||All Participants|Participants diagnosed with constipation who have been prescribed with lubiprostone for the first time in a real-world setting will be observed prospectively and followed up for 12 months after initiation of study medication. Treatment regimen, frequency of laboratory and clinical assessments will be determined by investigator in a routine clinical practice.
62129321|NCT01037985|EXPERIMENTAL|EXC 001|
62129322|NCT01037985|PLACEBO_COMPARATOR|Placebo|
62129323|NCT06074549||Open Label|DynamX Novolimus-eluting Coronary Bioadaptor System
62319558|NCT01856634|EXPERIMENTAL|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:~* Patient's \> 10 kg will receive DPF 10 mg BID + OBR~* Patient's \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~* Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
62319559|NCT01745627|EXPERIMENTAL|Laser Treatment|
62319560|NCT01096550|EXPERIMENTAL|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
62480284|NCT01585792|PLACEBO_COMPARATOR|Placebo|
62480285|NCT04657289|EXPERIMENTAL|Arm A [Q36W] 36-weeks between refill-exchange procedures|Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.
62688669|NCT01706315|EXPERIMENTAL|Cohort 4 - GSK2140944 2500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3
62688670|NCT01706315|PLACEBO_COMPARATOR|Cohort 4 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
62688671|NCT01706315|EXPERIMENTAL|Cohort 5 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4
61925691|NCT05006794|EXPERIMENTAL|Part B (Cohort B4): zamzetoclax + sacituzumab govitecan-hziy|Patients will receive escalating doses of zamzetoclax in combination with sacituzumab govitecan-hziy.
61925692|NCT05006794|EXPERIMENTAL|Part C (Cohort C1): zamzetoclax + docetaxel|Patients will receive ≤ MTD zamzetoclax in combination with docetaxel.
62129324|NCT01579370|ACTIVE_COMPARATOR|Quaternary ammonium|Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
62129325|NCT01579370|EXPERIMENTAL|Bleach|Rooms will be terminally cleaned using bleach-containing products.
62129326|NCT01579370|EXPERIMENTAL|Quaternary ammonium and UV-C light|Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
62688672|NCT01706315|PLACEBO_COMPARATOR|Cohort 5 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
62129327|NCT01579370|EXPERIMENTAL|Bleach and UV-C light|Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.
62129328|NCT04498234|EXPERIMENTAL|GROUP(A) (CONTROL GROUP)|Patients will receive standard regimen of anesthesia .
62480286|NCT04657289|ACTIVE_COMPARATOR|Arm B [Q24W] 24-weeks between refill-exchange procedures|Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.
62688673|NCT01706315|EXPERIMENTAL|Cohort 6 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5
62688674|NCT01706315|PLACEBO_COMPARATOR|Cohort 6 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
62129329|NCT04498234|EXPERIMENTAL|Group B|Patients will receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4.
62129330|NCT04498234|EXPERIMENTAL|Group C|Patients will receive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
62129331|NCT02575560||weekly use erolotinib vs history data|Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician
61925693|NCT05006794|EXPERIMENTAL|Part C (Cohort C4): zamzetoclax + sacituzumab govitecan-hziy|Patients will receive ≤ MTD zamzetoclax in combination with sacituzumab govitecan-hziy.
61925694|NCT02829918|EXPERIMENTAL|Nivolumab Treatment|This is a single arm study with two stage design using nivolumab in advanced biliary tract cancer (BTC), for participants who have failed or are intolerant to at least one line of therapy and no more than 2 lines of therapy. In the first stage, 18 participants will be accrued. If there is at least one response (or several participants with stable disease based on the study team's discretion), an additional 34 patients will be accrued for a total of 52 patients.
61925695|NCT01257802|ACTIVE_COMPARATOR|LUPRON|Monthly depot leuprolide acetate 3.75 mg injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
61925696|NCT01257802|PLACEBO_COMPARATOR|Placebo|Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
62688675|NCT05077605|EXPERIMENTAL|Functional residual capacity|Functional residual capacity measure during and after extubation
62480287|NCT06732284||Patients with sleep inertia and major depression|
62480288|NCT06732284||Patients with major depression without sleep inertia|
62480289|NCT06732284||Controls without mood disorders or sleep inertia|
62480290|NCT02510417|EXPERIMENTAL|VSTs against three viruses|Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.
62480291|NCT03567447|EXPERIMENTAL|Treatment group|This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
62480292|NCT03567447|PLACEBO_COMPARATOR|Non treatment group|This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
62480293|NCT05921227|EXPERIMENTAL|Alternative Treatment Including Augmentative and Alternative Communication|Once children are shown to not respond to the usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment, they will be placed in this arm, which will train them to use an Augmentative and Alternative Communication device as an additional means to use to 'say' a word.
62319561|NCT01096550|ACTIVE_COMPARATOR|Outpatient|Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
62129332|NCT02249559||GK subthalamotomy|Evaluate the safety and efficacy of unilateral GK subthalamotomy for PD in patients deemed poor candidates for DBS.
62319562|NCT04003636|EXPERIMENTAL|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
62480294|NCT05921227|ACTIVE_COMPARATOR|Usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment|Children who do appear to respond to treatment will continue with the full course of usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) intervention.
62480295|NCT04071652|EXPERIMENTAL|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
62129333|NCT01680250|EXPERIMENTAL|Sirolimus|Sirolimus administration group starting dose: 2mg/day target trough level: 4-10 ng/dL
62129334|NCT06135623||COVID-19 Group|Having a history of COVID-19 infection
62480296|NCT05598320|EXPERIMENTAL|TransCon CNP|Once weekly double-blinded treatment with SC injection of 100 µg/kg of TransCon CNP for 52 weeks
62480297|NCT05598320|PLACEBO_COMPARATOR|Placebo for TransCon CNP|Once weekly double-blinded treatment with SC injection of 100 µg/kg of Placebo for TransCon CNP for 52 weeks
62480298|NCT01799811||CLI patient's needing open bypass|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.
62480299|NCT05364424|EXPERIMENTAL|R/R DLBCL|Participants will receive up to 3 21-day cycles of glofitamab, rituximab, ifosfamide, carboplatin, and etoposide (glofit-R-ICE).
62480300|NCT03307317||Adult pilots|Healthy adults between the ages of 18-65 years
62480301|NCT03307317||AR infants|Infants with 12 months of age (+/- 2 weeks) with one of the following: observed developmental delay, sibling of a child with autism, premature birth, small for gestational age.
62480302|NCT03307317||TD infants|Healthy infants with 9 months of age (+/- 2 weeks)
62480303|NCT01056484|EXPERIMENTAL|Meditation|Mindfulness Based Relapse Prevention for Alcohol Dependence intervention + Standard of Care therapy
62480304|NCT01056484|OTHER|Wait-list control|Standard of Care therapy only
62480305|NCT06031883|EXPERIMENTAL|1|Ketamine group recieve induction and maintenance doses of ketamine by target controlled infusion in addition of propofol-dexmedetomidine as total intravenous anesthesia for patients undergoing craniotomy
62129335|NCT06135623||Non-COVID-19 Group|No history of COVID-19 infection
62480306|NCT06031883|EXPERIMENTAL|2|Fentanyl group recieve induction and maintenance doses of fentanyl by target controlled infusion in addition of propofol-dexmedetomidine as total intravenous anesthesia for patients undergoing craniotomy
62480307|NCT05421858|EXPERIMENTAL|Fosmanogepix IV/oral|"Fosmanogepix will be administered as an Intravenous (IV) infusion given directly into a vein. There is an option to switch from the IV infusion to the oral form of fosmanogepix which is taken by mouth.~Matching placebos for caspofungin and fluconazole will also be administered (a placebo does not have any medicine in it but looks just like the caspofungin and fluconazole)."
62480308|NCT05421858|ACTIVE_COMPARATOR|Caspofungin IV/ Fluconazole oral|"Caspofungin will be administered as an intravenous (IV) infusion given directly into a vein. There is an option to switch from the IV infusion to oral fluconazole which is taken by mouth.~Matching placebos for fosmanogepix will also be administered (a placebo does not have any medicine in it but looks just like the medicine fosmanogepix being studied)."
62480309|NCT03374176|ACTIVE_COMPARATOR|AMX-MET|"AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules.~1 capsule tid during 7 days."
62480310|NCT03374176|EXPERIMENTAL|Clindamycin|"Clindamycin Clindamycin 300 mg + placebo. Capsules.~1 capsule tid during 7 days."
62129336|NCT05208372||Laparotomy group|Patients who undergo radical laparotomy for gastric cancer.
62129337|NCT05208372||Laparoscopy group|Patients who undergo laparoscope-assisted radical gastrectomy for gastric cancer.
62129338|NCT02082548|EXPERIMENTAL|Intervention|educational intervention arm
62480311|NCT00840879|EXPERIMENTAL|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
62129339|NCT02082548|NO_INTERVENTION|control|Standard of care
62129340|NCT06079515|ACTIVE_COMPARATOR|Ali Akdağ|All injections were performed by him under the guidance of a Clarius portable USG device (L7 HD Linear Ultrasound Scanner). A total of 10 ml of a mixture of 1 ml of 40 mg triamcinolone acetonide (Kenakort-A ampoule) and 9 ml of 0.5% bupivacaine hydrochloride (Marcaine) was used in each injection.
62129341|NCT06079515|EXPERIMENTAL|Muhammet Hüseyin Sarı|Blind observer to injections
62319563|NCT04003636|PLACEBO_COMPARATOR|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
62319564|NCT02897193|ACTIVE_COMPARATOR|Dental implant with bone augmentation|patients will be installed with ICE Dental implant 4.2 mm diameter with Alpha-Bio's grafts horizontal bone augmentation
62319565|NCT02897193|EXPERIMENTAL|narrow implant|patients will be installed with NICE Dental implant 3.2 mm diameter
62129342|NCT00737958||1|Patients with documented stable coronary artery disease, symptoms of stable angina pectoris, and a positive standard BRUCE exercise stress test at 3 - 13 minutes.
62129343|NCT06220149||Post polypectomy cohort|
62129344|NCT00549848|EXPERIMENTAL|HD PEG|"Participants randomized to receive higher dose PEG-asparaginase during the continuation phase.~Interventions:~* Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~* Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
62319566|NCT00824499|EXPERIMENTAL|DPA|Regional complex intervention based on the Chronic Care Model
62480312|NCT00840879|ACTIVE_COMPARATOR|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
62480313|NCT06547177|NO_INTERVENTION|control|Pregnant women in the study's control group will not be subjected to any application other than routine hospital practices. They will not consume oral liquid or solid food, and their fluid needs will be met with 125 ml/hour of intravenous(iv) fluid (5% dextrose).
62480314|NCT06547177|EXPERIMENTAL|Fruit juice and water group|Fruit juice (100 ml juice once in the first hour of admission to the delivery room during the latent phase) = (cherry/apple juice, 100 ml, 50-54 kcal), then every 4 hours. It will be given in 100 ml. In addition, they will be allowed to take small amounts of water. (Total fluid intake will be recorded)
62480315|NCT06547177|EXPERIMENTAL|Water group|Water (as much as desired in 100 ml containers during the latent phase) (total water amount will be recorded). Pregnant women in all groups will not take oral fluids after transitioning to the active phase (\> 6 cm cervical dilatation).
62480316|NCT03354858||Follicular flushing|One ovary will be aspirated using follicular flushing (up to 5 times per follicle).
62129345|NCT00549848|ACTIVE_COMPARATOR|CD PEG|"Participants randomized to receive conventional dose PEG-asparaginase during the continuation phase..~Interventions:~* Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~* Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
62688676|NCT04362254|EXPERIMENTAL|Spesolimab|"During the maintenance treatment period 300 milligram (mg) Spesolimab was given by subcutaneous injection at Week 0 and then every 4 weeks for a total duration of 89 weeks.~Patient with a confirmed fistula relapse received a single intravenous infusion of 1200 mg Spesolimab followed by an intensified subcutaneous spesolimab maintenance dosing of 600 mg Spesolimab every 4 weeks."
62129346|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
62129347|NCT05264168||Rivaroxaban|Reference group
62129348|NCT05264168||Apixaban|Exposure group
62129349|NCT00903162|EXPERIMENTAL|Letrozole-Leuprolide|Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.
62129350|NCT00973986|ACTIVE_COMPARATOR|CYP3A4*1/*1|
62129351|NCT00973986|ACTIVE_COMPARATOR|CYP3A4*1/*1G|
62129352|NCT00973986|ACTIVE_COMPARATOR|CYP3A4*1G/*1G|
62129353|NCT01950780|EXPERIMENTAL|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
62129354|NCT05296213|EXPERIMENTAL|silver diamine fluoride-potassium iodide SDF-KI (riva star)|SDF-KI was applied once as a professional application over the early enamel lesions in cervical third of the buccal surface of molar teeth.
62319567|NCT00824499|NO_INTERVENTION|VR|
62319568|NCT03953586||bubble suction test and peristalsis in hydrosalpnix|. Group A: Women with unilateral or bilateral blockage of the distal end of the fallopian tubes with tubal distension.
62319569|NCT03953586||bubble suction test and peristalsis in normal tubes|Group B: Women with normal appearance of the fallopian tubes by HSG.
62319570|NCT05680129|EXPERIMENTAL|B1: XW003+MET|High dosage of XW003 once weekly
62319571|NCT05680129|EXPERIMENTAL|B2: XW003+MET|Low dosage of XW003 once weekly
62319572|NCT05680129|ACTIVE_COMPARATOR|B3: Dulaglutide+MET|1.5mg Dulaglutide once weekly
62319573|NCT03020524|EXPERIMENTAL|Dose level 1:|Autologous CD4 T-Cells0.8-1x10\^9 transduced CD4+T-cells administered IV as a single dose
62319574|NCT03020524|ACTIVE_COMPARATOR|Dose level 2|Autologous CD4 T-Cells 2.4-3x10\^9 transduced CD4+ T-cells administered IV as a single dose
62319575|NCT03020524|ACTIVE_COMPARATOR|Dose level 3|Autologous CD4 T-Cells 0.8-1x10\^10 transduced CD4+ T-cells administered IV as a single dose
62319576|NCT00084682|EXPERIMENTAL|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62319577|NCT01530399|EXPERIMENTAL|MDCO 1|MDCO-2010: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
62319578|NCT01530399|EXPERIMENTAL|MDCO 2|MDCO-2010: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
62480317|NCT03354858||No flushing|One ovary will be aspirated using direct aspiration (no flushing).
62480318|NCT01851135|EXPERIMENTAL|Patients with NF1|
62480319|NCT01851135|OTHER|Healthy controls|
62688677|NCT02048631||Oral Cancer Patients underwent Free Flap Reconstruction|
61925697|NCT06411561|EXPERIMENTAL|SLEEP + COG|"* Combination of SLEEP and COG interventions, for up to 7 days/nights + usual post-ICU inpatient care~* Personalized timing of morning COG sessions or evening COG sessions, based on CSM scale at baseline"
62480320|NCT06422507|ACTIVE_COMPARATOR|2 mg aflibercept|"Participants that will be enrolled to this treatment arm will receive 2 mg aflibercept every 8 weeks following 5 initial monthly doses starting at Baseline (visit 2) (2q8) for the chosen study eye. Randomization will be stratified according to baseline Central subfield thickness (CST) (\<400 µm, ≥400 µm), baseline Best corrected visual acuity (BCVA) (\<60 vs. ≥60 ETDRS letters) and prior treatment for DME."
62480321|NCT06422507|EXPERIMENTAL|8 mg aflibercept (high dose)|"Participants that will be enrolled to this treatment arm will receive 8 mg (high dose - HD) aflibercept every 16 weeks following 3 initial monthly doses, starting at Baseline (Visit 2) (HDq16) for the chosen study eye. Randomization will be stratified according to baseline Central subfield thickness (CST) (\<400 µm, ≥400 µm), baseline Best corrected visual acuity (BCVA) (\<60 vs. ≥60 ETDRS letters) and prior treatment for DME."
62480322|NCT06007664|EXPERIMENTAL|occupational therapy intervention group|
62480323|NCT03674619|ACTIVE_COMPARATOR|Surgical treatment|Anterior discectomy
62480324|NCT03674619|ACTIVE_COMPARATOR|Conservative treatment|Patients will attend an experienced specialist in physical medicine and rehabilitation and a physiotherapist.
62688678|NCT04668599||Patient with chronic lung or cardiac diseases|"This study will focus on patients with obstructive or restrictive lung diseases eligible for pulmonary rehabilitation.~Patient with cardiac disease such as heart failure, coronary artery disease or cardiomyopathies who are eligible for cardiac rehabilitation will also be included."
62688679|NCT04669197|OTHER|Treatment|Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine
61925698|NCT06411561|EXPERIMENTAL|COG|"* Daily 30-minute computerized cognitive training sessions (Lumosity), for up to 7 days + usual post-ICU inpatient care~* Personalized timing of morning COG sessions or evening COG sessions, based on CSM scale at baseline"
62129355|NCT05296213|EXPERIMENTAL|casein phosphopeptide amorphous calcium phosphate CPP-ACP(tooth mousse)|CPP-ACP cream was applied twice daily according to manufacturer's instructions over the early enamel lesions in cervical third of the buccal surface of molar teeth.
62129356|NCT05296213|EXPERIMENTAL|Experimental tricalcium silicate|Experimental tricalcium silicate paste was applied twice daily over the early enamel lesions in cervical third of the buccal surface of molar teeth
62129357|NCT05223517|EXPERIMENTAL|Acupucnture|
62129358|NCT05223517|SHAM_COMPARATOR|Sham Acupuncture|
62480325|NCT05599711|EXPERIMENTAL|Transitioning Together|Participants in this arm will receive the Transitioning Together intervention in English or Spanish either at BMC, at BMC's Supporting Parents \& Resilient Kids (SPARK) Center or on BMC Zoom.
62688680|NCT03578263|EXPERIMENTAL|carbetocin arm|carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby
61925699|NCT06411561|EXPERIMENTAL|SLEEP|-Nighttime use of earplugs and eye masks, for up to 7 nights + usual post-ICU inpatient care
61925700|NCT06411561|ACTIVE_COMPARATOR|AC|-Active control; delivery of educational modules on sleep and cognitive health + usual post-ICU inpatient care
62129359|NCT02912208|EXPERIMENTAL|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
62129360|NCT02912208|PLACEBO_COMPARATOR|Arm 2 (Placebo)|Arm 2 is the control arm
62129361|NCT01494922|EXPERIMENTAL|Open Label|
62480326|NCT05599711|ACTIVE_COMPARATOR|Usual Care|Participants in this arm will receive a referral to usual transition-related care through the BMC Developmental and Behavioral Pediatrics (DBP) clinic/the BMC Autism Program.
62480327|NCT05124405|EXPERIMENTAL|Heart Rate Tracker (Fitbit)|continuous heart rate activity
62480328|NCT05124405|EXPERIMENTAL|Continuous Glucose Monitor (CGM)|monitoring daily exercise-related activities
62480329|NCT06161961|EXPERIMENTAL|prosthetic group|prosthetic group performs the entire protocol with the prosthesis prototype.
62688681|NCT03578263|ACTIVE_COMPARATOR|oxytocin and ergometrine arm|oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist plus intramuscular ergometrine 0.2 mg after the birth of the baby
62688682|NCT01928537|EXPERIMENTAL|rigosertib sodium|Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
62688683|NCT03087149|EXPERIMENTAL|monitored group|The monitored group will received monitored vit D supplementation
62688684|NCT03087149|ACTIVE_COMPARATOR|standard group|The standard group will receive standard vit D supplementation
62688685|NCT01655446|EXPERIMENTAL|Robotic Rehabilitation with FES|Robotic rehabilitation combined Functional Electrical Stimulation (FES)
62129362|NCT02158819|NO_INTERVENTION|TKA with standard instrumentation|This arm consists of the Genesis II Total knee implant system or the Legion Primary total knee system with standard instrumentation
62129363|NCT02158819|ACTIVE_COMPARATOR|Total knee arthroplasty with Visionaire|This arm will consist of the Genesis II Total Knee Implant System or Legion Primary Total Knee System with the Visionaire patient-matched instrumentation
62319579|NCT01530399|EXPERIMENTAL|MDCO 3|MDCO-2010: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
62480330|NCT03763435||Antenatal Classes Received|Women who are involved into at least 3 comprehensive session of Antenatal pregnancy classes (educational) during the prenatal period.
61925701|NCT03512990|EXPERIMENTAL|Bupivacaine - Superior Trunk Block|"Patients scheduled for rotator cuff surgery received 6 mL of 0,5% bupivacaine in the superior Trunk.~6 mL of methylene blue will be injected into cadavers with the same technique."
62688686|NCT01655446|EXPERIMENTAL|Mirror Therapy|Mirror Therapy (MT)
62688687|NCT01655446|ACTIVE_COMPARATOR|Conventional Rehabilitation|Conventional Rehabilitation (CR) mainly focuses on occupational therapy training
62688688|NCT01655446|EXPERIMENTAL|Robotic Rehabilitation|Robotic Rehabilitation (RR)
62688689|NCT01655446|PLACEBO_COMPARATOR|Robotic Rehabilitation with PI|Robotic rehabilitation with Placebo Intervention (RR-PI)
62688690|NCT03173378||Narcoleptic Patients|Type 1 and Type 2 narcoleptic adult patients usually followed at the Lyon Sleep Medicine and Respiratory Disease center
62688691|NCT03173378||Control|Adult age-matched family members of the patients
62688692|NCT01013259|PLACEBO_COMPARATOR|Placebo|
62688693|NCT01013259|EXPERIMENTAL|Mutaflor|
62688694|NCT02402907|EXPERIMENTAL|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
62688695|NCT02402907|PLACEBO_COMPARATOR|Placebo cloth|A fragrance free cleansing cloth
62688696|NCT01666366|ACTIVE_COMPARATOR|In Situ Bilateral mammary grafting|Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
62688697|NCT01666366|ACTIVE_COMPARATOR|Y composite Bilateral mammary grafting|Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
62688698|NCT06154850|EXPERIMENTAL|Immersive Virtual Reality|Individuals will wear the headset for 10 minutes while playing NatureTrek application
62688699|NCT06154850|ACTIVE_COMPARATOR|Non-immersive Virtual Reality|Individuals will watch a video including scenes from NatureTrek application for 10 minutes.
62129364|NCT02653508|EXPERIMENTAL|Diet and Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, while the nutritional education comprised of a supplementary 15 minutes of group-based sessions that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
62319580|NCT01530399|EXPERIMENTAL|MDCO 4|MDCO-2010: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
62319581|NCT01530399|PLACEBO_COMPARATOR|Saline|Commercially available saline (0.9% NaCl solution)
62480331|NCT03763435||Without education|Groups are not randomized for not to give rise to ethical problems in order to maximize the community health care. Only women who are not involved into the educational classes due to their inaccessibility related to their own conditions or wishes.
62480332|NCT01563874||Cohort 1|This study involves a broad panel of lymphoma and lymphoid samples, which were previously procured under multiple protocols at the NIH, and for which there is excess tissue available for research.
62688700|NCT03956108|EXPERIMENTAL|MRI/Fusion biopsies|Stockholm3+MRI+targeted biopsies
62688701|NCT03956108|ACTIVE_COMPARATOR|Systematic biopsies|PSA+systematic biopsies
62688702|NCT02118831|ACTIVE_COMPARATOR|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
62688703|NCT02118831|ACTIVE_COMPARATOR|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
62688704|NCT02118831|ACTIVE_COMPARATOR|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
62688705|NCT05880784|PLACEBO_COMPARATOR|Usual Practice|Eight primary healthcare centers in the Bhaktapur district of Nepal will be selected as a control group. The centers will be assessed for the baseline PEN service evaluation and at the end of one year, evaluation will be performed again in the centers for any change in the PEN services.
61925702|NCT01742871||controls|Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults
61925703|NCT01742871||kaskadil|Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
61925704|NCT05045157|EXPERIMENTAL|percutaneous A1 pulley release with corticosteroid injection|
62688706|NCT05880784|ACTIVE_COMPARATOR|Peer coaching and clinical audit|Nine primary healthcare centers in the Bhaktapur district of Nepal will be selected as an intervention group. The centers will be assessed for the baseline PEN service evaluation and then will be provided the peer coaching and clinical audit sensitization within 6 months of the intervention period. At the end of one year, an evaluation will be performed again in the centers for any change in the PEN services.
62480333|NCT03686007|EXPERIMENTAL|Group I (MSM intervention)|Patients and FCGs receive the MSM intervention consisting of videos, a handbook, and research nurse coaching over 40-60 minutes, approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive research nurse support via telephone(separate sessions for FCGs and patients) over 20-30 minutes at 2 and 7 days, and 2 months post-discharge.
62480334|NCT03686007|ACTIVE_COMPARATOR|Group II (Attention Control)|"Patients and FCGs receive attention control intervention consisting of videos (American Cancer Society video on Clinical Trials), American Cancer Society print materials, and assistance from a CRA approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive assistance from CRAs via telephone at 2 and 7 days, and 2 months post-discharge."
62480335|NCT05063201|EXPERIMENTAL|Cariprazine|
62480336|NCT05063201|PLACEBO_COMPARATOR|Placebo|
62480337|NCT06741696|OTHER|group 1|randomly selected group 1
62480338|NCT06741696|OTHER|group 2|randomly selected group 2
62480339|NCT04896008|PLACEBO_COMPARATOR|Placebo plus background PAH therapy|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy
62480340|NCT04896008|EXPERIMENTAL|Sotatercept plus background PAH therapy|Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy
62480341|NCT02267187|EXPERIMENTAL|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
62480342|NCT06136728|ACTIVE_COMPARATOR|Dalfampridine only|10 mg tablet twice per day
62480343|NCT06136728|ACTIVE_COMPARATOR|Physical therapy|One-on-one outpatient physical therapy twice per week
62480344|NCT06136728|ACTIVE_COMPARATOR|Dalfampridine plus physical therapy|10 mg tablet twice per day while receiving one-on-one outpatient physical therapy twice per week
62480345|NCT06743412|EXPERIMENTAL|REGULAR MUSIC LISTENING|Patients randomized into this arm are provided with tablet and earphones for regular music listening during hospital stay (1 hour per day in average). After discharge, patients are instructed how to continue regular music listening till the follow-up visit. Patients are required to maintain a daily music listening diary to be presented at the follow-up visit.
62480346|NCT06743412|NO_INTERVENTION|NO REGULAR MUSIC LISTENING|Patients randomized into this arm do not receive instrumentation for regular music listening during hospital stay. At discharge, patients in this arm are not required to perform regular music listening.
62688707|NCT06257420||ME/CFS and Long-COVID patients with serological evidence of autophagy disruption|ME/CFS and Long-COVID patients with serological evidence of autophagy disruption at baseline will be prescribed once weekly rapamycin at a max dose of 6mg per week.
61925705|NCT05045157|ACTIVE_COMPARATOR|corticosteroid injection alone|
61925706|NCT06483074|ACTIVE_COMPARATOR|Intervention group|Patients randomized to intervention group will receive oral empagliflozin 10mg daily on top of optimized dose of RAAS inhibitor for 6 months
61925707|NCT06483074|NO_INTERVENTION|Control group|Patients randomized to control group will receive optimized dose of RAAS inhibitor for 6 months
62319582|NCT01530399|ACTIVE_COMPARATOR|Tranexamic acid|Tranexamic acid: 12 mg/kg loading dose; 5 mg/kg/h infusion; 0.556 mg/mL CPB priming
62480347|NCT04369937|EXPERIMENTAL|IMRT + Pembrolizumab + Cisplatin + ISA101b|"IMRT (Intensity Modulated Radiotherapy) of 70 Gy in 35 fractions over 7 weeks (5 fractions per week).~Pembrolizumab will be administered at 200 mg (fixed dose) IV every 3 weeks (+/- 3 days), beginning beginning one week (week -1) prior to concurrent cisplatin-IMRT.~Cisplatin will be administered at 100 mg/m2 IV on days 1(Week 0) and 22 (Week 3).~ISA101b will be administered as three rounds of vaccination 3-4 weeks apart via two SC injections per vaccination round at 100ug/peptide, before pembrolizumab treatment. Vaccination #1 will be administered 1 week before pembrolizumab."
62480348|NCT04311853||practitioner interviews|phone interviews conducted
62480349|NCT01537887|PLACEBO_COMPARATOR|Placebo|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
62480350|NCT01537887|EXPERIMENTAL|1200 milligrams (mg) LY2484595|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
62688708|NCT06257420||ME/CFS and Long-COVID patients without serological evidence of autophagy disruption|ME/CFS and Long-COVID patients without serological evidence of autophagy disruption at baseline will be prescribed once weekly rapamycin at a max dose of 6mg per week.
61925708|NCT03470974|EXPERIMENTAL|Intervention Group|The intervention group receives self-titration strategy training and lifestyle education.
62480351|NCT01537887|ACTIVE_COMPARATOR|400 mg Moxifloxacin|Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14-day washout period.
61925709|NCT03470974|NO_INTERVENTION|Control Group|The control group receives usual care and lifestyle education.
62480352|NCT06563401||population controls|Randomly sampled diabetes controls from the general Swedish population
62480353|NCT06563401||adult-onset T1D|people who developed T1D as adults 2001-2020 in Sweden
62480354|NCT06563401||T2D|people who developed T2D 2001-2020 in Sweden
62480355|NCT04170283|EXPERIMENTAL|Zanubrutinib (BGB-3111)|All participants to receive open-label zanubrutinib
62480356|NCT04170283|EXPERIMENTAL|Zanubrutinib in combination with Tislelizumab|Participants to receive the combination as in the parent study (Australia Only)
62688709|NCT05035173|EXPERIMENTAL|Intervention Arm|Participants will have available the services offered by the Women's Cancer Survivorship Clinic and will undertake electronic Patient Reported Outcomes at baseline, 2, 4, 6, 8, 10, 12 months (end of the study).
61925710|NCT06458959|EXPERIMENTAL|PEM+|
62129365|NCT02653508|EXPERIMENTAL|Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
62129366|NCT02653508|NO_INTERVENTION|Control|61 overweight and obese adolescents aged 13-15 years old were the control group of the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
62129367|NCT02810236|ACTIVE_COMPARATOR|No ultrasound|No ultrasound recommended. Discussion with radiologist.
62129368|NCT02810236|ACTIVE_COMPARATOR|Ultrasound|Ultrasound recommended.
62129369|NCT04625231|EXPERIMENTAL|Shared-Decision Making Tool Group|
62129370|NCT04625231|NO_INTERVENTION|Standard of Care Group|
62129371|NCT00977158||Throat Swab|Infants who have been diagnosed with cystic fibrosis
62129372|NCT04244058|ACTIVE_COMPARATOR|NMDA blocker|Comprehensive functional analyses of dynamic \[18F\]FPEB-PET signal at rest will be carried out in normal volunteers and patients with DOC due to severe brain injury over a 24-month time period. In each study, we will first evaluate mGluR5 occupancy within the frontal cortex, anterior cingulate cortex, insula, striatum and thalamus. Then, a single dose of amantadine (AMT), a compound that blocks NMDA-R and increases glutamate levels at the synaptic cleft, will be given to each subject or patient and at the time corresponding to the peak of the dose, a second \[18F\]FPEB-PET will be acquired.
62129373|NCT04244058|EXPERIMENTAL|NMDA blocker + L-DOPA|All the patients with DOC that participate in ARM 1 will follow the same methodology of ARM 1: measurement of mGluR5 occupancy at rest and following NMDA-R blockade with AMT by means of \[18F\]FPEB-PET after premedication with L-DOPA introduced 1 hour prior each \[18F\]FPEB-PET acquisitions.
62480357|NCT06561893|ACTIVE_COMPARATOR|Probiotic (L. plantarum) supplementation|Dose: 20 Billion CFU/day for 14 days (total of two pills of 10 Billion CFU)
62480358|NCT06561893|PLACEBO_COMPARATOR|Placebo (dextrose) supplementation|Dose: 700 mg of dextrose (total of two pills; 2 x 350 mg pills)
62688710|NCT05035173|ACTIVE_COMPARATOR|Control Arm|Participants will attend a baseline and end of the study visit (12-month time point) to the Women's Cancer Survivorship Clinic to undertake the baseline and complete end of study assessments. They will complete ePRO at baseline and at 12 months. They will have usual follow up care over the 12 month period of the study. Where participants in the control arm contact the Survivorship team for clinical or other advice, they will be referred to the usual care pathway.
62688711|NCT04192838|EXPERIMENTAL|LVHR|Laparoscopic incisional ventral hernia repair
62688712|NCT04192838|ACTIVE_COMPARATOR|OVHR|Open incisional ventral hernia repair
61925711|NCT06458959|NO_INTERVENTION|Usual Care|
61925712|NCT04028414|EXPERIMENTAL|Early Weight Bearing|Patients with ankle fractures will be instructed to weight bear as tolerated (WBAT) while in a boot with a heel to toe normal gait and wean from walker or crutches to a cane or no support device. At the 6 week post op visit, patients with ankle fractures will be instructed to wean from the boot and continue full weight bearing as tolerated until full weight bearing is achieved. Patients with plateau fractures will be instructed to begin WBAT until full weight bearing is achieved.
62129374|NCT02290470|EXPERIMENTAL|olanzapine Days 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~* Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~* Dexamethasone (16 mg intravenously on the day of chemotherapy), plus~* Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
62480359|NCT04777994|EXPERIMENTAL|Monotherapy Dose Escalation|ABBV-CLS-484 will be administered as a monotherapy in subjects with solid tumors
62480360|NCT04777994|EXPERIMENTAL|Combination Dose Escalation with PD-1 Inhibitor|ABBV-CLS-484 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
62480361|NCT04777994|EXPERIMENTAL|Monotherapy Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC)
62688713|NCT06639568||Interview participants|
62688714|NCT06223880|EXPERIMENTAL|AXS-05|AXS-05 tablets, taken twice daily
62688715|NCT06223880|ACTIVE_COMPARATOR|Bupropion|Bupropion tablets, taken twice daily
62480362|NCT04777994|EXPERIMENTAL|Combination Expansion with PD-1 Inhibitor|ABBV-CLS-484 will be administered at the determined recommended dose in combination with Programmed Cell Death-1 Inhibitor in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.
62129375|NCT02290470|EXPERIMENTAL|olanzapine+Dexamethasone d 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~* Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~* Dexamethasone (16 mg intravenously on the day of chemotherapy and 4 mg orally days 2, 3 post chemotherapy), plus~* Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
62480363|NCT04777994|EXPERIMENTAL|Combination Dose Escalation with VEGFR TKI|ABBV-CLS-484 will be administered in combination with a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) in subjects with solid tumors
62129376|NCT02290470|ACTIVE_COMPARATOR|dexamethasone days 1-3|"Dexamethasone + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as usual anti-nausea/vomiting drugs:~* Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~* Dexamethasone 16 mg intravenously on the day of chemotherapy (day 1), plus~* Dexamethasone 8 mg orally on days 2 and 3 post chemotherapy"
62129377|NCT01199536||1|patients with Helicobacter-positive duodenal ulcer
62129378|NCT05368831|EXPERIMENTAL|Oral dose of NST-1024, Caffeine, Flurbiprofen, Omeprazole, Metoprolol, and Midazolam|"Day 1: single oral dose of 100 mg caffeine, 50 mg flurbiprofen, 20 mg omeprazole, 100 mg metoprolol, and 2.5 mg midazolam~* Days 8 to 22: oral doses of 200 mg NST-1024 qd multiple-dose regimen~* Day 8: single oral dose of 100 mg caffeine, 50 mg flurbiprofen, 20 mg omeprazole, 100 mg metoprolol, and 2.5 mg midazolam coadministered with an oral dose of 200 mg NST-1024~* Day 21: single oral dose of 100 mg caffeine and 2.5 mg midazolam coadministered with an oral dose of 200 mg NST-1024."
62129379|NCT05435313|EXPERIMENTAL|combination therapy|"Combination: Fruquintinib plus Tislelizumab and HAIC (TOMOX/TOMIRI)~Maintenance: Fruquintinib plus Tislelizumab"
62129380|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
62129381|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
62129382|NCT00355095|ACTIVE_COMPARATOR|1|erythropoietin
62129383|NCT00355095|NO_INTERVENTION|2|Placebo
62129384|NCT04222946|EXPERIMENTAL|Experimental:|bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
62129385|NCT00947635|EXPERIMENTAL|Islet transplant|People with Type 1 diabetes undergoing islet transplantation
62129386|NCT00947635|EXPERIMENTAL|Liver transplant|People with liver failure undergoing liver transplantation
62129387|NCT00947635|EXPERIMENTAL|Control|Healthy normal people which serve as control group
62129388|NCT02121002|EXPERIMENTAL|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
62129389|NCT02121002|ACTIVE_COMPARATOR|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
62129390|NCT02121002|PLACEBO_COMPARATOR|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
62129391|NCT05239013|EXPERIMENTAL|Treatment Group|Subjects who receive the intervention
62129392|NCT03376152|ACTIVE_COMPARATOR|Treatment Arm|"Poverty households invited to attend cluster-level electric kettle promotion events and offered free kettles, information, and promotional materials 450 households in 15 clusters (30 households per cluster)"
62129393|NCT03376152|NO_INTERVENTION|Control Arm|450 households in 15 clusters (30 households per cluster)
62129394|NCT01020045||HIV-seropositive, HIV seronegative|No intervention - biologic samples were collected from both HIV positive and HIV negative subjects
62480364|NCT04777994|EXPERIMENTAL|Combination Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in combination with VEGFR TKI in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.
62480365|NCT05719493|NO_INTERVENTION|multicomponent-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
62480366|NCT05719493|EXPERIMENTAL|munticomponent-treatment benefiting group|Partcipants in the intervention group will receive the care from the usual practice plus the studied intervention.
62129395|NCT01020045||Treatment naive subjects|HIV-seropositive subjects naive to antiretroviral therapy. HIV-seronegative subjects otherwise healthy.
62129396|NCT05959590|EXPERIMENTAL|study group|Patients will receive Ferumoxides 11.2Mg Solution for Injection.
62129397|NCT01552577||TBI Group|Adults (civilian or military) with a history of one or more brain injuries / concussions.
62129398|NCT01552577||Control Group|Healthy adults (civilian or military) with no history of brain injury.
62129399|NCT03425552|EXPERIMENTAL|Test treatment|Paliperidone palmitate extended-release injectable suspension for intramuscular use 156 mg (100 mg of Paliperiodne)
62129400|NCT03425552|ACTIVE_COMPARATOR|Reference treatment|Paliperidone palmitate 156 mg (equivalent to Paliperidone 100 mg) extended release injectable suspension
62129401|NCT04702256|EXPERIMENTAL|Obinutuzumab arm|Obinutuzumab administration plus oral mycophenolate mofetil (MMF)
62480367|NCT06514612|EXPERIMENTAL|STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers|
62480368|NCT06514612|PLACEBO_COMPARATOR|Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers|
62480369|NCT03219853|EXPERIMENTAL|Lower selenium-status|
62480370|NCT03219853|EXPERIMENTAL|higher selenium|
62480371|NCT01368991|ACTIVE_COMPARATOR|Kryptonite|Sternal closure with stainless steel and kryptonite
62480372|NCT01368991|ACTIVE_COMPARATOR|Conventional Closure|Sternal closure with stainless steel wires
61925713|NCT04028414|NO_INTERVENTION|Delayed Weight Bearing|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
61925714|NCT06614712||Cohort 1|Pre-pricing \& reimbursement, incident renal disease cohort (study observation period 2020- 2024)
62319583|NCT05922267|EXPERIMENTAL|Active cycle of breathing technique|"Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing"
62480373|NCT03646292|EXPERIMENTAL|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 24 weeks
61925715|NCT06614712||Cohort 2|Post-pricing \& reimbursement, incident renal disease cohort (study observation period 2023-2024)
61925716|NCT03935620|EXPERIMENTAL|EMT|After a period of stable baseline performance (3 to 5 sessions) for parents and children the interventionists will apply the EMT Language Intervention.
62129402|NCT04702256|ACTIVE_COMPARATOR|Corticosteroids arm|Oral corticosteroids plus MMF
62129403|NCT02990234|ACTIVE_COMPARATOR|Capsular Repair|Capsular Repair arm. The first hip is randomized, opposite treatment on second hip. One Hip will receive the capsular repair while the other hip will not.
62129404|NCT02990234|PLACEBO_COMPARATOR|No Capsular Repair|Placebo arm. One hip is randomized to capsular repair while the other hip has no capsular repair.
62129405|NCT04353310|EXPERIMENTAL|Curcumin|
62129406|NCT04353310|PLACEBO_COMPARATOR|Placebo|
62480374|NCT03646292|EXPERIMENTAL|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 24 weeks
62480375|NCT03646292|EXPERIMENTAL|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg 1T + Empagliflozin 10mg 1T combination daily for 24 weeks
62480376|NCT03182075|EXPERIMENTAL|Active Training|OCD and hoarding disorder participants will receive active emotional reactivity training (14 sessions) via computer.
61925717|NCT04685590|EXPERIMENTAL|Treatment|Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb). Quercetin (Q) will be given as (4) 250 mg capsules daily (total 1000 mg daily) for the same 2 consecutive days (Thorne Research). Both are administered orally.
61925718|NCT04685590|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
61925719|NCT06552364|PLACEBO_COMPARATOR|Filtered Air with LABA/LAMA|Participants will inhale a ultra Long-Acting Beta-Agonist (LABA; vilanterol (25mcg)) + Long-acting Muscarinic Antagonist (LAMA; umeclidinium (62.5mcg)) combination medication once daily for 28+ days before sitting in a booth and being exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours.
61925720|NCT06552364|ACTIVE_COMPARATOR|Filtered Air with LABA/LAMA + ICS|Participants will inhale a LABA (vilanterol (25mcg)) + LAMA (umeclidinium (62.5mcg))+ Inhaled Corticosteroid (ICS; fluticasone furoate (100mcg)) medication once daily for 28+ days before sitting in a booth and being exposed to HEPA-filtered air for 2 hours.
62129407|NCT04077164||Individuals with Chronic Pain|Individuals who identify as having a chronic musculoskeletal pain condition.
62129408|NCT04077164||Partners|Partners (e.g., life partner, spouse, or significant other) of the individual with the chronic musculoskeletal pain condition.
62129409|NCT00967434|ACTIVE_COMPARATOR|Group A- atorvastatin in pre and postop|Atorvastatin 80 mg administered daily for at least 7 preoperative days, 80 mg on day of surgery and 80 mg daily for up to 7 postoperative days.
62129410|NCT00967434|ACTIVE_COMPARATOR|Group B- Atorvastatin postop|Placebo administered for up to 7 preoperative days, atorvastatin 80 mg administered on day of surgery and daily for up to 7 postoperative days.
62129411|NCT00967434|PLACEBO_COMPARATOR|Group C- Placebo|Patients receive placebo daily for up 7 preoperative days, placebo on day of surgery and placebo daily for up to 7 postoperative days.
62129412|NCT06044467|EXPERIMENTAL|Anti-human CCL24 monoclonal antibody (CM-101) - study Part One|"Anti-human CCL24 monoclonal antibody (CM-101)~NAFLD subjects that have normal liver functions - (Cohort 1: 2.5 mg/kg intravenously and Cohort 2: 5.0 mg/kg subcutaneously)"
62129413|NCT06044467|PLACEBO_COMPARATOR|Placebo - Study Part One|Placebo Comparator
62480377|NCT03182075|SHAM_COMPARATOR|Passive Training|OCD and hoarding disorder participants will receive passive computerized training (14 sessions) via computer.
62480378|NCT05460676|EXPERIMENTAL|Active tDCS + Mindfulness|
62480379|NCT05460676|SHAM_COMPARATOR|Sham tDCS + Mindfulness|
61925721|NCT06552364|ACTIVE_COMPARATOR|Diesel Exhaust with LABA/LAMA|Participants will inhale a LABA (vilanterol (25mcg)) + LAMA (umeclidinium (62.5mcg)) medication once daily for 28+ days before sitting in a booth and being exposed to diesel exhaust (standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5)) for 2 hours.
61925722|NCT06552364|EXPERIMENTAL|Diesel Exhaust with LABA/LAMA + ICS|Participants will inhale a LABA (vilanterol (25mcg)) + LAMA (umeclidinium (62.5mcg))+ Inhaled Corticosteroid (ICS; fluticasone furoate (100mcg)) medication once daily for 28+ days before sitting in a booth and being exposed to diesel exhaust (300ug/m3 of PM2.5) for 2 hours.
61925723|NCT00371501|ACTIVE_COMPARATOR|treatment arm 1|
61925724|NCT00371501|PLACEBO_COMPARATOR|Treatment arm 2|
61925725|NCT00371501|ACTIVE_COMPARATOR|treatment arm 3|aspirin
62688716|NCT03747237|EXPERIMENTAL|1. method, Edema measurement methods|"The surgeon will measure from three different places on the patient's face with the help of a paper ruler to measure the edema.~Tragus-Pogonion Tragus-Labial Comissura Angulus Mandible-Latheral Cantus Measurements will be made preoperative, postoperative 2. and 7. days and saved as milimetre."
61925726|NCT00371501|PLACEBO_COMPARATOR|treatment arm 4|placebo
61925727|NCT03163810|EXPERIMENTAL|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
61925728|NCT04852289||>=65 Female|Older Females
62339728|NCT04109235|EXPERIMENTAL|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
62688717|NCT03747237|NO_INTERVENTION|2. method, Edema measurement methods|Patients will be given edema scale.With the help of the edema scale, the patients will be evaluated the edema by themselves. When the patient stand in front of the mirror, they will be assessed the edema on their face. And a value between 0 and 5 will be pointed on the scale postoperative 2. and 7. days.
62688718|NCT05438160|OTHER|Schizophrenia treated with digital therapeutics app CT-155|Single group of People with Schizophrenia to be treated with digital therapeutics app CT-155
62688719|NCT05488964|EXPERIMENTAL|Exercise|Regular endurance training for 8 weeks
62688720|NCT05488964|NO_INTERVENTION|Control|Habitual living for 8 weeks
62129414|NCT06044467|EXPERIMENTAL|Anti-human CCL24 monoclonal antibody (CM-101) - Study Part Two|"Anti-human CCL24 monoclonal antibody (CM-101)~NAFLD/NASH patients with NAS \< 3 that are in general good health and have normal liver functions - 2.5 mg/kg intravenous infusion"
62129415|NCT06044467|PLACEBO_COMPARATOR|Placebo - Study Part Two|Placebo Comparator
62688721|NCT02090894|EXPERIMENTAL|UV Light|
62129416|NCT03767452|EXPERIMENTAL|Single-Arm|Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
62129417|NCT03352596|EXPERIMENTAL|intervention group|Eight weeks of low fructose diet with a maximum of 12 g of fructose
62688722|NCT04463927|EXPERIMENTAL|Intervention Group|The non-nutritive sucking is applied to the group during the examination for retinopathy of prematurity
62688723|NCT04463927|NO_INTERVENTION|Control Group|The non-nutritive sucking is not applied to the control group.
61925729|NCT04852289||>=65 Male|Older Males
61925730|NCT04852289||18-64 Female|Young Females
61925731|NCT04852289||18-64 Male|Young Males
61925732|NCT02103049|OTHER|Ezetimibe, dyslipidemia, kidney transplant|
61925733|NCT06663631|EXPERIMENTAL|chlorpromazine and promethazine of Very low dosage|patients will receive C+P（chlorpromazine and promethazine ,10 mg each)at the beginning of endovascular thrombectomy.
62129418|NCT03352596|NO_INTERVENTION|control group|Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO
62129419|NCT01086982|EXPERIMENTAL|Octreotide acetate LAR 30 MG|Test
62129420|NCT01086982|ACTIVE_COMPARATOR|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|
62129421|NCT01324453|EXPERIMENTAL|Post conditioning + PCI|
62129422|NCT01324453|ACTIVE_COMPARATOR|Standard PCI|
62129423|NCT03346616|EXPERIMENTAL|Texting Group|"The texting group received a daily text message containing a board style multiple choice question. If the participant wanted immediate feedback, the message contained a link to a website containing the answer to the question along with an explanation, the source material, and a more complete clinical vignette. One hour after the initial text message was sent, a follow up answer text message was delivered. Text messages were sent 6 days per week (Monday through Saturday) at 2 pm and 3 pm."
62480380|NCT05650775|ACTIVE_COMPARATOR|Methylphenidate Trial|3-week methylphenidate trial with weekly dose adjustments.
62480381|NCT05650775|ACTIVE_COMPARATOR|Mixed Amphetamine Salts Trial|3-week trial of mixed amphetamine salts with weekly dose adjustments.
62480382|NCT06400563|OTHER|MR-guided NIRS|"The MRg-NIRS device will be tested to see if it accommodates different breast sizes, covers the breast fully, includes the axilla, is compatible with commercial breast MRI coil and/or biopsy systems, and the signal-to-noise ratio is high enough for MRg-NIRS image reconstruction.~The study team will collect MRI-derived ROI data with T1, T2 and DCE-MRI sequences from 20 women with breast abnormalities and NIRS data concurrently. The study team will also collect diffuse optical signals at 48x48 detector source positions over one side of breast at 6 wavelengths."
62480383|NCT06206226|EXPERIMENTAL|Oh Happy Day Class-Digital Connections (OHDC-DC)|
62480384|NCT04626050|EXPERIMENTAL|Medical Music (Phase I)|Participants will complete four medical music sessions that are 20 minutes in length each.
62480385|NCT04626050|EXPERIMENTAL|Narrative Writing (Phase I)|Participants will complete four narrative writing sessions that are 20 minutes in length each.
62480386|NCT04626050|ACTIVE_COMPARATOR|Interpersonal Psychotherapy (Phase II)|IPT is comprised of ten 75-minute sessions scheduled twice weekly.
62480387|NCT04626050|ACTIVE_COMPARATOR|Prolonged Exposure Therapy (Phase II)|ET is comprised of ten 75-minute sessions scheduled twice weekly.
62480388|NCT06625463|EXPERIMENTAL|Experimental arm|Experimental arm receive 12 week home based cardiac rehabilitation include physical exercise, dietary management, smoking cessation and stress management
62480389|NCT06625463|NO_INTERVENTION|control arm|Control arm receive usually care
62480390|NCT06058663|EXPERIMENTAL|Cohort I: (Y90, tremelimumab on day 1, cycle 1, durvalumab)|Patients receive transarterial Y90 radioembolization and tremelimumab IV over 1 hour on day 1 of cycle 1 and durvalumab IV over 1 hour on day 1 of each cycle. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo mapping angiography during screening as well as CT and MRI or PET/CT during screening and on study. Patients also undergo blood sample collection throughout the trial and may undergo tumor biopsy during screening and on study.
62480391|NCT06058663|EXPERIMENTAL|Cohort II: (Y90, tremelimumab on day 14, cycle 1, durvalumab )|Patients receive transarterial Y90 radioembolization on day 1 of cycle 1 and receive tremelimumab IV over 1 hour on day 14 of cycle 1 and durvalumab IV over 1 hour on day 14 of each cycle. Cycles repeat every 42 days for cycle 1 and then every 28 days for cycles 2-24 in the absence of disease progression or unacceptable toxicity. Patients also undergo mapping angiography during screening, as well as CT and MRI or PET/CT during screening and on study. Patients also undergo blood sample collection throughout the trial and may undergo tumor biopsy during screening and on study.
62480392|NCT04986982|EXPERIMENTAL|Opicapone 50 mg|Opicapone (BIA 9-1067)
62480393|NCT04986982|PLACEBO_COMPARATOR|Placebo|Placebo
62480394|NCT05353647|EXPERIMENTAL|Treatment Arm|Open-label, non-randomized, single arm study of a single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a.
62688724|NCT03635996|EXPERIMENTAL|Etripamil NS 70 mg|The dose of etripamil to be evaluated in NODE-302 is 70 mg.
62688725|NCT06690034||group 1|Patient with Diabetic kidney disease according to KDIG
62480395|NCT01242098||Fostair switch cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair
62480396|NCT01242098||Seretide continuation cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide
61925734|NCT06663631|EXPERIMENTAL|chlorpromazine and promethazine of low-dosage|patients will receive C+P（chlorpromazine and promethazine ,20 mg each)at the beginning of endovascular thrombectomy.
61925735|NCT06663631|EXPERIMENTAL|chlorpromazine and promethazine of moderate dosage|patients will receive C+P（chlorpromazine and promethazine ,50 mg each)at the beginning of endovascular thrombectomy.
62339729|NCT04007055|EXPERIMENTAL|Experimental: screening/treating for HPR|Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
62480397|NCT06501924|EXPERIMENTAL|DA-005|Oral Botanical Supplement HIF-1a inhibitor
62480398|NCT06501924|ACTIVE_COMPARATOR|Topical Minoxidil 5%|Topical Minoxidil 5%
62480399|NCT06501924|EXPERIMENTAL|DA-002|Topical Alpha 1 Agonist
62480400|NCT00840281|EXPERIMENTAL|1|
62688726|NCT06690034||group 2|patients with diabetes without chronic kidney disease
62688727|NCT00913835|EXPERIMENTAL|Olaratumab and Liposomal Doxorubicin|Olaratumab and Liposomal Doxorubicin
62688728|NCT00913835|ACTIVE_COMPARATOR|Liposomal Doxorubicin: Optional Olaratumab Monotherapy|Liposomal Doxorubicin Monotherapy until disease progression. Upon disease progression the participant had the option to receive Olaratumab monotherapy.
62688729|NCT06174272|EXPERIMENTAL|Transitional Care Program|Participants will receive a digital scale and monitoring log, educational material, a phone call within 72 hours of discharge and weekly for 8 weeks, and a follow up appointment with a hepatologist within 4 weeks of discharge.
62688730|NCT06174272|NO_INTERVENTION|Standard of Care|Participants will be given typical discharge and follow up instructions.
61925736|NCT06663631|EXPERIMENTAL|chlorpromazine and promethazine of high dosage|patients will receive C+P（chlorpromazine and promethazine ,100 mg each)at the beginning of endovascular thrombectomy.
61925737|NCT06663631|PLACEBO_COMPARATOR|Placebo group|50 ml saline solution was delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
61925738|NCT05421728|EXPERIMENTAL|Participants: ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
62480401|NCT00840281|ACTIVE_COMPARATOR|2|
62688731|NCT02031913||HBV without FL|Chronic hepatitis B without steatosis
62688732|NCT02031913||HBV with FL|Chronic hepatitis B patients with steatosis
62688733|NCT05533372|EXPERIMENTAL|IA-14069 MAD|Subjects will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 10 days.
62480402|NCT05168735|EXPERIMENTAL|Intravenous Ketamine + Mindfulness Exercises|
62480403|NCT05168735|ACTIVE_COMPARATOR|Intravenous Ketamine + Academic Exercises|
62480404|NCT00489307|ACTIVE_COMPARATOR|Dexamethasone|"Dexamethasone 4 mg orally two times a day for 14 days.~On day 15 \[ ± 3 days\], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
62480405|NCT00489307|PLACEBO_COMPARATOR|Placebo|"Placebo by mouth (PO) twice daily for 14 days.~On day 15 \[ ± 3 days\], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
62480406|NCT00418938|EXPERIMENTAL|Arm A|FOLFIRI + Panitumumab
62480407|NCT00418938|EXPERIMENTAL|Arm B|FOLFIRI + Bevacizumab
61925739|NCT05421728|ACTIVE_COMPARATOR|Participants: Mailed Resources|Participants will receive printed advance care planning resources by mail.
62319584|NCT05922267|EXPERIMENTAL|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
62319585|NCT01306058|EXPERIMENTAL|Sorafenib & TRC105 in Hepatocellular CA|CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day
62319586|NCT00729118|EXPERIMENTAL|Lenalidomide + Vorinostat|Maintenance post autologous transplant
62319587|NCT01150071||Children born extremely preterm|national cohort of children born before 28 weeks' gestational age or with a birthweight less than 1000 g. 365 eligible survivors
61925740|NCT05421728|NO_INTERVENTION|Clinic Stakeholders|"Clinic stakeholders providing care for participants enrolled in the Participants: Enact Group Visits arm. Demographics, and adverse event data will not be collected for this arm."
61925741|NCT05421728|NO_INTERVENTION|Caregivers|Caregivers will be consented via postcard consent to facilitate patient participants' engagement in the trial and group visits. Outcome measure, demographics, and adverse event data will not be collected for this arm, however caregivers will assist participants in providing outcome measure data (responding to surveys, etc.)
62129424|NCT03346616|ACTIVE_COMPARATOR|Non Texting Group|The non-texting group received access to the journal articles from which the text message content was derived, but did not receive any text messages or any of the online material or question stems.
62129425|NCT00879749|PLACEBO_COMPARATOR|Saline|
62129426|NCT00879749|EXPERIMENTAL|Nexvax2|
62129427|NCT03272399|EXPERIMENTAL|H3-L6|High Omega-3, low Omega-6 diet
62129428|NCT03272399|ACTIVE_COMPARATOR|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
62129429|NCT01086826|ACTIVE_COMPARATOR|RT+CDDP/5-FU|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy."
62129430|NCT01086826|EXPERIMENTAL|RT+CETUXIMAB|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
62319588|NCT05993767|EXPERIMENTAL|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
62319589|NCT04292717|ACTIVE_COMPARATOR|Deficit-oriented training group|
62319590|NCT04292717|ACTIVE_COMPARATOR|Non-specific, standardised walking training group|
62319591|NCT06137521||Patients with good coronary collaterals|Coronary collateral circulation development was graded according to the Rentrop score, grade 2 (partial filling of the epicardial segment by collateral vessels); grade 3 (complete filling of the epicardial artery by collateral vessels) were defined as good coronary collateral circulation.
62319592|NCT06137521||Patients with poor coronary collaterals|Coronary collateral circulation development was graded according to the Rentrop score, grade 0 (no filling of any collateral vessels) and grade 1 (filling of side branches of the artery to be perfused by collateral vessels without visualization of the epicardial segment) were defined as poor coronary collateral circulation.
62480408|NCT06043037|ACTIVE_COMPARATOR|Immediate Implant Placement Using Socket Shield Technique with autogenous demineralized dentin graft|after immediate implantation using Socket Shield Technique, the palatal root portion will be converted to autogenous demineralized dentin graft and used for grafting the defect between the socket shield and the implant fixture
62319593|NCT00365976|PLACEBO_COMPARATOR|1|Placebo
62319594|NCT00365976|ACTIVE_COMPARATOR|2|Eszopiclone
62319595|NCT02752867|EXPERIMENTAL|Jianpi Yishen Huatan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
62480409|NCT06043037|EXPERIMENTAL|Immediate Implant Placement Using Socket Shield Technique only without grafting the defect|after insertion of immediate implant Using Socket Shield Technique, the bone defect between the socket shield and the implant fixture will be left ungrafted
62480410|NCT04358874|EXPERIMENTAL|Active follow-up|Participants randomized to the active follow-up arm will have follow-up visits in the AKI follow-up clinic every 4 weeks after discharge for a total of 90 days after discharge
61925742|NCT03939637|EXPERIMENTAL|Eltrombopag|Patients randomized to eltrombopag will be treated for 12 weeks, with the possibility to continue therapy for up to 1 year depending on response.
62688734|NCT05533372|EXPERIMENTAL|IA-14069 DDI|"Subjects will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 10 days.~On day 11, subjects will be adminiatrated oral dose of IA-14069 or matching placebo with methotrexate.~On day 21, subjects will be administrated methotrexate alone."
62688735|NCT05533372|EXPERIMENTAL|IA-14069 MAD RA patients|"Patients will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 28 days.~Patients will be on a stable dose of methotrexate throughout the study period."
62688736|NCT05457205|EXPERIMENTAL|Neuromodulation with 50 Hz and low intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 50 Hz and stimulation intensity of 0.45 x lowest motor threshold (reflex threshold in leg muscles).
62688737|NCT05457205|EXPERIMENTAL|Neuromodulation with 50 Hz and high intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 50 Hz and stimulation intensity of 0.90 x lowest motor threshold (reflex threshold in leg muscles).
61925743|NCT03939637|ACTIVE_COMPARATOR|Standard first-line therapy|"Subjects randomized to the standard therapy arm will receive one of three treatments at the discretion of the treating physician. Patients who previously failed standard management prior to study entry must be treated with a different agent than their original failed agent. e.g. Patient who failed steroids could receive either IVIg or anti-D if randomized to the standard treatment arm.~Standard therapy will be administered as commercially available drug.~Investigator may choose amongst the following:~* IVIg: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)~* Steroids: Prednisone/Prednisolone 4 mg/kg/day (Max 120 mg/day) x 4 days~* Rho(D) Immune Globulin: Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)"
62688738|NCT05457205|EXPERIMENTAL|Neuromodulation with 100 Hz and low intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 100 Hz and stimulation intensity of 0.45 x lowest motor threshold (reflex threshold in leg muscles).
62688739|NCT05457205|EXPERIMENTAL|Neuromodulation with 100 Hz and high intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 100 Hz and stimulation intensity of 0.90 x lowest motor threshold (reflex threshold in leg muscles).
62688740|NCT01678365|EXPERIMENTAL|ceftriaxone and metronidazole for complicated appendicitis.|Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
62688741|NCT01678365|ACTIVE_COMPARATOR|Ampicillin, gentamicin, and metronidazole|Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
61925744|NCT05437835|EXPERIMENTAL|Diffusion length and anesthetic effect|diffusion length of local anesthetics in the subparaneural space could predict anesthetic effect and duration of analgesia
62319596|NCT02752867|PLACEBO_COMPARATOR|The control group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
62688742|NCT03726879|EXPERIMENTAL|Atezolizumab +ddAC-PacHP|Participants will receive atezolizumab (atezo) 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 \& cyclophosphamide 600 mg/m2 IV), followed by atezo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8mg/kg IV loading dose) Q3W for 4 cycles, \& pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant and adjuvant setting: atezo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, \& pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezo+trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL dated 3 Feb 2021 treatment with atezo must be discontinued.
62738195|NCT02249091|EXPERIMENTAL|Cohort 1 / Selinexor 40 mg/m^2 in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m\^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a dose of 40 mg/m\^2 twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
61925745|NCT01674634|EXPERIMENTAL|XIAFLEX / XIAPEX|AA4500 (collagenase clostridium histolyticum)
61925746|NCT04095156||Prospective cohort|Patients with biopsy-proven idiopathic MN, who are candidate to receive a B-cell depleting treatment as per center clinical practice.
61925747|NCT04095156||Retrospective cohort|Patients with biopsy-proven idiopathic MN, who already received a B-cell depleting treatment as per center clinical practice.
61925748|NCT04095156||Healthy volunteers cohort|Subjects \> 18 years not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
62319597|NCT03619148|OTHER|High-Flow Humidified Nasal Oxygen - TOE participants|High-Flow Humidified Nasal Oxygen - standard care
62480411|NCT04358874|ACTIVE_COMPARATOR|Usual follow-up|Participants randomized to the usual follow-up arm will be called at home 4 weeks after the baseline visit to collect information on primary and secondary outcomes.
61925749|NCT06165627|OTHER|T30fA, then Biofinity Toric|Lehfilcon A toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during waking hours for at least 12 hours per day during each wear period (30 days \[-1/+3\] according to randomization assignment). Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE Cleaning \& Disinfecting Solution.
62319598|NCT03619148|ACTIVE_COMPARATOR|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen - staff volunteers
62319599|NCT05682807|NO_INTERVENTION|control group (group I)|will include 30 preterm neonates with BPD who will receive traditional therapy of BPD including minimizing exposure to oxygen, ventilation strategies, adequate nutrition and prudent administration of fluids
62319600|NCT05682807|ACTIVE_COMPARATOR|caffeine group (group II)|will include 30 preterm neonates with BPD who will receive traditional therapy of BPD in association with caffeine by intravenous route at a dose of 20 mg/kg loading dose with a 5-10 mg/kg/day maintenance dose given after 24 h ( Yuan et al., 2022) until discharge from the unit after clinical and laboratory improvement after two months.
62129431|NCT01086826|ACTIVE_COMPARATOR|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):~DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion"
62129432|NCT01086826|EXPERIMENTAL|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RADIOTHRAPY:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
61925750|NCT06165627|OTHER|Biofinity Toric, then T30fA|Comfilcon A toric contact lenses worn in Period 1, with lehfilcon A toric contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during waking hours for at least 12 hours per day during each wear period (30 days \[-1/+3\] according to randomization assignment). Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE Cleaning \& Disinfecting Solution.
62129433|NCT05025995|EXPERIMENTAL|Serious health game|Children played a serious health game with Garfield promoting health behavior, such as less intake of energy dense snacks, drink more water, and exercise more often.
62129434|NCT05025995|EXPERIMENTAL|control|Children in this condition did not play a serious health game and were in control condition.
62129435|NCT06407258|EXPERIMENTAL|SLEEPAC|In addition to treatment-as-usual (TAU), participants of the SLEEPAC arm will receive a multi-component sleep intervention combining elements of CBT-i, circadian adaptation, and physical activity counselling.
62129436|NCT06407258|NO_INTERVENTION|Control|Participants of the control group continue with their treatment as usual
62129437|NCT02579031|ACTIVE_COMPARATOR|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent Orsiro
62319601|NCT05682807|ACTIVE_COMPARATOR|probiotic group (group III)|will include 30 preterm neonates with BPD who will receive traditional therapy of BPD in association with probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months
62319602|NCT01666444|EXPERIMENTAL|PLD 40 mg/m2 plus VTX-2337|The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
62319603|NCT01666444|ACTIVE_COMPARATOR|PLD 40 mg/m2 plus placebo|The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only.
61925751|NCT00766441|ACTIVE_COMPARATOR|1|Sitagliptin 100mg
61925752|NCT00766441|ACTIVE_COMPARATOR|2|Sulphonylurea
62319604|NCT03510663|EXPERIMENTAL|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
62319605|NCT03510663|EXPERIMENTAL|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
62319606|NCT03510663|ACTIVE_COMPARATOR|Moxifloxacin|400mg tablet will be administrated once a week.
62319607|NCT03510663|PLACEBO_COMPARATOR|Placebo|Placebo will be intravenously administered once a week.
62339730|NCT04007055|NO_INTERVENTION|Control: guideline based therapy|Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
62339731|NCT04904926||Older Individuals|
62480412|NCT03939897|EXPERIMENTAL|Phase I Part A Dose 1 (copanlisib, abemaciclib, fulvestrant)|Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1 and 15 and 100 mg abemaciclib PO BID on days 2-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive 500 mg fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
62480413|NCT03939897|EXPERIMENTAL|Phase I Part A Dose 2 (copanlisib, abemaciclib, fulvestrant)|Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 and 150 mg abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive f500 mg fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
62688743|NCT03726879|PLACEBO_COMPARATOR|Placebo + ddAC-PacHP|Participants will receive placebo 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 \& cyclophosphamide 600 mg/m2 IV), followed by placebo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W for 4 cycles \& pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant \& adjuvant setting: placebo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, \& pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL, dated 3 Feb 2021 treatment with placebo must be discontinued.
62688744|NCT06686641||Non-infectious uveitis patients treated at a hospitals in the North Denmark Region|
62129438|NCT02579031|ACTIVE_COMPARATOR|Xience|Durable-polymer everolimus-eluting stent Xience
62129439|NCT04962750|EXPERIMENTAL|laser therapy|
62319608|NCT03818438||Case subjects adult patients with chronic ankle instability|"Male or female subjects aged 18-45, presenting :~* at least one acute lateral ankle sprain (i.e. initial ankle sprain more than 12 months before inclusion),~* at least one residual symptom (giving way OR sensation of instability OR recurrent ankle sprain), confirmed by a score \< 24 on the Chronic Ankle Instability Tool (CAIT)~* Impact on activities of daily living and sport, score \< 90% on Foot and Ankle Ability Measure (FAAM) and \< 80% on FAAM-sport Case subjects are free of any other lower extremity pathologies or pain Subjects presenting bilateral chronic ankle instability are excluded"
62319609|NCT03818438||Healthy subjects|Male or female subjects aged 18-45 (matched with case Healthy subjects), without any lower extremity pathologies
62319610|NCT03067662|EXPERIMENTAL|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
62319611|NCT03067662|NO_INTERVENTION|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
62319612|NCT03952897||Group 1|Subjects treated with balneotherapy for 10 days, previously diagnosed with knee and/or hip osteoarthritis, and subjects previously diagnosed with rheumatoid arthritis.
62319613|NCT01842061|EXPERIMENTAL|Active Living Program|Participants in the intervention group will receive a self-management program designed to reduce sedentary behaviour and increase physical activity. Specifically, they will be given an EASY Program Manual with strategies to break up sitting time during the day and increase utilitarian activity; this will include a section on how to set, monitor and maintain achievable goals. They will also be offered a pedometer program, group education sessions and encouraged to use public transport by providing free bus tickets.
62319614|NCT01842061|ACTIVE_COMPARATOR|Education|Control group participants will be offered monthly drop-in sessions that target information on general health and well-being unrelated to physical activity.
62319615|NCT04569305|EXPERIMENTAL|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy was applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of technique was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
62339732|NCT04904926||Healthy young to middle aged Individuals|
62129440|NCT04962750|SHAM_COMPARATOR|Control|
62129441|NCT06189534|EXPERIMENTAL|Arms of the study|Experimental group : participants in experimental group will receive 8-10 sessions of intervention in overall the course of study.
62129442|NCT06189534|NO_INTERVENTION|Control group|Control group: participants in control group will not receive any sessions of intervention.
62129443|NCT06521411|EXPERIMENTAL|Study Group|Low-income Chinese American immigrant families with a focus on adults 18+ years in Brooklyn will participate in a culturally adapted systems -level program for improving diet.
62129444|NCT03339115|EXPERIMENTAL|Cardiovalve Transfemoral Mitral Valve|Mitral replacement valve delivered through a transfemoral access and transseptal approach
62480414|NCT03939897|EXPERIMENTAL|Phase I Part B Dose 1b (copanlisib, abemaciclib, fulvestrant)|Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1 and 15 and 100 mg abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive 500 fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
62480415|NCT03939897|ACTIVE_COMPARATOR|Phase I Part B Dose 2b (copanlisib, abemaciclib, fulvestrant)|Patients receive 45 mg copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 and 100 mg abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive 500 mg fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
61925753|NCT06734689||ICI-tolerant patients without suspicion of myotoxicity (Controls)|300 Patients on ICI since at least 3 months with a minimum of 2 ICI doses received having no appearance (as compared to baseline known pre-ICI) of new cardio-muscular symptoms or ECG abnormality or wall motion abnormality or troponin-T increase (above Upper Limit of Normal if normal prior to ICI start, or over twice its troponin-T baseline value if abnormal before ICI start)
62480416|NCT05180422|EXPERIMENTAL|Dose Expansion|AMG 510/MVASI
62129445|NCT01226849|EXPERIMENTAL|Single Arm|"bortezomib, rituximab, ifosphamide, etoposide, carboplatin~Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended"
62319616|NCT04569305|ACTIVE_COMPARATOR|Conventional treatment|Simple moist gauze dressing applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of treatment was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
62319617|NCT01208896|EXPERIMENTAL|Rituximab|
62480417|NCT05620511|EXPERIMENTAL|Mindfulness based stress reduction|"1. Age \> 55 years.~2. Major depressive disorder (MDD).~3. Right handiness~4. with a score ≥ 24 on the MMSE"
62480418|NCT05620511|PLACEBO_COMPARATOR|Relaxation|"1. Age \> 55 years.~2. Major depressive disorder (MDD).~3. Right handiness~4. with a score ≥ 24 on the MMSE"
62319618|NCT03632512|EXPERIMENTAL|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
62319619|NCT03632512|PLACEBO_COMPARATOR|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
62480419|NCT04499677|EXPERIMENTAL|Favipiravir + Lopinavir/ritonavir (LPV/r)|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7
62480420|NCT04499677|EXPERIMENTAL|Favipiravir + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
62480421|NCT04499677|EXPERIMENTAL|Favipiravir placebo + Lopinavir/ritonavir (LPV/r)|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
62480422|NCT04499677|PLACEBO_COMPARATOR|Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
62480423|NCT06559345|EXPERIMENTAL|TMLI conditioning group|Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI) plus Cyclophosphamide
62480424|NCT06559345|ACTIVE_COMPARATOR|TBI conditioning group|Total Body Irradiation (TBI) plus Cyclophosphamide
62129446|NCT03086863|EXPERIMENTAL|verum electroacupuncture|"* Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~* Needle insertion by 10-15 mm and de qi sensation~* Park sham guide tubes~* Low frequency electronic stimulation (30 Hz)~* Retention for 20 minutes."
62129447|NCT03086863|SHAM_COMPARATOR|sham electroacupuncture|"* Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~* Needle installation without penetration~* Park sham guide tubes~* Low frequency electronic stimulation (30 Hz) for a fake noise without conduction~* Retention for 20 minutes."
62480425|NCT06313034|EXPERIMENTAL|experimental group|"Breastfeeding education will be given to mothers in the experimental group in 4 individual and face-to-face sessions based on motivational interviewing technique.~The first session of breastfeeding training based on motivational interviewing technique will be held in the delivery room where the mother is hospitalized before being discharged from the hospital. Other sessions will be held according to the monitoring frequency recommended in the Postnatal Care Management Guide of the Ministry of Health of the Republic of Turkey (2018). These will be done at the health institution where the mother receives service.~Second session; Between the 2th and 5th postpartum day Third session; Between the 13th and 17th postpartum day Fourth session; Between the 30th and 42th postpartum day The duration of each motivational interview is planned to be between 30-40 minutes on average."
62480426|NCT06313034|NO_INTERVENTION|control group|Before discharge, mothers in the control group will be given routine breastfeeding training by the midwife working in the delivery room in accordance with the mother/baby friendly hospital protocol.
62480427|NCT05949684|EXPERIMENTAL|Luspatercept|
62319620|NCT04788719|EXPERIMENTAL|Preoperative|Gait analysis kinematics and kinetics
62480428|NCT05949684|ACTIVE_COMPARATOR|Epoetin Alfa|
62480429|NCT06035250||Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy|This group comprises participants diagnosed with advanced gastric cancer. The participants will be treated with standard neoadjuvant chemotherapy regimens recommended by clinical guidelines. Treatment details, including the generic name of the drugs, dosage form, dosage, frequency, and duration, will be recorded according to the specific regimen.
62319621|NCT04788719|EXPERIMENTAL|Postoperative|Gait analysis kinematics and kinetics
62480430|NCT03106415|EXPERIMENTAL|Treatment (binimetinib, pembrolizumab)|Patients receive binimetinib PO BID on days 1-14 of cycle 1 and on days 1-21 of cycle 2 and subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycle 1 equals 14 days. Cycles 2 and beyond repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62480431|NCT06485908|EXPERIMENTAL|Patients receiving axitinib in combination with etoposide|"1. st stage: Dose escalation The first patient will be included at the level of 1.6 mg/m²/day of axitinib. Patients will be included by cohort of a maximum of 6 patients evaluable for DLT. In the absence of more than 2 patients with DLT during the first 28-day cycle, escalation to the next level will be allowed. Intra-patient dose escalation is not permitted. Non evaluable patients for DLT will be replaced. Six evaluable patients will be enrolled at the last dose level. RP2D will be the DMT or in the absence of DLT the maximum dose evaluated.~   Treatment will be continued until progression, or unacceptable toxicity for a period of 1 year.~   Depending on the number of DLTs observed, a maximum of 18 patients should be included.~2. nd stage: extension cohort For the second phase of the study, at RP2D, 2 cohorts of 9 patients (ependymoma, medulloblastoma) will be considered in the study. Treatment will be continued until progression, or unacceptable toxicity for a period of 1 year."
62688745|NCT05318443|EXPERIMENTAL|Experimental|SIBP04 \& Paclitaxel \& Carboplatin
61925754|NCT06734689||Patients with refuted suspicion of ICI-myocarditis (controls)|100 Cancer patients treated with ICI and with definite ICI-induced myocarditis according to last updated diagnostic criteria's
62319622|NCT01585129|EXPERIMENTAL|Postpartum Antibiotics|Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
62319623|NCT01585129|PLACEBO_COMPARATOR|No postpartum antibiotics|No further postpartum antibiotics
62319624|NCT01123239|EXPERIMENTAL|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches who have been trained to promote patient participation in the medical visit. The coaches, who themselves have diabetes, meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making."
62480432|NCT00001174||Healthy Volunteers|Healthy volunteers
62688746|NCT05318443|ACTIVE_COMPARATOR|Control group|Avastin \& Paclitaxel \& Carboplatin
62688747|NCT00909688|EXPERIMENTAL|1|BLI-489
62688748|NCT00909688|PLACEBO_COMPARATOR|2|placebo
62688749|NCT05030389|EXPERIMENTAL|Adapted Physical Activity (APA)|Participants receive a web-based adapted physical activity (APA) during 12 weeks, on the basis of three at-home sessions a week
61925755|NCT06734689||ICI-Myocarditis Cases (Cases)|100 Cancer patients treated with ICI admitted for a suspicion of ICI-myocarditis subsequently infirmed
62129448|NCT04008550|NO_INTERVENTION|No Pulmonary Arterial Hypertension before TAVI|No intervention has been done in this group of patients.
62129449|NCT04008550|OTHER|Pulmonary Arterial Hypertension before TAVI|In this group, a right heart catheterization is done 3 months after TAVI in order to evaluate PAH (persistence or regression).
62129450|NCT05310916|EXPERIMENTAL|Test group|(n=30): type 2 diabetes mellitus patients who will receive an oral antidiabetic along with dapagliflozin at a dose of 10 mg daily for 12 weeks.
62319625|NCT01123239|ACTIVE_COMPARATOR|Standard Diabetes Education|Patients receive one-on-one diabetes education sessions before each medical visit. These sessions are purely informational, and do not include the specific patient activation components of the coached care intervention.
62319626|NCT04499508|EXPERIMENTAL|Treatment with Optima Balt Coils|The APPLY study is a single-arm prospective study which means that everyone enrolled in the clinical trial will be/has been treated with the Optima Balt Coils.
62319627|NCT04911101|EXPERIMENTAL|7G needle|7G needle dimension used
61925756|NCT02729675|EXPERIMENTAL|Access Intervention|Worksites in this condition received weekly Fruit and Vegetable markets
62688750|NCT05030389|EXPERIMENTAL|Adapted Physical Activity + Bright Light Exposure (APA + BLE)|Participants receive a web-based APA program during 12 weeks on the basis of three at-home sessions a week, supplemented by a bright light exposure (BLE) during 12 weeks, on the basis of five at-home sessions a week
62688751|NCT05030389|EXPERIMENTAL|Galvanic Vestibular Stimulation (GVS)|Participants receive Galvanic Vestibular Stimulation (GVS) during two weeks, on the basis of five at-home sessions a week
62319628|NCT04911101|EXPERIMENTAL|10G needle|10G needle dimension used
62319629|NCT00278265|EXPERIMENTAL|MTX followed by fludarabine|MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles
62319630|NCT00187707|OTHER|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
62319631|NCT04770233|ACTIVE_COMPARATOR|Early ACL reconstruction|Early ACL reconstruction is performed within 12 weeks after ACL injury and is followed by rehabilitation led by a physiotherapist. ACL surgical technique and rehabilitation is pragmatic according to the routines at the including centre.
62319632|NCT04770233|ACTIVE_COMPARATOR|Primary ACL rehabilitation|"Primary ACL rehabilitation is active rehabilitaion led by a physiotherapist. Active rehabilitation will begin as early as possible after the ACL injury. The goal of rehabilitation is to stabilized the knee without an operation.~ACL reconstruciton is still an option after 6 months if the knee is unstable or do not allow adequat return to physical activity. If the patient sustain new knee injuries secondary to the ACL injury or has major instability, ACL reconstruction may be necessary before 6 months. The patients randomized to active rehabilitation will be routinely followed-up at his/her local hospital at 6 months."
62319633|NCT04994821|EXPERIMENTAL|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), (Soterix Medical mini-CT tDCS stimulator)
62319634|NCT04994821|SHAM_COMPARATOR|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
62319635|NCT04994821|EXPERIMENTAL|Active tDCS with Cognitive Reappraisal (CR)|Active Transcranial Direct Current Stimulation (tDCS) (Soterix Medical mini-CT tDCS stimulator), and Cognitive Reappraisal (CR)
62129451|NCT05310916|ACTIVE_COMPARATOR|Control group|(n=30): type 2 diabetes mellitus patients who will receive two oral antidiabetic agents for 12 weeks
62319636|NCT02509910||Standard therapy|intraoperative standard fluid therapy for major abdominal surgery
62319637|NCT02509910||Goal directed therapy|intraoperative goal directed fluid therapy based on an angorithm lead by SVV/CI for major abdominal surgery patients
62319638|NCT02951546|EXPERIMENTAL|Mediterranean diet|"Hypocaloric Mediterranean diet for a 4-month period;~Aerobic exercise training for a 4-month period;"
62319639|NCT02951546|EXPERIMENTAL|Low fat diet|"Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;~Aerobic exercise training for a 4- month period;"
62319640|NCT06444737|EXPERIMENTAL|Group O|Group ondansetron : parturients receiving intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia
62319641|NCT06444737|PLACEBO_COMPARATOR|Group C|Group control : receiving IV normal saline 5 ml (control group) 5 min before spinal anesthesia
62319642|NCT02610088|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin will be started in patient with type 2 diabetes mellitus
62688752|NCT05030389|ACTIVE_COMPARATOR|Health Education program (HE)|Participants receive a web-based health education program (HE) during 14 weeks, on the basis of one at-home session a week
62129452|NCT04290819|EXPERIMENTAL|Resistance Training with Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
62319643|NCT02610088|ACTIVE_COMPARATOR|Gliclazide|Gliclazide will be started in patient with type 2 diabetes mellitus
62688753|NCT04199689|EXPERIMENTAL|9vHPV vaccine|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
62688754|NCT04199689|PLACEBO_COMPARATOR|Placebo|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
62688755|NCT01345903|EXPERIMENTAL|Treatment (surgery)|Patients undergo robotic-assisted surgery using the da Vinci robot
62688756|NCT06027398|EXPERIMENTAL|SARS-CoV-2 RNA in masks|. After the participants had worn the masks for 8 h, the nurse collected the filters and placed each into a viral transport medium (VTM) tube This was placed inside a clean plastic bag, sprayed with alcohol, placed in an icebox and sent to the biomolecular laboratory for real-time RT-PCR SARS-CoV-2 testing.
61925757|NCT02729675|EXPERIMENTAL|Enhanced Intervention|Worksites in this condition received weekly Fruit and Vegetable markets and Educational Interventions including Campaigns, Newsletters, DVDs, A Website, and Chef Demonstrations
61925758|NCT02729675|ACTIVE_COMPARATOR|Comparison Intervention|Worksites in this condition received Stress and Physical Activity Interventions
62129453|NCT04290819|EXPERIMENTAL|Resistance Training with Caffeine|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
62319644|NCT05094154|ACTIVE_COMPARATOR|anti-pseudomonal cephalosporin|Participants in the anti-pseudomonal cephalosporin arm will receive at least one dose of an anti-pseudomonal cephalosporin.
62319645|NCT05094154|ACTIVE_COMPARATOR|anti-pseudomonal penicillin|Participants in the anti-pseudomonal penicillin arm will receive at least one dose of an anti-pseudomonal penicillin.
62319646|NCT02848846|EXPERIMENTAL|Robotic Hand|The two patient enrolled will perform the task requiring the use of the robotic hand.
62319647|NCT02229864|EXPERIMENTAL|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
62319648|NCT00266110|EXPERIMENTAL|Dendritic Cell Vaccine|Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion
62319649|NCT02235753|EXPERIMENTAL|High-intensity interval training, HIT-S|High-intensity aerobic interval training, short interval (HIT-S)
62319650|NCT02235753|EXPERIMENTAL|High-intensity interval training, HIT-L|High-intensity aerobic interval training, long interval (HIT-L)
62688757|NCT02793050||Trabectedin|Trabectedin give according the market authorization for advanced soft tissue sarcoma
62688758|NCT04876391|EXPERIMENTAL|Participants from parent trial (1368-0052) who were on placebo or active medication|
62688759|NCT05679934|EXPERIMENTAL|Home-Based Exercise|Patients who perform home-based exercise program
62319651|NCT02235753|NO_INTERVENTION|Usual care|control group
62319652|NCT01094340|OTHER|Thalidoide|CSF
62319653|NCT01214434|EXPERIMENTAL|Promiseb Topical Cream|
62319654|NCT01214434|SHAM_COMPARATOR|Bland emollient|
62319655|NCT01970579|EXPERIMENTAL|Paclitaxel coated balloon|
62319656|NCT01970579|ACTIVE_COMPARATOR|uncoated PTA catheter|
62319657|NCT06021652|EXPERIMENTAL|Virtual Reality|Participants electing to participate in the virtual reality based smoking cessation platform
62319658|NCT06021652|NO_INTERVENTION|Control|Those utilizing standard of care smoking cessation therapies
62319659|NCT01109901|OTHER|anterior submuscular transposition|it is kind of surgical method
62319660|NCT01109901|OTHER|Anterior subcutaneous transposition|it is kind of surgical method
62688760|NCT05679934|EXPERIMENTAL|Telerehabilitation|Patients who perform telerehabilitation exercise program
62688761|NCT05679934|NO_INTERVENTION|Control Group|No intervention
62688762|NCT04497155||Prehospital norepinephrine|Trauma patients that received norepinephrine in the prehospital setting or in the resuscitation unit .
61925759|NCT02855515|EXPERIMENTAL|Short-time diagnostic anaesthesia|The study population will consist of patients with obstructive sleep apnoea, which will be classified as mild, moderate, severe (patients who failed or refused primary CPAP treatment). The patients will undergo a short-time general anaesthesia in order to diagnose OSA when relaxed.
61925760|NCT01053949|ACTIVE_COMPARATOR|Drug on 21 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
62319661|NCT06675799|EXPERIMENTAL|Sleep Extension|Sleep-related psychoeducation will be provided in weekly lesson content. Phone coaching will revolve around sleep health and meeting sleep goals.
62319662|NCT06675799|ACTIVE_COMPARATOR|Healthy Living|Psychoeducation about general health (e.g., hand washing) will be provided in weekly lesson content. Phone coaches will not provide counseling or goal setting but may clarify terms or concepts.
62319663|NCT01935908|NO_INTERVENTION|Control Group|The control group will not receive levetiracetam as seizure prophylaxis.
62688763|NCT04497155||Prehospital no norepinephrine|Trauma patients that did not receive norepinephrine in the prehospital setting or in the resuscitation unit.
61925761|NCT01053949|ACTIVE_COMPARATOR|Drug on 28 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
62319664|NCT01935908|ACTIVE_COMPARATOR|Treatment Group|levetiracetam 500mg in adults, twice daily, administered by mouth, per tube, or IV. The route of administration will be dependent upon the patient's clinical status and ability to tolerate each form. In descending order of preference, route of administration will be: oral, per tube, IV.
62319665|NCT03375658|EXPERIMENTAL|Intervention arm|All vital signs registered as part of usual care are used for modelling patients state and trajectories and made available to clinicans via the Patient Deterioration Warning System in nursing and physician offices.
62319666|NCT03375658|NO_INTERVENTION|Control arm|Usual care
62319667|NCT04397068|OTHER|macular pucker wherefore vitrectomy|one eye phaco-vitrectomy and other eye only phaco. No other involvement of drug or device. Standard of care procedure
62319668|NCT03471676||Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording in children suffering from neuromuscular diseases
62319669|NCT01353833|PLACEBO_COMPARATOR|IL2-4|
62319670|NCT01353833|EXPERIMENTAL|IL2-2|1 millions IU of IL-2 per day
62319671|NCT01353833|EXPERIMENTAL|IL2-3|3 millions IU of IL-2 per day
62319672|NCT01353833|EXPERIMENTAL|IL2-1|0.33 millions IU of IL-2 per day
62319673|NCT06286787|EXPERIMENTAL|Intervention group|Participants in the intervention group will be invited to join the mountain craft training programme.
62319674|NCT06286787|PLACEBO_COMPARATOR|Placebo control group|Participants will be invited to join a control intervention that mimics the time and attention received by participants in the intervention group but will be designed to have no specific effect on the outcome variables.
62319675|NCT05355363|EXPERIMENTAL|Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
62319676|NCT04066556||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
62319677|NCT03229746|EXPERIMENTAL|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
62319678|NCT03229746|ACTIVE_COMPARATOR|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
62319679|NCT03229746|ACTIVE_COMPARATOR|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
62319680|NCT02025738|ACTIVE_COMPARATOR|MAGNET|magnet application over cardiac device
62319681|NCT02025738|ACTIVE_COMPARATOR|REPROGRAMING|reprograming of cardiac device by trained technician/electrophysiologist
62319682|NCT02025738|ACTIVE_COMPARATOR|NO ACTION|no action is performed if patient meets inclusion criteria
62319683|NCT01720511|EXPERIMENTAL|Purple Rice|Twice a day given purple rice with 5mg of resveratrol.
62319684|NCT01720511|ACTIVE_COMPARATOR|Brown RIce|Plain Purple rice given twice a day
62319685|NCT01554878||knee surgery|
62688764|NCT03830398|ACTIVE_COMPARATOR|Paracetamol|Parol group: intravenous infusion in 30 min Generic name: Parol Dosage form: intravenous Dosage: 1 gr Frequency: preop one dose only Duration: For one week
62688765|NCT03830398|ACTIVE_COMPARATOR|Deksketoprofen trometamol|Sertofen group: intravenous infusion in 30 min Generic name: Sertofen Dosage form: intravenous Dosage: 50 mg Frequency: preop one dose only Duration: For one week
62688766|NCT03830398|PLACEBO_COMPARATOR|Placebo|Placebo group: intravenous infusion in 30 min Generic name: Serum physiologic Dosage form: intravenous Dosage: 100 ml Frequency: preop one dose only Duration: For one week
62688767|NCT01348581|EXPERIMENTAL|Marigen Wound Dressing|
62688768|NCT04236947|EXPERIMENTAL|SCPP-YA group|SCPP-YA adapted to Chile consist of ten sessions promoting self-regulation strategies, prosocial, and problem-solving skills. It also includes a module (6 sessions) specially designed for substance use prevention, developing social competence, and assertiveness to deal with peer pressure. These 16 sessions will be implemented during an academic year (2020), and complemented with three booster sessions the following year (2021).
62688769|NCT04236947|NO_INTERVENTION|Control Group|The control schools will continue providing their traditional preventive actions.
62688770|NCT01498380|EXPERIMENTAL|Dexmedetomidine Rapid Bolus|All subjects will receive a rapid bolus of dexmedetomidine following induction of anesthesia with propofol and remifentanil and placement of laryngeal mask airway.
61925762|NCT06082271|ACTIVE_COMPARATOR|Cortisone (C)|To improve the outcome of the arthroscopy during the procedure, cortisone is injected for anti-inflammatory purposes at the end of the surgical procedure.
61925763|NCT06082271|EXPERIMENTAL|Hydrolyzed Collagen Peptides|The use is alternative to cortisone
62129454|NCT04290819|EXPERIMENTAL|Resistance Training with Caffeine and Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
62129455|NCT04290819|PLACEBO_COMPARATOR|Resistance Training with Placebo|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
62319686|NCT05438485||Methylmalonic Acidemia (MMA)|Approximately 60 subjects with Methylmalonic Acidemia
62319687|NCT05438485||Propionic Acidemia (PA)|Approximately 60 subjects with Propionic Acidemia
62319688|NCT04954469|EXPERIMENTAL|CoVAC-1 Vaccine|Peptide vaccination should be started as soon as possible after the screening visit. Or in case of two vaccinations: Peptide vaccination should be started as soon as possible after the screening visit (V1) and on day 42 (V5)
62319689|NCT02436486|PLACEBO_COMPARATOR|Placebo|
62319690|NCT02436486|EXPERIMENTAL|Idalopirdine 120 mg|Therapeutic dosages
62319691|NCT02436486|EXPERIMENTAL|Idalopirdine 360 mg|Supra-therapeutic dosages
62319692|NCT02436486|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|Positive Control
62319693|NCT02416908|EXPERIMENTAL|Phase I Schedule A (selinexor)|"* Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.~* Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~* Cladribine will be given 5 mg/m\^2/day IV once daily on Days 4-8.~* G-CSF will be given 300 mcg SC once daily on Days 3-8.~* Cytarabine will be given 2000 mg/m\^2/day IV once daily on Days 4-8.~* Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
62319694|NCT02416908|EXPERIMENTAL|Phase I Schedule B (selinexor)|"* Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.~* Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~* Cladribine will be given 5 mg/m\^2/day IV once daily on Days 4-8.~* G-CSF will be given 300 mcg SC once daily on Days 3-8.~* Cytarabine will be given 2000 mg/m\^2/day IV once daily on Days 4-8.~* Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
62480433|NCT00001174||Patients|Patients with bipolar disorder
62480434|NCT04512781|EXPERIMENTAL|Conventional Legacy Cannula Design (Control) - Prosoft Cannula - Unicorn Cannula|"During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.~Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded."
62688771|NCT03635866|EXPERIMENTAL|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
62688772|NCT01668199|EXPERIMENTAL|14C TZP-101|
61925764|NCT01236118|EXPERIMENTAL|30 milligrams (mg) LY2439821|Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
61925765|NCT01236118|EXPERIMENTAL|80 mg LY2439821|Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
61925766|NCT01236118|EXPERIMENTAL|160 mg LY2439821|Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
62129456|NCT01244672|ACTIVE_COMPARATOR|Trans-anal dearterialization|24 patients were assigned to the Transanal hemorrhoidal dearterialization with mucopexy arm, which is a Doppler guided procedure for suture ligation of hemorrhidal arteries rather than excisional
62129457|NCT01244672|ACTIVE_COMPARATOR|Ferguson|17 patients were randomized to Ferguson method, which is the operative gold standard for hemorrhoids. This is an excisional surgery.
62688773|NCT06124300|EXPERIMENTAL|Female Hormone Balance Supplement|Participants will add 1 scoop of the powder to a drink of choice every morning.
62688774|NCT05848089|OTHER|Treatment as usual (TAU) + EMA|Participants will receive TAU and be prompted to complete 4x/day smartphone-based EMA surveys of negative emotion and STBs.
62688775|NCT05848089|EXPERIMENTAL|Experimental intervention + TAU|Participants will receive TAU plus 3 brief sessions of CBT skills, one discretionary post-discharge skills booster session, and 4x/day EMA and prompted EMI, which guides in-the-moment CBT skills practice.
62688776|NCT04003142|EXPERIMENTAL|Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg|Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 30 mg orally, QD from week 13 up to Week 52 during extension treatment period.
61925767|NCT05928871|ACTIVE_COMPARATOR|preop|60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)
61925768|NCT05928871|ACTIVE_COMPARATOR|postop|"60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation)."
61925769|NCT01002482|EXPERIMENTAL|CGAO-based Glucose Control|Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.
61925770|NCT01002482|ACTIVE_COMPARATOR|Standard-Care Glucose Gontrol|Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.
62688777|NCT04003142|EXPERIMENTAL|Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg|Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 45 mg orally, QD from week 13 up to Week 52 during extension treatment period.
62688778|NCT04003142|PLACEBO_COMPARATOR|Double-blind Period: Placebo|Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, once daily (QD) up to week 12 during double-blind treatment period.
62688779|NCT04003142|EXPERIMENTAL|Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 30 mg orally, QD from week 13 up to week 52 during extension treatment period.
62688780|NCT04003142|EXPERIMENTAL|Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 45 mg orally, QD from week 13 up to week 52 during extension treatment period.
62688781|NCT03808077|EXPERIMENTAL|Interventional Group: Deep Neuromuscular Blockade|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
61925771|NCT05317416|EXPERIMENTAL|Arm A - Part 1|Elranatamab
61925772|NCT05317416|ACTIVE_COMPARATOR|Arm B - Part 1|Lenalidomide
61925773|NCT05317416|ACTIVE_COMPARATOR|Arm B - Part 2|Lenalidomide
61925774|NCT05317416|EXPERIMENTAL|Arm C - Part 2|Elranatamab
62129458|NCT01388725||SIRS|(1) temperature \> 38oC or \< 36oC; (2) pulse rate \> 90 beats/min; (3) ventilation rate \> 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) \< 32 mmHg; (4) white blood cell (WBC) count \>1 2,000μL-1 or \< 4000 μL-1 , or \> 10% immature cells.
62480435|NCT04512781|EXPERIMENTAL|Conventional Legacy Cannula Design (Control) - Unicorn Cannula - Prosoft Cannula|"During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.~Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded."
62480436|NCT05642780|EXPERIMENTAL|cohort A|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
62129459|NCT01388725||Sepsis|SIRS + infection
62129460|NCT02802995|EXPERIMENTAL|Treatment arm|Subjects receiving the study drug which is PRP/thrombin mixture
62129461|NCT02802995|NO_INTERVENTION|Control arm|Subjects receiving the standard of care for chronic venous wounds
62129462|NCT05212675|OTHER|short daily dialysis|7 days 2hours dialysis
62129463|NCT05212675|NO_INTERVENTION|conventional dialysis|3 times weekly 4hours dialysis
62480437|NCT05642780|EXPERIMENTAL|cohort B|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
62688782|NCT03808077|ACTIVE_COMPARATOR|Control Group: Moderate Neuromuscular Blockade|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
62688783|NCT00958425|EXPERIMENTAL|Hyaluronic acid gel|
62688784|NCT00958425|ACTIVE_COMPARATOR|Saline|
62129464|NCT01629316|EXPERIMENTAL|Text reminders, counseling, link coordinator|Text reminders, counseling, link coordination
62129465|NCT01629316|ACTIVE_COMPARATOR|Standard of care - control arm|
62129466|NCT00541268|EXPERIMENTAL|A - ICD implantation|Heart Failure nonischemic etiology treated by optimal medical treatment and receiving a prophylactic ICD
62129467|NCT00541268|ACTIVE_COMPARATOR|B - control|Heart Failure nonischemic etiology treated by optimal medical treatment
62129468|NCT03062813|EXPERIMENTAL|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
62129469|NCT03062813|ACTIVE_COMPARATOR|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
62129470|NCT00338572|ACTIVE_COMPARATOR|1|12-week exercise program
62129471|NCT00338572|EXPERIMENTAL|2|12-week combined exercise and diet program
62688785|NCT05230654|EXPERIMENTAL|fosaprepitant|Patients received intravenous Ganisetron plus dexamethasone followed by fosaprepitant infusion
62688786|NCT05230654|PLACEBO_COMPARATOR|Placebo|Patients received intravenous Ganisetron plus dexamethasone followed by normal saline
62480438|NCT05642780|EXPERIMENTAL|cohort C|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
62688787|NCT01983670|EXPERIMENTAL|health group 1|Health subjects received 30 mins delay antagonist activation temporal ES.
62129472|NCT00338572|NO_INTERVENTION|3|Non-intervention group
62129473|NCT01072006||Control Group|Control group without traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD)
62129474|NCT01072006||PTSD Group|PTSD (not TBI)
62129475|NCT01072006||TBI Group|TBI (no PTSD)
62129476|NCT01072006||TBI+PTSD Group|Combined TBI history and PTSD
62480439|NCT05642780|EXPERIMENTAL|cohort D|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
62480440|NCT05642780|EXPERIMENTAL|Cohort E|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
62688788|NCT01983670|EXPERIMENTAL|SCA group 1|SCA subjects received four weeks temporal ES assisted home training program.
62129477|NCT04728724|EXPERIMENTAL|Group A|Anti-PD-1 monotherapy
62129478|NCT04728724|EXPERIMENTAL|Group B|Anti-PD-1 plus chemotherapy
62129479|NCT04649021|EXPERIMENTAL|BNT162b2 18-85 years of age|
62688789|NCT01983670|NO_INTERVENTION|health group 2|health subjects controlled group
62688790|NCT01983670|NO_INTERVENTION|SCA group 2|SCA subjects controlled group
62129480|NCT04649021|PLACEBO_COMPARATOR|Placebo 18-85 years of age|
62129481|NCT03688360|EXPERIMENTAL|Therapist-guided in-session|The participants will engage in 2 x 45 minutes of exposure exercises conducted together with the therapist in the mental health care centre. In addition, they will conduct 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
62129482|NCT03688360|EXPERIMENTAL|Self-guided out-session|The participants will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
62129483|NCT03688360|EXPERIMENTAL|Parent-guided out-session|The participants and one of their parents will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises together with their parent out of session as a homework assignment.
62129484|NCT03390075||ResearchNow NuVal shoppers|a convenience sample of 665 shoppers at two NuVal chains.
62688791|NCT01991886|EXPERIMENTAL|nasal High Flow applied|Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
62688792|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
62688793|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
62688794|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.|COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
62129485|NCT02372253|EXPERIMENTAL|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
62129486|NCT02372253|PLACEBO_COMPARATOR|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
62129487|NCT06322212|EXPERIMENTAL|BBB function, cognition, and mood in T2DM adults with Thiamine treatment.|Analyze BBB function, cognition, and mood in T2DM adults with Thiamine treatment and compare to the placebo group.
62319695|NCT02416908|EXPERIMENTAL|Phase II (selinexor)|"* Selinexor will be given at the schedule as determined in Phase 1.~* Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~* Cladribine will be given 5 mg/m\^2/day IV once daily on Days 4-8.~* G-CSF will be given 300 mcg SC once daily on Days 3-8.~* Cytarabine will be given 2000 mg/m\^2/day IV once daily on Days 4-8.~* Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
62480441|NCT04275895|EXPERIMENTAL|Prematurely born Children|"Evaluation of different attention or/and postural activities :~1. Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~2. Child perception of the vertical compared to the real vertical~3. Evaluation of the posture of the child during different visual conditions~4. Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
62319696|NCT03179098|ACTIVE_COMPARATOR|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
62319697|NCT03179098|ACTIVE_COMPARATOR|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
62480442|NCT04275895|ACTIVE_COMPARATOR|Term born Children|"Evaluation of different attention or/and postural activities~1. Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~2. Child perception of the vertical compared to the real vertical~3. Evaluation of the posture of the child during different visual conditions~4. Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
62480443|NCT01120340|ACTIVE_COMPARATOR|mesalamine|Posology: mesalamine: 1,6 g/die for ten days every month for 24 months
62480444|NCT01120340|PLACEBO_COMPARATOR|placebo|
62480445|NCT03746795|NO_INTERVENTION|Standard spirometry|Standard spirometry measurement with a pneumotachograph alone.
62480446|NCT03746795|EXPERIMENTAL|EIT alone|Spirometric examinations realized using the EIT
62480447|NCT03746795|EXPERIMENTAL|Simultaneous standard spirometry and EIT|Simultaneous measurement by spirometer and EIT
62688795|NCT03908294||Chronic hepatitis C under antiviral treatment with DAA|Patients with chronic hepatitis C infection and planned DAA treatment are enrolled prospectively. Parameters of glucose metabolism and liver fibrosis are measured at baseline, during therapy and up to one year after end of treatment.
62129488|NCT06322212|PLACEBO_COMPARATOR|BBB function, cognition, and mood in T2DM adults without Thiamine treatment.|Analyze BBB function, cognition, and mood in T2DM adults without Thiamine treatment and compare to the Thiamine treatment group.
62129489|NCT04135885|EXPERIMENTAL|Intervention group|Intervention group: patients took 7 days of folic acid tablets before surgery (0.3mg/d for children aged 1-3, 0.4mg/d for children aged 4\~5 years, dissolved in 20ml brown sugar water.)
62129490|NCT04135885|EXPERIMENTAL|Placebo group|Placebo group: The patient received the same dose of brown sugar water for 7 days before surgery. Folic acid dose selection is based on the maximum daily intake of children（tolerable upper intake levels，UL）
62129491|NCT05891366|EXPERIMENTAL|WAL0921|Single intravenous infusion of investigational drug WAL0921
62129492|NCT05891366|PLACEBO_COMPARATOR|Placebo|Single intravenous infusion of normal saline
62129493|NCT00917202|EXPERIMENTAL|MB3|3 days
62129494|NCT00917202|EXPERIMENTAL|MB5|5 days
62129495|NCT00917202|EXPERIMENTAL|MB7|
62129496|NCT00566735|PLACEBO_COMPARATOR|1|
62129497|NCT00566735|ACTIVE_COMPARATOR|2, Galantamine|
62129498|NCT05555719|EXPERIMENTAL|Mandibular Protraction Appliance|the first group that received Mandibular Protraction Appliance
62129499|NCT05555719|EXPERIMENTAL|PowerScope Appliances|the first group that received PowerScope Appliances
62319698|NCT00084422|EXPERIMENTAL|Single Group|
62319699|NCT04024683||Serratus block group|Realization of a serratus block and para-vertebral catheter
62319700|NCT04024683||Control group|Realization of a para-vertebral catheter
62319701|NCT04390698|EXPERIMENTAL|nerve block+opioid-free general anesthesia|Paravertebral block with an ultrasound-guided technique; opioid-free general anesthesia
62319702|NCT04390698|SHAM_COMPARATOR|sham bock+opioid general anesthesia|Sham block by local infiltration at the same site of paravertebral block; opioid based general aneshesia
62480448|NCT01602939|EXPERIMENTAL|2CDA+IFN|
62688796|NCT00165308|EXPERIMENTAL|Tamoxifen|Single arm: Tamoxifen 20mg daily
62688797|NCT04127110|EXPERIMENTAL|Lorlatinib|"Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).~Lorlatinib will be taken continuously on a daily basis until disease progression, unacceptable toxicity, occurrence of any withdrawal criterion, whichever comes first."
61925775|NCT03300518|OTHER|pretreatment group|the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
61925776|NCT03300518|OTHER|control groups|In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
61925777|NCT03937869|OTHER|Single dose Solosec (secnidazole) 2g oral|Solosec 2 grams, oral
61925778|NCT05447039|ACTIVE_COMPARATOR|Montelukast treated|
61925779|NCT05447039|NO_INTERVENTION|Standard treatment|
61925780|NCT02013869|EXPERIMENTAL|Flow-I|"Wash in of desflurane (SupraneR) in an anaesthesia machine without below, a new technique that do not have abag/reservoir that is compressed but pushes the gas into the patient. This technique uses far less of fresh gas volume. Thus lower anaesthetic gas will be consumed per hour.~The primary outcome is the amount of anaesthetic consumed, the decrease in liquid desflurane (SupraneR) in the vaporiser of the ananesthetic machine. The vaporizer will be weighed before and after the anaesthetic to define the amount used."
61925781|NCT02013869|ACTIVE_COMPARATOR|Asys|"Wash in of desflurane (Suprane) in conventional anaesthesia machine Asys, with the anaesthesia machine Asys that has a bag/reservoir that is compressed for insufflation of gas into the patient, thus it is expected that more gas will be consumed per hour.~The primary outcome is the amount of anaesthetic consumed, the decrease in liquid desflurane (SupraneR) in the vaporiser of the ananesthetic machine. The vaporizer will be weighed before and after the anaesthetic to define the amount used."
61925782|NCT01496768|EXPERIMENTAL|Leucine|
61925783|NCT01496768|PLACEBO_COMPARATOR|Alanine|
61925784|NCT06659718||Oral semaglutide|Exposure group
61925785|NCT06659718||Sitagliptin|Reference group
61925786|NCT06594627|EXPERIMENTAL|Smart pillow group|There is one group that will receive an intervention: the utilization of a smart pillow to mitigate snoring issues and OSA symptoms.
62319703|NCT00122746|ACTIVE_COMPARATOR|Radiotherapy alone|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
62688798|NCT06426381|EXPERIMENTAL|There is therapeutic touch|Patients will be administered an Introduction Form and Spielberg State-Trait Anxiety Scale before surgery. The Vital Signs Record Form will be filled out on the patient's operating table. Then, therapeutic touch will be applied for 15-20 minutes during the surgery. After the procedure, the Vital Signs Record Form, Spielberg State Anxiety Scale and Perianesthesia Comfort Scale (PCS) will be administered.
62688799|NCT06426381|NO_INTERVENTION|No therapeutic touch|An Introduction Form and the Spielberg State-Trait Anxiety Scale will be administered to the patients. When you are taken to the operating table, a Vital Signs Record Form will be filled out. After the procedure is completed, the Vital Signs Record Form, Spielberg State Anxiety Scale and Perianesthesia Comfort Scale (PCS) will be administered.
62688800|NCT06601335|EXPERIMENTAL|AK117 in combination with AK112|
62688801|NCT06601335|ACTIVE_COMPARATOR|Placebo in combination with Pembrolizumab|
62688802|NCT06675175|EXPERIMENTAL|AZD4144|Participants will receive oral dose of AZD4144 for 28 days.
61925787|NCT05220631|EXPERIMENTAL|Cohort 1|Cohort 1 will start the intervention directly after randomization.
61925788|NCT05220631|ACTIVE_COMPARATOR|Cohort 2|Cohort 2 will serve as the control while cohort 1 is in the intervention stage. Cohort 2 will start the intervention after cohort 1 concludes the intervention.
61925789|NCT00797368|EXPERIMENTAL|Manual Therapy and Exercise|Manual Therapy and Exercise
61925790|NCT00797368|ACTIVE_COMPARATOR|Home Exercise|Home Exercise
62129500|NCT02627469|NO_INTERVENTION|Control|Common oral hygiene help administered by nursing staff
62129501|NCT02627469|EXPERIMENTAL|Intervention|Extended professional oral hygiene care Electric toothbrush (Oral-B Professional Care 7000) 1100 ppm sodium fluoride dentifrice (Zendium Classic, Opus Health Care AB/Zendium)
62319704|NCT00122746|EXPERIMENTAL|Radiotherapy plus Chemotherapy|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
62319705|NCT00524095|NO_INTERVENTION|1|standard of care
62319706|NCT00524095|EXPERIMENTAL|2|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
62688803|NCT06675175|PLACEBO_COMPARATOR|Placebo|Participants will receive oral dose of Placebo for 28 days.
62688804|NCT03208179|ACTIVE_COMPARATOR|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
62688805|NCT03208179|EXPERIMENTAL|IPTp-DP|Dihydroartemisinin-piperaquine \[3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days\] + placebo AZ at each scheduled antenatal visit
62480449|NCT01039363|EXPERIMENTAL|Vorinostat|Vorinostat combined with salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat maintenance
62480450|NCT05905640|NO_INTERVENTION|Control arm- Usual PrEP care pathway|At clinics that will serve as contemporaneous control clinics, eligible persons will receive PrEP according to the current client flow, which typically involves multiple room consultations. Quality improvement strategies will be promoted throughout the implementation period.
62480451|NCT05905640|OTHER|Intervention Arm- One Stop PrEP care pathway|In a one-stop arm, the number of client consultation rooms in the PrEP care pathway will be reduced to a single consultation room. All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider. Quality improvement strategies will be promoted throughout the implementation period.
62480452|NCT05821647|NO_INTERVENTION|Control group|"Objective to maintain a mean arterial blood pressure (MAP) above or equal to 65 mm Hg, as is standard care in out institution.~This is done using standard hemodynamic monitoring, which in our center consists of continuous arterial blood pressure monitoring and the pulse pressure variation parameter. The clinician will administer either fluids, inotropes, vasopressors, or a combination, or apply positional changes to maintain the set MAP threshold."
62688806|NCT03208179|EXPERIMENTAL|IPTp-DPAZ|Dihydroartemisinin-piperaquine \[3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days\] + AZ tablet \[1.5g over 3 days as 500mg per day\] at each scheduled antenatal visit.
62688807|NCT05634070|EXPERIMENTAL|Insertion of a custom-made 3D printed medical-grade polycaprolactone scaffold|Insertion of a custom-made 3D printed medical-grade polycaprolactone scaffold in the thorax region with autologous fat graft to camouflage pectus excavatum defect.
62688808|NCT05318378|EXPERIMENTAL|student|Twenty fifth-year medical students were asked to participate in the study
62688809|NCT05318378|ACTIVE_COMPARATOR|senior surgeon|As controls, we asked 3 independent board-certified orthopedic surgeons to participate in the study following the same conditions as described previously.
62688810|NCT02727699|EXPERIMENTAL|Xanamem™|Oral Xanamem™ capsules 10mg, to be administered once daily
62688811|NCT02727699|PLACEBO_COMPARATOR|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily
62688812|NCT06687915||Congenitally blind|Individuals with congenital visual impairment were included in this group.
62688813|NCT06687915||Healthy|Healthy sedentary individuals were included in this group.
62688814|NCT01903590|ACTIVE_COMPARATOR|Transvaginal Tape Surgery|Randomized 50 patients undergoing TVT
62688815|NCT01903590|EXPERIMENTAL|Transobturator tape surgery|Randomized 50 patients undergoing TOT
62688816|NCT02473302|PLACEBO_COMPARATOR|ham|160g per day during 4 days
62319707|NCT00524095|EXPERIMENTAL|3|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
62688817|NCT02473302|EXPERIMENTAL|ham + pomegranate extract|160g per day during 4 days
62688818|NCT02473302|EXPERIMENTAL|ham + tocopherol|160g per day during 4 days
62688819|NCT02473302|PLACEBO_COMPARATOR|rare sirloin steak|110g per day during 4 days
62688820|NCT02473302|EXPERIMENTAL|marinated rare sirloin steak|110g per day during 4 days
62688821|NCT02473302|EXPERIMENTAL|marinated cooked sirloin steak|110g per day during 4 days
62129502|NCT00854191|EXPERIMENTAL|1|4 half-day of simulator ERCP practice and usual training
62129503|NCT00854191|ACTIVE_COMPARATOR|2|Usual training
62129504|NCT03427021|EXPERIMENTAL|Arm A|will be treated with consistent exposure to oral ice
62319708|NCT05537324|EXPERIMENTAL|Brazil nut|50g Brazil nuts
62319709|NCT05537324|OTHER|Coconut|46g Coconut flakes
62319710|NCT03174860|EXPERIMENTAL|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.
62319711|NCT03174860|PLACEBO_COMPARATOR|Placebo|Placebo to be administered one hour before treatment.
62319712|NCT02052960|EXPERIMENTAL|CetuGEX™ plus chemotherapy|720 mg weekly administration
62319713|NCT02052960|ACTIVE_COMPARATOR|Cetuximab plus chemotherapy|250 mg/m2 weekly administration
62319714|NCT01395303||myocardial infarction|subjects with myocardial infarction in the Tromsø study end point registry
62319715|NCT01395303||type 2 diabetes|subjects with type 2 diabetes in the Tromsø study end point registry
62319716|NCT01395303||stroke|subjects with stroke in the Tromsø study end point registry
62319717|NCT01395303||fracture|subjects with fracture in the Tromsø study end point registry
62319718|NCT01395303||cancer|subjects with cancer in the Tromsø study end point registry
62319719|NCT01395303||death|subjects registered as dead in the Tromsø study end point registry
62319720|NCT01395303||aortic stenosis|subjects with aortic stenosis in the Tromsø study end point registry
62688822|NCT05961631||Positive Fluid Balance 500ml or more|Fluid Balance measured using Bio-electrical Impedance Analysis
62688823|NCT05961631||Fluid Balance 500ml or less|Fluid Balance measured using Bio-electrical Impedance Analysis
62688824|NCT04054882|EXPERIMENTAL|Sabin-IPV and DTaP|234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
62688825|NCT04054882|ACTIVE_COMPARATOR|Sabin-IPV only|234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
62688826|NCT04054882|ACTIVE_COMPARATOR|DTaP only|234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
62688827|NCT02180867|EXPERIMENTAL|Regimen A (pazopanib, chemoradiation)|See Regimen A Detailed Description.
62688828|NCT02180867|EXPERIMENTAL|Regimen B (chemoradiation)|See Regimen B Detailed Description.
62688829|NCT02180867|EXPERIMENTAL|Regimen C (pazopanib, radiation therapy)|"INDUCTION PHASE: Patients receive pazopanib PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 13-25. If applicable, patients undergo additional radiation therapy at week 13."
62688830|NCT02180867|EXPERIMENTAL|Regimen D (radiation therapy)|"INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: If applicable, patients undergo additional radiation therapy at week 13."
62688831|NCT04426513|ACTIVE_COMPARATOR|Only kinesiotherapy|Patients have only kinesiotherapy of hand without steroid anti-inflammatory drugs and magnetotherapy.
62688832|NCT04426513|EXPERIMENTAL|Kinesiotherapy with bipolar magnetic field|Patients have kinesiotherapy of hand and bipolar magnetic field. All patients without steroid anti-inflammatory drugs.
62688833|NCT04426513|EXPERIMENTAL|Kinesiotherapy with unipolar magnetic field|Patients have kinesiotherapy of hand and unipolar magnetic field. All patients without steroid anti-inflammatory drugs.
62688834|NCT04474301||Observational (survey administration)|Patients complete a survey over 10 minutes.
62688835|NCT01639690|EXPERIMENTAL|Autologous CD34+ cells transduced with TNS9.3.55|An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
62688836|NCT03719300|EXPERIMENTAL|Single Arm BC-819|inodiftagene vixteplasmid
62688837|NCT05845892|EXPERIMENTAL|Intervention|"Patients will be given written and oral consent by explaining the purpose of the study. Patients with fistula and non-grafted arms will be asked to fill out data collection forms at the first interview. Patients will then be asked to squeeze the stress ball 15 minutes before the start of hemodialysis treatment and for 15 minutes during hemodialysis treatment. This treatment will be performed during (nine) hemodialysis treatments. After the last session, data collection forms will be filled out again.~Use of stress Ball~1) place a stress ball in one hand (which hand will be left to the patients' wishes.) 2.squeeze the ball in your hand for 2-3 seconds after receiving it and then loosen it.~3.perform this application for a total of 30 minutes before and during hemodialysis treatment."
62688838|NCT05845892|NO_INTERVENTION|Control|"No intervention will be given to the control group other than standard treatment. Data collection forms will be completed before the first dialysis session and after the eighth session.~Before the first dialysis session and after the ninth session, the individual Introduction form, the Visual Analog scale (VAS) for stress level, the Beck anxiety scale and the hemodialysis comfort scale will be filled out."
62688839|NCT01139970|EXPERIMENTAL|Treatment (temozolomide and veliparib)|"Patients receive veliparib PO QD on day 1 and twice daily on days 4-12 and temozolomide PO QD on days 3-9 of course 1.~Beginning at least 30 days after the start of treatment, patients receive veliparib PO BID on days 1-8 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients achieving complete remission receive 5 more courses in the absence of disease progression or unacceptable toxicity."
62688840|NCT06098352|EXPERIMENTAL|PEBL Continuous Performance Task|Participants will take the PEBL Continuous Performance Task, a 14 minute attention test requiring participants to press the space bar when certain letters are shown on the screen.
62688841|NCT06110910||prospective cohort|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
62688842|NCT06110910||retrospective cohort|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
62688843|NCT06110910||ambispective cohort|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
62129505|NCT03427021|ACTIVE_COMPARATOR|Arm B|Will not be treated with consistent exposure to oral ice.
62319721|NCT01395303||control group|randomly selected controls from the Tromsø study
62688844|NCT05360225||Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The KRAS System (extraction kit, analytical kit, instrument and software) will be used to test FFPE biopsy (resected and core needle biopsy \[CNB\]/fine needle aspiration \[FNA\]) tumour tissue from NSCLC patients to establish KRAS G12C mutation status. This will be determined using the investigational device at Q2 Solutions Laboratories.
62688845|NCT05019963|ACTIVE_COMPARATOR|Usual Care|"Assessment. Participants randomized to the control arm will be offered assessment by a clinician, guided by the WHO Post COVID-19 case report form. This is a clinical tool developed by WHO to guide and document the sequelae of COVID-19 and to ensure that clinical and rehabilitation needs are identified.~Investigation. Clinician judgement will be used to decide on further testing needed for clinical care.~Management. Control participants will receive a rehabilitation plan developed with their health professional that will be implemented in the eight weeks after their initial consultation (baseline visit). The implementation will involve face to face or virtual care from a registered health professional provided by the clinic or research staff. This may be a combination of, but not limited to, occupational therapy, physical therapy and/or social work/counselling. The frequency of treatment visits will depend on the individual treatment plan after assessment."
62688846|NCT05019963|EXPERIMENTAL|Electronic Case Management plus Usual Care|Participants randomized to the experimental arm will receive assessment, investigation and management as the Active Comparator Arm plus access to an electronic case management platform - NexJ Connected Wellness (https://nexjhealth.com/) which complements the rehabilitation plan. This would include for example setting targets for activity that would be monitored with NexJ; educational materials; and support with medication adherence by reminders. The NexJ platform will include the following sections: Trusted Educational Content (Health Library); Symptom Tracking, Goal Setting, Community Forums and Reporting.
62688847|NCT04076657|EXPERIMENTAL|Brock String|Participants will receive instruction on Brock String therapy after first clinic visit (\<48 hours post) injury, and will complete home therapy exercise twice daily
62688848|NCT04076657|ACTIVE_COMPARATOR|Standard of Care|Participants will receive standard of care (i.e., no Brock String therapy within the first week post injury) but will be informed they will receive any therapy deemed necessary at follow up visit 7-10 days post injury, consistent with standard of care
62688849|NCT06571981||Patients with viral hepatitis|Every outpatient referred to the radiology department by a prescriber for abdominal US in the context of viral hepatitis
62129506|NCT00459602||Laparoscopic incisional hernia repair|Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh.
62129507|NCT00620997|EXPERIMENTAL|1|"patients randomized to 0.05% Proparacaine drops on a PRN basis for up to 7 days~Acetaminophen with Codeine for breakthrough pain~topical Gatifloxacin drops"
62319722|NCT05575713||Major depressive disorder|Patients diagnosed with severe depressive episode according to the diagnostic and Statistical Manual of mental disorders, 5th Edition (DSM-V);
62480453|NCT05821647|EXPERIMENTAL|Additional HPI guided treatment|"Objective to maintain a mean arterial blood pressure (MAP) above or equal to 65 mm Hg, as is standard care in out institution.~This is done using standard hemodynamic monitoring (as described for the control group) but is assisted by the Hypotension Prediction Index (HPI). This parameter is made available to the clinicians with the HemoSphere Advanced Monitoring Platform (HemoSphere) and is used to initiate treatment when the HPI values is ≥ 75.~It also provides additional advanced hemodynamic variables (e.g. cardiac output, systemic vascular resistance). The treating clinicians are trained to use these variables and are provided with a diagnostic flowchart to determine the cause (preload, contractility and afterload) of the upcoming hypotensive (MAP \< 65 mmHg) event. Timing of treatment and choice of treatment is then left to the discretion of the attending clinician."
62480454|NCT04784338|EXPERIMENTAL|Virtual shared teaching kitchen program|Participants will participate in virtual shared medical appointments that utilize the teaching kitchen
62319723|NCT05575713||healthy volunteer|Person who did not meet the DSM-V diagnosis of any mental disease, had no family history of psychiatric disease, and had no history of suicidal behavior.
62319724|NCT01556945|EXPERIMENTAL|Group A : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the GlaxoSmithKline (GSK) adjuvant system, number 2 (AS02) and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant concomitantly as separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
62319725|NCT01556945|EXPERIMENTAL|Group B : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
62319726|NCT01556945|EXPERIMENTAL|Group C: FMP1/AS02 + AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with adjuvant AS02 adjuvant alone at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
62319727|NCT01556945|EXPERIMENTAL|Group D : RTS,S/AS02 + AS02|RTS,S malaria vaccine given with the adjuvant AS02 and an adjuvant AS02 alone concomitantly at separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
62319728|NCT01556945|PLACEBO_COMPARATOR|Control cohort|Infectivity controls (unvaccinated). Non-randomized infectivity controls were recruited specifically for the malaria challenge phase of the trial.
62319729|NCT03332667|EXPERIMENTAL|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
62339733|NCT04158089|NO_INTERVENTION|No intervention|"Participants in the No intervention group will receive treatment (e.g., prenatal care) as usual."
62688850|NCT04680208||Planned ICU admission|Cases who were planned for postoperative ICU admission at the time of preanesthetic check up
62129508|NCT00620997|PLACEBO_COMPARATOR|2|"placebo drops on a PRN basis for up to 7 days post injury~Acetaminophen with Codeine for breakthrough pain~Gatifloxacin drops"
62129509|NCT03850613|EXPERIMENTAL|Intervention arm|Participants in the intervention arm download the E-painting mobile app and use this app to make their own painting.
62688851|NCT04680208||Unplanned ICU admission|Cases who got admitted to ICU postoperatively without anticipation
62688852|NCT06199752|ACTIVE_COMPARATOR|Placebo|Placebo consisted of identical capsules of powdered glucose polymer
62129510|NCT01812096|EXPERIMENTAL|the pharmacokinetic of bortezomib|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of subcutaneous administration of bortezomib
61925791|NCT05570201|EXPERIMENTAL|Experimental Group|By visiting the women who met the research criteria, the purpose of the study was explained and their written informed consent was obtained. This study was conducted in two sessions using pre- and post-tests. The Personal Information Form, the SFQ, and the HADS were filled out using the face-to-face interview method by the researcher for the women included in the music and training on the day of their hospitalization, which lasted for 30-45 minutes.
61925792|NCT02886689||1|patients will be those receiving any biotherapy
61925793|NCT02886689||2|patients will be those not receiving biotherapy : non indication, refusal, contraindication.
61925794|NCT01197729||STEMI|(ST-Elevation myocardial infarction)
61925795|NCT01197729||NSTEMI|Non-ST-Elevation myocardial infarction
61925796|NCT03458793|EXPERIMENTAL|The experimental group|The experimental group will take part in the 12 week intervention after randomisation consisting of group walking and educational workshops performed once weekly for up to 90 minutes in total for each session.
61925797|NCT03458793|NO_INTERVENTION|The control group|The control group will be a wait-listed arm that will be offered an intervention at 12 weeks after the randomisation (the delayed intervention).
61925798|NCT02701920||NICU infants and hat|Newborn infants of any gestation on the neonatal intensive care unit (NICU).
61925799|NCT02701920||NICU infants and sensor|Newborn infants of any gestation requiring heart rate monitoring on the neonatal intensive care unit.
61925800|NCT02701920||Newborns and surgical delivery|Well term newborn infants following birth by cesarean section.
61925801|NCT02701920||Newborns needing stabilisation|Newborn infants requiring resuscitation or stabilisation following birth.
61925802|NCT02701920||Parental feedback|Parental feedback of babies recruited into HeartLight will be sought.
61925803|NCT02701920||Healthcare provider feedback|Healthcare professionals caring for babies recruited into HeartLight will have their feedback on the device sought.
61925804|NCT01467583|EXPERIMENTAL|Renal failure on intermittent dialysis|These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
61925805|NCT01467583|EXPERIMENTAL|Renal failure-renal replacement therapy|These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
61925806|NCT01467583|EXPERIMENTAL|Renal failure, not on dialysis|These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
61925807|NCT04457973|EXPERIMENTAL|Active tDCS|
61925808|NCT04457973|PLACEBO_COMPARATOR|Sham tDCS|
61925809|NCT06034327|EXPERIMENTAL|Test Arm 1|Single vision, impact-resistant spectacle lenses
61925810|NCT06034327|OTHER|Test Arm 2|Single vision, impact-resistant spectacle lenses
61925811|NCT03071198|EXPERIMENTAL|Preoperative neoadjuvant CT|Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
61925812|NCT03071198|EXPERIMENTAL|Preoperative neoadjuvant CT-RCT|Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
61925813|NCT03071198|ACTIVE_COMPARATOR|Concurrent chemo-radiotherapy|Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
61925814|NCT05834673|OTHER|Usual Care Model|"Usual care arm :~The GPs will be educated on the ESC guidelines and Guideline Directed Management therapy (GDMT) Inclisiran is available for this arm"
62129511|NCT01812096|ACTIVE_COMPARATOR|Intravenous|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of intravenous administration of bortezomib
61925815|NCT05834673|OTHER|New Model of Care|"Model of care arm The GPs will be educated on the ESC guidelines and Guideline Directed Management therapy (GDMT) The Participants enrolled via these sites arm will be getting receive monthly SMS messages with regards to regarding cardiovascular health and appointment reminders (low touch engagement nudges) In addition, Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.~Inclisiran is available for this arm."
62480455|NCT06742918|ACTIVE_COMPARATOR|Syrup SBM|A Unani formulation which was used since many year to resolve the urinary symptoms, and is described in Unani and Ayurveda Books. This group was designed to observe its antimicrobial effects on Uropathogens
62688853|NCT06199752|PLACEBO_COMPARATOR|Synbiotics group|probiotic agent 25 Billion CFU (Nowfoods, USA), + Inulin capsules 1000mg two capsules once daily. Herbamama USA
62480456|NCT06742918|EXPERIMENTAL|Tablet HBR is Aqueous extract of Berberis.|Group II was given Tablet HBR (Aqueous extract Berberis). In a literature search it was found that Berberis was very effective against Uropathogens, especially E.coli.
62480457|NCT06742918|EXPERIMENTAL|Group III was given the combination of Tablet HBR and Syrup SBM.|The study was designed to identify the efficacy of the combination of the two medicines i.e. Tablet HBR and Syrup SBM, as HBR is a good antimicrobial aqueous extract and Syrup SBM is a very efficacious diuretic medicine. therefore, the combined effects were observed
61925816|NCT04707326||DTG based switchers to DTG/3TC|HIVRNA suppressed HIV patients who switched to DTG/3TC
62129512|NCT00374192|EXPERIMENTAL|1|Eszopiclone
62129513|NCT00374192|PLACEBO_COMPARATOR|2|Placebo
62129514|NCT01969981||PICC placement|
62129515|NCT01636687|PLACEBO_COMPARATOR|Placebo|Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
62480458|NCT06742918|PLACEBO_COMPARATOR|Placebo|Group IV received placebo.
62129516|NCT01636687|EXPERIMENTAL|Secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
62129517|NCT01636687|EXPERIMENTAL|Secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.
62129518|NCT02713906|EXPERIMENTAL|X-Ray Knee Guide group|Total knee arthroplasy using Materialise X-Ray Knee Guides
62129519|NCT05032261||Group 1: surviving Patients|Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
62129520|NCT05032261||Group 2: Deceased patients|Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
62129521|NCT03457948|EXPERIMENTAL|Group I [pembrolizumab, 177Lu DOTATATE]|Patients will be treated with pembrolizumab and intravenous peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE, Lutathera®) for up to four (4) sessions. Patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index \> 20% (well-differentiated grade 3) and any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor \< 75%. Patients who achieve progressive or stable disease response after cycle 4 may receive an additional 4 cycles of pembrolizumab and lutetium Lu-177 DOTATATE in the absence of disease progression or unacceptable toxicity and pembrolizumab for up to 35 cycles.
62129522|NCT03457948|EXPERIMENTAL|Group II [pembrolizumab, TAE] (CLOSED)|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have \< 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
62480459|NCT06729385||Obvious group|Patients with large artery atherosclerotic ischemic stroke, presenting 7 to 30 days after onset, and who have not received reperfusion therapy.
62480460|NCT05489289|ACTIVE_COMPARATOR|AK104|AK104 IV every three weeks
62129523|NCT03457948|EXPERIMENTAL|Group III [pembrolizumab, yttrium-90 microsphere RE] (CLOSED)|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have \< 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere Radio Embolization (RE) 3-15 days following the first dose of pembrolizumab.
62129524|NCT04223388|EXPERIMENTAL|Probiotic|
62129525|NCT04223388|PLACEBO_COMPARATOR|Placebo|
62319730|NCT03332667|EXPERIMENTAL|131I-MIBG with Dinutuximab and Vorinostat|Patients will receive vorinostat on days 0-13. 131I-MIBG will be received on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
62319731|NCT03130101|OTHER|80% basal insulin reduction|
62688854|NCT06199752|PLACEBO_COMPARATOR|Probiotics group|probiotic agent 25 Billion CFU (Nowfoods, USA)
62319732|NCT03130101|OTHER|50% basal insulin reduction|
62319733|NCT03130101|OTHER|100% basal insulin reduction|
62319734|NCT04528082|EXPERIMENTAL|Apremilast|Participants will receive apremilast orally in the double-blind 12 week treatment phase. Then the participants will continue to receive apremilast in the active 40 weeks treatment phase.
62480461|NCT05489289|PLACEBO_COMPARATOR|placebo|Placebo IV every three weeks
62688855|NCT04642209||Aggregometry|surgical timing will be guided by the results obtained by aggregometry
61925817|NCT04707326||DTG based triple drug cART|Matched HIVRNA suppressed patients who remained on triple drug DTG based cART
62688856|NCT03999073||Subjects with coarctation|
62688857|NCT03999073||Controls|
62319735|NCT04528082|PLACEBO_COMPARATOR|Placebo to Apremilast|Participants will receive the matching placebo orally in the double-blind 12 week treatment phase. Then the participants will receive apremilast in the active 40 weeks treatment phase.
62319736|NCT00722592|EXPERIMENTAL|Vintafolide + PLD|Participants receive vintafolide 2.5 mg intravenous (IV) bolus on Days 1, 3, 5, 15, 17, and 19 and Pegylated Liposomal Doxorubicin (PLD) weight-based dose, IV on Day 1 of each 4-week cycle.
62319737|NCT00722592|ACTIVE_COMPARATOR|PLD Alone|Participants receive PLD on Day 1 of each 4-week cycle.
62319738|NCT05015400|EXPERIMENTAL|Fluid Increase|The increased fluid intervention arm will begin on day 2 after the onset of bleeding (day 1) of their phase 1 menses through day 5. For the increased fluid intake intervention, participants will a) consume an additional 64 oz (1.89 L) of plain water only on top of habitual fluid intake and b) aim to at least urinate 5 times per day.
62319739|NCT05015400|NO_INTERVENTION|Fluid Habitual|The fluid habitual non-intervention arm will a) maintain normal fluid intake volume and beverage choices and a) urination frequency.
62319740|NCT01889810|ACTIVE_COMPARATOR|Vitamin D3 supplementation|Patients will take 3000IU (75 µg) Vitamin D3 supplementation per day for a period of 26 weeks.
62319741|NCT01889810|PLACEBO_COMPARATOR|Placebo|Placebo group
62319742|NCT00461266|EXPERIMENTAL|1|
62319743|NCT00461266|ACTIVE_COMPARATOR|2|
62319744|NCT01444521|EXPERIMENTAL|single-arm Irinotecan-Cisplatin|
62319745|NCT04739124||Diabetic patients|Patients presenting type 1 or type 2 diabetes, eligible for the prescription of Freestyle Libre
62319746|NCT04739124||Caregivers|Caregiver caring for diabetic patients and practicing therapeutic education on a regular basis
62319747|NCT04825093|EXPERIMENTAL|Intervention group|Women allocated to this group will be supplemented with 1,000 UI of vitamin D3.
61925818|NCT04707326||non-DTG based switchers to DTG/3TC|
62129526|NCT01840826|EXPERIMENTAL|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 \& 5.
62319748|NCT04825093|ACTIVE_COMPARATOR|Control group|The control group will consist of pregnant women supplemented with 400 UI of vitamin D3.
62480462|NCT05884320|EXPERIMENTAL|Cohort 1: ACC|Paritcipants will receive sacituzumab govitecan by vein on Days 1 and 8 of each cycle. The first dose will be given over about 3 hours. All other doses will be given over about 1-2 hours. Premedication for prevention of infusion reactions will be administered prior to each sacituzumab govitecan infusion.
61925819|NCT04707326||non-DTG based triple drug cART|Matched HIVRNA suppressed patients who remained on triple drug non-DTG based cART
61925820|NCT04638192|EXPERIMENTAL|subject-specific tACS|Constant current (1mA) will be applied for 20min at subject-specific stimulation frequency and latency
61925821|NCT04638192|EXPERIMENTAL|standard tACS|Constant current (1mA) will be applied for 20min at 20Hz with a fixed 25ms latency
61925822|NCT04638192|SHAM_COMPARATOR|Sham tACS|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect
62129527|NCT01840826|NO_INTERVENTION|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
62129528|NCT04775654|EXPERIMENTAL|Supplement|Participants consume 455mg of blackcurrant extract standardized to contain 50mg anthocyanins in a 2-capsule dose for 70 days.
62129529|NCT04775654|PLACEBO_COMPARATOR|Placebo|Participants consume 2 capsules of microcrystalline cellulose for 70 days.
62129530|NCT05541341||Acute Lymphoblastic Leukemia (ALL)|Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion
62129531|NCT05541341||Diffuse Large B-cell Lymphoma (DLBCL)|Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion
62129532|NCT05541341||Follicular Lymphoma (FL)|Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion.
62129533|NCT00392054|EXPERIMENTAL|Catheter Ablation|Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
62688858|NCT06183593|EXPERIMENTAL|Radiofrequency-evoked potentials (RFEPs)|The application of RF stimuli will be carried out using an adapted electrocoagulation device (ECD). These devices have several types of applicators, depending on the type of stimulation to be performed. In the bipolar mode, the applicator consists of a small clamp whose tips constitute the active and return electrodes, and the electric current flows only through the tissue captured between the two tips of the clamp. In the unipolar mode, the active electrode is an interchangeable tip with a variable surface (resembling for example a blade or a needle), and the return electrode is a metal plate in contact with another part of the volunteer's body. In this case, the current also flows from the active electrode to the return electrode, but over a considerably longer path. In both cases the physiological effect is similar: the stimulation elicits superficial, localized and limited heating of the tissue in the vicinity of the active electrode.
62688859|NCT06183593|EXPERIMENTAL|Pinprick evoked potentials|An automatic stimulator with a section of approximately 0.35 mm in diameter and with a blunt tip was developed to apply this type of stimulus. This stimulator has a calibrated spring, which allows force to be gradually applied, while providing a safety margin to avoid accidents during tests. This allows two types of measurements to be made depending on the speed with which the stimulus is applied.
62688860|NCT02202265|ACTIVE_COMPARATOR|Control diet (standard dietary)|Patients will receive a control diet based on standard dietary guidelines
62688861|NCT02202265|EXPERIMENTAL|Olive oil (30ml a day)|Patients will receive a control diet based on standard dietary guidelines + 30ml of olive oil a day
61925823|NCT00055471|EXPERIMENTAL|ZD4054 10 mg|1 x 10 mg oral tablets once daily
61925824|NCT00055471|EXPERIMENTAL|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
61925825|NCT00055471|EXPERIMENTAL|ZD4054 22.5 mg|2 x 10 mg + 1 x 2.5 mg oral tablets once daily
61925826|NCT05940324|EXPERIMENTAL|Ketamine + Naltrexone|"OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion.~Oral naltrexone 50 mg will be administered before the infusion."
61925827|NCT05940324|PLACEBO_COMPARATOR|Ketamine + Placebo|"OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion.~An oral inactive placebo will be administered before the infusion."
61925828|NCT05940324|NO_INTERVENTION|Healthy Volunteers|Healthy volunteers will have one fMRI scan visit.
62129534|NCT00392054|ACTIVE_COMPARATOR|Antiarrhythmic Drug Therapy|Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation
62129535|NCT03778242|ACTIVE_COMPARATOR|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
62129536|NCT03778242|PLACEBO_COMPARATOR|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
62129537|NCT03675256|EXPERIMENTAL|Arm 1|immediate Cervarix, delayed MenVeo vaccine
62129538|NCT03675256|EXPERIMENTAL|Arm 2|immediate Gardasil 9, delayed MenVeo vaccine
62129539|NCT03675256|ACTIVE_COMPARATOR|Arm 3|immediate MenVeo, delayed Gardasil 9 vaccine
62129540|NCT06176482|EXPERIMENTAL|Patients enrolled and surgically treated|
62129541|NCT06394284|EXPERIMENTAL|MDMA Assisted Therapy|This intensive therapy is comprised of 16 sessions of therapy with two therapists including three long sessions of MDMA assisted therapy followed by an overnight stay and then 3 weekly integration sessions.
62129542|NCT06394284|EXPERIMENTAL|SEA-IT|This intensive trauma focused therapy is comprised of 16 sessions of therapy with two therapists including three long sessions of between 6 to 8 hours followed by an overnight stay and then 3 weekly integration sessions. The therapy is modeled on components of Somatic Experiencing, Acceptance and Commitment Therapy and the psychedelic assisted therapy protocols.
62319749|NCT01775488|EXPERIMENTAL|Vortx Rx - Histotripsy BPH Device|The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
62688862|NCT02202265|EXPERIMENTAL|Nuts (30g a day)|Patients will receive a control diet based on standard dietary guidelines plus 30g of nuts a day
62688863|NCT01030809|NO_INTERVENTION|Usual Care practice|Patients managed according to usual care practices
62688864|NCT01030809|ACTIVE_COMPARATOR|Treatment Algorithm|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
62688865|NCT06506513|ACTIVE_COMPARATOR|control group|in this control group, patients will perform non-cardiovascular non-intensity training (stretching, meditation).
62129543|NCT04108923|ACTIVE_COMPARATOR|Ligasure ( group A)|
62129544|NCT04108923|ACTIVE_COMPARATOR|Conventional vessel ligation (group B)|
62129545|NCT03205436|EXPERIMENTAL|Graft|Affinity human amniotic membrane
62129546|NCT00158782|EXPERIMENTAL|Cohort 1|Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.
62129547|NCT00158782|EXPERIMENTAL|Cohort 2|Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.
62129548|NCT00158782|EXPERIMENTAL|Cohort 3|Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.
62319750|NCT03806595|EXPERIMENTAL|Intranasal lidocaine|1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
62319751|NCT03806595|PLACEBO_COMPARATOR|Intranasal normal saline|1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
61925829|NCT06630247|EXPERIMENTAL|Dose Escalation XL495|Group(s) of participants with advanced metastatic tumors who will receive increasing doses of XL495.
61925830|NCT06630247|EXPERIMENTAL|Dose Finding XL495 + ADC cytotoxic agents|Group(s) of participants with advanced metastatic tumors who will receive XL495 and Antibody drug conjugate (ADC) cytotoxic agents together at increasing doses.
61925831|NCT06630247|EXPERIMENTAL|Expansion XL495 + ADC cytotoxic agents|Group(s) of participants with urothelial cancer who will receive XL495 and ADC cytotoxic agents at the recommended dosage(s) of expansion (RDE \[s\]) determined during the dose-escalation and dose-finding stages.
61925832|NCT01210573||Device adjustment|Advanced or suspected advanced heart failure. Most are anticipated to have severely depressed ejection fraction (\<30% and typically \<20%), but patients with preserved ejection fraction and either hypertrophy or restrictive cardiomyopathy will also be eligible. Patients pulmonary hypertension, on any therapy (other than diuretics alone), are also felt to be at high risk of developing right heart failure and may also be included. Patients who have already undergone LVAD or cardiac transplant are also considered to have advanced heart failure and are eligible to participate, regardless of the severity of their symptoms at the time of enrollment.
61925833|NCT06631079|EXPERIMENTAL|NECVAX-NEO1|Oral DNA Vaccine
61925834|NCT03920618|ACTIVE_COMPARATOR|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
61925835|NCT03920618|ACTIVE_COMPARATOR|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
61925836|NCT03920618|EXPERIMENTAL|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
61925837|NCT03370289|EXPERIMENTAL|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
61925838|NCT05120349|EXPERIMENTAL|Osimertinib|Osimertinib 80mg, orally, once daily (Dose may be reduced to 40 mg once daily if required at the discretion of the investigator)
61925839|NCT05120349|PLACEBO_COMPARATOR|Placebo|Matching placebo for osimertinib, orally, once daily
61925840|NCT05128773|EXPERIMENTAL|Amcenestrant with tamoxifen-matching placebo arm|Amcenestrant dose, once daily, continuously. Tamoxifen-matching placebo, once daily, continuously.
61925841|NCT05128773|ACTIVE_COMPARATOR|Tamoxifen with amcenestrant-matching placebo|Tamoxifen dose, once daily, continuously. Amcenestrant-matching placebo, once daily, continuously.
61925842|NCT06505629|EXPERIMENTAL|the online Paired Emotion Reading Intervention (PERI)|
61925843|NCT06505629|ACTIVE_COMPARATOR|the online Paired General Reading Intervention (PGRI)|
61925844|NCT06505629|NO_INTERVENTION|Care as Usual (CAU)|
61925845|NCT00620789|ACTIVE_COMPARATOR|1|Cognitive-Behavior Therapy for insomnia (CBT-I) + Antidepressant medication
62129549|NCT00158782|EXPERIMENTAL|Cohort 4|Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.
62129550|NCT00158782|EXPERIMENTAL|Cohort 5|Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.
61925846|NCT00620789|PLACEBO_COMPARATOR|2|Cognitive Behavior Therapy for Insomnia (CBT-I) + placebo medication
61925847|NCT00620789|SHAM_COMPARATOR|3|Antidepressant medication + Sleep Hygiene Control (SH)
62129551|NCT00158782|EXPERIMENTAL|Cohort 6|Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.
62129552|NCT00158782|EXPERIMENTAL|Cohort 7|Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.
61925848|NCT04991103|EXPERIMENTAL|Induction - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DaraVRD)|Quadruplet therapy with DaraVRD in the treatment of newly diagnosed myeloma
61925849|NCT05479773|OTHER|Group A|"Treatment order:~1) Standard NIV mask ; 2) Lumena mask without suction ; 3) Lumena mask with suction."
61925850|NCT05479773|OTHER|Group B|"Treatment order:~1) Standard NIV mask ; 2) Lumena mask with suction ; 3) Lumena mask without suction."
62129553|NCT00158782|EXPERIMENTAL|Cohort 8|Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.
62129554|NCT00158782|EXPERIMENTAL|Cohort 9|Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.
61925851|NCT05479773|OTHER|Group C|"Treatment order:~1) Lumena mask without suction ; 2) Lumena mask with suction ; 3) Standard NIV mask."
61925852|NCT05479773|OTHER|Group D|"Treatment order:~1) Lumena mask with suction ; 2) Lumena mask without suction ; 3) Standard NIV mask."
61925853|NCT02500407|EXPERIMENTAL|Dose Escalation|Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
61925854|NCT02500407|EXPERIMENTAL|Dose Expansion|Participants will receive BTCT4465A (Mosunetuzumab) as a single-agent or in combination with atezolizumab.
61925855|NCT00573365|EXPERIMENTAL|Treatment|LED treatment with Gentlewaves Select™ handheld high energy LED array 5 to 10 minutes before each radiation treatment and again 5-10 minutes after each radiation treatment
61925856|NCT00573365|OTHER|Control|Radiation only
61925857|NCT04824183|EXPERIMENTAL|Music intervention|Music intervention that begins with patient education on WhatsApp will be delivered to participants 3 times within 48 hours before surgery followed by face-to-face monitoring of intervention usage.
61925858|NCT04824183|NO_INTERVENTION|Usual care|Participants in the control group will receive preoperative pain education via a one-on-one WhatsApp chat. The pain education will focus mainly on the type of pain to expect after surgery, how to report pain and how to request pain medication. MI will not be introduced to the participants in this group neither will there be any phone call for psychological support. Other preoperative care and postoperative care will be provided according to the hospital and ward practices.
61925859|NCT06706752|EXPERIMENTAL|Treatment Group|
61925860|NCT06706752|PLACEBO_COMPARATOR|Placebo Group|
61925861|NCT02761291|EXPERIMENTAL|gemcitabine dose escalation|In three combined drugs used in nasopharyngeal carcinoma, the valproic acid and valganciclovir administration will be followed by indication to find the maximum tolerance dose of gemcitabine.
61925862|NCT01756300|EXPERIMENTAL|Resistant Hypertension|The catheter-based (device: Celsius® ThermoCool® RD) renal denervation will serve to treat resistant hypertension.
61925863|NCT06668142|EXPERIMENTAL|A single-arm open label pilot study|A single-arm open label pilot study observing intraoperative and postoperative outcomes of the Beacon Platform in HoLEP.
62129555|NCT00158782|EXPERIMENTAL|Cohort 10|Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.
61925864|NCT00679744|ACTIVE_COMPARATOR|4 dose levels|Pyrimethamine at 6.25, 12.5, 25 and 37.5 mg/day will be evaluated sequentially, starting from 6.25 mg/day. Escalation from 6.25 mg/day to 12.5 mg/day, and from 12.5 mg/day to 25 mg/day, will not perform until all patients in the previous dose cohort have been treated for 4 weeks and until results obtained 4 weeks after treatment initiation do not reveal toxicity. Additionally, escalation from 25 mg/day to 37.5 mg/day will not perform until all patients in the 25-mg/day cohort have been treated for 8 weeks, and until results obtained 4 weeks after the 8-week treatment do not reveal toxicity. Dose escalation is considered complete, if 2 patients experience a Grade 3 Adverse Event (AE) or if 1 patient experiences a Grade 4 AE at a particular cohort.
61925865|NCT04448873|ACTIVE_COMPARATOR|Maintenance treatment group|After at least 2 years of remission of KHE, the participant receives sirolimus as usual. The serum concentration is supposed to be 5-7 ng/ml. If the effect or side effects of sirolimus require discontinuation, it is allowed to modify intervention, and if so, the patient stays in the maintenance group.
62129556|NCT05155917|EXPERIMENTAL|basal insulin and insulin pump|Subjects in the intervention group received insulin glargine sc (0.25 U/kg body weight) within 6 h of initiation of iv insulin infusion, as close to initiation of iv insulin as possible.
62688866|NCT06506513|ACTIVE_COMPARATOR|moderate-intensity low interval training group|In this group, patients will perform moderate-intensity low interval training.
62688867|NCT06506513|ACTIVE_COMPARATOR|high-intensity interval training|In this group, patients willp erform high-intensity interval training.
62688868|NCT03160573|ACTIVE_COMPARATOR|Test-Unflavored Rinse then Placebo Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
61925866|NCT04448873|EXPERIMENTAL|Guided discontinuation group|"After at least 2 years of remission of KHE, the discontinuation measurement should be guided by the clinician with the following principles:~1. 10% monthly reduction of the previous dose at most.~2. At least 5 half-lives between each reduction (2 weeks).~3. Blood concentration should be monitored monthly. Adjustment can be suggested according to the linear relationship between the dose and the blood concentration.~4. At least 6 months for the duration of guided discontinuation.~5. Regular assessments and evaluations should be done.~If the condition relapses or worsens during this process, dose of sirolimus should be adjusted to the previously effective dose. After a 3-month stabilization phase, 5% monthly reduction of the previous dose could be considered."
61925867|NCT03868124|EXPERIMENTAL|Implant Group 1|G2-TR intraocular implant containing Travoprost 75 mcg with high elution rate, plus postoperative placebo eye drops.
61925868|NCT03868124|EXPERIMENTAL|Implant Group 2|G2-TR intraocular implant containing Travoprost 75 mcg with low elution rate, plus postoperative placebo eye drops.
61925869|NCT03868124|ACTIVE_COMPARATOR|Control Group|Sham surgery + active-comparator eye drops
61925870|NCT05553951|EXPERIMENTAL|Interventions group|will receive systematic and structured nursing supervison about their adherence
62129557|NCT05155917|NO_INTERVENTION|insulin pump|Patients in the control group did not receive placebo injections.
62319752|NCT00634543|EXPERIMENTAL|Tramadol hydrochloride (HCl)/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3, 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
62319753|NCT00634543|ACTIVE_COMPARATOR|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
62319754|NCT03699982|EXPERIMENTAL|Cystic fibrosis patients|Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
62319755|NCT06634901|ACTIVE_COMPARATOR|Health Literacy Educational Session- Control Group Testing|Participants will receive pre- and post-testing at the same interval as the experimental arm. Rather than receiving the educational session intervention, participants will have lunch during the interval. The comparator group will receive the intervention after all primary and secondary outcome measures have been completed.
62319756|NCT06634901|EXPERIMENTAL|Health Literacy Educational Session- Experimental Group Testing|Participants are divided into groups of 6-10 adolescents each to receive the educational session intervention, with those aged 12-15 in different groups from those aged 16-18 due to potential differences in question focus.
62480463|NCT05884320|EXPERIMENTAL|Cohort 2: Non-ACC|Paritcipants will receive sacituzumab govitecan by vein on Days 1 and 8 of each cycle. The first dose will be given over about 3 hours. All other doses will be given over about 1-2 hours. Premedication for prevention of infusion reactions will be administered prior to each sacituzumab govitecan infusion.
61925871|NCT05553951|PLACEBO_COMPARATOR|Control group|Will receive usual care
62129558|NCT02929147|EXPERIMENTAL|Morphine 1 mg|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
62129559|NCT02929147|EXPERIMENTAL|Morphine 0.5|In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
62129560|NCT02929147|ACTIVE_COMPARATOR|Dexketoprofen & Placebo|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
62129561|NCT05390749|EXPERIMENTAL|POR-ROMTX|The experimental arm will be treated with 4 cycles of POR regimen （Pomalidomide 4mg d1-d14, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle). The response will be evaluated every 2 cycles. The patients with PD will drop out of the study.Patients with CR/PR/SD after 4 cycles of POR treatment will be treated with 2 cycles of RO-MTX regimen（methotrexate 3.5g/m2 civ d1, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle).
62129562|NCT05035446|EXPERIMENTAL|single-incision plus one-port laparoscopic surgery(SILS + 1)|It requires an auxiliary small incision and one more port to perform laparoscopic gastrectomy
62129563|NCT05035446|OTHER|conventional laparoscopic surgery(CLS)|It requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy
62480464|NCT04841096|EXPERIMENTAL|Group A1: Glimepiride (1mg) / Vildagliptin (50mg) / Metformin (500mg).|Tablets, orally, once a day. Initial dose for the first 45 days of intervention.
62480465|NCT04841096|EXPERIMENTAL|Group B1: Glimepiride (1mg) / Vildagliptin (50mg) / Metformin (500mg)|Tablets, orally, once a day. Initial dose for the first 45 days of intervention.
61925872|NCT02494700|EXPERIMENTAL|Treatment (low dose orbital EBRT)|Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.
62129564|NCT04918758|EXPERIMENTAL|Purastat Arm|Purastat 5ml once monthly for 3 months
62319757|NCT02102061|EXPERIMENTAL|multidisciplinary intervention|
62319758|NCT02102061|NO_INTERVENTION|control|
62319759|NCT02084134|ACTIVE_COMPARATOR|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
62319760|NCT02084134|NO_INTERVENTION|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
62319761|NCT01270893|EXPERIMENTAL|Nilotinib and Surgical Resection|
62319762|NCT01270893|EXPERIMENTAL|Nilotinib and Potential Resection|
62480466|NCT04841096|EXPERIMENTAL|Group A2: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day. Dose escalation if the patients meets established criteria.
61925873|NCT02687178|ACTIVE_COMPARATOR|Canrenone 50 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
62129565|NCT04918758|OTHER|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks
62129566|NCT00832325||1 individual interviews|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in an individual interview at their convenience.
62129567|NCT00832325||2 Focus Groups|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in a focus group at their convenience.
62129568|NCT00832325||3 Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews scheduled at their convenience.
62129569|NCT01981304||DES with a biodegradable polymer coating|Patients receiving the first carbonized bio-absorbable coated rapamycin-eluting coronary stent at time of percutaneous coronary intervention
62129570|NCT04728568|EXPERIMENTAL|Sintilimab|Sintilimab will be administered every 3 weeks Sintilimab will be administered through IV infusion
62129571|NCT04802369|ACTIVE_COMPARATOR|Identyfication of prognostic factors in VO2max<17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max\<17 ml/kg/min
62129572|NCT04802369|SHAM_COMPARATOR|Identyfication of prognostic factors in VO2max>17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max\>17 ml/kg/min
62129573|NCT05319626|EXPERIMENTAL|Intervention group 1|Compression socks with Textured insoles
62129574|NCT05319626|EXPERIMENTAL|Intervention group 2|Compression socks with Smooth insoles
62129575|NCT05319626|EXPERIMENTAL|Intervention group 3|Smooth socks with Textured insoles
62129576|NCT05319626|PLACEBO_COMPARATOR|Control group|Smooth socks with Smooth insoles
62129577|NCT02869334|EXPERIMENTAL|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
62129578|NCT02869334|EXPERIMENTAL|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
62319763|NCT05329467|OTHER|Validation|
62319764|NCT06590454|ACTIVE_COMPARATOR|Pyrvinium|Participants will receive Pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
62319765|NCT06590454|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo by mouth once each day for a total of 14 days.
62319766|NCT00011193||Non-Exercise Control Group|We randomly assigned 102 women in the non-exercise control group and were asked to maintain their level of activity for the 6-month study period.
62319767|NCT00011193||4-kcal/kg Energy Expenditure per week|We randomly assigned 155 women to the 4-kcal/kg per week group for 6 months.
62319768|NCT00011193||8-kcal/kg Energy Expenditure per week|We randomly assigned 104 women to the 8-kcal/kg per week group for 6 months.
62319769|NCT00011193||12-kcal/kg Energy Expenditure per week|We randomly assigned 103 women to the 12-kcal/kg per week group for 6 months.
62319770|NCT03574467||Bobath Approach Applied to Patient with Brain Tumors|
62319771|NCT03574467||Bobath Approach Applied to Patient with Stroke|
62319772|NCT02508701|OTHER|Altruistic inside-dorm|"Altruistic \& personal message with direct recommendation and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine"
62319773|NCT02508701|OTHER|Generic inside-dorm|"Generic message and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation"
62319774|NCT02508701|OTHER|Generic outside-dorm|"Generic message and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation"
62319775|NCT02508701|OTHER|Altruistic outside-dorm|"Altruistic \& personal message with direct recommendation and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine"
62319776|NCT01080989|OTHER|health screening and clinical diagnosis and treatment for p|The study project can be divided into two parts: (1) health screening for the community and (2) clinical diagnosis and treatment for patients at National Referral Hospital (NRH) in Solomon islands.
62319777|NCT03836118||IUI|all the IUI with controlled ovarian stimulation cycles in an academic tertiary ART center between January 1997 and December 2017
62480467|NCT04841096|EXPERIMENTAL|Group B2: Glimepiride (4mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day. Dose escalation if the patients meets established criteria.
62480468|NCT06350500|EXPERIMENTAL|Health Services Research (Patient Navigation)|Patients receive patient navigation services from a patient navigator as needed to improve knowledge about clinical and supportive care services, navigate to existing services, help manage barriers to care, and enhance skills related to management of cancer treatment
62319778|NCT02341014|EXPERIMENTAL|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle.
62480469|NCT00835588|EXPERIMENTAL|Pantoprazole|Pantoprazole Sodium 40 mg DR Tablet (test) dosed in first period followed by Protonix® 40 mg DR Tablet (reference) dosed in second period
62480470|NCT00835588|ACTIVE_COMPARATOR|Protonix®|Protonix 40 mg DR Tablet (reference) dosed in first period followed by Pantoprazole Sodium 40 mg DR Tablet (test) dosed in second period
62480471|NCT03474965|EXPERIMENTAL|Crizanlizumab|SEG101 (crizanlizumab) administered on Week 1 Day 1, Week3 Day 1 and Day 1 of every 4-week cycle
62480472|NCT06742853|EXPERIMENTAL|Ezetimibe + AZD0780|Participants will receive ezetimibe 10 mg and AZD0780 once daily (QD) for 4 weeks.
62480473|NCT06742853|EXPERIMENTAL|Rosuvastatin + Ezetimibe + AZD0780|Participants will receive rosuvastatin 20 mg, ezetimibe 10 mg and AZD0780 QD for 4 weeks.
62480474|NCT06742853|EXPERIMENTAL|Bempedoic Acid + Ezetimibe + AZD0780 (Optional Cohort)|Participants will receive bempedoic acid 180 mg, ezetimibe 10 mg and AZD0780 QD for 4 weeks.
62480475|NCT06742853|PLACEBO_COMPARATOR|Ezetimibe + Placebo|Participants will receive ezetimibe 10 mg and placebo QD for 4 weeks.
62480476|NCT06742853|PLACEBO_COMPARATOR|Rosuvastatin + Ezetimibe + Placebo|Participants will receive rosuvastatin 20 mg, ezetimibe 10 mg and placebo QD for 4 weeks.
62480477|NCT06742853|PLACEBO_COMPARATOR|Bempedoic Acid + Ezetimibe + Placebo (Optional Cohort)|Participants will receive bempedoic acid 180 mg, ezetimibe 10 mg and placebo QD for 4 weeks.
62480478|NCT02203903|EXPERIMENTAL|Tumor associated antigen lymphocytes (TAA-T)|"For Arm A Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first.~For Arm B Patients (pre-HSCT): TAA-T will be infused any time \> 7 days after previous therapy for relapsed disease.~For Arm C Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first. All infusions will be within 5 months post-HSCT.~Five different dosing levels will be evaluated. Two to four patients will be evaluated on each dosing schedule (see below). This protocol is designed as a phase I dose-escalation study.~Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2 Dose Level Five: 1 x 108 cells/m2 (ONLY applicable to Arm A patients)~Arm C patients will ONLY be enrolled at: Dose Level Four (4 x 107 cells/m2)"
62319779|NCT02174497||Control|Three day Bowel Preparation
62480479|NCT00905658|NO_INTERVENTION|Arm I|Patients are monitored via standard follow-up assessments every 3 weeks.
62480480|NCT00905658|EXPERIMENTAL|Arm II|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks.
62480481|NCT00905658|EXPERIMENTAL|Arm III|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.
62480482|NCT05763537|EXPERIMENTAL|Standard Doula Care Plus the PMAD Intervention|Participants in this arm will receive standard perinatal doula care provided by doulas trained in the DONA International doula training in addition to PMAD-specific care from their doulas.
62129579|NCT02869334|SHAM_COMPARATOR|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
62319780|NCT02174497||Study Arm|One day Bowel Preparation
62319781|NCT04039828|EXPERIMENTAL|Stratum|"Stratum 1: From 3 months to \<18 months= 175 Stratum 2: From 18 months to 59 months= 175~In total, 350 participants will be enrolled"
62319782|NCT02287792|EXPERIMENTAL|18-FDG PET/CT scan|All patients will undergo a whole body PET/CT scan
62319783|NCT01275261|NO_INTERVENTION|Foley catheter|Usual care - patients will have a Foley catheter placed on admission.
62319784|NCT01275261|EXPERIMENTAL|Nursing protocol to avoid Foley Catheter|No catheter will be placed on admission, and a nursing order protocol will be followed to avoid catheterization and avoid complications.
62480483|NCT05763537|ACTIVE_COMPARATOR|Standard Doula Care|Participants in this arm will receive standard perinatal doula care provided by doulas trained in the DONA International doula training.
62480484|NCT05763537|NO_INTERVENTION|Standard Maternal Care|In this arm participants will receive standard perinatal medical care and will not receive care from a doula.
62480485|NCT06541145|EXPERIMENTAL|Maternal Skin Decolonization|These decolonization methods have been safely tolerated in adults and children. We propose a combination of intranasal mupirocin and chlorhexidine baths for a 5-day decolonization regimen targeting pregnant women in their third trimester prior to delivery
62480486|NCT06541145|NO_INTERVENTION|Baseline or control dyads|Maternal-infant dyads without exposure to skin decolonization treatment
62480487|NCT00750243|EXPERIMENTAL|A|
62480488|NCT00750243|ACTIVE_COMPARATOR|B|
62480489|NCT03280862|ACTIVE_COMPARATOR|Control|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned preferentially in a posterolateral, non-apical position
62480490|NCT03280862|EXPERIMENTAL|Intervention|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned according to the latest electrical activation in the CS
61925874|NCT02687178|ACTIVE_COMPARATOR|Canrenone 100 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
62480491|NCT04173104|EXPERIMENTAL|Participants with Brain Cancer|Participants with new or suspected recurrent brain tumors
62129580|NCT03768752||Diastolic Dysfunction|Patients with pre-existing or new diastolic dysfunction.
62480492|NCT03749187|EXPERIMENTAL|Arm A (BGB-290, temozolomide)|Patients with grades III-IV newly diagnosed IDH1/2 mutant glioma receive 60mg PARP inhibitor BGB-290 PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
62480493|NCT03749187|EXPERIMENTAL|Arm B (BGB-290, temozolomide)|"Patients with grades I-IV recurrent IDH1/2 mutant glioma receive 60mg PARP inhibitor BGB-290 PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Cohort B0: Patients who are surgical candidates with grades I-IV recurrent IDH1/2 mutant glioma receive 60mg PARP inhibitor BGB-290 PO BID for 7 days, pre-surgery. After recovery from surgery, patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
62480494|NCT02045667|PLACEBO_COMPARATOR|Placebo|Placebo tablets three times daily orally
62480495|NCT02045667|ACTIVE_COMPARATOR|Mexiletine|Mexiletine 200mg three times daily orally
61925875|NCT06538649|EXPERIMENTAL|Statin|Rosuvastatin tablet(s) once daily for 6-12 months. Dose will start at 10 mg daily (5 mg daily for Asians), then increase to 20 mg for those tolerating and without contraindication.
61925876|NCT06538649|PLACEBO_COMPARATOR|Control|Placebo tablet(s) taken once daily for 6-12 months.
61925877|NCT02985203|EXPERIMENTAL|Vinorelbine oral|Oral Navelbine plus Cisplatin followed by metronomic oral vinorelbine.
62129581|NCT03768752||Normal Diastolic Function|Patients with normal diastolic function.
62129582|NCT01890811|EXPERIMENTAL|Boost High Protein|Boost high protein with added spirulina
62480496|NCT06532565|EXPERIMENTAL|Part A: GS-2121 Monotherapy Dose Escalation|Participants will receive escalating doses of GS-2121 monotherapy until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol.
62129583|NCT05287217|ACTIVE_COMPARATOR|Group 1: Scheduled pain control|Group 1 patients will be instructed to take 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 consecutive days after surgery regardless of whether they experience pain or not.
62129584|NCT05287217|ACTIVE_COMPARATOR|Group 2: Pain control as needed.|Group 2 patients will be instructed to take the 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 days after surgery only when needed to control pain.
62129585|NCT03111160|EXPERIMENTAL|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
61925878|NCT02985203|NO_INTERVENTION|Physician's choice|Observation or maintenance therapy other than orla navelbine.
61925879|NCT03911219||CANKADO (Arm A)|CANKADO application as eHealth support system: Patients use CANKADO for regular symptom self-reporting in addition to standard of care symptom management.
61925880|NCT03911219||Control (Arm B)|Control arm without eHealth support: Patients recieve standard of care symptom management.
62129586|NCT03111160|ACTIVE_COMPARATOR|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
62129587|NCT01849978|ACTIVE_COMPARATOR|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
62129588|NCT01849978|ACTIVE_COMPARATOR|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
62319785|NCT05764798|EXPERIMENTAL|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Zolpidem was given orally for basic treatment, with the treatment dose of 10mg/tablet per day, one tablet per time, once a day, before sleep, for 8 consecutive weeks. Shugan Jieyu Capsule was given orally, with a therapeutic dose of 0.36g/capsule, 2 capsules each time, twice a day, and once after breakfast and dinner.
62129589|NCT00493350||1|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.
62129590|NCT02088424||group A|cases with recurrent abortion with insulin resisance
62688869|NCT03160573|ACTIVE_COMPARATOR|Test-Flavored Rinse then Placebo Flavored Rinse|Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks. After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
62129591|NCT02088424||GROUP B|cases that are pregnant with no history of recurrent abortion with no insulin resistance
62129592|NCT04218890||SLE patients without lupus nephritis|"40 SLE patients~40SLE patients( All SLE pt. satisfied the ACR criteria for SLE diagnosis) these patients will be without any evidences of nephritis"
62129593|NCT04218890||SLE patients with lupus nephritis|40SLE patients with evidences of nephritis
62129594|NCT04218890||healthy control group|20 healthy subjects matched age and sex with be enrolled as healthy control group
62129595|NCT01675999|EXPERIMENTAL|1|"Perioperative simplified FOLFOX-4 chemotherapy~- Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by simplified FOLFOX-4 (8 cycles)."
62129596|NCT01675999|EXPERIMENTAL|2|Perioperative FOLFOX4+Cetuximab chemotherapy Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h)+ Cetuximab (IV 500 mg/m2 every 2 weeks) for 4 cycles followed by colectomy (3 to 5 weeks after), followed by simplified FOLFOX-4 + Cetuximab (8 cycles).
62129597|NCT01675999|OTHER|3|Surgery followed by FOLFOX4 chemotherapy No preoperative chemotherapy Colectomy (maximum 4 weeks after randomization) followed by simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 12 cycles.
62129598|NCT05874830|ACTIVE_COMPARATOR|FMT through colonoscopy|Patient gets FMT in ceacum and plasebo in duodenum.
62129599|NCT05874830|ACTIVE_COMPARATOR|FMT through duodenogastroscopy|Patient gets plasebo in ceacum and FMT in duodenum.
62688870|NCT03160573|PLACEBO_COMPARATOR|Flavored Oral Rinse-Placebo then Test-Flavored Rinse|Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
62688871|NCT03160573|PLACEBO_COMPARATOR|Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
62688872|NCT06480591||JAK2 V617F mutation positive MPN patients|Patients with MPN disease with a JAK2 mutation
62688873|NCT06480591||CALR-mutation positive patients|Patients with MPN disease with a CALR mutation
62129600|NCT05874830|PLACEBO_COMPARATOR|Plasebo|Patient gets plasebo in colonoscopy and in gastroscopy.
62129601|NCT00925587|ACTIVE_COMPARATOR|Q2W|Q2W administration of darbepoetin alfa.
62129602|NCT00925587|ACTIVE_COMPARATOR|QM|QM administration of darbepoetin alfa
62129603|NCT05456698|EXPERIMENTAL|Inotuzumab Ozogamicin|Each subject will be treated with Inotuzumab Ozogamicin
62480497|NCT06532565|EXPERIMENTAL|Part B: GS-2121 Monotherapy Dose Expansion|Participants with selected indications will receive GS-2121 monotherapy at the recommended dose for expansion.
62688874|NCT03633058|EXPERIMENTAL|0.75 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
61925881|NCT04076527||Group 1 - Incomplete Responder|"1. Primary Incomplete Responder: PBC patients demonstrating an insufficient response to the standard therapy with ursodeoxycholic acid (UDCA) after a minimum of 12 months of treatment (Paris II criteria).~2. Secondary Incomplete Responder: PBC patients demonstrating a satisfactory initial response to UDCA after a minimum of 12 months of treatment (Paris II criteria) followed by a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin \>1 mg/dl at any later time point during continuous UDCA-treatment."
61925882|NCT04076527||Group 2 - Responder|PBC patients demonstrating a satisfactory initial and contin-ued response to UDCA after a minimum of 12 months of treatment (Paris II criteria) without a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin \>1 mg/dl at any later time point during continuous UDCA-treatment.
61925883|NCT04076527||Group 3|Patients newly diagnosed for PBC receiving an approved PBC therapy for the first time. Patients are considered to be newly diagnosed if the initial diagnosis took place no later than six months prior to inclusion into the study.
61925884|NCT05570253|EXPERIMENTAL|SDX-7320 plus Eribulin (safety run-in period)|During the safety run-in period, the first 15 patients enrolled will be assigned to received study drug SDX-7320 plus Eribulin. Not randomized.
61925885|NCT05570253|EXPERIMENTAL|SDX-7320 plus Eribulin|Patients randomized to SDX-7320 plus Eribulin.
61925886|NCT05570253|PLACEBO_COMPARATOR|Eribulin Plus Placebo|Patients randomized to the control arm will receive placebo plus Eribulin.
61925887|NCT05132075|EXPERIMENTAL|JDQ443|Participants will be treated with JDQ443
61925888|NCT05132075|ACTIVE_COMPARATOR|Docetaxel|Participant will be treated with docetaxel following local guidelines as per standard of care and product labels
61925889|NCT03822468|EXPERIMENTAL|Ribociclib 400 mg|Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)
61925890|NCT03822468|ACTIVE_COMPARATOR|Ribociclib 600 mg|Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)
61925891|NCT06745011||Idiopathic polyneuropathy with abnormal cardiac 123I-MIBG scintigraphy|
61925892|NCT06745011||Idiopathic polyneuropathy with normal cardiac 123I-MIBG scintigraphy|
62688875|NCT03633058|EXPERIMENTAL|1.5 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
62688876|NCT06638541|ACTIVE_COMPARATOR|Uniform dose|Arm 1 (Uniform dose) will receive 27 Gy in 2 fractions to the whole prostate + seminal vesicles (SV), the CTV, with 0 mm CTV-PTV margin.
62688877|NCT06638541|EXPERIMENTAL|De-escalated dose|"Arm 2 (De-escalated dose) will use two dose levels:~The benign prostate (on MRI) will receive 20 Gy in 2 fractions with a 0mm PTV margin.~The intraprostatic tumour mass(es) as seen on MRI will receive 27 Gy in 2 fractions. A 4mm GTV-PTV margin will be added to the MR visible tumour to form PTV 27Gy."
62688878|NCT06501248|ACTIVE_COMPARATOR|Triticum aestivum|A group of 18 patients with a diagnosis of obesity without pharmacological or surgical treatment, who will receive 500 mg of triticum aestivum orally every 12 hours for 120 days.
62129604|NCT01136876|ACTIVE_COMPARATOR|Iopamidol|Non-ionic low-osmolar iodinated contrast media
61925893|NCT05983159|EXPERIMENTAL|Module 1: Slow-flow vascular malformations|Slow-flow vascular malformations with identified causative variants in the phosphoinositide 3-kinase (PI3K) signalling pathway will receive alpelisib (provided by Novartis Pharmaceuticals), an oral alpha-specific PI3-kinase inhibitor for a total duration of 48 weeks as monotherapy, followed by 24 weeks of follow-up.
62129605|NCT01136876|ACTIVE_COMPARATOR|Iodixanol|Non-ionic iso-osmolar iodinated contrast media comparator
62319786|NCT05764798|PLACEBO_COMPARATOR|Control group: Placebo combined with zolpidem|Zolpidem was given orally for basic treatment, with the treatment dose of 10mg/tablet per day, one tablet per time, once a day, before sleep, for 8 consecutive weeks. Placebo was given orally, with a therapeutic dose of 0.36g/capsule, 2 capsules each time, twice a day, and once after breakfast and dinner.
62319787|NCT03191396|EXPERIMENTAL|Semaglutide|Half the study participants are randomised to receive semaglutide
62688879|NCT06501248|PLACEBO_COMPARATOR|Placebo (calcined magnesia)|A group of 18 patients diagnosed with obesity without pharmacological or surgical treatment, who will receive 500 mg of placebo (calcined magnesia) orally every 12 hours for 120 days.
62688880|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
62688881|NCT06005623|EXPERIMENTAL|Intervention|Activity tracking and motivational feed-back by gamification.
62688882|NCT06005623|NO_INTERVENTION|Care as usual|Activity tracking without motivational feed-back
62688883|NCT01791205||Monotherapy|Eligible participants who received any biologic drug as a monotherapy in the 12 months prior to the study entry will be observed for Phase I. Participants who were enrolled in Phase I and received tocilizumab (TCZ) as a monotherapy will be observed for 18 months from the first infusion of TCZ in Phase II, where TCZ was prescribed according to the approved product information, local treatment guidelines and/or routine clinical practice.
62688884|NCT01791205||Combination Therapy|Eligible participants who received any biologic drug in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the 12 months prior to study entry will be observed for Phase I.
62688885|NCT04520230|EXPERIMENTAL|Group 1|Group 1: 15 patients with COPD who will receive inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination (160/4.5mcg) 2 inhalations bid).
62319788|NCT03191396|ACTIVE_COMPARATOR|Liraglutide|Half the study participants are randomised to receive liraglutide
62319789|NCT01595750|PLACEBO_COMPARATOR|Placebo|
62319790|NCT01595750|ACTIVE_COMPARATOR|Roflumilast|Roflumilast 500 mcg
61925894|NCT05983159|EXPERIMENTAL|Module 2: Fast-flow vascular malformations|Fast-flow vascular malformations with identified causative variants in the RAS-MEK-ERK signalling pathway will receive mirdametinib (provided by SpringWorks Therapeutics, Inc.), an investigational oral MEK inhibitor for a total duration of 48 weeks as monotherapy, followed by 24 weeks of follow-up.
61925895|NCT06496386||very elderly patients|patients older than 80 years
61925896|NCT06496386||elderly patients|patients younger than 80 years
62129606|NCT06342154|EXPERIMENTAL|endorphin massage group|The researcher will show husbands how to give endorphin massage to their pregnant wives. Additionally, they will be asked to choose one of three different instrumental relaxation music pieces played without lyrics to help them relax, and the chosen music will be sent to the pregnant women via WhatsApp. They will be instructed to play the music while performing the endorphin massage. Husbands of pregnant women in the experimental group will be asked to apply a total of 20 minutes of endorphin massage within 1 hour, divided into two sessions of 10 minutes each.
62129607|NCT06342154|NO_INTERVENTION|routine care group|They will receive routine nursing care.
62480498|NCT06532565|EXPERIMENTAL|Part C: Combination Dose Escalation of GS-2121 with Zimberelimab|Participants will receive escalating doses of GS-2121 in combination with zimberelimab until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol.
62129608|NCT05239650|EXPERIMENTAL|A：1L treatment|HLX07 \* 1000 mg+HLX10\* 200mg +mFOLFOX6, IV, Q2W
62319791|NCT03028025|ACTIVE_COMPARATOR|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
62688886|NCT04520230|EXPERIMENTAL|Group 2|Group 2: 15 patients with COPD who will receive inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg inhaled capsule once daily+ Budesonide inhalation 200 mcg twice daily).
62688887|NCT04520230|EXPERIMENTAL|Group 3|Group 3: 15 patients with COPD who will receive long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC). (Tiotropium 18 mcg inhaled capsule once daily+ Formoterol 12 mcg inhaled capsule twice daily)
61925897|NCT02171702|EXPERIMENTAL|BIBW 2992|dose escalation
61925898|NCT02171702|EXPERIMENTAL|BIBW 2992, fasted|food effect part: maximum tolerated dose of BIBW 2992
61925899|NCT02171702|EXPERIMENTAL|BIBW 2992, fed|food effect part: maximum tolerated dose of BIBW 2992
61925900|NCT06684457|EXPERIMENTAL|Pilot interventional arm|Single arm, wherein all consenting participants undergoing interaction with chatbot for atrial fibrillation education.
61925901|NCT06692764|EXPERIMENTAL|AZD0780|Following randomization to treatment sequence, participants receive AZD0780 during period 1 or 2.
61925902|NCT06692764|PLACEBO_COMPARATOR|Placebo|Following randomization to treatment sequence, participants receive Placebo during period 1 or 2.
61925903|NCT05272839|EXPERIMENTAL|Hypoglycemic food group|The patient will choose 2 food products clinically validated against diabetes, at the same dosage and the same mode of preparation as in the reference clinical trials. This will be done additionally to healthcare advice and standard medication if any.
62339734|NCT04158089|EXPERIMENTAL|Attachment Exercises|"Participants in the Attachment Exercises group will receive daily texts over the 2-week intervention period with activities to do from home that are designed to increase feelings of attachment (e.g., read a children's book aloud; sing a nursery rhyme; picture giving the baby a bath; tell the baby a story; etc.)."
62339735|NCT03628417|EXPERIMENTAL|Calcium Electroporation|"Calcium~Calcium chloride 220 mmol/L (9 mg/ml):~* Tumor \< 0.5 cm³ - 1 ml/cm³ tumor volume~* Tumor \> 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)"
62480499|NCT06532565|EXPERIMENTAL|Part D: Combination Dose Expansion of GS-2121 with Zimberelimab|Participants with selected indications will receive GS-2121 at the recommended dose for expansion in combination with zimberelimab.
62480500|NCT03325881|EXPERIMENTAL|SHP465|Participants will be randomized to receive SHP465 capsule 6.25 milligram (mg) orally once daily for 4 weeks.
61925904|NCT05272839|PLACEBO_COMPARATOR|Control group|The control group will receive only dietary advice and standard medication if any.
62129609|NCT05239650|EXPERIMENTAL|B：≥2L treatment|HLX07 \*1000 mg monotherapy,IV, Q2W
62129610|NCT04896034|PLACEBO_COMPARATOR|" control 1  fake MILTA device"|Fake device (control 1) which emits 10% red light (and no infrared) so that the difference between the two machines cannot be seen with the naked eye. The magnets present in the real device are absent in the fake machine and replaced by inert materials of the same mass.
61925905|NCT05407753|EXPERIMENTAL|Ketone ester|Subjects receive the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
61925906|NCT05407753|PLACEBO_COMPARATOR|Con|Subjects receive a non-caloric, taste matched placebo (water and sucrose octaacetate).
62480501|NCT03325881|PLACEBO_COMPARATOR|Placebo|Participant will receive placebo matching to SHP465 capsule orally once daily for 4 weeks.
62688888|NCT06498531|ACTIVE_COMPARATOR|WOMEN - ACETAZOLAMIDE oral capsule|Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
62688889|NCT06498531|ACTIVE_COMPARATOR|MEN - ACETAZOLAMIDE oral capsule|Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
62688890|NCT06498531|PLACEBO_COMPARATOR|WOMEN - PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
61925907|NCT05720702|EXPERIMENTAL|NAFLD Group|"The NAFLD group will be asked to take Hcy lowering supplements (Vitamin B12, Folate, Vitamin B6, and Betaine) daily for 12 weeks. Over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits. During the in person visits NAFLD participants will complete the following activities:~Review medical history; Physical examination; Vital signs (blood pressure, heart rate, respiratory rate, body temperature); Measure height, weight, body mass index, and waist circumference; Grip test; Fasting blood tests; Pregnancy test (if applicable); Fibroscan with CAP score; QOL questionnaire"
62480502|NCT00268879|PLACEBO_COMPARATOR|1|Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
62480503|NCT00268879|EXPERIMENTAL|2|Renzapride 4 mg QD. Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
62480504|NCT00268879|EXPERIMENTAL|3|Renzapride 2 mg BID: Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
62688891|NCT06498531|PLACEBO_COMPARATOR|MEN - PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
62688892|NCT05116644||Included patients|Included patients: 165
62688893|NCT06569641|EXPERIMENTAL|Feeding Assessment|While Feeding, use Neoneur Feeding System to measure feeding patterns (suck, swallow, and breathing)
62319792|NCT03028025|EXPERIMENTAL|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
62688894|NCT04384497|EXPERIMENTAL|Convalescent plasma treatment|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 7 CP infusions. CP will be given as a slow infusion over 1 hour. Patients will be monitored for adverse events, especially allergic reactions.
62688895|NCT04377919|ACTIVE_COMPARATOR|Cranberry|Administration of 2 capsules with 500mg (Miralys Ltda) of cranberry extract per day, for 8 weeks
62688896|NCT04377919|PLACEBO_COMPARATOR|Placebo|Administration of 2 capsules with 500mg of maize starch per day, for 8 weeks
62688897|NCT01821014|EXPERIMENTAL|Telemedicine First|Patients whose first physician visit during the clinic was using videoconference, a form of telemedicine, and whose second physician visit during the clinic was with a physician in-person.
62688898|NCT01821014|EXPERIMENTAL|Telemedicine Second|"Patients whose first physician visit during the clinic was with a physician in-person, and whose second physician visit during the clinic was using videoconference, a form of telemedicine. This is the reverse order of visits of the Telemedicine fist arm."
62688899|NCT01821014|ACTIVE_COMPARATOR|Two physician visits|Patients who had two sequential visits with different in-person physicians.
62688900|NCT01604798||Colorectal Cancer Patients|Patients with histologically confirmed colorectal cancer
62688901|NCT01604798||Healthy Controls|Healthy volunteers
62688902|NCT06100276|EXPERIMENTAL|3 single Ascending Dose Levels|"Experimental: 3 single Ascending Dose Levels~The study will be open-label with an initial plan to explore 3 dose levels of AMT-162 in approximately 6 to 12 Participants in total. Each Participant will receive a single dose of AMT-162 delivered via an intrathecal (IT) infusion and will be followed for up to 5 years after AMT-162 administration."
62688903|NCT06100276|EXPERIMENTAL|EXPANSION COHORT|"Expansion cohort: To further test selected dose from the SAD part in approximately 6 to 8 participants~The study will be open-label. Each Participant will receive a single dose of AMT-162 delivered via an intrathecal (IT) infusion and will be followed for up to 5 years after AMT-162 administration."
62688904|NCT01443312||Thalassemia Intermedia Patients|Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
62688905|NCT02395328|EXPERIMENTAL|Care worker home visitation|Care Workers provide biweekly home visits and offer residing caregivers and children information and psychosocial support, and encourage their awareness and accessing of external health and social services.
61925908|NCT02680899|EXPERIMENTAL|Curricular Intervention|The intervention is a novel science education curriculum in mental health and addiction called My Mind, My Body.
62129611|NCT04896034|EXPERIMENTAL|MILTA Device|The MILTA device used for the study is composed of a panel which gathers 18 emitters composed of red, green and blue LEDs, 3 nanopulsed infrared laser diodes (cold laser), 3 infrared diodes and a permanent magnet
62129612|NCT04896034|NO_INTERVENTION|" control 2  standard pain management with medication"|In first intention: PARACETAMOL: max 1 g x 4 / 24 h Second intention: IBUPROFEN: max 100 mg x 2 for 48 h Third intention: ACUPAN 20 mg in sugar 3 times per 24 h Last intention: ACTISKENAN 10 mg x 4 / 24 h
62319793|NCT06074822||Constitution of biocollection|Collection of remains of neuromuscular biopsy samples (nerve and muscles)
62319794|NCT02657252|ACTIVE_COMPARATOR|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
62319795|NCT02657252|ACTIVE_COMPARATOR|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
62319796|NCT01807507||Healthy Volunteers|
62319797|NCT05592470||PATEINTS|51 patients newly diagnosed with acute lymphoblastic leukemia
62688906|NCT02395328|NO_INTERVENTION|Wait List|Access to homework classes are made available to all participants' children at schools supported by the implementing organization.
62319798|NCT05592470||controls|51 normal persons
62319799|NCT05025072|EXPERIMENTAL|Test IMP|Hydroxycarbamide dispersible tablets (20 x 50 mg)
62319800|NCT05025072|ACTIVE_COMPARATOR|Reference IMP|Hydroxycarbamide film-coated tablet (1000 mg)
62319801|NCT03397797||Group with muscle relaxant|Rocuronium is used during the operation to maintain moderate relaxation.
62319802|NCT03397797||Group without muscle relaxant|Rocuronium is not used during the operation for the eletrophysiological monitoring.
62319803|NCT03067896|ACTIVE_COMPARATOR|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
62319804|NCT03067896|ACTIVE_COMPARATOR|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
62688907|NCT04564014|EXPERIMENTAL|ISSS Intervention|The intervention group will receive 5 weekly ISSS sessions in addition to the information about mental health, depression, anxiety and available treatment and community resources also recived by the control group.
61925909|NCT05386823|EXPERIMENTAL|3 mg/m² HF1K16|
61925910|NCT05386823|EXPERIMENTAL|6 mg/m² HF1K16|
61925911|NCT05386823|PLACEBO_COMPARATOR|Placebo|
61925912|NCT02273518|EXPERIMENTAL|Asasantin ER, new formulation I|
62129613|NCT00840177|EXPERIMENTAL|treatment|"Induction (1 cycle):~pravastatin 1280 mg/d PO D 1-8 idarubicin 12 mg/m2/d IV D 4-6 cytarabine 1.5 g/m2/d continuous IV D 4-7~Consolidation (up to 2 cycles):~pravastatin 1280 mg/d PO D 1-6 idarubicin 12 mg/m2/d IV D 4-5 cytarabine 1.5 g/m2/d continuous IV D 4-5"
62129614|NCT01049503|ACTIVE_COMPARATOR|Caries-active 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
62480505|NCT06614725|EXPERIMENTAL|OA-RSV Group|Older adults (OA) participants, 60 YOA and above, will receive a single dose of RSVPreF3 OA investigational vaccine at Day 1 and will be followed up until end of study (6 months post vaccine dose administration).
62688908|NCT04564014|ACTIVE_COMPARATOR|Wait-list control group|Members will receive information about mental health, depression, anxiety and available treatment and community resources but not ISSS during the intervention period.
61925913|NCT02273518|EXPERIMENTAL|Asasantin ER, new formulation II|
62129615|NCT01049503|ACTIVE_COMPARATOR|Caries-active 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
62480506|NCT06614725|PLACEBO_COMPARATOR|OA-Placebo Group|OA participants will receive a single dose of placebo at Day 1 and will be followed up until end of study (6 months post vaccine dose administration).
62688909|NCT03003065|OTHER|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
62688910|NCT00474357|EXPERIMENTAL|1|Bipolar patients participating in psychoeducation intervention
62688911|NCT00474357|NO_INTERVENTION|2|bipolar patients who do not participate in psychoeducation group
62688912|NCT00474357|NO_INTERVENTION|3|Therapists will complete questionnaires regarding myths about bipolar patients, no intervention
62688913|NCT01603368|ACTIVE_COMPARATOR|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938, 125 million bacteria/day
61925914|NCT02273518|ACTIVE_COMPARATOR|Asasantin ER, present commercial formulation|
62129616|NCT01049503|ACTIVE_COMPARATOR|Caries-active 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
62129617|NCT01049503|ACTIVE_COMPARATOR|Caries-inactive 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
62688914|NCT01603368|PLACEBO_COMPARATOR|Placebo|The same oil drops as the active study product but without Lactobacillus reuteri
62688915|NCT06675786|EXPERIMENTAL|I.V. House UltraDressing|The nurse who will perform the PVC will clean the area where the PVC will be applied with alcohol and cotton wool, let it dry and apply Teflon Introcan Safety I.V. Catheter No. 22-24 (B. Braun Medical Inc. Bethlehem, PA, USA) to the patients and apply the routine intravenous line fixation method of the clinic with a plaster. The patient with the PVC will then fill out an introductory information form. I.V. House UltraDressing (I.V. House, Inc., St. Louis, MO, USA) will be applied according to the manufacturer's instructions and secured with an anti-slip tape without the need for further taping. Catheter-induced complications such as dislodgement, phlebitis, infiltration, extravasation, catheter occlusion and folding of PVCs will be observed and recorded on the Peripheral Venous Catheter Observation Form and the effect of I.V. House UltraDressing will be evaluated.
62738196|NCT02249091|EXPERIMENTAL|Cohort 2 / Selinexor 60 mg flat dose in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m\^2 continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m\^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a flat dose of 60 mg twice weekly orally in weeks 1-3 of a 4-week cycle starting on day 2 (total of 6 doses per induction cycle)."
62738197|NCT04869059|EXPERIMENTAL|Transcranial direct current stimulation|20 minutes of 1 milliamp transcranial direct current stimulation to presupplementary motor area for 15 sessions
61925915|NCT06744296||Patients Receiving only Surgery|Patients in this group will only be those who receive surgery, and does not receive radiographic testing or chemotherapy.
62129618|NCT01049503|ACTIVE_COMPARATOR|Caries-inactive 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
62319805|NCT03067896|ACTIVE_COMPARATOR|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
61925916|NCT06744296||Patients receiving chemoradiotherapy|"* Newly diagnosed AJCC 8th edition Stage III-IVB mucosal SCC of the head and neck, which includes tumors arising from the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx, and larynx.~* Available tissue for tumor-informed ctDNA panel creation.~* Definitive treatment with standard of care surgery (arm 1) or chemoradiotherapy (arm 2)"
61925917|NCT04784299|EXPERIMENTAL|YVOIRE volume plus|Hyaluronic acid dermal filler
61925918|NCT04784299|ACTIVE_COMPARATOR|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
61925919|NCT06395948|EXPERIMENTAL|Part A: Induction Period: APG777|Participants will receive APG777 per protocol defined dosing regimen
61925920|NCT06395948|PLACEBO_COMPARATOR|Part A: Induction Period: Placebo|Participants will receive matching Placebo injections per protocol defined dosing regimen
61925921|NCT06395948|EXPERIMENTAL|Part A: Maintenance Period: APG777|Participants will receive 1 of 2 maintenance regimens of APG777 per protocol defined dosing regimen
61925922|NCT06395948|EXPERIMENTAL|Part B: Induction Period: APG777|Participants will receive APG777 in 1 of 3 regimens per protocol defined dosing regimen
62688916|NCT06675786|NO_INTERVENTION|Control|The nurse who will perform the PVC application will clean the area where the PVC will be applied with alcohol and cotton wool and leave it to dry, and the patients in both groups will be applied with a Teflon Introcan Safety I.V. Catheter (B. Braun Medical Inc. Bethlehem, PA, USA) numbered 22-24 and the clinic's routine intravenous line fixation method of fixation with a plaster will be applied. After the PVC is inserted, the introductory information form will be filled out and the duration of the stay of the PVC in the vascular access, dislodgement status and catheter-related complications such as dislodgement, phlebitis, infiltration, extravasation, catheter occlusion and folding of the PVCs will be observed and recorded on the Peripheral Venous Catheter observation form prepared by the researcher. Patients will remain in the study as long as they are hospitalized in the clinic and their PVCs are inserted. The time allocated for each patient is planned to last an average of 15 minut
61925923|NCT06395948|PLACEBO_COMPARATOR|Part B: Induction Period: Placebo|Participants will receive matching placebo injections per protocol defined dosing regimen
61925924|NCT06395948|EXPERIMENTAL|Part B: Maintenance Period: APG777|Participants will receive APG777 per protocol defined dosing regimen
61925925|NCT01721473||cigarette smokers with heavy marijuana use|With heavy marijuana use
61925926|NCT01721473||cigarette smokers with heavy caffeine use|with heavy caffeine use
62129619|NCT01049503|ACTIVE_COMPARATOR|Caries-inactive 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
62129620|NCT00708188|EXPERIMENTAL|Multidetector raw CT|
62129621|NCT01118858||Case|Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive impulsive, or inattentive type (ADD).
62129622|NCT01118858||Control|Healthy subjects: Age and gender matched subjects who do not meet any of the exclusion criteria
62129623|NCT00529789|EXPERIMENTAL|Duloxetine|
62129624|NCT05182385|EXPERIMENTAL|hematological relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~* Refractory BCP-ALL to primary induction therapy, including at least three cycles of standard chemotherapy~* Untreated first relapse of BCP-ALL with first remission duration \< 12 months or~* Second or greater relapse of BCP-ALL or refractory relapse or~* Relapse of BCP-ALL any time after allogeneic HSCT"
62688917|NCT05991687|ACTIVE_COMPARATOR|In-home|
62688918|NCT05991687|ACTIVE_COMPARATOR|Mail-in|
62129625|NCT05182385|EXPERIMENTAL|molecular relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~-Positivity of MRD marker of immunoglobulin/T-cell receptor gene rearrangements of greater than 0.01% if in first or second remission of BCP-ALL"
62129626|NCT03059212|EXPERIMENTAL|High frequency rTMS|Real rTMS, one session per day, for 10 days
61925927|NCT01721473||cigarette smokers w/o heavy caffeine and marijuana use|cigarette smokers without the heavy use of marijuana or caffeine
61925928|NCT01721473||non-smokers|not a regular cigarette user
62129627|NCT03059212|EXPERIMENTAL|High frequency rTMS with cognitive training|Real rTMS and cognitive training, one session per day, for 10 days
62129628|NCT03059212|SHAM_COMPARATOR|Sham rTMS|Sham rTMS, one session per day, for 10 days
61925929|NCT01721473||cigarette smokers with non-menthol cigarette preference|non-menthol cigarette preference
61925930|NCT01721473||cigarette smokers with menthol cigarette preference|menthol cigarette preference
61925931|NCT05394129||SurePath™|"The subjects are randomly assigned to SurePath™/Conventional test group at a ratio of 1:1.~In SurePath™ group, subjects who underwent SurePath™ liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
62129629|NCT05210569||Bilateral implantation of the Vivity IOL|Vivity intraocular lens (IOL)
62129630|NCT03608787|EXPERIMENTAL|Cohort 1-Early Intervention|Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
61925932|NCT05394129||Conventional|"The subjects are randomly assigned to SurePath™/Conventional test group at a ratio of 1:1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePath™ liquid cell test with the second obtained sample."
61925933|NCT05347446|ACTIVE_COMPARATOR|Hybrid ESD|Hybrid ESD is a modified ESD technique that uses snare-assisted resection as part of the procedure. With hybrid ESD, a circumferential mucosal incision followed by limited submucosal dissection is performed. Following this, a snare is placed around the lesion, slowly closed to allow resection by traversing the submucosal space
61925934|NCT05347446|ACTIVE_COMPARATOR|Non-Hybrid ESD|A partial or complete circumferential mucosal incision will be performed to expose the submucosa around and underneath the polyp. Endoscopic resection will then proceed via conventional ESD, submucosal tunneling or pocket technique.
61925935|NCT05893797|EXPERIMENTAL|Connected Management Platform|Participants with type 1 and type 2 diabetes wearing continuous glucose monitoring (CGM) will receive insulin lispro via the Tempo Pen as part of the connected insulin management platform.
61925936|NCT06734858|EXPERIMENTAL|SAT014 study group|"SAT-0014 + Conventional treatment\*~\*Conventional treatment: Pharmacological treatment received at baseline for the indication or simple counseling (excluding cognitive behavioral therapy and psychoanalytic counseling therapy)"
61925937|NCT06734858|OTHER|Control group|"Conventional treatment\*~\*Conventional treatment: Pharmacological treatment received at baseline for the indication or simple counseling (excluding cognitive behavioral therapy and psychoanalytic counseling therapy)"
61925938|NCT05944224|EXPERIMENTAL|SPH4336|
61925939|NCT05944224|EXPERIMENTAL|Cadonilimab|
61925940|NCT05944224|EXPERIMENTAL|SPH4336+ Cadonilimab|
61925941|NCT04177238|PLACEBO_COMPARATOR|Placebo|Identical in taste and colour to the supplement juice, but with no anthocyanin content
61925942|NCT04177238|EXPERIMENTAL|Cherry juice|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
61925943|NCT04177238|EXPERIMENTAL|Blueberry|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
61925944|NCT00938223|ACTIVE_COMPARATOR|4-peptide vaccine|Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A 2) and a tetanus helper peptide.
61925945|NCT00938223|ACTIVE_COMPARATOR|12-peptide vaccine|Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
62129631|NCT03608787|EXPERIMENTAL|Cohort 2-Delayed Intervention|Following baseline, participating outlets in this arm will receive receive Pseudo-Intoxicated Mystery Shops (P-I/MS) with no feedback. After 3 months they will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback.
61925946|NCT06404047|EXPERIMENTAL|Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance)|"Appendix A is a randomized controlled trial designed to evaluate the effect of a 12-week personalized cardiopulmonary rehabilitation intervention on exercise tolerance in participants with PASC.~Participants who meet eligibility criteria for Appendix A will be assigned to either Personalized Cardiopulmonary Rehabilitation (study intervention group) or Education (control group) in a 1:1 ratio. The intervention duration is 12 weeks with a follow-up period of 3 months (total study duration of 6 months).~Anticipated enrollment is 360 participants. Details about Appendix A: Cardiopulmonary Rehabilitation (Exercise Intolerance) are available under NCT06404060."
62129632|NCT05694442|EXPERIMENTAL|Lipmatte K|Participants will used Lipmatte K everyday for 4 weeks
62129633|NCT02477605|EXPERIMENTAL|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
62480507|NCT06614725|EXPERIMENTAL|Adults-AIR-RSV Group|Adult participants, 50-59 YOA, at increased risk (AIR) of RSV-LRTD, will receive a single dose of RSVPreF3 OA investigational vaccine at Day 1 and will be followed up until end of study (6 months post vaccine dose administration).
62129634|NCT02477605|ACTIVE_COMPARATOR|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
62129635|NCT00580918||1|Mild Traumatic Brain Injury group
62129636|NCT00580918||2|Normal healthy control group
62129637|NCT03080324|EXPERIMENTAL|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
62129638|NCT03080324|ACTIVE_COMPARATOR|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
62129639|NCT04083664||Control healthy subjects without anemia.|"1. Adults \> 18 years.~2. Age and sex matched.~3. No active infection or inflammation."
62129640|NCT04083664||ESRD with Hgb <11 g/dl.|"1. Adults \> 18 years.~2. ESRD patients on regular hemodialysis.~3. Hgb \< 11g/dl.~4. No apparent infection or inflammation."
62129641|NCT04083664||ESRD with Hgb ≥ 11 g/dl|"1. Adults \> 18 years.~2. ESRD patients on regular hemodialysis.~3. Hgb ≥ 11g/dl.~4. No apparent infection or inflammation."
62480508|NCT06614725|PLACEBO_COMPARATOR|Adults-AIR-Placebo Group|Adult participants, 50-59 YOA, at increased risk (AIR) of RSV-LRTD, will receive a single dose of placebo at Day 1 and will be followed up until end of study (6 months post vaccine dose administration).
62480509|NCT06613906|EXPERIMENTAL|Healsea Children treated group|Subjects of this arm will be treated with Healsea Children nasal spray during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days
61925947|NCT06404047|EXPERIMENTAL|Experimental: Appendix B - Structured Pacing (PEM)|"Appendix B is a randomized controlled trial designed to evaluate the effect of a 12-week Structured Pacing intervention on reducing the symptoms of post-exertional malaise (PEM) in participants with PASC.~Participants who meet eligibility criteria for Appendix B will be assigned to either Structured Pacing (study intervention group) or Usual Care (control group) in a 1:1 ratio. The intervention duration is 12 weeks with a follow-up period of 3 months (total study duration of 6 months).~Anticipated enrollment is 300 participants. Details about Appendix B: Structured Pacing (PEM) are available under NCT06404073."
61925948|NCT01902251|EXPERIMENTAL|Enzalutamide tablet|Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks
61925949|NCT01902251|ACTIVE_COMPARATOR|Enzalutamide capsule|Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks
61925950|NCT01915264||Group 1|
61925951|NCT03560830||Control|Sedentary control subjects with no medical or psychiatric disorder
61925952|NCT03560830||POTS GWI|GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.
61925953|NCT03560830||START|"START = Stress Test Activated Reversible Tachycardia One third of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change \~10 to 15 beats per minute) BEFORE EXERCISE, but AFTER EXERCISE (submaximal exercise stress tests) they developed postural orthostatic tachycardia with changes in heart rate of 30 or more between recumbent and standing. The effect was transient as it lasted about 36 to 48 hr.~The START group had brainstem atrophy and reduced brain activation during a cognitive task compared to sedentary control and other GWI subjects."
62688919|NCT05196529|EXPERIMENTAL|Inspiratory muscle training|The 8-week inspiratory muscle training protocol consists of using 80% of maximal inspiratory pressure (determined in lab), 3x per week, 6 sets of 6 repetitions. Each set will be separated by decreasing lengths of time over the 8 weeks starting at a 30 second interim. This totals 36 inhalations 3 times per week. Progress will be determined via weekly phone calls with the participants and progress will also be logged by participants over the 8 weeks.
62688920|NCT06379607|NO_INTERVENTION|Conventional Oxygen Therapy (COT)|Conventional Oxygen Therapy (COT) is the standard way to deliver oxygen to hypoxemic pediatric patients during an acute asthma exacerbation. Continuous albuterol will be administered via an aerogen set-up (aerogen mask, aerogen ultra, and a vibrating mesh nebulizer). Oxygen tubing will be connected to the wall and run at 2L/min as per the aerogen manufacturer's instructions.
62480510|NCT06613906|NO_INTERVENTION|Untreated arm|Subjects of this arm will not receive any treatment for the prevention of respiratory tract infection.
61925954|NCT03560830||STOPP|"STOPP = Stress Test Originated Phantom Perception Two thirds of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change \~10 to 15 beats per minute) both before and after 2 submaximal exercise stress tests. STOPP did not develop postural orthostatic tachycardia. their changes were equivalent to the sedentary control group.~The STOPP group increased brain activation of the basal ganglia and anterior insula during a cognitive task compared to sedentary control subjects."
61925955|NCT02670278||US-Washington, Idaho|healthy breastfeeding women and their infants
61925956|NCT02670278||US-California|healthy breastfeeding women and their infants
62129642|NCT01356069|EXPERIMENTAL|SB-APP Psychotherapy|Patients, who signed the informed consent, were randomly assigned to SB-APP in addition to TAU (n=18) or to TAU alone (n=17) groups. The SB-APP group received the usual treatment plus SB-APP (40 weekly sessions) for 10 or 11 months. At the term of the first year (T12) the TAU group continued with the TAU management with supportive weekly session whilst the SB-APP group was carried on with the psychiatric, nurse, educational management without any individual psychological support. The number of sessions performed by the two groups in the first year (T0-T12) was programmed to be almost the same to reduce the number of sessions bias comparing the specific quality of treatments.
62688921|NCT06379607|EXPERIMENTAL|"Low Flow High Flow Nasal Cannula at 4L/min"|A Fisher Paykl humidifier will be used for high flow humidification along with a flow meter and oxygen blender. A vibrating mesh nebulizer will be connected between the flow meter and the humidifier as per routine practice. Oxygen flow will be set to 4L/min and patient will be fitted with appropriately sized nasal prongs.
62738198|NCT04869059|SHAM_COMPARATOR|Sham transcranial direct current stimulation|20 minutes of sham transcranial direct current stimulation to presupplementary motor area for 15 sessions
62129643|NCT01356069|ACTIVE_COMPARATOR|TAU treatment|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators. The medication was administered according to the APA guidelines \[18\] for good clinical practice with regard to BPD.
62129644|NCT00621634|EXPERIMENTAL|1|Active treatment with omega-3 fish oil capsules (1 g each capsule, 50% DHA), 6 capsules each day for 12 weeks
62129645|NCT00621634|PLACEBO_COMPARATOR|2|Matching placebo treatment
62129646|NCT02191098|EXPERIMENTAL|ALT-803|ALT-803
62129647|NCT02134951|EXPERIMENTAL|ketamine|IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
62480511|NCT06741800||Patients desensitized by sublingual tablets|
62480512|NCT06321731||COPD patients initiating BGF|COPD patients ≥40 years old initiating BGF (budesonide/glycopyrronium bromide/formoterol fumarate) at least 12 months before start of data collection.
61925957|NCT02670278||Sweden|healthy breastfeeding women and their infants
61925958|NCT02670278||Spain|healthy breastfeeding women and their infants
61925959|NCT02670278||Peru|healthy breastfeeding women and their infants
61925960|NCT02670278||Kenya|healthy breastfeeding women and their infants
61925961|NCT02670278||Ethiopia-rural|healthy breastfeeding women and their infants
61925962|NCT02670278||Ethiopia-urban|healthy breastfeeding women and their infants
62129648|NCT02134951|PLACEBO_COMPARATOR|Placebo|Placebo group will receive normal saline
62688922|NCT06379607|EXPERIMENTAL|"High Flow High Flow Nasal Cannula at 2L/kg/min (max 60L/min)"|A Fisher Paykl humidifier will be used for high flow humidification along with a flow meter and oxygen blender. A vibrating mesh nebulizer will be connected between the flow meter and the humidifier as per routine practice. Oxygen flow will be set to 2L/kg/min (max 60L/min) and patient will be fitted with appropriately sized nasal prongs.
62688923|NCT06546592|EXPERIMENTAL|AI assisted contouring|Patients in this arm will have their contours/segmentations generated by a combination of the LOCATOR (AI) software before manual edits and checks by a radiation oncologist.
62129649|NCT04134611|ACTIVE_COMPARATOR|Knee arthroscopy with Hyaluronic acid injection|Those patients who received hyaluronic acid injection
62129650|NCT04134611|ACTIVE_COMPARATOR|Knee arthroscopy without Hyaluronic acid injection|Knee arthroscopy who did not Hyaluronic acid injection
62129651|NCT01402531|EXPERIMENTAL|Submucosal Bevacizumab|200mg Bevacizumab, submucosal injection
62129652|NCT04085874|EXPERIMENTAL|FBR group|weekly home visit and monthly group meeting for 12 weeks
62129653|NCT04085874|ACTIVE_COMPARATOR|non-FBR group|once nutrition counseling from standard health care services
62688924|NCT06546592|NO_INTERVENTION|Manual contouring|Patients in this arm will have standard of care which is fully manual contours/segmentations generated and checked by a radiation oncologist.
62129654|NCT02437006|NO_INTERVENTION|rehabilitation|half an hour physical and half an hour occupational therapy in rehabilitation
62129655|NCT02437006|EXPERIMENTAL|Low-intensity exercise|Low-intensity exercise plus rehabilitation
62129656|NCT02437006|EXPERIMENTAL|High-intensity exercise|High-intensity exercise plus rehabilitation
62688925|NCT02174770|EXPERIMENTAL|ACL BFR group|This group is patients with post-op from ACL reconstruction who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
62688926|NCT02174770|ACTIVE_COMPARATOR|ACL Standard Therapy|This group is patients with post-op from ACL reconstruction who are randomized into the standard therapy arm. They will receive ACSM guided-strength training as part of their post-operative physical therapy program.
62129657|NCT05520658|ACTIVE_COMPARATOR|group A|patients will receive intralesional combined digoxin and furosemide , one session every 2 weeks for maximum 6 sessions
62129658|NCT05520658|ACTIVE_COMPARATOR|group B|patients will receive intralesional 5 fluorouracil mixed with 1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
62129659|NCT04592575||TBI that are positive on screening tool|Patients that are identified on the AbilityLab Vestibular screening tool as possibly having vestibular dysfunction
62129660|NCT04592575||TBI patients not positive on screening tool|Patients that are not identified on the Ability Lab Vestibular screening tool as possibly having vestibular dysfunction
62129661|NCT02639975|EXPERIMENTAL|100 mg PBF-677|
61925963|NCT02670278||The Gambia-rural|healthy breastfeeding women and their infants
62738199|NCT03053440|EXPERIMENTAL|Arm A : Ibrutinib|Participants with the MYD88 mutation received Ibrutinib
61925964|NCT02670278||The Gambia-urban|healthy breastfeeding women and their infants
62129662|NCT02639975|EXPERIMENTAL|200 mg PBF-677|
62129663|NCT02639975|EXPERIMENTAL|400 mg PBF-677|
62129664|NCT02639975|EXPERIMENTAL|600 mg PBF-677|
62129665|NCT02639975|PLACEBO_COMPARATOR|Placebo 100 mg|
62738200|NCT03053440|ACTIVE_COMPARATOR|Arm B: Zanubrutinib|Participants with the MYD88 mutation received zanubrutinib
62738201|NCT06395896|EXPERIMENTAL|Breast Cancer Prevention Journey Program Group|"Participants will first receive structured The Fighting Breast Cancer training based on the Health Belief Model. Then they will be taken to mammography screening with a free transportation service and will be screened for cancer."
62738202|NCT06395896|OTHER|Routine Cancer Screening Program Group|Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health.
62738203|NCT05844111|EXPERIMENTAL|[14C] radiolabeled BGB-11417|Participants will receive a single dose of \[14C\]-BGB-11417
62738204|NCT06660095||Liver transplant recipients|T0: After the anesthesia induction, before the surgery T1: Intraoperative p50 value from the blood gas sample taken during the dissection stage T2: Intraoperative p50 value from the blood gas sample taken during the anhepatic stage T3: Intraoperative p50 value from the blood gas sample taken during the neohepatic stage T4: After the hepatic artery reperfusion T5: At the end of the surgery
62738205|NCT02665663|OTHER|healthy volunteers|"Constitution of a control group consisting of 20 healthy volunteers, matched for age and sex to establish a normal pressure force of the language depending on the age and sex value"
62738206|NCT02665663|OTHER|Patients with Amyotrophic Lateral Sclerosis|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis (ALS), included at diagnosis of the disease on clinical and electromyographic arguments addressed in speech pathology consultation without a complaint swallowing.
62738207|NCT02665663|OTHER|patients with Amyotrophic Lateral Sclerosis and swallowi|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis ( ALS) and swallowing disorders clinically objectified in the ENT consultation.
62738208|NCT01484483||Cohort|
62738209|NCT02308163|PLACEBO_COMPARATOR|Placebo|Participants were assigned to receive placebo to peficitinib once a day until week 12.
62738210|NCT02308163|EXPERIMENTAL|Peficitinib 100 mg|Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.
62738211|NCT02308163|EXPERIMENTAL|Peficitinib 150 mg|Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.
62738212|NCT02308163|ACTIVE_COMPARATOR|Etanercept|Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.
62738213|NCT01504516|EXPERIMENTAL|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
62738214|NCT01504516|ACTIVE_COMPARATOR|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
62738215|NCT03533816|EXPERIMENTAL|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
62738216|NCT03533816|EXPERIMENTAL|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
62738217|NCT03465579|OTHER|Cohort 1|Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy
62480513|NCT06589726|EXPERIMENTAL|Treatment Sequence 1: A-B-C-D|Participants will receive a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 1, followed by a single oral dose of moxifloxacin tablet (Treatment B) in treatment period 2, followed by a single oral low dose of enpatoran tablet (Treatment C) in treatment period 3, followed by a single oral high dose of enpatoran tablet (Treatment D) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.
62480514|NCT06589726|EXPERIMENTAL|Treatment Sequence 2: B-D-A-C|Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in treatment period 1, followed by a single oral high dose of enpatoran tablet (Treatment D) in treatment period 2, followed by a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 3, followed by a single oral low dose of enpatoran tablet (Treatment C) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.
62480515|NCT06589726|EXPERIMENTAL|Treatment Sequence 3: C-A-D-B|Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in treatment period 1, followed by a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 2, followed by a single oral high dose of enpatoran tablet (Treatment D) in treatment period 3, followed a by single oral of moxifloxacin tablet (Treatment B) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.
61925965|NCT02670278||Ghana|healthy breastfeeding women and their infants
62129666|NCT02639975|PLACEBO_COMPARATOR|Placebo 200 mg|
62129667|NCT02639975|PLACEBO_COMPARATOR|Placebo 400 mg|
62480516|NCT06589726|EXPERIMENTAL|Treatment Sequence 4: D-C-B-A|Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in treatment period 1, followed by a single oral low dose of enpatoran (Treatment C) in treatment period 2, followed by a single oral dose of moxifloxacin tablet (Treatment B) in treatment period 3, followed by a single oral dose of placebo matched to enpatoran (Treatment A) in treatment period 4. There will be a washout period of at least 10 days between each treatment period.
62319806|NCT02728635|ACTIVE_COMPARATOR|Group A- Women- Healthy 'pears'|This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
62319807|NCT02728635|ACTIVE_COMPARATOR|Group B- Women- Healthy 'apples'|The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
62480517|NCT05757453|EXPERIMENTAL|Experimental|mHealth group
62480518|NCT05955508|EXPERIMENTAL|Safety Run-In (Part 1)|Evaluation of initial safety and tolerability of the step-up regimen leading up to the start of full dose linvoseltamab.
62129668|NCT02639975|PLACEBO_COMPARATOR|Placebo 600 mg|
62480519|NCT05955508|EXPERIMENTAL|Expansion (Part 2)|Linvoseltamab monotherapy according to the same dosing schedule established in the safety run-in part.
62129669|NCT01881386||Lymphoma|Lymphoma patients before and after receiving standard CHOP therapy
62319808|NCT02728635|ACTIVE_COMPARATOR|Group C- Men- Healthy 'apples'|The group will consist of men with a BMI between 23 and 35 kg/m2.
62319809|NCT01985685|EXPERIMENTAL|Thiamine|200mg intravenous thiamine in 50ml 5% dextrose, single dose
62319810|NCT01985685|PLACEBO_COMPARATOR|Placebo|50ml intravenous 5% dextrose, single dose
62319811|NCT06307080|EXPERIMENTAL|Multi-mode thermal ablation combined with intravenous anti-PD-1 and chemotherapy|Multimodal ablation therapy +PD-1 antibody combined with intravenous chemotherapy was performed (carreilizumab 200 mg IV D1+ gemcitabine 1000mg/㎡ IV+ albumin binding paclitaxel 125mg/㎡ IV D1.8Q3W; For 6 weeks)
62319812|NCT06307080|ACTIVE_COMPARATOR|Intravenous anti-PD-1 and chemotherapy|Intravenous chemotherapy was performed (carreilizumab 200 mg IV D1+ gemcitabine 1000mg/㎡ IV+ albumin binding paclitaxel 125mg/㎡ IV D1.8Q3W; For 6 weeks)
62480520|NCT04610866|EXPERIMENTAL|1|Subjects will be treated with a maintenance dose of mitapivat previously assessed for safety and tolerability in the Phase I study for an initial 48 weeks and undergo safety monitoring, evaluation of pharmacokinetics and pharmacodynamics, and assessment of secondary laboratory and clinical endpoints at pre-specified intervals during the study period.
62480521|NCT05452902|EXPERIMENTAL|EXCAP Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
61925966|NCT01041495|EXPERIMENTAL|cyclobenzaprine ER|active drug
62129670|NCT01881386||Metastatic Colorectal|Patients with metastatic colorectal cancer
62129671|NCT01881386||Phase 1|Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
62129672|NCT01881386||Brain|Patients with primary brain tumours and patients with cerebral lymphoma
62129673|NCT01348217|ACTIVE_COMPARATOR|ARM A|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~1. Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)~2. Boost 10 Gy in 5 fr: PTV = +1cm.~3. Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)"
62129674|NCT01348217|EXPERIMENTAL|ARM B|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~1. 40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)~2. Boost 26 Gy in 13 fr: PTV = +1cm.~3. Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43)."
62319813|NCT05170139|EXPERIMENTAL|Caffeine|Dietary Supplement: Caffeine supplementation Participants will ingest caffeine in liquid form (3mg/kg) with carbohydrates.
62319814|NCT05170139|PLACEBO_COMPARATOR|Control condition|Participants will ingest a drink of carbohydrates without caffeine
62319815|NCT00175006||Tophi Participants|
61925967|NCT01041495|PLACEBO_COMPARATOR|placebo|placebo
62129675|NCT05877469|ACTIVE_COMPARATOR|mat pilates training group|Mat pilates training involve leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, swan dive, hovers, roll down, crisscross and planks. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
62129676|NCT05877469|EXPERIMENTAL|Functional training group|Functional training involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet squats and woodchop. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
62129677|NCT03606915||no pain|pain evaluation for patients performed surgery without painful condition (bleeding or others)
62129678|NCT03606915||acute pain|pain evaluation for patients performed surgery with painful condition within several days
62129679|NCT03606915||chronic pain|pain evaluation for patients performed surgery with the painful condition for over months
62319816|NCT03911674|EXPERIMENTAL|Oral stimulation|Oral stimulation protocol: manual stimulation of the oral sucking
62688927|NCT02174770|OTHER|Chronic Muscle Weakness|This is a crossover group where all subjects will be randomized to begin with either standard or blood flow restriction therapy for 4 weeks. After completion of the initial training, each subject will be switched to the opposite in an AB/BA crossover design.
61925968|NCT01171508||Breast cancer patients|12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.
61925969|NCT01473056|EXPERIMENTAL|Dose 1 JTK-853|
61925970|NCT01473056|EXPERIMENTAL|Dose 2 JTK-853|
61925971|NCT01473056|EXPERIMENTAL|Dose 3 JTK-853|
62129680|NCT00788034|EXPERIMENTAL|Lu AA21004|
62129681|NCT00788034|PLACEBO_COMPARATOR|Placebo|
62129682|NCT03930225|EXPERIMENTAL|study group|"In the study group, both patients and their family members will be required to attend a weekly 1 hour long psycho-educational sessions. Moreover assessment sessions will be attended also.~The stigma directed intervention program"
62319817|NCT03911674|NO_INTERVENTION|Control|No intervention
62319818|NCT05615701|OTHER|EOSedge imaging|Single arm study : All subjects include in the study underwent micro-dose EOS x-ray and digital radiography for radiographic evaluation of hip implant
62319819|NCT03974646|EXPERIMENTAL|intervention group|Participants assigned to the intervention group will receive both will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up , and a 12- weeks self-management intervention delivered by two dedicated and trained renal nurse educators. The intervention will involve three group-based sessions, CKD booklet and three follow-up phone calls.
61925972|NCT01473056|EXPERIMENTAL|Dose 4 JTK-853|
61925973|NCT01473056|PLACEBO_COMPARATOR|Placebo|
61925974|NCT03243266||CBC/Diff Reference Interval|Hematology routine diagnostic test
61925975|NCT03256188|EXPERIMENTAL|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
62480522|NCT05452902|ACTIVE_COMPARATOR|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
62688928|NCT02174770|EXPERIMENTAL|Knee Arthroscopy BFR|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
62688929|NCT02174770|ACTIVE_COMPARATOR|Knee Arthroscopy Standard|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the standard physical therapy arm. They will receive ACSM-guided strength training as part of their post-operative physical therapy program during normal post-op rehab.
62688930|NCT00569075||High Risk|High risk disease prone population
62129683|NCT03930225|OTHER|control group|"In the control group, only Patients will attend the psycho-educational sessions.~Family members and patients will be required to attend the assessment sessions."
62129684|NCT01902147||Elective major abdominal, thoracic, and arthroplasty surgery|All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS.
62129685|NCT03815136|ACTIVE_COMPARATOR|Chewing Gum|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy. Subjects chewed one piece of gum for approximately 15 min every 30 min at the first hour of the examination.
62319820|NCT03974646|NO_INTERVENTION|control group|Participants randomized to the control group in this study will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up. Usual care consisted of brief verbal information (2-5 minutes) about taking medications, reducing salt, smoking cessation and reducing alcohol consumption. There will no structured program but only the provision of written material to patients.
62480523|NCT06634797|EXPERIMENTAL|Sequence 1: mRNA-1273.712 then Placebo|Participants will receive mRNA-1273.712 followed by placebo 28 days later.
62480524|NCT06634797|EXPERIMENTAL|Sequence 2: Placebo then mRNA-1273.712|Participants will receive placebo followed by mRNA-1273.712 28 days later.
62480525|NCT01933620||Patient|Patients who might become colonized or infected with a multidrug-resistant organism
62480526|NCT02960295|EXPERIMENTAL|Virtual visit|"1. Self-monitoring of blood glucose (four times daily).~2. Self-weighing (weekly).~3. Self-checking of blood pressure (weekly).~4. Checking fetal heart rate (weekly).~5. Visits with caregivers."
62480527|NCT02308059||Patients with diabetes mellitus|Group I; the patients with diabetes mellitus who had peripheral neuropathy as diagnosed.
62688931|NCT00569075||Low Risk|Low risk disease population
62688932|NCT06239753|EXPERIMENTAL|Dynamic Neuromuscular Stabilization Applied|"Intervention Group I will receive DNS (Dynamic Neuromuscular Stabilization) applications in the hospital, led by a physiotherapist, once a week for 10 weeks. During each session, participants will be instructed to perform the DNS exercises at home and take notes. They will receive reminders via short message service (SMS) to practice the exercises at home. The DNS application for pregnant women involves checking the breathing pattern before starting exercises in all sessions. Pregnant women will be instructed to breathe through the nose, and if they find it challenging to maintain nasal breathing, the Body Oxygen Level Test (BOLT) score will be measured. If the BOLT score is low, guidance will be provided on how to increase it by adjusting the breathing technique."
62688933|NCT06239753|EXPERIMENTAL|Standard Prenatal Education Program Implementation|The group will receive the standard prenatal education program, consisting of 5 sessions of general education and 2 sessions of standard pregnancy exercises and respiratory exercises, as part of the hospital's prenatal education program. The educational topics will include one-hour sessions on pregnancy and nutrition, postpartum care and family planning, baby care and infant massage, breastfeeding and lactation education, and first aid for infants, under the headings of childbirth and coping methods for labor pain
62688934|NCT06239753|NO_INTERVENTION|Control|The control group will consist of pregnant women attending routine examinations at the hospital's maternity clinic. As per hospital policy, routine breastfeeding education is provided after the 32nd week during regular prenatal check-ups at the hospital.
62688935|NCT04013854|ACTIVE_COMPARATOR|Arm A: Adjuvant Nivolumab (Complete Pathological Response)|480 mg IV for up to one year
62688936|NCT04013854|ACTIVE_COMPARATOR|Arm B: Adjuvant Nivolumab (Less than Complete Response)|480 mg IV for up to one year
62129686|NCT03815136|PLACEBO_COMPARATOR|Control|The control group will not chew chewing gum while undergoing capsule endoscopy.
62129687|NCT03591159|ACTIVE_COMPARATOR|Membrane Sweeping Group|
62129688|NCT03591159|NO_INTERVENTION|Control Group|
62129689|NCT01571804|ACTIVE_COMPARATOR|pregabalin 150 mg group|one capsule of pregabalin 150 mg and one placebo capsule
62480528|NCT02308059||Control|Group II; healthy volunteers
62480529|NCT02709018|EXPERIMENTAL|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
62480530|NCT02709018|PLACEBO_COMPARATOR|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
62480531|NCT00298415|ACTIVE_COMPARATOR|A|Chemotherapy (mono)
62738218|NCT03465579|OTHER|Cohort 2|Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.
62319821|NCT02870452|EXPERIMENTAL|Hypnosis|Hypnosis for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
62480532|NCT00298415|EXPERIMENTAL|B|Chemotherapy (doublet)
62480533|NCT02247791|ACTIVE_COMPARATOR|Cemented femoral stem|Patient undergoing total hip arthroplasty surgery
62319822|NCT02870452|EXPERIMENTAL|Cognitive-Behavioral Therapy|Cognitive Behavioral Therapy for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
62480534|NCT02247791|ACTIVE_COMPARATOR|Uncemented femoral stem|Patients undergoing total hip arthroplasty
62480535|NCT03646175|EXPERIMENTAL|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
62480536|NCT03646175|PLACEBO_COMPARATOR|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
62480537|NCT05981040|ACTIVE_COMPARATOR|Arm 1|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
62480538|NCT05981040|ACTIVE_COMPARATOR|Arm 2|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
62480539|NCT05981040|ACTIVE_COMPARATOR|Arm 3|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
62480540|NCT05981040|PLACEBO_COMPARATOR|Arm 4|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
62480541|NCT01983969|EXPERIMENTAL|Azacitidine + Vorinostat + Gemcitabine + Busulfan + Melphalan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1. Dexamethasone 8 mg by vein twice a day from Day -11 AM to Day -2 PM. Caphosol oral rinses 30 mL four times a day used from Day -9. Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9. Pyridoxine 100 mg by vein or mouth three times a day from Day -1. Vorinostat 1000 mg by vein on Day -11 through Day -2. Gemcitabine loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8. Melphalan 60 mg/m2 by vein on Days -3 and -2. Azacitidine starting dose 15 mg/ m2 by vein on Day -11. Stem cell transplant on Day 0. Patients with CD20+ tumors receive rituximab 375 mg/m2 by vein on Days -9.
62480542|NCT04504617|EXPERIMENTAL|Intervention Group|This group will consist of six kebeles with a total of 90 pairs of mothers and their children that will receive the nutrition education intervention to enhance complementary feeding practices first. The six lessons will be delivered in a period of 6 weeks. Before the intervention this groups will be assessed with the baseline assessment. After the intervention, this group will be assessed in three time points (post-intervention, follow-up 1 and follow-up 2).
62480543|NCT04504617|ACTIVE_COMPARATOR|Delayed Intervention Group|This arm will consist of the six kebeles with a total of 90 pairs of mothers and their children that will not receive the intervention immediately. This group will first complete the baseline and the second assessment. After the second assessment, this group will receive the nutrition education intervention to enhance complementary feeding practices. After the intervention, this group will be assessed in two additional time points (post-intervention and follow-up 1).
62129690|NCT01571804|ACTIVE_COMPARATOR|pregabalin 300 mg group|two capsules of pregabalin 150 mg
62129691|NCT01571804|PLACEBO_COMPARATOR|placebo group|to receive two identical placebo capsules
62319823|NCT02870452|NO_INTERVENTION|Control Group|No psychological intervention - standard Haemophilia care
62319824|NCT00700752|ACTIVE_COMPARATOR|senofilcon A/balafilcon A|senofilcon A silicone hydrogel contact lens worn during first 4-week period, balafilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
62319825|NCT00700752|ACTIVE_COMPARATOR|balafilcon A/senofilcon A|balafilcon A silicone hydrogel contact lens worn worn during first 4-week period, senofilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
62480544|NCT02404870|EXPERIMENTAL|Admission 1 or 2|Canagliflozin
62480545|NCT02404870|PLACEBO_COMPARATOR|Admission 2 or 1|Placebo
62480546|NCT06293586|EXPERIMENTAL|Peribulbar group (Group P)|The peribulbar group (P group _ 40) received a peribulbar block with 0.25 mL/kg of a 1:1 local anesthetic mixture (LAM) of 0.5% bupivacaine and 2% lignocaine. Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.
62688937|NCT04013854|EXPERIMENTAL|Arm C: Adjuvant Combination (Less than Complete Response)|ipilimumab (1mg/kg) plus nivolumab (3mg/kg) for 4 doses and then nivolumab (480 mg) alone for a total of one year
62688938|NCT03636230|ACTIVE_COMPARATOR|Remote Patient Management|Remote monitoring only
62688939|NCT03636230|PLACEBO_COMPARATOR|Standard of Care|In-clinic visits
62129692|NCT02151370||Cohort|
62129693|NCT04611932|EXPERIMENTAL|Reference-Reference-Test|
62129694|NCT04611932|EXPERIMENTAL|Reference-Test-Reference|
62319826|NCT00841295|EXPERIMENTAL|Carnitine|Intervention 'Parenteral L-carnitine supplementation' Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
62319827|NCT00841295|PLACEBO_COMPARATOR|Controle|Intervention 'Parenteral supplementation with sterile water'
62319828|NCT02650284|OTHER|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
62688940|NCT06439784|EXPERIMENTAL|whole body SPEC/CT|Patient will endergo whole body SPECT/CT in treatment position
62688941|NCT01545310|EXPERIMENTAL|Group 1 (healthy), Group 2 (schizophrenia)|
62688942|NCT02343250|EXPERIMENTAL|Cinidipine/Valsartan tablet|Cinidipine/Valsartan tablet
62688943|NCT02343250|ACTIVE_COMPARATOR|Cilnidipine+Valsartan|coadministration of cilinidipine and valsartan
62129695|NCT04611932|EXPERIMENTAL|Test-Reference-Reference|
62129696|NCT00140790|ACTIVE_COMPARATOR|Valsartan 40mg|Standard Dose valsartan
62129697|NCT00140790|ACTIVE_COMPARATOR|Valsartan 160mg|High Dose valsartan
62319829|NCT02650284|OTHER|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using Stryker's robotic-arm assisted surgery system Mako
62319830|NCT06560918|EXPERIMENTAL|Pre-post single arm design|Participants will wear the hearing aids for a week while receiving the SEBAR. Outcomes will be assessed with and without hearing aids.
62319831|NCT01244334|ACTIVE_COMPARATOR|Difluprednate Ophthalmic Emulsion 0.05%|
62319832|NCT01244334|ACTIVE_COMPARATOR|Prednisolone acetate suspension 0.1%|
62319833|NCT02807454|EXPERIMENTAL|Daratumumab Plus Durvalumab Treatment|"* Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~* IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward"
62319834|NCT02807454|EXPERIMENTAL|Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment|"* Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~* IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward~* oral POM at 4mg/day on days 1 to 21~* oral/IV dex at 40mg/day (\>75 years old) or 20mg/day (\>75 years old) on days 1, 8, 15 and 22"
62319835|NCT06069557|NO_INTERVENTION|Control|There will be no intervention in this group.
62688944|NCT05462496|EXPERIMENTAL|Participants who had Chemotherapy Following Pancreatic Adenocarcinoma|Participants to be given antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.
62129698|NCT01164098|ACTIVE_COMPARATOR|Rituximab|Participants will receive Rituximab post within 24 of Kidney Transplant
62129699|NCT01164098|NO_INTERVENTION|No rituximab|Participants will not receive Rituximab within 24 hours of Kidney Transplant
62129700|NCT06518369||Non-intervention or standard of care group|20 Patients who received standard of care
62129701|NCT06518369||Prehabilitation Group|10 patients who take part in a prehabilitation program for 4-6 weeks before surgery
62129702|NCT02578836|EXPERIMENTAL|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
62319836|NCT06069557|EXPERIMENTAL|Experimental|An intervention will be made to this group
62319837|NCT00075751|EXPERIMENTAL|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone on the above schedule for up to 1 year at the discretion of the treating physician.
62319838|NCT03499041|EXPERIMENTAL|LY3314814 Control|LY3314814 administered orally to participants with normal hepatic function
62319839|NCT03499041|EXPERIMENTAL|LY3314814 Mild|LY3314814 administered orally to participants with mild hepatic impairment
62319840|NCT03499041|EXPERIMENTAL|LY3314814 Moderate|LY3314814 administered orally to participants with moderate hepatic impairment
62319841|NCT03499041|EXPERIMENTAL|LY3314814 Severe|LY3314814 administered orally to participants with severe hepatic impairment
62319842|NCT04077203|SHAM_COMPARATOR|Control|Those receiving no visual feedback because the handheld device monitor will be occluded with black tape (the control group).
62738219|NCT03465579|OTHER|Cohort 3a|Men with high-risk PCa (HR-PCa) prior to radical surgery.
62738220|NCT03465579|OTHER|Cohort 3b|Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).
62738221|NCT03758131|EXPERIMENTAL|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. Mi is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
62738222|NCT03758131|ACTIVE_COMPARATOR|Motivational Interviewing|In the Motivational Interviewing (MI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
62738223|NCT03758131|PLACEBO_COMPARATOR|Waitlist Control|Those dyads randomized to the Waitlist Control (WC) condition willl be offered teh PMI intervention at month 2 post-intervention for the PMI arm.
62738224|NCT06547697|EXPERIMENTAL|Low-to-High|In the first period, the participants will be receiving a dialysate sodium concentration of 138 mmol/L, in the second period 140 mmol/L and in the third period 142 mmol/L.
62738225|NCT06547697|EXPERIMENTAL|High-toLow|In the first period, the participants will be receiving a dialysate sodium concentration of 142 mmol/L, in the second period 140 mmol/L and in the third period 138 mmol/L.
62738226|NCT06547697|EXPERIMENTAL|No change|In all three periods the participants will be recieving the same dialysate sodium concentration of 140 mmol/L.
62129703|NCT02582736||Olanzapine|Exposure to olanzapine will be defined as a prescription for olanzapine on the date of cohort entry.
62319843|NCT04077203|EXPERIMENTAL|Test|Those receiving the ability to visualize their glucose levels via the handheld device (the biofeedback group).
62319844|NCT02222129|ACTIVE_COMPARATOR|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
62319845|NCT02222129|EXPERIMENTAL|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
62688945|NCT06468865|EXPERIMENTAL|Continuous glucose monitor|"The participants will wear a blinded (i.e. glucose levels are not displayed) Dexcom® G7 continuous glucose monitor for one week during the screening week.~After the screening week, the patients will be given dietary guidance on how to avoid hypoglycaemia and be given a capillary glucometer (standard treatment procedure). The patients will also use a continuous glucose monitor and receiver which displays real-time glucose levels, for 6 weeks, to learn how to avoid hypoglycaemia."
62688946|NCT06468865|NO_INTERVENTION|No continuous glucose monitor|"The participants will wear a blinded (i.e. glucose levels are not displayed) Dexcom® G7 continuous glucose monitor for one week during the screening week.~After the screening week, the patients will be given dietary guidance on how to avoid hypoglycaemia and be given a capillary glucometer (standard treatment procedure). The patients will not use a continuous glucose monitor during the following 5 weeks, but during week 6 the patient will wear a blinded continuous glucose monitor."
62688947|NCT00245154|EXPERIMENTAL|Arm I|Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
62688948|NCT00245154|ACTIVE_COMPARATOR|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel and carboplatin as in arm I.
62688949|NCT01350479||MRSA colonized|Residents with history of MRSA in the past year
62688950|NCT01350479||Not MRSA colonized|Residents without history of MRSA in the past year
62688951|NCT05598515|EXPERIMENTAL|Time-Restricted Feeding|
62129704|NCT02582736||Other atypical antipsychotics|Exposure to atypical antipsychotics will be defined as a prescription for an atypical antipsychotic other than olanzapine (clozapine, quetiapine, ziprasidone, paliperidone, or aripiprazole) on the date of cohort entry.
62129705|NCT02582736||Typical antipsychotics|Exposure to typical antipsychotics will be defined as a prescription for a typical antipsychotic (chlormezanone, chlorpromazine, chlorprothixene, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, mesoridazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, tetrabenazine, thiopropazate, thioproperazine, thioridazine, thiothixene, trifluoperazine or zuclopenthixol) on the date of cohort entry.
62129706|NCT02582736||Risperidone (reference)|Exposure to risperidone will be defined as a prescription for risperidone on the date of cohort entry.
62129707|NCT05097417|EXPERIMENTAL|traditional Chinese medicine combined with thermal or cold ablation|
62319846|NCT05385718||Observational|The observational group may include those 18 years and older, with retrospective MRI data, or those whom prospective MRI images are collected as a participant. This study is decentralized, non-therapeutic and non-interventional.
62319847|NCT03950102|EXPERIMENTAL|SBRT|SBRT will be used as the primary bridging therapy for HCC patients on waitlist
62319848|NCT02126644|OTHER|Single Arm|Single arm of 10 patients - efficacy and safety assessed pre and post peel
62129708|NCT05097417|ACTIVE_COMPARATOR|thermal or cold ablation|
62319849|NCT03802422|EXPERIMENTAL|Vitamin B12 hydrodissection|Ultrasound-guided hydrodissection with Vitamin B12 between carpal tunnel and median nerve.
62319850|NCT03802422|PLACEBO_COMPARATOR|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
61925976|NCT04240002|EXPERIMENTAL|Dose Escalation - 2 years to less than 21 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
61925977|NCT04240002|EXPERIMENTAL|Dose Escalation - 1 year to less than 2 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
61925978|NCT04240002|EXPERIMENTAL|Dose Escalation - 6 months to less than 1 year of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
61925979|NCT04240002|EXPERIMENTAL|Dose Expansion|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the dose determined in dose escalation portion. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
62129709|NCT04149808|ACTIVE_COMPARATOR|Xeroform Control|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with xeroform dressing, which is the standard of care.
62129710|NCT04149808|EXPERIMENTAL|Mepilex Ag Intervention|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with Mepilex Ag; the product being tested.
62129711|NCT04713735|PLACEBO_COMPARATOR|Control: Placebo|Control: Placebo
62129712|NCT04713735|EXPERIMENTAL|Investigational: 600 mg bovine lactoferrin supplement|Investigational: 600 mg bovine lactoferrin supplement
62319851|NCT03469245||abdominal aortic aneurysms treated by fenestrated endovascular|Patients have an abdominal aortic aneurysms treated by fenestrated endovascular anacondaTM of society Vascutek will be included. Predisurge society will perform numerical simulation.
62319852|NCT06512805|ACTIVE_COMPARATOR|Routine transport group|During the period from April 2024 to June 2024, pediatric patients transferred from the emergency department to the pediatric intensive care unit (PICU), and from the PICU to general wards will serve as the control group. They will undergo the hospital's current in-hospital transfer process.
62319853|NCT06512805|EXPERIMENTAL|Post-guideline transfer group|"During the period from September 2024 to November 2024, pediatric patients transferred from the emergency department to the pediatric intensive care unit (PICU), and from the PICU to general wards will undergo the in-hospital transfer process based on the Clinical Practice Guidelines for In-hospital Transfer of Pediatric Inpatients (2023 edition)."
62319854|NCT02892851|EXPERIMENTAL|Deep brain stimulation (DBS)|Deep brain stimulation of the subthalamic nuclei (STN-DBS)
62688952|NCT05081635||Delphi panel|The Delphi panel will include 30 Portuguese experts in post-graduate medical education. The expert panel will include participants from the residency programs directors' coordination group, from the medical residents representing committee, from patients representing associations, from health institutions management teams, from the Portuguese Medical Association and also authors of relevant scientific articles on medical education. Study participants will be required to answer the questions of 3 questionnaires included in each of the 3 rounds of the study.
62688953|NCT04479852|EXPERIMENTAL|SP-624|Daily oral capsule, 20 mg/day
62688954|NCT04479852|PLACEBO_COMPARATOR|Placebo|Daily oral capsule
62688955|NCT01201044|EXPERIMENTAL|Gemcitabine, Nedaplatin,BAI plus 3DCRT|"Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year.."
62688956|NCT01201044|OTHER|Gemcitabine, Nedaplatin, IV Plus 3DCRT|"Gemcitabine 100mg/m2, D1 \& D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.~for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year."
62319855|NCT03201328|ACTIVE_COMPARATOR|healthy subjects|
62319856|NCT03201328|EXPERIMENTAL|patients with unilateral cochlear implants|
62319857|NCT03201328|EXPERIMENTAL|patients with bilateral cochlear implants|
62319858|NCT02771808||diabetic patients|obtain biomarker samples from diabetic patients and examine for 1-1 \& 1-2 \& 2-2 haptoglobin genotype
62688957|NCT06440538|EXPERIMENTAL|PCMS + Contralateral Motor Training|
62688958|NCT06440538|ACTIVE_COMPARATOR|PCMS + Rest|
62319859|NCT01805700|EXPERIMENTAL|Regular caffeine enhanced energy drink|Regular caffeine enhanced energy drink (containing 240mg caffeine \& 84g glucose) e.g. regular red bull cans (x3)
62129713|NCT05260359|ACTIVE_COMPARATOR|6% BEMT HRIPT|During the challenge phase of the HRIPT portion of the study, there will be 6 patches (2 product patches, 2 vehicle controls. 1 saline control and 1 empty patch), leaving out the positive control.
62129714|NCT05260359|ACTIVE_COMPARATOR|6% BEMT Cumulative Irritation Study|During the Cumulative Irritation portion of the study there will be 7 patches (2 product patches, 2 vehicle controls, 1 positive control, 1 low-irritancy control, and 1 empty patch). The low-irritancy control patch will be a saline patch. The positive control will be a SLS patch. The negative control will be an undosed patch.
62319860|NCT01805700|EXPERIMENTAL|Diet Caffeine enhanced energy drink|Diet Caffeine enhanced energy drink ( containing 240mg of caffeine alone) e.g. Red Bull light)
62319861|NCT01805700|ACTIVE_COMPARATOR|Glucose drink|Glucose drink (containing 84g glucose alone)
62319862|NCT05777434|ACTIVE_COMPARATOR|Group A (Conventional Physical Therapy)|"Patients in this group will recieve conventional physical therapy including hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises (cervical bracing with deep neck flexor activation followed by extremity ROM) along with general flexibility exercises.~Each exercise would be performed with a hold time of 5-10 sec and 8-12 reps. A total of 12 sessions would be conducted over a period of 4 weeks."
62480547|NCT06293586|EXPERIMENTAL|sub-tenon group (group S)|Children in the sub-Tenon group (sub-Tenon group (S), n _ 40) received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
62480548|NCT06293586|ACTIVE_COMPARATOR|paracetamol (group C)|Children in the paracetamol group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
62480549|NCT06393387||Persons with HIV on DTG/3TC|All data for PWH, initiated on DTG/3TC or BIC/F/TAF, between May 1, 2019 through January 28, 2023, will be collected for purposes of this retrospective study. 400 PWH on DTG/3TC and 400 PWH on BIC/F/TAF, for a total of 800 PWH, will be selected at random for inclusion in this retrospective study.
62480550|NCT06393387||Persons with HIV on BIC/F/TAF|All data for PWH, initiated on DTG/3TC or BIC/F/TAF, between May 1, 2019 through January 28, 2023, will be collected for purposes of this retrospective study. 400 PWH on DTG/3TC and 400 PWH on BIC/F/TAF, for a total of 800 PWH, will be selected at random for inclusion in this retrospective study.
62480551|NCT03012529|ACTIVE_COMPARATOR|Active drug|Patients receive oral adjunctive rifampin therapy
62480552|NCT03012529|PLACEBO_COMPARATOR|Placebo|Patients receive oral riboflavin
62480553|NCT06601140|EXPERIMENTAL|EMOCARE|
62480554|NCT05276219|ACTIVE_COMPARATOR|Furosemide only|• Boluses of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
62480555|NCT05276219|ACTIVE_COMPARATOR|isosorbide dinitrate|• Boluses of 3 mg IV isosorbide dinitrate given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
62480556|NCT05276219|ACTIVE_COMPARATOR|isosorbide dinitrate + furosemide|• Boluses of both 3 mg IV isosorbide dinitrate + of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
62480557|NCT05047536|EXPERIMENTAL|KZR-261 with standard therapy: open-label|"Part 1 (Dose Escalation)~The initial dose cohort of the Dose Escalation will receive 1.8 mg/m2 of KZR-261. Subjects will receive 3 doses in a 28-day cycle.~___________________________________________~Part 2 (Dose Expansion)~Following safety review of all Dose Escalation cohorts and determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), KZR-261 will be evaluated for safety and preliminary efficacy in 4 tumor-specific cohorts and 1 all-tumor cohort to determine the recommended phase 2 dose (RP2D). The 4 tumor-specific cohorts will include:~* melanoma (including uveal melanoma)~* colorectal cancer~* prostate cancer~* mesothelioma"
61925980|NCT02929784|EXPERIMENTAL|Intervention|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Affected hemisphere anodal stimulation of the hand area of the primary motor cortex (C3/C4), Intensity of 2 mA (milliampere) for duration of 20 minutes. A total of 10 sessions: 5 sessions a week for 2 weeks.
61925981|NCT02929784|SHAM_COMPARATOR|Sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
61925982|NCT02929784|NO_INTERVENTION|no HSP|Patients hospitalized in the Loewenstein department of neurologic rehabilitation after first clinical stroke who do not have hemiplegic shoulder pain.
61925983|NCT06120777|EXPERIMENTAL|Test Subject|All subjects who are enrolled into the test group and participate in data collection have the Masimo INVSENSOR00069.
62480558|NCT05844605|EXPERIMENTAL|Prehabilitation|Adult patients affected by Brain Tumour and candidated for surgical treatment.
62480559|NCT05333471|EXPERIMENTAL|Interventional|As this is a single arm study, this arm includes all participants. Participants will receive fecal microbiota transplantation (FMT) delivered by colonoscopy as a treatment for chronic granulomatous disease (CGD)-associated colitis (AC).
62688959|NCT06440538|SHAM_COMPARATOR|Sham PCMS + Contralateral Motor Training|
62688960|NCT05736887|EXPERIMENTAL|N-Acetylcysteine arm|Subjects with recent history of COVID-19 infection randomized to receive N-Acetylcysteine.
62688961|NCT05736887|PLACEBO_COMPARATOR|Placebo arm|Subjects with recent history of COVID-19 infection randomized to receive placebo.
62688962|NCT02017834|EXPERIMENTAL|harmonic scalpel|
62480560|NCT06741735|EXPERIMENTAL|At-home fetal monitoring|Participants in this arm will be prescribed an INVU at-home fetal monitoring system. All training on the device use, troubleshooting, and accessing the cloud platform for telehealth (fetal) visits will be done by INVU through the INVU app. Non-stress testing will be done from home once or twice weekly as determined by provider at scheduled date and times.
62688963|NCT02017834|ACTIVE_COMPARATOR|standard technique|
62688964|NCT04619628|PLACEBO_COMPARATOR|Saline|Normal saline
62688965|NCT04619628|EXPERIMENTAL|Low dose cohort 1|COVI-VAC, single dose
62688966|NCT04619628|EXPERIMENTAL|Medium dose cohort 1|COVI-VAC, single dose
62688967|NCT04619628|EXPERIMENTAL|High dose cohort 1|COVI-VAC, single dose
62319863|NCT05777434|EXPERIMENTAL|Group B (Scapulothoracic Stabilization Exercises)|"Patients will recieve scapulothoracic stabilization exercises in addition to the convential physical therapy including hot pack, TENS, axial elongation, cervical isometrics and cervical stabilization exercises. SSE would include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance.~Each exercise would be performed with a hold time of 5-10 sec and 8-12 reps. A total of 12 sessions would be conducted over a period of 4 weeks."
62688968|NCT04619628|EXPERIMENTAL|Low dose cohort 2|COVI-VAC, two doses 28 days apart
62688969|NCT04619628|EXPERIMENTAL|Medium dose cohort 2|COVI-VAC, two doses 28 days apart
62688970|NCT04619628|EXPERIMENTAL|High dose cohort 2|COVI-VAC, two doses 28 days apart
62688971|NCT01213251|EXPERIMENTAL|Single Site Pacing|
62688972|NCT01213251|EXPERIMENTAL|Dual Site Pacing|
62688973|NCT01213251|NO_INTERVENTION|Control|
62688974|NCT02866331|EXPERIMENTAL|CB + G-CSF|
62688975|NCT02866331|PLACEBO_COMPARATOR|CB + placebo|
62688976|NCT02866331|EXPERIMENTAL|G-CSF|
62688977|NCT02866331|PLACEBO_COMPARATOR|Placebo|
62688978|NCT06053320|ACTIVE_COMPARATOR|Young Able-Bodied individuals|18-30 years old able-bodied individuals (healthy without any physical disability or neurological disorder).
62688979|NCT06053320|ACTIVE_COMPARATOR|Old Able-Bodied individuals|45-90 years old able-bodied individuals (healthy without any physical disability or neurological disorder).
62688980|NCT06053320|EXPERIMENTAL|Stroke with Spatial Neglect (SN) individuals|40-90 years individuals with more than 3 months following right hemisphere stroke.
62688981|NCT00071994|EXPERIMENTAL|Treatment (gefitinib)|Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62688982|NCT05942326|EXPERIMENTAL|Sleep GOALS|Weekly 15-to-20 minute educational video each, a commercial activity tracker (e.g., Fitbit) to monitor sleep and physical activity, wireless scale to monitor weight, and a lifestyle coach who will provide personalized support.
62688983|NCT05942326|ACTIVE_COMPARATOR|Education|Brochures that provide tips for improving sleep health, diet, and physical activity
62319864|NCT06385964|EXPERIMENTAL|SHR-4597|
62319865|NCT06385964|PLACEBO_COMPARATOR|SHR-4597 Placebo|
62319866|NCT01441687|EXPERIMENTAL|Arm I (PMU)|Patients receive digital rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then undergo a prostate biopsy.
62319867|NCT01441687|EXPERIMENTAL|Arm II (EPS)|Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.
62319868|NCT03837756|PLACEBO_COMPARATOR|Arm A: Placebo/Placebo|This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
62319869|NCT03837756|ACTIVE_COMPARATOR|Arm B: Lefitolimod/Placebo|This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
62688984|NCT00916526|EXPERIMENTAL|bronchial provocation test with mannitol|"Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.~After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests."
62319870|NCT03837756|ACTIVE_COMPARATOR|Arm C: Placebo/3BNC117 + 10-1074|This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
62688985|NCT04469946|EXPERIMENTAL|Exploratory|Participants were fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Pre-intervention measures were obtained within one week of the hearing aid fit and post-intervention measures were obtained after two months of daily hearing aid use.
62688986|NCT04591587|ACTIVE_COMPARATOR|Smile Group|Twenty patients (20) underwent SMILE surgery (first group)
62688987|NCT04591587|ACTIVE_COMPARATOR|Lenticule Group|Twenty patients (20) underwent lenticule implantation (second group)
62688988|NCT02496312|EXPERIMENTAL|ECOCAPTURE|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
62688989|NCT05557591|EXPERIMENTAL|Phase 2: Cemiplimab|Arm A: Cemiplimab is administered by IV infusion Q3W
62688990|NCT05557591|EXPERIMENTAL|Phase 2: BNT116 + Cemiplimab|Arm B: BNT116 is administered by IV injection. Cemiplimab is administered by IV infusion Q3W.
62688991|NCT00480025|EXPERIMENTAL|GSK1572932 Group|Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
62319871|NCT03837756|ACTIVE_COMPARATOR|Arm D: Lefitolimod/3BNC117 + 10-1074|This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
62319872|NCT03711071|EXPERIMENTAL|Intervention Group|The Intervention Group is allocated to a Workshop of communication training before data collection covering theoretical background and clinical implementation of ICE communication in association with frequent consultation contents.
62688992|NCT00480025|PLACEBO_COMPARATOR|Placebo Group|Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
62688993|NCT06639412|EXPERIMENTAL|Intervention arms|The intervention arm will receive the intervention.The intervention will be networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention \& control services.
62480561|NCT06741735|NO_INTERVENTION|In-office fetal monitoring|In this arm, typical standard of care in-office fetal monitoring visits will be done. Participants will have non-stress testing done in clinic once or twice weekly as determined by provider at scheduled date and times.
62480562|NCT06699433|EXPERIMENTAL|Virtual standardized patients (VSPs) training|Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases
62480563|NCT06699433|EXPERIMENTAL|Case teaching manuals|Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases
62480564|NCT06699433|EXPERIMENTAL|Case teaching videos|Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases
62480565|NCT02007733||Derivation Cohort|The derivation cohort includes patients enrolled in the first phase of the study, from February 2014 to June 2014. All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
62480566|NCT02007733||Validation Cohort|The validation cohort includes patients enrolled in the second phase of the study, from March 2015 to May 2015. All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
62688994|NCT06639412|ACTIVE_COMPARATOR|Control arm|Control Arm is an arm to which the intervention will not be implemented. The community in the control arm will receive NCD prevention and control measures given through the health care system.
62688995|NCT06381960|PLACEBO_COMPARATOR|Daily Chinese medicine placebo granules + regular chemotherapy;|Control group
62688996|NCT06381960|EXPERIMENTAL|Daily Fuzheng Quxie Recipe granules + regular chemotherapy|Treatment Group
62480567|NCT06742762|EXPERIMENTAL|Group 1|Participants with severe renal impairment will receive a single oral dose of AZD5004 under fasted conditions.
62480568|NCT06742762|EXPERIMENTAL|Group 2|Participants with normal renal function will receive a single oral dose of AZD5004 under fasted conditions.
62480569|NCT06742762|EXPERIMENTAL|Group 3 (Optional)|Participants with moderate renal impairment will receive a single oral dose of AZD5004 under fasted conditions.
62480570|NCT06450041|EXPERIMENTAL|Treatment|Patients will be treated with chemoimmunotherapy (temozolomide, irinotecan, GM-CSF, and dinutuximab) plus UD TGFβi NK cells.
62319873|NCT03711071|NO_INTERVENTION|Control Group|This group will not get the intervention before data collection.
62319874|NCT01877330|ACTIVE_COMPARATOR|Injection in interscalene groove|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove anterior and posterior to the brachial plexus nerves.
62480571|NCT00663663|EXPERIMENTAL|1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
62480572|NCT00663663|EXPERIMENTAL|2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
62480573|NCT06742567|EXPERIMENTAL|Study arm (Apixaban 2.5 mg bid)|"Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT. o In the event of stent thrombosis during the study period, considering the high ischemic risk, the patient will be switched to ticagrelor instead of clopidogrel, and aspirin will be discontinued while Apixaban will be continued. After four weeks, the patient will be switched to DAPT (aspirin~+ ticagrelor)."
62480574|NCT06742567|ACTIVE_COMPARATOR|Control group|The control arm will be of standard care i.e. DAPT in addition to other guideline directed medical therapy (GDMT).
62480575|NCT03643250|EXPERIMENTAL|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
62480576|NCT03643250|EXPERIMENTAL|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
62688997|NCT01505985|EXPERIMENTAL|Specialized Oral Nutritional Supplement|
62688998|NCT01505985|PLACEBO_COMPARATOR|Placebo|
62688999|NCT02714842|EXPERIMENTAL|Radiolabelled Diclofenac tablet A|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
62689000|NCT02714842|EXPERIMENTAL|Radiolabelled diclofenac tablet B|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
62689001|NCT02714842|ACTIVE_COMPARATOR|Voltaren|Single dose of enteric coated diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
62689002|NCT02714842|EXPERIMENTAL|Radiolabelled diclofenac tablet C|Single dose of delayed release diclofenac sodium (25 mg) tablet radiolabelled with 4 MBq 99mTc
62689003|NCT01613586|EXPERIMENTAL|Low dose ASP3652 twice daily|50 mg twice daily for 12 weeks
62689004|NCT01613586|EXPERIMENTAL|Medium dose ASP3652 twice daily|150 mg twice daily for 12 weeks
62689005|NCT01613586|EXPERIMENTAL|High dose ASP3652 twice daily|300 mg twice daily for 12 weeks
62689006|NCT01613586|PLACEBO_COMPARATOR|Placebo|Matching placebo twice daily for 12 weeks
62689007|NCT06570239|ACTIVE_COMPARATOR|Protocol A: Control group|Protocol A combines dry physiotherapy with psychological support. psychological support.
62689008|NCT06570239|EXPERIMENTAL|Protocol B: Intervention group|Protocol B combines hydrokinesitherapy and hydrothermal treatments, psychological psychological support.
62689009|NCT01245257||Alcoholic Hepatitis|Patients with alcoholic hepatitis
62689010|NCT06640504||Group 1|Patients newly admitted to ICU with sepsis or septic shock with manifestations suggestive of sepsis according to the guidelines of the 3rd International consensus definitions for sepsis and septic shock.
62689011|NCT02505074||Mitral Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the mitral valve with the Melody valve.
62689012|NCT02505074||Tricuspid Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the tricuspid valve with the Melody valve.
62689013|NCT06368674|EXPERIMENTAL|Intervention group Case Manager (CM)|The intervention group will receive extra follow-up by a CM after discharge.
62689014|NCT06368674|OTHER|Control group|The control group will receive usual follow-up after discharge, i.e. no active follow-up
62689015|NCT02762890|EXPERIMENTAL|Deep neuromuscular blockade|Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.
62689016|NCT02762890|ACTIVE_COMPARATOR|Moderate neuromuscular blockade|Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.
62689017|NCT05218161|ACTIVE_COMPARATOR|DA|Group DA: will be assigned to patients in whom dexmedetomidine alone will be used.
62689018|NCT05218161|EXPERIMENTAL|KD|Group KD: will be assigned to patients receiving ketamine plus dexmedetomidine.
62689019|NCT01543230|EXPERIMENTAL|CoMplete™ Acetabular Hip System (CoM)|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
62319875|NCT01877330|ACTIVE_COMPARATOR|Injection between nerve roots|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove inbetween the C5 and C6 nerve roots.
62689020|NCT05246839||Arm 1 - Usual Care (No Video)|Participant will receive the usual care pertaining to colorectal cancer (CRC) screening according to their respective clinical site and will not view either of the study videos.
62689021|NCT05246839||Arm 2 - Brief Video|Participant will watch a video pertaining to the importance of CRC screening.
62689022|NCT05246839||Arm 3 - Brief Video Plus|Participant will watch the same video as described in Arm 2, immediately followed by a second video pertaining to 3 CRC screening modalities: colonoscopy, FIT, and Cologuard.
62738227|NCT06277947|EXPERIMENTAL|C-HIPEC arm|Infuse paclitaxel (75mg/m\^2) and cisplatin (75mg/m\^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC with paclitaxel should be performed within 24 hours after cytoreductive surgery. The second HIPEC with cisplatin should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as diazoxide, or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
62319876|NCT01097616|EXPERIMENTAL|Suvorexant HD|Drug
62319877|NCT01097616|EXPERIMENTAL|Suvorexant LD|Drug
62319878|NCT01097616|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62319879|NCT06653010|EXPERIMENTAL|Single dose injection of REVO-UWD-01|Dose escalation will be performed for the single dose injection of REVO-UWD-01 for treating mCRC
62319880|NCT01025180|OTHER|Procalcitonin level|duration of the antibiotic treatment guided by procalcitonin level
62319881|NCT01025180|NO_INTERVENTION|physician's appreciation|duration of the antibiotic treatment based on physician's appreciation
62319882|NCT01447056|EXPERIMENTAL|LMP Specific T cells|LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
62319883|NCT01307995||GDM|Patients with Gestational Diabetes Mellitus found during pregnancy by means of 75g OGTT
62319884|NCT01307995||NGT|Pregnant patients with normal glucose tolerance as observed in 75g OGTT
62319885|NCT05030623|EXPERIMENTAL|Tadalafil|
62319886|NCT05030623|PLACEBO_COMPARATOR|Placebo|
62319887|NCT00089128|EXPERIMENTAL|Gemcitabine and Irnotecan|
62319888|NCT04466683|EXPERIMENTAL|Low radiation arm|A single dose of 35 cGY delivered to the whole thorax
62319889|NCT04466683|EXPERIMENTAL|High radiation arm|A single dose of 100 cGY delivered to the whole thorax
62319890|NCT04466683|NO_INTERVENTION|Control arm|Patients will receive no radiation therapy but will have research samples collected and best supportive care
62689023|NCT06673446|ACTIVE_COMPARATOR|control group (contour augmentation|"Teeth extraction : minimally invasive adjacent teeth extraction under anesthesia using periotome and forceps.~the empty sockets will be filled with a special collagen material (BioPlug) to aid healing for 4 to 8 weeks.~flap elevation : a full-thickness flap will be carefully raised using a crestal incision extended one tooth mesial and distal to the extraction location, then connected with two vertical incisions extended through the sulcus forming a trapezoid flap.~Implants Insertion: The two implant is then placed into the prepared sockets using surgical guide.~Bone Grafting: Any bone deficiencies are addressed by grafting. This involves placing a layer of (autogenous bone) directly on the two implants' surface, followed by a layer of a bone-grafting material (Demineralized Bone Matrix).~Membrane Placement: A double-layered collagen membrane is used to cover the grafted area.~Flap Closure: The previously lifted flap is repositioned and sutured back in place."
62689024|NCT06673446|ACTIVE_COMPARATOR|study group (VST)|"1. Access and Socket Preparation:~   * A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth. This creates a pouch for accessing the socket and surrounding bone.~  * Using special instruments from the VST kit.~2. Immediate Implant Placement with Guide:~   \* A prefabricated surgical guide ensures precise positioning of the implants directly into the socket.~3. Bone Grafting and Membrane:~   \* A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~4. Closure and Healing:~   * The small incision is stitched closed with sutures.~  * A temporary healing cap is placed on the implants to facilitate proper healing."
62480577|NCT03643250|EXPERIMENTAL|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
62480578|NCT03643250|EXPERIMENTAL|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
62480579|NCT03643250|EXPERIMENTAL|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
62689025|NCT04059822|EXPERIMENTAL|Slow and deep breathing|Daily practice of slow and deep breathing for 10 minutes per day. Breathing frequency will be 6 breaths per minute, with participants accessing a video aid to help guide their breathing. Breathing exercises will be conducted from enrolment until birth (maximum \~20 weeks if enrolment at 20 weeks gestation until \~40 weeks gestation birth)
62689026|NCT00595075|EXPERIMENTAL|1|Ramelteon 8 mg will be given once prior to a 2-hour nap
62689027|NCT00595075|PLACEBO_COMPARATOR|2|Placebo will be given once prior to a 2-hour nap
62319891|NCT06594523|EXPERIMENTAL|Denifanstat 50 mg|Denifanstat tablet, orally, once daily
62319892|NCT06594523|EXPERIMENTAL|Denifanstat 25 mg|Denifanstat tablet, orally, once daily
62319893|NCT06594523|PLACEBO_COMPARATOR|Placebo|Placebo tablet, orally, once daily
62339736|NCT03628417|EXPERIMENTAL|Bleomycin based electrochemotherapy|"Bleomycin~Bleomycin 1000 IU/ml:~* Tumor \< 0.5 cm³ - 1 ml/cm³ tumor volume~* Tumor \> 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)~Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU. Normal maximum limit for bleomycin is 15.000 IU/m² body surface area."
62480580|NCT00377260|EXPERIMENTAL|Amoxicillin-clavulanate|Reconstituted amoxicillin-clavulanate at 90/6.4 mg/kg/day in 2 divided doses for 10 days.
62480581|NCT00377260|PLACEBO_COMPARATOR|Placebo|Reconstituted placebo in 2 divided doses for 10 days.
62480582|NCT00304187|EXPERIMENTAL|Erythromycin|Subjects with Bulimia Nervosa will take erythromycin.
62480583|NCT00304187|PLACEBO_COMPARATOR|Placebo|Participants will take matched placebo.
62480584|NCT06725069||Agonist NMES|In the first group, NMES (Group 1=Agonist group) was applied to the wrist and finger flexors for 20 minutes in addition to conventional treatment.
62480585|NCT06725069||Antagonist NMES|In the second group, NMES (Group 2=Antagonist group) was applied to the wrist and finger extensors for 20 minutes in addition to conventional treatment.
62480586|NCT06725069||Exercise|Patients in the third group (Group 3=Control group) were included in an occupational rehabilitation program for 20 minutes to improve upper extremity functions in addition to conventional treatment.
62689028|NCT01813227|EXPERIMENTAL|Carfilzomib|Carfilzomib 20 mg/m2 on day 1, 2 then 56 mg/m2 days 8, 9 and 15, 16 over 30 minutes every 28 days. Dexamethasone 4 mg (8 mg if \> 45 mg/m2) orally each day of carfilzomib therapy. If less than a partial remission (PR) after 4 cycles, add rituximab 375 mg/m2 on day 16 of each cycle. Patients who meet the criteria for progression prior to 4 cycles of therapy will have rituximab added to their treatment. For patients receiving rituximab, the carfilzomib dose will be decreased to 27 mg/m2. Patients will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
62689029|NCT05663554|EXPERIMENTAL|WW Intervention|Participants in the intervention arm will be contacted by a WW Coach and will receive a voucher code that provides 12 months of access to the WW program and instructions for redeeming the code. The program will include access to weekly Virtual Workshops and the WW App. WW is a widely available, commercial behavioral weight management program that encourages healthy habits in the areas of food, activity, mindset, and sleep, with topics specific to diabetes.
62689030|NCT05663554|ACTIVE_COMPARATOR|Usual Care|Patients in the Usual Care Arm will continue to receive routine medical care by their healthcare provider. In addition, at the baseline visit, participants in the Usual Care Arm will receive one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments, based on current recommendations of the American Diabetes Association
62689031|NCT03673072|EXPERIMENTAL|Arm A (gemcitabine plus cisplatin)|Patients assigned to arm A will receive treatment with gemcitabine plus cisplatin. Chemotherapy will be administered for 3 cycles preoperatively (neoadjuvant part) and for 3 cycles postoperatively (adjuvant part).
62689032|NCT03673072|ACTIVE_COMPARATOR|Arm B (standard postoperative management)|Patients assigned to arm B will receive surgery directly, without receiving perioperative chemotherapy (Standard of Care / SOC). After surgery, adjuvant chemotherapy can be administered by investigator's choice.
62689033|NCT04985682|EXPERIMENTAL|Hemophilia A Group|Participants with hemophilia A were treated with ADVATE according to a regimen determined by the treating physician at the study site and in accordance with the national product label under standard clinical practice for 6.7 months.
62689034|NCT05856942|NO_INTERVENTION|Standard care|Patients will receive standard PrEP care in the clinic including in-person visits for triannual (every 4 months) HIV \& STI screening and comprehensive sexual health care.
62689035|NCT05856942|EXPERIMENTAL|Home-based care|Patients will have the option to complete their PrEP care from home including 1) self-collection of blood specimens for HIV, syphilis and creatinine; 2) self-swabs for extragenital GC/CT screening; and 3) telehealth follow-up. A maximum of two triannual follow-up visits per year may be conducted remotely; one visit per year must be in person. Participants also have the option to attend visits in person and are otherwise eligible to continue receiving comprehensive sexual health services in the clinic.
61925984|NCT05765812|EXPERIMENTAL|Phase 1 (Dose Escalation): Arm A - Debio 0123 + Temozolomide|Participants will receive intermittent Debio 0123, escalating doses along with temozolomide (TMZ) in each 28-day cycle for up to 2 years.
61925985|NCT05765812|EXPERIMENTAL|Phase 1 (Dose Escalation): Arm B - Debio 0123 + Temozolomide + Radiotherapy|Participants will receive intermittent Debio 0123, escalating doses along with TMZ and concomitant administration of radiotherapy (RT) for up to 6 weeks. As per Protocol _V4.0 Arm B has been permanently halted.
61925986|NCT05765812|EXPERIMENTAL|Phase 1 (Dose Escalation): Arm C - Debio 0123 + Temozolomide + Radiotherapy|Participants will receive intermittent Debio 0123, escalating doses along with TMZ and concomitant administration of radiotherapy (RT) for up to 6 weeks.
62129715|NCT00639795|ACTIVE_COMPARATOR|A|Patients randomized to receive thoracic paravertebral nerve blockade in addition to general endotracheal anesthesia during video assisted thoracoscopy procedure
62319894|NCT03598231|SHAM_COMPARATOR|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
62319895|NCT03598231|ACTIVE_COMPARATOR|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
62319896|NCT05951153|EXPERIMENTAL|Tributyrin nutritional supplement|Children between the ages of 2-17 with planned allogeneic hematopoietic cell transplantation with myeloablative preparative regimen, who also have standard of care nasogastric tube placement or existing gastric tubes will receive a daily dose of tributyrin.
62339737|NCT04397718|PLACEBO_COMPARATOR|Placebo + BSC|No active, only placebo (2 - prefilled syringes containing 3 ml of 0.9% saline) plus best supportive care.
62689036|NCT06691438|ACTIVE_COMPARATOR|prostate biopsies without virtual reality hypnosis headset|Biopsies are performed according to current recommendations
62689037|NCT06691438|EXPERIMENTAL|prostate biopsies with virtual reality hypnosis headset|Patient wearing a virtual reality headset put in place in the transfer room 15 minutes before the procedure and maintained throughout the procedure.
62689038|NCT05855759|ACTIVE_COMPARATOR|Acellular Dermal Matrix|Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix
62319897|NCT02050048|EXPERIMENTAL|High Volume Group (Intervention Arm)|"Patients will be randomized to receive intravenous Lactated Ringer's solution. In the high volume group (intervention arm), patients will receive fluids prior to, during, and after the completion of the procedure. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes"
62689039|NCT05855759|EXPERIMENTAL|Acellular Dermal Matrix with autologous orthobiologics|Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix with orthobiologics autologous: humeral bone marrow concentrate and subacromial bursa
62689040|NCT06351020|EXPERIMENTAL|LM-302|Patients will accept LM-302 monotherapy
62689041|NCT06351020|ACTIVE_COMPARATOR|Physician's choice Apatinib or Irinotecan|Patients will accept Apatinib or Irinotecan monotherapy
62689042|NCT01558258|EXPERIMENTAL|Mindfullness Meditation-based Intervention|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
61925987|NCT05765812|EXPERIMENTAL|Phase 1 (Dose Expansion): Debio 0123 + Temozolomide|Participants will receive Debio 0123, escalating doses along with temozolomide (TMZ) in each 28-day cycle for up to 2 years. Participants will receive one of the 2 selected doses for further investigation.
61925988|NCT05765812|EXPERIMENTAL|Phase 2: Debio 0123 RD + Temozolomide|Participants will receive intermittent Debio 0123 RD along with TMZ in each 28-day cycle for up to 2 years.
62689043|NCT01558258|NO_INTERVENTION|Wait-list control group|The wait-list control condition will control for naturally occurring changes in stress and other outcomes over the six-week intervention period. After the post-treatment assessments have been completed, those assigned to the wait-list control group will be able to participate in the MAP classes.
62689044|NCT04111536|ACTIVE_COMPARATOR|Liothyronine (LT3), then placebo|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
62689045|NCT04111536|PLACEBO_COMPARATOR|Placebo, then Liothyronine|A placebo tablet matching in appearance to LT3 tablets, dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
61925989|NCT06548074|EXPERIMENTAL|Prevention (H-PACE program)|See Detailed Description.
62319898|NCT02050048|ACTIVE_COMPARATOR|Low Volume Group (Control Arm)|Patients will be randomized to receive intravenous Lactated Ringer's solution. In the low volume group (control arm), patients will receive fluids at the start of the ERCP. The fluids will be administered via infusion at a rate of 1.5 cc/kg/hr. Fluids may be continued through the 90 minute post-procedure observation period.
61925990|NCT04980573|EXPERIMENTAL|Intervention|Participants receive a bottle of plant-based oil to inhale twice daily for 14 days.
62689046|NCT00874016|ACTIVE_COMPARATOR|Airtraq|Intubation with the use of the Airtraq
62689047|NCT00874016|ACTIVE_COMPARATOR|Direct Laryngoscopy|Intubation using direct laryngoscopy
62689048|NCT05013736||Infants|Pre-term and term born infants with corrected gestational age between term age and 24 months with radiologically-confirmed acute unilateral or bilateral brain lesions, including perinatal stroke, neonatal hemorrhagic or thrombotic stroke, involving the motor cortex and/or subcortical structures, and intracranial hemorrhage, involving the motor cortex and/or subcortical white matter, or periventricular leukomalacia. Parents/legal guardians able to attend study visits at the University of Wisconsin-Madison.
62689049|NCT00694590|EXPERIMENTAL|plerixafor|
62319899|NCT02232516|EXPERIMENTAL|Treatment (romidepsin, lenalidomide)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62319900|NCT01582282|PLACEBO_COMPARATOR|placebo|matched placebo BID
62319901|NCT01582282|ACTIVE_COMPARATOR|psyllium 3.4g BID|3.4g psyllium BID for a Total of 6.8g daily
62319902|NCT01582282|ACTIVE_COMPARATOR|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day
62480587|NCT02272803|EXPERIMENTAL|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Biological: Elotuzumab (BMS-901608)~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
62689050|NCT05989477|NO_INTERVENTION|Control Arm|The control arm will receive standard treatment.
62689051|NCT05989477|EXPERIMENTAL|Interventional Arm|Individuals within the intervention will receive standard care and access to the Breast Cancer Treatment Application (BCTA) for 13 months.
62319903|NCT06099717|EXPERIMENTAL|Test|Dual-cantilevered single implant bridge
62319904|NCT06099717|ACTIVE_COMPARATOR|Control|3-unit implant fixed dental prosthesis
62319905|NCT03466346|ACTIVE_COMPARATOR|Interpersonal psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
62319906|NCT03466346|ACTIVE_COMPARATOR|fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
62319907|NCT03466346|ACTIVE_COMPARATOR|Fluoxetine after IPT|participants who do not remit from MDD and PTSD after treatment with IPT may be randomized to fluoxetine.
62319908|NCT03466346|ACTIVE_COMPARATOR|IPT after fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT.
62319909|NCT03466346|ACTIVE_COMPARATOR|IPT + fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT + fluoxetine.
62319910|NCT04713020|EXPERIMENTAL|Effectiveness of Application Education Intervention|This study hopes that through the intervention of mobile device education programs, it can provide patients with easy access and repeated viewing and learning. It can replace traditional leaflet health education and reduce the workload of clinical nurses. It is hoped that it can effectively improve the self-care knowledge of stroke patients, improve self-efficacy, reduce the symptoms of depression, and increase the satisfaction of education and guidance. Eventually, patients can be prevented from recurring from stroke, and they can coexist peacefully with stroke and have a good quality of life.
62689052|NCT05320952|EXPERIMENTAL|working sleep apnea patients|50 sleep apnea patients with mild to moderate sleep apnea using WellO2 device for three months
62129716|NCT00639795|SHAM_COMPARATOR|B|Patients randomized to receive sham single-injection thoracic peripheral nerve blockade (no injection) in addition to general endotracheal anesthesia
62129717|NCT02931214|EXPERIMENTAL|GMI-1359|Dose escalation
62129718|NCT02931214|EXPERIMENTAL|Placebo|Dose escalation
62129719|NCT00780949|EXPERIMENTAL|1: Crohn's disease patient|intestinal biopsies
62129720|NCT06051955|OTHER|oral sodium sulfate|OSS is a colon cleansing agent administered in a split dose fashion, inducing diarrhea by drawing water into the intestine.
62129721|NCT01037634|EXPERIMENTAL|Oseltamivir|Participants will receive Oseltamivir to treat influenza.
62129722|NCT00522782|ACTIVE_COMPARATOR|A|Nebulized budesonide
62129723|NCT03352024|OTHER|Standard Care|Relational care used to help the patient by reducing the fear and anxiety
62129724|NCT03352024|OTHER|Hypnosis|Hypno-analgesia is used to help the patient by reducing the fear and anxiety
62129725|NCT06057116|EXPERIMENTAL|massage|Massage was applied to people who were hospitalized in the obstetrics ward of the pregnant woman, had a single fetus, awaiting spontaneous delivery, had no pregnancy complications, had no systemic disease, and agreed to voluntarily participate in the study.
62129726|NCT06057116|EXPERIMENTAL|acupressure|Acupressure for pregnant women who are hospitalized in the obstetrics service, have a single fetus, expect spontaneous delivery, do not have pregnancy complications, do not have any systemic disease, and agree to voluntarily participate in the study.
62319911|NCT04713020|OTHER|genaral care|Give patients routine care
62319912|NCT05946395|EXPERIMENTAL|Hearing aid and synchronous speech therapy|This arm will begin speech therapy at the same time as the fitting of the hearing aid.
62319913|NCT05946395|ACTIVE_COMPARATOR|Hearing aid and deferred speech therapy|This arm will begin speech therapy 3 months after fitting the device.
62480588|NCT02272803|ACTIVE_COMPARATOR|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
62689053|NCT00489359|EXPERIMENTAL|Pemetrexed/Carboplatin Phase 1|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
62689054|NCT00489359|EXPERIMENTAL|Pemetrexed/Carboplatin Phase 2|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
62129727|NCT06057116|NO_INTERVENTION|control group|No intervention was performed on the patients who were hospitalized in the obstetrics service of the pregnant woman, had a single fetus, awaiting spontaneous delivery, had no pregnancy complications, had no systemic disease, and agreed to voluntarily participate in the study.
62129728|NCT04644341||COVID survivors|Individuals who were infected by CPVID-19 and recovered.
62319914|NCT05413967|EXPERIMENTAL|Mills manipulation in addition to myofasical release therapy|mills manipulation
62319915|NCT05413967|EXPERIMENTAL|Nirschl exercises in addition to myofascial release therapy|Nirschel exercises
62319916|NCT02676349|EXPERIMENTAL|Arm B|Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy
62129729|NCT00106080|EXPERIMENTAL|Intervention|Audit and Feedback
62129730|NCT00106080|NO_INTERVENTION|Control|Usual care
62129731|NCT03072914|NO_INTERVENTION|The control group|The control group has a sphygmomanometer wound around the upper arm or lower extremity and applies the same pressure, but a 3-way stopcock is installed in the middle so that no pressure is applied.
62319917|NCT02676349|ACTIVE_COMPARATOR|Arm A|Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy
62319918|NCT05927246||Patients with Thoracic Malignancies|All patients undergoing RT for Thoracic Malignancies
62319919|NCT05927246||Patients with Breast Cancer|All patients undergoing RT for Breast Cancer
62319920|NCT00862381|EXPERIMENTAL|1|Hydrocortisone
62319921|NCT00862381|PLACEBO_COMPARATOR|2|Placebo
62319922|NCT01795040|EXPERIMENTAL|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
61925991|NCT04980573|PLACEBO_COMPARATOR|Placebo|Participants receive a bottle of inert oil to inhale twice daily for 14 days.
61925992|NCT05501262|ACTIVE_COMPARATOR|Standard of Care|Steroid and lidocaine injection
61925993|NCT05501262|EXPERIMENTAL|Study|Steroid and lidocaine injection with cryoablation
61925994|NCT02278341|EXPERIMENTAL|Roxadustat|Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
62689055|NCT06673823|EXPERIMENTAL|Experimental group|In the Experimental Group, Mirror Therapy will be applied by covering any birthmarks or scars on the less affected lower extremity (LE) if they obstruct the child's view. The therapy will take place in a distraction-free environment to help each child maintain focus and concentration. A mirror, at least 35 × 25 inches in size, will be placed between both LEs, with the more affected LE concealed behind a black curtain, allowing a clear reflection of the less affected LE. The child will be instructed to observe the mirror image of their more affected LE for one to two minutes. To begin, the therapist will visually demonstrate the technique.
61925995|NCT02278341|ACTIVE_COMPARATOR|ESA (Erythropoiesis Stimulating Agent) treatment|Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.
61925996|NCT06710106|EXPERIMENTAL|Prebiotic group|Natural yogurt with prebiotic formula
61925997|NCT06710106|PLACEBO_COMPARATOR|Placebo group|Natural yogurt with placebo formula
61925998|NCT04982588|EXPERIMENTAL|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)"
61925999|NCT01599832|EXPERIMENTAL|Treatment (pazopanib hydrochloride, DCE-MRI)|Patients receive pazopanib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7.
61926000|NCT04245371|ACTIVE_COMPARATOR|Active|Lidocaine Patch 1.8% applied to affected hand at night for 2 weeks following FDA approved dosing recommendations, i.e. 12 hours during each 24-hour daily cycle.
61926001|NCT04245371|PLACEBO_COMPARATOR|Placebo|Placebo Patch applied to affected hand at night for 2 weeks for 12 hours during each 24-hour daily cycle.
61926002|NCT01624805|EXPERIMENTAL|Treatment (methylprednisolone, hATG, cyclosporine, G-CSF)|Patients receive methylprednisolone IV over 10 minutes on days 1-4 and IV or PO with taper over days 5-30. Patients also receive horse anti-thymocyte globulin IV over 8 hours daily on days 1-4, cyclosporine PO BID on days 1-180, and pegfilgrastim or pegfilgrastim biosimilar SC on day 5 and/or filgrastim SC beginning on day 5 and continuing until absolute neutrophil count recovers. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
62129732|NCT03072914|ACTIVE_COMPARATOR|RIPC with RIPostC group|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
62129733|NCT04652791||Wangbi Capsule|Patients who are taking Wangbi Capsule for the treatment.
62480589|NCT00809250|EXPERIMENTAL|GM-K562/leukemia cell vaccine|Biological/Vaccine: GM-K562/leukemia cell vaccine Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
62480590|NCT03957226|EXPERIMENTAL|Trasnhumeral e-OPRA Implant|This arm includes patients with transhumeral amputation that will receive the e-OPRA implant system.
61926003|NCT02178683|NO_INTERVENTION|Tacrolimus and Mycophenolate Mofetil|Non-myeloablative allogeneic SCT from an HLA-Identical or non-identical family onor or unrelated donors, with fludarabine and low-dose TBI, with immunosuppression utilizing tacrolimus and MMF.
61926004|NCT03957590|EXPERIMENTAL|Tislelizumab + chemoradiotherapy|Tislelizumab once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
61926005|NCT03957590|PLACEBO_COMPARATOR|Placebo combined + chemoradiotherapy|Placebo once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
61926006|NCT03257176|EXPERIMENTAL|Stepping Stones and Creating Futures|Receive the 21 session intervention
61926007|NCT06182579|EXPERIMENTAL|RiMO-401|• Single intratumoral injection followed by radiation
61926008|NCT04059198|EXPERIMENTAL|Arm 1 - Inarigivir Soproxil Daily|Inarigivir Soproxil Alone 400 mg Inarigivir daily for 12 weeks followed by 400 mg daily in combination with TAF 25 mg daily for 12 weeks
61926009|NCT04059198|EXPERIMENTAL|Arm 2 - Inarigivir Soproxil 3 Times Weekly|400 mg Inarigivir 3 times weekly for 12 weeks followed by 400 mg 3 times weekly in combination with TAF 25 mg daily for 12 weeks
61926010|NCT04059198|EXPERIMENTAL|Arm 3 - Inarigivir Soproxil and TAF Daily|400 mg Inarigivir daily in combination with TAF 25 mg daily for 24 weeks
61926011|NCT04974918|EXPERIMENTAL|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of Lip defects|participants will be chosen according to liable age and information will be given about complications
61926012|NCT02133521|PLACEBO_COMPARATOR|Placebo|Placebo 3 x 1 tablet, given everyday for 28 days of study period
62480591|NCT04089917||Q Aspiration Catheter|mechanical thrombectomy for acute ischemic stroke
62480592|NCT05850416|EXPERIMENTAL|mGlide-Care|mHealth mediated HTN care model with self-monitoring and medication adjustment
62129734|NCT04652791||Other drugs|Patients who are not taking Wangbi Capsule for the treatment.
62129735|NCT05546307|EXPERIMENTAL|one relaxation session before the examination|
62129736|NCT05546307|ACTIVE_COMPARATOR|No relaxation session before the examination|
62129737|NCT04164459|EXPERIMENTAL|Xalost S|
62129738|NCT04164459|ACTIVE_COMPARATOR|Xalatan|
62319923|NCT01795040|PLACEBO_COMPARATOR|placebo without PUFAs|Placebo without PUFAs
62319924|NCT02222987|ACTIVE_COMPARATOR|Terbogrel|
62319925|NCT02222987|EXPERIMENTAL|Terbogrel with Clopidogrel|
62480593|NCT05850416|ACTIVE_COMPARATOR|Usual Care Plus|Usual Care including self-monitoring support
62480594|NCT05064891||Stroke patients|
62689056|NCT06673823|ACTIVE_COMPARATOR|Control group|In the Control Group, conventional therapy will include exercises such as stride standing to allow weight shifting between extremities, single leg standing, stooping and recovering from a standing position, standing on a balance board, and various balance training exercises. Additionally, the program will incorporate stretching exercises for the hip flexors, adductors, hamstrings, and calf muscles, along with gait training exercises conducted in an open environment.
62480595|NCT05064891||Participants without stroke|
62689057|NCT01985282||Nutrition Status and Physical Function|Nutrition questionnaire will be administered Physical functional status will be tested
62689058|NCT05833139|EXPERIMENTAL|BI 1810631 (R) followed by BI 1810631 + itraconazole (T)|
62689059|NCT04007679|EXPERIMENTAL|Pain education group|Pain education was conducted in physical conditions similar to the university classrooms where the study was performed for all participants.
62129739|NCT04164459|ACTIVE_COMPARATOR|Taflotan-S|
62129740|NCT00814905|PLACEBO_COMPARATOR|vaginal delivery 1|no further antibiotics after delivery (the patient will receive a saline infusion instead of antibiotics)
62129741|NCT00814905|ACTIVE_COMPARATOR|vaginal delivery antibotics2|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following vaginal delivery
62129742|NCT00814905|OTHER|cesarean delivery one dose3|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
62129743|NCT00814905|OTHER|cesarean multiple antibiotics 4|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
62129744|NCT02646358|EXPERIMENTAL|Cohort 1: Normal Renal Function|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
62480596|NCT06742775||Under 30|Healthy volunteers younger than 30 years
62129745|NCT02646358|EXPERIMENTAL|Cohort 2: Mild Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
62129746|NCT02646358|EXPERIMENTAL|Cohort 3: Moderate Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
62129747|NCT02646358|EXPERIMENTAL|Cohort 4: Severe Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
62129748|NCT02646358|EXPERIMENTAL|Cohort 5: End Stage Renal Disease|Vepoloxamer Injection, 50 mg/kg for 1 hour followed by 15 mg/kg/hr for 5 hours
62129749|NCT01104675|EXPERIMENTAL|ENMD-2076 treatment|
62129750|NCT02753738|EXPERIMENTAL|SSRI treatment|Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
62129751|NCT02753738|PLACEBO_COMPARATOR|Placebo treatment|Subjects will receive 21 days of placebo treatment while performing learning paradigms.
62129752|NCT00763152||stability of Beacons in prostatic bed|Patients implanted with the Calypso transponders following radical prostatectomy for prostate cancer will be followed for observation of transponder stability.
62319926|NCT02222987|ACTIVE_COMPARATOR|Clopidogrel|
62319927|NCT01129791|EXPERIMENTAL|Raw Milk first|Organic raw cow's milk
62319928|NCT01129791|PLACEBO_COMPARATOR|Pasteurized milk first|Organic pasteurized cow's milk
62319929|NCT01129791|PLACEBO_COMPARATOR|Non-Dairy Milk first|Unflavored soy milk
62319930|NCT04013737||Patients and Public|Exploration of patient and public engagement with antibiotic decision making in secondary care. Prospective evaluation of a co-designed intervention to support enhanced knowledge and understanding of infections and their management.
62319931|NCT04013737||Prescribers|Quantitative evaluation of the impact of using a clinical decision support system to support antibiotic decision making.
62319932|NCT02339298|ACTIVE_COMPARATOR|Music group|music application
62319933|NCT02339298|SHAM_COMPARATOR|Control group|only headphones
62319934|NCT03556683|EXPERIMENTAL|Hypertonic Saline|Subjects will inhale hypertonic saline before having a Mucociliary Clearance (MCC) scan
62319935|NCT01746992|EXPERIMENTAL|pirarubicin|3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate
62319936|NCT01746992|ACTIVE_COMPARATOR|doxorubicin|8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)
62480597|NCT06742775||Between 30 and 50|Healthy volunteers between 30 and 50 years
62480598|NCT06742775||More than 50|Healthy volunteers older than 50 years
62480599|NCT06496568|EXPERIMENTAL|Arm A|Participants in this group will receive inavolisib tablets, to be taken by mouth (PO), once daily (QD), on Days 1-21 of each cycle.
62480600|NCT06496568|EXPERIMENTAL|Arm B|Participants in this group will receive inavolisib tablets, to be taken PO, QD and atezolizumab given as an intravenous (IV) infusion once every 3 weeks (Q3W).
62480601|NCT01862731||1/Control Volunteers|Healthy controls
62480602|NCT01862731||2/Volunteers with Pain|Subjects with Chronic Idiopathic Patellofemoral Pain
62480603|NCT01165450|ACTIVE_COMPARATOR|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
62129753|NCT00873405|ACTIVE_COMPARATOR|SRSG|Silastic® ring sleeve gastrectomy (SRSG).
62129754|NCT00873405|OTHER|SRGB|Silastic® ring gastric bypass.
62689060|NCT06186401|EXPERIMENTAL|Cohort 1: Starting Dose (5 x 10^7 CAR+ cells)|Participants with newly diagnosed EGFRvIII+ GBM with unmethylated MGMT promotor status will undergo leukapheresis for manufacturing of E-SYNC T cells at least 2 weeks after completion of tnon-interventional, standard of care radiation therapy. Participants receive cyclophosphamide IV and fludarabine IV on days -5, -4, and -3 and then receive E-SYNC T cells IV on day 0. Participants will receive a single infusion of drug product (DP) (5 x 10\^7 CAR+ T cells) and be monitored for safety, presence of and possible synNotch \> CAR-T priming of the DP in the peripheral blood.
62129755|NCT01761201|EXPERIMENTAL|levofloxacin|Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
62129756|NCT01761201|ACTIVE_COMPARATOR|Isoniazid|"Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months"
62129757|NCT00132964|ACTIVE_COMPARATOR|Immobilizaton device|Below Knee walking cast
62319937|NCT05394272|EXPERIMENTAL|Efficacy of Energy Therapy - Pranic Healing with chronic pain|Energy therapy - Pranic Healing to be applied for 8 weeks weekly and 3 times 4 weeks apart for relief of chronic pain
62319938|NCT05394272|EXPERIMENTAL|Efficacy of Energy Therapy - Pranic Healing - with linked medical condition|Energy Therapy - Pranic Healing protocol for linked medical condition applied for 8 weeks weekly and 3 times 4 weeks apart , relevant BT/Urine sample /stool sample 4 weeks apart to evaluate changes.
62319939|NCT04297566||Crohn disease's patients|Crohn's disease patients seen in gastroenterology consultation or coming in day hospital for treatment
62319940|NCT05910021||Women with ODS and POP|This pilot study established and standardized an interdisciplinary surgical approach of laparoscopic resection rectopexy (L-RRP) combined with a laparoscopic mesh sacrocolpopexy (L-SCP) used synonymously for sacrohysteropey and sacrocervicopexy, as well. Additionally, an absorbable biological mesh (
62319941|NCT06688032|ACTIVE_COMPARATOR|Jarlsberg cheese|Daily oral intake of 75g and 90g Jarlsberg cheese to females and males, respectively
62319942|NCT06688032|ACTIVE_COMPARATOR|Norvegia cheese|Daily oral intake of 75g and 90g Norvegia cheese to females and males, respectively
62319943|NCT05794997||Propranolol or Carvedilol|Exposure group
62129758|NCT00132964|EXPERIMENTAL|Immobilization device|Removable ankle brace
62129759|NCT04739280||Single center registry for WACE|We propose a single center registry for patients requiring diagnostic, screening, or surveillance for potential or existing cardiac illness. All eligible patients will undergo an MCG with periodic follow-ups. No treatment decisions will be based on the MCG findings, until CardioFlux has appropriate FDA labelling for clinical use.
62129760|NCT00803387||Patients taking Xalatan with ocular dryness or irritation|"* patient must already be using xalatan for at least 1 month prior to study enrollment in both eyes and have complaints of dry eye and/or irritation.~* any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)"
62129761|NCT06133049||Ozanimod exposed|
62129762|NCT06133049||Other DMT exposed|
62129763|NCT06133049||Not DMT exposed|
62129764|NCT01985334|EXPERIMENTAL|A1 (any SABA and/or SAMA)|Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
62319944|NCT05794997||Atenolol, Bisoprolol or Sotalol|Reference group
62319945|NCT01773200||Aneurysmal Subarachnoid Hemorrhage|Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage
62319946|NCT02306772|EXPERIMENTAL|Formulation A|TP05 Coating A
62319947|NCT02306772|EXPERIMENTAL|Formulation B|TP05 Coating B
62339738|NCT04397718|EXPERIMENTAL|Degarelix + BSC|Active Degarelix (2 - prefilled syringes containing 3 ml of reconstituted Degarelix concentrated to 40mg/ml) plus best supportive care.
62689061|NCT06186401|EXPERIMENTAL|Cohort 1: Dose-escalation (1.5 x 10^8 CAR+ cells)|If there are no dose-limiting toxicities in the starting dose cohort, participants with newly diagnosed EGFRvIII+ GBM with unmethylated MGMT promotor status will undergo leukapheresis for manufacturing of E-SYNC T cells at least 2 weeks after completion of tnon-interventional, standard of care radiation therapy. Participants receive cyclophosphamide IV and fludarabine IV on days -5, -4, and -3 and then receive E-SYNC T cells IV on day 0. Participants will receive a single infusion of drug product (DP) (1.5 x 10\^8 CAR+ T cells) and be monitored for safety, presence of and possible synNotch \> CAR-T priming of the DP in the peripheral blood.
62689062|NCT06186401|EXPERIMENTAL|Cohort 2: Tissue analysis cohort|Participants with EGFRvIII+ glioblastoma recurrence after initial non-investigational, chemoradiation who need surgery will have the EGFRvIII H-scored based on digital image analysis of EGFRvIII immunohistochemistry (IHC) slides, with the score denoting both extent of and intensity of positive staining. Participants with an H-score of \>=250 will undergo leukapheresis for manufacturing of E-SYNC T cells at the maximum tolerated dose, or recommended dose based on results from cohort 1 more than 2 weeks after completion of their non-investigational, standard of care radiation therapy. Participants will receive a single infusion of drug product (DP) on day 0 and will be admitted to the hospital for surgical resection (non-investigational) between days 14 and 28, and monitored for safety, presence of and possible synNotch \> CAR-T priming of the DP in the peripheral blood, and anti-tumor response of E-SYNC T cells.
62129765|NCT01985334|EXPERIMENTAL|A2 (glycopyrronium)|Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
62129766|NCT01985334|EXPERIMENTAL|B1 (any LAMA or LABA and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA
62129767|NCT01985334|EXPERIMENTAL|B2 (glycopyrronium and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
62129768|NCT01985334|EXPERIMENTAL|C1 (any LABA and ICS)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC
61926013|NCT02133521|EXPERIMENTAL|DLBS1033|DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
61926014|NCT06040879|EXPERIMENTAL|PENG BLOCK|receiving pain relief through PENG and LFCN block
61926015|NCT06040879|ACTIVE_COMPARATOR|PCA|receiving morphine PCA analgesia
62129769|NCT01985334|EXPERIMENTAL|C2 (indacaterol/glycopyrronium)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)
62339739|NCT02237157|OTHER|Gemcitabine, Local Delivery (Dose 1)|Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
62480604|NCT01165450|PLACEBO_COMPARATOR|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
62689063|NCT06636422||Patients indicated for Motherwort injection|During the registration and enrollment period of the study, all patients who meet the clinical indications for the use of motherwort injection, as determined by the physician, and voluntarily agree to participate while fulfilling ethical requirements, will be recruited from designated medical institutions and departments. The observation period for each observer was established based on the clinical application of motherwort injection.
62689064|NCT06570590|ACTIVE_COMPARATOR|Arthroscopy|Using arthroscopy in minimally invasive lapidus procedure is the current standard of care. However a new screw is used (PROstep MIS 5mm Chamfer Screw). The new hardware is expected to be substantially equivalent to standard of care.
62689065|NCT06570590|EXPERIMENTAL|No Arthroscopy|Non-Arthroscopic Mini Arthrotomy Procedure (research-specific): Surgical procedure between the two treatment groups are equivalent except at the step of checking cartilage removal. After use of the cartilage burr the surgeon will make a small dorsal portal and use this to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint. The Principal Investigator wants to know if the mini arthrotomy procedure is as effective as the control because this procedure is faster and easier to perform.
62689066|NCT03358173||Conservative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
62689067|NCT03358173||Operative Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the humeral shaft fracture will be carried out
62689068|NCT03700125|EXPERIMENTAL|ECMO resuscitation|6 patients who meet the eligibility criteria will be treated by pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable and can establish ECMO flow within 30 minutes of collapse
61926016|NCT00546468|EXPERIMENTAL|Laparoscopy assisted distal gastrectomy|Laparoscopy assisted distal gastrectomy with D2 lymph node dissection.Surgery will be done in similar operative extent with control open distal gastrectomy. Omentectomy will be omitted.
62689069|NCT06515106|EXPERIMENTAL|Antibody-mediated LGI1 encephalitis patients|Participants of a prospective cohort in post-acute phase of the Antibody-mediated NMDA Receptor Encephalitis that will received a behavioral treatment.
62689070|NCT02067156|EXPERIMENTAL|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
62689071|NCT06563830|OTHER|Evaluation of MRRPI knowledge and attitude levels of nurses|Before the training application, the effectiveness of the training application will be evaluated by applying pre-test and training application followed by two patients and intermittent post-test after three months.
62689072|NCT06399107|EXPERIMENTAL|Experimental: Treatment (CD19/BCMA-CAR T cells, chemotherapy)|"Participants will be administered a one-time dose of the Drug Product, created using their own CD34+ hematopoietic stem cells which are gathered through plerixafor-induced mobilization and apheresis. These cells are then modified with the BAH243 lentiviral vector (LVV), which carries the human beta-A-T87Q globin gene.~Additionally, the same process of plerixafor mobilization and apheresis will be employed to collect rescue cells."
62689073|NCT02637674|EXPERIMENTAL|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF
62689074|NCT04072939||Single arm|dilated fundus exam
62689075|NCT05739994|EXPERIMENTAL|Dorsolateral prefrontal cortex (DLPFC)|Theta burst transcranial magnetic stimulation (cTBS) will be applied over dorsolateral prefrontal cortex (DLPFC).
62480605|NCT06213649|EXPERIMENTAL|Topical steroids|Participants in this arm will receive anti-amoebic therapy plus topical steroids.
62480606|NCT06213649|PLACEBO_COMPARATOR|Topical placebo|Participants in this arm will receive anti-amoebic therapy plus topical placebo.
62480607|NCT06497127|EXPERIMENTAL|Cohort 1|BW-00112 150 mg or volume-matched placebo on Day 1 and Day 90
62480608|NCT06497127|EXPERIMENTAL|Cohort 2|BW-00112 300 mg or volume-matched placebo on Day 1 and Day 90
62480609|NCT06497127|EXPERIMENTAL|Cohort 3|BW-00112 600 mg or volume-matched placebo on Day 1 and Day 90
62480610|NCT03904329||Obese Patients with non valvular AF|Obese Patients with non valvular AF using oral anti coagulants
62480611|NCT06054555|EXPERIMENTAL|ABP 206|Subjects will receive Dose A of ABP 206 via intravenous (IV) infusion.
62480612|NCT06054555|ACTIVE_COMPARATOR|Nivolumab|Subjects will receive Dose A of Nivolumab via IV infusion.
62480613|NCT06741397|EXPERIMENTAL|CAB Group|Participants receive lead-in injections comprising cabotegravir LA during month one and injections of a new formulation of CAB LA at Month 3, Month 5 and every 4 months thereafter to Month 29.
62480614|NCT02581553|EXPERIMENTAL|Sequence AB|Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)
62689076|NCT05739994|EXPERIMENTAL|Supramarginal gyrus (SMG)|Theta burst transcranial magnetic stimulation (cTBS) will be applied over the supramarginal gyrus (SMG).
62689077|NCT05739994|SHAM_COMPARATOR|Sham control group|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex.
62689078|NCT01961180|ACTIVE_COMPARATOR|active comparator|Drug: Cipralex
62319948|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine \[AZA\]/ 6-mercaptopurine \[6-MP\]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
62319949|NCT02605863|EXPERIMENTAL|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
62319950|NCT02605863|EXPERIMENTAL|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
62319951|NCT02755740|OTHER|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
62319952|NCT00486226||1 Endovascular|All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
62319953|NCT00279500|EXPERIMENTAL|single arm study|Argus 16 Retinal Stimulation System-single arm study.
62319954|NCT04688567|EXPERIMENTAL|Patient-driven iCBT|Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment program
62319955|NCT04688567|ACTIVE_COMPARATOR|Standardized iCBT (TAU)|Patients who are randomized to the control condition undergo the usual iCBT program available for anxiety disorders for a standardized time period of 8 weeks
62319956|NCT03301480||No contraception/18-19 years old|
62319957|NCT03301480||Use of ENG-I/18 - 19 years old|
62319958|NCT03301480||LNG-IUS/18-19 years old|
62480615|NCT02581553|EXPERIMENTAL|Sequence BA|Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).
62480616|NCT02581553|EXPERIMENTAL|Sequence CD|Day 1: lesinurad/allopurinol FDC tablets (Treatment C \[fasted\]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D \[fed\]).
62689079|NCT01961180|PLACEBO_COMPARATOR|placebo comparator|Drug: Placebo
62480617|NCT02581553|EXPERIMENTAL|Sequence DC|Day 1: lesinurad/allopurinol FDC tablets (Treatment D \[fed\]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C \[fasted\]).
62480618|NCT02581553|EXPERIMENTAL|Sequence EF|Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)
62480619|NCT02581553|EXPERIMENTAL|Sequence FE|Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).
62480620|NCT06741839|EXPERIMENTAL|nCLE guided biopsy|
62480621|NCT06741839|EXPERIMENTAL|Visual biopsy|
62689080|NCT05772130|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive a family letter and their genomic test report to share with at-risk first degree relatives on study.
62319959|NCT03301480||No Contraception/ 25 - 45 years old|
62319960|NCT03301480||Use of ENG-I/25 - 45 years old|
62319961|NCT03301480||LNG-IUS/25-45 years old|
62319962|NCT01858428|ACTIVE_COMPARATOR|Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
62339740|NCT02237157|OTHER|Gemcitabine, Local Delivery (Dose 2)|Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
62480622|NCT05746806|EXPERIMENTAL|Single arm|Patients with locally recurred prostate cancer will receive a ultrahypofractionated stereotactic radiotherapy to the radiologically identified lesion (Dose: 5 fractions with 7Gray every second work week day) combined with an androgen deprivation therapy (LHRH-agonist / -antagonist) for 6 months.
62480623|NCT06741826|EXPERIMENTAL|Group nCLE-NB-rEBUS|According to the preoperative planning, the bronchoscope was placed at the bronchial opening of the target lobe segment, and the catheter was operated to reach the target lesion under the guidance of virtual navigation and after reaching the target lesion, the ultrasonic probe was opened to observe whether the ultrasonic image of the target lesion could be detected, and the image recording was collected to confirm that the virtual navigation catheter had accurately reached the target lesion. The ultrasound probe was removed, the TX ™ disposable transbronchoscopic dilator catheter was inserted to establish a working channel, and the nCLE was inserted to probe the benign and malignant status of the pleural lesion to determine the biopsy location and image recording was taken. Then the biopsy equipment was inserted and delivered to the target lesion for biopsy, and 5 pieces of biopsy tissue were collected.
62689081|NCT05772130|EXPERIMENTAL|Arm II (provider-mediated contact)|Patients receive a family letter and their genomic test report to share with at-risk first degree relatives and relatives also receive provider-mediated contact to discuss genetic results on study.
62319963|NCT01858428|EXPERIMENTAL|Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
61926017|NCT00546468|ACTIVE_COMPARATOR|Open Distal Gastrectomy|Conventional standard D2 open distal gastrectomy without omentectomy.
61926018|NCT04997265|EXPERIMENTAL|Low Intensity Anticoagulation|For patients assigned to the low intensity anticoagulation strategy, clinical teams will be instructed to initiate low intensity anticoagulation at doses and frequencies commonly used for deep vein thrombosis (DVT) prophylaxis. The choice of anticoagulant, dose, and frequency of administration will be deferred to treating clinicians.
61926019|NCT04997265|ACTIVE_COMPARATOR|Moderate Intensity Anticoagulation|For patients assigned to the moderate intensity anticoagulation group, clinical teams will be instructed to initiate a continuous infusion of moderate intensity anticoagulation targeting either a partial thromboplastin time (PTT) of 40-60 seconds or an Anti-Xa level of 0.2 to 0.3 IU/mL. The choice of anticoagulant and approach to dosing will be deferred to treating clinicians.
61926020|NCT06199037|EXPERIMENTAL|SHR-1707|
62689082|NCT03696693||children with chronic rhinosinusitis|Children aged 6-18 years presented with symptoms of chronic rhinosinusitis will be recruited from the otorhinolaryngology out-patient clinic and department at Assiut University Hospital from October, 2018 to October, 2019.
62319964|NCT02205567||Group 2|1000 mg/day of Bergamot-derived product
62319965|NCT02205567||Group 1|500 mg/day of Bergamot-derived product
62319966|NCT01190657|EXPERIMENTAL|Selbex 50mg (14 days)|
62319967|NCT01190657|EXPERIMENTAL|Selbex 50mg (56 days)|
62319968|NCT06693856|ACTIVE_COMPARATOR|a high-dose group|methylprednisolone 500mg, D1-3, once every 4 weeks
62319969|NCT06693856|EXPERIMENTAL|a low-dose group|methylprednisolone 1mg/kg, D1-3, once every 4 weeks
62319970|NCT05327478||Non ECD|50-60 years old AND non ECD
62319971|NCT05327478||ECD|\>60 years old or ECD
62319972|NCT01974674|EXPERIMENTAL|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study
62319973|NCT04893330||patients|children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV
62319974|NCT01997567|ACTIVE_COMPARATOR|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
62319975|NCT01997567|PLACEBO_COMPARATOR|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
62319976|NCT00718861|PLACEBO_COMPARATOR|Placebo|Matching placebo administered intravenously.
61926021|NCT06199037|PLACEBO_COMPARATOR|SHR-1707 placebo|
61926022|NCT01721707|EXPERIMENTAL|Latanoprost+Brinzolamide combination|Latanoprost 0.005%(50 mg/ml)+brinzolamide 1%(10mg/ml) eye drops
62319977|NCT00718861|EXPERIMENTAL|Zoledronic acid|
62319978|NCT03636503|EXPERIMENTAL|Rituximab +Utomilumab+Avelumab|"* Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~* Utomilumab is administered intravenously over 1 hour once every 4 weeks~* Avelumab is administered intravenously over 1 hour once every 2 weeks"
62319979|NCT03636503|EXPERIMENTAL|Rituximab+Utomilumab+PF04518600|"* Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~* Utomilumab is administered intravenously over 1 hour once every 4 weeks~* PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
62319980|NCT03636503|EXPERIMENTAL|Rituximab+Avelumab+PF04518600|"* Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~* Avelumab is administered intravenously over 1 hour once every 2 weeks~* PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
62319981|NCT02074215|EXPERIMENTAL|Aerobic exercises|90-minute exercise sessions per week for 12 weeks
62319982|NCT02074215|ACTIVE_COMPARATOR|Stretch exercise|90-minute exercise sessions per week for 12 weeks
62319983|NCT00312780|EXPERIMENTAL|Arm 1: XL784|
62319984|NCT00312780|PLACEBO_COMPARATOR|Arm 2: Placebo Gel capsules|
62339741|NCT02237157|OTHER|Gemcitabine, Local Delivery (Dose 3)|Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
62339742|NCT02237157|OTHER|Gemcitabine, Local Delivery (Dose 4)|Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose
62689083|NCT03696693||children without chronic rhinosinusitis|Children have the same age and number in the study group which are presented with vocal symptoms and have not chronic rhinosinusitis will be recruited for the same duration.
62689084|NCT06675578|ACTIVE_COMPARATOR|Tulsi Gel group|Ocimum sanctum
62689085|NCT06675578|ACTIVE_COMPARATOR|Chlorhexidine Gel group|Chlorhexidine
61926023|NCT01721707|ACTIVE_COMPARATOR|Latanoprost|Latanoprost 0.005% (50 mg / ml)
61926024|NCT01139840|ACTIVE_COMPARATOR|vitamin D2|
61926025|NCT01139840|ACTIVE_COMPARATOR|vitamin D3|
62129770|NCT01985334|EXPERIMENTAL|D1 (any LAMA or LABA and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA
62129771|NCT01985334|EXPERIMENTAL|D2 (indacaterol/glycopyrronium and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
62129772|NCT02594735|OTHER|Open Label (One Arm)|A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
62319985|NCT01062646|EXPERIMENTAL|Multimodal music therapy|Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions.
62319986|NCT01062646|ACTIVE_COMPARATOR|community treatment as usual|
62129773|NCT03646136|EXPERIMENTAL|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
62129774|NCT03646136|ACTIVE_COMPARATOR|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
62129775|NCT05077618||patients with Alzheimer's disease|47 cases (patients with Alzheimer's disease)
62129776|NCT05077618||patients without Alzheimer's disease|47 patients without Alzheimer's disease
62129777|NCT04165967|EXPERIMENTAL|Tumor-infiltrating lymphocyte product (TIL) transfer|The TIL product will be produced from excised tumor lesions from the patient. Expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to Patient at Day 0.
62129778|NCT02799134|EXPERIMENTAL|group1|take Dexamethasone at 22:00 on the first day, 0.5mg
62129779|NCT02799134|PLACEBO_COMPARATOR|group2|take Vitamin C at 22:00 on the first day, 0.5mg
62129780|NCT02799134|OTHER|group3|take Dexamethasone at 15:00 on the second day, 0.5mg
62129781|NCT00972439|ACTIVE_COMPARATOR|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
62129782|NCT00972439|ACTIVE_COMPARATOR|Ovcon Fe®|Ovcon Fe® is an oral contraceptive that contains less progestin.
62319987|NCT01883583|EXPERIMENTAL|Pilot group|Contrast-enhanced Ultrasound And Sonoelastography of transplanted kidney will be performed for acquisition of a number of parameters and time-intensity curves, before ultrasound guided biopsy of transplanted kidney.
62319988|NCT00627640|EXPERIMENTAL|1|1 active (50 - 100 mg/day)
62319989|NCT00627640|PLACEBO_COMPARATOR|2|
62319990|NCT06430749|EXPERIMENTAL|Microwave Tissue Coagulation Arm|The Minimally invasive microwave coagulation surgery will be performed under general anesthesia for aiming to be provided total 65 patients.
62129783|NCT01087255|NO_INTERVENTION|Usual Care|Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
62129784|NCT01087255|EXPERIMENTAL|Electronic Pillbox Monitoring System|Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
62129785|NCT05493449|NO_INTERVENTION|Control Group|In this group, no milk (intervention) was provided
62319991|NCT06113354|EXPERIMENTAL|MRace Arm|Single-arm study of MRace Implant and Delivery System to treat severe mitral regurgitation All enrolled patients will receive the study device
62319992|NCT03366740|EXPERIMENTAL|GB mixed full strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the GB mixed full strength rice suji.~The allocated diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
62319993|NCT03366740|EXPERIMENTAL|Full strength rice suji alone|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.
62319994|NCT03366740|ACTIVE_COMPARATOR|3/4th strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.
62480624|NCT06741826|EXPERIMENTAL|Group NB-rEBUS|After anesthesia, electronic bronchoscope was inserted through laryngeal mask/tracheal intubation for routine bronchoscopy. According to the preoperative planning, the bronchoscope was placed at the bronchial opening of the target lobe segment, and the catheter was operated to reach the target lesion under the guidance of virtual navigation, and was placed about 1 cm away from the target. The radial ultrasonic probe was implanted, and after reaching the target lesion, the ultrasonic probe was opened to observe whether the ultrasonic image of the target lesion could be detected, and the image recording was collected to confirm that the virtual navigation catheter had accurately reached the target lesion. Take out the ultrasonic probe, insert it into the biopsy equipment, deliver it to the target lesion for biopsy, and collect 5 pieces of biopsy tissue.
62689086|NCT06433921|EXPERIMENTAL|Part 1|"Part 1 will consist of a 7 treatment, 7 period cross-over evaluation with all participants receiving the following treatments once, randomized to varying pre-specified sequences of:~* Zero dose (placebo of both salbutamol HFA-134a and salbutamol HFA-152a)~* 100 μg salbutamol HFA-134a~* 200 μg salbutamol HFA-134a~* 400 μg salbutamol HFA-134a~* 100 μg salbutamol HFA-152a~* 200 μg salbutamol HFA-152a~* 400 μg salbutamol HFA-152a~A minimum of a 2-day and maximum of a 7-day methacholine washout will separate each treatment period."
62480625|NCT06741553||Treated Group|This is an observational study. The investigators included early AD patients treated with Lecanemab, and evaluated them by plasma, magnetic resonance imaging (MRI) examination and clinical scale. The investigators observed the changes in MRI characteristics and clinical symptoms of patients after Lecanemab administration, evaluated the improvement effect of Lecanemab on cognitive function, and monitored the risk factors of adverse reactions.
62480626|NCT06743399||Experimental Group|"The experimental group included patients who received training, follow-up care, and the care bundle. Patients provided consent, completed demographic forms, and their PVC applications were assessed daily using the Phlebitis Care Bundle Follow-up Form. Full compliance with all care bundle parameters was required, and non-compliant patients were excluded. Nurses received feedback, and phlebitis symptoms were recorded daily. Monitoring continued until catheter removal or patient discharge. Data collection took place daily from 09:00-12:00, lasting about 2.5 hours."
62480627|NCT00472589||1|Healthy women
62480628|NCT00472589||2|Women with breast cancer
62480629|NCT06743191|EXPERIMENTAL|Assess the feasibility of Access Nourish in a 4-month study among adults with hypertension li|All participants will be prospectively assigned to receive a behavioral intervention that includes skills training, nutrient goal setting, self-monitoring via dietary tracking, personalized text message feedback, and adaptive health coaching. Participants will also receive a membership to Instacart+ and weekly grocery list recommendations from a health coach. All intervention will be delivered remotely using smartphone technology.
62738228|NCT06373354||Digital Breast Tomosynthesis (DBT)|Participants that agree to take part in this study, your standard follow-up imaging will be done using an FDA approved DBT system, but it will be different from the DBT system used for your routine screening. For example, if narrow-angle DBT was used for your routine screening, then you will have standard wide-angle DBT. If wide-angle DBT used for your routine screening, then you will have narrow-angle DBT. These images will be used for diagnosis and to help decide your further care.
62129786|NCT05493449|EXPERIMENTAL|UHT Milk|In this group, UHT Milk intervention was provided
62129787|NCT05493449|EXPERIMENTAL|Flavored Milk|In this group, flavored milk was provided to participants
62129788|NCT02459015|EXPERIMENTAL|Reaxon® Nerve Guide|Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
62129789|NCT02459015|ACTIVE_COMPARATOR|Autologous Nerve Graft|Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.
62129790|NCT04531592|EXPERIMENTAL|VPA plus SOC|A single dose of 140 mg/kg of VPA plus standard of care
62129791|NCT04531592|PLACEBO_COMPARATOR|Placebo plus SOC|A single dose of isotonic saline solution plus standard of care
62129792|NCT04076631||Hepatocellular Carcinoma|Patients with hepatocellular carcinoma undergo open hepatectomy.
62738229|NCT00904670|EXPERIMENTAL|Active|
62319995|NCT06309810|EXPERIMENTAL|Radiotherapy|"The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral 1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs)."
62319996|NCT04076124|EXPERIMENTAL|Active rTMS-DLPFC|This active group will receive high-frequency repetitive TMS stimulation.
62738230|NCT00904670|PLACEBO_COMPARATOR|Comparator|
62129793|NCT01694446|EXPERIMENTAL|Intraduodenal glucose or fructose|
62738231|NCT02889497|EXPERIMENTAL|300 subjects receive the first batch vaccine|300 subjects will be randomly received the first batch vaccine
62738232|NCT02889497|EXPERIMENTAL|300 subjects receive the second batch vaccine|300 subjects will be randomly received the second batch vaccine
62129794|NCT00999167|EXPERIMENTAL|HPN-100|
62129795|NCT00999167|PLACEBO_COMPARATOR|Placebo|
62129796|NCT03991754|EXPERIMENTAL|Amiodarone|Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.
62129797|NCT03991754|PLACEBO_COMPARATOR|Control|Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI
62129798|NCT04658693|EXPERIMENTAL|Multi contact electrode implant and implanted electromyography recording electrodes|"Fifteen subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
62129799|NCT01704300||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database \[GPRD\]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
62129800|NCT00914589|EXPERIMENTAL|FXIII17.5IU/Kg|Recombinant factor XIII at a single dose of 17.5 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
62319997|NCT04076124|EXPERIMENTAL|Active iTBS-DLPFC|This active group will receive intermittent theta-burst TMS stimulation.
62319998|NCT04076124|SHAM_COMPARATOR|Sham TBS-DLPFC or Sham rTMS-DLPFC|Patients in the sham group will receive the same iTBS or rTMS parameter stimulation, performing by a sham coil.
62319999|NCT04891250|EXPERIMENTAL|Intervention|Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio
62320000|NCT04891250|EXPERIMENTAL|Prophylaxis|An additional group of patients will be recruited will be randomized to either Ivermectin as prophylaxis (Intervention) or Standard of Care with no ivermectin (Control arm) in a 1:1 ratio
62320001|NCT05466149|EXPERIMENTAL|Furmonertinib 240mg QD|Treating patients of locally advanced or metastatic NSCLC with EGFR exon 20 insertions who have progressed during or after platinum-based chemotherapy.
62320002|NCT02005601|EXPERIMENTAL|Duloxetine|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
62320003|NCT02005601|PLACEBO_COMPARATOR|Control|Patients will receive 0mg of duloxetine
62689087|NCT06433921|EXPERIMENTAL|Part 2|"Part 2 is proposed to consist of up to a 7 treatment, 7-way cross-over pivotal evaluation with the following treatments given once, randomized to varying pre-specified sequences of:~* Zero dose (placebo of both salbutamol HFA-134a and salbutamol HFA-152a)~* 100 μg salbutamol HFA-134a~* 200 μg salbutamol HFA-134a~* 400 μg salbutamol HFA-134a~* 100 μg salbutamol HFA-152a~* 200 μg salbutamol HFA-152a~* 400 μg salbutamol HFA-152a~A minimum of a 2-day and maximum of a 7-day methacholine washout will separate each treatment period."
62320004|NCT01095952|EXPERIMENTAL|AVNS ON|Consulta downloaded with AVNS to provide high frequency bursting during fastly conducted AF. AVNS will be programmed on for five months. The feasibility and safety of the AVNS algorithm to reduce inappropriate shocks will be monitored.
62320005|NCT05415202||Remimazolam Sedation|"Patients receiving a nerve block prior to surgery or a re-block the day after surgery will receive remimazolam sedation for their nerve block.~The nerve block will then be performed under standard conditions with standard monitors. Remimazolam will be used for sedation following the guidelines on the label.~Dosing will be as follows:~Induction of Procedural Sedation For adult patients: Administer 5 mg intravenously over a 1-minute time period. For ASA\* III and IV patients: Administer 2.5 mg to 5 mg intravenously over 1 minute based on the general condition of the patient.~Maintenance of Procedural Sedation (as needed) For adult patients: Administer 2.5 mg intravenously over 15 seconds. At least 2 minutes must elapse prior to administration of any supplemental dose.~For ASA III and IV patients: Administer 1.25 mg to 2.5 mg intravenously over 15 seconds.~At least 2 minutes must elapse prior to administration of any supplemental dose."
62320006|NCT01746667|EXPERIMENTAL|Exposure in vivo|This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing \& Emmelkamp (1993).
62320007|NCT01746667|EXPERIMENTAL|Virtual Reality Exposure Therapy|"This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.~The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
62320008|NCT01746667|NO_INTERVENTION|Wait-list|Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
62320009|NCT05313919||1. Coronary microcirculatory disease|
62320010|NCT05313919||2. Epicardial vasospastic angina|
62689088|NCT05960435|EXPERIMENTAL|PNF group|Patients in the PNF group will deliver PNF stretching, active-assistive ROM exercises, PNF scapular patterns mobilization, posterior capsule stretching, and isometric strengthening for 3 weeks. Between 3-6 weeks PNF stretching and scapular mobilization exercises will progress and PNF strengthening and active ROM exercises will add to the program.
62320011|NCT05313919||3. Microvessel vasospastic angina|
62480630|NCT03937557|ACTIVE_COMPARATOR|men's hair count|
62480631|NCT03937557|PLACEBO_COMPARATOR|women's hair count|
62738233|NCT02889497|EXPERIMENTAL|300 subjects receive the third batch vaccine|300 subjects will be randomly received the third batch vaccine
62738234|NCT03515122||Persons with Spinal cord injury (SCI)|The total population of a specified group of persons with traumatic SCI will be invited to participate.
62129801|NCT00914589|EXPERIMENTAL|FXIII35IU/Kg|Recombinant factor XIII at a single dose of 35 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
62480632|NCT06720584|EXPERIMENTAL|Group 1: Immediate Treatment|Group 1 participants receive the intervention first which is completing the 4-month program. They will receive an additional survey when Group 2 completes the intervention.
62480633|NCT06720584|OTHER|Group 2: Wait-List Control (Delayed Intervention)|Group 2: Wait-List Control (Delayed Intervention) does not get the intervention while Group 1 is getting the intervention. Group 2 receives the intervention AFTER Group 1 has completed the intervention.
62738235|NCT03515122||Matched control group|A matched control group of the general population at a ratio of 3-4 to each person with SCI will be recruited from the Swedish Cardiopulmonary and Bioimage Study.
62738236|NCT02945358||Prolonged ICU stay|Group 1: adult cardiac surgery with cardiopulmonary pump with prolonged ICU stay Group 2: adult cardiac surgery with cardiopulmonary pump with non-prolonged ICU stay
62320012|NCT05313919||4. Non-cardiac disorder|
62738237|NCT04616313||c-cigarette never users|Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.
62738238|NCT04616313||former or current c-cigarette users|Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.
62738239|NCT04616313||never smokers|Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.
62738240|NCT05785286||Subject with male LUTS|Male subjects who have been bothered by male LUTS for at least 4 weeks and are still able to pass urine on their own without the need of assistance or urethral catheterization.
62738241|NCT05785286||Subject who is waiting for their transurethral ablative prostate surgery|Male subjects who are waiting for BPH surgery and are still able to pass urine on their own without the need of assistance or urethral catheterization.
62738242|NCT01271907|EXPERIMENTAL|Cohort 0|Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m\^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
62738243|NCT01271907|EXPERIMENTAL|Cohort 1|2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m\^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
62738244|NCT01271907|EXPERIMENTAL|Cohort 2|1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m\^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells
62738245|NCT00601692|EXPERIMENTAL|Regimen 1|Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
62738246|NCT00601692|EXPERIMENTAL|Regimen 2|Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
62738247|NCT06342492||Conduction System Pacing|Subjects who had lead placement via conduction system pacing approach
62738248|NCT06342492||Epicardial Lead Placement|Subjects who had lead placement via transthoracic, epicardial approach
62738249|NCT05040165|EXPERIMENTAL|Failure time analysis|"The primary objective is to evaluate the durability of the investigational device over its intended use lifetime (i.e. warranty period), specifically relating to any defect in the TPE material. Additionally, to gather information on the rate of side-effects, i.e. skin rashes, sores, etc.~Secondary objectives relate to gather information on how amputees use the liner, specifically:~* Intensity of use (days/week and hours/day)~* Alternation; i.e. switching every other day between liners~* Use of personal hygiene or cosmetic products~The following performance and safety aspects are to be verified:~• The ICEFORM line of devices are durable over their intended use lifetime."
62738250|NCT01576939|EXPERIMENTAL|IMRT Modulation|"All patients will undergo a computed tomography (CT) simulation study +/- a positron emission tomography (PET) scan using ≤ 3mm slices for radiation treatment planning. A standard, non-filling optimized IMRT (Intensity Modulated Radiation Therapy) plan will be generated and patients will be treated with megavoltage radiation over a course of \> 6 weeks with a planned tumor dose of \> 60 Gy. A medical doctor will perform weekly mucositis evaluation and grading for the measured site once a week during radiation therapy~Modulation of an IMRT plan to reduce the dose to less than 35 Gy delivered to adjacent normal mucosa surrounding the dental filling without compromising normal tissue or tumor doses."
62738251|NCT04878510|EXPERIMENTAL|Dexmedetomidine Intervention|Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada. Guidelines, the infusion will start at a mid-range dose of 0.6mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (Richmond Agitation-Sedation Scale \[RASS\] = -2 to +1 or Riker Sedation-Agitation Scale \[SAS\] 3-4).
62738252|NCT04878510|PLACEBO_COMPARATOR|Control Intervention|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 50mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans.
62738253|NCT05036655|ACTIVE_COMPARATOR|Intervention: PGMP|Sites will implement a perioperative glycemic management pathway based on national guidelines and current evidence, with support of an implementation scientist team.
62738254|NCT05036655|ACTIVE_COMPARATOR|Non-intervention: usual care|Sites will perform usual perioperative glycemic management.
62689089|NCT05960435|ACTIVE_COMPARATOR|Control group|Patients in the conservative group will deliver shoulder muscle static stretching, active-assistive ROM exercises, scapular mobilization, posterior capsule stretching, and isometric strengthening for 3 weeks. Between 3-6 weeks these exercises will progress and shoulder muscles strengthening via NMES and active ROM exercises will add to the program.
62689090|NCT05827237|EXPERIMENTAL|Clinical decision rule|Patients in whom the clinical decision rule is used to exclude acute coronary syndrome
62689091|NCT05827237|NO_INTERVENTION|Standard care|Patients in whom the general practitioner decides upon referral following local guidelines.
62689092|NCT01534221|ACTIVE_COMPARATOR|Study group two|Endeavor resolute drug eluting stent
62689093|NCT01534221|ACTIVE_COMPARATOR|Study group three|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
62320013|NCT03070418|EXPERIMENTAL|Abdulhai|One show man technique, it is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision.
62320014|NCT06513182|OTHER|Control - no wound protector|The (control - no wound protector) will not use the protector device during the course of the surgery. During surgery 4 tissue swab cultures will be obtained and sent to a laboratory for analysis.
62320015|NCT06513182|EXPERIMENTAL|Wound protector|Wound protector group will have an insertion of a wound protector after making an initial superficial approach to the shoulder. During surgery 4 tissue swab cultures will be obtained and sent to a laboratory for analysis. The wound protector will then remain in place until the end of the case during wound closure.
62480634|NCT06733597|ACTIVE_COMPARATOR|Cemented and Manual|
62480635|NCT06733597|ACTIVE_COMPARATOR|Cemented and Robotic|
62689094|NCT01534221|ACTIVE_COMPARATOR|Study group four|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
62689095|NCT01534221|ACTIVE_COMPARATOR|Study group five|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
62689096|NCT01534221|ACTIVE_COMPARATOR|Study group one|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
62689097|NCT05336760||ALS Patients|Patients with confirmed amyotrophic lateral sclerosis.
62689098|NCT05336760||Relatives|Close relatives of the patients included in the study.
62689099|NCT06184880|ACTIVE_COMPARATOR|A control group|"Patients will receive standard care, recommendations on physical activity.~patients should wear the wristband continuously for 7 days prior to scheduled hospital visit T0, T1, T2, T3, T4, T5"
62689100|NCT06184880|EXPERIMENTAL|B experimental Group|"1 or 2 physical activity sessions per week, either face-to-face or by videoconference at patient convenience: low-to-moderate intensity aerobic and anaerobic muscle-strengthening session and a 40-minute stretching/yoga session.~patients should wear the wristband continuously for 7 days prior to scheduled hospital visit T0, T1, T2, T3, T4, T5"
62689101|NCT06150742|EXPERIMENTAL|Niyad|1 mg/mL infusion of nafamostat mesylate
62129802|NCT00914589|PLACEBO_COMPARATOR|Placebo|Recombinant factor XIII placebo was administered as a single dose via slow i.v. push at a rate not exceeding two mL per minute.
62129803|NCT01204359|NO_INTERVENTION|follow-up|
62129804|NCT00858117|EXPERIMENTAL|Alemtuzumab and Rituximab|Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.
62129805|NCT01824485|EXPERIMENTAL|Group 2|Patients from Group 2 will receive an intra-articular injection of 1 ampoule (2ml) of OSTEONIL®, on a weekly basis, for 3 weeks (total of 3 injections)
62320016|NCT03391440|EXPERIMENTAL|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
62320017|NCT03120390|EXPERIMENTAL|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
62689102|NCT06150742|PLACEBO_COMPARATOR|Placebo|0.9% saline infusion
62689103|NCT04115293|EXPERIMENTAL|0.3 mg/kg zilucoplan (RA101495)|
62689104|NCT04115293|PLACEBO_COMPARATOR|Placebo|
62129806|NCT01824485|EXPERIMENTAL|Group 1|Patients from Group 1 will receive a single intra-articular injection of 3 ampoule (6ml) of OSTEONIL®
62738255|NCT01449396|SHAM_COMPARATOR|SHAM ACUPUNCTURE|Sham intervention: acupuncture needle without puncture nor stimulation
62738256|NCT01449396|EXPERIMENTAL|REAL ACUPUNCTURE|Experimental: acupuncture in selected points of the protocol designed
62738257|NCT01449396|OTHER|Control|Bed Rest
62738258|NCT03969745|EXPERIMENTAL|Time restricted feeding (TRF)|Participants restricted their daily energy intake window to between 8 am and 4 pm for two weeks. They were encouraged to not alter the quantity and composition of their diet or alter physical activity patterns.
62320018|NCT03120390|EXPERIMENTAL|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
62320019|NCT03120390|ACTIVE_COMPARATOR|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
62480636|NCT06733597|ACTIVE_COMPARATOR|Cementless and Manual|
62480637|NCT06733597|ACTIVE_COMPARATOR|Cementless and Robotic|
62480638|NCT04570748|EXPERIMENTAL|Group A|Direct anterior hip arthroplasty with capsule repair.
62480639|NCT04570748|ACTIVE_COMPARATOR|Group B|Surgery that the surgeon will not perform capsule repair after performing an initial capsulectomy during total hip arthroplasty
62689105|NCT04753359|EXPERIMENTAL|Med-A|"Med-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of the intervention. For subjects randomized to Med-A the study RD will instruct on adoption of an eating pattern consistent with a MedDiet using an individualized MedDiet exchange list and companion guide. Recommended daily exchanges are based on individual caloric needs to maintain weight. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet for 24 individual sessions (1-hour, held approximately weekly) in-person or virtually over the remaining 6 months. Additional asynchronous learning materials will be distributed weekly through a private Facebook group.~The Med-A group will be asked to maintain their usual physical activity."
62689106|NCT04753359|EXPERIMENTAL|WL-A|"WL-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the intervention. For WL-A, the focus will be on daily calorie restriction (-500-750 kcal/day) to achieve a 1-2 lb. per week WL and 5% WL from baseline at 6 months in the context of the subject's typical diet pattern. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet for 24 individual, virtual or in-person sessions (1-hour, held approximately weekly) over the remaining 6 months. Additional asynchronous learning materials will be distributed weekly through a private Facebook group.~The WL-A group will be prescribed an activity program. Physical activity will be monitored via FitBit."
62129807|NCT04626011|ACTIVE_COMPARATOR|Group One|Participants receiving full mouth disinfection and extractions in one stage.
62689107|NCT04753359|EXPERIMENTAL|WL-Med|"WL-Med will attend a one-hour, in-person session with a registered dietitian (RD) prior to the intervention. The RD will instruct on an eating pattern consistent with a MedDiet using an individualized exchange list. Exchanges are based on individual caloric needs to lose weight (WL-Med, calorie restriction to achieve a 1-2 lb. per week WL and 5% WL from baseline at 6 months). We will not ask subjects to abstain from alcohol despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet remotely or in-person for 24 individual sessions (1-hour, held approximately weekly). Additional asynchronous learning materials will be distributed weekly through a private Facebook group.~The WL-Med group will be prescribed an activity program. Some asynchronous lessons will contain information about physical activity. Physical activity will be monitored via FitBit."
62689108|NCT04753359|NO_INTERVENTION|Control|The study RD will meet individually with the Control group subjects in-person for 1-hour at the start of the 6-month intervention. Control participants will be instructed to maintain current eating and activity patterns and weight over the next 6 months. No dietary recommendations are provided, and they will receive weekly health newsletters that include non-diet related health topics (e.g., flu prevention). Contact will be made again at month-3 and post-intervention (month-6) research visits and during monthly phone calls to collect data pertaining to recent diet intake. At the month-3 assessment, weight will be checked and those with \>2.5% WL from baseline will receive additional instruction from the RD to maintain lifestyle patterns. All WL-Med materials are offered to the group in a self-guided format following the 6-month intervention.
62689109|NCT05967065|OTHER|Vestibular disorders|Patients uppfilling vestibular disorders diagnostic criterias
62689110|NCT05967065|OTHER|healthy control subjects|Patients without past or ongoing vestibular or balance disorders
62689111|NCT06674252|EXPERIMENTAL|Jiawei Bufei Tang|Oral administration of Jiawei Bufei Tang granules for 28 days, twice a day, 1 packet each time, and the medication must be taken with water.
62689112|NCT06674252|PLACEBO_COMPARATOR|Placebo granules|Take placebo granules orally for 28 days, twice a day, 1 pack each time, and the medication must be taken with water.
62689113|NCT01407341|EXPERIMENTAL|Supportive care (ChronOS)|Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
62689114|NCT05463471|EXPERIMENTAL|sodium acetate ringer|
62689115|NCT05463471|ACTIVE_COMPARATOR|albumin|
62689116|NCT05776004|EXPERIMENTAL|CAL02 with Standard of Care|CAL02 (a mixture of 2 liposomal components, both empty, unilamellar, liposomes) will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. CAL02 infusions will be administered over a 1 -2 hour period.
62689117|NCT05776004|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. Placebo will be prepared and administered following the same infusion protocol as CAL02. Placebo infusions will be administered over a 1 to 2 hour period.
62689118|NCT03607110||ketamine|ketamine used
62689119|NCT03607110||fentanyl|fentanyl used
62689120|NCT02106546|EXPERIMENTAL|Veliparib + Carboplatin + Paclitaxel|Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
62129808|NCT04626011|ACTIVE_COMPARATOR|Group Two|Participants receiving full mouth disinfection at stage one and extractions at stage two after 7 days.
62129809|NCT03447236|EXPERIMENTAL|Feuerstein Program|All subjects participating in the Feuerstein Program will be evaluated by anatomical and functional MRI as well as computerized cognitive assessment prior to and following intervention as outlined in the protocol.
62129810|NCT02505321|EXPERIMENTAL|fATDIVA - OTTT (Cases)|"Individuals identified with the polygenic lipodystrophy genetic variants of interest will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
62320020|NCT01439529|ACTIVE_COMPARATOR|Nominal|CRT device is programmed with the nominal values.
62129811|NCT02505321|EXPERIMENTAL|fATDIVA - OTTT (Controls)|"Control individuals carrying the average number of risk alleles and matched to individuals identified with the polygenic lipodystrophy genetic variants of interest for gender, age and BMI, will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
62129812|NCT00780351||SLEDD-f, vanco|Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
62129813|NCT00476346|ACTIVE_COMPARATOR|Calcium|Daily calcium supplementation Intervention: Calcium 2000mg / daily
62129814|NCT00476346|EXPERIMENTAL|Vitamin D|Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
62129815|NCT04313816||unique group|patients visiting their family physician
62129816|NCT01522794|EXPERIMENTAL|NOX-H94|Single dose of NOX-H94
62129817|NCT01522794|PLACEBO_COMPARATOR|Placebo|Single dose of placebo control
62129818|NCT01595334|ACTIVE_COMPARATOR|Study subjects desiring pregnancy|"Study subjects to be treated with rFSH, rLH throughout controlled ovarian hyperstimulation (COH) in appropriate dosages,considering age, body mass index (BMI), ovarian reserve, etc. and GnRH antagonist, cetrorelix in 0.25 mg/d when needed till the desired follicular maturity and the minimum required number of follicles are achieved.~INTRVENTIONS - Monitoring at regular intervals by transvaginal ultrasound and hormonal studies.Once pregnancy established by beta-human chorionic gonadotropin (hCG) and ultrasound will be supported by intervention of adequate luteal support by estrogen (E) + progesterone (P) for 12 weeks of gestation."
62129819|NCT01595334|OTHER|Control subjects desiring pregnancy|"Control subjects selected in randomized way,desiring pregnancy will be treated with gonadotrophins, rFSH and rLH in appropriate dosages considering age, BMI, ovarian reserve, etc. after standard downregulation with GnRH agonist, Leuprolide acetate, 1 mg/d under established 'Long Luteal Suppression Protocol' from the previous cycle.~INTERVENTIONS - Monitoring of response to treatment by hormonal study and sonography evaluation at regular intervals during COH till adequate number of mature follicles of minimum 18 mm mean diameter is achieved, to be followed by hCG trigger and ovum pick-up (OPU) and embryo transfer (ET). Chemical pregnancy by beta-hCG would be confirmed 14 days post-ET. Clinical pregnancy would be confirmed by sonography 6 weeks after ET (visibility of yolk sac and fetal heart-beat). Pregnancy support by E+P for 12 weeks would be provided."
62129820|NCT04704258|EXPERIMENTAL|TAVI + Embolic protection|Subjects with severe native aortic valve stenosis who meet the clinically approved indications for aortic valve interventions such as TAVI
62129821|NCT05508243|EXPERIMENTAL|Experimental|
62320021|NCT01439529|EXPERIMENTAL|Narrow QRS|CRT device is programmed by QRS optimization
62320022|NCT06636071|EXPERIMENTAL|Setrusumab|
62320023|NCT02273323|EXPERIMENTAL|Tea|Black tea
62320024|NCT02273323|PLACEBO_COMPARATOR|Placebo|Placebo
62320025|NCT00520676|EXPERIMENTAL|pemetrexed plus carboplatin|"Drug: pemetrexed 500 milligrams per square meter (mg/m\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram\*minute/milliLiter (mg\*min/mL), IV, q 21 days x 6 cycles maximum"
61926026|NCT02057627|EXPERIMENTAL|Perinatal Dyadic Psychotherapy|The Perinatal Dyadic Psychotherapy intervention consists of 8 home-based, nurse-delivered mother-infant sessions consisting of (a) a supportive, relationship-based, mother-infant psychotherapeutic component, and (b) a developmentally based infant-oriented component focused on promoting positive mother-infant interactions. The 8 sessions take place over three months with weekly 4 sessions (weeks 1 through 4) followed by 4 every other week sessions (weeks 5 through 8)
62129822|NCT00895531|ACTIVE_COMPARATOR|Peripheral Nerve group|Group will receive sciatic catheter placed before or after surgery by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
62129823|NCT00895531|EXPERIMENTAL|Depodur Group|patients will have an L2-L3 epidural placed while they are in the sitting position before or after femoral catheter placement. They will receive 7.5 mg Depodur via the epidural catheter. All of these patients will receive Singular 10 mg and Claritin 10 mg before the epidural Depodur is placed, as per our protocol of patients receiving EREM.
62689121|NCT02106546|PLACEBO_COMPARATOR|Placebo + Carboplatin + Paclitaxel|Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
62689122|NCT02993120||Cohort 1|For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.
62689123|NCT02993120||Cohort 2|• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.
62129824|NCT01593319|ACTIVE_COMPARATOR|ropivacaine|
62129825|NCT01593319|PLACEBO_COMPARATOR|Natrium chloride|
62129826|NCT02515305|EXPERIMENTAL|Test product|
62129827|NCT02515305|ACTIVE_COMPARATOR|Reference product|
62689124|NCT02993120||Cohort 3|For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks
62689125|NCT06520098|ACTIVE_COMPARATOR|Arm A : Continue BTKi single agent|Continue BTKi single agent (monotherapy) Standard Intervention
62689126|NCT06520098|EXPERIMENTAL|Arm B : BTKi + Venetoclax for 12 cycles, then discontinue|BTKi + Venetoclax for 12 cycles, then discontinue Experimental Intervention
62689127|NCT04578418|ACTIVE_COMPARATOR|Collagen + heavy slow resistance group|Daily collagen supplementation + heavy slow resistance training three times weekly for 12 weeks.
62689128|NCT04578418|EXPERIMENTAL|Placebo + heavy slow resistance group|Daily placebo supplementation + heavy slow resistance training three times weekly for 12 weeks.
61926027|NCT02057627|PLACEBO_COMPARATOR|Standard care plus depression monitoring|Standard care plus depression monitoring by phone on a schedule comparable to the intervention groups' home visits. Eight phone calls will take place over three months with weekly 4 calls (weeks 1 through 4) followed by 4 every other week calls (weeks 5 through 8). Phone monitoring will include administration of the Edinburgh Postnatal Depression Scale.
61926028|NCT05625620|EXPERIMENTAL|Experimental: Real tPCS|All patients will be randomized into daily cerebello- spinal tPCS or sham stimulation. Randomization will occur in a ratio of 1:1. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
62129828|NCT02515305|PLACEBO_COMPARATOR|Placebo product|
62129829|NCT03022812|ACTIVE_COMPARATOR|Exercises at a physiotherapy clinic|Neck-specific exercise at a physiotherapy clinic, 24 times during 12 weeks (plus an additional first visit).
62320026|NCT00520676|ACTIVE_COMPARATOR|docetaxel plus carboplatin|"Drug: docetaxel 75 mg/m\^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum"
61926029|NCT05625620|EXPERIMENTAL|Sham tPCS|All patients will be randomized into daily cerebello- spinal tPCS or sham stimulation. Randomization will occur in a ratio of 1:1. Sham tPCS arm will receive active tPCS. Then they will be crossed over to Real tPCS arm.
61926030|NCT03028350|EXPERIMENTAL|Ifetroban Oral Capsule|Oral ifetroban, 200 mg daily for 8 weeks
62480640|NCT06299280|EXPERIMENTAL|dual-task group|Cognitive tasks will be given simultaneously while students exercise in physical education class.
62689129|NCT04482062|EXPERIMENTAL|Edwards EVOQUE System & OMT|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation
62689130|NCT04482062|ACTIVE_COMPARATOR|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
62689131|NCT04482062|EXPERIMENTAL|Single-Arm Registry|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
61926031|NCT03028350|PLACEBO_COMPARATOR|Placebo Oral Capsule|Oral placebo daily for 8 weeks
61926032|NCT03258138|EXPERIMENTAL|More Intensive Program (MIP)|Participants will receive the more intensive program, which combines usual care with the full version of the healthy lifestyles program. Participants in this arm will meet weekly for group health and wellness learning sessions or brainstorming group sessions. In addition, they will meet monthly for individual sessions with a multidisciplinary health team, including a family physician, physical therapist and dietician to tailor their health goal development and action plans to their particular needs and situations. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
61926033|NCT03258138|EXPERIMENTAL|Less Intensive Program (LIP)|Participants will receive the less intensive program, which combines usual care along with health goal development. Participants in this arm will meet at baseline to set health goals with the support of a research assistant trained in theories of health behaviour and goal setting. They will also meet every three months to measure progress in achieving their goals. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
62320027|NCT01492231||Chart Review|Chart review of patients who had a procedure done at H. H. Chao Comprehensive Digestive Disease Center
62689132|NCT04482062|EXPERIMENTAL|Continued Access Study|Provides continued access to transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation.
61926034|NCT03882008|EXPERIMENTAL|Abatacept|Abatacept 125mg subcutaneous injection weekly for 24 weeks
61926035|NCT03187756|EXPERIMENTAL|Cyclophosphamide|
61926036|NCT05876260|EXPERIMENTAL|High-intensity interval exercise and post-exercise Greek yogurt (HIIE+GY)|Participants will consume greek yogurt following a single session of exercise
61926037|NCT05876260|ACTIVE_COMPARATOR|High-intensity interval exercise and post-exercise carbohydrate study supplement (HIIE +SS)|Participants will consume a carbohydrate-based study supplement following a single session of exercise
61926038|NCT04601922||Emergency Medicine Consultants|
62320028|NCT04919486|EXPERIMENTAL|Experiment group|non-weight bearing visual feedback intervention under the of Labview software, and used rowing machine equipment for exercise training for 30 minutes,then eselastic band exercise training for 30 minutes.
62320029|NCT04919486|ACTIVE_COMPARATOR|elastic band exercise|elastic band exercise under the Physiotherapist, and used elastic band for exercise training for 60 minutes,include muscles flexion the hip joint, muscles extention the hip joint,etc.
62320030|NCT05938439|EXPERIMENTAL|Interventional|The procedure consists in Medical Device (MAGUS) placement by endoscopy under general anesthesia with fluoroscopic control.
62320031|NCT06650761|EXPERIMENTAL|CDX-622|Eligible participants will receive up to three doses of CDX-622.
62320032|NCT06650761|PLACEBO_COMPARATOR|Normal Saline|Eligible participants will receive up to three doses of Normal Saline.
62320033|NCT03174743|PLACEBO_COMPARATOR|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
62480641|NCT06299280|EXPERIMENTAL|single-task group|Students exercise in physical education class.
62480642|NCT02908776|EXPERIMENTAL|Dietary supplement - Probiotics|4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.
61926039|NCT04601922||General Practitioners|
61926040|NCT04601922||Acute care nursing staff|
61926041|NCT04601922||Patients presenting with suspected cardiac chest pain|
61926042|NCT00808431|EXPERIMENTAL|Lifestyle counseling|Lifestyle counseling
61926043|NCT02495012|PLACEBO_COMPARATOR|control|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
61926044|NCT02495012|ACTIVE_COMPARATOR|treatment|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
62320034|NCT03174743|PLACEBO_COMPARATOR|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
62320035|NCT03174743|ACTIVE_COMPARATOR|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
62320036|NCT03174743|ACTIVE_COMPARATOR|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
62320037|NCT03605004||Negative|Adult patients with undiagnosed conditions who have received an uninformative negative result from exome sequence.
62320038|NCT03605004||VUS|Adult patients with undiagnosed conditions who have received one or more variants ofuncertain significance from exome sequence.
62320039|NCT04921722|EXPERIMENTAL|Topical use of sirolimus|Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
62320040|NCT04921722|ACTIVE_COMPARATOR|Oral use of sirolimus|Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
62320041|NCT06692595||Periodontitis patients|
62320042|NCT06692595||Individuals with healthy periodontium|
62320043|NCT03059303|EXPERIMENTAL|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
62320044|NCT03059303|EXPERIMENTAL|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
62320045|NCT03059303|EXPERIMENTAL|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
62320046|NCT03059303|EXPERIMENTAL|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
62320047|NCT03059303|EXPERIMENTAL|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
62689133|NCT06063551|EXPERIMENTAL|Testicular Biopsy|Patients meeting eligibility criteria are offered experimental procedure of testicular biopsy for clinical storage and use in laboratory research. The intervention does not involve a drug or device.
62320048|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62320049|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62320050|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62320051|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62320052|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62320053|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62480643|NCT02908776|PLACEBO_COMPARATOR|Placebo|Sachets with inactive substance indistinguishable from Ecoviesel
62689134|NCT06619236|EXPERIMENTAL|Rina-S|
62689135|NCT06619236|ACTIVE_COMPARATOR|Investigator's Choice|
62689136|NCT02799043|ACTIVE_COMPARATOR|Standard PVI|Standard catheter ablation including pulmonary vein isolation (PVI) procedure.
62689137|NCT02799043|EXPERIMENTAL|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by PVI.
62320054|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62320055|NCT03059303|EXPERIMENTAL|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
62320056|NCT02021500||Patients previously enrolled in study CA046|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
62320057|NCT01874782|EXPERIMENTAL|Transcranial electrical stimulation|Subject will be determined as autonomically complete or incomplete injury with measuring of the sympathetic skin responses (SSR+), an established protocol for measuring integrity of sympathetic spinal pathways, versus complete autonomic injury (SSR-).
61926045|NCT06022029|EXPERIMENTAL|Part 1a: Monotherapy Dose Escalation|ONM-501 will be administered as intratumoral injections once per week for three weeks, followed by three weeks without ONM-501 administration. Each dosing cycle will be 21 days.
61926046|NCT06022029|EXPERIMENTAL|Part 1b: ONM-501 in Combination with cemiplimab|ONM-501 will be administered as intratumoral injections once per week for three weeks followed by three weeks without ONM-501 administration. Each dosing cycle will be 21 days. The combination agent will be administered according to standard protocol, once every three weeks.
62320058|NCT06272383|EXPERIMENTAL|0.15mg/kg dexamethasone|Treatment with one dose of oral dexamethasone (0.15 mg/kg per dose; maximum single dose 3 mg)
61926047|NCT06022029|EXPERIMENTAL|Part 2: RDE ONM-501 in Combination with cemiplimab in indication-specific expansion cohorts|Once the recommended doses for expansion (RDEs) are determined for ONM-501 + ICI combination or ONM-501 monotherapy, the expansion phase of the study will be initiated. The expansion phase will enroll patients in one to three indication-specific expansion cohorts.
62320059|NCT06272383|ACTIVE_COMPARATOR|Standard practice of 0.6mg/kg dexamethasone|Treatment with one dose of oral dexamethasone (0.6 mg/kg per dose; maximum single dose 12 mg)
62320060|NCT03993353|EXPERIMENTAL|Tadalafil and Pembrolizumab|Tadalafil for up to 12 months and pembrolizumab for up to 24 months.
62320061|NCT03554499|EXPERIMENTAL|Hydrodissection|Bichectomy with hydrodissection = infiltration of 15ml per side of a special solution (250ml of saline 0.9% + 1mg of epinephrine + 20ml of 2% Lidocaine, equivalent to 0.0555mg of epinephrine and 22.2mg of Lidocaine per side), prior to the incision with the following distribution: 1ml in the form of a wheal in the oral mucosa with a 22G needle 1cm behind the Stenon canal opening that corresponds to the incision site and 14 ml on the virtual space where the buccal fat pad is located.
62738259|NCT03969745|ACTIVE_COMPARATOR|Caloric deficit|The investigators observed significant weight loss in the TRF group with participants reporting to consume \~400 kilocalories less per day. Therefore the investigators added a caloric deficit group to control for the effects of weight loss on metabolism. Total energy expenditure was measured for one week and was used to prescribe a 400 kilocalories/day energy deficit diet to follow for two weeks.
62738260|NCT04904744|PLACEBO_COMPARATOR|No message|No message sent
62738261|NCT04904744|ACTIVE_COMPARATOR|Low tailored message|2 text or phone reminders that child is overdue for well child check visit
62738262|NCT04904744|ACTIVE_COMPARATOR|Low tailored message plus COVID-19 vaccine message|2 text or phone reminders that child is overdue for well child check visit AND COVID-19 vaccine is available
62738263|NCT04017780|EXPERIMENTAL|Single-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator, single limb with intentional leaks.
62738264|NCT04017780|EXPERIMENTAL|Double-limb circuit with Intensive Care Unit ventilator|Non invasive ventilation delivered with an intensive care unit ventilator with a double limb circuit.
62738265|NCT04017780|EXPERIMENTAL|Double-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator with a double limb circuit.
62738266|NCT02657694||Sofosbuvir+Ledipasvir|Following patients treating with Sofosbuvir+Ledipasvir
62738267|NCT02657694||Sofosbuvir+Daclatasvir|Following patients treating with Sofosbuvir+Daclatasvir
62738268|NCT02657694||Sofosbuvir+Velpatasvir|Following patients treating with Sofosbuvir+Velpatasvir
62738269|NCT05287958||Healthy|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
62689138|NCT04883047|EXPERIMENTAL|experiment|"Women in the experimental group will be given care at the first stage of labor (will start in the latent phase) using Integrated Birth Support Strategies created in line with the Algorithm for Coping with Birth Pain.~Among the interventions made into a checklist, the interventions applied to the woman will be marked by the midwives and nurses working in the delivery room. The Scale for Coping with Birth Pain (DABS), which will be applied once in each phase (latent phase, active phase and transition phase), will guide the delivery of care; Care practices will differ depending on the woman's ability to cope with labor pain.At least 3 of each sub-heading of the physical comfort parameter, at least 1 of each sub-heading of the parameter of providing emotional comfort, at least 2 of each sub-heading of informative support and advocacy sub-parameters will be applied to pregnant women by midwives / nurses working in the delivery room."
61926048|NCT04509739|EXPERIMENTAL|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
61926049|NCT05947578|EXPERIMENTAL|CLZ-2002|CLZ-2002 injection is intramuscular in lower limbs on Day 1.
61926050|NCT06703983|ACTIVE_COMPARATOR|Classic Ketogenic diet|"This study includes two arms, with participants allocated using a blocked randomization process. In the control arm, participants will follow the Classic Ketogenic Diet (CKD), a standard dietary therapy for epilepsy.The CKD is highly restrictive, with approximately 90% of total calories derived from fat, 6% from protein, and 4% from carbohydrates and this diet is really challenging for patients to follow.~This arm will include 20 participants with drug-resistant epilepsy for whom the ketogenic diet has been asked by a pediatric neurologist and prescribed by a registered dietitian.Participants will be followed for three months, with parents documenting seizure frequency at each monthly follow-up visit.~At the end of the study period, seizure outcomes will be analyzed and categorized into four groups:~Seizure-free participants. Participants with \>90% seizure reduction. Participants with \>50% seizure reduction. Participants with \<50% seizure reduction (non-responders)."
62320062|NCT03554499|ACTIVE_COMPARATOR|Control|Bichectomy without hydrodissection = infiltration with 3ml per side of 2% Lidocaine with 1: 200,000 epinephrine ( equivalent to 0.015mg of epinephrine and 60mg of Lidocaine per side) at the operative site.
62689139|NCT04883047|NO_INTERVENTION|control|Pregnant women assigned to the control group will be followed up with the routine care applied in the delivery room.
62689140|NCT02130037|ACTIVE_COMPARATOR|psychotherapy only|
62689141|NCT02130037|EXPERIMENTAL|application|
62689142|NCT06643741||Pregnant subjects between 11 and 14 weeks gestation.|This is an observational study and no study-specific intervention is defined. PE screen test results will not be reported back to the physician or subject but will be compared to birth outcome data.
62689143|NCT06553157|PLACEBO_COMPARATOR|control group|placebo once daily for treatment period
62689144|NCT06553157|EXPERIMENTAL|intervention group|study drug once daily for treatment period
62320063|NCT01723280||80% oxygen group|
62689145|NCT05770180|EXPERIMENTAL|low dose test group|one dose, Day 0
62689146|NCT05770180|EXPERIMENTAL|high dose test group|one dose, Day 0
62689147|NCT05770180|ACTIVE_COMPARATOR|control group 1|one dose, Day 0
62689148|NCT05770180|ACTIVE_COMPARATOR|control group 2|one dose, Day 0
62320064|NCT01723280||30% oxygen group|
62320065|NCT01320579|EXPERIMENTAL|Group 2 Cis-UCA 5% emulsion cream|
62689149|NCT04414930|PLACEBO_COMPARATOR|Placebo|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
62689150|NCT04414930|ACTIVE_COMPARATOR|Active Drug|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.
62689151|NCT02946983|ACTIVE_COMPARATOR|Fructose - Neutral emotion condition|Intragastric infusion of fructose with neutral emotion induction
62689152|NCT02946983|ACTIVE_COMPARATOR|Fructose - Sad emotion condition|Intragastric infusion of fructose with sad emotion induction
62689153|NCT02946983|PLACEBO_COMPARATOR|Placebo - Neutral emotion condition|Intragastric infusion of distilled water with neutral emotion induction
62689154|NCT02946983|PLACEBO_COMPARATOR|Placebo - Sad emotion condition|Intragastric infusion of distilled water with sad emotion induction
62738270|NCT05287958||ALS|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
62738271|NCT02364245|EXPERIMENTAL|Kinect|Receive computer games training for 30 minutes and 30 minutes traditional OT.There are 3 sections for 1 week; the intervention period will be 8 weeks.
62738272|NCT02364245|PLACEBO_COMPARATOR|Traditional|The control group will receive traditional OT for 1 hour. There are 3 sections for 1 week; the intervention period will be 8 weeks.
62738273|NCT03652363|PLACEBO_COMPARATOR|Placebo|Placebo administered via convection enhanced delivery
62738274|NCT03652363|EXPERIMENTAL|glial derived neurotrophic factor|Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF), administered via convection enhanced delivery
62738275|NCT05069597|EXPERIMENTAL|Run-in Period: Creon-ABT|Participants will receive Creon-ABT daily for 28 days.
62738276|NCT05069597|EXPERIMENTAL|Treatment Period: Creon-AAPIS|Participants will receive Creon-AAPIS daily for 85 days.
62320066|NCT01320579|PLACEBO_COMPARATOR|Group 3 Placebo cis-UCA emulsion cream|
62689155|NCT06488833|EXPERIMENTAL|Komtü Programme (Komtü)|"The Komtü is a programme that aims to enhance the well-being and the emotional support of children by providing training and support to the entire school community, with a particular focus on teachers.~The Komtü programme comprises two distinct phases: the first, the Implementation Phase, is conducted over a period of three school years. During this phase, a specialist visits the school twice a week during the 1st and 2nd school years, and once a week during the 3rd school year. Some actions take place during this phase. For example, the specialist will provide training with reflective practice exercises, healing spaces and support for teachers and will also provide coaching for the school management team.~The second phase, the Sustainability Phase, is also conducted over three school years. This phase is designed as a follow-up phase, which is meant to ensure the continuity of the programme at the school even in the absence of the specialist's weekly visits from the centre."
62689156|NCT06488833|EXPERIMENTAL|Komtü Training and Reflective Practice|"This is a different version of the Komtü Programme that aims to enhance the well-being and the emotional support of children.~In Komtü Training and Reflective Practice, the Implementation Phase is modified. The 1st school year, the specialist will only provide training with reflective practice exercises. This means, the other actions that are usually carried out by the programme will not be offered.~In contrast to the original version, this would reduce the cost of the intervention and allow a greater number of schools to participate in the programme, as the specialist would have the time to intervene in more centres. It has been decided to prioritise training with reflective practice exercises as it is the core component that gives meaning to the functioning of the other activities that are developed throughout the programme."
62689157|NCT06488833|NO_INTERVENTION|Control group or Treatment as usual (TAU)|The school year will be developed as normal.
62689158|NCT02475863|EXPERIMENTAL|Warfarin dosing aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
62689159|NCT02475863|ACTIVE_COMPARATOR|Standard practice|Dosing adjustments according to the normal unit protocol
62689160|NCT05270031|EXPERIMENTAL|Eustachian tube dilation|Surgical Eustachian tube dilation in general anaesthesia
62689161|NCT05270031|NO_INTERVENTION|Control Group|nasal saline spray
62689162|NCT03941093|EXPERIMENTAL|Arm A|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
62689163|NCT03941093|PLACEBO_COMPARATOR|Arm B|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
62689164|NCT06042608|ACTIVE_COMPARATOR|Active intercostobrachial nerve block|Patient will receive local anesthetic injected around their intercostobrachial nerve in the axilla (armpit). They will still receive an active interscalene nerve block (gold standard) that helps with the rest of the shoulder pain.
62689165|NCT06042608|PLACEBO_COMPARATOR|Sham intercostobrachial nerve block|Patient will receive saline injected around their intercostobrachial nerve in the axilla (armpit). This is a sham intercostobrachial nerve block because saline is not an active medication. They will still receive an active interscalene nerve block (gold standard) that helps with the rest of the shoulder pain.
62738277|NCT01582516|EXPERIMENTAL|Delta24-RGD|Intracerebral slow continuous infusion of study drug in increasing dose
62738278|NCT00769171|ACTIVE_COMPARATOR|Arm 2|
62738279|NCT00769171|EXPERIMENTAL|Arm 1|
62738280|NCT01202916||Congenital Heart Disease|
62738281|NCT01202916||Healthy children|
62738282|NCT05267470|EXPERIMENTAL|Part 1: Combination Dose Exploration|Participants with SqNSCLC will receive escalating doses of bemarituzumab in combination with docetaxel.
62738283|NCT05267470|EXPERIMENTAL|Part 2: Combination Dose Expansion|Participants with SqNSCLC and FGFR2b overexpression will receive the dose of bemarituzumab in combination with docetaxel identified as safe during Part 1.
62480644|NCT04966104|EXPERIMENTAL|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consisted of:~* Automated digital counselling resources (educational pages, videos, tools, and trackers)~* Chatrooms available 24/7~* Weekly 30-minute webcasts led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4, 8, and 12, and trial completion (median = 8.5 months, range = 2 to 15 months)."
62480645|NCT04966104|NO_INTERVENTION|eUC|eUC provided educational HF self-care resources that are available to the public on professional heart health websites (e.g., Heart Failure Society of Canada, American Heart Association, European Society of Cardiology, Health Canada). Patients were provided with unlimited access to these resources. Subjects were invited by weekly emails to partake in these resources. Self-reported assessments are administered at baseline, months 4, 8, and 12, and trial completion (median = 8.5 months, range = 2 to 15 months).
62320067|NCT01320579|ACTIVE_COMPARATOR|Group 4 Protopic® 0.1% ointment|
62480646|NCT03502889|ACTIVE_COMPARATOR|Adductor Canal Block Alone|Control arm to receive Adductor Canal Block without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance
62480647|NCT03502889|EXPERIMENTAL|SPANK Block Plus Adductor Canal Block|Experimental arm to receive Adductor Canal Block plus SPANK Block (Sensory Posterior Articular Nerves of the Knee) without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance into the adductor canal plus 20cc ropivacaine 0.5% injected into the posterior tissues of the knee
62480648|NCT05660798|NO_INTERVENTION|combustion tobacco|
62480649|NCT05660798|EXPERIMENTAL|heated tobacco|
62480650|NCT06435429|EXPERIMENTAL|Zanidatamab plus physician's choice of chemotherapy|Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of zanidatamab plus physician's choice of chemotherapy (eribulin, or vinorelbine, or gemcitabine, or capecitabine).
62480651|NCT06435429|ACTIVE_COMPARATOR|Trastuzumab plus physician's choice of chemotherapy|Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of trastuzumab plus physician's choice of chemotherapy (eribulin, or gemcitabine, or vinorelbine, or capecitabine).
62480652|NCT06203119||68Ga-DOTA-BPP|68Ga-DOTA-BPP PET/CT: after intravenous injection of 2.96 MBq/ kg body weight of quality-controlled 68Ga-DOTA-BPP, a Siemens Biograph PET/CT scan will be applied within 1 h-2 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
62480653|NCT06203119||18F-FGD|18F-FDG PET/CT: after intravenous injection of 2.96 MBq/ kg body weight of quality-controlled 18F-FDG, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
62480654|NCT06742372|EXPERIMENTAL|combined inspiratory and aerobic exercise training|
62480655|NCT06742372|EXPERIMENTAL|aerobic exercise training|
62480656|NCT05786573|EXPERIMENTAL|Safety and Dose Confirmation Run-in Period (SRP): Obexelimab|Obexelimab will be administered as an SC injection for 24 weeks.
62480657|NCT05786573|EXPERIMENTAL|Randomized Control Period (RCP): Obexelimab|Obexelimab will be administered as an SC injection for 24 weeks.
62480658|NCT05786573|PLACEBO_COMPARATOR|Randomized Control Period (RCP): Placebo|Placebo will be administered as an SC injection for 24 weeks
62480659|NCT03427463|ACTIVE_COMPARATOR|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
62480660|NCT03427463|EXPERIMENTAL|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
62480661|NCT06163625|EXPERIMENTAL|Depression Group|
62480662|NCT06163625|OTHER|Control Group|
62480663|NCT05624450|EXPERIMENTAL|Tozorakimab|Approximately 2870 participants will be randomized in a 1:1 ratio. Arm 1 (n=approximately 1435) will receive a single dose of tozorakimab.
62480664|NCT05624450|PLACEBO_COMPARATOR|Placebo|Approximately 2870 participants will be randomized in a 1:1 ratio. Arm 2 (n=approximately 1435) will receive matching placebo.
62480665|NCT00470704|OTHER|Cohort 1|"This cohort is made up of participants without prior trastuzumab for MBC. Adjuvant or neoadjuvant trastuzumab was allowed, if the interval from trastuzumab completion to recurrence exceeded 1 year.~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
62480666|NCT00470704|OTHER|Cohort 2|"This cohort is made up of participants with one to two lines of chemotherapy for metastatic disease with at least one trastuzumab-containing regimen or patients who recurred within 12 months of adjuvant or neoadjuvant trastuzumab with up to one line of metastatic trastuzumab-based therapy~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
62738284|NCT05267470|EXPERIMENTAL|Part 3: Bemarituzumab Monotherapy|Participants with SqNSCLC and FGFR2b overexpression will receive bemarituzumab monotherapy.
62129830|NCT03022812|EXPERIMENTAL|Exercises with Internet support|Neck-specific exercise with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
62320068|NCT01320579|EXPERIMENTAL|Group 1 Cis-UCA 2.5% emulsion cream|
62320069|NCT06370702|EXPERIMENTAL|Handgrip Exercise Group|Participants will be instructed to firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
62320070|NCT06370702|NO_INTERVENTION|Standard Care Group|Participants will receive standard care that includes no instruction about conducting hand grip exercises.
62320071|NCT05041192|EXPERIMENTAL|Synaquell Group|Subjects will receive the dietary supplement, Synaquell, twice-daily during the hockey season.
62480667|NCT05672836|EXPERIMENTAL|Enavogliflozin Group|0.3 mg 1 tablet once daily
61926051|NCT06703983|ACTIVE_COMPARATOR|Low glycemic index therapy|"In intervention arm, patients will receive a low glycemic index diet(LGIT). The LGIT is a modified form of the ketogenic diet that restricts carbohydrate intake to sources with a glycemic index of less than 50. This diet provides approximately 60% of total calories from fat, 30% from protein, and 10% from carbohydrates.In the LGIT arm, there will be 20 participants who will follow a LGIT diet under the care of a Registered Dietitian and a Pediatric Neurologist.~After three months, seizure outcomes will be categorized into the following groups:~At the end of the study period, seizure outcomes will be analyzed and categorized into four groups:~Seizure-free participants. Participants with \>90% seizure reduction. Participants with \>50% seizure reduction. Participants with \<50% seizure reduction (non-responders). Results will be analyzed and compared with Classic Ketogenic diet which serves as the standard dietary therapy for epilepsy."
61926052|NCT02269826|EXPERIMENTAL|Vagisan® Moisturising Cream|non-hormonal vaginal cream for the treatment of vulvovaginal dryness
61926053|NCT02269826|ACTIVE_COMPARATOR|Gynomunal® vaginal gel|non-hormonal gel
61926054|NCT02698059|EXPERIMENTAL|Treated|iNAP® Sleep Therapy System Treatment
62689166|NCT04770545|EXPERIMENTAL|Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered monthly intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or monthly sham will receive IVT pegcetacoplan (15 mg/100 μL) monthly for up to approximately 36 months.
62689167|NCT04770545|EXPERIMENTAL|Pegcetacoplan, 15 mg/100 μL, every other month (EOM) for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered every other month (EOM) intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or EOM sham will receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to approximately 36 months.
62689168|NCT04781972|EXPERIMENTAL|Methylphenidate first|Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week.
61926055|NCT02698059|NO_INTERVENTION|Baseline/Control|Self-controlled, pre-treatment baseline
62689169|NCT04781972|PLACEBO_COMPARATOR|Placebo first|Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week.
62480668|NCT05672836|PLACEBO_COMPARATOR|placebo as add-on to standard of care treatment group|Placebo matching enavogliflozin
62320072|NCT05041192|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive the placebo twice-daily, during the hockey season.
62689170|NCT05434754|EXPERIMENTAL|eHealth Tool|The Intervention is a text messaging algorithm that will operate like a chatbot, querying adolescents with T1D about their confidence with different aspects of T1D self-management as they are preparing to transition to adult diabetes care. The intervention has 4 components of messaging: personalized Educational Content, Standard Educational Curriculum, Provide participant compensation for filling out the questionnaires, Question \& Answer feature.
62689171|NCT05434754|NO_INTERVENTION|Control|Participants randomized to the control arm will also be offered the same incentives to complete questionnaires (outcome measures) but will not receive any other components of the intervention - no personalized/customized support or diabetes resource messages and no reminders. Control arm participants will continue with their usual T1D transition care.
62689172|NCT04391751|EXPERIMENTAL|Single incision|Carpal tunnel release and basal joint arthroplasty through a single radial approach
61926056|NCT05721755|EXPERIMENTAL|Arm A (pembrolizumab and radiation)|Patients receive one cycle of pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV, and fluorouracil IV on study and then receive pembrolizumab IV with radiation therapy on study. Patients also undergo CT, PET/CT, and/or MRI throughout the trial.
62320073|NCT01819220|ACTIVE_COMPARATOR|amlodipine/valsartan|
62320074|NCT01819220|EXPERIMENTAL|hydrochlorothiazide/telmisartan|
62320075|NCT03936439||Consecutive stroke patient|All consecutive stroke patients from five time points, i.e. 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018 are selected for analysis.
62320076|NCT00931957|ACTIVE_COMPARATOR|Etanercept-MTX-Prednisolone|Methotrexate + Prednisolone + Etanercept
62480669|NCT05869955|EXPERIMENTAL|Administration of CC-97540|
62480670|NCT02544022||1/Phase 1 Focus Group|Patients with NF1 who have PNs and report experiencing pNF related pain and parents of these patients. (completed)
62320077|NCT00931957|OTHER|B, MTX-Prednisolone|Methotrexate + Prednisolone
62320078|NCT06693297|ACTIVE_COMPARATOR|Conventional loading of early placed implants|Early placed implants ( within 16 weeks of healing after Extraction of a tooth) will be conventionally loaded ( at least 8 weeks after implant placement )
62480671|NCT02544022||2/Phase 1 Patients|Patients with NF1 who have pNFs(completed)
62480672|NCT02544022||3/Phase 1 Parent|Parents of patients in cohort 2 (completed)
62480673|NCT02544022||4/Phase 2 Patients|Patients with NF1 who have pNFs and recent pNF-related pain
62480674|NCT02544022||5/Phase 2 Parents|Parents of patients (ages 8-17 years) enrolled in cohort 4
62689173|NCT04391751|ACTIVE_COMPARATOR|Double incision|Double approach: carpal tunnel release through palmar approach and basal joint arthroplasty through radial approach
62689174|NCT06673693|EXPERIMENTAL|SBRT combined with PD-1|Week 1: SBRT radiation therapy administered as 24Gy/3f, on days 1, 3, and 5. Weeks 2-5: Tislelizumab 200mg intravenous drip every 3 weeks, for a total of two cycles.
62320079|NCT06693297|EXPERIMENTAL|Immediate loading of early placed implants|Early placed implants (within 16 weeks of tooth extraction) will be loaded immediately with provisional screw retained crown
62320080|NCT01310595|EXPERIMENTAL|Manual mobilization on cervical spine|Manual mobilization given on cervical spine with infra-red therapy and self exercise and advice pamphlet.
61926057|NCT05721755|ACTIVE_COMPARATOR|Arm B (pembrolizumab monotherapy)|Patients receive one cycle of pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV, and fluorouracil IV on study and then receive pembrolizumab IV monotherapy on study. Patients also undergo CT, PET/CT, and/or MRI throughout the trial.
62320081|NCT01310595|ACTIVE_COMPARATOR|Infra-red radiation therapy|Infra-red radiation therapy with self exercise pamphlet given to patients with chronic mechanical neck pain.
62320082|NCT03083158|OTHER|Group 1|Older adults, aged 61-80 years
62320083|NCT03083158|OTHER|Group 2|Younger adults, aged 40-60 years
62320084|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
62320085|NCT02054533||IBD patients|patients with IBD undergoing intra-abdominal surgery
62320086|NCT06323590||Cohort A|Patients with AML, receiving standard induction chemotherapy
62320087|NCT00510588|OTHER|1|regular physical exercise training
62320088|NCT00510588|OTHER|2|regular physical exercise training + metformin
62320089|NCT00510588|OTHER|3|regular physical exercise training + glitazon
62320090|NCT00510588|NO_INTERVENTION|4|Control
62480675|NCT05231187||Prospective Arm|Subjects has had a diagnostic blood culture ordered per routine standard of care.
62480676|NCT05231187||Contrived Arm|Samples of healthy whole blood spiked with bacterial strains harboring the resistance gene targets on the T2Resistance Panel.
62480677|NCT05231187||Healthy Donor Arm|Healthy donor subjects.
62689175|NCT04104477||End-Stage CMC OA|"Individuals in this group had radiographic evidence of end-stage CMC OA defined as Eaton-Littler Stage III or Stage IV.~During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported."
62689176|NCT04104477||Early-Stage CMC OA (Control)|"Individuals in this group had radiographic evidence of early-stage CMC OA defined as Eaton-Littler Stage I or Stage II. Note, the Eaton-Littler scale does not include a stage 0, thus no evidence of disease falls under Stage I.~During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported."
62689177|NCT04910165|EXPERIMENTAL|Exparel|Liposomal Bupivacaine use as active ingredient in the block
62320091|NCT01011881||patients with pleuritis|
62320092|NCT04510922|EXPERIMENTAL|Droxidopa|100-600mg droxidopa TID
62320093|NCT03502707|PLACEBO_COMPARATOR|Cohort (C)1 Group (G)1: Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
62320094|NCT03502707|EXPERIMENTAL|C1 G2: RSV preF Protein|Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.
62320095|NCT03502707|PLACEBO_COMPARATOR|C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
62320096|NCT03502707|EXPERIMENTAL|C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5\*10\^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.
62320097|NCT03502707|EXPERIMENTAL|C1 G5: RSV preF Protein|Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
62320098|NCT03502707|PLACEBO_COMPARATOR|C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
62480678|NCT00001223||CF Patients|cystic fibrosis patients
62480679|NCT00001223||CF Relatives|relatives of cystic fibrosis patients
62480680|NCT06552091|NO_INTERVENTION|Standard group|standard care
62480681|NCT06552091|EXPERIMENTAL|Hypnosis group|experimental care with 3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
62320099|NCT03502707|EXPERIMENTAL|C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5\*10\^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
62320100|NCT03502707|PLACEBO_COMPARATOR|C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.
62320101|NCT03502707|EXPERIMENTAL|C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
62320102|NCT03502707|EXPERIMENTAL|C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo|Participants will receive separate intramuscular injections of 1\*10\^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
62320103|NCT03502707|EXPERIMENTAL|C2 G11: Ad26.RSV.preF and Placebo|Participants will receive intramuscular injection of 1\*10\^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
62320104|NCT03502707|EXPERIMENTAL|C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5\*10\^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
62320105|NCT03502707|EXPERIMENTAL|C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
62480682|NCT04855188|EXPERIMENTAL|YVOIRE Y-Solution 540|
62480683|NCT04855188|ACTIVE_COMPARATOR|YVOIRE volume plus|
61926058|NCT05721755|NO_INTERVENTION|Arm S (no intervention)|Patients proceed directly to Step II.
62480684|NCT04222413|EXPERIMENTAL|1/Arm 1|Escalating/de-escalation doses of metarrestin
62480685|NCT04222413|EXPERIMENTAL|2/Arm 2|MTD of metarrestin
62689178|NCT04910165|ACTIVE_COMPARATOR|Control|Ropivacaine use as active ingredient in the block
62689179|NCT01754740|EXPERIMENTAL|Study Group|19 patients whom received topical medication of urea 10%
62689180|NCT01754740|PLACEBO_COMPARATOR|Control Group|19 patients whom received placebo
62689181|NCT02909257|EXPERIMENTAL|same dose|patient is exposed to the same previously successful dose
62689182|NCT02909257|EXPERIMENTAL|lower dose|patient is exposed to a lower concentration dose
62129831|NCT00180505|OTHER|1|The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
62689183|NCT05484557|EXPERIMENTAL|study|treatment with Apixaban
62689184|NCT05484557|ACTIVE_COMPARATOR|Control|treatment with Enoxaparin
62689185|NCT04526158|EXPERIMENTAL|Mobile+Group LAMP Mindfulness-Based Intervention|8 weekly, synchronous interactive online group sessions; access to mobile app and a study website, with an accompanying workbook.
62689186|NCT04526158|EXPERIMENTAL|Mobile LAMP Mindfulness-Based Intervention|8 weekly asynchronous sessions, delivered on mobile app and study website, with an accompanying workbook; 3 engagement calls at the middle, beginning and end of the program.
62129832|NCT05264844|EXPERIMENTAL|masking tape group|Masking tape will be used
62320106|NCT03502707|EXPERIMENTAL|C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
61926059|NCT05721755|EXPERIMENTAL|Arm T (pembrolizumab, chemotherapy)|Patients receive pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV and fluorouracil IV on study.
62129833|NCT05264844|NO_INTERVENTION|standard catheter dressing group|Medical plaster to be used (It is routine practice in the clinic.)
62129834|NCT02176538|EXPERIMENTAL|Product 0405|Topical active investigational Product 0405
62129835|NCT02176538|PLACEBO_COMPARATOR|Placebo for Product 0405|Topical Placebo for Product 0405
62129836|NCT06495944|EXPERIMENTAL|Dazucorilant (300 mg) and itraconazole (200 mg)|On Days 1 and 8, each participant will receive a single oral dose of dazucorilant 300 mg, in a fed state. On Days 5-11, all participants will be administered once daily, oral doses of itraconazole 200 mg, in a fed state.
62129837|NCT04955431|PLACEBO_COMPARATOR|Normal Sleep (with 250 ug/m^3 PM2.5)|Participants will have a normal sleep opportunity the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise).
62689187|NCT04526158|NO_INTERVENTION|Usual Care|Engagement in usual care for 12 months as participants normally would. After the entire follow-up period is complete (12 months), participants in the usual care arm are given access to the Mobile LAMP materials MBI training on the app and study website, and the accompanying workbook.
62689188|NCT03209765|ACTIVE_COMPARATOR|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
62689189|NCT03209765|NO_INTERVENTION|No reminder|
62689190|NCT03514693|ACTIVE_COMPARATOR|PVI alone|PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
62689191|NCT03514693|PLACEBO_COMPARATOR|PVI plus additional ablation|PVI, additional CFAE or linear ablation after PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
62689192|NCT04066829|EXPERIMENTAL|Experimental: Default setting intervention|The arm will include all patients undergoing tonsillectomy at C.S. Mott Hospital by a pediatric otolaryngology faculty member at the University of Michigan.
62689193|NCT04066829|NO_INTERVENTION|No Intervention: Control (Usual Care)|The arm will include all patients undergoing tonsillectomy at University Hospital, Brighton Center for Specialty Care, or Livonia Center for Specialty Care by a general otolaryngology faculty member at the University of Michigan.
62689194|NCT06005831|OTHER|Sandbag|Sandbag
62689195|NCT01887197|EXPERIMENTAL|Repeatability|Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.
62129838|NCT04955431|EXPERIMENTAL|Restricted Sleep (with 250 ug/m^3 PM2.5)|Participants will have a restricted sleep opportunity (\~4 hours) the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise).
62320107|NCT03502707|EXPERIMENTAL|C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5\*10\^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
62320108|NCT03502707|EXPERIMENTAL|C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo|Data from C1 G10 will be pooled with those of C2 G16. Participants will receive separate intramuscular injections of 1\*10\^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and placebo in 1 arm on Day 57.
62320109|NCT03502707|EXPERIMENTAL|C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1\*10\^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and placebo in another arm on Day 1.
62320110|NCT03502707|PLACEBO_COMPARATOR|C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo in separate arms on Day 1 and in only 1 arm on Day 57.
62320111|NCT03502707|EXPERIMENTAL|C3 G19: Selected Regimen (SR)|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12 and month 24. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.
62689196|NCT01887197|EXPERIMENTAL|Response|Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).
62689197|NCT06645067||Cancer cachectic patients|This group is made up of patients suffering from cancer cachexia who take part in an APA programme at the medical-sports centre. These are patients who agree to have their energy expenditure measured at rest and during sub-maximal effort, as well as their level of physical activity and diet monitored for 7 days.
62689198|NCT06637475|EXPERIMENTAL|electric stimulation group|Individuals who meet the inclusion criteria and who have signed the consent form will be randomly divided into 2 groups (treatment and control groups). Randomization will be done by a researcher who is not involved in the study using computer-assisted randomization blocks. The treatment group patients will receive 3 sessions of external stimulation per week for 8 weeks, while the control group will not receive any intervention (consisting of patients waiting on the treatment list).
62689199|NCT06637475|NO_INTERVENTION|control group|
62689200|NCT06644716|EXPERIMENTAL|Patients with CUP|Patients diagnosed with CUP after standard diagnostic work-up including an \[18F\]FDG PET-CT
62129839|NCT03500393|ACTIVE_COMPARATOR|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
62129840|NCT03500393|EXPERIMENTAL|Remotely Supervised Exercise (REM)|The REM program is designed to function as an Acceptance-based health coaching intervention and will utilize theory-based behavior change techniques (i.e., goal setting/action planning, self-monitoring, receiving feedback, and reviewing relevant goals in the light of feedback) to promote adoption and adherence to the exercise prescription.
62129841|NCT06394375|EXPERIMENTAL|Opioid free anesthesia|"Patients in this group are given a combination of Dexmedetomidine, Lidocaine, Propofol, Sevoflurane, Rocuronium for induction and maintenance of general anesthesia. They are given rescue analgesia (fentanyl) when required, and Ephedrine as needed.~Patients were monitored using standard ASA monitoring and Connox.~Post operative pain score was assessed with NRS"
62689201|NCT02096887|OTHER|Patient Education|Patient Education
62129842|NCT06394375|ACTIVE_COMPARATOR|Opioid balanced anesthesia|"Patients in this group are given a combination of Opioid (Fentanyl), Lidocaine, Propofol, Sevoflurane, Rocuronium for induction and maintenance of general anesthesia. They are given Ephedrine as needed.~Patients were monitored using standard ASA monitoring and Connox.~Post operative pain score was assessed with NRS"
62129843|NCT01823133|EXPERIMENTAL|gemigliptin only|Multiple administrations of gemigliptin
62129844|NCT01823133|EXPERIMENTAL|rosuvastatin only|Multiple administrations of rosuvastatin
62129845|NCT01823133|EXPERIMENTAL|gemigliptin and rosuvastatin|Multiple administrations of gemigliptin and rosuvastatin
62129846|NCT01967836|OTHER|Glad Press 'n Seal|Cohort Subjects will use Glad Press 'n Seal product as a moisture barrier to an IV line
62320112|NCT03502707|EXPERIMENTAL|C3 G20: SR + Placebo for SR|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and Month 24, and a placebo at Month 12. The participants who are randomized to two-dose regimen will receive selected regimen on Day 1 and Day 57, and a placebo at Month 12.
62689202|NCT05558085|EXPERIMENTAL|EFNEP Group|Subjects will receive the EFNEP Eat Smart Being Active class series.
62689203|NCT05558085|NO_INTERVENTION|Control Group|Subjects will receive no EFNEP intervention.
62689204|NCT03460704|EXPERIMENTAL|CMS (Colistimethate Sodium)|Inhaled colistimethate sodium twice daily. The active pharmaceutical ingredient consisting of pure CMS one million international units (MIU) / 80 mg of CMS / 33 mg colistin base activity (CBA) was provided as a powder for nebuliser solution in 10R Internation Organization for Standardization (ISO) glass vials.
62129847|NCT01796067|EXPERIMENTAL|Mot. & Fam. Weight Loss + Online Interv.|Participants are randomized to motivational and family weight loss program plus the online intervention.
62129848|NCT01796067|EXPERIMENTAL|Mot. & Fam. Weight Loss + Online Control|Participants are randomized to motivational and family weight loss intervention and then the online control program.
62480686|NCT05934019|EXPERIMENTAL|EMPATIA|Participants in this group will access the online prevention program EMPATIA as a self-help online program during eight weeks.
62480687|NCT05934019|NO_INTERVENTION|Care As Usual|Participants in this group will gain access to the online prevention program EMPATIA after 12 months. All other kinds of interventions during participation are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory
62480688|NCT04632238|NO_INTERVENTION|Control|
62480689|NCT04632238|EXPERIMENTAL|Metrics-driven quality improvement (MDQI) intervention|
62480690|NCT05822414|EXPERIMENTAL|Erector Spinae Plane Block group|
62480691|NCT05822414|ACTIVE_COMPARATOR|Superior Trunk Block group|
62480692|NCT06590532|EXPERIMENTAL|Fusion group|patient undergoing endovascular aortic repair with fusion imaging system guidance
62480693|NCT06590532|ACTIVE_COMPARATOR|Control group|patient undergoing endovascular aortic repair without fusion imaging system guidance (only with X-rays and roadmaping)
62129849|NCT01796067|EXPERIMENTAL|Basic Health Educ. & Online Interv.|Participants are randomized to the basic health education program and then the online intervention program.
62129850|NCT01796067|ACTIVE_COMPARATOR|Basic Health Educ. & Online Control|Participants are randomized to the basic health education program and then to the online control program.
62480694|NCT06635629|OTHER|Desmopressin 10 mcg Ad-lib fluid|Desmopressin 10 mcg Ad-lib fluidHealthy volunteers only
62480695|NCT06635629|ACTIVE_COMPARATOR|Desmopressin 10 mcg NPO|Desmopressin 10 mcg
62480696|NCT06635629|ACTIVE_COMPARATOR|Desmopressin NPO 4 mcg|Desmopressin 4 mcg
62480697|NCT06635629|ACTIVE_COMPARATOR|Dexmopressin 10 mcg NPO + Dexamethasone|Desmopressin 10 mcgDexamethasone 1 mg pretreatment
62480698|NCT06743165|EXPERIMENTAL|DNS Group|This group includes 18 children with Dysfunctional voiding, aged between 6 and 14 years.
62129851|NCT06522958|EXPERIMENTAL|Intervention Group|Patients randomized to the intervention group will receive a high dissolving transitional food product.
62129852|NCT06522958|NO_INTERVENTION|Standard of Care Group|Patients randomized to the standard of care group will not receive a high dissolving transitional food product.
62480699|NCT06743165|ACTIVE_COMPARATOR|Standard exercise group|This group includes 18 children with Dysfunctional voiding, aged between 6 and 14 years.
62480700|NCT03451799|EXPERIMENTAL|Ketogenic diet+radiation+temozolomide|Ketogenic diet in combination with standard-of-care radiation and standard-of-care temozolomide
62480701|NCT04772079|EXPERIMENTAL|Active treatment deucravacitinib standard dose|
62480702|NCT04772079|EXPERIMENTAL|Active treatment deucravacitinib half-standard dose|
62480703|NCT04772079|PLACEBO_COMPARATOR|Placebo|
62689205|NCT03460704|PLACEBO_COMPARATOR|Placebo|Saline solution inhaled twice daily, provided and administered at the same way of the IMP.
62689206|NCT05063136|EXPERIMENTAL|Capecitabine+endocrine therapy|capecitabine (500mg, tid) (for 1 year)+standard endocrine therapy (at least 5 years)
62129853|NCT01047241|EXPERIMENTAL|Intranasal sufentanil/ketamine|Intranasal combination of sufentanil and ketamine. Dose of sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.
62129854|NCT02534064|EXPERIMENTAL|Group A: 2 yogurts|consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
62129855|NCT02534064|EXPERIMENTAL|Group B: 1 yogurt|consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
62129856|NCT02534064|NO_INTERVENTION|Group C: No yogurt|no changes in dietary habits during 24 weeks.
62129857|NCT00774124|EXPERIMENTAL|1 Telemedicine|Usual care plus telemonitoring
62480704|NCT04145141||1/ Cohort 1|Subjects with a diagnosis or suspicion of PLC
62480705|NCT02218996||Psychosocial treatment|Children and adolescents with anxiety disorders
62480706|NCT06177743||Coroflex ISAR NEO|Patients receiving percutaneous coronary intervention with Coroflex ISAR NEO stents
62480707|NCT06279247||narcolepsy group|
62480708|NCT06279247||health control group|
62480709|NCT06596018|ACTIVE_COMPARATOR|The control group|Patients in this group will continue to follow the original chemotherapy using anthracycline and/or taxane based regimens, according to their physician's preference and center policy
61926060|NCT05091203|SHAM_COMPARATOR|control|Control group in which vitamin D was not administrated.
62480710|NCT06596018|EXPERIMENTAL|The SBRT-combined group|The intervention group will receive SBRT treatment. The specific plan for SBRT is to target the primary tumor region with 24Gy/3. After the completion of SBRT, patients will continue the remaining courses of neoadjuvant chemotherapy.
62480711|NCT02815566|EXPERIMENTAL|Immediate switch|Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks
62480712|NCT02815566|ACTIVE_COMPARATOR|delayed switch|Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks
62480713|NCT03904147|EXPERIMENTAL|Randomized - Device Group|Subjects will undergo TriClip implantation and will continue to be managed on medical therapy, per physician discretion
62480714|NCT03904147|ACTIVE_COMPARATOR|Randomized - Control Group|Subjects will continue to be managed on medical therapy, per physician discretion
62480715|NCT03904147|EXPERIMENTAL|Single Arm Group|Subjects will receive the TriClip device and will continue to be managed on medical therapy, per physician discretion.
62689207|NCT05063136|PLACEBO_COMPARATOR|Placebo+endocrine therapy|oral placebo (tid) (for 1 year) + standard endocrine therapy (at least 5 years)
62480716|NCT03904147|EXPERIMENTAL|Continued Access Study (CAS)|Subjects will undergo TriClip implantation and will continue to be managed on medical therapy, per physician discretion
61926061|NCT05091203|ACTIVE_COMPARATOR|Study group|Study group in which Vitamin D was administered
61926062|NCT00995865|ACTIVE_COMPARATOR|High dose|
62129858|NCT00774124|ACTIVE_COMPARATOR|2 Standard of Care|Standard of care - women will monitor and record blood glucose levels four times a day.
62129859|NCT01850836|ACTIVE_COMPARATOR|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
62129860|NCT01850836|SHAM_COMPARATOR|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
62129861|NCT06409117|ACTIVE_COMPARATOR|Resorbable magnesium scaffold|3rd generation resorbable magnesium scaffolds
62129862|NCT06409117|ACTIVE_COMPARATOR|Drug eluting stent|Biodegradable polymer drug eluting stents
62129863|NCT03608995|EXPERIMENTAL|Premaquick©|
62129864|NCT03608995|OTHER|Quikcheck|
62689208|NCT03790956|EXPERIMENTAL|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
62689209|NCT03896568|EXPERIMENTAL|Part I (oncolytic adenovirus Ad5-DNX-2401)|Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.
62129865|NCT06169254|ACTIVE_COMPARATOR|High-frequency Transcranial Random Noise Stimulation (Hf-tRNS)|The stimulation parameters of hf-tACS include: 20 minutes at 101-640 Hz, 2 milliamps.
62480717|NCT06014866||LBBA INGEVITY+ Pacing|Patients indicated for anti-bradycardia pacing that have been implanted with an INGEVITY+ lead in the LBBA.
62480718|NCT05494801||Close Contacts|Close Contacts of EVD survivors, who were also previously in the PREVAIL III Neurology Substudy
62129866|NCT06169254|ACTIVE_COMPARATOR|Transcranial alternating current stimulation (tACS)|The stimulation parameters of HD-tACS include: 20 minutes at 40 Hz, 2 milliamps.
62129867|NCT06169254|SHAM_COMPARATOR|Sham transcranial current stimulation (tCS)|In sham condition, the stimulation only last for 30 seconds with the electrodes left in place for a further 20 minutes.
62129868|NCT00479635|EXPERIMENTAL|TPI 287|
62480719|NCT05494801||Patients (EVD Survivors)|Participants with a history of Ebola Virus Disease who were involved in the Neurology Substudy of the PREVAIL III Ebola Natural History Study
61926063|NCT00995865|ACTIVE_COMPARATOR|Mid Dose|
61926064|NCT00995865|PLACEBO_COMPARATOR|Placebo|NaCl Injectable 0.9%
62129869|NCT03419013|EXPERIMENTAL|Test of new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation
62129870|NCT04620902||Dementia|Dementia
62129871|NCT04620902||MCI|Mild cognitive impairment
62129872|NCT04620902||SCD|Subjective cognitive decline
62129873|NCT04620902||HC|Cognitively healthy control
62129874|NCT02234778|EXPERIMENTAL|Study Treatment|Each subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period. TGI SVF material injection will be completed within 4 hours of cell separation.
62129875|NCT01203813|EXPERIMENTAL|Physician Intervention|"Physicians randomized to the intervention will receive:~1. Electronic alerts during office visits for patients with chronic kidney disease~2. Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
62129876|NCT01203813|NO_INTERVENTION|Physician Control|Physicians randomized to the control arm will continue to manage their patients with chronic kidney disease according to routine primary care standards.
62129877|NCT04927520||Endovascular therapy group|Unruptured middle cerebral artery aneurysms treated with coil embolization
62480720|NCT06050122|EXPERIMENTAL|Patidegib Gel 2%|Patidegib Gel 2% (w/w), applied topically to the face twice daily for 12 months
62480721|NCT06050122|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel, applied topically to the face twice daily for 12 months
62480722|NCT06345339|EXPERIMENTAL|Group 1|Participants will receive Armour Thyroid for up to 81 weeks.
62480723|NCT06345339|EXPERIMENTAL|Group 2|Participants will alternate between Armour Thyroid and synthetic T4 for up to 81 weeks.
62480724|NCT03712618|ACTIVE_COMPARATOR|Group A|Group A: Long Transfusion followed by Short Transfusion in the first block
62480725|NCT03712618|ACTIVE_COMPARATOR|Group B|Group B: Short Transfusion followed by Long Transfusion in the first block
62480726|NCT06483789|EXPERIMENTAL|HB-1|HB-1 fixed dose, once daily.
62320113|NCT03502707|PLACEBO_COMPARATOR|C3 G21: Placebo for SR|If a one-dose regimen is selected, participants in this group will receive placebo for SR on Day 1 and at Month 12 and Month 24. The participants who are randomized to two-dose regimen will receive placebo for SR on Day 1, Day 57, and Month 12.
62320114|NCT06298370|ACTIVE_COMPARATOR|Group P|Patients in this group will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal drug will be administered at the L3-L4 intervertebral level with 10-15 mg of bupivacaine while the patient is in a sitting position.
62320115|NCT06298370|ACTIVE_COMPARATOR|Group M|Patients will receive intrathecal bupivacaine plus morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine.
62320116|NCT06298370|ACTIVE_COMPARATOR|Group P+M|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine plus morphine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine.
62320117|NCT03260335|EXPERIMENTAL|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
62320118|NCT03591705|EXPERIMENTAL|TACE-HAIC|hepatic artery chemo-lipiodolization with EADM, followed by FOLFOX-based chemotherapy artery infusion
62320119|NCT03591705|ACTIVE_COMPARATOR|HAIC|FOLFOX-based chemotherapy hepatic artery infusion
62320120|NCT06152263||Atrophic or Cancerous|In each image, the color values of atrophic or cancerous will be quantified using the International Commission on Illumination 1976 (L∗, a∗, b∗) color space. Histological microvascular density in biopsy or resected specimens will be evaluated using CD31 immunostaining. Color differences at the atrophic border and cancerous border, defined as Euclidean distances of color values between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa, will be calculated according to mucosal microvascular density.
62320121|NCT06152263||Non-atrophic or Non-cancerous|In each image, the color values of non-atrophic or non-cancerous will be quantified using the International Commission on Illumination 1976 (L∗, a∗, b∗) color space. Histological microvascular density in biopsy or resected specimens will be evaluated using CD31 immunostaining. Color differences at the atrophic border and cancerous border, defined as Euclidean distances of color values between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa, will be calculated according to mucosal microvascular density.
62320122|NCT00480454|ACTIVE_COMPARATOR|1|Stage 1 would require 12 per group low dose and 12 per group high dose (total 72)
62320123|NCT00480454|ACTIVE_COMPARATOR|2|Stage 2 would require 48 per group (total 144)
62480727|NCT06483789|EXPERIMENTAL|Telmisartan|Telmisartan fixed dose, once daily.
62320124|NCT03408080|EXPERIMENTAL|Open Arm|All subjects will receive the same dosage throughout the study.
62320125|NCT03769740||CPR Group|
62320126|NCT03666143|EXPERIMENTAL|Sitravatinib + Tislelizumab|Sitravatinib 120 mg was administered orally once daily in combination with tislelizumab 200 mg intravenously (IV) once every 3 weeks
62480728|NCT06483789|EXPERIMENTAL|Verapamil|Verapamil fixed dose, once daily.
62320127|NCT04220866|EXPERIMENTAL|Ulevostinag+Pembrolizumab|Participants receive ulevostinag 540 ug via intratumoral (IT) injection on Day 1 of every week for two 3-week cycles (Cycles 1-2), then on Day 1 of each 3-week cycle for up 33 cycles (Cycles 3-35), for a total of 35 cycles PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
62320128|NCT04220866|ACTIVE_COMPARATOR|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
62339743|NCT06473493|EXPERIMENTAL|Alverine Group|Compound Alverine Citrate Capsules (Lejiansu; specification: each capsule contains 60 mg of Alverine Citrate and 300 mg of Simethicone; manufactured by the French company UCB Pharma), 180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
62480729|NCT06483789|PLACEBO_COMPARATOR|Placebo|Placebo treatment, once daily
62480730|NCT05474027|EXPERIMENTAL|Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia|
62480731|NCT04336228|PLACEBO_COMPARATOR|Healthy Control Group|The healthy placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
62480732|NCT04336228|PLACEBO_COMPARATOR|Obsessive-Compulsive Disorder / High Compulsivity Control Group|The OCD/high compulsivity placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
62480733|NCT04336228|EXPERIMENTAL|Healthy Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
62480734|NCT04336228|EXPERIMENTAL|Obsessive-Compulsive Disorder / High Compulsivity Intervention Group|The OCD/high compulsivity intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
62480735|NCT00156767||Bone Marrow Transplant|Patients enrolled in an NCI protocols for bone marrow transplant for breast cancer using prednisone treatment.
62480736|NCT00156767||Cirrhosis|Adults on NIDDK protocol 91-DK-0213 with evidence of chronic liver disease with class A or B cirrhosis secondary to viral hepatitis
61926065|NCT00160966|ACTIVE_COMPARATOR|1|Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
61926066|NCT00160966|ACTIVE_COMPARATOR|2|Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
61926067|NCT00160966|ACTIVE_COMPARATOR|3|Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing
61926068|NCT02913040|EXPERIMENTAL|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
62320129|NCT01729910|EXPERIMENTAL|Parent education / behavioral counseling|Parents of children in the intervention group will be invited to participate in four group visits and two individual visits with their primary care provider as well as four follow-up phone calls with study personnel (project coordinator or registered dietician). Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls.
62320130|NCT01729910|PLACEBO_COMPARATOR|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
61926069|NCT02913040|ACTIVE_COMPARATOR|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
61926070|NCT00800748|EXPERIMENTAL|Group A|Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.
62129878|NCT04927520||Clipping surgery group|Unruptured middle cerebral artery aneurysms treated with clipping surgery
62129879|NCT01369004|EXPERIMENTAL|Daily self-weighing + feedback/lessons|Participants will be instructed to weigh daily and they will receive a smart scale for daily monitoring of weighing via the website bodytrace.com. They will also receive weekly emailed lessons with content related to behavioral weight control (e.g., How to control portion sizes, How to develop an exercise routine) as well as weekly emailed feedback from a registered dietitian on their daily weighing and weight loss progress.
62129880|NCT01369004|NO_INTERVENTION|Delayed Intervention Control Group|Participants will receive the same components of the experimental group with the exception of the weekly feedback after the 6-month study period is complete.
62129881|NCT00094822||Pegfilgrastim|
62129882|NCT00094822||PLACEBO|
62129883|NCT03772015||Study|"Patients who had the operation of laparoscopic lateral mesh suspension for apical prolapse will have magnetic resonance imaging preoperatively and at postoperative 6th month"
62129884|NCT03772015||Control|Multiparous, sexually active participants who have grade 0 or 1 (asymptomatic if exists) prolapse will have magnetic resonance imaging as a control group
62129885|NCT00681603|EXPERIMENTAL|1|13 cases that accepted subconjunctival injection of bevacizumab
62129886|NCT02990117||Asthmatic patient|Asthma patients aged \>18 in out-patient clinic of the first affiliated hospital of Xi'an Jiaotong university from November 2016 to January 2018 were investigated. A two-stage study was applied which was non-assumptive deep dive qualitative scoping to investigate the determinants of poor compliance in stage 1 asthma patients, and developed new questionnaire for cross sectional survey in stage 2 to obtain more accurate information about the critical issues on asthma management.
62129887|NCT01017146|EXPERIMENTAL|1|Tazarotene foam, 0.1%
62129888|NCT01017146|PLACEBO_COMPARATOR|2|Vehicle Foam
62129889|NCT02909413|EXPERIMENTAL|Group Desflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into Desﬂurane for maintenance. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
62129890|NCT02909413|ACTIVE_COMPARATOR|Group Sevoflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into sevoﬂurane for maintenance. The gas flow rate of Sevoflurane group is 2L/ min, include 50％O2 and 1.7-2.0% Sevoflurane.
62320131|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 1|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62480737|NCT00156767||Critical Care|Patients with a diagnosis of sepsis by the primary clinical provider in the Emergency room of ICU
62480738|NCT00156767||Healthy Volunteer|Healthy adult volunteers
61926071|NCT00800748|EXPERIMENTAL|Group B|Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.
61926072|NCT00800748|EXPERIMENTAL|Group C|Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.
61926073|NCT05587218|EXPERIMENTAL|Self-production|L2 lexical items self-produced at learning
61926074|NCT05587218|ACTIVE_COMPARATOR|Perception|L2 lexical items heard or observed an additional time at learning
61926075|NCT05344885|ACTIVE_COMPARATOR|DPT-standard|A standard digital parent training intervention
61926076|NCT05344885|EXPERIMENTAL|DPT-Enhanced|Enhanced digital parent training intervention
61926077|NCT02616432|EXPERIMENTAL|Tomosynthesis + FFDM|Women enrolled to DBT Arm will undergo manufacturer-defined DBT
62129891|NCT05234853|EXPERIMENTAL|"Monotherapy classic 3+3 design dose escalation and expansion"|
62129892|NCT03278587|ACTIVE_COMPARATOR|Community-based screening|
62320132|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 2|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62480739|NCT00156767||Known Adrenal Insufficiency|patients with known diagnosis of Adrenal Insufficiency
62320133|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 3|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62320134|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 4|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62320135|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 5|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62480740|NCT00156767||Nephrotic Syndrome|Adults enrolled in NIDDK protocols with diagnosis of nephrotic syndrome
62480741|NCT00156767||Post Surgical Treatment for Cushings|Patients with transient adrenal insufficiency secondary to successful surgical treatment of cushing's syndrome
62480742|NCT02203526|EXPERIMENTAL|Arm 1-A (original study design - prior to Amendment G)|TEDD-R (cycle 1) with ibrutinib; TEDDI-R with cytarabine (cycles 2-6)
62480743|NCT02203526|EXPERIMENTAL|Arm 1-B (original study design-prior to Amendment G)|TEDDI-R with cytarabine
62480744|NCT02203526|EXPERIMENTAL|Arm 2 (Dose Escalation; prior to Amendment 06/04/2021)|TEDDI-R with cytarabine, and isavuconazole
61926078|NCT02616432|NO_INTERVENTION|FFDM - Standard of Care for Screening|Women enrolled to the FFDM Arm will undergo bilateral digital mammogram with standard CC and MLO views acquired
62129893|NCT03278587|ACTIVE_COMPARATOR|Cataract camp program|
62129894|NCT03278587|ACTIVE_COMPARATOR|Community health worker program|
62129895|NCT03278587|NO_INTERVENTION|No intervention|
62129896|NCT00981643|EXPERIMENTAL|Multiple Sclerosis, Meditation group|Multiple Sclerosis, Meditation instruction and practice group
62129897|NCT00981643|NO_INTERVENTION|Multiple Sclerosis, Control group|Multiple Sclerosis, Control group
62129898|NCT00981643|EXPERIMENTAL|Peripheral Neuropathy, Meditation group|Peripheral Neuropathy, Meditation instruction and practice group
62129899|NCT00981643|NO_INTERVENTION|Peripheral Neuropathy, Control group|Peripheral Neuropathy, Control group
62129900|NCT05993078|EXPERIMENTAL|NS group|The patient will undergo NS 2000ml intravenous infusion swiftly after IVT.
62129901|NCT05993078|PLACEBO_COMPARATOR|Control group|The patient will the patients receive an NS 200-400ml after IVT.
62129902|NCT01668940|EXPERIMENTAL|Lillipops Iced Soothies (4 flavours)|"Initially, women will be given 1 multiflavour box of Lillipop samples minus the ginger flavour (4 flavours). Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
62129903|NCT01668940|EXPERIMENTAL|Lillipop Iced Soothies (Ginger flavour)|Initially, women will be given 1 Ginger flavor box of Lillipop samples. Each box contains 24 freezies (20 mL each). Each 20ml contains 80mg of dried ginger root. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 a day and to not have any other popsicles, freezies or other ginger products throughout the duration of the study (7 days). Due ginger's antiemetic property, a maximum daily dose is up to 1000mg/day of dried ginger root powder in pregnancy.They can request an additional box of freezies at each follow-up, as needed.All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol.
62129904|NCT01668940|ACTIVE_COMPARATOR|Mr. Freeze Freezies (4 flavours)|"Initially, women will be given 1 multiflavour box of Mr. Freeze samples. Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
62129905|NCT01668940|NO_INTERVENTION|Natural Course Group|"Women will not receive any freezies and will be asked to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days).~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
62129906|NCT04438343|EXPERIMENTAL|experimental group|
62129907|NCT04438343|ACTIVE_COMPARATOR|control group|
62129908|NCT04404166|EXPERIMENTAL|PINGS 2|
62129909|NCT04404166|NO_INTERVENTION|Standard of Care|
62129910|NCT02238483|EXPERIMENTAL|AZD7624|Active treatment
62129911|NCT02238483|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62129912|NCT02218060|EXPERIMENTAL|Force|Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test
62129913|NCT02218060|OTHER|Control|Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems
62129914|NCT03097770|EXPERIMENTAL|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on day 1 in the absence of disease progression or unacceptable toxicity.
62129915|NCT06416267||Clalit Health Services|Individuals over the age of 40 attending to the Clalit HMO clinics in the North of Israel for regular blood tests.
62129916|NCT06134258|OTHER|Fasting for 24 hours|
62129917|NCT06134258|OTHER|Fasting for 8 hours|
62129918|NCT05670834||control group (GroupA)|normal healthy non-cataractous volunteers aged ≥21 years
62129919|NCT05670834||Group B (experimental group 1)|cataractous patients aged \>50 years and diagnosed with senile cataract.
62129920|NCT05670834||Group C (experimental group 2)|cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract
62129921|NCT04665440|OTHER|Voice only then distraction|First intervention: mother's voice without tactile stimuli Second intervention: mother's voice with tactile stimuli
62129922|NCT04665440|OTHER|Distraction then voice only|First intervention: mother's voice with tactile stimuli Second intervention: mother's voice without tactile stimuli
62320136|NCT05262400|EXPERIMENTAL|Part 2A|PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and Endocrine Therapy)
62320137|NCT05262400|EXPERIMENTAL|Part 2B|PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior endocrine therapy and up to 1 prior line of chemotherapy for advanced or metastatic disease and no prior treatment with any CDK4/6 inhibitor for advanced disease)
62480745|NCT02203526|EXPERIMENTAL|Arm 3 (Dose Expansion; prior to Amendment 06/04/2021)|TEDDI-R with cytarabine and isavuconazole
62689210|NCT03896568|EXPERIMENTAL|Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)|Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.
62689211|NCT05665881|EXPERIMENTAL|Ephedrine|Ephedrine group: receive ephedrine (configured concentration 2 mg/mL). The individualized blood pressure control target was a 10% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
62480746|NCT02203526|EXPERIMENTAL|Arm 4 (Dose Expansion; Amendment 06/04/21)|TEDDI-R, cytarabine or methotrexate, isavuconazole, ibrutinib for 10 days
62689212|NCT05665881|EXPERIMENTAL|Phenylephrine|Phenylephrine group: receive intravenous infusion of phenylephrine (configured concentration 0.1 mg/mL) The individualized blood pressure control target was a 10% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
61926079|NCT03609580|EXPERIMENTAL|1 week Pre-operative Tamsulosin administration|
62320138|NCT05262400|EXPERIMENTAL|Part 2C|PF-07220060 + PF-07104091 + Letrozole (ER+/HER2- Breast Cancer with no prior treatment with any CDK4/6 inhibitor for advanced disease)
62320139|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 6|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62320140|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 7|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62320141|NCT05262400|EXPERIMENTAL|Part 1 Dose Escalation - Dose Level 8|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
62320142|NCT04187222|EXPERIMENTAL|Test Group|Mechanical treatment + Bifidobacterium animalis subsp. lactis
62320143|NCT04187222|PLACEBO_COMPARATOR|Control Group|Mechanical treatment + Placebo
62320144|NCT01884285|EXPERIMENTAL|Part A: AZD8186 monotherapy|Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
62689213|NCT05665881|EXPERIMENTAL|norepinephrine|norepinephrine group: intravenous infusion of norepinephrine (configured concentration of 6 μg/ml).The individualized blood pressure control target was a 10% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
62689214|NCT01121029|EXPERIMENTAL|Hematopoietic stem cells|
62689215|NCT01877278|ACTIVE_COMPARATOR|active|Group wearing the active device emitting pulsed electromagnetic fileds
62689216|NCT01877278|PLACEBO_COMPARATOR|placebo|Group wearing the device non-emitting pulsed electromagnetic fileds
61926080|NCT03609580|EXPERIMENTAL|3 days Pre-operative Tamsulosin administration|
61926081|NCT05007015|EXPERIMENTAL|Transanal Irrigation|This group will be instructed on the use of TAI to be perform daily for the three month duration of their treatment arm
62320145|NCT01884285|EXPERIMENTAL|Part C2: AZD8186/abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186.
62480747|NCT05171647|EXPERIMENTAL|M+P (Arm A)|Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
62320146|NCT01884285|EXPERIMENTAL|Part D1: AZD8186 and AZD2014|Combination dosing with AZD8186 and AZD2014 both given on an intermittent schedule at escalating dose levels of each IMP for combination dose finding
62320147|NCT01884285|EXPERIMENTAL|Part B: AZD8186 monotherapy|Part B - multiple dosing of intermittent dose schedule
62320148|NCT01884285|EXPERIMENTAL|Part D2: AZD8186/ AZD2014|Expanded cohort of patients will be treated at a tolerated combination dose level established in Part D1
62480748|NCT05171647|ACTIVE_COMPARATOR|R-GemOx (Arm B)|Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.
62480749|NCT05027958|OTHER|1|TST+ IGRA+
62689217|NCT04883775|EXPERIMENTAL|89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging|All subjects will receive a single, fixed, intravenous dose of MVT-2163, consisting of 3 mg (nominal mass - actual mass administered will likely vary between 2.0 and 2.5 mg) of MVT-2163 radiolabeled from 5 mCi to no less than 1.0 mCi (adjusted as of 16-Mar 2017) of 89Zr.Cohort 1 subjects will receive MVT-2163, with no MVT-5873 pre-dosing. Subjects in subsequent cohorts 2 and 3 will receive a dose of MVT-5873 15 minutes, \~ 2 hours, and \~4 hours prior to administration of MVT-2163. Future cohorts 4 and 5 may evaluate alternate time frames. Other cohorts may evaluate administration of MVT-5873 one week prior (D-7) to the day of MVT-2163 administration and a second administration of MVT-5873 the day of (D0) MVT-2163 administration. The re-entry (RE) and pre-surgery (PS) cohorts will administer MVT-2163 3 ± 1 hour after administration of MVT-5873.
62689218|NCT05668923|EXPERIMENTAL|Speech sound stimulation|Speech sound stimulation via behavioral, electrophysiological, and magnetic resonance imaging-based tasks
62689219|NCT04250207|EXPERIMENTAL|K-321 QID|K-321 Ophthalmic Solution Dose A
62689220|NCT04250207|EXPERIMENTAL|K-321 BID|K-321 Ophthalmic Solution Dose B
62320149|NCT01884285|EXPERIMENTAL|Part C1: AZD8186 & abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186 at escalating doses of AZD8186 for the purpose of dose finding
62320150|NCT06480474|EXPERIMENTAL|Experimental group|The first experimental group will have access to an online self-help program for depression. The program Deprexis® is a self-help, web-based intervention that proposed various modules to face depression. They will have access to the program for 8 weeks. They are asked to complete the modules as many times as they wish and to use to program at least 30 minutes, 1 or 2 times a week. They will be assessed at baseline (T0), mid-intervention (4-weeks, T1), post-intervention (8-weeks, T2) and for the follow-up (3 months post intervention, T3). They will be asked to complete online questionnaires.
62689221|NCT04250207|PLACEBO_COMPARATOR|Placebo|Vehicle Solution Dose
62339744|NCT04570657|EXPERIMENTAL|MEDI3506 Dose 1|Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
62480750|NCT05027958|OTHER|2|TST- IGRA-
62480751|NCT06183931|EXPERIMENTAL|ALXN2220|Participants will receive weight-based dose of ALXN2220 via intravenous (IV) infusion every 4 weeks (q4w) for at least 24 months up to a maximum of 48 months.
62480752|NCT06183931|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo via IV infusion q4w for at least 24 months up to a maximum of 48 months.
62689222|NCT06641297|ACTIVE_COMPARATOR|Active training|Training sessions involving playing the video game 'Guitar Hero'
62689223|NCT06641297|PLACEBO_COMPARATOR|Observation training|
62689224|NCT05396287||Controls|Healthy controls
62689225|NCT05396287||Vertebral Artery Hypoplasia|Healthy individuals with vertebral artery hypoplasia
62320151|NCT06480474|ACTIVE_COMPARATOR|Second Experimental group|The second experimental group will have access to both the online program as well as an online forum in which they will be divided into a group of 10 and they will be requested to ask, respond, and share their experiences with other participants. They will have access to the program and to the online forum for 8 weeks. They are asked to complete the modules as many times as they wish and to use to program at least 30 minutes, 1 or 2 times a week. They will be assessed at baseline (T0), mid-intervention (4-weeks, T1), post-intervention (8-weeks, T2) and for the follow-up (3 months post intervention, T3). They will be asked to complete online questionnaires.
62320152|NCT06480474|NO_INTERVENTION|Control group|The control intervention is a wait list control group that will, after the 8 weeks of treatment, have access to the online self-help program and will complete questionnaires (the same as the two experimental groups), reward task at baseline, at 8-weeks and at the follow-up (3 months post-intervention).
62320153|NCT01733069||No treatment|
62320154|NCT04742517|EXPERIMENTAL|Single ascending dose of ASP1128|Participants (6 for each cohort) will receive a single dose of ASP1128.
62320155|NCT04742517|PLACEBO_COMPARATOR|Single ascending dose of Placebo|Participants (2 for each cohort) will receive a single dose of matching Placebo.
62320156|NCT04742517|EXPERIMENTAL|Multiple ascending dose of ASP1128|Participants (9 for each cohort) will receive daily doses of ASP1128 for 7 consecutive days.
62320157|NCT04742517|PLACEBO_COMPARATOR|Multiple ascending dose of Placebo|Participants (3 for each cohort) will receive matching Placebo for 7 consecutive days.
62320158|NCT01048229|EXPERIMENTAL|Rasagiline|
62320159|NCT01048229|ACTIVE_COMPARATOR|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
62320160|NCT01492647|EXPERIMENTAL|JNJ 10229570-AAA 1.2%|
62320161|NCT01492647|EXPERIMENTAL|JNJ 10229570-AAA 3.6%|
62320162|NCT02467595|EXPERIMENTAL|R 0.15 group|"Rocuronium bromide 0.15 mg kg-1 group~1. Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.15 mg kg-1~2. After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~3. At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~4. When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy."
62480753|NCT02890355|EXPERIMENTAL|Arm I (veliparib and mFOLFIRI)|Patients receive veliparib PO BID every 12 hours on days 1-7, irinotecan hydrochloride IV over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5.
62480754|NCT02890355|ACTIVE_COMPARATOR|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3.
62320163|NCT02467595|ACTIVE_COMPARATOR|R 0.3 group|"Rocuronium bromide 0.3 mg kg-1 group~1. Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.3 mg kg-1~2. After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~3. At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~4. When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy."
62320164|NCT02467595|PLACEBO_COMPARATOR|S group|"saline~1. Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and saline.~2. After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~3. At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~4. When poor intubating condition., added rocuronium bromide0.3 mg kg-1 ."
62339745|NCT04570657|EXPERIMENTAL|MEDI3506 Dose 2|Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
62689226|NCT02411851|ACTIVE_COMPARATOR|Ingenol mebutate alone|At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
62480755|NCT01218854|EXPERIMENTAL|B-NASS|Block assisted needle angle selection system
62480756|NCT01218854|EXPERIMENTAL|L-NASS|laser assisted needle angle selection system
62689227|NCT02411851|EXPERIMENTAL|Ingenol mebutate and dermasil lotion|At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.
62689228|NCT04210102|OTHER|CR + LUS|Patient will be performed first the Chest radiography then the Lung ultrasound.
62689229|NCT04210102|OTHER|LUS + CR|Patient will be performed first the Lung ultrasound then the Chest radiography
62689230|NCT06673459|EXPERIMENTAL|TBICy|Patients enrolled in this arm will receive total body irradiation plus cyclophosphamide as conditioning regimen.
62689231|NCT06673459|ACTIVE_COMPARATOR|BuCy|Patients enrolled in this arm will receive busulfan plus cyclophosphamide as conditioning regimen.
62689232|NCT06475820|EXPERIMENTAL|Baricitinib and Cyclophosphamide|Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day.
62689233|NCT04043247|SHAM_COMPARATOR|Control Group|Same as TEAS group but without electrical stimulation
62689234|NCT04043247|EXPERIMENTAL|TEAS Group|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
62689235|NCT06211218||Cornea diseases diagnosed by artificial intelligence algorithm|
62689236|NCT05701345|EXPERIMENTAL|medical device used group|Wearable visual device(HMD)-VR-based software medical device(OMNIFIT DTx-MDD)
62480757|NCT01218854|EXPERIMENTAL|MD-NASS|mobile-device assisted needle angle selection system
62480758|NCT04613453|EXPERIMENTAL|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
62480759|NCT04613453|ACTIVE_COMPARATOR|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
62689237|NCT05701345|PLACEBO_COMPARATOR|medical device unused group|Patients receiving only standard treatment
62689238|NCT04245410||Patients surgically treated of pancreatic metastases from RCC|Patients surgically treated of pancreatic metastases from renal cell carcinoma. Pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy are included.
62480760|NCT00001971||Healthy individuals|Healthy individuals who have recovered from liver diseases or who are healthy volunteers
62480761|NCT00001971||Patients|Liver disease patients
62320165|NCT02826044|EXPERIMENTAL|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
62320166|NCT02826044|EXPERIMENTAL|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
62689239|NCT01433861|ACTIVE_COMPARATOR|LAPG|LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group
62689240|NCT01433861|ACTIVE_COMPARATOR|LATG|LATG : laparoscopy-assisted total gastrectomy group
62689241|NCT01992939|ACTIVE_COMPARATOR|Non-Healthy Subjects arm|Subjects in this arm will have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack
62320167|NCT02826044|EXPERIMENTAL|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
62320168|NCT02702193|EXPERIMENTAL|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers.
62320169|NCT02702193|NO_INTERVENTION|TAU|Treatment as usual - the usual outpatient substance abuse or mental health services received by the mothers with no additional services provided by the study team.
62320170|NCT05118139|EXPERIMENTAL|1.5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 1.5% ENDS products based on their preferred flavor.
62320171|NCT05118139|EXPERIMENTAL|2.4% nicotine cartridges|Subjects will self-assign to one of 2 flavor variants of 2.4% ENDS products based on their preferred flavor.
62480762|NCT02108028||Cohort 1A / Initial Young Adults with Children|Young adults who have a child(ren) and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
62689242|NCT01992939|ACTIVE_COMPARATOR|Healthy Subjects Arm|Subjects who do not have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities will be considered healthy subjects and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack.
62689243|NCT01487161|EXPERIMENTAL|FX006 10 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
62689244|NCT01487161|EXPERIMENTAL|FX006 40 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
62689245|NCT01487161|EXPERIMENTAL|FX006 60 mg|Single 3mL intra-articular (IA) injection Extended-Release Formulation
62689246|NCT01487161|ACTIVE_COMPARATOR|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide
62689247|NCT02565394|EXPERIMENTAL|Micro-Break with Dynamic Activity|Micro Break with web based application of a video to lead surgeons through dynamic exercise activities
62320172|NCT05118139|EXPERIMENTAL|5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 5% ENDS products based on their preferred flavor.
62320173|NCT04331158|EXPERIMENTAL|Dry cupping group|The dry cupping will be applied with a force of two suctions generating a negative pressure on the skin during the time of 15 minutes.
62320174|NCT04331158|PLACEBO_COMPARATOR|Dry cupping sham group|The dry cupping sham group will receive the same procedures as the dry cup group, with the difference that the negative pressure imposed after application will be released in a few seconds.
62320175|NCT04936451|OTHER|TENS / TENS ECOMODYN|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS / TENS ECOMODYN Patients first start with TENS during 2 months puis change with TENS ECOMODYN during 2 months with a wash-out period of 15 days
62480763|NCT02108028||Cohort 1B / Comparison Young Adults with Children|Young adults who have children and are 18- 39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
62689248|NCT02565394|NO_INTERVENTION|Comparator|A baseline survey will be completed following a surgical day with no dynamic activities
62689249|NCT06170242|EXPERIMENTAL|EDP-323 Arm A|Subjects will take EDP-323 Dose 1 orally for 5 days
62689250|NCT06170242|EXPERIMENTAL|EDP-323 Arm B|Subjects will take EDP-323 Dose 2 orally for 5 days
62689251|NCT06170242|PLACEBO_COMPARATOR|Placebo Arm C|Subjects will take matching placebo orally for 5 days
62689252|NCT04798820|ACTIVE_COMPARATOR|SE-STG|simplified dietary education arm in subtotal gastrectomy group.
62689253|NCT04798820|ACTIVE_COMPARATOR|IE-STG|intensive dietary education arm in subtotal gastrectomy group
62689254|NCT04798820|ACTIVE_COMPARATOR|SE-TG|simplified dietary education arm in total gastrectomy group.
62689255|NCT04798820|ACTIVE_COMPARATOR|IE-TG|intensive dietary education arm in total gastrectomy group
62689256|NCT01793129|EXPERIMENTAL|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
62689257|NCT01793129|PLACEBO_COMPARATOR|Normothermia|Control group (with esophageal temperature at or near 37.0°C) for 72 hours
62320176|NCT04936451|OTHER|TENS ECOMODYN / TENS|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS ECOMODYN / TENS Patients first start with TENS ECOMODYN during 2 months puis change with TENS during 2 months with a wash-out period of 15 days
62320177|NCT03711552||Quality of recovery|All enrolled patients will be asked to complete the ObsQoR-11 and QoR-15 questionnaires pre-surgery if feasible and at 24 and 48 hours post-surgery.
62689258|NCT02155972|ACTIVE_COMPARATOR|Bifidobacterium infantis|Bifidobacterium infantis (Align) 10.00 million cfu capsule once daily
62689259|NCT02155972|PLACEBO_COMPARATOR|Placebo|Placebo capsule once daily
62480764|NCT02108028||Cohort 2A / Initial Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
62689260|NCT06639308|ACTIVE_COMPARATOR|Group A : open fhl tendon transfer|the open surgery group The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
62738285|NCT05267470|EXPERIMENTAL|Part 4: Combination Immuno-chemotherapy|Participants with FGFR2b overexpression will receive the dose of bemarituzumab identified as safe during Part 1 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel.
62738286|NCT04654221||Male, BMI <= 24.9|Male subjects with a BMI of less than or equal to 24.9
62738287|NCT04654221||Female, BMI <= 24.9|Female subjects with a BMI of less than or equal to 24.9
62738288|NCT04654221||Male, BMI 25-29|Male subjects with a BMI of 25 to 29
62738289|NCT04654221||Female, BMI 25-29|Female subjects with a BMI of 25 to 29
62339746|NCT04570657|PLACEBO_COMPARATOR|Placebo|Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
62480765|NCT02108028||Cohort 2B / Comparison Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
62480766|NCT02108028||Cohort 3A / Initial Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
62697432|NCT03684980|EXPERIMENTAL|Arm D -Rituximab + MTX + Glucarpidase|Up to 12 patients will be included in Arm D of this study. Cycles will be 14 days long. All patients will receive MTX 3.5 g/m2 administered Day 1 of each cycle (+/- 7 days, a minimum of 14 days required between doses). Glucarpidase will be administered 24 hours (+/- 2 hr) after start of MTX infusion except in cycles 1-2 of Cohort B. Dose of glucarpidase will be 2000 units in Cohort A (first 4 patients) and 1000 units in Cohort B (remaining 8 patients). Patients in Arm D will receive 8 cycles of treatment. Cycles 1 and 2 will be administered in patient while Cycles 3-8 may be in the outpatient setting. Concurrent chemotherapy such as vincristine, procarbazine, and/or ibrutinib may be administered at the investigator's discretion and in accordance with standard of care. In Cohort B, all cycles will be administered with rituximab 500 mg/m2. Rituximab should be administered prior to glucarpidase (window -4 days).
61926082|NCT05007015|NO_INTERVENTION|Tradition care Control arm|This group tradition care group will have no modification to the care they have received prior to commencing the study. The patients in this group will use the usual dietary modifications and medications prescribed by the treating team to manage their LARS. No changes will be made to the treatment regime prescribed by their surgeon.
61926083|NCT01973543|EXPERIMENTAL|VY-AADC01 Dose 1|7.5 x 10\^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
61926084|NCT01973543|EXPERIMENTAL|VY-AADC01 Dose 2|1.5 x 10\^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
61926085|NCT01973543|EXPERIMENTAL|VY-AADC01 Dose 3|4.7x 10\^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
61926086|NCT05288699|EXPERIMENTAL|Aliento|Participants complete the brief (\~30 minute) intervention at baseline and will have access to intervention material for up to 3-months after the baseline appointment via the mobile health application.
61926087|NCT05270421|EXPERIMENTAL|Intervention Group|"40 mg of furosemide IV + IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
61926088|NCT05270421|ACTIVE_COMPARATOR|Control Group|"IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
62320178|NCT03564665|EXPERIMENTAL|400mg Magnesium Glycinate BID Arm|Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
62320179|NCT03564665|PLACEBO_COMPARATOR|Control Arm|Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
61926089|NCT02902978|EXPERIMENTAL|Cohort 1 to 7|Participants will receive a single dose of E6130 or placebo, administered in a dose-ascending manner under the fasted condition.
61926090|NCT02902978|EXPERIMENTAL|Cohort 8|Participants will receive a single dose of E6130 (determined in Cohort 1 to 7), administered in the specified order (fed/fasted or fasted/fed) to evaluate the food effect.
61926091|NCT03981796|ACTIVE_COMPARATOR|Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab|
61926092|NCT03981796|PLACEBO_COMPARATOR|Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
61926093|NCT03981796|ACTIVE_COMPARATOR|Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib|
61926094|NCT03981796|PLACEBO_COMPARATOR|Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
61926095|NCT05879718|EXPERIMENTAL|Group 1|PF-06823859
61926096|NCT05879718|PLACEBO_COMPARATOR|Group 2|Placebo
62320180|NCT06124443||Cases|Infants \& children of diabetic mothers
62320181|NCT06124443||Controls|Infants \& children of non-diabetic mothers
62320182|NCT03604471|OTHER|Atorvastatin|All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).
62320183|NCT04330508||Group A|Chronic hepatitis C without Cirrhosis
62320184|NCT04330508||Chronic hepatitis C with Cirrhosis|
62480767|NCT02108028||Cohort 3B / Comparison Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
62689261|NCT06639308|ACTIVE_COMPARATOR|Group B : endoscopic open fhl tendon transfer|"• Endoscopic FHL tendon transfer: The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. The FHL tendon is the main hindfoot endoscopic landmark as the neurovascular tibial bundle is located medial to it. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. The posterior fibulo-talocalcaneal ligament complex or Rouvière and Canela ligament is cut as proximal as possible in order to allow free movement of the FHL tendon and allows a straight FHL tendon trajectory to the most posterior aspect of the calcaneal bone.~The FHL tendon is pierced with a suture passer, and a lasso loop type suture is tied to provide traction on the tendon. The foot is held in plantar flexion with the hallux flexed, relaxing the flexor hallucis longus (FHL), and the traction suture is grasped an"
61926097|NCT06388434|EXPERIMENTAL|Protective Arm Training|Both groups (older adults and people with peripheral neuropathy) will be assessed pre- and post-intervention as well as midway through the training.
61926098|NCT06723522|ACTIVE_COMPARATOR|Active group|Received a dose of 2 mA HD-tDCS stimulation lasted for 20 min, with 30 s of ramp-up and ramp-down before and after the 20-min stimulation, respectively.
62480768|NCT02108028||Cohort 4 / Non-patient participants|Family members, friends, or health care providers of patient participant. COMPLETE
62480769|NCT05234983|EXPERIMENTAL|LifeFirst SWASTH brief advice intervention|"Described in the Intervention Description section"
62480770|NCT05234983|NO_INTERVENTION|Control: Educational pamphlets|In lieu of the intervention, participants will receive a high-quality evidence-based pamphlet tobacco cessation pamphlet created by the NSF team for low-SES audiences in Mumbai. After all data has been collected, community healthcare settings in the control arm will have the opportunity to receive the intervention.
61926099|NCT06723522|SHAM_COMPARATOR|Sham group|Received 1 min of ramping up/down without experiencing 2 mA HD-tDCS stimulation lasted for 20 min.
62480771|NCT03828994|EXPERIMENTAL|TECH-PN|Participants receive community health nurse visits, text-messaging support, additional testing and field based visits with a nurse practitioner.
62480772|NCT03828994|NO_INTERVENTION|TECH-N|Participants receive enhanced standard of care with community health nurse visits and text-messaging support.
62689262|NCT04045145|EXPERIMENTAL|Crinecerfont 50 milligrams (mg) Twice Daily (BID)|Crinecerfont administered orally for 14 consecutive days.
62738290|NCT04654221||Male, BMI >29|Male subjects with a BMI of greater than 29
61926100|NCT02809521|OTHER|Activity Liking|Subjects will look at images of people doing different types of activities (e.g., walking, skiing, watching television) and rate their liking of the activity.
61926101|NCT00255801|EXPERIMENTAL|Doxil and Targretin® (bexarotene)|Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
61926102|NCT03606395|EXPERIMENTAL|Single ascending dose_healthy subjects|"NV-5138:~Single dose of 150, 300, 600, 1000, 1600 or 2400 mg single dose of placebo"
61926103|NCT03606395|EXPERIMENTAL|Single dose in subjects with TRD|NV-5138 oral solution single dose (dose to be determined from Part A) single dose of placebo
61926104|NCT06515509|ACTIVE_COMPARATOR|Immediate Implants with loading|
61926105|NCT06515509|ACTIVE_COMPARATOR|Immediate Implants without loading|
61926106|NCT06745024|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients continue to receive SOC systemic anti-cancer therapy or observation and bone modifying agents as determined by the treating physician. Additionally, patients optional blood sample collection on study.
61926107|NCT06745024|EXPERIMENTAL|Arm II (RT, SOC)|Patients continue SOC as in Arm I. Patients also undergo conventional RT or SBRT QD for up to 5 days (5 fractions) in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI and optional blood sample collection on study.
62738291|NCT04654221||Female, BMI >29|Female subjects with a BMI of greater than 29
62320185|NCT04330508||Healthy Volunteers|
62320186|NCT02090114|EXPERIMENTAL|Cohort A:Post-enzalutamide|Men with castration-resistant prostate cancer who have progressed on enzalutamide will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with enzalutamide 160 mg by mouth daily.
62320187|NCT02090114|EXPERIMENTAL|Cohort B: Post-abiraterone|Men with castration-resistant prostate cancer who have progressed on abiraterone will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with abiraterone 1000 mg by mouth daily.
62320188|NCT02090114|EXPERIMENTAL|Cohort C: Castration Only|Men with metastatic prostate cancer who have only received first line hormone therapy with LHRH agonist alone or LHRH agonist plus an anti-androgen. Patients who have developed castrate resistance to first line therapy and have then received second line hormone therapy of any kind (including flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, enzalutamide, ARN-509 and investigational anti-androgens) are not eligible for enrollment in this cohort.
62320189|NCT02090114|EXPERIMENTAL|Cohort D: Mutation|Men with metastatic prostate cancer who have castrate resistant prostate cancer with inactivating somatic or germline mutations in the genes TP53, RB1 or PTEN identified using clinical grade sequencing of tumor tissue performed by qualified laboratory. Patients must have mutations in ≥2 of these genes to be eligible. Eligible patients must have progressed on first line hormone therapy with LHRH agonist alone and must have received at least one but not more than two second generation androgen ablative therapy (i.e. Abiraterone, Enzalutamide or Apalutamide).
62320190|NCT04142476|EXPERIMENTAL|Pharmaceutical Interview|Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance
62320191|NCT01835990|EXPERIMENTAL|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
62320192|NCT01835990|ACTIVE_COMPARATOR|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
62320193|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
62320194|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
62320195|NCT00325442|ACTIVE_COMPARATOR|Active|Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
62480773|NCT06447376|EXPERIMENTAL|Prophylactic siltuximab + epcoritamab|"Siltuximab Administration:~• Participants will receive a single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab. There is no planned dose escalation of siltuximab and epcoritamab dosing will be done following the standard planned ramp-up over the course of the first 3 weeks~Epcoritamab Infusion:~• The treatment regimen of epcoritamab is done in 28-day cycles. Epcoritamab is to be administered by subcutaneous injection. Participants can be treated for up to 24 cycles. Participants who achieve complete remission at the time of their disease response assessment after 12 cycles may be considered for early discontinuation of treatment."
62480774|NCT04660201|EXPERIMENTAL|Group 1|AV7909 liquid formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
61926108|NCT05161117|EXPERIMENTAL|virtual reality education|The experimental group will receive both an online fall prevention education module and additional education using a virtual reality simulation app for mobile devices designed for specifically for hospital caregivers
61926109|NCT05161117|ACTIVE_COMPARATOR|online education only|The control group will receive an online fall prevention education module
61926110|NCT01158703|ACTIVE_COMPARATOR|clopidogrel|aspirin and clopidogrel
61926111|NCT01158703|PLACEBO_COMPARATOR|sugar pill|aspirin and placebo
61926112|NCT00977808|EXPERIMENTAL|Closed-Loop Model Predictive Control (MPC)|Insulin dosing was performed by a model-predictive control (MPC) algorithm.
61926113|NCT00977808|PLACEBO_COMPARATOR|Open-Loop|Insulin dosing was performed by the patient (using their normal routine and personal insulin pump) under a physician's supervision.
61926114|NCT05838378|EXPERIMENTAL|Pictorial warnings|Participants randomized to this group will view pictorial cigarillo warnings.
61926115|NCT05838378|ACTIVE_COMPARATOR|FDA text-only warnings|Participants randomized to this group will view FDA text-only warnings.
61926116|NCT05838378|ACTIVE_COMPARATOR|Surgeon General text-only warnings|Participants randomized to this group will view Surgeon General text-only warnings.
61926117|NCT05709249|ACTIVE_COMPARATOR|intervention group|Subjects in the intervention group will be treated with XLJDOD compound granule.
62320196|NCT00325442|PLACEBO_COMPARATOR|Placebo Arm|Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
62320197|NCT02013193|EXPERIMENTAL|Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB)
62320198|NCT02013193|ACTIVE_COMPARATOR|uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion
62320199|NCT04742153|EXPERIMENTAL|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
62320200|NCT05644210||RTX+TA group|"Screening stage：Patients received 200mg of rituximab intravenously at week 0 and week 2.~Follow-up period：Telitacicept 160mg once a week for 24 weeks Basic treatment： Hydroxychloroquine、Prednisone、Warfarin、Aspirin"
62320201|NCT05644210||RTX group|"Screening stage：Patients received 200mg of rituximab intravenously at week 0 and week 2.~Follow-up period Basic treatment：Hydroxychloroquine、Prednisone、Warfarin、Aspirin"
62320202|NCT00620620|PLACEBO_COMPARATOR|Inhaled Placebo|Staccato Placebo
62320203|NCT00620620|EXPERIMENTAL|Inhaled Zaleplon 0.5 mg|Staccato Zaleplon 0.5 mg
62689263|NCT04872647|NO_INTERVENTION|Usual Diabetic Care|Usual diabetic care for this study will include a diabetic visit with their primary care provider at the beginning and end of the 12 weeks. They will also be asked to continue their current level of physical activity and eating habits.
62697433|NCT03684980|EXPERIMENTAL|Arm E-glucarpidase 1000u + MTX|Study treatment consists of glucarpidase 1000u, to be administered at least 24 hours after start of standard of care MTX. Patients will have a standard of care methotrexate level drawn within 6 hours of planned glucarpidase administration to confirm eligibility (must reflect MTX \> 100 nmol/L)
61926118|NCT05709249|PLACEBO_COMPARATOR|control group|Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).
62320204|NCT00620620|EXPERIMENTAL|Inhaled Zaleplon 1 mg|Staccato Zaleplon 1 mg
62320205|NCT00620620|EXPERIMENTAL|Inhaled Zaleplon 2 mg|Staccato Zaleplon 2 mg
62320206|NCT00620620|EXPERIMENTAL|Inhaled Zaleplon 4 mg|Staccato Zaleplon 4 mg
62320207|NCT02807909|EXPERIMENTAL|BMS-986177 and Itraconazole|Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days
62320208|NCT02807909|EXPERIMENTAL|BMS-986177 and Diltiazem|Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days
62320209|NCT00769704|ACTIVE_COMPARATOR|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.
62320210|NCT00769704|EXPERIMENTAL|Talimogene Laherparepvec|Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.
62320211|NCT01414088|PLACEBO_COMPARATOR|glucose|glucose 5 %
62320212|NCT01414088|ACTIVE_COMPARATOR|isotonic saline|isotonic saline 0.9 mg/ml
62320213|NCT01414088|ACTIVE_COMPARATOR|hypertonic saline|hypertonic saline 2.9 mg/ml
62320214|NCT01048996||Non ALI/ARDS|Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
62320215|NCT01048996||ALI/ARDS|Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
62320216|NCT00193674|EXPERIMENTAL|1|
62320217|NCT00193674|PLACEBO_COMPARATOR|2|
62320218|NCT04869579|EXPERIMENTAL|Selenious Acid + Standard Of Care (SOC)|Participants who are moderately-ill, severely-ill, or critically ill will receive a Selenious Acid infusion of 2000µg on day 1 as a loading dose infusion, followed by a continuous infusion of Selenious Acid at a maintenance dose of 1000µg daily on days 2-14 together with continued Standard Of Care therapy.
62320219|NCT04869579|ACTIVE_COMPARATOR|Standard Of Care (SOC) + Placebo|Participants will receive a Saline-based placebo infusion of 2000µg on day 1 as a loading dose, followed by continuous infusion of a Saline-based placebo at a maintenance dose of 1000µg daily on days 2-14. Standard Of Care is to be determined according to patients' clinical picture and may include Dexamethasone, Azithromycin, Ceftriaxone, Remdesivir, Convalescent Plasma.
62320220|NCT03586843|EXPERIMENTAL|Part A: Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous \[SC\] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
62320221|NCT03586843|EXPERIMENTAL|Part A: Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
62320222|NCT03586843|EXPERIMENTAL|Part A: Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
62320223|NCT03586843|EXPERIMENTAL|Part A: Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
62320224|NCT03586843|EXPERIMENTAL|Part A: Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
62320225|NCT03586843|EXPERIMENTAL|Part A: Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
62320226|NCT03586843|EXPERIMENTAL|Part B: JNJ-64565111|Participants will receive a single SC ascending doses of JNJ-64565111 on Days 1, 8, 15, 22, 29 and 36.
62320227|NCT04151381|PLACEBO_COMPARATOR|the control group|the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .
62320228|NCT04151381|ACTIVE_COMPARATOR|Amiophylline (2mg)|Aminophylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia
62320229|NCT04151381|ACTIVE_COMPARATOR|Aminophylline(4mg)|Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
62320230|NCT02272621|EXPERIMENTAL|Partial upper hemisternotomy aortic valve replacement|Partial upper hemisternotomy AVR will be performed according to current standard of care practices.
62320231|NCT02272621|EXPERIMENTAL|Full sternotomy aortic valve replacement|Full sternotomy AVR through a standard median sternotomy will be performed according to current standard of care practices.
62320232|NCT01401855||In Vivo Probe Prediction|
62320233|NCT01401855||Cytology Results|
62697434|NCT01356368|EXPERIMENTAL|Cisplatin,Docetaxel,Gemzar, Premetrexed|Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.
62320234|NCT01800604|EXPERIMENTAL|Pain Self-Management Arm #1|Pain Self-Management Intervention #1
62480775|NCT04660201|ACTIVE_COMPARATOR|Group 2|AV7909 lyophilized formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
62320235|NCT01800604|EXPERIMENTAL|Pain Self-Management Arm #2|Pain Self-Management Intervention #2
62320236|NCT01800604|EXPERIMENTAL|Pain Self-Management Arm #3|Pain Self-Management Intervention #3
62320237|NCT01800604|EXPERIMENTAL|Pain Self-Management Arm #4|Pain Self-Management Intervention #4
62320238|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
62320239|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
62320240|NCT05603910|EXPERIMENTAL|Lenvatinib, Pembrolizumab and Hypofractionated (Hypofx) External Beam Radiation Therapy (EBRT) Group|"Participants in this group will receive a combination treatment of Lenvatinib, Pembrolizumab, and Hypofx Pelvic EBRT over a period of approximately 10 to 12 weeks.~1. Lenvatinib - administered in a 3 plus 3 escalation/de-escalation design. Participants will receive 1 of 4 of the following dose levels:~   Dose level 1- 4 mg Dose level 2- 8 mg Dose level 3 (Starting dose) - 12 mg Dose level 4- 16 mg~2. Pembrolizumab- 200 mg IV will be administered on Day 1, 22 and 43~3. HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks."
62320241|NCT05492383|EXPERIMENTAL|Patients with severe symptomatic AS undergoing TAVI|Patients with severe symptomatic AS undergoing a TAVI procedure with a THV for which rapid pacing is considered necessary during valve implantation
62320242|NCT01257217|EXPERIMENTAL|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1 or AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT, lens assignment and model determined by preoperative keratometric astigmatism, bilateral implantation
62320243|NCT01257217|ACTIVE_COMPARATOR|Acri.LISA|Acri.LISA® 366D IOL or Acri.LISA® 466TD Toric IOL, lens assignment determined by preoperative keratometric astigmatism, bilateral implantation
62320244|NCT06482645|EXPERIMENTAL|Perilesional/regional systematic biopsy (PB/RSB) group|For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
62689264|NCT04872647|EXPERIMENTAL|Usual Diabetic Care Plus Virtual Health Coaching|"For the duration of the 12 weeks, Healthy at Home will provide health coaching in 10-20 minute phone calls weekly. They will request daily blood glucose logs as this is part of Healthy at Home's normal procedure. The health coach and subject will choose a patient-directed overarching goal such as lose weight, or improve my blood sugar numbers, etc. that the health coach will then help the patient turn into a SMART goal. They will do this by utilizing a list of lifestyle change categories as top priority goals from which to choose from in their patient-directed health coaching sessions. Texting will be utilized to request daily blood glucose and provide real-time coaching via text."
62689265|NCT03295786|PLACEBO_COMPARATOR|Placebo|Patients randomized to this group will receive 6 monthly infusions of placebo/vehicle
62689266|NCT03295786|EXPERIMENTAL|CDNF mid-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to mid-dose
62320245|NCT06482645|EXPERIMENTAL|Combination of systematic biopsy and targeted biopsy (TB+SB) group|For patients in the TB+SB group, three to five targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
62320246|NCT01335815||elective knee and limb endoprothesis|
62320247|NCT04210336|EXPERIMENTAL|PAPILOCARE|"Randomized patients will receive two different guidelines depending on the time of randomization:~* Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).~* Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
62320248|NCT04210336|PLACEBO_COMPARATOR|PLACEBO|"Randomized patients will receive two different guidelines depending on the time of randomization:~* Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).~* Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
62320249|NCT04079556|EXPERIMENTAL|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
62320250|NCT02461485|EXPERIMENTAL|1=BOW_01|1= Fermented Milk Product containing Probiotics
62320251|NCT02461485|EXPERIMENTAL|2=BOW_01 + fiber C|2= Fermented Milk Product containing Probiotics + Fibers C
62689267|NCT03295786|EXPERIMENTAL|CDNF high-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to high-dose
62480776|NCT05293041|EXPERIMENTAL|Argipressin|Patients will be treated with Empressin® 0.8 U/ml, 0.056 ml/kg/h during surgery.
62480777|NCT05293041|PLACEBO_COMPARATOR|Placebo|Patients will receive normal saline 0.056 ml/kg/h during surgery.
62480778|NCT05164367|EXPERIMENTAL|0.1 mg of atropine|1 gram of gel by topical application in the oral cavity once.
62480779|NCT05517421|EXPERIMENTAL|Batoclimab|Participants will be administered batoclimab 680 mg SC weekly for 12 weeks followed by 340 mg SC weekly for 12 weeks.
62480780|NCT05517421|PLACEBO_COMPARATOR|Placebo|Participants will be administered matching placebo SC weekly for 24 weeks.
62689268|NCT05033561|EXPERIMENTAL|2 doses, 1 week apart|Administration of 2 doses of nOPV2, 1 week apart
62480781|NCT05982314|EXPERIMENTAL|Gamma-PN3 50 mcg|In GPNV-001 participants will have received 2 doses of 50 mcg Gamma-PN3 at intervals of 4 weeks
62689269|NCT05033561|EXPERIMENTAL|2 doses, 2 week apart|Administration of 2 doses of nOPV2, 2 weeks apart
62689270|NCT05033561|ACTIVE_COMPARATOR|2 doses, 4 week apart|Administration of 2 doses of nOPV2, 4 weeks apart
62689271|NCT06644846|EXPERIMENTAL|SFRT arm|This is a single arm phase II study. All patients will receive the planned intervention ie. spatially fractionated radiation therapy using rapid rod technique.
61926119|NCT01295931|EXPERIMENTAL|IC-Green + Imaging|Indocyanine Green (IC-Green) Injections + Imaging
61926120|NCT03552965|ACTIVE_COMPARATOR|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
61926121|NCT03552965|ACTIVE_COMPARATOR|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
62129923|NCT04223258|EXPERIMENTAL|Automatic Oxygen Control|Infants randomized to this arm will be monitored using automatic oxygen control system on the ventilator. When infants oxygen saturation are out of the target range the ventilator will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation int he target range.
62129924|NCT04223258|ACTIVE_COMPARATOR|Manual oxygen control|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
62129925|NCT01316731|EXPERIMENTAL|Exercise|
62320252|NCT02461485|EXPERIMENTAL|3 =BOW_01 + fiber W|3= Fermented Milk Product containing Probiotics + Fibers W
62320253|NCT02461485|PLACEBO_COMPARATOR|4 = Control|4= Non fermented Milk Product with same color, texture and organoleptic properties as investigational products 1 to 3.
62320254|NCT01938820|ACTIVE_COMPARATOR|Entecavir Therapy|"Entecavir monotherapy:~entecavir, 0.5mg, qd, oral, for 2 years."
62129926|NCT02710851|EXPERIMENTAL|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
62129927|NCT02710851|EXPERIMENTAL|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
62320255|NCT01938820|EXPERIMENTAL|Entecavir plus Thymosin-α|entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
61926122|NCT06530615||Lung Neoplasm|Lung Cancer cases will be comprised of patients that are confirmed to have lung cancer based on bronchoscopy/ Bronchoalveolar Lavage (BAL) and other clinical testing.
62129928|NCT02710851|EXPERIMENTAL|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
62129929|NCT02710851|PLACEBO_COMPARATOR|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
62129930|NCT01309932|EXPERIMENTAL|A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin|Part A
62320256|NCT03648996|EXPERIMENTAL|Low-fructose diet, isocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose while maintaining baseline body weight.
61926123|NCT06530615||Lung Neoplasm Excluded|Lung Cancer excluded cases will be comprised of the remaining patients in whom lung cancer is excluded as a diagnosis based on bronchoscopy/ Bronchoalveolar Lavage (BAL) and other clinical testing.
61926124|NCT03913325|EXPERIMENTAL|PREVSAM model|
62320257|NCT03648996|EXPERIMENTAL|Allopurinol|Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)
62689272|NCT04637620|EXPERIMENTAL|NMDAE|An NMDA enhancer
62689273|NCT04637620|ACTIVE_COMPARATOR|SSRI|Sertraline (selective serotonin reuptake inhibitor)
62689274|NCT04637620|PLACEBO_COMPARATOR|Placebo|Placebo
62689275|NCT02442531|EXPERIMENTAL|CriPec® docetaxel|Docetaxel containing nanoparticle
62689276|NCT05052892||Training cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
62689277|NCT05052892||Validation cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
62689278|NCT01866150||Cohort|
62689279|NCT02003157|ACTIVE_COMPARATOR|hypnosis|embryo transfer procedure with hypnosis
62689280|NCT02003157|ACTIVE_COMPARATOR|usual|embryo transfer usual procedure
62689281|NCT06675123|EXPERIMENTAL|Treatment (pacritinib, BTK inhibitor)|Patients receive pacritinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also continue to receive BTK inhibitor per standard of care. Additionally, patients undergo blood sample collection, optional tissue biopsy, bone marrow biopsy and aspiration and PET/CT throughout the study.
62697435|NCT04943796||Part I: Participants with ADHD|Participants with psychiatric disorders undergoing ADHD diagnosis.
62480782|NCT05982314|EXPERIMENTAL|Gamma-PN3 250 mcg|In GPNV-001 participants will have received 2 doses of 250 mcg Gamma-PN3 at intervals of 4 weeks
62480783|NCT05982314|EXPERIMENTAL|Gamma-PN3 1000 mcg|In GPNV-001 participants will have received 2 doses of 1000 mcg Gamma-PN3 at intervals of 4 weeks
62480784|NCT05982314|ACTIVE_COMPARATOR|Pneumovax 23|In GPNV-001 participants will have received one 0.5ml dose of Pneumovax-23 followed by saline placebo 4 weeks later
62689282|NCT04325607|EXPERIMENTAL|Negative Pressure Wound Therapy with instillation|Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
62689283|NCT04325607|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
62689284|NCT00713193|EXPERIMENTAL|Cyclosporine and Plasma Exchange Arm|"Patients in this arm will receive cyclosporine (Neoral) at a dose of 2-3 mg/kg orally as an adjunct to plasma exchange.~All patients initiated daily PEX (one plasma volume), using plasma as the replacement fluid. Patients randomized to the CSA arm received CSA at a dose of 2-3 mg/kg (rounded to the nearest 50 mg increment) divided into a twice daily dosing (Figure 1a). Patients randomized to CSA did not receive steroids, but were permitted to receive hydrocortisone as required for any hypersensitivity reactions to the infused plasma. Daily PEX was continued until a clinical response was achieved, then patients received PEX every other day for 2 additional procedures, with the first day that the platelet count and LDH were normal counting as the first of the 2 procedures."
62689285|NCT00713193|ACTIVE_COMPARATOR|Prednisone and Plasma Exchange Arm|"Patients in this arm will receive prednisone at a dose of 1 mg/kg as an adjunct to plasma exchange.~All patients initiated daily PEX (one plasma volume), using plasma as the replacement fluid. Patients randomized to the corticosteroid arm received prednisone at a dose of 1 mg/kg/d rounded to the nearest 20 mg increment. Daily PEX was continued until a clinical response was achieved, then patients received PEX every other day for 2 additional procedures, with the first day that the platelet count and LDH were normal counting as the first of the 2 procedures."
62689286|NCT00974532|ACTIVE_COMPARATOR|Subjects with normal kidney function|eGFR \> 60 ml/min/m²
62129931|NCT01309932|EXPERIMENTAL|A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin|Part A
62129932|NCT01309932|ACTIVE_COMPARATOR|A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV|Part A
62129933|NCT01309932|EXPERIMENTAL|A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)|Part B
62320258|NCT03648996|PLACEBO_COMPARATOR|Placebo|Subjects assigned to this arm will receive placebo
62320259|NCT03648996|EXPERIMENTAL|Low-fructose diet, hypocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose with a 500 Calorie energy reduction.
62480785|NCT05982314|ACTIVE_COMPARATOR|Prevenar-13|In GPNV-001 participants will have received one 0.5ml dose of Prevenar-13 followed by saline placebo 4 weeks later
62480786|NCT05982314|PLACEBO_COMPARATOR|Placebo|In GPNV-001 participants will have received two doses of 0.5 ml saline placebo at intervals of 4 weeks.
62480787|NCT04521712|EXPERIMENTAL|Postpartum GDM|Women with GDM diagnosed early (\< 20 weeks gestation) or with routine 3rd trimester screening (\>=24 weeks) will be enrolled in this longitudinal study. All enrolled women will complete a oral glucose tolerance test and wear a continuous glucose monitor for 10 days at the 3 designated study time points (0-4 days, 4-6 weeks, and 6 months after delivery).
62129934|NCT01309932|EXPERIMENTAL|A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)|Part B
62129935|NCT01309932|EXPERIMENTAL|A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)|Part B
62129936|NCT01309932|EXPERIMENTAL|A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)|Part B
62129937|NCT02831361|EXPERIMENTAL|Gemigliptin 50mg|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
62129938|NCT02831361|PLACEBO_COMPARATOR|Gemigliptin 50mg placebo|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
62129939|NCT03218306|EXPERIMENTAL|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
62129940|NCT03218306|ACTIVE_COMPARATOR|Clinical Guided Analgesia|No SPI guidance
62129941|NCT05369507|NO_INTERVENTION|Treatment as Usual|TAU group will receive standard care coordination efforts by health care team throughout course of HCV treatment
62129942|NCT05369507|EXPERIMENTAL|Virtual Care Coordination|Participants will download a mobile phone app (emocha) to facilitate care coordination throughout course of HCV treatment
62129943|NCT05231317|EXPERIMENTAL|Experimental: Plant-based diet|Diet rich in fruit and vegetables (42% carbohydrates, 17.2% fibres; 15% proteins and 43% fats).
62129944|NCT05231317|ACTIVE_COMPARATOR|Active Comparator: Western diet|Diet Rich in Processed Foods (48% carbohydrates, 10.4% fibres; 14% proteins and 39% fats).
62129945|NCT01510717|EXPERIMENTAL|Multifocal IOL|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 \[SV25T0\], bilateral implantation
62129946|NCT01510717|ACTIVE_COMPARATOR|Monofocal IOL|AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation
62689287|NCT00974532|EXPERIMENTAL|CKD late Stage 3 and Stage 4|eGFR 15-40 ml/min/m²
62689288|NCT05679622|EXPERIMENTAL|FMT group|In the refractory ulcerative colitis group, our study is aims to explore repeated and multiple FMTs plus PEN in the treatment of refractory pediatric UC;
62689289|NCT06640543|EXPERIMENTAL|kinesiotape group|The participants will be treated with kinesiotape for 4 weeks
62689290|NCT06640543|EXPERIMENTAL|myofascial release group|The participants will be treated with myofascial release for 4 weeks
62689291|NCT05007639||Patients diagnosed BEFORE implementation of the public health intervention program|All adult patients (≥18 years old) diagnosed between 1 November 2006 and 31 December 2007 in the Aquitaine and Midi-Pyrénées administrative districts in South-West France (6 million inhabitants, 10% of the French population) with primary STS of any stage were included. Patients with visceral, bone, uterus or Kaposi's sarcoma, gastrointestinal stromal tumors, or mesotheliomas were not included. Patients being treated for recurrence, and patients diagnosed outside of the administrative districts were not eligible. STS diagnoses were made in public or private pathology laboratories. Data were collected from all relevant sources: pathology reports, medical records from private and public centers,
62320260|NCT04195750|EXPERIMENTAL|Belzutifan|Participants receive 120 mg of belzutifan orally once daily (QD)
62320261|NCT04195750|ACTIVE_COMPARATOR|Everolimus|Participants receive 10 mg of Everolimus orally once daily (QD)
62320262|NCT03206944|EXPERIMENTAL|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
62320263|NCT03206944|EXPERIMENTAL|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
62320264|NCT04809727|EXPERIMENTAL|Biopsy|four quadrant biopsy
62320265|NCT02601885|EXPERIMENTAL|Group 2|Participants will receive multiple doses of ABT-555 or placebo
62689292|NCT05007639||Patients diagnosed DURING implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 january 2008 and 31 october 2008."
62689293|NCT05007639||Patients diagnosed AFTER implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 November 2008 and 31 December 2009."
62689294|NCT02420314|EXPERIMENTAL|Ascorbate, paclitaxel, carboplatin|Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks
62689295|NCT06563570|OTHER|treatment group|The only group in the study was liver transplant patients who practised yoga online.
62320266|NCT02601885|EXPERIMENTAL|Group 3|Participants will receive multiple doses of ABT-555 or placebo
62320267|NCT02601885|EXPERIMENTAL|Group 1|Participants will receive multiple doses of ABT-555 or placebo
62689296|NCT05222789||TAP block|Patients receiving TAP block preoperatively, following routine clinical practice
62689297|NCT05222789||Non-TAP|Patients not receiving TAP block preoperatively, following routine clinical practice
62738292|NCT02485639|EXPERIMENTAL|Influenza Virus Vaccine Inactivated|All study participants received licensed inactivated influenza vaccine intramuscularly (IM) on Day 0.
62320268|NCT00893113|PLACEBO_COMPARATOR|Placebo, Then Alfuzosin|Participants first received 1 Placebo tablet once daily for 12 weeks. Participants then received a 10 mg tablet of Alfuzosin daily for 12 weeks.
62320269|NCT00893113|EXPERIMENTAL|Alfuzosin, Then Placebo|Participants first received a 10 mg tablet of Alfuzosin once daily for 12 weeks. Participants then received 1 Placebo tablet once daily for 12 weeks.
62689298|NCT06571175||Aortic stenosis|"Mild aortic stenosis:25 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.~Moderate aortic stenosis: 25 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.~Severe aortic stenosis: 50 patients were included at baseline, and those that still avoid exclusion criteria, will be invited to undergo repeat echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG."
62320270|NCT01959867|EXPERIMENTAL|SurgiMend® PRS (ADM)|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
62320271|NCT01959867|OTHER|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
62480788|NCT02476916|EXPERIMENTAL|AG-348 50 mg BID|Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
62480789|NCT02476916|EXPERIMENTAL|AG-348 300 mg BID|Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
62480790|NCT05623982|EXPERIMENTAL|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62480791|NCT03191058|EXPERIMENTAL|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
62480792|NCT03191058|ACTIVE_COMPARATOR|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q or the MECTA Sigma devices.
62480793|NCT00007150|OTHER|1/HH patients|HH patients
62689299|NCT06571175||Controls|The controls from baseline inclusion will be invited to undergo repeat echocardiography, blood test and CMRI
62689300|NCT01931826|ACTIVE_COMPARATOR|Endoscopic treatment alone|3 to 5 sessions of sclerotherapy till eradication of esophageal varices.
62689301|NCT01931826|ACTIVE_COMPARATOR|Total EGDS + endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
62689302|NCT04791748|EXPERIMENTAL|Children and adolescents patients with chronic vestibular deficits|Patients aged 7 to 17 years with chronic vestibular deficits
62689303|NCT04791748|ACTIVE_COMPARATOR|children and adolescents controls|Patients aged 7 to 17 years without chronic vestibular deficits
62689304|NCT04791748|ACTIVE_COMPARATOR|Adults without chronic vestibular deficits|
62689305|NCT04791748|ACTIVE_COMPARATOR|Adults with chronic vestibular deficits|
62689306|NCT03034811|OTHER|PPK subjects|Subjects that receive the Persona Partial Knee system
62480794|NCT06058949|EXPERIMENTAL|Health Protection and Promotion Program|
62480795|NCT06058949|ACTIVE_COMPARATOR|General Health Program|
62480796|NCT05524571|EXPERIMENTAL|Batoclimab|Participants will be administered batoclimab 680 mg SC weekly for 12 weeks followed by 340 mg SC weekly for 12 weeks.
62480797|NCT05524571|PLACEBO_COMPARATOR|Placebo|Participants will be administered matching placebo SC weekly for 24 weeks.
61926125|NCT03913325|ACTIVE_COMPARATOR|Treatment as usual|
62689307|NCT06379620|EXPERIMENTAL|Hi-OXSR group|Oxygen gas at 1 to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with increased inspired CO2 concentration produced by having the subject rebreathe some of their exhaled air. Total treatment is for 14 days.
61926126|NCT04964271||Low risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely low risk (PSA (prostate-specific antigen) \<10 ng/ml, and stage T1/T2a and Gleason score 3+3).
61926127|NCT04964271||High risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely high risk (PSA (prostate-specific antigen) \>20 ng/ml or stage T3 or higher or biopsy Gleason score 8-10).
61926128|NCT04964271||Healthy donor|Participants who are in good health and without history of cancer disease.
62129947|NCT05715398|EXPERIMENTAL|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle, Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
62129948|NCT04968366|EXPERIMENTAL|DC vaccine group|Subjects will receive five to eight doses of the DC vaccine through i.d. injection into regions near to the groin and axillary during they receive TMZ adjuvant chemotherapy
62320272|NCT03070730|OTHER|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
62320273|NCT03070730|OTHER|Placebos|"In this arm subjects are randomized to placebo tid.~Placebo is used to control the administration effect."
62320274|NCT03070730|OTHER|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
62320275|NCT01519427|EXPERIMENTAL|Treatment (selumetinib and Akt inhibitor MK2206)|Patients receive selumetinib PO BID on days 1-21 and Akt inhibitor MK2206 PO once weekly.
62480798|NCT00001853||Healthy volunteers|Healthy adult African Americans born in the United States, with American born parents or born in Africa with African born parents.
62480799|NCT04855227||Laparoscopic ventral hernia repair|These subjects will undergo a laparoscopic primary umbilical or incisional hernia repair.
62480800|NCT04855227||Robotic-assisted ventral hernia repair|These subjects will undergo a robotic-assisted primary umbilical or incisional hernia repair.
62480801|NCT05796154|OTHER|ear blood pressure monitor|
62480802|NCT05133531|EXPERIMENTAL|Cohort A|Randomized 1:1
62689308|NCT06370208|EXPERIMENTAL|Probiotic supplement group|Participants in this group will receive probiotic Streptococcus salivarius eK12 (Bactoblis® EVOLcontaining ca. 1 billion CFU of Streptococcus salivarius eK12/capsule) as daily one capsule (to be slowly dissolved in the mouth before sleeping at night time) for 3-months. There will be a further 3-months follow-up period.
62480803|NCT05133531|EXPERIMENTAL|Cohort B|Randomized 1:1
61926129|NCT05745038|EXPERIMENTAL|Arm 1 - SONATA Intervention|
61926130|NCT04054570||Adaptive servo-ventilation patients|All patients under adaptive servo-ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
61926131|NCT04054570||Barometric and Volumetric patients|All patients under barometric and volumetric ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
61926132|NCT06183216|EXPERIMENTAL|Infants aged 2 months in experimental group|35 participants aged 2 months will be randomized to receive Sinovac PCV13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.
61926133|NCT06183216|ACTIVE_COMPARATOR|Infants aged 2 months in control group|35 participants aged 2 months will be randomized to receive PREVNAR 13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.
61926134|NCT06183216|EXPERIMENTAL|Children aged 2-5 years in experimental group|35 children aged 2-5 years will be randomized to receive Sinovac PCV13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.
61926135|NCT06183216|ACTIVE_COMPARATOR|Children aged 2-5 years in control group|35 children aged 2-5 years will be randomized to receive PREVNAR 13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.
61926136|NCT06361238|EXPERIMENTAL|Liraglutide Group|Subcutaneous injection of liraglutide
62129949|NCT02818335|EXPERIMENTAL|LY3023414 Reference Fasted|Single oral dose of LY3023414 (Reference) on day one fasting.
62129950|NCT02818335|EXPERIMENTAL|LY3023414 Test Fasted|Single oral dose of LY3023414 (Test) on day one fasting.
62129951|NCT02818335|EXPERIMENTAL|LY3023414 Test Fed|Single oral dose of LY3023414 (Test) on day one after a meal.
62129952|NCT01595802||Subjects without Vasospasm|Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status.
62129953|NCT01595802||Subjects with Vasospasm|"Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.~Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm."
62129954|NCT01871324|EXPERIMENTAL|Lifestyle counseling|
62129955|NCT04432389|EXPERIMENTAL|ALLOB|Single injection of ALLOB at fracture site (4 ml)
62129956|NCT04432389|PLACEBO_COMPARATOR|placebo|Single injection of Placebo at fracture site (4 ml)
62129957|NCT00752713||1|Patients presenting to hospital with AMI
62129958|NCT00752713||2|healthy volunteers as control group
62480804|NCT06453616|EXPERIMENTAL|The Hello arm (Intervention arm)|"The intervention arms will receive the Hello Bundle (posters, email reminders, morning huddles, hello jar, hello board and a led example).~The bundle includes six components: displaying Hello posters all over the ICU, email reminders every week to study investigators (4 times for the 4 week study period), inciting Hello during morning huddles, lead by example by ICU heads, Hello Jar to insert messages emphasizing well being at work and posters to allow HCP write hello messages."
62480805|NCT06453616|NO_INTERVENTION|The usual arm (Controlled arm)|No intervention will be performed in the control groups which will behave as per their standard.
62689309|NCT06370208|NO_INTERVENTION|Control group|Participants in this group will not receive probiotic Streptococcus salivarius eK12 (Bactoblis® EVOL).
62480806|NCT06376045|PLACEBO_COMPARATOR|Treatment Arm A: Placebo|Participants will receive placebo by subcutaneous (SC) injection during the blinded treatment period.
62480807|NCT06376045|EXPERIMENTAL|Treatment Arm B: Dose 1 Rocatinlimab|Participants will receive dose 1 rocatinlimab by SC injection during the blinded treatment period.
62480808|NCT06376045|EXPERIMENTAL|Treatment Arm C: Dose 2 Rocatinlimab|Participants will receive dose 2 rocatinlimab by SC injection during the blinded treatment period.
62480809|NCT06376045|EXPERIMENTAL|Treatment Arm D: Dose 3 Rocatinlimab|Participants will receive dose 3 rocatinlimab by SC injection during the blinded treatment period.
62480810|NCT05600894|EXPERIMENTAL|Arm I (ASTX727, venetoclax)|Patients receive ASTX727 PO QD for 5 consecutive days starting on day 3 of treatment cycle 1; followed by day 1 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD on days 1 through 14 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsies, and collection of blood and buccal samples throughout the study.
62689310|NCT06586827|PLACEBO_COMPARATOR|Control Group|The current VCU-RRTC online course. Association of Community Rehabilitation Educators, accrediting body that has developed competencies for job coaches and that approved the online curriculum that has been provided through the VCU-RRTC for over a decade.
62480811|NCT05600894|ACTIVE_COMPARATOR|Arm II (ASTX727)|Patients receive ASTX727 PO QD for 5 consecutive days starting on day 3 of treatment cycle 1; followed by day 1 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not have response to treatment may cross over to Arm I. Patients also undergo bone marrow biopsies, and collection of blood and buccal samples throughout the study.
62480812|NCT05184335|ACTIVE_COMPARATOR|RP5063 15 mg once daily|administered OD for 28 days then flexibly 15-50mg over a period of 52 weeks.
62480813|NCT05184335|ACTIVE_COMPARATOR|RP5063 (brilaroxazine) 50 mg once daily|administered OD for 28 days, then flexibly 15-50mg over a period of 52 weeks
62480814|NCT05184335|PLACEBO_COMPARATOR|Placebo|administered OD for 28 days.
62689311|NCT06586827|EXPERIMENTAL|Experimental|The VCU-RRTC course plus TA (Technical Assistance). Association of Community Rehabilitation Educators, accrediting body that has developed competencies for job coaches and that approved the online curriculum that has been provided through the VCU-RRTC for over a decade.
62689312|NCT04316650|OTHER|SSRI Group|Treated by ISRS at inclusion
62689313|NCT04316650|OTHER|Anti-androgen Group|Treated by anti-androgen at inclusion
62689314|NCT04316650|OTHER|No SSRIs or antiandrogen treatment at inclusion|no treatment
62480815|NCT05979116|EXPERIMENTAL|study group|this study group will receive abdominal myofascial release
62480816|NCT05925491|EXPERIMENTAL|Neoadjuvant Pembrolizumab|Patients will receive pembrolizumab 200 mg + cisplatin 75mg/mq (or Carboplatin AUC 5) and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses, followed by standard of care.
62689315|NCT01592747|EXPERIMENTAL|Memantine 1|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.
62689316|NCT01592747|EXPERIMENTAL|Memantine 2|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.
62689317|NCT01592747|PLACEBO_COMPARATOR|Placebo|Dosing will be once daily for up to 12 weeks.
62689318|NCT06524180|EXPERIMENTAL|Telemedicine|"Patients will be (i) given a validated HBPM device (ORMON HEM-7120) with appropriate cuff size, (ii) taught the HBPM technique, and (iii) taught to record HBPM readings using the HealthCap mobile app on their smartphones.~Participants randomized to intervention will be reminded to take dual BP readings in the morning and evening for 1-2 weeks before the index consultation. These BP readings will be automatically sent to a computer at the clinic. When the HBPM mean is optimal (i.e., \<135/85 mmHg or \<130/80 mmHg \[for patients with cardiovascular diseases, renal diseases, and DM\]), other parameters will be checked using an online questionnaire. If no complaints are identified, the patient will have automatic drug refill and the physician appointment will be deferred for 16-18 weeks."
62129959|NCT03399669|EXPERIMENTAL|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
62697436|NCT04943796||Part II: Participants with ADHD|To collect pseudonymized data from participants who are underdiagnosed of ADHD with psychiatric disorders in daily clinical practice for up to 9 months from both Part I and II.
62129960|NCT00473252||Hemodialysis patients|
62129961|NCT00473252||Renal transplant patients|
62129962|NCT04307511|EXPERIMENTAL|low dose DAPT therapy|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment
62129963|NCT04307511|ACTIVE_COMPARATOR|standard dose DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
62129964|NCT04290013|EXPERIMENTAL|norethisterone -women with Dysfunctional uterine bleeding|
62129965|NCT04290013|EXPERIMENTAL|tranexemic acid-women with Dysfunctional uterine bleeding|
62129966|NCT03658408|EXPERIMENTAL|4-aminopyridine|Participants with recent prostatectomies receiving 4-aminopyridine
62129967|NCT03658408|PLACEBO_COMPARATOR|Placebo|Participants with recent prostatectomies receiving placebo
62129968|NCT04593056||Warfarin|Reference group
62320276|NCT06047431|EXPERIMENTAL|QL1706H|"Part 1 (Dose escalation): QL1706H will be administered in sequential cohorts each receiving 1 dose of QL1706H by subcutaneous injection on day 1 and QL1706 by IV infusion on day 22, from then on will recieve QL1706 on day 1 of every 21-day cycle (3 weeks). Dose escalation will continue until the projected cohorts has been finished.~Part 2 (Dose Exploration): The PK parameters of QL1706H will be tested at different administration intervals."
62320277|NCT02615717|EXPERIMENTAL|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
62320278|NCT02615717|ACTIVE_COMPARATOR|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
62320279|NCT03518229|EXPERIMENTAL|Intervention|Microsoft Band 2 application with UV messaging activated
62320280|NCT03518229|ACTIVE_COMPARATOR|Control|Microsoft Band 2 application (UV messaging not active)
62320281|NCT04743037|NO_INTERVENTION|Standard of Care (SOC)|The 15 attentional control group stroke survivors will receive phone calls over the 12-week intervention checking in with them on how they are doing in their everyday life. They will also receive stroke education materials, but they will not receive the same iSMART intervention as the intervention group.
62339747|NCT00618449|EXPERIMENTAL|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with 1 gm oral dose of Azithromycin; receive a second 1 gm oral dose of Azithromycin at Day 30; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
62480817|NCT04100135|EXPERIMENTAL|Test Arm|Device PFO closure with the GORE® CARDIOFORM Septal Occluder
62480818|NCT04100135|SHAM_COMPARATOR|Control Arm|Sham device PFO closure (PFO not closed)
62480819|NCT02834013|EXPERIMENTAL|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who complete 17 cycles (2 years) of therapy, may continue receiving the same treatment with nivolumab and ipilimumab, or receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) per physician discretion in the absence of disease progression or unacceptable toxicity. Patients who stop treatment prior to the completion of 17 cycles of therapy may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and on study. Patients also undergo MRI or CT throughout the trial. Additionally, patients undergo blood sample collection throughout the trial.
62480820|NCT02834013|EXPERIMENTAL|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15 and 29. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. After 17 cycles (2 years) of therapy, patients may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and on study. Patients also undergo MRI or CT throughout the trial. Additionally, patients undergo blood sample collection throughout the trial.
62480821|NCT04609904|EXPERIMENTAL|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
62480822|NCT04609904|EXPERIMENTAL|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
62480823|NCT04609904|ACTIVE_COMPARATOR|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
62480824|NCT04609904|ACTIVE_COMPARATOR|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
62480825|NCT06186765|OTHER|Single Arm - product does not have Communauté Européenne (CE) Mark in Europe|Observational
62480826|NCT03410875|EXPERIMENTAL|Untreated Hairy Cell Leukemia|Participants with HCL with no prior treatment for the disease
62480827|NCT06246357|EXPERIMENTAL|1/[68Ga]Ga-PentixaFor PET/CT or PET/MR|Participants will undergo \[68Ga\]Ga-PentixaFor PET/CT or PET/MR
62738293|NCT01016119|PLACEBO_COMPARATOR|Placebo|In this group we will use Placebo cream, in the early rehabilitations in the upper extremity
62129969|NCT04593056||Rivaroxaban|Exposure group
62129970|NCT02773693|ACTIVE_COMPARATOR|CPT|Cognitive Processing Therapy-cognitive only version (typically labeled CPT-C, but labeled CPT in this grant for simplicity) is a type of Cognitive Therapy addressing daytime symptoms of PTSD. This arm will have 12 twice-weekly sessions, followed by 6 weekly sessions.
62129971|NCT02773693|ACTIVE_COMPARATOR|CBTin+CPT|Cognitive Behavioral Therapy of Insomnia and nightmares (CBTin) will be used to address nighttime symptoms of PTSD during 6 weekly sessions, followed by 12 twice-weekly sessions of CPT.
62738294|NCT01016119|EXPERIMENTAL|Folrex|In this group we will use Folrex cream, in the early rehabilitations in the upper extremity
61926137|NCT06361238|PLACEBO_COMPARATOR|Vehicle Group|Subcutaneous injection of vehicle
61926138|NCT00478374|EXPERIMENTAL|1|
62129972|NCT02773693|ACTIVE_COMPARATOR|CPT+CBTin|12 twice-weekly sessions of CPT followed by 6 sessions of CBTin.
62129973|NCT02954211|EXPERIMENTAL|rTMS/PT|There will be only one group. All participants will receive 10 treatments of active repetitive transcranial magnetic stimulation combined with physical therapy.
62129974|NCT02101281|EXPERIMENTAL|Group 1 - rhNGF 20 μg/mL|(first planned dose): drop (35 μL) corresponding to 0.70 μg of rhNGF (recombinant human Nerve Growth Factor) was instilled into each eye twice a day (b.i.d.) every 12±2 h for a total daily dose of 2.8 μg (both eyes), for 28 consecutive days. The total dose was 78.4 μg/28 days.
62320282|NCT04743037|EXPERIMENTAL|iSMART|"The 15 iSMART participants will engage in video conference sessions between the pre and post visits. A health coach will collaboratively work with the participant to practice treatment strategies and set goals in weekly individual sections. In addition, all participants will engage in weekly group sessions with a health coach in order to learn and practice specific self-management skills and strategies in a group context. In addition, iSMART entails using an interactive SMS to provide ongoing support and self-monitoring of behavior change goals. The SMS is programmed to touch participants daily; the SMS system prompts participants to report their daily activities and progress in achieving goals via check-in messages and sends immediate, tailored feedback about their progress. If a participant is making progress toward their goal, the SMS system will suggest a change to the participant's goal between visits."
62320283|NCT02154854|EXPERIMENTAL|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
62320284|NCT02154854|EXPERIMENTAL|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
62320285|NCT05328778|EXPERIMENTAL|Normal Weight group|n=16, 18.5kg/m² ≤ BMI ≤ 24.9kg/m²
62320286|NCT05328778|EXPERIMENTAL|Obese group|n=16, 25≤BMI≤39.9kg/m²
62320287|NCT05328778|EXPERIMENTAL|Morbidly Obese group|n=16, BMI≥40kg/m²
62320288|NCT02452970|EXPERIMENTAL|RRx-001 the cisplatin and gemcitabine|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
62697437|NCT04892277|EXPERIMENTAL|Treatment (cyclophosphamide, fludarabine, IC19/1563)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5, -4, -3, or bendamustine IV over 10 minutes on days -4 and -3, and IC19/1563 IV on day 0. Patients also undergo bone marrow biopsy and aspiration, CT-PET or CT scans, MRI, and collection of blood and tissue samples throughout the trial.
61926139|NCT01100736|EXPERIMENTAL|Bosentan|Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy
62129975|NCT02101281|EXPERIMENTAL|Group 2 - rhNGF 4 μg/mL|after completion of Group 1 treatment, one drop (35 μL) corresponding to 0.14 μg of rhNGF (recombinant human Nerve Growth Factor) instilled into each eye b.i.d. every 12±2 h for a total daily dose of 0.56 μg, for 28 consecutive days. Total dose was 15.68 μg/28 days.
62129976|NCT02054923|EXPERIMENTAL|Routine video recording group|Intervention: Procedure: Implementation of routine videorecording of colonoscopy withdrawal
62320289|NCT00778752|EXPERIMENTAL|A|"Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.~* Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21~* Dose-level 0: 5 mg/d, day 1-21~* Dose-level 1: 10 mg/d, day 1-21~* Dose-level 2: 15 mg/d, day 1-21"
62320290|NCT06328075||Transthyretin cardiac amyloidosis (ATTR-CM)|Patients with an ATTR-CM and undergoing a transthoracic echocardiography
62738295|NCT05941208|NO_INTERVENTION|control group|
62738296|NCT05941208|ACTIVE_COMPARATOR|study group|receiving post operative continuous fascia iliaca compartement block for 24 hours
62738297|NCT01088204|ACTIVE_COMPARATOR|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
62738298|NCT01088204|EXPERIMENTAL|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
62738299|NCT04166591|ACTIVE_COMPARATOR|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
62738300|NCT04166591|EXPERIMENTAL|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
62738301|NCT02515799|ACTIVE_COMPARATOR|Tacholiquine|Inhalation
62738302|NCT02515799|PLACEBO_COMPARATOR|Saline Solution 0,9%|Inhalation
62738303|NCT02242214||Misoprostol 200 µg VDS|At the discretion of the investigator in accordance with their usual practice and consistent with the Dutch prescribing information.
62738304|NCT02764359|EXPERIMENTAL|IV Vancomycin loading dose- higher|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg
62738305|NCT02764359|EXPERIMENTAL|IV Vancomycin loading dose- lower|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg
62738306|NCT01175876|EXPERIMENTAL|1|Device: RIPC RIPC consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins Procedure: Carotid Artery Stenting
62738307|NCT01175876|SHAM_COMPARATOR|2|Procedure: Carotid Artery Stenting
62738308|NCT06404021|EXPERIMENTAL|Interventional cardiology procedures with engineer in remote support|
62738309|NCT06404021|ACTIVE_COMPARATOR|Interventional cardiology procedures with engineer in the electrophysiology laboratory|
62738310|NCT01638013|EXPERIMENTAL|Participants who completed 015K-CL-RAJ1|Participants who completed 015K-CL-RAJ1 (NCT02305849) study and met eligible criteria received starting dose of 50 milligrams (mg) peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and a lack of clinical response (DAS28-ESR \>= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
62689319|NCT06524180|ACTIVE_COMPARATOR|Usual care|Participants will continue receiving routine care, including anti-HT drug prescriptions, from their regular clinicians. In HK, patients with well-controlled HT are routinely seen every 16-18 weeks. Participants will also be given the same HBPM devices and taught the techniques. This is necessary because HBPM is a secondary outcome. According to the HK guidelines, all patients with HT are advised to regularly monitor their home BP, which can be considered as usual care.14 However, the patients will not be taught any BP measurement algorithm (such as that used in the telemedicine group). They will also be asked not to download or use any new HT mobile apps during the study period. In HK, all citizens have unlimited access to GOPCs and emergency departments for health problems. All participants are advised to seek medical help if BP becomes dangerously and persistently high (i.e. SBP ≥180 or DBP ≥110mmHg) or in case of any suspected medical emergencies.
62320291|NCT06328075||Controls|Patients without cardiac amyloidosis undergoing transthoracic echocardiography as part of cardiological follow-up
62320292|NCT05572229|EXPERIMENTAL|Tec-Dara|For patients assigned to cohort A (Tec-Dara) patients will receive Tec-Dara until documented PD or unacceptable toxicity
62320293|NCT05572229|EXPERIMENTAL|Tec-Len|For patients assigned to cohort B (Tec-Len) patients will receive Tec-Len until documented PD or unacceptable toxicity
62320294|NCT05853458|EXPERIMENTAL|Hydroxyurea (HU)|Participants will be treated with HU capsules, orally taken, for a maximum duration of 15 months.
62320295|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
62320296|NCT05258058|EXPERIMENTAL|MAAT-G Intervention|MAAT-G Workshops \& participant workbook use (8 workshops)
62320297|NCT04845776|EXPERIMENTAL|Treatment Group|This group receives the vitamin/mineral supplement, ANRC Essentials Plus, for 3 months
62320298|NCT04748783|PLACEBO_COMPARATOR|Sterile water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water
62320299|NCT04748783|ACTIVE_COMPARATOR|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
62320300|NCT04748783|ACTIVE_COMPARATOR|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
62320301|NCT04748783|ACTIVE_COMPARATOR|Peroxyl & Periogard|Subject participants will complete an on-label sequential rinse starting with Peroxyl (1st) 10ml for 60 seconds and then Periogard (2nd) 15ml for 30 seconds.
62320302|NCT04748783|ACTIVE_COMPARATOR|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
62320303|NCT01996319|ACTIVE_COMPARATOR|Treatment sequence I|QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days
62689320|NCT02933151|OTHER|Usual Care Protocol|Facility randomized to follow the usual care nutritional supplement protocol
62689321|NCT02933151|OTHER|Intensive Protocol|Facility randomized to follow the intensive nutritional supplement protocol
62129977|NCT02054923|ACTIVE_COMPARATOR|Control group|Intervention: Behavioral: No routine videorecording (on demand videorecording possible)
62129978|NCT02853565|EXPERIMENTAL|CAN008|CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.
62129979|NCT02498717|ACTIVE_COMPARATOR|RICE (control)|Standard of Care procedures including ice and elevation.
62129980|NCT02498717|EXPERIMENTAL|Cryocompression (experimental)|treatment using the GameReady cryotherapy system
62129981|NCT01725464|EXPERIMENTAL|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
62129982|NCT02502708|EXPERIMENTAL|Group 1 (CLOSED)|"Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days"
62129983|NCT02502708|EXPERIMENTAL|Group 2 (CLOSED)|"Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days"
62129984|NCT02502708|EXPERIMENTAL|Group 3 (CLOSED)|"Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days"
62129985|NCT02502708|EXPERIMENTAL|Group 3b|"Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m\^2 x 5 days"
62129986|NCT02502708|EXPERIMENTAL|Group 4|"Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.~Indoximod will be administered at 32 mg/kg/dose divided twice daily.~Cyclophosphamide to be given at 2.5 mg/kg/dose daily~Etoposide to be given at 50 mg/m2/dose daily"
62129987|NCT00593697|ACTIVE_COMPARATOR|A|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\> FE75C x3)
62689322|NCT05931718||Autoimmune hemolytic anemia|AIHA patients will be enrolled at diagnosis and stratified according to AIHA type (i.e. warm, cold, mixed, and atypical forms), sampled for peripheral blood for cytokine and NGS studies, and for feces for microbiome studies. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected. Patients will be followed up to collect treatments, responses, relapses, and complications (particularly thromboses and infections).
62129988|NCT00593697|ACTIVE_COMPARATOR|B|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
62129989|NCT02553161|EXPERIMENTAL|MED - Escitalopram with psychotherapy|Youth will also be assigned a board certified child psychiatrist (Drs. Singh or Chang at Stanford; Drs. DelBello or Patino at UC), who will be blind to treatment condition and see youth weekly for the first 4 weeks, then biweekly until 16 weeks. Youth in the MED condition will be given the USFDA (US Food \& Drug Administration) approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks.
62129990|NCT02553161|PLACEBO_COMPARATOR|No MED -Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
62129991|NCT02553161|NO_INTERVENTION|Healthy Control|60 (30 at Stanford, 30 at University of Cincinnati) 12- to 17-year old male and female typically developing healthy controls. Healthy controls will receive behavioral, neural, and physiological assessments at baseline only. healthy controls will be scanned at baseline only and serve as a reference group to determine whether MRI changes observed in the high-risk group from baseline to week 4 are toward or away from normal.
62129992|NCT05600335||ERAS group|
62129993|NCT05600335||Conventional group|
62129994|NCT06430788|EXPERIMENTAL|Emapalumab, then Standard IST|Participants will first receive Emapalumab for 6 weeks. After treatment with emapalumab, participants will receive standard IST with drugs called equine anti-thymocyte globulin (hATG) and cyclosporin (CsA) in addition to a lower dose of emapalumab
62129995|NCT06430788|EXPERIMENTAL|Emapalumab, then HCT|Participants will first receive Emapalumab for 6 weeks. After treatment with emapalumab, participants will have a standard hematopoietic stem cell transplant (HCT).
62320304|NCT01996319|ACTIVE_COMPARATOR|Treatment sequence II|Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days
62320305|NCT05603624|ACTIVE_COMPARATOR|Sterile glove|Sterile glove is usually the standard of care
62320306|NCT05603624|EXPERIMENTAL|Clean glove|Clean glove is usually not used or in the event of an emergency or lack of access to sterile gloves in the United States.
62320307|NCT00044044|EXPERIMENTAL|Lurasidone 20 mg|Lurasidone 20 mg tablets
62320308|NCT00044044|EXPERIMENTAL|Lurasidone 40 mg|Lurasidone 40 mg tablets
62320309|NCT00044044|EXPERIMENTAL|Lurasidone 80 mg|Lurasidone 2 40 mg tablets
62320310|NCT00044044|ACTIVE_COMPARATOR|Haloperidol 10mg|Haloperidol 10mg tablets
62320311|NCT00044044|PLACEBO_COMPARATOR|Placebo|Matching Placebo to Lurasidone and Haloperidol
62320312|NCT04166045|SHAM_COMPARATOR|Sham|Treatment at the bicep location
62320313|NCT04166045|ACTIVE_COMPARATOR|Verum|Treatment at the hand location
62320314|NCT01945931|EXPERIMENTAL|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The safe delivery smartphone application will be introduced to health workers in the intervention clusters.
62689323|NCT05931718||Immune thrombocytopenia|ITP patients will be enrolled at diagnosis and sampled for peripheral blood for cytokine and NGS studies, and for feces for microbiome studies. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected.Patients will be followed up to collect treatments, responses, relapses, and complications (particularly thromboses and infections).
62320315|NCT01945931|NO_INTERVENTION|Control|Health workers in the control clusters will not have access to the Safe Delivery App
62320316|NCT00110383|EXPERIMENTAL|1|Supervised therapy
62320317|NCT00110383|NO_INTERVENTION|2|Inhaled steroid use as usual care
62320318|NCT03792750|EXPERIMENTAL|Experimental Arm A|2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
62320319|NCT06586021|EXPERIMENTAL|Aortoseal Endostapling System|Prospective, early feasibility, non-randomized, single arm, multi-center, open-label clinical study
62320320|NCT05775692||Newborns and children with the usage of fluconazole|Newborn with fluconazole against infectious diseases.
62320321|NCT03640143||experimental group|children with clinical expression of lead poisoning data about venous blood lead will be reported
62320322|NCT05846386|EXPERIMENTAL|Aerobic and resistance training|aerobic exercises (intervention) on arm ergometer and resistance training using weights for post valve replacement surgery patients for 4 weeks, 3 times/week for the duration of 45-70 min/ session.
62320323|NCT05846386|ACTIVE_COMPARATOR|Aerobic training|aerobic exercises (intervention) on arm ergometer for post valve replacement surgery patients for 4 weeks, 3 times/week for the duration of 30-55 min/ session.
62320324|NCT03472482||Ab+ cognitively intact volunteers|"amyloid-positive cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
62689324|NCT05931718||Chronic idiopathic neutropenia/Autoimmune neutropenia|CIN/AIN patients will be enrolled at diagnosis and sampled for peripheral blood for cytokine and NGS studies, and for feces for microbiome studies. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected.Patients will be followed up to collect treatments, responses, relapses, and complications (particularly infections).
61926140|NCT01100736|EXPERIMENTAL|Sitaxsentan|Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy
62320325|NCT03472482||Ab- cognitively intact volunteers|"amyloid-negative cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
62320326|NCT03472482||amyloid-positive MCI patients|"amyloid-positive patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
62320327|NCT03472482||amyloid-negative MCI patients|"amyloid-negative patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
62320328|NCT03472482||AD patients|"patients in the dementia stage of Alzheimer's Disease~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
62320329|NCT03472482||LBD patients|"patients with Lewy Body Dementia~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
62320330|NCT04524936||obese patient with non-alcoholic fatty liver disease|
61926141|NCT01100736|PLACEBO_COMPARATOR|Placebo|Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy
62320331|NCT04524936||obese patient without non-alcoholic fatty liver disease|
62320332|NCT04524936||control group|
62320333|NCT04594408|NO_INTERVENTION|No epinephrine or TXA|No intervention given.
62320334|NCT04594408|ACTIVE_COMPARATOR|Epinephrine in irrigation fluid|Epinephrine intervention used.
62320335|NCT04594408|EXPERIMENTAL|Intravenous TXA|Tranexamic acid intervention used.
62320336|NCT04594408|EXPERIMENTAL|Epinephrine and TXA|Epinephrine and tranexamic acid intervention used.
62320337|NCT02886026|ACTIVE_COMPARATOR|Inpatient TUR-BT|Transurethral bladder tumor resection in operating theatre as inpatient.
62320338|NCT02886026|EXPERIMENTAL|laser bladder tumor destruction|Outpatient laser mediated destruction of bladder tumors (LMD-BT)
62480828|NCT04460937|EXPERIMENTAL|Treatment (radiation therapy, adavosertib)|Patients undergo radiation therapy QD 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive adavosertib PO QD for 2-5 days (depending on dose level) during weeks 1 and 3 of radiation therapy in the absence of disease progression or unacceptable toxicity.
62689325|NCT05931718||Myelodysplastic syndromes|MDS patients will be enrolled at diagnosis and sampled for peripheral blood for cytokine and NGS studies, and to evaluate red cell metabolism. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected. Patients will be followed up to collect treatments, responses, relapses, and outcome.
62689326|NCT04967001|EXPERIMENTAL|PSMAPET-MRI|
62689327|NCT04967001|EXPERIMENTAL|MRI-PSMAPET|
62480829|NCT02359825|NO_INTERVENTION|standard epineural repair <24 hours|epineural repair following treatment with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired \<24 hours after injury); no medication used
62480830|NCT02359825|NO_INTERVENTION|standard epineural repair >24 - 72 hours|epineural repair following irrigation with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term chronic injuries (\>24-\<72 hours after injury); no medication used
62480831|NCT02359825|NO_INTERVENTION|epineural repair with autografting within 48 hours|epineural repair with auto grafting within 48 hours; no medication used
62480832|NCT02359825|EXPERIMENTAL|epineural repair <24 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired \<24 hours after injury); PEG is used during the surgical procedure
62480833|NCT02359825|EXPERIMENTAL|epineural repair >24 but <72 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired \>24 hours but \< 72 hours after injury); PEG is used during the surgical procedure
62480834|NCT02359825|EXPERIMENTAL|epineural repair with autografting within 48 hours, using PEG|epineural repair with auto grafting within 48 hours
62480835|NCT04671485|ACTIVE_COMPARATOR|ARM A : standard care|standard care : Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
62480836|NCT04671485|ACTIVE_COMPARATOR|ARM B : standard care + Autohypnosis|"In addition to the standard care, the patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
62480837|NCT04671485|ACTIVE_COMPARATOR|ARM C : standard care + Musicotherapy|"In addition to the standard care, the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
62480838|NCT06592144|EXPERIMENTAL|Testosterone|Participants will receive 200 mg of testosterone cypionate intramuscularly every 5 days, up to a maximum of 3 doses.
62480839|NCT06592144|PLACEBO_COMPARATOR|Sesame oil|Participants will receive sesame oil (placebo) intramuscularly every 5 days, up to a maximum of 3 doses.
62480840|NCT05211115|EXPERIMENTAL|Split thickness flap + Volume stable collagen matrix|A split thickness flap will be raised with a micro-blade, keeping a flap thickness \>0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 6mm thick volume stable collagen matrix will be stabilised at the inner aspect of the flap.
62480841|NCT05211115|ACTIVE_COMPARATOR|Full thickness flap + Volume stable collagen matrix|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide by 6-8mm high volume stable collagen matrix will be stabilised at the inner aspect of the flap.
62480842|NCT05211115|ACTIVE_COMPARATOR|Split thickness flap + Autogenous connective tissue|A split thickness flap will be raised with a micro-blade, keeping a flap thickness \>0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
62689328|NCT06672627||Control group|Every participant will undergo occlusal analysis using conventional methods (8um articulating paper)
62689329|NCT06672627||Study group I|Every participant will undergo digital occlusal analysis using hand held device (occlusense)
62689330|NCT06672627||Study group II|Every participant will undergo digital occlusal analysis using intraoral scanner (Medit occlusal analyzer)
62689331|NCT06397625|PLACEBO_COMPARATOR|Group (Placebo)|"Group I (Control), will be operated with the same procedure but without electric current, and using placebo needles of the same size (Streitberger Placebo-Needle ® , Asiamed, Pullach, Germany), which will not pierce the surface of the patient's skin, but will cause a prick sensation. This process will be developed by resting the needle on the skin of the patient's perineum and pushing the handle of the needle until it touches the surface of the skin, producing in the patient the impression of penetration, although this is not the case."
62480843|NCT05211115|ACTIVE_COMPARATOR|Full thickness flap + Autogenous connective tissue|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
62480844|NCT02141919|EXPERIMENTAL|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Radiation Therapy (SABR)
62689332|NCT06397625|EXPERIMENTAL|Group (20 Hertz)|Group II will undergo continuous stimulation at a frequency of 20 Hertz, a pulse width of 200 μs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
62689333|NCT06397625|EXPERIMENTAL|Group 3 (50 Hertz)|Group III, will be intervened with continuous stimulation at a frequency of 50 Hz,a pulse width of 200 μs (18) and for a total of 20 minutes. The intensity will be set at the maximum tolerable threshold. In case the patient does not tolerate the treatment, due to increased fatigue, the 50 hertz will be alternated with the 20 hertz in bursts.
62480845|NCT02535702|EXPERIMENTAL|Attentional Bias Task|Subjects will briefly see two images side by side on a screen. Immediately after, a dot appears on the left or on the right. The subjects task is to press the left or right button, following the position of the image (left or right). Images can contain food-related items. We will also show short 1-minute food-related movies. Subjects will be asked to fast for three hours before this task begins.
62480846|NCT02535702|EXPERIMENTAL|Cue Reactivity Task|In this task subjects will view pictures of various items on the screen in front of them. Subjects will rate the items by how much they would like to have them. Subjects will choose how much they want the item by pressing a button.
62480847|NCT02535702|EXPERIMENTAL|Delay Discounting Task|Subjects will be asked to imagine whether they would receive money now or money later (in the future). The future money option may be several days from now or as far out as 6 weeks from now. For example, a s ubject may see a $100 option in 6 weeks or a $10 option now. Subjects will not receive actual money for participation in this task
62689334|NCT05185453|EXPERIMENTAL|Strengthening Connections for Change|Strengthening Connections for Change uses a group discussion format with activities that explore identity, adolescent-adult relationships, social networks, and community engagement. Youth invite their self-identified key adult supports to jointly participate in programming and curriculum includes youth-focused, adult-focused and jointly focused activities designed to build leadership skills, enhance intergenerational networks, challenge attitudes towards violence and retaliation, and reduce violence involvement. Through 12 sessions (2 hours/session) delivered weekly, Strengthening Connections offers leadership development coupled with strengths-based youth violence prevention programming.
62480848|NCT02535702|EXPERIMENTAL|Motivational Reward Task|Subjects will make a choice among some items presented on the screen in front of them. One of the items will be the winner item. The other items will be loser items. Each time a subject is presented with various items, they will choose the item they think is the winner item. Subjects will start with bonus points at the beginning of the task, so they can add more points to this amount as they continue to choose winner items.
62480849|NCT02535702|EXPERIMENTAL|NSPRD Task|During the MRI scan, subjects will get small electric shocks through electrodes placed on one of their toes. The shocks feel like an elastic band snapping against the skin. Right after a shock, subjects will see a dot on the computer screen. Subejcts will press a button to rate the intensity of the shock.
62480850|NCT02535702|EXPERIMENTAL|Reasoning Task|Subjects will identify changes in various shapes when they are displayed on the screen in front of them. Some changes of the shapes may be that they were rotated, enlarged, or multiplied. Subjects will choose the changes in the shapes by pressing a button.
62480851|NCT02535702|EXPERIMENTAL|Respiratory Challenge (RC) Task|Participants will be visually instructed to take a brief deep breath (inhale) and release the breath (exhale). They will inhale and exhale one more time with visual cues at specific times (60 seconds, 120 seconds, 180 seconds, 240 seconds, etc. with successive 60 seconds intervals). A black cross will remain centered on a grey slide during the normal respiration periods. To signal the RC periods, the slide will change color to yellow READY slide, then to green BREATHE IN slide, then to blue BREATHE OUT slide. The sequence will repeat one more time to Breath In and Breath Out and then finally go back to the yellow Breathe Normally slide. The instruction words will be written on the slides. Each slide will be shown for 3 seconds. The task will take a total of 15 minutes (total of 900 seconds with 14 RC periods).
62480852|NCT02535702|EXPERIMENTAL|Self-control Task|During the MRI scan, subjects will do a task that requires close concentration. Subjects will be asked to respond quickly to images on the computer screen, during which they will hear distracting noises. The subject will be able to remove the distraction in order to complete the task. During some sub-study sessions, subjects will start with no money ($0) and may be able to earn up to $40 if they do not remove the distraction. At other sub-study sessions, subjects will start with $40 and may lose between 25 to $1 each time they remove the distraction. Subjects cannot lose more than $40 in these sessions. Compensation for this sub-study is up to $40 per session, depending on their performance.
62480853|NCT02535702|EXPERIMENTAL|Spinner Task and MID Task (monetary incentive delay task)|The Spinner task requires the subject to participate in a game of chance while lying in the MRI scanner. Subjects will be asked to respond by pressing a button. The MID task is a reaction time task. The MID Task tests how quickly a subject can press a button to hit a target on the screen in front of them. If the subject presses the button as soon as the target appears, the subject will score points. Subjects should try to score as many points as you can.
62480854|NCT06161532|EXPERIMENTAL|Arm 1|Treatment with sacituzumab govitecan
62480855|NCT06161532|EXPERIMENTAL|Arm 2|Treatment with sacituzumab govitecan and atezolizumab
62480856|NCT03569631|EXPERIMENTAL|BPN14770|25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks
62480857|NCT03569631|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules, one capsule taken twice daily for 12 weeks
62480858|NCT02744677|EXPERIMENTAL|TPVR - Main Cohort|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
62689335|NCT05185453|ACTIVE_COMPARATOR|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth. Participants receive a 12 session job readiness training with linkages to businesses and employment opportunities. Discussions include a wide range of topics related to career exploration and job readiness.
62689336|NCT06674005|ACTIVE_COMPARATOR|CpLfe|Cucurbita pepo L. flower extract at 0.5% w/w in a cosmetic emulgel twice per day for 4 weeks
62689337|NCT06674005|PLACEBO_COMPARATOR|Placebo|cosmetic emulgel twice without the active comparatore twice per day for 4 weeks
62689338|NCT05686980|EXPERIMENTAL|Arm 1: Healthy Japanese Participants|Participants will receive ABBV-552 once a week for 21 Days.
62689339|NCT05686980|EXPERIMENTAL|Arm 2: Healthy Han Chinese Participants|Participants will receive ABBV-552 once a week for 7 Days.
62689340|NCT06265441|EXPERIMENTAL|Group A : Adductor canal block only|Patients will receive Adductor canal block under ultrasound guide of 20 ml bupivacaine 0.25%
62689341|NCT06265441|ACTIVE_COMPARATOR|Group B : Adductor canal + IPACK block|Patients will receive Adductor canal block and IPACK block under ultrasound guidance with 20 ml bupivacaine 0.25% for each block
61926142|NCT06294548|EXPERIMENTAL|Phase 1b: Valemetostat + Atezolizumab 1200 mg + Bevacizumab 15 mg/kg|"In Phase 1b patients will receive valemetostat (DS-3201) orally daily at their assigned dose level, plus atezolizumab 1200 mg intravenously (IV) on day 1, and bevacizumab 15 mg/kg IV on day 1 of each cycle.~During Phase 1b, a 3+3 dose escalation design will be utilized to define the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) with starting dose of valemetostat 150mg by mouth daily."
61926143|NCT06294548|EXPERIMENTAL|Phase II: Valemetostat + Atezolizumab 1200 mg + Bevacizumab 15 mg/kg|During Phase II, study participants will receive valemetostat (DS-3201) orally daily at MTD/RP2D, plus atezolizumab 1200 mg intravenously (IV) on day 1, and bevacizumab 15 mg/kg IV on day 1 of each cycle.
61926144|NCT03458663|EXPERIMENTAL|Prevena|Patients randomized to application of Prevena ™ and ACTIV.A.C ™ Therapy System 4-7 days post-operatively. Patients will return to the surgical day clinic to have the system removed either at day 7 or when/ if function ceases. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing
62320339|NCT04656964|EXPERIMENTAL|Remimazolam Tosilate group|Patients received remimazolam tosilate to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.4 ug/kg of remifentanil for 1 min during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
62320340|NCT04656964|ACTIVE_COMPARATOR|Midazolam group|Patients received midazolam to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.4 ug/kg of remifentanil for 1 min during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
62320341|NCT00744146|EXPERIMENTAL|1|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 50 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
62320342|NCT00744146|EXPERIMENTAL|2|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 100 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
62480859|NCT02744677|EXPERIMENTAL|TPVR - THV Registry|Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.
62480860|NCT02744677|EXPERIMENTAL|TPVR- S3UR Registry|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
62480861|NCT06693518|EXPERIMENTAL|Treatment A= Dabigatran Etexilate 150 mg|Treatment A= Dabigatran Etexilate 150 mg
62480862|NCT06693518|EXPERIMENTAL|Treatment B=Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg|Treatment B=Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
62480863|NCT06430866|EXPERIMENTAL|ABP 234|Participants will receive ABP 234 every 3 weeks (Q3W) for up to 12 months.
62689342|NCT04125758|EXPERIMENTAL|Mindfulness training|Participants will listen to one to two 3-30 minute audio recordings each day for 4 weeks between study visits (28 days total) through the Healthy Minds @Work smartphone app and record when they listen to each recording on a paper log. The app will also collect data on which recordings, when, and for how long participants listen.
62689343|NCT04125758|ACTIVE_COMPARATOR|Tracking time spent on mobile device|Participants will record how much time they estimate they have spent on their phone in the past 24 hours, each day for 4 weeks (28 days total) between study visits.
62689344|NCT02698787|EXPERIMENTAL|Group 1|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 1 will be receiving the FAST (experimental) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 1 will be switched to the commercially available ACE (control) sound coding strategy.
62689345|NCT02698787|EXPERIMENTAL|Group 2|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 2 will be the commercially available ACE (control) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 2 will be switched to the receiving intervention of the FAST (experimental) sound coding strategy. The experimental sound coding strategy will be used from 3-6 months post activation.
62689346|NCT03917901|EXPERIMENTAL|Anxiety Sensitivity Training|The Anxiety Sensitivity training (AST) will provide: (1) psychoeducation on anxiety sensitivity and its consequences, (2) psychoeducation on the relationship between anxiety sensitivity and obesity-related health behavior correlates, and (3) concrete, evidenced-based strategies to reduce anxiety sensitivity.
62689347|NCT03917901|PLACEBO_COMPARATOR|Health Control|The Health Control (HC) will cover general health care, such as information on wearing sunscreen and regular attendance to doctor appointments. The HC will not provide any recommendations or education on mood, dietary, or physical habits.
62689348|NCT06644638||Ofatumumab and Self-injectable DMT Cohort|Adult patients with multiple sclerosis (MS) who newly initiated ofatumumab or other self-injectable DMTs.
62689349|NCT06644638||Ofatumumab and Oral DMT Cohort|Adult patients with MS who newly initiated OMB or oral DMTs.
62689350|NCT05051345|EXPERIMENTAL|Goal 1 (Wellness app)|Participants download and use the Wellness app onto their smartphones. Participants also receive information on the services provided for pregnant women and smoking cessation.
62689351|NCT05051345|EXPERIMENTAL|Goal 2 (counseling, Wellness app, self-help)|Participants receive telephone counseling sessions over 30-45 minutes for a minimum of 6 sessions in the prenatal period and about 4-6 postpartum period. Participants who start counseling after birth, may receive 6-8 sessions up to 4 months postpartum. Participants may also use the Pregnancy and Wellness smartphone app that provides wellness messages, smoking cessation information, relapse prevention tips, and tips to create a smoke-free home. Participants also receive tobacco cessation self-help materials including National Partnership for Smoke Free Families and Forever Free Baby and Me.
62689352|NCT05051345|EXPERIMENTAL|Goal 3 (Smoke-free Homes)|Participants receive the Smoke-Free Homes kit providing guidance for how to talk with household members and visitors about not smoking inside the home. Participants may also receive 3 separate Smoke-Free Homes mailings over 6 weeks, and a coaching call from a Baby Steps for Health counselor to help follow the steps described in the mailed materials in order to set up a smoke-free home.
62689353|NCT05051345|EXPERIMENTAL|Goal 4 (counseling)|Non-pregnant participants receive telephone counseling sessions over 30 minutes for 6-8 sessions over a 3 month period.
62689354|NCT01554358|OTHER|Lifestyle counseling|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.
62689355|NCT01554358|NO_INTERVENTION|Control|"the subjects in the control group had been educated regarding general principles of healthy lifestyle that benefits T2D and obesity prevention, and also informed about the current evidence showing that the lifestyle intervention is effective in women at high risk for T2D during the run-in period."
62689356|NCT05283629|EXPERIMENTAL|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~* Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~* Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
62689357|NCT05283629|ACTIVE_COMPARATOR|Education Comparison Control|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
62320343|NCT00744146|EXPERIMENTAL|3|"Eight volunteers total.~Randomized such that six volunteers will receive Protexia as a single 250 mg dose and two volunteers will receive saline placebo of the same volume on Study Days 1 and 72.~Volunteers to be followed for approximately 142 days total."
62480864|NCT06430866|ACTIVE_COMPARATOR|Pembrolizumab|Participants will receive pembrolizumab Q3W for up to 12 months.
62320344|NCT00744146|EXPERIMENTAL|4|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 500 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
62320345|NCT00744146|EXPERIMENTAL|5|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 750 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
62320346|NCT01543451|EXPERIMENTAL|Elsiglutide|
62320347|NCT01543451|PLACEBO_COMPARATOR|Placebo|
61926145|NCT03458663|NO_INTERVENTION|Conentional postoperative care|patients randomized to convetional postoperative regime with a penrose drain (passive) and a dry draping for 24 hours and after usage of sanitary pads. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Drain is removed after 24 hours and Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing.
61926146|NCT01993251|ACTIVE_COMPARATOR|melatonin 0.5mg|
62689358|NCT03057340|EXPERIMENTAL|DRibble vaccine|Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.
62689359|NCT06638645||Patients undergoing a minimally invasive anatomical lung resection|Patients undergoing a minimally invasive anatomical lung resection, receiving perioperative care according to the ERAS protocol for Lung Surgery
62689360|NCT02063438|ACTIVE_COMPARATOR|Pericostal Suture Technique|A #2 Vicryl suture is placed along the superior aspect of the rib above the specific thoracic interspace. This suture is then passed below the inferior rib along the superior aspect of the next rib below. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
61926147|NCT01993251|ACTIVE_COMPARATOR|melatonin 2mg|
61926148|NCT01993251|ACTIVE_COMPARATOR|melatonin 6mg|
61926149|NCT01993251|PLACEBO_COMPARATOR|placebo|
61926150|NCT00655460|EXPERIMENTAL|eProtocol|
61926151|NCT01765660|EXPERIMENTAL|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
61926152|NCT01765660|EXPERIMENTAL|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10\^6 cells/kg, intravenously)every two weeks, four times for a cycle
61926153|NCT02180074||I|Women without PAD (ABI \>1.0 and \<1.4) or CAD, and \< 2 risk factors for cardiovascular disease (to serve as healthy controls)
61926154|NCT02180074||II|Women without PAD (ABI\>1.0 and \<1.4) or CAD and \> 2 risk factors for cardiovascular disease
61926155|NCT02180074||III|Women with PAD as defined by ABI \<0.9 and a coronary angiogram without any significant coronary artery disease.
62689361|NCT02063438|ACTIVE_COMPARATOR|Intracostal Suture Technique|A handheld drill is used to drill holes in the rib below the specific thoracic interspace. A #2 Vicryl suture is passed through each of the holes and then passed along the superior aspect of the rib above the specific thoracic interspace. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
62689362|NCT06609304|EXPERIMENTAL|axi-cel treatment|
62689363|NCT02121639|EXPERIMENTAL|AZD5363|AZD5363
62689364|NCT02121639|PLACEBO_COMPARATOR|Placebo|Placebo
62689365|NCT03576651|EXPERIMENTAL|JHL1149|
62689366|NCT03576651|ACTIVE_COMPARATOR|US-sourced-Avastin™|
62689367|NCT03576651|ACTIVE_COMPARATOR|EU-sourced Avastin™|
62689368|NCT06642831||Women with PCOS|Women in the age range of 15-25 years fulfilling the PCOS criteria defined by the International Evidence-based Guideline
61926156|NCT02180074||IV|Women with CAD without PAD, as defined by \>50% stenosis by coronary angiography and ABI \>1.0 and \<1.4.
62689369|NCT06642831||Women without PCOS (controls)|Women in the age range of 15-25 years who are negative for the diagnostic criteria of PCOS according to the International Evidence based guideline
62689370|NCT01505803|ACTIVE_COMPARATOR|Zinc supplement|
61926157|NCT02180074||V|Women with both CAD and PAD.
61926158|NCT05086952|EXPERIMENTAL|B-A-D-C|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design \[balanced for 1-period-carry-over\]).
61926159|NCT05086952|EXPERIMENTAL|C-D-A-B|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design \[balanced for 1-period-carry-over\]).
61926160|NCT05086952|EXPERIMENTAL|D-B-C-A|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design \[balanced for 1-period-carry-over\]).
61926161|NCT05086952|EXPERIMENTAL|A-C-B-D|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design \[balanced for 1-period-carry-over\]).
61926162|NCT06274567|EXPERIMENTAL|Active intermittent theta burst stimulation (iTBS)|The Active intermittent theta burst stimulation (iTBS) arm will receive active iTBS applied to the inferior parietal lobule (IPL)
61926163|NCT06274567|PLACEBO_COMPARATOR|Sham intermittent theta burst stimulation (iTBS)|The Sham intermittent theta burst stimulation (iTBS) arm will receive sham iTBS applied to the inferior parietal lobule (IPL)
61926164|NCT06732830|EXPERIMENTAL|DayDrop Advanced|DayDrop Advanced is an ocular lubricant drop based on γ-PGA and hyaluronic acid (0.1% sodium hyaluronate and 0.4% high molecular wieght polyglutamic acid), indicated to relieve dryness and eye irritation. DayDrop Advanced comes in a multi-dose container, type OSD ( Ophthalmic Squeeze Dispenser). Each container contains 10 mL of sterile product.
62320348|NCT00000451|EXPERIMENTAL|1|Naltrexone plus Sertraline
62320349|NCT00000451|EXPERIMENTAL|2|Naltrexone alone
62320350|NCT00606697|ACTIVE_COMPARATOR|Overall study|Male and female subjects, 18-64 years of age (inclusive), with a primary diagnosis of primary insomnia
62689371|NCT01505803|ACTIVE_COMPARATOR|Omega 3 supplement|
62689372|NCT01505803|ACTIVE_COMPARATOR|Zinc and omega 3 supplements|
62689373|NCT01505803|PLACEBO_COMPARATOR|Placebo supplement|
62697438|NCT01765387|EXPERIMENTAL|Spa therapy|A cycle of 3 Vichy shower and whirlpool baths are applied during 30-minutes period. Vichy sedative shower is applied for 90-120 sec to the sides of the trunk and the abdomen, avoiding as much as possible the gall bladder area, at a temperature of 36-38ºC. A short, partial jet spray followed the shower. A whirlpool bath is administered where subjects immersed the body until their clavicle level for a 10min period with a water temperature ranging 33.5-35.5 ºC. Aromatherapy application using lavender and chamomile oils is used in all Spa therapy sessions.
61926165|NCT02392871|EXPERIMENTAL|Radiotherapy|"Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.~Palliative RT will be delivered to symptomatic or bulky (\>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.~Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria."
61926166|NCT03968653|EXPERIMENTAL|Dose Escalation: Group A: Debio 0123|"Participants will receive Debio 0123 as monotherapy (Day -3), orally, daily for 3 days during Cycle 1 then in combination with carboplatin intravenous infusion from Cycle 2 onwards.~Depending on pharmacokinetics (PK) and safety results from previous cohorts, the Debio 0123 dosing regimen may be modified for subsequent cohorts."
61926167|NCT03968653|EXPERIMENTAL|Dose Escalation: Group B: Debio 0123|Participants will receive Debio 0123, orally, daily, for 6 days during each cycle in combination with carboplatin IV infusion.
61926168|NCT03968653|EXPERIMENTAL|Dose Expansion: Debio 0123|Participants with platinum-resistant selected solid tumors will receive Debio 0123, orally, daily, depending on the RP2D determined in the previous part, for 3 or 6 days during each cycle in combination with carboplatin IV infusion.
61926169|NCT02800759|ACTIVE_COMPARATOR|100% of JOINTRUS®|After randomization, 100% dose of JOINTRUS® is taken per day for 3 months in 7 sub-healthy persons \>18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
61926170|NCT02800759|ACTIVE_COMPARATOR|80% of JOINTRUS®|After randomization, 80% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons \>18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
62689374|NCT06229093|SHAM_COMPARATOR|Older Adults (OA)|The assignment of older adults to OA and OAg will be randomized. The within-subjects factor of stimulation modality includes 2 levels, to be administered in counterbalanced order: Visual (V, i.e., lights-only) and Audiovisual (AV, i.e., music-plus-lights). Each subject will be aware that they are receiving V and AV stimulation, and thus infer that we are comparing these two forms of stimulation and therefore assessing the effects of music. However, and important to the design of this study, all subjects will be blinded with respect to their group assignment; i.e., they will not know, until post-study debriefing, about the other arms of the study, and that the gamma-band stimulation is an active ingredient of the intervention.
62689375|NCT06229093|EXPERIMENTAL|Older Adults Gamma (OAg)|The assignment of older adults to OA and OAg will be randomized. The within-subjects factor of stimulation modality includes 2 levels, to be administered in counterbalanced order: Visual (V, i.e., lights-only) and Audiovisual (AV, i.e., music-plus-lights). Each subject will be aware that they are receiving V and AV stimulation, and thus infer that we are comparing these two forms of stimulation and therefore assessing the effects of music. However, and important to the design of this study, all subjects will be blinded with respect to their group assignment; i.e., they will not know, until post-study debriefing, about the other arms of the study, and that the gamma-band stimulation is an active ingredient of the intervention.
62689376|NCT06088043|EXPERIMENTAL|TAK-279|
62689377|NCT06088043|PLACEBO_COMPARATOR|Placebo|
62689378|NCT06088043|ACTIVE_COMPARATOR|Apremilast|
62689379|NCT06641284||The Female Group|Patients identified themselves as females (Apparent gender)
62129996|NCT01981174|ACTIVE_COMPARATOR|30-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
62129997|NCT01981174|ACTIVE_COMPARATOR|32-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
62129998|NCT00093015|ACTIVE_COMPARATOR|Active|
62129999|NCT00093015|PLACEBO_COMPARATOR|Placebo|
62130000|NCT01022892||Phase 1 - Pilot phase|Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm.
62320351|NCT00687154|ACTIVE_COMPARATOR|1 Sitting|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 1 sitting
62320352|NCT00687154|ACTIVE_COMPARATOR|4 Sittings|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 4 sittings.
62689380|NCT06641284||The Male Group|Patients identified themselves as males (Apparent gender)
62689381|NCT04966585|EXPERIMENTAL|Posaconazole|Subjects administered posaconazole (Noxafil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
62689382|NCT04966585|PLACEBO_COMPARATOR|Placebo|Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
62689383|NCT03906708||Premature Infants|Premature infants born between 24+0 and 36+6 weeks of gestation.
62689384|NCT02093520|ACTIVE_COMPARATOR|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
62689385|NCT02093520|ACTIVE_COMPARATOR|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
62689386|NCT01906320|EXPERIMENTAL|Training group|
62689387|NCT01906320|NO_INTERVENTION|Control Group|
62689388|NCT02607163|EXPERIMENTAL|dexmedetomidine|dexmedetomidine, 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
62689389|NCT02607163|PLACEBO_COMPARATOR|control|saline, same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
62130001|NCT01022892||Phase 2 - Blinded from CT Scan|This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study.
62320353|NCT06504082|ACTIVE_COMPARATOR|Letrozole + Single-Dose Methotrexate Group|Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.
62320354|NCT06504082|ACTIVE_COMPARATOR|Single-Dose Methotrexate|After confirming the diagnosis of tubal ectopic pregnancy, each patient received a single dose of intramuscular MTX (50 mg/m² MTX) on the same day.
62320355|NCT02369978|EXPERIMENTAL|Nifurtimox (NFX)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
62689390|NCT06640062|ACTIVE_COMPARATOR|Erector spinae plane block group|Patients received ultrasound-guided erector spinae plane block.
62689391|NCT06640062|EXPERIMENTAL|Oblique subcostal transversus abdominis plane block group|Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
62689392|NCT06559540|ACTIVE_COMPARATOR|Hypofractionated radiation (RT)|Breast/chest wall and regional nodal radiation (4256 cGy in 16 fractions over 3-4 weeks).
62689393|NCT06559540|EXPERIMENTAL|Ultra-hypofractionated breast/chest wall and regional nodal radiation (SWIFT RT)|Breast/chest wall and regional nodal radiation (2600 cGy in 5 fractions over 1-2 weeks).
62689394|NCT04380740|PLACEBO_COMPARATOR|Standard GVHD Prophylaxis + Abatacept + Placebo|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 4 doses of Abatacept (investigational product) + 4 doses of Placebo.
62130002|NCT02730871|EXPERIMENTAL|Simbrinza + Duotrav|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
62130003|NCT02730871|PLACEBO_COMPARATOR|Vehicle + Duotrav|Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
62130004|NCT01891084|ACTIVE_COMPARATOR|Paracetamol|"Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable."
62130005|NCT01891084|PLACEBO_COMPARATOR|Placebo|"(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable"
62130006|NCT00546754|EXPERIMENTAL|1|Drug Arm
62130007|NCT00546754|ACTIVE_COMPARATOR|2|active comparator
62130008|NCT05436119||GrowBaby|All pregnant women presenting at \< 19 weeks EGA for prenatal care covered by Molina Health of Nevada MCO will be offered the GrowBaby group nutrition and lifestyle program. Primary and secondary outcomes of those who opt out of the program will be compared to those who opt in. Additionally, all women who develop primary or secondary outcomes in the GrowBaby arm will be compared to those who do not develop primary or secondary outcomes (nested case-control). Outcomes will be compared locally, regionally and nationally within the Medicaid population, as well.
62130009|NCT02522468|EXPERIMENTAL|Radioactive Seed Localization|Radioactive Seeds
62130010|NCT02522468|ACTIVE_COMPARATOR|Wire Localization|Wire
62130011|NCT01232712|EXPERIMENTAL|ImMucin|Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
62130012|NCT03072316||SSM immediate DIEP|Unilateral skin sparing mastectomy with immediate DIEP
62480865|NCT03793179|EXPERIMENTAL|Arm A (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 6 weeks of disease progression, patients receive pemetrexed IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then may receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI during screening, CT scan and blood sample collection throughout the study, and may undergo PET scan throughout the study.
62689395|NCT04380740|EXPERIMENTAL|Standard GVHD Prophylaxis + Abatacept Extended dosing|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 8 doses of Abatacept.
62130013|NCT03072316||SSM immediate DIEP and PMRT|Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy
62130014|NCT03072316||mastectomy, PMRT, delayed DIEP|simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction
62130015|NCT03072316||SSM, temporizing implant, PMRT then DIEP|Unilateral SSM with temporizing implant, PMRT and subsequent
62130016|NCT05193695|NO_INTERVENTION|Control|Patients remained in the supine position for 20 minutes lying on a stretcher after dry needling.
62130017|NCT05193695|EXPERIMENTAL|Treadmill|The patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002).
62130018|NCT00591708|EXPERIMENTAL|B|Supplementation of a higher level of calcium (500-1300 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
62130019|NCT00591708|EXPERIMENTAL|A|Supplementation of a lower level of calcium (0-400 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
62689396|NCT04965064|EXPERIMENTAL|Experimental: Capecitabine and Neratinib.|"Neratinib 240 mg PO QD Daily On-going~Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going"
62689397|NCT01355666|EXPERIMENTAL|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
62689398|NCT04719312|EXPERIMENTAL|transconjunctival Y modification|
62689399|NCT05856526|PLACEBO_COMPARATOR|Placebo|
62689400|NCT05856526|EXPERIMENTAL|Spesolimab|
62689401|NCT01465165||Depressed, unmedicated|Participants with MDD who are not treated with any antidepressant medication
62689402|NCT01465165||Depressed, on antidepressant|Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
62689403|NCT01465165||Healthy control|Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants
61926171|NCT02800759|ACTIVE_COMPARATOR|62.4% of JOINTRUS®|After randomization, 62.4% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons \>18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
61926172|NCT02800759|PLACEBO_COMPARATOR|Starch 100%|After randomization, starch 100% was taken per day for 3 months in 7 sub-healthy persons \>18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
61926173|NCT06708468|EXPERIMENTAL|Intervention|The experimental group receives four-months of exercise-based intervention
61926174|NCT06708468|ACTIVE_COMPARATOR|Control|The control group follows usual care
61926175|NCT05295797|EXPERIMENTAL|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
61926176|NCT05295797|NO_INTERVENTION|Control|Participants in the waitlist control will be assigned to a waiting list and will be invited to participate in dance classes after the intervention arm 12-week dance program has ended
62689404|NCT06455631|EXPERIMENTAL|Oral Breast Milk and Facilitated Tucking|In the facilitated tucking position + oral breast milk group, preterm newborns will be placed in the facilitated tucking position by the researcher 15 minutes before the tape removal procedure and given oral breast milk 2 minutes before the tape removal procedure. The facilitated tucking position will be maintained until 2 minutes after the tape removal procedure. To prevent heat loss, the preterm newborns will be placed in the fetal position inside the incubator by using the incubator windows without opening the incubator lid.
61926177|NCT05559333|ACTIVE_COMPARATOR|zirconomer|zirconia reinforced glass ionomer cement
61926178|NCT05559333|ACTIVE_COMPARATOR|Equia Fil|High viscosity glass ionomer cement
61926179|NCT05559333|ACTIVE_COMPARATOR|glass carbomer|glass ionomer cement containing nano sized- carbonized particles.
62130020|NCT01625234|EXPERIMENTAL|Phase I: X-396 (ensartinib)|Dose escalation starting at 25 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops
62130021|NCT01625234|EXPERIMENTAL|Phase II: X-396 (ensartinib)|RP2D 225mg stratified based on prior treatment and CNS activity
62130022|NCT03681522|EXPERIMENTAL|Pelvic plexus block|The injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
62130023|NCT03681522|ACTIVE_COMPARATOR|Periprostatic nerve block|The injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle.
62689405|NCT06455631|EXPERIMENTAL|Kangaroo Care and Oral Breast Milk Odor|In the kangaroo care + oral breast milk group, preterm newborns will undergo kangaroo care 15 minutes prior to tape removal and receive oral breast milk 2 minutes before. During kangaroo care, mothers can interact with their babies but cannot feed them. After ensuring comfort, this position will be maintained for 15 minutes before tape removal. The nurse will then remove the tape while the baby is in kangaroo care, followed by an additional 2 minutes of kangaroo care. Kangaroo care can continue post-data collection based on maternal preference, baby's condition, and clinical circumstances.
62689406|NCT06455631|NO_INTERVENTION|Control|The newborns in the control group will undergo the routine nesting procedure of the clinic. All newborns will be placed in the lateral position. For ethical reasons, if babies cry during or after the procedure, gentle touch and verbal comfort will be provided to them.
62130024|NCT05517616|EXPERIMENTAL|[14C]APG-2575|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose of 400mg, 200μCi \[14C\] APG-2575 to healthy subjects.
62130025|NCT02378896|EXPERIMENTAL|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
62130026|NCT04192305||lung protective ventilation (LPV)|lung protective ventilation low tidal volume, minimum PEEP and higher PEEP and lung recruitment based on total lung compliance, low inspiratory oxygen concentration and CPAP during extubation without prior suctioning inside the endotracheal tube.
62130027|NCT04192305||routine lung ventilation (LV)|ventilation and adapting PEEP, LRM and oxygen only when saturation drops.
62689407|NCT02489487|EXPERIMENTAL|VM-1500 + Raltegravir|VM-1500 40 mg in combination with 400 mg Raltegravir
62689408|NCT02489487|EXPERIMENTAL|VM-1500 +Darunavir|VM-1500 40 mg in combination with 600 mg Darunavir boosted with 100 mg Ritonavir
62689409|NCT02489487|EXPERIMENTAL|VM-1500|VM-1500 40 mg alone
62689410|NCT03253627|EXPERIMENTAL|MBSR|Mindfulness-Based Stress Reduction
61926180|NCT05559333|ACTIVE_COMPARATOR|Tetric-evo ceram bulk fill|Bulk fill composite resin
61926181|NCT00880685|EXPERIMENTAL|Memantine|Memantine 10-30mg
62689411|NCT03253627|ACTIVE_COMPARATOR|Health Enhancement Program|Health Enhancement Program
62130028|NCT00359658|EXPERIMENTAL|1|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml
62689412|NCT05713838|EXPERIMENTAL|Durvalumab + Chemoradiotherapy|"Core Treatment:~* D1: Durvalumab (1500 mg, IV) PLUS FLOT (50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² 5-FU 24h)~* D15: FLOT (50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² 5-FU 24h),~* D29: Durvalumab (1500 mg, IV) PLUS mFOLFOX (85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² 5-FU bolus and 1600 mg/m² 5-FU 48h) PLUS 50 Gy radiotherapy~  * 5 weeks with 5 days a week radiotherapy (25 daily fractions, 2.0 Gy = ∑50Gy)~* D43: mFOLFOX (85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² 5-FU bolus, 1600 mg/m² 5-FU 48h) (radiation cont.)~* D57: Durvalumab (1500 mg, IV) PLUS mFOLFOX (85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² 5-FU bolus and 1600 mg/m² 5-FU 48h) (radiation cont.)~Maintenance Phase Durvalumab monotherapy max. 12 cycles à 4 weeks:~Durvalumab (1500 mg, IV, Q4W) D1"
62689413|NCT06296355|EXPERIMENTAL|Health Warning Label|Participants will view four products (a fruit-flavored drink, pretzels, a yogurt, and a breakfast cereal) each with a health warning label displayed on the front of package.
62689414|NCT06296355|EXPERIMENTAL|Identity Warning Label|Participants will view four products (a fruit-flavored drink, pretzels, a yogurt, and a breakfast cereal) each with an identity warning label displayed on the front of package.
62130029|NCT06520332|EXPERIMENTAL|10 Short implants will be placed in the residual vertical bone height of 5 to 8mm .|One short dental implant will be placed whose length will be less than or equal to 6mm.
62130030|NCT06520332|ACTIVE_COMPARATOR|10 Standard implants of length ≥ 10mm will be placed in augmented/native bone .|This Conventional Dental implant group will act as control.
62130031|NCT04149002|OTHER|Intervention Arm: Weekly IP3 text messages|"* A narrated powerpoint presentation describing the logistical details and medical rationale for components of the IP3. Participants will view the chapters of the presentation that are relevant to their specific IP3. There are a total of 4 possible chapters (lifestyle modifications, cervix length screening/cerclage, progesterone therapy, low dose aspirin). Each chapter of the presentation is \~ 10 - 15 min in length. Each chapter also includes a 4- 5 questions pre-test and the same questions are delivered as a post-test after the presentation.~* Print materials including a letter explaining the importance of prenatal care for preterm birth prevention to employers.~* Text messages sent weekly to encourage the patient to continue with their IP3 and provide basic pregnancy information~* Formal letter of encouragement from provider at 28 weeks gestation"
62689415|NCT06296355|OTHER|Barcode Label|Participants will view four products (a fruit-flavored drink, pretzels, a yogurt, and a breakfast cereal) each with a barcode control label displayed on the front of package.
62689416|NCT05752838||Diagnosed with LDH and had LDH-related radiating leg pain|
62689417|NCT05384548|EXPERIMENTAL|Problematic smart phone use course|
61926182|NCT06218459|EXPERIMENTAL|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
61926183|NCT06218459|PLACEBO_COMPARATOR|Jacobson's progressive relaxation|Jacobson's progressive relaxation is used in a range of conditions to relieve muscle tension and stress as part of self-management.
61926184|NCT06179433|EXPERIMENTAL|root canal treatment|Two-visit root canal treatment will be performed.
61926185|NCT06179433|ACTIVE_COMPARATOR|REP with I-PRF|The first appointment will be performed similar to the conventional RCT group. in the second appointment, i-PRF will be prepared by collecting venous blood and centrifugate at 700rpm for 3 minutes. i-PRF will be injected into canal followed by a bioceramic material.
61926186|NCT06179433|ACTIVE_COMPARATOR|REP with blood clot|The first appointment will be performed similar to the conventional RCT group. In the second appointment, after anesthetizing with 3% mepivacine, the canals will be re-entered and irrigated well with 17% EDTA. Bleeding will be induced by inserting sterile #25 K-file into the 2-3 mm beyond the apical foramen into periapical tissues.
61926187|NCT05822635||Subjects with complex pancreaticobiliary disease|All subjects will undergo the intraoperative endoscopy with either the SpyGlass Discover System or the SpyGlass DS Direct Visualization System.
61926188|NCT04647253|EXPERIMENTAL|AGENT DCB|Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
61926189|NCT04647253|ACTIVE_COMPARATOR|Commercially available, PTCA Dilation Catheter|
61926190|NCT05774977|EXPERIMENTAL|Group 1: A B C D E F|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: A B C D E F"
61926191|NCT05774977|EXPERIMENTAL|Group 2: B D A F C E|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: B D A F C E"
61926192|NCT05774977|EXPERIMENTAL|Group 3: C A E B F D|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: C A E B F D"
61926193|NCT05774977|EXPERIMENTAL|Group 4: D F B E A C|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: D F B E A C"
61926194|NCT05774977|EXPERIMENTAL|Group 5: E C F A D B|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: E C F A D B"
61926195|NCT05774977|EXPERIMENTAL|Group 6: F E D C B A|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: F E D C B A"
61926196|NCT04185246|EXPERIMENTAL|Single arm|"Subjects will be enrolled with sequential allocation to 1 of 3 cohorts with the following intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg.~Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day"
61926197|NCT05871606|EXPERIMENTAL|Dose 1 Group|Dose 1- Inhaled Nitrous Oxide (iNO) 40ppm.
61926198|NCT05871606|EXPERIMENTAL|Dose 2 Group|Dose 2- Inhaled Nitrous Oxide (iNO) 50ppm.
61926199|NCT05871606|EXPERIMENTAL|Dose 3 Group|Dose 3- Inhaled Nitrous Oxide (iNO) 60ppm.
61926200|NCT05871606|EXPERIMENTAL|Dose 4 Group|Dose 4- Inhaled Nitrous Oxide (iNO) 70ppm.
62689418|NCT06570226|EXPERIMENTAL|the hibiscus tea group|To drink the hibiscus tea for 10 weeks. At the beginning of the trial (week zero), the second week, the sixth week, and the tenth week after stopping drinking, the visual fatigue scale, blood pressure, and body composition were examined respectively. At the initial stage (0th week) and at the 10th week after stopping drinking, visual acuity examinations were performed.
62130032|NCT04149002|ACTIVE_COMPARATOR|Control Arm: General pregnancy text messages|"* a pre-intervention questionnaire~* a narrated powerpoint with general information about the clinic~* a post-presentation questionnaire~* text messages sent approximately weekly with general pregnancy information (e.g. today your baby is about the size of an apple)~* an exit interview"
62130033|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
62130034|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
62130035|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
62480866|NCT03793179|EXPERIMENTAL|Arm B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 6 weeks of disease progression, patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease progression or unacceptable toxicity and until to disease progression for pemetrexed. Patients undergo MRI during screening, CT scan and blood sample collection throughout the study, and may undergo PET scan throughout the study.
62689419|NCT06570226|NO_INTERVENTION|the boiled water drinking group|To drink the boiled water for 10 weeks. At the beginning of the trial (week zero), the second week, the sixth week, and the tenth week after stopping drinking, the visual fatigue scale, blood pressure, and body composition were examined respectively. At the initial stage (0th week) and at the 10th week after stopping drinking, visual acuity examinations were performed.
62689420|NCT04174482|EXPERIMENTAL|flat foot patients|20 patients recruited consecutively and candidates for surgery to correct the adult flat foot according to the Grice technique.
62689421|NCT05943574||Patients who received the XtraFix® Small External Fixation System|
62320356|NCT02369978|ACTIVE_COMPARATOR|Benznidazole (BZN)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
62320357|NCT02369978|PLACEBO_COMPARATOR|Placebo|120 days of treatment with matching placebo
62320358|NCT02855593||Physicians|Physicians who perform acupuncture
62689422|NCT06418269|EXPERIMENTAL|Therapeutic Play Group|
62689423|NCT06418269|NO_INTERVENTION|Control Group|
62130036|NCT02630823|EXPERIMENTAL|Arm 1: MK-3475|"* Patients will undergo endometrial biopsy followed by 2 doses of MK-3475 3 weeks apart. 3-4 weeks after the second dose of MK-3475, the standard of care surgical resection will take place, followed by standard of care adjuvant therapy. Tissue and blood will be collected at the time of surgical resection for immune analysis. For patients whose pathology confirms high-risk features and advanced stage, MK-3475 will be given every 3 weeks starting 4 -6 weeks after completion of adjuvant therapy for a maximum of 4 doses post-surgery.~* MK-3475 will be given intravenously at a dose of 200 mg over the course of 30 minutes.~* The standard of care chemotherapy will consist of 6 cycles of paclitaxel and carboplatin AUC 5 every 3 weeks for 6 cycles.~* The decision to administer radiation therapy will be per the treating physician. If the patient does not receive radiation therapy, then the patient will start MK-3475 every 3 weeks x 4 doses after the completion of chemotherapy."
62689424|NCT02412436|EXPERIMENTAL|Arm A: Depot medroxyprogesterone acetate|At study entry/week 0, participants received depot medroxyprogesterone acetate (DMPA) 150 mg administered intramuscularly as a single dose and co-administered with rifampicin (RIF) and efavirenz (EFV).
62689425|NCT00621114|ACTIVE_COMPARATOR|1|Patients in group 1 will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
62689426|NCT00621114|EXPERIMENTAL|2|Patients in group 2 will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
61926201|NCT05871606|EXPERIMENTAL|Dose 5 Group|Dose 5- Inhaled Nitrous Oxide (iNO) 80ppm.
61926202|NCT00295971|EXPERIMENTAL|Single arm of transplant|Receiving haplocompatible T cell depleted peripheral blood stem cell transplant
62130037|NCT03206515|OTHER|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
62130038|NCT03206515|OTHER|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
62689427|NCT01877057|EXPERIMENTAL|Saturn|For the different prototypes of pea protein extract used in this study pea protein NUTRALYS F85M or F85G, Acacia Gum 381A or 396I and water will be used.
62689428|NCT04106635|EXPERIMENTAL|PP group|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
61926203|NCT04401644|EXPERIMENTAL|primary arm|There will only be one set of participants with each participants samples and results as the comparator groups. There will be within group comparison of methods of detection of virus by two test methodologies. Post hoc validation of test performance against reference set.
61926204|NCT03729973|ACTIVE_COMPARATOR|Group (K)|"Group (K) (n=25): patients nebulized ketamine 50 mg(milgram) (1ml) plus 4ml normal saline.So total volume (5ml).~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized 1ml ketamine (Ketalar 50mg/VI Solution for Injection) by compressor nebulizing for 15 minutes."
61926205|NCT03729973|ACTIVE_COMPARATOR|Group (M)|"Group M(n=25) : patients nebulized isotonic magnesium sulfate 250mg (3ml)( 50% Magnesium Sulfate Injection)plus 1ml normal saline.~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
61926206|NCT03729973|ACTIVE_COMPARATOR|Group (L)|"Group (L) (n=25): patients nebulized lidocaine 2% 100mg .So total volume (5ml). In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
61926207|NCT03729973|ACTIVE_COMPARATOR|Group (C)|"Group (C) (n=25): patients nebulized normal saline(0.9%). 5ml .In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
61926208|NCT04841226|ACTIVE_COMPARATOR|Silq ClearTract™ 100% Silicone 2-Way Foley Catheter|Up to 82 subjects
61926209|NCT04841226|ACTIVE_COMPARATOR|Silver-coated Latex 2-Way Foley Catheter|Up to 82 subjects
61926210|NCT04841226|ACTIVE_COMPARATOR|Silicone-coated Latex 2-Way Foley catheter|Up to 82 subjects
62130039|NCT02628171|OTHER|Control|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of cashew nuts (control).
62320359|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
62689429|NCT04106635|ACTIVE_COMPARATOR|CP group|During the induction of anesthesia, cricoid pressure is applied by 30N force with three finger.
62689430|NCT05805150|EXPERIMENTAL|Control Lens, Then Test Lens|Participants will wear control lenses for one week and then crossover to test lenses for one week.
62689431|NCT05805150|EXPERIMENTAL|Test Lens, Then Control Lens|Participants will wear test lenses for one week and then crossover to control lenses for one week.
62689432|NCT02743312|EXPERIMENTAL|Torso Weights then Sham Weights|"No weights worn for 4 weeks. Garment with torso weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with sham weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
62689433|NCT02743312|EXPERIMENTAL|Sham Weights then Torso Weights|"No weights worn for 4 weeks. Garment with sham weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with torso weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
62689434|NCT04109482|EXPERIMENTAL|Relapsed or Refractory BPDCN|Treatment with MB-102.
62689435|NCT06478524|EXPERIMENTAL|Live music|Patients will have baseline data collection in the first week, followed by live music sessions and data collection during dialysis in the second week.
62689436|NCT06478524|ACTIVE_COMPARATOR|Pre-recorded music|Patients will have baseline data collection in the first week, followed by pre-recorded music sessions and data collection during dialysis in the second week.
62689437|NCT05571839|EXPERIMENTAL|PF-08046049|PF-08046049 monotherapy
61926211|NCT04972630|ACTIVE_COMPARATOR|Control|"Control group participants will be recruited from the cancer patients in need of palliative care at Tata Medical Center (TMC), Kolkata, India. Participants will be recruited and consented by TMC researchers. There will be random allocation to the control or Pal-Care group. The control group (n=45) will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
62130040|NCT02628171|ACTIVE_COMPARATOR|Cashew|Participants will receive a controlled diet, typical of an American diet, with 42 g/day of cashew nuts (base diet with cashew nuts).
62320360|NCT00400491|EXPERIMENTAL|1|
62320361|NCT00400491|PLACEBO_COMPARATOR|2|
62320362|NCT05975580|EXPERIMENTAL|Group A: Topiramate 50 mg|Topiramate will be started at 25 mg daily and the dose will be increased to 50 mg daily after 15 days. Responders at Month 4 will continue the same treatment until Month 12.
62320363|NCT05975580|EXPERIMENTAL|Group B: Topiramate 100 mg|Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
62320364|NCT05975580|EXPERIMENTAL|Group C: Phentermine 7.5 mg/Topiramate 50 mg|Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
62689438|NCT01514578|EXPERIMENTAL|TRV130A|
62689439|NCT01514578|PLACEBO_COMPARATOR|Dextrose in Water|
62130041|NCT02961569|OTHER|One open-label arm|Patients suspected of pulmonary TB will have sputum collection for acid fast bacilli by the classical strategy (Day 1, Day 2 and Day 3) and the intervention sputum collection for acid fast bacilli by the same day strategy (Hour 1, 2 and 3)
62320365|NCT05975580|EXPERIMENTAL|Group D: Phentermine 7.5 mg|Phentermine will be started at 7.5 mg daily. Responders at Month 4 will continue the same treatment until Month 12.
62320366|NCT05975580|EXPERIMENTAL|Group E: Phentermine 15 mg|Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
62320367|NCT05975580|EXPERIMENTAL|Group F: Phentermine 7.5 mg/Topiramate 50 mg|Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12. For Group F, topiramate will be dosed at 25 mg daily for the 15 days in Month 5 and 50 mg daily thereafter,
62320368|NCT05975580|PLACEBO_COMPARATOR|Group P: Placebo|Placebo group will receive placebo.
62320369|NCT00647842|EXPERIMENTAL|1|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
62320370|NCT00647842|ACTIVE_COMPARATOR|2|Fentanyl Transdermal System 25 mcg/h
62320371|NCT02081547||IPC status|presence of cancer cells.
61926212|NCT04972630|EXPERIMENTAL|Pal-Care|Intervention group participants will be recruited from cancer patients in need of palliative care at Tata Medical Center (TMC), Kolkata, India. Pal-Care will be delivered over a 6-month period. At baseline visit, the patient and their caregiver will meet with their community health worker (CHW) and clinical team and an individualized care plan will be created. Patients will be assigned to the CHW living nearest to their home. The CHW will make home visits to patients 1+ times weekly, depending on patient need. At each visit, the CHW will use resources from the WHO Palliative Care Toolkit to: 1)monitor patient condition, 2) provide basic palliative care (medication administration, wound care, catheter care), 3) deliver prescribed morphine, 4) teach caregivers to deliver care,5) monitor pain and symptom control, and 6) assist patients to access their oncologists and other resources. Timely communication between CHW and clinical team will be maintained using a tele-health platform.
61926213|NCT04972630|NO_INTERVENTION|Post-Intervention Interviews|Semi-structured interviews of stakeholder groups will be conducted by MUSC researchers who are well-trained and speak the local language, to evaluate the Pal-Care intervention. We will conduct 20 key informant interviews/KIIs (or until saturation is reached), representing Pal-Care clinical team members, CHWs and patients/caregivers, who participated in the intervention at TMC, India. Clinicians will include social workers, oncology nurses, cancer center administrators, counselors, and palliative care oncologists. Patients/ caregivers will be purposefully selected to represent experiences across different cancers, clinical problems and assigned CHWs. Interviews will be performed in-person or over a telehealth platform, as needed. Interviews will query barriers, facilitators, optimal strategies, experiences, needs and expectations for palliative care delivery. Interviews will be digitally recorded, transcribed and analyzed.
61926214|NCT05220410|EXPERIMENTAL|Psilocybin|25mg of Psilocybin
62130042|NCT01390818|EXPERIMENTAL|MSC1936369B and SAR245409 once daily|
62130043|NCT01390818|EXPERIMENTAL|MSC1936369B and SAR245409 twice daily|
62130044|NCT05738707||Recombinant protein vaccine|
62130045|NCT05738707||Adenovirus vector vaccine|
62130046|NCT01808339|EXPERIMENTAL|FF AM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the morning (approximately 09:00) and placebo in the evening (approximately 21:00) for 14 days (+/- 2 days).
62130047|NCT01808339|EXPERIMENTAL|FF PM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the evening (approximately 21:00) and placebo in the morning (approximately 09:00) for 14 days (+/-2 days).
62130048|NCT01808339|PLACEBO_COMPARATOR|Placebo|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects in this arm will receive Placebo in the evening and morning (at approximately 09:00 and 21:00) for 14 days (+/- 2 days).
62130049|NCT06445699|ACTIVE_COMPARATOR|Group 1 (Grp.1)|The patients received hydrogel dressing change at three days intervals
62130050|NCT06445699|EXPERIMENTAL|Group 2 (Grp.2)|The patients received ALA-PDT treatment at ten days intervals for 4 sessions.
62130051|NCT06445699|EXPERIMENTAL|Group 3 (Grp.3)|The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals.
62130052|NCT01404598|EXPERIMENTAL|naproxcinod 750 mg bid|
62130053|NCT01404598|EXPERIMENTAL|naproxcinod 3000 mg od|
62130054|NCT01404598|ACTIVE_COMPARATOR|naproxen 500 mg bid|
62130055|NCT04748939|ACTIVE_COMPARATOR|vaccine|Shingrix vaccine
62130056|NCT04748939|PLACEBO_COMPARATOR|placebo|normal saline injection (0.5mL)
62130057|NCT03786042|ACTIVE_COMPARATOR|E-cigarette ad exposure|Participants in the e-cigarette ad exposure condition will view e-cigarette ads on the computer screen while having their eye movements tracked
62130058|NCT03786042|SHAM_COMPARATOR|non e-cigarette ad exposure|Participants in the non e-cigarette ad exposure condition will view non e-cigarette ads on the computer screen while having their eye movements tracked
62689440|NCT03629678|NO_INTERVENTION|Control group (Booklets)|Group 1 will receive the control arm with a paper booklet of the patient-centered SCD-guidelines with education by a health care provider at a single visit
62689441|NCT03629678|ACTIVE_COMPARATOR|mobile health application|Group 2 will receive continuous access to technology-based patient-centered SCD-specific guidelines using a user-driven technological platform, plus a paper booklet of the guidelines with education by a health care provider at a single visit. The mobile app will include interactive content and a fully searchable collection of the SCD-specific guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
62130059|NCT01522898|ACTIVE_COMPARATOR|Medical Rate Control|Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
62339748|NCT00618449|ACTIVE_COMPARATOR|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); be treated at Day 30 with the WHO standard of care for trachoma - 1 gm oral dose of Azithromycin; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
62130060|NCT01522898|EXPERIMENTAL|AV nodal ablation|AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.
62130061|NCT04751838||Survivor cohort; Non-survivor Cohort|All patients were categorized according to the state of departure from the hospital, named survivor or non-survivor.
62339749|NCT02669862|EXPERIMENTAL|A-101 Solution 40|A-101 Solution 40% administered once per week
62689442|NCT00656643|EXPERIMENTAL|1|
62689443|NCT00656643|EXPERIMENTAL|2|
62689444|NCT00656643|EXPERIMENTAL|3|
62480867|NCT03793179|ACTIVE_COMPARATOR|Arm C (pembrolizumab, pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease progression or unacceptable toxicity and until to disease progression for pemetrexed. Patients undergo MRI during screening, CT scan and blood sample collection throughout the study, and may undergo PET scan throughout the study.
62480868|NCT06389084|EXPERIMENTAL|Intervention/treatment|One or two caregivers of each enrolled child will attend an 8-week virtual parent/caregiver education program delivered by a Public Health Nurse. Additionally, the Public Health Nurse will deliver up to 4 individual coaching calls designed to address participant-identified goals related to the group content. The coaching calls will focus on helping to apply the messages and skills from the group sessions and making community connections.
62480869|NCT06389084|NO_INTERVENTION|Control|Participants randomized to the control group receive regular health care.
62689445|NCT00656643|PLACEBO_COMPARATOR|4|
62480870|NCT03307343|EXPERIMENTAL|Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
62689446|NCT01348906|EXPERIMENTAL|Intermittent normoxia|Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
62689447|NCT06675877|ACTIVE_COMPARATOR|group A|Group A Cases only will receive in each dialysis session standard care together with VR camera.
62689448|NCT06675877|NO_INTERVENTION|group B|Group B control group undergo three to four dialysis sessions weekly; they will receive the standard care only in their dialysis sessions without VR camera
61926215|NCT05124301|EXPERIMENTAL|Perceptual learning|Reaching task in which visual information about target finger position is offset to induce a change in perception of the finger.
61926216|NCT05124301|ACTIVE_COMPARATOR|Control|Reaching task with accurate visual information.
62130062|NCT04751838||Training Cohort, Validation Cohort|the eligible patients randomly (7:3) into training cohort and validation cohort. The training cohort were used to build nomogram model, while the validation cohort validated the model.
62130063|NCT02652806|EXPERIMENTAL|FG-4592|Intervention is investigational treatment FG-4592
62689449|NCT06641570|EXPERIMENTAL|Aquatic Exercise Program + Land-exercise Program|"This intervention will include 8 sessions in 8 weeks, once a week. Each session will last between 25 to 35 minutes and will be divided into two components: core stability exercises and stretching of the trunk and lower limbs.~Core Stability Exercises: These will consist of isometric exercises maintained for 7-8 seconds, 8-12 repetitions, 1 set, with brief rest intervals of 3 seconds between repetitions and 30 seconds to 1 minute between exercises. Exercises will include abdominal hollowing, side bridge (both sides), supine extension bridge, lower limb extension from prone (both sides), and alternate arm and leg raise from quadruped.~Stretching Exercises: Participants will perform muscle stretching exercises, holding the maximum stretch for 30 seconds to 1 minute, and returning to the original position, followed by 5 to 10 seconds of rest. Each exercise will be repeated two to three times. Stretches will target the hamstrings, iliopsoas, piriformis, and tensor fasciae latae."
61926217|NCT06687889||vertebral fractures group|vertebral fractures group
62130064|NCT02652806|ACTIVE_COMPARATOR|EPO|Intervention is subject's current dose of Li Xue Bao (epoetin alfa)
61926218|NCT06687889||non vertebral fractures group|non vertebral fractures group
61926219|NCT05537025|EXPERIMENTAL|ARO-MMP7|single or multiple doses of ARO-MMP7 by inhalation of nebulized solution
61926220|NCT05537025|PLACEBO_COMPARATOR|Placebo|single or multiple doses of placebo by inhalation of nebulized solution
61926221|NCT03469388|EXPERIMENTAL|elective EVAR patients|Elective EVAR patients will be included in one arm only
62130065|NCT05955989|ACTIVE_COMPARATOR|Complete denture fabricated from Conventional heat curing|The patients in this group will receive complete dentures fabricated by conventional heat curing method. and they will receive soft lining of the complete dentures after one year.
62130066|NCT05955989|ACTIVE_COMPARATOR|complete denture fabricated by CAD/CAM milled technology|The patients in this group will receive complete dentures fabricated by CAD/CAM ( Computer aided design/ Computer aided manufacture) method. and they will receive soft lining of the complete dentures after one year.
62339750|NCT02669862|EXPERIMENTAL|A-101 Solution 45|A-101 Solution 45% administered once per week
62480871|NCT03307343|NO_INTERVENTION|Control|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
62480872|NCT06480825||Gingivitis group|patients affected by gingivitis
62480873|NCT06480825||Control group|Periodontally healthy patients
62480874|NCT04713449|EXPERIMENTAL|Empowered Survivor online|The online intervention, called Empowered Survivor (ES) is a self-management intervention for patients with head and neck cancer. The intervention contains the following modules: Introduction; Difficulty Swallowing and Muscle Strength; Oral Care; Long-term Follow-Up Care/Oral exams; Calm and Connect; and Maintaining.
62480875|NCT04713449|ACTIVE_COMPARATOR|Springboard Beyond Cancer|Springboard Beyond Cancer is a general resource for survivors of all cancer. It is a free self-management program for cancer survivors developed by trusted sources, the ACS and the NCI.
62480876|NCT04376190|NO_INTERVENTION|control group|12 patients treated with twin block functional appliance without low-level laser application for 9 month
62130067|NCT05955989|ACTIVE_COMPARATOR|complete denture fabricated by CAD/CAM 3D Printed technology|The patients in this group will receive complete dentures fabricated by 3D printing ( three dimension) method. and they will receive soft lining of the complete dentures after one year.
62689450|NCT06641570|ACTIVE_COMPARATOR|Aquatic Exercise Program|"This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.~The aquatic exercise sessions will include a warm-up phase: walking forwards, sideways, and backwards; a training phase: active range of motion exercises for the spine, upper and lower limbs; aerobic exercises with jumps and static running at various speeds; muscle strengthening, 8-12 repetitions, 1-2 sets, 8-10 exercises including hip flexion, extension, adduction, and abduction, knee flexion and extension, knee cycling, shoulder flexion, extension, and abduction, elbow flexion, extension, and pronation-supination, squatting, and stretching exercises for the neck, trunk, and limbs; and a relaxation/cool-down phase: including lying supine and low-impact exercises such as slow walking, squatting, and standing."
62689451|NCT01767987|ACTIVE_COMPARATOR|Ranolazine|Oral treatment Intervention: Drug: Ranolazine 1000 mg
62689452|NCT01767987|PLACEBO_COMPARATOR|Placebo|Oral treatment Intervention: Drug: Placebo
62689453|NCT05010005|EXPERIMENTAL|Ruxolitinib and Duvelisib|Ruxolitinib 20mg BID plus Duvelisib 25mg, 50mg, or 75mg BID. Patients will be instructed to take duvelisib and ruxolitinib by mouth every 12 hours, the same time each day, +/- 2 hours. Duvelisib and ruxolitinib will be provided via the institutional investigational pharmacy. The researchers will utilize a dose-escalation standard 3+3 design in which we evaluate 3 doses of duvelisib (25mg BID, 50mg BID, and 75mg BID) in combination with ruxolitinib 20mg BID. A minus-1 dose level of duvelisib (15mg BID) can be used if de-escalation is needed. The cohort expansion phase will have two treatment groups JAK/STAT activation or mutation present or JAK/STAT activation or mutation absent or unknown. Upon discussion with PI, the treating physician may increase dose up to 20 mg of ruxotlinib and/or 25 mg of duvelisib when deemed clinically favorable.
62689454|NCT00385515|EXPERIMENTAL|1|SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days
62689455|NCT00385515|PLACEBO_COMPARATOR|2|placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days
62689456|NCT04989166|ACTIVE_COMPARATOR|Nano-curcumin|80mg of Nano-curcumin daily
62689457|NCT04989166|PLACEBO_COMPARATOR|Placebo|Placebo
61926222|NCT04808284|EXPERIMENTAL|tDCS-SMA|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the supplementary motor area (SMA) for 30 minutes.
62320372|NCT00708994|ACTIVE_COMPARATOR|THC|"* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
61926223|NCT04808284|EXPERIMENTAL|tDCS- DLPFC|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC) for 30 minutes.
62130068|NCT05174234||People living with HIV|a group of PLWHIV (n=400): women and men aged 18 to 60 years old from Haiti followed at the Cayenne Hospital, the Kourou Hospital or the West Guyanese Hospital (Saint Laurent du Maroni)
62130069|NCT05174234||People not living with HIV|a group of immigrants from Haiti not known to be infected with HIV (n=1600): women and men aged 18 to 60 years from Haiti
62130070|NCT05174234||People living with HBV|a group of PLWHBV (n=400): women and men aged 18 to 60 years old from Haiti followed at the Cayenne Hospital, the Kourou Hospital or the West Guyanese Hospital (Saint Laurent du Maroni)
62130071|NCT05086354|EXPERIMENTAL|One group that all receive the intervention of jumping rope.|All participants will be in one group. Every participant receives the same intervention.
61926224|NCT04808284|SHAM_COMPARATOR|tDCS- SHAM|Participants randomized to this arm will receive a single session of Sham tDCS for 30 minutes, delivered to supplementary motor area (SMA) or to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC).
61926225|NCT04765059|EXPERIMENTAL|Treatment Arm A|All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (\[AUC\] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles
61926226|NCT04765059|PLACEBO_COMPARATOR|Treatment Arm B|All randomized patients will receive placebo QD with pemetrexed (500 mg/m\^2) (with pre-treatment) plus either cisplatin (75 mg/m\^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m\^2) on Day 1 of 21-day cycles
61926227|NCT05715671|EXPERIMENTAL|Esketamine for induction 0.15mg/kg and maintenance 0.15mg/kg/h|
61926228|NCT05715671|EXPERIMENTAL|Esketamine for induction 0.3mg/kg and maintenance 0.3mg/kg/h|
61926229|NCT05715671|NO_INTERVENTION|No esketamine|
61926230|NCT03455959|EXPERIMENTAL|Allergic Asthmatic or Healthy Control Adults|Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL and airway brushing
61926231|NCT03955380|ACTIVE_COMPARATOR|Active Comparator: Contraloid 160 mg|160 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
61926232|NCT03955380|ACTIVE_COMPARATOR|Active Comparator: Contralod 320mg|320 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
61926233|NCT03955380|PLACEBO_COMPARATOR|Placebo Comparator (for Contraloid) 160 mg|160 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
61926234|NCT03955380|PLACEBO_COMPARATOR|Placebo Comparator (for Contraloid) 320 mg|320 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
61926235|NCT01999101|EXPERIMENTAL|Px-104|Px-104 capsules, 5 mg
61926236|NCT01927302|EXPERIMENTAL|Naming Deficits|Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
62689458|NCT03717454|EXPERIMENTAL|Drug treatment|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.
62130072|NCT00741455|EXPERIMENTAL|Study Treatment|Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate
62320373|NCT00708994|PLACEBO_COMPARATOR|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
62320374|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group 1|
62689459|NCT03717454|EXPERIMENTAL|Surgery|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.
62697439|NCT01765387|NO_INTERVENTION|Control group|"The control group perform a rest session in supine position in a room with neutral temperature condition with a same duration to Spa session. Participants of both groups are encouraged to drink water ad libitum to prevent dehydration."
61926237|NCT01927302|EXPERIMENTAL|Spelling and/or Writing Deficits|Language treatment will focus on improving writing and/or spelling deficits in people who have aphasia. An experimental group will receive treatment focusing on improving spelling abilities and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
61926238|NCT01927302|EXPERIMENTAL|Sentence Processing|Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
61926239|NCT04890067||Localized Osteosarcoma|This cohort include patients affected by localized Osteosarcoma, referred to participating Institutions.
61926240|NCT06395753|EXPERIMENTAL|Cohort 1: Debio 4228 Dose Level 1|Participants will receive a single intramuscular (IM) administration of dose level 1 Debio 4228 on Day 1.
61926241|NCT06395753|EXPERIMENTAL|Cohort 2: Debio 4228 Dose Level 2|Participants will receive a single IM administration of dose level 2 Debio 4228 on Day 1.
61926242|NCT06395753|EXPERIMENTAL|Cohort 3|If any alternative dose is deemed necessary based on preliminary data, participants may be enrolled in Cohort 3 to receive Debio 4228 loading dose IM, on Day 1 followed by a maintenance dose IM, 12 weeks after receiving the loading dose (Day 85).
61926243|NCT02262052|OTHER|Phase 4 cohort study|MRDTI
61926244|NCT03753490|OTHER|ABC score guided therapy|Individual treatment recommendations based on the ABC-scores for stroke and bleeding.
62130073|NCT04672018|EXPERIMENTAL|Test group (Houtou Jianeweiling tablet )|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
62130074|NCT04672018|ACTIVE_COMPARATOR|Control group (Omeprazole enteric-coated tablet)|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
62130075|NCT04996589||Lean subjects|BMI 18.5-22
61926245|NCT03753490|OTHER|Standard care|Management according to local practice, national and international guidelines.
61926246|NCT03127956|EXPERIMENTAL|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face
62130076|NCT04996589||Obese subjects|BMI\>30
62130077|NCT04032353|OTHER|Medical Consortium|subjects involved in medical consortium for screening upper gastrointestinal canccers(MCSC)
62130078|NCT04238793|EXPERIMENTAL|Cohort 1|Dose 1 (low dose: 1×1011 VG/500 μL solution) or Placebo
62130079|NCT04238793|EXPERIMENTAL|Cohort 2|Dose 2 (medium dose: 1×1012 VG/500 μL solution) or Placebo
62689460|NCT05550428|EXPERIMENTAL|Treatment group|Participants in the intervention group will be exposed to PEMF treatment by a PEMF device (Quantum Tx, Singapore). Alternate legs will be exposed to PEMF treatment for 10 minutes per session, and the treatment regime will run biweekly for 8 weeks, summing up 16 sessions of PEMF exposure in total. All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.
62130080|NCT04238793|EXPERIMENTAL|Cohort 3|Dose 3 (high dose: 1×1013 VG/500 μL solution) or Placebo
62130081|NCT06419569|EXPERIMENTAL|high power laser|thirty patients will receive high-power laser and conventional physical therapy three times a week for eight weeks
62130082|NCT06419569|EXPERIMENTAL|low level laser|thirty patients will receive low level laser and conventional physical therapy three times a week for eight weeks
62130083|NCT06419569|ACTIVE_COMPARATOR|conventional physical therapy|thirty patients will receive conventional physical therapy three times a week for eight weeks
62130084|NCT00929760|ACTIVE_COMPARATOR|nephrologists|Combined management PCP: nephrologists (at least 4 nephrology visits/year)
62130085|NCT00929760|ACTIVE_COMPARATOR|Primary Care Physicians|Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG
62130086|NCT04425551|ACTIVE_COMPARATOR|Treated|"The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias.~The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn.~After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes."
62130087|NCT04425551|NO_INTERVENTION|Untreated|The lateral eye was observed as control.
62130088|NCT05380336||Patients with the Nivolumab weight-dependent dosage|Patients treated for their metastatic cancer with Nivolumab, with a dosage calculated upon their weight (3mg/kg every two weeks).
62130089|NCT05380336||Patients with the Nivolumab fixed dosage|Patients treated for their metastatic cancer with Nivolumab, with a fixed-dose regimen of 240 mg every 2 weeks or 480 mg every 4 weeks
62130090|NCT04960098||patient underwent hip and knee arthroplasty|Patients with hip and knee osteoarthritis underwent hip and knee arthroplasty included in inclusion criteria.
62320375|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group 2|
62320376|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group 3|
62130091|NCT03981926|NO_INTERVENTION|In-Person|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek atopic dermatitis care from primary care practitioners or dermatologists, just as they would in the real world.
62130092|NCT03981926|EXPERIMENTAL|Team-Based Connected Health (TCH)|The intervention arm is the team-based connected health (TCH) model, which purports to increase access to specialists and improve outcomes. Specifically, TCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. TCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
62689461|NCT05550428|SHAM_COMPARATOR|Sham group|Participants in the intervention group will be exposed to PEMF treatment by a PEMF device (Quantum Tx, Singapore). Alternate legs will be exposed to PEMF treatment for 10 minutes per session, and the treatment regime will run biweekly for 8 weeks, summing up 16 sessions of sham exposure in total.All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.
62689462|NCT02136355|EXPERIMENTAL|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
62689463|NCT06511193||Budenoside/Glycopyrronium/Formoterol|Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
62689464|NCT03696186|ACTIVE_COMPARATOR|Luminal type-1|Standard treatment
62130093|NCT02326987|EXPERIMENTAL|GLA5PR GLARS-NF1 tab.150mg(fasted)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
62130094|NCT02326987|EXPERIMENTAL|GLA5PR GLARS-NF1 tab.150mg(after high fat meal)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
62689465|NCT03696186|EXPERIMENTAL|Luminal type-2|Experimental treatment
62689466|NCT03696186|ACTIVE_COMPARATOR|Neuroendocrine type-1|Standard treatment
62130095|NCT02326987|ACTIVE_COMPARATOR|Lyrica Capsule 75mg(after high fat meal)|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
62130096|NCT03582722|EXPERIMENTAL|Orlistat Weight Loss Aid|Participants randomized to take orlistat at the over-the-counter dose for six months. Diet and exercise plus a daily multivitamin will also be recommended and monitored.
62130097|NCT03582722|PLACEBO_COMPARATOR|Placebo|Participants randomized to take a placebo to match orlistat at the over-the-counter dose for six months. Diet and exercise plus a daily multivitamin will also be recommended and monitored.
62320377|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group 4|
62320378|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group 5|
62320379|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group 6|
62320380|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group 7|
62320381|NCT06352437|EXPERIMENTAL|Part A: BI 3034701 dose group|
62320382|NCT06352437|PLACEBO_COMPARATOR|Part A: Placebo|
62320383|NCT06352437|EXPERIMENTAL|Part B: BI 3034701 dose group 1|
62320384|NCT06352437|EXPERIMENTAL|Part B: BI 3034701 dose group 2|
62320385|NCT06352437|EXPERIMENTAL|Part B: BI 3034701 dose group 3|
62689467|NCT03696186|EXPERIMENTAL|Neuroendocrine type-2|Experimental treatment
61926247|NCT04534218|EXPERIMENTAL|Experimental|"REGORAFENIB:~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.~METRONOMIC CHEMOTHERAPIES:~* Capecitabine: 625mg/m²/orally twice daily continuously for 6 months~* Cyclophosphamide: 50 mg per os, daily, for 6 months~ASPIRIN:~75 mg orally and daily until progression"
61926248|NCT02193425|EXPERIMENTAL|PET FDG &amp; MRI Scans|The test-retest reproducibility of the gender and aging effects on FC measures (lFCD, C, L and S) acquired in RS and TS conditions.
62130098|NCT06516250|EXPERIMENTAL|Group with serious game|The participants will recived the same theoretical master classes and they will use the serious game for a series of hours and will be able to learn using this new teaching methodology, whether on a computer or mobile.
62130099|NCT06516250|NO_INTERVENTION|Group traditional methods of learning|They will not be able to use the application, its teaching method will be based on theoretical master classes.
62130100|NCT01303445|ACTIVE_COMPARATOR|Treatment A|Aggrenox alone
62130101|NCT01303445|EXPERIMENTAL|Treatment B|Aggrenox and omeprazole
62320386|NCT06352437|EXPERIMENTAL|Part B: BI 3034701 dose group 4|
62320387|NCT06352437|PLACEBO_COMPARATOR|Part B: Placebo|
62320388|NCT04925414|EXPERIMENTAL|oxygenotherapy|
62320389|NCT04925414|PLACEBO_COMPARATOR|placebo air aerosol|
62320390|NCT01984476||Older Able-Bodied Controls|Subjects must be between the age of 55 and 65 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (\<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
62320391|NCT01984476||Spinal Cord Injured|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must be injured between 5 to 10 years, level of injury between C1-T12, non-ambulatory (wheelchair dependent), and AIS grade of A or B. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (\<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
62320392|NCT01984476||Age-Matched Able-Bodied Controls|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (\<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
62130102|NCT01303445|ACTIVE_COMPARATOR|Treatment C|Omeprazole alone
62130103|NCT01303445|EXPERIMENTAL|Treatment D|Aggrenox and omeprazole
62320393|NCT01070784|EXPERIMENTAL|1|
62320394|NCT01070784|ACTIVE_COMPARATOR|2|
62320395|NCT06693843|EXPERIMENTAL|Cohort 1|Participants will receive GSBR-1290 or Placebo administered orally.
61926249|NCT04319783|EXPERIMENTAL|Darolutamide|Darolutimide 600mg BD
61926250|NCT04319783|EXPERIMENTAL|Local consolidation Radiotherapy + Darolutamide|Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease
62130104|NCT01448317|EXPERIMENTAL|Cohort 1|Alirocumab dose 1 versus placebo
62320396|NCT06693843|EXPERIMENTAL|Cohort 2|Participants will receive GSBR-1290 or Placebo administered orally.
62320397|NCT06693843|EXPERIMENTAL|Cohort 3|Participants will receive GSBR-1290 or Placebo administered orally.
62339751|NCT02669862|PLACEBO_COMPARATOR|Vehicle Solution|Vehicle Solution administered once per week
62130105|NCT01448317|EXPERIMENTAL|Cohort 2|Alirocumab dose 2 versus placebo
62130106|NCT01448317|EXPERIMENTAL|Cohort 3|Alirocumab dose 3 versus placebo
62130107|NCT01448317|EXPERIMENTAL|Cohort 4|Alirocumab dose 4 versus placebo
62130108|NCT04847414||prospective group|all needed data will be collected from patients in this group through performing full medical examination and doing all necessary investigations for them
62130109|NCT04847414||retrospective group|all needed data will be collected from medical records either electronic or paper based from different diabetes clinics in upper Egypt
62130110|NCT05284136|EXPERIMENTAL|Crohn's disease exclusion diet (CDED)|16-week course of Crohn's disease exclusion diet (CDED) and Partial Enteral Nutrition.
62689468|NCT03696186|ACTIVE_COMPARATOR|Atypical type-1|Standard treatment
62689469|NCT03696186|EXPERIMENTAL|Atypical type-2|Experimental treatment
62320398|NCT06693895|EXPERIMENTAL|VNS Group|Participants receive 1 dose of a VNS vaccine, 1 dose of measles, mumps, and rubella (MMR) vaccine, 1 dose of hepatitis A (HAV) vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
62320399|NCT06693895|ACTIVE_COMPARATOR|VV Group|Participants receive 1 dose of a marketed VV, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
62130111|NCT05284136|ACTIVE_COMPARATOR|Steroids|oral prednisolone at an initial dose of 40 to 60 mg/day.
62130112|NCT01002521||Cases|Persons With Diabetes (PWD) who have current non-healing ulcer(s)
62130113|NCT01002521||Controls|Persons With Diabetes (PWD) with no current ulcers and no history of ulcers
61926251|NCT05080309|SHAM_COMPARATOR|Control|During labor the women will have free access to water only but not fruit juice or other calory source.
62130114|NCT02570022|EXPERIMENTAL|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
62130115|NCT02570022|ACTIVE_COMPARATOR|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
62130116|NCT01864889|EXPERIMENTAL|anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
62130117|NCT04597684|ACTIVE_COMPARATOR|Treatment/Intervention|Total Knee Arthroplasty (TKA) with cementless knees
62130118|NCT04597684|ACTIVE_COMPARATOR|Control|Total Knee Arthroplasty (TKA) with cemented knees
62130119|NCT03437369|EXPERIMENTAL|Ivabradine|Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days
62130120|NCT03437369|OTHER|Standard of Care|The study drug will be compared with standard of Care treatment
62689470|NCT05878366|ACTIVE_COMPARATOR|Arm 1|SMC in children under the age of 5 years, implemented by the MoH without directly observed treatment for the full course of SMC
62320400|NCT01959555||Retrospective collection of data|
62320401|NCT03823937||Fibromyalgia|Diagnosed with ACR 2016 criteria
62320402|NCT03823937||Control|18-70 years healthy subjects
62320403|NCT03223220|EXPERIMENTAL|Study Drug|Will receive Ketamine infusion, and Midazolam (Versed).
62320404|NCT03223220|PLACEBO_COMPARATOR|Placebo|Will receive Normal saline infusion and Midazolam (Versed).
62320405|NCT05585411|EXPERIMENTAL|LBBAP group|In this arm, a left bundle branch area pacing(LBBAP) lead will be attempted to be placed.
62320406|NCT05585411|ACTIVE_COMPARATOR|RVP group|In this arm, a Right ventricular pacing (RVP) lead will be attempted to be placed.
62130121|NCT05284435|EXPERIMENTAL|iCBT-Email (iCBT-E)|Parents will receive a weekly email from a therapist over the 12 weeks of treatment.
62320407|NCT02031380|EXPERIMENTAL|Open angle glaucoma - iDropper device|Device
62320408|NCT01074411|EXPERIMENTAL|Treatment (bortezomib, carboplatin)|Patients receive bortezomib IP and carboplatin IP on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62320409|NCT02422043|EXPERIMENTAL|type 1 diabetes adolescents cohort|The participants of the prospective cohort of adolescents will be 12 to 17 years of age, type 1 diabetics with insulin, included in TPE program
62320410|NCT01591018|EXPERIMENTAL|cardiac surgery with sonolysis|cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring)
62320411|NCT01591018|PLACEBO_COMPARATOR|cardiac surgery without sonolysis|cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring)
62320412|NCT02995681|EXPERIMENTAL|Pulmonary rehab and balance training|The intervention group will receive standard pulmonary rehab plus additional balance training.
62320413|NCT02995681|ACTIVE_COMPARATOR|Pulmonary rehab|The control group will receive pulmonary rehab only and a pulmonary rehab home program (walking and lower extremity resistance exercises) upon discharge from pulmonary. They will also receive the same monthly phone calls and three home visits at three, six and nine months to ensure proper technique and progression.
62689471|NCT05878366|EXPERIMENTAL|Arm 2|SMC in children under the age of 5 years, with directly observed treatment for the full course of SMC
62689472|NCT05878366|EXPERIMENTAL|Arm 3|SMC in children under the age of 10 years, with directly observed treatment for the full course of SMC
62689473|NCT06639932|EXPERIMENTAL|We-INtervention group|The interventionists at each study site will be either healthcare providers (e.g., nurses), social workers, or psychologists with at least 3 years of experience serving HIV-serodiscordant male couples.
61926252|NCT05080309|EXPERIMENTAL|Carbohydrate|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
61926253|NCT01759134|EXPERIMENTAL|Post Discharge Formula|Babies will be given formula for first three months post discharge
61926254|NCT05045547||Patients with febrile illness|Febrile patients attending village malaria workers (VMWs)
61926255|NCT05045547||Health centre staffs|Health centre staffs from 12 rural health centres
61926256|NCT05045547||Key stakeholders|"Key stakeholders , for example health managers and health professionals:~* the director, deputy-directors, and technical officers at the National Malaria Control Program;~* the directors and deputy-directors of the Provincial Health Departments in Battambang and Pailin province;~* health officers actively involved in community-based (malaria) programmes at the district levels in Battambang and Pailin provinces;~* health workers (i.e., nurses or doctors) actively involved in community-based (malaria) programmes in Battambang and Pailin provinces;~* community representatives and village malaria workers from villages in both Battambang Pailin province."
61926257|NCT06480864|EXPERIMENTAL|Adebrelimab+Chemotherapy→Adebrelimab+ Apatinib|Participants will receive adebrelimab plus carboplatin /cisplatin and etoposide during the induction phase (4-6 cycles of three weeks.). Thereafter, participants will receive maintenance (after induction phase) adebrelimab plus apatinib until persistent PD, intolerable toxicity or withdrawal of consent.
61926258|NCT01805271|EXPERIMENTAL|Everolimus|1 or 2 tablets/day (i.e.5 or 10 mg/day )
61926259|NCT01805271|PLACEBO_COMPARATOR|Placebo|1 or 2 tablets/day
61926260|NCT05291689|EXPERIMENTAL|MORF-057|
61926261|NCT06743477|EXPERIMENTAL|Supergraft|Hypertransplantation is an innovative treatment plan of Professor Ai Huisheng's team, which uses hematopoietic stem cell transplantation from healthy donors who are haplotype compatible with the patient, and observes the patient's cell reinfusion response, hematopoietic reconstitution, hemoglobin level and blood transfusion, thalassemia clonal clearance, immune reconstitution, endocrine function recovery, gastrointestinal function recovery, as well as the incidence of graft-versus-host disease, infection and other complications after transplantation.
61926262|NCT05909176|EXPERIMENTAL|Start the Conversation Package|The pre-intervention phase will last for 4 months (months 1-4). The only study activity during the pre-intervention phase is the collection of routine PrEP uptake data to establish a baseline for PrEP prescribing at the GYN residency clinics and local PrEP clinics. The implementation of the combined-care model at the LSU GYN residency clinic at UMCNO for 10 months (months 5-14). Then we will add implementation of the social media campaign in the NOLA area for 4 months (months 5-18); implementation of the combined-care model at LSU GYN residency clinic at UMCNO will continue. The layered approach allows for an opportunity to assess the effect of the combined-care model, and subsequently, to what extent the social media campaign additionally engages Black women and builds demand for PrEP.
61926263|NCT05093933|EXPERIMENTAL|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily. The vericiguat dose will be titrated to 5 mg and to 10 mg.
62689474|NCT06639932|ACTIVE_COMPARATOR|Usual care group|The participants in the control condition will receive regular care.
61926264|NCT05093933|PLACEBO_COMPARATOR|Placebo|Participants receive a starting matching placebo to vericiguat dose of 2.5 mg taken orally once daily. The matching placebo dose will be sham titrated to 5 mg and to 10 mg.
61926265|NCT01314612|EXPERIMENTAL|Group Intervention|Subjects randomly assigned to this arm of the study will receive the 9-week insomnia and nightmare intervention group once per week for 90 minutes in addition to continuing treatment as usual with medical and mental health providers.
61926266|NCT01314612|NO_INTERVENTION|Treatment as Usual|This group is randomly assigned to receive only treatment as usual and does not receive the active intervention of the insomnia and nightmare group treatment. This treatment will be made available to these members once the study is completed
61926267|NCT02660398|NO_INTERVENTION|Controls|Our control group will consist of an observational cohort of 40 patients in whom we will make quantitative assessments of the Train-of-four ratio (TOF ratio). This is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
61926268|NCT02660398|OTHER|Intervention|The intervention consists of a protocol for intraoperative management of neuromuscular blockade with rocuronium and reversal with neostigmine. A train-of-four count of 4 at the thumb will be confirmed prior to administration of an adjusted dose of neostigmine. TOF ratio is measured in the same manner as for the Control group, it is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
61926269|NCT00689091|EXPERIMENTAL|BIS group|This group will have BIS values visible and will receive alerts when the value is \>60.
61926270|NCT00689091|ACTIVE_COMPARATOR|MAC Alert|This group will receive an alert if total MAC (including intravenous infusions) is \<0.5 age-adjusted.
62689475|NCT04279067|EXPERIMENTAL|BCI-FES dorsiflexion therapy with physiotherapy|"Subjects will undergo placement of an EEG cap using standard technique connected to our custom BCI system. Subjects will provide 5 min of training EEG data as they engage in alternating epochs of idling and attempted foot dorsiflexion (of the paretic side). In the online phase, the subjects will perform 20-25 BCI-FES runs. A total of 12 sessions will be performed at a rate of 3x/week (over 4 weeks). Each BCI-FES therapy session will be followed by 1 hour of conventional physiotherapy.~Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises."
62130122|NCT05284435|ACTIVE_COMPARATOR|iCBT-Email and Videoconferencing (iCBT-EV)|Parents will receive a weekly email and six 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
62697440|NCT00143845|EXPERIMENTAL|Immunosuppression Taper|Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).
62130123|NCT01791816|EXPERIMENTAL|Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)|
62130124|NCT03780686|ACTIVE_COMPARATOR|Dopamine and norepinephrine infusion|Infusion doppamine (2-5mcg/kg/min) and norepinephrine (3mcg/kg/h) with restricted fluid
62320414|NCT01505491|EXPERIMENTAL|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
62320415|NCT01505491|ACTIVE_COMPARATOR|adalimumab - US|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
62320416|NCT01505491|ACTIVE_COMPARATOR|adalimumab - EU|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
62320417|NCT05758441|EXPERIMENTAL|Mentoring to be Active plus Family (MPBA+F)|"For the first phase, ten peer-mentoring sessions (1 day/week for 45 minutes each week) delivered virtually with a Project Leader, five peer mentors, and 8-10 mentees with 1:2 mentor/mentee ratios. Each session consists of a 10-15 minute content lesson followed by 20-30 minutes of guided practice, social support, feedback, and personal goal-setting for the following week in small peer mentor/mentee break-out rooms. Mentees track activities and efforts towards meeting personal goals. Parents return their child's weekly completed 'Tracker forms either electronically via the secure, password-protected project website or (if they prefer) by regular pre-paid mail service. The reinforcement component of MPBA+F is a guided, parent-directed 6-module (0nce a month for 6 months) program for parents/guardians to further support the child's home-based PA. Child participants assigned to MPBA will be provided the modules."
62320418|NCT05758441|ACTIVE_COMPARATOR|Tracking Health and Fitness|"Half of child participants will receive Tracking your Health and Fitness, a comparison program of 10 weekly, self-guided modules from Ohio State University (OSU) Extension mailed to their home.~Child participants assigned to the Tracking Health and Fitness program (comparison group) may voluntarily participate in a 6-month rewards-based self-regulation program to encourage sustainability of weekly PA."
62320419|NCT03743558|EXPERIMENTAL|children with adenoamygdala hypertrophy|
62130125|NCT03780686|ACTIVE_COMPARATOR|Norepinephrine|Infusion norepinephrine (3mcg/kg/h) with restricted fluid.
62130126|NCT03780686|NO_INTERVENTION|Standard fluid management|Standard fluid managements.
62130127|NCT06006611||Azvudine group|Azvudine group included COVID-19 patients treated with azvudine antiviral therapy;
62130128|NCT06006611||No antiviral group|No antiviral group included COVID-19 patients treated with no antiviral therapy;
62130129|NCT06006611||Monotamivir|Monotamivir group included COVID-19 patients treated with monotamivir antiviral therapy
62130130|NCT03657030|ACTIVE_COMPARATOR|Single Ascending Dose|The planned dose levels will be 1, 5, 25, 75, and 225 mg CVN424 and matching placebo.
61926271|NCT01926665|EXPERIMENTAL|Carfilzomib|Carfilzomib given in four doses, days 1, 2, 15 and 16, every 28 days for 6 months starting within 6 months post ASCT. Doses given in an escalated phase 1 design, starting at 20/20 mg/m2, later increased to 20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2. CFZ dose based on actual body surface area at baseline (cycle 1). Patients with a body surface area (BSA) greater than 2.2 m2 receive dose based upon a 2.2 m2 BSA. Adjustments are not made if weight gains or losses are less than or equal to 20% from baseline. Dexamethasone 4 mg by vein or mouth prior to each CFZ dose in cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, then it should be restarted and administered prior to subsequent doses for reactions.
61926272|NCT02480985|OTHER|Pituitary function evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to determine the risk factors and the outcome associated with pituitary disorders.
61926273|NCT03381274|EXPERIMENTAL|Oleclumab Dose 1 + Osimertinib Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab (MEDI9447) Dose 1 every 2 weeks (Q2W) and oral osimertinib Dose 1 once daily (QD).
61926274|NCT03381274|EXPERIMENTAL|Oleclumab Dose 2 + Osimertinib Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD. In Part 2 (dose-expansion), participants (including participants dosed at the RP2D in Part 1) will receive IV oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD until documentation of disease progression, intolerable toxicity, or development of other reason for treatment discontinuation, whichever occurs first.
61926275|NCT03381274|EXPERIMENTAL|Oleclumab Dose 1 + AZD4635 Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 1 QD.
61926276|NCT03381274|EXPERIMENTAL|Oleclumab Dose 1 + AZD4635 Dose 2|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 2 QD.
61926277|NCT03381274|EXPERIMENTAL|Oleclumab Dose 2 + AZD4635 Dose 2|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 2 Q2W and oral AZD4635 Dose 2 QD.
61926278|NCT06575452|OTHER|Cohort 1|"Prospective cohort: 80 patients and 20 healthy volunteers~* Grade 2 mutated Isocitrate Dehydrogenase (IDH) glioma: 20 patients~* IDH mutated grade 3 glioma: 20 patients~* Glioblastoma (GBM), IDH wild-type: 40 patients"
61926279|NCT06575452|OTHER|Cohort 2|"Retrospective cohort: 120 patients~* Grade 2 mutated Isocitrate Dehydrogenase (IDH) glioma: 40 patients~* IDH mutated grade 3 glioma: 40 patients~* Glioblastoma, IDH wild-type: 40 patients"
61926280|NCT06575452|OTHER|Cohort 3|Spatial epitranscriptomic cohort: 8 patients (grade 2 mutated Isocitrate Dehydrogenase (IDH ) glioma with grade 3 or grade 4 focus
61926281|NCT06664853|EXPERIMENTAL|Dexamethasone sodium phosphate|intravenous (IV) infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)
61926282|NCT06659679||New use of oral semaglutide|Exposure group
61926283|NCT06659679||New use of sitagliptin|Reference group
62130131|NCT03657030|ACTIVE_COMPARATOR|Multiple Ascending Dose|The planned dose levels will be 25, 75, and 150 mg CVN424 and matching placebo.
62130132|NCT01216722|EXPERIMENTAL|Resistance Strengthening|Body weight antigravity positioning and elastic resistance bands are used to provide resistance for strengthening in supine, sitting, and standing in subjects post liver transplant.
62130133|NCT01216722|NO_INTERVENTION|Usual Care Control|Subjects perform the usual care of progressive ambulation and increased activity post liver transplant
62130134|NCT04030624|EXPERIMENTAL|Remote Electronic Patient Monitoring|"* The Remote Electronic Patient Monitoring intervention will entail monitoring of vital sign data and patient reported assessments to address and manage any concerning issues identified.~* The Remote Patient Monitoring system uses algorithms that can indicate when patient vitals and patient-reported outcomes have changed.~* Automatic patient surveys are sent to the patient with results displayed on the clinician user interface (i.e., dashboard) on a computer located in the clinical area.~* Qualitative interviews with patient participants and their oncology clinicians using a semi-structured interview guide will be conducted."
62130135|NCT02025257|EXPERIMENTAL|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
62130136|NCT02025257|NO_INTERVENTION|Control|Patients are asked to live as usual.
62320420|NCT01728272|EXPERIMENTAL|blood concentration of metoprolol|how does off-pump miniperfusion and perfusion CABG influence the absorption of metoprolol after CABG
62320421|NCT04869956|OTHER|Standard diet|Dietary pattern: Standard diet
62320422|NCT04869956|EXPERIMENTAL|High - Fiber diet rich in PUFA|High - Fiber diet rich in PUFA
61926284|NCT06667687|EXPERIMENTAL|Escalation: Non-Hodgkin Lymphoma (NHL) ABBV-291|Participants with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), except chronic lymphocytic leukemia (CLL), will receive escalating doses of ABBV-291, as part of the 74 month study duration.
61926285|NCT06667687|EXPERIMENTAL|Expansion: Diffuse Large B-Cell Lymphoma (DLBCL) ABBV-291|Participants with R/R DLBCL will receive the recommended Phase 1 expansion dose (RP1ED) of ABBV-291, as part of the 74 month study duration.
62130137|NCT01240434|ACTIVE_COMPARATOR|Fascia closure of the surgical trocars|Arm in which all the surgical trocar orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone)
62130138|NCT01240434|NO_INTERVENTION|Trocar site without closure|All the orifices of the trocar site are left open, closing only the skin.
62320423|NCT04736511|OTHER|Healthy volunteers|Handball players
62320424|NCT04429425|OTHER|EA group|patients with colorectal surgery that willl be performed epidural anesthesia
62320425|NCT04429425|NO_INTERVENTION|non -EA group|patients with colorectal surgery that willl be performed only general anesthesia
62320426|NCT04743882||A|
62320427|NCT04743882||B|
62320428|NCT04743882||C|
62320429|NCT02944799|ACTIVE_COMPARATOR|Alendronate|Continues treatment with alendronate, 70mgs oral tablet once every week
62320430|NCT02944799|PLACEBO_COMPARATOR|Placebo|Placebo tablets, one every week
62320431|NCT02111824|EXPERIMENTAL|Group 2|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
62697441|NCT06402305||group A|Cases
62697442|NCT06402305||group B|Controls
62320432|NCT02111824|EXPERIMENTAL|Group 3|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
62320433|NCT02111824|NO_INTERVENTION|Group 1|Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.
62320434|NCT01383044|EXPERIMENTAL|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
62320435|NCT01383044|ACTIVE_COMPARATOR|carvedilol|carvedilol 6.25-12.5 mg per day
62320436|NCT02154269|EXPERIMENTAL|G-CSF|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
62689476|NCT04279067|EXPERIMENTAL|Dose-and intensity-matched physiotherapy|"Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.~In the dose-matched control group (Group 2), it will be 2 hours/session."
62689477|NCT04914273|EXPERIMENTAL|Sequence A: 1. Ingestion 2. Inhalation|Group A is treated in the following sequence: 1. oral drug 2. inhalative drug
62689478|NCT04914273|EXPERIMENTAL|Sequence B: 1. Inhalation 2. Ingestion|Group B is treated in the following sequence: 1. inhalative drug 2. oral drug
62697443|NCT05888922|EXPERIMENTAL|Active group|Oral minoxidil 1 mg (1 tablet, OD) + topical vehicle solution (1 ml, BID)
62697444|NCT05888922|ACTIVE_COMPARATOR|Control group|Oral placebo (1 tablet, OD) + topical 2% Minoxidil solution (1 ml, BID)
62480877|NCT04376190|EXPERIMENTAL|laser group|12 patients treated with twin block functional appliance with low-level laser application with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. The laser was applied at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points. Laser application was repeated weekly for three months according to a standard protocol
62689479|NCT03518060||Participants who received JULUCA|Virologically suppressed HIV positive participants, on a stable antiretroviral regimen, who switched to the 2-Drug Regimen JULUCA (Dolutegravir \[DTG\] / Rilpivirine \[RPV\]) were included in the study. Participants were followed-up for approximately 3 years during routine clinical practice.
62689480|NCT02320552||PD patients|Patients receiving peritoneal dialysis. No intervention
62689481|NCT02320552||HD patients|Patients receiving hemodialysis. No intervention
62689482|NCT05942222|ACTIVE_COMPARATOR|Dupilumab week 0-24 300 mg/2 weeks|Normal dose and interval of Dupixent i.e. 300 mg s.c. every 2 weeks
62689483|NCT05942222|ACTIVE_COMPARATOR|Mepolizumab week 0-24 100 mg/4 weeks|Normal dose and interval of Nucala i.e. 100 mg s.c. every 4 weeks
62689484|NCT05942222|ACTIVE_COMPARATOR|Dupilumab week 24-48 300 mg/4 weeks|Increased dosage interval of Dupixent i.e. 300 mg s.c. every 4 weeks - for subjects on Dupixent who met the 24 weeks effect criteria
62689485|NCT05942222|ACTIVE_COMPARATOR|Dupilumab week 24-48 300 mg/2 weeks|Normal dose and interval of Dupixent i.e. 300 mg s.c. every 2 weeks but for subjects who have crossed over after 24 weeks due to unmet effect criteria.
62689486|NCT05942222|ACTIVE_COMPARATOR|Mepolizumab week 24-48 100 mg/4 weeks|Normal dose and interval of Nucala i.e. 100 mg s.c. every 4 weeks but for subjects who have crossed-over after 24 weeks due to unmet effect criteria.
62689487|NCT03605550|EXPERIMENTAL|Treatment (PTC596)|PTC596 administered orally twice weekly (M/Th or T/F schedule) concomitantly with RT for 6 -7 weeks. Each subsequent cycle is defined as 28 days. Post RT patients will continue to receive PTC596 twice weekly for up to 26 cycles at RP2D of 200mg/m2 with a maximum dose capped at 400mg for patients with BSA ≥2.0
62689488|NCT02167347|EXPERIMENTAL|Family Intervention|Culturally Adapted Family intervention for Psychosis Sessions will be offered weekly basis
62689489|NCT02167347|NO_INTERVENTION|Control|"Caregiver ' s Patients who will be randomized to the treatment as usual arm will receive routine care"
62689490|NCT03320993|ACTIVE_COMPARATOR|Low Protein-Low Fat study|Subjects will receive a mixed meal with carbohydrates (70g) plus a low content of proteins and fats
62689491|NCT03320993|EXPERIMENTAL|High Protein-High Fat study|Subjects will receive a mixed meal with the same carbohydrates content of arm 1 (70g), but a greater amount of fats and proteins
62689492|NCT03320993|EXPERIMENTAL|High Protein-High Fat & alcohol study|Subjects will receive the same mixed meal of the High Protein-High Fat study plus 0,7g of alcohol per Kg of weight
62689493|NCT05392283|EXPERIMENTAL|Vacuum cupping|
62480878|NCT06730815||Hungarian women treated for breast cancer|
62480879|NCT06449066||Patients|CEREDIH (centre de reference des deficits immunitaires héréditaires) cohort Female patients, alive and \> 18 years old, registered at the CEREDIH who gave birth in an APHP maternity
62689494|NCT04046991|ACTIVE_COMPARATOR|HD-tDCS+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.
62689495|NCT04046991|SHAM_COMPARATOR|Sham+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,
62689496|NCT00775671|ACTIVE_COMPARATOR|Nebivolol|Nebivolol 5mg by mouth daily for 12 weeks.
62689497|NCT00775671|ACTIVE_COMPARATOR|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
62689498|NCT01162785|EXPERIMENTAL|First Dose SCH 721015|Part1: 2 Instillations of intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume
62689499|NCT01162785|EXPERIMENTAL|Second Dose SCH 721015|Part 2: Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration of SCH 721015 with Syn3 on same Day 1 and Day 4 regimen at same dose level.
62689500|NCT04585581|EXPERIMENTAL|diet + training|
62689501|NCT04585581|ACTIVE_COMPARATOR|controls|
62689502|NCT00576745|ACTIVE_COMPARATOR|1 Vicryl Suture|Patients will have their incision closed with vicryl suture
62689503|NCT00576745|EXPERIMENTAL|2 Steri-Strips|Patients will have their incisions closed with 3M Surgical-Strips
62130139|NCT03201822|EXPERIMENTAL|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
62320437|NCT02154269|PLACEBO_COMPARATOR|Saline|Subjects will be randomly assigned to receive saline for five days, during 4 cicles.
62689504|NCT03766906|EXPERIMENTAL|Talk STEM Familia App|This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.
62689505|NCT06198777||Healthy adults|
62689506|NCT05351229|PLACEBO_COMPARATOR|Placebo|Placebo, Intrathecal saline
62130140|NCT03201822|EXPERIMENTAL|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
62130141|NCT03201822|EXPERIMENTAL|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
62130142|NCT03201822|EXPERIMENTAL|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
62130143|NCT04272645|EXPERIMENTAL|Arm A - Abemaciclib 200 mg|Abemaciclib twice daily. 1 cycle of treatment is 21 days in length.
62130144|NCT04272645|EXPERIMENTAL|Arm B - Abemaciclib 150 mg + atezolizumab|Atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily.
62130145|NCT04272645|EXPERIMENTAL|Experimental: Arm C - Patients with CDK12 loss|"Group 1 - Atezolizumab: Patients with CDK12 loss will receive atezolizumab monotherapy on the first day of each 21-day cycle~Group 2 - Abemaciclib 150 mg + atezolizumab: Patients with CDK12 loss will receive atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily."
62130146|NCT04324450|EXPERIMENTAL|Patients radiotherapy +|Patients cured of a brain tumour and who have received radiotherapy in childhood
62130147|NCT04324450|EXPERIMENTAL|Patients radiotherapy -|Patients cured of a brain tumour and who have received surgery and/or chemotherapy but were not irradiated
62130148|NCT04324450|EXPERIMENTAL|Healthy volunteers|"Healthy volunteers (control group) matched in age, manual laterality, gender and parental education to Patients radiotherapy +"
62130149|NCT04929067|EXPERIMENTAL|Immunotherapy combined with neoadjuvant chemotherapy forlocally advanced HNSCC|
62130150|NCT05760235|EXPERIMENTAL|Liver transplant obese candidates|Subjects with an indication to liver transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2)
62130151|NCT04190316|OTHER|Evaluation of patient and patient-care environment ESBL|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
62130152|NCT06145568||Pregnant Women|Pregnant Women
62130153|NCT02894658|EXPERIMENTAL|Lipiflow system|Treatment through the use of heat and pulsatile pressure.
62480880|NCT06742229|OTHER|Group 1: Pregnant Subjects|This group is for pregnant subjects. They will have two ultrasound scans performed- One will be the standard of care ultrasound scan and the other will be research scan
62689507|NCT05351229|ACTIVE_COMPARATOR|Morphine|Intrathecal morphine
62480881|NCT06742229|OTHER|Group 2- Non pregnant Subjects|This group is for non-pregnant subjects. They will have one ultrasound scan performed- it will be the research scan
62480882|NCT06737445|ACTIVE_COMPARATOR|Radiofrequency thermal lesioning (RTL)|RTL was performed as a single session using the radiofrequency ablation device (NeuroTherm JK4A; NeuroTherm Ltd, Croydon, London, England).
62480883|NCT06737445|ACTIVE_COMPARATOR|Extracorporeal shock wave therapy (ESWT)|Patients underwent 3 ESWT sessions applied to the plantar heel area, once a week with the same ESWT dose (15 Hz, 2000 pulse, 4.0 bar energy density) using a BTL-5000 SWT device (BTL Industries, USA).
62480884|NCT06737445|ACTIVE_COMPARATOR|Corticosteroid Injection|An injection of 1 ml of betamethasone 40 mg/ml and 2 ml of bupivacaine 5 mg/ml was performed.
62480885|NCT05954741|ACTIVE_COMPARATOR|Group 1|Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset \< 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
62689508|NCT03092011|EXPERIMENTAL|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
62130154|NCT02894658|ACTIVE_COMPARATOR|Fellow eye warm compresses|Warm compresses to fellow eye and daily treatment with eyelid scrubs.
62689509|NCT03092011|ACTIVE_COMPARATOR|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
62689510|NCT04501705|EXPERIMENTAL|test group|
62689511|NCT03735901|ACTIVE_COMPARATOR|Experimental Intervention|White Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg.
62689512|NCT03735901|PLACEBO_COMPARATOR|Control Intervention|Matching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group.
62697445|NCT05888922|PLACEBO_COMPARATOR|Placebo group|oral placebo (1 tablet, OD) + topical vehicle solution (1 ml, BID)
62130155|NCT01737489|ACTIVE_COMPARATOR|LACE ( Listening And Communication Enhancement )|use the commercially available auditory training program which is administered by computer as daily lessons.
62130156|NCT01737489|ACTIVE_COMPARATOR|NOOK (Electronic reader)|will use an electronic reader (NOOK device) to do speech tracking
62130157|NCT01737489|NO_INTERVENTION|Control|
62130158|NCT05551455|OTHER|Normal Carbohydrate Availability|"Participants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period.~In the Normal Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit a net energy availability of 45 kcal/kg FFM, with \~60% of this energy intake from carbohydrates.~The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5)."
62130159|NCT05551455|EXPERIMENTAL|Low Carbohydrate Availability|"Participants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period.~In the Low Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit an energy availability of 45 kcal/kg FFM, with \~1.5 g/kg provided from carbohydrate and \~70-80% of energy intake in the form of fat.~The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5)."
62130160|NCT00507338|EXPERIMENTAL|ARC1779 low dose|0.1 mg/kg
62130161|NCT00507338|EXPERIMENTAL|ARC1779 mid dose|0.3 mg/kg
62130162|NCT00507338|EXPERIMENTAL|ARC1779 high dose|1.0 mg/kg
62130163|NCT00507338|ACTIVE_COMPARATOR|abciximab|labeled regimen for primary PCI
62130164|NCT02387242|EXPERIMENTAL|Group 1|10mg/kg Rifampicin
62130165|NCT02387242|EXPERIMENTAL|Group 2|20mg/kg Rifampicin
62130166|NCT02387242|EXPERIMENTAL|Group 3|30mg/kg Rifampicin
62130167|NCT04481074|EXPERIMENTAL|Inspiratory muscle training group|Group intervention: home-based interval inspiratory muscle training during 8 weeks, two sessions with two sets of 30 breaths with one minute rest between them. Load set is determinated weekly, aiming 50% of actual PImax and according to Borg Score.
62130168|NCT02724592|EXPERIMENTAL|intervention|intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
62130169|NCT02724592|ACTIVE_COMPARATOR|control|control group, only Fluoride varnish (Duraphat®)
62130170|NCT03501264|EXPERIMENTAL|Intervention group|This group receives the game
62130171|NCT03501264|ACTIVE_COMPARATOR|Control Group|This group receives LGBTQ resources only
62130172|NCT00813657|EXPERIMENTAL|Lifestyle counseling|
62130173|NCT03917303|ACTIVE_COMPARATOR|Adalimumab|Episodic adalimumab monotherapy as first line treatment for 6 months
62130174|NCT03917303|ACTIVE_COMPARATOR|Standard step-up care|Step-up care as first line treatment, starting with corticosteroids.
62130175|NCT06517875|EXPERIMENTAL|Momelotinib + Luspatercept|Participants with transfusion dependent primary myelofibrosis or post- PV/ ET myelofibrosis that is JAKi naïve or JAKi experienced will receive momelotinib and luspatercept.
62480886|NCT05954741|ACTIVE_COMPARATOR|Group 2|Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset \< 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
62480887|NCT05954741|ACTIVE_COMPARATOR|Group 3|Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset \< 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
62130176|NCT00168753|EXPERIMENTAL|1|
62480888|NCT02102191|ACTIVE_COMPARATOR|cigarette|common cigarette sold in the stores
62480889|NCT02102191|ACTIVE_COMPARATOR|e-cigarette|e-cigarette (Ovale Elips)
62130177|NCT03014375|EXPERIMENTAL|Etamicastat|Single administration. 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 50 mg, hard gelatina capsules
62130178|NCT05901896||study group|The study group consists of five volunteers who originally lived in a plain area. They will be living in a high-altitude region for one year.
62130179|NCT05901896||control group|Five healthy residents living on the high-altitude region , matched 1:1 by age, gender, and race, will serve as control group.
62130180|NCT06299228|EXPERIMENTAL|Experimental Group|The experimental group will receive sensorimotor intervention and traditional hand therapy
62320438|NCT04452812|EXPERIMENTAL|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
62130181|NCT06299228|EXPERIMENTAL|Control Group|Control Group will receive Hand Therapy only
62130182|NCT04277936|EXPERIMENTAL|Levetiracetam (LEV) 500 mg|Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
62130183|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
62130184|NCT02755415|ACTIVE_COMPARATOR|Static Standing Table Training|Patients in this group will receive standard hospital based rehabilitation as well as static standing table training
62130185|NCT02755415|EXPERIMENTAL|Robotic Gait Training|Patients in this group will receive standard hospital based rehabilitation as well as robot-assisted gait rehabilitation training
62320439|NCT04452812|PLACEBO_COMPARATOR|Best available treatment|"Best available treatment + Placebo (0.9% saline solution)~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Placebo will consist on 2 doses of 200 ml of 0.9% saline solution separated on a 12 hour interval."
62320440|NCT02782455|EXPERIMENTAL|CDobi|Calcium dobesylate is given in this group
62320441|NCT02782455|ACTIVE_COMPARATOR|Flavono|Flavonoids are given in this group
62320442|NCT04592276|EXPERIMENTAL|PS128|Each PS128 capsule contained 3 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg .
62480890|NCT05864807|EXPERIMENTAL|Interventional arm|Electrical stimulation to the dorsal genital nerve.
62130186|NCT02256254|ACTIVE_COMPARATOR|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
62480891|NCT02165007|EXPERIMENTAL|peripheral blood stem cell graft that are CD34+ selected|peripheral blood stem cell graft that are CD34+ selected. All patients will undergo reduced intensity conditioning regimen which followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device and Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year (see intervention).
62480892|NCT06741514||Parents or Legal Gaurdians|Parents or legal guardians of patients who were enrolled in the Precice IMLL arm of the retrospective data collection study (NUVA.IMLL0723).
62697446|NCT06197724||Training and testing cohort|
62130187|NCT02256254|PLACEBO_COMPARATOR|Placebo|2 placebo capsules every evening for 14 days
62130188|NCT05067621|EXPERIMENTAL|Receive treatment|Semaglutide (Wegovy) pen is a subcutaneous injection
62130189|NCT05067621|PLACEBO_COMPARATOR|Placebo|The placebo pen is almost exactly the same as the Wegovy subcutaneous injection except it does not contain the active ingredient, Semaglutide.
62130190|NCT03742050|ACTIVE_COMPARATOR|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
62130191|NCT03742050|PLACEBO_COMPARATOR|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention
62130192|NCT04958798|EXPERIMENTAL|Culturally Centered MOUD Implementation|Culturally centered program-level implementation intervention to increase the use of medications for opioid use disorder in healthcare and treatment settings serving AI/AN communities
62130193|NCT01211405|ACTIVE_COMPARATOR|Low dose MDMA|Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
62320443|NCT04592276|PLACEBO_COMPARATOR|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
62320444|NCT02385461||Inherited Thrombophilia|Women with Common Inherited Thrombophilias and previous foetal loss
62130194|NCT01211405|ACTIVE_COMPARATOR|Medium dose MDMA|Participants will receive 75 mg MDMA on each of two blinded experimental sessions
62689513|NCT06632860|EXPERIMENTAL|Experimental: 68Ga-TATE-RGD PET/ CT scan|About 30 patients with positive expression of somatostatin receptor SSTR2 and integrin receptor αvβ3 were included for PET imaging.
62689514|NCT04776824||Patients with confirmed amyloidosis|Confirmed diagnosis of amyloidosis w/wo cardiac involvement
62697447|NCT06197724||External validation cohort|
61926286|NCT06667687|EXPERIMENTAL|Expansion: Follicular Lymphoma (FL) ABBV-291|Participants with R/R FL will receive the RP1ED of ABBV-291, as part of the 74 month study duration.
61926287|NCT06667687|EXPERIMENTAL|Optimization: Mantle Cell Lymphoma (MCL) ABBV-291 Dose A|Participants with R/R MCL will receive the dose A of ABBV-291, as part of the 74 month study duration.
61926288|NCT06667687|EXPERIMENTAL|Optimization: MCL ABBV-291 Dose B|Participants with R/R MCL will receive the dose B of ABBV-291, as part of the 74 month study duration.
62130195|NCT01211405|EXPERIMENTAL|Full dose MDMA|Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.
62130196|NCT03958136|EXPERIMENTAL|Patients HR + and HER2-|"At each disease progression, patient will have specific interventions :~* Metastasis biopsy~* Biomarkers blood, urine and microbiota samples~* Patient Reported Outcome (PRO)"
62130197|NCT03958136|EXPERIMENTAL|Patients HER2 + with or without HR+|"At each disease progression, patient will have specific interventions :~* Metastasis biopsy~* Biomarkers blood, urine and microbiota samples~* Patient Reported Outcome (PRO)"
62130198|NCT03958136|EXPERIMENTAL|Patients triple negative (HR- and HER2-)|"At each disease progression, patient will have specific interventions :~* Metastasis biopsy~* Biomarkers blood, urine and microbiota samples~* Patient Reported Outcome (PRO)"
62697448|NCT06583720|EXPERIMENTAL|Control group|Participants in this group will perform brushing, dental floss and tongue scraper.
62697449|NCT06583720|EXPERIMENTAL|aPDT group|Participants in this group will receive brushing, dental floss, tongue scraper and aPDT with blue LED and annatto.
62697450|NCT06583720|EXPERIMENTAL|aPDT and Probiotics group|Participants in this group will receive brushing, dental floss, lingual scraper and aPDT with blue LED, annatto and probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®).
62130199|NCT02432950|EXPERIMENTAL|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
62130200|NCT02422784|PLACEBO_COMPARATOR|Control|Participants will be instructed to consume 240 mL of iced-tea daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
62130201|NCT02422784|ACTIVE_COMPARATOR|Rooibos Tea - Vitamin D3|Participants will be instructed to consume 240 mL of iced-tea fortified with 1000 IU water-soluable vitamin D3 daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
62320445|NCT02385461||Other Thrombophilias with Pregnancy loss|Women with Thrombophilias other than common inherited thrombophilias and previous foetal loss
62320446|NCT02385461||No thrombophilia|Women without thrombophilias and previous foetal loss
62320447|NCT02188121|EXPERIMENTAL|Statin and/or Angiotensin Receptor Blocker|Simvastatin 20mg PO daily and/or Losartan 25mg PO daily
62320448|NCT02188121|NO_INTERVENTION|Usual treatment|"We will compare the initial treatment intervention with usual treatment (control arm), with both arms superimposed on a system of regular monitoring base. The investigators will make no effort to alter or influence treatment or use of that treatment for subjects in the control arm. Note that our goal in the Control arm is to characterize usual treatment. We will not intervene in this care except in emergencies. Some patients who need care for metabolic syndrome may not be receiving it - just as they would if not in our trial."
62320449|NCT02412644|ACTIVE_COMPARATOR|Apremilast + apremilast|apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
62320450|NCT02412644|PLACEBO_COMPARATOR|apremilast + placebo|apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks
62320451|NCT04302389|EXPERIMENTAL|Lifestyle Modification Program|This 6-month intervention includes the use of three components: WW's mobile app, virtual workshops, and a private online community. The WW Program involves: self-monitoring of weight, dietary intake, and physical activity; making dietary changes; increasing physical activity; shifting to a more helpful mindset; and learning behavioral strategies to manage these goals. Each week, participants will set goals and weigh-in with a coach via virtual workshop. Participants will be encouraged to use the app and private online community daily and attend weekly virtual workshops. The weekly virtual workshop led by a trained WW Coach features a behavior change technique and enables the participant to practice it to support their goals. These are actionable techniques and strategies that are grounded in scientific research.
62320452|NCT03622164|ACTIVE_COMPARATOR|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
62320453|NCT03622164|EXPERIMENTAL|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
62320454|NCT01084616||Vaginal Dryness|
62320455|NCT01084616||Non-vaginal dryness|
62320456|NCT02433210|ACTIVE_COMPARATOR|Solute Clearance|Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
62320457|NCT02433210|ACTIVE_COMPARATOR|Hemocompatibility|Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
62320458|NCT02433210|ACTIVE_COMPARATOR|Solute removal rate|Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .
62320459|NCT01043523||Group 1|
62320460|NCT04291417||CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis. Results will not be used to manage patients.
62320461|NCT01011192||ke0 of 0.26 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 0.26 min-1 (Asena PK® - Cardinal Health)
62320462|NCT01011192||ke0 of 1.21 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 1.21 min-1 (Primea Orchestra® - Fresenius-Kabi basis)
62320463|NCT05265845|EXPERIMENTAL|Intervention|Interactive text messages that include goal setting, tailored feedback, and skills training.
62320464|NCT05265845|ACTIVE_COMPARATOR|Control|Text4Baby
62320465|NCT03976739||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
62320466|NCT03976739||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
62320467|NCT03976739||gastric cancer|patients with gastric cancer according to histopathological results
62320468|NCT04328623|ACTIVE_COMPARATOR|Infiltration|Ultrasound-guided hand infiltration
62320469|NCT04328623|EXPERIMENTAL|Hypnosis|Hypnosis before Ultrasound-guided hand infiltration
62339752|NCT06179615|OTHER|complete denture with prefabricated artificial teeth|complete denture constructed with prefabricated artificial teeth and inserted in the patient mouth to be used for 3, 6 months
61926289|NCT06667687|EXPERIMENTAL|Optimization: MCL ABBV-291 Dose C|Participants with R/R MCL will receive the dose C of ABBV-291, as part of the 74 month study duration.
61926290|NCT06367972|EXPERIMENTAL|NLST Arm|"Participants are assigned to Group 1, participants will be treated with next-line systemic therapy. The specific next-line systemic therapy will be determined by your doctor.~- If progression occurs (the disease gets worse), participants may cross over to Group 2 and receive LCT."
61926291|NCT06367972|EXPERIMENTAL|LCT Arm|Participants are assigned to Group 2, participants will be treated with LCT and then continue on same systemic therapy participants have been receiving followed by the next line systemic of therapy (if applicable). The specific treatments will be determined by your doctor.
61926292|NCT01863550|EXPERIMENTAL|Arm A (bortezomib, lenalidomide, dexamethasone)|Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
61926293|NCT01863550|EXPERIMENTAL|Arm B (carfilzomib, lenalidomide, dexamethasone)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
62689515|NCT02973022||Community CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group in the community will be exposed to the modified CC\&S educational sessions in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational sessions. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
61926294|NCT01863550|EXPERIMENTAL|Arm C (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
62130202|NCT02422784|ACTIVE_COMPARATOR|Rooibos Tea- Vitamin D3 & Calcium|Participants will be instructed to consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water-soluable vitamin D3 and 360 mg of calcium daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
62130203|NCT03888768|ACTIVE_COMPARATOR|ProPBM|Pre-operative: patient will be screened for iron deficiency and anemia and administered IV monofer Intra-operative:IV tranexamic Acid 1gm will be administered at the beginning of surgery and blood transfusion triggered by Allowable blood loss Post-operative: IV Iron monofer will be given to those with estimated blood loss \>1L and subsequent post operative follow up till 6month
62320470|NCT03907735||2nd trimester|Second trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained primarily after second trimester surgical abortions or Dilation and Evacuation (D\&E) procedures as well as after rare gravid hysterectomies or after late second trimester cesarean deliveries.
62689516|NCT02973022||Community Control Group|Once participants are randomized, they will be given survey 1. The control group in the community will be exposed to a nutrition education program in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational session. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
62689517|NCT02973022||ACEC CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group at ACEC (Adams-Columbia Electric Company) will be exposed to the modified CC\&S educational sessions in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. The researchers anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
61926295|NCT01863550|EXPERIMENTAL|Arm D (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
61926296|NCT04942353|EXPERIMENTAL|Home-based Exercise Rehabilitation|
61926297|NCT04942353|ACTIVE_COMPARATOR|Usual Care|
62130204|NCT03888768|NO_INTERVENTION|Standard Care|patient will received standard hospital practise
62697451|NCT06583720|EXPERIMENTAL|Probiotics group|Participants in this group will receive brushing, dental floss, lingual scraper and probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®).
61926298|NCT04597918|EXPERIMENTAL|Faricimab|Participants will receive 6 doses (one 6 mg faricimab intravitreal \[IVT\] injection every 28 days \[Q4W\]) starting at Day 1 and ending on the Day 140 visit. Participants will return for a safety follow-up visit (SFV) after ≥28 days and within \<35 days following their last study treatment.
61926299|NCT05120271|EXPERIMENTAL|GPC3+ solid tumors|One time intravenous administration of BOXR1030 after completion of cyclophosphamide and fludarabine LD chemotherapy
61926300|NCT03295461|ACTIVE_COMPARATOR|test group|SRP+ 10% Emblica officinalis irrigation
61926301|NCT03295461|ACTIVE_COMPARATOR|positive control group|SRP + 0.2% Chlorhexidine irrigation
62697452|NCT05167708|NO_INTERVENTION|control|the group underwent distalization, with no Micro-osteoperforation
61926302|NCT03295461|ACTIVE_COMPARATOR|negative control group|SRP + 0.9% Saline irrigation
61926303|NCT03295461|ACTIVE_COMPARATOR|test gropup|SRP +10% E. officinalis gel application
61926304|NCT03295461|PLACEBO_COMPARATOR|control group|received SRP+ placebo gel application.
61926305|NCT02902796|ACTIVE_COMPARATOR|Treatment group A|Group A will consist of sequence of treatment with 3 stimulation modes. They are, in order, 1000 hertz, standard, and burst stimulation. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
62130205|NCT02960204|ACTIVE_COMPARATOR|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.
62689518|NCT02973022||ACEC Control Group|Once participants are randomized, they will be given survey 1. The control group at ACEC will be exposed to a nutrition education program in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. We anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
62689519|NCT03027765||Egyptian children|"Population1:~Egyptian children with constructed space maintainers at Cairo University."
61926306|NCT02902796|ACTIVE_COMPARATOR|Treatment group B|Group B will consist of sequence of treatment with 3 stimulation modes. They are, in order, burst stimulation, standard, and 1000 hertz. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
61926307|NCT05585164|EXPERIMENTAL|Engage & Connect|
61926308|NCT05585164|EXPERIMENTAL|Symptom Review and Psychoeducation|
61926309|NCT01601964||Follow-up or medical treatment.|medical treatment
61926310|NCT01601964||Surgical treatment|Surgical treatment
61926311|NCT06243627|EXPERIMENTAL|Arm 1: Sunscreen C Color 2.0 Sun Protection Factor (SPF) 70 and Sunscreen M Very Light SPF 50|The participants will apply topically two colored sunscreens: C color 2.0 and M very light, one on each half of the face at least twice a day for 21 days.
62320471|NCT03907735||Non-pregnant|Myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in non-pregnant women undergoing gynecologic surgery under anesthesia for laparoscopic tubal ligation.
62689520|NCT03027765||Pediatric dentists|"Population2:~Pediatric dentists at Cairo University."
62689521|NCT06522386|EXPERIMENTAL|Pirtobrutinib, Rituximab and Venetoclax combination|
62689522|NCT06284915|EXPERIMENTAL|Group 1: MenACYW conjugate vaccine|Participants will receive MenACYW Conjugate Vaccine (MenQuadfi®): 2-dose schedule (1+1); dose 1 (priming dose) at 6-7 months of age and dose 2 (booster dose) at 12-13 months of age (MenQuadfi®)
62689523|NCT06284915|ACTIVE_COMPARATOR|Group 2: Nimenrix®|Participants will receive Nimenrix®: 2-dose schedule (1+1); dose 1 (priming dose) at 6-7 months of age and dose 2 (booster dose) at 12-13 months of age
61926312|NCT06243627|EXPERIMENTAL|Arm 2: Sunscreen C Color 2.0 SPF 70 and Sunscreen M Golden Color SPF 50|The participants will apply topically two colored sunscreens: C color 2.0 and M golden color, one on each half of the face at least twice a day for 21 days.
61926313|NCT06243627|EXPERIMENTAL|Arm 3: Sunscreen C Color 3.0 SPF 70 and Sunscreen M Very Light SPF 50|The participants will apply topically two colored sunscreens: C color 3.0 and M very light, one on each half of the face at least twice a day for 21 days.
61926314|NCT06243627|EXPERIMENTAL|Arm 4: Sunscreen C Color 3.0 SPF 70 and Sunscreen M Golden Color SPF 50|The participants will apply topically two colored sunscreens: C color 3.0 and M golden color, one on each half of the face at least twice a day for 21 days.
61926315|NCT06659744||New use of semaglutide injection|Exposure group
62689524|NCT03934684|EXPERIMENTAL|Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~* Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter.~* Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression"
62689525|NCT03934684|EXPERIMENTAL|Carfilzomib+Lenalidomide+Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted.~* Lenalidomide 25 mg is taken orally on days 1 to 21.~* Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination."
62689526|NCT06381791|EXPERIMENTAL|Epidiolex (cannabidiol)|Patients randomized to the Epidiolex group will take 150mg of Epidiolex with food twice daily for 14 days beginning the day of surgery.
62689527|NCT06381791|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo group will take 150mg of oral placebo solution with food for 14 days beginning the day of surgery.
62689528|NCT05516147|EXPERIMENTAL|Treatment|SAFE at Home Intervention
62689529|NCT06644625||MGUS and Smoldering Multiple Myeloma|Participants diagnosed with MGUS and smoldering multiple myeloma
62689530|NCT06644625||Other Plasma Cell Disorders|Participants diagnosed with other plasma cell disorders
62689531|NCT06674980|ACTIVE_COMPARATOR|Standard of Care - DFU|Debridement, reduction of bacterial burden, and proper moisture balance using dressings. Off-loading using the off-loading boot or total contact cast (TCC).
61926316|NCT06659744||New initiation of sitagliptin|Reference group
61926317|NCT06181279|EXPERIMENTAL|Individualized PEEP group|After recruitment maneuver, PEEP is titrated decreasingly using driving pressure guided individualised PEEP ventilation strategy, and the PEEP corresponding to the lowest driving pressure is the individualised PEEP.
61926318|NCT06181279|OTHER|Fixed PEEP group|After recruitment maneuver, PEEP is fixed at 8cmH2O.
61926319|NCT00775944|ACTIVE_COMPARATOR|Standard support|Standard 'Together Programme' telephone support for smoking cessation \& advice to obtain nicotine addiction treatment
61926320|NCT00775944|ACTIVE_COMPARATOR|Proactive telephone support|Proactive support \& advice to obtain nicotine addiction treatment
62689532|NCT06674980|EXPERIMENTAL|AM/Single - DFU|AM/Single is an air-dried, sterile single layer human amniotic membrane allograft.
61926321|NCT00775944|ACTIVE_COMPARATOR|Standard support & offer NRT|Reactive telephone support (i.e. Together Programme) and offer of voucher for cost free Nicotine Replacement Therapy
61926322|NCT00775944|ACTIVE_COMPARATOR|Proactive support & offer NRT|Proactive telephone support and offer of voucher for cost free NRT
62130206|NCT02960204|ACTIVE_COMPARATOR|Emricasan (25 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.
62480893|NCT05256147|EXPERIMENTAL|Intervention group|There is one group in this study and they will receive ibuprofen 400 mg before their narrow band UVB phototherapy session which occurs two to three times weekly. The treatment dose of NBUVB will start off at 150 mJ/cm2 and will be increased 10% as tolerated til the patient reaches 700 mJ/cm2. They will receive ibuprofen before each phototherapy session.
62480894|NCT06742645|EXPERIMENTAL|Community House Borgo Reno|The health workers of the Borgo Reno Community House perform the outpatient visit and after having identified the health problems they propose a possible treatment. Subsequently, the citizen included in the study is subjected to the intervention, short motivational interview (BMI). By putting the relationship, listening, assertive communication, motivation and direct involvement of the patient in the treatment path in the foreground, the trained workers conduct the BMI to motivate the users of the various services to improve their lifestyles. Objectives to be achieved within six months will be agreed upon. The short motivational interview lasts approximately 15 minutes
62320472|NCT03907735||1st trimester|First trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained after first trimester surgical abortions or suction dilation and curettage (D\&C).
62320473|NCT03907735||After term pregnancy (3rd trimester)|Third trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained at the time of cesarean delivery.
62320474|NCT04215991|EXPERIMENTAL|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg cefiderocol and participants ≥34 kg will receive 2000 mg.
61926323|NCT04446442|EXPERIMENTAL|Full Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1 mA will be administered over 20 minutes to the right crusI/II area of the cerebellum with a 15 second fade in period at the beginning and a 15 second fade out period at the end. During the tDCS administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
61926324|NCT04446442|SHAM_COMPARATOR|Sham Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1mA increased over 15 seconds and immediately decreased over 15 seconds to provide sensation associated with tDCS. During the sham administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
62320475|NCT04215991|EXPERIMENTAL|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered via IV every 8 hours for an expected 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
62320476|NCT04215991|ACTIVE_COMPARATOR|Multiple Dose Phase: Standard of Care Alone|Participants will receive standard of care treatment according to local standards.
62320477|NCT01127425|ACTIVE_COMPARATOR|1|Intervention: Surgery: laparoscopic sigmoid resection without fast track postoperative care
62320478|NCT01127425|ACTIVE_COMPARATOR|2|Intervention: Surgery: conventional (open) sigmoid resection without fast track postoperative care
62320479|NCT02690480|EXPERIMENTAL|PD-0332991(Palbociclib)+fulvestrant(FaslodexTM)|Fulvestrant 500mg, on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
62130207|NCT02960204|ACTIVE_COMPARATOR|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.
62130208|NCT02960204|PLACEBO_COMPARATOR|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.
62320480|NCT02690480|ACTIVE_COMPARATOR|Placebo+fulvestrant(FaslodexTM)|Fulvestrant 500mg on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
62320481|NCT02890082|EXPERIMENTAL|Tamoxifen stim in early follicular phase|Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3
62320482|NCT02890082|OTHER|Tamoxifen stim in late follicular phase|Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14
62320483|NCT02890082|OTHER|Tamoxifen stim in luteal phase|Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28
62320484|NCT04246671|EXPERIMENTAL|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E7 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E7 Inf.U.
62480895|NCT06742645|ACTIVE_COMPARATOR|Community House Navile|The health workers of the Navile Community House perform the outpatient visit and after having identified the health problems they propose a possible treatment. The users belonging to the control arm will complete the SF-36 questionnaire Send feedback
62480896|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
62480897|NCT06736626||Ischemic cohort|All patients sustaining an ischemic event (i.e., death, myocardial infarction, stroke, or stent thrombosis) after hospital discharge and within 1 year of PCI.
62480898|NCT06736626||Bleeding cohort|All patients sustaining a major bleeding event (i.e., requiring a blood transfusion or a repeat hospitalization) after hospital discharge and within 1 year of PCI.
62689533|NCT06674980|EXPERIMENTAL|AM/Double - DFU|AM/Double is an air-dried, sterile double layer human amniotic membrane allograft.
62689534|NCT06674980|ACTIVE_COMPARATOR|Standard of Care - VLU|Debridement, reduction of bacterial burden, and proper moisture balance using dressings. Compression using multilayer compression wraps.
62130209|NCT02740231|ACTIVE_COMPARATOR|Reference product|Hylan G-F 20
62320485|NCT04246671|EXPERIMENTAL|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E8 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E8 Inf.U.
62480899|NCT06517680|EXPERIMENTAL|Tight control group|Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.
62689535|NCT06674980|EXPERIMENTAL|AM/Single - VLU|AM/Single is an air-dried, sterile single layer human amniotic membrane allograft.
62689536|NCT06674980|EXPERIMENTAL|AM/Double - VLU|AM/Double is an air-dried, sterile double layer human amniotic membrane allograft.
62689537|NCT05175001|PLACEBO_COMPARATOR|Group R|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine in saline was administered under real-time ultrasound monitoring
62320486|NCT04246671|EXPERIMENTAL|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E9 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E9 Inf.U.
62320487|NCT04246671|EXPERIMENTAL|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E10 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E10 Inf.U.
62320488|NCT04246671|EXPERIMENTAL|Stage 2: Chordoma Cancer Cohort|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level defined in stage 1.
62320489|NCT04246671|EXPERIMENTAL|Stage 2: HER2-positive Breast Cancer Cohort (Trastuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of trastuzumab, every three weeks with three administrations in total at the dose defined in stage 1.
62320490|NCT04539301||Derivation cohort|In the derivation cohort, we will determined the conversion factor linking apixaban, rivaroxaban, fondaparinux, or danaparoid measured level, on the one hand, and heparin anti-Xa activity, on the other hand.
62320491|NCT04539301||Validation cohort|"In the validation cohort, for each tested anticoagulant, we will used the conversion factor determined in the derivation cohort to infer the estimated level of anticoagulant from heparin anti-Xa activity:~estimated anticoagulant level = conversion factor for this anticoagulant × heparin anti-Xa activity~The agreement between measured and estimated levels of each factor-Xa inhibitor will be assessed."
62320492|NCT02711670|EXPERIMENTAL|thiazide|Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating
62320493|NCT06392828||Group 1: no NAFLD, no prevalent CVD.|The aim of this group is to serve as control group. FLI \<30 or hepatic echography negative for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \< 5 % and no prevalent CVD according to ESC 202122.
62320494|NCT06392828||Group 2: NAFLD, no prevalent CVD|FLI \>60 or hepatic echography positive for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \> 5 % and no prevalent CVD according to ESC 202122.
62320495|NCT06392828||Group 3: no NAFLD, prevalent CVD|FLI \<30 or hepatic echography negative for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \< 5 % and prevalent CVD (chest angina, stroke, acute coronary syndrome, accute myocardial infarction).
62320496|NCT06392828||Group 4: NAFLD, prevalent CVD|FLI \>60 or hepatic echography positive for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \> 5 % and prevalent CVD (chest angina, stroke, acute coronary syndrome, accute myocardial infarction).
62320497|NCT05053139|EXPERIMENTAL|no PPX- no PPX - Mim8 PPXQW/QM|Participants not receiving prophylaxis will not enter the run-in period. In arm 1, participants will be randomised to continue no prophylaxis (on-demand treatment with their Standard of Care products) or Mim8 once-weekly or once-monthly prophylaxis in agreement with investigators in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) in agreement with the investigator, either weekly or monthly Mim8 prophylaxis regimen.
62320498|NCT05053139|EXPERIMENTAL|no PPX - Mim8 PPXQW - Mim8 PPXQW|Participants not receiving prophylaxis will not enter the run-in period. In arm 2a, participants will be randomised to Mim8 once-weekly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.
62320499|NCT05053139|EXPERIMENTAL|no PPX - Mim8 PPXQM - Mim8 PPXQM|Participants not receiving prophylaxis will not enter the run-in period. In arm 2b, participants will be randomised to Mim8 once-monthly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthy Mim8 prophylaxis regimen.
62320500|NCT05053139|EXPERIMENTAL|PPX - Mim8 PPXQW|Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 3, participants will be randomised to once-weekly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.
62320501|NCT05053139|EXPERIMENTAL|PPX- Mim8 PPXQM|Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 4, participants will be randomised to once-monthly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthly Mim8 prophylaxis regimen.
62320502|NCT01818817||TPVB group|In this group of patients thoracic paravertebral block is performed.
62320503|NCT01818817||GA group|In this group of patients general anesthesia is performed.
62320504|NCT03630640|EXPERIMENTAL|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
62480900|NCT06517680|ACTIVE_COMPARATOR|Control group|Patients will have the usual follow-up for this indication, i.e. a follow-up consultation 3 months after the 1st consultation with the rheumatologist to assess their clinical course.
62480901|NCT06741943|EXPERIMENTAL|Insulin pump therapy|Subject wearing insulin pump (model: AR-B200A) and continuous glucose monitoring (FreeStyle Libre)
62697453|NCT05167708|EXPERIMENTAL|Single MOP|the group underwent one time Micro-osteoperforation procedure
62697454|NCT05167708|EXPERIMENTAL|repeated MOP|the group underwent monthly Micro-osteoperforation procedure
62320505|NCT05572567||Rheumatoid Arthritis (RA) patients treated with biologic and nonbiologic DMARDs|to include all Japanese patients taking Tofacitinib
62480902|NCT06741813|ACTIVE_COMPARATOR|ASCT group|T-LBL patients achieving CR after induction chemotherapy and then received ASCT as first line consolidation
62480903|NCT06741813|EXPERIMENTAL|Allo-HSCT|T-LBL patients achieving CR after induction chemotherapy and received allo-HSCT as first line consolidation
62689538|NCT05175001|EXPERIMENTAL|Group RD|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine plus 4.67mg Diprospan in saline was administered under real-time ultrasound monitoring
62320506|NCT01417780|ACTIVE_COMPARATOR|AB103 0.25 mg/kg|
62320507|NCT01417780|ACTIVE_COMPARATOR|AB103 0.5 mg/kg|
62320508|NCT01417780|PLACEBO_COMPARATOR|Placebo|Normal saline (0.9% sodium chloride)
62320509|NCT01568190|EXPERIMENTAL|AVANZ|AVANZ Mites
62320510|NCT04514367|EXPERIMENTAL|ANX005|IV
62320511|NCT04048967|EXPERIMENTAL|Intervention|Preschool staffs will participate in 50 hours of professional development over 7 months focused on promotion of physical activity in the preschool setting. Staffs and investigators will work together to develop models to ensure children receive 60 minutes per day of moderate-to-vigorous physical activity, 90 minutes per week of motor challenging physical activity, 90 minutes per week of cognitively engaging games/play, and 90 minutes per week of physically active learning.
62320512|NCT04048967|NO_INTERVENTION|Control|Staffs receive no professional development and children will receive standard care.
62320513|NCT05232097|EXPERIMENTAL|Behavioral therapy|Behavioral therapy consisting of diaphragmatic breathing exercises and physiotherapy to relax tensed abdominal and thoracic muscles
62320514|NCT05346224|EXPERIMENTAL|Treatment group|HLX11 combined with trastuzumab and docetaxel will be adopted in the neoadjuvant treatment phase, and doxorubicin with cyclophosphamide will be administered in the adjuvant chemotherapy treatment phase, HLX11 combined with trastuzumab will be administered in the adjuvant treatment phase for HER-2 targeted.
62320515|NCT05346224|ACTIVE_COMPARATOR|Control group|Perjeta combined with trastuzumab and docetaxel will be adopted in the neoadjuvant treatment phase, and doxorubicin with cyclophosphamide will be administered in the adjuvant chemotherapy treatment phase, HLX11 or Perjeta combined with trastuzumab will be administered in the adjuvant treatment phase for HER-2 targeted.
62320516|NCT01259297|EXPERIMENTAL|Aliskiren + Amlodipine|"In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period."
62320517|NCT01259297|EXPERIMENTAL|Aliskiren + Hydrochlorothiazide (HCTZ)|"In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily."
62320518|NCT01259297|EXPERIMENTAL|Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg"
62320519|NCT01259297|EXPERIMENTAL|Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily"
62320520|NCT01259297|EXPERIMENTAL|Amlodipine + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily"
62320521|NCT01259297|EXPERIMENTAL|HCTZ + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily"
62320522|NCT01259297|PLACEBO_COMPARATOR|Placebo for Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily"
62320523|NCT01259297|PLACEBO_COMPARATOR|Placebo for Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily"
62320524|NCT03794726|ACTIVE_COMPARATOR|Orthodontic Molar Protraction|Molar protraction using orthodontic tooth movement alone
62320525|NCT03794726|EXPERIMENTAL|Orthodontic Molar Protraction and PAOO|Molar protraction using orthodontic tooth movement and adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO)
62480904|NCT06741579|ACTIVE_COMPARATOR|Conventional Medical Management (CMM) ONLY|
62480905|NCT06741579|EXPERIMENTAL|Peripheral Nerve Stimulation + Conventional Medical Management (PNS+CMM)|
62480906|NCT04447313|EXPERIMENTAL|Arm I (ACT)|Participants receive ACT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
62480907|NCT04447313|ACTIVE_COMPARATOR|Arm II (SBT)|Participants receive SBT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
62689539|NCT01197300|EXPERIMENTAL|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
62689540|NCT05753228|ACTIVE_COMPARATOR|COVID fatigue patients|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
62689541|NCT05753228|ACTIVE_COMPARATOR|Cancer fatigue patients|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
62689542|NCT05753228|ACTIVE_COMPARATOR|Healthy patients as controls|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
62689543|NCT06168968||Patient|(Secondary Prevention) Includes black (n=150) and white (n=150) patients greater than or equal to 18 years of age hospitalized for acute coronary syndrome (ACS), multi-vessel disease, or ischemic stroke undergoing intervention
62689544|NCT06168968||Family Member|(Primary Prevention) Includes black subjects (n=75) who are first or second-degree relatives of patients in Cohort 1 and have no history of prior hospitalization for cardiovascular or cerebrovascular disease
61926325|NCT05618431|OTHER|pregnant women|Pregnant woman 18 and 50 years oldbetween 10 and 40 weeks of pregnancy
61926326|NCT01812590|NO_INTERVENTION|Resting Trial|Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
62320526|NCT05949814||HIV-negative men who have sex with men (MSM) and transgender persons|
62320527|NCT06051279||Cases with TNH|Newborns with raised TSH level and normal FT4 (the confirmed raised TSH cases after thyroid hormone screening) that return normal without intervention within one month after birth.
62320528|NCT06051279||Cases with permanent congenital hypothyroidism|Newborns with raised TSH level and low FT4 (confirmed cases after thyroid hormone screening)
62320529|NCT06051279||Control group|Control group with matched age and gender with normal TSH at birth according to the neonatal TSH screening. Matched normal neonates will be selected to be compared with transient neonatal hyperthrotropinemia cases and permanent congenital hypothyroidism cases for studying of the predictors of transient neonatal hyperthyrotopinemia.
62320530|NCT00800033|EXPERIMENTAL|Aerobic exercise training|
62320531|NCT00800033|PLACEBO_COMPARATOR|Resistance exercise training|
62320532|NCT00800033|EXPERIMENTAL|pulse diet|Pulse based diet containing peas, lentils, and beans
62320533|NCT00800033|NO_INTERVENTION|Regular diet|
62320534|NCT05436938|EXPERIMENTAL|Psoriasis patients with mild severity, treatment group|with Jing Si herbal tea liquid packets use
62320535|NCT05436938|PLACEBO_COMPARATOR|Psoriasis patients with mild severity, placebo group|without Jing Si herbal tea liquid packets use
62320536|NCT05436938|EXPERIMENTAL|Psoriasis patients with moderate to severe severity, treatment goup|with Jing Si herbal tea liquid packets use
62320537|NCT05436938|PLACEBO_COMPARATOR|Psoriasis patients with moderate to severe severity, placebo group|without Jing Si herbal tea liquid packets use
62689545|NCT06564402|EXPERIMENTAL|Exposure + Positive Mental Rehearsal|Mental rehearsal of the positive aspects of exposure experience
61926327|NCT01812590|EXPERIMENTAL|Exercise Trial|Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
61926328|NCT02474680||Care Coordination Group|Patients participating in the Avera Care Coordination Program for Intervention 'Pharmacogenetic testing'
61926329|NCT01459848|ACTIVE_COMPARATOR|block play|30 minutes of block play with parent
62320538|NCT00886132|EXPERIMENTAL|Sunitinib|Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
62320539|NCT01870063||open heart surgery|
62689546|NCT06564402|ACTIVE_COMPARATOR|Exposure + Mental rehearsal|Mental rehearsal of the exposure experience
61926330|NCT01459848|EXPERIMENTAL|baby dvd|watch baby dvd with parent
61926331|NCT01272661|ACTIVE_COMPARATOR|Enhanced Curriculum|New Enhanced Breastfeeding Curriculum with 11 brief modules
62689547|NCT06230146|EXPERIMENTAL|Insulin group|Group I (n=15): Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution) Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas.
61926332|NCT01272661|ACTIVE_COMPARATOR|Enhanced Curriculum+Breastfeeding Doula|"Enhanced Curriculum + mother selects a support person to learn about breastfeeding with her and support her postpartum (breastfeeding doula)"
62320540|NCT01279135|ACTIVE_COMPARATOR|Conventional RT|Patients in this arm will receive conventional radiation with or without chemotherapy
62320541|NCT01279135|EXPERIMENTAL|Tomotherapy based IGRT|Patients in this arm will receive Tomotherapy based IGRT with or without chemotherapy
62320542|NCT04770168|EXPERIMENTAL|CBT Curriculum - First Cohort|Students will receive the 3-month cognitive behavioral therapy curriculum in the first half of the academic year.
61926333|NCT01272661|ACTIVE_COMPARATOR|Enhanced Curriculum +Father Support|Enhanced Curriculum+ mother provides father-friendly information about breastfeeding to her partner plus an invitation to an educational group for fathers
62320543|NCT04770168|EXPERIMENTAL|CBT Curriculum - Second Cohort (Waitlist Controls)|Students will receive the current school board curriculum as usual for the first half of the academic year, serving as wait-list controls. Since this is a stepped wedge trial, the winter cohort will receive the identical intervention as the fall cohort in the second half of academic year.
62320544|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
62320545|NCT03481764||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 5-14 years
62320546|NCT03481764||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
62339753|NCT06179615|OTHER|complete denture with CAD\CAM milled artificial teeth|complete denture constructed with CAD\\CAM Milled artificial teeth and inserted in the patient mouth to be used for 3, 6 months
62130210|NCT02740231|EXPERIMENTAL|JTA-004 50 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
62320547|NCT03481764||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
62480908|NCT06514807|EXPERIMENTAL|Ropeginterferon alfa-2b (tradename BESREMi®)|"Ropeginterferon alfa-2b (tradename BESREMi®) 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.~Ropeginterferon alfa-2b will be administered subcutaneously every 2 weeks at a dose of 125 µg / 250 µg / 500 µg per injection (depends on the optimal disease response) for up to 36 months of treatment."
62480909|NCT01441297|EXPERIMENTAL|study arm|BIBF 1120 study arm
62320548|NCT03481764||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
62320549|NCT03481764||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed epilepsia
62480910|NCT03990662||TMD|Patients (aged ≥18 years) with a diagnosis of Temporomandibular Disorders
62480911|NCT00151229|ACTIVE_COMPARATOR|strict control|systolic blood pressure control: less than 140 mm Hg
62480912|NCT00151229|ACTIVE_COMPARATOR|moderate control|systolic blood pressure control: 140 mm Hg to 149 mm Hg
62480913|NCT03671213|EXPERIMENTAL|Calypso|Calypso Knee System
62130211|NCT02740231|EXPERIMENTAL|JTA-004 50 (4 ml)|Sodium hyaluronate, plasma proteins and clonidine
62320550|NCT03481764||EFS: group of individuals with epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
62320551|NCT00920465|EXPERIMENTAL|one-visit|
62320552|NCT00920465|ACTIVE_COMPARATOR|two-visit|
62480914|NCT06742827|EXPERIMENTAL|Intervention|Intervention group: participants will receive an educational intervention on hemodialysis adherence)
62480915|NCT06742827|NO_INTERVENTION|Control|Control group:participants will receive conventional care provided by health professionals
62689548|NCT06230146|EXPERIMENTAL|Botulinum toxin group|Group II (n=15): Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
62689549|NCT06230146|EXPERIMENTAL|Triamcinolone acetonide group (control group)|Group III (control group) (n=15): Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
62689550|NCT02576197|ACTIVE_COMPARATOR|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
62320553|NCT04805021||Patients in the Acquired Hemophilia A group.|
62320554|NCT04805021||patients in the constitutional hemophilia A group.|
62480916|NCT02807987|EXPERIMENTAL|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
62689551|NCT02576197|PLACEBO_COMPARATOR|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
62689552|NCT06643897|OTHER|Qualitative Interview|All study staff who participate in the substudy will be interviewed through a 40-50 minute-qualitative interview.
62320555|NCT04805021||patients in the control subjects group.|
62320556|NCT04805021||patients in the group of patients with inflammatory pathology.|
62320557|NCT04885244||Operative|Multicenter, prospective, nonrandomized analysis of ASD patients w/diagnosis of congenital, degenerative, idiopathic, neuromuscular, inflammatory or iatrogenic spinal deformity. Participants must be scheduled to have 3 or more levels of Percutaneous posterior spinal instrumentation or 3 level stand alone lateral surgery within next 6 months.
62480917|NCT01501955|ACTIVE_COMPARATOR|Stanmore|25 patients will have the Stanmore prosthesis
62130212|NCT02740231|EXPERIMENTAL|JTA-004 100 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
62130213|NCT05662449||Ankle fracture with syndesmosis injury|Syndesmosis fixation using bioabsorbable screw
62130214|NCT04457752|ACTIVE_COMPARATOR|Dual Layer Amniotic Membrane (DLAM) + SOC|DLAM (Up to 10 weekly DLAM applications) + Standard of Care (sharp debridement, offloading, and proper moisture balance).
62130215|NCT04457752|NO_INTERVENTION|Standard of Care|Standard of Care: sharp debridement, offloading, and proper moisture balance.
62130216|NCT02995460|EXPERIMENTAL|interval training|4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
62689553|NCT03627468|EXPERIMENTAL|Gel, 5%|Sofpironium Bromide Gel, 5%, applied topically to each axilla once daily for 48 weeks
62130217|NCT02995460|NO_INTERVENTION|controls|No change in diet and training habits
62689554|NCT03627468|EXPERIMENTAL|Gel, 15%|Sofpironium Bromide Gel, 15%, applied topically to each axilla once daily for 48 weeks
62689555|NCT05912634||Conservative Type A Aortic Dissection Repair (TAAD-R)|The Conservative procedure will include patients receiving ascending aortic root sparing replacement with or without the implantation of the aortic hemiarch
62689556|NCT05912634||Extensive Type A Acute Aortic Dissection Repair (TAAD-R)|The extensive procedure will include patients receiving ascending aorta replacement associated to TARP
62689557|NCT06637553|PLACEBO_COMPARATOR|Placebo|Same weight as the treatment dissolved in 200cc of hot water once daily for 3 menstrual cycle
62689558|NCT06637553|EXPERIMENTAL|Treatment|The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once for 3 menstrual cycledaily
62689559|NCT02275533|EXPERIMENTAL|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy at screening, months 3, 6, and 12, as clinically indicated, and during off-study evaluation. Patients also undergo collection of blood samples at screening, weeks 9, 13, 25, and 53, and during off-study evaluation or at time of clinically suspected relapse. Patients may undergo ECHO as clinically indicated.
62689560|NCT02275533|ACTIVE_COMPARATOR|Arm II (observation)|Patients undergo standard of care clinical observation for up to 2 years. Upon disease relapse, patients may cross-over to Arm I. Patients also undergo bone marrow biopsy at screening, months 3, 6, and 12, as clinically indicated, and during off-study evaluation. Patients also undergo collection of blood samples at screening, weeks 9, 13, 25, and 53, and during off-study evaluation or at time of clinically suspected relapse. Patients may undergo ECHO as clinically indicated.
62689561|NCT06642467||Diabetic Group|Subjects age 18-59 years old who was diagnosed with type 2 diabetes mellitus, or pre DM or known to have abnormal Hba1c or blood glucose results
62689562|NCT06642467||Non diabetic Group|Subjects age 18-59 years old who never diagnosed to have diabetes mellitus or pre DM
62689563|NCT03032809||Intracranial vasculopathy|Patients diagnosed intracranial vasculopathy will be imaged further by high resolution vessel wall MR imaging on a 3Tesla MR scanner.
62689564|NCT06422247||Relapsed or refractory peripheral T-cell lymphoma initiating second-line systemic therapy|
62689565|NCT05214508|ACTIVE_COMPARATOR|COPD patient|COPD patients diagnosed based on spirometry, PFT and history
62689566|NCT05214508|NO_INTERVENTION|Control|Healthy volunteers
62130218|NCT01557985|EXPERIMENTAL|Transversus abdominis plane (TAP) Block|All participants in the study will receive a Transverses abdominis plane (TAP) Block in conjunction with their surgery.
62689567|NCT06300437|EXPERIMENTAL|Group jaw thrust|will include the children who will receive jaw thrusting during fiberoptic intubation.
62689568|NCT06300437|ACTIVE_COMPARATOR|Group control|will include the children who will not receive jaw thrusting (just sub laxed open mouth)
62697455|NCT05396404||observation|all subject data were retrieved from databank which is stored in the e-medical chart system.
62697456|NCT02085863|EXPERIMENTAL|Laquinimod|once daily oral doses of laquinimod (with combination oral contraceptives)
62697457|NCT02085863|PLACEBO_COMPARATOR|Placebo|Matching placebo (with combination oral contraceptives)
62697458|NCT03925467|EXPERIMENTAL|proximal acupoints|Acupuncture needles will be administered at proximal acupoints
62697459|NCT03925467|EXPERIMENTAL|distal acupoints|Acupuncture needles will be administered at distal acupoints
62130219|NCT01041794||1|
62130220|NCT00867867|ACTIVE_COMPARATOR|1|Ferrous Fumarate with Ferrous Sulphate
62130221|NCT00867867|ACTIVE_COMPARATOR|2|Ferric pyrophosphate with ferrous sulphate
62130222|NCT00867867|PLACEBO_COMPARATOR|3|Ferrous sulphate
62130223|NCT01837927|EXPERIMENTAL|NVA237|NVA237 inhaled via the Breezhaler® device once daily
62130224|NCT01837927|ACTIVE_COMPARATOR|Tiotropium|Tiotropium 5μg inhaled via the Respimat® device once daily
62697460|NCT03925467|PLACEBO_COMPARATOR|sham acupoints|Sham acupuncture needles will be administered in the abdominal sham acupoints.
62480918|NCT01501955|EXPERIMENTAL|Metaphyseal Hip Prosthesis|25 patients will have the Metaphyseal Hip Prosthesis (MHP) prosthesis
62480919|NCT05278221|OTHER|Healthy volunteers|Each healthy volunteer during Part I of the study will receive every 2 weeks a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo. All healthy volunteers will perform tests using the new software that combines Transcranial Magnetic Stimulation Combined With EEG/EMG,
62480920|NCT05278221|OTHER|Patients with focal epilepsy|Patients during Part II, will receive the treatment according to the treating physician's discretion, regardless of the protocol, either with Lacosamide, 300 mg p.o. or Brivaracetam, 100 mg p.o. All patients will perform tests using the new software that combines Transcranial Magnetic Stimulation Combined With EEG/EMG,
62480921|NCT06130345||Cohort 1: Influenza Vaccinated Concurrent Comparator|Participants who receive an elasomeran/davesomeran or an andusomeran vaccine in routine clinical practice are compared to participants who receive an influenza vaccine to observe differences in the rate of adverse events of special interest during an etiologically relevant window.
62480922|NCT06130345||Cohort 2: Medically Attended COVID-19 Concurrent Comparator|Participants who receive an elasomeran/davesomeran or an andusomeran vaccine in routine clinical practice are compared to participants who diagnosed with COVID-19 to observe differences in in the rate of adverse events of special interest during an etiologically relevant window.
62697461|NCT06092892|EXPERIMENTAL|Single Arm|
62697462|NCT02852707||Unilateral overhead throwing athletes|Volleyball attackers involved in competitive events ≥ 2 years, ≥18 years of age
62320558|NCT03688646|EXPERIMENTAL|Intervention group|Intensive nutrition intervention group receiving standardised oral nutrition supplement provided once daily throughout cancer treatment with 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement
62320559|NCT03688646|NO_INTERVENTION|Control group|Routine care were given to this group inclusive of 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement and also prescription of oral nutrition supplement where needed. Oral nutrition supplement was not provided
62320560|NCT05566756||Ofatumumab|Patients prescribed with ofatumumab
62320561|NCT00763204|EXPERIMENTAL|1|AN2728 Cream, 2%
62320562|NCT00763204|EXPERIMENTAL|2|AN2728 Cream, 1%
62320563|NCT00763204|EXPERIMENTAL|3|AN2728 Cream, 0.3%
62320564|NCT00763204|PLACEBO_COMPARATOR|4|AN2728 Cream Vehicle
62320565|NCT00763204|ACTIVE_COMPARATOR|5|Betnesol®-V Creme (betamethasone 0.1 %)
62320566|NCT06497426|EXPERIMENTAL|Water intake intervention|During one week, participants will be asked to drink 30 (for women) or 35 (for men) ml of water/Kg of weight/day distributed homogeneously during the day. The water requirements of subjects with overweight will be calculated with the corrected weight using the Wilkens formula. Water will be provided in the form of 1L bottles and recommendations about the amount of water to intake will be individualized and indicated by a mark on the bottle. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance. This water intake will be apart from usual meals. A dietitian will prepare the daily amount of mineral water in 1 liter bottles to facilitate the intervention supervision and compliance. All bottles will be identified by NID and date and will be retired and replaced every day at 8-9 am for compliance assessment. Participants will be asked to drink only the provided water.
62320567|NCT06497426|NO_INTERVENTION|Control intervention|Usual clinical practice with no especial attention to hydration. Participants will be able to freely drink whatever they want (ad libitum). Participants in the control group will be provided with 2 bottles of 1L (2L of water) every day, and more water will be provided if requested. Daily water intake will also be quantified.
62320568|NCT02928393|EXPERIMENTAL|Basmisanil|Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
62320569|NCT02928393|PLACEBO_COMPARATOR|Placebo|Placebo matched to basmisanil orally twice daily for 90 days.
62320570|NCT00945750|EXPERIMENTAL|Sequence 1: FCT with water → CT without water → CT with water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
62320571|NCT00945750|EXPERIMENTAL|Sequence 2: CT without water → CT with water → FCT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
62320572|NCT00945750|EXPERIMENTAL|Sequence 3: CT with water → FCT with water → CT without water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
62320573|NCT00945750|EXPERIMENTAL|Sequence 4: FCT with water → CT with water → CT without water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
62320574|NCT00945750|EXPERIMENTAL|Sequence 5: CT without water → FCT with water → CT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
62320575|NCT00945750|EXPERIMENTAL|Sequence 6: CT with water → CT without water → FCT with water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
62480923|NCT02015013|EXPERIMENTAL|Filgrastim|ICL and healthy volunteers will be given 10 microgram/kg daily for 5 days administered according to a vial-based algorithm to reduce wastage and increase the G-CSF dose given to lighter-weight donors to improve CD34+ yields
62697463|NCT02852707||Bilateral overhead athletes|Swimmers involved in competitive events ≥ 2 years, ≥18 years of age
62697464|NCT02852707||Non-athletes|Persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers), ≥18 years of age
62697465|NCT05826054|EXPERIMENTAL|Intervention|In this study, participants will receive increasing dosages of the Study Treatment (Montbretin A, MbA) at each treatment visit. The Study Treatment will be taken with a standardized meal (a meal that has specified quantities of carbohydrates, fats and proteins). At each visit, participants will receive one dose (in pill form) of MbA. As long as they are not experiencing any side effects, this dose will be gradually increased at each study visit (starting from 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, to 300 mg MbA).
62320576|NCT04877548|EXPERIMENTAL|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
62320577|NCT04877548|EXPERIMENTAL|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
62320578|NCT04877548|PLACEBO_COMPARATOR|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
62320579|NCT01883882|EXPERIMENTAL|taper support|Weekly visits with pharmacological and psychological support for opioid taper at 10% of original dose per week
62320580|NCT01883882|NO_INTERVENTION|Usual care|Usual care for chronic pain. All care allowed except buprenorphine.
62480924|NCT02015013|EXPERIMENTAL|Plerixafor|ICL and healthy volunteers will be given 0.24 mg/kg as a single dose (maximum dose: 40 mg) 11 hours prior to apheresis
62480925|NCT03279978|EXPERIMENTAL|BI 730357 25 mg fast|Subjects were orally administered BI 730357 25 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
61926334|NCT04767282|OTHER|Fruit and Vegetable Prescription|Each program participant will receive a fruit and vegetable prescription that is written by pediatricians to exchange for $15 of fresh produce. Prescriptions will be distributed during pediatric office visits and are redeemable at a local farmers' market and mobile market.
61926335|NCT00929812|ACTIVE_COMPARATOR|Glucagon hydrochloride|GlucaGen® 1 mg/1 ml intramuscularly
62130225|NCT03248271||Type 2 Diabetes, Insulin Naive|Study participants will be tested prior to and 3 and 6 months after starting insulin to manage their diabetes
62480926|NCT03279978|PLACEBO_COMPARATOR|Placebo fast|Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after a fasting period of at least 6 hours.
62689569|NCT06643533||FMT-Resistant HCC Cohort|"The triple therapy consists of:~Transarterial Chemoembolization (TACE): This procedure will be performed every 4-6 weeks based on the presence of significant arterial blood supply to the tumor, with a maximum of 4 TACE treatments allowed.~Lenvatinib: The generic name of the drug is lenvatinib. It will be administered orally in a dosage of 12mg per day for patients weighing 60kg or more, and 8mg per day for patients weighing less than 60kg. The treatment will be continuous with a fixed daily dosing schedule.~Sintilimab: It will be given every 3 weeks (Q3W). Fecal Microbiota Transplantation (FMT): The FMT capsules will be prepared by matching the gut microbiome profiles of healthy donors with those of patients who achieved a complete response to the triple therapy. The FMT capsules will be taken orally at a dosage of 30 capsules per day for the first 3 days of each treatment cycle.~The FMT intervention will be administered in 6 cycles, with each cycle lasting for 21 days (Q3W)."
62130226|NCT03333018||Aclidinium bromide monotherapy|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
62320581|NCT05845164|EXPERIMENTAL|Treatment|"The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory.~In order to help minimize the stinging feel of the treatment, we have chosen to ramp up time and frequency. For visits 2-6 (tDCS treatment visits), we will start with 0.5mA ramping up to 0.75mA for 5 minutes. Followed by a brief (8 sec) EEG recording. Then, we will apply 0.75mA to 1mA while watching the ACT video for 5 minutes. This will also be followed by 8 second EEG recording. The final application of current will be 1.0mA to 1.75mA for 10 minutes followed again by 8 second EEG recording."
62320582|NCT05845164|SHAM_COMPARATOR|Sham|"The sham group will receive ramped up current from 0.0mA not to exceed 0.5mA for the first minute at the initiation of each of the three ramp-ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
62320583|NCT02094586|EXPERIMENTAL|PXVX0200 Lot A|PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
62480927|NCT03279978|PLACEBO_COMPARATOR|Placebo fed|Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after the intake of a standard continental breakfast.
62480928|NCT03279978|EXPERIMENTAL|BI 730357 50 mg fast|Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours.
62480929|NCT03279978|EXPERIMENTAL|BI 730357 50mg/Placebo|Subject was orally administered mixed treatment of BI 730357 50 mg and placebo, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
62480930|NCT03279978|EXPERIMENTAL|BI 730357 50 mg fed|Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after the intake of a standard continental breakfast.
62689570|NCT01428713|ACTIVE_COMPARATOR|Group A-Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
61926336|NCT00929812|PLACEBO_COMPARATOR|Placebo|1 ml NaCl 0.9%
62320584|NCT02094586|EXPERIMENTAL|PXVX0200 Lot B|PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
62320585|NCT02094586|EXPERIMENTAL|PXVX0200 Lot C|PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
62320586|NCT02094586|PLACEBO_COMPARATOR|Placebo|Placebo physiological saline
62320587|NCT02183025|EXPERIMENTAL|Meloxicam 7.5 mg|
62320588|NCT02183025|EXPERIMENTAL|Meloxicam 15 mg|
62689571|NCT01428713|ACTIVE_COMPARATOR|Group B-Combined oral contraceptive pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
62689572|NCT03895476|ACTIVE_COMPARATOR|Collagen Plug with sutures|Palatal wound will be protected with collagen plug and sutures.
62689573|NCT03895476|ACTIVE_COMPARATOR|Platelet Rich Fibrin (PRF)|palatal wound will be protected with Platelet rich Fibrin
61926337|NCT06743997|EXPERIMENTAL|Sequence 1|Participants receive a single subcutaneous dose of the Test Drug(T), in the first period, followed by a washout period, and then a single subcutaneous dose of the Reference Drug(R) in the second period.
61926338|NCT06743997|EXPERIMENTAL|Sequence 2|Participants receive a single subcutaneous dose of the Reference Drug(R), in the first period, followed by a washout period, and then a single subcutaneous dose of the Test Drug(T) in the second period.
61926339|NCT06469398|EXPERIMENTAL|Laser Treatment|
62320589|NCT02183025|ACTIVE_COMPARATOR|Mefenamic acid 1500 mg|500 mg three times daily
62320590|NCT02288728|EXPERIMENTAL|Group B (double-track anastomosis)|Patients in the Group B will received the double-track anastomosis with proximal gastrectomy.
62480931|NCT03279978|EXPERIMENTAL|BI 730357 100 mg fast|Subjects were orally administered BI 730357 100 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
62320591|NCT02288728|OTHER|Group A (Gastric tube anastomosis)|Patients in the Group A (Gastric tube anastomosis) will take the gastric tube anastomosis with proximal gastrectomy.
62480932|NCT03279978|EXPERIMENTAL|BI 730357 200 mg fast|Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after a fasting period of at least 6 hours
62480933|NCT03279978|EXPERIMENTAL|BI 730357 200 mg fed|Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.
62320592|NCT00824486|ACTIVE_COMPARATOR|TIPP|Injury prevention education using TIPP materials
62480934|NCT03279978|EXPERIMENTAL|BI 730357 400 mg fed|Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 400 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.
62480935|NCT04858412|ACTIVE_COMPARATOR|HMB enriched amino acid arm|The patients randomized to the HMB enriched amino acid (HMB/EAA) arm will be given HMB/EAA for 90 days.
62480936|NCT04858412|PLACEBO_COMPARATOR|Balanced amino acid arm|The patients randomized to the Balanced amino acid (BAA) arm will be given BAA for 90 days.
62480937|NCT06743009|EXPERIMENTAL|Lac-Phe|Intravenous infusion of Lac-Phe
62480938|NCT06743009|PLACEBO_COMPARATOR|Control|Intravenous infusion of NaCl
62320593|NCT00824486|EXPERIMENTAL|Safe Home Model|Injury prevention education using safe home model
62320594|NCT01809262|EXPERIMENTAL|olodaterol 2 mcg|solution for inhalation
62320595|NCT01809262|EXPERIMENTAL|olodaterol 5 mcg|solution for inhalation
62320596|NCT01809262|EXPERIMENTAL|olodaterol 10 mcg|solution for inhalation
62320597|NCT01809262|EXPERIMENTAL|olodaterol 20 mcg|solution for inhalation
62320598|NCT01809262|EXPERIMENTAL|olodaterol 40 mcg|solution for inhalation
62320599|NCT01809262|PLACEBO_COMPARATOR|placebo|solution for inhalation
62320600|NCT02729454|ACTIVE_COMPARATOR|Exclusively physical therapy|The patients will be submitted to 15 therapeutical sessions two times per week with length of 40 minutes for motor physiotherapy . Each session of the motor physiotherapy will be constituted of exercises that include stretching (emphasizing the front of the torso), reinforcement (with emphasis in inferior members extensores); active exercises as transference (for example, to put into motion it bed or uprising of a chair), to reach and to grasp and training of balance and march.
62320601|NCT02729454|EXPERIMENTAL|Mental Practice And Physical Therapy|In the group submitted to the mental Practice the sessions will be individualized and occur in tranquil room after physical therapy (Same performed with the control group). During the mental practice the patient will be guided to stand, where he will be requested initially to identify and to sequencer the necessary joints for the accomplishment of an only step, being they:flexion of the thigh and leg rights, extension of the right leg more dorsiflexed of the right foot; touch of the heel and discharge of weight of the right foot and inclined body to the front. The sessions occur two times per week during 15 minutes.
62320602|NCT01401829|EXPERIMENTAL|75 weekly minutes walking|12-week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week
62320603|NCT01401829|EXPERIMENTAL|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week
62480939|NCT05094128||Participants Receiving Upadacitinib.|
61926340|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
62480940|NCT06626581||Excessive iodine group|Residents with papillary thyroid cancer who have lived in excessive iodine areas for a long time (5 years or more). According to the report of Shandong linstitute of Endemic Disease Prevention and Control, three sub centers were selected in excessive iodine group(Jining/Liaocheng/Heze).
62480941|NCT06626581||Suitable iodine group|Residents with papillary thyroid cancer who have lived in suitable iodine areas for a long time (5 years or more). According to the report of Shandong linstitute of Endemic Disease Prevention and Control, three sub centers were selected in suitable iodine group(Jinan/Shenyang/Haerbin).
62480942|NCT03690960|EXPERIMENTAL|electrospun TAP nanofibers|Revascularization procedure with Electrospun TAP nanofibers as as an intracanal medicament for immature necrotic teeth
62480943|NCT03690960|ACTIVE_COMPARATOR|modified TAP paste|Revascularization procedure with modified TAP paste as an intracanal medicament for immature necrotic teeth
62480944|NCT06705465|EXPERIMENTAL|Intervention group: video conference|
62480945|NCT06705465|NO_INTERVENTION|No intervention|
62480946|NCT06135051|EXPERIMENTAL|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets affected by Alzheimer's disease.
62480947|NCT06135051|SHAM_COMPARATOR|Sham stimulation|Sham stimulation that applies the device in the same way as verum but only delivers auditory sounds correspoding to the ultrasonic pulses.
62480948|NCT02511535|EXPERIMENTAL|Allergic patients|Allergic patients receive TBE booster vaccination
62480949|NCT02511535|EXPERIMENTAL|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
62130227|NCT03333018||Aclidinium bromide and formoterol|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
62130228|NCT03333018||New users of other COPD medication|New users of other COPD medications (tiotropium, other LAMAs, LABA, LABA/ICS, LAMA/LABA), prescribed as recorded in the database.
62320604|NCT01401829|ACTIVE_COMPARATOR|Stretching and Flexibility exercise|Stretching/Flexibility exercise
62320605|NCT04509128||A|Subjects hospitalized for a COPD acute exacerbation, undergoing arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, at admission and discharge.
62320606|NCT04509128||B|Subjects referred for pulmonary rehabilitation (PR) after a hospitalized COPD exacerbation, undergoing pulmonary function test, arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, before and after PR.
62320607|NCT02547077|EXPERIMENTAL|Wound Closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
62130229|NCT06065332|EXPERIMENTAL|Velez Intense Hydration Mask® (biotech cellulose face mask) Right Side|For 30 minutes after an aesthetic procedure, a Velez Intense Hydration Mask® (biotech cellulose face mask) was applied to the right side of the face
62480950|NCT02511535|ACTIVE_COMPARATOR|Healthy controls|Healthy controls receive TBE booster vaccination
62480951|NCT01044537|PLACEBO_COMPARATOR|Placebo|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
62320608|NCT02547077|ACTIVE_COMPARATOR|Wound Closure with 5-0 Fast Absorbing Gut|One side of the patient's wound defect will be assigned to wound closure with 5-0 fast absorbing gut sutures.
62689574|NCT03895476|ACTIVE_COMPARATOR|Collagen Plug with Cyanoacrylate (CPC)|Palatal wound will consist of collagen protection with the additional layer of cyanoacrylate surgical glue.
62689575|NCT03895476|ACTIVE_COMPARATOR|Palatal Stent|Palatal wound will be protected with palatal stent.
62689576|NCT02445365|EXPERIMENTAL|Active RIC|Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
62689577|NCT02445365|SHAM_COMPARATOR|Sham|As above with a cuff pressure of 20 mmHg
62689578|NCT06643715|EXPERIMENTAL|PANDA PLUS|
62320609|NCT00204893|EXPERIMENTAL|Open label|Each participant will be treated with three 3900 mg doses of calcium formate on each study day (i.e., days 1-14).
62320610|NCT02372903|EXPERIMENTAL|Endometriosis|Symptomatic patients with laparoscopic diagnosis of endometriosis
62320611|NCT00109733|EXPERIMENTAL|Standard dose group|0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
62320612|NCT00109733|EXPERIMENTAL|High dose group|0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
62689579|NCT06643715|NO_INTERVENTION|Tradition|
62689580|NCT06577441|ACTIVE_COMPARATOR|Arm A (ASTX727)|Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Arm B. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
62689581|NCT06577441|EXPERIMENTAL|Arm B (ASTX727, enasidenib)|Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
62689582|NCT06638125|EXPERIMENTAL|3D VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping|All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform.
62130230|NCT06065332|EXPERIMENTAL|Velez Intense Hydration Mask® (biotech cellulose face mask) Left Side|For 30 minutes after an aesthetic procedure, a Velez Intense Hydration Mask® (biotech cellulose face mask) was applied to the left side of the face
62130231|NCT01164670||Men|Men over 70 years old.
62130232|NCT01164670||Women|Women over 70 years old.
62130233|NCT00752453|EXPERIMENTAL|1|Dialysis during 4 hours
62130234|NCT00752453|EXPERIMENTAL|2|Dialysis during 6 hours
62130235|NCT00752453|EXPERIMENTAL|3|Dialysis during 8 hours
62130236|NCT04003675||Adolescent elite athletes|Adolescent boys and girls elite athletes over 16 years of age studying at elite sport high schools in Norway.
62320613|NCT04083040|OTHER|TAVI patients|Patient undergone TAVI
62689583|NCT06638125|ACTIVE_COMPARATOR|3D Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping|The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
62689584|NCT01486329|EXPERIMENTAL|VXM01|Investigational anti-angiogenic live cancer vaccine
62689585|NCT01486329|PLACEBO_COMPARATOR|Placebo|Placebo control
62130237|NCT04003675||Adolescent controls|Adolescent boys and girls over 16 years of age studying at regular high schools in Norway.
62130238|NCT04003675||Trainers and leaders|Trainers (with more than 20 percent employment status) at elite sport high schools, and leaders/principals at elite sport high schools and regular high schools.
62130239|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
62130240|NCT01577225|EXPERIMENTAL|OPSITE Post-Op Visible|Subject is randomized to OPSITE Post-Op Visible group or Tape\&Gauze group. Dressing should be used right after surgery and changed as needed.
62320614|NCT00619684|EXPERIMENTAL|Treatment (lenalidomide)|Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.
62480952|NCT01044537|EXPERIMENTAL|PF-04937319|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
62480953|NCT05167487||Experimental: platinum-based neoadjuvant treatment and surgery.|Resectable stage IIIA non-small cell lung cancer patients treated with platinum-based neoadjuvant treatment and surgery.
62480954|NCT04512235|EXPERIMENTAL|CAEL-101 combined with SoC plasma cell dyscrasia|The study is divided into 2 parts, the Primary Study and the Open-Label Extension Study. CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. It is planned that all patients will continue their double-blind treatment until the last patient is randomized in the study plus 18 months.
62480955|NCT04512235|PLACEBO_COMPARATOR|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). It is planned that all patients will continue their double-blind treatment until the last patient is randomized in the study plus 18 months.
62130241|NCT01577225|ACTIVE_COMPARATOR|Tape&Gauze|Subject is randomized to OPSITE Post-Op Visible group or Tape\&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.
62320615|NCT05413473|EXPERIMENTAL|MR guided radiotherapy|"MR-guided radiotherapy using the Alberta linac-MR P3 system. Contemporary radiotherapy techniques and fractionation schedules will be conducted in the following graduated stages with overlap between stages allowed:~Stage 1: Parallel-opposed pair treatments (palliative) Stage 2: 4 field box and breast treatments (curative or palliative) Stage 3: Radical treatments - multi-field 3DCRT (curative) Stage 4: Radical treatments - multi-field IMRT (curative)"
62320616|NCT01270672|EXPERIMENTAL|carvedilol, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
62320617|NCT01209754||Pregnant Women|Pregnant women exposed to an HIV prevention study agent during pregnancy
62130242|NCT00557206|EXPERIMENTAL|1|This is a single arm trial.
62320618|NCT01209754||Infant|Infants resulting from pregnancies where there exists maternal HIV prevention agent exposure
62320619|NCT02776280|PLACEBO_COMPARATOR|Negative control|Meal prepared with non-fluoridated water and salt
62320620|NCT02776280|EXPERIMENTAL|Fluoridated water|Meal prepared with fluoridated water
62320621|NCT02776280|EXPERIMENTAL|Fluoridated salt|Meal prepared with fluoridated salt
62320622|NCT03939130|EXPERIMENTAL|Fructose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive fructose based beverage, prepared as a solution with 10% fructose, water and flavoring powder, totaling 1.0g / kg of body mass / day of fructose.
62320623|NCT03939130|ACTIVE_COMPARATOR|Glucose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive glucose based beverage, prepared as a solution with 10% glucose, water and flavoring powder, totaling 1.0g / kg of body mass / day of glucose.
62320624|NCT03939130|EXPERIMENTAL|Fructose-rich diet and exercise|The subjects will perform the same protocol described in the intervention Fructose-rich diet, except for the inclusion of the physical exercise. During the 4-week intervention, participants will perform three sessions a week of 60 minutes of aerobic exercise at 60% of VO2 peak on cycle ergometer.
62320625|NCT05192057|EXPERIMENTAL|Hypertonic Saline inhalation|Participants randomized to the Hypertonic Saline inhalation arm will be prescribed a nebulizer for Hypertonic Saline Inhalation (5ml, 5.8%) two times a day for 12 weeks. Participants will also receive best supportive care for 12 weeks (see below).
62689586|NCT06501352|ACTIVE_COMPARATOR|Dexmeditomedine group|Patients in this group will receive Dexmeditomedine in Local anesthesia mixture.
62320626|NCT05192057|NO_INTERVENTION|Best supportive care|Participants randomized to the best supportive care arm will receive standard of care including management of predisposing (lung) disease, guidance in smoking cessation, respiratory physiotherapy (e.g. airway clearance), nutritional guidance, but no antimycobacterial treatment.
62320627|NCT05814770|EXPERIMENTAL|Finerenone|
62320628|NCT05814770|ACTIVE_COMPARATOR|Spironolactone|
62320629|NCT06258629||control group|Age and sex matched healthy control individuals
62689587|NCT06501352|ACTIVE_COMPARATOR|Neostigmine group|Patients in this group will receive Neostigmine in Local anesthesia mixture.
62320630|NCT06258629||Case group|Available number of patients with newly diagnosed as hematological malignancy
62689588|NCT06501352|PLACEBO_COMPARATOR|Control group|Patients in this group will receive saline (placebo) in Local anesthesia mixture.
61926341|NCT06731608|EXPERIMENTAL|OPTIONS intervention|OPTIONS is a multimodal intervention approach that includes providing clinical decision support (CDS) for healthcare providers, patients, and their caregivers focused on exercise, nutrition, and bone-enhancing medications using CDS in SNFs that use the same electronic health record system (PointClickCare).
61926342|NCT06731608|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced usual care includes access to the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit, a fall prevention program from the CDC.
62320631|NCT06258629||Case group after 6 months|Available number of patients with newly diagnosed as hematological malignancy after 6 months of starting treatment.
62320632|NCT05091060|EXPERIMENTAL|Erchonia HLS|635 nanometers (nm) laser application
62320633|NCT02787512|ACTIVE_COMPARATOR|Plastic stent|10 Fr plastic stent (Percuflex Amsterdam® or C-flex pigtail® or Advanix® Biliary stent)
62320634|NCT02787512|EXPERIMENTAL|Uncovered metal stent|Uncovered metal stent (WallFlex® Biliary RX stent)
62320635|NCT00995735||Transgastric|Patients submitted to Transgastric NOTES surgery
62320636|NCT00995735||Transvaginal|Patients submitted to Transvaginal surgery
62320637|NCT04997837|EXPERIMENTAL|PD-1 inhibitor and chemoradiotherapy|"PD-1 inhibitor+CapeOX/SOX/FOLFOX for 6 weeks, followed by chemoradiotherapy; 6 weeks of PD-1 inhibitor and CapeOX/SOX/FOLFOX for 6 weeks after chemoradiotherapy, followed by PD-1 inhibitor, till 12 months after chemoradiotherapy.~PD-1 inhibitor Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.~Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~Chemoradiotherapy Radiotherapy: 1.8 Gy/fx, 45-50.5Gy Chemotherapy: Capecitabine 625mg/m2 bid orally with radiotherapy; OR Tegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy."
62320638|NCT04997837|ACTIVE_COMPARATOR|Chemotherapy|"Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~CapeOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.~SOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off.~FOLFOX:~Oxaliplatin 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.~5-FU 2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W."
62320639|NCT06132685|EXPERIMENTAL|Arm I (NDS)|Patients receive tapering doses of dexamethasone on days 1-15. Patients also undergo blood sample collection at time of surgery, at follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo MRI and CT scan during inpatient stay as part of standard of care.
62320640|NCT06132685|EXPERIMENTAL|Arm II (RDS)|Patients receive tapering doses of dexamethasone on days 1-4. Patients may receive dexamethasone IV and restart the taper if clinically indicated. Patients also undergo blood sample collection at time of surgery, follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo MRI and CT scan during inpatient stay as part of standard of care.
62320641|NCT06692270|EXPERIMENTAL|Tislelizumab|
62320642|NCT05104151|EXPERIMENTAL|Group with nutritional bar|Participants will recieve two nutritional bars per day during eight weeks, and will receive a healthy habits intervention wich includes: nutritional intervention providing a caloric deficit of 500 calories, and a prescription of moderate physical activity from 60 to 90 minutes daily.
62320643|NCT05104151|ACTIVE_COMPARATOR|Group without nutritional bar|Participants will receive a healthy habits intervention wich includes nutritional intervention providing a caloric deficit of 500 calories, and a prescription of moderate physical activity from 60 to 90 minutes daily during eight weeks.
62320644|NCT03412422||Acute circulatory failure|Mechanically ventilated patients with acute circulatory failure, monitored with PiCCO method, who need fluid responsiveness assessment.
62320645|NCT01651182|PLACEBO_COMPARATOR|Standard Care|No tranexamic acid
62320646|NCT01651182|EXPERIMENTAL|Dose 1|1 g bolus + 1 g infusion from induction over 8 hours
62320647|NCT01651182|EXPERIMENTAL|Dose 2|1 g bolus + 10 mg/kg/hr from induction until end of surgery
62320648|NCT02991820|EXPERIMENTAL|Inexperienced users|Inexperienced users will include trainees (SRNAs, residents, fellows, and medical students) and nurses at NCH.
62320649|NCT02991820|EXPERIMENTAL|Experienced users|Experienced users will include faculty pediatric anesthesiologists CRNAs.
62320650|NCT05952167|PLACEBO_COMPARATOR|Placebo mechanical cervical traction|
62320651|NCT05952167|EXPERIMENTAL|Mechanical cervical traction|
62320652|NCT00300872|ACTIVE_COMPARATOR|1|Continuous positive airway pressure (CPAP)
62689589|NCT03787147|OTHER|Spinal Injection|Adults receiving Spinal Injection(SI) without Virtual Reality(VR).
62320653|NCT00300872|SHAM_COMPARATOR|2|Sham Continuous positive airway pressure (CPAP)
62320654|NCT02942550|ACTIVE_COMPARATOR|Methylnaltrexone|Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).
62689590|NCT03787147|ACTIVE_COMPARATOR|Google Cardboard|Adults receiving SI while using Google Cardboard Virtual reality head mounted display powered by a iPod touch
62320655|NCT02942550|PLACEBO_COMPARATOR|Placebo|Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).
62320656|NCT03888300|EXPERIMENTAL|Patient Group|Patients with obstructive pulmonary diseases receiving standard physiotherapy treatment
62320657|NCT04577859|ACTIVE_COMPARATOR|Study group|Those randomized to the study group will receive the esophageal cooling device- the ensoETM probe, during AF ablation treatment, under general anaesthetic. The cooling device is set to 4 degrees Celsius during ablation of the left atrial posterior wall.
62339754|NCT01111201||questionnaires|There will be four versions of the questionnaire, each slightly modified to be more specific toward the treatment paradigms in the respective target patient population (Breast Cancer/ Lymphoma/Autologous Bone Marrow Transplant/ Allogeneic Bone Marrow Transplant). All questionnaire versions will consist of seven sections.
62689591|NCT03787147|ACTIVE_COMPARATOR|Oculus|Adults receiving SI while using VR with Oculus Rift.
62689592|NCT03030534|EXPERIMENTAL|Experimental Group|Educational Package and software package
62689593|NCT03030534|ACTIVE_COMPARATOR|Control group|Health promotion tips
62697466|NCT06166433|EXPERIMENTAL|Intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period
62697467|NCT06166433|NO_INTERVENTION|Control|Assessment-only control
62689594|NCT05144737|OTHER|Immediate Intervention Group|Participants in the immediate intervention group will immediately begin 6 months of the adapted DPP lifestyle intervention with a Lifestyle Coach and remote monitoring of blood pressure and body composition. This will be followed by a 6-month observation period where the intervention (Lifestyle Coach) will be withdrawn. In this period, participants will be evaluated for the maintenance of lifestyle changes.
62697468|NCT05878067|EXPERIMENTAL|ABBV-444|Participants will administer 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.
62320658|NCT04577859|ACTIVE_COMPARATOR|Control group|Those randomized to the control group will receive standard of care, which is an esophageal temperature monitoring probe during their AF ablation procedure, under general anesthetic. The esophageal temperature probe is placed close to the level of ablation (the probe should be at the esophageal level where, opposite this, the ablation catheter is at, in the endocardial aspect of the posterior left atrium).
62320659|NCT05573165|EXPERIMENTAL|3h Group|the patient's parents are instructed to stop feeding 3 hours for scheduled anesthesia. (3 hours of preoperative fasting for breast milk)
62320660|NCT05573165|ACTIVE_COMPARATOR|4h Group|the patient's parents are instructed to stop feeding 4 hours for scheduled anesthesia (4 hours of preoperative fasting for breast milk)
62320661|NCT03360981|ACTIVE_COMPARATOR|diabetics incretin-users (arm 1)|epicardial tissue biopsy, and than treated by incretin therapy plus standard anti ischemic therapy.
62320662|NCT03360981|PLACEBO_COMPARATOR|diabetics never-incretin-users (arm 2)|epicardial tissue biopsy, and than treated by standard hypoglycemic drug therapy plus standard anti ischemic therapy.
62320663|NCT03360981|NO_INTERVENTION|non diabetics (arm 3)|non diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard anti ischemic therapy.
62320664|NCT04626219|EXPERIMENTAL|1|Period of 12 hours where participants eat regulated meals
62320665|NCT04626219|EXPERIMENTAL|2|Period of 12 hours where participants do not eat anything
62480956|NCT06619184|EXPERIMENTAL|NCEHFORSCS transplantation and MPG procedure|"The research was conducted on 21 participants.~Two vitiligo lesions from each participant that met the inclusion and exclusion criteria were treated with NCEHFORSCS transplantation and MPG procedure followed by observation of repigmentation.~The participants were informed that a series of procedures would be performed, including hair follicle extraction using the follicle unit extraction (FUE) procedure, followed by the preparation of NCEHFORSCS in PT Prodia StemCell Indonesia (ProSTEM®) laboratory, and transplantation of NCEHFORSCS on one VNS lesion while MPG procedure was performed on another lesion.~Follow-up was carried out at the 2nd week, 4th week, 8th week, 12th week, and 16th week after the NCEHFORSCS transplantation and MPG procedures to assess repigmentation of the lesions and side effects of the procedures."
62480957|NCT05117489|EXPERIMENTAL|Cohort 1 - 150 mg of miricorilant for 24 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 24 weeks.
62480958|NCT05117489|EXPERIMENTAL|Cohort 2 - 150 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 12 weeks.
62480959|NCT05117489|EXPERIMENTAL|Cohort 3 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MWF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily for 2 weeks, followed by 100 mg of miricorilant every Monday, Wednesday and Friday for 10 weeks.
62480960|NCT05117489|EXPERIMENTAL|Cohort 4 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 2 weeks, followed by 100 mg of miricorilant every Monday and Friday for 10 weeks.
62480961|NCT05117489|EXPERIMENTAL|Cohort 5 - 100 mg of miricorilant every MWF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday, Wednesday and Friday for 12 weeks.
62480962|NCT05117489|EXPERIMENTAL|Cohort 6 - 100 mg of miricorilant every MF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday and Friday for 12 weeks.
62689595|NCT05144737|OTHER|Delayed Intervention Group|Participants in the delayed intervention group will receive remote monitoring of blood pressure and body composition for the 1st 6 months (without the Lifestyle Coach) and then will receive the adapted DPP lifestyle intervention with a Lifestyle Coach after 6 months.
62689596|NCT06638086|EXPERIMENTAL|Per-rectal group|These neonates received Acetaminophen per rectally at dose of 40 mg/kg.
62689597|NCT06638086|ACTIVE_COMPARATOR|Intra-vanous group|These neonates received intravenous Acetaminophen at dose of 15 mg/kg.
62320666|NCT04631471|ACTIVE_COMPARATOR|Ibudilast|Increasing dose of Ibudilast up to 100mg/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
62320667|NCT04631471|PLACEBO_COMPARATOR|Placebo|Increasing dose of matched placebo containing mannitol instead of ibudilast up to 10 pills/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
62480963|NCT05117489|EXPERIMENTAL|Cohort 7 - 50 mg of miricorilant daily for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 50 mg once daily, for 12 weeks.
62480964|NCT05117489|EXPERIMENTAL|Cohort 8 - 100 mg of miricorilant daily for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 12 weeks.
62697469|NCT02853292||amoxicillin crystalluria|
62320668|NCT05219721|EXPERIMENTAL|CAR-GPRC5D cells|"The tolerability and safety of CAR-GPRC5D cells will be assessed according to the 3+3 dose-escalation design. There will be three dose levels, 0.5×10\^6, 1.0×10\^6, and 2.0×10\^6, CAR+T cells/kg. For each level, 3-6 subjects will be enrolled."
62320669|NCT01818167|ACTIVE_COMPARATOR|10% Benzoyl Peroxide Topical Body Wash|Subjects will use 10% benzoyl peroxide twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
62480965|NCT05117489|EXPERIMENTAL|Cohort 9 - 30 mg of miricorilant daily for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 30 mg once daily, for 12 weeks.
62697470|NCT04649905||Surgical Treatment|Patient's in this cohort will undergo surgical treatment for OCD of the knee.
62480966|NCT05117489|EXPERIMENTAL|Cohort 10 - 200 mg of miricorilant once a week for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 200 mg once weekly, for 12 weeks.
61926343|NCT06468215|EXPERIMENTAL|Study on Fertility Sparing Therapy in IA Stage G2 Endometrial Cancer Patients|Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
62480967|NCT05117489|EXPERIMENTAL|Cohort 11 - 150 mg of miricorilant twice weekly for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg twice weekly for 12 weeks.
62480968|NCT03834077|EXPERIMENTAL|Tissue flossing|Conventional physiotherapy consisted in electrotherapy and stretching in addition to tissue flossing.
62480969|NCT03834077|PLACEBO_COMPARATOR|Placebo comparator|Conventional physiotherapy consisted in electrotherapy and stretching in addition with tissue flossing without tension.
62480970|NCT02490072|EXPERIMENTAL|Dexmedetomidine group|
62480971|NCT02490072|PLACEBO_COMPARATOR|normal saline|
62480972|NCT02125435|EXPERIMENTAL|ASP2408 dose escalation cohort|
62130243|NCT01808768|EXPERIMENTAL|Alcaftadine|subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
62480973|NCT02125435|PLACEBO_COMPARATOR|Placebo dose escalation cohort|
62480974|NCT00798603|EXPERIMENTAL|pemetrexed + carboplatin + bevacizumab|Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease or partial or complete response after 6 courses may continue to receive pemetrexed disodium and bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
62480975|NCT05005026|ACTIVE_COMPARATOR|Virtual reality (VR) game 1|Participants will be asked to play a virtual reality game twice a day for 10 days.
62480976|NCT05005026|ACTIVE_COMPARATOR|Virtual reality (VR) game 2|Participants will be asked to play a virtual reality game twice a day for 10 days.
62480977|NCT01877317|EXPERIMENTAL|SelfFit adjusted hearing device|Hearing impaired people with mild to moderate sensorineural hearing loss (PTA124\<50 dB) in the test ear compare the performance of their hearing aids adjusted through SelfFit mobile medical App (I-Pad) with the performance of their hearing aids adjusted through conventional audiogram-based fitting.
62480978|NCT02291796|EXPERIMENTAL|Bezafibrate group|Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment
62480979|NCT02291796|NO_INTERVENTION|Control group|Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment
62480980|NCT06637423|EXPERIMENTAL|Sacituzumab tirumotecan|Participants receive intravesical Sacituzumab Tirumotecan for 6 weeks
62480981|NCT04958915||30 ° flexion position|Scan the knee at 30° flexion
62480982|NCT04958915||conventional flexion position|Routine body scan of the knee joint
62480983|NCT06557785|EXPERIMENTAL|Group 1 (25 mcg)|"25 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.~Followed by:~25 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24."
62480984|NCT06557785|EXPERIMENTAL|Group 2 (50 mcg)|"50 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.~Followed by:~50 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24."
62480985|NCT06557785|EXPERIMENTAL|Group 3 (100 mcg)|"100 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.~Followed by:~100 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24."
62130244|NCT01294215|EXPERIMENTAL|Arm 1|
62130245|NCT03980873|EXPERIMENTAL|Experimental|An experimental group. The psychological treatment includes 10 sessions of cognitive-behavioural treatment ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders
62130246|NCT03980873|NO_INTERVENTION|Control|Three-month waitlist
62130247|NCT06111924|EXPERIMENTAL|Task oriented circuit training based telerehabilitation (TOCT-TR) group|This group will recieve Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call in 18 sessions.
62130248|NCT06111924|EXPERIMENTAL|Clinic based Task oriented circuit training (TOCT-CR) group|This group will recieve In person treatment at clinical setting that will be Task oriented circuit training based telerehabilitation in 18 sessions.
62130249|NCT01238744|PLACEBO_COMPARATOR|Study I: control drink|
62130250|NCT01238744|EXPERIMENTAL|Study I: flaxseed drink|
62480986|NCT06557785|EXPERIMENTAL|Group 4 (150 mcg)|"150 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.~Followed by:~150 mcg CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24."
62130251|NCT01238744|ACTIVE_COMPARATOR|Study II: flaxseed drink|
62130252|NCT01238744|EXPERIMENTAL|Study II: flaxseed tablets|
62130253|NCT02880137|EXPERIMENTAL|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
62130254|NCT04593810|EXPERIMENTAL|INTELLiVENT-ASV|Use of INTELLIVENT-ASV after intubation and during all mechanical ventilation in the ICU.
62130255|NCT04593810|ACTIVE_COMPARATOR|Conventional ventilation|Use of conventional ventilation after intubation and during all mechanical ventilation in the ICU.
62130256|NCT01495624|PLACEBO_COMPARATOR|Ropivacaine with perineural dexamethasone|30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
62480987|NCT06165354|PLACEBO_COMPARATOR|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline.~The routine treatment regimen at Hanoi Obstetrics and Gynecology Hospital (Hanoi OGH) and Bac Ninh Center for Disease Control and Prevention (Bac Ninh CDC) depends on clinical symptoms, test results of bacterial staining and pathogen detected using multiplex real time PCR assay on day 0."
61926344|NCT06468215|EXPERIMENTAL|The Study on Fertility Sparing Therapy in IA Stage G2 Endometrial Cancer Patients|Treatment Option 2 is a combination therapy, consisting of oral MPA 500mg/d/MA 320mg/d combined with the intrauterine insertion of the levonorgestrel intrauterine system (LNG-IUS, Mirena IUD).
62130257|NCT01495624|ACTIVE_COMPARATOR|Ropivacaine with systemic steroid|30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
62320670|NCT01818167|ACTIVE_COMPARATOR|Provodine Topical Cream|Subjects will use Provodine Topical Cream twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
62320671|NCT03242928|PLACEBO_COMPARATOR|Placebo|Matching tablet of placebo taken orally BID
62320672|NCT03242928|EXPERIMENTAL|AFQ056|Mavoglurant was up titrated on a bid regimen followed by fixed-dose bid regimen: 50 mg bid from Day 1 to Day 7, 100 mg bid from Day 8 to Day 14, and then fixed-dose 200 mg bid for 84 days
62320673|NCT02207530|EXPERIMENTAL|MEDI4736|MEDI4736 monotherapy
62320674|NCT00371033|ACTIVE_COMPARATOR|1|Pregabalin
62480988|NCT06165354|EXPERIMENTAL|X-secret|"X-SECRET group receives the routine treatment and uses NaCl 0.9% plus B. subtilis, B. clausii, and B. coagulans at 5 billion CFU/5 mL (LiveSpo®️ X-SECRET).~The routine treatment regimen at Hanoi OGH and Bac Ninh CDC depends on clinical symptoms, test results of bacterial staining and pathogen detected using multiplex real time PCR assay on day 0."
62480989|NCT01532635|EXPERIMENTAL|Allogeneic HSCT Using Two Related Donors|"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28."
62480990|NCT05057039||hypertensive group|SBP \>=140mmHg, DBP \>=90mmHg, or use of antihypertensive drug
62480991|NCT05057039||normotensive group|SBP \<=140mmHg and DBP \<=90mmHg without use of antihypertensive drug
62480992|NCT03932058||osteosarcoma|
62480993|NCT03932058||chondrosarcoma|
62480994|NCT03932058||enchondroma|
62480995|NCT01726933|EXPERIMENTAL|LAS41008|up to 6 tablets/ day for 16 weeks double blind treatment period, randomized gastric resistant tablet
62480996|NCT01726933|PLACEBO_COMPARATOR|Placebo|up to 6 tablets/ day for 16 weeks randomized, double blind gastric resistant tablet
62480997|NCT01726933|ACTIVE_COMPARATOR|LASW1835|double blind, randomized gastric resistant tablet up to 6 tablets/ day for 16 weeks
62480998|NCT06732102|EXPERIMENTAL|DECIDE+ Arm with Biweekly Follow-up Calls|We will offer the DECIDE intervention as a group-based program. This program, facilitated by CHWs, will emphasize the importance of observational learning and group support to strengthen their CVD problem solving. Consistent with the DECIDE intervention's existing evidence-base, CVD problem solving is hypothesized to strengthen an individual's CVD self-management self-efficacy and skills, respectively. Increased self-management self-efficacy and skills are posited to increase the adoption of CVD-related health promotive behaviors. Participants in this arm will also receive 2 follow-up calls per month from their assigned CHW.
62480999|NCT06732102|EXPERIMENTAL|DECIDE+ Arm with a Monthly Follow-up Call|We will offer the DECIDE intervention as a group-based program. This program, facilitated by CHWs, will emphasize the importance of observational learning and group support to strengthen their CVD problem solving. Consistent with the DECIDE intervention's existing evidence-base, CVD problem solving is hypothesized to strengthen an individual's CVD self-management self-efficacy and skills, respectively. Increased self-management self-efficacy and skills are posited to increase the adoption of CVD-related health promotive behaviors. Participants in this arm will also receive 1 follow-up call per month from their assigned CHW.
62689598|NCT05571514|EXPERIMENTAL|Mother-of-pearl|"Patient randomized in the Mother-of-pearl group :~Mother of pearl supplementation: 2 capsules of 400mg = 800mg mother of pearl/day, equivalent to 320mg Ca/day~- Vitamin D: 50,000 IU/month (standard practice)"
62320675|NCT00371033|PLACEBO_COMPARATOR|2|Placebo
62320676|NCT06440304|ACTIVE_COMPARATOR|Fosfomycin|Upon the detection of a positive microbiological finding for A. baumannii, the Fosfomycin group will receive 8 grams of fosfomycin every 8 hours, along with an initial colistin bolus of 6 million IU, followed by 3 million IU every 8 hours. After the first day, the dosage will be adjusted based on kidney and liver function. This therapy will be administered for a total of 10 days.
62320677|NCT06440304|ACTIVE_COMPARATOR|Ampicilin/sulbactam|Upon the detection of a positive microbiological finding for A. baumannii, the Ampicilin/sulbactam group will receive an initial bolus dose of 2 grams of ampicillin and 1 gram of sulbactam, followed by a continuous infusion of 8 grams of ampicillin and 4 grams of sulbactam over 24 hours (maximum daily dose of 12 grams per day), along with a colistin bolus of 6 million IU, followed by 3 million IU every 8 hours. After the first day, the dosage will be adjusted based on kidney and liver function. This therapy will be administered for a total of 10 days.
62320678|NCT06440304|ACTIVE_COMPARATOR|Eravacyclin|Upon the detection of a positive microbiological finding for A. baumannii, the Eravacyclin group will receive eravacycline at a dose of 1 mg/kg every 12 hours for 60 minutes, along with a colistin bolus of 6 million IU, followed by 3 million IU every 8 hours. After the first day, the dosage will be adjusted based on kidney and liver function. This therapy will be administered for a total of 10 days.
62320679|NCT04805567||Patients with polyps and adenomas|The inclusion criteria are: (i) CRC screening; (ii) post-polypectomy surveillance; (iii) diagnostic assessment (anemia, lower gastrointestinal bleeding, abdominal pain, recent change in bowel habits); and (iv) age over 50 years.
62320680|NCT03195634||HVPG group|"When HVPG \> 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate \>55 beats per minute, or up to 12.5 mg/day.~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or\>20% from baseline."
62689599|NCT05571514|ACTIVE_COMPARATOR|Calcium carbonate|"Patient randomized in the Calcium carbonate control group :~Calcium carbonate supplementation: 2 capsules of 400mg= 800mg CaCO3/day, equivalent to 320mg Ca/day~- Vitamin D: 50,000 IU/month (standard practice)"
62689600|NCT06643546|EXPERIMENTAL|control|received only theoretical breastfeeding training
62689601|NCT06643546|EXPERIMENTAL|1st intervention group|theoretical breastfeeding training and model simulation training accompanied by scenarios
62689602|NCT06643546|EXPERIMENTAL|2nd intervention group|theoretical breastfeeding training and live simulation training with scenarios
62689603|NCT01755403|OTHER|Benznidazole|
62481000|NCT06732102|ACTIVE_COMPARATOR|CHW Standard of Care with Biweekly Follow-up Calls|CHWs currently serve Philadelphia residents by offering a wide range of personalized services aimed at improving their well-being. CHWs act as a crucial link between communities and healthcare providers, helping residents navigate the healthcare system. By offering guidance and social assistance, they improve community members' ability to communicate effectively with healthcare professionals. They also deliver health education that is culturally and linguistically appropriate, advocate for the health of individuals and communities, coordinate care through referrals and follow-up services, and assist eligible individuals in enrolling in federal, state, local, or nonprofit health and human services programs. Participants in this arm will receive a biweekly CHW Follow-up call.
62689604|NCT06539442|EXPERIMENTAL|Versius Surgical System|
62689605|NCT01531036|EXPERIMENTAL|shear wave imaging|Single arm study evaluating breast 3D elastography by means of shear wave propagation into breast tissue.
62689606|NCT06318546|ACTIVE_COMPARATOR|Control|This group will undergo spinal anesthesia using fentanyl (50 microgram) as adjuvant to intrathecal bupivacaine
62320681|NCT01671085|EXPERIMENTAL|1.0 milligrams per kilogram (mg/kg) of LY3015014|1.0 mg/kg of LY3015014 given subcutaneously (SQ) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
62320682|NCT01671085|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride injection given SQ (to match LY3015014) on 2 dosing occasions Q4W (Days 1 and 29).
62320683|NCT02350894||mTBI subjects|mTBI subjects with ongoing symptoms
62320684|NCT00359814|EXPERIMENTAL|1|Azathioprine administration: was stopped at day 0; Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily; Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
62320685|NCT01904877||HIV testing|Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
62320686|NCT01904877||Phase II: 367 HIV positive MSM|"* Linking to care:~* Providing enhanced HIV care."
62320687|NCT02098317|EXPERIMENTAL|TREATED GROUP|this group will treated with pearls containing DHA plus Vitamin D3 (500 mg and 800 IU, respectively) given orally in association with lifestyle intervention \[hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity\] for 24 weeks
62320688|NCT02098317|PLACEBO_COMPARATOR|PLACEBO GROUP|this group will treated with identical placebo pearls given orally in association with lifestyle intervention \[hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity\] for 24 weeks
62320689|NCT01848821|OTHER|OASIS half of wound|OASIS will be applied to one half of the wound and standard of care consisting of wound vac only will be applied to the other half.
62320690|NCT01848821|OTHER|Standard therapy half of wound|Standard therapy to half of wound will consistent of non-stick mesh and wound VAC application.
62320691|NCT01651130|ACTIVE_COMPARATOR|Carbetocin 100mcg|Carbetocin 100mcg, once following delivery of the fetal head.
62320692|NCT01651130|ACTIVE_COMPARATOR|Carbetocin 20mcg|Carbetocin 20mcg, once following delivery of the fetal head.
62320693|NCT01651130|ACTIVE_COMPARATOR|Carbetocin 15mcg|Carbetocin 15mcg, once following delivery of the fetal head.
62689607|NCT06318546|ACTIVE_COMPARATOR|Dexmedetomidine|This group will undergo spinal anesthesia using dexmedetomidine (10mg) as adjuvant to intrathecal bupivacaine
62689608|NCT03088111|OTHER|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
61926345|NCT05493618|EXPERIMENTAL|Single-arm, multi-institution|"Study Arm:~Pembrolizumab 200 mg IV q3 weeks Belantamab 2.5 mg/kg IV q3 weeks. Dex 40 mg IV q3 weeks (20 mg if patient \>75) Treatment will be administered on a 21-day cycle and will be continued until unacceptable toxicity or disease progression for up to 2 years (35 cycles)"
62320694|NCT01651130|ACTIVE_COMPARATOR|Carbetocin 10mcg|Carbetocin 10mcg, following delivery of the fetal head.
62320695|NCT01651130|ACTIVE_COMPARATOR|Carbetocin 5mcg|Carbetocin 5mcg, following delivery of the fetal head.
62320696|NCT01651130|ACTIVE_COMPARATOR|Carbetocin 2mcg|Carbetocin 2mcg, following delivery of the fetal head.
62320697|NCT02582749|ACTIVE_COMPARATOR|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
62320698|NCT02582749|EXPERIMENTAL|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
62320699|NCT06032403|NO_INTERVENTION|Control group|Consists of 100 participants followed for one year
62320700|NCT06032403|OTHER|Intervention group|Consists of 100 participants followed for one year
62339755|NCT05390424|EXPERIMENTAL|Drug user|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
62481001|NCT06732102|ACTIVE_COMPARATOR|CHW Standard of Care with Monthy Follow-up Calls|CHWs currently serve Philadelphia residents by offering a wide range of personalized services aimed at improving their well-being. CHWs act as a crucial link between communities and healthcare providers, helping residents navigate the healthcare system. By offering guidance and social assistance, they improve community members' ability to communicate effectively with healthcare professionals. They also deliver health education that is culturally and linguistically appropriate, advocate for the health of individuals and communities, coordinate care through referrals and follow-up services, and assist eligible individuals in enrolling in federal, state, local, or nonprofit health and human services programs. Participants in this arm will receive a Monthly CHW Follow-up call.
62481002|NCT03273153|EXPERIMENTAL|Cobimetinib and Atezolizumab|Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
62130258|NCT04764994|ACTIVE_COMPARATOR|Control Group|"Participants who will participated in the control group will receive a conventional physical therapy program for two hours. It will include two parts, each of them will be one hour and 15 minutes rest in between. The first part will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises. The second part will include: arm-reaching tasks, arm-hand tasks, manipulative tasks (grasping and release activities) and upper limb self-dependent tasks and the inclusion of the more affected upper limb in functional tasks of daily living activities.~The conventional treatment program will be applied for both groups by therapists, experienced in stroke rehabilitation.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
62320701|NCT04764123||AVNRT Cohort|"Patients admitted for electrophysiological study and ablation due to AVNRT tachycardia.~During the study and before the ablation high density electroanatomical mapping will be performed."
62481003|NCT03273153|ACTIVE_COMPARATOR|Pembrolizumab|Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
62689609|NCT04206943|EXPERIMENTAL|A Low Dose|4 x 10\^6 Car-T cell/ kg
62320702|NCT02829086|EXPERIMENTAL|Group I|Participants in Group I will receive the following interventions: Intro to Relationship Enhancement (8 hours), Family Stress and Conflict Management (8 hours), and case management
62339756|NCT01350960|PLACEBO_COMPARATOR|saline 0.9%|
62689610|NCT04206943|EXPERIMENTAL|B High Dose|6 x 10\^6 Car-T cell/ kg
62130259|NCT04764994|EXPERIMENTAL|Study Group|"Participants of study group will receive two hours treatment program that will include three parts, the first and the second parts (similar to that will be applied for participants in control group) will be together for one hour following by 15 minutes rest, then the third part will apply for one hour. The third part of the program will be one hour virtual reality intervention program by using Armeo Spring to simulate a range of upper limb tasks related to arm-reaching to target, reach and grasp (arm-hand activities) and manipulative tasks through using different games and soft-wares.~The conventional treatment part of the program will be applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program will be applied by another experienced physiotherapists, who are well trained in using Armeo Spring System.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
62689611|NCT06643793|EXPERIMENTAL|Irinotecan liposome (Ⅱ) combined with 5-fluorouracil, leucovorin, and bevacizumab|Irinotecan liposome (Ⅱ) + 5-FU/LV + bevacizumab
62689612|NCT04022213|EXPERIMENTAL|Group A|Participants with DSRCT who have undergone GTR of their abdominopelvic disease and who have no definitive radiological evidence of disease in liver or outside the abd/pelvis. Patients if deemed of likely benefit to the patient after completing IP RIT plus WAP-IMRT, or will be mandated if ANC is persistently \<500/ul despite use of G-CSF for \>1 week, or if patients experience life threatening febrile neutropenia.
62689613|NCT04022213|EXPERIMENTAL|Group B|DSRCT patients who have macroscopic residual disease OR who have previously experienced progression of disease while on treatment but have subsequently had a GTR
62689614|NCT04022213|EXPERIMENTAL|Group C|Participants with tumors other than DSRCT and will be enrolled onto an assessment arm to determine eligibility. Immunohistochemistry to assess B7H3 expression will be performed on frozen or paraffin embedded tissue using omburtamab (frozen tissue) or a commercially available anti-B7H3 antibody (if paraffin embedded).
62130260|NCT04030533|EXPERIMENTAL|Cohort 1: Guselkumab (SC): Dose 1|Participants will receive a single subcutaneous (SC) injection of guselkumab (dose 1), administered on Day 1.
62339757|NCT01350960|EXPERIMENTAL|Cohort 1|0.5 mg/kg in Healthy Subjects
62689615|NCT01475825|EXPERIMENTAL|Regimen A: Mipomersen|Subcutaneous injection of mipomersen 200 mg once weekly
62689616|NCT01475825|PLACEBO_COMPARATOR|Regimen A: Placebo|Placebo matching subcutaneous injection once weekly.
62689617|NCT01475825|EXPERIMENTAL|Regimen B: Mipomersen|Subcutaneous injection of mipomersen 70 mg thrice weekly.
62689618|NCT01475825|PLACEBO_COMPARATOR|Regimen B: Placebo|Placebo matching subcutaneous injection thrice weekly.
61926346|NCT05014490|EXPERIMENTAL|Exib (Test)|A single oral dose of the test product Exib 120 mg etoricoxib film-coated tablets.
62481004|NCT06562114|EXPERIMENTAL|TML-6 Granules|"This study consists of 5 parts, Part 1 (SAD): 5 cohorts of subjects are planned to be orally dosed, ranging from 100 mg - 1000 mg.~Part 2 (Food effect): All subjects in Cohort 2 of Part 1 will constitute Period 1 of Part 2 and will move to Period 2 to receive the same Investigational Product (IP) dose as in Period 1.~Part 3 (Elderly): One cohort of elderly subjects will receive a single dose of IP. A dose level of IP within the safe range defined in the Part 1 SAD study will be chosen~Part 4 (MAD): 2 cohorts of subjects are planned to be orally dosed once daily for 7 consecutive days, ranging from 400 mg - 800 mg.~Part 5 (MAD+Cerebrospinal Fluid, CSF PK): One cohort of elderly subjects will receive orally once daily for 7 consecutive days of IP. The dose level of IP defined in the Part 4 MAD study will be chosen."
62481005|NCT06562114|PLACEBO_COMPARATOR|Placebo|Placebo
62481006|NCT00960414|EXPERIMENTAL|SHINE A|Mindfulness training added to diet-exercise education.
61926347|NCT05014490|ACTIVE_COMPARATOR|Arcoxia® (Reference)|A single oral dose of the reference product Arcoxia® 120 mg etoricoxib film-coated tablets.
61926348|NCT02090868||Pre Introduction|Pre tool introduction cohort 22 patient participants who will receive standard care (no patients were recruited)
61926349|NCT02090868||Nurses|12 nurse participants who will take part in 2 focus group interviews and a teaching session (6 nurse participants were recruited)
61926350|NCT02090868||Post Introduction|Pre tool introduction cohort 22 patient participants who's ability to eat and drink orally will be assessed using the Oral Intake Screening Tool (no patient participants were recruited)
61926351|NCT03008408|EXPERIMENTAL|Arm I (ribociclib, everolimus, letrozole)|Patients receive ribociclib PO QD, everolimus PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61926352|NCT03008408|EXPERIMENTAL|Arm II (everolimus, letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61926353|NCT05558917|ACTIVE_COMPARATOR|PECS BLOCK 2|PECS 2 (or modified PECS) is a block that involves the administration of local anesthetic under ultrasound guidance between the great pectoral and small pectoral and between the small pectoral and serratus anterior.
61926354|NCT05558917|EXPERIMENTAL|ESP BLOCK|ESP block is a block that involves injection of local anesthetic below the elevator muscles of the spine.
61926355|NCT03640767|EXPERIMENTAL|message-based lifestyle intervention|The intervention group will receive 4 mobile phone messages per week for 24 weeks.
61926356|NCT03640767|NO_INTERVENTION|Control|no intervention
61926357|NCT04734106|EXPERIMENTAL|Desert Harvest Super-Concentrated, Freeze-Dried Aloe Vera Capsules|Participants will self-administer Desert Harvest super-concentrated, freeze-dried aloe vera capsules orally over a sixteen week period. The dosing regimen includes administering 3 capsules twice daily for the first month, 3 capsules three times daily for the second month, and 4 capsules three times daily for the third month. During the fourth month, participants will administer 10 capsules per day the first week (4 in the morning, 2 in the afternoon, and 4 in the evening), 8 capsules per day the second week (4 in the morning, 4 in the evening), 6 capsules per day the third week (3 in the morning, 3 in the evening), and 4 capsules per day the fourth week (2 in the morning, 2 in the evening). A participant must stay on a minimum of 6 capsules per day for the first three months in order to remain in the study.
61926358|NCT04734106|PLACEBO_COMPARATOR|Placebo|Participants will self-administer placebo capsules orally, matching the dosing regimen of the experimental treatment, over a sixteen week period. Placebo capsules will be identical in appearance and packaging to the experimental capsules.
61926359|NCT06218069|ACTIVE_COMPARATOR|Site EKUT (Tuebingen)|"Patients will receive a single subcutaneous administration of the immunotherapy sasanlimab in a fixed dose of 300 mg in a neo-adjuvant setting, followed by curative-intended surgery.~Patients will also receive a radiolabeled imaging tracer \[89Zr\]Zr-crefmirlimab berdoxam that entails two intravenous administrations of a fixed dose of 1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89; one at baseline and one at 2 weeks after sasanlimab injection."
61926360|NCT06218069|ACTIVE_COMPARATOR|Site Radboudumc (Nijmegen)|"Patients will receive a single subcutaneous administration of the immunotherapy sasanlimab in a fixed dose of 300 mg in a neo-adjuvant setting, and 3 days of non-ablative dose radiation therapy starting with sasanlimab injection. This is followed by curative-intended surgery.~Patients will also receive a radiolabeled imaging tracer \[89Zr\]Zr-crefmirlimab berdoxam that entails two intravenous administrations of a fixed dose of 1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89; one at baseline and one at 2 weeks after sasanlimab injection."
61926361|NCT05053230|EXPERIMENTAL|IM@Home|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or ovarian cancer
61926362|NCT05053230|OTHER|Enhanced usual care|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or ovarian cancer
61926363|NCT06259201|EXPERIMENTAL|Vagus Nerve Stimulation (VNS)|"Single-subject design: ABA, ABBA, or ABBBA~This study allows for a flexibility in the duration of research participation depending on one's response. The participant will be able to select one of the three design options (1, 2, or 3 months of VNS twice per day) in consultation with the study staff. That is, after the initial 1-month trial of VNS, the participant may choose to extend the VNS two more times (i.e., 1 or 2 months), for a total of 90 days."
61926364|NCT06629259|EXPERIMENTAL|Guanfacine Extended Release (XR)|Participants receive guanfacine XR, 3mg tablet orally, once per day for 12 weeks
61926365|NCT06629259|PLACEBO_COMPARATOR|Placebo|Participants receive guanfacine XR, placebo tablet orally, once per day for 12 weeks
62130261|NCT04030533|EXPERIMENTAL|Cohort 2: Guselkumab (SC): Dose 2|Participants will receive a single SC injection of guselkumab (dose 2), administered on Day 1.
62130262|NCT04030533|EXPERIMENTAL|Cohort 3: Guselkumab (IV): Dose 1|Participants will receive a single intravenous (IV) infusion of guselkumab (dose 1), administered on Day 1.
62689619|NCT05679557|NO_INTERVENTION|Conventional|"Perioperative care as usual according to exciting principles and guidelines"
62689620|NCT05679557|EXPERIMENTAL|Geriatric|Perioperative geriatric assessment and tailored interventions in relation to radical cystectomy.
62689621|NCT01157494||children with hemiplegia|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
62130263|NCT04030533|EXPERIMENTAL|Cohort 4: Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2), administered on Day 1.
62689622|NCT01946880|EXPERIMENTAL|Mycophenolate Mofetil Withdrawal|These subjects will taper off MMF per the protocol-specified schedule over 12 weeks and remain off MMF for the rest of their study participation (up to Week 60 or until the primary endpoint of disease reactivation is met, whichever comes first).
62689623|NCT01946880|ACTIVE_COMPARATOR|Mycophenolate Mofetil Maintenance|These subjects will continue MMF treatment (1000-3000 mg/day) for the rest of their study participation (up to Week 60).
62697471|NCT04649905||Nonoperative Treatment|Patient's in this cohort will undergo nonoperative treatment for OCD of the knee.
62130264|NCT04030533|EXPERIMENTAL|Cohort 5: Ustekinumab (IV): 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 milligrams per milliliter (mg/mL) solution on Day 1.
61926366|NCT05594043|EXPERIMENTAL|MK-6598|Participants will receive MK-6598 daily (QD) at escalating dose levels from 50-500 mg for up to a total of 35 cycles (up to approximately 24 months).
61926367|NCT05594043|EXPERIMENTAL|MK-6598 + Pembrolizumab|Participants will receive MK-6598 QD at escalating dose levels from 50-500, plus pembrolizumab 200 mg once every 21-day cycle for up to 35 cycles (up to approximately 24 months).
61926368|NCT01351246|EXPERIMENTAL|Intervention|
61926369|NCT03354559||pre-ECS group|Data collection from 01-01-2011 to 31-12-2012. Patients were treated according to a massive transfusion protocol with the following targets: fresh frozen plasma(FFP)/packed red blood cells(PRBCs) ratio ≥ 1:1.5, target platelet count \> 100.000 x 10 9/L
62320703|NCT02829086|EXPERIMENTAL|Group II|Participants in Group II will receive the following interventions: Intro to Relationship Enhancement (8 hours), RE \& Financial Management (8 hours), and case management
62320704|NCT02829086|NO_INTERVENTION|Group III|Participants in Group III will receive the the standard care of all participants, case management ONLY
62481007|NCT00960414|ACTIVE_COMPARATOR|SHINE B|Diet-exercise education.
62130265|NCT02265432|EXPERIMENTAL|Mobile technology intervention|"1. General physical activity educational materials~2. Wearable activity tracking devices to enable the intervention participants to self-monitor their physical activity behavior and receive real-time feedback~3. Access to an online map of Singapore providing location based information about leisure time physical activity opportunities~4. Personalized text messages which include, educational information, tailored theory-based motivational messages, as well as compliance enhancing reminders"
62320705|NCT02664285|OTHER|closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section.
62320706|NCT02664285|OTHER|No closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will not sutured after cesarean section.
62320707|NCT02979873|EXPERIMENTAL|Sirolimus|sirolimus
62481008|NCT03776396||Experimental cohort|"33 patient undergoing to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania, in which an innovative Perioperative Goal Directed Therapy (PGDT) protocol will be used."
62481009|NCT03776396||Historical control group|"33 patients underwent to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania in 2015, in which a PGDT protocol was not used, but a common hemodynamic monitoring, based on parameters such as central venous pressure and / or invasive arterial pressure, was performed."
62481010|NCT02480660|EXPERIMENTAL|Video Intervention Group|Subjects will be randomized to intervention group where participants will be asked to watch a 7 minute educational video.
62481011|NCT02480660|NO_INTERVENTION|Control Group|Subjects will be randomized to control group ( no intervention) and receive standard of educational care on adolescent to adult oriented health care transitions.
62130266|NCT02265432|OTHER|Control|1.General physical activity educational materials
62320708|NCT02979873|NO_INTERVENTION|Standard of Care|no intervention
62320709|NCT02099799|ACTIVE_COMPARATOR|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
62320710|NCT02099799|NO_INTERVENTION|Usual Care|Verbal instructions and written materials about exercise.
62320711|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
62320712|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
62481012|NCT04168398|EXPERIMENTAL|Plavix 75mg and juspirin 81 mg therapy|Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.
61926370|NCT03354559||ECS group|Data collection from 01-01-2013 to 31-12-2014. Patients were treated according to the ECS protocol.
62320713|NCT01847638|ACTIVE_COMPARATOR|Prolensa (bromfenac 0.07%)|Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
62339758|NCT01350960|EXPERIMENTAL|Cohort 2|1.5 mg/kg in Healthy subjects
62481013|NCT04168398|EXPERIMENTAL|Eliquis 2.5mg and juspirin 81 mg therapy):|Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin (juspirin) 81 mg.
62689624|NCT06365346|EXPERIMENTAL|Dyadic video-assisted gamified group-based music breathing therapy|"Parent-child dyads in the intervention group will receive video-assisted gamified music breathing therapy comprising 75-minute weekly sessions (first sessions: parents only; reminding 5 sessions: parent-child dyads) delivered face-to-face by a qualified music breathing practitioner with the aid of animations (mainly for sessions involving children) for 6 weeks. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing."
61926371|NCT04229004|ACTIVE_COMPARATOR|Gemcitabine combined with nab-paclitaxel|"Arm is closed to recruitment.~The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted as long as drug dosing and modification guidelines are followed."
61926372|NCT04229004|ACTIVE_COMPARATOR|mFOLFIRINOX|"Arm is closed to recruitment.~Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion"
61926373|NCT04229004|EXPERIMENTAL|pamrevlumab (FibroGen)|"Arm is closed to recruitment.~Experimental: Pamrevlumab in combination with gemcitabine/nab-paclitaxel.~Participants enrolled to this treatment arm will receive treatment with pamrevlumab in combination with gemcitabine and nab-paclitaxel.~Gemcitabine and nab-paclitaxel are FDA approved therapies for metastatic pancreatic cancer and will be supplied or obtained according to local clinical study agreements and in accordance with local guidelines."
61926374|NCT04229004|EXPERIMENTAL|Canakinumab and Spartalizumab|"Arm is closed to recruitment.~Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine.~Participants enrolled to this treatment arm will receive treatment with Canakinumab and Spartalizumab in combination with nab-paclitaxel and gemcitabine."
61926375|NCT04229004|EXPERIMENTAL|Experimental: SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.~All four agents (SM-88, methoxsalen, phenytoin, and sirolimus) should be dosed with approximately 240 mL (8 fl. oz.) of water in the morning. All four agents should be taken together consistently. SM-88 used with MPS should ideally be taken approximately 1 hour before or 2 hours after a meal."
62320714|NCT01847638|ACTIVE_COMPARATOR|Ilevro (nepafenac 0.3%)|Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
62320715|NCT02375698|EXPERIMENTAL|Gr 1 H56:IC31 5/500|5ug H56 + 500 ug IC31
62481014|NCT04485767|EXPERIMENTAL|Progressive Resistance Training Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend structured progressive resistance exercise training sessions 2 times/week for six months.
62481015|NCT04485767|ACTIVE_COMPARATOR|Flexibility and Balance Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend flexibility and balance exercises training sessions 2 times/week for six months.
61926376|NCT01327911|EXPERIMENTAL|Ciliary Neurotrophic Factor (CNTF)/NT-501|Biological/Vaccine:NT-501 implant
62320716|NCT02375698|PLACEBO_COMPARATOR|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
62320717|NCT00682825|EXPERIMENTAL|1|Bispectral index-guided protocol
62320718|NCT00682825|ACTIVE_COMPARATOR|2|End-tidal anesthetic gas-guided protocol
62320719|NCT04772365|EXPERIMENTAL|Treatment group A|
62320720|NCT04772365|PLACEBO_COMPARATOR|Treatment group B|
62320721|NCT06693375|EXPERIMENTAL|Dosing of IMP followed by MMUS evaluation|"In Part A, Each condition will be evaluated with MMUS after 7hours, 24hours 48hours and 72hours. The following conditions will apply:~Condition 1: Dose 1: 28 mg Fe (7 mg Fe/mL) Condition 2: Dose 2: 56 mg Fe (3,5 mg Fe/mL) Condition 3: Dose 2: 56 mg Fe (14 mg Fe/mL) Condition 4: Dose 3: 112 mg Fe (14 mg Fe/mL) In Part B, the dose level to be applied as well as the timepoint from MMUS evaluation, will be decided based on the outcome of Part A."
62320722|NCT02809417||LICORNE platform|
62320723|NCT02809417||Control|
61926377|NCT05571579||brain tumors|
61926378|NCT06149273|EXPERIMENTAL|Sleep School|Participants attend the Sleep School once a week for six weeks.
62320724|NCT06295731|EXPERIMENTAL|INBRX-106 plus pembrolizumab|Participants will receive INBRX-106 plus pembrolizumab, both given by intravenous (IV) infusion every 3 weeks (QW3)
62320725|NCT06295731|ACTIVE_COMPARATOR|pembrolizumab monotherapy (+ placebo in phase 3 part)|Participants will receive pembrolizumab (plus placebo in Phase 3), given by intravenous (IV) infusion every 3 weeks (QW3)
62481016|NCT02812420|EXPERIMENTAL|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1 of weeks 1 and 4. Beginning 4-6 weeks after the last infusion, patients undergo cystectomy with pelvic lymph node dissection surgery.
62481017|NCT02525445|ACTIVE_COMPARATOR|acupuncture positive communication|Genuine acupuncture needles combined with positive communication regarding the expected treatment effects
61926379|NCT06149273|ACTIVE_COMPARATOR|Treatment as usual|Participants receive short counselling about insomnia at the enrollment visit.
61926380|NCT01292785||Transsexual|Female-to-Male and Male-to-Female Transsexuals receiving hormonal therapy
61926381|NCT01292785||Healthy control subjects|receiving no hormonal therapy
62130267|NCT05325931|EXPERIMENTAL|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal Low Add Power (LA) and High Add Power (HA)
62320726|NCT01489787|EXPERIMENTAL|Phase I : HIFU|
62320727|NCT01489787|EXPERIMENTAL|Phase IIa : HIFU|
62320728|NCT01489787|EXPERIMENTAL|Phase IIb : HIFU|
62320729|NCT05399758||ICU sedated patients|Critical patients sedated with propofol and fentanyl The values obtained with the use of the NOL® index will be recorded and compared with the standard measurements of pain assessment (Behavioral Pain Scale (BPS) and/or CPOT)
62320730|NCT05809011|EXPERIMENTAL|Corticosteroid therapy plus standard-of-care|Patients randomized to this arm will receive a single-bolus intravenous injection of dexamethasone 20 mg at day 1 (as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization. Patients randomized to this arm will also receive standard-of-care therapy for acute heart failure.
62320731|NCT05809011|NO_INTERVENTION|Standard-of-care|Patients randomized to this arm will receive standard-of-care therapy for acute heart failure.
62320732|NCT05567068|OTHER|Control Group|This group will take mesalamine 1 g three times daily
62320733|NCT05567068|ACTIVE_COMPARATOR|Atorvastatin group|This group will take mesalamine 1 g three times daily plus atorvastatin 80 mg once daily.
62320734|NCT06332053|EXPERIMENTAL|Group A, Treatment Sequence (SY-5007-SY-5007/Itraconazole)|SY-5007 80mg, tablets, once daily on Day 1 and Day 11 before meal; Itraconazole 200mg, once or twice daily from Day 8 to Day 18.
62320735|NCT06332053|EXPERIMENTAL|Group B, Treatment Sequence (SY-5007-SY-5007/Rifampin)|SY-5007 160mg, tablets, once daily on Day 1 and Day 16 before meal, Rifampicin 600mg, once daily from Day 8 to Day 21.
62320736|NCT02811484|OTHER|Group 1|Insulin titration and behavioral therapy.
62481018|NCT02525445|SHAM_COMPARATOR|sham acupuncture positive communication|Sham acupuncture needles combined with positive communication regarding the expected treatment effects
62481019|NCT02525445|ACTIVE_COMPARATOR|acupuncture neutral communication|Genuine acupuncture needles combined with neutral communication regarding the expected treatment effects
62481020|NCT02525445|SHAM_COMPARATOR|sham acupuncture neutral communication|Sham acupuncture needles combined with neutral communication regarding the expected treatment effects
62481021|NCT02110277|EXPERIMENTAL|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
62481022|NCT03418753||single|subjects with abnormal intracranial pressure
62481023|NCT03183609|ACTIVE_COMPARATOR|Gluten|30 grams of gluten flour daily in protein shake
62689625|NCT06365346|ACTIVE_COMPARATOR|Online educational modules|Parent-child dyads in the control group will receive weekly online educational modules via email for 6 weeks. Such information will include definition, etiology, risk factors, signs and symptoms, and therapeutic interventions (pharmacological and nonpharmacological), its complications, and how to manage it.
62689626|NCT00586937||1|Lung Cancer Survivors
62689627|NCT04383639|ACTIVE_COMPARATOR|1|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
62689628|NCT04383639|EXPERIMENTAL|2|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
62689629|NCT04383639|EXPERIMENTAL|3|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
61926382|NCT04462419||Diagnostic (18F-fluciclovine, PET/MRI imaging)|Patients receive fluciclovine IV and undergo brain dynamic PET/MRI imaging over 50 minutes.
62320737|NCT02811484|PLACEBO_COMPARATOR|Group 2|Exenatide-LAR plus Dapagliflozin placebo, basal insulin titration, and behavioral therapy.
62320738|NCT02811484|EXPERIMENTAL|Group 3|Exenatide-LAR plus Dapagliflozin, basal insulin titration, and behavioral therapy.
62320739|NCT05347589|EXPERIMENTAL|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|
62320740|NCT05347589|ACTIVE_COMPARATOR|post isometric relaxation of the Quadratus lumborum|
62320741|NCT05628233|NO_INTERVENTION|Study Arm A (control arm)|Subjects receiving cisplatin-based chemotherapy without receiving SENS-401. This control arm will provide natural history data, particularly the incidence and the time to onset of hearing impairment due to ototoxicity.
62481024|NCT03183609|PLACEBO_COMPARATOR|Placebo|30 grams of rice flour daily in protein shake
62481025|NCT05543135||cases|patients with asymmetrical hearing loss
62481026|NCT05162105|EXPERIMENTAL|Evening shift followed by day shift (Quick Return)|Participants work a simulated evening shift, from 03:00PM to 11:00PM, followed by a simulated day shift, 07:00AM to 03:00PM, the following day.
62689630|NCT03136432||Children with cerebral palsy|Children with cerebral palsy, who can walking dependently and continuously for 6 minutes.
62689631|NCT05127265||adult ICU patients|adult patients aged 18 or older admitted to University of Florida Health Shands Gainesville ICU wards
62689632|NCT06674317|EXPERIMENTAL|Arm 1: Internet delivered Cognitive Behaviour Therapy for Insomnia group|This group you will have access to the internet delivered cognitive behavioral therapy for insomnia intervention following the completion of the first study entry questionnaire.
62689633|NCT06674317|OTHER|Arm 2: Wait list Control Group|This wait list control group will be offered access to the internet delivered cognitive behavioral therapy for insomnia intervention AFTER completion of the third online questionnaires 5 months after group assignment.
62689634|NCT00998959|EXPERIMENTAL|Mindfulness based stress reduction and problem solving therapy|
61926383|NCT05373771|ACTIVE_COMPARATOR|Post-intervention|
61926384|NCT05373771|NO_INTERVENTION|Delayed intervention|
62689635|NCT00998959|OTHER|Psychoeducation|
62130268|NCT05325931|ACTIVE_COMPARATOR|samfilcon A for Presbyopia|B+L ULTRA for Presbyopia Low Add Power (LA) and High Add Power (HA)
62320742|NCT05628233|EXPERIMENTAL|Study Arm B (treatment arm)|Subjects receiving 43.5 mg of oral SENS-401 b.i.d for up to 23 weeks. This arm will provide data on the potential protective effects of SENS-401 on cisplatin induced ototoxicity.
62320743|NCT00301067|EXPERIMENTAL|Cohort 1 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.2 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
62320744|NCT00301067|EXPERIMENTAL|Cohort 2 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.3 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
62339759|NCT01350960|EXPERIMENTAL|Cohort 3|5.0 mg/kg in Healthy subjects
62481027|NCT05162105|ACTIVE_COMPARATOR|Day shift followed by day shift|Participants work a simulated day shift, from 07:00AM to 03:00PM, followed by another simulated day shift, from 07:00AM to 03:00PM, the following day.
61926385|NCT06729645|EXPERIMENTAL|Patients with Rectal cancer|Patients will be initially treated with EBRT with 13 x 3 Gy to a total dose of 39 Gy to the primary tumor and pelvic lymph node, over a period of 2.5 weeks. Restaging with pelvic MRI and endoscopy will then be performed 6.5 weeks after completion of EBRT and prior to the first endorectal HDR-BT fraction to evaluate initial therapy response and the residual extent of the disease for target outlining. Following that, endorectal HDR-BT will be delivered with 3 x 8 Gy to a total dose of 24 Gy (dose prescription: 5 mm depth for cT1 tumors; 10 mm depth for cT2-3 tumors), with each endorectal brachytherapy application performed once weekly.
61926386|NCT01626638|EXPERIMENTAL|Experimental|
61926387|NCT03015883|EXPERIMENTAL|Diffusing Alpha Radiation Emitters Therapy (DaRT)|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed Devices
61926388|NCT02128828|EXPERIMENTAL|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
62689636|NCT05130281|EXPERIMENTAL|Social Support|Participants receive treatment with the Maya app in conjunction with social support incentives for 6 weeks.
62689637|NCT05130281|EXPERIMENTAL|Gain Framed|Participants receive treatment with the Maya app in conjunction with gain-framed incentives for 6 weeks.
61926389|NCT01955980|EXPERIMENTAL|Buparid; Treatment A|Buparid 1mg budesonide/2 ml nebulizer solution
61926390|NCT01955980|ACTIVE_COMPARATOR|Budes; Treatment B|Budes Nasal Spray 50 µg budesonide/pump
61926391|NCT03410823|EXPERIMENTAL|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
61926392|NCT02616471|EXPERIMENTAL|High-fat cheese (HFC) group|"The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US).~No further dairy and cheese consumption is allowed"
61926393|NCT02616471|EXPERIMENTAL|Low-fat cheese (LFC) group|The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed.
61926394|NCT02616471|ACTIVE_COMPARATOR|No-cheese/carbohydrate group (CTR)|For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed.
62130269|NCT03674047|EXPERIMENTAL|newly-diagnosed BOS|-Participants will take ruxolitinib twice every day
62130270|NCT03674047|EXPERIMENTAL|Established BOS|-Participants will take ruxolitinib twice every day
62320745|NCT00301067|EXPERIMENTAL|Cohort 3 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
62689638|NCT05130281|EXPERIMENTAL|Loss Framed|Participants receive treatment with the Maya app in conjunction with loss-framed incentives for 6 weeks.
62689639|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
62689640|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
62689641|NCT06675214|ACTIVE_COMPARATOR|Induction chemotherapy plus conventional concurrent chemoradiotherapy|
62689642|NCT06675214|EXPERIMENTAL|Induction chemotherapy plus gradient fractioned radiotherapy and concurrent chemotherapy|
62689643|NCT05504083|EXPERIMENTAL|D-0120 group 1|take D-0120 dose 1 orally during the treatment period.
62130271|NCT03788590|EXPERIMENTAL|Jenscare TAVI|Patients undergoing a Jenscare TAVI and delivery system
62130272|NCT01402479|ACTIVE_COMPARATOR|ramipril|open label single arm trial
62130273|NCT00581035|EXPERIMENTAL|1|Prevenar and Meningitec
62130274|NCT00581035|EXPERIMENTAL|2|Prevenar
62130275|NCT00581035|EXPERIMENTAL|3|Meningitec
62130276|NCT03381053||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
62320746|NCT00301067|EXPERIMENTAL|Expansion - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
62689644|NCT05504083|EXPERIMENTAL|D-0120 group 2|take D-0120 dose 2 orally during the treatment period.
62320747|NCT00764972|EXPERIMENTAL|Sorafenib and Vinorelbine|
62320748|NCT00614003|EXPERIMENTAL|1|decision support
62320749|NCT03048240|EXPERIMENTAL|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
62689645|NCT05504083|ACTIVE_COMPARATOR|Benzbromarone|take benzbromarone orally during the treatment period.
62689646|NCT05504083|EXPERIMENTAL|D-0120 group 3|take D-0120 dose 3 orally during the treatment period.
62689647|NCT02076009|EXPERIMENTAL|Daratumumab + lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
62320750|NCT00397280||1|Any healthy donors meeting inclusion/exclusion criteria
62320751|NCT01266707|EXPERIMENTAL|Vaccine|VEGRF1, VEGFR2
62320752|NCT02806778||Hypoxic brain injury|Consecutive out-of-hospital, post-cardiac arrest patients who remain comatose after successful resuscitation, admitted on ICU of University Hospital Ostrava. The patients will undergo BIS monitor-guided sedation and jugular bulb catheterisation.
62481028|NCT04654182|EXPERIMENTAL|Log reduction in bacterial count|Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period. Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.
62481029|NCT06366750|EXPERIMENTAL|Barzolvolimab 450 mg, then 150 mg Q4W|450 mg subcutaneous administration loading dose on Day 1 followed by 150 mg subcutaneous administration every 4 weeks, starting on Week 4, to Week 24.
62481030|NCT06366750|EXPERIMENTAL|Barzolvolimab 450 mg, then 300 mg Q4W|450 mg subcutaneous administration loading dose on Day 1 followed by 300 mg subcutaneous administration every 4 weeks, starting on Week 4, to Week 24.
62481031|NCT06366750|PLACEBO_COMPARATOR|Placebo|Matching placebo subcutaneous administration every 4 weeks, starting on Week 4, to Week 24.
62481032|NCT00665925|EXPERIMENTAL|1|R788, 100 mg tablet, orally, twice-a-day
61926395|NCT01982331|EXPERIMENTAL|LAIV H2N2 vaccine|LAIV H2N2 vaccine A/17/California/66/395 (H2N2) live monovalent influenza vaccine delivered intranasally 2 doses 1 month apart
61926396|NCT01982331|PLACEBO_COMPARATOR|Placebo|Placebo is composed of a lyophilizate containing the same concentrations of stabilizers as LAIV vaccine. It is prepared onsite in an identical fashion to the vaccine and delivered intranasally.
62320753|NCT01868373|OTHER|microbiota transplantation|Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
62320754|NCT03465800|ACTIVE_COMPARATOR|Self-Monitoring|Participants self-monitor their physical activity
62320755|NCT03465800|EXPERIMENTAL|Daily Incentives|daily payments for physical activity
62320756|NCT03465800|EXPERIMENTAL|Delayed Lump Sum Incentives|lump sum payments for physical activity
62320757|NCT04241237||Metastatic Breast Cancer patients|Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
62320758|NCT01856491|OTHER|RELIANCE 4-FRONT™ Passive Fixation|Single arm, all patients will be implanted with the RELIANCE 4-FRONT™ Passive Fixation lead
62481033|NCT00665925|EXPERIMENTAL|2|R788, 150 mg tablet, orally, once a day
62481034|NCT00665925|PLACEBO_COMPARATOR|3|Placebo, orally, either once a day, or twice a day
62481035|NCT02390518|EXPERIMENTAL|Stereotactic Radiosurgery|
61926397|NCT02779855|EXPERIMENTAL|Talimogene laherparepvec + Chemotherapy|Talimogene laherparepvec with Neoadjuvant Paclitaxel Chemotherapy treatment administration on an outpatient basis. Phase I: Dose Escalation to Determine Maximum Tolerated Dose (MTD). Phase II: Treatment at MTD.
61926398|NCT01184131|EXPERIMENTAL|Mentor Training|The group that is randomized into the intervention group to attend Mentor Training Sessions.
62481036|NCT06426225|ACTIVE_COMPARATOR|General Anesthesia|As premedication 0.03mg/kg midazolam was administered. During general anesthesia, 3 mg/kg propofol, 0.6 mg/kg rocuronium and 1 mcg/kg fentanyl were administered to all patients for induction.
62481037|NCT06426225|ACTIVE_COMPARATOR|Spinal Anesthesia|As premedication 0.03mg/kg midazolam was administered. After premedication Spinal Anesthesia applied. Group will be sedated with ketofol after spinal anesthesia. Ketamine:propofol mixture will be prepared as 1:1 5mg/ml propofol and 5mg/ml ketamine. Surgery will begin when the Ramsey sedation scale reaches 3.
62481038|NCT01995227|EXPERIMENTAL|AlloVax Treatment|Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.
62481039|NCT00271492|ACTIVE_COMPARATOR|I|Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
61926399|NCT01184131|NO_INTERVENTION|No Mentor Training|
61926400|NCT03495180|EXPERIMENTAL|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
61926401|NCT06745128|EXPERIMENTAL|Tirzepatide|Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 32-week period in accordance with FDA-prescribing label guidelines.
62320759|NCT05791318|EXPERIMENTAL|Cohort 1|10 total participants Cohort 1. 8 participants on VYD222 2 participants on placebo
62320760|NCT05791318|EXPERIMENTAL|Cohort 2|10 total participants Cohort 2. 8 participants on VYD222 2 participants on placebo
62320761|NCT05791318|EXPERIMENTAL|Cohort 3|10 total participants Cohort 3. 8 participants on VYD222 2 participants on placebo
62320762|NCT06521008|EXPERIMENTAL|Selctive drugs|consists of 20 women. They will receive selective anti Muscarinic drugs (5-10 mg) once per day for 12 weeks and instructions including bladder retraining.
62320763|NCT06521008|EXPERIMENTAL|Pelvic floor and abdominal strengthening|consists of 20 women. They will receive the same treatment in group (A), pelvic floor muscle training (PFMT) and abdominal strengthening 3 sessions/week for 12 weeks.
61926402|NCT02524964|EXPERIMENTAL|sodium tanshinone IIA sulfonate|sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days)
61926403|NCT02524964|SHAM_COMPARATOR|control|same volume/day of normal saline.
61926404|NCT06128824||Patients with probable CAA and cSS or fSAH|Patients with probable CAA and cortical superficial siderosis (cSS) or focal subarachnoid haemorrhage (fSAH)
61926405|NCT06128824||Patients with probable CAA without cSS or fSAH|Patients with probable CAA and intracerebral hemorrhage (ICH; micro- or macrohemorrhage) but without cSS or fSAH
61926406|NCT01483690|EXPERIMENTAL|Initial Dose Level|"Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24"
61926407|NCT01483690|EXPERIMENTAL|Modified Dose Level|"Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21"
61926408|NCT03923322|EXPERIMENTAL|Botanical Tincture|The 12-week study includes a 2-week screening, 8-week treatment, and 2-week withdrawal periods. A 2-week screening period will be used to establish the presence and persistence of trial entry criteria and train patients in the mode of data collection. Participants randomly assigned to the Botanical Tincture arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose. Participants who received Botanical Tincture during the study will be followed by a 2-week randomized withdrawal design to address the need for maintenance treatment to prevent sign or symptom recurrence. The participant will be randomly reassigned to receive either Botanical Tincture or placebo at a dosage of 2.5 ml once a day by mouth at any time during the day that they prefer.
61926409|NCT03923322|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to placebo arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose during the 8-week treatment period.
61926410|NCT06135168|EXPERIMENTAL|PEG-rhGH with new preparation|
61926411|NCT06135168|EXPERIMENTAL|PEG-rhGH with present preparation|
61926412|NCT03580148|ACTIVE_COMPARATOR|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
61926413|NCT03580148|ACTIVE_COMPARATOR|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
61926414|NCT02561624|EXPERIMENTAL|Intervention|Use of behaviour change communication via text messages to pregnant women receiving an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
61926415|NCT02561624|NO_INTERVENTION|Control|Control group receives no behaviour change communication via text message, but receives an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
61926416|NCT03913442|PLACEBO_COMPARATOR|Placebo|Placebo in capsule identical to study drug
61926417|NCT03913442|EXPERIMENTAL|Colchicine|"0.6 or 0.8 mg orally once daily.~Because recent studies suggest that a dose of 0.6mg may be sufficient for chronic inflammatory suppression and may reduce the already low risk of toxicity of 0.8mg, for the remainder (second half) of the study the dosage will be switched from 0.8mg to a 0.6mg dose to allow comparison of the two doses."
61926418|NCT00749580|EXPERIMENTAL|1: Boosted PI+RAL|Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
62689648|NCT02076009|ACTIVE_COMPARATOR|Lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
61926419|NCT00749580|NO_INTERVENTION|2: Boosted PI+NRTIs|Group 2 Continue the same regimen without change
61926420|NCT06617429|EXPERIMENTAL|GTX-102|Participants will receive GTX-102 via lumbar puncture (LP) during both the double-blind and open-label period
61926421|NCT06617429|SHAM_COMPARATOR|Sham-LP then GTX-102|Participants will receive sham procedure during the double-blind period and then will receive GTX-102 via LP during the open-label period
61926422|NCT06411353|EXPERIMENTAL|Patients|Patients will first undergo visit V1 (screening and enrolment). On day 0 they will have the surgery for VA creation (V2) and then the study follow-up visits will take place i.e., between 0 and 14 days, at 3 months, 6 months, 1 year and 2 years after VA surgery (V3-V7).
61926423|NCT05732831|EXPERIMENTAL|Dose Escalation|Participants with MTAP-deleted solid tumors (excluding primary CNS) will receive escalating doses of TNG462 single agent and in combination with pembrolizumab to estimate the MTD
61926424|NCT05732831|EXPERIMENTAL|Dose Expansion in NSCLC|Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG462 at the identified RP2D(s)
61926425|NCT05732831|EXPERIMENTAL|Dose Expansion in Mesothelioma|Participants with MTAP-deleted mesothelioma will receive TNG462 at the identified RP2D(s)
61926426|NCT05732831|EXPERIMENTAL|Dose Expansion in Pancreatic Ductal Adenocarcinoma|Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG462 at the identified RP2D(s)
61926427|NCT05732831|EXPERIMENTAL|Dose Expansion in Sarcoma|Participants with MTAP-deleted sarcoma (soft tissue or bone) will receive TNG462 at the identified RP2D(s)
61926428|NCT05732831|EXPERIMENTAL|Dose Expansion in Solid Tumors|Participants with other MTAP-deleted solid tumors will receive TNG462 at the identified RP2D(s)
61926429|NCT05732831|EXPERIMENTAL|Dose Expansion in NSCLC in Combination with Pembrolizumab|Participants NSCLC (squamous and non squamous) MTAP-deleted solid tumors will receive TNG462 at the identified RP2D(s)
61926430|NCT02487823|EXPERIMENTAL|BKM 120 (60 mg)|BKM120 (60 mg) in combination with LH-RH agonists and bicalutamide
61926431|NCT02487823|EXPERIMENTAL|BKM 120 (80 mg)|BKM120 (80 mg) in combination with LH-RH agonists and bicalutamide
61926432|NCT02487823|EXPERIMENTAL|BKM 120 (100 mg)|BKM120 (100 mg) in combination with LH-RH agonists and bicalutamide
62320764|NCT06521008|EXPERIMENTAL|diaphragmatic training|consists of 20 women. They will receive the same treatment in group (B), in addition to diaphragmatic training 3 sessions/week for 12 weeks.
61926433|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + Temozolomide (TMZ) 40 milligrams (mg) (Days 1-7)|Pamiparib 60 mg twice daily on Days 1 to 28 in combination with pulse dosing of TMZ 40 mg once daily on Days 1 to 7 within a 28-day cycle
61926434|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + TMZ 60 mg (Days 1-7)|Pamiparib 60 mg twice daily on Days 1 to 28 in combination with pulse dosing of TMZ 60 mg once daily on Days 1 to 7 within a 28-day cycle
61926435|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + TMZ 80 mg (Days 1-7)|Pamiparib 60 mg twice daily on Days 1 to 28 in combination with pulse dosing of TMZ 80 mg once daily on Days 1 to 7 within a 28-day cycle
62339760|NCT01350960|EXPERIMENTAL|Cohort 4|10 mg/kg in Healthy subjects
62689649|NCT01283945|EXPERIMENTAL|Lucitanib|
62481040|NCT00271492|PLACEBO_COMPARATOR|2|placebo group to be compared to the actual medication
62481041|NCT01321450||Group A|Preparation with Harmonic WAVE
62481042|NCT01321450||Group B|Preparation with conventional modalities
62481043|NCT05828511|EXPERIMENTAL|Phase 1 cohort|Linvoseltamab dose escalation (part A) and dose expansion (part B) for participants with NDMM who are treatment-naïve.
62481044|NCT05828511|EXPERIMENTAL|Phase 2 - transplant ineligible cohort|Transplant-ineligible participants, enrolled in dose expansion, will receive selected Linvoseltamab regimen until disease progression as per protocol.
62481045|NCT05828511|EXPERIMENTAL|Phase 2 - transplant eligible cohort|Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol
62689650|NCT04654052|OTHER|VerifyNow® PRUTest ≤30 (De-escalated Prasugrel Ticagrelor )|Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will be de-escalated to Clopidogrel 75 mg q.d during 11 months.
62689651|NCT04654052|OTHER|VerifyNow® PRUTest ≤30 (Prasugrel or Ticagrelor )|Active comparator: Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will continue with these previous treatment during 11 months.
62689652|NCT03981289||CAPN3 (LGMD2A)|Clinical Assessments, Biomarkers
62689653|NCT03981289||DYSF (LGMD2B)|Clinical Assessments, Biomarkers
62689654|NCT03981289||ANO5 (LGMD2L)|Clinical Assessments, Biomarkers
62320765|NCT03114241|ACTIVE_COMPARATOR|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
62320766|NCT03114241|NO_INTERVENTION|Control|Usual care.
62689655|NCT03981289||DNAJB6 (LGMD1D)|Clinical Assessments, Biomarkers
62689656|NCT03981289||Sarcoglycan (LGMD2D) (LGMD2E) (LGMD2C) (LGMD2F)|Clinical assessments
62689657|NCT02462057|NO_INTERVENTION|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
62320767|NCT03732768|EXPERIMENTAL|Radspherin|
62320768|NCT02707705|EXPERIMENTAL|: Auricular Acupuncture (needle patch) group A|Needle patch: Patients receiving the auricular acupuncture protocol with needles inserted on adhesive tape.
62320769|NCT02707705|PLACEBO_COMPARATOR|Needle-free patch: group P.|Patients who received the auricular acupuncture protocol with adhesive tape without needles.
62320770|NCT02707705|NO_INTERVENTION|No intervention: group C|Patients without any device or intervention.
62320771|NCT00667758|EXPERIMENTAL|1|Cetrorelix
62320772|NCT00667758|PLACEBO_COMPARATOR|2|NaCl solution
62320773|NCT01893723|EXPERIMENTAL|ANI guided remifentanil arm|remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
62320774|NCT01893723|OTHER|ANI blind arm|remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.
62320775|NCT01037374|EXPERIMENTAL|Difficult Airway Assessment Form|
62481046|NCT02795663|EXPERIMENTAL|parkinson's patient stimulated at STN level|15 parkinson's disease patients stimulated at STN level NIRS EEG HR recording
62481047|NCT02795663|EXPERIMENTAL|non STN|5 Parkinson's Disease patients who received stimulation in another target that the STN NIRS EEG HR recording
62481048|NCT02795663|EXPERIMENTAL|control|20 control patients undergoing DBS for the treatment of OCD NIRS EEG HR recording
62481049|NCT05517447|OTHER|Observational cohort|Proptosis responders in feeder studies will enter in a non-treatment observational study
62481050|NCT05517447|EXPERIMENTAL|Treatment Cohort|Proptosis non-responders in feeder studies will be administered batoclimab of 680 milligram (mg) subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks
62481051|NCT00860938|ACTIVE_COMPARATOR|Budesonide|
62481052|NCT00860938|PLACEBO_COMPARATOR|Placebo|
62481053|NCT05571592|EXPERIMENTAL|Cannabidiol 400mg|Participants assigned to 200mg twice-daily (400mg/day) dose for 3 weeks.
62481054|NCT05571592|EXPERIMENTAL|Cannabidiol 800mg|Participants assigned to 400mg twice-daily (800mg/day) dose for 3 weeks.
62481055|NCT05571592|PLACEBO_COMPARATOR|Placebo|Participants assigned to twice-daily placebo dose for 3 weeks.
62689658|NCT02462057|ACTIVE_COMPARATOR|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
62339761|NCT01350960|EXPERIMENTAL|Cohort 5|TBD mg/kg in FH subjects
62339762|NCT01193192||Arm #1 (Test Group)|100 subject administered Neevo® or NeevoDHA® daily
62689659|NCT02462057|ACTIVE_COMPARATOR|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
62481056|NCT00721435|EXPERIMENTAL|3D Tomosynthesis & 3D Ultrasound for breast masses|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
61926436|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + TMZ 100 mg (Days 1-7)|Pamiparib 60 mg twice daily on Days 1 to 28 in combination with pulse dosing of TMZ 100 mg once daily on Days 1 to 7 within a 28-day cycle
62130277|NCT03381053||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
62481057|NCT00721435|EXPERIMENTAL|3D Tomosynthesis/ 3D Ultrasound for healthy subjects|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
62689660|NCT02462057|ACTIVE_COMPARATOR|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
62320776|NCT03661541|EXPERIMENTAL|Group A, 6 or more outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months.~Subjects in group A will receive 2% Squaric Acid Dibutyl Ester (SADBE) dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."
62320777|NCT03661541|NO_INTERVENTION|Group B, 1 or 2 outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
62481058|NCT05811247|EXPERIMENTAL|AD109|AD109
62481059|NCT05811247|PLACEBO_COMPARATOR|Placebo|Placebo
62481060|NCT05387603|EXPERIMENTAL|177Lu-DOTATOC + Capecitabine|"Patients with 68Ga-DOTA- and 18F-FDG-PET-positive NET will receive a combination of intravenous 7.5 GBG (gigabequerel) 177Lu-DOTATOC for about 7 cycles in combination with capecitabine (4 cycles, cycle length 3 weeks, with one week without capecitabine, dosing 825 mg twice daily) and PRRT to a cumulative renal AD (absorbed dose) limit of 30 Gy and dosimetry-based PRRT.~."
62481061|NCT05387603|EXPERIMENTAL|177Lu-DOTATOC|Intravenous infusion for about 7 treatment cycles with 7.5 GBq 177Lu-DOTATOC with an interval of 10 ± 2 weeks and PRRT to a cumulative renal AD limit of 30 Gy and dosimetry-based PRRT.
62689661|NCT02462057|ACTIVE_COMPARATOR|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:~1. Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths~2. No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
62689662|NCT00087672|EXPERIMENTAL|CC-5013|
62689663|NCT06585865|EXPERIMENTAL|Resveratrol (RSV) group|Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
62689664|NCT06585865|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
62689665|NCT05454566|EXPERIMENTAL|Group 1: ICM-203 (Low dose)|3 to 6 subjects will receive a single intra-articular injection of ICM-203 at 6x10e12 vg into the target knee at Day 1
62130278|NCT01417910||Peripheral vascular disease|Subjects who have peripheral vascular disease
62130279|NCT05749523|OTHER|Exercise|Exercise vs. non-exercise
62130280|NCT04484935|EXPERIMENTAL|Nirsevimab|"1st RSV season: 50mg nirsevimab~1. st RSV season: 100mg nirsevimab~2. nd RSV season: 200mg nirsevimab"
62130281|NCT05146375||MSF1|Each member of the MSF1 family who consents to participate to the study will be included.
62481062|NCT05387603|ACTIVE_COMPARATOR|Standard 177Lu-DOTATOC|Standard treatment of 177Lu-DOTATOC with treatment for 4 cycles.
62481063|NCT04489719||Observational (biospecimen collection)|Patients receive standard of care radium Ra 223 dichloride given by IV bolus every 4 weeks for up to 6 cycles. Patients undergo collection of blood every 1-3 months during radium Ra 223 dichloride treatment.
62130282|NCT04900766|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Subjects with unresectable or metastatic bone and soft tissue sarcoma will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for a maximum of 6 cycles.
62130283|NCT04456751||No redo op|Patients with a single cardiac operation under extracorporeal bypass
62130284|NCT04456751||Redo op|Patients with a redo cardiac operation under extracorporeal bypass
62339763|NCT01193192||Arm #2 (Control group)|100 subject administered a prenatal vitamin daily
62689666|NCT05454566|EXPERIMENTAL|Group 2: ICM-203 (Medium dose)|3 to 6 subjects will receive a single intra-articular injection of ICM-203 at 2x10e13 vg into the target knee at Day 1
62481064|NCT00911274|EXPERIMENTAL|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by CellCept® 250 mg Capsule dosed in second period.
62481065|NCT00911274|ACTIVE_COMPARATOR|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
62689667|NCT05454566|EXPERIMENTAL|Group 3: ICM-203 (High dose)|3 to 6 subjects will receive a single intra-articular injection of ICM-203 at 6x10e13 vg into the target knee at Day 1
62481066|NCT04026815||60 - 65 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
62481067|NCT04026815||65 - 69 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
62481068|NCT04026815||70 - 74 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
62689668|NCT03492385|EXPERIMENTAL|1: 100 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
62689669|NCT03492385|EXPERIMENTAL|2: 300 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
62689670|NCT03492385|EXPERIMENTAL|3: 1000 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
62130285|NCT03450200|EXPERIMENTAL|Exercises Group|three times daily exercises of hands and fingers exercises and foot exercises which last for 10 minutes in eight weeks, and health education about diabetic foot care
62130286|NCT03450200|OTHER|Control Group|health education about diabetic foot care
62130287|NCT00423098|EXPERIMENTAL|Standard dose|Mycophenolate sodium was administered orally in combination with a standard dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 1 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
62320778|NCT03661541|NO_INTERVENTION|Group C, zero outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group C: 12 subjects with zero outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
62320779|NCT04318743|EXPERIMENTAL|autoinjector - vial/syringe - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
62320780|NCT04318743|EXPERIMENTAL|vial/syringe - autoinjector - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
62481069|NCT04026815||75 - 79 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
62481070|NCT04026815||80 - 84 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
62481071|NCT04026815||85 - 89 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
62481072|NCT04026815||≥90 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
62689671|NCT03492385|EXPERIMENTAL|4: 1000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
62689672|NCT03492385|EXPERIMENTAL|5: 3000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
62689673|NCT03492385|EXPERIMENTAL|6: 9000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
62689674|NCT03492385|EXPERIMENTAL|7: 18000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
62320781|NCT04318743|EXPERIMENTAL|vial/syringe - vial/syringe - autoinjector|Single dose of Glepaglutide 10 mg for each treatment sequence
62320782|NCT03705104|EXPERIMENTAL|EPIO (e-health intervention)|Participants will get access to one module every third day (total 9 modules). The app consists of cognitive behavioral pain self-management material, including educational material and relaxation training exercises.
62320783|NCT03705104|NO_INTERVENTION|treatment as usual|Participants will get treatment as usual during the study. All participants will get access to the app after ended study if interested.
62689675|NCT03492385|EXPERIMENTAL|8: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
62689676|NCT03492385|EXPERIMENTAL|9: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre and Post-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses and 180 mg 24 hours post-dose
62320784|NCT03705104|ACTIVE_COMPARATOR|Experimental without introduction group and follow up phone calls|One extra arm (non randomized) has been included to examine whether participants who receive the EPIO intervention without receiving an introduction session and follow up phone calls will still describe benefiting from the receiving the intervention
62320785|NCT02815397|EXPERIMENTAL|Single arm, open label|Metformin added to standard of care treatment for all patients
62481073|NCT04925791|EXPERIMENTAL|The IPC group|subjects will get a standardized pre-conditioning treatment 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of occlusion alternating with 5 minutes of reperfusion while seated.
62689677|NCT03492385|EXPERIMENTAL|10: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Txt)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
62689678|NCT06641596|PLACEBO_COMPARATOR|Placebo|2 x 500 mg capsules
62320786|NCT01861340|EXPERIMENTAL|Lenalidomide, Dexamethasone, and MEDI-551|Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles. MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4.
62320787|NCT04650321|EXPERIMENTAL|Home infusion of ocrelizumab|Patients will receive infusion of ocrelizumab at home, instead of at clinic.
62320788|NCT03851393|EXPERIMENTAL|Peptest™ analysis of saliva pepsin|Induction of cough with inhaled citric acid and measurement of saliva pepsin following citric acid cough challenge using the peptest lateral device
62320789|NCT01220752|EXPERIMENTAL|IMRT + carbon ion boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
62320790|NCT05870501|EXPERIMENTAL|Ketamine followed by midazolam|Ketamine 0.5mg/kg (three IV infusions) followed by midazolam 0.045mg/kg (three IV infusions)
62320791|NCT05870501|EXPERIMENTAL|Midazolam followed by ketamine|Midazolam 0.045mg/kg (three IV infusions) follower by ketamine 0.5mg/kg (three IV infusions)
62320792|NCT05521997|ACTIVE_COMPARATOR|Control Arm: Standard of Care Chemoradiation|-Participants will receive 7 weeks of standard of care chemoradiation.
62320793|NCT05521997|EXPERIMENTAL|Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation|-Participants will receive 2 weeks of telaglenastat and 7 weeks of standard of care chemoradiation plus telaglenastat.
62320794|NCT05339464|EXPERIMENTAL|Family wellness program- Group 1|This group will begin the family wellness program first; approximately, 5 weeks before group 2. The family wellness program consists of 8 parent-child workshops and text message reminders.
62320795|NCT05339464|EXPERIMENTAL|Family wellness program- Group 2|This group will begin the family wellness program approximately 5 weeks after group 1.The family wellness program consists of 8 parent-child workshops and text message reminders.
62320796|NCT04875819|EXPERIMENTAL|Menveo + Bexsero|
62320797|NCT04875819|EXPERIMENTAL|Prevenar13 + Pneumovax23|
62689679|NCT06641596|EXPERIMENTAL|Dietary Supplement 1|1 x 20 mg capsule of Cr-400 (formulation of 400 mcg of trivalent chromium with 6 mg of PE and 6 mg of SJ) + 1x500 capsule of PLA
62689680|NCT06641596|EXPERIMENTAL|Dietary Supplement 2|2 x 20 mg capsule of Cr-400 (formulation of 400 mcg of trivalent chromium with 6 mg of PE and 6 mg of SJ)
62689681|NCT06641596|EXPERIMENTAL|Dietary Supplement 3|1 x 500 mg capsule of PE (500mg) + 1 x 500 mg capsule of PLA
62689682|NCT06641596|EXPERIMENTAL|Dietary Supplement 4|2 x 500 mg capsules of PE (1000 mg)
62689683|NCT01446471||Cardiac Arrest|Patients in Cardiac Arrest will be enrolled
62689684|NCT04475380||All-comer patients requiring PCI|All-comer patients requiring percutaneous coronary intervention (PCI) for the treatment of significant coronary artery of bypass graft lesions that are suitable for treatment with Xience Sierra DES
62320798|NCT03988777||Prospective Magseed|This cohort includes patients with an impalpable breast lesion that are scheduled for breast conserving surgery with Magseed localisation after September 2018. Their data will be prospectively collected and analysed.
62320799|NCT03988777||Retrospective hooked-wire|This cohort includes patients with an impalpable breast lesion that were scheduled for breast conserving surgery with hooked-wire before September 2018. Their data will be retrospectively collected and analysed.
62320800|NCT03299517|EXPERIMENTAL|lidocaine|"Initial dose: antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).~Adittional dose: Lidocaine (0.75 mg / kg EV in 30 minutes)."
62481074|NCT04925791|OTHER|The CON group|subjects will get a controlled treatment of 20% of limb occlusion pressure 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of minimal occlusion alternating with 5 minutes of reperfusion while seated.
62689685|NCT01202357|EXPERIMENTAL|Case Management (1 year)|
62689686|NCT01202357|NO_INTERVENTION|Standard Care (1 year)|
62689687|NCT03338790|EXPERIMENTAL|nivolumab + rucaparib|Specified dose on specified days
62689688|NCT03338790|EXPERIMENTAL|nivolumab + docetaxel + prednisone|Specified dose on specified days
62320801|NCT03299517|EXPERIMENTAL|amiodarone|"Initial dose: antiarrythmic drugs Amiodarone (5 mg / kg EV in 30 minutes)~Adittional dose: Amiodarone (3 mg / kg EV in 30 minutes)"
62320802|NCT00390780|ACTIVE_COMPARATOR|Clotrimazole|Clotrimazole troches, 10 mg, 5 times per day for 14 days
62320803|NCT00390780|EXPERIMENTAL|miconazole Lauriad|Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days
62320804|NCT00138125|EXPERIMENTAL|Arm I|see intervention description for details
62320805|NCT01394029||deferasirox|
62320806|NCT03983876|EXPERIMENTAL|AVT02 100mg/mL in PFS|Prefilled Syringe Arm
62689689|NCT03338790|EXPERIMENTAL|nivolumab + enzalutamide|Specified dose on specified days
62130288|NCT00423098|ACTIVE_COMPARATOR|Low dose|Mycophenolate sodium was administered in combination with a reduced dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 0.5 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
62130289|NCT04578496|EXPERIMENTAL|Afamelanotide|
62130290|NCT02207972|ACTIVE_COMPARATOR|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
62130291|NCT02207972|ACTIVE_COMPARATOR|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
62320807|NCT03983876|EXPERIMENTAL|AVT02 100mg/mL in Autoinjector|Autoinjector Arm
62481075|NCT05404490|EXPERIMENTAL|Bupivacaine|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
62481076|NCT05404490|PLACEBO_COMPARATOR|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
62481077|NCT05572437|NO_INTERVENTION|Control Group|Patients randomized to the control group will be assessed for preoperative anxiety using the APAIS scale in the preoperative room and assessment of insomnia using the ISI scale both in the PACU and on the 1st day in the hospital ward. Pain assessment will be measured using the VAS scale in the PACU and on the first day on the hospital ward.
62689690|NCT04287829|EXPERIMENTAL|pembrolizumab and lenvatinib|"Patients will receive pembrolizumab 200mg/iv (fixed dose) every 3 weeks and lenvatinib 20mg QD in a three weekly cycle.~Treatment continues until disease progression by modified RECIST 1.1 for MPM, severe toxicity, serious intercurrent illness, patient request for discontinuation, need or use for any other anti-cancer agent other than protocol treatment, except for palliative radiotherapy, for a maximum period of 35 cycles"
62320808|NCT00370786|EXPERIMENTAL|1|
62320809|NCT04005443|OTHER|PET at 68Ga-NODAGA-RGD|The first PET scan will be performed within a maximum of one month following the initial ophthalmologic assessment including OCT and measurement of visual acuity (M0);
62320810|NCT04016883|SHAM_COMPARATOR|Conventional web platform|Participants asked to review the web platform for 4 weeks.
62320811|NCT04016883|EXPERIMENTAL|Problem Solving Therapy offered through a web platform|4 sessions with cognitive behavioral therapy, offered through a web platform. Each session will be offered per week.
62320812|NCT03715569||Cohort with CNS infections|"Otoacoustic emissions (OAE), Wide Band Tympanometry (WBT), Vestibular function tests. Audiometry. MOCA, eGOS are cognitive tests.~Biomarker is a protein found in the inner ear examined in the cerebral fluid."
62320813|NCT03715569||OAE/WBT control: Healthy individuals|Otoacoustic emissions in normal position with head. Otoacoustic emission in different head positions.
62320814|NCT03715569||OAE/WBT control: Systemic infection|Otoacoustic emission during admission
62320815|NCT03715569||OAE/WBT control: ICP changes|Otoacoustic emission on patients without an CNS infection before and after elective lumbare puncture with measurement of intracranial pressure (ICP).
62320816|NCT03715569||Biomarker control|Inner ear biomarkers in patients without CNS infection. Inner ear fluid examination from patients that underwent elective cochlea implantation.
62320817|NCT03351322|EXPERIMENTAL|ENERGI-F701|ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
62320818|NCT03351322|ACTIVE_COMPARATOR|Regaine|Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
62320819|NCT04996849||Observational (data collection)|Patients undergo data collection every 6 months for up to 15 years.
62320820|NCT02229968|EXPERIMENTAL|Amicar (ε-aminocaproic acid)|Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.
62320821|NCT02229968|PLACEBO_COMPARATOR|normal saline|Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.
62320822|NCT05108324|EXPERIMENTAL|zygomatic implant|patients receiving 2 zygomatic implants with 2 conventional implant in anterior region
62320823|NCT05108324|ACTIVE_COMPARATOR|conventional implant|patients receiving 4 conventional implant 2 in anterior region and 2 in posterior region with immediate loading
62130292|NCT05372146|EXPERIMENTAL|CHIVA group|43 participants. In the study group patients GSV was punctured 20-25 cm below SFJ. Radiofrequency catheter (ClosureFast) was inserted and positioned at SFJ distally to the superficial iliac circumflex vein. Four cycles were used for one segment below SFJ. After that catheter cooled down to 40C and was extracted. Phlebectomy was performed using Varady hooks after thermal ablation in both groups. All procedures were performed under tumescent anesthesia.
62320824|NCT01509586|EXPERIMENTAL|PREP (Potentially Reduced Exposure Product) Group|
62320825|NCT01509586|NO_INTERVENTION|cigarette group|
62320826|NCT04973111|EXPERIMENTAL|CT-868|SC dose of CT-868 Intervention: Drug: CT-868
62320827|NCT04973111|PLACEBO_COMPARATOR|Placebo|SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo
62320828|NCT04973111|ACTIVE_COMPARATOR|Active Comparator|SC dose of Active Comparator Intervention: Drug: Active Comparator
62320829|NCT05515549||Venous thrombosis group|"The venous blood of the patients under fasting state was collected, and the level of thrombus molecular markers was detected. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred."
62320830|NCT05515549||Group without venous thrombosis|"The venous blood of the patients under fasting state was collected, and the level of thrombus molecular markers was detected. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred."
62320831|NCT01158534|EXPERIMENTAL|Arm I|Patients receive oral celecoxib twice daily and recombinant interferon alpha-2b subcutaneously, once daily, 5 times a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62320832|NCT02362711|EXPERIMENTAL|NPC-16 Standard Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
62320833|NCT02362711|EXPERIMENTAL|NPC-16 Continuous Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
62320834|NCT02362711|PLACEBO_COMPARATOR|Placebo Group|Placebo for NPC-16
62320835|NCT00177268||CTCL, atopic dermatitis, eczema|Those subjects with cutaneous t-cell lymphoma and Sezary syndrome, atopic dermatitis, or eczema may participate as appropriate with the potential for blood, tissue or urine sampling.
62320836|NCT03092492||Cohort 1|Participants with bilateral early AMD and medium drusen in both eyes
62320837|NCT03092492||Cohort 2A|Participants with at least one eye with RPD , with small or medium-sized drusen in either eye
62320838|NCT03092492||Cohort 2B|Participants with at least 1 eye with RPD, with large drusen in either eye
62481078|NCT05572437|EXPERIMENTAL|Intervention Group|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-surgery room, during surgery and in the PACU.
62689691|NCT06121856||In-patients cardiothoracic intensive care|In-patients in the cardiothoracic intensive care department that were at least 16 years old and were fitted with an arterial line. There was no requirement to have diabetes but the study aimed to recruit a minimum of 20% subjects with diabetes.
62689692|NCT06638164|EXPERIMENTAL|Control Group|No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.
62320839|NCT03092492||Cohort 3|Healthy age-matched controls
62320840|NCT05378659||With Post-Operative Cognitive Dysfunction|"Subjects determined to have post-operative cognitive dysfunction based on the results of:~1. 4AT Delirium Test~2. Scoring on :~   1. Montreal Cognitive Assessment~  2. Oral Trails Test~  3. Stroop Test~  4. Symbol Digit Modalities Test~All subjects will undergo:~1. Blood sample collection~2. Cerebral spinal fluid collection~3. ERP testing~4. NACC Cognitive Battery~5. Grooved Pegboard testing"
62320841|NCT05378659||Without Post-Operative Cognitive Dysfunction|"Subjects determined to not have post-operative cognitive dysfunction based on the results of:~1. 4AT Delirium Test~2. Scoring on :~   1. Montreal Cognitive Assessment~  2. Oral Trails Test~  3. Stroop Test~  4. Symbol Digit Modalities Test~All subjects will undergo:~1. Blood sample collection~2. Cerebral spinal fluid collection~3. ERP testing~4. NACC Cognitive Battery~5. Grooved Pegboard testing"
62320842|NCT01492114|EXPERIMENTAL|Resveratrol first|"Subjects in the group resveratrol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
62320843|NCT01492114|ACTIVE_COMPARATOR|Placebo first|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
62689693|NCT06638164|EXPERIMENTAL|Virtual Reality Glasses Group(Experiment)|In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
62689694|NCT02440165|EXPERIMENTAL|Experimental|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
62320844|NCT06691217|PLACEBO_COMPARATOR|Placebo: Control|Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
62320845|NCT06691217|EXPERIMENTAL|Treatment: Canakinumab|Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
62320846|NCT00416637|EXPERIMENTAL|Bevacizumab (Avastin)|Bevacizumab given and then BP checked and skin biopsies obtained.
62320847|NCT06284928||Hypertension Group|This label would be assigned to the cohort of participants who have been newly diagnosed with hypertension. They are the primary focus of the study to explore the specific patterns in their gut microbiota related to hypertension.
62320848|NCT06284928||Control Group|This label would apply to the cohort of participants who do not have hypertension and are otherwise healthy. This group serves as a baseline to compare the microbiota patterns observed in the hypertension group.
62320849|NCT01108809||Patients with arterial hypertension|
62320850|NCT00854763||Hypertension|
62320851|NCT04205903|EXPERIMENTAL|Group I (paclitaxel, nilotinib hydrochloride monohydrate)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nilotinib hydrochloride monohydrate PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62320852|NCT04205903|PLACEBO_COMPARATOR|Group II (paclitaxel, placebo)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive placebo PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62320853|NCT03212547|EXPERIMENTAL|Experimental group|"Verbal interventions made on infants (accompanied by their mothers) who presents sustained social withdrawal detected on the child consultations (at 2, 6 and 12 months of corrected gestational age), made by neonatologists certifieds in the assess of Alarm Distress Baby Scale. Theintervention is described in a guide for Promotion of verbal interventions for interaction , and will be supplemented with a written guideline for parents."
62320854|NCT03212547|NO_INTERVENTION|Control group|Control group: infants will assist at child consultations (at 2, 6 and 12 months of corrected gestational age) whit non trained neonatologists. However, these group will receive a development stimulation guide adapted of the ministerial guides for the stimulation of development of the Ministry of Health of Chile.
62320855|NCT01869894|ACTIVE_COMPARATOR|uncovered double bare metallic stent (S&G Biotech.)|uncovered double bare metallic stent
62320856|NCT01869894|ACTIVE_COMPARATOR|uncovered single bare metallic stent (S&G Biotech.)|uncovered single bare metallic stent
62320857|NCT01869894|ACTIVE_COMPARATOR|uncovered single bare metallic stent (Taewoong Medical.)|uncovered single bare metallic stent
62320858|NCT03321240||The SEEG group|Group with the SEEG analysis
62320859|NCT03321240||The direct surgery group|Group with a direct surgery
62689695|NCT02440165|NO_INTERVENTION|Usual care|All participants, both in the intervention group and the control group, receive usual care containing a regular visit to a nurse who will perform a malnutrition screening with the MUST (Malnutrition Universal Screening Tool). If patients are 'malnourished', a visit to the dietician is suggested.
62320860|NCT00717418||1|"* cyclosporine ophthalmic emulsion 0.05%~* artificial tears"
62320861|NCT05652374|OTHER|Group A|Ialuril therapy for 6 months followed by nitrofuranoïne (or trimethoprim) prophylactic therapy for 6 months. In between therapies there is a 4 week wash-out period.
62320862|NCT05652374|OTHER|Group B|Nitrofuranoïne (or trimethoprim) prophylactic therapy for 6 months followed by Ialuril therapy for 6 months. In between therapies there is a 4 week wash-out period.
62320863|NCT03634605|EXPERIMENTAL|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
62320864|NCT03634605|PLACEBO_COMPARATOR|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
62320865|NCT06346340|EXPERIMENTAL|Miebo treatment|
62689696|NCT04279587|EXPERIMENTAL|Residential camp participant|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at a regional camp.
62320866|NCT03567291|EXPERIMENTAL|TEV-50717- Part A|All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
62320867|NCT03567291|EXPERIMENTAL|TEV-50717- Part B RW|TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.
62481079|NCT06350747|EXPERIMENTAL|Laughter Yoga group|The nurses selected for the experimental group will be provided with information about the study, and suitable days of the week will be determined for their participation, with two days per week designated. Written and verbal informed consent will be obtained from the volunteers on the first designated day. Subsequently, the nurses will be administered the Demographic Information Form, Perceived Stress Scale, Jenkins Sleep Scale, and Maslach Burnout Scale. Following this, the first session of the planned six sessions of laughter yoga will be conducted. The sessions, lasting approximately 30-45 minutes, will be scheduled between 15:00-16:00 on the two designated workdays per week for one month. After the final session, the nurses will be administered the Perceived Stress Scale, Jenkins Sleep Scale, and Maslach Burnout Scale as post-tests.
62481080|NCT06350747|NO_INTERVENTION|control group|The nurses selected for the control group will be provided with information about the study, and written and verbal informed consent will be obtained. Subsequently, the Control group will be administered the Demographic Information Form, Perceived Stress Scale, Jenkins Sleep Scale, and Maslach Burnout Scale. No interventions will be made, and the scales will be administered again after the second and third weeks from the initial assessment. After the final data collection from the control group, a laughter yoga session will be conducted.
62481081|NCT05842629||Patients with an adnexal lesion in the Central Denmark Region|
62481082|NCT01369368|EXPERIMENTAL|1|Azacitidine, valproic acid, all-trans retinoic acid, hydroxyurea, eventually donor leukocyte infusions
62481083|NCT05464186|EXPERIMENTAL|Whole milk|3 cups a day of whole milk for 1 year
62481084|NCT05464186|EXPERIMENTAL|Nonfat milk|3 cups a day of nonfat milk for 1 year
62320868|NCT03567291|PLACEBO_COMPARATOR|Placebo- Part B RW|Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.
62320869|NCT06503653|EXPERIMENTAL|Prospective part|"Prospective part: Patients admitted for syncope in the emergency department, diagnosed with syncope and not hospitalized.~Summoned within 7 to 10 days to a cardiology day hospital for examinations adapted to each patient: ECG - ETT - Holter ECG 72h - orthostatic hypotension test - post-emergency cardiology consultation - MAPA and +/- other examinations as required."
62481085|NCT06743113|EXPERIMENTAL|Treatment A (Hypoxic RBCs)|Transfusion of hypoxic red blood cells manufactured with Hemanext ONE system
62481086|NCT06743113|ACTIVE_COMPARATOR|Treatment B (Conventional RBCs)|Transfusion of conventional red blood cells
62481087|NCT02896985||Participants with Crohn's disease|Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.
62481088|NCT00672984|EXPERIMENTAL|Immediate-release Guanfacine HCl|
62481089|NCT00672984|ACTIVE_COMPARATOR|Moxifloxacin HCl|
62481090|NCT00672984|PLACEBO_COMPARATOR|Placebo|
62481091|NCT03984565|EXPERIMENTAL|Cannabidiol Treatment Arm|High-CBD sublingual product administered three times daily for the treatment period.
62481092|NCT03984565|PLACEBO_COMPARATOR|Placebo Treatment Arm|Placebo sublingual product administered three times daily for the treatment period.
62481093|NCT05710510|ACTIVE_COMPARATOR|Local Care + Model|Quarterly clinic visits with a local primary care provider
62481094|NCT05710510|ACTIVE_COMPARATOR|Team Care Model|An intensive group lifestyle intervention led by a lifestyle coach via Zoom, paired with quarterly clinic visits with a local primary care provider and the lifestyle coach, the coach joining via telemedicine.
62481095|NCT05433090|EXPERIMENTAL|Experimental|Patients will participate in an inpatient advance care planning intervention.
62481096|NCT04620603|EXPERIMENTAL|LDR + SOC Immunotherapy|Participants will receive one treatment of brachytherapy on treatment day 1 (LDRD1). After a minimum of 7 days but no more than 30 days to allow antigenic release, participants will then begin immunotherapy treatment with SOC immunotherapy at the standard FDA-approved dose. Standard immunotherapy will be administered on D1 of every standard of care cycle (either 14, 21, 28, or 42 day cycle) at the standard dose. Participants can receive up to 1 year of SOC immunotherapy.
61926437|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + TMZ 120 mg (Days 1-7)|Pamiparib 60 mg twice daily on Days 1 to 28 in combination with pulse dosing of TMZ 120 mg once daily on Days 1 to 7 within a 28-day cycle
62320870|NCT06503653|ACTIVE_COMPARATOR|Retrospective part:|"Retrospective part: Patients with syncope discharged home from the emergency department, before the creation of the network:~* Information sent to patients and record of patient's non-opposition;~* Patients are called back by telephone or, failing that, by a trusted support person or attending physician;~* What happens to these patients? Have they seen a cardiologist within 10 days? What additional examinations did they have in town? Recurrence? Did they return to the emergency department for the same reason?"
62320871|NCT06446739|EXPERIMENTAL|Low dose-intensity|The intervention arm will consist of low dose-intensity CRRT, defined as the hourly delivery of a total effluent of 10-15 mL/kg/hr while receiving CRRT. The intervention dose-intensity is based on the rationale that 10-15 mL/kg/hr is the lower threshold of dose-intensity currently provided in clinical practice and prior observational data showing this threshold is tolerated and safe.
62320872|NCT06446739|ACTIVE_COMPARATOR|Standard dose-intensity|The control arm will receive a dose-intensity CRRT of 25-30 mL/kg/hr while receiving CRRT, aligned with local practice and information by international clinical practice guidelines. The control dose-intensity is based on the rationale that this is currently recommended in clinical practice guidelines and is commonly applied in routine practice.
62320873|NCT01759784|EXPERIMENTAL|stem cell recipient|The patients who underwent mesenchymal stem cell transplantation.
62320874|NCT04581681|EXPERIMENTAL|Group CBT for Perinatal Anxiety|Using cognitive-behavioural therapy principles, this group therapy is intended to treat perinatal anxiety.
62320875|NCT04581681|ACTIVE_COMPARATOR|Waitlist Control|This is a control condition in which patients are randomly assigned to the waitlist control condition before receiving the treatment.
62320876|NCT00575822|ACTIVE_COMPARATOR|1|NDO Endoscopic Full-thickness Plicator procedure
62320877|NCT00575822|SHAM_COMPARATOR|2|Sham control procedure
62481097|NCT05100095|EXPERIMENTAL|Radiation therapy|Patients receive radiation therapy in 10 daily fractions (M-F) over 2 weeks.
62320878|NCT03691623|EXPERIMENTAL|EDP-938 Arm A|Subjects will take EDP-938 Dose 1 oral suspension for 5 days
62320879|NCT03691623|EXPERIMENTAL|EDP-938 Arm B|Subjects will take EDP-938 Dose 2 oral suspension for 5 days
62320880|NCT03691623|PLACEBO_COMPARATOR|Placebo Arm C|Subjects will take matching placebo oral suspension for 5 days
62320881|NCT03691623|EXPERIMENTAL|EDP-938 Arm D|Subjects will take EDP-938 Dose 3 oral suspension for 5 days
62320882|NCT03691623|EXPERIMENTAL|EDP-938 Arm E|Subjects will take EDP-938 Dose 4 oral suspension for 5 days
62320883|NCT03691623|PLACEBO_COMPARATOR|Placebo Arm F|Subjects will take matching placebo oral suspension for 5 days
62689697|NCT06471673|EXPERIMENTAL|Phase 1, Part 1 Monotherapy Phase|"Subject 1, Q2w for 4 doses~Subject 2, Q2w for 4 doses~Subject 3, Q2w for 4 doses Treatment is administered every 2 weeks for a total of 4 doses.~Initially, safety will be assessed on these 3 subjects. DLTs are defined as CTCAE Grade 3 or 4 adverse events that are suspected to be possibly related to study treatment.~If 1 of 3 Phase 1 subjects experience a DLT, that dose cohort will be expanded to another 3 patients before the combinational phase begins. A total of 3-6 subjects will be assessed for safety."
62320884|NCT05185882||1|"1. Single leg squat without a clue or focusing method~2. Single leg squat with an external focus~3. Sinlge leg squat with an internal focus"
62320885|NCT02467907|EXPERIMENTAL|Bevacizumab in Combination with Carboplatin and Paclitaxel|Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
62320886|NCT00123526|EXPERIMENTAL|1|Worksite intervention
62320887|NCT00123526|NO_INTERVENTION|2|Receive no intervention
62320888|NCT01748396|EXPERIMENTAL|Calcitriol + CaCO3|Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks
62320889|NCT01748396|ACTIVE_COMPARATOR|Calcitriol|Calcitriol 0.25mcg 1cap daily for 8 weeks
62320890|NCT02083445|PLACEBO_COMPARATOR|Control group|Once a week there will be an attendance cognitive session (specific sessions designed to work on aspects related to body perception, movement, space) and the extraction of blood samples will be carried out to determine the progenitor cells on the same day of the active groups.
62320891|NCT02083445|ACTIVE_COMPARATOR|Exercise group|Patients with past history of TBI will perform exercise sessions two hours three days a week during 12 weeks. The sessions will consist of aerobic, strength, flexibility, proprioception and balance activities and muscle electro-stimulation sessions or cycling sessions.
62697472|NCT05274477|EXPERIMENTAL|Fampridin SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 26 days depending on the individual scheduling of each subject."
61926438|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + TMZ 40 mg (Days 1-14)|Pamiparib 60 mg twice daily on Days 1 to 28 in combination with pulse dosing of TMZ 40 mg once daily on Days 1 to 14 within a 28-day cycle
62320892|NCT02083445|ACTIVE_COMPARATOR|Muscle electro-stimulation and IHH|Patients with past history of TBI will perform a 12 weeks program: intermittent hypobaric hypoxia (IHH) 2 hours at a simulated altitude of 4500 meters 3 days/week. Muscle electro-stimulation for two periods of 20 minutes during the stay in the hypobaric chamber.
61926439|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + TMZ 20 mg (Days 1-28)|Pamiparib 60 mg twice daily in combination with TMZ 20 mg once daily administered continuously on Days 1 to 28 within a 28-day cycle
62689698|NCT06471673|EXPERIMENTAL|Phase 1, Part 2 Combination Phase|"3 subjects will be treated every 3 weeks with the Bria-OTS regimen with a CPI (tislelizumab) in the Part 2 combination phase.~The Bria-OTS regimen consists of cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell line inoculation. On the same day as the cell inoculation, subjects will receive peginterferon alpha-2a. Subjects will also receive the CPI (tislelizumab) on the same day of the cell inoculation according to approved dosing.~Treatment is administered every 3 weeks in combination with the Bria-OTS regimen and CPI (tislelizumab)."
62689699|NCT06471673|EXPERIMENTAL|Phase 2 Expansion Cohort|"Once 3 patients have been safely treated with the Bria-OTS regimen and CPI (tislelizumab) for 2 cycles, Phase 2 will enroll an expansion cohort, consisting of up to an additional 9 subjects (for a total of 12 treated with the Bria-OTS regimen and CPI).~The Bria-OTS regimen consists of cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell line inoculation. On the same day as the cell inoculation, subjects will receive peginterferon alpha-2a. Subjects will also receive the CPI (tislelizumab) on the same day of the cell inoculation according to approved dosing.~Treatment is administered every 3 weeks in combination with the Bria-OTS regimen and CPI (tislelizumab)."
62689700|NCT03345225|ACTIVE_COMPARATOR|Control Group|Participants will be randomized to receive DEB-TACE utilizing a standard endhole microcatheter
62689701|NCT03345225|EXPERIMENTAL|Surefire Group|Participants will be randomized to receive DEB-TACE utilizing the Surefire Infusion System
62320893|NCT03742960|EXPERIMENTAL|Behavioral Sleep Restriction|Participants will be required to go to sleep half an hour later than their usual bedtime. Wake up time will be determined via their usual wake time.
62320894|NCT01005394||Navigated TMS|single arm study where all subjects will be studied using the Navigated TMS device
62320895|NCT06513364|EXPERIMENTAL|WH002|"Group A（ddWH002-ddEC）：~Regimen for Group A during Cycles 1-Cycles 4:~• Paclitaxel Medium/Long-chain Fat Emulsion Injection (Cholesterol-Conjugated), 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."
62320896|NCT06513364|ACTIVE_COMPARATOR|Paclitaxel Injection|"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."
62320897|NCT05272059|EXPERIMENTAL|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
62320898|NCT05272059|PLACEBO_COMPARATOR|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
62689702|NCT06642857||Patients with advanced gastric cancer|Advanced gastric cancer patients receiving chemotherapy combined with immunotherapy
62320899|NCT05272059|EXPERIMENTAL|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
62689703|NCT05272774|EXPERIMENTAL|Intervention group|The intervention group will get a 6-week online stress recovery intervention with the support from therapist.
62320900|NCT05272059|EXPERIMENTAL|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
62320901|NCT05272059|EXPERIMENTAL|Part B: MHS552|Participants will MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
62320902|NCT05272059|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
62320903|NCT03406949|EXPERIMENTAL|obrindatamab + retifanlimab|B7-H3 x CD3 DART protein + anti-PD-1 antibody
62320904|NCT03286166||Study arm|"20 subjects will undergo one session of PRP in which 60 cc of blood is drawn and centrifuged into 3 months of autologous serum tears.~• Subjects will utilize autologous tears twice daily in the study eye."
62320905|NCT03286166||Control Arm|Subjects in the control arm will receive study vehicle to be used twice daily in the left eye.
62320906|NCT06512363|EXPERIMENTAL|Ramelteon 8 mg QN|
62320907|NCT06512363|PLACEBO_COMPARATOR|Placebo|
62320908|NCT04803786||Transition from Xyrem to Xywav|
62481098|NCT05665608|ACTIVE_COMPARATOR|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
62689704|NCT05272774|EXPERIMENTAL|Control group|The control group will use the intervention with on-demand support. The control group will participate in the program at the same time as the intervention group.
62689705|NCT04248452|EXPERIMENTAL|Arm A (FOLXFOX)|Patients receive oxaliplatin IV over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62320909|NCT00449748|EXPERIMENTAL|RAD001|Oral 10 mg daily for 30 days
62320910|NCT00876174||Patients|20 patients with genotype 1, chronic hepatitis C who are to undergo standard antiviral therapy
62320911|NCT00876174||control|Group 2, (control): 10 healthy family members or significant others of patients who are to undergo standard antiviral therapy
62481099|NCT05665608|EXPERIMENTAL|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
62481100|NCT05667532||Contrast Enhanced Mammography|
62689706|NCT04248452|EXPERIMENTAL|Arm B (CAPOX)|Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62689707|NCT04248452|EXPERIMENTAL|Arm C (radiation therapy, FOLFOX)|One week post induction of patients in ARM A, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
62320912|NCT05923905|EXPERIMENTAL|FB1006 test group|Take FB1006 at night,30mg/day
62320913|NCT05923905|PLACEBO_COMPARATOR|placebo group|Take placebo at night,30mg/day
62320914|NCT03032068|EXPERIMENTAL|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
62320915|NCT04343885|EXPERIMENTAL|177Lu-PSMA+ Docetaxel|7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles. Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
62320916|NCT04343885|OTHER|Docetaxel (Control)|Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
62320917|NCT01744847|ACTIVE_COMPARATOR|DGT, Tracer Metro® Direct™ Wire Guide|Double guide wire technique was performed by Tracer Hybrid® Wire Guides and Tracer Metro® Direct™ Wire Guide
62320918|NCT01744847|ACTIVE_COMPARATOR|TPS, Tracer Hybrid® Wire Guides|trans pancreatic sphincterotomy was performed by Tracer Hybrid® Wire Guides
62320919|NCT04910971||Group 1: Recipients of BNT162b2 mRNA Covid-19 Vaccine|
62320920|NCT04910971||Group 2: Recipients of mRNA-1273 SARS-CoV-2 Vaccine|
62320921|NCT01809561||endometriosis|The study group will consist of women with suspected endometriosis facing surgical treatment
62320922|NCT01809561||no endometriosis|The control group will consist of healthy women facing gynecologic surgery for different indication
62320923|NCT05493956|EXPERIMENTAL|Consolidation chemoradiation|6 cycles of Chemotherapy with Gemcitabine and Cisplatin will be followed by Concurrent Chemo-radiation with capecitabine
62320924|NCT05493956|ACTIVE_COMPARATOR|Observation|6 cycles of Chemotherapy with Gemcitabine and Cisplatin will be followed by observation
62320925|NCT01563627|EXPERIMENTAL|Antiepileptic Drug resistant|Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates
62320926|NCT01563627|EXPERIMENTAL|Antiepileptic drug Controlled group|epilepsy well controlled by antiepileptic drugs
62320927|NCT04488692|EXPERIMENTAL|Model 1|Participants will receive 2 sessions of functional training per day, 15-min per session.
62320928|NCT04488692|ACTIVE_COMPARATOR|Model 2|Participants will receive 1 session of functional training and 1 session of sham intervention (therapist visiting and education) per day, 15-min per session.
62689708|NCT04248452|ACTIVE_COMPARATOR|Arm D (FOLFOX)|Post induction of patients in ARM A, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
62130293|NCT05372146|ACTIVE_COMPARATOR|Control group|43 participants. In the controls GSV was punctured at a distal part of a refluxing segment. Catheter was positioned at SFJ and conventional radiofrequency procedure was performed with four cycles below SFJ and two cycles for every next segment. Phlebectomy was performed using Varady hooks after thermal ablation in both groups. All procedures were performed under tumescent anesthesia.
62130294|NCT04156789||Sarcoidosis group|Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
62689709|NCT04248452|EXPERIMENTAL|Arm E (radiation therapy, CAPOX)|One week post induction of patients in ARM B, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
62689710|NCT04248452|ACTIVE_COMPARATOR|Arm F (CAPOX)|Post induction of patients in ARM B, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
62130295|NCT04156789||Control group|Control subjects have no sarcoidosis and will be sex, age (± 3 years), height (± 20 cm), and weight (± 15 kg) matched to sarcoidosis patients.
62130296|NCT01043601|EXPERIMENTAL|Inhaled PT005 7.2 µg|
62130297|NCT01043601|EXPERIMENTAL|Inhaled PT005 9.6 µg|
62130298|NCT01043601|PLACEBO_COMPARATOR|Inhaled Placebo|
62130299|NCT01043601|ACTIVE_COMPARATOR|Formoterol Fumarate 12 µg (Foradil Aerolizer)|
62130300|NCT03114410|EXPERIMENTAL|Re:MIX|In the experimental arm, the Re:MIX curriculum was implemented. The Re:MIX curriculum is a comprehensive teen pregnancy prevention consisting of ten hour-long sessions, delivered approximately once per week. The Re:MIX curriculum is taught by a professional health educator, partnered with a young parent educator who is a young parent (aged 18-25).
62130301|NCT03114410|NO_INTERVENTION|Comparison|"In the comparison arm, teachers were given the option of implementing the Healthy Youth, Healthy You curriculum (focusing on nutrition, mental health, and fitness) or proceed with business as usual (no curriculum)."
62130302|NCT00698919||Development cohort|A first group of one hundred patients with SIRS will be included to evaluate the accuracy of this new test.
62130303|NCT00698919||Validation Cohort|Depending on the result of the previous (development) cohort we will more accurately evaluate the need of number of patients with SIRS to include in the second cohort of patients.
62130304|NCT02354469||Contact/Collision Sport Athletes|Collegiate athletes who participate in contact or collision sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
62130305|NCT02354469||Non-contact Sport Athletes|Collegiate athletes who participate in non-contact sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
62130306|NCT02354469||Post-Concussion|Collegiate athletes who sustain a concussion will be assessed on a comprehensive battery of tests from the time of injury and incrementally throughout the following year post-injury.
62130307|NCT02354469||Healthy Control|Collegiate athletes who do not sustain a concussion but match the demographic profile of an individual enrolled as a post-concussion subject, will be assessed on the same tests and in a similar timeline as post-concussion subjects.
62130308|NCT00963404|EXPERIMENTAL|Tumor-boost|Image-guided tumorboost of the bladder cancer.
62697473|NCT05274477|PLACEBO_COMPARATOR|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
62320929|NCT03767205|EXPERIMENTAL|stroke patients|All participants perform overground walking and treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot).
62320930|NCT05979129|ACTIVE_COMPARATOR|ZEEP group|
62320931|NCT05979129|ACTIVE_COMPARATOR|Low PEEP|
62130309|NCT05402813||Cohort 1a|Patients without Cochlear Implant, with or without Hearing Aid(s) at study entry
62130310|NCT05402813||Cohort 1b|Patients receiving unilateral or bilateral Cochlear Implant(s) during the study period, after study entry
62130311|NCT05402813||Cohort 2|Patients with Cochlear Implant(s) (unilateral or bilateral) at study entry
62130312|NCT03980496|ACTIVE_COMPARATOR|omeprazole infusion (OI) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.
62130313|NCT03980496|ACTIVE_COMPARATOR|omeprazole bolus (OB) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.
62130314|NCT04638322|EXPERIMENTAL|HIFT Group|This group receives physical training based on exercises of high intensity interval functional training.
62320932|NCT05979129|ACTIVE_COMPARATOR|High PEEP|
62130315|NCT04638322|NO_INTERVENTION|No intervention group|This group does not receive any treatment.
62689711|NCT04377256|EXPERIMENTAL|Radiological assessement|Two CBCTs were recorded and compared, one at the baseline and the other at 4 months post-op. The bone resorption was quantified and analyzed using ITK-SNAP software
62130316|NCT00593866|EXPERIMENTAL|Radiation Dose Escalation with Gemcitabine|"INTENSITY MODULATED RADIOTHERAPY~Radiation dose escalation:~Total dose Dose per fraction BED\* Dose equivalent (1.8 Gy/fraction) Level 1 45.0 1.8 53.1 45.0 Level 2 50.0 2.0 60.0 50.4 Level 3 52.5 2.1 63.5 54.0 Level 4 55.0 2.2 67.1 57.0 Level 5 57.5 2.3 70.7 60.0 Level 6 60.0 2.4 74.4 63.0 Level 7 62.5 2.5 78.1 66.2 Level 8 65.0 2.6 81.9 69.4~* BED=Biological Effective Dose; =10 Five fractions weekly, fraction size determined by dose level~Gemcitabine:~1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment"
62130317|NCT02616068|EXPERIMENTAL|transdermal patch & placebo|transdermal patch 100 mg once a day for 7 days and placebo (for loxoprofen sodium 60 mg tablet) by mouth, every 8 hours for 7 days
62320933|NCT01034098||Post-menopausal women|Post-menopausal women (without hormone replacement therapy)
62130318|NCT02616068|ACTIVE_COMPARATOR|loxoprofen sodium & placebo|loxoprofen sodium 60 mg by mouth, every 8 hours for 7 days and placebo (for transdermal patch 100 mg) once a day for 7 days
62481101|NCT02854800|EXPERIMENTAL|Weekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per week. As part of the current study, they received 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
62481102|NCT02854800|EXPERIMENTAL|Biweekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once bi-weekly. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
62481103|NCT02854800|EXPERIMENTAL|Monthly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per month. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
62689712|NCT04377256|EXPERIMENTAL|Histomorphometric analysis|During implant placement (4 months after the bone grafting), a bone biopsy is collected and stained with several colorants to analyze the biological bone healing
62689713|NCT00000373|ACTIVE_COMPARATOR|olanzapine + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
62689714|NCT00000373|PLACEBO_COMPARATOR|placebo + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
62689715|NCT00991978|EXPERIMENTAL|89Zr-bevacizumab PET|89Zr-bevacizumab PET
62689716|NCT05155085|EXPERIMENTAL|Lirentelimab (AK002) SC 300 mg|Subjects in this arm will receive 7 doses of 300 mg of lirentelimab (AK002) administered subcutaneously every 2 weeks.
62689717|NCT05155085|OTHER|Placebo|Placebo
62689718|NCT06501209|EXPERIMENTAL|5A-5R-based counseling Only|Participants will get 5A-5R-based counseling with BCC materials
62689719|NCT06501209|EXPERIMENTAL|5A-5R-based counseling and Mobile based remote support|Participants will get 5A-5R-based counseling with BCC materials and Mobile based remote support
62689720|NCT06501209|NO_INTERVENTION|Control with usual care|Participants will get usual care only
62689721|NCT06675591||Rapid group correction|Patients whose serum sodium increased by ≥ 8 mEq/L within the first 24 hours.
62689722|NCT06675591||Slow group correction|Patients whose serum sodium increased by \< 8 mEq/L within the first 24 hours.
62689723|NCT00090064|EXPERIMENTAL|MDMA-assisted therapy (125 mg)|Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2 to 2.5 hours later by a second dose of 62.5 mg midomafetamine HCl during two 8-hour long blinded therapy sessions.
61926440|NCT03150810|EXPERIMENTAL|Dose Escalation: Pamiparib + TMZ 40 mg (Days 1-28)|Pamiparib 60 mg twice daily in combination with TMZ 40 mg once daily administered continuously on Days 1 to 28 within a 28-day cycle
62130319|NCT03840122|EXPERIMENTAL|A - ACB + IPACK with injection|50 arms: ACB + IPACK block with injection of local anesthetic of Ropivacaine, Epinephrine, Ketorolac, Clonidine and saline
62130320|NCT03840122|ACTIVE_COMPARATOR|B - ACB + IPACK without injection|50 arms: ACB + IPACK block without injection of local anesthetic
62130321|NCT01845844|EXPERIMENTAL|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
62130322|NCT01845844|ACTIVE_COMPARATOR|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
62320934|NCT03912571||Mild Cognitive Impairment (MCI)|Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
62320935|NCT03912571||Normal Cognition (NL)|Clinical Dementia Rating \[CDR\] of 0 or Global Deterioration Scale \[GDS\] of 1-2
62320936|NCT01178684||1: HIV-pos on d4T with neuropathy|
62320937|NCT01178684||2: HIV-pos on d4T without neuropathy|
62320938|NCT01178684||3: HIV-neg without peripheral neuropathy|
62320939|NCT01178684||4 HIV-pos on d4T with asymtomatic neuropathy|
62320940|NCT01798706|EXPERIMENTAL|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
62320941|NCT01798706|PLACEBO_COMPARATOR|Placebo|Placebo (matched to lixisenatide) QD for 24 Weeks.
62320942|NCT04964830|ACTIVE_COMPARATOR|Children with large overjet|Overjet ≥6 mm, planned orthodontic treatment with functional appliance
62320943|NCT04964830|NO_INTERVENTION|Control group|Neutral occlusion, no indication for orthodontic treatment, no prior orthodontic treatment
62320944|NCT02717689|EXPERIMENTAL|Biomarker arm|Biomarker based adjustment of corticosteroid dose.
62320945|NCT02717689|NO_INTERVENTION|Standard care|The subject's corticosteroid dose will be adjusted based upon asthma symptom control and lung function
62320946|NCT01264965|ACTIVE_COMPARATOR|Acetaminophen|
62320947|NCT01264965|ACTIVE_COMPARATOR|Long Acting Oxycodone|
62481104|NCT03522142|EXPERIMENTAL|INCB081776|Single-agent INCB081776.
62481105|NCT03522142|EXPERIMENTAL|INCB081776 + INCMGA00012|INCB081776 in combination with INCMGA00012.
62689724|NCT00090064|PLACEBO_COMPARATOR|Placebo with therapy|Participants will receive an initial dose of 125 mg placebo orally followed 2 to 2.5 hours later by a second dose of 62.5 mg placebo during two 8-hour long blinded therapy sessions.
62689725|NCT00968045|PLACEBO_COMPARATOR|Placebo|100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.
62689726|NCT00968045|EXPERIMENTAL|Study drug|Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start
62320948|NCT03254017|EXPERIMENTAL|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
62320949|NCT05148208|PLACEBO_COMPARATOR|Placebo|Supplementation of water
62320950|NCT05148208|ACTIVE_COMPARATOR|Creatine 0.5 mM|Supplementation of creatine dissolved in water to a final concentration of 0.5 mM of creatine in the dialysate
62689727|NCT02016885|EXPERIMENTAL|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
62689728|NCT02016885|EXPERIMENTAL|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
62689729|NCT02016885|EXPERIMENTAL|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
62689730|NCT02016885|EXPERIMENTAL|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
62320951|NCT05148208|ACTIVE_COMPARATOR|Creatine 1 mM|Supplementation of creatine dissolved in water to a final concentration of 1 mM of creatine in the dialysate
62320952|NCT05148208|ACTIVE_COMPARATOR|Creatine 1.5 mM|Supplementation of creatine dissolved in water to a final concentration of 1.5 mM of creatine in the dialysate
62320953|NCT05148208|ACTIVE_COMPARATOR|Creatine 2.0 mM|Supplementation of creatine dissolved in water to a final concentration of 2 mM of creatine in the dialysate
62320954|NCT03988816|EXPERIMENTAL|Roflumilast|Roflumilast tablets will be supplied at a concentration of 500 mcg. Each tablet contains 500mcg of the active ingredient in addition to the excipients: lactose monohydrate, corn starch, povidone and magnesium stearate. The coating contains hypromellose, macrogol, titanium dioxide, yellow iron oxide. Patients should take 1 tablet once daily, before, during or after meals, at the same time each day.
62320955|NCT03988816|PLACEBO_COMPARATOR|Placebo (control)|Roflumilast placebo-containing tablets will look similar to active roflumilast tablets and will be supplied to patients in packs identical to those of the active drug.
62689731|NCT02016885|PLACEBO_COMPARATOR|Vehicle|Vehicle Topical Wipes
62689732|NCT00940121|EXPERIMENTAL|1. mirabegron, low dose|Oral mirabegron 25 mg
62689733|NCT00940121|EXPERIMENTAL|2. mirabegron, middle dose|Oral mirabegron 50 mg
62689734|NCT00940121|EXPERIMENTAL|3. mirabegron, higher dose|Oral mirabegron 100 mg
62689735|NCT06449547||patients with anxiety|Patients in this group suffered from herpes zoster neuralgia and had a score more than or equal to 8 for Hospital Anxiety and Depression Scale- Anxiety questionnaire.
62689736|NCT06449547||patients without anxiety|Patients in this group suffered from herpes zoster neuralgia and had a score less than 8 for Hospital Anxiety and Depression Scale- Anxiety questionnaire.
62689737|NCT06449547||patients with depression|Patients in this group suffered from herpes zoster neuralgia and had a score more than or equal to 8 for Hospital Anxiety and Depression Scale- Depression questionnaire.
62130323|NCT04185571|EXPERIMENTAL|PEPA membrane|PEPA membrane is an adsorbant synthetic copolymer (Poly Ester Poly Arylate)
62320956|NCT01289392|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard treatment
62320957|NCT01289392|ACTIVE_COMPARATOR|Oral Appliance|Alternative treatment for obstructive sleep apnea patients
62320958|NCT01289392|ACTIVE_COMPARATOR|Physical Exercise|Aerobic and resistance physical exercises
62689738|NCT06449547||patients without depression|Patients in this group suffered from herpes zoster neuralgia and had a score less than 8 for Hospital Anxiety and Depression Scale- Depression questionnaire.
62697474|NCT04345328||Roux-en-Y gastric bypass|Patients who were planned for surgery with Roux-en-Y gastric bypass and were operated
62130324|NCT04185571|NO_INTERVENTION|non adsorbent membrane|Comparison with non adsorbent membrane used in routine
62130325|NCT00693121|PLACEBO_COMPARATOR|Placebo|Identical capsule to amantadine hydrochloride active intervention, administered twice daily x 14 days
62689739|NCT04482803|EXPERIMENTAL|Carbon nanoparticles labelled lymph nodes group|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes before NST.
61926441|NCT03150810|EXPERIMENTAL|Dose Expansion: Gastric Cancer|Participants with gastric or gastroesophageal junction cancer received TMZ 60 mg administered on Days 1 to 7 in combination with pamiparib 60 mg twice daily on Days 1 to 28 of each cycle
62130326|NCT00693121|ACTIVE_COMPARATOR|Amantadine|Amantadine hydrochloride 100mg capsule administered twice daily x 14 days
62130327|NCT02840747||Patients with CTCL|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).
62320959|NCT03196297|EXPERIMENTAL|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
62689740|NCT04215458|OTHER|sample collection|Collection of samples investigating for yeast colonization in either patients with inflammatory skin disease or healthy controls.
62689741|NCT06636838|NO_INTERVENTION|Spanish speaking patients seen by English-Speaking Provider|Spanish speaking patients will be seen by our English-speaking providers using a qualified interpreter.
62689742|NCT06636838|EXPERIMENTAL|Spanish-Speaking patients seen by a Spanish-speaking provider|Spanish speaking patients will be seen by our Spanish-speaking provider
62689743|NCT05124236|EXPERIMENTAL|Preoperative radiosurgery|The interventional arm is single fraction preoperative radiosurgery to a brain metastasis identified for neurosurgical resection.
62689744|NCT05124236|ACTIVE_COMPARATOR|Postoperative hypofractionated stereotactic radiotherapy|The active comparator arm is the standard of care of postoperative hypofractionated stereotactic radiotherapy to the surgical cavity in 5 fractions following resection of the brain metastasis.
62689745|NCT05301192|EXPERIMENTAL|Angiotensin-(1-7)|Participants will receive intravenous angiotensin-(1-7) at one study visit for 110 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 80 minutes. Infusion rates will be calculated for each participant based on body mass.
62689746|NCT05301192|PLACEBO_COMPARATOR|Saline|Participants will receive intravenous saline at one study visit for 110 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each participant based on body mass.
62689747|NCT02394574|ACTIVE_COMPARATOR|Clean Cookstove|Subjects will use ethanol stoves using bioethanol
62689748|NCT02394574|OTHER|Traditional Cookstove|Subjects will use traditional firewood or kerosine cookstove and receive education on how to reduce air pollution exposures
62689749|NCT06569511||MACE-positive|Patients who have experienced a major adverse cardiovascular event (MACE) within a 6-month period after percutaneous coronary intervention (PCI), including nonfatal ischemic stroke, nonfatal myocardial infarction, cardiovascular mortality, or emergency department admission due to heart failure.
62689750|NCT06569511||MACE-negative|Patients who have not experienced a major adverse cardiovascular event (MACE) within a 6-month period after percutaneous coronary intervention (PCI), including nonfatal ischemic stroke, nonfatal myocardial infarction, cardiovascular mortality, or emergency department admission due to heart failure.
62689751|NCT03211546||Femoral shaft fracture|Patients (children up to 16 years old) diagnosis of isolated closed femur shaft fracture (3.2-D) and open distal physis. Treatment strategies will follow standard of care (routine) procedures, either conservative (non-surgical) treatment or surgical treatment.
62689752|NCT00353119|PLACEBO_COMPARATOR|Placebo then etanercept|Patients randomized to initiate the study with placebo for the first 12 weeks - Group 1 then crossed over to etanercept 50mg twice weekly for weeks 12 to 24
62689753|NCT00353119|ACTIVE_COMPARATOR|Etanercept|Patients randomized to etanercept - Group 2. Patients received etanercept 50 mg subcutaneously twice weekly for 24 weeks
62689754|NCT00944840|ACTIVE_COMPARATOR|SP and amodiaquine|Study subjects received intermittent preventive treatment with SP plus amodiaquine.
62689755|NCT00944840|PLACEBO_COMPARATOR|SP placebo plus amodiaquine placebo|Intermittent preventive treatment with SP placebo and amodiaquine placebo
62689756|NCT01000116|ACTIVE_COMPARATOR|Fibrin glue|
62130328|NCT02840747||Patients with benign dermatoses|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.
62130329|NCT02840747||Healthy Controls|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.
62130330|NCT05279157|EXPERIMENTAL|ADASCs Group|5 patients, who will receive adipose tissue mesenchymal stem cells in a single dose as study treatment
62130331|NCT05279157|EXPERIMENTAL|Acellular laminas group|5 patients, who will receive decellularized corneal laminas as treatment medication
62320960|NCT02485366|EXPERIMENTAL|Rejuvenated PRBCs|The investigators will restore important energy molecules in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol).
62689757|NCT01000116|ACTIVE_COMPARATOR|Tacks|
62689758|NCT05538858||Mechanical Ventilation|Cohort will undergo standard of care treatment utilizing a general anesthetic with mechanical ventilation for a surgical procedure.
62689759|NCT05538858||Control|Cohort will undergo standard of care treatment utilizing a regional or neuraxial anesthetic without mechanical ventilation for a surgical procedure.
62689760|NCT05740826||Study group|People with temporomandibular disorder which was determined based on one of the following factors observed during the examination: acoustic symptoms, present temporomandibular joint pain, problems with opening the mouth, deviation of the jaw during abduction, or reported locking of the jaw.
62689761|NCT05740826||Control group|People without temporomandibular disorder.
62689762|NCT01894646|EXPERIMENTAL|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
62689763|NCT01894646|EXPERIMENTAL|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
62689764|NCT01894646|OTHER|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
62689765|NCT06036524|EXPERIMENTAL|Multi-modal imaging of myofascial pain|Participants with and without myofascial-related pain disease will receive multi-modal, multi-parametric, multi-scale imaging, including magnetic resonance imaging, surface electromyography, and fiber-optic imaging and sensing.
62689766|NCT05731544|EXPERIMENTAL|Phase 1 SAD Cohorts|"Phase 1 SAD Cohorts with healthy adults randomized 3:1 receiving BMF-219 or placebo.~A pair of sentinel subjects (randomly assigned 1 active drug and 1 placebo) will be dosed 48 hours prior to dosing of the remainder of subjects in each cohort."
62130332|NCT05279157|EXPERIMENTAL|ADASCs recellularized laminas group|5 patients, who will receive adipose tissue mesenchymal cells combined with decellularized corneal laminas as study treatment in a single intervention
62320961|NCT02057419||Contraceptive Method|"Protocol 1: 3-month use period for each of 3 contraceptive methods, randomly ordered. intravaginal ring, oral contraceptive pill, spermicide+condom; dosage and frequency as instructed...~Protocol 2: 3-month use period for 1st randomly assigned contraceptive method. At end of use period, user chooses to continue on 1st method or to switch to 2nd randomly assigned method for remaining 3-month use-period."
62689767|NCT05731544|EXPERIMENTAL|Phase 1 single dose food effect sub-study|Phase 1 single dose food effect sub-study with healthy adults randomized 1:1:1:1:1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high fat meal.
62689768|NCT05731544|EXPERIMENTAL|Phase 1 single dose tablet PK sub-study|Phase 1 single dose x3 PK tablet open-label sub-study with healthy adults randomized 1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high-fat meal).
62689769|NCT05731544|EXPERIMENTAL|Phase 2 MAD Cohorts|Phase 2 MAD Cohorts with healthy adults (MAD 1, randomized 3:1) or adults with T2D (MAD 2-4 \& 6-8, randomized 5:1) receiving BMF-219 or placebo. MAD 5 is BMF-219 only.
62689770|NCT05731544|EXPERIMENTAL|Phase 2 Expansion Cohort|Phase 2 Expansion Cohort adults with T2D randomized 3:1 ratio receiving BMF-219 or placebo.
62689771|NCT04565080||FMD Patients|adult FMD patients who participated in protocol 07-N-0190
62689772|NCT04565080||PD Patients|adult PD patients who participated in protocol 01-N-0206
62689773|NCT03913637|EXPERIMENTAL|Strategy Training|In addition to receiving everything in Enhanced Usual Care, participants will engage in 10 sessions over 5 weeks with a trained research interventionist. Participants will describe activities they do, no longer do, or have never done using the cards from the Activity Card Sort as a guide. The therapist will ask the participants to use this information to identify and prioritize activity-based goals to address in the remaining sessions. These sessions will take place in a location of the participant's choice and will last approximately 1 hour.
62689774|NCT03913637|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced usual care will allow older adults to interact with services and support. All mental health treatment (e.g., medications that you may be taking) and psychotherapy (e.g. counseling or social services) will be documented and monitored. Furthermore, all participants assigned to Enhanced Usual Care will receive the same assessments as other participants. The close monitoring will track potential changes in symptoms (e.g., depressive symptoms), and participants will be referred to services as appropriate.
62689775|NCT03150888||Hospital based hypertension cohort|
62689776|NCT03150888||Community based hypertension cohort|
62689777|NCT05566236|EXPERIMENTAL|board game|The participants received the usual standard of care(psychoeducation regarding Tourette Syndrome and one 50-mg tablet of pyridoxine daily), and they played the 60-minute parent-child board game at least once at home for consecutive 4 weeks.
62689778|NCT05566236|NO_INTERVENTION|Care as usual|The participants received the usual standard of care (psychoeducation regarding Tourette Syndrome and one 50-mg tablet of pyridoxine daily).
62689779|NCT04504669|EXPERIMENTAL|Monotherapy|Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years.
62689780|NCT04504669|EXPERIMENTAL|Combination Therapy|Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years.
62689781|NCT05181085|ACTIVE_COMPARATOR|NST 6179|double blind, single ascending and multiple ascending dose, sequential group design
62689782|NCT05181085|PLACEBO_COMPARATOR|Placebo|matched placebo arm
62689783|NCT02884479|EXPERIMENTAL|PT-112 + Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
62689784|NCT06466655|OTHER|MitoTempol|Two intradermal microdialysis probes will be inserted into the dermal layer of the ventral forearm and perfused with either lactated Ringer's solution (control) or MitoTempol (0.5 mM) to scavenge mitochondrial-derived superoxide.
62689785|NCT06213298|EXPERIMENTAL|Kava|75mg of Kava taken three times daily for 14 days. Participants will then enter into a washout period of 14-28 days.
62689786|NCT06213298|PLACEBO_COMPARATOR|Placebo|The placebo will be taken three times daily for 14 days. Participants will then enter into a washout period of 14-28 days.
62130333|NCT02584829|EXPERIMENTAL|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
62320962|NCT02057419||Sexual Lubricant Method|3-month use period for each of 3 sexual lubricant methods, randomly ordered. gel formulation, film formulation, insert formulation; dosage and frequency as instructed
62320963|NCT05890638|EXPERIMENTAL|Ipratropium / Levosalbutamol Fixed Dose Combination|"In this one-day study, patients will be administered Ipratropium / Levosalbutamol 1.25 mg \& 0.5 mg / 2.5 mL Nebuliser Solution at 6 hours intervals."
62689787|NCT03348462|EXPERIMENTAL|ethosomal anthralin|Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
62689788|NCT03348462|ACTIVE_COMPARATOR|liposomal anthralin|Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
62320964|NCT05890638|ACTIVE_COMPARATOR|Ipratropium + Levosalbutamol Free Dose Combination|"In this one-day study, patients will be administered Levosalbutamol 1.25 mg/3 mL Inhalation Solution and Ipratropium Nebulization Solution 500 mcg/2 mL at 6 hours intervals."
62320965|NCT01300871||Postmenopausal Women on Endocrine Therapy|Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
62320966|NCT05924100|EXPERIMENTAL|Luspatercept|
62320967|NCT06004531|EXPERIMENTAL|Health Promoting|The survey will be organized so health promoting behavioral scale questions will be asked first concerning personal wellbeing. This will be followed by eco-friendly behavior scale questions involving one's concern for the wellbeing of the planet. After this, there will be two surveys concerning loneliness and eco-anxiety before the intervention.
62320968|NCT06004531|EXPERIMENTAL|Eco-friendly behavior|The survey will be organized so eco-friendly behavior scale questions involving one's concern for the wellbeing of the planet will be asked first. This will be followed by health promoting behavioral scale questions concerning personal wellbeing. After this, there will be two surveys concerning loneliness and eco-anxiety before the intervention.
62689789|NCT01346592|ACTIVE_COMPARATOR|aTIV (6 to <72 months)|Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29
62689790|NCT01346592|ACTIVE_COMPARATOR|Comparator TIV (6 to <72 months)|Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29
62320969|NCT01555463|EXPERIMENTAL|Azelaic acid foam, 15% (BAY39-6251)|0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
62320970|NCT01555463|PLACEBO_COMPARATOR|Vehicle foam|0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
62320971|NCT04149327|EXPERIMENTAL|Antibiotics group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days plus a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
62689791|NCT01346592|ACTIVE_COMPARATOR|TIV (6 to <72 months)|Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29
62697475|NCT04345328||Sleeve Gastrectomy|Patients who were planned for surgery with Sleeve Gastrectomy and were operated
62697476|NCT04345328||Control group|Obese patients involved in a weight loss program that focuses on diet and lifestyle changes
62481106|NCT05216315|EXPERIMENTAL|tDCS. Transcranial direct current stimulation|The stimulation time was 20 minutes, with an initial and final ramp of 30 seconds so that the participant could adapt to the sensation of the current. 10 sessions. Constant current intensity of 2 mA The anode was placed on position F3, coinciding with the dorsolateral prefrontal cortex, and the cathode was placed on Fp2, coinciding with the right supraorbital area (rSO).
62481107|NCT05216315|SHAM_COMPARATOR|Sham stimulation|The sham group received direct current only on the ramps to generate a sensation of the effect.
62320972|NCT04149327|ACTIVE_COMPARATOR|Control group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
62320973|NCT02457351|EXPERIMENTAL|Roniciclib + Itraconazole|Pharmacokinetics and safety in patients with advanced solid tumor
62320974|NCT06400602|EXPERIMENTAL|Usual ED Care plus Health Coaching|
62320975|NCT06400602|ACTIVE_COMPARATOR|Usual ED Care plus Education|
62481108|NCT02977221|EXPERIMENTAL|Piezosurgery|Piezosurgery will be performed on the anterior lower segment of the dental arch in order to accelerate the correction of mandibular anterior crowding.
62481109|NCT02977221|NO_INTERVENTION|Ordinary Alignment|Treatment will be provided to the patients without any surgical interventions.
62481110|NCT02722239|EXPERIMENTAL|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
62697477|NCT06591741|OTHER|PCA administraton|
62689792|NCT04559464|OTHER|AeriSeal and Zephyr Valve Treatment|"Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-).~Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR)."
62689793|NCT05308459|EXPERIMENTAL|Step 1: Allocated to start the Data Health VET intervention phase January 2022|Participants receive the Data Health VET intervention in all its steps starting in January 2022
62689794|NCT05308459|EXPERIMENTAL|Step 2: Allocated to start the Data Health VET intervention phase August, 2022|Participants receive the Data Health VET intervention in all its steps starting in August 2022
62320976|NCT01685294|NO_INTERVENTION|Treatment as Usual (TAU)|Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.
62320977|NCT01685294|EXPERIMENTAL|Group Interpersonal Psychotherapy (IPT) for Depression + TAU|Participants will receive Group IPT for Depression + TAU.
62320978|NCT00814840|ACTIVE_COMPARATOR|Triple-site group|Triple-site resynchronization group
62320979|NCT00814840|ACTIVE_COMPARATOR|Standard resynchronization group|Standard (double-site) resynchronization group
62320980|NCT06671171||WatchX|"Participants will wear the investigational smartwatch (Apple Watch Series 9) concurrently for pre- and post-SaO2 and VO2max assessment during cardiopulmonary exercise test at Visit 1.~Through one-week study period, participants will record their oxygen saturation data collected by the smartwatch once daily in a provided log, preferably in the morning after waking and before any strenuous activity.~At Visit 2, participants will walk for a 6-Minute walk test and wear the investigational smartwatch (Apple Watch Series 9) concurrently for pre- and post-SaO2 and VO2max assessment during assessment."
62320981|NCT02402192|ACTIVE_COMPARATOR|Corifollitropin alfa|Under current practice, 67 participants will be stimulated with a single injection of 100 mg, sc of Corifollitropin alpha (Elonva®). From day 6 stimulation and even prior to induction of ovulation day, 0.25 mg / day was administered sc ganirelix (Orgalutran®). From day 8 stimulation and depending on the ovarian response, you can add recombinant FSH (Puregon) up to 150 IU by Puregon Pen® device. In the presence of 3 or more follicles ≥17 mm, ovulation is induced with a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) if there is no risk of OHSS, and 36 hours later he held the follicular puncture oocyte retrieval.
62320982|NCT02402192|ACTIVE_COMPARATOR|recombinant FSH|Under current practice, 67 participants will be stimulated with a daily dose of recombinant FSH. Administration of recombinant FSH (Puregon) starts at an initial dose of 150-225 IU / day by the Puregon Pen® device. From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of recombinant FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg or Decapeptyl hCG 6500u (Ovitrelle) is given if there is no risk of OHSS, and 36 hours then held follicular puncture for recovering oocytes.
62320983|NCT02402192|ACTIVE_COMPARATOR|HP- hMG|Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .
62320984|NCT03017586|EXPERIMENTAL|STN|DBS target with Subthalamic Nucleus (STN).
62320985|NCT03017586|EXPERIMENTAL|GPi|DBS target with Globus Pallidus Internus (GPi).
62320986|NCT06534944|EXPERIMENTAL|NR supplementation|1g daily NR
62689795|NCT03571633|EXPERIMENTAL|Paclitaxel+Trastuzumab+Pegfilgrastim|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
62320987|NCT03067766|EXPERIMENTAL|Workshop A (10 weeks - comic art creation workshop)|Patients and a family member, caretaker, or friend participate in an artist-led comic art therapy workshop over 2 hours once a week for 10 weeks. Patients and participants receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop and midway through the workshop.
62689796|NCT03571633|ACTIVE_COMPARATOR|Paclitaxel+Trastuzumab|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
62689797|NCT06123676|OTHER|Single arms|Single arm study
62689798|NCT01697501|EXPERIMENTAL|Chronic hepatitis B patients|
62689799|NCT04003402|EXPERIMENTAL|Sequence 1: Participants receiving treatment sequence A,B,C,D|"Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol"
62689800|NCT04003402|EXPERIMENTAL|Sequence 2: Participants receiving treatment sequence B,D,A,C|"Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol"
62689801|NCT04003402|EXPERIMENTAL|Sequence 3: Participants receiving treatment sequence C,A,D,B|"Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol"
62130334|NCT02584829|EXPERIMENTAL|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
62130335|NCT01186159|EXPERIMENTAL|Normal Saline|
62689802|NCT04003402|EXPERIMENTAL|Sequence 4: Participants receiving treatment sequence D,C,B,A|"Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol"
62320988|NCT03067766|EXPERIMENTAL|Workshop B and C (5 weeks - comic art creation workshop)|Patients participate in an artist-led comic art therapy workshop over 3 hours once a week for 5 weeks. Patients receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop.
62320989|NCT02629497|EXPERIMENTAL|Healthy subjects for Omega-6 protection|Platelets from healthy donors will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
62320990|NCT02629497|EXPERIMENTAL|T2DM patients for Omega-6 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
62320991|NCT02629497|ACTIVE_COMPARATOR|Healthy control for Omega-3 protection|Platelets from healthy donors will be assessed for regulation by Fish Oil (omega-3 fatty acid).
62320992|NCT02629497|ACTIVE_COMPARATOR|T2DM for Omega-3 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Fish Oil (omega-3 fatty acid).
62320993|NCT03852888|EXPERIMENTAL|mtugroup|All patients managed for rheumatoid arthritis (according to the ACR / EULAR 2010 criteria) in the Rheumatology Department of the University Hospital of Reims and treated with methotrexate monotherapy.
62689803|NCT06127771|NO_INTERVENTION|Standard of Care programming|Individuals' DBS will be programmed using SOC programming parameters.
62689804|NCT06127771|EXPERIMENTAL|Percept PC programming|Individuals' DBS will be programmed using the full capacity of Percept PC IPG.
62689805|NCT04498273|ACTIVE_COMPARATOR|Apixaban 2.5mg|Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
62689806|NCT04498273|ACTIVE_COMPARATOR|Apixaban 5mg|Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
62689807|NCT04498273|ACTIVE_COMPARATOR|Aspirin|Antiplatelet agent: low dose aspirin 81mg po qd
62689808|NCT04498273|PLACEBO_COMPARATOR|Placebo|Placebo
62689809|NCT01412216|EXPERIMENTAL|Fish Oil (Omega-3 Fatty Acids)|High-dose, short-duration dietary omega-3 fatty acids supplementation
61926442|NCT03150810|EXPERIMENTAL|Dose Expansion: Ovarian Cancer|Participants with ovarian cancer, fallopian cancer, or primary peritoneal cancer received TMZ 60 mg administered on Days 1 to 7 in combination with pamiparib 60 mg twice daily on Days 1 to 28 of each cycle
62130336|NCT00105807|OTHER|Arm 1|
62130337|NCT05193786|ACTIVE_COMPARATOR|Low PEEP group|In low PEEP group, the PEEP was 5 cmH2O and inspiratory pressure was 10-20 cmH2O in noninvasive ventilation.
62320994|NCT01819922|EXPERIMENTAL|PF-05175157|
62320995|NCT01819922|PLACEBO_COMPARATOR|Placebo|
62320996|NCT00938327||Rotarix Group|Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.
62320997|NCT05379322|EXPERIMENTAL|Group A (Anti-TNF)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the diffuse myeloid phenotype will be assigned to receive anti-TNF medication at the discretion of the treating physician.
62320998|NCT05379322|EXPERIMENTAL|Group B (JAK inhibitor)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the lymphoid- myeloid phenotype will be assigned to receive JAK inhibitor medication at the discretion of the treating physician.
62689810|NCT01412216|PLACEBO_COMPARATOR|Placebo|Placebo control
62320999|NCT05379322|EXPERIMENTAL|Group C (Anti-TNF or JAK inhibitor)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the pauci-cellular phenotype will be randomized to either anti-TNF or JAK inhibitor medication 1:1.
62130338|NCT05193786|EXPERIMENTAL|High PEEP group|In high PEEP group, the PEEP was 10-15 cmH2O and inspiratory pressure was 15-20 cmH2O in noninvasive ventilation.
62130339|NCT01692483||Abiraterone acetate plus prednisone|
62130340|NCT00548418|EXPERIMENTAL|I|"Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle~Bevacizumab 15 mg/kg day 1 of a 21 day cycle"
62130341|NCT04436900|EXPERIMENTAL|Intervention group|20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
62321000|NCT03542240|EXPERIMENTAL|Curcumin|
62481111|NCT02722239|EXPERIMENTAL|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
62481112|NCT05220098|EXPERIMENTAL|Dose-escalation Phase: TAK-280|Participants will receive TAK-280 intravenous (IV) infusion on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.
62481113|NCT05220098|EXPERIMENTAL|Cohort-expansion Phase: TAK-280 High or low Dose|Participants will receive either TAK-280 high or low dose in one selected indication and only one dose level of TAK-280 in the remaining indications as determined from the dose-escalation phase of the study in 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.
62321001|NCT03408873|EXPERIMENTAL|Patient Noncompliance|Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention
62321002|NCT06231940|EXPERIMENTAL|Complex Decongestive Therapy (CDT) in venous insufficiency|
62321003|NCT06231940|NO_INTERVENTION|Control group|
62481114|NCT05612204|EXPERIMENTAL|Biopsy under MRI|
62481115|NCT04786496|EXPERIMENTAL|ITP+SA Wise intervention (Incremental Theory of Personality Intervention with Self-affirmations)|Wise intervention (based on ITP and SA) consisting on several tasks to be completed individually. 30 minutes
62481116|NCT04786496|EXPERIMENTAL|ITP Wise intervention (Incremental Theory of Personality Intervention)|Wise intervention (based on ITP) consisting on several tasks to be completed individually. 30 minutes
62481117|NCT04786496|OTHER|Control Intervention|Educational intervention (about heritage conservation) consisting on several tasks to be completed individually. 30 minutes
62481118|NCT06705998|EXPERIMENTAL|BAR502 single dose|Each subject will receive an oral single-dose of BAR 502 \[Study Part A\]
62130342|NCT02941575|ACTIVE_COMPARATOR|Control|Implant superstructure crown: All ceramic, IPS Emax
62130343|NCT02941575|EXPERIMENTAL|Intervention|Implant superstructure crown: Hybrid ceramic, crystal Ultra crown
62481119|NCT06705998|PLACEBO_COMPARATOR|Placebo single dose|Each subject will receive an oral single-dose of placebo \[Study Part A\]
61926443|NCT03150810|EXPERIMENTAL|Dose Expansion: SCLC|Participants with Small Cell Lung Cancer (SCLC) received TMZ 60 mg administered on Days 1 to 7 in combination with pamiparib 60 mg twice daily on Days 1 to 28 of each cycle
62130344|NCT04248998|EXPERIMENTAL|Chemotherapy plus Fasting-Mimicking Diet (FMD)|"Experimental Arm A will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD.~Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles."
62321004|NCT01559207||Patients with VTE|"Group P is composed of all patients with a history of VTE. Group Px is a subgroup of 15 patients from group P. Members of Px are randomly selected from P."
62321005|NCT01559207||Healthy volunteers|"Group T: 15 healthy volunteers with no history of VTE will be included in this group."
62321006|NCT04866420||Poststroke fatigue|Participants who are experiencing fatigue post stroke.
62481120|NCT06705998|EXPERIMENTAL|BAR502 multiple doses|Each subject will receive a dose of BAR502 once a day for 14 days \[Study Part B\]
61926444|NCT03150810|EXPERIMENTAL|Dose Expansion: TNBC|Participants with triple negative breast cancer (TNBC) received TMZ 60 mg administered on Days 1 to 7 in combination with pamiparib 60 mg twice daily on Days 1 to 28 of each cycle
62321007|NCT02494349|EXPERIMENTAL|JLP-1207|JLP-1207 dosing in the fed state(high fat meal)
62321008|NCT02494349|EXPERIMENTAL|Solifenacin 5mg+Tamsulosin 0.2mg|Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)
62321009|NCT01912872|EXPERIMENTAL|Omalizumab + budesonide and formoterol|Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.
61926445|NCT03150810|EXPERIMENTAL|Dose Expansion: Other HRD+ Cancers|Participants with non-small cell lung cancer (NSCLC), esophageal cancer, squamous head and neck cancer, or soft tissue sarcomas whose tumors are homologous recombination deficiency (HRD)+ received TMZ 60 mg administered on Days 1 to 7 in combination with pamiparib 60 mg twice daily on Days 1 to 28 of each cycle
61926446|NCT06561971|EXPERIMENTAL|Non-Smokers|Full-mouth clinical periodontal measurements recorded and saliva obtained.
61926447|NCT06561971|EXPERIMENTAL|Light Smokers|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62321010|NCT01912872|ACTIVE_COMPARATOR|Budesonide and formoterol|Participants will receive budesonide and formoterol according to maximum daily dose.
62321011|NCT05106660|EXPERIMENTAL|Ambulatory Care Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy as ambulatory care procedure with same-day discharge
62321012|NCT05106660|ACTIVE_COMPARATOR|Next Day Discharge Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy with next day discharge
62321013|NCT06503302|EXPERIMENTAL|With Doppler ultrasound|The physician will use Doppler function detection to check if calcifications are under active inflammation before ultrasound-guided injection.
62697478|NCT05630456|EXPERIMENTAL|Intervention Group|In the intervention group, the researcher gave feedback on the subjects' exercise amount through telephone contact every 2 weeks during the 12-week study period. Through phone consultations, they answered questions about exercise or discussed problems, encouraged to continue exercising, answered questions or discussed problems related to wearable devices and apps, and encouraged continuous data transmission.
61926448|NCT06561971|EXPERIMENTAL|Heavy Smokers|Full-mouth clinical periodontal measurements recorded and saliva obtained.
61926449|NCT03312400|ACTIVE_COMPARATOR|200 mg Arm|100 mg twice a day
61926450|NCT03312400|ACTIVE_COMPARATOR|400 mg Arm|200 mg twice a day
61926451|NCT03875573|EXPERIMENTAL|Chemotherapy and radiotherapy|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy).
61926452|NCT03875573|EXPERIMENTAL|Chemotherapy and pre-operative radiotherapy plus durvalumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w.
62321014|NCT06503302|ACTIVE_COMPARATOR|Without Doppler ultrasound|The physician will only open the Doppler image in the non-calcified area for patient blinding before the ultrasound-guided injection.
62321015|NCT02114632|ACTIVE_COMPARATOR|Polyunsaturated fatty acids|"6 capsules of food supplement Eye q per day divided in two daily doses (558 mg EPA, 174 mg DHA, 60 mg GLA per day)"
62321016|NCT02114632|PLACEBO_COMPARATOR|placebo|6 capsules of olive oil per day divided in two daily doses.
62321017|NCT02290639|EXPERIMENTAL|Immediate Treatment|Four 30-minute sessions of Brief Cognitive Behavioral treatment starting immediately upon randomization.
62321018|NCT02290639|ACTIVE_COMPARATOR|Minimal Contact followed by treatment|6-week Minimal Contact period consisting of weekly phone calls starting immediately upon randomization. Experimental treatment will be provided to all subjects upon completion of Minimal Contact period.
62321019|NCT00633828|EXPERIMENTAL|A Intervention group|Increased physical education in primary school (daily)
62321020|NCT00633828|NO_INTERVENTION|B Control group|Normal physical education in primary school (typically once per week)
62321021|NCT01429246|ACTIVE_COMPARATOR|Normal Salt|100% Sodium Chloride
62321022|NCT01429246|EXPERIMENTAL|Salt Substitute|65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
62321023|NCT04983940|EXPERIMENTAL|Jatenzo Arm|Participants in this group will receive Jatenzo for 26 consecutive weeks.
62130345|NCT04248998|EXPERIMENTAL|Fasting-mimicking diet plus metformin plus chemotherapy|"Experimental Arm B will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD and daily metformin~Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles.~Metformin will be administered at an initial dosage of 850 mg/dya, and then escalated to the maximum dosage of 1700/day (two 850 mg tablets) if well tolerated. Metformin will be interrupted 7 days before surgery."
62321024|NCT00775359|EXPERIMENTAL|1|Fenofibrate 160mg Tablets of Ranbaxy
62321025|NCT00775359|ACTIVE_COMPARATOR|2|TriCor® 160 mg Fenofibrate Tablets
62321026|NCT02508168|EXPERIMENTAL|Sequence I: AB|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by alogliptin 12.5 mg tablets and metformin 1000 mg tablets, orally, once, on Day 1 of Period 2.
62697479|NCT05630456|PLACEBO_COMPARATOR|Control Group|In the case of the control group, physical activity is monitored by itself through wearable devices and smartphone apps without phone counseling.
62130346|NCT00289835|EXPERIMENTAL|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
62130347|NCT00289835|OTHER|Standard medical treatment|
62321027|NCT02508168|EXPERIMENTAL|Sequence II: BA|Alogliptin 12.5 mg tablets, orally and metformin 1000 mg tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 2.
62321028|NCT03483688|EXPERIMENTAL|CD19-directed CAR-T cells|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
62321029|NCT03827577|EXPERIMENTAL|LAT arm|"Lung resection (if primary in place) + local ablative therapy of all metastatic sites + standard medical treatment.~patients may be enrolled either before any systemic therapy or after 3 months of treatment without progression according to local coordinator decision"
62321030|NCT03827577|ACTIVE_COMPARATOR|Control Arm|"Standard medical treatment~Local ablative therapy on the brain will be administered in any case to patients harboring cerebral oligometastases"
62481121|NCT06660069|EXPERIMENTAL|Toothpaste/Mouthwash (SnF2 Toothpaste followed by CPC Mouthwash)|Participants will brush their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants will swish 20 milliliters (mL) of the mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
62481122|NCT06660069|ACTIVE_COMPARATOR|Negative Control Toothpaste (Sodium Fluoride Toothpaste)|Participants will brush their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
62689811|NCT05280145|EXPERIMENTAL|Patients benefitting ultrasound examination|This is the only arm of the study. Patients with an indicative clinical picture that leads the clinician to resort to the use of an ultrasound to potentially support the diagnosis, will be examined depending on clinical presentation for either the presence of pyelocaliceal dilatation, or hepatic steatosis. The patients will be assessed first with the echOpen device and second witn an ultrasound routinely used in the department. In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
62321031|NCT05392192|EXPERIMENTAL|ADX-629|Subjects will be randomized to receive ADX-629 300mg tablets administered orally twice a day for 14 days.
62321032|NCT05392192|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive matching placebo tablets administered orally twice a day for 14 days.
62321033|NCT03245671|ACTIVE_COMPARATOR|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
62321034|NCT03245671|ACTIVE_COMPARATOR|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
62321035|NCT03288779|OTHER|Theta Burst Stimulation Arm|This is a pilot open label study.
62321036|NCT05423158|EXPERIMENTAL|d-Coaching|Will receive home-based cardiac rehabilitation (HBCR) with digital coaching (d-Coaching) intervention
62321037|NCT05423158|NO_INTERVENTION|Usual Care|Will receive home-based cardiac rehabilitation (HBCR) alone
62321038|NCT01207739|ACTIVE_COMPARATOR|Doxycycline|
62321039|NCT01207739|ACTIVE_COMPARATOR|Clarithromycin and hydroxychloroquine|
62321040|NCT01207739|PLACEBO_COMPARATOR|Placebo|
62321041|NCT03026686||readmit|women who were re-admitted in the post partum period for a hypertensive disorder
62321042|NCT03026686||Controls|women with similar risk factors but did not require readmission
62321043|NCT04993027|EXPERIMENTAL|Vancomycin Group:|patients will have single dose of 1g vancomycin powder placed on their incision during surgery in addition to: pre- and post-operative intravenous antibiotic administration, sterile surgical helmet systems, saline pulse lavage irrigation, and antimicrobial drapes.
62321044|NCT04993027|NO_INTERVENTION|Control Group|pre- and post-operative intravenous antibiotic administration, sterile surgical helmet systems, saline pulse lavage irrigation, and antimicrobial drapes.
62481123|NCT06660069|ACTIVE_COMPARATOR|Reference Toothpaste (SnF2 Toothpaste)|Participants will brush their teeth with full ribbon of reference toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
62481124|NCT05354544|EXPERIMENTAL|SVF for treating scarred vocal folds|Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.
62481125|NCT06297863|EXPERIMENTAL|HEAD DOWN TILT -10° to -15° (HDT15)|"HDT15 will be applied in the intervention group in 2 different settings:~* in the Emergency Room, by tilting the stretcher to lower the head by -10° to -15° relative to the body of the patient; the degree of tilting will be checked using a dedicated digital inclinometer or a mobile phone app~* in the Angiography Suite, by tilting the angiography table to lower the head by -10° to -15° relative to the body of the patient, depending on the actual technology of the angiography system of each clinical site; the degree of tilting will be automatically checked using the angiography system HDT15 will start as soon as possible following randomisation in the Emergency Room (i.e. after vascular neuroimaging), and will be maintained during the transfer to the Angiography Suite, as well as during the entire thrombectomy procedure. HDT15 will end after the completion of mechanical thrombectomy."
62481126|NCT06297863|NO_INTERVENTION|USUAL POSITIONING|Patients randomised in the control group will be maintained in the usual position during the emergency room phase (0° to +30°) and on the angiography table (0°), according to standard practice. Mechanical thrombectomy will be performed as per usual care.
62689812|NCT03338920|EXPERIMENTAL|Sumatriptan nasal powder|Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
62689813|NCT03338920|PLACEBO_COMPARATOR|Placebo|Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.
62321045|NCT05667961||the function remitted off-medicine group|"* Off-medicine definition: Continuous antipsychotic maintenance therapy for at least two years before drug discontinuation and drug discontinuation of all reasons (treatment benefits, adverse events, socioeconomic difficulties, migration, stigma, etc.) for at least one year;~* Function remitted definition: Meet the criteria of functional remission in both WHOQoL-BREF (overall points ≥ 60) and FROGS (social functioning dimension points ≥ 33, daily life dimension points ≥ 12, and treatment dimension points ≥ 12)"
62321046|NCT05667961||the function not-remitted off-medicine group|"* Off-medicine definition: Continuous antipsychotic maintenance therapy for at least two years before drug discontinuation and drug discontinuation of all reasons (treatment benefits, adverse events, socioeconomic difficulties, migration, stigma, etc.) for at least one year;~* Function not-remitted definition: Fail to meet the criteria of functional remission in both WHOQoL-BREF and FROGS"
62321047|NCT05667961||the function remitted on-medicine group|"* On-medicine definition: Continuous antipsychotic maintenance therapy during the time this study is conducted~* Function remitted definition: Meet the criteria of functional remission in both WHOQoL-BREF and FROGS"
62321048|NCT05667961||the function not-remitted on-medicine group|"* On-medicine definition: Continuous antipsychotic maintenance therapy during the time this study is conducted~* Function not-remitted definition: Fail to meet the criteria of functional remission in both WHOQoL-BREF and FROGS"
62321049|NCT01312350|ACTIVE_COMPARATOR|CCRT only arm|no neoadjuvant chemotherapy before definitive CCRT
62321050|NCT01312350|EXPERIMENTAL|neoadjuvant chemotherapy arm|2 cycles of TPF chemotherapy before definitive CCRT
62321051|NCT05780853||Typically Developing Children (Control Group)|Typically developing children with no known neurodevelopmental disorder, medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.
62321052|NCT05780853||Children with a Diagnosed Neurodevelopmental Disorder (Clinical Group)|Children with a diagnosed neurodevelopmental disorder including: Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Specific Learning Disorder, or a Communication Disorder. Children must also have no known medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.
62321053|NCT05379023|OTHER|Face-to-face evaluation (FF), TeleNP evaluation|
62689814|NCT02914886|EXPERIMENTAL|Group 1|Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.
62689815|NCT02914886|ACTIVE_COMPARATOR|Group 2|Daily use of current insulin in insulin pump.The dosis will be according to the patient's former dosing scheme.
61926453|NCT03875573|EXPERIMENTAL|Chemotherapy & pre-op radiotherapy + durvalumab + oleclumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w and the addition of the anti-CD73 antibody oleclumab IV 3000 mg q2w for 4 administrations, followed by q4w for 3 administrations.
61926454|NCT05559879|EXPERIMENTAL|Cabo + Dostarlimab|Cabozantinib 40 mg by mouth every day + Dostarlimab 500 mg intravenous every 3 weeks followed by maintenance therapy: Cabozantinib 40 mg by mouth every day + Dostarlimab 1000 mg intravenous every 6 weeks
62321054|NCT05379023|OTHER|TeleNP evaluation, Face-to-face evaluation (FF)|
62321055|NCT01947374|EXPERIMENTAL|Chondrocyte implantation|From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
62321056|NCT01947374|EXPERIMENTAL|Microfractures|Subchondral bone perforations that allow a clot to be formed, and subsequent scar at the cartilage defect area.
62321057|NCT01981122|EXPERIMENTAL|Concurrent Arm|Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
62689816|NCT03523585|EXPERIMENTAL|Trastuzumab deruxtecan (DS-8201a)|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
62697480|NCT06132789|EXPERIMENTAL|Essen Experimental Group (18-60 years old)|The subjects received 1 dose of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried each at day 0, 3, 7, 14 and 28, with a total of 5 doses
62689817|NCT03523585|ACTIVE_COMPARATOR|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
62689818|NCT03523585|ACTIVE_COMPARATOR|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
62689819|NCT06611696|ACTIVE_COMPARATOR|Glucocorticoid group|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 5 months. If a patient fails to achieve BVAS=0 or normalization of CRP levels or normalization of ANCA levels, an investigator can keep 5mg/day of prednisolone and postpone the procedure of stopping prednisolone. Patients will also receive rituximab (375mg/m2/w x4).~During remission maintenance phase (6-24 months),, patients will receive rituximab (500mg/body) every 6 months as remission maintenance therapy.~In the case of inadequate response to the combination therapy of prednisolone and rituximab, additional administration of prednisolone 20mg/day (less than 2 weeks) can be allowed as the rescue therapy.~During remission maintenance phase, in the case of minor relapse, additional administration of prednisolone 20mg/day (less than 2 weeks) can be allowed as the rescue therapy. Minor relapse is defined as relapse with no major BVAS item."
62689820|NCT06611696|EXPERIMENTAL|Avacopan group|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 1 months. Patients will also receive avacopan (60mg/day) and rituximab (375mg/m2/w x4).~During remission maintenance phase (6-24 months), patients will receive avacopan (60mg/day) as remission maintenance therapy until the trial end.~In the case of inadequate response to the combination therapy of avacopan, prednisolone and rituximab, additional administration of prednisolone 20mg/day (less than 2 weeks) can be allowed as the rescue therapy.~During remission maintenance phase, in the case of minor relapse, additional administration of prednisolone 20mg/day (less than 2 weeks) can be allowed as the rescue therapy. Minor relapse is defined as relapse with no major BVAS item."
62689821|NCT01996046||Bone mets|Patients will undergo an \[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
62689822|NCT06020937||Control|Healthy patients
62689823|NCT06020937||Multiple Sclerosis 1|Patients with multiple Sclerosis and Trigeminal disorders
62689824|NCT06020937||Multiple Sclerosis 2|Patients with Multiple Sclerosis without trigeminal concerns
62689825|NCT05398666|SHAM_COMPARATOR|White LED|Participants will be asked to use white LEDs for 1-2 hours/day in a dark room in their home.
62689826|NCT05398666|EXPERIMENTAL|Green LED|Participants will be asked to use green LEDs for 1-2 hours/day in a dark room in their home.
62481127|NCT05862012|EXPERIMENTAL|Part 1: Dose Escalation|Participants with R/R MM will be administered ISB 2001 weekly on Days 1, 8, 15, and 22 of each 28-day cycle, with an additional step-up dose in Cycle 1 on Day 4. Treatment cycle duration is 28 days. Participants will receive ISB 2001 until disease progression, unacceptable toxicity occurs, any criterion for stopping the study treatment or participant withdrawal from the study
62481128|NCT05862012|EXPERIMENTAL|Part 2: Dose Expansion|Dose expansion cohorts will be initiated to further confirm safety and optimal biologically active dose. Participants will receive ISB 2001 until disease progression, unacceptable toxicity occurs, any criterion for stopping the study treatment or participant withdrawal from the study.
62481129|NCT05114460|PLACEBO_COMPARATOR|Naloxone 0 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana
62481130|NCT05114460|ACTIVE_COMPARATOR|Naloxone 0 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana
62481131|NCT05114460|ACTIVE_COMPARATOR|Naloxone 0 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
62481132|NCT05114460|ACTIVE_COMPARATOR|Naloxone 4 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
62481133|NCT05114460|EXPERIMENTAL|Naloxone 4 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
62321058|NCT01981122|EXPERIMENTAL|Sequential Arm|Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
62321059|NCT06133829|EXPERIMENTAL|Intervention Group|Demographic and baseline measures will be obtained from the participants electronically. The participant will receive at least 1 prenatal home visit and at least 1 postpartum home visit. During the visits, the home visitor will review the screening assessments that were completed at baseline, identify health and social needs (including but not limited to referrals to substance use treatment providers, domestic violence hotline/shelters, mental health providers, applications for public assistance, and basic needs provision),work with the client to prioritize their needs, assist with applications and connections to community resources, support the participant in communicating with medical and social service providers, and provide education to help the participant advocate for their health, think ahead for after delivery (prenatal), and understand infant health and safety. At 2 months postpartum, both intervention and control groups will receive a post- survey through REDCap.
62321060|NCT06133829|NO_INTERVENTION|Control Group|Demographic and baseline measures will be obtained from the participants electronically through REDCap surveys. The participants will receive standard care from the obstetric clinic. At approximately 2 months postpartum, both intervention and control groups will receive a post- survey through REDCap.
62321061|NCT01280123|EXPERIMENTAL|15 mg pioglitazone|15 mg pioglitazone
62321062|NCT01280123|EXPERIMENTAL|45 mg pioglitazone|45 mg pioglitazone
62321063|NCT01280123|PLACEBO_COMPARATOR|Matching Placebo|Placebo
62321064|NCT06692959|EXPERIMENTAL|PD1-Vaxx|All patients will be administered PD1-Vaxx intramuscularly into the deltoid region of the upper arm on days 1,15 and 29. Patients will undergo resection surgery within 21 days, but up to 42 days of completing trial treatment.
62321065|NCT04037423||PE patients treated with CDT|Acute pulmonary embolism patients undergoing catheter-directed embolectomy.
62321066|NCT06593912|ACTIVE_COMPARATOR|Cast|Postoperative immobilization with cast in 6 weeks.
62321067|NCT06593912|ACTIVE_COMPARATOR|Cast + Air Stirrup|Postoperative immobilization with cast in 3 weeks followed by Air Stirrup in 3 weeks. Early range of motion after 3 weeks postoperative.
62481134|NCT05114460|EXPERIMENTAL|Naloxone 4 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
62481135|NCT02826694|OTHER|Well infant, whole exome sequencing|Healthy infants and their parents enrolled in the study prenatally will participate. After the infant is born saliva sample will be collected for DNA extraction and whole exome sequencing will be done.
62481136|NCT02826694|OTHER|Diagnosed, whole exome sequencing|Infants and children with diagnosed conditions whose parents enroll in the study and consent to having their child sequenced will have saliva samples obtained and whole exome sequencing will be done on extracted DNA.
62481137|NCT04417660|EXPERIMENTAL|Bintrafusp alfa (M7824)|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
62481138|NCT06302335|EXPERIMENTAL|Povidone-iodine arm|Patients submitted to colorectal resections using Povidone-iodine in the surgical wound.
62481139|NCT06302335|ACTIVE_COMPARATOR|Saline solution arm.|Patients submitted to colorectal resections using saline solution in the surgical wound.
62481140|NCT00068731|EXPERIMENTAL|lycopene|"Patients receive oral lycopene twice daily on days 1-28. Courses repeat every 28 days for at least 4 months in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
62481141|NCT02030223|ACTIVE_COMPARATOR|Transversus abdominis plane block with 20 ml ropivacaine 0,75%|Transversus abdominis plane block with 20 ml ropivacaine 0,75%
62481142|NCT02030223|PLACEBO_COMPARATOR|Transversus abdominis plane block with 20 ml saline|Transversus abdominis plane block with 20 ml saline
62481143|NCT04955470|EXPERIMENTAL|Intravenous ketamine|Infusion of 0.5 mg/kg of ketamine, at maximum dose of 40 mg, over 40 minutes.
62481144|NCT04955470|ACTIVE_COMPARATOR|Intravenous midazolam|Infusion of 0.03 mg/kg of midazolam, at maximum dose of 2 mg, over 40 minutes.
62481145|NCT04955470|PLACEBO_COMPARATOR|Intravenous saline|Infusion of 0.9% saline over 40 minutes.
62481146|NCT05192486|EXPERIMENTAL|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62481147|NCT02311933|EXPERIMENTAL|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62689827|NCT02674763|EXPERIMENTAL|Dose Escalation Schedule A|IMGN779 administered on days 1 and 15 of a 28-day cycle
62689828|NCT02674763|EXPERIMENTAL|Dose Escalation Schedule B|IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle
62481148|NCT02311933|EXPERIMENTAL|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
62481149|NCT06446713|EXPERIMENTAL|Image guided hybrid hyper-fractioned dose escalation with proton therapy|
62481150|NCT05266001|ACTIVE_COMPARATOR|GM-CSF|Intravenous GM-CSF 125 mcg/m2/day x 7 days
62481151|NCT05266001|PLACEBO_COMPARATOR|Placebo|Intravenous placebo x 7 days
62481152|NCT06742515|EXPERIMENTAL|Treatment arm|Blinatumomab plus Reduced-dose Chemotherapy
62321068|NCT03018782|OTHER|Brief Pain Inventory Short Form|Completes the Brief Pain Inventory Short Form
62481153|NCT06042166|EXPERIMENTAL|Connecting and Reflecting Experience (CARE) Program|Participants will enroll in a 12-session CARE parenting group therapy.
62481154|NCT04403672||COVID-19 positive|ideSHi (CRO) investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.
61926455|NCT03845296|EXPERIMENTAL|Treatment (rucaparib)|Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62321069|NCT02016157|EXPERIMENTAL|Moxifloxacin, Chronic periodontitis|50 micrograms Moxifloxacin
62689829|NCT02674763|EXPERIMENTAL|Dose Escalation Schedule C|IMGN779 administered on days 1 and 8 of a 21-day cycle
62689830|NCT02674763|EXPERIMENTAL|Dose Expansion Cohort|Patients with Relapsed AML; IMGN779 administered at dose and schedule selected as the putative RP2D.
62689831|NCT06325852|EXPERIMENTAL|Phase 1|5 to 10 patients with tremor already treated with VIM-DBS but not doing well because of early or late loss of benefits will be recruited by the PI over a 6 months period. If interested, the potential participants will be screened, informed, and consented by a research coordinator. Before the replacement of their IPG (implantable pulse generator), a baseline measurement will be performed.
61926456|NCT05736406|EXPERIMENTAL|200 J/cm^2|Patient will undergo intraoperative Photodynamic therapy at 200 J/cm\^2
62321070|NCT01400971||MOSAIc Participants|Participants enrolled in Multinational Observational Study Assessing Insulin use (MOSAIc) who had complete treatment data during the study.
62321071|NCT06058780|ACTIVE_COMPARATOR|Implantable Collamer Lens (ICL)|
62321072|NCT06058780|ACTIVE_COMPARATOR|Implantable Intraocular Lens (IPCL)|
62321073|NCT06252610||PSC|Population will be consecutive patients with PSC, who will be referred to us by the MGB-affiliated hepatologists.
62321074|NCT05427851|EXPERIMENTAL|Group I: Platelet rich Fibrin (PRF) and Biodentine|
62321075|NCT05427851|EXPERIMENTAL|Group II: Diode Laser and Biodentine|
62321076|NCT05427851|EXPERIMENTAL|Group III: Diode laser + PRF + Biodentine|
62321077|NCT05579561|EXPERIMENTAL|Vegetarian ketogenic diet|Participants will be required to eat a diet that is very low in carbohydrates, moderate in vegetarian proteins, including fish and eggs, with added healthy fats
62321078|NCT05579561|ACTIVE_COMPARATOR|Omnivor ketogenic diet|Participants will be required to eat a diet that is very low in carbohydrates, moderate in animal protein, with added healthy fats.
62321079|NCT03403491|OTHER|Sequence 1|Usual care for 2 weeks followed by using patientMpower application \[+digital weighing scales \& BP monitor\] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
62321080|NCT03403491|OTHER|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application \[+digital weighing scales \& BP monitor\] for 4 weeks.
62321081|NCT04099901|EXPERIMENTAL|Anakinra|Dosage form: intravenous. Dosage: 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
62321082|NCT04099901|PLACEBO_COMPARATOR|Placebo|Dosage form: intravenous. Dosage: not applicable. Frequency: once daily. Duration: 15 days (day -2 until day +12).
62321083|NCT03319992|NO_INTERVENTION|Conventional treatment|The conventional treatment arm was conducted according to a set of exercises that were specifically designed in order to match the robotic treatment. Patients received both physical therapy (PT) and occupational therapy (OT) session, administered by the physiotherapists of the hospital. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals.
62321084|NCT03319992|EXPERIMENTAL|Robotic treatment|The patients enrolled in the robotic arm are going to be undergone a series of passive, assisted and active mobilization in upper limb task-oriented exercises implemented in 3d virtual environments. Briefly speaking, these tasks promote the upper arm multi-joints coordination during the execution of reaching movements and grasping actions of fixed virtual objects displaced in the space.
62321085|NCT02352246|EXPERIMENTAL|steady-state exercise (SSE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
62321086|NCT02352246|OTHER|high intensity intermittent exercise (HIIE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
62321087|NCT05131178|PLACEBO_COMPARATOR|Saline|ON-Q Pump® with continuous infusion of saline (270 mL of normal saline)
62321088|NCT05131178|EXPERIMENTAL|Bupivacaine|ON-Q Pump® with continuous infusion of bupivacaine (270 ml of 0.5 % bupivacaine)
62321089|NCT03394170||Osteoarthritis|Participants who are undergoing unicompartmental knee replacement will be considered OA status
61926457|NCT05736406|EXPERIMENTAL|400 J/cm^2|Patient will undergo intraoperative Photodynamic therapy at 400 J/cm\^2
62321090|NCT03394170||Non-Osteoarthritis|"Participants with an acute injury (occurring no more than 90 days prior to surgery) with no history of knee injury or surgery, will be considered Non-OA status"
62321091|NCT03813563||Mix group|Patients who used two balanced salt solutions during icu stay
62321092|NCT03813563||RL group|Patients who have only used lactated Ringer's during icu stay
62321093|NCT03813563||PLA group|Patients who have only used PlasmaLyte during icu stay
62321094|NCT04006743|NO_INTERVENTION|The routine care group|In the routine care group, while a neonatal nurse performed the OGT insertion procedure, physiological measurements of the highest value of heart rate and the lowest value of oxygen saturation were recorded by one researcher (the first author) 1 min before the procedure, during the process and after the process in 1st and 2nd minutes acquired for each infant in the unit with an individual monitor.
61926458|NCT05878561|EXPERIMENTAL|Fimasartan + Indapamide|Treatment Period I, II
61926459|NCT05878561|ACTIVE_COMPARATOR|Fimasartan + Indapamide placebo|Treatment Period I, II
61926460|NCT05391451|EXPERIMENTAL|Quadratus lumborum block (QLB) group|
61926461|NCT05391451|ACTIVE_COMPARATOR|Control group|
62321095|NCT04006743|EXPERIMENTAL|The swaddling group|In this group, preterm infants were given swaddling method.
62321096|NCT04006743|EXPERIMENTAL|The expressed breast milk group|In this group, preterm infants were given expressed breast milk method.
61926462|NCT03645681|EXPERIMENTAL|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
62321097|NCT04006743|EXPERIMENTAL|The facilitated tucking group|In this group, preterm infants were given facilitated tucking method.
62321098|NCT04006743|EXPERIMENTAL|The swaddling and expressed breast milk group|In this group, preterm infants were given combined swaddling and expressed breast milk method.
62321099|NCT04006743|EXPERIMENTAL|The facilitated tucking and expressed breast milk group|In this group, preterm infants were given combined facilitated tucking and expressed breast milk method.
62321100|NCT05942651|ACTIVE_COMPARATOR|active ccPAS4-ms|"Device: Magstim BiStim 2002 (The Magstim Company Ltd., Spring Gardens, Whitland, UK) and two small coils (40mm, figure-of-eight coils, Alpha B.I).~Coil 1 was positioned over right IFC at a 20° angle to the coronal plane with the handle pointing anteriorly, and coil 2 was positioned over right pre- SMA perpendicular to the midline.~The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT"
62481155|NCT04403672||COVID-19 Negative|"ideSHi investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.~In addition, 60 fresh specimens which will be tested at IEDCR will also be tested at ideSHi using RealDetect on a real time basis. These samples will also be blinded by IEDCR and sent to the testing laboratory (ideSHi). Of these 60 samples, 30 will be COVID-19 positive and 30 COVID- 19 negative samples. These fresh samples will be provided to ideSHi for testing and analysis for performance evaluation of RealDetect COVID-19 RT-PCR kit."
62481156|NCT06185088|OTHER|Participants with Ostomies|Patients who have ostomies, and who are already undergoing a minor procedure for routine health screening or other health matters as standard of care.
62481157|NCT06073223|EXPERIMENTAL|CQUPLE Intervention|"A novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon."
62689832|NCT06325852|EXPERIMENTAL|Phase 2|Ten patients with ET needing DBS-VIM surgery will be recruited and will receive Boston Scientific Genus IPG bilaterally connected to Boston Scientific Cartesia™ 8-contact Directional Leads. The programming will be done in four different settings/periods during the course of 8 months.
62689833|NCT06673563||Single tooth|Patient with the need of a single implant treatment
62321101|NCT05942651|SHAM_COMPARATOR|Control condition ccPAS100-ms.|"Device: Magstim BiStim 2002 (The Magstim Company Ltd., Spring Gardens, Whitland, UK) and two small coils (40mm, figure-of-eight coils, Alpha B.I).~Coil 1 was positioned over right IFC at a 20° angle to the coronal plane with the handle pointing anteriorly, and coil 2 was positioned over right pre- SMA perpendicular to the midline.~The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT"
62689834|NCT06673563||Multiple teeth|Patients in need of two or more dental implants
62321102|NCT02097706|ACTIVE_COMPARATOR|NMDA receptor antagonist|20mg/daily for 12 weeks (84 days)
62321103|NCT02097706|PLACEBO_COMPARATOR|Placebo tablet|1 capsule/daily for 12 weeks (84 days)
61926463|NCT01152450|EXPERIMENTAL|Tiotropium daily dose q.d.|two actuations delivered via Respimat® inhaler
62130348|NCT06465446|EXPERIMENTAL|IMM01 plus Tiselizuma|Participants will receive IMM01 (2.0mg/kg) intravenously each week and tislelizumab (200mg) once every 3 weeks in 3-week treatment cycle, for up to 2 years.
62321104|NCT06554301|PLACEBO_COMPARATOR|placebo in treatment pulmonary arterial hypertension|
62321105|NCT06554301|EXPERIMENTAL|empagliflozin in treatment pulmonary arterial hypertension|
62321106|NCT06402604|EXPERIMENTAL|Sports|Exercise training consists of 12-weeks of heartrate-controlled training on a cycle trainer at 70-80% individual heartrate reserve. The training will take place at a fitness center of the participant's own choice, women will receive a sport fee after inclusion. heartrate will be monitored continuously and recorded by a smartwatch. Training is personalized and consists of 60 minutes of cycling for 2 times (week: 1-6) to 3 times (week: 7-12) per week for one hour. Training includes intensity of 40 minutes on 70-80%. heartrate reserve (HRR) was calculated in the following manner: HHR=HRmax-HRrest, in which HRmax is assumed 220 bpm minus age.
62481158|NCT06073223|ACTIVE_COMPARATOR|Usual Care Control|The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
62481159|NCT05438550|ACTIVE_COMPARATOR|14-day bismuth-containing quadruple therapy (BQT)|14-day bismuth-containing quadruple therapy (BQT) Nexium (Esomeprazole, Astrazeneca Pharmaceutical Co., LTD.) 20mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
62689835|NCT06673563||Full-arch|Patients in need of at least one All-on-4 treatment (with or without additional placed implants)
62689836|NCT00247039|EXPERIMENTAL|Garlic extract|Garlic extract capsules
62689837|NCT00247039|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62689838|NCT04222504|EXPERIMENTAL|Intervention Salons|Intervention: Behavioral: Provision of sexual health preventative services in the salon setting
62689839|NCT04222504|NO_INTERVENTION|Control Salon|No Intervention
62689840|NCT02082782|EXPERIMENTAL|irreversible electroporation (IRE)|Single arm study: percutaneous or open irreversible electropration of CRLM
62689841|NCT03923998|EXPERIMENTAL|Neoadjuvant chemoradiotherapy followed by surgery|Preoperative chemotherapy with concurrent radiotherapy followed by definitive surgery
61926464|NCT01152450|EXPERIMENTAL|Tiotropium half daily dose b.i.d.|two actuations delivered via Respimat® inhaler
62321107|NCT06402604|EXPERIMENTAL|Sofa|Participants will participate in an mindfullness based stress reduction (MBSR) training. The training consists of 8 weekly sessions lasting 2,5 hours per session. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training will be offered online and is led by qualified teachers from Radboud university medical centre.
62321108|NCT06402604|NO_INTERVENTION|Waitlist|The participants are asked during the intervention not to follow any diet. Women in the control group will be asked to continue normal physical activities and not to undertake Mindfulness therapy during the study period for 12 weeks.
62321109|NCT00935857|EXPERIMENTAL|Balloon Colonoscopy|Colonoscopy using the single balloon colonoscopy system (novel endoscope to facilitate difficult colonoscopy).
62321110|NCT00935857|ACTIVE_COMPARATOR|Standard Colonoscopy|Colonoscopy using a standard adult colonoscope
62321111|NCT05339308|EXPERIMENTAL|Experimental|Magnesium oil application
62321112|NCT05339308|PLACEBO_COMPARATOR|Control|Natural mineral-free oil application
62481160|NCT05438550|EXPERIMENTAL|14-day Tegoprazan high-dose dual therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid
61926465|NCT01152450|PLACEBO_COMPARATOR|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
62321113|NCT06274411|EXPERIMENTAL|Standby cannulated ECMO|For standby cannulated ECMO procedures, femoral cannulas are inserted either by percutaneous approach or surgical approach. The primed circuit is connected to the inserted ECMO cannulas, clamps are kept on circuit, and ECMO is on standby during PCI. When PCI cause hemodynamic instability, clamps on circuit are removed, and VA-ECMO is initiated to maintain maintain adequate systemic pressure and perfusion.
62321114|NCT06274411|ACTIVE_COMPARATOR|Prophylactic ECMO|Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI. Femoral cannulas are inserted either by percutaneous approach or surgical approach. Following cannula placement, VA-ECMO is initiated to maintain adequate systemic pressure and perfusion during PCI.
62321115|NCT04923412|EXPERIMENTAL|Pulmonary branch of vagus nerve preserved|Pulmonary branch of vagus nerve is preserved during the mediastinal lymph node dissection using minimally invasive surgery
62321116|NCT04923412|EXPERIMENTAL|Pulmonary branch of vagus nerve not-preserved|Pulmonary branch of vagus nerve is not preserved during the mediastinal lymph node dissection using minimally invasive surgery
62321117|NCT03643432|ACTIVE_COMPARATOR|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
62689842|NCT01384045|NO_INTERVENTION|Usual Care|Patients continue to receive usual diabetes care without outreach by health promotions staff.
62481161|NCT05822089|EXPERIMENTAL|Monofocal IOL I vs. enhanced monofocal IOL I|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
62481162|NCT05822089|EXPERIMENTAL|Monofocal IOL II vs. enhanced monofocal IOL I|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm two (II) participants will receive a monofocal IOL (Sensar 1AAB00) vs. an enhanced monofocal IOL (ICB00)
61926466|NCT05468736|EXPERIMENTAL|Cohort-1(6 to < 12 y)-Part-1(Active Vaccine)|NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
62321118|NCT03643432|EXPERIMENTAL|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
62321119|NCT05019703|EXPERIMENTAL|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62321120|NCT02333240|NO_INTERVENTION|Usual care|"Women randomised to usual care will have their blood pressure monitored by their community midwife, and will have their anti-hypertensive medication adjusted by their general practitioner. There will be no intervention in this group.~All women will be followed up at ten days, four and six weeks, then three and six months postpartum and have their blood pressure measured by one of the study team."
62321121|NCT02333240|EXPERIMENTAL|Self-management|Self-management of postnatal anti-hypertensive treatment. Women will be provided with, and taught to use, a validated home blood pressure monitor, and perform daily BP readings. When treatment is discontinued we will ask them to continue daily BP measurements for 1 week. Provided these are \<140/90 mmHg they will be asked to check their BP weekly for the remainder of the trial period. The self-monitoring BP data will be collated centrally through the use of a smart phone app or SMS based system. This service will respond to participants regarding the level of their BP and what action is required. Women in the self-management group will have an individualised medication adjustment schedule developed by the research team in conjunction with the participant's obstetric team.
62321122|NCT03737149|EXPERIMENTAL|mymobility with Apple Watch|Post-operative mobile application-guided education and exercise paired with accurate and sensitive activity monitoring.
62321123|NCT03737149|NO_INTERVENTION|Standard of Care Physical Therapy|Standard of care patient education and post-operative physical therapy, as determined by local site guidelines and care pathways.
62321124|NCT05791799|EXPERIMENTAL|Etonogestrel implants group|Women will be subjected to etonogestrel implant (68mg) insertion.
62321125|NCT05791799|NO_INTERVENTION|control group|This group of women will not be intervened.
62321126|NCT06215339|EXPERIMENTAL|group where diet education is given|"Patients in the experimental group were given face-to-face diet education by the researcher in the waiting room for approximately 15 minutes and an Information Brochure was given.~Pre-training (pre-test) for hemodialysis patients Data collection tools were applied. All data collection tools were applied to these patients, except for the structured Patient Information Form for post-training measurements (intermediate measurement) 1 month after the training was given."
62321127|NCT06215339|NO_INTERVENTION|Control group|No treatment was performed on hemodialysis patients in this group. Only data collection forms were applied to the patients before the study (pretest), at the 1st week (intermediate measurement/1st measurement) and at the end of the study. (8th week) 3 times in total for 8 weeks.
62321128|NCT04254237|ACTIVE_COMPARATOR|Intervention group|Infraumbilical Hasson trocar incision.
62321129|NCT04254237|SHAM_COMPARATOR|Control group|Supraumbilical Hasson trocar incision.
62321130|NCT01377181||group A|the patients were accepted laparoscopic purse-string knot closing the internal hernia opening only
62321131|NCT01377181||group B|the patients were accepted the lateral umbilicus ligament covering the internal hernia opening region after the laparoscopic purse-string knot
62321132|NCT05704413||digestive cancer or IBD|Patient with digestive cancer or IBD having surgery with intestinal resection planned in the Visceral Surgery Department of St Antoine Hospital
62321133|NCT03273075|ACTIVE_COMPARATOR|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
62321134|NCT03273075|ACTIVE_COMPARATOR|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age \>75years, weight \<60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
62689843|NCT01384045|EXPERIMENTAL|Arm 1-Health Promotoin Outreach|Active outreach by health promotion staff to send diabetes report card and schedule services including laboratory testing and visits.
62689844|NCT05607303||Cases|MTF youth who will begin taking estrogen clinically in \< 6 months with or without headache
62689845|NCT05607303||Controls|Cisgender males with or without headache
62689846|NCT01548326|ACTIVE_COMPARATOR|Atorvastatin|will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
62689847|NCT01548326|PLACEBO_COMPARATOR|Placebo|will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
61926467|NCT05468736|PLACEBO_COMPARATOR|Cohort-1(6 to < 12 y)-Part-1(Placebo)|Placebo (normal saline)
61926468|NCT05468736|EXPERIMENTAL|Cohort-1(6 to < 12 y)-Part-2(Active Vaccine)|NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
62321135|NCT03273075|PLACEBO_COMPARATOR|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
62321136|NCT03273075|PLACEBO_COMPARATOR|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age \>75years, weight \<60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
62321137|NCT05563077|EXPERIMENTAL|Moderate-intensity interval training (MIIT)|24 participants with resistant hypertension will perform moderate-intensity interval training.
62321138|NCT05563077|EXPERIMENTAL|Moderate-intensity continuous training (MICT)|24 participants with resistant hypertension will perform moderate-intensity continuous training.
62689848|NCT04137757|EXPERIMENTAL|Lower Body Negative Pressure (LBNP)|Participants complete mental tasks and imaging while undergoing lower body negative pressure (LBNP).
62689849|NCT04137757|SHAM_COMPARATOR|Sham Pressure|Participants complete mental tasks and imaging with pressure noise but no pressure.
62689850|NCT05665751|EXPERIMENTAL|TLC-3595 Dose 1|Oral dose of TLC-3595 Dose 1
62689851|NCT05665751|EXPERIMENTAL|TLC-3595 Dose 2|Oral dose of TLC-3595 Dose 2
62321139|NCT05563077|NO_INTERVENTION|Usual care|24 participants with resistant hypertension will maintain usual care for 4 months.
62321140|NCT06245577|EXPERIMENTAL|Biomesh|"Biodesign (TM) Rectopexy Graft~Mesh used in the mesh sacropexy of the middle pelvic organ compartment (vagina, cervix, or uterus); the mesh fixes the middle pelvic organ compartment to the promontory"
61926469|NCT05468736|PLACEBO_COMPARATOR|Cohort-1(6 to < 12 y)-Part-2(Placebo)|Placebo (normal saline)
61926470|NCT05468736|EXPERIMENTAL|Cohort-2(2 to < 6 y)-Part-1(Active Vaccine)|NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
61926471|NCT05468736|PLACEBO_COMPARATOR|Cohort-2(2 to < 6 y)-Part-1(Placebo)|Placebo (normal saline)
61926472|NCT05468736|EXPERIMENTAL|Cohort-2(2 to < 6 y)-Part-2(Active Vaccine)|NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
61926473|NCT05468736|PLACEBO_COMPARATOR|Cohort-2(2 to < 6 y)-Part-2(Placebo)|Placebo (normal saline)
61926474|NCT05468736|EXPERIMENTAL|Cohort-3(6 to < 24 m)-Part-1(Active Vaccine)|NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
61926475|NCT05468736|PLACEBO_COMPARATOR|Cohort-3(6 to < 24 m)-Part-1(Placebo)|Placebo (normal saline)
61926476|NCT05468736|EXPERIMENTAL|Cohort-3(6 to < 24 m)-Part-2|NVX-CoV2373 (SARS-CoV-2 rS: 5 µg + Matrix-M adjuvant: 50 µg in 0.5 mL)
61926477|NCT05468736|PLACEBO_COMPARATOR|Cohort-3(6 to < 24 m)-Part-2(Placebo)|Placebo (normal saline)
61926478|NCT06547840|EXPERIMENTAL|Part 1 and Part 2|"Part 1: MOv18 IgE will be administered by intravenous infusion, in dose escalation cohorts, starting at 3 mg.~Part 2: MOv18 IgE will be administered by intravenous infusion at the dose determined in Part 1~Patients will receive treatment on Days 1, 8 and 15 of a 21-day cycle~Patients will continue to receive study drug until disease progression, unacceptable toxicity, withdrawal of consent, death, or until the sponsor terminates the study (whichever comes first)."
61926479|NCT05654883||HIV-negative, SQ-SQ, short interval|HIV-negative patients who received two subcutaneous mpox vaccinations with an interval of \<7 weeks between primer and booster doses.
61926480|NCT05654883||HIV-positive, SQ-SQ, short interval|HIV-positive patients who received two subcutaneous mpox vaccinations with an interval of \<7 weeks between primer and booster doses.
61926481|NCT05654883||HIV-negative, ID-ID, short interval|HIV-negative patients who received two intradermal mpox vaccinations with an interval of \<7 weeks between primer and booster doses.
61926482|NCT05654883||HIV-positive, ID-ID, short interval|HIV-positive patients who received two intradermal mpox vaccinations with an interval of \<7 weeks between primer and booster doses.
61926483|NCT05654883||HIV-negative, SQ-SQ, SQ-ID, ID-SQ or ID-ID, long interval|"HIV-negative patients who received either:~1. subcutaneous primer and booster mpox vaccinations, OR~2. intradermal primer and booster mpox vaccinations, OR~3. subcutaneous primer followed by intradermal booster mpox vaccination OR~4. intradermal primer followed by subcutaneous booster mpox vaccination~with the booster dose being taken after an interval of ≥7 weeks."
61926484|NCT05654883||HIV-positive, SQ-SQ, SQ-ID, ID-SQ or ID-ID, long interval|"HIV-positive patients who received either:~1. subcutaneous primer and booster mpox vaccinations, OR~2. intradermal primer and booster mpox vaccinations, OR~3. subcutaneous primer followed by intradermal booster mpox vaccination OR~4. intradermal primer followed by subcutaneous booster mpox vaccination~with the booster dose being taken after an interval of ≥7 weeks."
61926485|NCT05654883||SQ-ID or ID-SQ, short interval|"1. subcutaneous primer and intradermal booster mpox vaccinations, OR~2. intradermal primer and subcutaneous booster mpox vaccinations~with the booster dose being taken after an interval of \<7 weeks."
61926486|NCT05654883||1st Dose Only|Participants who receive a 1st dose of the mpox vaccination but elect not to take 2nd dose.
61926487|NCT05654883||Convalescent, No Vaccination|Participants who are convalescent from mpox infection who do not receive mpox vaccination.
61926488|NCT05654883||Convalescent, Vaccination Post-Infection|Participants who are convalescent from mpox infection who receive mpox vaccination after infection.
61926489|NCT05654883||BT after Vaccinations|Participants who experienced breakthrough (BT) mpox infections following mpox vaccination.
61926490|NCT04418232|EXPERIMENTAL|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
61926491|NCT05831540|EXPERIMENTAL|Group I (staff focus group)|Staff participate in facilitated planning discussions to develop CDS tools on study.
61926492|NCT05831540|EXPERIMENTAL|Group II (staff CDS tool utilization)|Staff receives CDS tools training and implements CDS tools to facilitate HPV vaccination on study.
61926493|NCT05831540|EXPERIMENTAL|Group III (parent survey)|Parents complete survey post-intervention on study.
61926494|NCT05441579|EXPERIMENTAL|Phase 1 - VR-BF BE|We are applying Behavioral Economics (BE)-based messaging and presentation strategies to patient recruitment and determining whether these strategies may enhance patient recruitment into a pediatric randomized clinical trial. Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
61926495|NCT05441579|ACTIVE_COMPARATOR|Phase 1 - VR-BF Biological|A similar to BE-based recruitment video using a standard biological approach on teenagers' decision to enroll in a clinical study will be used as comparison. Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
61926496|NCT05441579|EXPERIMENTAL|Phase 2 - Manage My Pain BE|We are applying Behavioral Economics (BE)-based messaging and presentation strategies to patient recruitment and determining whether these strategies may enhance patient recruitment into a pediatric randomized clinical trial. Phase 2 will focus on patients that would be enrolled into the control arm of a clinical trial with a control intervention, Manage My Pain application.
62321141|NCT06245577|ACTIVE_COMPARATOR|Synthetic mesh|"DynaMesh (TM) VASA~Mesh used in the mesh sacropexy of the middle pelvic organ compartment (vagina, cervix, or uterus); the mesh fixes the middle pelvic organ compartment to the promontory"
62321142|NCT03670082|EXPERIMENTAL|Group 1: Fasting condition in Period I|Subjects will be in fasting condition in Period I and in a fed condition in Period II.
62321143|NCT03670082|EXPERIMENTAL|Group 2: Fed condition in Period I|Subjects will be in fed condition in Period I and in fasting condition in Period II.
62321144|NCT04099056|ACTIVE_COMPARATOR|Participants with Major Depressive Disorder (MDD)|Participants with MDD will complete computer tasks while receiving TMS/ TI
62321145|NCT04099056|ACTIVE_COMPARATOR|Healthy Control|Participants without MDD will complete computer tasks while receiving TMS/TI
62321146|NCT02166593|EXPERIMENTAL|Pravastatin 40mg/Fenofibrate160mg|Pravastatin (40mg/day) Fenofibrate (160mg/day)
62321147|NCT02166593|ACTIVE_COMPARATOR|Atorvastatin Sodium|Atorvastatin Sodium (10mg/day)
62689852|NCT05665751|PLACEBO_COMPARATOR|Placebo|Oral dose of placebo-to-match
62130349|NCT06465446|ACTIVE_COMPARATOR|Physician's Choice Chemotherapy|"Participants will receive physician's choice of either bendamustine or gemcitabie.~Gemciabine: 90 or 120 mg/m\^2 on Day 1 and Day 2, IV, 4-week cycle, for up to 6 cycles.~Gemcitabine: 1000 mg/m\^2 on Day 1 and Day 8, IV, 3-week cycle, for up to 6 cycles."
62481163|NCT05822089|EXPERIMENTAL|Monofocal IOL III vs. enhanced monofocal IOL II|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm three (III) participants will receive a monofocal IOL (Vivinex XY1)vs. an enhanced monofocal IOL (Vivinex Impress).
62130350|NCT04484753|OTHER|Home Exercise Sheet|The participant took the sheet with the description of the exercises to his address.
62130351|NCT04484753|OTHER|Ipelvis mobile application|The participant received the app and performs home exercises guided by the app.
62130352|NCT04484753|ACTIVE_COMPARATOR|Home exercise sheet + Pelvic Physiotherapy|The participant did group physical therapy and used the exercise sheet at home on other days.
62130353|NCT04484753|ACTIVE_COMPARATOR|Ipelvis mobile application + Pelvic Physiotherapy|The participant did group physical therapy and used the mobile application on other days.
62130354|NCT01864512||ITP patients receiving eltrombopag therapy|
62481164|NCT05822089|EXPERIMENTAL|Enhanced monofocal IOL II vs. enhanced monofocal IOL II|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm four (IV) participants will receive an enhanced monofocal IOL (Vivinex Impress) bilateral with a monovision target
62481165|NCT05822089|EXPERIMENTAL|Monofocal IOL IV vs. enhanced monofocal IOL III|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm five (V) participants will receive an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
62481166|NCT05822089|EXPERIMENTAL|Enhanced Monofocal IOL IV vs. enhanced monofocal IOL IV with irregular astigmatism|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm six (VI) participants will receive an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed.
62130355|NCT06514482||NO OSA|Control group
62130356|NCT06514482||OSA WHITH CPAP|
62130357|NCT06514482||OSA WHITHOUT CPAP|
62130358|NCT01439048||Term infants|Infants born at greater than 37 weeks gestation
62130359|NCT01439048||Preterm Infants|Infants born at less than 37 weeks gestation
62130360|NCT01003834|PLACEBO_COMPARATOR|Control|Screening only
62130361|NCT01003834|ACTIVE_COMPARATOR|Assessment|Screening plus assessment
62130362|NCT01003834|EXPERIMENTAL|Computer Intervention|Screening, assessment, and computer-delivered intervention
62130363|NCT01003834|ACTIVE_COMPARATOR|Therapist Intervention|Screening, Assessment, and therapist-delivered intervention
62130364|NCT05326607|OTHER|First Arm|
62130365|NCT05326607|OTHER|Second Arm|
62130366|NCT04042207|ACTIVE_COMPARATOR|Reference treatment (Open-Loop)|Sensor-augmented pump therapy (SAP) namely the Low Glucose Predictive Suspend system or LGPS and a blinded glucose sensor (Dexcom G6) followed by a 48-week extension period in closed-loop condition
62130367|NCT04042207|EXPERIMENTAL|DBLHU system (Closed-Loop)|DBLHU software (a Model Predictive Control \[MPC\]-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleido insulin pump followed by a 48-week extension period in closed-loop condition
62130368|NCT06427863|EXPERIMENTAL|Treatment|Patients will receive three enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT once daily for a duration of 3 days.
62130369|NCT06427863|PLACEBO_COMPARATOR|Control|Patients will receive three enemas of a placebo of equal volume through the TET tube, followed by WMT once daily for a duration of 3 days.
62130370|NCT02555215|EXPERIMENTAL|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
62130371|NCT02160951|EXPERIMENTAL|LGH447|LGH447, QD
62130372|NCT01510977|ACTIVE_COMPARATOR|PEG|2L of polyethylene glycol addition immediately after first colonoscopy failure
62481167|NCT05822089|EXPERIMENTAL|Extended Depth of Focus IOL in eyes with irregular astigmatism|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm seven (VII) participants will receive an extended depth of focus IOL (IC-8 Apthera IOL) in one eye if irregular astigmatism is observed.
62481168|NCT03945773|EXPERIMENTAL|Cohort A|Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.
62481169|NCT03945773|EXPERIMENTAL|Cohort B|Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.
62481170|NCT06741865|EXPERIMENTAL|Lifestyle Intervention|This arm involves an active intervention with health coaching and lifestyle changes.
62481171|NCT06741865|ACTIVE_COMPARATOR|Standard Health Education|This arm receives a standard educational approach without the intensive intervention.
62481172|NCT03637764|EXPERIMENTAL|Cohort A: HCC: Isatuximab + Atezolizumab|Participants with hepatocellular carcinoma (HCC) received atezolizumab 1200 milligrams, every 3 weeks (Q3W), intravenous (IV) infusion along with isatuximab 10 milligrams per kilogram (mg/kg), IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable adverse events (AE), participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 106 weeks).
62481173|NCT03637764|EXPERIMENTAL|Cohort B: SCCHN: Isatuximab + Atezolizumab|Participants with squamous cell carcinoma of the head and neck (SCCHN) received atezolizumab 1200 milligrams,Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 108 weeks).
62130373|NCT01510977|EXPERIMENTAL|PEG + bisacodyl|One week after initial colonoscopy failure, conventional amount (5L) of polyethylene glycol together with bisacodyl administration
62130374|NCT01759264||Moderate-to-severe Crohn's disease|Adalimumab induction therapy participants with moderate-to-severe Crohn's Disease
62130375|NCT03640949|EXPERIMENTAL|Vasopressin and methylprednisolone|The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
62130376|NCT03640949|PLACEBO_COMPARATOR|Placebo|"The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl."
62130377|NCT02294617|ACTIVE_COMPARATOR|Nicotrol Inhaler|Subjects will use the Nicotine Inhaler for 3 days.
62130378|NCT02294617|ACTIVE_COMPARATOR|Electronic Cigarette|Subject will use the electronic cigarette for 3 days.
62689853|NCT05134883|EXPERIMENTAL|Propioceptive neuromuscular facilitation (PNF)|This group will undergo a PNF stretching on the hamstring muscles.
62689854|NCT05134883|ACTIVE_COMPARATOR|self myo-fascial release (SMR)|This group will undergo a SMR stretching on the hamstring muscles.
62689855|NCT00027300|EXPERIMENTAL|Group 1|Natalizumab 300 mg, IV
62130379|NCT06445257|EXPERIMENTAL|The ZRMT regimen is used to treat PCNSL|"zanubrutinib 160 mg BID orally rituximab: 375 mg/m2 intravenously on day 7, methotrexate: 3-3.5 g/m2 intravenously on day 1, and temozolomide 100 mg on days 1-5.~Treatment will be given for 6-8 cycles, and patients who achieve a partial response (PR) or better can choose to undergo ASCT if they meet the transplantation criteria. After transplantation or for patients who do not undergo transplantation, zanubrutinib monotherapy maintenance treatment will be administered at a dose of 160 mg BID orally for 2 years or until disease progression, death, or intolerable adverse reactions."
62130380|NCT04252586|EXPERIMENTAL|GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).
62130381|NCT00631436||1|If the individuals who meet the blast exposure criteria have a PCL score above 50 and meet the Hoge et al PCL criteria, thus indicating likely PTSD, they will be invited to participate as members of the Blast Exposed + PTSD group.
62130382|NCT00631436||2|Other individuals meeting the blast exposure criteria will be invited to participate in the as members of the Blast Exposed + No PTSD group if they have PCL scores below 30.
62689856|NCT00027300|PLACEBO_COMPARATOR|Group 2|Placebo IV infusion
62689857|NCT06549062||obese patients WHO class > 2|patients with a BMI \> 35 undergoing laparoscopic surgery. venous and capillary blood samples are collected to determine the concentrations of acetaminophen and its metabolites after intravenous administration of a first dose of 2g acetaminophen and after a fifth dose of 1g acetaminophen in steady state conditions.
62689858|NCT06549062||non obese and overweight patients|patients with a BMI between 18,5 - 30 undergoing laparoscopic surgery. Venous and capillary blood samples are collected to determine the concentrations of acetaminophen and its metabolites after intravenous administration of a first dose of 2g acetaminophen and after a fifth dose of 1g acetaminophen in steady state conditions.
62689859|NCT06638801|EXPERIMENTAL|Reach Out and Read plus intervention|Reach Out and Read Training in addition to coach-led caregiver-implemented early literacy and developmental program
62481174|NCT03637764|EXPERIMENTAL|Cohort C: EOC: Isatuximab + Atezolizumab|Participants with epithelial ovarian cancer (EOC) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 61 weeks).
62481175|NCT03637764|EXPERIMENTAL|Cohort D-1: GBM: Isatuximab + Atezolizumab|Participants with glioblastoma multiforme (GBM) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 54 weeks).
62481176|NCT03986697|ACTIVE_COMPARATOR|Bictarvy|Intervention group: those randomised to switch antiretroviral therapy to Bictegravir, Emtricitabine and Tenofovir Alafenamide fixed dose combination.
62481177|NCT03986697|NO_INTERVENTION|Usual therapy|Control group: those randomised to continue their usual antiretroviral regime
62481178|NCT06242145|ACTIVE_COMPARATOR|clopidogrel arm|The clopidogrel arm will receive (300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day)
62481179|NCT06242145|ACTIVE_COMPARATOR|cilostazol arm|The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day)
62481180|NCT05635812||Participants Autism Spectrum Disorders (ASD)|ASD according to DSM-5 criteria
62481181|NCT05635812||Participants 22q11.2|Participants with a genetic syndrome diagnosed by FISH or CGH-array
62481182|NCT05635812||Neurotypical participants|Neurotypical development
62689860|NCT06638801|ACTIVE_COMPARATOR|Reach out and Read only|Reach Out and Read at well child visits
62321148|NCT05183581|OTHER|Visually aroused erection (naked, clothing, blankets)|"Randomisation of the order of visually aroused erection will be conducted:~1. Naked - Naked \& Blanket - Clothing \& Blanket~2. Naked - Clothing \& Blanket - Naked \& Blanket~3. Naked \& Blanket - Naked - Clothing \& Blanket~4. Naked \& Blanket - Clothing \& Blanket - Naked~5. Clothing \& Blanket - Naked - Naked \& Blanket~6. Clothing \& Blanket - Naked \& Blanket - Naked"
62321149|NCT06332144|EXPERIMENTAL|Enrolled participants|Structural vs. Random sequences of stimuli; Intact vs. Degraded speech; Repeating 5-syllable nonwords or 2-syllable nonwords; Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data
61926497|NCT05441579|PLACEBO_COMPARATOR|Phase 2 - Manage My Pain Biological|A similar to BE-based recruitment video using a standard biological approach on teenagers' decision to enroll in a clinical study will be used as comparison. Phase 2 will focus on patients that would be enrolled into the control arm of a clinical trial with a control intervention, Manage My Pain application.
62130383|NCT00631436||3|Individuals reporting that they were not exposed to explosive blast will be recruited to participate. Those not exposed to blast but with PCL scores over 50 and meeting the Hoge et al PCL criteria will be invited to participate as members of the No Blast + PTSD group.
62130384|NCT00631436||4|Individuals not exposed to blast with PCL scores below 30 will be invited to participate as members of the No Blast + No PTSD group.
62130385|NCT06010862|EXPERIMENTAL|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg
62130386|NCT06010862|EXPERIMENTAL|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg
62130387|NCT01373385||Surgical|Patients receiving a surgical procedure for vesicoureteral reflux at Connecticut Children's Medical Center.
62130388|NCT01828554|EXPERIMENTAL|Xeloda (Capecitabine)|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
62130389|NCT00915564|EXPERIMENTAL|TMC435 + methadone|Supervised intake of individualized methadone dose (range, 30 to 150 mg once daily) from Day -14 to Day -1; followed by addition of 150 mg dose of TMC435 once daily from Day 1 to Day 7 along with methadone; and later followed by continued intake of individualized methadone 30 to 32 days follow-up.
62130390|NCT03991286|PLACEBO_COMPARATOR|Placebo|"Drug: Placebo~Ovulatory Agent:~Clomiphene Citrate"
62130391|NCT03991286|EXPERIMENTAL|experimental|"Drug: Astaxanthin 8mg~Drug: Ovulatory Agent Clomiphene Citrate"
62130392|NCT03197116|ACTIVE_COMPARATOR|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
62130393|NCT03197116|PLACEBO_COMPARATOR|No reminder|No additional reminder will be offered
62130394|NCT00767559|ACTIVE_COMPARATOR|1|"Variable dose warfarin: 5 mg beginning the night before surgery, followed by 5mg the PM of surgery\*, and then variable daily dose,until day 30 follow-up.~(target INR 2.0-2.5)"
62130395|NCT00767559|ACTIVE_COMPARATOR|2|"Fondaparinux:~2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*,or 6-8 hours after epidural catheter removal, and continued until follow-up (28 days +/-2) from day of surgery."
62130396|NCT00767559|ACTIVE_COMPARATOR|3|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily follow-up at Day 28 (+/-2 days from surgery)."
62130397|NCT04038814||VAP1 - historical group|Routine prevention of VAP
62130398|NCT04038814||VAP2 - study group|Modified prevention of VAP
62130399|NCT01842945|NO_INTERVENTION|Wait-list control|
62130400|NCT01842945|EXPERIMENTAL|Treatment with therapist contact|
62130401|NCT01842945|EXPERIMENTAL|Treatment without therapist contact|
62481183|NCT05603741|OTHER|Receiving Local Anesthetic Injection|"Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome~Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome"
62481184|NCT05447312|EXPERIMENTAL|Adaptive Music Intervention (AM)|The intervention will be an adaptive music program, in which participants will listen to music provided by the research team that has been enhanced with frequencies that elicit positive moods using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
62130402|NCT06233435|OTHER|PADSS at 6 hours|
62321150|NCT02253667|EXPERIMENTAL|HFONC|Patient will use HFONC with FiO2 enough to achieve SpO2\>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
62321151|NCT02253667|OTHER|Conventional oxygen|Patient will use venturi or reservoir mask with FiO2 enough to achieve SpO2\>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
62321152|NCT00382096|EXPERIMENTAL|Vildagliptin + Metformin Dose 1|
62130403|NCT06233435|OTHER|PADSS at 24 hours|
62321153|NCT00382096|EXPERIMENTAL|Vildagliptin + Metformin Dose 2|
62321154|NCT00382096|ACTIVE_COMPARATOR|Vildagliptin|
62130404|NCT04770831||Single Arm|QOL following MIBG
62130405|NCT03432858|ACTIVE_COMPARATOR|Vancomycin|
62130406|NCT03432858|ACTIVE_COMPARATOR|Cefazolin|
62130407|NCT03432858|PLACEBO_COMPARATOR|Saline|
62130408|NCT05188300|EXPERIMENTAL|Dorsal intercostal artery (DICA) perforator flaps|Retrograde dissection of free style perforator arising from DICA according to region of dorsal spine and identification of paraspinal muscle where perforator vessel was found
62130409|NCT05188300|EXPERIMENTAL|Trapezius musculocutaneous perforator flaps|Retrograde dissection of a free style perforator arising as a trapezius myocutenous perforator where the trapezius muscle is identified and a perforator vessel was isolated.
62130410|NCT05188300|EXPERIMENTAL|Lumbar artery perforators flaps|Retrograde dissection of free style perforator arising from lumbar artery according to region of lumbar spine and identification of lumbar fascia where perforator vessel was found
62689861|NCT06457217||LVO-MIS|Acute minor ischemic stroke induced by large vessel occlusion (LVO-MIS) within 24 hours
62689862|NCT06642012|ACTIVE_COMPARATOR|Arm 1: Cash only|Arm 1 participants received the cash only intervention. Households in this arm received 1 mobile cash transfer per month for 6 months.
62689863|NCT06642012|EXPERIMENTAL|Arm 2: Cash + Social Behavior Change Communication (SBCC)|Arm 2 participants received the cash + social behavior change communication intervention. Household received 1 mobile cash transfer per month for 6 months but mothers also received an SBCC package that included interpersonal communication (1:1 consultations for mothers), bi-monthly group sessions on key health and nutrition topics, and cooking demonstrations.
62689864|NCT06642012|EXPERIMENTAL|Arm 3: Cash + top-up cash|Arm 3 participants received the cash + top-up cash intervention. Households received 1 mobile cash transfer per month for 6 months, receiving the base cash amount plus an additional cash top-up amount.
62689865|NCT05045417||Cases with SLE|"110 patients with SLE will be divided to :~* 40 patients with lupus nephritis~* 40 patients interstitial lung disease~* 30 SLE patients without internal organ affection)"
62689866|NCT05045417||control group|30 sex and age matched healthy individuals as a control group
62689867|NCT01572441||12-14 year olds|No intervention administered. This is a longitudinal observational study including observation of behaviors and physiological responses.
62689868|NCT02134808|ACTIVE_COMPARATOR|Creatine|Subjects randomized to this study arm will receive 10 grams of creatine daily for 8 weeks.
62689869|NCT02134808|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this study arm will receive 10 grams of placebo daily for 8 weeks.
62689870|NCT02944045|PLACEBO_COMPARATOR|Placebo|Saline serum, same volume as in the Experimental arm.
62689871|NCT02944045|EXPERIMENTAL|Steroids|"Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day"
61926498|NCT05508867|EXPERIMENTAL|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
62689872|NCT04968834||GENOMIC PROFILING AND SPECIMEN BANKING REGISTRATION ARM|The research study procedures include screening for eligibility, reviewing and signing this consent form, collecting patient information and clinical data, obtaining previously collected bone marrow and blood samples, and completing a brief optional Household Survey. Bone marrow and blood samples may also be collected in the future as part of your routine clinical procedures
62689873|NCT00077285|EXPERIMENTAL|pts with intermediate- and high-risk rhabdomyosarcoma|
62321155|NCT00382096|ACTIVE_COMPARATOR|Metformin|
62321156|NCT01460641||CT perfusion|
62321157|NCT00611455|EXPERIMENTAL|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
62321158|NCT00611455|PLACEBO_COMPARATOR|1000 ml Saline|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
62321159|NCT04592380|EXPERIMENTAL|Stage 1: Clevidipine (double-blinded)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Clevidipine will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter per the Food and Drug Administration (FDA) approved clevidipine label, to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
62321160|NCT04592380|PLACEBO_COMPARATOR|Stage 1: Placebo (double-blinded)|Placebo will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Placebo will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter according to the same dosing instructions as for clevidipine to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
62689874|NCT01417988|EXPERIMENTAL|Empiric TB treatment|Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
61926499|NCT05508867|ACTIVE_COMPARATOR|Chemotherapy (Bendamustine or Gemcitabine)|Participants will receive physician's choice of EITHER bendamustine by IV infusion at a dose between 90 and 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose between 800 and 1200 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
62130411|NCT00890305|EXPERIMENTAL|CT-011 in combination with FOLFOX|"CT-011 (3 mg/kg) administered intravenously every 4 weeks for 4 weeks and every 12 weeks thereafter until disease progression or maximum tolerance.~FOLFOX (FOLFOX4 or mFOLFOX6) administered 7 days after the first administration of CT-011 and repeated every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation."
62321161|NCT04592380|EXPERIMENTAL|Stage 2: Clevidipine (open-label)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in an open-label fashion intravenously to all patients randomized to the clevidipine arm in Stage 2, following the same dosing instructions as in the clevidipine arm in Stage 1. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
62321162|NCT04592380|ACTIVE_COMPARATOR|Stage 2: Standard of Care (open-label)|For patients randomized to SOC, the infusion must be continuous, administered per the institution's treatment practice, and dose titration must be performed to a maximum allowed or maximum tolerated dose to achieve target SBP. If treatment with an alternative IV anti-hypertensive agent is required, the patient will be transitioned to an alternative IV antihypertensive agent according to the institutional standard of care.
62321163|NCT05329688|EXPERIMENTAL|Arm A|"Novel nutrition program :~Give nutrition health education every week and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease."
62321164|NCT05329688|ACTIVE_COMPARATOR|Arm B|Routine nutrition education Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
62321165|NCT03070977|EXPERIMENTAL|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.
62321166|NCT03070977|NO_INTERVENTION|Standard unit|Students in the control group receive training in standard psychiatric wards.
62321167|NCT05772715|ACTIVE_COMPARATOR|Orthosis group|
62321168|NCT05772715|EXPERIMENTAL|Orthosis + exercise group|
62321169|NCT00918528|ACTIVE_COMPARATOR|1. Internal urethrotomy|
62321170|NCT00918528|EXPERIMENTAL|2. Internal urethrotomy + mitomycin C|
62689875|NCT01417988|ACTIVE_COMPARATOR|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
62321171|NCT06639347|EXPERIMENTAL|SHR-A2102 + Adebrelimab injection+SHR-8068 injection|
62321172|NCT06024577|ACTIVE_COMPARATOR|Walking|Participants prescribed 150 minutes/week of moderate to vigorous walking.
62321173|NCT06024577|EXPERIMENTAL|Variety|Participants prescribed 150 minutes/week of moderate to vigorous variety of exercise. Each week participants will be prescribed a single different exercise (variety) which will include cycling, walking/jogging, yoga/Pilates, and cross-training.
62321174|NCT06024577|EXPERIMENTAL|Progressive|Participants prescribed 150 minutes/week of moderate to vigorous exercise. The exercises include cycling, walking/jogging, yoga/Pilates, and cross-training, and each week another exercise will be added to the list of options for participants. Participants may choose from the list of exercise. They do not have to do them all, and they can do as much or little (none) of whatever they choose.
62321175|NCT05845047|EXPERIMENTAL|PICTURE IT Intervention-CoDeLT Intervention|Participants will receive PICTURE IT Intervention for 15 sessions followed by Computer Delivered Lexical Treatment (CoDeLT)Intervention for 15 sessions
62697481|NCT06132789|EXPERIMENTAL|Essen Experimental Group (10-17 years old)|The subjects received 1 dose of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried each at day 0, 3, 7, 14 and 28, with a total of 5 doses
62321176|NCT05845047|ACTIVE_COMPARATOR|CoDeLT Intervention-PICTURE IT Intervention|Participants will receive Computer Delivered Lexical Treatment (CoDeLT) Intervention for 15 sessions followed by PICTURE IT Intervention for 15 sessions
62321177|NCT02769572|EXPERIMENTAL|real moxibustion plus placebo gel|In subjects with osteoarthritis of the knee
62321178|NCT02769572|ACTIVE_COMPARATOR|diclofenac sodium gel plus sham moxibustion|In subjects with osteoarthritis of the knee
62321179|NCT00916799|EXPERIMENTAL|Oximeter arm and non-oximetry arm|
62321180|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
62321181|NCT00863785|EXPERIMENTAL|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
62321182|NCT06111846|EXPERIMENTAL|Experimental: hBMMSC|1.0×10\^6/kg hBMMSC (participant's body weight) single dose 2.0×10\^6/kg hBMMSC (participant's body weight) single dose 2.0×10\^6/kg hBMMSC (participant's body weight) administered twice
62321183|NCT02775864||Antipsychotic|Individuals initiating treatment with an antipsychotic medication
62321184|NCT02775864||Antidepressant|Individuals initiating treatment with an antidepressant medication
62321185|NCT02775864||Benzodiazepine|Individuals initiating treatment with a benzodiazepine
62321186|NCT02775864||Mood stabilizer|Individuals initiating treatment with a mood stabilizer
62321187|NCT05590234|ACTIVE_COMPARATOR|Dexmedetomidine combined with bupivacaine group (DB group)|patients received 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%,
62481185|NCT05447312|ACTIVE_COMPARATOR|Traditional Music Intervention (TM)|The intervention will be traditional music therapy, in which participants will listen to music provided by the research team that has not been enhanced with frequencies using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
62481186|NCT05447312|NO_INTERVENTION|Control Group|The control intervention will be an audiobook provided by the research team that participants will listen to using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
62481187|NCT04031209||G7 G7 Acetabular System|All patients will receive G7 G7 Acetabular System
62321188|NCT05590234|ACTIVE_COMPARATOR|bupivacaine 0.25%,|patients received 20 ml of bupivacaine 0.25%
62321189|NCT05590234|PLACEBO_COMPARATOR|control group (S group)|patients received 20 ml of normal saline 0.9%.
62321190|NCT03183245|EXPERIMENTAL|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
62321191|NCT03183245|ACTIVE_COMPARATOR|Arteriovenous fistula (AVF)|The comparator is an autologous arteriovenous fistula created in the forearm or upper arm on Study Day 0.
62321192|NCT04005092|ACTIVE_COMPARATOR|Helmet Continuous Positive Airway Pressure(hCPAP)|Helmet CPAP produce a better physiological outcomes after 1-hour intervention
62321193|NCT04005092|ACTIVE_COMPARATOR|High Flow Nasal Cannula(HFNC)|HFNC produce a better physiological outcomes after 1-hour intervention
62321194|NCT04701099||On ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl during ECMO support.
62321195|NCT04701099||Off ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl after weaning off ECMO.
62321196|NCT05367687|EXPERIMENTAL|Treatment group|Camrelizumab Plus Rivoceranib (Apatinib)
62321197|NCT05367687|ACTIVE_COMPARATOR|Control group|Camrelizumab
62321198|NCT01278680|NO_INTERVENTION|Hold-out control|Hold-out control: participants will be asked to refrain from using the walkstations for the duration of the study (90 days).
62321199|NCT01278680|ACTIVE_COMPARATOR|Personal incentive|Personal incentive: Participants will receive $3 for each time they use the walkstation.
62481188|NCT02891863|EXPERIMENTAL|Acute Testing|Single-arm study - all subjects who meet the I\&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
61926500|NCT06039267||Healthy Controls|Healthy males and females, ages 50-90
62321200|NCT01278680|EXPERIMENTAL|Charitable incentive|Charitable incentive: $3 will be donated to charity every time the participant uses the walkstation.
62689876|NCT04804436|EXPERIMENTAL|Patients with nephrolithiasis|The real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
61926501|NCT06039267||Mild Cognitive Impairment|Males and females with mild cognitive impairment, ages 50-90
61926502|NCT06039267||Early Alzheimer's Disease|Males and females with early Alzheimer's disease, ages 50-90
61926503|NCT05497635|EXPERIMENTAL|A low dose of group|All subjects will be randomized to receive low dose of STSA-1002 or dose-matched placebo.
61926504|NCT05497635|EXPERIMENTAL|A middle dose of group|All subjects will be randomized to receive middle dose of STSA-1002 or dose-matched placebo.
61926505|NCT05497635|EXPERIMENTAL|A high dose of group|All subjects will be randomized to receive high dose of STSA-1002 or dose-matched placebo.
62321201|NCT05126823|EXPERIMENTAL|ACT face-to-face + app|Combines face-to-face ACT sessions with non-face-to-face activities and resources (mobile applications)
61926506|NCT04771897|EXPERIMENTAL|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with newly diagnosed DIPG or DMG will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level is reached and radiation therapy.
62481189|NCT05431699|OTHER|Screening population|Women eligible for HPV screening will receive both ScreenFire (experimental) and careHPV (active comparator) based on El Salvador's national guidelines.
62481190|NCT04521764|EXPERIMENTAL|Cohort 1 (single treatment MV-s-NAP)|Patients receive MV-s-NAP IT on day 1 in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, tumor biopsy and blood sample collection throughout the study.
62689877|NCT04804436|EXPERIMENTAL|Healthy control group|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
62689878|NCT05437055|EXPERIMENTAL|Single Arm|Use of Penumbra System including Thunderbolt in patients with acute ischemic stroke secondary to intracranial large vessel occlusion who are eligible for mechanical thrombectomy
62689879|NCT03823482|EXPERIMENTAL|Lidocaine group|Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.
62689880|NCT03823482|NO_INTERVENTION|Control group|Participants in control group will have general anesthesia without lidocaine administration.
62689881|NCT06001697|EXPERIMENTAL|Intervention|The treatment group will receive information regarding wellness factors by the doctor (health advice) and they will be asked to follow those recommendations for the duration of the study. In addition they will also receive a park prescription specifying a target amount of time to spend in nature, along with frequency of visits and recommended locations (e.g., specific parks), and information about parks and programming in the study area.
62689882|NCT06001697|OTHER|Control|The control group will receive regular health advice and information regarding wellness factors by the doctor and they will be asked to follow those recommendations for the duration of the study.
62689883|NCT03453515|EXPERIMENTAL|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
62689884|NCT03453515|OTHER|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
62689885|NCT06639607|EXPERIMENTAL|Phase I Stratum I: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster|"Patients with newly-diagnosed high-grade glioma or DMG may be enrolled any time within 42 days after completing radiation.~Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression.~Patients will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21.~Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter."
62689886|NCT06639607|EXPERIMENTAL|Phase I Stratum II: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster|"Patients with recurrent/progressive HGG or DMG with measurable disease can be enrolled at any point following recurrence regardless of any prior therapy.~Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression.~Patients will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21.~Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter."
62689887|NCT06639607|EXPERIMENTAL|Phase I Stratum III: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster|"Patients with recurrent/progressive MB or EPN with measurable disease can be enrolled at any point following recurrence regardless of any prior therapy.~Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression.~Patients will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21.~Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter."
62697482|NCT06132789|EXPERIMENTAL|Zagreb Experimental Group (18-60 years old)|The subjects received 2 doses of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried on day 0, 1 dose on day 7 and 1 dose on day 21, a total of 4 doses.
61926507|NCT04771897|EXPERIMENTAL|Part 2 BXQ-350 Tumor and Plasma Concentrations|Newly diagnosed DIPG or DMG patients undergoing neurosurgical biopsy prior to receiving radiation therapy will receive BXQ-350 at the MTD established in Part 1, or the highest planned dose level, and radiation therapy. Excised tumor tissue and plasma samples will be evaluated for SapC levels and pharmacodynamic effects.
62481191|NCT04521764|EXPERIMENTAL|Cohort 2 (multiple cycles MV-s-NAP)|Patients receive MV-s-NAP IT on day 1 of each cycle. Cycles repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, tumor biopsy and blood sample collection throughout the study.
62481192|NCT06741371|EXPERIMENTAL|Monocryl arm|
62481193|NCT06741371|NO_INTERVENTION|Vicryl arm|
62321202|NCT05126823|ACTIVE_COMPARATOR|ACT face-to-face|face-to-face ACT sessions
62321203|NCT05126823|NO_INTERVENTION|Waitlist|Waitlist group. After the second assessment of the two ACT groups (at post-treatment) this group will receive the face to face ACT intervention.
62481194|NCT06567314|EXPERIMENTAL|Ivonescimab|Participants found to be eligible to take part in this study, you will receive ivonescimab by vein over about 1-2 hours on Day 1 of each 21-day cycle (1 time every 3 weeks).
62481195|NCT03315806|ACTIVE_COMPARATOR|Beetroot Juice|Beetroot juice containing 9 mmol of nitrate per dose
62481196|NCT03315806|PLACEBO_COMPARATOR|Placebo juice (nitrate depleted)|Beetroot juice nitrate-depleted
62689888|NCT06639607|EXPERIMENTAL|Phase II: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster|"Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression.~Patients will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21.~Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter."
62689889|NCT04629521|EXPERIMENTAL|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
62689890|NCT03554330|ACTIVE_COMPARATOR|control group|Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.
62689891|NCT03554330|EXPERIMENTAL|single-RFA group|After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.
62689892|NCT03554330|EXPERIMENTAL|double-RFA group|The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).
62321204|NCT04255186|EXPERIMENTAL|Thermal CRMRF|"9 sessions in 3 week of Thermal CRMRF: The power of the RFCR equipment in this intervention will be 35 VA in capacitive method (10% of the maximum power of the equipment) and 30 W in the resistive method (15% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessiones a week).~In Thermal CRMRF it will be necessary to adapt to the patient's thermal sensitivity"
61926508|NCT05870579|EXPERIMENTAL|Arm 1|Participants will receive \[177Lu\]Lu- NeoB in combination with ribociclib and fulvestrant, in the dose escalation and the backfill parts of the study. Goserelin administration is only applicable for pre/peri-menopausal women and men.
62321205|NCT04255186|EXPERIMENTAL|Subthermal CRMRF|9 sessions in 3 week of Subthermal CRMRF: The power of the RFCR equipment in this intervention will be 7 VA in capacitive method (2% of the maximum power of the equipment) and 4 W in the resistive method (2% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessions a week).
62481197|NCT04023981|NO_INTERVENTION|Standard care alone|Patients randomly allocated to standard care will be cared for on the appropriate mattress indicated for use in that participating centre according to local policy e.g. foam mattress or dynamic air mattress. Standard care may also include a mattress overlay or the use of a wedge or pillows to maintain the position of the participant, or pressure offloading boots on the foot if the need arises during the study period.
62481198|NCT04023981|EXPERIMENTAL|Parafricta bootees plus standard care|Patients randomly allocated to Parafricta plus standard care will be cared for on the appropriate mattress as above and care may possibly include a mattress overlay or the use of a wedge or pillows. Participants will in addition be issued with Parafricta bootees (one pair and up to two spare pairs). The patient and clinical staff and the patient's carers will be instructed in the use of Parafricta bootees, which are intended to be worn throughout the day and night and removed only for normal daily washing or examination of the patient's feet. Either the slip-on bootees or the Velco-closure bootees will be selected for the participant at the judgment of the clinical ward nurses.
62481199|NCT06742190|EXPERIMENTAL|Part A - empasiprubart + IVIg-placebo|During the double blinded - double dummy part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm
62481200|NCT06742190|ACTIVE_COMPARATOR|Part A - IVIg + empasiprubart-placebo|During the double blinded - double dummy part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm
62481201|NCT06742190|EXPERIMENTAL|Part B - empasiprubart|After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg)
62689893|NCT01432431|EXPERIMENTAL|Supportive care (spiritual care)|See Detailed Description.
62689894|NCT06640413|EXPERIMENTAL|Part I - Dose Escalation - Cohort 1, Arm 1|In Arm 1, patients assigned to this cohort 1, receive monotherapy of \[177Lu\]Lu-OncoFAP-23 (3.7 GBq)
62689895|NCT06640413|EXPERIMENTAL|Part I - Dose Escalation - Cohort 2, Arm 1|In Arm 1, patients assigned to this cohort 2, receive monotherapy of \[177Lu\]Lu-OncoFAP-23 (7.4 GBq)
62689896|NCT06640413|EXPERIMENTAL|Part I - Dose Escalation - Cohort 3, Arm 1|In Arm 1, patients assigned to this cohort 3, receive monotherapy of \[177Lu\]Lu-OncoFAP-23 (11.1 GBq)
62130412|NCT00890305|ACTIVE_COMPARATOR|FOLFOX|FOLFOX (FOLFOX-4 or mFOLFOX6) administered every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.
62130413|NCT06083155||Normal CFT results: no coronary vasomotor dysfunction|Collection of data on anginal complaints, use of medication and major adverse cardiac events (MACE) by means of online patient questionnaires
62130414|NCT06083155||Abnormal CFT results: coronary vasomotor dysfunction|Comparison of patient reported outcomes of different endotype groups Collection of data on anginal complaints, use of medication and MACE by means of online patient questionnaires
62130415|NCT00370383|EXPERIMENTAL|Satraplatin|Satraplatin administered orally once daily for 5 consecutive days followed by erlotinib for 14 consecutive days
62130416|NCT00370383|EXPERIMENTAL|Erlotinib|Erlotinib administered orally once daily. Erlotinib - \[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-y\]- (3-ethynyl-phenyl)amine hydrochloride, molecular weight 393.4. This is a small molecule that competes with the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and blocking downstream signal transduction.
62130417|NCT03338816|EXPERIMENTAL|Givosiran/Givosiran|Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
62130418|NCT03338816|PLACEBO_COMPARATOR|Placebo/Givosiran|Matching placebo (normal saline \[0.9% NaCl\]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.
62130419|NCT03990649|PLACEBO_COMPARATOR|Double-Blind Treatment Period - Part A: Placebo|Soticlestat matching placebo tablets, orally, twice daily (BID) for Weeks 1, 2 and 3 in Double blind Titration Period. Soticlestat matching placebo tablets, orally BID for 12 weeks in Double blind Maintenance Period. Taper period (if participant did not continue to Part B): Dose of soticlestat matching placebo tablets was reduced to next lower dose every 3 days (maximum 6 days) until discontinuation.
62339764|NCT02551198|ACTIVE_COMPARATOR|HAPREP® (PEG-Asc)|"subjects randomized to 2L polyethylene glycol with ascorbic acid (PEG-Asc) were instructed to use PEG-Asc for bowel preparation~: PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]"
62689897|NCT06640413|EXPERIMENTAL|Part I - Dose Escalation - Cohort 4, Arm 2|In Arm 2, patients assigned to this cohort 4, receive combination of \[177Lu\]Lu-OncoFAP-23 at at the dose level below the Maximum Tolerated Dose (MTD) with L19IL2 (22.5 Mio IU).
62339765|NCT02551198|EXPERIMENTAL|SUCLEAR® (OSS)|"subjects randomized to oral sulfate solution were instructed to use oral sulfate solution (OSS) for bowel preparation~: OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]"
62339766|NCT04004559||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|Cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the training cohort.
62689898|NCT06640413|EXPERIMENTAL|Part I - Dose Escalation - Cohort 5, Arm 2|In Arm 2, patients assigned to this cohort 4, receive combination of \[177Lu\]Lu-OncoFAP-23 at MTD with L19IL2 (22.5 Mio IU).
62689899|NCT06640413|EXPERIMENTAL|Part II - Dose Expansion - Arm 1|10 patients receive the monotherapy of \[177Lu\]Lu-OncoFAP-23 at the recommended dose
62689900|NCT06640413|EXPERIMENTAL|Part II - Dose Expansion - Arm 2|10 patients receive the combination of \[177Lu\]Lu-OncoFAP-23 and L19IL2 at the recommended doses
62697483|NCT06132789|EXPERIMENTAL|Zagreb Experimental Group (10-17 years old)|The subjects received 2 doses of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried on day 0, 1 dose on day 7 and 1 dose on day 21, a total of 4 doses.
62697484|NCT04083378|ACTIVE_COMPARATOR|Arm I (standard of care ablation)|Patients undergo standard of care ablation.
62697485|NCT04083378|EXPERIMENTAL|Arm II (standard of care ablation, software-aided imaging)|Patients undergo standard of care ablation with software-aided imaging (Morfeus).
62130420|NCT03990649|EXPERIMENTAL|Double-Blind Treatment Period - Part A: Soticlestat|Soticlestat, tablet, orally, 100 mg BID for Week 1, followed by 2×100 mg tablets, soticlestat, orally BID for Week 2, further followed by 3×100 mg tablets, soticlestat, orally BID for Week 3. Dose was uptitrated every week based on safety and tolerability. Part A (Double blind Maintenance Period): 3×100 mg tablets, soticlestat, orally BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period (if participant did not continue to Part B): Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
62130421|NCT03990649|EXPERIMENTAL|Open-Label Extension Period - Part B: Soticlestat|Soticlestat, 2×100 mg tablets, orally, BID for Week 1, followed by 3×100 mg tablets, soticlestat, orally, BID for Week 2. Dose was uptitrated every week based on safety and tolerability. Part B (Open label extension: Maintenance Period): 3×100 mg tablets, soticlestat, orally, BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period: Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
62481202|NCT02756663|EXPERIMENTAL|Arm A: PAN (10mg) + CFZ + Dex|Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
62481203|NCT02756663|EXPERIMENTAL|Arm B: PAN (20mg) + CFZ + Dex|Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
62481204|NCT02756663|ACTIVE_COMPARATOR|Arm C: CFZ + Dex|Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
62130422|NCT02850744|OTHER|Single-arm|Open label, single arm including patients with progressive glioblastoma during or after temozolomide chemotherapy obtaining PQR309 80mg capsules.
62321206|NCT04255186|SHAM_COMPARATOR|Sham CRMRF|9 sessions in 3 week of sham stimulation: The application will be carried out in the same way as in the experimental groups, but in this case the manufacturer will introduce a simulated stimulation protocol so that the device does not emit current + 15 sessions in 3 week of exercise protocol (5 sessiones a week).
62321207|NCT06177834|ACTIVE_COMPARATOR|Classical dorsal slit circumcision technique|In this group, the patients who will operated with dorsal sleeve slit circumcision technique.
62321208|NCT06177834|EXPERIMENTAL|Alisklamp|In this group, the patients who will operated with Alisklamp technique.
62321209|NCT02136823|PLACEBO_COMPARATOR|sugar pill|sugar pill, oral administration, placebo capsule
62321210|NCT02136823|EXPERIMENTAL|riluzole|50mg tablet, single oral dose, one day (single dose)
62321211|NCT02136823|EXPERIMENTAL|isradipine|5mg capsule, single oral dose, one day (single dose)
62321212|NCT02136823|EXPERIMENTAL|memantine|5mg tablet, single oral dose, one day (single oral dose)
62321213|NCT02136823|EXPERIMENTAL|therapeutic stretching|Manual therapeutic stretching of tested muscle by licensed clinician
62321214|NCT00909376||1 - transabdominal sonography|Women who will have a transabdominal sonography done in the early second trimester.
62321215|NCT00909376||2 - transvaginal sonography|Women who will have a transvaginal sonography done in the early second trimester.
62321216|NCT02703792||Care home staff|Care home staff working in the homes in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
62321217|NCT02703792||NHS staff|GPs supporting residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
62321218|NCT02703792||Service user representatives|Service or carers of an older person with dementia attending and Age UK carers group
62321219|NCT02703792||Relatives of residents|Relatives of residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
62321220|NCT02137772|EXPERIMENTAL|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
62321221|NCT02137772|PLACEBO_COMPARATOR|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
62321222|NCT04747808|EXPERIMENTAL|LL-BMT1|Group 4 extended-wear contact lens printed with bimatoprost
62321223|NCT01957267||Glaucoma Group|Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
62321224|NCT01957267||Normal Group|Volunteers with healthy eyes
62321225|NCT01506414|EXPERIMENTAL|combination treatment|
62339767|NCT04004559||Sun Yat-sen University Cancer Center|Cohort of Sun Yat-sen University Cancer Center is validation cohort 1.
62339768|NCT04004559||Tungwah Hospital of Sun Yat-Sen University|Cohort of Tungwah Hospital of Sun Yat-Sen University is validation cohort 2.
62481205|NCT03663933|EXPERIMENTAL|1/RIC Arm|Reduced Intensity Conditioning Arm
62481206|NCT03663933|EXPERIMENTAL|2/IOC Arm|Immunosuppression Only Conditioning Arm
62481207|NCT03663933|NO_INTERVENTION|3/donor arm|Healthy Donor- Donors for recipients in arm 1 or arm 2
62321226|NCT03416582|EXPERIMENTAL|SMENC Group|"The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen.~During the telephone call, the patient will report the use of the Drinks Diary."
62321227|NCT06693219|EXPERIMENTAL|Study population|
62321228|NCT03251014|EXPERIMENTAL|YSS/salmon group|YSS followed by salmon
62481208|NCT05558501|EXPERIMENTAL|Mild Intermittent Hypoxia (MIH)|This arm of the protocol will receive mild intermittent hypoxia (8% oxygen) with end-tidal carbon dioxide maintained 2 millimeters of mercury above baseline, while in the laboratory.
62689901|NCT06541587|EXPERIMENTAL|mindfulness-based virtual reality|In addition to routine chemotherapy care, the intervention involves the use of a smart breast cancer chemotherapy mindfulness-based integrated virtual reality and multimodal physiological feedback training system module. This will be administered during each of the first to fifth inpatient chemotherapy sessions. The equipment operator, a researcher, will use the AI-Pico Neo 3 Pro headset, featuring a dual-eye resolution of 2880\*1600 pixels, a refresh rate of 90Hz, and a 110-degree field of view. The interpupillary distance, headset strap tightness, and volume will be adjusted according to the participant's comfort. The scenario content includes three shared scenes: beach, forest, and starry sky, from which participants can choose based on their preference. Each session will last 12 minutes and be conducted once. Participants will assume a semi-reclining position during the session. Monitoring will be conducted with the researcher assisting the participant on-site.
62481209|NCT05558501|SHAM_COMPARATOR|Sham Mild Intermittent Hypoxia (Sham MIH)|This arm of the protocol will receive sham MIH (the equivalent of room air), while in the laboratory.
62481210|NCT06514261|EXPERIMENTAL|Treatment (iadademstat, venetoclax, azacitidine)|"INDUCTION: Patients receive iadademstat PO QD on days 1-5, 8-12, and may also receive it on days 15-19, venetoclax PO QD on days 1-14 or 1-21 and azacitidine IV over 10-40 minutes or SC on days 1-7 or 1-5 and 8-9 of each cycle. Cycles repeat every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo buccal swab collection on study.~CONSOLIDATION: Patients receive iadademstat PO QD on days 1-5, 8-12 and may also receive it on days 15-19, venetoclax PO QD on days 1-7 or 1-14 and azacitidine IV over 10-40 minutes or SC on days 1-7 or 1-5 and 8-9 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and may undergo bone marrow aspiration throughout the study."
62481211|NCT03516539|EXPERIMENTAL|Group ML|Mcgrath videolaryngoscopy
62321229|NCT03251014|EXPERIMENTAL|Salmon/YSS group|Salmon followed by YSS
62481212|NCT03516539|ACTIVE_COMPARATOR|Group DL|direct Macintosh laryngoscope
62481213|NCT02087423|EXPERIMENTAL|MEDI4736|see below
62481214|NCT06055686|EXPERIMENTAL|Electrical Epidural Stimulation Test|Laboring women who request epidural analgesia will be given an electric stimulation at incremental points during catheter pull back with documentation of where stimulation was seen.
62321230|NCT06109623||SUI group|Female patients diagnosed with stress urinary incontinence in our hospital, who met the inclusion and exclusion criteria, and received six sex hormone tests.
62321231|NCT06109623||control group|Patients with non-stress urinary incontinence
62321232|NCT01390701|EXPERIMENTAL|transcutaneous electr. nerve stimulation|
62481215|NCT03835689|EXPERIMENTAL|Strongest Families Program Self-Managed (no coaching)|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
62321233|NCT01390701|ACTIVE_COMPARATOR|felodipin|
62321234|NCT05741385|EXPERIMENTAL|Group 1: Healthy participants|Every participant receives a cocktail of Caffeine, Warfarin sodium, Omeprazole, Metoprolol, Midazolam.
62321235|NCT05741385|EXPERIMENTAL|Group 2: F4 Child-Turcotte-Pugh class A (Child-Pugh A) participants (compensated)|"Every participant receives a cocktail of Caffeine, Warfarin sodium, Omeprazole, Metoprolol, Midazolam.~Compensated=without any disease symptoms"
62339769|NCT05380934|EXPERIMENTAL|TQH3821 Tablets (Single Administration Dose)|TQH3821 tablets, Single administration
62481216|NCT03835689|EXPERIMENTAL|Strongest Families Program with Group Telephone Coaching|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
62481217|NCT03835689|NO_INTERVENTION|Information Resource Website|They will not receive Strongest Families Intervention during the 10 month study phase, but will receive the usual care services and access to an Information Resource Website.
62481218|NCT05817357|EXPERIMENTAL|Installation of air purifier (Rensair Ltd - Rensair Compact)|Rensair Compact air purifier unit will be installed in the homes of all children/young people participating in this study for a period of one-year.
62481219|NCT05668013|EXPERIMENTAL|TEV-48574 Dose Regimen A for Ulcerative Colitis (UC)|Administered by subcutaneous infusion for participants with UC
62481220|NCT05668013|EXPERIMENTAL|TEV-48574 Dose Regimen A for Crohn's Disease (CD)|Administered by subcutaneous infusion for participants with CD
62481221|NCT05668013|EXPERIMENTAL|TEV-48574 Dose Regimen B for Ulcerative Colitis (UC)|Administered by subcutaneous infusion for participants with UC
62481222|NCT05668013|EXPERIMENTAL|TEV-48574 Dose Regimen B for Crohn's Disease (CD)|Administered by subcutaneous infusion for participants with CD
62130423|NCT03492424||Focal therapy for prostate cancer|"All men \>18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion.~The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy."
62130424|NCT00997490|EXPERIMENTAL|Verum|Neurapas balance, film-coated tablet
62130425|NCT00997490|PLACEBO_COMPARATOR|Placebo|
62130426|NCT00586222|PLACEBO_COMPARATOR|2|
62321236|NCT05741385|EXPERIMENTAL|Group 3: F4 Child-Turcotte-Pugh class B (Child-Pugh B) participants (decompensated)|"Every participant receives a cocktail of Caffeine, Warfarin sodium, Omeprazole, Metoprolol, Midazolam.~Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome"
62321237|NCT03803761|EXPERIMENTAL|Treatment (copanlisib, fulvestrant)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and fulvestrant IM over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62321238|NCT02868749|EXPERIMENTAL|Hyaluronic Acid filler 1 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery"
62339770|NCT05380934|PLACEBO_COMPARATOR|TQH3821 Placebo Tablets (Single Administration Dose)|TQH3821 placebo tablets, Single administration
62481223|NCT05457452|EXPERIMENTAL|Knee Brace|Use of a Knee Brace after ACL Reconstruction, the patient is put on a knee brace by an orthopedic doctor or orthopedic resident after ACL reconstruction
62481224|NCT05457452|NO_INTERVENTION|No Knee Brace|
62481225|NCT06742710|EXPERIMENTAL|Intervention Group|Liraglutide 3.0 mg or maximum tolerable dose/day and metformin 1500 mg/day
62481226|NCT06742710|ACTIVE_COMPARATOR|Control Group|Metformin 1500 mg/day
62481227|NCT06437691||Group A - Emergency Surgery Group|Patients underwent emergency surgery directly after coming to emergency department due to left sided obstructive colorectal cancer
62481228|NCT06437691||Group B - Stent Group|Left sided obstructive colorectal cancer patients underwent elective surgery following decompression via self-expandable metallic stent placement.
62130427|NCT00586222|NO_INTERVENTION|Healthy Comparsions|We will compare the BP group with 32 age-, gender-, and handedness-matched healthy adolescents. Subjects who have a first or second degree relative with a psychiatric history will be excluded from the healthy comparison group. Subjects must be safe to undergo MRI scanning as per Mayo MRI safety screening which is explained in detail elsewhere in this protocol. We will exclude the subjects with cardiac pacemakers, metallic clips, other bodily metallic implants and dental braces because of the MRS procedure. Subjects who cannot complete clinical assessments or the MRI scan and subjects who are not fluent in English will be excluded from the study.
62130428|NCT00586222|EXPERIMENTAL|1|
62481229|NCT05059028|ACTIVE_COMPARATOR|Oxytocin massage|
62481230|NCT05059028|ACTIVE_COMPARATOR|music therapy|
62481231|NCT05059028|NO_INTERVENTION|control group|
62481232|NCT06726850|PLACEBO_COMPARATOR|placebo|Participants will receive multiple doses of placebo matching GS1-144 tablet for 12 consecutive weeks.
62481233|NCT06726850|EXPERIMENTAL|GS1-144 tablet|Participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks.
62689902|NCT06541587|ACTIVE_COMPARATOR|mindfulness based audio practice|In addition to routine chemotherapy care, the intervention includes mindfulness-based audio exercises. Participants will use over-ear headphones that play the same content as experimental group A, but without virtual reality. This will be administered during each of the first to fifth inpatient chemotherapy sessions. The equipment operator, a researcher, will use Sony over-ear headphones, adjusting the fit and volume according to the participant's comfort. The audio content includes three background sounds: beach, forest, and starry sky, from which participants can choose based on their preference. Each session will last 12 minutes and be conducted once. Participants will assume a semi-reclining position during the session. Monitoring will be conducted with the researcher assisting the participant on-site.
62689903|NCT06541587|NO_INTERVENTION|control|routine chemotherapy care
62130429|NCT02208596|EXPERIMENTAL|Group A|In group A, propofol (1%) was mixed with etomidate in the ration of 1:1 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
62689904|NCT05547542|EXPERIMENTAL|Part A: Kappa Opioid Receptor (KOR) Cohort|"Participants will receive single dose of CVL-354, 25 mg, orally, on Day 1 along with \[11C\]-LY2795050, intravenous (IV) bolus injection of up to 20 millicurie (mCi) before the baseline and post-dose PET scans.~Based on the KOR receptor occupancy (RO) results from this cohort, dosing may be explored further in subsequent cohorts."
62689905|NCT05547542|EXPERIMENTAL|Part B: Mu Opioid Receptor (MOR) Cohort|"Part B will commence after Part A cohort is completed. Participants will receive single dose of CVL-354 150 mg, orally, on Day 1 along with \[11C\]-carfentanil, IV bolus injection of up to 20 mCi before the baseline and post-dose PET scans.~Based on the MOR RO results from this cohort, dosing may be explored further in subsequent cohorts."
62689906|NCT05454891|EXPERIMENTAL|High Fat High Protein (HFHP) Meal- extended then standard insulin bolus arm|Subjects will receive extended meal bolus for breakfast on the first day and standard meal bolus on the second day of the study.
62689907|NCT05454891|EXPERIMENTAL|High Fat High Protein (HFHP) Meal- standard then extended insulin bolus arm|Subjects will receive standard meal bolus for breakfast on the first day and extended meal bolus on the second day.
62689908|NCT02661347|ACTIVE_COMPARATOR|Active comparator: tDCS & Risperidone|In the active arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2 milliampere (mA) for 20 minutes, twice a day for five consecutive days, for a total of 10 sessions.
62689909|NCT02661347|SHAM_COMPARATOR|Sham comparator: tDCS & Risperidone|In the sham arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2mA for 1 minute, twice a day for five consecutive days, for a total of 10 sessions.
62689910|NCT05968742|EXPERIMENTAL|Healthy Volunteers|"Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days.~The use of a custom made acrylic intraoral stent (mouthguard) will be used to protect teeth on designated test sides for each study participant during normal oral hygiene (approximately 4 minutes each day: 2 times for 2 minutes) throughout the induction phase (Day 0-21)."
62689911|NCT02977871|NO_INTERVENTION|No Bladder Flap group|Routine uterine incision performed during cesarean section without incision and dissection of the bladder peritoneum.
62689912|NCT02977871|ACTIVE_COMPARATOR|Bladder Flap group|Routine uterine incision performed during cesarean section with an incision and a dissection of a bladder flap.
62689913|NCT03260322|EXPERIMENTAL|ASP8374 0.5 mg - Monotherapy Dose Escalation|Participants received ASP8374 0.5 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62689914|NCT03260322|EXPERIMENTAL|ASP8374 2 mg - Monotherapy Dose Escalation|Participants received ASP8374 2 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62689915|NCT03260322|EXPERIMENTAL|ASP8374 7 mg - Monotherapy Dose Escalation|Participants received ASP8374 7 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62689916|NCT03260322|EXPERIMENTAL|ASP8374 20 mg - Monotherapy Dose Escalation|Participants received ASP8374 20 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62689917|NCT03260322|EXPERIMENTAL|ASP8374 70 mg - Monotherapy Dose Escalation|Participants received ASP8374 70 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62689918|NCT03260322|EXPERIMENTAL|ASP8374 200 mg - Monotherapy Dose Escalation|Participants received ASP8374 200 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62130430|NCT02208596|EXPERIMENTAL|Group B|In group B, propofol (1%) was mixed with etomidate in the ration of 7:5 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
62130431|NCT02208596|EXPERIMENTAL|Group C|In group C, propofol (1%) will be injected continuously until the eyelash reflex disappears. During the operation, supplementary propofol will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
62130432|NCT06099249||No_AFib_Group|Subjects enrolled into No_AFib_Group must have no known medical history of AFib and in normal sinus rhythm at the time of screening.
62130433|NCT06099249||AFib_Group|Subjects enrolled into AFib_Group must have a known diagnosis of persistent or permanent AFib and be in AFib at the time of screening.
62130434|NCT01266122|NO_INTERVENTION|HIV/STI voluntary counseling and testing|Participants enrolled in the control arm will receive study assessments only.
62321239|NCT02868749|ACTIVE_COMPARATOR|Hyaluronic Acid filler 2 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery"
62130435|NCT01266122|EXPERIMENTAL|Behavioral intervention|Participants enrolled in the experimental condition will receive 4 group sessions and 4 individual sessions over 3 months. This intervention focuses on psychosocial concerns and HIV risk for MSM in India.
62130436|NCT02344641|EXPERIMENTAL|Exenatide|exenatide group receive exenatide (5μg, subcutaneous injection, Bid）
62321240|NCT00495664|EXPERIMENTAL|TITANOX|Titanium-nitride-oxide coated stent
62321241|NCT00495664|ACTIVE_COMPARATOR|PES|Paclitaxel-eluting stent
62481234|NCT05695209|EXPERIMENTAL|Coaching and Decision Aid|Individual coaching sessions and Decision Aid
62130437|NCT02344641|NO_INTERVENTION|control group|control group do not receive exenatide
62481235|NCT05695209|NO_INTERVENTION|Control|Wait-list control group
62481236|NCT06336200||Higher Kinesiophobia|"It is a group with a high level of kinesiophobia according to the Tampa kinesiophobia scale."
62481237|NCT06336200||Lower Kinesiophobia|"It is a group with a low level of kinesiophobia according to the Tampa kinesiophobia scale."
62481238|NCT06098755||Team 1. President George Washington (1732-1799) Notes:|variables
62481239|NCT06098755||Team 2. President Thomas Jefferson (1743 -1826) Notes:|variables
62481240|NCT06098755||Team 3. President Theodore Roosevelt (1858 - 1919) Notes:|variables
62481241|NCT06098755||Team 4. President Abraham Lincoln (1809 - 1865) Notes:|variables
62481242|NCT03683589||Study group|"Participants will receive deuterated water for 10 days before undergoing bariatric surgery.~Liver biopsy collected, lipids extracted and DNL measured via GC/MS."
62481243|NCT05756634|EXPERIMENTAL|CCAPB (intervention)|Intervention participants will receive an intervention focused on health care navigation and motivational enhancement.
62481244|NCT05756634|PLACEBO_COMPARATOR|Usual Care|Usual care participants will not receive the intervention.
62481245|NCT02222818|OTHER|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
62481246|NCT02222818|OTHER|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
62321242|NCT02974062|EXPERIMENTAL|Lumbar stabilization exercise|Lumbar stabilization exercised is a low-intensity exercise that focuses on motor control of deep abdominal and back muscles, rather than their strength or endurance. There are 3 main levels in this exercise; 1) co-contraction of deep abdominal and back muscles, 2) co-contraction with limb movement (self-perturbation), and 3) co-contraction with functional movement (i.e. walking, running, etc.)
62321243|NCT02974062|NO_INTERVENTION|Healthy control|No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
62321244|NCT04260022|EXPERIMENTAL|Cohort A|
62321245|NCT04260022|EXPERIMENTAL|Cohort B|
62321246|NCT04260022|EXPERIMENTAL|Cohort C|
62321247|NCT04260022|EXPERIMENTAL|Cohort D|
62321248|NCT01704781|EXPERIMENTAL|Part A: lenalidomide dose escalation|"All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.~Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)"
62481247|NCT01022983|ACTIVE_COMPARATOR|Levosimendan|
62481248|NCT01022983|PLACEBO_COMPARATOR|Povidon, waterfree etanol, glucosis 5%|
62481249|NCT05003232|NO_INTERVENTION|Control group|
62481250|NCT05003232|EXPERIMENTAL|Optimal MAP group|
62481251|NCT06558695|ACTIVE_COMPARATOR|Sevoflurane Group|In the Sevoflurane group, general anesthesia was maintained with sevoflurane at 0.8-1.0 minimum alveolar concentration (MAC).
62481252|NCT06558695|ACTIVE_COMPARATOR|TIVA group|In the TIVA (Total Intra Venous Anesthesia) group, a combination of propofol (50-150 μg/kg/min) and remifentanil (0.02-0.2 μg/kg/min) was used for general anesthesia instead of inhalational agents.
62321249|NCT01704781|EXPERIMENTAL|Part B: lenalidomide|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
62321250|NCT01704781|PLACEBO_COMPARATOR|Part B: lenalidomide placebo|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide placebo two days prior to and at the day of immunization.
62339771|NCT05380934|EXPERIMENTAL|TQH3821 Tablets (Food Effect)|TQH3821 tablets, 2 sequential periods (fasting and fed)
62481253|NCT06201234|EXPERIMENTAL|Arm A: Olaparib + elacestrant*|"Treatment will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study.~\* Together with GnRH analogue in pre- and perimenopausal women, and in men, at least two weeks prior to treatment.~* Elacestrant tablets 400 mg orally daily~* Olaparib 600 mg orally daily The protocol provides procedures for specific adverse events requiring dose modifications or delays."
62481254|NCT06201234|ACTIVE_COMPARATOR|Arm B: Olaparib|"Treatment will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study.~• Olaparib 600 mg orally once daily~The protocol provides procedures for specific adverse events requiring dose modifications or delays."
62481255|NCT04160013|EXPERIMENTAL|Discipline education|Education about discipline using the Play Nicely program (www.playnicely.org).
62481256|NCT04160013|PLACEBO_COMPARATOR|Cavity prevention|Education about cavity prevention using a 2 page handout.
62481257|NCT03420482|EXPERIMENTAL|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
62130438|NCT04978051|ACTIVE_COMPARATOR|Standard of Care (SoC)|
62130439|NCT04978051|EXPERIMENTAL|SoC + Icatibant|
62130440|NCT02201134|OTHER|sevoflurane|
62481258|NCT03420482|PLACEBO_COMPARATOR|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
62689919|NCT03260322|EXPERIMENTAL|ASP8374 700 mg - Monotherapy Dose Escalation|Participants received ASP8374 700 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62689920|NCT03260322|EXPERIMENTAL|ASP8374 1400 mg - Monotherapy Dose Escalation|Participants received ASP8374 1400 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62130441|NCT02503397||Latent iron deficiency|Infants with cord serum ferritin levels ≤ 75 ng/mL
62321251|NCT03865407|ACTIVE_COMPARATOR|Allopurinol|Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
62321252|NCT03865407|NO_INTERVENTION|Standard of Care Control|The treatment arm will be compared to a standard of care arm.
62689921|NCT03260322|EXPERIMENTAL|ASP8374 1400 mg - Monotherapy Dose Expansion|Participant received ASP8374 1400 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
62689922|NCT03260322|EXPERIMENTAL|ASP8374 20 mg - Combination Dose Escalation|Participants received ASP8374 20 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62689923|NCT03260322|EXPERIMENTAL|ASP8374 70 mg - Combination Dose Escalation|Participants received ASP8374 70 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62321253|NCT02310958||Children with inguinal hernia|Laparoscopic surgical hernia repair in children aged between 1 day and 16 years
62321254|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
62321255|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
62321256|NCT02316093||obese-chronic periodontitis patients|
62321257|NCT02316093||obese-gingivitis patients|
62321258|NCT02316093||obese-periodontally healthy controls|
62321259|NCT02316093||normal weight-chronic periodontitis patients|
62321260|NCT02316093||normal weight-gingivitis patients|
62321261|NCT02316093||normal weight-periodontally healthy controls|
62321262|NCT02731040||Controls|Women who are/have been on bisphosphonate therapy for osteoporosis who have not suffered an atypical femoral fracture
62321263|NCT02731040||Fracture Group|Women who are/have been on bisphosphonate therapy for osteoporosis who have suffered an atypical femoral fracture
62321264|NCT00287833|EXPERIMENTAL|Arm I (Bowman-Birk inhibitor concentrate)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
62339772|NCT05380934|PLACEBO_COMPARATOR|TQH3821 Placebo Tablets (Food Effect)|TQH3821 placebo tablets, 2 sequential periods (fasting and fed)
62321265|NCT00287833|PLACEBO_COMPARATOR|Arm II (placebo)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
62689924|NCT03260322|EXPERIMENTAL|ASP8374 200 mg - Combination Dose Escalation|Participants received ASP8374 200 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62689925|NCT03260322|EXPERIMENTAL|ASP8374 700 mg - Combination Dose Escalation|Participants received ASP8374 700 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62689926|NCT03260322|EXPERIMENTAL|ASP8374 1400 mg - Combination Dose Escalation|Participants received ASP8374 1400 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62689927|NCT03260322|EXPERIMENTAL|ASP8374 200 mg - Combination Dose Expansion|Participants received ASP8374 200 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62689928|NCT03260322|EXPERIMENTAL|ASP8374 700 mg - Combination Dose Expansion|Participants received ASP8374 700 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62689929|NCT03260322|EXPERIMENTAL|ASP8374 1400 mg - Combination Dose Expansion|Participants received ASP8374 1400 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
62689930|NCT01396876|ACTIVE_COMPARATOR|Clown|A clown is present during venipuncture
62689931|NCT01396876|NO_INTERVENTION|No clown|
62689932|NCT05003700|EXPERIMENTAL|HAIC(RALOX) plus Lenvatinib and Camrelizumab|Hepatic arterial infusion of oxaliplatin and raltitrexed every 3 weeks. Lenvatinib 8 mg once daily (QD) oral dosing. Camrelizumab 200mg intravenously every 3 weeks.
62689933|NCT06105398||Study group|Patients between the ages of 40-75 who had rotator cuff repair at least one year ago at the Orthopedics and Traumatology Clinic of Pamukkale University
62689934|NCT06105398||Control group|healthy adults between the ages of 40-75
62689935|NCT04493138|EXPERIMENTAL|Treatment (azacitidine, quizartinib)|Patients receive azacitidine SC or IV over about 30 minutes on days 1-5 and quizartinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62689936|NCT06145711|EXPERIMENTAL|to use cell|
62689937|NCT06675851|ACTIVE_COMPARATOR|Antidepressant treatment in MDD patients with bupropion|Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
62689938|NCT06675851|ACTIVE_COMPARATOR|Antidepressant treatment in MDD patients with escitalopram|Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
62689939|NCT06675851|NO_INTERVENTION|Healthy Controls without antidepressant intake|Healthy controls will only attend imaging procedures without medication intake
62697486|NCT06571435||Active young adult|Participants will be assess with International Physical Activity Questionnaire(IPAQ-SF), which measures the duration of vigorous and moderate activity, walking and sitting over the previous 7 days. After they are done with the questionnaire, if they have \>3000 MET/week score they will be considered as highly active group.
62321266|NCT00677027|EXPERIMENTAL|1|
62130442|NCT02503397||Normal iron status|Infants with cord serum ferritin levels \> 75 ng/mL.
62321267|NCT00677027|PLACEBO_COMPARATOR|2|
62130443|NCT02267824|EXPERIMENTAL|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
62130444|NCT02267824|OTHER|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
62130445|NCT00277355|EXPERIMENTAL|Minocycline|Minocycline (3:1 randomization) 100 mg capsules taken by mouth twice daily, 200 mg per day total for 18 months treatment duration.
62130446|NCT00277355|PLACEBO_COMPARATOR|Matching placebo|Sugar pill manufactured to mimic minocycline, 1 capsule taken by mouth twice daily for 18 months treatment duration.
62130447|NCT00897169|EXPERIMENTAL|A|
62130448|NCT00897169|EXPERIMENTAL|B|
62321268|NCT06094179|EXPERIMENTAL|A1 300mg|Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard
62130449|NCT05646329|EXPERIMENTAL|Experimental|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session. The session will last a maximum of 40 minutes. The session will be once a week. Motivational interview will be conducted individually and online with the experimental group. For individual interviews, the appropriate day and time will be determined with the researcher before the first session and the sessions will continue on the same day and time every week.
62130450|NCT05646329|NO_INTERVENTION|Waiting list group|"If the students in the control group make a request at the end of the study, an online individual motivational interview will be held. The intervention applied to the experimental group will also be applied to the control group at the end of the study.~Intervention: Behavioural Intervention Based on Problematic Internet Use"
62130451|NCT01933802|EXPERIMENTAL|autologous MSC-NP|intrathecal administration of autologous MSC-NP in three doses at three month intervals
62130452|NCT04739527|EXPERIMENTAL|Treatment arm|Patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
62321269|NCT06094179|EXPERIMENTAL|B1 600mg|Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard
62130453|NCT03844152|EXPERIMENTAL|Fermented whey concentrate|Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume. Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
62689940|NCT02500966|EXPERIMENTAL|DUDA device|"The number of patients to be recruited in this arm will be 145. Note: The first twenty-five patients who will be included in the study will be allocated in the intervention arm to safety analysis (phase 1); after that all eligible candidates will be randomized 1:1 (phase 2).~Procedure: Loop Electrosurgical Excision Procedure (LEEP) followed by implantation of the device called DUDA (plastic device developed in barretos cancer hospital that will be placed after conization. It has 2.5 cm in length and 5mm in diameter and remains within the endocervical canal for 30 days and is set at 4 points with nonabsorbable sutures in the ectocervix.)"
62689941|NCT02500966|ACTIVE_COMPARATOR|Control group|"The number of patients to be recruited in this arm will be 120.~Procedure: Loop Electrosurgical Excision Procedure (LEEP) without DUDA device"
62689942|NCT01299961|EXPERIMENTAL|Subcutaneous Abatacept|All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.
62321270|NCT06094179|EXPERIMENTAL|C1 600mg|Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard
62689943|NCT06409013||Observational|Patients receive ICG infusion prior to undergoing scheduled resection and have medical records reviewed on study.
62689944|NCT04551586|EXPERIMENTAL|Sequence 1|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~Period 2: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~Period 3: ACH-0145228 as power-in-capsule under fasted conditions (reference).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
62689945|NCT04551586|EXPERIMENTAL|Sequence 2|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~Period 2: ACH-0145228 as power-in-capsule under fasted conditions (reference).~Period 3: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
62689946|NCT04551586|EXPERIMENTAL|Sequence 3|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as power-in-capsule under fasted conditions (reference).~Period 2: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~Period 3: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
62689947|NCT01204385||Study Group|
62689948|NCT01408108|ACTIVE_COMPARATOR|Lightweight mesh repair|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
62689949|NCT01408108|ACTIVE_COMPARATOR|Primary crural repair|Laparoscopic primary posterior crural repair
62689950|NCT06602258|EXPERIMENTAL|E2814 Dose A + Lecanemab|Participants will receive E2814 Dose A administered as an intravenous (IV) infusion, every four weeks (Q4W) along with lecanemab administered as a subcutaneous (SC) injection, every week (QW) for up to 18 months.
62689951|NCT06602258|EXPERIMENTAL|E2814 Dose B + Lecanemab|Participants will receive E2814 Dose B administered as an IV infusion, Q4W along with lecanemab administered as a SC injection, QW for up to 18 months.
62689952|NCT06602258|EXPERIMENTAL|E2814 Dose C + Lecanemab|Participants will receive E2814 Dose C administered as an IV infusion, Q4W along with lecanemab administered as a SC injection, QW for up to 18 months.
62689953|NCT06602258|EXPERIMENTAL|E2814 Dose D + Lecanemab|Participants will receive E2814 Dose D administered as an IV infusion, Q4W along with lecanemab administered as a SC injection, QW for up to 18 months.
62689954|NCT06602258|EXPERIMENTAL|Placebo + Lecanemab|Participants will receive placebo administered as an IV infusion, Q4W along with lecanemab administered as a SC injection, QW for up to 18 months.
62689955|NCT02019173|EXPERIMENTAL|Boot camp balance training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
62689956|NCT02315976|EXPERIMENTAL|Propatyl nitrate|Patients treated with propatyl nitrate 10mg thrice daily
62689957|NCT06088277|EXPERIMENTAL|HIV text messages (TM HIV)|Eligible participants randomized into this arm will receive text messages to reduce the risk for HIV and promote HIV testing.
62130454|NCT01557335|EXPERIMENTAL|Clopidogrel (Plavix®) and PA32540|PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
62321271|NCT03686254|ACTIVE_COMPARATOR|The control Arm|bevacizumab and second-line chemotherapy
62689958|NCT06088277|ACTIVE_COMPARATOR|TM HL|Eligible participants randomized into this arm will receive text messages to promote healthy living, but not specific to HIV risk or testing..
62689959|NCT03816579|EXPERIMENTAL|PRO-A|Beef protein
62321272|NCT03686254|EXPERIMENTAL|The experimental Arm|RFA, bevacizumab and second-line chemotherapy
62339773|NCT05380934|EXPERIMENTAL|TQH3821 Tablets (Multiple Administration Dose)|TQH3821 tablets once every 12 hours for 7 times during the continuous administration phase.
62689960|NCT03816579|EXPERIMENTAL|PRO-B|Complementary proteins at each meal
62689961|NCT03816579|EXPERIMENTAL|PRO-C|Complementary proteins over 24 hours
62689962|NCT03816579|NO_INTERVENTION|CON|Low protein (\<5 g) meal
62689963|NCT06674967||LBB area pacing group|study group with LBB area pacing
62689964|NCT06674967||RV apical pacing area|study group with RV apical pacing
62689965|NCT05143619||Observational (surveys)|Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months.
62689966|NCT02579057|ACTIVE_COMPARATOR|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
62689967|NCT02579057|EXPERIMENTAL|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
62689968|NCT06569849|EXPERIMENTAL|De-Stress and Focus capsule- U001|
62689969|NCT06569849|EXPERIMENTAL|De-Stress and Focus capsule - I001|
62689970|NCT06569849|PLACEBO_COMPARATOR|Placebo capsules 001|
62689971|NCT06068192||28th day death group|Patient dies within 28 days after hospitalization
62689972|NCT06068192||non-28th day death group|The patient does not die within 28 days after hospitalization
62689973|NCT05157997|EXPERIMENTAL|Casirivimab and Imdevimab Antibody Cocktail|Patients receiving a Covid-19 positive liver, kidney, or heart transplant.
62689974|NCT06570460|ACTIVE_COMPARATOR|Oral estrogen treatment|Turner syndrome patients receiving oral estrogen treatment (Estrofem®)
62689975|NCT06570460|ACTIVE_COMPARATOR|Transdermal estrogen treatment|Turner syndrome patients receiving transdermal estrogen treatment (Divigel)
62689976|NCT06570460|NO_INTERVENTION|Controls|Healthy age-matched controls receiving no treatment
62689977|NCT05812300|EXPERIMENTAL|HA35 local injection of Periodontal Pocket group|The tissue-permeable 35 kDa low molecular hyaluronan fragment HA35 was freshly manufactured using pharmaceutical grade hyaluronidase PH20 injection (State Drug Administration H31022111) and joint cavity HA injection (State Drug Administration H20174089) mixed at room temperature for 20 min.
62689978|NCT06639477|ACTIVE_COMPARATOR|Concealed Control Intervention|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
62689979|NCT06639477|EXPERIMENTAL|Active Condition|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
62689980|NCT05874804|ACTIVE_COMPARATOR|Control CAPD treatment|The subjects will receive their standard CAPD treatment.
62689981|NCT05874804|EXPERIMENTAL|Carry Life UF|Three days per week, the subject will replace a 2.27% glucose dwell with the Carry Life® UF treatment. The remaining four days of the week, one 2.27% glucose dwell will be replaced by a 1.36% glucose dwell.
62689982|NCT06642324||HPV Positive HNSCC Population|Tissues from Head Neck Squamous Cell Carcinoma and HPV DNA-positive
62689983|NCT06642324||HPV Negative HNSCC Population|Tissues from Head Neck Squamous Cell Carcinoma and HPV DNA-negative
62689984|NCT06642324||Healthy Population|Healthy Population who does not have any carcinoma, chronic diseases, Genetic diseases, acute/chronic infectious diseases, etc.
62689985|NCT00248235|EXPERIMENTAL|PRET|Progressive Resistance Exercise Training: upper extremity 6-8 exercises
62321273|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
62689986|NCT00248235|ACTIVE_COMPARATOR|Standard Care|Standard Care: physical therapy - range of motion, 6-8 strengthening exercises
62689987|NCT05292703|EXPERIMENTAL|face-to-face group|In the face-to-face group, the intervention is a participatory activity based on art and olfactory stimulation which consists of practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, adapted to health circumstances and respecting social distancing measures. Due to the health crisis, the workshops will be offered in several groups ranging from 8 to 10 participants, these groups will be equal. A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities
62689988|NCT05292703|EXPERIMENTAL|remote group|For the remote group, immediately after randomization, they will receive the connection link to the internet application and an individual connection code. The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop. The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks.
62689989|NCT06674928||Normal Developing Children|"Children that were satisfied with the criteria as average or on-time growth based on the attainment of specific physical, cognitive, linguistic, social-emotional, and behavioral milestones across specific stages."
62689990|NCT06674928||Developmental Delay Children|Children who has not gained the developmental skills expected of him or her, compared to others of the same age.
62689991|NCT01588925|EXPERIMENTAL|Control group|Cochlear Implantation
62689992|NCT01588925|ACTIVE_COMPARATOR|Dexamethasone|Cochlear implantation using topical dexamethasone
62689993|NCT01588925|ACTIVE_COMPARATOR|Dexamethasone+Hyaluronic acid|Cochlear implantation using topical dexamethasone associated with hyaluronic acid
62689994|NCT03044899||Adult surgical patients|All surgeries in adult patients
62689995|NCT06207851|EXPERIMENTAL|Experimental|If abnormal blood vessels related to pain are identified by angiography, selective embolization is performed using Nexsphere-F.
62689996|NCT06674161||CVD with type 2 diabetes|
62689997|NCT06674161||CVD without type 2 diabetes|
62321274|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
62689998|NCT06674161||T2DM only without CVD|
62689999|NCT06674161||No T2DM and no CVD|
62690000|NCT06142305|EXPERIMENTAL|DDH surgery|DDH surgery open reduction and casting
62690001|NCT02685436|OTHER|omeprazole and domperidone|wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day).
62690002|NCT01783288|OTHER|All participants|"All participants will be administered all procedures as described previously.~Interventions:~Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test"
62690003|NCT05804084|EXPERIMENTAL|Acetazolamide, then Placebo|"Subjects will start with a 4-week ACETAZOLAMIDE regimen~Day 1-27: Acetazolamide 500mg at bedtime at home Day 28: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 4-week PLACEBO regimen:~Day 1-27: Placebo (matching Acetazolamide 500mg) at bedtime at home Day 28: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory"
62321275|NCT02963467|OTHER|Healthy Volunteers - non-smokers|control group: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke a dummy cigarette. Then V/Q will be measured again after 15 minutes.
62690004|NCT05804084|EXPERIMENTAL|Placebo, then Acetazolamide|"Subjects will start with a 4-week PLACEBO regimen~Day 1-27: Placebo (matching Acetazolamide 500mg) at bedtime at home Day 28: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 4-week ACETAZOLAMIDE regimen:~Day 1-27: Acetazolamide 500mg at bedtime at home Day 28: Acetazolamide 500mg at bedtime in the sleep laboratory"
62130455|NCT01557335|ACTIVE_COMPARATOR|EC aspirin, EC omeprazole, Clopidogrel|
62130456|NCT02543125|ACTIVE_COMPARATOR|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)\<6cm H2O,R:30 per minute .
62130457|NCT02543125|ACTIVE_COMPARATOR|NHFOV|NHFOV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,MAP：6-14 cm H2O,Hertz(HZ):5-10 to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)\<6cm H2O.
62130458|NCT03825978|ACTIVE_COMPARATOR|Intervention|An individual and comprehensive prenatal genetic counseling was given to all pregnant women in the intervention group, including all screening tests and diagnostic tests for prenatal diagnosis and screening tests at the first antenatal visit.
62321276|NCT02963467|OTHER|Healthy Volunteers - occasional smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
62321277|NCT02963467|OTHER|Healthy Volunteers - heavy-smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
62321278|NCT00475280|OTHER|Geriatric assessment|
62321279|NCT03328130|EXPERIMENTAL|Cohort 1 - Low Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the lowest dose. Dose-escalation will be performed after DSMC assessment.
62321280|NCT03328130|EXPERIMENTAL|Cohort 2a - Medium Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the medium dose. Confirmatory dose will be determined after DSMC assessment.
62321281|NCT03328130|EXPERIMENTAL|Cohort 2b - High Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the highest dose. Confirmatory dose will be determined after DSMC assessment.
62321282|NCT03328130|EXPERIMENTAL|Cohort 3 - High Dose (confirmatory cohort)|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
62130459|NCT03825978|NO_INTERVENTION|Control|There was no intervention from the first antenatal visit in the control group. Routine clinical information was given about prenatal screening and diagnostic tests.
62130460|NCT02352675||Congenital Heart Disease|Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital
62130461|NCT02352675||Non Congenital Heart Disease|Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.
62130462|NCT02622568|ACTIVE_COMPARATOR|Cryotherapy and Veregen|Cryotherapy will be performed on the day of first clinic visit according to current standard of care in Children's Medical Center pediatric outpatient dermatology clinic, which consists of two freeze/thaw cycles for maximum of 10 seconds each. Sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Sinecathecins 15% ointment will be applied to verrucous lesions twice daily. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
62130463|NCT02622568|EXPERIMENTAL|Veregen only|Veregen ™or sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Veregen ™ or sinecathecins 15% ointment will be applied to verrucous lesions twice daily per current Children's Medical Center protocol. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
62321283|NCT03328130|EXPERIMENTAL|Cohort 4 - High Dose - 13 years old or older population|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
62321284|NCT05847270|EXPERIMENTAL|Anterior and posterior treatment strategy|Anterior transoral release and reduction + posterior internal fixation and bone graft fusion
62321285|NCT05847270|EXPERIMENTAL|Simple Posterior Approach Treatment Strategy|posterior reduction and internal fixation
62321286|NCT05029076|EXPERIMENTAL|Liraglutide injection + Victoza|Subjects receive liraglutide injection in the first cycle and Victoza in the second cycle.
62321287|NCT05029076|EXPERIMENTAL|Victoza +Liraglutide injection|Subjects receive Victoza in the first cycle and liraglutide injection in the second cycle.
62321288|NCT04473261|EXPERIMENTAL|Iodine Complex (Capsule form)|Iodine Complex) capsule (200mg) will be given three times a day
62321289|NCT04473261|EXPERIMENTAL|Iodine Complex (Syrup form)|Iodine Complex syrup form (40ml) will be given three times a day
62339774|NCT05380934|PLACEBO_COMPARATOR|TQH3821 Placebo Tablets (Multiple Administration Dose)|TQH3821 placebo tablets once every 12 hours for 7 times during the continuous administration phase.
62321290|NCT04473261|PLACEBO_COMPARATOR|Standard Care Alone|Placebo as empty capsule. Treatment will be given for all 4 arms will be receiving standard care as per version 3.0 of clinical management guidelines for COVID-19 established by the Ministry of National Health Services of Pakistan COVID-19 guidelines of the study setting.
62321291|NCT04473261|EXPERIMENTAL|Iodine Complex (Nasal Spray)|Iodine complex throat spray of 2 puffs three times a day.
62321292|NCT05791825|EXPERIMENTAL|Receives CHIME|Half of the educators participating in the trial will be assigned to this condition. CHIME is an 8-week, mindfulness and self-compassion based intervention that teaches educators strategies to enhance socioemotional learning in the classroom. The primary endpoints are: educator mindfulness and self-compassion, educator emotional regulation, educator heart rate variability, educator wellbeing and socio-emotional learning, and educator responsiveness, support, and sensitivity in the classroom. The secondary endpoints are: child self-regulation and social skills and family-school relationships.
62321293|NCT05791825|NO_INTERVENTION|Wait-listed comparison|Half of the HS/EHS educators will be assigned to a waitlisted control group. Specifically, these educators will be scheduled to receive the intervention after a 6-month waiting period. During the interim period, they will complete the same assessments as Arm 1, but will continue to receive 'business as usual' support and professional development through typical Head Start/EHS programming.
62321294|NCT05174052|PLACEBO_COMPARATOR|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme.
62321295|NCT05174052|ACTIVE_COMPARATOR|Intervention Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme
62321296|NCT04579588||COVID-19 participants|
62321297|NCT04579588||Control participants|
62321298|NCT05961592|OTHER|Open Label|Probiotic
62321299|NCT00591227|ACTIVE_COMPARATOR|aspart detemir|these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
62321300|NCT00591227|NO_INTERVENTION|usual care|these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.
62321301|NCT04878640|ACTIVE_COMPARATOR|Group A|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
62321302|NCT04878640|ACTIVE_COMPARATOR|Group B|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
62321303|NCT00629694|ACTIVE_COMPARATOR|A-T|
62321304|NCT00629694|EXPERIMENTAL|A-M|
62321305|NCT05894018|EXPERIMENTAL|Fluzoparib+radioactive particle implantation|Fluzoparib 150 mg bid was given orally after meals for 2 months (60 days) in a continuous cycle 48h after radioactive particle implantation.
62321306|NCT05299710||Ovarian Tissue Cryopreservation|Children faced with a fertility threatening diagnosis will be offered ovarian tissue cryopreservation.Pre-surgery assessment will be done while your child is in the hospital or in the pediatric oncology, surgery, or anesthesia clinic as an outpatient. The surgical procedure used to remove your child's ovary is called laparoscopy. It is not required for the treatment of your child's cancer. Laparoscopic surgery is done under general anesthesia (your child will be asleep during the surgery) in the operating room.
62321307|NCT06692062|EXPERIMENTAL|Hypofractionated Radiotherapy|R0 resection: 42-48 Gy/14-16f or 40-44 Gy or 10-11f,40 Gy/8f R1 resection: 48-51 Gy/16-17f or 44-48 Gy/11-12f or 40-45 Gy/8-9f R2 resection: 51-60 Gy/17-20f or 48-56 Gy/12-14f or 45 -60Gy/9-12f
62690005|NCT06192797|EXPERIMENTAL|HAIC-len-puco|Patients with advanced intrahepatic cholangiocarcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and pucotenlimab as conversion therapy for downstaging.
62690006|NCT02954562||Anxiety|"Participants enrolled in study A randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness (NCT02427568) who meet further inclusion criteria for fMRI scan"
62690007|NCT01554709|EXPERIMENTAL|CardioGard Cannula|
62321308|NCT06692062|NO_INTERVENTION|Conventional Radiotherapy|R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f
62321309|NCT05228652||Affected Individuals|Virilised 46XX CAH individuals aged 16 years or above
62321310|NCT05228652||Parents of affected individuals|Parents of virilised 46XX CAH individuals aged 2 years and over.
62321311|NCT04547296|EXPERIMENTAL|BRS group|After entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.
62321312|NCT04547296|EXPERIMENTAL|ARS group|After entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.
62690008|NCT01554709|ACTIVE_COMPARATOR|Reference Cannula|
62690009|NCT03940521||HIV-A infected patients|
62690010|NCT05043831|EXPERIMENTAL|Direct Selective Laser Trabeculoplasty (DSLT)|Subjects will be treated with DSLT
62690011|NCT05043831|ACTIVE_COMPARATOR|Selective Laser Trabeculoplasty (SLT)|Subjects will be treated with SLT
62339775|NCT05380934|EXPERIMENTAL|TQH3821 Tablets + Methotrexate Tablets|Take Methotrexate Tablets once in the first cycle, take TQH3821 Tablets once every 12 hours in the second cycle for 6 times, and then TQH3821 Tablets + Methotrexate Tablets once in the third cycle.
62690012|NCT03753074|EXPERIMENTAL|Treatment Arm A (TAF)|390 subjects administered Tenofovir Alafenamide 25 mg once daily
61926509|NCT06488807|EXPERIMENTAL|Olfactory Enrichment Group|All participants enrolled in the olfactory enrichment group will receive twice sessions per day with an interval of at least 6 hours on preoperative day 1 and postoperative day 1-3 (or postoperative day 1-discharge day). Each session will last 30 minutes. Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, tangerine, green tea, cloves and eucalyptus). When pushing a button, 4 odors will be released in turn and participants will sniff each odor (approximately 4 ml odorized air) for approximately 30 seconds by a nasal catheter. Considering of the adaption of odors, 4 odors will be used in the morning session and another 4 odors will be used in the afternoon session.
62690013|NCT03753074|NO_INTERVENTION|Treatment Arm B (Best supportive care)|"390 subjects received best supportive care~During treatment period, among treatment arm B, subjects who are indicated for antiviral treatment will be treated with TAF as follows:~1. Based on the AASLD 2018 Guidelines of CHB (ALT 70≥ for male, 50≥ for female)~2. 40≤ALT levels\<70 IU/L (males) or 40≤ ALT levels\<50 IU/L (females) with evidence of significant fibrosis(F2; ≥7.2 kPa) as measured by either liver biopsy, Fibroscan or MR elastograpy performed within 3 months.~3. If they were clinically judged to have cirrhosis by investigators and confirmed with Fibroscan (≥ 12.0 kPa)."
62339776|NCT05380934|PLACEBO_COMPARATOR|TQH3821 Placebo Tablets + Methotrexate Tablets|Take Methotrexate Tablets once in the first cycle, take TQH3821 placebo tablets once every 12 hours in the second cycle for 6 times, and then TQH3821 placebo tablets + Methotrexate Tablets once in the third cycle.
62690014|NCT02743221|EXPERIMENTAL|Trifluridine/tipiracil + bevacizumab|"Trifluridine/tipiracil (S95005): film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride.~Bevacizumab: concentrate for solution for IV infusion containing 25mg/ml of bevacizumab.~Trifluridine/tipiracil was administered at 35 mg/m2/dose orally within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period, with bevacizumab administered intravenously at the dose of 5 mg/kg every 2 weeks at Day 1 and Day 15.This treatment cycle was repeated every 4 weeks."
62690015|NCT02743221|ACTIVE_COMPARATOR|Capecitabine + bevacizumab|Capecitabine was administered at 1250 mg/m² orally BID (bis in die)on Days 1-14 of each cycle, with bevacizumab (7.5 mg/kg, IV) administered on Day 1 of each cycle. This treatment cycle was repeated every 3 weeks
62697487|NCT06571435||Sedentary young adult|Participants will be assess with International Physical Activity Questionnaire(IPAQ-SF), which measures the duration of vigorous and moderate activity, walking and sitting over the previous 7 days. After they are done with the questionnaire, if they have \<600 MET/week score they will be considered as sedentary group.
62697488|NCT06570421|EXPERIMENTAL|Peroneal eTNM arm|All patients will receive treatment with peroneal eTNM
62697489|NCT00997763|ACTIVE_COMPARATOR|XIENCE V|everolimus-eluting stent
62697490|NCT00997763|ACTIVE_COMPARATOR|CYPHER|Using Cypher stent
61926510|NCT06488807|SHAM_COMPARATOR|Sham Group|The sham group will receive sham olfactory enrichment sessions, which is designed with the same pattern (twice a day, 30 min for each session, on preoperative day 1 and on postoperative day 1-3. The only difference is that there is no odor in the device. Water will be used in the dispenser.
62481259|NCT05806593|EXPERIMENTAL|Intervention (Get Back pilot)|"The intervention includes 5 core sessions (video call) and 5 booster sessions (telephone) over 12 weeks (1 week before until 11 weeks after surgery). All sessions will be led by a physiotherapist. The focus of each core session (1-5) is as follows:~1. To establish the patient as an active, equal partner in the treatment and to formulate a shared health plan according to person-centred care.~2. To reduce the threat value of postoperative pain and increase the patient's knowledge about the biopsychosocial nature of pain and positive effects of physical activity.~3. To detect barriers for postoperative physical activity and to support the patient to gradually start increasing physical activity.~4. To increase approach behavior for physical activity and reduce avoidance behavior by confronting fears and move towards personal goals.~5. To support the patient to independently continue with activity progress towards long term health and to formulate a maintenance plan."
62321313|NCT06401655|EXPERIMENTAL|Treatment group (pilot)|"The total time in this study for an ABI-survivor participant is 10 hours and 15 minutes which includes 7.5 hours of intervention time and 2.75 hours of data collection time.~This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant)."
62690016|NCT04097665||patients with expanded flaps|Patients will undergo tissue expansion. When the expanded flaps are harvested and transplanted, ICGA will be conducted intraoperatively. Meanwhile, the possible area of necrosis will be marked according to clinical experience. And then this area will be further divided into perfusion units (1\*1 square centimeter for each). The center of each perfusion unit will be marked as observation point, of which the fluorescence value will be recorded. After 1 week's follow-up postoperatively, the flap tissue will be determined by superimposing digital photography over ICGA imaging results, and the outcome of each observation point will be recorded. By analyzing the fluorescence value and outcome of each observation point, a cut-off point can be further identified to achieve both higher positive and negative predictive value, improving the utility and accuracy of ICGA in predicting the postoperative skin viability of expanded flaps.
62690017|NCT06383013|ACTIVE_COMPARATOR|High Dose Dosing Group|High Dose BB-101 topical solution will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.
62690018|NCT06383013|ACTIVE_COMPARATOR|Low Dose Dosing Group|Low Dose BB-101 topical solution will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.
62321314|NCT03127202|EXPERIMENTAL|Cardiac Resynchronization Therapy-Defibrillator|Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator
62321315|NCT02096198||Other CERAMAX COC 36mm Acetabular Cup|The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
62321316|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
62321317|NCT06692881||Ubrogepant|Participants will receive Ubrogepant as prescribed by their physician in routine clinical practice.
62321318|NCT02143986||Macrophagic activation syndrome|
62321319|NCT02143986||Still's disease|
62321320|NCT02143986||Hyperferritinemia|
62321321|NCT02143986||Sepsis|
62321322|NCT05055739|EXPERIMENTAL|SW|Patients undergoing sternal closure with steel wires
62321323|NCT05055739|EXPERIMENTAL|RP|Patients undergoing sternal closure with a rigid plate
62321324|NCT05805371|EXPERIMENTAL|Treatment plan I (PSCA CAR T-cells)|Patients undergo leukapheresis and lymphodepletion and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
62339777|NCT00654784|EXPERIMENTAL|1|
62339778|NCT00654784|PLACEBO_COMPARATOR|2|
61926511|NCT05926804|EXPERIMENTAL|Cases|140 children with H. pylori-persistent infection, who will receive eradication therapy
62481260|NCT05806593|NO_INTERVENTION|Control (standard physiotherapy)|The control group will follow standard physical therapy, meaning physical therapy as it is provided at each recruiting site when undergoing surgery due to spinal stenosis. As this may differ substantially between clinical sites nationally, data on frequency of physical therapy and the content of the physical therapy sessions during the study period will be collected as a control variable weekly from the control group.
62481261|NCT06548789|EXPERIMENTAL|Prebiotic food-enriched diet (PreFED)|Participants will identified from the clinic schedules and/or referred from participant's treating oncologists.
62481262|NCT03969628|EXPERIMENTAL|Multivariate risk assessment group (ICCMS®)|Multivariate risk assessment group (ICCMS®): multivariate caries risk assessment based on International Caries Classification and Management System (ICCMS™) guide
62690019|NCT06383013|PLACEBO_COMPARATOR|Placebo Dosing Group|Placebo will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.
62690020|NCT02150863|ACTIVE_COMPARATOR|Ultrapulse laser alone|
62690021|NCT02150863|ACTIVE_COMPARATOR|Ultrapulse laser plus Cellutome Harvesting system|
62690022|NCT02150863|NO_INTERVENTION|Control|
62690023|NCT06429657|EXPERIMENTAL|Ketamine with propofol|Propofol at a rate of 300 mcg/kg/hr (5 mcg/kg/min) with the addition of ketamine at a rate of 1000-5000 mcg/kg/hr (16.67 - 83.33 mcg/kg/min) (using weight at time of admission) with an additional 2 mg/kg (2000 mcg/kg) bolus of ketamine
62690024|NCT06429657|ACTIVE_COMPARATOR|SOC propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam|Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam.
61926512|NCT05926804|NO_INTERVENTION|Controls|70 children with H. pylori-persistent infection, who will not receive eradication therapy
61926513|NCT05926804|NO_INTERVENTION|Non infected Controls|60 adolescents with no H. pylori infection, they will not receive eradication therapy
62321325|NCT05805371|EXPERIMENTAL|Treatment plan II (PSCA CAR T-cells, radiation)|Patients undergo leukapheresis, radiation in 2 doses, and lymphodepletion, and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
62321326|NCT06385262|EXPERIMENTAL|Arm A|Chemotherapy and cemiplimab (PD-1 inhibitor) every 3 weeks for 3 cycles with alirocumab (PCSK9 inhibitor) every 4 weeks prior to surgery
62321327|NCT06385262|EXPERIMENTAL|Arm B|Chemotherapy and cemiplimab (PD-1 inhibitor) every 3 weeks for 3 cycles without alirocumab (PCSK9 inhibitor) prior to surgery
62321328|NCT05922423|EXPERIMENTAL|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
62321329|NCT05922423|PLACEBO_COMPARATOR|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
62321330|NCT02394444|EXPERIMENTAL|Preterm intervention TRT group|"Parents with premature infants received the intervention called Triadic parent-infant's Relationship Therapy (TRT) :~the psychological intervention included home visits twice month during the first four months and then monthly visits in the neonatal ward until the 18 months corrected age resulting in a total of 22 visits during the whole intervention; TRT gave attention to emotional distress and the promotion of parenting skills and attachment security; The three sessions of intervention targeted objectives specific to each child's development; A basic manual was designed to ensure uniformity of the defined themes during each session"
62321331|NCT02394444|NO_INTERVENTION|Preterm control group|Parents with premature infants without intervention program TRT (Triadic parent-infant's Relationship Therapy) received routine follow-up medical care with monthly visits to a practitioner for the first six months and then very three months
62321332|NCT02394444|NO_INTERVENTION|Full-term control group|Parents with full-term infants without intervention program TRT
62321333|NCT06692582|EXPERIMENTAL|EOS|
62321334|NCT06692582|ACTIVE_COMPARATOR|CHX|
62321335|NCT06692582|PLACEBO_COMPARATOR|Placebo - distilled water|
62339779|NCT06014710|EXPERIMENTAL|Experimental arm|Patients with swallowing disorders and healthy volunteers
62690025|NCT04503421|EXPERIMENTAL|BFR|"Patient will use the following rehabilitation protocol while incorporating blood flow restriction therapy:~* Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only~  * Sling immobilization with active wrist and shoulder ROM~ * Active extension of biceps to 30 degrees, No active flexion~* 6-9 weeks full active extension in brace~  * Maintain wrist and shoulder flexibility~ * Begin rotator cuff/deltoid isometrics, progress active extension in brace~* Weeks 9-12: Gently advance ROM to tolerance~  * Discontinue sling~ * Begin active flexion and extension against gravity.~ * Advance strength to light resistance, maintain flexibility/ROM~* Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
62130464|NCT01873326|EXPERIMENTAL|Paclitaxel, Ifosfamide and Cisplatin (TIP)|"Paclitaxel 120 mg/m2 IV over 120-180 min Days 1 and 2 (+/- 4 days)\* Mesna 120 mg/m2 IV (duration of infusion per institutional guidelines) approximately 30 minutes prior to initiation of ifosfamide Days 1-5 (+/- 4 days)\* Ifosfamide 1200 mg/m2 IV over approximately 60 to 120 min Days 1-5 or per institutional guidelines (mixed 1:1 with mesna) (+/- 4 days)\* Mesna\*\* 1200 mg/m2 IV over approximately 60-120 min or per institutional guidelines (mixed 1:1 with ifosfamide)(+/- 4 days)\* Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)\*~\*\*Additional mesna may be given at the discretion of the investigator~\*Paclitaxel or Ifosfamide or Mesna or Cisplatin or any combination of these agents can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
62130465|NCT01873326|ACTIVE_COMPARATOR|Bleomycin, Etoposide and Cisplatin (BEP)|"Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)\* Etoposide 100 mg/m2 IV over approximately 1 hour Days 1-5 (+/- 4 days)\* Bleomycin 30 U flat dose IV push Days 2, 8 and 15 (all +/- 4 days)~\*Etoposide or Cisplatin or both can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
62130466|NCT03628235||Early stage HDGECs|CAG length ≥ 40; DCL = 4, TFC ≥ 11
62130467|NCT03628235||Middle stage HDGECs|CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
62130468|NCT03628235||Late stage HDGECs|CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6
62130469|NCT03628235||Companions of early stage HDGECs|
62130470|NCT03628235||Companions of middle stage HDGECs|
62321336|NCT01996345|EXPERIMENTAL|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
62321337|NCT01996345|NO_INTERVENTION|Expectant Managment|Each participant will have standard care for placenta previa. This is the same care that a patient with a placenta previa would ordinarily receive even if she were not participating in the trial. The trial's participating investigators agree that the management outlined in this section is standard management for placenta previa.
62321338|NCT00863928|NO_INTERVENTION|Control Arm|No suppository given
62321339|NCT00863928|EXPERIMENTAL|B & O suppository|B \& O suppository, belladonna 16.2 mg and opium 60 mg suppository (Paddock Laboratories, Minneapolis, MN)
62481263|NCT03969628|EXPERIMENTAL|Simplified risk assessment group (dental caries experience)|Simplified risk assessment group (dental caries experience): simplified caries risk assessment based on dental caries experience (WHO criteria)
62481264|NCT02748707|EXPERIMENTAL|Arm 1|Celecoxib 200mg twice daily for 21 days
62481265|NCT02748707|EXPERIMENTAL|Arm 2|Erlotinib 150 mg once daily for 21 days
62481266|NCT02748707|EXPERIMENTAL|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
62130471|NCT03628235||Companions of late stage HDGECs|
62321340|NCT06324487|ACTIVE_COMPARATOR|SEP Group|The treatment will be individualized by calculating the appropriate resistance loads for the exercise program. All participants will undergo progressive exercises in sessions conducted by a physiotherapist.
62321341|NCT06324487|EXPERIMENTAL|BFRT Group|People in the BFRT categories will perform the exercise program at approximately 20-30% resistance of 1-RM, and an upper arm reinforcement occlusion cuff will be used during strengthening exercises with dumbbells for the rotator cuff and scapula girdles
62339780|NCT00723073||Caspofungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an Absolute Neutrophil Count (ANC) \< 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.
62339781|NCT00723073||Micafungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an Absolute Neutrophil Count (ANC) \< 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent
62481267|NCT02748707|SHAM_COMPARATOR|Arm 4|Control group with no drug
62130472|NCT00573482|ACTIVE_COMPARATOR|control group|Control (only exposure to the food labels and the new lower ED foods).
62130473|NCT00573482|EXPERIMENTAL|intervention group|Education in REDE techniques plus exposure to the food labels and the new lower ED foods.
62481268|NCT06742502|EXPERIMENTAL|Sintilimab plus rituximab followed by R-CHOP regimen|Participants will first receive sintilimab plus rituximab for 2 cycles, followed by interim PET-CT assessments. If patients achieve CR or CMR, they will continue to receive 2 courses of sintilimab plus rituximab, followed by 4 cycles of R-CHOP. Patients will receive 6 courses of R-CHOP if they do not achieve CR or CMR after 2 cycles of sintilimab plus rituximab. Patients will undergo PET-CT assessment and will receive 6 cycles of maintenance treatment with nintedanib if CR/CMR/PR is achieved and will be withdrawn from the study if SD/PD occurs. Total treatment cycles will not exceed 14 cycles.
62481269|NCT06171386|ACTIVE_COMPARATOR|microneedling|microneedling is a form of collagen induction therapy, often used in conjunction with platelet-rich plasma or hyaluronic acid - Patients will receive two treatments, once at 6-8 weeks following facial surgery, and the second at 12-16 weeks following facial surgery
62481270|NCT06171386|ACTIVE_COMPARATOR|dermabrasion|dermabrasion is a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization - Patients will receive the standard of care treatment 6-10 weeks following facial surgery
62481271|NCT06733701|EXPERIMENTAL|Intervention|During the procedure, patients will receive standard of care analgesia and VR-based intervention (VRReliever Software V0.3.4 fromXRHealth)
62481272|NCT06733701|PLACEBO_COMPARATOR|Control|VR headset without any scenery
62481273|NCT06741748|EXPERIMENTAL|Direct Warming method|The blastocyst designated for thawing will be placed in a pre-warmed, direct warming medium for one minute. Afterward, the embryo is transferred into an embryo culture medium within a time-lapse system, where it remains until the patient is ready for the embryo transfer procedure. This direct warming method significantly reduces the total procedure time to approximately 3 minutes, making it about ten times faster than the conventional multi-step thawing method.
62130474|NCT06145984|OTHER|Mindfulness first intervention, Fantasizing second intervention|Diary measures of thought patterns (experience sampling method \[ESM\]), behavioural measures (using the Sustained Attention to Response Task \[SART\]), actigraphy, (neuro)physiological measures (impedance cardiography \[ICG\], electrocardiography \[ECG\] and electroencephalogram \[EEG\]) and measures of depressive mood (self-report questionnaires) will be performed during the week before (pre-) the interventions and the week during (peri-) performance of the interventions. In-between pre-and peri-intervention measures, there is a one month wash-out period. In this arm mindfulness will be the first performed intervention, fantasizing the second performed intervention. The order of the interventions will be counterbalanced across participants.
61926514|NCT04623775|EXPERIMENTAL|Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))|
61926515|NCT04623775|EXPERIMENTAL|Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))|
62690026|NCT04503421|NO_INTERVENTION|Control (no BFR)|"patients will use following rehabilitation protocol without the use of blood flow restriction therapy:~* Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only~  * Sling immobilization with active wrist and shoulder ROM~ * Active extension of biceps to 30 degrees, No active flexion~* 6-9 weeks full active extension in brace~  * Maintain wrist and shoulder flexibility~ * Begin rotator cuff/deltoid isometrics, progress active extension in brace~* Weeks 9-12: Gently advance ROM to tolerance~  * Discontinue sling~ * Begin active flexion and extension against gravity.~ * Advance strength to light resistance, maintain flexibility/ROM~* Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
62339782|NCT05958095|EXPERIMENTAL|MamaLift Plus|Principles of Cognitive Behavioral Therapy used to treat PPD with App
62339783|NCT05958095|SHAM_COMPARATOR|Digital Sham App|Content on general mental health and wellbeing topics delivered with sham App
61926516|NCT04623775|EXPERIMENTAL|Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)|
61926517|NCT04623775|ACTIVE_COMPARATOR|Part 2: Arm D (Nivolumab + PDCT)|
62481274|NCT06741748|PLACEBO_COMPARATOR|Conventional multi-step thawing method|In the conventional multi-step thawing method, vitrified blastocysts are sequentially thawed using a series of pre-warmed thawing, dilution, and washing solutions. The blastocyst is first placed in a thawing solution for 1-3 minutes, followed by immersion in a dilution solution for 4-6 minutes to reduce cryoprotectant concentration. Finally, the blastocyst is transferred to a washing solution for 5-10 minutes for rehydration. The entire process takes approximately 30 minutes, after which the embryo is placed into an embryo culture medium in a time-lapse system until it is ready for embryo transfer.
62481275|NCT06741722|EXPERIMENTAL|DCMG|Patients are treated with DCMG chemotherapy regimen.
62339784|NCT04729556|EXPERIMENTAL|Sericin and chitosan cream|A flim-forming cream containing sericin and chitosan cream. Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).
61926518|NCT03953183|OTHER|P3P-1mg|Subjects randomized to exclusive use of P3P-1mg
61926519|NCT03953183|OTHER|P3P-2mg|Subjects randomized to exclusive use of P3P-2mg
61926520|NCT02245204|EXPERIMENTAL|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
62130475|NCT06145984|OTHER|Fantasizing first intervention, Mindfulness second intervention|Diary measures of thought patterns (experience sampling method \[ESM\]), behavioural measures (using the Sustained Attention to Response Task \[SART\]), actigraphy, (neuro)physiological measures (impedance cardiography \[ICG\], electrocardiography \[ECG\] and electroencephalogram \[EEG\]) and measures of depressive mood (self-report questionnaires) will be performed during the week before (pre-) the interventions and the week during (peri-) performance of the interventions. In-between pre-and peri-intervention measures, there is a one month wash-out period. In this arm fantasizing will be the first performed intervention, mindfulness the second performed intervention. The order of the interventions will be counterbalanced across participants.
62130476|NCT03285386|EXPERIMENTAL|Priming Exercise|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
62130477|NCT03285386|ACTIVE_COMPARATOR|Control|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling only.
62130478|NCT05984212|EXPERIMENTAL|dexmedetomidine infusion group|
62130479|NCT05984212|PLACEBO_COMPARATOR|normal saline infusion group|
62481276|NCT06145308|EXPERIMENTAL|HER2 expression group|Vedicetumab monotherapy or combination therapy
62481277|NCT06145308|EXPERIMENTAL|NTRK gene fusion or mutant group|NTRK inhibitor therapy
62481278|NCT06145308|EXPERIMENTAL|AR positive group|Antiandrogen therapy
62481279|NCT06145308|EXPERIMENTAL|TROP-2 positive group|Anti-trop-2 therapy
61926521|NCT06146179||Group 1|Group 1: Combined Anterior Suprascapular Nerve Block and Superficial Cervical Plexus Block
61926522|NCT05893979|ACTIVE_COMPARATOR|Test Lens Group|
61926523|NCT05893979|ACTIVE_COMPARATOR|Control Lens Group|
61926524|NCT05022446||Observational (survey)|Participants complete survey over 5-10 minutes.
61926525|NCT05646277||Test|first remote-assisted orthodontic teleconsultation
61926526|NCT05646277||Control|classic first consultation (face-to-face consultation)
61926527|NCT04732156|OTHER|Prospective multicenter cohort|"Constitution of a prospective multicenter cohort of 420 patients with suspected prostate cancer that will undergo prostate multiparametric MRI followed by systematic and targeted biopsy.~When available (i.e., at the end of the RHU PERFUSE program, November 2022), the final version of the CAD will be used retrospectively to assess the risk that the prostate/targeted lesions harbor ISUP ≥2 cancer.~In addition, a blood sample will be taken in all patients before the biopsy to assess the performance of the PHI index in predicting the presence of ISUP ≥2 cancer at systematic and targeted biopsy (ancillary study, secondary objective)."
61926528|NCT02207985|EXPERIMENTAL|Hematopoetic stem cell transplantation|Patients with pancreatic adenocarcinoma that have undergone Whipple surgery and show no sign of disease recurrence can be treated with hematopoietic stem cell transplantation to achieve an immunological anti-tumor effect.
62481280|NCT06145308|EXPERIMENTAL|Adenoid cystadenocarcinoma group（ACCgroup）|Small molecule tyrosine hormone inhibitor therapy
62481281|NCT06145308|EXPERIMENTAL|Albumin-paclitaxe group|Albumin-paclitaxel combined with platinum-based chemotherapy drugs
62481282|NCT06145308|EXPERIMENTAL|HR-positive group|CDK4/6 inhibitors + aromatase inhibitors or Fluvis
61926529|NCT05916950|EXPERIMENTAL|Thor Treatment|Treatment with the Thor system
62130480|NCT00856739||Group 1|
62481283|NCT06145308|EXPERIMENTAL|PI3K mutant group|PI3K inhibitors such as Apelis + Fluvis
62481284|NCT06145308|EXPERIMENTAL|Homologous Recombination repair defect group|Olapalil or Nilapalil or fluzopalil or pamipalil po;
62481285|NCT06145308|EXPERIMENTAL|Nectin-4 ADC group|Veentumab ± immune checkpoint inhibitor ;
62481286|NCT06145308|EXPERIMENTAL|Ivoximab group|Ivoximab+ albumin paclitaxel +Cisplatin
62481287|NCT06145308|EXPERIMENTAL|Apalolito vorellizumab group|Apalolito vorellizumab + Platinum dual drug + bevacizumab
62481288|NCT05312879|EXPERIMENTAL|Phase 2: VX-147|Participants will be randomized to receive different dose levels of VX-147.
62481289|NCT05312879|PLACEBO_COMPARATOR|Phase 2: Placebo|Participants will receive placebo matched to VX-147.
62481290|NCT05312879|EXPERIMENTAL|Phase 3: VX-147|Participants will receive VX-147 with the dose to be based on the outcome of Phase 2.
62481291|NCT05312879|PLACEBO_COMPARATOR|Phase 3: Placebo|Participants will receive placebo matched to VX-147.
62481292|NCT04777084|EXPERIMENTAL|Cohort A|Cohort A is evaluating the efficacy and safety of IBI318 in combined with lenvatinib in advanced NSCLC patients who had failed first-line PD-1/PD-L1 inhibitor therapy.
62130481|NCT03068624|EXPERIMENTAL|Treatment (cyclophosphamide, T-cells, aldesleukin, ipilimumab)|"PREPARATIVE REGIMEN: Patients receive cyclophosphamide IV over 30-60 minutes on day -2.~T-CELL INFUSION: Patients receive autologous CD8+ SLC45A2-specific T lymphocytes via hepatic arterial infusion via central catheter over 60 minutes on day 0. Within 6 hours of T-cell infusion, patients also receive aldesleukin BID SC for 14 days in the absence of disease progression or unacceptable toxicity.~POST T-CELL INFUSION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity."
62481293|NCT04777084|EXPERIMENTAL|Cohort B|Cohort B is the efficacy and safety of advanced NSCLC with EGFR-sensitive mutation /ALK fusion after EGFR-TKI /ALK-TKI treatment resistance.
62481294|NCT04777084|EXPERIMENTAL|Cohort C|Cohort C is the efficacy and safety of first-line treatment of advanced NSCLC with negative PD-L1 expression and EGFR, ALK, and ROS1 wild-type.
62130482|NCT01872078|EXPERIMENTAL|AZD4901 20 mg once a day|AZD4901 20 mg once a day
62130483|NCT01872078|EXPERIMENTAL|AZD4901 20mg twice a day|AZD4901 20mg twice a day
62130484|NCT01872078|EXPERIMENTAL|AZD4901 40 mg twice a day|AZD4901 40 mg twice a day
62130485|NCT01872078|EXPERIMENTAL|Placebo to match AZD4901|
62321342|NCT03234868|EXPERIMENTAL|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
62130486|NCT01449617||Aspirin plus clopidogrel|Patients undergoing stenting for critical carotid stenosis, either symptomatic (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.
62130487|NCT00205179|EXPERIMENTAL|Novasoy treated|100mg/day soy isoflavones
62130488|NCT00205179|PLACEBO_COMPARATOR|Placebo|100mg/day matching placebo
62321343|NCT03234868|ACTIVE_COMPARATOR|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
62481295|NCT05332756||Moyamoya disease patients|
62481296|NCT05332756||First-degree relatives of patients with Moyamoya Disease|
62481297|NCT04576117|ACTIVE_COMPARATOR|Efficacy Phase Arm II (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
62690027|NCT02854267||group without guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all registered situations of brain death patients on the database (nationwide) minus the situations occuring in the group with guide (22 intensive care units forming the 'RESEAU NORD FRANCILIEN' network). The period before the diffusion of the guide is from 1st of july 2012 to 30th of june 2014
62690028|NCT02854267||group without guide, after guide's diffusion|For this group, only the primary objective (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all the registered situations of brain death patients on the database minus the situations occuring in the group with guide ('RESEAU NORD FRANCILIEN'). The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
61926530|NCT05219123||No PD cannulation|Patients with native papilla undergoing ERCP for biliary indications with no inadvertent pancreatic duct cannulation
61926531|NCT05219123||Single PD cannulation|Patients with native papilla undergoing ERCP for biliary indications with a single inadvertent pancreatic duct cannulation with a guide wire
62481298|NCT04576117|EXPERIMENTAL|Feasibility & Efficacy Phase Arm I (selumetinib, vinblastine)|Patients receive vinblastine sulfate IV over 1 minute or IV infusion on days 1, 8, 15, and 22 and selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days. Patients receive selumetinib and vinblastine for a total duration of 17 cycles followed by 10 additional cycles of selumetinib alone in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
62481299|NCT05655078|NO_INTERVENTION|Standard of care|MPM participants who are on the standard of care watch and wait approach i.e. immediate treatment not suitable. Participants will have follow-up for 2 years (3 monthly in year 1, 4 monthly in year 2).
62130489|NCT03052335|EXPERIMENTAL|Pillcam® COLON 2 Capsule and colonoscopy|Persons with positive immunochemical fecal occult blood tests will be examined by second generation colon capsule endoscopy (CCE2) and optical colonoscopy afterwards.
62321344|NCT03234868|EXPERIMENTAL|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine \& MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled \& sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
62321345|NCT03234868|ACTIVE_COMPARATOR|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine \& MAZAK CNC machine:~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
62321346|NCT05552586|ACTIVE_COMPARATOR|Melatonin group|Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
62321347|NCT05552586|PLACEBO_COMPARATOR|Control group|Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.
62321348|NCT03348657|OTHER|Music intervention Group|Patients who participated to at least one music session provided by volunteers while being admitted to the geriatric assessment unit. Participation to the music sessions was voluntary.
62321349|NCT03348657|NO_INTERVENTION|Control Group|Patients who did not want to participate to the music sessions provided by volunteers while being admitted to the geriatric assessment unit
62321350|NCT00002706|EXPERIMENTAL|Arm I|Patients undergo vaginal hysterectomy and BSO via laparoscopy.
62321351|NCT00002706|ACTIVE_COMPARATOR|Arm II|Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
62321352|NCT05614674||Healthy group|People who don't suffer from low back pain
62321353|NCT05614674||People with low back pain|People who are suffering from low back pain. The pain level has to be at least 3 out of 10 according to Visual Analog Scale (VAS) to be in this group.
62321354|NCT04338945||Residents in surgical areas|
62321355|NCT03157635|EXPERIMENTAL|Part 1 (Healthy Volunteers): Crovalimab|Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg) intravenous (IV) infusion. Doses are planned to be escalated up to Cohort 5.
62481300|NCT05655078|EXPERIMENTAL|Proton beam therapy|MPM participants to receive 5 weeks of proton beam therapy to the hemithorax. Following completion of treatment participants will have follow-up at the referring centre for 2 years (3 monthly in year 1, 4 monthly in year 2).
62130490|NCT03692780|EXPERIMENTAL|Careseng 1370|
62130491|NCT03692780|PLACEBO_COMPARATOR|Matched Placebo|
62690029|NCT02854267||Group with guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018.
61926532|NCT06139692|EXPERIMENTAL|the dexmedetomidine group|In the experimental group, dexmedetomidine is used for intraoperative sedation. Dexmedetomidine is prepared as an 8μg/ml intravenous infusion. It begins with an initial loading dose of 1μg/kg, administered over a period exceeding 10 minutes.If dexmedetomidine fails to achieve a satisfactory level of sedation during surgery, physicians may opt for rescue sedation with propofol or consider transferring the patient to general anesthesia. Propofol (20ml 0.2g) starts with a loading dose of 0.3mg/(kg\*h) and a maintenance dose of 0.3-4mg/(kg\*h). The infusion rate can be adjusted based on the sedation effect to achieve the appropriate level of sedation during EVT.
62321356|NCT03157635|PLACEBO_COMPARATOR|Part 1 (Healthy Volunteers): Placebo|Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
62321357|NCT03157635|EXPERIMENTAL|Part 2 (PNH Participants): Crovalimab|PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg IV of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
62321358|NCT03157635|EXPERIMENTAL|Part 3 (PNH Participants): Crovalimab QW|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg weekly (QW) starting on Day 8 for a maximum treatment duration of 5 months.
62321359|NCT03157635|EXPERIMENTAL|Part 3 (PNH Participants): Crovalimab Q2W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg every 2 weeks (Q2W) for a maximum treatment duration of 5 months.
62321360|NCT03157635|EXPERIMENTAL|Part 3 (PNH Participants): Crovalimab Q4W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg every 4 weeks (Q4W) starting on Day 8 for a maximum treatment duration of 5 months.
62130492|NCT04045782|OTHER|single arm|Adult patients (≥ 18 years of age) with Ulcerative Colitis or Crohn's Disease on maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
62321361|NCT03157635|EXPERIMENTAL|Part 4 (eculizumab pretreated PNH Participants): Crovalimab|"PNH Participants pretreated with eculizumab will receive crovalimab:~Participants \>/= 100 kilograms (kg): loading dose of 1500 mg IV on Day 1; Participants \< 100 kg: loading dose of 1000 mg IV on Day 1. In all Participants, the remainder of the loading series schedule will be 340 mg subcutaneous (SC) on Days 2, 8, 15, and 22. For Participants \>/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients \< 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
62690030|NCT02854267||Group with guide, after guide's diffusion|For this group, the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database. The secondary endpoints (level of anxiety of the caregivers before the meeting with the next of kins as measured by the french short version of Spielberger test and compliance to the guide) will be assessed by the datasheet prospectively filled by the caregivers. The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
61926533|NCT06139692|ACTIVE_COMPARATOR|the midazolam group|In the control group, midazolam is used for intraoperative sedation. Midazolam is prepared as a 1mg/ml intravenous infusion. It starts with an initial intravenous push of 0.05mg/kg, followed by a maintenance dose of 0.04-0.2mg/kg administered intravenously via an infusion pump. If midazolam fails to achieve a satisfactory level of sedation during surgery, physicians may opt for rescue sedation with propofol or consider transferring the patient to general anesthesia. Propofol (20ml 0.2g) starts with a loading dose of 0.3mg/(kg\*h) and a maintenance dose of 0.3-4mg/(kg\*h). The infusion rate can be adjusted based on the sedation effect to achieve the appropriate level of sedation during EVT.
62321362|NCT03157635|EXPERIMENTAL|Part 4 (treatment naïve PNH Participants): Crovalimab|"Treatment naïve PNH Participants will receive:~Participants \>/= 100 kg: loading dose of 1500 mg IV on day 1; Participants \< 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants \>/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients \< 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
62321363|NCT03157635|EXPERIMENTAL|OLE (PNH Participants): Crovalimab|PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight \>/= 40 kg to \< 100 kg) or 1020 mg SC Q4W (body weight \>/= 100 kg) for up to a maximum treatment duration of ten years from entry into OLE.
61926534|NCT03972930|EXPERIMENTAL|Hypofractionated Radiotherapy for Soft Tissue Sarcoma|Participants will be treated with 3-8 fractions, with the maximum prescribed dose to the Planning Tumor Volume (PTV) volume being 60 Gy delivered over a period of at most 8 weeks.
61926535|NCT03643744|ACTIVE_COMPARATOR|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
61926536|NCT03643744|PLACEBO_COMPARATOR|PDT + Placebo|Patient receiving PDT taking placebo.
61926537|NCT03643744|ACTIVE_COMPARATOR|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
62321364|NCT05971290|EXPERIMENTAL|Continuous Positive Airway Pressure use|
62321365|NCT05971290|SHAM_COMPARATOR|Ambient air|
62321366|NCT03440372|EXPERIMENTAL|Administration of oral Ozanimod|
62321367|NCT03440372|PLACEBO_COMPARATOR|Administration of Placebo|
62321368|NCT05684978|EXPERIMENTAL|Single arm prospective study|"* Adults patients equal or greater than 18 years~* Patients in RSE that require IV anesthetic infusions. Note: RSE is defined as status epilepticus that fails to terminate after an adequate dose of benzodiazepines (1st line agents) and an AED (2nd line agent). Adequate doses have been defined in the screening (below).~* Patients taking oral contraception who will be on the study long term should be informed about additional alternative methods of contraception."
61926538|NCT03643744|PLACEBO_COMPARATOR|Control + Placebo|Control subject not receiving PDT taking placebo.
61926539|NCT00737464|EXPERIMENTAL|Mircera|Participant with chronic renal anemia will receive methoxy polyethylene glycol-epoetin beta \[Mircera\] intravenously (IV) \[(120, 200 or 360 micrograms (mcg)\] every 4 weeks for 12 weeks.
61926540|NCT01819376|EXPERIMENTAL|Intervention: Facebook updates|The experimental group will be encouraged to update their Facebook status regarding healthy lifestyle decisions at least once a day.
61926541|NCT01819376|NO_INTERVENTION|Control: No Facebook|This group will be encouraged not to share their healthy lifestyle decisions on Facebook.
61926542|NCT02531100|EXPERIMENTAL|BonyPid-500TM implantation|Standard of care (SOC) treatment (Manual and ultrasonic debridement and surface decontamination) followed by BonyPid-500TM implantation.
62321369|NCT05646797|EXPERIMENTAL|ASP2074 Dose Escalation (Part 1)|Participants will be assigned to sequentially or in parallel escalating dose/regimen cohorts of ASP2074 in three parts (Part A, B and C). Part B and Part C will be opened sequentially based upon sponsor review of emerging data.
62321370|NCT05646797|EXPERIMENTAL|ASP2074 Dose Expansion (Part 2) Colorectal Adenocarcinoma|Participants will receive ASP2074 with dose/regimen selected from dose escalation (Part 1).
62321371|NCT05646797|EXPERIMENTAL|ASP2074 Dose Expansion (Part 2) Esophageal or GEJ Adenocarcinoma|Participants will receive ASP2074 with dose/regimen selected from dose escalation (Part 1).
62321372|NCT05646797|EXPERIMENTAL|ASP2074 Dose Expansion (Part 2) Pancreatic Adenocarcinoma|Participants will receive ASP2074 with dose/regimen selected from dose escalation (Part 1).
62321373|NCT03015350||two lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
62690031|NCT00888771||1|
62690032|NCT00888771||2|
62690033|NCT00888771||3|
62690034|NCT00888771||4|
62690035|NCT03968406|EXPERIMENTAL|Treatment (talazoparib, radiation therapy)|Patients receive talazoparib PO QD beginning on days -10 to -7 and continuing for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy 5 days a week (Monday-Friday) for up to 7 weeks.
61926543|NCT02531100|OTHER|SOC treatment|Standard of care treatment (Manual and ultrasonic debridement and surface decontamination) only
61926544|NCT02369406|EXPERIMENTAL|Antepartum Cohort|"40 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART \< 7 days after birth. This cohort will include at least 15 children who start ART \< 3 days after birth.~All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine."
62130493|NCT02711865||MK-0646|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
62481301|NCT06558916|EXPERIMENTAL|Dexketoprofen trometamol|The study drugs were administered to patients suspected of having renal colic in random order: dexketoprofen trometamol IV 50 mg (ampoule containing Dexalgin 50 mg injectable solution) was prepared as a 250 mL solution in standard saline, with the same appearance. The drugs were given as a single dose over 15 minutes.
62481302|NCT06558916|EXPERIMENTAL|Meperidine|The study drugs were administered to patients suspected of having renal colic in random order: meperidine IV 50 mg (Aldolan 100 mg ampoule) was prepared as a 250 mL solution in standard saline, with the same appearance. The drugs were given as a single dose over 15 minutes.
62481303|NCT06558916|EXPERIMENTAL|Paracetamol|The study drugs were administered to patients suspected of having renal colic in random order: paracetamol IV 1000 mg (Perfalgan 10 mg/mL infusion solution) was prepared as a 250 mL solution in standard saline, with the same appearance.The drugs were given as a single dose over 15 minutes.
62690036|NCT01892189|EXPERIMENTAL|Sequence 1: Placebo + TAK-063 3 mg + TAK-063 30 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 milligram (mg), orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period."
62690037|NCT01892189|EXPERIMENTAL|Sequence 2: TAK-063 3 mg + TAK-063 30 mg + Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period."
61926545|NCT02369406|EXPERIMENTAL|Peripartum Cohort|"10 children who test HIV-negative within 96 hours after birth but test HIV-positive \<57 days after birth (peripartum HIV infection) and who are able to initiate ART \<57 days after birth. This cohort will include at least 10 children who start ART \< 21 days after birth.~The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine."
61926546|NCT02369406|NO_INTERVENTION|Control Cohort|25 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.
61926547|NCT01871857|ACTIVE_COMPARATOR|Normal saline and epinephrine|0.9 % saline with 0.5 ml of 1:1000 epinephrine inhalation
61926548|NCT01871857|EXPERIMENTAL|Hypertonic saline and epinephrine|3 ml 7% saline with 0.5 ml of 1:1000 epinephrine inhalation
61926549|NCT06143111|ACTIVE_COMPARATOR|Flotrac Group|In this group,an arterial catheter was inserted preoperatively. An indwelling radial artery catheter was connected to the hemodynamic monitoring system (EV1000; Edward Lifesciences Corp., Irvine, CA, USA) via FloTrac™ (Edwards Lifesciences Corp.) sensors.
61926550|NCT06143111|EXPERIMENTAL|BioZ Group|In this group,haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™) monitoring.
62130494|NCT02711865||Control|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
62130495|NCT01125124|ACTIVE_COMPARATOR|Silver Nitrate 1|Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
62130496|NCT01125124|EXPERIMENTAL|Silver Nitrate 2|Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
62130497|NCT01125124|EXPERIMENTAL|Silver Nitrate 3|Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
62130498|NCT05079126|EXPERIMENTAL|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC.
62130499|NCT05079126|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single IV bolus dose of 7 mL Normal Saline.
61926551|NCT00649415|ACTIVE_COMPARATOR|Arm 1|
61926552|NCT00649415|ACTIVE_COMPARATOR|Arm 2|
62130500|NCT05877807||Experimental : BACLOFEN|Patient will receive baclofen caps
62130501|NCT05877807||Placebo Comparator : PLACEBO|Patient will receive placebo caps (lactose)
62130502|NCT03918967|EXPERIMENTAL|CT-G11|CT-G11 Experimental Drug
62130503|NCT03918967|EXPERIMENTAL|CT-G20|CT-G20 Experimental Drug
62130504|NCT03918967|PLACEBO_COMPARATOR|CT-G11 Placebo|
62130505|NCT03918967|PLACEBO_COMPARATOR|CT-G20 Placebo|
62481304|NCT06377566|EXPERIMENTAL|BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine)|All patients will receive 2 cycles of brentuximab vedotin (BV) in combination with AVD chemotherapy (doxorubicin, vinblastine, dacarbazine). Prophylactic growth factor support will be mandated with each cycle. After 2 cycles of therapy, patients will undergo FDG-PET/CT scan (PET2). Patients with disease progression (Deauville 4 or 5) will be taken off study. Patients who achieve a PETnegative scan (Deauville score of ≤ 3) will receive 2 additional cycles of BV-AVD with no further therapy. In those with partial response or stable disease (Deauville score of 4 or 5), patients will be stratified by baseline metabolic tumor volume (bMTV) as bMTV-high (\> 150 cm3 ) or bMTV-low (≤ 150 cm3 ) as measured on pre-treatment FDG-PET/CT. In the bMTV-low group, patients will receive an additional 2 cycles of BV-AVD in combination with radiation therapy.
62481305|NCT03913377|EXPERIMENTAL|Observational|Eligible subjects that are habitual spectacle wearers will use their habitual optical correction and undergo ocular evaluations and questionnaires at the baseline and 1-week visit.
62481306|NCT03913377|EXPERIMENTAL|Interventional|Eligible subjects that are habitual contact lens wearers who own spectacles will be randomized into 1 of 2 sequences (Spectacle/ACUVUE OASYS 1-Day or ACUVUE OASYS 1-Day/Spectacle)
62481307|NCT06073951|EXPERIMENTAL|Arm I (Mates in Motion)|Dyads participate in the Mates in Motion program consisting of weekly sessions to train couples in the use of communal coping strategies to support one another in achieving PA goals and skill building focus on instruction and practice in effective communication, with emphases on adaptive speaking, responsive listening, and joint decision-making and problem-solving around PA over 8 weeks. Patient-partner dyads receive weekly step-count goals, complete walk-tests and questionnaires and wear an Actigraph device and Garmin activity tracker on study.
62481308|NCT06073951|ACTIVE_COMPARATOR|Arm II (usual care)|Patient-partner dyads wear an Actigraph device, compete walk-tests and questionnaires on study. Dyads receive usual care on study. Dyads receive a Garmin activity tracker at the end of the study.
62481309|NCT02710370||Controls|Patients who meet criteria for gastric bypass surgery, and do not have a documented history of Type 1 or Type 2 Diabetes.
62481310|NCT02710370||Participants with Type 2 Diabetes|Patients who meet criteria for gastric bypass surgery, and have a documented history of Type 2 Diabetes.
62690038|NCT01892189|EXPERIMENTAL|Sequence 3: TAK-063 30 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period."
62130506|NCT05443685|EXPERIMENTAL|ADX-629 treatment|Open label treatment with ADX-629
62130507|NCT05894252|EXPERIMENTAL|Experimental walking group|Participants in the intervention group will need to engage in a 30-minute walk on five days every week for a duration of 12 weeks. To assist them in monitoring their activity and complying with the intervention guidelines, participants will receive a complimentary fitness watch. Weekly step counts will be collected from participants, who will report their data through a researcher-provided online link. The watch will come with an accompanying app for participants to access their data, but the researchers will not have access to this app.
62321374|NCT03015350||one lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
62481311|NCT01728181|EXPERIMENTAL|Phase I|Will receive Tivozanib and Erlotinib treatment.
62481312|NCT01728181|OTHER|Phase II Group 1 (Standard of Care)|"Group 1: VeriStrat® predicts the chance of no benefit from erlotinib~• The patient will get standard-of- care"
62481313|NCT01728181|ACTIVE_COMPARATOR|Phase II Group 2 (arm 1)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 1: Patient will get the study drugs Erlotinib and Tivozanib"
62690039|NCT01892189|EXPERIMENTAL|Sequence 4: Placebo + TAK-063 3 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period."
62690040|NCT01892189|EXPERIMENTAL|Sequence 5: TAK-063 3 mg + TAK-063 300 mg+ Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period"
62321375|NCT03015350||two lung ventilation of Desflurane|In GroupSa, 6 % desflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
62321376|NCT03015350||one lung ventilation of desflurane|In GroupSa, 6 % desflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
62321377|NCT03997422|EXPERIMENTAL|Vertical Sleeve Gastrectomy (VSG)|Bariatric surgical procedure
62481314|NCT01728181|PLACEBO_COMPARATOR|Phase II Group 2 (arm 2)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 2: Patient will get the study drug erlotinib and placebo"
62481315|NCT06741657|EXPERIMENTAL|Part 1: AI versus PFS|Participants will receive SC dose of litifilimab injection via AI or PFS on Day 1 of the study.
62481316|NCT06741657|EXPERIMENTAL|Part 2: OBI versus PFS|Participants will receive SC dose of litifilimab injection via OBI or PFS on Day 1 of the study.
61926553|NCT06526195|EXPERIMENTAL|Randomized Arm - HM3 Group|Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization.
61926554|NCT06526195|EXPERIMENTAL|Randomized Arm - Control Group|Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines.
61926555|NCT06526195|EXPERIMENTAL|Single Arm Registry|Patients who do not meet the mean PAP threshold (mean PAP \<30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines.
61926556|NCT02309866||Genetic Testing|All participants determined eligible for the study will be placed into genetic testing arm.
61926557|NCT06556563|EXPERIMENTAL|Treatment Group|
61926558|NCT06556563|PLACEBO_COMPARATOR|Control Group|
61926559|NCT03522025|ACTIVE_COMPARATOR|GMK-UNI cemented fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
61926560|NCT03522025|EXPERIMENTAL|GMK-UNI cementless fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
61926561|NCT05603663|EXPERIMENTAL|Intervention arm|Young (25-44 years) overweight adults with high (top 20%) CVD PRS. The participants will be informed about their high PRS at the start of the study, calculated the overall CVD risk, and provided counseling and treatment of hypertension and/or high cholesterol if appropriate.
61926562|NCT05603663|NO_INTERVENTION|Control group #1|Young (25-44 years) overweight adults with high (top 20%) CVD PRS. The participants will be informed about the overall CVD risk and provided counseling and treatment of hypertension and/or high cholesterol if appropriate. The participants will be informed about their high PRS only at the end of the study.
61926563|NCT05603663|NO_INTERVENTION|Control group #2|Young (25-44 years) overweight adults with low (bottom 20%) CVD PRS. The participants will be informed about the overall CVD risk and provided counseling and treatment of hypertension and/or high cholesterol if appropriate. The participants will be informed about their low PRS only at the end of the study.
61926564|NCT03282851|EXPERIMENTAL|MSB11456|
62130508|NCT05894252|NO_INTERVENTION|Control|In the control group, participants will not be required to complete the 30 minutes of walking every day. Instead, they will be asked to continue with their daily routines and usual level of physical activity. participants will receive a complimentary fitness watch. Weekly step counts will be collected from participants, who will report their data through a researcher-provided online link. The watch will come with an accompanying app for participants to access their data, but the researchers will not have access to this app.
62321378|NCT01670630|ACTIVE_COMPARATOR|Sheathed speculum|"Investigators will perform a vaginal speculum examination with either a sheathed or a standard (non sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception."
62321379|NCT01670630|ACTIVE_COMPARATOR|Standard speculum examination|Investigators will perform a vaginal speculum examination with either a standard or a sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception.
62321380|NCT01005472|EXPERIMENTAL|sunitinib malate, temozolomide|
62321381|NCT04330235||Intervention Group|Children 2-10 years of age dining at fast-food restaurants in New York City and Philadelphia, where a healthy default beverage policy will be enacted.
62481317|NCT05866588|EXPERIMENTAL|experimental group|Participants in the experimental group will receive training and counseling consisting of a total of 8 modules from the 28th week of pregnancy to the fourth month of the postpartum period.
62481318|NCT05866588|NO_INTERVENTION|Control group|No educational counseling will be applied to the women in the control group. These participants will receive routine antenatal, natal and postnatal care
62690041|NCT01892189|EXPERIMENTAL|Sequence 6: TAK-063 300 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period."
62481319|NCT06012812|EXPERIMENTAL|SHR-1819 injection|
61926565|NCT03282851|ACTIVE_COMPARATOR|US-licensed Actemra|
61926566|NCT03282851|ACTIVE_COMPARATOR|EU-approved RoActemra|
61926567|NCT04509765|EXPERIMENTAL|Patients with Hematologic Malgnancies|
61926568|NCT03265327|EXPERIMENTAL|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
61926569|NCT03265327|PLACEBO_COMPARATOR|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
61926570|NCT03583515|EXPERIMENTAL|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
61926571|NCT03583515|PLACEBO_COMPARATOR|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
62130509|NCT00632749|EXPERIMENTAL|Schedule A|BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
62130510|NCT00632749|EXPERIMENTAL|Schedule B|BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
62321382|NCT04330235||Control Group|Children 2-10 years of age dining at fast-food restaurants in northern New Jersey, where a healthy default beverage policy will not be enacted.
62321383|NCT05634590|EXPERIMENTAL|Fruquintinib plus FOLFIRI/FOLFOX|Patients will receive fruquintinib plus FOLFIRI/FOLFOX. Oxaliplatin-based or irinotecan-based chemotherapy depending on previous chemotherapy (chemotherapy switch).
62481320|NCT04456972|EXPERIMENTAL|One arm only|
62481321|NCT05457413||Sleeve gastrectomy|Sleeve gastrectomy for weight loss
62481322|NCT06742541|EXPERIMENTAL|Patients with high compound hyperopic astigmatism|eyes with ≥3.50 D hyperopia and ≥2.00 D of astigmatism undergoing planned surgery receiving a spherical Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
62481323|NCT04230681|ACTIVE_COMPARATOR|Fentanyl|
62481324|NCT04230681|ACTIVE_COMPARATOR|Hydromorphone|
62481325|NCT04250545|EXPERIMENTAL|Treatment (CB-839 HCl, sapanisertib)|Patients receive glutaminase inhibitor CB-839 hydrochloride PO BID and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62481326|NCT06527404|EXPERIMENTAL|Arm A: Blinded Treatment|Participants will receive rocatinlimab dose 1 subcutaneously (SC) during Treatment Period A and B.
62481327|NCT06527404|EXPERIMENTAL|Arm B: Blinded Treatment|Participants will receive rocatinlimab dose 2 SC during Treatment Period A and B.
62481328|NCT06527404|EXPERIMENTAL|Arm C: Blinded Treatment|Participants will receive matching placebo SC during Treatment Period A and B.
62481329|NCT06527404|EXPERIMENTAL|Arm D: Open-label|Participants will receive open-label rocatinlimab dose 1 SC during Treatment Period B.
62481330|NCT05932563||The HPV vaccine group|"For retrospective cohort population: This study will be based on the database with HPV typing results before HPV vaccination, and the epidemiological characteristics such as adverse reaction symptoms after HPV vaccination in this population will be followed up by telephone or face-to-face, and 1 cervical exfoliated cell and 1 peripheral blood tube will be collected within 1-12 months after HPV vaccination.~For the prospective cohort:~All subjects will be enrolled at the time of the first dose of HPV vaccine, followed up 30-60 days after the last dose of HPV vaccine and 12 months after the last dose of HPV vaccine. One cervical exfoliated cell was collected at enrollment and two follow-up visits, and one peripheral blood tube was collected at 30-60 days follow-up after the last dose of HPV vaccine."
62481331|NCT05932563||Unvaccinated HPV group|Exfoliated cervical cells were collected to test for HPV genotyping, or HPV genotyping results had been available for nearly 1 year prior to enrollment
62481332|NCT01310998|EXPERIMENTAL|schizophrenic disorder|
62481333|NCT01310998|EXPERIMENTAL|other psychotic disorder|
62481334|NCT01310998|EXPERIMENTAL|no mental disorder|
62481335|NCT04972565|EXPERIMENTAL|Usual Care plus Inspiratory Muscle Training (IMT)|"Participants will attend the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network. The program consists of i) an individualized home-based rehabilitation and exercise program (twelve weeks of aerobic, neuromotor, and resistance-based exercises), ii) a self-management education intervention, and iii) a community resource engagement plan. Furthermore, patients attend four on-site sessions (a baseline assessment and three follow-up visits).~Participants in this group will also be provided with a personalized prescription for an IMT program for eight weeks to be performed in the home environment (two daily IMT sessions of 30 breaths, five days per week). Participants will be virtually supervised by the study team weekly with any adverse events closely monitored. Participants will receive instructions and feedback on how to optimize their home training efforts with direct observation of their IMT practice."
62481336|NCT04972565|NO_INTERVENTION|Usual Care|Participants will participate in the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network.
62481337|NCT06742684|NO_INTERVENTION|Only PCI|Patients only will receive a PCI according to standard of care
62481338|NCT06742684|EXPERIMENTAL|PCI with following SSO2 Therapy|Patient receive a PCI according to standard of care. Additionally patients in this arm will be treated right after the PCI with the SSO2 Therapy
62481339|NCT06743022|EXPERIMENTAL|Patients with interstitial lung disease|
62481340|NCT00106223|EXPERIMENTAL|1|Group receiving immediate treatment with cognitive behavioral therapy
62481341|NCT00106223|ACTIVE_COMPARATOR|2|Waitlist control group to begin CBT 3 months after other CBT group begins treatment
62481342|NCT03710629||NSCLC patients with driver genes|NSCLC patients and driver genes
62481343|NCT06741774|EXPERIMENTAL|combined phacoemulsification and implantation of Trabecular Meshwork Microstent Drainage System|Eyes with OAG and cataracts randomly divided into test group that were planned for combined phacoemulsification and implantation of Trabecular Meshwork Microstent Drainage System.
62481344|NCT06741774|ACTIVE_COMPARATOR|phacoemulsification|Eyes with OAG and cataracts randomly divided into control group that were planned for phacoemulsification alone.
62481345|NCT06670963|EXPERIMENTAL|Epoetin alfa +/- ferric derisomaltose|Epoetin alfa 50 units/kg IV 3 times weekly and ferric derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg
62130511|NCT02769819|EXPERIMENTAL|Intubation with a flexible fiberscope|Following induction of general anesthesia and administration of a neuromuscular blocking agent, intubation will be performed using a flexible fiberscope.
62130512|NCT06267690||high fibrosis group|No intervention had been adminstered during treatment of patients.
62321384|NCT00536731|ACTIVE_COMPARATOR|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
62481346|NCT06670963|PLACEBO_COMPARATOR|Placebo|0.9% NaCl
62130513|NCT06267690||low fibrosis group|No intervention had been adminstered during treatment of patients.
62321385|NCT00536731|ACTIVE_COMPARATOR|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
62321386|NCT00536731|ACTIVE_COMPARATOR|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
62321387|NCT04814355|EXPERIMENTAL|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
62481347|NCT04814160|ACTIVE_COMPARATOR|autogenous bone graft|autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
62481348|NCT04814160|EXPERIMENTAL|mix of bioactive glass and autogenous bone graft|1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
62481349|NCT06159673|EXPERIMENTAL|ACP-204 30 mg|Administration once daily at approximately the same time of day, with or without food
62481350|NCT06159673|EXPERIMENTAL|ACP-204 60 mg|Administration once daily at approximately the same time of day, with or without food
62481351|NCT06159673|PLACEBO_COMPARATOR|Placebo|Administration once daily at approximately the same time of day, with or without food
62481352|NCT06743204|EXPERIMENTAL|IN-STEP Intervention|
62481353|NCT06743204|ACTIVE_COMPARATOR|Standard-of-Care|
62130514|NCT01955226|EXPERIMENTAL|Tegaderm CHG clear dressing|Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
62130515|NCT01955226|ACTIVE_COMPARATOR|Standard clear Tegaderm dressing|Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
62130516|NCT01596933|EXPERIMENTAL|omega-3 fatty acid supplementation|omega-3 fatty acid supplementation (echium oil)
62321388|NCT00502905|EXPERIMENTAL|Busulfan + Fludarabine|Once a day for four days, Busulfan 130 mg/m\^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m\^2 over 1 hour.
62321389|NCT03338387|EXPERIMENTAL|Acipimox|Other Names: Olbetam
62321390|NCT03338387|PLACEBO_COMPARATOR|Placebo|"Other Names:~Placebo (for Olbetam)"
62321391|NCT04018014||< 30 kg/m2|patients with BMI \< 30/kg/m2
62481354|NCT06046053|EXPERIMENTAL|Placebo Vaginal Film with Square Corners|"A single 2 x 2 placebo vaginal film with square corners, inserted intravaginally once monthly for two months."
62481355|NCT06046053|EXPERIMENTAL|Placebo Vaginal Film with Rounded Corners|"A single 2 x 2 placebo vaginal film with rounded corners, inserted intravaginally once monthly for two months"
62481356|NCT02998229|EXPERIMENTAL|Artisse™ Intrasaccular Device|Study subjects with an unruptured or ruptured wide-neck bifurcating intracranial aneurysm will be treated by endovascular implantation of the Artisse™ Intrasaccular Device.
62321392|NCT04018014||>30 kg/m2|patients with BMI \> 30 kg/m2
62321393|NCT00233220|EXPERIMENTAL|1|Patients and doctors will take part in a multicomponent, multi-level intervention.
62321394|NCT00233220|ACTIVE_COMPARATOR|2|Patients will receive usual care.
62321395|NCT01806870|EXPERIMENTAL|Nutritional Supplements Zinc and SAMe|Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
62321396|NCT05910736|EXPERIMENTAL|Medicare AWV Toolkit|Practice-tailored intervention combining EHR tools with practice redesign workflows and templates for completing AWVs
62481357|NCT05254002|EXPERIMENTAL|Finerenone and Empagliflozin|Participants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days.
62481358|NCT05254002|EXPERIMENTAL|Finerenone and Empagliflozin placebo|Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days.
62481359|NCT05254002|EXPERIMENTAL|Empagliflozin and Finerenone placebo|Participants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days.
62130517|NCT01596933|PLACEBO_COMPARATOR|standard nutritional support|sunflower oil supplementation
62130518|NCT05235178||Study group|Due to catastrophic bleeding events in patients who are anticoagulated with FXa inhibitors undergoing emergency surgery on the proximal aorta and lack of antidote (not available in Norway and most likely not compatible with heparin), the department has decided to use hemadsorber in these cases.
62321397|NCT02184416||Observational Arm|"Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be:~* Sutent (prospective) - Inlyta~* Sutent (retrospective) - Inlyta~* Sutent - not further active treatment (supportive care)~* Sutent - other second line treatment (Nexavar (sorafenib), Votrient (pazopanib), Afinitor (everolimus), Torisel (temsirolimus), other))"
62130519|NCT02318901|EXPERIMENTAL|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
62130520|NCT02318901|EXPERIMENTAL|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
62321398|NCT01097330|ACTIVE_COMPARATOR|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia
62321399|NCT01097330|ACTIVE_COMPARATOR|Amiodarone|amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.
62321400|NCT01350778||Biomatrix stent|patients treated with Biomatrix stent
62321401|NCT00959296||Patients with a device implant|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
62321402|NCT03218852|EXPERIMENTAL|prednisone and cyclophosphamide|"1. prednisone(0.5mg/kg/day\*6 months)~2. cyclophosphamide(1g intravenous use,per 1 month\*6months);~3. supportive care,including ACE-I or ARBs and blood pressure control"
62481360|NCT06440343|EXPERIMENTAL|Carbohydrates|60g of maltodextrin + fructose, 2:1 ratio
62481361|NCT06440343|PLACEBO_COMPARATOR|Placebo|Preparation of colorants, sweeteners, aromas and acidulants
62481362|NCT06255171|OTHER|Nature articles - control 1|Participants will read posts and articles about nature.
62481363|NCT06255171|EXPERIMENTAL|Death by suicide articles|Participants will read posts and articles about death by suicide.
62481364|NCT06255171|OTHER|Articles about traffic-related deaths - control 2|Participants will read posts and articles about traffic-related deaths.
62321403|NCT03218852|EXPERIMENTAL|prednisone alone|"1. prednisone(0.5mg/kg/day\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
62321404|NCT04051593|EXPERIMENTAL|Treatment|Exercise
62321405|NCT01348282|EXPERIMENTAL|Lithium|Lithium group: Patients who will initiate therapy with lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
62321406|NCT01348282|ACTIVE_COMPARATOR|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
62321407|NCT01348282|NO_INTERVENTION|Control group|Patients who will not initiate treatment
62321408|NCT05942885|EXPERIMENTAL|Anxiety scores|
62321409|NCT04930640|EXPERIMENTAL|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal\[350 mg/day (Bacillus amyloliquefaciens spore 1x10\^9 CFU/day, GF101 200 U/day)\]
62321410|NCT04930640|PLACEBO_COMPARATOR|placebo group|1 times a day, 1 capsule for 1 time, before breakfast meal\[350 mg/day (Bacillus amyloliquefaciens spore 0 CFU/day, GF101 0 U/day)\]
62321411|NCT04561843||case group|Women complaining of any of the pelvic floor disorder symptoms such as: Pelvic organ prolapse (POP), Stress urinary incontinence (SUI), urgency symptoms of obstructed defecation, fecal incontinence (FI), pelvic pain, and/or sexual problems.
62321412|NCT04561843||control group|Women not complaining of any of the pelvic floor disorder symptoms
62321413|NCT05690828|EXPERIMENTAL|Group 1 (Cognitive remediation)|
62321414|NCT05690828|NO_INTERVENTION|Group 2 (No cognitive remediation)|
62321415|NCT01313026|ACTIVE_COMPARATOR|PNE first|patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
62321416|NCT01313026|ACTIVE_COMPARATOR|TAI first|Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
62321417|NCT01115946|EXPERIMENTAL|single-add first group|single administration first, then concomitant administration
62321418|NCT01115946|EXPERIMENTAL|combi-add first group|concomitant administration first, then single administration
62321419|NCT04955145|ACTIVE_COMPARATOR|Ruta C 60 group|Ascorbic Acid/Rutoside 60 tablet , each tablet contains: Rutin 60mg and Ascorbic acid 160mg Dosage:2 tablets three times daily for 4 months
62321420|NCT04955145|ACTIVE_COMPARATOR|C- Retard group|Ascorbic acid 500mg capsule dosage: 1 capsule two times daily for 4 months
62321421|NCT04955145|NO_INTERVENTION|Control group|No intervention
62321422|NCT04695730|ACTIVE_COMPARATOR|Active physical therapy|Active intervention (including both pain education and home exercises). A 60-minutes education session will be provided, concerning pain mechanisms and management and a demonstration of the exercises to perform individually at home. Home exercises will be performed daily. To support patients during the treatment, a booklet will be created. One 30-minutes booster session will be planned after 4 weeks. Patients will follow this active intervention for 8 weeks.
62321423|NCT04695730|EXPERIMENTAL|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
62321424|NCT06693674|EXPERIMENTAL|Entresto|
62321425|NCT06693674|PLACEBO_COMPARATOR|Placebo|
62321426|NCT02998892|ACTIVE_COMPARATOR|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 6 weeks. This intervention corresponds to the current recommendations.
62321427|NCT02998892|EXPERIMENTAL|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 9 hours, 5 days/week, by brisk walking for 6 weeks.
62321428|NCT01401426|ACTIVE_COMPARATOR|Single incision laparoscopic vertical sleeve gastrectomy|Active Comparator Patients in this group will undergo laparoscopic vertical sleeve gastrectomy through a single periumbilical incision.
62321429|NCT01401426|ACTIVE_COMPARATOR|Five port laparoscopic vertical sleeve gastrectomy|Patients in this group will undergo conventional laparoscopic vertical sleeve gastrectomy using 5 small incisions.
62321430|NCT02045277|EXPERIMENTAL|IDP-118 Lotion|halobetasol propionate \[HP\], tazarotene \[Taz\]
62321431|NCT02045277|ACTIVE_COMPARATOR|IDP-118 Monad HP Lotion|HP
62321432|NCT02045277|ACTIVE_COMPARATOR|IDP-118 Monad Taz Lotion|Taz
62321433|NCT02045277|ACTIVE_COMPARATOR|IDP-118 Vehicle Lotion|Vehicle
62321434|NCT02538237|EXPERIMENTAL|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
62321435|NCT02538237|SHAM_COMPARATOR|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
62321436|NCT06194201|EXPERIMENTAL|HRS9432|
62321437|NCT06194201|ACTIVE_COMPARATOR|Caspofungin Acetate for Injection|
62321438|NCT03997539|EXPERIMENTAL|pyrotinib 320mg + vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
62321439|NCT03997539|EXPERIMENTAL|pyrotinib 400mg + vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
62481365|NCT04092283|EXPERIMENTAL|Arm A (durvalumab, chemotherapy, durvalumab)|"STEP 1 (CONCURRENT THERAPY): Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycle 1 and day 1 of cycle 2. Patients also receive 1 of 3 treatment regimens per investigator choice: 1) etoposide IV over 60 minutes on days 1-5 and cisplatin IV over 60 minutes on days 1 and 8 every 28 days for 2 cycles; 2) pemetrexed disodium IV over 60 minutes and cisplatin IV over 60-120 minutes on day 1 every 21 days for 2 cycles; or 3) paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1 every 7 days for 6 cycles. Treatment continues in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of chemotherapy, patients receive radiation therapy 5 days a week for 6 weeks.~STEP 2 (CONSOLIDATION THERAPY): Within 14 days after the last dose of radiation (from Step 1), all patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
62321440|NCT03997539|EXPERIMENTAL|Pyrotinib + vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
62321441|NCT03997539|ACTIVE_COMPARATOR|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
62481366|NCT04092283|ACTIVE_COMPARATOR|Arm B (chemotherapy, durvalumab)|"STEP 1 (CONCURRENT THERAPY): Patients receive 1 of 3 investigator's choice treatment regimens and radiation therapy as in Arm A.~STEP 2 (CONSOLIDATION THERAPY): Within 14 days after the last dose of radiation (from Step 1), all patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
61926572|NCT02826135|EXPERIMENTAL|Pediatric patients with hypovolemic state|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output or decreased central venous pressure. Changes of blood pressure during abdominal compression is continuously recorded.
61926573|NCT02658058|ACTIVE_COMPARATOR|Landmark technique|As intervention, patients in this group are administered landmark guided midline spinal anesthesia.
61926574|NCT02658058|EXPERIMENTAL|Ultrasound-guided paramedian technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided paramedian technique using parasagittal oblique view
61926575|NCT02658058|EXPERIMENTAL|Ultrasound-guided midline technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided midline technique using transverse median view
61926576|NCT04147572|EXPERIMENTAL|Inhaler A, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type A
61926577|NCT04147572|EXPERIMENTAL|Inhaler B, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type B
61926578|NCT04147572|PLACEBO_COMPARATOR|Reference product, Spiriva modified HandiHaler|Placebo Spiriva, hard capsule inhaled via modified HandiHaler device
61926579|NCT04147572|EXPERIMENTAL|Substudy Test product Placebo Tiotropium Easyhaler|The substudy subjects will demonstrate the use of the inhaler.
61926580|NCT04147572|PLACEBO_COMPARATOR|Substudy Reference product Placebo Spiriva® HandiHaler|The substudy subjects will demonstrate the use of the inhaler.
61926581|NCT03371719|PLACEBO_COMPARATOR|Arm 1 (Radiation Therapy + Placebo)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or unacceptable toxicity.
61926582|NCT03371719|EXPERIMENTAL|Arm 2 (Radiation Therapy + Apalutamide)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
61926583|NCT04622735|EXPERIMENTAL|FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
62130521|NCT02318901|EXPERIMENTAL|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
62321442|NCT06058494||Single-Bundle|Single-bundle ACL reconstruction
62321443|NCT06058494||Single-Bundle+Lateral Plasty|Single-bundle ACL reconstruction with lateral plasty
62321444|NCT06058494||Double-Bundle|Double-bundle ACL reconstruction
62321445|NCT02916784||Sit-to-stand: Pass|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'pass' if the subjects could safely rise from the chair without using their arms and with no more than contact guarding assist.
62481367|NCT06016738|EXPERIMENTAL|Palazestrant (OP-1250)|Participants will receive Palazestrant
62481368|NCT06016738|ACTIVE_COMPARATOR|Standard of Care Endocrine Therapy|Participants will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
62481369|NCT02968212|EXPERIMENTAL|clofazimine|Participants receive lamprene
61926584|NCT04622735|ACTIVE_COMPARATOR|Paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
61926585|NCT04622735|ACTIVE_COMPARATOR|Nefopam hydrochloride 30 mg (X2)|Each dose: 2 tablets (included in masking capsule)
61926586|NCT01338142|PLACEBO_COMPARATOR|CCC|Crystalline calcium carbonate (CCC)
61926587|NCT01338142|EXPERIMENTAL|ACC|Amorphous calcium carbonate (ACC)
61926588|NCT05171049|EXPERIMENTAL|Abelacimab|Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
61926589|NCT05171049|ACTIVE_COMPARATOR|Apixaban|Apixaban administered orally twice a day
61926590|NCT05302908|EXPERIMENTAL|Spanish-speaking Latinx communities|Individual in-depth interviews with Spanish-speaking Latinx participants
61926591|NCT01145612|EXPERIMENTAL|Losartan|Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
62690042|NCT01892189|EXPERIMENTAL|Sequence 7: Placebo + TAK-063 30 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:~Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period"
61926592|NCT01145612|EXPERIMENTAL|Atenolol|Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
61926593|NCT05977361|ACTIVE_COMPARATOR|Resiting Epidural Catheter|
61926594|NCT05977361|ACTIVE_COMPARATOR|Intrathecal catheter placement|
61926595|NCT04811573|EXPERIMENTAL|EU-Otezla fasted(A)/ Japan-Otezla fasted(E)/ US-Otezla fasted(B)/ US-Otezla fed(D)/ EU-Otezla fed(C)|Treatment sequence AEBDC is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926596|NCT04811573|EXPERIMENTAL|US-Otezla fasted(B)/ EU-Otezla fasted(A)/ EU-Otezla fed(C)/ Japan-Otezla fasted(E)/ US-Otezla fed(D)|Treatment sequence BACED is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926597|NCT04811573|EXPERIMENTAL|EU-Otezla fed(C)/US-Otezla fasted(B)/US-Otezla fasted(D)/EU-Otezla fasted(A)/ Japan-Otezla fasted(E)|Treatment sequence CBDAE is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926598|NCT04811573|EXPERIMENTAL|US-Otezla fed(D)/ EU-Otezla fed(C)/ Japan-Otezla fasted(E)/ US-Otezla fasted(B)/ EU-Otezla fasted(A)|Treatment sequence DCEAB is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926599|NCT04811573|EXPERIMENTAL|Japan-Otezla fasted(E)/ US-Otezla fed(D)/ EU-Otezla fasted(A)/EU-Otezla fed(C)/ US-Otezla fasted(B)|Treatment sequence EDACB is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926600|NCT04811573|EXPERIMENTAL|EU-Otezla fasted(A)/ US-Otezla fasted(B)/ Japan-Otezla fasted(E)/ EU-Otezla fed(C)/ US-Otezla fed(D)|Treatment sequence ABECD is applied. The 5 treatments were separated by a washout period of at least 5 days.
62321446|NCT02916784||Sit-to-stand: Fail|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'fail' if the subjects could not rise from the chair without using their arms and/or with more than contact guarding assist.
62321447|NCT03572543|ACTIVE_COMPARATOR|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
62321448|NCT03572543|SHAM_COMPARATOR|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
61926601|NCT04811573|EXPERIMENTAL|US-Otezla fasted(B)/ EU-Otezla fed(C)/ EU-Otezla fasted(A)/ US-Otezla fed(D)/ Japan-Otezla fasted(E)|Treatment sequence BCADE is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926602|NCT04811573|EXPERIMENTAL|EU-Otezla fed(C)/ US-Otezla fed(D)/ US-Otezla fasted(B)/ Japan-Otezla fasted(E)/ EU-Otezla fasted(A)|Treatment sequence CDBEA is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926603|NCT04811573|EXPERIMENTAL|US-Otezla fed(D)/ Japan-Otezla fasted(E)/ EU-Otezla fed(C)/ EU-Otezla fasted(A)/ US-Otezla fasted(B)|Treatment sequence DECAB is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926604|NCT04811573|EXPERIMENTAL|Japan-Otezla fasted(E)/ EU-Otezla fasted(A)/ US-Otezla fed(D)/ US-Otezla fasted(B)/ EU-Otezla fed(C)|Treatment sequence EADBC is applied. The 5 treatments were separated by a washout period of at least 5 days.
61926605|NCT06299150|ACTIVE_COMPARATOR|direct resin composite mini-veneer|Composites resins have become the first choice for direct anterior and posterior restorations. The great popularity is related to their esthetic appearance and reduced need of sound tissue removal as compared with former treatments. Several studies have demonstrated that composite restorations may last long in clinical service. Composite restorations have demonstrated a good clinical performance with annual failure rates varying from 1% to 3% in posterior teeth and 1% to 5% in anterior teeth.
62321449|NCT01653366|EXPERIMENTAL|Arm A-Pedometer and Goal setting|"Physical Activity Goal Setting~Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log."
62321450|NCT01653366|NO_INTERVENTION|ARM B|Patients receive standard physical activity recommendations and follow up.
62321451|NCT05741593||Patients having had a stroke|elderly patients previously treated with an antithrombotic and admitted to hospital for an ischemic stroke
62321452|NCT02853331|EXPERIMENTAL|Pembrolizumab+Axitinib Combination Therapy|Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
62321453|NCT02853331|ACTIVE_COMPARATOR|Sunitinib Monotherapy|Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
62321454|NCT00493116|EXPERIMENTAL|1|
62321455|NCT00669539||Combined-Mechanism Amblyopia|
62321456|NCT00669539||Strabismus-Only Amblyopia|
62321457|NCT06691529||study group|500 patients presented at Nephrology unit/Internal Medicine department (Assiut University Hospital) In the period 2024-2026.
62321458|NCT06692504||Oral anticoagulant therapy|anti-vitamin K or direct oral anticoagulants therapy
62321459|NCT06692504||No oral anticoagulant therapy|no anti-vitamin K or direct oral anticoagulants therapy
62321460|NCT04857398|EXPERIMENTAL|Insulin icodec|The participants will receive an individualised weekly dose of subcutaneously (s.c.) insulin icodec for 6 weeks
62481370|NCT02968212|PLACEBO_COMPARATOR|sugar pill|Participants receive placebo
62321461|NCT04960566|EXPERIMENTAL|eCBT+|eCBT+ participants will be enrolled in 6, 45-minute sessions delivered via a secure video platform with a GI psychologist. To reinforce concepts reviewed in the sessions, participants will complete weekly home practice exercises. The targets are 1) improved maladaptive cognitive-affective processes associated with increased hypervigilance and symptom anxiety, 2) reduced behaviors associated with EHA including avoidance, increased medication/healthcare utilization and 3) reduced autonomic nervous system (ANS) arousal by increased HRV. Participants will learn to identify, question, and modify maladaptive thoughts, beliefs, and assumptions related to their symptoms (symptom anxiety). Systematic exposure to feared events are used to reduce maladaptive coping strategies (hypervigilance, PPI overuse, HCU). Specific, paced diaphragmatic breathing exercises (Resonance Frequency Breathing) designed to increase HRV are the last component (visceral hypersensitivity, reflux physiology).
62481371|NCT04481958|EXPERIMENTAL|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
62481372|NCT05224531|EXPERIMENTAL|CS1 480 mg dose group|480 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
62321462|NCT04960566|SHAM_COMPARATOR|Sham-SOC Lifestyle Coaching|Patients randomized to the SOC condition will receive lifestyle guidance recommended for patients with GERD over a period of 6, 45-minute sessions with the GI psychologist to maintain consistency of delivery between the two intervention arms. Topics include maintaining a healthy weight, identifying triggering food and drink, making healthy food choices, eating behaviors, smoking and/or alcohol use, and timing of meals. The SOC condition will be carefully designed to not include any principles of the eCBT+ condition rather be based solely on patient education and encouragement to practice lifestyle changes on their own.
62321463|NCT05650099||Implants in the posterior region|126 patients with one or two missing tooth/teeth in the posterior region were treated 10 years ago with dental implant treatment and implant-supported restorations
62321464|NCT06693869||Telephone pre-anesthetic evaluation|Surgical patients scheduled for elective non-cardiac surgery underwent pre-anesthetic evaluation through a telephone consultation, which included a review of medical history, medications, and risk factors made by anesthesiologists. No physical examination was conducted.
62321465|NCT06693869||In-Person pre-anesthetic evaluation|Surgical patients scheduled for elective non-cardiac surgery received an in-person pre-anesthetic evaluation performed by an anesthesiologist, which included a physical examination and a thorough risk assessment.
62321466|NCT03570840||obese children and adolescents|
62321467|NCT02205970|ACTIVE_COMPARATOR|TENS active|TENS (interactive): frequency (90 and 150 pps) and pulse duration (300 and 400μs)
62321468|NCT02205970|SHAM_COMPARATOR|TENS sham|Placebo lasting 35 minutes.
62321469|NCT03864172|PLACEBO_COMPARATOR|Usual intake + placebo fruit juice|Placebo fruit flavoured juice powder
62321470|NCT03864172|ACTIVE_COMPARATOR|Usual intake +SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF)
62321471|NCT03864172|ACTIVE_COMPARATOR|Adequate calcium +fruit juice placebo|Placebo fruit flavoured juice powder added with 600 mg calcium to meet RNI intake
62481373|NCT05224531|EXPERIMENTAL|CS1 960 mg dose group|960 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
62738311|NCT01638013|EXPERIMENTAL|Participants who completed 015K-CL-RAJ3|Participants who completed 015K-CL-RAJ3 (NCT02308163) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR \>= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
62321472|NCT03864172|ACTIVE_COMPARATOR|Adequate calcium + SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF) and 600 mg calcium to meet RNI intake
62321473|NCT04558645||Patients with type 1 diabetes mellitus|Patients with Type 1 diabetes mellitus willing to participate in the study
62321474|NCT04558645||Healthy controls|Healthy controls without chronic disease willing to participate in the study
62321475|NCT01099839|EXPERIMENTAL|one group|"Subjects will receive ASP1941 alone, Miglitol alone and ASP1941 + Miglitol in different order."
62321476|NCT03569423|EXPERIMENTAL|Transepithelial PRK|Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
62321477|NCT03569423|ACTIVE_COMPARATOR|Alcohol assisted PRK|Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
62321478|NCT06692244|EXPERIMENTAL|Personalized Titanium Mesh|Preoperative CBCT datas of participants are obtained to design and manufacture personalized titanium meshes.Use additive-manufactured personalized titanium meshes for guided bone regeneration.
62321479|NCT06692244|ACTIVE_COMPARATOR|Prefabricated Titanium Mesh|Use prefabricated titanium mesh for guided bone regeneration.
62321480|NCT05615597|OTHER|Para-discal infiltration|Single arm study
62321481|NCT06176963|EXPERIMENTAL|SB11 PFS|Subjects received a single dose of SB11 PFS containing 0.5 mg ranibizumab in 0.05 mL solution.
62321482|NCT06410781|EXPERIMENTAL|Radial Extracorporeal Shockwave|thirty patients with iliotibial band syndrome will receive Radial Extracorporeal Shockwave and traditional therapy three times a week for six weeks.
62481374|NCT05224531|EXPERIMENTAL|CS1 1920 mg dose group|1920 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
62481375|NCT05262491|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62481376|NCT06072339|EXPERIMENTAL|Experimental|The intervention group will benefit from the physiotherapist's use of lung ultrasound for the PEEP adjustment during the first NIV session.
62481377|NCT06072339|ACTIVE_COMPARATOR|Control|The conventional group will benefit from the NIV under the current terms.
61926606|NCT06299150|EXPERIMENTAL|IPS e.max CAD|"IPS e max likely refers to a type of dental material or technology. IPS e.max is a popular brand of lithium disilicate glass-ceramic used in dentistry for the fabrication of dental restorations such as crowns, veneers, inlays, onlays, and bridges.~IPS e.max restorations are known for their excellent esthetics, strength, and durability. They are designed to closely mimic the natural appearance of teeth while providing reliable performance and longevity. Dentists often choose IPS e.max restorations for their patients due to their versatility and ability to meet both esthetic and functional requirements."
61926607|NCT06504862|EXPERIMENTAL|Part 1: dabigatran-etexilate (Reference, R) then zongertinib and dabigatran-etexilate (Test, T)|
61926608|NCT06504862|EXPERIMENTAL|Part 2: Drug cocktail (Reference, R) then zongertinib and drug cocktail (Test, T)|"Drug cocktail:~Cocktail of rosuvastatin, metformin and furosemide"
61926609|NCT03283878|EXPERIMENTAL|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.~\< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose."
61926610|NCT03283878|EXPERIMENTAL|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively.~\< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.)."
61926611|NCT04312113|EXPERIMENTAL|Autologous mesenchymal stem cells|Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis.
61926612|NCT02442115||ASD with GID|Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
61926613|NCT02442115||ASD without GID|Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.
61926614|NCT06107231|EXPERIMENTAL|Honey alone and honey with almonds, then sucrose alone and sucrose with almonds|Participants will be provided honey alone once each day for 3 days, then honey plus almonds for an additional 3 days while wearing a continuous glucose monitor. After a 14 day wash-out, participants will be provided sucrose alone once each day for 3 days, then sucrose plus almonds for an additional 3 days while wearing a continuous glucose monitor.
61926615|NCT06107231|EXPERIMENTAL|Sucrose alone and sucrose with almonds, then honey alone and honey with almonds|Participants will be provided sucrose alone once each day for 3 days, then sucrose plus almonds for an additional 3 days while wearing a continuous glucose monitor. After a 14 day wash-out, participants will be provided honey alone once each day for 3 days, then honey plus almonds for an additional 3 days while wearing a continuous glucose monitor.
61926616|NCT02123043|NO_INTERVENTION|Control|The control group will not experience any wheelchair training or 'practice' with a manual wheelchair.
61926617|NCT02123043|EXPERIMENTAL|Motor learning-based training|The motor learning-based training, like the 'practice' condition, will consist of six visits over three weeks. Each visit will involve two 5-minute wheeling trials with 10-minutes of rest between trials. The motor learning-based training will focus on variable practice and sporadic feedback.
62130522|NCT05209477|OTHER|Lung ultrasound|"n patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~baseline, in supine position under protective ventilation after two minute of recruitment maneuver in pressure controlled ventilation at 1 hour following prone positioning application"
61926618|NCT02123043|ACTIVE_COMPARATOR|Practice wheeling|To provide a comparable amount of exposure to wheelchair propulsion, the practice group will participate in the same number of visits and wheeling time as the motor-learning based training group. This will allow us to determine whether the motor-learning based training is superior to exposure through practice. The practice group will come to the lab six times over three weeks and wheel for two 5-minute trials with a 10-minute rest break in between. Participants randomized to this group will receive no feedback.
61926619|NCT06045169|OTHER|Single Group|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
61926620|NCT02449720|ACTIVE_COMPARATOR|Laparoscopic Bowel Surgery: IPLA|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
62130523|NCT01159275|OTHER|1|First Generic LPV/r 200/50 mg BID, then cross over to Pediatric Aluvia 200/50 mg BID
61926621|NCT02449720|PLACEBO_COMPARATOR|Laparoscopic Bowel Surgery: Control|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
61926622|NCT02449720|ACTIVE_COMPARATOR|Open Bowel Surgery: IPLA|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
62130524|NCT01159275|OTHER|2|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
62130525|NCT02901197|ACTIVE_COMPARATOR|Education and Reminder|This arm will consist of participants in a location that receive with web based training and exposure to reminder posters in the workplace.
62690043|NCT01892189|EXPERIMENTAL|Sequence 8: TAK-063 30 mg + TAK-063 300 mg + Placebo|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 \& 2 are followed by 7 day washout period."
61926623|NCT02449720|PLACEBO_COMPARATOR|Open Bowel Surgery: Control|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
61926624|NCT06354829||Kidney cohort|Once assigned to the renal cohort, the relevant set of images will then be further assigned to a specific subpopulation depending on the pathology. In parallel, the associated anamnestic, demographic, and clinical data, will be included in a purpose-designed electronic Case Report Form (eCRF).
61926625|NCT06354829||Cerebral cohort|Once assigned to the cerebral cohort, the relevant set of images will then be further assigned to a specific subpopulation depending on the pathology. In parallel, the associated anamnestic, demographic, and clinical data, will be included in a purpose-designed eCRF.
61926626|NCT05162170||Primary Mediastinal large B-Cell Lymphoma (PMBCL)|The present study consists of a retrospective multicenter collection of series of consecutive patients diagnosed with PMBCL over the relevant time period (13 years, from 2007 to 2019 included).
61926627|NCT00728052|EXPERIMENTAL|Subjects receiving treatment sequence ABCD|Subjects will receive treatment sequence ABCD; A= placebo, B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, and D = GSK598809 dose 3.
61926628|NCT00728052|EXPERIMENTAL|Subjects receiving treatment sequence BACD|Subjects will receive treatment sequence BACD; B= GSK598809 dose 1 (75 milligrams), A= placebo, C = GSK598809 dose 2 and D = GSK598809 dose 3
61926629|NCT00728052|EXPERIMENTAL|Subjects receiving treatment sequence BCAD|Subjects will receive treatment sequence BCAD; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, A= placebo and D = GSK598809 dose 3.
62130526|NCT02901197|ACTIVE_COMPARATOR|Policy Change|This arm's participants will not receive an active intervention (education and reminders), however, policy change will take place in this location.
62130527|NCT03578198|EXPERIMENTAL|Rituximab + MG4101|"Drug: Rituximab + MG4101~Induction phase:~Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4)"
62130528|NCT04761536||A|patients undergoing ARR with primary anastomosis between November 2016 and December 2020 after centralization of rectal cancer cases
62130529|NCT04761536||B|patients undergoing ARR with primary anastomosis between January 2006 and October 2016
62130530|NCT00445315|EXPERIMENTAL|2|
62130531|NCT00445315|EXPERIMENTAL|3|
62130532|NCT00445315|EXPERIMENTAL|1|
62130533|NCT00445315|EXPERIMENTAL|4|
62130534|NCT00445315|PLACEBO_COMPARATOR|5|
61926630|NCT00728052|EXPERIMENTAL|Subjects receiving treatment sequence BCDA|Subjects will receive treatment sequence BCDA; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, D = GSK598809 dose 3 and A= placebo.
61926631|NCT04376177||Patients with Thoracic outlet syndrome|Patients referred to the University Hospital of Angers for the diagnostis or follow-up of thoracic outlet syndrome
61926632|NCT06067009|EXPERIMENTAL|Group 1 - Communication|Participants in this group will complete one session of communication training and will have 1 follow up call a month after the session has been completed.
62321483|NCT06410781|ACTIVE_COMPARATOR|traditional therapy|Thirty patients with iliotibial band syndrome will receive traditional therapy three times a week for six weeks.
61926633|NCT06067009|EXPERIMENTAL|Group 2 - Social Support Effectiveness|Participants in this group will complete 3 sessions of social support effectiveness training. All will complete 1 follow-up call after the 3 sessions have been completed.
61926634|NCT06067009|EXPERIMENTAL|Group 3 - Communication and Social Support Effectiveness|Participants assigned to this group will complete 4 sessions of communication and social support effectiveness training. One follow up call will be completed one month after the last session has been competed.
61926635|NCT06067009|PLACEBO_COMPARATOR|Group 4 - Wait-listed Control|Participants assigned to this group will receive no training sessions the first 12 weeks of enrollment. After 12 week data collection, they will be assigned to complete either communication (1 session) or social support effectiveness (3 sessions) training. One month after the completion of the training sessions a follow-up call will be made.
61926636|NCT06475339|ACTIVE_COMPARATOR|30/30 work/rest cycle first|Participants will first complete the 30/30 work/rest cycle, and then complete the other three conditions in a randomized fashion
62321484|NCT04530812|EXPERIMENTAL|Arm I (commercial kefir beverage)|Patients consume commercial kefir beverage daily for 3 months.
62321485|NCT04530812|ACTIVE_COMPARATOR|Arm II (usual diet)|Patients maintain usual diet for 3 months.
61926637|NCT06475339|EXPERIMENTAL|30/20 work/rest cycle first|Participants will first complete the 30/20 work/rest cycle, and then complete the other three conditions in a randomized fashion
61926638|NCT06475339|EXPERIMENTAL|40/30 work/rest cycle first|Participants will first complete the 40/30 work/rest cycle, and then complete the other three conditions in a randomized fashion
61926639|NCT06475339|EXPERIMENTAL|20/12 work/rest cycle first|Participants will first complete the 20/12 work/rest cycle, and then complete the other three conditions in a randomized fashion
61926640|NCT06400979|EXPERIMENTAL|Aromatherapy aromatab|Interventional aromatherapy tab used to deliver inhaled aromatherapy to participants
61926641|NCT02861131|EXPERIMENTAL|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
62321486|NCT01583582|EXPERIMENTAL|Refined peptide concentrate, 1200 mg|Refined peptide concentrate, 1 200 mg, once a day
61926642|NCT02861131|ACTIVE_COMPARATOR|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
62130535|NCT01579968||eptacog alpha users|
62321487|NCT01583582|EXPERIMENTAL|Refined peptide concentrate, 2 x 600 mg|Refined peptide concentrate, 600 mg, twice a day
62321488|NCT01583582|PLACEBO_COMPARATOR|Refined peptide concentrate, 0 mg|
62321489|NCT04559581||Patients newly initiating Nintedanib|
62321490|NCT00779090|EXPERIMENTAL|Group A_RM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
62321491|NCT00779090|NO_INTERVENTION|Group A_NRM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
62321492|NCT00779090|EXPERIMENTAL|Group B_RM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
62321493|NCT00779090|NO_INTERVENTION|Group B_NRM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
62690044|NCT01892189|EXPERIMENTAL|Sequence 9: TAK-063 300 mg + Placebo + TAK-063 30 mg|Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 \& 2 are followed by 7 day washout period
62690045|NCT02592655|ACTIVE_COMPARATOR|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
62690046|NCT02592655|ACTIVE_COMPARATOR|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
62690047|NCT02592655|EXPERIMENTAL|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
62690048|NCT02592655|EXPERIMENTAL|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
62690049|NCT05928572|EXPERIMENTAL|Nutrition-Focused Approach (NFA)|NFA arm participants will receive introduction to CGM from a diabetes care provider with emphasis placed on using the CGM data to adjust food choices. The NFA will encourage food choices that align with evidence-based nutrition recommendations for People with Diabetes (PWD), and that achieve internationally recognized glucose targets (e.g. glucose 70-180 mg/dL, and Time In Range \> 70%).
62690050|NCT05928572|ACTIVE_COMPARATOR|Self-Directed Approach (SDA)|The SDA arm participants will receive introduction to the CGM from a diabetes care provider using the CGM manufacturer-provided manuals and resources. The SDA will encourage participants to use the CGM device and apps in the way that feels most useful to them. The SDA is intended to reflect current CGM initiation practices, which focus on technical use of the CGM and a general review of CGM data.
62690051|NCT06675383||Acute ischemic stroke|Admitted with acute ischemic stroke and absence of atrial fibrillation on admission.
62690052|NCT06662695|EXPERIMENTAL|Ginger|Ginger-based supplement
62690053|NCT06662695|PLACEBO_COMPARATOR|Placebo|Capsules containing corn flour
62690054|NCT02808884|EXPERIMENTAL|Circulating tumor DNA assay- First test - Negative result|Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
62690055|NCT02808884|EXPERIMENTAL|Circulating tumor DNA assay - Second test- Negative result|Participants whose sample provided a positive result after first test, will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. We expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently. Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
62690056|NCT02808884|EXPERIMENTAL|Circulating tumor DNA assay - Second test- Positive result|Participants with positive results after first test will be contacted by an oncologist and sent a letter informing them of the result. They will be ask to return for a second blood draw. The letter will include contact info of the study team and the oncologist co-investigators. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn to allow repeat testing and confirmation that the mutation is consistently present. Participants whom additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw, will be contacted by an oncologist to explain the results and next steps. This should happen within about a week of the second blood draw. Pending oncological evaluation of the participant and study results, a PET-CT scan with FDG agent, and possibly other tests will be requested. Unless exams suggest otherwise, the default follow-up will be a full body PET-CT.
62690057|NCT01629888|EXPERIMENTAL|1 = Tested product|
62690058|NCT01629888|PLACEBO_COMPARATOR|2 = Control product|
62690059|NCT06295588|EXPERIMENTAL|Fucoidan|They will receive 4 grams daily of fucoidan extracted from F. Vesiculosus for 8 weeks.
62690060|NCT06295588|ACTIVE_COMPARATOR|Usual Care|They will receive usual care for 8 weeks followed by 4 grams daily of fucoidan extracted from U. Pinnatifida for 8 weeks.
62690061|NCT01254110||1|Enterally fed with leucine
62690062|NCT01254110||2|Enterally fed with glutamine
62690063|NCT01254110||3|Enterally fed with protein powder
62321494|NCT06074458|NO_INTERVENTION|Standard of Care|Participants in this arm follow standard of care procedures.
62690064|NCT04105361|EXPERIMENTAL|Study group|We will do posterior nasal neurectomy in patients with allergic rhinitis after FESS in one side of the nose
61926643|NCT02140632|EXPERIMENTAL|Local steroid injection|"The local injection of steroid is performed by the same investigator after the randomization. Using a sterile technique, 20mg methylprednisolone acetate premixed with lidnocaine is injected using a 25-gauge x 5/8 needle. The needle is inserted medially to the palmaris longus tendon at the distal palmar crease in the wrist at an angle of 45-degree to the forearm. The steroid is injected at approximately 1cm below the skin. The needle will be repositioned if there is any resistance to injection, or any pain or paraesthesia in the median nerve territory."
61926644|NCT02140632|ACTIVE_COMPARATOR|Wrist splinting|After randomization, the hands of the patients in the splinting group are splinted in neutral position with standard cotton-polyester splint. Patients are encouraged to use the splints during nighttime whenever possible for one month.
61926645|NCT06643026||Patients with digestive cancer traited by chemotherapy|Patients with malignant digestive tumors receiving active chemotherapy
61926646|NCT06643026||Patients with digestive cancer traited by immunotherapy|Patients with malignant digestive tumors receiving immunotherapy only
61926647|NCT05307731|EXPERIMENTAL|Fingoland group|The patients of this group were treated with Fingolimod 0.5mg per day, in addition to guideline based treatment.
61926648|NCT05307731|ACTIVE_COMPARATOR|Control group|The patients of this group were treated with diabetes drugs based on guideline
61926649|NCT05422612|EXPERIMENTAL|Intervention A: Fluoxetine HCl|
62130536|NCT02700516||Recurrent GN|Renal transplant recipients with biopsy-confirmed recurrent primary glomerulonephritis.
62321495|NCT06074458|ACTIVE_COMPARATOR|Diabetes Dashboard and Community Health Worker|Participants diabetes technology devices will be linked to a remote patient monitoring dashboard and will have access to a Smartphone application, as well as scheduled and as needed visits with a community health worker.
62321496|NCT06026254|EXPERIMENTAL|Combination Therapy|IMSA101 + ICI
62321497|NCT03479879|EXPERIMENTAL|Estradiol + Misoprostol|
62321498|NCT03479879|PLACEBO_COMPARATOR|Placebo + Misoprostol|
62321499|NCT00443404|ACTIVE_COMPARATOR|1|perioperative epidural analgesia
62690065|NCT04105361|EXPERIMENTAL|Control group|We will do FESS only in the other side of the nose
62690066|NCT05057546|EXPERIMENTAL|Premenopausal Group: GnRH antagonist|Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection.
62690067|NCT02393625|EXPERIMENTAL|Dose Escalation|
61926650|NCT05422612|PLACEBO_COMPARATOR|Intervention A Placebo|
62690068|NCT02393625|EXPERIMENTAL|Dose Expansion|
62690069|NCT05521178||Ibrutinib|Patients receiving ibrutinib for the treatment of CLL.
62690070|NCT05521178||Acalabrutinib|Patients receiving acalabrutinib for the treatment of CLL.
62690071|NCT04193176|EXPERIMENTAL|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
61926651|NCT05422612|EXPERIMENTAL|Intervention B Vilazodone|
61926652|NCT05422612|PLACEBO_COMPARATOR|Intervention B Placebo|
61926653|NCT05422612|EXPERIMENTAL|Intervention C Daridorexant|
61926654|NCT05422612|PLACEBO_COMPARATOR|Intervention C Placebo|
61926655|NCT04455360|EXPERIMENTAL|EMDR R-TEP intervention|Participants will receive a minimum of 2 and a maximum of 8 online EMDR R-TEP sessions, starting within 3-months of hospital discharge. Sessions will be delivered online by experienced, suitably trained and registered psychological practitioners.
61926656|NCT04455360|NO_INTERVENTION|Standard care|Patients will receive standard post-hospital discharge care.
61926657|NCT05927324|EXPERIMENTAL|Active treatment|CAVEAT active treatment group
61926658|NCT02427620|EXPERIMENTAL|Treatment (ibrutinib, rituximab, consolidation chemotherapy)|"PART I (IBRUTINIB PLUS RITUXIMAB): Patients receive ibrutinib PO QD on days 1-28 and rituximab IV over 6-8 hours on days 1, 8, 15, and 22 of cycle 1 and then over 4 hours on day 1 of cycles 3-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve complete response.~PART II (CONSOLIDATION THERAPY): Patients receive rituximab IV over 6 hours on day 1; dexamethasone PO or IV on days 1-4; cyclophosphamide IV over 3 hours BID on days 2-4; doxorubicin hydrochloride IV over 15-30 minutes on day 5; and vincristine sulfate IV over 15-30 minutes on day 5 of cycles 1, 3, 5, and 7. Patients also receive rituximab IV over 6 hours on day 1; methotrexate IV over 24 hours on day 2; and cytarabine IV over 2 hours BID on days 3 and 4 of cycles 2, 4, 6, and 8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
62130537|NCT02700516||Non-recurrent GN|Renal transplant recipients with non-recurrent primary glomerulonephritis.
62130538|NCT02700516||Non-GN|Renal transplant recipients with etiologies other than primary glomerulonephritis.
62130539|NCT02538458|ACTIVE_COMPARATOR|Test group|3 % hypertonic saline up to 72H.
62130540|NCT02538458|PLACEBO_COMPARATOR|Placebo control group|"* 3 % hypertonic saline up to 24H.~* Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
62130541|NCT05439317||knee osteoarthritis group|individuals being diagnosed with osteoarthritis and classified by K-L grading
62130542|NCT05439317||healthy group|individuals without knee pain or diagnosis of knee osteoarthritis
62321500|NCT00443404|ACTIVE_COMPARATOR|2|Iv PCA Fentanyl preoperative, Epidural analgesia postoperative
62321501|NCT00443404|ACTIVE_COMPARATOR|3|perioperative IV PCA Fentanyl, epidural anesthesia
62321502|NCT00443404|ACTIVE_COMPARATOR|4|perioperative IV PCA Fentanyl general anesthesia
62130543|NCT01879189|EXPERIMENTAL|Decision Aid|Those in the decision aid arm of the study will be given access to the breast cancer screening decision aid.
62321503|NCT00443404|PLACEBO_COMPARATOR|5|IV PCA with saline 0.9% and sc saline 0.9%in the L3-L4 area. IM meperidine, po codeine/acetaminophen, IV acetaminophen and IV parecoxib
62690072|NCT04193176|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
62690073|NCT03618069|NO_INTERVENTION|routine investigation|
62690074|NCT03618069|ACTIVE_COMPARATOR|study protocol CCI (CTA, cardiac CT) and MRI scans|
62690075|NCT06569745|EXPERIMENTAL|Verbal Explanation Group|Verbal Explanation Group
62690076|NCT06569745|EXPERIMENTAL|Animation Group|Animation Group
62690077|NCT06569745|EXPERIMENTAL|Peer-Led Reels Group|Peer-Led Reels Group
62690078|NCT06675396||chronic kidney with mood disorder|Patients developed mood disorder after chronic kidney disease development
62321504|NCT02165631||Group A-Simbinza|Patients in Group A will receive Simbrinza (brinzolamide) 1%/0.2%, with instruction for three times daily (every 8hours) administration of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
62321505|NCT02165631||Group B-Timolol|Patients in Group B will receive Timolol 0.5%, with instructions for twice daily administration (every 12 hours) of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
61926659|NCT02852213|EXPERIMENTAL|Single treatment arm|Single-stage dose-escalation, open-label safety study of AAV2-hAADC delivered by image-guided convection-enhanced delivery bilaterally into the substantia nigra pars compacta and the ventral tegmental area of pediatric patients with AADC deficiency. Primary aim is to determine the dose for future studies based on safety, biomarkers of pharmacological activity of AADC and clinical outcomes. Cohort 1 (3 subjects) will receive a single low dose of AAV2 hAADC. The total AAV2-hAADC dose will be infused via MR guided infusion into 4 sites in both the left and right SNc and VTA. Dose intervals will be 90 days between the first 3 subjects. Cohort 2 dose (4 subjects) will be determined by Cohort 1 results. Following Cohort 2, Cohort 3/4 will be dose and divided divided by age. Cohorts 3/4 will receive the same dose by MR guided infusion to 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 (24-47mo old) will have same vector concentration and lower volume of infusion than Cohorts 3/4
61926660|NCT05838625|EXPERIMENTAL|Digital Therapeutic A|Evaluate the efficacy and safety of digital therapeutic A as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
61926661|NCT05838625|EXPERIMENTAL|Digital Therapeutic B|Evaluate the efficacy and safety of digital therapeutic B as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
61926662|NCT05109975|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive Debio 0123 orally in escalating dose cohorts during each 21-day treatment cycle until progression of disease, unacceptable toxicity, participant's withdrawal, or Investigator's decision, whichever occurs first.
61926663|NCT05109975|EXPERIMENTAL|Part 2: Expansion|Debio 0123 at the RP2D established in Part 1 participants with uterine serous carcinoma (USC) (arm A), recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1 (arm B), and solid tumor with biomarker-driven selection (arm C).
61926664|NCT06709300||Study Cohort|Open-label treatment group with the EyeCool ETX-4143 device in eyes with ocular hypertension that meet the inclusion/exclusion criteria
61926665|NCT04690582|ACTIVE_COMPARATOR|Treatment As Usual|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a self-guided safety plan. As a recommended standard care practice with suicidal patients, the combination of CPT and safety plan represents treatment as usual. The safety plan will be assigned during the first therapy session.
61926666|NCT04690582|EXPERIMENTAL|Crisis Response Plan (CPT+CRP)|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a collaborative crisis response plan (CRP). The CRP includes many of the same elements as the safety plan (i.e., warning signs, self-management strategies, sources of social support, crisis services), but is created collaboratively by the patient with active input of their clinician rather than being self-guided. The CRP also includes a section focused on the participant's reasons for living, an addition that has been shown to increase positive emotional states (e.g., hope, optimism) and lead to faster reductions in suicidal intent. The CRP will be collaboratively created during the first therapy session.
61926667|NCT06745297|EXPERIMENTAL|Treatment group|
61926668|NCT06745297|PLACEBO_COMPARATOR|Placebo group|Applicable for part 1a and part 2 of the trial.
61926669|NCT06745271|EXPERIMENTAL|[14C]-tebapivat and [13C2,15N3]-tebapivat|Participants will receive a single oral dose of 10 milligrams (mg) \[14C\]-tebapivat containing 200 microcurie \[μCi\] of radiocarbon in a capsule followed by a single intravenous (IV) microdose of 0.1 mg \[13C2,15N3\]-tebapivat on Day 1.
61926670|NCT06638294||Patients with breast cancer leptomeningeal disease (LMD)|"Participation involves allowing access to participant medical records including the genetic information of the tumor, undergoing standard-of-care work up as indicated (this may include MRI of brain or spine, spinal tap, etc.), providing a cerebrospinal (CSF) sample (less than 2 tablespoons), blood sample (about 4 tablespoons) at baseline and possibly again after month, and answering online questionnaires monthly.~Johns Hopkins Molecular Tumor Board will review clinical and genetic information and provide treatment recommendations. CSF and blood will be collected at baseline no matter what treatment is recommended. If possible, collect CSF and blood again after one month. Additional blood and CSF sampling may also be obtained if/when therapy changes.~The oncologist will ultimately decide if participant will proceed with the recommend treatment or not. Health information and questionnaires are obtained to assess how participants are doing on therapy."
61926671|NCT06712628||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
61926672|NCT06712628||Tumor Necrosis Factor Inhibitor-Treatment|Participants will receive a tumor necrosis factor inhibitor treatment as prescribed by their physician according to local label.
61926673|NCT00457366|ACTIVE_COMPARATOR|Quetiapine|Quetiapine is being used in an ER setting on agitated patients, being administered orally.
61926674|NCT00457366|ACTIVE_COMPARATOR|Haloperidol|"Haloperidol is being used in an ER setting on agitated patients, administered IM. This is being used in combination with lorazepam and cogentin. We are comparing the use of this cocktail to quetiapine alone."
61926675|NCT00457366|ACTIVE_COMPARATOR|Lorazepam|"Lorazepam is being used in an ER setting on agitated patients, administered IM.This is being used in combination with haloperidol, and cogentin. We are comparing the use of this cocktail to quetiapine alone."
62321506|NCT01052597|PLACEBO_COMPARATOR|Placebo|
62321507|NCT01052597|EXPERIMENTAL|Curcumin|
62321508|NCT04328064|ACTIVE_COMPARATOR|Rosuvastatin Drug|Active drug-rosuvastatin 40 mg
62321509|NCT04328064|PLACEBO_COMPARATOR|Placebo drug|Placebo oral tablet
62321510|NCT03630614|EXPERIMENTAL|Electronic cigarette condition|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
62690079|NCT04365790||Patients with triple-negative breast cancer|Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
62321511|NCT03630614|ACTIVE_COMPARATOR|Varenicline condition|Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
62321512|NCT03630614|PLACEBO_COMPARATOR|Placebo condition|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
62690080|NCT04365790||Patients with HER2+ positive breast cancer|Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
61926676|NCT00457366|ACTIVE_COMPARATOR|Cogentin|"Cogentin is being used in an ER setting on agitated patients, administered IM.~This is being used in combination with haloperidol, and lorazepam. We are comparing the use of this cocktail to quetiapine alone."
61926677|NCT04704336|NO_INTERVENTION|Self-directed without Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and provided standard of care.
61926678|NCT04704336|EXPERIMENTAL|With Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.
61926679|NCT06409403|EXPERIMENTAL|da Vinci robotic TME|
61926680|NCT06409403|EXPERIMENTAL|Microhands robotic TME|
61926681|NCT06409403|ACTIVE_COMPARATOR|laparoscopic surgery TME|
61926682|NCT06480981|EXPERIMENTAL|Noribogaine 20mg|1 x Noribogaine 10mg capsule twice daily
61926683|NCT06480981|EXPERIMENTAL|Noribogaine 40mg|1 x Noribogaine 20mg capsule twice daily
61926684|NCT06480981|EXPERIMENTAL|Noribogaine 60mg|1 x Noribogaine 10mg capsule and 1 x Noribogaine 20mg capsule twice daily
61926685|NCT06480981|EXPERIMENTAL|Noribogaine 80mg|2 x Noribogaine 20mg capsule twice daily
61926686|NCT05367336|NO_INTERVENTION|Control|not receiving any narcotics
61926687|NCT05367336|EXPERIMENTAL|Morphine|the second group will be those receiving morphine
61926688|NCT05367336|EXPERIMENTAL|Fentanyl|the 3rd group will be those receiving fentanyl
61926689|NCT00729599|EXPERIMENTAL|1|Cetylpyridinium chloride during 21 consecutive days.
61926690|NCT01314157|EXPERIMENTAL|Physiotherapy treatment technique|"Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with technical isostretching"
61926691|NCT01314157|NO_INTERVENTION|Patients remained on the waiting list|Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with control group.
61926692|NCT06594068|EXPERIMENTAL|Anifrolumab|Lactating individuals 18 years of age or older receiving anifrolumab therapeutically who provide consent to participate will be included in the study. Milk collection will occur at a series of 14 timepoints, 1 pre-dose (spot) and 13 post-dose: Day 1 \[0-4 hours, 4-8 hours, 8-12 hours, 12-18 hours, 18-24 hours\], Day 3 \[48 hours, spot\], Day 4 (spot), Day 6 (spot), Day 8 (spot), Day 12 (spot), Day 16 (spot), Day 22 (spot), and Day 29 (prior to next dose, spot). Maternal serum will be collected Day 1 (pre-dose and 0-4 hours post-dose), Day 12, and approximately Day 29 (immediately preceding subsequent dose). Infant serum will be collected on approximately Day 30 following the next dose and after 24 hours of breast feeding.
61926693|NCT00765024|ACTIVE_COMPARATOR|Albendazole|Albendazole for 7 days
61926694|NCT00765024|EXPERIMENTAL|ivermectin|ivermectin 200 mcg/kg single dose
61926695|NCT00765024|EXPERIMENTAL|ivermectin 2 doses|ivermectin 200 mcg/kg two doses in 2 weeks
61926696|NCT02872571|EXPERIMENTAL|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
61926697|NCT05922553|EXPERIMENTAL|Active Ingredient Mukbang|Active Ingredient Mukbang will be allocated to the participants in the experimental group. The videos which presented the food images, eating sound and a relaxing and pleasant atmosphere will be sent in sequence through the short video platforms on the smart phone to the participants in the experimental group.
62321513|NCT05711667|EXPERIMENTAL|ARM I (Letermovir prophylaxis)|Patients receive letermovir PO or IV over 60 minutes QD starting on day +1 post-transplant for 14 weeks. Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.
62690081|NCT02157727||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
61926698|NCT05922553|ACTIVE_COMPARATOR|Common Mukbang|Common Mukbang on short video platforms will be allocated to the participants in the conditional group. The Mukbang videos which made and uploaded by popular Mukbang makers will be sent in sequence through the short videos platforms on the smart phone to the participants in the experimental group.
61926699|NCT05922553|PLACEBO_COMPARATOR|General short videos|General short videos without food cues will be allocated to the participants in the placebo control group. There will be no restrictions on the type of short video platforms and specific video content.
61926700|NCT00403403|PLACEBO_COMPARATOR|Placebo+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
61926701|NCT00403403|EXPERIMENTAL|Bevacizumab+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
61926702|NCT00843726|EXPERIMENTAL|Arm I|Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
61926703|NCT00843726|EXPERIMENTAL|Arm II|Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
61926704|NCT05696769||Youth with CTD Ages 8-12|"Youth (8-12 years) will be recruited for a qualitative interview using the exploratory questionnaire developed for the study. Parent/caregivers will also be asked questions related to their child's CTD. Participants will be asked for feedback on the ease of completion, content, readability and completion time.~After development of the TD Stigma scale, prior and new participants with CTD will be asked to complete the TD-Stigma scale with companion measures. Feedback on the scale will be elicited as well."
61926705|NCT05696769||Supporters: Parents/Caregivers|Qualitative interviews will be administered and adapted to the caregiver's perspective. Parents/caregivers will also be asked to complete questionnaires child's CTD history, family history and impact of CTD on different aspects of the child's life. Participants will be asked for feedback on the ease of completion, content, readability and completion time.
62690082|NCT02157727||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
62690083|NCT02157727||Control group, Prior Tele-expertise|
62690084|NCT02157727||Control group, during Tele-expertise|Infants hospitalized in health facilities not performing Tele-expertise while the exposed group use Tele-expertise
62321514|NCT05711667|ACTIVE_COMPARATOR|ARM II (No prophylaxis)|Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.
62321515|NCT04299399||nomal|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of biomechanics with other groups will be performed.
62690085|NCT05277935|ACTIVE_COMPARATOR|Use of the WeCancer app combined with the smartwatch|The Wecancer app will be used in a way, combined with a smartwatch, similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), feedback to the patient in the comments made, guidance on physical and eating exercises, reception and support from the Wecancer multidisciplinary team, consisting of a navigator nurse, psychologist, nutritionist and physiotherapist. During the survey period, participants should report their symptoms on the Wecancer app whenever possible, preferably daily.
61926706|NCT05696769||Provider/ advocate cohort|For providers and advocates, qualitative interview administered will begin with the participant's experience and qualifications in caring for individuals with CTD and adapted to the provider's perspective. Participants will be asked for feedback on the ease of completion, content, readability and completion time.
61926707|NCT05696769||Youth with CTD Ages 13-17|"Youth (13-17 years) will be recruited for a qualitative interview using the exploratory questionnaire developed for the study. Parent/caregivers will also be asked questions related to their child's CTD. Participants will be asked for feedback on the ease of completion, content, readability and completion time.~After development of the TD Stigma scale, prior and new participants with CTD will be asked to complete the TD-Stigma scale with companion measures. Feedback on the scale will be elicited as well."
61926708|NCT05696769||Adults with CTD Ages (18-30)|"Adults with CTD (Ages 18-30) will be recruited for a qualitative interview using the exploratory questionnaire developed for the study.~Participants will be asked for feedback on the ease of completion, content, readability and completion time.~After development of the TD Stigma scale, prior and new participants with CTD will be asked to complete the TD-Stigma scale with companion measures. Feedback on the scale will be elicited as well."
61926709|NCT05696769||Supporters: Partners/Spouses/Significant others|For Partners/Spouses/Significant others, qualitative interview administered will begin with the participant's experience and qualifications in caring for individuals with CTD and adapted to the supporter's perspective. Participants will be asked for feedback on the ease of completion, content, readability and completion time.
61926710|NCT06087614|EXPERIMENTAL|Arm 3 - DE-HyART|The radiation dose will be similar to 'arm 2'. In addition, the HSV identified on baseline FMISO scans will be contoured, and an isotropic margin of 5 mm will be given. This volume will be boosted in phase II to a total dose of 80 Gy. (Addition of 30 Gy in 3 Gy daily fraction added in phase II as a simultaneous integrated boost - SIB).
61926711|NCT06087614|ACTIVE_COMPARATOR|Arm 2 - Hypoxic Comparator Arm|The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
61926712|NCT06087614|PLACEBO_COMPARATOR|Arm 1 - Non-hypoxic arm|The patients will be treated with a standard of care where the treatment will not be controlled, and these patients will act as external control representing clinical practice. However, these patients will be discussed in the head and neck multispeciality clinic and follow the institutional approach. They will be subjected to treatment similar to 'arm 2' but are allowed protocol deviation as per treating radiation oncology discretion.
61926713|NCT04007432|EXPERIMENTAL|Older patients with hip fracture|Older patients admitted for hip fracture surgery
61926714|NCT05952492|EXPERIMENTAL|Stress Management Skills Training|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include stress management skills training and health education content.
61926715|NCT04759027||X-ray|Measurements of subacromial distance on standardized direct radiography
61926716|NCT04759027||ultrasound|Measurements of subacromial distance on ultrasound
61926717|NCT01514500|EXPERIMENTAL|Single dose (SD)|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
61926718|NCT01514500|EXPERIMENTAL|Multiple dose (MD)|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
61926719|NCT05274139|EXPERIMENTAL|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt, temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
61926720|NCT05274139|EXPERIMENTAL|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
61926721|NCT06743724|EXPERIMENTAL|Low-score group|The low-score group received rTMS at 1 Hz for 20 minutes per session, once daily, for a duration of 2 weeks.
61926722|NCT04525443||Patients with active SARS-CoV-2 infection.|Patients admitted for COVID-19 at Hospital Clínico San Carlos with positive SARS-CoV-2 polymerase chain reaction (PCR).
61926723|NCT04525443||Patients with past, not active, SARS-CoV-2 infection.|Patients with past infection (not active), demonstrated by serology and PCR.
61926724|NCT04525443||People without concurrent or past SARS-CoV-2 infection|Health personnel from the Cardiology Service of Hospital Clínico San Carlos who demonstrate by serology that they have not had SARS-CoV-2 infection.
61926725|NCT04597008|ACTIVE_COMPARATOR|Control|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
62321516|NCT04299399||seasonal allergic conjunctivitis(SAC)|Eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of corneal biomechanics with other groups and correlation analysis of corneal biomechanical parameters and other measurement indicators will be performed.
61926726|NCT04597008|EXPERIMENTAL|Treatment|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
61926727|NCT01682668|EXPERIMENTAL|Frequency of subthalamic stimulation|Comparison between healthy controls and PD patients (non-operable patients or who will be operated or already operated)
61926728|NCT05638477|EXPERIMENTAL|Parkinson's disease|Eye tracking using Eyelink 1000 during free-viewing of videos
61926729|NCT05638477|EXPERIMENTAL|Progressive Supranuclear Palsy|Eye tracking using Eyelink 1000 during free-viewing of videos
61926730|NCT05638477|EXPERIMENTAL|Multiple System Atrophy|Eye tracking using Eyelink 1000 during free-viewing of videos
61926731|NCT05638477|EXPERIMENTAL|Corticobasal Syndrome|Eye tracking using Eyelink 1000 during free-viewing of videos
61926732|NCT00844818|NO_INTERVENTION|Control|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
61926733|NCT00844818|EXPERIMENTAL|Intervention Group|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
61926734|NCT04391413|EXPERIMENTAL|OCT group|"OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data:~Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification.~Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel.~After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment."
61926735|NCT04391413|NO_INTERVENTION|Control group|Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.
61926736|NCT02425644|EXPERIMENTAL|Ponesimod|Subjects to receive 20 mg ponesimod
61926737|NCT02425644|ACTIVE_COMPARATOR|Teriflunomide|Subjects to receive 14 mg teriflunomide
61926738|NCT05933070|EXPERIMENTAL|Schedule of Assessments|"INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15.~* In Cohort 1, the initial planned dose is 1 x 10\^8 INKmune;~* In Cohort 2, the weekly dose will increase to 3 x 10\^8 INKmune;~* In Cohort 3, the weekly dose will increase to 5 x 10\^8 INKmune."
61926739|NCT03904615|ACTIVE_COMPARATOR|Whey Protein|30 g of whey protein twice daily during hospitalization and for 30 days after discharge
62321517|NCT04299399||vernal keratoconjunctivitis (VKC)|At first visit, eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured. All patients will adopt a unified medication regimen:0.1% tacrolimus eye drops four times daily; 0.1% flumirone eye drops twice daily; azelastine hydrochloride eye drops four times daily; hyaluronic acid sodium eye drops four times daily. After 1M, 0.1% flumilone eye drops will be replaced with 0.02% flumirone eye drops twice daily, and rest of the medication will remain unchanged. The same ophthalmological examinations will be performed again after 3 month medication.
62321518|NCT04299399||keratoconus|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of these parameters with other groups will be performed.
62321519|NCT04399967|EXPERIMENTAL|Intervention Group|Chat-based support+ COVID-19 specific advice + AWARD advice + COVID-related health warning leaflet + referral card + COSH booklet
62321520|NCT04399967|EXPERIMENTAL|Control Group|Text-based support + AWARD advice + warning leaflet + referral card + COSH booklet
62321521|NCT01723501|PLACEBO_COMPARATOR|sterile water|sterile water wipes
62321522|NCT01723501|EXPERIMENTAL|0.25% chlorhexidine|0.44% chlorhexidine digluconate wipes which will release 0.25% free chlorhexidine
62321523|NCT01461863|ACTIVE_COMPARATOR|protein calorie supplement|250 gm daily of specially designed porridge plus standard multivitamin
62321524|NCT01461863|PLACEBO_COMPARATOR|Multivitamin|Standard multivitamin control
62321525|NCT00406640|ACTIVE_COMPARATOR|A|
62321526|NCT00406640|ACTIVE_COMPARATOR|B|
62321527|NCT04632784|EXPERIMENTAL|Artiflex Presbyopic|About 125 - 140 subjects will receive the Artiflex Presbyopic lens bilaterally and will be followed for a period of 3 years.
61926740|NCT03904615|ACTIVE_COMPARATOR|Collagen Protein|30 g of collagen protein twice daily during hospitalization and for 30 days after discharge
61926741|NCT03904615|PLACEBO_COMPARATOR|Placebo|30 g of maltodextrin twice daily during hospitalization and for 30 days after discharge
61926742|NCT04354727|EXPERIMENTAL|APG-1252|
61926743|NCT04354727|EXPERIMENTAL|APG-1252 + Ruxolitinib|
61926744|NCT06698536|OTHER|Aktiia G2C cohort|Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).
61926745|NCT06659263|EXPERIMENTAL|30 mg RE104|A single subcutaneous injection of 30 mg RE104 for Injection
61926746|NCT04473625||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926747|NCT04473625||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926748|NCT04473625||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926749|NCT04473625||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926750|NCT04473625||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926751|NCT04473625||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926752|NCT04473625||Kidney/Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926753|NCT04473625||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926754|NCT04473625||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926755|NCT04473625||Pancreas|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926756|NCT04473625||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926757|NCT04473625||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
61926758|NCT04526301||Tablo Hemodialysis System|Home dialysis treatment with the Tablo Hemodialysis System
61926759|NCT02780219|EXPERIMENTAL|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
61926760|NCT02780219|EXPERIMENTAL|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
61926761|NCT02469376|EXPERIMENTAL|Diagnosis with GP1|Injection and scanning of \[18F\]-GP1
61926762|NCT04353414|ACTIVE_COMPARATOR|Pericapsular Injection (PCI) group|Subjects in PCI group will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
62690086|NCT05277935|NO_INTERVENTION|Using the WeCancer app|The Wecancer application similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), patient feedback on the comments made, guidance on physical and dietary exercises, reception and support of the Multidisciplinary cancer team composed of a navigator nurse, a psychologist, nutritionist and physiotherapist. During the research period, participants must report your symptoms in the Wecancer app whenever possible, preferably daily.
61926763|NCT04353414|ACTIVE_COMPARATOR|Transmuscular QL Block + Pericapsular Injection (PCI) group|Subjects in the TQLB group will receive the TQLB containing 30mL of 0.5% Bupivacaine Hydrochloride (HCL) plus PCI containing 20 mL of 0.25% of Bupivacaine Hydrochloride (HCL). For PCI, subjects will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
61926764|NCT02091219|EXPERIMENTAL|25(OH)D3|20 micrograms/day by mouth for 16 weeks
61926765|NCT02091219|EXPERIMENTAL|Vitamin D3|2,400 IU/day by mouth for 16 weeks
61926766|NCT04638673|EXPERIMENTAL|Active-Active Stimulation Group|This group will be randomized into the active stimulation group for weeks 1\&2 of stimulation and active stimulation during weeks 3\&4 of stimulation of study participation.
61926767|NCT04638673|SHAM_COMPARATOR|Sham-Active Stimulation Group|This group will be randomized into the sham stimulation group for weeks 1\&2 of stimulation and active stimulation for weeks 3\&4 of stimulation of study participation.
62321528|NCT01373567|EXPERIMENTAL|TINEFCON|Tablets of 700 mg.
62321529|NCT06348420|EXPERIMENTAL|ARMV (intervention group)|Under general anesthesia, patients are positioned in the left lateral decubitus position and undergo endoscopic examination of the esophagus and stomach. The surgery utilizes a single-channel gastroscope (EG29-i10, Pentax, Japan, or GIF-H290T, Olympus, Japan) and a high-frequency generator (VIO300D, Erbe, Germany). A transparent cap (D-201, Olympus, Japan) is attached to the gastroscope to improve visualization and aid in manipulating the flap valve. The DualKnife (Olympus, Japan) is selected for dissection due to its maneuverability in a retroflexed fashion. For patients with esophageal strictures obstructing scope passage, esophageal dilation is performed using Savary-Gilliard dilators (Cook Medical, USA) just before ARMV.
62690087|NCT06473103|EXPERIMENTAL|TPFM imaging of surgical margins|Excised tissue will be imaged with TPFM to determine the distance from tumor to nearest inked margin.
61926768|NCT04024878|EXPERIMENTAL|Stanfard Platinum|"* A total of 5 NeoVax immunizations will be administered over a 3-week period~* Two booster vaccinations will be given at Week 12~* Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks."
61926769|NCT04024878|EXPERIMENTAL|Stanfard Platinum with Surgical or Core Needle Biopsy|"* A total of 5 NeoVax immunizations will be administered over a 3-week period~* Two booster vaccinations will be given at Week 12~* Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.~* Will undergo required surgical or core needle biopsy at first recurrence with progression free interval"
61926770|NCT04616027|EXPERIMENTAL|Healthy participants with normal renal function|This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
61926771|NCT04616027|EXPERIMENTAL|Participants with T2DM with normal renal function|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1
61926772|NCT04616027|EXPERIMENTAL|Participants with T2DM with mild renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
61926773|NCT04616027|EXPERIMENTAL|Participants with T2DM with moderate renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
61926774|NCT04616027|EXPERIMENTAL|Participants with T2DM with severe renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
61926775|NCT01665612|EXPERIMENTAL|MPDS1|Contact lens care solution
61926776|NCT01665612|ACTIVE_COMPARATOR|MPDS2|Contact lens care solution
61926777|NCT01665612|ACTIVE_COMPARATOR|MPDS3|Contact lens care solution
61926778|NCT04612790|EXPERIMENTAL|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
61926779|NCT04612790|EXPERIMENTAL|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
61926780|NCT05828719|NO_INTERVENTION|Guideline-directed medical treatment group|In the GDMT group, medical treatment for patients with left ventricular dysfunction will be performed under current ACC/AHA/SCAI or ESC/EACTS guidelines for heart failure.
61926781|NCT05828719|EXPERIMENTAL|Revascularization group|"In the revascularization group, patients will undergo percutaneous coronary intervention (PCI) using standard techniques under current ACC/AHA/SCAI or ESC/EACTS guidelines. In the revascularization group, the procedure must be within 2 weeks of randomization.~Revascularization criteria is presented as below. Revascularization indication~1. Diameter stenosis \>90% by visual assessment~2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~   * Left main artery~  * Proximal to mid left anterior descending artery~  * Proximal left circumflex artery in left dominant coronary arterial system~  * Proximal to distal right coronary artery in right dominant coronary arterial system"
61926782|NCT03315182|EXPERIMENTAL|Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=2 participants)"
62690088|NCT04753567|EXPERIMENTAL|Actual pain patch|
62690089|NCT04753567|PLACEBO_COMPARATOR|Sham patch|
62690090|NCT01930708|EXPERIMENTAL|DMF|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
62690091|NCT05227365|OTHER|Single Treatment Arm Study|The Lenire device is a CE marked medical device intended to reduce the symptoms of tinnitus. It comprises a handheld controller, an intra-oral device called a Tonguetip that delivers gentle electrical stimulation to the tongue, and a set of wireless headphones that deliver audio stimulation to the ears. The sound and tongue stimulation are configured and calibrated to individual participant hearing and sensation characteristics during the initial fitting procedure completed by a trained clinician. The participants will receive 12 weeks of treatment, in which the first 6-weeks will consist of sound-only stimulation (PS6-No ETS) and the second 6-weeks will consist of bimodal stimulation (PS6, includes sound and tongue stimulation).
61926783|NCT03315182|EXPERIMENTAL|Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 2 (Med Dose): 5 X 10E13 vg/kg (n=4-5 participants)"
61926784|NCT03315182|EXPERIMENTAL|Cohort 3 (High Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 3 (High Dose): 1 X 10E14 vg/kg (n=4-8 participants)"
61926785|NCT05366075|EXPERIMENTAL|Intervention 1 (simple exercise program)|The intervention will include up to four sessions per day. It consists of sit-to stand exercises and walking along the corridor of the ward (for those who can walk).
61926786|NCT05366075|EXPERIMENTAL|Intervention 2 (comprehensive exercise program)|This intervention consists of two daily sessions (morning and afternoon). The morning session includes individualized supervised progressive resistance, balance, and walking training exercises, tailored to each participant's capacity. The resistance training includes using weight cuffs, involving mainly lower-extremity muscles. Balance and gait exercises includes different exercises such as line walking, stepping practice, and walking with small obstacles. The evening session consists of functional exercises using light loads, such as knee extension and flexion, hand training with a ball, and daily walking exercises (for those who can walk).
61926787|NCT05366075|NO_INTERVENTION|Control group|The control group will receive usual care, which may include physical rehabilitation when needed.
61926788|NCT04491253|EXPERIMENTAL|Intervention|The intervention is defined as informational support (transmission of information for health care, knowledge of DM2, nutrition, physical activity), instrumental (physical care) and emotional (management of anxiety, empowerment and decision-making).
61926789|NCT04491253|NO_INTERVENTION|Control|Control group will receive usual care treatment at the diabetes mellitus nursing consultation in primary care.
61926790|NCT03981822|ACTIVE_COMPARATOR|Part A: VP-102 2 hour-Active|For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.
62339785|NCT04729556|ACTIVE_COMPARATOR|Cavilon|"Active control is a commercial cream containing dimethicone as the substance forms a durable, thin, and transparent film. The cream is used as a moisturizer to prevent the skin against irritation, dryness, and pressure ulcers.~Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours)."
62339786|NCT05766839|EXPERIMENTAL|Patiromer|"4-week pharmacodynamic (PD)/dose-ranging period~Cohort 1: 6 to \<12 years of age~Cohort 2: 2 to \<6 years of age~Cohort 3: 0 to \<2 years of age); In Cohort 3, a minimum of 3 study participants will be assessed in the sub-group of 0 to \<6 months and another 3 study participants in the sub-group 6 to \<24 months of age."
61926791|NCT03981822|ACTIVE_COMPARATOR|Part A: VP-102 6-hour Active|For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
62481378|NCT03886129||Participants with Transient Ischaemic Attack|"Inclusion Criteria:~* Willing to participate~* Capacity to consent~* Aged \>18 years~* Able (in the Investigator's opinion) and willing to comply with all study requirements~* A diagnosis of acute (≤7 days) TIA, made by a specialist that fulfils the 2009 American Heart Association definition of TIA~* Good understanding of written and verbal English~Exclusion Criteria:~* Unwilling to take part~* Unable to consent~* Aged \<18 years~* Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~* Female participants who are pregnant, lactating or planning pregnancy during the course of the study~* Atrial fibrillation~* Severe heart failure (Ejection Fraction \<30%)~* Severe respiratory disease~* Inadequate bilateral transcranial Doppler windows~* Carotid stenosis ≥70% (unilateral or bilateral)~* Participant enrolled in an interventional research study.~* Poor understanding of written and verbal English"
62481379|NCT03886129||Healthy Control Participants|"Inclusion Criteria:~* Willing to participate~* Capacity to consent to the study~* Aged \>18 years~* Able (in the Investigator's opinion) and willing to comply with all study requirements~* Good understanding of written and verbal English~Exclusion Criteria:~* Unwilling to take part~* Unable to consent~* Aged \<18 years~* Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~* Female participants who are pregnant, lactating or planning pregnancy during the course of the study~* Atrial fibrillation~* Severe heart failure (Ejection Fraction \<30%)~* Severe respiratory disease~* Inadequate bilateral transcranial Doppler windows~* Carotid stenosis ≥70% (unilateral or bilateral)~* Participant enrolled in an interventional research study.~* Poor understanding of written and verbal English"
62481380|NCT02593773|EXPERIMENTAL|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
62321530|NCT06348420|NO_INTERVENTION|PPI (control group)|"Patients randomized to the PPI group will follow the PPI treatment scheme. If GERD symptoms are effectively controlled with their current PPI dosage for at least one month, the regimen is decreased by one step. Conversely, if symptoms are poorly controlled, the dosage is increased by one step based on the PPI algorithm, which aligns with best clinical practices. The use of PPI will be recorded in medication diaries using generic names listed in the table below and classified according to the daily dose and frequency. Dosage will be categorized as double dose = ≥30 or 40 mg per day, full dose = 30 or 40 mg per day, half dose = 15 or 20 mg per day, occasional or on demand = \< full dose taken for \< 50% of days in the follow-up period. Common medications include Nexium 20mg、Prevacid 30mg、Prilosec 20mg、Protonix 20mg、Aciphex20mg.The frequency of medication use is once a day."
62321531|NCT03949049|EXPERIMENTAL|Citacoline|Citacoline as neuroprotector
62321532|NCT03949049|PLACEBO_COMPARATOR|Placebo|Placebo
62321533|NCT05057585|EXPERIMENTAL|Exercise group|Each patient in the experimental group was given in-bed exercises for 15 minutes. An anxiety questionnaire was asked to both the experimental and control groups. It was expected that both the experimental and control group patients would be stable in the postoperative period. The same exercises were applied again for 15 minutes to the patients who were stable after the surgery. Then the patients were made to take steps around the bed. Pain levels were measured.
62321534|NCT05057585|NO_INTERVENTION|No treatment group|Apart from clinical protocols, no application was made in patient follow-up. Anxiety scale was filled and pain level was evaluated. Pain and anxiety scales were refilled within the same period without any application.
62321535|NCT01345786|EXPERIMENTAL|Commercial NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
62481381|NCT04060108||MDMA Within Subject Cross-over|Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions.
62481382|NCT06075264|ACTIVE_COMPARATOR|Artesunate ointment|Artesunate formulated as topical ointment, 40% Four 5-day cycles of artesunate ointment every 2 weeks
62481383|NCT06075264|PLACEBO_COMPARATOR|Placebo ointment|Placebo ointment Four 5-day cycles of placebo ointment every 2 weeks
62690092|NCT05708690|EXPERIMENTAL|Tranexamic Acid Topical|The treatment of interest was application of Topical Tranexamic Acid (5 gram in 50 mL warm normal saline). The topical will be poured into the pericardial and mediastinal cavities (after protamine administration), and sternum (before chest closure)
62690093|NCT05708690|PLACEBO_COMPARATOR|Placebo|The control group is given 100 mL of warm normal saline. The topical will be poured into the pericardial and mediastinal cavities (after protamine administration), and sternum (before chest closure).
62321536|NCT01345786|ACTIVE_COMPARATOR|Phase 3 NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch A), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
62321537|NCT01345786|EXPERIMENTAL|Commercial NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
62321538|NCT01345786|ACTIVE_COMPARATOR|Phase 3 NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch B), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
62690094|NCT06540014||Turkish|Belonging to Turkish race originally
62690095|NCT06540014||Syrian|Belonging to Syrian race originally
62690096|NCT04650256|EXPERIMENTAL|CAM arm|Participants will be given the CAM intervention during scheduled, standard of care radiotherapy (up to 6 weeks) and 8-12 weeks (weeks 14-18) after radiotherapy.
62690097|NCT02399995||patients following hepatectomy|
62690098|NCT06074497|EXPERIMENTAL|KGX101- Cohort -1|Dosage level: Dose level 1 Dose form: White-like lyophilized powder Route of administration: Intravenous
62690099|NCT06074497|EXPERIMENTAL|KGX101- Cohort 1|Dosage level: Dose level 2. Dose form: White-like lyophilized powder Route of administration: Intravenous
62690100|NCT06074497|EXPERIMENTAL|KGX101- Cohort 2|Dosage level: Dose level 3 Dose form: White-like lyophilized powder Route of administration: Intravenous
62690101|NCT06074497|EXPERIMENTAL|KGX101- Cohort 3|Dosage level: Dose level 4 Dose form: White-like lyophilized powder Route of administration: Intravenous
62690102|NCT06074497|EXPERIMENTAL|KGX101- Cohort 4|Dosage level: Dose level 5 Dose form: White-like lyophilized powder Route of administration: Intravenous
61926792|NCT03981822|ACTIVE_COMPARATOR|Part A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
61926793|NCT03981822|PLACEBO_COMPARATOR|Part A: Placebo|For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments.
61926794|NCT03981822|ACTIVE_COMPARATOR|Part B & A: VP-102 6 hour-Active|Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
61926795|NCT03981822|PLACEBO_COMPARATOR|Part B & A: 6-hour-Placebo|Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
61926796|NCT03981822|ACTIVE_COMPARATOR|Part B & A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
61926797|NCT03981822|PLACEBO_COMPARATOR|Part B & A: 24-hour-Placebo|Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
61926798|NCT04374968|EXPERIMENTAL|BFR Treatment|Patients will be recruited following ACL tear and medical screening for history of DVT/PE. Patients allocated to the BFR intervention group will undergo physical therapy with the use of a blood flow restriction cuff. Rehabilitation will consist of a structured home exercise program prior to surgery. We will instruct patients on how to perform home BFR and test them in the office to ensure competence. Following surgery patients will immediately be started in physical therapy. Therapy will consist of a structured program progressing from range of motion, to strength training and then functional tests. Both arms will use the same protocol with the only difference being use of BFR.
61926799|NCT04374968|NO_INTERVENTION|Control|The control arm will undergo the same pre and post operative physical therapy as the BFR group. They will undergo a structure home therapy program prior to surgery and an outpatient physical therapy program under the guidance of a therapist following surgery.
61926800|NCT04417543|ACTIVE_COMPARATOR|Memantine hydrochloride group|included 50 patients who received memantine
61926801|NCT04417543|PLACEBO_COMPARATOR|Placebo group|included 50 patients who received placebo
62130544|NCT01879189|NO_INTERVENTION|Standard of Care|Those in the standard of care arm will not be given access to the decision aid.
62130545|NCT01306500|EXPERIMENTAL|Gastric lavage Group|In neonates randomized to intervention Group (gastric lavage group) gastric lavage was done in the labor room after initial stabilization
62690103|NCT06074497|EXPERIMENTAL|KGX101- Cohort 5|Dosage level: Dose level 6 Dose form: White-like lyophilized powder Route of administration: Intravenous
62690104|NCT06074497|ACTIVE_COMPARATOR|KGX101 and Envafolimab|Part B combination therapy KGX101 with Envafolibmab. Dose form: Injection Route to administration: Injection
62690105|NCT05328765||With HIV Infection|Patients with CCA with HIV infection,
62690106|NCT05328765||Without HIV Infection|Patients with CCA without HIV infection,
62690107|NCT00812539|EXPERIMENTAL|"Diabetes Connected Health Tool Deluxe"|Subjects enrolled into the intervention arm will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal, where they can view their glucose readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to these subjects' information on the web portal).
62481384|NCT05877339||Osteoartritis|Patients with osteoarthritis among the participants
62481385|NCT05877339||Fibromyalgic Disease|Patients with fibromyalgia among the participants
62481386|NCT05877339||Control Group|Healthy people
62690108|NCT00812539|ACTIVE_COMPARATOR|"Diabetes Connected Health Tool Basic"|Control group will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal. where they can view their glucose readings in tabular form. Their physicians will not have access to this information.
62690109|NCT01838226|EXPERIMENTAL|Group Prevention Clinics|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
62690110|NCT01838226|NO_INTERVENTION|Treatment as usual control|Usual VA care
62690111|NCT06637982|EXPERIMENTAL|ridge splitting with allograft and pericardium membrane|
62690112|NCT06637982|EXPERIMENTAL|ridge splitting with extended platelet rich fibrin|
62690113|NCT01772771||Ancillary-correlative (biospecimen collection, chart review)|Patients' previously collected tissue samples are analyzed. Patients may also undergo collection of blood, saliva or buccal samples for analysis. Patients' medical records are reviewed.
62130546|NCT01306500|NO_INTERVENTION|No gastric lavage|Neonates randomized to 'No gastric lavage group' will receive supportive treatment as per standard unit protocol.
62130547|NCT01837940|PLACEBO_COMPARATOR|Placebo|
62321539|NCT06384807|EXPERIMENTAL|BHV-1510 Monotherapy Dose Escalation|
62321540|NCT06384807|EXPERIMENTAL|BHV-1510 in combination with Cemiplimab dose escalation|
62321541|NCT04267562|OTHER|Single-Arm, Open-Label Treatment with the Minitouch System|Eligible participants will undergo a single treatment (endometrial ablation) with the Minitouch System
62321542|NCT03693287|ACTIVE_COMPARATOR|Personalized-Parenteral Nutrition (P-PN)|"These patients will receive personalized parenteral nutrition (PN) as it is customary in the participating centers.~Dosing range: glucose from 9 to 13 g/kg/d, AA from 2.0 to 3.0 g/kg/d, and FAT from 1.5 to 2.5 g/kg/d.~Intravenous macronutrient intakes:~* PN day 1: 2.0 g/kg of AA, 1.6 g/kg of FAT and 9 g/kg of glucides.~* PN day 2: 2.5 g/kg of AA, 2.0 g/kg of FAT and 11 g/kg of glucides.~* PN day 3 and the days after: 3.0 g/kg of AA, 2.5 g/kg of FAT and 13 g/kg of glucides.~Intravenous vitamins will be supplied according to local clinical practice. Variations in macronutrient intakes will be tolerated within ±20%.~Nutritional goal: to ensure at least 2.5 g/kg/d of AA and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
62321543|NCT03693287|EXPERIMENTAL|Standardized-Parenteral Nutrition (S-PN)|"These patients will receive standardized parenteral nutrition (PN) by using a triple chamber bag (Numeta G13%E®).~Dosing range: 80-300 ml/d. Intravenous macronutrient intakes: 65 ml/kg at PN day 1, 80 ml/kg at PN day 2 and then 100 ml/kg from PN day 3.~Nutritional goal: to ensure at least 2.5 g/kg/d of amino acids (AA) and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
62321544|NCT04114994||Alzheimer's Disease|
62321545|NCT04114994||Mild Cognitive Impairment|
62321546|NCT04114994||Frontotemporal Dementia|
62321547|NCT04114994||Vascular Dementia|
62321548|NCT04114994||Parkinson Disease|
62321549|NCT04114994||Traumatic Brain Injury (TBI)|
62481387|NCT05600322|EXPERIMENTAL|Hexvix Blue light cystoscopy|In this study, enrolled patients will undergo standard White light cystoscopy and Blue light cystoscopy following Hexvix administration. Lesions detected during the cystoscopies will be resected or biopsied.
62481388|NCT05496348||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label
62321550|NCT04114994||Multiple Sclerosis|
62321551|NCT04114994||No diagnosis|
62321552|NCT05872438|OTHER|Multisite sampling|Vaginal, Oral and anal sampling for all participants
62321553|NCT00984802|EXPERIMENTAL|Low dose|
62321554|NCT00984802|EXPERIMENTAL|Mid Dose|
62321555|NCT00984802|EXPERIMENTAL|High Dose|
62321556|NCT00984802|PLACEBO_COMPARATOR|Placebo|
62321557|NCT01539837|PLACEBO_COMPARATOR|Placebo|Drug excipient
62321558|NCT01539837|ACTIVE_COMPARATOR|Deferiprone 20mg|20mg/kg/day deferiprone
62321559|NCT01539837|ACTIVE_COMPARATOR|Deferiprone 30mg|30mg/kg/day Deferiprone
62321560|NCT05314166|EXPERIMENTAL|"focused attention group"|"focused attention group: adult subjects practicing face-to-face focused attention meditation."
62481389|NCT06364891|OTHER|Intervention|Mobilisers in the intervention sites will be trained to use a digital mobile application to assist with segmenting clients and providing them with targeted messaging.
62481390|NCT06364891|OTHER|Control|Mobilisers in the control arm have been sensitised to the segmentation process but only have access to paper based resources.
62481391|NCT06628128|EXPERIMENTAL|Adult: 75 mg BID|
62481392|NCT06628128|EXPERIMENTAL|Adult: 150 mg BID|
62481393|NCT06628128|EXPERIMENTAL|Adolescent: 75 mg BID|
62481394|NCT06628128|EXPERIMENTAL|Adolescent: 150 mg BID|
62481395|NCT06742801|EXPERIMENTAL|Treatment with Onyx LES|Device; embolization with liquid embolic
62130548|NCT01837940|ACTIVE_COMPARATOR|dietary supplement|Lactobacillus reuteri DSM 17938
62321561|NCT05314166|ACTIVE_COMPARATOR|"contemplation group"|"contemplation group: adult subjects practicing face-to-face contemplation meditation."
62321562|NCT02890199|ACTIVE_COMPARATOR|Lidocaine group|0.5% lidocaine mixed with 1:200,000 epinephrine 70 milliliters (mL) will be used for local injection at the sacrospinous ligament and for anterior / posterior colporrhaphy
62321563|NCT02890199|EXPERIMENTAL|Bupivacaine liposomal group|1.3% bupivacaine liposomal (20 mL) injected at the sacrospinous ligament 0.5% lidocaine mixed with 1:200,000 epinephrine 50mL for the anterior / posterior colporrhaphy
62321564|NCT02112162|EXPERIMENTAL|Diagnostic (FDG PET/MRI, gene expression)|FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
62321565|NCT03013491|EXPERIMENTAL|CX-072|Monotherapy CX-072
61926802|NCT06207799|EXPERIMENTAL|Elranatamab|"1. Induction therapy - This is given to decrease the number of MM cells in the bone marrow.~2. Purging - This is done to remove leftover MM cells after induction therapy.~3. Stem cell mobilization - This is done to move stem cells from your bone marrow into the blood, so they can be collected for the autologous stem cell transplant.~4. Conditioning therapy - This is given to help prepare the body to receive the stem cell transplant.~5. Autologous stem cell transplant~6. Maintenance therapy - This is given to help control the disease after the stem cell transplant."
61926803|NCT03022227|EXPERIMENTAL|group A start with the remote session followed by on site|
61926804|NCT03022227|ACTIVE_COMPARATOR|group B start with on site followed by telemedecine|
61926805|NCT01713387|EXPERIMENTAL|gemcitabine , S-1|Level-2 Gem 800mg/msq, S-1 50mg/msq Level-1 Gem 800mg/msq, S-1 65mg/msq Level 1 Gem 1000mg/msq, S-1 65mg/msq Level 2 Gem 800mg/msq, S-1 80mg/msq
61926806|NCT06674109|EXPERIMENTAL|Empagliflozin 10mg|Participants in this arm will take empagliflozin 10mg daily
61926807|NCT06674109|PLACEBO_COMPARATOR|Placebo|Participants in this arm will take a placebo daily
61926808|NCT02636842|OTHER|Location|Deltoid or Gluteal Muscle
61926809|NCT03442387|EXPERIMENTAL|Positive frame|The numerical expressions were presented in a positive way: e.g. treatment was successful for 4 out of 10 persons.
61926810|NCT03442387|EXPERIMENTAL|Negative frame|The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
61926811|NCT00083512||1/Glioblastoma multiforme patients|Patients with histologically confirmed supratentorial Glioblastoma multiforme
61926812|NCT02163122|EXPERIMENTAL|NAC Followed by EEC|This arm will undergo allergy assessment first by NAC. After a rest and washout period, the same individuals will undergo assessment in an EEC.
61926813|NCT02163122|EXPERIMENTAL|EEC Followed by NAC|This arm will undergo allergy assessment first in an EEC. After a rest and washout period, the same individuals will undergo assessment by NAC.
61926814|NCT02163122|EXPERIMENTAL|Dose-finding Phase|An initial group of 6 to 12 participants with cat allergy as defined by the eligibility criteria will undergo a single-visit, stepwise dose-escalating nasal allergen challenge only, with the aim of estimating the most appropriate single dose of allergen to use in the randomized phase. Eligible participants who participate in the dose-finding phase may proceed to the randomized phase of the trial after a minimum 28-day washout period.
61926815|NCT00117286|EXPERIMENTAL|Degarelix (60 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 60 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
61926816|NCT00117286|EXPERIMENTAL|Degarelix (80 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 80 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
61926817|NCT01173861|EXPERIMENTAL|Physical activity counseling|Group receives face-to-face physical activity counseling.
62321566|NCT03013491|EXPERIMENTAL|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
62321567|NCT03013491|EXPERIMENTAL|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
62321568|NCT03013491|EXPERIMENTAL|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
62321569|NCT03013491|EXPERIMENTAL|CX-072 expansion|Monotherapy CX-072
62321570|NCT04738513|ACTIVE_COMPARATOR|Conventional preparation technique|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
62321571|NCT04738513|EXPERIMENTAL|Vertical preprartion|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using Vertical preparation technique.
62321572|NCT02697955|EXPERIMENTAL|Bupivacaine-epinephrine|10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine
62321573|NCT02697955|PLACEBO_COMPARATOR|Placebo|10 ml normal saline water (sodium chloride solution, 0,9%)
62321574|NCT02020343||Healthy|Not insulin resistant
62321575|NCT02020343||Insulin resistant|Insulin resistant by IVGTT
62321576|NCT02020343||Type 2 diabetics|Type 2 diabetics
62339787|NCT00706667|PLACEBO_COMPARATOR|1|Placebo for EPO and for Ferinject ®
62339788|NCT00706667|ACTIVE_COMPARATOR|2|Only Ferinject ® , Placebo for EPO
62339789|NCT00706667|ACTIVE_COMPARATOR|3|Ferinject ® + EPO
62339790|NCT04469374|EXPERIMENTAL|Jumping exercise|10 rest-inserted jumps performed three times per week
62339791|NCT04469374|SHAM_COMPARATOR|Balance exercise|Single-leg balances for 60 seconds on each leg
62339792|NCT01591213||Healthy Volunteers|Fourth grade students enrolled in Memphis-area schools.
61926818|NCT01173861|ACTIVE_COMPARATOR|Manual|Group receives physical activity manual.
61926819|NCT05921318||more than 5/10 HLA-mismatched allo-HSCT|more than 5/10 HLA-mismatched allo-HSCT
61926820|NCT06120504|EXPERIMENTAL|SGN-35T|SGN-35T monotherapy
61926821|NCT06744816|EXPERIMENTAL|Treatment with Qutenza Patch (Topical Capsaicin)|Up to 4 topical capsaicin patches will be applied on your feet for 30 minutes.
61926822|NCT05569811|ACTIVE_COMPARATOR|CHEMOTHERAPY|
61926823|NCT05569811|EXPERIMENTAL|HER3-DXd + Endocrine therapy (ET)|
62130549|NCT04698655|ACTIVE_COMPARATOR|Control group|"Asked to read a single-A4 page of brief osteoarthritis information (what is osteoarthritis)"
62130550|NCT04698655|EXPERIMENTAL|Treatment options group|"Asked to read brief osteoarthritis information + two A4 pages of information on treatment options (osteoarthritis treatment options)"
62690114|NCT04031950||test group|Test group will wear PSG
62130551|NCT04698655|EXPERIMENTAL|Treatment options + recommendation group|Asked to read brief osteoarthritis information + information on treatment options + receive hypothetical general practitioner recommendation for exercise
62130552|NCT03220100|EXPERIMENTAL|Stepped Palliative Care|All participants will receive palliative care Participants will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) every six weeks FACT-L scores will be used to determine which patients need to step up to every 6 week palliative care visits Patients on step 1 of the intervention will have a palliative care visit every 9 weeks Patients on step 2 of the intervention will have a palliative care visit every 6 weeks
61926824|NCT05569811|EXPERIMENTAL|HER3-DXd|
62130553|NCT03748186|EXPERIMENTAL|STRO-002 treatment|"Dose Escalation: STRO-002 at increasing dose levels~Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg"
62130554|NCT03431922|EXPERIMENTAL|endovascular denervation|endovascular denervation
62130555|NCT01030107||Children with Insufficient Sleep|Children who sleep approximately 9-10 hours/night
62321577|NCT01757704|EXPERIMENTAL|Open pleurae & conventional filling of heart|In this group both pleurae will be opened and the ventilator disconnected during cardiopulmonary bypass to ensure bilateral pulmonary collapse. However, after completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine and manual de-airing performed in a conventional manner and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is complete and patient has been weaned off the cardiopulmonary bypass the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
62339793|NCT04032171|EXPERIMENTAL|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
62339794|NCT04032171|ACTIVE_COMPARATOR|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
62130556|NCT02300675|NO_INTERVENTION|control arm|Patients follow the classic support prescription of hormonotherapy
62130557|NCT02300675|EXPERIMENTAL|therapeutic education program|Patients follow the 4 sessions of PEP hormonotherapy. The therapeutic education prgram is led by a trained educational team, inside a prevention center : Hygée centre.
62130558|NCT03210454|EXPERIMENTAL|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
62130559|NCT03210454|EXPERIMENTAL|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
62130560|NCT03210454|NO_INTERVENTION|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
62130561|NCT02740283|EXPERIMENTAL|Pregnant women|As a diagnostic study, the cohort will recruit 300 pregnant women who meet inclusion and exclusion criteria outlined below. OGTTs will be performed between 18 and 20 gestational weeks (early-OGTT) and 24 to 28 gestational weeks (regular-OGTT). Clinical and laboratory information of the mother and their offspring will be collected for analysis.
62130562|NCT03336905|EXPERIMENTAL|Physical Activity and Prevention|"* co-construction of supervised and non-supervised physical activity sessions with a physical activity trainer~* balance sheet (at diagnosis and 4 monthes+/- 2 months later) : IPAQ, QLQC30, 6-min walk test, anthropometric evaluation~* meetings and phone calls after the physical activity program to assess patient perception and satisfaction, and provide information and recommendations for cancer prevention"
62130563|NCT05444426|EXPERIMENTAL|Treatment Group|"A 24-session physiotherapy program will be applied to the patients in the treatment group.~The conventional physiotherapy program of the patients in the treatment group; will consist of 20 minutes of the hot pack, 20 minutes of conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound) on the shoulder joint for 5 minutes. In the exercise program; A combined exercise program including active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied. As the severity of pain decreases, strengthening exercises for the rotator cuff and scapulary muscles will be given."
62130564|NCT05444426|NO_INTERVENTION|Control Group|Pain, Active range of motion, balance, and postural stability will be assessed in the first week .
62130565|NCT03671551||Psychomotor/psychological evaluation|Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.
62130566|NCT04718909|EXPERIMENTAL|Regorafenib + sintilimab|Regorafenib combined with sintilimab.
62130567|NCT04718909|ACTIVE_COMPARATOR|Regorafenib|Regorafenib alone.
62130568|NCT01541436|ACTIVE_COMPARATOR|Capsaicin, UV-B, RIPC|
62690115|NCT04031950||Novel wearable device|THis group will wear the novel device
62690116|NCT04999202|EXPERIMENTAL|Dose escalation of BAY2416964|Six dose levels of BAY 2416964 (as determined in the first in human mono-therapy study of BAY2416964) are planned in combination with standard dose Pembrolizumab.
62690117|NCT04999202|EXPERIMENTAL|Dose expansion of BAY2416964 in tumor type specific cohort|To determine the RP2D of BAY2416964 in combination therapy with pembrolizumab. Participants will be enrolled in up to 3 tumor type-specific cohorts including relapsed/refractory non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and urothelial cancer.
62481396|NCT05666726|EXPERIMENTAL|1|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
62481397|NCT05666726|EXPERIMENTAL|2|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
62690118|NCT05247866|EXPERIMENTAL|Study Group|"30 patients will be given dupilumab (dose based on current approved doses or used in current EoE clinical trial, q weekly dosing) and monitored for clinical response after 12 weeks of therapy)~Dosing:~\>12 years of age \> 40 kg 300 SQ weekly 30- 40 kg 300 mg SQ Q2 weeks 15-29.9 kg 200 mg SQ Q2 weeks~6-11 years of age 5-15 kg 100 mg SQ Q2W 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W"
62690119|NCT05830097|EXPERIMENTAL|Ia stage - CBP-1019 Dose escalation/ Ib、II stage - CBP-1019 monotherapy|"Ia:Patients will receive CBP-1019 IV infusion every 2 weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.~Ib:Patients will receive CBP-1019 RP2D IV infusion every two weeks until disease Patients will receive CBP-1019 RP2D IV infusion every two weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue."
62130569|NCT01541436|SHAM_COMPARATOR|Capsaicin, UV-B|
62130570|NCT03855397|EXPERIMENTAL|Microneedles|Application of microneedle patch, 30G hypodermic needle (positive control) and flat patch (negative control) in the lip, buccal, tongue, palatal and gingival mucosa for pain and safety assessment
62130571|NCT04705675|EXPERIMENTAL|Experimental Group|The mothers in the experimental group (152) were administered.
62130572|NCT04705675|NO_INTERVENTION|Control Group|The mothers in the control group (152) were administered.
62321578|NCT01757704|EXPERIMENTAL|Intact pleurae & staged filling of heart|In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
62321579|NCT01697527|EXPERIMENTAL|Treatment (gene and vaccine therapy)|"CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~TRANSPLANT: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV on day 0. Patients also receive NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy ID on days 1, 14, and 30 and aldesleukin SC BID on days 1-14. Patients may receive 3 additional doses of NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy after day 90."
62130573|NCT03928522|ACTIVE_COMPARATOR|Pre-mixed tobramycin|patients will receive pre-mixed tobramycin cement
62130574|NCT03928522|ACTIVE_COMPARATOR|hand mixed tobramycin|patients will receive hand mixed tobramycin cement
62130575|NCT03928522|ACTIVE_COMPARATOR|hand mixed vancomycin|patients will receive hand mixed vancomycin cement
62130576|NCT03928522|EXPERIMENTAL|hand-mixed vancomycin and tobramycin|patients will receive hand mixed vancomycin and tobramycin
62481398|NCT05666726|EXPERIMENTAL|3|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
62481399|NCT05666726|EXPERIMENTAL|4|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
62481400|NCT05666726|EXPERIMENTAL|5|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
62130577|NCT03306368|NO_INTERVENTION|Treatment as Usual (TAU)|Participants receiving treatment as usual post-residential detox. TAU clinic-based treatment receiving standard clinic-based XR-NTX.
62130578|NCT03306368|EXPERIMENTAL|Youth Opioid Recovery Support (YORS)|"Youth Opioid Recovery Support consists of the following component:~Home delivery of XR-NTX, family framework, assertive continuing care incorporates outreach, home delivery of evidence based psychosocial treatment and case management in a model that specifically targets engagement and motivation in youth, contingency management."
62130579|NCT01913314|EXPERIMENTAL|[^14C]-LY2835219|Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) \[\^14C\] labeled drug
62130580|NCT02334436|EXPERIMENTAL|Botulinum toxin, Type A|Botulinum toxin, Type A
62481401|NCT06741475|EXPERIMENTAL|Caregiver-Assisted Strategy Training|"Trained therapists visit each participant once or twice weekly for 60 minutes per visit. In a total of 10 sessions over a maximum of 10 weeks, CaST program includes the following active ingredients: self-selected activity-based goals, dynamic performance analysis, global strategy (Goal-PlanDo-Check), massed practice, variable practice, increasing task difficulty, explicit and implicit feedback, guided discovery, action observation, and social interaction."
62130581|NCT02334436|PLACEBO_COMPARATOR|Placebo|0.9% sterile, unpreserved saline
62130582|NCT03348722||Active surveillance|Newly diagnosed low risk prostate cancer patients managed according to an active surveillance program
62130583|NCT03348722||Radical prostatectomy|Newly diagnosed low risk prostate cancer patients undergoing radical prostatectomy
62130584|NCT03348722||Radiotherapy|Newly diagnosed low risk prostate cancer patients undergoing radiotherapy (external or brachitherapy)
62130585|NCT03348722||Other radical treatment|Newly diagnosed low risk prostate cancer patients undergoing other radical treatments (HIFU, cryotherapy, others)
62130586|NCT04980274||Group 1|Patients with SOFA score \< 2 on admission
62130587|NCT04980274||Group 2|Patients with SOFA score equal to or \> 2 on admission and who improved after 48 hours of treatment
62130588|NCT04980274||Group 3|Patients with SOFA score equal to or \> 2 on admission and who did not improve after 48 hours of treatment
62130589|NCT04146519|EXPERIMENTAL|Study group|Autologous MMSC
62321580|NCT02805218|EXPERIMENTAL|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
62321581|NCT06554457||Fracture fixation|Fracture of upper or lower limbs or pelvis requiring internal fixation surgery
62481402|NCT06741475|SHAM_COMPARATOR|Education|Participants receive a dose-matched stroke education with 10 visits by well-trained research staff through face-to-face talks.
62481403|NCT06742983|EXPERIMENTAL|Isobutyl cyanoacrylate|Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution (periacryl 90 H.V) tissue adhesive will be applied on the ulcer site by using a pipette then rinsed with saline by using another pipette at least three times with an interval of at least 30 seconds once during the treatment episode to allow for complete polymerization, until achieving hemostasis
62481404|NCT06742983|EXPERIMENTAL|Chlorhexidine 0.2%|Application of chlorhexidine 0.2% (Elugel 2%) on finger tip then spread it on the ulcer site and gentle massaging twice daily for 9 days
62481405|NCT06742983|PLACEBO_COMPARATOR|normal saline|will be treated with cotton soaked with normal saline on the ulcer site 5 times per day
62481406|NCT03843294|EXPERIMENTAL|Nivolumab with TAA-T cell|Patients will receive doses of Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.If patient meets eligibility criteria for TAA-T cell infusion, the patient will receive two TAA-T cell infusions given 2 weeks apart
62481407|NCT06434064|EXPERIMENTAL|Treatment (tamoxifen, pegylated liposomal doxorubicin)|Patients receive tamoxifen PO QD on days 1-28 of each cycle and pegylated liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography, CT scan or MRI, tumor biopsy, and blood sample collection throughout the study.
62481408|NCT05727891|PLACEBO_COMPARATOR|Placebo|
62481409|NCT05727891|ACTIVE_COMPARATOR|Tonabersat (80 mg)|
62481410|NCT03302039|EXPERIMENTAL|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
61926825|NCT01155219|EXPERIMENTAL|Geltim LP®|Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
61926826|NCT01155219|ACTIVE_COMPARATOR|Xalatan®|Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
62130590|NCT04146519|PLACEBO_COMPARATOR|control group|
62130591|NCT01401023|EXPERIMENTAL|Clostridium difficile Patient|Open non-comparative trial
62321582|NCT06554457||Spinal fusion|Spinal fusion surgery
62321583|NCT06554457||Arthroplasty|Joint replacement surgery
62321584|NCT02371733|ACTIVE_COMPARATOR|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training using arm ergometer and breathing exercises.
62321585|NCT02371733|SHAM_COMPARATOR|Control Group|Sham: Control group will receive alternative upper extremity exercises and breathing exercises.
62321586|NCT05904886|EXPERIMENTAL|Atezolizumab + Bevacizumab + Tiragolumab|Atezolizumab plus bevacizumab plus tiragolumab will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62481411|NCT03302039|ACTIVE_COMPARATOR|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
62481412|NCT03302039|ACTIVE_COMPARATOR|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
62481413|NCT03146156|EXPERIMENTAL|Lifestyle Intervention|Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.
62481414|NCT03146156|NO_INTERVENTION|Usual Care|The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.
62130592|NCT02872675|EXPERIMENTAL|HOST-DM059 (Prebiotic)|HOST-DM059 is the only Second Generation Prebiotic, manufactured by Clasado Biosciences/HOST Therabiomics. HOST-DM059 consists of a specific type of carbohydrate/dietary fibre (GOS), and an enzyme extracted from species of Bifidobacteria (e.g. The β-Galacotosidase Enzyme, \& Bifidobacterium Bifidum). The enzyme from which HOST-DM059 is developed provides a highly selective source of energy for certain species of Bifidobacteria. HOST-DM059 encourages the growth and development of Bifidobacteria. Certain species of Bifidobacteria have been demonstrated to exert prominent immunomodulatory effects in terms of regulating systemic inflammation.
62321587|NCT05904886|PLACEBO_COMPARATOR|Atezolizumab + Bevacizumab + Placebo|Atezolizumab, bevacizumab plus placebo will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62321588|NCT06514469||Consultation|Patient who were administered sufentanil in acute trauma by paramedics after phone call consultation with medical doctor.
62321589|NCT06514469||Competency|Patient who were administered sufentanil in acute trauma by paramedics based on their competencies.
62321590|NCT03891069|EXPERIMENTAL|Interventional arm|Participants will be invited to play the five different Exergames, for a total of 5 minutes.
62481415|NCT04013217|EXPERIMENTAL|Eribulin ORA|To determine the MTD of Eribulin ORA (oral eribulin mesylate and HM30181A) when administered on Day 1 and Day 8 of a 3 weeks cycle.
62481416|NCT01852487|ACTIVE_COMPARATOR|Pumpkin Seed Oil|400mg/ day during 6 months
62481417|NCT01852487|PLACEBO_COMPARATOR|sweet potato starch|400mg/day during 6months
62481418|NCT05279742|EXPERIMENTAL|HFpEF-CKD with MANP and oral placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug MANP and an oral placebo followed by a 1 week washout period.
62481419|NCT05279742|EXPERIMENTAL|HFpEF-EI with MANP and oral placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug MANP and an oral placebo followed by a 1 week washout period.
62690120|NCT05136027|EXPERIMENTAL|Intervention group|Intervention group: In the exercise session will carry out a combined training in four parts, low- intensity interval training in a bicycle, resistance circuit training, low- intensity interval training in a bicycle, and CORE exercises.
62690121|NCT05136027|NO_INTERVENTION|Attention Control|Regular in-hospital treatment with occupational activity sessions with the same frequency and duration as the intervention group.
62321591|NCT03238144|OTHER|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
62321592|NCT01519570|EXPERIMENTAL|An informational packet regarding shingles and the HZV|
62321593|NCT01519570|NO_INTERVENTION|Standard medical care from their primary care physician|
62321594|NCT04012268|EXPERIMENTAL|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs. They will also accept medication treatment by professional neurologists.
62321595|NCT04012268|OTHER|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists.
62321596|NCT05375903|EXPERIMENTAL|UGN-301 monotherapy dose escalation (Arm A)|Dose escalation of UGN-301 monotherapy in patients with recurrent NMIBC with high grade (HG) Ta and/or T1 disease and/or CIS or recurrent intermediate risk (IR) low grade (LG) Ta and/or T1 disease.
62321597|NCT05375903|EXPERIMENTAL|UGN-301 dose escalation + UGN-201 combination (Arm B)|Dose escalation of UGN-301 in combination with a fixed dose of UGN-201 in patients with recurrent NMIBC with HG Ta and/or T1 disease and/or CIS.
62321598|NCT05375903|EXPERIMENTAL|UGN-301 dose escalation + gemcitabine combination (Arm C)|Dose escalation of UGN-301 in combination with a fixed dose of gemcitabine in patients with recurrent NMIBC with HG Ta and/or T1 disease and/or CIS.
62321599|NCT01253512|EXPERIMENTAL|THR-18 0.25mg/kg|Treatment with combination with Tissue Plasminogen Activator (tPA) treatment
62321600|NCT01253512|PLACEBO_COMPARATOR|Placebo treatment|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
62321601|NCT01253512|EXPERIMENTAL|THR-18 0.5mg/kg|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
62321602|NCT05666011|EXPERIMENTAL|Group A -- Right side is Intervention Arm, Left side is Control Arm|Right Arm will be treated with IPL activation of SNA (Silver Nanoparticles ) and left arm with IPL alone.
62321603|NCT05666011|EXPERIMENTAL|Group B -- Left side is Intervention Arm, Right side is Control Arm|Left Arm will be treated with IPL activation of SNA (Silver Nanoparticles ) and right arm with IPL alone.
62321604|NCT00345553||1|Biliary atresia subjects who have their native liver
62321605|NCT00345553||2|Biliary atresia subjects who have had a liver transplant
62321606|NCT03791983|EXPERIMENTAL|Therapy Group|
62321607|NCT03791983|OTHER|Control Group|
62321608|NCT06455787|EXPERIMENTAL|J-Valve Transfemoral (TF) System|
62321609|NCT04160156||Type 1 diabetes|Subjects attending metabolic clinic who were suggested to use long term sensor due to persistent hyperglycemia and hypoglycemia
62321610|NCT01863264|EXPERIMENTAL|Cold Thin Liquid Barium|"Poland Spring Natural Spring Water will be placed in a refrigerator set to 36 °F, this will allow the water to cool to approximately 4-9 °C. As described by several authors, these waters will be used to mix the barium powder (Varibar® Thin Liquid Barium Sulfate for Suspension) to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula.~the infant will be required to swallow 5 boluses of this cold liquid barium while bottle feeding."
62321611|NCT06326840|EXPERIMENTAL|metformin intervention|All participants were administered 1500 mg/day of metformin for eight weeks.
62321612|NCT03819179|EXPERIMENTAL|Serum|Burt's Bees Serum
62321613|NCT03819179|EXPERIMENTAL|Serum with Biulin|Burt's Bees Serum with Biulin
62690122|NCT05534490|EXPERIMENTAL|Massage group|The group will have a foot massage.
62321614|NCT03819179|EXPERIMENTAL|Serum with Berenew Complex|Burt's Bees Serum with Berenew Complex
62690123|NCT05534490|NO_INTERVENTION|Control group|The group will not have any intervention.
62690124|NCT05012813|EXPERIMENTAL|Supportive care (SFIT, biospecimen, interview)|Patients participate in SFIT, using humidified wood and fragrance oils, over 1 hour. on day 1, day 3 or 4 and on day 7. Patients also undergo blood sample collection at baseline and on days 3 or 4 and 7 and participate in interviews at baseline and post-treatment.
62690125|NCT05720091|EXPERIMENTAL|ZX-7101A|
62690126|NCT03984188|EXPERIMENTAL|Low-dose Theophylline Group|Participant in this group will receive low-dose theophylline in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment, over a one year period.
62690127|NCT03984188|PLACEBO_COMPARATOR|Placebo Group|Participant in this group will receive a placebo in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment.
61926827|NCT05539716|NO_INTERVENTION|No Intervention (Aim 1) Group|Participants in this group will not receive an intervention and will only undergo several testing procedures conducted within 3 to 4 weeks to assess OSA severity.
62321615|NCT03819179|EXPERIMENTAL|Serum with Ecoskin|Burt's Bees Serum with Ecoskin
62321616|NCT03819179|EXPERIMENTAL|Serum with Bonicell|Burt's Bees Serum with Bonicell
62690128|NCT05173363||Older adults with frailty and mild cognitive impairment|
62690129|NCT04070846|EXPERIMENTAL|[14C] LC350189|Single oral dose
61926828|NCT05539716|EXPERIMENTAL|PAP Therapy and Lifestyle Intervention (Aim 2) Group|Participants in the Aim 1 Group found to have moderate to severe OSA (defined as having a Apnea-Hypopnea Index (AHI) of 15.0 events/hour or more) randomized to this arm will receive the PAP therapy and Lifestyle Intervention for 12 weeks.
62321617|NCT03771144|EXPERIMENTAL|Experimental|
62321618|NCT03222479|EXPERIMENTAL|treatment arm|All individual is instructed to use the application we developed for 4 weeks
62321619|NCT06692868||FeProCAYA-Onc|Newly diagnosed
62321620|NCT06692868||FeProCAYA-Onc (MidTerm)|\>5 years after first diagnosis
62321621|NCT06692868||FeProCAYA-Onc (long-term)|\> 20 years after first diagnosis
62321622|NCT06692868||FeProCAYA-SCT|Stem cell transplantation
62321623|NCT02152865|ACTIVE_COMPARATOR|Lupeol|Patients are supposed to apply lupeol on one side of face two times per day for 8 weeks
61926829|NCT05539716|EXPERIMENTAL|Lifestyle Intervention Only (Aim 2) Group|Participants in the Aim 1 Group found to have moderate to severe OSA (defined as having a Apnea-Hypopnea Index (AHI) of 15.0 events/hour or more) randomized to this arm will receive only the Lifestyle Intervention for 12 weeks.
62321624|NCT02152865|PLACEBO_COMPARATOR|Control vehicle|Patients are supposed to apply vehicle control to another side of face two times per day for 8 weeks
62481420|NCT05279742|EXPERIMENTAL|HFpEF-CKD with Sacbitril/Valsartan with an injected placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug Sacbitril/Valsartan and an injected placebo followed by a 1 week washout period.
62481421|NCT05279742|EXPERIMENTAL|HFpEF-EI with Sacbitril/Valsartan with an injected placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug Sacbitril/Valsartan and an injected placebo followed by a 1 week washout period.
62481422|NCT05279742|PLACEBO_COMPARATOR|HFpEF-CKD with an oral and injected placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive an oral and injected placebo followed by a 1 week washout period.
62481423|NCT05279742|PLACEBO_COMPARATOR|HFpEF-EI with an oral and injected placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive an oral and injected placebo followed by a 1 week washout period.
62481424|NCT00636129||1|Relaxation Response + Stress Management Curriculum
62481425|NCT01260389|NO_INTERVENTION|control group|Usual pharmacist care in patients with Chronic Obstructive Pulmonary Disease (COPD).
62481426|NCT01260389|EXPERIMENTAL|pharmaceutical care intervention|A pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
62481427|NCT06562257|EXPERIMENTAL|Treatment Group (Standard Dressing and Honey)|In the treatment group, we combined standard procedures with the application of Nusantara Honey. A 120 cm gauze roll was soaked in a bowl containing 12 cc of Nusantara Honey for precisely 1 minute until saturation. Once the wound bed had risen sufficiently, the honey-soaked gauze was applied and covered with sterile gauze.
61926830|NCT00928798|EXPERIMENTAL|rapamycin|one facial side rapamycin and one facial side placebo
61926831|NCT04205994|EXPERIMENTAL|Tolcapone|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in a single 200mg dosage once in randomized, double-blind, counterbalanced fashion with a placebo.
62481428|NCT06562257|ACTIVE_COMPARATOR|Control Group (Standard Dressing)|The control group adhered to the established standard operating procedure (SOP) at the Larynx Pharynx subdivision of Dr. Sardjito Hospital. This protocol involved several steps of wound debridement, saline irrigation, gauze roll application, and Prontosan administration.
62481429|NCT01683045|EXPERIMENTAL|The Estech COBRA® Surgical System|
62481430|NCT04322292|EXPERIMENTAL|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene.
62690130|NCT00567229|EXPERIMENTAL|Lenalidomide and Rituximab|This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.
62690131|NCT06386432|EXPERIMENTAL|Arm I (EQQUAL-NM, Program A)|Participants receive self-guided smartphone app-delivered EQQUAL-NM (Program A) intervention on study. Participants also receive motivational messages, reminders and smoking cessation information via text messages. Some participants also complete at-home saliva sample collection during follow-up.
62690132|NCT06386432|ACTIVE_COMPARATOR|Arm II (EQQUAL-NM, Program B)|Participants receive self-guided smartphone app-delivered EQQUAL-NM (Program B) intervention on study. Participants also receive motivational messages, reminders and smoking cessation information via text messages. Some participants also complete at-home saliva sample collection during follow-up.
62690133|NCT05822245|EXPERIMENTAL|Phase 1 Cohort A|Cohort A - Low Dose
62690134|NCT05822245|EXPERIMENTAL|Phase 1 Cohort B|Cohort B - High Dose
61926832|NCT04205994|PLACEBO_COMPARATOR|Placebo|Placebo will be administered in a single pill once in randomized, double-blind, counterbalanced fashion with a placebo.
61926833|NCT05369403|EXPERIMENTAL|Lebrikizumab|Participants will receive Lebrikizumab by subcutaneous (SC) injection.
61926834|NCT03230253|EXPERIMENTAL|Sequential training group|Exercise training for 30 minutes followed by 30 minutes of cognitive-based intervention
62321625|NCT04747574|OTHER|EXO-CD24 exosome treatment|"Group 1, 5 patients are treated with 1x10\^8 exosome particles per 2 ml saline.~Group 2: 5 patients are treated with 5x10\^8 exosome particles per 2 ml saline.~Group 3: 20 patients are treated with 1x10\^9 exosomes particles per 2 ml saline.~Group 4: 5 patients are treated with 1x10\^10 exosomes particles per 2 ml saline.~The drug is aerosolized in normal saline for inhalation and administered via a standard hospital-grade inhalation device, QD for 5 days. Study treatment is given as an add-on to the standard of care."
61926835|NCT03230253|EXPERIMENTAL|Dual training group|Exercise training simultaneously combined cognitive-based intervention for 60 minutes
61926836|NCT03230253|ACTIVE_COMPARATOR|Control training group|non-aerobic exercise (e.g., stretch, range of motion exercise...) and unstructured cognitive rehabilitation programs (e.g., reading newspapers, playing board games...) for 60 minutes
62321626|NCT02284334||Low GI-High GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): low-glycemic index; test meal (Visit 2): high-glycemic index"
62321627|NCT02284334||High GI-Low GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): high-glycemic index; test meal (Visit 2): low-glycemic index"
62481431|NCT05311085|ACTIVE_COMPARATOR|Monotherapy (Cytisine only)|12 weeks of cytisine: Participants allocated cytisine will be instructed to follow the manufacturer's 25-day dosing regimen, then follow a maintenance dose of cytisine from day 26 to week 12. Participants will also receive six months of text-based smoking cessation support.
62690135|NCT05822245|EXPERIMENTAL|Phase 2 Cohort C|Cohort C - Low Dose or Sham
61926837|NCT05522387|EXPERIMENTAL|Experimental: 1.0 mg/kg XPro1595|Patients will receive XPro1595.
61926838|NCT03239964|ACTIVE_COMPARATOR|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
61926839|NCT03239964|ACTIVE_COMPARATOR|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
61926840|NCT02495233|EXPERIMENTAL|Gilteritinib 120mg + Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
61926841|NCT02495233|EXPERIMENTAL|Gilteritinib 80mg+ Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
61926842|NCT03376438||Prospective observational cohorts|1) Atrial flutter without fetal hydrops; 2) Atrial flutter with fetal hydrops; 3) Supraventricular tachycardia without fetal hydrops; and 4) Supraventricular tachycardia with fetal hydrops
62690136|NCT05822245|EXPERIMENTAL|Phase 2 Cohort D|Cohort D - High Dose or Sham
61926843|NCT05031598|EXPERIMENTAL|Long-term fasting|The participants will undergo 6-12 fasting days according to the Buchinger Wilhelmi fasting program
61926844|NCT04327310|EXPERIMENTAL|Meplazumab|The vial of meplazumab will be reconstituted with 1 mL of water for injection. The required amount of drug solution will be withdrawn and added to 100 mL sterile normal saline (0.9%) for IV infusion. A single dose of meplazumab will be infused over 60 minutes at a constant rate using an infusion pump.
62321628|NCT00867243||Group 1: HCV Positive|50 patients whom are HCV positive
62690137|NCT02056145|PLACEBO_COMPARATOR|Group 1|Group 1 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.9% saline solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 30 ml saline solution 0.9%.
62690138|NCT02056145|ACTIVE_COMPARATOR|Group 2|Group 2 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 20 cc 0.25% bupivacaine solution en 10 cc saline solution 0.9%.
62690139|NCT02056145|ACTIVE_COMPARATOR|Group 3|Group 3 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.25% bupivacaine solution for lateral femoral cutaneous block, for a total of 30 cc of 0.25% bupivacaine solution.
62690140|NCT01872000|EXPERIMENTAL|Multifocal IOL|Phacoemulsification and IOL inserted following cataract surgery
61926845|NCT04327310|PLACEBO_COMPARATOR|Placebo|100ml placebo will be infused over 60 minutes at a constant rate using an infusion pump, single time.
61926846|NCT05745285|EXPERIMENTAL|LLS Program and Usual Care Group|Participants in the LLS Program and Usual Care condition will receive LLS services such as information, services, and financial aid so that patients can have better access to healthcare and better quality of life. Participants will also receive the standard care. Participants will be in this group for 6 months.
62130593|NCT02872675|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin will be administered as a taste/appearance-matched sugar/carbohydrate.
62321629|NCT00867243||Group 2: HCV Negative|50 patients whom are HCV negative.
62321630|NCT06041529|EXPERIMENTAL|Telmisartan/Amlodipine/Chlorthalidonea 40/5/12.5 mg|Telmisartan/Amlodipine/Chlorthalidonea 40/5/12.5 mg will be orally administered during the study period
62321631|NCT06041529|ACTIVE_COMPARATOR|Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg|Telmisartan/Amlodipine 40/5 mg and Hydrochlorothiazide 25 mg will be orally administered each during study period
61926847|NCT05745285|NO_INTERVENTION|Usual Care Group|Participants will receive the standard care. Participants will be in this group for 6 months.
61926848|NCT06112743|EXPERIMENTAL|Mavacamten|
61926849|NCT05576129|ACTIVE_COMPARATOR|TGP-tACS|Patients perform a motor skill acquisition task with the affected hand during TGP-stimulation over the sensorimotor cortex on the lesioned side.
61926850|NCT05576129|SHAM_COMPARATOR|Sham-tACS|Patients perform a motor skill acquisition task with the affected hand during sham-stimulation over the sensorimotor cortex on the lesioned side.
62130594|NCT01574859||hypopituitarism|group of patients with hypopituitarism
62130595|NCT06160518|NO_INTERVENTION|Control|The children will receive the standard pharmacological treatment of the unit to manage pain and stabilize their physiological parameters throughout the three days of study.
62321632|NCT03645837|EXPERIMENTAL|10 minutes|Compression clamp release start after 10 minutes
62321633|NCT03645837|EXPERIMENTAL|20 minutes|Compression clamp release start after 20 minutes
62321634|NCT03645837|ACTIVE_COMPARATOR|30 minutes|Compression clamp release start after 30 minutes
62339795|NCT02034474|EXPERIMENTAL|tocilizumab|Tocilizumab will be administered at day 0, week 4 and week 8 via an iv drip over 60 min. Dose is 8mg/kg but may be reduced to 4mg/kg if intolerable. Maximum dose will be 800mg.
62690141|NCT01872000|ACTIVE_COMPARATOR|Standard IOL|Phacoemulsification and IOL inserted following cataract surgery
61926851|NCT05552157|EXPERIMENTAL|Stage 1: Remternetug|Active Remternetug- blinded
61926852|NCT05552157|PLACEBO_COMPARATOR|Stage 1: Matching Placebo (Remternetug)|Matching placebo
61926853|NCT05552157|ACTIVE_COMPARATOR|Stage 2: Remternetug Open Label|Open label will start after last dose of Stage 1
61926854|NCT06651970|ACTIVE_COMPARATOR|Treatment Arm A (Acalabrutinib Monotherapy)|All participants randomised to Arm A will receive treatment with the investigational product acalabrutinib.
61926855|NCT06651970|OTHER|Treatment Arm B|Patients in Arm B will receive investigator's choice of treatment its duration will be based on standard duration of therapy for that regimen or until disease progression/patient withdrawal/study termination, whichever occurs first.
61926856|NCT04423939|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation (HCT) Patients|20 HCT patients at Duke
61926857|NCT04423939|EXPERIMENTAL|Caregivers|20 HCT patients caregivers at Duke
61926858|NCT06462716|EXPERIMENTAL|BY101298|Dose Escalation: Subjects will receive a starting dose of 50 milligram (mg) of BY1298 as Capsule orally once daily, ascending to 100, 200, 300 and 400 mg. If MTD is not reached at 400 mg, other dosage will be explored.
61926859|NCT01149811||Fipamezole ODT Cohort 1|
62690142|NCT02669641|EXPERIMENTAL|Steatosis|Patients with diagnosed steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline
61926860|NCT01149811||Fipamezole ODT Cohort 2|
61926861|NCT05695534|NO_INTERVENTION|Standard education|Patients will be educated about the procedure in a standard way by a docture and a nurse
61926862|NCT05695534|EXPERIMENTAL|VR Education|Patients will be educated with the use of virtual reality
61926863|NCT03703596|EXPERIMENTAL|Anlotinib hydrochloric|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
61926864|NCT03703596|EXPERIMENTAL|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
61926865|NCT04120493|EXPERIMENTAL|Cohort 1|Low dose rAAV5-miHTT (6x10\^12 gc/subject).
61926866|NCT04120493|EXPERIMENTAL|Cohort 2|High dose rAAV5-miHTT (6x10\^13 gc/subject).
61926867|NCT04120493|SHAM_COMPARATOR|Cohorts 1, 2|Imitation (sham) surgery
61926868|NCT04120493|EXPERIMENTAL|Cohort 3|"Low dose rAAV5-miHTT (6x10\^12 gc/subject).~High dose rAAV5-miHTT (6x10\^13 gc/subject)."
61926869|NCT04456010||Infertile couple|Infertile couple who had a fertility treatment prescribed during the past 9 months which was not completed yet.
61926870|NCT03786614|ACTIVE_COMPARATOR|Discontinuation arm|This group will be discontinued from serotonergic antidepressants and shifting them to other categories of antidepressants, i.e., medications that work through dopamine or nor-epinephrine, or by reducing the serotonin signal rather than increasing synaptic serotonin, as might be accomplished with low dose, sub-anti-psychotic doses of some second-generation anti-psychotics.
61926871|NCT03786614|ACTIVE_COMPARATOR|Continuation arm|This group will continue taking serotonergic antidepressants which is the standard care of treatment.
61926872|NCT01082731|EXPERIMENTAL|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
62130596|NCT06160518|EXPERIMENTAL|Study group|The children will receive virtual reality intervention which will take place using a cell phone coupled with the three-dimensional image glasses. The cell phone will play three-dimensional games which will be downloaded for free. The options for images and games involved which children could choose freely, all games will be suitable for the age group of the study.
62339796|NCT02034474|PLACEBO_COMPARATOR|Placebo|Placebo will be administered intravenously via an iv drip over 60 min
61926873|NCT01082731|ACTIVE_COMPARATOR|Artemether- Lumefantrine|Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
62339797|NCT05500924|EXPERIMENTAL|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
61926874|NCT03622749|ACTIVE_COMPARATOR|Patients|Individuals with Bipolar 1 Disorder
61926875|NCT03622749|NO_INTERVENTION|Controls|Healthy controls
61926876|NCT06010836|NO_INTERVENTION|Control|Group getting standard treatment without script guided intervention in the preoperative period
61926877|NCT06010836|EXPERIMENTAL|Script guided intervention|Group getting script guided intervention during the preoperative conversation
61926878|NCT01638819|EXPERIMENTAL|Autologous Cord Blood Stem Cells|
61926879|NCT01638819|PLACEBO_COMPARATOR|Placebo|Saline
61926880|NCT06047301|EXPERIMENTAL|Pathways|Pathways focuses on increasing patient hope to support personal goal pursuit during treatment for advanced lung cancer.
61926881|NCT06047301|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced Usual Care focuses on providing patients with education around common lung cancer concerns (e.g., pain and fatigue management) and resources to support them (e.g., supportive services available nationally and at the treating cancer center).
61926882|NCT03111069|EXPERIMENTAL|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
61926883|NCT03111069|EXPERIMENTAL|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
61926884|NCT06199726||Round 1 Interviews and/or Focus Group|"Approximately12 people will be recruited complete interviews or focus groups in Round 1.~The participants will be provided with the REFLECT tool. There will be interviews and discussions via telephone or ZOOM and feedback will be obtained to enhance the REFLECT tool."
61926885|NCT06199726||Round 2 Interviews and/or Focus Group|"Approximately 13 people will be recruited to complete interviews or focus group in Round 2.~The participants will be provided with the REFLECT tool that has been modified to include feedback from Round 1 interviews/focus groups.~There will be interviews and discussions via telephone or ZOOM and feedback will be obtained on the enhanced tool."
61926886|NCT03771547||More 80|The first group included ERCP patients aged 80 and above.
61926887|NCT03771547||Less 80|The second group included those ERCP patients younger than 80.
62481432|NCT05311085|ACTIVE_COMPARATOR|Monotherapy (Nicotine e-cigarette only)|12 weeks of a nicotine e-cigarette. Participants will also receive six months of text-based smoking cessation support.
61926888|NCT04134260|ACTIVE_COMPARATOR|Arm I (hormone therapy, radiation therapy)|Patients receive standard of care hormone therapy per physician discretion for 24 months. Patients also undergo standard of care pelvis and prostate bed radiation therapy 5 days per week over 5-6 or 7-8 weeks beginning within 90 days of randomization in the absence of disease progression or unacceptable toxicity.
61926889|NCT04134260|EXPERIMENTAL|Arm II (hormone therapy, radiation therapy, apalutamide)|Patients undergo standard of care hormone therapy and radiation therapy as in Arm I. Patients also receive apalutamide PO QD on days 1-90. Cycles repeat every 90 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
62130597|NCT00510302||Melanoma Risk-Reduction|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
62130598|NCT02245555||Patients with benign prostatic hyperplasia|
62321635|NCT06321536|EXPERIMENTAL|Group 1: MT then Observation|Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition) during facility study period 1, followed by a wash-out period, during which several patients are expected to be discharged and new patients are expected to be admitted. In facility study period 2, all consenting MDRO-positive patients (i.e. control condition) will observed with weekly sampling during study period 2.
62321636|NCT06321536|EXPERIMENTAL|Group 2: Obervation then MT|Group 2 will reverse the order of the intervention and control conditions relative to Group 1 (i.e., will conduct observation during facility study period 1, have a wash-out period, and then will offer MT to all MDRO-positive patients during facility study period 2).
62321637|NCT05878938|EXPERIMENTAL|NNC0365-3769 (Mim8) PPX|Participants will receive Mim8 prophylaxis (PPX) subcutaneous (s.c.) injection using a prefilled fixed dose DV3407-C1 pen-injector.
62481433|NCT05311085|ACTIVE_COMPARATOR|Combination therapy (Cytisine plus a nicotine e-cigarette)|12 weeks of cytisine (as above) and 12 weeks of a nicotine e-cigarette. Participants will also receive six months of text-based smoking cessation support.
62481434|NCT00761813|EXPERIMENTAL|Single Sliding Hip Screw|
61926890|NCT06313879|EXPERIMENTAL|trained parent group|The experimental group will be given a total of 6 hours of training for 2 weeks, and they will be asked to fill out the State and Trait Anxiety Scale and the General Self-Efficacy Scale before and after the training. After 3 months of counseling, the scales will be filled in again.
61926891|NCT06313879|NO_INTERVENTION|uneducated parent group|The control group will be asked to fill out the State and Trait Anxiety Scale and the General Self-Efficacy Scale at the first interview. After 2 weeks, they will be asked to fill out the scales simultaneously with the experimental group, without any training. They will be asked to fill out the Parental Knowledge Test, State and Trait Anxiety Scale, and General Self-Efficacy Scale simultaneously with the experimental group, without any intervention for 3 months.
62321638|NCT06631833|EXPERIMENTAL|Intervention group 48 persons(YPAP)|Intervention measures based on the YPAP model.
61926892|NCT03961854|ACTIVE_COMPARATOR|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
61926893|NCT03961854|PLACEBO_COMPARATOR|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
61926894|NCT01450111|EXPERIMENTAL|Lacosamide 50 mg group|Lacosamide 50 mg tablet, once a day per os (po)
61926895|NCT01450111|PLACEBO_COMPARATOR|Placebo group matched with lacosamide 50 mg|Placebo matched with lacosamide 50 mg tablet, po
61926896|NCT01450111|EXPERIMENTAL|Lacosamide 100 mg group|Lacosamide 100 mg tablet, po
61926897|NCT01450111|PLACEBO_COMPARATOR|Placebo group matched with lacosamide 100 mg|Placebo matched with lacosamide 100 mg tablet, po
61926898|NCT01450111|EXPERIMENTAL|Lacosamide 200 mg group|Lacosamide 200 mg tablet, po
61926899|NCT01450111|PLACEBO_COMPARATOR|Placebo group matched with lacosamide 200 mg|Placebo matched with lacosamide 200 mg tablet, po
62130599|NCT05546710|EXPERIMENTAL|Treatment Arm|miraDry treatment
62130600|NCT02216552|EXPERIMENTAL|Resveratrol|Intervention: Resveratrol Oral supplementation of resveratrol (ResVida) 75 mg twice daily (with breakfast and dinner) for a total daily dose of 150 mg for the duration of 30 days.
62130601|NCT02216552|PLACEBO_COMPARATOR|Placebo|Intervention: Placebo Control Oral supplementation of placebo twice daily (with breakfast and dinner) for a total duration of 30 days.
62321639|NCT06631833|NO_INTERVENTION|Control group 48 persons|No intervention was used in the control group.
62321640|NCT06684847|EXPERIMENTAL|Double-blinded treatment period: Efgartigimod PH20 SC|Participants receiving efgartigimod PH20 SC during the double-blinded treatment period
62481435|NCT00761813|EXPERIMENTAL|Multiple Cancellous Screws|
62481436|NCT06160804|PLACEBO_COMPARATOR|Local standard of care|
62481437|NCT06160804|ACTIVE_COMPARATOR|Experimental change in care|
62481438|NCT01633268||Healthy Volunteers|Healthy men and women aged 18-65
62481439|NCT01304823|ACTIVE_COMPARATOR|glucose|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
62481440|NCT01304823|ACTIVE_COMPARATOR|glucose + lactisole|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
62130602|NCT05413629|NO_INTERVENTION|Group1 (n=33)|Control 1: Pretest negative and post test positive group
62481441|NCT01304823|ACTIVE_COMPARATOR|mixed liquid meal|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
62481442|NCT01304823|ACTIVE_COMPARATOR|mixed liquid meal + lactisole|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
62130603|NCT05413629|NO_INTERVENTION|Group 2 (n=33)|Control 2: Pretest positive and post test positive
62481443|NCT01304823|PLACEBO_COMPARATOR|saline + lactisole|saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole
62481444|NCT01993810|ACTIVE_COMPARATOR|Arm I (photon beam radiation therapy and chemotherapy)|"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel\* IV over 1 hour and carboplatin\* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36. Patients with non-squamous cell cancer may receive pemetrexed IV and carboplatin IV on every 21 days. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
62481445|NCT01993810|EXPERIMENTAL|Arm II (proton beam radiation therapy and chemotherapy)|"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel\* and carboplatin\*, etoposide and cisplatin, or pemetrexed and carboplatin (for non-squamous cell cancer patients only) as in Arm I. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
62321641|NCT06684847|PLACEBO_COMPARATOR|Double-blinded treatment period: Placebo PH20 SC|Participants receiving placebo PH20 SC during the double-blinded treatment period
62321642|NCT06684847|EXPERIMENTAL|Open-label treatment period|Participants receiving efgartigimod PH20 SC during the open-label treatment period
62321643|NCT04841499|EXPERIMENTAL|Treatment Arm|7 days of BASIS™ orally
62321644|NCT03614429|NO_INTERVENTION|Control|"Group 1: control group, n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
62321645|NCT03614429|EXPERIMENTAL|Ch group|"Group 2: Chlorhexidine group (Ch group), n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
62321646|NCT02556645|EXPERIMENTAL|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
62321647|NCT02556645|ACTIVE_COMPARATOR|PCT|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies.
62321648|NCT03313505||Patients who had been tested for S100B protein|
62321649|NCT03313505||Patients who have benefited from another strategy|
62321650|NCT01175551||Group 1|women screened at Penn OB/GYN Associates or Helen O. Dickens Center with a documented singleton pregnancy less than 18 weeks gestational age
62321651|NCT01175551||Group 2|Nulliparous pregnant women (no previous pregnancy greater than 15 weeks) screened at Penn OB/GYN Associates or Helen O. Dickens Center less than 18 weeks gestational age
62321652|NCT04445467|EXPERIMENTAL|Favipiravir|1800 mg Favipiravir twice daily on Day 1 followed by 800 mg Favipiravir twice daily for the next 13 days.
62321653|NCT04445467|PLACEBO_COMPARATOR|Placebo|Matched Placebo
62321654|NCT00858702|EXPERIMENTAL|1|olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks
62321655|NCT00858702|EXPERIMENTAL|2|olmesartan medoxomil and a diuretic tablet (of the thiazide class)
62321656|NCT00112151|EXPERIMENTAL|LowT+Resistance Training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
62321657|NCT00112151|EXPERIMENTAL|LowT+No Resistance training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~No exercise program"
62321658|NCT00112151|EXPERIMENTAL|HighT+Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
62321659|NCT00112151|EXPERIMENTAL|HighT+No Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~No exercise program"
61926900|NCT06632951|EXPERIMENTAL|Arm 1: Livmoniplimab (Dose A) + Budigalimab|Participants will receive livmoniplimab (dose A) in combination with budigalimab, as part of the approximately 3.5 years study duration.
62481446|NCT06117579|EXPERIMENTAL|Inspiratory muscle training group|"Step 1:~During the consultation to diagnose obstructive sleep disorder with the pulmonologist (following polysomnography) to set up continuous positive airway pressure (CPAP):~* Introduction of CPAP~* Epworth Sleepiness Scale (ESS)~* Maximum Inspiratory Pressure (MIP) measurement~* Explanation of exercise program and use of POWERBreathe~Step 2:~6-week telephone follow-up with measurement of Epworth Sleepiness Scale (ESS)~Step 3:~Follow-up visit at 12 weeks after introduction of CPAP:~* Review of CPAP implementation~* Epworth Sleepiness Scale (ESS)~* MIP measurement"
62481447|NCT06117579|NO_INTERVENTION|Control group|"Step 1:~During the consultation to diagnose obstructive sleep disorder with the pulmonologist (following polysomnography) to set up continuous positive airway pressure (CPAP):~* Introduction of CPAP~* Epworth Sleepiness Scale (ESS)~* Maximum Inspiratory Pressure (MIP) measurement~Step 2:~6-week telephone follow-up with measurement of Epworth Sleepiness Scale (ESS)~Step 3:~Follow-up visit at 12 weeks after introduction of CPAP:~* Review of CPAP implementation~* Epworth Sleepiness Scale (ESS)~* MIP measurement"
62481448|NCT01299662|EXPERIMENTAL|Poly ICLC|One 1.6 mg subcutaneous injection of the adjuvant, poly ICLC, in the upper arm.
62481449|NCT06626971|OTHER|Intervention|Subcutaneous daily injection of ARA 290 at a dose of 4mg for 12 weeks.
62481450|NCT05970172|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat orally (or via gastric tube as an aqueous dispersion, if necessary) 3 times per week. The 24-week treatment period is defined as 4 weeks of fixed dose treatment followed by 20 weeks of dose titration(s). Dose titrations will be based on hemoglobin (Hb) monitoring. Participants in the study may receive roxadustat treatment for up to 52 weeks.
61926901|NCT06632951|EXPERIMENTAL|Arm 2: Livmoniplimab (Dose B) + Budigalimab|Participants will receive livmoniplimab (dose B) in combination with budigalimab, as part of the approximately 3.5 years study duration.
61926902|NCT06632951|EXPERIMENTAL|Arm 3: Docetaxel, Paclitaxel, or Gemcitabine|Participants will receive docetaxel, paclitaxel, or gemcitabine, investigator's choice, as part of the approximately 3.5 years study duration.
62321660|NCT00112151|ACTIVE_COMPARATOR|Placebo+Resistance Training|"Placebo Group applies two 2.5 gm placebo packets~1 year standard Progressive Resistance Training(PRT) program"
62321661|NCT00112151|PLACEBO_COMPARATOR|Placebo+No Resistance Training|"Placebo group applies two 2.5 gm placebo packets~No exercise program"
62321662|NCT01983345|NO_INTERVENTION|Control|No prenatal surgical repair of myelomeningocele
62321663|NCT01983345|EXPERIMENTAL|Case - open surgical repair|Prenatal surgical repair of fetal myelomeningocele
61926903|NCT04643457|EXPERIMENTAL|Part A: Intravenous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
61926904|NCT04643457|EXPERIMENTAL|Part A: Intravenous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
61926905|NCT04643457|EXPERIMENTAL|Part A: Intravenous UCB9741 arm 3|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
61926906|NCT04643457|EXPERIMENTAL|Part A: Intravenous UCB9741 arm 4|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
61926907|NCT04643457|EXPERIMENTAL|Part A: Intravenous UCB9741 arm 5|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
61926908|NCT04643457|EXPERIMENTAL|Part A: Subcutaneous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
61926909|NCT04643457|EXPERIMENTAL|Part A: Subcutaneous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
61926910|NCT04643457|PLACEBO_COMPARATOR|Part A: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
61926911|NCT04643457|PLACEBO_COMPARATOR|Part A: Subcutaneous Placebo arm|Subjects randomized to this arm will receive subcutaneous Placebo to maintain the blinding.
61926912|NCT04643457|EXPERIMENTAL|Part B: Intravenous UCB9741 arm|Subjects randomized to this arm will receive pre-specified intravenous doses of UCB9741.
61926913|NCT04643457|PLACEBO_COMPARATOR|Part B: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
62130604|NCT05413629|EXPERIMENTAL|Group 3 (n=33)|Experimental 1: Pretest negative and post test positive
62321664|NCT04489771|EXPERIMENTAL|Belzutifan 200 mg|Participants receive 200 mg of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.
62321665|NCT04489771|EXPERIMENTAL|Belzutifan 120 mg|Participants receive 120 mg of belzutifan by oral administration, QD, until disease progression or discontinuation.
62321666|NCT01679145||Alcohol- dependent patients|Detoxified alcohol- dependent patients in an inpatient setting
62321667|NCT01679145||Control group|Age- and gender matched healthy controls
62321668|NCT00812916||RF ablation|RF Ablation using specialized CFAE software
62321669|NCT05774457|EXPERIMENTAL|Traditional intervention|Participants will receive traditional training in voice, in a standard clinical environment.
62321670|NCT05774457|EXPERIMENTAL|Virtual reality intervention|Participants will receive voice training under virtual reality conditions.
62481451|NCT02698579||Long-term followup|Participants who have received Lenti-D Drug Product in a parent clinical study (bluebird bio-sponsored clinical studies ALD-102 and ALD-104) and who meet the eligibility criteria for the Study LTF-304 will be followed in this long-term followup study for 13 years (for a total of 15 years of follow-up after drug product infusion in the parent studies).
62481452|NCT01701323|EXPERIMENTAL|Treatment (Ex-vivo expanded cord blood progenitors)|Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
62481453|NCT02905435|EXPERIMENTAL|Biodegradable Temporizing Matrix|Biodegradable Temporizing Matrix (BTM)
62130605|NCT05413629|EXPERIMENTAL|Group 4 ( n=33)|Experimental 2: Pretest positive and post test positive
62130606|NCT03108703|EXPERIMENTAL|SBRT|RCC patients
62321671|NCT01501578||telomerase mutation|Patients with interstitial lung disease and telomerase mutation
62321672|NCT01501578||control|Patients with idiopathic pulmonary fibrosis and without telomerase mutation
62321673|NCT04532463||Amphotericin B,Flucytosine, Fluconazole|Amphotericin B 1 mg/kg 1 week \& Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
62481454|NCT06112379|EXPERIMENTAL|Dato-DXd plus durvalumab|"Participants receive durvalumab every 3 weeks (Q3W) + Dato-DXd Q3W as neoadjuvant therapy prior to surgery; followed by 9 cycles of durvaluamb Q3W as adjuvant therapy post-surgery. Adjuvant chemotherapy may be given in combination with durvalumab only if participants have residual disease.~Olaparib may be given for participants with gBRCA-positive tumours and residual disease~Adjuvant chemotherapy may be one of these:~1. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) and carboplatin (weekly or Q3W) for 4 cycles (12 weeks);~2. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) for 4 cycles (12 weeks);~3. Carboplatin (weekly or Q3W) + paclitaxel (weekly) for 4 cycles (12 weeks);~4. Capecitabine (Q3W) for 8 cycles."
62481455|NCT06112379|ACTIVE_COMPARATOR|Pembrolizumab plus chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Adjuvant capecitabine (Q3W) for 8 cycles may be given in combination with pembrolizumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease.
62481456|NCT02396459|EXPERIMENTAL|MCT8 deficiency patients|Triac treatment
62481457|NCT00747305|EXPERIMENTAL|Sunitinib|Sunitinib will be administered for 8 weeks prior to sugery
62130607|NCT03989024|EXPERIMENTAL|Pulsatile Gonadotropin-releasing Hormone|Drug: Gonadorelin. Use Gonadorelin for 3 months to treat PCOS. The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.
62130608|NCT03989024|EXPERIMENTAL|Clomiphene|Use Clomiphene for 3 months to treat PCOS
62321674|NCT03491163||Patients|Syndecan-1 concentration evaluation
62321675|NCT01454401|OTHER|Weekly LeucoPatch treatment|Weekly treatment of diabetic foot ulcers with LeucoPatch
62321676|NCT06569082|EXPERIMENTAL|Individuals with Poor Graft Function or Failure Following Allogeneic HSCT|"The recipient will undergo evaluations, then undergo a single infusion of CD34 selected HSCT from the original donor.~No additional GvHD prophylaxis will be administered. Patients who develop GvHD will receive the standard of care based on the discretion of the treating physician .~Patients will receive supportive care per institutional standards and at the discretion of the treating physician."
62321677|NCT04840654|ACTIVE_COMPARATOR|Caudal block|This group will receive the Caudal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
62321678|NCT04840654|ACTIVE_COMPARATOR|Pudendal Block|This group will receive the Pudendal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
62321679|NCT00624130|EXPERIMENTAL|Arm 1|
62321680|NCT00624130|ACTIVE_COMPARATOR|Arm 2|
62321681|NCT06374498|EXPERIMENTAL|Patients with stable CAD or acute coronary syndromes undergoing invasive coronary angiography|Patients referred to the Cardiology Division of the Massachusetts General Hospital, undergoing coronary angiography for stable or acute coronary disease and eligible for percutaneous coronary intervention (PCI) will be eligible for the study.
62321682|NCT04591314|EXPERIMENTAL|Neurofeedback participants|All the participants studied.
62321683|NCT06097195|NO_INTERVENTION|Usual Care|Participant has usual care
62321684|NCT06097195|OTHER|Usual Care + BioEP|Participant has usual care + BioEP algorithm on their EEG
62481458|NCT04529772|EXPERIMENTAL|acalabrutinib + R-CHOP|Acalabrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
62481459|NCT04529772|PLACEBO_COMPARATOR|placebo + R-CHOP|Placebo plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
62481460|NCT06741423||retroperitoneal fibrosis|All recruited patients with retroperitoneal fibrosis
62481461|NCT06741423||retroperitoneal sarcoma|All recruited patients with retroperitoneal sarcoma
62130609|NCT04014439||Normal Diaphragm|Diaphragm thickness is 2 mm or more
62130610|NCT04014439||Thinning Diaphragm|Diaphragm thickness is less than 2 mm
62130611|NCT01553058|ACTIVE_COMPARATOR|Adalimumab (Humira)|Injection of the active drug Humira.
62321685|NCT01605396|EXPERIMENTAL|Ridaforolimus + Dalotuzumab + Exemestane|Participants receive ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.
62321686|NCT01605396|ACTIVE_COMPARATOR|Ridaforolimus + Exemestane|Participants receive ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.
62321687|NCT04913259|OTHER|Remote monitoring for elderly patients with cancer|
62130612|NCT01553058|PLACEBO_COMPARATOR|Placebo Injection|Injection of placebo in place of active Humira injection.
62130613|NCT01553058|ACTIVE_COMPARATOR|NB-UVB phototherapy|NB-UVB Phototherapy 3 times per week, no other intervention.
62130614|NCT06150508|NO_INTERVENTION|Comparative group|Comparators will not be provided with the O2O service, but will be treated as usual (TAU) through the 1st tier health care clinics/centers in Pyeongchang-gun county.
62321688|NCT03517046|EXPERIMENTAL|CartiLife (low-dose group)|Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
62481462|NCT06741423||other retroperitoneal diseases|All recruited patients with other retroperitoneal malignancies
62321689|NCT03517046|EXPERIMENTAL|CartiLife (high-dose group)|Total defect volume in High-dose group is 2 \~ 4 ㎤.
62321690|NCT06368921|EXPERIMENTAL|VRT106|
62321691|NCT03242096|EXPERIMENTAL|Sirolimus coated balloon|Treatment of in-stent restenosis with a sirolimus coated balloon
62321692|NCT03242096|ACTIVE_COMPARATOR|Paclitaxel coated balloon|Treatment of in-stent restenosis with a paclitaxel coated balloon
62321693|NCT06693401|ACTIVE_COMPARATOR|Physiotherapy programme|The active comparator arm consisted of implementing the conventional physiotherapy programme in accordance to the usual physiotherapeutic rehabilitation approach through a programme tailored to the specific difficulties of each individual and adapted to their needs on a session-by-session basis and framed according the European and American Guidelines for Physical Therapy in Parkinson's Disease.
62130615|NCT06150508|EXPERIMENTAL|Intervention group|"Intervention group will use the service app Value Health for life-log recording. They regularly record life-log data such as blood pressure, blood glucose, medication, diet, exercise, and weight. (As mentioned, glucose level and blood pressure measurements will be automatically shared with the app using Bluetooth function of the provided checkers.) Interventions through application include automated message and alarm service through the app, as well as personalized intervention messages, record management, and other interventions from the Smart Healthcare Center and the primary healthcare provider."
62130616|NCT05664204|EXPERIMENTAL|Systematic ECMO|VA-ECMO will be implanted before the first pulmonary artery cross-clamp, in a systematic manner
62321694|NCT06693401|EXPERIMENTAL|Physiotherapy programme + Occupational Therapy programme|The experimental arm consisted of adding an occupational therapy programme to the conventional physiotherapy programme. The occupational therapy intervention consisted in fine motor tasks exercises implemented to address hand dexterity by training hand function with a range of exercises that enhance the main skills that make our hands useful and functional, such as object manipulation, finger isolation, finger and hand extension and flexion, and coordination and handwriting exercises in Portuguese language.
61926914|NCT04784104|EXPERIMENTAL|Supraclaviculer block|The coronal oblique supraclavicular block will be applied to the first group with ultrasound guidance using a 22G 50 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.) Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
61926915|NCT04784104|EXPERIMENTAL|Infraclaviculer block|The lateral sagittal infraclavicular block will be applied to the second group with ultrasound guidance using a 22G 100 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.). Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
61926916|NCT04425824|EXPERIMENTAL|Toripalimab combine with Rituximab|"Experimental: Toripalimab combine with Rituximab~Induction period:~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Maintenance:~Toripalimab 240mg administered intravenously (IV) and Rituximab 375mg/m² on Day 1 of each 56-day cycle for 6 cycles."
61926917|NCT00000434|EXPERIMENTAL|1|Fit and Strong! is a multi-component exercise and health education program that incorporates flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
61926918|NCT01195077|EXPERIMENTAL|Seaweed, Spirulina, Seaweed + Spirulina|"Randomized to:~Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day."
61926919|NCT03751228|EXPERIMENTAL|BMS-986165 taste evaluation|BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners
61926920|NCT05673564||anatomical resection group|Anatomical resection was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
61926921|NCT05673564||nonanatomical resection group|Nonanatomical resection known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
61926922|NCT03492411|EXPERIMENTAL|eHealth Intervention|This group will receive information about an eHealth breastfeeding co-parenting resource. They will have a short demonstration of the site and will receive weekly emails for 6 weeks reminding them about the resource and their participation in the study.
61926923|NCT03492411|NO_INTERVENTION|Usual Care|This group will not receive any intervention. They will receive emails for 6 weeks reminding them that they are in the study.
61926924|NCT01515007|EXPERIMENTAL|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
61926925|NCT01515007|PLACEBO_COMPARATOR|Placebo|Liquid formulation of empty liposomes
61926926|NCT00095628|EXPERIMENTAL|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62130617|NCT05664204|ACTIVE_COMPARATOR|On-demand ECMO|"VA-ECMO will be implanted intraoperatively, in an unplanned manner if the hemodynamic and respiratory indices meet pre-planned criteria at different time-points:~a PaO2/FiO2 ratio\<100 mmHg or a respiratory acidosis, with pH\< 7.2, PaCO2\>60 mmHg, a mean pulmonary arterial pressure\>50mmHg (or 2/3 of MAP) and/or an acute pulmonal core at trans-esophageal echography monitoring an acute left ventricular dysfunction at trans-esophageal echography monitoring"
62339798|NCT05500924|EXPERIMENTAL|Control group|5 sets of functional activities each will be repeated for 3 times: Sit to stand Squat Stand to sit Stairs stepping Bridging
62339799|NCT03497026|EXPERIMENTAL|Robotic Bronchoscopy|Robotic bronchoscopy with Robotic Bronchoscopy Platform
61926927|NCT06256120|EXPERIMENTAL|R- fluid group|The group to which restrictive fluid replacement will be applied (Group R); 3 ml/kg/hour Ringer lactate (RL) solution will be given.
61926928|NCT06256120|EXPERIMENTAL|L- fluid group|7 ml/kg/hour RL solution will be given to the group that will receive a liberal liquid regimen (Group L).
61926929|NCT01056328|EXPERIMENTAL|St. Jude Medical Cardiac Ablation System|
61926930|NCT01056328|ACTIVE_COMPARATOR|FDA approved Open Irrigated Radio Frequency Ablation System|
61926931|NCT03491683|EXPERIMENTAL|Cohort A: Unmethylated MGMT Promoter|Cohort A will include participants with a glioblastoma tumor with an unmethylated MGMT promoter. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ; only during radiation therapy), if clinically indicated.
61926932|NCT03491683|EXPERIMENTAL|Cohort B: Methylated MGMT Promoter|Cohort B will include participants with a glioblastoma tumor with a methylated MGMT promoter or with indeterminate MGMT status. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ), if clinically indicated. Participants will continue to receive TMZ following radiation therapy, for up to six additional cycles, if clinically indicated.
62321695|NCT06691308|EXPERIMENTAL|CD276 positive recurrent or progressive glioblastoma|Inject WL276 CAR-T cells through local intracranial administration using the Ommaya device, once a week for 3 weeks. After 3 weeks of continuous administration, perform cranial MRI imaging to evaluate tumor progression and assess drug efficacy. Propose to deliver doses of 5 \* 10 \^ 6 CAR-T Cells and 1 \* 10 \^ 7 CAR-T Cells in sequence, with 3 subjects enrolled in each dose group
62481463|NCT03461445|ACTIVE_COMPARATOR|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
62481464|NCT03461445|EXPERIMENTAL|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
62481465|NCT06729268||Patients treated in the intensive care unit|Patients treated in the intensive care unit during the first six hours after admission.
62481466|NCT04509167|EXPERIMENTAL|Treatment|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
62481467|NCT03617198|EXPERIMENTAL|Cohort 1|Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells. All other study procedures are the same as Cohort 2.
62321696|NCT04449068||Evaluation of patients with Tourette's Gilles Syndrome|Neurological and neuropsychological evaluations of patients with Tourette's Gilles syndrome treated with high frequency bilateral stimulation of the anterior part of the internal pallid globus
62321697|NCT03408847|ACTIVE_COMPARATOR|MC-EVOO in addition to steroid therapy|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
62481468|NCT03617198|EXPERIMENTAL|Cohort 2|Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells. All other study procedures are the same as Cohort 1.
62697491|NCT05321602|EXPERIMENTAL|LY03010 156 mg treatment group, deltoid|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-\[2-\[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl\]ethyl\]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido\[1,2-a\]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 156 mg IM injection on Day 1 in the deltoid muscle."
61926933|NCT02003339|EXPERIMENTAL|RMIs|
61926934|NCT03624829||Exp: Patients of GPs with shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are randomized to shared care before the 12 months.
62130618|NCT02076659|EXPERIMENTAL|F8IL10 + MTX|"Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid.~An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication.~In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2."
62130619|NCT06520137||Group A with PPD ≤ 3 mm|
62130620|NCT06520137||Group B with PPD ≥ 4 mm|
62321698|NCT03408847|PLACEBO_COMPARATOR|Refined olive oil and steroid therapy|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
62321699|NCT06353945|EXPERIMENTAL|vaginal moisturizer|45 participants treated with vaginal moisturizer
62321700|NCT03252639||Patients with Renal Artery Stenosis|Patients with renal artery stenosis which may benefit from endovascular treatment will be recruited. Those patients who cannot benefit from this procedure will be excluded.
61926935|NCT03624829||Con: Patients of GPs without shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are not randomized to shared care before the 12 months, and all patients 16-65 years old who during 12 months have been in contact with a GP in any of the six GP center before the randomization and implementation of shared care.
61926936|NCT02723578|EXPERIMENTAL|Pemetrexed and Erlotinib|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and Erlotinib 150 mg PO once daily on days 1-21 every 21 days
61926937|NCT01830075|NO_INTERVENTION|Control group|The control group receives care as usual.
61926938|NCT01830075|EXPERIMENTAL|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
61926939|NCT05512364|EXPERIMENTAL|Experimental arm|elacestrant 400 mg/day orally once daily on a continuous dosing schedule
61926940|NCT05512364|ACTIVE_COMPARATOR|Control arm|standard endocrine treatment - the same they were receiving at the time of ctDNA detection
62130621|NCT04770649||COVID-19 vaccine recipients|Subjects who have an appointment to receive a COVID-19 vaccine, and are able to provide samples prior to and after their first vaccine dose.
62130622|NCT03837886|EXPERIMENTAL|Alkalosis group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of sodium bicarbonate
62321701|NCT05346393|EXPERIMENTAL|TIPS group|TIPS implant (transjugular intrahepatic portosystemic shunt)
62321702|NCT05346393|ACTIVE_COMPARATOR|Control group|Standard medication therapy with terlipressin and albumin. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
62321703|NCT00651118|ACTIVE_COMPARATOR|fluticasone propionate|
62321704|NCT00651118|EXPERIMENTAL|azelastineHcl/fluticasone propionate|
62321705|NCT00651118|PLACEBO_COMPARATOR|Placebo|
62481469|NCT06741488||fibromyalgia|No intervention will be made. The questionnaire will assess adherence to exercise and perceived barriers.
62481470|NCT06371300|ACTIVE_COMPARATOR|Red light only group|LLLT will be administered using the Espansione Group Ltd Eye-light unit. LLLT consisting of a wearable facial mask with red light emitting diodes (LEDs) is administered for 30 minutes.
62481471|NCT06371300|EXPERIMENTAL|Red plus blue light group|LLLT consisting of a wearable facial mask with red LEDs is administered for 15 minutes, followed by a mask with blue LEDs for another 15 minutes.
62481472|NCT06371300|SHAM_COMPARATOR|Sham treatment group|Sham treatment will be administered by using facial mask with red LEDs emitting at less than 10% fluence power output for 15 minutes, followed by a mask with blue LEDs emitting at less than 10% fluence power output for another 15 minutes.
62130623|NCT03837886|PLACEBO_COMPARATOR|Placebo group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
62321706|NCT00651118|ACTIVE_COMPARATOR|azelastine Hcl|
62321707|NCT06051253|EXPERIMENTAL|TDM-based group|At week 0,2, and 6, infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
62321708|NCT06051253|ACTIVE_COMPARATOR|Standard group|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
62321709|NCT00540176|EXPERIMENTAL|Cohort A|Recurrent disease with previous surgery, radiation therapy and/or chemotherapy
62321710|NCT00540176|EXPERIMENTAL|Cohort B|Newly diagnosed disease with no previous therapy
62321711|NCT00069095|EXPERIMENTAL|XELOX (oxaliplatin+capecitabine)|Patients in the 2-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
62481473|NCT06742281|EXPERIMENTAL|CVXGA (CVXGA50)|CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
62130624|NCT05796323||Methodist Health System Employees|All MHS employees, clinical and non-clinical.
62130625|NCT01902784|EXPERIMENTAL|Storytelling Interview|"Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST).~These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient)."
62481474|NCT06742281|ACTIVE_COMPARATOR|COMIRNATY®|COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
62481475|NCT03458520||Image Registry|patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
62697492|NCT05321602|EXPERIMENTAL|LY03010 156 mg treatment group, gluteal|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-\[2-\[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl\]ethyl\]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido\[1,2-a\]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 156 mg IM injection on Day 1 in the gluteal muscle."
61926941|NCT04838197||Caregiver|If the caregiver agrees and consents to participating in the study, basic demographic and social data will be collected at baseline. The caregiver will also complete the caregiver burden questionnaire via telephone call at five different time points: pre-operatively, and post-operative 48 hours, 1 week, 2 weeks, and 1 month.
61926942|NCT06455358|EXPERIMENTAL|61Cu-NODAGA-LM3 PET/CT before 68Ga-DOTATOC PET/CT|Participants randomized into this group undergo 61Cu-NODAGA-LM3 PET/CT between 24 hours to 4 weeks before routine 68Ga-DOTATOC PET/CT.
61926943|NCT06455358|EXPERIMENTAL|61Cu-NODAGA-LM3 PET/CT after 68Ga-DOTATOC PET/CT|Participants randomized into this group undergo 61Cu-NODAGA-LM3 PET/CT between 24 hours to 4 weeks after routine 68Ga-DOTATOC PET/CT.
61926944|NCT06441955|ACTIVE_COMPARATOR|Moderna COVID-19 Vaccine|Unvaccinated individuals: Two doses of Moderna COVID-19 Vaccine (2023-2024 Formula) are administered. The second dose is administered 1 month after the first. Moderna COVID-19 Vaccine to include the 2023-2024 formula. The Moderna COVID-19 Vaccine (2023-2024 Formula) includes a monovalent (single) component that corresponds to the Omicron variant XBB.1.5 of SARS-CoV-2. The Moderna COVID-19 Vaccine (2023-2024 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. The Moderna COVID-19 Vaccine, Bivalent is no longer authorized for use in the United States. Moderna COVID-19 Vaccine is a suspension for injection. A single dose is 0.25 mL. (3) History of a severe allergic reaction (e.g., anaphylaxis) to any component of Moderna COVID-19 Vaccine or following a previous dose of a Moderna COVID-19 vaccine.
61926945|NCT06441955|ACTIVE_COMPARATOR|Ritonavir-Boosted Nirmatrelvir (Paxlovid)|The COVID-19 Treatment Guidelines Panel (the Panel) recommends using nirmatrelvir 300 mg with ritonavir 100 mg (Paxlovid) orally (PO) twice daily for 5 days in nonhospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression (). Treatment should be initiated as soon as possible and within 5 days of symptom onset. Ritonavir-boosted nirmatrelvir is available through an FDA EUA for the treatment of mild to moderate COVID-19 in nonhospitalized adolescents aged 12 to 17 years and weighing ≥40 kg.4 For recommendations on using ritonavir-boosted nirmatrelvir in nonhospitalized children with COVID-19.
61926946|NCT06048614|EXPERIMENTAL|Intervention Arm (Saline Enema Arm)|"After randomisation, infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) earliest at 48 to 72 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds"
61926947|NCT06048614|ACTIVE_COMPARATOR|Control Arm (Glycerin Suppository Arm)|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
61926948|NCT01043510|EXPERIMENTAL|A1, first period|
61926949|NCT01043510|ACTIVE_COMPARATOR|A2, second period|
61926950|NCT01043510|ACTIVE_COMPARATOR|B1, first period|
61926951|NCT01043510|EXPERIMENTAL|B2, second period|
61926952|NCT02812355|EXPERIMENTAL|half heparinization|heparin I.V. 150 U/kg
61926953|NCT02812355|ACTIVE_COMPARATOR|full heparinization (300 U/kg)|heparin I.V. 300 U/kg
61926954|NCT03845374|EXPERIMENTAL|Conventional Antibiotics+ Hyper-CL™ lens|Conventional treatment with topical Antibiotics+ Hyper-CL™ lens
61926955|NCT03845374|NO_INTERVENTION|Conventional Antibiotics|Conventional treatment with topical Antibiotics
61926956|NCT05675982|EXPERIMENTAL|Minimal residual disease assessment|
61926957|NCT01482351|EXPERIMENTAL|MCI/OSA/CPAP Adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was equal to or greater than 4 hours per night over one year. CPAP adherence Intervention was provided by research staff.
62130626|NCT01902784|NO_INTERVENTION|Monitoring of well-being|Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
62481476|NCT02651948|EXPERIMENTAL|Transperineal prostate biopsy (TPB)|Transperineal prostate biopsy MRI-guided
62481477|NCT02651948|ACTIVE_COMPARATOR|Transrectal prostate biopsy (TRB)|Transrectal prostate biopsy echo-guided
62481478|NCT04501003|OTHER|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm.
61926958|NCT01482351|EXPERIMENTAL|MCI/OSA/CPAP Non-adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was less than 4 hours per night or CPAP use was withdrew for any reason over one year. Attention control intervention was provided by staff.
61926959|NCT06553027|EXPERIMENTAL|CVN424 75 mg|Participants will be administered with oral doses of 75 mg CVN424.
61926960|NCT06553027|EXPERIMENTAL|CVN424 150 mg|Participants will be administered with oral doses of 150 mg CVN424.
61926961|NCT06553027|PLACEBO_COMPARATOR|Placebo|Participants will be administered with placebo.
61926962|NCT06701721|EXPERIMENTAL|Sequential Multiple Ascending Doses|Participants will be sequentially enrolled to a low, medium, and high doses and receive a total of 3 monthly treatments.
61926963|NCT01763671|ACTIVE_COMPARATOR|Docetaxel|
61926964|NCT01763671|EXPERIMENTAL|Paclitaxel - Bevacizumab|
61926965|NCT04490824|ACTIVE_COMPARATOR|Treated Then Control Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale KELEA Excellerated Water for 2 days followed by inhaling water without an elevated level of KELEA for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
61926966|NCT04490824|PLACEBO_COMPARATOR|Control Than Treated Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale water without an elevated level of KELEA for 2 days followed by inhaling KELEA Excellerated water for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
61926967|NCT06628908|EXPERIMENTAL|Suzetrigine (SUZ)|Participants will be randomized to receive SUZ.
61926968|NCT06628908|ACTIVE_COMPARATOR|Pregabalin|Participants will be randomized to receive Pregabalin.
61926969|NCT06628908|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive placebo matched to SUZ and Pregabalin.
61926970|NCT06604715|EXPERIMENTAL|JNJ-87562761|Participants will receive JNJ-87562761 during the Part 1 (Dose escalation) to determine the recommended phase 2 dose (RP2D) regimen(s). The dose will be escalated sequentially until the RP2D regimen(s) have been identified. In Part 2 (Dose expansion) participants will receive JNJ-87562761 at the RP2D regimen(s) determined in Part 1.
61926971|NCT06247683|EXPERIMENTAL|trifocal intraocular lens|Bilateral Implantation of new trifocal intraocular lens
61926972|NCT04856202|ACTIVE_COMPARATOR|Intervention|A trained facilitator will schedule two facilitated Respecting Choices interviews with the patient and preferably, if the patient agrees, in the presence of a caregiver or relative.
61926973|NCT04856202|NO_INTERVENTION|Control|Care as usual
61926974|NCT01175837|EXPERIMENTAL|Short-term fasting prior to systemic chemotherapy|"COHORT I: Patients fast 24 hours before day 1 of course 2 of chemotherapy. If fast is well tolerated, patients may escalate fasting by 12 hours for each subsequent course of chemotherapy for up to 3 courses in the absence of unacceptable toxicity.~COHORT II: Patients fast at the longest fasting regimen found to be safe and tolerable in cohort I before day 1 of each course of course of chemotherapy for up to 4 courses in the absence of unacceptable toxicity."
61926975|NCT02105766|EXPERIMENTAL|Female participants with SCD or Beta-thalassemia receiving stem cell transplant with male donor|Female participants with Sickle Cell Disease (SCD) or Beta-thalassemia receiving stem cell transplant with male donor. Pentostatin given on days -21, -17, -13, -9 and oral cyclophosphamide from days -21 to -8, with the intention to be administered in the outpatient setting. Alemtuzumab on days 7 to 3, and 300 cGy TBI on day 2. Sirolimus started at a loading dose of 5mg PO every 4 hours for three doses on day -1 and adjusted to maintain trough levels between 10-15 ng/mL. The PBSC graft targeted to deliver .10 x 106 CD34+ cells/kg (minimum .5 x 106) and infused on day 0.
61926976|NCT02105766|EXPERIMENTAL|Participants with pre-existing antibodies and SCD or Beta-thalassemia receiving stem cell transplant|Participants with pre-existing antibodies and Sickle Cell Disease (SCD) or Beta-thalassemia receiving stem cell transplant. Pentostatin given on days -21, -17, -13, -9 and oral cyclophosphamide from days -21 to -8, with the intention to be administered in the outpatient setting. Alemtuzumab on days 7 to 3, and 300 cGy TBI on day 2. Sirolimus started at a loading dose of 5mg PO every 4 hours for three doses on day -1 and adjusted to maintain trough levels between 10-15 ng/mL. The PBSC graft targeted to deliver .10 x 106 CD34+ cells/kg (minimum .5 x 106) and infused on day 0.
62130627|NCT02697877||Patients with known or suspected coronary artery disease.|Patients with known or suspected coronary artery disease undergoing clinically ordered stress cardiac magnetic resonance imaging.
62690143|NCT06661421|EXPERIMENTAL|Dry Needling Group|Group A will receive Dry Needling Therapy (DNT) along with routine physical therapy. Each session includes a 5-minute warm-up, stretching, and strengthening exercises. Hamstring stretches will be done with the child supine, one leg flat, and the opposite hip flexed to 90°. Active knee extension will be held for 5 seconds, followed by a 40-second assisted stretch, repeated five times. If a short psoas is detected, psoas stretching will be done prone, with assisted hip extension for 5 seconds and a 40-second hold, repeated five times. Strengthening exercises, including squats, heel rises, and step-ups with a loaded backpack, will target the lower extremities. The program lasts one month with three sessions per week, gradually increasing in intensity. Dry Needling (DN) uses 0.30 × 50 mm needles, applying the fast-in, fast-out technique for 1 minute per muscle. DN is done once per week for 10 weeks, with at least 48 hours between treatments.
62481479|NCT06741449|ACTIVE_COMPARATOR|pilonidal sinus|
62481480|NCT05091437||Retrospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in the past; more preciously from March 2019 to the study initiation date. \[ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and \< 3 cm) for subject inclusion\].
62481481|NCT05091437||Prospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in imaging exams in routine clinical practice, prior to 30 days of informed consent given \[ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and \< 3 cm)) for subject inclusion\]. Subjects identified from different sources (Nodules identified incidentally and in lung cancer screening programs) will be considered.
62481482|NCT05487248|EXPERIMENTAL|Unresectable locally advanced or metastatic colorectal cancer patients|"● Samples collection:~* Collection of blood samples 6 x 9 ml at day 1~* Collection of blood samples 4 x 9 ml at day 15 and day 29~* Collection of blood samples 4 x 9 ml at week 8 or 12 and every 8 or 12 weeks thereafter (+/- 7 days) until evidence of progressive disease by RECIST 1.1 (according to local assessment)"
62481483|NCT06149429|EXPERIMENTAL|Single-Arm Open Pilot|"Pre- Post-intervention design. The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
62321712|NCT00069095|EXPERIMENTAL|XELOX (oxaliplatin+capecitabine) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
62321713|NCT00069095|ACTIVE_COMPARATOR|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)|Patients in the 2-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
62339800|NCT06282471|EXPERIMENTAL|Expressive Writing and Problem-Solving Therapy|Self-guided expressive writing and problem-solving therapy intervention for adult cancer survivors and adult informal caregivers thereof
62481484|NCT06732414||Conditions that may be initially evaluated or managed by A&amp;I but not categorized in 1 or 2 above|Conditions that may be initially evaluated or managed by an allergist-immunologist or rhinologist but not categorized in (1) or (2) above (eg, hypereosinophilia, mast cell disorders, pruritus, chronic cough, smell disorders)
62481485|NCT06732414||Individuals with a suspected allergic or atopic disease|Individuals with a suspected allergic or atopic disease, but without demonstrated allergen sensitization (eg, contact hypersensitivity, chronic spontaneous urticaria, drug allergy)
62481486|NCT06732414||Individuals with an allergic, atopic, or sinus disease|Individuals with an allergic, atopic, or sinus disease (eg, atopic dermatitis, eosinophilic esophagitis (EoE), asthma, chronic rhinosinusitis with polyposis) with documented allergen sensitization in the skin or blood
62481487|NCT01448590||Epidural Resite|After ADP, those patients who receive an epidural resite.
62481488|NCT01448590||Spinal catheter|After ADP, those who receive the epidural catheter into the spinal space
62481489|NCT06439485|EXPERIMENTAL|Part 1|Participants enrolled in Part 1, the dose of pemigatinib the participant receive will depend on when the participant join this study. Up to 2 dose levels of pemigatinib will be tested. Up to 6 participants will be enrolled at each dose level. The first group of participants will receive the highest dose level of pemigatinib. A second group will receive a lower dose of pemigatinib than the group before it, if intolerable side effects are seen.
62481490|NCT06439485|EXPERIMENTAL|Part 2|Participants in Part 2, you will receive pemigatinib at the recommended dose that was found in Part 1.
62481491|NCT05934981|EXPERIMENTAL|Low Pressure and warm and humidified CO2 insufflation|Low pressure pneumoperitoneum and use warm and humidified CO2 insufflation
61926977|NCT02105766|OTHER|Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor|Participants received filgrastim to mobilize peripheral blood stem cells for apheresis collection. Collected stem cells of donor will then be infused to HLA matched sibling.
62130628|NCT00678912|EXPERIMENTAL|1|Children are mechanically ventilated with Smartcare/PS
62481492|NCT05934981|ACTIVE_COMPARATOR|Low Pressure|Low pressure pneumoperitoneum
62481493|NCT06003387|EXPERIMENTAL|CSL222|Participants will receive CSL222 as a single intravenous (IV) infusion of 2 × 10\^13 genome copies per kilogram (gc/kg) on Day D.
62481494|NCT06425536|EXPERIMENTAL|Biorepair Total protection toothpaste|
62690144|NCT06661421|OTHER|Conventional Therapy Group|Sessions will include a 5-minute warm-up, stretching, and strengthening exercises. Hamstring stretches will be done with the child supine, one leg flat, and the opposite hip flexed to 90°. Active knee extension will be held for 5 seconds, followed by a 40-second assisted stretch, repeated five times. If a short psoas is detected, a prone psoas stretch will involve assisted hip extension for 5 seconds, followed by a 40-second hold, repeated five times. Strengthening exercises like squats, heel raises, and step-ups with a loaded backpack will target the lower extremities. The program will last one month, with three weekly sessions focusing on hamstring stretches and progressive resistance exercises.
62690145|NCT01737723||Study population|Stroke patients
62690146|NCT06085872|EXPERIMENTAL|PsyPills - Experimental|Each recruited student randomized in the experimental group will receive the PsyPills app.
62130629|NCT00678912|NO_INTERVENTION|2|Children are mechanically ventilated with usual care
62130630|NCT03750214|EXPERIMENTAL|Biop Coplposcopy System|Biop Colposcopy system procedure
62481495|NCT06425536|ACTIVE_COMPARATOR|Biosmalto Caries and Erosion|
62130631|NCT04458454||Examination of relaxin levels|This is a pilot study of 1 group of patients. The analysis of relaxin levels in serum and follicular fluid obtained on the day of puncture of the follicles in patients undergoing treatment in the IVF protocol is carried out.
62130632|NCT03268213|EXPERIMENTAL|Fecal microbial transplantation|Treated with fecal microbial transplantation
62130633|NCT03373708|EXPERIMENTAL|EC follow T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
62130634|NCT03373708|EXPERIMENTAL|TC follow endocrine|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for four cycles followed by goserelin acetate+tamoxifen for young patients/ letrozole for postmenopausal patients
62130635|NCT04364139|EXPERIMENTAL|Lower BP goal and Ramipril|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Ramipril 2.5 to 10 mg/d
62321714|NCT00069095|ACTIVE_COMPARATOR|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.
62321715|NCT00005022|EXPERIMENTAL|Arm 1|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
62321716|NCT00005022|EXPERIMENTAL|Arm 2|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/BID x last 5 days.
62690147|NCT06085872|ACTIVE_COMPARATOR|MoodWheel - Monitoring|The students randomized in the control group will complete the MoodWheel app.
61926978|NCT06532591|EXPERIMENTAL|Experimental: Cadonilimab +Paclitaxel/ Albumin-bound paclitaxel +Carboplatin|Drug:Cadonilimab +Paclitaxel/ Albumin-bound paclitaxel+Carboplatin neoadjuvant chemotherapy\[Cadonilimab, 10mg/kg ,d1,q3w; Paclitaxel 175mg/m2 ivgtt d1/Albumin-bound paclitaxel 260mg/m2,ivgtt(\>30min) ,d1,q3w; carboplatin AUC 5 ivgtt d1, q3w\] for 3 cycles.The patient was evaluated after 3 cycles of neoadjuvant chemotherapy. The surgery was performed 3-6 weeks after the completion of neoadjuvant chemotherapy. After surgery patients could receive up to 12 months of adjuvant chemotherapy.
61926979|NCT02772679|EXPERIMENTAL|PolyTregs+IL-2|Patients with type 1 diabetes mellitus will receive ex vivo expanded human autologous polyclonal regulatory T cells plus IL-2
61926980|NCT00630695|EXPERIMENTAL|1|Lanreotide LP 90
61926981|NCT00630695|PLACEBO_COMPARATOR|2|
61926982|NCT04503694|EXPERIMENTAL|Single arm|"* Induction treatment: treatment with nivolumab (240 mg intravenously on day 1 and 14) and regorafenib (60 mg/day orally from day 1 to 14)~* Standard SCRT: consists of 25 Gy delivered in 5 fractions (from day 22 to 26)~* Consolidation treatment: treatment with nivolumab (240 mg intravenously on day 29, 43 and 57) and regorafenib (60 mg/day orally from day 29 to 49)~* Surgery: Surgical resection will be performed according to the principles of TME (between day 74 and 87, i.e., between 7 to 8 weeks after completion of SCRT). As an alternative to surgery, subjects who achieve cCR can be offered a watch \& wait approach.~* Adjuvant chemotherapy: Administration of adjuvant chemotherapy will be left to the discretion of the treating physician The study also includes translational procedures (collection of tumour biopsies, blood and stool samples at pre-specified time points) for exploratory molecular and immune contexture analyses. These are mandatory for all study subjects."
61926983|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.~The dosing of all antibiotics will be adjusted according to creatinine clearance."
61926984|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
61926985|NCT05222243|ACTIVE_COMPARATOR|Calcium Hydroxide (CH)|Calcium Hydroxide is the gold standard for direct pulp capping depends on regeneration
61926986|NCT05222243|EXPERIMENTAL|MTA|Mineral trioxide aggregate used for pulp regeneration
61926987|NCT05222243|EXPERIMENTAL|Formocresol (FC)|composed of formaldehyde, cresol, glycerin and water used for fixation of pulp tissue
61926988|NCT06187675|ACTIVE_COMPARATOR|Choice|Participants will be given a choice of 3 strategies; Group A - they receive both nutrition and exercise components simultaneously, Group B - they receive the nutrition component first followed by introduction of the exercise component sequentially, or Group C - they receive the exercise component first followed by introduction of the nutrition component sequentially.
61926989|NCT06187675|EXPERIMENTAL|No choice|Participants will be yoked (matched) to a participant in the Choice group and they receive the same strategy as the person with a choice.
61926990|NCT05617794|EXPERIMENTAL|Treatment 1 - Diffusion Optics Technology (DOT) Pattern|
61926991|NCT05617794|ACTIVE_COMPARATOR|Treatment 2 - Control Spectacles|
61926992|NCT05916495|EXPERIMENTAL|Hybrid care arm|Remote review of information collected electronically will be combined with in person visits at a hospital
61926993|NCT05916495|ACTIVE_COMPARATOR|Standard of care arm|Patients will be seen in person at a hospital clinic.
62130636|NCT04364139|EXPERIMENTAL|Usual BP goal and Ramipril|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and participants assigned to Receive Ramipril 2.5 to 10 mg/d
62130637|NCT04364139|EXPERIMENTAL|Lower BP goal and Amlodipine|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
62321717|NCT00005022|EXPERIMENTAL|Arm 3|Large field radiation therapy 32.4 Gy, 1.8 Gy/fx/D/5 days x 18 fx, boost just in pm @ 1.8 Gy/fx on days 19 \& 20, then boost 1.8 Gy BID x last 5 days.
62321718|NCT00005022|EXPERIMENTAL|Arm 4|Large field radiation therapy 28.8 Gy, 1.8 Gy/fx/5 days x 16 fx, boost just in pm @ 1.8 Gy/fx on days 17-20, then boost 1.8 Gy BID x last 5 days.
62321719|NCT00005022|EXPERIMENTAL|Arm 5|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D 5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
62321720|NCT00005022|EXPERIMENTAL|Arm 6|Large field radiation therapy 25.2 Gy, 1.8 Gy/fx/5 days x 14 fx, boost just in pm @ 1.8 Gy/fx on days 15-20, then boost 1.8 Gy BID x last 5 days.
62339801|NCT02466321|EXPERIMENTAL|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
62339802|NCT00698789|EXPERIMENTAL|Treatment A|5 mg of INCB019602 in AM with placebo administration in PM
62130638|NCT04364139|EXPERIMENTAL|Usual BP goal and Amlodipine|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
62130639|NCT04364139|EXPERIMENTAL|Lower BP goal and Metoprolol|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
62690148|NCT06085872|EXPERIMENTAL|REThink Life Game|Students from experimental group who do not respond to PsyPills alone will play the REThink Life Game
61926994|NCT06468605|EXPERIMENTAL|JCXH-211|Open label single arm infusion of a single dose of JCXH-211, a self-replicating RNA (srRNA)-based human IL-12, administered intratumorally via convection-enhanced delivery (CED).
61926995|NCT00554112|ACTIVE_COMPARATOR|1|Exercise
61926996|NCT00554112|ACTIVE_COMPARATOR|2|Exercise
61926997|NCT00554112|NO_INTERVENTION|3|Control
61926998|NCT05468151|EXPERIMENTAL|Cold acclimation protocol|Participants with obesity (n = 20) will undergo weekly cold water immersions (water temperature 18ºC, two to three times a week, 30 minutes per day) for, at least, 12 weeks. Before and after the cold acclimation period, the participants will undergo PET/CT scans at room temperature and after controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes.
61926999|NCT05468151|OTHER|Acute cold exposure - control volunteers with obesity|"PET/CT scans will be carried out after 2 hours of cold exposure The participants in this group (n = 10) will undergo PET/CT scans at baseline and 12 weeks after the first scan.~The participants will undergo PET/CT scans at room temperature and after 2 hours of controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes."
61927000|NCT05468151|OTHER|Acute cold exposure - lean controls|PET/CT scans will be carried out after 2 hours of cold exposure The participants in this group (lean, n = 15) will undergo PET/CT scans at room temperature and after 2 hours of controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes.
61927001|NCT00746044||1|Healthy volunteers \>18y, 20 male, 20 female
61927002|NCT01720212|EXPERIMENTAL|Single dose group|
61927003|NCT01720212|EXPERIMENTAL|Multiple dose group|
61927004|NCT04186481||Minitac Ti 2.0 suture anchor|Subjects who have undergone extremities repair using the Minitac Ti 2.0 Suture anchor
61927005|NCT03834272|EXPERIMENTAL|1st Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo on surgical tissue.
61927006|NCT03834272|EXPERIMENTAL|2nd Tier Dose Level- LUM Imaging System|9 patients will be administered a single dose of LUM015 at 1.5 mg/kg. Imaging with the LUM imaging device will be performed in vivo on surgical tissue.
61927007|NCT03834272|EXPERIMENTAL|3rd Tier Dose Level- LUM Imaging System|6 patients will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo on surgical tissue.
61927008|NCT03834272|EXPERIMENTAL|Optimal Dose Arm|12 patients will receive LUM015 at the dose and timepoint selected based on the analysis of the data
61927009|NCT05799183|EXPERIMENTAL|Pre-test: ARM A|SHR-1210 before process changes 20 mg
62690149|NCT05681078|EXPERIMENTAL|A Matter of Balance Program|
61927010|NCT05799183|EXPERIMENTAL|Pre-test: ARM B|SHR-1210 after process changes 20 mg
61927011|NCT05799183|EXPERIMENTAL|Formal Test: ARM A|SHR-1210 before process changes 20 mg
61927012|NCT05799183|EXPERIMENTAL|Formal Test: ARM B|SHR-1210 after process changes 20 mg
61927013|NCT06733129|EXPERIMENTAL|KETOFOL|Ketofol: combination of Ketamine and Propofol : consecutive direct IV injection of Ketamine 1 mg/kg and Propofol 1 mg/kg after completing pre-oxygenation
61927014|NCT06733129|EXPERIMENTAL|KETAMINE|direct IV injection at dosage of 2 mg/kg after completing pre-oxygenation
62321721|NCT03318107|EXPERIMENTAL|Transvaginal probe (Photoacoustic + ultrasound imaging)|"* A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images~* This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points"
62321722|NCT05534555|OTHER|Febridx|Undergo FebriDx testing
61927015|NCT06733129|ACTIVE_COMPARATOR|PROPOFOL|direct IV injection at dosage of 2 mg/kg after completing pre-oxygenation.
61927016|NCT05104554|EXPERIMENTAL|Weekly IFA|Receive weekly IFA
61927017|NCT05104554|EXPERIMENTAL|Daily MMS|Receive daily MMS (including iron and folic acid as components)
62130640|NCT04364139|EXPERIMENTAL|Usual BP goal and Metoprolol|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
62130641|NCT03490045|EXPERIMENTAL|Intervention Condition|Postpartum women and their infants will be randomly assigned to the treatment condition and receive a diaper incentive for their participation.
62130642|NCT03490045|ACTIVE_COMPARATOR|Comparison Condition|Postpartum women and their infants will be randomly assigned to the control condition and will receive a conditional cash transfer of equivalent value of the diapers provided to the intervention group.
62321723|NCT00198341|EXPERIMENTAL|1|Radiological arm (Clinical Visit + X-Ray Chest)
62321724|NCT00198341|EXPERIMENTAL|2|Scan ARM : Clinical Visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous type)
62321725|NCT06561958||REKOVELLE|Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.
62321726|NCT04015297|EXPERIMENTAL|control|healthy controls
62690150|NCT06417229|EXPERIMENTAL|Part 1: Cohort 1 BMS-986365 Dose 1|
62690151|NCT06417229|EXPERIMENTAL|Part 1: Cohort 2 BMS-986365 Dose 2 Formulation 1|
61927018|NCT05104554|NO_INTERVENTION|Control|
61927019|NCT04123665|EXPERIMENTAL|Experimental Test Dentifrice|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
61927020|NCT04123665|PLACEBO_COMPARATOR|Control Dentifrice|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as sodium monofluorophosphate \[SMFP\] to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
61927021|NCT06693531||EoE Patients treated with DUPIXENT®|
62690152|NCT06417229|EXPERIMENTAL|Part 1: Cohort 2 BMS-986365 Dose 3 Formulation 2|
62690153|NCT06417229|EXPERIMENTAL|Part 1: Cohort 3 BMS-986365 Dose 4|
61927022|NCT05693844|EXPERIMENTAL|Pan-T booster co-expressing MSLN CAR T cell|Before the infusion of pan-T booster co-expressing MSLN CAR T cells, all enrolled patients need to undergo conditioning chemotherapy consisting of albumin-bound paclitaxel, cyclophosphamide, and fludarabine.
61927023|NCT04339166|EXPERIMENTAL|Group A|Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.
61927024|NCT04339166|NO_INTERVENTION|Group B|Single thawed blastocyst transfer with blastocyst selection according to morphologic score.
61927025|NCT03303248|EXPERIMENTAL|Web-based Educational Intervention|This group of participants will be given access to a web-based educational resource in addition to the standard of care.
61927026|NCT03303248|NO_INTERVENTION|Standard of Care|This group will be given only the standard of care during their clinic visit.
61927027|NCT05692180|EXPERIMENTAL|Benralizumab|Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection.
61927028|NCT05692180|PLACEBO_COMPARATOR|Placebo|Patients will receive a matching solution of the placebo via SC injection.
61927029|NCT03789084|EXPERIMENTAL|Cognitive-Behavioral Therapy|Brief Cognitive-Behavioral Therapy for Health Anxiety
61927030|NCT03789084|OTHER|Referral to mental health provider|Provider makes referral to a mental health provider
61927031|NCT04310020|EXPERIMENTAL|Treatment (hypofractionated radiation therapy, atezolizumab)|"RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week over 3 weeks for 15 fractions in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and may undergo MRI throughout the study, as well as blood sample collection on study."
62130643|NCT02424318|EXPERIMENTAL|Topiramate|topiramate 25mg twice for 1 week -\> topiramate 50mg twice for 7 weeks
62321727|NCT04015297|EXPERIMENTAL|patient|patients diagnosed with endometriosis
62321728|NCT02583672|EXPERIMENTAL|N-acetylcysteine|The first 10 GD1 subjects will take 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days. An interim analysis will be performed to determine if this dose produces changes in systemic redox status and brain glutathione (GSH) levels. If no signal of a significant change is observed, the remaining 20 subjects will receive up to 3600 mg NAC orally twice a day (7200 mg/day).
62321729|NCT06282757|EXPERIMENTAL|Placebo group|The placebo intervention group will be shown an online educational VR video.
61927032|NCT02701842|EXPERIMENTAL|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
61927033|NCT02701842|ACTIVE_COMPARATOR|Test/Re-Test|ImPACT Online will be administered at 2 time points.
61927034|NCT06659627|OTHER|Aerobic exercise therapy|AET will consist of three weekly sessions of aerobic workouts on a bicycle ergometer for a period of 16 weeks. The first training session will be supervised by an experienced physical therapist at the LUMC. Subsequently, participants will perform the remaining workouts at home. One session per week will be carried out independently at home. The other two sessions will be digitally supervised via a digital connection by students, who will be trained and supervised by an experienced physical therapist. During the intervention, training intensity will be adjusted based on the participant's rate of perceived exertion (Borg Rating of Perceived Exertion (RPE) scale).
62130644|NCT05058950||Phenotyped in Research Objectively: Cognitively Normal|"Participants with age ≥50 years and with a label of cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
62130645|NCT05058950||Phenotyped in Research Objectively: MCI|"Participants with age ≥50 years, with a label of MCI or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
62321730|NCT06282757|ACTIVE_COMPARATOR|Nocebo group|The nocebo intervention group will be shown an online educational VR video.
62321731|NCT01082913|EXPERIMENTAL|Sacral Surface Electrical (SSE)|
62321732|NCT01082913|NO_INTERVENTION|control|
62321733|NCT02316470|ACTIVE_COMPARATOR|VLA84 75 mcg (microgram) w/o Alum|VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
62690154|NCT06417229|EXPERIMENTAL|Part 1: Cohort 6 BMS-986365 Dose 5|
61927035|NCT06659627|OTHER|Cognitive behavioural therapy|The entire CBT program will be followed digitally through an online platform and will span 12-16 weeks. The program will be tailored to the individual participants' needs and preferences. Every week or every two weeks, the psychologist provides feedback on the finished sessions and gives new assignments. If necessary, the psychologist will contact a participant by phone for additional support.
62130646|NCT05058950||Phenotyped in Research Objectively: Exploratory Biomarker|"Participants with age ≥50 years, with documented positive result for an Alzheimer's disease biomarker, and with a label of subjective cognitive complaints or cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
62321734|NCT02316470|ACTIVE_COMPARATOR|VLA84 200 mcg w/o Alum|VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
62690155|NCT06417229|EXPERIMENTAL|Part 1: Cohort 7 BMS-986365 Dose 6|
62690156|NCT06417229|EXPERIMENTAL|Part 1: Cohort 8 BMS-986365 Dose 7|
62690157|NCT06417229|EXPERIMENTAL|Part 2: Cohort 4 BMS-986365 Dose 8 Fasted|
62690158|NCT06417229|EXPERIMENTAL|Part 2: Cohort 4 BMS-986365 Dose 9 Fed|
61927036|NCT06659627|OTHER|Usual care|Participants are not restricted in their activities, but will be instructed not to start a new exercise or cognitive behavioural program. Chronic physical therapy and psychological counselling in the context of usual care are allowed to continue.
61927037|NCT06593522|EXPERIMENTAL|Part 1: Dose Evaluation|Participants will be randomized to receive one of 2 active dose levels of AMG 193 orally (PO) daily (QD) in 28 days cycles. Part 1 of the study will determine the recommended phase 2 dose (RP2D).
61927038|NCT06593522|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive AMG 193 PO QD in 28-day cycles at the RP2D.
62321735|NCT02316470|ACTIVE_COMPARATOR|VLA84 200 mcg with Alum|VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
62321736|NCT02316470|PLACEBO_COMPARATOR|Placebo|Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
62321737|NCT06580067|EXPERIMENTAL|Pray Until Something Happens (PUSH) video clip|This intervention is a 30-minute petitionary prayer, named Pray Until Something Happens (PUSH) stress reduction intervention using a mobile smart device.
62690159|NCT06417229|EXPERIMENTAL|Part 2: Cohort 5 BMS-986365 Dose 10 Fasted Followed by Rabeprazole + Rabeprazole and BMS-986365|
62690160|NCT06060444|OTHER|In-Person|Control group
61927039|NCT06743958|EXPERIMENTAL|Intervention group|Specific strength and balance training during neoadjuvant chemotherapy
61927040|NCT06743958|NO_INTERVENTION|Control group|
62321738|NCT06580067|ACTIVE_COMPARATOR|Attention Control Group|The second group will have access to the same internet-based application to track daily their stress and pain levels but will not be able to view our Pray Until Something Happens intervention.
61927041|NCT03269461|EXPERIMENTAL|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
61927042|NCT03269461|EXPERIMENTAL|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
61927043|NCT03269461|EXPERIMENTAL|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
61927044|NCT00806871|ACTIVE_COMPARATOR|A|
61927045|NCT00806871|ACTIVE_COMPARATOR|B|
61927046|NCT00806871|PLACEBO_COMPARATOR|C|
61927047|NCT03937700|EXPERIMENTAL|CPWalker Robotic-Assisted Gait Training|Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours
61927048|NCT03485469|OTHER|Usual Care|The control group will benefit from a standard care dietary consultation in the service and 9 dietary consultations by phone every 15 days.
62321739|NCT06095973|OTHER|Cohort B|"Experimental : GB-6002 for subcutaneous injection at intermediate A dose. Placebo Comparator: Placebo for subcutaneous injection at intermediate intermediate A dose.~Active Comparator: Naropin injection(Ropivacaine hydrochloride), single dose."
62321740|NCT06095973|OTHER|Cohort C|Experimental : GB-6002 for subcutaneous injection at intermediate B dose. Placebo Comparator: Placebo for subcutaneous injection at intermediate B dose. Active Comparator: Naropin injection(Ropivacaine hydrochloride), single dose.
62690161|NCT06060444|EXPERIMENTAL|Telemedicine|
62690162|NCT04204616|EXPERIMENTAL|Nemolizumab|Participants weighing less than (\<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (\>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
61927049|NCT03485469|OTHER|Hypnosis|The experimental group will benefit from a dietary consultation in the service, 9 dietary consultations by telephone every 15 days to which will be associated 7 individual sessions of hypnosis and 3 individual sessions of learning to autohypnosis. A recording containing the induction of a self-hypnosis session will be given to the subject at the end of the 10 sessions, in order to promote the continuation of home-made autohypnosis.
61927050|NCT04791254||A - main study cohort|"This is the main study cohort. All patients with upper gastrointestinal (gastric, oesophageal and gastro-oesophageal) cancers attending the medical oncology clinic and commencing systemic therapy will be invited to participate.~They will receive dietician support as part of their standard treatment. They will undergo assessments of body composition as part of this assessment"
61927051|NCT04791254||Sub-cohort B|This sub-cohort will be invited to undergo more detailed fitness testing in the form of cardio-pulmonary exercise testing in addition to their routine care in the main cohort
61927052|NCT04791254||sub-cohort C|This sub-cohort will be invited to undergo an assessment of gut hormone and cytokine levels in addition to their routine care in the main cohort
61927053|NCT04791254||Cohort D|This is a cohort of healthy volunteers invited to act as a control to cohort C and undergo the gut hormone assessment
61927054|NCT03324672|ACTIVE_COMPARATOR|TRIGGER|
61927055|NCT03324672|EXPERIMENTAL|TRIGGER+CURETAPE|
61927056|NCT06419179|EXPERIMENTAL|Combination of olaparib and durvalumab after four cycles of standard 1st line treatment|"Study treatment (olaparib and durvalumab) starts with the initiation of maintenance therapy and is administered at a 28-day cycle until progression, unacceptable toxicity, or discontinuation for other reasons.~Induction therapy (four cycles of carboplatin/cisplatin, etoposide, durvalumab) is administered as part of standard of care."
62130647|NCT05058950||Aging Across Adulthood: MCI|Participants with age ≥50 years, with a diagnosis of MCI, mild neurocognitive disorder (MND), or cognitively impaired, not demented (CIND) will be enrolled virtually from the community.
62321741|NCT06095973|OTHER|Cohort D|Experimental : GB-6002 for subcutaneous injection at high dose. Placebo Comparator: Placebo for subcutaneous injection at high dose. Active Comparator: Naropin injection(Ropivacaine hydrochloride), single dose.
62339803|NCT00698789|EXPERIMENTAL|Treatment B|20 mg of INCB019602 in AM with placebo administration in PM
62690163|NCT05540184|EXPERIMENTAL|Hydration plus Trimetazidine|Hydration plus Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
62690164|NCT05540184|EXPERIMENTAL|Hydration ,Trimetazidine & allopurinol|Hydration plus Trimetazidine 35mg once daily will be given to patients before the procedure and up to 24 hours after the procedure and allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
62690165|NCT05540184|PLACEBO_COMPARATOR|Hydration|Hydration only will be given to the patients normal saline at the rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
62321742|NCT06095973|OTHER|Cohort A|Experimental : GB-6002 for subcutaneous injection at low dose. Placebo Comparator: Placebo for subcutaneous injection at low dose. Active Comparator: Naropin injection(Ropivacaine hydrochloride), single dose.
62481496|NCT06732960|EXPERIMENTAL|Efsubaglutide Alfa 5mg|10 eligible subjects will be randomized in a 8:2 manner to receive either Efsubaglutide Alfa or Placebo, Dose escalation of Efsubaglutide Alfa or Placebo should take place during the first 4 weeks after randomization as describe in detail description. All subjects should aim at reaching the recommended target dose of Efsubaglutide Alfa 5 mg once-weekly maintenances 4 weeks or the corresponding volume of Placebo.
62481497|NCT06732960|EXPERIMENTAL|Efsubaglutide Alfa 7.5mg|10 eligible subjects will be randomized in a 8:2 manner to receive either Efsubaglutide Alfa or Placebo, Dose escalation of Efsubaglutide Alfa or Placebo should take place during the first 4 weeks after randomization as describe in detail description. All subjects should aim at reaching the recommended target dose of Efsubaglutide Alfa 7.5 mg once-weekly maintenances 4 weeks or the corresponding volume of Placebo.
62481498|NCT06732960|EXPERIMENTAL|Efsubaglutide Alfa 10mg|10 eligible subjects will be randomized in a 8:2 manner to receive either Efsubaglutide Alfa or Placebo, Dose escalation of Efsubaglutide Alfa or Placebo should take place during the first 6 weeks after randomization as describe in detail description. All subjects should aim at reaching the recommended target dose of Efsubaglutide Alfa 10 mg once-weekly maintenances 4 weeks or the corresponding volume of Placebo.
62481499|NCT06732960|EXPERIMENTAL|Efsubaglutide Alfa 15mg|10 eligible subjects will be randomized in a 8:2 manner to receive either Efsubaglutide Alfa or Placebo, Dose escalation of Efsubaglutide Alfa or Placebo should take place during the first 8 weeks after randomization as describe in detail description. All subjects should aim at reaching the recommended target dose of Efsubaglutide Alfa 10 mg once-weekly maintenances 4 weeks or the corresponding volume of Placebo.
62481500|NCT06732960|EXPERIMENTAL|Efsubaglutide Alfa 20mg|10 eligible subjects will be randomized in a 8:2 manner to receive either Efsubaglutide Alfa orPlacebo, Dose escalation of Efsubaglutide Alfa or Placebo should take place during the first 12 weeks after randomization as describe in detail description. All subjects should aim at reaching the recommended target dose of Efsubaglutide Alfa 10 mg once-weekly maintenances 4 weeks or the corresponding volume of Placebo.
62481501|NCT06743425|EXPERIMENTAL|RAMP Reports|Submit RAMP reports weekly for 4 weeks and then monthly for 2 months.
62481502|NCT06743425|ACTIVE_COMPARATOR|Digital Education Handouts|Standard of care determined by the treating healthcare provider and digital education handouts (attention controls) distributed by the study team weekly for 4 weeks and then monthly for 2 months.
62481503|NCT06597695|EXPERIMENTAL|Open label|Open label, single arm study
62481504|NCT06627127|EXPERIMENTAL|Target stimulation|Stimulation of the Hypoglossal nerve (HGN) or Genioglossus muscle (GG) and a second functional target (Ansa Cervicalis - AC) or the strap muscles (sternohyoid and sternothyroid).
62481505|NCT06503250||Retrospective Cohort|Secondary data from medical records of approx 5 sites across China will be utilized. Patient identification period is between 28 Oct 2020 to 31 Dec 2023. The index date is defined as the earlier date of initiating Atezo+Bev or TACE after the initial diagnosis of unresectable HCC. Baseline period is defined as 60 days prior to the index date. Observation period is defined as the period from the index date until death, latest visit record during retrospective observation period, diagnosis of other primary cancer (except basal cell carcinoma), or 31 March 2024, whichever occurs first.
62481506|NCT04028479||Validation Cohort|Patients enrolled into the study to allow validation of a specific element, process, or endpoint. Validation will be done showing concordance with traditional interventional trial standards.
62481507|NCT04028479||Analysis Cohorts|Patient who are enrolled into the study to allow analysis to determine any association, effect, or benefit. Cohorts can be determined prospectively and/or retrospectively for data already collected, Cohorts are identified to highlight collection of information on patients who are already receiving any treatment or testing as determined by the physician and patient independent of this study. Because many analysis cohorts will be determined in patients already enrolled in the study, this group is inclusive of many different sub-groupings or specific analysis cohorts of patients.
62690166|NCT06127901||Single arm|Patients over 18 years of age undergoing urgent and scheduled surgery requiring hospital admission, under any type of anaesthesia.
61927057|NCT04258189|EXPERIMENTAL|Panel 1: Treatment Sequence ABDC|Participants will receive Treatment A (a single dose of JNJ-64417184 \[oral solution with preservatives\] in fasted condition) in treatment Period 1; followed by Treatment B (a single dose of JNJ-64417184 \[oral solution with preservatives\] in fed \[high-fat meal\] condition) in treatment Period 2; followed by Treatment D (a single dose of JNJ-64417184 \[oral solution without preservatives\] in fed \[high-fat meal\] condition) in treatment Period 3, followed by Treatment C (a single dose of JNJ-64417184 \[oral solution without preservatives\] in fasted condition) in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927058|NCT04258189|EXPERIMENTAL|Panel 1: Treatment Sequence BCAD|Participants will receive Treatment B in treatment Period 1; followed by Treatment C in treatment Period 2; followed by Treatment A in treatment Period 3, followed by Treatment D in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
62130648|NCT05058950||Aging Across Adulthood: Subjective Cognitive Complaint|Participants with age ≥50 years and positive screen result from Cognitive Function Instrument (CFI) will be enrolled virtually from the community.
62690167|NCT06496607|EXPERIMENTAL|Biological: Solrikitug Low Dose|Solrikitug
62690168|NCT06496607|EXPERIMENTAL|Biological: Solrikitug Mid Dose|Solrikitug
62690169|NCT06496607|EXPERIMENTAL|Biological: Solrikitug High Dose|Solrikitug
62690170|NCT06496607|OTHER|Placebo|Placebo
62321743|NCT04359823|EXPERIMENTAL|Statin/Cholesterol Combination Group|This arm will utilize 2% cholesterol and 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
62321744|NCT04359823|EXPERIMENTAL|Statin Alone Group|This arm will utilize 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
62339804|NCT00698789|EXPERIMENTAL|Treatment C|5 mg of INCB019602 in PM with placebo administration in AM
62339805|NCT00698789|EXPERIMENTAL|Treatment D|20 mg of INCB019602 in PM with placebo administration in AM
62690171|NCT06451458|EXPERIMENTAL|ECHO Intervention|10 FQHCs from the PMS health system will be randomized to the ECHO Intervention Arm. All healthcare team members in the intervention arm will attend ECHO program sessions, and the FQHCs are the primary subjects of the ECHO intervention. However, the investigators examine outcomes at both the level of the healthcare team and at the level of the patients who are empaneled to the healthcare team. Persons with DMMC cared for by the healthcare teams at the FQHC clinics are the patient population for this intervention.
61927059|NCT04258189|EXPERIMENTAL|Panel 1: Treatment Sequence CDBA|Participants will receive Treatment C in treatment Period 1; followed by Treatment D in treatment Period 2; followed by Treatment B in treatment Period 3, followed by Treatment A in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
62321745|NCT03501706|EXPERIMENTAL|Active Training (AT) Group|Participants will complete four computerized training programs to improve executive function (EF), including Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Words - Visual, Verbal Memory - Visual.
62321746|NCT03501706|NO_INTERVENTION|Control Training (CT) Group|Participants will complete the four computerized programs relating to executive function (EF), but will be provided with the answer (i.e., without memory requirements). That is, participants in the control condition will not be asked to engage their cognitive functions.
62321747|NCT04185324|EXPERIMENTAL|Standard zippering vest|Children receive three supervised sessions for them to practice engaging and pull up a zipper, using a standard teaching zippering vest.
62321748|NCT04185324|EXPERIMENTAL|Modified zippering vest|Children receive three sessions of specially designed zippering instruction using a modified zippering vest, where they can practice engaging and pulling up a zipper after being read a related story.
62321749|NCT02844582|EXPERIMENTAL|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62321750|NCT03549273|EXPERIMENTAL|Treatment|Glizigen® spray + Ocoxin-Visuid® oral solution
62321751|NCT03960710||Neuronal network Training group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~* Injection modalities (without injection, injected)~* Major hepatectomy surgery~* Importance of hepatic dysmorphia~* Presence of intraperitoneal fluid effusion~* Presence of renal polycystosis (especially on the right side)."
62321752|NCT03960710||Neuronal network Validation group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~* Injection modalities (without injection, injected)~* Major hepatectomy surgery~* Importance of hepatic dysmorphia~* Presence of intraperitoneal fluid effusion~* Presence of renal polycystosis (especially on the right side)."
62321753|NCT01676480|EXPERIMENTAL|ADT group|
62321754|NCT01676480|EXPERIMENTAL|Control group|
62690172|NCT06451458|ACTIVE_COMPARATOR|Comparator|10 FQHCs from the PMS health system will be randomized to the comparator arm which is usual care. Persons with DMMC cared for by the healthcare teams at the FQHC clinics are the patient population for this comparator arm.
62130649|NCT05058950||Aging Across Adulthood: Cognitively Normal With Risk Factor For Dementia|Participants with age ≥60 years and self-reported history of a minimum of 2-4 risk factors for cognitive decline will be enrolled virtually from the community.
62130650|NCT05058950||Aging Across Adulthood: Cognitively Normal Without Risk Factors For Dementia|Participants with age ≥60 years having missing descriptor of minimal risk factors for cognitive decline will be enrolled virtually from the community.
62130651|NCT05058950||Aging Across Adulthood: Cognitively Normal|Participants with age 21 to 59 years will be enrolled virtually from the community.
62130652|NCT03262831|EXPERIMENTAL|Arm 1: Yoga|"* Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga~* Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.~* The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel~* During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
62130653|NCT03262831|ACTIVE_COMPARATOR|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
62130654|NCT01727375|NO_INTERVENTION|Standard light|In this arm patients receive standard lightening conditions
62130655|NCT01727375|EXPERIMENTAL|Ciradian light|In this arm patients receive artificial ceiling light (circadian light) at the bedside.
62130656|NCT05806476|EXPERIMENTAL|C - C|caffeine intake during the run-in days and caffeine intake on the experimental day
62130657|NCT05806476|EXPERIMENTAL|C - P|caffeine intake during the run-in days and placebo intake on the experimental day
62130658|NCT05806476|EXPERIMENTAL|P - P|placebo intake during the run-in days and placebo intake on the experimental day
62130659|NCT05806476|EXPERIMENTAL|P - C|placebo intake during the run-in days and caffeine intake on the experimental day
62130660|NCT01073358|NO_INTERVENTION|Group A: No routine hilar lymphadenectomy|Resection of colorectal liver metastases without routine hilar lymphadenectomy
62130661|NCT01073358|EXPERIMENTAL|Group B: Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases.
62321755|NCT05314595|EXPERIMENTAL|modified technique|women were underwent modified technique (PPC+ bilateral uterine artery ligation)
62321756|NCT03543891||Control group|50 healthy volunteers were included in the healthy control group
62321757|NCT03543891||Thyroid cancer group|50 patients of thyroid cancer were included
62321758|NCT03170336|EXPERIMENTAL|amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks
62321759|NCT03170336|ACTIVE_COMPARATOR|hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
62690173|NCT01582555|EXPERIMENTAL|saline irrigation|a control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation;
62690174|NCT01582555|EXPERIMENTAL|intervention arm (group B),|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
62321760|NCT05635084|EXPERIMENTAL|YN001|YN001 (with a strength of 5 mL:10 mg). Subjects will be administered 250 to 500 mL of YN001 diluted in 5% dextrose injection up to 120 min(which allows a +/-5 min infusion window) intravenous infusion.
62321761|NCT05635084|PLACEBO_COMPARATOR|Matching placebo for YN001|Matching placebo for YN001 is 5% dextrose injection. Subjects will be administered 250 to 500mL of 5% dextrose injection up to 120 min (which allows a +/-5 min infusion window) intravenous infusion.
62690175|NCT06569927|EXPERIMENTAL|Intervention group|The intervention group implemented a perioperative position management program for congenital microtia based on the ADDIE model, in addition to routine position care.
62690176|NCT06569927|NO_INTERVENTION|Control Group|The control group received routine position care, which included perioperative verbal emphasis on the importance of position by nurses, intraoperative use of hydrocolloid positioning pads to prevent pressure injuries, postoperative nurse monitoring and encouragement of proper positioning, assistance with bed mobility, and guidance on safe ambulation techniques.
62690177|NCT02904096|EXPERIMENTAL|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
62690178|NCT02904096|EXPERIMENTAL|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
62690179|NCT06177431|EXPERIMENTAL|Monepantel treatment arm|Daily dose of 10 mg/kg body weight (QD)
62690180|NCT04620668|EXPERIMENTAL|Treatment Group (Wysa)|
62690181|NCT04620668|NO_INTERVENTION|Control Group|
62690182|NCT06265818|EXPERIMENTAL|The experimental group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Based on this, this group was given Active Breathing Exercises"
61927060|NCT04258189|EXPERIMENTAL|Panel 1: Treatment Sequence DACB|Participants will receive Treatment D in treatment Period 1; followed by Treatment A in treatment Period 2; followed by Treatment C in treatment Period 3, followed by Treatment B in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927061|NCT04258189|EXPERIMENTAL|Optional Panel 2: Treatment Sequence EFG|Participants will receive Treatment E (a single dose of JNJ-64417184 \[oral solution with or without preservatives\] in fasted condition) in treatment Period 1; followed by Treatment F (a single dose of JNJ-64417184 \[oral solution with or without preservatives\] in fed \[high-fat meal\] condition) in treatment Period 2; followed by Treatment G (a single dose of JNJ-64417184 \[oral solution with or without preservatives\] in fed \[high-fat meal\] condition) in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927062|NCT04258189|EXPERIMENTAL|Optional Panel 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927063|NCT04258189|EXPERIMENTAL|Optional Panel 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927064|NCT04258189|EXPERIMENTAL|Optional Panel 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927065|NCT04258189|EXPERIMENTAL|Optional Panel 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927066|NCT04258189|EXPERIMENTAL|Optional Panel 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
61927067|NCT03625206|EXPERIMENTAL|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
61927068|NCT03625206|PLACEBO_COMPARATOR|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
61927069|NCT05227703|EXPERIMENTAL|CVL-231 15 mg, once daily (QD)|Oral Dose
61927070|NCT05227703|EXPERIMENTAL|CVL-231 30 mg, once daily (QD)|Oral Dose
61927071|NCT05227703|PLACEBO_COMPARATOR|Placebo, once daily (QD)|Oral Dose
62130662|NCT03041064|EXPERIMENTAL|SPF 50/SPF 100|SPF 50 assigned to left side of face and body. SPF 100 assigned to right side of face and body
62130663|NCT03041064|EXPERIMENTAL|SPF 100/SPF 50|SPF 100 assigned to left side of face and body. SPF 50 assigned to right side of face and body
62321762|NCT05269134|EXPERIMENTAL|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotic treatment.
62321763|NCT05269134|PLACEBO_COMPARATOR|DAIR + Placebo + Antibiotics|Placebo will be administered in conjunction with antibiotic treatment.
62321764|NCT06551324|EXPERIMENTAL|Arm A|Investigational Arm A: PF-06821497 875 mg twice daily (BID) + enzalutamide 160 mg every day (QD)
62321765|NCT06551324|ACTIVE_COMPARATOR|Arm B|Comparator Arm B: Physician's choice of enzalutamide 160 mg QD or docetaxel 75 mg/m2 intravenous (IV) every 21 days
62321766|NCT00788658|PLACEBO_COMPARATOR|Diet modifications|Diet consultation and life style modifications for 6 sessions
62321767|NCT00788658|ACTIVE_COMPARATOR|Cognitive therapy|6 sessions of cognitive behavioral therapy
62321768|NCT06511713||the Clinical High Risk for Psychosis (CHR) Group|Through the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS), the participants should meet the Criteria of Prodromal Syndrome. Participants should fulfill at least one of the prodromal syndrome criteria: (1) brief intermittent psychotic syndrome, (2) attenuated positive symptom syndrome, or (3) genetic risk and deterioration syndrome
62321769|NCT06511713||the Clinically Diagnosed Common Mental Disorders Group|1,000 patients with common mental disorders, including 300 patients with schizophrenia, 300 patients with affective disorders, 200 patients with anxiety disorders, and 200 patients with cognitive impairment in the elderly.
62321770|NCT05720611|ACTIVE_COMPARATOR|Intervention group|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden. Participants will be asked to engage in a closed Facebook group.
62321771|NCT05720611|PLACEBO_COMPARATOR|Control Group|Participants in this group will complete all questionnaires but will not receive the digitally delivered course or access to Facebook.
62321772|NCT01099410||Group 1|volunteer subjects
62321773|NCT06692075|ACTIVE_COMPARATOR|Total ECLS in refractory OHCA|Emergency total extracorporeal life support ( ECLS ) in cardiopulmonary resuscitation of OHCA patients with refractory ventricular fibrillation or pulseless ventricular tachycardia
62690183|NCT06265818|ACTIVE_COMPARATOR|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
61927072|NCT06713642|EXPERIMENTAL|Eligible SPOTFIRE ST Participants|A maximum of 200 patients, representing the top 3-4 patient groups that were identified as benefitting most from a SPOTFIRE ST test through the provider survey, presenting at the Urgent Care facilities, will be enrolled.
61927073|NCT04482478|EXPERIMENTAL|EDL(Extract of Dolichos lablab Linne)|The randomly assigned target was given a Extract of Dolichos lablab Linne (EDL) 715 mg/day for 12 weeks.
61927074|NCT04482478|PLACEBO_COMPARATOR|Placebo comparator|The randomly assigned target was given a placebo for 12 weeks.
61927075|NCT02944071|EXPERIMENTAL|(Ranger & Ranger LE) and Ranger DCB|"The working length is 80cm and 135cm for Ranger DCB catheter and 90 cm and 150cm for Ranger SL and Ranger LE DCB catheter.~Multiple interventions:~Prior to or during Index Procedure:~* Prior to treatment of the index limb, successful (\< 30% residual stenosis) treatment of ipsilateral iliac inflow lesions may be performed~* Prior to treatment of the index limb, successful treatment of the arteries of the non-index limb may be performed~* Prior to treatment of the index limb, absence of clinical complications such as embolism, thrombosis, severe dissection, vessel rupture must be confirmed."
61927076|NCT01850264|ACTIVE_COMPARATOR|Quadripolar LV electrode|Application of a quadripolar LV electrode
61927077|NCT01850264|ACTIVE_COMPARATOR|Bipolar LV electrode|Application of a bipolar LV electrode
61927078|NCT05026645||adult inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
61927079|NCT05026645||Infant inflicted by a CBRNE weapon|Part of the population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
61927080|NCT05026645||Women inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
61927081|NCT05026645||Men inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
61927082|NCT05026645||Elderly inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
61927083|NCT05026645||Diagnosed with chronic disease(s) inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
61927084|NCT05026645||Clinician (adult) whom performs his/her clinical interventions|Clinician (adult) whom performs his/her clinical interventions while integrating competences in protections and decontamination. Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system. This is the case of when the clinician is required to ensure safety toward his/her patient while performing his/her interventions \& procedures.
61927085|NCT05026645||Clinician (adult) injured by duties circumstances|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system. This is the case of when the clinician becomes inflicted by a CBRNE weapon while intervening toward contaminated patient due to any failure in protection and decontamination.
61927086|NCT05023928|EXPERIMENTAL|Tumor antigen-sensitized DC vaccine|"Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times.~2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times."
61927087|NCT04490109|EXPERIMENTAL|B244 Suspension O.D. 5.0|One arm of 192 Subjects will be receiving a dose of B244 O.D. 5.0 suspension
61927088|NCT04490109|EXPERIMENTAL|B244 Suspension O.D. 20.0|Second arm of 192 subjects will receive a dose of B244 O.D. 20.0 suspension
62690184|NCT05830539|EXPERIMENTAL|Triple Negative Breast Cancer(TNBC)|"Group 1: IN10018 in combination with PLD in Subjects with previously-treated locally advanced or metastatic TNBC.~Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated locally advanced or metastatic TNBC."
62690185|NCT05830539|EXPERIMENTAL|Head and Neck Squamous Cell Cancer(R/M-HNSCC)|"Group 1: IN10018 in combination with PLD in Subjects with previously-treated R/M-HNSCC.~Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated R/M-HNSCC."
61927089|NCT04490109|PLACEBO_COMPARATOR|Placebo|Third arm of 192 subjects will receive a vehicle dosing.
61927090|NCT06168409|EXPERIMENTAL|2 mg baxdrostat|2 mg baxdrostat administered orally, once daily (QD).
61927091|NCT06168409|PLACEBO_COMPARATOR|Placebo|Placebo administered orally, once daily (QD)
61927092|NCT05388760|EXPERIMENTAL|Cohort 1 (6 to <12 years) - tralokinumab dose regimen A|
61927093|NCT05388760|EXPERIMENTAL|Cohort 1 (6 to <12 years) - tralokinumab dose regimen B|
61927094|NCT04409080|EXPERIMENTAL|Part A|Part A: Single ascending dose (SAD) escalation cohorts
61927095|NCT04409080|EXPERIMENTAL|Part B|Part B: Multiple REGN7257 dosages.
61927096|NCT06514443||osteoarthrits|adults with hip or knee osteoarthritis
61927097|NCT06514443||inflammatory arthritis|adults with rheumatoid arthritis or axial Spondyloarthritis
62690186|NCT05830539|EXPERIMENTAL|Platinum-resistant Ovarian Cancer|Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with platinum-resistant ovarian cancer.
62690187|NCT05830539|EXPERIMENTAL|Platinum-sensitive Ovarian Cancer(PSOC)|Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with Platinum-sensitive recurrent ovarian cancer.
61927098|NCT05588648|EXPERIMENTAL|Single Arm|Single arm, open-label, no blinding or randomization procedure will be involved.
61927099|NCT01266941|EXPERIMENTAL|Mild Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
61927100|NCT01266941|EXPERIMENTAL|Moderate Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
62481508|NCT04028479||Retrospective Chart Review Cohorts|"This arm will use retrospective data obtained through systematic chart review on previously seen patients to compare, contrast, or enhance the efforts of the prospective arms. Because most RWD has been traditionally obtained through retrospective methods, this is also considered the control arm. Data in this arm will be collected without any patient identifiers. This arm is optional."
62481509|NCT06741956|EXPERIMENTAL|Lifestyle intervention|A. Program to increase physical activity and impacts For the intervention, a biosensor -wearable device- (Fitbit Versa) will be used. The device is linked to an App (Weapom) that will allow users to quantify the number of steps (including the rate of steps per minute), the impacts and their intensity. Users will be given feedback from the application on the level of achievement of the objectives proposed in the impact program (EV). It will be proposed to achieve 50 vertical and multidirectional jumps per day (milestone 1. The number of jumps\> 3.9 G per day will be recorded 28, divided between 3-5 sets of 10-20 repetitions with a minimum 1-2 minute rest between sets. A frequency between 4-7 days per week will be used. In the same way, it will be recommended to reach 10,000 steps per day (milestone 2. The number of daily steps will be recorded) and, as far as possible, at a rapid pace (milestone 3. The number of daily minutes walking at a pace over 110 steps/minute will be
62481510|NCT06741956|NO_INTERVENTION|Control|Participants randomly assigned to CON will receive general advice from medical staff on the positive effects of physical activity and nutritional aspects for the prevention of osteoporosis. Participants in this group will carry the device, but will not have access to the App.
62130664|NCT05741645|EXPERIMENTAL|Study group|Study group consists of 15 participants, where the elastic kinesiotaping is applied and evaluations are made before and after.
62481511|NCT06415058||HemoIV Blood Sampling|Measurement of protocol specified blood parameters drawn from the HemoIV system
62481512|NCT06415058||Control Blood Sampling|Measurement of protocol specified blood parameters drawn from the contralateral control arm
62481513|NCT04519515|EXPERIMENTAL|Treatment With Juvederm Vollure Right|Injection of Juvederm Vollure on one half of the face, placebo on the other side
62690188|NCT05830539|EXPERIMENTAL|Small Cell Lung Cancer(SCLC)|Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated locally advanced or metastatic SCLC.
62690189|NCT05830539|EXPERIMENTAL|Other solid tumor|"Group 1: IN10018 in combination with PLD in Subjects with other previously-treated locally advanced or metastatic solid tumors.~Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with other previously-treated locally advanced or metastatic solid tumors."
62690190|NCT06487559|EXPERIMENTAL|Stage 1: Cohort 1 Livmoniplimab + Budigalimab Dose A|Participants will receive livmoniplimab Dose A in combination with budigalimab every 3 weeks for approximately 2 years.
61927101|NCT01266941|EXPERIMENTAL|Matched healthy volunteers|Once a moderate subject has been recruited, a healthy control subject should be recruited (matched to the moderate subject on gender, ethnicity, body mass index +/-15%, age +/-5 years). In total there will be 9 matched healthy volunteers 1 for each subject with moderate hepatic impairment.
61927102|NCT01266941|EXPERIMENTAL|Severe Hepatic Impairment|Severe subjects will not be enrolled into the study until 9 moderate subjects and their matched control subjects have completed the study and the safety and PK data have been reviewed.
61927103|NCT01331941|EXPERIMENTAL|Group 1|Cancer subjects with normal renal function.
61927104|NCT01331941|EXPERIMENTAL|Group 3|Cancer subjects with moderate renal impairment.
61927105|NCT01331941|EXPERIMENTAL|Group 4|Cancer subjects with severe renal impairment.
62130665|NCT05741645|SHAM_COMPARATOR|Control Group|To the participants in the control group, the elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
62130666|NCT00300131||1|Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
62481514|NCT04519515|EXPERIMENTAL|Treatment Juvederm Vollure Left|Injection of Juvederm Vollure on one half of the face, placebo on the other side
62690191|NCT06487559|EXPERIMENTAL|Stage 2: Cohort 2 Livmoniplimab + Budigalimab Dose B|Participants will receive livmoniplimab Dose B in combination with budigalimab every 3 weeks for approximately 2 years.
61927106|NCT01331941|EXPERIMENTAL|Group 2|Cancer subjects with mild renal impairment.
61927107|NCT06745661|EXPERIMENTAL|RLRL therapy group|The experimental group will undergo repeated low-level red-light therapy (RLRL). The light power through a 4-mm pupil is 0.29 mW for the RLRL device.
61927108|NCT06745661|SHAM_COMPARATOR|Sham therapy group|The sham group will use a sham device, which operates at only 10% of the active RLRL device's power. The light power through a 4-mm pupil is 0.03 mW for the sham device.
62130667|NCT04115423||Tocilizumab initiators|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving tocilizumab at least once from January 2013 to December 2018. Tocilizumab initiators are required to have no record of tocilizumab within 1 year prior to the first prescription of tocilizumab.
62130668|NCT04115423||Tumor necrosis factor inhibitors (TNFi) users|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving TNFi at least once from January 2013 to December 2018. TNFi users will be patients who had no record of tocilizumab and given specific TNFi during 1 year before the first prescription of TNFi.
62130669|NCT03569072|EXPERIMENTAL|Dose escalated functionally adapted radiation therapy|This is a single arm study
62130670|NCT01839331|EXPERIMENTAL|Ampion 4 mL Dose|4 mL Injection of Ampion
62130671|NCT01839331|PLACEBO_COMPARATOR|Placebo 4 mL Dose|4 mL Injection of Placebo
62481515|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
62481516|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
62481517|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
62481518|NCT06563297|EXPERIMENTAL|Participant Group|Neurosurgery with fixation
62690192|NCT06570356|OTHER|Post stroke patients|
62130672|NCT01839331|EXPERIMENTAL|Ampion 10 mL Dose|10 mL Injection of Ampion
62130673|NCT01839331|PLACEBO_COMPARATOR|Placebo 10 mL Dose|10 mL Injection of Placebo
62130674|NCT04377308|NO_INTERVENTION|Treatment As Usual|Participants may choose to not take fluoxetine and remain in the study
62481519|NCT05311046||Retrospective EHR-data only group|"Members of this group are pediatric patients between the ages of 3 months to 17 years inclusive, that presented to one of the six participating institution's emergency department between the years 2016-2021 and screened positive for suspicion of sepsis using the institution's existing pediatric sepsis screening protocol and receive a blood culture order. Current pediatric screening/alerting tools are known to be highly sensitive but poorly specific. Cases in this cohort will be comprised of those that are ultimately diagnosed with sepsis and/or receive protocolized sepsis treatment. Controls in this cohort will be those with a false positive alert, i.e., are not diagnosed with sepsis and do not receive protocolized sepsis treatment."
62481520|NCT05311046||Prospective EHR and Biomarker data group|"Members of this group are pediatric patients between the ages of 3 months to 17 years inclusive, that presented to one of the six participating institution's emergency department during the study enrollment period, screen positive for suspicion of sepsis using the institution's existing pediatric sepsis screening protocol, receive a blood culture order and provide informed consent/assent for the collection of a 1-5 mL blood sample to be used to measure PERSEVERE biomarkers. Members of this cohort will have also consented to the reuse of their medical record data for the research. Current pediatric screening/alerting tools are known to be highly sensitive but poorly specific. Cases in this cohort will be comprised of those that are ultimately diagnosed with sepsis and/or receive protocolized sepsis treatment. Controls in this cohort will be those with a false positive alert, i.e., are not diagnosed with sepsis and do not receive protocolized sepsis treatment."
62481521|NCT06395246|ACTIVE_COMPARATOR|Continuous caloric restriction|Continuous calorie restriction diet based on healthy Mediterranean diet recommendations
62690193|NCT06570356|OTHER|Post orthopedic fracture|
62690194|NCT04624399|EXPERIMENTAL|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
62690195|NCT06577675|EXPERIMENTAL|Study patients|Patients all suffering from emotional dysregulation but heterogeneous in terms of diagnosis and following a group DBT training programme.
62339806|NCT00698789|EXPERIMENTAL|Treatment E|7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
61927109|NCT03534934|EXPERIMENTAL|Baseline|"Smokers, defined has having at least a 10 pack-year lifetime history, with and without COPD will participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
61927110|NCT03534934|EXPERIMENTAL|3 year follow-up|"All subjects who completed a baseline visit will return for a follow-up visit and participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
61927111|NCT05875467|EXPERIMENTAL|Single Arm, Intervention with SE3 Game|This is a single arm study. This arm will receive the intervention. This intervention is a prototype of online game, about 50 minutes in duration. The online game provides gameplay that allows the user, with a gameplay narrative, to identify and remove sources of environmental hazards in the home environment. Participants play the prototype game for about 50 minutes at which time the intervention is complete.
61927112|NCT04243109|EXPERIMENTAL|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
61927113|NCT02961218|PLACEBO_COMPARATOR|Placebo|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
61927114|NCT02961218|EXPERIMENTAL|ACZ885|Monthly doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
61927115|NCT03367741|EXPERIMENTAL|Arm A (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15, then on day 1 beginning cycle 5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, and blood sample collection throughout the study and undergo biopsy at screening and optionally at follow up.
61927116|NCT03367741|EXPERIMENTAL|Arm B (nivolumab)|Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, and blood sample collection throughout the study and undergo biopsy at screening and optionally at follow up.
61927117|NCT04113382|EXPERIMENTAL|Participants aged 2 to <4 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (½ bottle \[approximately 80 mL\]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle \[approximately 80 mL\]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL."
61927118|NCT04113382|ACTIVE_COMPARATOR|Participants aged 2 to <4 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 4 ounce (oz) for every 30 minutes, one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
62339807|NCT00698789|PLACEBO_COMPARATOR|Treatment F|Placebo BID
61927119|NCT04113382|EXPERIMENTAL|Participants aged 4 to <9 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (1 bottle \[approximately 160 mL\]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle \[approximately 80 mL\]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum."
61927120|NCT04113382|ACTIVE_COMPARATOR|Participants aged 4 to <9 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 8 oz for every 30 minutes one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
61927121|NCT06390059|EXPERIMENTAL|TTFields + atezolizumab + gemcitabine and nab-paclitaxel|Patients receive TTFields at 150 kHzconcomitant with atezolizumab, gemcitabine and nab-paclitaxel until disease progression or loss of clinical benefit.
61927122|NCT06066710|EXPERIMENTAL|Propanolol and MRI|Participants will receive propranolol via oral capsule. The drug dosage will be titrated slowly to ensure the drug is tolerated well.
61927123|NCT06066710|PLACEBO_COMPARATOR|Placebo and MRI|Participants will receive placebo via oral capsule.
61927124|NCT04798768|EXPERIMENTAL|Patients implanted with S-ICD and leadless cardiac pacemaker|Patients implanted with an S-ICD and leadless cardiac pacemaker that complete intended testing based on the study protocol
61927125|NCT02025062|NO_INTERVENTION|Control|In the control arm, patients are followed-up by the head-and-neck physician, oncologist and radiotherapists and did not benefit of Comprehensive Geriatric Assessment.
61927126|NCT02025062|EXPERIMENTAL|Comprehensive Geriatric Assessment|The CGA (Comprehensive Geriatric Assessment) is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up.
62690196|NCT03497702|EXPERIMENTAL|Experimental|Patients receive neoadjuvant chemotherapy (doxorubicin 60mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 every 3 weeks for 4 cycles followed by docetaxel 75mg/m2 IV on day 1 every 3 weeks for 4 cycles) plus letrozole with or without leuproelin depending on menopausal status
62690197|NCT05597397|EXPERIMENTAL|Repeated Low-Level Red-Light Therapy (RLRL)|Single vision spectacles (SVS) \& RLRL.
61927127|NCT05186428|OTHER|"The before period"|
61927128|NCT05186428|EXPERIMENTAL|"the after period"|
61927129|NCT04581759|EXPERIMENTAL|RIPC|Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after endovascular treatment while in-hospital.
61927130|NCT04581759|SHAM_COMPARATOR|foundational treatment group (FT)|Patients in the FT group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs, during the study period without remote ischemic postconditioning after endovascular treatment.
61927131|NCT06636734|EXPERIMENTAL|Treatment (lovastatin, pembrolizumab)|Patients receive lovastatin PO QD and pembrolizumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, and CT, MRI or PET/CT throughout the study.
61927132|NCT05572190|EXPERIMENTAL|A1.1. 30 mg ETR028 Sentinel|30 mg ETR028 single oral dose (fasted)
61927133|NCT05572190|EXPERIMENTAL|A1.1. 30 mg ETR029 Sentinel|30 mg ETR029 single oral dose (fasted)
61927134|NCT05572190|ACTIVE_COMPARATOR|A1.1. 5 mg HCBT|5 mg hydrocodone bitartrate (HCBT) single oral dose (fasted)
61927135|NCT05572190|ACTIVE_COMPARATOR|A1.1. 10 mg HCBT|10 mg HCBT single oral dose (fasted)
61927136|NCT05572190|EXPERIMENTAL|A1.2. 30 mg ETR028|30 mg ETR028 single oral dose (fasted)
61927137|NCT05572190|EXPERIMENTAL|A1.2. 30 mg ETR029|30 mg ETR029 single oral dose (fasted)
62321774|NCT06692075|ACTIVE_COMPARATOR|standard ACLS in refractory OHCA|Emergency standard advanced cardiac life support ( ACLS ) in cardiopulmonary resuscitation of OHCA patients with refractory ventricular fibrillation or pulseless ventricular tachycardia. Bailout ECMO allowed after at least 45 minutes of CPR since collapse and 119 call or at least 15 minutes since arrival at emergency department
61927138|NCT05572190|EXPERIMENTAL|A2. <=60mg ETR028|\<=60 mg ETR028 single oral dose (fasted)
61927139|NCT05572190|ACTIVE_COMPARATOR|A2. <= 80mg HCBT|\<= 80mg HCBT single oral dose (fasted)
61927140|NCT05572190|EXPERIMENTAL|"B1. [ETR028 + ETR029] blend 1"|\[ETR028 - dose To Be Determined (TBD) + ETR029 - \<=30mg\] single oral dose (fasted)
62130675|NCT04377308|ACTIVE_COMPARATOR|Fluoxetine|Participants will take fluoxetine 20 mg initially, increasing as tolerated to a maximum of 60 mg until symptoms abate, then will be tapered by 20 mg per week off the fluoxetine Participants will be on fluoxetine for 2 weeks to 2 months depending on symptom duration
62130676|NCT06519292||ICI group|Patients that receive immune checkpoint inhibitors
61927141|NCT05572190|EXPERIMENTAL|"B1. [ETR028 + ETR029] blend 2"|\[ETR028 - dose TBD + ETR029 - \<=30mg\] single oral dose (fasted)
61927142|NCT05572190|EXPERIMENTAL|"B2. [ETR028 + ETR029] blend 3"|\[ETR028 - dose TBD + ETR029 - \<=30mg\] single oral dose (fasted)
61927143|NCT05572190|EXPERIMENTAL|"B2. [ETR028 + ETR029] blend 4"|\[ETR028 - dose TBD + ETR029 - \<=30mg\] single oral dose (fasted)
61927144|NCT05572190|EXPERIMENTAL|"B3. [ETR028 + ETR029] blend 1, 2, 3, or 4 (fed)"|\[ETR028 - dose TBD + ETR029 - \<=30mg\] single oral dose (fed)
61927145|NCT05572190|EXPERIMENTAL|"B3. [ETR028 + ETR029] blend 1, 2, 3, or 4 (fasted)"|"2-fold higher dose of \[ETR028 + ETR029\] blend 1, 2, 3, or 4 single oral dose (fasted)"
62130677|NCT06519292||Non-ICI group|Patients with similar malignancies, who do not receive immune checkpoint inhibitors
62130678|NCT05278533|EXPERIMENTAL|BioPlete™ Advanced Formula|"BioPlete™ Advanced Formula in Capsule~Intervention: Dietary Supplement: Multi-Vitamin"
62130679|NCT05278533|PLACEBO_COMPARATOR|Placebo|"Rice Flour in a capsule~Intervention: Other: Placebo"
62690198|NCT05462821|NO_INTERVENTION|Observation Group|Participants randomized to observation alone will not be allowed to receive any other treatment for IXT, except refractive correction, for 3 months.
62690199|NCT05462821|EXPERIMENTAL|Full Time Patching|Participants randomized to the full-time patching group will patch full-time (all waking hours) for 3 months up until the day before the 3-month primary outcome visit. Daily alternate patching will be prescribed (right eye on even days, left eye on odd days). No other treatment for IXT will be used, except for refractive correction.
61927146|NCT05572190|EXPERIMENTAL|"B4. [ETR028 + ETR029] blend 1, 2, 3, or 4"|"4-fold higher dose of \[ETR028 + ETR029\] blend 1, 2, 3, or 4 single oral dose (fasted)"
61927147|NCT05572190|EXPERIMENTAL|"B5. [ETR028 + ETR029] blend 1, 2, 3, or 4"|"8-fold higher dose of \[ETR028 + ETR029\] blend 1, 2, 3, or 4 single oral dose (fasted)"
61927148|NCT05572190|EXPERIMENTAL|"B6. [ETR028 + ETR029] blend 1, 2, 3, or 4"|"8-fold higher dose of \[ETR028 + ETR029\] blend 1, 2, 3, or 4 single oral dose (fed)"
61927149|NCT05992324|EXPERIMENTAL|Patients presenting with clinical suspicion of B-Lines|Patients will undergo two 8-zone protocol lung ultrasound exams. One exam will be conducted by an expert lung ultrasound user without Caption LungAI and will last approximately 5-10 minutes. The second exam will be conducted by a healthcare professional with Caption LungAI and will last approximately 15-20 minutes.
61927150|NCT04017247|ACTIVE_COMPARATOR|Intermittent treatment|Infusion of oxytocin for 6 hours at a time until patient delivers.
61927151|NCT04017247|ACTIVE_COMPARATOR|Continous treatment|Infusion of oxytocin continuously from patient admission for 16 hours.
61927152|NCT01296243|EXPERIMENTAL|Tesetaxel once every 3 weeks|
61927153|NCT04824859|EXPERIMENTAL|Experimental|The eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided.
61927154|NCT02715479|EXPERIMENTAL|Treatment A|Single DTG tablet under fed conditions for a specified period
61927155|NCT02715479|EXPERIMENTAL|Treatment B|Two BMS955176 tablets under fed conditions for a specified period
61927156|NCT02715479|EXPERIMENTAL|Treatment C|Single DTG tablet and Two BMS955176 tablets under fed conditions for a specified period
61927157|NCT00611039|EXPERIMENTAL|1|Darunavir 900mg + ritonavir 100 mg once a day
61927158|NCT00611039|ACTIVE_COMPARATOR|2|Darunavir 600mg + ritonavir 100mg twice day
61927159|NCT00625742|EXPERIMENTAL|Multimodal Treatment Strategy|Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.
61927160|NCT02464917|EXPERIMENTAL|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
61927161|NCT02464917|NO_INTERVENTION|Room air|This control arm will receive no supplemental oxygen
61927162|NCT06229782|OTHER|ODUS|"Orbital Doppler ultrasonography (ODUS)~Patients in whom brain death was suspected and the diagnostic procedure was initiated underwent ODUS .ODUS were performed during the apnoea test and the first neurological examination. At the second neurological examination at 12 hours, ODUS were repeated."
61927163|NCT06361797|ACTIVE_COMPARATOR|4cc bone marrow aspirate|Bone marrow aspirate, 4cc
61927164|NCT06361797|EXPERIMENTAL|20cc bone marrow aspirate|Bone marrow aspirate, 20cc
61927165|NCT06361797|EXPERIMENTAL|Bone marrow concentrate|20cc of whole bone marrow concentrated (varying quantities)
61927166|NCT05338151|OTHER|Brief Negotiated Interview (with referral and telephone booster) alone|All participants will receive BNI with referral and a 15-20 minute telephone booster delivered by a trained Health Promotion Advocate (HPA) at 2 weeks. The purpose of the BNI is to assist patients in recognizing and changing levels of alcohol consumption that pose health risks. The main goals of the BNI are to: 1) lessen ambivalence about reducing alcohol use; and 2) negotiate strategies for change. During BNI, the HPA will: 1) Raise the subject of alcohol; 2) Provide feedback: review the patient's alcohol consumption, make a connection to the patient's medical condition and reason for hospitalization; review guidelines for lower risk alcohol use; 3) Enhance motivation: have the patient identify on a readiness change ruler and develop discrepancy; and 4) Negotiate and Advise: negotiate goal, give advice, have patient complete drinking agreement; summarize and arrange follow-up.
61927167|NCT05338151|ACTIVE_COMPARATOR|BNI+MAUD|For either BNI+facilitated provision of MAUD or BNI+facilitated provision of MAUD+CBT4CBT, the HPA will provide education and counseling regarding MAUD as part of the BNI to the participant and communicate to the primary medical team that MAUD is indicated. The specific MAUD chosen will be made at the discretion of the patient and the primary medical team with recommendations from the study physicians, with a goal of prioritizing FDA approved medications. Participants will be encouraged to initiate (or receive as in the case of injectable naltrexone) MAUD prior to discharge and will be provided a prescription for a 30-day supply. Medications will be obtained through regular means and not provided directly through the study. During the BNI telephone booster, the HPA will inquire about and address any barriers to MAUD and encourage continued adherence.
62130680|NCT05801198|EXPERIMENTAL|Artemisia Afra|artemisia afra 10g/ day for 14 days
62130681|NCT05801198|EXPERIMENTAL|Artemisia Annua|artemisia annua 10g/ day for 14 days
62130682|NCT05801198|NO_INTERVENTION|No treatment|
62130683|NCT02808767|EXPERIMENTAL|Patients treated with Prasugrel|Prasugrel Loading dose: 60 mg Maintenance dose: 10 mg once-daily; patients \>75 years of age or \< 60 kg of weight receive a maintenance dose of 5 mg o.d.
62130684|NCT02808767|EXPERIMENTAL|Patients treated with ticagrelor|Ticagrelor Loading dose: 180 mg Maintenance dose: 90mg twice-daily
62130685|NCT04577924||Road traffic injury victims|"All RTI patients presenting to ED within 24 hours of injury is included in the study..~Individual's not consenting to be part of the study or withdrawing consent later on would be excluded. We also would exclude cases where pre-hospital care provider could not be traced or where reliable data patient could not be collected even after repeated interview."
62130686|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
62130687|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
62481522|NCT06395246|EXPERIMENTAL|eTRE|early (morning) time-restricted eating (eTRE) plus continuous caloric restriction diet based on healthy Mediterranean diet recommendations
62690200|NCT06352567||Breast Cancer|Patients diagnosed with breast cancer who underwent systemic adjuvant or neoadjuvant chemotherapy will be assessed with the European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire within completion of the systemic chemotherapy in 1-2 months.
62130688|NCT05618132|EXPERIMENTAL|Vasospastic angina|Interventional diagnostic protocol
61927168|NCT05338151|EXPERIMENTAL|BNI+MAUD+CBT4CBT|Participants randomized to BNI+facilitated provision of MAUD+CBT4CBT will be given a username and password to access the web-based program and be encouraged to begin accessing the program during their hospitalization. The HPA will assist each participant with login during the first session and be available to answer any questions. Participants will be asked to complete no more than two modules per week, with an expectation of completing all seven modules by the end of the 34-day post-discharge. The program tracks, for each participant, time logged onto the program, modules accessed, progress through the program from session to session, completion of homework assignments, and learning of CBT principles through brief quizzes. Participants will be allowed to repeat modules as desired. During the BNI telephone booster, the HPA will inquire about engagement with CBT4CBT, address any questions and problems with the program, and encourage practice of coping activities (i.e., homework).
61927169|NCT03089866||ASA Patients I or II|Participants are healthy (BMI \<35), 55years and older, and have the ability to follow instructions. In this population we will quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
61927170|NCT04248803|NO_INTERVENTION|Total etch control group|No gluma desensitizer application
61927171|NCT04248803|EXPERIMENTAL|TE - GLUMA application prior to acid etching|TE- Total Etch GLUMA - Desensitizing agent
62690201|NCT06642272|OTHER|Empagliflozin 10 MG|Head-to-head comparator
62690202|NCT06642272|OTHER|Dapagliflozin 10 MG|Head-to-head comparator
62690203|NCT05757726|EXPERIMENTAL|Interventional Arm|
61927172|NCT04248803|EXPERIMENTAL|TE - GLUMA application after acid etching|TE- Total Etch GLUMA - Desensitizing agent
61927173|NCT04248803|NO_INTERVENTION|Self etch control group|No gluma desensitizer application
61927174|NCT04248803|EXPERIMENTAL|SE - GLUMA application prior to acid etching|SE - Self Etch GLUMA - Desensitizing agent
62690204|NCT00260338|ACTIVE_COMPARATOR|Mesenchymal stromal cell|Mesenchymal stromal cell
61927175|NCT04248803|EXPERIMENTAL|SE - GLUMA application after acid etching|SE - Self Etch GLUMA - Desensitizing agent
61927176|NCT02112526|EXPERIMENTAL|Acalabrutinib|
61927177|NCT02675231|EXPERIMENTAL|150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant|150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
61927178|NCT02675231|EXPERIMENTAL|150 mg Abemaciclib + 8 mg/kg Trastuzumab|150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
61927179|NCT02675231|ACTIVE_COMPARATOR|8 mg/kg Trastuzumab + Standard of Care Chemotherapy|8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
61927180|NCT00842764|EXPERIMENTAL|Holmium: YAG laser|Subjects will go under minimally invasive Holmium: YAG laser blepharoplasty
61927181|NCT06623721|EXPERIMENTAL|Intervention|Patients undergoing prescribed neurorehabilitation therapy with additional intervention of movement-evoked auricular Vagus nerve stimulation.
61927182|NCT06744205|EXPERIMENTAL|Group 1 - Hexavalent (Combination 1)|Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 1)
62130689|NCT04244500||Influenza|Influenza testing
62690205|NCT01117662|EXPERIMENTAL|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
62690206|NCT01117662|PLACEBO_COMPARATOR|Control|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
62690207|NCT06357715|ACTIVE_COMPARATOR|"neurodynamic sliding mobilisation in the Slump position"|"slumpposition"
62690208|NCT06357715|PLACEBO_COMPARATOR|"mobilisation, out of the Slump position"|"no slumpposition"
61927183|NCT06744205|EXPERIMENTAL|Group 2 - Hexavalent (Combination 2)|Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 2)
61927184|NCT06744205|EXPERIMENTAL|Group 3 - Hexavalent (Combination 3)|Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 3)
61927185|NCT06744205|EXPERIMENTAL|Group 4 - Hexavalent (Combination 4)|Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 4)
61927186|NCT06744205|EXPERIMENTAL|Group 5 - Hexavalent (Combination 5)|Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 5)
62130690|NCT02574442||Initial Colposcopy Visit|Women with a scheduled colposcopy and biopsy appointment at the Women's Clinic at Vancouver General Hospital
62130691|NCT05859152|EXPERIMENTAL|ZP Bound Sperm Selection Oocyte Cohort|This is half of the patient's mature oocytes that will be inseminated via the ICSI procedure with sperm that has bound to the ZP of an immature oocyte.
62690209|NCT01321905|EXPERIMENTAL|Ergocalciferol|"Patients younger than 16 years of age are administered 35,000 IU ergocalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU ergocalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
61927187|NCT06744205|EXPERIMENTAL|Group 6 - Hexavalent (Combination 6)|Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 6)
61927188|NCT06744205|EXPERIMENTAL|Group 7 - TIV mRNA-HA Vaccine 1|Participants will receive a single dose of TIV mRNA-HA Vaccine 1
61927189|NCT06744205|EXPERIMENTAL|Group 8 - TIV mRNA-NA|Participants will receive a single dose of TIV mRNA-NA
61927190|NCT06744205|EXPERIMENTAL|Group 9 - TIV mRNA-HA Vaccine 2|Participants will receive single dose of TIV mRNA-HA Vaccine 2
61927191|NCT06744205|ACTIVE_COMPARATOR|Group 10 - QIV-SD|Participants will receive single dose of QIV-SD vaccine (for participants 50 to 64 years of age only)
61927192|NCT06744205|ACTIVE_COMPARATOR|Group 11 - QIV-HD|Participants will receive single dose of QIV-HD vaccine
61927193|NCT05062044||Multivitamins usage in pregravidal preparation|Participants start use of Elevit multiple micronutrient (MMN) before pregnancy.
61927194|NCT05062044||Multivitamins usage during pregnancy|Participants start use of Elevit multiple micronutrient (MMN) in the first trimester of pregnancy.
61927195|NCT05062044||Folic acid usage during pregnancy|Participants use folic acid in accordance with clinical guidelines.
61927196|NCT06317649|EXPERIMENTAL|Regimen 1 (azacitidine, venetoclax)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
61927197|NCT06317649|EXPERIMENTAL|Regimen 2 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
61927198|NCT06317649|EXPERIMENTAL|Regimen 3 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
61927199|NCT05350501|EXPERIMENTAL|Patients With Minimal Residual Disease of Colorectal Cancer|Patients With Circulating Tumor DNA-defined Minimal Residual Disease of Colorectal Cancer Stage II, III, or IV After Completion of Curative Therapy
61927200|NCT04730167||Retired Motorsport Pilots|Concussion assessment
62130692|NCT05859152|OTHER|Routine Care: Embryologist Selected Sperm Oocyte Cohort|This is half of the patient's mature oocytes that will be inseminated via the ICSI procedure per routine with sperm that is subjectively selected by the embryologist (based on morphology and mobility characteristics). This is the current standard of care for ICSI.
62321775|NCT02911064||Assessment Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being.
62690210|NCT01321905|EXPERIMENTAL|Cholecalciferol|"Patients younger than 16 years of age are administered 35,000 IU cholecalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU cholecalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
61927201|NCT06652737|EXPERIMENTAL|Cohort 1: Group 1a Adult 2x10e5 PfSPZ-LARC2 Vaccine|20-50-year-olds: 10 participants receive 3 injections of 2.0x10e5 PfSPZ-LARC2 Vaccine
61927202|NCT06652737|PLACEBO_COMPARATOR|Cohort 1: Group 1b Adult Normal Saline|20-50-year-olds: 5 participants receive 3 injections of normal saline
61927203|NCT06652737|EXPERIMENTAL|Cohort 1: Group 2a Adult 4x10e5 PfSPZ-LARC2 Vaccine|20-50-year-olds: 10 participants receive single injection of 4.0x10e5 PfSPZ-LARC2 Vaccine
61927204|NCT06652737|EXPERIMENTAL|Cohort 2: Group 3a 11-17year old 2x10e5 PfSPZ-LARC2 Vaccine|11-17-year-olds: 10 participants receive single injection of 2.0x10e5 PfSPZ-LARC2 Vaccine
61927205|NCT06652737|PLACEBO_COMPARATOR|Cohort 2: Group 3b 11-17 year-olds Normal Saline|11-17-year-olds: 5 participants receive single injection of Normal Saline
61927206|NCT06652737|EXPERIMENTAL|Cohort 2: Group 4a 6-10-year old 2x10e5 PfSPZ-LARC2 Vaccine|6-10-year-olds: 10 participants receive single injection of 2.0x10e5 PfSPZ-LARC2 Vaccine
62321776|NCT05895825|EXPERIMENTAL|Part 1: Dose Escalation|In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of EOC237 as monotherapy. Participants can receive EOC237 until disease progression, adverse event (AE), or other discontinuation criteria, whichever occurs first.
62339808|NCT05872594||study group|"all participants older than 18 years who agreed to participate (i.e., who clicked on the button agree after reading informed consent form) with no regard to sex, race, education, family status"
61927207|NCT06652737|PLACEBO_COMPARATOR|Cohort 2: Group 4b 6-10-year old Normal Saline|6-10-year-olds: 5 participants receive single injection of Normal Saline
61927208|NCT06652737|EXPERIMENTAL|Cohort 3: Group 5a 1-5-year old 2x10e5 PfSPZ-LARC2 Vaccine|1-5-year-olds: 10 participants receive one injection of 2.0x10e5 PfSPZ-LARC2 Vaccine
61927209|NCT06652737|PLACEBO_COMPARATOR|Cohort 3: Group 5b 1-5-year old Normal Saline|1-5-year-olds: 5 participants receive one injection of Normal Saline
61927210|NCT06652737|PLACEBO_COMPARATOR|Cohort 1: Group 2b: Adults Normal Saline|20-50 year olds: 5 participants receive single injection of Normal Saline
62690211|NCT01321905|NO_INTERVENTION|Control|Patients continue their ordinary vitamin supplementation without getting extra vitamin D supplements.
62130693|NCT02586597|EXPERIMENTAL|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
62130694|NCT02586597|EXPERIMENTAL|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
62130695|NCT02586597|SHAM_COMPARATOR|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
62321777|NCT05895825|EXPERIMENTAL|Part 2: Food influence-Group 1|"Food influence-Group 1: EOC237 was taken orally under fasted conditions, after a 3-day washout period, EOC237 was taken orally under fed conditions.~Participants can receive EOC237 until disease progression, AE, or other discontinuation criteria, whichever occurs first."
62321778|NCT05895825|EXPERIMENTAL|Part 2: Food influence-Group 2|"Food influence-Group 2: EOC237 was taken orally under fed conditions, after a 3-day washout period, EOC237 was taken orally under fasted conditions.~Participants can receive EOC237 until disease progression, AE, or other discontinuation criteria, whichever occurs first."
62321779|NCT02531269||Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)|
62321780|NCT02531269||Patients treated with DCV (NPP) + Simeprevir +/- RBV|
62321781|NCT02531269||Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV|
62321782|NCT02531269||Patients treated with DCV(post-marketing) + Simeprevir +/- RBV|
62321783|NCT00500045|EXPERIMENTAL|Treatment|Oral niacin
62321784|NCT01203904||Pulmicort|
62321785|NCT04209868|PLACEBO_COMPARATOR|Pre-PVB with saline|Placebo (20ml Saline) pre-PVB performed post-induction and pre-incision.
62321786|NCT04209868|EXPERIMENTAL|Pre-PVB with 0.5% Levo-bupivacaine|20ml 0.5% Levo-bupivacaine pre-PVB performed post-induction and pre-incision.
62321787|NCT03121742|PLACEBO_COMPARATOR|Treatment as usual [TAU] plus assessment|Patients will receive standard care plus assessment.
62321788|NCT03121742|EXPERIMENTAL|Treatment as usual [TAU] plus intervention|Patients will receive standard care plus an ecological momentary intervention.
62690212|NCT04336566|ACTIVE_COMPARATOR|Melatonin|5mg dose of melatonin manufactured by Good Neighbor Pharmacy
62690213|NCT04336566|PLACEBO_COMPARATOR|Placebo|Good Neighbor Pharmacy placebo tablet that looks the same without active ingredient
62690214|NCT02162173|EXPERIMENTAL|Endoscopy|All patients underwent the same endoscopy.
62130696|NCT06075524||Observational (Blood and stool sample collection)|Patients undergo blood sample collection throughout the study. Patients also undergo optional stool sample collection and have their medical records reviewed on study. In addition, patients provide previously-collected tissue sample, if available.
62321789|NCT01411293|EXPERIMENTAL|Low-Fat Dairy|Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
62321790|NCT01411293|ACTIVE_COMPARATOR|Rice Milk|Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
62321791|NCT04794699|EXPERIMENTAL|Part 1: Dose Escalation Monotherapy (Solid Tumors)|
62321792|NCT04794699|EXPERIMENTAL|Part 2: Monotherapy Dose Expansion (NSCLC, EG and Urothelial)|
62321793|NCT04794699|EXPERIMENTAL|Part 3: Combination Dose Escalation with docetaxel or paclitaxel (NSCLC, EG and Urothelial)|
62321794|NCT04794699|EXPERIMENTAL|Part 4: Combination Dose Expansion with docetaxel or paclitaxel (NSCLC, EG and Urothelial)|
62321795|NCT04794699|EXPERIMENTAL|Part 5: Combination Dose Escalation with sacituzumab govitecan (SG) (Urothelial)|
62321796|NCT04794699|EXPERIMENTAL|Part 6: Combination Dose Expansion with sacituzumab govitecan (SG) (Urothelial)|
62321797|NCT00158652|ACTIVE_COMPARATOR|1|
62321798|NCT00158652|EXPERIMENTAL|2|
62321799|NCT00158652|EXPERIMENTAL|3|
62321800|NCT03968367|EXPERIMENTAL|Magnetic activated sperm cell sorting for infertile man|A 0.5 mL aliquot of spermatozoa suspended in HTF-modified HEPES buffer, obtained either after sperm wash to remove the seminal plasma or after DGC, was centrifuged and the pellet (maximum of 107 cells) was resuspended in 80 uL of binding buffer with 20 uL of Annexin V-conjugated microspheres, both from the Annexin V microbead kit (Miltenyi Biotec, Huburn, CA, USA), for 15 min at room temperature. After addition of 400 lL of binding solution, the suspension was placed in the separation column (MiniMACS, Miltenyi Biotec). Labeled (apoptotic) cells were retained on the column and non-labeled (viable) cells passed through the column.
62321801|NCT02460822|EXPERIMENTAL|MyChemoCare|Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
62321802|NCT06693193|EXPERIMENTAL|Virtual Reality group|Participants will undergo three VR exposure sessions using Oculus headsets, presenting a virtual environment with realistic natural stimuli or customized environments tailored to individual preferences and valued activities. For each environment, auditory (e.g., animal sounds, wind rustling, type of music) and visual elements (e.g., presence of people, objects, or animals), as well as time of day and weather conditions, can be adjusted. The operator will customize the environment through a user-friendly smartphone app interface, enabling real-time parameter adjustments and content selection. During VR exposure, the operator can observe the participant's visual focus in real-time.
62321803|NCT05734547|EXPERIMENTAL|Stepping Together for Children after Trauma (ST-CT)|Parent-led, therapist assisted CBT treatment
62690215|NCT06637059||Training cohort|
62690216|NCT06637059||Internal validation cohort|
62690217|NCT06637059||External validation cohort|
62130697|NCT04018924|EXPERIMENTAL|T - Treated|After standard cleansing or debridement of all wounds, on wound or portion of wound selected for treatment is treated with EmoLED device. Then covered with hydro fibre medication and dressing or compressive dressing when needed on the whole wound (SOC). Treatment is repeated once a week.
62690218|NCT02117271|PLACEBO_COMPARATOR|nasal dilator strip|Breathe Right ® nasal dilator strip used during sleep
62130698|NCT01796236|ACTIVE_COMPARATOR|Minimally invasive surgery and BA400|This arm involves no soft tissue reduction around the BA400 implant.
61927211|NCT04509648|EXPERIMENTAL|Super Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will receive 5.2 Gy in 5 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular/infraclavicular region, internal mammary nodes, and any part of the axillary bed at risk) and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast at the discretion of radiation oncologist.
61927212|NCT05050682|EXPERIMENTAL|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
61927213|NCT06537596|EXPERIMENTAL|Part A|One Injection of 89Zr-TLX300-CDx
61927214|NCT06537596|EXPERIMENTAL|Part B|One Injection of 89Zr-TLX300-CDx
61927215|NCT06537596|EXPERIMENTAL|Part C|One Injection of 89Zr-TLX300-CDx
61927216|NCT05785104|EXPERIMENTAL|Myofascial release|The patients will receive myofascial release technique on cervical and lumbar regions three times per week for four weeks
61927217|NCT05785104|EXPERIMENTAL|Muscle energy technique|The patients will receive muscle energy technique for cervical and lumbar regions three times per week for four weeks
61927218|NCT05912452|EXPERIMENTAL|Percussion Massage Group|The group to which percussion massage therapy will be applied to the deltoid muscle.
61927219|NCT05912452|EXPERIMENTAL|Kinesiotape Group|The group to which kinesiotaping will be applied to the deltoid muscle.
61927220|NCT05912452|EXPERIMENTAL|Dynamic Stretching Group|The group to which dynamic stretching will be applied to the deltoid muscle.
61927221|NCT05758493|EXPERIMENTAL|Patients with ATTR-CM|Patients with ATTR-CM will undergo hybrid 124I-Evuzamitide PET/MRI imaging (or PET/CT) at baseline and in a subgroup, repeat imaging will be performed at an interval of 6-12 months.
61927222|NCT00174291|EXPERIMENTAL|Somatropin|
61927223|NCT06709924||Wrestling group|The ten participants who are expertise of wrestling and strong core muscle usage. After ingest the capsule, the signal transmission and intraabdominal pressure parameters were collected from receivers outside..
61927224|NCT06709924||Swimming group|The ten participants who are expertise of swim and strong core muscle usage. After ingest the capsule, the signal transmission and intraabdominal pressure parameters were collected from receivers outside..
61927225|NCT06161506|EXPERIMENTAL|1/Elidah Device|Elidah device application.
61927226|NCT03122301|ACTIVE_COMPARATOR|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
61927227|NCT03122301|SHAM_COMPARATOR|Saline|Saline injection
62130699|NCT01796236|ACTIVE_COMPARATOR|Traditional surgery and BA300|This arm involves traditional soft tissue reduction around the BA300 implant
61927228|NCT00270829|EXPERIMENTAL|1|Nesiritide given intrarenally
62130700|NCT05370794||standard IVM: urinary purified gonadotropins (uFSH and uhCG)|"uhCG = Pregnyl®, 5000IU/ vial, Organon-Merck: final concentration 100mIU/ml + uFSH = Menopur® 75mIU/ml, Ferring: final concentration 75mIU/ml.~Administered during 30h of in vitro maturation culture"
62130701|NCT05370794||Experimental IVM: recombinant gonadotropins (rFSH and rhCG)|"rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono : final concentration 100mIU/ml + rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono: final concentration 75mIU/ml.~Administered during 30h of in vitro maturation culture"
62130702|NCT02247817|EXPERIMENTAL|HYBRID|Hybrid transvenous/epicardial implantation of a CRT-(D) device.
61927229|NCT00270829|NO_INTERVENTION|2|No intrarenal drug administration
61927230|NCT05551936|EXPERIMENTAL|Investigational Group|"Phase 1:~90 mg/m\^2 of bendamustine by IV on Day 1 and 2 of a 28 day cycle (up to 3 Cycles)~375 mg/m\^2 of rituximab by IV on Day 1 of a 28 day cycle (up to 3 Cycles)~Participants enrolled in this phase will be given one of 3 different dose levels of tazemetostat along with the drugs above (for up to 3 Cycles). 3 patients will be assigned to the lowest dose level and if the dose is tolerated, 3 more patients will be enrolled one dose level higher. Up to 18 participants being enrolled.~Dose Level 1: 400 mg of tazemetostat orally twice daily~Dose Level 2: 600 mg of tazemetostat orally twice daily~Dose Level 3: 800 mg of tazemetostat orally twice daily~Phase 2:~6 patients from Phase 1 who were treated at the recommended Phase 2 dose will be added to 21 additional patients.~375 mg/m\^2 of rituximab through IV on Day 1 of a 28 day cycle (Cycles 1-6)~Tazemetostat orally twice daily of a 28 day cycle (Cycles 1-6)"
61927231|NCT02372890||All patients|Patients with head and neck squamous cell carcinoma with advanced primary tumor stages (cT3 or cT4), clinical suspicion of cervical lymph node metastases, cervical lymph node metastasis of unknown primary tumor (CUP) or patients with tumor recurrence scheduled for neck dissection.
62130703|NCT00709423|ACTIVE_COMPARATOR|1|
62130704|NCT00709423|PLACEBO_COMPARATOR|2|
62130705|NCT00034528|EXPERIMENTAL|Allogeneic stem cell transplantation|Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
62321804|NCT05734547|ACTIVE_COMPARATOR|Usual care|The types of interventions normally provided in the first-line municipal services
62321805|NCT03515603|ACTIVE_COMPARATOR|microsurgical technique|
61927232|NCT01520454|PLACEBO_COMPARATOR|Placebo|IV saline with heparin, oral water
62321806|NCT03515603|ACTIVE_COMPARATOR|endoscopic technique|
62690219|NCT02117271|EXPERIMENTAL|continuous positive airway pressure|nasal continuous positive airway pressure used during sleep
62690220|NCT02811614|EXPERIMENTAL|Experimental 1: Endoscopic Evacuation|Endoscopic hematoma evacuation with the help of a self-developed working channel.
62690221|NCT02811614|EXPERIMENTAL|Experimental 2: Stereotactic Aspiration|Place a catheter into the main body of the hematoma and aspirate blood.
62690222|NCT02811614|ACTIVE_COMPARATOR|Active Comparator: Craniotomy|Craniotomy with a big bone flap to for hematoma evacuation.
62690223|NCT01582581|ACTIVE_COMPARATOR|Telephonic CBT|Computer guided, cognitive behavioral therapy (CBT) delivered by a clinician-administered telephone intervention.
62481523|NCT06558929|EXPERIMENTAL|Occupational Intervention Group|The intervention group will participate in a 6-week occupational therapy program, which includes 3 group treatment sessions, 1 individual treatment session, and daily occupational tasks.
62481524|NCT06558929|OTHER|Control Group|The control group will be educated on sleep hygiene, and keep a record of any other treatment for sleep.
62481525|NCT05893290|ACTIVE_COMPARATOR|Therapeutic Exercise Group|The therapeutic exercise protocol will be taught to patients in the first session and will be done 3 times a week for 12 weeks.
62481526|NCT05893290|EXPERIMENTAL|Therapeutic Exercise+Basic Body Awareness (BBAT) Group|This group will receive BBAT as well as therapeutic exercises for 3 times a week for 12 week. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
62481527|NCT05893290|NO_INTERVENTION|Control Group|This group will not receive any treatment.
62481528|NCT02949739|ACTIVE_COMPARATOR|Intensive lifestyle modification|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study (Index cases). Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Intensive lifestyle modification follows clinically accepted, evidence based strategies to achieve \>7% reduction in weight through improved diet and increased physical activity, and is delivered as 9 face-face and 13 telephone contact sessions over 12 months.~Index cases will be followed for three years to identify new-onset T2D."
62321807|NCT02353078|EXPERIMENTAL|Sucralfate|This is a pilot study in which 6 patients with active EoE defined by consensus criteria (ref) who have undergone recent endoscopy will be administered sucralfate slurry 1 gram four times daily for four weeks following which repeat endoscopy with esophageal biopsies will be performed. Patients will be those who had not had medical treatment for EoE or those who have not responded to proton pump inhibitors.
62321808|NCT02353078|EXPERIMENTAL|Intraluminal Impedance|This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
62321809|NCT01517789|EXPERIMENTAL|Patients|
62321810|NCT04215354|EXPERIMENTAL|MAGNET GROUP|Patients were exposed to very low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional using magnet mattress.
62321811|NCT04215354|EXPERIMENTAL|VIRTUAL REALITY|"Balance training was done using the Wii Fit plus machine which required balance board .Using video game console designed by Nintendo.~The program consisted of three games: soccer heading, ski slalom and table tilt."
62321812|NCT04215354|ACTIVE_COMPARATOR|PLACEBO|Patients in the placebo group had identical program to magnet group. They were asked to lie down in the magnet mattress; however, the magnet was not switched on and the patient doesn't know (blind).
62321813|NCT04215354|NO_INTERVENTION|HEALTHY SUBJECT|healthy subjects with age, gender and BMI matched with the patients with MS were recruited to participate in the study. This group was recruited to establish the normal balance and fatigue parameters. Subjects in this group sign the consent form of healthy subjects and all measurement was taken as balance, fatigue, depression, quality of life and urinary incontinence screening questionnaire.
62321814|NCT06194435|EXPERIMENTAL|Telemedicine Group: Remote Assessments and Asynchronous Exercise Guidance|For the Telemedicine Group, the study initiates with a video call from the physician on day one via FaceTime or WhatsApp. During these calls, patients will receive guidance and complete Quick-DASH questionnaire and numeric-VAS scale. On the same day, they will also receive an exercise video and an exercise diary via WhatsApp. Follow-up video calls on the 7th day will serve as reminders and allow patients to ask questions. The final video call, scheduled for the 15th day, will involve completing the same questionnaire and scale. After this last remote interaction, patients will send photos of their completed exercise logs to the physician via WhatsApp for adherence tracking.
62321815|NCT06194435|ACTIVE_COMPARATOR|Control Group: In-Person Assessments in Clinic and Exercise Brochure|For the Control Group, the study begins with an in-person visit to the physician on day one. During this visit, patients will receive guidance, complete Quick-DASH questionnaire and numeric-VAS scale, and be provided with an exercise brochure. Additionally, patients will receive an exercise diary on the same day to record their exercise sessions. Follow-up visits to the physician's office at the hospital on the 7th day will serve as reminders and opportunities for patients to ask questions. On the 15th day, patients will revisit the hospital to complete the same questionnaire and scale. We will also assess the time spent and economic burden associated with hospital visits. Furthermore, exercise diaries will be collected for adherence tracking and progress evaluation.
62481529|NCT02949739|NO_INTERVENTION|Usual Care|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study.~Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Usual care group will comprise one diabetes prevention session and written material."
62481530|NCT03579615|EXPERIMENTAL|FIASP + closed loop device|Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
62690224|NCT01582581|SHAM_COMPARATOR|Wait List Control|Randomized wait list control with measurement of study outcomes at week 0, 3 and 5 after the initiation of waiting.
62690225|NCT06251973|EXPERIMENTAL|Participants diagnoses with Esophageal, Gastric, or Gastro-esophageal Junction Cancer|Participants with measurable disease and with evaluable disease as defined by RECIST v1.1 will be enrolled on this study.
62690226|NCT02025218|EXPERIMENTAL|Re-administration gefitinib|
61927233|NCT01520454|EXPERIMENTAL|High dose fat solution|Intralipid at high dose, with heparin and PO water
62481531|NCT03579615|ACTIVE_COMPARATOR|Insulin aspart (standard of care insulin) + closed loop device|Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
62130706|NCT05293808|EXPERIMENTAL|aspirin 100 mg bis in die|aspirin 100 mg twice daily for the first month after acute coronary syndrome
62130707|NCT05293808|ACTIVE_COMPARATOR|aspirin 200 mg|aspirin 200 mg once daily for the first month after acute coronary syndrome
62130708|NCT05293808|ACTIVE_COMPARATOR|aspririn 100 mg|aspirin 100 mg once daily
62321816|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
62321817|NCT06486922|EXPERIMENTAL|StEP OUT Intervention|See intervention description
62321818|NCT02045316||Preeclamptic pregnants|pregnants with preeclampsia
62321819|NCT02045316||Normal pregnants|pregnants without obstetric complications
62321820|NCT02237807|EXPERIMENTAL|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
62321821|NCT02237807|EXPERIMENTAL|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
62321822|NCT05017285|OTHER|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
62321823|NCT05017285|EXPERIMENTAL|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum.
62321824|NCT00235729|EXPERIMENTAL|1|Lofexidine 0.8 mg QID
62321825|NCT00235729|PLACEBO_COMPARATOR|2|Placebo QID
62321826|NCT03244891|EXPERIMENTAL|Studied subjects|"Each subject will be studied during two sequential phases:~1. before fluid challenge~2. after fluid challenge~During each phase, the subjects will be studied at:~1. baseline - spontaneously breathing~2. head down position - spontaneously breathing~3. baseline - positive pressure ventilation~4. head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
62321827|NCT04537390|OTHER|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
62321828|NCT04830995|EXPERIMENTAL|diet program|moderate restricted diet (1800-2000 kcal/day) for four weeks, 3 sessions weekly
62321829|NCT04830995|EXPERIMENTAL|high intensity interval training|high intensity interval training for four weeks, 3 sessions weekly
62321830|NCT00935220|EXPERIMENTAL|linagliptin|Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation
62321831|NCT00392444|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62321832|NCT00144001||Group 1|
61927234|NCT01520454|EXPERIMENTAL|Low dose fat solution|Low dose IV Intralipid with heparin and PO water
62130709|NCT02040831|EXPERIMENTAL|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
62130710|NCT02040831|PLACEBO_COMPARATOR|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
62130711|NCT03373448|ACTIVE_COMPARATOR|Labrida BioClean|Labrida BioClean- chitosan device.The brush bristles of the test device (Labrida BioClean® LABRIDA AS, Oslo Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed thus not causing harm to the tissues surrounding the implant. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
62130712|NCT03373448|OTHER|Titanium curettes|Peri-implant pockets will be debrided with titanium curettes.
62321833|NCT03927534|EXPERIMENTAL|Experimental|Mindful Eating program is apply face to face 7 sessions of 120 minutes/session. ME is apply in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
62321834|NCT03927534|NO_INTERVENTION|Control|Treatment As Usual (TAU) in Primary Care (PC) is any kind of treatment administered by the GP to the patient with overweight and obesity. According to nutritional status, overweight or obesity, as well as the presence of co-morbidity, different actions can comprise the treatment offered at a PC level. For individuals presenting with overweight (BMI 25-29.9 kg/m2) but with no co-morbidities, PC teams organise care plans to enable them to achieve a normal BMI range (BMI 18.5-24.9 kg/m2). In case of suicide risk, severe social dysfunction or worsening of symptoms, it is recommended that patients are referred to mental health facilities.
62321835|NCT01450930|ACTIVE_COMPARATOR|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
62321836|NCT01450930|ACTIVE_COMPARATOR|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
62321837|NCT05552378|OTHER|Single arm|
62321838|NCT03654248|EXPERIMENTAL|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
62321839|NCT03654248|ACTIVE_COMPARATOR|Individual Occupational Therapy|Individual intervention lasting 10 weeks
62321840|NCT04715724|EXPERIMENTAL|Baby doll with remote controlled jaw|In this arm, participants will complete a simulation using the Newborn Oral Assessment and Latch Simulator (NORALSim), which is designed to look, feel, and weigh like a healthy human newborn. The NORALSim's jaw can be remotely operated by the user to demonstrate attachment at the breast.
62321841|NCT04715724|ACTIVE_COMPARATOR|Baby doll with hand controlled jaw|In this arm, participants will complete a simulation using a cloth baby with a puppet-style jaw which can be opened and closed by the user to demonstrate attachment at the breast.
61927235|NCT01520454|EXPERIMENTAL|Oral fat|Oral fat load with IV saline
61927236|NCT05817279||AI-OCT|Group of 124 patients with equivocal BCC lesions. Of these lesions, OCT scans have been obtained in the past. These scans will be evaluated with AI-assistance.
62321842|NCT04715724|ACTIVE_COMPARATOR|Static baby doll|In this arm, participants will complete a simulation using a rigid, plastic baby with a static, open mouth.
61927237|NCT05817279||Unaided OCT|Group of 124 patients with equivocal BCC lesions (same patients as in AI-OCT group). Of these lesions, OCT scans have been obtained in the past. These scans will be evaluated without AI-assistance.
61927238|NCT06340178|EXPERIMENTAL|Fluid administration|Fluid is given in pleural or subpleural space during CT-guided lung biopsy.
61927239|NCT06340178|NO_INTERVENTION|No fluid administration|No additional fluid is given prior to the CT-guided lung biopsy.
62321843|NCT05071781|ACTIVE_COMPARATOR|Cortisol releasing hormone group|HVs will start with CRH infusion.
62321844|NCT05071781|PLACEBO_COMPARATOR|Placebo (sodium choride) group|HVs will start with NaCl 0.9% (placebo) infusion
61927240|NCT06211049|EXPERIMENTAL|Vitex agnus-castus BNO 1095 (20 mg)|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e., 113 days in case of a 28-day menstrual cycle).
61927241|NCT06211049|PLACEBO_COMPARATOR|Placebo|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e., 113 days in case of a 28-day menstrual cycle).
61927242|NCT06744686|EXPERIMENTAL|Part A (Healthy participants administered with HT-102 or placebo)|Healthy participants in all dose groups were randomly assigned to receive a single dose of HT-102 or placebo subcutaneously
61927243|NCT06744686|EXPERIMENTAL|Part B (Patients with CHB administered with HT-102 or placebo)|Patients with chronic hepatitis B in all dose groups were randomly assigned to receive 5 dose of HT-102 or placebo subcutaneously every week.
62321845|NCT04294264|EXPERIMENTAL|Treatment (TAS-102, oxaliplatin)|Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62481532|NCT03680313||Hypertension group|"All adult patients (above 18 year of age) were recruited between May, 2016 and June 2017, at Duc Giang General Hospital. The inclusion criteria are as followed:~* Patients have never been diagnosed with hypertension.~* Has been diagnosed with primary hypertension, but not take any treatment."
62481533|NCT03680313||Control group|A group of normal people with the similar age to hypertension group was recruited as control group at the same time
61927244|NCT02260674|EXPERIMENTAL|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
61927245|NCT02260674|EXPERIMENTAL|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
61927246|NCT02260674|PLACEBO_COMPARATOR|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
61927247|NCT01218633|PLACEBO_COMPARATOR|Saline|
61927248|NCT01218633|ACTIVE_COMPARATOR|GLP-1-(9,36)-amide|
61927249|NCT01218633|ACTIVE_COMPARATOR|Exendin-9,39 @30pmol/kg/min|
61927250|NCT01218633|ACTIVE_COMPARATOR|Exendin-9,39 @300pmol/kg/min|
61927251|NCT05744687|EXPERIMENTAL|SPH4336 Tablets 400mg|SPH4336 Tablets； Letrozole tablets
61927252|NCT05744687|PLACEBO_COMPARATOR|SPH4336 Tablets Placebo|SPH4336 Placebo； Letrozole tablets
61927253|NCT06723041|EXPERIMENTAL|Arm I (true acupressure)|Patients undergo true acupressure over 10 minutes on study. Patients that choose to learn self-administration acupressure at home receive educational information and undergo self-administration acupressure sessions at least BID for seven days.
61927254|NCT06723041|SHAM_COMPARATOR|Arm II (sham acupressure)|Patients undergo sham acupressure over 10 minutes on study. Patients that choose to learn self-administration acupressure at home receive educational information and undergo self-administration acupressure sessions at least BID for seven days.
61927255|NCT04322214|EXPERIMENTAL|COBI period (5 days) + Placebo period (5 days)|volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB
61927256|NCT04322214|EXPERIMENTAL|Placebo period (5 days) + COBI period (5 days)|volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB.
61927257|NCT04687774|EXPERIMENTAL|single-arm study|A single-arm of 30 treated patients is appropriate to generate additional local data on Exalt D Single-use Duodenoscope, since there is existing information in the previous study of Exalt D Single-use Duodenoscope in ERCP procedures and clinical literature regarding its performance.
61927258|NCT05542134||V-A ECMO without P2Y12 inhibitors|control group
61927259|NCT05542134||V-A ECMO with P2Y12 inhibitor at the time of ECMO|observational group 1
61927260|NCT05542134||V-A ECMO already recieving P2Y12 inhibitors|observational group 2
61927261|NCT06684327|EXPERIMENTAL|Nab-TIP|Participants will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.
62481534|NCT04362293|EXPERIMENTAL|Matched Sibling Donor (MSD)|Patients with a suitable HLA matched sibling donor (MSD) will be enrolled on the MSD arm.
61927262|NCT06745063|EXPERIMENTAL|Empagliflozin|12 week treatment with 10mg empagliflozin daily
61927263|NCT06745063|PLACEBO_COMPARATOR|Placebo|12 week treatment with 10mg placebo daily
61927264|NCT00048061|ACTIVE_COMPARATOR|Ibandronate 2.5 mg|Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
61927265|NCT00048061|EXPERIMENTAL|Ibandronate 50/50 mg|Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
62321846|NCT02691247|EXPERIMENTAL|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
61927266|NCT00048061|EXPERIMENTAL|Ibandronate 100 mg|Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
61927267|NCT00048061|EXPERIMENTAL|Ibandronate 150 mg|Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
61927268|NCT04854642|EXPERIMENTAL|T - R (fed then fasting condition)|Subjects were assigned to the sequence of treatments TR to receive Ladarixin in fed conditions (T treatment) during period 1 and in fasting conditions (R treatment) in period 2.
61927269|NCT04854642|EXPERIMENTAL|R - T (fasting then fed condition)|Subjects were assigned to the sequence of treatments RT to receive Ladarixin ini fasting conditions (R treatment) in period 1 and in fed conditions (T treatment) during period 2.
61927270|NCT03219879|EXPERIMENTAL|Telephone-administered continuation therapy|Cognitive-behavioral continuation therapy (T-CT) delivered over the telephone by trained psychotherapist
61927271|NCT03219879|ACTIVE_COMPARATOR|Usual care|Treatment as usual
61927272|NCT06691984|EXPERIMENTAL|Xaluritamig|Participants with metastatic castration-resistant prostate cancer (mCRPC) will be randomized to receive Xaluritamig as an intravenous (IV) infusion.
61927273|NCT06691984|ACTIVE_COMPARATOR|Cabazitaxel/Abiraterone/Enzalutamide|Participants with mCRPC will be randomized to receive cabazitaxel as an IV infusion, or a second androgen receptor-directed therapy of either abiraterone as oral tablets, or enzalutamide as oral tablets at the investigator's discretion.
61927274|NCT02524210|EXPERIMENTAL|Arm A|"* Period  Dabigatran~* Washout period (at least 6 days)~* Period  Rabeprazole + Dabigatran~* Washout period (at least 6 days)~* Period  Omeprazole + Dabigatran"
61927275|NCT02524210|EXPERIMENTAL|Arm B|"* Period Rabeprazole + Dabigatran ~* Washout period (at least 6 days)~* Period  Dabigatran~* Washout period (at least 6 days)~* Period  Omeprazole + Dabigatran"
61927276|NCT02524210|EXPERIMENTAL|Arm C|"* Period  Rabeprazole + Dabigatran~* Period  Omeprazole + Dabigatran~* Period  Dabigatran"
61927277|NCT04472260|OTHER|Sequence 1: PP->PP->V->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
61927278|NCT04472260|OTHER|Sequence 2: PP->V->V->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
61927279|NCT04472260|OTHER|Sequence 3: V->PP->PP->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
61927280|NCT04472260|OTHER|Saquence 4: V->V->PP->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
61927281|NCT04509102|ACTIVE_COMPARATOR|Active|Subjects randomized to Adderall will take an tablet/capsule by mouth daily.
62321847|NCT02691247|EXPERIMENTAL|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
61927282|NCT04509102|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar.
61927283|NCT03241069|EXPERIMENTAL|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
61927284|NCT03241069|EXPERIMENTAL|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured 5 minutes later)
61927285|NCT03241069|EXPERIMENTAL|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver 5minutes later.)
62321848|NCT02691247|PLACEBO_COMPARATOR|Placebo|A single infusion of placebo, consisting of the infusion solution only
62321849|NCT02703805|EXPERIMENTAL|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors.
62321850|NCT02703805|ACTIVE_COMPARATOR|Standard YMCA membership|A 12 week standard YMCA membership.
61927286|NCT03241069|EXPERIMENTAL|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
62130713|NCT04512482|EXPERIMENTAL|Experimental: Bromelain, Then Placebo|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the placebo rinse (powdered sugar), following the same protocol and series of intraoral photographs.
62481535|NCT04362293|EXPERIMENTAL|Haploidentical (HAPLO)|Patients without an eligible MSD who have a suitable haploidentical (HAPLO) donor available will be enrolled on the HAPLO arm of the study.
61927287|NCT05008055|EXPERIMENTAL|Capivasertib monotherapy|Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
61927288|NCT01887301|ACTIVE_COMPARATOR|Group 1: mild hepatic impairment|Mild hepatic impairment: eight patients of Child-Pugh Grade A (Score 5-6). All patients received Sativex treatment.
61927289|NCT01887301|ACTIVE_COMPARATOR|Group 2: Moderate hepatic impairment|Moderate hepatic impairment: eight patients of Child-Pugh Grade B (Score 7-9). All patients received Sativex treatment.
61927290|NCT01887301|EXPERIMENTAL|Group 3: Pugh Grade B (Score 7-9).|Severe hepatic impairment: eight patients of Child-Pugh Grade C (Score 10-15). All patients received Sativex treatment.
61927291|NCT01887301|ACTIVE_COMPARATOR|Group 4: Control group|Control Group: eight healthy subjects matched with respect to age (±10 years), weight (±10% body mass index \[BMI\]) and sex to the severe or most severe evaluable patients. All patients received Sativex treatment.
61927292|NCT06135415|EXPERIMENTAL|Tirbanibulin 10 mg/g|Participants will apply tirbanibulin 10 mg/g ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve complete clearance (CC) at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.
61927293|NCT06135415|PLACEBO_COMPARATOR|Vehicle ointment|Participants will apply vehicle ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve CC at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.
62690227|NCT03474484||np-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission
62690228|NCT03474484||p-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission
62690229|NCT05369000|EXPERIMENTAL|LAVA-1207|LAVA-1207
61927294|NCT05832021||WALANT|Patients with distal radius fracture who underwent surgical treatment under WALANT.
61927295|NCT05832021||Peripheral nerve block|Patients with distal radius fracture who underwent surgical treatment under peripheral nerve block.
62339809|NCT01317615|EXPERIMENTAL|RAD001 plus paclitaxel/carboplatin|Participants received RAD001 5 mg orally once daily in combination with carboplatin and paclitaxel for a maximum 4 cycles or until discontinuation.
62339810|NCT04204655||Cohort|rehabilitants of the phase B, C and D during neurological rehabilitation
62481536|NCT06742268||Arm 1: Spectacles with Cessation of SAT-001 Use|This group consists of pediatric participants who were previously assigned to receive SAT-001 along with single vision spectacles as part of the SAT-001 confirmatory trial (SAT-001-KP-002). In the extension phase, these participants will continue wearing single vision spectacles, but will no longer receive SAT-001 treatment. The aim is to monitor rebound myopia and long-term safety after the completion of the initial trial, focusing on any changes in refractive error and axial length, as well as any adverse effects associated with the cessation of SAT-001 use.
62481537|NCT06742268||Arm 2: Continued Spectacles Only|This group consists of pediatric participants who were assigned to the control group during the SAT-001 confirmatory trial and received only single vision spectacles. In the extension phase, they will continue wearing spectacles to assess rebound myopia and long-term safety, without the addition of SAT-001 treatment.
61927296|NCT03381573||Roflumilast exposed|Patients with COPD ever exposed to Roflumilast
61927297|NCT03381573||Roflumilast unexposed|Patients with COPD never exposed to Roflumilast
61927298|NCT06743698||Patients|Patients that participated in the META trial.
61927299|NCT06743698||Healthcare staff|Healthcare staff that were involved in the META trial.
61927300|NCT06706817|EXPERIMENTAL|Tezepelumab|Tezepelumab: Tezepelumab single dose subcutaneously injection.
61927301|NCT04351776|OTHER|VR-Biofeedback|
61927302|NCT04351776|OTHER|VR-Distraction|
62690230|NCT05369000|EXPERIMENTAL|LAVA-1207 with Low-Dose Subcutaneous IL-2 (LDSC IL-2)|LAVA-1207 with Low-Dose Subcutaneous IL-2 (LDSC IL-2)
62690231|NCT05369000|EXPERIMENTAL|LAVA-1207 plus Pembrolizumab|LAVA-1207 plus Pembrolizumab
62690232|NCT02244957|ACTIVE_COMPARATOR|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
62690233|NCT02244957|ACTIVE_COMPARATOR|Nocturnal oxygen|Nocturnal oxygen
62690234|NCT06375499|EXPERIMENTAL|T2769|"Hyaluronic acid, Trehalose, Naaga~Route of administration: topical, ocular use"
61927303|NCT04351776|OTHER|360 Video|
61927304|NCT03395054|OTHER|the stabilization group|the stabilization group performed cervical stabilization exercises in lying, sitting, standing and on a swisball 3times a week during 8 weeks.
62690235|NCT06375499|ACTIVE_COMPARATOR|Hylo-Forte®|"Hyaluronic acid~Route of administration: topical, ocular use"
61927305|NCT03395054|OTHER|the control group|the control group performed conventional exercises including neck isometric, isotonic and posture exercises 3 times a week during 8 weeks.
61927306|NCT01316328||BC patients after SSPBI|breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery
61927307|NCT05540639|EXPERIMENTAL|Intervention with modified Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, by a video, in a leaflet and at a website. The practice is described as spending 15 minutes every day from gestational week 28+0 to get to know the fetal movement pattern. The fetus must be awake when practicing Mindfetalness and the woman is suggested to lay on her left side when she observes fetal movements. In the leaflet the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek healthcare without unnecessary delay.
62321851|NCT04141345||Heart failure with chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (\<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
62690236|NCT06570499|OTHER|Patients with 4-8 osseointegrated implants|On the patient, we will successively take 6 impressions (2 conventional, 2 intraoral scanner, 2 photogrammetry) and then analyze these impressions to measure the repeatability of a technique. After each type of impression, a satisfaction questionnaire in VAS format will be given to the patient.
61927308|NCT05540639|NO_INTERVENTION|Routine care|Historical comparison of the maternal clinics before the intervention. No activities have been taken place.
61927309|NCT03923270|NO_INTERVENTION|Thoracic Radiotherapy plus Durvalumab|This Arm is a standard of care Arm. Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 13 doses
61927310|NCT03923270|EXPERIMENTAL|Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 4 doses and 75mg intravenously of Tremelimumab every 4 weeks for up to 4 doses
61927311|NCT03923270|EXPERIMENTAL|Thoracic Radiotherapy plus Durvalumab and Olaparib|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg orally of Olaparib twice a day
61927312|NCT03923270|EXPERIMENTAL|Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg Tremelimumab IV x 1 (single dose)
61927313|NCT05882643|EXPERIMENTAL|block group|"* Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3, post-tetanic count \> 1)~* Rocuronium (intravenous, 1.0 mg/kg)"
61927314|NCT05882643|ACTIVE_COMPARATOR|control group|"* Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)~* Rocuronium (intravenous, 0.3 mg/kg)"
61927315|NCT03245229|EXPERIMENTAL|Treatment A|In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h
61927316|NCT03245229|EXPERIMENTAL|Treatment B1|25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12
61927317|NCT03245229|EXPERIMENTAL|Treatment B2|"In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h.~Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17."
61927318|NCT06729073|EXPERIMENTAL|AMZ001|AMZ001 applied once daily for 7 consecutive days
61927319|NCT06729073|ACTIVE_COMPARATOR|Diclofenac diethylamine 1.16%|Reference product applied four-times daily for 7 consecutive days
61927320|NCT06394804|EXPERIMENTAL|Avutometinib, Defactinib, and Letrozole|Enrolled patients will be treated with avutometinib 3.2 mg PO, twice weekly (e.g. M/Th,Tu/F, or W/Sa) + defactinib 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle. Patients will also be treated with letrozole 2.5 mg PO daily, and pre/perimenopausal patients will also receive leuprolide acetate 3.75 mg subcutaneously every 4 weeks or 11.25 mg every 3 months for ovarian suppression while an ovary remains in situ.
61927321|NCT01564771||Group one|Adults ≥18 years of age with chest X-ray confirmed CAP
61927322|NCT04652232|ACTIVE_COMPARATOR|Treated group|This group will receive the RV3466F lotion and a neutral shampoo
61927323|NCT04652232|OTHER|Control group|This group will receive a neutral shampoo
61927324|NCT04437953|EXPERIMENTAL|Avatrombopag|Patients will receive an initial dose of Avatrombopag 60 mg on Day 1.Starting on Day 2, the dose will be Avatrombopag 20 mg daily.
61927325|NCT06706765|EXPERIMENTAL|Group Telehealth Behavioral Cough Suppression Therapy|
61927326|NCT03901534|NO_INTERVENTION|Community based Multi-Ethnic Study of Atherosclerosis (MESA)|"This cohort includes biospecimens collected from 1852 participants in the MESA sleep study \[Chen et al\]. Serum biomarkers were measured by immunoassay in the Laboratory for Clinical Biochemistry Research at the University of Vermont.~All participants in this cohort will be analyzed for only the Aim 1 outcome measures."
62321852|NCT04141345||Heart failure without chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (\<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. HF patients who did not have chronic lung disease were assigned as a non-CLD group.
62321853|NCT05077917|EXPERIMENTAL|Cromolyn|2mL of 1% cromolyn sodium solution delivered via nebulizer 4 times a day for 4 days followed by 4% cromolyn solution administered intranasally 4 times per day for 14 days
62481538|NCT00979147|EXPERIMENTAL|Modular Metal Tibial Baseplate|Patients who were randomized to receive the modular polished tibial baseplate/XLK TKA
62690237|NCT06418763|ACTIVE_COMPARATOR|Baobab spread mixed with fermented seaweed|Daily intake 2x 15g The product is available as a spread and will be consumed with bread
61927327|NCT03901534|NO_INTERVENTION|HeartBEAT and BestAir|"The cohort includes 62 men and 20 women with newly diagnosed moderate-to-severe OSA and without known severe lung disease, who had participated in either of two randomized trials of PAP therapy, the HeartBEAT \[Gottlieb et al\] and BestAIR \[Bakker et al\] studies. Participants were selected for this analysis based on mean PAP adherence of ≥4 hours daily over a follow-up period of 3 months in the HeartBEAT study and 6 months in the BestAIR study.~Morning serum samples drawn at baseline and at the end of the PAP treatment period were assayed using commercially available ELISA for each biomarker in the Laboratory for Clinical Biochemistry Research at the University of Vermont Larner College of Medicine.~All participants in this cohort will be analyzed for only the Aim 2 outcome measures."
61927328|NCT03901534|EXPERIMENTAL|CPAP treatment of OSA|"Participants with obstructive sleep apnea (OSA) will be treated with continuous positive airway pressure therapy (CPAP).~All participants in this cohort will be analyzed for only the Aim 3a outcome measures."
61927329|NCT03901534|EXPERIMENTAL|ILD screening for OSA|"Participants with interstitial lung disease (ILD) will be screened for OSA by polysomnography.~All participants in this cohort will be analyzed for only the Aim 3b outcome measures."
61927330|NCT01967758|EXPERIMENTAL|Cohort 1|Patients in Cohort 1 will receive ADU-623 at a dose of 3 x 10\^7cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
61927331|NCT01967758|EXPERIMENTAL|Cohort 2|Patients in Cohort 2 will receive ADU-623 at a dose of 3 x 10\^8cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
61927332|NCT01967758|EXPERIMENTAL|Cohort 3|Patients in Cohort 3 will receive ADU-623 at a dose of 3 x 10\^9cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
61927333|NCT06736405|ACTIVE_COMPARATOR|Pericapsular nerve group block|Pericapsular nerve group block will be applied to patients in addition to standard treatment to prevent postoperative pain.
61927334|NCT06736405|ACTIVE_COMPARATOR|No Pericapsular nerve group block|Pericapsular nerve group block will be applied to patients in addition to standard treatment to prevent postoperative pain.
61927335|NCT06729190|PLACEBO_COMPARATOR|Group A|"Physical therapy program The exercise session for one hour for each child , conducted 3times/ week for 3 successive months.~1. Flexibility exercises for shorted muscles and spastic muscles.~2. Strengthening training focusing on the trunk lower limb and upper limb muscles for weak muscles.~3. Postural control exercise in different positions and different surfaces~4. General endurance training~5. Exercises to facilitate hand function~6. Exercises included, grasping a cube, transferring cube, removing and placing pegs, releasing cube and placing cubes. Strengthening exercises of the intrinsic muscles of the hand"
61927336|NCT06729190|EXPERIMENTAL|Group B|The exercise session for one hour for each child same as group A, conducted 3times/ week for 3 successive months plus the combined biofeedback therapy and FES at anti spastic muscles (shoulders flexors, elbow and wrist extensors
61927337|NCT06352424|EXPERIMENTAL|A-B-C-D|"* A: Treatment Test 1 (T1): BI 1820237 + Placebo for BI 456906~* B: Treatment Test 2 (T2): BI 456906 + Placebo for BI 1820237~* C: Treatment Test 3 (T3): BI 1820237 + BI 456906~* D: Treatment Reference (R1, R2): Placebo for BI 1820237 + Placebo for BI 456906"
61927338|NCT06352424|EXPERIMENTAL|B-D-A-C|
61927339|NCT06352424|EXPERIMENTAL|C-A-D-B|
61927340|NCT06352424|EXPERIMENTAL|D-C-B-A|
61927341|NCT05753033|EXPERIMENTAL|SR750 tablet|Ascending single and multiple doses of SR750 orally
61927342|NCT05753033|PLACEBO_COMPARATOR|Placebo|Ascending single and multiple doses of placebo orally
61927343|NCT02312271||enterally fed adults|adult subjects with established enteral access receiving standard tube feeding formula
61927344|NCT06736366|ACTIVE_COMPARATOR|Coenzyme Q10 (ubiquinone)|Synonyms: Maltodextrin, capsule (HPMC - hydroxypropyl methyl cellulose), coenzyme Q10 (ubiquinone); Dosage: 2 capsules, total 100 mg Co-Q10
61927345|NCT06736366|EXPERIMENTAL|BMT® coenzyme Q10|Maltodextrin, BMT® coenzyme Q10 \[maltodextrin, coenzyme Q10 (ubiquinone), stabiliser (gum arabic), corn starch, olive oil, anti-caking agent (silicon dioxide), acidity regulators (acetic acid, citric acid)\], capsule (HPMC - hydroxypropyl methyl cellulose); Dosage: 2 capsules, total 100 mg Co-Q10
61927346|NCT05948956|EXPERIMENTAL|5-Session Ketone Ester Beverage & Exercise|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Qitone Pro-Ketone Powder™ and electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise.
62321854|NCT05077917|PLACEBO_COMPARATOR|Placebo|2-3mL of normal saline delivered via nebulizer 4 times a day for 4 days followed by intranasal administration of normal saline 4 times per day for 14 days
62321855|NCT04484519||Cognitively unimpaired|
62321856|NCT02528669|EXPERIMENTAL|RX Navigait|Individuals in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals. In addition, they will be given additional education about the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
62481539|NCT00979147|ACTIVE_COMPARATOR|All Polyethylene Tibial Baseplate|Patients who were randomized to receive the nonmodular APT/GVF TKA design.
62481540|NCT06328738|EXPERIMENTAL|Part 1: ELVN-002 + trastuzumab dose escalation|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
62690238|NCT06418763|PLACEBO_COMPARATOR|Baobab spread|Daily intake 2x 15g The product is available as a spread and will be consumed with bread
62690239|NCT05886244|EXPERIMENTAL|Eculizumab|Eculizumab will be administered by IV infusion.
62690240|NCT00908908|EXPERIMENTAL|1|
61927347|NCT05948956|PLACEBO_COMPARATOR|5-Session Electrolyte Beverage & Exercise|Participants will consume placebo electrolyte (EL) beverage, consisting of an electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise
61927348|NCT05948956|EXPERIMENTAL|12-Session Ketone Ester Beverage & Exercise|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Qitone Pro-Ketone Powder™ and electrolyte solution diluted in water, before each of 12 1-hour sessions of aerobic exercise.
61927349|NCT05948956|PLACEBO_COMPARATOR|12-Session Electrolyte Beverage & Exercise|Participants will consume placebo electrolyte (EL) beverage, consisting of an electrolyte solution diluted in water, before each of 12 1-hour sessions of aerobic exercise
61927350|NCT01716325|EXPERIMENTAL|Weight loss - ICT support|Weight loss - ICT support
61927351|NCT01716325|OTHER|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
61927352|NCT05899608|EXPERIMENTAL|Arm A - Ivonescimab and chemotherapy|Subject will receive ivonescimab and chemotherapy
61927353|NCT05899608|ACTIVE_COMPARATOR|Arm B - Pembrolizumab and chemotherapy|Subject will receive pembrolizumab and chemotherapy
61927354|NCT00504582|EXPERIMENTAL|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
61927355|NCT00504582|NO_INTERVENTION|No Fibrin Sealant|
61927356|NCT05225337|EXPERIMENTAL|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
61927357|NCT05225337|EXPERIMENTAL|Daily calorie restriction (CR)|25% energy restriction every day Diet counseling provided
61927358|NCT05225337|NO_INTERVENTION|Control|Ad libitum food intake, eating over more than 10 hours per day
61927359|NCT03793218|EXPERIMENTAL|Latera Device|The LATERA (Spirox Inc., Menlo Park, CA) device, an absorbable nasal implant comprised of a 70:30 blend of poly(L-lactide) and poly(D-lactide), is designed to provide support to the upper and lower lateral cartilages, thereby correcting nasal wall collapse. The implant was first used in the US and cleared by the FDA in 2016. It is designed as a ribbed cylindrical structure with a forked distal end. The implant is delivered endonasally, with a 16-gauge catheter, lateral to the upper and lower lateral cartilages and over the ascending process of the maxilla. The forked end rests on the ascending process of the maxilla and the flexible implant provides support the nasal sidewall soft tissue and cartilage. This non-toxic, biocompatible co-polymer has an extensive use in a variety of medical devices including suture materials and implants. In vivo studies demonstrate the copolymer to reliably decompose over an 18-24 month period.
61927360|NCT03793218|ACTIVE_COMPARATOR|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
61927361|NCT06388564|EXPERIMENTAL|Treatment Group A|Axatilimab will be administered at a protocol defined starting dose plus ruxolitinib at a protocol defined starting dose.
61927362|NCT06388564|EXPERIMENTAL|Treatment Group B|Ruxolitinib will be administered at a protocol defined starting dose.
61927363|NCT06388564|EXPERIMENTAL|Treatment Group C|Corticosteroids alone will be administered at a protocol defined starting dose.
61927364|NCT02696993|EXPERIMENTAL|Group A (nivolumab, SRS)|Patients receive nivolumab IV over 90 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
61927365|NCT02696993|EXPERIMENTAL|Group B (nivolumab, WBRT)|Patients then receive nivolumab as in Group A. Patients undergo WBRT once daily for 10 days.
61927366|NCT02696993|EXPERIMENTAL|Group C (nivolumab, ipilimumab, SRS)|Patients receive nivolumab as in Group A and ipilimumab IV over 90 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
61927367|NCT02696993|EXPERIMENTAL|Group D (nivolumab, ipilimumab, WBRT)|GROUP D: Patients receive nivolumab as in Group A and ipilimumab as in Group C. Patients undergo WBRT once daily for 10 days.
61927368|NCT00569829|EXPERIMENTAL|1|Cognitive behavioral therapy
61927369|NCT00569829|NO_INTERVENTION|2|Waitlist
61927370|NCT02908893|EXPERIMENTAL|Salient|"Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.~Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy."
61927371|NCT02908893|ACTIVE_COMPARATOR|NonSalient|"Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.~Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy"
61927372|NCT02908893|NO_INTERVENTION|Control|Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded.
61927373|NCT06701812|EXPERIMENTAL|Digoxin Treatment|Digoxin will be administered orally at a standard maintenance dosing. Each cycle will be 28 days.
61927374|NCT03718182|ACTIVE_COMPARATOR|Arm A - Cholecalciferol 400iu|Vitamin D3 (Cholecalciferol) 400 iu. Daily oral capsule. To be taken for 24 weeks (6 months)
61927375|NCT03718182|EXPERIMENTAL|Arm B - Cholecalciferol 3200iu/800iu|"Vitamin D3 (Cholecalciferol) supplement 3,200iu daily oral capsule. To be taken for 12 weeks (3 months).~Then switch to vitamin D3 supplement 800iu daily oral capsule. To be taken for 12 weeks (3 months)."
62321857|NCT02528669|NO_INTERVENTION|Control Group|Participants in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals but will not receive additional education regarding the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
61927376|NCT05670353|EXPERIMENTAL|Cannabis Derivatives|"Cannabis Derivatives (98% CBD, 2% THC) will be given orally starting at 10 mg daily and up-titrated to a maximum dose of 150 mg daily. Dose up-titration will be based on clinical response or side effects, whichever comes first. After 63 days of treatment, gradual withdrawal will be performed during one week.~All patients will take hormonal contraceptives, preferably progestagen-only.~All participants will perform invasive and non-invasive procedures with the nursing team. The invasive will be blood collections, to evaluate laboratory parameters. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as will pain threshold. In addition, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database, by the study coordination team."
61927377|NCT05670353|PLACEBO_COMPARATOR|Placebo|"Placebo will be given at the same protocol described before. The bottle, label, color and density of the contents will be the same.~All patients will take hormonal contraceptives, preferably progestagen-only. Then, at 70 days, there will be an open-label extension wherein all participants from control group will be offered a course of active treatment according to the same previous protocol.~All participants will perform invasive and non-invasive procedures with the nursing team. The invasive will be blood collections, to evaluate laboratory parameters. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as will pain threshold. In addition, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database, by the study coordination team."
61927378|NCT04884815|EXPERIMENTAL|Stage 1: UX701 Dose Level 1|Participants receive a single, peripheral intravenous (IV) infusion of UX701 at dose level 1.
61927379|NCT04884815|EXPERIMENTAL|Stage 1: UX701 Dose Level 2|Participants receive a single, peripheral IV infusion of UX701 at dose level 2.
61927380|NCT04884815|EXPERIMENTAL|Stage 1: UX701 Dose Level 3|Participants receive a single, peripheral IV infusion of UX701 at dose level 3.
61927381|NCT04884815|EXPERIMENTAL|Stage 2: UX701 or Placebo|Participants randomized 2:1 to receive UX701 or Placebo. Participants randomized to UX701 receive a single, peripheral IV infusion of UX701 at a dose selected in Stage 1. Participants randomized to placebo will receive a single, peripheral IV infusion of normal saline (placebo).
61927382|NCT04884815|EXPERIMENTAL|Stage 3: Placebo or UX701|Participants randomized in Stage 2 to UX701 will receive a single, peripheral IV infusion of normal saline (placebo). Participants randomized in Stage 2 to placebo will be eligible for a single, peripheral IV infusion of UX701 at the selected dose.
61927383|NCT02839278|EXPERIMENTAL|Immune-mediated inflammatory disease|Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
61927384|NCT02514317|EXPERIMENTAL|percutaneous treatment|percutaneous treatment of carpal tunnel syndrome under ultrasound guidance in interventional radiology room.
61927385|NCT04948567|EXPERIMENTAL|split-dose of Magnesium Sulfate solution|Those assigned to MSS group were instructed to take 30ml of 50% magnesium sulfate solution and then drink 600ml water on the evening before colonoscopy. 70ml of 50% MMS and then 1500ml water was taken at least 4 hours before procedure on the colonoscopy day.
61927386|NCT04948567|PLACEBO_COMPARATOR|split-dose of PEG|Patients in PEG group were instructed to take first dose of 1.5L PEG on the evening before colonoscopy and take the second dose of 1.5L PEG at least 4 hours before the colonoscopy procedure on the morning.
61927387|NCT01500512||Observation (observe patients undergoing SLN dissection)|Patients receive standard therapy including sentinel lymph node dissection. Patients are then observed to collect information about treatment and outcomes every 2 months for 2 years.
61927388|NCT05837117||Patient's Perspective|Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic. Participants may choose to complete the questionnaire electronically (via email link), in-person, or over the phone, whichever you prefer. Your demographic information (such as age, gender, ethnicity, marital status, and cancer diagnosis) will be collected from your medical record. Some of this information may also be asked of you during the questionnaire.
61927389|NCT00688142||1|Individuals with shift work sleep disorder
62321858|NCT05165810|ACTIVE_COMPARATOR|Arm 1: standard ART initiation + government-based HIV care + routine adherence support|Participants randomized to Arm 1 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\].
62690241|NCT04228731|EXPERIMENTAL|Outpatient|Patients in the outpatient group (same day discharge following TKA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
62690242|NCT04228731|ACTIVE_COMPARATOR|Inpatient|Patients in the inpatient group (following day discharge following TKA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
62321859|NCT05165810|EXPERIMENTAL|Arm 2: same-day ART + government-based HIV care + routine adherence support|Participants randomized to Arm 2 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\].
62321860|NCT05165810|EXPERIMENTAL|Arm 3: standard ART initiation + community-based HIV care + routine adherence support|Participants randomized to Arm 3 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\].
62690243|NCT01414790|EXPERIMENTAL|ADM group|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
62690244|NCT01414790|NO_INTERVENTION|control group|41 patients (control group) had a total parotidectomy alone
62690245|NCT02562703|ACTIVE_COMPARATOR|ACTIVE tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
62690246|NCT02562703|SHAM_COMPARATOR|SHAM tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be turned off after 60 seconds following previous trials.
62130714|NCT04512482|PLACEBO_COMPARATOR|Experimental: Placebo, Then Bromelain|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of powdered sugar that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the bromelain rinse, following the same protocol and series of intraoral photographs.
62130715|NCT03476811|NO_INTERVENTION|Control Group|Normal treatment paradigm (no anesthetic pump) with pain medications, only.
62321861|NCT05165810|EXPERIMENTAL|Arm 4: standard ART initiation + government-based HIV care + enhanced adherence support|Participants randomized to Arm 4 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\].
62321862|NCT05165810|EXPERIMENTAL|Arm 5: same-day ART initiation + community-based-based HIV care + routine adherence support|Participants randomized to Arm 5 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive routine adherence support should they experience treatment failure at 6 months \[usual care\].
61927390|NCT00688142||2|Healthy night shift workers without shift work sleep disorder
62481541|NCT06328738|EXPERIMENTAL|Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on days 1 - 14 of a 21-day cycle. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1 of a 21-day cycle.
62690247|NCT04667962||Hospital service change|This group is composed of caregivers who changed hospital service during COVID-19 health crisis.
62690248|NCT04667962||No hospital service change|This group is composed of caregivers who have not changed hospital service during COVID-19 health crisis.
61927391|NCT05871892|OTHER|18F-FDGal PET/CT or PET/MRI|Diagnostic scan.
61927392|NCT01780532|EXPERIMENTAL|Photo Acoustic Imaging|An exploratory, single armed, pilot study designed to evaluate the feasibility of Photo Acoustic Imaging (PAI) in a clinical setting.
61927393|NCT05650190|EXPERIMENTAL|Test Arm|Single vision, impact resistant spectacle lenses; Test Arm
61927394|NCT05650190|PLACEBO_COMPARATOR|Control Arm|Single vision, impact resistant spectacle lenses; Control Arm
61927395|NCT00684580||Observational Group|Data Collection
61927396|NCT06200116||Observational|Participants create and review output auto-segmentations of CT images using the AI algorithm and complete a survey about the performance/functionality of the auto segmentation algorithm on study.
62130716|NCT03476811|ACTIVE_COMPARATOR|Marciano Group|Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
62130717|NCT03476811|PLACEBO_COMPARATOR|Placebo Group|OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
62130718|NCT03112135|ACTIVE_COMPARATOR|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
62130719|NCT03112135|ACTIVE_COMPARATOR|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
62130720|NCT03112135|ACTIVE_COMPARATOR|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
62130721|NCT04739137||Study group|100 patients with diagnosed macular edema will be enrolled
62130722|NCT06374004|ACTIVE_COMPARATOR|Exercise Group|The exercise group will perform stretching and strengthening exercises involving the muscle groups around the shoulder and scapula for 12 weeks.
62321863|NCT05165810|EXPERIMENTAL|Arm 6: same-day ART initiation + government-based-based HIV care + enhanced adherence support|Participants randomized to Arm 6 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a government HIV clinic \[usual care\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\].
62690249|NCT06004583||Acne group|Acne Vulgaris Diagnosed Patients
62690250|NCT06004583||Control group|Healthy participants
62690251|NCT02370342|EXPERIMENTAL|Treatment (robot-assisted laparoscopic HIFU)|Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
62690252|NCT03070834|EXPERIMENTAL|rIVCF|Randomized to receive insertion of retrievable inferior vena cava filter until chemical anticoagulation can be safely administered.
62690253|NCT03070834|NO_INTERVENTION|Standard Care|Randomized to not receive insertion of retrievable inferior vena cava filter.
61927397|NCT06125054|EXPERIMENTAL|rt-fMRI NFT / Placebo|Participants get real time neurofeedback based on an experimental regions' activity and receive a 0.9% saline solution (i.v.) over 40 minutes.
61927398|NCT06125054|EXPERIMENTAL|rt-fMRI NFT / Ketamine|Participants get real time neurofeedback based on an experimental regions' activity and receive 0.71mg ketamine (i.v.) per kilogram bodyweight.
61927399|NCT06125054|PLACEBO_COMPARATOR|sham NFT / Placebo|Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive a 0.9% saline solution (i.v.) over 40 minutes.
61927400|NCT06125054|EXPERIMENTAL|sham NFT / Ketamine|Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.71mg ketamine (i.v.) per kilogram bodyweight.
61927401|NCT06571383|EXPERIMENTAL|Semaglutide|2.4mg or maximum tolerated dose(MTD) injected subcutaneously (under the skin, s.c) once weekly
62690254|NCT00456365|EXPERIMENTAL|Pravastatin|Pravastatin
61927402|NCT05633615|EXPERIMENTAL|Step I (lymphodepleting chemotherapy)|Patients receive lymphodepleting chemotherapy consisting of fludarabine IV and cyclophosphamide IV on study. Patients then receive tisagenlecleucel IV, axicabtagene ciloleucel IV, or lisocabtagene maraleucel IV on study.
61927403|NCT05633615|EXPERIMENTAL|Step II Arm I (mosunetuzumab)|Patients receive mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
62690255|NCT00456365|PLACEBO_COMPARATOR|Placebo|Placebo
61927404|NCT05633615|EXPERIMENTAL|Step II Arm II (polatuzumab vedotin)|Patients receive polatuzumab vedotin IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
61927405|NCT05633615|EXPERIMENTAL|Step II Arm III (polatuzumab vedotin, mosunetuzumab)|Patients receive polatuzumab vedotin IV and mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
62321864|NCT05165810|EXPERIMENTAL|Arm 7: standard ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 7 will i) initiate ART on a standard timeline \[usual care\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\].
62321865|NCT05165810|EXPERIMENTAL|Arm 8: same-day ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 8 will i) initiate ART on the day of enrollment \[experimental\], ii) receive ongoing care in a PWID-focused community-based site \[experimental\], and iii) receive enhanced adherence support should they experience treatment failure at 6 months \[experimental\].
62321866|NCT00637273|EXPERIMENTAL|1|
62321867|NCT00637273|ACTIVE_COMPARATOR|2|
62321868|NCT00637273|ACTIVE_COMPARATOR|3|
62321869|NCT04002440|ACTIVE_COMPARATOR|AMIA with SHARESOURCE|For this arm, dialysis nurses will review those patients using the AMIA with SHARESOURCE connectivity platform twice a week and will contact patients who meet certain triggers. They will then offer patients interventions, ie. a change in the preset AMIA ultrafiltration program, in order to achieve prescribed dry weight.
62321870|NCT04002440|PLACEBO_COMPARATOR|HomeChoice PRO|For this arm, routine standard of care for peritoneal dialysis patients will continue using the HomeChoice PRO device. Data regarding treatments will be captured on a chip to be analyzed at the end of 6 months to evaluate compliance with treatments.
62321871|NCT01150877|EXPERIMENTAL|Experimental Dietary Supplement (e.g., vitamins, minerals)|Experimental arm is supplemented with high-dose of vitamin D.
62321872|NCT01150877|NO_INTERVENTION|No Intervention|
62321873|NCT00835094|EXPERIMENTAL|Morning|
62321874|NCT00835094|EXPERIMENTAL|Evening|
62321875|NCT00728507|EXPERIMENTAL|1|Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
62321876|NCT00728507|ACTIVE_COMPARATOR|2|Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
62321877|NCT06077487|EXPERIMENTAL|Group A (K-MaP)|Participants will receive 0.5mg/kg of Ketamine orally with an equivalent quantity of placebo via an intramuscular injection on Day 0/Visit 4 and receive Meaning and Purpose (MaP) therapy 4 times, twice before (between days -13 and -1) ketamine administration, and twice afterward on days 3 (+/- 2 days) and 11 (+/- 3 days). The duration of treatment for ketamine plus MaP (K-MaP) therapy is approximately up to 28 days. Participants will be followed up to 35 days (+/-2 days) after ketamine administration.
62321878|NCT06077487|EXPERIMENTAL|Group B (K-Map)|Participants will receive 0.5mg/kg of Ketamine IM with a placebo oral solution on Day 0/Visit 4 and receive Meaning and Purpose (MaP) therapy 4 times, twice before (between days -13 and -1) ketamine administration, and twice afterward on days 3 (+/- 2 days) and 11 (+/- 3 days). The duration of treatment for ketamine plus MaP (K-MaP) therapy is approximately up to 28 days. Participants will be followed up to 35 days (+/-2 days) after ketamine administration.
62321879|NCT03755531|EXPERIMENTAL|Carbetocin|One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection after labor of the baby at once.
62321880|NCT03755531|ACTIVE_COMPARATOR|Oxytocin|One ml of Oxytocin (10 IU), was given as a bolus intravenous injection after labor of the baby at once.
62321881|NCT02391623|EXPERIMENTAL|Cohort 1|Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62321882|NCT02391623|EXPERIMENTAL|Cohort 2|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62321883|NCT02391623|EXPERIMENTAL|Cohort 3|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62321884|NCT02391623|EXPERIMENTAL|Cohort 4|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62321885|NCT02391623|EXPERIMENTAL|Cohort 5|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62321886|NCT02391623|EXPERIMENTAL|Cohort 6|Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
62321887|NCT05121077|EXPERIMENTAL|Moderate continuous training|Participants will continuously exercise at a workload between 50-60% of VO2peak on a bicycle ergometer.
62690256|NCT06569888|EXPERIMENTAL|LIPUS stimulation|LIPUS stimulation supplying the pre-clinically optimized energy dosage and conditions
62690257|NCT06691646|EXPERIMENTAL|Two training sessions per week|Train with RECOGNeyes gaze training game at home twice a week, for between 20 to 30 minutes per training session, for two weeks.
62690258|NCT06691646|EXPERIMENTAL|Three training sessions per week|Train with RECOGNeyes gaze training game at home three times per week, for between 20 to 30 minutes per training session, for two weeks.
62690259|NCT06691646|EXPERIMENTAL|Four training sessions per week|Train with RECOGNeyes gaze training game at home four times per week, for between 20 to 30 minutes per training session, for two weeks.
62690260|NCT03983239|EXPERIMENTAL|Fedratinib plus Rifampin|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of rifampin. On Day 17, a single dose of fedratinib will be concomitantly administered with rifampin.
62321888|NCT05121077|EXPERIMENTAL|Interval training|Participants will exercise at a varying workload between 50-60% of VO2peak during recovery and 80-90% of VO2peak during bouts of interval training on a bicycle ergometer.
62321889|NCT01881620|EXPERIMENTAL|COMBI TEP : PET / enhanced CT scan|COMBI TEP : PET / enhanced CT scan
62321890|NCT04705025|EXPERIMENTAL|Supportive care (BNT001 app, CBSM, interview)|Prior to participating in the study patients complete an online baseline questionnaire to assess anxiety and depression and general quality of life, as well as some specific questions related to their coping. They are also interviewed by a clinician who rates their level of anxiety and depression. After this, patients use the BNT001 app and undergo 10 sessions of CBSM over 45-60 minutes each consisting of cancer-specific educational videos, guided relaxation training, interactive exercises, and discussion modules. Following completion of the 5th session, patients undergo a telephone check-in assessment to see how things are going, update their treatments and medications, and schedule a phone call to assess for adverse events. At the end of the 10th session, patients complete a post-treatment online questionnaire and a phone debriefing interview to discuss their experience with the intervention.
62130723|NCT06374004|ACTIVE_COMPARATOR|Thoracic Mobilization Group|The exercise group will perform stretching and strengthening exercises involving the muscle groups around the shoulder and scapula for 12 weeks. In addition to the exercises, thoracic mobilization will be applied to the participants in this group 1 day a week for a total of 6 weeks.
62321891|NCT03511261|ACTIVE_COMPARATOR|10%Curcumin mucoadhesive gel|"Drug: Curcumin arm Curcumin10% mucoadhesive gel~Group 1 patients:~Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months"
62321892|NCT03511261|ACTIVE_COMPARATOR|Curcumin capsules 500mg|"Group 2 patients:~Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months"
62321893|NCT03511261|ACTIVE_COMPARATOR|5% Curcumin gel+Curcumin capsules 250mg|"Group 3 patients:~Drug: 5% Curcumin mucoadhesive gel \& Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months"
62690261|NCT03983239|EXPERIMENTAL|Fedratinib plus Efavirenz|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of efavirenz. On Day 17, a single dose of fedratinib will be concomitantly administered with efavirenz.
62690262|NCT04674319|EXPERIMENTAL|Brain engagement while using compesatory modes for walking|Brain engagemnent (recruitment of attention) is measured during four walking conditions
62130724|NCT05660941|EXPERIMENTAL|Ultrarapid-acting Lispro|ultrarapid-acting lispro delivered by hybrid closed loop system.
62130725|NCT05660941|ACTIVE_COMPARATOR|Insulin Lispro|Insulin lispro delivered by hybrid closed loop system.
62321894|NCT03511261|PLACEBO_COMPARATOR|Placebo capsules|Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months
62321895|NCT03765346|EXPERIMENTAL|Oxycodone IR ADF and placebo to match oxycodone API|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of manipulated oxycodone IR ADF (mass of 540 mg, containing oxycodone hydrochloride 30 mg).
62321896|NCT03765346|ACTIVE_COMPARATOR|Oxycodone API and placebo to match oxycodone IR ADF|Participants receive a single intranasal dose of oxycodone API powder (mass of 30 mg, containing oxycodone hydrochloride 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
62321897|NCT03765346|PLACEBO_COMPARATOR|Placebo to match oxycodone API and to match oxycodone IR ADF|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
62321898|NCT02134314|EXPERIMENTAL|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
62321899|NCT02134314|PLACEBO_COMPARATOR|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
62321900|NCT05612035|EXPERIMENTAL|MK-5475|Participants with PH-COPD will receive 380 µg of MK-5475 as an oral inhalation once daily for 24 weeks (base period) and thereafter for up to 42 months (optional extension period).
62321901|NCT05612035|PLACEBO_COMPARATOR|Placebo|Participants with PH-COPD will receive matching placebo as an oral inhalation once daily for 24 weeks (base period) and then 380 µg of MK-5475 as an oral inhalation once daily for up to 42 months (optional extension period).
62321902|NCT01428011||No treatment|African American/Black and Caucasian/White patients with hypertension
62321903|NCT05238896|EXPERIMENTAL|Baricitinib|Patients receiving baricitinib 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
62321904|NCT05238896|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
62321905|NCT04992832|EXPERIMENTAL|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.0\*10\^6/kg human umbilical cord mesenchymal stem cells at 0,6,12 week.
62321906|NCT04992832|PLACEBO_COMPARATOR|control group|The control group will be given the same dose of saline containing human albumin.
62690263|NCT00326014|EXPERIMENTAL|A|
62130726|NCT00798642|ACTIVE_COMPARATOR|Hypnotherapy|
62690264|NCT03702595|EXPERIMENTAL|Interventional group|Hip flexors stretching protocol
62690265|NCT06596759|EXPERIMENTAL|Diaphragmatic Breathing|Patients will complete the Mayo Bloating Questionnaire (MBQ) before referral to a physical therapist for in diaphragmatic breathing (DB) techniques over a 30-minute session. The patient will be instructed to complete 5-10 minutes of diaphragmatic breathing twice a day for a period of 4 weeks. At the end of the 4-week follow up period, patients will repeat the MBQ and self-report their adherence to daily diaphragmatic breathing.
62690266|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
62690267|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
62130727|NCT00798642|PLACEBO_COMPARATOR|Standard care|
62130728|NCT00798642|PLACEBO_COMPARATOR|Mind Body Therapy|
62690268|NCT04361487||Horizontal Cleavage Meniscal Tear|Participants with horizontal cleavage meniscal tears
61927406|NCT05633615|ACTIVE_COMPARATOR|Step II Arm IV (observation)|Patients undergo observation on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study. Patients with subsequent progression within 12 months of CAR T-cell therapy may crossover to Arm III.
61927407|NCT04547413|NO_INTERVENTION|Control Arm|"Control Arm will will complete a total of three visits:~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment~Monthly: Prevention Maintenance Intervention Messages from months 2-11~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
61927408|NCT04547413|ACTIVE_COMPARATOR|Intervention Arm|"Intervention Arm will will complete a total of four visits:~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment~Visit 2 (Day 2-30): Group Intervention Session, Feedback form, and post-intervention knowledge assessment (for intervention arm only)~Monthly: Prevention Maintenance Intervention Messages from months 2-11~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
61927409|NCT04559334|OTHER|open label|All participants will receive Tetrasodium EDTA Catheter Lock Solution (KiteLock™ 4% Sterile Catheter Lock Solution)
61927410|NCT06618287|EXPERIMENTAL|Group A|
62130729|NCT03284567|ACTIVE_COMPARATOR|Football fitness|"Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury."
62130730|NCT03284567|NO_INTERVENTION|Control group|Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
62321907|NCT04624893||Pola BR/R|Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.
62690269|NCT04361487||Complex Meniscal Tear|Participants with complex meniscal tears
61927411|NCT06618287|EXPERIMENTAL|Group B|
61927412|NCT04457154||Registry Population|Pediatric subjects (age 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation System for the treatment of moderate to severe obstructive sleep apnea (OSA)
61927413|NCT04073225|EXPERIMENTAL|MindPod Dolphin Arm|Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke.
61927414|NCT04073225|ACTIVE_COMPARATOR|Hand Bike Arm|Pedal Exerciser, a single-component upper-arm aerobic play. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
61927415|NCT05247255|ACTIVE_COMPARATOR|Intervention Group|Quadratus lumborum nerve block with 0.25% ropivacaine
61927416|NCT05247255|PLACEBO_COMPARATOR|Control Group|Quadratus lumborum nerve block with saline
61927417|NCT06744712|EXPERIMENTAL|Pharmacogenomic (PGx) Testing|
62130731|NCT05866978|OTHER|An integrated workplace intervention|Intervention: A group of employees at each workplace will develop and implement their own project activities at meetings four times during the intervention. Activities are implemented at workplaces for all employees. Employees will participate in one screening questionnaire prior to the intervention followed by five health checks and interview based questionnaires.
62130732|NCT05866978|NO_INTERVENTION|Reference|Reference: No intervention activities.
62130733|NCT02530216|NO_INTERVENTION|Usual care|Individuals in this arm will undergo usual care with their physician.
62130734|NCT02530216|EXPERIMENTAL|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
62130735|NCT05384366|OTHER|Neoadjuvant chemotherapy|Patients receiving neoadjuvant paclitaxel 175mg/m2 and carboplatin (AUC5) at three weekly interval by intravenous route
62130736|NCT06523205||non-smoking - periodontally healthy|participants who reported never smoking and periodontal healthy.
62130737|NCT06523205||smoking - periodontally healthy|participants who reported smoking \>10 cigarettes per day and periodontal healthy.
62130738|NCT06523205||non-smoking - periodontitis|participants who reported never smoking, with clinical attachment loss ≥3 mm in \>30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included.
62321908|NCT01421290|ACTIVE_COMPARATOR|Conservative treatment|
62321909|NCT01421290|ACTIVE_COMPARATOR|Surgery|
62690270|NCT04103931|NO_INTERVENTION|Usual Care|Participants will receive usual care and will not get the decision aid to review.
62321910|NCT06692426|EXPERIMENTAL|Arm A: MyoPAXon 25 x 10^6|MyoPAXon will be delivered via open intramuscular (IM) injection into a single EDB muscle for each participant as a one-time dose. The participants will be started on tacrolimus 1 week prior to dosing and stay on the maintenance dose on a BID schedule for 3 months after injection
62690271|NCT04103931|EXPERIMENTAL|Patient Decision Aid|"Participants in this arm will receive the patient decision aid, titled Treatment Choices for Aortic Stenosis to review."
62690272|NCT03582397|EXPERIMENTAL|Experimental|Subjects to receive virtual reality mirror therapy via WiseMind Software (Realiteer) 3x/week for 4 weeks.
62690273|NCT03116178|ACTIVE_COMPARATOR|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
62690274|NCT03116178|ACTIVE_COMPARATOR|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
62690275|NCT06644937|EXPERIMENTAL|TACE combination with Acoradine|
62321911|NCT06692426|EXPERIMENTAL|Arm B: MyoPAXon 50 x 10^6|MyoPAXon will be delivered via open intramuscular (IM) injection into a single EDB muscle for each participant as a one-time dose. The participants will be started on tacrolimus 1 week prior to dosing and stay on the maintenance dose on a BID schedule for 3 months after injection
62481542|NCT06328738|EXPERIMENTAL|Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously at 6 mg/kg IV cycle 1, day 2 followed by 4 mg/kg IV cycle 1, day 15, and then one dose at 4mg/kg IV every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on day 1 and 15 of a 28-day cycle.
62481543|NCT06328738|EXPERIMENTAL|Part 2C: ELVN-002 + trastuzumab + capecitabine dose escalation in breast cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on days 1 - 14 of a 21-day cycle.
62481544|NCT06328738|EXPERIMENTAL|Part 2D: ELVN-002 + trastuzumab + paclitaxel dose escalation in solid tumors|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Paclitaxel will be administered intravenously at 80 mg/m2 on days 1, 8, and 15 of a 21-day cycle.
62481545|NCT06328738|EXPERIMENTAL|Part 2E: ELVN-002 + trastuzumab + eribulin dose escalation in breast cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Eribulin will be administered intravenously at 1.4 mg/m2 on days 1 and 8 of a 21-day cycle.
62481546|NCT06328738|EXPERIMENTAL|Part 3A: ELVN-002 + trastuzumab dose expansion in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+
62481547|NCT06328738|EXPERIMENTAL|Part 3B: ELVN-002 + trastuzumab dose expansion in breast cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
61927418|NCT06744439|EXPERIMENTAL|BR1015|
61927419|NCT06744439|ACTIVE_COMPARATOR|BR1015-2 + BR1015-3|
61927420|NCT06744790||Post surgical (non-cardiac) PACU patients with anticipated overnight stay.|"In this study investigators will recruit patients that meet the following criteria:~Inclusion Criteria:~≥18 years old undergoing non-cardiac surgery Post-operative patients admitted to the PACU and expected to stay in the hospital for at least overnight Receiving supplemental oxygen via face mask in the PACU On continuous SpO2 saturation monitoring Receiving standard postoperative of care~Exclusion Criteria:~Requirement for any form of postoperative invasive ventilatory support Patients receiving only local or topical anesthesia Day/outpatient surgery Unable to cooperate with the application of the study device Surgical/nursing/anesthesia staff suggest no study-related monitoring because of medical situation"
61927421|NCT06744218|ACTIVE_COMPARATOR|Standard|
61927422|NCT06744218|EXPERIMENTAL|experimental|
61927423|NCT06745505|EXPERIMENTAL|Recieved Bowel Preparation|
61927424|NCT06745505|ACTIVE_COMPARATOR|Did not receive Bowel Preparation|
61927425|NCT04779229|EXPERIMENTAL|Parent Activation|This group of JPOs will deliver Parent Activation as a service to the juveniles and families on their caseloads.
61927426|NCT04779229|ACTIVE_COMPARATOR|Usual Services|This group of JPOs will deliver services as usual to the juveniles and families on their caseloads.
61927427|NCT04644068|EXPERIMENTAL|Module 1: AZD5305 Monotherapy|AZD5305 Monotherapy
61927428|NCT04644068|EXPERIMENTAL|Module 2: AZD5305 + Paclitaxel|AZD5305 + Paclitaxel
61927429|NCT04644068|EXPERIMENTAL|Module 3: AZD5305 + Carboplatin with or without Paclitaxel|AZD5305 + Carboplatin with or without Paclitaxel
61927430|NCT04644068|EXPERIMENTAL|Module 4: AZD5305 + Trastuzumab Deruxtecan|AZD5305 + T- DXd
61927431|NCT04644068|EXPERIMENTAL|Module 5 AZD5305 + Datopotamab Deruxtecan|AZD5305 + Dato-DXd
61927432|NCT04644068|EXPERIMENTAL|Module 6 AZD5305 + Camizestrant|AZD5305 + Camizestrant
61927433|NCT05409183|EXPERIMENTAL|CRD-740|Part A: Participants in Part A randomly assigned to this arm will take CRD-740 at two ascending dose levels over 12 weeks.
61927434|NCT05409183|PLACEBO_COMPARATOR|Placebo|Part A: Participants in Part A randomly assigned to this arm will take placebo at two ascending dose levels over 12 weeks.
61927435|NCT06106022|EXPERIMENTAL|Vonoprazan 10mg|Participants will receive vonoprazan 10mg QD for 14 days.
61927436|NCT06106022|EXPERIMENTAL|Vonoprazan 20mg|Participants will receive vonoprazan 20mg QD for 14 days.
61927437|NCT03502785|EXPERIMENTAL|Cohort A|Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 therapy. Cohort A participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
61927438|NCT03502785|EXPERIMENTAL|Cohort B|Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy. Cohort B participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
61927439|NCT06744920|EXPERIMENTAL|Remibrutinib arm|"Core Part: Remibrutinib tablet taken orally~\[Extension Part: Open-label remibrutinib tablet taken orally\]"
61927440|NCT06744920|PLACEBO_COMPARATOR|Placebo arm|"Core Part: Placebo tablet taken orally~\[Extension Part: Open-label remibrutinib tablet taken orally\]"
62321912|NCT06692426|EXPERIMENTAL|Arm C: MyoPAXon 100 x 10^6|MyoPAXon will be delivered via open intramuscular (IM) injection into a single EDB muscle for each participant as a one-time dose. The participants will be started on tacrolimus 1 week prior to dosing and stay on the maintenance dose on a BID schedule for 3 months after injection
62321913|NCT06692426|EXPERIMENTAL|Arm D: MyoPAXon 200 x 10^6|MyoPAXon will be delivered via open intramuscular (IM) injection into a single EDB muscle for each participant as a one-time dose. The participants will be started on tacrolimus 1 week prior to dosing and stay on the maintenance dose on a BID schedule for 3 months after injection
62690276|NCT05790031|EXPERIMENTAL|Intelligent Nighttime Brace|The design of intelligent nighttime brace will incorporate different mechanism, such as a) compression and pulling forces through a customisable rigid brace, b) lumbar flexion by using a supporting air-belt, c) three-point pressure system is used to exert corrective forces by the intelligent paddings in the transverse direction, d) adjust the pressure of the brace padding through a pressure monitoring system in accordance with the sleeping posture of the users
62690277|NCT05594875|EXPERIMENTAL|SHR-1921|
62690278|NCT04195256|EXPERIMENTAL|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
62690279|NCT04195256|EXPERIMENTAL|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
62690280|NCT04195256|EXPERIMENTAL|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
61927441|NCT06242691|EXPERIMENTAL|Part 1: MK-1200|In Part 1, participants will receive escalating doses of MK-1200 via intravenous (IV) infusion every 2 weeks (Q2W) until any discontinuation criteria are met.
61927442|NCT06242691|EXPERIMENTAL|Part 2: MK-1200 Cohort A|In Part 2, participants in Cohort A will receive either Dose 1 or Dose 2 of MK-1200 via IV infusion Q2W until any discontinuation criteria are met.
61927443|NCT06242691|EXPERIMENTAL|Part 2: MK-1200 Cohort B|In Part 2, participants in Cohort B will receive Dose 1 of MK-1200 via IV infusion Q2W until any discontinuation criteria are met.
61927444|NCT05005442|EXPERIMENTAL|Pembrolizumab/vibostolimab coformulation|Participants will receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.
62130739|NCT06523205||smoking - periodontitis|participants who reported smoking \>10 cigarettes per day for \>5 years with clinical attachment loss ≥3 mm in \>30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included.
62690281|NCT04195256|ACTIVE_COMPARATOR|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
62690282|NCT04963296|EXPERIMENTAL|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.
62321914|NCT03743584|EXPERIMENTAL|Targeted temperature management at 33°C|Cooling and temperature control at 33°C, according to the study protocol of the TTM2-trial
62321915|NCT03743584|ACTIVE_COMPARATOR|Standard care, early treatment of fever|Standard of care and normothermia. If temperature 37,8 °C or above use of device for temperature control.
62321916|NCT05975775||ambulatory patient cohort|Patients with prostate cancer for whom an ambulatory laparoscopic radical prostatectomy has been validated at a multidisciplinary consultation meeting.
62321917|NCT00401622|EXPERIMENTAL|OneTouch® Ultra®2 system|Test care group assigned to OneTouch® Ultra®2 system
62321918|NCT00401622|ACTIVE_COMPARATOR|Standard care|Control group receiving standard care with a traditional blood glucose monitoring system
62321919|NCT03616080|EXPERIMENTAL|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
62321920|NCT03616080|NO_INTERVENTION|control|children without soccer paly program usual activity and therapy
62321921|NCT02676310|EXPERIMENTAL|Cohort 1: Bimatoprost 0.3% (Formulation B)|0.25 mL of bimatoprost 0.3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
62321922|NCT02676310|EXPERIMENTAL|Cohort 2: Bimatoprost 1% (Formulation A)|0.25 mL of bimatoprost 1% (Formulation A) applied onto pre-specified area on the scalp once daily for 28 days.
62321923|NCT02676310|EXPERIMENTAL|Cohort 2: Bimatoprost 1% (Formulation B)|0.25 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
62321924|NCT02676310|EXPERIMENTAL|Cohort 3: Bimatoprost 1% (Formulation B)|1 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
62321925|NCT02676310|EXPERIMENTAL|Cohort 4: Bimatoprost 3% (Formulation B)|1 mL of bimatoprost 3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
62481548|NCT06328738|EXPERIMENTAL|Part 3C: ELVN-002 + trastuzumab dose expansion in other solid tumor type 1|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
62130740|NCT04797923|EXPERIMENTAL|Intraperitoneal paclitaxel with systemic chemotherapy|
62130741|NCT03091244||The individuals taking XLGB Capsule|The overall individuals taking XLGB Capsule with recommended dosage and achieving the inclusion criteria.
62321926|NCT00012727|OTHER|Arm 1|
62321927|NCT03458000|ACTIVE_COMPARATOR|Active Control|Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
61927445|NCT06325683|EXPERIMENTAL|Arm I (nivolumab, relatlimab)|Patients receive nivolumab IV over 30 minutes followed by relatlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study.
62321928|NCT03458000|EXPERIMENTAL|Experimental|Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
61927446|NCT06325683|ACTIVE_COMPARATOR|Arm II (lomustine)|Patients receive lomustine PO on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study.
61927447|NCT06744855|ACTIVE_COMPARATOR|Semiconductor circulation gloves|The gloves will have semiconductors embedded in the fabric.
62690283|NCT04963296|PLACEBO_COMPARATOR|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.
62690284|NCT05486065|EXPERIMENTAL|Semaglutide 2 mg|Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.
62690285|NCT05486065|PLACEBO_COMPARATOR|Semaglutide placebo 2 mg|Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.
62690286|NCT05486065|EXPERIMENTAL|Semaglutide 8 mg|Participants will receive once-weekly semaglutide 8 mg s.c. injection.
61927448|NCT06744855|PLACEBO_COMPARATOR|Placebo circulation gloves|The gloves will look identical to the active circulation gloves, but will not have semiconductors embedded into the fabric
62321929|NCT00585299|EXPERIMENTAL|Low-fat diet|20% kcals from fat diet followed for 8 weeks then 8 weeks of maintenance diet with visits to dietitian every other week
62690287|NCT05486065|PLACEBO_COMPARATOR|Semaglutide placebo 8 mg|Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.
62690288|NCT05486065|EXPERIMENTAL|Semaglutide 16 mg|Participants will receive once-weekly semaglutide 16 mg s.c. injection.
62690289|NCT05486065|PLACEBO_COMPARATOR|Semaglutide placebo 16 mg|Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.
62321930|NCT00585299|ACTIVE_COMPARATOR|Traditional|Traditional low-fat diet given and dietitian follows up in 16 weeks
62321931|NCT03224949||Healthy controls|
62321932|NCT03224949||Alcoholic hepatitis|
62321933|NCT03224949||Alcoholic steatosis|
62690290|NCT05293002|EXPERIMENTAL|Restorer Iliac Stent System|RESTORER Iliac Stent system for the treatment of Aorto-iliac lesions (TASC A, B, C and D) according to IFU
61927449|NCT06745817||Part 1 sample|Adult women (20-49 years) with different dietary habits
61927450|NCT06745817||Part 2 sample|Adult women (20-49 years) with different dietary habits invited from Part 1, including also subsamples of vegans, vegetarians, omnivores
62690291|NCT05074303|EXPERIMENTAL|Beta-glucan|500 mg/day beta-glucan
62690292|NCT05074303|PLACEBO_COMPARATOR|Placebo|500 mg/day cellulose
62690293|NCT06642987|EXPERIMENTAL|Vonoprazan Test 20mg|On the day of the visit, take 1 tablet of the experimental drug orally with 150 mL of water around 8 am.
62690294|NCT06642987|ACTIVE_COMPARATOR|Vonoprazan Reference 20mg|On the day of the visit, take 1 tablet of the comparator drug orally with 150 mL of water around 8 am.
62690295|NCT05516134|EXPERIMENTAL|Treatment|Participants who receive the intervention (all)
62690296|NCT05284617|EXPERIMENTAL|Active Treatment: HU6 Planned doses of HU6; N = 31|
62690297|NCT05284617|PLACEBO_COMPARATOR|Placebo Comparator Non-active study drug N = 31|
62690298|NCT03109067|EXPERIMENTAL|Standardized meal|"Standardized meal for :~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
62690299|NCT06466837|EXPERIMENTAL|Just-in-time Intervention|They will receive just-in-time intervention and 3 monthly nursing consultations.
62690300|NCT06466837|ACTIVE_COMPARATOR|Active Control|They will receive 6 bi-weekly nursing consultations.
62690301|NCT05896202|EXPERIMENTAL|Transcutaneous Auricular Vagus Nerve stimulation (taVNS) group|This group will receive supplemental videos on taVNS and TMS. Participants will be in this group for approximately 7 hours.
62690302|NCT05896202|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation (TMS) group|This group will receive a supplemental video on TMS only. Participants will be in this group for approximately 7 hours.
62690303|NCT04327817|OTHER|Multifidus ReActiv8 stimulator|The Mainstay ReActiv8 is an implantable electrical stimulation system that consists of an implantable pulse generator, implantable leads, programmer, activator and magnet.
61927451|NCT06492174|EXPERIMENTAL|AGENT DCB 40 mm|Agent DCB 40 mm is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
61927452|NCT06615479|EXPERIMENTAL|Arm A|
61927453|NCT06615479|ACTIVE_COMPARATOR|Arm B|
61927454|NCT05175352|EXPERIMENTAL|Administration of Cendakimab and Cytochrome P450 (CYP) substrates|
61927455|NCT06413498|EXPERIMENTAL|Anitocabtagene Autoleucel|Participants with RRMM will receive lymphodepletion chemotherapy with cyclophosphamide and fludarabine for 3 days followed by single dose of anitocabtagene autoleucel chimeric antigen receptor positive (CAR+) on Day 1.
62130742|NCT05048680|EXPERIMENTAL|Hypoxia - Rest|Sessions of intermittent hypoxia at rest; 3 sessions/week; 8 weeks. To be compared with the placebo (normoxia) group at rest.
62321934|NCT03224949||Alcoholic cirrhosis without HCC|
62321935|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
62321936|NCT03224949||Alcoholic cirrhosis with HCC|
62321937|NCT01465737||Patients with uterine cancer|All patients diagnosed with uterine cancer in Taiwan between 1979-2008
62321938|NCT04792151||PHP Youth|Youth ages 6-17 receiving standard of care treatment (i.e., transdiagnostic intervention for emotional disorders) in a partial hospitalization program
62321939|NCT06693544|EXPERIMENTAL|Healthy male older adults|
62321940|NCT06693544|EXPERIMENTAL|Healthy female older adults|
62321941|NCT03505320|EXPERIMENTAL|zolbetuximab (Cohort 1A)|Participants will be treated with zolbetuximab on a 21-day cycle in which zolbetuximab will be administered as a single agent every 3 weeks until disease progression, toxicity requiring cessation, start of another anti-cancer treatment or other treatment discontinuation criteria are met.
62321942|NCT03505320|EXPERIMENTAL|mFOLFOX6 plus zolbetuximab (Cohort 2)|Participants will be treated with zolbetuximab and mFOLFOX6 on a 42-day cycle in which zolbetuximab is administered on days 1 and 22, and mFOLFOX6 is administered on days 1, 15 and 29; however, for the first cycle, zolbetuximab will be administered on day 3 (instead of day 1) to allow for pharmacokinetic collection. Participants will receive up to 12 mFOLFOX6 treatments (4 cycles). Beginning at cycle 5, participants may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab for the remainder of the study per investigator's discretion. mFOLFOX6 treatment includes oxaliplatin: intravenous \[IV\] infusion, leucovorin: IV infusion, fluorouracil bolus: IV bolus, fluorouracil infusion: continuous IV infusion.
62321943|NCT03505320|EXPERIMENTAL|Pembrolizumab plus zolbetuximab (Cohort 3A)|Participants will be treated with zolbetuximab and pembrolizumab on a 21-day cycle. Loading dose of zolbetuximab will be administered at cycle 1, day 1 followed by maintenance dose of zolbetuximab once every 3 weeks (Q3W). Pembrolizumab will be administered to 3 to 6 subjects at a intravenously on day 1 of every 21-day cycle and will be infused 1 hour after the zolbetuximab infusion is completed. Tolerability and safety of zolbetuximab in combination with pembrolizumab will be evaluated during the 3-week dose-limiting toxicity (DLT) assessment period. If this cycle 1 dose is not tolerable, a lower dose of zolbetuximab in combination with pembrolizumab will subsequently be evaluated.
62321944|NCT03505320|EXPERIMENTAL|Zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4A/4B)|Participants will be treated with zolbetuximab and mFOLFOX6, nivolumab on a 42-day cycle. Cohort 4A: Loading dose of zolbetuximab in combination with nivolumab and mFOLFOX6 on cycle 1 day 1, followed by zolbetuximab in combination with nivolumab and mFOLFOX6 q2w \[days 15 and 29\] (1 cycle = 6 weeks). Tolerability and safety of zolbetuximab in combination with nivolumab, mFOLFOX6 will be evaluated during the 3-week DLT assessment period. If cycle 1 dose is not tolerable, a lower dose of dose zolbetuximab in combination with nivolumab and mFOLFOX6 will be subsequently evaluated. Cohort 4B: Subjects will be treated with the combination of zolbetuximab, mFOLFOX6 and nivolumab at the dose deemed tolerable in Cohort 4A. Subjects will receive up to 12 mFOLFOX6 treatments (4 cycles). For Cohorts 4A and 4B, beginning at cycle 5, subjects may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab and nivolumab for the remainder of the study per investigator's discretion.
62321945|NCT03505320|EXPERIMENTAL|Zolbetuximab in combination with FLOT (Cohort 5)|"Participants will be treated with zolbetuximab \& FLOT for a total of eight 2-week cycles. 4 cycles preoperatively \& 4 cycles postoperatively 6-12 weeks after surgery.~Preoperative: Participants will receive zolbetuximab loading dose on cycle 1 day 1, followed by FLOT on cycle 1 day 2. For cycles 2-4, participants may receive zolbetuximab maintenance dose in combination with FLOT, dosed on day 1 of each cycle. However, dosing may be split over 2 days with zolbetuximab administration on day 1 \& FLOT on day 2.~Post operative: Participants will receive zolbetuximab loading dose on cycle 5 day 1, followed by FLOT on cycle 5 day 2. For cycles 6-8, participants may receive zolbetuximab maintenance dose in combination with FLOT, dosed on day 1 of each cycle. However, dosing may be split over 2 days with zolbetuximab administration on day 1 and FLOT on day 2. For participants who experience a DLT during preoperative treatment on the loading dose, the postoperative loading dose may be lowered."
62321946|NCT02584634|EXPERIMENTAL|Group A|ALK negative Non-Small Cell Lung Cancer
62321947|NCT02584634|EXPERIMENTAL|Group B|ALK positive Non-Small Cell Lung Cancer
62321948|NCT04026503|EXPERIMENTAL|Live Long Walk Strong|8 week rehabilitation program
62321949|NCT04026503|ACTIVE_COMPARATOR|8 week wait list control|8 week wait list then followed by 8 weeks of the Live Long Walk Strong rehabilitation program
62321950|NCT04825275|EXPERIMENTAL|Posaconazole|Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
62321951|NCT04825275|NO_INTERVENTION|Control|Participants will not undergo any intervention.
62321952|NCT06266286|ACTIVE_COMPARATOR|Active Comparator|"Active stimulation sessions will last 1 hour each.~Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate several groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body."
62690304|NCT01418105|ACTIVE_COMPARATOR|Videofluroscopic swallow study (VFSS)|To investigate the swallowing ability of patients with neurologic problems
62690305|NCT01418105|ACTIVE_COMPARATOR|cervical spine isometric excercises|isometric exercises in patients with cervical spine scoliosis
62690306|NCT01418105|ACTIVE_COMPARATOR|Fiberoptic endoscopic esophageal study (FEES)|To investigate the anatomic structures during swallowing of patients with neurologic problems
62690307|NCT00661687|ACTIVE_COMPARATOR|Purevision Contact Lens #1|PureVision Soft Contact Lens Design (currently marketed)
62690308|NCT00661687|EXPERIMENTAL|PureVision Contact Lens #2|Redesign of the currently marketed PureVision soft contact lens.
61927456|NCT06413498|ACTIVE_COMPARATOR|Standard of Care Therapy (SOCT)|"Participants will receive the investigator's choice of one of the following therapies:~* pomalidomide, bortezomib, and dexamethasone (PVd) (21-day cycles)~* daratumumab, pomalidomide, and dexamethasone (DPd) (28-day cycles)~* carfilzomib, daratumumab, and dexamethasone (KDd) (28-day cycles)~* carfilzomib and dexamethasone (Kd) (28-day cycles)"
62690309|NCT01730729|EXPERIMENTAL|Treatment (cabergoline)|Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
61927457|NCT05342883|OTHER|Experimental: Resection, GammaTile and Stupp Protocol|Resection, Gamma Tile and Stupp Protocol
61927458|NCT06745349|EXPERIMENTAL|ICBT for insomnia|Therapist-guided, Internet-delivered cognitive behavioral therapy for insomnia (ICBTi)
61927459|NCT06744478||myopic children|Myopic children use Misight 1 Day Contact Lens every day for myopia and anisometropia control.
61927460|NCT05681169|EXPERIMENTAL|School-based HPV-counselling and HPV-vaccination|640 pupils
61927461|NCT05681169|NO_INTERVENTION|Control group|The control population will be approximately 2560 children comparable in age and regions in Denmark with similar high concentration of ethnic minority populations.
62321953|NCT06266286|SHAM_COMPARATOR|Sham Comparator|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
61927462|NCT06082284||Patients who come to the hospital for treatment|Patients attending the outpatient/emergency/inpatient department of Zhujiang Hospital over 18 years old.
61927463|NCT03043599|EXPERIMENTAL|Combination Therapy|Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy. Radiotherapy, followed by a 14 to 21 day break between radiotherapy and the beginning of study drug treatment.
61927464|NCT06465108|EXPERIMENTAL|Starting dose of 400 µg once-weekly by subcutaneous injection|
61927465|NCT06465108|EXPERIMENTAL|Starting dose of 600 µg once-weekly by subcutaneous injection|
61927466|NCT06465108|EXPERIMENTAL|Starting dose of 800 µg once-weekly by subcutaneous injection|
61927467|NCT06465108|PLACEBO_COMPARATOR|Placebo - once-weekly by subcutaneous injection|
61927468|NCT03530306|ACTIVE_COMPARATOR|PS1-PS4|
61927469|NCT03530306|ACTIVE_COMPARATOR|PS6-PS10|
61927470|NCT03530306|ACTIVE_COMPARATOR|PS7-PS4|
61927471|NCT03530306|ACTIVE_COMPARATOR|PS9-PS6|
61927472|NCT00027326||1/Patients|Candidate for or currently receiving radiotherapy
61927473|NCT06259227|EXPERIMENTAL|Intervention group|During the primary rehabilitation program, the intervention group will receive 2-3 individualized cardiorespiratory fitness training sessions per week.
61927474|NCT06259227|NO_INTERVENTION|Control group|The control group will receive usual care.
61927475|NCT06113445|EXPERIMENTAL|Experimental: Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
61927476|NCT06113445|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
61927477|NCT06744556|ACTIVE_COMPARATOR|DAV/IAV|"Induction therapy:~Ara-C 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2 or Idarubicin 10mg/m2/d, d1-2 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If the treatment achieves CR/CRi/CRh, proceed directly to consolidation therapy.~If the treatment does not achieve CR/CRi/CRh, enter the second induction phase with a different treatment regimen.~Second Induction Phase:~For patients with FLT3 or IDH1 mutations, targeted therapy can be chosen. If there is no FLT3 or IDH1 mutation or the patient is unwilling to use FLT3 or IDH1 inhibitors, switch to the HAV induction regimen.~Consolidation therapy:~1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older)~Maintenance therapy:~VA regimen: 6 courses Azacitidine 75 mg/m2/d on days 1-5, Venetoclax 400 mg on days 1-7."
61927478|NCT06744556|EXPERIMENTAL|HAV|"Induction Therapy:~Ara-C 100mg/m2/d, d1-5 HHT 2mg/m2/d, d1-5 Venetoclax 100mg d3, 200mg d4,400mg d5-11 If CR/CRi/CRh is achieved, proceed directly to consolidation therapy. If the treatment does not reach CR/CRi/CRh, enter the second induction phase with a different treatment regimen.~Second course:~For patients with FLT3 or IDH1 mutations, the corresponding targeted therapy can be selected, as before.~For patients without FLT3 or IDH1 mutations or those who do not want to use FLT3 or IDH1 inhibitors, the DAV/IAV induction regimen is changed.~If the treatment does not reach CR/CRi/CRh after two courses, the patient is discharged.~Consolidation therapy:~1. intermediate-dose Ara-C (ID-Ara-C): 2 cycles are used. Ara-C 1 g/m2/q12h on days 1, 3, and 5 (for patients aged 60-70 years) or Ara-C 500 mg/m2/q12h on days 1, 3, and 5 (for patients aged 70 years or older)~Maintenance therapy:~VA : 6 courses"
61927479|NCT05610774|EXPERIMENTAL|Group (D)|Patients will receive a loading dose of iv dexmedetomidine followed by a maintenance infusion.
61927480|NCT05610774|PLACEBO_COMPARATOR|Group (C)|patients will receive saline loading and infusion
61927481|NCT06745206|EXPERIMENTAL|rh-BNP arm|rh-BNP is reconstituted to a concentration of 10 μg/mL and administered as an initial intravenous bolus of 2 μg/kg over 15 minutes, followed by a continuous infusion at a rate of 0.01 μg/kg/min. The outcomes were measured 30 minutes after intervention. After that, according to the judgment of the clinicians, rh-BNP could be applied for up to 3 days.
61927482|NCT05985915|EXPERIMENTAL|Ianalumab Monthly|Ianalumab 300 mg s.c. monthly
61927483|NCT05985915|EXPERIMENTAL|Ianalumab 3 Monthly|Ianalumab 300 mg s.c. every three months and placebo once monthly between doses
61927484|NCT04892017|EXPERIMENTAL|Dose Escalation (Part 1, Cohort A Monotherapy)|DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation may continue to the next planned dose cohort.
61927485|NCT04892017|EXPERIMENTAL|Dose Escalation (Part 1, Cohort B Combination)|"Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.~Escalation Cohort B combination closed on January 8, 2024."
61927486|NCT04892017|EXPERIMENTAL|Dose Escalation (Part 1, Cohort C Combination)|"Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with binimetinib.~Escalation Cohort C combination closed on January 8, 2024."
62321954|NCT02444897|EXPERIMENTAL|Epidural PCA group|Epidural patient-controlled analgesia group
62321955|NCT02444897|ACTIVE_COMPARATOR|IV PCA group|Intravenous patient-controlled analgesia
62321956|NCT02260193|EXPERIMENTAL|AKB-6548, starting dose 1|
62321957|NCT02260193|EXPERIMENTAL|AKB-6548, starting dose 2|
62321958|NCT02260193|EXPERIMENTAL|AKB-6548, starting dose 3|
61927487|NCT04892017|EXPERIMENTAL|Dose Escalation (Part 1, Cohort D Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with sotorasib.
61927488|NCT04892017|EXPERIMENTAL|Expansion Cohorts 1, 2, 3 and 4 (Part 2)|Expansion Cohorts 1, 2, 3 and 4 DCC-3116 combinations will not open for enrollment.
61927489|NCT04892017|EXPERIMENTAL|Expansion Cohort 5 (Part 2)|DCC-3116 tablets orally given in combination with sotorasib in 28-day cycles to evaluate safety and preliminary efficacy of participants with NSCLC (with a documented mutation in KRAS G12C).
61927490|NCT05232916|PLACEBO_COMPARATOR|0.9% Normal Saline|0.9% normal saline in HLA-A\*02 positive and HER2/neu positive subjects administered intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
62130743|NCT05048680|PLACEBO_COMPARATOR|Normoxia - Rest|Sessions of normoxia at rest; 3 sessions/week; 8 weeks.
62130744|NCT05048680|EXPERIMENTAL|Hypoxia - Exercise|Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks. To be compared with the placebo (exercise under normoxia) group.
62321959|NCT06025292|ACTIVE_COMPARATOR|High Quality Protein Intake - Lean Pork|Meal patterns will mimic a standard American diet (50% carbohydrate, 15% protein, 35% fat), providing an isonitrogenous 0.8 g/kg/d protein, and meeting individual estimated daily energy requirements. We have chosen 0.8 g/kg/d as it is the recommend dietary allowance for protein in the US. This arm's protein source will be from lean pork.
62321960|NCT06025292|ACTIVE_COMPARATOR|Low Quality Protein Intake - Plant-Based|Meal patterns will mimic a standard American diet (50% carbohydrate, 15% protein, 35% fat), providing an isonitrogenous 0.8 g/kg/d protein, and meeting individual estimated daily energy requirements. We have chosen 0.8 g/kg/d as it is the recommend dietary allowance for protein in the US. This arm's protein source will be from plant-based protein (ie impossible burger, black bean burger, soy, etc).
62321961|NCT06271369||Tisa-cel cohort|Patients with at least one ICD-10 diagnosis for DLBCL who were at least 18 years old. Patients also had at least three months of continuous health plan enrollment before administration of CAR-T therapy and received tisa-cel following DLBCL diagnosis.
62321962|NCT06271369||Axi-cel cohort|Patients with at least one ICD-10 diagnosis for DLBCL who were at least 18 years old. Patients also had at least three months of continuous health plan enrollment before administration of CAR-T therapy and received axi-cel following DLBCL diagnosis.
62690310|NCT06671119|EXPERIMENTAL|Gastric Mucosal Ablation (GMA) following sleeve gastrectomy|Subjects will undergo endoscopic Gastric Mucosal Ablation (GMA) following sleeve gastrectomy. This will be performed by an experienced endoscopist specialized in bariatric endoscopy in a single endoscopic session.
62690311|NCT05938283|ACTIVE_COMPARATOR|Transvenous Implantable Defibrillator|Routine TV ICD implant
62690312|NCT05938283|ACTIVE_COMPARATOR|Subcutaneous Implantable Defibrillator|SICD ICD implant as per study protocol
62130745|NCT05048680|ACTIVE_COMPARATOR|Normoxia - Exercise|Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks.
62130746|NCT05862246||Children with pain|"These are children referred with fot and leg pain. Following outcomes will be measured on all included children:~Silvferskiölds test Height Weight Gender Age PROM child: Oxford Ankle and Foot Questionnaire for children PROM parent: Oxford Ankle and Foot Questionnaire for parents FPS pain scoring over 1 week"
62130747|NCT05862246||Control group children without pain|"Following outcomes will be measured on all included children in control group:~Silvferskiölds test Height Weight Gender Age"
62130748|NCT03419299||Pre- Application|Patients admitted prior to use of tube feeding application
62130749|NCT03419299||Post- Application|Patients admitted when tube feeding application was being used.
62130750|NCT01035034|EXPERIMENTAL|One-stop hybrid coronary revasularization|Percutaneous Coronary Intervention; Coronary Artery Bypass
62130751|NCT01035034|ACTIVE_COMPARATOR|PCI with stenting|Percutaneous Coronary Intervention
62130752|NCT01251224|ACTIVE_COMPARATOR|Education Group|This group will receive IPM education at baseline, and then the full IPM intervention after completing the study.
62130753|NCT01251224|EXPERIMENTAL|IPM Group|This group will receive the full IPM intervention at baseline.
62130754|NCT05358457|EXPERIMENTAL|Online Familiar Metacognitive Training|Metacognitive training for psychosis. The MCTf consists of 11 therapeutic units developed during weekly sessions lasting 45 and 60 minutes. Each unit contains abundant therapeutic material that includes psychoeducational information, exercises and case examples.The group will be composed of 3-4 mothers with psychosis and her adolescent children and two therapists. The application of the intervention will be by a secure videoconfering method.
62130755|NCT05358457|NO_INTERVENTION|Control group|The control group will be receive treatment as usual (TAU).
62130756|NCT02376244|EXPERIMENTAL|High intensity interval training (HIIT)|"Patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 16-17 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
62130757|NCT02376244|ACTIVE_COMPARATOR|Standard Care|"Patients assigned to this group will participate in usual standard care of cardiac rehabilitation.~Commonly, patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 11-15 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
62130758|NCT02262975||donepezil (Aricept)|
62130759|NCT04124042|EXPERIMENTAL|Stage A: 0.15 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150|Low dose active in Stage A and Stage B
62130760|NCT04124042|EXPERIMENTAL|Stage A: 0.15 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150|Low dose active in Stage A, high dose active in Stage B
62130761|NCT04124042|EXPERIMENTAL|Stage A: 0.45 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150|High dose active in Stage A, low dose active in Stage B
62130762|NCT04124042|EXPERIMENTAL|Stage A: 0.45 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150|High dose active in Stage A and Stage B
62130763|NCT04124042|PLACEBO_COMPARATOR|Stage A: Placebo, Stage B: 0.15 mg/mL XT-150|Inactive comparator in Stage A, low dose active in Stage B
62130764|NCT04124042|PLACEBO_COMPARATOR|Stage A: Placebo, Stage B: 0.45 mg/mL XT-150|Inactive comparator in Stage A, high dose active in Stage B
62130765|NCT04113096|EXPERIMENTAL|Breast Cancer Stage IV|Stage IV Breast Cancer: Dibenzyl trisulphide capsules (20mg once daily)/6 months
61927491|NCT05232916|EXPERIMENTAL|GLSI-100|GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects administered intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
62321963|NCT02030561|EXPERIMENTAL|Trastuzumab + NK cells|"During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.~From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.~Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1."
62321964|NCT02761993|ACTIVE_COMPARATOR|Group 1|Group 1 received ST266 treatment daily on Days 1 through 5, 8 through 12, 22, and 30, and then monthly for 7 months (Days 60, 90, 120, 150, 180, 210, and 240).
62690313|NCT03928015|EXPERIMENTAL|Adjunctive dronabinol|Dronabinol 5mg BID and adjusting within the range of 2.5mg - 10mg BID, as an adjunct to systemic analgesics
62690314|NCT03928015|ACTIVE_COMPARATOR|Systemic analgesics|Systemic analgesics only
61927492|NCT05232916|EXPERIMENTAL|GLSI-100, Open-label|Open-label arm: GLSI-100 immunotherapy in non-HLA-A\*02 positive and HER2/neu positive subjects administered intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
61927493|NCT03208868|ACTIVE_COMPARATOR|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
61927494|NCT03208868|ACTIVE_COMPARATOR|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
62481549|NCT06328738|EXPERIMENTAL|Part 3D: ELVN-002 + trastuzumab dose expansion in other solid tumor type 2|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
62690315|NCT05315778|EXPERIMENTAL|Anti-BCMA CAR T-cells infusion|R/R ITP patients will accept infusion of autologous anti-BCMA CAR T-cells with a total of 1.0-2.0×10e7/Kg. The patients will be follow-up for 6 months post CAR T-cell therapy.
62690316|NCT06641479||Pregnant women and their offspring|
62690317|NCT01480765|PLACEBO_COMPARATOR|Control: Placebo + Placebo|Placebo capsules and Placebo infusion
62690318|NCT01480765|ACTIVE_COMPARATOR|Pregabalin and Placebo infusion|Pregabalin capsules and Placebo infusion
62130766|NCT04113096|EXPERIMENTAL|Colon Cancer Stage IV|Stage IV Colon Cancer:Dibenzyl trisulphide capsules (20 mg one daily for 6 months
62130767|NCT04113096|EXPERIMENTAL|Cervical Cancer Stage IV|Stage IV Cancer of the Cervix: Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
62130768|NCT04113096|EXPERIMENTAL|Cancer of the Prostate Stage IV|Stage IV Prostate cancer:Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
61927495|NCT03993873|EXPERIMENTAL|Phase 1 elzovantinib|"The dose-escalation part of the study will determine the safety, tolerability, MTD, and RP2D of elzovantinib.~The dose-expansion part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.~Dose expansion cohorts: Cohort I (NSCLC, METΔex14, treatment Naive) Enrollment Closed; Cohort II (NSCLC with METΔex14, MET therapy pre-treated) Enrollment closed; Cohort III (MET amplified NSCLC, GCN≥10); Cohort IV (MET amplified GI cancer GC/GEJ, CRC/HCC, GCN≥10); Cohort V (NSCLC or GI MET amplified, GCN≥5 and \< 10); Cohort VI (Solid tumors with MET fusions, or oncogenic MET mutations or MET amplified other than GI/NSCLC"
61927496|NCT06439004|EXPERIMENTAL|Healthy volunteers|Healthy volunteers to evaluate the inter-period reproducibility of thirteen QST parameters.
61927497|NCT06581146||Participants with XLMTM|Pediatric and adolescent participants with XLMTM.
62130769|NCT00459212|EXPERIMENTAL|Arm I|Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
62130770|NCT05945108||Non-muscle-invasive bladder cancer or Muscle-invasive bladder cancer|"Defined as:~* T1 tumor and/or high-grade lesion (G3) and/or presence of CIS (Carcinoma in situ).~* Multifocal relapsed tumor and with at least one large lesion (diameter ≥ 3 cm);~Or:~-Diagnosis of early muscle-invasive urothelial bladder carcinoma."
62130771|NCT03593733|EXPERIMENTAL|Cold Water Immersion|Cold Water Immersion
62130772|NCT03593733|EXPERIMENTAL|Photobiomodulation Therapy|Photobiomodulation Therapy
62690319|NCT01480765|ACTIVE_COMPARATOR|Pregabalin + Ketamine infusion|Pregabalin capsules + Ketamine infusion
62690320|NCT06282198||Cases|Patients with Distal Femoral megaprosthesis
62690321|NCT06282198||Control|Healthy subjects
62690322|NCT04096235|EXPERIMENTAL|RAM Cannula|
62130773|NCT04138394|EXPERIMENTAL|Vitamin C|Patients will receive intravenous vitamin C at 50mg/kg every 6 hours for 96 hours
62130774|NCT04138394|PLACEBO_COMPARATOR|Control group|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
62130775|NCT06334913||MPN patients|U.K. based adult patients with MPN diagnosis.
62130776|NCT05836116||Individuals with Scoliosis|Humans with scoliosis, between age 18-35
62130777|NCT05836116||Healthy Group (Control group)|Healthy human subjects between age 18-35
62690323|NCT00648713|EXPERIMENTAL|1|Terbinafine Hydrochloride Tablets 250 mg
62690324|NCT00648713|ACTIVE_COMPARATOR|2|Lamisil® Tablets 250 mg
62690325|NCT04629950|EXPERIMENTAL|Rimegepant|Participants receive a rimegepant 75 mg tablet orally every other day for 16 weeks.
62690326|NCT04629950|PLACEBO_COMPARATOR|Placebo|Participants receive a placebo tablet matching rimegepant orally every other day for 16 weeks.
62690327|NCT02542215|EXPERIMENTAL|Cobiprostone 30 mcg four times daily|Cobiprostone oral spray, four times daily, in addition to standard care radiation and chemotherapy
62690328|NCT02542215|PLACEBO_COMPARATOR|Placebo 0 mcg four times daily|Matching placebo oral spray, four times daily, in addition to standard care radiation and chemotherapy
62321965|NCT02761993|ACTIVE_COMPARATOR|Group 2|Group 2 received ST266 treatment 2x/week (with at least 1 day between treatments) for the first 3 months, and then monthly for 5 months (Days 120, 150, 180, 210, and 240).
62321966|NCT02761993|PLACEBO_COMPARATOR|Group 3|Group 3 received commercially available sterile saline (0.9% sodium chloride) according to the same schedule as Group 1.
62481550|NCT06328738|EXPERIMENTAL|Part 3E: ELVN-002 + trastuzumab dose expansion in other solid tumor type 3|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
62481551|NCT06328738|EXPERIMENTAL|Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on Days 1 - 14 of a 21-day cycle. Oxaliplatin: will be administered intravenously at 130 mg/m2 on Day 1 of a 21-day cycle.
62690329|NCT01586897|EXPERIMENTAL|Use of Medication Metronome|Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
62690330|NCT01586897|ACTIVE_COMPARATOR|Usual Care|PCPs allocated to the control arm will continue with usual care practices for laboratory monitoring.
62690331|NCT02019836||sepsis group, control group|Sepsis group; infants with the diagnosis of high probable sepsis Control group; infants without sepsis
62690332|NCT00873886|EXPERIMENTAL|Oseltamivir (Tamiflu)|
62130778|NCT05910411|EXPERIMENTAL|Inelastic compression|Inelastic compression used in the treatment of lymphedema
62690333|NCT00873886|OTHER|Esterase|
62690334|NCT03014505|EXPERIMENTAL|FMT|Fecal Microbiota Transplantation via endoscope and/or cenema and the traditional treatments
62690335|NCT03014505|ACTIVE_COMPARATOR|The traditional treatments|
62130779|NCT01306786|ACTIVE_COMPARATOR|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
62321967|NCT04716946|EXPERIMENTAL|Participants with Early-stage Non-Small Cell Lung Cancer|Participants will be diagnosed with Stage I-IIIA NSCLC and will be ineligible for surgery and will have any level of PD-L1
62321968|NCT00903461|EXPERIMENTAL|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Subjects will receive a total of up to 7 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive a total EGFR AS dose of 1.92 milligrams in 1.78 milliliters on each weekly treatment. This dose may be delivered equally in the same tumor site per weekly session, the primary tumor or cervical lymph nodes.
62481552|NCT06328738|EXPERIMENTAL|Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously at 6 mg/kg IV cycle 1, day 2 followed by 4 mg/kg IV cycle 1, day 15, and then one dose at 4mg/kg IV every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on days 1 and 15 of a 28-day cycle.
62130780|NCT01306786|ACTIVE_COMPARATOR|Triple Therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
62130781|NCT06221436|EXPERIMENTAL|Mental Imagery|The Mental Imaging group will receive olfactory mental imagery technique and vagus breathing therapy for 1 hour in the morning and evening on the 1st, 2nd, 3rd and 4th days after surgery. In addition, the standard care (breathing exercises with Triflo, early walking, frequent position changes in bed) and treatment plan, which are the standard protocol of the Cardiovascular Surgery Service, will be continued by the clinic nurse and physician.
62130782|NCT06221436|NO_INTERVENTION|Control|The control group was given no intervention other than standard care (breathing exercise with Triflo, early ambulation, frequent position changes in bed) and treatment, which is the standard protocol of the Cardiovascular Surgery Service, by the clinic nurse and physician on the 1st, 2nd, 3rd and 4th days after surgery. Will not be implemented.
62130783|NCT02814838|EXPERIMENTAL|Ladarixin|Ladarixin oral capsule
62130784|NCT02814838|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule
62690336|NCT01942460|EXPERIMENTAL|Ferumoxytol|
61927498|NCT06744179||Exposed to pulmonary TB and Not exposed to pulmonary TB|we will enroll a group of individuals exposed to TB who have completed standard TB treatment (e.g., 6-9 months of anti-TB therapy). Simultaneously, we will recruit matched individuals without a history of TB from the same population to form the unexposed group. We will recruit post TB patients and age and sex-matched TB unexposed participants in a 1:1 ratio. We will enrol the unexposed group to compare post-TB sequelae data of study TB patients with that of a local non-TB population. Consequently, we will enrol 210 adult pulmonary TB cases and 90 child TB cases. Similarly, 210 adults and 90 children without TB disease will be included as the unexposed group.
61927499|NCT06252649|EXPERIMENTAL|Arm A: Sotorasib + Panitumumab + FOLFIRI|Sotorasib was taken daily (QD) as an oral tablet. Panitumumab and FOLFIRI were received every 2 weeks (Q2W) via intravenous infusion (IV).
61927500|NCT06252649|ACTIVE_COMPARATOR|Arm B: FOLFIRI with or Without Bevacizumab-awwb|Participants received FOLFIRI Q2W with or without bevacizumab-awwb.
62690337|NCT06673758|EXPERIMENTAL|experimental group|experimental group given tai chi exercises on three levels of two weeks sessions of total 10 session in five days of each week.
61927501|NCT06190509|ACTIVE_COMPARATOR|Candi5V half dose|
61927502|NCT06190509|ACTIVE_COMPARATOR|Candi5V half dose + adjuvant|
61927503|NCT06190509|ACTIVE_COMPARATOR|Candi5V target dose|
61927504|NCT06190509|ACTIVE_COMPARATOR|Candi5V target dose + adjuvant|
61927505|NCT06190509|PLACEBO_COMPARATOR|Placebo|
61927506|NCT06743971|EXPERIMENTAL|experimental|Parents will let their babies listen to ocean sounds during colic cries for 1 week.
61927507|NCT06743971|NO_INTERVENTION|control|Parents will continue with routine care practices during the baby's colicky cries
61927508|NCT06547216|EXPERIMENTAL|AOC 1020 Regimen|AOC 1020 Dose Regimen; Sixteen doses administered intravenously over 22 months. All participants will receive AOC 1020 at a dose level of 2mg/kg.
61927509|NCT05768139|EXPERIMENTAL|Dose Escalation (Advanced Solid Tumors)|"* Cohort A0: Advanced Solid tumors expressing PI3Kα mutations~* Cohort A1: HR+ breast cancer expressing PI3Kα mutations"
61927510|NCT05768139|EXPERIMENTAL|Dose Expansion|"* Cohort A1: HR+/HER2- breast cancer expressing PI3Ka mutations~* Cohort A2: Gynecologic cancers~* Cohort A3: Head and Neck Squamous Cell Carcinoma~* Cohorts A4/A5: Other solid tumors not included in Cohorts A1, A2, or A3 expressing PI3Kα mutations"
61927511|NCT05768139|EXPERIMENTAL|Dose Selection/Expansion: Combination STX-478 + fulvestrant|Cohort B: HR+/HER2- or HR+/HER2low breast cancer expressing PI3Kα mutations
61927512|NCT05768139|EXPERIMENTAL|Dose Selection/Expansion Combination STX-478 + fulvestrant + CDK4/6 inhibitor|Cohort C/D: HR+/HER2- or HR+/HER2low breast cancer expressing PI3Ka mutations
62130785|NCT05680389|EXPERIMENTAL|Minocycline|100 mg twice daily for 3 months
61927513|NCT04451863|PLACEBO_COMPARATOR|Placebo|0 mg THC, 0 mg myrcene, 0 mg BCP
61927514|NCT04451863|ACTIVE_COMPARATOR|Low strength THC|5 mg THC, 0 mg myrcene, 0 mg BCP
61927515|NCT04451863|ACTIVE_COMPARATOR|Higher strength THC|15 mg THC, 0 mg myrcene, 0 mg BCP
61927516|NCT04451863|ACTIVE_COMPARATOR|Low strength myrcene|0 mg THC, 0.5 mg myrcene, 0 mg BCP
61927517|NCT04451863|ACTIVE_COMPARATOR|High strength myrcene|0 mg THC, 12.0 mg myrcene, 0 mg BCP
61927518|NCT04451863|ACTIVE_COMPARATOR|Low strength BCP|0 mg THC, 0 mg myrcene, 0.5 mg BCP
61927519|NCT04451863|ACTIVE_COMPARATOR|High strength BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
61927520|NCT04451863|ACTIVE_COMPARATOR|Low THC + Low myrcene|5 mg THC, 0.5 mg myrcene, 0 mg BCP
61927521|NCT04451863|ACTIVE_COMPARATOR|Low THC + High myrcene|5 mg THC, 12.0 mg myrcene, 0 mg BCP
61927522|NCT04451863|ACTIVE_COMPARATOR|High THC + Low myrcerne|15 mg THC, 0.5 mg myrcene, 0 mg BCP
62130786|NCT05680389|PLACEBO_COMPARATOR|Placebo|twice daily for 3 months
62130787|NCT02489695|EXPERIMENTAL|axitinib + pembrolizumab|axitinib 10mg twice a day
62130788|NCT00912600||1|Elderly individuals presenting to one of 15 emergency departments and possibly qualifying for admission to an ICU
62130789|NCT01892683||Propofol|This study will investigate patients that undergo routine anesthesia for elective surgical procedure at the hospital of the University of Munich(Klinikum der Universität München. Patients will receive intravenous anesthesia with propofol.
62130790|NCT03510676|EXPERIMENTAL|NiTiDES|Single arm
62130791|NCT02029235|ACTIVE_COMPARATOR|Acetaminophen/Ibuprofen (AIBU) Group|Acetaminophen 500 mg and Ibuprofen 400 mg
62321969|NCT05925816|EXPERIMENTAL|Video|Short video with BA intervention ideas
61927523|NCT04451863|ACTIVE_COMPARATOR|High THC + High myrcene|15 mg THC, 12.0 mg myrcene, 0 mg BCP
61927524|NCT04451863|ACTIVE_COMPARATOR|Low THC + Low BCP|5 mg THC, 0 mg myrcene, 0.5 mg BCP
62130792|NCT02029235|ACTIVE_COMPARATOR|Acetaminophen/Hydrocodone (AH) Group|Acetaminophen 325 mg and Hydrocodone 5 mg
62321970|NCT05925816|EXPERIMENTAL|Active game|Feedback Twine game
62321971|NCT05925816|SHAM_COMPARATOR|Neutral game|Neutral Twine game
62321972|NCT05925816|NO_INTERVENTION|No intervention|
62321973|NCT05925816|EXPERIMENTAL|Video + Active game|Combines Video and Active game
62321974|NCT05925816|ACTIVE_COMPARATOR|Video + Neutral game|Combines Video and Neutral game
62321975|NCT02648048|EXPERIMENTAL|Vismodegib and Pirfenidone|Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
62321976|NCT04485169|EXPERIMENTAL|TPE Arm|In addition to standard care TPE was performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access was achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume was calculated as per Nadler's formula. Anticoagulant acid dextrose ratio was 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation was monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume was removed during each procedure. Replacement fluid was fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures were performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE was continued till recovery
62321977|NCT04485169|NO_INTERVENTION|NON TPE arm|Only supportive treatment offered including Vit C, Zinc, Vit D, famotidine, Enoxaparin and Methylprednisolone
62321978|NCT06549686|NO_INTERVENTION|the osteotomy monotherapy group|the osteotomy monotherapy
62321979|NCT06549686|EXPERIMENTAL|the osteotomy + RMSC combination therapy group|"the osteotomy + RMSC combination therapy~\*RMSC combination therapy R: Resection of unhealthy tissue MS: Marrow arrow Stimulating＝MSCs Recruitment C: Covered by Chondrocyte sheets"
62321980|NCT06243757||Minimally Invasive Proximal Gastrectomy/MIPG|Participants will undergo MIPG (Trial Procedure)
62321981|NCT06243757||Minimally Invasive Total Gastrectomy/MITG|Participants will undergo MITG (Standard of Care/Control Group)
62321982|NCT06692608|ACTIVE_COMPARATOR|Dynamic strength training|
62481553|NCT00029965||Glycoprotein Disorders|Glycoprotein Disorders
61927525|NCT04451863|ACTIVE_COMPARATOR|Low THC + High BCP|5 mg THC, 0 mg myrcene, 7.5 mg BCP
62130793|NCT03296540|ACTIVE_COMPARATOR|Uncrushed|6 Integral tablets Prasugrel as loading dose
62321983|NCT06692608|EXPERIMENTAL|Isometric strength training|
62481554|NCT00029965||Lysosomal Storage Diseases|Lysosomal Storage Diseases
62481555|NCT06743152|EXPERIMENTAL|synchronous telerehabilitation group|Synchronous telerehabilitation group will be applied a synchronous supervised online exercise program under the supervision of a physiotherapist
61927526|NCT04451863|ACTIVE_COMPARATOR|High THC + Low BCP|15 mg THC, 0 mg myrcene, 0.5 mg BCP
61927527|NCT04451863|ACTIVE_COMPARATOR|High THC + High BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
61927528|NCT06745700|EXPERIMENTAL|Brief Behavioural Activation|Five-session Brief Behavioral Activation intervention. Sessions 1 - 4 are completed once a week, and session 5 is a booster-session completed four weeks after session 4 and care as usual provided by Region Västmanland.
61927529|NCT06745700|OTHER|Care as Usual|Care as usual provided by Västmanland County hospital.
61927530|NCT06745765|EXPERIMENTAL|VR|Patients will use virtual reality before the procedure in addition to usual preoperative care.
61927531|NCT06745765|NO_INTERVENTION|NO VR|Patients will not use virtual reality; hence, they will experience usual preoperative care.
61927532|NCT06325709|EXPERIMENTAL|Single Arm Study|
62130794|NCT03296540|EXPERIMENTAL|Crushed|6 Crushed tablets Prasugrel as loading dose
62130795|NCT04240613|OTHER|women treated by TVT-O|All women treated by TVT-O during the years this study was made were included.
62130796|NCT00209742|EXPERIMENTAL|2|
61927533|NCT06745583|EXPERIMENTAL|EI-1071 dose|
61927534|NCT06745557|OTHER|Option 1|Location A is the experimental area and Location B is the control area
61927535|NCT06745557|OTHER|Option 2|Location A is the control area and Location B is the experimental area
61927536|NCT06744192||tear|Patients diagnosed hip labrum tear by a hip arthroscopy or by a comprehensive clinical diagnosis through an orthopaedic surgeon with 15 years of experience
62130797|NCT00209742|EXPERIMENTAL|3|
62130798|NCT00209742|ACTIVE_COMPARATOR|1|
62321984|NCT04133779||Group A (MS)|"* Age 18-55 years;~* Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS;~* Course of the disease: RR-SP-PP-CIS;~* Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS;~* Not in clinical relapse (at least 30 days after the last clinical relapse);~* Subjects treated or non-treated with immunomodulatory and immunosupressive drugs;~* Signature of the informed consent."
62321985|NCT04133779||Group B (HC)|"* Age 18-55 years;~* Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC);~* Signature of the informed consent.~The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study, or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres."
62321986|NCT04133779||Group C (OND)|"* Aged 18-55 years;~* Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy.~* Signature of the informed consent."
62481556|NCT06743152|EXPERIMENTAL|Asynchronous telerehabilitation group|Asynchronous telerehabilitation group will be applied an asynchronous video-based exercise program.
62690338|NCT06673758|OTHER|control group|15 participants are given art and crafts activity of two weeks
62690339|NCT06670417|EXPERIMENTAL|Group (A) (Experimental A): will receive extravascular low level laser therapy LLLT (laser watch dev|
62690340|NCT06670417|EXPERIMENTAL|B) (Experimental B): will receive Offloading exercise inform of burger allen exercise combined with|
62690341|NCT06670417|EXPERIMENTAL|(C) Control group will receive their prescribed hypoglycaemic medications(oral and insulin) and usua|
61927537|NCT06744192||non-tear|Patients no diagnosed hip labrum tear by a hip arthroscopy or by a comprehensive clinical diagnosis through an orthopaedic surgeon with 15 years of experience
61927538|NCT06745531|EXPERIMENTAL|TS-172 20~60 mg/day|
61927539|NCT06745531|PLACEBO_COMPARATOR|Placebo|
61927540|NCT04864106|EXPERIMENTAL|Study Group|Participants will undergo a endoscopic airway assessment in addition to the airway classification using the Mallampati score.
61927541|NCT06736522|EXPERIMENTAL|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP) consists of 14 sessions focused on youth civic engagement, leadership, and mindfulness.
61927542|NCT06736522|ACTIVE_COMPARATOR|EnvisionIT|EnvisionIT is a college and career-readiness program designed for students in grades 6-12. The EnvisionIT program will be delivered over 14 sessions, and focus on skills and career/college readiness.
61927543|NCT05557409|EXPERIMENTAL|AXS-05|Up to 5 weeks
61927544|NCT05557409|PLACEBO_COMPARATOR|Placebo|Up to 5 weeks
61927545|NCT06745648|EXPERIMENTAL|Patient con tension headache, migraine and mixed headache|
61927546|NCT02945072|ACTIVE_COMPARATOR|Sevoflurane group|general anesthesia will be maintained with sevoflurane
62130799|NCT03459677|EXPERIMENTAL|Back2School Condition|"The Back2School condition is a Modular Trans-Diagnostic Cognitive Behavioral Therapy (MTCBT) treating school absenteeism in youths.~The MTCBT intervention consist of 10 sessions and 4 school meetings, conducted over a period of 4 months."
62321987|NCT04133779||Group D (ONDi)|"* Age 18-55 years;~* subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases;~* Signature of the informed consent."
62321988|NCT01221467|ACTIVE_COMPARATOR|Overnight closed-loop combined with real-time CGM|
62321989|NCT01221467|ACTIVE_COMPARATOR|Real-time CGM alone|
62321990|NCT01883128|EXPERIMENTAL|Whole body MRI|Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.
62321991|NCT01883128|EXPERIMENTAL|MRI Targeted Biopsies|Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies
62321992|NCT01883128|EXPERIMENTAL|Focal Salvage Therapy|Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only
61927547|NCT02945072|EXPERIMENTAL|TIVA group|general anesthesia will be maintained with total intravenous anesthesia (propofol and remifentanyl)
61927548|NCT06743555|ACTIVE_COMPARATOR|Standard-of-care surgery|Participants undergo surgery followed by the same surveillance schedule as Arm A. ctDNA testing is conducted 3 weeks post-surgery and again at 6 months. Surveillance includes low-dose CT scans, physical examinations, and ECOG assessments every 3 months for 12 months, with long-term monitoring at regular intervals up to 5 years.
61927549|NCT06743555|EXPERIMENTAL|Observation without surgery|Participants undergo surveillance without surgery, including a low-dose CT scan of the thorax and upper abdomen, ECOG assessment, and physical examination every 3 months for the first 12 months. Additional ctDNA testing is performed 3 weeks post-randomization and at 6 months. Long-term follow-up includes similar assessments every 6-12 months up to 5 years.
61927550|NCT06735911|EXPERIMENTAL|Experimental: patient treated with a dermatology-oriented spa therapy|Thermal treatments among the following: Filiform shower, simple bath, aerated bath, general shower, compresses, nebulization inhalation, multiple local mud applications, and drinking cure.
61927551|NCT05519878|EXPERIMENTAL|Arm I (BWL)|Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses.
61927552|NCT05519878|EXPERIMENTAL|Arm II (OT)|Patients undergo 6 occupational therapist-led sessions over 60 minutes each.
61927553|NCT05519878|EXPERIMENTAL|Arm III (OT, BWL)|Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses and to complete the occupational therapist-led session over 60 minutes.
61927554|NCT05519878|ACTIVE_COMPARATOR|Arm IV (Control)|Patients undergo routine treatment and usual follow up care with their medical oncologist.
61927555|NCT06744595|EXPERIMENTAL|Health services research (EPIC message, genetic counseling)|Patients receive a personalized message through EPIC with education on the NCCN guidelines for genetic counseling and an offer for SOC genetic counseling. Patients then receive pre-genetic test counseling on study. Patients may then optionally undergo SOC genetic testing and collection of blood or saliva samples as well as receive post-genetic test counseling on study.
61927556|NCT06742320|EXPERIMENTAL|Education Group|Pre-test forms were applied to the children in the training group face to face by the researchers in the outpatient clinic. Children assigned to the training group received asthma education in a single session, 3 modules/each module lasting at least 15 minutes. Post-test forms were administered immediately after the training.The 2nd and 3rd follow-up tests will be administered online via Google Form in the 1st and 3rd months after the training is completed.
61927557|NCT06742320|NO_INTERVENTION|Control group|Pre-test forms will be applied to the control group face-to-face by researchers in the outpatient clinic.In the control group, follow-up tests (three weeks, 1 month and 3 months after the pre-tests) will be administered online via Google Form.
61927558|NCT06737016|ACTIVE_COMPARATOR|Oxybutynin and Trimethoprim/sulphamethoxazole|Patients will undergo maintenance therapy Anticholinergic, oxybutynin and Continous Antibiotic Prophylaxis,Trimethoprim/sulphamethoxazole daily
62130800|NCT03459677|ACTIVE_COMPARATOR|Treatment As Usual Condition|"The Treatment As Usual condition (TAU) consist of an array of interventions that the municipality is required to give youths presenting school absenteeism.~The TAU condition will last for 4 months."
62130801|NCT02213744|EXPERIMENTAL|MM-302 + trastuzumab|MM-302 + trastuzumab
62130802|NCT02213744|ACTIVE_COMPARATOR|Chemotherapy of Physician's Choice plus trastuzumab|Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine
62321993|NCT02016417|EXPERIMENTAL|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
62321994|NCT02016417|ACTIVE_COMPARATOR|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
62321995|NCT01020292|EXPERIMENTAL|NFV and Concurrent ChemoRads|
62321996|NCT05002192||ELP_ONLY|Patients who were diagnosed with community-acquired pneumonia and were treated with Eucalyptol, Limonene and Pinene Enteric Soft Capsules, not treated with other oral mucolytics.
62481557|NCT04930874|EXPERIMENTAL|ICU patients with COVID-19|NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure levels (MAP, ie 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using Tissue Oxygenation Index values and mean arterial pressure values in a regression analysis and will be considered sufficient if the relative Pearson correlation coefficient is less than 0.3. Cerebral blood flow will be assessed by blood flow index determination after intravenous infusion of 5 mg indocyanine.
62481558|NCT06742099|ACTIVE_COMPARATOR|Malignant Pleural effusion with pleurodesis|these are patients who have malignant pleural effusion and will have talc injected into the pleural cavity to induce pleurodesis
62481559|NCT06742099|ACTIVE_COMPARATOR|Malignant Pleural effusion with only chest tube for drainage|these are patients who have malignant pleural effusion but will only have intercostal chest tube inserted for drainage
62481560|NCT06185491|EXPERIMENTAL|HGI|Data collection from glucose monitoring systems. Dosage of glycated hemoglobin and glycated albumin
62690342|NCT02236013|EXPERIMENTAL|ASP2215 Dose Escalation (Part 1)|Successive dose escalation cohorts will determine the maximum tolerated dose (MTD)
61927559|NCT06737016|EXPERIMENTAL|Tamsulosin, Oxybutynin and Trimethoprim/sulfamethoxazole|Patients will undergo maintenance therapy Tamsulosin in addition to Anticholinergic, Oxybutynin and Continous Antibiotic Prophylaxis, Trimethoprim/sulfamethoxazole daily
61927560|NCT06364696|EXPERIMENTAL|ASP4396 Dose Escalation|Participants will receive ASP4396 in a 21-day cycle.
61927561|NCT06364696|EXPERIMENTAL|ASP4396 Dose Expansion|Participants will receive ASP4396 in a 21-day cycle.
61927562|NCT06743490||MG patients|MG patients with at least one of the symptoms of interest (i.e. dysarthria, dysphonia, proximal arm fatigue and/or ptosis). We aim to include 150 patients with Myasthenia Gravis.
61927563|NCT06743490||Non-MG participants|Non-MG participants that do not have a medical history of any of the symptoms of interest. We aim to include 75 controls.
61927564|NCT05880862|EXPERIMENTAL|Pelvic Floor Muscle Training|A 12-week, 6 visit, outpatient program of physical therapist delivered behavioral and pelvic floor muscle training (PFMT)
61927565|NCT05880862|ACTIVE_COMPARATOR|Mirabegron|Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.
61927566|NCT05880862|ACTIVE_COMPARATOR|Trospium Chloride|A 12-week course of Trospium -extended release, 60mg once daily.
61927567|NCT06744660|EXPERIMENTAL|OTC Study|This OTC study will take place in simulated home environments which will be set up within or near clinical settings (e.g., urgent care facilities). The study will enroll symptomatic subjects only. Candidate samples will be self-collected by participants (or collected by a guardian for participants under the age of 14 years) and comparator samples will be collected by a healthcare practitioner with informed consent and Institutional Review Board (IRB) approval. Each sample will be coded for confidentiality.
61927568|NCT05686551|EXPERIMENTAL|Tominersen 60 mg|
61927569|NCT05686551|PLACEBO_COMPARATOR|Placebo|
61927570|NCT05686551|EXPERIMENTAL|Tominersen 100 mg|
61927571|NCT06739096|EXPERIMENTAL|Short Wave Diathermy + Exercise|
61927572|NCT06739096|SHAM_COMPARATOR|Sham Short Wave Diathermy + Exercise|
61927573|NCT06744010|EXPERIMENTAL|Group A|sub sartorial canal block + popliteal block
62130803|NCT05530161||trauma induced coagulopathy|patients with INR\>1.2
62130804|NCT05530161||non-trauma induced coagulopathy|patients with INR≤1.2
62130805|NCT04502472|EXPERIMENTAL|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Patients hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome and meet eligibility criteria
62130806|NCT06520449|EXPERIMENTAL|68Ga-NTA-476 PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT|"A single dose of 68Ga-NTA-476 will be administered on Day 1 of the study as an intravenous bolus injection under the supervision of the study Investigator or appropriately qualified delegate. The planned injected activity (IA) of 68Ga-NTA-476 is 2-3.5 MBq/kg.~Following administration of 68Ga-NTA-476, participants will complete PET imaging at 0-30 minutes, 1 hour, and 4-6 hours. Each PET scan will take up to 30 minutes."
62130807|NCT00150813|EXPERIMENTAL|Levetiracetam|Subjects received open-label Levetiracetam.
62130808|NCT03580369|EXPERIMENTAL|Ligelizumab 120 mg|Ligelizumab 120 mg arm: 1 injection of 1.0 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
62130809|NCT03580369|EXPERIMENTAL|Ligelizumab 72 mg|Ligelizumab 72 mg arm: 1 injection of 0.6 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
62130810|NCT03580369|ACTIVE_COMPARATOR|Omalizumab 300 mg|Omalizumab 300 mg arm: 2 injections of 1.2 mL omalizumab q4w
61927574|NCT06744010|EXPERIMENTAL|Group B|femoral block + popliteal block
61927575|NCT04185532|EXPERIMENTAL|Rebound ACL brace and physiotherapy|The intervention will be the use of rebound ACL brace for 9 weeks, which initially is locked followed by a gradually increased range of motion. A standardized rehab protocol is applied.
61927576|NCT04185532|ACTIVE_COMPARATOR|Physiotherapy|A standardized rehab protocol comparable to the experimental group but with no brace
61927577|NCT06242470|EXPERIMENTAL|Cohort 1|
61927578|NCT06242470|EXPERIMENTAL|Cohort 2|
61927579|NCT06242470|EXPERIMENTAL|Cohort 3|
61927580|NCT06242470|EXPERIMENTAL|Cohort 4|
61927581|NCT06242470|EXPERIMENTAL|Cohort 5|
61927582|NCT06242470|EXPERIMENTAL|Cohort 6|
61927583|NCT06242470|EXPERIMENTAL|Expansion cohort 1|
61927584|NCT06242470|EXPERIMENTAL|Expansion cohort 2|
61927585|NCT06242470|EXPERIMENTAL|Expansion cohort 3|
61927586|NCT06242470|EXPERIMENTAL|Expansion cohort 4|
61927587|NCT06329401|EXPERIMENTAL|AP01 High Dose BID|Pirfenidone Solution for Inhalation
62130811|NCT03580369|PLACEBO_COMPARATOR|Placebo|Placebo-ligelizumab arm: 2 injections of 1.0mL of ligelizumab placebo from Week 0 through Week 20; 1 injection of 1.0mL of ligelizumab 120 mg + 1 injection of 1.0 mL ligelizumab placebo from Week 24 through Week 48
62130812|NCT01376700|EXPERIMENTAL|ADVATE - Prophylactic Regimen|Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
62321997|NCT05002192||EXP_ONLY|Patients diagnosed with community-acquired pneumonia and treated with an oral mucolytic drug other than Eucalyptol, Limonene and Pinene Enteric Soft Capsules.
61927588|NCT06329401|EXPERIMENTAL|AP01 Low Dose BID|Pirfenidone Solution for Inhalation
61927589|NCT06329401|PLACEBO_COMPARATOR|Placebo BID|Placebo solution for inhalation
61927590|NCT06105684|EXPERIMENTAL|Low dose capecitabine (Xeloda)|1000 mg capecitabine daily by mouth.
61927591|NCT05875545|ACTIVE_COMPARATOR|Breathing Exercise Group|Combined breathing and pelvic floor exercises
61927592|NCT05875545|ACTIVE_COMPARATOR|Control Group|Pelvic floor exercises
61927593|NCT06744517|ACTIVE_COMPARATOR|Follicular Phase Training|Exercise training in the follicular phase (\~days 1-14) of the participant's menstrual cycle
61927594|NCT06744517|EXPERIMENTAL|Luteal Phase Training|Exercise training in the luteal phase (\~days 15-28) of the participant's menstrual cycle
61927595|NCT06293079|ACTIVE_COMPARATOR|Telerehabilitation Group|An eight-week rehabilitation program will be implemented synchronously with the physiotherapist two days a week via video conferencing system.
61927596|NCT06293079|EXPERIMENTAL|Hybrid Telerehabilitation Group|The first two weeks of the eight-week program will be applied face to face in the clinic, and the six weeks will be applied synchronously with the physiotherapist via video conferencing system.
61927597|NCT06293079|ACTIVE_COMPARATOR|Clinic Group|An eight-week rehabilitation program will be implemented face to face in the clinic.
61927598|NCT06193486|EXPERIMENTAL|Dose Escalation|"Participants will undergo leukapheresis followed by lymphodepletion and infusion of MSGV1-PSCA-8T28Z. The lymphodepletion regimen includes cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) administered over 3 days (Days -5, -4, -3). The standard 3+3 design will be used to guide dose escalation/de-escalation decisions based on the cumulative number of patients who experience a dose limiting toxicity (DLT) at the current dose. The first cohort of 3 patients will be treated at dose level 1.~The target maximum doses infused at each dose level is:~Dose Level 1: 1x10\^5 cells/kg Dose Level 2: 3x10\^5 cells/kg Dose Level 3: 1x10\^6 cells/kg Dose Level 4: 3x10\^6 cells/kg Dose Level 5: 1x10\^6 cells/kg"
61927599|NCT06193486|EXPERIMENTAL|Dose Expansion|Participants will undergo leukapheresis followed by lymphodepletion and infusion of MSGV1-PSCA-8T28Z. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m\^2) and cyclophosphamide (500 mg/m\^2) prior to study day 0. Participants will then receive MSGV1-PSCA-8T28Z at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
61927600|NCT00752115|ACTIVE_COMPARATOR|A|Sildenafil plus carboplatin and weekly paclitaxel
61927601|NCT00752115|PLACEBO_COMPARATOR|P|carboplatin and weekly paclitaxel
62130813|NCT02846909|ACTIVE_COMPARATOR|Vaginal progesterone group|Will receive progesterone pessaries 400 mg once daily vaginally
62130814|NCT02846909|NO_INTERVENTION|No progesterone group|Will receive nothing
62130815|NCT03778515||Cases - Ankylosing Spondylitis Cohort|20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
62130816|NCT03778515||Controls - w/o Ankylosing Spondylitis|5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI
62130817|NCT01426698|ACTIVE_COMPARATOR|Immediate cord clamping|Infants in this arm will have had immediate cord clamping at birth which is routine care at the hospital
62321998|NCT05002192||ELP+AMB|Patients diagnosed with community-acquired pneumonia and treated with Eucalyptol, Limonene and Pinene Enteric Soft Capsules and ambroxol injection.
62321999|NCT05002192||EXP+AMB|Patients diagnosed with community-acquired pneumonia and treated with oral mucolytics and ambroxol injection other than Eucalyptol, Limonene and Pinene Enteric Soft Capsules.
62322000|NCT05002192||AMB_ONLY|Patients diagnosed with community-acquired pneumonia and treated with ambroxol injection alone.
62322001|NCT01772342|EXPERIMENTAL|Nocturnal Air Purification|"* Hepa Filtration with PureNight~* SHAM with PureNight"
62481561|NCT06414889|EXPERIMENTAL|Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis|"On Days 1-5, participants will receive a Granulocyte colony-stimulating factor (G-CSF), such as filgrastim, as an injection or by vein over about 5 minutes.~If the study doctor thinks it is needed, participants will also receive plerixafor as an injection under the skin on Day 5 (and 6, if you have 2 days of apheresis)."
62690343|NCT02236013|EXPERIMENTAL|ASP2215 Dose Expansion (Part 2)|Once the MTD has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort
61927602|NCT05273749|EXPERIMENTAL|TNX-102 SL Tablet, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
61927603|NCT05273749|PLACEBO_COMPARATOR|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
61927604|NCT06347159|EXPERIMENTAL|Part A: EDG-7500 Single Dose|
61927605|NCT06347159|EXPERIMENTAL|Part B: EDG-7500 Multiple Dose in Adults with Obstructive Hypertrophic Cardiomyopathy|EDG-7500 once daily for up to 28 days.
61927606|NCT06347159|EXPERIMENTAL|Part C: EDG-7500 Multiple Dose in Adults with Nonobstructive Hypertrophic Cardiomyopathy|EDG-7500 once daily for up to 28 days.
61927607|NCT06347159|EXPERIMENTAL|Part D: EDG-7500 Multiple Dose in Adults with Hypertrophic Cardiomyopathy|EDG-7500 daily for up to 48 weeks in participants who have completed Part B or C.
62690344|NCT02236013|EXPERIMENTAL|Alternative Anthracycline and Schedule (Part 3)|In Part 3, two cohorts will be enrolled to evaluate an alternative anthracycline and ASP2215 schedule
61927608|NCT06743568|OTHER|Self-expandable valve group|Patients who undergo transcatheter aortic valve replacement using self-expandable valves
61927609|NCT06743568|OTHER|Balloon-expandable valve group|Patients who undergo transcatheter aortic valve replacement using balloon-expandable valves
61927610|NCT06745622|EXPERIMENTAL|HSK39297|
62130818|NCT01426698|EXPERIMENTAL|Delayed Cord Clamping|Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
62322002|NCT05433103|EXPERIMENTAL|Low-Load Exercise with Blood Flow Restriction|The BFR intervention will combine low-load resistance training with between 60%-80% blood flow occlusion under the supervision of a licensed physical therapist.
61927611|NCT06579040|NO_INTERVENTION|Group I (Control)|Standard multi-modal therapy
61927612|NCT06579040|EXPERIMENTAL|Group II (Intervention)|Standard multi-modal therapy + 40 HBOT treatments (2 ATM for 90 mins daily, 5 days a week)
61927613|NCT05843578|EXPERIMENTAL|AGMB-129 High|AGMB-129 high dose
61927614|NCT05843578|EXPERIMENTAL|AGMB-129 Low|AGMB-129 low dose
61927615|NCT05843578|EXPERIMENTAL|Placebo|Matching placebo
61927616|NCT05657054|EXPERIMENTAL|Strength group|Group 1
61927617|NCT05657054|ACTIVE_COMPARATOR|Control group|Group 2
61927618|NCT05465174|EXPERIMENTAL|Group 1, Arm A: Neoadjuvant nivolumab|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of nivolumab within 14 days - 5 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected recommended phase 2 dose (RP2D) for each agent. Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
61927619|NCT05465174|EXPERIMENTAL|Group 1, Arm B: Neoadjuvant Tovorafenib|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of Tovorafenib within 7 days +/- 2 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent . Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
61927620|NCT05465174|EXPERIMENTAL|Group 1, Arm C: Neoadjuvant combination nivolumab and Tovorafenib|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of nivolumab (14 days -5 days prior) and one dose of Tovorafenib (7days +/- 2 days prior) to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent. Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
61927621|NCT05465174|EXPERIMENTAL|Group 2, Arm A: Neoadjuvant nivolumab|Participants with recurrent craniopharyngioma will receive one (1) dose of nivolumab within 14 days - 5 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent. If participants are eligible based on archival tissue alone, these participants will go directly on to receive combination therapy only.
61927622|NCT05465174|EXPERIMENTAL|Group 2, Arm B: Neoadjuvant Tovorafenib|Participants with recurrent craniopharyngioma will receive one (1) dose of Tovorafenib within 7 days +/- 2 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent.
61927623|NCT05465174|EXPERIMENTAL|Group 2, Arm C: Neoadjuvant combination nivolumab and Tovorafenib|Participants with recurrent craniopharyngioma will receive one (1) dose of nivolumab (14 days -5 days prior) and one (1) dose of Tovorafenib (7 days +/- 2 days) prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent.
61927624|NCT05465174|EXPERIMENTAL|Group 2, Arm D: Non-biopsy/resection participants|Non-biopsy/resection participants with recurrent disease will receive combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent.
62130819|NCT03110549|EXPERIMENTAL|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
62130820|NCT03110549|EXPERIMENTAL|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
62690345|NCT02236013|EXPERIMENTAL|Continuous ASP2215 Exposure during Consolidation (Part 4)|During Consolidation, ASP2215 will be given daily on day 1 up to day 56.
62690346|NCT06640608|EXPERIMENTAL|intervention group ( received ICBT in addition to routine antenatal care)|provide 6 consecutive an online modules
62690347|NCT06640608|NO_INTERVENTION|Control group|Received routine antenatal care only
62130821|NCT03110549|EXPERIMENTAL|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
62130822|NCT03110549|EXPERIMENTAL|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
62130823|NCT03110549|EXPERIMENTAL|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
62130824|NCT03110549|EXPERIMENTAL|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
62130825|NCT03110549|EXPERIMENTAL|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
62322003|NCT05433103|ACTIVE_COMPARATOR|Low-Load Exercise Control|The control group with consist only of low-load resistance training under the supervision of a licensed physical therapist.
62322004|NCT06135597||Aspergillosis|Patients with aspergillosis
62322005|NCT06135597||COVID|Patients with history of COVID infection and without aspergillosis
61927625|NCT05975047|EXPERIMENTAL|LIV001|"Drug: LIV001~Dosage level:~Part A will receive single dose of either one or 10 capsules of 280 mg capsule of IP or placebo on Day 1; Part B participants will receive multiple doses of 280 mg capsule of IP or placebo from Day 1 to Day 14 after overnight fast ;~Dosage form- capsule~Route of administration- Oral"
61927626|NCT05975047|PLACEBO_COMPARATOR|Placebo|Placebo comparator taken by participants randomized to the placebo arm across Part A, B and C of the study.
61927627|NCT06740773||Derivation Cohort|Identification of risk factors, development and internal validation of predictive models
62130826|NCT05351424|EXPERIMENTAL|Audiovisual Intervention- Radiation Therapy Education|Audiovisual video will be provided to the subjects as educational material.
62481562|NCT03712605|EXPERIMENTAL|Arm A (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1. Patients undergo PET-CT, CT, or MRI throughout the trial. Patients may also undergo blood and urine sample collection as clinically indicated at the discretion of the treating investigator.
62481563|NCT03712605|ACTIVE_COMPARATOR|Arm B (standard of care observation, radiation therapy)|Patients receive standard of care observation every 3 months for 1 year, and then every 6 months for 5 years. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1. Patients undergo PET-CT, CT, or MRI throughout the trial. Patients may also undergo blood and urine sample collection as clinically indicated at the discretion of the treating investigator.
61927628|NCT06740773||External Validation Cohort|External validation of the predictive models
61927629|NCT06744400|EXPERIMENTAL|Group 3 : 2 mg/kg/j|Group 3 receives treatment in accordance with health recommendations as part of prophylactic treatment for acute rejection after allogeneic solid organ transplantation, at the minimum dose, i.e., 2 to 5 mg/kg/day for 5 to 21 days.
61927630|NCT06744400|EXPERIMENTAL|Group 2 : 1 mg/kg/j|Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days).
61927631|NCT06744400|EXPERIMENTAL|Group 1 : 0,5 mg/kg/j|Group 1 receive treatment at lower doses than the recommended dose for the same duration (5 days).
61927632|NCT06740552||TTE cohort|The TTE cohort is the finally anlyzed population. The participates are enrolled upon meeting the inclusion/exclusion criteria.
61927633|NCT02956291|EXPERIMENTAL|Newly Diagnosed Brain Tumors|Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.
61927634|NCT02956291|EXPERIMENTAL|Treated tumors with possible recurrence|Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.
61927635|NCT06737601|EXPERIMENTAL|ESWT group|3 shock waves sessions, weekly, EDF 1500 pulses, 0.01-0,05 mJ/mm2 (minilith Storz, Swiss)
61927636|NCT06737601|NO_INTERVENTION|orthesis group|use of metacarpophalangeal orthosis for 4-6 weeks
61927637|NCT02802969|EXPERIMENTAL|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
61927638|NCT06745895|EXPERIMENTAL|Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES)|The MATCHES intervention includes three patient-level intervention strategies that will be rolled out in two waves. Patient-level strategies are: 1) a combined education booklet with information about CRC/CRC screening and HCV infections/liver cancer/HCV screening in English or Spanish, 2) access to free stool-based CRC screening, and 3) access to free HCV antibody testing.
61927639|NCT05119985|ACTIVE_COMPARATOR|Ultrasound guided cannulation|Ultrasound guided insertion of peripheral vein cannula.
61927640|NCT05119985|ACTIVE_COMPARATOR|Cannulation without ultrasound|Catheter insertion by conventional approach, without ultrasound guidance
61927641|NCT04786262|EXPERIMENTAL|VX-880|
61927642|NCT06737653|EXPERIMENTAL|antimicrobial gel containing postbiotics, lactoferrin, aloe barbadensis leaf juice powder and sodium|antimicrobial gel containing postbiotics, lactoferrin, aloe barbadensis leaf juice powder and sodium hyaluronate
61927643|NCT06737653|PLACEBO_COMPARATOR|Placebo group|Placebo gel
61927644|NCT06428019|EXPERIMENTAL|Arm A: Venetoclax + Obinutuzumab|Participants will receive venetoclax in combination with obinutuzumab, with a 5 week venetoclax ramp up.
61927645|NCT06428019|EXPERIMENTAL|Arm B: Venetoclax + Acalabrutinib|Participants will receive venetoclax in combination with acalabrutinib, with a 5 week venetoclax ramp up.
61927646|NCT06428019|EXPERIMENTAL|Arm C: Venetoclax + Acalabrutinib|Participants will receive venetoclax in combination with acalabrutinib, with a modified venetoclax ramp up A.
61927647|NCT06428019|EXPERIMENTAL|Arm D: Venetoclax + Acalabrutinib|Participants will receive venetoclax in combination with acalabrutinib, with a modified venetoclax ramp up B.
61927648|NCT06745466|NO_INTERVENTION|Natural cycle|Participants will undergo study measurements during the follicular phase of their natural menstrual cycle.
61927649|NCT06745466|EXPERIMENTAL|No to Low Endogenous Estrogen|Participants will undergo study measurements during 10 days of daily ganirelix acetate (Antagon) injections.
61927650|NCT06581068|EXPERIMENTAL|AURA assisted ART treatment|The laboratory element of the patient's ART treatment will be automated through the use of the AURA device. This includes sperm preparation and egg retrieval from follicular fluid. 1 out of every 4 eggs will be randomly removed from the AURA system and treated by standard care. The remaining eggs will be maintained in the AURA system and further processed automatically for egg denudation, fertilization, embryo culture, embryo cryopreservation.
62130827|NCT05351424|ACTIVE_COMPARATOR|Written Brochure- Radiation Therapy Education|Written brochures will be provided to the subjects as educational material.
62130828|NCT05351424|EXPERIMENTAL|Audiovisual Intervention- Cancer Clinical Trials|Audiovisual video will be provided to the subjects as educational material.
62322006|NCT06135597||Control|Patients without history of COVID infection and without aspergillosis
62322007|NCT06693804|EXPERIMENTAL|Welch Allyn PanOptic iExaminer Digital Imaging Kit|Novel digital instrument to visualize eyes and ears in clinical practice
61927651|NCT06743880||health care provider group|- Healthcare providers at the Gynecologic Oncology Unit have direct interactions with patients and can significantly influence their knowledge, attitudes, and decision-making regarding HPV vaccination.
62130829|NCT05351424|ACTIVE_COMPARATOR|Written Brochure- Cancer Clinical Trials|Written brochures will be provided to the subjects as educational material.
62130830|NCT03035396|EXPERIMENTAL|Diassess Influenza A and B Test|
62130831|NCT06288607||Patients|Patients with solar lentigo
62130832|NCT04717544|ACTIVE_COMPARATOR|Intervention Arm|"Healthcare providers from clinics participating in the intervention refer existing clients to study coordinators for smoking cessation services, wherein the coordinators link clients to the smoking cessation services, which include: 1) a weekly cognitive-behavioral therapy smoking cessation (CBT) counseling group; and 2) smoking cessation medication, which include varenicline (Chantix), bupropion (Zyban) and nicotine patches, gum, and lozenges. Clients interested in these medications will meet with the prescribing clinician to help choose the best prescription option.~In addition to linking clients to the smoking cessation services, coordinators will invite clients to participate in the outcome study.~Existing clients can sign-up for these services and/or the outcome study directly with the study coordinators and do not require a healthcare provider referral."
62130833|NCT04717544|NO_INTERVENTION|Treatment As Usual Arm|Existing clients can be referred to the outcome study by their healthcare providers from clinics designated as TAU or they can sign-up directly with the study coordinators.
62130834|NCT03773835|EXPERIMENTAL|HSK3486|0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,
62130835|NCT01199133|ACTIVE_COMPARATOR|Dpte and Dfar Allergen Extract|
62130836|NCT01199133|PLACEBO_COMPARATOR|Placebo tablets|
62130837|NCT05045196|EXPERIMENTAL|Patient and family member of patient undergoing elective open heart surgery- Intervention|Family randomized to the intervention group receiving Health-promoting conversation intervention
62130838|NCT05045196|NO_INTERVENTION|Patient and family member of patient undergoing elective open heart surgery- Control|Family of a patient undergoing elective open-heart surgery randomized to the intervention group receiving standard care
62130839|NCT06409299|ACTIVE_COMPARATOR|Azithromycin Oral Suspension 40 mg/ml|
62130840|NCT06409299|PLACEBO_COMPARATOR|Placebo Oral suspension|
62130841|NCT01449123|EXPERIMENTAL|Inhaler|Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
62130842|NCT01925365|EXPERIMENTAL|Wholegrain cereal oats|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.
62130843|NCT01925365|PLACEBO_COMPARATOR|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
62130844|NCT02058108|EXPERIMENTAL|Telbivudine|Patients of any age and weight\< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
62130845|NCT02058108|PLACEBO_COMPARATOR|Placebo|Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
62130846|NCT04854772|EXPERIMENTAL|Mind Body Syndrome Therapy for Long Covid|"The participants will receive an initial one-on-one interview, followed by 1 to 2 hour biweekly group interactive, educational sessions for 12 weeks. This program also includes a day-long retreat at the end of the required course period. Participants will also be provided reading materials to study during the intervention period"
62130847|NCT03085394|ACTIVE_COMPARATOR|Treatment arm|Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
62130848|NCT03085394|PLACEBO_COMPARATOR|Control Arm|Preoperative intravenous administration of 10ml normal saline.
62130849|NCT05408572|EXPERIMENTAL|Single Dose Level 1|6 healthy adults dosed with SON-1010 (Level 1) + 2 healthy adults dosed with Placebo
62130850|NCT05408572|EXPERIMENTAL|Single Dose Level 2|6 healthy adults dosed with SON-1010 (Level 2) + 2 healthy adults dosed with Placebo
62130851|NCT05408572|EXPERIMENTAL|Single Dose Level 3|6 healthy adults dosed with SON-1010 (Level 3) + 2 healthy adults dosed with Placebo
62130852|NCT05408572|EXPERIMENTAL|Single Dose Level 4|6 healthy adults dosed with SON-1010 (Level 4) + 2 healthy adults dosed with Placebo
62130853|NCT05408572|EXPERIMENTAL|Single Dose Level 5|6 healthy adults dosed with SON-1010 (Level 5) + 2 healthy adults dosed with Placebo
62130854|NCT02403297||Healthy|"Saliva will be collected from 58 subjects determined to be healthy according to the protocol."
62130855|NCT02403297||Gingivitis|Saliva will be collected from 58 subjects determined to have gingivitis according to the protocol.
62130856|NCT02403297||Periodontal disease|Saliva will be collected from 58 subjects determined to have periodontal disease according to the protocol.
62130857|NCT04728906|EXPERIMENTAL|Heart patch + cardiomyocytes - hAESC|Patients who undergo bypass (CABG) surgery are given heart patch in areas where grafting (bypass) is not feasible
62130858|NCT05958836||Micra TPS group|
62130859|NCT05958836||Traditional PM group|
62130860|NCT03776500|EXPERIMENTAL|Panel A - Active|N = 6, 150 mg twice daily of PBTZ169
62322008|NCT06693804|ACTIVE_COMPARATOR|Conventional non-digital instrument used in current clinical training and standard practice|Standard practice
62322009|NCT04116502|EXPERIMENTAL|A- Ruxolitinib|Treatment with Ruxolitinib
62322010|NCT04116502|ACTIVE_COMPARATOR|B- Hydroxycarbamide OR Interferon A|Best Available Therapy (BAT), Treatment with hydroxycarbamide OR Interferon A
62322011|NCT00130208|EXPERIMENTAL|Sulodexide|Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
62322012|NCT00130208|PLACEBO_COMPARATOR|Placebo|All patients will be on standard of care ACE or ARBs.
62322013|NCT05838755|EXPERIMENTAL|GSK3858279 Dose 1|Participants will receive GSK3858279 dose 1.
62322014|NCT05838755|EXPERIMENTAL|GSK3858279 Dose 2|Participants will receive GSK3858279 dose 2.
61927652|NCT03900793|EXPERIMENTAL|Dose Escalation and Expansion|"Part 1: This is a study escalating doses (Dose level 1-3) of losartan on a continuous daily dosing schedule and sunitinib (escalating on dose level 4) on a daily dosing with 4 weeks on, 2 weeks off. A cycle of therapy is 6 weeks (42 days).Dosing will be performed based on body surface area (BSA). This portion of the study uses a 3+3 design (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level).~Part 2: Once the Maximally Tolerated Dose (MTD) has been determined, 12 patients will enroll to the expansion cohort. These patients will receive the MTD as long as less then 33% of patients experience dose-limiting toxicities."
61927653|NCT01843413|EXPERIMENTAL|Treatment (SRS)|Patients undergo SRS guided by CT and MRI.
61927654|NCT05093335|EXPERIMENTAL|[68Ga]-Pentixafor|An intravenous bolus of 3 -5 mCi \[68Ga\]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. \[68Ga\]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). \[68Ga\]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.
61927655|NCT05665361|EXPERIMENTAL|1/ Phase I|Sasanlimab and deescalating doses of palbociclib
61927656|NCT05665361|EXPERIMENTAL|2/Phase II|Sasanlimab and palbociclib at the dose determined in Phase I (RP2D)
61927657|NCT02257736|EXPERIMENTAL|Group 1: AAP and apalutamide|Participants will receive apalutamide 240 milligram (mg) (4\*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4\*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
61927658|NCT02257736|PLACEBO_COMPARATOR|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4\*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
61927659|NCT05041426|EXPERIMENTAL|Letermovir|Participants who are CMV seropositive (CMV R+) will receive letermovir prophylaxis for 6 months, and participants who are CMV donor seropositive/recipient seronegative (CMV D+/R-) will receive letermovir prophylaxis for 12 months. Letermovir will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If letermovir is co-administered with cyclosporine A, the dosage of letermovir will be decreased to 240 mg once daily.
61927660|NCT05041426|ACTIVE_COMPARATOR|Valganciclovir|Historical controls will be lung transplant recipients for idiopathic pulmonary fibrosis from 2010-2019 who are CMV R+ or CMV D+/R-. CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
61927661|NCT06534671|EXPERIMENTAL|Diltiazem|IV diltiazem (0.25 mg/kg) will be given over 2 minutes. A second IV dose (0.35 mg/kg) may be given at 10 minutes.
61927662|NCT05267873||Duke Health System Electronic Health Record|Patients who received Duloxetine or Vortioxetine
62690348|NCT05949385|EXPERIMENTAL|ZX-7101A and Itraconazole|D1 and D31 Take ZX-7101A tablet 40mg (1 tablet, 40mg/ tablet）,oral，fasting； D26-D50 Itraconazole capsule 200mg(2 capsules, 100mg/ capsule) ，oral in 30min after breakfast.
62690349|NCT06640868|NO_INTERVENTION|Routine counseling|Randomized to routine counseling at 28-30 weeks
62690350|NCT06640868|ACTIVE_COMPARATOR|Routine counseling + MyChart nurse managing|Randomized to routine counseling at 28-30 weeks; not vaccinated by 34 weeks, and randomized to receive a MyChart message from the nurse encouraging vaccination at 34 weeks
62690351|NCT06640868|ACTIVE_COMPARATOR|Routine counseling + SMFM video|Randomized to routine counseling at 28-30 weeks; not vaccinated by 34 weeks, and randomized to watch the SMFM video on RSV vaccination at a prenatal visit at 34 weeks
62690352|NCT06640868|ACTIVE_COMPARATOR|Routine counseling/visual aid|Randomized to routine counseling and receipt of a visual aid encouraging RSV vaccination at 28-30 weeks
61927663|NCT05267873||Johns Hopkins Health System Electronic Health Record|Patients who received Duloxetine or Vortioxetine
61927664|NCT05267873||Randomized Controlled Trial 1 (NCT01153009)|Patients who received Duloxetine or Vortioxetine
61927665|NCT05267873||Randomized Controlled Trial 2 (NCT01140906)|Patients who received Duloxetine or Vortioxetine
61927666|NCT05267873||Randomized Controlled Trial 3 (NCT00672620)|Patients who received Duloxetine or Vortioxetine
61927667|NCT05267873||Randomized Controlled Trial 4 (NCT00635219)|Patients who received Duloxetine or Vortioxetine
61927668|NCT04947735|EXPERIMENTAL|CYPRESS Extension Test Arm|Single vision, impact resistant spectacle lenses; CYPRESS Test Arm 1 and CYPRESS Test Arm 2 will move into CYPRESS Extension Test Arm
61927669|NCT04947735|PLACEBO_COMPARATOR|CYPRESS Extension Control Arm|Single vision, impact resistant spectacle lenses; CYPRESS Control Arm remains in control lenses as the CYPRESS Extension Control Arm
61927670|NCT06121297|EXPERIMENTAL|CABA-201|"LN Cohort: Infusion of CABA-201 with preconditioning in subjects with LN~Non-renal SLE Cohort: Infusion of CABA-201 with preconditioning in subjects with SLE who do not meet criteria for inclusion in the LN cohort"
61927671|NCT06486948|ACTIVE_COMPARATOR|CT-156|Study App investigational treatment for adult patients diagnosed with Schizophrenia.
61927672|NCT06486948|EXPERIMENTAL|CT-156 + UXR|Study app investigational treatment for adult patients diagnosed with schizophrenia with up to five in-patient visits with three interviews for UXR (user experience research) arm.
61927673|NCT04325282|EXPERIMENTAL|Children with BECTS|Children will receive sham and active rTMS on 2 separate study visits separated by at least 1 week.
62130861|NCT03776500|PLACEBO_COMPARATOR|Panel A - Placebo|N = 2, 150 mg twice daily of PBTZ169 matching placebo
62690353|NCT06640868|ACTIVE_COMPARATOR|Routine counseling/visual aid + MyChart nurse message|Randomized to routine counseling and receipt of a visual aid encouraging RSV vaccination at 28-30 weeks; not vaccinated by 34 weeks, and randomized to receive a MyChart message from the nurse encouraging vaccination at 34 weeks
62481564|NCT06742697|EXPERIMENTAL|HSP Cohort|The whole cohort of HSP patients will receive the same comprehensive neurorehabilitation program aiming at improving gait capabilities (speed and endurance). The content and the dosis of the treatment will be personalized according to patient's specific needs and preferences.
62481565|NCT05291286|EXPERIMENTAL|BXQ-350|BXQ-350 will be administered by IV infusion
62481566|NCT05291286|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% normal saline) will be administered by IV infusion
62690354|NCT06640868|ACTIVE_COMPARATOR|Routine counseling/visual aid + SMFM video|Randomized to routine counseling and receipt of a visual aid encouraging RSV vaccination at 28-30 weeks; not vaccinated by 34 weeks, and randomized to watch the SMFM video on RSV vaccination at a prenatal visit at 34 weeks
62690355|NCT05599321||Historical Controls Cohort|Lung cancer patients who have previously undergone a clinical bronchoscopy. This group represents the current state-of-the-art bronchoscopy practice.
62690356|NCT05599321||Consented Clinical Bronchoscopy Cohort|Lung cancer patients, scheduled for bronchoscopy, who are consented for bronchoscopy assisted by the Virtual Navigator.
62690357|NCT06121921|EXPERIMENTAL|Intervention|Perioperative multi-component intervention
62690358|NCT06121921|NO_INTERVENTION|Control|Routine inpatient care
62690359|NCT06312358|EXPERIMENTAL|Teacher Professional Development Workshop and Coaching|Teachers will participate in a professional development workshop session (approximately 2 hours in duration) followed by 8 weekly coaching sessions (approximately 45-60 minutes in duration). The study team (trained coaches) will utilize the Practice-Based Coaching model (Snyder et al., 2015) to support teachers' use of developmentally appropriate practices in early childhood classrooms. Teachers will be coached to implement strategies that foster responsive and nurturing relationships with young children.
62322015|NCT05838755|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62322016|NCT06030895|EXPERIMENTAL|Sorafenib group|100 patients diagnosed with HCC for whom Sorafenib therapy is prescribed (400 mg twice daily) or (200mg twice daily), will be recruited from Mansoura University Hospital, Mansoura, Egypt.
62322017|NCT02574780|EXPERIMENTAL|Grupo I TFC|Women with lymphedema , perform complex physical therapy with manual lymphatic drainage, compression bandaging and exercises linfomiocinéticos.
62322018|NCT02574780|EXPERIMENTAL|Grupo II TFC X PFM|Standard treatment for lymphedema perform complex physical therapy associated with a muscular strength protocol.Muscle-building arm with load
62322019|NCT03285880|EXPERIMENTAL|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
62322020|NCT03285880|EXPERIMENTAL|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
62322021|NCT03285880|EXPERIMENTAL|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
62481567|NCT01000961|EXPERIMENTAL|RP103 Q12H|
62481568|NCT01000961|ACTIVE_COMPARATOR|Cystagon® Q6H|
62481569|NCT04086485|EXPERIMENTAL|1/Lu-177-DOTATATE + Olaparib escalation|Lu-177-DOTATATE and escalating doses of olaparib to determine the maximum-tolerated dose (MTD)
62481570|NCT04086485|EXPERIMENTAL|2/Lu-177-DOTATATE + Olaparib fixed dose|Lu-177-DOTATATE and olaparib at the MTD
62481571|NCT06356129|EXPERIMENTAL|Golcadomide + R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone)|
62690360|NCT02193347|EXPERIMENTAL|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
62130862|NCT03776500|EXPERIMENTAL|Panel B - Active|N = 6, 300 mg twice daily of PBTZ169
62322022|NCT02954835|ACTIVE_COMPARATOR|Prevena|Subjects randomized to the Prevena dressing will have the dressing in place for 5 to 7 days postoperatively and removed before discharge, or at the first outpatient visit.
62322023|NCT02954835|ACTIVE_COMPARATOR|Traditional Dressing|Subjects randomized to the traditional dressing will undergo dressing changes as per the standard protocol with the first dressing change at postoperative day 2 or 3, or at the discretion of the attending surgeon.
62339811|NCT04853524|EXPERIMENTAL|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) plus JNJ-56136379|Participants will receive a single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 1. Multiple oral doses of JNJ-56136379 once daily on Day 6 to Day 24. A single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 20.
62481572|NCT06356129|PLACEBO_COMPARATOR|Placebo + R-CHOP|
62481573|NCT06742021|EXPERIMENTAL|Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer|A Philips 3.0T MRI scanner was used, with a dStream Torso 32-channel coil. DCE-MRI was performed using a free-breathing sequence with a flow velocity of 3.0 m/s. The image quality assessment in this study was performed by two radiologists (one with 3 years of diagnostic experience and the other with 15 years of diagnostic experience), including both subjective and objective evaluations. Then, dynamic information from the 4D FreeBreathing DCE-MRI images taken before treatment and one week after immunotherapy/targeted therapy, along with routine clinical and pathological data, were used to construct predictive models for the efficacy of immunotherapy and targeted therapy. Finally, the MRI model was compared with the CT model, and the performance of both models was evaluated.
62481574|NCT06559657|EXPERIMENTAL|Wound area and depth measurement|The area of the pressure injuries was measured using digital planimetry, the imitoMeasure mobile application, and the three-dimensional wound measurement method. Depth was measured using a sterile cotton swab and the three-dimensional wound measurement method.
62481575|NCT00369421||Healthy Volunteers|Healthy Volunteers
62481576|NCT00369421||Patients|Patients with unique disorders
62481577|NCT00369421||Unaffected family members|Unaffected family members of patients
62481578|NCT06113705|EXPERIMENTAL|Experimental Arm|Multidisciplinary and innovative approach based on plasma markers of inflammation (cytokines, circulating RNA, and extracellular microvesicles), and multimodal imaging using 18F-GE-180 positron emission tomography (PET) and advanced MRI techniques,
62481579|NCT05187065|EXPERIMENTAL|Mobile-based education and exercise program|Mobile-based education and progressive relaxation and knee exercise program will be applied to the patients in the experimental group.
62690361|NCT05049824|EXPERIMENTAL|SFM Treatment Arm|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion
62690362|NCT03366831|ACTIVE_COMPARATOR|15 minute version without questions|15 minute version of the TMW-Newborn intervention video without questions interspersed
62481580|NCT05187065|NO_INTERVENTION|Standard of care|Mobile-based education and progressive relaxation and knee exercise program will not be applied to the patients in the control group, and the clinical routine will be maintained.
62322024|NCT05635734|EXPERIMENTAL|Experimental arm|"Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
62481581|NCT06289738|EXPERIMENTAL|Experimental|Takayasu Arteritis patients between the ages of 18-65
62481582|NCT04931810|EXPERIMENTAL|All Nations Breath of Life|ANBL is a culturally tailored smoking cessation program that incorporates group-based and individual counseling. Participants may elect to take pharmacotherapy, but are not required to do so.
62481583|NCT02010918|EXPERIMENTAL|glucosamine sulfate /chondroitin sulfate capsule|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
62481584|NCT02010918|EXPERIMENTAL|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
62481585|NCT02010918|ACTIVE_COMPARATOR|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
62481586|NCT03616886|EXPERIMENTAL|Phase I and Phase II Arm A|Patients are treated with paclitaxel, carboplatin, durvalumab and oleclumab.
62481587|NCT03616886|ACTIVE_COMPARATOR|Phase II Arm B|Patients are treated with paclitaxel, carboplatin and durvalumab.
62481588|NCT06725186|EXPERIMENTAL|RELAX Intervention|group-based RELAX telehealth intervention
62690363|NCT03366831|ACTIVE_COMPARATOR|15 minute version with questions|15 minute version of the TMW-Newborn intervention video with questions interspersed
62130863|NCT03776500|PLACEBO_COMPARATOR|Panel B - Placebo|N = 2, 300 mg twice daily of PBTZ169 matching placebo
62322025|NCT03585374|EXPERIMENTAL|A_test drug_Methoxyflurane (Penthrox®)|Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
62481589|NCT06725186|ACTIVE_COMPARATOR|Psychoeducational Waitlist Control|The psychoeducational component will consist of infographics regarding emotion regulation strategies and managing interpersonal conflict.
62481590|NCT05720949|NO_INTERVENTION|Group 1 - Control|Patients randomized to this group will receive an adductor canal block (ACB) and Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) nerve block.
62690364|NCT03366831|ACTIVE_COMPARATOR|7 minute version without questions|7 minute version of the TMW-Newborn intervention video without questions interspersed
62690365|NCT03366831|ACTIVE_COMPARATOR|7 minute version with questions|7 minute version of the TMW-Newborn intervention video with questions interspersed.
62690366|NCT03907202|ACTIVE_COMPARATOR|KBP-089|"Three cohorts:~* Cohort 1: starting dose 5 µg, maximum dose 20 µg, uptitration step 7 days, dose increment 5 µg~* Cohort 2: starting dose 7.5 µg, maximum dose 60 µg, uptitration step 3 days, dose increment 7.5 µg~* Cohort 3: starting dose 5 µg, maximum dose 120 µg, uptitration step 3 days, dose increment 5, 10, 15 and 20 µg"
62690367|NCT03907202|PLACEBO_COMPARATOR|Placebo|For all the cohorts, sentinel dosing for the first two patients will be performed 1:1 in a blinded manner.
61927674|NCT06743503|EXPERIMENTAL|treatment group|"Interventions: UB-VV400 with or without Rapamycin. Dosage and Administration:single dose of UB-VV400, 3.5 × 10\^8 TU, 10 × 10\^8 TU, 30 × 10\^8 TU, 90× 10\^8 TU , intravenous injection at Day 1.~For subjects receiving rapamycin, dosing should be planned to be initiated on Study Day 4 and continued for up to 60 days, as tolerated ."
62130864|NCT03776500|EXPERIMENTAL|Panel C - Active|N = 6, 600 mg once daily of PBTZ169
62130865|NCT03776500|PLACEBO_COMPARATOR|Panel C - Placebo|N = 2, 600 mg once daily of PBTZ169 matching placebo
62130866|NCT03776500|EXPERIMENTAL|Panel D - Active|N = 6, 600 mg twice daily of PBTZ169
62339812|NCT03550131|ACTIVE_COMPARATOR|Standard intervention|"Reducing Disabilities in Alzheimer's Disease (RDAD):~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
62481591|NCT05720949|EXPERIMENTAL|Group 2 - Intervention|"Patients randomized to this group will receive an adductor canal block (ACB), Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) nerve block, and the genicular nerve block (intervention).~The genicular nerve block is a total of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius."
62481592|NCT06628258|EXPERIMENTAL|Dry, sensitive, oily, mixed, normal skin type|"Test Product Name: Moiz Cleansing Lotion Product By: Glowderma Lab Private Limited Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.~Frequency: Twice a Day Route of Administration: Topical."
62481593|NCT06742996|EXPERIMENTAL|Arm A: sonrotoclax plus zanubrutinib|Sonrotoclax and zanubrutinib will be administered in combination.
62481594|NCT06742996|PLACEBO_COMPARATOR|Arm B: placebo plus zanubrutinib|Placebo and zanubrutinib will be administered in combination.
62481595|NCT04654143|EXPERIMENTAL|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo.
62481596|NCT04654143|EXPERIMENTAL|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo.
62690368|NCT02796482|OTHER|EnergieShake 1.5 kcal Complete Intervention|Single am of intervention of ONS, EnergieShake 1.5 kcal Complete, in the open label study are to be given to participants for 8 days, i.e. two bottles twice daily.
62130867|NCT03776500|PLACEBO_COMPARATOR|Panel D - Placebo|N = 2, 600 mg twice daily of PBTZ169 matching placebo
62130868|NCT02831231|ACTIVE_COMPARATOR|Xanomeline plus placebo|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
62481597|NCT04654143|EXPERIMENTAL|Food Effect|This cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo. Each participant will receive a single oral dose of BVL-GSK098 or placebo administered after the participant eats a high-fat, high calorie breakfast.
62322026|NCT03585374|ACTIVE_COMPARATOR|B_comparator_Morphine/Paracetamol/Ketoprofen|"The comparator to be administered will vary according to pain intensity and local clinical practice.~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .~Maximum time of infusion 10 minutes."
62322027|NCT03756974|EXPERIMENTAL|BX-1 (dronabinol)|BX-1
62481598|NCT04461964|EXPERIMENTAL|treatment group|Eligible participants will be identified by their treating physician and referred to the study research coordinator for enrollment. NYU standard practice in relation to pre-operative and intra-operative imaging studies will be explained. The role of the MvIGS system in this study will then also be explained. In each subject, they will perform posterior instrumentation utilizing the MvIGS spine navigation system for pedicle screw guidance and record data for intraoperative study endpoints
62481599|NCT06407505|EXPERIMENTAL|Acupressure group|During the episiotomy repair, the LI4 acupuncture point on the right hand of the participants in the experimental group will be compressed 10 times for 30 s in succession, followed by a 10 s break.
62481600|NCT06407505|PLACEBO_COMPARATOR|Placebo Group|A different point 1-1.5 cm away from the LI4 acupuncture point on the right hand of the participants in the placebo group will be compressed.
62481601|NCT06407505|NO_INTERVENTION|Control Group|Group receiving routine care.
62481602|NCT06737913|EXPERIMENTAL|HAIBrave-001 Arm 1|Arm 1 to receive Hepatic arterial infusion (HAI) of Adebrelimab (ADE) + intravenous infusion (IV) of Bevacizumab (Bev.) + Hepatic artery infusion chemotherapy (HAIC) with FOLFOX regimen
62481603|NCT06737913|EXPERIMENTAL|HAIBrave-001 Arm 2|Intravenous infusion (IV) of Adebrelimab (ADE) + intravenous infusion (IV) of Bevacizumab (Bev.)+ HAIC with FOLFOX regimen
62481604|NCT06728293|EXPERIMENTAL|Liver-Link Arm|Those randomized to the Liver-Link portion of the study will proceed through the Liver-Link component intervention. Participation in this study will last 6 months. Participants in this group are assessed for knowledge of their disease, quality of life, substance use, and for social needs at the beginning of the program. Those who screen positive for social needs or high-risk alcohol will see social work. Participants will attend 3 support groups and compelte exit surveys. Participants will have 3 milestone checks during the 6 month study period and will be referred back to social work if they do not meet milestones. Participants will also have a knowledge assessment after a total of 2 HCC-related visits.
62481605|NCT06728293|NO_INTERVENTION|Standard of Care Arm|Individuals in the standard of care portion of the study will complete several questionnaires at the enrollment visit . Over the duration of study participation (6 months), participants in this arm may meet with a social worker as part of their standard health care treatment and will receive education via these standard of care visits. After at least two visits related to HCC clinical care, and participants in this arm will be contacted and will be asked to complete the knowledge assessment tool. At tne end of study they will complete exit survieys via redcap or phone.
62130869|NCT02831231|EXPERIMENTAL|Xanomeline plus trospium|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose
62130870|NCT04729972|EXPERIMENTAL|NT-501 CNTF Implant|Participants from the NTMT-01/02 Extenstion study or participants from the NTMT-03 study which received an implant Studies with a CNFT implant in one eye will receive an implant in the fellow eye
62130871|NCT04215172||macrolides group|"Every patient of this group will be educated and instructed about usage, dosing and side effects of the drug.~Dose: azithromycin 500 mg three times weekly for 6 months. added to the conventional treatment."
62130872|NCT04215172||conventional group|Every patient of this group will receive the conventional treatment.
62130873|NCT03752034|EXPERIMENTAL|Muscle Fiber Fragments (MFF)|Participants undergoing rotator cuff repair will have autologous muscle tissue harvested. The tissue will be processed to obtain Muscle Fiber Fragments (MFFs) and administered via direct injection into the supraspinatus muscle belly.
62130874|NCT00610649|EXPERIMENTAL|Part 1: Block A MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days.
62130875|NCT00610649|PLACEBO_COMPARATOR|Part 1: Block A Placebo|Participants receive placebo BID for a total of 16 days.
62130876|NCT00610649|EXPERIMENTAL|Part 1: Block B MK-8777|Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 13 days.
62130877|NCT00610649|PLACEBO_COMPARATOR|Part 1: Block B Placebo|Participants receive placebo BID for a total of 13 days.
62130878|NCT00610649|EXPERIMENTAL|Part 1: Block C MK-8777|Participants receive MK-8777 initiated at 300 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 10 days.
62130879|NCT00610649|PLACEBO_COMPARATOR|Part 1: Block C Placebo|Participants receive placebo BID for a total of 10 days.
62130880|NCT00610649|EXPERIMENTAL|Part 1: Block D MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum dose determined by the results of Block A. Participants receive MK-8777 for a total of 13 days.
62130881|NCT00610649|PLACEBO_COMPARATOR|Part 1: Block D Placebo|Participants receive placebo BID for a total of 13 days.
62322028|NCT03756974|PLACEBO_COMPARATOR|Placebo|Placebo of BX-1
62322029|NCT00526864||Elderly patients|
62322030|NCT00526864||HIV infected patients|
62130882|NCT00610649|EXPERIMENTAL|Part 2: MK-8777 200 mg|Participants receive MK-8777 100 mg BID for 27 days followed by one day of 100 mg QD. Participants receive MK-8777 for a total of 28 days.
62130883|NCT00610649|EXPERIMENTAL|Part 2: MK-8777 800 mg|Participants receive MK-8777 200 mg BID for 3 days followed by 400 mg BID for 24 days followed by one day of 400 mg QD. Participants receive MK-8777 for a total of 28 days.
62130884|NCT00610649|PLACEBO_COMPARATOR|Part 2: Placebo|Participants receive placebo BID for 27 days followed by one day of placebo QD. Participants receive placebo for 28 days.
62130885|NCT05459233|OTHER|Doppler-echocardiography|Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements.
62690369|NCT04511468|EXPERIMENTAL|Experimental Group|A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard healthy lifestyle intervention
62690370|NCT04511468|PLACEBO_COMPARATOR|Control group|Placebo with standard healthy lifestyle intervention
61927675|NCT05423730|EXPERIMENTAL|WHITE WINE FOLLOWED BY WHITE GRAPE JUICE|"Participants will be randomized into one of the study drinking sequence groups: white wine followed by white grape juice or white grape juice followed by white wine.~The research study procedures include one screening visit to obtain informed consent, four study visits with blood draws, and ten weekly phone calls and online questionnaires over the ten weeks of the study.~-3 weeks of daily white wine followed by 3 weeks of daily white grape juice"
62130886|NCT05459233|OTHER|Invasive hemodynamic measurements|Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording).
62322031|NCT00526864||Immunosuppressed patients|
62322032|NCT05727566||Patients with primer myofascial pain sydrome|pain for at least three months (myofascial pain) reproductive-aged married womens (18-50 years)
62322033|NCT05727566||Healthy controls|Healthy control of reproductive-aged married women with compatible sociodemographic characteristics
62322034|NCT01391312|ACTIVE_COMPARATOR|botulinum toxin Type A|Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
62322035|NCT01391312|PLACEBO_COMPARATOR|placebo (Normal Saline)|Normal Saline (placebo) injected into the glabellar region on Day 0.
62322036|NCT02821793||Elderly patient (70 years and older)|
62322037|NCT02821793||Young patient (18 years - 69 years)|
62322038|NCT05725798||DM and Sitagliptin treatment|Cardiac surgery patients who suffer from diabetes mellitus type 2 and take Sitagliptin.
62322039|NCT05725798||DM without Sitagliptin treatment|Cardiac surgery patients who suffer from diabetes mellitus type 2 and do not take Sitagliptin.
62322040|NCT05725798||No DM|Cardiac surgery patients who do not suffer from diabetes mellitus type 2 and do not take Sitagliptin.
62322041|NCT06300762|EXPERIMENTAL|Cutimed Sorbion products|Within this arm the Cutimed Sorbion (Cutimed® Sorbion® Sachet/Sana/Border) products will be used for exudate managment.
62322042|NCT06300762|ACTIVE_COMPARATOR|Zetuvit (RespoSorb) products|Within this arm the comperator products Zetuvit® Plus/(RespoSorb® Super), Zetuvit® Plus Silicone/(RespoSorb® Silicone) and Zetuvit® Plus Silicone Border/(RespoSorb® Silicone Border) will be used for exudate management.
62322043|NCT02773914|EXPERIMENTAL|CGA intervention|The CGA intervention will include multidisciplinary teams consisting of physician, nurse (RN), physiotherapist (PT), occupational therapist (OT) and social worker (SW). The team will work according to CGA, and have the primary and continuing responsibility for planning of hospital care and discharge. CGA will include assessment of socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, as well as treatment and planning for discharge and follow-up.
62322044|NCT02773914|NO_INTERVENTION|Control group|The control group receives usual hospital care, that is care given at an ordinary medical hospital ward, without the specialized multi-disciplinary team approach and CGA.
62690371|NCT03683251|EXPERIMENTAL|PDS Implant Cohort 1 (US only)|"Participants with PDS implant from Study GX28228 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
62130887|NCT01467375|EXPERIMENTAL|A|
62130888|NCT02462616||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
62130889|NCT00441298|EXPERIMENTAL|1|Tenofovir gel (a reverse transcriptase inhibitor)
62130890|NCT00441298|PLACEBO_COMPARATOR|2|Universal HEC placebo
62130891|NCT04788212|EXPERIMENTAL|GBAT|10-week behavioral activation treatment group.
62130892|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
62130893|NCT01850459||IQ-Matched Control Subjects|
62130894|NCT01850459||Age-Matched Neurotypical Controls|
62130895|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
62130896|NCT04533061||Lung Transplant, Vaccine|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
62130897|NCT04533061||Healthy Control, Vaccine|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
62130898|NCT05229835|EXPERIMENTAL|Time restricted eating|Tasks for participants are to fast for 14 h during the day and eat 10h during 12 weeks period
62130899|NCT05229835|EXPERIMENTAL|Time restricted eating combined with exercise|Tasks for participants are to fast for 14 h during the day and eat 10h during 12 weeks period combined with aerobic exercise 3 times a week.
62130900|NCT05229835|EXPERIMENTAL|Exercise|Tasks for participants are to perform aerobic exercise 3 times a week.
61927676|NCT05423730|EXPERIMENTAL|WHITE GRAPE JUICE FOLLOWED BY WHITE WINE|"Participants will be randomized into one of the study drinking sequence groups: white grape juice followed by white wine.~The research study procedures include one screening visit to obtain informed consent, four study visits with blood draws, and ten weekly phone calls and online questionnaires over the ten weeks of the study.~- 3 weeks of daily white grape juice followed by 3 weeks of daily white wine"
62339813|NCT03550131|EXPERIMENTAL|Personalized intervention|"Innovations in Dementia Empowerment and Action (IDEA):~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
61927677|NCT04273555|EXPERIMENTAL|[18F]-Fluorodeoxyglucose (FDG) PET/ MRI|
61927678|NCT03366272|ACTIVE_COMPARATOR|(R)-GemOx|eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)
62690372|NCT03683251|EXPERIMENTAL|PDS Implant Cohort 2 (US only)|"Participants with PDS implant from Study GR40548 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
61927679|NCT03366272|EXPERIMENTAL|Nivo-(R)-GemOx|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
61927680|NCT06346886|EXPERIMENTAL|Intervention Group|African American adults with uncontrolled hypertension (HTN) will be assigned to complete an 11 week guided intervention using the FAITH! HTN app.
61927681|NCT06346886|NO_INTERVENTION|Control Group|African American adults with uncontrolled hypertension (HTN) will receive the standard of care of HTN management.
61927682|NCT06745843|OTHER|Participants|Questionnaire sent to patients
61927683|NCT06328608|EXPERIMENTAL|Single Arm - Pegunigalsidase alfa (PRX-102)|"For Cohort C, PXR-102 administered every two weeks at 1.0 mg/kg is believed to be the minimum effective dose.~For Cohorts A and B, the starting dose will be 1.0 mg/kg every two weeks but it may be adjusted on the outcomes of Stage I, with the support of the Data Safety Monitoring Board."
61927684|NCT05328908|EXPERIMENTAL|Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC)|
61927685|NCT05328908|ACTIVE_COMPARATOR|Arm B: Investigator's Choice|Treatment with Regorafenib or TAS-102
61927686|NCT06744608|ACTIVE_COMPARATOR|Structured Myofascial Release|The treatment program consisting of myofascial release techniques includes the following applications; 1. Anterolateral abdominal wall release (Until relaxation is felt); Along the fundus of the uterus, along the ovaries and the broad ligament of the uterus, combined mobilization with rotation of the uterus and hips in the supine position and sacral mobilization for three minutes. Myofascial release was started by placing the fingers/dorsal side of the hand on the fascia. Pressure was applied on the soft tissue. After the restricted layer was felt, the fascia was moved along the surface while in contact with the lower layers. The technique was applied for an average of 60-90 seconds, but if necessary, it was continued until relaxation was felt.
61927687|NCT06744608|ACTIVE_COMPARATOR|TENS (transcutaneous electrical nerve stimulation)|"The TENS (transcutaneous electrical nerve stimulation) treatment program was applied by a physiotherapist using two 50X50 mm electrodes on the lower abdomen using conventional TENS at 200 μs, 100 Hz, and 30 min.~."
61927688|NCT06744608|ACTIVE_COMPARATOR|lifestyle changes|Within the scope of education including lifestyle changes; Good nutrition. (what to take and what to avoid), supplements, relaxation training, meditation, exercise recommendations, avoiding tobacco smoke, warm showers, quality sleep (at least 6-8 hours), wearing comfortable clothes are included in the recommendations.
61927689|NCT04703166||Participants with Atrial Fibrillation or have Moderate-high risk factors for Atrial Fibrillation|"Participants who have atrial fibrillation or have moderate to high-risk factors for the development of atrial fibrillation as verified by the Atherosclerotic CardioVascular Disease (ASCVD) risk calculation tool.~Participants will be provided with a Samsung Galaxy Watch Active2 to wear daily and will also be asked to wear an ECG patch for 30-days at baseline, 6, 9 and 12 months.~A Cardiac MRI (CMR) will be taken at baseline and at 12 months."
61927690|NCT06744270|NO_INTERVENTION|Control group|The group in which no procedure was performed on the palatal wound area after free gingival grafting
61927691|NCT06744270|EXPERIMENTAL|i-PRF group|Immediately after the SDG operation, the venous blood taken from the patient will be centrifuged for 3 minutes at 2300 rpm in a centrifuge (PC-O2, Process for PRF, Nice, France) and two layers will be obtained: the lower layer is red blood cells and the upper layer is i-PRF. The i-PRF in the upper part of the tube will be collected with a syringe and transferred to the metal godet. 20-25 minutes will be waited for polymerization. After polymerization, the polymerized i-PRF will be applied to the wound surface in the donor area.
61927692|NCT06744270|EXPERIMENTAL|low-dose laser group|In the laser group, low-dose laser will be applied to the palatal donor area immediately after the FGG operation, on the 3rd, 5th, 7th and 14th days.
61927693|NCT06736327|EXPERIMENTAL|SKB500|Subjects will receive SKB500 once every three weeks (Q3W).
61927694|NCT06744764|EXPERIMENTAL|Haematology Patients|Patients will receive 1.5mT magnetic therapy twice per week for 4 consecutive weeks.
61927695|NCT06744764|NO_INTERVENTION|Haematology Patients (Case-matched)|Case-matched haematology patients will be recruited after 20 haematology patients receiving the intervention has been recruited. The parameters for matching would be chemotherapy vs bone marrow transplant, age and fitness level according to the short physical performance battery (SPPB) score (0-2, 3-9, 10-12).
61927696|NCT06744764|EXPERIMENTAL|Healthy Volunteers (PEMF)|Healthy volunteers will receive 1.5mT magnetic therapy twice per week for 4 consecutive weeks.
62481606|NCT06742788|EXPERIMENTAL|the taVNS group|The taVNS group receives Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) along with In Vitro Fertilization (IVF) treatment. The taVNS protocol is set at a pulse width of 500 µs and a frequency of 25 Hz, with an intensity value of 5 mA. The stimulation is to be carried out for a total of 2 hours daily, with the sessions divided into four parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.
61927697|NCT06744764|SHAM_COMPARATOR|Healthy volunteers (Sham)|Healthy volunteers will place their legs in the PEMF device, same as the volunteers receiving the therapy, twice per week for 4 consecutive weeks. However, no magnetic stimulation will be given to this group.
61927698|NCT06744426|EXPERIMENTAL|BR1015|
61927699|NCT06744426|ACTIVE_COMPARATOR|BR1015-2 + BR1015-3|
61927700|NCT03394612|OTHER|Option 1|Location A is the experimental area and Location B is the control area.
61927701|NCT03394612|OTHER|Option 2|Location A is the control area and Location B is the experimental area.
61927702|NCT05322590|EXPERIMENTAL|BXQ-350|BXQ-350 will be administered by IV infusion
61927703|NCT05322590|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% normal saline) will be administered by IV infusion (Stage 2 only)
62130901|NCT05229835|NO_INTERVENTION|Control|Tasks for participants are keeping their daily habits
62130902|NCT01622400|EXPERIMENTAL|Therapeutic education HTA Vasc|125 subjects who participate in the therapeutic education program
62322045|NCT02292199|EXPERIMENTAL|TENS High Frequency 100 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
62322046|NCT02292199|ACTIVE_COMPARATOR|TENS Low Frequency 4 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
61927704|NCT05471479|EXPERIMENTAL|AC administration|Participants will receive 1g/kg up to a maximum of 50g of activated charcoal by mouth or by naso-gastric tube. The intervention is giving over 15 minutes, as recommended. Activated charcoal can be mixed in a black soft drink to improve palatability and treatment adherence which is often done in usual practice.
61927705|NCT05471479|ACTIVE_COMPARATOR|No AC|Participants will not receive any activated charcoal
61927706|NCT06737289|EXPERIMENTAL|Guide Surgery Arm|Use of Surgical Guide
61927707|NCT06737289|PLACEBO_COMPARATOR|Control|Hand Free Implant Placement
62322047|NCT02292199|PLACEBO_COMPARATOR|TENS Placebo|The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
62322048|NCT05943977|EXPERIMENTAL|130 mg MB-102 DMID, then 130 mg MB 102-OMID|Participants will receive a single 130 mg dose of the MB-102 Domestic Manufactured Investigational Drug (DMID), and blood and urine samples will be collected per protocol. There will be a 5-day washout period between treatments, and then participants will receive a single 130 mg dose of the MB-102 Overseas Manufactured Investigational Drug (OMID). Blood and urine samples will be collected per protocol
62322049|NCT05943977|EXPERIMENTAL|130 mg MB-102 OMID, then 130 mg MB 102-DMID|Participants will receive a single 130 mg dose of the MB-102 Overseas Manufactured Investigational Drug (OMID), and blood and urine samples will be collected per protocol. There will be a 5-day washout period between treatments, and then participants will receive a single 130 mg dose of the MB-102 Domestic Manufactured Investigational Drug (DMID). Blood and urine samples will be collected per protocol.
62322050|NCT05943977|EXPERIMENTAL|Participants with eGFR ≥ 70 mL/min/1.73 m^2|130 mg of the MB-102 Domestic Manufactured Investigational Drug (DMID) will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR ≥ 70 mL/min/1.73 m\^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System
62322051|NCT05943977|EXPERIMENTAL|Participants with eGFR < 70 mL/min/1.73 m^2|130 mg of the MB-102 Domestic Manufactured Investigational Drug (DMID)will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR \< 70 mL/min/1.73 m\^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System
62322052|NCT05239728|EXPERIMENTAL|Belzutifan + Pembrolizumab|Participants receive belzutifan 120 mg orally once daily (QD) for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks (Q6W) for up to 9 administrations (up to approximately 54 weeks).
62322053|NCT05239728|EXPERIMENTAL|Placebo + Pembrolizumab|Participants receive placebo orally QD for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once Q6W for up to 9 administrations (up to approximately 54 weeks).
62322054|NCT06611748|EXPERIMENTAL|KeyGrip device implantation|"The KeyGrip system components will be implanted in a single surgical procedure, lasting up to 90 minutes.~For this study, a small receiver will be placed under the skin in the forearm. Two to four stimulating electrodes will be surgically placed in muscles of the hand or arm. Wires from these electrodes will be tunneled beneath the skin and connected to the receiver device located in the forearm.~The study participant will control the electrical stimulation by using a phone app that communicates to a power unit that is placed on the skin over the receiver. Following implantation of the device, periodic evaluations will be performed to assess their condition, and the operation and usefulness of the device.~Depending on the study participant's usage level, they may need to recharge the batteries every night."
62322055|NCT06062368|NO_INTERVENTION|Standard Duration|The participant will undergo an MRI scan using the manufacturer's rate of entry into and exit from the MRI machine. This rate of entry and exit is 20 seconds.
62322056|NCT06062368|EXPERIMENTAL|1-minute entry|The participant will undergo an MRI scan using a slower rate of entry than that specified by the manufacturer. This rate of entry is one minute (60 seconds).
62322057|NCT06062368|EXPERIMENTAL|2-minute entry|The participant will undergo an MRI scan using a slower rate of entry than that specified by the manufacturer. This rate of entry is two minutes (120 seconds).
61927708|NCT05276570|EXPERIMENTAL|ARO-RAGE|ARO-RAGE Inhalation
61927709|NCT05276570|PLACEBO_COMPARATOR|Placebo|(0.9% NaCl)
61927710|NCT06735625|EXPERIMENTAL|sickle cell patients over 15 and a half years old|sickle cell patients over 15 and a half years old with SS or Sβ0 phenotype
61927711|NCT06735625|OTHER|control patients over 15 and a half years old|control patients over 15 and a half years old without hemoglobin abnormalities, recruited at the hospital
61927712|NCT06735625|EXPERIMENTAL|pediatric sickle cell patients (aged between 3 and 15 and a half years)|pediatric sickle cell patients (aged between 3 and 15 and a half years) with SS or Sβ0 phenotype
61927713|NCT06735625|OTHER|pediatric control patients (aged between 3 and 15 and a half years)|pediatric control patients (aged between 3 and 15 and a half years) without hemoglobin abnormalities, recruited at the hospital
62130903|NCT01622400|NO_INTERVENTION|Control group|125 subjects who don't participate in the therapeutic education program
62130904|NCT01676558|EXPERIMENTAL|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
61927714|NCT05058651|EXPERIMENTAL|Arm I (atezolizumab, platinum drug, etoposide)|During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
61927715|NCT05058651|EXPERIMENTAL|Arm II (atezolizumab, platinum drug, etoposide, observation)|During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
61927716|NCT05058651|ACTIVE_COMPARATOR|Arm III (platinum drug, etoposide, observation)|During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
62322058|NCT06062368|EXPERIMENTAL|3-minute entry|The participant will undergo an MRI scan using a slower rate of entry than that specified by the manufacturer. This rate of entry is three minutes (180 seconds).
62322059|NCT06693596||Group 1: Surgical management|Patients aged ≤ 20 years of age recommended for surgery at that visit due to a suspicion of malignancy or pain.
62322060|NCT06693596||Group 2: Conservative management (follow-up)|Patients aged ≤ 20 not recommended for surgery due to suspicion of malignancy/complications, for which subjective impression was benign for all visits, and for which the tumour was still present at the next visit.
61927717|NCT00330798|EXPERIMENTAL|Nevanac|One drop, three times daily, in the assigned eye for the first three postoperative days
61927718|NCT00330798|PLACEBO_COMPARATOR|Acular LS|One drop, three times daily, in the assigned eye for the first three postoperative days
61927719|NCT06672666|EXPERIMENTAL|Hemp Derived Cannabidiol Extract|SunFlora's CBD Extract 50mg to 150mg titrated over 4 weeks
61927720|NCT06672666|PLACEBO_COMPARATOR|Placebo|Placebo substance to reflect same consistency as the experimental drug
62130905|NCT00639860|EXPERIMENTAL|Placing OSSIX-Plus in Extraction Site|Placement of OSSIX-Plus, a resorbable collagen membrane, and the promotion of bone healing following exodontia.
62130906|NCT02168400|EXPERIMENTAL|active tDCS|Subjects that are randomly assigned to this arm will receive 10 active transcranial direct current stimulation (tDCS) sessions
62130907|NCT02168400|SHAM_COMPARATOR|sham tDCS|Subjects randomly assigned to sham-tDCS (transcranial direct current stimulation) will receive very low current stimulation at beginning and end of session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
62130908|NCT02189915|EXPERIMENTAL|Creatine monohydrate|
62130909|NCT02487069|EXPERIMENTAL|MSD group|The patients will received HSCT from MSD.
62130910|NCT02487069|EXPERIMENTAL|MUD group|The patients will received HSCT from MUD.
62130911|NCT02487069|EXPERIMENTAL|HRD group|The patients will received HSCT from HRD.
62130912|NCT00436631|EXPERIMENTAL|diet|
62130913|NCT04433975|EXPERIMENTAL|Psychosocial Pain Management (PPMI)|Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
62130914|NCT04433975|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Two individual telephone educational sessions with research study therapist.
62130915|NCT06545565|EXPERIMENTAL|sodium acetate|
62130916|NCT06545565|ACTIVE_COMPARATOR|Sodium Chloride|
62322061|NCT03380117|EXPERIMENTAL|eBridge Online Counseling|In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students have the opportunity to engage with eBridge counselors via online dialogues, in which students and counselors exchange messages using a secure website.
62322062|NCT03380117|NO_INTERVENTION|Control|In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
62322063|NCT02320799|ACTIVE_COMPARATOR|treatment as usual|Usual Clinic psychosocial treatment
62322064|NCT02320799|EXPERIMENTAL|interpersonal psychotherapy|Interpersonal Psychotherapy is an evidence-based structured, brief psychotherapy which focuses on improving relationships in order to improve mood and reduce anxiety.
61927721|NCT05955261|EXPERIMENTAL|Low Risk|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Cytabrine, Danunorubicin Hydrochloride, Gemtuzumab Ozogamicin, Etoposide, Mitoxantrone Hydrochloride, Gilteritinib"
62130917|NCT01003405|EXPERIMENTAL|KUC-7483|
62130918|NCT00273624|EXPERIMENTAL|olanzapine|10 mg Olanzapine
62130919|NCT00273624|PLACEBO_COMPARATOR|placebo|Placebo
62130920|NCT01370343|EXPERIMENTAL|PF-04991532 alone|
62130921|NCT01370343|EXPERIMENTAL|PF-04991532 + cyclosporine|
62130922|NCT01227265|EXPERIMENTAL|Preladenant 2 mg|Participants received 2 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
62130923|NCT01227265|EXPERIMENTAL|Preladenant 5 mg|Participants received 5 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
62130924|NCT01227265|PLACEBO_COMPARATOR|Placebo|Participants received preladenant-matching placebo as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extention trial or return for a follow-up visit two (2) weeks later.
62339814|NCT03971084|PLACEBO_COMPARATOR|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
62481607|NCT06742788|SHAM_COMPARATOR|the staVNS group|The staVNS group receives sham transcutaneous auricular vagus nerve stimulation, along with In Vitro Fertilization (IVF) treatment. The staVNS protocol is set at a pulse width of 500 µs and a frequency of 1 Hz, with an intensity value of 5 mA. The stimulation of 1 Hz acts as a therapeutic signal below the threshold level and functions as a sham stimulus. The stimulation is to be carried out for a total of 2 hours daily, with the sessions divided into four parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.
62690373|NCT03683251|EXPERIMENTAL|PDS Implant Cohort 3 (US only)|"Participants in the intravitreal ranibizumab arm of Study GX28228 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
62690374|NCT03683251|EXPERIMENTAL|PDS Implant Cohort 4 (US only)|"Participants in the intravitreal ranibizumab arm of Study GR40548 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
62690375|NCT03683251|EXPERIMENTAL|PDS Implant Cohort 5 (ex-US only)|Participants from Study WR42221 who completed Week 24 but were not eligible to be randomized within WR42221 and who will be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
61927722|NCT05955261|EXPERIMENTAL|Intermediate Risk|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Cytabrine, Danunorubicin Hydrochloride, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Etoposide, Idarubin Hydrochloride, Mitoxantrone Hydrochloride, Gilteritinib"
61927723|NCT05955261|EXPERIMENTAL|High Risk|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Azacitidine, Cytabrine, Danunorubicin Hydrochloride, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Etoposide, Idarubin Hydrochloride, Gilteritinib"
61927724|NCT06418711|EXPERIMENTAL|Clofazimine Inhalation Suspension|MNKD-101 (Clofazimine Inhalation Suspension) is a micronized suspension with a concentration of 20 mg/mL. Study drug will be inhaled using the PARI breath-enhanced jet nebulizer system daily for 28 days in Cycle 1. Cycle 2 will commence after 56 days off treatment and resume daily for 28 days. Dose: 80 mg
61927725|NCT06418711|PLACEBO_COMPARATOR|Placebo|The placebo is comprised of isotonic saline (0.9% weight/volume sodium chloride). Study drug will be inhaled using the PARI breath-enhanced jet nebulizer system daily for 28 days in Cycle 1. Cycle 2 will commence after 56 days off treatment and resume daily for 28 days.
62339815|NCT03971084|ACTIVE_COMPARATOR|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
62481608|NCT06742788|NO_INTERVENTION|the IVF control group|The IVF control group refers to receiving only in vitro fertilization (IVF) treatment without any additional Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) treatment.
62481609|NCT03500081||Cancer Patients|Cancer patients with any solid tumor type planning to undergo a course of radiation therapy. Seventy-five patients in this group with any solid tumor type will consent to the genomic biomarker sub-study, which will be conducted with biopsy tissue samples to determine how genomic predictors of radiation response may correlate with tumor changes as seen on MRIs acquired during treatment.
62690376|NCT03683251|EXPERIMENTAL|PDS Implant Cohort 6 (ex-US only)|Participants from Study WR42221 randomized to the Q24W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
62690377|NCT03683251|EXPERIMENTAL|PDS Implant Cohort 7 (ex-US only)|Participants from Study WR42221 randomized to the Q36W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q36W
62690378|NCT03683251|EXPERIMENTAL|Sub-study 1: PDS Implant|Participants will receive PDS implant using TPC on Day 1 followed by refill-exchanges of ranibizumab 100 mg/mL via the PDS Q24W.
61927726|NCT06740838||Post-DXM ARR development cohort|Data from the first half of participants data will be used to generate post-DXM ARR (and possibly Ald) thresholds, which will be subsequently temporally validated in the confirmatory cohort.
61927727|NCT06740838||Post-DXM ARR confirmatory cohort|Post-DXM ARR thresholds will be applied among participants of the confirmatory cohort, however, these will also undergo the medication withdrawal, OSLT, and other PA confirmatory tests if indicated.
61927728|NCT05851443|PLACEBO_COMPARATOR|Inhaled Corticoseroid Long Acting Beta-Agonist(ICS-LABA) + placebo|Participants will receive stable background therapy with ICS-LABA in combination with placebo once daily (QD) for 24 weeks during the placebo-controlled period. Participants will be allocated to 1 of 3 doses of povorcitinib during the extension period of 28 weeks
61927729|NCT05851443|EXPERIMENTAL|ICS-LABA + povorcitinib Dose 1|Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 1 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks
61927730|NCT05851443|EXPERIMENTAL|ICS-LABA + povorcitinib Dose 2|Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 2 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks
62130925|NCT03224858|EXPERIMENTAL|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
62339816|NCT04178252|ACTIVE_COMPARATOR|standard drug|Standard treatment of primary headache with 10 mg metoclopramide IV in 150 ml saline given over 10 minutes
62339817|NCT04178252|ACTIVE_COMPARATOR|drug mask|Standard treatment plus eye mask
61927731|NCT05851443|EXPERIMENTAL|ICS-LABA + povorcitinib Dose 3|Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 3 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks
61927732|NCT03595293|EXPERIMENTAL|Experimental Group for AUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When patients encounter the alcohol image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
61927733|NCT03595293|SHAM_COMPARATOR|Sham Feedback Group for AUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When participants encounter the alcohol image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
61927734|NCT03595293|EXPERIMENTAL|Experimental Group for pOUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When patients encounter the pill image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
61927735|NCT03595293|SHAM_COMPARATOR|Sham Feedback Group for pOUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When participants encounter the pill image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
61927736|NCT06395103|EXPERIMENTAL|Zilovertamab vedotin|Participants receive escalating doses of zilovertamab vedotin via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks).
61927737|NCT06571045|EXPERIMENTAL|EYE103 Low Dose Treatment Arm|EYE103 Low Dose Treatment Arm
61927738|NCT06571045|EXPERIMENTAL|EYE103 High Dose Treatment Arm|EYE103 High Dose Treatment Arm
61927739|NCT06571045|ACTIVE_COMPARATOR|Ranibizumab Treatment Arm|Ranibizumab Treatment Arm
61927740|NCT06671262|ACTIVE_COMPARATOR|The control group|Patients in this arm receive only a single injection of toripalimab without any radiotherapy as an initial treatment. After a three-week interval, patients receive the standard neoadjuvant chemotherapy in combination with toripalimab, starting with four cycles of paclitaxel and toripalimab, followed by four cycles of epirubicin and toripalimab.
61927741|NCT06671262|EXPERIMENTAL|The SBRT-combined group 1|Patients enrolled in this treatment arm will undergo SBRT focused on the primary tumor, receiving a total dose of 24Gy divided into three fractions over the course of 3 to 5 working days. Following the radiation therapy, toripalimab will be administered between the second and fifth days post-treatment. After a three-week rest period, patients will commence the standard neoadjuvant chemotherapy regimen combined with toripalimab. This regimen will begin with four cycles of paclitaxel combined with toripalimab and followed by four cycles of epirubicin combined with toripalimab.
62130926|NCT03224858|ACTIVE_COMPARATOR|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
62322065|NCT00003207|EXPERIMENTAL|Phase 1 (Doxil & PSC 833)|Patients will receive Doxil at the standard dose of 20 mg/m2 IV for the 1st cycle. On the 2nd cycle of Doxil, the first patient will receive Doxil at 40% of standard dose or 8 mg/m2 (dose level 1) IV over one hr. 15 mn after the 2nd and subsequent cycles of Doxil, PSC 833 will be given at 2 mg/kg for 2 hrs. Simultaneously, a 72 hour CIVI of PSC 833 will be started with the loading dose. If no DLT occurs, then a double dose escalation of Doxil (dose levels 3, 5, 7 ) will be given to the same patient in the subsequent cycles until DLT occurs. On the 2nd cycle, Doxil will be given at the next dose level above the starting dose tolerated by the first patient. If no DLT occurs, a double dose escalation will also be done for the subsequent cycles (dose levels 5, 7, 9). The single-patient-cohort will terminate when a patient experiences DLT or when two episodes of grade 2 toxicity occur. At that point patients will be enrolled into cohorts of 3 patients to determine the MTD.
62322066|NCT04978376|EXPERIMENTAL|Time restricted eating|ad-libitum eating between 12:00-20:00
62322067|NCT04978376|EXPERIMENTAL|TRE with endurance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised endurance exercise per week
62322068|NCT04978376|EXPERIMENTAL|TRE with resistance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised resistance training per week
62322069|NCT04978376|NO_INTERVENTION|Control|no change in diet or physical activity
62322070|NCT01284322|EXPERIMENTAL|Fresolimumab|
62322071|NCT04933279|EXPERIMENTAL|Potassium iodide group|administrated the subjects with 150 ml - 200 ml iodine-containing spareribs soup delivering ≈ 600 µg or 1200 µg iodine
61927742|NCT06671262|EXPERIMENTAL|The SBRT-combined group 2|In this treatment protocol, patients will receive a total radiation dose of 24Gy in three fractions, specifically targeting the primary tumor. Concurrently, the axillary lymph nodes will be treated with a dose of 9Gy in three fractions. This radiation therapy will be conducted over a period of 3 to 5 working days. Following the radiation therapy, toripalimab will be administered between the second and fifth days after the completion of the radiation treatment. After a three-week interval, patients will proceed with the standard neoadjuvant chemotherapy regimen combined with toripalimab. This regimen includes an initial phase of four cycles of paclitaxel paired with toripalimab, which will be followed by a subsequent phase of four cycles of epirubicin paired with toripalimab.
61927743|NCT04855136|EXPERIMENTAL|Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)|bb2121 will be administered at a target dose of 450 x 10\^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.
61927744|NCT04855136|EXPERIMENTAL|Arm B- bb2121 in combination with BMS-986405 (JSMD194)|"* bb2121 will be administered at a target dose of 450 x 10\^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion~* Enrollment is closed for this Arm"
61927745|NCT06628362|PLACEBO_COMPARATOR|Arm 1: Placebo|
61927746|NCT06628362|EXPERIMENTAL|Arm 2: CT-388 Dose Level 1 (Low)|
61927747|NCT06628362|EXPERIMENTAL|Arm 3: CT-388 Dose Level 2|
61927748|NCT06628362|EXPERIMENTAL|Arm 4: CT-388 Dose Level 3|
61927749|NCT06628362|EXPERIMENTAL|Arm 5: CT-388 Dose Level 4 (High)|
61927750|NCT06739057||RV FAC Prediction Cohort|This cohort is designed to predict pediatric RV FAC using a deep learning model based on echocardiograms
61927751|NCT06739057||RV Disease Classification Cohort|The cohort is designed to employ a deep learning model to differentiate between normal pediatric hearts and pulmonary hypertension (PH), as well as between Tetralogy of Fallot (TOF) and PH, using echocardiograms.
61927752|NCT06739057||RV Function Assessment and Disease Classification Using A4C and PSAX View Cohorts|The cohort is designed to utilize A4C and PSAX echocardiographic views for pediatric RV function assessment and disease classification using deep learning models.
61927753|NCT06739057||LV Ejection Fraction (EF) Prediction Cohort|The cohort is designed to validate our new deep learning model for LV EF assessment.
61927754|NCT04541706|EXPERIMENTAL|Lorlatinib|The recommended dosage of lorlatinib is 100 mg orally once daily, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.
61927755|NCT06744673||Cohort A: Dayvigo-exposed Cohort|Pregnant women participants with a diagnosis of insomnia within the 6 months before the estimated date of conception (DOC) and who have received at least 1 dose of Dayvigo at any time from 10 days after the last menstrual period (LMP) that is, 4 days prior to the DOC, which is 5 times the product's half-life, until the pregnancy outcome (that is, any trimester) will be observed retrospectively.
61927756|NCT06744673||Cohort B: Comparator-exposed Cohort|Pregnant women participants with a diagnosis of insomnia within the 6 months before the estimated DOC and who have received at least 1 dose of drug indicated for the treatment of insomnia other than Dayvigo from 5 times the product's half-life prior to the estimated DOC until the pregnancy outcome, and no exposure to Dayvigo between 10 days after the LMP and the pregnancy outcome (that is, any trimester) will be observed retrospectively.
61927757|NCT06744673||Cohort C: Untreated Unexposed Comparator Cohort|Pregnant women participants with a diagnosis of insomnia within the 6 months before the estimated DOC and who were not exposed to any prescribed medication for the treatment of insomnia during pregnancy, that is, from 5 times the product's half-life prior to the estimated DOC until the pregnancy outcome (that is, any trimester) will be observed retrospectively.
61927758|NCT04216719|EXPERIMENTAL|OCM-RISE|Opioid court team provided external facilitation to generate action plans to develop and roll out or improve practice of the county opioid court.
62322072|NCT04933279|EXPERIMENTAL|Natural kelp group|administrated the subjects with a bowl of 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine in natural kelp).
62322073|NCT02869867|NO_INTERVENTION|Qutenza® without refrigerated cushion|Qutenza® without refrigerated cushion
62322074|NCT02869867|EXPERIMENTAL|Qutenza® with refrigerated cushion|Qutenza® with refrigerated cushion
62322075|NCT06219928|ACTIVE_COMPARATOR|Saline|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline..
62481610|NCT03500081||Healthy Volunteers|Faculty members in the Department of Radiation Oncology have volunteered to participate in this research project. They are investigators and are interested in the abilities of this new machine(MR-Linac) and the potential benefits to patients who will be treated in their department. These scans will be used to optimize scanning parameters for various body sites and to identify appropriate positioning methods for future patient treatments.
61927759|NCT06344780||Abemaciclib cohort|
61927760|NCT06344780||Palbociclib cohort|
61927761|NCT06344780||Dalpiciclib cohort|
61927762|NCT03965468|EXPERIMENTAL|Immunotherapy, chemotherapy, radiotherapy and surgery|"Durvalumab 1500 mg administered intravenously every 3 weeks for the first 4-6 cycles (during chemotherapy);~Tremelimumab 75mg administered intravenously every 3 weeks for the first 4-6 cycles (only cohort 2)~4-6 cycles of chemotherapy, carboplatin AUC5 every 3 weeks plus paclitaxel 175 mg/m2, every 3 weeks;~Stereotactic body radiotherapy (SBRT) of all oligo-metastatic lesions, in a maximum of 10 treatment fractions over 2 weeks, starting after week one of chemotherapy cycle 1 and completed within four weeks after start of durvalumab treatment;~Restaging at 3 months; if no disease progression, proceed to definitive local treatment (surgical resection of primary tumour or radiotherapy at a minimum dose of 60-66Gy to the primary tumour). Durvalumab continues at 1500 mg intravenously every 4 weeks until progression of disease or for a maximum of 1 year from start of treatment."
61927763|NCT06744894|EXPERIMENTAL|Maintenance Therapy|Patients were treated by Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
61927764|NCT06744569|EXPERIMENTAL|Part1: cohort1|BSA20%_0.3% (10g:30mg)
61927765|NCT06744569|EXPERIMENTAL|Part1: cohort2|BSA20%_1%(10g:100mg)
61927766|NCT06744569|EXPERIMENTAL|Part1: cohort3|BSA20%_2%(10g:200mg)
61927767|NCT06744569|EXPERIMENTAL|Part1: cohort4|BSA40%_2%(10g:200mg)
61927768|NCT06744569|EXPERIMENTAL|Part2: cohort1|QD_0.3%(10g:30mg)
62481611|NCT06743048|OTHER|TSLA Group|Tissue Sparing Laser Assisted Penile Implantation
61927769|NCT06744569|EXPERIMENTAL|Part2: cohort2|QD_1%(10g:100mg)
61927770|NCT06744569|EXPERIMENTAL|Part2: cohort3|QD_2%(10g:200mg)
61927771|NCT06744569|EXPERIMENTAL|Part2: cohort4|BID_2%(10g:200mg) or BID_1%(10g:100mg)
61927772|NCT06485687|EXPERIMENTAL|LIFU Neuromodulation|
61927773|NCT06139211|EXPERIMENTAL|Cohort 1: esophogeal squamous carcinoma|In Cohort 1, patients will be treated with JS015 in combination with paclitaxel or irinotecan
61927774|NCT06139211|EXPERIMENTAL|Cohort 2: gastric cancer|In Cohort 2, patients will be treated with JS015 in combination with paclitaxel
61927775|NCT06139211|EXPERIMENTAL|Cohort 3: gastric cancer|In Cohort 3, patients will be treated with JS015 in combination with toripalimab and XELOX
61927776|NCT06139211|EXPERIMENTAL|Cohort 4: colorectal cancer|In Cohort 4, patients will be treated with JS015 plus bevacizumab in combination with XELOX or FOLFIRI
61927777|NCT06139211|EXPERIMENTAL|Cohort 5: pancreatic cancer|In Cohort 5, patients will be treated with JS015 in combination with toripalimab, albumin-bound paclitaxel and gemcitabine
61927778|NCT06744127|EXPERIMENTAL|BR1015|
61927779|NCT06744127|ACTIVE_COMPARATOR|BR1015-1 + BR1015-2|
62690379|NCT03683251|EXPERIMENTAL|Sub-study 2: Cohort 1|Participants will undergo re-implantation with the updated PDS implant and receive 2 refill-exchanges of ranibizumab 100 mg/mL Q24W
62690380|NCT03683251|EXPERIMENTAL|Sub-study 2: Cohort 2a|Participants who received an updated PDS implant, have \< 24 weeks post-re-implantation follow-up and no refill exchange visit in the main study, will undergo two refill-exchange procedures with ranibizumab 100 mg/mL Q24W post main study re-implantation visit.
62322076|NCT06219928|ACTIVE_COMPARATOR|Ketamine|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
62322077|NCT06219928|ACTIVE_COMPARATOR|Dexmedetomidine|After intubation, the patient will be infused at a low dose of 1 mg/kg dexmedetomidine for the first 10 minutes, then 0.5 mg/kg/hour
62322078|NCT01598584|PLACEBO_COMPARATOR|placebo plus gemcitabine|we design placebo plus gemcitabine as control arm
62690381|NCT03683251|EXPERIMENTAL|Sub-study 2: Cohort 2b|Participants who received an updated PDS implant, have \< 48 weeks post-re-implantation follow-up and one refill exchange visit in the main study, will undergo one refill-exchange procedure with ranibizumab 100 mg/mL Q24W post main study re-implantation visit.
62690382|NCT00833274|EXPERIMENTAL|1|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
62322079|NCT01598584|EXPERIMENTAL|Mirtazapine plus gemcitabine|We design Mirtazapine plus gemcitabine as experimental arm
62322080|NCT06693102|EXPERIMENTAL|Digital intervention targeting cancer related cognitive imapriments.|Participants will undergo a digital intervention designed to address cognitive impairments. The program includes psychoeducation, cognitive training exercises, compensatory strategies, and cognitive restructuring. Weekly therapist support will be available via a chat function to provide guidance and feedback. Participants are encouraged to complete the intervention within a six-week timeframe.
62322081|NCT06693102|ACTIVE_COMPARATOR|Crossword and sudoku tasks|Participants will engage in crossword and Sudoku tasks, with a minimum recommended practice of 15 minutes per day over a six-week period.
62322082|NCT06313190|EXPERIMENTAL|Arm A|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week. Then patients in the study group (arm A) will receive sintilimab as adjuvant therapy for up to 6 cycles after the completion of radiotherapy.
62322083|NCT06313190|ACTIVE_COMPARATOR|Arm B|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week. Then patients in the control group (arm B) will be followed up regularly.
61927780|NCT06741670|EXPERIMENTAL|Breastfeeding Group|Breastfeeding was applied to the infants in this group before and during the heel lance procedure.
61927781|NCT06741670|EXPERIMENTAL|Vibration Group|Vibration was applied to the infants in this group before and during the heel lance procedure.
61927782|NCT06741670|EXPERIMENTAL|Breastfeeding+Vibration Group|Breastfeeding+Vibration was applied to the infants in this group before and during the heel lance procedure.
61927783|NCT06741670|NO_INTERVENTION|Control Group|In this group, infants received routine heel blood collection procedure.
61927784|NCT05370885|OTHER|Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.|"In Part 1 of the study, patients in Group A will receive VE202 for 8 weeks.~In Part 2 of the study, patients in Group A will receive VE202 placebo for 2 weeks.~In Part 3, patients will be followed for safety for 1 year from the start of treatment."
61927785|NCT05370885|OTHER|Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.|"In Part 1 of the study, patients in Group B will receive VE202 placebo for 8 weeks.~In Part 2 of the study, patients in Group B will receive VE202 for 2 weeks.~In Part 3, patients will be followed for safety for 1 year from the start of treatment."
61927786|NCT06120075|EXPERIMENTAL|Dose Escalation Cohort 1 - AB801 Dose Level 1|Participants will receive AB801 orally daily
61927787|NCT06120075|EXPERIMENTAL|Dose Escalation Cohort 2 - AB801 Dose Level 2|Participants will receive AB801 orally daily
61927788|NCT06120075|EXPERIMENTAL|Dose Escalation Cohort 3 - AB801 Dose Level 3|Participants will receive AB801 orally daily
61927789|NCT06120075|EXPERIMENTAL|Dose Escalation Cohort 4 - AB801 Dose Level 4|Participants will receive AB801 orally daily
61927790|NCT06120075|EXPERIMENTAL|Dose Escalation Cohort 5 - AB801 Dose Level 5|Participants will receive AB801 orally daily
61927791|NCT06120075|EXPERIMENTAL|Dose Escalation Cohort 6 - AB801 Dose Level 6|Participants will receive AB801 orally daily
62322084|NCT02498080|EXPERIMENTAL|DEB PTA|Devices: paclitaxel drug eluting balloon PTA
62322085|NCT02498080|ACTIVE_COMPARATOR|standard PTA|devices: standard balloon PTA
62322086|NCT00950690||Study Drug - Xalatan 0.005% eye drops|
62322087|NCT03874598|EXPERIMENTAL|Ear acupuncture|
62322088|NCT03874598|ACTIVE_COMPARATOR|Psychoeducation|
62322089|NCT06081621|EXPERIMENTAL|REGEND001|
62322090|NCT06081621|PLACEBO_COMPARATOR|Placebo|
62322091|NCT00596518|EXPERIMENTAL|PF-00734200|
62322092|NCT02590016|EXPERIMENTAL|Insulin-glucose-infusion|Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.
62339818|NCT04178252|ACTIVE_COMPARATOR|drug headset|Standard treatment plus headset
61927792|NCT06120075|EXPERIMENTAL|Dose Expansion Cohort 1- AB801 + Zimberelimab + Docetaxel|Participants with NSCLC with known mutation or deletion of serine/threonine kinase 11 gene will receive AB801 orally in combination with zimberelimab and docetaxel administered via intravenous (IV) infusion
62322093|NCT02590016|ACTIVE_COMPARATOR|Observation|Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.
62322094|NCT06692777|EXPERIMENTAL|Bergavit|Group Bergavit : 60 subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.
62322095|NCT06692777|PLACEBO_COMPARATOR|Placebo|Group Placebo: 60 subjects will take capsule equivalent amount of maltodextrin for 4 months.
62322096|NCT03014934||Cases: Prior Invasive Aspergillosis|History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria
62322097|NCT03014934||Controls: No prior proven Invasive Aspergillosis|Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis
62322098|NCT02384499|EXPERIMENTAL|ALLO-ASC group|Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter
62690383|NCT02963818|EXPERIMENTAL|Smartphone breathalyzer device & app|This is a small device that connects to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in an actual bar and during a two-week field period.
62690384|NCT02963818|EXPERIMENTAL|BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in an actual bar and during a two-week field period.
62322099|NCT02384499|PLACEBO_COMPARATOR|Normal saline group|0.9% normal saline with fibrin glue injection to the anal sphincter
62322100|NCT06618729|EXPERIMENTAL|Pea protein|Participants randomized to receive a meal containing 40 g of protein from pea protein extrudate
62322101|NCT06618729|EXPERIMENTAL|Wheat protein extrudate|Participants randomized to receive a meal containing 40 g of protein from wheat protein extrudate
62322102|NCT06618729|EXPERIMENTAL|Soy protein|Participants randomized to receive a meal containing 40 g of protein from soy protein extrudate
62322103|NCT06618729|ACTIVE_COMPARATOR|Chicken|Participants randomized to receive a meal containing 40 g of protein from chicken meat
62322104|NCT05684159|EXPERIMENTAL|Cohort 1|6 subjects will receive an intravenous (IV) infusion of NM8074 at every two weeks for a total of 7 doses
62322105|NCT05684159|EXPERIMENTAL|Cohort 2|6 subjects will receive weekly doses of 10 mg/kg for a total of 4 doses followed by biweekly doses at 20 mg/kg for a total of 5 doses
62481612|NCT06622239|EXPERIMENTAL|experimental group|naltrexone 50mg
62322106|NCT03484000|EXPERIMENTAL|Immediate MBCR group|The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
62322107|NCT03484000|OTHER|Waitlist control group|Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.
62322108|NCT06692699|ACTIVE_COMPARATOR|Assigned Intervention 1|Single vision spectacle lens
62322109|NCT06692699|EXPERIMENTAL|Assigned Intervention 2|A.R.R.E.S.T.® spectacle films
62322110|NCT06488573|NO_INTERVENTION|Treatment as usual|Treatment as usual
62322111|NCT06488573|EXPERIMENTAL|Nutritional intervention|Nutritional intervention based on the Brazilian Dietary Guidelines
62322112|NCT03404414|EXPERIMENTAL|18F-FDG PET/MRI and 18F-FDG PET/CT|The patients were injected with 370 MBq of 18F-FDG in one dose intravenously and underwent PET/MRI or PET/CT scan 1 hour later
62322113|NCT05361018|EXPERIMENTAL|Whole Body Vibration exercise - WBV|The vibration exercises take place on a tri-planar vibration platform (Power Plate) according to the initially determined setting for each individual (highest, though feasible neuromuscular response). . Each session lasts for about 15-30 min in total, leaving sufficient time for regeneration. Training consists of at least four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions and adherence are documented by the exercise supervisor. Adverse events are documented, and patients asked to give feedback regarding the feasibility and subjective impression of each individual setting. All training sessions will be supervised. The participants rating of perceived exertion (RPE) will be assessed immediately after each set of exercise.
62322114|NCT05361018|ACTIVE_COMPARATOR|Conventional Aerobic and Resistance exercise - CAR|exercise sessions commence with 20 min of moderate intensity continuous aerobic exercise at a rating of perceived exertion (RPE) of 13-15 on the Borg scale. Participants complete both resistance exercises and high intensity intermittent aerobic exercises during each session. The resistance training regimen consists of 8 exercises (leg press, biceps curls, triceps extensions, bench press, shoulder press, standing row, sit ups/Russian weighted abdominal twist, and prone lying back extensions. Participants complete 2 sets of 8-12 repetitions at an initial intensity of 70 % of their estimated 1 repetition maximum (1-RM) strength and increase to 80 % of estimated 1-RM when more than 12 repetitions can be correctly performed by the participant
62481613|NCT06622239|PLACEBO_COMPARATOR|comparison group|placebo
62481614|NCT06289517|EXPERIMENTAL|68Ga-Her2-affibody|Subjects with suspected or confirmed breast cancer will receive an intravenous injection of 68Ga-Her2-affibody followed by PET imaging.
61927793|NCT06120075|EXPERIMENTAL|Dose Expansion Cohort 2 - AB801 + Docetaxel|Participants with NSCLC will receive AB801 orally in combination with docetaxel IV infusion
62690385|NCT02963818|EXPERIMENTAL|Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in an actual bar and during a two-week field period.
62690386|NCT06642701|EXPERIMENTAL|EIT-guided group|Physical therapy guided by EIT
62690387|NCT06642701|OTHER|Non-EIT-guided group|Traditional physical therapy
62690388|NCT03062436|EXPERIMENTAL|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
62690389|NCT01681641|EXPERIMENTAL|Lifestyle counseling|Patients and spouses in the intervention group are offered 3 targeted meetings with the DBS nurse, focusing on goal setting for each individual, following DBS, based on patients and spouses own expectations, challenges and goals for everyday life after DBS.
62690390|NCT01681641|NO_INTERVENTION|Control group|Patients and spouses enrolled in a control group
62690391|NCT03453541|EXPERIMENTAL|Ketorolac Tromethamine|This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
62690392|NCT03453541|PLACEBO_COMPARATOR|0.9% Normal Saline|This group will receive 0.9% Normal Saline solution 1ml/60kg up to 1ml IV bolus (an equivalent volume as per kg Ketorolac Tromethamine dose) at the completion of the tonsillectomy in the operating room.
62690393|NCT02232932|EXPERIMENTAL|CAPECITABINE-Radiotherapy -Liver Transplantation|Neoadjuvant Radio-Chemotherapy (RC) and Liver Transplantation (LT)
62690394|NCT02232932|ACTIVE_COMPARATOR|RESECTION|Liver resection
62690395|NCT01548300||Enrolled participants|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The participants will be nonsmokers with cardiometabolic disease, that are not taking anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS is not allowed.
62690396|NCT05254418|EXPERIMENTAL|dulagutide arm|Patient will receive 1.5 mg injections per week for 12 weeks.
62130927|NCT05251844|EXPERIMENTAL|Email warning|"some individuals that accessed patients' data without authorization were randomly selected to receive an email warning. A sample email:~Dear Colleague,~The {Organization} proactive electronic record monitoring system has flagged you as having accessed the electronic patient record of {Patient_Name} on {Case_Event_Date}. A clear work-related purpose has not been identified for this access, and there are no approvals in place by the {Organization} Privacy Office to allow access to this record for personal purposes in accordance with A065. {Organization} takes the privacy of patient information very seriously. The {Organization} Privacy Office is now investigating this access as a potential privacy breach.~This potential noncompliance needs to be resolved immediately. To help determine whether a privacy breach has occurred, please respond to this email with answers to the following questions no later than 5 days from the date of this email...omitted due to length"
62130928|NCT05251844|NO_INTERVENTION|No eamil warning|individuals that were flagged as accessing patients' data without authorization on the same day as the experimental group were used as the control group
62130929|NCT03136042|EXPERIMENTAL|physiotherapists maneuvers|physiotherapy techniques
62322115|NCT02602236|EXPERIMENTAL|AOS-C2000-B|A new 2-piece appliance composed with 2 parts : a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
62322116|NCT02972723|EXPERIMENTAL|Metformin therapy, single arm|Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
62322117|NCT02592304|OTHER|dual energy ct|
62322118|NCT01098955|EXPERIMENTAL|ACT Group 1|Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.
62130930|NCT03136042|ACTIVE_COMPARATOR|hypertonic saline 3%|four nebulizations with 3% hypertonic saline.
62130931|NCT03136042|ACTIVE_COMPARATOR|saline + physiotherapy maneuvers|1 nebulizations + physiotherapy techniques
62130932|NCT02371512|EXPERIMENTAL|Percutaneous mitral valve repair (MitraClip system )|Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
62130933|NCT02371512|ACTIVE_COMPARATOR|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
62322119|NCT01098955|EXPERIMENTAL|MBC Group 2|Motivational and Behavioral Counseling (MBC). Varenicline 2 mg daily for 12 weeks.
62339819|NCT04178252|ACTIVE_COMPARATOR|drug mask headset|Standard treatment plus headset plus eye mask
62339820|NCT00306774|EXPERIMENTAL|1|Participants will receive vitamin D (cholecalciferol)
62339821|NCT00306774|PLACEBO_COMPARATOR|2|Participants will receive a matched placebo
62690397|NCT03464461|PLACEBO_COMPARATOR|0 mg|0 mg ketorolac - placebo
62690398|NCT03464461|ACTIVE_COMPARATOR|10 mg|10 mg ketorolac - low dose ketorolac
62690399|NCT03464461|ACTIVE_COMPARATOR|30 mg|30 mg ketorolac - usual dose ketorolac
62690400|NCT06675721||Vulnerable group|Individuals who are over 18 years old and are residents of the socioeconomically vulnerable neighborhoods.
62690401|NCT06675721||Health Professionals|Healthcare professionals who work in Natal.
62690402|NCT05846893|EXPERIMENTAL|SeQuent® Please NEO drug-coated balloon catheter|
62690403|NCT05846893|EXPERIMENTAL|Current-generation drug-eluting stent|
62690404|NCT00767208|EXPERIMENTAL|type 2 diabetic subjects|
62690405|NCT00767208|EXPERIMENTAL|overweight healthy subjects|
62690406|NCT06131840|EXPERIMENTAL|PF-08046050|PF-08046050 monotherapy
62690407|NCT03489083|EXPERIMENTAL|Trained Group|Subjects performing strength training three times per week for twelve weeks.
62690408|NCT03489083|PLACEBO_COMPARATOR|No Training Group|"Subjects performing placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks."
62690409|NCT06675032|EXPERIMENTAL|6~17 years old( Low dose)|"Dosage form: injection Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 24 months of age-17 years of age: 1 dose."
62690410|NCT06675032|EXPERIMENTAL|6~17 years old(High dose）|"Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 24 months of age-17 years of age: 1 dose."
62690411|NCT06675032|EXPERIMENTAL|24-71 months of age( Low dose)|"Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 24 months of age-17 years of age: 1 dose."
62690412|NCT06675032|EXPERIMENTAL|24-71 months of age(High dose)|"Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 24 months of age-17 years of age: 1 dose."
62130934|NCT04667780|EXPERIMENTAL|Colchicine|"This arm will receive Standard COVID-19 care + Colchicine~The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (\<50 ml/min/1.37m2), weight \<70 kg or age \>75 years old, the dose will be adjusted to the half."
62130935|NCT04667780|OTHER|Control - Standard COVID-19 care|This arm will receive standard COVID-19 care as per the hospital guidelines.
62339822|NCT03371160|EXPERIMENTAL|Nutriplace™ System|Placement of the Nutriseal™ Enteral Feeding Tube in the stomach or small intestine of adult patients who require feedings via the oro/nasoenteric route, using the Nutriplace™ System.
62339823|NCT03629392|EXPERIMENTAL|Low met/cys diet|Dietary intervention
62339824|NCT03629392|EXPERIMENTAL|Moderate met/cys diet|Dietary intervention
62690413|NCT06675032|EXPERIMENTAL|12-23 months of age( Low dose)|"Dosage form: injection Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 12-23 months age group: 2 doses, at least 2 months apart."
61927794|NCT06432764|EXPERIMENTAL|AZD7798|Arm consists of up to 2 panels
62339825|NCT03629392|ACTIVE_COMPARATOR|High met/cys diet|Dietary intervention
62690414|NCT06675032|EXPERIMENTAL|12-23 months of age( High dose)|"Dosage form: injection Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 12-23 months age group: 2 doses, at least 2 months apart."
62339826|NCT01353937|NO_INTERVENTION|Standard of Care|All patients will be receiving the Standard of Care treatments regardless of whether or not they are receiving study drug.
61927795|NCT06738316||Healthcare Worker Focus Groups|Self nominated participants from various healthcare worker professions and jobs. Doctors, Nurses, Therapists and Support Staff
61927796|NCT06199492|EXPERIMENTAL|tVisio-1|The device collects optical coherence tomography (OCT) images in an effort to identify tumor tissue before physical samples are collected. During the biopsy, a sterilized optical imaging probe will be placed through the standard biopsy guidance needle to collect a few images of the tissue at the tip of the biopsy needle. Then the regular biopsy will continue to collect a few biopsy cores.
61927797|NCT06079671|EXPERIMENTAL|Volrustomig|Volrustomig
62690415|NCT06675032|EXPERIMENTAL|7~11 months of age( Low dose)|"Dosage form: injection Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 7-11 months age group: 2 doses of primary immunization, with an interval of at least 1 month between the first two doses, and 1 booster dose after 12 months of age."
62690416|NCT06675032|EXPERIMENTAL|7~11 months of age( High dose)|"Dosage form: injection Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 7-11 months age group: 2 doses of primary immunization, with an interval of at least 1 month between the first two doses, and 1 booster dose after 12 months of age."
61927798|NCT06079671|PLACEBO_COMPARATOR|Placebo|Placebo
61927799|NCT05030766|EXPERIMENTAL|MT plus NRT Group|Participants who receive the Mindfulness Training (MT) intervention for 4 weeks in addition to 6 weeks of Nicotine Replacement Therapy (NRT).These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
61927800|NCT05030766|EXPERIMENTAL|CM plus NRT Group|Participants who receive the Contingency Management (CM) intervention for 4 weeks in addition to 6 weeks of NRT. These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
61927801|NCT05030766|EXPERIMENTAL|MT plus NRT with additional CM Group|Participants who received the MT intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional CM intervention for another 4 weeks.
62322120|NCT03421288|EXPERIMENTAL|Arm A: FLOT with Atezolizumab|Patients randomized to treatment Arm A will receive atezolizumab (840 mg IV over 1 hour) + FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of atezolizumab + FLOT followed by 8 additional 3-week treatment cycles with atezolizumab alone (maintenance setting: 1,200 mg q3w). FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
61927802|NCT05030766|EXPERIMENTAL|CM plus NRT with additional MT Group|Participants who received the CM intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional MT intervention for another 4 weeks.
61927803|NCT04671797|EXPERIMENTAL|Early Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at an early dinner time (DLMO-3h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
61927804|NCT04671797|EXPERIMENTAL|Late Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
61927805|NCT04671797|EXPERIMENTAL|Late Dinner + Late Sleep first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by delayed bedtime (DLMO+6h). This arm will cross-over to the other 2 arms in random order.
62130936|NCT00921154|EXPERIMENTAL|Ivermectin|Ivermectin
62130937|NCT02624141|EXPERIMENTAL|Epoetin Beta 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.
62130938|NCT04811716|EXPERIMENTAL|Pozelimab Q4W + Cemdisiran|
62130939|NCT04811716|EXPERIMENTAL|Pozelimab Q2W + Cemdisiran|
62339827|NCT01353937|ACTIVE_COMPARATOR|Novel Combination Therapy|AMD3100 (Plerixafor) injection with Regranex Gel topical application
62339828|NCT01353937|ACTIVE_COMPARATOR|Becaplermin (Regranex Gel)|Topical application
62130940|NCT05443737|EXPERIMENTAL|Multi-component oncofertility care intervention|Eligible cancer patients presenting to oncology clinical visits will receive care through the multi-component oncofertility care intervention.
62322121|NCT03421288|ACTIVE_COMPARATOR|Arm B: FLOT alone|Patients randomized to Arm B will receive FLOT alone for four 2-week treatment cycles prior to surgery. Following surgery, patients will receive four further 2-week cycles of chemotherapy alone. FLOT can be deescalated to FLO, FLT or FL in case of chemo-related toxicity at any time and at the discretion of investigator. Docetaxel 50 mg/m², d1 Oxaliplatin 85 mg/m², d1 Calciumfolinat 200 mg/m², d1 5-Fluorouracil 2600 mg/m², d1
62690417|NCT06675032|EXPERIMENTAL|2~3 months old (minimum) (6 weeks of age)( Low dose)|"Dosage form: injection Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 6 weeks to 3 months: one dose at the age of 2, 4 and 6 months for basic immunization, one dose at the age of 12\~15 months for booster immunization, and the first dose at the earliest age of 6 weeks."
62322122|NCT03441191|EXPERIMENTAL|Active AVS|Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
62690418|NCT06675032|EXPERIMENTAL|2~3 months old (minimum) (6 weeks of age)( High dose)|"Dosage form: injection Specification: 0.5 ml/piece Dosage: The preferred part for infants is the anterolateral thigh (vastus lateralis), and the deltoid muscle of the upper arm for toddlers and children, with a dose of 0.5 ml per 1 human use.~Duration of medication: 6 weeks to 3 months: one dose at the age of 2, 4 and 6 months for basic immunization, one dose at the age of 12\~15 months for booster immunization, and the first dose at the earliest age of 6 weeks."
62690419|NCT05064618|EXPERIMENTAL|Am80+GEM/nab-PTX (Phase I)|"●The dose-limiting toxicity (DLT) assessment period will be set at 4 weeks. After the DLT evaluation period, if no disease progression is observed based on RECIST v1.1, or no unacceptable toxicities are observed in the patient, the investigational drug will be administered orally twice a day after breakfast and dinner for up to 6 courses for each dosage group. However, for the modified dosage level 2 of the Phase I trial, the investigational drug will be administered orally twice a day after breakfast and dinner, starting from the first day (Day 1) of each course, and drug administration will be paused starting from the Day 15 GEM/nab-PTX administration. Furthermore, dose reduction or increase of the investigational drug will not be performed on the same subject.~Level 1: 6 mg (3 capsules). Level 2 \& Modified Level 2: 8 mg (4 capsules). Level 0: 4 mg (2 capsules) if DLT seen in \>33% of Level 1.~●(Phase I / II study) GEM (1000mg/m2) and nab-PTX (125mg/m2) are given intravenously."
62690420|NCT05064618|EXPERIMENTAL|Am80+GEM/nab-PTX (Phase II)|The investigational drug at the clinically recommended dose determined in the Phase I trial will be administered orally twice a day after breakfast and dinner, starting from the first day (Day 1) of each course, and drug administration will be paused starting from the Day 15 GEM/nab-PTX administration. This will continue for up to 6 courses. Furthermore, dose reduction or increase of the investigational drug will not be performed on the same subject.
62690421|NCT04310657|EXPERIMENTAL|Precision therapy|
62690422|NCT04310657|NO_INTERVENTION|control|
62690423|NCT06675318|ACTIVE_COMPARATOR|Control group|Patients with unilateral painful knee osteoarthritis who are applied to Gazi University Faculty of Medicine PM\&R will be included. 20 sessions of conventional physical therapy and rehabilitation (isometric exercises, TENS, hot pack) for the symptomatic extremity will be applied to patients In the active control group.
62690424|NCT06675318|EXPERIMENTAL|Study group|Patients with unilateral painful knee osteoarthritis who are applied to Gazi University Faculty of Medicine PM\&R will be included. 20 sessions of conventional physical therapy and rehabilitation for the symptomatic extremity combined with isokinetic strengthening exercises for the asymptomatic extremity will be applied to patients In the experimental group
62690425|NCT04986189|OTHER|Invitation to have a low dose CT thorax|All participants are invited to undergo a low dose CT thorax
62690426|NCT04306120|ACTIVE_COMPARATOR|noxious cold group|The group received noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
61927806|NCT05677139||Prospective Cohort|Participants with severe uncontrolled asthma will receive tezepelumab. Relevant demographics, baseline clinical data, and asthma control questionnaire-6 (ACQ-6) will be retrospectively collected. All patient reported outcomes (PROs) will be prospectively collected. Other outcomes of interest (tezepelumab patterns of utilization, lung function, asthma exacerbations, medication use, and healthcare resource utilization \[HRU\]) will be collected at baseline (retrospective collection for 52-week pre-index period during enrolment) and prospectively collected during enrolment for participants who enroll into the study before the first dose of tezepelumab, and for a period of up to 52 weeks (at Weeks 4, 12, 24, and 52) after the index date. The index date is defined as the date when participants receive the first dose of tezepelumab.
62130941|NCT05443737|NO_INTERVENTION|Usual Care|Eligible cancer patients presenting to oncology clinical visits will receive usual care.
62322123|NCT03441191|PLACEBO_COMPARATOR|Placebo Control AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (\<1 Hz) frequency (outside of the entrainment range).
62322124|NCT06681740|EXPERIMENTAL|Inspiratory muscle training group|The intervention group will be given an inspiratory muscle training device that will be regulated at 70% of their Maximum Inspiratory Pressure. This load is able to induce improvements in their musculature.
62322125|NCT06681740|SHAM_COMPARATOR|Control group|The control group will be given an inspiratory muscle training device that will be regulated with a load of 5 cm H2O. This load is not sufficient to induce changes in the musculature, so it will function as a placebo.
62322126|NCT06687174|EXPERIMENTAL|MY008211A 200 mg BID|200 mg taken twice a day.
62322127|NCT06687174|EXPERIMENTAL|MY008211A 400 mg BID|400 mg taken twice a day.
62322128|NCT06687174|PLACEBO_COMPARATOR|Placebo|Matching placebo to MY008211A taken twice a day.
62322129|NCT03177135|EXPERIMENTAL|AmnioSense diagnostic pantyliner|AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods
62322130|NCT02717871|EXPERIMENTAL|Treatment (PACK-CXL)|Photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL)
62339829|NCT01711320|PLACEBO_COMPARATOR|Placebo|oral dose of Placebo combined with two dose of Metformin (OGTTs)
62339830|NCT01711320|EXPERIMENTAL|Omeprazole|oral dose of Omeprazole (80 mg) combined with two dose of Metformin (OGTTs)
62339831|NCT05444478|EXPERIMENTAL|Microwave ablation|Patients only accepted microwave ablation
62339832|NCT05444478|EXPERIMENTAL|Microwave ablation plus lenvatinib|Patients accepted microwave ablation plus lenvatinib
61927807|NCT06742554|ACTIVE_COMPARATOR|Buprenorphine Transdermal Patch|"Participants in this arm will receive a 10 mg Buprenorphine transdermal patch, applied 4 hours before shoulder arthroscopic surgery. The patch delivers a steady dose of Buprenorphine for up to 7 days, providing sustained postoperative analgesia. All participants will also undergo an interscalene brachial plexus block (ISBPB) as part of their anesthesia protocol.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
62322131|NCT02717871|ACTIVE_COMPARATOR|Antimicrobial therapy|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).~OR~1b. a Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)~2. Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.~3. Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium"
62322132|NCT01752569|EXPERIMENTAL|Selumetinib treatment|Phase I is a dose-finding study to discover the maximum tolerated dose of selumetinib in combination with HAART. Phase II will consider the efficacy of selumetinib for treating Kaposi's sarcoma at the recommended phase II dose discovered in phase I.
62322133|NCT06476184|EXPERIMENTAL|Experimental arm|"Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~+/- combined with daily sub-cutaneous administrations of GCSF 30 MUI days 3 to 5, \& 10 to 12, \& 17 to 19 (at investigator discretion, as per standard of care)."
62322134|NCT06476184|ACTIVE_COMPARATOR|Standard|"Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy~+/- combined with peg-GCSF or GCSF daily sub-cutaneous administrations, at investigator discretion, as per standard of care."
62690427|NCT04306120|ACTIVE_COMPARATOR|noxious heat group|The group received noxious heat (46 - 47°C) stimuli on the affected leg for 30 minutes.
62690428|NCT04306120|ACTIVE_COMPARATOR|alternative thermal stimulation group|The group received alternative noxious heat (46 - 47°C) and noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
62690429|NCT04665765|EXPERIMENTAL|Treatment (PolaR-ICE)|"SALVAGE THERAPY: Patients receive polatuzumab vedotin IV on day 1, rituximab IV on day 1, etoposide IV on days 1-3, carboplatin IV on day 2, and ifosfamide IV on day 2 or days 1-3. Treatment repeats every 21 days for up to 2-3 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response or stable disease by C2D15 may receive 1 additional cycle of PolaR-ICE IV.~CONSOLIDATION THERAPY: Within 30-60 days after ASCT, patients receive polatuzumab vedotin IV on day 1. Treatment repeats every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity."
62690430|NCT04153162|EXPERIMENTAL|Stereotactic body radiation therapy|In patients with HCM and refractory symptoms from LVOTO, stereotactic body radiation therapy will be delivered locally to relieve symptoms
62690431|NCT04206787||Patients with non-small cell lung cancer (NSCLC)|
62690432|NCT04909801|EXPERIMENTAL|Arm 1: Abatacept + Methotrexate|
61927808|NCT06742554|ACTIVE_COMPARATOR|Tramadol|"Participants in this arm will receive Tramadol for postoperative pain management. The medication will be administered at a dose of 100 mg every 8 hours as needed, beginning after the interscalene brachial plexus block (ISBPB) wears off.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
61927809|NCT04519814|EXPERIMENTAL|all eligible patients|A total of 40 eyes in 40 consecutive patients, 22 years of age or older, with primary open-angle glaucoma (HPG + NPG), who did not reach target pressure, agree to participate in the study, and will be able to complete clinical follow-up and evaluation.
61927810|NCT06743620||Patients with persistent or recurrent SUI following surgical treatment who have received iltamiocel|
61927811|NCT06439407|EXPERIMENTAL|SAT-014|
61927812|NCT06439407|OTHER|Maintain previous treatment|
61927813|NCT03946358|EXPERIMENTAL|Atezolizumab and UCPVax|"Induction phase:~* Atezolizumab 1200 mg intravenous (IV) every 3 weeks since day 1~* UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase:~* UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)~* Atezolizumab 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
61927814|NCT03524092|PLACEBO_COMPARATOR|Maintenance Period: Miri Induction Responder (IR) - Placebo (PBO) Subcutaneous (SC)|Participants who were responders to blinded mirikizumab (miri) at Week 12 in induction study (LUCENT-1) randomized to withdraw from mirikizumab and start receiving PBO SC every 4 weeks (Q4W) from Week 0 of maintenance study (LUCENT-2) until Week 40 or until loss of response was confirmed.
61927815|NCT03524092|EXPERIMENTAL|Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC|Participants who were responders to blinded mirikizumab at Week 12 in induction study (LUCENT-1) randomized to continue to receive 200 mg mirikizumab SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
61927816|NCT03524092|OTHER|Maintenance Period: PBO IR - PBO SC|Participants who were responders to blinded placebo at Week 12 in induction study (LUCENT-1) continue to receive blinded placebo SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
61927817|NCT03524092|OTHER|Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV|Participants who received PBO SC or 200 mg mirikizumab SC Q4W during maintenance period and experienced a loss of response at or after Week 12, received rescue therapy with open label 300 mg mirikizumab intravenous (IV) Q4W for 3 doses.
61927818|NCT03524092|OTHER|Extended Induction: Induction Nonresponders - 300mg Miri IV|Participants who were nonresponders to blinded mirikizumab or placebo in induction study (LUCENT-1), received additional 3 doses of open label 300 mg mirikizumab IV Q4W during extended induction period from Week 0 of LUCENT-2 until Week 12.
61927819|NCT03524092|OTHER|Open Label Maintenance: Delayed Responders - 200 mg Miri SC|Participants who initially did not respond to induction study (LUCENT-1), but responded to extended induction therapy at Week 12 of LUCENT-2 (delayed responders), received 200 mg mirikizumab SC Q4W during open label maintenance period from Week 12 until Week 40.
62322135|NCT05240950|EXPERIMENTAL|MRD or positive ctDNA patients to inject anti-CEA CAR-T cells|Patients with liver metastasis of colorectal cancer after R0 surgery and adjuvant chemotherapy could not clear MRD (including patients with MRD still positive after the intermediate and final evaluation of adjuvant chemotherapy, and patients with MRD positive again after the end of adjuvant chemotherapy), and no measurable lesions or tumor remnants were found on imaging after surgery.
62322136|NCT01915849|EXPERIMENTAL|Sequence 1: LIK066 15 mg/Placebo/LIK066 50 mg/LIK066 150 mg|Period 1- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 150 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
62322137|NCT01915849|EXPERIMENTAL|Sequence 2: LIK066 50 mg/LIK066 15 mg/LIK066 150 mg/Placebo|Period 1- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days. 14 days washout periods between treatment periods.
62322138|NCT01915849|EXPERIMENTAL|Sequence 3: LIK066 150 mg/LIK066 50 mg/Placebo/LIK066 15 mg|Period 1- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 15 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
62322139|NCT01915849|EXPERIMENTAL|Sequence 3: Placebo/LIK066 150 mg/LIK066 15 mg/LIK066 50 mg|Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 50 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
62322140|NCT02178618|ACTIVE_COMPARATOR|Partially covered biliary self expandable metal stent|
62322141|NCT02178618|ACTIVE_COMPARATOR|Uncovered biliary self expandable metal stent|
62322142|NCT04626479|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to \~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
62322143|NCT04626479|EXPERIMENTAL|Coformulation Favezelimab/Pembrolizumab+ Lenvatinib|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
62322144|NCT04626479|EXPERIMENTAL|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
62322145|NCT04626479|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
62322146|NCT04626479|EXPERIMENTAL|Coformulation Vibostolimab/Pembrolizumab+Belzutifan|Participants will receive vibostolimab/pembrolizumab (coformulation of 200 mg vibostolimab and pembrolizumab 200 mg). Vibostolimab/pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Belzutifan will be administered orally QD until progressive disease or discontinuation.
62322147|NCT01084499|EXPERIMENTAL|Femara First, Then Peratra (Sequence 1)|Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.
62481615|NCT04241757||Patient with indication of ElectroCardioGram (ECG)|Patient with indication of ElectroCardioGram (ECG) will be included. They will have a collection of results ElectroCardioGram (ECG).
62481616|NCT01087307||Healthy Adult Volunteer|Healthy adult volunteer
62690433|NCT04909801|EXPERIMENTAL|Arm 2: (Adalimumab + Methotrexate) followed by (Abatacept + Methotrexate)|
62130942|NCT00557492|EXPERIMENTAL|Single Arm|"Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43~Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).~Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy"
62130943|NCT04654598|OTHER|BPA level|BPA (bisphenol A) in urine, blood and follicle fluid samples
62130944|NCT01095822|ACTIVE_COMPARATOR|Aliskiren|25 patients with recently diagnosed hypertension and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose \>200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose \> 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
62690434|NCT05819866|ACTIVE_COMPARATOR|Leriglitazone|Leriglitazone Treatment
61927820|NCT06740851||Touch® patients|"Patients who were treated with a primary trapeziometacarpal joint (TMJ) arthroplasty using the Touch® prosthesis for TMJ OA in our single-center prospective registry.~Patients had usually received treatments with splints, hand therapy and 1-3 steroid injections before undergoing surgery. Specific indications for primary TMJ implant arthroplasty included good trapezial bone stock without cysts, a trapezial height of at least 8 mm, no clinically relevant scaphotrapezoidal OA and no severe instability of the metacarpophalangeal joint."
61927821|NCT03900949|EXPERIMENTAL|Treatment (gemtuzumab ozogamicin, cytarabine, daunorubicin)|INDUCTION THERAPY: Cytarabine intravenously (IV) on days 1-7, daunorubicin IV on days 1-3 and midostaurin 50 mg orally (PO) twice daily (BID) on days 8-21. Gemtuzumab ozogamicin IV may be given either on days 1, or days 1 and 4 or days 1, 4 and 7. RE-INDUCTION THERAPY: Between days 14 and 21 of Induction Therapy, patients may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin per the treating physician. Patients may also undergo allogeneic stem cell transplantation (SCT) or receive consolidation therapy. CONSOLIDATION THERAPY: PATIENTS \< 60 YEARS: high dose cytarabine (HiDAC) IV on days 1, 3, and 5 and gemtuzumab ozogamicin IV on day 1 of cycle 1 and midostaurin 50 mg PO BID on days 8-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. PATIENTS \>= 60 YEARS: Same as above except cytarabine (MiDAC) IV on days 1, 3, and 5.
61927822|NCT06226818||experimental group|Women cared for in a women's centre
61927823|NCT06226818||comparator group|Women in a health centre or family planning centre.
61927824|NCT02122107||breast cancer survivors who had received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
61927825|NCT02122107||breast cancer survivors who had not received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
61927826|NCT02122107||non-cancer controls matched by age,education, and race|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
61927827|NCT06744803|EXPERIMENTAL|intervention group|Gamified Neuropathy Management Application
61927828|NCT06744803|NO_INTERVENTION|control group|no intervention
61927829|NCT06735534|OTHER|Single Arm Prospective|Repeat Ablation of Persistent Atrial Fibrillation, including Mitral Isthmus Catheter Ablation, with the FARAPULSE Pulsed Field Ablation System.
62322148|NCT01084499|EXPERIMENTAL|Peratra First, Then Femara (Sequence 2)|Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.
62322149|NCT06693427||General Anesthesia|Patients receiving general anesthesia only.
62322150|NCT06693427||General Anesthesia + Blocks|Patients receiving general anesthesia and peripheral nerve blocks
62322151|NCT03340077|EXPERIMENTAL|MOR Toolkit|Medicines Optimisation Review consultation + My clinical companion (patient questionnaire about their medications)
62322152|NCT03340077|ACTIVE_COMPARATOR|Standard of Care|Current standard of care for patients with HIV receiving antiretroviral therapy, which consists of a phamacists review of ART prescriptions.
62322153|NCT00745264|EXPERIMENTAL|2|400 mg Ketoprofen from Diractin to 4 joints
62322154|NCT00745264|EXPERIMENTAL|3|100 and 400 mg Ketoprofen used concomittant with heat
62322155|NCT00745264|EXPERIMENTAL|4|100 and 400 mg Ketoprofen concomittant with moderate exercise
62322156|NCT00745264|EXPERIMENTAL|1|100 mg ketoprofen to 2 joints
62322157|NCT01142986|EXPERIMENTAL|Low Threshold Stepped Care (LTSC)|Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
62322158|NCT01142986|EXPERIMENTAL|Voucher-Based Stepped Care (VBSC)|Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
62690435|NCT05819866|PLACEBO_COMPARATOR|Placebo|Placebo
62690436|NCT04788615|EXPERIMENTAL|ofatumumab|Oftatumumab 20mg auto injector syringes for subcutaneous injection on Day 1, Week 1 and 2, followed by subsequent monthly dosing, starting at Month 1.
62322159|NCT01142986|NO_INTERVENTION|Routine Stepped-Care (RSC)|Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
62322160|NCT00521339|EXPERIMENTAL|Apremilast 20 mg BID/ 30 mg BID|Apremilast 20 mg or 30 mg orally twice per day
62322161|NCT02645747||Group 1|The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
62322162|NCT05624255|EXPERIMENTAL|ophthalmology consultation|Patients eligible to calcium score will be offered an ophthalmologic consultation including Angio-Optical Coherence Tomography \[OCT\]
62322163|NCT05674747|EXPERIMENTAL|Group A-Weekly x 4wk|"Subjects will receive treatment on Day 0 and then weekly in the first month followed by monthly treatment to Month 6 (9 treatments).~Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months."
62481617|NCT03399500|ACTIVE_COMPARATOR|Usual Case Management (UCM)|Group receives standard case management at the shelter
62481618|NCT03399500|EXPERIMENTAL|UCM + Smartphone|Group receives standard case management and an unlimited smartphone
62481619|NCT03399500|EXPERIMENTAL|Smartphone Based Case Management (SPCM)|Group receives standard case management and an unlimited smartphone with the SPCM app
62481620|NCT05426265|EXPERIMENTAL|MEL-T01|MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects.
62481621|NCT05426265|ACTIVE_COMPARATOR|MEL-S01|MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements.
62481622|NCT05426265|NO_INTERVENTION|TAU|Treatment-as-usual.
62481623|NCT06359587|EXPERIMENTAL|Intervention Arm (Intervention Bundle Implementation)|This arm involves the time periods of the hospital units where the LTO bundle, including healthcare provider and patient engagement tools, is actively implemented.
62481624|NCT06359587|NO_INTERVENTION|Control Arm (No LTO Bundle Implementation)|This arm represents the time period of hospital units where the LTO bundle is not implemented.
62481625|NCT06649435||Patients with diagnosed heart failure|PPG signal will be measured on CE certified medical devices. Measurement Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.
61927830|NCT06745869|ACTIVE_COMPARATOR|diaphragmatic breathing exercise training group|Participants included in the diaphragmatic breathing exercise training group will be provided diaphragmatic breathing training by a physiotherapist before starting the exercise program.
61927831|NCT06745869|EXPERIMENTAL|aerobic exercise training group|The protocol given to the diaphragmatic breathing exercise training group will also be included in the exercise program of participants included in the aerobic exercise training group.
61927832|NCT06745869|NO_INTERVENTION|Control group|Participants included in the control group will be asked to continue their daily routines without changing their lifestyles.
61927833|NCT06263231|EXPERIMENTAL|INT230-6 Monotherapy|INT230-6 administered intratumorally. Participants will be dosed every 2 weeks (± 2 days) for up to a total of 5 treatment sessions (e.g., Days 1, 15, 29, 43 and 57). Once the participant has completed the treatment phase, they will continue into a 22-month maintenance phase, where investigators may inject new lesions or previously injected lesions with up to 175 mL of INT230-6 every 12 weeks (Q12W) ± 14 days. Dose volume in a session is dependent on the participants presenting tumor burden.
61927834|NCT06263231|ACTIVE_COMPARATOR|US Standard of Care|"Participants in this arm may receive any of the following depending on soft tissue sarcoma (STS) subtype and PI preference:~* Pazopanib: 800 mg PO every day until clinical deterioration or disease progression~* Trabectedin: 1.5 mg/m2 body surface area as 24-hour IV infusion every 3 weeks until clinical deterioration or disease progression~* Eribulin:~Non- European Union (EU) sites: 1.4 mg/m2 eribulin mesylate body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression EU sites: 1.23 mg/m2 (free base) body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression"
61927835|NCT05354947|EXPERIMENTAL|30 minute, dual site stimulation|Ultrasound Deliveryfor 30 minutes total: 15 minutes on the liver target site and 15 minutes on the intestinal target site.
62481626|NCT06649435||Healthy volunteers|PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.
62690437|NCT04788615|ACTIVE_COMPARATOR|First line DMT|"1. Glatiramer acetate minimum dose 20mg or maximum dose 40mg twice a day or three times a week or~2. Interferon minimum dose 22µg or maximum dose of 0.25mg 3 times a week or once a week or Every second week depending on preparation or~3. Peg-Interferon beta-1a minimum dose of 63µg or maximum dose of 125µg every 2 weeks (14 days) or~4. Teriflunomide 14 mg once a day or~5. Dimethyl fumarate minimum dose of 120mg or maximum dose of 240mg twice a day~6. Diroximel fumarate minimum dose of 231mg or maximum dose of 462mg twice a day"
61927836|NCT05354947|EXPERIMENTAL|60 minute, dual site stimulation|Ultrasound Delivery for 60 minutes total: 30 minutes on the liver target site and 30 minutes on the intestinal target site.
61927837|NCT06744491||Children|Children as defined by maturity offset via age from peak height velocity (aPHV \< -1.0 years).
61927838|NCT06744491||Adolescent|Adolescents as defined by maturity offset via age from peak height velocity (aPHV -0.5 to +1.5 years)
62481627|NCT01794403|EXPERIMENTAL|Extended Hypofractionation Radiotherapy (EHRT) Group|Participants in this group will receive the EHRT intervention over a period of 6 weeks.
62481628|NCT01794403|EXPERIMENTAL|Accelerated Hypofractionation Radiotherapy (AHRT) Group|Participants in this group will receive the AHRT intervention over a period of 2 weeks.
62481629|NCT06104618|EXPERIMENTAL|Treatment (Enfortumab vedotin)|Patients receive enfortumab vedotin IV over 30 minutes on days 1,8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62481630|NCT03233711|EXPERIMENTAL|Arm A (nivolumab)|Patients receive nivolumab while on study. Patients undergo sigmoidoscopy, colonoscopy or anoscopy, proctoscopy or digital rectal exam, x-ray, CT scan, MRI, biopsy and blood sample collection throughout the study.
62690438|NCT02826681|ACTIVE_COMPARATOR|Injectafer|750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)
61927839|NCT06744491||Young Adults|Young adults as defined by chronological age between ages 18 - 35 years
61927840|NCT06744491||Older Adults|Older adults as defined by chronological age between ages 60 - 80 years
61927841|NCT06007651|EXPERIMENTAL|LY3885125 (Part A)|Single ascending doses of LY3885125 administered subcutaneously (SC)
61927842|NCT06007651|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC
61927843|NCT06007651|EXPERIMENTAL|LY3885125 (Part B)|Repeat doses of LY3885125 administered SC
61927844|NCT06007651|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC
62481631|NCT03233711|OTHER|Arm B (clinical observation)|Patients undergo observation while on study. Patients undergo sigmoidoscopy, colonoscopy or anoscopy, proctoscopy or digital rectal exam, x-ray, CT scan, MRI, biopsy and blood sample collection throughout the study.
62481632|NCT01164241||1|Eczema
62481633|NCT01164241||2|unaffected relatives
62481634|NCT01164241||3|healthy volunteers
62481635|NCT01164241||4|other allergic phenotypes
62690439|NCT02826681|PLACEBO_COMPARATOR|Normal Saline|Placebo (15 ml of Normal Saline \[NS\]) IV push at 2 ml/minute on Day 0 and 7.
62322164|NCT05674747|EXPERIMENTAL|Group B-Biweekly x4wk|"Subjects will receive treatment on Day 0 and then every two weeks in the first month followed by monthly treatment to Month 6 (7 treatments).~Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months."
62322165|NCT05674747|EXPERIMENTAL|Group C-Biweekly x 24wks|"Subjects will receive treatment on Day 0 and then once every two weeks in the first six months (12 treatments).~Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months."
62690440|NCT04547387||Carotid Artery Stenting|Consecutive patients with symptoms or signs of ischemic cerebral injury eligible for endovascular carotid artery revascularization using direct carotid artery access and MicroNET covered carotid stent plaque exclusion under cerebral protection by temporary flow reversal
62690441|NCT03263533|EXPERIMENTAL|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
62690442|NCT03263533|EXPERIMENTAL|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
61927845|NCT05485831||Lennox Gastaut, Dravet Syndrome, and Tuberous Sclerosis Complex|Participants ≥2 years of age diagnosed with LGS, DS, and TSC.
61927846|NCT06744543|EXPERIMENTAL|Intervention|"SIGHT predictions will be generated prior to a scheduled encounter in one of the participating study clinics. Patients with a SIGHT probability above a predefined risk level (0.30 predicted risk based on our validation study and prior chart review by a genetic counselor, Morley et al, 2021 below) will prompt randomization to the standard care or SIGHT-guided intervention arm.~For patients randomized to the SIGHT-guided intervention arm, the clinician responsible for care in that encounter (determined in the usual course of care) will receive a message for that patient and details as to the contributing clinical features that led to the high probability.~The message will include a recommendation, but providers will have full discretion to offer genetic testing or refer to genetics providers. The management of screening will follow standard of care at VUMC."
61927847|NCT06744543|NO_INTERVENTION|Comparator|All remaining patients will be the comparator arm and will not be reviewed as to avoid ethical situations of withholding potentially important care.
61927848|NCT06745479|EXPERIMENTAL|Single Arm|There is only 1 arm in this study. In this arm of the study, participants are instructed to implement a cognitive strategy (i.e., way of thinking) during 1/2 of the trials of a behavioral, gambling task. On the other 1/2 of the trials they behave naturally without implementing the cognitive strategy.
61927849|NCT06096337|EXPERIMENTAL|Pulsed Field Ablation (PFA)|Pulsed Field Ablation (PFA) is used as the initial treatment for subjects with persistent atrial fibrillation (AF)
61927850|NCT06096337|ACTIVE_COMPARATOR|Anti-Arrhythmic Drug (AAD)|Anti-Arrhythmic Drug (AAD) is used as the initial treatment for subjects with persistent atrial fibrillation (AF)
61927851|NCT06738342|EXPERIMENTAL|Test group|
62690443|NCT01929525||Silver Nitrate|Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
62690444|NCT01959919||Arm 1: Device|
62690445|NCT06675058|EXPERIMENTAL|Primary teeth with deep proximal caries|In primary molars with deep proximal caries indirect pulp treatment will be performed by removing infected dentin while affected dentin in pulpal floor will be left in place. Teeth will be capped by a dressing material.
62690446|NCT06675058|ACTIVE_COMPARATOR|Primary teeth with deep occlusal caries|In primary molars with deep occlusal caries also IPT will be performed. Soft infected dentin will be carefully removed until the dried, hardened affected dentin with a leathery consistency reached then teeth will be capped by a dressing material
61927852|NCT06738342|ACTIVE_COMPARATOR|Control group|
61927853|NCT05550532|EXPERIMENTAL|Aticaprant|Participants will receive Aticaprant 10 milligrams (mg) tablet orally, once daily for 42 days during double-blind (DB) treatment phase in addition to their current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy. Participants who will complete the DB treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study 67953964MDD3003.
61927854|NCT05550532|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo tablet orally, once daily for 42 days during DB treatment phase in addition to their current antidepressant SSRI/SNRI therapy. Participants who will complete the DB treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study 67953964MDD3003.
61927855|NCT04808843||Dienogest|Patients with endometriosis who have been prescribed with Dienogest.
61927856|NCT04850118|ACTIVE_COMPARATOR|Group 1: Dose|Male participants 12-50 years of age treated by subretinal injection with the of AGTC-501
61927857|NCT04850118|ACTIVE_COMPARATOR|Group 2: Dose|Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501
61927858|NCT04850118|OTHER|Group 3: Control|Male participants 12-50 years of age in the untreated control group. Participants in the control group will be followed for a minimum of 24 months. After all participants have reached Month 12, participants in the control group will be given the option to receive the study drug in the fellow eye, if eligible.
61927859|NCT06625177|EXPERIMENTAL|TEV-53408|solution administered subcutaneously
62690447|NCT04367389|EXPERIMENTAL|Intervention|Participants receive a physical activity promotion intervention as well as an individualized exercise plan.
61927860|NCT04769310|OTHER|Patient arm|"All patients will undergo a CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
62690448|NCT04367389|NO_INTERVENTION|Control|
62339833|NCT00702585|EXPERIMENTAL|Org 36286 7.5 µg|Org 36286 7.5 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
62339834|NCT00702585|EXPERIMENTAL|Org 36286 15 µg|Org 36286 15 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
62481636|NCT06537622|OTHER|Intervention aim|To assess the effectiveness of the clinical practice guideline - cerebral palsy detecting early signs of CP at a younger age. More specifically, to reduce the age at detecting early signs of CP from an estimated CA of 11 months (prior to CPG-CP implementation) to 8 months. To determine whether using both the general movement assessment and Hammersmith infant neurological examination is more performant than the HINE alone in identifying early signs of CP. To examine if CPG-CP implementation is associated with better developmental functioning at 18-24 months CA.
62322166|NCT04742465|EXPERIMENTAL|Augmented reality|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
62322167|NCT00406315|OTHER|A1|atypical antipsychotic for the treatment of schizophrenia
62481637|NCT06537622|OTHER|Implementation aim|Using the RE-AIM framework : To assess REAch of the intervention strategies to the target audience of clinicians in CNFUN programs.To assess Implementation fidelity to the CPG-CP and the implementation strategies. To assess Maintenance of the CPG-CP over time.
62690449|NCT02898610|ACTIVE_COMPARATOR|Colchicine treatment|Colchicine 0.5mg/day plus usual care for 60 months
62322168|NCT06338865|ACTIVE_COMPARATOR|15mmHg (Conventional Laparoscopic Arm)|Standard Pressure, Conventional Laparoscopic Arm
61927861|NCT05986721|PLACEBO_COMPARATOR|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks
62322169|NCT06338865|EXPERIMENTAL|12mmHg (Conventional Laparoscopic Arm)|Lower Pressure, Conventional Laparoscopic Arm
62322170|NCT06338865|EXPERIMENTAL|10mmHg (Conventional Laparoscopic Arm)|Lowest Pressure, Conventional Laparoscopic Arm
62322171|NCT06338865|ACTIVE_COMPARATOR|15mmHg (Robotic-Assisted Laparoscopic Arm)|Standard Pressure, Robotic-Assisted Laparoscopic Arm
62322172|NCT06338865|EXPERIMENTAL|12mmHg (Robotic-Assisted Laparoscopic Arm)|Lower Pressure, Robotic-Assisted Laparoscopic Arm
62322173|NCT06338865|EXPERIMENTAL|10mmHg (Robotic-Assisted Laparoscopic Arm)|Lowest Pressure, Robotic-Assisted Laparoscopic Arm
62481638|NCT06236451|EXPERIMENTAL|Aripiprazole group|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
62481639|NCT06236451|ACTIVE_COMPARATOR|Risperidone group|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
62481640|NCT05303532|EXPERIMENTAL|Durvalumab|Participants will receive durvalumab.
62690450|NCT02898610|NO_INTERVENTION|Usual Standard of care alone|Normal standard of care remains for these patients
62322174|NCT05251935|EXPERIMENTAL|Foot Muscle Exercise|
62322175|NCT05251935|ACTIVE_COMPARATOR|Arch Support Insole and One Leg Balance Activities|
62690451|NCT02363283|EXPERIMENTAL|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
62322176|NCT01897415|EXPERIMENTAL|Autologous T cells|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
62322177|NCT02041351|EXPERIMENTAL|docetaxel|measurement evaluation every 2 months tomography of all measurable lesions in millimeters, to assess response rate, partial and complete responses.
62322178|NCT03037957||Group A Strep Assay|
62322179|NCT06207500|ACTIVE_COMPARATOR|Intervention Group|Patients were offered pharmacist- led medication reconciliation on admission and discharge coupled with patient counselling.
62322180|NCT06207500|NO_INTERVENTION|Control Group|Patients received standard care - only written instructions on discharge medications in the discharge letter, according to the standard practice.
62322181|NCT04611126|OTHER|Without Ipilimumab|"At Step 1, 6 patients will be treated without Ipilimumab pre tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2.~Depending on the safety and feasibility on step 2, 6 more patients can be included at step 1."
62322182|NCT04611126|OTHER|With Ipilimumab|"At Step 2, 6 patients will be included. Ipilimumab 3 mg/kg will be administered 2-6 weeks pre tumor harvest.~If no additional SAE/SAR compared to the previous completed pilot study at CCIT-DK is observed additional 6 patients can be included at Step 2. If on the other hand Step 2is not found safe additional 6 patients can be included at Step 1"
62322183|NCT02140918|EXPERIMENTAL|Fludrocortisone 100 μg|"* 100 μg/day (25 µg four times daily) of fludrocortisone during 5 days~* Investigations the sixth day"
62322184|NCT02140918|EXPERIMENTAL|Fludrocortisone 200 μg|"* 200 μg/day (50 µg four times daily) of fludrocortisone during 5 days~* Investigations the sixth day"
62322185|NCT02140918|EXPERIMENTAL|Fludrocortisone 400 μg|"* 400 μg/day (100 µg four times daily) of fludrocortisone during 5 days~* Investigations the sixth day"
62322186|NCT02140918|PLACEBO_COMPARATOR|Placebo|"* Placebo (four times daily) during 5 days~* Investigations the sixth day"
62322187|NCT00698516|EXPERIMENTAL|Open label, Single arm|Oral topotecan + IV Bevacizumab
62481641|NCT06088303|EXPERIMENTAL|CPT/PE with AWARE|"Participants randomized into this arm will receive either cognitive processing therapy (CPT) or prolonged exposure (PE) with the adjunctive writing intervention to amplify response and engagement (AWARE).~CPT and PE are both recommended as gold standard treatments by published PTSD clinical practice guidelines. Participants will choose whether to receive CPT or PE. The standard treatment length will be 8-15 weekly sessions; however, participants and providers may collaboratively agree to early completion or additional sessions as warranted. AWARE will be integrated into the CPT/PE sessions."
62481642|NCT06088303|ACTIVE_COMPARATOR|CPT/PE TAU|"Participants randomized into this arm will receive either cognitive processing therapy (CPT) or prolonged exposure (PE) treatment as usual (TAU).~CPT and PE are both recommended as gold standard treatments by published PTSD clinical practice guidelines. Participants will choose whether to receive CPT or PE. The standard treatment length will be 8-15 weekly sessions; however, participants and providers may collaboratively agree to early completion or additional sessions as warranted."
62481643|NCT06742892|EXPERIMENTAL|HLX43 DOSE 1|Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)
62481644|NCT06742892|EXPERIMENTAL|HLX43 DOSE 2|Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)
62481645|NCT06742892|EXPERIMENTAL|HLX43 DOSE 3|Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)
62481646|NCT06045689|EXPERIMENTAL|Cohort 1: erythropoiesis-stimulating agents (ESA) naïve|
62322188|NCT02226510|PLACEBO_COMPARATOR|Placebo|Placebo capsules (with an identical appearance to the active drug) and containing only microcrystalline cellulose PhEur
62322189|NCT02226510|ACTIVE_COMPARATOR|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day (metformin XL 500mg x2/day). They will continue on Metformin XL 500mg x2/day for two weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day (and stopped if this cannot be tolerated).
62481647|NCT06045689|EXPERIMENTAL|Cohort 2: ESA relapsed or refractory|
62481648|NCT05335369|NO_INTERVENTION|Usual care|Usual care
62481649|NCT05335369|EXPERIMENTAL|UR-GOAL|UR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
62481650|NCT06741631|NO_INTERVENTION|Control|Participants randomized to the control arm will receive standard of care. This consists of HIV home testing every 6 months, information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP, referrals to the local PrEP clinic, and referrals for local sexually transmitted disease testing.
62690452|NCT01143636|SHAM_COMPARATOR|Active tDCS - pelvic pain patients|ACTIVE tDCS: Subjects will receive a total of 10 consecutive sessions of active tDCS over a two-week period (administered Monday - Friday). During each session, the anode electrode will be placed over the primary motor cortex of the predominantly painful side.
62690453|NCT01143636|EXPERIMENTAL|Sham tDCS - pelvic pain patients|SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
62322190|NCT02859545|EXPERIMENTAL|Validation Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to validate which is provided by the research assistant.
62322191|NCT02859545|PLACEBO_COMPARATOR|Education Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to ask questions about treatments, which is provided by the research assistant.
62322192|NCT01514669||No treatment|No Tx, this is observational
62322193|NCT01004549||Bilateral intraocular lens implantation.|
61927862|NCT05986721|EXPERIMENTAL|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
62322194|NCT02629081||Controls & Cases|Controls (participants without heartburn or other GERD symptoms undergoing standard upper endoscopy for the following: anemia, weight loss, diarrhea, and screening for esophageal varices) and Cases (participants with heartburn or other GERD symptoms undergoing standard endoscopy for heartburn or other GERD symptoms.)
62322195|NCT01592851|EXPERIMENTAL|Arm 1|Dentifrice containing stannous fluoride
62322196|NCT01592851|ACTIVE_COMPARATOR|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
62322197|NCT01495897|OTHER|Healthy|Healthy volunteers
62322198|NCT01495897|EXPERIMENTAL|Dystonia|patients with Primary Dystonia
62322199|NCT01495897|EXPERIMENTAL|Parkinson|patients with Parkinson's disease
62322200|NCT01495897|EXPERIMENTAL|Essential tremor|patients with essential tremor with or without deep brain stimulation
62322201|NCT05816616||COPD-TLD patients|COPD patients to be treated with Targeted Lung Denervation and enrolled in Airflow-3 clinical trial at Temple University Hospital, and which are also willing to participate in hyperpolarized xenon imaging of their lungs prior and poste TLD treatment.
62322202|NCT02461914|EXPERIMENTAL|Warfaring and PEX168(200µg)|Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
62322203|NCT04529551|EXPERIMENTAL|1601A, 1601B product use order|Subjects will use 1601A for 1 week and then 1601B for 1 week.
62322204|NCT04529551|EXPERIMENTAL|1601B, 1601A product use order|Subjects will use 1601B for 1 week and then 1601A for 1 week.
62339835|NCT00702585|EXPERIMENTAL|Org 36286 30 µg|Org 36286 30 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
62339836|NCT00702585|EXPERIMENTAL|Org 36286 60 µg|Org 36286 60 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
62481651|NCT06741631|EXPERIMENTAL|Intervention|Participants randomized to the intervention arm will have access to MyPEEPS Mobile for the next 6 months. MyPEEPS Mobile is a secure web app with content delivered through games, scenarios, and role-plays within 22 mobile activities (true/ false questions, multiple choice, matching, videos).
62481652|NCT04799288|EXPERIMENTAL|Teriflunomide|Teriflunomide 14 mg daily
62481653|NCT05177107|EXPERIMENTAL|Group 1: Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
62481654|NCT05177107|PLACEBO_COMPARATOR|Group 2: Placebo|Placebo (normal saline) will be administered using the same schedule and techniques as for Group 1 (phage therapy).
62481655|NCT05554198|EXPERIMENTAL|Pilot Intervention|pre/post-test, mixed method study design with quantitative data collection at baseline and post-intervention and qualitative data collection once at post-intervention. Participants will have access to the Attend Behavior program for a full year, but intervention usage monitoring and study outcomes will be assessed until post-intervention (12-weeks post-baseline).
62481656|NCT06349980|EXPERIMENTAL|HLX53(1000mg)+ HLX10+ HLX04|HLX53+ HLX10+ HLX04 will be administered every 3 weeks until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62481657|NCT06349980|EXPERIMENTAL|HLX53(2000mg)+ HLX10+ HLX04|HLX53+ HLX10+ HLX04 will be administered every 3 weeks until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62481658|NCT06349980|PLACEBO_COMPARATOR|Placebo+ HLX10+ HLX04|Placebo+ HLX10+ HLX04 will be administered every 3 weeks until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62481659|NCT06700109|EXPERIMENTAL|Neural Ice injections|This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.
62481660|NCT06700109|ACTIVE_COMPARATOR|Corticosteroid injection|Intraarticular corticosteroid injection is defined as a single dose of Triamcinolone 40mg injected directly into the joint space.
61927863|NCT05691309||Study Cohort|Recipients of vancomycin
61927864|NCT06744933|EXPERIMENTAL|Self-administered auricular acupressure integrated with a smartphone application|Patients in this group will undergo TCM syndrome differentiation, and then be given 6 to 8 hypoallergic Vaccariae Semen ear patches on one ear. 6 of the auricular acupoints will be compulsory, while the additional 1 to 2 acupoints will be selected according to the TCM syndrome of the patient. These 6 mandatory acupoints were selected according to previous literature and expert opinion. The research staff will use an ear model to demonstrate to the patients how to press on the auricular acupoints and require them to perform a return demonstration to ensure they can perform auricular acupressure correctly by themselves. The patient will then be required to visit the clinic twice a week and will change a new set of ear patches on the same acupoints of the opposite ear. This intervention will last for 8 weeks. Their BMI (and weight) and their satiety level will be monitored once a week while they visit the clinic.
61927865|NCT06744933|NO_INTERVENTION|Usual care|The usual care group will receive no intervention. They will only be assessed on the outcomes.
61927866|NCT06744348||Entire Papila Preservation Tecnique|This innovative approach allows for vertical access to the defect site from the buccal and lingual sides without making incisions in the papillary region. Its goal is to minimize the risk of wound healing failure and the exposure of regenerative biomaterials by fully preserving the interdental papilla over the bony defect
61927867|NCT04073563|EXPERIMENTAL|Group #1|Investigational Infuse™ 2.1 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
61927868|NCT04073563|EXPERIMENTAL|Group #2|Investigational Infuse™ 4.2 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
62481661|NCT00540995|EXPERIMENTAL|Arm I: 1200cGy|"1200cGy = 150cGy x 8 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate."
62690454|NCT01143636|EXPERIMENTAL|Active tDCS - healthy|The healthy controls will undergo one day of treatment with active tDCS. All participants will receive both active and sham stimulation in a randomized order.
62690455|NCT01143636|EXPERIMENTAL|Sham tDCS - healthy|The healthy controls will undergo one day of treatment with sham tDCS. All participants will receive both active and sham stimulation in a randomized order.
62690456|NCT06529237||Children at Health Facilities|Finger-prick sampling (no internvention/clinical trail)
62690457|NCT06529237||Pregnant Women at ANC|Finger-prick sampling (no internvention/clinical trail)
61927869|NCT04073563|ACTIVE_COMPARATOR|Control|Local bone autograft and supplemented with cancellous allograft as needed.
61927870|NCT06734104|EXPERIMENTAL|Interactive Video Group|
61927871|NCT06734104|ACTIVE_COMPARATOR|Control : Non-Interactive Video Group|
62481662|NCT00540995|EXPERIMENTAL|Arm II: 1350cGy|1350cGy = 150cGy x 9 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.
62690458|NCT06529237||All ages|Finger-prick sampling (no internvention/clinical trail)
61927872|NCT06744504|ACTIVE_COMPARATOR|standard-dose Cytarabine|"Induction therapy:~Cytarabine (Ara-c) 100mg/ m2/ day, day 1-7; Daunorubicin (DNR) 60mg/m2/ day, day 1-3; Those who did not meet CR were treated with IAC regimen.~IAC:~IDA 8 mg/m2/d, D1-3; Ara-c 100 mg/m2, D1-7; CTX 350mg/m2, D2,5;~Post-remission treatment options:~High dose Ara-C(HDAC) : 3 cycles Ara-C 3g/㎡/q12h, days 1, 3 and 5 For patietns RUNX1-RUNX1 MRD reduction \< 3 logs after 2 courses, allo-transplantation is recommended if donor is available."
61927873|NCT06744504|EXPERIMENTAL|Intermediate-dose Cytarabine|"Induction therapy:~Cytarabine (Ara-c) 100mg/ m2/ day, day 1-4; 1g/㎡/q12h, day 5-7; Daunorubicin (DNR) 60mg/m2/ day, day 1-3; Those who did not meet CR were treated with IAC regimen.~IAC:~IDA 8 mg/m2/d, D1-3; Ara-c 100 mg/m2, D1-7; CTX 350mg/m2, D2,5;~Post-remission treatment options:~High dose Ara-C(HDAC) : 3 cycles; Ara-C 3g/㎡/q12h, days 1, 3 and 5. For patietns RUNX1-RUNX1 MRD reduction \< 3 logs after 2 courses, allo-transplantation is recommended if donor is available."
61927874|NCT06567769|EXPERIMENTAL|Cohort 1|
62322205|NCT01259492|EXPERIMENTAL|Ritalin LA 40 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2, continued in same dose till week 9. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
62322206|NCT01259492|EXPERIMENTAL|Ritalin LA 60 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14.In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
62322207|NCT01259492|EXPERIMENTAL|Ritalin LA 80 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3 and to 80 mg at week 4. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
62322208|NCT01259492|PLACEBO_COMPARATOR|Placebo|Period 1- Placebo controlled Period 2 - The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose (40, 60 or 80 mg). In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
62481663|NCT05047172|EXPERIMENTAL|Experimental Arm: Ticagrelor and Aspirin|Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
62481664|NCT05047172|ACTIVE_COMPARATOR|Standard of Care Arm: Clopidogrel and Aspirin|Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily)
62690459|NCT01460277|EXPERIMENTAL|Hydrokinesiotherapy|A 6-week water-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
62690460|NCT01460277|ACTIVE_COMPARATOR|Conventional exercise intervention|A 6-week land-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
62690461|NCT04781842|EXPERIMENTAL|Boxing Club Group|Participation in a weekly boxing program designed for people with Parkinson Disease
62690462|NCT04781842|NO_INTERVENTION|Control group|No changes to regular physical activity during the study period
62690463|NCT06637644||Patients implanted with right-sided ventricular assist device|
62690464|NCT04439357|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62690465|NCT01242384|NO_INTERVENTION|Expectant Management|
62690466|NCT01242384|EXPERIMENTAL|Placement of cervical pessary since 23 weeks until 37 weeks|
62690467|NCT02455726|EXPERIMENTAL|Mg-group|"Standard therapy plus magnesium oxide.~* Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~* A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
62690468|NCT02455726|PLACEBO_COMPARATOR|C-group|"Standard therapy plus fructose.~* Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~* A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
62690469|NCT05806190||Study group|Participants who live with insulin- treated diabetes and adrenal insufficiency.
62690470|NCT05806190||Control group|Participants who live with adrenal insufficiency and NOT with insulin-treated diabetes.
62690471|NCT01871922|PLACEBO_COMPARATOR|General anesthesia + placebo|Propofol/remifentanil anesthesia + saline
62690472|NCT01871922|ACTIVE_COMPARATOR|General anesthesia + atropine|Propofol/remifentanil anesthesia + atropine
62690473|NCT02344472|EXPERIMENTAL|Chemotherapy with docetaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus docetaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
62690474|NCT02344472|EXPERIMENTAL|Chemotherapy with paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus paclitaxel.Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
62690475|NCT02344472|EXPERIMENTAL|Chemotherapy with vinorelbine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus vinorelbine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
62690476|NCT02344472|EXPERIMENTAL|Chemotherapy with capecitabine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus capecitabine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
62690477|NCT02344472|EXPERIMENTAL|endocrine therapy with exemestane|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus exemestane.
62690478|NCT02344472|EXPERIMENTAL|endocrine therapy with fulvestrant|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus fulvestrant.
61927875|NCT06567769|EXPERIMENTAL|Cohort 2|
61927876|NCT06567769|EXPERIMENTAL|Cohort 3|
62322209|NCT06692400|EXPERIMENTAL|Participants who undergo endotracheal tube (ETT) suctioning.|Participants will receive ETT suctioning as part of routine care.
62322210|NCT06692400|NO_INTERVENTION|Participants who do not undergo ETT suctioning during the observation period.|Participants will not receive ETT suctioning during the observation periood.
62322211|NCT02765477||Angiogram Cohort w Acute Coronary Occlusion|Inclusion Criteria: Angiogram Cohort. Patients who present 1) directly through the study site Emergency Department (ED) OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1.Underwent urgent or emergent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to chest pain \[CP\] and/or shortness of breath \[SOB\]) AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, a group of patients will be identified who had angiographic evidence of ACO, defined as an acute lesion with TIMI flow 0 or 1 when evaluated by an experienced study-site adjudicator.
62322212|NCT02765477||Non-ACO Angiogram Cohort|Inclusion Criteria: Angiogram Cohort. Each study site will first identify adult patients (age 18 years or older) who presented to the study site 1) directly through the study site ED OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1. Underwent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to CP and/or SOB AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, those who had TIMI-2 or greater flow will be identified for several research questions.
62322213|NCT02765477||Random ED Sample w Paced Rhythm but No AMI|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly select 5 unique encounters for every one 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The primary control group selected from this search will be all patients in this group who do not meet criteria for acute myocardial injury, as defined by 1) all troponins below the 99th percentile or 2) Peak troponin \< 3x the upper limit of normal AND no rise and/or fall of \> 30%."
62322214|NCT02765477||ED Patients w Paced Rhythm Without AMI excluded|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly 5 unique encounters for every 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The secondary control group will include patients in this group in whom Acute MI cannot be excluded because they either have at least 1 troponin \> 3x the upper limit of normal or they have at least 1 troponin between 1x and 3x the ULN AND have a rise and/or fall of at least 30%."
62322215|NCT02028338|EXPERIMENTAL|Dapivirine ring|dapivirine vaginal ring (25 mg)
62322216|NCT02028338|PLACEBO_COMPARATOR|Placebo ring|silicone vaginal ring
62322217|NCT03819803|EXPERIMENTAL|Steroid refractory GI-aGvHD|"Patients with GI-aGvHD not sufficiently responding to GvHD therapy with corticosteroids.~Intervention: Fecal microbiota transplantation"
62322218|NCT06665477|EXPERIMENTAL|Subject treated with Restylane Volyme|
62322219|NCT06665477|NO_INTERVENTION|Subject non-treated with Restylane Volyme|
62322220|NCT06692946|PLACEBO_COMPARATOR|Treatment As Usual (TAU)-Control group|25 children were randomly assigned to the TAU control group, stratified by cognitive level (IQ or DQ \< 70) and language impairment (verbal /non-verbal patients). They undergo Traditional treatement for ASD (CBT and PT).
62322221|NCT06692946|EXPERIMENTAL|Experimental Group: Cooperative parent mediated therapy and Cognitive Behavioural therapy|"Children were randomly assigned to the experimental group, stratified by cognitive level (IQ or DQ \< 70) and language impairment (verbal /non-verbal patients).~The experimental group consists in 25 children exposed to Cooperative Parent Mediated Therapy as an add on treatment to the TAU (CBT and PT)"
62481665|NCT05047172|EXPERIMENTAL|Experimental Arm: Rivaroxaban and Aspirin|Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
62481666|NCT05554328|EXPERIMENTAL|Arm I (selumetinib, olaparib)|Patients receive selumetinib PO BID and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
61927877|NCT05154487|EXPERIMENTAL|Apelisib and Fulvestrant|alpelisib 300mg orally daily of each 28-day cycle fulvestrant 500mg IM on Day 1 and Day 15 of Cycle 1, then 500mg IM on Day 1 of each 28-day cycle.
61927878|NCT06739330||Study group|Patients with metabolic dysfunction-associated fatty liver disease (MAFLD)
61927879|NCT06739330||Control group|Healthy control patients
61927880|NCT04946825|EXPERIMENTAL|Quit cigarettes, but continue using e-cigarettes, with nicotine replacement therapy and text support|Participants in this arm will be instructed to quit tobacco cigarettes with nicotine replacement therapy (patches and lozenges) and text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
62322222|NCT03117049|EXPERIMENTAL|ONO-4538 group|"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
62481667|NCT05554328|ACTIVE_COMPARATOR|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
62481668|NCT06466733|EXPERIMENTAL|Endovascular Embolization|Embolization of the middle meningeal artery
62481669|NCT06466733|ACTIVE_COMPARATOR|Surgical Evacuation of Hematoma|Burr hole or craniotomy
62481670|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
62481671|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
62481672|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
62481673|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
62481674|NCT06742359||patients with subacromial impingement syndrome|
62481675|NCT06516354|OTHER|Portable Sleep Apnea Screening|Application of portable sleep apnea screening device on inpatient stroke/TIA patients for at least 5 hours of sleep in one night or 8 hours of sleep over 2 consecutive nights.
62322223|NCT03117049|PLACEBO_COMPARATOR|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
62322224|NCT05424900|EXPERIMENTAL|REThink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
62322225|NCT05424900|NO_INTERVENTION|Monitoring|Participants in this arm will be monitored for a total of eight weeks, for comparison with the REThink game intervention (after four weeks).
62481676|NCT06546202||Diabetic peripheral neuropathic pain|Participants who have been diagnosed with diabetic peripheral neuropathic pain and presented with pain symptoms.
62481677|NCT06546202||Chemotherapy-induced peripheral neuropathy|Participants who have chemotherapy-induced peripheral neuropathy regardless of the presence of pain symptoms.
62322226|NCT04850040|EXPERIMENTAL|Camrelizumab+Apatinib Mesylate+Oxaliplatin|An study of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.
62322227|NCT02588846|EXPERIMENTAL|Stage 1: Optimise nodal treatment margin|During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
62322228|NCT02588846|EXPERIMENTAL|Stage 2: Use treatment margin|During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
62322229|NCT01241513|EXPERIMENTAL|N-acetyl-L-Cysteine|N-Acetyl-L-Cysteine
62481678|NCT05183126|ACTIVE_COMPARATOR|Normal SMA (>7310 mm^2)|Standard paclitaxel infusion time.
62481679|NCT05183126|EXPERIMENTAL|Low SMA (5120 - 7310 mm^2) and Sarcopenic SMA (<5120 mm^2)|Adjusted paclitaxel infusion time during only one dose; standard paclitaxel infusion time for all other doses.
61927881|NCT04946825|EXPERIMENTAL|Quit cigarettes and quit e-cigarettes with nicotine replacement therapy and text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with nicotine replacement therapy (patches and lozenges) and text message support.
62322230|NCT01241513|PLACEBO_COMPARATOR|Placebo|placebo
62322231|NCT03363828||Normal microbiota|Based on qPCR and Next gen sequencing
62322232|NCT03363828||Abnormal microbiota|Based on qPCR and Next gen sequencing
62322233|NCT01449019|ACTIVE_COMPARATOR|intravenous infusion|
62322234|NCT01449019|EXPERIMENTAL|intraduodenal perfusion|
62322235|NCT05060510|NO_INTERVENTION|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
62690479|NCT02344472|EXPERIMENTAL|endocrine therapy with anastrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus anastrozole.
62690480|NCT02344472|EXPERIMENTAL|endocrine therapy with letrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus letrozole.
62690481|NCT02344472|EXPERIMENTAL|Chemotherapy with nab-Paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus nab-Paclitaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
62690482|NCT02344472|EXPERIMENTAL|Chemotherapy with eribulin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus eribulin. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
62690483|NCT02344472|EXPERIMENTAL|endocrine therapy with leuprorelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus leuprorelin.
62130945|NCT01095822|EXPERIMENTAL|Aliskiren + Valsartan|25 patients with recently diagnosed hypertension, and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose \>200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose \> 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
62130946|NCT06517459|EXPERIMENTAL|GLB CVA Latino|"The GLB program, adapted for Latino individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The goal of the GLB program is to help the participant achieve and maintain a 5-7% weight-loss using a two-pronged approach:~1. Physical activity: This is based upon recommendations by the American Heart Association and the American College of Sports Medicine (ACSM) to achieve 150 minutes of moderate intensity activity each week. Walking is the primary activity recommended.~2. Healthy eating: Based on United States Department of Agriculture guidelines, the GLB emphasizes healthy eating patterns and tracking dietary intake. Key recommendations include individuals consuming (1) a variety of vegetables, (2) whole fruits, (3) whole grains, (4) fat-free or low-fat dairy, (5) a variety of lean proteins, and (6) oils at every meal"
62130947|NCT06107751|ACTIVE_COMPARATOR|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
62481680|NCT05592574||Spondyloarthritis without biological treatment and in failure of 2 NSAIDS|
62481681|NCT06722521|EXPERIMENTAL|Intensive lipid-lowering therapy without aspirin|"In this group, patients with coronary calcification (Agatston score ≥100) and no physiologically significant CAD who need primary prevention will receive intensive lipid-lowering therapy with pitavastatin 4 mg/ezetimibe 10 mg without aspirin.~Drug: pitavastatin 4mg/ezetimibe 10mg without aspirin"
62481682|NCT06722521|ACTIVE_COMPARATOR|Moderate-Intensity Lipid-Lowering Therapy with Aspirin|"In this group, patients with coronary calcification (≥100 Agatston score) and no physiologically significant Coronary artery disease (CAD) who need primary prevention will receive moderate-intensity lipid-lowering therapy with pitavastatin 2 mg plus aspirin.~Drug: pitavastatin 2mg with aspirin~Under the clinical judgment of the physician, statins can be uptitrated to pitavastatin 4mg according to LDL response, and aspirin can be switched to clopidogrel in case of adverse reaction to aspirin"
62481683|NCT06732986||Athletes|The participants in the athlete group were volleyball players competing in the 1st or 2nd division of the Portuguese National Championship, training and/or competing for more than 20 hours per week.
62481684|NCT06732986||Non Athletes|The participants in the non-athlete group had no prior experience in any jumping sport.
62481685|NCT06084416|EXPERIMENTAL|Dose Level 1|Subjects will receive sovilnesib once daily at Dose Level 1 in 28-day cycles.
62690484|NCT02344472|EXPERIMENTAL|endocrine therapy with goserelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus goserelin.
62690485|NCT05513573|EXPERIMENTAL|HLX07+HLX10+chemotherapy|
62690486|NCT05513573|EXPERIMENTAL|Placebo+HLX10+chemotherapy|
62690487|NCT02071732|ACTIVE_COMPARATOR|Real rTMS|Real rTMS is real continuous theta burst stimulation.
62690488|NCT02071732|SHAM_COMPARATOR|Sham rTMS|Sham rTMS is sham continuous theta burst stimulation.
62481686|NCT06084416|EXPERIMENTAL|Dose Level 2|Subjects will receive sovilnesib once daily at Dose Level 2 in 28-day cycles.
62690489|NCT04179084|EXPERIMENTAL|fruquintinib + Sintilimab|
62690490|NCT06643000|EXPERIMENTAL|Triple therapy|furmonertinib combined with bevacizumab and pemetrexed
62690491|NCT02579759|ACTIVE_COMPARATOR|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
62690492|NCT02579759|ACTIVE_COMPARATOR|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
62690493|NCT02579759|PLACEBO_COMPARATOR|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
62690494|NCT06640361|EXPERIMENTAL|Olverembatinib|
62690495|NCT04699877|EXPERIMENTAL|Gilteritinib (Severe Renal Impairment)|Participants with severe renal impairment received a single oral dose of 20 milligrams (mg) of gilteritinib on day 1, under fasting conditions.
62690496|NCT04699877|EXPERIMENTAL|Gilteritinib (Normal Renal Function)|Participants with normal renal function received a single oral dose of 20 mg of gilteritinib on day 1, under fasting conditions.
62690497|NCT06174779|EXPERIMENTAL|HM11260C|Weekly administration by subcutaneous injection
62481687|NCT06084416|EXPERIMENTAL|Dose Level 3|Subjects will receive sovilnesib once daily at Dose Level 3 in 28-day cycles.
62481688|NCT06084416|EXPERIMENTAL|Dose Level 4|Subjects will receive sovilnesib once daily at Dose Level 4 in 28-day cycles.
62481689|NCT01409499|EXPERIMENTAL|A, surgery|The patients in this group will receive palliative resection of HCC, then take sorafenib as remain therapy.
62481690|NCT01409499|EXPERIMENTAL|B, TACE|Patients in group B will receive transcatheter hepatic arterial chemoembolization, then take sorafenib as remain therapy.
61927882|NCT04946825|EXPERIMENTAL|Quit cigarettes, but continue using e-cigarettes, with text support.|Participants in this arm will be instructed to quit tobacco cigarettes with text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
61927883|NCT04946825|EXPERIMENTAL|Quit cigarettes and quit e-cigarettes with text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with text message support.
62322236|NCT05060510|ACTIVE_COMPARATOR|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
62690498|NCT06174779|PLACEBO_COMPARATOR|Placebo|Weekly administration by subcutaneous injection
62322237|NCT05813210|EXPERIMENTAL|Combined stress test (pharmacological and physical stress)|Patients are first stressed ergometrically and perfusion is assessed. Subsequently, drug induced stress perfusion is performed, as in the usual protocol.
62481691|NCT01409499|EXPERIMENTAL|C, sorafenib|Patients in group C will receive monotherapy of sorafenib.
62322238|NCT05813210|ACTIVE_COMPARATOR|Pharmacological stress test|One group receiving only pharmacological stress test with Regadenoson.
62322239|NCT02937103|EXPERIMENTAL|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62322240|NCT05458284|ACTIVE_COMPARATOR|real acupuncture (RA)|Real Acupuncture weekly till taxane completion
62481692|NCT02266095|ACTIVE_COMPARATOR|Oval-8 Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee). Oval-8 splints are not commonly used for treatment of thumb CMC arthritis.~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
62481693|NCT02266095|ACTIVE_COMPARATOR|Tee Pee Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
62690499|NCT03552445|ACTIVE_COMPARATOR|Tetanus-diphtheria (Td) and PCV13|
62690500|NCT03552445|ACTIVE_COMPARATOR|PCV13 alone|
62690501|NCT03552445|ACTIVE_COMPARATOR|Td alone|
62690502|NCT02520362||Postmenopausal Women|Postmenopausal Women
62322241|NCT05458284|PLACEBO_COMPARATOR|sham acupuncture (SA)|Sham Acupuncture weekly till taxane completion
62322242|NCT02379923|EXPERIMENTAL|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
62339837|NCT00702585|PLACEBO_COMPARATOR|Placebo|Placebo to Org 36286 administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
62481694|NCT02266095|ACTIVE_COMPARATOR|Forearm Based Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
62690503|NCT02520362||Women with post menopausal osteoporosis|Women with post menopausal osteoporosis
61927884|NCT04775082|EXPERIMENTAL|Liraglutide 3.0 mg|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
61927885|NCT04775082|PLACEBO_COMPARATOR|Placebo|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
61927886|NCT05899452|EXPERIMENTAL|Bubbles|Patient will receive bubble distraction method prior to and during the placement of their IV cannula
61927887|NCT05899452|ACTIVE_COMPARATOR|Video|Patient will receive video distraction on an tablet computer prior to and during the placement of their IV cannula
62339838|NCT02168673||Group 1|Healthy non-smokers
62481695|NCT05770388|ACTIVE_COMPARATOR|Control Group|Participants will receive a brief contact intervention (via phone call or chat) in which a clinical psychologist will assess their general mental health status and level of suicidal risk, and will provide an intervention based on the principles of motivational interviewing and psycho-educational information along with a list of mental health services available within and outside the University. Participants will also receive instructions on how to download and use a mobile app.
62481696|NCT05770388|EXPERIMENTAL|Intervention Group|Participants will receive a brief contact intervention (via phone call or chat) in which a clinical psychologist will assess their mental health status and level of suicidal risk and will provide an intervention based on the principles of motivational interviewing and psycho-educational information along with a list of mental health services available within and outside the University. Participants will also receive instructions on how to download and use a mobile app. Additionally, participants will also receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary. After two months, this group will receive a new contact with a clinical psychologist via phone call or chat. In this contact, mood and level of suicidal risk will be assessed, and participants will be encouraged to seek mental health help if they have not already done so.
62481697|NCT06502379|EXPERIMENTAL|Part 1: SAD Cohort 1 - AZD8965 (Dose 1)|Participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1.
62690504|NCT02520362||Prolia for unapproved indications|Patients who receive Prolia for unapproved indications
62690505|NCT02520362||Men with osteoporosis|Men with osteoporosis treated with denosumab
62481698|NCT06502379|EXPERIMENTAL|Part 1: SAD Cohort 2 - AZD8965 (Dose 2)|Participants will receive a single dose of AZD8965 (Dose 2) or matching placebo to AZD8965 on Day 1.
62690506|NCT02520362||Men and women who receive Prolia with Glucocorticoid exposure|Drug: denosumab subcutaneous injection
62690507|NCT02202577|EXPERIMENTAL|Chlorhexidine - Isopropyl alcohol|Pre-operative skin preparation with Chlorhexidine Gluconate- Isopropyl alcohol
62690508|NCT02202577|EXPERIMENTAL|Povidone-Iodine Scrub and Paint|Pre-operative skin preparation with Povidone-Iodine Scrub and Paint
62690509|NCT05586282||Patients with a circulatory failure|All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.
62690510|NCT06637228|EXPERIMENTAL|Intervention Group|Participants in the intervention group engaged in a structured integrated exercise program designed to improve physical function and emotional well-being. The program lasted for 12 weeks, with sessions held three times a week. Each session lasted for 50 minutes and included a combination of strength training, aerobic exercises, stretching, and balance activities. The exercise regimen aimed to enhance muscle strength, endurance, flexibility, and overall quality of life, specifically targeting the symptoms of sarcopenia and depression.
62690511|NCT06637228|NO_INTERVENTION|Control Group|The control group continued with their usual treatment and daily activities.
62690512|NCT04359329|EXPERIMENTAL|Active|Estradiol Patch
61927888|NCT06739239||All patients implanted with EV-ICD in France|
61927889|NCT05179824||Group 1: Standard of Care (SOC) CGP|This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions. The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.
61927890|NCT04436640|EXPERIMENTAL|Bimekizumab|Subjects will receive bimekizumab throughout the Treatment Period.
61927891|NCT06745453|EXPERIMENTAL|Erector Spinae Plane Block|This group will receive the erector spinae plane block
61927892|NCT06745453|SHAM_COMPARATOR|Sham Procedure|This group will receive a sham injection.
61927893|NCT06743750||Study sample|There is only one group in this study
61927894|NCT05487235|EXPERIMENTAL|Dose-finding Stage: GDC-1971|Participants will receive GDC-1971 tablet or capsule at assigned dose, orally once daily (QD) on Days 1-21 of each cycle, along with atezolizumab 1200 milligrams (mg) intravenous (IV) infusion once every 3 weeks (Q3W), until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet versus (vs) capsule formulations.
61927895|NCT05487235|EXPERIMENTAL|Expansion Stage: GDC-1971|Participants will receive GDC-1971 orally at the assigned dose QD on Days 1-21 of each cycle and atezolizumab 1200 mg IV on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet vs capsule formulation, the effect of food and acid-reducing agents on GDC-1971.
62690513|NCT04359329|NO_INTERVENTION|Control|No intervention
62690514|NCT06569797|EXPERIMENTAL|experimental group|Feeding infant formula with added milk oligosaccharides and optimized for multiple nutrients
62690515|NCT06569797|ACTIVE_COMPARATOR|control group|Feeding with regular infant formula milk powder
62690516|NCT06569797|ACTIVE_COMPARATOR|Breastfeeding group|Breastfeeding with breast milk
62690517|NCT03492294||patients with disorders of consciousness|patients with disorders of consciousness from several brain injury have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state. These patients were scaned by functional magnetic resonance imaging.
61927896|NCT00959140|EXPERIMENTAL|CD3+ T-cell depletion|CD3+ T-cell depletion
62130948|NCT06107751|SHAM_COMPARATOR|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
62690518|NCT00967486|ACTIVE_COMPARATOR|Routine Shunt|These patients are called routine as the routine method of carotid endarterectomy is used.
62690519|NCT00967486|ACTIVE_COMPARATOR|Selective Shunt|These patients are selectively used for shunting or not shunting based on systolic pressure \< 40mmHg. This group is further used as subgroup analysis.
62690520|NCT05732870||Participant undergoing orthopaedic surgery|"* Patients with osteoarthritis undergoing total joint arthroplasty, osteotomy or arthrodesis of any joint (including hip, knee, shoulder, elbow, ankle).~* Patients with fractured neck of femurs undergoing hemiarthroplasty or total hip arthroplasty, or other internal fixation procedure.~* Patients undergoing acute low-velocity or fragility fracture fixation surgery."
62690521|NCT05039489|EXPERIMENTAL|The schizophrenia patients with medication-resistant auditory hallucinations|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
62690522|NCT05039489|ACTIVE_COMPARATOR|The schizophrenia patients with general auditory hallucinations|Drug intervention
62690523|NCT05039489|NO_INTERVENTION|The healthy controls|MRI scan at baseline and no drugs treatment
62690524|NCT05039489|EXPERIMENTAL|Drug + cTBS intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug + cTBS intervention (the left temporoparietal cortex as the stimulation target)
62690525|NCT05039489|ACTIVE_COMPARATOR|Drug intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug intervention
62690526|NCT05039489|EXPERIMENTAL|The schizophrenia patients with medication-resistant auditory hallucinations from the fourth arm|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
62690527|NCT00438282|NO_INTERVENTION|1|Control group
62690528|NCT00438282|EXPERIMENTAL|2|Paraprofessional home visits
62690529|NCT00438282|EXPERIMENTAL|3|Nurse home visitation
62690530|NCT04990947||Bariatric surgery (Roux-en-Y Gastric Bypass)|Patients who are eligible for RYGB
61927897|NCT06745167|EXPERIMENTAL|Pulsed field ablation|Utilizing pulsed field ablation (PFA), combining pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation, aiming to target all potential arrhythmic substrates.
61927898|NCT06745167|ACTIVE_COMPARATOR|Radiofrequency Ablation|Using conventional radiofrequency ablation technology, combines pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation, aiming to target all potential arrhythmic substrates.
61927899|NCT03963583|EXPERIMENTAL|HEROIC Intervention Group|This group will receive the HEROIC intervention.
61927900|NCT03963583|EXPERIMENTAL|Waitlist Control Group|The waitlisted group will receive usual care for caregivers for the first 12 weeks, which is normally limited to inclusion in some clinical assessment and teaching during patient visits. Waitlisted participants will receive monthly study postcards to encourage retention. After 12 weeks, they will begin the intervention.
61927901|NCT06745921|EXPERIMENTAL|Group 1A|A single, low dose, of 4 mcg of HydroVax-001B West Nile Virus (WNV) vaccine administered intramuscularly once on Day 1, Day 29, and Day 181. N=12
61927902|NCT06745921|EXPERIMENTAL|Group 1B|A single, high dose, of 10 mcg of HydroVax-001B West Nile Virus (WNV)vaccine administered intramuscularly once on Day 1, Day 29, and Day 181. N=12
61927903|NCT06745921|PLACEBO_COMPARATOR|Group 2A|A 0.5 mL dose of placebo, consisting of 0.9 % of NaCl, administered intramuscularly once on Day 1, Day 29, Day 181. N=3
61927904|NCT06745921|PLACEBO_COMPARATOR|Group 2B|A 0.5 mL dose of placebo, consisting of 0.9 % of NaCl, administered intramuscularly once on Day 1, Day 29, Day 181. N=3
61927905|NCT06745726||Single cohort|N/A, this is an observational study.
61927906|NCT05453578|ACTIVE_COMPARATOR|Stage 1/2a Arm 2|4x10\^7 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
62690531|NCT04990947||Lifestyle group|Patients with a BMI \> 30 who will start a lifestyle program
61927907|NCT05453578|ACTIVE_COMPARATOR|Stage 1/2a Arm 3|4x10\^8 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
61927908|NCT05453578|ACTIVE_COMPARATOR|Stage 1/2a Arm 4|4x10\^9 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
61927909|NCT05453578|PLACEBO_COMPARATOR|Stage 2a Arm 1|25 mL of 0.9 percent Sodium Chloride saline solution administered intravenously for 30 mins as a single dosage. N=8
61927910|NCT05453578|PLACEBO_COMPARATOR|Stage 2b Arm 1|25 mL of 0.9 percent Sodium Chloride saline solution administered intravenously for 30 mins as a single dosage. N=17
61927911|NCT05453578|ACTIVE_COMPARATOR|Stage 2b Arm 2|WRAIR-PAM-CF1 concentration determined after post stage 2a analysis, administered intravenously with 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. N=17
62690532|NCT06567262|EXPERIMENTAL|CAD/CAM metallic removable partial denture|CAD/CAM technology will be used to scan the oral cavity to create a 3D model that can be digitally surveyed. After designing RPD digitally by computer software, wax pattern can be constructed by milling or rapid prototyping technology. This wax pattern would be cast conventionally into RPD framework.
62481699|NCT06502379|EXPERIMENTAL|Part 1: SAD Cohort 3 - AZD8965 (Dose 3)|Participants will receive a single dose of AZD8965 (Dose 3) or matching placebo to AZD8965 on Day 1.
62481700|NCT06502379|EXPERIMENTAL|Part 1: SAD Cohort 4 - AZD8965 (Dose 4)|Participants will receive a single dose of AZD8965 (Dose 4) or matching placebo to AZD8965 on Day 1.
62481701|NCT06502379|EXPERIMENTAL|Part 1: SAD Cohort 5 - AZD8965 (Dose 5)|Participants will receive a single dose of AZD8965 (Dose 5) or matching placebo to AZD8965 on Day 1.
61927912|NCT06732856|EXPERIMENTAL|Treatment|
62481702|NCT06502379|EXPERIMENTAL|Part 2: MAD Cohort 1 - AZD8965 (Dose 1)|Participants will receive multiple doses of AZD8965 (Dose 1) or matching placebo to AZD8965 from Day 1 to Day 8.
62481703|NCT06502379|EXPERIMENTAL|Part 2: MAD Cohort 2 - AZD8965 (Dose 2)|Participants will receive multiple doses of AZD8965 (Dose 2) or matching placebo to AZD8965 from Day 1 to Day 8.
62481704|NCT06502379|EXPERIMENTAL|Part 2: MAD Cohort 3 - AZD8965 (Dose 3)|Participants will receive multiple doses of AZD8965 (Dose 3) or matching placebo to AZD8965 from Day 1 to Day 8.
62481705|NCT06502379|EXPERIMENTAL|Part 3A: SAD Cohort 1 (Japanese) - AZD8965 (Dose 1)|Japanese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1.
62481706|NCT06502379|EXPERIMENTAL|Part 3A: SAD Cohort 2 (Japanese) - AZD8965 (Dose 2)|Japanese participants will receive a single dose of AZD8965 (Dose 2) or matching placebo to AZD8965 on Day 1.
62481707|NCT06502379|EXPERIMENTAL|Part 3A: SAD Cohort 3 (Chinese) - AZD8965 (Dose 1)|Chinese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1.
62481708|NCT06502379|EXPERIMENTAL|Part 3B: Single and multiple ascending dose (SMAD) Cohort 1 (Japanese) - AZD8965 (Dose 1)|Japanese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1, followed by multiple doses of AZD8965 or matching placebo from Day 3 until Day 9.
62481709|NCT06502379|EXPERIMENTAL|Part 3B: SMAD Cohort 2 (Chinese) - AZD8965 (Dose 1)|Chinese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1, followed by multiple doses of AZD8965 or matching placebo from Day 3 until Day 9.
61927913|NCT06588738|EXPERIMENTAL|ESK-001|ESK-001 administered as an oral tablet
62130949|NCT06100185|ACTIVE_COMPARATOR|Stimulation|Short duration repetitive (SDR-) tES with a frequency of 0.75Hz
62130950|NCT06100185|SHAM_COMPARATOR|Sham Condition|Sham condition using a low current amplitude at 25 Hz.
62322243|NCT05663723|ACTIVE_COMPARATOR|Intervention group with the IV and V LED board|Time of Applications will for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
62322244|NCT05663723|ACTIVE_COMPARATOR|Intervention group with the IV, V and Violet LED board|Time of Applications will be for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
62322245|NCT05663723|PLACEBO_COMPARATOR|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application. Women will receive a booklet with guidelines for the correct use of the LED board and will be instructed to continue their usual physical activities and mark the daily frequency of application of the LED board
62322246|NCT02929992|EXPERIMENTAL|Home ART initiation|Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
62322247|NCT02929992|EXPERIMENTAL|Hybrid model|Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
62322248|NCT02929992|ACTIVE_COMPARATOR|Clinic ART initiation, monitoring and resupply|This is the standard of care arm. Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
62481710|NCT06502379|EXPERIMENTAL|Part 4: Food Effect Cohort - AZD8965|Participants will receive 2 single dose treatments of AZD8965 \[following an overnight fast of at least 10 hours in a fasted state or a fed state (after a high fat meal)\].
62481711|NCT05592678||Predicted Responders|Group assignment determined by a response predictor algorithm derived from remotely acquired caregiver reports of cognitive performance. The donepezil administered during the study is prescribed by the subject provider as standard of care.
61927914|NCT06588738|PLACEBO_COMPARATOR|Placebo|Matching oral placebo
61927915|NCT06588738|ACTIVE_COMPARATOR|Apremilast|Apremilast administered as an oral capsule
62130951|NCT03886116|ACTIVE_COMPARATOR|Exercise|"Patient randomized are required to squeeze a soft ball 10 times for a set. They are required to perform 3 sets of 10 squeezes each at a 1 Minute interval.~3 sets of exercises to be performed twice in the Morning and Evening, for a total of 6 weeks."
62690533|NCT06567262|ACTIVE_COMPARATOR|Conventional metallic removable partial denture|Conventional RPD design involves the production of stone casts, geometric characterization of the tooth and soft tissues related to the path of insertion, and careful designation of RPD components (major and minor connectors, rests, clasps, and base retention) using a direct waxing method.
62690534|NCT03261375|EXPERIMENTAL|Renal denervation (RDN) Group|Receive standardized 2 drugs (Nifedipine and hydrochlorothiazide) treatment and renal denervation treatments (RDN)
61927916|NCT06745050|EXPERIMENTAL|MM! Intervention|Participants in the MM! arm will receive standard care plus the individualized, interactive text message intervention. MM! includes three messages per week in month one, then two messages per week for the six-month intervention period. Messages are personalized based on participants' preferred name, language, religion, having children, and preferred message delivery time. Participants are asked to send a brief, standardized reply to each message, indicating that they are doing well or that they have a question or problem.
61927917|NCT06745050|NO_INTERVENTION|Standard Care|Participants in the control arm will receive standard care according to Kenyan guidelines, including clinic-based adherence education and counseling. This includes clinic-based ART adherence education and counseling provided by nurses specializing in HIV care.
61927918|NCT06731504|EXPERIMENTAL|Abatacept/tacrolimus/mycophenolate mofetil (ABA/Tac/MMF) following omidubicel HCT|Abatacept 10 mg/kg is given on day -1, +5, +14, and +28 in combination with standard of care tacrolimus and mycophenolate mofetil-based GVHD prophylaxis. This regimen will follow an omidubicel transplantation.
61927919|NCT05777603|EXPERIMENTAL|Arm 1|Pembrolizumab + de-escalating doses of aztreonam and vancomycin
61927920|NCT06745076|EXPERIMENTAL|Arm I (MRD negative)|"CYCLES 1-2: Patients receive nivolumab IV, doxorubicin IV, vinblastine IV and dacarbazine IV on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo MRD testing.~CYCLES 3-4: Patients receive nivolumab IV, doxorubicin IV, vinblastine IV and dacarbazine IV on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression of unacceptable toxicity.~CYCLES 5-6: Patients receive nivolumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo echocardiography or MUGA scan, PET/CT scan, questionnaire and blood sample collection throughout the study."
61927921|NCT06745076|EXPERIMENTAL|Arm II (MRD positive)|"CYCLES 1-2: Patients receive nivolumab IV, doxorubicin IV, vinblastine IV and dacarbazine IV on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo MRD testing.~CYCLES 3-6: Patients receive nivolumab IV, doxorubicin IV, vinblastine IV and dacarbazine IV on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 4 additional cycles (total of 6 cycles) in the absence of disease progression or unacceptable toxicity.~Patients undergo echocardiography or MUGA scan, PET/CT scan, questionnaire and blood sample collection throughout the study."
61927922|NCT05617677|EXPERIMENTAL|Arm 1: Deucravacitinib|
61927923|NCT05617677|PLACEBO_COMPARATOR|Arm 2: Placebo|
61927924|NCT03652545|EXPERIMENTAL|TAA-T|"Three different dosing schedules will be evaluated.~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2~Group A patients (DIPG): The first TAA-T dose will be infused any time more than or equal to 14 days after completion of radiotherapy.~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time more than or equal to 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.~Ideally, patients should not receive other systemic antineoplastic agents for at least 42 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
61927925|NCT05071859||GOBACK|The patient must have been diagnosed with cancer at ≤25 years of age and have been diagnosed with one or more congenital anomalies reported through the APEC14B1 registry intake data. For all patients in APEC14B1 with self-reported congenital anomalies the investigators will: 1) recruit cases; 2) administer the GOBACK Study questionnaire; 3) collect biological samples for sequencing; and 4) obtain medical records to verify anomalies. Medical records will be used to validate self-reported congenital anomalies and is a crucial step prior to sequencing. Additionally, the investigators will be able to identify those with well-established cancer predisposition syndromes that involve congenital anomalies, such as WAGR syndrome.
61927926|NCT06619561|EXPERIMENTAL|Vimseltinib|Escalating doses of vimseltinib in 28 day cycles.
61927927|NCT05873439|EXPERIMENTAL|Arm A: RSI predicts dose ≤ 60 Gy|Participants will receive standard RT dose of 60Gy in 30 fractions targeting the primary tumor and any involved regional lymph nodes.
61927928|NCT05873439|EXPERIMENTAL|Arm B: RSI predicts dose > 60 Gy|Participants will receive treatment with RxRSI guided boost to the primary tumor up to 81Gy (2.7Gy/fraction).
61927929|NCT05873439|EXPERIMENTAL|Arm C: unable to calculate RSI|Participants in will receive standard RT dose of 60Gy in 30 fractions targeting the primary tumor and any involved regional lymph nodes.
61927930|NCT06745310||Individuals with high body mass index|
61927931|NCT06745310||Individuals with normal body mass index|
61927932|NCT05040386|ACTIVE_COMPARATOR|Usual COPD Care|Participants randomized to this arm will receive the standard of care for COPD.
61927933|NCT05040386|EXPERIMENTAL|Intervention (EPIC plus Usual COPD Care)|Participants randomized to this arm will receive the experimental treatment for COPD (i.e. EPIC plus usual COPD care).
62130952|NCT03886116|NO_INTERVENTION|No Exercise|Patient is not required to do any exercise.
62322249|NCT04855721|EXPERIMENTAL|AUR101 400 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
62322250|NCT04855721|EXPERIMENTAL|AUR101 200 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
62322251|NCT04855721|EXPERIMENTAL|AUR101 400 mg PO QD|Patients will receive AUR101 / placebo in double blind, double dummy manner
62690535|NCT03261375|SHAM_COMPARATOR|Control Group|Receive standardized 2 drugs (Nifedipine and hydrochlorothiazide) treatment and renal artery angiography only
62322252|NCT04855721|PLACEBO_COMPARATOR|Placebo|Patients will receive AUR101 / placebo in double blind, double dummy manner
62322253|NCT06475989|ACTIVE_COMPARATOR|Arm A (Dabrafenib and trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, blood sample collection and may undergo MRI throughout the study.
62322254|NCT06475989|EXPERIMENTAL|Arm B (Cabozantinib)|Patients receive cabozantinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, blood sample collection and may undergo MRI throughout the study.
62339839|NCT02168673||Group 2|Healthy non-smokers
62690536|NCT02120261|EXPERIMENTAL|TPI with Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
61927934|NCT06550141|EXPERIMENTAL|Emapalumab|"Leukapheresis will happen within approximately 5 days of eligibility confirmation.~Emapalumab is given as a single dose on Day -1 by intravenous infusion over about 1 hour.~Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.~Axicabtagene ciloleucel will be given once on Day 0 by intravenous infusion over about 30 minutes."
61927935|NCT06453642|EXPERIMENTAL|GPX® Embolic Device|
61927936|NCT05259709|EXPERIMENTAL|Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab|"Part A:~Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment."
61927937|NCT05259709|EXPERIMENTAL|Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab|"Part B:~Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A."
61927938|NCT05092373|EXPERIMENTAL|Cohort 1 (TTF, cabozantinib)|Patients receive TTF continuously for at least 18 hours per day on days 1-21 of each cycle. Patients also receive cabozantinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61927939|NCT05092373|EXPERIMENTAL|Cohort 2 (TFF, atezolizumab, nab-paclitaxel)|Patients receive TTF continuously for at least 18 hours per day on days 1-28 of each cycle. Patients also receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each cycle and atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61927940|NCT06744907|ACTIVE_COMPARATOR|10% Povidone-Iodine Arm|A single-use sealed packet of three 10% povidone-iodine swabs will be opened via standard sterile technique. Three topical applications of 10% povidone-iodine along the length of the subdermis, using each of the 3 swab sticks provided from the sterile single-use packet. The solution will be allowed to dry at least three minutes. A culture will be obtained by rubbing an Eswab along the incision in the subdermis. Surgical exposure will proceed. After exposure is complete, an additional culture will be obtained with an Eswab in the deep wound. After corrective maneuvers are complete a final culture will be obtained with an Eswab just prior to wound closure.
61927941|NCT06744907|ACTIVE_COMPARATOR|Saline Arm|Three sterile swabs will be provided for soaking in sterile saline. Three applications of sterile saline along the length of the subdermis, using each of the 3 swabs soaked in sterile saline. The solution will be allowed to dry at least three minutes. A culture will be obtained by rubbing and Eswab along the incision in the subdermis. Surgical exposure will proceed. After exposure is complete, and additional culture will be obtained with and Eswab in the deep wound. After corrective maneuvers are complete a final culture will be obtained with and Eswab just prior to wound closure.
61927942|NCT06548490|EXPERIMENTAL|Investigational group|Participants randomized to semaglutide will be started at a low dose (0.25 mg once per week) which will be gradually increased weekly until 1.0 mg is reached at Week 4 of the intervention.
61927943|NCT06548490|PLACEBO_COMPARATOR|Control group|Participants in the control group will have placebo administered once per week.
61927944|NCT06745934|NO_INTERVENTION|Business as Usual|Participants in this arm will continue with daily life as usual.
61927945|NCT06745934|EXPERIMENTAL|Healthy Minds Program|Participants in this arm engage with the Healthy Minds Program app.
61927946|NCT04305548|EXPERIMENTAL|Trabectedin|Trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
62339840|NCT05274113|ACTIVE_COMPARATOR|Group 1: Block with Ropivacaine + Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine and 4 mg of dexamethasone will be administered
62481712|NCT05592678||Predicted Non-Responders|Group assignment determined by a response predictor algorithm derived from remotely acquired caregiver reports of cognitive performance. The donepezil administered during the study is prescribed by the subject provider as standard of care.
61927947|NCT06132945|EXPERIMENTAL|Cabozantinib and Nivolumab With Radiation Therapy|"Patients being newly initiated on cabo/nivo will be started on with cabozantinib 40 mg PO daily and nivolumab 480 mg IV day Q4 weeks~o Dose de-escalation of cabozantinib for toxicity will be allowed per prespecified toxicity dose levels~Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist. Standard institutional regimens such as 18-24 Gy in a single fraction, 24-27 Gy in three fractions, and 25-30 Gy in five fractions are permissible."
61927948|NCT06533423|NO_INTERVENTION|controlgroup|There are no established standards for identifying and addressing self-management needs in rheumatology outpatient consultations. Participants allocated to the control group will receive usual care, which consists of planned sessions with a rheumatologist and occasionally a nurse, a physiotherapist, and an occupational therapist. Those who started DMARDs of any type had an appointment with a nurse and a follow-up phone call. All participants will have the possibility to contact the outpatient clinic and talk to a nurse. Participants in the control group will be encouraged to maintain their usual daily routines and self-management practices until the follow-up assessment is conducted.
62339841|NCT05274113|ACTIVE_COMPARATOR|Group 2: Ropivacaine Block + IV Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine will be administered and patients will receive dexamethasone intravenously
62481713|NCT04081701|OTHER|Meningioma|Cohort of 30 subjects with meningioma.
62322255|NCT00793884||Diabetes Education|Latino individuals with diabetes who are attending the Emory Latino Diabetes Education Program (ELDEP) will be followed in order to collect outcomes on clinical measurements. The class curriculum follows the American Association of Diabetes Educators (AADE) seven self-care behaviors: healthy eating, being active, monitoring, medication use, problem-solving and healthy coping. Program participants attend an initial 3 hour diabetes education class conducted in Spanish and then are invited to return to monthly follow-up sessions covering topics of meal planning, exercise, medications and complications. The follow-up sessions include activities such as dance lessons, cooking demonstrations, and sharing.
62322256|NCT06195280|EXPERIMENTAL|superficial endometriosis|Endometriosis is a chronic, estrogen-dependent inflammatory disease secondary to tissue growth outside the uterine cavity, affecting approximately 10% of women of childbearing age.
62322257|NCT03259542|EXPERIMENTAL|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
62322258|NCT05638776|EXPERIMENTAL|REGEND001 Autologous Therapy Product|Transplantation of REGEND001 Autologous Therapy Product
62481714|NCT04081701|OTHER|Non-Meningioma|"Cohort of 60 subjects with non-meningioma:~(esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma and SSTR-positive tumors metastatic to the brain)"
62481715|NCT06743061||Group I|
62481716|NCT02912559|EXPERIMENTAL|Arm I (combination chemotherapy, atezolizumab)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, beginning in cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.
62690537|NCT02120261|ACTIVE_COMPARATOR|TPI with Lidocaine & Triamcinolone Acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
61927949|NCT06533423|EXPERIMENTAL|intervention group|Participants allocated to the intervention group will receive the NISMA Intervention in addition to usual care.
61927950|NCT06624228|EXPERIMENTAL|Bimekizumab|Study participants will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding during treatment period.
61927951|NCT06624228|ACTIVE_COMPARATOR|Risankizumab|Study participants will receive assigned risankizumab dosage regimen and placebo to maintain the blinding during treatment period.
61927952|NCT06744465||NearWave monitoring|Breast cancer patients receiving neoadjuvant chemotherapy treatment followed by surgery will be monitored by a noninvasive handheld imaging device before, during and after chemotherapy.
61927953|NCT06743919|EXPERIMENTAL|group 1|patient will receive 20 ml bupivacaine 0.25% plus 500 mg magnesium sulfate in 5ml normal saline on both sides.
61927954|NCT06743919|EXPERIMENTAL|group 2|patients will receive 20 ml bupivacaine 0.25% plus o .5 microg per kg dexmedetomidine in 5 ml normal saline on both sides.
61927955|NCT06743919|PLACEBO_COMPARATOR|group 3|patients will receive 20 ml bupivacaine 0.25% plus 5 ml normal saline on both sides.
61927956|NCT06229457|EXPERIMENTAL|Girls PLAY program|
61927957|NCT01752491|EXPERIMENTAL|15g Ascorbate|"During radiation therapy:~* Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.~* Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.~* Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).~After radiation therapy:~* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
61927958|NCT01752491|EXPERIMENTAL|25g Ascorbate|"If the 15g arm is tolerated, the study opens the 25g arm.~During radiation therapy:~* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~* Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
61927959|NCT01752491|EXPERIMENTAL|50g arm|"If the 25g arm is tolerated, the study opens the 50g arm.~During radiation therapy:~* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~* Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
61927960|NCT01752491|EXPERIMENTAL|62.5g|"If the 50g arm is tolerated, the study opens the 62.5g arm.~During radiation therapy:~* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~* Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
62322259|NCT05638776|PLACEBO_COMPARATOR|Placebo|Transplantation of Placebo
62322260|NCT02124187|EXPERIMENTAL|eCig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
62481717|NCT02912559|ACTIVE_COMPARATOR|Arm II (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.
62481718|NCT01449981|EXPERIMENTAL|Integrated Twelve-Step Facilitation|
62481719|NCT01449981|EXPERIMENTAL|Cognitive Behavioral Therapy|
62481720|NCT06667674|EXPERIMENTAL|Intervention group|Participants will receive cognitive behavioral therapy treatment (iCBT) for prolonged grief.
62481721|NCT06667674|ACTIVE_COMPARATOR|Active control|Participants will receive psychoeducation about grief and common grief reactions.
62481722|NCT06667674|NO_INTERVENTION|Waitlist control|Participants will be offered the iCBT treatment for prolonged grief after 10 weeks.
62481723|NCT06742216|EXPERIMENTAL|Monosialoganglioside|Monosialoganglioside GM1, 200 mg/day, for 12-14 days
62481724|NCT06742216|PLACEBO_COMPARATOR|Placebo|Placebo, for 12-14 days
62481725|NCT06742632||first trimester abortion|
62481726|NCT06742632||second trimester abortion|
62481727|NCT00540787|ACTIVE_COMPARATOR|Drug Treatment|
62322261|NCT02124187|SHAM_COMPARATOR|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
62322262|NCT02124187|PLACEBO_COMPARATOR|Nicotine free inhalator|nicotine free inhalator for 12 weeks
62322263|NCT00055419|EXPERIMENTAL|400 mg/m2|
62322264|NCT02599766|EXPERIMENTAL|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
62322265|NCT02599766|ACTIVE_COMPARATOR|standard therapy|"Standard therapy without the presence of an animal."
62322266|NCT06211504|ACTIVE_COMPARATOR|MDCO without STI|"1. For patients with preoperative gastrocnemius-soleus complex tightness, defined as a preoperative dorsal extension of the ankle less than 5 degrees, with the knee completely extended, a Strayer´s procedure will be performed before the other procedures.~2. MDCO will be performed where the distal aspect of the calcaneus is separated from the proximal aspects, slided medially and fixed with two screws.~3. After the MDCO, FDL will be transferred to the navicular bone.~4. The spring ligament will be assessed. If ruptured, it will be reconstructed. If not ruptured, it will be tightened.~5. A plantarflexing open wedge osteotomy of the medial cuneiform (Cotton osteotomy) will be performed if pre-/perioperative findings indicate it."
62322267|NCT06211504|EXPERIMENTAL|MDCO with STI|"1. In patients with preoperative gastrocnemius-soleus complex tightness, defined as a preoperative dorsal extension of the ankle less than 5 degrees, with the knee completely extended, a Strayer´s procedure will be performed before the other procedures.~2. Thereafter, an STI (ProStop® Arthroereisis Subtalar Implant, Arthrex GmbH, Munich, Germany) will be inserted into the sinus tarsi.~3. MDCO will be performed where the distal aspect of the calcaneus is separated from the proximal aspects, slided medially and fixed with two screws.~4. After the MDCO, FDL will be transferred to the navicular bone.~5. The spring ligament will be assessed. If ruptured, it will be reconstructed. If not ruptured, it will be tightened.~6. A plantarflexing open wedge osteotomy of the medial cuneiform (Cotton osteotomy) will be performed if pre-/perioperative findings indicate it."
62322268|NCT05110898|EXPERIMENTAL|Fixed-dose Olmesartan 20mg/40 mg + Indapamide 1,5 mg|
62322269|NCT05110898|ACTIVE_COMPARATOR|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|
62322270|NCT05507944||Healthcare workers at Oslo University Hospital|"Occupational control.~Environmental exposure during commuting."
62322271|NCT05507944||Hairdressers|"Occupational exposure for airway irritants during hairdressing.~Environmental exposure during commuting."
62481728|NCT00540787|ACTIVE_COMPARATOR|ThermoCool Radiofrequency Catheter|Radiofrequency catheter used.
62481729|NCT06743178|NO_INTERVENTION|No exposure control group|This group was not exposed to any drug-related photo.
62481730|NCT06743178|EXPERIMENTAL|Photo of person injecting drugs|Participants randomized to this arm were exposed to a photo of a person injecting drugs.
62481731|NCT06743178|EXPERIMENTAL|Photo of Emergency Medical Services (EMS) responding to an overdose (White)|Participants randomized to this arm were exposed to a photo of EMS responding to a white person who had overdosed.
62481732|NCT06743178|EXPERIMENTAL|Photo of EMS responding to an overdose (Black)|Participants randomized to this arm were exposed to a photo of EMS responding to a Black person who had overdosed.
62481733|NCT06743178|EXPERIMENTAL|Photo of a person receiving treatment (Jail)|Participants randomized to this arm were exposed to a photo of a person receiving methadone treatment in jail.
62481734|NCT06743178|EXPERIMENTAL|Photo of a person receiving treatment (Community)|Participants randomized to this arm were exposed to a photo of a person receiving methadone treatment in a community setting.
62481735|NCT06743178|EXPERIMENTAL|Photo of a person in recovery (White)|Participants randomized to this arm were exposed to a photo of a white person in recovery in their workplace.
62481736|NCT06743178|EXPERIMENTAL|Photo of a person in recovery (Black)|Participants randomized to this arm were exposed to a photo of a Black person in recovery in their workplace.
62481737|NCT06743178|EXPERIMENTAL|Photo of a family member of an overdose decedent|Participants randomized to this arm were exposed to a photo of a person who had lost a family member to an overdose.
62481738|NCT04258605||ASHCOM Shoulder System subjects|Subjects implanted with the ASHCOM Shoulder System
62481739|NCT06742242|EXPERIMENTAL|The Use of Non-ICG-Enhanced Lymphatic Vessels for LVA|The use of non-ICG-enhanced lymphatic vessels for LVA
62481740|NCT03831256|ACTIVE_COMPARATOR|Standard of care (2nd tier NIPS)|For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
62690538|NCT02180672|ACTIVE_COMPARATOR|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
62690539|NCT02180672|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
61927961|NCT01752491|EXPERIMENTAL|75g Ascorbate|"If the 62.5g arm is tolerated, the study opens the 75g arm.~During radiation therapy:~* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~* Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
62130953|NCT02306954|ACTIVE_COMPARATOR|High Dose IL-2|"Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.~Patients assigned to the IL-2 arm who have disease progression after the first two IL-2 cycles have the option to receive SBRT followed by 2 additional cycles of IL-2."
62130954|NCT02306954|EXPERIMENTAL|High Dose IL-2 and SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before IL-2 starts (the following Monday). Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
62690540|NCT03377322|ACTIVE_COMPARATOR|Treatment|Probiotics capsules
62690541|NCT03377322|PLACEBO_COMPARATOR|Placebo|Placebo capsules containing maltodextrin
62690542|NCT02431026|EXPERIMENTAL|Cooling present|"Cooling pack activated before start of MRI scan for the condition cooling present."
62690543|NCT02431026|NO_INTERVENTION|No cooling present|"Cooling pack will not be activated in the condition no cooling present."
61927962|NCT01752491|EXPERIMENTAL|87.5g Ascorbate|"If the 75g arm is tolerated, the study opens the 87.5g arm.~During radiation therapy:~* Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~* Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~* Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~* Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~* Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
61927963|NCT06129539|EXPERIMENTAL|Debio 4326|Participants will receive the first injection of Debio 4326, on Day 1 in Part A followed by a second injection 52 weeks later in Part B of the study.
61927964|NCT05710107|ACTIVE_COMPARATOR|PENG + LFC Block|The pericapsular nerve group (PENG) block is an ultrasound-guided approach, first described by Giron-Arango et al. for the blockade of the articular branches of the femoral, obturator and accessory obturator nerves that provide sensory innervation to the anterior hip capsule \[5,6\]. In the PENG block, a low-frequency, curvilinear probe is used to visualize the anterior inferior iliac spine, iliopsoas tendon, and iliopubic eminence. After placing a subcutaneous skin wheel with lidocaine, a blunt regional anesthesia needle is inserted using in-plane ultrasound guidance. The needle is advanced until the tip lies on the lateral and inferior margin of the iliopsoas tendon between the anterior inferior iliac spine (lateral) and iliopubic eminence (deep).
61927965|NCT05710107|ACTIVE_COMPARATOR|QL Block|The lateral QL block is performed by injecting local anesthetic deep to the transversus abdominis aponeurosis and superficial to the fascia transversalis with direct ultrasound guidance. After completing consent, placing monitors and providing mild sedation, the patient is positioned laterally and the muscular anatomy (external oblique, internal oblique, transverse abdominis, quadratus lumborum and latissimus dorsi muscles) identified. After placing a subcutaneous skin wheel with lidocaine, a blunt regional anesthesia needle is inserted using in-plane ultrasound guidance. Local anesthetic is deposited incrementally with frequent aspiration in the anterolateral border of the quadratus lumborum muscle at the junction of the transversalis fascia, outside the anterior layer of the thoracolumbar fascia and superficial to the fascia transversalis.
61927966|NCT06393608|ACTIVE_COMPARATOR|Magnesium sulfate|Patients in the first group will receive an amber bottle of 250 milliliters containing treatment.The treatment is a solution of MgSO4 25% with sterile water base (Epsom salt solution, concentrated to 25% \[SSE25\]).
61927967|NCT06393608|PLACEBO_COMPARATOR|Water|Patients in the second group will receive an amber bottle of 250 milliliters containing the placebo.The placebo is sterile water.
61927968|NCT00596180||1|HBOT
61927969|NCT03678389|EXPERIMENTAL|1|ENDOSPHENOIDAL COIL
61927970|NCT06424769|ACTIVE_COMPARATOR|Enhanced Digital Care Arm|Participants will receive brief check-in surveys about their IBD symptoms minimally once a month, via text messaging. Participants will also receive IBD educational text messages twice each week.
61927971|NCT06424769|PLACEBO_COMPARATOR|Specialized Education Arm|Participants in this arm will receive IBD educational text messages twice each week.
61927972|NCT03073967|EXPERIMENTAL|Part C, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
61927973|NCT03073967|ACTIVE_COMPARATOR|Part C,|"Investigator's Choice:~Foscarnet iv, 40 mg/kg tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg body weight given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, topically applied 3 times per week, for up to 28 days and potential prolongation for up to additional 14 days."
61927974|NCT03073967|EXPERIMENTAL|Part D, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
61927975|NCT03073967|EXPERIMENTAL|Part E, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
62130955|NCT01286714|EXPERIMENTAL|clips OST|
62130956|NCT05425862|EXPERIMENTAL|Treatment with both talazoparib and pidnarulex|At the time of registration, patients will be assigned to the specific dose-schedule of talazoparib and pidnarulex depending on where the study is at in terms of dose-escalation or dose-expansion
62130957|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
62130958|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
62690544|NCT06087536|EXPERIMENTAL|OMN6 treatment|OMN6 on top of Meropenem and Colistin
62690545|NCT06087536|PLACEBO_COMPARATOR|Placebo|Placebo on top of Meropenem and Colistin
62690546|NCT04160598|PLACEBO_COMPARATOR|Placebo group|bolus 50 ml nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
62690547|NCT04160598|EXPERIMENTAL|IV Mg ++ group|continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate.
62690548|NCT03989284|EXPERIMENTAL|Peer counseling group|Peer counselors performed 1-hour home visits weekly to their assigned clients for three months.
62690549|NCT03989284|EXPERIMENTAL|Social engagement group|Senior citizens joined 3-hour weekly social events held at the OSCA Center for three months.
62690550|NCT03989284|EXPERIMENTAL|Combination group|Senior citizens in this group underwent both peer counseling and social engagement interventions mentioned above.
62690551|NCT03989284|NO_INTERVENTION|Control group|Senior citizens in this group had access to usual or standard care from health and aged care services that were usually available.
62690552|NCT04586751|ACTIVE_COMPARATOR|study group|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed. In specific, using the in-plane insertion technique, after visualization of the entire needle as a bright hyperechoic line and aiming between pectoralis major and pectoralis minor at the 3rd rib level, 2 ml of normal saline 09% will be injected first, to verify the correct position of the needle. Followingly, 10 mL ropivacaine 0.5% will be injected in order to block the lateral and medial pectoral nerves. Finally, another 15 ml of ropivacaine 0.5% plus 4 mg of dexamethasone will be injected between the pectoralis minor muscle and the anterior serratus muscle,at the level of the 4th and 5th ribs, after negative aspiration, to block the intercostal and intercostobrachial nerves. Using the color Doppler the vessels will be identified, so that their puncture is avoided during the procedures.
62690553|NCT04586751|SHAM_COMPARATOR|control group|no regional block will be performed
61927976|NCT03073967|EXPERIMENTAL|Part F, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
61927977|NCT05355402|EXPERIMENTAL|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 49 weeks.
61927978|NCT05355402|PLACEBO_COMPARATOR|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
61927979|NCT06743633||Prospective study: Cardiovascular disease patients on β-blockers therapy atleast from last 1 year|Evaluation of depression status using ICD 10, HADS, PHQ-9
61927980|NCT06743633||Prospective study: Cardiovascular disease patients without β-blockers therapy|Evaluation of depression status using ICD 10, HADS, PHQ-9.
61927981|NCT06743633||Retrospective study: Clinically diagnosed Depression patients + Cardiovascular comorbidities|To determine the prevalence of patients on β-blocker use among clinically diagnosed depression patients with cardiovascular comorbidities by reviewing their medical records.
61927982|NCT06743633||Retrospective study:Clinically diagnosed Depression + Cardiovascular comorbidities without β-blocker|To determine the prevalence of patients without β-blocker use among clinically diagnosed depression patients with cardiovascular comorbidities by reviewing their medical records.
61927983|NCT05439772|NO_INTERVENTION|Control|Pediatric patients between the ages of 2-20 who have a clinical indication for colonoscopy, who will undergo standard colonoscopy preparation of polyethylene glycol and bisacodyl
61927984|NCT05439772|EXPERIMENTAL|Ondansetron|Pediatric patients between the ages of 2-20 who have a clinical indication for colonoscopy, who will undergo standard colonoscopy preparation of polyethylene glycol and bisacodyl with the addition of one dose of ondansetron prior to initiating bowel preparation.
62130959|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
62130960|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
62130961|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
62130962|NCT03553472||Vedolizumab therarpy|12 IBD patients on vedolizumab maintenance therapy every 4-8 weeks
61927985|NCT05160584||Participants with Relapsed/Refractory Multiple Myeloma|Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant.
62130963|NCT03553472||Prednisone and Anti-TNF therapy|12 IBD patients on Anti-TNF maintenance therapy as combination or mono therapy along with at least 10mg of prednisone
62130964|NCT05806060|EXPERIMENTAL|De novo or DFI≥12m Arm 1|If patients were De novo or their disease-free interval (DFI) were more than or equal to 12 months and were randomized to experimental arm, they would receive VEGFR BP102 with nab-palitaxel (Nab-P). And maintained by VEGFR and capecitabine if intolerable toxicity was observed with no progression.
62130965|NCT05806060|ACTIVE_COMPARATOR|De novo or DFI≥12m Arm 2|If patients were De novo or their disease-free interval (DFI) were more than or equal to 12 months and were randomized to control arm, they would receive nab-palitaxel (Nab-P). And maintained by capecitabine if intolerable toxicity was observed with no progression.
62690554|NCT01881932|NO_INTERVENTION|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
61927986|NCT04852783|EXPERIMENTAL|Attempted to Treat|Attempted to treat (ATT) with the investigational device
61927987|NCT05042388|EXPERIMENTAL|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Group intervention comprised of didactics and trainings in cognitive behavioral therapy relapse prevention skills and mindfulness meditation.
61927988|NCT05042388|ACTIVE_COMPARATOR|Treatment-As-Usual (TAU)|Standard procedure for residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on issues related to mental health and substance use disorders; and medication counseling. No aspect of the treatment-as-usual services provided entails mindfulness training or components of mindfulness training.
61927989|NCT06046014|EXPERIMENTAL|Expressive Writing (EW)|four- week, in- home, Body Image (BI)- focused EW intervention
61927990|NCT06046014|ACTIVE_COMPARATOR|Attention Control|four- week control writing program
61927991|NCT06743711||Patients|Adults with severe mental illness in treatment with antipsychotic medications
62690555|NCT01881932|EXPERIMENTAL|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
62690556|NCT01881932|ACTIVE_COMPARATOR|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
61927992|NCT06743711||Healthy controls|Adults without present or previous mental illness, and no first-degree relatives with present or previous mental illness, matched to the patient group for gender, age, and BMI.
61927993|NCT02435810||Family Member|A family member of a patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
61927994|NCT02435810||Patient|Patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
61927995|NCT04728451|ACTIVE_COMPARATOR|Full-Time Spectacle Wear|Parents are asked to encourage their child to wear the spectacles full-time (all waking hours). A study staff member works closely with families throughout the child's participation to provide support and encouragement and to make suggestions on methods parents can use to maximize spectacle wear.
61927996|NCT04728451|ACTIVE_COMPARATOR|Ad-Lib Spectacle Wear|Parents are asked to encourage their child to wear the spectacles as much as possible for the initial 30 days after dispensing, and thereafter to continue to offer the spectacles to the child but not force the child to wear them if they resist or refuse. Limited support for parents is provided with regard to maximizing spectacle wear.
61927997|NCT06744751|ACTIVE_COMPARATOR|Fecal Microbiota Transplantation|The FMT capsules used in this study contain processed, frozen stool from healthy donors, providing gut microbiota from these individuals. They are available in two doses: size 0 capsules contain 175 mg of bacterial powder, and size 3 capsules contain 85 mg of bacterial powder. The FMT capsules meet relevant manufacturing standards. Patients take the capsules once daily, with a dose of 4 capsules per day, over a period of 12 days (for a total of 48 capsules). Capsules are selected based on age: patients under 16 use size 3 capsules, while those aged 16 and older use size 0 capsules.
61927998|NCT06744751|PLACEBO_COMPARATOR|Placebo|The placebo capsules, manufactured by the same company, are identical in appearance, size, color, dosage form, weight, and taste to the FMT capsules. Starch is used as the main ingredient to mimic the FMT capsules.
62322272|NCT03642015|EXPERIMENTAL|listening music|The participants in the music group selected the music they preferred from different genres. During the 15-min intervention period before the gastroscopy procedure, the experimental group rested by listening to music and sitting on a comfortable chair
62690557|NCT02990702|ACTIVE_COMPARATOR|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block group patients (Group R) will receive 30 cc %0.5 Bupivacaine
62690558|NCT02990702|ACTIVE_COMPARATOR|Ultrasound guided infraclavicular block|Ultrasound guided coracoid infraclavicular block group patients (Group C) will receive 30 cc %0.5 Bupivacaine
62322273|NCT03642015|NO_INTERVENTION|Control|control group rested only by sitting on a comfortable chair
62322274|NCT06553313|OTHER|the control group of knee arthritis|Monitoring the stability of protein expression, pulse wave and meridian energy in the serum of the KOA control group (participants without knee pain).
62322275|NCT06350539||Affected Subjects|Subjects in this group will have a solid tumor cancer diagnosis.
61927999|NCT04313712||Participants|All study participants will be observed before and after they receive ibogaine-magnesium therapy.
61928000|NCT06744998|EXPERIMENTAL|Hemopatch® group|Hemopatch® application after axillary dissection
61928001|NCT06744998|NO_INTERVENTION|No Hemopatch® group|No Hemopatch® application after axillary dissection
61928002|NCT06739083|EXPERIMENTAL|e-mentoring program|The e-mentoring program is planned to last four weeks to facilitate the adaptation process of newly recruited nurses in intensive care units via the e-mentoring website.
61928003|NCT00764504|EXPERIMENTAL|Primary|Primary shoulder
61928004|NCT00764504|EXPERIMENTAL|Revision|Revision shoulder
61928005|NCT00764504|EXPERIMENTAL|Continued Access|Primary shoulder subjects enrolled at a later date in order to collect more data.
61928006|NCT06551142|EXPERIMENTAL|Phase 1a: Dose escalation-GSK5764227|
62322276|NCT06350539||Healthy Control|Subjects in this group will serve as healthy controls.
62322277|NCT06692010|EXPERIMENTAL|Group CPB|Clavipectoral fascia plane block group
62322278|NCT06692010|EXPERIMENTAL|Group ISBP & SCPB|Interscalene brachial plexus block \& superficial cervical plexus block group
62130966|NCT05806060|EXPERIMENTAL|DFI<12m Arm 1|If patients' disease-free interval (DFI) were less than 12 months and were randomized to experimental arm, they would receive VEGFR BP102 with treatment of physician's choice (TPC).
62130967|NCT05806060|ACTIVE_COMPARATOR|DFI<12m Arm 2|If patients' disease-free interval (DFI) were less than 12 months and were randomized to control arm, they would receive physician's choice (TPC).
62130968|NCT01094184|EXPERIMENTAL|Bevacizumab 10 mg/kg Q2W|Participants will receive bevacizumab at a dose of 10 milligrams per kilogram (mg/kg) every 2 weeks (Q2W) as intravenous infusion along with paclitaxel every week (Q1W) or docetaxel every 3 weeks (Q3W) as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
62322279|NCT06693115|EXPERIMENTAL|CGM with alerts|"The experimental group will have a Dexcom 7 CGM placed by a trained and credentialed member of the research team, or by a trained care team member (e.g. nurse, physician, diabetes educator).~CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels~2. CGM alerts to interstitial glucose level of 150 mg/dL or less."
62322280|NCT06693115|NO_INTERVENTION|CGM without alerts|"The control group will have a Dexcom 7 CGM placed by a trained and credentialed member of the research team, or by a trained care team member (e.g. nurse, physician, diabetes educator).~The control group will have the device placed and glucose levels will be collected, but the device will not be set to alert (though note that the Dexcom 7 CGM will always alert when glucose drops below 55 mg/dl, so this alert will exist for both groups)."
62130969|NCT01094184|EXPERIMENTAL|Bevacizumab 15 mg/kg Q3W|Participants will receive bevacizumab at a dose of 15 mg/kg Q3W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
62130970|NCT02861066|EXPERIMENTAL|Mindfulness-based Intervention|6 week, abbreviated group MBI treatment for depression and anxiety
62130971|NCT06337058|EXPERIMENTAL|experimental group|intervention group
62322281|NCT00813553|PLACEBO_COMPARATOR|beta-alanine 0|
62322282|NCT00813553|EXPERIMENTAL|beta-alanine 1|
62322283|NCT00813553|EXPERIMENTAL|beta-alanine 2|
61928007|NCT06551142|EXPERIMENTAL|Phase 1b: Dose expansion-GSK5764227|
62130972|NCT06337058|NO_INTERVENTION|control group|control group
62130973|NCT06521151|EXPERIMENTAL|egg based diet and Audio based nutrition education - group (arm-1)|76 pregnant women will be recruited to receive both egg based diet and audio based nutrition education
62690559|NCT01929603|EXPERIMENTAL|Olaparib alone, olaparib+rifampicin|Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
62481741|NCT03831256|EXPERIMENTAL|First-tier NIPS|For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
62130974|NCT06521151|EXPERIMENTAL|egg based diet alone- group (arm-2),|76 pregnant women will be recruited to receive egg based diet alone
62481742|NCT05143931|ACTIVE_COMPARATOR|WW Only|WW is commercially-available weight management program focusing on diet, physical activity and mindset skills.
62481743|NCT05143931|EXPERIMENTAL|WW + Home modification and grocery delivery (AVOID)|WW + modification of home food environment + online grocery shopping and delivery
62481744|NCT05143931|EXPERIMENTAL|WW + Inhibitory control training (RESIST)|WW + daily gamified inhibitory control training
62481745|NCT05143931|EXPERIMENTAL|WW + Home food modification and grocery delivery (AVOID) + Inhibitory control training (RESIST)|WW + modification of home food environment + online grocery shopping and delivery + daily gamified inhibitory control training
62481746|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
62322284|NCT06259955|EXPERIMENTAL|intervention group|The trainings were conducted in Gazi University Faculty of Health Sciences Seminar Hall and Nursing Practice Laboratory with one group on Monday and Tuesday and the other group on Wednesday and Thursday. Students could miss the eight-session program at most two times. It was planned to make up for the absent course in consultation with the instructor. 37 Students attended the training regularly.
62322285|NCT06259955|NO_INTERVENTION|control group|Throughout the study, the control group continued its routine lecture and clinical practice program. They were called only at the end of the course for the pre-test, interim measurement and post-test on the course days.
62322286|NCT02678988|EXPERIMENTAL|A1: Tocilizumab AI followed by PFS-NSD in abdomen|Participants will receive two single doses of 162 milligrams (mg) tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in abdomen.
62322287|NCT02678988|EXPERIMENTAL|A2: Tocilizumab AI followed by PFS-NSD in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2) in thigh.
62481747|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
62481748|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
62481749|NCT00872729|ACTIVE_COMPARATOR|Cystagon®|Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
62481750|NCT00872729|EXPERIMENTAL|RP103|Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
62481751|NCT01016613||Chronic Kidney Disease Cohort|chronic kidney disease patients with any type of kidney disease
62130975|NCT06521151|EXPERIMENTAL|Audio based nutrition education alone -group (arm- 3).|76 pregnant women will be recruited to receive audio based nutrition education alone
62130976|NCT06521151|NO_INTERVENTION|control arm (Arm-4)|72 pregnant women will be employed in the control group to receive routine health education
62130977|NCT04608305|EXPERIMENTAL|phase I - Group Ia, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E5 pfu/ml or saline placebo at day 0
62322288|NCT02678988|EXPERIMENTAL|A3: Tocilizumab AI followed by PFS-NSD in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in upper arm.
62322289|NCT02678988|EXPERIMENTAL|B1: Tocilizumab PFS-NSD followed by AI in abdomen|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in abdomen.
62481752|NCT01016613||Matched Control Group|Healthy controls
62481753|NCT01016613||Trios|First degree relatives of pediatric chronic kidney disease cohort members
62481754|NCT05032807|EXPERIMENTAL|Novel lipid formulation then standard formulation|
62481755|NCT05032807|EXPERIMENTAL|Standard formulation then lipid formulation|
62481756|NCT05931458|ACTIVE_COMPARATOR|Group 1|Infliximab
61928008|NCT06551142|ACTIVE_COMPARATOR|Phase 1b: Dose expansion- Topotecan|
62481757|NCT05931458|EXPERIMENTAL|Group 2|Appendectomy
62481758|NCT04979663|EXPERIMENTAL|experimental group|Combination of Gemox, Donafenib and Tislelizumab
62481759|NCT05385757||Childhood Uveitis|Children \<18 years old newly diagnosed with non-infectious uveitis
62481760|NCT04349475|EXPERIMENTAL|Omega 3 Supplementation|Supplementation of 4g of DHA/EPA daily
62481761|NCT04349475|PLACEBO_COMPARATOR|Safflower Oil Supplement|Supplementation of Safflower Oil daily
62481762|NCT03609203||Patients|
62481763|NCT03609203||Controls|
62481764|NCT06561594|EXPERIMENTAL|Experimental group|30subjects：GenSci094 was administered for 12 weeks，150ug/0.5ml（weight\>60kg）or 100ug/0.5ml（weight≤60kg）；GenSci094 with chorionic gonadotropin for injection was administered for 52 weeks，150ug/0.5ml（weight\>60kg）or 100ug/0.5ml（weight≤60kg）with chorionic gonadotropin for injection.
62481765|NCT06561594|PLACEBO_COMPARATOR|Placebo group|30subjects：GenSci094 Placebo was administered for 12 weeks，150ug/0.5ml（weight≥60kg）or 100ug/0.5ml（weight\<60kg）；GenSci094 Placebo with chorionic gonadotropin for injection was administered for 52 weeks，150ug/0.5ml（weight≥60kg）or 100ug/0.5ml（weight\<60kg）with chorionic gonadotropin for injection.
62481766|NCT06015984|EXPERIMENTAL|Web-Based 8-week Asynchronous Renal Transplantation Nurse Training|"1. Week: application of pre-tests~1. Month: administration of post-tests 3. Month: administration of post-tests"
62481767|NCT06015984|NO_INTERVENTION|non-trained nurse group|"1. Week: application of pre-tests~1. Month: administration of post-tests 3. Month: administration of post-tests"
62481768|NCT06626997|EXPERIMENTAL|Study Group|Participants will consume a 250cl bottle of soluble fibre-enriched kombucha mid-morning or mid-afternoon, avoiding consumption after eating. The drink will be included in a healthy eating plan. They will be advised to continue their usual physical activity during the 6 weeks of the study.
62481769|NCT06626997|PLACEBO_COMPARATOR|Control Group|Participants will consume one 250cl bottle of a similar unfermented and unfortified beverage mid-morning or mid-afternoon, avoiding consumption after eating. The beverage will be included in a healthy eating plan. Participants will be advised to continue their usual physical activity for the 6 weeks of the study.
62481770|NCT01988376|EXPERIMENTAL|Women with cervical cancer receive Surepath for screening|Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
62481771|NCT01988376|ACTIVE_COMPARATOR|Women receive conventional Pap smear for screening|Women who will receive conventional Pap smear for screening
62481772|NCT03806257|NO_INTERVENTION|Control|Subjects in the control arm will receive standard of care, which consists of mobilization to a bedside chair at least once, and ambulate one-half ICU circumference on postoperative day one. On postoperative days two through five, the subject will be mobilized to the bedside chair at least once, and ambulated at least once with target of one full ICU circumference. These subjects will receive gait training and safe ambulation education, and wear a FitBit Charge 2 watch for five days after surgery.
62481773|NCT03806257|EXPERIMENTAL|Enhanced Physical Therapy Protocol|Subjects in the experimental arm will recieve a FitBit Charge 2 watch, and will be mobilized to the bedside chair on postoperative day zero. On postoperative day two subjects will be mobilized to the bedside chair twice, ambulate one-half of the ICU circumference, and receive gait and safe ambulation training. On postoperative days two through five, subjects will mobilize to the bedside chair three times, and will be encouraged to ambulate three times, each time with a target of one full ICU circumference.
62322290|NCT02678988|EXPERIMENTAL|B2: Tocilizumab PFS-NSD followed by AI in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
62322291|NCT02678988|EXPERIMENTAL|B3: Tocilizumab PFS-NSD followed by AI in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
62481774|NCT02281994|ACTIVE_COMPARATOR|Active PEMF|Active device emits Pulsed Electromagnetic Field (PEMF)
62481775|NCT02281994|PLACEBO_COMPARATOR|Control/no PEMF|control/placebo device does not emit Pulsed Electromagnetic Field (PEMF)
62481776|NCT01154712|ACTIVE_COMPARATOR|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
62690560|NCT01532219|EXPERIMENTAL|Internet-delivered Psychodynamic Treatment|Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
62690561|NCT01532219|ACTIVE_COMPARATOR|Internet-delivered structured support|Participants in the active control condition will receive a structured support treatment via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail.
61928009|NCT02386969|EXPERIMENTAL|Active rTMS then sham rTMS|Active rTMS in 1st period and sham rTMS in 2nd period
61928010|NCT02386969|EXPERIMENTAL|Sham rTMS then active rTMS|Sham rTMS in 1st period and active rTMS in 2nd period
62322292|NCT02992470|EXPERIMENTAL|Hydrolyzed oyster extract|A 250 mg, film-coated oblong (rectangle) shaped tablet of oyster extract
62322293|NCT02992470|PLACEBO_COMPARATOR|Placebo|A 250 mg, film-coated oblong (rectangle) shaped tablet of maltodextrin
62322294|NCT06621472|EXPERIMENTAL|• Group R: Retrolaminar block (RLB)|Patients will receive bilateral ultrasound guided retrolaminar block with injection of 20 ml bupivacaine 0.25% in each side.
62322295|NCT06621472|EXPERIMENTAL|Group T. Subcostal transversus abdominis plane block (STAP)|Patients will receive bilateral Ultrasound guided subcostal TAP with injection of 20 ml bupivacaine 0.25% in each side.
62322296|NCT06621472|EXPERIMENTAL|Epidural|By loss of resistant technique and catheter insertion at the level of thoracic vertebrae (7-10)
62322297|NCT00384540|OTHER|Cardiovascular events vs Dobutamine stress echocardiography|
62322298|NCT03955107|OTHER|Continuous Glucose Monitoring System|
62322299|NCT01188044||Study group|Healthy children
62322300|NCT05762185|EXPERIMENTAL|nursing consultation|
62690562|NCT02953431|PLACEBO_COMPARATOR|Sham CPAP|Participants will be randomized to Sham CPAP
62690563|NCT02953431|ACTIVE_COMPARATOR|CPAP 10|Participants will be randomized to CPAP 10
62690564|NCT03053232|EXPERIMENTAL|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
62481777|NCT01154712|SHAM_COMPARATOR|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
62481778|NCT06714565||Older adults who have experienced a fall.|
62481779|NCT01770223|EXPERIMENTAL|Boceprevir + PegIFN-2b + RBV|All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).
62481780|NCT00211263|EXPERIMENTAL|Enhanced Clinical Intervention|
62481781|NCT00211263|ACTIVE_COMPARATOR|Clinical Intervention|
62481782|NCT03399214|EXPERIMENTAL|IOP Injection, Phase 1b, Cohort 1|IV injection, 0.27 mg/kg
62481783|NCT03399214|EXPERIMENTAL|IOP Injection, Phase 1b, Cohort 2|IV injection, 0.54 mg/kg
62481784|NCT02552758|EXPERIMENTAL|Omega-3 fatty acid|omega-3 fatty acid
62481785|NCT02552758|PLACEBO_COMPARATOR|placebo|placebo
62322301|NCT03531619||Dizziness|Patients referred to a neuro-otological clinic due to dizziness who answer that they do not suffer from neck pain
62322302|NCT03531619||Dizziness and neck pain|Patients referred to a neuro-otological clinic due to dizziness who answer that they suffer from neck pain
62322303|NCT03531619||Neck pain|Patients referred to a rehabilitation center due to neck pain who answer that they do not suffer from dizziness
62322304|NCT03531619||Neck pain and dizziness|Patients referred to a rehabilitation center due to neck pain who answer that the suffer from dizziness
62481786|NCT02281253|EXPERIMENTAL|With metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
62481787|NCT02281253|EXPERIMENTAL|Without metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
62481788|NCT05019560|ACTIVE_COMPARATOR|Group A|"In group A:~* The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.~* Patients received inhalation induction using sevoflurane 8% and fentanyl 2 µg/kg was administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated then atracurium 0.5 mg/kg was given intravenously and sevoflurane reduced to 2%, then laryngoscopy and intubation were done when action of neuromuscular blocker (NMB) was confirmed by the disappearance of T3,T4. During this time, mask assisted ventilation with 100% oxygen was used to achieve normocapnia"
62690565|NCT03053232|ACTIVE_COMPARATOR|Endoclips|Use of endoclips to close gastrointestinal perforation.
62322305|NCT03531619||Healthy Control|Healthy Controls without neck pain or dizziness
62322306|NCT06019780|EXPERIMENTAL|Experimental interventional group A (Blood flow restriction training)|"Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption with pneumatic cuff for blood flow restriction"
62322307|NCT06019780|ACTIVE_COMPARATOR|Control group B|"Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption without blood flow restriction"
62322308|NCT03938376||Potential Prostate Cancer|Biopsy naïve patients with rising Prostate Specific Antigen (PSA) results referred by their Urologist for a standard of care (SOC) biopsy.
62322309|NCT01704248|PLACEBO_COMPARATOR|Routine self-instillation technique|The participants first use the Routine self-instillation technique for two weeks and then switch to the Eye Drop Guide technique for another two weeks.
62322310|NCT01704248|EXPERIMENTAL|Eye Drop Guide technique|The participants first use the Eye Drop Guide technique for two weeks and then switch to the Routine self-instillation technique for another two weeks.
62322311|NCT04220528|EXPERIMENTAL|Radical chemoradiotherapy plus oral capecitabine/teggiol|Patients with newly diagnosed, non-metastatic stage N3 NPC was given Teggio 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving radical chemoradiotherapy.
62322312|NCT04531319||Case Group|Covid 19 (+) patients
62322313|NCT04531319||Control Group|Healthy volunteers
62322314|NCT04454996|EXPERIMENTAL|Non-erosive reflux disease test group|
62481789|NCT05019560|ACTIVE_COMPARATOR|Group B|"In group B:~* The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.~* In group B: propofol 1.5 mg/kg and fentanyl 2 µg/kg were administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated and then atracurium 0.5 mg/kg was given intravenously. Propofol infusion 6 mg/kg/hr was started, until action of neuromuscular blocker (NMB) was confirmed by disappearance of T3,T4, then laryngoscopy and intubation were done. The used dosing regimen is according to previous guidelines \[8\] \[9\].No inhalational agent was used. Mask assisted ventilation was used to achieve normocapnia."
62481790|NCT05594095|EXPERIMENTAL|SNF1 1A: PIK3CA mutation|PIK3CA inhibitors +Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.
62481791|NCT05594095|EXPERIMENTAL|SNF1 1B: AKT pathway mutation|AKT pathway inhibitors +Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.
62481792|NCT05594095|EXPERIMENTAL|SNF1 1C: without above mutation|Everolimus 10mg po qd+Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.
62481793|NCT05594095|EXPERIMENTAL|SNF2 2A|Treatment of physician' choice+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib 15mg po qd for 4 weeks as a cycle
62481794|NCT05594095|EXPERIMENTAL|SNF3 3A: Stratification of BRCA/PALB2 expression|Fluzoparib SHR3162 100mg po qd+Dalpiciclib 125mg po qd for 4 weeks as a cycle
62481795|NCT05594095|EXPERIMENTAL|SNF4 4A: HER2 low|SHR-A1811
62481796|NCT05594095|ACTIVE_COMPARATOR|The control arm|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
62481797|NCT05594095|EXPERIMENTAL|SNF3 3B:|Fluzoparib SHR3162 100 mg qd+Treatment of physician' choice
62481798|NCT05594095|EXPERIMENTAL|SNF4 4B:|Apatinib 250mg qd+Treatment of physician' choice
62481799|NCT05594095|EXPERIMENTAL|SNF1 1D: without above mutation|Everolimus 10mg po qd+Treatment of physician' choice
62481800|NCT05594095|EXPERIMENTAL|SNF1 1E: HER2 LOW|Everolimus 10mg po qd+SHR-A1811
62481801|NCT05594095|EXPERIMENTAL|SNF1 1F: HER2 zero|Everolimus 10mg po qd+SHR-A1921
62481802|NCT05594095|EXPERIMENTAL|SNF2 2B: HER2 zero|SHR-A1921+Pd-1 mab (Carrelizumab 200mg Q2W)+bevacizumab 7.5mg po ivgt t for 3 weeks as a cycle
62481803|NCT05594095|EXPERIMENTAL|SNF2 2C:|HER3 -ADC+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle
62481804|NCT05594095|EXPERIMENTAL|SNF2 2D:|Nectin4-ADC+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle
62481805|NCT05594095|EXPERIMENTAL|SNF2 2E: HER2 low|SHR-A1811+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib for 3 weeks as a cycle
62481806|NCT05594095|EXPERIMENTAL|SNF3 3C:|CDK4i（SHR-6209 PR2D+PARP1i（SHR-1167 PR2D）
62481807|NCT05594095|EXPERIMENTAL|SNF3 3D:|PARP1i（SHR-1167 PR2D)+Famitinib 5mg po qd for 4 weeks as a cycle
62481808|NCT05594095|EXPERIMENTAL|SNF3 3E: HER2 low|PARP1i（SHR-1167 PR2D)+SHR-A1811 for 3 weeks as a cycle
62481809|NCT05594095|EXPERIMENTAL|SNF3 3F: HER2 zero|PARP1i（SHR-1167 PR2D)+SHR-A1921 for 3 weeks as a cycle
62481810|NCT05594095|EXPERIMENTAL|SNF4 4C|Famitinib 20mg po qd
62481811|NCT05594095|EXPERIMENTAL|SNF4 4D|Sorafenib 0.4g bid
62481812|NCT05594095|EXPERIMENTAL|SNF4 4E|Apatinib 500mg qd
62322315|NCT04454996|PLACEBO_COMPARATOR|Non-erosive reflux disease control group|
62322316|NCT04454996|EXPERIMENTAL|Diarrhea-type irritable bowel syndrome test group|
62322317|NCT04454996|PLACEBO_COMPARATOR|Control group with diarrheal irritable bowel syndrome|
62322318|NCT04454996|NO_INTERVENTION|Healthy control group|
62322319|NCT06594848|PLACEBO_COMPARATOR|Placebo|Placebo consists in 4 g of maltodextrin with food coloring (blue and green dyes) to match the color on the active comparator (Black Rice Extract). The placebo will be dissolved in 200 ml of water.
62322320|NCT06594848|ACTIVE_COMPARATOR|Black rice extract|Active comparator consists in 2 g of Black Rice Extract and 2 g of maltodextrin. The Black Rice Extract will be dissolved in 200 ml of water.
62322321|NCT01905397|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump (also 510K cleared) may be used in some cases with the Prevena dressings as to achieve the negative pressure
62481813|NCT05594095|EXPERIMENTAL|SNF4 4F: HER2 low|Famitinib+SHR-A1811 for 3 weeks as a cycle
62481814|NCT05594095|EXPERIMENTAL|SNF4 4G|Famitinib+HER3-ADC for 3 weeks as a cycle
62322322|NCT01905397|ACTIVE_COMPARATOR|Conventional wound therapy|Traditional wound therapy (sterile bandages and dressing)
62481815|NCT05594095|EXPERIMENTAL|SNF4 4H|Famitinib+Nectin4-ADC for 3 weeks as a cycle
62481816|NCT02882776|OTHER|Ginger drink once daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water once a day for continuous 5 days.
62481817|NCT02882776|OTHER|Ginger drink twice daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water twice a day for continuous 5 days.
62481818|NCT04939051|EXPERIMENTAL|Arm I (OCA)|Patients receive OCA PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo liver ultrasound during screening, EGD with biopsies, brushings and gastric aspirate at end of treatment visit and blood sample collection throughout the study.
62481819|NCT04939051|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo liver ultrasound during screening, EGD with biopsies, brushings and gastric aspirate at end of treatment visit and blood sample collection throughout the study.
62481820|NCT04847466|EXPERIMENTAL|1/Arm 1|1-week lead in for PD-L1 CAR NK cell monotherapy followed by combination therapy of Pembrolizumab plus N-803
62322323|NCT06691880|EXPERIMENTAL|Video Gaming Technology (VGT) based arm training|Patients who meet inclusion criteria will be assessed for level of arm impairment and allocated to either MindPod VGT or Bimanual Arm Trainer VGT based on the severity of impairment. Patients will complete up to 60 minutes of VGT treatment in addition to the standard of care therapy (Physical, occupational, and or speech therapy). Patients will be monitored before, during, and after the sessions for tolerance and response to the treatment. This will include physiological response using measures such as blood pressure, heart rate, and pulse oximeter. Self reported pain and fatigue will be collected using visual analog scales. Safety issues that are predefined as line dislodgement, falls, change in vital signs or pain necessitating interruption of the therapy session will be measured and calculated as the number of adverse events as a proportion of the number of sessions attended
62339842|NCT04399512|ACTIVE_COMPARATOR|Patients with liver cirrhosis|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in MELD(model for end stage liver disease) will be checked after treatment.
62481821|NCT00262392|EXPERIMENTAL|Pamidronate|Pamidronate
62481822|NCT00262392|ACTIVE_COMPARATOR|radiation|radiation
62481823|NCT04509453|EXPERIMENTAL|McGRATH|
62481824|NCT04509453|ACTIVE_COMPARATOR|Macintosh|
62481825|NCT01294020|EXPERIMENTAL|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B of the study.
62481826|NCT06741605||Pregnant women with cervical pain|Pregnant women with cervical pain in their third trimester will be assessed to investigate the relationship between biomechanical risk factors and neck pain in pregnant women.
62481827|NCT06742333|EXPERIMENTAL|Treatment Group|Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12
61928011|NCT04521608|EXPERIMENTAL|Intervention- Home Pulmonary Rehabilitation|Participants enrolled in the intervention arm will be offered a Home-based pulmonary rehabilitation program with health coaching.
61928012|NCT04521608|NO_INTERVENTION|Control- Choice|This arm receives the standard of care which includes the choice of PR at a facility or through telehealth. Center based PR involves attending a medical center gym where they can do exercises and receive disease specific education. Telehealth PR is delivered virtually through the computer or telephone.
61928013|NCT05314504|EXPERIMENTAL|Test group|Treatment administration to subjects
61928014|NCT05314504|NO_INTERVENTION|Control group|After primary endpoint evaluation, eligible subjects will receive treatment at Week 12
61928015|NCT04902326|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Receives one intervention: automated educational text messages
61928016|NCT04902326|EXPERIMENTAL|Financial Incentives|Receives two interventions: automated educational text messages and financial incentives.
61928017|NCT04902326|EXPERIMENTAL|Tailored Messages|Receives two interventions: autonomy-supportive automated educational text messages and tailored text messages.
61928018|NCT04902326|EXPERIMENTAL|Combo Arm-Financial Incentives Plus Tailored Messages Arm|Receives three interventions: autonomy-supportive automated educational text messages, tailored text messages, and financial incentives.
61928019|NCT00650234|EXPERIMENTAL|1|Metformin Hydrochloride ER Tablets 500 mg
61928020|NCT00650234|ACTIVE_COMPARATOR|2|Glucophage® XR Tablets 500 mg
61928021|NCT03654027|EXPERIMENTAL|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
61928022|NCT03654027|ACTIVE_COMPARATOR|Docetaxel|Docetaxel (75mg/m2 IV d1)
61928023|NCT06076564||Informants|Informants are individuals who knew someone who had a fatal stimulant overdose. Once a decedent is selected, their records will be reviewed to familiarize the interviewer with the situation of their death. Informants will be identified using contacts that the OCME used during their investigation, death records from the state, or emergency contacts from medical records, followed by recommendations from any of those contacts.
61928024|NCT06076564||Living Persons who use Stimulants|To identify resilience factors and risk reduction strategies among living persons who use stimulants, study staff will conduct interviews with up to 60 adults who use either cocaine or methamphetamine.
62322324|NCT04180059|EXPERIMENTAL|CTL 19 : T cell therapy|Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg. After study of toxicity of the 4 injected patients, choice has been made to stop the CRM method to choose the dose and to test only 2 doses for each last patients : 100 x 10\^4 cells/kg (actual level 5) and 500 x 10\^4 cells/kg (choice based on compassionnal injections data at the level 5)
61928025|NCT06710509|NO_INTERVENTION|Control Group|
61928026|NCT06710509|EXPERIMENTAL|Experimental Group|Group receiving the messages
61928027|NCT06327542|NO_INTERVENTION|Usual Care|Participants will receive care as usual provided through their primary care providers. Usual care includes medical diagnostic evaluation, analgesic drug therapies, recommendations for physical activity, and sometimes referral to specialist physicians or physical therapy. Usual care was chosen as a comparison arm for this study because it is practical and clinically relevant. Participants randomized to usual care will be put on a waitlist and can access group acupuncture or IGMV after their final study visit.
61928028|NCT06327542|EXPERIMENTAL|Group Acupuncture|Participants randomized to acupuncture will receive 12 weeks of acupuncture treatments delivered in a group setting, dosing similar to prior research. Acupuncture point selection and other treatment details will follow responsive manualization, a protocol developed for the largest clinical trial of group acupuncture to date. A licensed acupuncturist experienced with administering group acupuncture treatments will determine each participant's traditional Chinese medicine diagnosis and administer 8-10 acupuncture needles on distal points of participant's body (below the knees, from the elbows to the hands, and on the head). Duration of assessment, needle placement and retention will be 30-45 minutes. Details of acupuncture treatments (e.g., frequency and duration, traditional Chinese medicine diagnosis, number of needles and points used) will be documented in electronic health records.
61928029|NCT06327542|EXPERIMENTAL|Integrative Group Medical Visits (IGMV)|IGMV will consist of a 12-week program that provides education on the biopsychosocial model of pain and multimodal treatments; physical movement; mindfulness training; and peer support. Non-pharmacologic approaches are based on guidelines on chronic pain management; feedback of experts, staff, and patients; and feasibility with the greatest potential to benefit participants. Participants will receive a binder with educational materials.
61928030|NCT06327542|EXPERIMENTAL|Group Acupuncture and IGMV|Both group acupuncture and IGMV. Along with usual care, participants will be offered weekly group acupuncture treatments and integrative group medical visits as described above.
61928031|NCT05973214|EXPERIMENTAL|CBT|
62322325|NCT06114953|EXPERIMENTAL|Mizoribine group|Mizoribine, glucocorticoid, tacrolimus
62322326|NCT06114953|ACTIVE_COMPARATOR|Mycophenolate group|Mycophenolate mofetil, glucocorticoid, tacrolimus
61928032|NCT05973214|OTHER|Waitlist|
61928033|NCT05300633|EXPERIMENTAL|Intervention arm|Family member/concerned significant other
62322327|NCT05998993|EXPERIMENTAL|Radiation|A total of 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
62322328|NCT05528042|OTHER|N/A, only one arm|All the patients that would like to participate and those where the inclusion criteria are past, are available to make the test. No drugs are administered.
62130978|NCT04608305|EXPERIMENTAL|phase I - Group Ib, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E6 pfu/ml or saline placebo at day 0
62339843|NCT04399512|ACTIVE_COMPARATOR|Normal healthy patients|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis
62130979|NCT04608305|EXPERIMENTAL|phase I - Group Ic, Prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E7 pfu/ml or saline placebo at day 0
62130980|NCT04608305|EXPERIMENTAL|phase I - Group Id, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
62130981|NCT04608305|EXPERIMENTAL|phase II - Group IIa, prime, low dose*|"Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E5 pfu/ml or saline placebo at day 0.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62481828|NCT06742333|ACTIVE_COMPARATOR|Comparator group|Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks. The randomization will take place at the end of V1, baseline visit, after verifying the selection criteria and written consent, by the investigator in charge of the patient in each center.
62481829|NCT05502835|EXPERIMENTAL|conventional fluid management group|patients will do elective open colonic mass resection and anastomosis will receive Infusion of 6 ml/kg/hr. Ringer's solution.
62130982|NCT04608305|EXPERIMENTAL|Phase II - Group IIb, Prime, low dose, elderly subjects*|"Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1\*10E5 pfu/ml or saline placebo at day 0.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62130983|NCT04608305|EXPERIMENTAL|phase II - Group IIc, Prime, medium dose*|"Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E6 pfu/ml or saline placebo at day 0.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62130984|NCT04608305|EXPERIMENTAL|phase II - Group IId, Prime, medium dose, elderly subjects*|"Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1\*10E6 pfu/ml or saline placebo at day 0.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62130985|NCT04608305|EXPERIMENTAL|Phase II - Group IIe, prime, high dose*|"Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1\*10E7 pfu/ml or saline placebo at day 0.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62130986|NCT04608305|EXPERIMENTAL|Phase II - Group IIf, Prime, high dose, elderly subjects*|"Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1\*10E7 pfu/ml or saline placebo at day 0.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62130987|NCT04608305|EXPERIMENTAL|phase II - Group IIg, prime-boost, low dose*|"Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E5 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62130988|NCT04608305|EXPERIMENTAL|phase II - Group IIh, prime-boost, low dose, elderly subjects*|"Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.~\*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
62130989|NCT04608305|EXPERIMENTAL|phase II - Group IIi, prime-boost, medium dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E6 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
62322329|NCT01734993|EXPERIMENTAL|Tocilizumab|Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of \>1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.
62322330|NCT06038097|EXPERIMENTAL|Early intervention arm|Radiofrequency Pallidotomy at earliest available date
62322331|NCT06038097|NO_INTERVENTION|Delayed intervention arm|Radiofrequency pallidotomy offered at 12 weeks following agreeing to participate in the study
62322332|NCT06693492|EXPERIMENTAL|Chronic patients (DOC duration >=1 year)|"* Assessment with US technique to characterized the pathophysiological features of chronic DOC~* For the Interventional part of the project, the selected patients in this arm will be treated with a single session of US neuromodulation and the following measures will be collected before and after the intervention:~Coma Recovery Scale-revised; Resting state fMRI; EEG-based neurophysiological indices"
62322333|NCT06693492|EXPERIMENTAL|Post-acute patients (DOC duration <1 year)|"* Assessment with US technique to characterized the pathophysiological features of post-acute DOC and explore its predictive value for chronicization~* For the Interventional part of the project, the selected patients in this arm will be treated with a single session of US neuromodulation and the following measures will be collected before and after the intervention:~Coma Recovery Scale-revised; Resting state fMRI; EEG-based neurophysiological indices"
62322334|NCT05165576|EXPERIMENTAL|Child-centered communication|The child's preparation for the MRI scanning is conducted using a child-centered communication type of interaction
62322335|NCT05165576|ACTIVE_COMPARATOR|Magnetic Resonance Imaging (MRI) Simulation Toy|The child's preparation for the MRI scanning is conducted through provision of general information about the MRI exam simulated with an MRI toy
62322336|NCT05165576|NO_INTERVENTION|General information about the Magnetic Resonance Imaging (MRI) exam|The child's preparation for the MRI scanning is based on the provision of routine information about the MRI exam
62322337|NCT02361749|ACTIVE_COMPARATOR|Myectomy group|Subjects will undergo anal myectomy for their anal sphincter.
62322338|NCT02361749|ACTIVE_COMPARATOR|Botox Group|Subjects will undergo Botulinum toxin injection into their anal sphincter.
62322339|NCT01232972|EXPERIMENTAL|oocyte freezing|includes any women who elects to preserve her fertility by vitrifying her unfertilized eggs.
62481830|NCT05502835|ACTIVE_COMPARATOR|ppv group|patients will do elective open colonic mass resection and anastomosis. Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
62481831|NCT02919540|EXPERIMENTAL|kangaroo care approach|the kangaroo care approach will be implemented for dyads who agree to participate
62322340|NCT04695847|EXPERIMENTAL|Part 1: M1231|Participants with solid tumors for whom no effective standard therapy exists will be included in this Part. Dose escalation of M1231 will be administered as single agent.
62481832|NCT02919540|NO_INTERVENTION|control group|routine care will be implemented
62130990|NCT04608305|EXPERIMENTAL|phase II - Group IIj, prime-boost, medium dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E6 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
62130991|NCT04608305|EXPERIMENTAL|phase II - Group IIk, prime-boost, high dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E7 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
62130992|NCT04608305|EXPERIMENTAL|phase II - Group IIl, prime-boost, high dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E7 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
62481833|NCT06742398|ACTIVE_COMPARATOR|Carbohydrate Mouth Rinse|Subjects will be instructed to complete the 12.8 km time trial (TT) as quickly as possible. They will be able to adjust the speed on the treadmill throughout the TT but will have no knowledge of what speed they are actually running at. The researcher will monitor the progress of the TT, and the completion time will be recorded. The carbohydrate mouth rinse treatment will be given just before the start of the TT and every 12.5% of the TT, but not after the completion of the TT.
62130993|NCT04608305|EXPERIMENTAL|phase II - Group IIm, prime-boost, top dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1\*10E8 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
62130994|NCT04608305|EXPERIMENTAL|phase II - Group IIn, prime-boost, top dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1\*10E8 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
62130995|NCT05207241||Control group|Under the professional guidance of doctors, participating women (1) breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding
62322341|NCT04695847|EXPERIMENTAL|Part 2: Cohort A M1231: Metastatic NSCLC|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) expressing Epidermal Growth Factor Receptor (EGFR) and Mucin 1 (MUC1) on archival tumor tissue will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
62322342|NCT04695847|EXPERIMENTAL|Part 2: Cohort B M1231: Metastatic Esophageal Squamous Cell Carcinoma|Participants with metastatic esophageal squamous cell carcinoma will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
62322343|NCT04618692|ACTIVE_COMPARATOR|Surgical Loupes|In this group , patients will undergo biliary reconstruction using surgical loupe
62322344|NCT04618692|ACTIVE_COMPARATOR|Microscope|In this group , patients will undergo biliary reconstruction using microscope
62322345|NCT03629626|NO_INTERVENTION|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
62322346|NCT03629626|EXPERIMENTAL|ERAS protocol|preoperative / intraoperative/ postoperative management
62322347|NCT05520619|EXPERIMENTAL|Tislelizumab plus CRT with maintenance|Patients will receive 2 cycles of 3-weekly schedule of induction chemotherapy, consisting of paclitaxel 135-175 mg/m2, cisplatin 75 mg/m2, and tislelizumab 200mg on day 1 prior to CRT. Then all patients will receive standard fractionation radiation therapy scheme: 50.4 Gy in 28 fractions, concurrently with paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks and 2 cycles of tislelizumab. Patients in Arm A will receive 12 additional cycles of tislelizumab after the completion of radiotherapy.
62322348|NCT05520619|EXPERIMENTAL|Tislelizumab plus CRT without maintenance|Patients will receive 2 cycles of 3-weekly schedule of induction chemotherapy, consisting of paclitaxel 135-175 mg/m2, cisplatin 75 mg/m2, and tislelizumab 200mg on day 1 prior to CRT. Then all patients will receive standard fractionation radiation therapy scheme: 50.4 Gy in 28 fractions, concurrently with paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks and 2 cycles of tislelizumab. Patients in Arm B will receive 4 cycles of tislelizumab in total.
62339844|NCT02864940|EXPERIMENTAL|Intervention Arm|Using the cognitive exercises on Lumosity for 10 weeks
62339845|NCT02864940|ACTIVE_COMPARATOR|Control Arm|Using online crossword puzzles for 10 weeks.
62130996|NCT03580135|EXPERIMENTAL|Propolis powder|"* resin (50%),~* vegetable Balsam, wax~* essential aromatic oils (30%)~* salivary secretions (10%)~* pollen(5%)~* other substances (5%) including amino acids~  ,ethanol vitamin A, B complex, and E, minerals, steroids~* ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.~* Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
62322349|NCT02713581||Women with proximal VTE|"Patients will correspond to cases of proximal venous thromboembolism. They will be recruited during consultations conducted for the chronic management of a history of proximal venous thromboembolism or thrombophilia following a recent history of proximal venous thromboembolism. Venous thromboembolism, outside of acute phase episodes, has good symptom stability over time; no difference is to be expected between patients with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease.~Intervention: Blood sampling"
62481834|NCT06742398|SHAM_COMPARATOR|Water Mouth Rinse|Subjects will be instructed to complete the 12.8 km time trial (TT) as quickly as possible. They will be able to adjust the speed on the treadmill throughout the TT but will have no knowledge of what speed they are actually running at. The researcher will monitor the progress of the TT, and the completion time will be recorded. The water mouth rinse treatment will be given just before the start of the TT and every 12.5% of the TT, but not after the completion of the TT.
62481835|NCT06742398|EXPERIMENTAL|Carbohydrate Dissolvable Strip|Subjects will be instructed to complete the 12.8 km time trial (TT) as quickly as possible. They will be able to adjust the speed on the treadmill throughout the TT but will have no knowledge of what speed they are actually running at. The researcher will monitor the progress of the TT, and the completion time will be recorded. The carbohydrate dissolvable strip treatment will be given just before the start of the TT and every 12.5% of the TT, but not after the completion of the TT.
62481836|NCT03030664|ACTIVE_COMPARATOR|L.reuteri|probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
62481837|NCT03030664|PLACEBO_COMPARATOR|Placebo|Same formulation as probiotics, without active substance. 5 drops per day will be delivered
62481838|NCT06742866|EXPERIMENTAL|Experimental group (Intravenous + Oral Amiodarone)|Within 24 hours post-operation, patients will receive an intravenous amiodarone loading dose of 300 mg QD along with oral amiodarone 200 mg BID. This regimen will be continued for 3 days, after which intravenous amiodarone will be discontinued, and oral amiodarone 200 mg BID will be continued for 3 months.
62130997|NCT03580135|ACTIVE_COMPARATOR|Mineral Tri Oxide|"* Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.~* A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
62481839|NCT06742866|PLACEBO_COMPARATOR|Control group (Oral Amiodarone only)|Postoperatively, instead of administering intravenous amiodarone, sodium chloride injection was used as a placebo, and oral amiodarone 200 mg BID was directly given for 3 months.
62481840|NCT06446479|EXPERIMENTAL|Placebo first, Dronabinol second|This arm will receive placebo on the first visit, and dronabinol on the second visit
62322350|NCT02713581||Women with >1 healthy pregnancy|"This populations is composed of healthy, female, adult volunteers (\<50 years in age) that have had at least 1 healthy pregnancy.~Intervention: Blood sampling"
62322351|NCT01617434|EXPERIMENTAL|Liraglutide|
62481841|NCT06446479|EXPERIMENTAL|Dronabinol first, Placebo second|This arm will receive dronabinol on the first visit, and placebo on the second visit.
62481842|NCT06559904|OTHER|Mediterranean diet|Mediterranean diet was applied to this group according to the needs of the individuals. The explanation was made through the Mediterranean diet training document and sample menu prepared by the researcher. The individuals were asked to apply this diet for 12 weeks. The individuals' compliance with the diet was evaluated with food consumption records in 4-week periods. Blood samples were taken from the individuals at the beginning of the treatment as biological material and at the end, blood samples and follicle fluid samples were collected according to the adjuvant treatment. Fatty acid analyses were performed with gas chromatography.
62481843|NCT06559904|NO_INTERVENTION|Control group|This group did not receive any intervention. Food consumption records, blood samples and follicular fluid samples were taken only once from individuals who came for IVF treatment.
62481844|NCT06489262|EXPERIMENTAL|"Healthy Together (Juntos)"|"Participants will receive the Healthy Together (Juntos) digital intervention. The six-month intervention includes an intensive phase comprised of eight modules and coaching sessions delivered in the first three months and a maintenance phase comprised of three modules and coaching sessions delivered in the subsequent three months."
62481845|NCT06489262|NO_INTERVENTION|Control|This group will receive a digital standard of care - a list of publicly available lifestyle apps and websites that they may access at their discretion.
62130998|NCT02709850|PLACEBO_COMPARATOR|Cohorts A, D: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
62690566|NCT00544947||D, F|"Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.~Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section."
62690567|NCT00918398|EXPERIMENTAL|1|AZD1981, 100 mg iv infusion
62690568|NCT00918398|EXPERIMENTAL|2|AZD1981, 514 mg oral solution
62130999|NCT02709850|EXPERIMENTAL|Cohorts A, D: IONIS ANGPTL3-LRx 20 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 20 milligrams (mg) subcutaneously on Day 1.
62131000|NCT02709850|EXPERIMENTAL|Cohorts A, D: IONIS ANGPTL3-LRx 120 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 120 mg subcutaneously on Day 1.
62322352|NCT01617434|PLACEBO_COMPARATOR|Placebo|
62322353|NCT03237832|PLACEBO_COMPARATOR|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
62322354|NCT03237832|PLACEBO_COMPARATOR|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
62131001|NCT02709850|PLACEBO_COMPARATOR|Cohorts B, C: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
62131002|NCT02709850|EXPERIMENTAL|Cohorts B, C: IONIS ANGPTL3-LRx 40 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 40 mg subcutaneously on Day 1.
62131003|NCT02709850|EXPERIMENTAL|Cohorts B, C: IONIS ANGPTL3-LRx 80 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 80 mg subcutaneously on Day 1.
62131004|NCT02709850|PLACEBO_COMPARATOR|Cohorts AA-DD: Placebo|Participants received IONIS ANGPTL3-LRx-matching placebo subcutaneously once per week for 6 weeks.
62322355|NCT03237832|PLACEBO_COMPARATOR|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
62322356|NCT03237832|PLACEBO_COMPARATOR|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
62322357|NCT03237832|PLACEBO_COMPARATOR|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
62322358|NCT02606045|ACTIVE_COMPARATOR|Group I|Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
62322359|NCT02606045|ACTIVE_COMPARATOR|Group II|Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
62322360|NCT03765567|EXPERIMENTAL|Intervention Arm|Subjects randomized to the Intervention Arm will receive usual care plus two (2) grams of Vancomycin powder administered topically. In the emergency room prior to surgical intervention, a qualified member of the study team or clinical team member will apply 2 grams of vancomycin powder directly to the open fracture site such that all visible surfaces of the wound are completely and uniformly covered, including bone edges.
62322361|NCT03765567|NO_INTERVENTION|Control Arm|Subjects randomized to the Control Arm will receive usual care for open long bone fracture as determined by the treating physician.
62322362|NCT03765567|NO_INTERVENTION|Observational Arm|Subjects who otherwise meet the criteria to be included in the study but are not able to provide consent, either themselves or through a Legally Authorized Representative, will be placed in the Observational Arm and receive usual care with no experimental intervention.
62322363|NCT06322992||Cancer Patients Undergoing Treatment|The investigators will recruit 60 diverse cancer patients from the statewide M Health Fairview system to participate in month-long feasibility tests. The enrolled participants will be asked to: 1) Install the prototype app from the Google Play or Apple App Store on their smartphone (the investigators will provide a smartphone with the app pre-installed to participants who do not own one); 2) Carry the smartphone for 30 consecutive days while outside the home; 3) Keep smartphone location and motion services active; 4) Confirm and correct (if needed) smartphone-detected activities and trips; 5) Use the app interface to provide additional information on treatment-related activities and trips along with well-being ratings; and 6) Review a logistic toxicity summary report that will be available within the app towards the end of the field test.
62322364|NCT06692348|EXPERIMENTAL|Orforglipron|Participants will receive different sequences of Orforglipron doses administered as either single capsule or multiple capsules at different dose levels under either fasted or fed condition.
62322365|NCT05598931||Healthy Controls|Subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in which various TMS coil positions will be recorded. The brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. Data from Yr1 will be used by the programmer as a training sample, and from Yr2 as a test sample.
62322366|NCT01175070|EXPERIMENTAL|Pegaptanib|Participants receiving 6-weekly treatment with pegaptanib sodium (Macugen \[TM\]) for ischaemic diabetic macular oedema over a 30 week period.
62322367|NCT03872583|EXPERIMENTAL|Understanding MRI in MS (website)|Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
62322368|NCT03872583|ACTIVE_COMPARATOR|Control website|Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
62322369|NCT06155682|ACTIVE_COMPARATOR|Active rTMS|multiple trains of active transcranial magnetic stimulation in a day (using the active TMS coil), for multiple days
62322370|NCT06155682|SHAM_COMPARATOR|sham rTMS|multiple trains of sham transcranial magnetic stimulation in a day (using the sham comparator TMS coil), for multiple days
62322371|NCT03841149||VolUS3D patients|Patients with renal tumour
62322372|NCT02126111|ACTIVE_COMPARATOR|DEPIGOID phleum|The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
62322373|NCT02126111|PLACEBO_COMPARATOR|DEPIGOID Placebo & DEPIGOID Phleum|"This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract."
62322374|NCT05377034|EXPERIMENTAL|Study Arm|SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab
62322375|NCT05377034|EXPERIMENTAL|Control Arm|SIRT-Y90 + placebos (IV)
62322376|NCT02120651|ACTIVE_COMPARATOR|Fibrin monomer|40 patients, the material was ready to use in the case of the fibrin monomer it was maintained in cooling according to the indications of lab maintenance and it was taken out a few minutes before using the material to prepare it according to instructional use and thus ensure that the conditions of maintenance of equipment are appropriate to the best outcome with their use.
62322377|NCT02120651|PLACEBO_COMPARATOR|Hemostatic sponge|40 patients, the material was ready to use in the case of the hemostatic sponge was cut into small size, prepared and impregnated with hydrocortisone as in the standard procedure.
62690569|NCT00918398|EXPERIMENTAL|3|AZD1981, 500 mg oral tablet A
62690570|NCT00918398|EXPERIMENTAL|4|AZD1981, 500 mg oral tablet B
62690571|NCT02048046||ECMO|
62131005|NCT02709850|EXPERIMENTAL|Cohorts AA-DD: IONIS ANGPTL3-LRx 10 mg|Participants received IONIS ANGPTL3-LRx 10 mg subcutaneously once per week for 6 weeks.
62322378|NCT03830801|EXPERIMENTAL|IVLCM tethered capsule for biopsies|IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.
62322379|NCT04743635|EXPERIMENTAL|Targeted Verifiable Subcision (TVS) with the Avéli device, mITT|"Modified intent to treat population (n=68). The modified intent to treat population was used to evaluate effectiveness.~The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks"
62481846|NCT06741982|EXPERIMENTAL|Treatment Cohort|"1. Tislelizumab administration on days 1 and 22, and afatinib continuous administration from days 1 to 42~2. Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.~3. Standard of care surgery"
62481847|NCT04884841||Patients with postoperative complications|Patients with postoperative complications
61928034|NCT05319769||Zero fluoroscopy|"Zero fluoroscopy Patients undergoing AF ablation using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography.~Reconstruction of a bipolar map of the right atrium with a mapping catheter. Then, the interatrial septum is reconstructed and the oval fossa is defined. Transseptal puncture is performed using the steerable introducer (which can be viewed on the EAM) through which, a transseptal needle is introduced. The introducer is positioned at the fossa ovalis. The transseptal needle is advanced to perform the puncture of the septum. After accessing the left atrium, the mapping catheter is introduced iusing the introducer, with which all the structures of the left atrium are mapped. In addition, with intracardiac echocardiography, it is possible to identify important structures such as the pulmonary veins and the esophagus. The pulmonary veins are isolated by means of a catheter."
61928035|NCT05319769||Traditional approach|"Traditional approach Patients who have undergone atrial fibrillation ablation procedure using the traditional approach.~The procedure is based on 3D reconstruction using intracardiac ultrasound first and then electroanatomical mapping of the left atrium through a transseptal approach guided by integration of fluoroscopy and intracardiac ultrasound. The transseptal puncture is performed using a transseptal needle which is brought into place using a long introducer with a dilator. The fluoroscopic support is essential as the introducer is not viewable with 3D mapping systems. After accessing the left atrium, through the previously used introducer, a mapping catheter is taken to the left atrium for electro-anatomical reconstruction. Subsequently, the antral pulmonary veins are isolated by means of an ablator catheter with irrigated tip."
62322380|NCT04743635|EXPERIMENTAL|Targeted Verifiable Subcision (TVS) with the Avéli device, Roll-in|The roll-in population (n=6) was excluded from the effectiveness analyses. For Investigators that have not previously performed an Avéli procedure, two (2) participants were classified as roll-in participants. The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks
62322381|NCT03736083|ACTIVE_COMPARATOR|Freestyle Libre Group|Freestyle Libre Group: Participants will use the Freestyle Libre flash glucose monitoring system throughout the study for 2-3 months.
62322382|NCT03736083|NO_INTERVENTION|Control Group (standard diabetes care)|This group will receive standard care. At the around 1 week and 2 month visits, control group subjects will use a blinded Freestyle Libre Pro to provide data that can be used to compare glucose variability between groups. The Libre sensor will allow the study team to measure glucose values but the subjects will not have access to this information for management/treatment decisions and usual diabetes care will be unaffected. The Freestyle Libre Pro last 14 days, can be activated in clinic, and the sensor can be returned in person or via mail where the investigators will download the data.
62322383|NCT06333015|EXPERIMENTAL|enVista Beyond EY IOL|Subjects implanted with enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY
62322384|NCT06333015|ACTIVE_COMPARATOR|enVista MX60E monofocal IOL|Subjects implanted with enVista MX60E monofocal IOL
62322385|NCT06693713|EXPERIMENTAL|Pilot Group|This group will receive an 8 week course on mental health knowledge. The series has been designed as an eight-week program for youth ages 11-15 that uses games, short films, discussion questions, and exercises to engage with mental health and faith topics.
62322386|NCT06693713|NO_INTERVENTION|Comparison Group|This group will not receive any mental health information, but will continue using their normal youth group material as planned. They will participate in the baseline and end line surveys.
62322387|NCT01937130|EXPERIMENTAL|IDN-6556 5 mg|Dosed twice daily
62322388|NCT01937130|EXPERIMENTAL|IDN-6556 25 mg|Dosed twice daily
62481848|NCT04884841||Patients without postoperative complications|Patients without postoperative complications
62481849|NCT00001184||1|Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study.
62131006|NCT02709850|EXPERIMENTAL|Cohorts AA-DD: IONIS ANGPTL3-LRx 20 mg|Participants received IONIS ANGPTL3-LRx 20 mg subcutaneously once per week for 6 weeks.
62131007|NCT02709850|EXPERIMENTAL|Cohorts AA-DD: IONIS ANGPTL3-LRx 40 mg|Participants received IONIS ANGPTL3-LRx 40 mg subcutaneously once per week for 6 weeks.
62322389|NCT01937130|EXPERIMENTAL|IDN-6556 50 mg|Dosed twice daily
62322390|NCT01937130|PLACEBO_COMPARATOR|Placebo|Dosed twice daily
62322391|NCT00114972|EXPERIMENTAL|PCI with DES|
62322392|NCT00114972|ACTIVE_COMPARATOR|CABG (coronary artery bypass graft)|Coronary Artery Bypass Graft
62322393|NCT04498429|EXPERIMENTAL|Integrated Manual and Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Integrated/Manual Cueing intervention.
62131008|NCT02709850|EXPERIMENTAL|Cohorts AA-DD: IONIS ANGPTL3-LRx 60 mg|Participants received IONIS ANGPTL3-LRx 60 mg subcutaneously once per week for 6 weeks.
62481850|NCT04878263|ACTIVE_COMPARATOR|Control group|
62481851|NCT04878263|EXPERIMENTAL|FIL-EAS ic group|
62131009|NCT04542005|EXPERIMENTAL|q3h albuterol|Using q3h as discharge criteria from hospital
62322394|NCT04498429|EXPERIMENTAL|Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Verbal Cueing intervention
62322395|NCT06472895|EXPERIMENTAL|treatment group|Subjects will receive AK112 (RP2D, administered intravenously，Q3W)
62322396|NCT06692751||IMR<25|People without microvascular angina
62322397|NCT06692751||IMR≥25|People with microvascular angina
62322398|NCT04922892|EXPERIMENTAL|Total Parathyroidectomy Alone|Total Parathyroidectomy Alone , without autotransplantation
62322399|NCT04922892|ACTIVE_COMPARATOR|Total Parathyroidectomy With Autotransplantation|Total Parathyroidectomy With Autotransplantation
62322400|NCT05163990|EXPERIMENTAL|TEAS group|10 minutes before intraspinal anesthesia, bilateral Neiguan points and Zusanli points are given dense wave transcutaneous acupoint electrical stimulation with the frequency of 10/50Hz. The intensity is based on the maximum tolerance of the participant, and the stimulation last until 30 minutes after subarachnoid administration.
62322401|NCT05163990|NO_INTERVENTION|Control group|Electrodes are connected at bilateral Neiguan points and Zusanli points 10 minutes before intraspinal anesthesia, but no transcutaneous acupoint electrical stimulation is given, the duration is the same as that of the TEAS group.
62322402|NCT04919993|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Group intervention; topics include psychoeducation about sleep, sleep restriction, stimulus control, relaxation strategies, and cognitive restructuring.
62322403|NCT00782925|EXPERIMENTAL|1|"Study intervention:~* A face/profile X-ray of their entire spine at baseline~* Educational program~* Exercise program~* Self-led exercises~* A follow-up at 12 and 24 months with their occupational therapist.~* A follow-up at 18 months with a physical therapist.~* Workers received also at the end of the educational program written standardized information about back pain (the back book, an information booklet) 1.~  1. Coudeyre E., Tubach F., Rannou F. \& all, Effect of simple information booklet on pain persistance after an acute episode of low back pain: a non- randomised trial in a primary care setting. PLoS ONE. 2007 ; 2 : e706"
62322404|NCT00782925|NO_INTERVENTION|2|"Control intervention :~* No intervention~* A face/profile X-ray of their entire spine at baseline~* A follow-up at 12 and 24 months with their occupational therapist,~* A follow-up at 18 months with a physical therapist."
62322405|NCT02051244||Subjective memory loss|Subjects who report memory loss, that may or may not be confirmed by an informant, but have normal cognitive tests ( MMSE scores of 27 or above out of 30. SLUMS scores of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education).
62481852|NCT06564311|EXPERIMENTAL|Obexelimab|Obexelimab will be administered as a subcutaneous injection for 24 weeks
61928036|NCT01577654|EXPERIMENTAL|Arm A: EC145 alone|EC145 alone
61928037|NCT01577654|EXPERIMENTAL|Arm B: EC145 + Docetaxel|EC145 + Docetaxel
62131010|NCT04542005|NO_INTERVENTION|q4h albuterol|Using q4h as discharge criteria from hospital
62131011|NCT03669822||Inpatient ulcerative colitis patients|Patients hospitalized for acute severe ulcerative colitis will be invited to enroll. Participants will be treated at the discretion of their treating physicians per standard of care. We expect some participants will be treated with standard versus accelerated infliximab dosing, permitting comparison, in addition to other treatment strategies.
62322406|NCT02051244||Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment - defined as being problems with memory, language or another essential cognitive ability that are severe enough to show up on cognitive tests but not to interfere with daily life. MMSE score of 23-27 out of 30. SLUMS score of 16-19 for subjects with less than 8 years of education or 20-26 for those who have 12 or more years of education.
62322407|NCT02051244||Control|Subject who do not report memory loss and have normal cognitive tests. MMSE of 27 or above out of 30. SLUMS score of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education.
62322408|NCT03216551||The assumed selective lymph node dissection group|Patients with consolidation tumor ratios ≤ 0.5 tumors will be considered to have negative mediastinal metastasis. Patients with intraoperative lepidic predominant adenocarcinoma diagnosis will be considered to have negative mediastinal metastasis. Patients with an apical tumor will be considered to have negative inferior mediastinal lymph node metastasis. If both N1 nodes and visceral pleural invasion are negative, patients with peripheral non-apical-segment upper lobe tumors will be considered to have negative inferior medistinal lymph node metastasis. If N1 nodes are negative, patients with left superior segment tumors will be considered to have negative 4L lymph node metasis, and patients with left basal segment tumors will be considered to have negative superior mediastinal lymph node metastasis.
62481853|NCT06564311|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as a subcutaneous injection for 12 weeks
62481854|NCT06026488||All enrolled patients|All patient who signed the consent form for participation to the study
62481855|NCT02475681|ACTIVE_COMPARATOR|Arm A - Obinutuzumab in Combination with Chlorambucil|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 1 Day 1. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
62322409|NCT05091489||Men who have sex with men (MSM) non-using PrEP|Focus group (10 persons)
62322410|NCT05091489||Male entertainment workers|Focus group (10 persons)
62481856|NCT02475681|EXPERIMENTAL|Arm B - Acalabrutinib in Combination with Obinutuzumab|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 2 Day 1. Acalabrutinib (ACP-196) will be orally administered starting on Cycle 1 Day 1. Daily administration of Acalabrutinib (ACP-196) will continue until disease progression or unacceptable toxicity.
62481857|NCT02475681|EXPERIMENTAL|Arm C - Acalabrutinib Monotherapy|Acalabrutinib (ACP-196) will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
61928038|NCT01577654|ACTIVE_COMPARATOR|Arm C: Docetaxel alone|Docetaxel alone
61928039|NCT03300531|EXPERIMENTAL|P-PRP|Blood will be drawn and pure platelet-rich plasma will be injected into the tendon.
61928040|NCT03300531|EXPERIMENTAL|PRP|Blood will be drawn and platelet-rich plasma will be injected into the tendon.
62322411|NCT05091489||Free-lance based entertainment female workers non-using PrEP|Focus group (10 persons)
62322412|NCT05091489||Venue-based entertainment female workers non-using PrEP|Focus group (10 persons)
62322413|NCT05091489||Transgender women (TGW) non-using PrEP|Focus group (10 persons)
62322414|NCT05091489||Healthcare workers in charge of key-populations|Focus group (10 persons)
62322415|NCT05091489||Community workers in charge of key-populations|Focus group (10 persons)
62322416|NCT05091489||PrEP users|Focus group (10 persons)
62322417|NCT05091489||NCHADS|Individual semi-directive interview (1 person) (NCHADS: operational unit of the Ministry of Health in charge of health sector policy development for HIV/AIDS)
62322418|NCT05091489||National Aids Authority|Individual semi-directive interview (1 person) (National Aids Authority: in charge to lead, manage, coordinate and facilitate the comprehensive and multi-sectoral response to HIV and AIDS in Cambodia)
62322419|NCT05091489||Ministry of Health|Individual semi-directive interview (1 person)
62322420|NCT05091489||Key influencer in the MSM and/or TGW community|Individual semi-directive interview (1 person)
62481858|NCT06741462|ACTIVE_COMPARATOR|Intervention Group|Participants in the intervention group were patients with proven care level who had been provided ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were gathered using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1).
62690572|NCT05938569|EXPERIMENTAL|All subjects|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
62690573|NCT05459753|EXPERIMENTAL|Parkinson's Disease|Individuals with idiopathic Parkinson's disease.
62690574|NCT04622267|ACTIVE_COMPARATOR|Standard suture|Standard antimicrobial suture (vicryl) - control arm
62690575|NCT04622267|EXPERIMENTAL|Barbed suture|Barbed suture type is STRATAFIX Symmetric PDS Plus Knotless Tissue
61928041|NCT03300531|ACTIVE_COMPARATOR|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) )
61928042|NCT04605263|ACTIVE_COMPARATOR|STN DBS|Subjects will receive traditional bilateral STN devices and stimulation.
62322421|NCT05091489||Key influencer in the EW community|Individual semi-directive interview (1 person)
62481859|NCT06741462|NO_INTERVENTION|Control Group|Participants in the control group were patients with proven care level who were not provided with ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were collected using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1). In addition, after the end of the observation period (from t0 to t1), the participants in the control group were offered an extension of a further 3 months on average using ADELE (from t1 to t2).
62481860|NCT01571700||Study|Patients with pulmonary hypertension.
62481861|NCT01571700||Control|ASD patients or patients with normal hearts
62481862|NCT03776552|ACTIVE_COMPARATOR|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program \[8-week LED (\<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks \<1300 kcal/day and 4 weeks \<1500 kcal/day)\] followed by a 36-weight loss maintenance program.
62481863|NCT03776552|ACTIVE_COMPARATOR|Gradual weight loss (GWL) program|16-week GWL-program (estimated total energy expenditure minus 800-1000 kcal/day) followed by a 36-weight loss maintenance program.
62481864|NCT06741566|PLACEBO_COMPARATOR|Control group|
62481865|NCT06741566|ACTIVE_COMPARATOR|Insulin group|
62690576|NCT06568432|NO_INTERVENTION|Control group|The control group will not have any intervention, as the control (usual care)
62690577|NCT06568432|EXPERIMENTAL|Intervention group|CRP+SAA POCT will be provided in 20 village clinics in the intervention group and additional physician training on the use of CRP+SAA POCT will be provided (including centralized and unified training, distribution of physician training manuals and desk reminders)
62690578|NCT02645370|ACTIVE_COMPARATOR|Active Comparator:Topiramate|The treatment with TPM is initiated at a 50 mg daily dose and sequentially increase every 7 days, as tolerated, in 25 mg increments up to a target dose of 150 mg total/day.
62690579|NCT02645370|EXPERIMENTAL|Experimental:Danzhen|The treatment with Danzhen is 3 tablets triple daily.
62322422|NCT05091489||Khana|"Individual semi-directive interview (1 person)~Khana : an umbrella organization belonging to the HIV/AIDS international Alliance"
62322423|NCT05091489||High class and hidden MSM|Individual semi-directive interview (1 person)
62322424|NCT05091489||Discontinued PrEP user|Individual semi-directive interview (1 person)
62322425|NCT02750813|OTHER|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
62481866|NCT06741566|ACTIVE_COMPARATOR|Dexmedetomidine group|
62481867|NCT06580054|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and photographs of tumor throughout the study.
62481868|NCT06742736||Prompt|PATIENTS INITIATING BGF WITHIN 30-DAYS OF EXACERBATION
62481869|NCT06742736||DELAYED|PATIENTS INITIATING BGF WITHIN 31-180 DAYS OF EXACERBATION
62690580|NCT01903863|EXPERIMENTAL|Scheduled fresh frozen plasma|Patients enrolled in this arm will receive scheduled fresh frozen plasma treatment every 48 hours.
62690581|NCT01903863|ACTIVE_COMPARATOR|Control|Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
62690582|NCT02839928|EXPERIMENTAL|Treatment|The experimental arm consists of children given intranasal Ketamine 1 mg/kg, once
62322426|NCT02750813|OTHER|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
62322427|NCT02123017|EXPERIMENTAL|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses
62322428|NCT02123017|EXPERIMENTAL|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses
62481870|NCT06742736||VERY DELAYED|PATIENTS INITIATING BGF WITHIN 181-365 DAYS OF EXACERBATION
62690583|NCT05952310|EXPERIMENTAL|Allogeneic Natural Killer cells|Low doses (1x106/UI/m2) of subcutaneous interleukin-2 (IL-2) will be administered every 48h for a maximum of 6 doses, in conjunction with the NK cell infusion, to favor the expansion and antitumor effect of the NK cells.
62690584|NCT03721367||Urea Cycle Disorders|
62690585|NCT02943499|ACTIVE_COMPARATOR|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
62481871|NCT06145282|EXPERIMENTAL|Cohort 1|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors. Cohort 1 will receive a single dose of PT-Cy; 50 mg/kg, on day +3 post-HCT
62322429|NCT02123017|EXPERIMENTAL|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses
62481872|NCT06145282|EXPERIMENTAL|Cohort 2|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors. Cohort 2 will receive a total of two doses of PT-Cy; 50mg/kg, on days +3 and +4 (total 100 mg/kg) post-HCT
62481873|NCT06619483|EXPERIMENTAL|BAY3018250 Dose 1|Participants will receive BAY3018250 Dose 1.
62481874|NCT06619483|EXPERIMENTAL|BAY3018250 Dose 2|Participants will receive BAY3018250 Dose 2.
62481875|NCT06619483|PLACEBO_COMPARATOR|Placebo|Participants will receive the matching placebo to BAY3018250.
62481876|NCT02243852||Growth Hormone Deficiency (n=16)|16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement) will be compared with 16 healthy controls. Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be assessed in each of cohort to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
62481877|NCT02243852||Healthy Controls (n=16)|16 healthy controls will be compared with 16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement). Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be measured in all cohorts to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
62481878|NCT02243852||Growth Hormone Replacement Therapy (n=16)|"GHD patients, who are eligible for GH replacement therapy as part of their routine clinical care, according to the National Institute for Clinical Excellence (NICE) recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire score (AGHDA score\>11) will be recruited. These patients attend the Joint Endocrine clinic at University Hospital Aintree, Liverpool, and those who are about to commence growth hormone replacement will be asked to participate in this observational study.~Anthropometric, biochemical including measurement of FGF21 and MR evaluation will be carried out in patients who are to be treated with GH as part of their routine clinical care immediately prior to GH therapy and after six months of replacement treatment. The type of GH and dose of treatment will be at the discretion of the treating physician. Standard doses will be used and patients will remain under the care of the supervising"
62481879|NCT04198207||VNS Group|VNS group: 20 patients with no localilzed epileptogenic tuber in the brain, and with VNS and multiple anti-seizure medicines.
62690586|NCT02943499|EXPERIMENTAL|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
62690587|NCT03063645|EXPERIMENTAL|Group ABC|AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)
61928043|NCT04605263|EXPERIMENTAL|STN-PPN DBS|Patients will be implanted with both bilateral STN and bilateral PPN devices. These patients will undergo a crossover between 3 and 15 months post-op in which they will double-blindly receive PPN stimulation for six months and have stimulation turned off for six months. All patients will receive stimulation from 0-3 months post-op (mapping visits occur in this window) and from 15-27 months.
62322430|NCT03872401|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W).
62481880|NCT04198207||Control Group|Control group: 50 patients with no localilzed epileptogenic tuber in the brain, and with multiple anti-seizure medicines.
62690588|NCT03063645|EXPERIMENTAL|Group BCA|AC-SD-01 (50g), AC-SD-01 (75g), AC-1202
61928044|NCT05115942|EXPERIMENTAL|Hydronidone group|Patients were orally received hydronidone capsules,3 capsules each time, t.i.d. for 52 weeks.
62322431|NCT03872401|EXPERIMENTAL|Evolocumab 140 mg Q2W|Participants will receive 140 mg evolocumab by subcutaneous injection Q2W.
62690589|NCT03063645|EXPERIMENTAL|Group CAB|AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)
62322432|NCT01263535|EXPERIMENTAL|SENSIMED Triggerfish|
61928045|NCT05115942|PLACEBO_COMPARATOR|The placebo group|Patients were orally received placebo capsules,3 capsules each time, t.i.d. for 52 weeks.
62322433|NCT00400933|EXPERIMENTAL|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
62322434|NCT04438603||IgAN patients at low risk of disease progression|n = 30, incipient disease
62322435|NCT04438603||IgAN patients at high risk of disease progression|n = 60, incipient disease
62322436|NCT04438603||Long-term stable patients|n = 30, follow-up for at least 15 years
62322437|NCT04438603||Progressive IgAN patients|n = 30
62322438|NCT04438603||Healthy control|n = 30
62322439|NCT04832841||SARS-CoV-2 naive|Kidney transplant recipients without previous SARS-CoV-2 infection verified by absence of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
62322440|NCT04832841||SARS-Cov-2 exposed|Kidney transplant recipients with previous SARS-CoV-2 exposition verified by positivity of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
62322441|NCT04832841||Waiting list|Kidney transplant recipients who were vaccinated on waiting list (a) SARS-CoV-2 naive (b) SARS-Cov-2 exposed
62322442|NCT04617613|ACTIVE_COMPARATOR|Standard triple therapy|Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.
62322443|NCT04617613|EXPERIMENTAL|Quadruple therapy group|Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.
62322444|NCT06510296|EXPERIMENTAL|Digital Mind Body Intervention|Participants randomized to the Digital Mind Body mobile intervention will receive a unique user identification (user ID) to access the DMBI mobile application. Randomized in a 2:1 ratio for DMBI intervention vs Waitlist Control
62481881|NCT03914300|EXPERIMENTAL|Treatment (cabozantinib S-malate, nivolumab, ipilimumab)|Patients receive cabozantinib S-malate PO QD on days -14 to -1 prior to cycle 1, days 1-42 of cycles 1-4 and days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1, 15, and 29 of cycles 1-4 and day 1 of subsequent cycles and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Treatment repeats every 42 days for cycles 1-4 and every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening, and blood sample collection throughout the study.
62481882|NCT06737367||training set|
62481883|NCT06737367||external test set|
62481884|NCT01689077|ACTIVE_COMPARATOR|24 hours hypothermia|24 hours hypothermia
62481885|NCT01689077|EXPERIMENTAL|48 hours hypothermoa|48 hours hypothermia
62481886|NCT06741501|EXPERIMENTAL|"C Single Flap Plasty Reconstruction"|"1. C-shaped flap creation: A 3.0 cm wide by 3.5 cm high C-shaped flap is marked on the anterior gastric wall, 1.5-2.5 cm distal to the stomach transection line. The flap is created by carefully separating the submucosa from the muscular propria using an electric scalpel, forming a left-opening flap. This flap will later be used to cover the anastomotic site.~2. Esophagogastric anastomosis: The esophagus and stomach are anastomosed intracorporeally. After continuous suturing of the posterior esophageal wall to the remnant stomach, the common opening between the esophagus and the stomach is closed.~3. Flap coverage: After anastomosis, the C-shaped flap is sutured over the anastomotic site, reinforcing it by covering both the esophageal stump and the gastric window, which helps prevent complications like leakage or reflux."
62481887|NCT06741501|ACTIVE_COMPARATOR|Normal Reconstruction|"1. Preparation of the Remnant Stomach and Esophagus: After the resection of the proximal stomach, the remaining stomach is prepared for direct anastomosis with the esophagus. The esophageal stump and gastric stump are aligned, typically without additional modifications to the gastric wall.~2. End-to-End or End-to-Side Anastomosis: The esophagus is directly connected to the remnant stomach, either in an end-to-end or end-to-side fashion, using a stapler or manual suturing techniques."
61928046|NCT04564547|EXPERIMENTAL|Group 1: ISL 20 mg + Ulonivirine 100 mg|Participants receive ISL 20 mg (Parts 1-3) + ulonivirine 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD) \[Part 1\].
61928047|NCT04564547|EXPERIMENTAL|Group 2: ISL 20 mg + Ulonivirine 200 mg|Participants receive ISL 20 mg (Parts 1-3) + ulonivirine 200 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
61928048|NCT04564547|EXPERIMENTAL|Group 3: ISL 20 mg + Ulonivirine 400 mg|Participants receive ISL 20 mg (Parts 1-3) + ulonivirine 400 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
61928049|NCT04564547|ACTIVE_COMPARATOR|Group 4: BIC/FTC/TAF|Participants receive placebo to ISL + placebo to ulonivirine QW (Part 1) and BIC/FTC/TAF 50 mg/200 mg/25 mg QD (Parts 1 and 2).
61928050|NCT05832177||Community Members who attend Cancer CientoUno (101) program|Community members who opt to participate in the online Cancer CientoUno (101) training program. They will be asked to complete a registration survey and the programs self-paced educational modules. At the start of the course, they will be asked to complete a brief survey. After every module, they will be asked to complete a brief survey. In addition, community members will be asked to complete a midterm survey and a 6-month follow up survey.
61928051|NCT05832177||Community Members who Attend Symposium|Community members who opt to attend this symposium which will offer educational presentations focused on prevention, nutrition, clinical trials, and specific cancer types addressed in breakout sessions. Participants will be asked to complete a registration form and a post-event evaluation form.
61928052|NCT05832177||Community Members who Attend Charlas (Talks)|Community members who opt to attend these charlas (talks) which will offer education on a variety of cancer-related topics. The topics are selected in response to each event, given the community interest or need for a specific cancer-related topic. Participants will be asked to complete a registration form and a post-event evaluation form.
61928053|NCT05832177||Community Members who Attend Presentations|Community members who opt to attend and researchers (including those from the PHSU-MCC U54 partnership) will participate in these presentations to generate a discussion about ongoing research and have an opportunity for community members learn and provide feedback on on-going and completed research projects. Presentations from El Puente events will occur in Spanish (in Puerto Rico and Florida) and in English (in Florida). Attendees will be asked to complete a registration form and a post-event evaluation.
62322445|NCT06510296|NO_INTERVENTION|Waitlist Control|Patients randomized to the Waitlist Control arm/group will not receive the DMBI until the end of the study. During the study, to control for expectancy and attention, the Waitlist Control will receive a weekly email with generic tips on a healthy lifestyle in IBD. Randomized in a 2:1 ratio for DMBI intervention vs Waitlist Control
62322446|NCT05601999|EXPERIMENTAL|GNR-060|Main group (122 patients) - GNR-060
62322447|NCT05601999|ACTIVE_COMPARATOR|Metalyse|Control group (122 patients) - Metalyse
62322448|NCT05795465|EXPERIMENTAL|Part 1 Cohort 1: GEn-1124|Subjects in cohort 1 will receive low dose GEn-1124 BID intravenous 5 days.
62322449|NCT05795465|EXPERIMENTAL|Part 1 Cohort 2: GEn-1124|Subjects in cohort 2 will receive high dose GEn-1124 BID intravenous for 5 days.
62322450|NCT05795465|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will receive a placebo in a matching dosing regimen (Placebo BID intravenous for 5 days).
62481888|NCT01126762|EXPERIMENTAL|Dietary advice and grocery store card|Dietary advice to consume low mercury, high DHA fish plus a grocery store gift card to support the purchase of fish
62481889|NCT01126762|EXPERIMENTAL|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
62481890|NCT01126762|PLACEBO_COMPARATOR|Control|General dietary advice not focused on fish intake
62481891|NCT05226533|EXPERIMENTAL|Niclosamide 432mg|Niclosamide 432mg (intramuscular injection) + Remdesivir
62481892|NCT05226533|EXPERIMENTAL|Niclosamide 960mg|Niclosamide 960mg (intramuscular injection) + Remdesivir
62481893|NCT05226533|PLACEBO_COMPARATOR|Placebo|Placebo (intramuscular injection) + Remdesivir
62481894|NCT02157051|EXPERIMENTAL|Arm 1 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 1 injection ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
62481895|NCT02157051|EXPERIMENTAL|Arm 2 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/M2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
62481896|NCT02157051|EXPERIMENTAL|Arm 3 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 3 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
62481897|NCT02157051|EXPERIMENTAL|Arm 4 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 1 additional STEMVAC vaccine at 3 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
62481898|NCT06741592|EXPERIMENTAL|EDDY Group|The effect of the EDDY device, preferred for root canal irrigation activation, on postoperative pain formation
62131012|NCT04294173|EXPERIMENTAL|video group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the experimental group in the classroom setting. Video presentation including powerpoint presentation and tracheostomy care skill application will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained by the researchers to the video group students in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be watched by the video-assisted teaching method, and the video of tracheostomy care The videos will be sent to students via e-mail. A two-day warning message will be sent to the students from the WhatsApp group to watch the video by the researchers. A week later, students will be invited to the basic skills laboratory for tracheostomy care.
62322451|NCT05795465|EXPERIMENTAL|Part 2: GEn-1124|Depending on the analysis of part 1, subjects in part 2 will receive GEn-1124 BID intravenous for 5 days.
62322452|NCT03854591||Gunshot related injury|Patients admitted to orthopaedic trauma service with gunshot related injury
62322453|NCT05151653|EXPERIMENTAL|BI 765250 arm|
62481899|NCT06741592|EXPERIMENTAL|PUI Group|The effect of the passive ultrasonic activation method, preferred for root canal irrigation activation, on postoperative pain formation
62481900|NCT06741592|NO_INTERVENTION|Control Group|Root canal treatment performed with conventional irrigation without the use of any activation method
62322454|NCT05151653|PLACEBO_COMPARATOR|Placebo arm|
62322455|NCT01954121|EXPERIMENTAL|Levetiracetam|Levetiracetam 1000 mg/day
62322456|NCT01954121|ACTIVE_COMPARATOR|Carbamazepine|Carbamazepine 400 mg/day
62322457|NCT03321786||Legionnaires' Disease Volunteers|Volunteers who have been diagnosed/survivors of Legionnaire's Disease
62322458|NCT03321786||Healthy Volunteers|Volunteers who are healthy.
62322459|NCT02345642|ACTIVE_COMPARATOR|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
62481901|NCT03307577|EXPERIMENTAL|UHE-101 cream, 1%|Cream is applied twice a day
62322460|NCT02345642|EXPERIMENTAL|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
62322461|NCT04550442|EXPERIMENTAL|Treatment (venetoclax, azacitidine)|Patients receive venetoclax PO daily on days 1-14 and azacitidine IV over 15 minutes or SC on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
62322462|NCT06150105||sprint-trained|Sprint-trained athletes: 6 male and 6 female, aged average 15 y.,
62322463|NCT06150105||endurance-trained|Endurance-trained athletes: 6 male and 6 female, aged average 15 y.,
62322464|NCT06041672|EXPERIMENTAL|Warm Water Hand Baths|Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes.
62481902|NCT03307577|PLACEBO_COMPARATOR|Vehicle cream|Cream is applied twice a day
62481903|NCT06670053||On blocker|Transmasculine youth who will begin taking testosterone clinically in \< 6 months with or without headache and who have been on pubertal blocker, a gonadotropin hormone releasing (GnRH) agonist for at least 3 months.
62481904|NCT06670053||No blocker|Transmasculine youth who will begin taking testosterone clinically in \< 6 months with or without headache and who have no history of pubertal blocker.
62481905|NCT02224781|EXPERIMENTAL|Arm A (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm C.~Patients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial."
62481906|NCT02224781|EXPERIMENTAL|Arm B (BRAF inhibitor therapy)|"Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm D.~Patients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial."
62481907|NCT02224781|EXPERIMENTAL|Arm C (BRAF inhibitor therapy)|"Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial."
62481908|NCT02224781|EXPERIMENTAL|Arm D (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT, ECHO or MUGA, and collection of blood samples throughout the trial."
62481909|NCT06703333|EXPERIMENTAL|Experimental arm|"Single group assignment in which SPS patients will receive ECP as an add-on therapy on the following schedule:~* Months 1-3: One ECP cycle (two consecutive days) every other week for 3 months (12 procedures).~* Months 4-6: One ECP cycle every month for 3 months (6 procedures)."
62481910|NCT06729632|EXPERIMENTAL|Safety Arm|Non-firefighter control subjects will receive MTH-treatment and normothermia-sham through the device alternated over 8 sessions. Subjective assessments and audiologic testing pre- and post-treatments will be compared between MTH-treatment and sham in each subject. n=24.
62481911|NCT06729632|EXPERIMENTAL|Efficacy Arm 1 - Treatment|Firefighters will receive hypothermia treatment delivered with ReBound devices, applied post-work shift. Baseline hearing function will be measured prior to initiation of the treatment. Treatments and functional assessments will be repeated quarterly over one year. Temporary and permanent threshold changes in this chronically noise exposed group of firefighters receiving MTH-treatment will be compared with firefighters receiving sham-treatment and with controls receiving MTH-treatment. Subjects in this group will also be sent home with a device to use after noise exposure during the study period. They will complete weekly, remote surveys collecting data on their noise exposure and device use. n=24.
62481912|NCT06729632|NO_INTERVENTION|Efficacy Arm 2 - Non-Therapeutic|"Firefighters will receive non-therapeutic treatment delivered with normothermic ReBound devices, applied post-work shift. Baseline hearing function will be measured prior to initiation of the treatment. Treatments and functional assessments will be repeated quarterly over one year. n=24."
62481913|NCT06729632|ACTIVE_COMPARATOR|Efficacy Arm 3 - Control|Age- and sex-matched non-firefighter control group will receive MTH-treatment quarterly over the same duration. Baseline hearing function will be measured prior to initiation of the treatment. Treatments and functional assessments will be repeated quarterly over one year. Subjects in this group will also be sent home with a device to use after noise exposure during the study period. They will complete weekly, remote surveys collecting data on their noise exposure and device use. n=24.
62481914|NCT01438203|EXPERIMENTAL|Thrust manipulation|Clinicians will use thrust manipulation at a targeted level to provide the treatment on selected individuals
62481915|NCT01438203|ACTIVE_COMPARATOR|Non-thrust manipulation|Clinicians will apply non-thrust manipulation (targeted) as performed in a clinical manner for treatment for included individuals
61928054|NCT05832177||Community Members who Access Series of Virtual Lunch and Learn Podcasts|Community members will have access to a series of virtual Lunch and Learn podcasts, which will be 30-minute long, pre-recorded sessions in English and/or Spanish. Podcast sessions will cover updated cancer-relevant recommendations from the United States Preventive Services Task Force (USPSTF). Reach will be tracked with number of visits and/or other access metrics.
61928055|NCT05832177||U54 Partnership Investigators|These CE workshops will be mandatory for all partnership researchers who receive U54 funding in the proposed renewal period including Full, Pilot, and Developmental projects. The CE workshops are aimed to increase researchers' knowledge about the best strategies to establish teamwork with community members to achieve mutual benefits and advance translational research in cancer.
62322465|NCT06041672|NO_INTERVENTION|Routine care|Including preoperative instructions, postoperative care, and monitoring of vital signs.
62322466|NCT05874219|EXPERIMENTAL|Local antibiotic spray|Local antibiotic spray (n=75) The intervention Sprayed 1 to 3 times /day for 45 day Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU Bivatracin Spray
61928056|NCT05832177||Lay Community Members|Lay community members will opt to participate in a 2-day CE workshop series. The goal is to include trained lay community members to actively participate in cancer prevention education and research. These activities will facilitate community-academic partnerships between the Partnership researchers and community members.
62322467|NCT05874219|ACTIVE_COMPARATOR|Mupirocin 2% ointment|(The standard) 10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm mupirocin 2% ointment
62322468|NCT04906239|ACTIVE_COMPARATOR|Group ESP|While the patient is in a sitting position, A ultrasound probe covered with a sterile sheath will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After the T 4-5 transverse process and the erector spinae muscle above it are shown, a quincke-type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal with the entrance made using the in-plane technique. When the transverse process is touched, the needle will be pulled out and a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.The same procedure will be repeated on the contralateral side of the T5 spinous process and half of the remaining bupivacaine dose will be injected. The total volume of bupivacaine injected on both sides will be 20 mL.
62322469|NCT04906239|NO_INTERVENTION|Group Control|"No block will be made to the control group.~After extubation, 1mg / kg tramadol will be applied routinely to both groups, and PCA (Patient Control Analgesia) and morphine consumption and VAS (visual analog scale) pain scores of both groups will be evaluated and recorded at the 1st, 4th, 12th and 24th hour. When VAS is 3, patients will be advised to press the PCA device."
62322470|NCT05301322|EXPERIMENTAL|Coadministration Group|RSVpreF and SIIV followed by placebo a month later
62131013|NCT04294173|NO_INTERVENTION|demonstration group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the control group in the classroom setting. Powerpoint presentation will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained to the control group students by the researchers in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be taken to the basic skills laboratory and tracheostomy care will be performed on the dummy by the researchers using the demonstration method. Then, students will be given the output of the powerpoint presentation and asked to study the lecture notes for a week. A two-day warning message will be sent by the researchers to students from the WhatsApp group to study. A week later, students will be invited to the basic skills laboratory to practice tracheostomy care.
62131014|NCT02415088|ACTIVE_COMPARATOR|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
62131015|NCT02415088|ACTIVE_COMPARATOR|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
62131016|NCT05758766|NO_INTERVENTION|Regular diet|Participants will continue their regular diet.
62322471|NCT05301322|EXPERIMENTAL|Sequential Administration Group|Placebo and SIIV followed by RSVpreF a month later
62322472|NCT06112340|ACTIVE_COMPARATOR|Low Dose|Active Arm Low Dose Linsitinib
62690590|NCT04403776|EXPERIMENTAL|Treatment A, separated washout phase, followed Treatment B.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
62131017|NCT05758766|EXPERIMENTAL|Plant based omega 3 Fatty Acid|Participants ingest their regular diet supplemented with a plant-based omega-3-FA
62131018|NCT01753986|EXPERIMENTAL|Brief Alcohol Intervention plus Standard Batterer intervention|Brief Alcohol Intervention plus 40 hours of Standard Batterer intervention
62131019|NCT01753986|PLACEBO_COMPARATOR|General Health Improvement plus Standard batterer intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer intervention
62131020|NCT02379819|EXPERIMENTAL|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
62131021|NCT04965272|EXPERIMENTAL|Cariprazine 0.75 mg/day + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 0.75 mg/day oral, once daily for 6 weeks
62131022|NCT04965272|EXPERIMENTAL|Cariprazine 1.5 mg/day + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 1.5 mg/day oral, once daily for 6 weeks
62131023|NCT04965272|EXPERIMENTAL|Cariprazine 3.0 mg/day + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 1.5 mg/day oral for 2 weeks followed by cariprazine 3.0 mg/day oral, once daily for 4 weeks.
62131024|NCT04965272|PLACEBO_COMPARATOR|Placebo + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + oral placebo, once daily for 6 weeks
62131025|NCT03011489|EXPERIMENTAL|Vacuum formed aligners group|This group will receive Vacuum formed aligners in addition to taping for 3 Months with follow-up every 1-2 weeks
62131026|NCT03011489|NO_INTERVENTION|control group|This group will not receive any treatment
62322473|NCT06112340|ACTIVE_COMPARATOR|High Dose|Active Arm High Dose Linsitinib
62322474|NCT03466320|EXPERIMENTAL|Phase I Dose Escalation Segment 1 - T7-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -9, -8 and -7.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 7 days (T7) after the end of the preconditioning regimen"
62131027|NCT03189472|EXPERIMENTAL|active tDCS|
62131028|NCT03189472|SHAM_COMPARATOR|sham tDCS|
62322475|NCT03466320|EXPERIMENTAL|Phase I Dose Escalation Segment 1 - T3-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
62322476|NCT03466320|EXPERIMENTAL|Phase I Dose Escalation Segment 1 - T3-DL2|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 2: 3x108 NKR-2 (adjusted at 4.6x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
62322477|NCT03466320|EXPERIMENTAL|Phase I Dose Escalation Segment 1 - T3-DL3|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 3: 1x109 NKR-2 (adjusted at 1.5x107 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
62131029|NCT04572945||1- Cases: Diabetic patients with CKD.|classified according to estimated GFR into 5 stages according to KIDGO 2012 classification.
62131030|NCT04572945||2- Controls: Diabetic patients without CKD.|defined as patients who have normal kidney function test, normal urine analysis and normal ultrasound findings.
62131031|NCT03858413||Chronic kidney disease stage V|No intervention
62131032|NCT03858413||Chronic kidney disease stage III|No intervention
62131033|NCT02934789|ACTIVE_COMPARATOR|Study group: surgical arm|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
62131034|NCT02934789|ACTIVE_COMPARATOR|Control group: medical arm|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids
62131035|NCT00700986|EXPERIMENTAL|1|
62131036|NCT00700986|PLACEBO_COMPARATOR|2|
62131037|NCT03327870||1|Sjogren's Syndrome
62131038|NCT03327870||2|Sicca
62131039|NCT03327870||3|Incomplete Sjogren's Syndrome
62131040|NCT03327870||4|Healthy Volunteers
62131041|NCT03327870||5|Excluded by 2016 ACR/EULAR Classificastion Criteria
62131042|NCT00692042|EXPERIMENTAL|1|
62131043|NCT03853161|EXPERIMENTAL|Vapotherm arm|Preterm infants in this arm will be given respiratory support of heated humidified high flow via Precision Flow Vapotherm, Exeter, USA
62481916|NCT06742931|EXPERIMENTAL|Discontinuation of antiplatelet agent group|In this group, antiplatelet monotherapy will be discontinued at the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, all antiplatelet agents will be discontinued after randomization.
62481917|NCT06742931|ACTIVE_COMPARATOR|Continuation of antiplatelet agent group|In this group, lifelong antiplatelet monotherapy will be continued after the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, DAPT will be changed to single antiplatelet therapy (aspirin or clopidogrel). The choice between aspirin or clopidogrel will be determined by the physician's discretion.
62481918|NCT04440436|EXPERIMENTAL|IM19 CAR-T cells|IM19 CAR-T cells be administrated in two dose level
62481919|NCT06743373|EXPERIMENTAL|Cannabis-Using|The cannabis-using arm will consist of 60 young people reporting regular cannabis use. They will participate in a 1-week baseline protocol followed by a 4-week cannabis discontinuation protocol (intervention).
62481920|NCT06743373|NO_INTERVENTION|Control|The control arm will consist of 30 young people without current cannabis use. They will participate in a 1-week baseline protocol. No intervention will be administered.
61928057|NCT05832177||Community Members who Join Community Advisory Panel (CAP)|The Community Advisory Panel (CAP) members will include individuals who are cancer survivors, family members/caregivers of cancer survivors, and/or representatives from healthcare, community- and faith-based organizations who are invited to join the CAP and accept the invitation. The PHSU-MCC Partnership utilizes a CAP to inform and guide overall outreach activities in PR and FL. Two CAPs, one at MCC and one at PHSU have been organized. Previous CAP members will be retained if interested and new CAP members added as needed.
61928058|NCT05832177||U54 Partnership Investigators and CAP Members|During standing CAP meetings, partnership investigators present their ongoing research to members of the CAPs. Researchers who receive U54 funding in the proposed renewal period including Full, Pilot, and Developmental projects can request CAP feedback on topics along the research continuum from concepts for new research projects, ideas for recruitment, or dissemination of fundings.
61928059|NCT05832177||Community Leaders and Stakeholders|Community leaders from disadvantaged socioeconomic areas and Stakeholders of healthcare organizations with whom the Program has established previous collaborative relationships will participate in the CBTP. The stakeholders include nurses, community health educators, clinical social workers, among other healthcare professionals.
62131044|NCT03853161|EXPERIMENTAL|NIPPV arm|Preterm infants in this arm will be given respiratory support of Nasal Intermittent Positive Pressure Ventilation via the Leoni Plus neonatal ventilator
62131045|NCT00676091|EXPERIMENTAL|13vPnC|13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
62131046|NCT00676091|ACTIVE_COMPARATOR|7vPnC|7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
62131047|NCT03182816|EXPERIMENTAL|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
62131048|NCT02538341|ACTIVE_COMPARATOR|Zostavax (Zoster Vaccine Live)|Zostavax (zoster vaccine live) is used to prevent herpes zoster (HZ) virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active herpes zoster (HZ) vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
62322478|NCT03466320|EXPERIMENTAL|Phase I Dose Escalation - extension|This extension segment will enroll more patients (to reach 9 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
62322479|NCT03466320|EXPERIMENTAL|Phase II Segment 1|This extension segment will enroll more patients (to reach 13 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
62481921|NCT04484012|EXPERIMENTAL|Treatment (CD19 CAR T cells, acalabrutinib)|Patients receive acalabrutinib PO BID on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells IV on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.
62481922|NCT05387954|ACTIVE_COMPARATOR|Antiplatelet therapy|Aspirin OR clopidogrel
62481923|NCT05387954|EXPERIMENTAL|Oral anticoagulants, Direct-Acting|Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
62481924|NCT05387954|EXPERIMENTAL|PFO closure|PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel
62481925|NCT05355545|EXPERIMENTAL|Virtually supervised exercise|In the first half of the study (weeks 0 to 12), participants will receive a virtually supervised exercise program. In the second half of the study (weeks 13 to 24), participant will continue to receive the virtually supervised exercise program.
61928060|NCT05832177||Stakeholders|Physicians, nurses, psychologists, and other stakeholders within the communities under the partnership umbrella will participate in the Cancer 101 Stakeholders program.
61928061|NCT06334692||Cases|Sera from patients with biopsy-proven idiopathic MCD or FSGS who provided consent to store their samples in the certified biobank (Mario Negri Biological Resources Centre - Rare Diseases and Renal Diseases Biobank - CRB). Serum samples will be tested for the levels of anti-nephrin autoantibodies by in-house ELISA and results confirmed by commercial ELISA kits.
61928062|NCT06334692||Controls|Sera from patients with biopsy-proven idiopathic membranous nephropathy who provided consent to store their samples in the certified biobank (Mario Negri Biological Resources Centre - Rare Diseases and Renal Diseases Biobank - CRB). Samples will be tested for the levels of anti-nephrin autoantibodies by in-house ELISA and results confirmed by commercial ELISA kits.
61928063|NCT01352468|EXPERIMENTAL|Multifaceted Cognitive Training|Cognitive Training with 4 different tasks each of which gets progressively more difficult as children obtain proficiency.
61928064|NCT01352468|SHAM_COMPARATOR|Sham Cognitive Training|Cognitive Training with 4 different tasks which does not get progressively more difficult throughout training
61928065|NCT06628869|ACTIVE_COMPARATOR|Fructanase|Total 400 inulinase activity units (INU) per dose
61928066|NCT06628869|PLACEBO_COMPARATOR|Placebo|Maltodextrin
61928067|NCT02966639||LDS Patients|All patients with a diagnosis of single-level Lumbar Degenerative Spondylolisthesis who present to the DHMC Spine Center.
61928068|NCT05735834|EXPERIMENTAL|Arm A - Rituximab + Zanubrutinib|"Zanubrutinib (160 mg BID orally continuous dosing) is administered for 12 cycles of 28 days each. After cycle 12:~1. Patients in Complete Response (CR) will stop treatment and enter the follow-up phase.~2. Patients in partial response (PR) will continue zanubrutinib treatment (160 mg BID orally continuous dosing) for 12 additional cycles of 28 days each for a total of 24 cycles.~3. Patients in stable disease (SD) or progressive disease (PD) will stop treatment and will enter the follow-up phase.~Rituximab is infused at the dose of 375 mg/m2 iv on days 1, 8, 15, and 22 of cycle 1 (28 days per cycle), then on day 1 of cycles 3, 6, 9, and 12 (28 days per cycle). After cycle 12:~1. Patients in CR will stop treatment and enter the follow-up phase.~2. Patients in PR will go on with rituximab 375 mg/m2 IV on day 1 of cycles 15, 18, 21, and 24 (28 days per cycle).~3. Patients in SD or PD will discontinue treatment and will enter the follow-up phase."
61928069|NCT05735834|ACTIVE_COMPARATOR|Arm B - Rituximab|"Rituximab is infused at the dose of 375 mg/m2 iv on days 1, 8, 15, and 22 of cycle 1 (28 days per cycle), then on day 1 of cycles 3, 6, 9, and 12 (28 days per cycle). After cycle 12:~1. Patients in CR will stop treatment and enter the follow-up phase.~2. Patients in PR will go on with rituximab 375 mg/m2 iv on day 1 of cycles 15, 18, 21, and 24 (28 days per cycle).~3. Patients in SD or PD will discontinue treatment and will enter the follow-up phase"
61928070|NCT04998682|EXPERIMENTAL|Targeted Axillary Dissection (TAD)|During standard of care (SoC) surgery to remove breast cancer, study participants will undergo a sampling of lymph nodes in the axilla first and then complete removal of axillary lymph nodes under the arm.
61928071|NCT06200714||IPF patients|Clinical management of interstitial lung diseases (IPF) or other progressive pulmonary fibrosis (PPF) patients who experienced nintedanib-associated diarrhoea
61928072|NCT02896933||patients with multiple sclerosis|recruited in a former study
62131049|NCT02538341|PLACEBO_COMPARATOR|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
62131050|NCT03949413||Control group (A)|30 normal children
62131051|NCT03949413||study Group (B)|30 children from both sexes (22 boys and 8 girls) with attention deficit hyperactivity disorder (ADHD)
62131052|NCT01307267|EXPERIMENTAL|Portion A|PF-05082566 single agent in patients with advanced cancer
61928073|NCT02896933||healthy control subjects|
61928074|NCT05969431||fathers of mature infants|Fathers of newborns' above 37 weeks of gestation
61928075|NCT05969431||fathers of moderate and late preterm infants|Fathers of moderate and late preterm infants, i.e. gestational age from 32 0/7 to 36 6/7 weeks of gestation.
61928076|NCT05969431||fathers of very low birth weight preterm infants|Fathers of very low birth weight preterm infants, i.e. gestational age from 22 0/7 to 31 6/7 weeks of gestation and with a birth weight below 1500 g.
62131053|NCT01307267|EXPERIMENTAL|Portion B|PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma
62322480|NCT03466320|EXPERIMENTAL|Phase II Segment 2|Enrollment in the Phase II part of the study will be divided in 2 consecutive segments, with 13 patients in total in the segment 1 and 30 new patients in segment 2 (43 patients in total) if the study is not terminated due to futility, according a Simon's two-stage optimal design
62322481|NCT00339014|ACTIVE_COMPARATOR|Group 1|Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day
61928077|NCT05325424|OTHER|Experimental Group|Laparoscopic splenectomy
61928078|NCT01867411||ex-smokers|former smokers who have quit
61928079|NCT01867411||never smokers/vapers|never smoked/vaped nicotine
61928080|NCT01867411||non-treatment seeking smokers/vapers|smokers/vapers not interested in quitting nicotine
61928081|NCT01867411||Treatment seeking smokers/vapers|smokers/vapers interested in quitting nicotine
62131054|NCT01876602|EXPERIMENTAL|Exercise prescription|"Participants are given an exercise prescription in the form of a target heart rate range for exercising. The range is determined based on their personal preferences so that it is an intensity that feels good."
62131055|NCT01876602|ACTIVE_COMPARATOR|traditional exercise|participants are given an exercise prescription based on percent of vo2 peak
62131056|NCT02204982|EXPERIMENTAL|Duvelisib + Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
62322482|NCT00339014|ACTIVE_COMPARATOR|Group 2|Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day
62322483|NCT00339014|ACTIVE_COMPARATOR|Group 3|Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day
62322484|NCT00339014|ACTIVE_COMPARATOR|Group 4|Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day
62322485|NCT00339014|ACTIVE_COMPARATOR|Group 5|Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day
62322486|NCT00339014|ACTIVE_COMPARATOR|Group 6|Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day
62322487|NCT00339014|PLACEBO_COMPARATOR|Group 7|
62322488|NCT00978445|EXPERIMENTAL|Home/Standard|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was at home first then in clinic INR and interaction with a care giver.
62481926|NCT05355545|ACTIVE_COMPARATOR|Health education|In the first half of the study (weeks 0 to 12), participants will receive a health education program. In the second half of the study (weeks 13 to 24), participant will receive a the virtually supervised exercise program.
62481927|NCT06626841||Female athletes|Female functional fitness training athletes. The participants had to be nulliparous, had been practicing FFT or weightlifting for at least 2 years, trained a minimum of 3 days/week that did not include pelvic floor exercises, and had no medical contraindications or previous pelvic floor surgeries
62690591|NCT04403776|EXPERIMENTAL|Treatment B, separated washout phase, followed Treatment A.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~Washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
61928082|NCT06482918|EXPERIMENTAL|Top-Down Cognitive Remediation|Executive functions training
61928083|NCT06482918|EXPERIMENTAL|Bottom-Up Cognitive Remediation|Perceptual training
61928084|NCT06482918|NO_INTERVENTION|Treatment-As-Usual|Treatment as usual
61928085|NCT02917993|EXPERIMENTAL|Itacitinib + osimertinib|
62690592|NCT06569654|EXPERIMENTAL|Intervention group|The intervention group received additional task-oriented repetitive training using the SaeboFlex orthosis, a dynamic wrist-hand-finger orthosis designed to facilitate upper limb rehabilitation in stroke participants. The SaeboFlex orthosis is a custom-fabricated, non-electric mechanical device that assists participants with significant upper extremity weakness, particularly those without active finger extension, in performing repetitive task practice
61928086|NCT06227455|SHAM_COMPARATOR|Ti PTFE|TI PTFE is pre-bent and adapted over a 3D printed model for the alveolar defect area after virtual augmentation then used intra-operative over the mixture of Autogenous and xenograft particles.
61928087|NCT06227455|ACTIVE_COMPARATOR|Customized zirconia Barrier|After virtual augmentation of the defect area, a customized 3D zirconia barrier is designed on a specialized software (Autodesk Meshmixer). The exported STL file of the designed barrier is milled and sterilized. Intra-operatively, the initial try-in of the zirconia barrier is done to allow for adjustment and ensuring a proper fit and tension-free primary closure.
61928088|NCT04643821|EXPERIMENTAL|NAC 25mg/kg, calcitriol 0.05mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.05mcg/kg iv q 12h, for 10 days, starting within 6h of birth
62481928|NCT05429476|EXPERIMENTAL|Alteplase with standard therapy|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
62481929|NCT05429476|NO_INTERVENTION|Standard therapy|Standard therapy
62481930|NCT04527315||COVID-19 ICU Patients|
62481931|NCT04527315||Control|
62690593|NCT06569654|NO_INTERVENTION|Control group|"Both the control and intervention groups received regular rehabilitation, which included physical therapy, occupational therapy and visual cognitive rehabilitation.~During the regular rehabilitation program, participants received a comprehensive range of therapies aimed at improving their overall functional abilities and quality of life. The key components of the regular rehabilitation included:"
62481932|NCT06609889|EXPERIMENTAL|ION283 Arm|Open label evaluation of ION283. All subjects with Lafora disease enrolled in this study will receive ION283.
62481933|NCT01908556|EXPERIMENTAL|Letrozol|All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
61928089|NCT04643821|EXPERIMENTAL|NAC 25mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
61928090|NCT04643821|EXPERIMENTAL|NAC 40mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 40mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
61928091|NCT03478852||Single Arm|Single arm open enrollment of patients with standard of care treatment and evaluation
61928092|NCT06323889|ACTIVE_COMPARATOR|Modified Alternate Day Fasting (mADF)|"Participants in the mADF group will be instructed to eat every second-day ad libitum (feast days), and to consume a very low carbohydrate snack, restricted to the evening, provided by the study team and to otherwise abstain from calorie intake on the rest of the fast day."
61928093|NCT06323889|ACTIVE_COMPARATOR|Time-Restricted Eating (TRE)|TRE participants are instructed to eat two main meals and limit snacking from 12:00 to 20:00 daily, and to fast from 20:00 until 12:00 daily
61928094|NCT06323889|OTHER|Control group|The control group will receive guidance on a quantitative reduction in total caloric intake by following a balanced diet, but no timing window for food intake will be prescribed to the participants in the control group.
61928095|NCT03544775||Isolated General Anesthesia|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have not had a nerve block identified using physician billing codes.
61928096|NCT03544775||Peripheral Nerve Block|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have a nerve block identified using physician billing codes.
61928097|NCT05855070|EXPERIMENTAL|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid 6 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
61928098|NCT05855070|EXPERIMENTAL|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
61928099|NCT05950958|EXPERIMENTAL|Multimodal therapy group|"Continuous regional cerebral oxygen saturation and processed electroencephalogram (EEG) are monitored.~Multimodal therapy with conventional care are provided to prevent delirium. Ongoing orientation: 3 times per day Sensory correction: the hearing device and the glasses are supplied. Cognitive stimulation: a portable monitor is used to provide visual stimulation, and a directional speaker is used to avoid disturbing the alarm of the patient's life supportimng system.~Sleep promotion: the lights are turned off from 10 pm to 7 am, and the indirect light source is used if necessary."
62322489|NCT00978445|EXPERIMENTAL|Standard/Home|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was an in clinic INR and interaction with a care giver, then the Home protocol was as described.
62322490|NCT06238479|EXPERIMENTAL|LY4101174 (Dose-escalation, Cohort A1)|Escalating doses of LY4101174 administered intravenously (IV).
62481934|NCT06737887|EXPERIMENTAL|Stoma simulation group|"1. Patients are informed about the study 24 hours before surgery.~2. The patient is given a patient information form and The State-Trait Anxiety Inventory.~3. The stoma simulation is started.~4. The stoma simulation is ended on the morning of the surgery and the patient's state anxiety is measured.~5. During the discharge, the patient's adaptation to the stoma is evaluated using the Ostomy Adjustment Inventory.~6. 1 months after surgery, the patient's adaptation to the stoma is evaluated again using the Ostomy Adjustment Inventory."
62690594|NCT03652428|OTHER|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:~Gemcitabine + nab-paclitaxel:~• Administered per institutional standard every 7 days for 3 weeks~Part II:~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.~Part III:~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy~OR~Chemo per discretion of MD if not resectable"
62690595|NCT03344705|EXPERIMENTAL|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
62690596|NCT03161262|EXPERIMENTAL|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
62690597|NCT03161262|NO_INTERVENTION|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
62690598|NCT00836901|EXPERIMENTAL|Amoxicillin Calvulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 40-57 mg Chewable Tablet (reference) dosed in second period
61928100|NCT05950958|NO_INTERVENTION|Conventional care group|"Continuous regional cerebral oxygen saturation and processed electroencephalogram (EEG) are monitored.~Conventional care: If sedation is required, dexmedetomidine is considered as the first-line sedative drug. The sedation is interrupted daily and the possibility of awakening is assessed. Pain with NRS score above 3, is controlled with opioid.~For patients with Richmond Agitation Sedation Scale (RASS) -4 or -5, possible items are provided."
61928101|NCT06089473|OTHER|Experimental: Pre-habilitation plus usual outpatient care|An intervention including exercise and education.
61928102|NCT06089473|OTHER|No Intervention: Usual outpatient care|The control group will receive usual outpatient care provided to kidney transplant candidates. All participants in the control group will receive educational resources received by intervention group participants at trial completion.
61928103|NCT05036720|EXPERIMENTAL|LTP+Dads|Participants in this arm will be offered the LTP+Dads intervention. The intervention will be delivered by trained Community Health Workers (CHWs). This will be co-facilitated by LTP+ master trainers.
61928104|NCT05036720|OTHER|Wait-list control:|Participants in this arm will be offered the intervention once the LTP+ arm have completed their outcome assessment. For example, in each Union Council (UC) once the LTP+ arm has completed the intervention and 4th month outcome assessment the wait-list control group in the same UC will be offered the intervention.
61928105|NCT05036720|OTHER|Optional mothers component|To facilitate changes in co-parenting and optimize impact on child development, the partners of fathers who participate will be offered optional LTP+ group sessions running parallel to LTP+Dads.
61928106|NCT06598033|EXPERIMENTAL|VC plus herbal medicine|Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
61928107|NCT00267189|ACTIVE_COMPARATOR|Reduced CNI dose + everolimus ± steroids|Reduced CNI dose + everolimus (1.5 mg twice daily (b.i.d)) ± steroids
62690599|NCT00836901|ACTIVE_COMPARATOR|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (test) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (reference) dosed in second period
62690600|NCT00310141|ACTIVE_COMPARATOR|Standard Care Group|Written self-help materials, counseling, and 6-week nicotine patch supply
62690601|NCT00310141|ACTIVE_COMPARATOR|Computer Treatment Group (CDT)|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
62690602|NCT00310141|EXPERIMENTAL|CDT Pilot|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
62690603|NCT01988558|EXPERIMENTAL|Treated Group|Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
62690604|NCT01988558|PLACEBO_COMPARATOR|Placebo Group|
62690605|NCT06077513|EXPERIMENTAL|CAD-CAM Ti-Mesh frame|Participants randomized into this arm will have their tooth loss treated with CAD-CAM designed and preprinted Ti-MESH during surgery.
61928108|NCT00267189|EXPERIMENTAL|CNI continuation ± MPA/AZA ± Steroids|Standard CNI dose ± MPA/AZA ± steroids
61928109|NCT05851105|EXPERIMENTAL|Experimental|Three transfusion-dependent α-thalassaemia subjects aged 12-35 years will be reinfused with α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
61928110|NCT00845780|EXPERIMENTAL|withdrawal amiodarone|withdrawal amiodarone afer at least 6 months of sinus rhythm maintenance on amiodarone therapy
61928111|NCT00845780|ACTIVE_COMPARATOR|continuation amiodarone|continuation of amiodarone after 6 months of sinus rhythm maintenance on amiodarone therapy
62322491|NCT06238479|EXPERIMENTAL|LY4101174 (Dose-optimization, Cohort A2)|Comparing 2 or more doses (evaluated during dose escalation) of LY4101174 administered IV.
62322492|NCT06238479|EXPERIMENTAL|LY4101174 (Dose-expansion, Cohort B1, B2, C1-C5))|LY4101174 administered IV.
62322493|NCT04935879|EXPERIMENTAL|inclacumab, 30 mg/kg|Participants will receive inclacumab 30 mg/kg administered IV every 12 weeks
62322494|NCT04935879|PLACEBO_COMPARATOR|placebo|Participants will receive placebo administered IV every 12 weeks.
62322495|NCT01613469|OTHER|5FU/Leucovorin- post distal rectal srgy|Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer
62322496|NCT05222347||Comparison of biochemical parameters of OLT drinkers|Compared biochemical parameters of OLT smokers and nonsmokers
62690606|NCT06077513|ACTIVE_COMPARATOR|Conventional Ti-Mesh frame|Participants randomized into this arm will have their tooth loss treated with conventional chairside fabrication of Ti-MESH during surgery.
62690607|NCT00468546|PLACEBO_COMPARATOR|Placebo Plus Methotrexate|Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
62322497|NCT05222347||Comparison of biochemical parameters of OLT nondrinkers|Compared biochemical parameters of OLT smokers and nonsmokers
62690608|NCT00468546|EXPERIMENTAL|Rituximab plus Methotrexate|Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
62322498|NCT06108323|EXPERIMENTAL|Action observation plus exercise|Therapeutic exercise plus action observation training
62690609|NCT05674565|EXPERIMENTAL|Loading dose only|Those receiving only the loading dose of magnesium sulphate 4 gm infusion over 20 minutes therapy within one hour before delivery without the maintenance dose
62690610|NCT05674565|EXPERIMENTAL|Loading plus maintenance dose|Receiving magnesium sulphate loading 4 gm infusion over 20 minutes, followed by maintenance therapy 1gm per hour infusion until delivery or completion of 24 hours, the sooner.
62690611|NCT05674565|NO_INTERVENTION|Control|comparable number of women who did not receive magnesium sulphate neuroprotection for any reason
62322499|NCT06108323|SHAM_COMPARATOR|Sham observation plus exercise|Therapeutic exercise plus sham action observation training
62322500|NCT06692257||Individuals without MIH|All permanent molars without indices compatible with MIH
62322501|NCT06692257||Individuals with MIH|At least one permanent molar with indices compatible with MIH (code 2, 21, 22 and 3 - Ghanim criteria)
62322502|NCT03719560|EXPERIMENTAL|CNS prophylaxis protocol|Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.
62322503|NCT01772225||Deceased Group|Subjects in this group will include the deceased patients from each of the three countries.
62322504|NCT01772225||Living Group|Subjects in this group will include living patients aged 18 years or older from each of the three countries.
62322505|NCT04030481||Group A: Sevoflurane, sufentanil and rocuronium|sevoflurane (1-3%)and sufentanil (0.5-2 mcg/kg/h) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
62322506|NCT04030481||Group B: Propofol, sufentanil and rocuronium|propofol (4-12 mg/kg/h) and sufentanil (0.5-2 mcg/kg/h/) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
62322507|NCT03123939|EXPERIMENTAL|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)
62322508|NCT06281028|OTHER|A : SOLACEA-H/HYDROLINK-NVU|"The dialysis sessions will take place in the following order :~Wash - SOLACEA-H dialysis - Wash - HYDROLINK-NVU dialysis"
62322509|NCT06281028|OTHER|B : HYDROLINK-NVU/SOLACEA-H|"The dialysis sessions will take place in the following order :~Wash - HYDROLINK-NVU dialysis - Wash - SOLACEA-H dialysis"
62690612|NCT01063569|ACTIVE_COMPARATOR|Oral hydrocortisone|
62690613|NCT01063569|EXPERIMENTAL|Continous subcutaneous hydrocortisone infusion|
62131057|NCT02204982|PLACEBO_COMPARATOR|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
62131058|NCT02730923|EXPERIMENTAL|Arm A: AZD2014 plus anastrozole|
62131059|NCT02730923|ACTIVE_COMPARATOR|Arm B: anastrozole alone|
62322510|NCT05669482|EXPERIMENTAL|Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib|To determine the recommended phase 2 dose (RP2D) for gemcitabine Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib in patients with untreated metastatic PDAC.
62322511|NCT05669482|EXPERIMENTAL|Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib RP2D|To determine the efficacy of the RP2D identified in Part A in untreated metastatic PDAC patients
62322512|NCT04729959|EXPERIMENTAL|Group I (tocilizumab, atezolizumab, FSRT)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days in the absence of disease progression or unacceptable toxicity. Starting 4 weeks from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial.
62322513|NCT04729959|EXPERIMENTAL|Group II, Arm I (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial, as well as blood sample and tumor tissue collection on study.
62322514|NCT04729959|EXPERIMENTAL|Group II, Arm II (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3-5 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab IV over 60 minutes with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and tumor tissue collection on study. Patients undergo MRI throughout the trial, as well as blood sample and tumor tissue collection on study.
62322515|NCT01791868|EXPERIMENTAL|Intravenous sodium valproate|"Intravenous sodium valproate:~30 mg/kg during 15 min then 1 mg/kg/h during 12 h"
62322516|NCT01791868|PLACEBO_COMPARATOR|Intravenous Placebo|"Intravenous Placebo:~NaCl 0,9 % during 15 min at first then during 12 h."
62690614|NCT03349996|EXPERIMENTAL|LifeStream Peripheral Stent Graft System|Patients treated with the LifeStream Peripheral Stent Graft System
62481935|NCT06737887|NO_INTERVENTION|Control group|"1. Patients are informed about the study 24 hours before the surgery.~2. The patient is given a patient information form and The State-Trait Anxiety Inventory.~3. The patient's state anxiety is measured on the morning of the surgery.~4. During the discharge, the patient's adaptation to the stoma is evaluated using the Ostomy Adjustment Inventory.~5. 3 months after the surgery, the patient's adaptation to the stoma is evaluated again using the Ostomy Adjustment Inventory."
62481936|NCT06741618|ACTIVE_COMPARATOR|Control|Participants randomized to the control arm will receive standard of care information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP, referrals to the local PrEP clinic, and referrals for local sexually transmitted disease testing, and will have access to the MyPEEPS Mobile App during the study.
62690615|NCT06429085|EXPERIMENTAL|People diagnosed with Multiple Sclerosis|Use of powered Rex robotic exoskeleton to enable the practice of core stability balance exercises
62690616|NCT06441188|EXPERIMENTAL|Healthy Subjects|Healthy volunteers with no breast cancer or breast symptoms. Subjects will undergo 1 hour of non-invasive ultrasound scanning of the nipple and its adjacent tissues.
62690617|NCT01791179|EXPERIMENTAL|Substance Abuse Treatment Group|
62322517|NCT06126705|EXPERIMENTAL|Group A|Patients who are surgically resectable or borderline surgically resectable plan to undergo primary lesion resection and peripheral lymph node dissection, and suspect the presence of peripheral lymph nodes or distant metastasis; Pathological results of postoperative primary lesion and lymph node dissection can be obtained
62322518|NCT06126705|EXPERIMENTAL|Group B|For patients diagnosed or suspected of postoperative recurrence or late metastasis through routine imaging examination, there is at least one measurable lesion (with a short diameter of ≥ 1.5cm for lymph node lesions and ≥ 1cm for non lymph node lesions); Patients who can undergo imaging follow-up for 3-6 months or undergo pathological biopsy and puncture.
62322519|NCT06148233|EXPERIMENTAL|patients with Alzheimer's Disease|AD subjects recruited from geriatric wards or memory clinics.
62322520|NCT06148233|EXPERIMENTAL|Cognitively normal control group|Cognitively normal subjects recruited from the community
62690618|NCT04013971|OTHER|AGRF Biofeedback Game Followed by the Traditional biofeedback Interface|Post-stroke participants randomized to receive the two gait training biofeedback interfaces in the order of the AGRF biofeedback game first and the traditional, non-game-based, interface second. Participants will also complete a control condition where no biofeedback is provided.
62322521|NCT05815329|EXPERIMENTAL|rehabilitation group|Outpatients undergoing neurorehabilitation through Neurotablet
62690619|NCT04013971|OTHER|Traditional biofeedback Interface Followed by the AGRF Biofeedback Game|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of the traditional, non-game-based, interface first and the AGRF biofeedback game second. Participants will also complete a control condition where no biofeedback is provided.
62690620|NCT04013971|OTHER|Optional Game with VR|Post-stroke participants attending a separate, optional, session to complete preliminary or exploratory testing of the VR version of the biofeedback game (head-mounted AR or VR display), which will be used to determine feasibility and preliminary effects of VR-based feedback on gait.
62690621|NCT05620719|ACTIVE_COMPARATOR|Clinic-based Cognitive Behavioral Therapy (CCBT)|CCBT provides CBT for posttraumatic headache through 8 face-to-face, in-clinic sessions.
62690622|NCT05620719|ACTIVE_COMPARATOR|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|TCBT provides 8-sessions of CBT for posttraumatic headache using telemedicine technology rather than attending in-office sessions. Additionally, TCBT includes instructions for each session specific to the mechanics of a telehealth encounter (e.g., asking participant for name, location, and accessible phone number for location in case of technical failure or crisis). All TCBT participants must be enrolled at the MTF or VA from which they were recruited, and the treatment facility will be notified that they are receiving TCBT in case a crisis arises and needs to be managed by the site.
62690623|NCT05620719|ACTIVE_COMPARATOR|Treatment As Usual|Participants will continue to engage in clinical care as usual for 8 weeks. Research staff will call the TAU participants weekly to assess for adverse events. Research staff at each site will be trained on standardized assessment of usual care activities using forms adapted from our single-site trial.
62690624|NCT06539260|EXPERIMENTAL|VitD group|The Parkinson's disease patients included in the study underwent analysis of peripheral blood vitamin D levels, among other assessments. Patients with low vitamin D levels (Vit D \< 30 ng/ml) were randomly assigned in a 1:1 ratio to two groups: one receiving vitamin D3 and the other receiving a placebo (PL). The vitamin D group was supplemented with vitamin D for a period of 3 months.
62322522|NCT05815329|NO_INTERVENTION|waiting list|Outpatients not undergoing rehabilitation during the study. They will have the possibility to carry on the rehabilitation at the end of the study
62481937|NCT06741618|EXPERIMENTAL|Intervention|Participants randomized to the intervention arm will have access to the MyPEEPS mobile application and Electronic peer PrEP navigation for the entire 12-month study period.
62339846|NCT01752582|OTHER|BuMA stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~BuMA stent Arm:About 35 patients will undergoing implantation of BuMA stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
62481938|NCT06641310|EXPERIMENTAL|Endurance exercise therapy comprising treadmill walking|Endurance exercise therapy
62481939|NCT05605535|EXPERIMENTAL|Combination of Oregovomab and chemotherapy|Six (6) cycles of chemotherapy with oregovomab given only at specific cycles (Cycle 1, Cycle 3, Cycle 4, Cycle 6 and Cycle 6 plus 12 weeks).
62481940|NCT05605535|PLACEBO_COMPARATOR|Combination of Placebo and chemotherapy|Six (6) cycles of chemotherapy with placebo given only at specific cycles (Cycle 1, Cycle 3, Cycle 4, Cycle 6 and Cycle 6 plus 12 weeks).
62481941|NCT04939038|ACTIVE_COMPARATOR|Control Arm|Standard wound care for diabetic wound ulcer
62481942|NCT04939038|EXPERIMENTAL|Immediate revascularization|Patient will have revascularization 0 - 7 days after initial wound assessment and then receive standard wound care for diabetic wound ulcer
62481943|NCT06128629|EXPERIMENTAL|NTLA-2001|Single intravenous (IV) infusion of NTLA-2001
62481944|NCT06128629|PLACEBO_COMPARATOR|Placebo|Single IV infusion of normal saline
62481945|NCT03089983|ACTIVE_COMPARATOR|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
62481946|NCT03089983|ACTIVE_COMPARATOR|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
62481947|NCT03089983|ACTIVE_COMPARATOR|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
62481948|NCT03089983|EXPERIMENTAL|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
62481949|NCT02977403|EXPERIMENTAL|AB Retraining|Active treatment - the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
62481950|NCT02977403|SHAM_COMPARATOR|Control sham|Sham Comparator program - the probe randomly replaces the neutral or food picture. There is no correlation between picture type and probe location
62481951|NCT05373173|EXPERIMENTAL|Tele-assessment + In-person assessment|All families will receive an in-person tele-assessment appointment and an in-person evaluation.
62481952|NCT04196907|EXPERIMENTAL|Test subjects|All subjects are enrolled and receive Rad-67 Pulse Oximeter and DCI Mini sensor for measurement of hemoglobin.
62481953|NCT06731023||Unsuccessful culture attempts group|Bismuth-containing quadruple therapy (vonoprazan 20 mg bid + bismuth 0.6g bid + amoxicillin 1g bid + rifabutin 0.15g bid)
62481954|NCT06731023||Demonstrate sensitivity to both amoxicillin and rifabutin group|Bismuth-containing quadruple therapy (vonoprazan 20 mg bid + bismuth 0.6g bid + amoxicillin 1g bid + rifabutin 0.15g bid)
62481955|NCT06731023||Drug susceptibility testing group|Two non-resistant antibiotics are selected based on drug susceptibility testing outcomes. If a patient shows sensitivity to only one antibiotic, a combination of that sensitive antibiotic with high-dose metronidazole is administered.
62481956|NCT06742437||Normozoospermic|Semen samples with normal sperm parameters as defined by the World Health Organization guidelines (e.g., normal sperm concentration, motility, and morphology).
62481957|NCT06742437||Teratozoospermic|Semen samples with abnormal sperm morphology, where the percentage of morphologically normal sperm is below the threshold set by the World Health Organization (i.e., 4%).
62322523|NCT04143542|EXPERIMENTAL|Groups Q|"In abdominal surgeries, USG guided Quadratus Lumborum 2 blocks are performed for postoperative analgesia. For this purpose, Quadratus Lumborum Block 2 (QLB 2) are frequently used blocks.~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
62322524|NCT04143542|EXPERIMENTAL|Groups T|"In abdominal surgeries, USG guided TAP blocks are performed for postoperative analgesia. For this purpose, TAP blocks are frequently used blocks.~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
62481958|NCT06742437||Asthenozoospermic|Semen samples characterized by reduced sperm motility, where the percentage of progressive motile sperm is below the threshold set by the World Health Organization (i.e., 32%).
62481959|NCT06742437||Oligozoospermic|Semen samples with a low sperm concentration, below the World Health Organization reference value (i.e., less than 15 million sperm per milliliter).
62481960|NCT06742437||Cryopreserved semen|Semen samples that have been preserved through freezing and stored at ultra-low temperatures.
62481961|NCT06743243|EXPERIMENTAL|Group T|Tegoprazan OD tab. 50 mg PO + Saline 20 ml IV, one hour before general anesthesia.
62481962|NCT06743243|ACTIVE_COMPARATOR|Group F|Famotidine 20 mg/10 ml + Saline 10 ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.
62481963|NCT06743243|PLACEBO_COMPARATOR|Group C|Tegoprazan OD tab. 50 mg placebo PO + Saline 20 ml IV, one hour before general anesthesia.
62481964|NCT04373096|ACTIVE_COMPARATOR|Group C (Control)|Will use current IPAC-UHN PPE as described under assigned intervention:
62481965|NCT04373096|EXPERIMENTAL|Group H (enhanced PPE group )|Will use modified IPAC-UHN PPE including the prototype hood as described under assigned intervention:
62481966|NCT03059979|ACTIVE_COMPARATOR|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
62481967|NCT03059979|PLACEBO_COMPARATOR|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
62481968|NCT05432557|EXPERIMENTAL|Group E|patients will receive ultrasound guided external oblique intercostal plain block.
62481969|NCT05432557|EXPERIMENTAL|Group T|patients will receive ultrasound guided subcostal transversus abdominis plane block.
62131060|NCT04570592|PLACEBO_COMPARATOR|Granisetron|Granisetron 1 mg (1ml) + Normal saline 1ml
62481970|NCT05432557|PLACEBO_COMPARATOR|Group C|patients won't receive LA injection
62690625|NCT06539260|PLACEBO_COMPARATOR|PL group|The Parkinson's disease patients included in the study underwent analysis of peripheral blood vitamin D levels, among other assessments. Patients with low vitamin D levels (Vit D \< 30 ng/ml) were randomly assigned in a 1:1 ratio to two groups: one receiving vitamin D3 and the other receiving a placebo (PL). The placebo group was supplemented with a placebo for a period of 3 months.
62322525|NCT04143542|NO_INTERVENTION|Groups C|There was no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg, and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with the target of EtCO2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC). Anesthesia will be discontinued and tracheal extubation will be done once the patient fulfills the extubation criteria.Tramadol 100 mg i.v. Before 15 min end of surgery. The patient control analgesia device will administer all patients.
62322526|NCT00069082|ACTIVE_COMPARATOR|Civamide|Nasal Solution 0.01%
62322527|NCT00069082|PLACEBO_COMPARATOR|Placebo|Placebo nasal solution with sodium chloride 10%
62322528|NCT06692465|EXPERIMENTAL|Experimental: GT20029|
62322529|NCT06692465|PLACEBO_COMPARATOR|Placebo Comparator: GT20029 Matching Placebo|
62690626|NCT06058351|EXPERIMENTAL|ABI-motion group|Patients following outpatient rehabilitation after implementation of the ABI-motion program
62131061|NCT04570592|EXPERIMENTAL|Granisetron and Dexamethasone|Granisetron 1mg (1ml) + Dexamethasone 4mg (1ml)
62131062|NCT03287622|EXPERIMENTAL|Education Intervention + Nudge|This group will receive BOTH the scenario-tailored STOMP educational feedback AND the behavioral Nudge intervention
62131063|NCT03287622|EXPERIMENTAL|Standard of Care + Nudge|This group will receive routine, standard of care information AND the behavioral Nudge intervention
62131064|NCT03287622|EXPERIMENTAL|Educational Intervention no Nudge|This group will receive scenario-tailored opioid message (STOMP) feedback and NO behavioral nudge intervention.
62131065|NCT03287622|NO_INTERVENTION|Standard of Care no Nudge|This group will receive only standard of care information and NO behavioral nudge intervention.
62131066|NCT06262282||People with cystic fibrosis who are receiving phage treatment for NTM.|People with cystic fibrosis who have identified at least one phage effective against their NTM infection and are receiving treatment with the phage. These subjects will remain on guideline based NTM antibiotic treatment and their standard CF care. They will receive therapeutic phage twice daily for 1 year.
62131067|NCT06262282||People with cystic fibrosis who are not receiving phage treatment for NTM.|People with cystic fibrosis who have not identified any phage effective against their NTM infection and are not receiving phage treatment. These subjects will continue with guideline based NTM antibiotic treatment for their NTM disease and standard CF care.
62131068|NCT05512858|NO_INTERVENTION|phase 1|Data on restrictions and aggression events in the department will be collected throughout the two phases, and the participants will undergo an evaluation process.
62131069|NCT05512858|EXPERIMENTAL|phase 2|Data on restrictions and aggression events in the department will be collected throughout the two phases, and the participants will undergo an evaluation process. n addition, the subjects who participate in the intervention will wear an Empatica-E4 wristband to monitor autonomous metrics during their stay in the sensory stimulation room and will undergo a brief interview regarding their experience using the room.
62131070|NCT00739531||Asthmatics|Subjects with asthma
62131071|NCT04469543||MTHFR polymorphism|
62131072|NCT03345901|EXPERIMENTAL|Pemafibrate|.2 mg pemafibrate orally BID
62131073|NCT03345901|PLACEBO_COMPARATOR|Placebo|Placebo pill orally BID
62131074|NCT02634892|NO_INTERVENTION|Standard of Care (SOC)|Patients receive usual or standard of care regarding management of early stage pressure ulcers
62131075|NCT02634892|EXPERIMENTAL|SOC plus PRO-TECT|Patients receive usual or standard of care plus the addition of PRO-TECT.
62131076|NCT02057939|EXPERIMENTAL|Enzalutamide|Enzalutamide, Androgen Deprivation, and Radiation Therapy
62131077|NCT02241070|EXPERIMENTAL|mindulness-based intervention|Mindulness-based intervention was eight weeks of mindfulness training with forty-five minutes of homework practice every day during the training course. A leader and a professional facilitator led the group. The leader was a long-term mindfulness and vipassana meditation trainer who had practiced both types of meditation for more than two decades and had completed mindfulness trainer education; the professional facilitator was a mindfulness practitioner and a psychiatrist. The group met weekly for two hours in-session at the workplace.
62131078|NCT02241070|NO_INTERVENTION|waiting-list control|passive control group
62131079|NCT05496842||Rehabilitation patients with post-COVID-19 Syndrome|This group includes rehabilitation patients with and without respiratory muscle training
62131080|NCT00654589|EXPERIMENTAL|deferasirox|
62131081|NCT06288334|EXPERIMENTAL|Pediatric patients treated with cetirizine|Pediatric patients who were being treated with cetirizine to fight allergic diseases.
62131082|NCT01261312|EXPERIMENTAL|Daily Regimen|"* SGI-110 daily x5 dosing on a 28-day course~* SGI-110 daily x10 dosing on a 28-day course"
62131083|NCT01261312|EXPERIMENTAL|Weekly Regimen|"* SGI-110 weekly dosing for three weeks on a 28-day course~* SGI-110 twice weekly dosing for three weeks on a 28-day course"
62131084|NCT01556724|ACTIVE_COMPARATOR|0.2% ropivacaine nerve block (standard of care)|0.2% ropivacaine in lumbar plexus nerve catheter infusions for postoperative analgesia
62131085|NCT01556724|EXPERIMENTAL|0.1% ropivacaine infusion in nerve block catheter|0.1% ropivacaine in lumbar plexus nerve catheter infusions
62131086|NCT06241716|ACTIVE_COMPARATOR|Ultrasound-assisted localization, US-AS|
62131087|NCT06241716|EXPERIMENTAL|Real-time ultrasound guidance, US-RTG|
62131088|NCT00077493|ACTIVE_COMPARATOR|1|BL22 immunotoxin
62131089|NCT00077493|ACTIVE_COMPARATOR|2|antibody therapy
62131090|NCT00077493|ACTIVE_COMPARATOR|3|immunotoxin therapy
62131091|NCT00077493|ACTIVE_COMPARATOR|4|monoclonal antibody therapy
62131092|NCT03826875|EXPERIMENTAL|Treatment|Patients randomized to the fluoxetine treatment group will be initially prescribed fluoxetine 20mg/day for a period of one year.
62131093|NCT03826875|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo group will be initially prescribed placebo 20mg/day for a period of one year.
62481971|NCT06203951|NO_INTERVENTION|Standard of Care|In all arms, participants will receive syndromic STI assessment from study nurses at the antenatal clinic per Kenyan national guidelines, which entails a clinician (i.e., nurse, physician, clinical officer) using an algorithm asking whether clients have symptoms of vaginal discharge, lower abdominal pain, or genital ulcers followed by a physical examination for signs that match the self-reported symptoms. Based on clinical presentation, treatment is prescribed. Study nurses will capture information on symptoms, treatment acceptance, and dispensation. All participants will be provided with a study phone number to call at any time free of charge for clarifying questions or concerns with STI medication use.
62481972|NCT06203951|EXPERIMENTAL|Universal Testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment.
62481973|NCT06203951|EXPERIMENTAL|Asymptomatic Only Testing|Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment.
62481974|NCT06741917|EXPERIMENTAL|Oral Levofloxacin|
62481975|NCT06741917|ACTIVE_COMPARATOR|Intravenous cefmetzole|
62481976|NCT06419205|OTHER|Open Label|Subcutaneous Infusions
62690627|NCT06058351|NO_INTERVENTION|Control group|Patients following outpatient rehabilitation before implementation of the ABI-motion program
61928112|NCT04806789||Children with suspected acute appendicitis|"Cohort: Children with suspected acute appendicitis. Clinical examination (including history of nausea, vomiting, temperature, information of rebound tenderness, right iliac fossa pain, duration of symptoms, gender and weight) and blood samples will be obtained at the emergency department (blood gas, C-reactive protein, neutrophiles and white blood cell count). Radiology (ultrasound and/or computed tomography) will be performed thereafter.~Outcome measures~Primary outcome measure: Plasma sodium. To investigate if plasma sodium is an independent predictor of perforation in children with acute appendicitis. In advance, five variables (Plasma sodium, C-reactive protein, symptom duration, age and temperature) will be included in the final multivariable analysis"
61928113|NCT05247424|EXPERIMENTAL|Early unfractionated heparin|Administration of UFH at a dose of 100 IU/kg body weight at first medical contact. Addition of UFH before coronary intervention according to ACT measurement after coronary angiography before coronary intervention.
61928114|NCT05247424|NO_INTERVENTION|Control - Unfractionated heparin for coronary intervention only|Control arm with administration of UFH at a dose of 100 IU/kg body weight after coronary angiography before coronary intervention.
61928115|NCT04019587||Test of reliability and validity|
62322530|NCT03345836|PLACEBO_COMPARATOR|Part 1 (Double-blind): Placebo|Participants received upadacitinib matching placebo tablets, orally, once daily (QD) for 12 weeks during the Double-blind (DB) Induction Period.
62322531|NCT03345836|EXPERIMENTAL|Part 1 (Double-blind): Upadacitinib 45 mg|Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.
62322532|NCT03345836|EXPERIMENTAL|Part 2 (Open-label): Upadacitinib 45 mg|Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.
62322533|NCT03345836|EXPERIMENTAL|Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo|Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.
62322534|NCT03345836|EXPERIMENTAL|Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg|Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.
62322535|NCT03345836|EXPERIMENTAL|Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg|Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
62322536|NCT00832754|EXPERIMENTAL|RDT+ACT group|RDT+ACT group (ACT offered to RDT positive cases only)
62322537|NCT00832754|ACTIVE_COMPARATOR|Clinical judgement+ACT group|Clinical judgement+ACT group (ACT offered to all suspected cases of malaria by clinical judgement)
62322538|NCT00581711|NO_INTERVENTION|Control|Usual Care
62322539|NCT00581711|EXPERIMENTAL|HIT Intervention without feedback|3-Part Intervention: Training, Otitis Media Episode Grouper, Clinical Decision Support
62322540|NCT00581711|EXPERIMENTAL|HIT Intervention with feedback|4-Part Intervention: Training, Episode Grouper, Clinical Decision Support, and Physician Feedback.
62322541|NCT00581711|EXPERIMENTAL|Feedback only|1 part intervention: Physician Feedback
62322542|NCT02313935|EXPERIMENTAL|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
62322543|NCT02313935|EXPERIMENTAL|PTC|Physical training only. Participants use the FitForAll exergaming computer platform as the physical training component (PTC).
62322544|NCT02313935|EXPERIMENTAL|CTC|Cognitive training only. Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
62322545|NCT02313935|NO_INTERVENTION|Passive|Passive Control Participants do not receive an intervention serving as passive controls
62322546|NCT02313935|ACTIVE_COMPARATOR|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the AUTH team. The software is called VideoGrade and uses YouTube documentaries.
62322547|NCT03344731|EXPERIMENTAL|Experimental Group|Patient with any form ob brain damage
62322548|NCT03344731|OTHER|Control Group|Healthy volounteers
62481977|NCT04901169|EXPERIMENTAL|Angiotensin II (Giapreza)|Giapreza (synthetic human angiotensin II), initiated at 5 ng/kg/min and titrated to between 1.25 ng/kg/min and 40 ng/kg/min, administered by continuous intravenous infusion.
62481978|NCT04901169|PLACEBO_COMPARATOR|Saline|Sterile 0.9% saline, initiated and titrated at an equivalent volume infusion rate to the study drug, administered by continuous intravenous infusion.
62690628|NCT03380273|NO_INTERVENTION|pre-intervention|The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
62322549|NCT02743403|ACTIVE_COMPARATOR|Neurodyn Portable TENS|"Subjects in this study arm will receive active treatment. The active TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The subject receives both devices at the same time. The parameters of the active TENS are: frequency (f) of 100 Hertz (Hz) oscillator every 0.5 seconds pulse duration (T) 200 microseconds (microsiemens) and the amplitude (I) will be adjusted at the time of application the carboxiterapia.~The application of Carboxytherapy is realized by a carboxy Derm S20-1C equipment Derm® mark, which uses carbon dioxide (CO2) medical and non-toxic.~Each prick with a needle carboxiterapia will 100ml / min and will last 1 minute long.~Before each puncture will be adjusted to the intensity of TENS as sensitivity of the subject."
62322550|NCT02743403|PLACEBO_COMPARATOR|Placebo TENS- Neurodyn Portable TENS|"Subjects in this study arm will receive placebo treatment. The placebo TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The application of placebo TENS will be made by the same unit of active TENS; however, it is used a device specially developed for this study. The device remains active only during the first 30 seconds of application. After this time, the current amplitude will gradually decrease over the next 15 seconds until it reaches zero, thereby interrupting the emission of electrical power to the remainder of the application time. The display of placebo TENS device shows a light on all the time of application, indicating the patient that the device is active."
62322551|NCT02743403|NO_INTERVENTION|Control|"Subjects in this study arm only receive the application carboxiterapia through Carboxyderm S20-1C equipment, Tone Derm® brand.~The group (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS."
62322552|NCT06387719||Control group (CG)|Adolescents with obesity, measured as body mass index (BMI) z-score above 2 standard deviations, and no BED/PREC-BED
62322553|NCT06387719||BED group|adolescents with obesity, measured as BMI z-score above 2 standard deviations, and BED
62322554|NCT06387719||PREC-BED group|adolescents with obesity, measured as BMI z-score above 2 standard deviations, PREC-BED
62322555|NCT03679208|EXPERIMENTAL|Stage 1 Safety cohort|Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.
62322556|NCT03679208|EXPERIMENTAL|Stage 2 Performance (test group)|One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.
62322557|NCT03679208|ACTIVE_COMPARATOR|Stage 2 Performance (control group)|One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.
62690629|NCT03380273|OTHER|post-intervention|Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.
61928116|NCT04487522||Retromuscular ventral hernia repair|These subjects will undergo an open, a laparoscopic, or a robotic-assisted retromuscular ventral hernia repair.
61928117|NCT04487522||Retromuscular TAR ventral hernia repair|These subjects will undergo an open or a robotic-assisted retromuscular transversus abdominis release (TAR) ventral hernia repair.
61928118|NCT06631170|EXPERIMENTAL|Roflumilast cream 0.15%|Active comparator
61928119|NCT06631170|PLACEBO_COMPARATOR|Vehicle cream|Placebo comparator
61928120|NCT00707694||Probands|Ashkenazi Jews ages 95 and older
61928121|NCT00707694||Offspring|Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95
61928122|NCT00707694||Controls|Ashkenazi Jewish people with no family history of longevity
61928123|NCT06281678|EXPERIMENTAL|IBI363|IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks.
61928124|NCT01809691|EXPERIMENTAL|ADT + TAK-700|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~TAK-700, 300 mg, PO, twice daily"
61928125|NCT01809691|ACTIVE_COMPARATOR|ADT + Bicalutamide|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~Bicalutamide, 50 mg, PO, q daily"
61928126|NCT02421939|EXPERIMENTAL|Gilteritinib|Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.
61928127|NCT02421939|ACTIVE_COMPARATOR|Salvage Chemotherapy|Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m\^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m\^2 daily by IV for 5 days, etoposide 100 mg/m\^2 daily by IV for 5 days and cytarabine 1000 mg/m\^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m\^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m\^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m\^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m\^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
61928128|NCT04913220|EXPERIMENTAL|Cohort A: Melanoma|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
61928129|NCT04913220|EXPERIMENTAL|Cohort B: cutaneous squamous cell carcinoma (CSCC)|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
61928130|NCT05882292|EXPERIMENTAL|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
62131094|NCT03544515|SHAM_COMPARATOR|Scaling and use of inactive Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an inactive fashion
62690630|NCT06452511|ACTIVE_COMPARATOR|Metformin|In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) who are experiencing infertility will participate. These participants will receive Letrozole for ovulation induction in combination with Metformin. The study will monitor these women to assess the efficacy of this treatment regimen on inducing ovulation and improving pregnancy outcomes. Participants will be closely observed for any side effects and their progress will be regularly evaluated to determine the effectiveness of Metformin as an adjunct therapy to Letrozole in this specific patient population.
62131095|NCT03544515|EXPERIMENTAL|Scaling and use of active Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an active fashion
62322558|NCT05909345||Knee Osteoarthritis|
62322559|NCT05909345||Nonspecific Low Back Pain|
62322560|NCT05909345||healthy peers|
62322561|NCT02280681||Couples with ovarian failure|Heterosexual couples confronted with infertility due to ovarian failure between the age of 18 and 44 years old treated in the K.U.Leuven and
62131096|NCT06521541|EXPERIMENTAL|Multimodal prehabilitation group|Patients received multimodal prehabilitation combined with ERAS before the gastrectomy.
62131097|NCT06521541|ACTIVE_COMPARATOR|ERAS group|The ERAS pathway was followed in patients in the ERAS group.
62322562|NCT02280681||Clinicians|Clinicians who indicated an interest in reproductive medicine in their membership of the Belgian Society for Reproductive Medicine (BSRM).
62322563|NCT06000722||Healthcare practitioners|Participants who are trained healthcare practitioners involved in the care of patients with current or previous diabetic foot ulcer disease
62690631|NCT06452511|ACTIVE_COMPARATOR|Pep2Dia|In the Pep2dia arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) who are experiencing infertility will participate. These participants will receive Letrozole for ovulation induction in combination with Pep2dia. The study will monitor these women to assess the efficacy of this treatment regimen on inducing ovulation and improving pregnancy outcomes. Participants will be closely observed for any side effects, and their progress will be regularly evaluated to determine the effectiveness of Pep2dia as an adjunct therapy to Letrozole in this specific patient population.
62690632|NCT02913326|EXPERIMENTAL|Dabigatran etexilate|
62690633|NCT02913326|ACTIVE_COMPARATOR|Warfarin|
62322564|NCT02407951|EXPERIMENTAL|CBIT group|
62322565|NCT02407951|PLACEBO_COMPARATOR|Psycho-Educational group|
62322566|NCT04483739|EXPERIMENTAL|Krd Induction|4 28 day cycles of Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
62322567|NCT04483739|EXPERIMENTAL|Isa-KRd induction|"Isatuximab= 10 mg/kg IV on day 1, 8, 15, and 22 during Cycle 1, followed by 10 mg/kg IV on days 1 and 15 during Cycles 2 to 4.~Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22"
62322568|NCT04483739|EXPERIMENTAL|KRd post ASCT consolidation|4 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
62322569|NCT04483739|EXPERIMENTAL|Isa-KRd post ASCT consolidation:|4 28 day cycles of Isatuximab= 10 mg/kg IV on days 1 and 15 on cycles 5-8 Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
62322570|NCT04483739|EXPERIMENTAL|KRd light consolidation|12 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
62322571|NCT04483739|EXPERIMENTAL|Isa-KRd light consolidation|Isatuximab= 10 mg/kg IV on day 1 Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
62131098|NCT03836378|EXPERIMENTAL|Deep Cleaning and Intervention|One side of the participant's mouth will receive a deep cleaning in addition to the placement of a BioXclude™ membrane in the deep pocket sites. The participant will then be followed for 9 months with routine care.
62131099|NCT03836378|NO_INTERVENTION|Deep Cleaning Only|One side of the participant's mouth will receive deep cleaning (scaling and root planning) only. The participant will then be followed for 9 months with routine care.
62322572|NCT06692088||Migraine|Patients diagnosed with either high frecuancy episodic or chronic migraine and prescribed with anti-CGRP/CGRPr monoclonal antibodies without having started their treatment.
62322573|NCT06692088||Healthy controls|Subjects without history of migraine or any other primary headache.
62322574|NCT06203548|OTHER|Metabolic dysfunction-associated steatotic liver disease|Adult patients with intrahepatic triglyceride content \>=5% by MRI-PDFF
62322575|NCT01842620|EXPERIMENTAL|OXEMET 1000 mg coated tablets|Generic undergoing bioequivalence study against reference
62322576|NCT01842620|ACTIVE_COMPARATOR|GLAFORNIL 500 mg tablets|Reference drug for bioequivalence study
62322577|NCT06212557|EXPERIMENTAL|Active Treatment as Usual plus KIOS App|Treatment as usual in clinics with the use of the KIOS App
62131100|NCT02724956|EXPERIMENTAL|Ambu AuraGain|"SGAD placement using Ambu AuraGain~* Lubricate airway tube of SGAD \& pass the aScope through until visualization of the carina.~* Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.~* Pass ETT tube down the insertion cord of the Ambu aScope \& verify placement.~* Inflate cuff and remove aScope."
62131101|NCT02724956|EXPERIMENTAL|Teleflex LMA Protector|"SGAD placement using the Teleflex LMA Protector~* Lubricate airway tube of SGAD \& pass the aScope through until visualization of the carina.~* Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.~* Pass ETT tube down the insertion cord of the Ambu aScope \& verify placement.~* Inflate cuff and remove aScope."
62131102|NCT02773524|EXPERIMENTAL|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
62131103|NCT02773524|PLACEBO_COMPARATOR|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
62131104|NCT05028673|EXPERIMENTAL|Lu AG06466 Capsule, Fasted State|Participants will receive 1 capsule of Lu AG06466 in a fasted state.
62131105|NCT05028673|EXPERIMENTAL|Lu AG06466 Tablet, Fasted State|Participants will receive 1 tablet of Lu AG06466 in a fasted state.
62131106|NCT05028673|EXPERIMENTAL|Lu AG06466 Tablet, Fed State|Participants will receive 1 tablet of Lu AG06466 in a fed state (high-fat meal).
62131107|NCT05028673|EXPERIMENTAL|Lu AG06466 Tablet + Antacid, Fasted State|Participants will receive 1 tablet of Lu AG06466 dosed in combination with antacid in a fasted state.
62131108|NCT04321603|OTHER|People living with HIV|Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three.
61928131|NCT06743867|EXPERIMENTAL|Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)|Drug: Pressurized Intraperitoneal Aerosol Chemotherapy
61928132|NCT03610815|EXPERIMENTAL|mSBIRT|Mobile Screening, Brief Intervention, Referral to Treatment (mSBIRT)
61928133|NCT03610815|ACTIVE_COMPARATOR|SBIRT-CTS),|Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision strategy
62131109|NCT03819829|OTHER|Blood sample|Blood sample
62131110|NCT03753308||1a, HBV patients / no scheduled biopsy|"Intervention : Blood Sampling~Eligibility criteria :~* Male or female, Age of 18 or older, Weight over 40kg~* Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~* Patients who signed a non-opposition~* Patient affiliated to social security insurance~* HBsAg positive for more than 6 months~* known status of HBeAg (positive or negative)~* Treated or not with an antiviral"
62322578|NCT06212557|SHAM_COMPARATOR|Treatment as Usual plus KIOS education App|Treatment as usual in clinics with the use of the KIOs education App (Sham)
62322579|NCT06079476|EXPERIMENTAL|Phase 4: Romosozumab|Participants will be dosed with two subcutaneous (SC) injections of romosozumab once a month for 12 months.
62131111|NCT03753308||1b, HBV patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~* Male or female, Age of 18 or older, Weight over 40kg~* Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~* Patients who signed a non-opposition~* Patient affiliated to social security insurance~* HBsAg positive for more than 6 months~* known status of HBeAg (positive or negative)~* Treated or not with an antiviral~* Patient with a liver biopsy indication as part of the treatment within 3 months."
62131112|NCT03753308||2, NASH patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~* Male or female, Age of 18 or older, Weight over 40kg~* Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~* Patients who signed a non-opposition~* Patient affiliated to social security insurance~* The existence of at least one element of metabolic syndrome~* Steatosis detected by non-invasive tests (echo, CAP, MRI)"
62131113|NCT03753308||3, Blood samples from healthy donors|"* No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research.~* The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor)."
62131114|NCT04527822|EXPERIMENTAL|Discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
62131115|NCT04527822|ACTIVE_COMPARATOR|Standard Care|
62131116|NCT03359317|EXPERIMENTAL|jogging|At least 5 times/week
62131117|NCT03224390|EXPERIMENTAL|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
62131118|NCT03224390|NO_INTERVENTION|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
62131119|NCT03308292|NO_INTERVENTION|Control Group|
62322580|NCT04582500||patients undergoing CTC receiving iohexol|Patients will be recruited from a pool scheduled to undergo screening or diagnostic CTC for clinical purposes. They will be given 50 ml of Iohexol as a oral contrast
62322581|NCT01637051|OTHER|Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock|The tibial component has a monoblock design
62322582|NCT01637051|OTHER|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|The tibial component has a modular design
62322583|NCT04180527||Pre-Quality Improvement Initiative|This group of patients have not received previous patients' stories about their hip or knee surgery before undergoing their own hip or knee surgery.
62131120|NCT03308292|EXPERIMENTAL|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
62131121|NCT05619952|EXPERIMENTAL|White Button Mushroom|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) + 14 grams white button mushroom powder, and a Wegmans Food Market Brand Big Hawaiian bun
62131122|NCT05619952|EXPERIMENTAL|Shiitake Mushroom|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) + 14 grams Shiitake mushroom powder, and a Wegmans Food Market Brand Big Hawaiian bun
62131123|NCT05619952|NO_INTERVENTION|Control|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) and a Wegmans Food Market Brand Big Hawaiian bun.
62131124|NCT05004558|EXPERIMENTAL|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
62322584|NCT04180527||Post-Quality Improvement Initiative|This group of patients have received previous patients' stories regarding about their hip or knee surgery before undergoing their own hip or knee surgery.
62322585|NCT05588362|EXPERIMENTAL|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
62322586|NCT05588362|NO_INTERVENTION|Traditional Glasses Procurement Group|(1) The control group will receive standard of care in which a prescription for glasses will be dispensed as a paper copy prescribed by the examiner before randomization. The research assistant will use a script (attached) that instructs families how to procure glasses traditionally through Masshealth. The participant/family will be instructed to bring the paper prescription to an optical shop that carries MassHealth frames. A printout of local optical shops that carry MassHealth frames will be provided to the patient.
62131125|NCT03237975|EXPERIMENTAL|Be the Expert for Your Own (BEYO)|BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
62322587|NCT02545296|OTHER|In-vitro Diagnostics|All infants are recruited into the same arm.
62322588|NCT02959710|EXPERIMENTAL|Group 1|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
62322589|NCT02959710|EXPERIMENTAL|Group 2|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
62690634|NCT06548516|ACTIVE_COMPARATOR|Control group (conventional scalpel surgery)|After administering local infiltrative anesthesia with articaine hydrochloric acid combined with epinephrine 1:100,000, the frenum will be grasped with a straight hemostat positioned in the vestibule. The tissue adjacent to the upper and lower surfaces of the hemostat will then be incised using a no.15 scalpel. The excised diamond-shaped portion of the frenum will be removed with the hemostat. Subsequently, a horizontal incision will be made on the periosteum with a scalpel to prevent fiber reattachment. The wound site will be primarily closed using absorbable sutures (4/0, Pegelak), which will be removed one week post-operatively.
61928134|NCT06745323|EXPERIMENTAL|Treatment Arm A: Dose 1 Tarlatamab|Participants will receive dose 1 of Tarlatamab by intravenous (IV) infusion during the treatment period.
61928135|NCT06745323|EXPERIMENTAL|Treatment Arm B: Dose 2 Tarlatamab|Participants will receive dose 2 of Tarlatamab by IV infusion during the treatment period.
61928136|NCT06745323|EXPERIMENTAL|Treatment Arm C: Dose 3 Tarlatamab|Participants will receive dose 3 of Tarlatamab by IV infusion during the treatment period.
61928137|NCT06245044|EXPERIMENTAL|No MI Help|No MI help will be presented during the verification tasks
61928138|NCT06245044|EXPERIMENTAL|Scenario #1|MI help will be presented in the form of a pop-up message the participant's decision differs from the MI's determination.
61928139|NCT06245044|EXPERIMENTAL|Scenario #2|MI help will be displayed concurrently with the filled and reference images.
61928140|NCT06744231|PLACEBO_COMPARATOR|Pre-intervention|In the pre-intervention sequence(s), pregnant and parenting people in participating counties will experience treatment-as-usual.
61928141|NCT06744231|ACTIVE_COMPARATOR|Post-intervention|In the post-intervention sequence(s), pregnant and parenting people in participating counties will experience care enhanced with Thriving Hearts components, including point-of-care HDP prevention, health care providers equipped with resources for coping with secondary trauma, and proactive provision of social and material support.
61928142|NCT06501040|EXPERIMENTAL|Health Services Research (educational video)|Participants view educational video consisting of information on the purpose of clinical trials, myths associated with clinical trials, and how to find more information about clinical trials.
61928143|NCT01236014||Eltrombopag & standard of care|
61928144|NCT01236014||Romiplostim & standard of care|
62322590|NCT02959710|EXPERIMENTAL|Group 3|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
62322591|NCT01295905|EXPERIMENTAL|delefilcon A|Investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
62322592|NCT01295905|ACTIVE_COMPARATOR|narafilcon B|Commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
62322593|NCT04667195||Suspected acute pyelonephritis|Diagnosis of APN suspected at the initial clinical assessment by the receiving emergency department physician
62322594|NCT03521167|NO_INTERVENTION|T|traditional opioid based regimen
62322595|NCT03521167|ACTIVE_COMPARATOR|MD|multimodal group with dexmedetomidine
62322596|NCT03521167|PLACEBO_COMPARATOR|M|multimodal with saline placebo
62322597|NCT03519308|EXPERIMENTAL|Arm A|
61928145|NCT01236014||Standard of care|
61928146|NCT04975152|EXPERIMENTAL|Neoadjuvant Cemiplimab Treatment|Participants will receive cemiplimab 350 mg IV at least 3 weeks prior to surgical resection. After surgery they will continue to receive 350 mg cemiplimab every 3 weeks for up to 8 additional doses.
61928147|NCT06726577|EXPERIMENTAL|Experimental drug group|
61928148|NCT06726577|PLACEBO_COMPARATOR|Placebo group|
61928149|NCT06476808|EXPERIMENTAL|Arm 1: Dose Escalation|
61928150|NCT06476808|EXPERIMENTAL|Arm 2: Dose Expansion|
61928151|NCT00484718|ACTIVE_COMPARATOR|A|
61928152|NCT00484718|ACTIVE_COMPARATOR|B|
61928153|NCT00484718|PLACEBO_COMPARATOR|C|
61928154|NCT06745882|EXPERIMENTAL|Cohort 1|Non-interventional prospective cohort and participants will receive standard of care pembrolizumab with or without chemotherapy.
61928155|NCT06745882|EXPERIMENTAL|Cohort 2: arm A|Cohort 2 Arm A will enroll patients with NSCLC with PD-L1 TPS status ≥1% and ctDNA tumor fraction low/negative and be treated with pembrolizumab monotherapy.
61928156|NCT06745882|EXPERIMENTAL|Cohort 2: arm B|Cohort 2 Arm B will enroll patients with NSCLC with any PD-L1 status and ctDNAtumor fraction intermediate/high -OR- PD-L1 TPS\<1% and any ctDNA level treated with chemotherapy plus pembrolizumab.
61928157|NCT05906095|OTHER|Intervention (each site serves as own control)|wedge-based cluster randomized, controlled trial design with each SVH acting as its own control
62322598|NCT03519308|EXPERIMENTAL|Arm B|
62322599|NCT01400334||Ischemic Cardiomyopathy|Subjects with ischemic cardiomyopathy \[pre-enrollment left ventricular ejection fraction ≤0.35, with coronary artery disease documented by cardiac catheterization, a history of definite myocardial infarction, or reversible ischemia on nuclear imaging\] who are considered eligible to receive an implantable cardiac defibrillator for the primary prevention of sudden cardiac death.
62322600|NCT04874909|OTHER|"Case Patient"|Patient with ciliopathy
62322601|NCT04874909|OTHER|Healthy related individual|Individual without ciliopathy but related to a patient with ciliopathy (father, mother, brother, sister)
62322602|NCT04874909|OTHER|"Negative Control patient"|patient without renal disease
62322603|NCT04874909|OTHER|"Positive Control patient"|"patient with renal disease other that ciliopathy but with a similar renal function to the ciliopathy group (case patient)"
62322604|NCT06017232|EXPERIMENTAL|Intervention group|Group of participants receiving the hybrid telerehabilitation intervention
62322605|NCT02285764|EXPERIMENTAL|Nutritional Supplement|One 237 ml oral supplement consumed two times a day; Not commercially available.
62322606|NCT02285764|OTHER|Standard of Care|As determined by the study site
62322607|NCT02896426|EXPERIMENTAL|Collaborative Problem Solving|Participants will attend parent group sessions led by trained group leaders and learn the Collaborative Problem Solving approach.
62322608|NCT02896426|ACTIVE_COMPARATOR|Positive Solutions For Families|Participants will attend parent group sessions and learn the Positive Solutions for Families approach, a group that is usually offered by Head Start.
62481979|NCT03988595|EXPERIMENTAL|aerobic training 90 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
62481980|NCT03988595|EXPERIMENTAL|aerobic training 150 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
62481981|NCT03988595|EXPERIMENTAL|aerobic training 225 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
62481982|NCT03988595|EXPERIMENTAL|aerobic training 300 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
62481983|NCT03988595|EXPERIMENTAL|aerobic training 375 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
62481984|NCT06480552|EXPERIMENTAL|TEV-56278 Monotherapy; Dose Escalation|
62481985|NCT06480552|EXPERIMENTAL|TEV-56278 Monotherapy; Dose Expansion|
62481986|NCT06480552|EXPERIMENTAL|TEV-56278 in Combination with Pembrolizumab; Dose Escalation|
62690635|NCT06548516|EXPERIMENTAL|Diode laser group|The frenectomy procedure will be performed under local infiltrative anesthesia, specifically articaine hydrochloric acid with epinephrine 1:100,000. A straight hemostat, similar to that used in the C group, will be employed to secure the frenum. Laser energy will be applied to the upper and lower sections of the frenum adjacent to the hemostat, utilizing a diode laser device equipped with a 400 µm diameter, plain-ended optical fiber tip. Frenectomy will performed with a 980 nm diode laser with 1.7 W power in continuous wave mode.The wound site will be allowed to heal by secondary intention without the application of sutures.
62690636|NCT04783428||Prior TIO Burosumab Clinical Trial Participants|
62690637|NCT04783428||Adults Who Have Not Participated In Prior Burosumab Clinical Trials|
62690638|NCT04783428||Pediatrics Who Have Not Participated In Prior Burosumab Clinical Trials|
62690639|NCT06637384|NO_INTERVENTION|Control Group 1|The sockets untreated with hyaluronic acid and corticosteroid injection were designated as control group 1 where wound healing took place naturally via clot formation.
62339847|NCT01752582|OTHER|EXCEL stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~EXCEL stent Arm:About 35 patients will undergoing implantation of EXCEL stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
62339848|NCT00495495|EXPERIMENTAL|Ozone treatment|Ozone treatment of randomly selected study tooth for 60 seconds
62481987|NCT05238740|ACTIVE_COMPARATOR|Intervention group 5-5.4 cc ViviGen®|Biological: 5-5.4 cc ViviGen® The ALIF or XLIF fusion patients assigned to this group will receive 5-5.4 cc ViviGen®
62481988|NCT05238740|ACTIVE_COMPARATOR|Control group 4-6mg rhBMP-2|Biological: 4-6mg rhBMP-2 The ALIF or XLIF fusion patients assigned to this group will receive 4-6mg rhBMP-2
62690640|NCT06637384|ACTIVE_COMPARATOR|Group 2|Patients treated with 0.2 % Hyaluronic acid (Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy) applied in extraction socket.
62690641|NCT06637384|ACTIVE_COMPARATOR|Group 3|The extraction socket of these patients were treated with a single dose of Hy-Cortisone Injection 250 mg (Generic name: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan).
62690642|NCT03428347|EXPERIMENTAL|Group 1|1.4 mg/kg body weight
62690643|NCT03428347|EXPERIMENTAL|Group 2|7 mg/kg body weight
62322609|NCT06217536|EXPERIMENTAL|Phase 1b, Cohort 1 (Extremity and Trunk Sarcoma)|Participants will receive up to 3.2 mg/m\^2 of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity and trunk sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
62339849|NCT00495495|PLACEBO_COMPARATOR|Placebo, no ozone|Placebo treatment (no ozone) of randomly selected study tooth for 60 seconds.
62339850|NCT01676142||Patients with NTM pulmonary infection|
62339851|NCT01676142||Patients with other pathogen related lung infection|
62690644|NCT03428347|EXPERIMENTAL|Group 3|14 mg/kg body weight
62690645|NCT03116022|ACTIVE_COMPARATOR|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
62690646|NCT03116022|EXPERIMENTAL|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
62690647|NCT03116022|PLACEBO_COMPARATOR|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
62690648|NCT05059626|OTHER|Simvastatin|30 days of Simvastatin (10mg/day)
62690649|NCT05059626|OTHER|bazedoxifene + conjugated estrogen|30 days of bazedoxifene + conjugated estrogen (0.45mg/20mg/day)
62131126|NCT03237975|ACTIVE_COMPARATOR|Routine health education|To neutralize the effect of extra attention from the facilitator, participants in control group will receive routine health education on topics related to type 2 diabetes. Contents for the routine education will be based on the national guideline of basic public health service for diabetes and specific implementation protocols in each community. Participants in control group will receive 5-weekly education packet at the same time with participants in intervention group. The patients will not be given any strengths-based information, but they are free to discuss their disease status with nurses or physicians at their regular follow-up appointments.
62690650|NCT06675136|EXPERIMENTAL|Treatment (nab-paclitaxel PIPAC, paclitaxel, ramucirumab)|Patients receive nab-paclitaxel PIPAC IP over 40 minutes on day 1 and SOC paclitaxel IV over 60 minutes on days 15, 22, 29, 43, and 50 and ramucirumab IV over 30-60 minutes on days 15, 29 and 43 of each cycle. Cycles repeat every 8 weeks (56 days) for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may then continue SOC paclitaxel IV on days 1, 8, and 15 and ramucirumab IV on days 1 and 15 of each cycle per physician as deemed appropriate. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, tumor biopsy, and CT or MRI throughout the study.
62690651|NCT06167746|ACTIVE_COMPARATOR|Digital Health Information (DHI)|Digital health information is delivered through a website tailored with care transitions and self-care information for all participants over the 6-month study.
62131127|NCT00891332|EXPERIMENTAL|1|S-1 plus LV
62339852|NCT01676142||Patient with NTM pulmonary colonization|
62481989|NCT06581939|EXPERIMENTAL|Rehabilitation group|Individualized rehabilitation program
62481990|NCT06581939|ACTIVE_COMPARATOR|Control group|Usual care
62481991|NCT04992390|EXPERIMENTAL|Immediate intervention arm|Immediate access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome).
62481992|NCT04992390|EXPERIMENTAL|Delayed intervention arm|Usual care for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome), followed by access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks.
62481993|NCT05873699|EXPERIMENTAL|Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging|"Participants will have the HP-MR scan within the 4 weeks before your scheduled surgery.~Hyperpolarized C-Pyruvate will be injected by vein during the scan. Your vital signs (temperature, blood pressure, heart rate and respiration \[breathing\]) will be monitored during the scan. The estimated time of the scan is a couple of minutes, but you may be in the room of the MRI for up to 30 minutes for preparation. The entire process of obtaining the MRI (and possible blood draw) may be up to half of a work day (not including your personal travel time)."
62690652|NCT06167746|EXPERIMENTAL|Virtual Health Coaching + DHI|Study participants in the intervention group will receive 10-session virtual health coaching intervention sessions delivered over 6 months.
62690653|NCT06284681|EXPERIMENTAL|Weight-Focused Health Coaching with Intensified Lifestyle Approach for Nonresponders|Participants will start with weight-focused health coaching for 7 weeks and individuals achieving \<3% weight loss will be given a 4-month membership to the YMCA and enrolled in group fitness classes.
62690654|NCT06284681|EXPERIMENTAL|Weight-Neutral Health Coaching with Intensified Lifestyle Approach for Nonresponders|Participants will start with weight-neutral health coaching for 7 weeks and individuals achieving \<150 minutes of moderate physical activity will be given a 4-month membership to the YMCA and enrolled in group fitness classes.
62481994|NCT06092671|EXPERIMENTAL|Family-Centered group (F group)|Both children and parents received family-centred perioperative care for anaesthesia including video education, anaesthesia mask practice, e-manual learning,etc. And children will be accompanied by their parents during anaesthsia induction and recovery.
62339853|NCT03145194|EXPERIMENTAL|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
62481995|NCT06092671|NO_INTERVENTION|Routine group (R group)|The child received clinical standard preoperative education and anesthesia induction. It is recommended to give sedatives (such as oral midazolam or dexmedetomidine nasal drops, etc.) before surgery. The child was not accompanied by the parents during the anesthesia induction period and the awakening period.
62481996|NCT06562452|EXPERIMENTAL|Right sides were randomly allocated to treatments with i-PRF|The amount of i-PRF was standardized as 2mL and was injected submucosal into the distobuccal and distopalatal side of the canine tooth (1mL for each side) under local anesthesia for pain control.
62481997|NCT06562452|EXPERIMENTAL|Left sides were randomly allocated to control sides.|The placebo was standardized as 2mL and was injected submucosal into the distobuccal and distopalatal side of the canine tooth (1mL for each side) under local anesthesia for pain control.
62481998|NCT01410227|EXPERIMENTAL|PK 80 Arm (minimum of 22 subjects with severe VWD)|PK assessment (80 IU/kg rVWF) + 12-month treatment period
62481999|NCT01410227|EXPERIMENTAL|PK 50 Arm (14 subjects with type 3 VWD)|Two single-blinded PK assessments (50 IU/kg rVWF + rFVIII/placebo) + 12-month treatment period
62131128|NCT05424796|EXPERIMENTAL|Group 1: Physiological saline (Control group) (n=30)|In this group, hemostasis was achieved by checking the saline soaked cotton pellet placed over canal orifices and into the pulp chamber at 2-minute intervals.
62131129|NCT05424796|EXPERIMENTAL|Group 2: Hemostasis and cavity disinfection with NaOCl (n=30)|In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices and into the pulp chamber to achieve complete hemostasis.
62131130|NCT05424796|EXPERIMENTAL|Group 3: Hemostasis and cavity disinfection with KTP laser (n=30)|In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy). After initial hemorrhage control, complete hemostasis was achieved by exposure to a KTP laser (532 nm wavelength) in noncontact mode at 1.5 W of power with a pulse mode (Ton 100 ms, Toff 100 ms) for 2 s. The diameter of optical fiber was 300 μm. Laser application was repeated 3 times if required. After bleeding control was achieved, cavity disinfection was performed by laser application with a noncontact circular movement for 5 s using 1 W power and 300 nm tip.
62131131|NCT02335554|EXPERIMENTAL|MoodHacker|Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.
62131132|NCT02335554|ACTIVE_COMPARATOR|Alternative Care|Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment
62131133|NCT02851667|EXPERIMENTAL|Training group|Resident training programs such as talks, day camp and thematic activities were delivered in training group.
62131134|NCT05075694|EXPERIMENTAL|Experiment|Therapeutic touch (TT) is a treatment that takes an average of 15-20 min, in which energy in the universe is transferred through the hands of the practitioner to eliminate the imbalance in the individual's energy field and facilitate healing. The intervention group (TT group) received therapeutic touch for 10 minutes a day for five consecutive days. The practice was implemented in line with Therapeutic Practice Procedure.
62131135|NCT05075694|SHAM_COMPARATOR|Control|Placebo: Sham Therapeutic Touch (STT) The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with Sham Therapeutic Touch Practice Procedure (STTPP).
62322610|NCT06217536|EXPERIMENTAL|Phase 1b, Cohort 2 (Extremity Myxoid Liposarcoma)|Participants will receive up to 3.2 mg/m\^2 of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity myxoid Liposarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
62131136|NCT02787031||Neuraxial anesthesia|Participants in this group will be those who had a spinal or epidural anesthetic without concurrent general anesthesia
62131137|NCT02787031||General anesthesia|Participants in this group will be those who had general anesthesia, including those who had a general plus a concurrent spinal or epidural anesthetic.
62322611|NCT06217536|EXPERIMENTAL|Phase 1b, Cohort 3: Retroperitoneal Sarcoma|Participants will receive up to 3.2 mg/m\^2 of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 6 weeks of pre-operative conventional external beam radiation therapy given as 45-50.4 Gy delivered over 25-28 fractions starting on cycle 1 for participants with retroperitoneal sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
62322612|NCT06217536|EXPERIMENTAL|Phase 2, Cohort 1: Extremity and trunk sarcoma|Participants will receive the maximum tolerated dose of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity and trunk sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
62339854|NCT03145194|PLACEBO_COMPARATOR|Placebo|Patients will receive Placebo (2 matching tablets)
62339855|NCT05982925||MS Participant|Adults with multiple sclerosis
62339856|NCT05982925||Control Participant|Adults without neurologic disease
62131138|NCT00891631|EXPERIMENTAL|iSBIRT|Participants will complete the iSBIRT system.
62131139|NCT00891631|EXPERIMENTAL|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system and technological extenders
62131140|NCT00891631|NO_INTERVENTION|TAU|Participants will receive Treatment as Usual from their primary care provider.
62131141|NCT03401372|EXPERIMENTAL|Doxycycline/BCD chemotherapy|Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy
62131142|NCT03401372|ACTIVE_COMPARATOR|BCD chemotherapy|Bortezomib-cyclophosphamide-dexamethasone chemotherapy
62131143|NCT06005857|EXPERIMENTAL|Experimental group|The group will receive standard hand therapy program + rehabilitation program sustained by the use of a digital application.
62131144|NCT06005857|ACTIVE_COMPARATOR|Control group|The control group will receive a standard hand therapy program + paper-based (standard) rehabilitation program.
62131145|NCT04784026||Healthy Control Group|Healthy children who come to Afyonkarahisar Ege Youth and Sports Club Association for the purpose of sports, newly registered and between the ages of 6-18 will constitute the control group of the study.
62131146|NCT04784026||Case Group|The sample of the study will be inpatient and outpatient pediatric patients between the ages of 6-18 who have been diagnosed with cancer in the Pediatric Hematology-Oncology Clinics of Afyonkarahisar Health Sciences University Health Application and Research Center Department of Pediatrics.
62482000|NCT01410227|EXPERIMENTAL|PK 50 Only Arm (minimum of 7 subjects with type 3 VWD)|PK assessment (50 IU/kg rVWF) only, no treatment of bleeding episodes
62482001|NCT01410227|EXPERIMENTAL|Treatment Only (up to 7 subjects independent of VWD subtype)|Treatment of bleeding episodes for a total of 12 months
62482002|NCT03848377||Automated EMG/SSEP monitored|"In this study, all patients will be monitored for SSEP and EMG. For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored.~As this is an observational study, no intervention is planned."
62482003|NCT01036971||1|potential research subjects
62482004|NCT05402358||Specific-Diagnosis|There were four specific-diagnosis groups covering four specialities: Dermatology, Rheumatology, Diabetes and Cardiology. Participants were categorised into these groups dependent on the speciality from which the referral originated or the participants primary condition. Participants attending a specific-diagnosis group were required to have a diagnosis relating to that speciality. All participants received the Living Well with a Long-Term Condition intervention
62690655|NCT06284681|EXPERIMENTAL|Weight-Focused Health Coaching with Enhanced Medical Management|Participants will start with weight-focused health coaching for 7 weeks and individuals achieving \<3% weight loss will meet with their primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
62690656|NCT06284681|EXPERIMENTAL|Weight-Neutral Health Coaching with Enhanced Medical Management|Participants will start with weight-neutral health coaching for 7 weeks and individuals achieving \<150 minutes of moderate physical activity will meet with their primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
62322613|NCT06217536|EXPERIMENTAL|Phase 2, Cohort 2: Extremity myxoid liposarcoma|Participants will receive the maximum tolerated dose of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity myxoid Liposarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
62322614|NCT06217536|EXPERIMENTAL|Phase 2, Cohort 3: Retroperitoneal sarcoma|Participants will receive the maximum tolerated dose of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 6 weeks of pre-operative conventional external beam radiation therapy given as 45-50.4 Gy delivered over 25-28 fractions starting on cycle 1 for participants with retroperitoneal sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
62322615|NCT02887534|EXPERIMENTAL|Arm 1|three times medication; SPARC1401-low dose
62322616|NCT02887534|EXPERIMENTAL|Arm 2|three times medication; SPARC1401-mid dose
62322617|NCT02887534|EXPERIMENTAL|Arm 3|three times medication; SPARC1401-high dose
62322618|NCT02887534|ACTIVE_COMPARATOR|Active comparator|Reference1401; To be administered 3 times a day
62322619|NCT02887534|PLACEBO_COMPARATOR|Arm 5|Placebo1401 - 3 three times a day
62322620|NCT06392100|EXPERIMENTAL|Mindfulness-Based Intervention in Generation Z Nursing Students During Clinical Practicum|The experimental group received mindfulness-based stress reduction intervention for 8 weeks.
62690657|NCT05362305|EXPERIMENTAL|Essential Coaching for Every Mother|Mothers in the intervention group will receive in-hospital education by a non-study nurse midwife while on the postnatal ward prior to discharge as per standard protocol on the unit. On the third day after birth, mothers will receive daily text messages to 6 weeks postpartum. The messages will be sent automatically each day based on the date of birth of the infant.
62690658|NCT05362305|NO_INTERVENTION|Standard Care|Mothers will receive in-person education provided by a non-study nurse midwife while on the postnatal ward prior to discharge as per current standard protocol on the unit. Mothers in this group will not receive any further text messages from the program.
62690659|NCT05918185||Observational (Surveys, cGA, blood sample, EHR review)|Patients complete surveys and undergo cGA, blood sample collection, and EHR review on study.
62690660|NCT02513641|EXPERIMENTAL|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs per night) to moderate hypoxia (\~2,400 meters) using the Hypoxico Altitude Training Systems device.
62690661|NCT06007157|EXPERIMENTAL|SGLT2i-treated patients|
62690662|NCT06007157|ACTIVE_COMPARATOR|Non SGLT2i-treated patients|
62322621|NCT06392100|NO_INTERVENTION|line care messages in Generation Z Nursing Students During Clinical Practicum|The control group received line care messages weekly from instructors during clinical practicum.
62690663|NCT06640777|EXPERIMENTAL|LEAF-4L6715 (Liposomal Transcrocetin) + Supportive Care|"LEAF-4L6715 administered Intravenously 200 mg every 12h for 2 days, then 200 mg Intravenously every 24 hours for 8 days (total 10 days dosing)~Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure"
62482005|NCT05402358||Mixed-Diagnosis|There were four mixed-diagnosis groups; participants who do not fall into the above specialities, or had number of co-morbid conditions, or were unable to attend the specified dates for any of the four specific-diagnosis groups, were invited to attend a mixed-diagnosis group.All participants received the Living Well with a Long-Term Condition intervention
62131147|NCT00220038||Normal|700 healthy adult volunteers will be drawn from the New York City area
62322622|NCT01335568|EXPERIMENTAL|surgery|chronic liver insufficiency, cirrhosis
62322623|NCT02064439|EXPERIMENTAL|Arm 1|Rivaroxaban 10 mg once daily for 12 months
62690664|NCT06640777|ACTIVE_COMPARATOR|Supportive Care|Description: Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
62690665|NCT00214669|EXPERIMENTAL|1|"Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.~Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Lorig's chronic disease self-management programme.~Improved follow-up in primary care through appointment-booking by the specialist nurse."
62322624|NCT02064439|EXPERIMENTAL|Arm 2|Rivaroxaban 20 mg once daily for 12 months
62690666|NCT00214669|NO_INTERVENTION|2|Usual Care
61928158|NCT04970056||Cohort 1|"Individuals without history of PDAC meeting any of the following criteria:~1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.~2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family~3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family~4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+~5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+~6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+"
62131148|NCT06336473|EXPERIMENTAL|Skin biopsy|
62322625|NCT02064439|ACTIVE_COMPARATOR|Arm 3|ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
62690667|NCT00968279||Atrial Fibrillation|
62690668|NCT05650827|NO_INTERVENTION|Standard Care Control|"Participants allocated to control receive first line chemotherapy the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.~Participants allocated to control are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program. There will be no diet restrictions."
62690669|NCT05650827|EXPERIMENTAL|Exercise and protein supplements intervention group|"Participants allocated to intervention receive first line chemotherapy and the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.~The intervention consists of resistance training and a daily protein supplement."
62690670|NCT01373411|PLACEBO_COMPARATOR|Placebo|Placebo twice daily. Study drug will be started within 48 hours of CABG.
62690671|NCT01373411|ACTIVE_COMPARATOR|ticagrelor 90 mg|Taken twice daily. Study drug will be started within 48 hours of CABG.
62690672|NCT05968937|ACTIVE_COMPARATOR|Vaginal baclofen suppository|Baclofen 20mg in Supposibase F vaginal suppository daily per vagina
62690673|NCT05968937|PLACEBO_COMPARATOR|Vaginal placebo suppository|Supposibase F vaginal suppository daily per vagina
62690674|NCT05597124|EXPERIMENTAL|Cardio-Dance Fitness|This is the experimental group. Participants will meet three times a week for dance classes for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
62131149|NCT03298789|EXPERIMENTAL|Experimental condition|7 series of static stretching will be conducted in the experimental condition. Activation exercises will be performed after 7th series of static stretching.
62131150|NCT03298789|OTHER|Control|7 series of static stretching will be conducted in the control condition.
62322626|NCT06471140||IVF-pregnancy achieved following modified natural FET cycle, autologous embryo transfer|One corpus luteum, control group, autologous embryo transfer
62322627|NCT06471140||IVF-pregnancy achieved following programmed FET cycle, autologous embryo transfer|No corpus luteum, study group, autologous embryo transfer
62322628|NCT06471140||IVF-pregnancy achieved following egg donation in a FET cycle|One corpus luteum or no corpus luteum, study group, donor egg recipient.
62322629|NCT02402218|ACTIVE_COMPARATOR|Usual Care|Participants receive standard of care for Hepatitis C in the clinic.
62322630|NCT02402218|EXPERIMENTAL|Usual care plus peer-mentors|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection.
62322631|NCT02402218|EXPERIMENTAL|Usual care plus incentives|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain goals during the course of the study.
62690675|NCT05597124|ACTIVE_COMPARATOR|Strength, Flexibility & Balance|This is the active control group. Participants will meet three times a week for strength, flexibility, and balance exercises for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
62690676|NCT01069718||Clinical Group|In the Clinical group bottle feedings will be attempted by the bedside nurses, using techniques suggested in the feeding plan. The Infant Feeding Specialist will observe at least one feeding per day to assure that the feeding plan is being adhered to. If, in the judgment of the person feeding the infant, the infant is unable to complete the bottle feeding, the remaining volume will be given via an indwelling gavage tube. During all gavage feedings, both total and partial, infants will be offered a pacifier to suck on.
62131151|NCT04565119||Severe traumatic brain injury (TBI)|This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.
62131152|NCT01346254|EXPERIMENTAL|Vildagliptin|16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily
62131153|NCT01346254|EXPERIMENTAL|Pioglitazone|16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily
62322632|NCT00633139|EXPERIMENTAL|Cohort 1|Cohort 1: 50 U/kg Recombinant human Arylsulfatase A (rhASA)
62131154|NCT01346254|PLACEBO_COMPARATOR|Placebo|16 patients randomized into this arm will receive placebo medication orally once daily
62322633|NCT00633139|EXPERIMENTAL|Cohort 2|Cohort 2: 100 U/kg Recombinant human Arylsulfatase A (rhASA)
62322634|NCT00633139|EXPERIMENTAL|Cohort 3|Cohort 3: 200 U/kg Recombinant human Arylsulfatase A (rhASA)
61928159|NCT04970056||Cohort 2|"Individuals without history of PDAC meeting any of the following criteria:~1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+~2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family~3. 1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member"
61928160|NCT04970056||Cohort 3|Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)
61928161|NCT04970056||Cohort 4|Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.
61928162|NCT04970056||Cohort 5|Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
61928163|NCT04970056||Cyst Cohort|Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)
61928164|NCT04970056||Cohort 6a|"Individuals diagnosed with PDAC after enrollment in PRECEDE meeting any of the following criteria:~1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other~2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11"
61928165|NCT04970056||Cohort 6b|"Individuals with a personal history of PDAC meeting any of the following criteria:~1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other~2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11~3. Diagnosed ≤ age 45"
61928166|NCT05335070|EXPERIMENTAL|Temporo-masseteric Nerve Block (TMNB) Injection with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the side/s of lower wisdom molar extraction/s
61928167|NCT06496581|ACTIVE_COMPARATOR|Arm A (Control arm): Standard of Care (SoC) alone|"The SoC is defined as one the following treatment which was initiated 6 to 8 months ahead of inclusion in this trial and still ongoing at the time of the randomization and continued at least until the CRPC stage is reached.:~* ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapyª~* ADT with docetaxelᵇ plus an ARSI (i.e. abiraterone + prednisone, or darolutamide,) ± radiotherapyª~ª Radiotherapy can be part of any standard treatment aforementioned as long as it is not PSMA-based and completed at least 4 weeks ahead of randomization OR planned right after randomization in arm A.~ᵇ Whenever docetaxel was part of the systemic treatment initiation, its administration must have been completed at least 4 weeks ahead of randomization."
61928168|NCT06496581|EXPERIMENTAL|Arm B (Experimental arm): 177Lu-PMSA-617 + SoC|"Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles. Upon 177Lu-PMSA-617 treatment completion, the ongoing standard systemic treatment is to be maintained and continued at least until the CRPC stage is reached.~The SoC is defined as one the following treatment which was initiated 6 to 8 months ahead of inclusion in this trial and still ongoing at the time of the randomization:~* ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapyª~* ADT with docetaxelᵇ plus an ARSI (i.e. abiraterone + prednisone, or darolutamide,) ± radiotherapyª~ª Radiotherapy can be part of any standard treatment aforementioned as long as it is not PSMA-based completed at least 4 weeks ahead of randomization OR planned right after 177Lu-PSMA-617 in arm B.~ᵇ Whenever docetaxel was part of the systemic treatment initiation, its administration must have been completed at least 4 weeks ahead of randomization."
61928169|NCT05396833|EXPERIMENTAL|Part A1: Tuvusertib and Lartesertib|
61928170|NCT05396833|EXPERIMENTAL|Part A1.1: Tuvusertib and Lartesertib|Assessment of the Effect of Food (Low-fat Meal) on the PK of M4076 Monotherapy Followed by Treatment with M1774 in Combination with M4076
61928171|NCT05396833|EXPERIMENTAL|Part A1.2: Tuvusertib and Lartesertib|Relative Bioavailability Assessment of Tuvusertib Tablet (TF1) vs Capsule Followed by Treatment with Tuvusertib in Combination with Lartesertib
61928172|NCT05396833|EXPERIMENTAL|Part A2: Tuvusertib and Lartesertib|ATM in prostate cancer (Part A2)
61928173|NCT05396833|EXPERIMENTAL|Part A3: Tuvusertib and Lartesertib|ARID1A in endometrial cancer
61928174|NCT05396833|EXPERIMENTAL|Part A2/A3: Tuvusertib and Lartesertib|Tablet formulation (TF1, test) compared to a capsule formulation (reference)
61928175|NCT05396833|EXPERIMENTAL|Part B1: Tuvusertib and Avelumab|
61928176|NCT02071147|OTHER|Standard clinical intervention|Patients reviewed at 6 weeks (+/- 1 week) as is our normal practice and recalled for a further evaluation if deemed appropriate. Patients will be instructed to visit their optometrist once their eye has fully recovered from the operation for provision of glasses.
61928177|NCT02071147|OTHER|No Clinical Follow up|No routine follow-up appointment is made. Patients will be instructed to visit their optometrist between 6-8 weeks post-operative for review of the patient's glasses.
61928178|NCT03225144||Patients|patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols
61928179|NCT06651502|EXPERIMENTAL|dental implant placement and immediate temporary restoration|"1. pre-operative: comprehensive exam, standard-of-care x-rays, cone beam computed tomography (CBCT), dental optical scan~2. intra-operative: dental implant placement and immediate provisionalization~3. 4-week follow-up~4. 12-week impression~5. Delivery of final restoration~6. follow-ups at 1 year and 2-year post-implant restoration"
61928180|NCT06744699||Formula-fed infants|Formula-fed infants either goat milk-based infant formula or cow's milk-based infant formula
62339857|NCT05982925||Other Neuroinflammatory Participants|Adults with a neuroinflammatory disease that is not multiple sclerosis
62690677|NCT01069718||NTrainer Group|"In the NTrainer group, three feedings per day will be given via gavage tube while the infant is receiving NTrainer stimulation. The stimulation will be done by alternating 3 minute epochs of NTrainer stimulation with 3 minutes of sucking on a regular pacifier, up to a total time of 30 minutes.~Every other day, 15 minutes prior to a feeding that is not one of the study sessions, each infant's suck strength and coordination will be measured using the NTrainer device in its NeoSuck RT Assessment mode.~On the day after the study intervention period is completed each infant will be assessed by an investigator unaware of the infant's study group assignment."
61928181|NCT05641831|EXPERIMENTAL|ARM I (canakinumab)|Patients receive canakinumab SC on study. All patients also undergo ECHO and chest x-ray during screening, collection of blood samples during screening and follow up, and bone marrow biopsy and aspiration throughout the trial.
61928182|NCT05641831|PLACEBO_COMPARATOR|ARM II (placebo)|Patients receive placebo SC on study. All patients also undergo ECHO and chest x-ray during screening, collection of blood samples during screening and follow up, and bone marrow biopsy and aspiration throughout the trial.
61928183|NCT05407714|EXPERIMENTAL|SpaceOAR Treatment Arm|Single arm, up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.
62322635|NCT02440178|EXPERIMENTAL|micafungin prophylaxis|Patients received 50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to recovery of neutrophil count (absolute neutrophil count \> 500/μg for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity.
62322636|NCT03555539|EXPERIMENTAL|Part 1: Healthy Match|Single 200-milligram (mg) dose of danicopan on Day 1 in healthy participants (matched control group with normal hepatic function).
61928184|NCT06470672|EXPERIMENTAL|SHR-A1921+Adebrelimab|Via intravenous infusion
61928185|NCT03315754|EXPERIMENTAL|TOOKAD Soluble 4 mg/kg|TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
61928186|NCT06174805|EXPERIMENTAL|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
61928187|NCT05755620|EXPERIMENTAL|Arm 1, Low Dose|10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 10 mcg of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 10 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
61928188|NCT05755620|EXPERIMENTAL|Arm 2, Medium Dose|10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 25 mcg of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 25 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
61928189|NCT05755620|EXPERIMENTAL|Arm 3, High Dose|10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 50 mcg of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 50 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
61928190|NCT05755620|EXPERIMENTAL|Arm 4, Optimal Dose|10 healthy adult volunteer subjects from 18-49 years of age will receive the selected optimal dose of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The optimal dosing group will be selected based on safety outcomes from the 10 mcg, 25 mcg, and 50 mcg dosing groups. For the optimal dose, the highest dose with no identified safety concerns as determined by the Safety Review Committee (SRC) will be selected. N =10
61928191|NCT05755620|ACTIVE_COMPARATOR|Arm 5, IIV4|10 healthy adult volunteer subjects from 18-49 years of age will receive licensed Quadrivalent Influenza Vaccine (IIV4), administered intramuscularly once. Subjects receiving IIV4 will be followed for safety, but only their immune responses will be compared to those of participants receiving H1ssF_3928 mRNA Vaccine. N=10
61928192|NCT05230914|EXPERIMENTAL|Simple imaging|NCCT and CTA will be used to screen patients for endovascular treatment
61928193|NCT05230914|ACTIVE_COMPARATOR|Standard imaging|NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
61928194|NCT06288477|ACTIVE_COMPARATOR|full-strength FC|Formocresol pulpotomy is one of the most common procedure in cases of mechanical and carious exposure in primary teeth.
61928195|NCT06288477|EXPERIMENTAL|Neo-Putty®|Neo-Putty® as dressing agents in pulpotomized primary molars. NeoPUTTY® is composed of extremely fine inorganic tricalcium/dicalcium silicate powders in a water-free organic liquid and contains tantalum oxide as the radiopacifying agent.
62322637|NCT03555539|EXPERIMENTAL|Part 1: Moderate HI|Single 200-mg dose of danicopan on Day 1 in participants with moderate HI.
62322638|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
62322639|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
62322640|NCT00755352|EXPERIMENTAL|1|pravastatin tablets and Welchol tablets
62322641|NCT00755352|PLACEBO_COMPARATOR|2|pravastatin tablets and Welchol placebo tablets
62322642|NCT02324530|EXPERIMENTAL|Lung tumors|Patients with \> 1 cm tumor motion simulated using 4DCT with and without CPAP
62322643|NCT02324530|EXPERIMENTAL|Left sided Breast cancer|Patients with heart abutting chest wall will be simulated using 4DCT with and without CPAP
62322644|NCT02324530|EXPERIMENTAL|Abdominal tumors|Patient with liver metastases for SBRT or pancreatic tumors will be simulated using 4DCT with and without CPAP
62322645|NCT05146232|ACTIVE_COMPARATOR|Opioid free group|After induction of aesthesia, anesthesia maintained by sevoflurane and continuous unfusion of lidocaine, ketamine, dexmeditomedine and Paracetamol.
62690678|NCT03211845|EXPERIMENTAL|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
61928196|NCT06743607|ACTIVE_COMPARATOR|Immediate Intervention|"For the immediate intervention group, each participant will complete the following:~* Initial baseline evaluation~* 24 training sessions (3x/week for eight weeks) of UE FTP+TSS (two training sessions/week will be completed in the home with caregiver/companion support; the third weekly session will be conducted via videoconference with a research therapist)~* Post-treatment evaluation (after eight weeks of training) and follow-up evaluation (four weeks after post-treatment evaluation).~* Post-treatment and follow-up assessments will be conducted over two days: assessments completed without TSS on day one and with TSS on day two."
62690679|NCT01044459|EXPERIMENTAL|Aclidinium Bromide 200 µg|aclidinium bromide, inhaled, 52 weeks of treatment
62690680|NCT01044459|EXPERIMENTAL|Aclidinium Bromide 400 µg|aclidinium bromide, inhaled, 52 weeks of treatment
62690681|NCT05874037|EXPERIMENTAL|Fluvoxamine|
62690682|NCT05874037|PLACEBO_COMPARATOR|Placebo|
61928197|NCT06743607|ACTIVE_COMPARATOR|Waitlist Control|"The waitlist control group will participate in a protocol similar to the immediate intervention group, except:~* 12-week waiting period before starting the active intervention.~* Assessments will be completed at 0, 8, and 12 weeks before starting the active intervention to control for spontaneous recovery.~* Post-treatment evaluation (after eight weeks of training)~* Follow-up assessment (four weeks after the post-treatment evaluation)."
61928198|NCT04791709|EXPERIMENTAL|HOLA Group|Participants in this group will receive a multicomponent intervention for 16 weeks.
61928199|NCT04386967|EXPERIMENTAL|Dose expansion|Dose expansion trial comprises of 2 cohorts. In cohort 1, OH2 injection will be administered at 1x10e7CCID50/mL . In cohort 2, OH2 injection will be administered at 1x10e7CCID50/mL in combination with Keytruda injection, an anti-PD-1 antibody, and the first doses of the two anti-tumor agents will be administered on the same day.
61928200|NCT05895344|EXPERIMENTAL|proton-therapy|Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
61928201|NCT05895344|ACTIVE_COMPARATOR|photon radiotherapy|Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
61928202|NCT05171075|EXPERIMENTAL|Abelacimab|Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
61928203|NCT05171075|ACTIVE_COMPARATOR|Dalteparin|Dalteparin administered subcutaneously daily
61928204|NCT06745687|EXPERIMENTAL|CM-336( BCMA/CD3 bispecific antibody)|Patients enrolled in the trial will receive CM336 subcutaneously, which is an BCMA/CD3 bispecific antibody therapy.
61928205|NCT06307652|EXPERIMENTAL|balcinrenone/dapagliflozin 15 mg/10 mg|Patients will be randomized 1:1:1 to either combination of balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
61928206|NCT06307652|EXPERIMENTAL|balcinrenone/dapagliflozin 40 mg/10 mg|Patients will be randomized 1:1:1 to either combination of balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
61928207|NCT06307652|ACTIVE_COMPARATOR|dapagliflozin 10 mg|Patients will be randomized 1:1:1 to either combination of balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
61928208|NCT04029688|EXPERIMENTAL|Dose Escalation: Solid Tumors: Idasanutlin Single Agent|
61928209|NCT04029688|EXPERIMENTAL|Neuroblastoma: Idasanutlin + Venetoclax|
61928210|NCT04029688|EXPERIMENTAL|Neuroblastoma: Idasanutlin + Cyclophosphamide + Topotecan|
61928211|NCT04029688|EXPERIMENTAL|AML: Idasanutlin + Venetoclax|
61928212|NCT04029688|EXPERIMENTAL|AML: Idasanutlin + Fludarabine + Cytarabine|
61928213|NCT04029688|EXPERIMENTAL|ALL: Idasanutlin + Venetoclax|
61928214|NCT05462613|EXPERIMENTAL|Experimental|Regorafenib + metronomic Capecitabine + metronomic Cyclophosphamide + low-dose Aspirin followed by second line of chemotherapy (Bevacizumab + FOLFOX or FOLFIRI)
61928215|NCT05462613|ACTIVE_COMPARATOR|Control|Second line of chemotherapy (Bevacizumab + FOLFOX or FOLFIRI)
61928216|NCT06744777|EXPERIMENTAL|Ribavirin + Standard Treatment|Participants in this group will receive the standard treatment for dengue fever alongside Ribavirin. Ribavirin will be administered orally at a dose of 15 mg/kg body weight twice daily (BD) for a total duration of 7 days.
61928217|NCT06744777|ACTIVE_COMPARATOR|Standard Treatment Alone|Participants in this group will receive only the standard treatment for dengue fever, which includes supportive care such as intravenous fluids and platelet transfusions, as required. No additional pharmacological intervention will be provided.
61928218|NCT01834001||1/Untreated prostate cancer|Patients with untreated prostate cancer
61928219|NCT01834001||2/Radiotherapy treated prostate cancer|Patients with prostate cancer who have already received definitive radiotherapy and have experienced biochemical failure
61928220|NCT05796167|EXPERIMENTAL|Pimavanserin (Nuplazid)|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks for patients with Parkinson disease psychosis (e.g., visual hallucinations, delusions) and sleep problems
61928221|NCT04420884|EXPERIMENTAL|Part 1 (Monotherapy Dose Escalation Phase): Dazostinag Safety Lead-in + Dazostinag SA [Part 1A]|"Safety Lead-in: Dazostinag 0.1 mg, infusion, intravenously (IV), once weekly, on Days 1, 8 and 15 in 21-day treatment cycles.~Dazostinag SA Dose Escalation (Part 1A): Dazostinag single agent (SA), infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the Dazostinag SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in."
62690683|NCT06472024|EXPERIMENTAL|Verum Acupuncture|The verum acupuncture group will receive actual acupuncture therapy 2 times per week for 3 weeks
62322646|NCT05146232|ACTIVE_COMPARATOR|Opioid based group|After induction of aesthesia, anesthesia maintained by continuous remifentanyl infusion
61928222|NCT04420884|EXPERIMENTAL|Part 1B (Combination Dose Escalation Phase): Dazostinag + Pembrolizumab|Dazostinag escalating doses (0.2 mg and above) in combination with pembrolizumab 200 mg, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycle. Pembrolizumab 200 mg will be administered 1 hour prior to Dazostinag once every 3 weeks (Q3W). The dosing will be initiated when at least two dose levels (DLs) of Part 1A have been evaluated.
61928223|NCT04420884|EXPERIMENTAL|Arm A: Japan Safety Lead-in Dazostinag + Pembrolizumab|"Dazostinag 5.0 mg, infusion, IV, in Japanese participants with advanced or metastatic solid tumors on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab 200 mg administered Q3W, IV, on Day 1 in each 21-day cycle.~Additional dose levels of Dazostinag (such as 14.0 mg) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead-in."
61928224|NCT04420884|EXPERIMENTAL|Arm B: Japan Safety Lead-in Dazostinag Transitioned to Pembrolizumab|"Dazostinag 5.0 mg, infusion, IV, as an SA once on Day 1 in Cycle 0 (cycle length=7 days) in Japanese participants with advanced or metastatic solid tumors based on confirmation of tolerability in Arm A. Following Cycle 0 (7 days), participants will be transitioned to the same dose level of dazostinag on Days 1, 8, and 15 of each 21-day cycle in combination with pembrolizumab administered Q3W, IV, on Day 1 in each 21-day cycle.~Additional dose levels of dazostinag (such as ≥ 7.0 mg) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead-in."
61928225|NCT04420884|EXPERIMENTAL|Part 2A (SCCHN CPS ≥ 1 Dose Expansion and Optimization Phase): Dazostinag + Pembrolizumab|Dazostinag 5.0 mg, infusion, IV, will be administered in participants with squamous cell carcinoma of head and neck (SCCHN) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.
61928226|NCT04420884|EXPERIMENTAL|Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy|Dazostinag 5.0 mg, infusion, IV, will be administered in participants with SCCHN at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. Pembrolizumab infusion, IV will be administered at 200 mg Q3W. Platinum-based chemotherapy comprising the combination of carboplatin (target area under the curve of 5 milligrams per milli Liters per minute (mg/mL/minute) \[AUC 5\]) or cisplatin (100 milligrams per square meter \[mg/m\^2\] Day 1 of each treatment cycle), and 5-fluorouracil (\[5-FU\]; 1000 mg/m\^2 per day for 4 consecutive days) Q3W for up to 6 cycles.
61928227|NCT04420884|EXPERIMENTAL|Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC|Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite instability-high /mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W.
61928228|NCT04420884|EXPERIMENTAL|Part 3B (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC|Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite stable/mismatch repair proficient (MSS/pMMR) CRC at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. along with pembrolizumab 200 mg infusion, IV, Q3W.
61928229|NCT04605055|EXPERIMENTAL|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
61928230|NCT04605055|EXPERIMENTAL|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
61928231|NCT05831891|EXPERIMENTAL|Fruquintinib combine with Serplulimab|Patients will receive Fruquintinib 5mg, qd, 2w on/1w off, combined with Serplulimab 4.5mg/kg, IV drip, d1, q3w.
61928232|NCT06418425|EXPERIMENTAL|Intervention|Participants randomly assigned to the intervention group will be taught specific resistance, balance and aerobic exercises by the care co-ordinator and participants will receive a leaflet with pictorial guide on the home-based exercise regime. The participants will be given a monitoring log to record the date and frequency of exercise they do. The participants will be advised to consume adequate protein and they will also receive another leaflet on protein consumption as part of a balanced diet.
61928233|NCT06418425|NO_INTERVENTION|Usual Care|Participants in the control group will receive usual care at the polyclinic which does not include counselling on dietary protein intake and home-based exercise program.
61928234|NCT06745180|EXPERIMENTAL|Peer Coach and SMS|SMS and peer coach interventions focused on physical activity maintenance
61928235|NCT06745180|EXPERIMENTAL|Peer Coach|Peer coach intervention focused on physical activity maintenance
61928236|NCT06745180|EXPERIMENTAL|Short Message Service (SMS)|SMS intervention focused on physical activity maintenance
61928237|NCT06745180|OTHER|Usual Care|Written materials focused on physical activity maintenance
61928238|NCT06745102|EXPERIMENTAL|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo or 0.75 mg soluble Xanthohumol)
61928239|NCT06745102|EXPERIMENTAL|Iso-alpha Acids|Participants receive a study drink supplemented with Iso-alpha Acids (0 mg = Placebo or 45 mg Iso-alpha Acids)
61928240|NCT06745102|EXPERIMENTAL|Xanthohumol + Iso-alpha Acids|Participants receive a study drink supplemented with Xanthohumol + Iso-alpha Acids (0 mg = Placebo or 0.75 mg + 45 mg soluble Xanthohumol + Iso-alpha Acids)
62131155|NCT00031694|EXPERIMENTAL|Treatment (paclitaxel, bryostatin 1)|Patients receive paclitaxel IV over 1 hour on day 1 followed by bryostatin 1 IV over 1 hour on day 2 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62131156|NCT01718041|EXPERIMENTAL|VRS-317|Active treatment arm
62131157|NCT00962702|EXPERIMENTAL|Exclusion of Left Atrial Appendage|Exclusion of Left Atrial Appendage
62131158|NCT04856826|EXPERIMENTAL|echo guidance|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
62690684|NCT06472024|SHAM_COMPARATOR|Sham Acupuncture|The Sham acupuncture group will receive Sham acupuncture therapy 2 times per week for 3 weeks
62322647|NCT03464058|EXPERIMENTAL|Part 1: Regimen A|Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.
62690685|NCT05879159|EXPERIMENTAL|Accelerated Recovery Protocol|"Accelerated Recovery after Minimally Invasive Hepatic Surgery (ARAMIS-Hep)~Participants randomized to this arm will undergo a recovery pathway that potentially allows for discharge on the day of surgery (post-operative day 0).~* You will receive a clear liquid diet, be encouraged to ambulate independently, and opioid use will be minimized in the recovery unit.~* You will be assessed in the post-operative recovery unit. If you meet discharge criteria, you will be discharged the afternoon/evening of surgery. If you do not, you will be admitted for overnight observation.~* You will have a telehealth video visit on post-operative days 1 and 2~* You will have in-person clinic visit within 14 days of discharge.~You will fill out about 14 questionnaires over a 30-day period to assess how you are feeling regarding your recovery"
61928241|NCT04846517|OTHER|TMS Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
61928242|NCT04472429|PLACEBO_COMPARATOR|Group A : carboplatin+paclitaxel+placebo|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle
61928243|NCT04472429|EXPERIMENTAL|Group B : carboplatin+paclitaxel+retifanlimab|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle
61928244|NCT04528173|ACTIVE_COMPARATOR|Traditional Care Group (TCG)|Traditional anesthetic with opioids group will receive institutional standard clinical care for tonsillectomy, including a standardized opioid dose at the beginning of the case and again at the end if needed. Dexmedetomidine and Ketorolac will not be used intra-operatively in this cohort to prevent confounding.
61928245|NCT04528173|EXPERIMENTAL|Opioid-Free Group (OFG)|Opioid-Free group will receive institutional standard clinical care for tonsillectomy, without opioids, but including Dexmedetomidine and Ketorolac.
61928246|NCT06046287|EXPERIMENTAL|Daratumumab and hyaluronidase-fihj|
61928247|NCT06745388|EXPERIMENTAL|Magnesium, IV|Intravenous magnesium 2 grams given over 20 minutes intra-operatively
61928248|NCT06745388|EXPERIMENTAL|Ketamine, IV|Intravenous ketamine 0.5 milligrams per kilogram dosed to ideal bodyweight, IV push intra-operatively
61928249|NCT06745388|PLACEBO_COMPARATOR|Placebo|No administration of placebo infusion, ketamine or magnesium intra-operatively
61928250|NCT06410885|EXPERIMENTAL|Observational, part 1 (blinded)|
61928251|NCT06410885|EXPERIMENTAL|Diagnostic, part 2 (unblinded)|
61928252|NCT01946204|EXPERIMENTAL|Treatment Arm A: Apalutamide|
61928253|NCT01946204|PLACEBO_COMPARATOR|Treatment Arm B: Placebo|
61928254|NCT06745193|EXPERIMENTAL|chidamide+Camrelizumab+Apatinib|
61928255|NCT06745193|PLACEBO_COMPARATOR|SOC|Irinotecan or Docetaxel or Paclitaxel
61928256|NCT05856890|EXPERIMENTAL|Group 1a: HepB mAb19 1 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 1 mg/kg.
61928257|NCT05856890|EXPERIMENTAL|Group 2a: HepB mAb19 3 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 3 mg/kg.
61928258|NCT05856890|EXPERIMENTAL|Group 3a: HepB mAb19 10 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 10 mg/kg.
61928259|NCT05856890|EXPERIMENTAL|Group 4a: HepB mAb19 30 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 30 mg/kg.
61928260|NCT05856890|EXPERIMENTAL|Group 5: Maximum tolerated dose, IV|Single intravenous infusion of HepB mAb19, dosed at the MTD
61928261|NCT05856890|PLACEBO_COMPARATOR|Group 1b: Placebo 1 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 1 mg/kg.
61928262|NCT05856890|PLACEBO_COMPARATOR|Group 2b: Placebo 3 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 3 mg/kg.
61928263|NCT05856890|PLACEBO_COMPARATOR|Group 3b: Placebo 10 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 10 mg/kg.
62322648|NCT03464058|EXPERIMENTAL|Part 1: Regimen B|Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.
61928264|NCT05856890|PLACEBO_COMPARATOR|Group 4b: Placebo 30 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 30 mg/kg.
61928265|NCT06546826||BARP|collagen-bonegraft-collagen
61928266|NCT06546826||unassisted|unassisted healing
61928267|NCT06546826||Tooth root|tooth root and PRF
61928268|NCT06546826||Ice Cream Cone Technique|bonegraft and collagen membrane
61928269|NCT06560021|ACTIVE_COMPARATOR|Limited biopsy strategy|Targeted biopsies plus 2 random biopsies in 2 segments to assess for inflammation
61928270|NCT06560021|ACTIVE_COMPARATOR|Random biopsy strategy|Targeted biopsies plus 4 biopsies every 10 cm throughout the colon, at a minimum in all segments of the colon known to have been affected by IBD at any time
61928271|NCT06042751|EXPERIMENTAL|Exercise Therapy|Six online consultations focusing on exercise therapy, each lasting 50 minutes every two weeks, resulting in 300 min in 3 months.
61928272|NCT06042751|EXPERIMENTAL|Psychotherapy|Six online consultations focusing on psychotherapy, each lasting 50 minutes every two weeks, resulting in 300 min in 3 months.
61928273|NCT06042751|EXPERIMENTAL|Combined exercise and psychotherapy|Both interventions (exercise and psychotherapy) are combined. Six biweekly online session with 50% exercise therapy (a 25 min) and 50% psychotherapy (a 25 min) will take place, resulting in 300 min overall therapy in 3 months. The content of the procedure is simultaneous to the interventions described in the exercise therapy arm and the psychotherapy arm, respectively.
61928274|NCT05727904|EXPERIMENTAL|Arm A|Lifileucel plus Pembrolizumab
61928275|NCT05727904|ACTIVE_COMPARATOR|Arm B|Pembrolizumab alone with Optional Crossover Period
61928276|NCT04556890|EXPERIMENTAL|Active rTMS/Active iTBS DFPLC/Sham Pain M1|
61928277|NCT04556890|EXPERIMENTAL|Active rTMS/Active iTBS|
62322649|NCT03464058|EXPERIMENTAL|Part 1: Regimen C|Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.
62690686|NCT05879159|EXPERIMENTAL|Comparison/Control Arm|"Standard Post-operative recovery pathway after minimally invasive hepatic surgery.~Participants randomized to this arm will undergo our institution's standard recovery pathway for minimally invasive liver surgery.~* You will be transferred to the Transitional PACU for overnight observation.~* Your diet will be advanced to gastrointestinal first food diet on Post-operative Day 1, with opioid weaning and frequent ambulation.~* You will be discharged once criteria are met.~* You will have an in-person clinic visit within 14 days of discharge.~You will fill out about 14 questionnaires over a 30-day period to assess how you are feeling regarding your recovery."
62690687|NCT06083454|EXPERIMENTAL|Durvalumab as monotherapy|Two cycles of Durvalumab 1500 mg every 3 weeks, as monotherapy
62690688|NCT06083454|EXPERIMENTAL|Combination of pharmacological ascorbate plus Durvalumab|Combination of pharmacological ascorbate 75 grams intravenously three times a week x 4 weeks plus Durvalumab 1500 mg every 3 weeks for two cycles
62690689|NCT06083454|ACTIVE_COMPARATOR|Control (no neoadjuvant therapy)|Serve as control and patients will not receive any neoadjuvant therapy before going to surgery. Once randomize, they can go to surgery without any delays.
62690690|NCT03070067||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
62690691|NCT03070067||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
62690692|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
61928278|NCT05126862|EXPERIMENTAL|MindTrails pilot|This intervention involves completion of five, 20-minute MindTrails online training sessions over five weeks.
61928279|NCT06744322|NO_INTERVENTION|Standard Care|Patients undergo a standard post-infarction care, with discharge at 72 (+/-24 hours) after invasive management of acute myocardial infarction.
61928280|NCT06744322|EXPERIMENTAL|Fast discharge strategy|Fast discharge at 24 (+/-12) hours after invasive management of acute myocardial infarction.
61928281|NCT06745141|EXPERIMENTAL|Periodontal Health Intervention Group|"Participants in this arm will receive comprehensive periodontal health interventions, including:~1. Full periodontal evaluation using dental mirrors and probes (assessing visible plaque, probing depth, bleeding on probing, and attachment loss).~2. Supragingival scaling, root planing, and professional plaque removal.~3. Temporary restoration of carious lesions and extraction of root remnants, as needed.~4. Personalized oral hygiene instruction, including the use of multi-tufted brushes, toothpaste, floss, and interdental brushes."
61928282|NCT06745141|NO_INTERVENTION|Standard Care Group|Participants in this arm will receive standard care without specific periodontal interventions. This includes routine medical management for myocardial infarction, as per standard clinical guidelines, without structured periodontal treatment.
61928283|NCT01999361|EXPERIMENTAL|Myfortic treatment|Treatment with Myfortic
61928284|NCT02252172|ACTIVE_COMPARATOR|Lenalidomide and Dexamethasone (Rd)|Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
61928285|NCT02252172|ACTIVE_COMPARATOR|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
61928286|NCT06741930|ACTIVE_COMPARATOR|Ketamine group|The Ketamine group received IV ketamine at a dosage of 0.5-1.0 mg/kg.
61928287|NCT06741930|ACTIVE_COMPARATOR|Midazolam group|The Midazolam group received IV midazolam at a dosage of 0.15-0.40 mg/kg.
61928288|NCT06741930|ACTIVE_COMPARATOR|Propofol group|The Propofol group received IV propofol at a dosage of 0.5-1.0 mg/kg.
61928289|NCT04467021|EXPERIMENTAL|Arm A (intensive systolic blood pressure management)|Patients receive intensive systolic blood pressure management for 6 months. Patients receive increased blood pressure medication every 2 weeks while systolic blood pressure is 120 mmHg or higher. Patients also monitor blood pressure at home 1 day a week (4 times in 1 day) every 2 weeks, and upload the recorded blood pressure readings to the provider and to a central blood pressure monitoring team. Patients with changes in blood pressure medications monitor blood pressure readings on 3 days in 1 week (4 times in 1 day).
62322650|NCT03464058|EXPERIMENTAL|Part 1: Regimen D|Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.
62690693|NCT06641453|EXPERIMENTAL|GPC3 CAR-T cell therapy|Enrolled patients will receive a single infusion of GPC3 CAR-T cells at a starting dose of 1×10\^6 cells/kg.
62690694|NCT01215305||Visiting outpatient departments, if symtoms|patients with upper GI symptoms, visiting the outpatient departments of peripheral hospitals in Greece
62690695|NCT03268278|ACTIVE_COMPARATOR|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
62690696|NCT03268278|PLACEBO_COMPARATOR|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
62690697|NCT02038647|EXPERIMENTAL|Alisertib (MLN8237) + Paclitaxel|Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m\^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).
61928290|NCT04467021|ACTIVE_COMPARATOR|Arm B (usual blood pressure management)|Patients receive standard blood pressure management for 6 months. Patients receive blood pressure medications per doctor's instruction. Patients also monitor blood pressure at home 1 day (4 times in 1 day) every 2 weeks, and upload the recorded blood pressures to a central monitoring team.
62322651|NCT03464058|EXPERIMENTAL|Part 1: Regimen E|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.
62322652|NCT03464058|EXPERIMENTAL|Part 1: Regimen F|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.
62482006|NCT05942469|EXPERIMENTAL|FOREST + Assessments|UCAN staff will participate in Monthly Skill Sessions and complete FOREST content modules in the Learning Management System (LMS). Staff will also be invited to complete annual assessments for primary and secondary outcome measures, as well as annual interviews and focus groups to gather feedback on progress, implementation, and content.
62482007|NCT00835263|EXPERIMENTAL|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
62482008|NCT00835263|ACTIVE_COMPARATOR|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
62690698|NCT02038647|PLACEBO_COMPARATOR|Placebo + Paclitaxel|Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m\^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).
62482009|NCT00115063|EXPERIMENTAL|1|"Intensive Medical Intervention including Low Calorie Liquid Diet, Weight loss medications, Group Behavioral Therapy and a Tool Box approach"
62690699|NCT06230991|EXPERIMENTAL|SIM05|One sachet twice daily for 16 weeks
62690700|NCT05287737||Referred for Total pancreatectomy with islet autotransplantation|Followed up for up for 15 years after TPIAT.
62690701|NCT06569420|EXPERIMENTAL|Foritinib Succinate|"Foritinib Succinate capsules will be administered orally at a dose of 160 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death.~Other Names: SAF-189s"
62690702|NCT06569420|ACTIVE_COMPARATOR|Control: Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
62690703|NCT06248710|EXPERIMENTAL|Condition 1: Oxytocin + dog present|
62690704|NCT06248710|EXPERIMENTAL|Condition 2: Oxytocin + no dog present|
62690705|NCT06248710|EXPERIMENTAL|Condition 3: Placebo + dog present|
62690706|NCT06248710|PLACEBO_COMPARATOR|Condition 4: Placebo + no dog present|
62690707|NCT05050955||LungCare Surveillance (500 Cases)|Observational evaluation of diagnostic performance characteristics of AlloSure Lung to detect a spectrum of rejection and allograft infection.
62322653|NCT03464058|EXPERIMENTAL|Part 2: Regimen G|Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.
62322654|NCT03464058|EXPERIMENTAL|Part 2: Regimen H|Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.
62322655|NCT03464058|EXPERIMENTAL|Part 2: Regimen I|Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.
62690708|NCT06570681|NO_INTERVENTION|Standard Care|If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. If the vehicle is in the control arm the patient is triaged by the on-call neurologist based on a standard telephone call
61928291|NCT06744829|EXPERIMENTAL|Patients treated with endogastric balloon STELLA in weight loss|
62322656|NCT03464058|EXPERIMENTAL|Part 2: Regimen J|Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.
62322657|NCT03464058|EXPERIMENTAL|Part 3: Regimen K|Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).
62482010|NCT00115063|ACTIVE_COMPARATOR|2|Access to Weight Loss Informational Website sponsored by the Mayo Clinic
62482011|NCT02421822|EXPERIMENTAL|Fitwits Intervention|Fitwits office tool and games
62482012|NCT00955448|EXPERIMENTAL|SIS Mesh (Cook Medical)|Anterior prolapse repair will be reinforced using SIS mesh
62322658|NCT03464058|EXPERIMENTAL|Part 3: Regimen L|Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
62322659|NCT03464058|EXPERIMENTAL|Part 3: Regimen M|Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
62322660|NCT05326399||renal biopsy|Standard percutaneous biopsy has been performed in all participants. Light microscope, fluorescence microscope and electron microscope were used for assessment of kidney issue
62482013|NCT00955448|ACTIVE_COMPARATOR|No-mesh|Anterior prolapse repair with no mesh reinforcement
62482014|NCT00518258||1|Patient Group
62482015|NCT00518258||2|Control Group
62482016|NCT03933592|ACTIVE_COMPARATOR|Thoracic epidural|thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
62690709|NCT06570681|ACTIVE_COMPARATOR|Video call assisted assessment of acute stroke|If the patient is eligible for study inclusion, the last symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via the video-call and triage the patient.
62690710|NCT06580938|EXPERIMENTAL|Part 1|Dose escalation monotherapy
62690711|NCT06580938|EXPERIMENTAL|Part 2|Dose escalation (combination therapy)
62690712|NCT06580938|EXPERIMENTAL|Part 3|Dose optimization/ expansion (combination therapy)
62690713|NCT04582812|EXPERIMENTAL|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training|
62690714|NCT04582812|ACTIVE_COMPARATOR|Isolated high-intensity inspiratory muscle training|
62690715|NCT06060509|EXPERIMENTAL|Wheat corn germ blended oil group|Participants in the intervention group replaced the daily cooking oil with wheat and corn germ oil, and were given 25-30 g of cooking oil per day according to the recommended intake of the Chinese Nutrition Society. Lunch and dinner were cooked using a uniform recipe for both intervention and control groups, and breakfast was self-cooked under the uniform dietary guidelines.
62322661|NCT06693258|EXPERIMENTAL|Experimental group|thyroidectomy by robotic surgery via axillary approach
62322662|NCT06693258|ACTIVE_COMPARATOR|Control group|thyroidectomy by standard conventional surgery
62482017|NCT03933592|EXPERIMENTAL|Serratus plane block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 min before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
62482018|NCT05921188|EXPERIMENTAL|More Familiar Sounds|Children in this condition will learn new words whose sounds are more like the sounds in the words the child already understands.
62482019|NCT05921188|ACTIVE_COMPARATOR|Less Familiar Sounds|Children in this condition will learn new words whose sounds are less like the sounds in the words the child already understands.
62482020|NCT05387408|OTHER|participating union health fund|"The investigators will recruit three health funds into a single arm trial. Each health fund will receive the intervention, Workplace Opioid Prevention Guidelines. The intervention is a set of guidelines containing information and suggested changes the health fund may make to their health and safety program specifically to prevent and manage opioid abuse in their workforce. The health fund the investigators receive the intervention after completing baseline data collection. The investigators will provide assistance with using the intervention as needed over a 6 month period of time, and measure changes the health fund makes to their health and safety program based on information in the guidelines. At 6 months, the investigators will repeat baseline data collection for the efficacy trial."
62482021|NCT00294047|EXPERIMENTAL|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
62482022|NCT00294047|PLACEBO_COMPARATOR|Aluminium Hydroxide Group|Subjects received 3 doses of Aluminium Hydroxide \[Al(OH)3\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
61928292|NCT05227690|EXPERIMENTAL|CVL-231 10 mg, once daily (QD)|Oral Dose
61928293|NCT05227690|EXPERIMENTAL|CVL-231 30 mg, once daily (QD)|Oral Dose
62322663|NCT06691334|ACTIVE_COMPARATOR|Group A: 10 cases will be group which is PRP injection 2 ml below urethra in one month interval.|Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under urethra.
62322664|NCT06691334|ACTIVE_COMPARATOR|Group B: 10 cases will be group B which is PRP combined together with vaginal HIFU.|Procedure: 3 cycles of vaginal HIFU together with 3 cycles of platelet-rich plasma injection treatment in 4 weeks intervals
62322665|NCT02004756|EXPERIMENTAL|Fontan Patients|Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
62690716|NCT06060509|OTHER|Peanut oil group|Participants in the Peanut oil group replaced the daily cooking oil with Peanut oil, and were given 25-30 g of cooking oil per day according to the recommended intake of the Chinese Nutrition Society. Lunch and dinner were cooked using a uniform recipe for both intervention and control groups, and breakfast was self-cooked under the uniform dietary guidelines.
62690717|NCT00003907|EXPERIMENTAL|Hepatocellular carcinoma|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
62690718|NCT00003907|EXPERIMENTAL|Neuroendocrine hepatic metastases|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
61928294|NCT05227690|PLACEBO_COMPARATOR|Placebo, once daily (QD)|Oral Dose
61928295|NCT05365581|EXPERIMENTAL|Monotherapy Dose Escalation (Phase 1)|"A dose escalation design will be used to determine the Maximum Tolerated Dose (MTD) and/ or the Recommended Phase 2 Dose (RP2D) regimens to be further evaluated in the Monotherapy Dose Expansion arms.~Monotherapy Dose escalation part consists of six parts (Part A, B, C, D, E, and F), and approximately 86 patients would be enrolled in total. Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in each part. The study will open with the Part A dosing schedule, while subsequent cohorts will be opened sequentially or in parallel based upon sponsor review of emerging data."
62131159|NCT04856826|NO_INTERVENTION|conventional|insertion of a peripheral venous catheter conventionally
62131160|NCT04967742|EXPERIMENTAL|A group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 10 μg in V-122 study.
62131161|NCT04967742|EXPERIMENTAL|B group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 30 μg in V-122 study.
62131162|NCT04967742|EXPERIMENTAL|C group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 100 μg in V-122 study.
62322666|NCT02004756|NO_INTERVENTION|Healthy Controls|Healthy age-matched adolescents
62322667|NCT06658613||Group C|Patients not intubated at the end of the bronchoscopy during the neuromuscular block reversal and weaning course.
62322668|NCT06658613||Group I|Patients intubated at the end of the bronchoscopy during the neuromuscular block reversal and weaning course.
62322669|NCT05057273|EXPERIMENTAL|BT-11 880 mg|Oral once daily tablet
62322670|NCT05057273|ACTIVE_COMPARATOR|Standard of care|Biologic
62322671|NCT04304495|EXPERIMENTAL|Intervention|"In addition to the usual care arm, the Intervention arm will receive a physical therapy and pharmacy consultation in the ED. PTs will perform a fall risk assessment and provide recommendations on the safety of discharge. Pharmacists will perform medication review, recommend cessation or tapering of medication that increase fall risk using motivational interviewing (MTM) techniques.~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
62690719|NCT02826785|EXPERIMENTAL|Cognitive strategy training|The cognitive strategy training intervention consists of 6 weekly \~1 hour sessions. It is delivered in an individual, face-to-face format in the client's home. It is a behavioral intervention that teaches people metacognitive, problem-solving and other compensatory strategies to address self-identified cognitive performance problems, and it uses practice and homework to promote strategy learning, retention and transfer.
62690720|NCT03557905|ACTIVE_COMPARATOR|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse at an FiO2 of 0.5. .
62690721|NCT03557905|ACTIVE_COMPARATOR|Group II|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse at an FiO2 of 0.3.
61928296|NCT05365581|EXPERIMENTAL|Monotherapy Dose Expansion (Phase 1b) Gastric/GEJ cancer|Participants will receive ASP2138 at the candidate RP2D regimens determined in Monotherapy Dose Escalation arm.
61928297|NCT05365581|EXPERIMENTAL|Monotherapy Dose Expansion (Phase 1b) Pancreatic cancer|Participants will receive ASP2138 at the candidate RP2D regimens determined in Monotherapy Dose Escalation arm.
61928298|NCT05365581|EXPERIMENTAL|Combination Therapy Dose Escalation (Phase 1) Part G - First-line Gastric/GEJ Cancer|"A dose escalation design will be used to determine the MTD and/ or the RP2D regimens to be further evaluated in the Combination Dose Expansion arms.~In combination dose escalation part G approximately 24 patients would be enrolled in total. Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in combination with pembrolizumab and mFOLFOX6 as first line therapy."
61928299|NCT05365581|EXPERIMENTAL|Combination Therapy Dose Escalation (Phase 1) Part H - Second-line Gastric/GEJ Cancer|"A dose escalation design will be used to determine the MTD and/ or the RP2D regimens to be further evaluated in the Combination Dose Expansion arms.~Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in combination with ramucirumab and paclitaxel as second line therapy."
61928300|NCT05365581|EXPERIMENTAL|Combination Therapy Dose Escalation (Phase 1) Part I - First line Pancreatic Cancer|"A dose escalation design will be used to determine the MTD and/ or the RP2D regimens to be further evaluated in the Combination Dose Expansion arms.~Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in combination with mFOLFIRINOX as first line therapy."
62131163|NCT04093752|EXPERIMENTAL|5 mg Tirzepatide|Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).
62690722|NCT03165500|ACTIVE_COMPARATOR|Diazepam|Sedation of the anxious patient with diazepam 5 mg for measuring vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
62690723|NCT03165500|ACTIVE_COMPARATOR|Midazolam|Sedation of the anxious patient with midazolam 7.5 mg for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
62690724|NCT03165500|ACTIVE_COMPARATOR|Nitrous Oxide + Oxygen Gas|Inhaled sedation of the mixture of 40% of nitrous oxide and 60% of oxygen gas for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
62690725|NCT03344887|ACTIVE_COMPARATOR|RBC Transfusion from male donor|For the treatment of anemia
62131164|NCT04093752|EXPERIMENTAL|10 mg Tirzepatide|Participants received 10 mg tirzepatide administered SC QW.
62690726|NCT03344887|ACTIVE_COMPARATOR|RBC Transfusion from female donor|For the treatment of anemia
62131165|NCT04093752|EXPERIMENTAL|15 mg Tirzepatide|Participants received 15 mg tirzepatide administered SC QW.
62131166|NCT04093752|ACTIVE_COMPARATOR|Insulin Glargine|Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between 72-100 milligrams per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm.
62131167|NCT01777373||Idiopathic pulmonary fibrosis (IPF)|Idiopathic pulmonary fibrosis (IPF)
62131168|NCT01777373||Control|Control
62131169|NCT01777373||Non-IPF interstitial lung disease (ILD)|Non-IPF interstitial lung disease (ILD)
62131170|NCT01777373||Uncharacterized ILD|Uncharacterized ILD
62131171|NCT06290882|ACTIVE_COMPARATOR|Robotic Heller Myotomy.|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the Robotic Heller Myotomy group
62690727|NCT04393935|EXPERIMENTAL|Pharmacy Delivered PrEP Intervention|Customers of the study pharmacies who participate in the intervention to receive PrEP through the pharmacy.
62131172|NCT06290882|ACTIVE_COMPARATOR|Peroral Endoscopic Myotomy.|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the Peroral Endoscopic Myotomy group
62131173|NCT02544880|EXPERIMENTAL|Tadalafil plus Vaccine Group (Phase I)|The first 6 participants will be enrolled in the open label Phase I portion of the study and will receive Tadalafil, Anti-mucin 1 (MUC1) Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
62690728|NCT04628208||Negative for COVID-19|Subject determined to be negative for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
62690729|NCT04628208||Positive for COVID-19|Subject determined to be positive for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
62690730|NCT01235637|ACTIVE_COMPARATOR|Alfentanil|
62690731|NCT01235637|SHAM_COMPARATOR|Sufentanil|
62690732|NCT02997007|EXPERIMENTAL|MCI-active|Patients will receive verum tDCS over the angular gyrus on five consecutive days.
62690733|NCT02997007|SHAM_COMPARATOR|MCI-sham|Patients will receive sham tDCS over the angular gyrus on five consecutive days.
62690734|NCT02997007|EXPERIMENTAL|Healthy Old-active|Participants will receive verum tDCS over the angular gyrus on five consecutive days.
62690735|NCT02997007|SHAM_COMPARATOR|Healthy old-sham|Participants will receive sham tDCS over the angular gyrus on five consecutive days.
62690736|NCT03568123|EXPERIMENTAL|MC polyethylene bearing|Persona Total Knee System with MC polyethylene bearing
62690737|NCT03568123|ACTIVE_COMPARATOR|CR polyethylene bearing|Persona Total Knee System with a CR polyethylene liner.
62690738|NCT05252702|OTHER|Single Arm|Non randomized arm
62322672|NCT04304495|NO_INTERVENTION|Usual care arm|"The ED clinician will perform a standard medical evaluation, including a focused history and exam to identify injuries, laboratory tests and radiologic imaging. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics).~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
62322673|NCT00734422|EXPERIMENTAL|VRET with yohimbine|Virtual Reality Exposure Therapy will be combined with the administration of yohimbine hydrochloride
62322674|NCT00734422|PLACEBO_COMPARATOR|VRET with placebo|Virtual Reality Exposure Therapy will be combined with an inactive placebo pill (Albochin).
62322675|NCT06669104||Lobectomy , Segmentectomy Wedge resection of lung|
62482023|NCT06120803|EXPERIMENTAL|Esomeprazole 40 mg daily with thoracic radiation therapy and concomitant chemotherapy|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy (TRT). TRT will be delivered as per the discretion of the treating physicians.
62322676|NCT06669104||Anterior Mediastinal Tumour Resection|
62482024|NCT04150133|ACTIVE_COMPARATOR|Traditional Clear Liquid Arm|Following instructions with FDA-labeled clear liquids
62482025|NCT04150133|EXPERIMENTAL|Low Residue Diet Arm|Following instructions for a low residue diet along with FDA-labeled clear liquids
62482026|NCT05402137|EXPERIMENTAL|Experimental (Weight Stigma) Arm|"Participants undergoing the experimental (Weight Stigma) arm are exposed to an interaction partner (a trained confederate) who endorses anti-fat attitudes. Prior to their interaction, participants exchange a Getting to Know You Questionnaire with the confederate, where the confederate endorses anti-fat attitudes. During their interaction with the confederate, participants are told they will be completing consumer rating tasks with another participant in the study. During the ostensible consumer rating task, participants in the experimental condition rate items such as a diet magazine, body sunscreen, running shoes, and a size small T-shirt labeled as size large to bolster the weight stigma manipulation."
62482027|NCT05402137|NO_INTERVENTION|Control Arm|"Participants undergoing the control arm are also exposed to an interaction partner (a trained confederate) who does not endorse anti-fat attitudes. Prior to their interaction, participants exchange a Getting to Know You Questionnaire with the confederate; however, the confederate does not endorse anti-fat attitudes. During their interaction with the confederate, participants are told they will be completing consumer rating tasks with another participant in the study. During the ostensible consumer rating task, participants in the control condition rate items such as an interior design magazine, face sunscreen, regular (non-running) shoes, and a size large T-shirt correctly labeled as size large to avoid weight stigma."
62482028|NCT06689098||Patients with suspected inflammatory cardiomyopathy|"Adult patients experiencing cardiac symptoms such as chest pain or pressure, dyspnea on exertion, and heart racing are included after rule out of obstructive coronary artery disease by coronary angiography (ANOCA). Patients have to be stable enough to undergo advanced imaging and magnetocardiography measurements. Patients on immunosuppressive therapy and/or with intracardiac metal devices are excluded.~110 patients for this group are planned."
62482029|NCT06689098||Cardiac Healthy Controls|"Healthy individuals with no history of cardiac disease and unremarkable physical exam, 12-lead ECG, and echocardiography.~220 patients for this group are planned"
62482030|NCT03246763|EXPERIMENTAL|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
62690739|NCT05757050|EXPERIMENTAL|"Re-Focus Tablets Verum"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
62690740|NCT05757050|PLACEBO_COMPARATOR|"Re-Focus Tablets Placebo"|The placebo will be a matched control
62322677|NCT06669104||Posterior Mediastinal Tumour Resection|
62690741|NCT03728686|EXPERIMENTAL|3mins|Different given time: Fentanyl 2mcg/kg was given at either time 3 minutes before intubation
62690742|NCT03728686|ACTIVE_COMPARATOR|2mins|Different given time: Fentanyl 2mcg/kg was given at either time 2 minutes before intubation
62690743|NCT03728686|NO_INTERVENTION|control|Different given time: Fentanyl 2mcg/kg was given at either time 1 minute before intubation
62690744|NCT01518179|EXPERIMENTAL|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
62690745|NCT01518179|OTHER|Control|Routine follow up and treatment
62690746|NCT01909245|EXPERIMENTAL|Single Arm Study|Allogenic Human Islet Cell Transplant with immunosuppression
62322678|NCT00906022|EXPERIMENTAL|Astron Pulsar Stent|Device: Astron Pulsar Stent
62322679|NCT00906022|ACTIVE_COMPARATOR|PTA alone|Device: Balloon angioplasty alone
62690747|NCT05885594|OTHER|AUD-Alcohol Use Disorder|60 adult men and women who have alcohol use disorder will undergo up to 2 PET/CT scans each approximately 60 minutes of dynamic scanning starting at the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.
62690748|NCT05885594|OTHER|HV-Healthy Volunteer|30 adult men and women between the ages of 18-65 who do not have alcohol use disorder and are a healthy volunteer will be enrolled in this study.
62322680|NCT06291220|EXPERIMENTAL|Part A: Cohort 1.1 ABBV-453 Dose A|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose A is achieved, during the 5 year study duration.
62690749|NCT06636669|EXPERIMENTAL|Treatment- Probiotics and standard of care|Participants randomized into this are will receive Culturelle probiotic and standard of care.
62690750|NCT06636669|ACTIVE_COMPARATOR|Controls- Standard of care|Participants randomized into this are will receive standard of care.
62690751|NCT00192478|ACTIVE_COMPARATOR|1|MEDI-524
62690752|NCT00931541|EXPERIMENTAL|A|AZD6088 oral solution
62690753|NCT00931541|EXPERIMENTAL|B|Placebo oral solution
62690754|NCT06097897|EXPERIMENTAL|Imaging using the SVO-ID|Patients will have their eyes imaged with the SVO-ID as part of a study visit.
62690755|NCT04996745|EXPERIMENTAL|Intervention Group|Patients randomized to the intervention group of the RCT will be given tablet-based education. The first clinic follow-up visit will consist of screening for consent, providing a QR code for Orthokids, and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will be provided with the tablet for repeat education, with Orthokids and the post-intervention questionnaire will be distributed. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care.
62690756|NCT04996745|NO_INTERVENTION|Control Group|"Patients randomized to the control group of the RCT will receive the standard clinic experience. This group will not be exposed to any education enrichment about their child's fracture except for the physician's explanation within the exam room.~The first clinic follow-up visit will consist of screening for consent and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will consist of conducting the post-intervention questionnaire. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care."
62690757|NCT01338597|EXPERIMENTAL|standard|3 trocars are needed. two in the circumareolar region and one in the parasternal region. the dissection area begins from the trocar site and extends to the neck.
62690758|NCT01338597|EXPERIMENTAL|limited dissection|the dissection is reduced by creating a long tunnel from the trocar site and the dissection area confined in the upper chest wall and in the neck.
62690759|NCT02659371|EXPERIMENTAL|Low energy diet|Low energy diet (800 kcal/d) for eight weeks, following 4 weeks on reintroduction supplying 1200 kcal/d.
61928301|NCT05365581|EXPERIMENTAL|ASP2138 + Pembrolizumab & mFOLFOX6 Combination Therapy Dose Expansion (Phase 1b) Gastric/GEJ Cancer|Participants will receive candidate RP2D regimens of ASP2138 in combination with pembrolizumab \& mFOLFOX6 as first line therapy determined in Combination Therapy Dose Escalation arm.
61928302|NCT05365581|EXPERIMENTAL|ASP2138 + Ramucirumab & Paclitaxel Combination Therapy Dose Expansion (Phase 1b) Gastric/GEJ Cancer|Participants will receive candidate RP2D regimens of ASP2138 in combination with ramucirumab and paclitaxel as second line therapy determined in Combination Therapy Dose Escalation arm.
61928303|NCT05365581|EXPERIMENTAL|ASP2138 + mFOLFIRINOX Combination Therapy Dose Expansion (Phase 1b) Pancreatic Cancer|Participants will receive candidate RP2D regimens of ASP2138 in combination with mFOLFIRINOX as first line therapy in pancreatic cancer determined in Combination Therapy Dose Escalation arm in combination with mFOLFIRINOX as first line therapy in pancreatic cancer.
61928304|NCT05587842|ACTIVE_COMPARATOR|Non-weightbearing Group|"At 0 weeks to 2 weeks post operation, subjects will be provided CAM (controlled ankle motion walking) boot and instructed to be non-weightbearing on the ankle, using crutches for assistance. During 2nd week, subject will visit clinic where staples/stitches will be removed, with instructions to continue non-weightbearing w/ crutches. Instructions for limited range of motion to be given, passive/active range of motion out of boot will be allowed. Between 2 to 6 weeks, the subject will continue with non-weightbearing and follow range of motion instructions. After 6 weeks, the subject will begin weightbearing as tolerated. Instructions for limited range of motion to be given, and be weaned from orthosis.~At each follow-up visit, as part of the subject's standard of care, a physical examination and radiographic assessments will be completed, and that data collected for research purposes. Subject will also be requested to complete outcome questionnaires during their participation."
62131174|NCT02544880|EXPERIMENTAL|Tadalafil plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
62131175|NCT02544880|EXPERIMENTAL|Tadalafil plus Vaccine Placebo Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, placebo for the Anti-MUC1 Vaccine and placebo for the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
62690760|NCT06080204|EXPERIMENTAL|Octreotide group|Patients in the octreotide group received octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months, with the start of clinical intervention following surgery.
62690761|NCT06080204|NO_INTERVENTION|Control group|No adjuvant therapy after surgery.
62690762|NCT06119321||Normal control group|
62690763|NCT06119321||Subclinical keratoconus|
62690764|NCT06119321||Keratoconus|
62690765|NCT01772251|EXPERIMENTAL|Oshadi Icp & placebo|
62690766|NCT01769131||Allis|
62690767|NCT01769131||Tenaculum|
62690768|NCT03426397||Study population|
62690769|NCT06428188|EXPERIMENTAL|CD19/BCMA-CAR T cells, chemotherapy|Patients will be administered fludarabine phosphate intravenously (IV) over a 30-minute period on days -4 to -2. Additionally, cyclophosphamide will be administered intravenously (IV) over 60 minutes on day -2. Subsequently, patients will receive BCMA/CD19 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0. Patients who exhibit positive responses to the initial dose of BCMA/CD19 CAR T cells, do not experience unacceptable side effects, and have a sufficient quantity of cells available may be eligible to receive 2 or 3 additional doses of BCMA/CD19 CAR T cells.
62690770|NCT05087446|EXPERIMENTAL|Early assessment group|
62690771|NCT05087446|ACTIVE_COMPARATOR|Usual admission procedure group|
62690772|NCT06634862|OTHER|intermittent pneumatic pressure group|Intermittent Pneumatic Compression (IPC) is a mechanical method of applying compression to the limbs and has a number of therapeutic uses. The device consists of a pair of inflatable sleeves wrapped around the leg and an electric pneumatic pump that inflates the sleeves with air, compressing the deep veins and displacing blood proximally. The working principle of IPC is based on passively increasing blood flow by applying external pressure to the extremity, but the exact physiological mechanisms are only partially understood. However, despite its widely recognised use and positive effects on circulatory conditions, the literature on the use of IPC in musculoskeletal treatment is limited. The available evidence has been investigated in several studies, including the efficacy of IPC, its effect on vasodilatory effects in distal skeletal muscle and its effect on serum indices of muscle function, pain and muscle damage. Studies have also reported improvements in exercise duration as wel
62690773|NCT06634862|OTHER|Soft Tissue Mobilization Technique Group|The Graston Technique (GT) is a form of instrument-assisted soft tissue mobilisation that uses stainless steel instruments to perform manual therapy on soft tissues. It is widely used by clinicians to treat various soft tissue disorders. Research has reported that it effectively promotes the inhibition of adhesion of treated tissues and collagen synthesis. Furthermore, the graston technique has been used to manage pain and range of motion limitations caused by scar tissue and musculoskeletal injuries. Overall, the graston technique has been studied in a variety of contexts and has demonstrated potential effects on range of motion, pain relief and musculoskeletal conditions. Some studies reported direct effects on specific outcomes, while others emphasised its potential when combined with other therapeutic interventions. These findings contribute to the understanding of the graston technique as a modality for soft tissue mobilisation and musculoskeletal disorders in the field of physio
62690774|NCT06634862|OTHER|Percussive Therapy Group|Percussive therapy has gained popularity in recent years as a potential intervention to alleviate muscle soreness and fatigue after exercise. This therapy involves the use of a mechanical system to provide percussive massage and its effectiveness in promoting recovery and reducing muscle soreness has been a topic of interest in the field of sports medicine and rehabilitation. Several studies have investigated the acute effects of percussive therapy on muscle recovery and pain, aiming to understand its potential benefits for athletes and individuals engaged in physical activities. Furthermore, the use of percussive therapy with resistance training has been shown to have acute effects on movement speed, suggesting the potential to influence exercise performance and recovery. These findings contribute to the understanding of how percussive therapy can influence muscle function and recovery processes. In the context of pain management, exercise therapy is advocated as an effective treatm
62690775|NCT06634862|NO_INTERVENTION|control group|In the control group, quadriceps fatigue protocol was applied, measurements were taken on two separate days and no intervention was made.
62690776|NCT06673875|EXPERIMENTAL|Aniball-inco|training muscles with vaginal device to excercise of pelvic floor muscle.
62690777|NCT06673875|ACTIVE_COMPARATOR|RHB|training muscles without device to excercise of pelvic floor muscle.
62690778|NCT05821894||Carotid Plaque Imaging Project (CPIP)|
62690779|NCT06644404|EXPERIMENTAL|Enavogliflozin 0.3mg, once daily|
62690780|NCT06644404|EXPERIMENTAL|Metformin 1,000mg, BID|
62690781|NCT06644404|EXPERIMENTAL|Glimepiride 2mg, once daily|
62690782|NCT01194544||population undergoing EGD in health examination.|
62322681|NCT06291220|EXPERIMENTAL|Part A: Cohort 1.2 ABBV-453 Dose B|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose B is achieved, during the 5 year study duration.
62322682|NCT06291220|EXPERIMENTAL|Part A: Cohort 1.3 ABBV-453 Dose C|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose C is achieved, during the 5 year study duration.
62322683|NCT06291220|EXPERIMENTAL|Part A: Cohort 1.4 ABBV-453 Dose D|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose D is achieved, during the 5 year study duration.
62690783|NCT03092193|EXPERIMENTAL|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
62131176|NCT02544880|EXPERIMENTAL|Tadalafil Placebo plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive placebo for Tadalafil, the Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
62131177|NCT02544880|OTHER|Control Group|For eligible participants who opt out of receiving study intervention. Participants in this group will receive SOC treatment only.
62131178|NCT03159273|EXPERIMENTAL|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
62322684|NCT06291220|EXPERIMENTAL|Part A: Cohort 1.5 ABBV-453 Dose E|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose E is achieved, during the 5 year study duration.
62322685|NCT06291220|EXPERIMENTAL|Part B: Cohort 2.1 ABBV-453 Dose E|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose E is achieved, during the 5 year study duration.
62322686|NCT06291220|EXPERIMENTAL|Part B: Cohort 2.2 ABBV-453 Dose E|Participants will no participate in the debulking period and receive escalating doses of ABBV-453, until the dose E is achieved, during the 5 year study duration.
62322687|NCT01414816||Group 1|
62322688|NCT05907967|ACTIVE_COMPARATOR|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62131179|NCT03159273|NO_INTERVENTION|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
62131180|NCT05437952|EXPERIMENTAL|Taurine and Exercise (Tau+Ex)|Participants who will receive 3g of taurine supplementation associated with physical training in the period of 16 weeks.
62131181|NCT05437952|EXPERIMENTAL|Placebo and Exercise (PL+Ex)|Participants who will receive 3g of placebo supplementation associated with physical training in the period of 16 weeks.
62322689|NCT05907967|SHAM_COMPARATOR|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62322690|NCT04868461|ACTIVE_COMPARATOR|Unheated whey protein (UWP)|"Participants are given a preload of 200 mL of unheated whey protein (UWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
62322691|NCT04868461|ACTIVE_COMPARATOR|Heated whey protein (HWP)|"Participants are given a preload of 200 mL of heated whey protein (HWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
62322692|NCT04868461|ACTIVE_COMPARATOR|Casein (Cas)|"Participants are given a preload of 200 mL of Casein (Cas) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
62482031|NCT03246763|EXPERIMENTAL|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
62322693|NCT04868461|PLACEBO_COMPARATOR|Water|The water has the same banana flavor and sweetness to match the protein beverages. Participants receive the same amount of water like protein beverages - 200mL.
62322694|NCT02325674||Metreleptin|"Metreleptin new-users~Metreleptin prevalent users"
62690784|NCT03092193|EXPERIMENTAL|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
62690785|NCT01462331|OTHER|VitaSugar/VitaFiber-IMO dose-1|A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
62690786|NCT01462331|OTHER|VitaSugar/VitaFiber-IMO dose-2|A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
62690787|NCT01462331|PLACEBO_COMPARATOR|Placebo|A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
61928305|NCT05587842|EXPERIMENTAL|Early weightbearing (as tolerated) Group|"At 0 weeks to 2 weeks post operation, subjects will be provided CAM (controlled ankle motion walking) boot and instructed to be non-weightbearing on the ankle, using crutches for assistance. During 2nd week, subject will visit clinic where staples/stitches will be removed, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given, passive/active range of motion out of boot will be allowed. Between 2 to 6 weeks, subject will continue with weightbearing as tolerated in orthosis, following range of motion instructions. After 6 weeks, the subject will continue with weightbearing as tolerated, and be weaned from orthosis.~At each follow-up visit, as part of the subject's standard of care, a physical examination and radiographic assessments will be completed, and that data collected for research purposes. Subject will also be requested to complete outcome questionnaires during their participation."
61928306|NCT05853575|EXPERIMENTAL|Adagrasib 600mg BID|Adagrasib 600mg BID without regard to food
61928307|NCT05853575|EXPERIMENTAL|Adagrasib 400mg BID|Adagrasib 400mg BID with food
61928308|NCT03984201|ACTIVE_COMPARATOR|iTBS over L-DLPFC to dACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the dorsal anterior cingulate cortex (dACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
62131182|NCT05437952|EXPERIMENTAL|Taurine (Tau)|Participants who will receive 3g of taurine supplementation in the period of 16 weeks.
62131183|NCT05437952|PLACEBO_COMPARATOR|Placebo (PL)|Participants who will receive 3g of placebo supplementation in the period of 16 weeks.
62131184|NCT03185650|OTHER|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
62131185|NCT03185650|OTHER|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
62322695|NCT01106534|PLACEBO_COMPARATOR|12 month DAPT arm|placebo + aspirin
62322696|NCT01106534|ACTIVE_COMPARATOR|30 month DAPT arm|clopidogrel + aspirin OR prasugrel + aspirin
62322697|NCT00320385|EXPERIMENTAL|Arm 1: Lapatinib plus Trastuzumab|Lapatinib 1000mg once daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly
62322698|NCT00320385|EXPERIMENTAL|Arm 2: Lapatinib|Lapatinib 1500mg once daily
62339858|NCT01255826|ACTIVE_COMPARATOR|Sustained lung inflation followed by CPAP|"Sustained pressure-controlled inflation using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel, Auckland, New Zealand).~This will be followed by early CPAP."
62339859|NCT01255826|ACTIVE_COMPARATOR|Conventional self inflating bag and mask ventilation|Intermittent bag and mask ventilation using a self-inflating bag with an oxygen reservoir.
62690788|NCT06209372||Group PENG (P)|Group PENG (P) received the PENG block with 20 mL of 0.25% bupivacaine under ultrasound guidance at preoperative care unit (PCU). The linear ultrasound probe for the PENG block was placed parallel to the imaginary line passing between the spina iliaca anterior inferior and the iliopubic eminence (IPE). The 80mm peripheral block needle was advanced with the in-plane technique, and the block was completed by injecting 20 mL of 0.25% bupivacaine.
62690789|NCT06209372||Group Control (C)|Group Control (C), patients who did not prefer the block were given 10 mg of IV bolus tramadol, followed by 10 mg/hr infusion at preoperative care unit (PCU).
62690790|NCT05027789|ACTIVE_COMPARATOR|Self-Guided Group|Subjects in this group will be provided education on memory support strategies and healthy lifestyles. Participants will decide how they want to implement this information into their daily lives. The study will also provide information on various commercially available digital and other tools that might help participants implement healthy changes their lives. One in every three participants will be enrolled in this group (selected randomly).
62690791|NCT05027789|ACTIVE_COMPARATOR|Structured Group|Subjects in this group will will be provided with specific recommended behavior targets (e.g., like how much exercise you should engage in each week). Participants will also receive an iPad to use throughout the study and follow up period with the digital application installed. Subjects will be asked to use the digital application to record their activity and to receive reminders to complete this information. Two in every three participants will receive the iPad and digital application. Participants in this group will receive training on how to use the digital application. The researchers can install the digital application on the subjects' personal iPad or smartphone if they prefer.
62339860|NCT04614116|OTHER|Biopsy without cold induction|Participants will undergo a fat biopsy after the first scan, without cooling
62690792|NCT04216550||Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
62482032|NCT03246763|EXPERIMENTAL|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
62690793|NCT06019494|EXPERIMENTAL|Low aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary with an aspiration flow rate of 0.42ml/sec.
62339861|NCT04614116|OTHER|Biopsy with cold induction|Participants will undergo a fat biopsy after the second scan, with cooling
62690794|NCT06019494|EXPERIMENTAL|High aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary with an aspiration flow rate of 0.62ml/sec.
62690795|NCT01418846||adult hematology patients|
62690796|NCT01418846||pediatric patients age 5-18years|
62690797|NCT01418846||adult pneumology patients|
62690798|NCT04570943|EXPERIMENTAL|Gabrinox followed by stereotactic radiotherapy|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
62690799|NCT02389738|EXPERIMENTAL|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
62690800|NCT06641622||delayed graft function|DGF was defined as a decrease in daily plasma creatinine of less than 10% from the previous day for 3 consecutive days within 1 week postoperatively, or if serum creatinine (SCr) did not decrease to 400 μmol/L within 1 week after surgery
62690801|NCT06641622||immediate graft function|Recipients who did not develop DGF were categorized as IGF
62690802|NCT05515575|EXPERIMENTAL|Niraparib|This study will utilize Simon's two-stage design: 16 patients will be enrolled in the first portion of this study. If 4 or more patients are progression-free at 12 weeks, an additional 16 patients will be enrolled for a total of n = 32 patients enrolled.
62690803|NCT04755387|OTHER|Ticagrelor 90mg|Standard strategy group receive ticagrelor 90mg twice daily
62690804|NCT04755387|EXPERIMENTAL|Ticagrelor 60/45mg|De-escalation strategy group receive ticagrelor 60 mg twice daily or 45mg twice daily if patients with body weight \<60kg, or age \>75 years old.
61928309|NCT03984201|ACTIVE_COMPARATOR|iTBS over L-DLPFC to sgACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the subgenual cingulate cortex (sgACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
61928310|NCT03984201|SHAM_COMPARATOR|Sham iTBS over L-DLPFC|"Participants will receive sham iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system.~Sham stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
61928311|NCT06745258||Veterans Participating in Lung Cancer Screening who Smoke|Veterans participating in lung cancer screening who smoke and are receiving care at participating VA medical centers
62339862|NCT01040208|EXPERIMENTAL|flibanserin 50 mg to 100 mg qhs|Patient to receive one tablet of flibanserin 50 mg and one tablet of flibanserin placebo qhs for 14 days then will receive 2 flibanserin tablets of 50 mg qhs
62339863|NCT01040208|EXPERIMENTAL|flibanserin 100 mg qhs|Patient to receive 2 flibanserin tablets of 50 mg qhs
62339864|NCT01040208|EXPERIMENTAL|placebo 2 tablets qhs|Patient to receive 2 placebo tablets of 50 mg qhs
62482033|NCT03246763|EXPERIMENTAL|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
62482034|NCT05911308|EXPERIMENTAL|Neoadjuvant therapy|Subjects with operable Non-Small Cell Lung Cancer received neoadjuvant durvalumab plus platinum doublet chemotherapy and neoadjuvant durvalumab plus platinum doublet chemotherapy in combination with abequolixron (RGX-104), an LXR/ApoE agonist.
62482035|NCT04118335|EXPERIMENTAL|Intervention Group|The individuals in the intervention group were asked to gargle with 5 ml black mulberry syrup three times a day after meals and wait average one minute in the mouth and then swallow, in addition to the standard practice of the clinic. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. The patients were followed for 15 days. The 15-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
62482036|NCT04118335|NO_INTERVENTION|Control Group|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
62482037|NCT03629054|EXPERIMENTAL|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
62482038|NCT03629054|EXPERIMENTAL|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
62482039|NCT01619904|EXPERIMENTAL|Goal-Directed Therapy|
62322699|NCT05489133|EXPERIMENTAL|Modified prolonged exposure (add on)|The psychological intervention modified Prolonged Exposure Therapy (mPE) is applied, in addition to Treatment as usual (TAU) (that is, an Add-on). mPE is a trauma-focused evidence-based cognitive behavioral therapy (CBT) shown to be effective in treating PTSD. We will use imaginal exposure in the sessions with the patient describing the traumatic event in detail while being recorded for later listening and homework, and in vivo exposure for visiting specific places or people. Psychoeducation and controlled breathing exercises play a secondary role in PE. We have adapted the mPE to the current SAC settings in Norway where nurses or social workers, not psychologist, as a rule are performing the psychosocial follow-up for rape victims. In this project we plan for three to five once or twice weekly nurse-/social worker-led mPE interventions, given early after the assault.
62482040|NCT01619904|ACTIVE_COMPARATOR|Standard Therapy|
62482041|NCT04479527|EXPERIMENTAL|the group of HAIC combined with carilizumab and apatinib mesylate treatment|"cTACE or DEBTACE+FOLFOX scheme HAIC, arterial chemotherapy scheme: OXA 65-85mg/m2 arterial H0-4 pump, calcium folinate 200mg/ m2 intravenous pump H2-4, 5-FU 1g-1.5g/ m2 arterial H4-24 pump, once every 6-8 weeks, the interventional treatment times are determined by researchers according to the patient's condition, and two times are adjacent.~Apatinib mesylate tablets, 250mg/ time, once a day. Take it about half an hour after a meal (the daily medication time should be as same as possible), and take it with warm boiled water.~Karelizumab, 200mg, was given intravenously for 30 minutes (including the flushing time, the whole infusion time was not shorter than 20 minutes and not longer than 60 minutes), and the medication period was q3w(±3 days)."
62482042|NCT04803487|EXPERIMENTAL|the Micro Hand S robot group|41 patients were randomly allocated in the Micro Hand S robot group and cholecystectomy was performed using the Micro Hand S robot.
62482043|NCT04803487|OTHER|the da Vinci robot group|41 patients were randomly allocated in the da Vinci robot group and cholecystectomy was performed using the da Vinci robot.
62482044|NCT05065281|EXPERIMENTAL|Education|Participants that have undergone the educational intervention
62482045|NCT05065281|NO_INTERVENTION|Waitlist|Participants still waiting to cross over to intervention arm
62131186|NCT02215707|EXPERIMENTAL|Group 1|"Group 1: 5 doses of 2.7x10\^5 PfSPZ Vaccine; homologous 3D7 CHMI~Grp 1 (n=15) gets 5 doses of 270,000 PfSPZ per dose (4 doses at 4 wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 and 2 start immunizations together.~1 subj in each of Grps 1 and 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/Grp 2 pilot subjects: 1st subject will be immunized, observed on site for minimum 1 hr; the 2nd subject may be immunized, will also be observed for minimum 1 hr. If no safety concerns are identified after 24 hrs that trigger the stopping rules, then rest of subjects in Grps 1 and 2 will be immunized.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (Pf3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
62482046|NCT02744287|EXPERIMENTAL|Arm 1: Phase 1 Dose Escalation|Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.
62322700|NCT05489133|NO_INTERVENTION|Treatment as usual (TAU)|Standard care at the sexual assault center (SAC), that is mostly nurse-/social worker-led psychoeducation at varying intervals and extent, and medical follow-up at the SAC.
62322701|NCT00430625|EXPERIMENTAL|VPRIV®-45 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
62322702|NCT00430625|EXPERIMENTAL|VPRIV®-60 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
62322703|NCT04286867|EXPERIMENTAL|Alcohol Moderation Group 1|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
62322704|NCT04286867|ACTIVE_COMPARATOR|Alcohol Moderation Group 2|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
62322705|NCT05746351|ACTIVE_COMPARATOR|epidural Bupivacaine with Dexmedetomidine in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with Dexmedetomidine 0.5 μg/ml
62322706|NCT05746351|ACTIVE_COMPARATOR|epidural Bupivacaine with fentanyl in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with fentanyl 2 μg/ml.
62690805|NCT03008213|EXPERIMENTAL|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
61928312|NCT06745258||Participating VA Medical Centers|Seven sites that have agreed to participate in implementation intervention
61928313|NCT03821935|EXPERIMENTAL|Dose Escalation: Cohort 1 Livmoniplimab|Various doses of Livmoniplimab administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).
61928314|NCT03821935|EXPERIMENTAL|Dose Escalation: Cohort 2 Livmoniplimab + Budigalimab|Various doses of Livmoniplimab + Budigalimab administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).
62322707|NCT05746351|ACTIVE_COMPARATOR|epidural Bupivacaine with Nalbuphine in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with 0.2 mg/ml Nalbuphine.
62322708|NCT04229446|EXPERIMENTAL|Receive the music based intervention|After the healthcare workers have accomplished the MBC program the eight week intervention program will be applied by the trained staff at the intervention wards. The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement. The movement will be adapted to their physical capacity.
62322709|NCT04229446|NO_INTERVENTION|Standard care group|Standard care for participants in this group
62322710|NCT02429427|EXPERIMENTAL|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
62322711|NCT02429427|PLACEBO_COMPARATOR|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
62322712|NCT00553917||1|Pregnant women currently taking Prozac for the treatment of depression
62322713|NCT00553917||2|Pregnant women currently taking Zoloft for the treatment of depression
62322714|NCT00553917||3|Pregnant women not currently using medication for the treatment of depression
62322715|NCT00553917||4|Pregnant women with no history of, symptoms of, or treatment for depression
62322716|NCT05588895|EXPERIMENTAL|Notification|The notification arm will have its CT scans interpreted and reported according to standard clinical practice. A standardized notification message using the EHR will be sent to the patient's Stanford affiliated non-EP cardiologist, if present, or the primary care clinician if there is no non-EP cardiologist. After a two week delay from notifying the patient's non-EP cardiologist or PCP, a standardized notification message will be sent to the patient. The message will include an image of the CAC from the chest CT. All communications will be signed by the Principal Investigator. Any treatment decisions will be made by the patient and their clinician.
62322717|NCT05588895|NO_INTERVENTION|Usual Care|"The usual care arm will have its CT scans interpreted and reported according to standard clinical practice. This may mention the presence of CAC in the official radiology imaging report, per usual practice. The usual care arm will not receive any notification beyond this standard of care.~We intend to notify patients in the usual care arm at the end of 6 months if we determine that notification is effective at increasing statin rates."
62322718|NCT04154267|EXPERIMENTAL|Intervention|In addition to the routine evaluation commonly carried-out at this post-transplant period, protocol biopsies will be performed at the 10th-week post-transplantation in high-risk transplant recipients. Biopsy fragments will be evaluated for tissue immune aggression (mainly cellular and antibody-mediated rejections) and other conditions such as infections, particularly polyomavirus and cytomegalovirus and medication toxicities.
62322719|NCT04154267|NO_INTERVENTION|Control|Patients will only undergo routine noninvasive evaluation at this post-transplant period
62322720|NCT04061980|EXPERIMENTAL|Arm I (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61928315|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 3 Livmoniplimab + Budigalimab|Participants with programmed cell death protein 1 (PD-1)-naïve pancreatic adenocarcinoma will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
61928316|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 4 Livmoniplimab + Budigalimab|Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
61928317|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 5 Livmoniplimab + Budigalimab|Participants with PD-1-naïve hepatocellular carcinoma (HCC) will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
62322721|NCT04061980|EXPERIMENTAL|Arm II (encorafenib, binimetinib, nivolumab) - CLOSED|Patients receive encorafenib PO QD and binimetinib PO BID as in arm I. Patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62322722|NCT00843297|ACTIVE_COMPARATOR|CG|Coolgard: invasive Cooling
62322723|NCT00843297|ACTIVE_COMPARATOR|AS|ArcticSun: Surface-Cooling
62322724|NCT00843297|SHAM_COMPARATOR|UnCOOL|No Cooling-Therapy due to non-operational cooling-devices
62322725|NCT06221631||Group 1: Healthy Controls|Healthy individuals with a predefined healthy lifestyle (s. inclusion/exclusion criteria), without any progressive disease or any neurological disorder (aside from primary headaches)
62322726|NCT06221631||Group 2: Patients with Multiple Sclerosis|Patients with MS with a similar healthy lifestyle (s. inclusion/exclusion criteria), who are able to walk without more than one-sided walking aid (max. EDSS of 6 points), no relapse activity in the last 6 months, without any other progressive disease or other neurological disorder (aside from primary headaches)
62131187|NCT02215707|EXPERIMENTAL|Group 2|"Grp 2: 5 doses of 2.7x10\^5 PfSPZ Vaccine; heterologous 7G8 CHMI~Grp 2 (n=15) gets 5 doses of 270,000 PfSPZ/dose (4 doses at 4wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 / 2 start immunizations together.~1 subj in each of Grps 1 / 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/ 2 pilot subj: 1st subj will be immunized, observed on site for min 1 hr; 2nd subj may be immunized, will also be observed for min 1 hr. If no safety concerns after 24 hrs that trigger stopping rules, then rest of Grps 1 / 2 will be immunized.~Approx 3 wks after final dose, Grps 1/3 have homologous CHMI; 2-3 days later, Grp 2 will undergo heterologous CHMI (Pf7G8) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1/3 have 2nd homologous CHMI; 2-3 days later, Grp 2 will undergo 2nd heterologous CHMI (7G8 strain) with 6 Infectivity Controls. Subj will be followed for 8 wks after last CHMI for safety purposes."
62322727|NCT02146989||Cerebral Palsy|Children and adolescents with spastic unilateral Cerebral Palsy (with perinatal acquired hypoxic ischemic incidents), aged 7 to 18 years, MACS levels I-III.
62322728|NCT02146989||Healthy controls|Children and adolescents without Cerebral Palsy
62322729|NCT02543398|OTHER|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
62322730|NCT02543398|OTHER|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
62690806|NCT03211858|EXPERIMENTAL|SAR341402|SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
62690807|NCT03211858|ACTIVE_COMPARATOR|NovoLog/NovoRapid|NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.
61928318|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 6 Livmoniplimab + Budigalimab|Participants with PD-1-ref head and neck squamous cell carcinoma (HNSCC) will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
61928319|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 7 Livmoniplimab + Budigalimab|Participants with PD-1-naïve microsatellite stable colorectal cancer (MSS-CRC) \[unselected\] will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
61928320|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 8 Livmoniplimab + Budigalimab|Participants with non-small cell lung cancer (NSCLC) \[programmed death ligand 1 (PDL1) relapsed/refractory (R/R)\] will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
61928321|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 10A Livmoniplimab + Budigalimab|Participants with microsatellite stable colorectal cancer (MSS-CRC) \[consensus molecular subtype 4 (CMS4) enriched\] will receive livmoniplimab at the dose B Q3W plus budigalimab Dose B administered Q3W.
61928322|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 10B Livmoniplimab + Budigalimab|Participants with MSS-CRC (CMS4 enriched) will receive livmoniplimab at the dose C Q3W plus budigalimab Dose B administered Q3W.
61928323|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 11A Livmoniplimab + Budigalimab|Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the Dose B Q3W plus budigalimab Dose B administered Q3W.
61928324|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 11B Livmoniplimab + Budigalimab|Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the Dose C Q3W plus budigalimab Dose B administered Q3W.
61928325|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 11C Budigalimab|Participants with PD-1-ref urothelial cancer will receive budigalimab Dose B administered Q3W.
61928326|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 12A Livmoniplimab + Budigalimab|Participants with PD-1-naïve ovarian granulosa (OG) cell tumors will receive livmoniplimab at the Dose B Q3W plus budigalimab Dose B administered Q3W.
61928327|NCT03821935|EXPERIMENTAL|Dose Expansion: Cohort 12B Livmoniplimab + Budigalimab|Participants with PD-1-naïve ovarian granulosa (OG) cell tumors will receive livmoniplimab at the Dose C Q3W plus budigalimab Dose B administered Q3W.
61928328|NCT02307617||Group 2|Adolescent participants who plan to start selective serotonin reuptake inhibitor (SSRI) treatment for their depression. Data will be collected prior to the start of the medication and again 6 weeks after the start of the medication.
61928329|NCT02307617||Medication Responders|Adolescent participants who have responded to SSRI treatment for their depression.
62690808|NCT02848027|EXPERIMENTAL|Regenexx-SD procedure|Measure components of knee synovial fluid collected 2-4 days before and after Regenexx SD procedure
62690809|NCT01933152||Group 1|
62690810|NCT03366259|ACTIVE_COMPARATOR|Group A (Misoprostol group)|200 mcg rectal Misoprostol administration before cesarean section
62690811|NCT03366259|PLACEBO_COMPARATOR|Group B (control group)|No prostaglandins administration before cesarean section
61928330|NCT02307617||Medication Non-Responders|Adolescent participants with depression that has not responded to SSRI treatment.
61928331|NCT02307617||Healthy Controls|Adolescent participants who have no current or past mental health diagnoses.
61928332|NCT03538678|EXPERIMENTAL|Kwit app|Use of Kwit smartphone app
61928333|NCT03538678|NO_INTERVENTION|Standard of care|Patient initiated follow-up post discharge
61928334|NCT06091020|EXPERIMENTAL|NT 201|Subcutaneous injections of up to 300 units NT 201 into the peripheral neuropathic pain area
61928335|NCT06091020|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of placebo into the peripheral neuropathic pain area
61928336|NCT02234934|EXPERIMENTAL|Lentiviral G1XCGD Gene Therapy, Part A|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after myeloreductive conditioning
61928337|NCT02234934|EXPERIMENTAL|Lentiviral G1XCGD Gene Therapy, Part B|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after modified myeloreductive conditioning including increased monitoring and rescue treatment
61928338|NCT05240534|PLACEBO_COMPARATOR|Control group (ET-Text)|Participants will receive ElderTree on a laptop.
62690812|NCT01681875|EXPERIMENTAL|0.8 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)"
62690813|NCT01681875|EXPERIMENTAL|0.26 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar"
62690814|NCT01681875|EXPERIMENTAL|0.12 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar"
62690815|NCT01681875|EXPERIMENTAL|0.07 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar"
62690816|NCT01681875|EXPERIMENTAL|0.03 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar"
61928339|NCT05240534|EXPERIMENTAL|Experimental group (ET-Voice)|Participants will receive ElderTree on a smart system.
61928340|NCT06745609|NO_INTERVENTION|Control group|Participants in the control group are scheduled for surgery in compliance with the Danish cancer patient pathway guarantees (within 14 days).
62322731|NCT06692712|EXPERIMENTAL|MELPIDA Treatment|Eligible subjects (N=8) will receive a single open-label intrathecal administration of MELPIDA and follow up to week 260.
62322732|NCT06692712|NO_INTERVENTION|Matched Prospective Concurrent Control Arm|Approximately 16 untreated age- and disease- matched controls with confirmed AP-4-related disease (SPG47, SPG50, or SPG52) will be enrolled and attend study visits concurrent with the MELPIDA treatment arm.
62322733|NCT06682962|SHAM_COMPARATOR|Sham group|"0µA to therapy amplitude, ramping up in 30 seconds; directly followed by 0µA stimulation for 30 minutes.~Stimulation will be performed once per week, for 30 minutes, for 18 months."
62322734|NCT06682962|EXPERIMENTAL|TES group|"0µA to therapy amplitude, ramping up in 30 seconds; directly followed by stimulation with the therapy amplitude for 30 minutes.~Stimulation will be performed once per week, for 30 minutes, for 18 months."
62322735|NCT02684240|EXPERIMENTAL|Nitazoxanide|Participants with drug-sensitive tuberculous randomized to the NTZ arm will receive nitazoxanide 1000 mg po twice daily for 14 days. After this time point, participants will be switched to WHO standard tuberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol.
62322736|NCT02684240|OTHER|Control|Participants with drug-sensitive tuberculosis randomized to the standard therapy arm will receive WHO standard tuberculosis therapy involving isoniazid 300 mg po daily, rifampin 600 mg po daily, pyrazinamide 25 mg/kg po daily and ethambutol 15 mg/kg po daily.
62322737|NCT02797106||health care professionals|health care professionals potentially involved in assessment and/or treatment of drooling in children with Cerebral Palsy.
62322738|NCT00833248|EXPERIMENTAL|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
62322739|NCT00833248|ACTIVE_COMPARATOR|Goserelin (3.6 mg) + bicalutamide (50 mg)|"On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively."
62690817|NCT01681875|EXPERIMENTAL|0.04 mg nicotine with 13 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar"
61928341|NCT06745609|EXPERIMENTAL|Intervention with Pre-KiT prehabilitation|Participants in the intervention group are scheduled for surgery after four weeks of Pre-KiT prehabilitation. The prehabilitation consists of a geriatric guided assessment with relevant targeted interventions, a home exercise program and assisted smoking cessation.
61928342|NCT05752266|EXPERIMENTAL|Probiotic Arm|Participants allocated to PRO arm will be administered personalized probiotic pills.
61928343|NCT05752266|PLACEBO_COMPARATOR|Placebo Arm|Participants allocated to PRO arm will be administered maltodextrin placebo pills similar in appearance to probiotic pills.
62322740|NCT02834312|EXPERIMENTAL|2.5 mg estetrol|
62322741|NCT02834312|EXPERIMENTAL|5 mg estetrol|
62322742|NCT02834312|EXPERIMENTAL|10 mg estetrol|
62322743|NCT02834312|EXPERIMENTAL|15 mg estetrol|
62322744|NCT02834312|PLACEBO_COMPARATOR|placebo|
62322745|NCT04718987|EXPERIMENTAL|Prostate Cancer Patients|Low- or favourable intermediate-risk prostate cancer patients
62690818|NCT01681875|OTHER|Usual brand|"very low nicotine content cigarettes~Usual brand cigarettes (control condition)"
62690819|NCT03228732|PLACEBO_COMPARATOR|Placebo 1|"Visit 1:~Study Day 1: Hyperinsulinemia/ euglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
62690820|NCT03228732|PLACEBO_COMPARATOR|Placebo 2|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
61928344|NCT01177332|EXPERIMENTAL|Fasted|Two-hour cycling test, fasted condition
61928345|NCT01177332|OTHER|Glucose-fed|Two-hour cycling test, glucose-fed condition
61928346|NCT04082559|OTHER|Antibiotic treatment|"Patients with active disease will be randomized and will receive a prescription for one of two antibiotic regimens.~1. Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks~2. Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks"
62322746|NCT00953550|EXPERIMENTAL|Rocuronium-Sugammadex|
62322747|NCT00953550|ACTIVE_COMPARATOR|Succinylcholine|
62322748|NCT00844428|EXPERIMENTAL|Eculizumab|
62322749|NCT00668343|ACTIVE_COMPARATOR|1|
62322750|NCT00668343|PLACEBO_COMPARATOR|2|
62322751|NCT02214199|ACTIVE_COMPARATOR|Exercise Therapy|Home exercises for 30 minutes (2/weeks) with muscle stretching and strengthening the shoulder girdle.
62322752|NCT02214199|EXPERIMENTAL|Manipulative Therapy Techniques|Lift Technique for mid-thoracic spine. Mobilization by low cervical spine on the upper lateral thoracic translation. Technical Dog flexion for high thoracic spine (T1-T4). Technical Dog flexion for mid-thoracic spine (T5-T8). Technical Dog flexed to low thoracic spine (T9-T12). Direct drive technology prone to mid-thoracic spine.
62482047|NCT02744287|EXPERIMENTAL|Arm 2: Phase 2 Dose Expansion|Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.
62322753|NCT03023644|EXPERIMENTAL|Cogmed Working Memory Training|The group randomized to the intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the children's responses, time spent on each task, and evolution curves.
62482048|NCT06733675|EXPERIMENTAL|Part 1|Part 1 will enroll at least 16 participants who will receive a single oral dose of ceftibuten and ledaborbactam etzadroxil following a 10-hour fast on 3 occasions in a fixed sequence: (a) Ceftibuten and ledaborbactam etzadroxil as separate capsules; (b) Ceftibuten-ledaborbactam etzadroxil as fixed-dose combination capsules; (c) Ceftibuten-ledaborbactam etzadroxil as fixed-dose combination capsules after 5 days of esomeprazole orally once daily
62131188|NCT02215707|EXPERIMENTAL|Group 3|"Grp 3 (n=15) will receive 3 doses by DVI of 450,000 PfSPZ/dose (of PfSPZ Vaccine) at 8 wk intervals (starting approx. 4 wks after Grps 1 and 2 get 1st immunization).~3 subjects in Grp 3 will be immunized approx 24 hrs prior to rest of grp (pilot subjects). The 3 subjects will be immunized sequentially with min 2 hr observation period between subjects (and a 2 hr observation of 3rd subject as well). If no safety concerns identified in pilot subjects after 24 hours that trigger the stopping rules, the rest of subjects in Grp 3 will be immunized as scheduled.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
62690821|NCT03228732|ACTIVE_COMPARATOR|Fluoxetine|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine~Visit 2:~same as visit 1"
62131189|NCT02215707|NO_INTERVENTION|CHMI Controls.1|n = 6, infectivity controls for 1st homologous CHMI (3D7) occurring approximately 3 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
62131190|NCT02215707|NO_INTERVENTION|CHMI Controls.2|n = 6, infectivity controls for 1st heterologous CHMI (7G8) occurring approximately 3 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
62131191|NCT02215707|NO_INTERVENTION|CHMI Controls.3|n = 6, infectivity controls for 2nd homologous CHMI (3D7) occurring approximately 24 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
62322754|NCT03023644|NO_INTERVENTION|Standard of Care|Children randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, a child in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like children assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
62322755|NCT00540449|ACTIVE_COMPARATOR|Efavirenz|Efavirenz 600mg once daily for 96 weeks
62322756|NCT00540449|EXPERIMENTAL|TMC278|TMC278 25 mg tablet once daily for 96 weeks
62322757|NCT03613090|EXPERIMENTAL|Collagen-hydroxyapatite Scaffold (Syn-Oss)|Placement of a collagen-hydroxyapatite scaffold (Syn-Oss), placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material).
62322758|NCT03613090|ACTIVE_COMPARATOR|Collagen Scaffold (Colla-Plug)|Placement of a collagen scaffold (Colla-Plug) over a blood clot, placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material). The Colla-Plug material is placed adjacent to the blood clot that has formed inside the root canal space. It act as a matrix for the subsequent placement of the mineral trioxide aggregate material. It has been used as the standard of care in regenerative endodontics since 2004.
62322759|NCT00668291||CNC|Primary pigmented nodular adrenocortical disease (PPNAD) and the Carney complex (CNC)
62322760|NCT00668291||MC-L|cardiac myxoma or isolated lentiginosis
62131192|NCT02215707|NO_INTERVENTION|CHMI Controls.4|n = 6, infectivity controls for 2nd heterologous CHMI (7G8) occurring approximately 24 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
62322761|NCT04337450|ACTIVE_COMPARATOR|SOC|Standard-of-care (SOC)
62322762|NCT04337450|EXPERIMENTAL|DTG/3TC|Dolutegravir (DTG) and lamivudine (3TC) (known as DTG/3TC)
62322763|NCT03978494|EXPERIMENTAL|Period 1: Advagraf®; Period 2: Generic tacrolimus|In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.
62322764|NCT03978494|EXPERIMENTAL|Period 1: Generic tacrolimus; Period 2: Advagraf®|In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.
62322765|NCT01736202|ACTIVE_COMPARATOR|Palm oil orally|oral fat load
62482049|NCT06733675|EXPERIMENTAL|Part 2 Group 1|Part 2 Group 1 will enroll 10 participants. Each will receive oral doses of Ceftibuten-ledaborbactam etzadroxil as fixed-dose capsules for 7 days (Fasted Group)
62482050|NCT06733675|EXPERIMENTAL|Part 2 Group 2|Part 2 Group 2 will enroll 10 participants. Each will receive oral doses of Ceftibuten-ledaborbactam etzadroxil as fixed-dose capsules for 7 days (Fed Group)
62131193|NCT06137105||Group 1|Group I : Romiplostim and Eltrombopag
62131194|NCT06137105||Group 2|Group II : recived corticosteroid.
62131195|NCT01222039|EXPERIMENTAL|Conventional treatment plus high dose: 3x10e6 cells / Kg.|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
62690822|NCT03228732|ACTIVE_COMPARATOR|DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with DHEA~Visit 2:~same as visit 1"
62690823|NCT03228732|ACTIVE_COMPARATOR|Fluoxetine and DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine and DHEA~Visit 2:~same as visit 1"
62690824|NCT06425341|EXPERIMENTAL|HRS-5635 Injection dose 1|
62690825|NCT06425341|EXPERIMENTAL|HRS-5635 Injection dose 2|
62690826|NCT06425341|EXPERIMENTAL|HRS-5635 Injection dose 3|
62690827|NCT06425341|EXPERIMENTAL|HRS-5635 Injection dose 4|
61928347|NCT04082559|OTHER|Combination therapy (Antibiotics + diet)|"1. Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks.~2. Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks."
62322766|NCT01736202|ACTIVE_COMPARATOR|Canola oil orally|Oral fat load
62322767|NCT01736202|PLACEBO_COMPARATOR|Water orally|oral water administration as control
62482051|NCT06733675|EXPERIMENTAL|Part 2 Group 3|Part 2 Group 3 will possibly enroll 10 participants. Following availability of PK and safety data from Groups 1 and 2, a determination will be made regarding whether or not Group 3 is needed and the dosing conditions that apply
61928348|NCT04082559|OTHER|Nutritional prevention|"Patients in clinical remission will be recruited to a dietary prevention study.~1. Mediterranean diet~2. Control- based on the American Dietetic Association recommendations for patients with IBD~3. Personalized nutrition group- based on prior results from study- NCT02858557"
61928349|NCT02957565|EXPERIMENTAL|Video 1: No EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
61928350|NCT02957565|EXPERIMENTAL|Video 1: No EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
61928351|NCT02957565|EXPERIMENTAL|Video 2: With EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
61928352|NCT02957565|EXPERIMENTAL|Video 2: With EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
61928353|NCT04620759|EXPERIMENTAL|Psilocybin Treatment|Participants will be administered 25mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.
61928354|NCT04620759|PLACEBO_COMPARATOR|Placebo|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.
61928355|NCT04826003|EXPERIMENTAL|Part I: Dose-escalation of RO7122290|The dose-escalation of RO7122290 will use a QW dosing schedule of RO7122290 in combination with a Q3W dosing interval for cibisatamab with obinutuzumab pre-treatment. The starting dose for RO7122290 will be 35 mg, which represents the human equivalent dose for the minimal pharmacologically active dose (1 mg/kg) in mice.
61928356|NCT04826003|EXPERIMENTAL|Part II: Dose-expansion of RO7122290|Part II of this study will evaluate selected dose levels of RO7122290 from Part I (a QW RO712290 administration in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment) in a Q3W regimen in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment.
61928357|NCT05997680|EXPERIMENTAL|Yoga group|Participants with CHD undergoing neurodevelopmental assessments and benefiting from the 8-week yoga intervention in addition to standard of care.
62131196|NCT01222039|EXPERIMENTAL|Conventional treatment plus low dose: 1x10e6 cells / Kg|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
62131197|NCT01193894|EXPERIMENTAL|Profermin|
62131198|NCT01193894|ACTIVE_COMPARATOR|Fresubin|
62322768|NCT00628511||observation|
62690828|NCT06189365||Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
62690829|NCT04804345||The aprotinin group,|all patients receiving a first infusion 1M KIU before surgical incision followed by a steady dose of 250 000 KIU/h with an additional dose of 1M KIU added to the cardiopulmonary bypass unit.
62322769|NCT06039254|EXPERIMENTAL|Healthy subjects group|
62322770|NCT06039254|EXPERIMENTAL|Mild renal impairment group|
62322771|NCT06039254|EXPERIMENTAL|Moderate renal impairment group|
62322772|NCT02005653|EXPERIMENTAL|DEC + ALB sequential|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
62690830|NCT04804345||The tranexamic acid group|all patient receiving tranexamic acid following each local center standarded protocol
62690831|NCT05811013|EXPERIMENTAL|Transcranial static magnetic field stimulation (tSMS)|Transcranial static magnetic field stimulation (tSMS) will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months.
62690832|NCT05811013|SHAM_COMPARATOR|Sham tSMS|Sham Transcranial static magnetic field stimulation (tSMS) Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain). Real and sham magnets will be held with an ergonomic helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
62690833|NCT05892393|EXPERIMENTAL|Cohort A ([89Zr]DFO-YS5, single scan|Participants receive \[89Zr\]DFO-YS5 IV and undergo a single PET/CT or PET/MRI scan 5-7 days post-injection. Participants also receive fludeoxyglucose F-18 IV and undergo PET/CT or PET/MRI scan within 28 days prior to day 1
62322773|NCT02005653|EXPERIMENTAL|DEC + ALB co-admin|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
62482052|NCT02415127|EXPERIMENTAL|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
62482053|NCT02415127|PLACEBO_COMPARATOR|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
62322774|NCT02005653|EXPERIMENTAL|DEC + DOXY co-admin|Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
62322775|NCT02005653|ACTIVE_COMPARATOR|Diethylcarbamazine (DEC)|Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days
62322776|NCT01783522|EXPERIMENTAL|Arm I (preventative nutritional supplementation)|Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
62322777|NCT01783522|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
62322778|NCT02024711|EXPERIMENTAL|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
62322779|NCT02024711|ACTIVE_COMPARATOR|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
62322780|NCT06692049||Disorders of Sex Development (DSD)|The study seeks to find out if removing gonadal tissue in adolescents and children at risk for losing fertility potential (the ability to have children) and who are scheduled to receive a gonadectomy (removal of gonads) for clinical purposes may preserve, or keep, their ability to have children in the future. Additionally, donated research tissue would be used to study long-term ways to preserve and restore reproductive function of children diagnosed with DSD
62322781|NCT05402501||Patients with multiple sclerosis (MS)|Patients will participate in an online lifestyle program organized by Voeding Leeft, which consists of four main topics: diet, physical activity, relaxation and sleep.
62322782|NCT01911182|EXPERIMENTAL|Inhalation of low concentration of CO2|
62322783|NCT01911182|ACTIVE_COMPARATOR|caffeine only|
62322784|NCT01356602|EXPERIMENTAL|Canakinumab, pre-filled syringes (PFS)|Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
62322785|NCT01356602|ACTIVE_COMPARATOR|Canakinumab, lyophilizate (LYO)|The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
62322786|NCT01356602|ACTIVE_COMPARATOR|Triamcinolone Acetonide|The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
62322787|NCT04770337|SHAM_COMPARATOR|Sham treatment|Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.
62322788|NCT04770337|EXPERIMENTAL|STARSTIM device treatment|Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.
62322789|NCT04070378|EXPERIMENTAL|Open-label Treatment|This is an open-label pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease. During the treatment phase, eligible subjects will receive daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion over 3-5 minutes (15 mL) once weekly for 8 weeks followed by daratumumab SC 1800 mg every 2 weeks for 16 weeks.
62322790|NCT05024045|EXPERIMENTAL|LOXO-338 (Monotherapy)|LOXO-338 administered orally.
62322791|NCT05024045|EXPERIMENTAL|LOXO-338 + Pirtobrutinib (Combination)|LOXO-338 administered orally in combination with pirtobrutinib
62322792|NCT00016523|EXPERIMENTAL|Inhaled Nitric Oxide|Inhaled Nitric Oxide
62322793|NCT00016523|ACTIVE_COMPARATOR|Placebo|Inhaled Oxygen
62322794|NCT04520113|ACTIVE_COMPARATOR|Standard Tracing|"Households of tuberculosis index patients receive standard household contact tracing during regular weekday business hours."
62322795|NCT04520113|EXPERIMENTAL|Holiday Tracing|Households of tuberculosis index patients in rural South Africa receive household contact tracing during holidays (Christmas and Easter).
62482054|NCT05432817|EXPERIMENTAL|Cognitive Processing Therapy (CPT) group|Participant groups to receive CPT to treat PTSD
62131199|NCT05946421||Severe Asthma patients on biologics|
62322796|NCT04520113|EXPERIMENTAL|Evening / Weekend Tracing|Households of tuberculosis index patients in urban South Africa receive household contact tracing during evenings and weekends.
62322797|NCT01605071|ACTIVE_COMPARATOR|Early Postmenopausal|Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy
62322798|NCT01605071|ACTIVE_COMPARATOR|Late Postmenopausal|Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy
62322799|NCT03115489|PLACEBO_COMPARATOR|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
62482055|NCT05432817|NO_INTERVENTION|Waitlist Control|Participant groups will provide data as a control group first, and will then receive CPT to treat PTSD
62690834|NCT05892393|EXPERIMENTAL|Cohort B ([89Zr]DFO-YS5, multiple scans|Participants receive \[89Zr\]DFO-YS5 IV and undergo four PET/CT or PET/MRI scans on days 1, 2, 3-4, and 5-7 post-injection. Participants also receive fludeoxyglucose F-18 IV and undergo PET/CT or PET/MRI scan within 28 days prior to day 1
62690835|NCT06673719|EXPERIMENTAL|SPECT/CT or HRM-NDT|
62131200|NCT05946421||Healthy controls|
62131201|NCT05447871|EXPERIMENTAL|Ultrasound guided single injection modified 4 in 1 block technique|Patients in this group will receive ultrasound guided single injection modified 4 in 1 block with 25 ml bupivacaine 0.25%
62482056|NCT06742177|ACTIVE_COMPARATOR|Group Bi-level ESPB|The block procedure is performed immediately before surgery begins after general anesthesia induction, with the patient in the lateral decubitus position. For the block, sterile conditions are provided with USG, and the erector spinae muscle and vertebral process are visualized, and the in plane technique is used. The target vertebral level for bi-level ESPB is two levels, T5 and T7. The block needle is advanced in the caudo-cranial direction, and the potential area between the erector spinae muscle and the transverse process of the relevant vertebra is targeted. The block location is confirmed by injecting 2 ml of saline between the transverse process and the muscle. After the block location is confirmed, a total of 40 ml of 0.25% bupivacaine is applied, using 20 ml of 0.25% bupivacaine for a single level.
62482057|NCT06742177|ACTIVE_COMPARATOR|Group M-TAPA Block|The procedure is performed in the supine position immediately before surgery after general anesthesia induction and the in plane technique is used. The transversus abdominis, internal oblique and external oblique muscles are identified at the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. The block needle is advanced in the caudo-cranial direction and a deep angle is given with the probe in the sagittal direction to the costochondral angle at the edge of the 10th rib to visualize the lower surface of the costal cartilage in the midline. The block location is confirmed by injecting 2 ml of saline onto the transverse abdominis muscle under the 10th costal cartilage. After the block location is confirmed, 20 ml of 0.25% bupivacaine is used. This procedure is repeated for the opposite side and a total of 40 ml of 0.25% bupivacaine is used.
62482058|NCT01783366|NO_INTERVENTION|CONTROL|In the control group (Group A) inserting the lubricated NG tube through the nostril, at that time head maintained in the neutral position.
62482059|NCT01783366|ACTIVE_COMPARATOR|tube-exchanger|The tube-exchanger group (Group B) made use of tube-exchanger G36402 (CAEC, \[cook medical, Bloomington, IN\]) as a stylet that was lubricated and inserted within 20-F NGT until the tip of the tube-exchanger was at the tip of the NGT
62482060|NCT05947084|EXPERIMENTAL|Study Formula 1_365 Day Grass-Fed Cow's Milk Infant Formula|Infant formula meets all nutrient requirements of the FDA.
62482061|NCT05947084|EXPERIMENTAL|Study Formula 2_Goat Milk Infant Formula|Infant Formula meets all nutrient requirements of the FDA.
62482062|NCT05947084|EXPERIMENTAL|Study Formula 3_Cow's Milk Infant Formula void of A1-BetaCasein|Infant Formula meets all nutrient requirements of the FDA.
62482063|NCT05947084|ACTIVE_COMPARATOR|Study Formula 4_USDA Organic iron fortified infant formula|Infant Formula meets all nutrient requirements of the FDA.
62690836|NCT06017986|EXPERIMENTAL|Stimulus: UPF1|In a whole room metabolic chamber participants will consume a \~300 kcal meal consisting of ultra-processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
62690837|NCT06017986|EXPERIMENTAL|Stimulus: UPF2|In a whole room metabolic chamber participants will consume a \~300 kcal meal consisting of ultra-processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
62690838|NCT06017986|EXPERIMENTAL|Stimulus: UPF3|In a whole room metabolic chamber participants will consume a \~300 kcal meal consisting of ultra-processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
62131202|NCT05447871|ACTIVE_COMPARATOR|Ultrasound guided adductor canal block technique|Patients in this group will receive ultrasound guided aduuctor canal block with 20 ml bupivacaine 0.25%
62131203|NCT02233595||Adjuvant chemotherapy|
62322800|NCT03115489|ACTIVE_COMPARATOR|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
62322801|NCT06693908|EXPERIMENTAL|Vixarelimab|Participants will receive subcutaneous (SC) injections of vixarelimab during the treatment period.
62322802|NCT03566108|EXPERIMENTAL|VISTA|VISTA incision with CAF and ADM
62482064|NCT06743386|EXPERIMENTAL|EUS-Guided Radiofrequency Ablation (RFA)|Therapeutic procedure that combines endoscopic ultrasound (EUS) with radiofrequency ablation technology according to the practices of the investigating center
62482065|NCT01050556|PLACEBO_COMPARATOR|Placebo|Placebo daily
62482066|NCT01050556|EXPERIMENTAL|Folic Acid 400 ug|400 µg folic acid daily
62131204|NCT03390296|EXPERIMENTAL|Arm A (anti-OX40 antibody PF-04518600)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62322803|NCT03566108|ACTIVE_COMPARATOR|Sulcular Tunnell access|Sulcular tunnel surgery with CAF and ADM
62322804|NCT00542685|EXPERIMENTAL|PD 0332334 300 mg BID|
62482067|NCT01050556|EXPERIMENTAL|Folic Acid 800 ug|800 µg folic acid daily
62482068|NCT01050556|EXPERIMENTAL|Creatine|creatine daily
62482069|NCT01050556|EXPERIMENTAL|Creatine + Folic Acid|creatine + folic acid daily
62131205|NCT03390296|EXPERIMENTAL|Arm B (azacitidine, venetoclax, GO)|Patients receive azacitidine IV over 10-40 minutes or via injection SC on days 1-7 or 1-5 and 8-9. Patients also receive venetoclax PO on days 1-28 and GO IV over 2 hours on day 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62322805|NCT00542685|PLACEBO_COMPARATOR|Placebo BID|
62322806|NCT00542685|EXPERIMENTAL|PD 0332334 225 mg BID|
62322807|NCT00542685|EXPERIMENTAL|PD 0332334 175 mg BID|
62482070|NCT06743269|EXPERIMENTAL|High-Resistance Inspiratory Muscle Strength Training Group|Subjects will partake in 5 sets of 6 inspiratory maneuvers (total: 30 maneuvers/session) 6 days a week for 6 weeks using the POWERbreathe K3 device to monitor adherence.
62690839|NCT06017986|ACTIVE_COMPARATOR|Stimulus: MPF1|In a whole room metabolic chamber participants will consume a \~300 kcal meal consisting of minimally processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
62690840|NCT06017986|ACTIVE_COMPARATOR|Stimulus: MPF2|In a whole room metabolic chamber participants will consume a \~300 kcal meal consisting of minimally processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
62690841|NCT06017986|ACTIVE_COMPARATOR|Stimulus: MPF3|In a whole room metabolic chamber participants will consume a \~300 kcal meal consisting of minimally processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
62690842|NCT01831336||Orsiro DES|
62690843|NCT02228330|EXPERIMENTAL|uni-lateral obturator nerve block|"Patients scheduled for TUR for bladder tumor Intervention: uni-lateral obturator nerve block.~non-blocked obtorator side of each patient will be used as control"
62690844|NCT06657612||Bifid median nerve|Patients (diagnosed with carpal tunnel syndrome) with bifid median nerve
62690845|NCT06657612||Control group|Patients (diagnosed with carpal tunnel syndrome) with normal median nerve
61928358|NCT05997680|NO_INTERVENTION|Waitlist control group|Participants with CHD undergoing neurodevelopmental assessments at the same time as the yoga group participants and benefiting from standard of care only during the 8 weeks of the intervention. The yoga intervention will be made available to all waitlist control group participants once their trial wave is completed.
61928359|NCT06744842|EXPERIMENTAL|Genicular Nerve Block Group|A nerve block will be performed on 22 patients using lidocaine injection under ultrasound guidance. After obtaining informed consent, the procedure will be carried out following sterilization, with 2% lidocaine hydrochloride injected at a total volume of 6 mL, distributed as 2 mL for each of the superomedial, superolateral, and inferomedial branches of the genicular nerve. After the injection, bleeding control will be performed, and the procedure will be concluded. All ultrasound-guided injections will be performed by a single physician, and the examination, investigations, treatment, and clinical evaluations of the patients will be conducted by the physicians participating in the study.
61928360|NCT06744842|ACTIVE_COMPARATOR|Exercise group|"Exercise group:~A home exercise program will be provided, including isometric strengthening exercises for the quadriceps muscles and stretching exercises for the hamstring muscles."
61928361|NCT06743581|EXPERIMENTAL|Neoadjuvant cemiplimab and dupilumab combination therapy|Neoadjuvant immunotherapy administered prior to thoracic surgery
61928362|NCT05605093|EXPERIMENTAL|S-217622 (ensitrelvir) plus standard of care (SOC)|Study investigational agent (ensitrelvir) will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
61928363|NCT05605093|PLACEBO_COMPARATOR|placebo plus standard of care (SOC)|Study investigational placebo will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
62690846|NCT04582487|OTHER|Biological evaluation|A combined approach of Drug Sensitivity and Resistance Profiling (DSRP) and molecular-cytogenetic findings is used in order to prioritize compounds for tailored therapies.
62690847|NCT05018728|EXPERIMENTAL|Voxelotor|Children with sickle cell anemia taking voxelotor for 12 weeks.
61928364|NCT06744062|EXPERIMENTAL|BR1015|
61928365|NCT06744062|ACTIVE_COMPARATOR|BR1015-1 + BR1015-2|
61928366|NCT03571321|EXPERIMENTAL|Ruxolitinib|"Participants will receive ruxolitinib in addition to standard chemotherapy.~Standard Chemotherapy Consists of:~* Remission consolidation therapy (lasting 8 weeks)~* Interim Maintenance (lasting 8 weeks)~* Delayed Intensification (lasting 8 weeks~* Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)~Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care."
62482071|NCT06743269|ACTIVE_COMPARATOR|Low-Resistance Inspiratory Muscle Strength Training Group|Subjects will partake in 5 sets of 6 inspiratory maneuvers (total: 30 maneuvers/session) 6 days a week for 6 weeks using the POWERbreathe K3 device to monitor adherence.
61928367|NCT06736899|ACTIVE_COMPARATOR|Balloon Angioplasty (BA)|
61928368|NCT06736899|ACTIVE_COMPARATOR|Orbital Atherectomy (OA)|
62322808|NCT05840770|EXPERIMENTAL|Treatment (Cemiplimab)|Patients receive cemiplimab IV and undergo blood sample collection while on study. Patients undergo MRI, CT scan and PET scan throughout the study.
62322809|NCT03774745|EXPERIMENTAL|Progesterone|"Micronized progesterone 200mg oral capsules starting 24 hours after mifepristone 200mg ingestion (day 1).~Progesterone treatment days 2-4: two capsules twice daily orally. Progesterone treatment days 5-15, 16 or 17: two capsules once daily orally."
61928369|NCT02829437||Retrospective Observational Group|Patients who received treatment for EST Patients with EST diagnosis prior August 2016
61928370|NCT02829437||Prospective Observational Group|Patients who will receive treatment for EST Patients with EST diagnosis after August 2016
62131206|NCT03390296|EXPERIMENTAL|Arm C (azacitidine, GO, avelumab)|Patients receive azacitidine and GO as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62482072|NCT05963568|EXPERIMENTAL|Intervention|Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn \& replaced with the Polypill if they are already receiving such treatments before enrollment.
62482073|NCT05963568|NO_INTERVENTION|Control arm|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention with drugs and doses left at the discretion of the treating physicians. Since our focus is to isolate the effect of the polypill strategy itself \& create equipoise, at study inception providers for patients in both study arms will receive a brief one-time (Skype-based) training \& a one time email synopsis on guideline recommended biomarker targets after stroke.
62482074|NCT02294487||Subjects|Individuals over 50 who are going to get the seasonal flu vaccine, pneumococcal, HIB, and/or meningococcal vaccination and either have multiple myeloma or do not have multiple myeloma.
61928371|NCT04214392|EXPERIMENTAL|Treatment (CAR T cell therapy) I|Arm 1 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via single delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one CAR T cell infusion delivered intracranial intratumoral or intracavitary \[ICT\] and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T cell treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
62322810|NCT03774745|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
62322811|NCT04420871|ACTIVE_COMPARATOR|capecitabine reference formulation at a single dose of 150 mg|150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
62322812|NCT04420871|EXPERIMENTAL|capecitabine test formulation at a single dose of 150 mg|The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.
62322813|NCT06041698|EXPERIMENTAL|Group I (TXT-Chatbot )|Patients receive a text message notification and complete surveys through TXT-Chatbot Q2W for 6 months.
62322814|NCT06041698|EXPERIMENTAL|Group II (MyChart/Patient Portal)|Patients receive an email notification and complete surveys through MyChart/Patient Portal Q2W for 6 weeks.
62322815|NCT03268746|EXPERIMENTAL|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag following cataract removal. Both eyes will be implanted.
62322816|NCT01600547||fall clinic population|women, aged + 65 years
62322817|NCT01600547||control fallers|randomly selected community aged matched female controls with a fall episode
62322818|NCT01600547||control non fallers|randomly selected community aged matched female controls, with out fall episodes
62322819|NCT02883465|OTHER|Single arm|
62322820|NCT03124615|EXPERIMENTAL|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
62322821|NCT06350604|EXPERIMENTAL|Project WHADE: A Partner-Based Physical Activity Program for Women|Behavioral and cognitive skills to promote physical activity behavior
62322822|NCT00758927|PLACEBO_COMPARATOR|2|Placebo administration for 10 weeks with exercise and diet therapy
62322823|NCT00758927|EXPERIMENTAL|1|Omacor 4 gram per day with exercise and diet therapy for 10 weeks
62322824|NCT03042611|EXPERIMENTAL|Rivoceranib Plus BSC|Participants will receive rivoceranib 700 milligrams (mg) orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.
62322825|NCT03042611|EXPERIMENTAL|Placebo|Participants will receive matching placebo to rivoceranib orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.
62322826|NCT05897138|EXPERIMENTAL|Lenvatinib plus Tislelizumab|
62322827|NCT06376604|EXPERIMENTAL|FMD|In addition to the standard care, subject will consume a 5-day fasting mimicking diet.
62322828|NCT06376604|ACTIVE_COMPARATOR|Control|Subjects will receive the standard care and no dietary changes.
62322829|NCT03844633|EXPERIMENTAL|Intervention arm|Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
62322830|NCT03844633|PLACEBO_COMPARATOR|Placebo arm|0.9% sodium chloride injection provided within 48 hours of childbirth
62322831|NCT03844633|NO_INTERVENTION|Open arm|No intervention provided
62482075|NCT06510309|EXPERIMENTAL|Rituximab + Venetoclax|"33 participants will be enrolled and will complete study procedures as follows:~* Baseline visit with screening assessments, scans, and tumor and bone marrow biopsies.~* Induction Period:~  * CT/MRI scans at week 4.~ * Weeks 1 - 4: Predetermined dose of Rituximab 1x weekly.~ * Weeks 5 - 8: Predetermined dose of Venetoclax 1x daily.~* Maintenance Period:~  * CT/MRI scan on weeks 12, 36, 60, 84, and then every 6 months after week 96.~ * Predetermined dose of Venetoclax 1x daily for up to week 96, then once every 6 months.~ * Predetermined dose of Rituximab 1x weekly at weeks 12, 24, 36, and 48.~* End of Treatment Visit: CT/MRI scan, tumor biopsy, and bone marrow biopsy.~* Follow up: In-clinic visit at 1 year after finishing study drugs."
62482076|NCT02156102||Microbiome with active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants with active leg ulcers and sickle cell disease.
62482077|NCT02156102||Microbiome with no active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants without active leg ulcers but do have sickle cell disease.
62482078|NCT02156102||Non-microbiome participants|We will recruit but not obtain microbiome samples from participants with sickle cell disease
62482079|NCT06559085|EXPERIMENTAL|Laproscopic posterior mesh rectopexy (Wells or LPMR)|After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported
62482080|NCT06559085|EXPERIMENTAL|Laparoscopic lateral mesh rectopexy (Orr-Loygue)|This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years.
62482081|NCT05879055|EXPERIMENTAL|PM8002+FOLFIRI|Subjects will be administered with PM8002 plus FOLFIRI via intravenously (IV) Q2W until disease progression or intolerable toxicity for a maximum of 2 years.
62482082|NCT03489278||Affected|Affected with ALS or a related disorder.
62482083|NCT03606408|OTHER|osilodrostat|open label, with patients receiving same dose as provided in the parent study
62482084|NCT06046820|EXPERIMENTAL|INZ-701|Subjects randomized to the INZ-701 arm will be administered a 2.4 mg/kg once weekly dose by subcutaneous (SC) injection for the duration of the 52-week Randomized Treatment Period and the Open-label Extension Period.
62482085|NCT06046820|ACTIVE_COMPARATOR|Control Arm (Conventional Therapy)|Subjects randomized to the control arm will continue taking their conventional therapy as clinically indicated by their treating physician for the duration of the 52-week Randomized Treatment Period.
62482086|NCT06742840|EXPERIMENTAL|HRS-2129 experimental group|
62131207|NCT03390296|EXPERIMENTAL|Arm D (azacitidine, venetoclax, avelumab)|Patients receive azacitidine and venetoclax as in Arm A and avelumab as in Arm C. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62131208|NCT03390296|EXPERIMENTAL|Arm E (azacitidine, avelumab, anti-OX40 antibody PF-04518600)|Patients receive azacitidine and avelumab as in Arm C and anti-OX40 antibody PF-04518600 as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62322832|NCT06181396|EXPERIMENTAL|Immediate oxytocin|This arm will receive oxytocin when entering 2nd stage (full dilation)
62482087|NCT06742840|PLACEBO_COMPARATOR|HRS-2129 placebo group|
62482088|NCT02498600|ACTIVE_COMPARATOR|Group I (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
62482089|NCT02498600|EXPERIMENTAL|Group II (nivolumab, ipilimumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
62131209|NCT03390296|EXPERIMENTAL|Arm F (GO, glasdegib)|Patients receive GO IV over 2 hours on days 1, 4, and 7, and glasdegib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62131210|NCT01794858|EXPERIMENTAL|Therapeutic Hypothermia|"Primary - Organ specific outcome at 28 days Logistic Organ Dysfunction Score (LOD) will be compared before and after TH. Change in LOD will reflect LOD day 4 minus LOD day 1 (Ehrmann, Can J Anesth 2006).~Secondary~* Lab values: D-Dimer, IL-6, CRP~* APACHE II Scores Day 1 and after TH (day 4)~* Length of stay in the ICU and hospital~* Prevalence of infections~* 28-day mortality~* Hypothermia-related side effects: cardiac arrhythmia, electrolyte balance, hyperglycemia, bleeding, acute pancreatitis"
62322833|NCT06181396|OTHER|Delayed oxytocin|This arm will receive oxytocin one hour after entering 2nd stage (full dilation)
62322834|NCT01222338|ACTIVE_COMPARATOR|Immunomodulator intervention|Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
62322835|NCT01222338|PLACEBO_COMPARATOR|placebo|Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
62322836|NCT00404781|EXPERIMENTAL|optimal antiplatelet|cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
62322837|NCT00404781|ACTIVE_COMPARATOR|standard antiplatelet|aspirin and clopidogrel for all patients
62322838|NCT04742946|EXPERIMENTAL|TR Group|Personalized digital physiotherapy program 4 weeks. One session per day. Web and mobile application. Auto-Exercise
62322839|NCT01818622|EXPERIMENTAL|Patient-group blue-blockers|N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
62482090|NCT06338085|EXPERIMENTAL|intervention group|The researcher will provide the intervention group with Emotional Freedom Technique (EFT) training, which will last for 2 sessions of 45 minutes with 1 day intervals.Participants will then be asked to continue the techniques taught during the training on their own once a day for 8 weeks.
62482091|NCT06338085|NO_INTERVENTION|control group|no intervention will be made to the control group
62131211|NCT00840229|EXPERIMENTAL|1 capsular & intra-articular|corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
62131212|NCT00840229|ACTIVE_COMPARATOR|2 intra-articular|corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
61928372|NCT04214392|EXPERIMENTAL|Treatment (CAR T cell therapy) II|Arm 2 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy and the lateral ventricle. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with two CAR T cell infusions (intracranial intratumoral or intracavitary \[ICT\]) and also into the lateral ventricle (intracranial intraventricular \[ICV\]) and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
61928373|NCT06744361|EXPERIMENTAL|S-ketamin|Intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
61928374|NCT06744361|ACTIVE_COMPARATOR|Propofol|Prehospital intravenous or intraosseous bolus administration of a minimum dose of 0.25 mg/kg propofol
62322840|NCT01818622|PLACEBO_COMPARATOR|Patient group clear-lensed goggles|N= 21 (Patient group) clear-lensed goggles from 06 p.m. to 08 a.m. in addition to TAU.
62322841|NCT01818622|EXPERIMENTAL|Non-bipolar control-group blue-blockers|N= 42 For baseline day 1-7: Actiwatch Spectrum worn at the wrist of dominant hand, day 8-14 continued wearing of Actiwatch spectrum + blue-blocking goggles from 6 p.m. to 08 a.m. In addition to selfreport forms described in the outcome section self report forms Horne-Ostberg Morningness-Eveningness Questionaire (HOMEQ)and Seasonal Pattern Assessment Questionaire (SPAQ).
62322842|NCT01166659|EXPERIMENTAL|CyPass Micro-Stent|Subjects receive the CyPass Micro-Stent
62322843|NCT06127225|EXPERIMENTAL|Treatment 1|1 caplet of Proliverenol 500 mg twice daily
62322844|NCT06127225|EXPERIMENTAL|Treatment 2|2 caplets of Proliverenol 500 mg once daily
62482092|NCT06406621|NO_INTERVENTION|Standard Care|"Will be provided with the best recommended standard of care based on recommendations from published studies and guidelines2,10,13,25,26 including educating on the importance and application of chronic hair removal to provide a standardized education and training to all patients in the control group. They will have the option to schedule additional in-person visits for further education and training on hair removal."
62482093|NCT06406621|EXPERIMENTAL|Laser group|"Description: Laser hair depiction treatment with Nd:YAG laser every 4-6 weeks to obtain a total of 5 treatments. Similar to the control group, they will also receive the best recommended standard care including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments."
62482094|NCT06738277|EXPERIMENTAL|Bmab 1200 AI (Biosimilar Ustekinumab)|
61928375|NCT02643498|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
61928376|NCT06425198|EXPERIMENTAL|Group A: Mild Hepatic Impairment BMS-986278|
61928377|NCT06425198|EXPERIMENTAL|Group B: Moderate Hepatic Impairment BMS-986278|
61928378|NCT06425198|EXPERIMENTAL|Group C: Severe Hepatic Impairment BMS-986278|
61928379|NCT06425198|EXPERIMENTAL|Group D: Normal Hepatic Function BMS-986278|
61928380|NCT06521567|EXPERIMENTAL|Part 1- Dose determination|
61928381|NCT06521567|EXPERIMENTAL|Part 2- Dose expansion|
61928382|NCT06373263|EXPERIMENTAL|Dissemination tool (infographic)|Infographic
61928383|NCT06373263|ACTIVE_COMPARATOR|Plain-language summary|Plain-language summary
61928384|NCT06628687||Omaveloxolone|Participants with FA who were exposed to omaveloxolone at any time during pregnancy (from 12 days prior to conception through the end of pregnancy outcome), and/or at any time during lactation (up to 1 year of infant age or weaning, whichever comes first).
61928385|NCT05845931|ACTIVE_COMPARATOR|woman|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm 1 and arm 2.
61928386|NCT05845931|ACTIVE_COMPARATOR|men|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm 1 and arm 2.
61928387|NCT04551066|EXPERIMENTAL|Group A : parsaclisib + ruxolitinib|Participants will receive parsaclisib and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
61928388|NCT04551066|PLACEBO_COMPARATOR|Group B : placebo + ruxolitinib|Participants will receive placebo and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
61928389|NCT03030404||Cohort 1|Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.
61928390|NCT06745713|EXPERIMENTAL|Experimental Group|They completed the chest tube care management training programme which includes 5 modules, 4 case scenarios and interactive questions on www.gtbyep.com website.
61928391|NCT06745713|ACTIVE_COMPARATOR|Control Group|The subject content of chest tube care management in the nursing education curriculum was given. After the pre- and post-tests were completed in the training programme in which the experimental group was included, the control group was also included in the training programme on www.gtbyep.com. The control group also completed the training content as applied to the experimental group.
61928392|NCT06569095||MDS-EB|
61928393|NCT04845685|EXPERIMENTAL|CGM Patients|Subjects with diabetes mellitus or medication induced diabetes that have been admitted to the hospital after a surgery for organ transplantation or scheduled for organ transplant surgery will be fitted with a CGM monitor to monitor glucose levels during hospitalization
62482095|NCT06738277|ACTIVE_COMPARATOR|Bmab 1200 PFS (Biosimilar Ustekinumab)|
62482096|NCT06742606|EXPERIMENTAL|patients diagnosed as IBD aged from 1 month to 16 years|"study will include 2 groups of pediatric IBD patients planned to start biological treatment or change to other biological therapy and each group formed of 20 patients Group~1 of patients will receive Adalimumab while Group 1 will receive ustekinumab"
62690848|NCT06117631|EXPERIMENTAL|Group A: Centering Parenting|At each well-child check from 2- to 24-months, a trained bilingual facilitator from the CommUnityCare Centering Parenting program will present curriculum in person during 2-hour visits in a room with 3-8 mother-baby pairs per group. During each session, each mother-baby pair will be pulled out to a private medical room for a brief individual well child appointment with the pediatrician. During this appointment, infant measurements, physical exam, and discussion of unique concerns will take place before the pair returns to the session. There are 8 scheduled well child checks by the age of two, where regular parenting topics will be covered (i.e. discipline, safety, co-parenting, sibling relationships, childcare, development). Each Centering session is expected to last approximately 2 hours, for a total commitment of approximately 16 hours across 8 group sessions over the course of 22 months for each participant. Total time of enrollment should be approximately 22-24 months.
61928394|NCT06076642|EXPERIMENTAL|TAK-881|"Epoch 1: Participants who completed study TAK-881-3001 (NCT05755035) and met eligibility criteria will receive TAK-881 subcutaneous (SC) infusion using investigational needle sets at the same dose and same treatment interval as at the last infusion in TAK-881-3001 (NCT05755035) at Week 1 and at Weeks 13 and Week 25 of study TAK-881-3002.~Epoch 2: Participants with anti-rHuPH20 antibody titer \>=1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or Study TAK-881-3002 Epoch 1, will continue receiving TAK-881 every 12 weeks for up to Week 121.~After the first TAK-881 infusion in study TAK-881-3002, the interval and/or the dose may be adjusted only at scheduled site visits at the investigator's discretion."
61928395|NCT06745752||postpartum women|In the study, the upper back, lower back and pelvic girdle pain status of the participants in the postpartum period will be monitored.
61928396|NCT06734923||Patient who has conducted online research on orthodontics|online research on orthodontics
61928397|NCT06616194|EXPERIMENTAL|Rimegepant|Experimental medicine under study
61928398|NCT06616194|PLACEBO_COMPARATOR|Placebo|A placebo does not have any medicine in it but looks just like the medicine being studied.
61928399|NCT05710640|EXPERIMENTAL|Blinded phase|Participants will receive 5 minutes of active tcVNS or sham tcVNS daily for 8 weeks.
61928400|NCT05710640|EXPERIMENTAL|Open-Label phase|Participants will receive 5 minutes of stimulation via the active tcVNS for 8 weeks after a double-blind, sham-controlled 8- week period.
61928401|NCT06531512|EXPERIMENTAL|Xianglei Tangzu Gao plus Standard of Care|Xianglei Tangzu Gao will be applied twice daily for up to 16 weeks to the Target Ulcer.
61928402|NCT06531512|PLACEBO_COMPARATOR|Vehicle Cream plus Standard of Care|Vehicle cream will be applied twice daily for up to 16 weeks to the Target Ulcer
61928403|NCT03801876|EXPERIMENTAL|Group I (PBT, Chemotherapy, Esophagectomy)|Patients undergo PBT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU \[with capecitabine as an acceptable substitute for 5-FU\]) per institutional standards while undergoing PBT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
61928404|NCT03801876|ACTIVE_COMPARATOR|Group II (IMRT, Chemotherapy, Esophagectomy)|Patients undergo IMRT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU \[with capecitabine as an acceptable substitute for 5-FU\]) per institutional standards while undergoing IMRT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
61928405|NCT06295809|EXPERIMENTAL|Pembrolizumab plus V940 with SOC|Participants will receive V940 1 mg intramuscular (IM) injection every 3 weeks (q3w) for up to 6 weeks and pembrolizumab 400 mg intravenous (IV) infusion every 6 weeks (q6w) up to 12 weeks as neoadjuvant therapy prior to surgery; followed by V940 1 mg IM injection q3w up to 21 weeks and pembrolizumab 400 mg IV infusion q6w or until discontinuation.
61928406|NCT06295809|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants will receive surgical resection as per local guidelines with/without adjuvant radiation therapy (RT) at investigator's discretion.
61928407|NCT06295809|EXPERIMENTAL|Pembrolizumab with SOC|Participants will receive pembrolizumab 400 mg IV infusion q6w up to 12 weeks as neoadjuvant therapy prior to surgery; followed by pembrolizumab 400 mg IV infusion q6w or until discontinuation.
61928408|NCT06745245|EXPERIMENTAL|Experimental: Arm Intervention|Intervention group: The specialized oral supplement is provided, with the consumption of 1 dose (15 g) per day along with individualized nutritional advice. For 1.5 months
61928409|NCT03866525|EXPERIMENTAL|Dose escalation and dose expansion|"A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion.~In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts."
61928410|NCT06745570|EXPERIMENTAL|Group Intervention|All participants will receive group-based lifestyle modification and sleep treatment (16, 90-minute sessions over 16 weeks). All sessions will be delivered on Zoom (remotely) to small groups (n=5-10 each) of participants. The intervention involves lifestyle modification content (e.g., nutritional education, physical activity education, stimulus control, goal setting) and sleep content (e.g., psychoeducation regarding sleep and eating behavior, sleep tracking, establishing regular sleep-wake times).
61928411|NCT06743685|EXPERIMENTAL|HEALthy Beginnings Intervention group|Middle-aged, and older, homeless women (MAO-HW) participating in the HEALthy Beginnings Intervention
61928412|NCT04883957|EXPERIMENTAL|Cohort A: R/R NHL|Participants with R/R NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or transformed NHL, will receive oral BGB-11417 until the MTD (or maximum ascending dose \[MAD\]) and the RP2D can be determined.
61928413|NCT04883957|EXPERIMENTAL|Cohort B: R/R CLL/SLL (low tumor burden)|Participants with low tumor burden R/R CLL/SLL will receive oral BGB-11417 until the MTD (or MAD) and the RP2D can be determined.
62131213|NCT00840229|PLACEBO_COMPARATOR|3 placebo|placebo injections (Lidocaine) in capsule and intra-articular
62690849|NCT06117631|ACTIVE_COMPARATOR|Group B: Bright by Text|This group will receive standard of care individual well child checks with their regular CommUnityCare pediatrician, with standard anticipatory guidance on feeding and sleep. Additionally, this group will be enrolled in a text-based parenting coaching program. The Bright by Text program will provide parenting tips two to three times weekly; tailored through community partner United Way of Central Texas offering local parent support and resources. The Bright by Text program is a message subscription program rather than an application. Participants may decide on their own how much to engage with the text-based program, so total time commitment cannot be estimated. Total time of enrollment should be approximately 22-24 months.
62690850|NCT06117631|NO_INTERVENTION|Group C: Standard of Care|This group will receive standard of care individual well child checks with their regular pediatrician, with standard anticipatory guidance on feeding and sleep. Total time of enrollment should be approximately 22-24 months.
62690851|NCT06190990|OTHER|additional effects of exer gaming with otago exercises|"Strengthening training~* Sitting knee extension~* Standing hip abduction~* Standing knee flexion~* Tip toe~* Heel tiptoe Balance training~* Knee bends~* Backward walking~* Walk in figure 8~* Sideways walking~* Tandem stands~* Tandem walking~* 1-leg stand~* Heel walking~* Toe walking~* Heel-toe walking backward~* Sit to stand After Otago exercises, the participants will receive the following exer-gaming based exercises.~* Football player~* Boat~* Volleyball beach"
62690852|NCT06190990|OTHER|exer gaming based exercises|"The participants will receive the following exer-gaming based exercises.~* Football player~* Boat~* Volleyball beach"
61928414|NCT04883957|EXPERIMENTAL|Cohort C: R/R CLL/SLL (high tumor burden)|Participants in this cohort will not be enrolled until the RP2D for Cohort B is established. Participants will be treated with the monotherapy ramp-up schedule and the RP2D established in Cohort B.
62322845|NCT06127225|EXPERIMENTAL|Treatment 3|2 caplets of Proliverenol 500 mg twice daily
62322846|NCT06127225|PLACEBO_COMPARATOR|Treatment 4|2 caplets of Placebo daily
62322847|NCT06693765|EXPERIMENTAL|Cohort 1: AZD4144|Participants with severe renal impairment will receive a single oral dose of AZD4144 on Day 1.
62322848|NCT06693765|EXPERIMENTAL|Cohort 2: AZD4144|Healthy participants with normal renal function will receive a single oral dose of AZD4144 on Day 1.
62322849|NCT06693765|EXPERIMENTAL|Cohort 3: AZD4144|Participants with ESKD on intermittent haemodialysis will receive a single oral dose of AZD4144 on the first day of Treatment Period 1 and Treatment Period 2.
62322850|NCT00178360|EXPERIMENTAL|Music Therapy|Subject will participate in one, individual, half-hour long music therapy session every other week and one hour-long group music therapy session each month, for a period of three months.
62322851|NCT00178360|NO_INTERVENTION|Standard Care|During the Standard Care time period, participants will continue to receive all of the medical care that they would normally receive for the treatment of Huntington's Disease, without the addition of music therapy services.
62322852|NCT03797950|NO_INTERVENTION|Control|No active intervention
62322853|NCT03797950|EXPERIMENTAL|Voice Reminder (Group A)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Enrolled women will receive reminders via mobile phone to highlight the importance of early vaccinations for newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Information on where and when these vaccines will be available in the woman's community will be provided."
62322854|NCT03797950|EXPERIMENTAL|Cash Incentive (Group B)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Volunteers will encourage enrolled women to seek early vaccination for their newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Volunteers will provide information on where and when these vaccines will be available in the woman's community. Volunteers and enrolled women will receive small monetary rewards via mobile money for receiving OPV0 and BCG vaccinations on time."
62322855|NCT00653835|EXPERIMENTAL|Ezetimibe + Simvastatin|
62690853|NCT00615160|EXPERIMENTAL|A|PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)
62690854|NCT00615160|EXPERIMENTAL|B|combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28
62131214|NCT03902132|EXPERIMENTAL|Core Stability exercises group|Core Stability exercises
62131215|NCT03902132|ACTIVE_COMPARATOR|Traditional low back physical therapy group|Traditional low back physical therapy management
62131216|NCT00945789|EXPERIMENTAL|EPO HIE Group|Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
62322856|NCT00653835|ACTIVE_COMPARATOR|Simvastatin|
62322857|NCT04207567|EXPERIMENTAL|Intervention Arm|Participants in this arm will be instructed to perform one set each of push-ups, angled-rows and bodyweight squats every weekday without supervision for a total of 24 weeks. They will receive the equipment necessary to perform the exercises as well as guidance on proper performance. They will also receive training in the Tiny Habits® Method at baseline and digital coaching for the duration of the study.
62322858|NCT04207567|NO_INTERVENTION|Waitlist Control Arm|"Participants in the control arm will be instructed to refrain from resistance training for the initial 12 weeks of the study.~Note that, after the 12-week follow-up assessment (at which the primary outcome of composite reps will be assessed), this group will begin the RT program. They will receive the same equipment, training, and coaching as the intervention group, and they will continue the RT program for 12 weeks, followed by a 24-week assessment."
62322859|NCT02481960|EXPERIMENTAL|Treatment arm|Intraparenchymal administration of CM-BC2 irinotecan drug-eluting bead in recurrent high grade glioma.
62690855|NCT00837135|EXPERIMENTAL|All Subjects|Screening for Eligibility into Trial
62690856|NCT00837135|EXPERIMENTAL|ARM A|GI-4000 Vaccine
62322860|NCT00079612|EXPERIMENTAL|Arm 1|
62322861|NCT00079612|PLACEBO_COMPARATOR|Arm 2|
62322862|NCT00815412|ACTIVE_COMPARATOR|Counseling in use of health care|
62322863|NCT00815412|ACTIVE_COMPARATOR|Counseling in diet, exercise|
62322864|NCT00815412|PLACEBO_COMPARATOR|Contol group|
62482097|NCT02264977|EXPERIMENTAL|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
62322865|NCT03165981|OTHER|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
62322866|NCT03165981|OTHER|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
62322867|NCT01452074|OTHER|Exercise Training with Weight Loss|"During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, \~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week~After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight"
62322868|NCT05152160|EXPERIMENTAL|Treatment group|Umbilical Cord Mesenchymal Stem Cell Therapy
62690857|NCT00837135|EXPERIMENTAL|ARM B|GI-4000 Vaccine + Activated T Cells
62690858|NCT00837135|EXPERIMENTAL|After GI-4000 Vaccine #4|GI-4000 Monthly - For those with incomplete removal of tumor GI-4000 Monthly + Chemotherapy - For those with complete removal of tumor
62690859|NCT04154163||Stage 1 Participants|"Blood test Day 1 DBS and venous blood~Blood test Day 2 DBS (+/- and venous blood)~Blood test Day 15 DBS only~Blood test Day 16 DBS only"
61928415|NCT05081583|EXPERIMENTAL|Study Arm 1: Baseline|An anticipated twenty type 2 diabetic subjects (10 males, 10 females) will be administered a single dose of midazolam (0.5 mg) intravenously via a peripherally inserted catheter in conjunction with their daily oral administration of metformin. Plasma and urine will be collected from 0-24 hours post-midazolam administration. Participants will take their metformin as prescribed for the entirety of the study with no interruption in pharmacotherapy.
61928416|NCT05081583|EXPERIMENTAL|Study Arm 2: Acute Goldenseal Exposure|For Arm 2, the same 20 subjects will be administered a single dose of goldenseal (3.3 g) orally 30 minutes prior to administration of midazolam (as described in Arm 1). Plasma and urine will be collected in a manner identical to that in Arm 1. With respect to midazolam administration, a washout period of 7 days will separate Arm 2 from Arm 1.
61928417|NCT05081583|EXPERIMENTAL|Study Arm 3: Chronic Goldenseal Exposure|For Arm 3, the same 20 subjects will be administered goldenseal (1.1 g) orally three times daily for 27 days. On the 28th day, participants will be administered the goldenseal three times daily, as well as the single dose of midazolam (as described in Arm 1). Plasma and urine will be collected in a manner identical to that in Arm 1. A designated washout period for midazolam will not be necessary to separate Arm 3 from Arm 2 since there will be 27 days of goldenseal administration prior to the midazolam administration.
62322869|NCT01201538|EXPERIMENTAL|Single arm|
62322870|NCT03014219|EXPERIMENTAL|Only 1 arm: treatment with MSC-AFP|Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells.
62322871|NCT06693323|EXPERIMENTAL|AHCC|Oral Drug
62322872|NCT04557449|EXPERIMENTAL|1A Monotherapy Escalation Arm 1|PF-07220060 Monotherapy Escalation
62322873|NCT04557449|EXPERIMENTAL|1A Monotherapy Escalation Arm 2|PF-07220060 Monotherapy Escalation
62322874|NCT04557449|EXPERIMENTAL|1A Monotherapy Escalation Arm 3|PF-07220060 Monotherapy Escalation
62690860|NCT04154163||Stage 2 Participants|"Non-drug naive participants:~Blood test Day 1 DBS~Blood test Day 2 DBS~Blood test Day 15 DBS~Blood test Day 16 DBS~Drug naive participants:~Blood test Day 1 DBS~Blood test Day 2 DBS~Blood test Day 3, 4, or 5 DBS~Blood test Day 4, 5 or 6 DBS~Blood test Day 15 DBS~Blood test Day 16 DBS"
62690861|NCT01840072|EXPERIMENTAL|Active antihypertensive treatment|Active antihypertensive treatment
62690862|NCT01840072|NO_INTERVENTION|Usual care|Discontinue all home BP medications.
61928418|NCT06745375|EXPERIMENTAL|Healthy participants|All healthy participants wear two different contact lenses, one with the correct power and one with +/- 2.00 Ds to actual refraction. All lenses are commercially available. No 2nd arm.
61928419|NCT06265233|EXPERIMENTAL|ERP combined with Improv Group Therapy|Participants will attend 90-minute ERP + improv group therapy sessions for 12 consecutive weeks. They will also complete homework between sessions, answer questions, and complete questionnaires.
61928420|NCT02972372|ACTIVE_COMPARATOR|CRT group|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
61928421|NCT02972372|ACTIVE_COMPARATOR|Surgery group|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
61928422|NCT06743464|EXPERIMENTAL|Rifaximin+SOC|Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7 SOC (Standard of care) means both group will recieve similar post of care which is standard protocol at ILBS.
61928423|NCT06743464|ACTIVE_COMPARATOR|Non Rifaximin + SOC|SOC (Standard of care) means both group will recieve similar post of care which is standard protocol at ILBS.
61928424|NCT06225596|EXPERIMENTAL|Cohort 1: BT8009 Arm 1|Participants will receive BT8009 and a standard dose of pembrolizumab.
62322875|NCT04557449|EXPERIMENTAL|1A Monotherapy Escalation Arm 4|PF-07220060 Monotherapy Escalation
62322876|NCT04557449|EXPERIMENTAL|1B Combination Dose Finding Arm 1|PF-07220060 with Letrozole combination Escalation
62322877|NCT04557449|EXPERIMENTAL|1B Combination Dose Finding Arm 2|PF-07220060 with Letrozole Combination Escalation
62322878|NCT04557449|EXPERIMENTAL|1C Combination Dose Finding Arm 1|PF-07220060 with Fulvestrant Combination Escalation
62690863|NCT05764083||Inpatient Cohort|COVID-19-positive or -suspected inpatients: Eligible inpatient cohort participants include Veterans who receive inpatient care at VHA facilities and are tested for SARS-CoV-2. Members of this inpatient cohort include those with and without SARS-CoV-2 infection.
62690864|NCT05764083||Outpatient Cohort|COVID-19-positive or -suspected outpatients: Eligible outpatient cohort participants include Veterans who seek care in (1) VA medical center emergency departments, (2) VA medical center urgent care clinics, or (3) VA medical center COVID-19-specific testing sites, and who are tested for SARS-CoV-2 but do not require hospital admission at the time of evaluation. Members of this outpatient cohort include those with and without SARS-CoV-2 infection.
62482098|NCT04947553|EXPERIMENTAL|AXS-05 (dextromethorphan-bupropion)|"* Up to 52 weeks in the open-label segment;~* Up to 24 weeks in the randomized double-blind segment (if applicable)"
62690865|NCT05764083||Community Living Center Cohort|Community Living Center residents: Eligible Community Living Center cohort participants include all residents who reside in VA medical center-operated Community Living Centers. Members of this Community Living Center cohort include those with and without SARS-CoV-2 infection.
62690866|NCT06466096||postoperative delirium(POD) and postoperative neurocognitive disorder(pNCD)|Delirium (CAM scale ) was assessed 7 days after surgery and divided into POD and non-POD groups; one of the above scenarios indicated postoperative delirium;The patients in the POD group were evaluated for cognitive function at 1 month and 12 months after surgery to determine whether pNCD occurred. The patients in the POD group were further divided into pNCD subgroup and non-PNCD subgroup, and fMRI scanning were performed.
61928425|NCT06225596|EXPERIMENTAL|Cohort 1: BT8009 Arm 2|Participants will receive BT8009 and a standard dose of pembrolizumab.
61928426|NCT06225596|ACTIVE_COMPARATOR|Cohort 1: Arm 3|Participants will receive Platinum-based combination chemotherapy +/- avelumab maintenance
61928427|NCT06225596|EXPERIMENTAL|Cohort 2: BT8009 Arm 1|Participants will receive BT8009.
61928428|NCT06225596|EXPERIMENTAL|Cohort 2: BT8009 Arm 2|Participants will receive BT8009.
61928429|NCT06225596|EXPERIMENTAL|Cohort 2: Arm 3: BT8009 (Not Recruiting)|Participants will receive BT8009 and a standard dose of pembrolizumab.
61928430|NCT06745856|ACTIVE_COMPARATOR|5-fluorouracil|antimetabolite to prevent wound healing
61928431|NCT06745856|PLACEBO_COMPARATOR|placebo|Subconjunctival placebo.
61928432|NCT05154825||Spine Surgery Participants|Spine surgical candidates that will be receiving posterior only surgery for spinal deformity
61928433|NCT06551987|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Insomnia|6 weekly, 50-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
62322879|NCT04557449|EXPERIMENTAL|1C Combination Dose Finding Arm 2|PF-07220060 with Fulvestrant Combination Escalation
62690867|NCT06644144||Idiopathic Pulmonary Fibrosis/Familial Pulmonary Fibrosis|
62690868|NCT06644144||fibrotic ILD|Patients with a diagnosis of: chronic Hypersensitivity Pneumonitis (cHP), unclassifiable ILD (uILD), idiopathic NSIP or CTD-ILD.
62690869|NCT06644144||Interstitial Lung Abnormalities|
61928434|NCT06551987|ACTIVE_COMPARATOR|Brief Behavioral Therapy for Insomnia|4 weekly, 30-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
61928435|NCT06745115||Healthy control group|Individuals who are physically healthy with no underlying diseases and have not been hospitalized within the past two years. Recruitment for healthy volunteers will be conducted through notices and online media.
61928436|NCT06745115||Sepsis Patient Group|Patients with confirmed infections, having qSOFA ≥ 2 and SOFA ≥ 2, will be screened and confirmed by a physician to meet the inclusion criteria. After physician confirmation that the inclusion criteria are met, patients will be informed and asked to sign an informed consent form. Blood samples (10 cc) will be collected within 24 hours before and after hospitalization entry. One week post-discharge and on the 28th day post-diagnosis, a nurse will follow up to inquire about their health status.
62322880|NCT04557449|EXPERIMENTAL|2B Combination Dose Expansion|PF-07220060 with Letrozole Combination Expansion
62322881|NCT04557449|EXPERIMENTAL|2C Combination Dose Expansion|PF-07220060 with fulvestrant Combination Expansion
62690870|NCT02150993|EXPERIMENTAL|Arm A : TDF + FTC (or 3TC) + ZDV|Tenofovir + Emtricitabine or Lamivudine + Zidovudine
62690871|NCT02150993|EXPERIMENTAL|TDF+FTC (or 3TC) +LPV/r|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
62690872|NCT02150993|EXPERIMENTAL|Arm C : TDF +FTC (or 3TC) + RAL|Tenofovir + Emtricitabine or Lamivudine + Raltegravir
61928437|NCT06745115||Infected Non-Sepsis Patient Group|Patients with infections and a SOFA score of 1 will be screened and confirmed by a physician to meet the inclusion criteria. After obtaining informed consent, a nurse will collect a 10 cc blood sample within 24 hours of qualification. Within 7 days of ICU admission, physicians will assess whether patients with non-sepsis infections progress to sepsis. If so, these patients will be categorized into the sepsis patient group.
61928438|NCT06745778||ICD or CRT-D patients who have received LBBP implantation|Patients' EGMs can be recorded by Holter DR220
61928439|NCT06744738|NO_INTERVENTION|Usual care|The usual care group received the usual care offered by the center to all patients, which included printed, paper-based, and verbal instructions. The written material included knowledge about diet recommendations for dialysis patients based on National Kidney Foundation recommendations. Verbal instructions were provided by the physician, including information regarding their medications, dialysis, diet, and fluid intake based on their condition and monthly lab results. Medications are provided to all patients at no cost, and pharmacists provide instructions on how to use them.
61928440|NCT06744738|EXPERIMENTAL|pharmacist-led behavioral change technique|"The intervention was developed based on the behavior change technique taxonomy (v1). This intervention was designed to improve adherence to all therapeutic aspects of hemodialysis patients, including the dialysis program, medications, diet, and fluids. Additionally, the effect of the pharmacist intervention on physiological indices (serum potassium, total calcium, phosphate, IDWG, and hemoglobin) was examined.~The program was explicitly created for implementation in an actual setting, ensuring that the time allocation for participants and facilitators (the party responsible for conducting the PL-BCT) remained reasonable in most contexts.~The BCT components were developed after the identification and coding of the BCTs from previous interventional studies that contain behavioral components and result in positive effects on one or more hemodialysis patients' adherence domains toward their therapeutic regimen (dialysis program, medications, diet, and fluid)."
62322882|NCT04557449|EXPERIMENTAL|1D Monotherapy Food Effect|PF-07220060 Monotherapy Food Effect
62322883|NCT04557449|EXPERIMENTAL|1A Monotherapy Escalation Arm 5|PF-07220060 Monotherapy Escalation
62482099|NCT04947553|PLACEBO_COMPARATOR|Placebo|Up to 24 weeks in the randomized double-blind segment (if applicable)
62690873|NCT06240455|ACTIVE_COMPARATOR|WP1302 400μg|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
62690874|NCT06240455|ACTIVE_COMPARATOR|WP1302 800μg|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
61928441|NCT06744621||Infrequent|Patients will undergo one fingerstick on admission for their labor process.
62131217|NCT00945789|NO_INTERVENTION|Control HIE|Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
62131218|NCT00945789|OTHER|Healthy Controls|Healthy newborn without hypoxic ischemic encephalopathy
62131219|NCT03655262|EXPERIMENTAL|1 Session|1 neuro-reinforcement session
62322884|NCT04557449|EXPERIMENTAL|1F Combination Dose Finding|PF-07220060 with Enzalutamide Escalation
62322885|NCT04557449|EXPERIMENTAL|1E DDI Cohort|PF-07220060 DDI with Midazolam
62322886|NCT04557449|EXPERIMENTAL|2D Combination Dose Expansion|PF-07220060 with enzalutamide Combination Expansion
62322887|NCT04557449|EXPERIMENTAL|2A Combination Dose Expansion|PF-07220060 with fulvestrant combination dose expansion
62322888|NCT04557449|EXPERIMENTAL|2E Combination Dose Expansion|PF-07220060 Monotherapy OR PF-07220060 plus fulvestrant combination therapy
62322889|NCT05139368|EXPERIMENTAL|Treatment (hypo-fractionated radiotherapy)|Patients undergo hypo-fractionated radiotherapy over 3 weeks in the absence of disease progression or unacceptable toxicity.
62322890|NCT03641469|EXPERIMENTAL|Green Sun Dynamic Brace|Historical measures of brace effectiveness (in- and out-of-brace Cobb angles), wear time, and brace-related quality of life will be compared to those measured after the subject is fit with a Green Sun dynamic brace.
62322891|NCT00544128|ACTIVE_COMPARATOR|Epzicom Arm|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
62322892|NCT00544128|ACTIVE_COMPARATOR|Truvada Arm|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
62322893|NCT03357276|EXPERIMENTAL|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62322894|NCT03357276|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62322895|NCT05738096|EXPERIMENTAL|TGN patients|Patients with TGN who will undergo rhizotomy surgery as the standard of care
62322896|NCT05738096|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers for whom TSEPS will be recorded in a lab setting
62322897|NCT05828264|NO_INTERVENTION|Control group|children in the control group will be received standard care. Control group children will not receive any distraction techniques.
62322898|NCT05828264|EXPERIMENTAL|Quantum Touch|The children in the quantum touch groups will received quantum touch application during the venipuncture procedure by the expert nurse
62322899|NCT04603677||Acute phase of SARS-CoV-2 infection|Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.
62322900|NCT04603677||Convalescent phase of SARS-CoV-2 infection|Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.
62322901|NCT01796353|EXPERIMENTAL|sexual rehabilitation|exercise plus psycho-education
62322902|NCT01796353|ACTIVE_COMPARATOR|usual care|usual care
62322903|NCT01383200|ACTIVE_COMPARATOR|Tetracaine R/Lidocaine L|Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
62322904|NCT01383200|ACTIVE_COMPARATOR|Tetracaine L/Lidocaine R|Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.
62322905|NCT05398003|EXPERIMENTAL|Study population|12 patients with neck and upper limb pain who have failed multidisciplinary treatment and are candidates for cervical medullary stimulation will be included.
62322906|NCT03879668|EXPERIMENTAL|eIPOS|The cohort will include all participants who are cared for by the participating specialist palliative home care teams when implementing eIPOS.
62482100|NCT00128960||1|Participants with different types of diseases and conditions who have undergone an allogeneic (donor) stem cell transplant.
62482101|NCT06743347|EXPERIMENTAL|Phase Contrast MRI|
61928442|NCT06744621||Frequent|Patients will undergo fingersticks every 4 hours in latent labor and 2 hour in active labor during their labor process.
61928443|NCT06745089|EXPERIMENTAL|IPL arm|
61928444|NCT06745089|EXPERIMENTAL|TPT arm|
61928445|NCT06745089|ACTIVE_COMPARATOR|Control arm|
62131220|NCT03655262|EXPERIMENTAL|3 Sessions|3 neuro-reinforcement sessions
62131221|NCT03655262|EXPERIMENTAL|5 sessions|5 neuro-reinforcement sessions
62131222|NCT05172323|EXPERIMENTAL|3DCT-guided group|PCI guided with 3DCT results and IVUS
62131223|NCT05172323|PLACEBO_COMPARATOR|Angiography-guided group|PCI guided by operator and IVUS
62131224|NCT05916001|ACTIVE_COMPARATOR|A, Impact oral + Colorectal Surgery|"the supplement Oral Impact will be administered 3 times a day for 10 days before the operation.~Colon surgery will be performed according to standard clinical practice."
62482102|NCT06351332|EXPERIMENTAL|Phase 1: Dose Escalation Arm|"Participants will be enrolled in a standard 3+3 dose-escalation scheme to establish a Maximum Tolerated dose (MTD) of Azenosertib, starting at Dose Level 0, de-escalating to Dose Level -1, and escalating to Dose Levels 1 and 2.~* Baseline visit with CT or MRI scan.~* CT or MRI scan every 9 weeks until 27 weeks then every 12 weeks.~* Cycle 1 through End of Treatment:~  * Days 1 through 5, 8 through 12, and 15 through 19 of 21 Day Cycle: Predetermined dose of Azenosertib 1 x daily.~ * Day 1 of 21 Day Cycle: Predetermined dose of Pembrolizumab 1x daily.~ * Days 1 and 8 of 21 Day Cycle: Predetermined dose of Carboplatin 1x daily.~* End of Treatment visit~* Follow up: every 6 months~* Dose de-escalation and escalation will follow dose-limiting toxicities specifications (DLTs) per the protocol. The MTD is the highest dose level with ≤1 DLT in a cohort of 6 participants and the study will proceed to Phase 2."
62482103|NCT06351332|EXPERIMENTAL|Phase 2: AZENOSERTIB + PEMBROLIZUMAB + CARBOPLATIN|"Participants will complete:~* Baseline visit with CT or MRI scan and tumor biopsy.~* CT or MRI scan every 9 weeks until 27 weeks then every 12 weeks.~* Cycle 1 through End of Treatment:~  * Days 1 through 5, 8 through 12, and 15 through 19 of 21 Day Cycle: Predetermined dose of Azenosertib 1x daily.~ * Day 1 of 21 Day Cycle: Predetermined dose of Pembrolizumab 1x daily.~ * Days 1 and 8 of 21 Day Cycle: Predetermined dose of Carboplatin 1x daily.~* Tumor biopsy during Cycle 2.~* End of Treatment visit~* Follow up: every 6 months"
62482104|NCT00923442||1|patients (from \>/= 1 to 75 years old) diagnosed with any hematologic malignancy or pre-malignant condition
62482105|NCT05649956|EXPERIMENTAL|Letrozole|Letrozole 2.5 mg orally
62482106|NCT05649956|NO_INTERVENTION|Observation|Observation
62482107|NCT06025721|EXPERIMENTAL|CV-Homes Intervention|Behavioral treatment by a wellness coach.
62482108|NCT03545906|EXPERIMENTAL|TEAM-UP Intervention Group|
62482109|NCT03545906|ACTIVE_COMPARATOR|Enhanced Care Comparison Group|
62482110|NCT06328777|EXPERIMENTAL|CABA-201|"Severe Skin Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with severe skin involvement~Organ Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with organ involvement"
62482111|NCT02595905|ACTIVE_COMPARATOR|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62482112|NCT02595905|EXPERIMENTAL|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61928446|NCT05242367|ACTIVE_COMPARATOR|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
61928447|NCT05242367|SHAM_COMPARATOR|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62482113|NCT06278779|ACTIVE_COMPARATOR|Esketamine group|"Dosing of esketamine intranasal spray will be guided by the Spravato® Product Information. This involves a starting dosage of 28 or 56 mg, with dose adjustment up to 84 mg as required to optimise response. Dose adjustments will be based on effectiveness and tolerability to the previous dose. The recommended treatment protocol is twice per week for 4 weeks, then weekly in weeks 5-8, then option of weekly-fortnightly maintenance treatment for responders. After week 8, patients may continue treatment as guided by the ketamine clinic psychiatrist."
61928448|NCT06745154|EXPERIMENTAL|Prevention (QUEST)|Patients receive access to the Ohio Tobacco Quitline, receive nicotine patches, gum, or lozenges for up to 8 weeks. Patients also participate in tobacco cessation counseling sessions for 5 sessions over 8 weeks. Patients additionally undergo cognitive assessment and nasal swab collection on study.
61928449|NCT05319587|EXPERIMENTAL|Liposomal annamycin|
61928450|NCT06743594||LASIK|Femtosecond-LASIK in myopia
61928451|NCT06743594||KLEx|Kerato-lenticule Extraction in myopia
61928452|NCT06743594||Traditional Cataract Surgery|Cataract Surgery with Phacoemulsification
62690875|NCT06240455|ACTIVE_COMPARATOR|WP1302 1200μg|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
62690876|NCT06240455|PLACEBO_COMPARATOR|WP1302 Placebo|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
62690877|NCT04229017|ACTIVE_COMPARATOR|Anterior Cervical Discectomy and Fusion (ACDF)|ACDF is a a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate. The plate is intended to stabilize the treated levels until fusion occurs.
62690878|NCT04229017|EXPERIMENTAL|Circumferential Cervical Fusion (CCF)|Circumferential Cervical Fusion (CCF) is a combination of ACDF and Posterior Cervical Fusion (PCF) procedures. The PCF is completed with Posterior Cervical Stabilization System (PCSS).
61928453|NCT06743594||Laser-Assisted Cataract Surgery|Cataract Surgery with LenSx Femtosecond Laser
61928454|NCT05672524|EXPERIMENTAL|Participant with Rectal Adenocarcinoma|Participants will have HER2-positive locally advanced rectal adenocarcinoma.
61928455|NCT05041387||Neuromuscular disorders|Patients with neuromuscular disorders, no specific diagnosis
61928456|NCT06744725|EXPERIMENTAL|Dual-function semirigid thoracoscopy|Patients received pleural biopsy using dual-function semirigid thoracoscopy.
62482114|NCT06278779|ACTIVE_COMPARATOR|Racemic ketamine|"Treatment administration will follow standard clinical practice in the recruiting clinic, with a recommendation to follow an evidence-based and established dose-optimising approach, given by injection, twice per week for 4 weeks, then the frequency of further treatments (week 5 - month 6) will be based on the clinical judgement of the ketamine clinic psychiatrist.~Dosing will be adjusted by the ketamine clinic psychiatrist, based on clinical response, safety and tolerability. The psychiatrist will review the patient before each treatment, over the first 4 weeks, to judge the dose level required.~Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted using an ascending dose titration schedule if the patient has not shown clinical response and if side effects are adequately tolerated.~."
62482115|NCT06396286|EXPERIMENTAL|experimental|severe adolescent idiopathic scoliosis Lenke 1
62482116|NCT01836380|EXPERIMENTAL|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
62482117|NCT01836380|EXPERIMENTAL|Cycling Training|The cycling training will be conducted in the newly-constructed Exercise Training Intervention Core-Laboratory in the Department of Kinesiology and Health Education on the University of Texas campus. In the first 2-3 weeks a cycling instructor will provide personalized skill feedback to the subjects in the cycle training group. Subjects will cycle 15-20 minutes/day at a relatively low intensity of exercise while they receive cycling skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
62482118|NCT04793971||postoperative cases|patients that underwent percutaneous release of the paratenon for chronic midportion Achilles tendinopathy
62482119|NCT05350072|EXPERIMENTAL|Arm A|ianalumab
62482120|NCT05350072|PLACEBO_COMPARATOR|Arm B|placebo
62482121|NCT06743256|EXPERIMENTAL|Magnetic Surgical System in laparoscopic gynecological procedures|
62482122|NCT03703154||Study Arm|The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
62690879|NCT00697385|EXPERIMENTAL|TA|on treatment
62690880|NCT03683082|ACTIVE_COMPARATOR|PAH patients|Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask
62690881|NCT03683082|SHAM_COMPARATOR|PAH patients (crossover)|Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask
62690882|NCT01397591|EXPERIMENTAL|Ofatumumab with Bortezomib|Ofatumumab was given intravenously on cycle 1 day 1 at a dose of 300mg, followed by a cycle 1 day 8 dose of 1000mg. During cycles 2 through cycle 6, Ofatumumab was given at a dose of 1000mg on day 1 of each cycle, with no dosing on any other day of the cycle. Bortezomib was given intravenously at a dose of 1.6mg/m2 on days 1, 8, and 15 of each cycle, following the Ofatumumab infusion, if given.
62690883|NCT04913116||SARS-Cov-2 positives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
62131225|NCT05916001|PLACEBO_COMPARATOR|B, Placebo group + Colorectal Surgery|A Placebo will be administered 3 times a day for 10 days before the operation. Colon surgery will be performed according to standard clinical practice.
62322907|NCT03879668|NO_INTERVENTION|Historic control|The cohort will include all participants that were cared for by the participating specialist palliative home care teams in the last 6 months before the implementation of eIPOS.
62690884|NCT04913116||SARS-CoV-2 negatives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
62690885|NCT00814983|EXPERIMENTAL|Naive T-cell Depleted Stem Cell Transplant|Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.
61928457|NCT06744725|EXPERIMENTAL|Semirigid thoracoscopy|Patients received pleural biopsy using semirigid thoracoscopy
62322908|NCT03879668|NO_INTERVENTION|Prospective control|The cohort will include participants who are in the care of the participating specialist palliative home care teams at the same time as the eIPOS group, but who do not use eIPOS.
62322909|NCT00733356|EXPERIMENTAL|Vyvanse Treatment|All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
62690886|NCT00814983|ACTIVE_COMPARATOR|Stem Cell Transplant No Manipulation|Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation
62690887|NCT06405347|NO_INTERVENTION|Pre-Intervention Participants|Randomly selected patients who had been discharged within the two months prior to the intervention will be recruited to provide information via a survey.
61928458|NCT06743646|EXPERIMENTAL|Treatment group|Each Participant in this group will receive a unilateral subretinal injection of ZVS101e in the study eye
61928459|NCT06743646|NO_INTERVENTION|Control group|Participants in the control group will receive no treatment
62322910|NCT06178133||FFR|In this single-center cross-sectional study, we included patients with non-acute myocardial infarction who were admitted to the Department of Cardiology at Peking University Third Hospital for FFR testing from January 2019 to December 2021.
62322911|NCT05545813|EXPERIMENTAL|Probiotic|Participants will be randomized to receive the probiotic formulation for 8 weeks.
62322912|NCT05545813|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive the placebo formulation for 8 weeks.
62322913|NCT05184296|EXPERIMENTAL|cohort 1|Participants taking VA-ECMO during the period of study are referred to as cohort 1
62322914|NCT05184296|NO_INTERVENTION|cohort 2|Patients receiving only conventional therapy without ECMO belong to cohort 2
62482123|NCT03703154||Control Arm|Patients in the control arm will remain on the immediate release Tacrolimus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
62690888|NCT06405347|EXPERIMENTAL|Whole Health Intervention Participants|Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle.
62690889|NCT01137565|EXPERIMENTAL|AMG 853|
62690890|NCT01137565|PLACEBO_COMPARATOR|Placebo|
62690891|NCT06372080|EXPERIMENTAL|Resistance training with hydrolyzed collagen ingestion in healthy young men|"Healthy young men, pair-matched by age, body mass, height, and baseline strength, will be randomly allocated to the collagen (COL) or placebo (PLA) group.~Pre- and post-training assessments are patellar tendon properties, maximal knee flexor and extensor strengths and vastus lateralis muscle morphology using an isokinetic dynamometer and ultrasound scan.~Participants will perform the 10-week progressive resistance training program three times per week and training loads will be adjusted weekly based on the prior session's performance.~In each session, two different calorie-matched beverages were given immediately before the start of resistance training. 30 grams of hydrolyzed collagen (HC) and 30.5 grams of maltodextrin were used for COL and PLA respectively. HC or maltodextrin was mixed with 250 milliliters of water, 50 milligrams of vitamin C and 3 grams non-caloric sweetener which was used to mask flavour in an opaque bottle."
62690892|NCT06372080|EXPERIMENTAL|Resistance training with hydrolyzed collagen ingestion in healthy young women|The intervention procedure is the same as for Arm 1 except that the participants will be healthy young women (not men).
62690893|NCT03411044||Subjects with a Fitmore Hip Stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and who received the Fitmore Hip Stem.
62690894|NCT05888233|EXPERIMENTAL|Allopurinol - African American Veterans|Subjects will receive Allopurinol (300mg/daily) for 4 weeks. If tolerated, dose will be increased to 600mg/daily for an additional 4 weeks. Subjects will take Allopurinol (300-600mg/daily) for 8 weeks total
62131226|NCT05369936|EXPERIMENTAL|Lavender group|On the day of the lavender group, after filling the first phase questionnaire, 20 drops of the lavender oil will be added to the electrical aromatherapy vaporizer near the patient's chair at a distance of 20 cm in the waiting room. After 20 minutes, the second phase questionnaire will be given to the patient, and then the patient will be transformed to dental clinics in which the lavender vaporizer will be placed near the dental unit at a distance of 20 cm. The vaporizer will be also prepared by adding 20 drops of the lavender which will be added added every 20 minutes until the dental sitting will be finalized, and the third questionnaire will be answered. At home, the patients will be asked to pour 3 drops of the lavender on a pad and inhale it for 5 minutes from 10 cm distance every one hour until they attend on the next day to answer the fourth questionnaire.
62131227|NCT05369936|PLACEBO_COMPARATOR|Placebo group|The plain distal water vapors will be used as placebo, the good ventilation of the waiting room and clinics will be performed to ensure that the lavender scent is completely removed from the environment. The patients will inhale the vapors of the plain distal water
62131228|NCT00516477|EXPERIMENTAL|dose cohort 1|1.5E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
62690895|NCT02261792|ACTIVE_COMPARATOR|A : 24 hours bed rest|24 hours bed rest
62131229|NCT00516477|EXPERIMENTAL|dose cohort 2|4.8E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
62131230|NCT00516477|EXPERIMENTAL|dose cohort 3|1.5E11 vector genomes voretigene neparvovec-rzyl in 300 microliters administered subretinally
62690896|NCT02261792|EXPERIMENTAL|B : 24 hours Trendelenburg position|24 hours Trendelenburg position
62690897|NCT00237627|EXPERIMENTAL|Part 1|Doxil + PS-341
62690898|NCT00237627|EXPERIMENTAL|Part 2|Doxil + Velcade
62690899|NCT00747201|ACTIVE_COMPARATOR|2 Packaged intervention only|Patients will be seen by providers who receive the intervention package only.
62690900|NCT00747201|EXPERIMENTAL|1 Packaged intervention, training, and technical assistance|Patients will be seen by providers who receive the packaged intervention, along with provider training and ongoing technical assistance.
62690901|NCT06641726||Cohort 1|40,000 participants with linked EHR and baseline assessments will provide a DNA sample only, via saliva or blood. This cohort will comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 13,300 patients in each group).
62131231|NCT06013137|EXPERIMENTAL|Experimental|This group will have access to the Therabot smartphone application. They will interact with the generative chatbot daily to discuss their mental health. Each participant in this group will have some benchmark symptoms of depression, anxiety, or eating disorders. They will fill out questionnaires every 4 weeks to describe changes in symptoms.
62131232|NCT06013137|NO_INTERVENTION|Control|This group will not have access to the Therabot App. They will fill out questionnaires every 4 weeks to describe changes in symptoms. Each participant in this group will have some benchmark symptoms of depression, anxiety, or eating disorders.
62322915|NCT02851680|EXPERIMENTAL|Fongitell test|
62482124|NCT05757960|EXPERIMENTAL|Physiotherapy|Using a strictly defined physiotherapy protocol, the effects on temporomandibular dysfunctions are studied.
62131233|NCT06212843|EXPERIMENTAL|Group A (Plyometric training)|
62131234|NCT06212843|OTHER|Group B (Conventional)|
62131235|NCT01651767|EXPERIMENTAL|Panel I|Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
62131236|NCT01651767|EXPERIMENTAL|Panel II|Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
62131237|NCT01651767|EXPERIMENTAL|Panel III|Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
61928460|NCT03800693|ACTIVE_COMPARATOR|2-hour infusion group|Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62322916|NCT02851680|ACTIVE_COMPARATOR|serum galactomannan|
62690902|NCT06641726||Cohort 2|9,000 participants with linked EHR and baseline assessments patients will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood. This cohort will also comprise even distribution across neuropsychiatric disorders including Schizophrenia, Major depressive disorder (MDD), and Bipolar diagnostic groups (approximately 3000 patients in each group).
61928461|NCT03800693|EXPERIMENTAL|6-hour infusion group|Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
61928462|NCT04218708|ACTIVE_COMPARATOR|counseling + nicotine replacement therapies NRT|A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (NRT). Participants will also receive their NRT to last them to the following visit based on their baseline smoking.
62131238|NCT01651767|EXPERIMENTAL|Panel IV|Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.
62131239|NCT03465527|EXPERIMENTAL|Prednisolone|"Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days~Hydration, antibiotics, allopurinol, nutritional supplements, and so on."
62131240|NCT04067219|EXPERIMENTAL|Single arm|HIV-1 infected patients
62131241|NCT04034771|EXPERIMENTAL|propofol and melatonin|propofol iv infusion and melatonin 10 mg tablet through a nasogastric tube, once at admission.
62131242|NCT04034771|ACTIVE_COMPARATOR|propofol and placebo|propofol iv infusion and a placebo tablets through a nasogastric tube once at admission
62131243|NCT03751449|EXPERIMENTAL|Group I (active treatment)|Participants complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
61928463|NCT04218708|ACTIVE_COMPARATOR|Counseling + Standardized Research E-cigarettes (SREC)|Participants in the SREC arm to practice using the SREC and give them instructions to return with their SREC and used refill tanks on every visit. A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (SREC). Participants will also receive their SREC to last them to the following visit based on their baseline smoking.
61928464|NCT06256367||Cariprazine|Participants will receive cariprazine as prescribed by their physician in routine clinical practice. The decision to initiate cariprazine should be made prior to, and independently from, the decision to participate in this study.
61928465|NCT05212090|OTHER|Pre-THA|Subjects will be receiving EOS imaging prior to Total Hip Arthoplasty
61928466|NCT05212090|OTHER|Post-THA|Subjects will be receiving EOS imaging after Total Hip Arthroplasty
61928467|NCT06744244||Mild Birth Asphyxia|Term newborns (37-41 weeks of gestational age) with signs of moderate asphyxia at birth (cord pH \< 7.10 and/or BE \> -12), with mild asphyxia at birth.
61928468|NCT06744244||Moderate - Severe Birth Asphyxia|Term newborns (37-41 weeks of gestational age) with signs of moderate asphyxia at birth (cord pH \< 7.10 and/or BE \> -12) with moderate asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy, who don't need hypothermia treatment and with severe asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy who don't need hypothermia treatment.
61928469|NCT06745791||Spinal MRI and CT|Subjects referred to the radiology department for an MRI and CT scan of the spine having symptoms related to a spine disorder with suspected underlying involvement of osseous structures, will be asked to participate in this study.
61928470|NCT05718583|EXPERIMENTAL|RA Patients who are Inadequate Responders to Current RA Treatment|Oral butyrate will be taken at 1000 mg three times daily with meals by RA patients who have active disease and are currently taking methotrexate (MTX) at prescriber's recommended dose. There will be no dose escalation of the study supplement. Clinical data to assess for adverse events, stool, urine samples and peripheral blood will be collected at baseline, 1 month, and with an optional 2-month time-point.
61928471|NCT06568081|EXPERIMENTAL|SloMo|
61928472|NCT04063267|EXPERIMENTAL|E cigarettes|
61928473|NCT04063267|ACTIVE_COMPARATOR|Nicotine Replacement Therapy|
61928474|NCT04246112|EXPERIMENTAL|Treatment group|Participants are diagnosed with tic disorder and/or Tourette syndrome. They will undergo treatment to improve overall handwriting skills.
61928475|NCT05696392|EXPERIMENTAL|Treatment Group: Ruxolitinib|ruxolitinib cream 1.5% will be applied twice daily (BID) as a thin film.
61928476|NCT06241118|EXPERIMENTAL|Amlitelimab dose 1|Subcutaneous injection as per protocol
61928477|NCT06241118|EXPERIMENTAL|Amlitelimab dose 2|Subcutaneous injection as per protocol
62131244|NCT03751449|ACTIVE_COMPARATOR|Group II (waitlist)|Participants are placed on a waitlist for 12 weeks and then complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
62131245|NCT05487118|PLACEBO_COMPARATOR|Placebo PBMT + MCE|Placebo photobiomodulation therapy (PBMT), with a dose of 0 J, will be applied before a protocol of motor control exercises (MCE).
62131246|NCT05487118|ACTIVE_COMPARATOR|Active PBMT + MCE|Active photobiomodulation therapy (PBMT), with a dose of 30 J, will be applied before a protocol of motor control exercises (MCE).
61928478|NCT06241118|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection as per protocol
61928479|NCT03310957|EXPERIMENTAL|LV + pembrolizumab|LV + pembrolizumab
62131247|NCT02250430|EXPERIMENTAL|Topical SB204|Topical application of SB204 2% and 4% twice daily for 2 days and once on Day 3
62131248|NCT06229301||Experienced-nomogram Group|Patients who underwent Small incision lenticule extraction (SMILE) from March 2014 to October 2018 in Refractive Surgery Center of Tianjin Eye Hospital and had at least three months of postoperative follow-up were included in this group. The Nomogram were based on experience of the surgeon.
62690903|NCT06641726||Cohort 3|1000 participants with Dementia who have linked EHR and assessments will provide DNA, RNA, peripheral blood mononuclear cells (PBMCs), plasma and serum via blood.
62690904|NCT06564740|EXPERIMENTAL|Stem Cell Application Group|In this group, UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg. The applications will be applied after kasai portoenterostomy.
62690905|NCT06564740|SHAM_COMPARATOR|Control|In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to Biliary Atresia patients will continue to be administered.
62690906|NCT05777863|EXPERIMENTAL|High-intensity group|The high-intensity group receives a supervised multidomain lifestyle intervention consisting of weekly group meetings. During the weekly group meetings, information and exercises are provided, and participants are able to exchange experiences and advice with other group members.
62690907|NCT05777863|NO_INTERVENTION|Low-intensity group|The low-intensity group only receives access to general lifestyle-related health information through biweekly leaflets, which are provided through e-mail.
62690908|NCT04913090|EXPERIMENTAL|Part A-experimental|Single Ascending Dose (SAD) phase
61928480|NCT04297085|EXPERIMENTAL|Cases|
61928481|NCT05358353|EXPERIMENTAL|Bare Temporary Spur Stent System|Treatment with the Temporary Bare Spur Stent System (Spur Stent System).
61928482|NCT06677970|ACTIVE_COMPARATOR|Conventional BP magnagement group (SBP <180 mmHg)|
62131249|NCT06229301||AI-nomogram Group 1|Patients who underwent Small incision lenticule extraction (SMILE) from November 2018 to May 2021 in Refractive Surgery Center of Tianjin Eye Hospital and had at least three months of postoperative follow-up were included in this group. AI-predicted nomogram was obtained and used on patients who underwent surgery.
62690909|NCT04913090|PLACEBO_COMPARATOR|Part A-placebo|Single Ascending Dose (SAD) phase
62690910|NCT04913090|EXPERIMENTAL|Part B-experimental|multiple ascending dose (MAD) phase
61928483|NCT06677970|ACTIVE_COMPARATOR|Intensive BP raising group (20% increase in SBP, maximum of 180 mmHg )|
62690911|NCT04913090|PLACEBO_COMPARATOR|Part B-placebo|multiple ascending dose (MAD) phase
62690912|NCT04913090|EXPERIMENTAL|Part C1-experimental|Food Effect (FE) phase
61928484|NCT04793776|EXPERIMENTAL|Manage Emotions to Reduce Aggression (MERA)|MERA is 3 individual 90-minute sessions delivered over 3 weeks.
61928485|NCT04793776|ACTIVE_COMPARATOR|Present Centered Psychotherapy (PCT)|PCT delivered in 3 individual 90-minute sessions over 3 weeks.
61928486|NCT05629585|EXPERIMENTAL|Dato-DXd in combination with Durvalumab|Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Durvalumab 1120 mg IV Q3W x 9 cycles
61928487|NCT05629585|EXPERIMENTAL|Dato-DXd|Arm 2: Dato-DXd 6 mg/kg IV Q3W x 8 cycles
61928488|NCT05629585|ACTIVE_COMPARATOR|Investigators Choice Therapy|"Arm 3: Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles~Pembrolizumab\* (200 mg IV on Day 1, Q3W) for 9 cycles~Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles + pembrolizumab\* (200 mg IV on Day 1, Q3W) for 9 cycles~\* Only participants who have received prior pembrolizumab in the neoadjuvant setting should receive pembrolizumab as part of their adjuvant therapy on Arm 3."
61928489|NCT05121545|OTHER|Pro-GRID treatment Arm|Patients enrolled in this study will receive spatially-fractionated radiotherapy or GRID-therapy, which involves delivering a one-time treatment of high dose radiation to small amounts of tumor in a manner that creates alternating regions of high and low dose radiation within the tumor. Patients will receive 2 (lowest dose) to 18 Gy (highest dose) in a single fraction.
61928490|NCT04901195|EXPERIMENTAL|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period.
61928491|NCT04901195|EXPERIMENTAL|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period.
61928492|NCT06679400|EXPERIMENTAL|Massage with communication level 1|The therapist and the participant will have this level of communication (known as level 1 here). Further details will be explained at the end of the study.
61928493|NCT06679400|EXPERIMENTAL|Massage with communication level 2|The therapist and the participant will have this level of communication (known as level 2). Further details will be explained at the end of the study.
61928494|NCT06634420|ACTIVE_COMPARATOR|Arm A: NTLA-2002|Arm A: NTLA-2002 (50 mg; single IV infusion)
61928495|NCT06634420|PLACEBO_COMPARATOR|Arm B: Placebo|Arm B: Placebo (saline; single IV infusion)
61928496|NCT06323044|EXPERIMENTAL|Arm A (MedSupport)|Participants receive the MedSupport intervention consisting of three components: universal screening for adherence barriers, tailored virtual education enhancement, and communication of barriers to activate multidisciplinary healthcare teams for 12 months. Participants also use the MEMS device to track oral chemotherapy adherence at baseline and follow-up. Patients also undergo blood sample collection throughout the study.
61928497|NCT06323044|ACTIVE_COMPARATOR|Arm B (usual care)|Participants receive usual care consisting of medical consultations and supportive care for 12 months. Participants also use the MEMS device to track oral chemotherapy adherence at baseline and follow-up. Patients also undergo blood sample collection throughout the study.
62131250|NCT06229301||AI-nomogram Group 2|Patients who underwent Small incision lenticule extraction (SMILE) from January 2023 in Refractive Surgery Center of Tianjin Eye Hospital and had at least three months of postoperative follow-up were included in this group. The datasets used to train AI(Artificial Intelligence) models have been continuously updated for better accuracy since 2018, the newest AI-predicted nomogram was obtained and used on patients who underwent surgery.
62131251|NCT06229301||Good Surgical Effect and Changes of Biological Parameters|-0.50D \< spherical equivalent (SE) \< 0.50D
62131252|NCT06229301||Poor Surgical Effect and Changes of Biological Parameters|spherical equivalent (SE) \<-0.50D or \>0.50D
62690913|NCT04913090|EXPERIMENTAL|Part C2-experimental|Food Effect (FE) phase
62690914|NCT04028167|EXPERIMENTAL|Sequential FLOT followed by chemoradiation|Sequential Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/Leucovorin followed by chemoradiation with concurrent carboplatin and paclitaxel
62690915|NCT06674148|EXPERIMENTAL|Qifangfeixian granule group|62 cases in the group , 2 times a day, each time 1 bag of Qifangfeixian granules, oral administration
62690916|NCT06674148|PLACEBO_COMPARATOR|Placebo control group|62 control group patients were orally administered with 1 bag of placebo twice a day
62690917|NCT05701631||non-HIV patients hospitalized for suspected PCP|non-HIV patients hospitalized for suspected PCP
62482125|NCT04563520|EXPERIMENTAL|Experimental treatment|"Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI. If there is less than a good' response in bleed event response efficacy as stated above at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with max dose no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days without further discussion with the PI."
62482126|NCT06041971|EXPERIMENTAL|Group A|Two-week control period before the use of the AIDANET system.
62482127|NCT06041971|EXPERIMENTAL|Group B|Two-week control period after the use of the AIDANET system.
62482128|NCT03125447|EXPERIMENTAL|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
62482129|NCT03125447|ACTIVE_COMPARATOR|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
62482130|NCT05239195|ACTIVE_COMPARATOR|Video Laryngoscope Group|For patients assigned to the video laryngoscope group, the operator will use a video laryngoscope on the first laryngoscopy attempt. A video laryngoscope will be defined as a laryngoscope with a camera and a video screen. Trial protocol will not dictate the brand of video laryngoscope.
62482131|NCT05239195|ACTIVE_COMPARATOR|Direct Laryngoscope Group|For patients assigned to the direct laryngoscope group, the operator will use a direct laryngoscope on the first laryngoscopy attempt. A direct laryngoscope will be defined as a laryngoscope without a camera or a video screen. Trial protocol will not dictate the brand of direct laryngoscope or the blade shape.
62690918|NCT03141970|EXPERIMENTAL|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
62690919|NCT03141970|NO_INTERVENTION|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
62690920|NCT05402345|EXPERIMENTAL|GlcNAc|GlcNAc powder
62690921|NCT05402345|PLACEBO_COMPARATOR|Placebo|Placebo xylose
62690922|NCT06675734||Experimental Group (Group E)|After the operation, study groups will be formed according to the post operative analgesia method determined and applied by the periodontologist. Accordingly, individuals to whom diclofenac sodium-containing ampoule was administered intramuscularly within 1 hour following the operation will be included in the study group.
62690923|NCT06675734||Control Group (Group C)|Patients who do not require intramuscular administration of diclofenac sodium containing ampoule will be included in the control group.
62482132|NCT06561516|EXPERIMENTAL|Red ginseng group|The Red ginseng group will consume red ginseng (ginsenoside 500mg/T) for three months starting one month after surgery. Patients take 2 tablets of 500mg ginsenoside twice daily.
62482133|NCT06561516|NO_INTERVENTION|Control group|The control group will not receive any intervention during the experimental periods.
62690924|NCT05346718|EXPERIMENTAL|Sequence A: Exposure to no pollen (placebo), then to first pollen concentration|Participants are first exposed to no pollen, then challenged with the first pollen concentration, and finally all following concentrations.
62690925|NCT05346718|EXPERIMENTAL|Sequence B: Exposure to first pollen concentration, then to no pollen (placebo)|Participants are first challenged with the first pollen concentration, then with no pollen, and finally with all following concentrations.
62131253|NCT05493644||group A|Within 3 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
62131254|NCT05493644||group B|Within 3 to 6 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
62131255|NCT05493644||group C|Within 6 to 12 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
62482134|NCT00137254|ACTIVE_COMPARATOR|A|
62482135|NCT06087640|EXPERIMENTAL|MF59-adjuvanted influenza vaccine|MF59-adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains or MF59-adjuvanted TIV containing 2 influenza type A strains and 1 influenza type B strain
62482136|NCT06087640|OTHER|Non-adjuvanted influenza vaccine|Non-adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains or Non-adjuvanted TIV containing 2 influenza type A strains and 1 influenza type B strain
62482137|NCT06709222|ACTIVE_COMPARATOR|control|the group that received robotic rehabilitation only
62482138|NCT06709222|EXPERIMENTAL|exercise|group receiving robotic rehabilitation and dual-task exercises
62482139|NCT04975880|OTHER|Hemodialysis Treatments|All subjects will receive hemodialysis treatments using the SC+ machine for all phases of the trial including in-clinic training, transition, and in the home setting.
62690926|NCT03712761||Supplementation with Enriched Protein®|Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
62690927|NCT03712761||Low protein breakfast|No supplementation
62690928|NCT03712761||High protein breakfast|No supplementation
62690929|NCT04466033|EXPERIMENTAL|Magneto Microcatheter|
62690930|NCT01933763|EXPERIMENTAL|Group A|Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
62690931|NCT01933763|EXPERIMENTAL|Group B|Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
62690932|NCT03196479|ACTIVE_COMPARATOR|ketamine:propofol ratio of 1:6|K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
62322917|NCT05469932|ACTIVE_COMPARATOR|Treatment|"Pre-treatment medical examination by an ophthalmologist and self-filled questionnaire.~Four treatment sessions. Each session includes 20 minutes with the instrument active at power level 4. Post-treatment medical examination by an ophthalmologist and self-filled questionnaire."
62482140|NCT05631964|EXPERIMENTAL|Study treatment|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62482141|NCT06743230|ACTIVE_COMPARATOR|Conventional Training|Conventional training includes flexibility exercises, strengthening exercises, running, balance and sport-specific technique work 5 days per week.
62482142|NCT06743230|EXPERIMENTAL|Neuro athletic training|Conventional training includes flexibility exercises, strengthening exercises, running, balance, and sport-specific technique work 5 days per week.Neuro athletic training includes exercises that stimulate the visual, vestibular and proprioceptive systems. The neuroathletic training includes 3 days per week for 8 weeks.
62482143|NCT03972306|EXPERIMENTAL|Group A: Cohorts A1-A4|"Participants (participants pretreated with ocrelizumab) will receive a single injection of subcutaneous (SC) ocrelizumab co-mixed with rHuPH20 in the abdomen. For every new dose level, recruitment will be staggered by enrolling 1 participant in each cohort followed by a 48-hour waiting period to review safety and tolerability data by the Safety Monitoring Committee (SMC) prior to enrolling subsequent participants in the same cohort. Currently, the planned dose escalation steps for patients who enroll in Group A are as follows:~* Cohort A1: 40 mg of SC ocrelizumab~* Cohort A2: 200 mg of SC ocrelizumab~* Cohort A3: 600 mg of SC ocrelizumab~* Cohort A4: 1200 mg of SC ocrelizumab"
62482144|NCT03972306|EXPERIMENTAL|Group A: Cohort A5|In the non-randomized subphase, participants will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.
62482145|NCT03972306|EXPERIMENTAL|Group A: Cohort AA|Participants will receive a single 600-mg dose ocrelizumab by intravenous (IV) infusion
62482146|NCT03972306|EXPERIMENTAL|Group B: Cohorts B1-B4|"Ocrelizumab treatment- naive participants will receive a minimum of 3 patients in Cohort B will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.~* Cohort B1: 40 mg of SC ocrelizumab~* Cohort B2: 200 mg of SC ocrelizumab~* Cohort B3: 600 mg of SC ocrelizumab~* Cohort B4: 1200 mg of SC ocrelizumab"
62482147|NCT06639451|EXPERIMENTAL|RANGER™ Paclitaxel Coated Balloon|RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the AVF at the index procedure.
62482148|NCT06422520|EXPERIMENTAL|Phase 1a: Part A (Monotherapy Dose Escalation)|BGB-C354 monotherapy doses at sequentially increasing levels.
62482149|NCT06422520|EXPERIMENTAL|Phase 1a: Part B (Safety Expansion)|Participants will enroll at safe dose levels recommended by the Safety Monitoring Committee (SMC) for further evaluation.
62690933|NCT03196479|ACTIVE_COMPARATOR|ketamine:propofol ratio of 1:4|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
61928498|NCT03674424|EXPERIMENTAL|DD-MVAC + avelumab|"Methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) given in combination with Avelumab.~DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2. Each cycle is given every 2 weeks for a maximum of 4 administrations Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 2 every 2 weeks.~Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
62322918|NCT05469932|PLACEBO_COMPARATOR|Placebo|"Pre-treatment medical examination by an ophthalmologist and self-filled questionnaire.~Four treatment sessions. Each session includes 20 minutes with the instrument active at power level 0. Post-treatment medical examination by an ophthalmologist and self-filled questionnaire."
62322919|NCT04150640|EXPERIMENTAL|Cohort 1: HER2 Negative|Participants in Cohort 1 (HER2-negative) will be treated with nal-IRI (50 mg/m\^2 - intravenously over 90 min), 5-FU (2400 mg/m\^2 over 46 hrs), and oxaliplatin (60 mg/m\^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
62322920|NCT04150640|EXPERIMENTAL|Cohort 2: HER2 Positive|Participants in Cohort 2 (HER2-positive) will be treated with nal-IRI (50 mg/m\^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m\^2 over 46 hrs), and oxaliplatin (60 mg/m\^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
62322921|NCT04150640|EXPERIMENTAL|Cohort 3: HER2 Negative|Participants in Cohort 3 (HER2-negative) will be treated with nal-IRI (50 mg/m\^2 - intravenously over 90 min), 5-FU (2400 mg/m\^2 over 46 hrs), oxaliplatin (60 mg/m\^2), and nivolumab. (240 mg). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle
62322922|NCT04150640|EXPERIMENTAL|Cohort 4: HER2 Positive|Participants in Cohort 4 (HER2-positive) will be treated with nal-IRI (50 mg/m\^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m\^2 over 46 hrs), oxaliplatin (60 mg/m\^2), and pembrolizumab (400 mg). Each cycle is 42 days. Participants will receive chemotherapy and trastuzumab treatments on day 1, 15, and 29 of each cycle. Pembrolizumab will be given on day 1 of each cycle.
62322923|NCT02889510|OTHER|liraglutide|7-week subcutaneous liraglutide treatment once daily
62322924|NCT02889510|OTHER|placebo|7-week subcutaneous placebo treatment once daily.
62322925|NCT05892783|EXPERIMENTAL|experimental group|This group will receive myofascial release on the PF of both legs, namely foam rolling, plantar fascia specific stretching and soft tissue mobilization.
62482150|NCT06422520|EXPERIMENTAL|Phase 1b: Part C (Monotherapy Expansion)|BGB-C354 will be administered at the recommended dose for expansion (RDFE).
62482151|NCT06422520|EXPERIMENTAL|Phase 1b: Part D (Combination Therapy Expansion)|BGB-C354 and tislelizumab will be adminsitered at doses determined by the SMC.
62482152|NCT06737354|EXPERIMENTAL|IVB103 Treatment Arm（Low dose）|Intraocular injection of a single low dose of IVB103
62482153|NCT06737354|EXPERIMENTAL|IVB103 Treatment Arm（Intermediate dose）|Intraocular injection of a single intermediate dose of IVB103
62690934|NCT01415687|ACTIVE_COMPARATOR|PEG Arm|Patients randomized to this arm of the trial will be following preparation instructions using Polyethylene Glycol-Based Lavage in a split dose format
62690935|NCT01415687|ACTIVE_COMPARATOR|Pico-Salax + Bisacodyl Arm|Patients randomized to this arm will follow preparation instructions using Pico-Salax preparation plus Biscacodyl in a split dose format
62482154|NCT06737354|EXPERIMENTAL|IVB103 Treatment Arm（High dose）|Intraocular injection of a single high dose of IVB103
62482155|NCT06297122||Patients|"All consecutive children under the age of 18 years with community-acquired or healthcare-associated severe Group A Streptococcus (GAS) infections admitted to Necker hospital between January 1, 2018, and December 31, 2023. Among GAS infections, invasive and probable invasive GAS illnesses will be distinguish.~Invasive GAS infection will be defined as: isolation by culture or polymerase chain reaction of GAS from a normally sterile site; or isolation of GAS from a sterile or non-sterile site accompanied by necrotizing fasciitis or streptococcal toxic shock syndrome.~Probable invasive GAS will be defined as acute infections with GAS isolated from a non-sterile site, which includes sputum, otorhinolaryngology surgical specimens (mastoiditis, ethmoiditis, pharyngeal abscess) accompanied with one or more of the following severity criteria:intravenous antibiotics;surgery; and/or admission to the pediatric intensive care unit."
62482156|NCT04711057|EXPERIMENTAL|Pulmonary Rehabilitation + Community-based PA program|After PR, the experimental group will integrate a community-based PA program.
61928499|NCT03674424|EXPERIMENTAL|CG+ avelumab|"Cisplatin, gemcitabine (CG) consists of Gemcitabine 1000 mg/m2 iv in day 1 and day 8 and Cisplatin 70 mg/m2 iv in day 1. Each cycle is given every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
61928500|NCT03674424|EXPERIMENTAL|PG+ avelumab|"Paclitaxel, gemcitabine (PG) consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15. Each cycle is repeated every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
61928501|NCT03674424|EXPERIMENTAL|Avelumab|"Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (iv) infusion once every 2 weeks. Dose reductions are not allowed.~Avelumab will be given alone for 4 administrations. Cystectomy will be performed 2 weeks after the last administration of avelumab"
61928502|NCT05948579|EXPERIMENTAL|Intervention B Vilazodone|
61928503|NCT05948579|PLACEBO_COMPARATOR|Intervention B Placebo|
61928504|NCT06008353||Adult patients newly diagnosed with ES-SCLC|The study will include consecutive adult patients newly diagnosed with ES-SCLC (patients with the recurrent limited stage disease are also eligible).
61928505|NCT06745674|NO_INTERVENTION|Waitlist control group|
61928506|NCT06745674|EXPERIMENTAL|ACT group|
61928507|NCT06047171|EXPERIMENTAL|Standard treatment + ALE.F02 low dose infusions|Standard treatment + ALE.F02 low dose infusions
61928508|NCT06047171|EXPERIMENTAL|Standard treatment + ALE.F02 high dose infusions|Standard treatment + ALE.F02 high dose infusions
61928509|NCT06047171|PLACEBO_COMPARATOR|Standard treatment + placebo infusions (inactive substance)|Standard treatment + placebo infusions (inactive substance)
61928510|NCT06047171|EXPERIMENTAL|Standard treatment + ALE.F02 maximum dose infusions|Standard treatment + ALE.F02 maximum dose infusions
62131256|NCT05493644||group D|After 12 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
62131257|NCT05990816||Arthroplasty Patients|Only one group that consist patients who underwent primary total joint arthroplasty
62482157|NCT04711057|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates PA recommendations.
62131258|NCT01365598|PLACEBO_COMPARATOR|Placebo|Non-active drug
62322926|NCT05892783|NO_INTERVENTION|control group|This group will receive advice only.
62322927|NCT05155787|EXPERIMENTAL|Group with neurofeedback training|The neurofeedback training system records the brain waves from the subject and converts the original brain wave signal into frequency energy through spectrum analysis. The system will help the subject to find self relax method for producing more alpha waves. Each person will arrange training three times a week for four weeks.
61928511|NCT05682560|EXPERIMENTAL|RegeneCyte|HPC, Cord Blood
62131259|NCT01365598|EXPERIMENTAL|Low dose primaquine (PQ1)|Lowest experimental dose of primaquine base: 0.1mg/kg
61928512|NCT05682560|PLACEBO_COMPARATOR|Placebo|Normal Saline
62131260|NCT01365598|EXPERIMENTAL|Intermediate dose primaquine (PQ2)|Intermediate experimental dose of primaquine base: 0.4mg/kg
62131261|NCT01365598|ACTIVE_COMPARATOR|Reference dose primaquine (PQ-R)|WHO-recommended dose of primaquine base: 0.75mg/kg
62322928|NCT05155787|SHAM_COMPARATOR|Group with shame neurofeedback training|In the shame group, the system is not feedback to the actual wave. Each person will arrange training three times a week for four weeks.
62322929|NCT06404125||Group 1 (Patients without central sensitization)|Patients with rotator cuff lesions lasting more than three months and without central sensitization will be included in group 1. (n=18)
62322930|NCT06404125||Group 2 (Patients with central sensitization)|patients with rotator cuff lesions lasting more than three months and central sensitization will be included in group 2. (n=18)
62322931|NCT00608335|EXPERIMENTAL|1. Micafungin 3.0 mg|IV
62322932|NCT00608335|EXPERIMENTAL|2. Micafungin 4.5 mg|IV
62322933|NCT00001262|EXPERIMENTAL|Copper histidine|
62322934|NCT03249350|ACTIVE_COMPARATOR|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
62322935|NCT03249350|EXPERIMENTAL|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
62322936|NCT01741194|EXPERIMENTAL|AC-1204|Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
62482158|NCT04442646|EXPERIMENTAL|ASG= Asthma School Group, with educational intervention|"experimental asthma school group (ASG) will attend control visits as Control Group every three months. In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day"
62482159|NCT04442646|NO_INTERVENTION|CG= Control Group, With no educational intervention|Control group will attend control visits every three months.
62322937|NCT01741194|PLACEBO_COMPARATOR|Placebo|Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
62482160|NCT04581304|EXPERIMENTAL|Bio-Oss Collagen|Transcrestal approach sinus augmentation using Geistlich Bio-Oss Collagen®.
62482161|NCT04581304|ACTIVE_COMPARATOR|Bio-Oss Granules|Transcrestal approach sinus augmentation using Geistlich Bio-Oss®.
62482162|NCT06743334||All primary series recipients using monovalent vaccine|All individuals who received first dose with monovalent vaccine as primary series (6 months or older).
62482163|NCT06743334||First booster recipients with monovalent vaccine|All individuals who received first booster recipients with monovalent vaccine (5 years of age or older).
62482164|NCT06743334||Second booster recipients with monovalent vaccine|All individuals who received second booster recipients with monovalent vaccine (5 years of age or older).
62482165|NCT06743334||All booster recipients using bivalent vaccine|All individuals who received booster recipients using bivalent vaccine (12 years of age or older).
62482166|NCT06743334||Single-dose primary series recipients with bivalent vaccine|All individuals who received single-dose primary series recipients with bivalent vaccine (12 years of age or older).
62482167|NCT06743334||Primary series recipients with first dose of monovalent vaccine and second dose of bivalent vaccine|All individuals who received primary series recipients with first dose of monovalent vaccine and second dose of bivalent vaccine (12 years of age or older).
62482168|NCT05450393||PillCam SB procedure and deep enteroscopy (Device-assisted enteroscopy, DAE)|Subjects with abnormal PillCam SB3 procedure followed by DAE (if performed).
62482169|NCT06741878|ACTIVE_COMPARATOR|Exercise Training (Biological) + Board Games (Psychosocial) + Diet Consultation (Nutritional)|
62482170|NCT06741878|ACTIVE_COMPARATOR|Exercise Training (Biological) + Diet Consultation (Nutritional)|
62482171|NCT06741878|ACTIVE_COMPARATOR|Board Games (Psychosocial) + Diet Consultation (Nutritional)|
62482172|NCT06741878|NO_INTERVENTION|Inactive Control (No Treatment)|
62322938|NCT02514512|NO_INTERVENTION|Standard SABR|Patients receive standard treatment
62482173|NCT06722235|EXPERIMENTAL|Mezagitamab|Participants will receive mezagitamab injection, SC, once weekly (QW). They will receive 8 weekly doses, followed by 8 weekly doses off, and then receive 8 more weekly doses.
62482174|NCT06722235|PLACEBO_COMPARATOR|Placebo|Participants will receive mezagitamab placebo-matching injection, SC, QW. They will receive 8 weekly doses, followed by 8 weekly doses off, and then receive 8 more weekly doses.
62482175|NCT06742723|EXPERIMENTAL|Baxdrostat/dapagliflozin|Participants randomised to the baxdrostat/dapagliflozin arm will initially receive a lower dose of baxdrostat and standard dose dapagliflozin. For participants that meet the up-titration criteria, baxdrostat may be up-titrated to higher dose.
62482176|NCT06742723|PLACEBO_COMPARATOR|Placebo/dapagliflozin|Patients will receive one dose of dapagliflozin comparator in combination with matching placebo daily.
62482177|NCT06742749|EXPERIMENTAL|Group 1|For the proximal level of psoas tenotomy at the pelvic brim, the hip was slightly flexed to relax the iliopsoas muscle; the iliacus muscle fibers were retracted anteriorly until the deeply seated posteromedially psoas tendon was isolated and transected
62482178|NCT06742749|ACTIVE_COMPARATOR|Group 2|. For the distal level of iliopsoas tenotomy just above the lesser trochanter, the thigh was put in the position of FABER (flexion, abduction, and external rotation). A curved right-angle hemostatic clamp was used to retract and bring the iliopsoas tendon into the field. Then, the tendinous fibers were transected.
62482179|NCT01956084|EXPERIMENTAL|LMP1/2 CTLs (Group A)|Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant
62482180|NCT01956084|EXPERIMENTAL|LMP1/2 CTLs (Group B)|Patients receiving CTLs in relapse following allogeneic stem cell transplant
62482181|NCT06742671||Patient suspected of Giant Cell Arteritis|"Patient over 50 years old suspected of Giant Cell Arteritis and presenting at least one of the following signs:~Visual symptoms~* Transient vision loss (amaurosis)~* Anterior or posterior ischemic optic neuropathy~* Occlusion of the central retinal artery and/or its branches~* Diplopia due to paralysis of the oculomotor muscles~* Ocular ischemic syndrome~Suggestive signs and symptoms:~* Recent headaches \< 4 months~* Jaw claudication~* Scalp tenderness~* Abnormal temporal artery examination - beaded appearance, prominence, widening, tenderness~* Elevated C-reactive protein ≥ 10 mg/l~Systemic symptoms:~* Fever~* Anemia~* Upper limb claudication~* Polymyalgia rheumatica Suggestive imaging result~* Positive positron emission computed tomography scan~* CT scan aortitis"
62482182|NCT06459258|ACTIVE_COMPARATOR|Non-NMES control group|Subjects of the control group undergo a conventional standardized strength training program (3x/week, 30 minutes for 6 weeks) with concentric, eccentric, and functional training exercises.
62322939|NCT02514512|EXPERIMENTAL|MLC Tracking SABR|Patients are treated with MLC tracking
62322940|NCT03166358|EXPERIMENTAL|hatha yoga intervention|Participants randomized to the intervention are asked to attend 8 hatha yoga classes delivered in a group format.
62322941|NCT03166358|NO_INTERVENTION|waitlist control|Participants randomized to the waitlist control condition complete assessments while the intervention group completes the yoga intervention. They are given the option to complete 8 hatha yoga classes delivered in group format once the waitlist period is finished.
62322942|NCT03958617|ACTIVE_COMPARATOR|On condition|Ongoing thalamic deep brain stimulation
62322943|NCT03958617|SHAM_COMPARATOR|Off condition|Switched off thalamic deep brain stimulation, sham stimulation
62322944|NCT06269211|EXPERIMENTAL|Toripalimab|Neoadjuvant Toripalimab 240 mg IV on cycle 1 day 1 (C1D1), C2D1 and C3D1 before radical surgery for lung cancer. The participants will attend follow-up visits based on molecular residual disease (MRD) and receive adjuvant treatment including EGFR-TKI or chemotherapy if recommended.
62322945|NCT01512394|ACTIVE_COMPARATOR|Standard bowel prep|Standard bowel prep
62322946|NCT01512394|EXPERIMENTAL|No bowel prep|No bowel prep
62690936|NCT06564922|EXPERIMENTAL|Postnatal Counselling on Exclusive Breast Feeding|Counseling on exclusive breastfeeding (EBF) emphasizes starting within the first hour after birth and maintaining it for six months. It covers feeding frequency, proper positioning, and attachment techniques to enhance breastfeeding effectiveness. Benefits include reduced neonatal infections and lower maternal disease risks. The counseling warns against mixed feeding, which can lead to increased infection susceptibility and malnutrition. It also highlights postpartum danger signs in newborns, such as fever and irritability, encouraging early medical intervention. This comprehensive approach aims to empower mothers with knowledge, promoting healthier breastfeeding practices and improving outcomes for both mother and child.
62690937|NCT06564922|NO_INTERVENTION|Individualized Immediate Postnatal Counselling on Exclusive Breast Feeding|Usual counselling will be given.
62690938|NCT02965313|ACTIVE_COMPARATOR|SSLS Procedure|
61928513|NCT05890677|EXPERIMENTAL|Group A : Surgical Group|"According to the pragmatic study design, neither the diagnostic workup nor the surgery will be standardized in order to offer surgeons considerable leeway on how to perform lymphatic surgery, which resembles the flexibility in usual care. The key aspects of the preoperative workup and the surgery including the number of LVAs (Lymphovenous Anastomosis), harvesting of lymph nodes (donor site), time of surgery, and practical details will be registered."
61928514|NCT05890677|ACTIVE_COMPARATOR|Group B: Conservative Complex Physical Decongestion Therapy (control group)|CDT (Conservative Complex Physical Decongestion Therapy) will be performed as in usual care, following the pragmatic study design. The key aspects like frequency of lymphatic drainage, time when lymphatic drainage is performed and time and class of compressive garments are used will be documented. CDT incorporates two stages of treatment. The first treatment phase (intensive phase) entails skincare, MLD (manual lymphatic drainage), exercises aimed at improvement of mobility/range of motion in the shoulder, elbow or wrist joints, and compression therapy through bandaging. Most patients undergo this phase shortly after the diagnosis of LE. CDT in the second phase (maintenance phase) aims to maintain the achieved limb volume/ circumference reduction through compression with therapeutic elastic compression garment for the arm. Skincare, mobility exercises and MLD is continued in this phase if needed
61928515|NCT06200779|ACTIVE_COMPARATOR|Intervention group|Patients randomized to the Intervention group will receive a prescription for oriented H. pylori eradication treatment according to the following rules: a) clarithromycin-sensitive strain (independently of levofloxacin resistance test result) - PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days; b) clarithromycin-resistant and levofloxacin-sensitive strain - PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days; c) clarithromycin-resistant and levofloxacin-resistant strain - bismuth quadruple therapy (Pylera®) for 10 days. At least 4 weeks after stopping antibiotics (and at least 2 weeks after stopping PPIs), an eradication control test will be carried out using a respiratory test (urea breath test) or endoscopic biopsies (if clinical indication for that).
61928516|NCT06200779|ACTIVE_COMPARATOR|Control group|Patients randomized to the Control group will receive a prescription for empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®) for 10 days. At least 4 weeks after stopping antibiotics (and at least 2 weeks after stopping PPIs), an eradication control test will be carried out using a respiratory test (urea breath test) or endoscopic biopsies (if clinical indication for that).
61928517|NCT06744166|EXPERIMENTAL|TENS-WAA group|Patients assigned to the TENS-WAA group will receive transcutaneous electrical nerve stimulation (TENS) based on Wrist-Ankle Acupuncture theory (WAA) for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively.
61928518|NCT06744166|SHAM_COMPARATOR|sham TENS-WAA group|Patients assigned to the sham TENS-WAA group will receive sham stimulation （without stimulation）for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively.
61928519|NCT05706116|EXPERIMENTAL|Trichuris trichiura Egg Inoculum 150 eggs|150 Trichuris trichiura eggs
61928520|NCT05706116|EXPERIMENTAL|Trichuris trichiura Egg Inoculum 300 eggs|300 Trichuris trichiura eggs
61928521|NCT05706116|EXPERIMENTAL|Trichuris trichiura Egg Inoculum 450 eggs|450 Trichuris trichiura eggs
61928522|NCT06344793||CDK 4/6 Inhibitor plus endocrine treatment cohort|
61928523|NCT06344793||Chemotherapy cohort|
61928524|NCT06216483|PLACEBO_COMPARATOR|No PDM Alert|No PDM alert will be placed on subject's record
61928525|NCT06216483|EXPERIMENTAL|PDM Alert|PDM alert will be placed on subject's record
62322947|NCT05183958|EXPERIMENTAL|Combined radiotherapy group|"Chemotherapy :TP program (paclitaxel 175mg/m 2 d1, carboplatin AUC=5 d1 IV Q3W; or paclitaxel 175mg/m 2 d1, cisplatin 75mg/m 2 d1, or paclitaxel 175mg/m 2 d1, cis Platinum 25mg/m 2 d1-3 IV (Q3W, up to 4 cycles). Fluorouracil + cisplatin, cisplatin 80 mg/m 2 d1 IV and 5-Fu 800 mg/m 2 continuous IV d1-5 Q3W (up to 4 cycles).Or cisplatin 50mg/m 2 IV d1; LV 200mg/m 2 IV d1; 5-Fu 2000mg/m 2 24 hours continuous IV d1; or cisplatin 80mg/m 2 IV d1, capecitabine 1000mg/m 2 PO BID d1-14.~Camrelizumab :200mg every 3 weeks,maximum 6 cycles.~The experimental group received radiotherapy of the lesion within 8 weeks after the end of chemotherapy and immunotherapy. Immunotherapy shall be started within 8 weeks after the end of all radiotherapy.~The maintenance immunotherapy of the two groups was: Camrelizumab 200mg Q3W, until PD or toxicity is intolerable or up to 24 months."
62339865|NCT05692648|EXPERIMENTAL|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
62339866|NCT05692648|EXPERIMENTAL|Hourly position change group:|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
62690939|NCT02965313|ACTIVE_COMPARATOR|BSSVF-M Procedure|
62690940|NCT00298155|ACTIVE_COMPARATOR|Group 1|Goserelin + dutasteride
62690941|NCT00298155|ACTIVE_COMPARATOR|Group 2|Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
62482183|NCT06459258|EXPERIMENTAL|NMES group|"Experimental group subjects undergo a motion-triggered NMES shoulder strengthening training program (3x/week, 30 minutes for 6 weeks) using the Shoulder Pacemaker (NCS Lab Srl, Modena, Italy), a motion activated stimulation device to strengthen muscular disbalances. This is accomplished through varying neuromuscular electrical stimulation intensity based on the angle of motion of the arm producing subtetanic contraction and provoking supraspinal neural adaptations.~Electrode placement: electrode 1, inferior to the scapular spine (infraspinatus, teres minor, + posterior deltoid); electrode 2, medial to the medial scapula border (lower trapezius + rhomboids) .~Sets x repetitions: 3x20; Levels: Level 1-3; Exercise 1: L1: Supported row, L2: Front raises in 45°, L3 Front raises (thumbs up); Exercise 2: L1: Resisted front raises, L2: Crossbody resisted raises, L3: Crossbody 'forehand swing'; Exercise 3: L1: Rear dealt fly, L2: Single arm resisted row, L3: Underhand serve"
62482184|NCT06451614|EXPERIMENTAL|SpaceIT Hydrogel System|Subjects randomized to the investigational arm will undergo a hydrogel procedure with the SpaceIT investigational device.
62482185|NCT06451614|ACTIVE_COMPARATOR|Commercially available Boston Scientific Spacer|Subjects randomized to the control arm will undergo a hydrogel procedure with the Boston Scientific commercially available SpaceOAR or SpaceOAR VUE device.
61928526|NCT06137118|EXPERIMENTAL|Part A: AZD0486 Dose Escalation|Ascending dose level cohorts of AZD0486 in B-ALL participants aged 16-80 years.
62322948|NCT05183958|PLACEBO_COMPARATOR|Non-radiotherapy group|"Chemotherapy :TP program (paclitaxel 175mg/m 2 d1, carboplatin AUC=5 d1 IV Q3W; or paclitaxel 175mg/m 2 d1, cisplatin 75mg/m 2 d1, or paclitaxel 175mg/m 2 d1, cis Platinum 25mg/m 2 d1-3 IV (Q3W, up to 4 cycles). Fluorouracil + cisplatin, cisplatin 80 mg/m 2 d1 IV and 5-Fu 800 mg/m 2 continuous IV d1-5 Q3W (up to 4 cycles).Or cisplatin 50mg/m 2 IV d1; LV 200mg/m 2 IV d1; 5-Fu 2000mg/m 2 24 hours continuous IV d1; or cisplatin 80mg/m 2 IV d1, capecitabine 1000mg/m 2 PO BID d1-14.~Camrelizumab :200mg every 3 weeks,maximum 6 cycles.~The control group continued Camrelizumab after 3 weeks of the 4 cycles of chemotherapy combined with immunotherapy.~The maintenance immunotherapy of the two groups was: Camrelizumab 200mg Q3W, until PD or toxicity is intolerable or up to 24 months."
62322949|NCT05140525|ACTIVE_COMPARATOR|participants with inoperable CTEPH|subject with inoperable Chronic thromboembolic Pulmonary Hypertension
62322950|NCT05140525|ACTIVE_COMPARATOR|post PTE residual CTEPH|Subject with post pulmonary endarterectomy (PTE) residual Chronic Thromboembolic Pulmonary Hypertension
62322951|NCT04212494|EXPERIMENTAL|Thrombus aspiration|Upfront manual thrombus aspiration followed by PCI
62322952|NCT04212494|ACTIVE_COMPARATOR|PCI Alone|PCI without upfront manual thrombus aspiration
62322953|NCT02884791|EXPERIMENTAL|Fasting (Healthy)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
62322954|NCT02884791|EXPERIMENTAL|Fasting (metabolic syndrome)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
62322955|NCT04963712|EXPERIMENTAL|Zadaxin-HIV(n=20)|Study participants will be given Zadaxin (1.6 mg subcutaneous injection, once a day) in the first 2 weeks, and changed frequency (1.6 mg subcutaneous injection, twice a week) in the successive 22 weeks.
62322956|NCT03527056|EXPERIMENTAL|Oral capsule fecal transplantation|Enrolled patients who have screened positive for CRE in the stool will receive fecal transplant via OpenBiome oral capsules. The patient is given 90 minutes to swallow all capsules and does not require any anesthesia or sedation. Stool samples to test for CRE will be taken 10 days and 30 days after the fecal transplant.
62322957|NCT03527056|NO_INTERVENTION|Observation|Enrolled patients who have screened positive for CRE in the stool will have stool samples to test for CRE taken 10 days and 30 days after initial enrollment.
62322958|NCT02742649|EXPERIMENTAL|Fixed Combination (FC) Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one segment of timolol maleate combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
62322959|NCT02742649|EXPERIMENTAL|Bimatoprost Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
62322960|NCT02742649|EXPERIMENTAL|Timolol Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of timolol and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
62322961|NCT03588767|EXPERIMENTAL|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
62322962|NCT03588767|ACTIVE_COMPARATOR|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
62322963|NCT04266860|EXPERIMENTAL|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
62322964|NCT04266860|NO_INTERVENTION|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
62322965|NCT06397872|EXPERIMENTAL|Severe renal impairment|
62482186|NCT02532244||sample collection|Each participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line.
62482187|NCT06742450|EXPERIMENTAL|Constant current (CC) subthalamic nucleus deep brain stimulation|
62482188|NCT06742450|ACTIVE_COMPARATOR|Constant voltage (CV) subthalamic nucleus deep brain stimulation|
61928527|NCT06137118|EXPERIMENTAL|Part B: Dose Optimization|Up to 2 cohorts will be evaluated prior declared safe-doses and schedules in order to determine the recommended phase 2 dose (RP2D). Participants, aged 12-80 years, will receive AZD0486 IV infusions and will be randomized in a 1:1 ratio.
61928528|NCT06137118|EXPERIMENTAL|Part C: Dose Expansion|Part C will consist of 1 cohort of participants aged 12-80 years, treated with the optimal dose selected in Part B and receive IV AZD0486 monotherapy.
61928529|NCT06738407|EXPERIMENTAL|On-demand doxyPEP|Participants will take by mouth doxycycline 200 mg as soon as possible and within 72 hours after any condomless oral, vaginal/front hole, and/or anal sex in addition to standard of care STI testing/treatment and sexual health counseling.
62322966|NCT06397872|EXPERIMENTAL|Normal Healthy Match|Matched to severe renal impairment
62322967|NCT03550326||general anesthesia|Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management.
62690942|NCT00298155|ACTIVE_COMPARATOR|Group 3|Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
61928530|NCT06738407|EXPERIMENTAL|Weekly doxycycline|Participants will take by mouth doxycycline 200 mg weekly regardless of sexual activity in addition to standard of care STI testing/treatment and sexual health counseling.
61928531|NCT06738407|NO_INTERVENTION|Quarterly STI testing/treatment and sexual health counseling|Participants will be followed per standard of care with quarterly STI testing/treatment and sexual health counseling.
61928532|NCT00526045|EXPERIMENTAL|Escalation|
61928533|NCT00526045|EXPERIMENTAL|HER2 Positive|
61928534|NCT00526045|EXPERIMENTAL|ER+ breast cancer|
61928535|NCT06578949|EXPERIMENTAL|Ravulizumab|During the Primary Treatment Period, participants will receive a weight-based loading dose of ravulizumab on Day 1 followed by weight-based maintenance dose of ravulizumab on Day 15 and once every 8 weeks (q8w) thereafter for a total of 26 weeks. On Day 183, all participants will enter a 32-week Extension Treatment Period and receive ravulizumab. Beginning on Day 183, participants will receive a maintenance dose of ravulizumab q8w for an additional 32 weeks.
61928536|NCT03935295|EXPERIMENTAL|Botulinum Toxin|"The investigators plan to administer approximately 1000 U Dysport ® in the concave-sided paraspinal musculature of the major curve, based on an estimated total dose of 1000 U, the maximum allowable dose. The total dose per treatment session will not exceed 15 units/kilogram or 1000 units, whichever is lower. If two curves are equivalent within 3˚, both will be treated, however, the dosing (described above) will be divided equally across both curves.~There will be two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
61928537|NCT03935295|PLACEBO_COMPARATOR|Placebo|"Control patients will receive an injection of placebo specifically prepared as a control for this study. The same volumes as indicated in the experimental arm description will be injected.~These will be administered during two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
61928538|NCT06745219|EXPERIMENTAL|Herombopag|Cervical cancer patients who developed thrombopenia after receiving radiotherapy and platinum-based chemotherapy were enrolled
61928539|NCT06272461|EXPERIMENTAL|IV-Lido|Intravenous Lidocaine dose loading than continuous infusion
61928540|NCT06272461|ACTIVE_COMPARATOR|IV-Keta|Intravenous Ketamine dose loading than continuous infusion
61928541|NCT06073132|EXPERIMENTAL|Part A AC-203|Double-blind, AC-203 Diacerein 1% ointment, QD
61928542|NCT06073132|PLACEBO_COMPARATOR|Part A Vehicle ointment|Double-blind, Vehicle ointment, QD
61928543|NCT06073132|EXPERIMENTAL|Part B AC-203|Open-label extension phase, AC-203 Diacerein 1% ointment, QD
61928544|NCT05536895|EXPERIMENTAL|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
61928545|NCT05536895|ACTIVE_COMPARATOR|MD-CT|An evaluation with conventional, standard of care, multi-detector CT (MD-CT)
61928546|NCT03022656|ACTIVE_COMPARATOR|Monitor Only|A brace monitor will be embedded inside the brace to monitor compliance.
61928547|NCT03022656|ACTIVE_COMPARATOR|Active Brace System|An active brace device will be embedded inside the brace to dynamically control interface pressure and monitor compliance.
61928548|NCT05452564|EXPERIMENTAL|Baricitinib|"Potential participants will be pre-screened through review of the electronic medical record from Emory or Grady. Or if a potential participant receives care elsewhere, a release of medical information form will be signed and sent to the medical center that the individual goes to. The study team will enroll individuals who have well controlled HIV. Participants will then be randomized to either baricitinib or placebo.~Patients randomized to Baricitinib group will receive Baricitinib at dose of 2 mg oral for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10."
61928549|NCT05452564|PLACEBO_COMPARATOR|Placebo|"Potential participants will be pre-screened through review of the electronic medical record from Emory or Grady. Or if a potential participant receives care elsewhere, a release of medical information form will be signed and sent to the medical center that the individual goes to. The study team will enroll individuals who have well controlled HIV. Participants will then be randomized to either baricitinib or placebo.~Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10."
61928550|NCT05685602|EXPERIMENTAL|Treatment (CA-4948, gemcitabine, nab-paclitaxel)|Patients receive CA-4948 orally (PO), gemcitabine intravenously (IV), and nab-paclitaxel IV on study. Patients undergo magnetic resonance imaging (MRI), computed tomography (CT) scan, positron emission tomography (PET) scan, and/or x-ray imaging throughout the trial. Patients also undergo tumor biopsies and blood sample collection during screening and on study.
61928551|NCT05776810|EXPERIMENTAL|All eligible participants|"All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.~Interventions:~Diagnostic Test: Head Up Tilt Table (HUT) Device: Implantable Loop Recorder"
62322968|NCT03241797|EXPERIMENTAL|Patients who suggested having AIP|Patients who suggested having AIP and underwent EUS-FNA biopsy by using a standard 22-gauge aspiration needle were enrolled between January 2013 and May 2017.
61928552|NCT06456190|EXPERIMENTAL|Video, Above Threshold, Text|Participants in this condition will receive the STAR intervention video and those who are above threshold on PTSD or opioid misuse at 1 week will be randomized to receive the textSTAR intervention.
61928553|NCT06456190|EXPERIMENTAL|Video, Above Threshold, No Text|Participants in this condition will receive the STAR intervention video and those who are above threshold on PTSD or opioid misuse at 1 week will be randomized to not receive textSTAR.
62322969|NCT02060201|OTHER|Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting|Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods
62690943|NCT06189612|EXPERIMENTAL|Group1: Clinical reasoning-based physiotherapy + cervical movement control training|Physiotherapeutic treatment is carried out based on the results of a subjective and physical examination performed at the outset. It may thus include various manual therapy treatment approaches targeting the maxillary and/or cervical or thoracic regions and adapted individually to each patient. In addition, one third of each treatment time is used to gradually teach patients the abnormal (positive) tests of the test battery for assessing motor control of the cervical region as a self-exercise for home use. To do this, patients are also given access via a quick response (QR) code to a website where they can find videos and instructions for the exact exercises that are in their home program.
62322970|NCT02060201|OTHER|Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
62322971|NCT02060201|OTHER|Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
62322972|NCT02060201|OTHER|Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting|Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods
62322973|NCT02060201|OTHER|Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
62322974|NCT02060201|OTHER|Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
62322975|NCT01455428|EXPERIMENTAL|Lyrica (pregabalin)|
62322976|NCT01455428|PLACEBO_COMPARATOR|Placebo|
62322977|NCT05890963|ACTIVE_COMPARATOR|Arm 1: Oral ART|Participants will receive standard daily oral ART.
62322978|NCT05890963|EXPERIMENTAL|Arm 2: 10E8.4/iMab 600mg IV.|Participants will receive a single dose of 10E8.4/iMab 600mg IV.
62322979|NCT05890963|EXPERIMENTAL|Arm 3: 10E8.4/iMab 600mg IM.|Participants will receive a single dose of 10E8.4/iMab 600mg IM.
62322980|NCT05890963|EXPERIMENTAL|Arm 4:10E8.4/iMab 1800mg IV.|Participants will receive a single dose of 10E8.4/iMab 1800mg IV.
62322981|NCT05890963|EXPERIMENTAL|Arm 5: Combination 10E8.4/iMab and VRC07-523LS therapy|Participants will receive a single dose of combination therapy with both 10E8.4/iMab 1800mg IV. and VRC07-523LS 1200mg IV.
62322982|NCT06691958|ACTIVE_COMPARATOR|Standard tortilla chip for Sensory Study|Snack comparable to marketed version
62322983|NCT06691958|EXPERIMENTAL|Thicker than standard tortilla chip with same amount of seasoning per 100g for Sensory Study|Snack
61928554|NCT06456190|EXPERIMENTAL|Video, Below Threshold|Participants in this condition will receive the STAR intervention video and will be below threshold on PTSD and opioid misuse at 1 week and will not be randomized to receive further intervention.
62131262|NCT05957016|EXPERIMENTAL|local advanced rectal cancer|local advanced rectal cancer are defined as T3/4NanyM0 or T1-2N+M0
62322984|NCT06691958|ACTIVE_COMPARATOR|Standard extruded chip for Sensory Study|Snack comparable to marketed version
62322985|NCT06691958|EXPERIMENTAL|Bigger extruded chip with same seasoning per 100g for Sensory Study|Snack
62322986|NCT06691958|EXPERIMENTAL|Bigger extruded chip with same concentration of seasoning on surface per 100g for Sensory Study|Snack
62322987|NCT06691958|ACTIVE_COMPARATOR|Standard tortilla chip for Ad libitum Study|Snack comparable to marketed version
62322988|NCT06691958|EXPERIMENTAL|Thicker than standard tortilla chip with same seasoning per 100g for Ad libitum Study|Snack
62322989|NCT06691958|ACTIVE_COMPARATOR|Standard extruded chip for Ad libitum Study|Snack comparable to marketed version
62322990|NCT06691958|EXPERIMENTAL|Bigger extruded chip with same seasoning per 100g for Ad libitum Study|Snack
62322991|NCT06691958|EXPERIMENTAL|Bigger extruded chip with same concentration of seasoning on surface per 100g for Ad libitum Study|Snack
62322992|NCT04120792|EXPERIMENTAL|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
62322993|NCT04120792|ACTIVE_COMPARATOR|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
62322994|NCT04120792|ACTIVE_COMPARATOR|Cognitive training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
62322995|NCT04120792|ACTIVE_COMPARATOR|Neutral Video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
62322996|NCT06586515|EXPERIMENTAL|Phase 1a: LY3962673 Dose Escalation|Escalating doses of LY3962673 administered orally.
62322997|NCT06586515|EXPERIMENTAL|Phase 1b: LY3962673 Dose Expansion|LY3962673 administered orally either alone or in combination with other chemotherapy agents.
62322998|NCT04871633|ACTIVE_COMPARATOR|Remdesivir|patients having drug Remdesivir in addition to conventional treatment according to disease grade (steroids, anticoagulants, antibiotics if needed, oxygen therapy, paracetamol, antihistamine)
62322999|NCT04871633|OTHER|Conventional|patients having Standard Conventional therapy only.
62323000|NCT03661073|EXPERIMENTAL|Stroke|The investigator will include patients with stroke (either hemorrhagic or ischemic) with or without neglect in the experimental group.
62323001|NCT03661073|SHAM_COMPARATOR|Healthy subjects|The investigator will include healthy subjects aged-matched to participants of the experimental group in the control group.
62323002|NCT03694574|OTHER|Low schizotypy|Schizotypy score \< 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, \& Jahn, 1997)
62323003|NCT03694574|OTHER|High schizotypy|Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, \& Jahn, 1997)
62690944|NCT06189612|EXPERIMENTAL|Group 2: Clinical reasoning-based physiotherapy + orofacial movement control training|Physiotherapeutic treatment is carried out based on the results of a subjective and physical examination performed at the outset. It may thus include various manual therapy treatment approaches targeting the maxillary and/or cervical or thoracic regions and adapted individually to each patient. In addition, one third of each treatment time is used to gradually teach patients the abnormal (positive) tests of the test battery for assessing motor control of the orofacial region as a self-exercise for home use. To do this, patients are also given access via a QR code to a website where they can find videos and instructions for the exact exercises that are in their home program.
62482189|NCT06311214|EXPERIMENTAL|Cohort A (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial, undergo biopsy after enrollment to cohort but prior to treatment and again on study, and undergo collection of blood samples after enrollment to cohort but prior to treatment. Patients may optionally undergo biopsy at the time of progression and may optionally undergo collection of blood samples on study and at the time of progression.
62690945|NCT06189612|ACTIVE_COMPARATOR|Group 3: Clinical reasoning-based physiotherapy + standard exercises|Physiotherapeutic treatment is carried out based on the results of a subjective and physical examination performed at the outset. It may thus include various manual therapy treatment approaches targeting the maxillary and/or cervical or thoracic regions and adapted individually to each patient. In addition, one third of each treatment time is used to gradually teach patients general coordination- and strength exercises for the jaw and the cervical region as a self-exercise for home use. To do this, patients are also given access via a QR code to a website where they can find videos and instructions for the exact exercises that are in their home program.
62690946|NCT01946269|ACTIVE_COMPARATOR|Standard group|
62323004|NCT06674499|EXPERIMENTAL|Self-help rehabilitation model|
62323005|NCT06674499|PLACEBO_COMPARATOR|Conventional rehabilitation model|
62323006|NCT02778867|ACTIVE_COMPARATOR|1-Food Elimination Diet (1FED)|Participants eliminate milk from the diet in Phase 1
62323007|NCT02778867|ACTIVE_COMPARATOR|6-Food Elimination Diet (6FED)|Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1
62323008|NCT02778867|OTHER|1FED Non-Responders (6FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2
62323009|NCT02778867|OTHER|6FED Non-responders (SGC)|Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2
62323010|NCT05633576|ACTIVE_COMPARATOR|steroid eye drops|In this treatment arm, patients will self-administer the steroid eye drops three times a day for four consecutive weeks.
62323011|NCT05633576|PLACEBO_COMPARATOR|Placebo|In this treatment arm, patients will self-administer the placebo eye drops three times a day for four consecutive weeks.
62323012|NCT00387660|EXPERIMENTAL|Metastatic SCLC|Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
62323013|NCT00387660|EXPERIMENTAL|Relapsed SCLC|Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles
62323014|NCT02471248|EXPERIMENTAL|Ankle Robot with Power Assistance|In this experimental group, the Ankle Robot assists the ankle dorsiflexion when the stroke patients voluntarily perform the swing phase gait movement.
62323015|NCT02471248|PLACEBO_COMPARATOR|Sham group|In this sham group, the Ankle Robot provides very low assistance to generate tactile feedback to the stroke patients indicating they are performing the swing phase gait movement, but no assistance will be given to support their ankle dorsiflexion.
62323016|NCT00594152|NO_INTERVENTION|1Control|Standard treatment of type 1 diabetes mellitus with 3-4 subcutaneous injections of insulin daily
62323017|NCT00594152|EXPERIMENTAL|Treatment|Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.
62323018|NCT04163146|EXPERIMENTAL|Healthy children and adolescents|Healthy children and adolescents aged 6 to 18 years (N=100) for the assessment of normal PEF and FEV1 variability.
62323019|NCT04163146|EXPERIMENTAL|Asthmatic children and adolescents|Children and adolescents aged 6 to 18 years with diagnosed asthma (N=100) for the assessment of PEF and FEV1 variability in asthmatics.
62323020|NCT06669676|ACTIVE_COMPARATOR|Acupuncture|patients will be given acupuncture in addition to standard medical treatment to prevent ponv
62323021|NCT06669676|ACTIVE_COMPARATOR|No Acupuncture|patients will be given acupuncture in addition to standard medical treatment to prevent ponv
62323022|NCT03704792|EXPERIMENTAL|Adult CLD Group|Only one group of patients in the study: adult patients with chronic liver disease (CLD), all etiologies combined, who will have a FibroScan 530 Compact examination to calculate the CAP value.
62323023|NCT05153733|EXPERIMENTAL|RIFRAM implant|RIFRAM implant
62323024|NCT00928473|EXPERIMENTAL|Lifestyle counseling|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
62323025|NCT06693466||Adult-onset HD stage 1|"The adult-onset HD stage 1 group (total function capacity 11-13) include 10 participants.~The subjects will be undergo three different pain test batteries ."
62323026|NCT06693466||Adult-onset HD stage 2-3|"The adult-onset HD stage 2-3 group (total function capacity 3-10) include 10 participants.~The subjects will be undergo three different pain test batteries ."
62339867|NCT05692648|OTHER|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation.
62690947|NCT01946269|ACTIVE_COMPARATOR|Goal-directed therapy (GDT) protocol|
62339868|NCT05019040|EXPERIMENTAL|PA1010 5 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 5 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
62482190|NCT06311214|EXPERIMENTAL|Cohort B (enfortumab vedotin)|Patients receive enfortumab vedotin IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial, undergo biopsy after enrollment to cohort but prior to treatment and again on study, and undergo collection of blood samples after enrollment to cohort but prior to treatment. Patients may optionally undergo biopsy at the time of progression and may optionally undergo collection of blood samples on study and at the time of progression.
62482191|NCT06311214|EXPERIMENTAL|Cohort C (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial, undergo biopsy after enrollment to cohort but prior to treatment and again on study, and undergo collection of blood samples after enrollment to cohort but prior to treatment. Patients also undergo ECHO or MUGA at screening and on study. Patients may optionally undergo biopsy at the time of progression and may optionally undergo collection of blood samples on study and at the time of progression.
62482192|NCT06311214|OTHER|Screening (record review, IHC assay)|"SCREENING STEP 1: Patients who have previously undergone SOC RNA testing have the results of their SOC RNA testing reviewed. Patients whose tumor expresses an appropriate TOI by RNA testing proceed to screening step 2.~SCREENING STEP 2: Patients have TOI expression testing at the protein level by IHC assay performed on previously collected tissue. Patients with high Trop-2 protein expression are assigned to Cohort A. Patients with high nectin-4 protein expression are assigned to Cohort B. Patients with high HER2 protein expression are assigned to cohort C."
62482193|NCT06743451|EXPERIMENTAL|Health workers of Joshipur rural municipality and Female community health volunteers|Health workers will receive Training on GMP guideline, while FCHV will be mobilized for inviting mothers and caretakers having under two years children.
62482194|NCT03532282|ACTIVE_COMPARATOR|ONLINE ONLY|Online cognitive behavioral therapy for insomnia
62482195|NCT03532282|EXPERIMENTAL|STEPPED CARE|Cognitive behavioral therapy for insomnia online or therapist-led or sequentially both
62482196|NCT06067828|ACTIVE_COMPARATOR|BGF MDI|Pressurized MDI fixed combination product of Budesonide 160 μg, Glycopyrronium 7.2 μg, and Formoterol Fumarate 4.8 μg per actuation.
62482197|NCT06067828|ACTIVE_COMPARATOR|BFF MDI|Pressurized MDI fixed combination product of Budesonide 160 μg and Formoterol Fumarate 4.8 μg per actuation.
62482198|NCT06067828|PLACEBO_COMPARATOR|Placebo|Placebo as pressurized inhalation suspension.
62482199|NCT06606262|EXPERIMENTAL|Tonsillotomy|A potential non-inferior surgical procedure for treating recurrent acute tonsillitis.
62482200|NCT06606262|ACTIVE_COMPARATOR|Tonsillectomy|The current standard surgical procedure for treating recurrent acute tonsillitis.
62482201|NCT06445049|NO_INTERVENTION|Standard Care|The participant will receive the current standard intensive care.
62482202|NCT06445049|ACTIVE_COMPARATOR|brief test|"The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation."
62323027|NCT04499950|EXPERIMENTAL|SLOW-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose \<5%, designated slow responders, will continue BWL and initiate Contrave (SLOW-BWL). The SLOW-BWL arm will receive at least 16 weeks of Contrave \[as per the Food and Drug Administration (FDA) recommended administration\] starting at week 9 and discontinue if ≥5% weight loss is not achieved at month 6.
62323028|NCT04499950|ACTIVE_COMPARATOR|FAST-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose ≥5%, designated fast responders, will continue with BWL alone (FAST-BWL)
62482203|NCT06736743||NICU Infants|One cohort of infants who were admitted and discharged during the study period.
62482204|NCT06742593|EXPERIMENTAL|MT027|
62482205|NCT06741787||Patients desensitized by sublingual spray|Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
62482206|NCT06149286|EXPERIMENTAL|Odronextamab+Lenalidomide|"In part 1 (safety run-in), participants with R/R indolent lymphoma (FL and MZL), will receive odronextamab in combination with lenalidomide.~In part 2, 1:1 randomized participants with indolent lymphoma (FL/MZL), will receive odronextamab in combination with lenalidomide."
62482207|NCT06149286|EXPERIMENTAL|Rituximab+Lenalidomide|In part 2 only, 1:1 randomized participants with R/R lymphoma (FL and ML), will receive rituximab in combination with lenalidomide (R2) followed by lenalidomide monotherapy.
62697493|NCT05321602|EXPERIMENTAL|LY03010 351 mg treatment group, deltoid|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-\[2-\[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl\]ethyl\]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido\[1,2-a\]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the deltoid muscle."
62339869|NCT05019040|EXPERIMENTAL|PA1010 10 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 10 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
62339870|NCT05019040|EXPERIMENTAL|PA1010 20 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 20 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
62482208|NCT04949256|EXPERIMENTAL|Part 1: Pembrolizumab + Lenvatinib + Chemotherapy|In the induction phase, participants receive pembrolizumab 400mg intravenously (IV) every 6 weeks (Q6W) for 2 cycles (each cycle length = 6 weeks) plus Lenvatinib 8 mg orally (PO) once daily (QD) plus chemotherapy with FP (cisplatin 80 mg/m\^2 and 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2) IV every 3 weeks for 4 administrations at the investigator's discretion (approximately 12 weeks). In the consolidation phase, participants receive pembrolizumab 400 mg IV Q6W for 16 cycles (each cycle length = 6 weeks) and Lenvatinib 20 mg PO until progressive disease or discontinuation (approximately 96 weeks).
62482209|NCT04949256|EXPERIMENTAL|Part 2: Pembrolizumab + Lenvatinib + Chemotherapy|In the induction phase, participants receive pembrolizumab 400mg intravenously (IV) every 6 weeks (Q6W) for 2 cycles (each cycle length = 6 weeks) plus Lenvatinib 8 mg orally (PO) once daily (QD) plus chemotherapy with FP (cisplatin 80 mg/m\^2 and 5-FU 4000 mg/m\^2) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2) IV every 3 weeks for 4 administrations or mFOLFOX6 (oxaliplatin 85 mg/m\^2, 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2, and leucovorin 400 mg/m\^2 \[or levoleucovorin 200 mg/m\^2\] once every 2 weeks \[Q2W\] for 6 administrations at the investigator's discretion (approximately 12 weeks). In the consolidation phase, participants receive pembrolizumab 400 mg IV Q6W for 16 cycles (each cycle length = 6 weeks) and Lenvatinib 20 mg PO until progressive disease or discontinuation (approximately 96 weeks).
62482210|NCT04949256|ACTIVE_COMPARATOR|Part 2: Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 400 mg IV every 6 weeks for 18 cycles (each cycle length = 6 weeks, approximately 2 years) plus chemotherapy with FP (cisplatin 80 mg/m\^2 IV Q3W for up to 6 administrations \[up to \~18 weeks\] and 5-FU 4000 mg/m\^2 IV Q3W for up to 35 administrations \[up to \~2 years\]) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2 Q3W for up 6 administrations \[up to \~18 weeks\]) or in combination with mFOLFOX6 (oxaliplatin 85 mg/m\^2, 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2 and leucovorin 400 mg/m\^2 \[or levoleucovorin 200 mg/m\^2\] IV Q2W for up to 52 administrations \[approximately 2 years\]).
62482211|NCT00001823||A/Surgery Branch Protocol Candidates|Patients suspected of having, or with biopsy proven, malignant disease being evaluated for or treated on NCI Surgery Branch protocols
62482212|NCT02648542|ACTIVE_COMPARATOR|CAS vs. tDCS|Assess the efficacy of compensatory auditory stimulation (CAS) versus transcranial direct current stimulation (tDCS)
62482213|NCT02648542|SHAM_COMPARATOR|Combined CAS+tDCS vs. Sham|Assess the efficacy of combined compensatory auditory stimulation (CAS) + transcranial direct current stimulation (tDCS) versus sham stimulation
62482214|NCT06254807|EXPERIMENTAL|CT-0525|"Cohort 1: 3 participants will be treated with a single IV administration of CT-0525 (3 billion CAR positive cells) on Day 1.~Cohort 2: 3 participants will be treated with a single IV administration of CT-0525 (10 billion CAR positive cells) on Day 1."
62482215|NCT05615688|EXPERIMENTAL|Orthodontic Separators Placed|Elastomeric separators will be placed on the mesial and distal of the lower first permanent molars for a total of four separators per subject.
62690948|NCT06642818|EXPERIMENTAL|Intervention group|During the inclusion visit, urine collection jars will be given to the patient for collection at inclusion and at 3 months. Within the week after the inclusion visit: urine collection will be performed twice a day during 3 days at the patient's home and will be stored in the refrigerator at the participants' home. In the week following this collection, the PREVENIR platforms will be used. At three months, the clinical research officer will contact the patient to remind her of the need to collect urine twice a day during 3 days. This urine collection will be carried out with the same organization as at inclusion. Then, after this urine collection, all the participating women will be interviewed, with a questionnaire identical to the one used for the face-to-face inclusion, in order to allow for the measurement of exhaled Carbon Monoxide (CO). Within 3 to 5 months after inclusion, participating women of the intervention group only,will be invited to participate to the qualitative study.
62697494|NCT05321602|EXPERIMENTAL|LY03010 351 mg treatment group, gluteal|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-\[2-\[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl\]ethyl\]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido\[1,2-a\]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the gluteal muscle."
62323029|NCT02191085|NO_INTERVENTION|Standard Management|"Patients in the Standard Management arm will be assessed without any interventions.Patients will be assessed by a sleep respirologist and follow a management plan that is determined by the sleep physician and patient. This plan may involve polysomnography or the initiation of PAP therapy. If further testing is ordered, follow-up may occur with the physician or with an ACP, at the physician's discretion. For patients initiating PAP therapy, the decision to delegate follow-up to an ACP will be left up to the physician, as the intent of this study is to observe real-world practice and not to change the management of individual patients."
62323030|NCT02191085|ACTIVE_COMPARATOR|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient."
62323031|NCT05553548|EXPERIMENTAL|biologically oriented alveolar ridge preservation (BARP) group|for alveolar ridge preservation using demineralized bovine bone graft layer in the most coronal part of the extracted tooth socket
62323032|NCT05553548|ACTIVE_COMPARATOR|bone graft (entire apico-coronal extension)|alveolar ridge preservation using demineralized bovine bone graft on the entire apico-coronal extension.
62482216|NCT06741969|EXPERIMENTAL|Nipocalimab|Participants will receive nipocalimab subcutaneously (SC) along with standard of care treatments. At the Week 48 visit, eligible participants from both studies will have the option to enter an open-label long-term extension (OLE) phase, where they will continue to receive nipocalimab until Week 143 or until the study intervention is discontinued and participants opt to withdraw from the study.
62323033|NCT03100435|EXPERIMENTAL|Er:YAG Laser|Er:YAG Laser only
62131263|NCT02184806|EXPERIMENTAL|1- orthotopic graft|
62131264|NCT02184806|EXPERIMENTAL|2- heterotopic graft|
62323034|NCT03100435|ACTIVE_COMPARATOR|Carbon Fiber Curette|Carbon fiber curette only
62323035|NCT03100435|EXPERIMENTAL|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
62323036|NCT03100435|NO_INTERVENTION|No Treatment|No treatment (control)
62339871|NCT06011330||study group|fruquintinib combined with anti-PD-1 antibodies
62323037|NCT06692387|ACTIVE_COMPARATOR|Active control group|Ten people will be encouraged to increase their physical activity level, measured in step counts on the patients' own smartphone, with 10% compared to their own baseline level.
62482217|NCT06741969|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo subcutaneously along with standard of care treatments. At the Week 48 visit, eligible participants from both studies will have the option to enter an OLE phase, where they will receive nipocalimab until Week 143 or until the study intervention is discontinued and participants opt to withdraw from the study.
62690949|NCT06642818|NO_INTERVENTION|Non-intervention group|During the inclusion visit, urine collection jars will be given to the patient for collection at inclusion and at 3 months. Within the week after the inclusion visit: urine collection will be performed twice a day during 3 days at the patient's home and will be stored in the refrigerator at the participants' home. At three months, the clinical research officer will contact the patient to remind her of the need to collect urine twice a day during 3 days. This urine collection will be carried out with the same organization as at inclusion. Then, after this urine collection, all the participating women will be interviewed, with a questionnaire identical to the one used for the face-to-face inclusion, in order to allow for the measurement of exhaled CO. In the non-intervention group, the full intervention will take place at this time. The control group is a waiting list type control group. The procedure will be performed at the end of the study, i.e. three months after inclusion.
62690950|NCT05321745|EXPERIMENTAL|Repeated and multiple FMTs plus PEN|repeated and multiple FMTs plus PEN(50% of total calories as polymeric diet, Peptamen, Nestle, Vevey, Switzerland) in refractory pediatric CD
62690951|NCT04349098|EXPERIMENTAL|Selinexor 20 mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
62690952|NCT04349098|PLACEBO_COMPARATOR|Placebo|Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
62690953|NCT04642430|ACTIVE_COMPARATOR|Apixaban group|"5 mg PO, twice daily for 12 months of treatment. A dose reduction\* to 2.5 mg twice daily will apply if patients meet 2 of 3 following criteria: age \> 80 years; weight \< 60 kg; creatinine \>133 micromol/L.~\*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
62323038|NCT06692387|EXPERIMENTAL|Step count increase 50%|Ten people will be encouraged to increase their physical activity level, measured in step counts on the patients' own smartphone, with 50% compared to their own baseline level.
62690954|NCT04642430|ACTIVE_COMPARATOR|Rivaroxaban Group|"20 mg PO, once daily for 12 months of treatment. A dose reduction\* to 15 mg daily will apply to patients with creatinine clearance \<50 ml/min.~\*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
62690955|NCT05267600|EXPERIMENTAL|efgartigimod PH20 SC|participants receiving efgartigimod PH20 SC on top of Prednisone
62690956|NCT05267600|PLACEBO_COMPARATOR|placebo PH20 SC|participants receiving placebo PH20 SC on top of Prednisone
62690957|NCT02399566|EXPERIMENTAL|Experimental|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
62690958|NCT02399566|ACTIVE_COMPARATOR|Comparator|followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy
62482218|NCT06124339|ACTIVE_COMPARATOR|Cognitive activity - VR spatial navigation only|VR spatial navigation program will consist of a spatial navigation program that increases difficulty and length per trial over time. Spatial navigation is the ability to navigate between multiple elements/landmarks widely used in computer games. A trial is a test of performance or quality of someone or something.
62690959|NCT04248153|EXPERIMENTAL|Group A|BR55 will be performed in the early follicular phase first and in the late follicular phase thereafter.
62690960|NCT04248153|EXPERIMENTAL|Group B|BR55 will be performed in the late follicular phase first and in the early follicular phase thereafter.
62690961|NCT03608631|EXPERIMENTAL|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
62690962|NCT04576559|EXPERIMENTAL|Modified dental visual aids|
62690963|NCT04576559|ACTIVE_COMPARATOR|Regular dental visual aids|
62323039|NCT06692387|EXPERIMENTAL|Step count increase 100%|Ten people will be encouraged to increase their physical activity level, measured in step counts on the patients' own smartphone, with 100% compared to their own baseline level.
62690964|NCT06675916|EXPERIMENTAL|PENG block|Total hip prosthesis with infiltration of lidocaine hydrochloride by ultrasound-guided PENG block
62690965|NCT06675916|ACTIVE_COMPARATOR|Intra-articular infiltration|Total hip prosthesis with intra-articular infiltration of lidocaine hydrochloride
62690966|NCT05338320|ACTIVE_COMPARATOR|General anesthesia and Ultrasound Guided Erector Spinae Plane Block|
62690967|NCT05338320|ACTIVE_COMPARATOR|General anesthesia and intrathecal morphine|
62690968|NCT05338320|OTHER|General anesthesia using intravenous fentanyl (1µg/kg)|
62131265|NCT05851677||RC48-ADC|RC48-ADC for breast cancer
62131266|NCT02764645|EXPERIMENTAL|CardioGard group|"Patients in whom the CardioGard Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in two points: 1. The aortic vent.~2. The suction cannula of the 'Cardiogard cannula'."
62131267|NCT02764645|ACTIVE_COMPARATOR|Control group|Patients in whom a 22Fr curved Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in the aortic vent alone.
62131268|NCT02369289||vegans|a vegan diet in the last 3 years
62131269|NCT02369289||omnivores|aminal-based diet, comsumption of aminal products at least 3 times a week
62131270|NCT05087758|EXPERIMENTAL|Matrion decellularized placental membrane|Matrion placental membrane graft will be use to treat subjects diagnosed with a diabetic foot ulcer.
62131271|NCT05087758|ACTIVE_COMPARATOR|Conventional Care Wound Management|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diabetic foot ulcer diagnosis.
62482219|NCT06124339|ACTIVE_COMPARATOR|Physical activity - Cycling only|The physical activity program will consist of a stationary bike cycling program. Each day will consist of a cycling program of varying levels of difficulty for 20-50 minutes.
62482220|NCT06124339|EXPERIMENTAL|Combined, simultaneous physical and cognitive activity|The combined physical and cognitive activity VR program will consist of a spatial navigation program that increases difficulty and length per trial over time.
62482221|NCT06742346|NO_INTERVENTION|1: Passive control|Participants receiving no messages throughout the study
62690969|NCT03579719|EXPERIMENTAL|Balovaptan + Itraconzole|Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
61928555|NCT06456190|EXPERIMENTAL|No Video, Above Threshold, Text|Participants in this condition will not receive the STAR intervention video and those who are above threshold on PTSD or opioid misuse at 1 week will be randomized to receive the textSTAR intervention.
61928556|NCT06456190|NO_INTERVENTION|No Video, Above Threshold, No Text|Participants in this condition will not receive the STAR intervention video and those who are above threshold on PTSD or opioid misuse at 1 week will not be randomized to receive the textSTAR intervention.
61928557|NCT06456190|NO_INTERVENTION|No Video, Below Threshold|Participants in this condition will not receive the STAR intervention video and will be below threshold on PTSD and opioid misuse at 1 week and will not be randomized to receive further intervention.
61928558|NCT06398808|ACTIVE_COMPARATOR|Arm 1 (ZYIL1 capsules & placebo)|ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
61928559|NCT06398808|ACTIVE_COMPARATOR|Arm 2 (ZYIL1 capsules & placebo)|ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
61928560|NCT03408340|EXPERIMENTAL|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
61928561|NCT03408340|ACTIVE_COMPARATOR|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
61928562|NCT06743672||Emergency department patients with chest pain|"We will enroll adult patients (age \>25) presenting to the ED with chest pain or symptoms consistent with coronary disease, but who do not have an MI or clear alternative diagnosis. Our age cutoff is consistent with prior literature, demonstrating a very low risk of symptomatic coronary disease below age 25.~Inclusion Criteria~1. Symptoms of chest pain or of suspected cardiac ischemia;~2. Age 25 or older;~3. Hs-cTn concentration below diagnostic criteria for myocardial infarction, as specified in the Fourth Universal Definition of MI49;~Exclusion Criteria~1. Acute ischemic ECG changes (ST segment elevation or depression, new T-wave inversion, New left bundle branch block; Wellen's/DeWinter T waves);~2. Alternative diagnosis identified in the ED (e.g. pneumonia, pulmonary embolism, aortic dissection, pancreatitis; peri/myocarditis);~3. Acute coronary syndrome or revascularization in previous 30 days;~4. Expected lifespan \< 6 months per treating"
61928563|NCT06122662|EXPERIMENTAL|AMX0035|"AMX0035 administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study~For participants electing to continue into the open-label phase at Week 52; AMX0035 will be administered once daily for first 2 weeks and then twice daily for remainder of open-label phase"
61928564|NCT06122662|PLACEBO_COMPARATOR|Placebo|Placebo administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study
61928565|NCT04300855|EXPERIMENTAL|Sunphenon® 90D|Participants will be administered a standardized formulation of whole Green Tea Catechin for 24 months. The daily dose of Green Tea Catechin will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
61928566|NCT04300855|PLACEBO_COMPARATOR|Placebo|Participants will be administered a placebo for 24 months. The daily dose of placebo will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
61928567|NCT04364048|EXPERIMENTAL|Induction durvalumab, chemoradiation, consolidation durvalumab|Induction durvalumab at 1500 mg intravenously (IV) on Day 1 of a four week cycle for 1 cycle, followed by concurrent definitive chemoradiation, followed by consolidation durvalumab at 1500 mg IV Day 1 of every 4 week cycle for up to 12 cycles.
61928568|NCT06745544|EXPERIMENTAL|RYMA group|Participants in this arm will engage in the Rhythm- and Multitask-Based Activity (RYMA) exercise program, a multicomponent intervention that combines strength, balance, coordination, and cognitive-motor training. The intervention also incorporates Activities of Daily Living (ADL)-based exercises to address real-world functional needs. The program is delivered over 26 weeks and includes music-based exercises designed to improve fall prevention, bone health, and cardiovascular outcomes.
61928569|NCT06745544|NO_INTERVENTION|Usual Care/No Structured Exercise Intervention|Participants in this arm will continue their usual daily routines without any structured exercise intervention during the first 26 weeks.
61928570|NCT06743802|EXPERIMENTAL|Coenzyme Q10|
61928571|NCT06743802|PLACEBO_COMPARATOR|Placebo|
61928572|NCT06744387||patients with reconstructive flap surgery on upper or lower limb using a fasciocutanous tigh flap|
62339872|NCT02847728||Single Arm Design|The study encompasses a single arm design with 417 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 772 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.
62482222|NCT06742346|ACTIVE_COMPARATOR|2: Non-tailored messages|Participants will receive daily non-tailored messages for the entire two weeks
62482223|NCT06742346|EXPERIMENTAL|3: Linguitically tailored messages|Participants will receive linguistically tailored messages for the entire two weeks
62482224|NCT06742346|EXPERIMENTAL|4: Crossover arm|Participants in arm 4 will receive both non-tailored and tailored messages for one week each: tailored messages in week 1 and non-tailored in week 2 (arm 4a) and non-tailored in week 1 and tailored in week 2 (arm 4b
62690970|NCT02051387|ACTIVE_COMPARATOR|Cannabidiol|Cannabidiol capsule, 200 mg single dose
62690971|NCT02051387|EXPERIMENTAL|Cannabidiol CR|Cannabidiol tablet, various dosages
62482225|NCT04652856|EXPERIMENTAL|Electrical and Sham Electrical Brain Stimulation|Electrical brain stimulation and sham electrical brain stimulation will be administered to all participants.
62482226|NCT06742463|EXPERIMENTAL|Treatment arm|Venetoclax for 4weeks(adjust according to BM on Day15), oral; Homoharringtonine for 1 week,iv; Cytarabine for 10-14 dsys, sc; G-CSF.
62482227|NCT05115110|EXPERIMENTAL|RO7204239 + Risdiplam|"Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive RO7204239 (low or high dose) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with RO7204239 + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
62690972|NCT02051387|EXPERIMENTAL|Amisulpride and Cannabidiol CR|Interaction between Amisulpride and Cannabidiol CR
62690973|NCT02051387|EXPERIMENTAL|Olanzapine and Cannabidiol CR|Interaction between Olanzapine and Cannabidiol CR
62690974|NCT02051387|EXPERIMENTAL|Quetiapine and Cannabidiol CR|Interaction between Quetiapine and Cannabidiol CR
62690975|NCT02051387|EXPERIMENTAL|Risperidone and Cannabidiol CR|Interaction between Risperidone and Cannabidiol CR
61928573|NCT04750954|EXPERIMENTAL|Treatment (peposertib, lutetium Lu 177 dotatate)|Patients receive peposertib PO QD or BID on days 1-21 and lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/MRI throughout the trial and undergo collection of blood samples on study.
61928574|NCT06744049|EXPERIMENTAL|Embryo transfer with Transfer Direct System (TDS)|The trial has a single assignment group aimed at patients of reproductive age who attend the clinic with a desire for a child and undergo Assisted Reproduction Treatment (ART) with an euploid single embryo transfer (SET) after corresponding hormone replacement therapy (HRT) has been carried out.
61928575|NCT05741034|EXPERIMENTAL|JUVÉDERM® VOLITE™|"Participants will receive VOLITE for initial treatment and exit the study at month 12 after last treatment.~Participants may have the opportunity to receive optional touch-up treatment of VOLITE during the follow-up duration period."
61928576|NCT05741034|OTHER|Control - No Treatment|Participants in the control group will receive no treatment. At Month 2, these participants will have the option to receive VOLITE treatment and exit the study at month 9 after last treatment.
61928577|NCT06484062|EXPERIMENTAL|Cohort I (cirtuvivint)|Patients receive cirtuvivint PO QD Monday-Friday on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening. In addition, patients undergo blood sample collection and bone marrow aspiration and biopsy at screening and on study.
61928578|NCT06484062|EXPERIMENTAL|Cohort II (cirtuvivint)|Patients receive cirtuvivint PO once QD on days 1, 4, 8, 11, 15, 18, 22, and 25 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening. In addition, patients undergo blood sample collection and bone marrow aspiration and biopsy at screening and on study.
62323040|NCT06421428||Women's single sample|The population under investigation will be made up of women aged ≥ 18 years (excluding pregnant women and women who have given birth less than 40 days) suffering from urinary incontinence and who understand and speak in the Italian language. Will be enrolled on a voluntary basis women who have already had at least a couple of pelvic floor rehabilitation meetings at the outpatient clinic of the San Raffaele Hospital in Milan, within the time frame foreseen by the study, because they are also able to narrate their experience of re-education of the pelvic floor.
62323041|NCT05130034|EXPERIMENTAL|Home-based pulmonary rehab for fibrotic interstitial lung disease|Subjects diagnosed with fibrotic interstitial lung disease will participate in a home-rehab program that promotes more physical activity in daily life.
62690976|NCT02051387|PLACEBO_COMPARATOR|Cannabidiol CR and Placebo|Cannabidiol CR levels without interaction with antipsychotics
61928579|NCT06484062|EXPERIMENTAL|Cohort III (cirtuvivint, ASTX727)|Patients receive cirtuvivint PO QD on days 1, 4, 8, 11, 15, 18, 22, and 25 and ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening. In addition, patients undergo blood sample collection and bone marrow aspiration and biopsy at screening and on study.
61928580|NCT06484062|EXPERIMENTAL|Cohort IV (cirtuvivint, ASTX727, venetoclax)|Patients receive cirtuvivint PO QD on days 1, 4, 8, 11, 15, 18, 22, and 25, ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening. In addition, patients undergo blood sample collection and bone marrow aspiration and biopsy at screening and on study.
61928581|NCT00106925||1|allogeneic stem cell transplant recipients
61928582|NCT00106925||2|Donors
61928583|NCT03319667|EXPERIMENTAL|Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm|"1. Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone~2. Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone"
62323042|NCT04250298|OTHER|Iron deficient blood donors|Daily intake of 30 mg of sucrosomal iron during 90-120 days (male and female whole blood donors)
62339873|NCT04496791|EXPERIMENTAL|Successor of Phonak Audéo M-90|Phonak Hearing instrument (HI) with modified precalculation.
62339874|NCT04496791|ACTIVE_COMPARATOR|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent RIC device from Phonak which will be fitted to the participants individual hearing loss.
62690977|NCT05941585|EXPERIMENTAL|mitoxantrone hydrochloride liposome injection combined with of cytarabine|Patients will receive mitoxantrone hydrochloride liposome injection combined with standard-dose of cytarabine.
62690978|NCT05941585|EXPERIMENTAL|mitoxantrone hydrochloride liposome with cytarabine and homoharringtonine|Patients will receive mitoxantrone hydrochloride liposome injection combined with intermediate-dose of cytarabine and homoharringtonine.
62690979|NCT05941585|EXPERIMENTAL|mitoxantrone hydrochloride liposome injection combined with cytarabine and venetoclax|Patients will receive mitoxantrone hydrochloride liposome injection with cytarabine and venetoclax.
62690980|NCT02125422|EXPERIMENTAL|Cefaly tDCS|"Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, for 5 consecutive days in 9 HV. The anode is placed over the left DLPFC.~2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, for 5 consecutive days in 9 HV"
61928584|NCT03319667|ACTIVE_COMPARATOR|Bortezomib/Lenalidomide/Dexamethasone = VRd arm|"1. Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone~2. Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone"
62131272|NCT03344588|ACTIVE_COMPARATOR|artery preserving varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group A (APV), testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
62131273|NCT03344588|ACTIVE_COMPARATOR|artery ligation varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group B (ALV), all vascular channels will be ligated without identifying or sparing the internal spermatic arteries
62131274|NCT03396900|ACTIVE_COMPARATOR|RhBMP-2 Protein, Recombinant|15 subjects treated with corticotomy with rhBMP-2 (C+BMP)
62131275|NCT03396900|EXPERIMENTAL|Conventional Corticotomy|15 subjects treated with conventional corticotomy (C) as in the PAOO protocol
62131276|NCT04163536|ACTIVE_COMPARATOR|cortisteroids arm|
62131277|NCT04163536|PLACEBO_COMPARATOR|placebo arm|
62323043|NCT02552355|EXPERIMENTAL|Metformin/Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin.
62323044|NCT02552355|PLACEBO_COMPARATOR|Placebo/Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo.
62323045|NCT02552355|ACTIVE_COMPARATOR|Metformin/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin
62323046|NCT02552355|ACTIVE_COMPARATOR|Placebo/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.
62131278|NCT05376436||Exercise challenge test (ECT) with and without nose clip (NC).|"All participants after receiving informed consent were invited for 2 visits. Visit 1 - ECT performed with NC. Visit 2 - ECT performed without NC. Demographic and clinical data and measurements of vital signs, exercise data and lung functions were recorded.~ECT completed on treadmill.~Questionnaires:~Total Nasal Symptom Score (TNSS 0-6). Asthma Control Test (ACT 5-25) . Positive ECT = drop in FEV1 \>12% from baseline"
62323047|NCT02200458|EXPERIMENTAL|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
62323048|NCT06386653|EXPERIMENTAL|Whole-body planar scintigraphy and SPECT with [123I]I-DARPIN-Ec1 in lung cancer|At least five (5) evaluable subjects with lung cancer.
62323049|NCT06386653|EXPERIMENTAL|Whole-body planar scintigraphy and SPECT with [123I]I-DARPIN-Ec1 in ovarian cancer|At least five (5) evaluable subjects with ovarian cancer.
62323050|NCT04151017|EXPERIMENTAL|Autologous fibrin glue|
62323051|NCT04151017|ACTIVE_COMPARATOR|Sutures|
62323052|NCT01103349|EXPERIMENTAL|BI 671800|Patients receive BI 671800 capsules twice daily
62690981|NCT04725110|EXPERIMENTAL|T3 Intervention|Participants in this arm will receive the experimental intervention.
62323053|NCT01103349|ACTIVE_COMPARATOR|Montelukast|Patients receive Montelukast encapsulated tablets once daily
62690982|NCT04725110|PLACEBO_COMPARATOR|Placebo Therapy|Participants in this arm will receive placebo therapy.
61928585|NCT03319667|OTHER|Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm|4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone
61928586|NCT01630850|EXPERIMENTAL|Allogenic islet cells (human, U. Chicago)|
62323054|NCT01103349|PLACEBO_COMPARATOR|Placebo|Patients receive placebo capsules and/or encapsulated placebo tablets
62690983|NCT06536881|EXPERIMENTAL|Fasting prior to chemotherapy|Prior to chemotherapy administration, a trial of a 24-hour water-only fast will be conducted; at least 1 successful 24-hour fast is required to proceed with the fasting intervention during chemotherapy. A total of 3 trials is allowed (for a maximum of 48 hours fasting).
62690984|NCT05936437|EXPERIMENTAL|Study arm|Eligible subjects aged 20 to 60 years and in good general health, with grade 3 to 4 moderate-to-severe atrophic post-acne scars according to the Goodman Baron classification
62690985|NCT06252532|ACTIVE_COMPARATOR|Frontal Stimulation|Direct Cortical Stimulation (DCS) in alpha and theta frequencies is applied through electrodes located in the frontal cortex.
62131279|NCT00780234|EXPERIMENTAL|Arm 1: pioglitazone|Current or former smokers receive 6 months of treatment with pioglitazone
62482228|NCT05115110|ACTIVE_COMPARATOR|Placebo + Risdiplam|"Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive placebo (low or high dose-matched) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with placebo + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
62482229|NCT03196258|EXPERIMENTAL|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
62482230|NCT03196258|NO_INTERVENTION|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
62131280|NCT00780234|PLACEBO_COMPARATOR|Arm 2: placebo|Current or former smokers receive 6 months of treatment with placebo
62131281|NCT06028672|EXPERIMENTAL|Toripalimab Plus Actinomycin-D|Toripalimab 200mg intravenously(IV) every 2 weeks (Q2W) Actinomycin-D 1.25mg/m2，2mg max dos, intravenously(IV) every 2 weeks (Q2W)
62323055|NCT02998437|EXPERIMENTAL|Ilaprazole 10mg|"Period 1: Ilaprazole 10mg 1 tab.m one a day~Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day"
62323056|NCT02998437|ACTIVE_COMPARATOR|Clarithromycin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day"
62323057|NCT02998437|ACTIVE_COMPARATOR|Amoxicillin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day"
62482231|NCT06742944||Participants age 50-80 with normal cognition or mild impairment|All participants will provide 10 plasma samples over the course of 9 weeks. This is an observational cohort study (no intervention(s) administered)
62482232|NCT02684747|EXPERIMENTAL|Treatment - Autologous Transfusion|Participants will be randomized to the treatment group (autologous transfusion)
62482233|NCT02684747|PLACEBO_COMPARATOR|Control - Normal Saline (Placebo)|Participants will either be randomized to the control group (saline transfusion)
62131282|NCT06028672|ACTIVE_COMPARATOR|Actinomycin-D Alone|Actinomycin-D 1.25mg/m2，2mg max dos, intravenously(IV) every 2 weeks (Q2W)
62131283|NCT06104449|EXPERIMENTAL|Opevesostat|Participants receive opevesostat 5 mg by oral tablets twice daily plus dexamethasone 1.5 mg by oral tablets and fludrocortisone acetate 0.1 mg oral tablet once daily continuously until progression. Hydrocortisone up to 100 mg oral dose will also be provided to participants for use as rescue medication.
62131284|NCT06003517||Patients with perioperative safety events|Patients with perioperative safety events, including post extubation tracheal intubation, intraoperative cardiac arrest, allergic reactions.
62131285|NCT06003517||Patients without perioperative safety events|Patients without perioperative safety events, including post extubation tracheal intubation, intraoperative cardiac arrest, allergic reactions.
62131286|NCT05900921|EXPERIMENTAL|Experimental: Trilaciclib+Chemotherpy+Tislelizumab|"Participants received Trilaciclib (240mg/m2) in combination with Paclitaxel (175mg/m2), Cisplatin (AUC=5), and Tislelizumab (200mg) treatment, every 3 weeks for up to 4-6 cycles (Induction).~Following induction, patients will receive trilaciclib with tislelizumab for every 3 weeks"
62131287|NCT05900921|ACTIVE_COMPARATOR|Active Comparator: Chemotherpy+Tislelizumab|"Participants received Paclitaxel (175mg/m2), Cisplatin (AUC=5), and Tislelizumab (200mg) treatment, every 3 weeks for up to 4-6 cycles (Induction).~Following induction, patients will receive tislelizumab for every 3 weeks until PD"
62131288|NCT03593876|EXPERIMENTAL|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
62131289|NCT04802382|EXPERIMENTAL|Arm 1 - CimetrA-1|a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
62131290|NCT04802382|EXPERIMENTAL|Arm 2 - CimetrA-2|a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
62131291|NCT04802382|PLACEBO_COMPARATOR|Arm 3 - Placebo|composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
62131292|NCT00998881|EXPERIMENTAL|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
62131293|NCT00998881|PLACEBO_COMPARATOR|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
62131294|NCT02795052|OTHER|Arm 1- Intravenous and Intranasal BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
62323058|NCT06018831|EXPERIMENTAL|Urine and Ultrasound Screening|About 10,000 children called KunQi Cohort are born in Jiangsu Province(8,000 in Kunshan and 2,000 in Qidong) and about 3,000 born in Shanghai. Children will receive urine and ultrasound screening in 0-3 months ,and complete 3 to 6 years of follow-up( at least one type screening every year)
62482234|NCT05329961|EXPERIMENTAL|Single Arm|HPV 9-valent human papillomavirus vaccine (Gardasil 9) - 0.5mL intramuscular dose - 2 doses (Month 0, 12)
62482235|NCT00830024|EXPERIMENTAL|Alprazolam (test)|Alprazolam 3 mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
62482236|NCT00830024|ACTIVE_COMPARATOR|Xanax XR®|Xanax XR® 3 mg Tablet (test) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
62482237|NCT03162315|NO_INTERVENTION|Fresh embryo transfer|fresh embryo transfer (standard of care)
62482238|NCT03162315|EXPERIMENTAL|Freeze all|Vitrification of all embryos and replacement of a thawed embryo in a subsequent cycle
62323059|NCT03066817|PLACEBO_COMPARATOR|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
62482239|NCT03168763|EXPERIMENTAL|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
61928587|NCT06744257|EXPERIMENTAL|Online exercise program|The online education arm will be provided with password access to our online patient education platform (https://www.teampfp.com/my-knee-cap-pain) that contains four modules; \[a\] Understand your pain; \[b\] How do I start to exercise; \[c\] Treatment options; \[d\] Case studies. The aim of each module is to provide people with knowledge they can put into practice (experiential learning) and facilitating their self-management. A short quiz at the end of each module assesses user engagement and knowledge retention.
62131295|NCT03844919|EXPERIMENTAL|rTMS + CBIT|Repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
62131296|NCT03844919|ACTIVE_COMPARATOR|Sham rTMS + CBIT|Sham repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
62131297|NCT02222493|EXPERIMENTAL|PF-06438179|
62131298|NCT02222493|ACTIVE_COMPARATOR|Infliximab|
62131299|NCT04691024|EXPERIMENTAL|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
62131300|NCT04691024|OTHER|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
62131301|NCT00709098|ACTIVE_COMPARATOR|iloprost power 6|iloprost power 15
62131302|NCT00709098|EXPERIMENTAL|iloprost power 15|iloprost power 15
62131303|NCT02332577|EXPERIMENTAL|Pristinamycin + Placebo|Pristinamycin: 500 mg tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days Amoxicillin Placebo: capsule, 2 capsules x 3 /day for 7 to 9 days.
62323060|NCT03066817|EXPERIMENTAL|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid \[DRISDOL\]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
61928588|NCT06744257|NO_INTERVENTION|Standard of Care|The control arm will receive no additional care whilst on the ESNEFT physiotherapy waiting list. Their involvement in the trial will end at six-weeks follow up and they will then be provided with access to the online education platform if they request it.
62131304|NCT02332577|ACTIVE_COMPARATOR|Amoxicillin + Placebo|Amoxicillin: 500 mg capsule, 2 capsules x 3/day for 7 to 9 days Pristinamycin Placebo: tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days.
62131305|NCT03050957|EXPERIMENTAL|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
62323061|NCT02234583|EXPERIMENTAL|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
62482240|NCT03168763|EXPERIMENTAL|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
62482241|NCT03168763|EXPERIMENTAL|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
62482242|NCT03168763|EXPERIMENTAL|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
62482243|NCT06352645|EXPERIMENTAL|Interventional Group|Those randomized into the interventional group will be asked to use the Bixdo Ultra Compact Water Flosser twice a day for 8 weeks.
62482244|NCT06352645|ACTIVE_COMPARATOR|Control Group|Those randomized into the control group will be asked to only use the study provided manual toothbrush and toothpaste twice a day for 8 weeks.
62482245|NCT06130553|EXPERIMENTAL|AZD3470 Monotherapy|Part A dose escalation and back-fill cohorts and Part B dose optimization and expansion cohorts of varying doses of AZD3470
62482246|NCT01004835||Migraine Disease|Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
61928589|NCT06745518|EXPERIMENTAL|TS-172|
61928590|NCT06745518|PLACEBO_COMPARATOR|Placebo|
61928591|NCT04228172||Parkinson's disease (PD) glucocerebrosidase (GBA) carriers|Parkinson's disease subjects with GBA mutation
62131306|NCT03050957|EXPERIMENTAL|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
62131307|NCT03803748|EXPERIMENTAL|Eyestil Plus®|"It's a clinical comparative performance study. Eyestil Plus® eyedrops multidose to be not inferior to Vismed multidose eye drops. Eyestil Plus is an ophthalmic aqueous formulation, multidose sterile preservative free, medical device, class IIB and CE marked. It contains 0.4% sodium hyaluronate. It is not available yet in the French Market.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period,"
62131308|NCT03803748|NO_INTERVENTION|Vismed|"Vismed Multi® is also a sterile multidose preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period.~The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes."
62131309|NCT02348866|ACTIVE_COMPARATOR|Group 1|home laundered/home-donned
62131310|NCT02348866|ACTIVE_COMPARATOR|Group 2|Hospital laundered/home-donned
62131311|NCT02348866|ACTIVE_COMPARATOR|Group 3|Home laundered/hospital donned
62131312|NCT02348866|ACTIVE_COMPARATOR|Group 4|Hospital laundered/hospital donned
62323062|NCT06176040|EXPERIMENTAL|TAVO101: High Dose|TAVO101 IV Infusion given as loading dose, every 2 months (Q2M), every 3 months (Q3M).
62690986|NCT06252532|SHAM_COMPARATOR|Frontal Parietal Stimulation|Direct Cortical Stimulation (DCS) in in-phase and anti-phase theta frequencies is applied through electrodes located in the frontal and parietal cortex.
61928592|NCT04228172||Parkinson's disease (PD) non glucocerebrosidase (GBA) carriers|Parkinson's disease subjects without GBA mutation
61928593|NCT06132893|EXPERIMENTAL|BHV-7000 25 mg|
62323063|NCT06176040|EXPERIMENTAL|TAVO101: Medium Dose|TAVO101 IV Infusion given as loading dose and Q3M.
62323064|NCT06176040|EXPERIMENTAL|TAVO101: Medium Low Dose|TAVO101 IV Infusion given as loading dose and Q2M.
62323065|NCT06176040|EXPERIMENTAL|TAVO101: Low Dose Control|TAVO101 IV Infusion given as loading dose and Q2M.
62323066|NCT05629416|EXPERIMENTAL|Cultural safety training and behaviour change intervention|- Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples
62690987|NCT06421311||Participants with muscle invasive urothelial carcinoma receiving nivolumab|
61928594|NCT06132893|EXPERIMENTAL|BHV-7000 50 mg|
61928595|NCT06132893|PLACEBO_COMPARATOR|Placebo|
61928596|NCT06735950|EXPERIMENTAL|Volunteering-in-Place Program|Participants in this arm will engage in a volunteer activity in the assisted living facility chosen based on their interests and capabilities.
61928597|NCT06735950|ACTIVE_COMPARATOR|Recreational Activity|Participants in this arm will engage in a current events group
61928598|NCT06741163|PLACEBO_COMPARATOR|Placebo|Participants will be randomly allocated to receive the placebo, which is a water-based shot with similar appearance and taste but without the active ingredients of the test product. The placebo will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the placebo before their training session on each intervention day (Day 5, Day 6, and Day 7).
62131313|NCT02886195|EXPERIMENTAL|PC plus erlotinib|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1; concurrent erlotinib 150mg/d d1-21, per 3 week, for 4-6cycles, then erlotinib 150mg/d maintain therapy
62131314|NCT02886195|ACTIVE_COMPARATOR|erlotinib|"erlotinib 150mg/d until progress disease"
62131315|NCT02886195|ACTIVE_COMPARATOR|PC|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1 for 4-6 cycles
62131316|NCT05141136|EXPERIMENTAL|Ultrasound probe sagittal group|A thoracic 2 paravertebra block is performed with the ultrasound probe placed sagittal and the needle in plane with respect to the probe.
62131317|NCT05141136|ACTIVE_COMPARATOR|Ultrasound probe transverse group|A thoracic 2 paravertebra block is performed with the ultrasound probe placed transverse and the needle in plane with respect to the probe.
62131318|NCT02590432|EXPERIMENTAL|LINZESS® 145 μg (CIC, Open Label)|LINZESS® (linaclotide) 145 μg capsules, orally, once daily for up to 52 weeks for participants with CIC. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
62131319|NCT02590432|EXPERIMENTAL|LINZESS® 290 μg (IBS-C, Open Label)|LINZESS® 290 μg capsules, orally, once daily for up to 52 weeks for participants with IBS-C. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
62131320|NCT02590432|EXPERIMENTAL|LINZESS® 290 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 290 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
62323067|NCT05155696|EXPERIMENTAL|Kefir probiotic drink|Daily kefir for 6 weeks.
62323068|NCT05155696|PLACEBO_COMPARATOR|placebo comparator|Daily non-fermented dairy based equivalent drink for 6 weeks.
61928599|NCT06741163|EXPERIMENTAL|Intervention|Participants will be randomly allocated to receive the test product, which is a water-based shot containing olive leaf extract (100mg Oleuropein), vitamins, and other active ingredients. The product will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the test product before their training session on each intervention day (Day 5, Day 6, and Day 7).
61928600|NCT05764863|EXPERIMENTAL|young healthy adults|Participants need to complete three experimental conditions associated with fMRI recording of brain activity. In condition A (Visual Spatial), participants will see the sequences presented from left to right; in condition B (Visual No Spatial), participants will see sequences of items presented in the middle of the screen; and in condition C (Auditory), the sequences will be presented in an auditory format.
61928601|NCT03986034|EXPERIMENTAL|Relapsed/Refractory CLL pts|Ages 18 and older
61928602|NCT01158508|EXPERIMENTAL|Remote Ischemic Preconditioning|Patients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
61928603|NCT06286644|EXPERIMENTAL|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0mg = Placebo; 0,125 mg; 0,375 mg or 0,75 mg soluble Xanthohumol)
62323069|NCT01566123|EXPERIMENTAL|A|Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma
62323070|NCT01737619|EXPERIMENTAL|Diagnostic (PET/CT, lymph node mapping)|Patients undergo PET/CT prior to surgery. Patients then undergo intraoperative lymph node mapping with indocyanine green solution, given via superficial and deep cervical injection during full lymphadenectomy.
62323071|NCT05054933|OTHER|ultrasound capsule endoscopy examination|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
62323072|NCT05755191|EXPERIMENTAL|NEU-411|Part A: Single-ascending dose cohorts; food effect; Part B: Multiple-ascending dose cohorts (7 days)
62323073|NCT05755191|PLACEBO_COMPARATOR|Placebo|Part A: Single-ascending dose cohorts; food effect; Part B: Multiple-ascending dose cohorts (7 days)
62323074|NCT00849433||1|30 patients with asthma
62323075|NCT00849433||2|30 patients with COPD
62690988|NCT00607477|ACTIVE_COMPARATOR|1|Minoxidil
62690989|NCT00607477|ACTIVE_COMPARATOR|2|Hydralazine
62690990|NCT03804255||Observational (survey)|Participants complete a self-administered web-based Biomarker Survey and may also complete an Outcome Validation Survey.
62339875|NCT03523221|ACTIVE_COMPARATOR|Dexamethasone arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
62690991|NCT04606316|EXPERIMENTAL|Nivolumab and Ipilimumab Before and After Surgery|"One dose of nivolumab plus ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
61928604|NCT06286644|EXPERIMENTAL|Iso-alpha-Acids|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo; 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
62131321|NCT02590432|EXPERIMENTAL|LINZESS® 145 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
62131322|NCT02590432|EXPERIMENTAL|LINZESS® 72 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
62690992|NCT04606316|EXPERIMENTAL|Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab After Surgery|"One dose of nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
61928605|NCT06286644|EXPERIMENTAL|Xanthohumol/Iso-alpha-Acids|Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo; 0,125 mg + 15 mg, 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
61928606|NCT06740474|EXPERIMENTAL|Part A: SAD Cohorts 1-5, ABI-6250|
61928607|NCT06740474|PLACEBO_COMPARATOR|Part A: SAD Cohorts 1-5, Placebo|
62131323|NCT02590432|EXPERIMENTAL|LINZESS® 145 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was reduced to 72 μg, if applicable.
62131324|NCT02590432|EXPERIMENTAL|LINZESS® 72 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
62131325|NCT02590432|EXPERIMENTAL|LINZESS® 72 μg (CIC, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with CIC.
61928608|NCT06740474|EXPERIMENTAL|Part A: SAD Food Effect Cohort 6 or 7: ABI-6250|
61928609|NCT06740474|PLACEBO_COMPARATOR|Part A: SAD Food Effect Cohort 6 (if applicable): Placebo|
61928610|NCT06740474|EXPERIMENTAL|Part B: MAD Cohorts 1-4, ABI-6250|
61928611|NCT06740474|PLACEBO_COMPARATOR|Part B: MAD Cohorts 1-4, Placebo|
61928612|NCT04586959|EXPERIMENTAL|Surgery With UM (Arm MAN UA)|Subjects that undergo a MIS approach with a uterine manipulator (experimental arm)
61928613|NCT04586959|ACTIVE_COMPARATOR|Surgery Without UM (Arm Control)|Subjects that undergo a MIS approach without a uterine manipulator (control arm)
61928614|NCT05198583|EXPERIMENTAL|Intervention|The intervention group will have a play-based intervention, including online games, analogue card games as well as a weekly coaching session to enhance executive functions.
61928615|NCT05198583|NO_INTERVENTION|Control|The control group will get access to the online games, a list of the analogue card games used and fact sheets about possibilities to enhance executive functions in everyday life (which are used in the intervention group during the coachings) after finishing the study.
61928616|NCT06744309|ACTIVE_COMPARATOR|Group A (Cool Roof and Heat Literacy Interventions)|"Cool roof intervention: Roofs will be painted with UV-resistant paint to reduce thermal absorption.~Heat literacy intervention: Participants will receive education and training on heat-related health risks and coping strategies."
61928617|NCT06744309|ACTIVE_COMPARATOR|Group B (Cool Roof Intervention Only)|Cool Roof intervention: Roofs will be painted with UV-resistant white paint to reduce thermal absorption
61928618|NCT06744309|ACTIVE_COMPARATOR|Group C (Heat Literacy Intervention Only)|-Heat literacy intervention: Participants will receive education and training on heat-related health risks and coping strategies.
62131326|NCT02590432|EXPERIMENTAL|LINZESS® 72 μg (IBS-C, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with IBS-C.
62131327|NCT04907513||Amotivational Syndrome|Patients required an external drainage of the cerebrospinal fluid.
62131328|NCT03710798|EXPERIMENTAL|Low carbohydrate high fat diet|Low carbohydrate high fat (LCHF) diet
62131329|NCT01256840||Calorie Restricting Group|
62131330|NCT01256840||Normal-eating controls|
62131331|NCT01256840||Obese comparison group|
62482247|NCT02193282|EXPERIMENTAL|Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
62690993|NCT04606316|EXPERIMENTAL|Placebo-Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab and Ipilimumab After Surgery|"One dose of placebo-nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks"
61928619|NCT06744309|NO_INTERVENTION|Group D (Control Group)|No intervention will be provided, serving as a control group for comparison.
61928620|NCT04333771|PLACEBO_COMPARATOR|Placebo|
61928621|NCT04333771|EXPERIMENTAL|SHR0302 dose1|
61928622|NCT04333771|EXPERIMENTAL|SHR0302 dose2|
61928623|NCT03427060|EXPERIMENTAL|Coversin treatment|Coversin - 22.5mg followed by 45mg for 6 months.
61928624|NCT05683392|EXPERIMENTAL|Control-IQ 2.0 Lower Range First, then Standard Range|After a two week run in period with Control-IQ 1.5, participants will use t:slim X2 pump with Control-IQ technology 2.0 with a lower range for two weeks, followed by use of t:slim X2 pump with Control-IQ technology 2.0 with a standard range for two weeks.
61928625|NCT05683392|EXPERIMENTAL|Control-IQ 2.0 Standard Range First, then Lower Range|After a two week run in period with Control-IQ 1.5, participants will use t:slim X2 pump with Control-IQ technology 2.0 with a standard range for two weeks, followed by use of t:slim X2 pump with Control-IQ technology 2.0 with a lower range for two weeks.
61928626|NCT04732117|EXPERIMENTAL|Secukinumab Arm|Secukinumab 150 mg PFS s.c.
61928627|NCT04732117|PLACEBO_COMPARATOR|Placebo Arm|Placebo 150mg PFS s.c.
62323076|NCT05910801|EXPERIMENTAL|Treatment (Tafasitamab, lenalidomide, venetoclax)|Patients receive tafasitamab IV, lenalidomide PO and venetoclax PO while on study. Patients may undergo lumbar puncture during screening. Patients undergo CT scan and blood sample collection and may undergo MRI and tumor biopsy on study and during follow-up. Patients undergo PET/CT, bone marrow biopsy, and bone marrow aspirate throughout the study.
62323077|NCT02793167|NO_INTERVENTION|Usual care|patients will receive standard clinical care by the doctor in charge.
62323078|NCT02793167|EXPERIMENTAL|AKI alert|an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
62323079|NCT00914199|EXPERIMENTAL|Kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent using kissing balloon dilatation
62323080|NCT00914199|EXPERIMENTAL|No kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent and not using kissing balloon postdilatation
61928628|NCT04482309|EXPERIMENTAL|Part 1 Cohort 1|Biliary tract cancer
61928629|NCT04482309|EXPERIMENTAL|Part 1 Cohort 2|Bladder cancer
61928630|NCT04482309|EXPERIMENTAL|Part 1 Cohort 3|Cervical cancer
61928631|NCT04482309|EXPERIMENTAL|Part 1 Cohort 4|Endometrial cancer
62323081|NCT06692621||O:oxytocin|In the oxytocin group, oxytocin ('Synpitan forte 5 IU/ml im/iv ampoule, Deva İlaç Sanayi, Turkey)' was administered 20 IU intravenously (5 IU intravenous bolus followed by 15 IU/hour infusion) in accordance with the recommendations of the Ministry of Health of the Republic of Turkey.
62323082|NCT06692621||C:carbetocin|In the carbetocin group, carbetocin 'Pabal 100 microgram/ml iv solution for injection ampoule, Ferring GmbH, Germany) was diluted with 20 ml of 0.9% NaCl solution and administered over 30-60 seconds.
62482248|NCT02193282|PLACEBO_COMPARATOR|Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
62482249|NCT02193282|EXPERIMENTAL|Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
61928632|NCT04482309|EXPERIMENTAL|Part 1 Cohort 5|Ovarian cancer
61928633|NCT04482309|EXPERIMENTAL|Part 1 Cohort 6|Pancreatic cancer
61928634|NCT04482309|EXPERIMENTAL|Part 1 Cohort 7|Rare tumors
61928635|NCT04482309|EXPERIMENTAL|Part 2 Cohort A|Any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer)
61928636|NCT04482309|EXPERIMENTAL|Part 2 Cohort B|Any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer)
61928637|NCT04482309|EXPERIMENTAL|Part 2 Cohort C|HER2 IHC 2+ or 1+ endometrial cancer
61928638|NCT04482309|EXPERIMENTAL|Part 2 Cohort D|HER2 IHC 2+ or 1+ ovarian cancer
61928639|NCT04482309|EXPERIMENTAL|Part 2 Cohort E|HER2 IHC 2+ or 1+ cervical cancer
62323083|NCT02758886|EXPERIMENTAL|Stress reduction method|Participants randomized into the PYSA group engaged in a 10 minute direct interaction with the animals (dogs and cats) of the Pet Your Stress Away program
62323084|NCT02758886|PLACEBO_COMPARATOR|Control|Participants randomized into the Control group watched a 10 minute slide show of dog and cat photos
62482250|NCT02193282|ACTIVE_COMPARATOR|Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
62482251|NCT06475846|EXPERIMENTAL|Treatment group A: HRS5580|
62482252|NCT06475846|EXPERIMENTAL|Treatment group B: HRS5580|
61928640|NCT04383119|EXPERIMENTAL|Arm A|Trabectedin at the dose of 1.5 mg/m2-1.3 mg/m2 with a top-dose of 2.6 total mg per cycle (according the clinical practice in pretreated patients and in all our ISG studies) will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles
61928641|NCT04383119|ACTIVE_COMPARATOR|Arm B|Gemcitabine 800-1000 mg/m2 will be administered via a central venous catheter on days 1,8 every 21 days
61928642|NCT04383119|ACTIVE_COMPARATOR|Observational Cohort|Treatmen according clinical practice (not defined in advance). The patient who will refuse randomization between Arm A and B can choose to participate to the observational cohort to the study, where they will be treated according clinical practice
61928643|NCT06163651|EXPERIMENTAL|Treatment Group|The treatment group consists of parents who meet our eligibility criteria. Parents in the treatment group will receive PCAP-1 services through the work of highly trained, closely-supervised case managers.
61928644|NCT06163651|NO_INTERVENTION|Control Group|"The control group consists of parents who meet our eligibility criteria and are part of administrative data from the Oklahoma Department of Human Services in a comparable county to our intervention county. Parents in the control group can access services as usual in the community, but will not receive PCAP in any form."
61928645|NCT05316129|EXPERIMENTAL|Intraperitoneal treatment- Dose Level 1|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
61928646|NCT05316129|EXPERIMENTAL|Intravenous treatment - Dose Level 1|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^5 by Intravenous (IV).
61928647|NCT05316129|EXPERIMENTAL|Intraperitoneal treatment- Dose Level 2|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
61928648|NCT05316129|EXPERIMENTAL|Intravenous treatment - Dose Level 2|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^5 by Intravenous (IV).
61928649|NCT05316129|EXPERIMENTAL|Intraperitoneal treatment- Dose Level 3|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
61928650|NCT05316129|EXPERIMENTAL|Intravenous treatment - Dose Level 3|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^6 by Intravenous (IV).
62482253|NCT06475846|EXPERIMENTAL|Treatment group C: HRS5580|
62482254|NCT06475846|ACTIVE_COMPARATOR|Treatment group D: Ondansetron|
62482255|NCT06475846|PLACEBO_COMPARATOR|Treatment group E: blank preparation.|
62482256|NCT06743295|EXPERIMENTAL|Hearing Aid only|Patients with hearing impairment who do not have a Cochlear implant
62482257|NCT06743295|EXPERIMENTAL|Cochlear Implant with Hearing Aid|Patients with hearing impairment who have a single-sided implant (using a hearing aid on the opposite ear)
62482258|NCT06398314|ACTIVE_COMPARATOR|1-2 fractions of 8 Gy (Gray)|
62482259|NCT06398314|ACTIVE_COMPARATOR|5 fractions of 5 Gy (Gray)|
61928651|NCT05316129|EXPERIMENTAL|Intraperitoneal treatment- Dose Level 4|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
61928652|NCT05316129|EXPERIMENTAL|Intravenous treatment - Dose Level 4|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10\^6 by Intravenous (IV).
62323085|NCT02758886|NO_INTERVENTION|Non-treatment|Participants randomized into the No-treatment group silently waited for 10 minutes without engaging in any physical or electronic social interactions.
62482260|NCT00746421|EXPERIMENTAL|1|Quetiapine XR 200-400 mg/day
62482261|NCT00746421|PLACEBO_COMPARATOR|2|Placebo one pill per day matching 200, 300, or 400 mg
62482262|NCT06742814|NO_INTERVENTION|control group|usal nursing care
62482263|NCT06742814|EXPERIMENTAL|intervation group|stress ball
62482264|NCT01470976|ACTIVE_COMPARATOR|Goal-directed Therapy (GDT) Protocol|
62482265|NCT01470976|ACTIVE_COMPARATOR|Standard Protocol|
62131332|NCT00722046|EXPERIMENTAL|PF-04360365 0.1 mg/kg|
62131333|NCT00722046|EXPERIMENTAL|PF-04360365 0.5 mg/kg|
62131334|NCT00722046|EXPERIMENTAL|PF-04360365 1 mg/kg|
62131335|NCT00722046|PLACEBO_COMPARATOR|Placebo|
62131336|NCT00722046|EXPERIMENTAL|PF-04360365 3 mg/kg|
62131337|NCT00722046|EXPERIMENTAL|PF-04360365 8.5 mg/kg|
62131338|NCT02973594|ACTIVE_COMPARATOR|Ivabradine|Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
62131339|NCT02973594|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.
62131340|NCT06384820|EXPERIMENTAL|cemiplimab|
62131341|NCT06384820|EXPERIMENTAL|fianlimab+cemiplimab|
62323086|NCT02758886|PLACEBO_COMPARATOR|Observation|Participants randomized into the observation group observed 10 minutes of others in the general PYSA program petting cats and dogs, while they 'waited in line' for there turn.
62323087|NCT04442334||The LITMUS Study Cohort|Prospectively recruited NAFLD patients, recruited according to The European NAFLD Registry study protocol.
62323088|NCT04442334||The LITMUS Metacohort|Collated data and biological samples on patients with histologically characterised NAFLD prospectively recruited at contributing academic centres across Europe.
62482266|NCT06296537|EXPERIMENTAL|Dynamic Neuromuscular Stabilization Training Group|A dynamic neuromuscular stabilization training program consisting of a series of special exercises based on the developmental kinesiology steps of a healthy baby will be prepared and applied for athletes in the DNS group. As the sessions progress, elastic bands will be used to create resistance in the exercises as the participants gain stabilization. All exercises will start with 1 set of 3 repetitions and increase to 1 set of 20 repetitions. All exercises will be performed barefoot.
62482267|NCT06296537|EXPERIMENTAL|Balance Training Group|An intervention program will be prepared for balance training group in which balance training is added to an effective postural stability program. As the sessions progress, hand and ankle sandbags will be used together with the exercises. All exercises will start with 1 set of 10 repetitions and increase to 3 sets of 15 repetitions. Exercises will be performed barefoot.
62482268|NCT06296537|ACTIVE_COMPARATOR|Conventional Training Group|A program including stretching, joint range of motion, strengthening and postural control exercises will be prepared for athletes in the conventional group. As the sessions progress, hand and ankle sandbags will be used together with the exercises. All exercises will start with 1 set of 10 repetitions and increase to 3 sets of 15 repetitions. Exercises will be performed barefoot.
62482269|NCT02875392|EXPERIMENTAL|Fucoidan use|FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
62482270|NCT02875392|PLACEBO_COMPARATOR|placebo pills|placebo capsule 6 per day (before breakfast and supper)
62131342|NCT01598870||Patients with cirrhosis and ascites|Patients requiring diagnostic and/or therapeutic paracentesis.
62131343|NCT04810260|ACTIVE_COMPARATOR|HIV +|Patients will have the application and use it to increase their awareness about their medical condition.
62131344|NCT04810260|ACTIVE_COMPARATOR|HIV -|Patients will have the application and use it to increase their awareness about their medical condition.
62131345|NCT03192215|EXPERIMENTAL|Active agent: Apixaban|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban
62131346|NCT03192215|ACTIVE_COMPARATOR|Active control: Aspirin|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin
62131347|NCT03706521|EXPERIMENTAL|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
62131348|NCT05942092||ROLL|
62131349|NCT05942092||SEED|
62131350|NCT04056624|EXPERIMENTAL|Low dose|1 x 6 ounces of carotenoid-containing juice (6 mg carotenoids/6 oz)
62131351|NCT04056624|EXPERIMENTAL|High dose|2 x 6 ounces of carotenoid-containing juice (12 mg carotenoids/12 oz)
62131352|NCT04056624|PLACEBO_COMPARATOR|Placebo|12 ounces of apple juice (negligible carotenoids 0.06 mg/12 oz)
62323089|NCT04442334||EFPIA Clinical Trial Cohort|Collated data and biological samples on patients with histologically characterised NAFLD that have participated in phase 2 and phase 3 trials of IMPs for NAFLD.
62323090|NCT03452150|EXPERIMENTAL|Daily oral dose of D-0316|
62323091|NCT00705224||Patients with chronic hepatitis C|Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
62482271|NCT06694259|ACTIVE_COMPARATOR|Pneumatic retinopexy with transscleral cryopexy|
62482272|NCT06694259|ACTIVE_COMPARATOR|Pneumatic retinopexy with laser photocoagulation|
62131353|NCT03752151|EXPERIMENTAL|MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode|Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.
62323092|NCT02817555|ACTIVE_COMPARATOR|Epoetin alfa|Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
62482273|NCT06463860||Double reading of all cases with and without software output|Double reading of all cases with and without software output
62482274|NCT05502679|ACTIVE_COMPARATOR|Traditional Group|6-week non-weight bearing of the affected lower limb rehabilitation protocol (TG)
62482275|NCT05502679|EXPERIMENTAL|Weight-bearing Group|Immediate lower limb weight bearing to tolerance rehabilitation protocol (WBG)
62482276|NCT04534205|EXPERIMENTAL|Part A (Safety run-In) - BNT113 + Pembrolizumab|Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.
62131354|NCT04159779||Venetoclax Participants|Participants for whom the treating physician has decided to treat with venetoclax before enrollment in this study.
62131355|NCT01761487|OTHER|One arm only - Gentamicin and polymyxin E|All subjects will receive:Gentamicin and polymyxin E paste applied on buccal surface four times daily + gentamicin + polymyxin E PO + Strict contact precautions
62131356|NCT04454879|EXPERIMENTAL|standard roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive standard dosage of roxadustat according to weight.
62131357|NCT04454879|EXPERIMENTAL|lower roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive lower dosage of roxadustat according to weight.
62131358|NCT01188655||Treatment Group Enbrel|
62131359|NCT01409824|NO_INTERVENTION|without CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will not be implemented
62131360|NCT01409824|EXPERIMENTAL|with CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will be implemented, parallel to the performance based incentive package
62131361|NCT05382754|EXPERIMENTAL|HSAT first|Participants will be randomized to undergo HSAT before receiving their clinical, in-lab polysomnography
62131362|NCT05382754|ACTIVE_COMPARATOR|PSG first|Participants will be randomized to undergo HSAT after receiving their clinical, in-lab polysomnography.
62131363|NCT03849352|OTHER|Lifestyle Arm|Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology
62131364|NCT05284565|OTHER|Results of reading|All patients who were prick tested and accepted to participate in the study, were prospectively included in the study in only one arm. All of their tests were read by the device and the manual procedure.
62131365|NCT01152398|EXPERIMENTAL|MVA-BN-HER2|
62131366|NCT02825641|ACTIVE_COMPARATOR|Expectant Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score\<6).~Labor induction will be initiated with Dinoprostone after 24 hours of waiting depending on obstetric history and cervical conditions."
62131367|NCT02825641|ACTIVE_COMPARATOR|Expectant Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score\<6).~Labor induction will be initiated with oxytocin after 24 hours of waiting depending on obstetric history and cervical conditions."
62131368|NCT02825641|EXPERIMENTAL|Active Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score\<6).~Labor induction will be initiated with Dinoprostone on presentation depending on obstetric history and cervical conditions."
62131369|NCT02825641|EXPERIMENTAL|Active Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score\<6).~Labor induction will be initiated with oxytocin on presentation depending on obstetric history and cervical conditions."
62131370|NCT01039155|EXPERIMENTAL|Treatment (azacitidine, oxaliplatin)|Patients receive azacitidine IV over 15-30 minutes on days 1-5 and oxaliplatin IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62131371|NCT01837875|NO_INTERVENTION|Control|Mailed informational literature
62131372|NCT01837875|ACTIVE_COMPARATOR|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
62323093|NCT02817555|ACTIVE_COMPARATOR|Darbepoetin alfa|"Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase."
62323094|NCT05092815|EXPERIMENTAL|HLX208|Participants receive HLX208 450mg bid po
62482277|NCT04534205|EXPERIMENTAL|Part B (Randomized phase) - BNT113 + Pembrolizumab|BNT113 in combination with pembrolizumab.
62482278|NCT04534205|ACTIVE_COMPARATOR|Part B (Randomized phase) - Pembrolizumab monotherapy|Pembrolizumab monotherapy.
62482279|NCT05240417|EXPERIMENTAL|Study group|"Pontic-shield will be performed as ridge preservation technique."
62690994|NCT05815264|EXPERIMENTAL|Experimental group aged 18-59 years|Subjects in the age group 18-59 years received 1 dose of 0.5 mL 23-valent pneumococcal polysaccharide vaccine
62690995|NCT05815264|ACTIVE_COMPARATOR|Control group aged 18-59 years|Subjects in the age group 18-59 years received 1 dose of 0.5 mL pneumococcal vaccine polyvalent
61928653|NCT05316129|EXPERIMENTAL|Intraperitoneal treatment- Dose Level 5|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^7. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
62131373|NCT01837875|EXPERIMENTAL|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
62131374|NCT01645033|EXPERIMENTAL|TAU plus computerized CBT|Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
61928654|NCT05316129|EXPERIMENTAL|Intravenous treatment - Dose Level 5|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10\^7 by Intravenous (IV).
62131375|NCT01645033|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]"
62131376|NCT02541461|OTHER|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI \< 25 kg/m2
61928655|NCT02669069|ACTIVE_COMPARATOR|PS1|
62131377|NCT02541461|OTHER|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
62323095|NCT00192335|ACTIVE_COMPARATOR|1|CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
62323096|NCT00192335|ACTIVE_COMPARATOR|2|FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
62323097|NCT06153693|PLACEBO_COMPARATOR|Placebo|Placebo once daily (QD) for 12 weeks
62323098|NCT06153693|EXPERIMENTAL|Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
62323099|NCT06153693|EXPERIMENTAL|Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
62323100|NCT04415489|ACTIVE_COMPARATOR|Office Hysteroscopy|Use of office hysteroscope with operative port to evaluate uterine cavity, and potentially treat minor abnormalities within the same procedure with hysteroscopic graspers. This involve inserting the hysteroscope through the cervix and instillation of saline for a direct look at the cavity.
62323101|NCT04415489|NO_INTERVENTION|Saline Infusion Sonography (SIS)|This is our institution's current first line approach for screening evaluation of the uterine cavity. If not enrolled in the study, patients are required to do this to move forward with embryo transfer. It involves instillation of saline into the uterus via a small catheter with simultaneous imaging with pelvic ultrasound.
62323102|NCT05055635|EXPERIMENTAL|Doseescalated pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day.
62482280|NCT05240417|ACTIVE_COMPARATOR|Positive control (ridge preservation)|Deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction.
61928656|NCT02669069|ACTIVE_COMPARATOR|PS2|
61928657|NCT02669069|ACTIVE_COMPARATOR|PS3|
61928658|NCT06582589|EXPERIMENTAL|Healsea Children treated group|Subjects of this arm will be treated with Healsea Children nasal spray (1 puff in each nostril twice daily) during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days
61928659|NCT06582589|NO_INTERVENTION|untreated group|Subjects of this arm will not receive any treatment for the prevention of respiratory tract infection.
61928660|NCT06419582|EXPERIMENTAL|BHV-7000|
61928661|NCT06419582|PLACEBO_COMPARATOR|Placebo|
61928662|NCT06377852|EXPERIMENTAL|Arm 1: Indicated Dose|Arm 1 of the study is the indicated dosing regimen, provided in the FDA approved drug label: participants will start cycle 1 with either 125mg dose of palbociclib or 600mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant).
61928663|NCT06377852|EXPERIMENTAL|Arm 2: Titrated Dose|Arm 2 is the titrated dosing regimen: participants will start cycle 1 with either 100 mg or 75 mg dose of palbociclib or 400 mg or 200 mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant). For cycle 2 and for subsequent cycles, escalation to the indicated dose will be based on treatment tolerance.
61928664|NCT03898960||Mechanical Thrombectomy|NIMBUS Device
61928665|NCT04572763|EXPERIMENTAL|Dose Escalation Copanlisib + Venetoclax|"Phase 1~* Dose escalation will occur using a 3+3 design~* Copanlisib will be administered IV on days 1, 8 and 15 in 28 day cycle~* Venetoclax will be administered orally daily for each 28-day cycle. During cycle 1, a venetoclax dose ramp-up is performed in the outpatient setting"
61928666|NCT04572763|EXPERIMENTAL|Recommended phase II dose (RP2D) Copanlisib + Venetoclax|Patients will be treated with copanlisib in combination with venetoclax, administered at the Recommended phase II dose (RP2D).
61928667|NCT06683482||Participants with Advanced Breast Cancer Living in Spain and their Caregivers|Participants with different types of breast cancers living in Spain will be observed in this study. Participants will not receive any study drug in this study.
61928668|NCT05061550|EXPERIMENTAL|Arm 1: Oleclumab + Durvalumab + Platinum doublet chemotherapy (CTX)|"Participants will receive Durvalumab + Oleclumab + CTX as neoadjuvant treatment and Durvalumab + Oleclumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
61928669|NCT05061550|EXPERIMENTAL|Arm 2: Monalizumab + Durvalumab + CTX|"Participants will receive Durvalumab + Monalizumab + CTX as neoadjuvant treatment and Durvalumab + Monalizumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
61928670|NCT05061550|EXPERIMENTAL|Arm 3: Volrustomig (Dose Exploration) + CTX|"Participants will receive Volrustomig + CTX as neoadjuvant treatment and Volrustomig as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
61928671|NCT05061550|EXPERIMENTAL|Arm 4: Dato-DXd + durvalumab + single agent platinum|"Participants will receive Dato-DXd + durvalumab + single agent platinum as neoadjuvant treatment and durvalumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery:~Carboplatin or Cisplatin"
62131378|NCT02866968|EXPERIMENTAL|Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|All patients included will undergo FLAPS in one eye.
62131379|NCT03202199|EXPERIMENTAL|PET/MRI|PET/MRI examination
62131380|NCT02551536|ACTIVE_COMPARATOR|Group A|FDC tablet of montelukast 10 mg and levocetrizine 5 mg was given once daily for 4 weeks
62131381|NCT02551536|EXPERIMENTAL|Group B|FDC tablet of montelukast 10 mg and fexofenadine 120 mg was given once daily for 4 weeks
62323103|NCT03924674|ACTIVE_COMPARATOR|Stepped Wedge Group 1: Sept. 2019 Launch|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
62323104|NCT03924674|ACTIVE_COMPARATOR|Stepped Wedge Group 2: Nov. 2019 Launch|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
61928672|NCT05061550|EXPERIMENTAL|Arm 5: AZD0171 + durvalumab + CTX|"Participants will receive AZD0171 + durvalumab + CTX as neoadjuvant treatment and AZD0171 + durvalumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
61928673|NCT05061550|EXPERIMENTAL|Arm 6: Rilvegostomig + CTX|"Participants will receive Rilvegostomig + CTX as neoadjuvant treatment and Rilvegostomig as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
61928674|NCT05061550|EXPERIMENTAL|Arm 7: Dato-DXd + Rilvegostomig + single agent platinum|"Participants will receive Dato-DXd + Rilvegostomig + single agent platinum as neoadjuvant treatment and Rilvegostomig as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery:~Carboplatin or Cisplatin"
61928675|NCT02933970|NO_INTERVENTION|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
61928676|NCT02933970|OTHER|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
61928677|NCT06403111|EXPERIMENTAL|Chemotherapy+Immunotherapy+FMT|
61928678|NCT03621592|EXPERIMENTAL|Cutimed® Sorbact®|Participants in this group will receive the Cutimed Sorbact intervention for 6 weeks.
61928679|NCT03621592|ACTIVE_COMPARATOR|Acticoat®|Participants in this group will receive the Acticoat intervention for 6 weeks.
61928680|NCT05756621||Dual anti-glutamate therapy (DUAL)|"Patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual dose reduction according to clinical evolution."
61928681|NCT05756621||Control (OTHERS)|Patients who received any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs ketamine and perampanel.
61928682|NCT05501912|EXPERIMENTAL|Monotherapy Dose Escalation and Dose Expansion|In US studies, dose escalation started at a 25 mg BID dose and subsequent dose-escalation groups included: 50 mg BID, 100 mg BID, 150 mg BID, 225 mg BID and 325 mg BID. In this study, the actual dose escalation will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials when the enrolment of the China study actually initiates, and subsequent escalated doses may be adjusted as appropriate (e.g., the escalated doses following 150 mg BID in the China study may be adjusted to 200 mg BID, 250 mg BID and 300 mg BID. The actual priming dose and subsequent escalated doses for the China study are determined by the SMC) The dose expansion stage in this study will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level (MTD or the optimal dose needs to be reviewed by the SMC and subjects are safe and tolerable at that dose level).
61928683|NCT06743841|EXPERIMENTAL|Nutritional Supplement|1 sachet of nutritional supplement (30g) in the morning and 1 sachet (30g) in the afternoon during 8 weeks. A total of 60g daily.
61928684|NCT06743841|PLACEBO_COMPARATOR|Control|1 sachet of placebo supplement (30g) in the morning and 1 sachet (30g) in the afternoon during 8 weeks. A total of 60g daily.
61928685|NCT05587036|EXPERIMENTAL|Rifaximin|Rifaximin oral tablets, 550 mg, twice daily, two-weeks
62131382|NCT04746833|EXPERIMENTAL|SUMMIT|Participants randomized to the experimental intervention will participate in a Motivational Interviewing (MI) session lasting between 30 and 60 minutes with study psychologist. All MI sessions will be audiotaped using a VA-approved digital recorder and transcribed verbatim. Participants will subsequently be shown how to access SUMMIT via a set of unique anonymized login credentials and to navigate the components of SUMMIT on one or more devices, depending on their preference. They will then be trained on how to complete the outcome surveys.
62131383|NCT04746833|PLACEBO_COMPARATOR|control|Participants randomized to the control intervention will use an eHealth comparator: My Pain Diary: Chronic Pain Management (iPhone, Android). This app includes a pain monitoring functioning only, and thus will only minimally overlap, if at all, with SUMMIT's components. Control participants will not participate in a MI session. Participants will download the app and be shown how to use the My Pain Diary app and trained how to complete the outcome surveys
62131384|NCT05143996|EXPERIMENTAL|Part A - Single ascending dose (SAD) design of IV administered CLN-049|Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration
62131385|NCT05143996|EXPERIMENTAL|Part B - Multiple ascending dose (MAD) design of IV administered CLN-049|Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration
62482281|NCT05240417|NO_INTERVENTION|Negative control (fresh socket)|No intervention will be performed after tooth extraction. Blood clot will be maintained after extraction.
62482282|NCT00127985|EXPERIMENTAL|Active|IV 6-methyl-prednisolone
62482283|NCT00127985|PLACEBO_COMPARATOR|Comparator|IV Placebo
62482284|NCT05188508|EXPERIMENTAL|Recurrent enhancing grade II and III IDH-mutated gliomas that have failed previous therapy|All patients will receive pembrolizumab for two cycles prior to the addition of olaparib and temozolomide. Combination olaparib and temozolomide will be added in cycle 3. Combination therapy will continue through cycle 11 (cycles 3-11 = 27 weeks or approximately 6 months). Patients will then continue on pembrolizumab maintenance for a maximum of 35 cycles (two years) or until progression of disease or unacceptable toxicity.
61928686|NCT05587036|PLACEBO_COMPARATOR|Placebo|Placebo oral tablets, twice daily, two-weeks
61928687|NCT06213545|EXPERIMENTAL|In-Clinic interpretation|After doing patch test, patient come to Siriraj hospital to interpret the results at 48 hr and 72 hr.
61928688|NCT06213545|EXPERIMENTAL|Photo interpretation|After doing patch test, patient take a photo to Siriraj hospital by LINE application to interpret the results at 48 hr, 72 hr and 7 days
61928689|NCT06040086|EXPERIMENTAL|Tozorakimab|Dosing subcutaneously tozorakimab
61928690|NCT06040086|PLACEBO_COMPARATOR|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
61928691|NCT06744946|EXPERIMENTAL|the first arm thoracoscopic talc poudrage and the second arm Bleomycin -Tranxemic mic acid mixture|the first arm is talc insufflation through medical thoracoscopy the second arm involve bleomycin- tranxemic acid mixture injection in intercostal tube
62131386|NCT05143996|EXPERIMENTAL|Part C - Multiple ascending dose (MAD) design of SC administered CLN-049|Patients with relapsed/refractory AML or MDS will receive CLN-049 via SC injection
62482285|NCT05188508|EXPERIMENTAL|Recurrent IDH-wildtype gliomas and homologous recombination deficiency (HRD).|Five patients will receive pembrolizumab for two cycles prior to the addition of olaparib and temozolomide. Combination olaparib and temozolomide will be added in cycle 3. Combination therapy will continue through cycle 11 (cycles 3-11 = 27 weeks or approximately 6 months). Patients will then continue on pembrolizumab maintenance for a maximum of 35 cycles (two years) or until progression of disease or unacceptable toxicity. This cohort will be analyzed descriptively.
62690996|NCT05815264|EXPERIMENTAL|Experimental group aged ≥60 years|Subjects in the age group ≥60 years received 1 dose of 0.5 mL 23-valent pneumococcal polysaccharide vaccine
62690997|NCT05815264|ACTIVE_COMPARATOR|Control group aged ≥60 years|Subjects in the age group ≥60 years received 1 dose of 0.5 mL pneumococcal vaccine polyvalent
61928692|NCT06710132|EXPERIMENTAL|Substudy GC: M9140 Monotherapy - Part A CEACAM5 High|
61928693|NCT06710132|EXPERIMENTAL|Substudy GC: M9140 Monotherapy - Part B CEACAM5 Low|
61928694|NCT06710132|EXPERIMENTAL|Substudy NSCLC: M9140 Monotherapy - Part A CEACAM5 High EGFR Wt|
61928695|NCT06710132|EXPERIMENTAL|Substudy NSCLC: M9140 Monotherapy - Part B CEACAM5 High EGFR mut|
61928696|NCT06710132|EXPERIMENTAL|Substudy PDAC: M9140 Monotherapy - Part A CEACAM5 High|
61928697|NCT06271018||Aortitis in GCA|Adult patients with active aortitis associated with GCA, requiring treatment with Tocilizumab biosimilar used within the scope of its market authorization (standard of care)
61928698|NCT06005168|NO_INTERVENTION|Standard of Care|The patients assigned to this group have cefazolin dose assignments based on body weight, which is the standard of care.
61928699|NCT06005168|ACTIVE_COMPARATOR|Morphomic-based|The patients assigned to this group have cefazolin dose assignments based on body depth and kidney function.
61928700|NCT02969707|EXPERIMENTAL|Active rTMS|The active group will receive repetitive Transcranial Magnetic Stimulation
61928701|NCT02969707|SHAM_COMPARATOR|Sham rTMS|The sham repetitive Transcranial Magnetic Stimulation group will have the stimulation blocked.
61928702|NCT05649137|EXPERIMENTAL|Semaglutide 7.2 mg|Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram \[mg\], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.
61928703|NCT05649137|EXPERIMENTAL|Semaglutide 2.4 mg|Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.
61928704|NCT05649137|PLACEBO_COMPARATOR|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.
61928705|NCT05655520|EXPERIMENTAL|Cohort 1 (Direct Rollover)|Participants from studies 718-CIH-201 (NCT05107128) and 718-CIH-202 (NCT05358821) who will sign the informed consent for study 718-CIH-301 ≤7 days after the last day of the corresponding parent study. Participants will receive Sage-718 from Day 1 up to Month 48.
61928706|NCT05655520|EXPERIMENTAL|Cohort 2 (Gap Rollover)|Participants from studies 718-CIH-201 (NCT05107128) and 718-CIH-202 (NCT05358821) who will sign the informed consent for study 718-CIH-301 after a gap of \>7 days after the last day of the corresponding parent study. Participants will receive Sage-718 from Day 1 up to Month 48.
62131387|NCT06423534|EXPERIMENTAL|Study GROUP|Each primigravida in the study group during the last three trimesters will receive three sessions of knowledge, breast care, and breastfeeding technique after filling out a questionnaire (pretest). During 1 month from delivery, we will conduct a post-test with them (after 2 weeks and after 4 weeks) to explore the effect of breastfeeding health educational programs on practices and breastfeeding self-efficacy
62131388|NCT06423534|ACTIVE_COMPARATOR|Control group|The control group was selected first and received a brochure leaflet delivered by the researcher. They didn't receive the health educational program
62131389|NCT04141514|EXPERIMENTAL|intervention group|therapeutic fasting
62131390|NCT04141514|NO_INTERVENTION|control group|usual alimentation
62690998|NCT05815264|EXPERIMENTAL|Experimental group aged 2-17 years|Subjects in the age group 2-17 years received 1 dose of 0.5 mL 23-valent pneumococcal polysaccharide vaccine
62690999|NCT05815264|ACTIVE_COMPARATOR|Control group aged 2-17 years|Subjects in the age group 2-17 years received 1 dose of 0.5 mL pneumococcal vaccine polyvalent
61928707|NCT05655520|EXPERIMENTAL|Cohort 3 (De Novo)|Participants who were not previously included in any SAGE-718 clinical study. Participants will receive Sage-718 from Day 1 up to Month 48.
62131391|NCT02187887|EXPERIMENTAL|Personalized normative feedback|Intervention participants receive feedback correcting their misperceptions of the drinking behavior and attitudes of fellow veterans
62131392|NCT02187887|NO_INTERVENTION|Control|Control participants receive feedback correcting their misperceptions of the video game playing behavior and attitudes of fellow veterans
62131393|NCT01646749|EXPERIMENTAL|Protein intake of 5 energy percent (En%)|
62131394|NCT01646749|EXPERIMENTAL|Protein intake of 15 En%|
62131395|NCT01646749|EXPERIMENTAL|Protein intake of 30 En%|
62131396|NCT06287489|OTHER|Mediterranean diet phase followed by regular diet phase|Three-month of M phase, one month of washout and three month of R phase
62131397|NCT06287489|OTHER|Regular diet phase followed by Mediterranean diet phase|Three-month of R phase followed by three month of M phase
62482286|NCT01274338|EXPERIMENTAL|Arm A (age >= 18, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
62482287|NCT01274338|EXPERIMENTAL|Arm B (age >= 18, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
61928708|NCT05359328|OTHER|Controled Hypoxia - Healthy Volunteers|
61928709|NCT05664113|EXPERIMENTAL|Stratum A|Diagnosed with GvHD
61928710|NCT05664113|EXPERIMENTAL|Stratum B|GI Dysfunction
61928711|NCT05644665|EXPERIMENTAL|Arm A: Ozanimod|
61928712|NCT05644665|PLACEBO_COMPARATOR|Arm B: Placebo|
61928713|NCT04799275|EXPERIMENTAL|Arm I (oral azacitidine, R-miniCHOP)|Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486 PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.
61928714|NCT04799275|ACTIVE_COMPARATOR|Arm II (R-miniCHOP)|Patients receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.
61928715|NCT06150183|EXPERIMENTAL|BNT314 Monotherapy|Escalating dose levels and backfill cohorts
61928716|NCT06150183|EXPERIMENTAL|BNT314 + pembrolizumab|The BNT314 starting dose for the SRI combination therapy will be one DL lower than the RP2D/MTD/maximum administered dose (MAD) determined from the monotherapy dose escalation.
61928717|NCT02211859|EXPERIMENTAL|BI 2536|single escalating dose, followed by repeated administration in patients with clinical benefit
61928718|NCT06113016|ACTIVE_COMPARATOR|Arm A (fisetin, physical activity handout)|Patients receive fisetin PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive handout on the importance of physical activity during baseline. Patients undergo collection of blood samples on study.
61928719|NCT06113016|EXPERIMENTAL|Arm AB (fisetin, tailored exercise training)|Patients receive fisetin PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive individually tailored supervised exercise training consisting of 30-45 minutes of aerobic training and 20-30 minutes of resistance training three times a week over 16 weeks. Patients undergo collection of blood samples on study.
62691000|NCT04527744|EXPERIMENTAL|the Yonsei point group|Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point.
62691001|NCT04527744|ACTIVE_COMPARATOR|the levator labii superioris alaeque nasi muscle group|For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
62691002|NCT06638021|NO_INTERVENTION|Pre-TECU Implementation|No intervention administered.
62691003|NCT06638021|EXPERIMENTAL|Post-TECU Implementation|When an ED clinician enters an uncertain diagnosis for a patient being discharged, the TECU BPA will notify the clinician to counsel the patient about uncertainty while additionally triggering automated 1) insertion and printing of the patient handout and 2) provision of a hyperlink for the clinician-facing checklist to guide the discharge conversation.
61928720|NCT06113016|ACTIVE_COMPARATOR|Arm B (placebo, tailored exercise training)|Patients receive placebo PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive individually tailored supervised exercise training consisting of 30-45 minutes of aerobic training and 20-30 minutes of resistance training three times a week over 16 weeks. Patients undergo collection of blood samples on study.
61928721|NCT06113016|ACTIVE_COMPARATOR|Arm C (placebo, physical activity handout)|Patients receive placebo PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive handout on the importance of physical activity during baseline. Patients undergo collection of blood samples on study.
61928722|NCT06309966|EXPERIMENTAL|BHV-7000 50 mg|
61928723|NCT06309966|EXPERIMENTAL|BHV-7000 75 mg|
61928724|NCT06309966|PLACEBO_COMPARATOR|Placebo|
62131398|NCT02996136|EXPERIMENTAL|Nasal Swab|Nasal Swab
62131399|NCT02996136|EXPERIMENTAL|Nasopharyngeal Swab|Nasopharyngeal Swab
62131400|NCT01411631|ACTIVE_COMPARATOR|Grape juice|Participants will drink 100% concord grape juice daily for 12 weeks
61928725|NCT06445062|EXPERIMENTAL|Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC|RMC-6236 (QD) and Bevacizumab with 5-fluorouracil-based regimens
61928726|NCT06445062|EXPERIMENTAL|Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC|RMC-6236 (QD) and Cetuximab with or without mFOLFOX6
61928727|NCT06445062|EXPERIMENTAL|Subprotocol C: metastatic PDAC|RMC-6236 (QD) and Gemcitabine with Nab-paclitaxel
61928728|NCT04318548|EXPERIMENTAL|MenB+MenACWY Group|Subjects will receive 1 dose rMenB+OMV NZ given concomitantly with MenACWY at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of placebo at Day 91.
61928729|NCT04318548|EXPERIMENTAL|MenB Group|Subjects will receive 1 dose of rMenB+OMV NZ and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of MenACWY at Day 91.
61928730|NCT04318548|EXPERIMENTAL|MenACWY Group|Subjects will receive 1 dose of MenACWY and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ each at Day 61 and at Day 91.
61928731|NCT03940950|EXPERIMENTAL|SVF (Stromal Vascular Fraction) Group|Subjects with knee osteoarthritis (OA) will receive Autologous Adipose-Derived SVF (Stromal Vascular Fraction) cells
61928732|NCT03940950|PLACEBO_COMPARATOR|Placebo Group|Subjects with knee osteoarthritis (OA) will be treated with a placebo
61928733|NCT05984368|EXPERIMENTAL|Part 1|A single ascending dose (SAD) study divided into 7 dose groups: 2 mg (exploratory dose), 24 mg, 50 mg, 100 mg, 200 mg, and 300 mg, 400 mg (optional dose group), with 2 mg enrolling 2 subjects (all receiving the test drug) and the remaining 8 subjects in each group (6 test drug, 2 placebo).
62131401|NCT01411631|PLACEBO_COMPARATOR|Placebo drink|Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
62131402|NCT03282526|EXPERIMENTAL|Whole body plethysmography|
61928734|NCT05984368|EXPERIMENTAL|Part 2|Multiple ascending dose (MAD) study, divided into 3 dose groups: 100 mg, 200 mg and 300 mg, each group included 8 healthy subjects (6 test drug, 2 placebo).
61928735|NCT01016704|NO_INTERVENTION|Control|
61928736|NCT01016704|EXPERIMENTAL|Incentive|
62131403|NCT03282526|ACTIVE_COMPARATOR|spirometery|
62131404|NCT04079244|ACTIVE_COMPARATOR|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children"
62131405|NCT04079244|ACTIVE_COMPARATOR|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
62131406|NCT02476409|EXPERIMENTAL|Tolvaptan|Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily
62691004|NCT06564350||Modified Physical Performance test (MPPT)|Participants will perform MPPT with and without the wearable seonsors.
61928737|NCT04700111|EXPERIMENTAL|Treatment 1 - DOT Pattern|Spectacle lens or treatment 1
61928738|NCT04700111|ACTIVE_COMPARATOR|Treatment 2 - Control Spectacles|Comparator lens or control arm
61928739|NCT04669574||Group 1|Participants who are newly diagnosed and have initiated front-line treatment.
61928740|NCT04669574||Group 2|Participants who have previously had one progression.
61928741|NCT04669574||Group 3|Participants who have previously had a second recurrence.
61928742|NCT04669574||Group 4|Participants who are on imaging surveillance and not receiving anti-neoplastic treatment
62131407|NCT02476409|PLACEBO_COMPARATOR|Placebo|Augmentation of current dose of loop diuretic
62131408|NCT06140732|EXPERIMENTAL|camrelizumab combined with apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
62131409|NCT01957969||Principal Population|Patients who undergo a definitive neuro-stimulator implantation.
62131410|NCT01957969||Annex Population|Patients who do not respond to the temporary test for the neurostimulator implantation
62691005|NCT06669039|ACTIVE_COMPARATOR|Conventional Inferior Alveolar nerve block|
62691006|NCT06669039|EXPERIMENTAL|Computer-controlled Intraligamentary local anaesthesia|
61928743|NCT02910583|EXPERIMENTAL|Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax|Participants receive 420 mg of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment (ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule) for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
61928744|NCT02910583|EXPERIMENTAL|MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).~Participants with confirmed uMRD are randomized to receive ibrutinib 420 mg orally once daily on a continuous schedule until MRD-positive relapse, disease progression (PD), or unacceptable toxicity.~After MRD-positive relapse or disease progression (PD) by iwCLL criteria, participants can reintroduce 400 mg venetoclax with a 5-week ramp up. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
61928745|NCT02910583|PLACEBO_COMPARATOR|MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).~Participants with confirmed uMRD are randomized to receive placebo orally once daily on a continuous schedule until MRD-positive relapse, PD or unacceptable toxicity.~If MRD-positive relapse or PD is confirmed after restaging per iwCLL criteria, participants can first reintroduce oral daily ibrutinib with the option of subsequently reintroducing 400 mg venetoclax with a 5-week ramp up, if subsequent disease relapse per iwCLL criteria occurs after ibrutinib reintroduction. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
62131411|NCT01609218|EXPERIMENTAL|80 mg LY2140023|Single oral dose of 80 milligrams (mg) LY2140023 administered alone
62131412|NCT01609218|EXPERIMENTAL|80 mg LY2140023 + 75 g aqueous activated charcoal|Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 grams (g) aqueous activated charcoal.
62131413|NCT06407882|EXPERIMENTAL|Experimental Group|Group A will perform Conductive exercises (CE) in addition to routine physical therapy. Conductive exercises program will include Squat-position, Rising from squat to stand, Sitting on the stool, Prone lying, High kneeling and half kneeling, Sitting, lying and high kneeling, Walking in parallel bars, Sitting to standing, Floor to standing, Picking up toys from the floor, Balance on one foot on different surfaces and heights, Crawling over foams of different sizes and shapes, Climbing steps or stairs sometimes while carrying a toy. These exercises will improve motor skills and activities of daily living by improving the muscle strength
62482288|NCT01274338|EXPERIMENTAL|Arm C (age >= 18, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cyclees in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
62691007|NCT06207162|EXPERIMENTAL|neural fingerprinting of MOUD|Study participants will have one in-person screening (2 hours), 6 in-person visits for fMRI scans conducted biweekly (4 hours), and will be computationally assessed 12 times, once per week for 12 weeks. After participation in the main study, participants will be asked to complete a 15-minute follow up every month for an additional three months
62691008|NCT05129969||Ovarian cancer|"Female patients with high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):~* with newly diagnosed FIGO stage IIb-IV OC who are starting systemic treatment, independent of the treatment intention (adjuvant/curative or palliative) or~* with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting their systemic treatment for first recurrent/relapsed disease."
62691009|NCT05129969||Endometrial cancer|Female patients with locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.
62691010|NCT02312128|ACTIVE_COMPARATOR|Early Mobilisation|"receives a removable plastic cast for one week and is allowed to move the wrist directly postoperative.~Interventions:~* Range of Motion measurement (ROM),~* Grip strength measurement,~* VAS Score according to the visual analogue scale ().~* Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~* X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
62691011|NCT02312128|ACTIVE_COMPARATOR|Cast Group|"receives a non removable cast for 5 weeks~Interventions:~* Range of Motion measurement (ROM),~* Grip strength measurement,~* VAS Score according to the visual analogue scale ().~* Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~* X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
62691012|NCT04696575|EXPERIMENTAL|Treatment (lamivudine, chemoimmunotherapy)|"INDUCTION: Patients receive lamivudine PO QD on days 1-28. Patients also receive carboplatin IV over 30-60 minutes and atezolizumab IV on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lamivudine PO QD on days 1-28 and atezolizumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Patients who are not eligible for atezolizumab as outlined in exclusion criteria or who refuse to receive atezolizumab may still be treated in this study with carboplatin and etoposide as the IV drug component, in addition to lamivudine orally administered."
61928746|NCT02910583|EXPERIMENTAL|MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).~Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg orally once daily on a continuous schedule until PD or unacceptable toxicity.~In case of confirmed PD after restaging per iwCLL criteria, participants can continue ibrutinib and reintroduce venetoclax treatment. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
61928747|NCT02910583|EXPERIMENTAL|MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).~Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. Venetoclax was allowed for administration up to 2 years cumulatively from first dose started in the pre-randomization phase to last dose in the randomization phase."
61928748|NCT05897125|EXPERIMENTAL|TELE-TOC plus Usual Care|Patients randomized to this arm will receive the TELE-TOC intervention as well as the standard COPD care via the institution's COPD readmission reduction program.
61928749|NCT05897125|ACTIVE_COMPARATOR|Usual Care|Patients randomized to this arm will receive standard COPD care via the institution's COPD readmission reduction program.
61928750|NCT06470451|EXPERIMENTAL|HyBryte (0.25% Hypericin)|HyBryte gel is applied twice weekly for 18 weeks.
62131414|NCT06407882|ACTIVE_COMPARATOR|Routine Physical Therapy|Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
62131415|NCT00822367|EXPERIMENTAL|Nutritional suplements|
61928751|NCT06470451|PLACEBO_COMPARATOR|Placebo|Placebo gel is indistinguishable from HyBryte gel, and is applied twice weekly for 18 weeks.
61928752|NCT05267106|EXPERIMENTAL|Cohort A: IDH-wild-type GBM|Participants with histopathologically proven, WHO Grade 4, IDH-wild-type GBM OR molecular diagnosis of IDH-wild-type, diffuse astrocytic glioma with molecular features of Grade 4 GBM that are recurrent, harboring FGFR1-3 fusions/or other rearrangements, or with a defined FGFR1-3 mutation or in-frame deletion.
61928753|NCT05267106|EXPERIMENTAL|Cohort B: Other gliomas other than GBM|Participants with other histopathologically proven gliomas other than GBM, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors that are recurrent, harboring FGFR1-3 fusions/or other rearrangements or with a defined FGFR1-3 activating mutation or in-frame deletion
62339876|NCT03523221|PLACEBO_COMPARATOR|Placebo arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
61928754|NCT05641155|EXPERIMENTAL|Adult Cochlear implant|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters
62131416|NCT05746715||genetic Creutzfeldt-Jakob Disease (CJD) patients|A group of patients diagnosed with CJD, who are carriers of E200K mutation in the PRNP gene (gCJD)
62131417|NCT05746715||Healthy first degree relatives|A group of first-degree healthy relatives (HR) (both carriers and non-carriers of the E200K mutation in the PRNP gene) of patients diagnosed with gCJD.
62131418|NCT00558506|EXPERIMENTAL|A|Abatacept
62691013|NCT06640595||Cold Temperature|Performance of the procedure under cold temperature (-20°C)
62691014|NCT06640595||Normal Temperature|Performance of the procedure under normal temperature (+20°C)
62691015|NCT05818930|OTHER|REMI vs Conventional EEG|REMI EEG is as Diagnostically useful as conventional EEG at monitoring patients with suspected seizure events.
62691016|NCT03396861|EXPERIMENTAL|Subconjunctival aflibercept|Subconjunctival aflibercept 2 milligrams (mg) /0.05 milliliters (mL) administered at baseline visit and possibly again at Month 1 visit depending on initial response.
61928755|NCT06286657|EXPERIMENTAL|Intervention|Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
61928756|NCT06286657|EXPERIMENTAL|Placebo|Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
61928757|NCT05846451|EXPERIMENTAL|Arm 1|"Sixteen non-naive\* participants (8 males, 8 females) will be administered a single low dose (2 g) of a well-characterized kratom product by mouth as a tea. Pupil diameter will be measured from 0-12 hours. A washout of at least 10 days will separate Arms 1 and 2.~\*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks"
61928758|NCT05846451|ACTIVE_COMPARATOR|Arm 2|The same 16 participants will be administered a single low dose (10 mg) of immediate-release oxycodone by mouth as a tablet. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 2 days will separate Arms 2 and 3.
61928759|NCT05846451|EXPERIMENTAL|Arm 3|The same 16 participants will be administered a single low dose (2 g) of kratom as a tea. After 15 minutes, the subjects will be administered a single low dose (10 mg) of oxycodone as a tablet by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 10 days will separate Arms 3 and 4.
61928760|NCT05846451|EXPERIMENTAL|Arm 4|The same 16 participants will self-administer a single low dose (2 g) of kratom as a tea once daily at home. On the fifth day, subjects will return to the research setting, where they will be administered a single low dose (2 g) of kratom, followed 15 minutes later by a single low dose (10 mg) of oxycodone by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours.
61928761|NCT03391531|ACTIVE_COMPARATOR|levobupivacaine|Echo-guided bilateral subcostalTAP block will be performed using levobupivacaine \[Chirocaine®\] 0.375% Epi 1/200000.
61928762|NCT03391531|PLACEBO_COMPARATOR|Saline|Echo-guided bilateral subcostal TAP block will be performed with saline Epi 1/200000 in the control group.
61928763|NCT04544956|EXPERIMENTAL|GSK3228836 300 mg|Participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).
61928764|NCT06267430|EXPERIMENTAL|Intervention group|The participants allocated to the intervention group will receive the personalised training program 'KleuterExtra', developed by dr. Lex Wijnroks from Utrecht University. All parents will receive the book 'Speels Brein' ('Playful Brain') and an age-appropriate addition for preschoolers to this book.
61928765|NCT06267430|NO_INTERVENTION|Control group|As described, the parents of the control group will also receive the book 'Speels Brein' ('Playful Brain') and the age-appropriate addition for preschoolers to this book.
61928766|NCT05351294|EXPERIMENTAL|Arm 1|All enrolled patients will receive standard oncologic care at the discretion of the treating physicians, but will also complete the EORTC QLQ-C30, EQ-5D-5L, PTPQ, FAMCARE-P16 at baseline before randomization. Follow-up assessment using EORTC QLQ-C30, PTPQ, FAMCARE-P16 will occur every 3 months, and using EQ-5D-5L will occur every 1 month, for a total of 12 months. These will be administered during standard-of-care clinic or infusion center visits.
62691017|NCT06571604||Dislocation group|Patients who underwent primary total hip arthroplasty with preoperative CT-scan and encountered an episode of dislocation.
61928767|NCT05351294|EXPERIMENTAL|Arm 2|Patients enrolled in Arm 2 will also be seen be a radiation oncologist during the course of the study. The RO will review the patient's most recently completed EQ 5D-5L questionnaires and perform a complete History and Physical evaluation to determine if there is any immediate role for PRT. Based on the patient's type of cancer and areas of spread, the RO will also discuss types of symptoms that could develop in the future, and give instructions and educational materials to the patient so he/she can better identify those symptoms early on.
62131419|NCT01472900|EXPERIMENTAL|Er:YAG laser|
62131420|NCT01472900|ACTIVE_COMPARATOR|BP gel|
62131421|NCT05756335|EXPERIMENTAL|Behavioral intervention|Subjects are presented with a simultaneous sequence of faces and spoken words. Face stimuli include a representative sample of realistic faces across a range of ages. Spoken word stimuli are simple nouns spoken by a single female speaker.
62691018|NCT06571604||Control group|Patients underwent primary total hip arthroplasty with preoperative CT-scan, who did not experience any episodes of dislocation within two years post-surgery, adhering to the previously outlined exclusion criteria (group control).
62691019|NCT06643780|ACTIVE_COMPARATOR|Denosumab group|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
62691020|NCT06643780|PLACEBO_COMPARATOR|Zolendronic acid group|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
62691021|NCT01291160|EXPERIMENTAL|Epiflo Treatment|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
62697495|NCT06548438|EXPERIMENTAL|Photodynamic diagnosis using Hexvix|Transurethral resection of the bladder (TURB) is performed using photodynamic diagnosis (PDD) which involves the of use the study drug (Hexvix) to allow for better visualisation and subsequent resection
62482289|NCT01274338|EXPERIMENTAL|Arm D (age 12-17, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity.
62482290|NCT01274338|EXPERIMENTAL|Arm E (ages 12-17, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
62482291|NCT01274338|EXPERIMENTAL|Arm F (ages 12-17, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity. (ages 12-17)
62131422|NCT05512052|EXPERIMENTAL|Hannah Cervical Cup (2 mm)|
62323105|NCT03924674|ACTIVE_COMPARATOR|Stepped Wedge Group 3: Jan. 2020 Launch|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
62323106|NCT04527172||systemic lupus patients|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
62323107|NCT04527172||Healthy subjects|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
62323108|NCT03475888|ACTIVE_COMPARATOR|Group A|Patients who have undergone a successful percutaneous CTO recanalization
62323109|NCT03475888|ACTIVE_COMPARATOR|Group B|Patients who have undergone a failed percutaneous CTO recanalization or have an untreated CTO
62323110|NCT02000986|EXPERIMENTAL|Specimen Collection/Risk Factor Assessment -> Diet/Exercise ->|Specimen Collection/Risk Factor Assessment -\> Diet/Exercise -\> Chemotherapy
62323111|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
62323112|NCT04633824||Patients with private insurance|
62323113|NCT04633824||Patients with public/self-payer insurance|
62323114|NCT05027646|EXPERIMENTAL|Part 1 - Bioequivalence|Bioequivalence will be measured in approximately 42 healthy male and female subjects at a single center in the US to achieve at least 33 completers.
62323115|NCT05027646|EXPERIMENTAL|Part 2 - Adhesion|Adhesion will be measured in approximately 90 healthy male and female subjects are planned to be enrolled at a single center in the US.
62323116|NCT03709888||Observation Group|Subjects will be identified from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be treated with memantine XR-pregabalin combination therapy.Patients who agree to participate will be asked to complete study questionnaires prior to the start of their CIPN treatment and once per week for six weeks during their treatment.
62323117|NCT05416931|EXPERIMENTAL|ACD440 Gel 14mg/g|Topically applied to painful neuropathic area twice daily for 7 days
62323118|NCT05416931|PLACEBO_COMPARATOR|Placebo Gel|Topically applied to painful neuropathic area twice daily for 7 days
62482292|NCT06742125|EXPERIMENTAL|DCB group|premature STEMI patients undergo revascularization using DCB
62482293|NCT06742125|ACTIVE_COMPARATOR|DES group|premature STEMI patients undergo revascularization using DES
62323119|NCT00235846|ACTIVE_COMPARATOR|Conventional vein harvest|Conventional open vein harvest from the lower leg
62323120|NCT00235846|EXPERIMENTAL|Endoscopic vein harvest|Endoscopic vein harvest from the calf
62323121|NCT01358500|EXPERIMENTAL|Fentanyl|
62482294|NCT01730092||Healthy Volunteers|Enroll up to 120 healthy volunteers, in order to obtain approximately 55 evaluable healthy volunteers matched to pulmonary arterial hypertension subjects for age and gender
62482295|NCT01730092||Pulmonary Arterial Hypertension Subjects|150 subjects with pulmonary arterial hypertension; male or female, age grater than or equal to 18 99 years
62482296|NCT06035224|EXPERIMENTAL|AK104 combine with lenvatinib|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
62691022|NCT01291160|SHAM_COMPARATOR|Sham Device|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
61928768|NCT05930275||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
61928769|NCT04427384||GammaTile|Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.
62131423|NCT05512052|EXPERIMENTAL|Hannah Cervical Cup (4 mm)|
62131424|NCT05512052|EXPERIMENTAL|Hannah Cervical Cup (6 mm)|
62131425|NCT06515678||Main analysis - antihypertensive therapy with bevacizumab (ACEi or CCBs)|"Adjuvant/maintenance bevacizumab after ovarian cancer debulking surgery with antihypertensive therapy monotherapy.~Any patients with bevacizumab treated with monotherapy ACEi (arm A) or CCB (arm B) up to 6 months following debulking surgery"
62323122|NCT03342612|EXPERIMENTAL|Brain Magnetic Resonance Imaging (MRI)|Neuroimaging protocol to assess brain changes after minor head trauma and over the time.
62323123|NCT02426983|ACTIVE_COMPARATOR|Direct Current Stimulation active|Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
62691023|NCT05061836|EXPERIMENTAL|Dextrose0|Acetate Ringer's solution
62691024|NCT05061836|EXPERIMENTAL|Dextrose1|1.25%dextrose equivalence
62691025|NCT05061836|EXPERIMENTAL|Dextrose2|2.5%dextrose equivalence
62691026|NCT05061836|ACTIVE_COMPARATOR|Dextrose5|5%dextrose
62691027|NCT03968042|PLACEBO_COMPARATOR|Regular treatment (RT)|Combination of vitamin B1, B6, C, E and mecobalamine
62691028|NCT03968042|EXPERIMENTAL|RT with NGF|Nerve growth factor adding to regular treatment
62691029|NCT03968042|EXPERIMENTAL|RT with EDV|Edaravone adding to regular treatment
62691030|NCT02006290|EXPERIMENTAL|1|
62691031|NCT02006290|PLACEBO_COMPARATOR|2|
62691032|NCT06108544|EXPERIMENTAL|TAK-279|
62691033|NCT06108544|PLACEBO_COMPARATOR|Placebo|
62323124|NCT02426983|SHAM_COMPARATOR|Direct Current Stimulation sham|In sham sessions, the device will have the same placement and intensity, but will only be turned on for 30 seconds. The DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. This will occur in two separate sessions, occurring within weeks.
62691034|NCT06108544|ACTIVE_COMPARATOR|Apremilast|
62691035|NCT05902754|EXPERIMENTAL|Sulforaphane tablets|People in the experimental group will be advised to take 2 tablets a day with a meal for 28 days.
62691036|NCT05902754|PLACEBO_COMPARATOR|Placebo tablets|People in the placebo group will be advised to take 2 tablets a day with a meal for 28 days.
62691037|NCT05849246|EXPERIMENTAL|tusamitamab ravtansine + sintilimab|Sintilimab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
62691038|NCT05849246|EXPERIMENTAL|Tusamitamab ravtansine + Sintilimab + carboplatin/ cisplatin + pemetrexed|Sintilimab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin / cisplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
62691039|NCT05849246|PLACEBO_COMPARATOR|Sintilimab + carboplatin/ cisplatin + pemetrexed|Pemetrexed will be infused over 10 minutes after Sintilimab infusion on Day 1 and then Q3W. Carboplatin/ cisplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
62691040|NCT05837897|EXPERIMENTAL|Induction Period: Vedolizumab 300 mg|Participants will receive vedolizumab 300 mg IV infusion on Days 1,15, and 43 (Weeks 0, 2, and 6) in the 14-week Induction Period.
62691041|NCT05837897|PLACEBO_COMPARATOR|Induction Period: Placebo|Participants will receive vedolizumab placebo-matching IV, infusion on Days 1,15, and 43 (Weeks 0, 2, and 6) in the 14-week Induction Period.
62339877|NCT03172520|EXPERIMENTAL|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the automatic periodic stimulating(APS) electrode during parotidectomy surgery.
62339878|NCT05255913|EXPERIMENTAL|group 1|
62691042|NCT05837897|EXPERIMENTAL|Open-label Extension (OLE) Period: Vedolizumab 300 mg|All participants completing the Week 14 visit, irrespective of their response status, will continue in the OLE without unblinding of their baseline treatment group and will receive vedolizumab 300 mg, IV infusion, Q8W, on Days 99, 155, 211, 267, 323, and 379 (Weeks 14, 22, 30, 38, 46 and 54). Starting from Day 127 (Week 18) until the end of OLE Period up to approximately 58 weeks, participants who are nonresponders or who have disease worsening are eligible to receive 300 mg vedolizumab Q4W.
62691043|NCT03930511|NO_INTERVENTION|PADL at the beginning of PR|First assessment of patients starting Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
62691044|NCT03930511|EXPERIMENTAL|PADL at discharge of PR|Assessment of patients at discharge of Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
62691045|NCT03930511|NO_INTERVENTION|PADL at 6 months follow-up|Half-a-year reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
62691046|NCT03930511|NO_INTERVENTION|PADL at 1 year follow-up|Yearly reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
62691047|NCT04809805|EXPERIMENTAL|Dose escalation of BAY2666605|Approximately 7 or 8 dose levels are planned.
62691048|NCT04809805|EXPERIMENTAL|Dose expansion of BAY2666605|Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
62691049|NCT06675864|EXPERIMENTAL|YTB323 Cohort 1|Participants will receive one dose of YTB323
62691050|NCT06675864|EXPERIMENTAL|YTB323 Cohort 2|Participants will receive one dose of YTB323
62691051|NCT06675864|EXPERIMENTAL|YTB323 Cohort 3|Participants will receive one dose of YTB323
62691052|NCT06675864|EXPERIMENTAL|YTB323 Cohort 4|Participants will receive one dose of YTB323
62691053|NCT02088554|EXPERIMENTAL|Model 400 aortic valve bioprosthesis|
62691054|NCT06638580||Control|Systemically and periodontally healthy
62691055|NCT06638580||PD|systemically healthy periodontitis
62691056|NCT06638580||MetS|periodontally healthy metabolic syndrome
62691057|NCT06638580||PD-MetS|periodontitis and metabolic syndrome combined
62691058|NCT06640439|SHAM_COMPARATOR|Control Group|The irradiation protocol was the same as that of the experimental group, and the light source used was simulated light. After surgery, patients took ibuprofen 0.3 g bid for 3 consecutive days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 consecutive days.
62697496|NCT06548438|NO_INTERVENTION|White light|Transurethral resection of the bladder (TURB) is performed using the standard white light procedure
62482297|NCT06742086|EXPERIMENTAL|Stage 1: Sequence 1: Venetoclax|Participants will receive commercial venetoclax following a high-fat meal (Regimen A), followed by venetoclax hot melt extrusion-03 (HME-03) dose A following a high-fat meal (Regimen B), followed by venetoclax HME-03 dose B following a high-fat meal (Regimen C), finally followed by venetoclax HME-03 dose A following fasting (Regimen D), as part of the approximately 18 month study duration.
62691059|NCT06640439|EXPERIMENTAL|Treatment Group|LED light was irradiated 4 times (830 nm, 50 mW/cm2, 60 J/cm2, 1200 s) on D1 (before and after surgery), D2, and D3, which was extraoral irradiation. After surgery, ibuprofen 0.3 g bid for 3 consecutive days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 consecutive days were taken.
62691060|NCT03531541|ACTIVE_COMPARATOR|active TENS and CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust)."
62691061|NCT03531541|PLACEBO_COMPARATOR|placebos TENS and CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies\[42-44\]. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect"
62691062|NCT03531541|ACTIVE_COMPARATOR|placebo TENS and active CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
62691063|NCT03531541|ACTIVE_COMPARATOR|active TENS and placebo CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
62691064|NCT00000930||A|HIV-infected individuals enrolled in HIVNET D01
62691065|NCT00000930||B|Individuals with newly acquired HIV infection
62691066|NCT06211868||Observational cohort|
62691067|NCT06211868||Randomised cohort|
61928770|NCT06401330|EXPERIMENTAL|Stage I, Arm I (EE-4A)|Patients receive the EE-4A regimen: Dactinomycin IV over 1-5 or 10-15 minutes on day 1 and vincristine IV on days 1, 8, \& 15 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive dactinomycin IV over 1-5 or 10-15 minutes on day 1 and vincristine IV on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928771|NCT06401330|EXPERIMENTAL|Stage I, Arm II (nephrectomy)|Patients undergo nephrectomy on study.
61928772|NCT06401330|EXPERIMENTAL|Stage II, Arm I (EE-4A)|Patients receive one cycle of the EE-4A regimen as in STAGE I FHWT Arm I. Patients receive six cycles of the EE-4A regimen as in STAGE I FHWT Arm I. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
62131426|NCT06515678||Complementary group - arm C1 - bevacizumab without antihypertensive therapy|Patients treated with bevacizumab without initiation of antihypertensive treatment within 6 months following debulking surgery
62131427|NCT06515678||Complementary group - arm C2 - standard chemotherapy alone|Patients who were only treated by standard chemotherapy within 6 months following debulking surgery without bevacizumab
62131428|NCT06515678||Complementarity analysis - 1st-line CCB vs ACEi vs ARBs|"Adjuvant/maintenance bevacizumab after ovarian cancer debulking surgery with antihypertensive therapy monotherapy.~Any patients with bevacizumab treated with Renin Angiotensin Aldosterone System (RAAS) inhibitor drug among ACEi (arm A) versus angiotensin receptor blocker ARB (arm R) versus CCB (arm B)"
62323125|NCT02426983|ACTIVE_COMPARATOR|NMDA antagonist active|Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON). Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
62323126|NCT02426983|PLACEBO_COMPARATOR|NMDA antagonist placebo|Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
62323127|NCT02046343|EXPERIMENTAL|Physical Activity|Weekly promotora-led group sessions on physical activity (16 weeks) and followed by monthly telephone counseling and newsletters during the 24 week maintenance period. Promotoras will also implement environmental change strategies to increase the number of PA program offerings available to study participants.
62323128|NCT02046343|PLACEBO_COMPARATOR|Community Health and Safety|Weekly promotora-led group sessions on home safety/first aid (16 weeks) followed by and monthly generic health education materials and informational telephone calls during the 24 week maintenance period.
62323129|NCT01695980|EXPERIMENTAL|LMA with modified retractor|LMA with modified retractor
62323130|NCT01695980|ACTIVE_COMPARATOR|ETT with non modified retractor|ETT with non modified retractor
62131429|NCT06515678||Sensitivity analysis|"Sensitivity analysis S1 - Impact of Antihypertensive Treatment Switching. The investigators will utilize time-varying inverse probability of censoring weights (IPCW). The first step of the IPCW method consists in censoring patients who interrupt their initially assigned treatment. The second step of the IPCW method is thus to use IPCW with baseline covariates and time-dependent covariates linked to the treatment switching. (i) Number of cardiology consultations, (ii) Number of nephrology consultations or proteinuria, (iii) Number of cardiovascular events related to hypertension (MACE broad)~Sensitivity analysis S2 - Exclusion of patients with isolated proteinuria or elevated proteinuria: The investigators will reproduce the main analysis, excluding patients with signs of isolated proteinuria or elevated proteinuria."
62131430|NCT01149707|EXPERIMENTAL|PUR 0110 Rectal Enema 250 mg|Active treatment
62323131|NCT06637826|NO_INTERVENTION|Blank Control Group|
62691068|NCT03284385|EXPERIMENTAL|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62691069|NCT00625105|ACTIVE_COMPARATOR|Biofeedback|HRV coherence biofeedback procedure
62691070|NCT00625105|SHAM_COMPARATOR|Sham intervention|Passive monitor viewing
62691071|NCT06187714||0.25ml/sec|
61928773|NCT06401330|EXPERIMENTAL|Stage II, Arm II (EE-4A, DD-4A)|Patients receive one cycle of the EE-4A regimen as in STAGE I FHWT Arm I. Patients receive cycles 2-9 of the DD-4A regimen: Dactinomycin IV over 1-5 or 10-15 minutes on day 1 of cycles 3, 5, 7, \& 9, vincristine IV on days 1, 8, \& 15 of cycles 2-3 and day 1 of cycles 4-9, and doxorubicin IV over 3-15 minutes on day 1 of cycles 2, 4, 6, \& 8. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928774|NCT06401330|EXPERIMENTAL|Stage II, Arm III (EE-4A, VIVA)|Patients receive one cycle of the EE-4A regimen as in STAGE I FHWT Arm I. Patients receive cycles 2-9 of the VIVA regimen: Dactinomycin IV over 1-5 or 10-15 minutes on day 1 of cycles 3, 5, 7, and 9, vincristine IV on days 1, 8, and 15 of cycles 2-3 and day 1 of cycles 4-8, and doxorubicin IV over 3-15 minutes on day 1 of cycles 2, 4, 6, \& 8. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928775|NCT06401330|EXPERIMENTAL|Stage III, Arm I (DD-4A, EE-4A)|Patients able to undergo an upfront nephrectomy receive cycle 1 treatment of the DD-4A regimen: Dactinomycin IV over 1-5 or 10-15 minutes on day 1 and vincristine IV on days 1, 8, and 15. Patients receive cycles 2-7 of the EE-4A regimen as in STAGE I FHWT Arm I. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
62691072|NCT06187714||0.5ml/sec dose|
61928776|NCT06401330|EXPERIMENTAL|Stage III, Arm I-Upfront/Delayed (DD-4A, EE-4A)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-7 of the EE-4A regimen as in STAGE I FHWT Arm I above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928777|NCT06401330|EXPERIMENTAL|Stage III, Arm II (DD-4A)|Patients able to undergo an upfront nephrectomy receive cycle 1 treatment of the DD-4A regimen: Dactinomycin IV over 1-5 or 10-15 minutes on day 1 and vincristine IV on days 1, 8, and 15. Patients receive cycle 2 treatment of the DD-4A regimen as in STAGE II FHWT Arm II above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928778|NCT06401330|EXPERIMENTAL|Stage III, Arm II-Upfront/Delayed (DD-4A, UH-3)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the UH-3 regimen: Vincristine IV on days 1, 8, \& 15 of cycles 1, 5, 7, 10, \& 13, and days 1 \& 8 of cycles 3, 4, 8, \& 11, doxorubicin IV 3-15 minutes on day 1 of cycles 1, 5, 7, 10, \& 13, cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1, 5, 7, 10, \& 13, and days 1-4 of cycles 2, 6, 9, 12, \& 14, carboplatin IV over 15-60 minutes on day 1 of cycles 2, 6, 9, 12, and 14, etoposide IV over 60-120 minutes on days 1-4 of cycles 2, 6, 9, 12, \& 14, and irinotecan IV over 90 minutes on days 1-5 of cycles 3, 4, 8, \& 11. Treatment repeats every 21 days for 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928779|NCT06401330|EXPERIMENTAL|Stage III, Arm IIA (MVI)|Patients receive the MVI regimen: Vincristine IV on days 1, 8, \& 15 of cycle 3, days 8 \& 15 of cycle 4, and day 1 of cycles 5 \& 7-13, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of cycles 3, 7, 9, 11, \& 13, doxorubicin IV over 3-15 minutes on day 1 of cycles 3, 7, 9, 11, \& 13, cyclophosphamide IV over 15-30 minutes daily on days 1-5 of cycles 4 and 6, irinotecan IV over 90 minutes daily on days 1-5 of cycles 5, 8, 10 \& 12, and etoposide IV over 60-120 minutes daily on days 1-5 of cycle 6. Treatment repeats every 21 days for 11 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
62131431|NCT01149707|EXPERIMENTAL|PUR 0110 Rectal Enema 500 mg|Active treatment
62323132|NCT06637826|EXPERIMENTAL|Disinfectant Use Control Group|
62323133|NCT04541849||Critically ill patients|
62323134|NCT02796690||Group Methicillin susceptible Staphylococcus aureus (MSSA)|
62323135|NCT02796690||Group methicillin resistant Staphylococcus aureus (MRSA)|
62339879|NCT05255913|ACTIVE_COMPARATOR|group 2|
62482298|NCT06742086|EXPERIMENTAL|Stage 1: Sequence 2: Venetoclax|Participants will receive Regimen B, followed by Regimen C, followed by Regimen A, finally followed by Regimen D, as part of the approximately 18 month study duration.
62691073|NCT04601493|NO_INTERVENTION|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
62691074|NCT04601493|EXPERIMENTAL|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
62691075|NCT04601493|EXPERIMENTAL|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration \& Nudge intervention.
62691076|NCT04601493|EXPERIMENTAL|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration \& nudge interventions.
62691077|NCT04270019|EXPERIMENTAL|Experimental|This group will receive polyethylene glycol (50% weight/volume) applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
62691078|NCT04270019|PLACEBO_COMPARATOR|Control|This group will receive normal saline applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
62482299|NCT06742086|EXPERIMENTAL|Stage 1: Sequence 3: Venetoclax|Participants will receive Regimen C, followed by Regimen A, followed by Regimen B, finally followed by Regimen D, as part of the approximately 18 month study duration.
62482300|NCT06742086|EXPERIMENTAL|Stage 2: Sequence 1: Venetoclax|Participants will receive Regimen A, followed by Regimen B, finally followed by Regimen C, as part of the approximately 18 month study duration.
62691079|NCT02776176|EXPERIMENTAL|ERAS group|Patients receive the Enhanced Recovery After Surgery program during the peri-operative period.
62691080|NCT02776176|OTHER|Traditional group|Patients receive the Traditional program during the peri-operative period.
62691081|NCT02408029||Trauma Patients Group|Patients undergoing treatment for injuries and trauma.
62691082|NCT05743673||Validation Cohort|Older subjects (\>60 years old) presenting for moderate to high-risk surgical procedure with reported subjective metabolic equivalents of \>4 METS and with a score of \<2 on the revised cardiac risk index (RCRI) undergoing submaximal exercise testing.
62691083|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
61928780|NCT06401330|EXPERIMENTAL|Stage III, Arm IIB (M)|Patients receive the M regimen: Cyclophosphamide IV over 15-30 minutes daily on days 1-5 of cycles 3, 4, 7, \& 9, etoposide IV over 60-120 minutes daily on days 1-5 of cycles 3, 4, 7, \& 9, vincristine IV on days 8 \& 15 of cycles 3 \& 4 and day 1 of cycles 5, 6, 8, 10, \& 11, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of cycles 5, 6, 8, 10, \& 11, and doxorubicin IV over 3-15 minutes of cycles 5, 6, 8, 10, \& 11. Treatment repeats every 21 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928781|NCT06401330|EXPERIMENTAL|Stage III, Arm III-Upfront/Delayed (DD-4A, MVI)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928782|NCT06401330|EXPERIMENTAL|Stage III, Arm IV-Upfront/Delayed (DD-4A, M)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
62131432|NCT01149707|EXPERIMENTAL|PUR 0110 Rectal Enema 1000 mg|Active treatment
62482301|NCT06742086|EXPERIMENTAL|Stage 2: Sequence 2: Venetoclax|Participants will receive Regimen B, followed by Regimen C, finally followed by Regimen A, as part of the approximately 18 month study duration.
62482302|NCT06742086|EXPERIMENTAL|Stage 2: Sequence 3: Venetoclax|Participants will receive Regimen C, followed by Regimen A, finally followed by Regimen B, as part of the approximately 18 month study duration.
62691084|NCT01643174||Surgical treatment|
61928783|NCT06401330|EXPERIMENTAL|Stage III, Arm IX-Upfront/Delayed (MVI)|Patients receive cycles 5-13 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928784|NCT06401330|EXPERIMENTAL|Stage III, Arm V-Upfront/Delayed (DD-4A)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the DD-4A regimen as in STAGE II FHWT Arm II above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928785|NCT06401330|EXPERIMENTAL|Stage III, Arm VA-Upfront/Delayed (DD-4A)|Patients receive cycles 5-9 of the DD-4A regimen as in STAGE II FHWT Arm II above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928786|NCT06401330|EXPERIMENTAL|Stage III, Arm VB-Upfront/Delayed (M)|Patients receive the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
62482303|NCT05490888|EXPERIMENTAL|single dose of PHIN-214|single ascending dose of PHIN-214
61928787|NCT06401330|EXPERIMENTAL|Stage III, Arm VI-Upfront/Delayed (DD-4A, MVI)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
62131433|NCT01149707|PLACEBO_COMPARATOR|Placebo Enema|Placebo comparator
62131434|NCT03785405|EXPERIMENTAL|sacubitril/valsartan|single arm, open label sacubitril/valsartan
62131435|NCT06136351|EXPERIMENTAL|ZBR|
62131436|NCT00650104|ACTIVE_COMPARATOR|Active|Open label medication - Ropinirole CR
62131437|NCT05557006||All patients|Patients who meet the inclusion criteria
62323136|NCT06297460|EXPERIMENTAL|STEPPS program|The only condition is the experimental one. Participants receive the STEPPS program
62482304|NCT05490888|EXPERIMENTAL|multiple daily dosing of PHIN-214|multiple doses of PHIN-214, daily for 28 days
62482305|NCT04862039|EXPERIMENTAL|Virtual Reality (VR) devices|intervention group (VR).
62482306|NCT04862039|NO_INTERVENTION|control group|the standard of care (control group, no VR)
62482307|NCT04173858||Experimental|Patients with confirmed opioid-induced constipation diagnosis and inadequate response to laxatives.
62691085|NCT06674811||Patient|Children and young adults 3-18 years old who are undergoing surgical resection of an extracranial solid tumor.
62691086|NCT06674811||Caregiver|Primary caregiver or parent of a a child or young adults 3-18 years old who is undergoing surgical resection for an extracranial solid tumor and has agreed to participate in the study.
62691087|NCT00131885|PLACEBO_COMPARATOR|Levonorgestrel 1.5 with Placebo Herb|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a placebo herb daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
62482308|NCT06743321|EXPERIMENTAL|The intervention group|Patients in the intervention group will receive Speech-to-Speech Voice-Cloning Care (SVCC) as an addition to their standard ICU care.
62482309|NCT06743321|NO_INTERVENTION|The controlled group|Patients in the controlled group will only receive standard ICU care.
62323137|NCT05355090|EXPERIMENTAL|Protein Pacing|During the 8 week trial, the Protein Pacing (PP) group will consume 3 daily servings of whey protein powder mixed with water at timed intervals: morning (0600-0800), afternoon (1000-1400), and evening (2000-2200) in addition to their normal food intake.
62323138|NCT05355090|NO_INTERVENTION|Standard Diet|The participants in the CON will continue with their usual habitual dietary intake over the 8-week study and receive no intervention.
62323139|NCT01013948||N/A (Survey study)|
62323140|NCT05692193|EXPERIMENTAL|experimental group|"* A 'Patient Pain Education Brochure', which was prepared the day before the surgery, was given, and at the same time, the training was given verbally and in writing for an average of 20-30 minutes in the patient's own room.~* Vital sessions and pain assessment were performed during admission to the ward before the training.~* Pain was evaluated together with the patient's vital signs at the 15th, 30th, 45th, 60th minutes, 2nd, 4th, 6th, 12th, and 24th hours after the surgery.~* Comfort assessment was performed at the 24th hour after surgery."
62323141|NCT05692193|NO_INTERVENTION|control group|"* One day before the operation, vital signs and pain were evaluated during hospitalization.~* Pain was evaluated together with the patient's vital signs at the 15th, 30th, 45th, 60th minutes, 2nd, 4th, 6th, 12th, and 24th hours after the surgery.~* Comfort assessment was performed at the 24th hour after surgery."
62323142|NCT04451434|EXPERIMENTAL|Danicopan 200 mg Fasted|Fasting participants will receive a single dose of 200 mg danicopan.
62323143|NCT04451434|EXPERIMENTAL|Danicopan 200 mg Fed|Fed participants will receive a single dose of 200 mg danicopan.
62323144|NCT04451434|EXPERIMENTAL|Danicopan 400 mg Fed|Fed participants will receive a single dose of 400 mg danicopan.
62323145|NCT04990245||patients with ulcerative colitis|patients with ulcerative colitis and planned endoscopy as part of routine care
62323146|NCT06691997||group 1|RA patients with Type 2 diabetes
62323147|NCT04105543|EXPERIMENTAL|CLR 131 Dose Escalation|"Enrollment will start at dose level 1 (first 4 participants). Participants will receive 2 doses of CLR 131 intravenously with the first dose on day 1 followed by the second dose on day 8.~Dose Level -1 (de-escalation dose, if toxicities warrant) = 12.5 mCi/m\^2 Dose Level 1 (beginning dose) = 15.6 mCi/m\^2 Dose Level 2 (escalation dose) = 18.75 mCi/m\^2~Dose escalation will proceed with no limiting toxicities at each level (maximum of 8 participants at each dose level). With maximum tolerated dose confirmed, an expansion phase will proceed."
62323148|NCT04637659||Healthy non-treated teeth|Healthy teeth being treated for restorative or prosthodontics reasons
62482310|NCT06743217||Group A|All patients which are younger than 65 years old and underwent emergency cholecystectomy between 2020 and 2024
62482311|NCT06743217||Group B- Elderly Group|All patients ≥ 65 years old and underwent emergency cholecystectomy between 2020 and 2024
62691088|NCT00131885|ACTIVE_COMPARATOR|Levonorgestrel 1.5 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took St. John's Wort (SJW) 900 mg a Day orally for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
62691089|NCT00131885|ACTIVE_COMPARATOR|Levonorgestrel 2.25 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules three times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 2.25 mg
62691090|NCT00131885|ACTIVE_COMPARATOR|Levonorgestrel 1.5 with SJW 1500 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules five times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
62323149|NCT04637659||Healthy treated teeth|Teeth being retreated for restorative or prosthodontics reasons
62323150|NCT04637659||Irreversible pulpitis|Teeth being treated because of a poor pulpal status
62323151|NCT04637659||Post-treatment apical periodontitis|Teeth being retreated due to the presence of an apical lesion
62323152|NCT04637659||Necrosis|Teeth being treated because of pulpal necrosis
62323153|NCT05022004|EXPERIMENTAL|BRIN-20-01|
62323154|NCT05022004|ACTIVE_COMPARATOR|Azopt®|
62482312|NCT06726135||Experts in the field of rehabilitation with knowledge in outcome monitoring and service evaluation|"This study has one study cohort, consisting of a diverse panel of expert clinicians, researchers and managers from a variety of professional backgrounds.~These study participants will be purposefully selected based on their knowledge of which demographic, socio-economic and healthcare related variables, as well as any associated outcome measure instruments should be collected as part of a rehabilitation dataset to evaluate the clinical efficacy and cost effectiveness of inpatient multidisciplinary rehabilitation."
62482313|NCT06742203|EXPERIMENTAL|Exosomm treatment|"Experimental Group: WPMDE1 - Whey Protein Milk-Derived Exosomes~Administered as a powder dissolved in water and taken orally twice daily in pre-measured sachets."
62482314|NCT06177457|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 1)|Dose level 1: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
62482315|NCT06177457|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 2)|Dose level 2: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
62131438|NCT05076942|EXPERIMENTAL|Chemoradiation|Inguinofemoral radiotherapy (48-50 Gy in 1.8 Gy daily fractions, with a boost dose to the involved inguinal site for a total equivalent dose of 56 Gy over 5-6 weeks, preferably with simultaneous integrated boost technique) combined with weekly cisplatin 40 mg/m2 intravenously on days 1, 8, 15, 22 and 29
62131439|NCT05003778|ACTIVE_COMPARATOR|Traditional equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using traditional equipment (i.e., power racks, barbells, dumbbells, etc.)
62323155|NCT06693349|ACTIVE_COMPARATOR|Contaminated immature permanent teeth|treatment of contaminated immature permanent teeth through either revascularization or apexification procedures
62323156|NCT06693349|ACTIVE_COMPARATOR|uncontaminated immature permanent teeth|treatment of uncontaminated immature permanent teeth through either revascularization or apexification procedures
62323157|NCT00850759|EXPERIMENTAL|virtual reality|street-crossing training in a virtual pedestrian environment
62323158|NCT00850759|ACTIVE_COMPARATOR|computer and video|exposure to training in pedestrian safety via computer software, internet games, and television videos
62323159|NCT00850759|ACTIVE_COMPARATOR|streetside training|one-on-one training in street-crossing skills by an adult, at a streetside location
62323160|NCT00850759|NO_INTERVENTION|no-contact control|no-contact control group.
62323161|NCT02300077|ACTIVE_COMPARATOR|Control|Control (Intra-operative administration of opioids, other than methadone)
62482316|NCT06177457|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 3)|Dose level 3: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
62131440|NCT05003778|EXPERIMENTAL|Minimal equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.)
62131441|NCT05003778|EXPERIMENTAL|Minimal equipment resistance and endurance training with blood flow restriction|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.) while wearing upper- and lower-body blood-flow restriction cuffs
62131442|NCT03242148|EXPERIMENTAL|Toffee Nasal Pillows Mask|Participants will be placed on this arm for a total of 14 +- 5 days from visit 2. participants will be using the Toffee mask during this treatment arm
62131443|NCT02200094||Outpatients with essential hypertension|
62131444|NCT04619290|EXPERIMENTAL|Methylene blue treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
62131445|NCT04619290|ACTIVE_COMPARATOR|Conventionally treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
62131446|NCT05205798|EXPERIMENTAL|Participants|Food consumption using plates with a diameter of 23 cm first then using plates with a diameter of 31 cm
62131447|NCT00823472|EXPERIMENTAL|Start rFSH cycle day 2|
62131448|NCT00823472|EXPERIMENTAL|Start rFSH on cycle day 5|
62131449|NCT01507038|EXPERIMENTAL|Group A|
62131450|NCT01507038|EXPERIMENTAL|Group B|
62131451|NCT01507038|EXPERIMENTAL|Group C|
62131452|NCT01507038|PLACEBO_COMPARATOR|Group D|
62131453|NCT01647581|EXPERIMENTAL|Clip|A clip is been placed at the polypectomy site.
62131454|NCT01647581|PLACEBO_COMPARATOR|No Clip|A hemoclip is not placed at the site of the polypectomy.
62131455|NCT00484055|ACTIVE_COMPARATOR|treatment|"Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt."
62482317|NCT06177457|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 4)|Dose level 4: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
62482318|NCT06177457|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 5)|Dose level 5: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
62131456|NCT03771352|OTHER|RxSight RxLAL IOL|Eligible patients will be implanted with the RxSight RxLAL intraocular lens (IOL)
62131457|NCT06429943||A|Cerebrolysin administration
62131458|NCT06429943||B|without Cerebrolysin administration
62131459|NCT04373434|EXPERIMENTAL|Healthy Homes/Healthy Families (HH/HF) Intervention|Participants randomized to the HH/HF study intervention will work with a coach through phone calls and text messages for 12 weeks to set goals targeting home-based environmental determinants of dietary behaviors.
62323162|NCT02300077|ACTIVE_COMPARATOR|Treatment methadone 0.1 mg/kg|methadone 0.1 mg/kg
62323163|NCT02300077|ACTIVE_COMPARATOR|Treatment methadone 0.15 mg/kg|
62323164|NCT02341170|EXPERIMENTAL|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation (25 Gy in 10 fractions)
62323165|NCT02341170|NO_INTERVENTION|Observation|Observation
62323166|NCT01864642|EXPERIMENTAL|osteopathic manipulative treatment|osteopathic manipulative treatment (OMT)
62323167|NCT00720239|NO_INTERVENTION|0|
62323168|NCT00720239|EXPERIMENTAL|1|Experimental Group 1 (n = 10) will receive TalidermR to the wound once during the treatment phase.
62323169|NCT00720239|EXPERIMENTAL|2|Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
62482319|NCT06177457|EXPERIMENTAL|PF-07293893 and Placebo (Cohort 6, Optional)|Dose level 6: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
61928788|NCT06401330|EXPERIMENTAL|Stage III, Arm VII-Upfront/Delayed (DD-4A, M)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928789|NCT06401330|EXPERIMENTAL|Stage III, Arm VIII-Upfront/Delayed (UH-3)|Patients receive the UH-3 regimen as in STAGE III FHWT (UPFRONT BIOPSY/DELAYED NEPHRECTOMY) Arm II above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928790|NCT06401330|EXPERIMENTAL|Stage III, Arm X-Upfront/Delayed (M)|Patients receive cycles 5-11 of the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928791|NCT06401330|EXPERIMENTAL|Stage IV Arm I-Upfront-Delayed (DD-4A, EE-4A)|Patients in Stage IV Arm I receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-7 of the EE-4A regimen as in STAGE I FHWT Arm I above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928792|NCT06401330|EXPERIMENTAL|Stage IV Arm II-Upfront-Delayed (DD-4A, UH-3)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the UH-3 regimen as in STAGE III FHWT (UPFRONT BIOPSY/DELAYED NEPHRECTOMY) Arm II. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928793|NCT06401330|EXPERIMENTAL|Stage IV Arm III-Upfront-Delayed (DD-4A, MVI)|Patients in Stage IV Arm III receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928794|NCT06401330|EXPERIMENTAL|Stage IV Arm IV-Upfront-Delayed (DD-4A, M)|Patients in Stage IV Arm IV receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928795|NCT06401330|EXPERIMENTAL|Stage IV Arm IX-Upfront-Delayed (MVI)|Patients receive cycles 5-13 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928796|NCT06401330|EXPERIMENTAL|Stage IV Arm V-Upfront-Delayed (DD-4A)|Patients in Stage IV Arm V receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the DD-4A regimen as in STAGE II FHWT Arm II above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928797|NCT06401330|EXPERIMENTAL|Stage IV Arm VA-Upfront-Delayed (DD-4A)|Patients in Stage IV Arm VA receive cycles 5-9 of the DD-4A regimen as in STAGE II FHWT Arm II above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928798|NCT06401330|EXPERIMENTAL|Stage IV Arm VB-Upfront-Delayed (M)|Patients receive the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928799|NCT06401330|EXPERIMENTAL|Stage IV Arm VI-Upfront-Delayed (DD-4A, MVI)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928800|NCT06401330|EXPERIMENTAL|Stage IV Arm VII-Upfront-Delayed (DD-4A, M)|Patients in Stage IV Arm VII receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928801|NCT06401330|EXPERIMENTAL|Stage IV Arm VIII-Upfront-Delayed (UH-3)|Patients in Stage IV Arm VIII receive the UH-3 regimen as in STAGE III FHWT (UPFRONT BIOPSY/DELAYED NEPHRECTOMY) Arm II above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928802|NCT06401330|EXPERIMENTAL|Stage IV Arm X-Upfront-Delayed (M)|Patients in Stage IV Arm X receive cycles 5-11 of the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
62482320|NCT06177457|EXPERIMENTAL|Midazolam drug-drug interaction (Cohort 7, Optional)|Drug-drug interaction assessment of pharmacokinetics interaction in PF-07293893 and midazolam
62482321|NCT06177457|EXPERIMENTAL|Metabolism and elimination of PF-07293893 (Cohort 8, Optional)|Determination of excretion routes and metabolite profiling of PF-07293893.
62482322|NCT06177457|EXPERIMENTAL|Skeletal muscle imaging (Cohort 8, optional)|Evaluation of the effect of 14-days of daily PF-07293893 on skeletal muscle glycogen in healthy adult participants
61928803|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm I (DD-4A, MVI)|Patients in Stage IV Extrapulmonary Arm I receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928804|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm II (DD-4A, M)|Patients in Stage IV Extrapulmonary Arm II receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928805|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm III (DD-4A, MVI)|Patients in Stage IV Extrapulmonary Arm III receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
62323170|NCT00720239|EXPERIMENTAL|3|Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
62323171|NCT00690716|EXPERIMENTAL|1|Nasal CO2
62323172|NCT00690716|PLACEBO_COMPARATOR|2|Inactive Placebo
62339880|NCT00059215|EXPERIMENTAL|Prasugrel (CS-747) 40 mg LD/7.5 mg MD|Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days
62339881|NCT00059215|EXPERIMENTAL|Prasugrel (CS-747) 60 mg LD/10 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days
62482323|NCT04266197|EXPERIMENTAL|RT234 0.5 mg Cohort 1|RT234 at a capsule dose strength of 0.5 mg.
62482324|NCT04266197|EXPERIMENTAL|RT234 1.0 mg Cohort 2|RT234 at a capsule dose strength of 1.0 mg.
62482325|NCT04266197|EXPERIMENTAL|RT234 2.0 mg Cohort 3|RT234 at a capsule dose strength of 2.0 mg.
62131460|NCT04373434|ACTIVE_COMPARATOR|Control|Participants in the control condition will receive two mailings which focus on the same dietary outcomes as the HH/HF intervention but without the home environment emphasis.
62691091|NCT04250051|EXPERIMENTAL|Treatment (combination chemotherapy, ivosidenib)|"INDUCTION: Patients receive filgrastim SC QD on days 0-6, fludarabine phosphate IV QD over 30 minutes on days 1-5, cytarabine IV QD over 4 hours on days 1-5, and ivosidenib PO QD on days 7-28. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
62691092|NCT06642870||Study involves a series of focus groups followed by a cross-sectional survey of people with RAIRDs|Systemic lupus erythematosus, systemic vasculitis, inflammatory myositis, systemic sclerosis, Sjogren's syndrome, ANCA-associated vasculitis.
62131461|NCT02704507|EXPERIMENTAL|Topical steroid|Topical retinoid plus topical steroid applied daily to half of the face for 4 weeks, followed by 4 weeks of topical tretinoin. Patients will be randomized to which side receives the topical steroid.
62131462|NCT02704507|PLACEBO_COMPARATOR|Topical emollient|Topical retinoid plus topical emollient applied daily to the opposite half of the face for 4 weeks, followed by 4 weeks of topical tretinoin.
62131463|NCT03368768||Contact group email of Mahidol-Oxford Research Unit (MORU)|The investigator aims to have at least 100 adult people who could provide information for the total of one year. This expects that at least 20 of those 100 people would have common cold or diarrhea at least one time over one year period. This should provide more than 80% power to detect whether the proportion of having antibiotics when they have common cold or diarrhea was lower than 50% or not. The hypothesized proportion was 20% as stated by the national strategy against AMR in Thailand
62691093|NCT02772120|ACTIVE_COMPARATOR|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
62691094|NCT02772120|ACTIVE_COMPARATOR|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
62691095|NCT00273780|ACTIVE_COMPARATOR|Adherence counseling|
62131464|NCT01605773|EXPERIMENTAL|repaglinide|
62131465|NCT01605773|ACTIVE_COMPARATOR|glyburide|
62131466|NCT01970813|ACTIVE_COMPARATOR|Study group|acupuncture and bee venom acupuncture point injection
62131467|NCT01970813|SHAM_COMPARATOR|Control group|sham acupuncture and normal saline injections
62131468|NCT01970813|NO_INTERVENTION|Waiting group|no additional intervention
62131469|NCT02703558|NO_INTERVENTION|No dye|Participants will not receive a preoperative or intraoperative dye prior to their intraoperative concomitant cystoscopy.
62323173|NCT05859880|EXPERIMENTAL|Active intervention|Participants will attend four group-based expressive writing sessions led by a trained facilitator. All sessions will be delivered via videoconference. Sessions will occur weekly over the course of 4 consecutive weeks and will not exceed 60 minutes in length. Each session will include a 15- to 20-minute writing stint whereby participants are asked to write about their deepest thoughts and feelings regarding their loved one's cancer and their role as caregiver. All participants will be given a Rocketbook for this purpose, a spiral notebook that has the look and feel of a standard paper notebook but uses a pen with erasable ink. The writing stint will be followed by a group discussion; participants will be invited to share what they wrote about (if so desired) and their reactions to the writing process. Each session will end with a debriefing and erasure of the writing content just created. This will ensure privacy of the material and may be perceived as cleansing.
62323174|NCT05859880|PLACEBO_COMPARATOR|Waitlist control|Procedures are exactly the same as for the experimental arm but delayed.
62482326|NCT06742476|NO_INTERVENTION|control group|Patients in the group A will undergo tracheal intubation without apneic oxygenation
62691096|NCT00273780|ACTIVE_COMPARATOR|Alarm device|
62691097|NCT00273780|ACTIVE_COMPARATOR|Counseling and alarm|Participants in this arm will receive both education counseling and a pocket alarm device.
62691098|NCT00273780|NO_INTERVENTION|Control|
62691099|NCT01033669||Dry Powder Inhalers|
62131470|NCT02703558|ACTIVE_COMPARATOR|Phenazopyridine|Participants will receive a single 200mg oral dose of phenazopyridine with a sip of water 30 minutes prior to their surgery which involves an intraoperative concomitant cystoscopy.
62131471|NCT02703558|ACTIVE_COMPARATOR|Fluorescein|Participants will receive 0.25cc of 10% intravenous sodium fluorescein administered by anesthesia during their surgery, immediately prior to their intraoperative concomitant cystoscopy.
62323175|NCT00554021||1|Department of Traumatology and Critical Care Medicine, National Defense Medical College
62482327|NCT06742476|EXPERIMENTAL|apniec oxygenation group|Patients in the group B will undergo tracheal intubation in addition to apneic oxygenation at a flow 0.2 mg/kg using nasal cannula
62691100|NCT05686486|EXPERIMENTAL|Tai Chi inspired gymnastics practiced in a family caregiver-resident dyad (residents)|15 participants in 3 groups with 5 residents per group who benefited with 5 family caregivers from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
61928806|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm IV (DD-4A, M)|Patients in Stage IV Extrapulmonary Arm IV receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928807|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm IX (MVI)|Patients in Stage IV Extrapulmonary Arm IX receive cycles 5-13 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928808|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm V (DD-4A, UH-3)|Patients in Stage IV Extrapulmonary Arm V receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the UH-3 regimen as in STAGE III FHWT (UPFRONT BIOPSY/DELAYED NEPHRECTOMY) Arm II above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928809|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm VI (DD-4A, MVI)|Patients in Stage IV Extrapulmonary Arm VI receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928810|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm VII (DD-4A, M)|Patients in Stage IV Extrapulmonary Arm VII receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928811|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm VIII (UH-3)|Patients in Stage IV Extrapulmonary Arm VIII receive the UH-3 regimen as in STAGE III FHWT (UPFRONT BIOPSY/DELAYED NEPHRECTOMY) Arm II above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928812|NCT06401330|EXPERIMENTAL|Stage IV Extrapulmonary Arm X (M)|Patients in Stage IV Extrapulmonary Arm X receive cycles 5-11 of the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928813|NCT06401330|EXPERIMENTAL|Stage IV Lung Metastases Arm I (DD-4A)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-9 of the DD-4A regimen as in STAGE III FHWT (UPFRONT BIOPSY/DELAYED NEPHRECTOMY) Arms V and VA above. Patients also undergo CT, CT/MRI, ultrasound, and X-ray imaging throughout the trial.
61928814|NCT06401330|EXPERIMENTAL|Stage IV Lung Metastases Arm II (DD-4A, M)|Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928815|NCT06401330|EXPERIMENTAL|Stage IV Lung Metastases Arm III (DD-4A, MVI)|Stage IV patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
61928816|NCT05070728|SHAM_COMPARATOR|Sham Comparator|Intravitreal sham injection
61928817|NCT05070728|ACTIVE_COMPARATOR|FAI insert (0.05 mg fluocinolone acetonide)|Fluocinolone acetonide (FA) intravitreal 0.05 mg insert (Yutiq 0.05 mg).
61928818|NCT05635643|EXPERIMENTAL|Arm 1a: CHS-114 Dose Escalation|Arm 1 monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CHS-114 as monotherapy in up to 25 participants with advanced solid tumors, to determine the recommended dose for expansion (RDE).
61928819|NCT05635643|EXPERIMENTAL|Arm 1b: CHS-114 Dose Expansion|Arm 1b monotherapy expansion will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CHS-114 monotherapy at 2 dose levels (potential recommended dose for expansion \[RDE\]) in up to 5 participants in each dose level with Head and Neck Squamous Cell Carcinoma (HNSCC).
62131472|NCT02988089|EXPERIMENTAL|clarithromycin dependant group|"Patients in this group will receive 14-day bismuth-based quadruple therapies guided by the susceptibility of clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d.~The kinds of 2 antibiotics will be depend on the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
62131473|NCT02988089|EXPERIMENTAL|6 antibiotics dependant group|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, a bismuth and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d."
62131474|NCT02988089|OTHER|salvage therapy for negative culture|when the results of culture are negative, patients will receive Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, Colloidal Bismuth Pectin 200 mg (IAFB regimen) or Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, tetracycline 750 mg (IAFT regimen)，all are used twice daily except tetracycline which is taken 3 times daily.
62691101|NCT05686486|ACTIVE_COMPARATOR|Tai Chi inspired gymnastics practised individually (residents)|30 participants in 3 groups with 10 residents per groups who benefited separately from the family caregivers from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
61928820|NCT05635643|EXPERIMENTAL|Arm 2: CHS-114 + toripalimab Dose Expansion|Arm 2 combination dose expansion will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CHS-114 in combination with toripalimab at 2 dose recommended Phase 2 dose \[RDE\] levels in up to 6 participants in each dose level with Head and Neck Squamous Cell Carcinoma (HNSCC).
61928821|NCT06175234|OTHER|Catheter ablation for Paroxysmal or Persistent Atrial Fibrillation|Subjects scheduled to undergo endocardial mapping and Pulmonary Vein Isolation (PVI) in the treatment of atrial fibrillation. For patients with persistent AF, left atrial posterior wall isolation (PWI) may also be performed in addition to PVI at the discretion of the investigator
61928822|NCT06074003|EXPERIMENTAL|Females|Female participant group
61928823|NCT06074003|EXPERIMENTAL|Males|Male participant group
62482328|NCT05752721|EXPERIMENTAL|Food Pantry Scheduled to Transition to Online Ordering|Low-income adults who have visited the food pantry that is scheduled to transition to online ordering at least once. Participants will complete an in-person survey and a research assistant will record the food items they received in the relevant visit to the pantry. After the transition to online ordering at the intervention food pantry, participants will again complete the survey. Food selections for participants in the this arm will be accessible through the online ordering platform.
62482329|NCT05752721|NO_INTERVENTION|Food Pantry NOT Scheduled to Transition to Online Ordering|Low-income adults who have visited the food pantry that is NOT scheduled to transition to online ordering at least once. Participants will complete an in-person survey and a research assistant will record the food items they received in the relevant visit to the pantry. After the transition to online ordering at the intervention food pantry, participants will again complete the survey. Participants in this arm will record their food selections and send them to the study team.
62323176|NCT01740622|EXPERIMENTAL|Injury Intervention Group|In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq.ft.) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1-meter (\~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years.
62323177|NCT01740622|NO_INTERVENTION|Control Group|Participants who are assigned to the control group will have their medical claims examined related to injury in the home. Households in this control condition will also be provided with information sheets on child safety developed by the American Academy of Pediatrics, The Injury Prevention Program (TIPP). These age-based recommendations for child safety are provided as standard of care at many pediatric offices.
62323178|NCT06613841|EXPERIMENTAL|Imaging Cohort|Up to 15 subjects will enroll in this imaging study at the University of Pennsylvania. Those with a diagnosis of a new intra-axial brain mass that is consistent with GBM per the opinion of a Penn neuroradiologist OR New contrast-enhancing lesion or lesions showing increased enhancement (\>25% increase) in a patient with a historical diagnosis of glioblastoma.
62323179|NCT06692218|OTHER|CT|All patients will have a non-contrast, ECG-gated CT heart to adjudicate implant position of leadless pacemaker.
62323180|NCT06693076||Acute laparoscopic cholecystectomy|Patients with gallbladder inflammation. ERCP may be involved if a gallstone is detected in the common bile duct perioperatively.
62323181|NCT06315088|EXPERIMENTAL|Einkorn Diet|Healthy adult volunteers (not suffering from chronic pathologies) and non-smokers, having an omnivorous diet, and agreeing to change their eating habits for 3 months (reducing meat consumption by half and replacing it with einkorn).
62323182|NCT06693505|EXPERIMENTAL|caffeine trial (CAF)|caffeinated chewing gum first, then followed with placebo gum, at least four weeks later Each trial was separated by at least four weeks to avoid interactive effects.
62323183|NCT06693505|PLACEBO_COMPARATOR|placebo trial (PL)|placebo gum first, then followed with caffeinated chewing gum, at least 4 weeks later. Each trial was separated by at least four weeks to avoid interactive effects.
62323184|NCT03734107|EXPERIMENTAL|PREP-DC Intervention|50 participants will be randomized to the Plan, Reflect, and Engage with Providers for Diabetes Care (PREP-DC) intervention. Participants will complete 3 intervention sessions with study interventionists and will receive text messages and other study resources during the active intervention period (3 months).
62323185|NCT03734107|NO_INTERVENTION|Standard Care Comparison|50 participants will be randomized to standard care and will participate in regular diabetes clinic visits and receive standard materials on the transition to adult diabetes care, as they would have done without participation in this study.
61928824|NCT05436418|NO_INTERVENTION|Donors (Haplo HCT)|Research on collected samples
61928825|NCT05436418|NO_INTERVENTION|Donors (Matched HCT)|Research on collected samples
62691102|NCT05686486|NO_INTERVENTION|Control group (residents)|15 participants in 3 groups with 5 residents. As well as their family carers, they did not benefit from the intervention the study. They will be able to continue their usual activities. At the end of the study, they will be offered the 24 sessions of the Tai Chi inspired gymnastics programme in family caregiver-resident dyad.
62131475|NCT02988089|OTHER|salvage therapy for failed eradication|If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
62131476|NCT03722316|EXPERIMENTAL|MCI/Mild Dementia|"Twenty participants will be allocated to this arm if they demonstrate mild impairments in cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
62323186|NCT00989430|EXPERIMENTAL|Prism Adaptation Treatment|Two weeks of prism adaptation treatment followed by 4 weekly assessments and long-term follow-ups at the 3rd and 6th months.
62482330|NCT06736990|EXPERIMENTAL|CAL101|
62482331|NCT06736990|PLACEBO_COMPARATOR|Placebo|
62691103|NCT05686486|EXPERIMENTAL|Tai Chi inspired gymnastics practiced in a family caregiver-resident dyad (family caregivers)|15 participants in 3 groups with 5 family caregivers per group who benefited with 5 residents from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
61928826|NCT05436418|EXPERIMENTAL|Phase I Dose De-escalation (Haplo HCT)|PTCy at de-escalating doses to assess for safety and determine Phase II dose
61928827|NCT05436418|EXPERIMENTAL|Phase I Dose De-escalation (Matched HCT)|PTCy at de-escalating doses to assess for safety and determine Phase II dose
61928828|NCT05436418|EXPERIMENTAL|Phase I Pilot for Comparative Data (Haplo HCT)|Standard PTCy 50 mg/kgday on days +3 and +4
61928829|NCT05436418|EXPERIMENTAL|Phase I Pilot for Comparative Data (Matched HCT)|Standard PTCy 50 mg/kg/day on days +3 and +4
62323187|NCT00989430|NO_INTERVENTION|Control: Standard Rehabilitation Care|Participants will continue with their standard inpatient rehabilitation care. They will be assessed with cognitive and functional scales for tracking their recovery.
62482332|NCT03954808|EXPERIMENTAL|Motor imagery training group|Children with Cerebral Palsy. Motor imagery training group will receive a traditional physiotherapy and motor imagery training within a specific program, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes MI training). The motor imagery training will be designed for the individual basis with standard protocols. All sessions will be performed in the clinic.
61928830|NCT05436418|EXPERIMENTAL|Phase II Efficacy (Haplo HCT)|PTCy at shortest duration, safe dose (from Phase I)
61928831|NCT05436418|EXPERIMENTAL|Phase II Efficacy (Matched HCT)|PTCy at shortest duration, safe dose (from Phase I)
61928832|NCT06684639|EXPERIMENTAL|Experimental group|GD2 positive relapsed or refractory neuroblastoma
61928833|NCT05423249|EXPERIMENTAL|Treatment Group|The treatment group will receive oral ferrous sulfate 325mg (containing 65 mg of elemental iron) once daily, an oral prenatal vitamin once daily, oral ascorbic acid 500mg once daily, and oral docusate sodium 100mg twice daily as needed.
61928834|NCT05423249|PLACEBO_COMPARATOR|Placebo Group|The placebo group will receive a placebo bill, the same oral prenatal vitamin, and oral docusate sodium 100mg twice daily as needed.
61928835|NCT03213457|PLACEBO_COMPARATOR|Placebo|Placebo for elagolix administered twice daily (BID) plus placebo for estradiol/norethindrone acetate (E2/NETA) administered once daily (QD) for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
61928836|NCT03213457|EXPERIMENTAL|Elagolix / Elagolix + E2/NETA|Elagolix 200 mg BID alone for the first 6 months of the 12-month placebo-controlled Treatment Period and elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the second 6 months, followed by elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
61928837|NCT03213457|EXPERIMENTAL|Elagolix + E2/NETA|Elagolix 200 mg BID + E2/NETA 1 mg/0.5 mg QD for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
61928838|NCT06743789|EXPERIMENTAL|20 Gy Radiation Dose (Arm 1 Group 1)|"Arm 1:~Group 1 (3 participants) - will receive a dose of 20 Gy (Gray, a measurement of radiation) in a single study intervention (one study intervention day)"
61928839|NCT06743789|EXPERIMENTAL|15 Gy Radiation Dose (Arm 1 Group 2)|"Arm 1:~Group 2 (3 participants) - will receive a dose of 15 Gy in a single study intervention (one study intervention day)"
61928840|NCT06743789|EXPERIMENTAL|10 Gy Radiation Dose (Arm 1 Group 3)|"Arm 1:~Group 3 (3 participants) - will receive a dose of 10 Gy in a single study intervention (one study intervention day)"
61928841|NCT06743789|EXPERIMENTAL|12 Gy Radiation Dose for 3 fractions (Arm 2 Group 1)|"Arm 2:~Group 1 (3 participants) - will receive a dose of 12 Gy (Gray, a measurement of radiation) given over 3 days (Days 1, 2 and 3). (Total radiation dose = 36Gy)"
61928842|NCT06743789|EXPERIMENTAL|10 Gy Radiation Dose for 3 fractions (Arm 2 Group 2)|"Arm 2:~Group 2 (3 participants) - will receive a dose of 10 Gy (Gray, a measurement of radiation) given over 3 days (Days 1, 2 and 3). (Total radiation dose = 30Gy)"
61928843|NCT06743789|EXPERIMENTAL|8Gy Radiation Dose for 3 fractions (Arm 2 Group 3)|"Arm 2:~Group 3 (3 participants) - will receive a dose of 8 Gy (Gray, a measurement of radiation) given over 3 days (Days 1, 2 and 3). (Total radiation dose = 24Gy)"
61928844|NCT02185560||BAY43-9006|NEXAVAR treatment group
61928845|NCT04214184|EXPERIMENTAL|Increased Sleep Duration Intervention|Following baseline assessments, participants will complete a 4-week increased sleep duration intervention followed by one night of sleep in the lab on this increased sleep duration schedule. In the morning, participants will have blood collected for metabolomics analyses and complete oral glucose tolerance testing
62323188|NCT02629523|EXPERIMENTAL|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
62323189|NCT03778177|EXPERIMENTAL|Trigeminal Neuralgia Pain Diagnosis|Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
62323190|NCT05399628|EXPERIMENTAL|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with a LISA catheter with a marked tip
62323191|NCT05399628|ACTIVE_COMPARATOR|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with a LISA catheter with an unmarked tip
62323192|NCT04567316|EXPERIMENTAL|[14C]-radiolabelled BI 1358894|\[14C\]-radiolabelled BI 1358894 (part 1)
62323193|NCT04567316|EXPERIMENTAL|BI 1358894|BI 1358894 (part 2)
62323194|NCT06027242|PLACEBO_COMPARATOR|Without oral glutamine supplementation|15 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
62323195|NCT06027242|ACTIVE_COMPARATOR|With oral glutamine supplementation|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
62323196|NCT04841304||Patients receiving hemodialysis with diabetes|Patients receiving chronic hemodialysis with a diagnose of Type 1 diabetes or Type 2 diabetes (diagnosed according to the criteria of the World Health Organization) and receiving glucose-lowering treatment
61928846|NCT06744413|EXPERIMENTAL|Prehabilitation|Prehabilitation arm groups will receive preoperative intervention which includes exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline.
62482333|NCT03954808|ACTIVE_COMPARATOR|Cerebral Palsy control group|Children with Cerebral Palsy. Traditional physiotherapy control group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
62482334|NCT03954808|NO_INTERVENTION|Typically developing control group|Age matched healthy individuals, with no treatment.
62131477|NCT03722316|ACTIVE_COMPARATOR|Healthy Older Adults|"Participants are allocated to this arm if they demonstrate healthy cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
62131478|NCT06221059|EXPERIMENTAL|HRS-1780 dose 1|
62131479|NCT06221059|EXPERIMENTAL|HRS-1780 dose 2|
62323197|NCT04841304||Patients receiving hemodialysis without diabetes|Patients receiving chronic hemodialysis without diabetes (no known diagnosis of diabetes, and HbA1c \< 48 mmol/mol at inclusion)
62323198|NCT02495649|OTHER|[18F]-DOPA|evaluate the added value of PET-CT with \[18F\]-DOPA tracer for Assessment of the Myocardial Sympathetic Denervation in patients with or suspected with Parkinson's disease.
62691104|NCT05686486|ACTIVE_COMPARATOR|Tai Chi inspired gymnastics practised individually (family caregivers)|30 participants in 3 groups with 10 family caregivers per groups who benefited separately from the residents from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
62131480|NCT06221059|ACTIVE_COMPARATOR|Henagliflozin Proline|
62131481|NCT06221059|PLACEBO_COMPARATOR|Placebo|
62131482|NCT06197217|EXPERIMENTAL|WPV01|
62131483|NCT06197217|PLACEBO_COMPARATOR|Placebo|
62131484|NCT05789953||Development of the machine learning model|Perioperative clinical routine data are going to be assessed as per standard. Postoperatively, a standardized lung sonography is going to be performed in the recovery room. Patients will then be visited on the ward on postoperative day 1, 3 and 7 for clinical examination to detect postoperative pulmonary complications according to the criteria elaborated by the StEP- collaboration.
62131485|NCT02236793|EXPERIMENTAL|BioChaperone PDGF-BB|BioChaperone PDGF-BB administered every other day at the dose of 4µg/cm² for 20 weeks or until wound closure, associated with Standard of Care
62131486|NCT02236793|PLACEBO_COMPARATOR|Standard of Care|Normal saline solution applied every other day at the same volume for up to 20 weeks, associated with standard wound care
62323199|NCT05817773|EXPERIMENTAL|breastfeeding cradle|After the control group was given breastfeeding education and the baby was breastfed, the questionnaire and breastfeeding self-efficacy scale were applied at the 6th hour postoperatively. The experimental group was given breastfeeding education and the baby was placed in a nursing cradle and the baby was breastfed. Then, the questionnaire and breastfeeding self-efficacy scale were applied at the 6th hour postoperatively.
62323200|NCT06692114|EXPERIMENTAL|active treatment group|The resting motor threshold (RMT) of the patient was measured before the first treatment. Symptom induction was performed before each treatment to achieve moderate anxiety in patients. The magnetic stimulation intensity was 100% RMT, using the deep transcranial magnetic stimulation coil H7 for treatment, with the stimulation area being the anterior cingulate cortex (ACC) and medial prefrontal cortex (mPFC). Treatment was administered twice daily for 20 minutes each time for 2 weeks.
62323201|NCT06692114|SHAM_COMPARATOR|sham group|The same RMT test as the active treatment group was accepted, and symptom induction was performed before treatment to achieve moderate anxiety. During treatment, the coil in the shame treatment group only produces sound and scalp vibration, and does not generate a real magnetic field. There is no other difference between the two coils. The frequency and number of treatments were the same as those in the active treatment group.
62339882|NCT00059215|EXPERIMENTAL|Prasugrel (CS-747) 60 mg LD/15 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days
62482335|NCT01103843|ACTIVE_COMPARATOR|Maintenance Dose Arm|Open label clopidogrel 75 mg daily or prasugrel 10 mg daily
62482336|NCT01103843|ACTIVE_COMPARATOR|Loading Dose Arm|Clopidogrel 600 mg or Prasugrel 60 mg at time of PCI.
62691105|NCT05686486|NO_INTERVENTION|Control group (family caregivers)|15 participants in 3 groups with 5 family caregivers. As well as the residents, they did not benefit from the intervention the study. They will be able to continue their usual activities. At the end of the study, they will be offered the 24 sessions of the Tai Chi inspired gymnastics programme in family caregiver-resident dyad.
62691106|NCT04007731|EXPERIMENTAL|High protein, high fibre and creatine load bar (DrRip)|1 new protein bar (260 kcal) after training every day
62691107|NCT04007731|ACTIVE_COMPARATOR|Voltage energy bar|1 control commercially available protein bar (260 kcal) after training every day
61928847|NCT06744413|NO_INTERVENTION|Control group|Standard care treatment: application of ERAS pathways (Enhanced Recovery After Surgery)
62131487|NCT00387452|ACTIVE_COMPARATOR|1|
62131488|NCT00387452|ACTIVE_COMPARATOR|2|
62131489|NCT00387452|NO_INTERVENTION|3|No intervention, only testing during 6 months.
62131490|NCT02596113||No pathological findings|blood and biopsy samples from normal colon mucosa
62131491|NCT02596113||>1 cm adenomatous polys|blood and biopsy samples from the polyp
62131492|NCT02596113||Colorectal cancer|blood (plasma) and biopsy samples from colorectal cancer
62131493|NCT01040689|PLACEBO_COMPARATOR|Placebo|olodaterol placebo and/or Tiotropium placebo inhaled once daily
62131494|NCT01040689|EXPERIMENTAL|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
62131495|NCT01040689|EXPERIMENTAL|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
62131496|NCT01040689|ACTIVE_COMPARATOR|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
62482337|NCT03110991|EXPERIMENTAL|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
62323202|NCT03969901|EXPERIMENTAL|IMI/REL|Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
62691108|NCT00728533|EXPERIMENTAL|1|"* Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~* Maintenance doses of 360 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months"
62691109|NCT00728533|EXPERIMENTAL|2|"* Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~* Maintenance doses of 480 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months."
61928848|NCT05652283|EXPERIMENTAL|experience group|Pamiparib 40 mg, BID, oral, 3 weeks as a cycle, 3 cycles Surufatinib 250 mg, QD, oral, 3 weeks as a cycle, 2 cycles
62339883|NCT00059215|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.
62482338|NCT03110991|EXPERIMENTAL|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
62691110|NCT06645158||normal neonate|gestational age \>= 35wk; did not admitted to hospital for any reason; did not need phototherapy within 60h after birth;
61928849|NCT05662397|EXPERIMENTAL|HST-1011 Monotherapy Dose Escalation (Part A1)|Multiple dose levels of HST-1011 to be evaluated.
61928850|NCT05662397|EXPERIMENTAL|HST-1011 Monotherapy Dose Optimization (Part A2)|Evaluation of HST-1011 monotherapy dose/dose regimen.
61928851|NCT05662397|EXPERIMENTAL|HST-1011 Dose Escalation in Combination with cemiplimab (Part B1)|Multiple dose levels of HST-1011 to be evaluated in combination with cemiplimab.
61928852|NCT05662397|EXPERIMENTAL|HST-1011 Dose Optimization in Combination with Cemiplimab (Part B2)|Evaluation of HST-1011 in combination with cemiplimab.
61928853|NCT06160908|SHAM_COMPARATOR|Core phase: sham irradiation group.|
61928854|NCT06160908|EXPERIMENTAL|Core phase: Near infrared light therapy|
61928855|NCT06160908|EXPERIMENTAL|Extension phase: Near infrared light therapy|This arm includes participants who finish the core phase from the core phase experimental group and the core phase sham comparator group. The intervention is the same as the intervention in the core phase.
61928856|NCT06256198||Group S|survivors
61928857|NCT06256198||Group M|non survivors
61928858|NCT03099681||Epitheloid Sarcoma patients|Patients with diagnosis of localized or advanced epitheloid sarcoma seen in the Italian reference centers for sarcoma treatment that receive treatment for Epitheloid Sarcoma
61928859|NCT06744452|EXPERIMENTAL|App-usage across a 12 week time period|Use of the harmony application, with 6- and 12-week follow-up. Measurements will be taken at baseline as well as at 6- and 12-week follow-up.
61928860|NCT06744452|NO_INTERVENTION|Waitlist-control group|Use of the harmony application after a 12-week waiting period. Measurements will be taken at baseline as well as at 6- and 12-week follow-up.
62482339|NCT03110991|NO_INTERVENTION|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
61928861|NCT06047886|EXPERIMENTAL|Treatment population|"Patients status post allogeneic hematopoietic stem cell transplantation for a neoplastic hematologic disorder with the need of a CD34 selected stem cell boost for graft failure or low graft function will receive a CD34 selected hematopoietic stem cell infusion with or without preceding conditioning.~Fludarabine 25 mg/mq day 1 - 5 + 2 Gray Total body irradiation depending on clinician's discretion (with the addition of cyclophosphamide 14.5 mg/kg for two doses for haploidentical or matched unrelated donor with at least one major HLA mismatch). Recommendation to use a conditioning regimen include complete loss of donor chimerism, trilineage cytopenias."
61928862|NCT05877430|EXPERIMENTAL|CJRB-101 with pembrolizumab|"Phase 1 includes patients with selected types of advanced or metastatic cancers. Patients will be given with either low or high dose levels of CJRB-101 in combination with pembrolizumab.~Phase 2 includes patients with selected types of advanced or metastatic cancers. Patients will be given with the CJRB-101 dose selected from Phase 1 in combination with pembrolizumab."
61928863|NCT03834493|EXPERIMENTAL|Pembrolizumab + Enzalutamide|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression.
61928864|NCT03834493|PLACEBO_COMPARATOR|Placebo + Enzalutamide|Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression.
61928865|NCT06745362|EXPERIMENTAL|Intervention group|lifestyle intervention including information about ketosis level
61928866|NCT06745362|ACTIVE_COMPARATOR|control group|lifestyle intervention without information about ketosis level
61928867|NCT04064060|EXPERIMENTAL|ACE-536|Luspatercept will be administered as a subcutaneous (SC) injection to participants by the study staff at the clinical site and administration will be documented in the subject's source record.
61928868|NCT03019679||Study group|Patients with polycystic ovary syndrome
61928869|NCT03019679||Control group|Patients without polycyctic ovary syndrome
61928870|NCT06706947|EXPERIMENTAL|Lymphaticovenous Anastomosis|
62691111|NCT06641362||Treatment Group|Participant controlled with standard ECG measurement and VDI UHF-ECG measurement both taken sequentially.
62691112|NCT00859885||1|Patients who receive antithrombotic treatment only
62691113|NCT00859885||2|Patients who undergo percutaneous device closure
62482340|NCT06742528|ACTIVE_COMPARATOR|Group A (Ferrous sulphate)|Group A will be given Ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form.
62482341|NCT06742528|ACTIVE_COMPARATOR|Group B (Iron Polymaltose complex)|Group B will be given Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks.
62691114|NCT00213525||Patients With Scleroderma|Assessments of questionnary for environmental factors research
62131497|NCT03035994|EXPERIMENTAL|Overloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% greater than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
62131498|NCT03035994|EXPERIMENTAL|Underloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% lower than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
62131499|NCT03035994|EXPERIMENTAL|Average|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at the average of each participant's baseline vertical ground reaction force between limbs. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
62482342|NCT06741891|EXPERIMENTAL|Auricular stimulation.|Auricular stimulation. Stimulation in the ear will be performed for 5 min twice daily for 12 weeks.
62131500|NCT03035994|NO_INTERVENTION|Control|Participants will walk for 20 minutes on a force-instrumented treadmill and will not be provided biofeedback.
62131501|NCT04002622|EXPERIMENTAL|TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
62323203|NCT03969901|ACTIVE_COMPARATOR|Active Control|Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.
62323204|NCT02641119||Albumin|Patients receiving any amount of 5% albumin during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician.
62323205|NCT02641119||Saline-only|Patients receiving only saline during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician
62323206|NCT06675513|EXPERIMENTAL|Single dose injection of WD-01|Dose escalation will be performed for the single dose injection of WD-01 for treating mCRC
62482343|NCT06741891|SHAM_COMPARATOR|Auricular non-stimulation|Auricular non-stimulation. The device is placed to the ear but no stimulation will occur. The procedure is performed for 5 min twice daily for 12 weeks.
62482344|NCT06742424|EXPERIMENTAL|PD-L1 Antibody + Bevacizumab + HAIC-FOLFOX|"Participants will receive:~* PD-L1 antibody 1200mg intravenously every 3 weeks~* Bevacizumab 15mg/kg intravenously every 3 weeks~* HAIC-FOLFOX regimen (up to 6 cycles) consisting of:~  * Oxaliplatin 130 mg/m² via hepatic arterial infusion over 3 hours~ * Leucovorin 400 mg/m² via hepatic arterial infusion over 2 hours~ * Fluorouracil 400 mg/m² bolus via hepatic arterial infusion at hour 5, followed by 2400 mg/m² continuous hepatic arterial infusion over 46 hours~ * HAIC treatment repeats every 3 weeks for up to 6 cycles After completion of HAIC, participants will continue to receive PD-L1 antibody and bevacizumab until disease progression, unacceptable toxicity, or up to 24 months of treatment. Tumor assessments will be performed every 9 weeks for the first 48 weeks, then every 12 weeks thereafter."
62691115|NCT00213525||Healthy Controls|Assessments of questionnary for environmental factors research
62691116|NCT02380235|EXPERIMENTAL|PEG-somatropin|0.12mg/kg/w
62691117|NCT02380235|EXPERIMENTAL|PEG-Somatropin|0.20mg/kg/w
62697497|NCT03636022|EXPERIMENTAL|VR System|Participants will then be assigned one week of daily exposure homework. Patients randomized to the intervention condition will take home the VR system for homework.
61928871|NCT04262856|EXPERIMENTAL|Arm 1 (zimberelimab monotherapy)|Participants will receive zimberelimab as an intravenous (IV) infusion.
61928872|NCT04262856|EXPERIMENTAL|Arm 2 (domvanalimab and zimberelimab combination therapy)|Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.
62131502|NCT02660970|ACTIVE_COMPARATOR|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
62131503|NCT02660970|PLACEBO_COMPARATOR|Placebo-band|Children will have to wear a 'placebo-wristband'
62131504|NCT02660970|ACTIVE_COMPARATOR|Iberogast|Children will have to take Iberogast drops
62131505|NCT02660970|PLACEBO_COMPARATOR|Placebo-drops|Children will have to take placebo-drops
62131506|NCT06331494|EXPERIMENTAL|Butylphthalide|The Butylphthalide group will receive Butylphthalide Sodium Chloride injection (100ml, twice/day) for the initial 10±3 days, followed by oral Butylphthalide soft capsules (0.2g, triple/day) for day 11±3 to day 180.
62131507|NCT06331494|PLACEBO_COMPARATOR|Placebo|The Placebo group will receive Butylphthalide Placebo injection (100ml, twice/day) for the initial 10±3 days, followed by oral Butylphthalide Placebo soft capsules (0.2g, triple/day) for day 11±3 to day 180.
62131508|NCT01548170|ACTIVE_COMPARATOR|Sunitinib 50mg|Sunitinib 50 mg administered as a single dose.
62131509|NCT01548170|EXPERIMENTAL|Sunitinib 37.5mg + Ketoconazol 200mg|"The drugs will be administered as follows:~* Sunitinib 37.5mg oral single dose.~* Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
62482345|NCT06742294|OTHER|Experimental group|Schools allocated to the intervention group will receive interventions including teacher professional development and support, smartphone FMS rating system, teacher training materials, parent materials
62482346|NCT06742294|PLACEBO_COMPARATOR|Wait-list control group|The wait-list control group will receive the same intervention after post-test
62482347|NCT06717269|EXPERIMENTAL|NX-5948 tablet and capsule under fasted and fed conditions|Cohort 1: Single dose of NX-5948 tablet under fasted and fed conditions. Also, single dose of NX-5948 capsule under fasted conditions.
62482348|NCT06717269|EXPERIMENTAL|NX-5948 tablet combined with esomeprazole under fasted conditions|Cohort 2: Single dose of NX-5948 tablet combined with esomeprazole under fasted conditions. Also, a single dose of NX-5948 capsule under fasted conditions.
62482349|NCT05405231|EXPERIMENTAL|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase Military and Veteran's Crisis Line (MVCL) use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
62482350|NCT05405231|ACTIVE_COMPARATOR|Passive Implementation|The PI condition includes an educational resource brochure describing the Military and Veteran's Crisis Line (MVCL), including the phone number for the crisis line, as well as other mental health services available to National Guard members.
62482351|NCT03734861|EXPERIMENTAL|BreatheSmart System|"* BreatheSmart mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)"
62482352|NCT03734861|ACTIVE_COMPARATOR|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
62482353|NCT02648438|EXPERIMENTAL|Treatment sequence 1|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
62323207|NCT03552549|EXPERIMENTAL|PEG-Intron|Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.
62323208|NCT03552549|EXPERIMENTAL|INTRON A|Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units \[MIU\]/m\^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m\^2 three times per week) for 48 weeks post-surgery.
62482354|NCT02648438|EXPERIMENTAL|Treatment sequence 2|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
62482355|NCT03364192|EXPERIMENTAL|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
62482356|NCT03505905|EXPERIMENTAL|Pregnenlone (phase 1 and 2)|Participants will receive pregnenolone at phase 1 (baseline-WK 7) and 2 (WK 8-16). The titration schedule is as follows: at baseline a 50 mg (BID, 7 days). WK 1=150 mg (BID, 7 days); WK 2=250 mg (BID, 14 days) and WK 4=250 mg (BID, 14 days) (BID, 14 days). At phase 2 (WK 8) to maintain the double blind of rerandomization, treatment in all conditions recommence at a dosage frequency similar to phase 1. At WK 8=250 mg (BID, 7 days); at WK 9=250 mg (BID, 7 days); WK 10=250 mg (BID, 14 days) and WK 12=250 mg (BID, 14 days) . During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (BID, 4 days) and 50 mg (BID, 4 days), discontinue.
62482357|NCT03505905|PLACEBO_COMPARATOR|Placebo rerandom to placebo|Participants will receive placebo at phase 1 (baseline-WK 7) \& treatment response assessed (MADRS score reduced \<50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1= placebo (7 days); at WK 2=placebo (14 days) and WK 4=placebo (14 days). Placebo nonresponders rerandomized to placebo: At WK 8=placebo (7 days);WK 9=placebo (7 days);WK 10=placebo (14 days) and WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo (4 days) and placebo (4 days), discontinue.
62482358|NCT03505905|EXPERIMENTAL|Placebo rerandom to pregnenolone|Participants will receive placebo at phase 1 (baseline-WK 7) \& treatment response assessed (MADRS score reduced \<50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) \& WK 4=placebo (14 days). Placebo nonresponders who are rerandomized to pregnenolone: At WK 8=250 mg (7 days);WK 9=250 mg (7 days);WK 10=250 mg (14 days) \& WK 12=250 mg (14 days). During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (4 days) and 50 mg (4 days), discontinue.
62323209|NCT02990637|ACTIVE_COMPARATOR|OLECOL|Olive leaf extract
62323210|NCT02990637|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62323211|NCT06693180||HBOT|Received complementary HBOT
62323212|NCT06693180||Control|Standard care therapy
62323213|NCT02994069|EXPERIMENTAL|Every 3 Weeks Cisplatin + XRT|Every 3 Weeks Cisplatin + XRT
62323214|NCT02994069|EXPERIMENTAL|Weekly Cisplatin + XRT|Weekly Cisplatin + XRT
61928873|NCT04262856|EXPERIMENTAL|Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)|Participants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
61928874|NCT05720039|EXPERIMENTAL|Robotic NSM with da Vinci SP|Subjects randomized to this arm will undergo robotic NSM (RNSM) procedures
61928875|NCT05720039|ACTIVE_COMPARATOR|Open NSM|Subjects randomized to this arm will undergo conventional open NSM procedures
61928876|NCT05717907|NO_INTERVENTION|Control group|conventional nasotracheal intubation procedure
61928877|NCT05717907|EXPERIMENTAL|Guided group|use suction catheter guided endotracheal tube through the nasal passage
61928878|NCT05903495|EXPERIMENTAL|DBS-ON|Titration will be based on stimulation parameters used in previous studies examining the role of DBS of the NAc in the treatment o OCD and depression as well as the parameters utilized in the initial pilot study conducted by the team.
61928879|NCT05903495|SHAM_COMPARATOR|DBS-OFF|"For participants randomized to the DBS-OFF condition, titration sessions will be conducted identically to the DBS-ON arm, the only difference is that no stimulation is delivered and therefore, no actual adjustments made"
61928880|NCT06743659|NO_INTERVENTION|Pre-Alert|In the Pre-Alert phase of 6 months, patients meeting enrollment criteria will be identified but the clinician will not be notified regarding the possible diagnosis of Familial Hypercholesterolemia.
61928881|NCT06743659|EXPERIMENTAL|Alert|"In the Alert phase of 18 months, an on-screen alert through the Electronic Health Record will notify the ambulatory care clinician of record that the patient has a definite, probable, or possible diagnosis of FH but has not been recognized as such."
61928882|NCT05054010||Early Breast Cancer patients|Early stage breast cancer category is based on the definition of the European Society of medical Oncology and is defined as disease confined to the breast with or without regional lymph node involvement
61928883|NCT05054010||Metastatic Breast Cancer patients|Metastatic breast cancer category is based on the definition of the European Society of Medical Oncology and is defined as disease spread to other parts of the body, such as bones, liver or lungs (also called stage IV). Tumours at distant sites are called metastases.
62131510|NCT01548170|EXPERIMENTAL|Sunitinib 37.5 mg + Ketoconazol 400 mg|"The drugs will be administered as follows:~* Sunitinib 37.5mg oral single dose.~* Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
62131511|NCT01548170|EXPERIMENTAL|Sunitinib 25mg + Ketoconazol 200mg|"The drugs will be administered as follows:~* Sunitinib 25mg oral single dose.~* Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
62131512|NCT01548170|EXPERIMENTAL|Sunitinib 25mg + Ketoconazol 400mg|"The drugs will be administered as follows:~* Sunitinib 25mg oral single dose.~* Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
62131513|NCT06326931|EXPERIMENTAL|Thermal pulsation group|Group treated in both eyes with a single Systane iLux thermal pulsation treatment
62131514|NCT06326931|ACTIVE_COMPARATOR|Warm compress group|Group treated in both eyes with 10 minute application of Bruder warm compress mask, twice daily for 8 weeks
62131515|NCT01101594|EXPERIMENTAL|hLL1-DOX|4 Different dose levels of hLL1-DOX will be studied in groups of 3-6 patients. Once an optimal dose has been found, up to additional 30 patients will be studied at that dose level.
62131516|NCT00830934|ACTIVE_COMPARATOR|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
62131517|NCT00830934|EXPERIMENTAL|Group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
62131518|NCT04038736|EXPERIMENTAL|Healthy subjects at averge risk for CRC|All subjects are healthy who didn't have any known polyps in past colonoscopy and who arw candidates for CRC screening
62131519|NCT04038736|EXPERIMENTAL|Healthy subjects at high risk for CRC|Subjects who had polyps in former colonoscopy, subjects who have family history of CRC or subjects who have positive stool blood test.
62131520|NCT01255501|EXPERIMENTAL|NI-0701|
62131521|NCT01255501|PLACEBO_COMPARATOR|Placebo|
62131522|NCT00533910|PLACEBO_COMPARATOR|Placebo|Will be given placebo and follow the exact procedures as the experimental section
62131523|NCT00533910|EXPERIMENTAL|Drug|
62131524|NCT04677192|EXPERIMENTAL|Microwave Ablation Combined with Chemotherapy|All patients will receive microwave ablation of oligohepatic metastasis and chemotherapy according to NCCN guidelines,and the efficacy was evaluated every 8 weeks until the disease progressed or the patient could not tolerate it.
62131525|NCT04999917|EXPERIMENTAL|intraoperative high-resolution PET-CT imaging of resected breast tumor.|
61928884|NCT05054010||Healthy donors|Participants who are in good health and without history of cancer disease
61928885|NCT05706129|EXPERIMENTAL|Part A: [68Ga]Ga-DPI-4452|Participants will receive \[68Ga\]Ga-DPI-4452, a single dose on Day 1.
61928886|NCT05706129|EXPERIMENTAL|Part B: [177Lu]Lu-DPI-4452|Participants will receive a single dose of \[68Ga\]Ga-DPI-4452, at screening then escalating doses of \[177Lu\]Lu-DPI-4452, on Day 1 of each (Q4W or Q6W) cycle and RP2D will be determined.
62131526|NCT03406936|ACTIVE_COMPARATOR|Daily interruption of sedation|Daily interruption of sedation will be done at 7 am daily by stoppage of midazolam infusion
62131527|NCT03406936|NO_INTERVENTION|No Sedation|No sedation will be given after initiation of mechanical ventilation
62131528|NCT05237752|EXPERIMENTAL|LG00034053|White to slightly brown powder, dosage (6mg, 15mg, 45mg; dose escalation design), single dose administration
62131529|NCT05237752|PLACEBO_COMPARATOR|Placebo|Clear liquid, single dose administration
61928887|NCT05706129|EXPERIMENTAL|Part C: [177Lu]Lu-DPI-4452|Participants will receive a single dose of \[68Ga\]Ga-DPI-4452, at screening and RP2D dose of \[177Lu\]Lu-DPI-4452, on Day 1 of each cycle (Q4W or Q6W) the treatment period.
62131530|NCT04946487||group 1|patients in this group destructed the posterior ligamentous complex of the adjacent segment
62131531|NCT04946487||group 2|patients in this group did not destruct the of the posterior ligamentous complex of the adjacent segment
62131532|NCT02255877|ACTIVE_COMPARATOR|Zip Surgical Skin Closure|Subjects randomized to receive one knee (left or right) closed with ZipSurgical Skin Closure and the other knee closed with standard staples
62323215|NCT05620836|EXPERIMENTAL|Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 54 weeks.
62482359|NCT03505905|PLACEBO_COMPARATOR|Placebo responsive cont placebo|Participants will placebo throughout phase 1 (baseline- WK 7) \& treatment response assessed (MADRS score reduced \<50% at WK8). Responders continue to receive placebo at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) \& WK 4=placebo (14 days). Placebo responders remain on placebo: At WK 8, placebo (7 days); WK 9=placebo (7 days); WK 10=placebo (14 days) \& WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo= 4 days) and placebo=4 days, discontinue.
62482360|NCT06082102|EXPERIMENTAL|Orelabrutinib|
62482361|NCT06082102|PLACEBO_COMPARATOR|Placebo|
62482362|NCT03824691|EXPERIMENTAL|Cabozantinib + Durvalumab|Subjects will receive 1500 mg durvalumab (MEDI4736) IV infusion every 28 days + Cabozantinib 40 mg orally once daily
62482363|NCT01801501||Critical Care Patients|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock
62482364|NCT05172180||The control group|The control group consisted of 54 patients who received Ringer's solution at an average daily dose of 8.1 ml/kg/day as the main infusion solution from the time of transfer to the intensive care unit
62691118|NCT03644758||professional and voluntary firefighter|Professional and voluntary firefighter in Service Departmental Fire and Rescue of Loire will be included. They will have to answer at the self-administrated questionnaires. It is composed of 5 parts: socio-demographic data and personal medical history, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Insomnia Severity Index (ISI) and stop-BANG questionnaire.
61928888|NCT03143374|EXPERIMENTAL|Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease|Individuals who have been diagnosed with FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD-ALS may participate in this study if they are 18 years of age or older; most participants will be receiving care at the clinical practices of the of the University of Pennsylvania and at Pennsylvania Hospital Department of Neurology. Healthy control subjects will also be recruited for this study.
62323216|NCT05620836|EXPERIMENTAL|Povorcitinib Dose B|Participants will receive Povorcitinib Dose B for 54 weeks.
62482365|NCT05172180||The test group|Fifty one patients in the test group received the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate) at an average daily dose of 8.3 ml/kg/day for the same purpose
62482366|NCT06730113||Healthy control lean participants (Y-Lean)|A prospective, observational study design in youth aged 12-25 years to compare Y-T2DM with age and BMI-matched youth with overweight or obesity (Y-OW) and age-matched healthy lean peers (Y-Lean).
62482367|NCT06730113||Y-T2DM|A prospective, observational study design in youth aged 12-25 years to compare Y-T2DM with age and BMI-matched youth with overweight or obesity (Y-OW) and age-matched healthy lean peers (Y-Lean).
62482368|NCT06730113||Youth with overweight/ obesity (Y-OW|A prospective, observational study design in youth aged 12-25 years to compare Y-T2DM with age and BMI-matched youth with overweight or obesity (Y-OW) and age-matched healthy lean peers (Y-Lean).
62482369|NCT06742658||All patients undergoing an outpatient procedure eligible for the Rapid Move.|Patients who went to the Rapid Move after their outpatient procedure. Eligible procedures are: gastroscopy, coloscopy, vasectomy, scrotal surgery, circumcision or other minor penile surgery, intravesical Botox, insertion or removal of eardrum tubes in adults, sinus irrigation in adults, sleep endoscopy, bronchoscopy, removal of osteosynthetic material in the lower leg and foot, and tooth extraction (including wisdom teeth) and upper-forearm orthopaedic surgery (excluding prosthetic surgery).
62482370|NCT05234788|EXPERIMENTAL|TransRadial access|Patients in this group are thus treated using a TRA approach
62691119|NCT02441400||EndoStim LES Stimulation System implant.|Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.
62323217|NCT05620836|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
62323218|NCT01570985|ACTIVE_COMPARATOR|Steroid injection Without distension|Group 1 consists of patients receiving Triamcinolone acetonide 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and a total of 4 ml solution.
62323219|NCT01570985|ACTIVE_COMPARATOR|Steroid with distension|Patients in group 2 will receive intraarticular Triamcinolone Acetonide 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
62323220|NCT01570985|NO_INTERVENTION|Control|Group 3 will serve as control group and patients in this group could receive any other treatment other than corticosteroid injections or per oral corticosteroid medication. The control group will remain without treatment with corticosteroids, in injection or tablet form till 61 days, which is also the last day of the outcome measurements.
62323221|NCT03419026||breast cancer|
62691120|NCT00970177|EXPERIMENTAL|low dose of antigen + low dose of adjuvant|
62691121|NCT00970177|EXPERIMENTAL|high dose of antigen + high dose of adjuvant|
62691122|NCT00970177|EXPERIMENTAL|high dose of antigen|
62691123|NCT04019327|EXPERIMENTAL|Metastatic Castration Resistant Prostate Cancer|Participants have Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
62697498|NCT03636022|EXPERIMENTAL|Control Condition|Participants will then be assigned one week of daily exposure homework. Participants assigned to control will be instructed to complete imaginal exposures.
61928889|NCT04380129|EXPERIMENTAL|Μusic therapy-conversation sessions|
61928890|NCT04380129|ACTIVE_COMPARATOR|Music listening|
62323222|NCT03419026||control|
62323223|NCT02043301|ACTIVE_COMPARATOR|Single 150 mg PF-04950615 dose administered to the abdomen|
62323224|NCT02043301|EXPERIMENTAL|Single 150 mg PF-04950615 dose administered to the upper arm|
62323225|NCT02043301|EXPERIMENTAL|Single 150 mg PF-04950615 dose administered to the thigh|
62482371|NCT05234788|ACTIVE_COMPARATOR|TransFemoral Access|Patients in this group are thus treated using a TFA approach.
62482372|NCT06475053|ACTIVE_COMPARATOR|NaturalVue|NaturalVue Enhanced Multifocal 1 Day contact lens
62323226|NCT05447377|EXPERIMENTAL|SII Yellow Fever Vaccine Lot A|"SII-YFV Lot A:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot A will be administered concomitantly with an MMR and a Men A vaccine."
61928891|NCT05703672|EXPERIMENTAL|Varenicline and electronic cigarette|At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive 1mg varenicline to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.
61928892|NCT05703672|PLACEBO_COMPARATOR|Placebo and electronic cigarette|At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive placebo pills to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.
61928893|NCT05703672|OTHER|Open label electronic cigarette|All participants will receive an initial 6-week supply of the study electronic cigarette.
61928894|NCT06483932|ACTIVE_COMPARATOR|Control|A diet with a reduced calorie intake
61928895|NCT06483932|EXPERIMENTAL|Barberry|A diet with a reduced calorie intake, coupled with the consumption of barberry
61928896|NCT06282159|PLACEBO_COMPARATOR|Placebo|
61928897|NCT06282159|EXPERIMENTAL|DNTH103 low dose Q2W|
61928898|NCT06282159|EXPERIMENTAL|DNTH103 high dose Q2W|
61928899|NCT05608369|EXPERIMENTAL|Study drug + Standard of care chemoradiation|Participant will be pre-treated with study drug followed by continuation of standard chemoradiation
61928900|NCT02747303|ACTIVE_COMPARATOR|Stereotactic Radiosurgery to 2 mm GTV to PTV margins|
61928901|NCT02747303|EXPERIMENTAL|Stereotactic Radiosurgery to 0 mm GTV to PTV margins|
61928902|NCT05621460|EXPERIMENTAL|500mL carbonated water first, then 500mL of still water, then 50mL of still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL carbonated water on the first test day, 500mL still water on the second test day, then 50mL still water on the third day.
61928903|NCT05621460|EXPERIMENTAL|500mL still water first, then 500 mL carbonated water, then 50mL still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL still water on the first test day, 500mL carbonated water on the second test day, then 50mL still water on the third day.
61928904|NCT05621460|EXPERIMENTAL|500mL carbonated water first, then 50mL of still water, then 500mL of still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL carbonated water on the first test day, 50mL still water on the second test day, then 500mL still water on the third day.
61928905|NCT05621460|EXPERIMENTAL|500mL still water first, then 50mL still water, then 500 mL carbonated water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL still water on the first test day, 50mL still water on the second test day, then 500mL carbonated water on the third day.
62323227|NCT05447377|EXPERIMENTAL|SII Yellow Fever Vaccine Lot B|"SII-YFV Lot B:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot B will be administered concomitantly with an MMR and a Men A vaccine."
62482373|NCT06475053|ACTIVE_COMPARATOR|MiSight|MiSight 1 Day contact lens
62482374|NCT06627322|ACTIVE_COMPARATOR|Standard treatment arm (HbA1c 7.0% target)|Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Treatment and Follow-up : Maximum 4 years
61928906|NCT05621460|EXPERIMENTAL|50mL still water first, then 500mL still water, then 500 mL carbonated water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 50mL still water on the first test day, 500mL carbonated water on the second test day, then 500mL carbonated water on the third day.
61928907|NCT05621460|EXPERIMENTAL|50mL still water first, then 500mL carbonated water, then 500 mL still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 50mL still water on the first test day, 500mL still water on the second test day, then 500mL still water on the third day.
61928908|NCT05506904|EXPERIMENTAL|Extubation Advisor|Wave form data from participants' spontaneous breathing trials (SBT) will be analyzed using Extubation Advisor (EA) to generate an EA report that provides clinical decision support regarding extubation.
61928909|NCT05506904|NO_INTERVENTION|Standard of Care Arm|Participants will undergo SBTs as directed by clinicians. The EA device will not be used.
61928910|NCT04653454|EXPERIMENTAL|CGM Patients|Patients with diabetes mellitus admitted to the hospital and using a CGM will be encouraged to continue to use these devices in inpatient setting. The device alarms of high or low glucose levels will be communicated to the nursing staff.
61928911|NCT04329975||Participants with Nocturia|Participants with nocturia due to nocturnal polyuria treated with MINIRINMELT OD Tablet 25μg or 50μg as per daily clinical practice.
61928912|NCT04081896||In Clinic Rehabilitation|Participants who are undergoing supervised exercise based rehabilitation in the SpineZone clinic
61928913|NCT04081896||Online Rehabilitation|Participants who will be undergoing online-based coaching and exercise as prescribed via telephone, online chat, or web-based interactions with SpineZone rehabilitation staff (physical therapists and physicians)
62323228|NCT05447377|EXPERIMENTAL|SII Yellow Fever Vaccine Lot C|"SII-YFV Lot C:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot C will be administered concomitantly with an MMR and a Men A vaccine."
62482375|NCT06627322|EXPERIMENTAL|Intensive treatment arm (HbA1c 6.0% target): plus real-time CGM|Randomly assigned into 2 sub-groups Device: Dexcom G7 plus Kakaohealthcare Pasta. (Barozen Fit is also available.) Treatment and Follow-up : Maximum 4 years
61928914|NCT04318717|EXPERIMENTAL|Pembrolizumab + Hypofractionated radiation therapy|"* Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).~* Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy."
61928915|NCT06745596|ACTIVE_COMPARATOR|Cataract with limited anterior pars plana vitrectomy|group I included twelve patients who underwent phacoemulsification combined with limited anterior pars plana vitrectomy
61928916|NCT06745596|ACTIVE_COMPARATOR|Cataract without limited anterior pars plana vitrectomy|group II included twelve patients that underwent phacoemulsification only
61928917|NCT03702686|EXPERIMENTAL|FEEDBACK system|Mother / infant dyad will use the FEEDBACK system during a breastfeeding session.
61928918|NCT02759744|EXPERIMENTAL|1|ultrasound image-guided focal ablation
61928919|NCT03768063|EXPERIMENTAL|Atezolizumab Monotherapy|Participants will receive atezolizumab by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
61928920|NCT03768063|EXPERIMENTAL|Combined Agents with Atezolizumab|Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
61928921|NCT03768063|ACTIVE_COMPARATOR|Comparator Treatment|Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
61928922|NCT06484621|EXPERIMENTAL|Acceptance and Commitment Therapy-Based Physical Activity Intervention|Provides experiential training in values-clarification and acceptance strategies to increase autonomous motivation for achieving self-determined physical activity goal via group-based workshops, email feedback, and brief support telephone calls.
61928923|NCT06484621|ACTIVE_COMPARATOR|Physical Activity Education Intervention|Provides didactic instruction on physical activity and behavioral strategies for achieving prescribed physical activity goals via group-based workshops, email feedback, and brief support telephone calls.
61928924|NCT06735872|EXPERIMENTAL|Non invasive ventilation|This group will receive a unique 10-minute session of non invasive ventilation with standard parameters directly on the CT table. The treatment will be delivered via a naso-buccal mask.
61928925|NCT06735872|EXPERIMENTAL|High flow oxygen therapy|This group will receive a unique 10-minute session of high flow oxygen directly on the CT table. The treatment will be delivered via a nasal cannula
61928926|NCT05995002|NO_INTERVENTION|Control|Conventional drug treatment with a general recommendation for a healthy diet.
61928927|NCT05995002|EXPERIMENTAL|Anthocyanin-rich diet group|Conventional drug treatment with a weekly food plan aims to increase the consumption of anthocyanin-rich sources
61928928|NCT05827614|EXPERIMENTAL|Single Agent Dose Escalation|Single agent BBI-355, administered orally in 28-day cycles
61928929|NCT05827614|EXPERIMENTAL|Single Agent Dose Expansion|Single agent BBI-355, administered orally in 28-day cycles
61928930|NCT05827614|EXPERIMENTAL|Dose Escalation in Combination with EGFR Inhibitor|Combination therapy of BBI-355 and EGFR inhibitor erlotinib, administered orally in 28-day cycles.
61928931|NCT05827614|EXPERIMENTAL|Dose Escalation in Combination with FGFR Inhibitor|Combination therapy of BBI-355 and FGFR1-4 inhibitor futibatinib, administered orally in 28-day cycles.
61928932|NCT02332746||Middle-aged women|Middle-aged women (35-64 years)
61928933|NCT06201884|EXPERIMENTAL|Adapted physical activity|Adapted physical activity on a walking platform
61928934|NCT05304936|EXPERIMENTAL|HCW9218|Experimental Arm: HCW9218
61928935|NCT04764357|EXPERIMENTAL|Cooling Cap Therapy|Participants receiving cooling cap therapy
61928936|NCT05832307|ACTIVE_COMPARATOR|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program, which will be comprised of the following core components: informatics and data analytic tools, evidenced-based education and communication, a multidisciplinary leadership team, and end-user engagement. Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative with lead site facilitation during the trial period.
61928937|NCT05832307|ACTIVE_COMPARATOR|Existing inpatient influenza vaccination practices|Usual care is defined as the inpatient influenza vaccination practices that currently exist at a given site.
61928938|NCT06440317||Hemofiltration membranes (the oXiris® membrane and the HF1400 ® membrane)|Eligible patients for this study will undergo renal replacement therapy using two hemofiltration membranes commonly used in intensive care units.
61928939|NCT06220604|EXPERIMENTAL|JNJ-77242113|Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
61928940|NCT06220604|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
61928941|NCT06220604|ACTIVE_COMPARATOR|Deucravacitinib|Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
62131533|NCT02255877|ACTIVE_COMPARATOR|Steel Staples|Subjects randomized to receive one knee (left or right) closed with Staples and the other knee closed with ZipSurgical Skin Closure
62482376|NCT05255601|EXPERIMENTAL|Relatlimab + Nivolumab|
62691124|NCT06675500|ACTIVE_COMPARATOR|Group A (Study group)|"After completion of surgical procedure and successful weaning off Cardiopulmonary bypass the patients will be divided into two groups group A will receive 2 gm of Mg Sulfate diluted in 30 cc normal 0.9 % saline via intravenous infusion over 1 hour (1 Mg sulfate ampoule = 10 cc) .~On ICU arrival group A will continue receiving 1 gm of Mg sulfate per hour for five hours via continuous IV infusion.~After 5 hours, group A will receive 200 mg of Mg sulfate per hour for 19 hours via continuous IV infusion, then oral replacement of mag added 1 gm/8 hours tablet.~Total time of Mg/placebo infusion is 24 hours, and oral tablets for 1 week just before hospital discharge.~Total serum Magnesium level will be measured immediately post weaning of cardiopulmonary bypass, on ICU arrival, after 24 and 48 hours."
62691125|NCT06675500|PLACEBO_COMPARATOR|Group B (Control group)|"After completion of surgical procedure and successful weaning off Cardiopulmonary bypass the patients will be divided into two groups group B will receive 50 cc normal 0.9 % saline via intravenous infusion over same period.~On ICU arrival group B will same volume and rate of normal saline. After 5 hours, group B will receive same fluid volume and rate of normal saline followed by oral inert starch tablets.~Total time of Mg/placebo infusion is 24 hours, and oral tablets for 1 week just before hospital discharge.~Total serum Magnesium level will be measured immediately post weaning of cardiopulmonary bypass, on ICU arrival, after 24 and 48 hours."
62691126|NCT05625802|EXPERIMENTAL|Erector Spinae Plane Block (ESPB)|
62691127|NCT05625802|NO_INTERVENTION|External control|
62691128|NCT06138158|EXPERIMENTAL|Exercise and Education Group|They will perform an exercise program oriented according to the back school, as well as educational guidelines related to pain.
62691129|NCT04245098|EXPERIMENTAL|Amyloid|Biopsy
62691130|NCT02062008|OTHER|Cardiac patients receiving PET/MR|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
62691131|NCT06551727|ACTIVE_COMPARATOR|Control group|After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
62691132|NCT06551727|EXPERIMENTAL|Intervention group|After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term. In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database.
62691133|NCT06675279||Individuals with migraine|The demographic information of individuals with migraines, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test-6, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
62691134|NCT06641648|EXPERIMENTAL|NK cell treatment in AML replase after HSCT|The relapsed AML patients will receive donor NK cells injections for a total dose of twice per 2 weeks up to 3 dose levels (1.0×108 cells/dose，5.0×108 cells/dose，2.0×109 cells/dose), followed by low-dose interleukin-2 (1mIU ih, Qd) for 28 days.
62691135|NCT06565000|EXPERIMENTAL|Group 1|
62691136|NCT06565000|EXPERIMENTAL|Group 2|
62691137|NCT06674551|EXPERIMENTAL|Suprascapular nerve block and Axillary nerve block ( Group A)|Patients will receive Suprascapular nerve block (SSNB) and Axillary nerve block (AXNB) 30 minutes before the induction of general anaesthesia.
62691138|NCT06674551|EXPERIMENTAL|Interscalene nerve block (Group B)|Patients will receive Interscalene nerve block (ISB) 30 minutes before the induction of general anaesthesia.
62691139|NCT05761964|EXPERIMENTAL|Health and Harmony|Participants will take part in a program combining yoga practices and Christian spirituality.
62691140|NCT05761964|OTHER|Health Education (Control)|Participants will take part in a series of health education sessions.
61928942|NCT06410287|EXPERIMENTAL|Site 1|Participants from the hospital randomized to the experimental group will be first to receive an invitation to complete the web-based educational program. The program will be open for one month. Thirty days after a participant completes the program, they will be sent a link to a follow up survey (web-based). At 60 days, participants who completed the program and the first follow up survey will be randomized to complete a second follow up survey or participate in a 1:1 interview.
62691141|NCT06632613|EXPERIMENTAL|ENN0403 capsules, low dose|
62691142|NCT06632613|EXPERIMENTAL|ENN0403 capsules, high dose|
62691143|NCT06632613|EXPERIMENTAL|Placebo|
62691144|NCT01248819|ACTIVE_COMPARATOR|Instillation|Instillation of Ropivacaine 100 mg in the abdominal cavity
62131534|NCT02172872|ACTIVE_COMPARATOR|standard combination chemotherapy|
62131535|NCT02172872|EXPERIMENTAL|decitabine|
62131536|NCT04135040|EXPERIMENTAL|Lysine metabolic availability|Lysine metabolism from pure amino acids and cereal foods in children.
62482377|NCT06558500||group 1|delivered vaginally with successful induction of labor
62691145|NCT01248819|EXPERIMENTAL|Nebulization|Nebulization of Ropivacaine 60 mg in the abdominal cavity
62691146|NCT06643559|ACTIVE_COMPARATOR|patients with cognitive rehabilitation|Patient which have started antiseizure monotherapy plus have been included cognitive rehabilitation programme.
62691147|NCT06643559|NO_INTERVENTION|Patients Without Cognıtıve Rehabilitation|
62691148|NCT04878757|EXPERIMENTAL|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
62691149|NCT04878757|NO_INTERVENTION|Control - Business-As-Usual|Involves participation in the schools' typical math program
62691150|NCT03206450||Observational (questionnaire, biospecimen collection)|Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
62691151|NCT01787747|EXPERIMENTAL|Cohorts A and C|Single dose (D1) followed by twice daily dosing for 7 days
62131537|NCT03698084||Active|200 infants enrolled; family demographics collected and samples at day 5 (venepuncture, nasopharyngeal swab, urine and stool), actively followed up through their first RSV season for signs of respiratory symptoms. If respiratory symptoms are due to RSV infection (by point of care testing) samples as taken at day 5 are repeated at time of infection and again 7 weeks later. Annual questionnaire enquiring into respiratory illness, hospitalisations and family health and health quality of life, for up to 3 years.
62131538|NCT03698084||Passive|1800 infants enrolled; family demographics collected. Questionnaire follow up at 1 year of age enquiring into respiratory illness, hospitalisations and family health and health quality of life. If infant was hospitalised in first year of life, follow up will continue for up to 3 years.
62131539|NCT00634075|EXPERIMENTAL|1|
62131540|NCT00634075|PLACEBO_COMPARATOR|2|
62323229|NCT05447377|ACTIVE_COMPARATOR|STAMARIL®|"STAMARIL is a Live attenuated Yellow Fever Virus (17D-204 Strain) not less than 1000 IU/dose produced in specified pathogen-free chick embryos.~Solvent: Sodium Chloride 2.0 mg; Water for injections up to 0.5 mL.~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of STAMARIL will be administered concomitantly with an MMR and a Men A vaccine."
62323230|NCT06190210||Congenital heart disease|Neonates with congenital heart disease necessitating treatment before the age of 6 months, either surgical or through cardiac catheterization
62482378|NCT06558500||group 2|failed induction and delivered with C/S
62482379|NCT06741644|EXPERIMENTAL|Dose Escalation|Participants will be administered escalating doses of CS2009.
61928943|NCT06410287|OTHER|Site 2|Participants from the hospital randomized to the control setting will receive an invitation to complete a survey that collects baseline data for the outcome (stigma toward perinatal substance use) and demographic information. After thirty days, participants will be invited to complete the web-based educational program. Thirty days after completion, they will receive a link to a web-based follow up survey.
62482380|NCT06741644|EXPERIMENTAL|Dose Expansion|Participants will be administered the recommended dose(s) of CS2009 according to dose-escalation data.
61928944|NCT02008045||Neonates at Risk for Brian Injury|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
61928945|NCT02008045||Term Neonates|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
61928946|NCT04302493|EXPERIMENTAL|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course.
61928947|NCT04302493|ACTIVE_COMPARATOR|Stroke Support Group (SSG)|As a control group, participants will participate in 8 weeks of weekly Stroke Support Group.
61928948|NCT06504446|EXPERIMENTAL|NOC-110 1mg|NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler.
61928949|NCT06504446|EXPERIMENTAL|NOC-110 3mg|NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler.
61928950|NCT06504446|EXPERIMENTAL|NOC-110 6mg|NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler.
61928951|NCT06504446|PLACEBO_COMPARATOR|Placebo|"The matching placebo contains inhalation grade lactose blended with arginine. The blend is taste masked to the active drug product to minimize unblinding due to taste differences.~The matching placebo will be administered via the same inhaler."
61928952|NCT04567615|EXPERIMENTAL|Arm A : Nivolumab|
61928953|NCT04567615|EXPERIMENTAL|Arm B : Nivolumab + Relatlimab Dose 1|
61928954|NCT04567615|EXPERIMENTAL|Arm C : Nivolumab + Relatlimab Dose 2|
61928955|NCT03388437|EXPERIMENTAL|NI-NAVA|Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum \< 5 for 72 hours post extubation
61928956|NCT03388437|ACTIVE_COMPARATOR|NIPPV|Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation
62131541|NCT01118754|EXPERIMENTAL|DE-101 ophthalmic suspension high dose|
62131542|NCT01118754|EXPERIMENTAL|DE-101 ophthalmic suspension low dose|
62131543|NCT01118754|PLACEBO_COMPARATOR|DE-101 ophthalmic suspension vehicle|
62323231|NCT06371872||patients with rotator cuff injuries|"Patients will be recruited during their first consultation for treatment of a rotator cuff injury. Patients will then be contacted by telephone or e-mail every year to monitor the progress of their disease and their treatment.~Patients will be asked to complete self-questionnaires assessing shoulder function, quality of life and satisfaction. These questionnaires will be accessible via a secure website."
62323232|NCT06554626|EXPERIMENTAL|Treatment arm|"Induction Cycle 1 and 2: Venetoclax for 2 weeks,oral; Blinatumomab for 2weeks, iv; Dexamethasone.~Consolidation Cycle 3 and 5: Inotuzumab ozogamicin, iv. Cycle 4: Methotrexate, iv. Cycle 6: Venetoclax for 2 weeks,oral; Pegaspargase, im. Complete at least 6 intrathecal injections within 6 cycles."
62482381|NCT06699134||Patients with TKA|Patients with primary total knee replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
62482382|NCT06699134||Patients with THA|Patients with primary total hip replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
62482383|NCT06680271|EXPERIMENTAL|Telehealth interventions|The intervention group will consist of 25 subjects receiving a multicomponent physical exercise intervention (aerobic, strength, flexibility, and neuromotor) delivered by a physical therapist via the Microsoft Teams platform.
62482384|NCT06680271|ACTIVE_COMPARATOR|Home Intervention|The control group will consist of 25 subjects receiving traditional physical therapy at home from a physical therapist
62482385|NCT06402201|EXPERIMENTAL|CDR404|Dose escalation
61928957|NCT05902793|EXPERIMENTAL|Investigational device: V.A.C. VERAFLO™ Dressing Kit|NPWT consists in applying topical sub-atmospheric pressure to a wound that is covered with V.A.C. VERAFLO™ Dressing, sealed with drape and connected by a tube to a suction pump applying -125mmhg pressure with a drainage collection system. Instillation and dwell of a topical wound solution in the wound bed cycled at set intervals of 10 minutes every 3.5 hours without negative pressure applied. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first).
62131544|NCT01953692|EXPERIMENTAL|Cohort 1: Myelodysplastic Syndrome (MDS)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
62323233|NCT06646692|EXPERIMENTAL|Mindful Self Compassion Classes|(MSC) is a mind-body integrative health intervention that utilizes meditations, other contemplative practices, home practices, and experiential exercises (including group discussions) to increase SC. MSC can be done in groups of 10-25. To increase feasibility of MSC for use in residential drug treatment facilities we will aim to adapt MSC to 7 sessions (6 weekly sessions in alignment with the MSC short course plus the half day retreat included in the full course to facilitate skill consolidation). Sessions will be conducted in a group-based format: prior research found group-based formats equivalent to individual-level interventions for PTSD/SUD.
62482386|NCT06742580||Bell palsy patient group|Patients who applied to our hospital due to idiopathic facial paralysis within the first month
62482387|NCT06742580||control group|Healthy individuals with no known health problems
61928958|NCT05902793|ACTIVE_COMPARATOR|Negative pressure wound drainage material|A Negative pressure wound drainage material manufactured by Guangdong Shuangling Pharmaceutical Co., Ltd. (with unspecified pressures ranging from -150 to -380mmHg ) was selected as the control group treatment device, which can apply the NPWT therapy with wall suction. This control device is widely used in clinical institutions in China to deliver NPWT. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first).
61928959|NCT06710366||Newborns|Newborns born at the centre
61928960|NCT05523167|EXPERIMENTAL|EFG PH20 SC|participants receiving efgartigimod PH20 SC on top of background treatment
61928961|NCT05523167|PLACEBO_COMPARATOR|PBO PH20 SC|participants receiving placebo PH20 SC on top of background treatment
61928962|NCT06704646||Patients passed away within one year|Records their age, gender, preoperative comorbidities, and calculated their Charlson comorbidity index. We also collected information on tumor location, serum levels of carcinoembryonic antigen (CEA), preoperative clinical TNM staging, and postoperative pathological TNM staging
61928963|NCT06704646||Patient survived the first post-operative year|Records their age, gender, preoperative comorbidities, and calculated their Charlson comorbidity index. We also collected information on tumor location, serum levels of carcinoembryonic antigen (CEA), preoperative clinical TNM staging, and postoperative pathological TNM staging
61928964|NCT05938465|EXPERIMENTAL|Phase 1b Open Label|EXE-346 live biotherapeutic product, 1500x10\^9 colony forming units (CFU) twice daily (BID), 4 weeks
61928965|NCT05938465|EXPERIMENTAL|Phase 2: Active Arm|EXE-346 live biotherapeutic product, 1500x10\^9 CFU BID, 8 weeks
61928966|NCT05938465|PLACEBO_COMPARATOR|Phase 2: Placebo Arm|Powder containing same inactive ingredients as EXE-346 but none of the active ingredients, BID, 8 weeks
61928967|NCT05938465|EXPERIMENTAL|Phase 2 Open Label Extension (optional)|EXE-346 live biotherapeutic product, 1500x10\^9 CFU BID, 8 weeks
61928968|NCT06744374||COPD Patients|COPD patients initiating BGF or MITT
61928969|NCT04184895|EXPERIMENTAL|ASP2390 Low Dose (Cohort 1)|Participants will receive a low dose of ASP2390 once weekly for a total of 12 doses. After all participants in cohort 1 complete 4 doses of treatment, the overall safety and tolerability of the dose will be evaluated by the Dose Escalation Committee (DEC).
61928970|NCT04184895|PLACEBO_COMPARATOR|Placebo Low Dose (Cohort 1)|Participants will receive a low dose of matching Placebo once weekly for a total of 12 doses.
61928971|NCT04184895|EXPERIMENTAL|ASP2390 High Dose (Cohort 2)|Participants will receive a high dose of ASP2390 once weekly for a total of 12 doses. The dose for cohort 2 may be adapted after the DEC evaluates emergent safety and tolerability data.
61928972|NCT04184895|PLACEBO_COMPARATOR|Placebo High Dose (Cohort 2)|Participants will receive a high dose of matching Placebo once weekly for a total of 12 doses.
61928973|NCT01168271||Children Ages 0-3 years|Children aged 0-3 years in Ouelessebougou,
61928974|NCT01168271||Febrile Hospitalized Children|Febrile hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Tour(SqrRoot)(Copyright) Hospital in Bamako
61928975|NCT01168271||Later Childhood and Adolescence|Re-enrollees who were originally enrolled at birth and completed the Pregnant Women and Newborn Cohort
61928976|NCT01168271||Non-Hospitalized Children|Febrile non-hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Tour(SqrRoot)(Copyright) Hospital in Bamako
61928977|NCT01168271||Pregnant Women + Newborns|Pregnant women presenting for antenatal consultations and delivery and their newborns
61928978|NCT05778266|ACTIVE_COMPARATOR|L-Cit + HIIT|adolescents will be supplemented with 6 g/day of L-citrulline and 3 sessions per week of HIIT for 12 weeks
61928979|NCT05778266|ACTIVE_COMPARATOR|L-Cit|adolescents will be supplemented with 6 g/day of L-citrulline but without do exercise for 12 weeks
61928980|NCT05778266|PLACEBO_COMPARATOR|Placebo + HIIT|adolescents will be supplemented with 6 g/day of Carboxymethyl cellulose and 3 sessions per week of HIIT for 12 weeks
61928981|NCT06417814|EXPERIMENTAL|Group 1: Dato-DXd + Osimertinib Combination Therapy|Participants will receive Dato-DXd 6 mg/kg as IV infusion Q3W on Day 1 of every 21-day cycle, and osimertinib 80 milligrams (mg) once daily (QD) orally, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or other discontinuation criterion is met.
61928982|NCT06417814|EXPERIMENTAL|Group 2: Dato-DXd Monotherapy|Participants will receive Dato-DXd 6 milligrams per kilogram (mg/kg) as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of every 21-day cycle, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or other discontinuation criterion is met.
61928983|NCT06417814|EXPERIMENTAL|Group 3: Platinum-based Doublet Chemotherapy|Participants will receive pemetrexed 500 milligrams per meter square (mg/m2) in combination with carboplatin (AUC5) or cisplatin 75 mg/m2 as IV infusion Q3W for 4 cycles followed by pemetrexed maintenance 500 mg/m2 as IV infusion Q3W, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or another discontinuation criterion is met.
61928984|NCT06036914|EXPERIMENTAL|Ultra-high dose diuretic group|Subjects with decompensated heart failure requiring hospitalization will receive IV bumetanide.
62482388|NCT02641444||Efavirenz|Receiving efavirenz as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
61928985|NCT06036914|ACTIVE_COMPARATOR|Standard dose diuretic group|Subjects with decompensated heart failure requiring hospitalization will receive IV furosemide.
61928986|NCT06679348|EXPERIMENTAL|Virtual Reality Walking Exercise|Walking in virtual reality combined with treadmill exercise
62131545|NCT01953692|EXPERIMENTAL|Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
62131546|NCT01953692|EXPERIMENTAL|Cohort 3: Relapsed/Refractory (R/R) Hodgkin lymphoma (HL)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
62323234|NCT06646692|EXPERIMENTAL|Treatment as Usual|"Selecting appropriate attention control groups for behavioral intervention research, particularly for mindfulness-based interventions, can be problematic. Comparator groups often also improve as they tend to target related mechanisms (e.g., social support, health behaviors, improved attention). After weighing the pros and cons, a treatment as usual (TAU) approach was selected, whereby the MSC will be compared to TAU. However, to control for the confound of weekly compensation, TAU participants will meet with study staff seven times over the 6-week period and fill out short psychosocial surveys on non-distressing topics (e.g., personality tests, attitudes surveys) in exchange for compensation commensurate with the MSC group. We believe this will also help with retention of the TAU group over time and strike an appropriate balance between controlling for the effects of study participation while minimizing confounds that often occur with active control groups in behavioral trials."
62323235|NCT03357822|EXPERIMENTAL|Sequential combination therapy group|Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks
62323236|NCT03357822|ACTIVE_COMPARATOR|Nucleoside therapy group|Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks
62323237|NCT00676273|ACTIVE_COMPARATOR|1|TVTO
62482389|NCT02641444||Atazanavir|Receiving atazanavir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
62482390|NCT02641444||Raltegravir|Receiving raltegravir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
62482391|NCT02641444||Maraviroc|Receiving maraviroc as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
62482392|NCT06742112||Overweight and obese individuals|
62482393|NCT06743126|EXPERIMENTAL|Experimental arm|Non-myeloablative chemotherapy for lymphodepletion (LD) over 4 days using fludarabine (FLU) and cyclophosphamide (CY), one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
62482394|NCT06743126|ACTIVE_COMPARATOR|Control arm- investigator's choice|Investigator's choice of treatment approved by the respective Competent Authority (nivolumab plus relatlimab \[Opdualag®\], lifileucel, nivolumab, pembrolizumab, ipilimumab, or chemotherapy \[e.g., dacarbazine, temozolomide, paclitaxel, alb-bound paclitaxel, or paclitaxel plus carboplatin\]) as determined by the site investigator in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC), optional bridging therapy.
62482395|NCT05061719|EXPERIMENTAL|Lumateperone 42 mg|
62482396|NCT03854318||Family|Direct family members of enrolled patients will be asked to enroll in the study to provide specimens for genetic testing, next-generation sequencing, and other related studies.
62482397|NCT03854318||RUNX1|Patients enrolled in this protocol will have been referred with a known or suspected RUNX1 mutation.
61928987|NCT06679348|EXPERIMENTAL|Walking on Treadmill|walking on treadmills
62482398|NCT05301608|EXPERIMENTAL|Psilocybin First|Psilocybin (10mg) will be administered one time orally as a capsule taken with water. Expected duration of acute effects is approximately 6 hours. After a period of a washout, participants will switch to the placebo intervention.
62482399|NCT05301608|PLACEBO_COMPARATOR|Placebo First|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water. After a period of a washout, participants will switch to the Psilocybin intervention.
61928988|NCT05583227|EXPERIMENTAL|Tezepelumab Low Dose|Tezepelumab subcutaneous injections, in accessorised pre-filled syringes
61928989|NCT05583227|EXPERIMENTAL|Tezepelumab High Dose|Tezepelumab subcutaneous injections, in accessorised pre-filled syringes
61928990|NCT05583227|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injections, in accessorised pre-filled syringes
62131547|NCT01953692|EXPERIMENTAL|Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
62131548|NCT01953692|EXPERIMENTAL|Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
62131549|NCT01953692|EXPERIMENTAL|Cohort 4C: R/R Follicular Lymphoma (FL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
62323238|NCT00676273|ACTIVE_COMPARATOR|2|TVTS
62482400|NCT05139836||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe atopic dermatitis.
62482401|NCT05148299|EXPERIMENTAL|Pegcetacoplan|sterile solution in stoppered glass vial given as 1080 mg infusion 3 times weekly for 12 weeks.
62482402|NCT04374864|EXPERIMENTAL|Trilaglibtin 50 mg|Samples from 6 healthy, adult, male, Egyptian volunteers (age: 25-39 years, average weight: 89.8 kg, average body mass index (BMI): 34.2) were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144 and 168 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one Zafatek® tablet nominally containing 50 mg trilagliptin. Blood samples (1 mL of each sample) were centrifuged at 3000 rpm for 5 min.
62691152|NCT01787747|EXPERIMENTAL|Cohorts B and D|Single dose (D1) followed by twice daily dosing for 7 days
62691153|NCT01787747|EXPERIMENTAL|Cohorts E and F|Single dose (D1) followed by twice daily dosing for 7 days
61928991|NCT05750173||Investigational CTA-only cohort|100 consecutive patients that are not already diagnosed with significant (≥50%) proximal stenosis of the left anterior descending artery (LAD) OR the left main coronary artery (LM) and who have not previously undergone coronary revascularisation.
62131550|NCT01953692|EXPERIMENTAL|Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
62323239|NCT05886647|EXPERIMENTAL|Group 1 experimental|"group composed by patients with respiratory disorders, which will undergo 12 sessions of neurostimulation by HD-tDCS 4x1 (tDCS 1x1, developed by Soterix Medical Inc.).~A current of 3 mA will be provided, positioning a central electrode (anode) on the left diaphragmatic primary motor cortex (4 cm lateral to the midline and 1 cm anterior to the binaural line) and the four return electrodes in a radius of 8 cm to the around. At the same time, inspiratory muscle training (IMT) will be performed by KH2; PowerBreathe International Ltd. UK with visual feedback, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI. The initial load will be through the maximum inspiratory pressure (MIP) achieved in the initial evaluation, using 40% of the total MIP in the first three weeks and 70% of the protocol will be used 40% of the MIP in the remaining three weeks and 70% in the remaining weeks."
62482403|NCT06737055|EXPERIMENTAL|Home Visitors|The participants in Phase 1 of the proposed study are individuals who provide services to perinatal women who are at risk of postpartum depression. The investigators will recruit 35 adults ages 18 years or older who provide health, well-being, and/or mental health services/treatment to pregnant and postpartum women to participate in Phase 1 of this study. Job titles that meet inclusion criteria include nurses, nurse practitioners, family support workers, therapists, counselors, doulas, lactation consultants, childbirth educators, social workers, public health workers, midwives, and nurse midwives. The investigators will not select participants based on age, gender, sex, or racial or ethnic identity.
62482404|NCT06737055|EXPERIMENTAL|Expectant and New Parents|"Phase 2 participants will be given access to the educational materials about sleep and the investigators will collect information about their sleep.~To qualify for enrollment, Phase 2 participants must be:~* expectant parents OR new parents up to 1 year postpartum~* 18 to 45 years old~* receiving community-based health, well-being, and or mental health services or treatment from individuals who participated in Phase 1~* speak and read English or Spanish~* have access to a smart phone to view the training videos and complete the sleep diaries and assessments~* are experiencing clinically significant sleep difficulties defined as an Insomnia Severity Index score greater than 7 The investigators will exclude potential participants who are parents whose infants will not be living in the home or who will have a nighttime caregiver"
62482405|NCT04733183|EXPERIMENTAL|Arm1: DTIC + L19TNF|Patients will receive Dacarbazine (DTIC) on Day 1 and L19TNF on Days 1, 3 and 5 every 21 days.
62482406|NCT04733183|ACTIVE_COMPARATOR|Arm 2: DTIC|Patients will receive Dacarbazine (DTIC) on Day 1 every 21-day cycle .
62482407|NCT06742970|NO_INTERVENTION|Usual care after TAVI|3 months usual care after TAVI
62691154|NCT01787747|EXPERIMENTAL|Cohorts G and I|Single dose (D1) followed by twice daily dosing for 7 days
62691155|NCT01787747|EXPERIMENTAL|Cohorts H and J|Single dose (D1) followed by twice daily dosing for 7 days
62691156|NCT03686189|EXPERIMENTAL|Intervention arm|Participants will be treated with Iliac Bifurcation Stent Graft System
62691157|NCT05327569|EXPERIMENTAL|Experimental group|"xperimental group will consist of 30 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years. In addition to the conventional physiotherapy program, myofascial chain release techniques will be applied to this group.~Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.~Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 45 minutes."
61928992|NCT05750173||CTA+ICA control cohort|At least 50 consecutive patients who have not already been diagnosed with significant (≥50%) LM / proximal LAD stenosis an who have not previously undergone conronary revascularisation and will undergo CTA. If LM / proximal LAD stenosis of ≥50% can be ruled out and ICA is also performed prior to TAVI these patients will serve as control group.
61928993|NCT06497075||Albendazole only|Schoolchildren aged 5-14 years of 10 schools randomized to receive the standard deworming treatment of a single dose of albendazole 400mg.
61928994|NCT06497075||Ivermectin and albendazole|Schoolchildren aged 5-14 years of 10 schools randomized to receive the combination treatment of a single dose of ivermectin 200ug/kg (according to height category using a dose-pole) plus albendazole 400mg.
62323240|NCT05886647|SHAM_COMPARATOR|Group 2 sham comparator|The participants allocated in the control group will receive the sham HD tDCS for 20 minutes associated with the IMT, following for this training the same load guidelines, duration and load increment used in the experimental group.
61928995|NCT00923026||A/Gene Therapy|Patients who have received gene therapy
61928996|NCT00923026||B/Non-Gene Therapy|Patients who have not received gene therapy
61928997|NCT06743932||varicocel patients|varicocele patients will be follow up after Ligation and Sclerotherapy
61928998|NCT05371054|EXPERIMENTAL|1/Phase 1: Arm 1 Dose Escalation|VVIP-VIP152 and venetoclax at escalating doses with prednisone at fixed doses to determine the MTD and RP2D of VIP152 and venetoclax
61928999|NCT05371054|EXPERIMENTAL|2/Phase 2: Arm 2 Dose Expansion|VVIP- VIP152 and venetoclax at the RP2D with prednisone at fixed doses
61929000|NCT04365374|EXPERIMENTAL|Surgical Resection and GammaTile Therapy|Surgical Resection and GammaTile Therapy
61929001|NCT04365374|ACTIVE_COMPARATOR|Surgical Resection and Stereotactic Radiation Therapy|Surgical Resection and Stereotactic Radiation Therapy
61929002|NCT05102916||Patient population|Children, adolescents and adults diagnosed with a NMD (DMD/BMD/IMD; SMA; COL-6; LAMA-2) who are treated or living in Switzerland.
61929003|NCT03628677|EXPERIMENTAL|Domvanalimab Monotherapy|Varying Doses of domvanalimab Monotherapy
61929004|NCT03628677|EXPERIMENTAL|Domvanalimab + zimberelimab Q2W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
61929005|NCT03628677|EXPERIMENTAL|Domvanalimab + zimberelimab Q3W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
61929006|NCT03628677|EXPERIMENTAL|Domvanalimab + zimberelimab Q4W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
61929007|NCT03628677|EXPERIMENTAL|Domvanalimab and Zimberelimab Q6W combination therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
62131551|NCT01953692|EXPERIMENTAL|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 20 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles.
62131552|NCT01953692|EXPERIMENTAL|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 25 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.
62691158|NCT05327569|NO_INTERVENTION|Control group|"Control group will consist of 30 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years. Only conventional physiotherapy program will be applied to this group.~Conventional treatment will consist of muscle strengthening, stretching exercises and patellar mobilization. The muscle groups to be strengthened are: M. gluteus maximus, M. gluteus medius, M. Quadriceps, Core group of muscles. The muscle groups and tendons to be stretched are: M. Hamstrings, achilles tendon and iliotibial band. The exercises will be performed as 10 repetitions and 3 sets. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 45 minutes."
62691159|NCT05538208|ACTIVE_COMPARATOR|MMFBSA|MMF dosed as per body-surface area
62691160|NCT05538208|EXPERIMENTAL|MMFPK|MMF dosed as per pharmacokinetically-guided precision-dosing
62323241|NCT04317482|OTHER|Standard social stress task|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three standard scenarios presented in counterbalanced order. This will involve approximately 30 minutes of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
62691161|NCT05682443|EXPERIMENTAL|Arm A: ONC-392 plus lutetium Lu 177 vipivotide tetraxetan|Arm A receives ONC-392, IV infusion, for up to 9 doses, plus lutetium Lu 177 vipivotide tetraxetan IV infusion, Q6W for up to 6 doses.
62131553|NCT03759236|EXPERIMENTAL|Health Messaging via SMS|Clinics randomized to this arm will receive the health messaging via SMS intervention. Flyers and information cards will be made available in all exam rooms and the waiting room, which contain information about the health messaging program. Patients must voluntarily elect to enroll in the program using their mobile device. Patients who enroll will receive a variety of health messages on topics including HPV Vaccine, Cervical Cancer screening, Birth Control options, Menstrual Problems, diet and exercise. Text messages are sent out using a third party interface, Twilio, at a frequency of 2 times each week for a duration of 1 year. These are one-way messages which only allow for texts to be sent to the participant.
62131554|NCT03759236|ACTIVE_COMPARATOR|CDC Pamphlets|The clinic randomized to this control arm will receive standard Center for Disease Control health pamphlets about the HPV Vaccine. Flyers are posted in the clinic waiting room and exam room.
62131555|NCT02803476||Cases|Polycystic ovary syndrome (PCOS) female patients. 20-35 years of age.
62131556|NCT02803476||Controls|Non-PCOs female subjects. 20-35 years of age.
62691162|NCT05682443|ACTIVE_COMPARATOR|lutetium Lu 177 vipivotide tetraxetan|lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses.
62691163|NCT04722315|EXPERIMENTAL|MAD diet group|15 adult participants with confirmed KMT2D pathogenic mutations. Baseline labs and education about Modified Atkins Diet. Then 12 weeks on a Modified Atkins Diet. Weekly urine dips for ketones and diet logs. Blood draw every 3 weeks.
62691164|NCT00935207||Pediatric Pain Diary|Patients will be give a pain diary to complete.
62691165|NCT06031779||gastric cancer|
62691166|NCT06031779||non-gastric cancer|
62691167|NCT02640131|EXPERIMENTAL|BSHR Intervention|"Couples will attend 30-minute clinic consultations with an Urologist and a Sexual Health Counsellor and receive session-specific chapters of the Kindness, Intimacy, Sexuality and Satisfaction manual over the course of the intervention.~The BSHR Intervention involves two complementary components; the bio-medical, and the psychosocial. The bio-medical component for both arms intervention includes an urologist consultation at a pre-operative appointment and 5 f/u appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.~The psychosocial component aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive sexual health counseling and manualized support."
62691168|NCT02640131|ACTIVE_COMPARATOR|Attention Control|"Survivorship Counseling: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) and receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You Manual. The bio-medical component is the same in both arms.~The core topics discussed during over 7 counseling sessions include: preparation for immediate post-surgery recovery, Kegel exercises, nutrition and prostate cancer, exercise and prostate cancer, and maintaining healthy lifestyle change."
62691169|NCT01123187|EXPERIMENTAL|islet transplantation|Islet transplantation
62131557|NCT06392412|EXPERIMENTAL|VR Group|
62131558|NCT06392412|ACTIVE_COMPARATOR|Control Group|
62131559|NCT04319432|EXPERIMENTAL|3 days voice rest|
62131560|NCT04319432|EXPERIMENTAL|7 days voice rest|
61929008|NCT03628677|EXPERIMENTAL|Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
62131561|NCT04945135||liver donors|
62131562|NCT03717506|EXPERIMENTAL|Test product|GDC 268 Lotion applied topically as directed.
62131563|NCT03717506|ACTIVE_COMPARATOR|Reference Product|Clindamycin Phosphate Lotion, 1% applied topically as directed.
62131564|NCT03717506|PLACEBO_COMPARATOR|Placebo|GDC Vehicle lotion applied topically as directed.
62323242|NCT04317482|OTHER|Stressful experience in the ED|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three experiences surrounding their most stressful ED visit. These experiences are presented in counterbalanced order. This will involve approximately 30 of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
62131565|NCT01230450|EXPERIMENTAL|Single-incision Mini-slings (SIMS- Ajust)|AjustTM has polypropylene fixing anchors (one is fixed and the other adjustable) which are anchored onto the obturator membrane. The pulley like system enables adjustment of the tension once the arms have been anchored. Once in place, the anchors rest at right angles to insertion which is claimed to reduce the chances of anchor dislodgment
62131566|NCT01230450|OTHER|standared med urethral sling (SMUS)|standard med urethral sling (SMUS)TVT-O, was done as originally described by Deleval et al.
62131567|NCT00746343|EXPERIMENTAL|IRRI|"The integrated risk reduction intervention (IRRI) consists of three components:~1. psychiatric treatment by a study psychiatrist~2. assessment, referral, monitoring, and coordination by a certified registered nurse practitioner (CRNP) of medical treatment provided by the subject's own primary care physician~3. a healthy lifestyle behaviors program delivered by a lifestyle coach. The treating psychiatrist will work in collaboration with a CRNP and a lifestyle coach. The CRNP will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care and will follow-up on adherence to the medical treatment recommendations. The CRNP will be responsible for coordinating the psychopharmacological care provided by the psychiatrist, the healthy lifestyle behaviors program that will be delivered by the lifestyle coach, and the medical care provided by the subject's PCP."
62323243|NCT04877015|ACTIVE_COMPARATOR|Active Vibrotactile Coordinated Reset (vCR)|Participants in this arm will receive active vCR stimulation.
62323244|NCT04877015|SHAM_COMPARATOR|Sham Vibrotactile Coordinated Reset (vCR)|Participants in this arm will receive sham vCR stimulation.
62323245|NCT05147129||Postmenopausal with vulvar lichen sclerosus|Includes postmenopausal patients with clinically-active vulvar lichen sclerosus, as determined by biopsy or examination by a vulvar specialist
62323246|NCT05147129||Postmenopausal without vulvar lichen sclerosus|Includes postmenopausal patients without vulvar lichen sclerosus
62323247|NCT01279538|EXPERIMENTAL|ASKP1240 lowest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
62323248|NCT01279538|EXPERIMENTAL|ASKP1240 low dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
62323249|NCT01279538|EXPERIMENTAL|ASKP1240 high dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
62323250|NCT01279538|EXPERIMENTAL|ASKP1240 highest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
62691170|NCT05545527||RAPIDIRON IV iron intervention arm 1|Maternal participants in this arm were given a single dose of an IV iron formulation - ferric carboxymaltose - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
61929009|NCT05146973|EXPERIMENTAL|Single administration of 177Lu-DOTA-TLX591|Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart.
61929010|NCT05562622|EXPERIMENTAL|SightGlass Vision Test Arm 1|Single vision, impact-resistant spectacle lenses
61929011|NCT05562622|OTHER|Test Arm 2|Single vision, impact-resistant spectacle lenses
61929012|NCT04925752|EXPERIMENTAL|Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF|"Participants will receive the following for approximately 52 weeks:~* Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~* Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~* Oral LEN 600 mg on Days 1 and 2~Participants will receive oral LEN if SC injections are not available"
61929013|NCT04925752|EXPERIMENTAL|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for approximately 52 weeks:~* SC LEN placebo every 26 weeks~* Oral F/TDF 200/300 mg once daily~* PTM Oral LEN on Days 1 and 2~Participants will receive oral LEN placebo if SC injections are not available"
62131568|NCT00746343|EXPERIMENTAL|PCCM|"Psychiatric Care with Medical Monitoring (PCMM)~The psychiatric care with medical monitoring condition (PCMM) consists of two components:~1. psychiatric treatment by a study psychiatrist~2. assessment and referral by a psychiatric research nurse for medical treatment provided by the subject's own primary care physician.~The treating psychiatrist will be assisted by a psychiatric nurse clinician who will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care."
62131569|NCT04095715||Children and adults with unexplained hemorrhagic syndrome|Patients with spontaneous or induced hemorrhagic manifestations who are present for a consultation to investigate a thrombopathy or during follow-up consultations as part of their usual care.
62131570|NCT05150912|ACTIVE_COMPARATOR|Neuro dynamic|Neurodynamic techniques.
62131571|NCT05150912|ACTIVE_COMPARATOR|desensitization|Desensitization maneuvers
62131572|NCT04828590||Patients with suspected CAD containing at least one 30%-90% coronary CTA stenosis|Patients' datasets with suspected CAD containing at least one 30%-90% coronary CTA stenosis; and ICA-FFR was measured on vessels with diameters greater than 2 mm will be analyzed. Diagnostic performance based on CT-derived FFR using DVFFR software will be compared with the diagnostic performance from ICA-FFR measurements.
62131573|NCT04542733|ACTIVE_COMPARATOR|mTORi with reduced-dose tacrolimus|Patient will received everolimus with target trough concentration of 3-6 ng/mL and tacrolimus with target trough concentration of 2-4 ng/mL. Duration for this regimen would be at least 3 months.
62323251|NCT01279538|PLACEBO_COMPARATOR|Placebo|Participants received a single 30-minute matching placebo infusion on Study Day 1, followed by a 90-day follow-up period.
62323252|NCT02307019|EXPERIMENTAL|Program on specific prevention of health|The caregivers will be randomly assigned to an experimental group, to receive the program on specific prevention of health. The workshop will be performed twice a month, two hours a day, during a 4-week period.
62323253|NCT02307019|ACTIVE_COMPARATOR|Program on general prevention of health|Control group will receive an intervention by mean of a general health program to manage the common situations when a caregiver is caring for a patient with dependency. The workshop will be performed two a month, two hours a day, during a 4-week period.
62691171|NCT05545527||RAPIDIRON IV iron intervention arm 2|Maternal participants in this arm were given a single dose of an IV iron formulation - iron isomaltoside - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
62131574|NCT04542733|ACTIVE_COMPARATOR|reduced-dose tacrolimus|Patient will receive tacrolimus with target concentration of 3-6 ng/mL with or without leflunomide 100 mg/day loading dose for 5 days, followed by 40 mg/day thereafter. Duration for this regimen would be at least 3 months.
62131575|NCT00206986|EXPERIMENTAL|1|
62131576|NCT00206986|EXPERIMENTAL|2|
62131577|NCT04979715|EXPERIMENTAL|intervention group (Group 1)|"From the first postoperative day, with the approval of the surgeon performing the operation, the postoperative exercise program will be started once a day under the supervision of a physiotherapist during the stay of the participants in the hospital.~At the same time, participants will be directed to moderate intensity aerobic exercise (walking, jogging...) for 150 min/week. Information will be given on the importance of physical activity and increasing the level of physical activity. In addition, a brochure containing explanatory information about the postoperative physiotherapy program after breast surgery will be given to the participants."
62131578|NCT04979715|ACTIVE_COMPARATOR|control group (Group 2)|The patients in the control group will be informed about the postoperative physiotherapy program and patient education will be provided by the physiotherapist before the operation. Within the knowledge and approval of the surgeon performing the operation, preoperatively, respiratory control, diaphragmatic breathing, relaxation exercises, passive-active assistive-active range of motion exercises are shown by the physiotherapist, and patient education is provided with information about possible postoperative complications and what needs to be considered. will be given.
62323254|NCT03321552|EXPERIMENTAL|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
62323255|NCT02945449|EXPERIMENTAL|Dose I|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
62323256|NCT06149403|EXPERIMENTAL|OTL-203|Eligible subjects randomized to Arm 1 will receive an intravenous (IV) infusion of OTL-203 gene therapy. Subjects will receive conditioning regimen with busulfan and fludarabine prior to OTL-203 infusion.
62323257|NCT06149403|ACTIVE_COMPARATOR|Allo-HSCT|Eligible subjects randomized to Arm 2 will receive allogeneic hematopoietic stem cell transplantation. Subjects will receive conditioning regimen with busulfan and fludarabine prior to allo-HSCT.
62323258|NCT02558738||Ectoin Ear Spray|treatment according to instruction for use
62323259|NCT02558738||Normison ear spray|treatment according to instruction for use
62323260|NCT06189001|EXPERIMENTAL|Oxytocin|Intravenous oxytocin 0.2 IU/minute for 300 minutes Approx. 500 ml
62323261|NCT06189001|OTHER|Placebo|intravenous saline (0.9% NaCl) infusion for 300 minutes Approx. 500 ml
62323262|NCT05121857||ACLR group|Individuals who are 7 months post primary ACLR
62691172|NCT05545527||RAPIDIRON active comparator arm|Maternal participants in this arm of the RAPIDIRON Trial were given ferrous sulfate tablets with 60mg elemental iron each and instructed to take two per day (one in the morning and one at night) throughout their pregnancy.
62691173|NCT04464733|EXPERIMENTAL|Treatment group A|single dose
62131579|NCT04979715|NO_INTERVENTION|routine follow-up (Group 3)|only preoperative patient information is given.
62691174|NCT04464733|EXPERIMENTAL|Treatment group B|single dose
62691175|NCT04464733|EXPERIMENTAL|Treatment group C|single dose; food effect
62131580|NCT01497704|EXPERIMENTAL|YN968D1|Active therapy arm for safety evaluation
62323263|NCT05121857||healthy control group|Healthy uninjured individuals who are actively playing sport and have not sustained any knee injuries, ankle injuries or concussions.
62323264|NCT04207853|EXPERIMENTAL|whole body vibration in diabetics (G1)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
62691176|NCT04464733|EXPERIMENTAL|Treatment group D|single dose
62691177|NCT04464733|EXPERIMENTAL|Treatment group E|single dose
62691178|NCT04464733|EXPERIMENTAL|Treatment group F|multiple doses
62691179|NCT04464733|EXPERIMENTAL|Treatment group G|multiple doses
62691180|NCT04464733|EXPERIMENTAL|Treatment group H|multiple doses
62691181|NCT04464733|EXPERIMENTAL|Treatment group I|multiple doses
62691182|NCT04464733|EXPERIMENTAL|Treatment group J|multiple doses
62691183|NCT04464733|EXPERIMENTAL|Treatment group K|single dose
62691184|NCT04464733|EXPERIMENTAL|Treatment group L|single dose
62131581|NCT02779634|PLACEBO_COMPARATOR|Placebo|Placebo three times daily
62131582|NCT02779634|ACTIVE_COMPARATOR|Active|Pills of 100 mg ubiquinol three times daily
62131583|NCT00006349|EXPERIMENTAL|donepezil + vitamin E|"Patients receive oral donepezil daily and vitamin E twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
62323265|NCT04207853|SHAM_COMPARATOR|the sham vibration group in diabetics (G2)|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
62323266|NCT04207853|NO_INTERVENTION|diabetic control group (G3)|no treatment
62323267|NCT04207853|ACTIVE_COMPARATOR|whole body vibration group in non-diabetics (G4)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
62323268|NCT04207853|SHAM_COMPARATOR|"the vibration group  sham in non-diabetics (G5)"|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
62323269|NCT04207853|NO_INTERVENTION|non-diabetic control group (G6)|no treatment
62691185|NCT04464733|EXPERIMENTAL|Treatment group M|single dose
62691186|NCT04464733|EXPERIMENTAL|Treatment group N|multiple doses
62691187|NCT04464733|EXPERIMENTAL|Treatment group O|multiple doses
62482408|NCT06742970|EXPERIMENTAL|Telematic intervention|"Telematic intervention will be performed by a specialized company hired by the investigational team.~Trained nurses will contact patients assigned to the intervention groups by videocalls at weeks 1,3,5,7,9,11 and 12 after the admission. The specialized nurses will supervise the exercise program sessions (based on an adaptation of he VIVI FRAIL program), correcting potential mistakes and recommending the optimal way for performing the training program. Patients will take a 200 ml dose of hyperproteic, hypercaloric nutrition supplements daily one hour after performing the exercise session. Information about the optimal diet adapted to the clinical profile of patients will be also provided. Additionally, health information about the disease, the importance of adherence to treatments and recommendations and the best measures for controling cardiovascular risk factors, comorbidities and avoiding clinical complications will be also provided"
62482409|NCT01653951|EXPERIMENTAL|Nurse-led care management|Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
62482410|NCT01653951|EXPERIMENTAL|peer-led self managment|Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups
62482411|NCT06742619||gruops|patient supine position
62482412|NCT06742619||groupp|patient prone position
62482413|NCT06742619||grupsitting|patient sitting position
62482414|NCT05479552||MCI-AD|Will be diagnosed using 'preclinical AD' criteria of mild cognitive impairment supported by a positive biomarker for AD. MCI defined as: 1. History of cognitive decline, noticed by either the patient, family member(s) or a medical practitioner but still independent in most complex daily activities. 2. Documentation of cognition not normal e.g., by MoCA or neuropsychological testing; 3. Does not meet the definition of dementia with MOCA \<18 or global CDR 1 or greater (although exceptions may exist with appropriate justification). 4. Supportive AD biomarker (has positive biomarkers for both Aβ and neuronal injury using CSF or neuroimaging).
62482415|NCT05479552||MCI-DLB|Will be diagnosed as prodromal probable MCI-DLB based on consensus criteria using 2 or more core clinical features of DLB (with or without the presence of biomarkers) or 1 or more core clinical features with 1 or more indicative biomarkers (reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET reduced Iodine-MIBG uptake on myocardial scintigraphy, PSG confirmation of REM without atonia).
62323270|NCT04290962|EXPERIMENTAL|Supportive Care (web-based lifestyle intervention)|Participants complete the 12-month Precision Nutrition Coaching Program web-based lifestyle intervention consisting of physical activity at home or a local gym, nutritional/lifestyle habit with a new focus biweekly, and educational lessons about health, nutrition, fitness, or behavior change.
62323271|NCT05005156|ACTIVE_COMPARATOR|Active vaccine Ad5-nCoV|two dose of active vaccine Ad5-nCoV
62482416|NCT00884637||CNV subjects|
62482417|NCT04897256|EXPERIMENTAL|TURN-IT group|Participants in the treatment group will attend supervised, 1-hour classes, 3 times per week for 6 weeks, one-on-one with the same exercise trainer, overseen by a physical therapist investigator.
62482418|NCT04897256|NO_INTERVENTION|No Intervention Control Group|Participants in this group will be tested at baseline and 6 weeks later. They will go about their normal daily life during the 6 week period.
62482419|NCT04109131|OTHER|CNS metastases from solid tumours|"The study will be organised on three time-periods based on the time of the 1st CNS event:~Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event"
62482420|NCT06245408|EXPERIMENTAL|Dazodalibep Dose 1|Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.
62691188|NCT02419066||men and women with CD4 >=350|electronic monitoring of ARV adherence in men and women with CD4 \>=350
61929014|NCT04925752|EXPERIMENTAL|LEN Open-Label Extension (OLE) Phase|"Participants will be offered entry into the LEN OLE Phase, following the completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days).~Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2.~All participants in the LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first.~After completing the LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an ESDD visit, be referred to local PrEP services if needed, and have a 30-day follow-up visit."
62691189|NCT02419066||pregnant women with CD4 >=350|electronic monitoring of ARV adherence in pregnant women with CD4 \>=350
62691190|NCT02419066||men and women with CD4 <200|electronic monitoring of ARV adherence in men and women with CD4 \<200
61929015|NCT04925752|EXPERIMENTAL|PK Tail Phase|"Participants who prematurely discontinue study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days).~Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit."
62482421|NCT06245408|EXPERIMENTAL|Dazodalibep Dose 2|Participants will be administered dose 2 of dazodalibep by IV infusion.
62482422|NCT06245408|PLACEBO_COMPARATOR|Placebo|Participants will be administered placebo by IV infusion.
62323272|NCT05005156|PLACEBO_COMPARATOR|Placebo for Ad5-nCoV vaccine|one dose of placebo for Ad5-nCoV vaccine
62691191|NCT06674642|EXPERIMENTAL|Traditional Indigenous Foods diet|Participants will consume a diet comprised of traditional indigenous foods.
62482423|NCT05487625|EXPERIMENTAL|Narratives|High-ventilated cigarette smokers will be exposed to a narrative about the negative consequences of smoking ventilated cigarettes and all of the conditions described in the intervention section.
62482424|NCT05487625|EXPERIMENTAL|Fact sheet|High-ventilated cigarette smokers will be exposed to fact sheet about the negative consequences of smoking ventilated cigarettes and all of the conditions described in the intervention section.
62482425|NCT05487625|EXPERIMENTAL|Control|High-ventilated cigarette smokers will be not be exposed to any messages and will complete all of the conditions described in the intervention section.
62482426|NCT05896995|EXPERIMENTAL|Pilates Exercise|pilates exercise+ Mckenzie Exercise Six weeks, twice a week
62482427|NCT05896995|ACTIVE_COMPARATOR|Mckenzie Exercise|Mckenzie Exercise Six weeks, twice a week
62482428|NCT03922724|EXPERIMENTAL|1/RIC Arm|Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
62482429|NCT03922724|EXPERIMENTAL|2/IOC Arm|Immunosuppression Only Conditioning, plus allogeneic HCT with GVHD prophylaxis
62482430|NCT03922724|NO_INTERVENTION|3/Donor Arm|Donors for Recipients in Arm 1, Arm 2, Arm 4, or Arm 5
62482431|NCT03922724|EXPERIMENTAL|4/mRIC Arm|modified Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
62482432|NCT03922724|EXPERIMENTAL|5/ATL-RIC Arm|modified Reduced Intensity Conditioning Arm for ATL patients, plus allogeneic HCT with GVHD prophylaxis
62482433|NCT05719558|EXPERIMENTAL|ASP1002 Dose Escalation (Part 1)|Participants will be assigned to sequentially escalating doses of ASP1002. Each dose level will open sequentially based upon sponsor review of emerging data.
62482434|NCT05719558|EXPERIMENTAL|ASP1002 Dose Expansion (Part 2) non-small cell lung cancer (NSCLC)|Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
62482435|NCT05719558|EXPERIMENTAL|Experimental: AS1002 Dose Expansion (Part 2) urothelial carcinoma (UC)|Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
62482436|NCT05719558|EXPERIMENTAL|Experimental: ASP1002 Dose Expansion (Part 2) colorectal cancer (CRC)|Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
62482437|NCT00027274||1|All families with a member who has one of the relevant syndromes.
62482438|NCT05513677|ACTIVE_COMPARATOR|Standard of Care|Standard of Care
62691192|NCT01940744|EXPERIMENTAL|Prescriptive Mobilization|"The prescriptively applied non-thrust manipulation will be involve a central lumbar posterior-anterior directed at L4 and L5. The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Patients will be seen for 4 visits."
62691193|NCT01940744|ACTIVE_COMPARATOR|Pragmatic Mobilization|The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
62482439|NCT05513677|EXPERIMENTAL|M4D coated catheter|Experimental
62482440|NCT06741540|NO_INTERVENTION|Supportive psychotherapy group|"Neoadjuvant chemotherapy with supportive psychotherapy and sham tDCS. A neoadjuvant chemotherapy regimen will be recommended to the patient based on the guidelines, combined with the patient's molecular typing and condition. Neoadjuvant chemotherapy lasts for 21 days per cycle, and the patient needs to be hospitalized for neoadjuvant chemotherapy once. During each neoadjuvant chemotherapy hospitalization, a full-time staff member will be arranged to perform sham tDCS treatment for the patient.~The rest of the treatment was consistent with the tDCS group, but no current passed through the head-mounted device in this group.~During the treatment，all patients in this group will recieve supportive psychotherapy, with mainly provide psychological support to patients."
62482441|NCT06741540|EXPERIMENTAL|tDCS with supportive psychotherapy group|Neoadjuvant chemotherapy with supportive psychotherapy and tDCS. A neoadjuvant chemotherapy regimen will be recommended to the patient based on the guidelines, combined with the patient's molecular typing and condition. Neoadjuvant chemotherapy lasts for 21 days per cycle, and the patient needs to be hospitalized for neoadjuvant chemotherapy once. During each neoadjuvant chemotherapy hospitalization, a full-time staff member will be arranged to perform tDCS treatment for the patient. The treatment is a head-mounted device, which is performed 1 hour before neoadjuvant chemotherapy and 2 hours after neoadjuvant chemotherapy. Each tDCS treatment lasts about 30 minutes. The patient's activities are not affected during the treatment, and no additional harm or pain is caused to the patient. A total of 6 tDCS treatments are completed per cycle of neoadjuvant chemotherapy, and 36 tDCS treatments will be completed during the entire treatment process.
62482442|NCT06726993|EXPERIMENTAL|Unrestricted kinematic alignment|reproducing the constitutional tibiofemoral tridimensional alignment and knee laxity. It is almost a pure bone procedure with only exceptional collateral ligament release, which has been shown to reliably position knee components.
62482443|NCT06726993|EXPERIMENTAL|Restricted kinematic alignment|reproducing patient's constitutional knee anatomy within a safe range while avoiding extreme or pathological anatomies that have been demonstrated to exist.
62482444|NCT01714895|OTHER|High plasma insulin-Low plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
62482445|NCT01714895|OTHER|Low plasma insulin-High plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
62482446|NCT05816785|EXPERIMENTAL|Imatinib Cetuximab Combination|Participants will receive two doses of CTX and a minimum of an 8 day (maximum 14 day) course of imatinib prior to definitive surgery or definitive radiation/chemoradiation.
61929016|NCT06740435|EXPERIMENTAL|Enhanced Telemedicine Care|Specialty care for type 2 diabetes delivered via telemedicine by an endocrinologist, with additional multidisciplinary support from the diabetes care team.
62131584|NCT00006349|PLACEBO_COMPARATOR|placebo|"Patients receive oral placebo twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
62131585|NCT03005925|EXPERIMENTAL|connected group|remote monitoring by smartphone in the care management of patients with rheumatoid arthritis
62131586|NCT03005925|ACTIVE_COMPARATOR|control group|standard outpatient follow-up by physical consultation
62131587|NCT03825575|EXPERIMENTAL|Incontinence and low level laser therapy|Intervention: Low level laser therapy (sacral neuromodulation or photobiomodulation) will be administered to patients with fecal incontinence
62323273|NCT05233631||T-EUS Patients|Any patient who has undergone clinically indicated and/or standard of care T-EUS procedures from October 2014 - June 2022.
62323274|NCT06529289|OTHER|Training to Female Community Health Volunteers|"Female Community Health Volunteers received a one-day training on hypertension knowledge and blood pressure measurement skills. The training included sessions on hypertension knowledge and practical demonstrations of BP measurement techniques. The effectiveness of the training was assessed by measuring the baseline and end-line hypertension knowledge and BP measurement skills."
62323275|NCT03198169|EXPERIMENTAL|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
61929017|NCT06740435|ACTIVE_COMPARATOR|Usual Care|Specialty care for type 2 diabetes delivered via telemedicine by an endocrinologist following usual clinical care protocols.
61929018|NCT06744023|EXPERIMENTAL|EXPERIMENTAL GROUP|Upon admission to the ward from the postoperative intensive care unit, the experimental group underwent environmental remediation for three days. The environmental arrangements ensured that the patient room maintained an appropriate temperature range of 18-26 °C and humidity values of 30-60%. Monitoring took place at 21:00, 22:00, and 23:00 on Days 1, 2, and 3. On Days 1, 2, and 3, the patient room's light brightness gradually decreased at 21:00, 22:00, and 23:00. On the morning of the fourth day, the patients were interviewed face-to-face, and the research questionnaires were filled out.
61929019|NCT06744023|NO_INTERVENTION|CONTROL GROUP|The patients in the control group continued to receive standard treatment and care. On the morning of the fourth day after the patients were admitted to the ward from the postoperative intensive care unit, the patients were interviewed face-to-face and the Personal Information Form, RCSQ, and HAD Scale were completed.
61929020|NCT06469151|EXPERIMENTAL|Cohort 1: AZD5148 (dose 1) IM|Participants will receive AZD5148 (dose 1) or matching placebo as an IM injection
61929021|NCT06469151|EXPERIMENTAL|Cohort 2a: AZD5148 (dose 2) IM|Participants will receive AZD5148 (dose 2) or matching placebo as an IM injection
61929022|NCT06469151|EXPERIMENTAL|Cohort 2b: AZD5148 (dose 2) IM|Participants of Chinese descent will receive AZD5148 (dose 2) or matching placebo as an IM injection
61929023|NCT06469151|EXPERIMENTAL|Cohort 3: AZD5148 (dose 2) IV|Participants will receive AZD5148 (dose 2) or matching placebo as an IV bolus
61929024|NCT06469151|EXPERIMENTAL|Cohort 4a: AZD5148 (dose 3) IV|Participants will receive AZD5148 (dose 3) or matching placebo as an IV bolus
61929025|NCT06469151|EXPERIMENTAL|Cohort 4b: AZD5148 (dose 3) IV|Participants of Chinese descent will receive AZD5148 (dose 3) or matching placebo as an IV bolus
61929026|NCT06469151|EXPERIMENTAL|Cohort 5: AZD5148 (dose 4) IV|Participants will receive AZD5148 (dose 4) or matching placebo as an IV bolus
61929027|NCT04915248|EXPERIMENTAL|All patients registered in the DALYA trial|"Treatment consists of an induction phase (every 21 days) planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase (every 28 days), planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator decision."
61929028|NCT06107504|EXPERIMENTAL|Intervention group|After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. After then, we will spray 1g of sucralfate powder and 0.5g of tranexamic acid powder through a duodenoscope precisely on the EST wound in the intervention group.
61929029|NCT06107504|NO_INTERVENTION|Control group|After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation.
61929030|NCT05349682|EXPERIMENTAL|GAE and MRI treatment arm|GAE is geniculate artery embolization.
61929031|NCT02787369|EXPERIMENTAL|Combination of ACY-1215 With Ibrutinib|ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
61929032|NCT02787369|EXPERIMENTAL|Combination of ACY-1215 With Idelalisib|ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
61929033|NCT04790370|ACTIVE_COMPARATOR|Anticoagulation|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
62131588|NCT00991497|ACTIVE_COMPARATOR|24 hours compression bandaging|
62131589|NCT00991497|ACTIVE_COMPARATOR|5 days compression bandaging|
62323276|NCT03198169|EXPERIMENTAL|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
62323277|NCT03198169|EXPERIMENTAL|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
62482447|NCT06743282|EXPERIMENTAL|Senyo|Subjects randomized to the Senyo group will begin receiving intervention immediately, and will move to the follow-up phase after 12 weeks.
62482448|NCT06743282|ACTIVE_COMPARATOR|Waitlist|Subjects randomized to the waitlist group will serve as a control group and receive intervention after 12 weeks on the waitlist.
62482449|NCT05745493|EXPERIMENTAL|Social Engage Coaching (S-ENG)|Social Engage Coaching is 10 individual sessions of coaching to increase social connection.
62482450|NCT05025527|EXPERIMENTAL|bpMRI|Man receive the bpMRI for Prostate cancer(PCa) screening
62482451|NCT05025527|ACTIVE_COMPARATOR|PSA|Man receive the PSA blood test for Prostate cancer screening
62323278|NCT03198169|EXPERIMENTAL|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
62323279|NCT05988541|OTHER|Atraumatic rotator cuff tendon repair|Ultrasonography imaging of the operated shoulder
62323280|NCT05988541|OTHER|Contralateral shoulder|Ultrasonography imaging of the contralateral shoulder
62323281|NCT01596075|EXPERIMENTAL|Oral Cannabidiol|Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
62482452|NCT06741410||Ephedrine|"Cesarean delivery cases where spinal block was administered and hypotension was managed with intravenous ephedrine.~Hospital electronic database will be searched to identify cases of cesarean delivery in years 2020 - 2022. After that, manual review of the medical notes will follow in order to extract cases where spinal block was administered and ephedrine was used to treat spinal - related hypotension. Further chart analysis will yield demographic and hemodynamic data of the parturient, as well as clinical data of the neonate (weight, gender, Apgar score).~Further laboratory data on neonatal acid - base status will be acquired from hospital's laboratory electronic database. Attention will be paid to assure that identification of the patients would not be possible using data acquired for the study. All data will be anonymized and accessible only for investigators."
62131590|NCT02075736|EXPERIMENTAL|KTP laser|device
62131591|NCT02075736|ACTIVE_COMPARATOR|TUR-P|device
62131592|NCT06060119|EXPERIMENTAL|Comparison of Microneedling for Gingival Augmentation- A Randomized Case Control Trial|1. TEST GROUP (n = 12) - Microneedling on the selected a non-steroidal anti-inflammatory drug (Tab Ibuprofen 400mg) and antibiotic Amoxicillin 500mg thrice daily for three days after meals will be prescribed. In patients allergic to Amoxicillin, Clindamycin 300mg thrice daily is prescribed13
62131593|NCT06060119|EXPERIMENTAL|Comparison of Microneedling with for Gingival Augmentation- A Randomized Case Control Trial|2.CONTROL GROUP (n = 12) - Subepithelial connective tissue grafting at the contralateral site non-steroidal anti-inflammatory drug (Tab Ibuprofen 400mg) and antibiotic Amoxicillin 500mg thrice daily for three days after meals will be prescribed. In patients allergic to Amoxicillin, Clindamycin 300mg thrice daily is prescribed13
62131594|NCT03697707|EXPERIMENTAL|Cohort 1: Low dose|patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
61929034|NCT04790370|ACTIVE_COMPARATOR|Anticoagulation and EkoSonicTM Endovascular System|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
62131595|NCT03697707|EXPERIMENTAL|Cohort 2: High dose|patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
62323282|NCT02490150|EXPERIMENTAL|Day 5|Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
62323283|NCT02490150|ACTIVE_COMPARATOR|Day 7|Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
62323284|NCT03318640|EXPERIMENTAL|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month.
62323285|NCT03318640|NO_INTERVENTION|Control|Patient will have usual medical care.
62323286|NCT04893746|PLACEBO_COMPARATOR|Placebo|
62323287|NCT04893746|EXPERIMENTAL|TWK10-L|Low dose
62323288|NCT04893746|EXPERIMENTAL|TWK10-H|High dose
62323289|NCT06688331|EXPERIMENTAL|TregsCD20|"Infusion of Treg preparation at day 0 + 4 doses of antiCD20 antibody; second infusion of Treg preparation at time +90±30days Interventions: ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) + Anti-CD20 (rituximab)"
62323290|NCT06688331|EXPERIMENTAL|Tregs only|"Infusion of Treg preparation at day 0 + 4 doses of placebo; second infusion of Treg preparation at time +90±30 days"
62323291|NCT06688331|EXPERIMENTAL|CD20 only|"Infusion of Treg sham at day 0 + 4 doses of antiCD20 antibody; second infusion of Treg sham at time +90±30days"
62323292|NCT06688331|PLACEBO_COMPARATOR|Control group|"Infusion of Treg sham at day 0 + 4 doses of placebo; second infusion of Treg sham at time +90±30days"
62323293|NCT03107780|EXPERIMENTAL|Treatment (MDM2 inhibitor AMG 232 [KRT-232])|See Detailed Description
62323294|NCT02096393|EXPERIMENTAL|Patient specific instrumentation|The patient will undergo using patient specific instrumentation
62738312|NCT01638013|EXPERIMENTAL|Participants who completed 015K-CL-RAJ4|Participants who completed 015K-CL-RAJ4 (NCT02305849) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR \>= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
61929035|NCT06496139|EXPERIMENTAL|Treatment group|Therapist-guided self-help internet-delivered cognitive behavioural therapy for PMDD
61929036|NCT06496139|NO_INTERVENTION|Control group|Waiting list
61929037|NCT05815160|EXPERIMENTAL|Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin|Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
61929038|NCT05815160|EXPERIMENTAL|Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin|Participants will receive Debio 0123 recommended dose determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
61929039|NCT05155059|SHAM_COMPARATOR|Control|Sham TMS stimulation using a sham coil
61929040|NCT05155059|EXPERIMENTAL|Treatment|Active TMS stimulation using an active TMS coil
61929041|NCT04024462|ACTIVE_COMPARATOR|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
62131596|NCT00731237||1|The procedures undergone by this group will be evaluated for: Acute performance, deliverability and resource utilization during the procedure in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience.
62131597|NCT00434304|EXPERIMENTAL|Ropinirole PR/XR|
62323295|NCT02096393|ACTIVE_COMPARATOR|Standard instrumentation|The patient will undergo surgery using standard instrumentation
61929042|NCT04024462|EXPERIMENTAL|Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the PH FDC SC for a total of 18 cycles.
61929043|NCT05601752|EXPERIMENTAL|Autologous genetically modified ADP-A2M4CD8 cells|
61929044|NCT05601752|EXPERIMENTAL|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|
62131598|NCT02680457|ACTIVE_COMPARATOR|Insulin Degludec - Insulin Glargine|Insulin Degludec 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Glargine 10 IU SC every 24 hours for 6 days
62323296|NCT05873452|EXPERIMENTAL|Kaitoh Atherectomy System|Eligible participants will undergo atherectomy using the Kaitoh Atherectomy System.
62323297|NCT02864745|EXPERIMENTAL|Early rehabilitation arm|These patients will receive very early (\<48 hours after ICU admission), protocolised, intensive rehabilitation, which will include functional electrical stimulation-assisted cycle ergometry.
62323298|NCT02864745|ACTIVE_COMPARATOR|Standard-of-care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
62323299|NCT03908138|ACTIVE_COMPARATOR|RDD group|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
61929045|NCT06745830||Invasive LUAD who underwent surgical resection|
61929046|NCT05259085|EXPERIMENTAL|ALXN2050|"Cohort 1: Mild IHR Cohort 2: Moderate IHR Cohort 3: Severe IHR Cohort 4: Healthy Control~Participants will receive ALXN2050"
61929047|NCT06335173|EXPERIMENTAL|Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg|Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period.
61929048|NCT06335173|EXPERIMENTAL|DBT Period: sabirnetug 50 mg/kg|Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period.
62323300|NCT03908138|ACTIVE_COMPARATOR|VDD group|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
62323301|NCT05307289|OTHER|melanoma inclusion|Biopsy of a metastasis allowing melanoma diagnosis and realization of primary cultures for metabolomics. An additional 20ml blood sample will also be taken to quantify circulating metabolites and to isolate PBMC.
62323302|NCT03022305|EXPERIMENTAL|Group one - standard therapy|Standard physical therapy treatment for shoulder and hip malalignment will be administered for one week.
62323303|NCT03022305|EXPERIMENTAL|Group two - neuromuscular therapy|Experimental neuromuscular physical therapy treatment for shoulder and hip malalignment will be administered for one week. This therapy is exercised based.
62323304|NCT03022305|NO_INTERVENTION|Group three - no treatment|No physical therapy treatment will be given to this group.
62323305|NCT02619253|EXPERIMENTAL|Dose Finding Cohort|Estimate the Recommended Phase 2 Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. Patients will be treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in 2 patient cohorts according to the 3 + 3 standard design (100 and 200 mg).
62738313|NCT01404559|ACTIVE_COMPARATOR|Prosthetic foot 1 (Ossur Variflex)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 1 (Ossur Variflex).
61929049|NCT06335173|PLACEBO_COMPARATOR|DBT Period: Placebo|Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period.
61929050|NCT06335173|EXPERIMENTAL|Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg|Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period.
62131599|NCT02680457|ACTIVE_COMPARATOR|Insulin Glargine - Insulin Degludec|Insulin Glargine 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Degludec 10 IU SC every 24 hours for 6 days
62131600|NCT00003834|EXPERIMENTAL|oxaliplatin + leucovorin + fluorouracil|Patients receive oxaliplatin IV over 2 hours on day 1, then leucovorin calcium IV over 2 hours with fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Patients with stable disease continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable. Patients who achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates continue treatment in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a response are treated until best response or until disease is deemed resectable. Patients who achieve a CR or PR and are resected may receive 2 to 4 additional courses of therapy at the discretion of the investigator. Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
62482453|NCT06741410||Phenylephrine|"Cesarean delivery cases where spinal block was administered and hypotension was managed with intravenous phenylephrine infusion~Hospital electronic database will be searched to identify cases of cesarean delivery in years 2020 - 2022. After that, manual review of the medical notes will follow in order to extract cases where spinal block was administered and infusion of phenylephrine was used to treat spinal - related hypotension. Further chart analysis will yield demographic and hemodynamic data of the parturient, as well as clinical data of the neonate (weight, gender, Apgar score).~Further laboratory data on neonatal acid - base status will be acquired from hospital's laboratory electronic database. Attention will be paid to assure that identification of the patients would not be possible using data acquired for the study. All data will be anonymized and accessible only for investigators."
62482454|NCT06493019|EXPERIMENTAL|Pembrolizumab plus carbopltin and paclitaxel|"All patients in the chemoradiation phase will receive a combination of pembrolizumab, carboplatin, and paclitaxel. For the first 6 cycles (a cycle is a week) carboplatin and paclitaxel will be administered by IV every week. Pembrolizumab will be administered by IV on cycles 1 and 4.~The next phase is the maintenance phase. This will occur from cycle 7-14 with each cycle being 6 weeks. Pembrolizumab will be administered every cycle."
62482455|NCT06114095||Disease group|Disease-specific experimental cohort of cardiovascular and neurological diseases (atrial fibrillation secondary to valvular heart disease, carotid atherosclerosis, moyamoya disease)
62482456|NCT06114095||Healthy control group|
62131601|NCT00785915|EXPERIMENTAL|1|
62131602|NCT00785915|PLACEBO_COMPARATOR|2|given (2 subjects in each ethnic/dose group)
62131603|NCT03847259||A(public school)|"it will be consists of 200 adolescent female from public schools, their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire.~pain will be evaluated by VISUAL ANALOG SCALE(VAS) .stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21)."
62323306|NCT02619253|EXPERIMENTAL|Expansion Cohort|Once the Expansion Test Dose is identified, the Dose Expansion Phase will be opened and the combination will be tested in patients with advanced renal cell or urothelial cell carcinoma. Forty-five patients with prior treatments will be enrolled in three expansion cohorts: 15 anti-PD1 naive renal and urothelial patients, 15 anti-PD1 resistant renal and urothelial patients (defined as patients with transient clinical response or without clinical response to prior immune-checkpoint inhibition), and 15 patients with androgen-sensitive or castration-resistant prostate cancer.
62323307|NCT04230486|EXPERIMENTAL|Experimental Group Virtual Reality (VR) Treatment|Visual Auditory Virtual Reality rehabilitation for visual hemianopia
62323308|NCT06692933|EXPERIMENTAL|Arm 1: clopidogrel alone|Participants will be administered a single oral dose (75 mg) of clopidogrel. Blood and urine will be collected for 24 hours.
62482457|NCT06250881||without ocular complication|The normal group was compared with the pathological group
62691194|NCT06638567|EXPERIMENTAL|Basal Bolus|"Patients daily dose of insulin is calculated by their treatment team: In insulin naive patients 0.4-0.5IU/kg and 0,3IU/kg for patients aged\>70 or patients with impaired kidney function with an estimated glucose filtration rate \<60ml/min and 80-100% of own insulin for insulin-users. They receive half of this daily dose in long-acting insulin once a day. The other half of their total daily dose of insulin is provided as short-acting mealtime insulin. This short-acting insulin is administered before each meal. When needed, extra insulin can be given when needed.~The measurements of blood glucose values are before each meal and at bedtime (4x/day)."
62131604|NCT03847259||B(international school)|it will be consists of 200 adolescent female from international schools their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire .pain will be evaluated by VISUAL ANALOG SCALE (VAS).stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21).
62131605|NCT03251222|EXPERIMENTAL|Dexmedetomidine group|Patients who will receive Dexmedetomidine intranasal prior the sedation with remifentanil
62131606|NCT03251222|PLACEBO_COMPARATOR|Placebo Concentrate|Patients will recive 0.9% NaCl
62131607|NCT01261052|ACTIVE_COMPARATOR|FMPD/APD intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the first 13 hours, the original artificial pancreas algorithm FMPD, will be used to control the subject's blood glucose. After 13 hours, the adaptive component or APD will be used to control the subject's blood glucose for the remaining 20 hours.
62131608|NCT01261052|ACTIVE_COMPARATOR|APD only intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the entire study, the adaptive component or APD will be used to control the subject's blood glucose.
62131609|NCT05736133|EXPERIMENTAL|Physiotherapist-led primary care model for hip and knee pain|The index intervention will incorporate a PT within the primary care team and make them available at the first point of contact for people with hip or knee pain. There will be 4 key components of this intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need (e.g., no insurance coverage for PT).
62131610|NCT05736133|ACTIVE_COMPARATOR|Usual physician-led primary care model for hip and knee pain|Participants will be seen by a primary care physician or a nurse practitioner, depending on the current practice at the clinic. Participants in both groups will be permitted to seek additional care outside of the primary care clinic.
62323309|NCT06692933|EXPERIMENTAL|Arm 2: chronic hemp (30 mg CBD) + clopidogrel|Participants will self-administer a single low dose of hemp (30 mg CBD) as an oral softgel at home daily for 5 consecutive days. On day 6, participants will return to the research setting, where they will be administered a single low dose of hemp (30 mg CBD) and a single oral dose of clopidogrel (75 mg). Blood will be collected for 72 hours and urine will be collected for 24 hours.
62482458|NCT06250881||fundus opportunistic infections|AIDS patients are prone to opportunistic fundus infection, which show a characteristic changes in fundus photography. It was designed to describe the characteristics of this group of patients.
62482459|NCT06250881||Microvascular disease|Microvascular disease is an early characteristic of fundus changes in AIDS patients, with characteristic changes in fundus photography.
62482460|NCT06250881||uveitis|The uveitis patients in this study were mainly caused by treponema pallidum infection.
61929051|NCT06745635|OTHER|Usual Care Group|This arm will continue to follow the routine activities and standard procedures established by the public health system.
61929052|NCT06745635|OTHER|Multifaceted Intervention Group|"This group will implement a multifaceted quality improvement and process strategy composed of:~Video-based training on vaccine management. Development of an optimized Cold Chain Manual, streamlining guidelines for vaccine handling.~Technical documents providing comprehensive guidance on the appropriate management of vaccines and their respective immunization schedules.~Technical documents addressing the management of errors identified post-vaccination and offering recommendations for public guidance"
61929053|NCT03206099||Biological relatives|Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
61929054|NCT03206099||Healthy volunteers|Select internal controls
61929055|NCT03206099||Probands|Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
61929056|NCT06451250|EXPERIMENTAL|Adult Day Services|Adult Day Service use for family member with dementia
61929057|NCT06499805|ACTIVE_COMPARATOR|AUD (audiologist-based)|In this group, the audiologist-based fitting will be used to provide prescription hearing aids.
62131611|NCT00419341|EXPERIMENTAL|IgPro20|Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
62131612|NCT04700189|EXPERIMENTAL|Treatment with Streamline following cataract surgery|Treatment with Streamline System following phacoemulsification
62131613|NCT02226536|PLACEBO_COMPARATOR|control|Usual diet without any orientation
62131614|NCT02226536|ACTIVE_COMPARATOR|fractioned diet without glucose|Fractioned diet without glucose
62131615|NCT03813498|EXPERIMENTAL|intervention group|
62691195|NCT06638567|NO_INTERVENTION|Sliding Scale|Short-acting insulin is administered when blood glucose value is above 10,0 mmol/L according to a standardized dosage schedule. The measurements of blood glucose values are before each meal and at bedtime (4x/day).
62323310|NCT06692933|EXPERIMENTAL|Arm 3: chronic hemp (240 mg CBD) + clopidogrel|Participants will repeat the Arm 2 procedures using a higher dose of hemp (240 mg CBD)
62323311|NCT04821622|EXPERIMENTAL|Arm 1|Talazoparib plus enzalutamide
62691196|NCT00837122||Control|Control subjects are nondiabetics ethnically matched to patients
62691197|NCT00837122||T2D|Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
62131616|NCT03813498|OTHER|control group|
62131617|NCT04255290|EXPERIMENTAL|Experimental group|Leg Squat Lounge: The player will be placed in squat position and her partner will be placed behind, suspending the most posterior leg in the air. With the leg that is supported, you will perform a monopodal jump with controlled fall, supporting the foot from tip to heel. It will be done with both lower limbs performing 1 series of 5 repetitions with 30 seconds of rest between sets. 180 jump: The footballer will start in bipodal support, with the trunk erect and hands on the hips. Perform a bipodal jump with a 180º turn during this, keeping the fall for 2 seconds. Each repetition, the turn will be done in a different sense. It will carry out 2 series of 20 sec of execution with 20 sec of rest between series. Brad jump stick landing: The player will stand in hands-free standing. Perform a bipodal jump as far as possible. The knees will not exceed the tip of the foot and the fall will be with a trunk position as straight as possible. He will make 5 jumps the first two weeks.
62323312|NCT04821622|ACTIVE_COMPARATOR|Arm 2|Placebo plus enzalutamide
62323313|NCT02092740||Seminoma|Seminoma
62323314|NCT02092740||Non-Seminoma|Non-Seminoma
62323315|NCT01820689|EXPERIMENTAL|Tympanometry measurement|
62323316|NCT02122861|EXPERIMENTAL|ID-LV305|Dose escalation and expansion cohort including treatment of melanoma
62738314|NCT01404559|ACTIVE_COMPARATOR|Prosthetic foot 2 (Ossur Ceterus)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 2 (Ossur Ceterus).
62323317|NCT03378011|ACTIVE_COMPARATOR|UVA1 phototherapy|UVA1 phototherapy in acral vitiligo
62323318|NCT03378011|ACTIVE_COMPARATOR|Topical PUVA|Topical PUVA in acral vitiligo
62482461|NCT01747668|PLACEBO_COMPARATOR|Control Supplement|soft-gel placebo capsules, 2 capsules from the placebo bottle per day
62738315|NCT01404559|ACTIVE_COMPARATOR|Prosthetic foot 3 (Endolite Elite Blade)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 3 (Endolite Elite Blade).
61929058|NCT06499805|EXPERIMENTAL|OTC (over-the-counter)|In this group, over-the-counter fitting will be used to provide over-the-counter hearing aids.
61929059|NCT03937830|EXPERIMENTAL|1/Arm 1|Durvalumab, bevacizumab and tremelimumab
61929060|NCT03937830|EXPERIMENTAL|2/Arm 2|Durvalumab, bevacizumab, tremelimumab and TACE
61929061|NCT03937830|EXPERIMENTAL|3/Arm 3|Durvalumab, low-dose bevacizumab, and tremelimumab
61929062|NCT06137144|EXPERIMENTAL|Module 1: Part A (Dose Escalation) and Part B (Dose Expansion/Optimization)|"In Part A, participants with Relapsed/Refractory classical Hodgkin Lymphoma (cHL) will take AZD3470 tablets orally until PD, unacceptable toxicity, or withdrawal of consent.~In Part B, adult and adolescent participants with r/r cHL will take AZD3470 tablets orally until PD, unacceptable toxicity, or withdrawal of consent."
61929063|NCT06502561|EXPERIMENTAL|Subjects receiving a single 400 mg dose of Aramchol meglumine in Period 1|A single 400 mg dose of Aramchol meglumine will be administered to all study subjects in Period 1.
62323319|NCT06692634|EXPERIMENTAL|Group 1|Reduce tidal volume from 7 ml/kg to 5 ml/kg. Set end-inspiratory pause. respiratory rate reduction until 20% of the basal condition, together with a new increase in end-inspiratory pause.
62323320|NCT06692634|EXPERIMENTAL|Group 2|Reduce tidal volume from 7 ml/kg to 5 ml/kg. Set end-inspiratory pause. respiratory rate reduction until 20% of the basal condition, and after that, will be set a new increase in end-inspiratory pause.
62323321|NCT02674581|EXPERIMENTAL|Healthy Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
62323322|NCT02674581|EXPERIMENTAL|Mild Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
62482462|NCT01747668|EXPERIMENTAL|Experimental Supplement A|soft-gel capsules; 1 capsule from the experimental bottle and 1 capsule from the placebo bottle per day
62323323|NCT02674581|EXPERIMENTAL|Moderate Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
62323324|NCT02674581|EXPERIMENTAL|Severe Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
62323325|NCT02674581|EXPERIMENTAL|End Stage Renal Disease Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
62323326|NCT06684769|EXPERIMENTAL|Chitosan brush with Emdogain FL|Furcation Involved areas will be treated with the oscillating chitosan brush Labrida BioClean® and Straumann® Emdogain® FL at Baseline
62482463|NCT01747668|EXPERIMENTAL|Experimental Supplement B|soft-gel capsules; 2 capsules from the experimental bottle per day
62482464|NCT04633564|EXPERIMENTAL|MYL-1402O|"Patients will begin Period 1 receiving bevacizumab combination therapy (MYL-1402O15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as MYL-1402O ).~In Period 2, eligible patients will continue to receive bevacizumab ( MYL- 1402O) every 3 weeks as monotherapy."
62482465|NCT04633564|ACTIVE_COMPARATOR|Avastin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin).~In Period 2, eligible patients will continue to receive bevacizumab (Avastin) every 3 weeks as monotherapy."
62482466|NCT01018862|ACTIVE_COMPARATOR|MP03-36 (0.15% solution)|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
62482467|NCT01018862|ACTIVE_COMPARATOR|MP03-33 (0.10% solution)|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
61929064|NCT06502561|ACTIVE_COMPARATOR|Subjects receiving a second dose of Aramchol meglumine or Aramchol free acid in Period 2|In Period 2, study subjects will be randomized 1:1 to receive Aramchol meglumine or 300 mg tablet of Aramchol free acid (Reference)
61929065|NCT06502561|ACTIVE_COMPARATOR|Subjects receiving a second dose of Aramchol meglumine or Aramchol free acid in Period 3|In Period 3, study subjects will be randomized 1:1 to receive Aramchol meglumine or 300 mg tablet of Aramchol free acid (Reference)
61929066|NCT06567119|ACTIVE_COMPARATOR|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs)
61929067|NCT06567119|PLACEBO_COMPARATOR|Placebo|Sterile isotonic solution
61929068|NCT05692960|EXPERIMENTAL|Hypnotic Relaxation Intervention (HRI)|"The hypnotic relaxation intervention consists of three different audio files, each about 20 minutes in length. These three hypnotic inductions build upon each other. The first hypnotic induction audio focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second hypnotic induction audio focuses more specifically on body image related to sexuality and being a sexual being. The third hypnotic induction audio focuses on sexual desire, passion, and energy. Each hypnotic induction will be used for two weeks, three times per week for a total of six weeks of hypnosis.~The vaginal moisturizer component of this arm is the same as that described for the VVA study arm."
61929069|NCT05692960|OTHER|Vulvovaginal Atrophy (VVA)|This study arm might best be described as standard of care. Vulvovaginal dryness will be treated with a daily moisturizer for two weeks, then every other day for the remaining six weeks. Vaginal moisturizer will be applied at night, before sleep and after all sexual activity. Several moisturizers are available, including vaginal DHEA (IntraRosa®). Due to the need for reproducibility, we have decided to use one non-hormonal vaginal moisturizer, Replens™ moisture, which is a vaginal moisturizer consisting primarily of a purified water, glycerin, and mineral oil. Other ingredients included in the formulation are polycarbophyl, carbomer, homopolymer type B, hydrogenated palm oil glyceride, sorbic acid, sodium hydroxide. The moisturizing gel was determined to be a medical device for marketing by the FDA in 2010. It is non-hormonal (unlike vaginal DHEA) and therefore will be more likely to be acceptable by a broader range of oncology providers.
61929070|NCT06317285|EXPERIMENTAL|GSK3915393|Participants will receive GSK3915393
61929071|NCT06317285|EXPERIMENTAL|Placebo|Participants will receive placebo.
61929072|NCT06312553|EXPERIMENTAL|Experimental: Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring|"The Mindfulness-Based Diabetes Education (MBDE) program will be delivered in 8, 2-hour weekly sessions, then 2 booster sessions, total duration of 6 months. MBDE will be delivered over Zoom with content delivered by the interventionist per the program manual. Participants will be provided with a tablet and WIFI hotspot. Sessions will be video-recorded and made available to participants in case of missed sessions.~Once randomized, participants will receive a glucometer and test strips; supplies will be delivered to their homes within 7 days of randomization. Study team will review the use of the device. Participants will be instructed to monitor blood glucose 4 times a day. Data collected will be transmitted electronically to the remote patient monitoring system and monitored from 8 a.m. to 5 p.m. on weekdays. Data summaries will be reviewed bimonthly, and clinical summaries will be sent to clinicians."
62323327|NCT06684769|SHAM_COMPARATOR|Chitosan brush alone|Furcation Involved areas will be treated with the oscillating chitosan brush Labrida BioClean® at Baseline
62323328|NCT02654327|NO_INTERVENTION|Standard Care|Standard care with conventional lung protective mechanical ventilation
62323329|NCT02654327|EXPERIMENTAL|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
62482468|NCT01018862|PLACEBO_COMPARATOR|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
62738316|NCT01404559|NO_INTERVENTION|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
62738317|NCT04248244|EXPERIMENTAL|Early Palliative Care Integration|12 months of PC with concurrent standard treatment for MM, QOL assessments
62323330|NCT00647777|EXPERIMENTAL|1|Olanzapine Tablets 5 mg
62323331|NCT00647777|ACTIVE_COMPARATOR|2|Zyprexa® Tablets 5 mg
62323332|NCT06260176|EXPERIMENTAL|Green labels|"green label added to healthy product slots; no additional labels shown for less healthy products and 1 poster per machine explaining the labels"
62323333|NCT06260176|EXPERIMENTAL|Traffic light labels|red/yellow/green labels added to slots for less healthy/moderately healthy/healthy products, respectively and 1 poster per machine explaining the labels
61929073|NCT06312553|ACTIVE_COMPARATOR|Standard Diabetes Self Management Education|Standard DSME will be delivered by a certified diabetes educator in four biweekly sessions of 2 hours duration; topics will include healthy eating, physical activity, medication usage, self-monitoring, preventing and managing complications, healthy coping, and problem solving.18 Standard DSME will be delivered in groups of 8-12 participants via Zoom.
61929074|NCT06449287|EXPERIMENTAL|Ketogenic Diet|Participants will have all their meals prepared in the Instructional Kitchen in the Ohio Union, irrespective of group assignment. They will receive a daily caloric intake equal to 75% of their estimated requirement to maintain weight, which should result in weight loss over the 6-week period. For those in the ketogenic groups, daily macronutrient intake will consist of 35 g of carbohydrates and moderate protein calculated as 1.5 g/kg of reference weight. The remaining caloric intake will consist of fat. A wide range of whole foods will be incorporated into the meals, including non-starchy vegetables, meats, nuts and seeds, oils, cheese, butter, cream, and eggs. The menu will be shared with participants prior to enrolling in the study so they know what to expect in terms of the meal plans.
61929075|NCT06449287|EXPERIMENTAL|Ketogenic Diet + Ketone Salt|Participants will have all their meals prepared in the Instructional Kitchen in the Ohio Union, irrespective of group assignment. They will receive a daily caloric intake equal to 75% of their estimated requirement to maintain weight, which should result in weight loss over the 6-week period. For those in the ketogenic groups, daily macronutrient intake will consist of 35 g of carbohydrates and moderate protein calculated as 1.5 g/kg of reference weight. The remaining caloric intake will consist of fat. A wide range of whole foods will be incorporated into the meals, including non-starchy vegetables, meats, nuts and seeds, oils, cheese, butter, cream, and eggs. The menu will be shared with participants prior to enrolling in the study so they know what to expect in terms of the meal plans. This group will also be provided a ketone salt supplement to take x2 daily.
61929076|NCT06449287|ACTIVE_COMPARATOR|Low Fat Diet +Placebo|The low-fat comparison group will also be provided all their food. Their diet will also be restricted in calories and have the same level of protein, but it will be lower in fat and higher in carbohydrate. The low-fat diet will consist of approximately 25% fat, with the remaining calories coming from carbohydrates (approximately 55% after accounting for protein at around 20%). Added sugars will be kept relatively low (less than 25 g/day) with a focus on unprocessed carbohydrate-rich foods. Saturated fat will be limited to less than 10% of total energy, with a focus on unsaturated fat sources.
61929077|NCT03328455|EXPERIMENTAL|Inhibitory control training|"In the inhibitory control training condition, participants will be trained with tasks that involve both response withholding and rule switching. For example, participants will sort polygons based on features (e.g., shape or color) and will be asked to either provide or withhold sorting responses when presented with different cues. Rule-switching is introduced when participants must inhibit the rule used in the previous trial set and change the focus of their attention to a new sorting and/or inhibitory rule. Task difficulty will progressively increase over the course of training based on participants' abilities."
61929078|NCT03328455|SHAM_COMPARATOR|knowledge-based training|The knowledge-based training condition serves as the control, in which participants will be presented with questions from different categories such as vocabulary, science, or geography and asked to select the correct answer from 4 alternatives within a certain time limit. Task difficulty will progressively increase over the course of training based on participants' abilities.
61929079|NCT05574114|EXPERIMENTAL|Radiation Therapy Before CAR T Cell Therapy|For the purposes of this protocol, day 0 will be considered the date of planned CAR T infusion. BRT Part I (intervention is 9 fractions of 3 Gy to a total dose of 27 Gy). Post-BRT Phase I re- evaluation period: Following delivery of the first 9- fractions of BRT, patients will have a period for recovery, and undergo protocol-mandated reassessment (e.g., PET scan and biopsy). Patients will receive standard of care lymphodepleting chemotherapy. Substitutions to the lymphodepleting regimen will be permitted at the discretion of the treating investigator. Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy). Day -1: No protocol scheduled treatment interventions. Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product, as an inpatient or outpatient, at the discretion of the treating investigator.
61929080|NCT06745739|EXPERIMENTAL|Intervention|Received the Life Skills Training Workplace Prevention Program
61929081|NCT06745739|NO_INTERVENTION|Control|Did not receive the Life Skills Training Workplace Prevention Program
61929082|NCT06745947|EXPERIMENTAL|Episodic Future Thinking App|EFT is a behavioral economic intervention designed to improve decision-making by reducing delay discounting and improving demand. The EFT intervention will be administered through a combination of in-person counseling sessions and mobile health (mHealth) technology via an app platform.
61929083|NCT06745947|NO_INTERVENTION|Control Group|Standard of Care: The standard of care group will receive brief information and supportive counseling around PrEP adherence, methamphetamine use reduction and engaging in safe sexual behaviors. Participants will also receive counseling on a topic of concern identified by the participant.
61929084|NCT06149520|EXPERIMENTAL|BAY3018250 Dose 1|Participants will receive BAY3018250 Dose 1.
61929085|NCT06149520|EXPERIMENTAL|BAY3018250 Dose 2|Participants will receive BAY3018250 Dose 2.
61929086|NCT06149520|PLACEBO_COMPARATOR|Placebo to BAY3018250|Participants will receive placebo to BAY3018250.
61929087|NCT06741384|ACTIVE_COMPARATOR|Diaphragmatic breathing exercises group|30 women participating in diaphragmatic breathing plus aerobic training.
61929088|NCT06741384|ACTIVE_COMPARATOR|Control group|30 women participating in aerobic training only.
61929089|NCT02986516|EXPERIMENTAL|Randomized Cohort|Participants who will decided to undergo to randomization, will receive surgical treatment or definitive radiotherapy according with randomization assignment
61929090|NCT02986516|ACTIVE_COMPARATOR|Prospective Cohort|Participants who will not decide to be randomized, will received the surgical or definite radiotherapy treatment according to their choice
61929091|NCT05861427|EXPERIMENTAL|Atogepant Dose A|Participants will receive atogepant dose A once daily (QD) for 24 weeks.
62323334|NCT06260176|EXPERIMENTAL|Physical activity calorie equivalent labels|labels added to slots that display products' calorie content in terms of physical activity required to burn those calories and 1 poster per machine explaining the labels
62323335|NCT06260176|EXPERIMENTAL|Sweetened beverage tax posters|1 poster per machine; no labels; posters reminded consumers of the Philadelphia sweetened beverage tax and encouraging healthier choices
62323336|NCT02956174|EXPERIMENTAL|Co-Cr single crown|Co-Cr single crown
62482469|NCT03053362|EXPERIMENTAL|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
62482470|NCT03053362|OTHER|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
62482471|NCT04884308|EXPERIMENTAL|Cystic Fibrosis|Participants with Cystic Fibrosis.
62482472|NCT04884308|EXPERIMENTAL|Non Cystic Fibrosis Bronchiectasis|Participants with Non Cystic Fibrosis Bronchiectasis.
62482473|NCT04884308|ACTIVE_COMPARATOR|Healthy Volunteer|Participants with no condition (healthy volunteers).
62482474|NCT02070783|EXPERIMENTAL|ARA290|11-amino acid, linear peptide ARA290; intravenous injection with 2 mg ARA290 (single dosage).
62482475|NCT02070783|PLACEBO_COMPARATOR|Placebo|saline (NaCl 0.9%)
62691198|NCT05335434|EXPERIMENTAL|INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT|"The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations. Participants will receive the study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first~-THOR LX2.3 with LED Lollipop"
61929092|NCT05861427|EXPERIMENTAL|Atogepant Dose B|Participants will receive atogepant dose B QD for 24 weeks.
62131618|NCT04255290|ACTIVE_COMPARATOR|Control group|"Nordic Funds: One player will stand on her knees, while the other, behind, fixes her legs. The kneeling footballer must drop forward in a controlled manner until she touches the ground and returns to the starting position. The Diver: Player in monopodal support on the lower limb to work, performing hip flexion with the arms forward and the opposite lower limb back, looking for a horizontality in the pelvis (with 10º-20º knee flexion) It will be done with both lower limbs.~The Glider: With the footballer standing in front of her partner, holding both of them by the shoulders, she lets one leg slide back while the other stays fixed. To return to the starting position, it will be helped by the other player, while the knee will not exceed 10 degrees of flexion. The distribution of all the exercises will be: 2 sets of 5 repetitions with 20 sec rest between sets"
62323337|NCT02956174|ACTIVE_COMPARATOR|Contralateral sound tooth|Contralateral sound tooth
62323338|NCT01255397|EXPERIMENTAL|Male Infertility Protocol|
62323339|NCT02269059|EXPERIMENTAL|GT1 Participants|Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
62482476|NCT00421304|PLACEBO_COMPARATOR|Placebo|Participants will receive a single intravenous (IV) dose of placebo matched to motavizumab on Day 0 of the study.
62482477|NCT00421304|EXPERIMENTAL|Motavizumab 30 mg/kg|Participants will receive a single IV dose of motavizumab 30 mg/kg on Day 0 of the study.
62482478|NCT00421304|EXPERIMENTAL|Motavizumab 100 mg/kg|Participants will receive a single IV dose of motavizumab 100 mg/kg on Day 0 of the study.
62482479|NCT05437068|EXPERIMENTAL|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
62323340|NCT02269059|EXPERIMENTAL|GT3 Participants|Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
62691199|NCT04029662|EXPERIMENTAL|Group Valsalva Maneuver|Patients who undergo spinal anesthesia and perform Valsalva maneuver to reduce the pain intensity
62691200|NCT04029662|NO_INTERVENTION|Group Control|Patients who undergo spinal anesthesia and perform nothing to reduce the pain intensity
62691201|NCT04537156|EXPERIMENTAL|HPV vaccine (6,11,16,18,31,33,45,52,58 Types)|Participants in this arm would receive 270μg/0.5ml HPV vaccines (6,11,16,18,31,33,45,52,58 Types).
62738318|NCT02649959|EXPERIMENTAL|Open Label|CM-AT
62738319|NCT05582395|EXPERIMENTAL|Mavacamten|
61929093|NCT05861427|EXPERIMENTAL|Atogepant Dose C|Participants will receive atogepant dose C QD for 24 weeks.
62131619|NCT04806529|EXPERIMENTAL|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|The experimental group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
62131620|NCT04806529|PLACEBO_COMPARATOR|The Comparator Group - Placebo|The comparator group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
62131621|NCT01363492|EXPERIMENTAL|Replagal 0.2 mg/kg every other week (EOW)|
62131622|NCT05342233||Endovascular treatment Group|Patients receiving endovascular treatments
62691202|NCT04537156|ACTIVE_COMPARATOR|HPV vaccine (16,18 Types)|Participants in this arm would receive 60μg/0.5ml HPV vaccines (16,18 Types).
61929094|NCT05861427|EXPERIMENTAL|Placebo|Participants will receive placebo QD for 12 weeks. Participants will be re-randomized at week 12 to receive atogepant dose A, dose B or dose C QD for 12 weeks.
61929095|NCT01519154|ACTIVE_COMPARATOR|Propofol|Propofol 10 mg/h as maintenance infusion
61929096|NCT01519154|EXPERIMENTAL|Ketamine-Propofol|Additional Ketamine at induction, Propofol 5 mg/h as maintenance infusion
61929097|NCT05093478|EXPERIMENTAL|Treatment|
61929098|NCT04404569|EXPERIMENTAL|Continued Treatment|"Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study.~The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose."
61929099|NCT05698459|EXPERIMENTAL|OH2|Administration：intratumoral injection Frequency：once every 3 weeks
62691203|NCT05102448|EXPERIMENTAL|Tofacitinib|Partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
61929100|NCT06003426|EXPERIMENTAL|BMS-986278 Dose 1|
61929101|NCT06003426|EXPERIMENTAL|BMS-986278 Dose 2|
61929102|NCT06003426|PLACEBO_COMPARATOR|BMS-986278 Placebo|
61929103|NCT03623074|EXPERIMENTAL|Test Arm 1|Single vision, impact-resistant spectacle lenses
61929104|NCT03623074|EXPERIMENTAL|Test Arm 2|Single vision, impact-resistant spectacle lenses
61929105|NCT03623074|OTHER|Test Arm 3|Single vision, impact-resistant spectacle lenses
62691204|NCT05102448|ACTIVE_COMPARATOR|Methotrexate|Participates would be given tablets of methotrexate (2.5mg per tablet) 15mg each week, the treatment duration will last 12 months during the whole follow-up period.
62691205|NCT04494698|ACTIVE_COMPARATOR|DuoTherm VibraCool Back Device|A low back pain relief device incorporating multiple speeds and patterns of vibration and optional heat, cold, or pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice daily for 20 minutes.
62691206|NCT04494698|ACTIVE_COMPARATOR|Multimodal TENS Unit|LG SMART TENS stimulator is a portable electrotherapy device featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
62738320|NCT05582395|PLACEBO_COMPARATOR|Placebo|
61929106|NCT05595499|EXPERIMENTAL|Arm A (fisetin)|Patients receive fisetin PO on days 1, 2, and 3. Treatment repeats every 2 weeks for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples throughout the trial.
61929107|NCT05595499|PLACEBO_COMPARATOR|Arm B (placebo)|Patients receive placebo PO on the trial. on days 1, 2, and 3. Treatment repeats every 2 weeks for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples throughout the trial.
61929108|NCT05067634|EXPERIMENTAL|12 to < 18 year olds|
61929109|NCT05067634|EXPERIMENTAL|6 to <12 years old|
61929110|NCT05067634|EXPERIMENTAL|4 to <6 years old|
61929111|NCT05067634|EXPERIMENTAL|2 to <4 years old|
61929112|NCT05109351|EXPERIMENTAL|Participating to Boost Meal Participation|Intervention group will receive marketing and communication strategies developed by researchers, community organizations, parents, school nutrition directors, and other school stakeholders.
61929113|NCT05109351|NO_INTERVENTION|Control|Usual care.
61929114|NCT05708352|EXPERIMENTAL|Keto-Diet|Intensive 18-week Keto Diet intervention.
61929115|NCT05708352|PLACEBO_COMPARATOR|Standard Anti-Cancer Diet|Standard Anti-Cancer Diet with Dietitian support
61929116|NCT05325034|ACTIVE_COMPARATOR|Early intervention|Participants randomised to 'early' will receive the intervention at baseline through 6 months. while those randomised to 'late' will receive standard-of-care and represent a control arm over this period.
61929117|NCT05325034|OTHER|Late intervention|Those randomised to 'late' will receive standard-of-care and represent a control arm to the early intervention group.
61929118|NCT03592693|EXPERIMENTAL|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
61929119|NCT03592693|PLACEBO_COMPARATOR|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
61929120|NCT06422806|EXPERIMENTAL|Arm A (doxorubicin and pembrolizumab|Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA scan, standard imaging scans and blood sample collection throughout the study.
62482480|NCT04432636|OTHER|Prospective French population based cohort|"* Data collection of environmental factors at the recruitment~* Collection of maternal feces~* Collection of infant feces:~* A food questionnaire completed by the mother the week after delivery, a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year and a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years~* A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day~* The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up"
62482481|NCT01302548|EXPERIMENTAL|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
62482482|NCT01302548|ACTIVE_COMPARATOR|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
62482483|NCT01609257|EXPERIMENTAL|Norovirus Bivalent VLP Vaccine|Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.
62482484|NCT01609257|PLACEBO_COMPARATOR|Placebo|Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.
62482485|NCT00402103|EXPERIMENTAL|Aliskiren/Amlodipine|
61929121|NCT06422806|ACTIVE_COMPARATOR|Arm B (doxorubicin)|Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. At time of disease progression, patients may begin receiving pembrolizumab alone IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of additional progression or unacceptable toxicity. Patients also undergo ECHO or MUGA scan, standard imaging scans and blood sample collection throughout the study.
61929122|NCT06744075|OTHER|CELERITY Arm|CT DNA Collection at baseline, mid-treatment and at the end of treatment
61929123|NCT05848284|EXPERIMENTAL|VDyne System Treatment Arm|Device
62323341|NCT06586320|OTHER|ON, One visit|"Subject visit one time at clinic for tests and assessments. Subject type are Essential Tremor (ET), Healthy Control (HC) or Idiopathic Parkinson's Disease (IPD).~The first arm will include the majority of subjects that will be enrolled in a onetime only study procedure performance. Subjects of this arm will carry the diagnosis of IPD, ET, or HC. After the completion of their first research visit and completing study procedures, there will be no future visits or procedures."
62323342|NCT06586320|OTHER|OFF/ON|"Subject visit one time at clinic for tests and assessments without medication, carry out tests and assessments, then take medication according to the protocol, then carry our tests and assessments.~Subject type are Idiopathic Parkinson's Disease."
62323343|NCT06586320|OTHER|ON, Longitudinal|IPD subjects will be asked to repeat the study visit and procedures every 6 months for longitudinal monitoring.
62323344|NCT06674096|EXPERIMENTAL|RLC-CRCHOP|"Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11"
62323345|NCT03959540||Cohort 1|Standard of care (including L-DOPA) + starting opicapone
62323346|NCT03959540||Cohort 2|Standard of care (including L-DOPA)
62482486|NCT00402103|EXPERIMENTAL|Aliskiren/Amlodipine/HCTZ|
61929124|NCT06057038|EXPERIMENTAL|Monotherapy (non-CNS Malignant Solid Tumors): GEN1042|
61929125|NCT06057038|EXPERIMENTAL|Combination Therapy Cohort 1 [HNSCC]: GEN1042+Pembro+Chemotherapy|
62482487|NCT01367054|EXPERIMENTAL|Metformin|500 mg
62482488|NCT04056585|EXPERIMENTAL|Brachial plexus block with intermittent pneumatic compression|Hand and forearm surgery is performed after axillary brachial plexus block with intermittent pneumatic compression for 3 minutes.
62482489|NCT04056585|PLACEBO_COMPARATOR|Brachial plexus block|Hand and forearm surgery is performed after axillary brachial plexus block only.
62482490|NCT06559280|EXPERIMENTAL|experimental group|Use ketamine for postoperative analgesia and intraoperative induction
62482491|NCT06559280|NO_INTERVENTION|control group|Not using ketamine for postoperative analgesia and intraoperative induction
62482492|NCT02332863|ACTIVE_COMPARATOR|Back-loaded needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G back-loaded needle. CRFs will be used to record data for primary and secondary endpoints.
61929126|NCT06057038|EXPERIMENTAL|Combination Therapy Cohort 2 [HNSCC and NSCLC]: GEN1042+Pembro|
61929127|NCT06057038|EXPERIMENTAL|Combination Therapy Cohort 3 [HNSCC]: GEN1042+Pembro+Chemotherapy|
62323347|NCT06017063|EXPERIMENTAL|Intervention arm|Patients and caregivers will participate in support program encompassing six video interventions with the BPI. Both participate in the intervention at the same time and together. The intervention starts within two weeks after start of the radiochemotherapy phase, see also figure 2. Patients and caregivers will receive an invitation link to the Vidyo sessions and can log in together to participate in the sessions.
62482493|NCT02332863|EXPERIMENTAL|Preloaded Needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G preloaded needle. CRFs will be used to record data for primary and secondary endpoints.
62482494|NCT00787124||1|\< 28 weeks gestation, \< 30 days of age, \< 3 previous transfusions
62482495|NCT00787124||2|\< 28 weeks gestation, \>=30 days of age, \>= 3 previous transfusions
62482496|NCT06208358|ACTIVE_COMPARATOR|real tACS|Device: Transcranial Alternating Current Stimulation In recent years, transcranial alternating current stimulation (tACS) has been widely used to regulate brain neural activity and improve cognitive function because of its non-invasive, portable, and easy-to-operate characteristics. tACS can effectively improve 9 cognitive functions, including visual attention, working memory, long-term memory, executive control, fluid intelligence, learning, decision-making, motor learning, and motor memory
62482497|NCT06208358|SHAM_COMPARATOR|sham tACS|Device: Transcranial Alternating Current Stimulation In recent years, transcranial alternating current stimulation (tACS) has been widely used to regulate brain neural activity and improve cognitive function because of its non-invasive, portable, and easy-to-operate characteristics. tACS can effectively improve 9 cognitive functions, including visual attention, working memory, long-term memory, executive control, fluid intelligence, learning, decision-making, motor learning, and motor memory
62482498|NCT05826119|ACTIVE_COMPARATOR|Magnesium sulfate|Before induction, a bolus of 20 mg/kg magnesium sulfate in 100 mL saline was administered for 15 minutes, followed by a continuous infusion of 20 mg/kg/hour until the skin was closed.
62482499|NCT05826119|ACTIVE_COMPARATOR|Placebo|The control group received only 100 ml of saline 15 minutes before induction.
62482500|NCT02589301|EXPERIMENTAL|Pegfilgrastim|Pegfilgrastim (Hematopoietic Growth Factor) injectable solution 6 mg / 0,6mL in a single subcutaneous application.
62482501|NCT02589301|ACTIVE_COMPARATOR|Neulastim (pegfilgrastim)|Neulastim injectable solution 6 mg / 0,6mL in a single subcutaneous application.
62482502|NCT03510923||Patients who underwent an appendectomy|Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
62482503|NCT03510923||Patients who underwent a cholecystectomy|Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
62482504|NCT00216736|PLACEBO_COMPARATOR|1|This group received intravenous phenothiazine treatment for migraine (dosing at physician discretion) plus placebo. Patients and clinicians were blinded.
62482505|NCT00216736|EXPERIMENTAL|2|This group received intravenous phenothiazine migraine treatment (dosage at physician discretion) plus oral dexamethasone 8mg at time of emergency department discharge. Patients and clinicians were blinded.
62482506|NCT05943613|PLACEBO_COMPARATOR|Group B|control group : will receive 2 ml (10 mg) of intrathecal hyperbaric Bupivacaine (0.5%) and another syringe containing 1 ml of Dextrose 5%.
62482507|NCT05943613|ACTIVE_COMPARATOR|Group BC|will receive 2 ml (10 mg) of intrathecal hyperbaric Bupivacaine (0.5%) and another syringe containing Clonidine (30 µg) diluted in Dextrose 5% to a total volume of 1 ml.
61929128|NCT06057038|EXPERIMENTAL|Combination Therapy Cohort 4 [HNSCC and NSCLC]: GEN1042+Pembro|
61929129|NCT05527964||Patients with severe refractory atopic dermatitis|Patients eligible for Dupixent therapy of AD
62131623|NCT05342233||Conservative treatment Group|Patients receiving conservative treatments, including blood pressure control, bowel rest, antithrombotic therapy, nutrition treatment and pain management.
62482508|NCT05943613|ACTIVE_COMPARATOR|Group BN|will receive 2 ml (10 mg) of intrathecal hyperbaric Bupivacaine (0.5%) and another syringe containing Neostigmine (10 µg) diluted in Dextrose 5% to a total volume of 1 ml.
62482509|NCT04640129|ACTIVE_COMPARATOR|TDF group|tenofovir 300mg taken orally per day.
62482510|NCT04640129|EXPERIMENTAL|peg-IFN-α plus TDF group|peg-IFN-α 180ug given subcutaneous injection per week combined with tenofovir 300mg taken orally per day .
62482511|NCT00746395|ACTIVE_COMPARATOR|lubiprostone 24mcg single dose|lubiprostone 24mcg single dose po prior to capsule endoscopy
61929130|NCT05981300||Ages 8-25 with delayed gastric emptying|Participants aged 8-25 with delayed gastric emptying of solids based on gastric emptying scintigraphy
62482512|NCT00746395|PLACEBO_COMPARATOR|Sugar pill|Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
62482513|NCT06556849||Group A: patients oldest than 10 years that wear DIMS lens|myopic patients oldest than 10 years of age that wore Defocus Incorporated Multiple Segments (DIMS) spectacles
62482514|NCT06556849||Group B: patients oldest than 10 years that wear (control group)|myopic patients oldest than 10 years of age that wore single vision spectacle lenses (control group)
62482515|NCT06556849||Group C: patients youngest than 10 years that wear DIMS lens|myopic patients youngest than 10 years of age that wore Defocus Incorporated Multiple Segments (DIMS) spectacles
62482516|NCT06556849||Group D: patients youngest than 10 years (control group)|myopic patients youngest than 10 years of age that wore single vision spectacle lenses (control group)
62482517|NCT01058213|ACTIVE_COMPARATOR|Aerobic training alone|8 weeks of gentle chair (sham) training followed by 8 weeks of interval aerobic training on a stationary bicycle
62482518|NCT01058213|EXPERIMENTAL|Sequential Resistance then Aerobic Training|8 weeks of resistance training of the lower body followed by 8 weeks of interval aerobic training on a stationary bicycle
61929131|NCT05981300||Ages 8-25 with normal gastric emptying|Participants aged 8-25 with normal gastric emptying of solids based on gastric emptying scintigraphy
61929132|NCT06743984|ACTIVE_COMPARATOR|Single shade resin composite technique|Nanohybrid single shade resin composite
61929133|NCT06743815||group|patients subjective for colonoscopy
62131624|NCT04092205|EXPERIMENTAL|Experimental: Treatment|28 days treatment with NBMI 600 mg/day
62482519|NCT01058213|ACTIVE_COMPARATOR|Concurrent resistance and aerobic training|8 weeks of gentle chair (sham) exercise followed by 8 weeks of concurrent resistance training of the lower body and interval aerobic training on a stationary bicycle
62482520|NCT00975754|EXPERIMENTAL|1|Pulmicort pMDI
62482521|NCT00975754|EXPERIMENTAL|2|Budesonide pMDI
62482522|NCT00975754|EXPERIMENTAL|3|Budesonide pMDI + Aerochamber Zero-stat spacer
62482523|NCT00975754|EXPERIMENTAL|4|Pulmicort repulses via Spira Nebuliser
62482524|NCT00975754|EXPERIMENTAL|5|Pulmicort Turbohaler
62482525|NCT05832658|EXPERIMENTAL|EMG-Biofeedback|Mendelsohn maneuver and effortful swallow exercise will be applied through game-based emg-biofeedback to patients with post-stroke dysphagia.
62482526|NCT05832658|ACTIVE_COMPARATOR|Classic Therapy|Mendelsohn maneuver and effortful swallow exercise with only verbal feedback will be applied to patients with post-stroke dysphagia.
62482527|NCT03904381|ACTIVE_COMPARATOR|stand-alone procedure of XEN implantation in phakic eyes|
62482528|NCT03904381|ACTIVE_COMPARATOR|stand-alone procedure of XEN implantation in pseudophakic eyes|
62323348|NCT06017063|NO_INTERVENTION|Control arm|Patients and caregivers randomized to the control group, they will not receive the 6-week intervention by the psycho-oncologist. However, they are still entitled to guideline-based psycho-oncology counseling according to the guideline and local standard if they wish. Subsequently, they will be supported regarding coping with the disease, how to improve their mood, or which strategies are available in dealing with the disease. This conversation will last 30-60 minutes.
62323349|NCT02039336|EXPERIMENTAL|Dacomitinib + PD-0325901|Dacomitinib: oral tablets PD-0325901: oral capsules
62482529|NCT03904381|ACTIVE_COMPARATOR|XEN implantation combined with cataract extraction|
62482530|NCT05564091|ACTIVE_COMPARATOR|Cataract surgery combined with ab-interno canaloplasty|Ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.)
62482531|NCT05564091|OTHER|Control: Cataract surgery|Cataract surgery alone
62482532|NCT03405688|EXPERIMENTAL|Acute transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
62482533|NCT03405688|OTHER|Control - Acute transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
62482534|NCT03405688|EXPERIMENTAL|Chronic transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
62482535|NCT03405688|OTHER|Control - Chronic transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
62482536|NCT03405688|EXPERIMENTAL|Transfusion prior to surgery|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
62482537|NCT03405688|OTHER|Control - Transfusion prior to surgery|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
61929134|NCT06737562|EXPERIMENTAL|ISBCS|Both eyes will be operated on during the same surgical procedure. Surgery will be performed in accordance with the iSBCS (International Society of Bilateral Cataract Surgeons) General Principles for Excellence in ISBCS (Immediate Sequential Bilateral Cataract Surgery) \[12\] by investigating ophthalmic surgeons or co-investigators with at least two years' experience in cataract surgery.
61929135|NCT06737562|ACTIVE_COMPARATOR|DSBCS|Only one eye will be operated on during the first surgiczal procedure. The second eye will be operated on during a second surgical procdure delayed from 3 weeks +/- 1 week. Surgeries will be performed according to current guidelines by investigating or co-investigating ophthalmic surgeons with at least two years' experience in cataract surgery.
61929136|NCT05939427|EXPERIMENTAL|NGAGE tool group|Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
62482538|NCT02278757|PLACEBO_COMPARATOR|Low protein diet (LPD)|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
62482539|NCT02278757|EXPERIMENTAL|High protein diet (HPD)|HPD received a diet with higher protein content (1.34gr/kg body weight). HPD and LPD diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR). Meal replacements (drinks and bars), and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
61929137|NCT05939427|NO_INTERVENTION|Non-Intervention|Will receive usual care standards.
61929138|NCT06743906||uveitis patient|participants will be recruited from the ophthalmology outpatient clinic of Assiut University Hospitals.- Patient with posterior uveitis (infectious or non-infectious posterior uveitis).
61929139|NCT05567406|EXPERIMENTAL|Belumosudil|Participants will receive belumosudil orally, once daily (QD) or twice daily (BID) if they are taking strong CYP3A4 inducers or proton pump inhibitors.
62482540|NCT00371839|ACTIVE_COMPARATOR|Mild Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 20-39 decibels hearing level (dBHL)
62482541|NCT00371839|ACTIVE_COMPARATOR|Moderate Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 40-49 decibels hearing level (dBHL)
62482542|NCT00371839|ACTIVE_COMPARATOR|Moderate-Severe Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz greater than 50 decibels hearing level (dBHL)
62482543|NCT05264597||ACLR group|Patients after ACLR with a standardized followup in the Sport Medicine department
62482544|NCT05264597||Control group|Age and sexe-matches volunteers
62482545|NCT03786172|EXPERIMENTAL|Smoking cessation Intervention|Standardised counseling session + motivational gadget + Nicotine replacement therapy (NRT)
61929140|NCT02466737|EXPERIMENTAL|no axillary surgery|
61929141|NCT02466737|ACTIVE_COMPARATOR|sentinel lymph node biopsy|standard arm in first randomization
61929142|NCT02466737|EXPERIMENTAL|sentinel lymph node biopsy alone|
61929143|NCT02466737|ACTIVE_COMPARATOR|completion axillary lymph node dissection|standard arm in second randomization
61929144|NCT04148833|EXPERIMENTAL|LDE-Paclitaxel|Paclitaxel carried by a lipid nanoparticle (LDE-Paclitaxel)
61929145|NCT04148833|PLACEBO_COMPARATOR|LDE-Placebo|Lipid nanoparticle (LDE)
62339884|NCT03025217|EXPERIMENTAL|TLC Program|The TLC Program consists of one in-person visit with a licensed dietician and biweekly phone coaching sessions. During the program, the dietician will 1) identify specific nutrition goals, 2) review and tailor the education materials to the patient's needs, and 3) set up regular telephone coaching sessions of up to two sessions per month for six months for each patient. Motivational interviewing and nutrition/health coaching will be provided.
62339885|NCT03645772|EXPERIMENTAL|Plyometric exercise|12-week progressive exercise program, consisting of plyometric exercises such as countermovement jump, forward and sideways step-up.
62482546|NCT03786172|ACTIVE_COMPARATOR|Usual care|A 10-second brief advice to quit smoking
62482547|NCT03260686|EXPERIMENTAL|Video Guided Group|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician. In addition the participants will receive a personalised video guide of their exercises, filmed during their therapy session to use for independent practice when back on the ward.
62482548|NCT03260686|NO_INTERVENTION|Treatment as usual|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician
62482549|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
62482550|NCT06056414|EXPERIMENTAL|Energy Resonance by Cutaneous Stimulation|one Energy Resonance by Cutaneous Stimulation session performed before macrobiopsy
62482551|NCT01969123|EXPERIMENTAL|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
62482552|NCT01969123|EXPERIMENTAL|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
62482553|NCT01969123|PLACEBO_COMPARATOR|EVP-6124 Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
62482554|NCT01789463|ACTIVE_COMPARATOR|Self rehabilitation|Self rehabilitation
62482555|NCT01789463|EXPERIMENTAL|Self rehabilitation plus physiotherapy|Self rehabilitation plus physiotherapy
62482556|NCT06015958|ACTIVE_COMPARATOR|Active Comparator: Streptococcus salivarius M18 toothpaste dose 1|Streptococcus salivarius M18 toothpaste containing 1 million cfu/g
61929146|NCT03480906|EXPERIMENTAL|Microdose administration|Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD
62131625|NCT04867824|ACTIVE_COMPARATOR|Control|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
62131626|NCT04867824|EXPERIMENTAL|Case|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure vanilla essential oil (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
62339886|NCT03645772|ACTIVE_COMPARATOR|Resistance exercise|12-week resistance exercise program for the leg muscles (2-4 sets of 8-15 repetitions at 8-15RM, leg press, leg extension, calve extension).
62482557|NCT06015958|ACTIVE_COMPARATOR|Active Comparator: Streptococcus salivarius M18 toothpaste dose 2|Streptococcus salivarius M18 toothpaste containing 10 million cfu/g
62482558|NCT05962476|EXPERIMENTAL|Parkinson's Disease|"Participants will use the vibro-acoustic device 90-120 days for 6 hours at night on the Apollo Neuro setting Sleep and Renew."
62482559|NCT04116957|OTHER|Tracking System|Nurse location data collection using the original NFER system at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
62482560|NCT04116957|OTHER|New Tracking System|Nurse location data collection using the upgraded NFER system at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
62482561|NCT05744232|EXPERIMENTAL|Intervention- Low calorie diet/ Total diet replacement|Participants in the intervention group will be offered a dietitian-delivered intervention over 6 months, similar to the NHS pilot of low calorie diets for type 2 diabetes remission. The intervention starts with 12 weeks of low-energy total diet replacement (approx. 860 kcal/day) in a nutritionally replete package of soups, shakes, and bars. It continues with stepped food reintroduction (maximum 6 weeks) as a low-calorie, nutrient-rich diet personalised to the individual participant circumstances and preferences, and weight maintenance (6 weeks).
62482562|NCT05744232|OTHER|Control- usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded. Participants will be offered an invitation to a 30-45' 1:1 session with the research dietitian at the end of the study to provide help and signposting as required for the management of their diabetes.
62482563|NCT05619692|EXPERIMENTAL|SAGE-718|Participants will receive 1.2mg of SAGE-718 orally once daily for the first 6 weeks Days 1 to 42 \[±2 days\], followed by 0.9 mg of SAGE-718 for the remainder of the Treatment period up to Day 84 Visit \[±7 days\].
62482564|NCT05619692|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo-matching capsule once daily orally throughout the treatment period for up to Day 84.
62482565|NCT02709057|ACTIVE_COMPARATOR|Life-style intervention 1|Life-style intervention in participants with low genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
62482566|NCT02709057|ACTIVE_COMPARATOR|Life-style intervention 2|Life-style intervention in participants with high genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
61929147|NCT03480906|ACTIVE_COMPARATOR|Eyedrop administration|Latanoprost ophthalmic solution administered as an eyedrop
61929148|NCT04318327|EXPERIMENTAL|PHE885 (Part A)|Relapsed and/or refractory multiple myeloma (r/r MM) patients will receive PHE885.
61929149|NCT04318327|EXPERIMENTAL|PHE885 (Part B)|Newly diagnosed multiple myeloma (NDMM) patients will receive PHE885.
62323350|NCT05050630|EXPERIMENTAL|TR2-ICE|All patients eligible for inclusion were treated with TR2-ICE, and the first efficacy evaluation was conducted after the second course of treatment. If the patient can achieve complete response (CR), partial response (PR), and disease stability (SD), the clinical benefit is considered, and the TR2-ICE treatment regimen is continued. The second efficacy assessment was performed after the 4th course of treatment. If patients achieved complete response (CR) or partial response (PR) compared to baseline, the clinical treatment was considered effective and the TR2-ICE treatment regimen was continued. After the completion of six courses of induction chemotherapy, an end-of-course assessment was performed. Patients with CR and PR can choose to undergo autologous hematopoietic stem cell transplantation consolidation therapy, or lenalidomide or Tirelarizin monotherapy or both combination maintenance therapy.
62482567|NCT02709057|NO_INTERVENTION|Control 1|No intervention in participants with low genetic risk score
62482568|NCT02709057|NO_INTERVENTION|Control 2|No intervention in participants with high genetic risk score
62482569|NCT02679729|EXPERIMENTAL|Part A, Dose Level 1|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
61929150|NCT04536831|EXPERIMENTAL|Vitamin D group|Consisted of 48 patients selected on admission via lottery method those will be given Vitamin D mega dose
61929151|NCT04536831|PLACEBO_COMPARATOR|Normal Saline group|Consisted of 48 patients selected on admission via lottery method those will be given Normal saline
61929152|NCT03989167|EXPERIMENTAL|Intervention group|Group receiving the Clinical decision support
62131627|NCT06516107||1 Group of parents of children with diplegic cerebral palsy|Parents of children between the ages of 2 and 4.8 who had been diagnosed with diplegic CP and were in a stable clinical and medical state will be included in this study. However, parents of children with behavioral problems, a history of ongoing heart disease, a botulinum toxin injection within the six months previous to the study, chronic chest disease, significant visual or auditory impairment, or parents with limited literacy will not allowed to participate in the study
62482570|NCT02679729|EXPERIMENTAL|Part A, Dose Level 2|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
62482571|NCT02679729|EXPERIMENTAL|Part A, Dose Level 3|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
62482572|NCT02679729|EXPERIMENTAL|Part A, Dose Level 4|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
61929153|NCT03989167|NO_INTERVENTION|Control group|Group receiving standard care
61929154|NCT05062278|EXPERIMENTAL|Intravenous Vinblastine|Single dose intravenous vinblastine (6mg/m2) in bolous.
61929155|NCT05062278|ACTIVE_COMPARATOR|Oral Hydroxiurea|Patient will recieve oral hydroxiurea at a dose of 50mg/kg/day until response or administration of induction chemotherapy
61929156|NCT05463367|EXPERIMENTAL|Chronic Back Pain with Opioid Use|"Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows:~1. treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid;~2. treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or~3. treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo."
61929157|NCT05463367|EXPERIMENTAL|Chronic Back Pain with Opioid Misuse Disorder|"Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows:~1. treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid;~2. treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or~3. treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo."
61929158|NCT06352333|ACTIVE_COMPARATOR|group A|Cornerpocket supraclavicular ultrasound guided brachial plexus block
61929159|NCT06352333|ACTIVE_COMPARATOR|group B|Parasagital supraclavicular ultrasound guided brachial plexus block
61929160|NCT04643470|EXPERIMENTAL|Zanubrutinib Low Dose|Participants will receive zanubrutinib 40 mg twice daily (BID) for 72 weeks
61929161|NCT04643470|EXPERIMENTAL|Zanubrutinib High Dose|Participants will receive zanubrutinib 160 mg twice daily (BID) for 72 weeks
61929162|NCT04643470|EXPERIMENTAL|Zanubrutinib Medium Dose|Participants will receive zanubrutinib 160 mg once daily (QD) for 72 weeks
61929163|NCT04643470|EXPERIMENTAL|Placebo|Participants will receive placebo to match zanubrutinib for 72 weeks
61929164|NCT04582708|EXPERIMENTAL|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after abdominal surgery.
61929165|NCT01600118|ACTIVE_COMPARATOR|ESWT|Extracorporeal shockwave therapy
61929166|NCT01600118|PLACEBO_COMPARATOR|ESWT Placebo|No extracorporeal shockwave therapy
61929167|NCT06685640|EXPERIMENTAL|prefabricated stainless steel crowns (Group A)|Groups that received prefabricated stainless steel crowns
62131628|NCT03122158|ACTIVE_COMPARATOR|Major depressive disorder|In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
62131629|NCT03122158|ACTIVE_COMPARATOR|Anxiety disorders|In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
62691207|NCT04660682|EXPERIMENTAL|Modified static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the modified cross-body stretching position. Additionally, they will receive standard physiotherapy program.
62691208|NCT04660682|EXPERIMENTAL|Traditional static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the traditional standing cross-body stretching position. Additionally, they will receive standard physiotherapy program.
62691209|NCT04660682|ACTIVE_COMPARATOR|Control Group|The participants in this group will receive sham stretching and standard physiotherapy.
62691210|NCT03546257||EUS|group using conventional WLE and EUS
62691211|NCT03546257||ME-NBI|group using WLE and ME-NBI.
62482573|NCT02679729|EXPERIMENTAL|Part A, Dose Level 5|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
62691212|NCT03615768|EXPERIMENTAL|Adapalene-Clindamycin Combination Gel|
62691213|NCT03615768|ACTIVE_COMPARATOR|Adapalene Gel|
62323351|NCT02726750||Observational (biospecimen collection)|Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
62691214|NCT03615768|ACTIVE_COMPARATOR|Clindamycin Gel|
62691215|NCT06690255|EXPERIMENTAL|Spanish PRT Online|Participating parents will receive access to a 12-week online course designed to teach Pivotal Response Treatment (PRT) strategies in Spanish. The course includes 10 instructional lessons and check-ins with a researcher via secure videoconference.
62691216|NCT01690325|EXPERIMENTAL|Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.|Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.
62691217|NCT01690325|EXPERIMENTAL|Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid|Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.
62691218|NCT01652404|EXPERIMENTAL|Procalcitonin-guided treatment|The duration of antibiotics will be determined by the procalcitonin levels.
61929168|NCT06685640|EXPERIMENTAL|Prefabricated zirconia crowns (Group B)|Groups that received prefabricated zirconia crowns
61929169|NCT03359239|EXPERIMENTAL|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
61929170|NCT03759288|EXPERIMENTAL|(Stage 1) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
61929171|NCT03759288|EXPERIMENTAL|(Stage 1) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
62323352|NCT04145297|EXPERIMENTAL|Treatment: all patients|"Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily.~Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level. Both medications will be administered in 28-day cycles"
62323353|NCT02653378|ACTIVE_COMPARATOR|DIET ARM|A 25% energy depletion (daily for 3 days) induced by reducing the amount of energy intake that would otherwise keep the individual in energy balance.
62482574|NCT02679729|EXPERIMENTAL|Part A, Dose Level 6|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
62482575|NCT02679729|EXPERIMENTAL|Part A, Dose Level 7|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
62691219|NCT01652404|ACTIVE_COMPARATOR|Conventional treatment|The duration of antibiotics will be determined by the treating physician.
62691220|NCT03308331|EXPERIMENTAL|HIV-1 smokers|
62691221|NCT03308331|NO_INTERVENTION|HIV-1 nonsmokers|
62691222|NCT03308331|ACTIVE_COMPARATOR|Healthy control smokers|
62691223|NCT03308331|NO_INTERVENTION|Healthy control nonsmokers|
61929172|NCT03759288|PLACEBO_COMPARATOR|(Stage 1) Placebo|Intravenous placebo on Days 1, 29, and 57, followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
61929173|NCT03759288|EXPERIMENTAL|(Stage 2) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
62691224|NCT03308331|ACTIVE_COMPARATOR|HIV-1 nonsmokers using nicotine patch|
62691225|NCT03308331|NO_INTERVENTION|HIV-1 nonsmokers using placebo patch|
62691226|NCT03308331|ACTIVE_COMPARATOR|Healthy control nonsmokers using nicotine patch|
62691227|NCT03308331|NO_INTERVENTION|Healthy control nonsmokers using placebo patch|
62691228|NCT02163356|EXPERIMENTAL|Primary therapy|Fenretinide/LXS oral powder 1500 mg/m2/day for 7 days plus ketoconazole 6 mg/kg/day for 7 days plus single dose vincristine (dose escalating) given on day 3. Starting dose of vincristine is 0.75 mg/m2/dose. Followed by 14 days of rest.
62691229|NCT05305703|EXPERIMENTAL|Cervical muscles Stretching|Stretching is applied to the effected muscles in order to increase the muscle length and flexibility by breaking adhesions. Stretching exercises considerably decrease neck pain and improve range of motion
62691230|NCT05305703|EXPERIMENTAL|Soft tissue mobilization with trigger point release.|Soft tissue mobilization increases skin temperature, a rise in skin temperature indicates increase blood flow of involved area, provide relaxation and reduce muscle tension.Trigger point therapy is consisting of rubbing and pressing on trigger points.Heavy pressure must be applied to release trigger, light pressure is not effective. Pressure should be applied slowly and released slowly for best results and the pressure should be maintained until there is a change in pain
62738321|NCT04193449||Adult patients undergoing colonoscopy|All patients' ≥18 years of age who underwent endoscopy at Portsmouth Hospitals NHS Trust, including repeat colonoscopies performed for surveillance purposes aged ≥18 in either males or females.
61929174|NCT03759288|EXPERIMENTAL|(Stage 2) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous on Day 85 and every 4 weeks through Week 48
61929175|NCT03759288|ACTIVE_COMPARATOR|(Stage 2) Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50
61929176|NCT03632343|EXPERIMENTAL|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain \>3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
61929177|NCT03632343|EXPERIMENTAL|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
62131630|NCT01168544|EXPERIMENTAL|loading dose and 50.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
62131631|NCT01168544|EXPERIMENTAL|Loading dose and 25.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
62131632|NCT01168544|ACTIVE_COMPARATOR|800 IU vit D3/dag|800 IU vit D3/dag
62131633|NCT03067948|EXPERIMENTAL|Intervention - Positive Screen Shared|In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to the participant's next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to the next HIV primary care visit.
62131634|NCT03873896|EXPERIMENTAL|Blocked finger|The experimental arm will be the ring finger of the volunteer that is blocked (randomized either right or left hand) with a digital nerve block (described elsewhere in the submission). The skin wrinkle test (diagnostic test) will be applied to this arm
62323354|NCT02653378|ACTIVE_COMPARATOR|EX ARM|A 25% energy depletion (daily for 3 days) induced by performing aerobic exercise at 50% of V02max.
62323355|NCT01829035|NO_INTERVENTION|Arm S|sorafenib 400mg bid daily po until progression
62323356|NCT01829035|EXPERIMENTAL|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
62323357|NCT05490953|PLACEBO_COMPARATOR|Group A with placebo|Patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus placebo, during the first two cycles of chemotherapy.
62323358|NCT05490953|EXPERIMENTAL|Group B with pentoxifylline|"Patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus pentoxifylline, during the first two cycles of chemotherapy.~Pentoxifylline dose of 20 mg/kg/day, maximum dose 1200 mg/day"
62323359|NCT00748826||Infliximab -Rheumatoid Arthritis Participants|
62131635|NCT03873896|ACTIVE_COMPARATOR|Unblocked finger|The control arm will be the finger of the same volunteer that is not under the influence of digital nerve block. This will be the corresponding digit (the ring finger) on the opposite hand of the side that was blocked (determined by coin toss). The skin wrinkle test (diagnostic test) will be applied to this arm
62131636|NCT06203873|EXPERIMENTAL|Biodegradable Occluder Cohort|
62131637|NCT06203873|ACTIVE_COMPARATOR|Metal Occluder Cohort|
62131638|NCT01284374||Male Adolescents|Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
62323360|NCT05420519|EXPERIMENTAL|CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
62323361|NCT06692283|EXPERIMENTAL|Denifanstat 50 mg|Denifanstat tablet, orally, once daily
62738322|NCT02792309|EXPERIMENTAL|MotherWise Programming|Three components: (1) 18 hours of core workshop sessions using the Within My Reach relationship education curriculum supplemented with content on mother-infant relationships; (2) case management services; and (3) optional relationship education workshops for couples.
62738323|NCT02792309|NO_INTERVENTION|Control|No program services
61929178|NCT03632343|NO_INTERVENTION|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
61929179|NCT01389518|ACTIVE_COMPARATOR|Paracetamol,Chlorpheniramin,Phenylephrin|
61929180|NCT01389518|PLACEBO_COMPARATOR|Placebo|
62131639|NCT01284374||Parents of Male Adolescents|Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
62131640|NCT01284374||Health Care Providers for Males 13-17 yo|Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
62131641|NCT05401513|EXPERIMENTAL|Pilates Group|12-weeks exercise program, twice a week, with Pilates method exercises.
62131642|NCT05401513|NO_INTERVENTION|Control Group|12-weeks maintaining their normal physical activity routine.
62131643|NCT03572075|EXPERIMENTAL|Group A|assessment of symptoms at the first medical examination; standard care protocol; pelvic floor physiotherapy; assessment of symptoms after four months
62131644|NCT03572075|EXPERIMENTAL|Group B|assessment of symptoms at the first medical examination; standard care protocol; assessment of symptoms after four months
62131645|NCT04522466|EXPERIMENTAL|Patients infected by SARS-CoV-2 treated by Hydroxychloroquine|Blood sample on patients infected by SARS-CoV-2 treated by Hydroxychloroquine
62131646|NCT01388361|EXPERIMENTAL|IDeg (non-randomised)|
62323362|NCT06692283|PLACEBO_COMPARATOR|Placebo|Placebo tablet, orally, once daily
62323363|NCT02583789|ACTIVE_COMPARATOR|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
62323364|NCT02583789|PLACEBO_COMPARATOR|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
62691231|NCT06434636|ACTIVE_COMPARATOR|Intervention Group (I)|Patients' vital values will be recorded before surgery.10 mg/kg tranexamic acid (Transamine 10% IV/IM Solution for Injection) is added into 100 cc serum through the appropriate vascular access and injected for 15 minutes.The amount of bleeding in the surgical field will be evaluated by the surgeon using the Boezaart Scale.Intraoperatively, hemodynamic changes such as bradycardia, tachycardia, arrhythmia and agents used such as vasopressors, antiarrhythmics and vagolytics will be recorded in the patient.Post-Operatively the surgeon's quality of vision will be questioned with the Surgeon Satisfaction Scale.Postoperative 0th, 12th, and 24th developments - the presence of vomiting and postoperative complaints will be questioned.The presence of bleeding or complications in the first 2 weeks after surgery will be questioned.The presence of thromboembolic events and other services will be questioned within 12 weeks after surgery.
62691232|NCT06434636|PLACEBO_COMPARATOR|Control Group (C)|"Preoperative vital values of the patients will be recorded.100 cc of physiological saline will be sent through the appropriate vascular access in 15 minutes.~The amount of bleeding in the surgical field will be evaluated by the surgeon using the Boezaart Scale. Intraoperatively, hemodynamic changes such as bradycardia, tachycardia, arrhythmia that develop in the patient, and agents such as vasopressors, antiarrhythmics, and vagolytics used will be recorded.~Postoperatively the surgeon's quality of vision will be questioned with the Surgeon Satisfaction Scale. The presence of nausea and vomiting and postoperative complaints will be questioned at the 0th, 12th, and 24th postoperative hours. The presence of surgical bleeding or complications that occur in the first 2 weeks of surgery will be questioned. The presence of thromboembolic events and other complications will be questioned within 12 weeks postoperatively."
62691233|NCT06495099|EXPERIMENTAL|group A|The training group A will be treated by core stability exercises and Russian electrical stimulation
62691234|NCT06495099|ACTIVE_COMPARATOR|group B|The training group B will be treated by core stability exercises.
62691235|NCT01717274|EXPERIMENTAL|Hot saline irrigation|Hot saline is prepared by first placing 2 litres of sterile normal saline (0.9%) into a basin (IntraTemp Therma BasinTM) that is wrapped in a sterile disposable drape (IntraTemp Therma Basin DrapeTM). The basin is then placed in a medical grade warmer (IntraTemp Fluid Warming SystemTM). The warmer is set to heat the saline up to a temperature of 50 degrees Celsius. An external digital thermometer is placed in the saline at all times to ensure that the temperature is between 45-50 degrees.
62691236|NCT01717274|NO_INTERVENTION|Room temperature saline irrigation|Room temperature saline is prepared in the same manner as the experimental arm except that the warmer is switched off and the temperature of the saline in the basin is left to equilibrate to the temperature of the operating room.
62691237|NCT06675344|EXPERIMENTAL|Apollo Neuro Device|Apollo Neuro Device
62691238|NCT06675344|SHAM_COMPARATOR|Sham Device|Study participants will be randomized 1:1 (Apollo Neuro device : Sham device) Devices are identical; however, the sham device will be set to a frequency that has no therapeutic benefits.
62131647|NCT01388361|EXPERIMENTAL|IDeg + IAsp|
62131648|NCT01388361|EXPERIMENTAL|IDeg + liraglutide|
62323365|NCT01579539|EXPERIMENTAL|Patients|Patients with moderate to severe thyroid-associated ophthalmopathy
62323366|NCT05989685||Study group|Adolescents between the ages of 13-21 who meet diagnostic criteria for an autism spectrum disorder.
62323367|NCT05989685||Control group|Adolescents aged 13-21 years without a lifetime psychiatric diagnosis.
62323368|NCT01262261|EXPERIMENTAL|Probuphine|patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
62323369|NCT01587872|EXPERIMENTAL|DBC|Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.
62323370|NCT02936505|ACTIVE_COMPARATOR|Arm A:Cyclosporine|Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.
62323371|NCT02936505|EXPERIMENTAL|Arm B:Tacrolimus|Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.
62691239|NCT04535115|EXPERIMENTAL|Group 1|Starting LRM (Lung Recruitment Maneuver)
62691240|NCT04535115|EXPERIMENTAL|Group 2|Starting VtC (Tidal Volume Challenge)
62323372|NCT03474523|EXPERIMENTAL|Experimental or Diathermy-Radiofrecuency|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
62691241|NCT06640452|EXPERIMENTAL|older adults|The population concerned of patients who has overcome an acute event and completed intensive inpatient rehabilitation. The patient we are referring to has already returned home and needed to maintain the goals achieved or increase functionality.
62691242|NCT05657145||Familiar Adenomatous Polyposis|All patient in this group will have the NuView device used to assist in the visualization of the papilla.
62131649|NCT04695483|EXPERIMENTAL|Corifollitropin alpha group|Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
62131650|NCT04695483|ACTIVE_COMPARATOR|FSH group|Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
62131651|NCT02331745|EXPERIMENTAL|Granulocyte colony-stimulating factor|"Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).~Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time"
62131652|NCT02331745|ACTIVE_COMPARATOR|standard treatment|Standard treatment alone
62131653|NCT03215823||1. Easy endotracheal intubation|Easy endotracheal intubation
62323373|NCT03474523|ACTIVE_COMPARATOR|Control or Cavitation|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
62323374|NCT03274336|ACTIVE_COMPARATOR|interview|questionnaire after face-to-face interview
62323375|NCT03274336|PLACEBO_COMPARATOR|brochure|questionnaire interview plus brochure
62323376|NCT03274336|PLACEBO_COMPARATOR|movie|questionnaire interview plus movie
62323377|NCT00399984|EXPERIMENTAL|1|
62323378|NCT00399984|NO_INTERVENTION|2|
62482576|NCT02679729|EXPERIMENTAL|Part B, Dose Level 1|Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
62482577|NCT02965859|EXPERIMENTAL|Metacavir Enteric-coated Capsule 80mg|"1. Metacavir Enteric-coated Capsules 80mg~2. Metacavir Enteric-coated Capsules Placebo 240mg~3. Adefovir Dipivoxil Capsule Placebo 10mg;"
62482578|NCT02965859|ACTIVE_COMPARATOR|Metacavir Enteric-coated Capsules 160mg|"1. Metacavir Enteric-coated Capsules 160mg~2. Metacavir Enteric-coated Capsules Placebo 160mg~3. Adefovir Dipivoxil Capsule Placebo 10mg;"
62691243|NCT02816112|ACTIVE_COMPARATOR|Ciprofloxacin|Oral tablet taken twice a day at home starting 5 days after chemotherapy for 14 days for every cycle of TC
62691244|NCT02816112|ACTIVE_COMPARATOR|G-CSF|Daily injection at home for the number of days as chosen by the treating physician
62131654|NCT03215823||2. Difficult endotracheal intubation|Difficult endotracheal intubation
62131655|NCT01755936||Controls|Patients will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
62131656|NCT01755936||Aortic Stenosis patients|All patients who agreed to study will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
62323379|NCT05005208|EXPERIMENTAL|Rehabilitation Group|PD subjects will be going through a rehabilitation program based on an Irish dance with the support of the technological platform SI-ROBOTICS
62323380|NCT06692309||Perioperative Neurocognitive Disorders|"Postoperative delirium was assessed using the confusion assessment method for the intensive care unit (CAM-ICU) or the 3-minute diagnostic interview for the confusion assessment method(the 3D-CAM).~Cognitive levels were assessed 1 day before surgery and 1 week after surgery (7±2 days) using the Montreal Cognitive Assessment (MoCA). Patients were followed up one month (30±2 days) after surgery using the Telephone version of the Montreal Cognitive Assessment Scale (T-MoCA)."
62131657|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
62131658|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
62323381|NCT06692309||No-Perioperative Neurocognitive Disorders|"Postoperative delirium was assessed using the confusion assessment method for the intensive care unit (CAM-ICU) or the 3-minute diagnostic interview for the confusion assessment method(the 3D-CAM).~Cognitive levels were assessed 1 day before surgery and 1 week after surgery (7±2 days) using the Montreal Cognitive Assessment (MoCA). Patients were followed up one month (30±2 days) after surgery using the Telephone version of the Montreal Cognitive Assessment Scale (T-MoCA)."
62691245|NCT03403738|ACTIVE_COMPARATOR|Enhanced usual Care|usual care plus comprehensive resource list
62131659|NCT04019405||Frailty status|Frailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.
62131660|NCT03487172|OTHER|Right Side Treated|Subjects will be randomized to have their right side treated with PLLA and their left side treated with normal saline.
62131661|NCT03487172|OTHER|Left Side Treated|Subjects will be randomized to have their left side treated with PLLA and their right side treated with normal saline.
62131662|NCT02416115|ACTIVE_COMPARATOR|R group|Thirty minutes before end of surgery, patients in R group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, patients in R group received PCA morphine 1 mg/ml
62131663|NCT02416115|ACTIVE_COMPARATOR|N group|Thirty minutes before end of surgery, patients in N group (n=30) received normal saline. In the post anesthetic care unit, group N received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
62323382|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
62482579|NCT02965859|PLACEBO_COMPARATOR|Metacavir Enteric-coated Capsules 320mg|"1. Metacavir Enteric-coated Capsules 320mg~2. Adefovir Dipivoxil Capsule Placebo 10mg"
62482580|NCT02965859|ACTIVE_COMPARATOR|Adefovir Dipivoxil Capsule|"1. Metacavir Enteric-coated Capsules Placebo 320mg~2. Adefovir Dipivoxil Capsule 10mg;"
62482581|NCT02965859|PLACEBO_COMPARATOR|Placebo|"1. Metacavir Enteric-coated Capsules Placebo 320mg~2. Adefovir Dipivoxil Capsule Placebo 10mg;"
62482582|NCT02615249|EXPERIMENTAL|Metal Allergen Epicutaneous Patch|8 allergens were tested. Not all subjects tested each allergen. Section reports number of subjects with positive responses to each allergen.
62482583|NCT00650377|EXPERIMENTAL|1|Finasteride Tablets 5 mg
62482584|NCT00650377|ACTIVE_COMPARATOR|2|Proscar® Tablets 5 mg
62482585|NCT02518945|PLACEBO_COMPARATOR|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
62482586|NCT02518945|ACTIVE_COMPARATOR|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
62482587|NCT02462681|ACTIVE_COMPARATOR|bupivacaine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% paravertebrally, divided into 3-4 ml in each level
62691246|NCT03403738|EXPERIMENTAL|BBN|Bounce Back Now intervention
62131664|NCT02416115|EXPERIMENTAL|RN group|Thirty minutes before end of surgery, patients in Ramosetron and naloxone (RN) group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, group RN received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
62691247|NCT06355050||Patients receiving ultrahypofractionated radiotherapy|
62691248|NCT06355050||Retrospective reference cohort|"reference cohort of patients who underwent normofractionated radiotherapy or moderately hypofractionated radiotherapy earlier.~matching 1:1:1 by tumor stage and risk profile (d'Amico)"
62691249|NCT05406453|NO_INTERVENTION|Madagascar standard of care|"Description :~* Passive case finding,~* Smear microscopy testing, and~* household contact tracing"
62691250|NCT05406453|NO_INTERVENTION|Best practices|"Description :~* Active case finding,~* Smear microscopy~* Xpert MTB/RIF Ultra testing (= rapid test by Genexpert for tuberculosis (TB) and rifampin resistance (RIF-R)) and~* household contact tracing"
62482588|NCT02462681|ACTIVE_COMPARATOR|bupivacaine + 0.5 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 0.5 mg/kg ketamine paravertebrally divide into 3-4 ml in each level
62482589|NCT02462681|ACTIVE_COMPARATOR|bupivacaine + 1 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 1mg/kg ketamine paravertebrally divide into 3-4 ml in each level
62482590|NCT06320067|ACTIVE_COMPARATOR|Arm A of SABR Comparison|SoC (ADT + ARSI ± docetaxel + local RT)
62482591|NCT06320067|EXPERIMENTAL|Arm S of SABR Comparison|SoC (ADT + ARSI ± docetaxel + local RT) + SABR
62482592|NCT06320067|ACTIVE_COMPARATOR|Arm A of 177Lu-PSMA-617 Comparison|SoC (ADT + ARSI ± docetaxel ± local RT)
62482593|NCT06320067|EXPERIMENTAL|Arm P of 177Lu-PSMA-617 Comparison|SoC (ADT + ARSI ± docetaxel ± local RT) + 177Lu-PSMA-617
61929181|NCT06710639|ACTIVE_COMPARATOR|Health Education Program|Instructions and recommendations will be provided in an informational leaflet to encourage an active and healthy lifestyle, promoting self-care and good health practices. This leaflet will include the new WHO guidelines recommending specific measures to reduce the risk of cognitive impairment. These measures are: eating healthy foods, engaging in physical activity, maintaining social contact, doing challenging cognitive games, getting good sleep, managing stress, staying hydrated, and avoiding smoking and excessive alcohol consumption.
62131665|NCT05748730|EXPERIMENTAL|iCHART|"iCHART is an intervention that includes 3 components previously studied in within the ETUDES Center including a:~1. Safety Planning App for suicidal youth which enables a primary care provider to streamline the gold standard of care for those with current suicidality symptoms through an app (instead of a paper based version);~2. Mental Health Screener questionnaire that gathers additional mental health symptoms, treatment preferences, and family's readiness for treatment engagement to help primary care provider make a personalized, tailored treatment plan a suicidal youth is more likely to adhere to;~3. Text Messages which aims to provide texts for 2-3 weeks to motivate you to engage with the safety plan and recommended treatment following the patient visit.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
62131666|NCT05748730|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
62131667|NCT03097679|ACTIVE_COMPARATOR|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
62691251|NCT05406453|EXPERIMENTAL|Novel intervention|"Description :~* Active case finding,~* Smear microscopy~* Xpert MTB/RIF Ultra testing and~* household contact tracing"
62691252|NCT04163081|EXPERIMENTAL|Quit Card Intervention (QCI)|Study intervention group.
62131668|NCT03097679|ACTIVE_COMPARATOR|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
62131669|NCT02032940||Standard Sequence Imaging MRI|Patients requiring MRI. All Comers accepting study participation.
62131670|NCT02032940||Additional Pulse Sequence Increased|Patients requiring MRI. All comers accepting study participation and the run of additional pulse sequences during MRI procedure.
62131671|NCT04131153|OTHER|Conventional radiofrequency ablation group|Conventional radiofrequency ablation procedures
62131672|NCT04131153|EXPERIMENTAL|Three-step radiofrequency ablation group|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
62131673|NCT02396602|EXPERIMENTAL|Intervention|After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes. They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
62131674|NCT02396602|NO_INTERVENTION|Control|After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
62131675|NCT04146324||Adjuvant nivolumab therapy|Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia
62131676|NCT05035966||Prediabetes|In the case-control study, prediabetes was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. Prediabetes was defined as impaired fasting glucose (FPG ≥6.1 mmol/L and \<7.0 mmol/L, and 2-h post-glucose load \<7.8 mmol/L) and/or impaired glucose tolerance (FPG \<6.1 mmol/L, and 2-h post-glucose load ≥7.8 mmol/L and \<11.1 mmol/L). In the nested case-control study, new-onset prediabetes was defined as FPG ≥6.1 mmol/L and \<7.0 mmol/L.
62339887|NCT03645772|ACTIVE_COMPARATOR|Walking|12-week progressive walking program.
62482594|NCT06320067|ACTIVE_COMPARATOR|Arm A(N) of Niraparib Comparison|SoC (ADT + Apalutamide ± docetaxel ± local RT)
62482595|NCT06320067|EXPERIMENTAL|Arm N of Niraparib Comparison|SoC (ADT ± docetaxel ± local RT) + Nira-AA+P
62482596|NCT03810586|EXPERIMENTAL|Comparing blood pressure measurement|In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
62691253|NCT04163081|NO_INTERVENTION|Usual Care (UC)|Study control group.
62691254|NCT01234376||Control patients|
62691255|NCT01234376||Patients with eosinophilic esophagitis|
62691256|NCT05152485|ACTIVE_COMPARATOR|BIIB104 0.5 mg Reference Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release liquid-filled hard-shell capsule, orally, on Day 1 in the fasted state.
62691257|NCT05152485|EXPERIMENTAL|BIIB104 0.5 mg Test Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fasted state.
62691258|NCT05152485|EXPERIMENTAL|BIIB104 0.5 mg Test Formulation (Fed State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fed state.
61929182|NCT06710639|EXPERIMENTAL|Cognitive Training Program|The cognitive training program (CT) focused on everyday cognition (EC) will be conducted individually. Each participant will receive a dossier specifically designed for the study. The intervention will consist of four training periods over 4 months (Period 1, P1; Period 2, P2; Period 3, P3; Period 4, P4), with 20 activities in each period. Each period will last one month (with 5 activities per week). To ensure compliance and therapeutic adherence, two types of follow-up will be carried out: in-person or via telematic (video call).
62131677|NCT05035966||Healthy control|In the case-control study, healthy control was defined as FPG \<6.1 mmol/L and 2-h post-glucose load \<7.8 mmol/L. In the nested case-control study, healthy control was defined as FPG \<6.1 mmol/L.
62131678|NCT00281554|EXPERIMENTAL|1|
62323383|NCT06196476|NO_INTERVENTION|Control Group|The participants in this group received routine nursing information in which the nurse discussed general knowledge of climate change awareness regarding the management of reducing Climate Anxiety effects to primary health care nurses.
62691259|NCT05884528||Complex-free BoNT/A formulation|Patients exclusively treated with the complex-free (CF) formulation (incobotulinumtoxinA). A maximum of 328 patients will be enrolled in this group.
62131679|NCT00869011|EXPERIMENTAL|1|Exercise
62131680|NCT00869011|NO_INTERVENTION|2|No structured exercise program
62131681|NCT04659018||patient|individual performing a screening colonoscopy
62131682|NCT04279366||Winter course|The recruited particpants attending the winter course
62131683|NCT04279366||Fall course|The recruited particpants attending the winter course
62131684|NCT06301204|PLACEBO_COMPARATOR|control group|control group patient give no drug administration during bimaxillary orthognathic surgery.
62131685|NCT06301204|ACTIVE_COMPARATOR|group 1(intravenous administration of 250 mg tranexamic acid)|group 1 (TRANEXEL 250 mg/5 mL) patients administered 250 mg tnx acid during the whole bimaxillary orthognathic surgery
62131686|NCT06301204|ACTIVE_COMPARATOR|group 2 (intravenous administration of 500 mg tranexamic acid)|group 2 (TRANEXEL 250 mg/5 mL) patients administered 500 mg tnx acid during the whole surgery.
62131687|NCT03484988|PLACEBO_COMPARATOR|Placebo oil|Ingredients: Corn oil, 500mg per capsule
62131688|NCT03484988|EXPERIMENTAL|Echium oil|Ingredients: Echium oil,500mg per capsule
62131689|NCT03484988|EXPERIMENTAL|Mixed oil|Ingredients:Mixed oil(Echium oil,camelina oil,safflower oil) 500mg per capsule
62131690|NCT04137497||Patients with disorders of consciousness|
62131691|NCT04137497||Patients with unresponsive wakefulness syndrome|
62131692|NCT04137497||Patients with minimally conscious state|
62131693|NCT00901901|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)|Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)
62131694|NCT00901901|ACTIVE_COMPARATOR|Sorafenib (Nexavar, BAY43-9006) + Placebo|Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)
62323384|NCT06196476|EXPERIMENTAL|Intervention Group|"The participants in this group received an empowerment-based intervention in terms of interactive digital-based educational program regarding the promoting literacy, pro-environmental attitudes, self-efficacy, and reducing climate anxiety.~The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session"
62691260|NCT05884528||Complex-containing BoNT/A formulations|Patients exclusively treated with a single complex-containing (CC) formulation (onabotulinumtoxinA or abobotulinumtoxinA). A maximum of 328 patients will be enrolled in this group.
61929183|NCT05598385|ACTIVE_COMPARATOR|Percutaneous cannulation|Percutaneous peripheral cannulation will be applied. An ultrasound is performed preoperative, at discharge and during the follow-up consultation.
62131695|NCT04019509|ACTIVE_COMPARATOR|Tg AB positive, TPO AB negative|Includes patients with only anti-thyroglobuline autoantibodies present and no anti-thyreoperoxydase antibodies at start of fertility treatment.
62131696|NCT04019509|ACTIVE_COMPARATOR|Tg AB negative, TPO AB negative|Includes patients without thyroid autoantibodies at start of fertility treatment
62131697|NCT04019509|ACTIVE_COMPARATOR|Tg AB positive, TPO AB positive|Includes patients with anti-thyroglobuline autoantibodies and anti-thyreoperoxydase antibodies at start of fertility treatment.
62131698|NCT05298813|EXPERIMENTAL|Active|
62131699|NCT05298813|PLACEBO_COMPARATOR|Placebo|
62131700|NCT01840748||no vasodilator|patients receiving no vasodilator
62131701|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
62131702|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
62131703|NCT05952258|ACTIVE_COMPARATOR|Magnetic stimulation therapy|Participants will sit fully clothed on the magnetic stimulator chair, with knees apart at about the width of their shoulders, feet flat on the floor. The stimulator will be activated and the intensity gradually increased as tolerated by the participant up to an intensity of 100%. There are a total of 6 treatment sessions (twice per week) over 3 weeks.
62131704|NCT05952258|PLACEBO_COMPARATOR|Sham therapy|Participants will sit fully clothed on the magnetic stimulator chair, with knees apart at about the width of their shoulders, feet flat on the floor. The stimulator will be activated and the intensity gradually increased as tolerated by the participant up to an intensity of 5%. There are a total of 6 treatment sessions (twice per week) over 3 weeks.
62131705|NCT04695197|ACTIVE_COMPARATOR|Artemether-lumefantrine|Artemether-lumefantrine, standard 3-day antimalarial treatment regimen.
62131706|NCT04695197|EXPERIMENTAL|Pyronaridine-artesunate|Pyronaridine-artesunate, standard 3-day antimalarial treatment regimen.
62131707|NCT01477268|OTHER|zoloft|Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
62131708|NCT02125110|EXPERIMENTAL|study group (cohort PELAGIE)|100 children included in the cohort PELAGIE
62131709|NCT02125110|EXPERIMENTAL|pilot group (no cohort PELAGIE)|10 children not included in the PELAGIE cohort to optimise MRI
62131710|NCT04106869|ACTIVE_COMPARATOR|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (\<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
62131711|NCT04106869|PLACEBO_COMPARATOR|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 ( 40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
62482597|NCT03442530|ACTIVE_COMPARATOR|Tobacco Treatment As Usual (TTAU)|Eligible women assigned to the control group will be informed of the risks of tobacco use and benefits of quitting using the ACOG 5A's approach by their healthcare provider.5 This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The study coordinator will invite participants to complete the tobacco use questionnaires (TUQ),urine cotinine validation, and Expired Air Carbon Monoxide (EACO) analysis to assess ongoing tobacco use at the designated time points.
62482598|NCT03442530|EXPERIMENTAL|ToPIC|Eligible women assigned to the intervention will receive TTAU plus ToPIC administered by the CTTS. At least once monthly, at routinely scheduled prenatal visits or through telephone, the CTTS will provide cessation counseling. The CTTS will invite participants to complete TUQs,urine cotinine validation and EACO analysis to assess ongoing tobacco use at the designated time points.
61929184|NCT05598385|ACTIVE_COMPARATOR|Open cannulation|Open peripheral cannulation will be applied. An ultrasound is performed preoperative, at discharge and during the follow-up consultation.
61929185|NCT05822544|EXPERIMENTAL|Oral Solution|Oral solution of TLC-6740
61929186|NCT05822544|PLACEBO_COMPARATOR|Placebo|Oral dose of TLC-6740 placebo-to-match
61929187|NCT05822544|EXPERIMENTAL|Tablet|Tablet formulation of TLC-6740
61929188|NCT05822544|EXPERIMENTAL|Drug Metabolizing Enzyme|Oral dose of omeprazole, voriconazole, or itraconazole
62482599|NCT06626607||CCB group|Patients' postoperative antihypertensive includes CCB (Calcium Calcium Entry Blockers)
61929189|NCT03441243||Case group:Cesarean section urgently|- 43 patients had an emergency caesarean section between 01/01/2015 and 31/12/2016.
61929190|NCT03441243||Case group:Hemorrhage of deliverance|- 85 patients had haemorrhage of the delivery with need for a transfusion between 01/01/2015 and 31/12/2017.
61929191|NCT03441243||Control group: delivery physiological low path|- A control group will consist of 128 patients who had a physiological low birth delivery over the same period.
61929192|NCT02730338|ACTIVE_COMPARATOR|Arm A: Supervised exercise group|Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support
62482600|NCT06626607||non-CCB group|Patients' postoperative antihypertensive does not include CCB
62691261|NCT05884528||Switcher CF to CC BoNT/A formulations|The CF to CC switcher group includes all patients that were switched from a CF to a CC BoNT/A formulation. If more than one switch occurred, the first switch determines the group. Both switcher groups will in sum not exceed 325 patients.
61929193|NCT02730338|OTHER|Arm B: Self directed exercise group|Self directed exercise and psychosocial support group
61929194|NCT06675812|ACTIVE_COMPARATOR|Active group|The participant will receive information on what treatment that is offered in their municipal, how the help-seeking process goes (where they can be anonymous etc), and tailored information regarding the barriers that the participant has stated preventing him or her for seeking help today.
61929195|NCT06675812|NO_INTERVENTION|Referral to municipal care|At the anonymous help service where the intervention will be used, is standard practice to refer the person to the municipal care, if he or she request for more help.
61929196|NCT05205954|EXPERIMENTAL|Hepatology Hospital at Home|Patients with cirrhosis presenting with symptomatic ascites receive their care in the home.
61929197|NCT05205954|NO_INTERVENTION|Usual Hepatology Care|Patients with cirrhosis presenting with symptomatic ascites receive their care in the hospital, as usual.
61929198|NCT03395925|EXPERIMENTAL|Celon Pro Surge|Ablation of thyroid tissue
61929199|NCT06710548|EXPERIMENTAL|ARM 1: Revitalize Intervention|"120 participants will be randomized in a 1:1 fashion stratified by PARP inhibitor type and study site and will complete the following:~* Baseline visit with questionnaires.~* Participants will use Wisepill pillbox as instructed for PARP inhibitor medication.~* 8 weekly intervention sessions via Zoom or telephone.~* 1 and 2 month telehealth booster sessions.~* Questionnaires at 5-6 weeks, 2, 4, and 6 months."
61929200|NCT06710548|NO_INTERVENTION|ARM 2: Enhanced Usual Care|"120 participants will be randomized in a 1:1 fashion stratified by PARP inhibitor type and study site and will complete the following:~* Baseline visit with questionnaires.~* Standard of care educational materials about fatigue and cancer care will be provided to participants. Access to supportive care services such as social work, psychology, and chaplains will also be provided.~* Questionnaires at 5-6 weeks, 2, 4, and 6 months."
61929201|NCT03613610|ACTIVE_COMPARATOR|Three needles group|
61929202|NCT03613610|ACTIVE_COMPARATOR|Single needle group|
61929203|NCT04160728|EXPERIMENTAL|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
61929204|NCT04160728|EXPERIMENTAL|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work.
61929205|NCT04160728|EXPERIMENTAL|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts.
62131712|NCT04513314|ACTIVE_COMPARATOR|Standard of Care Only Group|Patients maintained with mechanical ventilation will be treated with standard of care after cessation of paralytic agents.
62131713|NCT04513314|ACTIVE_COMPARATOR|Treatment Arm Group|Patients maintained with mechanical ventilation will be treated with standard of care, plus Valproate on Days 1-7 after cessation of paralytic agents, and then augmented by the addition of Quetiapine beginning Days 3-7 if there are no improvement in RASS score.
62482601|NCT01576705|EXPERIMENTAL|Thyroxin + folinic acid|
62323385|NCT04978948||Myasthénie|Blood samples will be collected
62482602|NCT01576705|ACTIVE_COMPARATOR|Thyroxin+folinic acid placebo|
62482603|NCT01576705|ACTIVE_COMPARATOR|Thyroxin placebo+ folinic acid|
62482604|NCT01576705|PLACEBO_COMPARATOR|Thyroxin placebo+ folinic acid placebo|
62691262|NCT05884528||Switcher CC to CF BoNT/A formulations|The CC to CF switcher group includes all patients that were switched from a CC to a CF BoNT/A formulation. If more than one switch occurred, the first switch determines the group. Both switcher groups will in sum not exceed 325 patients.
62131714|NCT05769764||Cohort 1: NSCLC|Participants with NSCLC will be included in this cohort if they do not meet requirements for inclusion in Cohorts 2-4.
62323386|NCT04978948||Myopathie inflammatoire (Myosite)|Blood samples will be collected
62691263|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pancreatic|SMART will be administered per each individual disease site standards
62691264|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Renal|SMART will be administered per each individual disease site standards
62691265|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Central Lung|SMART will be administered per each individual disease site standards
62691266|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Adrenal Metastases|SMART will be administered per each individual disease site standards
62131715|NCT05769764||Cohort 2: EGFR-mutated (EGFRm) NSCLC Previously Treated With a 3rd Generation EGFR TKI|Participants with EGFR-mutated (EGFRm) NSCLC previously treated with a 3rd generation tyrosine kinase inhibitor (TKI) with matched samples.
62131716|NCT05769764||Cohort 3: ALK+ NSCLC|Participants with ALK+ NSCLC with matched samples.
62131717|NCT05769764||Cohort 4: NSCLC Harboring a KRAS p.G12C Mutation or EGFR Exon 20 Insertion|Participants with NSCLC harboring a Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C mutation or EGFR exon 20 insertion.
62131718|NCT00996229|EXPERIMENTAL|Caloric restriction + placebo supplementation|
62131719|NCT00996229|EXPERIMENTAL|Omega-3 supplementation|
62131720|NCT00996229|PLACEBO_COMPARATOR|Placebo supplementation|
62131721|NCT00996229|EXPERIMENTAL|Resveratrol supplementation|
62323387|NCT04978948||Neuropathie autoimmune|Blood samples will be collected
62323388|NCT04978948||Néphropathies autoimmunes|Blood samples will be collected
62323389|NCT04978948||Hépatite auto-immune|Blood samples will be collected
62323390|NCT04978948||Pancréatite auto-immune|Blood samples will be collected
62323391|NCT04978948||Purpura Thrombopénique Immunologique|Blood samples will be collected
62323392|NCT04978948||Dermatose bulleuse|Blood samples will be collected
62323393|NCT04978948||Thyroïdite autoimmune|Blood samples will be collected
62323394|NCT04978948||Sclérose en plaque|Blood samples will be collected
62323395|NCT04978948||Sclérose latérale amyotrophique|Blood samples will be collected
62323396|NCT04978948||Polyarthrite Rhumatoïde|Blood samples will be collected
62323397|NCT04978948||Spondylarthrite axiale|Blood samples will be collected
62323398|NCT04978948||controls|Patients without autoimune desease\* Blood samples will be collected
62323399|NCT04978948||Lichen plan buccal auto-immun (LPB)|Blood samples will be collected
62691267|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Liver Metastases|SMART will be administered per each individual disease site standards
62323400|NCT04978948||"lichen plan buccal allo-immun liée à une GvHD ( Graft versus Host Disease )"|Blood samples will be collected
62323401|NCT04978948||Lupus érythémateux systémique|Blood samples will be collected
62323402|NCT04978948||Sclérodermie|Blood samples will be collected
62691268|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Metachronous Oligometastatic Nodes|SMART will be administered per each individual disease site standards
62691269|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Oligoprogressive Oligometastatic Nodes/Soft Tissue|SMART will be administered per each individual disease site standards
62691270|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Synchronous Oligometastatic Nodes/Soft Tissue|SMART will be administered per each individual disease site standards
62131722|NCT05137834|EXPERIMENTAL|"Exercise with a peanut ball."|"The rehabilitation program consists of mobility- and functional training exercises with a peanut ball."
62131723|NCT05137834|ACTIVE_COMPARATOR|"Exercise without peanut ball"|"The rehabilitation program consists of standard mobility- and functional training exercises without a peanut ball."
62131724|NCT02909192|ACTIVE_COMPARATOR|Bright light therapy|Participants will be treated twice daily with bright light therapy.
62131725|NCT02909192|ACTIVE_COMPARATOR|Dim-Red light therapy|Participants will be treated twice daily with dim-red light therapy.
62131726|NCT00448734|EXPERIMENTAL|1|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
62131727|NCT00448734|ACTIVE_COMPARATOR|2|Docetaxel
62131728|NCT06340100||concussed contact sports athlete|"Informed Consent: Participants are provided with information about the study, including its purpose, procedures, potential risks, and benefits. They are given the opportunity to ask questions and provide informed consent before participating.~Baseline Assessments: Before any interventions or assessments, participants undergo baseline evaluations of their vestibular function and cognitive abilities. This helps establish a starting point for comparison and allows researchers to identify any pre-existing impairments.~Concussion History Questionnaires: Participants complete questionnaires or interviews to provide detailed information about their history of concussions, including the number, severity, and timing of each injury."
62323403|NCT02639117|OTHER|Vismodegib|Vismodegib 150 mgs po qd. Open label.
62323404|NCT02460588|PLACEBO_COMPARATOR|Corticosteroid with placebo|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid."
62323405|NCT02460588|EXPERIMENTAL|Corticosteroid associated with Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
62323406|NCT00781781|EXPERIMENTAL|1|"High risk patients (at least one GVHD high risk criterion):~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive)."
62691271|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate|SMART will be administered per each individual disease site standards
62691272|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Borderline Resectable Pancreas|SMART will be administered per each individual disease site standards
62482605|NCT06366386||Persons living with HIV and hypertension|Persons living with HIV and hypertension aged 18 years and above will receive integrated screening (blood pressure measurement) and treatment of hypertension in their respective models of HIV care. The models of HIV care include the clinic based HIV care and community based HIV care. Treatment of hypertension will be based on a simplified one page protocol adapted from the WHO HEARTS packages for hypertension control. Health workers will be trained to titrate hypertension medications for PLHIV with hypertension using the three medications is a step wise manner: Amlodipine, Hydrochlorothiazide and Losartan.
62482606|NCT00834717|EXPERIMENTAL|Granisetron|Granisetron 1 mg Tablet (test) dosed in first period followed by Kytril® 1 mg Tablet (reference) dosed in second period
62482607|NCT00834717|ACTIVE_COMPARATOR|Kytril®|Kytril 1 mg Tablet (reference) dosed in first period followed by Granisetron 1 mg Tablet (test) dosed in second period
62482608|NCT03797703|EXPERIMENTAL|Treatment|Patients will be randomly allocated into the treatment group. The treatment group will receive a 15 mL lidocaine gel enema rectally immediately following completion of the procedure.
62482609|NCT03797703|NO_INTERVENTION|Control|Patients will be randomly allocated into the control group. The control group will not receive a rectal enema.
62482610|NCT01229800|ACTIVE_COMPARATOR|Split dose PEG|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
62482611|NCT01229800|ACTIVE_COMPARATOR|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
62482612|NCT06627218|EXPERIMENTAL|Adhere to Recommendations for PCC Management|Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
62482613|NCT06627218|NO_INTERVENTION|Liberal PCC Management|Liberal PCC Management in Major Bleeding Following Trauma
62482614|NCT05199064||Chronic refractory migraine patients|25 patients who were diagnosed as having chronic refractory migraine and were refractory to conventional treatments, such as oral medications, GONB,and botulinum toxin injection were evaluated.All patients received pulsed RFtherapy to the GON from the proximal (C2) level in the pain clinic between September 2020 and September 2021.
62482615|NCT01501253|EXPERIMENTAL|CKD-828 2.5/40mg|CKD-828 2.5/40mg
62691273|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Brain Metastases|SMART will be administered per each individual disease site standards
61929206|NCT04160728|EXPERIMENTAL|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
61929207|NCT04160728|SHAM_COMPARATOR|Business as usual scenario|No interference with the usual work day of the participants.
61929208|NCT04160728|SHAM_COMPARATOR|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment.
61929209|NCT01270061|ACTIVE_COMPARATOR|HIV testing|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
61929210|NCT01270061|EXPERIMENTAL|General Health Screening|In Group 2 (Intervention), a theory-based video is used to obtain informed consent for a free general health screening that includes a blood pressure check, blood glucose measurement, and an HIV test.
62323407|NCT00781781|EXPERIMENTAL|2|"Low Risk patients (no GVHD high risk criterion):~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive)."
62482616|NCT01501253|EXPERIMENTAL|CKD-828 2.5/80mg|CKD-828 2.5/80mg
62482617|NCT01501253|ACTIVE_COMPARATOR|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg
62482618|NCT00004933|EXPERIMENTAL|Homoharringtonine|
62482619|NCT00004933|ACTIVE_COMPARATOR|Hydroxyurea|
62482620|NCT05524051|EXPERIMENTAL|TIN816|TIN816
62482621|NCT05524051|PLACEBO_COMPARATOR|Placebo|Placebo
62691274|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mesothelioma|SMART will be administered per each individual disease site standards
61929211|NCT05113394|EXPERIMENTAL|Experimental arm|HDM sublingual Immunotherapy (HDM-SLIT) with Odactra® for 3 years to high-risk infants aged between 6 to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after discontinuation of treatment.
61929212|NCT05113394|PLACEBO_COMPARATOR|Placebo arm|Placebo administered sublingually for 3 years to high-risk infants aged between 6 to 12 months with outcome of asthma development assessed 1.5 years after discontinuation of treatment.
61929213|NCT06001385|EXPERIMENTAL|Regimen A (MAC: Busulfan and Fludarabine, PBSC HCT; Reduce Dose PTCy|"Patients Receive:~Patients receive:~Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3 Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
62131729|NCT02352909|ACTIVE_COMPARATOR|Control|Education will be given on how to modify running training to encourage improvement of symptoms.
62323408|NCT04982432|EXPERIMENTAL|Orismilast|Orismilast tablet, oral administration, multiple titrated doses twice daily, 10 mg up to 40 mg, morning and evening, 16 weeks treatment.
62323409|NCT01452776|EXPERIMENTAL|TAK-438 10 mg QD|
62691275|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate Boost|SMART will be administered per each individual disease site standards
62691276|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pelvic Re-Irradiation|SMART will be administered per each individual disease site standards
62691277|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Spine|SMART will be administered per each individual disease site standards
62131730|NCT02352909|EXPERIMENTAL|Muscle recruitment|Subjects will receive an additional exercise program targeting non task-specific strengthening and motor control exercises of the lower limb.
62131731|NCT02352909|EXPERIMENTAL|Reduction of knee loading|Subjects will receive additional personalized advice on how to modify running gait in order to reduce mechanical loads at the knee (gait retraining).
61929214|NCT06001385|EXPERIMENTAL|Regimen B (MAC: Fludarabine and TBI, PBSC HCT; Reduce Dose PTCy|"Patients receive:~Fludarabine (90 mg/m2 total dose) IV on days -7 to -5 Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
62482622|NCT04035187|EXPERIMENTAL|Sequence A (fast, medium, oral solution, then slow)|Participants first receive fast tablet, then medium tablet, then oral solution, and then slow tablet. Washout period is (at least) one week.
61929215|NCT06001385|EXPERIMENTAL|Regimen C (RIC: Fludarabine and Busulfan; PBSCT HCT; Reduced Dose PTCy|"Patients receive:~Fludarabine (150-180 mg/m2 total dose) IV on days -6 to -2 Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
61929216|NCT06001385|EXPERIMENTAL|Regimen D (RIC: Fludarabine and Melphalan; PBSCT HCT; Reduced Dose PTCy|"Patients receive:~Fludarabine (125-150 mg/m2 total dose) IV on days -7 to -3 Melphalan (100-140 mg/m2) IV on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
61929217|NCT06001385|EXPERIMENTAL|Regimen E (NMA: Fludarabine, Cyclophosphamide, and TBI; PBSCT HCT; Reduced Dose PTCy|"Patients receive:~Fludarabine (150mg/m2 total dose) IV on days -6 to -2 Cyclophosphamide (29-50mg/kg) IV on days -6 and -5 TBI (200cGy) on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
62691278|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Single-Fraction Kidney Tumors|SMART will be administered per each individual disease site standards
62691279|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--1/3 Fraction for Oligometastatases in the Abdomen/Pelvis|SMART will be administered per each individual disease site standards
61929218|NCT03832075|EXPERIMENTAL|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated with Berg Balance Scale, Timed Up and Go test and Korebalance balance system for balance disorder.
62131732|NCT00764023||No treatment|
62131733|NCT00764023||human samples|
62131734|NCT00194610|EXPERIMENTAL|Botox injection|Subjects were injected with Botulinum toxin A in a mix of 50 U diluted in 2 cubic centimeters of normal saline. With the subjects in the dorsal lithotomy position, one injection of 25 international units was given into the bladder neck at the 3 o'clock position and another of 25 international units was given into the 9 o'clock position
62131735|NCT00194610|PLACEBO_COMPARATOR|Normal saline|Subjects were injected in the bladder neck with 1 cubic centimeter normal saline into the 3 o'clock and 6 o' clock positions in the perineum, while in the dorsal lithotomy position
62131736|NCT03498768||Inpatients with lung nodules|All inpatients in our department are invited to finish the questionnaire at inpatient education on the first day of hospitalization as the baseline date, then they are followed up by phone call to reevaluate their psychosocial status at 6 months and 1 year after the surgery.
62131737|NCT01185561|NO_INTERVENTION|Usual medical care|Participants assigned to this arm represent the control group and will receive usual medical care only.
62482623|NCT04035187|EXPERIMENTAL|Sequence B (medium, slow, fast, then oral solution)|Participants first receive medium tablet, then slow tablet, then fast tablet, and then oral solution. Washout period is (at least) one week.
62482624|NCT04035187|EXPERIMENTAL|Sequence C (slow, oral solution, medium, then fast)|3, 4, 2, 1 Participants first receive slow tablet, then oral solution, then medium tablet, then fast tablet. Washout period is (at least) one week.
62482625|NCT04035187|EXPERIMENTAL|Sequence D (oral solution, fast, slow, then medium)|Participants first receive oral solution, fast tablet, then slow tablet, and then medium tablet. Washout period is (at least) one week.
62691280|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Post-Operative Radiation Therapy in Lung Cancer|SMART will be administered per each individual disease site standards
62691281|NCT04115254|EXPERIMENTAL|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mediastinal and Hilar Lymph Nodes|SMART will be administered per each individual disease site standards
62691282|NCT06332339|EXPERIMENTAL|Treatment 1|16055 NFL delta Gly4 trimer, 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate intramuscular (IM) injections (0.27 mL each) at months 0, 2, 4, 8, and 12.
62691283|NCT06332339|EXPERIMENTAL|Treatment 2|"16055 NFL delta Gly4 trimer, 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each) at months 0 and 2.~Ad4-Env145NFL, 5 x 108 viral particles (vp) to be administered intranasally (IN) (0.07 mL into 1 nostril) at month 4.~Trimer 4571, 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each) at months 8 and 12."
62131738|NCT01185561|EXPERIMENTAL|Psychoeducational intervention|Participants assigned to this arm represent the experimental group and will receive group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes
62131739|NCT00227994|EXPERIMENTAL|Galantamine|Galantamine for 12 weeks
62131740|NCT00227994|EXPERIMENTAL|Donepezil|Donepezil for 12 weeks
62131741|NCT03567941|PLACEBO_COMPARATOR|Placebo|Single dose
62131742|NCT03567941|EXPERIMENTAL|Hydrocodon bitartrate-acetaminophen arm 1|Single dose
62131743|NCT03567941|EXPERIMENTAL|Hydrocodon bitartrate-acetaminophen arm 2|Single dose
62323410|NCT01452776|EXPERIMENTAL|TAK-438 20 mg QD|
62323411|NCT04080154|EXPERIMENTAL|Anlotinib|Anlotinib p.o., qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
62323412|NCT06692920|EXPERIMENTAL|Study group|Parkinson's patients with DBS surgery planned as part of routine clinical care
62323413|NCT06390982|EXPERIMENTAL|tislelizumab|"CRT followed by 4 cycles of tislelizumab plus CAPOX and clinical response assessment:~participants with CR (cCR+ pCR confirmed by local resection of ncCR): another 4 cycles of tislelizumab plus CAPOX and 9 cycles of tislelizumab, then watch and wait.~participants with non-CR: underwent TME"
62131744|NCT03567941|ACTIVE_COMPARATOR|Reference|Single dose
62131745|NCT03488745|EXPERIMENTAL|IntelliCare + Phone Coaching|Participants will receive IntelliCare apps with phone coaching for 7 weeks. In this arm, participants will pick two IntelliCare apps to use every week. Participants will receive a phone coaching call before they use the apps, for approximately 30 minutes, as well as 3 weeks after initiating app use (10 minute call).
62131746|NCT02118064|EXPERIMENTAL|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
62131747|NCT04530149|ACTIVE_COMPARATOR|serratus anterior plane block group|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where either the bupivicaine injected. After the injection, the needle is taken out.
62131748|NCT04530149|PLACEBO_COMPARATOR|Placebo injection group|The injection of normal saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where saline is injected. After the injection, the needle is taken out.
62131749|NCT02097069|OTHER|Subgroup A|folic acid 400 mcg/day
62131750|NCT02097069|EXPERIMENTAL|Subgroup B|myo-inositol 2000 mg twice a day
62323414|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
62323415|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
62691284|NCT06332339|EXPERIMENTAL|Treatment 3|"16055 NFL delta Gly4 trimer, 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each) at months 0 and 2.~Trimer 4571, 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each) at month 4.~Ad4-Env145NFL, 5 x 108 vp to be administered IN (0.07 mL into 1 nostril) at months 8 and 12."
62738324|NCT02982772|EXPERIMENTAL|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.~Doses will be tailored and adjust as need it"
61929219|NCT06637332|EXPERIMENTAL|Daptomycin|Daptomycin given by injection at a dose determined by the treating clinicians but no less than 6mg/kg
62131751|NCT02097069|EXPERIMENTAL|Subgroup C|D-chiro-inositol 250 mg twice a day
62131752|NCT02097069|EXPERIMENTAL|Subgroup D|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
62131753|NCT04497766|EXPERIMENTAL|Nebulized magnesium sulphate|100mg of mgso4 in 20ml of normal saline via ultrasonic nebulizer
62131754|NCT04497766|EXPERIMENTAL|Intravenous magnesium sulphate|Magnesium sulphate according to weight will be given intravenously.
62323416|NCT06687278|EXPERIMENTAL|The Initiative Group|Those participating in this group will receive an Interpersonal Relationship Psychotherapy-Based Intervention Program, comprising two individual sessions and eight group sessions.
62323417|NCT06687278|NO_INTERVENTION|The Control Group|The control group will be left unaltered throughout the course of the study. In the event that participants are already undergoing medical and/or supportive care outside of the parameters of the study, they shall continue to receive such care according to standard protocols.
62323418|NCT05379361|EXPERIMENTAL|Emotional Intelligence Intervention Group|Nursing students, whose Emotional Intelligence skills were aimed to be developed, formed the intervention group.
62131755|NCT06361953|EXPERIMENTAL|Alph-Theta|15 sessions of alpha (8-12Hz) and theta (4-8Hz) push on Pz based on 10-20 international system
62131756|NCT06361953|EXPERIMENTAL|Sensory Motor Rhythm|15 sessions of sensory-motor rhythm (12-15Hz) push on Cz based on 10-20 international system
62131757|NCT03113630|EXPERIMENTAL|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
62131758|NCT03113630|EXPERIMENTAL|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
62131759|NCT03113630|EXPERIMENTAL|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
62131760|NCT03113630|ACTIVE_COMPARATOR|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
62131761|NCT03113630|ACTIVE_COMPARATOR|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
62131762|NCT03113630|ACTIVE_COMPARATOR|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
62131763|NCT05469841|EXPERIMENTAL|Pupillometry|Pain will be evaluated via pupillometry with 3 successive measurements
62131764|NCT02262468||MOM total hip replacements|all patients with MOM 36mm hip replacements
62323419|NCT05379361|PLACEBO_COMPARATOR|Environmental Awareness Educational Group|It is a group created to eliminate the risk of interaction about the intervention made due to the fact that nursing students are studying in the same semester and at the same faculty. Different from the intervention group, the students selected for this group were trained on environmental awareness, which is not related to Emotional Intelligence concepts and skills.
62691285|NCT06673745|EXPERIMENTAL|Instrumental assisted soft tissue mobilization|Instrument assisted soft tissue mobilization (IASTM) and dynamic cupping are manual therapy techniques used to address soft tissue restrictions and improve joint mobility and function. In the context of children with post-fracture elbow stiffness, these techniques can have several physiological effects. (14) This process involves the use of specialized tools to apply pressure and friction to the affected soft tissues. Which can help break down scar tissue and adhesions that may have formed following the fracture, allowing for improved tissue flexibility and mobility. This can stimulate blood flow to the area, promoting tissue healing and reducing inflammation
61929220|NCT06637332|ACTIVE_COMPARATOR|Vancomycin|Vancomycin given by injection at a dose determined by the treating clinicians to achieve a trough-based or AUC-based target
62691286|NCT06673745|EXPERIMENTAL|Dynamic cupping therapy|Dynamic cupping, on the other hand, utilizes suction cups placed on the skin to create negative pressure. This can help stretch and release tight muscles and fascia, increasing tissue flexibility and reducing stiffness. The rhythmic movement of the cups which can also stimulate lymphatic drainage and promote circulation, this will increase the removal of metabolic waste products and will also reduce swelling. (16) Both the techniques can help address the underlying soft tissue restrictions and joint stiffness commonly seen following a fracture. By improving tissue flexibility reducing inflammation, and enhancing circulation IASTM and dynamic cupping can contribute to restoring normal elbow range of motion and function in children with post fracture elbow stiffness. Instrument assisted soft tissue mobilization is one of the recently used popular myofascial intervention. It is known to improve the range of motion, function and improvestrigger point of the muscles. In recent studies it i
61929221|NCT06180694|EXPERIMENTAL|Reminiscence group|The research will be conducted in a pre-test post-test single-group, quasi-experimental research design.In this research, reminiscence therapies will be administered to individuals with dementia in sessions of approximately 45 minutes, once a week for 8 weeks. In order to hold group discussions where life stages are discussed in the program, individuals with dementia will be divided into 4 groups of 7 people each. It is aimed for the groups to be distributed homogeneously. In this regard, 4 groups consisting of similar individuals will be created, taking into account sociodemographic variables (age, gender, etc.) and dementia stage.
62131765|NCT05042375|EXPERIMENTAL|camrelizumab + famitinib|
62131766|NCT05042375|EXPERIMENTAL|pembrolizumab|
62131767|NCT05042375|EXPERIMENTAL|camrelizumab|
62131768|NCT05180851|EXPERIMENTAL|Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumors|"1.Only 1 lesion: If the tumor volume is less than or equal to 10 cm3, the whole tumor is injected radially and evenly.~If the tumor volume was \>10 cm3, the tumor was evenly divided into five quadrants and injected into one quadrant at a time.~2. If there are 2 or more lesions, the most manageable tumor injection is selected; 3. Priority should be given to the body surface metastases that meet the evaluation criteria for tumor efficacy.~4. According to patients' conditions (e.g., patients with thorax and ascites), the investigator and the research group and cooperative units jointly explored other drug administration approaches (e.g., bladder infusion, thorax and abdominal cavity administration)"
62131769|NCT00623987|ACTIVE_COMPARATOR|A|warfarin treatment
62323420|NCT05379361|NO_INTERVENTION|No Intervention: Control Group|The control group consisted of the students who continued their nursing education and did not have any intervention or application for the development of emotional intelligence skills.
61929222|NCT03306862|EXPERIMENTAL|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
61929223|NCT03306862|EXPERIMENTAL|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
61929224|NCT03306862|PLACEBO_COMPARATOR|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
61929225|NCT00109174|OTHER|One arm|Subjects receive the same test
62131770|NCT00623987|NO_INTERVENTION|B|withholding warfarin therapy
62131771|NCT02361918||Anastomotic leakage|Patient had anastomotic leakage
62131772|NCT02361918||No anastomotic leakage|Patient had no anastomotic leakage
62323421|NCT03832998|EXPERIMENTAL|Dose Level 1|Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
61929226|NCT05870293|EXPERIMENTAL|RESPONSE GROUP|The study will be done online and the application will be explained to the patients. Randomly selected groups will be made using a single-blind technique, not knowing which group is the intervention group. Pre-test will be applied to the diabetic patients included in the experimental groups and control groups. After the preliminary tests are applied to the individuals with diabetes in the intervention 1 group, a nurse coaching interview will be held with diabetes by applying the 'walt disney' method. In accordance with the principles of coaching, 2 sessions will be held under the management of the patient. After the first session, 10 days later, in the second session, life coaching with diabetes will be done with the Walt Disney method. After 10 days after the 2nd interview, the final tests will be applied at the end of the 1st month.
61929227|NCT05870293|NO_INTERVENTION|control group|The control group will be given a pre-test and a post-test 1 month later without any intervention.
62131773|NCT01973816|EXPERIMENTAL|Medical treatment|The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.
62131774|NCT01973816|ACTIVE_COMPARATOR|Surgical|The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.
62131775|NCT00663624|EXPERIMENTAL|Experimental|Subcutaneous aspart insulin every 2 hours
62131776|NCT00663624|PLACEBO_COMPARATOR|Active Comparator|Usual care as prescribed by the ED physicians
62339888|NCT01870219|ACTIVE_COMPARATOR|Group S|In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.
61929228|NCT05090566|EXPERIMENTAL|Sub-Study A|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
61929229|NCT05090566|EXPERIMENTAL|Sub-Study B|BCMA-CD3 bispecific antibody + immunomodulatory drug
61929230|NCT01164540|EXPERIMENTAL|1|Oral Treatment
62482626|NCT04221958||Electrocardiogram (ECG) Mapping|Participants will have 10 superficial electrode-patches placed on their chest in two vertical columns of 5 electrode-patches. The channels V1-V5 will be connected to one of the columns. The channel V6 will be connected to each of the electrode-patches in the second column ad recordings will be taken for approximately 2 minutes on each electrode-patch. ECG readings will be recorded.
62482627|NCT05113953|EXPERIMENTAL|Centanafadine 400 mg|Participants received centanafadine 200 mg SR tablets, orally, twice daily (BID) at a TDD of 400 mg for 8 weeks.
62482628|NCT05113953|EXPERIMENTAL|Centanafadine 200 mg|Participants received centanafadine 100 mg SR tablets, orally, BID at a TDD of 200 mg along with centanafadine matching placebo tablets, orally, BID for 8 weeks.
62482629|NCT05113953|PLACEBO_COMPARATOR|Placebo|Participants received centanafadine matching placebo tablets, orally, BID for 8 weeks.
62482630|NCT00859521|EXPERIMENTAL|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
62482631|NCT00859521|ACTIVE_COMPARATOR|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
62482632|NCT02885909|ACTIVE_COMPARATOR|Insulin protocal with CGM|Insulin protocal with continue glucose monitor
62482633|NCT02885909|ACTIVE_COMPARATOR|Insulin protocal|Insulin protocal with convential glucose monitor
62482634|NCT02885909|NO_INTERVENTION|Convential treatment|Convential insulin treatment and glucose monitor
62482635|NCT01023334|EXPERIMENTAL|Intraocular lidocaine,topical anesthesia,MSICS|experimental group:manual small incision cataract surgery under topical anesthesia with intracameral lidocaine
62482636|NCT01023334|EXPERIMENTAL|intracameral balanced salt solution,topical anesthesia,MSICS|control group:manual small incision cataract surgery under topical anesthesia with intracameral balanced salt solution.
62482637|NCT06560801|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin + standard of care
62691287|NCT06333652|EXPERIMENTAL|Revulizumab Treatment|Subjects will receive an single-dose infusion of Ravulizumab.
62691288|NCT04269863|EXPERIMENTAL|Control Group|This group of 75 patients is the control group that will be receiving the standard lowest dosage of 81mg aspirin.
62691289|NCT04269863|EXPERIMENTAL|Treatment Group|This group of 75 participants is the treatment group that will be receiving personalized aspirin dosage between 81mg-325mg (within standard clinical recommendations), which will be determined based on platelet analysis via PFA-200.
62691290|NCT05278715|EXPERIMENTAL|optic pathway glioma|
62691291|NCT04627974||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
62691292|NCT01435642||A|
62691293|NCT06326541|EXPERIMENTAL|music therapy|music therapy
62691294|NCT02172261|EXPERIMENTAL|Sequence ABC|"1. Treatment A: BI 10773 once daily from day 1 to 5~2. Treatment B: BI 10773 and glimepiride once on day 1~3. Treatment C: Glimepiride once on day 1"
62691295|NCT02172261|EXPERIMENTAL|Sequence CAB|"1. Treatment C: Glimepiride once on day 1~2. Treatment A: BI 10773 once daily from day 1 to 5~3. Treatment B: BI 10773 and glimepiride once on day 1"
62131777|NCT02867059|EXPERIMENTAL|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
62691296|NCT01443026|EXPERIMENTAL|Lycopene|Lycopene 30 mg/day
61929231|NCT01164540|PLACEBO_COMPARATOR|2|Oral treatment
62131778|NCT02867059|EXPERIMENTAL|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
62339889|NCT01870219|ACTIVE_COMPARATOR|Group K|In group K, ketamine was given to 1mg/kg ıv bolus.
62482638|NCT06560801|NO_INTERVENTION|Standard of care|standard of care only
62482639|NCT04848987|ACTIVE_COMPARATOR|Etch-and-rinse (Variolink N) resin cement|For etch-and-rinse resin cement, 40 inlays were cemented by Variolink N resin cement.
62482640|NCT04848987|PLACEBO_COMPARATOR|Self-etch (Panavia F2.0) resin cement|Regarding self-etch resin cement, 40 inlays were cemented by Panavia F2.0 resin cement.
62482641|NCT04848987|NO_INTERVENTION|Self-adhesive (RelyX Unicem) resin cement|For self-adhesive resin cement, 40 inlays were cemented by RelyX Unicem resin cement.
62482642|NCT04392999|EXPERIMENTAL|Platelet Rich Plasma|One time injection of 1.5-6cc of platelet rich plasma prepared from a blood sample into cervical facet joints. There is no trade/generic name
62482643|NCT04392999|ACTIVE_COMPARATOR|Dexamethasone Sodium Phosphate|Corticosteroid: 0.5 cc saline and 0.5cc of 10 mg/mL dexamethasone per facet joint (up to 6 mL total volume for 4 facet injections)
62482644|NCT04370509|EXPERIMENTAL|Cohort A (Pembrolizumab monotherapy)|"Preoperative treatment consists of 200mg pembrolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles (9 weeks).~Within 14-21 days following the end of treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.~Within 21-42 days after surgery, patients with R0 resection or R1 resection receive 400 mg pembrolizumab every 42 days for up to 9 cycles (1 year) and patients with R2 resection receive pembrolizumab every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
62691297|NCT01443026|PLACEBO_COMPARATOR|Placebo|Placebo
62691298|NCT05887466|EXPERIMENTAL|Low Dose Group|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Study group : 6 subjects~3. Dosage: 3.15X10\^6 cells/body (6 tracks in total, 52.5X10\^4 cells per track)"
62691299|NCT05887466|EXPERIMENTAL|High Dose Group|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Study group : 6 subjects~3. Dosage: 6.30X10\^6 cells/body (6 tracks in total, 105X10\^4 cells per track)"
62691300|NCT04744792||Patients|All the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
62691301|NCT04744792||Spouses|Spouses of the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
62738325|NCT02982772|ACTIVE_COMPARATOR|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.~Standard Flavored gums will be used as needed for 10 weeks."
62482645|NCT04370509|EXPERIMENTAL|Cohort B (Pembrolizumab + VEGF-TKI)|"Preoperative treatment consists of 200 mg pembrolizumab IV on day 1 of each cycle, and 5mg axitinib (a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)) PO BID on days 1-42 of each cycle. Axitinib maybe titered in select patients after cycle 1. Treatment repeats every 21 days for up to 3 cycles (9 weeks).~Within 14-21 days following the end of pre-operative treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.~Within 21-42 days after surgery, patients with an R0 or R1 resection receive 400 mg pembrolizumab and 1, 3, 5, 7 or 10 mg axitinib PO BID every 42 days for up to 9 cycles (1 year), and patients with an R2 resection receive pembrolizumab IV and axitinib PO BID every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
62482646|NCT06626815|NO_INTERVENTION|Classic kangaroo position group (control group)|
62482647|NCT06626815|EXPERIMENTAL|Lateral kangaroo position group|
62482648|NCT06626815|EXPERIMENTAL|Reverse kangaroo position group|
62131779|NCT02195297|ACTIVE_COMPARATOR|ANTICELLULITE GMG GIULIANI|Each included subject applied ANTICELLULITE GMG GIULIANI mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
62131780|NCT02195297|ACTIVE_COMPARATOR|SOMATOLINE|Each included subject applied SOMATOLINE CREAM mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
62131781|NCT04781790||Patients with Bone marrow failure|Standard of care of patients with bone marrow failure
62323422|NCT03832998|EXPERIMENTAL|Dose Level 2|Participants will be randomized to one of two doses determined by their body-weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
62323423|NCT03832998|PLACEBO_COMPARATOR|Placebo|
62323424|NCT01958034|EXPERIMENTAL|Dietary supplement with bilberry extract|Billberry powder 3 times daily for 2 months.
62323425|NCT01958034|NO_INTERVENTION|Control|No dietary supplement with bilberry extract
62323426|NCT03095183|PLACEBO_COMPARATOR|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
62482649|NCT02319980|ACTIVE_COMPARATOR|Surgical intervention|All participants in this group will be assigned to receive extracranial-intracranial arterial bypass surgery.
62482650|NCT02319980|NO_INTERVENTION|Conservative management(medical management)|All participants in this group will be assigned to receive conservative management or medical management which involves drug therapy as considered appropriate for medical symptoms by the treating investigator.
62482651|NCT04356729|EXPERIMENTAL|Atezolizumab and Bevacizumab|"The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.~* Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks~* Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.~Treatment will be administered on an outpatient basis Study treatment will continue until study doctors decide to stop therapy due to criteria which may include disease progression, adverse events or changes in condition. Participants will be followed for survival health information following treatment until the study ends, which could be approximately 5 years from start of treatment"
62482652|NCT04504747||RH+|Prospective blood and biopsie analyses
62131782|NCT03921580|PLACEBO_COMPARATOR|Control Canned Tuna|Control Canned Tuna
62131783|NCT03921580|EXPERIMENTAL|Enriched Canned Tuna Variety 1|Enriched Canned Tuna Variety 1: Wakame fiber
62323427|NCT03095183|ACTIVE_COMPARATOR|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
62323428|NCT01318083|ACTIVE_COMPARATOR|Alogliptin 12.5 mg QD and Glimepiride QD or BID|
62323429|NCT01318083|ACTIVE_COMPARATOR|Alogliptin 25 mg QD and Glimepiride QD or BID|
62323430|NCT01318083|ACTIVE_COMPARATOR|Glimepiride 1, 2, 3 or 4 mg QD or BID|
62482653|NCT04504747||HER2+|Prospective blood and biopsie analyses
62482654|NCT04504747||TN|Prospective blood and biopsie analyses
62697499|NCT06177704||Patients with diagnosis of probable/definite DRT after LAAO|"Patients with diagnosis of probable/definite DRT after LAAO detected by transesophageal echocardiography (TEE) or cardiac computed tomography (CT).~In all patients after the LAAO procedure, a first imaging evaluation at 45 to 90 days, and a second imaging evaluation at 12 months is recommended.~In case of DRT diagnosis, and following the recent SCAI/HRS recommendations, a repeat imaging at 45- to 90-day intervals is recommended to assess for DRT resolution with eventual cessation of anticoagulation.~In case of DRT resolution, a sequential imaging evaluation at ±90-day, ±180-day, and ±365 days after the imaging test where DRT was resolved is recommended"
62131784|NCT03921580|EXPERIMENTAL|Enriched Canned Tuna Variety 2|Enriched Canned Tuna Variety 2: Polyphenols
62323431|NCT03660371|EXPERIMENTAL|PPV/MP|Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
62323432|NCT03660371|ACTIVE_COMPARATOR|PPV without MP|Control Group: Subjects do not undergo ILM peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
62482655|NCT04667338||Narcolepsy Type 1|Participants with confirmed diagnosis of narcolepsy type 1 (NT1) defined by the International Classification of Sleep Disorders, Third Edition (ICDS-3) will be observed for up to 16 months.
62482656|NCT04667338||Narcolepsy Type 2|Participants with confirmed diagnosis of narcolepsy type 2 (NT2) defined by the ICDS-3 will be observed for up to 16 months.
62482657|NCT06627543||Gaucher type patients|
62323433|NCT03931486||Operatively treated patients with Achilles tendon rupture|Cohort of operatively treated patients with acute Achilles tendon rupture.
62323434|NCT05303571||Monodof|monofocal and EDOF lens
62323435|NCT05303571||Bidof|Bifocal and EDOF lens
62323436|NCT02824380|EXPERIMENTAL|Sequence A|Period 1: DA-4001 H(High dose) Period 2: DA-4001 L(Low dose)
62323437|NCT02824380|EXPERIMENTAL|Sequence B|Period 1: DA-4001 L(Low dose) Period 2: DA-4001 H(High dose)
62339890|NCT01218789|EXPERIMENTAL|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
62339891|NCT00756496|EXPERIMENTAL|1|
62339892|NCT02851433|EXPERIMENTAL|Sevoflurane Group|
61929232|NCT01843088|EXPERIMENTAL|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
61929233|NCT01843088|PLACEBO_COMPARATOR|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
61929234|NCT05053113|EXPERIMENTAL|Group 1 (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls over 30-45 minutes each from a health coach weekly during month 1, twice monthly during months 2-4, and monthly during months 5-6 for a total of 12 phone calls that focus on identifying needs, practicing autonomy supportive behaviors, and the development of a mutual support plan. Participants also engage in at least one physical activity per week with their partner and monitor their own and each other's activity using a FitBit. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days. Participants also receive an electronic newsletter twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity.
61929235|NCT05053113|ACTIVE_COMPARATOR|Group 2A (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls from a health coach as in Intervention I that focus on providing support for behavioral skills, including monitoring physical activity, goal-setting, and problem-solving to overcome barriers to physical activity. Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
62131785|NCT02545738|EXPERIMENTAL|Liraglutide|Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
62691302|NCT06638177||Health Professionals Follow-Up Study|The HPFS is an ongoing prospective study of 51,529 male health professionals (dentists, veterinarians, pharmacists, optometrists, osteopaths, and podiatrists) who were 40 to 75 years of age at enrollment in 1986. Approximately 97% of participants were of white European descent. Similar to the NHS cohorts, participants have been followed through mailed biennial questionnaires (https://www.hsph.harvard.edu/hpfs/hpfs-questionnaires/) that ascertained medical history, lifestyle, and health-related behaviors, as previously described.88,89 The 2004, 2006, and 2008 questionnaires included questions that elicited information on history of HZ and the year when the episode of HZ occurred. The upcoming 2024 questionnaire will also elicit information on history of HZ, whether participants had been vaccinated against HZ and the date of vaccination.
62691303|NCT06638177||Nurses Health Study|In 1976, the NHS I enrolled 121,700 female nurses ages 30 to 55 years who returned a mailed questionnaire regarding their medical history and lifestyle.85,86 There were no exclusions by race; 95% were white reflecting the racial make-up of nurses at that time. Participants receive follow-up questionnaires biennially to record newly diagnosed illnesses and to update lifestyle factors and every 4 years received semiquantitative food frequency questionnaires (FFQs).87 The questionnaires (available at https://nurseshealthstudy.org/participants/questionnaires) are administered every other year, and the 40-year follow-up exceeds 90% of eligible person-time. Information on history of HZ and the date at which HZ occurred was collected on the 2000, 2004, 2008, 2012, 2019, 2021 and 2023 biennial questionnaires. The 2021 and 2023 questionnaires also collected information on whether participants had been vaccinated against HZ and the date of vaccination.
62323438|NCT06092372|NO_INTERVENTION|Control|Participants in the control group will be asked to fill out online surveys and book appointments for blood sample collection and weight measurements at the beginning and at the end of the study. In addition, participants will be asked to report their weight two more times during the study (in months 2 and 4) with an online survey that will be sent via the MyBiobank portal. The participation in the study ends with another personal visit to the clinic for blood sampling and weight measurement six months after registration. No other personal advice or support is provided to this group.
62339893|NCT02851433|ACTIVE_COMPARATOR|Propofol Group|
62339894|NCT05528874|EXPERIMENTAL|Group 1: randomized to receive recipe 4 after the 5 days single arm study, and then recipe 5|Healthy volunteers that signed informed consent. Will consume all recipes in crescent order.
62339895|NCT05528874|EXPERIMENTAL|Group 2: randomized to receive recipe 5 after the 5 days single arm study, and then recipe 4|Same as before but randomized to receive recipe 5 before recipe 4.
62691304|NCT06638177||Nurses Health Study II|In 1989, 116,430 female registered nurses from 15 states ages 25-42 years completed the initial questionnaire and comprise the NHS II. There were no exclusions by race; 2% were black, 2% Asian, and 2% Hispanic. As in NHS I, participants receive follow-up questionnaires biennially (https://nurseshealthstudy.org/participants/questionnaires) to record newly diagnosed illnesses and to update lifestyle factors and every 4 years received semiquantitative food frequency questionnaires.87 The average follow-up rate over 30 years is \> 90% of eligible person-time. The 2001, 2005, 2013, 2017, 2019, 2021 and 2023 NHS II questionnaires included questions that elicited information on history of HZ and the year when the episode of HZ occurred. The 2017, 2021 and 2023 questionnaires also collected information on whether participants had been vaccinated against HZ and the date of vaccination.
62738326|NCT02661386|OTHER|Manometry Device|"During the last 10 minutes of subjects waking up from anesthesia, the motility procedure will be performed."
62738327|NCT01195519||peritoneal dialysis and hemodialysis patients|peritoneal dialysis and hemodialysis patients
62738328|NCT00412958|EXPERIMENTAL|Ocriplasmin 25µg|25µg of ocriplasmin intravitreal injection
61929236|NCT05053113|ACTIVE_COMPARATOR|Group 2B (FitBit, newsletter, accelerometer)|Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 to share basic health education related to physical activity and provide support for engagement. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
62131786|NCT02545738|PLACEBO_COMPARATOR|Placebo|Placebo s.c. for 12 weeks.
62131787|NCT02624258|EXPERIMENTAL|RNA CART19 cells|CD19 RNA redirected autologous T-cells (RNA CART19 cells)
62131788|NCT01972724|EXPERIMENTAL|Pioglitazone 15 mg (Double-Blind)|Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
62482658|NCT04629326|EXPERIMENTAL|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans
62482659|NCT01904162|EXPERIMENTAL|healthy young adult males|healthy young adult males receiving 400 mg finafloxacin single dose
62482660|NCT01904162|EXPERIMENTAL|healthy young adult females|healthy young adult females receiving 400 mg finafloxacin single dose
62482661|NCT01904162|EXPERIMENTAL|healthy elderly adult males|healthy elderly adult males receiving 400 mg finafloxacin single dose
62482662|NCT01904162|EXPERIMENTAL|healthy elderly adult females|healthy elderly adult females receiving 400 mg finafloxacin single dose
62482663|NCT03600363|EXPERIMENTAL|metformin arm|
62482664|NCT03600363|PLACEBO_COMPARATOR|control arm|
62482665|NCT06235203|ACTIVE_COMPARATOR|The control group|Endoscopic surgery + adjuvant therapy
62482666|NCT06235203|EXPERIMENTAL|The experimental group|Neoadjuvant therapy +endoscopic surgery + adjuvant therapy
62482667|NCT02407548|EXPERIMENTAL|combined group|each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.
62482668|NCT02407548|EXPERIMENTAL|CoQ10 group|each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.
62482669|NCT02407548|OTHER|placebo group|each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.
62482670|NCT06243380||Patients with a possible allergy to beta-lactam antibiotics|Minors and adults with a possible allergy to beta-lactam antibiotics.
62482671|NCT05309135|ACTIVE_COMPARATOR|Low dose Rho kinase inhibitor Y-27632|Low dose Rho kinase inhibitor Y-27632
62482672|NCT05309135|ACTIVE_COMPARATOR|Mid dose Rho kinase inhibitor Y-27632|Mid dose Rho kinase inhibitor Y-27632
62482673|NCT05309135|ACTIVE_COMPARATOR|High dose Rho kinase inhibitor Y-27632|High dose Rho kinase inhibitor Y-27632
62482674|NCT06561984|EXPERIMENTAL|Intervention group|The intervention group will receive antenatal educational sessions regarding modes of delivery in addition to the routine care in the antenatal clinic
62482675|NCT06561984|NO_INTERVENTION|Control group|The control group will receive only the routine care in the antenatal clinic
62482676|NCT06200363|EXPERIMENTAL|T3011 + Regorafenib|
62482677|NCT03022643|NO_INTERVENTION|Pain Patients|40 Pain Patients will be screened for social and behavioral rhythms with no treatment involved. All patients will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
62482678|NCT03022643|NO_INTERVENTION|Controls|40 Controls will be screened for social and behavioral rhythms with no treatment involved. All Controls will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
62482679|NCT03022643|EXPERIMENTAL|Treatment|10 patients from the original 40 will receive Interpersonal Social Rhythms Psychotherapy and Bright Light Device therapy to improve social and behavioral rhythms.
62482680|NCT00492076|ACTIVE_COMPARATOR|1|Pangramin Plus Dermatophagoides pteronyssinus 100%
62691305|NCT06639022|ACTIVE_COMPARATOR|Serratus posterior superior intercostal plane block|After the patients are monitored and in the supine position, after appropriate field sterilization, a serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacain) under ultrasound guidance. In the intraoperative period, intravenous analgesics (dexketoprofen 50 mg, tramadol 100 mg) will be given.
62482681|NCT00492076|PLACEBO_COMPARATOR|2|Pangramin Plus placebo
62482682|NCT04050709|EXPERIMENTAL|PD-L1 t-haNK Dose Level 1|PD-L1 t-haNK will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 1 is 3 to 6.
62482683|NCT04050709|EXPERIMENTAL|PD-L1 t-hanK Dose Level 2|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 2 is 3 to 6.
62482684|NCT04050709|EXPERIMENTAL|PD-L1 t-haNK Dose Level Recommended phase 2 dose (RP2D)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into RP2D is 4.
62482685|NCT04050709|EXPERIMENTAL|PD-L1 t-haNk Dose -1a (if needed)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level -1a is 3 to six, if needed.
62691306|NCT06639022|ACTIVE_COMPARATOR|Erector spinae plane block|After the patients are monitored and in the supine position, after appropriate field sterilization, a erector spinae plane block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacain) under ultrasound guidance. In the intraoperative period, intravenous analgesics (dexketoprofen 50 mg, tramadol 100 mg) will be given.
62482686|NCT02557035|EXPERIMENTAL|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
62482687|NCT02557035|ACTIVE_COMPARATOR|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
62482688|NCT00419640|EXPERIMENTAL|LAS + DAO ON|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.
62482689|NCT00419640|EXPERIMENTAL|LAS + DAO OFF|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.
62482690|NCT00419640|EXPERIMENTAL|RAA + DAO ON|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.
62482691|NCT00419640|ACTIVE_COMPARATOR|RAA + DAO OFF|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.
62482692|NCT05635448|EXPERIMENTAL|Intervention|Will be offered the BT coaching intervention over 4-months (February 1st 2023- May 31st 2023).
62482693|NCT05635448|PLACEBO_COMPARATOR|Waitlist control|Will be offered the coaching intervention following 4-month waitlist control (September 1st 2023 - December 31st 2023).
62738329|NCT00412958|EXPERIMENTAL|Ocriplasmin 75µg|75µg of ocriplasmin intravitreal injection
62738330|NCT00412958|EXPERIMENTAL|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
62482694|NCT06352775|EXPERIMENTAL|Prospective Treatment Group|Patients receive calcium carbonate (500mg every 4 hours, per standardized treatment protocol) plus standard-dose oxytocin for labor induction
62482695|NCT06352775|NO_INTERVENTION|Retrospective Historical Control Group|Patients who presented for induction at the same institution within the previous three years and received standard-dose oxytocin alone for labor induction and were not treated with calcium carbonate
62482696|NCT01711632|EXPERIMENTAL|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
62482697|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
62482698|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
62482699|NCT02957942|EXPERIMENTAL|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
62482700|NCT02957942|ACTIVE_COMPARATOR|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
62482701|NCT06562868|ACTIVE_COMPARATOR|Bulk-fill Composite Resin|Before starting the restoration procedure, local anesthesia was administered to the tooth or teeth. The caries were removed and the preparation was completed. Following the washing and drying of the cavities, cotton rolls and saliva ejectors were placed to ensure isolation. An appropriate matrix system and wooden wedges were applied. A 0.2% chlorhexidine gluconate solution was used as the cavity disinfectant. Subsequently, the enamel surfaces of the teeth were roughened for 30 seconds using a selective etching technique with 37% phosphoric acid. The universal dental adhesive system was applied according to the manufacturer's instructions. Restorations were performed with Filtek One Bulk Fill Restorative , ensuring that each layer did not exceed 4 mm in thickness.The restorations were evaluated according to FDI criteria at baseline, 1 year and 2 years.
61929237|NCT05780710|OTHER|Meds2023 GROUP 1|"GROUP 1 participants are asked to wear the Aktiia bracelet continuously every day for 13 weeks in total and initialize their Aktiia bracelet with the Aktiia cuff at different timepoints.~In parallel, GROUP 1 participants are asked to take 3 successive Blood Pressure lowering drugs during 2 weeks per treatment. Treatment periods are followed by 2 weeks of washout (no treatment)."
61929238|NCT05780710|OTHER|Meds2023 GROUP 2|"GROUP 2 participants are asked to wear the Aktiia bracelet continuously every day for 19 weeks in total and initialize their Aktiia bracelet with the Aktiia cuff at different timepoints.~In parallel, GROUP 2 participants are asked to stop their previous antihypertensive monotherapy for the first 2 weeks of the study participation and then take 3 successive blood pressure-lowering medications during 2 weeks per treatment. Treatment periods are followed by 2 weeks of washout (no treatment). Finally, they resume their initial monotherapy intake for a period of 4 weeks."
62323439|NCT06092372|EXPERIMENTAL|Diet Intervention|Participants in the diet intervention group will be asked to fill out online surveys and book appointments for blood sample collection and weight measurements at the beginning and at the end of the study. After visiting the clinic for the first time, each participant will be contacted to start a diet coaching program and to obtain an activity tracking device. In addition, each participant will be asked to report their weight two more times during the study (in months 2 and 4) with an online survey that will be sent to them via the online portal of the study (OmaBiopankki portal). The study participation ends with another personal visit to the clinic for blood sampling and weight measurement six months after registration.
62323440|NCT03474133|EXPERIMENTAL|Brentuximab|Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
62323441|NCT04212793|EXPERIMENTAL|NIR endoscopic TSS with 4.5 mg bevacizumab-800CW|IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
62323442|NCT04212793|EXPERIMENTAL|NIR endoscopic TSS with 10 mg bevacizumab-800CW|IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
62323443|NCT04212793|EXPERIMENTAL|NIR endoscopic TSS with 25 mg bevacizumab-800CW|IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
62323444|NCT02673593|PLACEBO_COMPARATOR|Placebo|Taken orally as a single dose (Cohorts 1 - 4) Taken orally as a multiple daily dose for 28 days (Cohorts 5 - 7)
62482702|NCT06562868|ACTIVE_COMPARATOR|Traditional Posterior Composite Resin|Before starting the restoration procedure, local anesthesia was administered to the tooth or teeth. The caries were removed and the preparation was completed. Following the washing and drying of the cavities, cotton rolls and saliva ejectors were placed to ensure isolation. An appropriate matrix system and wooden wedges were applied. A 0.2% chlorhexidine gluconate solution was used as the cavity disinfectant. Subsequently, the enamel surfaces of the teeth were roughened for 30 seconds using a selective etching technique with 37% phosphoric acid. The universal dental adhesive system was applied according to the manufacturer's instructions. Restorations were performed with Clearfil Majesty Posterior.The restorations were evaluated according to FDI criteria at baseline, 1 year and 2 years.
62482703|NCT06562868|ACTIVE_COMPARATOR|High-filler Flowable Composite Resin|Before starting the restoration procedure, local anesthesia was administered to the tooth or teeth. The caries were removed and the preparation was completed. Following the washing and drying of the cavities, cotton rolls and saliva ejectors were placed to ensure isolation. An appropriate matrix system and wooden wedges were applied. A 0.2% chlorhexidine gluconate solution was used as the cavity disinfectant. Subsequently, the enamel surfaces of the teeth were roughened for 30 seconds using a selective etching technique with 37% phosphoric acid. The universal dental adhesive system was applied according to the manufacturer's instructions. Restorations were performed with high-filler flowable composite resin.The restorations were evaluated according to FDI criteria at baseline, 1 year and 2 years.
62482704|NCT04964973|ACTIVE_COMPARATOR|Control Group|1. Control group. Patients have performed the conventional postsurgical program without adding TENS.
62482705|NCT04964973|EXPERIMENTAL|Experimental Group|Experimental group. The application of TENS has been added to the physiotherapy program. It had a frequency of 100 Hz and a phase duration of 100 µsec for a period of 30 minutes (through channel 1 of the TENS equipment), receiving and feeling the patient the physical sensation of the current.
62323445|NCT02673593|EXPERIMENTAL|DS102 100mg Single Dose|Taken orally once by Cohort 1
62691307|NCT06639022|ACTIVE_COMPARATOR|Group without peripheral nerve block|After the patients are monitored, they will be operated under general anesthesia without peripheral nerve block and intraoperative intravenous analgesics (dexketoprofen 50 mg, tramadol 100 mg) will be given.
62691308|NCT01045733|EXPERIMENTAL|IQ Toric IOL|AcrySof IQ Toric intraocular lens (IOL) randomly assigned to one eye, with AcrySof IQ Aspheric IOL with Limbal Relaxing Incision (LRI) procedure in the fellow eye for contralateral implantation.
62691309|NCT01045733|ACTIVE_COMPARATOR|IQ Aspheric IOL + LRI|AcrySof IQ Aspheric intraocular lens (IOL) with Limbal Relaxing Incision (LRI) procedure randomly assigned to one eye, with AcrySof IQ Toric IOL in the fellow eye for contralateral implantation
62691310|NCT01720836|EXPERIMENTAL|Stage IA or I/II NSCLC or neuroendocrine carcinoid tumor|Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
62691311|NCT01720836|EXPERIMENTAL|Stage IB/II/IIIA|Resection and adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
62323446|NCT02673593|EXPERIMENTAL|DS102 500mg Single Dose|Single Dose taken orally on three separate occasions by Cohort 2 (second and third dose assessing food effect)
62323447|NCT02673593|EXPERIMENTAL|DS102 1000mg Single Dose|Taken orally once by Cohort 3
62323448|NCT02673593|EXPERIMENTAL|DS102 2000mg Single Dose|Taken orally once by Cohort 4
62323449|NCT02673593|EXPERIMENTAL|DS102 500mg Multiple Dose|Taken orally once a day for 28 days by Cohort 5
62323450|NCT02673593|EXPERIMENTAL|DS102 1000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 6
62323451|NCT02673593|EXPERIMENTAL|DS102 2000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 7
62323452|NCT02433223||2006 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation
62323453|NCT02433223||2011 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 results.
62323454|NCT02433223||2013 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 \& 2011 results.
62323455|NCT02433223||2015 Patients|Group added to reflect recency of practice. Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 \& 2011 results.
62323456|NCT02226094|EXPERIMENTAL|DWT device dose A|Deep Wave Trabeculoplasty (DWT) dose A (10 second spot treatments).
62323457|NCT02226094|ACTIVE_COMPARATOR|Ellex Tango SLT machine|Selective Laser Trabeculoplasty (SLT)
62323458|NCT02226094|SHAM_COMPARATOR|DWT Sham|Deep Wave Trabeculoplasty (DWT) but device not applied to ocular surface.
62323459|NCT02226094|EXPERIMENTAL|DWT device dose B|Deep Wave Trabeculoplasty (DWT) dose B (20 second spot treatments).
62691312|NCT01720836|EXPERIMENTAL|Stage IIIA or IIIB|Concomitant chemo-irradiation followed by 3 cycles of vaccine + PolyICLC.
62131789|NCT01972724|EXPERIMENTAL|Pioglitazone 30 mg (Double-Blind)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
62323460|NCT06258811|EXPERIMENTAL|Experimental arm|Neoadjuvant immunochemotherapy (albumin paclitaxel+cisplatin+tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation + tislelizumab maitainance)
62323461|NCT06258811|NO_INTERVENTION|Control arm|Standard therapy of radical surgery +adjuvant therapy (radiation/chemoradiation)
62323462|NCT04040088|EXPERIMENTAL|Cohort A (68Ga-DOTATATE, PET/CT)|Patients with newly diagnosed high-risk neuroendocrine cancer receive 68Ga-DOTATATE intravenously (IV) and undergo PET/CT over 20-30 minutes at diagnosis (before any treatment) and at the time of radiation treatment planning.
62323463|NCT04040088|EXPERIMENTAL|Cohort B (68Ga-DOTATATE, PET/CT)|Patients with previously diagnosed high-risk neuroendocrine cancer receive 68Ga-DOTATATE IV and undergo PET/CT over 20-30 minutes at the time of radiation treatment planning.
62323464|NCT02989636|EXPERIMENTAL|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
62323465|NCT02989636|EXPERIMENTAL|Arm II (nivolumab, SRS)|Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
62323466|NCT02718794|EXPERIMENTAL|Simulation training first|A highly customized interactive medium or program that allows individuals to learn and practice real world activities in an accurate, realistic, safe and secure environment.
62323467|NCT02718794|EXPERIMENTAL|Problem-based learning first|Instructional use of examples or cases to teach using problem-solving skills and critical thinking.
62323468|NCT02237053|ACTIVE_COMPARATOR|Glucagon with Octreotide and insulin|Overnight (10 hours) infusion of glucagon, then 3 hours infusion of glucagon with concurrent infusions of Octreotide and insulin.
62323469|NCT02237053|PLACEBO_COMPARATOR|Placebo, Glucagon with Octreotide and Insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of glucagon with concurrent infusions of Octreotide and insulin.
62323470|NCT02237053|PLACEBO_COMPARATOR|Placebo, with Octreotide and insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of saline with concurrent infusions of Octreotide and insulin.
62323471|NCT01707069|EXPERIMENTAL|Group 1: 4mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who are skin test negative to Japanese Red Cedar pollen or Mountain Cedar pollen and have no reactive Cry J 2 antibodies.~Group 1: will receive 4mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered to be the optimal DNA vaccine dose based on historical clinical data from other DNA vaccine studies). The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) of a 4 mg dose at 14 day intervals."
62339896|NCT05564286|EXPERIMENTAL|fosaprepitant group|Intravenous fosaprepitant of 150mg was given before cisplatin administration on day 1. All patients received tropisetron 5mg and dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
62482706|NCT04964973|PLACEBO_COMPARATOR|Placebo Group|Placebo group. In this group, the same program as group 2 was proposed, using, in this case, channel 2, which did not activate the electric current, and the patient did not receive any physical sensation
62691313|NCT06639113|EXPERIMENTAL|Self administration of medication by the patient|Self administration of medication by the patient
62131790|NCT01972724|EXPERIMENTAL|Pioglitazone 30 mg (Open-Label)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
62131791|NCT05519202|EXPERIMENTAL|SOX and Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1) The treatment period of the above drugs was 3 weeks, and the duration of preoperative treatment was 3 cycles. After treatment, the patient underwent surgery after evaluation. Four cycles of adjuvant therapy with the original regimen (preoperative) were performed after surgery.
62131792|NCT02488720||Clinically normal older inviduals|500 clinically normal older individuals with florbetapir positron emission tomography (PET) scan that does not show evidence of brain amyloid pathology at screening.
62131793|NCT03403478|NO_INTERVENTION|Control group|The volunteers will be instructed to remain in an orthostatic position immersed in water up to the imaginary line of the xiphoid process for 45 minutes without performing jerky body movements.
62131794|NCT03403478|EXPERIMENTAL|LICE|The light-intensity continuou exercise (LICE) session comprises a 45-minute of guide walking into the pool at 55-60% of maximum heart rate (HRmax). The HR will be checked every 2 minutes during the whole session.
62131795|NCT03403478|EXPERIMENTAL|MICE|The moderate-intensity continuous exercise (MICE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (30 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 30 minutes and will be performed by 3 sets of 5 exercises lasting 2 minutes each one at 70-75% HRmax. For all phases, HR will be measured every 2 minutes during the whole session.
62691314|NCT06639113|NO_INTERVENTION|Administration of medication by the nurses|Administration of medication by the nurses during medication administration rounds
62131796|NCT03403478|EXPERIMENTAL|HIIE|The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
62131797|NCT03403478|EXPERIMENTAL|Aquatic exercise training|The participants will be submitted to a 12-weeks of aquatic exercise program, twice a week, for 1 hour each day.
62131798|NCT02711436|ACTIVE_COMPARATOR|Computed Tomography Scan|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with Computed Tomography scan.
62323472|NCT01707069|EXPERIMENTAL|Group 2: 2mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four half (2 mg) dose dosing regimen.~Group 2: will receive 2 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection(considered ½ of the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive three (3) additional 2 mg doses at 14 day intervals between doses (4 doses in total)."
62323473|NCT01707069|EXPERIMENTAL|Group 3: 4 mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four full (4 mg) dose dosing regimen.~Group 3: will receive 4 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive 3 additional 4 mg doses at 14 day intervals between doses (4 doses in total)."
62323474|NCT04315649|EXPERIMENTAL|3D movie|3D movie viewing
62339897|NCT05564286|ACTIVE_COMPARATOR|control group|The control group was delivered tropisetron 5mg and dexamethasone 5mg only.
62482707|NCT06394648||Geriatric individuals living in nursing homes|Geriatric individuals living in nursing homes will be included.
62691315|NCT04421664|EXPERIMENTAL|Treatment|Participants in this arm will receive the study drug, hydroxychloroquine.
62691316|NCT04421664|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo treatment.
62691317|NCT03952351|EXPERIMENTAL|CTCA with standard care|Patients will be referred for CT Coronary Angiography, ideally within 2 weeks of randomisation
62691318|NCT03952351|NO_INTERVENTION|Standard care|
62691319|NCT06149442|EXPERIMENTAL|Dose of five muscle incisions|Subjects treated in this group will receive an in-out technique with a dosage of five incisions in the myofascial trigger point of the levator scapulae muscle.
62691320|NCT06149442|EXPERIMENTAL|Dose of ten muscle incisions|Subjects treated in this group will receive an in-out technique with a dosage of ten incisions in the myofascial trigger point of the levator scapulae muscle.
62691321|NCT06149442|EXPERIMENTAL|Dose of fifteen muscle incisions|Subjects treated in this group will receive an in-out technique with a dosage of fifteen incisions in the myofascial trigger point of the levator scapulae muscle.
62131799|NCT02711436|ACTIVE_COMPARATOR|Fast Magnetic Resonance Imaging|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with T1/T2-weighted MRI.
62691322|NCT06639737|ACTIVE_COMPARATOR|control|Standard care : total intravenous anesthesia followed by stroke volume optimization using oesophageal doppler
62691323|NCT06639737|EXPERIMENTAL|preoperative echography|Stroke volume optimization using transthoracic echocardigraphy (sub aortic velocity time integral) before induction of total intravenous anesthesia
62131800|NCT05381233|OTHER|hemiplegic group|hemiplegic patient
62131801|NCT05381233|OTHER|Group diaplegic|diaplegic patient
62131802|NCT05381233|OTHER|group quadriplegic|quadriplegic patient
62131803|NCT00198315|ACTIVE_COMPARATOR|Surgery Control|Patients will receive standard of care surgical removal of their tumor.
61929239|NCT05780710|OTHER|Meds2023 GROUP 3|"GROUP 3 participants are asked to wear the Aktiia bracelet continuously every day for 4 weeks in total and initialize their Aktiia bracelet with the Aktiia cuff at different timepoints.~In parallel, GROUP 3 participants are asked to take their initial antihypertensive medication that doesn't allow them to have controlled blood pressure for 1 week. For the following 3 weeks of the study participation, GROUP 3 participants are asked to take an individualized antihypertensive therapy assigned by the investigator."
61929240|NCT06701006|NO_INTERVENTION|Usual Care|
61929241|NCT06701006|EXPERIMENTAL|Integrated skills and safety planning app|Use of Jaspr app in clinic + at home
62323475|NCT03473379||Phase 1: concept elicitation and coding|The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.
62323476|NCT03473379||Phase 2: Item generation and analysis|The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.
62323477|NCT03473379||Phase 3: Instrument refinement and internal validation|The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire
62323478|NCT03473379||Phase 4: External validation|In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments
62323479|NCT02532634|EXPERIMENTAL|ramosetron, aprepitant, dexamethasone|"1. Ramosetron 0.3mg IV day1~2. Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~3. Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
62691324|NCT03286569|ACTIVE_COMPARATOR|Active upper Wilson appliance|Active upper arch Wilson quadhelex appliance
62691325|NCT03286569|PLACEBO_COMPARATOR|Non active upper expansion appliance|Non-Active upper arch Wilson quadhelex appliance
62691326|NCT06016725|EXPERIMENTAL|Arm 1 (nutritional counseling, resistance training)|Patients participate in online nutritional counseling over 30 minutes in weeks 1, 3, 5, 7, 9, and 11, and participate in online resistance training sessions weekly over 30 minutes in weeks 1-6 and biweekly at weeks 8, 10, and 12. Patients also receive educational materials at baseline.
62323480|NCT02532634|ACTIVE_COMPARATOR|palonosetron, aprepitant, dexamethasone|"1. Palonosetron 0.25mg IV day1~2. Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~3. Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
61929242|NCT05210231|EXPERIMENTAL|Active anodal tDCS|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
61929243|NCT05210231|SHAM_COMPARATOR|Sham anodal tDCS|The direct electric current will apply through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For the sham condition, the electrodes will be placed at the same positions as for the anodal tDCS. However, the stimulator will turn off after 30 s of stimulation. As a result, subjects will report the same sensory feelings from the beginning of the real tDCS conditions, specifically itching and tingling feelings on the scalp for the first few seconds of tDCS, but not thereafter, whether or not the stimulation will continue or stop.
61929244|NCT03271229|ACTIVE_COMPARATOR|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
61929245|NCT03271229|ACTIVE_COMPARATOR|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
61929246|NCT00295828|ACTIVE_COMPARATOR|1|Panretinal Photocoagulation (PRP)
61929247|NCT00295828|ACTIVE_COMPARATOR|2|Panretinal Photocoagulation and Macugen Intravitreal Injection
62323481|NCT02065869|EXPERIMENTAL|BPX-501 T cells and rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).~Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
62323482|NCT06573073||NSCLC with EGFR mutation|
62691327|NCT06016725|ACTIVE_COMPARATOR|Arm 2 (educational materials)|Patients receive educational materials at baseline.
62691328|NCT01472185|PLACEBO_COMPARATOR|Placebo|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
62691329|NCT01472185|EXPERIMENTAL|Ranolazine|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
62691330|NCT02512939|EXPERIMENTAL|Contacts of TB cases|Blood test, not yet marketed, development phase
62691331|NCT01837550|ACTIVE_COMPARATOR|Control group|no professional support
62482708|NCT06394648||Geriatric individuals living at home|Geriatric individuals living at home will be included.
62691332|NCT01837550|EXPERIMENTAL|Intervention group|Professional support via Internet
62738331|NCT00412958|PLACEBO_COMPARATOR|Placebo|Intravitreal injection of placebo
62738332|NCT01887613||Regnite group|Patients who receive Regnite
61929248|NCT05516953|NO_INTERVENTION|Group 1(Control group)|include 50 patients scheduled for sleeve gastrectomy
61929249|NCT05516953|EXPERIMENTAL|Group 2|which include 50 patients scheduled for sleeve gastrectomy
61929250|NCT05514717|EXPERIMENTAL|XMT-2056|XMT-2056 alone (monotherapy)
61929251|NCT02744469||New patients|''New tuberculosis patients'' are patients just diagnosed for tuberculosis, and who were never treated for tuberculosis or who are treated for less than 1 month. In total, 1192 new patients will be recruited.
61929252|NCT02744469||Retreatment patients|''Retreatment tuberculosis patients'' are patients just diagnosed for tuberculosis and who were previously treated for tuberculosis (for a duration of 1 month at least). This group includes: patients with treatment relapse, failure and patients who return after default. In total, 298 retreatment patients will be recruited.
62691333|NCT06645028|EXPERIMENTAL|Intensive treatment programme|Intervention Group: 8-day intensive treatment where each treatment day consists of the following schedule: Physical activity: 30 minutes Prolonged Exposure (PE): 90 minutes Physical activity: 30 minutes Lunch Physical activity: 60 minutes Eye Movement Desensitization and Reprocessing (EMDR): 90 minutes Physical activity: 30 minutes (omitted on days 4 and 8) Dinner Psychoeducation (omitted on days 4 and 8) Participants stay at the SÄS patient hotel during the treatment (with a three-day weekend break between treatment days 1-4 and 5-8). The treatment concept includes therapist rotation, meaning that participants switch therapists between PE and EMDR sessions. The purpose of this is to increase focus on the processing process rather than the relationship between the therapist and the client.
62691334|NCT06645028|ACTIVE_COMPARATOR|Treatment as usual|Control group: 16 treatment sessions (90 minutes in duration) either Eye movement desensitisation and reprocessing (EMDR) or Prolonged Exposure (PE) in a standard outpatient format-weekly sessions. Participants can choose to attend 6 sessions of Psychoeducation for PTSD in a group format before starting EMDR or PE.
62691335|NCT04415151|EXPERIMENTAL|Tofacitinib|Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
62691336|NCT04415151|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered.
62691337|NCT03788044|EXPERIMENTAL|Application-driven education (AF-EduApp substudy)|Education will be given via a newly developed application. Medication adherence (oral anticoagulation) will be measured using a special bottle cap that fits on a medication bottle. The patients in this group will receive feedback (notification and/or alarm) during the entire study period via this application when these patients have to take their medication.
61929253|NCT03686826||multiple sclerosis patients|
61929254|NCT03686826||healthy volunteers|
61929255|NCT03986151|ACTIVE_COMPARATOR|Conventional radial access|
61929256|NCT03986151|EXPERIMENTAL|Distal radial access|
61929257|NCT04351555|PLACEBO_COMPARATOR|Arm 1: Placebo with platinum-based chemotherapy|Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
61929258|NCT04351555|EXPERIMENTAL|Arm 2: Osimertinib with platinum-based chemotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
61929259|NCT04351555|EXPERIMENTAL|Arm 3: Osimertinib monotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)
61929260|NCT02725853|EXPERIMENTAL|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
61929261|NCT02725853|ACTIVE_COMPARATOR|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
61929262|NCT02725853|SHAM_COMPARATOR|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
62131804|NCT00198315|EXPERIMENTAL|MedPulser EPT with Bleomycin|Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
62323483|NCT01666236|OTHER|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
62323484|NCT02431585|OTHER|rechallenge|Double blind placebo controlled cross over
62323485|NCT02474940|EXPERIMENTAL|Intervention #1|NF-HYP
62323486|NCT02474940|EXPERIMENTAL|Intervention #2|MM-HYP
62323487|NCT02474940|EXPERIMENTAL|Intervention #3|HYP-ONLY
62323488|NCT01849250|EXPERIMENTAL|Arm I (Docosahexaenoic Acid)|Docosahexaenoic Acid orally twice a day (PO BID) for 12 weeks.
62323489|NCT01849250|PLACEBO_COMPARATOR|Arm II (placebo)|Placebo orally twice a day (PO BID) for 12 weeks.
62323490|NCT06692816|EXPERIMENTAL|PEMT|It was planned for this group to apply PEMT to the painful knee region with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057, May, 2012 Arcugnano (VI)-Italia) with a physiotherapist who is trained in using the device and has at least 5 years of experience, at a frequency of 50 Hz, an intensity of 85 Gauss (8.5 milliTesla) and for 30 minutes. The treatment period was planned as a total of 20 sessions, 5 days a week for 4 weeks. As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
62482709|NCT05236348|EXPERIMENTAL|Patients 21-60yo with Aktiia.product-us|All study participants will wear the Aktiia.product-us during 9 visits that will be held over the span of seven days.
62482710|NCT05236348|EXPERIMENTAL|Patients 60-85yo with Aktiia.product-us|All study participants will wear the Aktiia.product-us during 9 visits that will be held over the span of seven days.
62691338|NCT03788044|EXPERIMENTAL|In-person education (AF-EduCare study)|Education will be given on regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
61929263|NCT06448013|EXPERIMENTAL|Dose Escalation + Dose Expansion|Participants found to be eligible to take part in this study, you will be assigned to a dose level of ziftomenib based on when you join this study. Up to 4 dose levels of ziftomenib will be tested. Up to 6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the recommended dose of ziftomenib is found.
61929264|NCT06710197|EXPERIMENTAL|Group 1|Anakinra SC injection 100mg daily x 14 days
61929265|NCT06710197|NO_INTERVENTION|Group 2|Patients will receive standard of care treatment
61929266|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
61929267|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
61929268|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
61929269|NCT00978432|EXPERIMENTAL|Arm 1a (RAD001 followed by LBH589)|"Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
61929270|NCT00978432|EXPERIMENTAL|Arm 1b (LBH589 followed by RAD001)|"Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
61929271|NCT00978432|EXPERIMENTAL|Doublet (Combination RAD001 and LBH589)|Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.
61929272|NCT05290545|EXPERIMENTAL|Haplo-PBSC+Cord group|The third party UCB will be infused the day after infusion of PBSCs from HID.
61929273|NCT05290545|ACTIVE_COMPARATOR|Haplo-PBSC+BM group|The BMSCs from the same HID will be infused the day after infusion of PBSCs.
61929274|NCT06287918|EXPERIMENTAL|Stage I - dose escalation|Dose escalation of 3HP-2827 in patients with advanced solid tumors.
61929275|NCT06287918|EXPERIMENTAL|Stage II - expansion|Expansion evaluating the recommended dose and schedule of 3HP-2827 identified from Stage I.
61929276|NCT02779712|ACTIVE_COMPARATOR|Remote Ischaemic Conditioning|Remote ischaemic conditioning (RIC group): 4 cycles of intermittent limb ischaemia - alternating 5 minutes inflation (20mmHg above systolic BP) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
61929277|NCT02779712|SHAM_COMPARATOR|Control|Control: 4 cycles of alternating 5 minutes inflation (up to 30 mmHg) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
61929278|NCT00586846|EXPERIMENTAL|1|
61929279|NCT02962947|PLACEBO_COMPARATOR|PLACEBO|Placebo will be taken daily during the study period
61929280|NCT02962947|ACTIVE_COMPARATOR|PROPRANOLOL|Study participants in the treated group will take 80 mgR propranolol once daily .
61929281|NCT06161480|OTHER|Weighted Blanket|To prevent and or mitigate delirium in adult ICU patients in urban and rural populations.
61929282|NCT03522753|EXPERIMENTAL|Staples|For short single incisions, these patients will receive superficial closure using only metal skin staples. Closure will be performed by resident or fellow involved in the case.
61929283|NCT03522753|ACTIVE_COMPARATOR|Suture|For short single incisions, these patients will receive superficial closure using only nylon sutures. No metal skin staples will be used. Closure will be performed by resident or fellow involved in the case.
61929284|NCT03522753|OTHER|Half Staple Half Suture|Some patients will receive both nylon sutures and metal skin staples for superficial closure. If multiple incisions are involved, each incision will count as 1 in the alternation method (i.e. toe 1 will be all sutures, then toe 2 will be all staples). For long incisions, closure will alternate between nylon sutures and metal skin staples on the part of the incision which is closer (more proximal) or farther away (more distal) from the rest of the body.
61929285|NCT05440149|ACTIVE_COMPARATOR|The Control group|"* If patients received mastectomy, post-mastectomy radiation therapy (PMRT) should be performed.~* If patients received breast conserving surgery (BCS), whole breast irradiation (WBI) + Regional radiotherapy (RT) should be performed."
61929286|NCT05440149|EXPERIMENTAL|The Experimental group|"* If patients received mastectomy, No PMRT should be performed.~* If patients received BCS, WBI alone should be performed."
61929287|NCT05428098|EXPERIMENTAL|experiment group|In addition to standard care, patients will be given discharge training, planned within the framework of the Life model, one day before discharge. It is planned that the discharge training will be given by the researcher in the patient's room and by providing an accompanying person. Written training material will be delivered to the patients for their re-use after the training.
61929288|NCT05428098|NO_INTERVENTION|control group|standard care will be applied
61929289|NCT03711266|EXPERIMENTAL|PE-PC|Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.
61929290|NCT03970213|PLACEBO_COMPARATOR|Control Group|Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
61929291|NCT03970213|EXPERIMENTAL|TXA Group|One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
62131805|NCT04719858|EXPERIMENTAL|Intervention|Intervention group that will install the #LIFEGOALS app.
62131806|NCT04719858|NO_INTERVENTION|Control|Control group that will not receive any intervention.
62482711|NCT03037463||Parkinson's Disease|
62323491|NCT06692816|SHAM_COMPARATOR|SHAM|It was planned for this group to receive sham PEMT, with the electromagnetic field device turned off, for a total of 20 sessions, 5 days a week for 4 weeks, for 30 minutes each session, and a therapeutic exercise program, for a total of 20 sessions, 5 days a week for 4 weeks, for 30 minutes each session, including range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises, by a trained physiotherapist with at least 5 years of experience, and for the patients to do these exercises three times a day, in 3 sets, with 10 repetitions.
62323492|NCT00999128|EXPERIMENTAL|Part 1|
62323493|NCT00999128|EXPERIMENTAL|Part 2|
61929292|NCT04665739|EXPERIMENTAL|Arm I (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30-40 minutes on day 1 of each cycle. Treatment repeats every 56 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET during screening. Patients also undergo CT or MRI during screening and on the trial as well as FDG PET and SPECT on the trial. Additionally, patients undergo blood and tissue sample collection during screening and on the trial.
61929293|NCT04665739|ACTIVE_COMPARATOR|Arm II (everolimus)|Patients receive everolimus PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may be able to cross-over to Arm I. Patients undergo PET during screening. Patients also undergo CT or MRI during screening and on the trial as well as FDG PET and SPECT on the trial. Additionally, patients undergo blood and tissue sample collection during screening and on the trial.
61929294|NCT00145600|EXPERIMENTAL|Unfavorable Risk, Group 2|Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
61929295|NCT00145600|EXPERIMENTAL|Favorable Risk|Favorable Risk arm in patients with Hodgkin's Disease (n=91).
61929296|NCT00145600|EXPERIMENTAL|Intermediate Risk|Intermediate Arm in patients with Hodgkins's disease (n=46).
62323494|NCT05368428|EXPERIMENTAL|Supportive Care (TENS)|Patients undergo TENS therapy daily over 1 hour for 14 days in the absence of disease progression or unacceptable toxicity.
61929297|NCT00145600|EXPERIMENTAL|Unfavorable Risk, Group 1|Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).
61929298|NCT05365412||Colorectal cancer group|Patients treated after being diagnosed with colorectal cancer
61929299|NCT06403436|EXPERIMENTAL|TT125-802 single agent|
61929300|NCT02288143|EXPERIMENTAL|COOL-COS|All women will receive the intervention: Letrozole, Clomiphene, and low-dose hMG for the controlled ovarian stimulation.
61929301|NCT01388920|EXPERIMENTAL|Tesamorelin 2 mg|Tesamorelin 2 mg/day
61929302|NCT01388920|EXPERIMENTAL|Tesamorelin 3 mg|Tesamorelin 3 mg/day
61929303|NCT01388920|PLACEBO_COMPARATOR|Placebo|Placebo
61929304|NCT05128929|EXPERIMENTAL|Experimental Treatment Oral Hymecromone (H01)|Treatment will be initiated. Participants will be administered 800 mg of oral H01 two times a day (total dose: 1600 mg/day). Participants will continue to be on treatment for 24 weeks and will be monitored with assessments.
61929305|NCT05128929|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo will receive oral tablet placebo (inactive ingredients) two times a day. Participants will continue to be on placebo for 24 weeks and will be monitored with assessments.
61929306|NCT02752971|EXPERIMENTAL|Bupivacaine|A dilution of Bupivacaine 0,25% , 15 ml was infiltrated in surgical wound after close the aponeurosis
61929307|NCT02752971|EXPERIMENTAL|Bupivacaine, sodium diclofenac|A dilution of Bupivacaine 0,25% and sodium diclofenac 75 mgr, was infiltrated in surgical wound after close the aponeurosis
61929308|NCT02752971|EXPERIMENTAL|Sodium diclofenac|A dilution of sodium diclofenac 75 mgrs (3ml) and 12 ml of solution 0,9% was infiltrated in surgical wound after close the aponeurosis
61929309|NCT04944940||Healthy Volunteers|Healthy male participants who are age and sex matched to the SBMA participants
61929310|NCT04944940||Patients with Spinal and bulbar muscular atrophy (SBMA)|Male participants with genetically confirmed SBMA
61929311|NCT01872260|EXPERIMENTAL|LEE011 + letrozole Arm 1|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day
61929312|NCT01872260|EXPERIMENTAL|BYL719 + letrozole Arm 2|BYL719 - daily (dose escalating) letrozole - 2.5 mg/day
61929313|NCT01872260|EXPERIMENTAL|LEE011 + BYL719 + letrozole Arm 3|LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day
62323495|NCT06692452|EXPERIMENTAL|Tazemetostat + CHOP Therapy + Transplant Elected|"Enrolled participants will complete:~* Baseline visit~* Prephase Period: Days -14 through -1: Predetermined dose of Tazemetost 2x daily~* Induction Period: Cycles 1 through 6 (21 day cycles):~  * Cycle 1 Day 1: tumor biopsy and CT scan~ * Day 1: Predetermined dose of Cyclophosphamide once, Doxorubicin once, and Vincristine once~ * Days 1 through 5: Predetermined dose of Prednisone 1x daily~ * Days 2 through 21: Predetermined dose of Tazemetost 2x daily~ * Prior to Cycle 4 Day 1: Pet-CT scan~* Note, treatment will stop if participants do not respond to the drugs after the first 3 cycles~* Bone marrow biopsy and Pet-CT scan at end of Cycle 6~* Maintenance Period:~* Day 0: autologous stem cell transplant with BiCNU, Etoposide, Cytarabine, and Melphalan (BEAM)~* Day 100: PET-CT scan~* Cycles 1 through 6 (28 day cycles):~  --Days 1 through 28: Predetermined dose of Tazemetost 2x daily~* After Cycle 3: CT scan~* Cycle 4 Day 1: CT scan~* End of treatment visit~* Follow up is for 4 years"
62482712|NCT03037463||Control|
62482713|NCT04034290|EXPERIMENTAL|Stage 1 (GamFluVac intranasal drip)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated by intranasal drip
62738333|NCT00869492|OTHER|A|instructed nadifloxacine 1% cream twice dailly, and placebo for benzoyl peroxide 5% solution once dailly
61929314|NCT01872260|EXPERIMENTAL|LEE011+ BYL719+letrozole Arm 4|LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day
61929315|NCT06707285||ACL injured group , non-injured group|
61929316|NCT01739673|EXPERIMENTAL|Ultraviolet-A and riboflavin|
62131807|NCT06366984|EXPERIMENTAL|Plastibell group|plastibell method applied for circumcision
62131808|NCT06366984|EXPERIMENTAL|open method circumcision|open method of circumcision applied
62131809|NCT01236560|EXPERIMENTAL|Arm I (vorinostat, Phase II Arm A)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at the maximum-tolerated dose determined in the feasibility study. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
62323496|NCT06692452|EXPERIMENTAL|Tazemetostat + CHOP Therapy + Transplant Not Elected|"Enrolled participants will complete:~* Baseline visit~* Prephase Period: Days -14 through -1: Predetermined dose of Tazemetost 2x daily~* Induction Period: Cycles 1 through 6 (21 day cycles):~  * Cycle 1 Day 1: tumor biopsy and CT scan~ * Day 1: Predetermined dose of Cyclophosphamide once, Doxorubicin once, and Vincristine once~ * Days 1 through 5: Predetermined dose of Prednisone 1x daily~ * Days 2 through 21: Predetermined dose of Tazemetost 2x daily~ * Prior to Cycle 4 Day 1: Pet-CT scan~* Note, treatment will stop if participants do not respond to the drugs after the first 3 cycles~* Pet-CT scan at end of Cycle 6.~* Maintenance Period:~* Cycles 1 through 6 (28 day cycles):~  --Days 1 through 28: Predetermined dose of Tazemetost 2x daily.~* After Cycle 3: CT scan~* Cycle 4 Day 1: CT scan~* End of treatment visit~* Follow up is for 4 years"
62323497|NCT06316258|EXPERIMENTAL|Compassion focused therapy group|6 week compassion focused therapy group for adults with ABI
62323498|NCT03911544|ACTIVE_COMPARATOR|TIVA anesthesia with BIS monitoring|The depth of anesthesia will be adjusted with the help of BIS monitoring.
62323499|NCT03911544|NO_INTERVENTION|TIVA anesthesia without BIS monitoring|The depth of anesthesia will adjusted as in standard practice (clinical signs of poor anesthesia such as increase in blood pressure and/or heart rate, tearing and profuse sweating)
61929317|NCT05293015|EXPERIMENTAL|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
61929318|NCT05293015|NO_INTERVENTION|Regular diabetes management|The patient would go to the endocrinology outpatient clinic before hospitalization to regulate blood glucose, and be managed by by orthopedic medical staff through hospitalization. If necessary, the endocrinologist is consulted. And after the hospital, patients would be followed up by orthopedic medical staff.
61929319|NCT01836224|ACTIVE_COMPARATOR|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65.
61929320|NCT01836224|EXPERIMENTAL|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
61929321|NCT01812772|EXPERIMENTAL|Double J-stent with a long tether|Following ureteroscopy patients will have placed a double J-stent with a long tether.
61929322|NCT01812772|ACTIVE_COMPARATOR|Double J-stent without a long tether|Following ureteroscopy patients will have a double J-stent placed without a long tether
61929323|NCT03276819|EXPERIMENTAL|Cohort A|"Samples collection and Tobacco and alcohol status follow-up for patient with OPML:~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples"
61929324|NCT03276819|EXPERIMENTAL|Cohort B|"Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research"
61929325|NCT03276819|EXPERIMENTAL|Cohort C|Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research
61929326|NCT06275412|ACTIVE_COMPARATOR|Educational Attention Control (EAC) + Standard Medical Care|
61929327|NCT06275412|EXPERIMENTAL|The 3Ms 2.0 Intervention + Standard Medical Care|
61929328|NCT02038452|ACTIVE_COMPARATOR|Steroid Injection|Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
61929329|NCT02038452|ACTIVE_COMPARATOR|Wrist Splint|Wrist splint to be worn at night
61929330|NCT05939388|EXPERIMENTAL|Auricular Acupressure Pad Group|All subjects who qualify and agree to be in the study will be given Auricular Acupressure using an acupressure pad containing acupressure seeds for 4 days in addition to their regular standard of care pain medication.
61929331|NCT04768673|EXPERIMENTAL|Group 1|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation I / Period 3: CKD-393 Formulation II
61929332|NCT04768673|EXPERIMENTAL|Group 2|Period 1: CKD-393 Formulation I / Period 2: CKD-393 Formulation II / Period 3: CKD-501, D759, H053
61929333|NCT04768673|EXPERIMENTAL|Group 3|Period 1: CKD-393 Formulation II / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation I
61929334|NCT04768673|EXPERIMENTAL|Group 4|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation II / Period 3: CKD-393 Formulation I
62323500|NCT05916196|EXPERIMENTAL|Recurrent or metastatic uterine cancer|"Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania.~\[18F\]fluoroestradiol (FES) PET/CT imaging will be used to evaluate estrogen receptor (ER) activity in areas of disease known by standard of care imaging (e.g. CT, MRI, Bone Scan, FDG PET/CT, ultrasound) or clinical exam. For patients starting a new line of therapy, imaging will occur prior to starting new therapy. For patients who completed an initial scan and are starting new therapy, some patients may also undergo a second FES PET/CT scan at the time of suspected progression of disease to compare for changes in FES uptake measures (prior to initiation of next line therapy)."
62323501|NCT03340792|EXPERIMENTAL|Exoskeleton robot ambulation training|Ambulation training utilizing an exoskeleton robot
62323502|NCT02230124|EXPERIMENTAL|MRE|
62323503|NCT00502606||patients with provisional crowns|the same patient would serve as control and test
62323504|NCT01009996||Coronary bifurcation lesions|
62738334|NCT00869492|OTHER|B|instructed nadifloxacine 1% cream twice dailly, and active benzoyl peroxide 5% solution once dailly
61929335|NCT04768673|EXPERIMENTAL|Group 5|Period 1: CKD-393 Formulation I / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation II
62323505|NCT06693440||Experimental group|PD-1 inhibitor combined therapy, 200mg, iv, q3w, 1 year for adjuvant therapy or 2 years for advanced therapy
61929336|NCT04768673|EXPERIMENTAL|Group 6|Period 1: CKD-393 Formulation II / Period 2: CKD-393 Formulation I / Period 3: CKD-501, D759, H053
61929337|NCT02386800|EXPERIMENTAL|Ruxolitinib monotherapy or ruxolitinib plus panobinostat in combination|All participants will receive either ruxolitinib monotherapy or ruxolitinib in combination with panobinostat, at the same dose/schedule that they were taking in the parent study.
61929338|NCT05490238|EXPERIMENTAL|Distal radial access|Distal radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
61929339|NCT05490238|ACTIVE_COMPARATOR|Conventional radial access|Conventional radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
61929340|NCT06422208|EXPERIMENTAL|Autologous midbrain dopamine neurons|
61929341|NCT05689697|PLACEBO_COMPARATOR|Placebo group|Patients will recieve matched by taste and color shot of 25 ml liquid in ampules
61929342|NCT05689697|EXPERIMENTAL|Active treatment group|Patients will recieve shot of PanTrek 25 ml in anpules
61929343|NCT03524079||BrS Group|Ajmaline 17-(Chloroacetate) Monohydrochloride
61929344|NCT03524079||No BrS group|Ajmaline 17-(Chloroacetate) Monohydrochloride
61929345|NCT04565184|EXPERIMENTAL|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
61929346|NCT04565184|ACTIVE_COMPARATOR|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
61929347|NCT05252065||Patients with NSCLC|all stage N2-3 non-small cell lung cancer patients receive intensity-modulated radiotherapy (IMRT). The prescription dose of PTV is 60-70Gy.
61929348|NCT05529069|EXPERIMENTAL|Pirtobrutinib (LOXO-305) and Venetoclax (combination)|Participants will have study visits every week during Cycle 1, and then on Day 1 of every cycle for the first year. After that, they will have study visits on Day 1 of every 2 cycles.
61929349|NCT01254903|EXPERIMENTAL|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
61929350|NCT06701656|EXPERIMENTAL|Cohort C: bevacizumab|
61929351|NCT06701656|PLACEBO_COMPARATOR|Cohort C: placebo|
61929352|NCT06709131|EXPERIMENTAL|CAR-T cells（ chimeric antigen receptor T cells）|CAR-T cells（ chimeric antigen receptor T cells）
61929353|NCT06198764|EXPERIMENTAL|Colistimethate sodium for Injection + Meropenem|Intravenous infusion of colistimethate sodium for injection for 7-14 days. Meropenem intravenous infusion once every 8 hours or 12 hours.
62323506|NCT06693440||Control group|PD-1 inhibitor mono-therapy, 200mg, iv, q3w, 1 year for adjuvant therapy or 2 years for advanced therapy
62323507|NCT02191917||Measurement of Respiratory Muscle Strength|
62323508|NCT02087319|EXPERIMENTAL|platelet-rich plasma|hair loss, baldness
62323509|NCT06429683|EXPERIMENTAL|Sexually transmitted diseases training for young adolescents aged 17-21|To evaluate the effectiveness of sexually transmitted diseases education given to young adolescents aged 17-21 years
61929354|NCT06198764|ACTIVE_COMPARATOR|Coly-Mycin® M Parenteral + Meropenem|Intravenous infusion of Coly-Mycin® M Parenteral for 7-14 days. Meropenem intravenous infusion once every 8 hours or 12 hours.
61929355|NCT06235281|EXPERIMENTAL|POTELIGEO & Phototherapy combination therapy|POTELIGEO (mogamulizumab-kpkc) will be given according to FDA approved dose and scheduled for 8 cycles. After 2 cycles of POTELIGEO, all subjects will start phototherapy as combination therapy.
61929356|NCT05268107|EXPERIMENTAL|Dupilumab|The 3 groups of patients (Asian, African American, and Caucasian) will all receive the same intervention.
61929357|NCT06536439|EXPERIMENTAL|DIPLANN-tool + conventional CT imaging|Pre-operative planning and peri-operative guidance with DIPLANN-tool and conventional CT imaging.
61929358|NCT06536439|ACTIVE_COMPARATOR|Conventional CT imaging alone|Pre-operative planning and peri-operative guidance with conventional CT imaging alone (standard of care).
61929359|NCT06473987|EXPERIMENTAL|Personalized cognitive-sensorimotor VR/AR training|Thinking task integrated walking and balance training program
61929360|NCT06473987|ACTIVE_COMPARATOR|Traditional dual-task training|Walking and balance training similar to standard of care group but will also perform additional thinking tasks during training.
61929361|NCT06473987|ACTIVE_COMPARATOR|Standard of Care|Standard walking and balance training
61929362|NCT02881099||Recent diagnosis (P3)|Primary cohort; participants recruited if diagnosed within the last three years
61929363|NCT02881099||Early diagnosis (P50)|Participants recruited if diagnosed before the age of 50 years old
61929364|NCT02881099||Relatives (R)|Siblings of existing participants
61929365|NCT06437353|EXPERIMENTAL|First-line and maintenance therapy regimen|"First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily."
61929366|NCT06147453|ACTIVE_COMPARATOR|Aerobika OPEP device|"The OPEP system (Aerobika®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. OPEP therapy (Aerobika ®) enforces resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucus.~Participants will take home the device and use it twice daily for 16 weeks."
61929367|NCT06147453|NO_INTERVENTION|Standard of care|Standard of care management for 16 weeks.
61929368|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
61929369|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
61929370|NCT06455839|EXPERIMENTAL|Guided Respiration Mindfulness Therapy|
62738335|NCT01892150|EXPERIMENTAL|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
61929371|NCT05868018||DPT A|Students from University A received their typical evidence based practice education over 3 years.
61929372|NCT05868018||DPT B|Students from University B received their typical evidence based practice education over 3 years.
61929373|NCT05868018||DPT C|Students from University C received their typical evidence based practice education over 3 years.
61929374|NCT05868018||MSPT|Students from University D received their typical evidence based practice education over 2 years.
61929375|NCT05454267||Healthy Volunteer Group|Participants who have never smoked or vaped
61929376|NCT05454267||High Frequency Vaping Group|Participants who vape \>20 days per month.
61929377|NCT05454267||Low-Frequency Vaping Group|Participants who vape \< 20 days per month
61929378|NCT01539317|ACTIVE_COMPARATOR|Topical liquid lidocaine|
61929379|NCT01539317|PLACEBO_COMPARATOR|Topical Saline|
61929380|NCT05193825|ACTIVE_COMPARATOR|Group A|Patients in Group A (active comparator) will have their internal pulse generator (IPG) adjusted by conventional procedures, i.e. by regular visits at their caregivers hospital.
61929381|NCT05193825|EXPERIMENTAL|Group B|Patients in Group B (experimental) will have their internal pulse generator (IPG) adjusted by using a novel software (Abbot NeurosphereTM Virtual Clinics) that allows for remote IPG programming and with the aid of a visual analogue scale (VAS).
61929382|NCT06513728|EXPERIMENTAL|Single arm study|Single arm study. All sites will receive the intervention.
61929383|NCT06005974|EXPERIMENTAL|AXIN1 Cohort|Participants will receive REC-4881 12mg PO dosed QD
61929384|NCT06005974|EXPERIMENTAL|APC Cohort|Participants will receive REC-4881 12mg PO dosed QD
61929385|NCT04235803|EXPERIMENTAL|Telemedicine|Patients in the telemedicine arm will have their post-operative week one visit via a telemedicine portal.
61929386|NCT04235803|NO_INTERVENTION|Routine|Patient in the routine arm will have their post-operative week one visit in clinic.
61929387|NCT04735536|EXPERIMENTAL|Active Treatment- CT1812|Active Treatment- CT1812 at a dose of 300mg
61929388|NCT04735536|PLACEBO_COMPARATOR|Control - Placebo|Drug: Placebo Non-active study drug
62131810|NCT01236560|EXPERIMENTAL|Arm II (temozolomide, Phase II Arm B)|Patients undergo RT as in the feasibility arm and receive temozolomide PO once daily for 42 days by day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
62131811|NCT01236560|EXPERIMENTAL|Arm III (Bevacizumab, Phase II Arm)|Patients undergo RT as in the feasibility arm and receive bevacizumab IV over 30-90 minutes on days 22 and 36. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
61929389|NCT06544330|EXPERIMENTAL|SYNCAR-001 + STK-009|"Dose escalation: A single fixed dose of autologous SYNCAR-001 CAR-T intravenously (IV) will be administered in combination with ascending doses of STK-009 subcutaneously (SC) in non-lymphodepleted patients.~Dose expansion: A single fixed dose of autologous SYNCAR-001 CAR-T IV will be administered in combination with STK-009 SC at the RP2D in non-lymphodepleted patients."
61929390|NCT03978988|EXPERIMENTAL|Thrombectomy + Carotid Stenting|"Intravenous thrombolysis will be administered if possible. Standard mechanical thrombectomy(MT) will be performed with a balloon Guide Catheter. MT technique will be left at the discretion of the operators.~Concerning the cervical disease, emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion. An intravenous bolus of 250mg of Aspirin (up to Imaging 24H) will be given at the end of the procedure in case of absence of complication.~Intravenous sedation or general anesthesia will be permitted.A second antiplatelet agent is used if a thrombus is formed : IV or nasogastric tube (choice by operator) A dual antiplatelet therapy is administered after 24H imaging follow-up excluding intracranial hemorrhagic complications (discretion of the local practice)"
61929391|NCT03978988|NO_INTERVENTION|Thrombectomy alone|"Endovascular procedure:~Intracranial thrombectomy alone (carotid angioplasty may be performed)"
61929392|NCT00846742|EXPERIMENTAL|Treatment|Participants receive Stanford V Chemotherapy with or without radiation therapy. Patients receive doxorubicin hydrochloride IV and vinblastine IV on day 1 of weeks 1, 3, 5, and 7; mechlorethamine hydrochloride IV on day 1 of weeks 1 and 5; vincristine sulfate IV and bleomycin IV on day 1 of weeks 2, 4, 6, and 8; etoposide IV on day 1 of weeks 3 and 7; and prednisone orally (PO) three times daily every other day of weeks 1-8. Beginning 2-3 weeks after completion of chemotherapy, patients not achieving complete response undergo radiation therapy to individual nodal sites (tailored fields)
61929393|NCT03707431|EXPERIMENTAL|Web-based CBT (WebMAP)|Receives access to WebMAP
61929394|NCT03707431|ACTIVE_COMPARATOR|Pain Education (WebED)|Receives access to WebED
61929395|NCT06382805|ACTIVE_COMPARATOR|Control group|The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program.
62323510|NCT00540969|EXPERIMENTAL|Arm I (percutaneous cryoablation)|Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
61929396|NCT06382805|ACTIVE_COMPARATOR|kinesiotaping group|"Kinesio tape application will be applied to the kinesio tape group in addition to physiotherapy.~The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program."
61929397|NCT06382805|ACTIVE_COMPARATOR|high intensity laser therapy group|High-intensity laser application will be applied to the high-intensity laser group in addition to physiotherapy. The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program.
61929398|NCT06026410|EXPERIMENTAL|Arm #1: RAS-altered advanced solid tumors|"Patients with advanced solid tumors and the following:~* HRAS-mutant and/or amplified tumors (any solid tumor type)~* HRAS overexpression (only for HNSCC tumors)~* KRAS and/or NRAS and/or HRAS-mutant and/or amplified for NSCLC or CRC~* KRAS-mutant and/or amplified PDAC"
61929399|NCT06026410|EXPERIMENTAL|Arm #2: Advanced or metastatic RCC|Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC
61929400|NCT06026410|EXPERIMENTAL|Arm #3: Advanced or metastatic NSCLC, CRC, or PDAC|Patients with KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC who have received at least 1 prior systemic therapy for advanced or metastatic disease
61929401|NCT05742958|EXPERIMENTAL|Intrathecal morphine (Group ITM)|12.5-15 mg hyperbaric 0.5% bupivacaine + 0.1 mg (0.1 mL) morphine with a single dose intrathecal injection through the L4-L5 interval (spinal anesthesia) + placebo adductor canal block (with 30 mL saline) will be administered.
61929402|NCT05742958|EXPERIMENTAL|Adductor canal block (Group ACB)|Spinal anesthesia from L4-L5 interval with 12.5-15 mg hyperbaric 0.5% bupivacaine + adductor canal block (30 mL 0.25% bupivacaine) will be applied.
61929403|NCT06636227|PLACEBO_COMPARATOR|Placebo|Placebo arm
61929404|NCT06636227|ACTIVE_COMPARATOR|Diclofenac 50mg|In this arm participants will receive 50mg of Diclofenac
61929405|NCT06636227|ACTIVE_COMPARATOR|Diclofenac 75mg|In this arm participants will receive 75mg of Diclofenac
61929406|NCT06636227|ACTIVE_COMPARATOR|Diclofenac 100mg|In this arm participants will receive 100mg of Diclofenac
62323511|NCT00540969|ACTIVE_COMPARATOR|Arm II (external-beam radiotherapy)|Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.
61929407|NCT06441864|EXPERIMENTAL|2-week baseline|Participants will receive treatment after a 2-week baseline assessment period
61929408|NCT06441864|EXPERIMENTAL|4-week baseline|Participants will receive treatment after a 4-week baseline assessment period
61929409|NCT05053152|PLACEBO_COMPARATOR|Arm I (placebo, SABR)|Patients receive placebo PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
61929410|NCT05053152|EXPERIMENTAL|Arm II (relugolix, SABR)|Patients receive relugolix PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
61929411|NCT01387373|EXPERIMENTAL|chemotherapy|
61929412|NCT05627661|EXPERIMENTAL|Autoimmune Epilepsy with Biosensors|Subjects with suspected autoimmune epilepsy will wear biosensors on wrist or upper arm during the at home monitoring period.
61929413|NCT05627661|ACTIVE_COMPARATOR|Healthy Controls with Biosensors|Neurologically normal adult healthy controls will wear biosensors on wrist or upper arm during the at home monitoring period.
61929414|NCT06274528|EXPERIMENTAL|Lemborexant 10 mg|Lemborexant is a capsule, taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.
61929415|NCT06274528|EXPERIMENTAL|Lemborexant 20 mg|Lemborexant is a capsule, taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.
61929416|NCT06274528|PLACEBO_COMPARATOR|Placebo|Placebo is in capsule form and contains an inactive substance. It is taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.
61929417|NCT04037254|EXPERIMENTAL|Phase I (niraparib, GnRH, IMRT)|Patients receive niraparib PO QD and receive standard of care GnRH agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity.
61929418|NCT04037254|ACTIVE_COMPARATOR|Phase II, Arm I (GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
61929419|NCT04037254|EXPERIMENTAL|Phase II, Arm II (niraparib, GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
61929420|NCT05959746|EXPERIMENTAL|Patients with suspected acute stroke|
62323512|NCT06011005|EXPERIMENTAL|(Group A) Ethyl Chloride (EC)|Topical application for 30 sec.
61929421|NCT02883647||retreatment|"1. Patients with HBV DNA \> 2000 IU/ml and ALT ≥ 5×ULN;~2. Patients with HBV DNA \> 2000 IU/ml and 2×ULN \< ALT ≤ 5×ULN, but have clinical symptoms.~Intervention: Patients of this group will receive Entecavir 0.5mg/d or Tenofovir 300mg/d again."
61929422|NCT02883647||non-retreatment|"1. Patients with HBV DNA ≤ 2000 IU/ml;~2. Patients with HBV DNA \> 2000 IU/ml and ALT ≤ 2×ULN;~3. Patients with HBV DNA \> 2000 IU/ml and 2×ULN \< ALT ≤ 5×ULN, but have no clinical symptoms."
61929423|NCT05859555|OTHER|Intervention: Thematic quality circles - Deprescription|
61929424|NCT05859555|NO_INTERVENTION|No intervention|
61929425|NCT06690814|EXPERIMENTAL|Ficus septica exudate|
62323513|NCT06011005|ACTIVE_COMPARATOR|(Group B) Benzocaine gel 20% (BC)|BC 20% Topical gel application for 30 sec and left for 1 minute.
62323514|NCT05766891|EXPERIMENTAL|Group 1|Participants will receive hypnosedation before and during surgery as well as local anesthesia and pain/nausea medications during surgery
62323515|NCT05766891|EXPERIMENTAL|Group 2|Participants will receive hypnosedation before surgery and standard general anesthesia during surgery.
61929426|NCT06690814|EXPERIMENTAL|Pterocarpus indicus exudate|
61929427|NCT06690814|EXPERIMENTAL|Curcuma longa aqueous extract|
61929428|NCT06690814|ACTIVE_COMPARATOR|Savlon antiseptic cream (cetrimide with chlorhexidine digluconate )|
61929429|NCT06690814|NO_INTERVENTION|Control|
61929430|NCT03739671|PLACEBO_COMPARATOR|Non-vitamin D supplementation|Group not receiving vitamin D supplementation
61929431|NCT03739671|EXPERIMENTAL|Vitamin D supplementation|Group receiving vitamin D supplementation
61929432|NCT02180269|EXPERIMENTAL|Cohort A|Single oral dose of either JNJ-54861911, 25 milligram (mg) tablet or matched placebo tablet on Day 1.
62323516|NCT05766891|EXPERIMENTAL|Group 3|Participants will receive standard general anesthesia alone. You will not receive hypnosedation.
62323517|NCT01147315|EXPERIMENTAL|Hybrid bone substitution|Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow
62323518|NCT05782920|ACTIVE_COMPARATOR|PRP- treated Group A|15 female patients will receive 2 vaginal PRP injections one month apart.
61929433|NCT02180269|EXPERIMENTAL|Cohort B|Single oral dose of either JNJ-54861911, 50 mg (2\*25 mg tablets) or matched placebo tablets on Day 1.
61929434|NCT02180269|EXPERIMENTAL|Cohort C|Single oral dose of either JNJ-54861911, 100 mg (4\*25 mg tablets) or matched placebo tablets on Day 1.
61929435|NCT02080858|EXPERIMENTAL|Ticagrelor + Apixaban + ASA|180 mg Ticagrelor loading dose + apixaban 2.5 mg bid + 300 mg ASA loading dose (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg + 100 mg ASA od to reach steady state conditions within 4.5 days
61929436|NCT02080858|ACTIVE_COMPARATOR|Ticagrelor + Apixaban|180mg ticagrelor loading dose + apixaban 2.5 mg bid (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg to reach steady state conditions within 4.5 days
61929437|NCT02629484|ACTIVE_COMPARATOR|Focused Cardiac Ultrasound|participants randomised to receive focused cardiac ultrasound prior to surgery for hip fracture
61929438|NCT02629484|NO_INTERVENTION|Standard care (clinical assessment)|Participants randomised to standard care receive clinical assessment of the patient
61929439|NCT05745532|EXPERIMENTAL|Experimental|Ten transfusion-dependent β-thalassaemia subjects aged 8-16 years will be reinfused with β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q.
62131812|NCT01236560|EXPERIMENTAL|Arm IV (temozolomide, Phase 3 Arm B)|Patients undergo RT as in the Arm II and receive temozolomide PO once daily for 42 days beginning on day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
62131813|NCT01236560|EXPERIMENTAL|Arm V (vorinostat/bevacizumab, Phase 3, Chemoradiotherapy)|Patients receive treatment as in phase II, arm I or phase II, arm III, whichever was established as superior in phase II. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
62131814|NCT01236560|EXPERIMENTAL|Feasibility (vorinostat)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at 230 mg/m2/day. In the event of 2 or more DLTs, participants will de-escalate to vorinostat at 180 mg/m2/day. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
62323519|NCT05782920|ACTIVE_COMPARATOR|PRP-HA treated Group B|15 female patients will receive 2 vaginal PRP-non-cross-linked HA injections spaced a month apart.
62323520|NCT05782920|ACTIVE_COMPARATOR|Control Group C|15 female patients will receive topical non-cross-linked hyaluronic acid gel applied every three days for 2 months as a control group
61929440|NCT03039972||Pulmonary Hypertension|Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
61929441|NCT03436654|EXPERIMENTAL|ADT + Apalutamide|
61929442|NCT03436654|EXPERIMENTAL|ADT + Apalutamide + Abiraterone Acetate + Prednisone|This arm is no longer being assigned to subjects.
61929443|NCT03436654|EXPERIMENTAL|Apalutamide, SBRT, Radiation|
61929444|NCT03137771|ACTIVE_COMPARATOR|Arm 1 (maintenance chemotherapy)|Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61929445|NCT03137771|EXPERIMENTAL|Arm 2 (SBRT + maintenance chemotherapy)|Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.
61929446|NCT04981860|EXPERIMENTAL|Treatment naïve participants First Group L|Treatment naïve participants randomized to receive Betadine on the left eye and Avenova on the right Eye
62323521|NCT05609968|EXPERIMENTAL|Pembrolizumab + Sacituzumab Govitecan|Participants receive sacituzumab govitecan 10mg/kg intravenous (IV) infusion once weekly on Day 1 and Day 8 of a continuous 21-day cycle until progressive disease (PD) requiring discontinuation, unacceptable toxicity, withdrawal of consent, or death. Participants receive pembrolizumab 200mg IV infusion on Day 1 every 3 weeks (Q3W) for up to 35 cycles (each cycle length = 21 days).
62323522|NCT05609968|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200mg IV infusion on Day 1 Q3W for up to 35 cycles (each cycle length = 21 days).
62323523|NCT02549690|ACTIVE_COMPARATOR|Testosterone gel|Testosterone gel 10mg, used transdermally, once a day. Treatment duration: 6-8 weeks
62323524|NCT02549690|ACTIVE_COMPARATOR|DHEA|DHEA 25mg tablet, orally, three times per day. Treatment duration: 6-8 weeks
62323525|NCT05110183|EXPERIMENTAL|electrical and optical hybrid stimulation stimulation|Patients with large tumors of the skull base, requiring a translabyrinthine craniotomy with sacrifice of their cochlea and vestibular system during the tumor resection may participate. A recording electrode will be placed on the round window, a cochleostomy will be created, and different Light delivery systems (LDSs) will be inserted into the cochlea. LDSs include angle polished optical fibers to determine the accuracy of the orientation of the radiation beam, and hybrid arrays of small optical sources and electrical contacts to evaluate electric-alone stimulation as a reference, and compare it to optic-alone and combined electrical and optical stimulation. Compound action potentials (CAPs) of the auditory nerve will be recorded.
62323526|NCT06578585|EXPERIMENTAL|Ubrogepant with Lu AG09222|Participants will receive 2 doses of ubrogepant, then participants will receive Lu AG09222 followed by additional doses of ubrogepant.
62323527|NCT06578585|PLACEBO_COMPARATOR|Ubrogepant with Placebo|Participants will receive 2 doses of ubrogepant, then participants will receive placebo followed by additional doses of ubrogepant.
61929447|NCT04981860|EXPERIMENTAL|Treatment naïve participants Second Group R|Treatment naïve participants randomized to receive Avenova on the left eye and Betadine on the right Eye
61929448|NCT04981860|EXPERIMENTAL|Participants undergoing intravitreal injection First Group L|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group L are patients that are having intravitreal injections and will receive betadine in the left eye and Avenova in the right eye.
62691339|NCT03788044|EXPERIMENTAL|Online education (AF-EduCare study)|Education will be given on regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
62691340|NCT03788044|NO_INTERVENTION|Standard care (AF-EduCare study and AF-EduAppsub study)|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
62691341|NCT00941395|EXPERIMENTAL|Arm I (smoker, survey)|Participants who currently smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2. Participants also complete 3 internet surveys over 20 minutes.
62691342|NCT00941395|EXPERIMENTAL|Arm II (non-smoker, survey)|Participants who currently do not smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2.
62691343|NCT03314896|EXPERIMENTAL|Laparoscopic surgery for T4 colon tumor|Laparoscopic surgery for T4 colon cancers
62691344|NCT03314896|NO_INTERVENTION|Open surgery for T4 colon tumor|Conventional open surgery for T4 colon cancers
62691345|NCT06031402|EXPERIMENTAL|Early endoscopy group|Intervention of endoscopy is within 12 hours after admission
62691346|NCT06031402|ACTIVE_COMPARATOR|Delayed endoscopy group|Intervention of endoscopy is within 12-24 hours after admission
62691347|NCT06640465|EXPERIMENTAL|Ubiquinol + geranylgeraniol combination (Designs for Health - CoQnol™ 200)|
61929449|NCT04981860|EXPERIMENTAL|Participants undergoing intravitreal injection Second Group R|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group R are patients that are having intravitreal injections and will receive betadine in the right eye and Avenova in the left eye.
62323528|NCT00540722|EXPERIMENTAL|Treatment (R-(-)-gossypol acetic acid)|"Patients receive oral R-(-)-gossypol once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Patients undergo tumor tissue and blood sample collection at baseline and periodically during study for biomarker correlative studies. Archived tumor tissue samples, if available, are analyzed for Bcl-2 family protein expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain for BH3 members only) and MGMT gene methylation status. Blood samples are analyzed for apoptotic protein levels (Bcl-2) by enzyme-linked immunosorbent assay."
62323529|NCT01213485||Cohort|
62482714|NCT04034290|EXPERIMENTAL|Stage 1 (GamFluVac with the help of a spray dispenser)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated intranasally with the help of a spray dispenser
61929450|NCT05529940|EXPERIMENTAL|Neoadjuvant FOLFIRINOX|6 cycles of neoadjuvant mFOLFIRINOX followed by surgical resection and 6 cycles of adjuvant mFOLFIRINOX
61929451|NCT05529940|ACTIVE_COMPARATOR|Upfront Surgery|surgical resection followed by 12 cycles of adjuvant mFOLFIRINOX
62482715|NCT04034290|EXPERIMENTAL|Stage 2 Vaccine|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
61929452|NCT03778957|EXPERIMENTAL|Arm A|Transarterial Chemoembolization (TACE) in combination with Durvalumab
62131815|NCT03988842|EXPERIMENTAL|Alteplase & Unfractionated Heparin & Apixaban|Alteplase 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
62131816|NCT03988842|ACTIVE_COMPARATOR|Placebo & Unfractionated Heparin & Apixaban|Alteplase placebo solution 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
62131817|NCT03664960|EXPERIMENTAL|1 to 3.0 mg/kg of AK002|Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg
62323530|NCT05468957|ACTIVE_COMPARATOR|Perclose Only|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
62339898|NCT05341674||Model of the stump scanned with a 3d scanner|For the artificial intelligence-based software planned to be created, the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner. The scanned patterns were saved as point clouds
62339899|NCT05341674||Socket matched to stump|The socket parts of the prostheses used by the same patients (with other group) were also scanned with the same scanner device and recorded.
62482716|NCT04034290|PLACEBO_COMPARATOR|Stage 2 (Controll Group)|Placebo
62482717|NCT06557421|EXPERIMENTAL|VEN-AZA de-escalation|VEN-AZA de-escalation
62691348|NCT06640465|EXPERIMENTAL|Geranylgeraniol (Annatto-GG™ 300)|
62691349|NCT06640465|EXPERIMENTAL|Ubiquinol (Jarrow Formulas QH-absorb® 200 mg)|
62691350|NCT06640465|EXPERIMENTAL|Ubiquinone (NOW CoQ10 200mg)|
62691351|NCT06640465|PLACEBO_COMPARATOR|Placebo|
62691352|NCT02776735|EXPERIMENTAL|Sarilumab|Participants received one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants received the selected dose regimen once this was identified. Sarilumab was given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for 73 participants enrolled in dose-finding and second portions and 84 weeks for approximately 29 participants enrolled in third portion)
62691353|NCT03757117|EXPERIMENTAL|Intervention|Feminizing hormone therapy and peer navigation
62691354|NCT03443401||patient participants|patients with chronic low back pain receiving standard physical therapy care
62323531|NCT05468957|EXPERIMENTAL|Perclose with Statseal Device|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
62323532|NCT03800706|EXPERIMENTAL|TQB2450|
62323533|NCT04379804|ACTIVE_COMPARATOR|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery. The tissue between the carotid artery and the trachea was dissected gently parallel to the direction of the nerve until the nerve is identified visually and,or by hand held stimulation probe. After the identification of RLN, the vessels of inferior thyroid lobe was ligated. The nerve was dissected along its course to the entry point, and then the thyroid lobe was totally dissected from the trachea and the lobectomy was completed. If adverse EMG changes were encountered during lateral approach, traction was released immediately and waited for recovery.
62323534|NCT04379804|ACTIVE_COMPARATOR|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN nerve was identified at the point of entry both visually and with hand held stimulation probe. The RLN dissection was proceeded craniocaudally by the division of the suspensory ligaments of the berry through the level of inferior thyroid artery. After the identification and visualitzation of the RLN through its whole course, the medial and inferior vessels of the thyroid gland were dissected and ligated. Then, the lobe was dissected from the trachea and lobectomy was completed.
62323535|NCT03736837|EXPERIMENTAL|Anlotinib Plus Icotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Icotinib 125mg p.o, tid. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
62323536|NCT05570916|EXPERIMENTAL|Test Article - Zip-stitch Clips|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
62323537|NCT05570916|OTHER|Reference Group|Will not be comparative against the test article, but will be performed for reference and safety.
62323538|NCT06373081|EXPERIMENTAL|Anti-CD19-CD3E-CAR-T Cells treatment|Anti-CD19-CD3E-CAR-T cells, Autologous T-cells expressing a chimeric antigen receptor directed to CD19.
62323539|NCT02075502|EXPERIMENTAL|Exercise therapy|Claudication, no peripheral revasc
62323540|NCT02075502|PLACEBO_COMPARATOR|Exercise advice|Claudication, no peripheral revasc
61929453|NCT03778957|EXPERIMENTAL|Arm B|Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab
61929454|NCT03778957|PLACEBO_COMPARATOR|Arm C|Transarterial Chemoembolization (TACE) in combination with Placebos
61929455|NCT06682650|ACTIVE_COMPARATOR|Usual QI|I-teams in each Usual QI clinic will be provided a pre-set protocol to implement the I2 tool into routine clinic CRC screening workflow (which they will define via a provided checklist). The protocol instructs the clinic to provide access to I2 zero to two weeks before a clinic visit, review the patient's I2 screening intentions with the patient in the clinic visit, at which time staff will order and schedule CRC screening in the visit. I2 may be completed on-line or via a paper form. I-teams will meet monthly to make progress on their implementation of I2, and complete a report/meet a study staff member monthly (separately) to report on their meetings and progress but will not receive coaching or skill training.
62323541|NCT02075502|EXPERIMENTAL|lower extremity ET, exercise therapy|
62691355|NCT03443401||Physical Therapy clinician participants|Licensed physical therapist that is providing standard physical therapy care for a patient participant
62323542|NCT02075502|PLACEBO_COMPARATOR|lower extremity ET, exercise advice|
62691356|NCT04369612|ACTIVE_COMPARATOR|Standard of care|Standard follow-up after kidney transplantation during the first 7-8 post-transplant weeks
62691357|NCT04369612|EXPERIMENTAL|Home-based monitoring|Every second visit will be performed without patients actually visiting the hospital. They take a capillary blood sample themselves, send it to the lab and get a telecom follow-up by treating physician the same day.
62323543|NCT02075502|EXPERIMENTAL|Peripheral open intervention, exercise therapy|
62691358|NCT05681949|NO_INTERVENTION|Participants' cases discussed in tumor conference without ADBoard|Participants' cases are discussed in tumor conference without the use of ADBoard, according to conventional practice.
62323544|NCT02075502|PLACEBO_COMPARATOR|Peripheral open intervention, exercise advice|
62323545|NCT00073333|ACTIVE_COMPARATOR|1|Social skills training and exposure
62323546|NCT00073333|ACTIVE_COMPARATOR|2|Exposure treatment
62323547|NCT00073333|PLACEBO_COMPARATOR|3|Placebo
62323548|NCT06235099|EXPERIMENTAL|Diagnostic imaging with Copper Cu 64 PSMA I&T|Copper Cu 64 PSMA I\&T Injection
62323549|NCT03344601|NO_INTERVENTION|Reference Cohort|A 12-month longitudinal evaluation of physical fitness and physical activity assessments in a cohort of individuals with HD (n=60) recruited from the Enroll-HD platform study.
62323550|NCT03344601|EXPERIMENTAL|Physcial Activity Intervention|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to a 12-month physical activity and coaching intervention.
62323551|NCT03344601|NO_INTERVENTION|Activity as usual control|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to continue with physical activity as usual for 12 months
62323552|NCT01224912|EXPERIMENTAL|Internet Deliviered CBT for Insomnia|Cognitive behavioral self-help method for insomnia via the Internet
62323553|NCT03105440|EXPERIMENTAL|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
62482718|NCT05133804|EXPERIMENTAL|Treatment with Reboxetine and Methylphenidate|"During the first 3 weeks of the study, subjects in the active treatment group will take reboxetine at a dose of 4mgper day, with the instructions to start at 2mg per day for 3 days and then increase the dosage to 4mg per day for 26 days, i.e. until completion of the study.~On day 22 of the study, the patients will take the first dosage of10mg Ritalin or a placebo, and remain in the clinic for 2 hours to guard safety and guidance during possible occurrence of side effects such as anxiety, palpitations, etc. During the observation time in the clinic, 6 Ritalin IR 10mg and 3 Reboxetine 4mg pills will be handed out to the participants. These pills will be taken at the responsibility of the subject at8:00 AM (Ritalin and Reboxetine) and at noon (Ritalin only) at the following three days."
62482719|NCT05133804|PLACEBO_COMPARATOR|Treatment with Placebo|The patients will take placebos according to the medication schedule of the treatment group.
62482720|NCT04377087|EXPERIMENTAL|Olaparib|Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.
62482721|NCT06242912|EXPERIMENTAL|Therapy|Regular disease assessment (eg radiographic imaging) and quality of life (QOL) questionnaires
62482722|NCT05581329|EXPERIMENTAL|Group A: acupoints on the left hand|Participants will be received acupuncture at the control acupoint (Yuji - LU10) in the first trial phase, and the second trial phase will be conducted after 07 days at the research acupoint (Houxi - SI3). In each time, skin surface temperature at the neck area will be recorded.
62482723|NCT05581329|EXPERIMENTAL|Group B: acupoints on the right hand|Participants will be received acupuncture at the control acupoint (Yuji - LU10) in the first trial phase, and the second trial phase will be conducted after 07 days at the research acupoint (Houxi - SI3). In each time, skin surface temperature at the neck area will be recorded.
62482724|NCT04053153|EXPERIMENTAL|Use of musical instrument|
62482725|NCT04053153|SHAM_COMPARATOR|Use of sham musical instrument|
62482726|NCT06626984|NO_INTERVENTION|Intravenous LPS only|LPS dose 2ng/kg.
62482727|NCT06626984|EXPERIMENTAL|Intravenous LPS AND Intravenous Fluid Therapy*|"\*The first 5 participants recruited to this study will receive intravenous fluid therapy only. This will allow us to directly elucidate the effects of intravenous fluid therapy on markers of vascular injury, markers of systemic inflammation, microcirculatory function and venous congestion in healthy volunteers.~LPS dose 2ng/kg. Intravenous fluid 30ml/kg in total (maximum volume of 2500mls). Administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr. The administration is to commence 90 minutes following intravenous LPS."
62482728|NCT06626984|EXPERIMENTAL|Intravenous LPS AND Imatinib Therapy|LPS dose 2ng/kg. Imatinib 600mg 1 hour prior to LPS administration.
62131818|NCT05161585|EXPERIMENTAL|ctDNA dynamic monitoring + routine postoperative follow-up|"ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total. At the same time, routine postoperative follow-up is given.~To be pointed out, after the completion of the adjuvant chemotherapy, if the ctDNA test indicates positive, patients will immediately perform chest, abdominal and pelvic CT and other imaging tests to determine whether there is recurrence /metastasis. If it is not confirmed, repeat the imaging review every two months, and continue to perform ctDNA test every three months. If the following ctDNA test is negative for two consecutive times, the above imaging reexamination will return to the routine follow-up frequency. In addition, during the follow-up, the following situations may occur: the imaging examination has found recurrence/metastasis, but the ctDNA test is still negative. At this time, the patient will be informed and treated in time of the recurrence/metastasis."
62482729|NCT06626984|EXPERIMENTAL|Intravenous LPS AND Intravenous Fluid Therapy AND Imatinib Therapy|"LPS dose 2ng/kg. Intravenous fluid 30ml/kg in total (maximum volume of 2500mls). Administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr. The administration is to commence 90 minutes following intravenous LPS.~Imatinib 600mg 1 hour prior to LPS administration."
62482730|NCT00042874|EXPERIMENTAL|Treatment (combination chemotherapy)|Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
62131819|NCT05161585|NO_INTERVENTION|routine postoperative follow-up|Only routine postoperative follow-up is given as follows: Physical examination and CEA were performed every 3-6 months for the first 2 years, every 6 months within the third to fifth year, and then annually. Chest/abdominal/pelvis computed tomography was performed annually for up to 5 years, and colonoscopy was performed for proper patients the first year after treatment and repeated in the third year if no advanced adenoma was found and then every 5 years.
62482731|NCT01586520||Disease positive|Imaging or biopsy evidence of disease
62482732|NCT01586520||Disease negative|No evidence of disease
62482733|NCT03635320|EXPERIMENTAL|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
62691359|NCT05681949|EXPERIMENTAL|Participants' cases discussed in tumor conference with ADBoard|Participants' cases will be evaluated by ADBoard directly before they are discussed in the tumor conference.
62482734|NCT03635320|ACTIVE_COMPARATOR|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
62482735|NCT06561906||Normal control|Subjects without memory complaints and associated worries and do not meet the diagnostic criteria for mild cognitive impairment (MCI) are recruited as normal control (NC).
62482736|NCT06561906||Subjective cognitive decline|Subjects who complain of memory decline within the last 5 years and express worries associated with memory decline and do not meet the diagnostic criteria for MCI are defined as subjective cognitive decline (SCD).
62691360|NCT06674707|EXPERIMENTAL|Agility Training with Foot Mobilization|Agility Training with Foot Mobilization along with simple conventional treatment
62691361|NCT06674707|ACTIVE_COMPARATOR|Agility Training without Foot Mobilization.|Agility training without foot mobilization along with simple conventional treatment.
62482737|NCT06561906||Mild cognitive impairment|Participants are considered MCI patients with scores \>1 standard deviation (SD) below the normative means in both subtests within one cognitive domain or \>1 SD below the normative means in three single tests in three different domains.
62691362|NCT02607722||IPF patients receiving Nintedanib|Patients diagnosed with idiopathic pulmonary fibrosis (IPF) based upon the most recent ATS/ERS/JRS/ALAT guideline and who initiated treatment with Ofev Capsules after the launch were registered into this study basically within 14 days from initiation of Ofev Capsules (from October 2015 to May 2023).
62691363|NCT06053580|EXPERIMENTAL|Valsartan|Valsartan 40mg capsule taken twice daily for 24 weeks.
62131820|NCT00304031|ACTIVE_COMPARATOR|Conventional adjuvant TMZ|Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.
62131821|NCT00304031|EXPERIMENTAL|Dose-dense adjuvant TMZ|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.
62131822|NCT00304031|OTHER|No adjuvant TMZ (not randomized )|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.
62131823|NCT00000936|EXPERIMENTAL|Induction|subjects receiving hOKT3 induction therapy
62131824|NCT00000936|ACTIVE_COMPARATOR|Induction Free Therapy|Patients not receiving induction therapy
62131825|NCT05771350|EXPERIMENTAL|online hemodiafiltration|
62131826|NCT05771350|ACTIVE_COMPARATOR|high flux hemodialysis|
62131827|NCT05771350|ACTIVE_COMPARATOR|low flux hemodialysis|
62131828|NCT02639286|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously (SC)
62323554|NCT03105440|EXPERIMENTAL|Virtual reality|"The software used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation Together with Federal University of Uberlândia. This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
62323555|NCT03105440|EXPERIMENTAL|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
62323556|NCT03105440|EXPERIMENTAL|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
62323557|NCT03105440|EXPERIMENTAL|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
62323558|NCT03105440|EXPERIMENTAL|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
62482738|NCT06561906||Alzheimer's disease dementia|Patients are diagnosed as AD dementia by an experienced neurologist based on MMSE and CSF/PET biomarker evidence.
62131829|NCT02639286|EXPERIMENTAL|ISIS 304801|300 mg of study drug administered via SC
62131830|NCT01895699|EXPERIMENTAL|contrast group (Ioversol)|Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
62323559|NCT01173627|EXPERIMENTAL|A - Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche
62323560|NCT01173627|ACTIVE_COMPARATOR|B - Actiq 400 mcg|Actiq 400 mcg
62323561|NCT04506177||Permanent Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) suture for vaginal mesh attachment
62482739|NCT02749266|EXPERIMENTAL|Chiropractic Activator Adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
62482740|NCT02749266|SHAM_COMPARATOR|Chiropractic sham adjustment|Participant will receive a sham (simulated) chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
62482741|NCT04822259|EXPERIMENTAL|JOURNEY II BCS TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
62482742|NCT04822259|EXPERIMENTAL|JOURNEY II CR TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
62482743|NCT02179788|EXPERIMENTAL|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
62691364|NCT06053580|PLACEBO_COMPARATOR|Placebo|Placebo capsule taken twice daily for 24 weeks.
62131831|NCT01895699|PLACEBO_COMPARATOR|Placebo group|
62131832|NCT01895699|OTHER|alpha-lipoic acid group|Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
62131833|NCT04126707|EXPERIMENTAL|[14C] HQP1351|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of \[14C\] HQP1351 to healthy Chinese male subjects.
62131834|NCT03470376|EXPERIMENTAL|Nutraceutical combination (NC)|Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months
62131835|NCT03470376|ACTIVE_COMPARATOR|No nutraceutical combination (noNC)|Patients on standardized diet regimen without taking any NC
62131836|NCT04406792|EXPERIMENTAL|DPP+doula divas|Enrolled participants will have access to an online DPP with other Black post-partum mothers who have had GDM. The teams will be led by doula divas trained in aspects of motivational interviewing and trained on the Healthiby platform.
62482744|NCT02179788|PLACEBO_COMPARATOR|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
62691365|NCT06597513|EXPERIMENTAL|auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab|Complete two 21-days cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1, followed by G-CSF for stem cell mobilization. Receive dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 followed by autologous stem cell reinfusion for two 21-day cycles. If eligible, participants will receive standaed-dose etoposide and carboplatin plus adebrelimab 1200 mg on day 1 for four cycles. Finally, participants may enter a maintenance phase with adebrelimab1200 mg every 21 days.
62691366|NCT06443242|EXPERIMENTAL|Low-Dose Laser Acupuncture (LLA) Group|In the Low-Dose Laser Acupuncture (LLA) group, participants receive treatments using the xS-998D06 semiconductor laser acupoint therapeutic device from Nanjing Xiaosong Medical Instruments. This device operates at a wavelength of 780 nm and an output power of 5 mW. Each 20-minute session involves securing the device's probe to specific acupoints (Baihui, Yintang, Anmian, Shenmen, Neiguan, Sanyinjiao, and Taichong) using medical tape. Treatments occur daily for 5 consecutive days each week, with a two-day break, over a 6-week period. All participants, regardless of group assignment, will maintain their regular antidepressant regimen.
62691367|NCT06443242|SHAM_COMPARATOR|Sham Laser Acupuncture (SLA) Group|Participants in the Sham Laser Acupuncture (SLA) group undergo a sham treatment involving the same procedure and acupoint targeting as the LLA group. The difference lies in the instrument probe being fixed to the acupoint but emitting a dummy laser, simulating the acupuncture experience without actual laser emission. All participants, regardless of group assignment, will maintain their regular antidepressant regimen.
62691368|NCT06443242|OTHER|Control Group|The control group, which serves as a non-intervention comparison, will continue their standard treatment regimen using SSRIs (Selective Serotonin Reuptake Inhibitors).
62691369|NCT06637033|EXPERIMENTAL|Chewing Food Group|This group will be given routine rehabilitation training, oral tube feeding and Chewing Food training for 15 days.
62691370|NCT06637033|ACTIVE_COMPARATOR|Control Group|This group will be given routine rehabilitation training, oral tube feeding for 15 days.
62691371|NCT01831882||Major Depressive Disorder|
62691372|NCT01831882||Healthy Control|
62691373|NCT04433572|ACTIVE_COMPARATOR|Temsirolimus|Temsirolimus delivered to adventitia and perivascular tissue after primary revascularization
62691374|NCT04433572|PLACEBO_COMPARATOR|Placebo|Saline placebo delivered to adventitia and perivascular tissue after primary revascularization
62691375|NCT04250844||Botulinum|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy with intrapyloric botulinum injections and if clinically applicable endoscopic functional luminal imaging probe (EndoFLIP). The dosage will be determined by the patient's physician.
62691376|NCT04250844||Control|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy without intrapyloric botulinum injections.
62131837|NCT04406792|ACTIVE_COMPARATOR|DPP only|Online DPP only support without doula as team lead. The participants will be in groups with a diverse group of patients that are non-mothers but who are at risk of type 2 diabetes.
62323562|NCT04506177||Delayed Absorbable Monofilament Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using delayed absorbable monofilament (polydioxanone, PDS) suture for vaginal mesh attachment
62323563|NCT00001604||1|Subjects with a family history of stuttering
62323564|NCT05547763|EXPERIMENTAL|resorbable plates, test group|after a surgical procedure under general anesthesia , resorbable plates will be placed on the fracture site of the mandibule in 20 patients out of 40 total sample size and will be compared with the titanium plates in the control group
62323565|NCT05547763|EXPERIMENTAL|titatnium plates, control group|after a surgical procedure under general anesthesia , titanium plates will be placed on the fracturte site in the mandible in 20 patients out of 40 total sample size and will be compared to the test group containing resorbable plates
62323566|NCT03638089|EXPERIMENTAL|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
62323567|NCT02411812|EXPERIMENTAL|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
62691377|NCT01481103|ACTIVE_COMPARATOR|Acupuncture group|Participants will keep a headache diary for 4weeks and then attend eight weekly acupuncture sessions. Acupuncture will be done by a licensed acupuncturist and will last approximately 25 minutes. Following the acupuncture sessions, participants will keep a headache diary for an additional 4 weeks
62691378|NCT01481103|NO_INTERVENTION|Control group|participants will be asked to maintain a daily diary of headache occurrences and OTC medication use for 16 weeks.
62691379|NCT06424119|EXPERIMENTAL|ICR-No Food|Intensive Cardiac Rehab (ICR) 72-session program without C2life® supplied food
62691380|NCT06424119|EXPERIMENTAL|ICR-Food|Intensive Cardiac Rehab (ICR_ 72-session program with C2life® supplied food
62323568|NCT02411812|ACTIVE_COMPARATOR|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
62323569|NCT02411812|ACTIVE_COMPARATOR|Twin-Block appliances|Group treated with Twin-Block appliance.
62323570|NCT00931788|EXPERIMENTAL|Intensive pharmacist case management|
62323571|NCT00931788|ACTIVE_COMPARATOR|Usual care|
62323572|NCT02637791|EXPERIMENTAL|Intervention|The virtual glove in their homes for a period of 8 weeks and advised to try to build up to using the system for a maximum of 20 minutes 3 times a day for 8 weeks.
62323573|NCT02637791|NO_INTERVENTION|Control|Usual care
62482745|NCT03487081|EXPERIMENTAL|Social regulation|Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.
62482746|NCT03487081|ACTIVE_COMPARATOR|Self regulation|Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.
62482747|NCT04398056|EXPERIMENTAL|Chemotherapy plus radiotherapy and Toripalimab|Patients were treated with PF chemotherapy for a maximum of six cycles followed by loco-regional radiotherapy combined with toripalimab.
62482748|NCT02855853|EXPERIMENTAL|serious game|
62482749|NCT02855853|PLACEBO_COMPARATOR|control|
62691381|NCT06424119|ACTIVE_COMPARATOR|TCR-No Food|Traditional Cardiac Rehab (TCR) 36-session program without C2life® supplied food
62691382|NCT06564168||Cases|Crtitically ill Patients with diabetes mellitus type 2.
62131838|NCT01418794|ACTIVE_COMPARATOR|Low dose rapamycin group|Concentration of rapamycin was 1.5%
62131839|NCT01418794|EXPERIMENTAL|High dose rapamycin group|Concentration of rapamycin is 2.5%
62131840|NCT01014273|ACTIVE_COMPARATOR|Trans-femoral access|Femoral artery PCI access site
62131841|NCT01014273|ACTIVE_COMPARATOR|Trans-radial access|Radial artery PCI access site
62131842|NCT03295747|EXPERIMENTAL|180 mg|180 mg of peppermint oil
62323574|NCT05714020|ACTIVE_COMPARATOR|Real rTMS|The active rTMS protocol is a 15-minute 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses using a real TMS coil. The target is the primary motor cortex.
62323575|NCT05714020|SHAM_COMPARATOR|Sham rTMS|The sham rTMS protocol is performed by a sham coil. The sham rTMS protocol is a 15-minute 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses. The target is the primary motor cortex.
62323576|NCT00797459|EXPERIMENTAL|Restylane and Restylane with Lidocaine|This is a split-face design injecting both Restylane and Restylane-L injectable gels, administered once. Each subject received Restylane on one side of the face, and Restylane-L on the other. Subjects were blinded to which side of their face received Restylane or Restylane-L. The study was randomized and treatments successive.
62323577|NCT03271931|NO_INTERVENTION|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
62323578|NCT03271931|EXPERIMENTAL|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
62323579|NCT03271931|EXPERIMENTAL|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
62323580|NCT01673724|EXPERIMENTAL|pramipexole|dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks
62323581|NCT01673724|ACTIVE_COMPARATOR|Bromocriptine|bromocriptine dosage form: white round tablet
62323582|NCT06276972||Scoliosis|scoliotic adolescents ranged in age from 10- 18 years will be enrolled
62482750|NCT06237049|EXPERIMENTAL|BNT162b2 (Omi XBB.1.5)/RIV and placebo|Participants will receive a single injection combination of BNT162b2 (Omi XBB.1.5) and RIV and normal saline placebo
62691383|NCT06564168||Controls|All critically ill patients not Diabetes mellitus type 2.
62691384|NCT03656614||sugammadex 0.125|Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
62691385|NCT03656614||Sugammadex 0.25|Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
62691386|NCT03656614||Sugammadex 0.5|Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
62691387|NCT03656614||Sugammadex 1.0|Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
62691388|NCT03656614||Sugammadex 2.0|Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
62691389|NCT03656614||Neostigmine 10|Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
62691390|NCT03656614||Neostigmine 25|Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
62131843|NCT03295747|EXPERIMENTAL|360 mg|360 mg of peppermint oil
62131844|NCT03295747|EXPERIMENTAL|540 mg|540 mg of peppermint oil
62131845|NCT05280275|EXPERIMENTAL|Part 1: Dose Finding|"Belantamab mafodotin will be administered as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose:~1. Cohort 1: 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle~2. Cohort 2: 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle~Administration schedule for daratumumab 1800mg SC (fixed dose):~Cycles 1-2: days 1, 8, 15, 22 Cycles 3-6: days 1, 15 Cycles 7+: day 1~Lenalidomide: 25 mg/d on day 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants \< 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years"
62131846|NCT06383793||overlap|
62131847|NCT06383793||Π|
62131848|NCT06499558|OTHER|Classical Training|In the professional skills laboratory, students in the control group will practice family planning education skills
62131849|NCT06499558|OTHER|Standard Patient Interviews|Students in the standard patient education group will receive standard patient education including a family planning counseling scenario.
62131850|NCT04834141||Kyphotic Group|"Participants with kyphosis angle ≥ 40 degrees joined the kyphosis group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
62691391|NCT03656614||Neostigmine 40|Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
61929456|NCT06682650|EXPERIMENTAL|NPT-PLA|"Clinics randomized to NPT-PLA will also define their CRC screening workflow via a checklist and preset I2 implementation protocol but will be trained initially then receive monthly support to facilitate a Participatory Learning in Action (PLA) session. NPT-PLA i-teams will identify barriers and supports to I2 implementation, and use Normalization Process Theory (NPT) constructs to guide identification, selection and ordering of action steps to progress implementation e.g. (before taking the step) does everyone understand the step to be taken, does everyone who needs to act 'buy in', (during implementation of the step) is everyone who needs to act actually taking action to complete the step, (after the step is taken) did taking the step have the intended impact, if not what happened? . NPT-PLA I-teams can adapt the I2 implementation protocol to fit their context, including when and how patients are presented with I2, to maximize I2 implementation and CRC screening completion."
61929457|NCT06466382|ACTIVE_COMPARATOR|Control Arm|"Physicians and patients randomized to the SOC arm will not receive the treatment recommendation of the mTB and thus will undergo the standard treatment consisting of 2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly.~Either q3w regime or q1w regime."
61929458|NCT06466382|EXPERIMENTAL|Interventional Arm|The intervention studied is a treatment recommendation by a specialized molecular tumorboard. This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.
61929459|NCT05295680|EXPERIMENTAL|Hymecromone|Participants will receive Hymecromone for six months + Standard Of Care (SOC), and will be followed for an additional nine months.
61929460|NCT05295680|NO_INTERVENTION|Standard Of Care (SOC)|Participants will receive Standard Of Care (SOC), and will be followed for 15 months.
61929461|NCT05862727|EXPERIMENTAL|PASS Arm1|Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, such as establishing daytime and bedtime routines, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.
61929462|NCT05862727|ACTIVE_COMPARATOR|PASS Arm2|Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, including in home and public settings, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.
61929463|NCT02546115|ACTIVE_COMPARATOR|Intervention|standard practice (structured rehabilitation programme) + TNS
62323583|NCT01142219|EXPERIMENTAL|L-arginine|0.1g/kg/day for 6 months
61929464|NCT02546115|ACTIVE_COMPARATOR|control|standard practice (structured rehabilitation programme)
61929465|NCT06105554|EXPERIMENTAL|Phase 1 (dose escalation)|Phase 1, the dose of belumosudil mesylate participants receive will depend on when participants join this study. The first group of participants will receive the lowest dose level of belumosudil mesylate.
61929466|NCT06105554|EXPERIMENTAL|Phase 2 (dose expansion)|Phase 2, participants will receive belumosudil mesylate at the recommended dose that was found in Phase 1.
61929467|NCT02557295||Remsima™|Patients who have received only Remsima or switched from non-biologic treatment to Remsima were included in this analysis group.
61929468|NCT02557295||Switch to Remsima I|Patients who switched from Remicade to Remsima were included in this analysis group.
61929469|NCT02557295||Switch to Remsima II|Patients who switched to Remsima from biologic treatment other than Remicade were included in this analysis group.
61929470|NCT02557295||Remicade|Patients who have received only Remicade or switched from non-biologic treatment to Remsima were included in this analysis group.
61929471|NCT02557295||Switch to Remicade I|Patients who switched from Remsima to Remicade were included in this analysis group.
61929472|NCT02557295||Switch to Remicade II|Patients who switched to Remicade from biologic treatment other than Remsima will be included in this analysis group.
61929473|NCT02557295||Other Anti-TNF|"Following patients were included in other anti-TNF group.~* Patients who have received only anti-TNF other than Remsima or Remicade~* Patients who switched from non-biologic treatment to anti-TNF other than Remsima or Remicade~* Patients who switched from biologic treatment other than anti-TNF before study enrolment to anti-TNF other than Remsima or Remicade"
61929474|NCT02557295||Switch to Other Anti-TNF|Patients who switched from Remsima or Remicade to other anti-TNF other than Remicade will be included in this analysis group
61929475|NCT02557295||Biologic Naïve|Patients who received only non-biologic treatment will be included in this analysis group
61929476|NCT05309590||Dose Reduction|All patients recruited to the study will have reduced their swallowed steroid medication from twice to once daily as part of the standard-of-care.
61929477|NCT06624449|EXPERIMENTAL|Cold Debriefing|The researcher assigned a cold debriefing (after one-day post-simulation) for undergraduate nursing students in the intervention group.
61929478|NCT06624449|OTHER|Hot Debriefing|The control group received a hot debriefing (immediately after the simulation).
62323584|NCT03865017|EXPERIMENTAL|Regulatory T cells|Biologicals: Autologous Regulatory T cells (1.7\*10\^5 cells/kg, i.v) other name: GB301
62323585|NCT03865017|PLACEBO_COMPARATOR|Placebo|Saline+cell suspension solution infusion
62323586|NCT03074162|EXPERIMENTAL|Diclofenac Sodium (A)|
62323587|NCT03074162|EXPERIMENTAL|Diclofenac & Capsaicin (B)|
62691392|NCT03656614||Neostigmine 55|Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
62691393|NCT03656614||Neostigmine 70|Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
62691394|NCT03656614||Placebo|Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3
62482751|NCT06237049|EXPERIMENTAL|BNT162b2 (Omi XBB.1.5) and RIV|Participants will receive BNT162b2 (Omi XBB.1.5) and RIV
62131851|NCT04834141||Control Group|"Participants with kyphosis angle \< 40 degrees for the control group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
62131852|NCT02117752|EXPERIMENTAL|Dapsone Gel Subset 1|Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
62323588|NCT03074162|ACTIVE_COMPARATOR|Diclofenac Sodium Topical Gel|
62323589|NCT04706182|EXPERIMENTAL|Combined PRF and PSG|
62323590|NCT04706182|EXPERIMENTAL|Only PRF|
62323591|NCT04706182|EXPERIMENTAL|Only PSG|
62323592|NCT04706182|NO_INTERVENTION|Control (no treatment)|
62323593|NCT04478292|EXPERIMENTAL|Group A|"* Group A1： tumor is completely resected at diagnosis and receives no adjuvant chemotherapy（well differentiated fetal \[WDF\] histology HB) ；~* Group A2：tumor is completely resected followed by 2 cycles of standard dose cisplatin monotherapy （non-well differentiated fetal histology HB)"
62323594|NCT04478292|EXPERIMENTAL|Group B|"* Patients will be randomized to one of 2 arms: Arm CDDP or Arm CDDP plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy (6 cycles of standard dose cisplatin monotherapy with or without STS). All the patients in 2 arms will receive 6 cycles chemotherapy in total.~* Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.~* Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
62323595|NCT04478292|EXPERIMENTAL|Group C|"* Patients in Group C will have locally advanced tumors including PRETEXT I-III tumors with a positive VPEFR annotation factor and all PRETEXT IV tumors.~* Patients will be randomized to one of 2 arms: Arm C5VD or Arm C5VD plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy. All the patients in 2 arms will receive 6 cycles chemotherapy in total.~* Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.~* Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
62323596|NCT04478292|EXPERIMENTAL|Group D|"* These patients have metastatic disease, suspected HB patients ≥ 8 years of age, or have an AFP ≤ 100 at diagnosis.~* Patients will receive initial chemotherapy according to the cisplatin-intensive SIOPEL-4 induction regimen. Resection (including transplant) of the primary tumor should be completed after induction Block 3, but primary tumor resection can be planned any time after completing induction therapy.~* Following 3 blocks of induction chemotherapy, patients will be stratified into 2 risk groups: Group D1 includes patients who either have a chemotherapy-induced lung CR or are rendered a lung CR by surgical metastasectomy. These patients will have chemotherapy consolidation with carboplatin/doxorubicin. In Group D2, patients will have not yet achieved a lung CR at the end of induction Block 3. These patients will get intensified consolidation therapy of carboplatin/doxorubicin with vincristine/irinotecan.~* Resection of pulmonary nodules should be considered in Group D2."
62323597|NCT06377644|OTHER|Dry Needling|
62691395|NCT06673901||study group (A)|This study enrolled 95 females (52 PCOS, 43 Controls) who agreed to participate in this research. They signed an informed consent after explaining the existence, purpose, and advantages of the study, notifying them of their right to refuse or withdraw at any time. Patients were excluded from the study if they suffered from skeletal deformities (one case), had previous spinal surgeries (one case), had leg length discrepancy (one case) and two cases received hormone replacement therapy
62691396|NCT06673901||control group (B).|Patients were referred by the gynecologist, based on Rotterdam PCOS Diagnostic Criteria in adults (14), having irregular menstrual cycles (less than 8 menstrual cycles/year or more than 35 days between cycles), painful menses and premenstrual abdominal bloating, and headaches. Forty-three healthy females not suffering from any gynecological condition were referred by a gynecologist and considered the
62691397|NCT04976855|EXPERIMENTAL|Part I Cohort 1 INDV-2000 100 mg QD|Healthy volunteers will receive INDV-2000 100 mg once daily for 7 days.
62131853|NCT02117752|EXPERIMENTAL|Dapsone Gel Subset 2|Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
62323598|NCT06377644|EXPERIMENTAL|Kinesio taping|
62323599|NCT01167595|EXPERIMENTAL|PEP uP Protocol|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
62323600|NCT01167595|NO_INTERVENTION|Standard Feeding Protocol|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
62323601|NCT02875314|EXPERIMENTAL|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
62482752|NCT06237049|ACTIVE_COMPARATOR|BNT162b2 (Omi XBB.1.5) and placebo|Participants will receive BNT162b2 (Omi XBB.1.5) and normal saline placebo
62482753|NCT06237049|ACTIVE_COMPARATOR|RIV and placebo|Participants will receive RIV and normal saline placebo
62482754|NCT02369822|EXPERIMENTAL|Vitamin C supplemented|patients with refractory idiopathic epilepsy will receive vitamin C supplement according to age for 1 month
62482755|NCT02369822|NO_INTERVENTION|None supplemented|followed up for 1 month
62482756|NCT04821349|OTHER|Single arm study|Standard reading Group vs AI-assisted reading Group
62691398|NCT04976855|PLACEBO_COMPARATOR|Part I Cohort 1 Placebo|Healthy volunteers will receive placebo once daily for 7 days.
62131854|NCT01637246||POAG or OHT|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
62482757|NCT02261389|NO_INTERVENTION|Arm A, usual follow-up practice|Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice
62482758|NCT02261389|EXPERIMENTAL|Arm B, tumor markers assessment|Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.
62482759|NCT02951858|EXPERIMENTAL|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
62482760|NCT02951858|ACTIVE_COMPARATOR|Control Group|The participants only receive the materials about the harm of substance use.
62482761|NCT03428880|ACTIVE_COMPARATOR|spinal morphine|intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
61929479|NCT04526418|EXPERIMENTAL|24/7 EEG™ SubQ System|To demonstrate the electrographic seizure recording effectiveness of the 24/7 EEG™ SubQ system by comparison to simultaneous inpatient video-EEG data.
61929480|NCT02572193|EXPERIMENTAL|Active case|POEM procedure
61929481|NCT03979430|OTHER|Intervention|There is only one arm with the intervention.
61929482|NCT05925075||RDS|Infant born less than 32 weeks gestation with diagnosis of respiratory distress syndrome. Lung ultrasounds will be performed on day of life 7, 14, 21, 28 and at corrected gestational age of 36 weeks.
61929483|NCT05925075||PDA|In addition to being less than 32 weeks gestation, subject can qualify for study and receive a lung ultrasound scan at time of echo diagnosis of patent ductus arteriosus (PDA).
61929484|NCT05925075||Steroid|"Aims are :~A: To evaluate changes in LUS scores pre and post treatment with systemic steroid course.~B: To evaluate the predictive ability of LUS for successful extubation following course of systemic steroids.~Lung ultrasound scans will be done prior to initiation of post-natal steroid, day 1, day 3, day 7, day 10 of treatment and 1 week after steroid is discontinued."
61929485|NCT06455995|ACTIVE_COMPARATOR|DEPTH-Standard|Participants in the Standard Group will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. Standard group will receive no guidance on energy intake distribution (standard lifestyle intervention).
61929486|NCT06455995|EXPERIMENTAL|DEPTH-Morning|Participants in the Morning Group will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. They will also have time-based energy intake goals of 70% of kcal within the first 6 hrs of the eating window and 30% of kcal within the last 6 hrs of the eating window (a morning-loaded energy distribution).
61929487|NCT06455995|EXPERIMENTAL|DEPTH-Evening|Participants in the Evening Group will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. They will also have time-based energy intake goals of 30% of kcal within the first 6 hrs of the eating window and 70% of kcal within the last 6 hrs of the eating window (an evening-loaded energy distribution).
61929488|NCT00378105|EXPERIMENTAL|lenalidomide, dexamethasone, bortezomib combination|In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.
61929489|NCT02136108|EXPERIMENTAL|OPENtext|OPENtext will target cognitive, affective, and behavioral strategies through a single, brief in-person assessment, followed by 12 weeks of theoretically-informed text messages, a core set of information organized in a 'frequently asked questions' structure, interactive peer support, static resources on key patient-identified topics, and a library of peer stories accessible throughout the study period.
62131855|NCT04403789|EXPERIMENTAL|Intervention Group|During the intervention period they will receive 2 hours per week of group exercise sessions during working hours for 12 weeks. However, after the intervention period, there will be no change in working hours
62131856|NCT04403789|ACTIVE_COMPARATOR|Delayed Intervention Group (Control group)|During the intervention period there will be no change in working hours. However, after the intervention period they will receive 2 hours of exercise time during working hours per week for 4 weeks
62131857|NCT05563740|EXPERIMENTAL|Intervention Group|"All received care for alcohol withdrawal state as is routinely provided at the centre by their respective treating doctors and followed up as directed. All treatment and follow up decisions were made by the respective treating doctors. Study team did not have any role in it.~In addition all received a session of Brief Intervention (BI) for alcohol, at the time of recruitment and again after completing detoxification. Further, patient or designated caregiver received daily phone calls and Information was provided regarding any queries related to their withdrawal or detoxification process. Adverse outcomes such as sedation, seizure, confusion were enquired for and records were kept. Patient was encouraged to continue the treatment and report back for scheduled follow ups and in case of any adverse outcomes patient was asked to report back to the treating doctor and an appointment was facilitated. Phone calls were discontinued once detoxification (CIWA \< 8) was complete."
62482762|NCT03428880|ACTIVE_COMPARATOR|quadratus lumborum block|"intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline.~Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side."
62482763|NCT02125981|EXPERIMENTAL|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
62482764|NCT02125981|PLACEBO_COMPARATOR|Control|taking placebo drug
62482765|NCT01015703|EXPERIMENTAL|CoVaccine HT|
62482766|NCT06561490||placental volume and thickness in normal singleton pregnancy|
62482767|NCT02055547|EXPERIMENTAL|Part 1 - Panel A - MK-8521 100μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and matching placebo (PBO) in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482768|NCT02055547|EXPERIMENTAL|Part 1 - Panel A - PBO > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482769|NCT02055547|EXPERIMENTAL|Part 1 - Panel A - MK-8521 100μg > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482770|NCT02055547|EXPERIMENTAL|Part 1 - Panel B - MK-8521 150μg > PBO > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, PBO in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482771|NCT02055547|EXPERIMENTAL|Part 1- Panel B- MK-8521 150μg > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62323602|NCT02875314|EXPERIMENTAL|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
62323603|NCT02875314|EXPERIMENTAL|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
62323604|NCT03558893|EXPERIMENTAL|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
62323605|NCT04126070|EXPERIMENTAL|COHORT 1: DNA damage repair defects (DDRD) +/- Inflamed Tumor|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.~* Androgen Deprivation Therapy: Given per standard care for duration of study~* Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage~* Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
62482772|NCT02055547|EXPERIMENTAL|Part 1 - Panel B - MK-8521 150μg > MK-8521 200μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482773|NCT02055547|EXPERIMENTAL|Part 1 - Panel B - PBO > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received PBO in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482774|NCT02055547|EXPERIMENTAL|Part 2 - Panel C - MK-8521 50μg > MK-8521 72μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 50μg Days 1 to 5 and MK-8521 72μg Days 6 to 10 in a single treatment period.
62482775|NCT02055547|EXPERIMENTAL|Part 2 - Panel D - MK-8521 100μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
62131858|NCT05563740|NO_INTERVENTION|Control Group|All participants received care for alcohol withdrawal state as is routinely provided at the centre by their respective treating doctors and followed up as directed. All treatment and follow up decisions were made by the respective treating doctors. Study team did not have any role in it.
62482776|NCT02055547|EXPERIMENTAL|Part 2 - Panel E - MK-8521 125μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
62482777|NCT02055547|EXPERIMENTAL|Part 2 - Panel F - MK-8521 72μg > MK-8521 125μg|Obese male participants of 45 to 65 years of age received a single dose of MK-8521 72μg Days 1 to 7 and MK-8521 125μg Days 8 to 14 in a single treatment period.
62482778|NCT02055547|PLACEBO_COMPARATOR|Part 2 - Panels C+D+E - Pooled Placebo|Healthy male participants of 18 to 45 years of age received PBO once daily for 10 days.
62131859|NCT05519670|EXPERIMENTAL|Only Arm|niraparib + capecitabine treatment
62131860|NCT00885924|ACTIVE_COMPARATOR|Active treatment|Desmopressin 0.3 microgram/kg
62131861|NCT00885924|PLACEBO_COMPARATOR|Placebo|NaCl 0.9%
62131862|NCT05875987||Obstetric Patients|Obstetric patient population experiencing excessive bleeding around the time of delivery
62131863|NCT03021369|ACTIVE_COMPARATOR|Pleural drainage system Medela|These patients receive the digital Medela system
62131864|NCT03021369|ACTIVE_COMPARATOR|Pleural drainage system Ocean|These patients receive the analogue Maquet system
62482779|NCT02055547|PLACEBO_COMPARATOR|Part 2 - Panel F - Placebo|Obese male participants of 45 to 65 years of age received a single dose of PBO Days 1 to 14.
62482780|NCT02055547|EXPERIMENTAL|Part 3 - Panel H - MK-8521 125μg > MK-8521 35μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, MK-8521 35μg (low dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482781|NCT02055547|EXPERIMENTAL|Part 3 - Panel H - MK-8521 35μg > PBO > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, PBO MK-8521 in the second treatment period, and 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482782|NCT02055547|EXPERIMENTAL|Part 3 - Panel H - PBO > MK- 8521 125μg > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 125μg (high dose) in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482783|NCT02055547|EXPERIMENTAL|Part 3 - Panel H - PBO > MK- 8521 35μg > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 35μg (low dose) in the second treatment period, and MK-8521 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482784|NCT02055547|EXPERIMENTAL|Part 3 - Panel H - MK-8521 125μg > PBO > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, PBO in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62131865|NCT02164240|EXPERIMENTAL|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
62131866|NCT04556981|EXPERIMENTAL|M72/AS01E vaccine|
62482785|NCT02055547|EXPERIMENTAL|Part 3 - Panel H - MK-8521 35μg > MK-8521 125μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, MK-8521 125μg (high dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
62482786|NCT06319482|EXPERIMENTAL|Proactive CPAP Therapy (Intervention)|Patients will undergo CPAP enabled with proactive therapy.
61929490|NCT02136108|ACTIVE_COMPARATOR|OPENnav|Peer Navigation is currently offered to some individuals in this Medicaid population but not all. Peer navigators interact with patients by phone/text and at home visits. Efforts focus on drivers of a patient's ED use, and may include providing or identifying patient support, improving health literacy, assisting with transportation vouchers, health education, family support, accessing housing services, and orienting to other community support services.
62131867|NCT04556981|PLACEBO_COMPARATOR|Placebo|
62323606|NCT04126070|EXPERIMENTAL|COHORT 2: Inflamed Tumor without DNA repair defects (DDRD)|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.~* Androgen Deprivation Therapy: Given per standard care for duration of study~* Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage~* Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
62323607|NCT04126070|EXPERIMENTAL|COHORT 3: Biomarker Negative|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.~* Androgen Deprivation Therapy: Given per standard care for duration of study~* Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage~* Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6"
62323608|NCT04475185|EXPERIMENTAL|MakAir|
62323609|NCT03204227|EXPERIMENTAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
62323610|NCT03204227|ACTIVE_COMPARATOR|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
62323611|NCT00859898|EXPERIMENTAL|Dapagliflozin + Metformin XR|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"
62482787|NCT06319482|ACTIVE_COMPARATOR|Conventional APAP Therapy (Control)|Patients will undergo conventional APAP therapy.
62482788|NCT01343004|PLACEBO_COMPARATOR|Placebo|Placebo identical in appearance to BA058 study drug
61929491|NCT04924205|NO_INTERVENTION|Outpatient Physical Therapy|
61929492|NCT04924205|EXPERIMENTAL|Smart Orthotic Device (FM2 Knee Brace)|
61929493|NCT01490554|EXPERIMENTAL|autologous fibroblast grafts|autologous fibroblast grafts
61929494|NCT02172066|EXPERIMENTAL|Narrative Exposure Therapy (NET)|During NET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for emotions, cognitions, sensory information, and physiological reactions to link the traumatic events to an autobiographical context, namely time and place. In total the Individuals receive 6 sessions of NET, every session lasting between 1,5 and 2 hr depending on the needs of the participant.
61929495|NCT02172066|NO_INTERVENTION|No treatment control|
61929496|NCT04723654||ICU Population|Patients admitted to one of 3 ICUs at Lurie Childrens
62482789|NCT01343004|EXPERIMENTAL|BA058 80 mcg (abaloparatide)|
62482790|NCT01343004|ACTIVE_COMPARATOR|teriparatide|Blinded until after randomization, then open-label
61929497|NCT04723654||Non-ICU Population|Healthy volunteers who are under 18 years of age, whose parents consent to their participation, and who are willing to visit CAMP for a one time study visit can participate in this study.
61929498|NCT01071473|OTHER|Exercise Group|Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
61929499|NCT02966041|EXPERIMENTAL|Ondansetron|Ondansetron 4mg IV at time of discontinuation of Propofol Infusion
62131868|NCT05591755|EXPERIMENTAL|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)|
62131869|NCT05591755|EXPERIMENTAL|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)|
62131870|NCT05591755|EXPERIMENTAL|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)|
62131871|NCT05591755|EXPERIMENTAL|Vehicle ophthalmic solution (n = 56)|
62131872|NCT06215053|OTHER|group 1|Following induction of anesthesia, ESP block will be performed before the surgery begins
62691399|NCT04976855|EXPERIMENTAL|Part I Cohort 2 INDV-2000 100 mg BID|Healthy volunteers will receive INDV-2000 100 mg twice daily for 7 days.
62323612|NCT00859898|EXPERIMENTAL|Dapagliflozin + Placebo|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."
62691400|NCT04976855|PLACEBO_COMPARATOR|Part I Cohort 2 Placebo|Healthy volunteers will receive placebo twice daily for 7 days.
62691401|NCT04976855|EXPERIMENTAL|Part II Cohort 1 INDV-2000 200 mg BID|Healthy volunteers will receive INDV-2000 200 mg twice daily for 28 days.
62691402|NCT04976855|PLACEBO_COMPARATOR|Part II Cohort 1 Placebo|Healthy volunteers will receive placebo twice daily for 28 days.
62131873|NCT06215053|OTHER|group 2|An ESP block will be performed before waking the patient at the end of surgery.
62131874|NCT05598554|EXPERIMENTAL|Study Group|chair-based yoga program with tele-rehabilitation was applied to elderly people.
62131875|NCT05598554|ACTIVE_COMPARATOR|Control Group|1 session of training was given on the effect of physical activity and exercise on function and quality of life.
62131876|NCT05101941|EXPERIMENTAL|immediate dental implants|
62323613|NCT00859898|ACTIVE_COMPARATOR|Metformin XR + Placebo|"Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"
61929500|NCT02966041|PLACEBO_COMPARATOR|Saline|2 mL IV Normal Saline at time of discontinuation of Propofol Infusion
61929501|NCT05289531||Rectal resection patients|Four Turkish centers participated in data collection in 2016. The inclusion criteria were rectal adenocarcinoma within 15 cm from the anal verge and LAR with either PME or TME. All patients had bowel continuity restored for at least 18 months when invited for the study. Exclusion criteria included failed R0 surgery, recurrence or dissemination, having intestinal stoma, previous cancer (except minor skin cancers) dementia and inability to speak Turkish (i.e., the need for a translator during treatment). A research assistant at each center identified the consecutive series of eligible patients for each participating consultant surgeon
61929502|NCT05289531||52 patients re-questioned to answer the same questionaire as control group|"The test-retest reliability of the LARS score was evaluated by asking 52 randomly selected subgroup of eligible patients to repeat the assessment of the LARS score 2 to 4 weeks after their initial response. Agreement between tests for the LARS score category and for each of the five LARS score items is presented as proportions with 95% confidence intervals. We considered it a perfect agreement if the patient ticked the exact same response category at both tests, a moderate agreement if responses differed by one category, while 'no agreement' was applied to patients whose responses differed by two or more categories.~The intraclass correlation coefficient was used to evaluate the agreement between the initial test and the retest. The limit of agreements was calculated by using the Bland-Altman method. An ICC between 0.61 and 0.80 is considered strong agreement. A p value less than 0.05 was considered significant."
61929503|NCT06343350||Retinal imaging|Participants will undergo retinal imaging with and without mydriatic agent to dilate the pupils.
62323614|NCT04209504||Continuous Perineural Catheter|Placement of preoperative continuous perineural catheter using 25 milliliters (mL) 0.5% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.
62323615|NCT04209504||10 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
61929504|NCT05607797|EXPERIMENTAL|Patients with gout|Patients aged 18-70 with gout diagnosis in their medical record or claiming to have gout according to ACR/EULAR (American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria.
62691403|NCT04976855|EXPERIMENTAL|Part II Cohort 2 INDV-2000 400 mg BID|Healthy volunteers will receive INDV-2000 400 mg twice daily for 28 days.
62691404|NCT04976855|PLACEBO_COMPARATOR|Part II Cohort 2 Placebo|Healthy volunteers will receive placebo twice daily for 28 days.
62691405|NCT04976855|EXPERIMENTAL|Part III INDV-2000 400 mg BID + SUBOXONE SL Film|Participants with opioid use disorder will receive SUBOXONE sublingual (SL) film for 6 days during the run-in period. Participants will then receive SUBOXONE SL film alone for 2 days, then SUBOXONE SL film and INDV-2000 for 7 days followed by INDV-2000 dosing alone for 4 days.
62691406|NCT05644132|EXPERIMENTAL|Thumb base joint prosthesis|
62691407|NCT06633549|EXPERIMENTAL|Educated|Educated Group
61929505|NCT05607797|EXPERIMENTAL|Patients with CKD|"Patients aged 18-70, in dialysis or with CKD clinically diagnosed on the basis of markers of kidney damage or decreased kidney function.~Patients will be recruited in dialysis centers of Wé and Maré and during the monthly nephrology consultations in medical centers."
61929506|NCT05607797|PLACEBO_COMPARATOR|Control group|Persons aged 30-80 without gout or CKD. The recruitment will be done among people visiting the medical centers of Lifou and Maré for administrative or vaccination reasons.
61929507|NCT06703242|OTHER|Health promotion intervention group|A one time six-session weekly intervention group for mothers of children with ADHD in the ultra-orthodox community.
62131877|NCT05271994||Endoscopic biliary drainage|Patients with distal malignant biliary obstruction, who need endoscopic biliary drainage
62131878|NCT02919449|EXPERIMENTAL|MV-NIS and Atezolizumab|MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
62323616|NCT04209504||20 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 20mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
62323617|NCT01419249|OTHER|Retrospective cohort|
62323618|NCT00456963|EXPERIMENTAL|Diet, exercise and Enalapril|one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
62323619|NCT00456963|ACTIVE_COMPARATOR|Diet, Exercise and Losartan|one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
62323620|NCT00456963|PLACEBO_COMPARATOR|Diet, exercise and Placebo|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
62691408|NCT06633549|OTHER|Uneducated|Uneducated Group (Control)
62691409|NCT04923997|EXPERIMENTAL|Health Coaching|All participants will be in the health coaching group. Participants on study will receive a health coach for 6 months.
62691410|NCT04918771|EXPERIMENTAL|Raphamin|Tablet for oral use.
62691411|NCT04918771|PLACEBO_COMPARATOR|Placebo|Tablet for oral use.
62691412|NCT05178654|EXPERIMENTAL|[14C]PF-07321332|Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
62691413|NCT02220400|EXPERIMENTAL|Ketamine|Ketamine infusion group
62691414|NCT02220400|PLACEBO_COMPARATOR|Placebo|Normal saline infusion
62691415|NCT06644690|EXPERIMENTAL|1- CO-OP with Creative Dance|Participants in this experimental group will receive the CO-OP (Cognitive Orientation to daily Occupational Performance) approach combined with creative dance interventions. The creative dance component will involve simple, structured movements designed to enhance cognitive and motor functions such as attention, memory, and coordination. The intervention will be administered three times per week for 60-minute sessions over an 8-week period. This group will alternate between CO-OP activities and creative dance exercises, integrating both to improve daily functional performance and cognitive abilities.
61929508|NCT04295655|EXPERIMENTAL|Global Exercise Group|all patients received the Control Group treatment added to global exercise treatment. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises. The number of repetitions was adapted to the subject's response taken into account the perceived dyspnea and fatigue during the exercise performance.
61929509|NCT04295655|EXPERIMENTAL|Functional Electrostimulation Group|"all patients received the Control Group treatment plus neuromuscular stimulation therapy (SEFAR Rehab X2, DJO France S.A.S., France) on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
61929510|NCT04295655|ACTIVE_COMPARATOR|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy.
62482791|NCT01883713||Heart surgery during CPB|All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 \> 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
62482792|NCT01916239|EXPERIMENTAL|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
62482793|NCT01916239|EXPERIMENTAL|Pomegranate extract formulation-1|New pomegranate extract formulation-1
62482794|NCT01916239|EXPERIMENTAL|Pomegranate extract formulation-2|New pomegranate extract formulation-2
61929511|NCT06050395|EXPERIMENTAL|MONITOR group: Monitoring of a Nutrition Intervention to Optimize treatment Response|Participants randomized to the MONITOR arm will be provided dietary coaching biweekly to discuss nutrition concerns, anti-inflammatory diet compliance, and set SMART goals based on their most recent Vioscreen food frequency questionnaires.
61929512|NCT06050395|ACTIVE_COMPARATOR|Standard Usual Care|Standard Usual Care participants will receive usual nutrition care received in the Moffitt Cancer Center pancreatic clinic, in addition to handouts on diet.
62482795|NCT06469645|EXPERIMENTAL|Intervention Group|Patients randomised in this group will be taking the SLGT2 inhibitor (empagliflozin) on top of their regular medications for 6 months.
62482796|NCT06469645|NO_INTERVENTION|Control Group|Patients randomised in this group will continue to have their guideline directed conservative management with no changes in their regular medications.
62482797|NCT06561074|EXPERIMENTAL|Treatment w/Calaspargase pegol-mknl + Decitabine + Venetoclax|
62482798|NCT01885117|EXPERIMENTAL|TIVf (18 to ≤ 60 years)|Adult subjects aged 18 to ≤ 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
62482799|NCT01885117|EXPERIMENTAL|TIVf (≥ 61 years)|Adult subjects aged ≥ 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
62482800|NCT05831657|EXPERIMENTAL|Prevent It 2.0 Swedish|A free, anonymous, internet-delivered, clinician-guided, cognitive behavioral therapy (CBT) intervention delivered in Swedish.
62482801|NCT05831657|ACTIVE_COMPARATOR|Waitlist Swedish|Waitlist Swedish Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior in Swedish.
62482802|NCT05831657|EXPERIMENTAL|Prevent It 2.0 German|A free, anonymous, internet-delivered, clinician-guided, cognitive behavioral therapy (CBT) intervention delivered in German
62691416|NCT06644690|ACTIVE_COMPARATOR|CO-OP Only|Participants in this active comparator group will receive the CO-OP (Cognitive Orientation to daily Occupational Performance) approach without any additional creative dance interventions. The CO-OP approach will focus on cognitive and metacognitive strategies to improve daily occupational performance. Sessions will take place three times per week for 60 minutes over an 8-week period. This group will engage in problem-solving and goal-setting activities to enhance functional and cognitive outcomes without the integration of dance or physical movement activities.
62691417|NCT06644976||early surgery|
61929513|NCT06699732|EXPERIMENTAL|Experimental|Who receives intervention i.e. Mindful Self Compassion Therapy
61929514|NCT06699732|ACTIVE_COMPARATOR|Waitlist Control|Who would receive intervention after study completion
62323621|NCT03175744|EXPERIMENTAL|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
62482803|NCT05831657|ACTIVE_COMPARATOR|Waitlist German|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior in German
62482804|NCT05831657|EXPERIMENTAL|Prevent It 2.0 Portuguese|A free, anonymous, internet-delivered, clinician-guided, cognitive behavioral therapy (CBT) intervention delivered in Portuguese
62482805|NCT05831657|ACTIVE_COMPARATOR|Waitlist Portuguese|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior in Portuguese
62482806|NCT01342133||Newborns|
62482807|NCT01342133||Mothers|
62482808|NCT03835286|EXPERIMENTAL|Vitamin C|Vitamin C experimental group
62482809|NCT03835286|PLACEBO_COMPARATOR|Control|Placebos Controlled group
62691418|NCT06644976||late surgery|
62691419|NCT04119037|EXPERIMENTAL|Group I (cordotomy)|Patients undergo a cordotomy over 1-2 hours.
62691420|NCT04119037|SHAM_COMPARATOR|Group II (morphine, fake cordotomy)|Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours.
61929515|NCT01385176|EXPERIMENTAL|Therapy|"Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.~The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.~Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
61929516|NCT01385176|SHAM_COMPARATOR|Control|"Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
61929517|NCT01699932|EXPERIMENTAL|Arm 1|24-week treatment period: starting dose will be of 2/1000 mg or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M® ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M® , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and \> 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
61929518|NCT04632303|EXPERIMENTAL|Early Palliative Care|Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.
62323622|NCT03175744|ACTIVE_COMPARATOR|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
61929519|NCT04632303|NO_INTERVENTION|Standard Care Arm|Palliative care visit only upon request from attending oncologist(s) or patient/family.
61929520|NCT05868577|EXPERIMENTAL|corticosteroid injection/ local anesthetic (CSI/LA)|"The PI will then administer the (CSI/LA) injection using an infracalcaneal needle peppering technique as follows:~1. The hypodermic needle is inserted using infracalcaneal injection approach.~2. The hypodermic needle is withdrawn while at the same depositing injectate~3. The hypodermic needle is redirected without emerging from the skin. The PI will perform steps 1-3 standardly 20-25 times."
61929521|NCT05868577|PLACEBO_COMPARATOR|local anesthetic (LA)/Saline injection|"The PI will then administer the (LA/Saline) injection using an infracalcaneal needle peppering technique as follows:~1. The hypodermic needle is inserted using infracalcaneal injection approach.~2. The hypodermic needle is withdrawn while at the same depositing injectate~3. The hypodermic needle is redirected without emerging from the skin. The PI will perform steps 1-3 standardly 20-25 times."
61929522|NCT06654258|EXPERIMENTAL|Spiritual Self-Care App|Smartphone app
61929523|NCT06705894||S-M group|Gratrointestinal endoscopy is undergone with anesthsia.
61929524|NCT06705894||S-R group|Gratrointestinal endoscopy is undergone without anesthsia.
61929525|NCT05851326|EXPERIMENTAL|Active Sonodyn Therapy (Treatment Group)|Patients will remain on treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.
61929526|NCT05851326|SHAM_COMPARATOR|Sham Therapy (Control Group)|Patients will remain on sham treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.
61929527|NCT04872218|EXPERIMENTAL|Abatacept|
61929528|NCT04872218|PLACEBO_COMPARATOR|Placebo|
61929529|NCT06348134|EXPERIMENTAL|Phase 1: All Participants|"All participants will receive a combination of:~* docetaxel (starting dose - 75 mg/m2), increasing to 100mg/m2 by cycle 2 (if tolerated) for 4-6 cycles (for a total of 18 weeks). Docetaxel will be give as an injection.~* trastuzumab and pertuzumab (loading dose of 1200 mg of pertuzumab and 600 mg trastuzumab) for 52 weeks followed by 600 mg pertuzumab and 600 mg trastuzumab every 3 weeks for 15 cycles (for a total of 52 weeks). These two drugs will be given as subcutaneous injections under the skin."
61929530|NCT06348134|EXPERIMENTAL|Phase 2 - Operable (participants who are able to have surgery)|"Participants in this group will have breast cancer that shows a complete or incomplete response (as assessed by ultrasound) to the study drug combination given in phase 1 of study. Based on how their breast cancer responds to the phase 1 study drugs, participants in this group will:~- undergo surgery and will continue to receive pertuzumab (600 mg) and trastuzumab (600 mg) for 36 weeks. Participants may also receive hormone therapy (as recommended by study doctor) based on status of breast cancer. This drug will be given as an injection under the skin.~Some participants in this group may also receive tamoxifen (as an oral tablet; 20 mg daily for 10 years after surgery), letrozole (as an oral tablet 2.5 mg daily for 10 years after surgery) and/or goserelin (hormone injection 10.8 mg every 1-3 months) based on their human epidermal growth factor receptor 2 (HER2) status as assessed by the treating doctor."
62131879|NCT02717117|EXPERIMENTAL|Feeding|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
62131880|NCT02044809|PLACEBO_COMPARATOR|Placebo|
62131881|NCT02044809|EXPERIMENTAL|Cannabidiol 200mg Oral|
62131882|NCT02044809|EXPERIMENTAL|Cannabidiol 400mg Oral|
62131883|NCT02044809|EXPERIMENTAL|Cannabidiol 800mg Oral|
62323623|NCT04733677||OSR M-1 N95|All subjects will be fitted with an OSR M1 N95 mask
62323624|NCT04975607|EXPERIMENTAL|Music Therapy Group|
62323625|NCT04975607|NO_INTERVENTION|Control Group|
62323626|NCT05858294|EXPERIMENTAL|Cognitive Behavioral Therapy program|"Access to the Alena CBT-based therapy programme for 4 weeks. Each of the four therapy modules gradually became available on a weekly basis until all four were available in the final intervention week. Participants were instructed to complete one module per week. Each therapy module consisted of psychoeducational content, guided psychological reflection and perspective-taking exercises, and, where appropriate, skills training exercises such as attention training, public speaking, and exposure experiments to be completed in real life."
62323627|NCT05858294|NO_INTERVENTION|Waitlist control|Waitlist control. Participants in this arm were given access to the CBT content at the end of the 4-week trial period.
62691421|NCT05274919||Patients scheduled for brain MRI with contrast injection|Inclusion at Erasmus MC and LUMC: The first cohort consists of 60 patients scheduled for brain MRI as part of their standard clinical diagnostic procedure and in whom contrast agent administration is part of their standard radiological assessment. These patients do not necessarily have a brain tumor as the purpose here is to develop and evaluate the vascular signature mapping sequence in general. Usually, such testing would be done in healthy volunteers, but contrast agent is required for the vascular signature mapping sequence. To avoid unnecessary contrast agent administration, the sequence will be tested in this patient cohort instead. In this study part, the outcome is the optimized protocol itself, with which the investigators could obtain additional information about the vascular structure throughout the brain. Therefore this group of subjects is expected to be sufficiently homogeneous for the research aim of this part of the study.
62691422|NCT05274919||Patients diagnosed with suspected glioma scheduled for brain MRI|Inclusion at Erasmus MC and LUMC: The second cohort consists of 20 glioma patients in whom the vascular signature mapping sequence is tested specifically for glioma and for a direct comparison between 3T and 7T, where the 3T scan is an extension of the diagnostic care and the additional 7T scan is optional. This number of patients is sufficient to provide information on differences in the ability to measure tumor vascularity between 3T and 7T, while minimizing the extra patient burden.
62482810|NCT02028715|PLACEBO_COMPARATOR|Experimental (Normal Saline)|Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
62738336|NCT05425498|EXPERIMENTAL|Physical Activity Program Group|In the physical activity group, In the physical activity group, a 12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model. Assessments will perform just before starting to study, at the end of 12 weeks (just after the physical activity program), and the end of 24 weeks.
61929531|NCT06348134|EXPERIMENTAL|Phase 2 - Inoperable (participants who are not able to have surgery)|Participants in this group will have breast cancer that shows a partial response (as assessed by ultrasound) to the study drugs given in phase 1 or their breast cancer stayed the same or got worse after receiving study drugs during phase 1. Based on how their breast cancer responds to the phase 1 study drug regimen, participants in this group will receive trastuzumab emtansine (intravenously) plus standard chemotherapy as recommended by their doctor.
61929532|NCT05184478|EXPERIMENTAL|Group A (MC then placebo)|Group A will receive medicinal cannabis during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive placebo during Treatment Period 2 (70 days).
61929533|NCT05184478|EXPERIMENTAL|Group B (placebo then MC)|Group B will receive placebo during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive medicinal cannabis during Treatment Period 2 (70 days).
61929534|NCT00666796|PLACEBO_COMPARATOR|A|
61929535|NCT00666796|EXPERIMENTAL|B|
61929536|NCT00666796|EXPERIMENTAL|C|
61929537|NCT00666796|EXPERIMENTAL|D|
61929538|NCT03052907|OTHER|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
61929539|NCT06370273|ACTIVE_COMPARATOR|TiLLI-High Intervention|"A non-inferiority trial in people with temporary lower limb immobilisation at high risk of VTE comparing Direct Oral AntiCoagulants (DOACs) (intervention) to parenteral prophylaxis (routine care). Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidance.~Intervention medications:~Rivaroxaban 10mg once daily via oral ingestion. OR Apixaban 2.5mg twice daily via oral ingestion."
61929540|NCT06370273|ACTIVE_COMPARATOR|TiLLI-High Routine Care|"A non-inferiority trial in people with temporary lower limb immobilisation at high risk of VTE comparing Direct Oral AntiCoagulants (DOACs) (intervention) to parenteral prophylaxis (routine care). Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidance.~Routine Care:~Enoxaparin 40mg once daily via subcutaneous injection OR Tinzaparin 4500 IU once daily via subcutaneous injection OR Dalteparin 5000 IU once daily via subcutaneous injection OR Fondaparinux 2.5mg once daily via subcutaneous injection"
61929541|NCT06370273|ACTIVE_COMPARATOR|TiLLI-Low Intervention 1 (DOAC)|"A superiority trial in people with temporary lower limb immobilisation at low risk of VTE comparing parenteral prophylaxis (intervention) or Direct Oral AntiCoagulants (DOACs) (intervention) to no pharmacological prophylaxis (routine care). Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidance.~Intervention medication:~DOACs:~Rivaroxaban 10mg once daily via oral ingestion. OR Apixaban 2.5mg twice daily via oral ingestion."
61929542|NCT06370273|ACTIVE_COMPARATOR|TiLLI-Low Intervention 2 (Parenteral prophylaxis)|"A superiority trial in people with temporary lower limb immobilisation at low risk of VTE comparing parenteral prophylaxis (intervention) or Direct Oral AntiCoagulants (DOACs) (intervention) to no pharmacological prophylaxis (routine care). Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidance.~Parenteral prophylaxis:~Enoxaparin 40mg once daily via subcutaneous injection OR Tinzaparin 4500 IU once daily via subcutaneous injection OR Dalteparin 5000 IU once daily via subcutaneous injection OR Fondaparinux 2.5mg once daily via subcutaneous injection"
61929543|NCT06370273|NO_INTERVENTION|TiLLI-Low Routine Care|"A superiority trial in people with temporary lower limb immobilisation at low risk of VTE comparing parenteral prophylaxis (intervention) or Direct Oral AntiCoagulants (DOACs) (intervention) to no pharmacological prophylaxis (routine care). Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidance.~Routine care: No pharmacological prophylaxis"
62482811|NCT02028715|ACTIVE_COMPARATOR|Experimental (IV Acetaminophen)|Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
62482812|NCT05334875|ACTIVE_COMPARATOR|Electroretinogram test (ERG)|ERG test will be done for each subject twice and compare the results to assess repeatability of the test.
62482813|NCT05334875|ACTIVE_COMPARATOR|Visual evoked potential test (VEP)|VEP test will be done for each subject twice and compare the results to assess repeatability of the test.
62482814|NCT05072535|EXPERIMENTAL|Part 1-Group A|Subjects will receive 200 mg HA121-28 tablet A on Day 1 of the first cycle, followed by tablet B on Day 36 of the second cycle, in the fasted state.
62482815|NCT05072535|EXPERIMENTAL|Part 1-Group B|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle, followed by tablet A on Day 36 of the second cycle, in the fasted state.
62482816|NCT05072535|EXPERIMENTAL|Part 2-Group C|Subjects will receive 200 mg HA121-28 tablet B on Day1 of the first cycle in fasted state, followed by tablet B on Day 36 of the second cycle in the fed state.
62482817|NCT05072535|EXPERIMENTAL|Part 2-Group D|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle in the fed state, followed by tablet B on Day 36 of the second cycle in fasted state.
62482818|NCT06259630|EXPERIMENTAL|Placebo followed by Nicotine Arm|Participant receives placebo on day 1 and nicotine on day 2.
62482819|NCT06259630|EXPERIMENTAL|Nicotine followed by Placebo Arm|Participant receives nicotine on day 1 and placebo on day 2.
62482820|NCT06259630|PLACEBO_COMPARATOR|Placebo followed by Placebo Arm|Participant receives placebo on day 1 and day 2.
62482821|NCT05464563|EXPERIMENTAL|Patient group|"Patients have electroencephalogram records during :~* a phase of rest;~* a task of self-compassion~* a task of empathy."
62482822|NCT05464563|EXPERIMENTAL|Control group|"Healthy volunteers have electroencephalogram records during :~* a phase of rest;~* a task of self-compassion~* a task of empathy."
62482823|NCT06512909|NO_INTERVENTION|Control Group|"Voluntary Information and Consent Form, Patient Information Form and Visual Analogue Anxiety Scale will be filled out.~Standard injection practice will be applied. Visual Comparison Scale (VAS-VAS), Satisfaction Assessment Scale (MDS) and Visual Analog Anxiety Scale (VAS-A) will be filled out within one minute after the procedure."
62482824|NCT06512909|EXPERIMENTAL|Virtual Reality Glasses|"Voluntary Information and Consent Form, Patient Information Form and Visual Analogue Anxiety Scale will be filled out.~The individual will be shown a video containing relaxing nature images via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video. Visual Comparison Scale (VAS-VAS), Satisfaction Assessment Scale (MDS) and Visual Analog Anxiety Scale (VAS-A) will be completed within one minute after the procedure."
62482825|NCT06512909|EXPERIMENTAL|Stress ball|"Voluntary Information and Consent Form, Patient Information Form and Visual Analogue Anxiety Scale will be filled out.~The individual will be given a stress ball on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, the intramuscular injection will begin and the procedure will be performed while squeezing the ball. Visual Comparison Scale (VAS-VAS), Satisfaction Assessment Scale (MDS) and Visual Analog Anxiety Scale (VAS-A) will be filled out within one minute after the procedure."
61929544|NCT00704808||Patients|Patients with newly diagnosed and operated glioblastoma multiforme.
62697500|NCT03096431|ACTIVE_COMPARATOR|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
61929545|NCT01741012|EXPERIMENTAL|Gardasil|0.5 ml single dose Gardasil vaccine given at three separate visits
62482826|NCT03031821|EXPERIMENTAL|Metformin|Metformin 850 mg PO OD X 30 days, then 850mg PO BID for a total of 18 months
62482827|NCT03031821|PLACEBO_COMPARATOR|Placebo|"Placebo Oral Tablet~1 tablet (850mg) PO OD X 30 days, then 850mg PO BID for a total of 18 months"
62482828|NCT02839252|EXPERIMENTAL|Intervention Group|After the baseline tools have been completed, the child will be given the Iggy Comic Book and trading cards. Parents and their children will then watch a 12-minute Iggy Video. At the completion of the video and prior to going home, the child and parent will complete the same 2 measures on asthma knowledge and self-efficacy. At 1-month after this clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
62482829|NCT02839252|NO_INTERVENTION|Control Group|After the baseline tools have been completed, the parent and child will go home. At 1-month after the initial study clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
61929546|NCT03771053|EXPERIMENTAL|Ezetimibe with simvastatin group|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
61929547|NCT03771053|ACTIVE_COMPARATOR|Simvastatin group|simvastatin 40mg everyday for 12 months after PCI
61929548|NCT02343133|EXPERIMENTAL|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
61929549|NCT02343133|PLACEBO_COMPARATOR|Placebo|Single subcutaneous dose
61929550|NCT06507553|ACTIVE_COMPARATOR|Group 1 (Stage 1)|Trivalent-Darwin standard dose (SD) formulation will be administered in a single injection to participants aged 18 to 49 years old
61929551|NCT06507553|EXPERIMENTAL|Group 2 (Stage 1)|Augment-Tasmania SD formulation will be administered in a single injection to participants aged 18 to 49 years old
61929552|NCT06507553|EXPERIMENTAL|Group 3 (Stage 1)|TIV-2X Darwin SD formulation will be administered in a single injection to participants aged 18 to 49 years old
61929553|NCT06507553|EXPERIMENTAL|Group 4 (Stage 1)|Trivalent-Tasmania SD formulation will be administered in a single injection to participants aged 18 to 49 years old
61929554|NCT06507553|ACTIVE_COMPARATOR|Group 5 (Stage 2)|Trivalent-Darwin high dose (HD) formulation will be administered in a single injection to participants of 60 years and older
61929555|NCT06507553|EXPERIMENTAL|Group 6 (Stage 2)|Augment-Tasmania HD formulation will be administered in a single injection to participants of 60 years and older
62482830|NCT01153503|ACTIVE_COMPARATOR|Ketorolac 30 mg, IV + TAP block|"Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
62482831|NCT01153503|ACTIVE_COMPARATOR|TAP block|"Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery~First 24-h Postoperative: IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
62482832|NCT01153503|NO_INTERVENTION|Ketorolac 30 mg|"Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
62482833|NCT02464254|EXPERIMENTAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
62482834|NCT02464254|ACTIVE_COMPARATOR|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
62482835|NCT03880461|EXPERIMENTAL|Lifestyle Intervention|The goal of the intervention is to help women achieve GWG within the range recommended by the Institute of Medicine. The lifestyle intervention will be delivered through 1 telephone counseling session with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and weekly e-mails of core lifestyle intervention sessions. Personalized text messages and 1:1 telephone coaching sessions will be given to those who are not meeting the GWG guidelines.
62482836|NCT03880461|NO_INTERVENTION|Usual Care - Control|Usual Medical Care
62482837|NCT03260153|EXPERIMENTAL|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
62482838|NCT03260153|PLACEBO_COMPARATOR|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
61929556|NCT06507553|EXPERIMENTAL|Group 7 (Stage 2)|TIV-2X Darwin HD formulation will be administered in a single injection to participants of 60 years and older
61929557|NCT06507553|EXPERIMENTAL|Group 8 (Stage 2)|Trivalent-Tasmania HD formulation will be administered in a single injection to participants of 60 years and older
62482839|NCT05356481|EXPERIMENTAL|Experimental Group A|will recieve (low frequency segmental muscle vibration of 41 Hz over flexors muscles of upper limb Pectoralis minor, Biceps brachii, Flexor carpi muscle + general physical therapy session ) The transducer applied perpendicular to the muscle near its distal tendon insertion.The application consisted of 3 vibration sessions each with duration of 5 minutes for each muscle with 1 minute interval separated these sessions during the interval muscle vibration will interrupted and the subject will request to relax the muscle
62482840|NCT05356481|EXPERIMENTAL|Experimental Group B|group receive (low frequency segmental muscle vibration of 41 Hz over extensors muscles of upper limb Triceps brachii, Extensor carpi radialis longus \& brevis + general physical therapy session ) The transducer applied perpendicular to the muscle near its distal tendon insertion The application consisted of 3 vibration sessions each with duration of 5 minutes for each muscle with 1 minute interval separated these sessions during the interval muscle vibration will interrupted and the subject will request to relax the muscle
62482841|NCT06398262||Study population|This study will be conducted in surgical patients in the peri-operative unit of Karolinska University Hospital (Huddinge site), Stockholm, Sweden and will focus on patients after upper abdominal surgery. In order to ensure a balanced distribution of men and women, at a minimum 40% of the total subject population will be male and 40% will be female.
62482842|NCT02584907|EXPERIMENTAL|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
62482843|NCT02584907|NO_INTERVENTION|Standered Enteral Nutrition|Diet in standard group will be 20% from protein, 30% from fat and 50% from carbohydrate
61929558|NCT01064427||Chemotherapy group|Breast cancer patients treated by adjuvant chemotherapy after their surgery. The time points of data collection are before the start of the first, second, fourth and sixth cycle of chemotherapy. If patients are treated by radiotherapy after the chemotherapy, there are 2 measurements points pre- and post radiotherapy.The others measurement points are at 12,18 and 24 months after surgery.
61929559|NCT01064427||No chemotherapy group|Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
62323628|NCT02695485|OTHER|sensate flap|the donor nerve harvested with the flap
62323629|NCT03555279|EXPERIMENTAL|Probation Staff (PS) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm intervention is delivered by Probation Staff working at the intervention site. Dosage is 8 2-hour sessions delivered over two weeks.
62738337|NCT05425498|NO_INTERVENTION|Control group|In the control group, information about physical activity will be given without applying the physical activity program. Control group's assessments will be performed when they are included in the study, at the end of 12 weeks and 24 weeks.
62738338|NCT05546658|EXPERIMENTAL|Immediate Psilocybin|This arm will receive two sessions of psilocybin first (20mg in first session and then, if well tolerated, 30mg).
61929560|NCT05881460|ACTIVE_COMPARATOR|Active vibrotactile coordinated reset|Participants will receive active Vibrotactile Coordinated Reset stimulation.
61929561|NCT05881460|SHAM_COMPARATOR|Sham vibrotactile coordinated reset|Participants will receive inactive Vibrotactile Coordinated Reset stimulation.
61929562|NCT06334276||Fatal drowning|This group of patients have died before 30 days after the drowning incident.
61929563|NCT06334276||Non-fatal drowning|This group of patients have survived until 30 days after the drowning incident.
61929564|NCT03098628|ACTIVE_COMPARATOR|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
61929565|NCT03098628|ACTIVE_COMPARATOR|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
61929566|NCT03098628|ACTIVE_COMPARATOR|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
61929567|NCT03098628|ACTIVE_COMPARATOR|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
61929568|NCT03098628|OTHER|Z - Control|Control group. PCV vaccine given at end of study (24 months)
61929569|NCT02208375|EXPERIMENTAL|Arm I (olaparib, vistusertib)|CONTINUOUS AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 5-28 of course 1 and alone on days -3 to -1 of week -1) and vistusertib PO BID on days 1-28 (alone on days 1-4 of week 1).
61929570|NCT02208375|EXPERIMENTAL|Arm II (olaparib, vistusertib)|INTERMITTENT AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 3-28 on course 1 and alone on days -5 to -3 of week -1) and vistusertib 4 PO BID for 2 days on and 5 days off (alone on days 1-2 of week 1).
61929571|NCT02208375|EXPERIMENTAL|Arm III (olaparib, capivasertib)|INTERMITTENT AZD5363 DOSING: Patients receive olaparib PO BID on days 1-28 (on days 5-28 of course 1 and alone on days -3 to -1 of week -1) and capivasertib PO BID for 4 days on and 3 days off (alone on days 1-4 of week 1).
61929572|NCT06080425|OTHER|Medical Nutrition Therapy|Medical Nutrition therapy is an intervention that will be administered to the participants for 6 months.
61929573|NCT02978560||control|The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
61929574|NCT02978560||Wound Group|The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care.
62323630|NCT03555279|EXPERIMENTAL|Youth Representative (YR) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm intervention is delivered by young adults who were formally in the juvenile justice system. Dosage is 8 2-hour sessions delivered over two weeks.
62482844|NCT03685305|EXPERIMENTAL|Hypocaloric diet with hunger reduction strategy|Participants will be prescribed a hypocaloric diet with additional instructions to promote hunger reduction. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
62738339|NCT05546658|ACTIVE_COMPARATOR|Delayed Psilocybin|Waitlist control. This arm will receive psilocybin after the waiting period is over (20mg in first session and then, if well tolerated, 30mg).
62738340|NCT06166342|PLACEBO_COMPARATOR|Placebo sachet|consume 1 sachet per day
61929575|NCT04957355|EXPERIMENTAL|Effect of functional electrical stimulation on reactive balance and laboratory falls|"All individuals will be assigned to the experimental group and will undergo the testing and training procedure across two separate sessions. During the first session, the participants will go through the complete initial screening process. If eligible for the study, the participants will perform the experimental training protocols during the second session.~Experimental Protocol The quadriceps, hamstrings, tibialis anterior, gastrocnemius, and the trunk muscle group on the stroke-affected side (weaker side) will be stimulated according to the participant's comfort and tolerance. The range of the intensity allowed by the device is 0-50milliamperes (mA). The frequency of the electrical stimulation device ranges from 1-60Hz."
61929576|NCT00832390|EXPERIMENTAL|1|sitagliptin
61929577|NCT04471597|PLACEBO_COMPARATOR|Control group|patients will receive 5ml of normal saline 0.9% topically 15 min before the expected end of surgery.
62323631|NCT06692491|NO_INTERVENTION|Standard treatment Group|Patients with rare tumours in this group will undergo standard treatment in accordance with the leading domestic and international guidelines (NCCN/ESMO/CSCO/CACA) and clinical trial.
62323632|NCT06692491|EXPERIMENTAL|Criteria-Fulfilled ICF Group|Intervention in this group is to perform PDOs culture and drug screening of lesions from patients with rare tumours who failed to standard treatment and fully meet the inclusion and exclusion criteria. The MTB will review the results of the drug screening and NGS, and subsequently determine the personalised chemotherapy, targeted or immunological agents.
62323633|NCT06692491|EXPERIMENTAL|Compassionate-Use ICF Group|Patients with rare tumours who failed to standard treatment and do not meet the requisite criteria (e.g. active hepatitis B, underlying disease in the exclusion criteria, symptomatic brain metastases) will provide informed consent and undergo PDOs culture and drug screening. The MTB will review the results of the drug screening and NGS, and subsequently determine the personalised chemotherapy, targeted or immunological agents.
62323634|NCT06692491|EXPERIMENTAL|RWS ICF Group|Patients with rare tumours who failed to standard treatment will be included in a real-world study cohort and receive clinically conventional treatment if they do not undergo PDOs culture and NGS testing successfully or are unwilling to base their treatment on the results of PDOs and NGS for various reasons.
62323635|NCT04542798|EXPERIMENTAL|NPPG (neuropatic pain group) PRF|Pulsed radiofrequency neuromodulation of dorsal root ganglia
62323636|NCT04542798|ACTIVE_COMPARATOR|NPPG (neuropatic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
62323637|NCT04542798|EXPERIMENTAL|NMPG (nociceptive/mechanic pain group) WCRF|Water cooled radiofrequency of the medial branch of the dorsal nerve
62323638|NCT04542798|ACTIVE_COMPARATOR|NMPG (nociceptive/mechanic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
61929578|NCT04471597|ACTIVE_COMPARATOR|bupivacaine group|patients will receive 5ml of bupivacaine 0.5% topically 15 min before the expected end of surgery.
61929579|NCT05199727|EXPERIMENTAL|Shockwave group|This group will receive 6 sessions (2 per week) with average 6,000 shocks per session with the PiezoWave2 unit
61929580|NCT05199727|ACTIVE_COMPARATOR|Medical Treatment Group|This group will receive self-administered Tadalafil on-demand
62738341|NCT06166342|EXPERIMENTAL|TCI153 sachet|consume 1 sachet per day
62482845|NCT03685305|ACTIVE_COMPARATOR|Hypocaloric diet without hunger reduction strategy|Participants will only be prescribed a hypocaloric diet. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
62323639|NCT00909987|EXPERIMENTAL|Single arm|"Neoadyuvant chemotherapy with XELOX: Xeloda 1000mg/m2/12h dayly, day one in the afternoon until day 15 in the morning; plus oxaliplatin 130mg/m2 (day 1); and Bevacizumab 7.5 mg/kg (day 1)during 3 cycles (each cycle of 3 weeks).~Followed by a selective use of chemoradiotherapy with radiotherapy (50.4Gy, 28 sesions of 1.8Gy during 5 weeks) plus Xeloda 825mg/m2/12h dayly."
62482846|NCT01473173|EXPERIMENTAL|CJ-12420 50mg|"* Single dose~* 8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)"
62482847|NCT01473173|EXPERIMENTAL|CJ-12420 100mg|"* Single dose~* 8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)"
62482848|NCT01473173|EXPERIMENTAL|CJ-12420 200mg|"* Single dose~* 8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)"
62482849|NCT01473173|EXPERIMENTAL|CJ-12420 400mg|"* Single dose~* 8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)"
62482850|NCT01473173|EXPERIMENTAL|CJ-12420 100mg (repeated dose)|"Repeat doses~* 100mg is the anticipated dose~* 8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)"
62482851|NCT01473173|EXPERIMENTAL|CJ-12420 200mg (repeated dose)|"Repeat doses~* 200mg is the anticipated dose~* 8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)"
62482852|NCT01473173|ACTIVE_COMPARATOR|Esomeprazole 40mg|8 volunteers will be administered Esomeprazole 40mg
62482853|NCT02699463|ACTIVE_COMPARATOR|Continous Positive Airway Pressure|Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
62482854|NCT02699463|PLACEBO_COMPARATOR|Control Group|Participants will receive standard care (Sleep hygiene counseling) during the study.
62482855|NCT00841659|EXPERIMENTAL|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
62482856|NCT00841659|ACTIVE_COMPARATOR|Paxil®|Paxil® 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
62482857|NCT03581097|EXPERIMENTAL|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
62482858|NCT03581097|NO_INTERVENTION|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
62482859|NCT04754984|EXPERIMENTAL|Intervention|One-time in-person workshop with pelvic floor physiotherapist
62482860|NCT04754984|NO_INTERVENTION|Control|Standard care
62323640|NCT01971476|EXPERIMENTAL|All patients|Volasertib will be administered as intravenous infusion
62323641|NCT06625723|ACTIVE_COMPARATOR|Control Group|Standard postoperative care for patients undergoing rotator cuff repair.
62323642|NCT06625723|EXPERIMENTAL|Sleep Aid Group|Standard postoperative care for patients undergoing rotator cuff repair PLUS the use of the sleep assistive device postoperatively.
62323643|NCT06246058||Survey Group 1 - Support|Receives a vignette with partner support component before answering AA-Med response items.
62323644|NCT06246058||Survey Group 2 - Control|Receives a vignette without partner support component before answering AA-Med response items.
62323645|NCT06246058||Recruitment Group 1 - Casual|Recruited by staff wearing casual attire.
62323646|NCT06246058||Recruitment Group 2 - Formal|Recruited by staff wearing formal (clinical) attire
62482861|NCT03874052|EXPERIMENTAL|Treatment (ruxolitinib, venetoclax)|Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
62482862|NCT03501511|ACTIVE_COMPARATOR|IDF modules|Diabetes educations using IDF Arabic translated modules
62482863|NCT03501511|EXPERIMENTAL|Conversational Maps|Diabetes Educations using Ramadan fasting conversational maps (Arabic maps)
62697501|NCT03096431|ACTIVE_COMPARATOR|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
62323647|NCT02512263|EXPERIMENTAL|Intervention group|They will have to do all the tests and to follow the home-based training program during 9 weeks.
62323648|NCT02512263|NO_INTERVENTION|control group|They will have to do all the tests but not to follow the home-based training program.
62482864|NCT03442322|ACTIVE_COMPARATOR|transdisciplinary approach|The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
62482865|NCT03442322|ACTIVE_COMPARATOR|multidisciplinary approach|The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
62323649|NCT06693622||Patients|556 eligible patients will be recruited across 5 participating sites to complete a discrete choice-based conjoint survey. The survey will be distributed to eligible patients via Sawtooth internet survey at the time of a clinic appointment or remotely via video chat.
62323650|NCT01180140|NO_INTERVENTION|1|without seamguard
62323651|NCT01180140|EXPERIMENTAL|2|with seamguard
62482866|NCT04613167|EXPERIMENTAL|Alirocumab|The first group of patients will receive 150 mg of alirocumab every two weeks subcutaneously for 6 months
62482867|NCT04613167|EXPERIMENTAL|Evolocumab|the second group of patients will receive evolocumab 140 mg every two weeks subcutaneously for 6 months
62482868|NCT04613167|EXPERIMENTAL|Control group|Control group will be included in the treatment after 6 months. During this time, the control group will not receive treatment with alirocumab or evolocumab, only standard guidelines-based treatment
62482869|NCT02937259|EXPERIMENTAL|Self-admission|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
62482870|NCT05257564|OTHER|Diagnostic|Fingerstick collection and venous whole blood collection.
62482871|NCT05245006|EXPERIMENTAL|Cohort A: 89Zr-DFO-YS5|Participants receive one dose of 89Zr-DFO-YS5 up to 3 millicurie (mCi), and undergo a whole body PET performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total. The optimized scan time will be used for imaging in cohorts B and C. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
62323652|NCT02830841|EXPERIMENTAL|DR-RIPC (donor and recipient RIPC group)|Both donors and recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm(donor) or right lower limb(recipient) and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
62482872|NCT05245006|EXPERIMENTAL|Cohort B: 89Zr-DFO-YS5, YS5 antibody|Participants receive either a 20mg or 50mg dose of YS5 prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. The optimal dose of unmodified YS5 antibody will be used in the following cohorts C \& D. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
62482873|NCT05245006|EXPERIMENTAL|Cohort C: 89Zr-DFO-YS5, Optimal dose YS5 antibody|Participants receive optimal dose of YS5 antibody prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
62482874|NCT05245006|EXPERIMENTAL|Cohort D: 89Zr-DFO-YS5, Optimal dose YS5 antibody, Multiple Scans|Participants will receive optimal dose of YS5 prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a series of whole body PET scans performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total. Participants in have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
62482875|NCT02645253|EXPERIMENTAL|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
62482876|NCT02645253|EXPERIMENTAL|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
62482877|NCT02645253|EXPERIMENTAL|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
62691423|NCT05274919||Patients with (suspected) glioma|"Inclusion at Erasmus MC and LUMC: The third cohort consists of 100 adult patients referred for biopsy or surgery of suspected glioma. The diagnosis of glioma is based on a multitude of factors, such as initial presentation (headaches, vomiting, potential changes in character). Based on the initial presentation a patient may be suspected of having a glioma, which is often confirmed using imaging. Although a true conclusion requires analysis of tissue, in an overwhelming majority of the cases (99%), analysis of the imaging is sufficient to confirm the presence of glioma. Thus, the investigators can be relatively certain about the inclusion of glioma patients based on the initial presentation and imaging alone.~Since there is a close collaboration with the Neurology departments of both the LUMC and Haaglanden Medical Center (HMC) in The Hague, the investigators broaden their inclusion capacity also to this hospital."
61929581|NCT00777205|ACTIVE_COMPARATOR|Enhanced Usual Care|Patients in the enhanced usual care arm received their usual mental health care, a copy of the Depression Helpbook, and bi-weekly study mailings with depression management tips.
61929582|NCT00777205|EXPERIMENTAL|Telephone-based peer support|Participants in the intervention arm received usual mental health care and biweekly study mailings. In addition, they had access to a telephone platform over which they could make free calls to their peer partner for mutual peer support over a 6-month period of time.
61929583|NCT03186898|EXPERIMENTAL|Proton Therapy (Radiation Therapy)|Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.
61929584|NCT03186898|EXPERIMENTAL|Photon Therapy (Radiation Therapy)|Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.
61929585|NCT01309308|EXPERIMENTAL|The membranes swept group|This group will have a sweeping of the membranes after the 38th of gestation at hospital, in order to reduce the latency period until labor. Sweeping of the membranes is done by the insertion of examiners finger between the decidua and fetal membranes and by the circular movement of the finger, the membranes are detached from the decidua.
62323653|NCT02830841|SHAM_COMPARATOR|S-RIPC (sham RIPC)|Patients had a deflated cuff placed on the right upper arm or right lower limb for 30 min
62323654|NCT02830841|EXPERIMENTAL|R-RIPC (recipient RIPC group)|Recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right lower limb and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
62482878|NCT02645253|EXPERIMENTAL|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
62691424|NCT03002857|EXPERIMENTAL|Classical LMA|Classical LMA insertion: LMA-C insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
61929586|NCT01309308|SHAM_COMPARATOR|No sweeping group|This group will not have sweeping of the membranes, will only have vaginal ultrasound
61929587|NCT04466228|EXPERIMENTAL|Stim1 high dose|This group will receive high dose non-invasive transcranial electrical stimulation
61929588|NCT04466228|EXPERIMENTAL|Stim2 low dose|This group will receive low dose non-invasive transcranial electrical stimulation
61929589|NCT04466228|SHAM_COMPARATOR|Sham control|This group will receive sham control non-invasive transcranial electrical stimulation
62131884|NCT02133820|ACTIVE_COMPARATOR|12 hourly capsule fasted|4 mg 12 hourly capsule - strong pain killer fasted
62323655|NCT02830841|EXPERIMENTAL|D-RIPC (donor RIPC group)|Donors receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
62482879|NCT05398094|EXPERIMENTAL|Experimental: Induction treatment + Post-Induction Phase|"Patients enrolled in the study will receive AMG510 (Sotorasib) 960mg once daily for 2 cycles (Q4W) in the induction phase and AMG510 (Sotorasib) 960 mg once daily (Q4W) in the treatment postinduction phase.~Treatment post-induction phase only for patients with SD, PR or CR after induction treatment. This treatment will be administered until progression disease (PD), unacceptable toxicity, patient or physician's decision to discontinue or death."
61929590|NCT00825851|ACTIVE_COMPARATOR|continuous smoking|subjects smoke 20 cigarettes per day
61929591|NCT00825851|ACTIVE_COMPARATOR|smoking cessation and NRT|subjects quit smoking and use transdermal nicotine patch
61929592|NCT00825851|PLACEBO_COMPARATOR|smoking cessation and placebo patch|subjects quit smoking and use placebo patch
62323656|NCT05397613|EXPERIMENTAL|STAIR|Participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR). Participants will complete self-report measures pre, post, and at one month intervals.
62323657|NCT05397613|EXPERIMENTAL|Waitlist control|First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures. Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR). Participants will complete self-report measures pre, post, and at one month intervals.
62323658|NCT04098952|ACTIVE_COMPARATOR|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
62323659|NCT04098952|EXPERIMENTAL|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
62323660|NCT01629485|EXPERIMENTAL|Whole Task|Trainees will undergo whole task mastery training in the TEP simulator after completing the video curriculum portion.
62323661|NCT01629485|EXPERIMENTAL|Part Task|Trainees will undergo a random part task mastery training in the TEP simulator after completing the video portion of the curriculum.
61929593|NCT00825851|NO_INTERVENTION|never smokers|subjects being never smokers and who refrain from smoking
61929594|NCT00515047||Eczema Herpeticum (EH)|Participants with AD who currently have or have had EH
62323662|NCT06512415|ACTIVE_COMPARATOR|10 mcg group|patient will receive the study dry once developed severe post-spinal hypotension
62323663|NCT06512415|ACTIVE_COMPARATOR|15 mcg group|patients will receive the study dry once developed severe post-spinal hypotension
62323664|NCT06693700|EXPERIMENTAL|MSK Participants who are current smokers|10 MSK participants who are current smokers and receiving tobacco treatment will be enrolled.
62323665|NCT01073956|PLACEBO_COMPARATOR|Inactive electrotherapy|Inactive electrotherapy is applied to the painful points
62323666|NCT01073956|ACTIVE_COMPARATOR|Ultrasound|Ultrasound electrotherapy is applied to the painful points
62482880|NCT04349553|EXPERIMENTAL|ZH9PA 1x10^9 CFU|1mL ZH9PA 1x10\^9 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
61929595|NCT00515047||Non-EH|Participants with AD who do not have and have never had EH
61929596|NCT00515047||Healthy Controls|Healthy participants without a history of AD
61929597|NCT03728985|ACTIVE_COMPARATOR|Primary Study Arm|TAAA requiring only TAMBE System. Crawford Type IV TAAA and Pararenal (n= 102)
62131885|NCT02133820|ACTIVE_COMPARATOR|12 hourly capsule fed|4 mg 12 hourly capsule - strong pain killer fed
61929598|NCT03728985|EXPERIMENTAL|Secondary Study Arm|TAAA requiring TAMBE System and CTAG Device(s). Crawford Type I-III (n= 20 - 100)
61929599|NCT06708182|EXPERIMENTAL|Experimental: Positive emotion skills intervention|Participants will go through a 6-week positive emotion skills course where 1 new skill lesson opens each week.
61929600|NCT06343389||group A|Cirrhotic patients with Acute kidney injury
61929601|NCT06343389||group B|Cirrhotic patients without Acute kidney injury
62131886|NCT02133820|EXPERIMENTAL|12 hourly capsule with antagonist fasted|4 mg 12 hourly capsule strong painkiller with antagonist fasted
62131887|NCT02133820|EXPERIMENTAL|12 hourly capsule with antagonist fed|4 mg 12 hourly capsule strong painkiller with antagonist fed
62131888|NCT06142357||Secukinumab|Pediatric patients with moderate-to-severe plaque psoriasis receiving secukinumab.
62131889|NCT06243094||microbiologically confirmed VAP|patients who meet ATS/IDSA 2005 VAP criteria with microbiological confirmation
62131890|NCT06243094||non microbiologically confirmed VAP|patients who do not meet ATS/IDSA 2005 criteria with microbiological confirmation
62131891|NCT01515436|ACTIVE_COMPARATOR|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
62323667|NCT01073956|ACTIVE_COMPARATOR|Monopolar radiofrequency|Monopolar radiofrequency electrotherapy is applied to the painful points
62323668|NCT05523362|EXPERIMENTAL|Blinded followed by Unblinded|"During Phase 1 (10 days), the patient wears the Dexcom G6 Pro CGM in blinded mode and is unaware and unable to access the data. The patient performs standard care, self-monitoring with twice daily glucose checks using standard finger-sticks and a glucometer device. During this phase, the medical providers are also blinded to the CGM data and continue standard care without any specific intervention.~During Phase 2 (3 months), the patient wears the Dexcom G6 Personal CGM in un-blinded mode and the medical providers have access to the data via Clarity and/or direct download via the transmitter. CGM data are collected continuously in each phase and at the end of each phase."
62323669|NCT02998008|OTHER|Diabetes type 2 patients|diabetes type 2 patients whose cardiac function is tested after 4x4 high intensity interval training
62482881|NCT04349553|EXPERIMENTAL|ZH9PA 1x10^10 CFU|1mL ZH9PA 1x10\^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
62738342|NCT00000401|EXPERIMENTAL|1|The low dose group will receive CII 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks.
62131892|NCT01515436|ACTIVE_COMPARATOR|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
62131893|NCT04140331||complicated post-operative evolution|Patients with a postoperative intensive care unity length of stay ≥ 5 days after elective cardiac surgery. They will have an accelerometer.
62131894|NCT04140331||simple post-operative evolution|Patients with a postoperative intensive care unity length of stay \< 5 days after elective cardiac surgery. They will have an accelerometer.
62323670|NCT02998008|OTHER|Healthy volunteers|healthy volunteers whose cardiac function is tested after 4x4 high intensity interval training
62323671|NCT01797107|EXPERIMENTAL|Treatment eye|Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
62323672|NCT01797107|PLACEBO_COMPARATOR|Durasite|Vehicle of Azasite used as placebo
62323673|NCT03283163|EXPERIMENTAL|Chronic Pain//PTSD group|This group of trauma-exposed participants with chronic musculoskeletal pain and varying degrees of PTSD severity will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise. Exercise training is aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
62323674|NCT00017316|EXPERIMENTAL|Arm I|Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
62323675|NCT04964024||Residents in Nursing homes|
62323676|NCT04964024||Health professionals in Nursing homes|
62323677|NCT02984826|ACTIVE_COMPARATOR|Strength training|Intervention with specific strength training program runs for 10 weeks.
62482882|NCT04349553|EXPERIMENTAL|ZH9PA 1x10^10 CFU plus ZH9 1x10^10 CFU|1mL ZH9PA 1x10\^10 CFU suspension in normal saline and 1mL ZH9 1x10\^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
62482883|NCT04349553|PLACEBO_COMPARATOR|Placebo|1mL (Cohorts 1 and 2) or 2mL (Cohort 3) normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
62482884|NCT06433739||appropriate catheter type selection|This group will include all peripheral venous catheterizations for which the appropriate catheter type selection according to the standardized algorithm has been performed
62691425|NCT03002857|EXPERIMENTAL|I-gel|I-gel LMA insertion: The I-gel LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
61929602|NCT06707402|EXPERIMENTAL|Combined individual home-based and supervised group-based walking exercise|"43 people with Parkinsons disease would be randomly assigned to this experimental group. The group will receive the intervention WALK, that covers a personalized exercise program and group exercise session. It further covers the same as in the HOME group."
61929603|NCT06707402|ACTIVE_COMPARATOR|Individual home-based exercise|43 people with Parkinsons disease would be randomly assigned to this active comparator group. The group receives the intervention (HOME) that covers an activity tracker and motivational telephone calls. It further covers the same as in the CON group.
61929604|NCT06707402|SHAM_COMPARATOR|Control group|43 people with Parkinsons disease would be randomly assigned to this sham comparator group. The group will only receive a short lecture in Parkinsons disease and exercise after completing the baseline test and allocated to the group.
61929605|NCT06621914|EXPERIMENTAL|BFR80|Low load blood flow restriction training with high-pressure cuff (80% AOP) in addition to standard residential rehabilitation consisting of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
62131895|NCT05814146|EXPERIMENTAL|Lower dialysate bicarbonate|A lower dialysate bicarbonate will be used in the experimental arm (30 mEq/L).
62131896|NCT05814146|ACTIVE_COMPARATOR|Higher dialysate bicarbonate|A higher dialysate bicarbonate will be used in the active comparator arm (35 mEq/L).
62131897|NCT04599088|EXPERIMENTAL|Brain functional MRI with simplified urodynamics|Females with urgency urinary incontinence
62323678|NCT02984826|ACTIVE_COMPARATOR|Ergonomic and posture|Intervention, the control group will be trained in ergonomics and posture.
62323679|NCT04635696|EXPERIMENTAL|Ethyl Chloride|Ethyl Chloride topical anesthetic mist will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
62323680|NCT04635696|PLACEBO_COMPARATOR|Tissue culture grade water|Tissue culture grade water (Nature's Tears Eyemist) will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
62323681|NCT01993329|EXPERIMENTAL|Gefapixant 50/ Gefapixant 300/ Placebo|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
62323682|NCT01993329|EXPERIMENTAL|Gefapixant 50/ Placebo/ Gefapixant 300|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
62323683|NCT01993329|EXPERIMENTAL|Gefapixant 300/ Gefapixant 50/ Placebo|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
62482885|NCT06433739||inappropriate catheter type selection|This group will include all peripheral venous catheterizations for which an inappropriate catheter type selection according to the standardized algorithm has been performed
62482886|NCT06066047|EXPERIMENTAL|TOUCH ATTENTIVE TREATMENT|15 minutes of osteopathic treatment with operator's touch attention
62482887|NCT06066047|SHAM_COMPARATOR|AUDITORY ATTENTIVE TREATMENT|15 minutes of osteopathic treatment with operator's auditory attention
61929606|NCT06621914|ACTIVE_COMPARATOR|BFR40|Low load blood flow restriction training with low-pressure cuff (40% AOP) in addition to standard residential rehabilitation consisting of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
61929607|NCT06687681|EXPERIMENTAL|Test group|patients will recieve 3 cources of 2\* 10 8 intrathecal infusion of NK cells every 3 weeks
61929608|NCT06687681|NO_INTERVENTION|Control group|patients will recieve only conventional treatment
61929609|NCT05049655||Cohort 1|Babies who were fed commercial formula, study formula, or were fed with human milk in the SS-101-18 study that consented to the BH-10118-02 study
61929610|NCT05049655||Cohort 2|Babies fed with commercial formula (including ByHeart formula) or fed with human milk
61929611|NCT05617209||Severe and/or moderate haemophilia A and B|At the end of the consultation and follow-up of the disease, an additional blood sample of 35 ml (8 tubes) will be taken
62323684|NCT01993329|EXPERIMENTAL|Gefapixant 300/ Placebo/ Gefapixant 50|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
62323685|NCT01993329|EXPERIMENTAL|Placebo/ Gefapixant 50/ Gefapixant 300|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
62323686|NCT01993329|EXPERIMENTAL|Placebo/ Gefapixant 300/ Gefapixant 50|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
62323687|NCT02329795||Standard chemoradiotherapy|Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
62482888|NCT06066047|NO_INTERVENTION|CONTROL|The volunteers lay for 15 minutes in the same environment as the volunteers in the other two groups, without being touched in any way.
62482889|NCT03393754|EXPERIMENTAL|Sci-B-Vac® Hepatitis B Vaccination|Sci-B-Vac® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.
62691426|NCT03002857|EXPERIMENTAL|The Baska Mask®|The Baska Mask® insertion: The Baska Mask® insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
62131898|NCT05706870|EXPERIMENTAL|GN-037 cream|"Psoriatic patients will receive GN-037 cream in 2:2:1 ratio~Psoriatic patients will receive GN-037 cream twice daily on a selected body target lesion~GN-037 cream will be applied as a thin film layer for 4 weeks."
62323688|NCT01458444|ACTIVE_COMPARATOR|BIPAP|Non invasive ventilation (VNI) by BIPAP® vision
62323689|NCT01458444|EXPERIMENTAL|OPTIFLOW|OPTIFLOW system
62691427|NCT05654181|EXPERIMENTAL|Cohort 1|Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
62323690|NCT06424067|EXPERIMENTAL|Efficacy in NSCLC|n=22 NSCLC Any adult patients with lung cancer progressed on 2L+ systemic therapy n=any eligible patients from safety lead-in
62323691|NCT06424067|EXPERIMENTAL|Efficacy in SCLC|n=16 SCLC Any adult patients with lung cancer progressed on 2L+ systemic therapy n=any eligible patients from safety lead-in
62323692|NCT01056887||Primary Polydip, D. insipidus|
62323693|NCT06692413||Withings device users|Active Withings device users having at least 2 years of device data
62323694|NCT02371759|EXPERIMENTAL|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
62323695|NCT02371759|EXPERIMENTAL|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
62482890|NCT03393754|ACTIVE_COMPARATOR|Engerix-B® Hepatitis B Vaccination|Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.
62482891|NCT03129841|EXPERIMENTAL|early dinner+Diet|
62482892|NCT03129841|EXPERIMENTAL|late dinner+Diet|
62691428|NCT05654181|EXPERIMENTAL|Cohort 2|Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
62691429|NCT05654181|EXPERIMENTAL|Cohort 3|Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
62738343|NCT00000401|EXPERIMENTAL|2|The high dose group will receive CII 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks.
61929612|NCT05725096|ACTIVE_COMPARATOR|CCTA-based strategy group|Subjects will be managed following the CCTA -based coronary heart disease prevention strategy for lipid-lowering treatment and follow-up.
61929613|NCT05725096|SHAM_COMPARATOR|Chinese guidelines for lipid management (2023)|The baseline assessment will be completed on the same day as consent is gained. Every subjects will complete a comprehensive assessment including questionnaires and objective assessments.
61929614|NCT04045301|EXPERIMENTAL|Omalizumab 16 mg/kg|"Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
62323696|NCT02371759|ACTIVE_COMPARATOR|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
62323697|NCT02371759|ACTIVE_COMPARATOR|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
62323698|NCT02371759|EXPERIMENTAL|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
62323699|NCT02371759|EXPERIMENTAL|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
62323700|NCT02371759|ACTIVE_COMPARATOR|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
62323701|NCT02371759|ACTIVE_COMPARATOR|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
62323702|NCT01328288||1|long-term follow-up of HIV-infected children
62323703|NCT06191354|EXPERIMENTAL|Dose-escalation|SKG0201 one-time deliver
62323704|NCT05523401|EXPERIMENTAL|10 mg 2C-B|2C-B (10 mg)
62323705|NCT05523401|EXPERIMENTAL|20 mg 2C-B|2C-B (20 mg)
62323706|NCT05523401|EXPERIMENTAL|30 mg 2C-B|2C-B (30 mg)
62323707|NCT05523401|ACTIVE_COMPARATOR|125 mg MDMA|MDMA (125 mg)
62691430|NCT02115971|EXPERIMENTAL|Jumping exercise|"Physical therapy with a focus on specific jumping exercise. The jumping exercise will be performed for 12 weeks (3x/week), with a break of day between workouts. The 40-minute workout is completed 2 times under supervision in the clinic's internal training group for outpatients. 1 time they train on their own at home, based on a defined training program. The training process is documented by the training protocol.~The incipient exercise intensity is taking personal performance into account. The exercise intensity is increased by a progressive scheme."
62323708|NCT05523401|ACTIVE_COMPARATOR|25 mg Psilocybin|Psilocybin (25 mg)
62323709|NCT05523401|PLACEBO_COMPARATOR|Placebo|Placebo
62323710|NCT06689566|EXPERIMENTAL|genistein group|
62323711|NCT01293396|ACTIVE_COMPARATOR|Biphasic Insulin Aspart 30|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
62323712|NCT01293396|ACTIVE_COMPARATOR|Biphasic Insulin Aspart 70|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
62323713|NCT01293396|ACTIVE_COMPARATOR|Insulin Aspart|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
62323714|NCT04581980|NO_INTERVENTION|Control|This arm will receive no exercise
62323715|NCT04581980|EXPERIMENTAL|Moderate Intensity Exercise|This group will exercise on a cycle ergometer (Lode Bike) at moderate intensity. Moderate intensity will be defined by the lactate threshold. A heart rate monitor will be utilized at all times to record heart rate.
62323716|NCT04581980|EXPERIMENTAL|High Intensity Exercise|This group will exercise on a cycle ergometer (Lode Bike) at high intensity. High intensity will be defined by an by 75% of the difference between the lactate threshold and peak.
62738344|NCT05360693|EXPERIMENTAL|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done 3-5mm into the bone apical to the socket according to the manufacturer's instructions. Patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface.
61929615|NCT04045301|EXPERIMENTAL|Omalizumab 8 mg/kg|"Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
61929616|NCT04045301|PLACEBO_COMPARATOR|Placebo|"Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
62323717|NCT01096082|PLACEBO_COMPARATOR|Placebo|
62323718|NCT01096082|EXPERIMENTAL|Lithium Carbonate|
62323719|NCT01127230||Liposuction patients|Patients who already opted and are scheduled for liposuction.
62323720|NCT06184269|ACTIVE_COMPARATOR|BR1017-1A+BR1017-1B|
62323721|NCT06184269|EXPERIMENTAL|BR1017-1|
62323722|NCT06334029||Epilepsy|Recording of resting state EEG and MRI
62323723|NCT06334029||Control group|EEG resting state data recording
62323724|NCT04527016|EXPERIMENTAL|Microbiota and eosinophils phenotype based therapy|The children will be treated with different protocol(Fluticasone propionate (FP),Azithromycin,or FP+Azithromycin) according to their Blood eosinophils level and airway microbiota pattern for 3 months and follow up for 1 year.
62323725|NCT04527016|ACTIVE_COMPARATOR|Clinical guidelines based therapy|The children will be treated as directed by their paediatrician, the clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016 (FP or montelukast for 3 months，or intermittent budesonide inhalation suspension during wheezing episode) and follow up for 1 year.
62323726|NCT02733692|EXPERIMENTAL|GURHL Code Smartphone application|Experimental arm will receive the 'Understanding Reproductive Health for Ladeez (GURHL) Code 'app' (application) for their smartphone with sexual health information. The intervention is embedded in the smart phone application. This includes sexual and reproductive health knowledge, plus access to a National Planned Parenthood health educator, and directions to other nearby clinics. Participants will be assessed using A-CASI at 3 months after enrollment.
62323727|NCT02733692|NO_INTERVENTION|Control|"The control arm will receive usual care. That is, they will receive a web-based flyer. This flyer will include a list of clinics and other trusted available resources, but without hyperlinks.~Participants will be assessed using A-CASI at 3 months after enrollment."
62323728|NCT05142657||Case|Patients who have gallstone pancreatitis
62323729|NCT05142657||Control|Patients who have only gallstone
61929617|NCT03828318|EXPERIMENTAL|Patient Activation Arm|
61929618|NCT03828318|NO_INTERVENTION|Standard Care Arm|
61929619|NCT05623345|EXPERIMENTAL|Group 1|Placebo from Day 1/Week 0 to Week 15, then izokibep from Week 16 to Week 51
61929620|NCT05623345|EXPERIMENTAL|Group 2|Izokibep Dose 1 from Day 1/Week 0 to Week 51
61929621|NCT05623345|EXPERIMENTAL|Group 3|Izokibep Dose 2 from Day 1/Week 0 to Week 51
61929622|NCT05623345|EXPERIMENTAL|Group 4|Izokibep Dose 3 from Day 1/Week 0 to Week 51
61929623|NCT06123650|PLACEBO_COMPARATOR|Control group (GA)|Group (A) will receive conventional Oropharyngeal physical therapy program for dysphagia including; Exercise therapy for the oropharyngeal and tongue muscles , neuromuscular electrical stimulation in addition to sham transcranial magnetic stimulation on the contralesional cerebral hemisphere.
61929624|NCT06123650|ACTIVE_COMPARATOR|Study group (GB)|Group (B) will received low frequency (1 Hz) repetitive transcranial magnetic stimulation to the contralesional cerebral hemisphere in addition to the same Oropharyngeal physical therapy program for dysphagia as in group A.
61929625|NCT06333340|ACTIVE_COMPARATOR|Oxytocin 5IU|IV oxytocin 5 IU diluted in 10 mL normal saline over 1 min followed by continuous infusion of 250 mIU/min over 4 hours.
61929626|NCT06333340|ACTIVE_COMPARATOR|Carbetocin 100mcg|IV carbetocin 100 mcg diluted in 10 mL normal saline over 1 min followed by placebo infusion for 4 hours after the delivery of the fetus.
61929627|NCT06164197|EXPERIMENTAL|Lokomat|
61929628|NCT06164197|EXPERIMENTAL|Balance Trainer|
61929629|NCT02145988|EXPERIMENTAL|DLBS1033|DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period
61929630|NCT02145988|PLACEBO_COMPARATOR|Placebo|Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period
61929631|NCT06448585|PLACEBO_COMPARATOR|Placebo Stage 1 (first 90 days)|"Control group (n= 30):~Stage 1: Under treatment with subcutaneous immunotherapy (ITE) but not receiving any dietary supplement, serving as a comparison for the variables collected in the study, for 90 days."
61929632|NCT06448585|EXPERIMENTAL|Dietary supplement Stage 1 (first 90 days)|"Experimental group (n= 30):~Stage 1: Participants receive the dietary supplement (1 sachet/day; contains 3 grams), in addition to the ITE treatment, for 90 days."
61929633|NCT06448585|PLACEBO_COMPARATOR|Placebo Stage 2 (last 90 days)|Stage 2: In addition to the ITE treatment, they receive the dietary supplement (1 sachet/day; contains 3 grams), but they do not receive the pork extract with diamine oxidase enzyme and serve as a comparison for the variables collected in the study, for 90 days.
61929634|NCT06448585|EXPERIMENTAL|Dietary supplement Stage 2 (last 90 days)|Stage 2: In addition to the ITE treatment, they receive the dietary supplement (1 sachet/day; contains 3 grams) and mini-tablets with pork extract containing diamine oxidase enzyme (3 mini-tablets/day), for 90 days.
62482893|NCT06500858|EXPERIMENTAL|Supportive care (virtual exercise sessions)|Patients receive a welcome package with exercise equipment and participate in virtual-exercise sessions over 60-90 minutes weekly for 6 weeks. Participants are also receive access to optional drop-in classes, monthly newsletters and online fitness buddy matching program and are encouraged to participate in a walking program on study.
62738345|NCT05360693|ACTIVE_COMPARATOR|immediate implant placement with bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done 3-5mm into the bone apical to the socket according to the manufacturer's instructions. Patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface.
61929635|NCT04913766|ACTIVE_COMPARATOR|Services as usual|Persons screening positive for depression will be referred from community-based organizations. The referrals will be made to mental health specialists who will provide care based on their standard of care.
62323730|NCT06306612|EXPERIMENTAL|Experimental group|The experimental group start with 6 cycles of induction chemohormonal therapy followed with cytoreductive prostatectomy and postoperative adjuvant radiotherapy if needed. All patients continued maintenance therapy.
62323731|NCT06306612|ACTIVE_COMPARATOR|Control group|The control group start with 6 cycles of chemohormonal therapy followed by continued maintenance therapy.
61929636|NCT04913766|EXPERIMENTAL|Problem Management Plus|Persons screening positive for depression will be offered Problem Management Plus delivered by community based organization staff.
61929637|NCT00701376|OTHER|liver function|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
61929638|NCT00562744|EXPERIMENTAL|SIM|Participants complete training and assessment of performance in PALS scenarios using high-fidelity simulator
61929639|NCT00562744|NO_INTERVENTION|MAN|Participants complete training and assessment of performance in PALS scenarios using mannequin
61929640|NCT02841527|ACTIVE_COMPARATOR|Gastric Band|The procedure will involve an operation in which a gastric Band and port will be fitted using a laparoscopic technique.
62323732|NCT01247818|EXPERIMENTAL|PH-10 Treatment (High Dose Cohort)|
62323733|NCT01247818|EXPERIMENTAL|PH-10 Treatment (Mid Dose Cohort)|
61929641|NCT02841527|ACTIVE_COMPARATOR|Gastric Bypass|The procedure will involve a laparoscopic operation in which a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
61929642|NCT02841527|ACTIVE_COMPARATOR|Sleeve Gastrectomy|The procedure involves an operation which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach using a laparoscopic technique.
61929643|NCT05722522|EXPERIMENTAL|Secukinumab|"* Name and Strength: 2 X Secukinumab 150 mg / 1 mL~* Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~* Randomized in a 1:1 ratio"
62131899|NCT05706870|ACTIVE_COMPARATOR|Clobetasol 17-propionate cream|"Clobetasol 17-propionate cream will be applied in 2:2:1 ratio~Psoriatic patients will receive clobetasol 17-propionate cream twice daily on a selected body target lesion~Clobetasol 17-propionate will be applied as a thin film layer for 4 weeks."
62323734|NCT01247818|EXPERIMENTAL|PH-10 Treatment (Low Dose Cohort)|
62323735|NCT01247818|PLACEBO_COMPARATOR|Vehicle Control|
62323736|NCT04752189|ACTIVE_COMPARATOR|Standard MMH Curriculum Implementation|Teachers will receive the MMH curriculum manual, standard training and as-needed technical assistance, provided to them by the health coordinators; consistent with standard REP.
61929644|NCT05722522|PLACEBO_COMPARATOR|Placebo|"* Name and Strength: 2 X Placebo / 1 mL~* Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~* Randomized in a 1:1 ratio"
61929645|NCT05384587|EXPERIMENTAL|Asciminib|80 mg initial oral dose taken once a day with possible dose escalation
62482894|NCT06502301||Postmenopausal women with vertebral fractures|Thoracolumbar radiograph, computed static posturography, fracture risk assessment tool (FRAX) scores, Dual-energy x-ray absorptiometry (DXA) measurements, serum 25(OH)D values, tandem test, timed up and go test (TUG), Berg balance scale (BBS) were performed.
61929646|NCT06236243|ACTIVE_COMPARATOR|G1899 Korean Red Ginseng Extract Powder 120 mg/tablet|480 mg of Korean Red Ginseng Extract powder per day for a total of 12 weeks.
61929647|NCT06236243|ACTIVE_COMPARATOR|G1899 Korean Red Ginseng Extract Powder 500 mg/tablet|2000 mg of Korean Red Ginseng Extract Powder per day for a total of 12 weeks.
61929648|NCT06236243|PLACEBO_COMPARATOR|Placebo|Inactive Ingredients
61929649|NCT06419231|ACTIVE_COMPARATOR|Butyrate Formulation|Butyrate Formulation: Take daily in the morning with 8 oz. (240ml) of water
62738346|NCT02923830|ACTIVE_COMPARATOR|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
62738347|NCT02923830|EXPERIMENTAL|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
61929650|NCT06419231|ACTIVE_COMPARATOR|Butyrate + Polyphenol Formulation|Butyrate + Polyphenol Formulation: Take daily in the morning with 8 oz. (240ml) of water
62131900|NCT05706870|PLACEBO_COMPARATOR|Placebo|"Placebo cream will be applied in 2:2:1 ratio~Psoriatic patients will receive placebo cream twice daily on a selected body target lesion~Placebo cream will be applied as a thin film layer for 4 weeks."
62323737|NCT04752189|EXPERIMENTAL|Enhanced Replicating Effective Programs (REP)|We will deploy Enhanced REP to include additional tailoring of the MMH curriculum to include trauma-informed approaches, tailored trauma-focused curriculum training, and implementation facilitation, ongoing specialized implementation support.
62482895|NCT06502301||Postmenopausal women without vertebral fractures|Thoracolumbar radiograph, computed static posturography, fracture risk assessment tool (FRAX) scores, Dual-energy x-ray absorptiometry (DXA) measurements, serum 25(OH)D values, tandem test, timed up and go test (TUG), Berg balance scale (BBS) were performed.
62482896|NCT06112626|EXPERIMENTAL|Intervention Group|Intervention Group: In addition to the current educational document available for CHG bathing, patients in the intervention group would be provided access to a CHG bathing video through multiple avenues (QR codes placed in the room/unit, video provided on unit iPads). Nurses will be instructed to provide QR codes to patients to scan and watch the video. Patients can scan the QR code using their own smart device or through unit-based iPads. After viewing the video, there is another QR code to scan that goes to a short patient survey.
62482897|NCT06112626|NO_INTERVENTION|Control Group|Control Group: Patients in the control group would have access to the current education available (patient education document) - usual care
61929651|NCT06419231|PLACEBO_COMPARATOR|Placebo|Placebo: Take daily in the morning with 8 oz. (240ml) of water
62131901|NCT01534494|EXPERIMENTAL|psilocybin|
62131902|NCT05674149|OTHER|Multi-Spectral Camera|Multi-Spectral Camera will be used in order to capture images of different skin conditions
62131903|NCT06224946||women under 37 weeks of gestation age|217 women under 37 weeks of gestation age
62131904|NCT06224946||women above 37 weeks of gestation age|97 women above 37 weeks of gestation age
62131905|NCT03315481|ACTIVE_COMPARATOR|SAX catheter insertion|Ultrasound guided cather insertion in the short axis (SAX) of the adductor canal. Injection of lidocaine through the catheter
62131906|NCT03315481|ACTIVE_COMPARATOR|LAX catheter insertion|Ultrasound guided cather insertion in the long axis (LAX) of the adductor canal. Injection of lidocaine through the catheter
62323738|NCT05639920||Group A|
61929652|NCT02821806||Cohort 1|Healthy Volunteers
61929653|NCT03717142|NO_INTERVENTION|Auto-fluorescence|No LUM015 injection will be given to three (3) patients, in each indication, to measure baseline tissue fluorescence. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
62131907|NCT03561519|ACTIVE_COMPARATOR|FMT|IBS patients randomized to receive FMT from a healthy donor.
62323739|NCT05714306|EXPERIMENTAL|Arm A - PEP-DC1 + low dose cyclophosphamide|In arm A, patients will receive PEP-DC1 vaccine in combination with low dose cyclophosphamide.
61929654|NCT03717142|EXPERIMENTAL|1st Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
61929655|NCT03717142|EXPERIMENTAL|2nd Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
61929656|NCT03717142|EXPERIMENTAL|3rd Tier Dose Level|After an interim analysis, the dosing for the 3 patients, in each indication, will be administered a single dose of LUM015 of no greater than 3.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
61929657|NCT01801072|ACTIVE_COMPARATOR|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days.
62323740|NCT05714306|EXPERIMENTAL|Arm B - OC-DC + low dose cyclophosphamide followed by PEP-DC2 + low dose cyclophosphamide|In arm B, patients will receive first, the OC-DC vaccine in combination with low dose cyclophosphamide, then PEP-DC2 vaccine in combination with low dose cyclophosphamide. Finally, patients will be vaccinated with the personalized PEP-DC2 to continue maintenance vaccination.
61929658|NCT01801072|NO_INTERVENTION|No levetiracetam|No levetiracetam during the operative phase.
61929659|NCT06708871||Therma ablation|
61929660|NCT06708871||Parathyroidectomy|
62131908|NCT03561519|PLACEBO_COMPARATOR|Placebo|IBS patients randomized to receive autologous FMT (fecal suspension made of their own feces) as a placebo.
62131909|NCT05156736||Young Pakistanis|Young pakistani population with no history of cardiovascular disease and stroke
62131910|NCT05704920|EXPERIMENTAL|IA Group|Patients with at least one nodule (\> 6mm) for whom the multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
62691431|NCT02115971|ACTIVE_COMPARATOR|Strength exercise|"Physical Therapy with a focus on stability and strength exercise. Strength exercise arm has also same duration of 12 weeks with comparable intensity. The program is according to a predetermined program. The 60-minute training is completed twice under supervision in the clinic's internal training group for outpatients.There is no contact with participants of other group.~Between the two exercise sessions there is a training free day. The training process is documented by the training protocol. The incipient exercise intensity is considering personal performance. The intensity is increased after workout usual principles. The exercises are described with clear image and load parameters. The training exercises are regularly monitored."
62691432|NCT06637852|EXPERIMENTAL|SUFICS-PACT|The Sexual and Urinary Function Improvement for Cancer Survivors- Promoting Access to Collaborative Treatment (SUFICS-PACT) intervention integrates a collaborative care model in primary care to facilitate problem identification, comprehensive treatment, and close follow-up for sexual and urinary dysfunction.
62691433|NCT06637852|NO_INTERVENTION|Usual care|Participants assigned to this group will continue with usual care.
62691434|NCT06641999|EXPERIMENTAL|Tinnitus Implant System|Tinnitus Implant
62691435|NCT05787782|EXPERIMENTAL|Masimo INVSENSOR00063|All subjects are enrolled into this arm and will have temperature measurements obtained.
62691436|NCT04637347|OTHER|IP-ISV|In plane infraclavicular subclavian vein catheterization
62691437|NCT04637347|OTHER|IP-SSV|In plane supraclavicular subclavian vein catetherization
62691438|NCT04586660|EXPERIMENTAL|Surgically unsalvageable disease|Participants with surgically unsalvageable disease (eg, sacral, spinal Giant cell tumor of bone \[GCTB\], or multiple lesions including pulmonary metastases).
62691439|NCT04586660|EXPERIMENTAL|Surgically salvageable disease|Participants with surgically salvageable disease whose planned on-study surgery is associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy).
62691440|NCT06549647|PLACEBO_COMPARATOR|Placebo laser on acpoints + low caloric diet|It will be consisted of 20 obese women diagnosed as having PCOS. Each will receive placebo laser on acupoints (3 sessions/week, 17 minutes/ session) in addition to low caloric diet for 3 months.
62691441|NCT06549647|EXPERIMENTAL|Laser acupuncture + low caloric diet|It will be consisted of 20 obese women diagnosed as having PCOS who will receive the same low caloric diet as in group (A) in addition to application of laser acupuncture on (REN 4,5), (ST 25,29,36,40), (CV 3,6,10,12),(SP 6), (L14), 1 minutes for each points (17 minutes/session), 3 times/week for 3 months.
62691442|NCT01974947||Infertile men|Man partner of an infertile couple. Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
62691443|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
62691444|NCT05894746|EXPERIMENTAL|gluten-free|The study participants will start the gluten-free diet and be asked to exchange any products they normally buy with similar products. Three days in the week they will eat a meal with gluten free pasta. Two to six hours after the meal they will take samples at home and store until they return to the clinic.
62131911|NCT05704920|OTHER|Group not IA analysis|Patients with at least one nodule (\> 6mm) for whom the multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
62131912|NCT04592393|EXPERIMENTAL|Abbreviated PB MRI|Short and Focused non-contrast MRI for surveillance
62131913|NCT03133234||EGFR T790M Patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
62131914|NCT03433690|EXPERIMENTAL|High Intensity Interval Training|Twelve weeks of High Intensity Interval Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
62323741|NCT02897973||Transtibial lower limb amputation|unilateral amputation below knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
62323742|NCT02897973||Transfemoral lower limb amputation|unilateral amputation above knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
62323743|NCT02897973||Controls|Able-bodied individuals without amputation
62323744|NCT01230671|EXPERIMENTAL|Yoga|Patients in this arm will receive yoga therapy
62323745|NCT01230671|PLACEBO_COMPARATOR|No yoga|Patients will not have yoga in this arm
62323746|NCT02395887||Intervational|Patients with back or neck pain who are a candidates for operational intervention.
62691445|NCT05894746|ACTIVE_COMPARATOR|gluten|The study participants will continue the gluten-free diet and be asked to exchange any products they normally buy with similar products. Three days however, in the week they will eat a meal with regular gluten containing pasta. Two to six hours after the meal they will take samples at home and store until they return to the clinic.
62691446|NCT05894746|ACTIVE_COMPARATOR|probiotic|The study participants will continue the gluten-free diet and be asked to exchange any products they normally buy with similar products. During the week they will also take probiotic (Probion, Active) every morning and every evening. Three days however, in the week they will eat a meal with regular gluten containing pasta. Two to six hours after the meal they will take samples at home and store until they return to the clinic.
62691447|NCT06195956|ACTIVE_COMPARATOR|Shoulder Impingement Rehabilitation|"rehabilitation program consisting of strengthening exercises (for scapular stabilizers and rotator cuff) and stretching exercises (for pectoralis major, pectoralis minor, latissimus dorsi, levator scapula).~Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months"
62691448|NCT06195956|EXPERIMENTAL|Shoulder Impingement Rehabilitation with LL KC Exercise|"rehabilitation program consisting of strengthening exercises (for scapular stabilizers and rotator cuff) and stretching exercises (for pectoralis major, pectoralis minor, latissimus dorsi, levator scapula) in addition to lower limb kinetic chain exercise.~Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months"
62691449|NCT01813357|PLACEBO_COMPARATOR|Placebo|sugar pill that is encapsulated so as to appear identical to the active agent
62131915|NCT03433690|ACTIVE_COMPARATOR|Moderate training|Twelve weeks of Moderate Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
62482898|NCT04342663|EXPERIMENTAL|Fluvoxamine|Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
62482899|NCT04342663|PLACEBO_COMPARATOR|Placebo|Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.
62482900|NCT01490567|PLACEBO_COMPARATOR|placebo|Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
62482901|NCT01490567|ACTIVE_COMPARATOR|donepezil|Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
62691450|NCT01813357|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 20mg daily
62691451|NCT01648322|EXPERIMENTAL|80 µg/kg/dose of F-627|This dose of F-627 given only to subjects that are to have TC chemotherapy.
62323747|NCT02395887||Control|Men or women who haven't seek for spine surgery consultation.
62323748|NCT01205191|EXPERIMENTAL|CBT-ubiquitous|
62131916|NCT02379715|EXPERIMENTAL|Remifentanil|When the particapants arrived into the operating room, the investigators applied standard monitoring and after preoxygenation, 2 mg remifentanil was diluted into 50 ml of normal saline (40 μg/ml solution) and was infused by Target concentration infusion (TCI) via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) using the pharmacokinetic model. Investigator started to infuse remifentanil at 4 ng/ml and after the Ce of remifentanil reached the target concentration level, opened the dial of desflurane vaporizer at 4 vol%. After 30 seconds, increase the concentration of desflurane 8% and 12% at last. If there is no spontaneous respiration or loss of consciousness, the muscle relaxant esmerone 0.6mg/kg is injected and after 90 seconds the tracheal intubation is performed.
62131917|NCT04863261|ACTIVE_COMPARATOR|Intervention|Clinics randomized to the intervention. A notification will be sent to the provider when a patient on CAB+RPV LA needs to be scheduled for their injections or when an appointment needs to be confirmed. Alerts are sent out to the provider when a patient is due or overdue for their injections.
62482902|NCT03398486|EXPERIMENTAL|Kinesiotaping|Original kinesiotaping active tapes Duration: 2 times Application maintenance 5 days with a break for the weekend Muscle application on the masseter muscle area, using a tape (5 cm wide) dissected into 2 parts called tails, which included the treatment site without their tension.
62482903|NCT03398486|EXPERIMENTAL|inactivation of trigger points (TrP)|Duration: 10-20 minutes of surgery; 2 inactivation treatments Between the treatments 5 days break
62482904|NCT04430725||Observational (microwave ablation, wedge excision, CT)|Patients undergo standard care microwave ablation or wedge resection followed by contrast-enhanced CT imaging at 1, 6, 12, 18 and 24 months. Patients also complete questionnaires over 10-15 minutes at baseline up to 9 months.
62323749|NCT01205191|PLACEBO_COMPARATOR|CBT-placebo|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management
62323750|NCT01205191|ACTIVE_COMPARATOR|CBT-TAU|Cognitive behavioural Therapy provided 'As Usual'
62691452|NCT01648322|EXPERIMENTAL|240 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
62691453|NCT01648322|EXPERIMENTAL|320 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
62691454|NCT01648322|ACTIVE_COMPARATOR|Neulasta® (pegfilgrastim)|Given to subjects receiving TC or TAC chemotherapy.
62323751|NCT02994589|EXPERIMENTAL|OASIS® wound matrix|OASIS wound matrix is a biologic extracellular matrix derived from porcine small intestine submucosa. Some components of OASIS wound matrix are similar to human dermis including types of collagens, elastin, glycoproteins and proteoglycans. In addition, OASIS wound matrix retains some growth factors that have been suggested to aid in the wound healing process. It is a FDA approved wound dressing indicated for use in a variety of ulcers, abrasions and surgical wounds.
62482905|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
62482906|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
62482907|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
62482908|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
62482909|NCT04365387|EXPERIMENTAL|Nemolizumab|Participants will receive a loading dose of nemolizumab (60 milligram \[mg\]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) will then be administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.
62482910|NCT04365387|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo via 2 SC injections at baseline. Placebo will then be administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.
62482911|NCT06182449|EXPERIMENTAL|Virtual Reality Distraction|Use of virtual reality (VR) during maternal milk expression.
62482912|NCT06182449|ACTIVE_COMPARATOR|Standard Treatment|Mothers will express their maternal milk in a private room in the NICU with their baby or a photo of the baby.
62482913|NCT05109377|OTHER|5mg tadalafil|5mg tadalafil
62482914|NCT05109377|OTHER|20mg tadalafil|20 mg tadalafil
62482915|NCT06626620|EXPERIMENTAL|IV Magnesium Sulfate|Magnesium sulfate, a smooth muscle relaxant, has been shown to have bronchodilatory effects by inhibiting calcium influx into smooth muscle cells.
62691455|NCT06638333||Children between 6 months and 5 years|
62691456|NCT01085955||Acute Peripartum|pregnant women who have recently given birth and diagnosed with peripartum cardiomyopathy
62691457|NCT01085955||Healthy Peripartum|Healthy pregnant women who have recently given birth, used as controls
62691458|NCT01085955||Healthy, non-pregnant women|Healthy non-pregnant women without cardiac disease, used as controls
62691459|NCT01085955||New Non-ischemic CMP|Women 18-60 years old who have been diagnosed with non-ishemic cardiomyopathy within the last 6 months and have an ejection fraction less than OR equal to 45% by echocardiogram.
62691460|NCT04878471|EXPERIMENTAL|ASP5354|Three participants in three dose levels will receive a single intravenous dose of ASP5354 on Day 1 under fasting conditions.
62691461|NCT04878471|PLACEBO_COMPARATOR|ASP5354 Matching Placebo|One participant in three dose levels will receive a single intravenous dose of matching placebo on Day 1 under fasting conditions.
61929661|NCT06497569|EXPERIMENTAL|STRONG Intervention|"Participants will receive an initial consultation and biweekly follow-up visits with a study dietitian for 90 days.~During the follow-up visits, the study dietitian will review the dietary plan and goals, review the dietary food log, and discuss any challenges with dietary intake and recommendations for improving dietary intake.~Participants will keep a daily diary of food intake with a Fitbit smartphone app and a Fitbit wearable device for 90 days, complete 6 questionnaires, and have the option to participate in a voluntary interview about the intervention."
61929662|NCT06497569|ACTIVE_COMPARATOR|Usual Care Intervention|Participants will be referred to a study dietitian based on their standard-care clinician's discretion, complete 6 questionnaires, and have the option to participate in a voluntary interview about the intervention.
61929663|NCT02812407|EXPERIMENTAL|Mucosal Impedance|"Patient's having a clinically indicated endoscopy, a high resolution impedance manometry and a 24 hour pH impedance study.~During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. This device has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it."
61929664|NCT03657862|EXPERIMENTAL|SDF treated|application of 38% silver diamine fluoride solution
61929665|NCT03657862|PLACEBO_COMPARATOR|Placebo|application of a placebo (tonic water)
61929666|NCT03767595|EXPERIMENTAL|ProACT Adjustable Continence Therapy for Men|Patients implanted with ProACT Adjustable Continence Therapy for Men
61929667|NCT06458595|EXPERIMENTAL|KH658|
61929668|NCT06709105|EXPERIMENTAL|Kinesiotape application|The application was performed using 5 cm x 5 m kinesio tape material. After preparing the standing patient in terms of clothing and skin readiness, the patient was asked to lean forward. To adhere the tape to the right paravertebral region, the lower end of the tape was first adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. Then, while the patient was leaning forward, a slight rotation to the left was requested, and in this position, the tape was adhered upwards along the paravertebral muscles without any tension. When applying the tape to the left paravertebral region, the same procedure was mirrored as on the right, with the tape again applied without any tension. The third tape was applied while the patient was standing upright and leaning slightly forward, placed over the sacroiliac joints and parallel to the floor, stretching the tape by 25%.
61929669|NCT06709105|SHAM_COMPARATOR|Sham group|Sham Kinesio taping was applied to the patients in the control group. In this sham protocol, Kinesio bands were attached between the 12th rib on both sides and the corresponding sacroiliac joint, passing over the paravertebral muscles without employing any specific banding technique. The third tape was adhered between both sacroiliac joints, also without any adhesive technique. Patients were inquired about any discomfort and informed that the tapes would remain in place until the second session.
61929670|NCT06707012|EXPERIMENTAL|Experimental|We will prescribe metformin with starting dose of 500 mg metformin once daily, titrated up to 2000 mg/day based on tolerance along with standard treatment of depression according to Maudsley guidelines.
61929671|NCT06707012|PLACEBO_COMPARATOR|placebo group|Identical placebo tablets, following the same titration schedule as the metformin group along with standard treatment of depression
61929672|NCT03287583|EXPERIMENTAL|SBIRT|SBIRT intervention for Gambling
61929673|NCT03287583|OTHER|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
61929674|NCT03828773|OTHER|high-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): homozygous for rs230561 and/or rs381652
61929675|NCT03828773|OTHER|low-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): other than homozygous for rs230561 and/or rs381652
61929676|NCT03660488|ACTIVE_COMPARATOR|Benzathine Penicillin G|"Patients of the Penicillin Group will receive the standard of care treatment. This is one intramuscular injection of 2.4 million units Benzathine Penicillin G. The group will consist of 50 patients."
61929677|NCT03660488|EXPERIMENTAL|Cefixime Group|"Patients of the Cefixime Group will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.~The group will consist of 50 patients."
61929678|NCT02343081|ACTIVE_COMPARATOR|Temodal|Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
62131918|NCT04863261|NO_INTERVENTION|Control|Clinics randomized to the control group. No alerts or notification will be sent. The providers will manage their CAB+RPV LA patients using standard of care in their clinic.
61929679|NCT02343081|EXPERIMENTAL|Dralitem|Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
61929680|NCT03332771|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
62131919|NCT02721901|EXPERIMENTAL|iEAT Manual Intervention|Caretakers of 10 children will be randomized to participate in the integrated Eating Aversion Treatment (iEAT) intervention. iEAT is a technology-based manual which aims to increase the child's food consumption.
62323752|NCT02994589|ACTIVE_COMPARATOR|Tegaderm™(Absorbant, 3M)|Transparent dressing allows for wound monitoring without changing the dressing Clear design takes the guesswork out of application over the wound Novel acrylic polymer pad technology designed to handle low to moderate wound drainage. No dressing breakdown in the wound. Low friction surface minimizes potential for friction and shear. Allows for gentle removal from skin. Barrier to external contaminants, body fluids, bacteria and viruses.
62323753|NCT02994589|ACTIVE_COMPARATOR|Xeroform™|Xeroform™ Occlusive Petrolatum Gauze. 3% Bismuth Tribromophenate in a special petrolatum blend on fine mesh gauze. Non-adherent. Clings and conforms to all body contours.
62323754|NCT04940936|NO_INTERVENTION|A - control|The patients are offered high or lower dose according to usual practice
62691462|NCT05055427|EXPERIMENTAL|• Experimental: Investigational arm|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) and the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.
62691463|NCT05055427|NO_INTERVENTION|• Controlled arm|Patients receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline
62691464|NCT04318301||ACEI/ARB|COVID-19 patients with hypertension who had previously taken ACEI/ARB for antihypertensive treatment
62691465|NCT04318301||non ACEI/ARB|COVID-19 patients with hypertension who had not previously taken ACEI/ARB for antihypertensive treatment
61929681|NCT03332771|EXPERIMENTAL|Sotagliflozin 200 mg|Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
61929682|NCT03332771|ACTIVE_COMPARATOR|Glimepiride|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
61929683|NCT03332771|PLACEBO_COMPARATOR|Placebo|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
61929684|NCT03150485|EXPERIMENTAL|etafilcon A Toric Multifocal|
62323755|NCT04940936|EXPERIMENTAL|B - Intervention|The Patient Decision Aid is used during the consultation to aid in the decision on high or lower dose.
62323756|NCT04099316|EXPERIMENTAL|Older adults|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
62323757|NCT04099316|EXPERIMENTAL|Older adults-Control|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
62323758|NCT04099316|NO_INTERVENTION|No intervention|Metabolic diseases, Hypertension (150/90mmHg), Myocardial infarction within 6 months. Fractures within 6 months.
62482916|NCT06626620|EXPERIMENTAL|IV Terbutaline|Terbutaline, a beta-2 agonist, is used intravenously to provide systemic bronchodilation when inhaled bronchodilators are not effective.
62482917|NCT03448263|EXPERIMENTAL|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
62482918|NCT03448263|EXPERIMENTAL|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
62482919|NCT03448263|EXPERIMENTAL|Reciproc instruments|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
62482920|NCT02767804|EXPERIMENTAL|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
62691466|NCT00658073|ACTIVE_COMPARATOR|A|Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.
61929685|NCT03150485|ACTIVE_COMPARATOR|etafilcon A Multifocal|
61929686|NCT06710522||PATIENTS UNDERGOING LAPAROSCOPIC TUBA LIGATION SURGERY|COMPARISON OF PATIENTS UNDERGOING GENERAL AND SPINAL ANESTHESIA AS ANESTHESIA METHODS IN LAPAROSCOPIC TUBE LIGATION SURGERY
61929687|NCT05579847||Study Participants|Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
61929688|NCT06157398|OTHER|Diet Intervention|Participants will be provided with a diet that has an increased intake of fish high in Omega-3 fatty acids as well as fruits and vegetables in comparison to their baseline intakes as assessed by the study dietician.
61929689|NCT04199936|EXPERIMENTAL|EMG leg|Quadriceps muscle group of postoperative patients randomly selected leg which will undergo electrical muscle stimulation for upto 2 hours on each postoperative day
61929690|NCT04199936|NO_INTERVENTION|Control leg|Quadriceps muscle group of postoperative patients leg not selected to undergo electrical muscle stimulation
61929691|NCT02974309|EXPERIMENTAL|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
62323759|NCT01011920|EXPERIMENTAL|MTX+ AraC|Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
62323760|NCT01011920|EXPERIMENTAL|Ara-C +Rituximab|Arm B Rituximab 375 mg/m2 conventional infusion d -5 \& 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
62323761|NCT01011920|EXPERIMENTAL|Ara-C + rituximab+thiotepa|Arm C Rituximab 375 mg/m2 conventional infusion d -5 \& 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
62323762|NCT01011920|EXPERIMENTAL|WBRT 36 Gy +/- boost 9 Gy|ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
62323763|NCT01011920|EXPERIMENTAL|BCNU + Thiotepa + APBSCT|Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
62323764|NCT04929236|EXPERIMENTAL|Panzyga High Dose|2.0g/kg of PANZYGA administered intravenously every four weeks over a period of sixteen weeks for a total of five treatment dosages.
62482921|NCT02767804|ACTIVE_COMPARATOR|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
62482922|NCT00525213|ACTIVE_COMPARATOR|A|
62482923|NCT00525213|ACTIVE_COMPARATOR|B|
62482924|NCT00525213|ACTIVE_COMPARATOR|C|
62482925|NCT00525213|PLACEBO_COMPARATOR|D|
62482926|NCT03254225|EXPERIMENTAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
62482927|NCT03254225|NO_INTERVENTION|Control|in this arm, the group will remain sedentary for the same period of the experimental group, and they will be invited to engage on the raining program after the sedentary period
62482928|NCT04836494|EXPERIMENTAL|BBP-671 for SAD|The SAD portion of the study will consist of up to 8 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
62691467|NCT00658073|ACTIVE_COMPARATOR|B|Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.
62691468|NCT00658073|ACTIVE_COMPARATOR|C|Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A.
62691469|NCT05711797|EXPERIMENTAL|ZX-7101A 80mg Mild or moderate liver insufficiency|
62691470|NCT05711797|EXPERIMENTAL|ZX-7101A 80mg Normal liver function|
62691471|NCT04977986|EXPERIMENTAL|ZYN002 - transdermal gel|Pharmaceutically manufactured. Cannabidiol is formulated as a clear gel for transdermal delivery.
62691472|NCT04977986|PLACEBO_COMPARATOR|Placebo transdermal gel|Placebo is formulated as a clear gel for transdermal delivery.
61929692|NCT02974309|SHAM_COMPARATOR|Routine|All youth in this condition are asked to follow the routine that their clinical team has established.
61929693|NCT05930951|ACTIVE_COMPARATOR|OBT076 only|OBT076, administration at 3mg/kg, (IV ≥ 3h infusion) on Day 1 every 21 days (3-week cycle) until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment or patient refusal whichever comes first.
62691473|NCT06644547|EXPERIMENTAL|Intervention 'Gezond en goed met elkaar'|see description of the intervention 'Gezond en goed met elkaar'
62691474|NCT06644547|NO_INTERVENTION|Control group|Participants do not receive the intervention yet. They have to wait 3 months before they start with the intervention. They will fill out questionnaires at baseline, 3, 6 and 9 months.
62691475|NCT06644547|NO_INTERVENTION|Control group 2|Participants do not receive the intervention yet. They have to wait 6 months before they start with the intervention. They will fill out questionnaires at baseline, 3, 6 and 9 months.
62691476|NCT06190379|EXPERIMENTAL|Intervention|Essential oil blend in an inhaler stick
61929694|NCT05930951|EXPERIMENTAL|OBT076 -Balstilimab|3 cycles of OBT076, administration at 3mg/kg, IV (≥ 3h infusion) on Day 1 every 21 days (3-week cycle) followed by Balstilimab, administration at 450mg, IV, on Day 1 every 21 days (3-week cycle) until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment or patient refusal whichever comes first.
62691477|NCT06190379|PLACEBO_COMPARATOR|Placebo|blank inhaler stick
61929695|NCT03888924|EXPERIMENTAL|BCG treated patients|a single dose of Bacille Calmette-Guerin vaccine
61929696|NCT03888924|PLACEBO_COMPARATOR|Placebo treated patients|a single dose of placebo.
61929697|NCT04036331|ACTIVE_COMPARATOR|Adolescent Participants|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
61929698|NCT04036331|EXPERIMENTAL|Caregivers of Adolescent Participants|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
61929699|NCT04036331|EXPERIMENTAL|Co-enrollment|This condition is for dyads that are co-enrolled in This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.
61929700|NCT03448653|EXPERIMENTAL|Colonoscopy with NBI|
62323765|NCT04929236|EXPERIMENTAL|Panzyga Low Dose|1.0g/kg of PANZYGA administered intravenously every four weeks over a period of sixteen weeks for a total of five treatment dosages.
62691478|NCT04169243|EXPERIMENTAL|Intervention|Women randomized to the New Nordic Diet meet the study dietician at week 30 for 1.5 hr of individual diet treatment according to the New Nordic Diet and a cognitive behavioral approach. The diet advice include evenly distributed meals over the day, foods low in fat and rich in fibre, 500 g fruit and vegetables daily, fish 2-3 times a week and keyhole foods. Participants will prepare their own food but are provided with recipes and food bags containing ingredients and foods to be consumed during the two-week intervention At gestational age 32 weeks, women meet with a dietitian and will be instructed to continue with the New Nordic Diet diet throughout pregnancy on their own.
62691479|NCT04169243|ACTIVE_COMPARATOR|Control|The control women receive diet advice according to usual care.
62691480|NCT06510231|EXPERIMENTAL|Inspiratory muscle training (IMT) group|IMT performed at 40% maximal inspiratory pressure (MIP) for 30 minutes 7 days a week for 8 weeks.
62323766|NCT03773523|EXPERIMENTAL|Experimental: active tDCS|Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
62691481|NCT06510231|SHAM_COMPARATOR|SHAM group|IMT performed at 2% maximal inspiratory pressure (MIP) for 30 minutes 7 days a week for 8 weeks.
62697502|NCT03096431|ACTIVE_COMPARATOR|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
61929701|NCT04711135|EXPERIMENTAL|GEP-NET and PPGL|All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
62131920|NCT02721901|ACTIVE_COMPARATOR|Control group|Caretakers of 10 children will be randomized to participate in the control group. Participants assigned to the control group will be able to receive the iEAT treatment after the study ends.
62131921|NCT04498624|ACTIVE_COMPARATOR|inverted flap|
62131922|NCT04498624|ACTIVE_COMPARATOR|peeling internal limiting membrane (ILM)|
62131923|NCT01460667|ACTIVE_COMPARATOR|IV acetaminophen|
62131924|NCT01460667|PLACEBO_COMPARATOR|IV 0.9% normal saline|
62323767|NCT03773523|SHAM_COMPARATOR|Sham Comparator: sham tDCS|Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function. There will be a total of 5 sham tDCS sessions.
62323768|NCT01563562|EXPERIMENTAL|Bardoxolone Methyl 20 mg|
62323769|NCT01058174|EXPERIMENTAL|micafungin|intravenous infusion
62323770|NCT01058174|ACTIVE_COMPARATOR|standard care|intravenous infusion
62323771|NCT05966909||Solid cancer patients|Patients with solid cancer who underwent the placement of a PICC or PICC-PORT for chemotherapy.
62323772|NCT05727163|EXPERIMENTAL|HAI group|"FOLFOX given via Hepatic Artery Infusion (HAI) in Combination With intravenous Irinotecan With or Without Bevacizumab.~Dexamethasone 25 mg via HAI (Pre-chemotherapy) Anisodamine (654-2) 10 mg HAI (Pre-chemotherapy) Oxaliplatin 85 mg/m2 via HAI over 3 hours Leucovorin 200 mg/m2 via HAI FU 400 mg/m2 via HAI FU 2.4g/m2 via HAI over 48 hours Irinotecan 150 mg/m2 intravenously Bevacizumab 5 mg/kg intravenously~The above regimen was given on Day 1 and repeated after 14 days. Patients will typically receive a maximum of 12 courses (preoperative and/or postoperative) unless disease progression is detected, intolerable adverse effects, or the patient refuses further treatment."
62339900|NCT04627298|ACTIVE_COMPARATOR|Video Game|This arm tests use of video game to help preteens in the decision to pursue HPV vaccination. Participants in the intervention group are asked to play the Land of Secret Gardens game and complete 3 tasks: (1) play a shield game with blue spikey virus balls, (2) find hidden objects in 4 different garden sheds, and (3) create a potion (vaccine). Participants in the intervention arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance, the Physical/Emotional/Narrative Presence Scale (PENS) to gauge preteens' immersion in the game, and game play experience.
62697503|NCT06363708|EXPERIMENTAL|Tislelizumab+Carboplatin+Paclitaxel|Tislelizumab 200mg D1 +Carboplatin(AUC=5) D1+Paclitaxel(175 mg/m2 ) D1, every 3 weeks (21 days) is a treatment cycle
61929702|NCT06158100|EXPERIMENTAL|VEN/AZA Dose Escalation/De-Escalation Cohort|"Participants in this group will begin Venetoclax and Azacitidine (VEN/AZA) combination therapy between day +42 and day +100 following hematopoietic cell transplant (HCT) infusion. VEN/AZA combination therapy will be administered for up to six (6) cycles, followed by up to six (6) additional cycles of Venetoclax monotherapy in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.~Participants may also receive donor lymphocyte infusions (DLI) at the discretion of the treating physician, if certain criteria are met.~Participants will receive up to one year (12 cycles) of study therapy, followed by up to one year of follow-up. Total participation duration is up to two years."
61929703|NCT06158100|EXPERIMENTAL|VEN/AZA Expansion Cohort|"Participants in this group will receive VEN/AZA therapy at the most appropriate dose determined in Part 1. Participants may also receive donor lymphocyte infusions (DLI) at the discretion of the treating physician, if certain criteria are met.~Participants will receive up to one year (12 cycles) of study therapy, followed by up to one year of follow-up. Total participation duration is up to two years."
61929704|NCT05185115|EXPERIMENTAL|Intervention group (A)|Patients treated with 3 liters per minute oxygen delivered via nasal cannula duration hospitalization
61929705|NCT05185115|OTHER|Control group (B)|No oxygen therapy during hospitalization
61929706|NCT03415854|EXPERIMENTAL|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
61929707|NCT04300621|EXPERIMENTAL|Treatment Sequence 1: OTF 1, 4, 2, 3|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 1 in period 1; followed by OTF 4 in period 2; followed by OTF 2 in period 3; followed by OTF 3 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
61929708|NCT04300621|EXPERIMENTAL|Treatment Sequence 2: OTF 2, 1, 3, 4|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 2 in period 1; followed by OTF 1 in period 2; followed by OTF 3 in period 3; followed by OTF 4 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
61929709|NCT04300621|EXPERIMENTAL|Treatment Sequence 3: OTF 3, 2, 4, 1|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 3 in period 1; followed by OTF 2 in period 2; followed by OTF 4 in period 3; followed by OTF 1 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
62131925|NCT06135246|ACTIVE_COMPARATOR|Standard Care group|Participants will receive standard compression bandaging and wound care alone without high-intensity laser therapy. Bandaging will be applied weekly and wound care will be performed as per institutional protocols.
62131926|NCT06135246|EXPERIMENTAL|High Intensity laser therapy + Standard care group|Participants will receive high-intensity laser therapy 3 times per week for 8 weeks or until ulcer closure in addition to standard care.
62131927|NCT03448510|EXPERIMENTAL|Irreversible electroporation treatment|Subjects will receive irreversible electroporation of the prostate
62131928|NCT03448510|ACTIVE_COMPARATOR|standard medication group|Subjects will receive either α-blocker or 5α reductase monotherapy or combination therapy.
62131929|NCT02888860||Group 1|Patients with candidemia
62131930|NCT02888860||Group 2|Patients without colonization during follow up
62131931|NCT02888860||Group 3|Patients without colonization at admission, with subsequent colonization during hospitalization
62131932|NCT02888860||Group|Patients colonized at admission, and during the whole hospitalization
61929710|NCT04300621|EXPERIMENTAL|Treatment Sequence 4: OTF 4, 3, 1, 2|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 4 in period 1; followed by OTF 3 in period 2; followed by OTF 1 in period 3; followed by OTF 2 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
61929711|NCT06710912|EXPERIMENTAL|Group ACT|Participants of this arm underwent 4 weeks of weekly session of acceptance and commitment therapy (ACT).
62691482|NCT05626335||Study group|From all the patients meeting the inclusion criteria every third patients was randomly chosen and invited to participate in the study. Written informed consent was obtained from every participant. Thus 100 patients have agreed to participate. All fixed retainers (stainless steel braided rectangular wire) were bonded in both arches by the same experienced clinician, who subsequently made impression for thermally formed splints and delivered them on the day of debonding. The effect of each of the procedures was verified by two independent experienced clinicians. On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0). The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3). The displacements were assessed by superimposition of the scans. The patients were recommended to wear removable retainers 22h/day. They were instructed to immediately report a failure and to apply immediately to the office in case of failure.
62691483|NCT00619918|EXPERIMENTAL|Nebulized 3% Saline|3% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting.
61929712|NCT06710912|ACTIVE_COMPARATOR|Treatment-as-usual (TAU) group|The participants in this group received standard treatment for major depressive disorder
61929713|NCT04220827|EXPERIMENTAL|Treatment (paclitaxel)|Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.
61929714|NCT06405620|EXPERIMENTAL|Robot intervention|the child uses the assistance robot
61929715|NCT03613597|EXPERIMENTAL|Etoposide plus Lobaplatin group|Chemotherapy:etoposide plus lobaplatin (EL)
61929716|NCT03613597|ACTIVE_COMPARATOR|Etoposide plus Cisplatin group|Chemotherapy:etoposide plus cisplatin (EP)
61929717|NCT03458754||Patients|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
61929718|NCT03458754||Healthy controls|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
61929719|NCT05591742|PLACEBO_COMPARATOR|placebo|As it is blinded, no one knows which arm participants enter. After 3 months the other arm is entered.
61929720|NCT05591742|ACTIVE_COMPARATOR|Femidur|As it is blinded, no one knows which arm participants enter. After 3 months the other arm is entered.
61929721|NCT05558124|EXPERIMENTAL|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of CPX-351 in combination with Gemtuzumab Ozogamicin in participants with newly diagnosed acute myeloid leukemia. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
61929722|NCT04158791||EMM-I|Group with an intact IS/OS junction
62323773|NCT05727163|ACTIVE_COMPARATOR|Systemic Chemotherapy group|"Systemic FOLFOXIRI With or Without Bevacizumab~Irinotecan 150mg/m2 intravenously Oxaliplatin 85 mg/m2 intravenously over 3 hours Leucovorin 200 mg/m2 intravenously FU 400 mg/m2 intravenously 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours Bevacizumab 5 mg/kg intravenously~Note: (UGT\*28 7/7, UGT\*6 A/A, UGT\*28 6/7 and UGT\*6 A/G patients, Irinotecan dosage was reduced to 130 mg/m2)~The above regimen was given on Day 1 and repeated after 14 days. Patients will typically receive a maximum of 12 courses (preoperative and/or postoperative) unless disease progression is detected, intolerable adverse effects, or the patient refuses further treatment."
62323774|NCT04000672|ACTIVE_COMPARATOR|HTO with navigation|High Tibial Osteotomy is offered to patients with symptomatic medial compartment knee osteoarthritis (OA)
62323775|NCT04000672|EXPERIMENTAL|HTO with navigation + PSI jig|"3D printed patient specific metal jigs (PSI jig) are created based on the pre-operative CT image. After that, calibrated osteotome is used to achieve the desired correction with the use of navigation for overall lower limb alignment, which is the same as the Active Comparator group."
62323776|NCT00387387|EXPERIMENTAL|FOLFOX 6 + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.
62323777|NCT00387387|EXPERIMENTAL|CapeOx + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m\^2 twice daily.
62323778|NCT04769583|ACTIVE_COMPARATOR|concomitant quadruple therapy (QC)|PPI (esomeprazole: 40 mg x 2 per day) with the amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day) for 14 days
62323779|NCT04769583|PLACEBO_COMPARATOR|triple therapy (TT)|PPI (esomeprazole: 40 mg x 2 per day) with amoxicillin (1 g x 2 per day) and clarithromycin (500 mg x 2 per day) AND PLACEBO for 14 days.
62323780|NCT01680406|ACTIVE_COMPARATOR|Artemether-lumefantrine|Weight-based dose to be administered as fixed-dose combination twice daily for three days.
62323781|NCT01680406|EXPERIMENTAL|Artemether-lumefantrine and primaquine|"Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
62697504|NCT05583955|EXPERIMENTAL|Active|Escalating doses of NOE-105 capsules
61929723|NCT04158791||EMM-D|Group with a disrupted IS/OS junction
62131933|NCT02888860||Group 5|Patients who develop colonization during hospitalization and become negative at discharge
62131934|NCT02496377|ACTIVE_COMPARATOR|Group 1: Per Os Tardyferon|EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).
62323782|NCT01680406|ACTIVE_COMPARATOR|Chloroquine|Chloroquine will be given in a weight-based dose to be administered once daily for three days.
62691484|NCT00619918|PLACEBO_COMPARATOR|Nebulized 0.9% Saline|0.9% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting.
62691485|NCT06643078|EXPERIMENTAL|HL231 Solution for Inhalation|
62691486|NCT06643078|ACTIVE_COMPARATOR|Ultibro|
62691487|NCT06637696|ACTIVE_COMPARATOR|Blood Culture Bundle Group|In this group, blood culture collection was performed using a checklist other than the standard criteria.The checklist for the blood culture contamination precaution package (Table 1) was prepared using guidelines from the Turkish Society of Clinical Microbiology.
62691488|NCT06637696|PLACEBO_COMPARATOR|Control Blood Culture Group|In this group the standard practice in both periods was aseptic, non-contact technique for blood culture collection. For this purpose, hands were cleaned with antibacterial liquid soap (Klorhexin scrub antibacterial liquid soap 4-% Ekin Medical), the patient's skin was cleaned with povidone iodine 10% solution (Betadix 10% solution- Natural Medical Pharma) using sterile gloves, waited at least 30 seconds and then povidone iodine was removed from the skin with 70% alcohol.
62691489|NCT04573504|EXPERIMENTAL|Antibiotic Group|The antibiotic regimen chosen is based on the Royal College of Obstetricians and Gynecologists' recommendations (Augmentin and Flagyl or Clindamycin and Flagyl if they are allergic to Penicillin). The dosage for the antibiotics are the following: Flagyl 500mg po BID (twice a day) X 5 days, Clindamycin 400 mg po TID (three times a day) X 5 days, Augmentin 875mg po BID X 5 days.
62131935|NCT02496377|EXPERIMENTAL|Group 2: IV Ferinject|EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
62131936|NCT01263613|OTHER|Biopsy|biopsy
62131937|NCT06130228|EXPERIMENTAL|Multi-ingredient supplement (PDT-MIS)|Multi-ingredient supplementation (PDT-MIS) consists of daily intake of high-quality proteins, creatine, vitamin D, calcium, plant extracts (green coffee bean, green tea, beet root, and forskolin), and Omega-3 fatty acids. Concurrent with supplementation, patients will do mixed rehabilitative exercise (cardio and strength) and respiratory muscle training four days a week.
62131938|NCT06130228|PLACEBO_COMPARATOR|Placebo (PLA)|Placebo (PLA) consists of daily intake of collagen, safflower, and microcrystalline cellulose. Concurrent with supplementation, patients will do mixed rehabilitative exercise (cardio and strength) and respiratory muscle training four days a week.
62131939|NCT04763707||Group 1 : Hepatocellular carcinoma HCC patients with HCV|40 HCV-related liver cirrhosis patients with HCC on top (Group 1).
62131940|NCT04763707||Group 2 : Cirrhotic patients with HCV|30 HCV-related liver cirrhosis patients(Group 2).
62323783|NCT01680406|EXPERIMENTAL|Chloroquine and primaquine|"Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
62323784|NCT05278416|ACTIVE_COMPARATOR|Lumoral treatment -device and Lumorinse tablets|Subjects will receive detailed instructions for the use of Lumoral treatment -device and Lumorinse tablets. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day.
62691490|NCT04573504|PLACEBO_COMPARATOR|Placebo Group|Women randomized not to receive antibiotics will be given placebo tablets postpartum, so they will all have an identical experience to the women in the experimental (antibiotic) group.
62691491|NCT06319053|EXPERIMENTAL|Laparoscopy|Adult study participants who are planned to undergo intraperitoneal laparoscopic surgery
62691492|NCT05722769|EXPERIMENTAL|CSTOP Now! Child Sex Trafficking Stops with You|For this RCT, our research team has created CSTOP Now! online, interactive learning management system training. This CSTOP Now! online training will be offer to middle school staff in Kentucky counties randomized to this experimental intervention arm. This training seeks to provide middle school staff with information and resources to identify, intervene in, and prevent child sex trafficking (CST). This training will provide middle school staff with the knowledge, skills, and efficacy to intervene with children at risk of or experiencing CST. This training will also provide staff with skills to disrupt harmful attitudes or misinformation about CST.
61929724|NCT05344833|EXPERIMENTAL|Isatuximab and Lenalidomide Maintenance|"All participants will receive:~Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39. Lenalidomide 10mg PO Days 1-21 Cylces 1-3 (all cycles 28 days) Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression."
61929725|NCT06642935|EXPERIMENTAL|Device :TICI G2 Clinical Investigation System|Totally implantable cochlear Implant
62131941|NCT04763707||Group 3 : Healthy control|20 healthy volunteers will be included as controls(Group 3).
62323785|NCT05278416|NO_INTERVENTION|Standard of Care|Subjects will receive oral hygiene instructions for the sonic toothbrushing and the use of interdental cleaning devices. They will not receive an additional intervention.
62323786|NCT03527446|EXPERIMENTAL|Normal Weight|BMI ≥ 18.5 \< 25.0 km/m2 Sprint Interval Training
62482929|NCT04836494|PLACEBO_COMPARATOR|Placebo for SAD|The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
62697505|NCT05583955|PLACEBO_COMPARATOR|Placebo|Escalating doses of matching placebo
62697506|NCT01573429|OTHER|Dermal Carboxymethylcellulose arm|d-BPA administered dermally using a carboxymethylcellulose suspension
62697507|NCT01573429|OTHER|Dermal ethanol arm|d-BPA is administered dermally using an ethanol solution
62323787|NCT03527446|EXPERIMENTAL|Individuals living with Obesity|BMI ≥ 30.0 km/m2 Sprint Interval Training
62323788|NCT03125746|EXPERIMENTAL|LXI-15029|
62323789|NCT03125746|EXPERIMENTAL|LXI-15029+Exemestane|
62323790|NCT03933917|EXPERIMENTAL|Large Volume Acute Normovolemic Hemodilution|All the participants will undergo Large Volume Acute Normovolemic Hemodilution.
62323791|NCT03969706|EXPERIMENTAL|Single Arm|Abemaciclib 200mg tablet PO twice daily administered on 28-day cycles Subjects remain on treatment until tumor progression or unacceptable toxicity.
62323792|NCT03623984|EXPERIMENTAL|Gallium Dotatate|All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
62323793|NCT05550727|EXPERIMENTAL|PorchLight|
62482930|NCT04836494|EXPERIMENTAL|BBP-671 for MAD|The MAD portion of the study will consist of up to 6 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
62482931|NCT04836494|PLACEBO_COMPARATOR|Placebo for MAD|The MAD portion of the study will consist of up to 6 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
62482932|NCT04836494|EXPERIMENTAL|BBP-671 for SAD Food Effect|Eight (8) healthy male or female adult subjects will be randomized to receive BBP-671.
62482933|NCT04836494|EXPERIMENTAL|BBP-671 for PA and MMA Patients|Up to sixteen (16) patients with either PA or MMA will receive BBP-671.
62482934|NCT06559878|EXPERIMENTAL|The order of metabolic visits: 1.Normal saline, 2.Lipid emulsion, 3.Ethanol|
62482935|NCT06559878|EXPERIMENTAL|The order of metabolic visits: 1. Normal saline, 2. Ethanol, 3. Lipid emulsion|
62482936|NCT06559878|EXPERIMENTAL|The order of metabolic visits: 1.Lipid emulsion, 2.Normal saline, 3.Ethanol|
62482937|NCT06559878|EXPERIMENTAL|The order of metabolic visits: 1.Lipid emulsion, 2.Ethanol, 3.Normal saline|
62482938|NCT06559878|EXPERIMENTAL|The order of metabolic visits: 1. Ethanol, 2. Normal saline, 3. Lipid emulsion|
62482939|NCT06559878|EXPERIMENTAL|The order of metabolic visits: 1. Ethanol, 2. Lipid emulsion, 3. Normal saline|
62482940|NCT02577653|OTHER|subjects|participant undergoing posturographic evaluation
61929726|NCT02131532|EXPERIMENTAL|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
61929727|NCT04513717|ACTIVE_COMPARATOR|Arm I (de-intensification study)|Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity.
62482941|NCT04476511|ACTIVE_COMPARATOR|Slower Loading Dose|30.000IU cholecalciferol once weekly for ten weeks
62482942|NCT04476511|ACTIVE_COMPARATOR|Moderate Loading Dose|30.000IU cholecalciferol twice weekly for five weeks
62482943|NCT01640197|PLACEBO_COMPARATOR|Placebo|Methyl Cellulose administered in identical capsules as the active.
62482944|NCT01640197|ACTIVE_COMPARATOR|500mg resveratrol|Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
61929728|NCT04513717|EXPERIMENTAL|Arm II (de-intensification study)|Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity.
61929729|NCT04513717|ACTIVE_COMPARATOR|Arm III (intensification study)|Patients undergo RT over 2-11 weeks and receive ADT as in Arm I.
62323794|NCT05550727|NO_INTERVENTION|Control|
62323795|NCT04417088|EXPERIMENTAL|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to Carboplatin administration.
62339901|NCT04627298|NO_INTERVENTION|No Video Game|This arm does not test the video game. Participants in the comparison arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance.
62482945|NCT04754035|EXPERIMENTAL|venetoclax + ibrutinib|
62482946|NCT04200274||Mental Health Nurses in Germany|Nurses in Germany currently working with patients with mental disorders
62482947|NCT01604941|EXPERIMENTAL|SPD602|50 mg/kg/day orally twice daily for 24 weeks
62482948|NCT05456763|EXPERIMENTAL|group A|150 mg sodium butyrate twice a day for 12 weeks
62482949|NCT05456763|PLACEBO_COMPARATOR|group B|placebo capsules twice a day for 12 weeks
62482950|NCT06377410|ACTIVE_COMPARATOR|Participant with stable COPD who received Syrup prospan|Participant who fulfiled inclusion criteria with stable COPD and received Syrup prospan for 1 month
62482951|NCT06377410|ACTIVE_COMPARATOR|Participant with stable COPD who received N-Acetylcysteine|Participant who fulfiled inclusion criteria with stable COPD and received SN-Acetylcysteine for 1 month
62482952|NCT02623413||Sites implementing contact precautions|"Centers isolating for VRE may only participate if complying with the following standards:~* Contact precautions triggered by the initial detection of VRE~* Patients discharged as a VRE-carrier must be placed in contact isolation upon readmission~* Termination of contact precautions after at least two consecutive VRE-negative consecutive fecal screening cultures~* Resumption of contact isolation on first subsequent VRE-positive culture~Contact precautions must encompass the following measures:~* Patients: Placement in single rooms. Cohorting is only permitted, in case of unavailability of single rooms~* Staff and visitors: Wearing of gloves and gowns when entering the room.~* Patients: Wearing of gloves and gowns when leaving the room."
62482953|NCT02623413||Sites not implementing contact precautions|Only VRE colonized or infected patients with urinary or fecal incontinence or diarrhea (defined as \> 3 loose bowel movements/day), must be isolated in single rooms at any time during the study.
62697508|NCT01573429|OTHER|Oral arm|d-BPA administered orally
62697509|NCT02329587|EXPERIMENTAL|ERP plus tDCS|ERP plus anodal tDCS of right inferior frontal gyrus
62482954|NCT03138967|EXPERIMENTAL|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
62482955|NCT03138967|ACTIVE_COMPARATOR|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
61929730|NCT04513717|EXPERIMENTAL|Arm IV (intensification study)|Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
61929731|NCT00923936|ACTIVE_COMPARATOR|KS;classic/HIV+not improved on antiviral|Kaposi's Sarcoma (KS) in patients who are Human immunodeficiency virus (HIV) Negative, HIV infected with stable disease for one year despite antiretroviral therapy or progressive disease despite 4 months of antiretroviral therapy.
62482956|NCT05913128|ACTIVE_COMPARATOR|First arm|Glandular Urethral Disassembly technique
62482957|NCT05913128|ACTIVE_COMPARATOR|Second arm|Tubularized Incised Plate technique
62691493|NCT05722769|ACTIVE_COMPARATOR|Prevent Child Abuse Kentucky Online Training|With input from Prevent Child Abuse Kentucky, our team developed training delivered via LMS and designed to identify child sex trafficking among middle school students. Only for middle school staff in counties randomized to the active comparator, we offer this online training using the same approach as that for staff in the intervention condition.
62691494|NCT06313866|NO_INTERVENTION|control|Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.
61929732|NCT00923936|ACTIVE_COMPARATOR|All other advanced HIV-asociated KS|All other patients with advanced acquired immune deficiency syndrome (AIDS)-associated KS
61929733|NCT06707909|ACTIVE_COMPARATOR|Menaquinone group|"Tooth extraction will perform under local anesthesia All sockets were thoroughly curetted to remove granulation tissue, followed by irrigation and rinsing with sterile saline. the socket will be filled with crushed capsule of vitamin k2(menaquinone) and cover with an absorbent sponge a Figure of eight tension-free non-resorbable 3-0 sutures will be placed over the filled socket to stabilize the graft material in the socket and to achieve soft tissue stability.~Bone density and socket dimensions will be evaluated immediately after extraction with graft material and after 4 months by using a cone beam computed tomography (CBCT) radiograph and at the time of implant placement core biopsy will be taken for histomorphometric analysis."
62323796|NCT04914637|ACTIVE_COMPARATOR|interlaminar epidural steroid injection plus dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. Also, dry needling will be applied to the active trigger points for the patients in this group.~Interlaminar epidural steroid injection will be applied at week 0, while dry needling will be applied in 3 sessions per week (week 0, week 1, week 2). The first session of the dry needling will be in the same day with interlaminar epidural steroid injection."
62323797|NCT04914637|SHAM_COMPARATOR|interlaminar epidural steroid injection plus sham dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered same as the arm titled interlaminar epidural steroid injection plus dry needling. The only difference in the interventions in this arm is that dry needling is applied without penetrating the skin. The blunt tip of the needle will be used in sham intervention.~Interlaminar epidural steroid injection will be applied at week 0, while sham dry needling will be applied in 3 sessions per week (week 0, week 1, week 2)"
62323798|NCT04914637|OTHER|interlaminar epidural steroid injection only|Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). No dry needling or sham dry needling will be used.
62339902|NCT03206242||initial|0 month begin physiotherapy
62339903|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
61929734|NCT06707909|NO_INTERVENTION|control group|"Tooth extraction will perform under local anesthesia All sockets were thoroughly curetted to remove granulation tissue, followed by irrigation and rinsing with sterile saline. the socket will be left to heal without grafting, and it will be covered with an absorbent sponge. A figure-of-eight tension-free non-resorbable 3-0 sutures will be placed over the socket.~Bone density and socket dimensions will be evaluated immediately after extraction with graft material and after 4 months by using a cone beam computed tomography (CBCT) radiograph and at the time of implant placement core biopsy will be taken for histomorphometric analysis."
61929735|NCT05298878|EXPERIMENTAL|Virtual home-based rehabilitation plus usual outpatient care|An 8-week home-based virtual rehabilitation program consisting of exercises and education plus usual care.
61929736|NCT05298878|NO_INTERVENTION|Usual outpatient care|The control group will receive usual outpatient care which consists of any medical outpatient follow-up visits. The participants will receive a set of written generic instructions on how to manage symptoms and engage in physical activity after critical illness.
61929737|NCT05408845|ACTIVE_COMPARATOR|Arm I (docetaxel, trastuzumab)|Patients receive docetaxel IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive trastuzumab IV over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62339904|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
62691495|NCT06313866|EXPERIMENTAL|Electronuchal acupuncture group treatment|Use the neck needle to take the Fengchi and Gongxue on both sides (1.5cm directly below Fengchi point).
61929738|NCT05408845|EXPERIMENTAL|Arm II (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61929739|NCT03070886|ACTIVE_COMPARATOR|Arm I (androgen deprivation therapy, EBRT)|Patients receive androgen deprivation therapy comprising leuprolide acetate, goserelin acetate, degarelix, bicalutamide, flutamide, or nilutamide for 6 months. Beginning 8 weeks after the start of androgen deprivation therapy, patients receive EBRT for 7.5 weeks.
61929740|NCT03070886|EXPERIMENTAL|Arm II (androgen deprivation therapy, EBRT, docetaxel)|Patients receive androgen deprivation therapy and EBRT as in Arm I. Within 4-6 weeks after completion of radiation therapy, patients receive docetaxel IV over 1 hour on day 1 of every 21 days for 6 cycless in the absence of disease progression or unexpected toxicity.
61929741|NCT02826850|SHAM_COMPARATOR|Genicular nerves|Neurotomy by radiofrequency of genicular nerves knee guided by fluoroscopy
61929742|NCT02826850|ACTIVE_COMPARATOR|Saphenous Nerve|Neurotomy of saphenous nerve by radiofrequency on the distal third of the thigh, guided by ultrasound
61929743|NCT05090124|EXPERIMENTAL|anti-TNF treatment|"Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. The actual Adalimumab product selected at site will be dictated by what is used in standard care.~The single-use, pre-filled syringe will be removed from storage at 2-8oC at least 30 minutes prior to administration to allow the contents to come to room temperature. The pre-filled syringe will be visually inspected for discolouration and particulates as per the product Summary of Product Characteristics.To facilitate maintenance of the blind, the pre-filled syringe (PFS) presentation will be used. The pen presentation will not be used."
61929744|NCT05090124|PLACEBO_COMPARATOR|Placebo|Sodium chloride 0.9% for injection will be used as a placebo to adalimumab. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. Prior to administration, the prepared placebo syringe will be visually inspected for discolouration and particulate matter prior to administration.
61929745|NCT02933580|EXPERIMENTAL|Cohort A: JNJ-56136379 (25 mg) or Placebo|Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1\*25-mg tablet) or placebo on Day 1, fasted conditions.
61929746|NCT02933580|EXPERIMENTAL|Cohort B: JNJ-56136379 (150 mg) or Placebo|Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2\* 25-mg tablet and 1\*100-mg tablet) or placebo on Day 1, fasted conditions.
61929747|NCT02933580|EXPERIMENTAL|Cohort C: JNJ-56136379 (300 mg) or Placebo|Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3\*100-mg tablet) or placebo on Day 1, fasted conditions.
62131942|NCT03818893|EXPERIMENTAL|New Combination Immunotherapy|"Patients will receive Pembrolizumab once every 3 weeks and a maximum of 35 doses over 105 weeks .~The patients should be inpatient during treatment with GEN0101 in each treatment cycle and may be outpatient during off-treatment period with GEN0101, observation period, follow-up period with Pembrolizumab.~GEN0101 in a vial will be reconstituted with 1 mL of sterile distilled water and then will be injected intracutaneously (including skin tumor site). Nonetheless, it will not be deemed as deviation if an injection has been given subcutaneously unintentionally, e.g., leakage around the peri-injection sites.~A dose will be 60,000 mNAU in total, and 1 mL per injection site should be administered to 6 injection sites in total. For a patient, the total dose in a treatment cycle will be 360,000 mNAU (360 NAU), and the total dose over 2 treatment cycles will be 720,000 mNAU (720 NAU)."
62131943|NCT05810194||StrataXRT|
62131944|NCT05810194||Standard of care|
62482958|NCT04571684|EXPERIMENTAL|Intervention Arm (HITSystem 2.1)|Participants enrolled at intervention sites will received HITSystem 2.1-supported PMTCT services through 6 months postpartum. Interventions received will include: text messages to patients to support medication adherence, appointment attendance, and hospital delivery and algorithm-driven alerts to notify providers when follow up services are missed.
62482959|NCT04571684|NO_INTERVENTION|Control Arm (Standard of care)|Participants enrolled at control sites will receive standard of care PMTCT services, with no HITSystem 2.1 tracking or follow up.
61929748|NCT02933580|EXPERIMENTAL|Cohort D: JNJ-56136379 (600 mg) or Placebo|Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6\*100-mg tablet) or placebo on Day 1, fasted conditions.
61929749|NCT06511895|EXPERIMENTAL|AZD4205 treatment|Cohort 1: Newly enrolled participants with r/r PTCL who were never exposed to AZD4205 (receive 150 mg or 75 mg). Cohort 2: Participants from other completed AZD4205 study if they are still benefiting from AZD4205 (receive 150 mg).
61929750|NCT06709716|EXPERIMENTAL|Preoperative QL block with liposomal bupivacaine, intra-operative incisional injections with placebo|Subjects will receive a pre-operative quadratus lumborum nerve block with liposomal bupivacaine and then an intra-operative placebo injection at each incision site with saline.
61929751|NCT06709716|ACTIVE_COMPARATOR|Preoperative QL block with placebo, intra-operative incisional injection with bupivacaine|Subjects will undergo a sham pre-operative quadratus lumborum block procedure with saline and then an intra-operative injection of local anesthetic (0.25% bupivacaine) at each incision site.
61929752|NCT00846287|ACTIVE_COMPARATOR|Drug Subjects|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. BROVANA (arformoterol tartrate) Inhalation Solution is supplied as 2 mL of arformoterol tartrate solution packaged in 2.1 mL unit-dose, low-density polyethylene (LDPE) unit-dose vials. Each unit-dose vial contains 15 mcg of arformoterol (equivalent to 22 mcg of arformoterol tartrate) in a sterile, isotonic saline solution, pH-adjusted to 5.0 with citric acid and sodium citrate. After administration of the drug, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
62131945|NCT01178034|EXPERIMENTAL|pharmacogenetic warfarin dose|Warfarin maintenance dose on the basis of demographic/pharmacogenetic data
62339905|NCT01019486|EXPERIMENTAL|Type 1 Diabetic Subjects|Regadenoson 400mcg slow IV bolus to identify assess myocardial blood flow (MBF). Stratified by coronary calcium score of below 100 or greater than score of 100 for low and high risk individuals respectively.
62482960|NCT01746056|ACTIVE_COMPARATOR|Heat Patch Continuous|applied 2 hrs daily for 12 weeks
62697510|NCT02329587|ACTIVE_COMPARATOR|ERP plus sham tDCS|ERP plus sham tDCS of right inferior frontal gyrus
62482961|NCT01746056|ACTIVE_COMPARATOR|Heat Patch Noncontinuous|applied 2 hrs daily 2 weeks on and 2 weeks off for 12 weeks
62482962|NCT02630797|PLACEBO_COMPARATOR|Blueberry baseline|No blueberry products provided as part of the usual dietary intake
61929753|NCT00846287|PLACEBO_COMPARATOR|Saline|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the placebo (nebulized saline solution) will be administered (2.1 mL). After administration of the placebo, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
61929754|NCT03091660|ACTIVE_COMPARATOR|Arm I (BCG solution)|INDUCTION: Patients receive TICE BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive TICE BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
62323799|NCT01572532|EXPERIMENTAL|Intervention Screening and Treatment|"CHWs will collect urine and vaginal samples for all women enrolled. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison. Vaginal specimens will be collected via sterile self-administered vaginal swabs. The women will be instructed by the CHW to insert a Dacron swab \~4-5 cm into the vagina, allow the swab to stand for 15 seconds, and then rotate 360 degrees prior to withdrawal. The CHW will gently roll out the swab onto a plain glass slide and allow to air dry prior to transport to Sylhet field laboratory.~A midstream urine specimen will be obtained for urine culture. The mother will be instructed to separate the labia and collect 20-30mL of midstream urine into a sterile container which will be immediately refrigerated in a cool specimen box."
62323800|NCT01572532|NO_INTERVENTION|Control Arm|Standard care will be administered, including antenatal and postnatal care. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison.
62323801|NCT03238235|EXPERIMENTAL|Givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
62323802|NCT03238235|PLACEBO_COMPARATOR|Placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
62323803|NCT06693661|OTHER|Intervention: Kidney Health Coaching|Participants will receive patient-centered health coaching delivered by two full-time kidney health coaches for six months.
62323804|NCT06693661|OTHER|Control: Usual Care|Participants will receive usual care based on where patients are identified (Emergency Room- ER, Primary Care, Hospital Discharge, Primary Care, or Nephrology)
62323805|NCT00814073|EXPERIMENTAL|Masitinib & BSC|Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
62323806|NCT00814073|PLACEBO_COMPARATOR|Placebo & BSC|Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
62323807|NCT02151409|EXPERIMENTAL|NNC 0151-0000-0000 i.v.|Dose escalation trial
62323808|NCT02151409|EXPERIMENTAL|NNC 0151-0000-0000 s.c.|Dose escalation trial
62323809|NCT02151409|PLACEBO_COMPARATOR|Placebo|
62323810|NCT05041374||Study Cohort|Patients with known or suspected gastrointestinal disease
62323811|NCT04174638|EXPERIMENTAL|"Intervention Group"|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring.
62482963|NCT02630797|ACTIVE_COMPARATOR|Blueberry Low|One blueberry product per day containing an equivalent of 0.75 cups of fresh blueberries provided as part of usual dietary intake for 42 days
62482964|NCT02630797|ACTIVE_COMPARATOR|Blueberry Medium|Two blueberry products per day containing an equivalent of 1.5 cups of fresh blueberries provided as part of usual dietary intake for 42 days
62482965|NCT02630797|ACTIVE_COMPARATOR|Blueberry High|Four blueberry products per day containing an equivalent of 3 cups of fresh blueberries provided as part of usual dietary intake for 42 days
62482966|NCT05911152||Intracorporeal anastomosis|Patients underwent laparoscopic colorectal surgery with intracorporeal anastomosis
61929755|NCT03091660|EXPERIMENTAL|Arm II (Tokyo-172 strain BCG solution)|INDUCTION: Patients receive Tokyo-172 strain BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
61929756|NCT03091660|EXPERIMENTAL|Arm III (Tokyo-172 strain BCG solution with priming)|PRIME: Patients receive Tokyo-172 strain BCG vaccine once ID. INDUCTION: Within 21 days, patients receive Tokyo-172 strain BCG solution as in Arm II. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution as in Arm II.
62323812|NCT04174638|NO_INTERVENTION|"Control Group"|The control group received routine hemodialysis treatment and nursing care in the hemodialysis unit.
62323813|NCT04468958|EXPERIMENTAL|10mg/kg SAB-185|10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)
62323814|NCT04468958|EXPERIMENTAL|25mg/kg SAB-185|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
62323815|NCT04468958|EXPERIMENTAL|25mg/kg SAB-185 x 2 doses|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%). Cohort 3 will receive a second 25mg/kg dose of SAB-185 7 days (+/-2) after the first treatment.
62482967|NCT05911152||Extracorporeal anastomosis|Patients underwent laparoscopic colorectal surgery with extracorporeal anastomosis
62482968|NCT05628103|EXPERIMENTAL|SEP-363856|SEP-363856 flexibly dosed
62482969|NCT04281472|EXPERIMENTAL|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC in both stage A as stage B
62697511|NCT05852431|EXPERIMENTAL|Pegozafermin - 30mg once a week|
62323816|NCT04468958|EXPERIMENTAL|50mg/kg SAB-185|50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
62323817|NCT04468958|PLACEBO_COMPARATOR|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
62323818|NCT04969016|EXPERIMENTAL|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
62323819|NCT04969016|ACTIVE_COMPARATOR|Stapler|surgical wound closure with stapler
62323820|NCT04628559|ACTIVE_COMPARATOR|Dexmedetomine|Patients recieving Dexmedetomidine.
62323821|NCT04628559|ACTIVE_COMPARATOR|Ketamine|Patients recieving Ketamine.
62323822|NCT04628559|PLACEBO_COMPARATOR|Placebo|Patients recieving Saline.
62482970|NCT04281472|PLACEBO_COMPARATOR|Placebo|patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B
62482971|NCT01712906|EXPERIMENTAL|3.50±0.25logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.
62482972|NCT01712906|EXPERIMENTAL|4.25±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
62482973|NCT01712906|EXPERIMENTAL|5.00±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
62482974|NCT01712906|PLACEBO_COMPARATOR|0 logCCID50/ml in adults|0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.
61929757|NCT02179086|ACTIVE_COMPARATOR|Arm A1 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
61929758|NCT02179086|EXPERIMENTAL|Arm B (photon IMRT)|"Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
61929759|NCT02179086|ACTIVE_COMPARATOR|Arm A2 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
62482975|NCT01712906|EXPERIMENTAL|3.50±0.25logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.
62482976|NCT01712906|EXPERIMENTAL|4.25±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
61929760|NCT02179086|EXPERIMENTAL|Arm C (proton beam radiation therapy)|"Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
62131946|NCT05957731|EXPERIMENTAL|Agonist Contract-relax group:|"In the agonist contract-relax group, participants were positioned in a supine position. A trained physiotherapist then passively dorsiflexed the ankle to its maximum available range and held it for 15 seconds, while ensuring that the knee remained straight by placing a hand on it. Following this, participants were instructed to perform a maximal voluntary isometric~35~contraction of the planter flexors for five seconds, while maintaining the stretched position.~After a 30-second rest period, the physiotherapist returned the ankle to the starting position of 0 degrees and repeat the procedure without any rest. This stretching protocol was repeated four times, with each repetition lasting 2 minutes. For the soleus muscles, the same procedure was performed, but with a slightly flexed initial position of the knee."
62323823|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
62323824|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
62323825|NCT03909763|EXPERIMENTAL|Berberine plus danazol|Berberine plus danazol group
62323826|NCT04362579||Subjects seen in hospital|Subjects will be recruited from Prentice Women's Hospital inpatient antepartum and labor and delivery services, and the outpatient Obstetrics and Gynecology practice, located within Galter tower with the assistance of staff.
62482977|NCT01712906|EXPERIMENTAL|5.00±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
62323827|NCT04362579||Home Study subjects|Subjects will be prescreened by an IRB approved staff and recruited from Prentice Women's Hospital's Department of Obstetrics and Gynecology.
62339906|NCT01019486|ACTIVE_COMPARATOR|Nondiabetic Subjects|Regadenoson myocardial perfusion imaging (MPI) Intervention: Regadenoson (400mcg slow IV bolus) stress to assess myocardial blood flow (MBF) and MPI to identify occult coronary artery disease (CAD). These individuals serve as an active control with higher risk non-diabetic individuals with scores greater than 100.
62482978|NCT01712906|PLACEBO_COMPARATOR|0 logCCID50/ml in children (5-15 years old)|0 logCCID50/ml in 18 children aged 5-15 years old on day 0.
62482979|NCT01712906|EXPERIMENTAL|3.50±0.25logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.
61929761|NCT06296381||Patients in the ICU|The ICU sample will comprised patients of both sexes, aged between 18 and 90 years old, able to do volitional tests and without barriers to the assessment of peripheral muscle strength.
62482980|NCT01712906|EXPERIMENTAL|4.25±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
62482981|NCT01712906|EXPERIMENTAL|5.00±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
62482982|NCT01712906|PLACEBO_COMPARATOR|0 logCCID50/ml in children (2-4 years old)|0 logCCID50/ml in 18 children aged 2-4 years old on day 0.
62482983|NCT01712906|ACTIVE_COMPARATOR|Attenuated Mumps vaccine in children (2-4 years old)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.
62482984|NCT01712906|EXPERIMENTAL|3.50±0.25logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.
62482985|NCT01712906|EXPERIMENTAL|4.25±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
62482986|NCT01712906|EXPERIMENTAL|5.00±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
62482987|NCT01712906|PLACEBO_COMPARATOR|0 logCCID50/ml in infants|0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.
62697512|NCT05852431|EXPERIMENTAL|Pegozafermin - 20mg once a week|
62482988|NCT01712906|ACTIVE_COMPARATOR|Attenuated Mumps vaccine in infants|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.
62482989|NCT02742194|PLACEBO_COMPARATOR|Placebo|Conventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.
62482990|NCT02742194|EXPERIMENTAL|Ginger group|Conventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
61929762|NCT06296381||Healthy Participants|The healthy sample will comprised volunteers of both sexes, aged between 18 and 90 years old, able to do volitional tests and without barriers to the assessment of peripheral muscle strength.
61929763|NCT01462786|EXPERIMENTAL|ATX-101 in abdomen area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
61929764|NCT01462786|EXPERIMENTAL|ATX-101 in submental area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
61929765|NCT02981810|ACTIVE_COMPARATOR|control|tonsillectomy
61929766|NCT02981810|EXPERIMENTAL|coblation|coblation of the tonsills
61929767|NCT05871996||Group 1|Individuals with a diagnosis of cancer known to palliative care services. This group completes Case Report Form for Group 1.
61929768|NCT05871996||Group 2|"Individuals with a diagnosis of cancer receiving anti-cancer treatment known to oncology services.~This group completes Case Report Form for Group 2"
61929769|NCT02316912|ACTIVE_COMPARATOR|Single dose level 1 active|Six subjects ATX2417 I mg tablet once.
61929770|NCT02316912|ACTIVE_COMPARATOR|Single dose level 2 active|Six subjects ATX2417 2x1 mg tablet once.
61929771|NCT02316912|ACTIVE_COMPARATOR|Single dose level 3 active|Six subjects ATX2417 5 mg tablet once.
61929772|NCT02316912|ACTIVE_COMPARATOR|Single dose level 4 active|Six subjects ATX2417 4x5 mg tablets once.
61929773|NCT02316912|ACTIVE_COMPARATOR|Single dose level 5 active|Six subjects ATX2417 to be determined.
61929774|NCT02316912|ACTIVE_COMPARATOR|Multiple dose level 1 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
61929775|NCT02316912|ACTIVE_COMPARATOR|Multiple dose level 2 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
61929776|NCT02316912|PLACEBO_COMPARATOR|Single dose level 1 placebo|Two subjects one placebo tablet once.
61929777|NCT02316912|PLACEBO_COMPARATOR|Single dose level 2 placebo|Two subjects one placebo tablet x2 once.
61929778|NCT02316912|PLACEBO_COMPARATOR|Single dose level 3 placebo|Two subjects one placebo tablet once.
61929779|NCT02316912|PLACEBO_COMPARATOR|Single dose level 4 placebo|Two subjects two placebo tablets once.
62482991|NCT01463579|EXPERIMENTAL|Exercise programme|
61929780|NCT02316912|PLACEBO_COMPARATOR|Single dose level 5 placebo|Two subjects four placebo tablets once.
61929781|NCT02316912|PLACEBO_COMPARATOR|Multiple dose level 1 placebo|Two subjects matching placebo(s) once daily for 8 days
62482992|NCT01463579|OTHER|Standard Care|
62482993|NCT04185272|EXPERIMENTAL|non-metastatic colon cancer|
62482994|NCT04185272|EXPERIMENTAL|metastatic colon cancer|
62482995|NCT03999216|ACTIVE_COMPARATOR|Loop only|Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.
62482996|NCT03999216|ACTIVE_COMPARATOR|Loop + Thiazide|Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.
62482997|NCT05594238|ACTIVE_COMPARATOR|Arm A|First stage intervention: Telephone engagement Second stage intervention: Telehealth Motivational Interviewing-Cognitive Behavioral Therapy (MI-CBT program)
61929782|NCT02316912|PLACEBO_COMPARATOR|Multiple dose level 2 placebo|Two subjects matching placebo(s) once daily for 8 days.
61929783|NCT02316912|ACTIVE_COMPARATOR|Single dose level 6 active|Six subjects ATX2417 to be determined.
61929784|NCT02316912|ACTIVE_COMPARATOR|Single dose level 7 active|Six subjects ATX2417 to be determined.
61929785|NCT02316912|PLACEBO_COMPARATOR|Single dose level 6 placebo|Six subjects placeboto be determined.
61929786|NCT02316912|PLACEBO_COMPARATOR|Single dose level 7 placebo|Six subjects placebo to be determined.
61929787|NCT05953376|EXPERIMENTAL|Empiric calcium administration|Patients in this arm will receive 2g IV calcium with the initial transfusion
61929788|NCT05953376|NO_INTERVENTION|No empiric calcium administration|Patients in this arm will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion
61929789|NCT02730520||Immuno-allergology patients|Patients followed within the Immuno-Allergology Service of the CHU Brugmann Hospital, who received an allergy assessment between 01/01/2015 and 31/12/2015. At least 1400 dermis will be analyzed. The allergens tested include: dermatophagoides pteronyssinus (DEPT), dermatophagoides farinae (DPF), blomia, cat, dog, cockroach, orchardgrass, timothy grass, alder, hazel,birch, olive tree, cypress, ash, latex, aspergillus, alternaria, cladosporium, peanut, hazel.
61929790|NCT02692885||Healthy Volunteers|Individuals known to have brown adipose tissue, identified by PET/CT following participation/scanning in other clinical studies
61929791|NCT02692885||Surgical Patients|Individuals undergoing planned, clinically-indicated surgeries
61929792|NCT06132399|ACTIVE_COMPARATOR|Commercial non-immersive virtual reality group (CVR)|Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan).
61929793|NCT06132399|EXPERIMENTAL|Gamified, fully immersive and stroke-specific virtual reality group (RESET)|The RESET virtual reality software will be integrated in the META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US).
61929794|NCT06132399|ACTIVE_COMPARATOR|Usual care (UC)|3 session/week of 90 minutes of physical therapy and occupational therapy.
61929795|NCT06497231|ACTIVE_COMPARATOR|Bioactive Giomer Material|Deep margin elevation and subsequent restoration will be done using bioactive giomer material
61929796|NCT06497231|ACTIVE_COMPARATOR|Nanohybrid resin composite|Deep margin elevation and subsequent restoration will be done using nanohybrid resin composite
62482998|NCT05594238|ACTIVE_COMPARATOR|Arm B|First stage intervention: Telephone engagement Second stage intervention: Enhanced Telephone engagement
62697513|NCT05852431|PLACEBO_COMPARATOR|Placebo once a week|
62323828|NCT05346952|EXPERIMENTAL|TQB2450 injection + carboplatin + pemetrexed|TQB2450 injection：1200 mg, Intravenous drip d1； carboplatin ：Area Under Curve 5mg/mL/min，Intravenous drip d1；Pemetrexed: 500mg/m2，Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to TQB2450 injection（1200 mg, Intravenous drip d1）+Pemetrexed（500mg/m2，Intravenous drip d1）+ Anlotinib (10mg, peros every day, d1-14) . The regimen is repeated every 3 weeks until the disease progresses.
62323829|NCT05346952|ACTIVE_COMPARATOR|TQB2450 injection + Anlotinib + Pemetrexed|Tilelizumab: 200 mg, Intravenous drip d1;carboplatin : AUC 5mg/mL/min, Intravenous drip d1；Pemetrexed: 500mg/m2, Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to Tilelizumab (200 mg, Intravenous drip d1)+Pemetrexed (500mg/m2，Intravenous drip d1).The regimen is repeated every 3 weeks until the disease progresses.
62482999|NCT05594238|ACTIVE_COMPARATOR|Arm C|First stage intervention: Telephone engagement Second stage intervention: Not Applicable (NA), proceed directly to follow up
62483000|NCT05594238|ACTIVE_COMPARATOR|Arm D|First stage intervention: Portal Engagement Second stage intervention: NA, proceed directly to follow up
62483001|NCT05594238|ACTIVE_COMPARATOR|Arm E|First stage intervention: Portal Engagement Second stage intervention: Enhanced Portal Engagement
62483002|NCT05594238|ACTIVE_COMPARATOR|Arm F|First stage intervention: Portal Engagement Second stage intervention: Telehealth MI-CBT program
62483003|NCT03639077|EXPERIMENTAL|Allograft bone alone|
62483004|NCT03639077|EXPERIMENTAL|Allograft and xenograft mixture|
62483005|NCT03997019|ACTIVE_COMPARATOR|group A|opioid analgesia
62483006|NCT03997019|ACTIVE_COMPARATOR|group B|ESP block
62483007|NCT06152796|EXPERIMENTAL|Paracetamol|preterms receive oral/iv paracetamol at the dose of 15 mg/kg every 6 h for 3 days.
62483008|NCT06152796|EXPERIMENTAL|Ibuprofen|preterms receive oral ibuprofen at the initial dose 10 mg/kg, followed by 5 mg/kg after 24 and 48 h
62483009|NCT00467103||Chronic Stroke patients with Nonfluent Aphasia|patients with left hemisphere (LH) stroke who have chronic nonfluent aphasia
62483010|NCT05892081|NO_INTERVENTION|Control group|The control group received the usual care of the unit.
62483011|NCT05892081|EXPERIMENTAL|Colloid group|Received cold cream three times a day on the rash area while diaper changing by the researcher plus the usual care
62483012|NCT05892081|EXPERIMENTAL|Colloid oatmeal group|Received colloid oatmeal cream three times a day on the rash area while diaper changing by the researcher plus the usual care
62483013|NCT05692362||Healthy People|People with solitary pulmonary nodule， without any other pulmonary diseases.
62483014|NCT05692362||Chronic Airway Diease People|People with COPD or Asthma
62691496|NCT06313866|EXPERIMENTAL|Smell therapy group treatment|The volatile oil of Acorus calamus is packed in the sniffer. Smell at the sniffing end, breathe evenly, 5-10 minutes each time, 3-5 times a day, for a total of 4 weeks of treatment.
61929797|NCT03453411||Non interventional study|
61929798|NCT06708754|EXPERIMENTAL|Active Treatment: PBM Therapy|"Participants who received bilateral neck RT will be treated with PBM to a total of 12 sites - 6 sites on each side of the neck and face along the 3 neck nodal levels (II, III, IV) of the sternocleidomastoid muscle (SCM), along the major salivary glands (parotid, and submandibular) and masseter\].~Treatment will occur at two timepoints:~* At least 3 months and less than 18 months after RT completion of last dose to any site~* Between 18 and 36 months after RT completion of last dose to any site"
62131947|NCT05957731|EXPERIMENTAL|Antagonist contract-relax group:|"In the antagonist stretching groups, participants were positioned in a supine position. A trained physiotherapist stretched the antagonist\&#39;s muscle, and then participants were instructed to perform a maximal voluntary isometric contraction of dorsiflexion for 5 seconds while maintaining a stretched position. The knee was kept straight during this contraction.~Following the contraction, the physiotherapist held the ankle at that angle for another 10 seconds by placing a hand on it. After a 30-second rest period, the physiotherapist returned the ankle to the starting position of 0 degrees and repeat the procedure without any rest intervals."
62323830|NCT04722393|EXPERIMENTAL|Pulmonary Rehabilitation Group|An 8-week comprehensive outpatient PR program including respiratory exercises, aerobic and strengthening training
62323831|NCT04722393|OTHER|Control Group|Respiratory exercises
62483015|NCT05692362||Pulmonary fibrosis people|People were diagnosised pulmonary fibrosis by chest Computer Tomography, and restrictive ventilatory impairment by pulmonary function test.
62483016|NCT03596567|EXPERIMENTAL|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of =\> 90 ml/min
62483017|NCT03596567|EXPERIMENTAL|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of =\> 30ml/min and \< 60 ml/min
62483018|NCT03596567|EXPERIMENTAL|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of \< 30 ml/min and not requiring dialysis
62483019|NCT04211779|EXPERIMENTAL|Real tDCS and Exercise|tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and active tDCS intervention at the same time.
62483020|NCT04211779|SHAM_COMPARATOR|Sham tDCS and Exercise|Sham tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and sham tDCS intervention at the same time.
62483021|NCT04211779|OTHER|Exercise|Exercise group in which will receive the active intervention of aerobic exercise training no tDCS intervention.
62483022|NCT01960296|EXPERIMENTAL|Clopidogrel|Continue home dose of clopidogrel into surgery
62483023|NCT01960296|ACTIVE_COMPARATOR|Discontinue|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
62483024|NCT04676503|EXPERIMENTAL|Test Arm - Biovaginil 480 mg capsules|All patients will be treated with 1 capsule/day of BIOVAGINIL for two treatment cycles of 14 days each.
62483025|NCT00792753|EXPERIMENTAL|1. DESyne DES|Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System
62483026|NCT00792753|ACTIVE_COMPARATOR|2. Medtronic Endeavor DES|Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System
62691497|NCT06313866|EXPERIMENTAL|The combined treatment|The electro-neuchal acupuncture combined with sniffing and suction therapy group is treated with sniffing and suction therapy on the basis of electro-neuchal acupuncture treatment.
61929799|NCT06708754|SHAM_COMPARATOR|Sham Treatment|"Participants who received bilateral neck RT will be treated with SHAM PBM to a total of 12 sites - 6 sites on each side of the neck and face along the 3 neck nodal levels (II, III, IV) of the sternocleidomastoid muscle (SCM), along the major salivary glands (parotid, and submandibular) and masseter\].~Treatment will occur at two timepoints:~* At least 3 months and less than 18 months after RT completion of last dose to any site~* Between 18 and 36 months after RT completion of last dose to any site"
61929800|NCT05935722|EXPERIMENTAL|Parenting Young Children|Home based parenting programme for supporting parent with IDDs. 3-6 months of structured coaching sessions.
61929801|NCT05935722|ACTIVE_COMPARATOR|Treatment as Usual|Variety of interventions as usually provided by the social services.
61929802|NCT03035409|EXPERIMENTAL|Supportive Care (anamorelin, physical activity, counseling)|Patients receive anamorelin hydrochloride PO QD and undergo physical activity consisting of resistance exercises and a home walking program. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo nutritional counseling on day 21.
61929803|NCT05057715|ACTIVE_COMPARATOR|Cohort 1|Single dose of 3.3x10(12) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
61929804|NCT05057715|ACTIVE_COMPARATOR|Cohort 2|Single dose of 1x10(13) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
61929805|NCT05057715|ACTIVE_COMPARATOR|Cohort -1|In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.
62131948|NCT02001818|EXPERIMENTAL|Nilotinib or Imatinib with Peginterferon|"Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration).~Patients intolerant of nilotinib may be switched to appropriate doses of imatinib"
62131949|NCT00756067|EXPERIMENTAL|Formulation 1|
62131950|NCT00756067|EXPERIMENTAL|Formulation 2|
62131951|NCT00756067|EXPERIMENTAL|Formulation 3|
62131952|NCT00756067|EXPERIMENTAL|Formulation 4|
62131953|NCT00756067|EXPERIMENTAL|Formulation 5|
62131954|NCT00756067|EXPERIMENTAL|Formulation 6|
61929806|NCT05425589|OTHER|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
61929807|NCT06708507||Grade 3-4 aGVHD patients|
61929808|NCT06708507||Grade 1-2 aGVHD patients|
61929809|NCT05511519|EXPERIMENTAL|ATI-450|ATI-450 50mg oral tablet BID
61929810|NCT05511519|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet BID
61929811|NCT06557174|EXPERIMENTAL|IMC-002|intravenous injection of 0.8mg/kg、1.2mg/kg
61929812|NCT06557174|ACTIVE_COMPARATOR|mycophenolate mofetil， MMF|mycophenolate mofetil will be administrated as monotherapy control for 0.2g daily oral.
61929813|NCT00519298|EXPERIMENTAL|1|
61929814|NCT00519298|PLACEBO_COMPARATOR|2|
61929815|NCT00519298|ACTIVE_COMPARATOR|3|
61929816|NCT03811535|EXPERIMENTAL|Somapacitan weekly|Participants will receive somapacitan weekly for 52 weeks (main trial period). Participants completing the main trial period in both the treatment arms ('Somapacitan weekly' and 'Norditropin® daily') will receive somapacitan weekly for 3 years (extension trial period).
61929817|NCT03811535|ACTIVE_COMPARATOR|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks (main trial period).
61929818|NCT04831606|ACTIVE_COMPARATOR|Control Arm|Patients will receive a biweekly standard treatment at home according to the International Working Group on Diabetic Foot consisting of: Debridement of the lesion, unloading with a brace up to the calf, non-removable (except for contraindications), dressing of the wound with advanced dressings in use at the specialized center and in the home care network.
61929819|NCT04831606|EXPERIMENTAL|EmoLED Arm|Patients on top of the standard treatment of the control arm will receive EmoLED blue light irradiation for two minutes at each biweekly medication.
61929820|NCT04386057|EXPERIMENTAL|Safety Lead-In Cohort|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis.~Test the safety of study drugs in combination and define dose levels.~* LY3214996~* HCQ"
61929821|NCT04386057|EXPERIMENTAL|LY3214996 and HCQ Combination|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis. Combined dosage per determined Lead-In Cohort~* LY3214996~* HCQ"
61929822|NCT04386057|EXPERIMENTAL|LY3214996-Monotherapy|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days.Treatment will be administered on an outpatient basis.~-LY3214996"
62131955|NCT00756067|ACTIVE_COMPARATOR|23 valent pneumococcal vaccine|
62131956|NCT00806169|EXPERIMENTAL|1|group I (n=17) nonproliferative DR and ischemic maculopathy
62131957|NCT00806169|EXPERIMENTAL|2|group II (n=38) nonproliferative DR without ischemic maculopathy
62131958|NCT00806169|EXPERIMENTAL|3|group III (n=18) proliferative DR with or without ischemic maculopathy
62131959|NCT03478917||Arm 1|Subjects previously enrolled onto protocol 05-H-0019 who were hospitalized with vasoocclusivecrisis.
62131960|NCT06403020|ACTIVE_COMPARATOR|Group Q|Group Q (n=23) will have a qadratus lumboroum (QL) block.
62131961|NCT06403020|ACTIVE_COMPARATOR|Group R|Group R (n=23) will have a rectus sheath (RS) block.
62131962|NCT01747070|ACTIVE_COMPARATOR|tDCS and EAC sham|Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
62483027|NCT00792753|EXPERIMENTAL|3. DESyne BD DES|Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System
62131963|NCT01747070|PLACEBO_COMPARATOR|tDCS sham and EAC sham|The subjects will receive 05 sessions of tDCS sham and EAC sham. The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC sham consists of placement of rubber electrodes in the same areas of active stimulation (beside the spinous processes of L1 to S2, muscles vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus). The electrodes are connected to the same device electro, for 30 minutes, but without passage of electrical stimulation to the patient. The device is kept on and in front of the patient, with the lights blinking.
62691498|NCT06313866|OTHER|normal|The volatile oil of Acorus calamus is packed in the sniffer. Smell at the sniffing end, breathe evenly, 5-10 minutes each time, 3-5 times a day, for a total of 4 weeks of treatment.
62691499|NCT06313866|SHAM_COMPARATOR|Sham group|In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.
62691500|NCT01256047|ACTIVE_COMPARATOR|group A|preoperative immunonutrition
61929823|NCT04386057|EXPERIMENTAL|Cross Over Arm|"Participants who are enrolled to Arm 2 who experience radiologic disease progression on monotherapy will have the option to cross-over to receive treatment with the combination. Crossover will occur at the treating investigator's discretion following consultation and approval from the overall principal investigator. Combined dosage per determined Lead-In Cohort~* LY3214996~* HCQ"
61929824|NCT06187428|EXPERIMENTAL|PainSMART-strategy (intervention) group|"Patients eligible for inclusion first contact the physiotherapy department and are triaged by a physiotherapist and booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients randomised to the intervention group receive the PainSMART-strategy as an adjunct to usual MSKP physiotherapy management.~The strategy includes; exposure to the film 'Be PainSMART:er' at baseline, together with ratings of the clarity of the film's key-messages, a second film exposure prior to the initial consultation and three questions related to the film at the initial consultation.~Baseline data collection will occur prior to first exposure to the film. The film is available exclusively via the questionnaires via Region Östergötland's Quick channel. Therefore it is not shareable or available via online searching."
61929825|NCT06187428|ACTIVE_COMPARATOR|Usual physiotherapy management (control) group|Patient participants randomised to the control group will follow the usual physiotherapy management pathway at the physiotherapy departments participating in the study.
61929826|NCT02438527|EXPERIMENTAL|Chest Compressions Only|"After recruitment and consenting, volunteers in the chest compressions only arm will receive a chart with a description of Basic Life Support without mouth to mouth ventilations. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
61929827|NCT02438527|EXPERIMENTAL|Standard CPR|"After recruitment and consenting, volunteers in the standard CPR arm will receive a chart with a description of Basic Life Support. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart (including the initial check, chest compressions and mouth to mouth ventilations) for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
61929828|NCT05198609|EXPERIMENTAL|Camrelizumab, Apatinib Plus FOLFOX-HAIC|
61929829|NCT05198609|ACTIVE_COMPARATOR|Camrelizumab and Apatinib|
61929830|NCT02811601|EXPERIMENTAL|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery
61929831|NCT05008185||Regenerative Peripheral Nerve Interface|symptomatic neuroma is excised, and the end of the peripheral nerve is implanted into a small denervated free muscle graft harvested from the patient
61929832|NCT05008185||Traction Neurectomy|simple excision and traction neurectomy
61929833|NCT06574165|EXPERIMENTAL|Moderate Intensity Continuous Training|20 Veterans living with fibromyalgia and 20 Veterans living without fibromyalgia will undergo a 6-week structured exercise intervention. The intervention will include twice weekly, center-based, aerobic exercise consisting of continuous treadmill walking. Each center-based session will include 45 minutes of aerobic exercise in addition to balance and flexibility exercises to promote cool-down. During each exercise session, they will also be asked to wear a heart rate monitor to measure mean pulse during their exercise sessions.
61929834|NCT05069558|EXPERIMENTAL|Investigational PFO Closure Device|PFO closure with the study Occlutech Flex II PFO device.
62691501|NCT01256047|NO_INTERVENTION|group B|ordinary diet
62691502|NCT03277872|ACTIVE_COMPARATOR|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
62691503|NCT03277872|ACTIVE_COMPARATOR|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
62691504|NCT06639516|EXPERIMENTAL|Intervention group|Bifidobacterium longum capsules (10\^11 CFU) twice daily for 14 days
62691505|NCT06639516|PLACEBO_COMPARATOR|Placebo group|Placebo capsules twice daily for 14 days
61929835|NCT05069558|ACTIVE_COMPARATOR|Standard of Care PFO Closure Device|PFO closure with either of the standard of care PFO occlusion devices; Amplatzer PFO Occluder or the Gore Cardioform PFO Occluder.
61929836|NCT04923542|EXPERIMENTAL|Phase 1: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. In the phase I portion, safety will be monitored initially by a 3+3 design. If unexpected neurologic toxicities are noted, the dose of radiation therapy will be modified.
61929837|NCT04923542|EXPERIMENTAL|Phase 2: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation at the phase 1 dose to sites of brain metastases or post-operative cavities with continued abemaciclib.
61929838|NCT01244945|EXPERIMENTAL|L. reuteri DSM 17938|
61929839|NCT01244945|PLACEBO_COMPARATOR|Placebo|
62691506|NCT01933555|EXPERIMENTAL|Empowerment program|The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women.
61929840|NCT03589547|EXPERIMENTAL|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur \> 3 weeks and \<7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
61929841|NCT00775476|ACTIVE_COMPARATOR|NAC|2.4 g - 4.8 g of NAC daily starting after 3 month open label titration period.
61929842|NCT00775476|PLACEBO_COMPARATOR|Placebo|2.4 g - 4.8 g of placebo per day after 3 month open label titration period.
61929843|NCT06449378|EXPERIMENTAL|Hernia Repair|single arm study, no control arm
61929844|NCT06546969|EXPERIMENTAL|Chemoimmunotherapy + SFRT + Deep Hyperthermia|"1. Gemcitabine 1000mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles~2. Cisplatin 25mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles~3. Durvalumab 1500mg via intravenous infusion on day 1 of every 21-day cycle for up to 8 cycles~4. Deep hyperthermia and spatially-fractionated radiotherapy will be administered to 1 measurable lesion on cycle 2-day 1 and deep hyperthermia alone will be delivered to the same lesion on cycle 3-day 1 and cycle 4-day 1"
61929845|NCT03012516|EXPERIMENTAL|PAP-treatment by physiotherapist.|Enhanced PAP-support by physiotherapist including fitness test, individualized dialogue concerning PA, prescribed PAP and a 7 times follow-up during the one year intervention..
61929846|NCT03012516|ACTIVE_COMPARATOR|Ordinary PAP-treatment at the health care centre.|Ordinary PAP-treatment at the health care centre including individualized dialogue concerning PA, prescribed PAP and an individually adjusted follow-up.
61929847|NCT05269251||Axillary Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
62323832|NCT05664048|EXPERIMENTAL|Dry heat application group|"The participants were informed that they could use the thermophore whenever they felt pain throughout the menstrual cycle. On the first day of the period, they were asked to complete the Visual Analog Scale and Menstrual Symptom Questionnaire before using the thermophore; apply heat on their sole whenever they felt pain in the first three days of the menstrual period when pain is more intense; rate level of pain twice a day at 12-hour intervals on a daily basis, using the Visual Analog Scale; and complete the Menstrual Symptom Questionnaire on the last day of the period. On the other hand, the students in the control group completed only the related forms. The students who were previously trained on heat application were trained once again by the researcher as a reminder and then their written consents were obtained through the informed consent form."
62323833|NCT05664048|NO_INTERVENTION|Control group|"The students in the control group completed only the related forms (Visual Analog Scale and Menstrual Symptom Questionnaire) in the period of the menstruation."
62483028|NCT02318420|EXPERIMENTAL|Women in labour|"All women in labour during the study period (4 months baseline and the 9th-12th month of the intervention) will be included for this pre- vs. post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~1. All stillbirths~2. All maternal deaths~3. All women with severe hypertensive disorders~4. A randomized selected group of women delivering a the study site, approximately 300-600 each year."
62483029|NCT02318420|EXPERIMENTAL|Health care providers|All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
62483030|NCT00836472|EXPERIMENTAL|Glyburide Metformin|Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
62483031|NCT00836472|ACTIVE_COMPARATOR|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
62691507|NCT01933555|NO_INTERVENTION|Control group|Standard care, which was routine check ups and care provided by health care professionals.
62691508|NCT05918770|EXPERIMENTAL|experimental group|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition)
62691509|NCT05918770|NO_INTERVENTION|control group|will follow the standard usual care guidelines at the centre where patients will be opportunistically referred to specialised care
61929848|NCT05269251||Infraclavicular Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
62691510|NCT02361697|OTHER|DTI-MRI|MRI of the brain with specific DTI-sequences according to a specific investigation protocol
62691511|NCT02523027|EXPERIMENTAL|Experimental Group 1:|Oral nutritional supplement (List No S691/Z0) and dietary counseling
62691512|NCT02523027|EXPERIMENTAL|Experimental Group 2|Oral nutritional supplement (List No- P968/Z0) and dietary counseling.
62691513|NCT02523027|NO_INTERVENTION|Control Group|Dietary Counselling only.
61929849|NCT05269251||Interscalene Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
61929850|NCT04627571||Patient Population|Patients diagnosed with neurotrophic keratopathy.
61929851|NCT06028347|EXPERIMENTAL|sa-mRNA vaccine dose 1|
61929852|NCT06028347|EXPERIMENTAL|sa-mRNA vaccine dose 2|
61929853|NCT06028347|EXPERIMENTAL|sa-mRNA vaccine dose 3|
61929854|NCT06028347|PLACEBO_COMPARATOR|Placebo|
61929855|NCT06294535|EXPERIMENTAL|prebent titanium mesh|reconstruction of fractured orbital walls with perbent titanium mesh
61929856|NCT06294535|EXPERIMENTAL|customized titanium implant (patient specific implant)|econstruction of fractured orbital walls with patient specific implant (customized titanium implant)
61929857|NCT03177291|ACTIVE_COMPARATOR|Squamous Cell Lung Cancer (SQCLC)|Arm A Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus paclitaxel in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
61929858|NCT03177291|ACTIVE_COMPARATOR|Non-Squamous Cell Lung Cancer (SQCLC)|Arm B Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus pemetrexed in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
61929859|NCT06570395||OMT Intervention|"The OMT intervention group will be patients who consent to participating in OMT through the Southwest Women's Clinic and Cass Community Clinic in Niles, MI.~Case Inclusion:~1. Pregnant patients, ages 18-34~2. Primiparous and multiparous~3. Gestational age ≥34 weeks~4. Delivering at Corewell Health South Saint Joseph or Niles hospitals~5. Consent for treatment or as a control~Case Exclusion:~1. Absolute contraindications to OMT~2. Acute abdomen~3. BP \>160/110~4. Unexplained visual disturbances~5. Heavy vaginal bleeding preceding delivery~6. \<34 weeks gestational age~7. Treatment refusal~8. Magnesium sulfate received for seizure prophylaxis in setting of preeclampsia w/ severe features or severe gestational HTN~9. Scheduled c-section due to prior OB conditions"
62691514|NCT01308788||aqueous suppressant|aqueous suppressant treated
61929860|NCT06570395||Control Group|The control group will be patients who consent to participating in the control group through the Southwest Women's Clinic and Cass Community Clinic in Niles, MI.
62691515|NCT01308788||aqueous outflow|aqueous outflow treated
62691516|NCT05796193|EXPERIMENTAL|Py-PBO LLIN|Veeralin is a long-lasting net of 130 deniers containing the pyrethroid insecticide alpha-cypermethrin 6.0 g/kg (216 mg/m2) and the synergist piperonyl butoxide (PBO) 2.2 g/kg (79.2 mg/m2) and manufactured by VKA polymers.
62691517|NCT05796193|EXPERIMENTAL|Py-CFP LLIN|Interceptor® G2 is a long-lasting dual insecticide treated nets of 100 deniers combining Alpha-cypermethrin 2.4 g/kg (100 mg/m2) and Chlorfenapyr 4.8 g/kg (200 mg/m2) manufactured by BASF
62691518|NCT05796193|ACTIVE_COMPARATOR|Py LLIN|MAGNet® is a long-lasting net of 150 deniers containing the pyrethroid insecticide alpha-cypermethrin 5.8 g/kg (261 mg/m2) only and manufactured by VKA polymers.
61929861|NCT00767442||1|Health volunteer
61929862|NCT00767442||2|Patient with suspected oral mucosa lesion
61929863|NCT02370771|EXPERIMENTAL|Patient with hand osteoarthritis|Biological sampling and Radiographic evaluation of patient with erosive and non erosive hand osteoarthritis
62131964|NCT01747070|ACTIVE_COMPARATOR|tDCS sham and EAC|Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
62131965|NCT01747070|EXPERIMENTAL|tDCS and EAC|Subjects will receive 05 sessions of transcranial direct current stimulation(tDCS) and electroacupuncture(EAC). The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline. The electroacupuncture consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
62131966|NCT05915546|EXPERIMENTAL|Emraclidine (Fasted then Fed)|Single oral dose of Emraclidine 15 mg tablet under fasted (without food) condition followed by fed condition in treatment period 1 and 2, respectively.
62691519|NCT05812170|EXPERIMENTAL|Educational online session about PF|Participants will attend an 90-minutes educational online session.
62691520|NCT05812170|NO_INTERVENTION|Control|Despite the fact that all athletes will be invited to participate in the study, those who did not attend the educational session will be considered as control group. These participants will not receive any educational session or information about PF prior to be evaluated.
62691521|NCT01337479||Participants of specific phase III entecavir studies|Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections
62691522|NCT02487329|ACTIVE_COMPARATOR|Calcium hydroxide|Direct pulp capping with a self-hardening calcium hydroxide paste
61929864|NCT05294536|EXPERIMENTAL|Liraglutide injection (RD12014)+ Victoza|Subjects receive liraglutide injection(RD12014) in the first cycle and Victoza in the second cycle.
61929865|NCT05294536|EXPERIMENTAL|Victoza + Liraglutide injection (RD12014)|Subjects receive Victoza in the first cycle and liraglutide injection(RD12014) in the second cycle.
62323834|NCT03089177|EXPERIMENTAL|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
62483032|NCT02714465|EXPERIMENTAL|Hyperbaric oxygen therapy|All patients underwent radiosurgery with clinical and instrumental signs of cerebral radionecrosis
62483033|NCT01510938|PLACEBO_COMPARATOR|Placebo|1 g of rice maltodextrin will be reconstituted in 25-50 ml of tepid water or juice and immediately fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
62483034|NCT01510938|EXPERIMENTAL|Probiotic|"powder of L. acidophilus DDS-1, B. lactis UABLA-12, 50 mg of fructooligosaccharide~1 g of probiotic will be reconstituted in 25-50 ml tepid water or juice and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer."
62483035|NCT03679091|EXPERIMENTAL|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
62483036|NCT03679091|ACTIVE_COMPARATOR|clopidogrel|To observe the safety and efficacy between low-dose ticagrelor and standard-dose clopidogrel.
62483037|NCT01693523|EXPERIMENTAL|Minocycline|Minocycline 100 mg by mouth two times a day (200 mg/day). Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
62483038|NCT01693523|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules by mouth twice a day. Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
62483039|NCT04311164||Steno Tech Survey Respondents|A cohort of individuals with type 1 diabetes treated with CSII at either SDCC or NOH participating in the Steno Tech Survey.
62483040|NCT04311164||General Type 1 Diabetes Population|A cohort consisting of the entire population of people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort (ca. 25.000 individuals).
61929866|NCT02616562|EXPERIMENTAL|Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
61929867|NCT02616562|EXPERIMENTAL|Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.08 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
61929868|NCT02616562|EXPERIMENTAL|Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)|Participants receive the same dose (0.16 mg/kg/week) of NNC0195-0092 (somapacitan) during all 4 trial periods.
61929869|NCT02616562|ACTIVE_COMPARATOR|Open labelled daily Norditropin® (0.034 mg/kg/day)|Participants receive Norditropin during the main trial, the extension period and the safety extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the long-term safety extension periods.
61929870|NCT03913403||Intervention|Participants will receive 2 ECHO's and 2 Blood Draws
61929871|NCT02393690|EXPERIMENTAL|Arm I (selumetinib, iodine I-131)|Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.
61929872|NCT02393690|ACTIVE_COMPARATOR|Arm II (placebo, iodine I-131)|Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
61929873|NCT06176794|EXPERIMENTAL|Extended release torsemide|
61929874|NCT06176794|ACTIVE_COMPARATOR|Immediate release torsemide|
61929875|NCT04166227|ACTIVE_COMPARATOR|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
61929876|NCT04166227|ACTIVE_COMPARATOR|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
62483041|NCT06534996|EXPERIMENTAL|Treatment group|During the 2-week intervention, all participants are required to take 150ml of SCD-2101 liquid (a Chinese herbal medicine formula containing four herbs) twice per day
62483042|NCT00107991|EXPERIMENTAL|Treatment arm|Open-label treatment with etanercept 50 mg/week subcutaneous injection
62483043|NCT03648580|EXPERIMENTAL|Intervention group|Give the verbal nutrition education and supply Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
62483044|NCT03648580|OTHER|Control group|just give the verbal nutrition education.
62483045|NCT03692611|EXPERIMENTAL|Skills to Manage Pain (STOMP)|The intervention group will receive treatment as usual plus the STOMP behavioral intervention. The STOMP behavioral intervention consists of 12 intervention sessions (6 group and 6 individual sessions). The sessions will be completed over a period of 12-16 weeks from enrollment. The first intervention session will be a group session for all participants followed by individual and then alternating group and individual sessions for the rest of the intervention. The intervention group will utilize a study manual on pain management in which they will use with each session.
61929877|NCT06518642|EXPERIMENTAL|active stimulation|A current strength of two mA will be consistently applied for 30 minutes, with 30 seconds of ramping up and ramping down periods.
62323835|NCT03089177|NO_INTERVENTION|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
62323836|NCT06004882|EXPERIMENTAL|Group 1 (standard steroid injection)|Participants will receive 1 standard steroid injection.
62323837|NCT06004882|EXPERIMENTAL|Group 2 (PNS therapy plus 1 standard steroid injection).|Participants will receive PNS therapy plus 1 standard steroid injection.
62323838|NCT06004882|EXPERIMENTAL|Group 3 (PNS therapy plus 1 placebo injection)|Participants will receive PNS therapy plus 1 placebo injection.
62323839|NCT02811133|EXPERIMENTAL|Inositol|Subjects will receive inositol
62323840|NCT04562064||keratoconus group|patients with keratoconus implanted with the Myoring 360 degree, KeraRing 355 degree, KeraRing one segment, KeraRing two segments ICRS .corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system .pentacam data that will be included
62323841|NCT04614545|EXPERIMENTAL|Virtual Visits|"All patients will be seen face to face on visit 1. Patient will be evaluated by an obesity-medicine specialist and also by a registered dietitian and exercise physiologist via telemedicine. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated), and will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored remotely and patients will receive a remote scale and a remote blood pressure cuff.~Subjects will then initiate 3 one to one virtual visits with the obesity specialist. On each of this visit the five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. A personalized nutrition and exercise program will be developed. If felt relevant by the provider, subjects may also be referred to a mental health specialist and/or sleep clinic. All medical care will be provided virtually."
62323842|NCT04614545|ACTIVE_COMPARATOR|Face to face visits|"All patients independently of the randomization arm will be seen face to face on visit 1. Patients will be evaluated by an obesity-medicine specialist and patient will also be seen face to face by a registered dietitian and exercise physiologist. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated). Patients will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored in each of the visits.~Subjects will then initiate 3 face to face visits with the obesity specialist provider every 4 weeks. The five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress.~The patient will be provided a personalized nutrition and exercise program and may be referred to a mental health specialist and/or sleep clinic per provider discretion. All medical care will be provided via a face-to-face manner."
62323843|NCT04838691|EXPERIMENTAL|interpersonal relations counseling applied|8 sessions of interpersonal relations counseling, each lasting 40 minutes, were applied for 2.
62323844|NCT04838691|NO_INTERVENTION|no application|No action taken.
62323845|NCT03232424|EXPERIMENTAL|NovoTTF-200A + Temozolomide Chemoradiation|NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
62323846|NCT03524677||Non metastatic pancreatic cancer|patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging
62323847|NCT01444495|ACTIVE_COMPARATOR|Short time interval|Patients operated on 7-10 days after completing preoperative radiotherapy 5x5Gy.
62323848|NCT01444495|EXPERIMENTAL|Long time interval|Patients operated on 4-5 weeks after completing preoperative radiotherapy 5x5Gy.
62323849|NCT00450203|EXPERIMENTAL|ECX + Bevacizumab|ECX + Bevacizumab
62483046|NCT03692611|ACTIVE_COMPARATOR|comparison group|The comparison group will receive treatment as usual.The comparison group will also be provided with the intervention manual, however, no additional treatment will be provided to participants allocated to the control group. The group will not receive the PSM intervention.
61929878|NCT06518642|SHAM_COMPARATOR|sham stimulation|Current application will remain identical to the active stimulation, except that stimulation will be tampered off after 30 seconds. This duration (30 secs) was selected based on previous studies indicating that mild discomfort during active current application, such as tingling, would commonly be experienced up to 30 seconds only before subsiding
62323850|NCT00450203|ACTIVE_COMPARATOR|Epirubicin, Cisplatin and Capecitabine|ECX chemotherapy
62323851|NCT00450203|EXPERIMENTAL|ECX + Lapatinib|ECX + Lapatinib
62323852|NCT04228991|ACTIVE_COMPARATOR|Control|Conventional fractionation for locoregional radiotherapy
62323853|NCT04228991|EXPERIMENTAL|Experimental|Hypofractionation for locoregional radiotherapy
62323854|NCT06233032|EXPERIMENTAL|Group E|
62323855|NCT06233032|EXPERIMENTAL|Group D|
62323856|NCT00887718|EXPERIMENTAL|PET scan for lymphoma assessment|
62323857|NCT03421002|EXPERIMENTAL|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour. Micafungin will be administered for a minimum of 14 days until 1 of the following conditions applied: •Negative results (absence of Candida growth) from at least 2 consecutive blood cultures and/or resolution of clinical and laboratory symptoms and reduction of mannan antigen blood level (\< 125 pg/mL) are obtained. •In case of meningitis, hydrocephalus and external ventricular derivation, negative results (absence of Candida growth) from at least 2 consecutive cerebral spinal fluid (CSF) cultures associated with resolution of clinical and laboratory symptoms. •Interruption (including addition or switch to another antifungal agent or dosage change of micafungin) due to demonstration of therapy failure.
62323858|NCT02949765|ACTIVE_COMPARATOR|Iron sulfate 105 mg|Iron sulfate 105 mg: 1 pill/day is administered
62323859|NCT02949765|EXPERIMENTAL|Iron-rich diet|Iron-rich diet recommendations are given
62323860|NCT02986958|EXPERIMENTAL|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
62323861|NCT02986958|PLACEBO_COMPARATOR|Usual Care|Care as usual with their primary care provider
62483047|NCT00446966|EXPERIMENTAL|fish oil , corn oil|Highly purified pharmaceutical grade omega three polyunsaturated fatty acids
62483048|NCT00446966|PLACEBO_COMPARATOR|placebo|olive oil
62323862|NCT02597842|EXPERIMENTAL|shuangxuezu|Patients were given 30min of TEAS before induction until the end of the operation at two acupoints.
61929879|NCT06708247|ACTIVE_COMPARATOR|Standard Peri-implant Reconstructive Therapy|Participants in this arm receive standard peri-implant reconstructive therapy for the management of peri-implantitis. This includes mechanical debridement of the implant surface, bone grafting using autogenous bone from the tuberosity, and the use of a resorbable collagen membrane to promote bone regeneration. The intervention aims to reduce inflammation, improve bone regeneration, and stabilize the implant site.
61929880|NCT06708247|EXPERIMENTAL|Peri-implant Reconstructive Therapy with Electrolytic Cleaning|Participants in this arm undergo peri-implant reconstructive therapy combined with electrolytic cleaning for enhanced decontamination of the implant surface. This includes mechanical debridement, electrolytic cleaning to remove biofilm and contaminants while preserving the implant surface, followed by bone grafting using autogenous bone from the tuberosity and coverage with a resorbable collagen membrane. This intervention is intended to improve clinical outcomes, enhance bone regeneration, and achieve better implant stability compared to the standard therapy alone.
61929881|NCT05659056|EXPERIMENTAL|Pyrotinib, trastuzumab, paclitaxel-albumin|
61929882|NCT06313008|EXPERIMENTAL|Empagliflozin|Eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
61929883|NCT06313008|EXPERIMENTAL|Vildagliptin|60 patients recieved vildagliptin as add-on group (vildagliptin 50 mg/day as the initial dose).
61929884|NCT06544057|EXPERIMENTAL|CBT-MI|Behavioural Therapy (CBT) with Motivational Interviewing (MI) techniques. It comprises six individual sessions delivered via real-time video (Zoom) on mobile or computer platforms. Sessions last approximately 45 to 60 minutes each.
61929885|NCT06544057|NO_INTERVENTION|Wait-list|Control group will undergo recruitment and screening and be assigned to a wait-list, to undergo the intervention after the active group. Data collection will continue as in the active arm, to compare with that collected in the active arm
61929886|NCT05730634|EXPERIMENTAL|Intervention arm|Atorvastatin 40mg once daily.
61929887|NCT06710652|EXPERIMENTAL|rTMS|
61929888|NCT06710652|SHAM_COMPARATOR|sham rTMS|
61929889|NCT01678937||Control Group|"Ten Healthy individuals will have blood drawn (4 green top tubes(40 ml = 8 tsp.)) at one time point at Northwestern for control purposes. Blood will be drawn to conduct the following tests:~1. Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~2. Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~3. HLA microchimerism \& HLA G."
61929890|NCT01678937||Monotherapy Group|"Monotherapy patients \[cyclosporine (CyA) (10 patients), Tacrolimus (5 patients), mycophenolate mofetil (MMF) (10 patients), rapamycin (10 patients)\]: Blood will be drawn at one time point (4 green top tubes (40 ml = 8 tsp.)) to conduct the following tests:~1. Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~2. Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~3. HLA microchimerism \& HLA G."
61929891|NCT01678937||Conversion Group|Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
61929892|NCT02669238|EXPERIMENTAL|Implant|Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
61929893|NCT02669238|ACTIVE_COMPARATOR|Oral treatment|Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)
61929894|NCT01437878|EXPERIMENTAL|iloprost|single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
61929895|NCT01437878|PLACEBO_COMPARATOR|placebo|matching placebo using the power disc-6 with I-neb AAD system
61929896|NCT03709641|EXPERIMENTAL|Restylane Defyne receiver|Participants will receive Restyane Defyne injected into punctum of one eye.
61929897|NCT05050162|EXPERIMENTAL|ARM I (high-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
61929898|NCT05050162|EXPERIMENTAL|Arm II (low-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
61929899|NCT05050162|EXPERIMENTAL|Arm III (high-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
62323863|NCT02597842|EXPERIMENTAL|neiguanxuezu|Patients were given TEAS at neiguan acupoint.
62323864|NCT02597842|EXPERIMENTAL|zusanlixuezu|Patients were given TEAS at Zusanli acupoint.
62323865|NCT02597842|SHAM_COMPARATOR|duizhaozu|Patients were not given TEAS at two acupoints.
62323866|NCT00851955||1. Normal pancreas patients|Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
62323867|NCT00851955||2. Chronic pancreatitis patients|Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
62131967|NCT05915546|EXPERIMENTAL|Emraclidine (Fed then Fasted)|Single oral dose of Emraclidine 15 mg tablet under fed condition followed by fasted (without food) condition in treatment period 1 and 2, respectively.
61929900|NCT05050162|EXPERIMENTAL|Arm IV (low-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
61929901|NCT04128774||GBM-dexa|Participants with clinical diagnosis of GBM, that require dexamethasone due to neurological deficits. Dose is based on the clinical judgement of the treating physician but should be given at least two weeks. Dexamethasone is given once a day.
61929902|NCT04128774||GBM-control|Participants with clinical diagnosis of GBM not requiring dexamethasone treatment.
61929903|NCT06337500|EXPERIMENTAL|Iowa Gambling Task - ecologic|The participant performs the card selection task in its ecological version (with real cards).
61929904|NCT06337500|ACTIVE_COMPARATOR|Iowa Gambling Task - virtual|The participant performs the card selection task in its virtual version (computer task).
61929905|NCT06337500|EXPERIMENTAL|Iowa Gambling Task - hybrid|"The participant performs the card selection task thanks to our homemade interface LAB-Life."
61929906|NCT06337500|EXPERIMENTAL|Game of Dice Task - ecologic|The participant performs the dice-rolling task in its ecological version (with real dices).
62691523|NCT02487329|EXPERIMENTAL|Er,Cr:YSGG laser + calcium hydroxide|Direct pulp capping using Er,Cr:YSGG laser combined with calcium hydroxide
62691524|NCT02487329|EXPERIMENTAL|TheraCal LC|Direct pulp capping with resin based tricalcium silicate material
61929907|NCT06337500|ACTIVE_COMPARATOR|Game of Dice Task - virtual|The participant performs the dice-rolling task in its virtual version (computer task)
61929908|NCT06337500|EXPERIMENTAL|Game of Dice Task - hybrid|"The participant performs the dice-rolling task thanks to our homemade interface LAB-Life."
61929909|NCT06135493|NO_INTERVENTION|Control arm|These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting
61929910|NCT06135493|EXPERIMENTAL|Intervention arm|These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting plus losartan 100mg
61929911|NCT04824729||French PAD revascularized population|Patients with lower-extremity peripheral artery disease (PAD) who have undergone lower limb revascularization (PAD revascularized population) in France from 2016 to 2019.
61929912|NCT04824729||French VOYAGER PAD-like population|"VOYAGER PAD-like patients in France from 2016 to 2019.~This population will be constituted to fit the VOYAGER PAD clinical trial population. It will be created using the VOYAGER PAD exclusion criteria and resembles a subgroup of the PAD revascularized population."
61929913|NCT03309150|EXPERIMENTAL|Part A1: Berzosertib|
61929914|NCT01610271|EXPERIMENTAL|Air Barrier System|The Air Barrier System will be employed throughout the surgical procedure for this group of patients.
61929915|NCT01610271|NO_INTERVENTION|Control|The Air Barrier System will not be used during the surgical procedure for this group of patients.
61929916|NCT06710964|EXPERIMENTAL|Mechanistic Self-Dehumanization Condition|A self-dehumanized future condition (i.e., a futuristic paradigm that likens the individual to a machine)
61929917|NCT06710964|ACTIVE_COMPARATOR|Control Condition|Control Condition
61929918|NCT05573386||Filgrastim to Pegfilgrastim|Participants in this group will receive filgrastim treatment, followed by pegfilgrastim treatment at the 8-week mark.
61929919|NCT05573386||Pegfilgrastim to filgrastim|Participants in this group will receive pegfilgrastim treatment, followed by filgrastim treatment at the 8-week mark
61929920|NCT05672199|PLACEBO_COMPARATOR|Placebo|Participants who were receiving the placebo during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive the placebo.
61929921|NCT05672199|EXPERIMENTAL|Efavaleukin Alfa Dose 1 (Low Dose)|Participants who were receiving efavaleukin alfa dose 1 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 1.
61929922|NCT05672199|EXPERIMENTAL|Efavaleukin Alfa Dose 2 (Moderate Dose)|Participants who were receiving efavaleukin alfa dose 2 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 2.
61929923|NCT05672199|EXPERIMENTAL|Efavaleukin Alfa Dose 3 (High Dose)|Participants who were receiving efavaleukin alfa dose 3 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 3.
62323868|NCT00851955||3. Pancreatic cancer patients|Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
62323869|NCT01598857|EXPERIMENTAL|Blisibimod|
61929924|NCT06708052|EXPERIMENTAL|voodoo flossing intervention|"The voodoo flossing intervention used the standard voodoo flossing, wrapping a voodoo flossing (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
61929925|NCT06708052|SHAM_COMPARATOR|control|The control group did not use voodoo flossing.
62323870|NCT01598857|PLACEBO_COMPARATOR|Placebo|
62323871|NCT01477892|EXPERIMENTAL|low dose remifentanil|continuous infusion of remifentanil 0.1mcg/kg/min
62691525|NCT02487329|EXPERIMENTAL|Er,Cr:YSGG laser + TheraCal LC|Direct pulp capping using Er,Cr:YSGG laser combined with resin based tricalcium silicate material
62691526|NCT06454916|EXPERIMENTAL|Study Group: Prospective Evaluation of the Flexagon SFM Device with OTOLoc|This is a multicenter, single-arm study in which clinical outcomes are prospectively evaluated for a minimum of 70 subjects undergoing small bowel anastomosis using the Flexagon SFM Device with OTOLoc.
62691527|NCT03362632||Infection Group|Patients with end stage liver disease with SBP
62691528|NCT03362632||Non-infection Group|Patients with end stage liver disease without SBP
62691529|NCT02093273|ACTIVE_COMPARATOR|tOPV commercial batch (Bio Farma)|tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)
62691530|NCT02093273|EXPERIMENTAL|tOPV pilot batch|tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)
62483049|NCT05921214|EXPERIMENTAL|Familiar Words|In this condition, children will learn new words that come from semantic categories (e.g., animals, body parts) from which they currently understand at least several words.
62483050|NCT05921214|ACTIVE_COMPARATOR|Less-Familiar Words|In this condition, children will learn new words that come from semantic categories (e.g., animals, body parts) from which they currently understand few or no words.
62483051|NCT06412861|ACTIVE_COMPARATOR|ketamine-propofol|0.5 mg/kg ketamine + 1 mg/kg propofol will be administered. Ramsey Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
62483052|NCT06412861|ACTIVE_COMPARATOR|fentanyl-propofol|1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
62483053|NCT04522258|PLACEBO_COMPARATOR|Placebo|Refined cereal flour
62483054|NCT04522258|ACTIVE_COMPARATOR|Dietary fiber|Fermentable cereal bran
62483055|NCT00586989||1|Patient with Barrett's Esophagus with a history of High grade dysplasia or early esophageal adenocarcinoma
62483056|NCT05251727|EXPERIMENTAL|Lowest Dose|Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)
62691531|NCT06637839|EXPERIMENTAL|Moderate-Intensity Locomotor Training Program|Treatment will be administered for 10 consecutive 1-hour sessions over a 10-day period. Therapists will deliver the assigned intervention as part of standard care.
61929926|NCT03887403|EXPERIMENTAL|Multimodal Intervention|Multimodal Intervention Based on Person-centered Communication
61929927|NCT03887403|ACTIVE_COMPARATOR|Usual Care|Patients receive usual advices in primary health care centers
62131968|NCT01337622|EXPERIMENTAL|No routine check for gastric residuals|
62323872|NCT01477892|ACTIVE_COMPARATOR|high dose remifentanil|continuous infusion of remifentanil 0.25mcg/kg/min
62323873|NCT03241056|EXPERIMENTAL|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
62323874|NCT03241056|ACTIVE_COMPARATOR|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
62323875|NCT05178953|EXPERIMENTAL|pentoxifylline group|"Group 1: Patients receiving pentoxifylline (TRENTAL 400 mg tablets, OSPS; 400 mg, twice daily) Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients.~These volunteers receive two pentoxifylline tablets(400 mg) daily for 3 month, (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)~Other names:~Trental"
62323876|NCT05178953|EXPERIMENTAL|Zinc Sulfate group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate tablet(229 mg) daily for 3 month,(Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
62323877|NCT05178953|EXPERIMENTAL|pentoxifylline+ zinc group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate(220mg) tablet+ two pentoxifylline tablets(400 mg) daily for 3 month (TRENTAL 400 mg modified release tablets, OSPS; 400 mg +Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
62323878|NCT06467760|EXPERIMENTAL|Device Implantation|Single arm study - Device implanted
62323879|NCT06158490|EXPERIMENTAL|JYP0061 15 mg Group|Participants in this arm will receive 15 mg of JYP0061 once daily for a total treatment period of 12 weeks.
62323880|NCT06158490|EXPERIMENTAL|JYP0061 30 mg Group|articipants in this arm will receive 30 mg of JYP0061 once daily for a total treatment period of 12 weeks.
62323881|NCT06158490|PLACEBO_COMPARATOR|Placebo Group|Participants in this arm will receive a placebo once daily for a total treatment period of 12 weeks.
62323882|NCT05387720|ACTIVE_COMPARATOR|Study Group A|Study Group A (25 patients) will receive manual diaphragmatic facilitation (PNF) technique in addition to traditional chest physiotherapy
62323883|NCT05387720|ACTIVE_COMPARATOR|Study Group B|Study Group B (25 patients) will receive trigger sensitivity adjustment on mechanical ventilator in addition to traditional chest physiotherapy.
62131969|NCT01337622|ACTIVE_COMPARATOR|Routine check for gastric residuals|
62323884|NCT05387720|ACTIVE_COMPARATOR|Study Group C|Study Group C (25 patients) will receive a concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique in addition to traditional chest physiotherapy.
62483057|NCT05251727|EXPERIMENTAL|Low Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
62483058|NCT05251727|EXPERIMENTAL|Medium Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
62483059|NCT05251727|EXPERIMENTAL|High Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
62483060|NCT05251727|EXPERIMENTAL|Highest Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
62691532|NCT06637839|EXPERIMENTAL|High-Intensity Locomotor Training Program|Treatment will be administered for 10 consecutive 1-hour sessions over a 10-day period. Therapists will deliver the assigned intervention as part of standard care.
62691533|NCT06637839|ACTIVE_COMPARATOR|High-Step Count Locomotor Training Program|Treatment will be administered for 10 consecutive 1-hour sessions over a 10-day period. Therapists will deliver the assigned intervention as part of standard care.
62691534|NCT06076135|EXPERIMENTAL|Treatment Stage Ⅰ|1Gy/1F ILDR + PD-1/PD-L1 inhibitors.
61929928|NCT04269486||Inpatient participant|Inpatients who signed the informed consent form that she will be observed during the hospitalization period
61929929|NCT06074536|EXPERIMENTAL|Interventional arm|The recruited GPs will be randomized into 2 parallel groups (interventional and control). Following this randomization, the GPs from the interventional group will undergo face-to-face training to the patient-centered approach.
61929930|NCT06074536|NO_INTERVENTION|Control arm|The GPs of the control group will take care the patient according to current screening recommendations and procedures organized by the colorectal cancer (CCR) mass screening.
62131970|NCT03792620|EXPERIMENTAL|Cyclo Thal Dex Daratumumab|"Eligible patients will be enrolled and treated according to the following elicited schema: Cyclo Thal Dex- Daratumumab (cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week (28 days cycle)- 4 cycles. ) + Daratumumab 16mg/Kg every week on cycles 1 and 2 and every other week at cycles 3 and 4- (total of 12 doses). Then Daratumumab 16mg/Kg after D+30, every other week as pre consolidation until starts full consolidation D+90-120 every other week (total of 4 doses) + thal100mg D1-28 during sixteen weeks as full consolidation. Follow by Daratumumab 16mg/Kg once a month as maintenance until progression or limiting adverse event (total of 28 planning doses).~Total scheme Daratumumab doses= 50 doses = PROTOCOL MAXDARA."
62131971|NCT01382849||CAA positive microbleeders|Cerebral amyloid angiopathy (CAA) positive microbleeders
62323885|NCT04125914|EXPERIMENTAL|Prevention (weight management, health behavior intervention)|Participants undergo weight management and health behavior intervention with a combination of 4 components for 16 weeks. TELEPHONE COACHING: Participants receive 1 phone call each week from a coach over 30-45 minutes to discuss diet, physical activity and goal setting. EMAIL COACHING: Participants receive 1 phone call to discuss the process over 10-15 minutes and then receive 1 email each week for 16 weeks. NO COACHING: Participants receive 1 phone call the first week over 10-15 minutes to discuss the process. TEXT MESSAGING: Participants receive 7-12 text messages comprising information about diet and physical activity each week for 16 weeks. SELF-MONITORING: Participants record their food intake and weight directly into the Fitbit website or application 4-7 days each week or 1 day each week for 16 weeks. FAMILY TEAM INTERVENTION: Participants receive 2 group phone calls and join a Facebook group that is monitored by research staff where they can interact with each other and coaches.
62131972|NCT01382849||probable CAA macrobleeders|
61929931|NCT03973073|EXPERIMENTAL|camouflage group|Topical applications and/or NB-UVB plus Capulin TM on-demand treatment period
62483061|NCT05251727|PLACEBO_COMPARATOR|Placebo|"Lyophilized placebo reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
62483062|NCT02316223|EXPERIMENTAL|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
62483063|NCT02316223|ACTIVE_COMPARATOR|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
61929932|NCT03973073|OTHER|blank group|Topical applications and/or NB-UVB on-demand treatment
62131973|NCT01382849||CAA negative microbleeders|
62131974|NCT00632203|EXPERIMENTAL|Temozolomide treatment|Subjects will receive temozolomide at a dose of 75 mg/m\^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
62131975|NCT00632203|NO_INTERVENTION|Observation|Observation
62131976|NCT01989741|OTHER|sleep restriction|Longitudinal study of response to sleep restriction. Comparison between baseline values and sleep restriction values
62131977|NCT04843475||MPNs patients who have echocardiographic probability of PH.|
62131978|NCT04843475||MPNs patients who do not have echocardiographic probability of PH|
62131979|NCT03305536|ACTIVE_COMPARATOR|Interventional|1000 mcg/day of Vitamin K2 + 5000 IU/day Vitamin D3 as a treatment to decalcifiy the valve
62131980|NCT03305536|ACTIVE_COMPARATOR|interventional|5000 IU/day of Vitamin D3 will be given to measure the progression of the disease along the time of the study
62323886|NCT01340235|EXPERIMENTAL|Oral erythromycin|Oral erythromycin
62323887|NCT00912158|ACTIVE_COMPARATOR|CPAP + ST|Continuous positive airway pressure (CPAP) and Standard medical therapy (ST)
62131981|NCT00243503|EXPERIMENTAL|A|
62131982|NCT00199082|EXPERIMENTAL|Experimental|This is a single arm trial with complex chemotherapy (6 cycles) stratified by age, subtype (Burkitt-leukemia vs Burkitt-lymphoma) and initial involvement
62131983|NCT01582100|EXPERIMENTAL|GERD subjects with nausea|subjects with GERD and nausea will receive treatment with Reletex
62483064|NCT02316223|NO_INTERVENTION|Usual care|Clinician-centric strategy and EMR-based clinician decision support
62483065|NCT06103812||Hyalo4 Skin Gel|
62483066|NCT06558968|ACTIVE_COMPARATOR|polyetheretherketone|"PEEK 'Polyetheretherketone' Victrex® is a type of polymer with suitable mechanical and~physical properties. It is a resilient material with high flexural strength and resistance~to deformation. Therefore, it can be used in fixed prosthesis and space maintainers"
62483067|NCT06558968|ACTIVE_COMPARATOR|monolithic zirconia|BruxZir® is a type of monolithic zirconia with higher flexural strength and fracture toughness than the classic zirconia and can withstand the changes in temperature in the oral cavity. Therefore it can be used as a space maintainer
62483068|NCT00545428|EXPERIMENTAL|1|Rhinoplasty
62691535|NCT06076135|EXPERIMENTAL|Treatment Stage Ⅱ|2-3Gy/2-3F ILDR + PD-1/PD-L1 inhibitors.
61929933|NCT06619847|EXPERIMENTAL|VX-993|Participants will be randomized to receive different dose levels of VX-993.
61929934|NCT06619847|ACTIVE_COMPARATOR|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will be randomized to receive HB/APAP.
61929935|NCT06619847|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive placebos matched to VX-993 and HB/APAP.
61929936|NCT04991935|EXPERIMENTAL|Administration of CC-93538|Participants are administered CC-93538 dose subcutaneously once weekly
61929937|NCT06413212||Case group|Participants who were diagnosed as advanced malignancy and would receive 2 cycles of personal therapy based on PTC drug screening tests.
61929938|NCT05896748|EXPERIMENTAL|Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg|Participants received an intramuscular (IM) injection of CAB LA 400 mg and RPV LA 600 mg on week -4 during the Screening phase. Participants then received a sub-cutaneous (SC) injection of CAB LA 400 mg + RPV LA 600 mg on Day 1 of Week 1, Week 4 and Week 8 (once in every 4 weeks (Q4W)) for a total of 12 weeks during the SC abdominal Injection Phase. 4 weeks later, participants returned to the clinic for an IM gluteal injection (at Week 12) of CAB LA 400 mg + RPV LA 600 mg during the Return to Gluteal Injection Phase and subsequent gluteal injection occurred after Q4W at Week 16.
61929939|NCT06287606|EXPERIMENTAL|CTP0302-A|2 days split-dose
61929940|NCT06287606|EXPERIMENTAL|CTP0302-B|One day dose
61929941|NCT06287606|ACTIVE_COMPARATOR|Conventional OST|2 days split-dose
61929942|NCT00695578|EXPERIMENTAL|Biafin on left arm|Subjects were randomized to apply Biafine® to wounds on the left forearm and polysporin (standard of care) to wounds on the right forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
61929943|NCT00695578|EXPERIMENTAL|Biafin on right arm|Subjects were randomized to apply Biafine to wounds on the right forearm and Polysporin to wounds on the left forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
61929944|NCT00415454|EXPERIMENTAL|Gene therapy|Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation
61929945|NCT02312921||PREDICT|"Delivery system changes where a team of dental providers (dentists, dental hygienists, case managers, community outreach workers and others) within Advantage Dental Services, LLC provide evidence-based screening, risk assessment and primary and secondary preventive care in non-conventional community settings (WIC, Head Start and similar settings) and seamless, timely and appropriate evidence-based care in dental clinics.~Payment plan model based on global budgeting and Alternative Quality Contract (pay-for-performance) for dental providers within Advantage Dental Services, LLC (Advantage) with the goal of incentivizing implementation of delivery system changes aimed at reducing disparities in dental care utilization and oral health for low-income mothers and children.."
61929946|NCT02312921||Control|Usual care
61929947|NCT02734420|EXPERIMENTAL|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs; Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up: Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
61929948|NCT02734420|EXPERIMENTAL|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette; Follow up; Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
61929949|NCT02584933|EXPERIMENTAL|ceritinib|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent ceritinib study at the time of the rollover.
61929950|NCT06707363||After orthopedic surgeries|"This study focuses on patients who have undergone either emergency or elective orthopedic surgeries, specifically those involving significant interventions on the musculoskeletal system, such as joint replacements or fracture repairs. The cohort consists of adult participants (aged 18 years and older) who have been informed about the study and provided their consent to participate. This population will include both males and females.~Interventions of interest: psychological questionnaires, pain assessment, longitudinal follow-up."
61929951|NCT06299839|EXPERIMENTAL|PAS-004 Capsules|Sequential dose escalation: 2 mg, 4 mg, 8 mg, 15 mg, 22 mg, 30 mg, 37 mg, and 45 mg
61929952|NCT06299839|EXPERIMENTAL|PAS-004 Tablets|A single cohort at the 4mg dose using tablet formulation of PAS-004
61929953|NCT05802173|EXPERIMENTAL|TDM-105795 topical solution, 0.0025%|Daily dose of 0.0025% of TDM-105795 topical solution
61929954|NCT05802173|EXPERIMENTAL|TDM-105795 topical solution, 0.02%|Daily dose of 0.02% of TDM-105795 topical solution
61929955|NCT05802173|PLACEBO_COMPARATOR|TDM-105795 topical vehicle solution|Daily dose of placebo for TDM-105795 topical solution
61929956|NCT06083935|ACTIVE_COMPARATOR|Metformin + Combined oral contraceptive|Metformin (Glucophage ® 500 tablets twice daily)+ Combined oral contraceptive (standard therapy) (Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily)
61929957|NCT06083935|EXPERIMENTAL|Diosmin /Hesperidin + Combined oral contraceptive|Diosmin /Hesperidin (Daflon two tablets 500 mg daily)+ Combined oral contraceptive((Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily)
62323888|NCT00912158|ACTIVE_COMPARATOR|BiPAP + ST|Bilevel positive airway pressure (BiPAP) and standard medical therapy (ST)
61929958|NCT06083935|ACTIVE_COMPARATOR|Diosmin /Hesperidin +Metformin + Combined oral contraceptive combination|Diosmin /Hesperidin (Daflon two tablets 500 mg daily) +Metformin (Glucophage ® 500 tablets twice daily) + Combined oral contraceptive combination (Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
61929959|NCT06691672|EXPERIMENTAL|Imaging Arm|
61929960|NCT05113095||Darvadstrocel|Darvadstrocel, 24 mL suspension of 120 million cells as a perilesional injection, once. Participants received interventions as part of routine medical care.
61929961|NCT02800902|PLACEBO_COMPARATOR|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
62323889|NCT00912158|ACTIVE_COMPARATOR|ST|Standard Medical therapy (ST)
62323890|NCT00957346|EXPERIMENTAL|Mifepristone + Misoprostol|200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
61929962|NCT02800902|ACTIVE_COMPARATOR|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
61929963|NCT02800902|ACTIVE_COMPARATOR|group 3|SRP followed by 1.2% Atorvastatin (ATV) gel
62131984|NCT00533546|EXPERIMENTAL|Tier One|Participants will receive APC by intravenous injection, receiving 50% of dose as a bolus and the remainder as an infusion over one ho.
62131985|NCT00771160|EXPERIMENTAL|1|MK0476 5mg
62131986|NCT00771160|EXPERIMENTAL|2|MK0476 10mg
62323891|NCT00957346|PLACEBO_COMPARATOR|Misoprostol|Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses
62323892|NCT06693453|SHAM_COMPARATOR|Sham Group|Sham Coparator: 38 patients were treated with acupuncture using Khanh Phong 20x15 needles inserted into specific acupuncture points. Afterward, the acupuncture needles were connected to electrodes to administer electrical stimulation through the KWD808-1 electroacupuncture machine. The Sham group will receive placebo dry cupping therapy using two size 1 acrylic cups (internal diameter 4.5 cm), with a distance of 3 cm between each cup, placed parallel to the spine, bilaterally along the boundaries of acupoints BL17, BL23, and B25. This group will undergo placebo dry cupping therapy for 7 minutes, every 4 days (3 sessions over 2 weeks). However, the cups will be prepared with small holes \<2 mm in diameter to release the negative pressure within seconds. Double-sided tape will be used to ensure the cups remain attached and in contact with the skin.
62691536|NCT03602495|EXPERIMENTAL|Donafenib|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
61929964|NCT03830112|EXPERIMENTAL|Pilates exercise with Theraband|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based exercises with Theraband® (blue color) from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based exercises with Theraband® (blue color) from week five to eight.~(saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
61929965|NCT03830112|ACTIVE_COMPARATOR|Pilates exercise|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based mat exercises from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based mat exercises from week five to eight. (saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
61929966|NCT04673149|EXPERIMENTAL|GLS-5310 0.6mg [Group 1a]|0.6mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
61929967|NCT04673149|EXPERIMENTAL|GLS-5310 1.2mg [Group 1b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
61929968|NCT04673149|EXPERIMENTAL|GLS-5310 1.2mg [Group 1c]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 12.
61929969|NCT04673149|PLACEBO_COMPARATOR|Placebo [Group 2a]|Placebo will be intradermally administered on Day 0 and Week 8 (or Week 12).
61929970|NCT04673149|EXPERIMENTAL|GLS-5310 1.2mg [Group 2b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8 (or Week 12).
61929971|NCT06187662|EXPERIMENTAL|Default Bias|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs.
61929972|NCT06187662|EXPERIMENTAL|Loss Aversion|"This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.~Sites in this arm will also receive a checklist to guide blood culture decisions, that clinicians at sites will be asked to consult and complete prior to ordering or not ordering a blood culture."
61929973|NCT05806879|EXPERIMENTAL|Maternity Napkins|"The intervention group will receive maternity napkins to manage postpartum lochia with the following specifications:~* Length is 230-240mm, to be able to provide adequate coverage.~* Width is 150-155mm with wings.~* Thickness is 3-5mm.~* The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute"
61929974|NCT05806879|NO_INTERVENTION|Continued Use of Current Methods|The control group will continue to use their current indigenous methods for managing postpartum lochia.
61929975|NCT04530019||MR Group|Following standard MRI-guided Brachytherapy, patients will have images analyzed for quantification of residual tumor versus fibrosis. We will pilot-test an endovaginal coil, a deflectable MR stylet, real-time planning software, and auto-segmentation of normal and tumor tissue.
61929976|NCT06245629||Bortezomib-bendamustine-melphalan|Myeloma patients receiving bortezomib-bendamustine-melphalan at autologous hematopoietic stem cell transplantation first relapse.
62131987|NCT02813369||naloxegol|patients exposed to naloxegol
62131988|NCT02813369||non-PAMORA laxative|patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
62131989|NCT01714492||Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|subjects implanted with the Sigma Posterior Stabilizing Rotating Platform TKA including a polyethylene insert with 4 beads
62131990|NCT03647956|EXPERIMENTAL|Arm 1|Using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
62131991|NCT04362930||Neurological and psychiatric impact of COVID-19|Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection
62691537|NCT03602495|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
62131992|NCT04362930||Impact of Covid-19 in patients with neurological pathology|patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection
61929977|NCT06245629||high-dose melphalan|Myeloma patients receiving high-dose melphalan at autologous hematopoietic stem cell transplantation at first relapse.
61929978|NCT05060887|EXPERIMENTAL|OVX836 - 180µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180μg dose on Day 1.
62483069|NCT04584749|EXPERIMENTAL|LIDOCAINE|"2% lidocaine will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
62483070|NCT04584749|PLACEBO_COMPARATOR|PLACEBO|"0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction . After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine/placebo.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing Physiological Serum as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
62483071|NCT04251429|EXPERIMENTAL|Immediate Intervention Group|SHIFT study team provides coaching to Health and Safety Committee to implement a participatory program for increasing committee effectiveness.
62483072|NCT04251429|OTHER|Delayed Intervention Group|Active Comparator for 2 years: status quo program remains in place with new ongoing data collection. Then experimental intervention as above.
62483073|NCT00835484|EXPERIMENTAL|1|
62483074|NCT00835484|ACTIVE_COMPARATOR|2|
62483075|NCT06441591|EXPERIMENTAL|Vinpocetine + Standard Therapy|Vinpocetine capsules, 30 mg, twice daily, with meals for 3 months
62483076|NCT06441591|PLACEBO_COMPARATOR|Placebo + Standard Therapy|Placebo, twice daily, with meals for 3 months
62483077|NCT01666262|EXPERIMENTAL|A/17/CA/2009/38 (H1N1)|
62483078|NCT01666262|PLACEBO_COMPARATOR|Stabilizer|
62483079|NCT05027503|ACTIVE_COMPARATOR|Control Group|Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks
62483080|NCT05027503|EXPERIMENTAL|Training Group|In addition to home-based respiratory physiotherapy, 30 min exercises with the hippotherapy simulator will be done.
62483081|NCT02022150||Body composition in paracentesis|Taking blood samples and bioelectrical impedance, Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF) before and after paracentesis.
62483082|NCT04626154|ACTIVE_COMPARATOR|Respiratory insufficiency or distress|Patients demonstrating respiratory insufficiency or distress.
62483083|NCT04626154|SHAM_COMPARATOR|No respiratory insufficiency or distress.|Patients NOT demonstrating respiratory insufficiency or distress.
61929979|NCT05060887|EXPERIMENTAL|OVX836 - 300µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 300μg dose on Day 1.
61929980|NCT05060887|EXPERIMENTAL|OVX836 - 480µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 480μg dose on Day 1.
62483084|NCT05474079|EXPERIMENTAL|Statin users exercise intervention|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% heart rate reserve (HRR) three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
62483085|NCT05474079|NO_INTERVENTION|Statin users conventional care control|Participants randomized to the conventional primary care control group will not receive any supervision or guidance throughout the 12-week intervention beyond the initial standard healthcare advice provided by their general practitioner (GP).
62483086|NCT05474079|EXPERIMENTAL|Non-statin users exercise intervention|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
62483087|NCT05474079|NO_INTERVENTION|Non-statin users conventional care control|Participants randomized to the conventional primary care control group will not receive any supervision or guidance throughout the 12-week intervention beyond the initial standard healthcare advice provided by their GP.
62483088|NCT00003766|EXPERIMENTAL|Arm A|06-benzylguanine (100mg/m2 16 hrs before anticipated tumor tissue removal)
62483089|NCT06169150||Healthy Controls|Biological relatives or unrelated persons without a known diagnosis of neuroinfectious disease or neuroinflammation.
61929981|NCT05060887|PLACEBO_COMPARATOR|Saline solution (B. Braun Ecoflac® Plus)|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day 1.
61929982|NCT06708767|EXPERIMENTAL|Low dose|400 mg/kg CZ10 intravenous administration
61929983|NCT06708767|EXPERIMENTAL|Medium dose|800 mg/kg CZ10 intravenous administration
61929984|NCT06708767|EXPERIMENTAL|High dose|1200 mg/kg CZ10 intravenous administration
61929985|NCT05561374|EXPERIMENTAL|Low-dose OKN-007, two times a day (BID)|Dose Escalation Cohort 1
61929986|NCT05561374|EXPERIMENTAL|Low-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 2
61929987|NCT05561374|EXPERIMENTAL|Mid-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 3
61929988|NCT05561374|EXPERIMENTAL|High-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 4
61929989|NCT06484673|EXPERIMENTAL|Bosentan 32 mg Dispersible Tablets|Bosentan 32 mg Dispersible Tablets
61929990|NCT06484673|ACTIVE_COMPARATOR|Tracleer® 32 mg Tablets for Oral Suspension|Tracleer® 32 mg Tablets for Oral Suspension (Tracleer® 32 mg Dispersible Tablet) (Bosentan)
61929991|NCT02030054|ACTIVE_COMPARATOR|atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
61929992|NCT02030054|ACTIVE_COMPARATOR|rosuvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin(20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
61929993|NCT01866722|ACTIVE_COMPARATOR|Usual Care|Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
61929994|NCT01866722|ACTIVE_COMPARATOR|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
62131993|NCT02283749|EXPERIMENTAL|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
62131994|NCT00962234||Metabolism|Lung cancer patients who exhibit abnormalities in lipid measures.
62483090|NCT06169150||Primary or acquired immunodeficiency|Known or suspected infection or inflammation of the nervous system or post infection sequelae, or is at risk of developing such a neurologic complication.
62483091|NCT05412576|EXPERIMENTAL|IVL0.5 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
62483092|NCT05412576|EXPERIMENTAL|IVL1.0 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
62483093|NCT05412576|EXPERIMENTAL|IVL1.5 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
62483094|NCT05412576|PLACEBO_COMPARATOR|Placebo group|At the beginning of surgery, in the placebo group, the same dose of normal saline as the experimental groups will be given until the procedure is over.
61929995|NCT01866722|ACTIVE_COMPARATOR|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
61929996|NCT02305888|EXPERIMENTAL|LEO 43204, 0.018% once daily for 3 days|
61929997|NCT02305888|EXPERIMENTAL|LEO 43204, 0.037% once daily for 3 days|
61929998|NCT02305888|EXPERIMENTAL|LEO 43204, 0.1% once daily for 3 days|
61929999|NCT05300152|EXPERIMENTAL|ACTIVA BioACTIVE Base/Liner|is a BioACTIVE glass-incorporated light-curable pulp capping material also known as light-cured resin-modified calcium silicate
62131995|NCT04460807|EXPERIMENTAL|Exemestane|"Standard chemotherapy: paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.~+~Exemestane: single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
62483095|NCT04825847|ACTIVE_COMPARATOR|Electroencephalographic (EEG)-guided group|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
62483096|NCT04825847|ACTIVE_COMPARATOR|Standard Care (SC) group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
61930000|NCT05300152|ACTIVE_COMPARATOR|Mineral trioxide aggregate (MTA)|is a bioactive materials containing calcium silicate
61930001|NCT05651659|EXPERIMENTAL|Interventions municipalities|Locally adapted TIME (Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms) intervention. Municipalities will be randomly assigned to either the intervention group or the control group. A biostatician will perform the randomisation procedure independently of the project management team and the municipalities. The project management team will provide the home care services in the municipalities with the randomisation and allocation results immediately following this procedure. The intervention will start with the educational sessions (described below) within one to two weeks after randomisation.
61930002|NCT05651659|NO_INTERVENTION|Control municipalities|Care as usual
61930003|NCT06658574|EXPERIMENTAL|Oral acetaminophen - Tablet|Acetaminophen 650 mg tablet by mouth
62483097|NCT01830335|EXPERIMENTAL|Drug|Indomethacin 1.2 mg kg 1 dose
62483098|NCT01830335|PLACEBO_COMPARATOR|Placebo|flour capsule
61930004|NCT06658574|EXPERIMENTAL|Oral acetaminophen - Liquid|Acetaminophen 650 mg liquid by mouth
61930005|NCT04870957|EXPERIMENTAL|MBSR (mindfulness-based stress reduction)|Run-in treatment then MBSR.
61930006|NCT04870957|EXPERIMENTAL|PT and exercise|Run-in treatment then PT and exercise
61930007|NCT04870957|EXPERIMENTAL|Acupressure|Run-in treatment then Acupressure
61930008|NCT04870957|EXPERIMENTAL|Duloxetine|Run-in treatment then Duloxetine
61930009|NCT04870957|EXPERIMENTAL|MBSR then PT and exercise|Run-in treatment then 8 weeks of MBSR, and then 8 weeks of PT and exercise.
61930010|NCT04870957|EXPERIMENTAL|MBSR then Acupressure|Run-in treatment, then 8 weeks of MBSR, and then 8 weeks Acupressure.
61930011|NCT04870957|EXPERIMENTAL|MBSR then Duloxetine|Run-in treatment, then 8 weeks of MBSR, and then approximately 8 weeks of Duloxetine
61930012|NCT04870957|EXPERIMENTAL|PT and exercise then MBSR|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of MBSR.
61930013|NCT04870957|EXPERIMENTAL|PT and exercise then Acupressure|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of Acupressure
61930014|NCT04870957|EXPERIMENTAL|PT and exercise then Duloxetine|Run-in treatment, then 8 weeks of PT and exercise, and then approximately 8 weeks of Duloxetine
61930015|NCT04870957|EXPERIMENTAL|Acupressure then MBSR|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of MBSR
61930016|NCT04870957|EXPERIMENTAL|Acupressure then PT and exercise|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of PT and exercise.
61930017|NCT04870957|EXPERIMENTAL|Acupressure then Duloxetine|Run-in treatment, then 8 weeks of Acupressure, and then approximately 8 weeks of Duloxetine
61930018|NCT04870957|EXPERIMENTAL|Duloxetine then MBSR|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of MBSR.
61930019|NCT04870957|EXPERIMENTAL|Duloxetine then PT and exercise|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of PT and exercise
61930020|NCT04870957|EXPERIMENTAL|Duloxetine then Acupressure|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks Acupressure.
61930021|NCT04870957|EXPERIMENTAL|PainGuide|Run-in treatment only with no additional treatments.
61930022|NCT06157567|EXPERIMENTAL|Treatment Group|Study subjects may be treated with any of the Profound Matrix applicators: Sublime, Sublative RF and/or Matrix Pro. Treatments may include combination of applicators or additional commercial devices per PI discretion.
61930023|NCT05760573|NO_INTERVENTION|Usual care plus school supplies and resources|This group will not be enrolled in the Family Wellness Program. They will receive usual care from their regular clinician plus a backpack with schools supplies and a list of resources.
61930024|NCT05760573|EXPERIMENTAL|Famliy Wellness Program|This group will be enrolled in the Family Wellness Program which consists of 8 weekly parent-child workshops prior to the children entering kindergarten as well as 4 booster sessions during the child's kindergarten year. As part of the program families will receive school supplies, books and resources.
61930025|NCT06252285|EXPERIMENTAL|Group 1 RSVt Vaccine|Participants will receive 2 intranasal administrations of RSVt vaccine
61930026|NCT06252285|PLACEBO_COMPARATOR|Group 2 Control|Participants will receive 2 intranasal administrations of placebo
62483099|NCT00886522|EXPERIMENTAL|Intrabone cord blood infusion|All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
62483100|NCT01261039|ACTIVE_COMPARATOR|Solar bed UV-radiation|Solar bed UV-radiation
62483101|NCT01261039|SHAM_COMPARATOR|Solar bed with UV filter|Solar bed with UV filter
62483102|NCT01117623|EXPERIMENTAL|Arm 1|
62483103|NCT01117623|EXPERIMENTAL|Arm 2|
62483104|NCT01117623|EXPERIMENTAL|Arm 3|
62483105|NCT01117623|EXPERIMENTAL|Arm 4|
62483106|NCT01117623|EXPERIMENTAL|Arm 5|
62483107|NCT01117623|EXPERIMENTAL|Arm 6|
61930027|NCT06128200|ACTIVE_COMPARATOR|Active|Subjects in this arm will undergo treatment with the NEUROMARK device.
61930028|NCT06128200|SHAM_COMPARATOR|Sham|Subjects in this arm will undergo the procedure with a Sham device. Sham control participants will be offered the option to receive active treatment after the 90-day follow-up provided they still meet all eligibility criteria.
61930029|NCT05440214|EXPERIMENTAL|Dialectical Behavior Therapy - Skill Training|
61930030|NCT05440214|NO_INTERVENTION|Treatment As Usual|
61930031|NCT06264310|PLACEBO_COMPARATOR|Placebo|8 study subjects will receive placebo once daily subcutaneous injection for 7 days.
61930032|NCT06264310|EXPERIMENTAL|5.0 mg R2R01|8 study subjects will receive 5.0 mg R2R01 once daily subcutaneous injection for 7 days.
61930033|NCT06264310|EXPERIMENTAL|7.5 mg R2R01|8 study subjects will receive 7.5 mg R2R01 once daily subcutaneous injection for 7 days.
61930034|NCT06264310|EXPERIMENTAL|10.0 mg R2R01|8 study subjects will receive 10.0 mg R2R01 once daily subcutaneous injection for 7 days.
61930035|NCT06416670|NO_INTERVENTION|Usual skilled nursing facility care|Control subjects will receive care at a skilled nursing facility as per usual.
61930036|NCT06416670|ACTIVE_COMPARATOR|Rehab at home|Intervention subjects will receive care in their home from a specialized care team.
61930037|NCT06543043|EXPERIMENTAL|Part A: Phenytoin + Sonrotoclax|Part A is designed to determine the effect of multiple doses of phenytoin on sonrotoclax in healthy participants.
61930038|NCT06543043|EXPERIMENTAL|Part B: Itraconazole + Sonrotoclax|Part B is designed to determine the effect of multiple doses of itraconazole on sonrotoclax in healthy participants.
61930039|NCT05712252||Fallers without a fracture|Individuals who obtain no fracture.
61930040|NCT05712252||Fallers with a fracture|Individuals who obtain one or several fractures through fall. This group can be further subgrouped according to type of fracture.
61930041|NCT03186885|EXPERIMENTAL|In-Person Family Intervention|Healthy Frio In-Person Family-focused Intervention; In-person group setting at a community center
61930042|NCT03186885|EXPERIMENTAL|Remote Technology Family Intervention|Healthy Frio Remote Technology Family-focused Intervention; Home-based delivered remotely with technology
62483108|NCT01117623|EXPERIMENTAL|Arm 7|
61930043|NCT03186885|ACTIVE_COMPARATOR|Control|Control; Participants will receive standard health education materials, a community resource guide, and encouragement to follow up with their primary care provider for office-based counseling.
62483109|NCT01117623|EXPERIMENTAL|Arm 8|
62483110|NCT06085703|EXPERIMENTAL|Henagliflozin Group|Henagliflozin will be initiated and maintained at 5mg/ day every morning until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Empagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
62691538|NCT01469156|EXPERIMENTAL|Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)|"Intraocular injection of 1.0 or 2.0 mg/0.05 cc ranibizumab.~Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met"
62483111|NCT06085703|EXPERIMENTAL|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/ day every morning until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Gliclazide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
62691539|NCT01469156|ACTIVE_COMPARATOR|Ranibizumab 0.5 mg|"Intraocular injection of 0.5 mg/0.05 cc ranibizumab.~Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met"
62691540|NCT01515215|ACTIVE_COMPARATOR|High-frequency Left rTMS|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 42 Trains, 5 second duration, 25 second inter-train interval."
62691541|NCT01515215|ACTIVE_COMPARATOR|Bilateral rTMS|"Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval."
62131996|NCT04460807|PLACEBO_COMPARATOR|Placebo|"Standard chemotherapy : paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.~+~Placebo: single oral tablet until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
62323893|NCT06693453|EXPERIMENTAL|Intervention Group|38 patients were treated with acupuncture using Khanh Phong 20x15 needles inserted into specific acupuncture points. Afterward, the acupuncture needles were connected to electrodes to administer electrical stimulation through the KWD808-1 electroacupuncture machine. Dry cupping will be applied using 6 size 1 acrylic cups (internal diameter 4.5 cm), with a distance of 3 cm between each cup, parallel to the spine, bilaterally according to the boundaries of acupoints BL17, BL23, and B25. This group will perform electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and dry cupping for 10 minutes every 4 days (3 sessions over 2 weeks).
62323894|NCT01609959|ACTIVE_COMPARATOR|Azilsartan group|
62323895|NCT01609959|ACTIVE_COMPARATOR|Valsartan group|
62323896|NCT00878072|EXPERIMENTAL|Famciclovir|
62323897|NCT00096746||A1|HIV infected individuals on first line ATV based HAART with presence of I50L mutation.
62323898|NCT00096746||A2|HIV infected PI naïve on failed NNRTI based regimen.
62323899|NCT01217658|EXPERIMENTAL|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
62323900|NCT01217658|ACTIVE_COMPARATOR|AAP Education|Those receiving the control group allocation will be counseled in the American Academy of Pediatrics guidelines regarding Infant Colic (AAP Infant Colic counseling).
62323901|NCT05547438|EXPERIMENTAL|Treatment Arm 1|0.8, 4, 8, or 16 mg/mL NTS-104 solution for IV infusion
62323902|NCT05547438|PLACEBO_COMPARATOR|Treatment Arm 2|Single administration of placebo at the same volume and duration
62323903|NCT05940987|EXPERIMENTAL|Intervention Group|"Participants in the intervention group will receive one 20-30 minutes 5A smoking cessation health consultation after enrollment; They will be given regular phone-based smoking cessation intervention once a week in the first month and once a month thereafter (15 times in total). Participants will be followed at 2, 6, 12 months, and cotinine urine test kits will be mailed to those who have self-reported smoking cessation at follow-up, which is used to confirm whether they have quitted smoking or not. (smoking cessation is defined as urine cotinine levels below 200 ng/mL)."
62323904|NCT05940987|NO_INTERVENTION|Control Group|"Participants in the control group will receive one 20-30 minute 5A smoking cessation health consultation after enrollment; Phone-based smoking cessation intervention will not be regularly given after enrollment."
62323905|NCT03393013|EXPERIMENTAL|KZR-616 45 mg + standard of care therapy (Phase 1b)|"Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy.~Two Phase 1b cohorts received 45 mg at some point during the study.~Cohort 1 received 45 mg zetomipzomib frozen maleate weekly for 13 weeks.~Cohort 2a followed a step-up dosing procedure. Patients received zetomipzomib frozen maleate, 30 mg weekly for 2 weeks, followed by 45 mg weekly for 2 weeks then followed by 60 mg weekly for 9 weeks.~KZR-616 was administered as a SC injection."
61930044|NCT00907868|ACTIVE_COMPARATOR|Arm I|Patients undergo whole breast irradiation (WBI) once daily for 5 weeks (weekdays only).
61930045|NCT00907868|EXPERIMENTAL|Arm II|Patients undergo WBI as in arm I and a radiation tumor bed boost once daily for 8 days (weekdays only).
62323906|NCT03393013|EXPERIMENTAL|KZR-616 60 mg + standard of care therapy (Phase 1b)|"Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy.~Four Phase 1b cohorts received 60 mg at some point during the study.~Cohort 2 received 60 mg zetomipzomib frozen maleate weekly for 13 weeks.~Cohorts 2a, 2b, and 2c all followed a step-up dosing procedure. Patients in Cohort 2a received zetomipzomib frozen maleate, 30 mg weekly for 2 weeks, followed by 45 mg weekly for 2 weeks then followed by 60 mg weekly for 9 weeks. Patients in Cohort 2b received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 60 mg weekly for 12 weeks. Patients in Cohort 2c (tolerability strategies cohort) received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 60 mg weekly for 12 weeks.~KZR-616 was administered as a SC injection."
62323907|NCT03393013|EXPERIMENTAL|KZR-616 75 mg + standard of care therapy (Phase 1b)|"Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy.~One Phase 1b cohort received 75 mg at some point during the study.~Cohort 3 followed a step-up dosing procedure. Patients in Cohort 3 received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 75 mg weekly for 12 weeks.~KZR-616 was administered as a SC injection."
61930046|NCT06707844|EXPERIMENTAL|Tissue flossing|"* Tissue flossing involves wrapping a latex band around the calf muscles with 50-75% elongation, followed by active ankle movements (dorsiflexion, plantarflexion, circles, heel raises).~* Protocol: 4 sets of 8 repetitions, 10-second rest between sets~* Performed twice weekly for 3 weeks."
61930047|NCT06707844|ACTIVE_COMPARATOR|Myofascial release|"* Myofascial release is a manual therapy applying sustained pressure on the calf muscles to release fascial restrictions.~* Protocol: 3 sets of 2-minute pressure applications with a 1-minute break between sets~* Performed twice weekly for 3 weeks"
61930048|NCT06710444|ACTIVE_COMPARATOR|Group I|This group will receive ultrasound-guided erector spinae plane block
61930049|NCT06710444|EXPERIMENTAL|Group II|This group will receive ultrasound-guided Retrolaminar plane block
61930050|NCT05221827||MIBC|Patients with clinically and pathologically confirmed diagnosis of MIBC stage II-IIIA, planned to undergo RC.
62483112|NCT03077451|EXPERIMENTAL|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
61930051|NCT06321757||Patients with small native vessel coronary artery disease|- Patients with small native vessel coronary artery disease y/or patients with High Bleeding Risk
61930052|NCT04121416|EXPERIMENTAL|Oxycodone group|
62323908|NCT03393013|EXPERIMENTAL|KZR-616 60 mg + standard therapy (Phase 2)|"60 mg dose level of KZR-616 selected based on data from the phase 1b dose escalation and administered to patients with active lupus nephritis in combination with standard therapy including at least one immunosuppressive agent.~KZR-616 was administered as a SC injection weekly at a dose of 60 mg for 24 weeks (including a step-up from an initial Week 1 dose of 30 mg).~\*\* See Limitations/Caveats for additional information"
62483113|NCT01197391|EXPERIMENTAL|Cohort 1|Dose 1 versus placebo
62483114|NCT01197391|EXPERIMENTAL|Cohort 2|Dose 2 versus placebo
61930053|NCT04121416|EXPERIMENTAL|Sufentanil group|
61930054|NCT01440062|EXPERIMENTAL|Verum (high dose)|verum arm receiving high dose Vitamin D oil
61930055|NCT01440062|EXPERIMENTAL|Verum (low dose)|low dose arm receiving neutral oil and low dose of Vitamin D
61930056|NCT02162849|EXPERIMENTAL|Varenicline + Placebo Patch|"Varenicline dosing follows the recommended 12 week course: 0.5 milligram mg/day by mouth for Days 1-3, 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter. Participant takes Varenicline 1-10 days after Visit 1.~Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo. Some of the counseling sessions may be recorded by video and/or audio tape.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
61930057|NCT02162849|EXPERIMENTAL|Nicotine Patch + Placebo Tablet|"Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.~Starting on Day 8, and then every day after that, participant applies 1 nicotine patch.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
61930058|NCT06708078|EXPERIMENTAL|Canhope follow-up|Day 0: Post-announcement interview with allied health professionals (information and support interview) and then between Day 7 and Day 14, phone call (support relationship, answers to questions), followed by a hotline dedicated to questions. Between month 3 and month 10: patient focus group.
61930059|NCT06708078|NO_INTERVENTION|Usual Care|Announcement of a management by the neuroradiologist and frequency of imaging follow-up, information media
61930060|NCT00780390|PLACEBO_COMPARATOR|CRPS patients without spinal cord stimulation|CRPS patients declining spinal cord stimulation therapy. Autonomic Function will be assessed at baseline and again within 2 years.
61930061|NCT00780390|EXPERIMENTAL|CRPS patients: candidates for spinal cord stimulator|CRPS patients who are candidates for spinal cord stimulator implant. These patients will have Autonomic Function assessments before and after the Standard of Care spinal cord stimulation implant
62131997|NCT01627652|EXPERIMENTAL|altitude|subjects will be studies at sea level and at high altitude
62323909|NCT06649383|EXPERIMENTAL|VR group|This group use VR glasses during surgery
62323910|NCT06649383|NO_INTERVENTION|Control group|Control group without intervention, conventional treatment
62323911|NCT03295097|OTHER|Clinical Decision Support System|The Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.
62483115|NCT03035643|EXPERIMENTAL|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
62483116|NCT00633672|EXPERIMENTAL|1|20mg Oral tablet daily
62483117|NCT00633672|EXPERIMENTAL|2|40mg oral tablet daily
62483118|NCT00633672|ACTIVE_COMPARATOR|3|150mg oral twice daily
62691542|NCT01515215|SHAM_COMPARATOR|Sham rTMS|Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
62131998|NCT01784575|EXPERIMENTAL|Patient Navigator Intervention|The Patient Navigator Intervention arm will have two 20 minute interactive sessions with a patient navigator in which they will learn about quality measures and view scores on the Massachusetts Health Quality Partner's website.
62131999|NCT01784575|ACTIVE_COMPARATOR|Control|The control arm will receive an information pamphlet about health care quality.
61930062|NCT04935359|EXPERIMENTAL|Safety run-in part: NIS793+gemcitabine+nab-paclitaxel|In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel.
61930063|NCT04935359|EXPERIMENTAL|Randomized part: NIS793+gemcitabine+nab-paclitaxel|"Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel~Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped."
61930064|NCT04935359|PLACEBO_COMPARATOR|Randomized part: placebo+gemcitabine+nab-paclitaxel|"Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel~Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped."
61930065|NCT05834413|EXPERIMENTAL|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"Phase1： Chemotherapy：Proposed platinum-containing two-drug adjuvant chemotherapy, vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin within 8 weeks after surgery, according to CSCO guidelines (2022).~TCM1 granules：oral granules, HeWeiYangXueFang , twice a day, every 21 days for 4 cycles.~Phase 2： One of the following agents may be selected after chemotherapy ：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab.A total of 12 cycles will be performed or the patient will discontinue the drug due to intolerable toxic side effects.~TCM2 granules：oral granules, FeiPingFang , twice a day, every 21 days for 12 cycles."
61930066|NCT05834413|PLACEBO_COMPARATOR|chemotherapy plus TCM 1 placebo&ICIs plus TCM2 placebo|"Phase1： Chemotherapy：Proposed platinum-containing two-drug adjuvant chemotherapy, vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin within 8 weeks after surgery, according to CSCO guidelines (2022).~Placebo1 granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect , twice a day, every 21 days for 4 cycles.~Phase 2：One of the following agents may be selected after chemotherapy：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab.A total of 12 cycles will be performed or the patient will discontinue the drug due to intolerable toxic side effects.~Placebo2 granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, twice a day, every 21 days for 12 cycles."
61930067|NCT04226534|OTHER|Maximal effort test|Physiological database
61930068|NCT01852370|EXPERIMENTAL|BOLT+BMT|All patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
61930069|NCT05462873|EXPERIMENTAL|Part 1: Dose escalation|Dose escalation with QEQ278 single agent
61930070|NCT05462873|EXPERIMENTAL|Part 2: Dose expansion|Dose expansion with QEQ278 single agent
61930071|NCT01008631|EXPERIMENTAL|dialysis|Two doses of sodium thiosulfate
61930072|NCT01008631|EXPERIMENTAL|healthy volunteer|One dose of sodium thiosulfate
61930073|NCT06709326|EXPERIMENTAL|Primary metastatic prostate cancer|Men who have not previously received treatment for prostate cancer.
62132000|NCT06261710|EXPERIMENTAL|Sonography Only|The use of ultrasound parameters to asses the progress of labour from admission to delivery. Namely, Angle of Progression, Head Perineum Distance, Midline Angle and Cervix Dilatation at 3-4 hour intervals until delivery.
62132001|NCT06261710|NO_INTERVENTION|Traditional|The traditional use of internal vaginal examination to assess cervix dilatation, fetal head position, station and orientation within the pelvis during the course of labour as routinely performed every 3-4 hours in labour and until delivery.
61930074|NCT06709326|EXPERIMENTAL|PSA relapse|Men with PSA recurrance after surgery.
62132002|NCT03791905|EXPERIMENTAL|TP Arm|Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (\<35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
61930075|NCT06709326|OTHER|Healthy research subjects|Control group to distinguish tumor-specific changes from normal signals.
61930076|NCT05249192|EXPERIMENTAL|Immediate UC removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
61930077|NCT05249192|ACTIVE_COMPARATOR|Early UC removal|Urinary catheter removal on first postoperative day (6 a.m.) as per standard protocol
61930078|NCT06192394|SHAM_COMPARATOR|Control Group|"Patients in the control group will undergo the standard bowel preparation determined by the hospital, which includes the following steps:~* No solid food should be consumed after the evening meal 2 days before colonoscopy.~* Only clear liquids should be consumed the day before colonoscopy.~* If the colonoscopy is scheduled for 12:00 PM, nothing should be eaten or drank after midnight on the preceding night; if the colonoscopy is scheduled for the afternoon, nothing should be consumed after 06:00 AM on the same day.~* The entire X-M Diet syrup should be consumed with plenty of water within 1 hour at 4:00 PM and 8:00 PM the day before colonoscopy. Additionally, an enema (BT Enema) should be administered at 11:00 PM the night before and at 07:00 AM on the day of colonoscopy."
61930079|NCT06192394|ACTIVE_COMPARATOR|Chewing Gum Group|"All patients in the gum-chewing group will receive the following interventions in addition to standard bowel preparation:~* Patients will be instructed to chew xylitol gum for 20 minutes at three intervals (17:00-19:00, 19:00-21:00, 21:00-23:00) after consuming the prescribed X-M Diet syrup on the day before the procedure.~* Following the administration of an enema on the procedure day, patients will be instructed to chew gum every 2 hours for 20 minutes until one hour before the scheduled procedure time."
62691543|NCT06399484|EXPERIMENTAL|Neural mobilization group|Manual mobilizations of the median nerve.
62691544|NCT06399484|PLACEBO_COMPARATOR|Placebo group|wrist movements no producing sliding of the median nerve
62691545|NCT03469609|EXPERIMENTAL|Perioperative mucous fistula refeeding|Perioperative mucous fistula refeeding between enterostomy creation and enterostomy closure
62483119|NCT06562179|EXPERIMENTAL|da Vinci SP® Single-Port Robotic Surgical System|"This study will be separated into four stages, depending on the condition the participant is diagnosed with. Each Participant will go through (1) one operation.~Stage One will include five (5) subjects who undergo cholecystectomy and five (5) subjects who undergo hiatal hernia repair with fundoplication (Nissen or Toupet) for a total of ten (10) subjects.~Stage Two will include five (5) subjects who undergo gastrectomy and five (5) subjects who undergo distal pancreatectomy for a total of ten (10) subjects.~Stage Three will include five (5) subjects who undergo pancreaticoduodenectomy and five (5) subjects who undergo esophagectomy for a total of ten (10) subjects.~Stage Four will include five (5) subjects who undergo hepatectomy"
62483120|NCT03589430||1 child A|child A liver cirrhosis
62483121|NCT03589430||2 child B|child B liver cirrhosis
62483122|NCT03589430||3 child C|child C liver cirrhosis
62483123|NCT03216967|ACTIVE_COMPARATOR|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
62483124|NCT03216967|EXPERIMENTAL|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
61930080|NCT06192394|ACTIVE_COMPARATOR|Walking Exercise Group|"All patients in the walking group will receive the following interventions in addition to standard bowel preparation:~* Patients will be asked to drink the prescribed X-M diet syrup 1 day before the procedure and then walk for 1 hour at two specific times (from 18:00 to 19:00 and from 22:00 to 23:00).~* On the day of the procedure, after the enema, patients will be instructed to walk from 08:00 until one hour before the scheduled procedure time.~* Patients will be given a pedometer to count their steps and will be asked to walk at least 3000 steps before the colonoscopy procedure."
61930081|NCT06413680|EXPERIMENTAL|Phase 1: Dose Escalation|Multiple dose level (DL) Cohorts to identify the recommended Phase 2 dose (RP2D)
61930082|NCT06413680|EXPERIMENTAL|Phase 2: Dose Expansion|Cohort 1: Melanoma Participants Cohort 2: Clear-cell renal-cell carcinoma (ccRCC) participants
61930083|NCT03927807|EXPERIMENTAL|repetitive hourly dose of oral misoprostol|The dose will be 10 microgram oral misoprostol that will be administered hourly up to 12 doses or till onset of regular uterine activity.
61930084|NCT03927807|EXPERIMENTAL|two hourly dose of oral misoprostol|The dose will be 20 microgram oral misoprostol solution that will be administered every 2 hours up to 6 doses or till onset of regular uterine activity.
62323912|NCT03651999||dream workshop|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse anesthetist, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; The nurse anesthetist explains the hospitalization process and will help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...); the child will be able to customize his mask and choose the blanket he wants to take along; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
62323913|NCT03651999||control|"No dream workshop"
62323914|NCT06499259|EXPERIMENTAL|Intervention group|Data collection tools will be applied to the mothers in the experimental group and the mandala painting activity will begin. The mandala painting program will consist of a total of 7 mandala painting sessions with 40-minute sessions every day for 7 days. The researcher will accompany the first mandala painting activity. She will answer the participant's questions. The mother will do the remaining 6 mandala coloring sessions alone every day; at the end of the 6 days, the researcher will reapply the data collection tools.
62323915|NCT06499259|NO_INTERVENTION|Control group|No application will be made to the mothers in the control group within the scope of the research. Data collection forms will be applied as the first measurement when they are included in the study; at the end of 7 days, the same mothers will fill out the data collection forms again as the last measurement.
62323916|NCT00004568||Inherited Neurological Patients|Includes individuals and families with a known or unknown inherited neurological condition.
62323917|NCT02945761|ACTIVE_COMPARATOR|High concentration of sugar solution|Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
62483125|NCT00351039|EXPERIMENTAL|Bevacizumab, Erlotinib, Pemetrexed|Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer
62483126|NCT05723393|EXPERIMENTAL|20 ml T2 ESPB group|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
61930085|NCT04624438|EXPERIMENTAL|Electromyostimulation - EMS|Experimental group comprised of healthy young adults that undergoes unilateral isometric training using electromyostimulation over quadriceps femoris
62483127|NCT01798264|EXPERIMENTAL|10 mcg./day|ITCA 650 (exenatide in DUROS)
61930086|NCT04624438|EXPERIMENTAL|Voluntary activation - VOLUNTARY|Experimental group comprised of healthy young adults that undergoes unilateral isometric training based on voluntary activation of quadriceps femoris
61930087|NCT04624438|EXPERIMENTAL|Combination of EMS and VOLUNTARY - COMBINED|Experimental group comprised of healthy young adults that undergoes unilateral isometric training that combines electromyostimulation and voluntary activation of quadriceps femoris.
61930088|NCT04624438|NO_INTERVENTION|Control group - CONTROL|Group of healthy young adults who received no intervention.
62483128|NCT01798264|EXPERIMENTAL|20 mcg/day|ITCA 650 (exenatide in DUROS)
62483129|NCT01798264|EXPERIMENTAL|40 mcg/day|ITCA 650 (exenatide in DUROS)
62483130|NCT01798264|EXPERIMENTAL|80 mcg/day|ITCA 650 (exenatide in DUROS)
62483131|NCT01348438|OTHER|Single arm study|
62483132|NCT03060486|EXPERIMENTAL|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
62483133|NCT03961828|EXPERIMENTAL|Thalassemia with HCV|The study was carried out upon 50 β-thalassaemic children infected with hepatitis C virus who attended for a medical check-up at the Hematology Unit, Pediatric Department, Tanta University Hospital. Hepatitis C virus infection was diagnosed by serological detection of HCV-Ab, and quantitative detection of serum HCV RNA by polymerase chain reaction (PCR).
62483134|NCT01490372||GDM offspring|Children born from gestational diabetes mellitus pregnancy
62483135|NCT01490372||No-GDM offspring|Children born from a normal pregnancy
62483136|NCT06541327||CAR-T|Chimeric antigen receptor modified T cells
62483137|NCT06253572|EXPERIMENTAL|1|Education
62691546|NCT03469609|NO_INTERVENTION|No mucous fistula refeeding|No perioperative mucous fistula refeeding
62691547|NCT04832152|OTHER|Feasibility trial group|One group (arm) trial where all will receive treatment.
61930089|NCT02972840|EXPERIMENTAL|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
61930090|NCT02972840|PLACEBO_COMPARATOR|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
61930091|NCT04274478|OTHER|Single group|
61930092|NCT06474663|EXPERIMENTAL|Phase 1|Participants enrolled in Phase 1, the dose level of cladribine, cytarabine, decitabine, and sorafenib will depend on when you join this study. Up to 2 dose levels of this drug combination may be tested. Between 3-6 participants will be enrolled in each dose level. The first group of participants will receive the starting dose level of this drug combination. If no intolerable side effects are seen, the next group of participants will receive the higher dose level of this drug combination.
61930093|NCT06474663|EXPERIMENTAL|Dose Expansion|Participants enrolled in Dose Expansion, you will receive cladribine, cytarabine, decitabine, and sorafenib at the recommended dose level found in Phase 1.
61930094|NCT05053321|EXPERIMENTAL|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
61930095|NCT05748665|EXPERIMENTAL|remimazolam|remimazolam induction
61930096|NCT05748665|ACTIVE_COMPARATOR|etomidate|etomidate induction
61930097|NCT00478881|EXPERIMENTAL|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
62483138|NCT04685291|ACTIVE_COMPARATOR|Group 1: Control|Systemic conventional pain management. Adult patients with acute fractures of the clavicle, who are scheduled to have internal fixation of the fracture within the next 24 hours receive oral and intravenous pain management.
62483139|NCT04685291|ACTIVE_COMPARATOR|Group 2: Nerve Block|Adult patients with acute fractures of the clavicle, who are scheduled for an internal fixation of the fracture within the next 24 hours will receive an ultrasound-guided block of the supraclavicular nerves using a maximum of 3 ml of a long-acting local anesthetic. The injection is carried out directly in the emergency department following a sonographic or radiological diagnosis.
62483140|NCT05191680|EXPERIMENTAL|Apalutamide 6 months|Participants will receive apalutamide 240 mg (4 x 60 mg tablets) orally once a day for up to 6 months.
62483141|NCT05191680|EXPERIMENTAL|Apalutamide 3 months + Placebo 3 months|Participants will receive apalutamide 240mg (4 x 60 mg tablets) orally once a day for up to 3 months followed by placebo to match apalutamide (4 tablets) orally once a day for up to 3 months.
62483142|NCT05191680|PLACEBO_COMPARATOR|Placebo 6 months|Participants will receive placebo to match apalutamide (4 tablets) orally once a day for up to 6 months.
62483143|NCT05406050|EXPERIMENTAL|TR|Subjects first receive a single-dose of 0.75 μg test eldecalcitol soft capsule (T, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China) in the first treatment period and to receive the reference (R, produced by Chugai Pharmaceutical Co., Ltd. Japan) in the second treatment period.
62483144|NCT05406050|EXPERIMENTAL|RT|Subjects first receive a single-dose of 0.75 μg reference eldecalcitol soft capsule (R, produced by Chugai Pharmaceutical Co., Ltd. Japan) in the first treatment period and to receive test capsule (T, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China) in the second treatment period.
62691548|NCT02868931|EXPERIMENTAL|INPUT|INPUT consists of 12 lessons comprising all relevant information in order to treat diabetes with an insulin pump. Patients learn to effectively use the different features of their pump in order to improve not only glycemic control but also to improve the implementation of pump therapy in daily life. Psychological and motivational aspects of living with diabetes and living with an insulin pump are addressed as well.
62691549|NCT02868931|NO_INTERVENTION|Waiting list|Patients are randomly assigned to the waiting list. After completion of the 6-month follow-up, these patients will also receive training with INPUT.
62691550|NCT03684785|EXPERIMENTAL|Dose Escalation Phase 1b|Determine the recommended Phase 2 dose of cavrotolimod in combination with pembrolizumab.
62691551|NCT03684785|EXPERIMENTAL|Dose Expansion Phase 2; Merkel cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on an anti-PD-1 / anti-PD-L1 therapy.
61930098|NCT00478881|PLACEBO_COMPARATOR|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
61930099|NCT03964766|EXPERIMENTAL|rotary instrumentation|endodontic treatment will be performed with the use of pedo rotary files that will be activated by engine
61930100|NCT03964766|ACTIVE_COMPARATOR|hand istrumentation|endodontic treatment will be performed with the use of conventional hand files
61930101|NCT05079516|EXPERIMENTAL|Primary motor cortex--Exp 1|Theta burst transcranial magnetic stimulation (cTBS) will be applied over primary motor cortex.
61930102|NCT05079516|EXPERIMENTAL|Somatosensory cortex--Exp 1|Theta burst transcranial magnetic stimulation (cTBS) will be applied over primary somatosensory cortex.
61930103|NCT05079516|SHAM_COMPARATOR|Vertex sham--Exp 1|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex.
61930104|NCT05079516|EXPERIMENTAL|Anterior superior parietal lobule--Exp 2|Theta burst transcranial magnetic stimulation (cTBS) will be applied over Anterior superior parietal lobule.
61930105|NCT05079516|EXPERIMENTAL|Ventral premotor cortex--Exp 2|Theta burst transcranial magnetic stimulation (cTBS) will be applied over Ventral premotor cortex.
62483145|NCT02121067|EXPERIMENTAL|LNG-IUS placed at 2 weeks postpartum|Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum
62483146|NCT00903877|EXPERIMENTAL|Placebo followed by T3|Participants receive placebo for 4 weeks. Following placebo, participants begin T3 treatment at 25 mcg per day, for 4 weeks. Following this, participants begin T3 treatment at 50 mcg per day, for 4 more weeks.
61930106|NCT05079516|EXPERIMENTAL|Cerebellar cortex--Exp 2|Theta burst transcranial magnetic stimulation (cTBS) will be applied over cerebellar cortex.
61930107|NCT05079516|SHAM_COMPARATOR|Vertex sham--Exp 2|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex.
61930108|NCT05250089|EXPERIMENTAL|Emergency physicians|"Each participant will have to carry out two simulation sessions. The first simulation will correspond to the usual evaluation, that is to say it will take place on a day that will not be preceded by night duty during the three previous nights.~The second simulation will correspond to the assessment twenty-four hours after the end of a call, in the post-recovery period. The participant must therefore have performed a night shift the day before the day when the simulation takes place. This call must have a minimum duration of twelve hours on night shifts."
62323918|NCT02945761|ACTIVE_COMPARATOR|conventional surgical dressing change|conventional surgical dressing change:separated suture, expanded the wound, placed drainage ribbon gauze and used hydrogen peroxide or(and) PVP to wash the wound; the decision-making power of these operators is determined by a doctor. After the doctor confirms granulation cleaning in the wound, the decision-making power of suture is also determined by a doctor.
62483147|NCT06001463|EXPERIMENTAL|reduce the severity, and enhance healing of radiation dermatitis|The patient received part of the breast/neck skin CSMed® dressing or clinical routine skin care.
62483148|NCT06474936|EXPERIMENTAL|Intervention|Food habits education regarding the Mediterranean diet adapted according to the country of origin.
62483149|NCT05975905|EXPERIMENTAL|Arm 1 (N=20)|KER-012 (Dose A) subcutaneously (SC) (every 4 weeks \[Q4W\]) Treatment Period: Dose A for 24 weeks; Extension Period: Dose A for another 72 weeks
62691552|NCT03684785|EXPERIMENTAL|Dose Expansion Phase 2, cutaneous squamous cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and cemiplimab in patients with advanced cutaneous squamous cell carcinoma that have progressed on an anti-PD-1.
61930109|NCT03149510|EXPERIMENTAL|Mobile Application|Participants will be using a mobile application, activity monitor and scale.
61930110|NCT03149510|NO_INTERVENTION|Control Group|Participants will receive standard of care.
61930111|NCT00606827|EXPERIMENTAL|A|Bicarbonate
61930112|NCT00606827|ACTIVE_COMPARATOR|B|Saline
61930113|NCT04654468|EXPERIMENTAL|Crovalimab|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
61930114|NCT06708845|EXPERIMENTAL|Dose Level 1|
61930115|NCT06708845|EXPERIMENTAL|Dose Level 2|
61930116|NCT02636374|EXPERIMENTAL|Guided Imagery|Participants listened to a pregnancy-specific guided imagery recording on four separate occasions during their pregnancies. Perceived stress was measured immediately pre and post each listening session using the Perceived Stress Measure-9 (PSM-9).
61930117|NCT04873128|EXPERIMENTAL|Healthy adults|"Healthy adults who had no infection with SARS-CoV-2 virus before or had recovered from COVID-19 and plan to take the various COVID-19 experimental vaccine candidates or had already one dose of COVID-19 vaccine and are going to have the second vaccination with a different vaccine.~Study related procedures:~1-3 days before application of the first vaccine dose (blood sample 1) 7-10 days after first dose of vaccine (blood sample 2), 1-3 days before second dose of vaccine (blood sample 3) 7-10 days after second vaccine dose (blood sample 4) 6-12 Months after second vaccine dose (blood sample 5, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
61930118|NCT04873128|EXPERIMENTAL|COVID-19 vaccinated subjects with side effects|"COVID-19 vaccinated subjects with diagnosed central thrombosis, anaphylactic shock or other major or minor complications such as dermatitis.~Study related procedures: Blood sample will be taken without time frame 1-3 days after admission to the hospital (severe side effects) or consulting a doctor (mild side effects) (blood sample 1) during treatment (blood sample 2) After subject is recovered (blood sample 3) 6-12 Months after recovering (blood sample 4, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
61930119|NCT04882501|ACTIVE_COMPARATOR|Actual aromatherapy product|QUEASEEase quick tab Aromatherapy product 50 % chance of participant receiving based on randomization
61930120|NCT04882501|PLACEBO_COMPARATOR|Placebo product|Placebo product (normal saline) 50% chance of participant receiving based on randomization
61930121|NCT06127121||Digital Art Activity|"Visit 1, Participants will be asked to complete a symptom questionnaire and then you will interact with the digital art tool. Participants will first complete a short breathing exercise, and then Participants will interact with the digital art tool. The digital tool combines a digital canvas with a collage activity. Participants will be asked to choose a background and then answer questions about your general well-being and your physical and emotional symptoms as they relate to cancer and cancer treatment.~Visit 2, Participants will be asked to fill out the symptom questionnaire, complete another activity such as listening to meditative music for 10 minutes, and then fill out the symptom questionnaire again.~Visit 3, Participants will fill out the symptom questionnaire and engage in the digital art activity again. Participants will then be asked to fill out 3 other questionnaires about your feelings of distress."
61930122|NCT05005520|ACTIVE_COMPARATOR|Active Comparator: Single ascending dose DTRI-031|Drug: DTRI-031 Single doses of DTRI-031 delivered via intravenous injection. Ascending dose levels will be evaluated.
62323919|NCT03554538|EXPERIMENTAL|Web app exercises|An evidence based exercise program for the shoulder pain. Web application with multimedia animations with the tailored exercise program for each patient in this group.
62323920|NCT03554538|ACTIVE_COMPARATOR|Exercises|An evidence based exercise program for the shoulder pain.
62323921|NCT03468283|EXPERIMENTAL|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
62323922|NCT03468283|NO_INTERVENTION|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
62483150|NCT05975905|EXPERIMENTAL|Arm 2 (N=20)|KER-012 (Dose B) SC (Q4W) Treatment Period: Dose B for 24 weeks; Extension Period: Dose B for another 72 weeks
61930123|NCT05005520|PLACEBO_COMPARATOR|Placebo Comparator: Single Dose Placebo|Drug: Placebo Single doses of placebo delivered via intravenous injection, matched to DTRI-031 cohorts
61930124|NCT02119091|EXPERIMENTAL|Moxifloxacin|Single oral dose 400 mg
62132003|NCT03791905|EXPERIMENTAL|FOLFOX Arm|Patients with baseline PET scan assigned to this Arm will receive three cycles of 2-weekly schedule of induction chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU), consisting of oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2, and 5-FU 2 g/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (\<35% decrease in SUVmax) crossed over to TP regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
62132004|NCT04444804||Rivaroxaban|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
62323923|NCT05645484||18F-PFPN PET imaging|For clinically suspected or confirmed melanoma patients, targeted melanin-specific imaging 18F-PFPN PET/MR was performed. CT was instead when MRI was contraindicated. PET images, clinical characteristics, and follow-up information will be collected for prognostic analyses.
62323924|NCT05645484||18F-FDG PET imaging|For clinically suspected or confirmed melanoma patients, general metabolic imaging 18F-FDG PET PET/CT was performed. PET images, clinical characteristics, and follow-up information will be collected for prognostic analyses.
62323925|NCT03119376|NO_INTERVENTION|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
62323926|NCT03119376|EXPERIMENTAL|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
62483151|NCT05975905|EXPERIMENTAL|Arm 3 (N=20)|KER-012 (Dose C) SC (Q4W) Treatment Period: Dose C for 24 weeks; Extension Period: Dose C for another 72 weeks
62483152|NCT05975905|PLACEBO_COMPARATOR|Arm 4 (N=30)|Treatment Period: Placebo for 24 weeks; Extension Period: Dose B for another 72 weeks
61930125|NCT02119091|PLACEBO_COMPARATOR|Placebo|Single oral dose
61930126|NCT03211273||Patient cohort|Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
61930127|NCT06458426|EXPERIMENTAL|Rigid Pylon|The prosthesis will be given a commercial prosthetic foot and a rigid pylon that connects the prosthetic foot to the socket.
61930128|NCT06458426|EXPERIMENTAL|Shock-absorbing Pylon|The prosthesis will be given a commercial prosthetic foot and a compressive 'shock-absorbing' pylon that connects the prosthetic foot to the socket.
61930129|NCT04802174|EXPERIMENTAL|1/ Phase I|Dose escalation of Berzosertib + lurbinectedin
61930130|NCT04802174|EXPERIMENTAL|2/ Phase II|Berzosertib + lurbinectedin at MTD
61930131|NCT01706692||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
61930132|NCT01706692||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
61930133|NCT01706692||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
61930134|NCT01706692||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
61930135|NCT01706692||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
61930136|NCT01706692||Fumaric acids|Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
61930137|NCT01706692||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
61930138|NCT01706692||Other anti-psoriatic systemic treatments|e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
61930139|NCT03487549|EXPERIMENTAL|VP-102|Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.
61930140|NCT06543394|ACTIVE_COMPARATOR|Postcard/behavioral letter/4 calls|Mailed a priming postcard, followed by a prospect theory-informed recruitment letter, followed by up to 4 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
61930141|NCT06543394|ACTIVE_COMPARATOR|No postcard/behavioral letter/4 calls|Mailed a prospect-theory informed recruitment letter that is not preceded by a priming postcard, followed by up to 4 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
62323927|NCT03119376|NO_INTERVENTION|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
62323928|NCT04598165|EXPERIMENTAL|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
62483153|NCT04222023|EXPERIMENTAL|IVIG group|Administration of a single dose of IVIG at day 10+/- 4 days, day 41 +/- 7 days and day 62 +/- 7 days. The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
62483154|NCT04222023|NO_INTERVENTION|Control group|
62483155|NCT00486239|EXPERIMENTAL|1|Behavioral TLE 1A
62483156|NCT00486239|EXPERIMENTAL|2|TLE Arm II
62483157|NCT00486239|EXPERIMENTAL|B|Control Arm B
62323929|NCT04598165|NO_INTERVENTION|No SMS Control|Control receiving standard of care.
62323930|NCT02674997||Study participants|Participants with Hemophila A
62323931|NCT06109116|EXPERIMENTAL|Self myofascial release + Conventional PT|"The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel concentrating on the medial arch for 2 minutes in sitting position, with as much pressure as they could, pushing into discomfort but not pain. Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility Conventional PT including Hot pack, Knee to chest exercise, bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise.~."
62323932|NCT06109116|OTHER|Conventional PT|Hot pack, Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins Type: Self myofascial release to improve hamstring flexibility
62323933|NCT02424955|EXPERIMENTAL|3D Perfusion Ultrasound|undergo 3D ultrasound perfusion imaging with perflutren
62323934|NCT05288985|EXPERIMENTAL|Erector spinae plane catheter group in addition to Systemic Analgesia|
62323935|NCT05288985|ACTIVE_COMPARATOR|Systemic Analgesia Only Group|
62323936|NCT02927808|EXPERIMENTAL|Intervention group - Motivational Interview|"Patients assigned to the intervention group will be given a leaflet entitled Information leaflet about LDL Cholesterol that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge."
62323937|NCT02927808|NO_INTERVENTION|Control group|Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.
62483158|NCT01318369|EXPERIMENTAL|Namisol|Namisol (dronabinol) single dose 8 mg
62483159|NCT01318369|ACTIVE_COMPARATOR|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
62483160|NCT04057287||NASH related Cirrhosis|
61930142|NCT06543394|ACTIVE_COMPARATOR|Postcard/control letter/4 calls|Mailed a priming postcard, followed by a usual care control recruitment letter, followed by up to 4 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
61930143|NCT06543394|ACTIVE_COMPARATOR|No postcard/control letter/4 calls|Mailed a usual care control recruitment letter that is not preceded by a priming postcard, followed by up to 4 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
62132005|NCT04444804||Low-molecular-weight heparin (LMWH) and Phenprocoumon|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
62323938|NCT03919916|EXPERIMENTAL|Serratus plane block and patient controlled analgesia|"Initial local anaesthetic bolus of 0.4 ml/kg of 0.25% levobupivacaine. Subsequent continuous local anaesthetic infusion of 0.125% levobupivacaine~Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes"
62323939|NCT03919916|ACTIVE_COMPARATOR|Patient controlled analgesia only|Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes
62323940|NCT03430882|EXPERIMENTAL|Treatment (sapanisertib, paclitaxel, carboplatin)|Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62323941|NCT06687876|EXPERIMENTAL|Metformin|1000 mg (twice a day 500 mg) metformin orally will be administered during a 2-week period. This is followed by the standard of care, which is neoadjuvant chemoradiotherapy, involving paclitaxel (50 mg/m2), carboplatin (AUC=2), and radiotherapy (23 x 1.8 Gy over five weeks) followed by surgical resection.
62323942|NCT00530322||A|"Patients who have had previous open colorectal surgery and are referred for a further operative procedure, at which time a second-look laparoscopy can be performed."
62323943|NCT00530322||B|"Patients who have had a previous laparoscopic colorectal procedure and are having a second-look procedure"
62323944|NCT03175380|EXPERIMENTAL|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
62323945|NCT00942773|ACTIVE_COMPARATOR|CYP2C19 extensive metabolizer|
62323946|NCT00942773|ACTIVE_COMPARATOR|CYP2C19 heterozygous extensive metabolizer|
62323947|NCT00942773|ACTIVE_COMPARATOR|CYP2C19 poor metabolizer|
62483161|NCT04057287||Healthy Controls|
62483162|NCT04057287||First Degree Relatives of NASH related Cirrhosis|
62483163|NCT04057287||HBV Disease Control|
62483164|NCT01357668||Patients with JIA who are treated with Abatacept|Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
61930144|NCT06543394|ACTIVE_COMPARATOR|Postcard/behavioral letter/2 calls|Mailed a priming postcard, followed by a prospect theory-informed recruitment letter, followed by up to 2 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
61930145|NCT06543394|ACTIVE_COMPARATOR|No postcard/behavioral letter/2 calls|Mailed a prospect theory-informed recruitment letter that is not preceded by a priming postcard, followed by up to 2 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
62132006|NCT01279668|EXPERIMENTAL|Montelukast|
62132007|NCT01279668|PLACEBO_COMPARATOR|Placebo|
62483165|NCT02173886|EXPERIMENTAL|Bupropion|Bupropion SR and XL, single dosages of each separated by a wash-out period
62483166|NCT01782053|EXPERIMENTAL|Control condition|Current packaging with warning on side replaced with one of 9 mandated warning statements
61930146|NCT06543394|ACTIVE_COMPARATOR|Postcard/control letter/2 calls|Mailed a priming postcard, followed by a usual care control recruitment letter, followed by up to 2 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
61930147|NCT06543394|ACTIVE_COMPARATOR|No postcare/control letter/2 calls|Mailed a usual care control recruitment letter that is not preceded by a priming postcard, followed by up to 2 phone call attempts to schedule patient to attend an adherence counseling session with a clinical pharmacist trained in brief negotiated interviewing
61930148|NCT05979727|PLACEBO_COMPARATOR|Placebo|
61930149|NCT05979727|ACTIVE_COMPARATOR|Low dose of RE02|
61930150|NCT05979727|ACTIVE_COMPARATOR|Moderate dose of RE02|
61930151|NCT05979727|ACTIVE_COMPARATOR|High dose of RE02|
61930152|NCT01468103|EXPERIMENTAL|PACS|primary angle closure suspects
61930153|NCT01468103|EXPERIMENTAL|PAC|primary angle closure
61930154|NCT03486431|EXPERIMENTAL|Level I|5 x 7 Gy SABR
61930155|NCT03486431|EXPERIMENTAL|Level II|3 x 10 Gy SABR
61930156|NCT03486431|EXPERIMENTAL|Level III|1 x 20 Gy SABR
61930157|NCT05826184|EXPERIMENTAL|Time restricted eating|Individuals will eat between 12-8pm ad libitum, fasting from 8-12pm.
61930158|NCT05826184|EXPERIMENTAL|TRE+ prebiotic supplement|Individuals will eat between 12-8pm ad libitum, fasting from 8-12pn with the addition of a prebiotic fiber supplement with the first eating bout of the day.
62132008|NCT04629625|EXPERIMENTAL|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2\*3 min
62132009|NCT04629625|ACTIVE_COMPARATOR|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
62323948|NCT01257646||Recent stroke group|These patients have hemiplegia following a stroke within the last 6 months
62323949|NCT01257646||Old stroke group|The patients have hemiplegia following a stroke that took place at least a year ago
62323950|NCT03762850|EXPERIMENTAL|sparsentan|Double-blind: Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400- mg and continue treatment to Week 110.
62323951|NCT03762850|ACTIVE_COMPARATOR|irbesartan|Double-blind: Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
62323952|NCT03762850|EXPERIMENTAL|dapagliflozin + sparsentan (Sub study)|OLE Sub study: Dapagliflozin will be administered daily as a 5-mg oral tablet, in addition to 400-mg of Sparsentan, for a period of 12 weeks.
61930159|NCT03449108|EXPERIMENTAL|ICI Ovarian Cancer, Sarcomas, Triple Negative Breast Cancer (LN-145-S1, nivolumab)|Ipilimumab will be administered as a single dose prior to tumor resection. Nivolumab will be administered once prior to tumor resection. Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 15-30 minutes daily on days -5 to -1, LN-145-S1 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses. Within 12 weeks after receiving LN-145-S1, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks and continued until unacceptable toxicity, progression, or start of another cancer therapy.
61930160|NCT03449108|EXPERIMENTAL|Thyroid Cohort (LN-145)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 15-30 minutes daily on days -5 to -1, autologous tumor infiltrating lymphocytes LN-145 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses.
61930161|NCT06446258|EXPERIMENTAL|Experimental Group|Two manual therapy treatments (myofascial release, soft tissue mobilization) in the lower abdominal area and the cesarean section scar, two weeks apart.
61930162|NCT02587039|PLACEBO_COMPARATOR|Control: Usual care|This group will receive usual care and delirium assessments.
61930163|NCT02587039|EXPERIMENTAL|Treatment: Ischemic Pre-conditioning|Remote Ischemic pre-conditioning before cardiac surgery and delirium assessments.
61930164|NCT05105022|EXPERIMENTAL|propofol|Propofol at a dose of 2mg/kg will be administered I.V. .
61930165|NCT05105022|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane (4%) will be used for inhalational induction.
61930166|NCT05981391||Tinnitus and PTSD (T+P)|Active duty service members and/or veterans with PTSD and tinnitus.
61930167|NCT05981391||Tinnitus Only (TO)|Active duty service members and/or veterans with only tinnitus/no PTSD.
61930168|NCT05981391||PTSD Only (PO)|Active duty service members and/or veterans with only PTSD/no tinnitus.
61930169|NCT05981391||Healthy Controls|Active duty service members and/or veterans with no PTSD and no tinnitus.
61930170|NCT02936102|EXPERIMENTAL|FAZ053 single agent|
61930171|NCT02936102|EXPERIMENTAL|FAZ053 + PDR001|
61930172|NCT06582264|EXPERIMENTAL|Vancomycin preconditioning followed by MB310|Vancomycin 125mg QID for 5 days plus 2 day wash-out prior to receiving MB310 PO (2 capsules once a day) for 12 weeks
61930173|NCT06582264|PLACEBO_COMPARATOR|Vancomycin preconditioning followed by Placebo|Vancomycin 125mg QID for 5 days plus 2 day wash-out prior to receiving MB310-matching placebo PO (2 capsules once a day) for 12 weeks
61930174|NCT06273540|EXPERIMENTAL|STP7 (mavoglurant) modified release film-coated tablet|"Participants will take STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule:~* Day 3: 50 mg BID;~* Day 4: 100 mg BID;~* Days 5-9: 200 mg BID,~* Day 10: 200 mg only the morning dose.~Morning STP7 (mavoglurant) doses must be taken within 30 minutes of beginning a meal."
61930175|NCT06273540|PLACEBO_COMPARATOR|Placebo|Participants will take matched placebo on a dosing schedule identical to that of STP7 (mavoglurant) and morning doses must be taken within 30 minutes of beginning a meal.
61930176|NCT06710847|EXPERIMENTAL|Part 1: Dose escalation of GSK4418959 monotherapy|Participants will receive GSK4418959 as monotherapy.
62132010|NCT04629625|PLACEBO_COMPARATOR|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2\*3 min
62132011|NCT06322043|EXPERIMENTAL|Volume correction with Investigational Device|Subjects will be injected subcutaneously with the Investigational Device to correct volume deficiencies.
62691553|NCT03684785|EXPERIMENTAL|Exploratory Phase 2, Merkel cell carinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
62691554|NCT03684785|EXPERIMENTAL|Exploratory Phase 2, Subcutaneous Dosing Cohort|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with no cutaneous, subcutaneous, or accessible nodal tumor lesions amenable that have progressed on anti-PD-1 / anti-PD-L1 therapy.
62691555|NCT03684785|EXPERIMENTAL|Exploratory Phase 2, Melanoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with locally Advanced or Metastatic Melanoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
62691556|NCT03684785|EXPERIMENTAL|Exploratory Phase 2, Liver Lesion|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with metastatic solid tumors with liver metastases that have progressed on anti-PD-1 / anti-PD-L1 therapy.
62691557|NCT02594072|EXPERIMENTAL|SABR with androgen suppression|Stereotactic ablative radiotherapy (SABR) with a prescribed dose of 36.25 Gy in 5 fractions over 5 weeks (one treatment day per week). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
62691558|NCT02594072|ACTIVE_COMPARATOR|EBRT with androgen suppression|Conventional external beam radiation therapy (EBRT) with a prescribed dose of 73.68 Gy in 28 fractions (5 treatment days per week over 5.5 weeks). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
61930177|NCT06710847|EXPERIMENTAL|Part 2: Dose expansion of GSK4418959 monotherapy|Participants will receive GSK4418959 as monotherapy.
61930178|NCT06710847|EXPERIMENTAL|Part 3: Dose escalation of GSK4418959 plus PD-1 inhibitor|Participants will receive GSK4418959 plus PD-1 inhibitor.
61930179|NCT03319225||Tetraplegia|Persons with Tetraplegia
61930180|NCT03319225||Paraplegia|Persons with Paraplegia
61930181|NCT03319225||Neurologically-intact|Neurologically-intact controls
61930182|NCT05622370|EXPERIMENTAL|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
62323953|NCT03762850|EXPERIMENTAL|sparsentan (Sub Study)|OLE Sub study: Sparsentan will be administered daily as a dose of 400-mg for a period of 12 weeks.
62323954|NCT02995343|EXPERIMENTAL|Hypogastric and/or uterine artery ligation|Patients who had been ligated hypogastric artery and or uterine artery for ceasing uterine bleeding during c-section
62323955|NCT02995343|NO_INTERVENTION|Normal postpartum women|
62323956|NCT02948140|EXPERIMENTAL|Stroke|
62323957|NCT05832164|EXPERIMENTAL|Multifactorial intervention|HIV patients
62691559|NCT02323620|NO_INTERVENTION|Standard care|Optimal standard care after myocardial infarction.
62691560|NCT02323620|EXPERIMENTAL|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor autologous cells aspiration and intracoronary infusion of the cells.
62691561|NCT04808011|EXPERIMENTAL|Treatment|Each subjects will be treated with his prescribed dialysis device for 14 days, followed by a treatment period of 30 days with the investigational IDA system, and concluding with additional 14 days of treatment with the prescribed dialysis device.
62691562|NCT03615131||MRI-TRUS fusion prostate biopsy|Single Arm Study, MRI and Prostate-Biopsy on same patient, individual patient acts as own control for intervention
62691563|NCT03035214|OTHER|Prevention of dysplasia through steroids|Failure of lung tolerance to oxygen reduction will be defined as oxygen saturation 80 to 87% for 5 minutes, or \<80% for 1 minute, then inspired oxygen will be increased back to the base line. This will be considered as an early predictor of evolving bronchopulmonary dysplasia. If there is no hypoventilation, dexamethasone will be given 0.25 mg/ kg/ d divided twice for 5 days intravenous.
62691564|NCT06636903|EXPERIMENTAL|Acupressure group|Acupressure will be applied to the experimental group before suturing.
62691565|NCT06636903|NO_INTERVENTION|control group|No intervention will be made to the control group. Routine emergency room practice will be carried out.
61930183|NCT05622370|EXPERIMENTAL|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
62323958|NCT03415724|ACTIVE_COMPARATOR|1.8 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.
62323959|NCT03415724|ACTIVE_COMPARATOR|3.6 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.
62132012|NCT03791593|EXPERIMENTAL|Experimental group|The patient will receive evolocumab 420 mg/month on top of guideline-driven medical treatment
62132013|NCT03791593|NO_INTERVENTION|Control group|The patient will continue guideline-driven medical treatment
62132014|NCT02080754|PLACEBO_COMPARATOR|sham arm|sham sellick maneuver
62132015|NCT02080754|EXPERIMENTAL|sellick arm|effective sellick maneuver
62132016|NCT05097001|EXPERIMENTAL|Computer|Programming based on computer-guided assessment
62132017|NCT05097001|ACTIVE_COMPARATOR|CLINICAL|Programming based on clinically-guided assessment
62132018|NCT03941067|EXPERIMENTAL|Pre-event massage|
62132019|NCT03941067|NO_INTERVENTION|Control|
62132020|NCT00864552||Group 1|
62132021|NCT00350792|EXPERIMENTAL|Pemetrexed + Carboplatin|"Pemetrexed: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles.~Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."
62132022|NCT05374889|EXPERIMENTAL|Exercise Group|Athletes were asked to throw the ball at predetermined targets in different positions with their eyes closed. In the first exercise, the athlete was positioned 2 m from the target in a sitting position, facing the marked lines on the wall. It was asked to make 3 trial shots with a basketball ball while the eyes were open, from the bottom up to the 3 lines on the wall. Then the shots were made while the eyes were closed. In the next exercise, it was requested to make 3 trial shots from the bottom up by looking at the same 3 lines marked in the supine position at the distance of 1 m from the target. Then the shots were made with the eyes facing the ceiling. The last exercise was in a standing position, from the line marked 5 m from the target to the basket, it was requested to make 3 trial free throw with eyes open to the basket. Then, after each throw, the athlete was asked to turn around his own axis and continue to next throw, with eyes closed.
62483167|NCT01782053|EXPERIMENTAL|Text plus picture|Revised packaging with half of front and back of pack showing FDA proposed warning including image.
62483168|NCT01782053|EXPERIMENTAL|Picture plus additional warning text|Same as text plus picture but containing additional text elaborating on the basis for the warning.
62132023|NCT05374889|NO_INTERVENTION|Control Group|Control group did not participate in any exercise program.
62323960|NCT03415724|ACTIVE_COMPARATOR|1.8 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
62323961|NCT03415724|ACTIVE_COMPARATOR|3.6 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
62323962|NCT06554223|EXPERIMENTAL|SUSTAIN-DSD Arm|
62323963|NCT06554223|OTHER|Enhanced (guideline-driven) Standard of Care (E-SoC)|
62323964|NCT02568826|EXPERIMENTAL|IDN 5243|IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities for intramuscular administration in 4 mg/mL vials. It will be administered twice daily for 5 consecutive days with the first administration in the morning (8.00-10.00 AM) and the second in the evening (6.00-8.00 PM).
62323965|NCT01191294|EXPERIMENTAL|Medical Students|3rd year medical students during their primary care clerkship
62323966|NCT06523426||Patient treated by spinal endoscopy|elderly patients, over 75 years old, treated by spinal endoscopy
62323967|NCT03525587|ACTIVE_COMPARATOR|Ongoing r-hGH therapy|"Patients on long-term r-hGH therapy.~Intervention: Use of MAGHD App/MAGHD Framework"
62323968|NCT03525587|ACTIVE_COMPARATOR|Previous r-hGH therapy|"Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will).~Intervention: Use of MAGHD App/MAGHD Framework"
61930184|NCT05622370|ACTIVE_COMPARATOR|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
61930185|NCT03392324|EXPERIMENTAL|PRIMA|Implantation of PRIMA device
61930186|NCT03988543|NO_INTERVENTION|Usual Care|Patients will receive current standard care of EHR-integrated symptom monitoring.
62132024|NCT05493969|OTHER|DTG/3TC|Subjects will switch to dolutegravir (DTG) plus lamivudine (3TC) or fixed dose combination DTG/3TC for 48 weeks.
62132025|NCT05758012||oxytocin group|Oxytocin 5 IU will be administered by a trained anaesthetist as a one-minute IV injection.
62132026|NCT05758012||Carbetocin group|Carbetocin 100 μg will be administered by a trained anaesthetist as a one-minute IV injection.
62323969|NCT03525587|ACTIVE_COMPARATOR|Never treated|"Patients never treated for any reason (according to age, contraindications or lack of patient's consent).~Intervention: Use of MAGHD App/MAGHD Framework"
62483169|NCT00925964||Patients exposed|Patients with Systolic Pressure Index \<0,9 ou \>1,4.
62483170|NCT00925964||Patients not exposed|Patients with Systolic Pressure Index \>0,9 ou \<1,4.
62323970|NCT05926986|EXPERIMENTAL|Study group|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
62483171|NCT00553241||1|"Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China~Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour."
62483172|NCT01544049||Fallopian tube removal|Women who have had one or both fallopian tube(s) removed as method of ovarian cancer prevention.
62483173|NCT01852721|EXPERIMENTAL|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
61930187|NCT03988543|EXPERIMENTAL|Enhanced Care|Patient will receive current standard care of EHR-integrated symptom monitoring, plus patient self-management intervention.
62132027|NCT06435819|EXPERIMENTAL|ECA-2D|Participants read a patient education document with the assistance of an embodied conversational agent rendered in 2D on a computer monitor.
62323971|NCT05926986|EXPERIMENTAL|Control group|No additional treatment will be practiced to the control group.
62323972|NCT02078622||COPD, Education and Case Management|Respiratory Therapist Education and Case Management
62323973|NCT06351345|OTHER|Pulmonary Arterial Hypertension Patients Receving Sotatercept|PAH patients receiving sotatercept as treatment for their PAH
62323974|NCT05657743|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62691566|NCT05356130|NO_INTERVENTION|Treatment as Usual (TAU)|"Usual care services control group"
62483174|NCT01852721|EXPERIMENTAL|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
62691567|NCT05356130|ACTIVE_COMPARATOR|Minimal BLT Encouragement|Two minimal written communications promoting BLT as a promising treatment and outlining steps for patients to self-initiate. Arm 2 will not include any phone coaching or adherence promotion.
62691568|NCT05356130|ACTIVE_COMPARATOR|Enhanced BLT Encouragement + Adherence Promotion|2-4 brief calls to encourage BLT use, advise on purchase of a light box (LB), assist with obtaining compensation for LB purchase, educate for correct LB use, and provide motivational interviewing (MI) as needed to promote adherence. Arm 3 participants will also receive the written educational material on BLT.
62691569|NCT05735119||Subscapularis Tendon Injuries|Tapestry Biointegrative Implant
62691570|NCT02951819|EXPERIMENTAL|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
62691571|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
62323975|NCT06063434|EXPERIMENTAL|Night Shift|Night Shift 2024 is a customized, theory-based adventure video game in which the player takes on the character of Andy Jordan, a young emergency medicine physician who moves home after the disappearance of his grandfather and takes a job at a local community hospital. The investigators will ask participants to play Night Shift for 2 hours upon enrollment (or within 2 weeks), and then come back to the game quarterly to play it again for 20 minute booster sessions. They will unlock additional game content each quarter to make the experience more enjoyable.
62691572|NCT04471727|EXPERIMENTAL|MK-6070 monotherapy dose escalation with 1 week dosing interval|Participants will receive MK-6070 once weekly (Q1W) via intravenous (IV) infusion during each 21-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation or the Sponsor decides to stop enrollment.
62691573|NCT04471727|EXPERIMENTAL|MK-6070 monotherapy dose escalation with 2 week dosing interval|Participants will receive MK-6070 via IV infusion once every 2 weeks (Q2W) of a 28-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation, or the Sponsor decides to stop enrollment.
62691574|NCT04471727|EXPERIMENTAL|MK-6070 monotherapy dose escalation with 3 week dosing interval|Participants will receive MK-6070 via IV infusion once every 3 weeks (Q3W) of a 21-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation, or the Sponsor decides to stop enrollment.
62691575|NCT04471727|EXPERIMENTAL|MK-6070 dose escalation with atezolizumab|Small cell lung cancer (SCLC) participants will receive MK-6070 via IV infusion Q2W during each 28-day cycle and Atezolizumab via IV infusion every 4 weeks (Q4W) on Day 1 of each 28-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation, or the Sponsor decides to stop enrollment.
62323976|NCT06063434|ACTIVE_COMPARATOR|Usual education|Participants will receive their usual continuing medical education, but nothing additional.
62691576|NCT04471727|EXPERIMENTAL|MK-6070 dose escalation in combination with I-DXd|SCLC participants will receive MK-6070 via IV infusion Q2W during each 42-day cycle and I-DXd via IV infusion Q3W on Day 1 and Day 22 of each 42-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation, or the Sponsor decides to stop enrollment.
62691577|NCT06199882|EXPERIMENTAL|SBRT Sequential Surufatinib Combined With Immunotherapy|"SBRT :~Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week).~Drug treatment (every 3 weeks is a treatment cycle) :~1) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
62691578|NCT01581671||Patients having a first time angiogram|Patients who are coming to the Cardiac Cath Lab to have an angiogram for the first time
62691579|NCT01491919|EXPERIMENTAL|Low Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
62691580|NCT01491919|EXPERIMENTAL|Medium Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
62691581|NCT01491919|EXPERIMENTAL|High Dose: Lisinopril|Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.
62323977|NCT04353622|ACTIVE_COMPARATOR|Robot-assisted Treatment|Rehabilitation protocol was applied with robotic device (HOUSTONBIONİCS ExoRehab UE1).
62691582|NCT03756961|ACTIVE_COMPARATOR|Control|"Control group: The patients receive the routine based anesthesiological treatment during bariatric surgery (Gastric By-Pass or Sleeve Gastrectomy). It consists of:~General anesthesia induction: TCI Remifentanil Cpt 6 ng/ml/ Cp 3.2 ng/m, Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) adjusted via BIS (40-60) and Remifentanil Cp 4-10 ng/ml.~Post-operative pain management: Oxycodone 2.5 mg iv if the pain is rated by patient NRS ≧3. Paracetamol 1 g/6 h and Diclofenac 80 mg/24 h."
62323978|NCT04353622|ACTIVE_COMPARATOR|Conventional Physiotherapy|Conventional physiotherapy program included neurophysiological approaches.
62323979|NCT05816239||Patients being evaluated for bronchoscopic lung volume reduction (BLVR).|
62483175|NCT01843179|EXPERIMENTAL|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
62483176|NCT05735145|EXPERIMENTAL|concurrent chemoradiotherapy combined with adjuvant chemotherapy|Adjuvant chemotherapy in patients with locally advanced cervical cancer who achieved CR after concurrent chemoradiotherapy
62483177|NCT05735145|OTHER|concurrent chemoradiotherapy|Observation of patients with locally advanced cervical cancer who achieved CR after concurrent chemoradiotherapy
62483178|NCT01009229|OTHER|1|
62483179|NCT05979662|EXPERIMENTAL|Group one|Patients will undergo endoscopic frontal sinus surgery grade 6(Draf III).
62323980|NCT05687201||APOE-E4 (ε2/ε4,ε3/ε4,ε4/ε4) group|All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
62691583|NCT03756961|EXPERIMENTAL|Intervention|"Induction: Dexmedetomidine 0.2 micrograms/kg/h iv 5 min, Esketamine 0.1mg/kg + Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) BIS (40-60), Dexmedetomidine 0.2 micrograms/kg/h, Esketamine 0.1-0.3mg/kg/h och 0.1 mg/kg in case of hypertension. At the end of surgery, Lidocaine 1 mg/kg iv (max 4 mg/kg /4 h)~Post-operative: Dexmedetomidine (0.1-0.2 micrograms/kg/h up to 4 h post-operative). If the pain is rated NRS ≧3: Transcutaneous Nerve Stimulation (TENS) with high intensive 40-50 mA for 1 minute, if the patient still NRS ≧3, the TENS treatment is repeated one more time. If pain NRS ≧3 after two treatments with TENS: Esketamine 0.1mg/kg iv + Lidocaine 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS still ≧3 within 30 minutes after both TENS and Esketamine/Lidocaine, 2.5 mg Oxycodone iv, with a 10 minutes intervals until NRS \< 3. Perioperative and at discharge, PCC will be used for the the intervention (Phase 2 patients)"
62691584|NCT01246518|ACTIVE_COMPARATOR|MOB015 for 3 months|
62323981|NCT05687201||APOEε3(ε3/ε3) group|All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
62323982|NCT04510857|EXPERIMENTAL|MOVE-IT Home Exercise Program (HEP)|Participants will be asked to employ the MOVE-IT system for upper extremity practice at home 1 hour/day, 5 days/week over a 10-week period.
61930188|NCT06568484|EXPERIMENTAL|Bedaquiline|4 weeks of daily bedaquiline
61930189|NCT06568484|ACTIVE_COMPARATOR|3HP or 1HP|"3 months of weekly isoniazid (H) and rifapentine (P) or~1 month of daily isoniazid (H) and rifapentine (P)"
61930190|NCT06568484|ACTIVE_COMPARATOR|Levofloxacin|6 months of daily levofloxacin
61930191|NCT02399007|EXPERIMENTAL|Total Hip System made in China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China
61930192|NCT02399007|ACTIVE_COMPARATOR|Total Hip System made outside of China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China
61930193|NCT05976438|OTHER|Open label arm 1|Participants will be randomised to AB sequence of drugs A: 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B: Approximately 8 weeks of 25mg Chlortalidone
61930194|NCT05976438|OTHER|Open label arm 2|Participants will be randomised to BA sequence of drugs B: Approximately 8 weeks of 25mg Chlortalidone A: 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg
61930195|NCT03153410|EXPERIMENTAL|Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4|
61930196|NCT04837092|EXPERIMENTAL|FR104 Treatment|
61930197|NCT02526836|OTHER|Comparison group|"including the number of cases with complete data who underwent surgery using the conventional method.~Conventional surgery"
61930198|NCT02526836|ACTIVE_COMPARATOR|Intervention group|"including a convenient sample of about 20 patients which is expected to be recruited, for whom Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) will be done.~Complete mesocolic excision with central vascular ligation"
61930199|NCT02789878|EXPERIMENTAL|ADT and Abiraterone|"* Goserelin 10.8 mg, single dose, subcutaneously.~* Abiraterone 1,000 mg, once daily, orally for 3 months.~* Prednisone 5 mg, once daily, orally for 3 months."
61930200|NCT02789878|EXPERIMENTAL|ADT, Abiraterone and Apalutamide|"* Goserelin 10.8 mg, single dose, subcutaneously.~* Abiraterone 1,000 mg, once daily, orally for 3 months.~* Prednisone 5 mg, once daily, orally for 3 months.~* Apalutamide 240 mg, once daily, orally for 3 months."
61930201|NCT02298985|ACTIVE_COMPARATOR|curcumin|curcumin 3 g/day for 6 months
61930202|NCT02298985|PLACEBO_COMPARATOR|placebo|curcumin 3 g/day for 6 months
61930203|NCT06130527|ACTIVE_COMPARATOR|Nicardipine|Nicardipine is a dihydropyridine derivative vasoselective drug. Rapid onset of action i.v. nicardipine is used when rapid control of blood pressure is needed. The potential role of i.v. nicardipine was shown in many cardiovascular and neurovascular surgical procedures and surgical procedures in which CH was performed with hemostasis (6).
62323983|NCT04510857|ACTIVE_COMPARATOR|Usual Care Treatment (UCT) Control|Children in the UCT group will be followed as they continue to receive their previously prescribed therapy services. These children will not receive any treatment services through the study as UCT group participants.
61930204|NCT06130527|ACTIVE_COMPARATOR|Remifentanil|"Although remifentanil has unique pharmacokinetic properties, its pharmacodynamic effects are similar to those of other opioids. Remifentanil has dose-dependent analgesic, sedation and respiratory suppression side effects. All of these effects are antagonized by the mu receptor-specific opioid antagonist naloxone. Remifentanil has vagotonic and sympatholytic effects, and common side effects are bradycardia (heart rate \<50 beats/min) and hypotension (SBP \<80 mm Hg). Other common side effects are itching, nausea and vomiting, and chest wall stiffness after bolus administration (35).~The elderly population is more sensitive to opioid effects. It has been shown that it suppresses the delta wave in EEG due to the effects of opioids in the cerebral cortex. This feature is twice as common in the elderly as in the younger population."
61930205|NCT05499650|EXPERIMENTAL|Exercise Group|Patients will be required to undergo an exercise program. Pre-intervention and post-intervention outcomes will be compared in each patient.
61930206|NCT06193577|EXPERIMENTAL|Phaseolus Vulgaris L. Dry Extract|Test
61930207|NCT06193577|PLACEBO_COMPARATOR|Placebo|Control
61930208|NCT00717444|EXPERIMENTAL|1|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
61930209|NCT00717444|EXPERIMENTAL|2|contingency management for abstinence plus 12-step facilitation therapy
61930210|NCT01551537||Cohort Group|Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka.
62132028|NCT06435819|EXPERIMENTAL|ECA-3D|Participants read a patient education document with the assistance of an embodied conversational agent in virtual reality.
62323984|NCT06693778||Select Primary Care Practices|Select pediatric primary care practices (3 urban and 3 suburban) that are evaluating patients for mild traumatic brain injury with an electronic clinical decision support tool.
62132029|NCT06435819|NO_INTERVENTION|CONTROL|Participants read a patient education document without assistance.
62691585|NCT01246518|ACTIVE_COMPARATOR|MOB015 for 9 months|
62691586|NCT06675643||Observational|Patients undergo standard of care treatment with ipilimumab/nivolumab and answer questions and enter symptoms in the mobile Vigilant application. Patients wearing a compatible watch have their vital signs recorded at the same time symptoms are being entered. Based on the severity of symptoms, patients may be recommended to reach out to their healthcare team or to go to the emergency room. Additionally, patients complete a survey and may have their medical charts reviewed on study.
62691587|NCT03361631|EXPERIMENTAL|arm treated with MSC|"* Type 1 diabetic man~* Aged from 18 to 50 years~* Having a diabetes evolving for at least 10 years~* Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot~* Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)~* IIEF-5 score less than or equal to 10"
62691588|NCT03090165|EXPERIMENTAL|Arm A - Phase I|"Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.~Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.~Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.~Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 25 patients."
62691589|NCT04577703|EXPERIMENTAL|CT053PTSA (dose escalation)|"Patients were treated in 5 dose cohorts of 15 mg, 30 mg, 60 mg, 100 mg, and 150 mg QD capsules.~Patients receive treatment with CT053PTSA once on Cycle 0 Day 1 following a 7-day treatment-free withdrawal period to observe the safety and pharmacokinetic of CT053PTSA.~After that, Patients receive treatment with CT053PTSA per orally, beginning on Cycle 1 Day 1 for 28 day following a 7-day treatment-free withdrawal period to observe efficacy of CT053PTSA and determine to continue taking medicine or not. Each cycle had 28 days."
62691590|NCT01799135|EXPERIMENTAL|Experimental Arm|"Stereotactic Body Radiation Therapy: either 54 Gy in 3 fractions or 50-60 Gy in 5 fraction over a span of 15 days at most.~DCE-MRI was performed at four time points during therapy: at baseline prior to SBRT, 1-2 days after the first treatment fraction, 1-2 weeks after the end of the SBRT course, and 3 months after completing radiotherapy.~4D-CT scan 3 months after completing radiotherapy."
62691591|NCT05338268|EXPERIMENTAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.
62691592|NCT05338268|ACTIVE_COMPARATOR|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
61930211|NCT02594540|EXPERIMENTAL|Feet Mechanical Stimulation|The feet mechanical stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
62691593|NCT06632873|EXPERIMENTAL|1.48-3.33 GBq of 177Lu-TATE-RGD|The patients were intravenously injected with the dose about 1.48-3.33 GBq(60-100m Ci) 177Lu-TATE-RGD and underwent 68Ga-TATE-RGD PET/CT scans before and after the treatment.
62691594|NCT05218434|EXPERIMENTAL|Part A - 5mg AX-158|AX-158 oral Single (Single Ascending Dose)
62691595|NCT05218434|EXPERIMENTAL|Part A - 10mg AX-158|AX-158 oral Single (Single Ascending Dose)
62691596|NCT05218434|EXPERIMENTAL|Part A - 15mg AX-158 or Placebo|AX-158 oral Single (Single Ascending Dose)
62691597|NCT05218434|EXPERIMENTAL|Part A - 25mg AX-158|AX-158 oral Single (Single Ascending Dose)
62691598|NCT05218434|EXPERIMENTAL|Part A -50mg AX-158|AX-158 oral Single (Single Ascending Dose)
62691599|NCT05218434|EXPERIMENTAL|Part B - 15mg AX-158 Fed state|AX-158 oral single dose with food
62691600|NCT05218434|EXPERIMENTAL|Part B - 15mg AX-158 Fasted|AX-158 oral single dose without food
62691601|NCT05218434|EXPERIMENTAL|Part C - 5mg AX-158|AX-158 oral daily dose for 10 days (Multiple Ascending Dose)
61930212|NCT02594540|SHAM_COMPARATOR|Sham Feet Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
61930213|NCT03978481||Eradicated group|Gastric cancer patients received subtotal gastrectomy, with Helicobacter pylori eradication
61930214|NCT03978481||Negative group|Gastric cancer patients received subtotal gastrectomy, without Helicobacter pylori eradication or Helicobacter pylori negative
62132030|NCT05136157|ACTIVE_COMPARATOR|Study group|Bolus-Infusion approach of rapidly acting crystalline insulin. The patient intra-operative blood glucose will be divided by 100. The resultant rapidly acting crystalline insulin units will be given intravenously over 10 minutes, and then continued as an intra-venous infusion per hour. The Capillary Blood Glucose (CBG) will be measured every 30 minutes and in the PACU with readjustment of the bolus-infusion dose as required
62323985|NCT06693778||Comparison Primary Care Practices|Pediatric primary care practices that are NOT using the electronic clinical decision support tool to evaluate patients for mild traumatic brain injury.
62691602|NCT05218434|EXPERIMENTAL|Part C - 10mg AX-158|AX-158 oral daily dose for 10 days (Multiple Ascending Dose)
62323986|NCT00676481|ACTIVE_COMPARATOR|1|Phase III participants who are educated about risk of HIV infection before receiving a rapid HIV test
62323987|NCT00676481|NO_INTERVENTION|2|Phase III participants who are not educated about risk of HIV infection before receiving a rapid HIV test
62323988|NCT06332781|ACTIVE_COMPARATOR|Standard of Care|Standard of care
62483180|NCT05979662|ACTIVE_COMPARATOR|Group two|Patients will undergo endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
62691603|NCT05218434|EXPERIMENTAL|Part C - 15mg AX-158|AX-158 oral daily dose for 10 days (Multiple Ascending Dose)
62323989|NCT06332781|EXPERIMENTAL|Experimental|Gentamicin
62323990|NCT00298610|EXPERIMENTAL|Artesunate and Malarone|Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
62691604|NCT05218434|EXPERIMENTAL|Part A - Placebo|Placebo oral Single (Single Ascending Dose)
62691605|NCT05218434|EXPERIMENTAL|Part C - Placebo|Placebo oral daily dose for 10 days (Multiple Ascending Dose)
62483181|NCT05450653|EXPERIMENTAL|FETO with GOLDBAL2|A detachable balloon will be inserted in the fetal airway during the FETO procedure.
62691606|NCT06549777|EXPERIMENTAL|SE-group|The participant allocated to the SE-group will receive the same information sheet (taking approximately 30 minutes to read) as the control group in addition to the SE-treatment (Payne et al., 2010) consisting of 15 sessions conducted by certified SE therapists, with an adapted focus on specifically (C)PTSD and CM, as described in a manual available upon request from the authors. Sessions 1-3 focus on general practices for establishing a sense of self, contacting own space and positive interoceptive experiences. Sessions 4-6 aim to establish self-defensive behavior, to get into contact with one's own strength and with a sense of autonomy and attachment. Sessions 7-9 focus on working with depression, shame and anger. Sessions 10-12 include work with childhood patterns and sessions 13-15 aim at integrating the previous therapeutic work in daily life situations and at recapitulating some of the interventions.
62691607|NCT06549777|ACTIVE_COMPARATOR|Control|The control group will receive an information sheet with psychoeducation about (C)PTSD (e.g., advice on self-care for symptom relief, available treatment options) and information about how to seek help/treatment within the Swedish health care system (taking approx.30 minutes to read). During the 20-week period the participant will be free to seek treatment of any kind and will additionally receive three phone calls (10 -15 minutes each time) from a research assistant (supervised by one of the project members). These calls aim to monitor participants' progress in seeking treatment and address any questions or concerns they may have regarding their involvement in the study. In addition, the calls aim to remind participants of completing the study questionnaires, in case they missed completing one or several of them.
62691608|NCT02419911|OTHER|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
62691609|NCT02419911|OTHER|Clearify|Clearify Visualization System used during laparoscopic surgery
62691610|NCT05198245||Pregnancies in women with migraine and exposure to rimegepant|
62691611|NCT05198245||Pregnancies in women with migraine exposed to other medications|Pregnancies in women with migraine exposed to other medications indicated for the treatment of migraine
62691612|NCT05198245||Pregnancies in women without migraine|
62691613|NCT00807482||1|People who have been definitively diagnosed with primary ciliary dyskinesia (PCD).
61930215|NCT03866187|EXPERIMENTAL|Group A1_Step A|Subjects aged 18-65 years receive one dose of each of the study vaccines, Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation at Day 1, Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169.
61930216|NCT03866187|ACTIVE_COMPARATOR|Group A2_Step A|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 low dose formulation, one dose each at Days 1, 57, 113 and 169.
61930217|NCT03866187|PLACEBO_COMPARATOR|Group A3_Step A|Subjects aged 18-65 years receive four doses of placebo, one dose each at Days 1, 57, 113 and 169.
61930218|NCT03866187|EXPERIMENTAL|Group B1_Step B|Subjects aged 18-65 years receive one dose of each of the study vaccines, ChAd155-hIi-HBV high dose formulation at Day 1, MVA-HBV high dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at Day 169.
61930219|NCT03866187|ACTIVE_COMPARATOR|Group B2_Step B|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 high dose formulation, one dose each at Days 1, 57, 113 and 169.
61930220|NCT03866187|ACTIVE_COMPARATOR|Group B3_Step B|Subjects aged 18-65 years receive two doses of placebo, one each at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation at Day 169.
61930221|NCT03866187|EXPERIMENTAL|Group C1_Step C|Subjects aged 18-65 years receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 1 and the 3 following doses of MVA-HBV high dose formulation co-administered with HBc-HBc-HBs/AS01B-4 high dose formulation at Day 57, 113 and Day 169.
61930222|NCT03866187|ACTIVE_COMPARATOR|Group C2_Step C|Subjects aged 18-65 years receive two doses of placebo at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 169.
61930223|NCT04649242|ACTIVE_COMPARATOR|BHV3000 (active drug)|BHV3000 (rimegepant) 75 mg or 50 mg ODT
61930224|NCT04649242|PLACEBO_COMPARATOR|Placebo|Matching 75 mg or 50 mg ODT placebo
61930225|NCT00807976||Study group|Type 2 diabetic patients aged 70 years and older.
62691614|NCT04231851|EXPERIMENTAL|CPX-351 and Glasdegib|"In Induction, subjects receive 44mg/m2/100mg/m2 IV on days 1, 3 and 5 and Glasdegib 100mg PO daily on days 6 to 28.~If re-induction is needed: Subjects receive 44mg/m2/100mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~In consolidation: Subjects receive 29mg/m2/65mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~If maintenance is required, Subjects receive Glasdegib 100mg PO daily for up to one year"
62691615|NCT02458118|EXPERIMENTAL|Secretin|Secretin 1 IU/kg over 3 min
62691616|NCT06076226||Donors aged 40 years or older|
61930226|NCT00807976||Control group|Patients aged 70 years and older, with no history of type 2 diabetes mellitus.
61930227|NCT05446181||Old with perioperative delirium|
61930228|NCT05446181||Old without perioperative delirium|
61930229|NCT05130723||Patients|Pediatric patients aged 2-18 years administered with fluconazole for the treatment or prophylaxis of invasive fungal infections.
61930230|NCT06705946|EXPERIMENTAL|Aqua vest group|Participants in this group will perform Dynamic Stability Training (DST) sessions twice a week for 12 weeks while wearing an aqua vest. Each session will focus on dynamic stability exercises aimed at improving balance, lower limb joint moment distribution, and gait. Each session will last for 50 minutes
62323991|NCT03640091|EXPERIMENTAL|Pre-extractive inter-radicular implant bed preparation|
61930231|NCT06705946|ACTIVE_COMPARATOR|Weight vest group|Participants in this group will perform the same Dynamic Stability Training (DST) sessions twice a week for 12 weeks, but with a weight vest instead of an aqua vest. Each session will focus on balance, lower limb joint moment distribution, and gait, lasting for 50 minutes
62323992|NCT03126136|EXPERIMENTAL|Pregnant women|
62323993|NCT03884101|EXPERIMENTAL|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
62691617|NCT06076226||Donors aged < 40|
62132031|NCT05136157|ACTIVE_COMPARATOR|Control group|The sliding scale approach of rapidly acting crystalline insulin will be used according to the intra-operative blood glucose; 4 IU of insulin will be given when the CBG 180-250 mg/dl, 6 IU of insulin will be given when the CBG 251-300 mg/dl, 8 IU of insulin will be given when the CBG 301-350 mg/dl and 10 IU of insulin will be given when the CBG 351-400 mg/dl (5). The CBG will be measured every 30 minutes and in the PACU.
62132032|NCT04613700|ACTIVE_COMPARATOR|Secretin|
62691618|NCT06569381|EXPERIMENTAL|Group A|take the tablet under fasting condition ,1 tablet at a time, once a day. Test product (T): Pirfenidone Modified-Release Tablets Strength: 600 mg/tablet Batch No.: 08532 Content: 600 mg/tablet Valid to: January 2025 Storage Conditions: sealed at normal temperature (10-30°C) Manufacturer: Overseas Pharmaceuticals, Ltd.
62132033|NCT04613700|PLACEBO_COMPARATOR|Placebo|
61930232|NCT06362759|EXPERIMENTAL|TOUR006 - 50 MG|50 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints)
62132034|NCT04412317||Children < 15 years old|Patients under 15 years old who consults a physician on an outpatient basis or in the emergency room and who requires a Sars-CoV-2 RT- PCR (nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction) diagnostic
62323994|NCT03884101|ACTIVE_COMPARATOR|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
62323995|NCT00496873|EXPERIMENTAL|Cytoxan + Rituxan + Nipent|Cytoxan 600 mg/m\^2 on Day 1 of 21-day cycle. Rituxan 375 mg/m\^2 on Day 1 of 21 Day Cycle. Nipent 4 mg/m\^2 on Day 1 of 21 Day Cycle.
62323996|NCT02639182|EXPERIMENTAL|AGS-16C3F|Participants received 1.8 milligram per kilogram (mg/kg) of AGS-16C3F once every three weeks by single intravenous (IV) infusion.
62323997|NCT02639182|ACTIVE_COMPARATOR|Axitinib|Participants received 2 to 10 milligram (mg) of axitinib twice daily by oral administration as defined in the product label and per local institutional guidelines.
62483182|NCT05562778|EXPERIMENTAL|Chatbot|Subjects will receive a text message initiating a chatbot conversation that relies on natural language processing to gather personal and family cancer. Subjects are identified by the chatbot as meeting National Comprehensive Cancer Network (NCCN) high-risk criteria. Next, subjects undergo pre-test genetic counseling via the chatbot and then clinicians are notified (via the chatbot portal) that the subject meets high-risk criteria. For subjects meeting high-risk criteria (based on the chatbot evaluation), the clinician will complete genetic counseling and recommend genetic testing during the visit. For subjects interested in genetic testing, the clinician will order genetic testing.
62691619|NCT06569381|EXPERIMENTAL|Group B|take the tablet under fed condition ,1 tablet at a time, once a day. Test product (T): Pirfenidone Modified-Release Tablets Strength: 600 mg/tablet Batch No.: 08532 Content: 600 mg/tablet Valid to: January 2025 Storage Conditions: sealed at normal temperature (10-30°C) Manufacturer: Overseas Pharmaceuticals, Ltd.
62691620|NCT06637319||Healthy Volunteers|Healthy volunteers \> 18 years of age
61930233|NCT06362759|EXPERIMENTAL|TOUR006 - 25 MG|25 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints)
61930234|NCT06362759|EXPERIMENTAL|TOUR006 - 15 MG|15 mg administered subcutaneously at Days 1, 30, 60, 90, 120, and 150
61930235|NCT06362759|PLACEBO_COMPARATOR|Placebo|Administered subcutaneously at Days 1, 30, 60, 90, 120, and 150
61930236|NCT06708039|EXPERIMENTAL|Mobile Instant Messaging Application based Self-Management and Exercise Programme (SMEP)|The experimental group will receive the self-management and exercise programme, which will be delivered using mobile messaging application (WhatsApp), twice per week for five weeks. In addition, the experimental group will also continue their Elderly Day Care Centre routine activities.
61930237|NCT06708039|NO_INTERVENTION|Control Group|The control group will continue their PAWE routine activities only
61930238|NCT04109456|EXPERIMENTAL|Part 1, Monotherapy Arm|The safety and tolerability of IN10018 monotherapy will be assessed. Other dose levels may be explored if necessary.
61930239|NCT04109456|EXPERIMENTAL|Part 2, Combination Arm|"The safety and tolerability of IN10018 in combination with Cobimetinib will be assessed. Other dose levels may be explored if necessary.~A modified 3+3 design will be used."
61930240|NCT04109456|EXPERIMENTAL|Part 3, Combination Arm|The safety and tolerability of IN10018 in combination with Cobimetinib and Atezolizumab will be assessed.
61930241|NCT05805488|PLACEBO_COMPARATOR|Placebo sachet|
62132035|NCT05286489|EXPERIMENTAL|group A|Qigong exercise program twice weekly for 8 weeks postmastectomy in addition to traditional medical and physical therapy treatment.
62323998|NCT05427825|EXPERIMENTAL|ERAS group|Patients in the experimental group receive the protocolized anesthetic care bundle including EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
62323999|NCT05427825|ACTIVE_COMPARATOR|Control|Patients in the control group receive standard anesthetic care including bispetral index-guided balanced anesthesia and regular hemodynamic care protocols.
62324000|NCT01975935|PLACEBO_COMPARATOR|Placebo|Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
61930242|NCT05805488|EXPERIMENTAL|TCI904 sachet|
61930243|NCT04526327|OTHER|exercise group|Female and male patients over 70 years of age with osteoporosis and sarcopenia
61930244|NCT05540106|ACTIVE_COMPARATOR|Blank Paper and Pencil|
61930245|NCT05540106|EXPERIMENTAL|Nature Coloring Packet|
61930246|NCT05540106|EXPERIMENTAL|Geometric Shape Coloring Packet|
62132036|NCT05286489|OTHER|group B|traditional medical and physical therapy treatment only .
62132037|NCT01464034|EXPERIMENTAL|Carfilzomib, Pomalidomide, Dexamethasone|All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
62132038|NCT02395913|ACTIVE_COMPARATOR|R|
62132039|NCT02395913|EXPERIMENTAL|T1|
62132040|NCT02395913|EXPERIMENTAL|T3|
62132041|NCT02395913|EXPERIMENTAL|T4|
62132042|NCT05722158|PLACEBO_COMPARATOR|Placebo|This group will be provided with a placebo solution for comparative purposes.
62324001|NCT01975935|EXPERIMENTAL|Amlexanox|Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
62324002|NCT01792622||Phase I Patient Interviews|Indepth interviews will be completed with approximately 15 patients.
62324003|NCT01792622||Phase II Patient Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
62324004|NCT06693206||Nurse group|Nurses will be evaluated in terms of burnout, aerobic capacity and musculoskeletal pain.
62483183|NCT05562778|NO_INTERVENTION|Usual Care|Personal and family cancer history will be collected by the clinician during the subject's visit. Clinicians will evaluate the patient's personal/family history according to National Comprehensive Cancer Network (NCCN) high-risk criteria. For subjects recognized by the clinician as meeting NCCN criteria, the clinician will complete genetic counseling and recommend genetic testing. For subjects interested in genetic testing, the clinician will order genetic testing.
62483184|NCT04325321|OTHER|Stress reactivity|Stress reactivity test
62483185|NCT04272216||Treatment with HydroPearl via radial access|all patients will be in the same group/cohort in this open-label, single-arm, observational registry.
62691621|NCT01918358|EXPERIMENTAL|Fixed-dose combination VR 160/20 mg-1|Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.
62691622|NCT01918358|EXPERIMENTAL|Fixed-dose combination VR 160/20 mg-2|Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.
62691623|NCT01918358|EXPERIMENTAL|Valsartan 160mg placebo + Rosuvastatin 20mg|Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.
62132043|NCT05722158|EXPERIMENTAL|Collagen-based product CP1|This group will be provided with a the collagen-based product CP1, which will be compared to the placebo group.
62132044|NCT05722158|EXPERIMENTAL|Collagen-based product CP2|This group will be provided with a the collagen-based product CP2, which will be compared to the placebo group.
62132045|NCT05722158|EXPERIMENTAL|Collagen-based product CP3|This group will be provided with a the collagen-based product CP3, which will be compared to the placebo group.
62132046|NCT05722158|EXPERIMENTAL|Collagen-based product CP4|This group will be provided with a the collagen-based product CP4, which will be compared to the placebo group.
62132047|NCT00531596|ACTIVE_COMPARATOR|A|EMSAM 6mg/24hr
62132048|NCT00531596|ACTIVE_COMPARATOR|B|EMSAM 9mg/24Hr
62132049|NCT00531596|ACTIVE_COMPARATOR|C|EMSAM 12mg/24Hr
62132050|NCT00087139|EXPERIMENTAL|Arm I|"Patients are stratified according to prior chemotherapy (none vs 1 prior taxane-containing regimen vs 2 prior cytotoxic regimens).~Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62132051|NCT03003624|EXPERIMENTAL|Colorado microdissection needle group|In patients selected for Colorado® needle group incision was given with Colorado® needle tip ( N103 A which is 3 cm length straight, 3/32 in sleeve diameter),
62132052|NCT03003624|EXPERIMENTAL|Cautery group|Electrosurgery tip was used to give incisions.
62132053|NCT03003624|ACTIVE_COMPARATOR|BP Blade group|No.15 surgical blade was used to give incisions.
62483186|NCT03045757||Healthy Newborn|Healthy Newborn
62483187|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
61930247|NCT05540106|EXPERIMENTAL|Activity Book|
61930248|NCT00847639|EXPERIMENTAL|Lenalidomide|Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
61930249|NCT05165225|EXPERIMENTAL|Pyrotinib|Experimental: Patients will receive Pyrotinib combined with Epirubicin and Cyclophosphamide followed by Docetaxel
62132054|NCT03209778|ACTIVE_COMPARATOR|Control group|Control participants without psychiatric nor neurological history
62132055|NCT03209778|EXPERIMENTAL|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
62132056|NCT04833179|EXPERIMENTAL|fecal transplant|Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. The treatment will be given in the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment.
62132057|NCT04833179|PLACEBO_COMPARATOR|placebo|Placebo capsule that can not be differentiate from the focal transplant capsule will be given in the same interval as the fecal transplant procedure written above.
62132058|NCT01704196|ACTIVE_COMPARATOR|Nepicastat|Nepicastat 120mg and 100mg riboflavin (once per day) for 11 weeks
62132059|NCT01704196|PLACEBO_COMPARATOR|Placebo|Placebo capsule containing 100mg riboflavin (once per day) for 11 weeks.
62132060|NCT06396598|EXPERIMENTAL|Supportive Care (electronic symptom monitoring program)|Patients and their caregivers participate use the electronic symptom monitoring program to log symptoms QW for 24 weeks. Patients and their caregivers also watch a video and review education materials prior to starting the remote symptom monitoring program.
62132061|NCT04414826|ACTIVE_COMPARATOR|Mindfulness + Compassion (MC) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching both mindfulness and compassion skills.
62132062|NCT04414826|ACTIVE_COMPARATOR|Mindfulness Alone (MO) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching mindfulness skills alone.
62132063|NCT04414826|PLACEBO_COMPARATOR|Waitlist Control (WL)|Those in the wait-list control condition will wait one week and complete a one-week follow-up assessment before being randomized to one of the two intervention conditions.
62132064|NCT02639091|EXPERIMENTAL|BAY 94-9343 + Pemetrexed + Cisplatin|Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
62483188|NCT04137835|EXPERIMENTAL|Showmotion|"Performing an analysis requires the positioning of sensors on the patient's skin in predetermined positions, according to the related protocols. Each sensor positioned on patient's skin provides both raw data (accelerometer, magnetometer, gyroscope) and the orientation matrix, representing the orientation of the local System of Reference (SoR) with respect to a fixed SoR. A proprietary sensor-fusion algorithm allows provides an accurate estimate of the orientation, as assessed by stereo-photogrammetric system-based testing.~Data from each sensor are sampled at 50 Hz and transferred wirelessly to a laptop with a proprietary software that processes the data according to the biomechanical model chosen for the analysis."
62132065|NCT05175898||VA-ECMO|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest.
61930250|NCT06325020||Patients with possible angina|"Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events."
61930251|NCT04804020|ACTIVE_COMPARATOR|NC (Natural cycle)|Performing the first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter to a level of 20 IU/l or more detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
61930252|NCT04804020|ACTIVE_COMPARATOR|mMC (modified Natural cycle)|Performing the first ultrasound scan on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
61930253|NCT04804020|ACTIVE_COMPARATOR|AC (Artificial cycle)|Preparing the endometrium by using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
61930254|NCT04742387||1|Medical records of subjects enrolled on various studies conducted by HAMB/CCR from 1/1/2005 to 12/1/2020
61930255|NCT02746367||MDD|Patients diagnosed with Major Depressive Disorder
61930256|NCT02746367||BPI|Patients diagnosed with bipolar I
61930257|NCT02746367||BPII|Patients diagnosed with bipolar II
61930258|NCT06707051|EXPERIMENTAL|Group A|Group A included 50 Patients fulfilling the inclusion and exclusion criteria, was given Tranexamic acid for bleeding of endometrial origin
61930259|NCT06707051|EXPERIMENTAL|Group B|Group B included 50 Patients fulfilling the inclusion and exclusion criteria, was given Calcium Dobesilate for bleeding of endometrial origin
61930260|NCT04210323|EXPERIMENTAL|Shotblocker group|ShotBlocker® was used by an experienced registered nurse under the researcher supervision. The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
61930261|NCT04210323|PLACEBO_COMPARATOR|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
61930262|NCT04210323|NO_INTERVENTION|Control group|Subcutaneous injection was performed with normal subcutaneous drug administration steps by an experienced registered nurse and no additional method was applied. The application process of each patient was managed by the researcher.
61930263|NCT05045833|EXPERIMENTAL|5 mg SYN-020|1 x 5 mg oral capsule, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
61930264|NCT05045833|EXPERIMENTAL|15 mg SYN-020|1 x 15 mg oral capsule, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
61930265|NCT05045833|EXPERIMENTAL|45 mg SYN-020|3 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
62483189|NCT01748773|EXPERIMENTAL|Combination Therapy|Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.
62691624|NCT03340116||Pre-operative cohort|This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention
61930266|NCT05045833|EXPERIMENTAL|75 mg SYN-020|5 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
61930267|NCT05045833|EXPERIMENTAL|≤ 75 mg SYN-020 (new formulation)|≤ 5 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
61930268|NCT02759354|EXPERIMENTAL|Group Vaxelis (3+1)|Participants previously vaccinated with a 3-dose primary series of Vaxelis® at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
61930269|NCT02759354|ACTIVE_COMPARATOR|Group Infanrix hexa (3+1)|Participants previously vaccinated with a 3-dose primary series of INFANRIX® hexa at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
61930270|NCT02759354|EXPERIMENTAL|Group Vaxelis (2+1)|Participants previously vaccinated with a 2-dose primary series of Vaxelis® at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
61930271|NCT02759354|ACTIVE_COMPARATOR|Group Infanrix hexa (2+1)|Participants previously vaccinated with a 2-dose primary series of INFANRIX® hexa at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
61930272|NCT01845233||Non invasive ventilation|
61930273|NCT06021288|EXPERIMENTAL|Intervention Group|CRRT will be established with a draining dose (effluent dose) of 10-15ml/kg/h in pursuit of establishing a controlled azotaemia.
62132066|NCT05175898||ECMELLA|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella® micro-axial pump.
62132067|NCT03643900|EXPERIMENTAL|indomethacin with stenting group|Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
62132068|NCT03643900|ACTIVE_COMPARATOR|indomethacin group|Rectal indomethacin 100mg at preoperative 30min in 100 patients
62132069|NCT01620203||Control|Matched group of control infants without diagnosis of intracranial hemorrhage
62132070|NCT01620203||Intracranial Hemorrhage|Group of preterm infant with diagnosis of intracranial hemorrhage.
62691625|NCT03340116||Post-operative cohort|This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
61930274|NCT06021288|ACTIVE_COMPARATOR|Control Group|"Standard of Care:~CRRT will be established with a draining dose (effluent dose) of 25-30ml/kg/h"
61930275|NCT01743950|ACTIVE_COMPARATOR|Bevacizumab-naïve with recurrent IDH wildtype high grade glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
61930276|NCT01743950|ACTIVE_COMPARATOR|Bevacizumab-exposed with refractory recurrent IDH wildtype high grade glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
61930277|NCT01743950|ACTIVE_COMPARATOR|Bevacizumab-naïve with recurrent IDH mutant glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
61930278|NCT01743950|ACTIVE_COMPARATOR|Bevacizumab-exposed with recurrent IDH mutant glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
61930279|NCT01878617|EXPERIMENTAL|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
61930280|NCT01878617|EXPERIMENTAL|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
61930281|NCT01878617|EXPERIMENTAL|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
61930282|NCT01878617|EXPERIMENTAL|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
61930283|NCT01878617|EXPERIMENTAL|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
61930284|NCT01878617|EXPERIMENTAL|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
62132071|NCT02949375|PLACEBO_COMPARATOR|Placebo Arm|Gel capsule containing Placebo to be taken once per day
62132072|NCT02949375|ACTIVE_COMPARATOR|4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken once per day
62132073|NCT02949375|ACTIVE_COMPARATOR|6mg GRI-0621|6mg GRI-0621 gel capsule to be taken once per day
62132074|NCT01264289|EXPERIMENTAL|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
62132075|NCT01264289|ACTIVE_COMPARATOR|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck \& Co. Inc
62132076|NCT03556085|EXPERIMENTAL|Venous sinus stenting|Subjects will have stenting of the transverse-sigmoid sinus
62483190|NCT03123315|EXPERIMENTAL|Cook Bush DL™ Ureteral Illuminating Catheter|As part of this study an additional tool will be used during the hysterectomy. This tool is called a Cook Bush DL™ Ureteral Illuminating Catheter, which is a lighted ureteral stent. This is a very thin tube that goes into the ureter. A urologist, who is an expert at placing these devices, will insert a stent into each ureter during surgery. The lighted stents will help effectively find the ureters and keep track of them during the surgery. This same procedure is already being done in many other forms of abdominal surgery to help find the ureter. The stents will be removed before the surgery is complete and treatment will not differ in any other way.
62691626|NCT06630689|NO_INTERVENTION|control group|Babies in the control group will receive treatment and care according to neonatal intensive care unit procedures. No intervention will be applied.
62132077|NCT06281912||adolescent/childhood|patients \<20 years old with with stage III and IV melanoma diagnosis
62132078|NCT06281912||young adult|patients \< 30 years with stage III and IV melanoma diagnosis
62132079|NCT03953001|EXPERIMENTAL|Buzzy|Buzzy was used during Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel.
62132080|NCT03953001|ACTIVE_COMPARATOR|Control|Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel only.
62132081|NCT01669005||Bone marrow transplant unit patients|hospitalized patients in the bone marrow transplant unit for an autologous or allogeneic hematopoietic stem cells transplantation or induction/consolidation chemotherapy
62691627|NCT06630689|EXPERIMENTAL|Dry Full Body Massage Group|Unlike the control group, dry whole body massage was applied to the babies who were followed up after completing the phototherapy treatment process.
61930285|NCT01878617|EXPERIMENTAL|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
61930286|NCT01878617|EXPERIMENTAL|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
61930287|NCT05086744|EXPERIMENTAL|Iptacopan 200 mg BID|Iptacopan 200 mg BID
61930288|NCT03489551|EXPERIMENTAL|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
61930289|NCT05419908|EXPERIMENTAL|Fezolinetant|Participants received 90 milligrams (mg) fezolinetant capsules orally, twice daily (BID) for a period of 12 weeks
61930290|NCT05419908|PLACEBO_COMPARATOR|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
61930291|NCT04966741|EXPERIMENTAL|Setmelanotide: PPL Group|Participants with POMC)/PCSK1/LEPR biallelic mutations collectively referred to as PPL received setmelanotide at a dose of 0.5 milligrams (mg) per day (QD) via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.
61930292|NCT04966741|EXPERIMENTAL|Setmelanotide: BBS Group|Participants with BBS received setmelanotide at a dose of 0.5 mg QD via SC injection for 52 weeks. The dose was escalated by increments of 0.5 mg every 2 weeks, if tolerated, at the dose escalation visits (Weeks 2, 4, and 6) to a maximum dose of 0.5 to 2.0 mg QD with the maximum dose based on body weight. Following the last dose in this study, participants who were considered likely to benefit from continued setmelanotide treatment and who had completed this trial could be eligible to enter an open-label long-term extension (LTE) trial with setmelanotide.
61930293|NCT06695650|EXPERIMENTAL|Mandala Group|"Students in the intervention group will be provided with mandala templates and coloring materials. They will be asked to color for 15 minutes twice a week over a two-month period. Email reminders will be sent to the students about the coloring sessions, and they will submit their completed mandalas to the researchers every Friday.~Demographic Characteristics Form and a pre-test using the Test Anxiety Inventory. Thirty minutes before the exam, the Test Anxiety Inventory will be applied as a post-test."
61930294|NCT06695650|NO_INTERVENTION|Control Group|"Non intervention. Demographic Characteristics Form and a pre-test using the Test Anxiety Inventory. Thirty minutes before the exam, the Test Anxiety Inventory will be applied as a post-test."
61930295|NCT05993039|ACTIVE_COMPARATOR|Inhalational Anesthesia|"Adults:~The control group will receive general inhalational anesthesia (sevoflurane, isoflurane). The will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with isoflurane 1.5-2% or sevoflurane 1-2%.~Children (12 or younger) induced with a combination of volatile anesthetic gases, including sevoflurane (up to 8%) and nitrous oxide gas (up to 70%). Those who are older than 12 will have an intravenous line placed in the preoperative area and as such will be induced with remifentanil and propofol as above. For maintenance, children in the control arm will receive 0.6 - 1.5% sevoflurane."
62132082|NCT02460393|PLACEBO_COMPARATOR|Placebo group|The arm is as a control group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
62132083|NCT02460393|EXPERIMENTAL|experimental group|The arm is as an experimental group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
62324005|NCT05756673|OTHER|Brush Only|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes under virtual supervision in the morning. At home, participants will brush a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary.
62324006|NCT05756673|EXPERIMENTAL|Brush/Rinse (LISTERINE ZERO Alcohol Mouthwash COOL MINT)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes and then rinse for 30 seconds with LISTERINE ZERO Alcohol Mouthwash COOL MINT under virtual supervision in the morning. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary.
62483191|NCT01862601|EXPERIMENTAL|JetTouch injections|
62483192|NCT03506672|EXPERIMENTAL|Experimental group|Approach based on the meanings of vocal behaviours
62483193|NCT03506672|ACTIVE_COMPARATOR|Control group|Usual practices of formal caregivers regarding vocal behaviours
62483194|NCT05068284|EXPERIMENTAL|Induction Phase: ABBV-154 Randomized Dose A|Varying doses of ABBV-154 as described in the protocol.
62483195|NCT05068284|EXPERIMENTAL|Induction Phase: ABBV-154 Randomized Dose B|Varying doses of ABBV-154 as described in the protocol.
62132084|NCT02411084|EXPERIMENTAL|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
62691628|NCT06630689|EXPERIMENTAL|Oil Full Body Massage Group|Unlike the control group, the babies in this group received a full body oil massage. The full body oil massage was applied using pure baby olive oil.
62132085|NCT02411084|ACTIVE_COMPARATOR|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
62132086|NCT04127669|EXPERIMENTAL|Arm A|Active substance treatment with OSU6162. Starting dose for all patients in the OSU6162 treatment group is 15 mg BID. The dose is taken orally as one circular coated tablet of 15 mg together with a light meal in the morning and one tablet around lunch unless otherwise agreed upon. In order to aim at optimal dosing of OSU6162, some flexibility is allowed. The investigators are able to modify the dose for individual patients based on how well the treatment is tolerated and how well the patients respond to it. In the case where there is no clear response, the dose can be increased to maximally 30 mg BID (intermediate dosage is allowed) after 4 weeks of treatment; it is also possible to decrease the dose to a lower level (even below 15 mg BID) if a higher dose is not tolerated and/or there is a perceived weakened therapeutic effect with the higher dose. All dose changes will be performed while retaining the blind.
62132087|NCT04127669|PLACEBO_COMPARATOR|Arm B|Placebo treatment. Starting dose for all patients in the placebo group is one circular coated tablet (with identical appearance to active treatment tablets 15 mg) taken BID, according to the same schedule as active treatment. The dose may be increased or decreased in the same manner as for active treatment.
62132088|NCT02560649|EXPERIMENTAL|A:PEG+NUC (HBsAg<200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus nucleoside analogue(NUC):~HBsAg\<200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
62132089|NCT02560649|ACTIVE_COMPARATOR|B:PEG+NUC(HBsAg>200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus+nucleoside analogue(NUC):~HBsAg\>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
62132090|NCT02560649|ACTIVE_COMPARATOR|C:NUC(HBsAg>200IU/ml at week 24)|"nucleoside analogue(NUC):~HBsAg\>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
62132091|NCT04064086|ACTIVE_COMPARATOR|Comprehensive Pre-ESRD Patient Education (CPE)|These patients will receive CPE for a total of up to 3 session in an intent-to-teach format, either via Face-to-face or telemedicine delivery.
62132092|NCT04064086|ACTIVE_COMPARATOR|Enhanced Usual Care|This group will receive usual care. This care will be enhanced by providing them with the freely available education material for the Kidney Disease Education
62132093|NCT02232295|ACTIVE_COMPARATOR|Conventional group|Conventional group consist of Upper extremity task oriented functional exercises. Components of Task oriented training include weight bearing, supportive reactions, and reaching, grasping, holding and release activities.
62132094|NCT02232295|EXPERIMENTAL|Graded Motor imagery group and Conventional group|"Graded Motor imagery is a three stage process, was performed five days a week for six weeks of one hour duration. It comprises of:~* Left Right discrimination training (Implicit Motor Imagery) - 2 weeks~* Explicit Motor Imagery (Imagined movements) - 2 weeks~* Mirror Therapy - 2 weeks"
62132095|NCT02523716|EXPERIMENTAL|Hypoxia|Mild hypoxia of 15% oxygen, equivalent altitude of 2440m over a period of 7 days
62132096|NCT02523716|SHAM_COMPARATOR|Normoxia|Exposure to normal, sea-level air
62132097|NCT02621086|EXPERIMENTAL|Level 1|10g of Cellodextrin
62132098|NCT02621086|EXPERIMENTAL|Level 2|20g of Cellodextrin
62132099|NCT02621086|EXPERIMENTAL|Level 3|30g of Cellodextrin
62132100|NCT02621086|EXPERIMENTAL|Level 4|50g of Cellodextrin
62132101|NCT03810859|EXPERIMENTAL|All patients|Blood sample
62132102|NCT04011813||"Control arm, H-"|semen treated without hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
62132103|NCT04011813||"Experimental arm, H+"|semen treated with a 50mM hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
62132104|NCT05075486|EXPERIMENTAL|Intervention group|Group who recieve collaborative quality improvement during study period.
62132105|NCT00550394|ACTIVE_COMPARATOR|Quetiapine and Placebo|Quetiapine and Placebo
62132106|NCT00550394|EXPERIMENTAL|Quetiapine and Topiramate|Quetiapine and Topiramate
62132107|NCT02055742||Specimen Collection|
62132108|NCT04772300|EXPERIMENTAL|Sirolimus DCB group|Intervention with Sirolimus-coated balloon catheter
62132109|NCT04772300|ACTIVE_COMPARATOR|POBA group|Intervention with non-coated balloon catheter (POBA)
62339907|NCT06379802|EXPERIMENTAL|Individualized physical activity and diet|The intervention group will receive (offered) an optimal prescription of physical activity and diet based on medical (comorbidities, risk profile, medications, symptoms) and psycho-social (preferences for physical activities and diet, barriers-facilitators, social support, readiness to change, accelerometry and predicted VO2-max data (Ekblom Bak ergometer test), resting energy expenditure and knowledge and skills (lifestyle education school for achieving knowledge and skills in handling change in diet and physical activity in daily life) and support (health promotors, behavioral change app, food diary app, face-to-face, phone/online coaching, physical activity (aerobic training, strength training) in group and nudging.
62691629|NCT06402136|EXPERIMENTAL|Single dose level 1 or placebo|Dose level 1. SAD study part.
62691630|NCT06402136|EXPERIMENTAL|Single dose level 2 or placebo|Dose level 2. SAD study part.
62691631|NCT06402136|EXPERIMENTAL|Single dose level 3 or placebo|Dose level 3. SAD study part.
62483196|NCT05068284|EXPERIMENTAL|Induction Phase: ABBV-154 Randomized Dose C|Varying doses of ABBV-154 as described in the protocol.
62483197|NCT05068284|EXPERIMENTAL|Induction Phase: ABBV-154 Randomized Dose D|Varying doses of ABBV-154 as described in the protocol.
62483198|NCT05068284|PLACEBO_COMPARATOR|Induction Phase: Randomized Placebo|Fixed dose placebo as described in the protocol.
62483199|NCT05068284|EXPERIMENTAL|Re-Induction Phase: ABBV-154 Randomized Dose A|Varying doses of ABBV-154 as described in the protocol.
62483200|NCT05068284|EXPERIMENTAL|Re-Induction Phase: ABBV-154 Randomized Dose B|Varying doses of ABBV-154 as described in the protocol.
62483201|NCT05068284|EXPERIMENTAL|Maintenance Phase: ABBV-154 Randomized Dose A|Fixed dose ABBV-154 every other week.
62483202|NCT05068284|EXPERIMENTAL|Maintenance Phase: ABBV-154 Randomized Dose B|Fixed dose ABBV-154 every other week.
62483203|NCT05068284|PLACEBO_COMPARATOR|Maintenance Phase: Randomized Placebo|Fixed dose placebo every other week.
62691632|NCT06402136|EXPERIMENTAL|Single dose level 4 or placebo|Dose level 4. SAD study part.
62691633|NCT06402136|EXPERIMENTAL|Single dose level 5 or placebo|Dose level 5. SAD study part.
62691634|NCT06402136|EXPERIMENTAL|Multiple dose level 1 or placebo|Dose level 1. MAD study part.
62691635|NCT06402136|EXPERIMENTAL|Multiple dose level 2 or placebo|Dose level 2. MAD study part.
61930296|NCT05993039|ACTIVE_COMPARATOR|Total Intravenous Anesthesia (TIVA)|"Adults:~The comparator arm will receive total intravenous anesthesia (propofol and remifentanil). They will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, and lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with propofol 100-200mcg/kg/min, remifentanil 0.05-2µg/kg/min.~Children (12 or younger) induced with a combination of volatile anesthetic gases, including sevoflurane (up to 8%) and nitrous oxide gas (up to 70%). Those who are older than 12 will have an intravenous line placed in the preoperative area and as such will be induced with remifentanil and propofol as above. For maintenance, they will receive 100-200mcg/min propofol and 0.05-2µg/kg/min remifentanil."
61930297|NCT04758910|ACTIVE_COMPARATOR|High Flow Oxygen Therapy|Tracheostomized patients will undergo a spontaneous breathing trial with high flow oxygen therapy.
61930298|NCT04758910|ACTIVE_COMPARATOR|T-piece|Tracheostomized patients will undergo a spontaneous breathing trial with T-piece as a standard of care.
61930299|NCT01913132|NO_INTERVENTION|Standard wound dressing OPEN|Standard wound dressing
61930300|NCT01913132|EXPERIMENTAL|PICO dressing OPEN|Negative pressure wound therapy with PICO (Smith \& Nephew)
61930301|NCT01913132|NO_INTERVENTION|Standard dressing EVAR|Standard wound dressing
62691636|NCT06402136|EXPERIMENTAL|Multiple dose level 3 or placebo|Dose level 3. MAD study part.
62691637|NCT00748527|ACTIVE_COMPARATOR|Arm I|Patients receive carboplatin IV over 30-60 minutes on day 1.
62691638|NCT00748527|EXPERIMENTAL|Arm II|Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
62691639|NCT06252987|SHAM_COMPARATOR|common group|routine training
61930302|NCT01913132|EXPERIMENTAL|PICO dressing EVAR|Negative pressure wound therapy with PICO (Smith \& Nephew)
62483204|NCT05259657|EXPERIMENTAL|Lymfit intervention|Participants randomized to the intervention group will be allocated a pre-registered Inspire II model Fitbit. The kinesiologist will design a personalized exercise prescription for the participant. The kinesiologist will follow up with the participants every 2 weeks for 3 months to discuss their progress and to modify or advance their exercise prescriptions as needed.
62483205|NCT05259657|OTHER|Wait-list control arm|The control group participants will begin receiving the Lymfit intervention 3 months after they sign the consent form.
62483206|NCT02795572|EXPERIMENTAL|Intervention Group|The intervention group will receive a daily dose of Vitamin D 2000 IU, Vitamin B6 100 mg, Vitamin B12 100 mcg and Omega-3 Fatty Acids 2700 mg \[900 mg TID (600 mg EPA, 300 mg DHA)\].
62483207|NCT02795572|NO_INTERVENTION|Reference Group|Reference group will receive usual care.
62483208|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
62483209|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
62483210|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
62483211|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
62483212|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
62691640|NCT06252987|EXPERIMENTAL|tDCS group|tDCS
61930303|NCT03775161|EXPERIMENTAL|V-LAP™ System|Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home
61930304|NCT05796557|ACTIVE_COMPARATOR|Higher platelet transfusion strategy|Participants randomized to this arm will be transfused if the platelet count is \< 90 x 10e9 cells/L.
61930305|NCT05796557|EXPERIMENTAL|Lower platelet transfusion strategy|Participants randomized to this arm will be transfused if the platelet count is \< 50 x 10e9 cells/L.
61930306|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
62132110|NCT02472275|EXPERIMENTAL|Treatment (PLX3397, radiation therapy, ADT)|Patients receive multitargeted tyrosine kinase inhibitor PLX3397 PO BID for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday) beginning at month 3, and undergo ADT with leuprolide acetate, goserelin acetate, or degarelix injections in any month.
62132111|NCT06255262|EXPERIMENTAL|Durvalumab in combination with surufatinib|"1. Safety introduction phase (6 cases)~2. Dose expansion phase (24 cases)"
62691641|NCT06252987|EXPERIMENTAL|rTMS group|rTMS
62691642|NCT06252987|EXPERIMENTAL|Combination group|tDCS-rTMS
62691643|NCT05372068|EXPERIMENTAL|Concrete household floor|
62691644|NCT05372068|NO_INTERVENTION|Non-intervention|
62691645|NCT03113188|EXPERIMENTAL|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
62483213|NCT03333551|EXPERIMENTAL|Patients with AL cardiac amyloid|Patients enrolled will be patients \> 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.
61930307|NCT05575141|ACTIVE_COMPARATOR|rTAR|Patients randomized in the robotic group will undergo the technique for intra-and perioperative management for robotic complex abdominal wall repair cases as used in the center. A robotic surgical platform (da Vinci X or da Vinci Xi Surgical System, Intuitive Surgical, Aubonne, Switzerland) will be used and a retrorectus +/- retromuscular mesh placement performed. Use of component separation or not will be at the discretion of the surgeon. In principle the posterior layer and the anterior fascia will be closed avoiding a bridging technique. Drain management and mesh fixation are left to the surgeon's preference.
61930308|NCT05575141|ACTIVE_COMPARATOR|oTAR|Patients randomized in the open group will undergo the technique for intra-and perioperative management for open complex abdominal wall repair cases as used in the center. A retrorectus +/- retromuscular mesh placement performed. Use of component separation or not will be at the discretion of the surgeon. In principle the posterior layer and the anterior fascia will be closed avoiding a bridging technique. Drain management and mesh fixation are left to the surgeon's preference.
62132112|NCT05363436|NO_INTERVENTION|Control|Normal Standard Practices of Prescribing
62132113|NCT05363436|EXPERIMENTAL|Intervention|Providers prescribed a base of 15 narcotic pills
62132114|NCT02795754|EXPERIMENTAL|GSK2838232 PIB (50 mg+100 mg+200 mg)+Placebo|During Part 1A, subjects will receive QD single dose of either GSK2838232 50 mg, 100 mg or 200 mg or placebo in each of the four visits (one treatment per visit).Subjects will also receive RTV along with all the doses and QD RTV for 48hours (2 doses) before all doses of GSK2838232 and placebo.
62132115|NCT02795754|EXPERIMENTAL|GSK2838232 PIB+IR1+IR2|During Part 1B, subjects will receive either GSK2838232 PIB, GSK2838232 IR1 or IR2 in each of the three visits (one treatment per visit) after at least 10 hours fasting and IR1 or IR2 after fat meal at visit 4.
62132116|NCT02795754|EXPERIMENTAL|GSK2838232 PIB (20mg/50 mg/100 mg/200 mg)/Placebo|During Part 2, subjects will receive repeated QD doses of either GSK2838232 (20 mg, 50 mg, 100 mg or 200 mg) or placebo for 11 days. Subjects will also receive RTV along with all the doses of GSK2838232 and placebo.
62132117|NCT01821989|ACTIVE_COMPARATOR|Low Dose|Lactoferrin,dose of 100 mg/day.
62324007|NCT05756673|EXPERIMENTAL|Interdental Brush/Brush|"Participants will use their interdental brush according to their personalized mouth map, rinse with water then brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes under virtual supervision in the morning. At home, participants will brush a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. Throughout the study, only tooth brushing will be performed a second time in the evening (no interdental brush use). First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary."
62324008|NCT05756673|EXPERIMENTAL|Interdental Brush/Brush/Rinse (LISTERINE COOL MINT Antiseptic Mouthwash)|"Participants will use their interdental brush according to their personalized mouth map, rinse with water, brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes and then rinse for 30 seconds with LISTERINE COOL MINT Antiseptic Mouthwash under virtual supervision in the morning. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. Throughout the study, only tooth brushing will be performed a second time in the evening (no interdental brush use). First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary."
62483214|NCT06395792||Participants With DS or LGS|Participants with a medical record of diagnosis with either DS or LGS that are treated in the participating hospitals and reside in the reference area of these hospitals will be included and data will be retrospectively collected for the period between 01 January 2021 to 31 December 2022.
61930309|NCT02367989|PLACEBO_COMPARATOR|Control without fibre|"Intervention: 0g barley β-glucan no fibre.~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
61930310|NCT02367989|EXPERIMENTAL|low barley β-glucan|"Intervention: 2g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
61930311|NCT02367989|EXPERIMENTAL|medium barley β-glucan|"Intervention: 4g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
62132118|NCT01821989|EXPERIMENTAL|High Dose|Lactoferrin, dose of 150 mg/kg/ twice daily.
62132119|NCT01821989|PLACEBO_COMPARATOR|Control|Receive placebo in form of distilled water.
62132120|NCT04718610|ACTIVE_COMPARATOR|Control|Patients will receive only caner treatment. No osteopathic treatment.
62483215|NCT06627660|NO_INTERVENTION|Group C|Control group
62483216|NCT06627660|ACTIVE_COMPARATOR|Group V|Repeated Valsalva maneuver will be done after recovery from anesthesia
62132121|NCT04718610|EXPERIMENTAL|Osteopathic intervention|Patients will receive cancer treatment associated with osteopathic intervention
62132122|NCT06150833|EXPERIMENTAL|Boya IVIG|Patients with primary immunodeficiency will switch to Boya IVIG and optimize the posology in a run-in period of 2 to 6 administrations. In the one-year test period, the patients will receive the test IVIG at 21- or 28-day intervals and be followed. The minimum IgG concentration will be measured in all participants at all visits. The other pharmacokinetic parameters will be measured between visits 4 and 5 in 20 adult participants by taking additional blood samples. An independent Safety Data Monitoring Committee (SDMC) will periodically monitor adverse events.
62132123|NCT06482632|OTHER|Discectomy of Omohyoid|Patient undergoing an anterior cervical discectomy (ACDF) and fusion will have the Omohyoid removed to determine the effect of dysphagia after surgery.
62132124|NCT06482632|OTHER|No discectomy of Omohyoid|Patient undergoing an anterior cervical discectomy (ACDF) and fusion will not have the Omohyoid removed to determine the effect of dysphagia after surgery.
62132125|NCT04048681|EXPERIMENTAL|Diet Soda|12oz can of Diet Coke
62483217|NCT06265753|EXPERIMENTAL|Experimental Group|Who received 10 minutes gastrocinemius function massage and 45 minutes classic physiotherapy exercise
62483218|NCT06265753|SHAM_COMPARATOR|Control group|Who received 10 sham applicaiton massage and 45 minutes classic physiotherapy exercise
62483219|NCT05198622|EXPERIMENTAL|Intercostobrachial Nerve Preservation Arm|Intercostobrachial nerve preserving axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
61930312|NCT02367989|EXPERIMENTAL|high barley β-glucan|"Intervention: 6g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
62132126|NCT04048681|ACTIVE_COMPARATOR|Soda|12oz can of Coke
62132127|NCT04048681|PLACEBO_COMPARATOR|Carbonated Water|12oz can of carbonated (unflavored) water
62132128|NCT02849054|EXPERIMENTAL|4, 5, 6ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 5ml/kg, 6ml/kg. Measurement of PTPdi
62132129|NCT02849054|EXPERIMENTAL|4, 6, 5ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 6ml/kg, 5ml/kg. Measurement of PTPdi
62132130|NCT02849054|EXPERIMENTAL|5, 4, 6ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 4ml/kg, 6ml/kg. Measurement of PTPdi
62132131|NCT02849054|EXPERIMENTAL|5, 6, 4ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 6ml/kg,4ml/kg. Measurement of PTPdi
62132132|NCT02849054|EXPERIMENTAL|6, 5, 4ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 5ml/kg, 4ml/kg. Measurement of PTPdi
62483220|NCT05198622|ACTIVE_COMPARATOR|Intercostobracial Nerve Sacrifice Arm|Intercostobrachial nerve sacrificing axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
62132133|NCT02849054|EXPERIMENTAL|6, 4, 5ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 4ml/kg, 5ml/kg. Measurement of PTPdi
62483221|NCT05012358||Observational Cohort|no intervention
62483222|NCT02825680|ACTIVE_COMPARATOR|Enhanced NCP Support|Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
62483223|NCT02825680|EXPERIMENTAL|LEAP Intervention|Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
62483224|NCT06628011|EXPERIMENTAL|Intervention group|This group will be encouraged to perform two aerobic interval training sessions per week for 12 weeks, on their own and not at the exercise training clinic, while receiving digital follow-up support through HelsaMi and exercise guidance through the exercise app. The digital follow-up through HelsaMi will consist of overview of treatment progress and schedule, communication with health care personnel (video consultation or chat up to 2 times per week), notifications reminding them to exercise, exercise diary, questionnaires, and educational content.
62483225|NCT06628011|NO_INTERVENTION|Control gorup|This group will be encouraged to perform the same exercise training but without any follow-up support
62483226|NCT05885412|EXPERIMENTAL|RP-A601|Single ascending dose of RP-A601 in 2 consecutive cohorts
62483227|NCT01842477|EXPERIMENTAL|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
62483228|NCT03798457||Patients with CAP hospitalized in IM|Data of Patients with Community-acquired pneumonia (CAP) hospitalized in Internal Medicine Units will be collected for this study; no intervention is planned for this study
61930313|NCT02367989|PLACEBO_COMPARATOR|control with fibre|"Intervention: 0g barley β-glucan with fibre~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
61930314|NCT03892473|EXPERIMENTAL|Flexible Assertive Community Treatment (FACT)|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
62132134|NCT03840421|EXPERIMENTAL|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
62132135|NCT03840421|ACTIVE_COMPARATOR|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
62132136|NCT04156204|EXPERIMENTAL|Adolescent and Young Adult (AYA) Kidney Transplant Recipients|AYA kidney transplant recipients will receive a Medication Event Monitoring System (MEMS) in the form of a medication bottle and cap system and once daily tacrolimus XR 1-10mg
62132137|NCT00677469|EXPERIMENTAL|I|Cholestyramine 2g BID, Methimazole 10mg TID, and Propranolol 20mg BID
62132138|NCT00677469|EXPERIMENTAL|II|Cholestyramine 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
62132139|NCT00677469|PLACEBO_COMPARATOR|III|Placebo powder 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
62132140|NCT05359653|EXPERIMENTAL|Clemastine 8 mg, then Placebo|Group 1 will receive the treatment (clemastine 8mg/day) for the first 90 days and then switch to the placebo (a sugar pill) for the remaining 90 days
62132141|NCT05359653|EXPERIMENTAL|Placebo, then Clemastine 8 mg|Group 2 will receive the placebo (a sugar pill) for the first 90 days and then switch to the treatment (clemastine 8mg/day) for the remaining 90 days
62132142|NCT04750070|EXPERIMENTAL|Dopamine arm|Children in the dopamine arm (Treatment plan A) will receive dopamine, 8 microgram/kg/min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
61930315|NCT03892473|ACTIVE_COMPARATOR|Care as usual (CAU)|Active Comparator: CAU (Care as usual) Patients with SMI receiving usual care, meaning mostly medical treatment
61930316|NCT03776487|EXPERIMENTAL|Treatment (chemotherapy, immunotherapy, IMRT)|"INDUCTION CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours and fluorouracil IV over 48 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients also receive fluorouracil IV continuously for 5 days per week and undergo 25 fractions of IMRT for 5 weeks. Patients undergo surgical resection 5-7 weeks after completing radiation therapy.~Within 8-12 weeks post-surgery, patients with residual disease may receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 courses (16 weeks) then every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
61930317|NCT06197347|EXPERIMENTAL|Web-based nursing intervention|Web-based intervention (8 sessions weekly) which includes the support of a nurse that aims to increase physical activity and quality of life for older people living with heart disease, as well as enhancing knowledge, motivation and self-efficacy.
61930318|NCT03798626|EXPERIMENTAL|Cohort A: 1st line colorectal cancer|Treatment for 1st line metastatic colorectal cancer (mCRC) with Gevokizumab, modified FOLFOX6, bevacizumab
61930319|NCT03798626|EXPERIMENTAL|Cohort B: 2nd line colorectal cancer|Treatment for 2nd line mCRC with Gevokizumab, FOLFIRI, bevacizumab
61930320|NCT03798626|EXPERIMENTAL|Cohort C: 2nd line gastroesophageal cancer|Treatment for 2nd line metastatic gastroesophageal cancer (mGEC) with Gevokizumab, paclitaxel, ramucirumab
62132143|NCT04750070|EXPERIMENTAL|Adrenaline arm|Children in the adrenaline arm (Treatment plan B) will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
62324009|NCT05756673|EXPERIMENTAL|Interdental Brush/Brush/Rinse (LISTERINE ZERO Alcohol Mouthwash COOL MINT)|"Participants will use their interdental brush according to their personalized mouth map, rinse with water, brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes and then rinse for 30 seconds with LISTERINEZERO Alcohol Mouthwash COOL MINT under virtual supervision in the morning. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. Throughout the study, only tooth brushing will be performed a second time in the evening (no interdental brush use). First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary."
62324010|NCT05176262||4FED Group|EoE patients recruited to this observational study will be monitored for treatment response to 4FED and treatment responders will be monitored during food reintroduction
62324011|NCT01879605|EXPERIMENTAL|Enema|Docusate natrium and sorbitol, 240 ml enema, the evening before surgery
62483229|NCT00500201|EXPERIMENTAL|Subjects in treatment sequence AB|In treatment sequence AB first subjects will be randomized to receive treatment A (two tablets of 60 milligram \[mg\] of SB-773812) and one placebo tablet. Then subjects will receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets . There will be a wash-out period of 20 days between.
62324012|NCT01879605|ACTIVE_COMPARATOR|Suppository|Bisacodyl, suppository 10 mg, the evening before surgery.
62324013|NCT01879605|NO_INTERVENTION|Control grup|No intervention
62324014|NCT01958736|EXPERIMENTAL|Experimental|Ballistic Strength Training
62324015|NCT01958736|ACTIVE_COMPARATOR|Control|Usual care Physiotherapy
62324016|NCT02951988|EXPERIMENTAL|Rapastinel 450 mg Weekly|Rapastinel 450 milligrams (mg) intravenous (IV) once a week during OLTP followed by rapastinel 450 mg IV once a week during DBTP.
62324017|NCT02951988|EXPERIMENTAL|Rapastinel 450 mg Every 2 Weeks|Rapastinel 450 mg IV once a week during OLTP followed by rapastinel 450 mg IV once every 2 weeks during DBTP.
62324018|NCT02951988|PLACEBO_COMPARATOR|Placebo|Rapastinel 450 mg IV once a week during OLTP followed by placebo-matching rapastinel 450 mg IV once a week during DBTP.
62324019|NCT00518453|EXPERIMENTAL|Arm 1: Fluvirin|
62324020|NCT04227249||Experimental|women who do not undergo lymph node dissection
62324021|NCT06034704|EXPERIMENTAL|Magnetic Fascial Ball|In the experimental group, a fascial ball made of cork containing 3 magnets of 0.15 tesla was used. The magnetic fascia ball diameter is 6 centimetres.
62324022|NCT06034704|PLACEBO_COMPARATOR|Non-Magnetic Fascial Ball|In the placebo group, a fascial ball made of cork without magnets. The non-magnetic fascia ball diameter is 6 centimetres.
62324023|NCT05472597||nuMoM2b Heart Health Study Cohort|A large and diverse (both geographically and demographically) group of adult women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospective collected thereafter.
62324024|NCT05313633|EXPERIMENTAL|Wii group|Children in this group will receive a designed physical therapy and occupational therapy programs
61930321|NCT03798626|EXPERIMENTAL|Cohort D: 2nd or 3rd line renal cell carcinoma|Treatment for 2nd or 3rd line metastatic renal cell carcinoma (mRCC) with Gevokizumab, cabozantinib
61930322|NCT01224665|ACTIVE_COMPARATOR|Arm I|therapeutic conventional surgery therapeutic standard lymphadenectomy
61930323|NCT01224665|EXPERIMENTAL|Arm II|therapeutic conventional surgery therapeutic extended lymphadenectomy
61930324|NCT02296944||Children aged under 7 years old when tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
61930325|NCT02296944||Children aged 7 to 10 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
61930326|NCT02296944||Children aged 11 to 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
61930327|NCT02296944||Children aged over 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
61930328|NCT00414921|ACTIVE_COMPARATOR|1|clonidine
62324025|NCT05313633|EXPERIMENTAL|plyometric group|Children in this group will receive a designed physical therapy and occupational therapy programs and plyometric training
62324026|NCT04180813||Linagliptin Initiators|
62324027|NCT04180813||Acarbose Initiators|
62324028|NCT02008929|OTHER|MG4101|Ex vivo expanded allogeneic NK cell
62132144|NCT04750070|ACTIVE_COMPARATOR|Blood transfusion arm|Children in the blood transfusion arm (Treatment plan C) will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
62132145|NCT00704314|ACTIVE_COMPARATOR|1|Simvastatin therapy, 80 mg/d for 8 weeks
62132146|NCT00704314|PLACEBO_COMPARATOR|2|Placebo, one pill daily for 8 weeks
62324029|NCT00916955||Individuals with 22q11.2 deletions|Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
62324030|NCT06692231|NO_INTERVENTION|Controle Arm|Control arm: will have no specific intervention
62324031|NCT06692231|EXPERIMENTAL|Intervention Arm|Intervention arm: Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
62324032|NCT00002677|EXPERIMENTAL|Arm I|Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
62324033|NCT01266798|EXPERIMENTAL|Portal arm|
62324034|NCT01266798|NO_INTERVENTION|Treatment as usal|
62324035|NCT01180374|EXPERIMENTAL|Active Canabidiol and Active Delta-9-THC|
62324036|NCT01180374|PLACEBO_COMPARATOR|Placebo and Active Delta-9-THC|
62324037|NCT01180374|EXPERIMENTAL|Active Cannabidiol and Placebo|
62324038|NCT01180374|PLACEBO_COMPARATOR|Placebo and Placebo|
62324039|NCT04495361|EXPERIMENTAL|Online learning portal|Final year medical students will use an online learning portal in which three case scenarios of under five pneumonia patients will be displayed each month. Based on history and examination, the user will diagnose and manage the patient.
62324040|NCT06684431|EXPERIMENTAL|Vaccine|N-pVAX1 vaccine
62324041|NCT03471754|EXPERIMENTAL|Treatment Arm A|TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.
62324042|NCT02086565|EXPERIMENTAL|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
62324043|NCT02086565|ACTIVE_COMPARATOR|portal training|Participants are assured internet access and taught to use the patient portal
62324044|NCT00985855|EXPERIMENTAL|Cisplatin, vinorelbine|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.
62324045|NCT00985855|EXPERIMENTAL|Cisplatin, etoposide|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.
62324046|NCT02535949|EXPERIMENTAL|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
62324047|NCT02535949|EXPERIMENTAL|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
62324048|NCT02535949|PLACEBO_COMPARATOR|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
62324049|NCT03851380||Treatment Resistant Major Depression|Patients with treatment resistant major depression
62324050|NCT03851380||COVID Stress|Veterans with COVID-19-related distress
62324051|NCT05784909|EXPERIMENTAL|patients diagnosed with bladder outlet obstruction due to BPH|all symptomatic patients with BPH with failure medical management or prefer minimal invasive procedure from the start.
62324052|NCT02219555||Non-surgical treatment|When clinically indicated, subjects will receive a standard of care carpal tunnel injection whose volume and specific steroid drug will be based on the recommendation of the treating clinician
62324053|NCT02219555||Surgical treatment|When clinically indicated, subjects will receive standard of care carpel tunnel release surgery as recommended by treating clinician
62324054|NCT01002625|EXPERIMENTAL|1. PF-04457845 followed by placebo|PF-04457845 followed by placebo
62324055|NCT01002625|EXPERIMENTAL|2. Placebo followed by PF-04457845|Placebo followed by PF-04457845
62324056|NCT02244450|EXPERIMENTAL|Screened patients|SCID screening: more drops of blood are placed on a second Guthrie card when current screening (72 hours of life ) is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
62324057|NCT02244450|NO_INTERVENTION|Control group|SCID children diagnosed without screening by pediatricians local referents DIP
62324058|NCT02379741|EXPERIMENTAL|ADC-1013 intratumoral|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.
62324059|NCT02379741|EXPERIMENTAL|ADC-1013 intravenous|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intravenous infusion every second week until complete response, confirmed progressive disease, or clinical deterioration.
62132147|NCT01730352|NO_INTERVENTION|H. pylori no treatment|Observational group, with clinical and platelet count follow-up
62132148|NCT01730352|EXPERIMENTAL|H. pylori triple therapy|Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
62132149|NCT01392638|PLACEBO_COMPARATOR|sugar pill|Intervention: sugar pill
62132150|NCT01392638|ACTIVE_COMPARATOR|sildenafil|Intervention: sildenafil citrate
62132151|NCT02178241|EXPERIMENTAL|Treatment (eribulin mesylate and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62697514|NCT03862950|PLACEBO_COMPARATOR|Placebo Medication|The placebo will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
62324060|NCT05622500|EXPERIMENTAL|Best endovenous reconstruction + best medical treatment (compression +/- anti-thrombotic therapy).|The intervention arm consists of participants undergoing best endovenous reconstruction under the guidance of intra-vascular ultrasound in addition to best medical treatment (compression +/- antithrombotic therapy).
62324061|NCT05622500|ACTIVE_COMPARATOR|Best medical treatment alone (compression +/- anticoagulation).|The comparator arm will consist of participants receiving best medical treatment alone.
62324062|NCT04297384|ACTIVE_COMPARATOR|Group I (standard educational materials, surveys)|Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
61930329|NCT00414921|ACTIVE_COMPARATOR|2|methylphenidate
61930330|NCT00414921|ACTIVE_COMPARATOR|3|methylphenidate and clonidine
61930331|NCT00414921|PLACEBO_COMPARATOR|4|
61930332|NCT03813771|EXPERIMENTAL|Abnormal T-cells: Benepali + T2T Care|"Treatment Arm C will receive Benepali and methotrexate combination therapy and followed as per T2T care over a total duration of 24 weeks. Sulfasalazine or Hydroxychloroquine may be added to therapy at follow up visits in-line with T2T care.~Benepali will be administered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).~Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks."
61930333|NCT03813771|ACTIVE_COMPARATOR|Abnormal T-cells: Methotrexate + T2T Care|"Treatment Arm B will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination synthetic DMARD (Including sulfasalazine and/or hydroxychloroquine).~therapy if not achieving low disease activity (LDA) at, or after, 8 weeks)."
61930334|NCT03813771|OTHER|Normal T-cells: Methotrexate + T2T Care|Treatment Arm A will receive standard T2T care as per Arm B.
61930335|NCT05891561|EXPERIMENTAL|Pertuzumab|4 cycles of taxane, Pertuzumab, Trastuzumab
61930336|NCT05384275|NO_INTERVENTION|No intervention: Standard Oxygen Therapy|Standard oxygen therapy arm patients will be given 30-40% inspired O2 and flow 2-6 l/min via nasal prongs or non-rebreathing mask (not humidified and not heated) post extubation. Monitoring of saturations, respiratory rate and arterial gases will happen 15 minutes post extubation and then as per local policy thereafter. If saturations \< 93% then FiO2 will be increased as per respiratory escalation protocol. Standard oxygen therapy will be given for a minimum of 16 hours post extubation.
61930337|NCT05384275|ACTIVE_COMPARATOR|High-Flow Nasal Therapy|High-flow nasal therapy arm patients will be given AIVRO 2 high flow oxygen therapy machines post extubation, start at 30-40% inspired O2 and flow 30 l/min then up to 50 l/min over 5-10 min. Monitoring of saturations, respiratory rate and arterial gases will happen after 15 minutes post extubation and then as per local policy thereafter. If saturations \< 93% then increase FiO2 as per respiratory escalation protocol. High flow nasal therapy will be given for a minimum of 16 hours post extubation.
61930338|NCT04189835||Kidney transplant recipients|Adults and children undergoing kidney transplantation in Norway and the western part of Denmark.
61930339|NCT06399198|EXPERIMENTAL|smoker|
61930340|NCT06399198|EXPERIMENTAL|non-smoker|
62132152|NCT04047719||Intent-to-Diagnose Population|All subjects enrolled in the study that have at least one Karius Test with a valid result
62132153|NCT02879760|EXPERIMENTAL|Ad/MAGEA3, MG1-MAGEA3 and pembrolizumab|"Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.~MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts: Cohort 1: Days 15 \& 18 at 1x 10e10 pfu.~Cohort 2: Days 15 \& 18 at 1x 10e11 pfu. Cohort 3: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 4: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 5: Day 15 at 3x 10e11 pfu; Day 18 at 3 x 10e12 pfu. Pembrolizumab will be administered IV every 3 weeks starting on Day 22."
62132154|NCT01586936||eptacog alpha users|
62132155|NCT04705311|EXPERIMENTAL|pain neuroscience education plus rotator cuff repair rehabilitation|
62132156|NCT04705311|ACTIVE_COMPARATOR|rotator cuff repair rehabilitation|
62132157|NCT02805816||Study group|Children with suspicion of CD based on positive serology (TG2 \>2 times upper limit of normal) and classical clinical manifestations or belonging to high risk groups, who underwent gastroscopy with intestinal biopsies.
62132158|NCT02805816||Control group|Children without suspicion of CD who underwent gastroscopy and duodenal biopsies for other reasons (abdominal pain, failure to thrive, vomiting, eg)
62132159|NCT03305146|EXPERIMENTAL|single arm|"For inoperable patients with indeterminate cystic lesions of the pancreas,a EUS FNA will be performed and molecular biology analysis of pancreatic intra-cyst fluid collected by EUS FNA will be performed.~For operable patients, after the pancreatic surgery, molecular biology analysis of extemporaneous pancreatic tissue specimen biopsy will be conducted."
62324063|NCT04297384|EXPERIMENTAL|Group II (personalized information, surveys)|Participants receive personalized information about their cancer, treatment, and side effects. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
61930341|NCT04952753|EXPERIMENTAL|Safety run-in: NIS793+SOC (Investigational arm 1)|In the safety run-in part for investigational arm 1, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of the NIS793
61930342|NCT04952753|EXPERIMENTAL|Expansion: NIS793+SOC (Investigational arm 1)|In the expansion part, participants in the investigational arm 1 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in
61930343|NCT04952753|ACTIVE_COMPARATOR|Expansion: SOC (control arm)|In the expansion part, participants in the control arm will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)
62691646|NCT06645392||Group A, (Visual transparent bladed trocar group)|visual transparent bladed trocar of diameter 10 mm is used for abdominal entry; the assistant holds the laparoscope mounted in the cannula of the trocar, and the surgeon lowers the unit (laparoscope and mounted cannula) deep into the umbilical wound where the surgeon uses the muscles of the dominant wrist to rotate the cannula clockwise while keeping the forearm horizontal the patient's abdomen. Downwards axial pressure during rotation is kept to a minimum. Rotation serves to lift the anterior abdominal wall and transpose successive tissue layers onto the cannula's outer thread. The white anterior rectus fascia, red rectus fascia, pearly white posterior rectus fascia, yellowish preperitoneal space, and transparent greyish peritoneal membrane are all observed sequentially on the monitor. Further clockwise rotation parts the peritoneal membrane radially to advance the cannula incrementally into the peritoneal cavity under direct visual control while avoiding cannula overshot
61930344|NCT04952753|EXPERIMENTAL|Safety run-in: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the safety run-in part for investigational arm 2, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793 and tislelizumab to confirm the RP2D of NIS793.
62132160|NCT04805853||type 2 diabetes without polycystic ovary syndrome|The treatment of type 2 diabetes is based on the Chinese Medical Association Diabetes Branch '2017 China Type 2 Diabetes Prevention Guidelines' for lifestyle adjustment and diabetes drug treatment.The research physician decides the diabetes treatment measures of the research object; the blood sugar control goal is that glycosylated hemoglobin is less than 7%.
62132161|NCT04805853||polycystic ovary syndrome without type 2 diabetes|The treatment of polycystic ovary syndrome is based on the '2018 Polycystic Ovary Syndrome Chinese Diagnosis and Treatment Guidelines' by the Endocrinology Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association and the Guide Expert Group '2018 Polycystic Ovary Syndrome Expert consensus on diagnosis and treatment of endocrinology' for lifestyle and drug treatment.
62132162|NCT04805853||polycystic ovary syndrome with type 2 diabetes|Treatment is as above.
62483230|NCT00500201|EXPERIMENTAL|Subjects in treatment sequence BA|In treatment sequence BA first subjects will be randomized to receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets. Then subjects will receive treatment A (two tablets of 60 mg of SB-773812) and one placebo tablet. There will be a wash-out period of 20 days between.
61930345|NCT04952753|EXPERIMENTAL|Expansion: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the expansion part, participants in the investigational arm 2 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FLOFOX6 or FOLFIRI) with NIS793 and tislelizumab at the RP2D for NIS793 defined in the safety run-in
61930346|NCT06172465|ACTIVE_COMPARATOR|group external oblique intercostal plane block|While patients are still under general anesthesia, external oblique intercostal block (EOIB) will be performed bilaterally according to appropriate asepsis/antisepsis rules at end of the surgery.
61930347|NCT06172465|ACTIVE_COMPARATOR|group oblique subcostal transversus abdominis plane block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
61930348|NCT03724175|EXPERIMENTAL|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks to treat pouchitis in ulcerative colitis patients with antibiotic refractory or antibiotic dependent pouchitis
61930349|NCT04924179|EXPERIMENTAL|Tislelizumab plus Fruquintinib and SBRT|
61930350|NCT02653027|EXPERIMENTAL|Lumacaftor Ivacaftor|Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
61930351|NCT06707831||Study sample|Children with hemiplegic cerebral palsy aged 4 to 18 years
61930352|NCT03929484|EXPERIMENTAL|Group A|Each patient will receive oxygen for 1 hour using a novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the standard nasal cannula alone (Period 2).
61930353|NCT03929484|EXPERIMENTAL|Group B|Each patient will receive oxygen for 1 hour using a standard nasal cannula alone (Period 1), followed by a 1-hour period of continued use of the novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 2).
61930354|NCT06202456|EXPERIMENTAL|Huazhi Rougan granule|
61930355|NCT02917473|OTHER|Control|"Education and counseling as commonly delivered to the patients in clinical practice.~Brief oral counseling to the patient focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for their first-degree relatives, who should be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examination"
62132163|NCT00017472|EXPERIMENTAL|Arm I|Patients receive apolizumab IV over at least 2 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a complete or partial response who relapse after 2 months may receive an additional course of therapy provided they still express the 1D10 antigen.
62132164|NCT03809416|NO_INTERVENTION|Control|32 biopsy specimens from acne scars will be excised without any treatment.
62132165|NCT03809416|SHAM_COMPARATOR|Lasers plus Normal Saline Solution|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of normal saline solution.
62132166|NCT03809416|ACTIVE_COMPARATOR|Lasers plus Platelets Rich Plasma (PRP)|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of platelets Rich Plasma (PRP).
62132167|NCT05621499|EXPERIMENTAL|experimental group1|HAIC
62132168|NCT05621499|EXPERIMENTAL|experimental group 2|Lenvatinib+Sintilimab
62132169|NCT04484675|ACTIVE_COMPARATOR|Group IH(inhaled milrinone)|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
62483231|NCT06183125|EXPERIMENTAL|TCM-based anti-sedentariness intervention group|TCM-based anti-sedentariness intervention
62483232|NCT06183125|OTHER|Wait-list control group|After the completion of all evaluations, the intervention content will be administered to the experimental group in the same manner.
62483233|NCT04965935|EXPERIMENTAL|Dapagliflozin Tablets|Patients will be randomized to therapy with dapagliflozin 10mg PO daily for 12 weeks.
62324064|NCT03165357|EXPERIMENTAL|Sodium bicarbonate|"Group taking oral NaHCO3 supplementation in a progressive-dose regimen.~Interventions:~The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
62324065|NCT03165357|PLACEBO_COMPARATOR|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin).~Interventions:~The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
62483234|NCT04965935|PLACEBO_COMPARATOR|Placebo Matching Dapagliflozin Tablets|Patients will be randomized to therapy with placebo matching dapagliflozin tablets PO daily for 12 weeks.
61930356|NCT02917473|EXPERIMENTAL|Intervention group|"Education and counseling as commonly delivered to the patients in clinical practice and written advice for their first-degree relatives.~In addition to oral counseling to the patient, written advice will be provided to patients for their relatives focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for first-degree relatives, who should also be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examinations."
61930357|NCT06704464||Test Group|Patients with Multiple Sclerosis
61930358|NCT06704464||Control Group|healthy controls
61930359|NCT04250714||Treatment patients|Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use
61930360|NCT06707623|EXPERIMENTAL|Pulmonary Rehabilitation (+Physiotherapy) Group|Patients with Dysfunctional Breathing participating in an individualized Rehab Programme that will combine exercise and physiotherapy.
61930361|NCT06707623|EXPERIMENTAL|Control Group (physiotherapy)|Patients with dysfunctional breathing in control group will receive respiratory physiotherapy (breathing retraining)
61930362|NCT06707129||Case group|After successful patient screening and enrollment, visits will be conducted every 6 months to collect the following information: Physical examination, accompanying diseases, hematology: blood routine, coagulation function, serology, imaging, body fat measurement, liver puncture information (if applicable). Lifestyle questionnaire: Dietary characteristics, sleep/wake time, daily sitting time, exercise duration, exercise mode. Health education and lifestyle intervention guidance should be provided to patients based on exercise mode. When adjusting lifestyle for at least 1 year and no more than 3 years, a second liver biopsy should be performed to evaluate liver histological changes.
61930363|NCT04115644|PLACEBO_COMPARATOR|Group 1 (control)|will receive an injection of 5 cc 0.25% Marcaine without epinephrine
61930364|NCT04115644|EXPERIMENTAL|Group 2 (ketorolac)|will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
61930365|NCT04115644|OTHER|Group 3 (kenalog)|Pt will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone. Group 3 is standard of care
61930366|NCT03547986|EXPERIMENTAL|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
61930367|NCT03547986|EXPERIMENTAL|IVUS with Intraarterial pressure measurement (IAP)|Standard angiography and Intra-Vascular Ultrasound (IVUS) with Intraarterial pressure measurement (IAP) are performed on the same patients (paired data)
61930368|NCT05964335|EXPERIMENTAL|NAL ER 27 mg|BID
61930369|NCT05964335|EXPERIMENTAL|NAL ER 54 mg|BID
61930370|NCT05964335|EXPERIMENTAL|NAL ER 108 mg|BID
61930371|NCT05964335|PLACEBO_COMPARATOR|Placebo|Placebo, tablets BID
61930372|NCT01753804||Study participants|All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.
61930373|NCT05112991|EXPERIMENTAL|Envafolimab + Lenvatinib|Subjects receive lenvatinib daily and envafolimab once on Day 1 and 15 of the first cycle and at the beginning of each subsequent 4 week treatment cycle D1.
61930374|NCT05112991|EXPERIMENTAL|Envafolimab|Subjects receive envafolimab once on Day 1 and 15 of the first cycle and at the beginning of each subsequent 4 week treatment cycle D1.
61930375|NCT03490968|OTHER|Healthy Subjects|
61930376|NCT03490968|EXPERIMENTAL|Peripheral Artery Disease (PAD) with Supervised Exercise|Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
61930377|NCT03490968|ACTIVE_COMPARATOR|PAD Subjects Who Undergo Revascularization of the Leg|This group of subjects are receiving leg revascularization as part of standard of care.
61930378|NCT00443612|EXPERIMENTAL|1|"* 12 weeks on treatment 1~* 2 week washout period~* 12 weeks on treatment 2"
61930379|NCT00443612|EXPERIMENTAL|2|"* 12 weeks on treatment 2~* 2 week washout period~* 12 weeks on treatment 1"
61930380|NCT02445443||LEGION Hinge Knee System|This group will be receiving the LEGION Hinge device.
61930381|NCT01218282|EXPERIMENTAL|Home Exercise Training Group A1|Patients assigned to this arm maintain the prescribed walking speed during the training with a metronome
61930382|NCT01218282|EXPERIMENTAL|Home Exercise Training Group A2|Patients assigned to this arm cover a fixed distance in a given period of time.
61930383|NCT01218282|NO_INTERVENTION|Control|
61930384|NCT06002685|EXPERIMENTAL|Attachment and Biobehavioral Catch-up (ABC) program|The ABC program consists of 10 1 -hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic.
61930385|NCT06002685|ACTIVE_COMPARATOR|Home-Based Book-of-the-Week (HBOW) program|The HBOW program consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. A trained RA will utilize a standard set of questions to ask about the mother's and child's well-being.
62483235|NCT06353139|ACTIVE_COMPARATOR|The traditional olfactory training|
62483236|NCT06353139|EXPERIMENTAL|The modified olfactory training|
62483237|NCT01299207||CAD treated with Xience stents|Patients with CAD who undergo successful stenting with the Xience drug-eluting stent will represent the patient population.
62691647|NCT06645392||Group B ( Ternamian bladeless trocar group)|Ternamian bladeless trocar of diameter 10 mm is used for abdominal entry; this trocar is hollow in which a laparoscope is loaded for the distal crystal tip to transmit real-time monitor images while transecting abdominal wall tissue layers. The assistant holds the laparoscope during entry allowing the wrist to move freely while the surgeon applies significant axial thrust through the dominant upper body muscles while twisting the handle to advance the trocar tip and dissect successive tissue layers on its way towards the abdomen. A considerable axial force is applied by the surgeon for the retention of the push-through trocar design with no mechanism to offset overshoot.
62691648|NCT04543617|EXPERIMENTAL|Arm A: Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab.
61930386|NCT01354067|ACTIVE_COMPARATOR|Control group|The control group will receive standardized patient education four times, once every two weeks, during the eight week intervention period.
61930387|NCT01354067|EXPERIMENTAL|High-repetitive single limb training|The experimental group will receive a high-repetitive single limb exercise regime, three times a week for two months. In addition, the exercise group will receive patient education at four occasions during the intervention period.
61930388|NCT05621915||conventional oxygen therapy|Patients treated with conventional oxygen in Infectious Diseases Ward.
61930389|NCT05621915||mechanical ventilation|Patients who are mechanically ventilated and treated in ICU.
61930390|NCT05621915||mechanical ventilation and ECMO|Patients who are mechanically ventilated and on ECMO treated in ICU.
61930391|NCT05116085|EXPERIMENTAL|Tislelizumab|Tislelizumab administered intravenously before surgery during the neo-adjuvant phase
61930392|NCT04237012|EXPERIMENTAL|Dextenza|Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed
61930393|NCT04237012|ACTIVE_COMPARATOR|Over the counter Artificial tears|Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert
61930394|NCT06424483|EXPERIMENTAL|Treatment: Group psychotherapy|Treatment group receiving psychotherapy
61930395|NCT06424483|NO_INTERVENTION|Waitlist|Waitlist control
61930396|NCT04592250||Observational (survey)|Participants will complete a survey packet that is estimated to take about 30 minutes. The survey packet will be collected at baseline and at 6 months.
61930397|NCT01554228||Bariatric Surgery|
61930398|NCT03599635|EXPERIMENTAL|liposomal bupivacaine|These patients will receive liposomal bupivacaine for a pectoralis block infiltration by the anesthesiologist.
61930399|NCT03599635|ACTIVE_COMPARATOR|bupivacaine|These patients will receive incisional bupivacaine infiltration by the surgeon.
62132170|NCT04484675|ACTIVE_COMPARATOR|Group Iv(Intravenous milrinone)|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
62691649|NCT04543617|EXPERIMENTAL|Arm B: Tiragolumab Placebo + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab matching placebo.
62691650|NCT04543617|PLACEBO_COMPARATOR|Arm C: Tiragolumab Placebo + Atezolizumab Placebo|Participants will receive matching placebos to tiragolumab and atezolizumab.
61930400|NCT02610569|ACTIVE_COMPARATOR|standart endoscopy|Intervention: 2 standard endoscopy during anti-TNFalpha or vedolizumab treatment
61930401|NCT02610569|EXPERIMENTAL|PillCamCOLON (C2)|Intervention : 2 PillCamCOLON (C2) during anti-TNFalpha or vedolizumab treatment
61930402|NCT06608368|EXPERIMENTAL|Test Dentifrice|Participants will dose the toothbrush provided with a strip of test dentifrice containing 5% weight by weight (w/w) NovaMin (Calcium Sodium Phosphosilicate) and 1040 parts per million (ppm) fluoride as sodium fluoride on each brushing occasion and will brush for one timed minute twice daily (morning and evening) for up to 5 weeks. Participants will use the dentifrice for 2 weeks pre tooth bleaching, 1 week during tooth bleaching and 2 weeks post tooth bleaching application. At Week 3, participants will perform the first application of tooth bleaching as per the instructions provided and continue the application once daily for up to 7 days.
62132171|NCT06461468||HCM-Labeled Cases|Cases with maximum left ventricular wall thickness exceeding 15 mm (including the right ventricular component of the septum) without any other explanation for ventricular hypertrophy (e.g., severe hypertension, cardiac amyloidosis, severe aortic stenosis (AS)). The measurement could be made in an echocardiogram or on magnetic resonance imaging (MRI).
62132172|NCT06461468||Control Cases (Non-HCM)|No diagnosis of HCM.
62132173|NCT02678936|EXPERIMENTAL|PRP|The operation will be performed with application of platelet rich plasma
62132174|NCT02678936|NO_INTERVENTION|non-PRP|The operation will be performed without addition of platelet-rich plasma
62132175|NCT03189589|EXPERIMENTAL|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
62132176|NCT03189589|EXPERIMENTAL|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
62132177|NCT05736185|EXPERIMENTAL|EIT-PEEP strategy|PEEP selected by EIT which remained at 15 min
62132178|NCT05736185|EXPERIMENTAL|Low FiO2-PEEP strategy|PEEP selected by low FiO2-PEEP table which remained at 15 min
61930403|NCT06608368|ACTIVE_COMPARATOR|Positive Control Dentifrice|Participants will dose the toothbrush provided with a strip of positive control dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride on each brushing occasion and will brush for one timed minute twice daily (morning and evening) for up to 5 weeks. Participants will use the dentifrice for 2 weeks pre tooth bleaching, 1 week during tooth bleaching and 2 weeks post tooth bleaching application. At Week 3, participants will perform the first application of tooth bleaching as per the instructions provided and continue the application once daily for up to 7 days.
62132179|NCT05736185|EXPERIMENTAL|High FiO2-PEEP strategy|PEEP selected by high FiO2-PEEP table which remained at 15 min
62483238|NCT01970566|EXPERIMENTAL|IE-MCR|Intense Exercise/Moderate Calorie Restriction
62483239|NCT01970566|ACTIVE_COMPARATOR|TP-CBT|Topiramate-Phentermine plus cognitive behavioral therapy
62483240|NCT01970566|ACTIVE_COMPARATOR|CBT|cognitive behavioral therapy
62483241|NCT02417363||Group A|the control group,healthy individuals
62483242|NCT02417363||Group B|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium
62483243|NCT02417363||Group C|patients with periodontitis, but healthy renal conditions
62483244|NCT02417363||Group D|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis
62691651|NCT04355832|PLACEBO_COMPARATOR|Placebo 1|The participants will be randomized to placebo infusion.
62691652|NCT04355832|PLACEBO_COMPARATOR|Placebo 2|The participants will be randomized to placebo infusion.
61930404|NCT06608368|ACTIVE_COMPARATOR|Reference Dentifrice|Participants will dose the toothbrush provided with a strip of reference dentifrice containing 1100 ppm fluoride as sodium fluoride on each brushing occasion and will brush for one timed minute twice daily (morning and evening) for up to 5 weeks. Participants will use the dentifrice for 2 weeks pre tooth bleaching, 1 week during tooth bleaching and 2 weeks post tooth bleaching application. At Week 3, participants will perform the first application of tooth bleaching as per the instructions provided and continue the application once daily for up to 7 days.
61930405|NCT00557401|EXPERIMENTAL|XP19986 SR3, 20 mg QD|XP19986, 20 mg QD for approximately 32 days
61930406|NCT00557401|EXPERIMENTAL|XP19986 SR3, 40 mg QD|XP19986, 40 mg QD for approximately 32 days
62132180|NCT01091740|EXPERIMENTAL|ZES resolute (Endeavor Resolute)|
62132181|NCT01091740|ACTIVE_COMPARATOR|EES (Xience)|
62132182|NCT05007587|EXPERIMENTAL|Lenvatinib，Then HAIC of mFOLFOX regimen|Cohort1：Participants were treated with 8mg lenvatinib (weight\<60kg) or 12mg lenvatinib (weight\>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.
62132183|NCT05007587|EXPERIMENTAL|Lenvatinib，Then HAIC of ROX regimen|Cohort2：Participants were treated with 8mg lenvatinib (weight\<60kg) or 12mg lenvatinib (weight\>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
62132184|NCT02330926|EXPERIMENTAL|multimodal intervention|standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)
62132185|NCT02330926|ACTIVE_COMPARATOR|standard care|standard palliative care
62132186|NCT04029909|EXPERIMENTAL|Gimatecan 0.6mg/m2/d|Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
62132187|NCT04029909|EXPERIMENTAL|Gimatecan 0.8mg/m2/d|Three or six patients will be treated with the dose of 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
62132188|NCT04029909|EXPERIMENTAL|Gimatecan 0.4mg/m2/d|Three or six patients will be treated with the dose of 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
62132189|NCT01322477||Hepatocellular Carcinoma|Patients with advanced HCC
62132190|NCT04884295|EXPERIMENTAL|XVR011|Single Ascending Dose with 3 dose cohorts: low dose - medium dose - high dose (Phase 1)
62132191|NCT01571570|EXPERIMENTAL|Treatment A|Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
62483245|NCT03061591|ACTIVE_COMPARATOR|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.~Pukka's Wholistic Turmeric"
62483246|NCT03061591|PLACEBO_COMPARATOR|Placebo|Identical placebo capsules
62483247|NCT04806035|EXPERIMENTAL|Cohort A: TG-1801|"TG-1801 Single Agent~As per protocol v3.0, Cohort A is no longer enrolling."
62483248|NCT04806035|EXPERIMENTAL|Cohort B: TG-1801|TG-1801 Single Agent, escalating doses
62483249|NCT04806035|EXPERIMENTAL|Cohort C: TG-1801 + Ublituximab|"TG-1801 in combination with ublituximab~As per protocol v3.0, ublituximab will be discontinued and the Cohort C is no longer enrolling."
62483250|NCT05125900|ACTIVE_COMPARATOR|Resin modified glass ionomer|Group received proximal box elevation using resin modified glass ionomer
62691653|NCT04355832|EXPERIMENTAL|GLP-1|The participants will be randomized to Glucagon-like peptide-1 infusion.
62691654|NCT06113367||Patients with advanced/metastatic UTUC treated with second-line anti-PD-(L)1 immunotherapy|
61930407|NCT00557401|EXPERIMENTAL|XP19986 SR3, 60 mg QD|XP19986, 60 mg QD for approximately 32 days
62132192|NCT01571570|EXPERIMENTAL|Treatment B|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
62132193|NCT01571570|EXPERIMENTAL|Treatment C|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
62132194|NCT01571570|EXPERIMENTAL|Treatment D|Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
62132195|NCT01571570|EXPERIMENTAL|Treatment E|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
62132196|NCT01571570|EXPERIMENTAL|Treatment F|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
62132197|NCT01571570|EXPERIMENTAL|Treatment G|Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
62132198|NCT01571570|EXPERIMENTAL|Treatment H|Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
62132199|NCT01571570|EXPERIMENTAL|Treatment I|Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
62483251|NCT05125900|PLACEBO_COMPARATOR|Glass hybrid|Group received proximal box elevation using glass hybrid
62483252|NCT05125900|ACTIVE_COMPARATOR|Bulk fill flowable resin composite|Group received proximal box elevation using bulk fill flowable resin composite
62483253|NCT05125900|PLACEBO_COMPARATOR|Ion-releasing material|Group received proximal box elevation using ion-releasing material
62691655|NCT05868655|EXPERIMENTAL|Exercise withVideo-Based|
62691656|NCT05868655|ACTIVE_COMPARATOR|Standart Exercise-Home-Based|
62691657|NCT05201495|EXPERIMENTAL|Treatment|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
62691658|NCT01399645|EXPERIMENTAL|Liraglutide-Metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day until the end of the study.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
62691659|NCT01399645|EXPERIMENTAL|Insulin-Metformin|"Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU. The patients will be taught to increase their insulin dose by 1 unit each day until achieving an FPG ≤ 7.0 mmol/L.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
62691660|NCT01127958|ACTIVE_COMPARATOR|SeQuent Please|PCI with drug-eluting balloon
62691661|NCT01127958|ACTIVE_COMPARATOR|Xience Prime|PCI with a drug-eluting stent
62691662|NCT03735121|EXPERIMENTAL|Atezolizumab (Part 2)|Atezolizumab
62691663|NCT03735121|EXPERIMENTAL|Cohort 1: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+recombinant human hyaluronidase (rHuPH20), followed by Atezolizumab
62691664|NCT03735121|EXPERIMENTAL|Cohort 2: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
61930408|NCT00557401|EXPERIMENTAL|XP19986 SR3, 30 mg BID|XP19986, 30 mg BID for approximately 32 days
61930409|NCT00557401|PLACEBO_COMPARATOR|Placebo|Placebo for approximately 32 days
61930410|NCT06025747|EXPERIMENTAL|Treatment (abemaciclib, radiation therapy, surgery)|Prior to surgery, patients receive abemaciclib orally PO BID on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy over 28 fractions starting on cycle 1 day 15 in the absence of disease progression or unacceptable toxicity. After completion of radiation therapy, patients may undergo surgery. Patients also undergo CT or MRI during screening and on study.
61930411|NCT04926454|EXPERIMENTAL|TAP block|patients will receive general anesthesia followed by Tap block at the end of the operation.
61930412|NCT04926454|EXPERIMENTAL|Caudal block|patients will receive general anesthesia followed by caudal block at the beginning of the operation.
61930413|NCT06709248|EXPERIMENTAL|Intervention|In this feasability study following established clinical practice, all participants are included in the intervention Life Coping Program.
61930414|NCT03843112|ACTIVE_COMPARATOR|Vivag Plus|Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.
61930415|NCT03843112|PLACEBO_COMPARATOR|Placebo|Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.
61930416|NCT02699216|EXPERIMENTAL|Phase 1 Active Treatment|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
61930417|NCT02699216|PLACEBO_COMPARATOR|Phase 1 Sham Treatment|Subjects will undergo 8 sham treatments, approximately 11 minutes, with a non-functional device to the enrolled eyes daily for three consecutive days during week 1, with no treatments on day 4 and 5. Followed by 8 active treatments, for approximately 11 minutes, for three consecutive days, with an active device during week 2, with no treatments on day 4 and 5.
61930418|NCT02699216|EXPERIMENTAL|Phase 2 Open Label|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
61930419|NCT03358537|ACTIVE_COMPARATOR|Clear Liquid Diet|110 subjects received clear liquid diet 24 hours before colonoscopy
61930420|NCT03358537|ACTIVE_COMPARATOR|Low-residue Diet|105 subjects received a prespecified low-residue diet 24 hours before colonoscopy
62691665|NCT03735121|EXPERIMENTAL|Cohort 3: Atezolizumab+rHuPH20(Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
61930421|NCT04766827|EXPERIMENTAL|albumin-bound paclitaxel combined with cisplatin (AP regimen)|Paclitaxel (albumin combined type) 260 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; Cisplatin: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles;
61930422|NCT04766827|ACTIVE_COMPARATOR|docetaxel combined with cisplatin (TP regimen)|docetaxel: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; cisplatin: 75 mg/m2, d1 every three weeks for a cycle, a total of dosing 2 cycles;
62132200|NCT04953273|EXPERIMENTAL|Vigitrauma|"Contact by phone at 3 weeks after the consultation in a clinical forensic medicine unit, and a second phone call if necessary.~If the subject is not contacted after the second phone call, he will receive a postcard."
62691666|NCT03735121|EXPERIMENTAL|Atezolizumab + rHuPH20 (Part 2)|Atezolizumab + rHuPH20
62691667|NCT06162507|EXPERIMENTAL|CM310 group A|CM310 injection, subcutaneous injection, once every 3 weeks.
62691668|NCT06162507|EXPERIMENTAL|CM310 group B|CM310 injection, subcutaneous injection, once every 2 weeks.
62691669|NCT01013337|EXPERIMENTAL|Arm I (Acupuncture)|Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments).
62691670|NCT01013337|SHAM_COMPARATOR|Arm II (Placebo)|Patients undergo 10, 20-minute sessions of sham acupuncture treatments over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at non-acupuncture points.
62691671|NCT01013337|NO_INTERVENTION|Arm III (Control)|Wait-list control patients are contacted by phone at the same frequency as real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
62691672|NCT06369662||AML Patients|Adult patients (from 18 - 60 years) diagnosed as AML
62691673|NCT06302985|EXPERIMENTAL|ICG for CLMs|"Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed. Smaller blood vessels could be cut by Ligasure or ultrasonic knife directly, and thicker blood vessels and bronchi should be cut by Hemolock until the lesion resection was completed."
62691674|NCT02731482|EXPERIMENTAL|Training Group|Patients with bronchiectasis in home-based pulmonary rehabilitation
62132201|NCT04953273|NO_INTERVENTION|Control group|Usual follow-up.
62132202|NCT01663181||urogynecologic patients undergoing outpatient cystoscopy|
62132203|NCT01663181||urogynecologic patients undergoing outpatient-urodynamics|
62132204|NCT03548857||COPD patients|COPD patients on the waiting list for a lung transplantation
62691675|NCT02731482|ACTIVE_COMPARATOR|Control Group|Patients with bronchiectasis in usual care and recommendations for performing exercises
61930423|NCT02156531|PLACEBO_COMPARATOR|Attention Control Condition|3.c.14.5. Arm 1: Attention Control Condition. The minimally effective attention-control group procedure is identical to the active CBM procedure except that during the presentation of the trials where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. Thus, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active versions of CBM in Arms 2 and 3.
61930424|NCT02156531|EXPERIMENTAL|Arm 2: Self-administered CBM only|3.c.14.6. Arm 2: Self-Administered CBM Only. Youth assigned to this arm will receive the self-administered active CBM intervention. As described above in detail, in the 80% of CBM trials where a neutral and disgust face are both presented, the probe always replaces the neutral face. Thus, participants are trained to disengage their attention from threat. These youth do not receive Adherence Promotion telephone calls.
61930425|NCT02156531|EXPERIMENTAL|Arm 3: Self-administered CBM + Adherence Promotion|3.c.14.7. Arm 3: Self-Administered CBM + Adherence Promotion. Youth assigned to this arm will receive both the self-administered active CBM intervention and the telephone coach calls to deliver the Adherence Promotion (AP) procedures. AP procedures are intended to compensate for the important nonspecific 'scaffolding' provided by research staff when CBM has been traditionally delivered in laboratories. This includes technical assistance with use of the program, support/encouragement, motivational enhancement, and brainstorming solutions to barriers to regular sessions. The addition of AP to the 3rd arm of this trial attempts to recreate much of this nonspecific, yet likely important, support of in-person interventions, which we hypothesize will lead to greater participant adherence to the program and therefore better clinical outcomes.
61930426|NCT06449222|EXPERIMENTAL|Cohort 1 Arm 1 - BNT327 DL1 + Nab-paclitaxel|
61930427|NCT06449222|EXPERIMENTAL|Cohort 1 Arm 2 - BNT327 DL2 + Nab-paclitaxel|
61930428|NCT06449222|EXPERIMENTAL|Cohort 2 Arm 1 - BNT327 Optimized dose + Paclitaxel|
61930429|NCT06449222|EXPERIMENTAL|Cohort 2 Arm 2 - BNT327 Equivalent Q3W dose + Gemcitabine + Carboplatin|
61930430|NCT06449222|EXPERIMENTAL|Cohort 2 Arm 3 - BNT327 Equivalent Q3W dose + Eribulin|
61930431|NCT05957055|ACTIVE_COMPARATOR|Methylphenidate first, lisdexamfetamine second|Initial treatment after PT training - methylphenidate (prolonged-release tablet) once-daily with dose optimization for 5-7 weeks and 6 months total therapy then change to lisdexamfetamine once-daily with dose optimization for 5-7 weeks and 6 months total therapy.
61930432|NCT05957055|ACTIVE_COMPARATOR|Lisdexamfetamine first, methylphenidate second|Initial treatment after PT training - lisdexamfetamine once-daily with dose optimization for 5-7 weeks and 6 months total therapy then change to methylphenidate (prolonged-release tablet) once-daily with dose optimization for 5-7 weeks and 6 months total therapy.
61930433|NCT01762046|OTHER|Glipizide and Metformin|On day 1, subjects will receive a single oral dose of glipizide 5 mg, and will have blood drawn at various time points for up to 240 minutes. During study days 2-7, the participants will fill out a dietary intake food record, including 3 weekdays and one weekend day. During days 6-8, the subject will receive a short-course metformin treatment of four 500-mg doses. On the morning of study day 8, 60 minutes after taking the fourth metformin dose, the subject will do a 75g Oral Glucose Tolerance Test. Blood draws will again be taken at time points for 120 minutes.
61930434|NCT03284437|NO_INTERVENTION|Usual Care|Usual medical care provided to patients in the ICU.
61930435|NCT03284437|EXPERIMENTAL|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
62324066|NCT05085158||Group 1|HIV-infected children with non-malarial febrile illnesses (NMFIs) less than 5 years old
62324067|NCT05085158||Group 2|HIV-infected children and adolescents with non-malarial febrile illnesses (NMFIs) but less than 15 years old
61930436|NCT02147002|ACTIVE_COMPARATOR|omega 3 acids 1|Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)
61930437|NCT02147002|ACTIVE_COMPARATOR|omega 3 acids 2|Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)
61930438|NCT02147002|ACTIVE_COMPARATOR|omega 3 acids 3|Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)
61930439|NCT02147002|ACTIVE_COMPARATOR|omega 3 acids 4|Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum
61930440|NCT02075970|EXPERIMENTAL|Epoetin Alpha study 1|"Epoetin Alpha Tthe number of separate doses (per kg) to be given over 4 weeks by day of age will not exceed 10. These will be administered as follows: day of life (DOL) 2 (1200 U), DOL 4 (600 U), DOL 5 (600 U), DOL 6 (600U), DOL 7 (600 U), DOL 9 (600 U), DOL 14 (600 U), DOL 15 (600 U), DOL 16 (1200 U), and DOL 28 (600 U). The greatest dose in any 1 wk period is 3600 U.~Infant study 1 Drug Intervention: all infants will be treated with Epoetin Alpha during the first four weeks of life to provide data for determining: 1) the PK/PD model determined optimized Epoetin Alpha dosing schedule; and 2) clinical and laboratory covariates predictive of which infants are good and poor Epoetin Alpha responder."
61930441|NCT02075970|PLACEBO_COMPARATOR|Epoetin Alpha study 2|"Epoetin Alpha dosing schedule will be determined based on the results of Infant Study 1.~Infant Study 2 is a randomized, masked study to test the hypothesis that optimized Epoetin Alpha treatment of VLBW infants predicted to be good responders will result in the elimination of RBCTx relative to poor responders.~Infant Study 2 in Years 4 and 5 will make use of the knowledge acquired in Infant Study 1 to test the central hypothesis that RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders."
62324068|NCT05831059|EXPERIMENTAL|A group|First receive pulse radio frequency treatment and then receive sham operation treatment
62324069|NCT05831059|ACTIVE_COMPARATOR|B group|First receive sham operation treatment and then receive pulse radio frequency treatment
62324070|NCT03970226|EXPERIMENTAL|Tocilizumab Administration: Phase 0|In Phase 0, patients will receive one dose of tocilizumab prior to surgery.
62324071|NCT03970226|EXPERIMENTAL|Tocilizumab Administration: Feasibility Phase|During the Feasibility Phase, patients will receive tocilizumab every 2 weeks for up to 13 cycles (approximately 1 year). Patients will be followed for up to 5 years.
62324072|NCT04793672||Patients with malignant tumors and healthy people|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
62324073|NCT05649514|EXPERIMENTAL|Single arm|Prodromal Alzheimer's patients
62691676|NCT06369155|EXPERIMENTAL|Azenosertib|"25 participants will be enrolled and will complete study procedures as follows:~* Baseline visit with assessments and CT or MRI scan.~* CT or MRIs scans every 2 cycles.~* Cycle 1 through End of Treatment:~  --Days 1 through 5, 8 through 12, and 15 through 19: Predetermined dose of Azenosertib 1x daily.~* End of Treatment visit."
62691677|NCT02500836|EXPERIMENTAL|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
61930442|NCT02075970|EXPERIMENTAL|Biotinylated red blood cells|Individual fetal RBC lifespans will be determined by administering biotinylated red blood cells, both autologous and allogeneic, simultaneously. Left over red blood cells are examined to determine red cell survival.
61930443|NCT04545359|EXPERIMENTAL|Neurofeedback Group|Participants from this group perform actual neurofeedback training, i.e they are instructed to control -- decrease -- in real-time a sound that is inversely related to the amplitude of their own alpha activity, obtained from Melomind EEG signals.
61930444|NCT04545359|SHAM_COMPARATOR|Control Group|Participants from this group perform sham neurofeedback based on the feedback sounds generated by the participants from the Neurofeedback Group at the same step of the training program.
61930445|NCT05881278|EXPERIMENTAL|Subjects requiring a Heart Transplant|Device: Preservation of hearts for transplant.
61930446|NCT03611010|EXPERIMENTAL|Cohort 1|Cohort 1 = Baseline daily dose of 10 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
61930447|NCT03611010|EXPERIMENTAL|Cohort 2|Cohort 2 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
61930448|NCT03611010|EXPERIMENTAL|Cohort 3|Cohort 3 = Baseline daily dose of 40 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
61930449|NCT03611010|EXPERIMENTAL|Cohort 4|Cohort 4 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then SC study drug for up to 15 days
61930450|NCT03686488|EXPERIMENTAL|TAS 102 and Ramucirumab|TAS 102 (Lonsurf) and Ramucirumab 10 MG/ML Intravenous Solution (CYRAMZA) administered concurrently.
62132205|NCT04524494||RAS- active medication|Patients taking RAS- active medication (ACE- Inhibitor, Angiotensin II AT1 Antagonist (Sartan)) on a daily Basis for at least 6 months for medical reasons
62324074|NCT06693284|EXPERIMENTAL|Experimental group|newly diagnosed, PRC2 deficient, primary malignant peripheral nerve sheath tumors (MPNSTs)
62738348|NCT04379687|EXPERIMENTAL|Virtual reality|"1. st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control. 15 minutes~2. nd part: Experimental training program for static and dynamic balance in sitting and standing by immersive Virtual Reality. 15 minutes"
61930451|NCT06643611|EXPERIMENTAL|Continuous Glucose Monitor|Patients in the intervention arm will receive a continuous glucose monitor in addition to usual care. These patients will be scheduled at least once monthly for clinical pharmacy visits.
61930452|NCT06643611|ACTIVE_COMPARATOR|Usual Care|Patients in the usual care arm will have routine physician office visits every 3 months if HbA1c outside goal or every 6 months if HbA1c within goal. Medication regimens will be managed by physicians, nurse practitioners, and physician assistants.
61930453|NCT06319352|EXPERIMENTAL|Active UroShield|Active UroShield Device
61930454|NCT06319352|SHAM_COMPARATOR|Sham UroShield|Inactive UroShield device
61930455|NCT02948283|EXPERIMENTAL|Treatment (metformin hydrochloride, ritonavir)|"SINGLE AGENT STAGE : Patients receive metformin hydrochloride PO BID on days 1-7 in the absence of disease progression or unacceptable toxicity.~COMBINATION REGIMEN STAGE: Patients receive metformin hydrochloride PO BID and ritonavir orally PO BID on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
61930456|NCT06575309||Pregnant women|
61930457|NCT04284267|NO_INTERVENTION|Healthy Control|This group consists of individuals with no psychiatric diagnosis.
62132206|NCT04524494||no RAS- active medication|Patients not taking RAS- active medication
62132207|NCT01741441||WAR and MR patients|Consecutive patients with MR and WAR selected for laparoscopic total fundoplication (LTF) were included in a prospective clinical study. Gastroesophageal function was assessed by clinical validated questionnaires, upper endoscopy, esophageal manometry and 24-h impedance pH monitoring before and 12 and 60 months after LTF. Gastric scintigraphy was preoperatively performed in all patients.
62324075|NCT01984346|EXPERIMENTAL|Convergent Procedure|Procedure/Surgery: Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
61930458|NCT04284267|EXPERIMENTAL|Bipolar Group|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive high-dose TMS (i.e., 1800 pulses) and sham TMS.
61930459|NCT04796337|EXPERIMENTAL|Sotatercept Treatment|Participants rolling over from a blinded parent study will begin sotatercept at a dose of 0.3 mg/kg SC for Visit 1. Dose will escalate to 0.7 mg/kg SC at Visit 2 through remainder of the study. Participants rolling over from an unblinded parent study will continue sotatercept at their current dose and if at dose \< 0.7 mg/kg SC can titrate up to 0.7 mg/kg SC for the remainder of the study.
61930460|NCT01906385|EXPERIMENTAL|186Rhenium Liposome Treatment|"Arm~Phase I:~Experimental: Dose Escalation for Cohorts 1-8 Each participant will receive a single administration of 186RNL. At each dose level, a minimum of three to a maximum of six participants will be enrolled.~If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.~The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below:~COHORT ACTIVITY Cohort 1 (1.0 mCi) Cohort 2 (2.0 mCi) Cohort 3 (4.0 mCi) Cohort 4 (8.0 mCi) Cohort 5 (13.4 mCi) Cohort 6 (22.3 mCi) Cohort 7 (31.2 mCi) Cohort 8 (41.5 mCi)~Phase 2:~Single arm, prospective study utilizing a non-DLT dose obtained from the dose escalation portion of IND 116117, NIH-NCI Grant (22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL and 8.8 mL total volume)."
62483254|NCT05911633|OTHER|Single arm|Transarterial Chemo Embolization (TACE) with BioPearl™ microspheres loaded with Doxorubicin
62483255|NCT05701384|EXPERIMENTAL|Lazertinib 160mg arm|
62483256|NCT01322633||Pantoprazole|Patients who received treatment with pantoprazole tablets for at least 240 days within a 12-month period from 2000 through 2003.
62691678|NCT02500836|EXPERIMENTAL|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
62691679|NCT02500836|PLACEBO_COMPARATOR|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
62483257|NCT01322633||Other proton pump inhibitors|Patients who received treatment with any other proton pump inhibitor for at least 240 days within a 12-month period from 1996 through 2003.
62483258|NCT05581407|ACTIVE_COMPARATOR|Licensed seasonal influenza vaccine|
62483259|NCT05581407|EXPERIMENTAL|1/5th of licensed seasonal influenza vaccine plus 1 mg LiteVax Adjuvant|
62483260|NCT05581407|EXPERIMENTAL|1/5th of licensed seasonal influenza vaccine plus 4 mg LiteVax Adjuvant|
62483261|NCT01804608|EXPERIMENTAL|Sensorimotor|Sensorimotor, this arm will receive sensorimotor and hip muscle strengthening.
61930461|NCT02819518|EXPERIMENTAL|Part 1: Pembrolizumab + Nab-paclitaxel|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle.
61930462|NCT02819518|EXPERIMENTAL|Part 1: Pembrolizumab + Paclitaxel|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle.
61930463|NCT02819518|EXPERIMENTAL|Part 1: Pembrolizumab + Gemcitabine/Carboplatin|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS gemcitabine/carboplatin 1000 mg/m\^2 (gemcitabine) and an Area Under the Curve (AUC) 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
61930464|NCT02819518|EXPERIMENTAL|Part 2: Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS one of three background chemotherapy regimens at investigator's discretion: 1) nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m\^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
61930465|NCT02819518|ACTIVE_COMPARATOR|Part 2: Placebo + Chemotherapy|Participants receive placebo (normal saline) IV on Day 1 of each 21-day cycle PLUS one of three background chemotherapy regimens at investigator's discretion: 1) nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m\^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
62132208|NCT02819414|PLACEBO_COMPARATOR|Control Group|Treatment with placebo at a volume of 2.25 cc/kg/dose x 4/day to be given with feeds, or in place of feed when baby is receiving \<2 cc/kg/feed.
62483262|NCT01804608|ACTIVE_COMPARATOR|Strength|Strength, this arm will receive only hip muscle strengthening.
62483263|NCT02987153|EXPERIMENTAL|KYPHO-IORT - 10 Gy and Kyphoplasty|Intra-operative radiation therapy followed by standard kyphoplasty
62483264|NCT03044210|OTHER|Cockayne patients|"Interventions performed:~* blood sample~* urinary collection~* metabolic evaluation~* clinical evaluation"
62483265|NCT03044210|OTHER|Control subjects|"Interventions performed:~* urinary collection~* metabolic evaluation~* clinical evaluation"
62483266|NCT03121716|EXPERIMENTAL|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
62483267|NCT06556017||Patients assessed for ILQ using the standard manual surveillance method|Patients undergoing colorectal surgery enrolled in the nationwide ILQ surveillance programme and assessed for ILQ using the standard manual surveillance method.
62483268|NCT06556017||ILQ patients assessed by Open IA's ChatGPT 4 chatbot|Patients undergoing colorectal surgery enrolled in the nationwide ILQ surveillance programme and assessed for ILQ using the Open IA's ChatGPT 4 chatbot.
62483269|NCT05676749|EXPERIMENTAL|C-TIL051|C-TIL051 plus IL-15 (NKTR-255) and Pembrolizumab
62483270|NCT01440803|ACTIVE_COMPARATOR|Teriparatide (Forteo)|Daily injection of Teriparatide for treatment of idiopathic osteoporosis
62483271|NCT01440803|PLACEBO_COMPARATOR|Placebo saline injection|Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.
62483272|NCT01099189||Observed cohort|All patients recruited. Observed for clinical outcomes
62483273|NCT01121601|EXPERIMENTAL|Group COSEAL|
62483274|NCT01121601|ACTIVE_COMPARATOR|Reference group|
62483275|NCT06258746|EXPERIMENTAL|160 mg/100 μCi [14C]HSK31679|\[14C\]HSK31679
62483276|NCT03579394|ACTIVE_COMPARATOR|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
62483277|NCT03579394|EXPERIMENTAL|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
61930466|NCT05408975|EXPERIMENTAL|Active to Sham Transcranial direct current stimulation|Subjects in this arm will first be randomly assigned to receive active stimulation. After completion of active stimulation, subjects will be assigned to sham stimulation.
61930467|NCT05408975|EXPERIMENTAL|Sham to Active transcranial direct current stimulation|Subjects in this arm will first be randomly assigned to receive sham stimulation. After completion of sham stimulation, subjects will be assigned to active stimulation.
62324076|NCT01984346|ACTIVE_COMPARATOR|Standalone Endocardial Catheter Ablation|Procedure/Surgery: Endocardial Catheter Ablation Treatment
62324077|NCT01830153|EXPERIMENTAL|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
62324078|NCT00804193|EXPERIMENTAL|Test Product|Ciclopirox Olamine Topical Suspension
62324079|NCT00804193|ACTIVE_COMPARATOR|Reference Product|Loprox® Topical Suspension 0.77%
62324080|NCT00804193|PLACEBO_COMPARATOR|Vehicle Product|placebo of test product
62324081|NCT04413240|EXPERIMENTAL|Telerehabilitation group|"Patients in this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain telerehabilitation (motor, speech and/or cognitive) with VRRS, K-Wand and Khymu connected to a workstation (Telecockpit)."
62324082|NCT04413240|ACTIVE_COMPARATOR|Conventional rehabilitation group|"The patients assigned to this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain rehabilitation (motor, speech and/or cognitive). It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated."
62324083|NCT04241042||Down syndrome volunteers|Males and females from 16 to 35 years
62324084|NCT04241042||Healthy volunteers|Males and females from 18 to 35 years
62324085|NCT04117685||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
62324086|NCT04117685||Arm II: Prior treatment at center|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
62738349|NCT04379687|ACTIVE_COMPARATOR|Control group|"1. st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control.15 minutes~2. nd part: Training program for static and dynamic balance in sitting and standing, according to Bayouk. 15 minutes"
61930468|NCT06051448|ACTIVE_COMPARATOR|Promoting Resilience in Stress Management (PRISM)|
61930469|NCT06051448|ACTIVE_COMPARATOR|Clinical-focused narrative (CFN)|
61930470|NCT03711227||Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level. These patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the Emergency Department and while an inpatient. Then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qSOFA score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.
61930471|NCT03812432|EXPERIMENTAL|near-infrared cholecystocholangiography|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence. Once the fundus is grasped and retracted, a needle-tipped cholangiogram catheter is introduced through the skin, adjacent to gallbladder. The catheter, guided by a grasping or dissecting instrument, is used to puncture the infundibulum of the gallbladder. Nine milliliters of bile is aspirated from the gallbladder into a syringe and and a indocianine green solution is injected into the gallbladder. The catheter is removed and the puncture site pinched closed with a grasper. Dissection is then performed under either ambient light or near-infrared mode. The surgical view of the gallbladder dissection is toggled back and forth between the two viewing.
62738350|NCT06540703|EXPERIMENTAL|Therapeutic Ketogenic Diet|Subjects will be placed on a therapeutic ketogenic diet (TKD) for a duration of 14 weeks.
62738351|NCT05724862|EXPERIMENTAL|Needle-less jet anaesthesia|Infiltration anaesthesia without needle
61930472|NCT04751396||Part A (Interview)|Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.
62324087|NCT04117685||Arm III: Prior treatment at outside center|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
62324088|NCT00661752||FBP studies|standard filtered backprojection image processing/reconstruction of full-time acquisition data
62324089|NCT00661752||half-time WBR|wide-beam reconstruction of simulated half-time acquisitions from standard full-time acquisitions
62324090|NCT00661752||Quarter-time stress|4 seconds per stop post-stress SPECT acquisitions reconstructed by the wide-beam reconstruction method
62324091|NCT00661752||Quarter-time rest|6 seconds per stop rest SPECT acquisitions reconstructed by the wide-beam reconstruction method
62324092|NCT04527224|EXPERIMENTAL|AstroStem-V|AstroStem-V which consists of three syringes and each syringe contains 1.0 x 10\^8 cells / 3mL of saline with 30% human serum
62324093|NCT03987412|EXPERIMENTAL|Behavioral intervention|Pregnant women randomized to the behavioral intervention group will recieve a face-to-face education about the risks of GDM at their local rearch centers. Then they will be provided with a mobile APP incorporating nutrition, exercise and phycological support. They will also have regular prenatal care in their local hospitals.
62324094|NCT03987412|NO_INTERVENTION|Control group|Pregnant women randomized to the control group only have regular prenatal care in their local hospitals.
62324095|NCT00222729|EXPERIMENTAL|Pemetrexed & Bevacizumab|
62324096|NCT02273154|EXPERIMENTAL|paroxetine and buspirone group|receive paroxetine (20-60mg/d) and buspirone(30mg/d)
62324097|NCT02273154|ACTIVE_COMPARATOR|paroxetine group|receive paroxetine (20-60mg/d)
62324098|NCT03993691|EXPERIMENTAL|All Participants|Participants that have undergone standard of care, conventional 2D radiographic imaging of wrist for presumed or known scaphoid, wrist or distal radius fractures will receive the Tomo-E scans within two weeks.
61930473|NCT04751396||Part B Group I (standard information)|Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
62132209|NCT02819414|ACTIVE_COMPARATOR|Treatment Group|Treatment with paracetamol drops at 15 mg/kg/dose x 4/day. Drops will be diluted 1:15 in order to reduce osmolality. This will yield a dose of 2.25 ml/kg/dose, to be given with feeds, or in place of feed when baby is receiving \<2 cc/kg/feed.
62132210|NCT05700487|NO_INTERVENTION|Control Group|Patients in this group continued their routine medicaltreatmentprogram without any treatment
62132211|NCT05700487|EXPERIMENTAL|Intervention Group|Pelvic floor exercises (PTE) training in the preoperative period, regular PTE was performed three times a day for 6 months in the postoperative period, and the continuity of the exercises was checked by telephone
62132212|NCT05938426|ACTIVE_COMPARATOR|ET-101|Treatment group
62132213|NCT05938426|SHAM_COMPARATOR|Sham Device|Sham group
62132214|NCT03176654|EXPERIMENTAL|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
62132215|NCT03176654|SHAM_COMPARATOR|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
62132216|NCT05945017|EXPERIMENTAL|Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|Daily dose of 6x109 UFC Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) from 7 days of life until reaching a postmenstrual age of 34 weeks or discharge
62132217|NCT05945017|NO_INTERVENTION|Control|Untreated control group
62132218|NCT00253890|ACTIVE_COMPARATOR|Trazodone|50-150mg (50mg capsules) at bedtime for 90 days
62132219|NCT00253890|PLACEBO_COMPARATOR|Placebo|1-3 capsules at bedtime for 90 days
62132220|NCT03932162|PLACEBO_COMPARATOR|Young Adult|One small area of skin will undergo treatment with a small amount of UVB.
62132221|NCT03932162|ACTIVE_COMPARATOR|Geriatric Adult|Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injections with saline. Then the injected areas will be treated with a small amount of UVB.
62132222|NCT01952769|EXPERIMENTAL|treatment of DIPG with MDV9300|treatment of diffuse pontine glioma with MDV9300 with the combination of radiation and low dose cyclophosphamide
62132223|NCT02034916|EXPERIMENTAL|talazoparib|"Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression \> 8 weeks following the last dose of platinum~Cohort 2) Subjects who have received \> 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease"
62738352|NCT05724862|ACTIVE_COMPARATOR|Conventional injection anaesthesia|Regular infiltration anaesthesia
62132224|NCT05783570|EXPERIMENTAL|EU307 CAR-T Cell|
62132225|NCT04219215|EXPERIMENTAL|Hyperbaric oxygenation|Patients with T2D receive an 2 hour treatment with 100 % oxygen in a hyperbaric chamber
62132226|NCT04219215|EXPERIMENTAL|Ambient Air|Patients with T2D receive an 2 hour treatment with 21% oxygen in a hyperbaric chamber
62132227|NCT06408818|EXPERIMENTAL|Intervention Program: Media Aware Parent -Tween|Participants will have access to an intervention between pre-test and post-test assessments. The intervention, Media Aware Parent -Tween, is an online program for parents of tweens ages 9-12 designed to help parents have effective conversations with their child about body image, sexual development, gender stereotypes, romantic relationships, and media.
62132228|NCT06408818|ACTIVE_COMPARATOR|Active Control Resource|Parents will have access to medically-accurate information about topics such as body image, sexual development, gender stereotypes, and romantic relationships.
62132229|NCT02005406||wei group and control group|wei group(n=25) and control group(n=24)
62132230|NCT02546999|EXPERIMENTAL|botox|Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
62132231|NCT02546999|PLACEBO_COMPARATOR|placebo|Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
62738353|NCT06537765|EXPERIMENTAL|Therapeutic ultrasound (US) Group|It will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, Therapeutic US, 3 sessions, per week for eight weeks.
62132232|NCT00391196|PLACEBO_COMPARATOR|Placebo|
62132233|NCT00391196|EXPERIMENTAL|CP-945,598|
62132234|NCT00391196|EXPERIMENTAL|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
62132235|NCT06239012|EXPERIMENTAL|position measurement with BePoW device compared with MCPAA scale measurements|Each patient will have position measurement with BePoW device and, at the same time, will have MCPAA scale measurements
62132236|NCT03567252|EXPERIMENTAL|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
62132237|NCT03567252|NO_INTERVENTION|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
62132238|NCT05363449|EXPERIMENTAL|UHE-103 Cream|Subjects will apply at least a total of 4 grams\* of the test article, covering both feet twice daily for 2 weeks
62324099|NCT01963117|EXPERIMENTAL|Combined hypertermia and RT|Combined hypertermia and radiothearpy
62324100|NCT06179654|EXPERIMENTAL|Preoperative PFPT|This group of patients will be instructed to start pelvic floor physical therapy 1 month before surgery.
62324101|NCT06179654|NO_INTERVENTION|Postoperative PFPT|This group of patients will be instructed to start pelvic floor physical therapy after surgery (standard of care).
62738354|NCT06537765|EXPERIMENTAL|Transcutaneous Electrical Nerve Stimulation (TENS) Group|It will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, TENS therapy, 3 sessions, per week for eight weeks.
61930474|NCT04751396||Part B Group II (educational tool)|Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
61930475|NCT06000111|EXPERIMENTAL|Face-Down Positioning for 3-Days and Nights|Patients allocated to this study arm will maintain face-down positioning for 3-days and nights post-operatively. Patients will be advised to posture immediately following surgery and will be advised to posture for 50 minutes of each hour. Patients will be advised that during their 10-minute break each hour, they should avoid face-up positioning. FDP will be advised during both waking and sleeping hours.
61930476|NCT06000111|ACTIVE_COMPARATOR|Face-Down Positioning for 7-Days and Nights|Patients allocated to this study arm will maintain face-down positioning for 7-days and nights post-operatively. Patients will be advised to posture immediately following surgery and will be advised to posture for 50 minutes of each hour. Patients will be advised that during their 10-minute break each hour, they should avoid face-up positioning. FDP will be advised during both waking and sleeping hours.
61930477|NCT05465746||Adults with an indication of SAH screening|Patients who attend the physician's office or the emergency room (ER) with signs and symptoms of high systemic arterial blood pressure will be indicated for ABPM and TTE
61930478|NCT04834752||Patients tested for COVID-19|Patients who were tested for COVID-19 nasopharyngeal polymerase chain reaction (PCR)
61930479|NCT06166602|ACTIVE_COMPARATOR|Group 1|PENG block was planned to be applied to group 1 patients with 20 cc of 0.25% bupivacaine.
61930480|NCT06166602|ACTIVE_COMPARATOR|Group 2|PENG block was planned to be applied to group 2 patients with 10 cc of 0.25% bupivacaine.
61930481|NCT04082832|ACTIVE_COMPARATOR|Cu(II)ATSM|Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
61930482|NCT04082832|PLACEBO_COMPARATOR|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
61930483|NCT03598309|ACTIVE_COMPARATOR|Curcumin C3 complex® +Lovaza®|"Group A:~4 grams Lovaza®, 2 grams twice a day (BID). 2 grams by mouth daily, AM and PM 8,000 mgs CUR Curcumin C3 complex® tablets, divided into 2 doses. 4 grams by mouth, twice a day, AM and PM."
61930484|NCT03598309|ACTIVE_COMPARATOR|Curcumin C3 complex® +Lovaza® +Placebo|"Group B:~2 grams Lovaza®, 1 gram twice a day, AM and PM. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs twice a day, AM and PM.~1 placebo capsule twice a day, AM and PM."
61930485|NCT03598309|ACTIVE_COMPARATOR|Placebo only|Placebo: Two matching placebo capsules twice a day (BID), taken by mouth, AM and PM
61930486|NCT03248843|EXPERIMENTAL|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
61930487|NCT06689800|EXPERIMENTAL|Let's Get REAL family health communication tool: Patients (8-12 years of age)|Patients and parent(s) will be given the Let's Get REAL family health communication tool to use up to one month prior to their SCTCT consultation visit. It is a guide for pediatric patients and their families to learn about and discuss SCTCT. Participants will complete demographic and baseline surveys prior to using the tool, and then additional surveys up to one month after SCTCT consultation visit and up to one month post-discharge from SCTCT. SCTCT consultation visits will be audio-recorded. Participants may also participate in an optional semi-structured interview up to 8 weeks after SCTCT consultation.
61930488|NCT06689800|EXPERIMENTAL|Let's Get REAL family health communication tool: Patients (13-17 years of age)|Patients and parent(s) will be given the Let's Get REAL family health communication tool to use up to one month prior to their SCTCT consultation visit. It is a guide for pediatric patients and their families to learn about and discuss SCTCT. Participants will complete demographic and baseline surveys prior to using the tool, and then additional surveys up to one month after SCTCT consultation visit and up to one month post-discharge from SCTCT. SCTCT consultation visits will be audio-recorded. Participants may also participate in an optional semi-structured interview up to 8 weeks after SCTCT consultation.
61930489|NCT06689800|EXPERIMENTAL|Let's Get REAL family health communication tool: Parents|Patients and parent(s) will be given the Let's Get REAL family health communication tool to use up to one month prior to their SCTCT consultation visit. It is a guide for pediatric patients and their families to learn about and discuss SCTCT. Participants will complete demographic and baseline surveys prior to using the tool, and then additional surveys up to one month after SCTCT consultation visit and up to one month post-discharge from SCTCT. SCTCT consultation visits will be audio-recorded. Participants may also participate in an optional semi-structured interview up to 8 weeks after SCTCT consultation.
62132239|NCT05363449|ACTIVE_COMPARATOR|Naftin (naftifine hydrochloride) Cream, 2%|Subjects will apply at least a total of 5 grams\* of the test article, covering the interdigital areas of both feet and to the groin once daily for 2 weeks
62132240|NCT01318655|EXPERIMENTAL|NKTR-118|
62132241|NCT01318655|PLACEBO_COMPARATOR|Placebo|
62132242|NCT02538653|EXPERIMENTAL|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
62324102|NCT01823822|EXPERIMENTAL|Oral protein supplement (Tested product)|
62324103|NCT01823822|ACTIVE_COMPARATOR|Iso-caloric supplement (Control product)|
62324104|NCT04424433|OTHER|Normoxaemia First|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second.
62324105|NCT04424433|OTHER|Hyperoxia First|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second.
62483278|NCT02175095|EXPERIMENTAL|Regorafenib and FLT-PET|After checking the eligibility for the study entry, patients will be scheduled to perform \[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy). Additional \[18F\]FDG-PET will be performed before treatment and at 8 weeks (just once at the point of first response evaluation).
62483279|NCT03577938|EXPERIMENTAL|Chinese herbal medicine|One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
62483280|NCT03577938|OTHER|Control (blank)|Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.
62483281|NCT06187142|EXPERIMENTAL|Intervention Group (Group PCS, subgroup PCS-1+PCS-2+PCS-3)|Personalized Chat Support (PCS) + Multi-component Optional Support (MOS) + 5A's / 5R's advice + health warning leaflet +Self-help booklet
62483282|NCT06187142|EXPERIMENTAL|Control Group (Group GCS, subgroup GCS-1+GCS-2+GCS-3)|Group Chat Support (GCS) + Personalized Chat Support (PCS) + 5A's / 5R's advice + health warning leaflet +Self-help booklet
62483283|NCT05858333|NO_INTERVENTION|Group 1: (day 5 group)|Women will undergo ICSI, and verification-thawed blastocysts will be transferred after 5 days of ovulation (60cases).
62483284|NCT05858333|EXPERIMENTAL|Group 2: (day 3-5 group)|Women will undergo ICSI, who had cryopreserved embryos on day 3 then thawed and embryos will be allowed for extended cultured for 2 additional days and then will be transferred as blastocysts after 5 days of ovulation (60 cases).
62483285|NCT02818530|EXPERIMENTAL|IOP by tomoneter and ultrasound|Intraocular pressure will be measured by electronic tomometer (tonopen) at different point of time after induction of anaesthesia in patients undergoing robotic assisted surgery under steep Trendelenberg position. Anterior chamber depth will be measured by ultrasound at the same time intervals.
62483286|NCT00603499|ACTIVE_COMPARATOR|1|Magnesium chloride
62324106|NCT01515176|EXPERIMENTAL|Treatment (ofatumumab, dinaciclib)|Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
62324107|NCT04756635|EXPERIMENTAL|Experimental Group|Measures taken before and after the defined IF periods. Two groups of participants will be included in this project: 1) resistance trained group (tested for neuromuscular function, anaerobic capacity and body composition); 2) endurance trained group (tested for aerobic and anaerobic capacity and body composition). Experimental condition: pre- and post-4 weeks of IF. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48- hour interval) to ensure full recovery.
62324108|NCT04756635|OTHER|Control Group|Participants of each group serving as their own controls. Control condition: pre- and post4 weeks of normal diet. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48-hour interval) to ensure full recovery.
62483287|NCT00603499|PLACEBO_COMPARATOR|2|Placebo
62483288|NCT03942770|ACTIVE_COMPARATOR|Active Comparator: Group A (Intensive incentives)|"Group A will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will also have the opportunity to earn more incentives for providing negative results. For the first 3 weeks, these additional incentives will scale based on the number of consecutive days of sustained negative samples. For the remaining weeks incentives will be based on a randomized prize drawing."
62483289|NCT03942770|ACTIVE_COMPARATOR|Active Comparator: Group B (Prize-based incentives)|"Group B will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will only have the opportunity to earn more incentives based on a randomized prize drawing if they submit a negative sample."
62483290|NCT03942770|SHAM_COMPARATOR|Sham Comparator: Group C (Intensive incentives)|Group C serves as a direct control group to Group A and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
62483291|NCT03942770|SHAM_COMPARATOR|Sham Comparator: Group D (Price-based incentives)|Group D serves as a direct control group to Group B and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
62483292|NCT03942770|NO_INTERVENTION|No Intervention: Group E (no incentives)|Group E will have no monitoring intervention, they will only complete assessment sessions.
61930490|NCT04743505|EXPERIMENTAL|Phase I Dose Level 1: APL-101 + Standard of Care Osimertinib|"* After 8-16 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~* APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose twice daily on Days 1 through 28 of each 28-day cycle~* Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
61930491|NCT04743505|EXPERIMENTAL|Phase I Dose Level 2: APL-101 + Standard of Care Osimertinib|"* After 8-16 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~* APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose twice daily on Days 1 through 28 of each 28-day cycle~* Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
62324109|NCT00532948|EXPERIMENTAL|1|
62324110|NCT01261728|EXPERIMENTAL|Gemcitabine and Cisplatin|This is a Phase II Study of Gemcitabine and Cisplatin (GC) as neoadjuvant chemotherapy in patients with upper tract high-grade urothelial carcinoma who are candidates for radical nephroureterectomy or distal ureterectomy.
62324111|NCT06693128|EXPERIMENTAL|Camrelizumab and Apatinib and S-1 and Oxaliplatin|
62483293|NCT00896688||Healthy Volunteers|It will involve 5 volunteers and they will undergo C arm fluoroscopic guided cervical medial branch blocks (C2-C7) on unilateral position and then followed by the 3D ultrasound machine for visualization of needle position.
62738355|NCT06537765|EXPERIMENTAL|US + TENS Group|It will include 15 women, who will receive their hormonal treatment as prescribed by the gynecologist in addition to, both Therapeutic US and TENS therapy, 3 sessions, per week for eight weeks.
61930492|NCT04743505|EXPERIMENTAL|Phase II: APL-101 + Standard of Care Osimertinib|"* After 8-16 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~* APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose (this dose will be determined in Phase I of the study) twice daily on Days 1 through 28 of each 28-day cycle~* Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
61930493|NCT04110067||1|SMILE - Correction of eyes with myopia of more than -7.75 D
61930494|NCT05650528|EXPERIMENTAL|Part A|Six single-ascending dose levels (Cohort A1\\Cohort A2\\Cohort A3\\Cohort A4\\Cohort A5\\Cohort A6) of SAD QG101-23-0 capsules (n=6) or placebo (n=2)
61930495|NCT05650528|EXPERIMENTAL|Part B|Three multiple-ascending dose levels (Cohort B1\\Cohort B2\\Cohort B3) of MAD QG101-23-0 capsules (n=6) or placebo (n=2)
61930496|NCT05650528|EXPERIMENTAL|Part C|Cohort A3 Group 1 (n=8) and Group 2 (n=6, additional recruitment) participated in the food effect study. The subjects took QG101-23-0 capsules while under fasting or fed condition.
61930497|NCT03267732|ACTIVE_COMPARATOR|1|Pegilodecakin (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
61930498|NCT03267732|ACTIVE_COMPARATOR|2|Pegilodecakin (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
61930499|NCT05591846|EXPERIMENTAL|Face-to-face training|Face-to-face training group: In the study, the trainings were given face to face in a meeting room suitable for individuals. Documents were explained and animations and interviews were watched.
61930500|NCT05591846|EXPERIMENTAL|web-based training|web-based training Group:In the study, trainings were given to individuals through the website established. Training videos, animations, interviews and documents have been added to the website.
61930501|NCT05591846|NO_INTERVENTION|Control group|Control group: No application has been made.
61930502|NCT06223737|ACTIVE_COMPARATOR|patients non-operated|Each patient will be measured for an EOS x-ray and at the human performance lab at the clinic for optoelectronic motion capture of the spinal movements.
61930503|NCT06223737|ACTIVE_COMPARATOR|patients operated|Each patient will be measured for an EOS x-ray and at the human performance lab at the clinic for optoelectronic motion capture of the spinal movement
61930504|NCT06223737|OTHER|healthy controls|Each participant will be measured as control group for an EOS x-ray and at the human performance lab at the clinic for optoelectronic motion capture of the spinal movement
61930505|NCT06543355|EXPERIMENTAL|BFA + NADA protocol|Modified BFA + NADA treatment, twice per week over 4 weeks for a total of 8 treatments at the clinic. All participants will also have the small seeds placed to facilitate at-home acupressure treatment
61930506|NCT06708377|EXPERIMENTAL|Dry needling of masseter muscle|"Experimental group included Dry needling of masseter muscle for 30 second to 2 minutes into the trigger point.~Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day."
62132243|NCT02538653|ACTIVE_COMPARATOR|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
62132244|NCT05663346|EXPERIMENTAL|Cannabis & Cancer digital educational intervention|This intervention includes different asynchronous pedagogical modalities that allow, among other things, to reactivate the participants' previous knowledge and promote their autonomy in their learning process. These modalities focus on various problems that oncology nurses may encounter about the use of cannabis in oncology (eg, how to tackle the subject, what are the correct times to approach the topic). To this end, various pedagogical modalities that encourage the active participation of nurses are integrated into the training (eg, interactive videos, and quizzes). Scientific articles and links to external resources (official public websites) are also included so that nurses can consult the content at their own pace. Different aspects related to the use of cannabis are addressed in the training (eg, beneficial effects, and potential side effects).
62132245|NCT05663346|ACTIVE_COMPARATOR|Standard information regarding cannabis use in oncology|The comparator is composed of an email with basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
61930507|NCT06708377|ACTIVE_COMPARATOR|Myofacial massage therapy|Control group included Myofascial massage - sliding and kneading, for 30 minutes per session/3x per week. Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day.
61930508|NCT03422627|EXPERIMENTAL|Phase 1: Efavaleukin Alfa Multiple Ascending Doses|Efavaleukin will be administered as multiple ascending doses (MAD) across cohorts 1-5. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen.
62132246|NCT01408394|ACTIVE_COMPARATOR|100 mg immediate release form|This is the formulation currently in use
62132247|NCT01408394|EXPERIMENTAL|90 mg controlled release|This is the low dose of the controlled release form
62324112|NCT06693128|EXPERIMENTAL|Camrelizumab and S-1 and Oxaliplatin|
62132248|NCT01408394|EXPERIMENTAL|180 mg controlled release form|This is the medium controlled release dose
62132249|NCT05893719||Experimental: iNedit, iNdeep, iNtercept|Study devices
62132250|NCT00331136|EXPERIMENTAL|Group A (Tablets)|Pyronaridine artesunate 6:2 mg/kg. The tablet strength is 48:16 mg oral PA, with the number of tablets depending on body weight.
62132251|NCT00331136|EXPERIMENTAL|Group B (Tablets)|Pyronaridine artesunate 9:3 mg/kg. The tablet strength is 72:24 mg oral PA, with the number of tablets depending on body weight.
62132252|NCT00331136|EXPERIMENTAL|Group C (Tablets)|Pyronaridine artesunate 12:4 mg/kg. The tablet strength is 96:32 mg oral PA, with the number of tablets depending on body weight.
62132253|NCT00331136|EXPERIMENTAL|Group D (Granules)|Pyronaridine artesunate 9:3 mg/kg. The sachet of granules strength is 60:20 mg PA, with the number of sachets depending on body weight, and is administered as a suspension with water.
62132254|NCT05224557||New onset HFrEF AA patients|New onset HFrEF AA patients
61930509|NCT03422627|EXPERIMENTAL|Phase 2: RP2D Efavaleukin Alfa|"The phase 2 portion of this study will be conducted as a single arm, multi-center, open label trial in subjects with steroid refractory chronic graft versus Host Disease (cGVHD). All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for up to 52 weeks plus protocol permitted background therapy for cGVHD.~Due to early study termination the Phase 2 portion of the study was never opened."
61930510|NCT06424327||Participants with Lung Cancer|Participants undergoing planned pulmonary segmentectomy for primary lung cancer
61930511|NCT05814497|EXPERIMENTAL|Healthy Controls|Healthy controls with no history of chronic pain.
61930512|NCT05814497|EXPERIMENTAL|Headache and Migraine|Individuals who have migraine with headaches.
62324113|NCT00136747|EXPERIMENTAL|BUPROPION|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
62483294|NCT00896688||Candidates for upper and lower cervial medical branch blocks|This will involve 25 patients and they will follow the same procedures as the healthy volunteers.
61930513|NCT05814497|EXPERIMENTAL|Functional Abdominal Pain Disorder (FAPD)|Individuals who have functional abdominal pain disorder.
61930514|NCT05814497|EXPERIMENTAL|Localized and Diffuse/Widespread Musculoskeletal Pain (MSK)|Individuals with chronic musculoskeletal pain.
61930515|NCT05814497|EXPERIMENTAL|Complex Regional Pain Syndrome (CRPS)|Individuals with complex regional pain syndrome.
62132255|NCT05224557||New onset HFrEF Caucasian patients|New onset HFrEF Caucasian patients
62132256|NCT03614273|ACTIVE_COMPARATOR|Group 1 (HS)|Nebulized with 4 ml of 3% hypertonic saline for a duration of 20 minutes
62132257|NCT03614273|ACTIVE_COMPARATOR|Group 2 (Adr)|Nebulized with 0.1 mg/kg of adrenaline (non-racemic solution, 1:1000 concentration), which was diluted in normal saline to make it a 4 ml solution, for a duration of 20 minutes
62132258|NCT02456467||Cardiac Surgery Patients|Intervention: Procedure: Blood specimen collection
62132259|NCT06224517||Patients of ischemic stroke|Inclusion criteria are as follows: first-onset cerebral ischemic stroke within the previous 3 months, which is confirmed clinically by computed tomography scans or magnetic resonance imaging; sufficient cognition to understand procedures and provide informed consent. Exclusion criteria are as follows: hemorrhagic stroke, cerebellar or brainstem lesions which may affect autonomic or balance; concurrent neurological or neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis, etc.), brain tumor, malignancy, limb deficiency or amputation.
62132260|NCT03926039|EXPERIMENTAL|sharing decision-making program interventions|"Description of conventional traditional treatment options and add sharing decision-making program The intervention measures in this study sharing decision-making plan mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process."
62483295|NCT00957021|OTHER|Triathlon® PS Total Knee System|Triathlon® PS Total Knee System
62132261|NCT03926039|NO_INTERVENTION|Description of traditional treatment options|Description of conventional traditional treatment options
62483296|NCT05372744|EXPERIMENTAL|Experimental group (anticipatory)|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing intensive emotional reactions and consequent rumination tendencies. They take the nasal spray once in the laboratory.
61930516|NCT06408259|EXPERIMENTAL|Ozanimod|
61930517|NCT06408259|ACTIVE_COMPARATOR|Fingolimod|
61930518|NCT03046173|EXPERIMENTAL|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
61930519|NCT03046173|EXPERIMENTAL|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
61930520|NCT06347016|EXPERIMENTAL|Plozasiran Injection|4 doses of plozasiran (ARO-APOC3) by subcutaneous (sc) injection
61930521|NCT06347016|PLACEBO_COMPARATOR|Placebo|calculated volume to match active treatment by sc injection
61930522|NCT04585373|EXPERIMENTAL|(24 hours)|kinesio-tapping along with conventional therapy
61930523|NCT04585373|EXPERIMENTAL|(48hours)|kinesio-tapping along with conventional therapy
61930524|NCT04585373|EXPERIMENTAL|(72 hours)|kinesio-tapping along with conventional therapy
61930525|NCT03953898|EXPERIMENTAL|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity, or absence of remission after 6 cycles for patients without prior exposure to IDH inhibitors, or for up to 12 cycles. Patients also undergo bone marrow aspiration and collection of blood throughout the study.
61930526|NCT06491550|EXPERIMENTAL|Part A1-Cohort 1|Participants will receive one single ascending dose of AZD4144.
62132262|NCT05826860|NO_INTERVENTION|Control group|Survey only, no mindfulness/storytelling intervention
62132263|NCT05826860|EXPERIMENTAL|Intervention group|Mindfulness and storytelling workshop intervention plus survey
62132264|NCT05880355|EXPERIMENTAL|Dapansutrile|Subjects randomized to receive oral dapnsutrile
62132265|NCT05880355|PLACEBO_COMPARATOR|Control|Subjects randomized to receive oral placebo
62132266|NCT04044859|EXPERIMENTAL|Autologous genetically modified ADP-A2M4CD8 cells|
62324114|NCT00136747|EXPERIMENTAL|placebo|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
62324115|NCT00136747|EXPERIMENTAL|memantine|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
62324116|NCT03433846||Preterm Infants|Blood samples will be obtained from preterm and former preterm infants at birth and then monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
62483297|NCT05372744|EXPERIMENTAL|Experimental group (reactive)|Participants receive a nasal spray that is in fact a placebo. Participants of this group are told, however, that it helps to regulate experienced intensive emotional reactions and to distance oneself from consequent ruminative thoughts. They take the nasal spray once in the laboratory.
62483298|NCT05372744|NO_INTERVENTION|No-treatment control group|Participants do not receive the nasal spray and continue with the following task.
62483299|NCT03835780||People with inflammatory bowel disease|All individuals with an existing or incident diagnosis of IBD during the study period
62132267|NCT03420196|EXPERIMENTAL|Supervised Rehabilitation program|It will be consist in a supervised exercise program by physical therapist, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility
62324117|NCT03433846||Term Infants|Blood samples will be obtained from term control infants admitted to the NICU monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
62324118|NCT02692820|EXPERIMENTAL|Probiotic|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of probiotics (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (each at 2.5 x 109 colony forming units (CFUs)). The product contains freeze-dried bacteria and excipients in a gelatin capsule.
62324119|NCT02692820|PLACEBO_COMPARATOR|Placebo|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of the placebo containing excipients alone in a gelatin capsule
62324120|NCT02533648|EXPERIMENTAL|Allopurinol|Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month
62324121|NCT02533648|PLACEBO_COMPARATOR|Placebo|Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month
62324122|NCT06329141|EXPERIMENTAL|Vutiglabridin 400 mg Multiple Dose|Multiple oral dosing of vutiglabridin 400 mg for 24 weeks
62132268|NCT03420196|ACTIVE_COMPARATOR|Nonsupervised rehabilitation program|It will consist in an exercise program for home, nonsupervised, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility. The patients will perform an exercise program at home.
62132269|NCT04760938|EXPERIMENTAL|Outdoor Behavioral Healthcare (OBH)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
62324123|NCT06329141|EXPERIMENTAL|Vutiglabridin 800 mg Multiple Dose|Multiple oral dosing of vutiglabridin 800 mg for 24 weeks
62483300|NCT03835780||People with rheumatoid arthritis|All individuals with an existing or incident diagnosis of RA during the study period
62483301|NCT03835780||People with psoriatic arthritis|All individuals with an existing or incident diagnosis of IBD during the study period
62132270|NCT04760938|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
62324124|NCT06329141|PLACEBO_COMPARATOR|Placebo|Multiple oral dosing of placebo
62483302|NCT03835780||Controls|Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period
62483303|NCT04471922|EXPERIMENTAL|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.~"
62483304|NCT04471922|PLACEBO_COMPARATOR|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
62483305|NCT04471922|ACTIVE_COMPARATOR|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
62483306|NCT00227370|ACTIVE_COMPARATOR|1|Valganciclovir 900 mg QD for 9 months post lung transplant.
62132271|NCT02480205|EXPERIMENTAL|NeuroBox to deliver the NeuroPAP|
62132272|NCT02918591|EXPERIMENTAL|Empagliflozine|All type 2 diabetic participant will be treated during 2 month with Empagliflozine 10 to 25 mg daily during 2 month.
62324125|NCT03309332|EXPERIMENTAL|Device|Subjects implanted with the AMPLATZER™ PFO Occluder.
62324126|NCT02518620|EXPERIMENTAL|ALX-0061 150 mg q2w (+ MTX)|
62324127|NCT04286191|EXPERIMENTAL|Up-conditioning (UC) Group|
62324128|NCT04286191|SHAM_COMPARATOR|Control (NC) Group|
62324129|NCT05336968|ACTIVE_COMPARATOR|Triamcinolone acetonide - Ropivacaine - Normal Saline|"Subject would receive:~Triamcinolone acetonide, 40 mg/mL. 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
62324130|NCT05336968|EXPERIMENTAL|Ketorolac - Ropivacaine - Normal Saline|"Subject would receive:~Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
62324131|NCT05336968|EXPERIMENTAL|Triamcinolone acetonide - Ketorolac - Ropivacaine|"Subject would receive:~Triamcinolone acetonide, 40 mg/mL Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
62324132|NCT05614739|EXPERIMENTAL|Phase 1a: Cohort A1 LOXO-435 Monotherapy Dose Escalation|LOXO-435 administered orally to participants with FGFR3-altered advanced solid tumors.
62483307|NCT00227370|PLACEBO_COMPARATOR|2|placebo for 9 months post lung transplant
62483308|NCT05853445||JAK inhibitor naive|JAK inhibitor naive patients
62483309|NCT05853445||JAK inhibitor pre-treated|JAK inhibitor pre-treated patients (Jakavi® or any other JAK inhibitor for ≥3 months)
62483310|NCT01116739|EXPERIMENTAL|COHS administered fluoride varnish and oral health education|Paraprofessionals, called community oral health specialists (COHS), will be trained to administer fluoride varnish and oral health education to head start children quarterly for 2 years.
62483311|NCT01116739|ACTIVE_COMPARATOR|Usual care|Usual care will include regular dental services provided by the Indian Health Service.
62697515|NCT03862950|ACTIVE_COMPARATOR|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
61930527|NCT06491550|EXPERIMENTAL|Part A1- Cohort 2|Participants will receive one single ascending dose of AZD4144.
61930528|NCT06491550|EXPERIMENTAL|Part A1-Cohort 3|Participants will receive one single ascending dose of AZD4144.
62132273|NCT03848572|NO_INTERVENTION|Usual care|Patients will enter standard 12-month clinical follow-up
62132274|NCT03848572|EXPERIMENTAL|Re-Score strategy|Patients will enter a novel strategy of 12-month follow with repetitive assessment of PRECISE-DAPT score at 3-month intervals
62324133|NCT05614739|EXPERIMENTAL|Phase 1a: Cohort A2 LOXO-435 Monotherapy Dose Optimization|LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma. (Cohort to be implemented as needed, based on Sponsor's discretion.)
62324134|NCT05614739|EXPERIMENTAL|Phase 1b: Cohort B1 LOXO-435 Monotherapy Dose Expansion|LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who were previously treated with an FGFR inhibitor.
62324135|NCT05614739|EXPERIMENTAL|Phase 1b: Cohort B2 LOXO-435 Monotherapy Dose Expansion|LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.
62324136|NCT05614739|EXPERIMENTAL|Phase 1b: Cohort B3 LOXO-435 Plus Pembrolizumab|LOXO-435 administered orally in combination with pembrolizumab administered intravenously (IV) to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.
61930529|NCT06491550|EXPERIMENTAL|Part A2-Japanese cohort 1|Participants will receive one single ascending dose of AZD4144.
62324137|NCT05614739|EXPERIMENTAL|Phase 1b: Cohort C1 LOXO-435 Monotherapy Dose Expansion|LOXO-435 administered orally to participants with advanced solid tumors who have not received a prior FGFR inhibitor.
62324138|NCT00695084|EXPERIMENTAL|1|Treatment with Constraint-Induced Movement Therapy
62324139|NCT05590195|EXPERIMENTAL|PreforPro|Preforpro Dosage form - capsule Dosage - participants will consume one capsule per day for 2 months treatment period
62324140|NCT05590195|PLACEBO_COMPARATOR|Placebo|placebo will come in a capsule, which has to be consumed one capsule per day for 2 months treatment period
62324141|NCT06265532|ACTIVE_COMPARATOR|EGCG 300 mg|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided anti-fibrotic for 12 weeks.
62324142|NCT06265532|PLACEBO_COMPARATOR|Placebo for EGCG 300 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided anti-fibrotic. The number of placebo capsules will be equal to that of 300 mg EGCG.
62324143|NCT06265532|ACTIVE_COMPARATOR|EGCG 600 mg|Patients enrolled in this group will be given oral capsule EGCG 600 mg daily with doctor provided anti-fibrotic for 12 weeks.
62324144|NCT06265532|PLACEBO_COMPARATOR|Placebo for EGCG 600 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided anti-fibrotic. The number of placebo capsules will be equal to that of 600 mg EGCG.
62483312|NCT05866263|EXPERIMENTAL|green walking and intelligence game group|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group
62483313|NCT05866263|ACTIVE_COMPARATOR|control group|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the 20 were in the control group
62483314|NCT06356558|EXPERIMENTAL|Pre-Post Arm|"The overall pilot trial will last for 2.5 years at 2 sites. For each of the 2 sites:~* Baseline data will be acquired over 6-12 months (pre-intervention)~* The intervention (VISACT) will be delivered over a 1-month period and then maintained~* Experimental data will be acquired over 18-24 months (post-intervention)"
61930530|NCT06491550|EXPERIMENTAL|Part A2: Japanese Cohort 2|Participants will receive one single ascending dose of AZD4144.
61930531|NCT06491550|EXPERIMENTAL|Part A3-Chinese Cohort|Participants will receive one single ascending dose of AZD4144.
61930532|NCT06491550|EXPERIMENTAL|Part B1- Cohort 1|Participants will receive multiple ascending doses of AZD4144.
61930533|NCT06491550|EXPERIMENTAL|Part B1- Cohort 2|Participants will receive multiple ascending doses of AZD4144.
61930534|NCT06491550|EXPERIMENTAL|Part B1- Cohort 3|Participants will receive multiple ascending doses of AZD4144.
62132275|NCT00737542|PLACEBO_COMPARATOR|A|
62132276|NCT00737542|EXPERIMENTAL|B|
62132277|NCT00819546|OTHER|Only one arm on this study.|
62324145|NCT00840645|EXPERIMENTAL|1. YM178|
62324146|NCT03868228|EXPERIMENTAL|Treatment with PIPAC|Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
62324147|NCT01468727|EXPERIMENTAL|xylitol wipe|
62324148|NCT01468727|PLACEBO_COMPARATOR|placebo wipe|
62324149|NCT06577870|EXPERIMENTAL|Immersive sensory projections|"Patients will benefit from an immersive sensory environment in the hospital room. This IHP immersive sensory environment consists of the following elements:~* light frescoes on the theme of nature, of the canopy type, diffused by a generative circadian cycle.~* a soundtrack made up of nature sounds and sounds of life outside the hospital, broadcast in an immersive (moving sounds in the room), random (non-repetitive sounds over time) and generative way.~* essential oils"
62691680|NCT03536858|ACTIVE_COMPARATOR|Centrality|The patients at clinic one who receive hemodialysis on Tuesday, Thursday, Saturday and the patients on the Monday, Wednesday, Friday schedule at clinic two, will be assigned to the Centrality arm. Two patients per hemodialysis shift with the highest centrality will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patients selected by centrality will have a centrality greater than 1 standard deviation (SD) from the mean of the other patients on their hemodialysis clinic shift and a clustering less than 1 SD from the mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
62691681|NCT03536858|ACTIVE_COMPARATOR|Clustering|The patients at clinic one who receive hemodialysis on Monday, Wednesday, Friday and the patients on the Tuesday, Thursday, Saturday schedule at clinic two, will be assigned to the Clustering arm.Two patients per hemodialysis shift with the highest clustering coefficient will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patient selected by clustering coefficient, will have a clustering coefficient greater than 1 SD from the mean of the other patients on their hemodialysis clinic shift and centrality 1 SD less than a mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
62324150|NCT06577870|ACTIVE_COMPARATOR|No immersive sensory projections|Standard (control) group: Patients will not have any Immersion Health Project-type immersive sensory projection in the hospital room.
62324151|NCT05067790|EXPERIMENTAL|Higher Dose Nusinersen|All participants in the core study period, previously treated with risdiplam (nusinersen-naive participants and nusinersen-experienced participants), will receive HD nusinersen, administered as 2 loading doses of 50 milligrams (mg) each, approximately 2 weeks apart, followed by maintenance doses of 28 mg approximately every 4 months. Following the core study period, participants may be given the opportunity to receive maintenance doses of 28 mg nusinersen administered approximately every 4 months up to 2 years during the optional long-term extension (LTE) period.
62324152|NCT03471091|EXPERIMENTAL|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
62324153|NCT03471091|NO_INTERVENTION|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
62324154|NCT04610242|EXPERIMENTAL|Experimental group|Patients undergo diagnostic tests before the initial infusion of rituximab, including skin prick tests, intradermal tests, and challenge tests successively. If the skin test shows a positive result, the patient will receive desensitization procedure, and if the skin test is negative, the challenge test will be done, meaning normal infusion of rituximab according to manufacturer instructions. All the HSRs in the process of desensitization or normal infusion will be recorded. Peripheral blood will be drawn from all the subjects during their infusion to investigate the mechanism of HSRs to rituximab.
62324155|NCT04366986||Pregnant Women|Women who are currently pregnant
62324156|NCT04366986||Post-partum women|Women who have been pregnant in the past 6 months
62324157|NCT06653023|EXPERIMENTAL|Single dose injection of REVO-UWD-03|Dose escalation will be performed for the single dose injection of REVO-UWD-03 for treating HCC and NSCLC
62324158|NCT02464787|EXPERIMENTAL|Medical Students|Medical students willing to maintain the increased consumption of LifePak Nano dietary supplements, two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period, to maintain the logs and to report at each of the times that measurements will be made.
62324159|NCT00830453|EXPERIMENTAL|Hyperbaric oxygen|Hyperbaric oxygen, 1.5 atmospheres absolute, 60 minutes door-to-door, 60 daily sessions.
62324160|NCT06517186||HFpEF|Participants with HFpEF
62324161|NCT06517186||Non-HFpEF|Participants without HFpEF
62324162|NCT03762525|OTHER|ECG gated CTA pre and post operative at Gore IBE|To prospectively enroll 15 patients that are scheduled for endovascular aneurysm repair using the Gore IBE device in conjunction with its dedicated self expanding Internal Iliac component. Each patient will have an ECG gated CTA scan before the operation and 6-8 weeks after operation, in stead of a regular CT scan.
62483315|NCT06563505|EXPERIMENTAL|Treatment w/Mosunetuzumab + Zanubrutinib|
62483316|NCT01522820|EXPERIMENTAL|Cohort 1a (vaccine therapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.
62483317|NCT01522820|EXPERIMENTAL|Cohort 1b (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.
62691682|NCT06674564|NO_INTERVENTION|control group|patients in this group will not having any interventions except the usual treatment before and after surgery
62691683|NCT06674564|ACTIVE_COMPARATOR|zinc group|patients in this group will take 50 mg zinc sulfate beside the usual treatment
62691684|NCT06674564|ACTIVE_COMPARATOR|probiotics group|patients in this group will take probiotics beside the usual treatment
62691685|NCT06674564|ACTIVE_COMPARATOR|zinc and probiotics proup|patients in this group will take zinc and probiotics beside the usual treatment
62691686|NCT06076213|EXPERIMENTAL|Artesunate-amodiaquine|tablets of ASAQ Winthrop®
62483318|NCT01522820|EXPERIMENTAL|Cohort 1c (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.
61930535|NCT06491550|EXPERIMENTAL|Part B2- Japanese Cohort|Participants will receive multiple ascending doses of AZD4144.
61930536|NCT06491550|EXPERIMENTAL|Part C Cohort- Treatment C1|Participants will receive Rosuvastatin.
62483319|NCT01522820|EXPERIMENTAL|Cohort 1d (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.
61930537|NCT06491550|EXPERIMENTAL|Part C cohort- Treatment C2|Participants will receive rosuvastatin and AZD4144.
62132278|NCT01639131|EXPERIMENTAL|Gemcitabine and Docetaxel|Patients were treated with gemcitabine 800 mg/m2 on days 1 and 8 and docetaxel 70 mg/m2 on day 8 of each 21-day cycle. Patients received filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle. Patients were treated until disease progression or unacceptable adverse events (AEs), or withdrawn of the consent.
62324163|NCT03762525|OTHER|ECG gated CTA post operative at Gore IBE and Cook IBD|To compare 15 patients that have been treated in the period October 2006- July 2016 with the Cook IBD with a non-dedicated IIA component (Advanta-V12 or Fluency) and 15 matched patients treated with Gore IBE device. Each patient will have an ECG gated CTA after the operation, at the first doctor's appointment, in stead of a regular CT scan.
62324164|NCT01959386||HER2 Positive Breast Cancer Participants|Participants with HER2 positive tumors who are considered for treatment with trastuzumab SC according to the judgement of physician and according to the actual summary of product characteristics will be observed for a period of approximately 1 year and will be followed for an additional 2 years.
62324165|NCT03587038|EXPERIMENTAL|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
62324166|NCT03587038|EXPERIMENTAL|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
62324167|NCT03080220|EXPERIMENTAL|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
62691687|NCT06076213|EXPERIMENTAL|Artemether-lumefantrine|tablets of Coartem Dispersible®
62324168|NCT03080220|EXPERIMENTAL|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
62324169|NCT03080220|PLACEBO_COMPARATOR|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
62691688|NCT04062552|EXPERIMENTAL|Virtual Learning Collaborative|
61930538|NCT06491550|PLACEBO_COMPARATOR|Part A1- Placebo|Participants will receive matching placebo.
62132279|NCT04101656||Experimental: APBI (Accelerated Partial Breast Irradiation)|APBI 28 Gy in 5 fractions of 5.6 Gy, using external radiotherapy with modulated intensity technique (IMRT)
62324170|NCT01143350|EXPERIMENTAL|EHPAD Training and Stimulation|"EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
62324171|NCT01143350|PLACEBO_COMPARATOR|2- EHPAD control|EHPAD of the reference group, will have their habitual functioning
62324172|NCT04841135|OTHER|Alzheimer disease group|
62324173|NCT04841135|OTHER|Control|
62324174|NCT04841135|OTHER|Neurotypicals|
62324175|NCT03801304|EXPERIMENTAL|Atezolizumab associated with vinorelbine|"* Atezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle.~* Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg."
62324176|NCT05995717|EXPERIMENTAL|PKU UP|All participants will be assessed by their dietitian and prescribed an appropriate amount of the study product, PKU UP, to manage their phenylketonuria.
62691689|NCT04062552|EXPERIMENTAL|Technical Assistance|
62691690|NCT00657683|EXPERIMENTAL|1|
62691691|NCT00657683|PLACEBO_COMPARATOR|2|
62697516|NCT05660538|EXPERIMENTAL|VX-548|Participants will be randomized to receive different dose levels of VX-548.
62697517|NCT05660538|ACTIVE_COMPARATOR|Pregabalin|Participants will receive pregabalin.
61930539|NCT06491550|PLACEBO_COMPARATOR|Part A2- Placebo|Participants will receive matching placebo.
61930540|NCT06491550|PLACEBO_COMPARATOR|Part A3- Placebo|Participants will receive matching Placebo.
61930541|NCT06491550|PLACEBO_COMPARATOR|Part B1- Placebo|Participants will receive matching Placebo.
61930542|NCT06491550|PLACEBO_COMPARATOR|Part B2- Placebo|Participants will receive matching Placebo.
62132280|NCT02035904|EXPERIMENTAL|Levobupivacaine|Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours
62132281|NCT02035904|PLACEBO_COMPARATOR|Saline|patient controlled infusion 5 ml bolus, lock out 2 hours
62132282|NCT05931510|EXPERIMENTAL|Group A|Myofascial release
62132283|NCT05931510|EXPERIMENTAL|Group B|Post isometric relaxation
62132284|NCT04291092|EXPERIMENTAL|single-arm|single-arm
62132285|NCT03898310|EXPERIMENTAL|Cranberry Extract Capsules|36mg of proanthocyanidins in cranberry capsules
62132286|NCT03898310|PLACEBO_COMPARATOR|Placebo Capsules|
62691692|NCT03692169||CSC patients|Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns. This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
62691693|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
61930543|NCT05922046|EXPERIMENTAL|Subjects with Parkinson's Disease over 65 years of age|Individuals diagnosed with Parkinson's disease who are at least 65 years old on the date of initial assessment will be selected.
61930544|NCT05922046|EXPERIMENTAL|Subjects with Parkinson's disease under 65 years|Individuals diagnosed with Parkinson's disease aged between 18 and 64 years on the date of the initial assessment will be selected.
62691694|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
62691695|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
62691696|NCT03202173|ACTIVE_COMPARATOR|normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
62691697|NCT03202173|EXPERIMENTAL|lymphoid hyperplasia|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of nasopharyngeal mucosa after intravenous injecting 10% fluorescein..
62691698|NCT03202173|EXPERIMENTAL|nasopharyngeal carcinoma|pCLE images of nasopharyngeal carcinoma, which was associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
62324177|NCT00692900|EXPERIMENTAL|1|intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin
62324178|NCT00692900|EXPERIMENTAL|2|intravenous (IV) oxaliplatin and intraperitoneal(IP) docetaxel
62691699|NCT05866523|ACTIVE_COMPARATOR|Standard of Care Historic Control|Control group will get treatment as usual, which consists of medical care by primary admitting service
62691700|NCT05866523|ACTIVE_COMPARATOR|Team based inpatient ARTAS|Eligible patients after the study consent process will receive Antiretroviral Treatment Access Study (ARTAS) intervention by social-worker and a medical consultation by an infectious disease physician
62324179|NCT03914820|EXPERIMENTAL|Experimental|ARM A: Prophylactic surgery plus HIPEC CO2 performed with mitomycin
62324180|NCT03914820|ACTIVE_COMPARATOR|Comparator|ARM B: Standard surgey without HIPEC CO2 The arm B is with standard surgery without HIPEC CO2
62691701|NCT05643430|EXPERIMENTAL|BioFreedom Ultra|All patients will receive the BioFreedom Ultra as per treatment.
62691702|NCT01188993|ACTIVE_COMPARATOR|septic shock TPT then TEE|Group 1: Each patient will be assessed by both the transpulmonary thermodilution technique and transesophageal echocardiography (TEE)..
62691703|NCT01188993|ACTIVE_COMPARATOR|septic shock TEE then TPT|Goup 2: Each patient will be assessed by both transesophageal echocardiography (TEE) and the transpulmonary thermodilution technique.
62691704|NCT03345082|EXPERIMENTAL|0.5 mg ranibizumab with 2.0 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
62691705|NCT03345082|EXPERIMENTAL|0.5 mg ranibizumab with 0.5 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
61930545|NCT01158664|EXPERIMENTAL|0.6 mm tread pitch implant|
62324181|NCT03468192|EXPERIMENTAL|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
62324182|NCT03468192|NO_INTERVENTION|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
62324183|NCT01234402|EXPERIMENTAL|Ramucirumab DP + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
62324184|NCT01234402|EXPERIMENTAL|Icrucumab + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
62483320|NCT01522820|EXPERIMENTAL|Cohort 2 (vaccine therapy with or without immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.
61930546|NCT01158664|EXPERIMENTAL|0.1 mm tread pitch implant|
61930547|NCT05632354|EXPERIMENTAL|Treatment|Osivelotor
61930548|NCT02414672|EXPERIMENTAL|CareSTEPS|CareSTEPS provides skills training in six domains that are central to the caregiving role: self-care, stress management, symptom management, effective communication, problem-solving, and social support.
61930549|NCT02414672|NO_INTERVENTION|Usual Medical Care (UMC)|Patients receive standard oncologic and generalist palliative care from their healthcare team.
61930550|NCT03624400|EXPERIMENTAL|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
61930551|NCT03624400|ACTIVE_COMPARATOR|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
61930552|NCT06515041|OTHER|MUSEUM VISITS with mediation: group A|This group of volunteers will visit the museum with a mediation (I.E. description of the painting tables by a professional).
61930553|NCT06515041|OTHER|MUSEUM VISITS without mediation: group B|This group of volunteers will visit the museum without a mediation (I.E. description of the painting tables by a professional).
61930554|NCT06515041|OTHER|Control group|This group of volunteers will not visit the museum.
62483321|NCT02507128|EXPERIMENTAL|GLP-1 group|The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).
62483322|NCT02507128|PLACEBO_COMPARATOR|Control group|the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).
62483323|NCT05539157|EXPERIMENTAL|Phase 1a:Dose escalation|"JCXH-211 will be delivered by intratumoral injection in 3 stages:~Single administration stage A single administration of JCXH-211 administered to cutaneous or subcutaneous lesions in escalating doses.~Multiple administration stage Up to 3 doses of JCXH-211 administered to a cutaneous or subcutaneous lesion in escalating doses. Assigned dose to be determined on the data from the single administration arm.~Visceral administration stage JCXH-211 administered to a visceral lesion in escalating doses. Assigned dose to be determined on the data from the single and multiple administration arms."
62483324|NCT05539157|EXPERIMENTAL|Phase 1b:Dose expansion|JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase 1a.
62483325|NCT04906148|EXPERIMENTAL|Smokers|Smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
62132287|NCT05837455|EXPERIMENTAL|Low-risk group|"* Baseline breast MRI and research specimen collection prior to the start of treatment with standard of care anastrozole. All patients will have one 28-day cycle of anastrozole, followed by determination of breast cancer risk category by incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic subtype by PAM50.~* An additional blood draw for research purposes at Week 4 (no breast tumor biopsy at this time point) and continue to receive 5 additional 28-day cycles of anastrozole.~* After completion of \~6 months of neoadjuvant treatment, will undergo post-treatment breast MRI followed by standard of care surgery."
62132288|NCT05837455|EXPERIMENTAL|High-risk endocrine-sensitive group|"* Baseline breast MRI and research specimen collection prior to the start of treatment with standard of care anastrozole. All patients will have one 28-day cycle of anastrozole, followed by determination of breast cancer risk category by incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic subtype by PAM50.~* An additional blood draw and breast tumor tissue collection at Week 4 to assess Ki67. Patients with Week 4 Ki67 ≤10% (the high-risk endocrine-sensitive group) will continue to receive 5 additional 28-day cycles of anastrozole.~* After completion of \~6 months of neoadjuvant treatment, will undergo post-treatment breast MRI followed by standard of care surgery."
62324185|NCT01234402|ACTIVE_COMPARATOR|Capecitabine*|"Crossover Study:~\* At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given.~Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant."
62324186|NCT00780468|ACTIVE_COMPARATOR|1|Existing diet plan
62483326|NCT04906148|EXPERIMENTAL|Non-smokers|Non-smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
62483327|NCT04112823|ACTIVE_COMPARATOR|Dexamethasone 4mg|Dexamethasone 4mg, administered intravenously
62483328|NCT04112823|ACTIVE_COMPARATOR|Dexamethasone 16mg|Dexamethasone 16mg, administered intravenously
62483329|NCT01371435||Patients prescribed PAXIL|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
62483330|NCT01545193||Age 18-50|This is a younger study cohort who is anticipated to have a lower incidence of residual neuromuscular blockade
62483331|NCT01545193||Age 70-90|This is a older study cohort who is anticipated to have a higher incidence of residual neuromuscular blockade
62483332|NCT01524185|EXPERIMENTAL|FamilyLive|Multi-therapist group intervention for families with a history of intergenerational neglect and trauma exposure
62483333|NCT01524185|ACTIVE_COMPARATOR|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
62483334|NCT04423549||tested group|
62483335|NCT04423549||controlled group|
62483336|NCT04797663|ACTIVE_COMPARATOR|Nd-YAG laser|laser hair removal
62483337|NCT04797663|EXPERIMENTAL|TCA 20%|chemical peel
62483338|NCT00735540||A|Acute organic diseases
62483339|NCT00735540||B|Patients with chronic diseases
61930555|NCT01775462|EXPERIMENTAL|EDI200, 3mg/kg|Five doses of EDI200 given at 3 mg/kg twice weekly
62483340|NCT00735540||C|Patients with psychiatric diagnosis
62324187|NCT00780468|EXPERIMENTAL|2|New diet plan
62324188|NCT05157672|EXPERIMENTAL|Cinnamon|Arm 1 will consist of administration of a single dose of cinnamon (2 g) with water by mouth to 6 subjects (3 biological men, 3 biological women). Blood will be drawn from 0-48 hours. Urine will be collected from 0-24 hours. The subjects may or may not elect to participate in Arms 2-5. If they do, a washout of at least 7 days will occur between Arm 1 administration of cinnamon and the Arm 2 administration of nicotine.
62483341|NCT05140759|EXPERIMENTAL|Implanted device|Implantation and activation of an automated continual water removal system, including 4-months follow up
62483342|NCT06628063||normal third trimestric scam|cases in which second and third trimestric scan show no additional benefit over second trimestric scan alone
62483343|NCT06628063||new finding in third trimestric scan|cases in which second and third trimestric scan show additional benefit over second trimestric scan alone
62483344|NCT05905276|ACTIVE_COMPARATOR|Standard of Care|Patients in the usual care arm of the trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
62483345|NCT05905276|EXPERIMENTAL|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
62483346|NCT03796611||multiple sclerosis patient|MS is defined according to McDonald criteria 2017. MS patients included have a disease duration of less than 1 year
62483347|NCT03796611||other neurological inflammatory disease|autoimmune encephalitis, myasthenia gravis, chronic inflammatory demyelinating polyradiculitis
61930556|NCT01775462|EXPERIMENTAL|EDI200, 10 mg/kg|Five doses of EDI200 given at 10 mg/kg twice weekly
62691706|NCT03345082|SHAM_COMPARATOR|0.5 mg ranibizumab with sham|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
62483348|NCT03796611||neurological non inflammatory disease|benign intracranial hypertension, degenerative disorder
62483349|NCT03796611||healthy controls|transfusion volunteers from transfusion center
62483350|NCT00028587|EXPERIMENTAL|Group I (paclitaxel, carboplatin, bortezomib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and bortezomib IV over 3-5 seconds on days 2, 5, and 8.
62483351|NCT00028587|EXPERIMENTAL|Group II (bortezomib, paclitaxel, carboplatin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2
62483352|NCT06455514|EXPERIMENTAL|Magnesium Sulfate|Treatment of initial magnesium sulfate bolus followed by a continuous drip.
62483353|NCT06455514|PLACEBO_COMPARATOR|Saline solution|Treatment of equivalent volume of normal saline.
62691707|NCT05305573|EXPERIMENTAL|COVID-19 Vaccine HIPRA 40 ug/dose|
61930557|NCT03187951|EXPERIMENTAL|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
62324189|NCT05157672|EXPERIMENTAL|Nicotine|Arm 2 will consist of administration of a single dose of nicotine gum (2 mg) to 16 subjects (8 biological men, 8 biological women). If these subjects participated in Arm 1, they will have completed a washout of 7 days since administration of cinnamon before starting Arm 2. Blood and urine will be collected from 0-12 hours relative to nicotine administration. Participants will undergo a washout of at least 4 days before beginning Arm 3.
62324190|NCT05157672|EXPERIMENTAL|Letrozole|Arm 3 will consist of administration of a single oral dose of letrozole (2.5 mg) to the same 16 subjects who participate in Arm 2. Blood and urine will be collected from 0-240 hours and 0-24 hours, respectively, relative to letrozole administration. Participants will undergo a washout of at least 14 days before beginning Arm 4.
62324191|NCT05157672|EXPERIMENTAL|Cinnamon + Nicotine|The same 16 subjects will self-administer the cinnamon product (2 g) three times daily for five consecutive days. On the sixth day, subjects will be administered cinnamon (2 g) and nicotine gum (2 mg). Cinnamon will be administered two additional times. Blood and urine will be collected from 0-12 hours relative to nicotine administration. Participants will undergo a washout of at least 4 days before beginning Arm 5.
62324192|NCT05157672|EXPERIMENTAL|Cinnamon + Letrozole|The same 16 subjects will self-administer the cinnamon product (2 g) three times daily for five consecutive days. On the sixth day, subjects will be administered cinnamon (2 g) and letrozole (2.5 mg). Cinnamon will be administered two additional times. Blood and urine will be collected from 0-240 hours and 0-24 hours, respectively, relative to letrozole administration.
62324193|NCT02858193|EXPERIMENTAL|Test - Reference (1.35 g of SCMC-lys monohydrate salt powder - Fluifort® syrup 90 mg SCMC-lys/mL)|In this arm, a single oral dose of test product (1 sachet; 1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was orally administered, under fasting conditions, in the first period (day 1, Visit 3, 8:00 ± 1h ), and, after a wash-out period of at least 4 days, a single dose of the reference product Fluifort® syrup 90 mg SCMC-lys/mL (15 mL of syrup, 1.35 g of SCMC-lys) was orally administered, under fasting conditions, in the second study period (day 1, visit 5, 8:00 ± 1h).
62324194|NCT02858193|EXPERIMENTAL|Reference - Test (Fluifort® syrup 90 mg SCMC-lys/mL-1.35 g of SCMC-lys monohydrate salt powder)|In this arm, a single oral dose of reference product Fluifort® syrup 90 mg SCMC-lys/mL (15 mL of syrup, 1.35 g of SCMC-lys) was orally administrated, under fasting conditions, in the first period (day 1, Visit 3, 8:00 ± 1h ), and, after a wash-out period of at least 4 days, a single dose of the test product 1 sachet; 1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base was orally administered, under fasting conditions, in the second study period (day 1, visit 5, 8:00 ± 1h).
62324195|NCT04014153||Group 1 (5-year prognosis)|
62324196|NCT04014153||Group 2 (1-year prognosis)|
62483354|NCT05441670|EXPERIMENTAL|Art and Physical Therapy|45-minutes of AT immediately followed by 30 minutes of PT Monday through Friday for 2 weeks. Targeting media that offer fluidity and tactile input, two were chosen for this study: oil pastels week 1 and gouache without brush during week 2.
62483355|NCT05441670|ACTIVE_COMPARATOR|Physical Therapy|PT Monday through Friday for 2 weeks.
62483356|NCT01175135|EXPERIMENTAL|PF-02545920 5 mg|
62483357|NCT01175135|EXPERIMENTAL|PF-02545920 15 mg|
62483358|NCT01175135|PLACEBO_COMPARATOR|Placebo|
62483359|NCT01175135|ACTIVE_COMPARATOR|Risperidone 3 mg|
62483360|NCT04937439|EXPERIMENTAL|Segmental trunk training A|Children in this group will receive specially designed physical therapy program while wearing a segmental trunk support from the level of pelvis to a level just below the rib cage.
62483361|NCT04937439|ACTIVE_COMPARATOR|Segmental trunk training B|Children in this group will receive the same program given to (group A) while wearing a segmental trunk support from the level of pelvis to a level just below the inferior angle of scapula.
62483362|NCT04937439|ACTIVE_COMPARATOR|Segmental trunk training C|will receive the same program given to (group A and B) while wearing a segmental trunk support from the level of last rib to the level of the inferior angle of scapula.
62483363|NCT04865003||DNI group|patients with infection of two or more deep neck spaces (DNI group)
62483364|NCT04865003||DNI + DNM group|patients with infection of two or more deep neck spaces with secondary descending necrotizing mediastinitis (DNI + DNM group)
62483365|NCT06562309||high inflammatory risk|hsCRP ≥ 3mg/L
62483366|NCT06562309||low inflammatory risk|hsCRP \< 1mg/L
62691708|NCT05305573|ACTIVE_COMPARATOR|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|
62738356|NCT06365437|EXPERIMENTAL|Arm 1|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
61944522|NCT06434298|EXPERIMENTAL|Choose to Move|"CTM (Phase 4) is a 3-month, flexible, choice-based health-promoting program for low active older adults. CTM includes:~1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by an activity coach. Meetings cover a health-related discussion topic and provide time for social connection among participants. Meetings can be held online or in-person.~Community-based seniors' services organizations that deliver CTM may adapt the program (e.g., deliver in a different language, adapt for cultural or geographical factors) to fit the needs of the older adults they serve but the two components listed above will be retained."
62691709|NCT03508479|EXPERIMENTAL|RG-HRV16 Inoculation|While wearing a dental bib, subjects will be asked to blow the nose prior to inoculation. With the head tilted back, a total of 0.5 mL (0.25 mL/nostril) will be administered using the MAD Nasal™ Intranasal Mucosal Atomization Device. Subjects instructed not to blow nose for 30 minutes afterwards.
62132289|NCT05837455|EXPERIMENTAL|High-risk endocrine-resistant group|"* Baseline breast MRI and research specimen collection prior to the start of treatment with standard of care anastrozole. All patients will have one 28-day cycle of anastrozole, followed by determination of breast cancer risk category by incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic subtype by PAM50.~* An additional blood draw and breast tumor tissue collection at Week 4 to assess Ki67. Patients with Week 4 Ki67 \>10% (the high-risk endocrine-resistant group) will receive escalated therapy with \~5-6 additional months of standard of care chemotherapy (combination anthracycline- and/or taxane-based at the discretion of their physician).~* After completion of \~6 months of neoadjuvant treatment, will undergo post-treatment breast MRI followed by standard of care surgery."
62132290|NCT04286113|ACTIVE_COMPARATOR|Control group|Participants will receive non-personalized information (one-size-fits-all) diet, sleep and physical activity recommendations via messaging delivered by app.
62132291|NCT04286113|EXPERIMENTAL|Intervention Group|Participants will receive personalized messages about achieving healthy diet, physical activity and sleep as well as summary of their performance for the week and month. They will also receive personalized content about research volunteerism and altruistic activities.
62132292|NCT02009228|ACTIVE_COMPARATOR|Single-port laparoscopy|The three-channel single-port: a 1.5-cm horizontal intraumbilical skin incision, a 1.5-cm to 2-cm rectus fasciotomy to open the peritoneal cavity, and the insertion of an Alexis small wound retractor (Applied Medical, Rancho Santa Margarita, CA). The wrist portion of a size 6.5 surgical glove was fixed to the outer ring of the wound retractor. A 12-mm trocar was inserted through a small hole made in one of the fingertips of the glove and advanced into the abdominal cavity. Two additional holes for the accessory channels were made in another fingertip of the glove, and two conventional 5-mm trocars were inserted through the holes.
62132293|NCT02009228|ACTIVE_COMPARATOR|Conventional laparoscopy|The 12-mm main troca was inserted via subumbilical incision after fully insufflation by verness needle and other 3 working 5-mm trocas were inserted under vision at right middle abdominal, left middle abdominal and suprapubic incisions.
62324197|NCT04662710|EXPERIMENTAL|Lenvatinib + Pembrolizumab + Chemotherapy|Participants receive lenvatinib administered orally (PO) every day (QD) in combination with pembrolizumab intravenously (IV) every 6 weeks (Q6W) plus chemotherapy with either capecitabine and oxaliplatin (CAPOX) or chemotherapy with 5-FU, leucovorin, and oxaliplatin (mFOLFOX6). Induction with lenvatinib 8 mg QD plus pembrolizumab (400 mg Q6W) plus chemotherapy (CAPOX or mFOLFOX6) will be administered for 2 cycles (approximately 12 weeks), followed by consolidation with lenvatinib 20 mg QD plus pembrolizumab (400 mg Q6W) for 16 cycles. A cycle is 6 weeks (42 days).
62324198|NCT04662710|EXPERIMENTAL|Chemotherapy|Participants receive chemotherapy with either CAPOX Q3W or mFOLFOX6 Q2W. A cycle is 6 weeks (42 days).
62324199|NCT01643915|ACTIVE_COMPARATOR|Control group|Patients with conventional treatment. No distraction method during the treatment visits.
62132294|NCT02026128||Active Uveitis|Physician-confirmed diagnosis of uveitis of any origin.
62132295|NCT01172418|ACTIVE_COMPARATOR|Thymoglobulin and Daclizumab|Group I: Our standard steroid avoidance protocol, i.e., 3 daily doses of 1 mg/kg of Thymoglobulin®, the first to be infused at surgery, accompanied by 2 doses of anti-CD25 humanized monoclonal antibody, the first also to be given at surgery, and the second 2 weeks later. (controls)
62132296|NCT01172418|EXPERIMENTAL|Thymoglobulin and Alemtuzumab|Group II: A new steroid avoidance protocol in which 1 dose of 1 mg/kg of Thymoglobulin® is to be infused at surgery followed by 1 dose of alemtuzumab (Campath-1H) at 0.3 mg/kg within 24 hours. No further antibody therapy will be used.
62132297|NCT04553458||Favorable outcome|Cure or stable disease
62132298|NCT04553458||Unfavorable outcome|Progressive (deteriorate/Recurrence) or Death
62132299|NCT02173717|EXPERIMENTAL|Dabigatran etexilate|"Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence.~1. Single oral administration of dabigatran etexilate on Day 1;~2. Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9;~3. Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout;~4. Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout"
62132300|NCT01534741|ACTIVE_COMPARATOR|Dialyser|FX CorDiax 60 dialyzer
62132301|NCT01534741|ACTIVE_COMPARATOR|FXDialyser|FX 60 dialyzer
62324200|NCT01643915|EXPERIMENTAL|Experimental group 1|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
62324201|NCT01643915|EXPERIMENTAL|Experimental group 2|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
62324202|NCT00307593|ACTIVE_COMPARATOR|1|Rituximab
62324203|NCT00307593|ACTIVE_COMPARATOR|2|Infliximab
62324204|NCT06658873||Group D|Radial arterial cannulation from the distal part af the artery at the level of the styloid process.
62691710|NCT00944645|ACTIVE_COMPARATOR|A|MK0524A Source 1 (Phase III manufacturing site)
62691711|NCT00944645|ACTIVE_COMPARATOR|B|MK0524A Source 2 (commercial manufacturing site)
62691712|NCT01969578|ACTIVE_COMPARATOR|Chemotherapy|"Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel~Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy"
61930558|NCT03187951|EXPERIMENTAL|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
62483367|NCT02095379||oligosecretary|Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
62483368|NCT02421653|EXPERIMENTAL|MNP90 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
62483369|NCT02421653|EXPERIMENTAL|MNP45 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
61930559|NCT00974766|ACTIVE_COMPARATOR|Low-dose glucocorticoid|Low-dose steroid
61930560|NCT00974766|ACTIVE_COMPARATOR|High-dose glucocorticoid|High-dose steroid
61944523|NCT06247566||68Ga-Pentixafor PET/CT|Patients with Primary Aldosteronism (PA) accompanied by bilateral adrenal lesions undergoing 68Ga-Pentixafor PET/CT to discriminate PA forms with unilateral from bilateral excess aldosterone production, so as to determine whether to choose surgical treatment.
62324205|NCT06658873||Group P|Radial arterial cannulation from the proximal part af the artery 5 cm proximal to the level of the styloid process.
62483370|NCT02421653|EXPERIMENTAL|IODISED OIL + INERT MNP|Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
62483371|NCT02421653|ACTIVE_COMPARATOR|NON-IODISED MNP + INERT OIL|Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
62483372|NCT03013413|EXPERIMENTAL|Diagnostic (elastography imaging using the Aixplorer system)|Patients undergo ultrasound-based elastography imaging using the Aixplorer system followed by standard of care ultrasound-guided prostate biopsy over approximately 25 minutes.
62483373|NCT00507117|ACTIVE_COMPARATOR|PSG|
62483374|NCT03283358|EXPERIMENTAL|Person-centered follow up|The intervention program is a person-centered health promotion program led by a nurse and consists of two telephone calls (15 minutes each) at two weeks and nine months after surgical treatment for Intermittent Claudication and three visits (45 - 60 min) at six weeks, six months and one year after treatment. The program includes a baseline assessment, an individual plan for self-care and educational information about Intermittent Claudication, received treatment and secondary prevention (medication and modifiable risk factors). The purpose is to enhance self-care in terms of adherence to medication and to recommended changes of lifestyle.
62324206|NCT03912922|EXPERIMENTAL|Sit regime|Subjects will follow the sit regime during four days. Each day consists of 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
62324207|NCT03912922|EXPERIMENTAL|Sit less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 3 hours walking, 4 hours standing and 8 hours sleeping.
62324208|NCT03912922|EXPERIMENTAL|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours sitting, 1 hour walking, 1 hour standing, 1 hour exercise and 8 hours sleeping. The cycle session will be at approximately 60% maximal power. Exact cycling intensity and duration will be calculated to ensure equal total energy expenditure between the sitting less and the exercise regime.
62324209|NCT04615689||Infants with febrile urinary tract infection|The investigators will recruit infants hospitalized for acute febrile urinary tract infection. Before starting antibiotics treatment, The investigators will collect feces with the informed consents from infants' parents.
62324210|NCT04615689||Healthy infants|The investigators will recruit healthy controls from the clinics for routine check up with the informed consents from infants' parents.
62324211|NCT01710228|PLACEBO_COMPARATOR|Methylprednisolone placebo|"subjects will be randomized 1:1 to receive either:~1. Methylprednisolone placebo or~2. Methylprednisolone"
62324212|NCT01710228|EXPERIMENTAL|methylprednisolone|"subjects will be randomized 1:1 to receive either:~1. Methylprednisolone placebo or~2. Methylprednisolone"
62324213|NCT01902420||patients with acromegaly|patients with acromegaly caused by a growth hormone secreting pituitary adenoma
62324214|NCT01902420||healthy control|healthy volunteers without a personal or family history of pituitary adenoma
62324215|NCT06035432||Open access software 1|
62324216|NCT06035432||Open access software 2|
62483375|NCT03283358|NO_INTERVENTION|Standard follow up|Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
62324217|NCT06035432||Non open access paid software 1|
62324218|NCT06035432||Non open access paid software 2|
62324219|NCT05300867|ACTIVE_COMPARATOR|Robotic|
62483376|NCT02606032|ACTIVE_COMPARATOR|Metronidazole+doxycylcine+terbinafine|Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days
62483377|NCT02606032|PLACEBO_COMPARATOR|Placebo|Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days
62324220|NCT05300867|ACTIVE_COMPARATOR|Controll|
62324221|NCT06278987|EXPERIMENTAL|PENG block and cryoablation|Patients undergoing hip fracture repair aged 18-85
62324222|NCT06278987|EXPERIMENTAL|fascia iliaca compartment block|Patients undergoing hip fracture repair aged 18-85
62483378|NCT02856308|EXPERIMENTAL|Hairstetics hair implant device|Subjects will undergo the Hairstetics prosthetic hair implantation starting with a test of up to 100 fibers and up to 2 additional implantation sessions with up to 1500 fibers overall per subject. The implantation will be carried out according to the device IFU.
62324223|NCT02487628|EXPERIMENTAL|HQ® Matrix Soft Tissue Mesh|HQ® Matrix Soft Tissue Mesh is a warp-knitted, multifilament, bioengineered scaffold which is comprised of the silk fibroin protein of the Bombyx mori (B. mori) silkworm. The porous network structure makes it soft and pliable and convenient to implant. The mesh is mechanically strong, biocompatible, and long-term bioresorbable. The pore size is suitable for macrophage migration and recruitment, which hinders bacteria growth. The mesh is provided in single sheets of varying widths and lengths and may be cut to the shape or size desired for a specific application. It is sterile and for single-patient use only.
61930561|NCT01119560||Ancillary-Correlative (Questionnaire, saliva & tissue sample)|The biologic mother of the patient is asked to complete a Diet History Questionnaire about diet during pregnancy, and information on demographics, lifestyle factors, medication used during pregnancy, history of breast feeding, and family history of cancer or birth defects. Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen samples are collected from both biologic parents and the patient. Tissue samples previously stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted from samples, amplified and analyzed using real-time PCR quantitation assay, and genotyped using single nucleotide polymorphisms.
61930562|NCT06430346|EXPERIMENTAL|Exercise prehabilitation|In this trial participants will participate in an exercise program for 5 to 17 weeks, varying with treatment plans. Participants will receive resistance training equipment and participate in resistance training sessions twice per week (approximately 30-45 minutes per session). A Fitbit device will be provided to monitor step counts.
61930563|NCT04974047|EXPERIMENTAL|Cohort A (Responder)|Participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% will receive 3 cycles of tislelizumab (200 milligrams \[mg\]/cycle) plus 2 cycles of chemotherapy doublet (cisplatin + paclitaxel)
61930564|NCT04974047|EXPERIMENTAL|Cohort B (Non-responder)|Participants with a decrease in PET SUVmax \< 35% will receive 3 cycles of tislelizumab (200 mg/cycle) plus 2 cycles of investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) plus concurrent radiotherapy (40 grays/20 fractions).
61930565|NCT06428045|EXPERIMENTAL|Part 1: STARLITE Dose Escalation/De-Escalation Cohort|"Participants in this group will undergo Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MR-guided LITT) on Day 0 after stereotactic needle biopsy. On Day 7, participants will begin combination antiretroviral therapy (ART) consisting of Abacavir, Lamivudine, and dose escalation/de-escalation of Ritonavir (RTV), to determine the recommended Phase 2 dose (RP2D) of Ritonavir. Participants will receive up to 12 months of ART.~Beginning Day 14 through Day 180, participants will receive adjuvant therapy, standard of care consisting of focal radiotherapy and Temozolomide therapy. Participants will receive focal radiotherapy for six weeks (42 days). Participants will be administered Temozolomide up to Day 180.~Participants will receive up to 12 months of study therapy, followed by up to 12 months of follow-up. Total participation duration is up to 24 months."
61930566|NCT06428045|EXPERIMENTAL|Part 2: STARLITE Dose Expansion Cohort|"Participants in this group will undergo Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MR-guided LITT) after biopsy on Day 0. On Day 7, participants will begin combination antiretroviral therapy (ART) consisting of Abacavir, Lamivudine, and the recommended phase 2 dose (RP2D) of Ritonavir determined in Part 1. Participants will receive up to 12 months of ART.~Beginning Day 14 through Day 180, participants will receive adjuvant therapy, standard of care consisting of focal radiotherapy and Temozolomide therapy. Participants will receive focal radiotherapy for six weeks (42 days), and Temozolomide therapy, during and following radiotherapy up to Day 180.~Participants will receive up to 12 months of study therapy, followed by up to 12 months of follow-up. Total participation duration is up to 24 months.~Total participation is approximately two years."
61930567|NCT05039853|EXPERIMENTAL|A brief cognitive task-based based intervention|Participants will engage in a brief cognitive task including: a memory reminder procedure, playing the computer game, Tetris, on a smart-device using mental rotation +/- Booster.
61930568|NCT05039853|PLACEBO_COMPARATOR|Placebo activity|Participants will engage with a placebo activity: listening to a pod-cast for approximately 15 minutes on a smart-device.
61930569|NCT06707753|EXPERIMENTAL|AL-001 Dose 1|Injection of low dose
61930570|NCT06707753|EXPERIMENTAL|AL-001 Dose 2|Injection of medium dose
61930571|NCT06707753|EXPERIMENTAL|AL-001 Dose 3|Injection of high dose
61930572|NCT04091750|EXPERIMENTAL|Single Arm|Nivolumab 3mg/kg IV plus Ipilimumab 1mg/kg IV every 3 weeks x 4 cycles with Cabozantinib 40mg PO daily for 12 weeks (Induction); Followed by Maintenance therapy: Nivolumab 480mg IV every 4 weeks for up to 92 weeks; Cabozantinib 40mg PO daily for up to 92 weeks; Maintenance therapy will continue for up to 92 weeks to complete 2 years total of treatment if tolerating therapy well and disease is controlled.
61930573|NCT02745210|EXPERIMENTAL|Experimental|13C Magnetic resonance (MR) spectroscopy.
61930574|NCT05887648|EXPERIMENTAL|SinDance|Participants in the SinDance group will attend an educational briefing session on the importance of exercising, and participate in a 6-week SinDance exergame intervention
61930575|NCT05887648|NO_INTERVENTION|Control|Participants in the control group will attend usual activities offered by the senior activity centres. The control group will be offered an opportunity to play the SinDance exergame after completing the last data collection (i.e. 3-months from baseline).
61930576|NCT03708627|EXPERIMENTAL|Bimatoprost in more proptotic eye|Patients instill Bimatoprost in their more proptotic eye one nightly
61930577|NCT03708627|NO_INTERVENTION|Control|Bimatoprost is not instilled in the patient's fellow eye
61930578|NCT02750943|EXPERIMENTAL|Stannous Fluoride|Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
61930579|NCT02750943|ACTIVE_COMPARATOR|Sodium Monofluorophosphate|Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
61944524|NCT02655978||Healthy Volunteers|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
62483379|NCT03785730|EXPERIMENTAL|Non-restorative cavity control - NRCC|Enlargement with metallic sandpaper associated with toothbrushing/1000 ppm fluoride toothpaste.
62483380|NCT03785730|ACTIVE_COMPARATOR|Resin composite restoration - RCR|Selective carious lesion removal and restoration with resin composite.
62483381|NCT01732224|EXPERIMENTAL|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
61930580|NCT03334708||Locally Advanced or Metastatic Pancreatic Cancer Cohort|For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.
61930581|NCT03334708||Acute Benign Pancreatic Pathology Control Cohort|For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter
61930582|NCT03334708||Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl|For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.
61930583|NCT03334708||Healthy Control|For normal controls, blood specimens will be drawn once at study baseline.
61930584|NCT02788474|PLACEBO_COMPARATOR|placebo|
61930585|NCT02788474|EXPERIMENTAL|nintedanib|
61930586|NCT02188342|EXPERIMENTAL|HIT exercise training|
61930587|NCT04597164||Artificial liver support system group|100 patients in this group will receive treatment of double plasma molecular adsorption system, low volume plasma exchange, and comprehensive internal medical treatment
61930588|NCT04597164||Comprehensive medical treatment group|100 patients in this group will receive comprehensive internal medical treatment.
61930589|NCT05235139|EXPERIMENTAL|IOL implantation experimental|Experimental arm: Premium monofocal intraocular lens.
61930590|NCT05235139|ACTIVE_COMPARATOR|IOL implantation active comparator|Comparator arm: EDOF intraocular lens.
61930591|NCT03913546|SHAM_COMPARATOR|Sham spinal manipulation|Participants in the 'sham' group will receive a sham mechanical thrust (force set at level 0) instead of an actual one. In the force level 0, no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition. Therefore, the subject does not distinguish between intervention or placebo.
61930592|NCT03913546|EXPERIMENTAL|Actual spinal manipulation|Participants in the actual actual spinal manipulative therapy (SMT) group will be assessed through the Activator basic method. SMT will be performed with the Activator IV Adjusting Instrument (Activator Methods International, Phoenix, AZ) varying the force level depending on the adjusted segment.
61930593|NCT06166004|EXPERIMENTAL|BalanceTrainer|"Balance Trainer Exercises (30 min) Person-Specific Rehabilitation Program~1. Stretching and Strengthening Exercises~2. Mat Activities~3. Joint Range of Motion Exercises~4. Static and Dynamic Balance Exercises~5. Walking Exercises"
61930594|NCT06166004|OTHER|Control Group|"Person-Specific Rehabilitation Program~1. Stretching and Strengthening Exercises~2. Mat Activities~3. Joint Range of Motion Exercises~4. Static and Dynamic Balance Exercises~5. Walking Exercises"
61930595|NCT05942027|PLACEBO_COMPARATOR|Group 1: Control group|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b). Patients will be treated with ramipril 10 mg/day and a placebo match Coenzyme Q10 capsules once per day.The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
61930596|NCT05942027|ACTIVE_COMPARATOR|Group 2: Coenzyme Q10|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b).Patients will be treated with ramipril 10 mg/day and Coenzyme Q10 capsules (CoQ10) 200 mg/day.The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
61930597|NCT06520670||Patient with Lupus nephritis diagnosed by biopsy.|
61930598|NCT06520670||Patient with SLE without nephritis.|
61930599|NCT06520670||Patient with nephritis of other reasons|Patient with nephritis of other reasons; acute proliferative glomerulonephritis (postinfectious and infection associated), crescentic glomerulonephritis, else.
62483382|NCT01732224|ACTIVE_COMPARATOR|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
62483383|NCT02990286|EXPERIMENTAL|Rituximab with Mycophenolate Mofetil|
62483384|NCT02990286|PLACEBO_COMPARATOR|Placebo of rituximab with Mycophenolate Mofetil|
61930600|NCT06293924||Pericarditis patients|Patients with acute idiopathic or post-cardiac injury pericarditis who require diagnostic or therapeutic pericardiocentesis. Four ml of pericardial fluid should be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 ethylenediaminetetraacetic acid (K3-EDTA) tubes.
61930601|NCT06293924||Pericardial effusion patients without inflammation|Subjects with non-inflammatory pericardial effusion who require diagnostic or therapeutic pericardiocentesis. Four ml of pericardial fluid should be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes.
61930602|NCT06293924||Cardiac surgery pericardial effusion|Patients who undergo cardiac surgery that involves a pericardiotomy. During cardiac surgery, 4 ml of pericardial fluid is collected and analyzed upon opening the pericardial sac. Four ml of pericardial fluid should be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes.
61930603|NCT02804529|EXPERIMENTAL|Meng's Point entry|Meng's entry involved a 0.2 cm horizontal or vertical incision using the Veress needle in the cross of lateral border of the left rectus abdominis and rib arch.
61930604|NCT02804529|EXPERIMENTAL|Palmer's Point entry|Palmer's entry involved a 0.2 cm horizontal or vertical incision with the Veress needle in the left midclavicular line approximately 3 cm caudal to the 10th rib
61930605|NCT02804529|EXPERIMENTAL|Periumbilllicus entry|Periumbilllicus entry involved a 0.2 cm horizontal or vertical midline incision using the Veress needle in the lower or uper border of the umbilicus.
61930606|NCT02642874|EXPERIMENTAL|Methocarbamol|Methocarbamol twice daily
61930607|NCT02642874|PLACEBO_COMPARATOR|placebo|Calcium carbonate twice daily
62483385|NCT02254005|EXPERIMENTAL|single dose escalation|
62483386|NCT05235854|ACTIVE_COMPARATOR|Meniscal wall infiltration group|Administration of Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe under ultrasound control.
62483387|NCT05235854|ACTIVE_COMPARATOR|Intra-articular infiltration group|"The procedure is identical in all respects to the experimental group, except that the ultrasound procedure is mimicked and the infiltration of dexamethasone 2 mg (Diprostene®) is performed intra-articularly.~Administration Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe."
62483388|NCT03494127|EXPERIMENTAL|Group A|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
62483389|NCT03494127|EXPERIMENTAL|Group B|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
61930608|NCT05321927|SHAM_COMPARATOR|Control group|Sham stimulation will be applied over rectus femoris, tibialis anterior, the median nerve and the thenar eminence on both sides for 10 min to each limb, one at a time. Stimulation is delivered for 10 min to each limb, one at a time in three 10 minute sessions per week, for 4 weeks.
61930609|NCT05321927|ACTIVE_COMPARATOR|Strength-training group|Three training sessions for 10 minutes per muscle per week, for 4 weeks during which sham stimulation will be applied.
61930610|NCT05321927|ACTIVE_COMPARATOR|Trancutaneous Electrical Nerve Stimulation (TENS)|Trancutaneous Electrical Nerve Stimulation (TENS) stimulation applied over rectus femoris, tibialis anterior, the median nerve and the thenar eminence on both sides for 10 min to each limb, one at a time. Stimulation is delivered for 10 min to each limb, one at a time in three 10 minute sessions per week, for 4 weeks.
61930611|NCT05321927|EXPERIMENTAL|TENS with strength training|Three training sessions for 10 minutes per muscle per week, for 4 weeks during which Trancutaneous Electrical Nerve Stimulation (TENS) stimulation is applied over rectus femoris, tibialis anterior, the median nerve and the thenar eminence on both sides for 10 min to each limb, one at a time.
61930612|NCT06475274|EXPERIMENTAL|RMC-035 high-dose|RMC-035 60 mg
61930613|NCT06475274|EXPERIMENTAL|RMC-035 low-dose|RMC-035 30 mg
62483390|NCT06182722||Major Depressive Disorder (MDD)|Patients with major depressive disorder. These patients consisted of two cohorts. The first cohort is expected to consist of 15 participants for nested cohort study. The rest form the second cohort.
61930614|NCT06475274|PLACEBO_COMPARATOR|Placebo|Placebo (tris-buffer)
61930615|NCT05916430||General Population Screening Cohort|A general population cohort of 9-month-old infants presenting for well-child visits will be screened initially at 9 months of age, and then screened again sequentially at 12, 15, 18, 21, and 24 months, to test screening performance relative to outcome status with autism or developmental disabilities.
61930616|NCT03519386|EXPERIMENTAL|Implant Group 1|G2-TR intraocular implant containing travoprost 75 mcg with high elution rate, plus postoperative placebo eye drops.
61930617|NCT03519386|EXPERIMENTAL|Implant Group 2|G2-TR intraocular implant containing travoprost 75 mcg with low elution rate, plus postoperative placebo eye drops.
61930618|NCT03519386|ACTIVE_COMPARATOR|Control Group|Sham surgery + active-comparator eye drops
61930619|NCT00925990|EXPERIMENTAL|CTS-1027 + ribavirin|Study drug plus ribavirin
61930620|NCT00925990|EXPERIMENTAL|CTS-1027 + placebo|Study drug plus placebo for ribavirin
61930621|NCT05798611|EXPERIMENTAL|Arm 1 [ART0380 monotherapy (endometrial cancer patients)]|Patients with persistent or recurrent endometrial cancer (EC) will receive ART0380 monotherapy in one of two dose regimens for a 21-day cycle.
61930622|NCT05798611|EXPERIMENTAL|Arm 2 [ART0380 monotherapy (solid tumors patients)]|Patients with advanced or metastatic solid tumors will receive ART0380 monotherapy in one of two dose regimens for a 21-day cycle.
61930623|NCT05146154|EXPERIMENTAL|Pharmacokinetic cohort|After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.
61930624|NCT05146154|EXPERIMENTAL|Safety cohort|After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm
61930625|NCT04426812||MTurk sample|Data collected from a sample of participants in an online convenience platform called MTurk who self-identify as having chronic pain.
61930626|NCT04426812||KnowledgePanel|Data collected from a sample of panel members in an online representative panel called KnowledgePanel who self-identify as having chronic pain.
61930627|NCT06545825||Standard enteral nutrition|Patients with prolonged or chronic critical illness and brain injury receiving standard enteral nutrition
61930628|NCT05080660|EXPERIMENTAL|LY3526318|Participants received 250 mg of LY3526318 orally, once daily for the first 4 weeks and were switched to placebo once daily for the next 4 weeks of the treatment period.
61930629|NCT05080660|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally, once daily, for 8-weeks treatment period.
61930630|NCT04180215|EXPERIMENTAL|Ph I, Group 1 and Group 2|Patients with HPV 16+ HNSCC or Non-HNSCC who had tumor progression or recurrence on standard of care therapy.
61930631|NCT04180215|EXPERIMENTAL|Ph I, Group 3 and Group 4|Patients with HPV 16+ HNSCC or Non-HNSCC who had tumor progression or recurrence on standard of care therapy.
61930632|NCT04180215|EXPERIMENTAL|Ph II, Group B|Patients with HPV 16+ HNSCC who are eligible to receive immune checkpoint inhibitor as part of standard of care.
61930633|NCT04180215|EXPERIMENTAL|Ph II, Group E|Patients with HPV 16+ HNSCC who are eligible to receive pembrolizumab as part of 1L standard of care.
61930634|NCT04180215|EXPERIMENTAL|Ph II, Group F|Patients with HPV 16+ cancers who had tumor progression or recurrence on standard of care therapy and who are eligible to receive pembrolizumab as part of 2L+ standard of care..
61930635|NCT04180215|EXPERIMENTAL|Ph I, sub-study|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy
62324224|NCT02487628|ACTIVE_COMPARATOR|ULTRAPRO® Partially Absorbable Lightweight Mesh|ULTRAPRO® Partially Absorbable Lightweight Mesh (Ethicon, Inc.) is manufactured from approximately equal parts of absorbable poliglecaprone-25 monofilament fiber and non-absorbable polypropylene monofilament fiber. Designed for open and laparoscopic hernia repairs, it allows surgeons the versatility to perform various hernia repairs with a single technology. It offers excellent strength with minimal foreign body mass, to allow patients to heal more naturally with increased comfort and mobility.
62483391|NCT06182722||Healthy controls|Healthy normal volunteers.
61930636|NCT05035511|EXPERIMENTAL|Responders vs Non-responders|After the tDCS outcome recorded immediately after tDCS treatment, participants will be categorized into responders and non-responders based on the percentage of change in the total SRS score (primary outcome). Participants that show reductions of at least 10% in the total SRS scores as compared to baseline scores will be considered responders.
61930637|NCT02204007|EXPERIMENTAL|3D imaging, surrogate bone model|3D imaging \& surrogate bone model
62324225|NCT05331612|EXPERIMENTAL|Blended intervention condition|"Blended intervention condition, consisting of 5 face-to-face group sessions lasting 2 hours every 2 weeks, alternated with the online treatment protocol carried out by the participants in a self-applied. The intervention has a period of duration of 13 weeks and it is composed by 8 modules (Motivation for change, Psychoeducation, Stimulus control, Cognitive restructuring, Urge surfing and emotion regulation, Planning of significant activities, Coping skills and exposure with response prevention, and Relapse prevention). These modules is based in the online platform and manualized protocol treatment Sin jugar, ganas (Díaz-Sanahuja et al., 2021)."
62483392|NCT02625974|EXPERIMENTAL|Nifurtimox 60 days / Arm 1|Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
61930638|NCT02204007|NO_INTERVENTION|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
62483393|NCT02625974|EXPERIMENTAL|Nifurtimox 30 days / Arm 2|Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
62483394|NCT04150029|EXPERIMENTAL|MBG453+Venetoclax +Azacitidine|Patients will receive MBG453 in combination with Venetoclax and Azacitidine
62483395|NCT04660864|EXPERIMENTAL|Rhinochill|Treatment with nasal cavity cooling 10 minutes during three consecutive migraine attacks.
61930639|NCT00750880|EXPERIMENTAL|1|
61944525|NCT02655978||Medically Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
61944526|NCT02655978||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).
61944527|NCT02737280|ACTIVE_COMPARATOR|Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
61944528|NCT02737280|EXPERIMENTAL|High flow oxygen therapy|High flow nasal cannula oxygen therapy with Airvo (TM, Fisher \& Paykel Healthcare) device
61944529|NCT03666624|EXPERIMENTAL|Personalized care network|9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
61944530|NCT03666624|NO_INTERVENTION|Routine medical care|No intervention
61944531|NCT04238416|EXPERIMENTAL|IV BCAA + Lactulose|IV Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
61944532|NCT04238416|ACTIVE_COMPARATOR|Lactulose alone|Oral Lactulose alone
61944533|NCT01191918|EXPERIMENTAL|donepezil|donepezil plus Lithium
61944534|NCT01191918|PLACEBO_COMPARATOR|Control|Placebo plus Lithium
61944535|NCT01593189|EXPERIMENTAL|KITS Program|The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
61944536|NCT01593189|NO_INTERVENTION|Services as usual|Families continued to receive any services that they had been receiving in the community.
61944537|NCT03879395||Cohort|Patients with stage IV malignant melanoma with abdominal metastasis (M1c) that underwent abdominal surgery with metastasectomy during the study period.
61944538|NCT03867188|EXPERIMENTAL|Liiposomal Bupivacaine Group|Qualified participants with a soft tissue sarcoma of the thigh will be given the alternative protocol utilizing liposomal bupivacaine (Exparel®). The alternative protocol will utilize general or spinal anesthesia, but will also include the use of intraoperative liposomal bupivacaine instead of a regional nerve block.
61944539|NCT03867188|NO_INTERVENTION|Control Group|A retrospective control group will be assembled from electronic medical records of 3 patients who underwent resection of a soft tissue sarcoma of the thigh and will be accessed and analyzed for the variable of interest.
62483396|NCT02922569|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training and mindfulness training requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
62483397|NCT02922569|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training and traumatic brain injury information session requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
62483398|NCT02991196|EXPERIMENTAL|DS-8273a + nivolumab|Participants will receive their treatment dose until discontinuation for any reason, or trial completion, within two years
61944540|NCT03564431||controls|
61944541|NCT03564431||T2DM patients|
61944542|NCT03564431||depression patients|
62324226|NCT05331612|NO_INTERVENTION|Waiting list control condition|Waiting list control group receives the blended treatment when the intervention has finished in the experimental group (blended group intervention).
61944543|NCT03564431||T2DM with depression patients|
62324227|NCT01427569|EXPERIMENTAL|IZN-6D4 Gel|patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel
62483399|NCT02853643|EXPERIMENTAL|25 mg Dose|Single dose of 25 mg ASN002
61944544|NCT06419335|EXPERIMENTAL|Cohort 1 Crohn's Disease Patients with Fatigue|
62483400|NCT02853643|EXPERIMENTAL|50 mg Dose|Single dose of 50 mg ASN002
62483401|NCT02853643|EXPERIMENTAL|100 mg Food effect cross over|100 mg single dose under both fasted and fed conditions in a cross over fashion
61944545|NCT06419335|NO_INTERVENTION|Cohort 2 Crohn's Disease without Fatigue|
61944546|NCT06419335|EXPERIMENTAL|Cohort 3 Healthy Volunteers|
61944547|NCT02959983|ACTIVE_COMPARATOR|Eluxadoline|Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
61944548|NCT02959983|PLACEBO_COMPARATOR|Placebo|Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
61944549|NCT03475680|EXPERIMENTAL|"1)  MBP and oral antibiotics  group"|"Sennosides colonic preparation Oral Gentamycin Oral Ornidazole~* Sennosides colonic preparation (X-PREP) :~  1 per day, on day -2 and day -1.~* Gentamycin :~  80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~* Ornidazole :~  1. g per day (2 tablet per day), on day -2 and day -1; In tablets."
62483402|NCT05900648|EXPERIMENTAL|Regorafenib and XmAb20717|Participants will receive regorafenib and XmAb20717 for up to 6 cycles (6 months). Participants will take regorafenib by mouth on Days 1-21 of each cycle. Participants will rest (not take regorafenib) on Days 21-28 of each cycle. Participants will also receive XmAb20717 by vein on Days 1 and 15 of each cycle. Each infusion should take about 60 minutes.
62324228|NCT01427569|PLACEBO_COMPARATOR|Placebo Hydrogel|patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4
62324229|NCT03536429|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62324230|NCT03536429|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62324231|NCT01752842|EXPERIMENTAL|Fenofibrate|One fenofibrate 160 mg capsule per day for 12 weeks
62324232|NCT01752842|PLACEBO_COMPARATOR|Placebo for fenofibrate|One inert sugar pill per day for 12 weeks
62324233|NCT01990599|OTHER|Nasopharyngeal Tube|Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention.
62324234|NCT05326750|EXPERIMENTAL|Real tACS|Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
62324235|NCT05326750|PLACEBO_COMPARATOR|Sham tACS|Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus)
62324236|NCT01386099|EXPERIMENTAL|PSN821|
62324237|NCT01386099|PLACEBO_COMPARATOR|Placebo|
62324238|NCT06693388|ACTIVE_COMPARATOR|Serial Casting Only|
62324239|NCT06693388|ACTIVE_COMPARATOR|Serial Casting + Exercise|
62324240|NCT06693388|ACTIVE_COMPARATOR|Serial Casting + Exercise + WBV|
62324241|NCT02017678|EXPERIMENTAL|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
62324242|NCT05387395||complete vaccination|Complete vaccination was defined as administering two doses of mRNA or AstraZeneca vaccine, administration of one dose of Jansen vaccine, or administration of one dose of any vaccine in patients with a history of COVID19 infection.
62324243|NCT05387395||incomplete vaccination|Other cases were defined as incomplete or absent vaccination.
62324244|NCT00005655|EXPERIMENTAL|1|rhIL-12 in combination with rhIL-2
62324245|NCT06250283|EXPERIMENTAL|Resveratrol|Dietary Supplement: Resveratrol (500 mg) + 500 mg calcium and 400 IU vitamin D3
61930640|NCT03174197|EXPERIMENTAL|Adjuvant phase (temozolomide, atezolizumab)|Patients receive temozolomide PO on days 1-5 and atezolizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62324246|NCT06250283|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo (500 mg) + 500 mg calcium and 400 IU vitamin D3
62324247|NCT05511246|ACTIVE_COMPARATOR|Control|Endocardial radiofrequency ablation of ventricular tachycardia
62324248|NCT05511246|EXPERIMENTAL|Venous ethanol|Endocardial radiofrequency ablation of ventricular tachycardia combined with venous ethanol ablation of the tachycardia substrate
62324249|NCT04174105|EXPERIMENTAL|Initial Dose Cohort|3x10\^13 vg/kg of AT845 administered via intravenous infusion
62324250|NCT04174105|EXPERIMENTAL|Second Dose Cohort|6x10\^13 vg/kg of AT845 administered via intravenous infusion
62324251|NCT04174105|EXPERIMENTAL|Third Dose Cohort|1x10\^14 vg/kg of AT845 administered via intravenous infusion
62324252|NCT04246177|EXPERIMENTAL|Lenvatinib plus Pembrolizumab plus TACE|Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years \[\~35 cycles\] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (\~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
62324253|NCT04246177|ACTIVE_COMPARATOR|Oral Placebo plus IV Placebo plus TACE|Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (\~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (\~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
62483403|NCT05572398|EXPERIMENTAL|STAC-T|"STAC-T is a brief technology-based bullying bystander intervention using four strategies: Stealing the show, Turning it over, Accompanying others, and Coaching compassion. The online curriculum is delivered to middle-school students."
61930641|NCT03174197|EXPERIMENTAL|Concurrent phase (temozolomide, atezolizumab, RT)|Patients receive temozolomide PO daily on days 1-42 and atezolizumab IV over 30-60 minutes on day 1, 15, 29, and 42. Patients undergo RT 5 days per week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
62324254|NCT01675219|EXPERIMENTAL|Group B|Blue light TUR-BT with no adjuvant instillations
62324255|NCT01675219|ACTIVE_COMPARATOR|Group A|White light TUR-BT with no adjuvant instillations
62324256|NCT01675219|EXPERIMENTAL|Group C|White light TUR-BT with six weekly optimized mitomycin-C instillations.
62324257|NCT01675219|EXPERIMENTAL|Group D|Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.
62324258|NCT06115421|EXPERIMENTAL|oral low doses of Roxadustat three times weekly plus iron supplement,|
62324259|NCT06115421|ACTIVE_COMPARATOR|Erythropoiesis-stimulating agents (ESAs)|
62324260|NCT02107911||men who have sex with men|MSM who seek voluntary HIV counseling and testing service at the Anonymous Clinic, TRC-ARC, including those who describe risky sexual exposure to HIV within the preceding 72 hours and meet nPEP criteria.
62483404|NCT05572398|NO_INTERVENTION|Assessment Only Control|
62483405|NCT00740103|EXPERIMENTAL|1|Semapimod 60 mg IV x 3 days q 6 - 8 weeks
62324261|NCT03615846||Dual Anti-Platelet Therapy (DAPT)|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
62324262|NCT03615846||One Anti Platelet Medication Only|"Whole blood from patients who are currently receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
62324263|NCT03615846||naive|No medication with anti-platelet effects There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care.
62324264|NCT00450372|EXPERIMENTAL|ADI-PEG 20|
62483406|NCT01902719|EXPERIMENTAL|Community Health Worker (CHW) Intervention|Participants randomized to this arm will receive the Community Health Worker Intervention that will include training in the use of home blood pressure machine, education on diet and exercise, and one-on-one support to assist with overcoming barriers to hypertension control (e.g., accessing healthcare, social and community services).
62483407|NCT01902719|EXPERIMENTAL|CHW Intervention and Communication Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and a communication skills training to partner with their physician providers in a way that encourages their greater involvement and shared decision-making with their physicians about hypertension care.
62324265|NCT04497558|EXPERIMENTAL|ERA group|In the experimental group, those patients undergo endometrial receptivity array. According to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out.
62483408|NCT01902719|EXPERIMENTAL|CHW and Problem Solving Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and the Problem Solving Skills Training Intervention, a 9-week peer based self-management intervention to help patients improve their hypertension self-management by learning and employing skills to overcome their self-identified barriers to self-management.
61930642|NCT02406950|EXPERIMENTAL|Sitagliptin|All participant will exam brachial artery endothelium-dependent flow-mediated dilatation (FMD). After then, pneumatic cuff wiil be inflated to 200 mmHg for 15 minutes to induce brachial artery ischemia. At the end of ischemia, 15 minutes of reperfusion was performed to induce reperfusion injury. After ischemia-reperfusion (IR) injury, brachial artery FMD will be measured again. After randomization, sitagliptin group will be treated by single dose of sitagliptin (Januvia) 50mg. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
61930643|NCT02406950|PLACEBO_COMPARATOR|Placebo|After brachial artery FMD measurement, IR injury for each 15 minutes will be performed, and brachial artery FMD will be measured again. After randomization, placebo group will be treated by nothing. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
61930644|NCT02406950|OTHER|Sitagliptin and glibenclimide|If sitagliptin treatment show preventive effects of IR injury, the investigator will perform additional experiment to explore the mechanism (Protocol 2 study). Additional 15 healthy volunteers will be treated 5 mg of glibenclamide (Euglucon) 1 hour before administration of 50 m g of sitagliptin. In 2 hours after sitagliptin administration, FMD measurement before and after IR injury will be performed as described above.
61930645|NCT02676466|EXPERIMENTAL|Fish oil Active|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
61930646|NCT02676466|PLACEBO_COMPARATOR|Fish oil Placebo|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
61930647|NCT02676466|ACTIVE_COMPARATOR|Losartan Active|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
61930648|NCT02676466|PLACEBO_COMPARATOR|Losartan Placebo|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
61930649|NCT02676466|ACTIVE_COMPARATOR|Fish oil Active + Losartan Active|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
61930650|NCT02676466|OTHER|Fish oil Active + Losartan Placebo|"This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.~In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan."
62324266|NCT04497558|NO_INTERVENTION|Control group|In the control group, those patients do not receive any treatment before next cycle of transfer. In the control group, no intervention will be performed.
61930651|NCT02676466|OTHER|Fish oil Placebo + Losartan Active|"This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.~In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months."
62483409|NCT06133101|PLACEBO_COMPARATOR|2% Fat Cows Milk|Participants randomized to this arm will consume 2% fat cow's milk twice daily for 12 weeks.
62483410|NCT06133101|EXPERIMENTAL|Standard Soy Milk|Participants randomized to this arm will consume standard soy milk twice daily for 12 weeks.
61930652|NCT02676466|OTHER|Fish oil Placebo + Losartan Placebo|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
62483411|NCT01221129||Dietary Restriction|
62483412|NCT00387933|EXPERIMENTAL|Gleevec + PTK787/ZK 22584 + Hydroxyurea|Patients with recurrent or relapsing glioblastoma multiforme (GBM) will be given daily doses of Gleevec and PTK787/ZK 22584 orally in combination with fixed doses of hydroxyurea.
62483413|NCT04223791|EXPERIMENTAL|DOR/ISL|A fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and placebo to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) for 96 weeks.
62483414|NCT04223791|ACTIVE_COMPARATOR|BIC/FTC/TAF|50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to FDC DOR/ISL for 96 weeks. Participants will be offered the option to receive open-label FDC DOR/ISL from Week 144 to Week 156.
62483415|NCT06627946|EXPERIMENTAL|TAP group|Local anesthesia 0.25% bupivacine 20ml was administered at the transversus abdominis plane in TAP group (experiment)
62132302|NCT02587169|EXPERIMENTAL|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
62132303|NCT05685433|EXPERIMENTAL|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
62132304|NCT02351310|ACTIVE_COMPARATOR|Betamethasone|Betamethasone: 12 mg given intramuscularly (IM), 24 hours apart or if as in some hospitals occasionally occurs and betamethasone is unavailable - • 4 doses of Dexamethasone IM 6 mg, 12 hours apart
62132305|NCT02351310|PLACEBO_COMPARATOR|Normal Saline|Quantity Sufficient (QS) of Normal Saline (NS) given intramuscularly (IM), 24 hours apart or if hospital is using Dexamethasone in place of Betamethasone then administer NS x 4 doses 12 hours apart
62132306|NCT06114602||Pre-Intervention|Patients who have a medical appointment with a urologist in HIBA but did not receive any reminder.
62132307|NCT06114602||Post-Intervention|Patients who have a medical appointment with a urologist in HIBA but did receive an email reminder of the appointment.
62132308|NCT06181916|EXPERIMENTAL|Amp mHealth App|Amp, video-based, virtual support system on an mHealth platform with resources and tools to help YBMSM living with HIV become and stay virally suppressed.
62483416|NCT06627946|ACTIVE_COMPARATOR|WI group|Local anesthesia 0.25% bupivacine 20ml was administered or infiltrated along the cesarean wound in WI group as a an active comparator
62483417|NCT05001958|EXPERIMENTAL|Action observation|
62483418|NCT03423654|EXPERIMENTAL|Training Group|Spatial training
62483419|NCT03423654|OTHER|Control Group|Letter number matching
61930653|NCT02259218||Ancillary-Correlative|Prospectively collected blood, urine, and tissue samples are analyzed for potential predictive biomarkers via metabolomic and other molecular profiling.
62132309|NCT06181916|NO_INTERVENTION|Standard of Care|Standard of care (SOS) linkage to care services typically provided by linkage specialists, health navigators, or case workers.
62132310|NCT02075554|OTHER|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
62132311|NCT04545918||Infertile Female|90 female patients with infertility undergoing an ovarian stimulation with use of exogenous gonadotropins.
62132312|NCT03369509||hypersensitivity drug reaction|Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.
62132313|NCT05000424|EXPERIMENTAL|Intervention|Participants in this group will receive a fragrant plant based massage oil with the addition of clary sage essential oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
62132314|NCT05000424|PLACEBO_COMPARATOR|Control|Participants in this group will receive a fragrant plant based massage oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
62483420|NCT03340623||Mammary reconstruction by DIEP with venous coupler|
62132315|NCT00377182|ACTIVE_COMPARATOR|PEGASYS with COPEGUS|
62483421|NCT03340623||Mammary reconstruction by DIEP without venous coupler|
62132316|NCT00377182|EXPERIMENTAL|RO5024048 1500mg in combination with PEGASYS|
62132317|NCT00377182|EXPERIMENTAL|RO5024048 3000mg in combination with PEGASYS|
62132318|NCT00377182|EXPERIMENTAL|RO5024048 in combination with PEGASYS and COPEGUS|
62483422|NCT02901379|EXPERIMENTAL|Atorvastatin 80mg|Subjects who will receive atorvastatin 80mg for two weeks
62483423|NCT02901379|ACTIVE_COMPARATOR|Atorvastatin 10mg|Subject who will receive atorvastatin 10mg
62483424|NCT05315713|EXPERIMENTAL|Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) Tiragolumab|Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
62483425|NCT05315713|EXPERIMENTAL|Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IV|"Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)~Note: This arm did not enroll any participants."
62483426|NCT03698357|EXPERIMENTAL|Interactive video balance-based exercise|Fifteen participants in group A will undergo 30 minutes a day and 3 days a week interactive video balance-based exercise intervention for four weeks.
61930654|NCT06709417|EXPERIMENTAL|Experimental Arm|"Eligible participants will first receive two cycles of sintilimab in combination with liposomal paclitaxel and cisplatin. After two cycles, an evaluation will be conducted. Patients deemed eligible for surgery will undergo surgical resection, followed by up to one year of adjuvant sintilimab. The necessity of postoperative adjuvant radiotherapy will be determined by the investigator.~For patients deemed ineligible for surgery, concurrent chemoradiotherapy will be administered. Four weeks after the completion of concurrent chemoradiotherapy, a second surgical evaluation will be performed. Patients eligible for surgery at this stage will undergo surgical resection followed by adjuvant sintilimab treatment. Those who remain ineligible for surgery will continue sintilimab treatment after concurrent chemoradiotherapy."
61930655|NCT06448247|EXPERIMENTAL|SAD Cohorts 1-5 Experimental Arm|Participants will receive a single dose of SPY001-001 in a dose escalation format
61930656|NCT06448247|PLACEBO_COMPARATOR|SAD Cohorts 1-5 Placebo Arm|Participants will receive a single dose of placebo
61930657|NCT06448247|EXPERIMENTAL|MAD Cohorts 1-3 Experimental Arm|Participants will receive two doses of SPY001-001 in a dose escalation format
61930658|NCT06448247|PLACEBO_COMPARATOR|MAD Cohorts 1-3 Placebo Arm|Participants will receive two doses of placebo
61930659|NCT06448247|EXPERIMENTAL|SAD Cohorts 6-7 Experimental Arm|Participants of Japanese descent will receive a single dose of SPY001-001
61930660|NCT06448247|PLACEBO_COMPARATOR|SAD Cohorts 6-7 Placebo Arm|Participants of Japanese descent will receive a single dose of placebo
62324267|NCT03233776|EXPERIMENTAL|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
61930661|NCT06448247|EXPERIMENTAL|SAD Cohorts 8-9 Experimental Arm|Participants of Chinese descent will receive a single dose of SPY001-001
61930662|NCT06448247|PLACEBO_COMPARATOR|SAD Cohorts 8-9 Placebo Arm|Participants of Chinese descent will receive a single dose of placebo
61930663|NCT05992571|PLACEBO_COMPARATOR|Placebo|Single dose of a taste-matched calorie-free placebo
61930664|NCT05992571|EXPERIMENTAL|β-OHB|Single dose of a ketone monoester (\[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate; 0.6 g β-OHB/kg body weight)
61930665|NCT05961332|EXPERIMENTAL|Fundus autofluorescence (FAF) imaging|
61930666|NCT01456390|OTHER|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
61930667|NCT03472066||a group of women who have been conized|Previous conization
61930668|NCT03472066||control group with asymptomatic patients|on routine second trim no previous conization
61930669|NCT05668403|EXPERIMENTAL|B007:350mg|"B007:350mg Subcutaneous injection was administered on days 1 and 15~B007 matched Placebo Subcutaneous injection was administered on days 1 and 15"
61930670|NCT05668403|EXPERIMENTAL|B007:700mg|"B007: 700mg Subcutaneous injection was administered on days 1 and 15~B007 matched Placebo Subcutaneous injection was administered on days 1 and 15"
61930671|NCT05668403|EXPERIMENTAL|B007:1000mg|"B007: 1000mg Subcutaneous injection was administered on days 1 and 15~B007 matched Placebo Subcutaneous injection was administered on days 1 and 15"
61930672|NCT04014023|EXPERIMENTAL|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
61930673|NCT04014023|EXPERIMENTAL|DWP16001 Bmg|DWP16001 Bmg, Tablets, Orally, Once daily
62324268|NCT03422133||Pre-Implementation Phase|"Participants in this group (before the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.~Patients will be recruited using standardized procedures, and process and outcome measures will be recorded using the same tools and methods in both study phases to decrease the risk of measurement and selection bias."
62324269|NCT03422133||Post-Implementation Phase|Participants in this group (after the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
62324270|NCT00872170|ACTIVE_COMPARATOR|Intervention|Participants with thalassemia who have pulmonary hypertension will receive sildenafil for 12 weeks.
62324271|NCT00872170|NO_INTERVENTION|Control|Participants with thalassemia who do not have pulmonary hypertension will be part of a control group and will only be undergoing screening/baseline assessments.
62324272|NCT01929044|EXPERIMENTAL|Buscopan® (hyoscine butylbromide)|1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
62324273|NCT01929044|ACTIVE_COMPARATOR|654-II(anisodamine)|1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection
61930674|NCT04014023|EXPERIMENTAL|DWP16001 Cmg|DWP16001 Cmg, Tablets, Orally, Once daily
61930675|NCT04014023|PLACEBO_COMPARATOR|Placebo|Placebo, Tablets, Orally, Once daily
61930676|NCT03290079|EXPERIMENTAL|Pembrolizumab & Lenvatinib treatment|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks, in addition to 20 mg Lenvatinib by mouth every day of each 3 week cycle. Estimated average length of treatment per participant: 4 months.
62324274|NCT03477565|EXPERIMENTAL|Sperimental group|"Patients who belong to the sperimental group (SPER) will receive the standard treatment and Kinesio tape lymphatic drainage technique application.~The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and physiotherapy counseling."
61930677|NCT05677048|NO_INTERVENTION|Group 1 (Standard of Care Group)|"Participants (probands, those with a hereditary cancer syndrome) are sent a family letter to share with relatives. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic testing.~Relatives of probands randomized to the usual care arm will have access to the family letter if probands decide to share it with them, and will receive study surveys. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic testing"
61930678|NCT05677048|EXPERIMENTAL|Group 2 (Free genetic testing and counseling group)|Enrolled relatives will receive a letter and baseline survey with information to contact the tele-genetics company to arrange free genetic counseling and testing. This letter will be given to the relatives directly by the study
61930679|NCT05677048|EXPERIMENTAL|Group 3 (IGNITE-TX Group)|"Relatives of probands randomized to the IGNITE-TX intervention will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX Hub (access online educational material through a platform). Relatives will have also access services of a family genetic navigator. Study investigators and navigators will not directly provide genetic counseling and/or testing in this arm"
61930680|NCT05677048|EXPERIMENTAL|Group 4 (IGNITE-TX and free genetic testing and counseling group)|"Relatives randomized to this arm will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX Hub (access online educational material through a platform) and information to contact the tele genetics company. This arm will receive both the IGNITE-TX Intervention and access to free genetic testing and counseling services, as well as access to assistance from family genetic navigator"
62324275|NCT03477565|NO_INTERVENTION|Control group|"Patients who belong to the control group (CONTR) will receive only the standard treatment. Standard treatment consists in physiotherapy evaluation and counseling. The educational part, the demonstration of the exercises and the prosthesis mobilization are included in this treatment."
61930681|NCT01773772|EXPERIMENTAL|Progesterone|Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those \> or = 42 kg.
61930682|NCT01773772|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo at 1600 h and again at 2000 h.
61930683|NCT06710301|EXPERIMENTAL|Navigation task|Administration of the navigation task in an immersive virtual reality environment with recording of the EEG signal
61930684|NCT03205137||Telmisartan and hydrochlorothiazide group|
61930685|NCT03205137||Telmisartan and amlodipine group|
61930686|NCT03205137||Telmisartan+hydrochlorothiazide double-pill combination group|
61930687|NCT03205137||telmisartan+amlodipine double-pill combination group|
61930688|NCT02594241|ACTIVE_COMPARATOR|Methylprednisolone|Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.
61930689|NCT02594241|PLACEBO_COMPARATOR|Physiological saline|Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
61930690|NCT05885555|EXPERIMENTAL|Single-arm|All eligible participants will receive ianalumab at the same dose.
61930691|NCT03562637|EXPERIMENTAL|Adagloxad simolenin + OBI-821 in conjunction with SOC|"Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks.~Patient will also receive standard of care (SOC) treatment."
61930692|NCT03562637|ACTIVE_COMPARATOR|Standard of Care treatment|"Study visit intervals will be identical to those in Arm 1.~Patient will receive standard of care (SOC) treatment."
61930693|NCT03583164|EXPERIMENTAL|Olorofim (F901318)|"Olorofim (F901318) was given orally for up to 90 days in the Main Study Phase and could be continued for those participants entering the Extended Treatment Phase.~Patients received fixed doses comprising of a 1-day loading dose of 150 mg of olorofim twice a day followed by a maintenance dose of 90 mg of olorofim twice a day.~Up until Protocol Amendment 06, 58 patients received a weight-based olorofim dosing consisting of a 1-day loading dose of 4 mg/kg/day on Day 1, then a maintenance dose of 2.5 mg/kg/day (divided into 2 or 3 doses). The dose was then adjusted based on plasma levels of olorofim with the maximum total daily dose of 300 mg."
61930694|NCT03633409||IBD patients and healthy volunteers|We will recruit IBD patients and healthy volunteers
61930695|NCT03568084|EXPERIMENTAL|MEFAP|MEFAP (multicomponent physical activity program) for 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
61930696|NCT03568084|ACTIVE_COMPARATOR|Control: usual practice|No intervention. Individuals allocated to this arm, will be look after as usual in their health Centers.
61930697|NCT05492500|EXPERIMENTAL|Main cohort (Cohort A): ponsegromab low dose|Participants will receive a low dose Q4W SC
61930698|NCT05492500|EXPERIMENTAL|Main cohort (Cohort A): ponsegromab medium dose|Participants will receive a medium dose Q4W SC
61930699|NCT05492500|EXPERIMENTAL|Main cohort (Cohort A): ponsegromab high dose|Participants will receive a high dose Q4W SC
61930700|NCT05492500|PLACEBO_COMPARATOR|Main cohort (Cohort A): placebo|matched placebo
61930701|NCT05492500|EXPERIMENTAL|Open-label, PK Cohort (Cohort B): ponsegromab low dose|Participants will receive a low dose Q4W SC
61930702|NCT05492500|EXPERIMENTAL|Open-label, PK Cohort (Cohort B): ponsegromab medium dose|Participants will receive a medium dose Q4W SC
61930703|NCT05492500|EXPERIMENTAL|Open-label, PK Cohort (Cohort B): ponsegromab high dose|Participants will receive a high dose Q4W SC
61930704|NCT05492500|EXPERIMENTAL|Optional Cohort C: ponsegromab low dose|Participants will receive a low dose Q4W SC
61930705|NCT05492500|PLACEBO_COMPARATOR|Optional Cohort C: placebo|matched placebo
62324276|NCT06476275|EXPERIMENTAL|Influenza A/Texas/71/2017 (H3N2)|Recombinant H3N2 (A/Texas/71/2017 (H3N2), clade 3C3a) influenza virus at 106 TCID50 dose. This dose has an attack rate of \>70%, and a good safety profile related to adverse events reporting. Each vial of virus stock and diluent will be individually labeled with the product name, description and caution statement.
61930706|NCT05492500|EXPERIMENTAL|Optional Cohort D: ponsegromab high dose|Participants will receive a high dose Q4W SC
61930707|NCT05492500|PLACEBO_COMPARATOR|Optional Cohort D: placebo|matched placebo
61930708|NCT02415621|OTHER|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
61930709|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
61930710|NCT05789082|EXPERIMENTAL|Cohort A - Combination Dose Finding + Dose Expansion|"Participants enrolled in this cohort will receive divarasib (different dose levels will be evaluated) once a day (QD) combined with pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).~During the expansion stage, some participants are planned to be randomized to one divarasib combination dose level; other participants are planned to be randomized to another divarasib combination dose level. Divarasib will be given in combination with pembrolizumab."
62483427|NCT03698357|ACTIVE_COMPARATOR|Conventional physiotherapy|Another 15 participants allocated to the group B will receive 30 minutes a day and 3 days a week conventional rehabilitation for four weeks.
62483428|NCT00881751|EXPERIMENTAL|Arm 1: bevacizumab and erlotinib|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28.
61930711|NCT05789082|EXPERIMENTAL|Cohort B - Combination Dose Finding + Dose Expansion|Participants enrolled in this cohort will receive divarasib (different dose levels will be evaluated) QD combined with pembrolizumab 200 mg IV Q3W plus investigator's choice of platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed.
61930712|NCT05864170|EXPERIMENTAL|Experimental|Three transfusion-dependent β-thalassaemia subjects aged 18-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q
61930713|NCT04981392|EXPERIMENTAL|Intervention Arm|Primary care text message outreach to unvaccinated patients and resources to support PCPs
61930714|NCT04981392|NO_INTERVENTION|Control Arm|Patients will receive usual care
61930715|NCT05671757|EXPERIMENTAL|4 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 4 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
61930716|NCT05671757|EXPERIMENTAL|8 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 8 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
61930717|NCT05671757|EXPERIMENTAL|16 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 16 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
61930718|NCT01845883|OTHER|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
61930719|NCT06324448|EXPERIMENTAL|Primary motor cortex|The anodal electrode is positioned in the primary motor cortex (Cz) and the cathodal electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
61930720|NCT06324448|EXPERIMENTAL|Left dorsolateral prefrontal cortex|The anodal electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathodal electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
61930721|NCT03292211|EXPERIMENTAL|early mobilization|early mobilization group will commence rehabilitation consisting of out-of-bed mobilization (including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.)
61930722|NCT03292211|OTHER|early standard intervention|early standard intervention included bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and the facilitation techniques during the period in a stroke center.
61930723|NCT05800860|EXPERIMENTAL|GH001 - Part 1|GH001 is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience \[PE\]) at the previously administered dose.
61930724|NCT05800860|PLACEBO_COMPARATOR|Placebo - Part 1|Placebo is administered via inhalation, as an IDR consisting of up to 3 doses of Placebo, on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a PE) at the previously administered dose.
61930725|NCT05800860|OTHER|Open-Label Extension (OLE) - Part 2|Patients can receive up to five GH001 IDRs as needed during the OLE based on the patient's clinical response.
61930726|NCT05534087|EXPERIMENTAL|mFOLFIRINOX intensified chemotherapy|"6 cycles of mFOLFIRINOX~- Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks"
61930727|NCT05534087|ACTIVE_COMPARATOR|FOLFOX or CAPOX adjuvant chemotherapy|"FOLFOX 6 cycles or CAPOX 4 cycles~* FOLFOX regimen: 6 cycles every 2 weeks or~* CAPOX regimen: 4 cycles every 3 weeks"
61930728|NCT04360863||Youth smokers|Participants of Youth Quitline
61930729|NCT04240470|EXPERIMENTAL|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
61930730|NCT02835560|EXPERIMENTAL|Experimental|Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid
61930731|NCT02835560|ACTIVE_COMPARATOR|Active Comparator|"Esoprazole~Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid"
61930732|NCT06707415|EXPERIMENTAL|EMG evaluated group|Participants are evaluated in both the MT1 and the Natus Dantec Keypoint systems
61930733|NCT06206213||Healthy Young University Students|This study involves just one group which will be consist of 40 healthy young adults (university students). It will include both males and females and all of them will be exposed to the same protocol.
61930734|NCT05555771|EXPERIMENTAL|Counterpressure Maneuvers|"Participants will receive standard of care treatment (behavioural intervention and avoidance measures, as indicated in Usual Care), alongside training in counter pressure maneuvers. Training in counterpressure maneuvers will be delivered through a handout and video that will show three maneuvers (i.e. arm-tensing, squatting, and leg-crossing) that patients enrolled in the intervention arm can perform when they begin to experience common signs and symptoms of syncope. Patients will be instructed to start with one of the maneuvers and if their symptoms do not go away, move on to a second or third maneuver if needed."
62132319|NCT04452201|EXPERIMENTAL|Guided Participation (GP)|A GP intervention is participatory formal and informal education to support learning of a practice beyond what could occur as efficiently and effectively without guidance. GP uses strategies for teaching-learning that make best use of the family's situation and opportunities, tailored to the parents' needs. The overall goal of the GP intervention is to support parent couples in effectively communicating for parenting work, including care-giving and maintaining the couple's relationship
62691713|NCT01969578|EXPERIMENTAL|Androgen Deprivation Therapy (ADT)|"ADT = bicalutamide + triptorelin~Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized."
62691714|NCT06384352|EXPERIMENTAL|Part 1: Dose-Escalation Part|Dose-Escalation Part
62132320|NCT04452201|NO_INTERVENTION|Usual Care (UC)|The UC group will receive standard of care
62324277|NCT06476275|SHAM_COMPARATOR|Sham Product|The viral stock diluent will be used as a sham inoculum, without the viral stock added. Each vial of sham will be labeled with the product name, description and caution statement.
62691715|NCT06384352|EXPERIMENTAL|Part 2: Backfill Enrollment Part|Backfill Enrollment Part
62691716|NCT06384352|EXPERIMENTAL|Part 3: Dose-Expansion Part|Dose-Expansion Part
62691717|NCT01950039|ACTIVE_COMPARATOR|Betaine|
61930735|NCT05555771|ACTIVE_COMPARATOR|Usual Care|Participants will receive standard of care treatment for their diagnosis of syncope. This primarily includes behavioural interventions and avoidance measures (e.g., stay hydrated, increase salt intake, avoid hot situations, avoid standing for long periods of time, engage in regular physical activity). Some patients may be prescribed medication (Midodrine, Fludrocortisone) at the discretion of their physician.
61930736|NCT06710808|EXPERIMENTAL|Virtual walking and transcranial direct current stimulation of 2 milliampere for 20 minutes|
61930737|NCT02435329||Healthy volunteers|"10 healthy volunteers~* Anthropometric measures: Height, weight, BMI, waist circumference~* Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~* Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~* Assessment of skin microcirculation with Laser Doppler Iontophoresis~* Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~* Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
61930738|NCT02435329||Type 2 diabetes without neuropathy|"10 patients~* Anthropometric measures: Height, weight, BMI, waist circumference~* Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~* Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~* Assessment of skin microcirculation with Laser Doppler Iontophoresis~* Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~* Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
61930739|NCT02435329||Type 2 diabetes with painful neuropathy|"10 patients~* Anthropometric measures: Height, weight, BMI, waist circumference~* Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~* Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~* Assessment of skin microcirculation with Laser Doppler Iontophoresis~* Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~* Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
62132321|NCT05103618|ACTIVE_COMPARATOR|Healthy Control Couple Pairs|All healthy control subjects, 6 couple pairs (12 subjects) healthy controls in which neither member has Parkinson's Disease will receive a baseline and follow up FDOPA PET scan. All subjects will be asked to complete the surveys. The control group will receive training materials in the practice of OM which the couple will be asked to practice for the next 2-3 months. The couple-pair will begin the OM practice initially (in between the baseline and follow up scans. FDOPA scans and surveys will be conducted with both members of the couple pair at approximately 2-3 months.
61930740|NCT02435329||Type 2 diabetes with painless neuropathy|"10 patients~* Anthropometric measures: Height, weight, BMI, waist circumference~* Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~* Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~* Assessment of skin microcirculation with Laser Doppler Iontophoresis~* Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~* Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
61930741|NCT02435329||Type 2 diabetes with Charcot foot|"10 patients~* Anthropometric measures: Height, weight, BMI, waist circumference~* Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~* Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~* Assessment of skin microcirculation with Laser Doppler Iontophoresis~* Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~* Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
61930742|NCT04920318|EXPERIMENTAL|active TDCS|During intervention excitatory/anodal tDCS will be administered alongside speech-language therapy 5 days a week for 2 weeks. The exact location of the stimulation and electrode configuration will be targeted individually based on the optimal site identified in fMRI. TDCS will be administered with NeurConn1 Channel DC- Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes using sponge electrodes with a 30-s ramp-up and ramp-down period
61930743|NCT04920318|SHAM_COMPARATOR|sham TDCS|The sham will be administered alongside speech-language therapy 5 days a week for 2 weeks. For sham, stimulation will be ramped up and then down to 0 milliamperes (mA) in the first minute of stimulation. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
61930744|NCT03536897||IORT|All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome. Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered. Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery. After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
61930745|NCT06596031|EXPERIMENTAL|Health coaching|"Participants randomized to the intervention group will receive access to the Active Wait program, which includes remote, self-paced (asynchronous) education, exercise, and nutritional advice delivered via a web-based platform. The participants in the intervention group will have access to the program, in conjunction with health coaching.~Patients undertaking health coaching will be assigned a personal health coach who will provide support to increase their ability to self-manage through self- regulation principles of behaviour change. Health coaching sessions will be delivered remotely (via telephone or video conferencing) a maximum of 8-times during a 12-week intervention period. Sessions are limited to 1 hour, offering education, self-management strategies, barrier and facilitator identification, support and encouragement, goal setting, action planning and self-monitoring with the intention to facilitate positive and sustainable lifestyle and behaviour changes."
61930746|NCT06596031|ACTIVE_COMPARATOR|Digital toolkit|Patients in the active-comparator group will be given a link to the same Digital Toolkit. The digital toolkit is a 12-week non-contact programme titled Active Wait, which offers education, self-management techniques and an unsupervised strength programme. The website Active Wait can be accessed via the link: https://protect-au.mimecast.com/s/8_5gCP7yRZiWn3q3FzwqnS?domain=sheffieldachesandpains.com/
62324278|NCT01617681|EXPERIMENTAL|Valsartan 0.25 mg/kg|Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
62691718|NCT01950039|PLACEBO_COMPARATOR|Placebo|
62691719|NCT02475356||Mirena|Mirena treatment group
62691720|NCT05512455||virtual articulator mounting using an average facebow|indirect virtual mounting in MS VA by using an average facebow
62691721|NCT05512455||virtual articulator mounting by using average values|virtual mounting in MS VA by using average values;
62691722|NCT05512455||virtual articulator mounting by using professional facial scanner|virtual mounting in MS VA by using professional facial scanner
62691723|NCT05512455||virtual articulator mounting by using smartphone facial scanner|virtual mounting in MS VA by using smartphone facial scanner
62691724|NCT05512455||virtual articulator mounting by using CBCT located in Bergstrom's point|virtual mounting in MS VA by using CBCT located in Bergstrom's point
62691725|NCT05512455||virtual articulator mounting by using CBCT located in the medial poles of the condyle|virtual mounting in MS VA by using CBCT located in the medial poles of the condyle
62691726|NCT05512455||virtual articulator mounting by using JMA|virtual mounting in CA VA by using JMA,as the group to compare with the other mounting procedures.
62691727|NCT05067985||SARS-CoV-2 pregnant women|After receiving approval from the local ethics committee and permission to use the hospital archives, we included records of spinal anesthesia performed on confirmed SARS- CoV-2 patients in the Ankara City Hospital between April 2020 and February 2021, as well as related data, in our study. Patients who did not have their data gathered, or whose operation took more than 3 hours due to any reason, were excluded from the study
62691728|NCT06640517|EXPERIMENTAL|NTK|netakimab given subcutaneously during main period, open-label period and treatment discontinuation period
61930747|NCT05741840|EXPERIMENTAL|PBT-A|PBT-A includes the elements of family based behavioral treatment for children with obesity, delivered exclusively to a parent via telehealth.
61930748|NCT05741840|ACTIVE_COMPARATOR|Health Education|This program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress delivered exclusively to a parent via telehealth.
61930749|NCT04602689|EXPERIMENTAL|Fibrin glue group|Spread Fibrin glue(Greenplast Q™) at iatrogenic ulcer after gastric ESD
61930750|NCT04602689|NO_INTERVENTION|Control group|No intervention after gastric ESD
61930751|NCT01325623|OTHER|Model 106 VNS Therapy System|Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.
61930752|NCT04647071|PLACEBO_COMPARATOR|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
61930753|NCT04647071|EXPERIMENTAL|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
61930754|NCT05097989|EXPERIMENTAL|LN Cohort: ALXN2050 180 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
61930755|NCT05097989|EXPERIMENTAL|LN Cohort: ALXN2050 120 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
61930756|NCT05097989|PLACEBO_COMPARATOR|LN Cohort: Placebo|Participants diagnosed with LN with an active flare will receive matched placebo in addition to standard-of-care background therapy.
61930757|NCT05097989|EXPERIMENTAL|IgAN Cohort: ALXN2050 180 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
61930758|NCT05097989|EXPERIMENTAL|IgAN Cohort: ALXN2050 120 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
61930759|NCT05097989|PLACEBO_COMPARATOR|IgAN Cohort: Placebo|Participants diagnosed with IgAN will receive matched placebo in addition to standard-of-care background therapy.
61930760|NCT02360215|EXPERIMENTAL|WBRT + Memantine|Whole brain radiation therapy (WBRT) and memantine
61930761|NCT02360215|EXPERIMENTAL|HA-WBRT/IMRT+ Memantine|Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) using intensity modulated radiation therapy (IMRT) and memantine
61930762|NCT03694002|EXPERIMENTAL|Arm A (ramucirumab, carboplatin, paclitaxel)|Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.
62324279|NCT01617681|EXPERIMENTAL|Valsartan 4 mg/kg|Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
62324280|NCT01617681|EXPERIMENTAL|Valsartan 1 mg/kg|Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
62324281|NCT00848692|EXPERIMENTAL|1|Rituximab
62324282|NCT00848692|PLACEBO_COMPARATOR|2|Placebo (saline)
62691729|NCT06640517|PLACEBO_COMPARATOR|PBO|placebo given subcutaneously during main period and treatment discontinuation period
62691730|NCT06640517|ACTIVE_COMPARATOR|ADA|adalimumab given subcutaneously during main period
62691731|NCT02609503|EXPERIMENTAL|Open label|Pembrolizumab
62691732|NCT02609503|OTHER|Radiation|Intensity Modulated Radiation Therapy (IMRT)
62691733|NCT04427345||Covid19 infection related patients|Patients admitted to COVID wards of the S. Gerardo Hospital of Monza, including Intensive Care wards.
62691734|NCT04522739|EXPERIMENTAL|Spironolactone|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.
62691735|NCT04522739|PLACEBO_COMPARATOR|Placebo|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
62697518|NCT06482034|EXPERIMENTAL|Group 1|Intervention Type: Drug Intervention Name: N-acetylcysteine (NAC) Other Intervention Names: NAC Intervention Description: Patients will receive N-acetylcysteine sachets (600mg) twice daily. They will dissolve the NAC sachet in a cup of water, gargle for 60 seconds, and swallow it. The treatment will start 3 days before the beginning of radiotherapy and continue for 2 weeks after the completion of the radiotherapy schedule.
62324283|NCT03695432|EXPERIMENTAL|Vaccine|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
62324284|NCT03695432|EXPERIMENTAL|Probiotic|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic
62324285|NCT03695432|PLACEBO_COMPARATOR|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
61930763|NCT03694002|ACTIVE_COMPARATOR|Arm B (carboplatin, paclitaxel)|Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
61930764|NCT01394718|PLACEBO_COMPARATOR|Saline Placebo|Control subjects will receive saline as placebo at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
61930765|NCT01394718|EXPERIMENTAL|Intravenous Acetaminophen|Subjects will receive the first dose of intravenous (IV) acetaminophen (at 15 mg/kg, with maximum doses based on patient age and weight) at the time of skin closure intra-operatively and will continue to receive IV acetaminophen for 42 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
61930766|NCT06709430|EXPERIMENTAL|Standardized Patient Group|Students will be divided into standardized patient group and control groups. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the experimental group.
61930767|NCT06709430|NO_INTERVENTION|Classical education group|Theoretical courses, case-based pain management laboratory practice, and clinical practice processes will be applied to students in the control group.
62691736|NCT06639139|EXPERIMENTAL|CogFun RG occupational therapy|Occupational Therapy Remote Group Intervention . 21 weekly, online group sessions (4-6 participants in each group), lasting 90 minutes. Sessions are structured, comprising opening, collaborative learning, and summary. Session topics include learning about ADHD as a biological disorder of executive functioning, understanding the impact of ADHD on daily life, discovering strategies for coping with ADHD through exploration of life experiences, and preparing for future self-management.
62324286|NCT03695432|PLACEBO_COMPARATOR|Placebo probiotic|capsul
62324287|NCT02294721|EXPERIMENTAL|Without feedback|Participants compress the chest of the manikin without CPR feedback device
62324288|NCT02294721|EXPERIMENTAL|With feedback|Participants compress the chest of the manikin with CPR feedback device.
62691737|NCT06639139|NO_INTERVENTION|Waitlist Control Group|Waiting list, no intervention. After waitlist period will receive the same intervention as the first arm
62691738|NCT05294523|ACTIVE_COMPARATOR|Rocuronium priming dose 0.06mg/kg|Add the priming dose of rocuronium 0.06mg/kg after the first supramaximal stimulation data measured
62691739|NCT05294523|ACTIVE_COMPARATOR|Rocuronium priming dose 0.12mg/kg|Add the priming dose of rocuronium 0.12mg/kg after the first supramaximal stimulation data measured
62691740|NCT05294523|ACTIVE_COMPARATOR|Rocuronium priming dose 0.18mg/kg|Add the priming dose of rocuronium 0.18mg/kg after the first supramaximal stimulation data measured
62691741|NCT06636825|PLACEBO_COMPARATOR|Placebo|Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
62691742|NCT06636825|EXPERIMENTAL|Experimental|400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
62691743|NCT03759197|EXPERIMENTAL|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
62691744|NCT03759197|PLACEBO_COMPARATOR|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
62691745|NCT06612866|OTHER|Kera-Diet treatment|
62691746|NCT06136403|EXPERIMENTAL|deucravacitinib treatment|challenge-dechallenge -rechallenge design
62691747|NCT06638229|EXPERIMENTAL|StimaWell|Participants in the StimaWELL group had previously received electrotherapy treatment for the entire spine for 4 weeks, 2 days a week. Before the treatment, participants were informed about their medical condition and the planned treatment. The StimaWELL 120MTRS system (StimaWELL® 120MTRS; Schwa-medico, Wetzlarer Straße 41-43, 35630 Ehringshausen, Germany) was used for the treatment and a stimulation mat was used to apply electrical stimulation along the entire back. The 12 channels of the mat provided different current intensities to different areas and the system offered programs tailored to various therapeutic goals.
61930768|NCT06256757|EXPERIMENTAL|A（extracorporeal fenestration）|Based on the preoperative CTA reconstructions, the diameter of the aorta and branch vessels, lengths, angles to the arch, clock positions, and related relationships are measured, and a preoperative design for the fenestrations is developed. The outer sheath of the stent graft is then pushed back for several centimeters under sterile conditions, allowing the proximal portion of the stent graft to be released. The length of the released segment should be one to two centimeters distal from the location of fenestration. Using a sterile ruler, the location of the fenestration is determined in accordance with the preoperative plan. The 12 o'clock position is considered to be at the front of the trigger. The position of the stent graft relative to the trigger is also referred to as the 12 o'clock position. If the fenestration must avoid stent struts, then the fenestration is deemed to be at 12 o'clock, as is the position of the trigger relative to the stent graft.
62324289|NCT05844566|OTHER|Decision Support System (DSS)|Patients of this cohort are seen at a site randomised to the availability of the DSS. These patients will be provided routine clinical care including local/national prescribing guidelines during the course of the study. In addition to routine clinical care, the DSS which is available online, is a tool intended for clinicians to estimate the clinical benefit of any LLT regimen, whether monotherapy or combination therapies.
62324290|NCT05844566|NO_INTERVENTION|Non-Decision Support System (Non-DSS)|Patients of this cohort are seen at a site randomised to no availability of a DSS (Non-DSS). These patients will be provided routine clinical care including local / national prescribing guidelines during the course of the study.
62324291|NCT05380414|EXPERIMENTAL|Metastatic/advanced PDAC Patients|Tumor samples
62324292|NCT05998408|EXPERIMENTAL|Subjects with hypoplastic MDS|Subjects are defined as patients with a diagnosis of hMDS clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.
62324293|NCT05998408|EXPERIMENTAL|Subjects with MAA|Subjects are defined as patients with a diagnosis of MAA clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.
62324294|NCT05998408|EXPERIMENTAL|Subjects with PRCA|Subjects are defined as patients with a diagnosis of PRCA clinically confirmed by a licensed physician or advanced practitioners who meet the inclusion and exclusion criteria and can provide informed consent.
62483429|NCT00881751|ACTIVE_COMPARATOR|Arm 2: sorafenib tosylate|Patients receive oral sorafenib tosylate twice daily on days 1-28.
62132322|NCT05103618|ACTIVE_COMPARATOR|Active Couple Pairs Parkinson's Group|"15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD.~The female subject will undergo the baseline scan. Both members of the couple will complete surveys. The active group will receive training materials in the practice of OM which they will be asked to practice for the next 2-3 months The active couple-pair will begin the OM practice initially (in between the baseline and follow up). FDOPA scans will be conducted with female members with PD the couple pair at approximately 2-3 months."
62132323|NCT05103618|OTHER|Waitlist Couple Pairs Parkinson's Group|15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD. The female subject will undergo the baseline scan. Both members of the couple will complete surveys The waitlist period in which the female member with PD will continue to receive standard of care for those 2-3 months; who then receive follow up scan. After the follow up scan, the waitlist group may be trained in the practice of OM for the next two months (but there will not be an additional FDOPA scan). Couple-pairs in the waitlist group will be asked to complete surveys at baseline and follow up scan and again after completing the OM Meditation practice. Couple pairs will engage in OM Meditation together approximately 3-4 times a week after the baseline and follow up scans for 2-3 months but female subjects with PD will not receive and additional post OM Meditation FDOPA scan
62691748|NCT06638229|NO_INTERVENTION|Waitlist|Patients presenting to the clinic for treatment and waiting without intervention in the waitlist group after routine evaluation.
62691749|NCT06674746|EXPERIMENTAL|intervention|Using the simple random numbers table from the population in the risk group, 60 randomly selected students will be randomly assigned to the experimental and control groups as 30 students. A two-stage stratified random method will be used in order to make assignments to the intervention and control groups equally and homogeneously. Firstly; The class and gender strata determined by scanning the literature will be created. Afterwards, each class and the male and female students in these classes will be determined. Then, the students in each stratum will be assigned to the intervention and control groups according to the two-layer random method, one intervention and one control.
62691750|NCT06674746|NO_INTERVENTION|control|Using the simple random numbers table from the population in the risk group, 60 randomly selected students will be randomly assigned to the experimental and control groups as 30 students. A two-stage stratified random method will be used in order to make assignments to the intervention and control groups equally and homogeneously. Firstly; The class and gender strata determined by scanning the literature will be created. Afterwards, each class and the male and female students in these classes will be determined. Then, the students in each stratum will be assigned to the intervention and control groups according to the two-layer random method, one intervention and one control.
62691751|NCT03112928|EXPERIMENTAL|Phantom Motor Execution (PME)|Phantom motor execution is decoded via myoelectric pattern recognition and promoted via serious gaming in virtual and augmented reality.
61930769|NCT06256757|SHAM_COMPARATOR|B（In situ fenestration）|From the left brachial artery (LBA), a 6F angle-adjustable sheath (Lifetech, Inc., Shenzhen, China) is introduced retrogradely until its tip reaches the aortic stent graft. The tip is then adjusted to be as perpendicular as possible to the larger curve of the aortic stent graft. Once the sheath gets to the ideal position, a flexible needle (21 gauge, Futhrough, Lifetech, Inc.) is employed to create the fenestration in the aortic stent graft. Following the puncture, a 0.018-inch guidewire (V-18 ControlWire; Boston Scientific, Natick, MA) is inserted through the needle aperture and into the ascending aorta.
61930770|NCT05753631||SRP+i-PRF (test)|Injectable platelet-rich fibrin (i-PRF) application into the selected deep periodontal pocket after scaling and root planning (SRP) procedure.
61930771|NCT05753631||SRP (Control)|No agent was applied to the periodontal pocket after scaling and root planning.
61930772|NCT06707467|EXPERIMENTAL|nineteen patients with internal temporomandibular disarrangement-group 1|Nineteen randomly selected patients with internal temporomandibular disarrangement
61930773|NCT06707467|ACTIVE_COMPARATOR|nineteen patients with internal temporomandibular disarrangement-group 2|nineteen randomly selected patients with internal temporomanidbular disarrangement
61930774|NCT06707467|EXPERIMENTAL|nineteen patients with internal temporomandibular disarrangement-group 3|nineteen selected patients with internal temporomandibular disarrangements
61930775|NCT06286358||Interventional treatment|Patients with severe aortic valve disease or thoracic aortic aneurysm in whom interventional treatment has been previously decided by the Heart Team (i.e. the multidisciplinary team of cardiologists and cardiac surgeons treating the patient, independently of the research team) Patients with different severities of AVD or TAA, and healthy subjects. The KCG measurements and video recordings are consecutive to an echocardiography or cardiac MRI, and will be carried out in Erasme hospital.
61930776|NCT06286358||Aortic valve disease of different severities|Patients with aortic stenosis and/or aortic regurgitation and/or bicuspidy of different severities. The KCG measurements consecutive to the echocardiography and/or cardiac MRI will be carried out during their clinical management in Erasme hospital.
61930777|NCT06286358||Control|Subjects matched to the two other groups according to their age, gender, body surface area and left ventricular ejection fraction (LVEF), without AVD or TAA. The KCG measurements will be made immediately after the echocardiography and/or MRI in Erasme hospital.
62132324|NCT05749224|EXPERIMENTAL|Patients Who Have Temporomandibular Joint Disorder|Helkimo index will be applied to the patients have temporomandibular disorder.
62132325|NCT05749224|EXPERIMENTAL|Healthy Controls|Helkimo index will be applied to healthy people.
62132326|NCT00868504||examined by endoscopy|Patients, examined by endoscopy, being screened for GI tract tumors
62132327|NCT01634789|EXPERIMENTAL|Test Treatment 1: bazedoxifene|Test Treatment 1
62132328|NCT01634789|EXPERIMENTAL|Test Treatment 2: bazedoxifene|Test Treatment 2
62132329|NCT01634789|EXPERIMENTAL|Test Treatment 3: bazedoxifene|Test Treatment 3
62132330|NCT01634789|EXPERIMENTAL|Reference Treatment: bazedoxifene/conjugated estrogens|Reference Treatment
62324295|NCT05998408|EXPERIMENTAL|Subjects with SAA|Subjects are defined as patients with a diagnosis of SAA clinically confirmed by a licensed physician oran advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.
62738357|NCT06365437|EXPERIMENTAL|Arm 2|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
62132331|NCT00704769||1|Children with a history of perennial allergic rhinitis
61930778|NCT02402920|EXPERIMENTAL|Part A (LS-SCLC, pembrolizumab, chemoradiotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade \> 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity.
61930779|NCT02402920|EXPERIMENTAL|Part B (ES-SCLC, pembrolizumab, radiation therapy)|Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity.
61930780|NCT05780931||Treatment Group|This is the group of study subjects which will undergo study-related rehabilitation procedures.
61930781|NCT05780931||Control Group|This is the group of study subjects which will undergo control (sham) rehabilitation procedures (in addition to all their regularly scheduled treatments and interventions).
61930782|NCT02560181|OTHER|HDR whole gland salvage treatment|Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10.5Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart
61930783|NCT05591989|EXPERIMENTAL|Treatment|Subjects will undergo treatment with the NEUROMARK System
61930784|NCT05583344|EXPERIMENTAL|High Dose GSK4532990|
61930785|NCT05583344|EXPERIMENTAL|Low Dose GSK4532990|
62132332|NCT05845515|ACTIVE_COMPARATOR|laparoscopic orchiopexy|laparoscopic orchiopexy group
62132333|NCT05845515|ACTIVE_COMPARATOR|open orchiopexy|open orchiopexy group
62132334|NCT04669028|EXPERIMENTAL|NE3107|Hard gelatin capsule containing 20 mg micronized NE3107 drug substance blended with common excipients for oral formulations
62132335|NCT04669028|PLACEBO_COMPARATOR|placebo|Hard gelatin capsule containing only common excipients for oral formulations
62324296|NCT05998408|EXPERIMENTAL|Subjects with TLGL|Subjects are defined as patients with a diagnosis of TLGL clinically confirmed by a licensed physician or advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.
62324297|NCT04201769|EXPERIMENTAL|Arm A|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~No further anti-emetic prophylaxis on days 2 thorough 4."
62324298|NCT04201769|EXPERIMENTAL|Arm B|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~Oral dexamethasone 4 mg once per day in the morning of days 2 and 3."
62324299|NCT04201769|ACTIVE_COMPARATOR|Arm C|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~Oral dexamethasone 4 mg twice per day on days 2 thorough 4."
62324300|NCT03363048|EXPERIMENTAL|Restricted|
62324301|NCT03363048|EXPERIMENTAL|Restriction plus Incentive|
62324302|NCT03363048|NO_INTERVENTION|Control|
62324303|NCT06691269|EXPERIMENTAL|PBM- Study 1|In PBM group, the selected tooth will receive one burst of light application (20 seconds) before being subjected to sensibility testing and gingival probing.
62483430|NCT00932477|EXPERIMENTAL|Artificial Tear Formulation 1|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
61930786|NCT05583344|PLACEBO_COMPARATOR|Placebo|
61930787|NCT06402084||group A|cases
62324304|NCT06691269|NO_INTERVENTION|no PBM - Study 1|In the control (no PBM) group, the selected tooth will be subjected to sensibility testing and gingival probing without PBM.
62324305|NCT06691269|EXPERIMENTAL|PBM- Study 2|PBM (one burst/ 20 seconds application) at injection site (prior to local anesthesia infiltration)
62324306|NCT06691269|ACTIVE_COMPARATOR|no PBM- Study 2|Topical benzocaine at injection site (prior to local anesthesia infiltration)
62324307|NCT06691269|EXPERIMENTAL|PBM- Study 3|PBM (one burst/ 20 seconds application) followed by traditional tooth preparation with burs/handpiece and placement of restoration. Additional bursts may be provided every 20 minutes depending on the length of the procedure and patient-reported discomfort.
62324308|NCT06691269|ACTIVE_COMPARATOR|no PBM- Study 3|Topical benzocaine/Local infiltration followed by traditional tooth preparation with burs/handpiece and placement of restoration.
62483431|NCT00932477|EXPERIMENTAL|Artificial Tear Formulation 2|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
62483432|NCT00932477|ACTIVE_COMPARATOR|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
62483433|NCT01665495|NO_INTERVENTION|Pericardiocentesis|Pericardial fluid drained by simple echo-guided pericardiocentesis
61930788|NCT06402084||group B|controls
61930789|NCT03604692|EXPERIMENTAL|Cohorts of escalating dose levels of axatilimab|"Escalating dose levels of axatilimab to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D).~Intravenous (IV) infusion; axatilimab at a dose of 0.15 milligrams (mg)/kilogram (kg) to 3 mg/kg."
61930790|NCT03604692|EXPERIMENTAL|Phase 2 Dose Expansion|"Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size.~IV infusion; axatilimab at a dose of 1 mg/kg."
61930791|NCT04595604|EXPERIMENTAL|Trimodal prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~Physical status (walking, respiratory training) Nutrition (nutritional supplements) Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
61930792|NCT04595604|ACTIVE_COMPARATOR|ERAS + nutritional prehabilitation|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
62132336|NCT00767754|OTHER|paroxetine cr|single arm
62132337|NCT06497881||Stroke|Persons after a stroke. See inclusion/exclusion.
62132338|NCT06497881||Controls|Healthy persons. See inclusion/exclusion.
62132339|NCT03450434|EXPERIMENTAL|XC8 2 mg|XC8 2mg orally
62132340|NCT03450434|EXPERIMENTAL|XC8 10 mg|XC8 10 mg orally
62132341|NCT03450434|EXPERIMENTAL|XC8 100 mg|XC8 100 mg orally
62132342|NCT03450434|PLACEBO_COMPARATOR|Placebo|Placebo 2 mg, 10 mg or 100 mg orally
62132343|NCT02647905|EXPERIMENTAL|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
62691752|NCT03112928|ACTIVE_COMPARATOR|Phantom Motor Imagery (PMI)|Use the same device and visual stimulation as PME, with the difference that participants imagine to perform, rather than execute phantom movements. Myoelectric activity is used to monitor that the subjects do not produce muscular contractions but only imagine the movements.
62691753|NCT05520736|EXPERIMENTAL|Intervention|Prospectively received appointment reminders, motivational interviews and targeted vaccine drives.
62691754|NCT00911157|EXPERIMENTAL|Fondaparinux|
61930793|NCT05371678|ACTIVE_COMPARATOR|Therapeutic motor control interventions|Treatment duration will be 8 weeks. Therapeutic motor control intervention therapy sessions will be 2 days a week. Therapeutic motor control intervention will include education about defecation and physiology, dietary advices, core stabilization exercises, pelvic floor muscle training with surface Electromyographic-Biofeedback and breathing exercises. In the first session education and dietary advices will be given to patient. Dietary advices will be given by dietitian. Two surface electromyographic electrodes will be applied on external anal sphincter muscle position.
62132344|NCT03137836|EXPERIMENTAL|Intervention|Sit-to-stand desks (Ergotron LearnFit®) will replace standard desks. In addition, meeting with parents and teacher's training will be conducted in order to support behavior change.
62132345|NCT03137836|NO_INTERVENTION|Control|Control classroom will maintain their routine in sitting desks.
62132346|NCT02994316|EXPERIMENTAL|children under the age of 16 diabete with ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm with ketoacidosis (bicarbonate \< 15mmol/L)"
62132347|NCT02994316|SHAM_COMPARATOR|children under the age of 16 diabete without ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm without ketoacodosis (bicarbonate\> 15 mmol/L)"
62132348|NCT03037892|ACTIVE_COMPARATOR|Midazolam and Fentanyl|Midazolam and Fentanyl Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain
62132349|NCT03037892|EXPERIMENTAL|Midazolam and Remifentanil|Midazolam and Remifentanil Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
62483434|NCT01665495|ACTIVE_COMPARATOR|Extended pericardial drainage|Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return\<30ml
62483435|NCT06136039|EXPERIMENTAL|Sarcopenia|Patients were categorized into preoperative sarcopenia
61930794|NCT05371678|ACTIVE_COMPARATOR|Conventional treatment|Treatment duration will be 8 weeks. Conventional treatment will include education about defecation and physiology, dietary advices and laxative therapy. In the first session education and dietary advices will be given to patient. Dietary advices will be given by dietitian. Laxative therapy will be given by pediatric surgery.
61930795|NCT03960931|EXPERIMENTAL|Aquatic rehabilitation|
61930796|NCT03960931|EXPERIMENTAL|Land based physical activities|
62132350|NCT03037892|EXPERIMENTAL|Remifentanil|Remifentanil Group Patients will receive only Remifentanil in the same doses as given in group 2. During the procedure if the pain is excessive and persistent in spite of increasing the respective doses as prescribed in each group, or causing loss of cooperation of patient and interfering in the performance of procedure, the patients will be given sleep dose of Inj Propofol and further anaesthesia care as required will be provided for same.
62691755|NCT00911157|OTHER|unfractionated heparin|
62691756|NCT03510715|EXPERIMENTAL|Alirocumab|"Participants with BW less than (\<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to \[\>=\] 50 kg.~Participants with BW \>=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks."
62132351|NCT04657172|EXPERIMENTAL|Pilocarpine 1% Solution|1% pilocarpine ophthalmic solution administered with the Optejet dispenser
62132352|NCT04657172|EXPERIMENTAL|Pilocarpine 2% Solution|2% pilocarpine ophthalmic solution administered with the Optejet dispenser
62132353|NCT04657172|PLACEBO_COMPARATOR|Placebo Solution|Placebo ophthalmic solution administered with the Optejet dispenser
62132354|NCT04511767||ASD group|the autism spectrum disorder group
62483436|NCT06136039|NO_INTERVENTION|normal|normal groups according to the AWGS 2019 criteria.
62483437|NCT04313764|ACTIVE_COMPARATOR|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
62483438|NCT04313764|ACTIVE_COMPARATOR|Group Infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
62691757|NCT02695888|EXPERIMENTAL|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
62691758|NCT02695888|EXPERIMENTAL|Control group|Web-based behavioral intervention for healthy lifestyles.
62691759|NCT06198010|ACTIVE_COMPARATOR|Arm I (enhanced usual care)|Patients receive enhanced usual care, which includes access to the educational and pain self-management materials developed for the ASCENT trial (the ASCENT guide).
62738358|NCT06365437|EXPERIMENTAL|Arm 3|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
61930797|NCT03960931|OTHER|Conventional rehabilitation|
61930798|NCT06708195|EXPERIMENTAL|Group I :Experimental|"Patients in this group will receive 15 minutes of extraoral TENS applied to the skin over the bilateral parotid glands. The treatment will consist of 3 sessions per week for 3 weeks.~Intervention:~Type: Active TENS Frequency: 3 sessions per week Session duration: 15 minutes Application area: Skin over the bilateral parotid glands"
61930799|NCT06708195|SHAM_COMPARATOR|Control|"Patients in this group will receive 15 minutes of extraoral TENS applied to the skin over the bilateral parotid glands. However, the device will be inactive ( sham ). This treatment will consist of a single session.~Intervention:~Type: Inactive TENS Frequency: 1 session Session duration: 15 minutes Application area: Skin over the bilateral parotid glands"
61930800|NCT05578703|EXPERIMENTAL|Gastric Fundic Ablation plus Endoscopic Sleeve Gastroplasty|Subjects will undergo fundic mucosal ablation followed by endoscopic sleeve gastroplasty
61930801|NCT06710171|ACTIVE_COMPARATOR|Online training about counseling GBM about HIV prevention with a focus on PrEP|"The intervention at the user level will consist of brief counseling by the participating provider about PrEP and tailored linkage to available information resources or services. This will be delivered through healthcare providers in the intervention arm, who would have completed a 60-minute online training designed by the research team.~The intervention consists of using a theory-informed approach to user-centered brief counselling about PrEP uptake, designed specifically to help busy front-line providers in public health, sexual health and primary care settings advance clients along the PrEP cascade (specifically, supporting clients who meet evidence-based criteria for PrEP in accepting provider recommendations to use it) and provide linkage to care for related conditions."
61930802|NCT06710171|OTHER|Care as usual|Care as usual plus a list of available community resources related to HIV prevention and/or sexual health relevant to GBM
61930803|NCT05528952|EXPERIMENTAL|Experimental Arm (Arm A)|Atezolizumab + Bevacizumab + UCPVax
61930804|NCT05528952|OTHER|Control Arm (Arm B)|Atezoliumab + Bevacizumab
61930805|NCT04797000|EXPERIMENTAL|Eltrombopag Arm|Participants randomized to a 1: 1 ratio will take eltrombopag.
61930806|NCT04797000|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to a 1: 1 ratio will take Placebo.
61930807|NCT01302379|ACTIVE_COMPARATOR|Metformin + lifestyle intervention|
61930808|NCT01302379|ACTIVE_COMPARATOR|Placebo + lifestyle intervention|
62132355|NCT04511767||GDD group|the global developmental disorder group
62132356|NCT04511767||LD group|the language disorder group
62691760|NCT06198010|EXPERIMENTAL|Arm II (ASCENT intervention)|Patients receive the ASCENT guide and attend 3 video or phone calls over 30 minutes each with their CHW and/or PCM. During the first call, patients discuss barriers to receiving help for their pain with their CHW. During the second call, patients work with their PCM to develop an action plan for addressing their pain using the different techniques and interventions detailed in the ASCENT guide. During the third and final call, patients meet with both their CHW and PCM to discuss specialist recommendations for their pain management plan. After the final visit, patients will be contacted by the CHW or PCM every other week to monitor their progress and may also be contacted as-needed based on the their reported pain intensity, symptoms, or reported barriers.
62697519|NCT06482034|EXPERIMENTAL|Group2|Arm 2 Intervention Type: Drug Intervention Name: Zinc sulfate Other Intervention Names: Zinc Intervention Description: Patients will receive zinc sulfate capsules (25mg) thrice daily at 8-hour intervals. The treatment will start 3 days before the beginning of radiotherapy and continue for 2 weeks after the completion of the radiotherapy schedule.
61930809|NCT01302379|ACTIVE_COMPARATOR|Metformin + standard dietary guidelines|
61930810|NCT01302379|PLACEBO_COMPARATOR|Placebo + standard dietary guidelines|
61930811|NCT04025710|OTHER|all patients|
61930812|NCT01917929|OTHER|Secur-Fit Advanced|Secur-Fit Advanced Hip Stem
61930813|NCT06242678|EXPERIMENTAL|SCS trial lead|placement of spinal cord stimulator trial leads
61930814|NCT06674382|EXPERIMENTAL|Haplo-SCT group|Patients in this group will undergo haploidentical hematopoietic stem cell transplantation for the treatment of myelofibrosis.
61930815|NCT04632953||Cohort 1: Previously Treated with Triheptanoin|Patients who have been previously treated with triheptanoin in clinical studies: UX007-CL201 (NCT01886378), UX007-CL202 (NCT02214160), UX007-CL302 (2022-001539-10), Investigator Sponsored Trials (ISTs), or UX007-EAP (NCT03773770).
61930816|NCT04632953||Cohort 2: Currently or Previously Treated with Triheptanoin|New patients enrolling into the DMP currently or previously treated with triheptanoin (excluding those in Cohort 1).
62132357|NCT02007590|EXPERIMENTAL|Aerosure 25 Hz|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
62132358|NCT02007590|SHAM_COMPARATOR|Aerosure sham|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
61930817|NCT04632953||Cohort 3: Triheptanoin Naïve|New patients enrolling into the DMP with no exposure to triheptanoin (naïve).
61930818|NCT01994590|EXPERIMENTAL|Dovitinib + Abiraterone Acetate + Prednisone|"Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle. Starting dose will be 400 mg daily.~Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.~Participant to take 5 mg oral prednisone, twice daily."
61930819|NCT03557827|SHAM_COMPARATOR|control|Mechanical debridement by periodontal curets alone
62132359|NCT02007590|NO_INTERVENTION|No device|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
62132360|NCT03547102|ACTIVE_COMPARATOR|Cherry concentrate|8 weeks supplementation with montmorency cherry concentrate
62132361|NCT03547102|PLACEBO_COMPARATOR|Placebo concentrate|8 weeks supplementation with placebo isoenergetic cherry concentrate
62324309|NCT01176396|ACTIVE_COMPARATOR|Caries prevention active intervention|Patients receive CAMBRA related products like CHX, 5000ppm F-toothpaste etc according to their risk level
61930820|NCT03557827|ACTIVE_COMPARATOR|Photodynamic Therapy|Mechanical debridement by periodontal curets and supplement with photodynamic appliance
61930821|NCT05581030|EXPERIMENTAL|Hyper-CVAD + Calaspargase pegol Treatment|Participants will receive calaspargase pegol administered over 1 hour with each cycle of Hyper-CVAD, mini-CVD, and late intensification, beginning with Cycle 1B. Responding patients will have dose reduction of HyperCVAD for Cycles 2B-4B. Participants with CD20+ ALL will also be given Rituximab once per cycle.
62324310|NCT01176396|PLACEBO_COMPARATOR|control treatment|Patients receive treatment according to standard of care
62324311|NCT01921270|EXPERIMENTAL|Dysport Injections|Participants with OMD who have been previously treated with any botulinum toxin Type A will be injected with Dysport®.
62324312|NCT04126369|EXPERIMENTAL|mindfulness intervention|12 mindfulness sessions for 3 months (1 session per week)
62691761|NCT06644794|EXPERIMENTAL|P4mNC group|On days 8-12 of the menstrual cycle (MC), depending on the length of the patient's MC, transvaginal ultrasound is used to monitor follicular development and endometrial growth. Vaginal micronized progesterone (Utrogestan, Besins, Belgium) is started at 200 mg in the afternoon and 200 mg in the evening when the dominant follicle reached ≥16 mm and the endometrial thickness is at least 7 mm. A blastocyst is transferred on day 5 after the addition of progesterone. On day 14 after blastocyst transfer, serum β-hCG levels are measured. Upon positive serum pregnancy testing, progesterone support will continue until 8-10 weeks of gestation. However, afternoon progesterone use is eliminated for 30 days after embryo transfer.
61930822|NCT03554616|EXPERIMENTAL|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
61930823|NCT03554616|EXPERIMENTAL|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
61930824|NCT03554616|EXPERIMENTAL|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
61930825|NCT03554616|ACTIVE_COMPARATOR|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
61930826|NCT00381121||Kidney disease cohort|Individuals with a clinically indicated biopsy are recruited and/or surplus tissue that remains from past clinical interventions is obtained.
61930827|NCT02172053|ACTIVE_COMPARATOR|Compensatory Workplace Exercise (CWE)|Comparative Group will receive a light training protocol including warming up, stretching and resisted exercise using elastic bands.
61930828|NCT02172053|EXPERIMENTAL|Individual Resistance Exercise (IRE)|Intervention group will receive training protocol including warming up, stretching a specific resistance training with increase progressive load.
61930829|NCT05316688|EXPERIMENTAL|Diagnostic (tozuleristide, surgery, NIR imaging)|Beginning 1 hour before surgery, patients receive tozuleristide intravenously (IV) over 1-5 minutes. Patients then surgical resection per standard of care and undergo near infrared (NIR) imaging with standard of care device.
61930830|NCT03833167|EXPERIMENTAL|Pembrolizumab|Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.
61930831|NCT03833167|PLACEBO_COMPARATOR|Placebo|Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.
61930832|NCT04233034|ACTIVE_COMPARATOR|HCL and placebo|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~\[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.\]"
61930833|NCT04233034|ACTIVE_COMPARATOR|HCL and verapamil|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~\[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.\]"
61930834|NCT04233034|ACTIVE_COMPARATOR|non-HCL and verapamil|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~\[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.\]"
62324313|NCT04126369|ACTIVE_COMPARATOR|Psycho educative programme|12 psycho educative sessions for 3 months (1 session per week)
62324314|NCT05360277|EXPERIMENTAL|Tislelizumab + Capecitabine|"Tislelizumab 200mg every 3 weeks, or 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
62324315|NCT05360277|ACTIVE_COMPARATOR|Best supportive care|Best supportive care was the standard care in this setting.
62324316|NCT03774693|ACTIVE_COMPARATOR|GS [General anesthesia]|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
62691762|NCT06644794|ACTIVE_COMPARATOR|HRT group|Endometrial preparation will begin on the second day of the menstrual cycle with oral estradiol (E2) valerate at a dose of 2 mg twice daily. When the patient's endometrial thickness is ≥7 mm, vaginal progesterone administration will be initiated at a dose of 200 mg 3 times daily. On day 5 of the progesterone administration, blastocysts are thawed and transferred. For patients with endometrial thickness \<7 mm, patients continued oral E2 until the endometrium is ≥7 mm. On day 14 after blastocyst transfer, serum β-hCG levels are measured. Upon positive serum pregnancy testing, E2 and progesterone supplementation is continued for 8-10 weeks of gestation.
61930835|NCT04233034|PLACEBO_COMPARATOR|non-HCL and placebo|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~\[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.\]"
61930836|NCT06500780|EXPERIMENTAL|Coaching and Decision Aid|Intervention group (Individual coaching sessions and Decision Aid)
61930837|NCT06500780|NO_INTERVENTION|Control|Wait-list control group
62324317|NCT03774693|ACTIVE_COMPARATOR|GR [General anesthesia + regional block]|"Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.~Also patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block. Fentanyl boluses of 0.5 mcg.Kg-1 will be given when needed to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1."
62324318|NCT01241838|PLACEBO_COMPARATOR|Normal left ventricular size|Postoperative patient with normal left ventricular size
62324319|NCT01241838|ACTIVE_COMPARATOR|Left ventricular hypertrophy|Postoperative patient with left ventricular hypertrophy
62324320|NCT06261138||TACE group|Patients included in the study underwent either conventional TACE (cTACE) or drug-eluting beads TACE (DEB-TACE) procedures performed by experienced interventional radiologists, taking into account tumor burden, patient tolerance, and individual preferences.
62324321|NCT06261138||Combination group|Systemic treatment commenced within one month after the initial TACE procedure, depending on the proper liver function. Anti-angiogenic agents involved in this study mainly comprised multikinase tyrosine kinase inhibitors. ICIs included therapies targeting programmed cell death protein 1 and its ligands.
62324322|NCT00747890|ACTIVE_COMPARATOR|I|
62324323|NCT00747890|OTHER|II|
62324324|NCT02823262|EXPERIMENTAL|Decision Aid|"Post Initial Surgical Consultation~* Including background questionnaire and randomization into Decision Aid Group or Control Group:~* The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.~  -- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.~* Assessment at One week after participants surgical consultation and five months after surgical consultation"
62324325|NCT02823262|ACTIVE_COMPARATOR|No Decision Aid|"Post Initial Surgical Consultation~* Including background questionnaire and randomization into Decision Aid Group or Control Group:~* Participant will receive Usual Care assistance when making treatment decisions.~* Assessment at One week after participants surgical consultation and five months after surgical consultation"
62324326|NCT05085392|EXPERIMENTAL|Experimental Group Yoga|35 rural teachers in a southwestern Montana school district participating in a trauma-informed yoga intervention
62324327|NCT05085392|NO_INTERVENTION|No Intervention|No participants were assigned to the No Intervention Arm
62324328|NCT05704543|ACTIVE_COMPARATOR|Extended-release Buprenorphine: Abdomen|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the abdomen on Day 1.
62324329|NCT05704543|EXPERIMENTAL|Extended-release Buprenorphine: Upper Arm|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the back of the upper arm on Day 1.
62324330|NCT05704543|EXPERIMENTAL|Extended-release Buprenorphine: Buttocks|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the buttocks on Day 1.
62324331|NCT05704543|EXPERIMENTAL|Extended-release Buprenorphine: Thigh|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the thigh on Day 1.
62324332|NCT00003546|EXPERIMENTAL|gemcitabine + radiation|Patients receive radiation therapy 5 days per week for 5 1/2 weeks and gemcitabine IV over 30 minutes not greater than 2 hours prior to radiation therapy twice weekly. This combination radiation therapy and chemotherapy is followed by 2 weeks of rest. Patients with stable or responding disease receive a higher dose of gemcitabine IV over 30 minutes weekly for 3 weeks followed by 1 week of rest. This 4 week course is repeated 3 more times for a total of 16 weeks of gemcitabine therapy alone. Patients are followed every 2 months for the first year and then every 3 months for the next 2 years or until disease progression. Upon documentation of disease progression, patients are followed every 3 months for survival and secondary malignancy.
62324333|NCT04385797||Dyads|Community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers
62324334|NCT06075758||ribociclib ambispective|Ambispective patients should have initiated Ribociclib, in combination with hormonal therapy, for at least 12 months before the patient's recruitment date and are still on Ribociclib in combination with hormonal therapy at recruitment. These patients will be followed up till progression, death, Ribociclib discontinuation due to adverse events, or till a maximum period of 6 months, whichever comes first.
62324335|NCT06075758||ribociclib retrospective|Retrospective patients should have been on Ribociclib in combination with hormonal therapy for at least 18 months and stopped the medication before the patient's recruitment
62324336|NCT06663358||Cardiac Cohort|Patients with Fabry-related cardiac disease
62324337|NCT06663358||Naïve Cohort|Patients naïve to prior Fabry disease treatment
62324338|NCT06663358||Long-Term Cohort|Patients previously participating in the pegunigalsidase alfa open label extension study and transitioning to routine care
62324339|NCT03817593||Transcendental Meditation (TM)|"Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.~To ensure the quality of practice, a group follow-up will be performed 10 days after a completion of the course, and then each participant will receive personal meetings with TM instructor on a weekly basis during the first month, and twice a month for the second and third months.~After additional 3 months participants in this group will be examined again, to assess sustainability of the effect"
62324340|NCT03817593||controls|Control group - Treatment as usual (TAU)
62324341|NCT05474040|ACTIVE_COMPARATOR|opioid|2.5mg/iv morphine every 6hr postoperative
62324342|NCT05474040|ACTIVE_COMPARATOR|multimodal|combination of Gabapentin Orally (600 mg) the night before surgery and 2 hours before anesthesia induction plus dexmedetomidineIV bolus 1 μg/kg/10min + infusion pump 0.5 μg /kg/hrs intraoperative. Bupivacaine(scalp block) R/A 20ml 0.5% Postoperative. Acetaminophen IV 10-15 mg/kg 8hr postoperative. NSAIDs(ketorolac IV15-30mg every 6 postoperative
62324343|NCT02196142|ACTIVE_COMPARATOR|Cortisol first, Placebo second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
62324344|NCT02196142|ACTIVE_COMPARATOR|Placebo first, Cortisol second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
62324345|NCT02512692|EXPERIMENTAL|90Y TARE with Gemcitabine and Cisplatin|"90Y TARE will be given on day 3 or 4 of cycle 1 and start at 75% of the dose calculated by the body surface area formula and escalated by 25% per cohort in combination with cisplatin 25 mg/m2 and gemcitabine 300 mg/m2 in cycles 1 and 2.~Once the 90Y TARE has reached the 100% dose level, the gemcitabine dose will increase to 600mg/m2 in dose level 3 and 1000mg/m2 in dose level 4. The cisplatin dose will remain at 25/mg/m2.~For all dose levels, from cycle 3 to cycle 8, the cisplatin dose will be 25mg/m2 and the gemcitabine dose will be 1000mg/m2."
62324346|NCT04842721|ACTIVE_COMPARATOR|Hypertonic Saturated Saline Mouth Rinse Active Arm|The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.
62324347|NCT04842721|PLACEBO_COMPARATOR|Plain Water Control Arm|The Control Rinse is a 25 ml of Plain Tap Water.
62324348|NCT02298270|EXPERIMENTAL|Relaxation Response Resiliency Program|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
62324349|NCT02298270|PLACEBO_COMPARATOR|Health Education|Participants will receive and 8-week general stress and health education program, with none of the active relaxation and resiliency-based components being tested in the experimental condition.
62324350|NCT04717843|EXPERIMENTAL|Patients with embolic strokes of undetermined source.|Patients over 18 years old, with embolic strokes of undetermined source, fulfilling the TOAST criteria. The intervention consists of a 4D Flow MRI.
62324351|NCT04717843|EXPERIMENTAL|Patients with non-paroxysmal AF.|Patients over 18 years old, with non-paroxysmal AF. The intervention consists of a 4D Flow MRI.
62324352|NCT04717843|ACTIVE_COMPARATOR|Heathy volunteers|The control group will include volunteers over 45 years old with no history of cardio-vascular or neuro-vascular disease. The last will be certified by a pre inclusion protocol containing a medical consultation, a Holter ECG and a trans-thoracic echocardiography. The age of 45 was chosen to get comparable age group and set the analyses free of the age-related effect on the cardiac hemodynamic. The intervention consists of an ECG, holter ECG, Trans thoracic echocardiography ETT, Blood sample and 4D Flow MRI.
62324353|NCT04717843|EXPERIMENTAL|ESUS and non-paroxysmal AF patients with cardiac MRI|ESUS and non-paroxysmal AF patients (fulfilling the group 1 et 2 criteria) and who had had cardiac MRI, in a retrospective way. It corresponds to retrospective inclusion of patients which had MRI in the year before the beginning of the study.
62324354|NCT00366834|PLACEBO_COMPARATOR|Control|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
62324355|NCT00366834|EXPERIMENTAL|Single dose oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
61930838|NCT06161948|EXPERIMENTAL|Time-restricted group|Time-restricted enteral nutrition therapy group
62132362|NCT02345174|EXPERIMENTAL|Imaging Phase + Continuation Phase|In Part 1 of the study, participants will receive a dose of 89Zr-GSK2849330 (Dose 1), with an activity of no more than 37 MegaBequerel (MBq) and a variable total dose of GSK2849330. PET scans will be acquired within 7 days. Two weeks after Dose 1 participants will receive second dose of 89Zr-GSK2849330 (Dose 2) and a variable total dose of GSK2849330. Participants will continue to receive unlabelled GSK2849330 (in Part 2) either at established dose level or as decided by medical monitor.
61930839|NCT06161948|OTHER|Continuous group|Continuous enteral nutrition control group
61930840|NCT04898114|EXPERIMENTAL|NebMag|Nebulized magnesium sulfate and oral sildenafil
62132363|NCT02877797|NO_INTERVENTION|standard Esophagogastroduodenoscopy|standard Esophagogastroduodenoscopy
62132364|NCT02877797|EXPERIMENTAL|cap assisted Esophagogastroduodenoscopy|cap assisted Esophagogastroduodenoscopy
62132365|NCT05751161|EXPERIMENTAL|effect of gait training with AS on dynamic balance, gait and functional independence in stroke|Patients with chronic stroke receive gait training with auditory stimuli to improve dynamic balance, gait and functional independence.
62132366|NCT05751161|OTHER|effect of conventional gait training on dynamic balance, gait and functional independence in stroke|Patients in this group receive conventional gait training only to improve dynamic balance, gait and functional independence .Patients did not receive auditory stimuli for gait training.
62132367|NCT00111631|EXPERIMENTAL|1|
62132368|NCT00111631|EXPERIMENTAL|2|
62132369|NCT00111631|EXPERIMENTAL|3|
62132370|NCT00111631|PLACEBO_COMPARATOR|4|
62132371|NCT02545634|PLACEBO_COMPARATOR|Placebo powder|Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
62132372|NCT02545634|EXPERIMENTAL|Probiotic powder|The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
62132373|NCT03003572||patients with primary Sjögren's syndrome|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.
61930841|NCT04898114|PLACEBO_COMPARATOR|Control|Nebulized placebo (isotonic saline) and oral sildenafil
61944550|NCT03475680|PLACEBO_COMPARATOR|"2)  MBP alone  group"|"Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole~* Sennosides colonic preparation (X-PREP) :~  1 per day, on day -2 and day -1.~* Placebo for oral gentamycin:~Same presentation as oral gentamycin x4 per day on day -2 and day -1. - Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1."
62324356|NCT00366834|EXPERIMENTAL|3-day oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 \& 3
62324357|NCT00366834|EXPERIMENTAL|3-day IV/oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 \& 3
62324358|NCT04908449|EXPERIMENTAL|Rectus sheath block block with PIFB (experimental arm)|PIFB with local anesthetic with RSB with local anesthetic (bupivacaine)
62324359|NCT04908449|PLACEBO_COMPARATOR|Rectus sheath block with PIFB (placebo arm)|PIFB with local anesthetic with RSB placebo (saline)
62324360|NCT03950570|EXPERIMENTAL|Phase 1: Dose Escalation|"Advanced solid tumors or metastatic breast cancer: Treatment with a single oral agent, ORIN1001.~Relapsed, refractory metastatic breast cancer: Treatment with a combination of ORIN1001 and Abraxane."
62324361|NCT03950570|EXPERIMENTAL|Phase 2: Dose Expansion|Relapsed refractory metastatic breast cancer that are Triple negative, ER+ or HER2- and treated with a single agent (ORIN1001) or in combination with ORIN1001 and Abraxane.
62324362|NCT02991053|ACTIVE_COMPARATOR|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
62324363|NCT02991053|ACTIVE_COMPARATOR|block; ketamine with laryngeal mask; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Transversus Abdominis Plane block.
62324364|NCT02991053|ACTIVE_COMPARATOR|block and ketamine ıh/ıl|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
62324365|NCT02991053|ACTIVE_COMPARATOR|ıh/ıl block; ketamine; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
62324366|NCT02991053|ACTIVE_COMPARATOR|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
62324367|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core.
62324368|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes + Fitness Membership|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive a 6-month membership to the Peloton fitness app.
62324369|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes + Mental Imagery|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. In addition, participants will receive access to online mental guided imagery sessions. Guided positive exercise imagery scripts were developed based on work from Williams et al. and prompt several sensory and emotional experiences.
62738359|NCT06365437|EXPERIMENTAL|Arm 4|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
62324370|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes + Mental Imagery + Fitness Membership|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive a 6-month membership to the Peloton fitness app. In addition, participants will receive access to online mental guided imagery sessions. Guided positive exercise imagery scripts were developed based on work from Williams et al. and prompt several sensory and emotional experiences.
62324371|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive Move individualized support sessions. The 1:1 support sessions are designed to help participants adopt the physical activity messages from each Move group-based class into their daily lives.
62339908|NCT06379802|NO_INTERVENTION|Standard of care|The control group will receive (be offered) usual care defined as written lifestyle advices based on the general recommendations for diet (Nordic Nutrition Recommendations, 2012. Integrating nutrition and physical activity. Copenhagen: Nordic Council of Ministers, 2014) and PA (World Health Organization. World Health Organization guidelines on physical activity and sedentary behavior, 2020), including a healthy and varied diet, aiming at 300 mins/week of medium intensity aerobic PA and strength training two times per week.
61944551|NCT03475680|EXPERIMENTAL|"3)  Oral antibiotics alone  group"|"Oral Gentamycin Oral Ornidazole~* Gentamycin :~  80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~* Ornidazole :~  1. g per day (2 tablet per day), on day -2 and day -1; In tablets."
62324372|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes + Fitness Membership + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive a 6-month membership to the Peloton fitness app. Participants will also receive Move individualized support sessions. The 1:1 support sessions are designed to help participants adopt the physical activity messages from each Move group-based class into their daily lives.
62324373|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes + Mental Imagery + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive Move individualized support sessions. The 1:1 support sessions are designed to help participants adopt the physical activity messages from each Move group-based class into their daily lives. In addition, participants will receive access to online mental guided imagery sessions. Guided positive exercise imagery scripts were developed based on work from Williams et al. and prompt several sensory and emotional experiences.
62324374|NCT06116435|EXPERIMENTAL|PreventT2 + Move group-based classes + Fitness Membership + Mental Imagery + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum, integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian. Participants will also receive a 6-month membership to the Peloton fitness app. Participants will also receive Move individualized support sessions. In addition, participants will receive access to online mental guided imagery sessions.
62324375|NCT02242890|OTHER|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
62324376|NCT00960440|EXPERIMENTAL|Sequence 1|
62324377|NCT00960440|EXPERIMENTAL|Sequence 2|
62324378|NCT00960440|PLACEBO_COMPARATOR|Sequence 3|
62324379|NCT00960440|PLACEBO_COMPARATOR|Sequence 4|
62324380|NCT04713917|ACTIVE_COMPARATOR|Gel Group|Two applications of HA gel (Mucogyne®) per week during one year.
62324381|NCT04713917|EXPERIMENTAL|Laser Group|Laser CO2 for vulvovaginal area during 2 sessions (15 min) at visits D0 and M6.
62324382|NCT04713917|EXPERIMENTAL|HA Injection Group|Injection of 1 mL of HA at D0 and M6 (DESIRIAL®).
62324383|NCT04438746|EXPERIMENTAL|Group receiving CBAT|
62324384|NCT04438746|PLACEBO_COMPARATOR|Group receiving general emotion training|
62324385|NCT03704597|ACTIVE_COMPARATOR|7-hour cryotherapy|Standard of care
62324386|NCT03704597|EXPERIMENTAL|2-hour cryotherapy|Experimental treatment
62324387|NCT03742336|EXPERIMENTAL|Arm 1|Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.
62324388|NCT03742336|EXPERIMENTAL|Arm 2|Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.
62324389|NCT06419920|ACTIVE_COMPARATOR|Flat terrain training|Walking on a standard, flat treadmill or mat.
61930842|NCT04000880|EXPERIMENTAL|Project 1: Diet-Exercise|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
62324390|NCT06419920|EXPERIMENTAL|Uneven terrain training|Walking on an uneven terrain treadmill or mat.
62324391|NCT04420481|ACTIVE_COMPARATOR|Growth hormon group|A 12 month study, consisting of a 9 months growth hormone treatment phase followed by a 3 month growth hormone treatment-free period.
62324392|NCT04420481|PLACEBO_COMPARATOR|Control group|A 12 month study, consisting of a 9 month placebo treatment phase followed by a 3 month treatment-free period.
61944552|NCT03475680|PLACEBO_COMPARATOR|"4)  No preparation  group"|"Oral placebo Gentamycin Oral placebo Ornidazole~- Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1~- Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
61944553|NCT01398553|EXPERIMENTAL|Armeo Spring|
62324393|NCT06692205||Primary open-angle glaucoma|Patients with primary open-angle glaucoma diagnosed by glaucoma professionals
62324394|NCT06692205||Healthy controls|Healthy controls were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
62324395|NCT02085239|ACTIVE_COMPARATOR|Lidocaine alone|Lidocaine: 8-10 ml of Lidocaine by subcutaneous injection
62324396|NCT02085239|EXPERIMENTAL|Lidocaine Ropivacaine|"Lidocaine Ropivacaine~* 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection"
62324397|NCT02796924|EXPERIMENTAL|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
62324398|NCT03328078|EXPERIMENTAL|Emavusertib (CA-4948) dose escalation|Part A1: Dose-level cohorts with up to approximately 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for emavusertib.
62339909|NCT05055167|EXPERIMENTAL|Envafolimab|Elderly NSCLC Patients with high PD-L1 expression
61944554|NCT01398553|ACTIVE_COMPARATOR|conventional physiotherapy|
61944555|NCT02009306|EXPERIMENTAL|PecFent and Epistatus|Medication administered by family / carer for symptoms
62483439|NCT04285814||Normal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with normal results.
62483440|NCT04285814||Abnormal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with abnormal results.
62483441|NCT05100212|ACTIVE_COMPARATOR|Adult-RBC transfusions|Adult-red blood cell concentrate transfusions
62483442|NCT05100212|EXPERIMENTAL|CB-RBC transfusions|Cord blood-red blood cell concentrate transfusions
62483443|NCT02647463|EXPERIMENTAL|Attachment and Biobehavioral Catch-up|10-session intervention for parents and infants aimed at increasing parents' nurturance and following the lead, and reducing frightening behavior
62483444|NCT02647463|NO_INTERVENTION|Waitlist Control|Waitlist Control
62691763|NCT06635694||Usual Care|"Responsible clinician will request surveillance imaging and ultrasound appointment will be booked using an automated call/recall system. A formal invitation to surveillance and an informational sheet will be sent by post to patient's home address, addressing concerns including fear, and FAQs e.g. duration of scan and level of discomfort. Patients will receive a reminder 2 weeks prior to their appointment. Results will be automatically sent to the relevant hepatology unit and GP. Patients will be informed of results by mail or through patientknowsbest app, and invited for repeat ultrasound in 6 months. Patients with abnormal results will be contacted by the direct care team to organise further investigations. Non-attendance will be followed by a further appointment letter/text. Patients who fail to attend 2 appointments will be contacted by the direct care team. Their reasons for non-attendance will be recorded and GP contacted."
62691764|NCT06635694||Patient Navigator|Patients will receive usual care plus a scripted phone call from a Patient Navigator the week prior to the surveillance appointment to remind patients, offer to reschedule the appointment if the patient is unable to attend, and address any concerns about the appointment. All other procedures will be the same as usual care. Additionally, Navigators will call patients who have not attended surveillance imaging appointments to explore any barriers to attendance and how these might be addressed.
62691765|NCT05917288|EXPERIMENTAL|Participants receiving belimumab + Standard of care (SOC)|Participants will receive belimumab 200 milligrams SC injection according the Baseline body weight plus SOC.
62691766|NCT06640920|EXPERIMENTAL|Cohort A|NSI-8226
62691767|NCT06640920|EXPERIMENTAL|Cohort B|NSI-8226
62691768|NCT06640920|EXPERIMENTAL|Cohort C|NSI-8226
62691769|NCT06640920|EXPERIMENTAL|Cohort D|NSI-8226
62691770|NCT02834741|PLACEBO_COMPARATOR|SAD Phase|"Up to 36 subjects: 50 - 1200 mg NYX-2925, Up to 12 subjects: placebo~6 additional subjects will receive a fed dose of NYX-2925, 2 additional subjects will receive a fed dose of placebo (Food Effect Cohort)~6 additional subjects will receive 1 dose of 50 mg NYX-2925 followed by a lumbar puncture at 1 and 4 (3 subjects) or 2 and 8 (3 subjects) hours post dose"
62691771|NCT02834741|PLACEBO_COMPARATOR|MAD Phase|"Up to 24 subjects : 150 - 600 mg NYX-2925 daily for 7 days, up to 6 subjects : placebo daily for 7 days~6 additional subjects will receive 300 mg NYX-2925 daily for 7 days and undergo lumbar puncture on Day 6 in order to have two CSF samples taken (CSF Cohort)."
62691772|NCT03855540||Study group|Adult patients with documented paroxysmal, nonvalvular atrial fibrillation with CHA2DS2-VASc score \> 2 (for females \> 3) and sinus rhythm at the time of inclusion. In total 100 patients will be included.
62691773|NCT03855540||Control group|"Patients without a history of palpitations or irregular heart rhythm. AFib will be excluded with the help of 7 days ECG Holter and ECG event recorder monitoring. In total 100 patients will be included.~Propensity matching according to the:~* CHA2DS2-VASc parameters~* LVEF: preserved (\<40%), mid-range (40-49%) and reduced (\>50%)~* Presence of diastolic dysfunction~* Glomerular filtration rate: (≥1,5 ml/s), (1,4-1 ml/s) and (0,9-0,5 ml/s)~* Drugs: ACE-I/ARB, betablockers, digoxin, amiodarone~* BMI: (\<30kg/m2), (30-39kg/m2) and (≥40kg/m2)~* Smoking (\>5 cigarettes per day)"
62691774|NCT04937166|EXPERIMENTAL|DSP107 in combination with azacitidine or azacitidine plus venetoclax.|"DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study.~Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle.~Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards."
62339910|NCT00734786|PLACEBO_COMPARATOR|2|Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
62339911|NCT06009224|NO_INTERVENTION|Conventional|Conventional ERAS program
62483445|NCT00935012|EXPERIMENTAL|Open-Label|
62483446|NCT05413096|PLACEBO_COMPARATOR|placebo tube|neutral material without any biological effects
62483447|NCT05413096|ACTIVE_COMPARATOR|Combination of diclofenac potassium and propolis|active agents combination of diclofenac potassium 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel
62483448|NCT06201390|EXPERIMENTAL|Stable sleep|Participants will be asked to maintain a consistent sleep pattern for two weeks.
62483449|NCT06201390|NO_INTERVENTION|Habitual Sleep|Participants will be asked to maintain their usual sleep pattern for two weeks.
62483450|NCT05608642|ACTIVE_COMPARATOR|Group given intravenous hydration|The first group consists of patients given 500 cc intravenous saline for 1 hour.
62483451|NCT05608642|ACTIVE_COMPARATOR|Group given intravenous prednisolone|Second group; consists of patients who were given 80 mg of intravenous prednisolone for the first 4 days and then given gradually decreasing doses of prednisolone in the following days.
62483452|NCT05608642|ACTIVE_COMPARATOR|Group given intravenous lidocaine|Third group; includes patients given 2 mg/kg intravenous lidocaine by 1-hour infusion.
62483453|NCT05582915||Adult patients with severe Bell's palsy|Adult patients recently diagnosed with severe Bell's palsy and referred to the ENT Department by A\&E or by general practitionner.
62483454|NCT05143047|NO_INTERVENTION|Control|Participants in the usual care group will receive standard-of-care discharge communications per unit routine, including counseling regarding prescribed medications and post-discharge instructions, return precautions, and follow-up appointments by the pediatric nursing staff.
62738360|NCT06365437|ACTIVE_COMPARATOR|Arm 5|ATG administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
62738361|NCT00232284|ACTIVE_COMPARATOR|Sertaline|8 week course of sertraline 50-100mg for those who fail to respond to CBT within first 4 weeks of study entry
62324399|NCT03328078|EXPERIMENTAL|Emavusertib (CA-4948) and ibrutinib dose escalation|Part A2: Evaluate escalating dose levels of oral emavusertib in combination with 560 mg QD or 420 mg QD of oral ibrutinib. The starting dose of emavusertib to be used in combination will be 200 mg twice a day (BID). It is anticipated that 12 to 20 patients at a potential dose level will be required to establish optimal combination dosing.
62483455|NCT05143047|EXPERIMENTAL|Intervention|Participants in the intervention group will receive supplementary medication discharge instructions in addition to the standard communications. They will receive instructions on how to submit information and complete study surveys securely through their cellphones during their child's home treatment period.
62483456|NCT02220049|EXPERIMENTAL|Velcade|Dose level Dose(mg/m²) d1-5, d8-12, d15-19 Cohort -2 Velcade 0.3 mg/m² Cohort -1 Velcade 0.4 mg/m² Cohort 1 Velcade 0.5 mg/m² Cohort 2 Velcade 0.6 mg/m² Cohort 3 Velcade 0.7 mg/m² Cohort 4 Velcade 0.8 mg/m² Cohort 5 Velcade 0.9 mg/m² Cohort 6 Velcade 1.0 mg/m² Cohort 7 Velcade 1.1 mg/m²
62691775|NCT06290778|EXPERIMENTAL|Brief Unified Protocol|This workshop includes education regarding basic human emotions, why we have emotions, how they help us, how they can get in the way, and how they are related to psychological health problems, including among firefighters. Skills that are helpful in managing strong or unwanted emotions will be taught and practiced during the workshop. A workshop manual will be provided. Brief videos summarizing the material will be emailed over the course of the month following the workshop.
62691776|NCT06290778|ACTIVE_COMPARATOR|Psychoeducation|This workshop provides education regarding signs and symptoms of psychological health challenges that are most commonly experienced by firefighters. These include posttraumatic stress, depression, anxiety, and alcohol and substance misuse. This workshop is a standard part of fire academy training. A workshop manual will be provided. Brief videos summarizing the material will be emailed over the course of the month following the workshop.
62691777|NCT02457793|EXPERIMENTAL|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
62691778|NCT02457793|EXPERIMENTAL|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
62691779|NCT02457793|EXPERIMENTAL|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
62738362|NCT00232284|PLACEBO_COMPARATOR|Placebo|8 week course of placebo
62324400|NCT03328078|EXPERIMENTAL|Emavusertib (CA-4948) and ibrutinib dose expansion|In two PCNSL Expansion Cohorts (Part B), emavusertib in combination with ibrutinib will be administered in patients with PCNSL. In Cohort 1, emavusertib 100 mg BID will be administered with ibrutinib 560 mg QD consecutively in a 28-day cycle in approximately 6 to 9 patients. In Cohort 2, CA-4948 200 mg BID will be administered with ibrutinib in at least 9 patients.
62324401|NCT03186404|PLACEBO_COMPARATOR|Placebos|Placebos
62324402|NCT03186404|EXPERIMENTAL|Statin|Atorvastatin 40mg
62324403|NCT04477304|EXPERIMENTAL|Behavioral Intervention Arm|Clinicians in clinics randomized to the intervention group will be prompted with an EHR nudge when the prescribing history for the patient falls into one of the following three categories: Opioid naïve, At-risk for long-term use, or Long-term opioid recipient. These EHR-based nudges include elements of accountable justification, defaults and precommitments. Clinicians will also receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
62324404|NCT04477304|NO_INTERVENTION|Control|Clinicians in clinics randomized to the control group will receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
62324405|NCT04472923|ACTIVE_COMPARATOR|Control group|Patients belonging to the control group received conventional physical therapy program in the form of diet and Kegel exercises.
62324406|NCT04472923|EXPERIMENTAL|Study group|Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training
62324407|NCT06692023|EXPERIMENTAL|High-intensity NPPV|Patients will receive high-intensity NPPV
62324408|NCT06692023|ACTIVE_COMPARATOR|Low-intensity NPPV|Patients will receive low-intensity NPPV
62483457|NCT00205777|ACTIVE_COMPARATOR|A|
62483458|NCT00205777|PLACEBO_COMPARATOR|B|
62483459|NCT05814783|EXPERIMENTAL|Integrated digital CBTI|Therapists will be trained to integrate digital CBTI alongside routine psychotherapy. Patients will receive integrated digital CBTI
62483460|NCT03572335||HIV positive with normal PFT's|HIV positive with normal baseline DLco. Subjects with DLco\>80% predicted after adjustments for Hgb and Co
62324409|NCT02271243||Subject with suspected MBI|
62324410|NCT02271243||Subjects without suspected MBI|
62324411|NCT01669369|PLACEBO_COMPARATOR|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
62324412|NCT01669369|EXPERIMENTAL|Lithium Carbonate|Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
62324413|NCT01096771|EXPERIMENTAL|ClinOleic 20%|96 hour continuous infusion.
62324414|NCT01096771|ACTIVE_COMPARATOR|Intralipid 20%|96 hour continuous infusion.
62324415|NCT02244359|EXPERIMENTAL|Training|Online tutorial, decision aid and interactive workshop
62324416|NCT02244359|OTHER|Usual care|Usual care
62324417|NCT01630044|EXPERIMENTAL|TNM device, active treatment|This is an active-only assessment of the experimental neuromodulation device
62483461|NCT03572335||HIV positive with mild DLco impairment|HIV positive with mild DLco impairment DLco \<80% predicted after adjustments for Hgb and Co.
62483462|NCT03498235|EXPERIMENTAL|Team Sevoflurane|
62483463|NCT03498235|EXPERIMENTAL|Team Propofol|
62483464|NCT03783897|EXPERIMENTAL|EDP-305 and Oral Contraceptive|
62132374|NCT01535690|EXPERIMENTAL|laser and methilene blue|After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler (Profi III Bios, Dabi Atlante, Ribeirão Preto, São Paulo, Brazil) for 1 hour. Specific tips were used (Perio sub, Dabi Atlante, Ribeirão Preto, São Paulo, Brazi). PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl (Photon Laser III - PL7336, DMC, São Carlos -São Paulo, Brazil) was applied (660 nm, 100 mW, 9 J, 90 seconds per site, 320 J/cm2).
62132375|NCT02422615|EXPERIMENTAL|Ribociclib + fulvestrant|Ribociclib was administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. For participants who did not tolerate the protocol-specified dosing schedule, dose adjustments were permitted in order to allow the patient to continue the study treatment.
62324418|NCT05937854|PLACEBO_COMPARATOR|Placebo|Encapsulated placebo one or 2 encapsulated tablets po QD
62324419|NCT05937854|ACTIVE_COMPARATOR|tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
62324420|NCT03175003|ACTIVE_COMPARATOR|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
62324421|NCT03175003|ACTIVE_COMPARATOR|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
62324422|NCT03175003|EXPERIMENTAL|Food Product 3|Experimental 1
62324423|NCT03175003|EXPERIMENTAL|Food Product 4|Experimental 2
62324424|NCT00997633||Peritoneal carcinomatosis|Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment
62483465|NCT06308484|ACTIVE_COMPARATOR|Active transcutaneous vagus nerve stimulation|The tVNS device consisted of two titan electrodes mounted on a gel frame and connected to a wired neurostimulation device (tVNS Health GmbH, Germany). Electrodes were placed on the cymba conchae. Stimulation intensity of 0.5 mA, delivered with a pulse width of 200-300 μs at 25 Hz.
62691780|NCT02457793|EXPERIMENTAL|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
62691781|NCT02457793|EXPERIMENTAL|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
62691782|NCT02457793|EXPERIMENTAL|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
62691783|NCT06322901|EXPERIMENTAL|test side|A mid-crestal incision was made on the test side with a no. 12 scalpel and a sulcular incision was made around the first natural tooth and a 5-mm vertical incision was made disto-obliquely to the distal crestal incision
62691784|NCT06322901|ACTIVE_COMPARATOR|control side|Only a mid-crestal incision was made on the control side with a no. 12 scalpel and a sulcular incision was made around the first natural tooth
62691785|NCT06572774|EXPERIMENTAL|C3Link strategies|Community liaison will host group education sessions and facilitate cervical and breast cancer screening
62691786|NCT06572774|EXPERIMENTAL|C3Link Plus Strategies|In addition to group education sessions, the Community Liaison will offer women one-on-one education, counseling and navigation support to address barriers.
62691787|NCT06572774|ACTIVE_COMPARATOR|One-time education|Participants will receive educational brochure on importance of breast and cervical cancer screening
62691788|NCT05073432|EXPERIMENTAL|Experimental|Electronic completion of Geriatric Assessment and Conjoint Analysis with result output.
62324425|NCT05323786|EXPERIMENTAL|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
62324426|NCT05323786|PLACEBO_COMPARATOR|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
62324427|NCT06219005|EXPERIMENTAL|Emergency Medicine attending physicians and residents|
62324428|NCT01465178|ACTIVE_COMPARATOR|2000 IU vitamin D3|Cholecalciferol 2,000 IU capsules
62324429|NCT01465178|PLACEBO_COMPARATOR|Placebo|Non-matching placebo, gelatin filled capsules
62324430|NCT03293199|ACTIVE_COMPARATOR|Chest tube drainage|This group will undergo chest tube drainage as an intervention for spontaneous pneumothorax treatment.
62324431|NCT03293199|ACTIVE_COMPARATOR|Needle aspiration|This group will undergo repetitive needle aspiration as an intervention for spontaneous pneumothorax treatment.
62339912|NCT06009224|EXPERIMENTAL|Experimental|complete ERAS program (Conventional ERAS program + Epidural analgesia + Fluid balance)
62691789|NCT06421441|EXPERIMENTAL|Experimental|Experimental group (Education group)
62691790|NCT06421441|NO_INTERVENTION|Control group|Control group
62691791|NCT01927848|EXPERIMENTAL|Rosehip|Dosage: 3 capsules once daily with meals (daily dose: 2.25 g powder).
62691792|NCT01927848|PLACEBO_COMPARATOR|Placebo|Dosage: 3 capsules once daily with meals
62691793|NCT04067622|OTHER|Exersides restraints first|Patients in this arm will wear the novel Exersides restraint during hours 1-4 on Day 1, then switched to soft wrist restrains during hours 5-8. On Day 2, patients in this arm will will wear soft wrist restraints during hours 1-4, and Exersides during hours 5-8. They will then wear Exersides during study days 3-6.
62691794|NCT04067622|OTHER|Traditional restraints first|Patients in this arm will wear soft wrist restraints during hours 1-4 on Day 1; they will then be switched to the novel Exersides restraint during hours 5-8. On Day 2, patients in this arm will will wear Exersides during hours 1-4, and soft wrist restraints during hours 5-8. They will then wear soft wrist restraints during study days 3-6.
62738363|NCT01703052|EXPERIMENTAL|CHF 6001 SD or placebo|Single administration of CHF 6001 dose levels 1 to 7 or placebo
62738364|NCT01703052|EXPERIMENTAL|CHF 6001 MD or placebo|Multiple administration of CHF 6001 dose levels 1 to 5 or placebo
62691795|NCT04785352|NO_INTERVENTION|Standard well-baby care|Children in this arm (control group), as well as children in the two intervention groups, will receive standard care as outlined in the Essential Package of Health Services by Haiti's Ministry of Public Health and Population (MSPP). This includes a World Health Organization (WHO) immunization schedule of vaccines, high dose vitamin A supplements, and growth monitoring and promotion.
62324432|NCT02558881||Virtual colonoscopy|"With virtual colonoscopy, the patient does not need to be hospitalized for examination, which is usually done without hospitalization. A bowel preparation is necessary. It may vary from site to site, but it generally comprises polyethylene glycol or sodium phosphate. The residual stools are marked by ingestion of a radiopaque product to differentiate colic lesions. But no contrast agent is injected intravenously. The patient should be supine and a rectal probe is set up to inject either air or CO2. The vesting period does not exceed thirty seconds apnea, and overall completion time of the examination (patient table) is about 10 minutes."
62324433|NCT02558881||Colon capsule|The colon capsule comprises two cameras located at both ends. Image acquisition is set between four to thirty-five images per second. It begins immediately after ingestion of the capsule which allows recording of esophageal and gastric images. She paused for 2 hours (to save batteries) while crossing the small intestine. It is reactivated in the terminal ileum. The films analysis time is approximately 1 hour, and the capsule remains on average 3 hours in the colon.
62324434|NCT05858944|EXPERIMENTAL|Intensive Home BP Control|Participants randomized into the intensive treatment arm will have a goal of home BP\<125/75 mmHg.
62324435|NCT05858944|ACTIVE_COMPARATOR|Standard Home BP Control|Participants randomized into the standard treatment arm will have a goal of home BP within 125-134/75-84 mmHg.
62324436|NCT05259553|EXPERIMENTAL|Patients with multiple myeloma|Adult patient, over 18 years old, with newly diagnosed multiple myeloma, indication of chemotherapy.
62324437|NCT04742257|EXPERIMENTAL|Active Stimulation|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
62324438|NCT04742257|SHAM_COMPARATOR|Sham Stimulation|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
62324439|NCT01925001|EXPERIMENTAL|MP4CO|Escalating doses of MP4CO, administered intravenously
62324440|NCT01925001|ACTIVE_COMPARATOR|Sodium chloride solution|Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
62324441|NCT05280704|OTHER|V1 Lidocaine, D2 Saline|Will undergo volar technique 1st with 4 mL of 1% lidocaine and then dorsal technique 2nd with 4 mL of 0.9% sterile saline. This is a 1-time dose.
62324442|NCT05280704|OTHER|V1 Saline, D2 Lidocaine|Will undergo volar technique 1st with 4 mL of 0.9% sterile saline and then dorsal technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
62324443|NCT05280704|OTHER|D1 Lidocaine, V2 Saline|Will undergo dorsal technique first with 4 mL of 1% lidocaine and then volar technique second with 0.9% sterile saline. This is a 1-time dose.
62324444|NCT05280704|OTHER|D1 Saline, V2 Lidocaine|Will undergo dorsal technique 1st with 4 mL of 0.9% sterile saline and then volar technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
62324445|NCT04473443||Cohort A|Patients with a challenging anatomy, including bicuspid aortic valve, severely calcified aortic valves or small aortic roots
62324446|NCT04473443||Cohort B|Consecutive patients eligible for TAVI with ACURATE-NEO2 valve
62324447|NCT03637868|EXPERIMENTAL|Eribulin|eribulin 1.4 mg/m² administered intravenously between 6 and 7 cycles.
62324448|NCT03732872||Patient with habits and having OSMF|Patients who had history of arecanut chewing habit in any form and composition and who were not undergone any treatment for their current condition i.e, OSMF
62324449|NCT03732872||Patients with habits and had no clinical symptoms of OSMF|Patients who had history of arecanut chewing habit in any form and composition and had no symptoms of OSMF clinically
62324450|NCT03732872||Healthy human volunteers|patients who reported no history of areacnut chewing habits and had no clinical symptoms of OSMF
62324451|NCT04567966|EXPERIMENTAL|Cortical bone plate|A cortical plate was harvested from the external oblique ridge and split in half. Then one plate was fixed at a distance from the atrophied ridge and autogenous bone chips were used to fill the gap between the plate and the ridge.
62324452|NCT04567966|ACTIVE_COMPARATOR|Cortico-cancellous block graft|A cortico-cancellous block graft was harvested from the symphysis of the mandible and fixed to the atrophied ridge.
62324453|NCT03493308|EXPERIMENTAL|Pain neuroscience and exercise|Participants will received an 8 week intervention consisting of pain neuroscience education and exercise. Pain neuroscience education will be conducted in line with international guidelines, covering the neurophysiology of pain, transition from from acute to chronic pain and the nervous system ability to modulate the pain experience. exercise will include general exercise and dance.
62324454|NCT02754778|NO_INTERVENTION|control group|no intervention, regular family life
62324455|NCT02754778|ACTIVE_COMPARATOR|intervention group|6 month of regular conditional workout 1-3 times a week
62324456|NCT05415956|EXPERIMENTAL|Walking exercise therapy|"7 week intervention group. 6-12 persons per group. 2 sessions per week, 14 sessions in total.~Surface: the investigators aim to involve as much forest/gravel trails as possible, with up/down hill walking.~Uneven session numbers: warm-up (6 minutes at BORG 10-11), continous walking (starting at 12-20 minutes at BORG 13-14 and progressing to 20-40 minutes at BORG 15-16, adjusted according to the starting level of each participant) and cool-down (approximately 10 minutes at BORG 10-11).~Even session numbers: warm-up (6 minutes at BORG 10-11), intermittent walking (starting at 3-4 intervals of 2 minutes at BORG 14-15 and progressing to 4-5 intervals of 2-3 minutes at BORG 16-17; with all intervals being interspersed by 1 minute rest) and cool-down (approximately 10 minutes at BORG 10-11)."
62324457|NCT05415956|NO_INTERVENTION|Control/Waitlist|7 week control/waitlist group. Continuation of habitual lifestyle during the 7 week intervention period (yet these participants will receive the exact walking exercise therapy afterwards).
62691796|NCT04785352|EXPERIMENTAL|Nutrition Intervention|Children in this arm will receive one egg per day for six months.
61944556|NCT02009306|ACTIVE_COMPARATOR|Standard subcutaneous medication|Standard subcutaneous medication - diamophine and / or midazolam administered by nursing staff
62324458|NCT02166840|EXPERIMENTAL|Self expanding metal stent|Patients with self expanding metal stent inserted into bile duct.
62324459|NCT02166840|ACTIVE_COMPARATOR|Plastic stent|Patients with obstructive jaundice who got a plastic stent inserted into bile duct.
62324460|NCT01366222|PLACEBO_COMPARATOR|Placebo|
62324461|NCT01366222|ACTIVE_COMPARATOR|Food concentrates (FC)|Food concentrates (FC) was including fruit and vegetable, fish and probiotics.
62324462|NCT06036433|ACTIVE_COMPARATOR|Randomized, Placebo Controlled, Double-Blind Clinical Trial Real ( Active) vs. Placebo (Sham)|"The first arm includes the real (active) group (n=30) and the placebo (sham) group (n=30). Both groups will self-administer their at-home photobiomodulation (PBM) therapy with devices that either emit active light energy or emit no light energy, respectively. The 30 minute treatment is completed 3 x per week. The protocol includes abdominal PBM treatment with a hand held infrared device and transcranial PBM treatment with an infrared \& red LED helmet. Participants are taught how to administer their own treatment and are provided with weekly follow-up. At the completion of the 24 treatments the devices are returned. Post outcome measurement testing is conducted at baseline and 1 and 4 weeks after the last PBM treatment. An inclusion criteria requires that subjects have been exercising 3 x per week before entering the study and continue the minimum level of exercise throughout the study.~Data from the Real group will be compared with the results from in the Placebo group."
62324463|NCT06036433|OTHER|Active and Placebo Cross Over|After the first arm of the study is completed and the post treatment assessments administered, participants in the Active and Placebo groups will be offered the option to complete 8 weeks of real (active) at-home PBM treatment of the abdomen and head (transcranial), 3 x per week for a total of 24 treatments. Each treatment takes approximately 30 minutes to complete. The devices are then returned. Outcome measurement testing will be conducted at Weeks 1 and 4 weeks after the last treatment.
62324464|NCT06692101|ACTIVE_COMPARATOR|Group A (Oral Care)|"Participants received oral care twice daily for at least five days. Oral care procedures included:~* Preparation: Necessary tools and suction devices were prepared, and patients were assisted in upright sitting before oral care.~* Oral Assessment: A flashlight and toothbrush were used to perform an oral assessment and remove food debris. Saliva was aspirated if necessary.~* Oral Cleaning: Oral cleaning tools, including a toothbrush, dental floss, and interdental brush, were utilized with fluoridated toothpaste (fluoride \>1,000 ppm, \<0.5 cm³). The Bass method of brushing was employed for toothbrushing.~* Tongue Cleaning: The anterior two-thirds of the tongue was cleaned with a moistened toothbrush following brushing."
62324465|NCT06692101|ACTIVE_COMPARATOR|Group B (O-NMES)|"Participants received the same oral care as Group A, and NMES therapy was administered after each oral care session. NMES therapy involved:~* Equipment: NMES was administered using VitalStim® (Chattanooga, TN, USA).~* Preparation: Participants were instructed to shave facial hair and cleanse the neck skin with alcohol wipes before electrode placement.~* Electrode Placement: Four electrode pads were placed horizontally above and below the hyoid bone. (Figure 1.)~* Stimulation Parameters: The NMES unit provided dual-pole stimulation across four channels at a fixed pulse rate of 80 Hz and a fixed biphasic pulse duration of 300 μs.~* Session Duration and Intensity: Each session lasted 30 minutes, with the stimulation intensity gradually increased in intervals of 0.5 mA, adjusted based on patient feedback, and set to the maximum tolerance level defined by the patient."
62324466|NCT06692101|NO_INTERVENTION|Group C (Control)|Participants received standard care per the unit's existing protocol, which included oral care administered by nurses and verbal education provided to patients and their caregivers to encourage oral hygiene practices at least once daily.
62324467|NCT03889093|OTHER|Yttrium-90|This single arm study is to evaluate immunologic changes following the treatment of primary or secondary malignancies of the liver utilizing beta-emitting, Yttrium-90.
62324468|NCT02060617|EXPERIMENTAL|Impairment-Based Group|The impairment-based intervention will be a multi-modal treatment approach utilizing manual therapy of the thoracolumbosacral spine and hips as well as motor control exercises. Patient education will also be provided.
62324469|NCT02060617|ACTIVE_COMPARATOR|Classification-Based Group|Patients in this group will be categorized into subgroups according to the Treatment-Based Classification (TBC) Algorithm and treated accordingly. Patient education will also be provided.
62324470|NCT06682481||Children with obesity|Children with obesity followed within the pediatric endocrine and diabetes unit of the University Hospitals of Geneva, Switzerland. The investigators will do prospective measures in 50 children aged 12 to 15 years, at the time of a planned oral glucose tolerance test and again, 2 years later.
62324471|NCT03992469|EXPERIMENTAL|E-B-FAHF-2|Low dose EBFAHF-2 (29 mg/kg/d divided two times a day) for 2 weeks followed by a full dose (71mg/kg/d divided two times a day) for 6 weeks
61930843|NCT04000880|EXPERIMENTAL|Project 2: Exercise-Diet|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
61930844|NCT04000880|EXPERIMENTAL|Project 3: Combined Diet and Exercise|Participants will receive the diet and exercise content simultaneously in combined web-based sessions. Participants will receive and participate in web-based sessions that focus on diet and exercise for 12 months. Participants will be encouraged to track their diet, weight and physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
61930845|NCT06648798|EXPERIMENTAL|Intervention|Participants will be involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).
62324472|NCT03992469|PLACEBO_COMPARATOR|Placebo|capsules are identical in appearance to EBFAHF-2 capsules
62324473|NCT01821170|EXPERIMENTAL|Cognitive remediation|
62324474|NCT01821170|ACTIVE_COMPARATOR|Supportive psychotherapy|
62324475|NCT01821170|ACTIVE_COMPARATOR|Methylphenidate|
62324476|NCT03048721|EXPERIMENTAL|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
62324477|NCT03048721|EXPERIMENTAL|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
62132376|NCT02422615|PLACEBO_COMPARATOR|Placebo + fulvestrant|"Placebo was administered orally for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. For participants who did not tolerate the protocol-specified dosing schedule, dose adjustments were permitted in order to allow the patient to continue the study treatment.~Participants were unblinded after the implementation of protocol amendment 4 (29-Jan-20) and were given the option to crossover to treatment with ribociclib and fulvestrant."
62324478|NCT02739334|EXPERIMENTAL|ENRICH|The intervention will integrate the Play and Learning Strategies (PALS) program, a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler with Coordinated Approach To Child Health (CATCH), a behaviorally-based school health promotion program based on Social Cognitive Theory (SCT) to increase opportunities for healthy eating and activity.
62483466|NCT06308484|SHAM_COMPARATOR|Sham transcutaneous vagus nerve stimulation|Stimulation parameters equivalent to active but sham stimulation was administered by positioning the electrodes on the central part of the left earlobe rather than the outer auditory canal, as the earlobe lacks vagus innervation.
62483467|NCT06308484|ACTIVE_COMPARATOR|Closed-loop AM-tACS increase frontal midline theta oscillation|We will deliver amplitude-modulated transcranial alternating current stimulation (AM-tACS) using two circular rubber electrodes (4 cm diameter) positioned at the Fpz and Cz locations of the international 10-20 system. The AM-tACS stimulation waveform features a carrier signal frequency of 10 kHz, an amplitude of ±1 mA, and a signal that is real-time synchronized with theta oscillations of the frontal midline. In the active condition target oscillations (frontal midline theta) will be increased.
62132377|NCT04287985|PLACEBO_COMPARATOR|Placebo|Placebo, normal saline (0.9% NaCl) will be administered IV
62132378|NCT04287985|EXPERIMENTAL|Low Dose - VIS649|Low dose of VIS649 administered IV
62132379|NCT04287985|EXPERIMENTAL|Medium Dose - VIS649|Medium dose of VIS649 administered IV
62324479|NCT02739334|ACTIVE_COMPARATOR|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
62324480|NCT06302205|SHAM_COMPARATOR|Sham Group|Home-based low-intensity exercise training without subsequent physical activity intervention.
62324481|NCT06302205|EXPERIMENTAL|Moderate-intensity (MIT)|Home-based moderate-intensity exercise training with subsequent physical activity intervention.
62324482|NCT06302205|EXPERIMENTAL|Combined moderate and high-intensity (MHIT)|Home-based moderate- and high-intensity exercise training with subsequent physical activity intervention.
62324483|NCT02236546|EXPERIMENTAL|FDG-PET/CT|Patients undergo \[18F\]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). Molecular assays on biopsied tissue obtained from a subset of patients will also undergo molecular assays, the results from which will be correlated with FDG-PET/CT data.
62324484|NCT06059378|OTHER|AI-assisted classification for diminutive polyps during a colonoscopy procedure|AI-assisted classification for diminutive polyps during a colonoscopy procedure using the CAD-eye detection and classification system for patienst who agree to undergo optical diagnosis of diminutive colorectal polyps
62324485|NCT05794945||Breastfeeding mothers|In this study breastfeeding mothers will be included. Samples will be collected from breast-feeding mothers experiencing mastitis Samples will be collected from breast-feeding mothers after the mastitis episode is resolved Breastfeeding mothers will be sampled at each mastitis episode, and with the final sample collected after a maximum of 12 months
62324486|NCT04263662||Pre-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours prior to implementation of an analgesia-sedation algorithm.
62324487|NCT04263662||Post-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours after implementation of an analgesia-sedation algorithm.
62324488|NCT02145910|EXPERIMENTAL|WBRT + Vemurafenib|Patients undergo WBRT once daily (QD) for 10 doses
62324489|NCT02145910|EXPERIMENTAL|SRS + Vemurafenib|Patients undergo SRS (gamma knife, tomotherapy, cyberknife, or megavoltage LINAC radiation therapy) on day 1
62324490|NCT06678347|EXPERIMENTAL|Intervention group|Participants in this arm includes employees of managers in the intervention group (that are participating in the intervention programme).
62339913|NCT05947747|EXPERIMENTAL|Group 1: investigational drug EXO-CD24 at a dose of 10^10|60 patients who will receive a 5-day treatment with the investigational drug EXO-CD24 at a dose of 10\^10
62483468|NCT06308484|SHAM_COMPARATOR|Closed-loop AM-tACS decrease frontal midline theta oscillation|Equivalent to the active comparator - except here the target oscillation will be suppressed.
62483469|NCT01484912|EXPERIMENTAL|STA-2|"STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
61930846|NCT06471790||Walking Epidural Analgesia for Labor|Pregnant women in labor who benefit from walking epidural analgesia technique will be monitored using inertial wearable sensors beginning from the first stage of labor and up to delivery.
61930847|NCT04406610|EXPERIMENTAL|GD2 CAR-T|Treated by GD2 CAR-T therapy intravenously
61930848|NCT04406610|NO_INTERVENTION|Control|With no medical intervention
62132380|NCT04287985|EXPERIMENTAL|High Dose - VIS649|High dose of VIS649 administered IV
62132381|NCT03750539|ACTIVE_COMPARATOR|Standard Treatment|External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
62132382|NCT03750539|EXPERIMENTAL|hypofractionated treatment|External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
62132383|NCT05178459||Diabetic|Patient diagnosed with diabetes
62691797|NCT04785352|EXPERIMENTAL|Grandi Byen|This arm comprises a multicomponent intervention on responsive parenting, nutrition, hygiene, and one egg per day for six months for children.
62691798|NCT00005626|EXPERIMENTAL|Irinotecan Treatment|Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
62691799|NCT04510740||Hepatocellular Carcinoma (HCC)|Patients with Hepatocellular Carcinoma (HCC)
62691800|NCT04510740||Cholangiocarcinoma (CCC)|Patients with Cholangiocarcinoma (CCC)
62691801|NCT03660449|EXPERIMENTAL|Experiment|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
62132384|NCT05178459||Neuropathic without diabetes|Patient diagnosed with neuropathy without diabetes
62324491|NCT06678347|NO_INTERVENTION|Wait-list control group|"Participants in this arm includes employees of managers randomised to the control group (that are not participating in the intervention programme during the study period).~Managers randomised to the control group will be offered to participate in the intervention programme after the last follow-up assessment. No further employee assessments will be made after the follow-up."
62324492|NCT05388435|EXPERIMENTAL|Part 1: Dose Escalation Phase|Part 1 is a dose escalation phase to evaluate the safety, tolerability, and define the MTD and RP2D. Part 1 is a 3+3 design.
62324493|NCT05388435|EXPERIMENTAL|Part 2: Dose Expansion Phase|Part 2 includes tumor-specific expansion cohorts utilizing the MTD/RP2D doses (determined from Part 1) to further explore safety and anti-tumor activity of SKL27969, in addition to the PK and PD from the patients with the selected tumor types.
62324494|NCT04775212|ACTIVE_COMPARATOR|desflurane|patients to be anesthetized with desflurane
62324495|NCT04775212|ACTIVE_COMPARATOR|sevoflurane|patients to be anesthetized with sevoflurane
62324496|NCT02203253|ACTIVE_COMPARATOR|Thalidomide Group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
62483470|NCT01484912|PLACEBO_COMPARATOR|Placebo|"Placebo capsule, containing non-active ingredients.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
62691802|NCT02668757|OTHER|HeartHab application arm|Patients in the HeartHab application arm will receive the mobile application during study period.
62691803|NCT03218475|EXPERIMENTAL|MR Guided Focused Ultrasound|
62691804|NCT03842280||Prolonged mechanical ventilation|Prolonged mechanical ventilation with tracheostomy
62691805|NCT06002477|EXPERIMENTAL|Anticholinergic Challenge|All participants will receive oral mecamylamine for 1 day
62691806|NCT06002477|PLACEBO_COMPARATOR|Placebo Challenge|All participants will receive oral placebo for 1 day
62691807|NCT04603287|EXPERIMENTAL|Study treatment|Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62691808|NCT03066739|ACTIVE_COMPARATOR|LO-low dose remifentanil|low dose remifentanil (LO, 0.1 micrograms/kg/mL),
62691809|NCT03066739|ACTIVE_COMPARATOR|HI-high dose remifentanil with placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
62691810|NCT03066739|ACTIVE_COMPARATOR|HN-high dose remifentanil with ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone).
62691811|NCT06383806|EXPERIMENTAL|Treatment|The Treatment arm will receive the intervention immediately following the first assessment.
62324497|NCT02203253|PLACEBO_COMPARATOR|Placebo Group|Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
62324498|NCT02664636|EXPERIMENTAL|The study population|"The study population consists of patients 20 and 75 years of age who have had a supra-tentorial ischemic or hemorrhagic stroke. The study covers consulting or hospitalized patients at the neurological rehabilitation service (NHS) of Grau du Roi Medical Center, part of the Nîmes University Hospital. Most patients originate from a 2-4 week stay in the neurological acute care, cardiac or polyvalent departments of the University Hospitals of Montpellier or Nîmes.~Intervention: Physiotherapy~Intervention: Occupational therapy~Intervention: Functional near-infrared spectroscopy"
62324499|NCT01038284|SHAM_COMPARATOR|Control|
62324500|NCT01038284|ACTIVE_COMPARATOR|Patient education|
62324501|NCT06126653|EXPERIMENTAL|Phase 1: Low Dose|ARD-501 for 7 days at 0.2 mg/kg
62691812|NCT06383806|OTHER|Waitlist|The Waitlist arm will undergo a waiting period following the first assessment and then will receive the treatment after the second assessment.
62132385|NCT02567656|EXPERIMENTAL|Single arm|RP6530 administered orally twice a day.
62132386|NCT00603954|ACTIVE_COMPARATOR|TBI + fludarabine|Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
62324502|NCT06126653|PLACEBO_COMPARATOR|Phase 2: Placebo|Placebo for 7 days
62324503|NCT06126653|EXPERIMENTAL|Phase 2: High Dose|ARD-501 for 7 days at 0.5 mg/kg
62324504|NCT06126653|EXPERIMENTAL|Phase 2: Crossover Placebo to High Dose|ARD-501 for 7 days at 0.5 mg/kg
62324505|NCT06126653|PLACEBO_COMPARATOR|Phase 2: Crossover High Dose to Placebo|Placebo for 7 days
62324506|NCT00592397|EXPERIMENTAL|1|All participants underwent the same dietary intervention
62691813|NCT02144337|EXPERIMENTAL|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
62691814|NCT02144337|NO_INTERVENTION|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
62132387|NCT00603954|ACTIVE_COMPARATOR|TLI + ATG|Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.
62483471|NCT02466451||Children operated at birth on CDH and EA|Standardized Questionnaires:For not collaborative patients,\< 4 years:Standardized questionnaire collecting anamnestic-clinical data;Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents) For collaborative patients, \>4 years:Standardized questionnaire collecting anamnestic-clinical data;Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar);Spirometry;6-minutes walk test (WT 6'); Prick tests;Children Quality of life questionnaire (KINDL questionnaire);Psychological test (Raven Matrices);Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents).
62691815|NCT05669027|EXPERIMENTAL|Experimental Condition|Mobile Neurofeedback intervention arm
62691816|NCT05669027|PLACEBO_COMPARATOR|Control Condition|Sham-control arm
62691817|NCT02463435|ACTIVE_COMPARATOR|Nutritional intervention|Patients under only nutritional intervention for weight loss
62691818|NCT02463435|EXPERIMENTAL|Nutritional intervention plus olive oil|Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation
62691819|NCT02463435|EXPERIMENTAL|Olive oil|Patient under habitual food consumption plus extra virgin olive oil supplementation
62691820|NCT02414841|ACTIVE_COMPARATOR|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
61930849|NCT06150820|OTHER|Participants with Late-Onset Pompe Disease|Adolescent or adult participants with LOPD.
62691821|NCT02414841|PLACEBO_COMPARATOR|Placebo|Placebo administered at the time of radiocephalic fistula creation
62691822|NCT02598973|ACTIVE_COMPARATOR|Exercise|aerobic walking
62691823|NCT02598973|NO_INTERVENTION|No exercise|normal activity
61930850|NCT06087835|EXPERIMENTAL|Zibotentan/Dapagliflozin dose A or Zibotentan/Dapagliflozin dose B|Drug dose (dose A or B) are determined based on eGFR values. Participants will receive daily oral dose of zibotentan/dapagliflozin in fixed dose combination.
61930851|NCT06087835|ACTIVE_COMPARATOR|Dapagliflozin alone|Participants will receive daily oral dose of dapagliflozin.
61930852|NCT06119724|ACTIVE_COMPARATOR|Bipolar enbloc resection of bladder tumors|Patients who have odd number will be in the first group which will be enrolled in bipolar enbloc group
62483472|NCT05173350|EXPERIMENTAL|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
61930853|NCT06119724|ACTIVE_COMPARATOR|Thulium enbloc resection of bladder tumors|patients who have even number will be in the second group which will be Thulium-Yag laser enbloc group
62132388|NCT01691846|EXPERIMENTAL|aleglitazar|
62132389|NCT01691846|PLACEBO_COMPARATOR|placebo|
62132390|NCT04910698||Short course treatment|Patients who received antibiotic for 7 or less days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
62483473|NCT05173350|ACTIVE_COMPARATOR|Active Comparator|The active comparator group does not receive the full set of RETAIN intervention activities.
61930854|NCT02869061|EXPERIMENTAL|ADRC injection|Subjects will be undergone liposuction under local anesthesia. Adipose-derived regenerative cells (ADRC) will be isolated from lipoaspirate by enzymatic digestion. Transurethral bladder neck resection followed by the injection of ADRC suspension will be performed. This is a single arm study with no control. All patients receive cell therapy.
61930855|NCT01483807|EXPERIMENTAL|SPT-B then SPT-R|Participants first received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
61930856|NCT01483807|EXPERIMENTAL|SPT-R then SPT-B|Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
62132391|NCT04910698||Long course treatment|Patients who received antibiotic for more than 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
62132392|NCT03945123|EXPERIMENTAL|Ginseng trial|compare experimental group to controlled group
62132393|NCT00599469|OTHER|1|Far Infrared Radiation
62691824|NCT04297735|ACTIVE_COMPARATOR|Standard of care group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
62691825|NCT04297735|EXPERIMENTAL|Telemedicine group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
62691826|NCT05933603|EXPERIMENTAL|Ato-oxy|0.5 mg/kg (max 40 mg) atomoxetine and 5 mg oxybutynin
62691827|NCT01448304|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
62691828|NCT01448304|EXPERIMENTAL|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
62691829|NCT01893450|ACTIVE_COMPARATOR|methimazole|methimazole 30 mg daily during one year
62324507|NCT02699515|EXPERIMENTAL|MSB0011359C (M7824)|
62324508|NCT01406665||increased diabetes risk|the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes
62691830|NCT01893450|ACTIVE_COMPARATOR|methimazole, bromocriptine|methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
62691831|NCT01893450|ACTIVE_COMPARATOR|pentoxifylline|methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year
62691832|NCT06429735|EXPERIMENTAL|Neuralink N1 Implant and R1 Robot|Implantation of the N1 Implant by the R1 Robot.
62483474|NCT02072096|EXPERIMENTAL|Strategy A (Glucose-Dependent)|Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists \[GLP-1 RA\]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
62483475|NCT02072096|ACTIVE_COMPARATOR|Strategy B (Reference)|Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
62483476|NCT02380976|EXPERIMENTAL|Test 1|First phase: DW330SR+DW1030 7 days after Second phase: DW340
62483477|NCT02380976|EXPERIMENTAL|Test 2|First phase: DW340 7 days after Second phase: DW330SR+DW1030
62483478|NCT01066858||Maternal/infant antepartum exposure|"* HIV-infected women exposed to TDF during pregnancy~* Infants of HIV-infected women exposed to TDF during pregnancy"
62483479|NCT01066858||Maternal/infant postpartum exposure|"* HIV-infected women exposed to TDF while breastfeeding~* Infants of HIV-infected women exposed to TDF while breastfeeding"
62483480|NCT01066858||Maternal/infant antepartum no exposure|"* HIV-infected women not exposed to TDF during pregnancy~* Infants of HIV-infected women not exposed to TDF during pregnancy"
62483481|NCT01066858||Maternal/infant postpartum no exposure|"* HIV-infected women not exposed to TDF during breastfeeding~* Infants of HIV-infected women not exposed to TDF during breastfeeding"
62483482|NCT04790526|EXPERIMENTAL|Group A|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
62483483|NCT04790526|EXPERIMENTAL|Group B|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
62483484|NCT04790526|EXPERIMENTAL|Group C|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
62483485|NCT04790526|EXPERIMENTAL|Group D|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
62483486|NCT03641079|EXPERIMENTAL|brinjal peel extract containing cream|intervention-brinjal peel extract containing cream, dose-twice daily for 12 weeks
62483487|NCT00838136|EXPERIMENTAL|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
62483488|NCT00838136|ACTIVE_COMPARATOR|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
62483489|NCT02125461|EXPERIMENTAL|MEDI4736|MEDI4736 (intravenous infusion)
61930857|NCT06252298|EXPERIMENTAL|Dose-finding and dose-expansion|"Dose-finding stage: The dose escalation in this study is pre-defined in nine dose groups. The dose escalation starts with 0.01mg and proceeds from low to high doses.~Dose-expansion stage: Patients will be randomly assigned to receive different doses of SCTC21C at a ratio of 1:1. Doses of SCTC21C will be determined based on the data obtained in the Dose-finding stage."
61930858|NCT03895021|EXPERIMENTAL|Intervention|This multifaceted, adapted program focuses preventing falls through balance and strength exercises, teachings from guest experts (e.g., PT, Pharmacist, vision) and at-home safety education. Participants attended weekly 2-hour group sessions (8 -12 persons) over the course of 8 weeks delivered in Spanish by trained Hispanic/Latino personnel in two communities in Wisconsin.
61944557|NCT02009306|EXPERIMENTAL|Epistatus Alone|"From 28/11/17 following approval from sponsor, ethics committee and MHRA a 3rd observational arm was introduced:~Epistatus administered PRN by family / carer for symptoms"
61944558|NCT03872323|ACTIVE_COMPARATOR|Endovascular treatment|
62483490|NCT02125461|PLACEBO_COMPARATOR|PLACEBO|Placebo (matching placebo for intravenous infusion)
62483491|NCT03186651|EXPERIMENTAL|Trans Vagina Support|Tension Free Vaginal Support (TVS):The subjects in the TVS Group used pads during week 1 (Baseline), fitted, trained and selected device size week 2 and used the selected device size during week 3 (treatment week).
62483492|NCT03186651|NO_INTERVENTION|Standard Care|Standard of care (SoC): The subjects in the SoC group continued with conventional treatment i.e. using pads during week 1, 2 and 3. They were offered to use the TVS device for two weeks after completion of week 3.
61944559|NCT03872323|ACTIVE_COMPARATOR|Open surgery|
61944560|NCT00507091|EXPERIMENTAL|ZD6474 (vandetanib) 100mg|
61944561|NCT00507091|EXPERIMENTAL|ZD6474 (vandetanib) 300mg|
61944562|NCT02135770|EXPERIMENTAL|Unfractionated Heparin|Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion
61944563|NCT02135770|PLACEBO_COMPARATOR|Placebo|Normal saline packed in same form with trial drugs.
62132394|NCT01837394|ACTIVE_COMPARATOR|Block arm|Ultrasound guided block of the SN and ONP with 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
62132395|NCT01837394|PLACEBO_COMPARATOR|Placebo arm|Ultrasound guided placebo block of the SN and ONP with 7.5 ml of isotonic saline solution injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
61930859|NCT06709456|EXPERIMENTAL|Pleural drainage|Ultrasonography-guided pleural drainage with insertion of a small-bore intrapleural catheter (typically pig-tail type catheter, size 6-14 French), conducted by e.g., intensivists or radiologists, as by local standards, of the pleural cavity with the estimated largest pleural effusion as soon as possible. A time interval of up to 24 hours from randomisation to intervention is expected. If bilateral pleural effusions ≥ 2 cm are present at randomisation, drainage of contralateral pleura should be conducted as soon as possible according to local standards, at least within 24 hours from insertion of the first pleural catheter unless pleural effusion has receded to \< 2 cm prior to drainage. Inserted pleural catheters remain connected to a closed pleural drainage system, in situ and open until removed at clinicians' discretion according to local standards. New pleural effusion ≥ 2 cm during ICU stay within 90 days from randomisation will be drained similarly.
61930860|NCT06709456|NO_INTERVENTION|No pleural drainage|No pleural drainage is conducted during ICU stay in 90 days from randomisation, unless escape protocol criteria are present being suspected or confirmed haemothorax, suspected or confirmed pneumothorax, suspected or confirmed pleural empyema, suspected or confirmed pleural malignancy, or indication for therapeutic pleural drainage as per the treating clinician and invasive or non-invasive mechanical ventilation or mask CPAP with arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio ≤ 13.3 kPa in the most recent ABG analysis, high-flow humidified oxygen therapy with a flow ≥ 50 L/min and a PaO2/FiO2 ratio ≤ 13.3 kPa in the most recent ABG analysis, or persistent respiratory acidosis with a pH \< 7.25 and an arterial partial pressure of carbon dioxide (PaCO2) \> 6.0 kPa on the most recent ABG analysis in spite of non-invasive ventilation for \> 1 hour.
61930861|NCT04936230|EXPERIMENTAL|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, bone scan and/or PET scan, as well as optional urine and blood sample collection throughout the study.
61930862|NCT04936230|EXPERIMENTAL|Arm B (pembrolizumab, SBRT)|Patients receive pembrolizumab as in Arm A. Patients also undergo SBRT QD every other day for 3 fractions over 2 weeks that must be completed before 12 weeks after the first dose of pembrolizumab in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, bone scan, and/or PET scan, as well as optional urine and blood sample collection throughout the study.
61930863|NCT02769676|EXPERIMENTAL|3-week visit|Participants randomized to this arm will receive an additional visit at 3-weeks postpartum
61930864|NCT02769676|ACTIVE_COMPARATOR|usual care|Participants randomized to this arm will receive usual postpartum care, including the standard timing for a postpartum visit.
62324509|NCT06372665||Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Group|Healthy children aged 8 months and above who choose to receive the study vaccine for primary immunization at their own expense in Jiangsu Province
62483493|NCT06628232|EXPERIMENTAL|pacifier with breast milk group|swaddling in the mother's lap together with giving a pacifier dipped in breast milk
61930865|NCT00815269|ACTIVE_COMPARATOR|1|Halothane anesthesia: induction and maintenance with different doses
61930866|NCT00815269|EXPERIMENTAL|2|Isoflurane anesthesia: induction and maintenance with different doses
61930867|NCT00815269|EXPERIMENTAL|3|Sevoflurane anesthesia: induction and maintenance with different doses
61930868|NCT00815269|EXPERIMENTAL|4|Desflurane anesthesia: induction and maintenance with different doses
61930869|NCT00815269|EXPERIMENTAL|5|Enflurane anesthesia: induction and maintenance with different doses
61930870|NCT01869972||Wide PHE group|Subjects prescribed diet alone to treat their PKU who have \>1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age \<12 years and 120 - 600 umol/L for age ≥ 12 years.
61930871|NCT01869972||Target PHE group|Subjects prescribed diet alone to treat their PKU who have ≤ 1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age \<12 years and 120 - 600 umol/L for age ≥ 12 years.
61930872|NCT01869972||Kuvan(TM) group|Subjects on Kuvan(TM) (any dose for at least 3 months with no dosage change for most recent 1 month) ± diet therapy
62324510|NCT03369301||Gammanorm|Patients on Gammanorm per standard of care
61930873|NCT01869972||Control group|Subjects with non-PKU hyperphenylalaninemia (maximum phenylalanine level 120 - 599 umol/L on no therapy).
61930874|NCT00017238|EXPERIMENTAL|Treatment (KRN5500)|"Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose."
61930875|NCT01563744|EXPERIMENTAL|EGD-assisted colonoscopy prep|2 liters of polyethylene glycol instilled through the channel of the endoscope during EGD when colonoscopy expected the following day. Patients follow a clear liquid diet, then ingest an addition 1 liter polyethylene glycol 4 hours prior to colonoscopy. Patients are also given a tap water enema 1 hour prior to colonoscopy.
62132396|NCT04562675|EXPERIMENTAL|Intervention group (IG)|LHA intervention group (IG)
62132397|NCT04562675|PLACEBO_COMPARATOR|Control group (CG)|brochure-only control group (CG)
62132398|NCT01268228||Residual ic ECG ST elevation in SB|
62132399|NCT01268228||Residual ic ECG ST elevation in MB|
62324511|NCT03369301||Other Subcutaneous Immunoglobulin|Patients on subcutaneous immunoglobulin treatments other than Gammanorm
62324512|NCT03240198||COPD|
62324513|NCT03240198||Controls|
62324514|NCT06693232|OTHER|Micro-mobile learning|Critical care nurses will assess before intervention for the three outcomes
62339914|NCT05947747|PLACEBO_COMPARATOR|Group 2: treatment in a clean sterile saline solution (placebo)|30 patients who will receive a 5-day treatment in a clean sterile saline solution (placebo)
62483494|NCT06628232|EXPERIMENTAL|heel heating group|swaddling in the mother's lap together with local dry heat application
62132400|NCT06413095|EXPERIMENTAL|Pembrolizumab Alone or in Combination with MK-0482 or MK-4830|Patient with HNSCC or STS with surface accessible lesions who are scheduled for tumor or regional node dissection as part of their standard treatment will be injected two to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of pembrolizumab as a single agent or in combination with MK-0482 or MK-4830. Each microdose is simultaneously injected in a columnar fashion through each of 5 or 8 needles by the CIVO Micodose Injection Device (MID) into a single solid tumor or effaced metastatic lymph node.
62132401|NCT00665340|PLACEBO_COMPARATOR|Arm 1|
62132402|NCT00665340|EXPERIMENTAL|Arm 2|
61930876|NCT01563744|ACTIVE_COMPARATOR|Standard Colonoscopy Prep|Split-dose polyethylene glycol (2 liters pm prior to colonoscopy, 1 liter 4 hours prior to colonoscopy)), clear liquid diet, metoclopramide 10 mg IV 30 minutes prior to procedure, tap water enema 1 hr prior to colonoscopy
61930877|NCT00504985||Fatigue in Emergency Center Patients|
61930878|NCT05632406||Adults without obesity|body mass index below 30 kg/m\^2
61930879|NCT05632406||Adults with obesity|body mass index above 30 kg/m\^2
61930880|NCT00964132|EXPERIMENTAL|NRX194204|
61930881|NCT04514003||SARS-CoV-2 PCR positive cases|Antibody tests will be performed every 6 months for 2 years
61930882|NCT04514003||SARS-CoV-2 PCR negative cases|Antibody tests will be performed at baseline
61930883|NCT04514003||Population controls|A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.
61930884|NCT02316548|NO_INTERVENTION|No Radiation Therapy|Patients do not receive radiation therapy (RT).
61930885|NCT02316548|EXPERIMENTAL|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
61930886|NCT01037322|ACTIVE_COMPARATOR|cannabidiol in drops|cannabidiol given in drops of olive oil sub lingual 5 mg twice daily
61930887|NCT01037322|PLACEBO_COMPARATOR|placebo in drops|olive oil given in drops sub lingual
61930888|NCT06405139|EXPERIMENTAL|Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine|Patients will receive a modified FOLFOXIRI regimen (nanoliposomal irinotecan 60mg/m2, oxaliplatin 85 mg/m2, and capecitabine 800 mg/m2 twice daily, day 1 to 7), repeated every two weeks. The efficacy and resectability were evaluated every four cycles. Patients who had lesions that were radically resectable after evaluation will receive surgery. This medication will be administrated until disease progression or unacceptable toxicity or resectability or up to a maximum of 12 cycles.
61930889|NCT05526989|EXPERIMENTAL|Dostarlimab and Niraparib treatment|Participants will be given 500 mg Dostarlimab IV every 3 weeks for 4 cycles followed by 1000 mg every 6 weeks, along with 200 mg Niraparib by mouth once daily days 1-21 of all cycles.
61930890|NCT05743036|EXPERIMENTAL|Dose Escalation|Participants will receive different doses of ZN-c3 in combination with different doses of Encorafenib and a fixed dose of Cetuximab
61930891|NCT05743036|EXPERIMENTAL|Dose Expansion|Participants will receive recommended dose of ZN-c3 and encorafenib as determined in dose escalation phase in combination with cetuximab
61930892|NCT06637215|EXPERIMENTAL|laparoscopic colorectal day surgery|laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
61930893|NCT06637215|ACTIVE_COMPARATOR|traditional laparoscopic colorectal surgery|traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
61930894|NCT06709690||Paediatric patients|Children who have clinical symptoms and are suspected of having malignant tumors after being evaluated by clinical pediatricians and require 18F-FDG PET/MR examination to further clarify their conditions.
61930895|NCT04741997|ACTIVE_COMPARATOR|Surveillance|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will receive adjuvant treatment for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
61930896|NCT04741997|EXPERIMENTAL|Encorafenib and Binimetinib after Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
61930897|NCT04741997|EXPERIMENTAL|Encorafenib and Binimetinib after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
61930898|NCT04741997|EXPERIMENTAL|Nivolumab after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will receive nivolumab for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
61930899|NCT03954041|EXPERIMENTAL|BIIB093 3 mg|Participants will be administered BIIB093 3 milligrams per day (mg/day) as a IV bolus followed by rapid and slow intravenous (IV) infusions for 96 hours.
62132403|NCT00873613|NO_INTERVENTION|Direct ophthalmoscopy|
62132404|NCT00873613|EXPERIMENTAL|Non-dilated retinal photography|
62483495|NCT06628232|EXPERIMENTAL|combined intervention group|all interventions combined (swaddling in the mother's lap together with giving a pacifier dipped in breast milk and heel heating
62483496|NCT06628232|OTHER|Control|swaddling the baby in the mother's lap
61930900|NCT03954041|EXPERIMENTAL|BIIB093 5 mg|Participants will be administered BIIB093 5 mg/day as a IV bolus followed by rapid and slow IV infusions for 96 hours.
61930901|NCT03954041|PLACEBO_COMPARATOR|Placebo|Participants will be administered BIIB093 matching placebo as a IV bolus followed by rapid and slow IV infusions for 96 hours.
61944564|NCT00191906|EXPERIMENTAL|Atomoxetine first, then Placebo|Atomoxetine, 1.2 mg/kg/day, by mouth (PO) for 4 weeks, 2 week washout period and cross-over to placebo, every day (QD), PO for 4 weeks
62324515|NCT03422991|OTHER|Congestive Heart Failure patients Cohort|Cluster of patients with congestive heart failure NYHA ≥2, with at least one cardiac decompensation, NT-proBNP (N-terminal pro-brain natriuretic peptide) \> 500 ng/l. Will be followed during 18 months.
62483497|NCT02183311|EXPERIMENTAL|BI 1356 BS - single rising dose|
62691833|NCT00945542|OTHER|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR\>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
61930902|NCT06705153|EXPERIMENTAL|laughter yoga group|"The patients in the intervention group will have laughter yoga for 2 sessions per week (total 8 sessions) for 4 weeks in the form of meetings via zoom with the help of a smart cell phone/computer and the patients in the control group will not have laughter yoga. Patients in both groups will be evaluated for IBS-SSS at baseline and at the end of weeks 1, 2, 3 and 4. Patients in both groups will be administered DASS-42, PSQI and IBS-QOL at baseline and at the end of the 4th week. Laughter yoga is a four-part program that lasts about 40 minutes and is led by a leader. These are deep breathing exercises (5-10 minutes), clapping and warm-up exercises (10 minutes), childlike games (10 minutes) and laughter exercises (15 minutes). The philosophy of laughter yoga, a non-invasive and non-pharmacological therapy method that includes breathing techniques that combine unconditional laughter with relaxation and breathing exercises, is based on the statement movement creates emotion."
61930903|NCT06705153|NO_INTERVENTION|control group|Patients in the control group will not receive laughter yoga and will use their routine treatment. Patients in both groups will be evaluated for IBS-SSS at baseline and at the end of weeks 1, 2, 3 and 4. Patients in both groups will be administered DASS-42, PSQI and IBS-QOL at baseline and at the end of the 4th week.
61930904|NCT06709560|ACTIVE_COMPARATOR|Heart Rate Reserve (HRR)-Based Exercise Intensity Prescription|The exercise intensity is based solely on HRR.
61930905|NCT06709560|EXPERIMENTAL|Blood Pressure-Matched Exercise Intensity Prescription|Instead of relying on HRR, exercise intensity is tailored to replicate the average systolic blood pressure achieved in the initial HRR-based session.
61930906|NCT06549218|OTHER|newborn screening|All newborns participating in the study will receive a genetic newborn screening for predefined treatable diseases. Newborns participating in the TREAT-panel developing symptoms suggestive of a genetic disease during the first 2 years of life can receive whole genome sequencing.
61930907|NCT01194427|EXPERIMENTAL|Vorinostat and Tamoxifen|Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.
61930908|NCT03436563|EXPERIMENTAL|Treatment (M7824)|Patients receive M7824 IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity (Cohorts A,B, and C) or for six doses in patients with detectable circulating tumor DNA (ctDNA) following resection of all known liver metastases (Cohort D).
61930909|NCT05577871|ACTIVE_COMPARATOR|dex group|patients medicated with dexmedetomidine.
61930910|NCT05577871|PLACEBO_COMPARATOR|control group|patients took placebo normal saline.
61930911|NCT05500599|NO_INTERVENTION|midazolam (Group M)|receive 0.5 mg/kg midazolam orally approximately 30 min before the induction of anaesthesia
61930912|NCT05500599|ACTIVE_COMPARATOR|fentanyl (Group F)|receive 10 μg/kg fentanyl orally approximately 30 min before the induction of anaesthesia
61930913|NCT00557427|EXPERIMENTAL|A|hypericum 250mg tablets twice daily for 8 weeks
61930914|NCT00557427|ACTIVE_COMPARATOR|B|fluoxetine 20mg - 40mg daily for 8 weeks
61930915|NCT05736198||Dexmedetomidine|Dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
61930916|NCT05736198||Placebo|Normal Saline, midazolam, and fentanyl (titrated to effect) to facilitate the intubation
61930917|NCT02775604|OTHER|Home-Based Video|GoPro Camera
61930918|NCT02775604|OTHER|Paper Checklist|Homeowner Print Checklist
61930919|NCT05712369|EXPERIMENTAL|Prospective cohort|Patients with INS due to biopsy-proven MCD or FSGS or MesGN candidate to anti-CD20 monoclonal antibodies therapy.
62132405|NCT02987192|EXPERIMENTAL|traditional group|Traditional group patients will receive cutting type 22 gauge needles
62132406|NCT02987192|EXPERIMENTAL|minimally invasive group|minimally invasive group patients will receive pen type 27 gauge needles
62691834|NCT00945542|EXPERIMENTAL|Preemptive transfusion|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. This corresponds to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
61930920|NCT05712369|EXPERIMENTAL|Retrospective cohort|Patients with INS due to biopsy-proven MCD or FSGS or MesGN, treated with anti-CD20 monoclonal antibodies therapy.
61930921|NCT05712369|ACTIVE_COMPARATOR|Healthy volunteers cohort|Subjects not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
61944565|NCT00191906|EXPERIMENTAL|Placebo first, then Atomoxetine|Placebo, every day (QD), by mouth (PO) for 4 weeks, 2 week washout period and cross-over to atomoxetine 1.2 mg/kg/day, PO for 4 weeks
62132407|NCT05953675|ACTIVE_COMPARATOR|Control arm|Standard procedure of isotonic saline with heparin as lock-solution
62132408|NCT05953675|EXPERIMENTAL|Intervention arm|3 mL of 70% ethanol as lock-solution
62339915|NCT02417909||Healthy volunteers|This group is composed of healthy teenagers that volunteered to participate in the trial and that will answer questionnaires about quality of life. Parents will anwser questionnaires too.
62339916|NCT02417909||Obese teenagers|This group is composed of obese teenagers that have been recruited to participate in the trial and that will answer different questionnaires quality of life. Parents will anwser questionnaires too.
62483498|NCT02183311|EXPERIMENTAL|BI 1356 BS - multiple rising dose|
62483499|NCT02183311|ACTIVE_COMPARATOR|Placebo|
62483500|NCT04906538|ACTIVE_COMPARATOR|anterior cruciate ligament reconstruction with internal suture augmentation technique|This group will be operated by using all-inside ACLR technique with internal suture augmentation technique
62483501|NCT04906538|ACTIVE_COMPARATOR|anterior cruciate ligament reconstruction without internal suture augmentation technique|This group will be operated by using all-inside ACLR technique without internal suture augmentation technique
62691835|NCT05930535|EXPERIMENTAL|Parenting for Lifelong Health|"Parenting Program Parenting for Lifelong Health (PLH) for parents and their teens aged 10-14 years old with Helping Adolescents Thrive comics at home"
62691836|NCT05323734|EXPERIMENTAL|Ganaxalone (GNX)|oral suspension, 3 times a day (TID)
62691837|NCT05323734|PLACEBO_COMPARATOR|Placebo matching GNX|oral suspension, TID
62691838|NCT06641102|EXPERIMENTAL|Participants with Chronic Back Pain in Self-Guided Program|Participants with CBP in a self-guided program that includes videos, guided meditations, and worksheets that are delivered to users in 10 different topical modules.
61930922|NCT03875820|EXPERIMENTAL|Dose Escalation Phase|"Escalating doses of VS-6766 (RO5126766) and Defactinib (VS-6063) were evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation followed a 3+3 design with a maximum of four patient cohorts.~This arm is now complete."
61930923|NCT03875820|EXPERIMENTAL|Dose Expansion KRAS mutant NSCLC Cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).~This arm is now complete."
61930924|NCT03875820|EXPERIMENTAL|Dose Expansion biopsy cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).~This arm is now complete."
61930925|NCT03875820|EXPERIMENTAL|Dose Expansion LGSOC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with LGSOC (20 patients).
61930926|NCT03875820|EXPERIMENTAL|Dose Expansion CRC cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with CRC (10 patients).~This arm is now complete."
61930927|NCT03875820|EXPERIMENTAL|Dose Expansion KRAS G12V mutant NSCLC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS G12V mutant NSCLC (10 patients).
62324516|NCT04718181|EXPERIMENTAL|Part 1|"Cohort A+B: participants will receive, in a five-period crossover way, a single oral dose of risdiplam oral solution 5 mg in fasted state and thereafter risdiplam/F21 or F22 dispersible tablet 5 mg as tablet in fasted and fed states; tablet dispersed in water in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations.~Cohort C+D: participants will receive, in a two-period fixed sequence design, a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state and omeprazole 40 mg once daily for 7 days + a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state, on the 7th day of omeprazole. There will be a 14-day wash-out between the two treatment periods.~Cohort E: participants will receive, in a two-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations."
62324517|NCT04718181|EXPERIMENTAL|Part 2 (optional)|"Group 1: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F21) as swallowed tablet in both fed and fasted states.~Group 2: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F21) as tablet dispersed in water in both fed and fasted states."
62324518|NCT04718181|EXPERIMENTAL|Part 3 (optional)|"Group 1: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F22) as swallowed tablet in both fed and fasted states.~Group 2: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F22) as tablet dispersed in water in both fed and fasted states."
62691839|NCT06641102|EXPERIMENTAL|Participants with Chronic Back Pain in Coach Assisted Program|Participants with CBP in a one-on-one coaching program that sets users up with trained PRT coaches who will walk them through the program individually.
61930928|NCT03875820|EXPERIMENTAL|Dose Expansion RAS/RAF mutant endometrioid cancer cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with RAS/RAF mutant endometrioid subtype of gynaecological cancers (ovarian, endometrial, endometriosis-related) (10 patients).
61930929|NCT03875820|EXPERIMENTAL|Dose Expansion pancreatic cancer|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with pancreatic cancer (10 patients).
62324519|NCT02786355|OTHER|Maximum bimanual compression|Squeeze through Frova bougie with maximum bimanual compression
62324520|NCT02786355|OTHER|Normal bimanual compression|Squeeze through Frova bougie with normal bimanual compression
62483502|NCT05235568|OTHER|Valvosoft|Treatment with VALVOSOFT device
62483503|NCT02832921|EXPERIMENTAL|VR cognitive tasks + treadmill|This is the primary group of interest, in which the investigators hypothesize the greatest cognitive gains since motor activity will augment cognitive activity.
62691840|NCT06641102|ACTIVE_COMPARATOR|Participants receiving Standard of Care|Standard of care (SOC) control group in adults with CBP.
61930930|NCT05868044|EXPERIMENTAL|PRIMUS|PRIMUS system
61930931|NCT02005432|ACTIVE_COMPARATOR|SS-PRP arm|panfotocoagulation (PRP) single shoot (ETDRS) + 0,05ml intravitreal injection anti-VEGF (ranibizumabe)
61930932|NCT02005432|EXPERIMENTAL|MS-PRP arm|Multiple shoot panfotocoagulation (PASCAL) plus IVR
61930933|NCT02005432|OTHER|IVR arm|only IVR (intravitreal Ranibizumabe)
62691841|NCT06639880|EXPERIMENTAL|study group|triple attack protocol which includes a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
61930934|NCT06708663|EXPERIMENTAL|HX009+IN10018|
61930935|NCT06503471|EXPERIMENTAL|stem cell and collagen transplantation group|Human Umbilical Cord Mesenchymal Stem Cells
61930936|NCT06503471|ACTIVE_COMPARATOR|control group|collagen transplantation
61930937|NCT06710704|EXPERIMENTAL|Transcutaneous pulsed radiofrequency group|Patients underwent transcutaneous pulsed radiofrequency at the affected elbow.
61930938|NCT06710704|ACTIVE_COMPARATOR|Control group|Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
61930939|NCT04543409|EXPERIMENTAL|Benralizumab|Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
61930940|NCT04543409|PLACEBO_COMPARATOR|Placebo|Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
61930941|NCT06707610|EXPERIMENTAL|Part A: Dose-escalation Phase Part B: Dose-expansion Phase|A dose-escalation study to determine the MTD and the subsequent doses for dose expansion study (Part B). A dose-expansion study which will enroll the select indications.
61930942|NCT06275581|EXPERIMENTAL|Ketac Universal test group|intra-individual (split-mouth) study
61930943|NCT06275581|ACTIVE_COMPARATOR|Ketac Molar Quick control group|intra-individual (split-mouth) study
61930944|NCT04585152|EXPERIMENTAL|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells) How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~Where: in Hospital When and how much: once; diluted in 1000 ml of normal saline."
61930945|NCT04585152|ACTIVE_COMPARATOR|Mycophenolate mofetil|"Drug Name: Mycophenolate Mofetil (MMF)~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis Procedures: MMF 1,200 mg/m2 orally divided in 2 daily doses"
61930946|NCT04944095||SARS-CoV-2 Antibody Levels|This is a single arm study by Southlake Diagnostics Inc. whereby changes in plasma antibody levels (IgG and total) are determined over 12 months on individuals residing in over 300 associated nursing homes, extended care facilities and over-55 residences following vaccination with one of the authorized SARS-CoV-2 vaccines (Pfizer, Moderna or J \&J). No interventions are involved. The investigators are not responsible for administering the vaccines or determining subject eligibility or willingness to receive the vaccine. Blood samples will be drawn and plasma IgG and total antibodies will be determined at baseline, 3, 6, 9 and 12 months post-vaccination.
61930947|NCT00667602|EXPERIMENTAL|MenACWY-CRM197 (2 doses) + Concomitant Vaccines|Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
61930948|NCT00667602|EXPERIMENTAL|MenACWY-CRM197 (1 dose) + Concomitant Vaccines|Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
61930949|NCT00667602|ACTIVE_COMPARATOR|MenC (1 dose) + Concomitant Vaccines|Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
61930950|NCT04621565|EXPERIMENTAL|Hydrocortisone withholding group|Patients receive no hydrocortisone
61930951|NCT04621565|ACTIVE_COMPARATOR|Hydrocortisone group|Patients receive routine hydrocortisone
61930952|NCT06207968||Arthroplasty|"Knee prostheses are intended for patients suffering from functionally serious diseases of the knee causing daily disability that is insufficiently improved by medical treatment.~The functional diseases are among:~* Knee osteoarthrosis~* Osteonecrosis of the knee~* Inflammatory disease~* Patellofemoral arthritis~The patients having benefited from an arthroplasty will be followed for at least 15 years (until 20 years)."
61930953|NCT06207968||Ligament reconstruction|"Ligament reconstruction surgery should be considered for patient who have undergone a rupture of the anterior and/or posterior cruciate ligaments requiring partial or total reconstruction.~The patients having benefited from a ligament reconstruction will be followed for at least 5 years."
61930954|NCT05437263|EXPERIMENTAL|Brepocitinib Dose Level 1 PO QD|
62691842|NCT06639880|ACTIVE_COMPARATOR|control|the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise
62691843|NCT04491175|ACTIVE_COMPARATOR|DuoTherm|A low back pain relief device incorporating 8 harmonic patterns of mechanical stimulation (vibration) capable of neuromodulatory nociceptor block and vasodilation, and optional heat, cold, and pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice a day for 20 minutes.
62691844|NCT04491175|ACTIVE_COMPARATOR|Multimodal TENS|An 8-channel TENS unit (LG Smart). Patients will be instructed to use the TENS twice a day for 20 minutes.
62691845|NCT01337661||COPD subjects|Adult male and female subjects with COPD
61930955|NCT05437263|EXPERIMENTAL|Brepocitinib Dose Level 2 PO QD|
61930956|NCT05437263|PLACEBO_COMPARATOR|Placebo PO QD|
61930957|NCT05620641|EXPERIMENTAL|Group 1|include 50 patients scheduled for sleeve gastrectomy
61930958|NCT05620641|EXPERIMENTAL|Group 2|include 50 patients scheduled for sleeve gastrectomy
61930959|NCT06682169|EXPERIMENTAL|Rovadicitinib|Rovadicitinib: 10mg, taken orally on an empty stomach twice a day, with a minimum interval of 8 hours between each dose, and an optimal interval of 12 hours. Every 28 days is a treatment cycle.
62324521|NCT03464708|EXPERIMENTAL|HMB|HMB 3 g/day until hospital discharge or 28-days (whichever comes first). HMB to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
62324522|NCT03464708|PLACEBO_COMPARATOR|Placebo|Placebo (lactose) 3 g/day until hospital discharge or 28-days (whichever comes first). Placebo to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
62483504|NCT02832921|ACTIVE_COMPARATOR|VR cognitive tasks - treadmill|This group will be an active control, receiving the VR cognitive training without treadmill walking, to examine whether the motor component augments the effect of the VR in the experimental group.
62691846|NCT00622206|ACTIVE_COMPARATOR|1|Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
62691847|NCT01416831|ACTIVE_COMPARATOR|Arm A: IL-2 Monotherapy|Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2. Crossover patients will be included in Arm A.
62691848|NCT01416831|EXPERIMENTAL|Arm B: SBRT + IL-2|Patients will receive two doses of radiation before receiving high-dose IL-2.
62691849|NCT02771327|EXPERIMENTAL|CPAP plus gas|Treatment with Boussingnac valve CPAP during 6 hour, starting immediately after weaning
62691850|NCT02771327|ACTIVE_COMPARATOR|Usual treatment(ventimask plus gas)|ventimask
61930960|NCT06682169|ACTIVE_COMPARATOR|Imatinib or Methotrexate or Mycophenolate or Rituximab|"Methotrexate tablets: 10mg, orally, once a week or 5mg, orally, twice a week.~Metoprolol ester: 250mg-500mg, bid, orally.~Imatinib: 100-400mg, qd, oral.~Rituximab: 375mg/m2, administered intravenously once a week for 4 consecutive weeks."
61930961|NCT00814788|EXPERIMENTAL|Bicalutamide + Everolimus|Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61930962|NCT04595344|ACTIVE_COMPARATOR|Diagnostic cystoscopy , Binaural beat group|patients listened to binaural beats
61930963|NCT04595344|ACTIVE_COMPARATOR|Diagnostic cystoscopy, Classical music group|patients listened to classical music
61930964|NCT04595344|PLACEBO_COMPARATOR|Diagnostic cystoscopy , Placebo group|patients no audio only headphones
61930965|NCT04595344|ACTIVE_COMPARATOR|Ureteral stent removal, Binaural beat group|patients listened to binaural beats
61930966|NCT04595344|ACTIVE_COMPARATOR|Ureteral stent removal ,Classical music group|patients listened to classical music
61930967|NCT04595344|PLACEBO_COMPARATOR|Ureteral stent removal, Placebo group|patients no audio only headphones
61930968|NCT05732623||Early onset colorectal cancer|Patients with colorectal cancer diagnosed before the age of 50 years
62324523|NCT03568539|EXPERIMENTAL|IBI308|
62324524|NCT06050863|EXPERIMENTAL|Group I - Silk Fibroin|test group 1 is treated with silk fibroin
62691851|NCT02007161|ACTIVE_COMPARATOR|Nutritional State|"Fed vs. Fasted State~Diclofenac potassium 50 mg"
62691852|NCT02007161|ACTIVE_COMPARATOR|Use of a PPI|"Nexiam (esomeprazole) 40 mg~Diclofenac potassium 50 mg"
62691853|NCT06305390||single arm|
62691854|NCT06549985|EXPERIMENTAL|Peer Empowered Endometriosis Pain Support (PEEPS)|Participants in this arm will receive PEEPS plus usual care. PEEPS is comprised of eight weekly two-hour sessions delivered to groups of 6-10 participants. The sessions provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Participants additionally receive peer and clinician support.
62691855|NCT06549985|ACTIVE_COMPARATOR|Education|Participants in this arm will receive an educational handout providing the basics of endometriosis pathophysiology, diagnosis, and treatment plus usual care
61930969|NCT05732623||Control|"Individuals meeting all the following:~* aged \<50 years~* no history of colorectal cancer~* at least one negative screening test (at least a fecal occult blood test with high sensitivity)"
61930970|NCT06692036|NO_INTERVENTION|Control group (standard treatment)|"Patients in the control group received standard treatment by the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021."
61930971|NCT06692036|EXPERIMENTAL|Intervention group (standard treatment + ABP)|Intervention Type：Patients in the intervention group, based on standard treatment, received two 6-hour adaptive blood purification (ABP) treatments within 24 hours after enrollment, that is, patients did not indicate renal replacement therapy (RRT), only coupled plasma filtration and adsorption (CPFA) therapy is used to adsorb inflammatory factors; for patients with acute kidney injury (AKI) and meeting RRT indications, CPFA+RRT (plasma filtration adsorption dialysis, PFAD) treatment is used.
61930972|NCT03525093|ACTIVE_COMPARATOR|Hypnosis + health education|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home plus health education booklet on coping with stress
62132409|NCT06256640|EXPERIMENTAL|Intervention|
62132410|NCT04183452||17-Hydroxyprogesterone Caproate 250 mg IM Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 250 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
62132411|NCT04183452||17-Hydroxyprogesterone Caproate 275 mg SC Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 275 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
61930973|NCT03525093|OTHER|Health education alone|Patients receive a health education booklet to improve coping with stress
61930974|NCT06695299|EXPERIMENTAL|study group|the study group received the selected exercise program in addition to Kinesthetic and Visual Motor Imagery Training
61930975|NCT06695299|EXPERIMENTAL|control group|the control group which received the selected exercise program
61930976|NCT05736835|EXPERIMENTAL|CVXGA|CVXGA single intranasal dose 10e7 PFU
62324525|NCT06050863|ACTIVE_COMPARATOR|Group II -Chlorhexidine|test group 2 is treated with chlorhexidine
62324526|NCT06050863|EXPERIMENTAL|Group III - Combination of Fibroin and Chlorhexidine|test group 3 is treated with combination of silk fibroin and chlorhexidine
62324527|NCT03140254|ACTIVE_COMPARATOR|comparator|Chlorhexidine gluconate
62324528|NCT03140254|EXPERIMENTAL|experimental|BDIP-0001
62324529|NCT03140254|PLACEBO_COMPARATOR|placebo|Vehicle
62324530|NCT06693245||Observation of Pain and Analysis of Related Factors During Microwave Ablation Treatment of Saphenous|Among 155 patients, our team measured the diameter of the great saphenous vein preoperatively according to the CEAP classification and ultrasound measurements. We performed endovenous microwave ablation of the great saphenous vein along with foam sclerotherapy and point stripping treatment. We documented the operating room temperature, puncture site, VAS scores during puncture and catheter placement, the amount of injected tumescent fluid, radiofrequency generator used, and data at the conclusion of the surgery. A descriptive analysis of intraoperative pain scores was conducted to evaluate the level of pain experienced during the surgery. A nonparametric test was utilized to analyze the relationship between preoperative and intraoperative factors and the level of pain experienced during the surgery.
62324531|NCT03046472|EXPERIMENTAL|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.~Total duration 12 weeks/3 months"
62324532|NCT03046472|ACTIVE_COMPARATOR|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
62324533|NCT04786028|EXPERIMENTAL|Isatuximab with CyBorD and Lenalidomide Maintenance|This is a single arm study of Isatuximab administered intravenously in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD), and Lenalidomide maintenance treatment
62324534|NCT00589472|EXPERIMENTAL|Treatment (Antihormone therapy and enzyme inhibitor therapy)|Patients receive bicalutamide PO QD for 1 month and leuprolide acetate IM or goserelin acetate SC once a month until surgery. Patients also receive vorinostat PO QD beginning on the first day of androgen depletion therapy and continuing for up to 8 weeks or until the day of surgery. Patients then undergo an open or laparoscopic radical prostatectomy. Patients with positive surgical margins undergo immediate adjuvant external beam radiotherapy to the prostatic fossa, based on the judgment of the treating physician.
62324535|NCT04246372|EXPERIMENTAL|On Treatment|Tofacitinib 5mg oral tablets twice daily for 16 weeks
62324536|NCT04280601|OTHER|Low vitamin level at baseline|At specific time points we will measure vitamin D status (baseline and 12-months) and re-enforcing vitamin D supplementation in those with insufficient or deficient vitamin D levels. More specifically, we will ask patients with insufficient or deficient vitamin D levels at enrollment to increase vitamin D intake by 1,000 IU units (to a maximum of 2,000 IU if the patient is already on vitamin D supplementation) for the 12 month period.
62324537|NCT02379156|EXPERIMENTAL|Cool Temperature Exposure / No Drug|Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
62324538|NCT02379156|EXPERIMENTAL|Cool Temperature Exposure with Drug|Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
62324539|NCT06453447|EXPERIMENTAL|Prednisone|40 mg PO once daily for 14 days starting day of surgery
62324540|NCT06453447|PLACEBO_COMPARATOR|Placebo|placebo tablet PO once daily for 14 days starting day of surgery
62324541|NCT02364193|EXPERIMENTAL|Thoracic fluid status assessment|"Cardiac MRI by a 1.5 Tesla scanner:~* Left ventricular ejection fraction (LVEF), tracing short axis endocardial borders.~* CO, phase contrast angiography.~* Fluid challenge by auto-transfusion by distal leg compression using inflatable cuffs (Lympamat Digital Gradient system).~* DCE-MRI, bolus injection of Gd-CA intravenously by an injector. Each subject will receive repeated injections (10% of maximum dose).~* BIS, impedance will be measured continuously using ImpediMed-SFB7 and surface electrodes on the thorax. ."
62324542|NCT04225624|EXPERIMENTAL|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation.
62324543|NCT04225624|ACTIVE_COMPARATOR|Supportive Psychotherapy (SPT)|Individuals with repetitive negative thinking receiving Supportive Psychotherapy.
61930977|NCT05736835|PLACEBO_COMPARATOR|Placebo|0.9% sterile saline
61930978|NCT05732987||Biobank- samples from NMID patients|600 samples from NMID patients from the Biobank Dermatology Unispital Basel (USB) (Biobank USB) and from the biobank of the Dermatology Department of the University Hospital Zürich (USZ) (Biobank USZ) will be included.
62324544|NCT04081844|EXPERIMENTAL|Fixed-Sequence|Period 1: Fasted state+HCP1306, Period 2: Fasted state+HGP0904+HGP0608, Period 3: Fasted state+HCP1306+HGP0904+HGP0608
62483505|NCT02832921|SHAM_COMPARATOR|scientific TV documentary + treadmill|This group will watch a scientific TV documentary while walking on the treadmill. This control group will permit examination of whether the VR cognitive training, which requires an especially active cognitive effort while walking on the treadmill, is more advantageous than passively watching a scientific TV documentary while performing the same motor task as the experimental group.
62324545|NCT05299203|EXPERIMENTAL|Dose Escalation and Expansion|In the dose escalation phase, 9 patients will be included in 3 groups with 3 patients as one group. In the dose expansion phase, the concentration of Sapropterin dihydrochloride tablets (BH4) aqueous solution will be performed according to the effective concentration of dose escalation phase, and 9 patients will be enrolled.
62483506|NCT02832921|NO_INTERVENTION|Passive control|This group of participants will not receive any intervention but will be assessed with the same battery of assessments as the other three groups, permitting comparisons of the cognitive and neurobiological outcomes of the intervention groups to that of the natural course of decline/deterioration of these at-risk individuals.
62483507|NCT02193022|EXPERIMENTAL|Miltefosine|
62483508|NCT04398147|EXPERIMENTAL|phase ⅠLow single dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
62483509|NCT04398147|PLACEBO_COMPARATOR|phase ⅠPlacebo low single dose (18-<55)|6 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
62483510|NCT04398147|EXPERIMENTAL|phase ⅠLow 2 dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
62324546|NCT04809467|EXPERIMENTAL|tafasitamab + parsaclisib|"Participants will be assigned to disease specific cohorts based on the histology of their underlying disease.~Cohort 1: R/R DLBCL Cohort 2: R/R MCL Cohort 3: R/R FL Cohort 4: R/R MZL Cohort 5: R/R CLL/SLL"
62324547|NCT06111053|EXPERIMENTAL|ENDS and CI|Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).
62483511|NCT04398147|PLACEBO_COMPARATOR|phase ⅠPlacebo low 2 dose (18-<55)|6 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
62483512|NCT04398147|EXPERIMENTAL|phase ⅠLow single dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
62483513|NCT04398147|PLACEBO_COMPARATOR|phase ⅠPlacebo low single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
62483514|NCT04398147|EXPERIMENTAL|phase ⅠLow 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
62483515|NCT04398147|PLACEBO_COMPARATOR|phase ⅠPlacebo low 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
62483516|NCT04398147|EXPERIMENTAL|phase ⅠMedium single dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
61930979|NCT05732987||Formalin-fixed and paraffin-embedded (FFPE) samples|About 50 of formalin-fixed and paraffin-embedded (FFPE) samples from the Dermatology USB collected before 2014 for RNA and protein expression analyses will be reused. The patients in questions are informed about the study and the coded use of their samples.
61930980|NCT05732987||Biobank- samples from controls|2'700 anonymized control genomes as well as 150 anonymized control samples for the proteomics approach can be used as control samples from the biobank of the Dermatology Department of the University Hospital Zürich (Biobank Dermatology USZ).
62483517|NCT04398147|PLACEBO_COMPARATOR|phase ⅠPlacebo medium single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
62483518|NCT04398147|EXPERIMENTAL|phase ⅠMedium 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
61930981|NCT05732987||Fresh skin samples from healthy donors|A maximum of 20 fresh skin samples from healthy donors are required per skin location. They will be requested from healthy volunteers after information about the study and receiving the informed consent.
61930982|NCT05276180|EXPERIMENTAL|Arm A) Multifactorial intervention strategy|Experimental: Multifactorial intervention strategy for safe patient handling and movement (PHM) - Arm A The multifactorial intervention strategy for care units randomized to Arm A includes: 1) Swedish guideline for PHM and digital introduction for using the guideline (two workshops for manager and implementation team) 2) Training modules (theoretical and practical - one session) 3) Risk assessment with TilThermometer (four times) and 4) Fall risk assessment using Downton Fall Risk Index (DFRI) or existing fall risk assessment instrument at the care unit (all patients) and 5) Work environment mapping with Structured Multidisciplinary Work Environment Survey (SMET) including active/personal feedback
61930983|NCT05276180|ACTIVE_COMPARATOR|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
62324548|NCT06111053|EXPERIMENTAL|No ENDS and CI|Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).
62483519|NCT04398147|PLACEBO_COMPARATOR|phase ⅠPlacebo medium 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
62483520|NCT04398147|EXPERIMENTAL|Phase II Low single dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
62483521|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo low single dose (18-<55)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
62483522|NCT04398147|EXPERIMENTAL|Phase II Low 2 dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
62483523|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo low 2 dose (18-<55)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
62483524|NCT04398147|EXPERIMENTAL|Phase II Low single dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
62483525|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo low single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
62324549|NCT06111053|EXPERIMENTAL|ENDS and NI|Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).
62324550|NCT06111053|EXPERIMENTAL|No ENDS and NI|Participants in this arm will receive information about the comparative risk of electronic nicotine devices (ENDs) relative to smoking and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).
62324551|NCT04470310|ACTIVE_COMPARATOR|glimepiride|glimepiride 1mg monotherapy and glimepiride 2mg monotherapy
62324552|NCT04470310|ACTIVE_COMPARATOR|alogliptin|alogliptin 25mg monotherapy
62483526|NCT04398147|EXPERIMENTAL|Phase II Low 2 dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
62483527|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo low 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
62483528|NCT04398147|EXPERIMENTAL|Phase II medium single dose (55-<85)|50 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
61930984|NCT06318026|EXPERIMENTAL|Centralized Intervention|A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use.
61930985|NCT06318026|EXPERIMENTAL|Primary Care Intervention|A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
61930986|NCT06318026|NO_INTERVENTION|Usual Care|Usual primary care
61930987|NCT06707597||Patient Interaction Group|Patients who undergo the same surgical procedure on the same day and stay in the same room during the postoperative period will form this group.
61930988|NCT06707597||Control group|Patients who undergo the same surgical procedure on the same day and stay in a single room during the postoperative period will form this group.
61930989|NCT06708624|EXPERIMENTAL|FYB201 0.5 mg (0.05 mL of 10 mg/mL)|FYB201 provided in a pre-filled syringe (PFS), containing 0.5 mg of 10 mg/mL ranibizumab in 0.05 mL for intravitreal (IVT) administration
61930990|NCT06709066|EXPERIMENTAL|mivacurium chloride|mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
61930991|NCT06709066|ACTIVE_COMPARATOR|succinylcholine|succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
61930992|NCT06378866|ACTIVE_COMPARATOR|Group A (SBRT, APRI, ADT)|Patients undergo SBRT and receive APRI (abiraterone and prednisone, apalutamide, darolutamide, or enzalutamide) and ADT (leuprolide, triptorelin, histrelin, goserelin, degarelix, or relugolix). Cycles repeat every 4 months (16 weeks) for up to 6 months in the absence of unacceptable toxicity. Patients then undergo watchful waiting thereafter until disease progression.
61930993|NCT06378866|EXPERIMENTAL|Group B (SBRT, watchful waiting)|Patients undergo SBRT with watchful waiting. Cycles repeat every 4 months (16 weeks) in the absence of disease progression or unacceptable toxicity.
61930994|NCT06438562|EXPERIMENTAL|Vitamin A #1|Bouillon fortified with vitamin A formulation #1 plus unfortified oil
61930995|NCT06438562|EXPERIMENTAL|Vitamin A #2|Bouillon fortified with vitamin A formulation #2 plus unfortified oil
61930996|NCT06438562|ACTIVE_COMPARATOR|Unfortified bouillon positive control|Unfortified bouillon plus vitamin A fortified oil
61930997|NCT06660550|ACTIVE_COMPARATOR|Needlescopic inguinal hernia repair|
61930998|NCT06660550|ACTIVE_COMPARATOR|Traditional laparoscopic inguinal hernia repair|
61930999|NCT06708286|EXPERIMENTAL|Phase II, ≥18 years old, Experimental vaccine|One dose of Tdcp on Day 0
61931000|NCT06708286|ACTIVE_COMPARATOR|Phase II, ≥18 years old, Control vaccine|One dose of PPV23 on Day 0
61931001|NCT06708286|EXPERIMENTAL|Phase II, 7-17 years old, Experimental vaccine|One dose of Tdcp on Day 0
62324553|NCT04470310|ACTIVE_COMPARATOR|alogliptin - pioglitazone|Alogliptin 25mg+pioglitazone 15mg combination
62324554|NCT03207022|ACTIVE_COMPARATOR|lidocaine 2% with normal saline|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
61931002|NCT06708286|ACTIVE_COMPARATOR|Phase II, 7-17 years old, Control vaccine|One dose of PPV23 on Day 0
61931003|NCT06708286|EXPERIMENTAL|Phase III, ≥18 years old, Experimental vaccine|One dose of Tdcp on Day 0
61931004|NCT06708286|ACTIVE_COMPARATOR|Phase III, ≥18 years old, Control vaccine|One dose of PPV23 on Day 0
61931005|NCT06708286|EXPERIMENTAL|Phase III, 7-17 years old, Experimental vaccine|One dose of Tdcp on Day 0
61931006|NCT06708286|ACTIVE_COMPARATOR|Phase III, 7-17 years old, Control vaccine|One dose of PPV23 on Day 0
61931007|NCT06708286|EXPERIMENTAL|Phase III, 6 years old, Experimental vaccine|One dose of Tdcp on Day 0
61931008|NCT06708286|ACTIVE_COMPARATOR|Phase III, 6 years old, Control vaccine|One dose of DTaP on Day 0
61931009|NCT05660681|EXPERIMENTAL|glycerin 0.7%/PEG 400 0.3%|20 patients will receive glycerin 0.7%/PEG 400 0.3% lubricant eye drops three times per day for 28 days.
61931010|NCT05660681|ACTIVE_COMPARATOR|polyethylene glycol 400 0.4%/propylene glycol 0.3%|10 patients will receive polyethylene glycol 400 0.4%/propylene glycol 0.3% lubricant eye drops three times per day for 28 days.
61931011|NCT01234207|ACTIVE_COMPARATOR|Randomized Order of Interventions 1|Randomized to first wear standard, non-free-form, non-customized PAL spectacles, then second, crossover to wear individually customized free-form surfaced PAL spectacles
61931012|NCT01234207|ACTIVE_COMPARATOR|Randomized Order of Interventions 2|Randomized to first wear individually customized free-form surfaced PAL spectacles, then second, crossover to wear standard, non-free-form, non-customized PAL spectacles
62483529|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo medium single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
62483530|NCT04398147|EXPERIMENTAL|Phase II medium 2 dose (55-<85)|50 subjects，Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
62483531|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo medium 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
62483532|NCT04398147|EXPERIMENTAL|Phase II Low 1 or 2 dose (18-<55)|100 subjects，Ad5-nCoV containing 5E10 vp, 1or2 dose, Intramuscular administration ，according to the Previous trial results
62483533|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo 1 or 2 dose (18-<55)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
62483534|NCT04398147|EXPERIMENTAL|Phase II Low or medium dosage 1 or 2 dose (55-<85)|100 subjects，Ad5-nCoV containing 5E10 vp or 10E10vp, 1or2 dose, Intramuscular administration，according to the Previous trial results
62483535|NCT04398147|PLACEBO_COMPARATOR|Phase II placebo Low or medium,1 or 2 dose (55-<85)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
61931013|NCT02385214|EXPERIMENTAL|Arm A Wide Local Excision = 1cm Margin|"ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
61931014|NCT02385214|ACTIVE_COMPARATOR|Arm B Wide Local Excision = 2cm Margin|"ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
61931015|NCT01137318|EXPERIMENTAL|Cognitive remediation and Behavioral Intervention|
61931016|NCT01137318|PLACEBO_COMPARATOR|Low Level Cognitive Remediation and Behavioral Parent Traning|
61931017|NCT05537090|EXPERIMENTAL|BV100 Plus Midazolam|A total 2 doses of midazolam and 9 doses of BV100 will be administered to each participant per specified dosing schedule
61931018|NCT00608543|OTHER|Aripiprazole augmentation|This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment.
61931019|NCT03740867|EXPERIMENTAL|Group1|"Those with poor cognition (MOCA score\<23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
61931020|NCT03740867|EXPERIMENTAL|Group2|"Those with good cognition (MOCA score≥23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
62483536|NCT03889639|EXPERIMENTAL|Cohort 1: SAR442168 5 mg Then Placebo|Participants received SAR442168 5 milligrams (mg), orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
62483537|NCT03889639|EXPERIMENTAL|Cohort 1: SAR442168 15 mg Then Placebo|Participants received SAR442168 15 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
62483538|NCT03889639|EXPERIMENTAL|Cohort 1: SAR442168 30 mg Then Placebo|Participants received SAR442168 30 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
62483539|NCT03889639|EXPERIMENTAL|Cohort 1: SAR442168 60 mg Then Placebo|Participants received SAR442168 60 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
62483540|NCT03889639|EXPERIMENTAL|Cohort 2: Placebo Then SAR442168 5 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 5 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
61931021|NCT05653726|EXPERIMENTAL|Telemonitoring group|Follow-up group by telematic consultations and non-invasive daily telemonitoring of weight, blood pressure, heart rate, peripheral oxygen saturation and electrocardiogram.
61931022|NCT05653726|NO_INTERVENTION|Control gropu|Usual care follow-up group
62691856|NCT05700617|ACTIVE_COMPARATOR|1:1 Randomization to Milrinone or Dobutamine|Patients will be randomized 1:1 to either Milrinone or Dobutamine. Milrinone will be given as a bolus at a dose of 5 mcg/kg/min over 15 minutes, for a total of 75 mcg/kg. For patients randomized to the arm for maintenance milrinone, they will be maintained at 0.125-0.375 mcg/kg/min. Patients may be randomized to dobutamine will be infused at 10-40 mcg/kg/min during the infusion phase and for those randomized to dobutamine for maintenance, they will be kept at 5-10 mcg/kg/min.
61931023|NCT05211518|OTHER|Tasty&Healthy|Tasty\&Healthy intervention: subjects will receive dietary advice to exclude pro-inflammatory dietary components
62324555|NCT03207022|EXPERIMENTAL|lidocaine 2% with clonidine|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.
62324556|NCT04040712|EXPERIMENTAL|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
62324557|NCT04040712|SHAM_COMPARATOR|Sham FMT|Sham fecal microbiota transplantation
61931024|NCT05211518|OTHER|Habitual diet|Habitual diet: subjects will continue their habitual diet.
61931025|NCT02661451|EXPERIMENTAL|TAVR (with SAPIEN 3 THV) and OHFT|Transcatheter heart valve and Optimal Heart Failure Therapy
61931026|NCT02661451|ACTIVE_COMPARATOR|OHFT|Optimal Heart Failure Therapy
61931027|NCT04755153|EXPERIMENTAL|Practice Facilitation|Practice Facilitation to support implementation of the Kaiser Blood Pressure Control Bundle
62324558|NCT01276067|EXPERIMENTAL|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
62324559|NCT01276067|ACTIVE_COMPARATOR|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
62324560|NCT06692179|EXPERIMENTAL|Experimental group|Male and female patients, ages 18-75, diagnosed with colon polyps or early (stage I or II) colorectal cancer or medically refractory diverticulitis.
61931028|NCT04755153|ACTIVE_COMPARATOR|Non-Practice Facilitation|implementation of the Kaiser Blood Pressure Control Bundle without Practice Facilitation
62324561|NCT04090931|EXPERIMENTAL|Heat-Activated Nickel-Titanium Archwires|"Heat-activated NiTi (HANT) Group (TruFlex™ Thermal Nickel-Titanium, Ortho Technology, USA):~* 0.014-inch HANT~* 0.016-inch HANT"
62324562|NCT04090931|EXPERIMENTAL|Superelastic Nickel-Titanium Archwires|"Superelastic NiTi (SENT) Group (TruFlex™ Nickel-Titanium, Ortho Technology, USA):~* 0.014-inch SENT~* 0.016-inch SENT"
62483541|NCT03889639|EXPERIMENTAL|Cohort 2: Placebo Then SAR442168 15 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 15 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
61931029|NCT06708351|EXPERIMENTAL|Aim 2, Arm I (ENHANCE LINKAge)|Patients receive HPV self-testing kit and instruction on how to perform HPV self-testing on study. Patients undergo vaginal self-swab and receive results by text message. Patients also receive mobile text message reminders for triage or treatment for women that test positive with HPV.
61931030|NCT06708351|ACTIVE_COMPARATOR|Aim 2 (standard care)|Patients undergo standard of care at clinics that have VIA testing
61944566|NCT00191906|NO_INTERVENTION|Normal Control|Normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population.
62324563|NCT00895349|EXPERIMENTAL|1|CT Abdomen and Pelvis + whole body PET-CT
62324564|NCT00895349|ACTIVE_COMPARATOR|2|CT Abdomen and Pelvis
62324565|NCT01896037|EXPERIMENTAL|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
62324566|NCT03596177|EXPERIMENTAL|MEDI0382|Participants will receive subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
62324567|NCT03596177|PLACEBO_COMPARATOR|Placebo|Participants will receive SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.
62324568|NCT06048055|ACTIVE_COMPARATOR|Group 1 (GA)|Twenty Egyptian male stroke patients will receive 30 minutes of transcutaneous vagal nerve stimulation at tragus of left ear immediately after a 30 minutes session of selected physical therapy program.
62324569|NCT06048055|SHAM_COMPARATOR|Group 2 (GB)|Twenty Egyptian male stroke patients will receive 30 minutes of sham vagal nerve stimulation at tragus of left ear immediately after a 30 minutes session of selected physical therapy program.
62324570|NCT00189007|EXPERIMENTAL|Allopurinol|500 mg allopurinol/ 50 mL water for injection intravenously
62324571|NCT00189007|PLACEBO_COMPARATOR|Placebo|500 mg mannitol/50 mL water for injection intravenously
62324572|NCT03537768|ACTIVE_COMPARATOR|UPA 30mg|
62324573|NCT03537768|ACTIVE_COMPARATOR|LNG 1.5 mg|
62324574|NCT03537768|ACTIVE_COMPARATOR|LNG 3.0|
62324575|NCT06121947|EXPERIMENTAL|The DBS electrodes are implanted into MLR.|The DBS electrodes are implanted into MLR.MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation, and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide, and guide on rehabilitation training and electrical stimulation therapy. Device: GPi-DBS devices DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).
62324576|NCT06121947|ACTIVE_COMPARATOR|The electrodes are implanted into the patient's vagus nerve|The electrodes are implanted into the patient's vagus nerve. A pre-surgery assessment was performed. Device implantation was done under general anesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunneled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
62324577|NCT05325814||Device: Continuous monitoring system|Continuous monitoring system Recruited patients will be continuously monitored with Isansys Lifetouch patch, Nonin WristOx 3150, Isansys wireless blood pressure monitor (Meditech Blue BP-05) and standard monitoring at the post anesthesia care unit
62324578|NCT04301882||interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
62324579|NCT04301882||direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
62324580|NCT03362346||Neurocritical patients|Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others.
62324581|NCT04314167|EXPERIMENTAL|LDL lowering therapy|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
62324582|NCT02310971|EXPERIMENTAL|Biologic/Vaccine|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
62324583|NCT04946136|EXPERIMENTAL|Gait modification|In this pilot study, participants modify their gait patterns guided by real-time visual feedback on their medial knee load while walking on an instrumented treadmill.
62324584|NCT00648843|EXPERIMENTAL|1|Oxybutynin Chloride Extended-release Tablets 5 mg
62324585|NCT00648843|ACTIVE_COMPARATOR|2|Ditropan XL® Tablets 5 mg
62324586|NCT01893840|EXPERIMENTAL|FlowOx|5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
62324587|NCT04845698|EXPERIMENTAL|With i-Dashboard|Multi-disciplinary rounds are conducted with the assistance of i-Dashboard.
62324588|NCT04845698|NO_INTERVENTION|Without i-Dashboard|Multi-disciplinary rounds are conducted without the assistance of i-Dashboard. The team members collect data using standard electronic medical records.
62483542|NCT03889639|EXPERIMENTAL|Cohort 2: Placebo Then SAR442168 30 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 30 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
62691857|NCT05700617|ACTIVE_COMPARATOR|1:1 Randomization to Dobutamine or Milrinone|Patients will be randomized 1:1 to either Milrinone or Dobutamine. Dobutamine will be infused at 10-40 mcg/kg/min during the infusion phase, and for those randomized to dobutamine for maintenance, they will be kept at 5-10 mcg/kg/min. Milrinone will be given as a bolus at a dose of 5 mcg/kg/min over 15 minutes, for a total of 75 mcg/kg. For patients randomized to the arm for maintenance milrinone, they will be maintained at 0.125-0.375 mcg/kg/min.
62691858|NCT04635280|EXPERIMENTAL|Closed-loop automatic insulin delivery system|Adults type 1 diabetic patients equipped with a closed-loop automatic insulin delivery system (or artificial pancreas)
61944567|NCT00191906|NO_INTERVENTION|Reading Disordered Control|The reading disordered control group is comprised of children with reading disorder who receive standard remedial teaching therapy.
62132412|NCT03144518|EXPERIMENTAL|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
62132413|NCT03144518|ACTIVE_COMPARATOR|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
62132414|NCT05427305|EXPERIMENTAL|TAB008|Eligible patients received TAB008 15 mg/kg every three weeks for 6 cycles, then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death.
62132415|NCT05427305|ACTIVE_COMPARATOR|Bevacizumab|Eligible patients received bevacizumab-EU 15 mg/kg every three weeks for 6 cycles, then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death.
62132416|NCT00731614|EXPERIMENTAL|Arm 1|Cognitive Behavior Therapy + mirror retraining
62132417|NCT00731614|ACTIVE_COMPARATOR|Arm 2|Supportive psychotherapy
62324589|NCT04712578|EXPERIMENTAL|Caffeinated Pre-workout Supplement|This arm will consist of ingestion of the commercially available, caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
62324590|NCT04712578|ACTIVE_COMPARATOR|Non-Caffeinated Pre-Workout Supplement|This arm will consist of ingestion of the commercially available, non-caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
62324591|NCT04712578|PLACEBO_COMPARATOR|Placebo|This arm will consist of a flavor-matched placebo beverage without the active components contained in the supplements administered in the other study arms.
62324592|NCT04363086|EXPERIMENTAL|TAU|
62324593|NCT04363086|EXPERIMENTAL|iFD|
62324594|NCT04363086|EXPERIMENTAL|iFD + weekly phone calls|
62324595|NCT00833235||Patients with dry eye|No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.
62324596|NCT00833235||Patients with no history of dry eye|No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.
62324597|NCT05232942||Studied group|The study population will consist of patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (galcanezumab, fremanezumab or eptinezumab) or else its receptor (erenumab), with positive response, and discontinue the treatment.
62324598|NCT02846376|EXPERIMENTAL|Group A - Nivolumab|"Nivolumab for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~* Dose level 1: 1 mg/kg~* Dose level 2: 3 mg/kg"
62324599|NCT02846376|EXPERIMENTAL|Group B - Ipilimumab|"Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~* Dose level 1: 0.3 mg/kg~* Dose level 2: 1.0 mg/kg~* Dose level 3: 3.0 mg/kg"
62324600|NCT02846376|EXPERIMENTAL|Group C - Nivolumab + Ipilimumab|"* Nivolumab 3 mg/kg for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~* Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~  * Dose level 1: 0.3 mg/kg~ * Dose level 2: 0.6 mg/kg~ * Dose level 3: 1.0 mg/kg"
62324601|NCT05657288|EXPERIMENTAL|Hypoxia|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
62691859|NCT02559856|ACTIVE_COMPARATOR|Apixaban|10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.
62691860|NCT02559856|ACTIVE_COMPARATOR|Rivaroxaban|15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.
62691861|NCT05435157||Diabetic patients|Diabetic patients undergoing scheduled surgery
62691862|NCT05435157||Non-diabetic patients|Non-diabetic patients undergoing sheduled surgery
61944568|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
61944569|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
61944570|NCT03820180|EXPERIMENTAL|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
61944571|NCT03820180|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS® 250/50
62132418|NCT02808351|EXPERIMENTAL|Berberine|Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.
62132419|NCT02808351|NO_INTERVENTION|Blank control|Blank control of berberine administration
62324602|NCT04072354|EXPERIMENTAL|SEP-363856 50mg|SEP-363856 50mg dosed once daily
62324603|NCT04072354|EXPERIMENTAL|SEP-363856 75mg|SEP-363856 75mg dosed once daily
62324604|NCT04072354|PLACEBO_COMPARATOR|Placebo|Placebo dosed once daily
62339917|NCT02338492|EXPERIMENTAL|Photodynamic Bone Stabilization System|Photodynamic Bone Stabilization System (PBSS) is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone
62691863|NCT00322218|EXPERIMENTAL|Zevalin|"Patients received Zevalin.~Zevalin Therapeutic Regimen:~Day 1: Initial administration of 250 mg/m\^2 rituximab, followed immediately by administration of 185 MBq of \[111In\]-ibritumomab tiuxetan ,in centers where centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.~- Day 7-9: Rituximab 250 mg/m\^2, followed immediately by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg given as a slow intravenous push over 10 minutes.~Two treatment days one week apart were followed by a 12-week safety period."
62691864|NCT00322218|NO_INTERVENTION|Observational|Patients in this arm did not receive any reference therapy; they remained free of any anti-lymphoma therapy and were observed for relapse. This was non-interventional Stage consisting of a longterm follow-up period (until completion of a median observation period of 5 years).
62691865|NCT06564727|EXPERIMENTAL|Uniportal VATS approach|patient treated by Uniportal VATS technique
62691866|NCT06564727|ACTIVE_COMPARATOR|VATS resection|patients treated by VATS technique
61931031|NCT06130800||Wheelchair|"The inclusion criteria to participate in the study are being in a wheelchair, preserved cognitive status and having sufficient ability to Oral occlusion for carrying out respiratory tests. The exclusion criteria are following: presence of respiratory diseases or in treatment of respiratory diseases, serious orthopedic diseases that interfere with measurements and those with a diagnosis of dementia. In addition, those who present any contraindication for carrying out the procedure will be excluded.~of the respiratory pressure measurement tests, as established in the SEPAR guidelines. The objectives of the study and the methodology to be used will be explained to all participants.~An information sheet will be provided and the informed consent sheet will be given to them."
61931032|NCT06130800||wanderers|"The inclusion criteria to participate in the study are to have functional ambulation, preserved cognitive status and have sufficient ability to Oral occlusion for carrying out respiratory tests. The exclusion criteria are following: presence of respiratory diseases or in treatment of respiratory diseases, serious orthopedic diseases that interfere with measurements and those with a diagnosis of dementia. In addition, those who present any contraindication for carrying out the procedure will be excluded.~of the respiratory pressure measurement tests, as established in the SEPAR guidelines. The objectives of the study and the methodology to be used will be explained to all participants.~An information sheet will be provided and the informed consent sheet will be given to them."
61931033|NCT01496976|EXPERIMENTAL|Immunotherapy|Combination Regimen Followed by Consolidative Therapy: Ofatumumab/High Dose Methylprednisolone (HDMP) plus Ofatumumab/Lenalidomide
62132420|NCT02876016|EXPERIMENTAL|awake brain surgery|Exploration of the cortical area of the brain awake surgery
62132421|NCT04327843|EXPERIMENTAL|CAE + LAI|Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)
62132422|NCT01086163||Omacor dose titration|"Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:~* survived first-time AMI more than 12 months ago~* stable medical treatment during the last 3 months (except removal of Plavix)~* Ethnicity: Caucasians~* Males, 50 - 60 yrs~* non-diabetics~* excluded are those who eat more than one meal of fish / week~* excluded are those who take omega-3 supplements of any sorts"
62132423|NCT01457313||BTKA|patients undergoing bilateral staged total knee arthroplasty
62132424|NCT01421407|ACTIVE_COMPARATOR|High Intensity Focused Ultrasound|
62324605|NCT04200170|EXPERIMENTAL|Intervention Arm|Eligible participants had been scheduled for either weekly or biweekly sessions with their therapists. Participants in the intervention arm were asked to download the Rose application on to their personal mobile phones and were given their therapist's unique ID for verification in the app. During the first week of the study, participants were prompted to complete key surveys and assessments at predetermined time intervals. Participants seen weekly will use the app for a total of 5 weeks and receive weekly in-person therapy for a total of 4 weeks (one-week application only lead-in, four weeks application plus in-person psychotherapy). Participants seen biweekly will use the app for a total of 10 weeks and receive biweekly in-person therapy for a total of 8w weeks (two-week application only lead-in, eight weeks application plus in-person psychotherapy).
62691867|NCT01586910|EXPERIMENTAL|Medtronic CoreValve® System TAVI|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
61931034|NCT03824106|EXPERIMENTAL|Arm1.Control|Participants randomized to the control arm will not receive any of the Frailty Rehabilitation Interventions. Participants in the control arm will receive Vitamin D.
61931035|NCT03824106|EXPERIMENTAL|Arm2.Group Exercise|Participants will attend the exercise program, twice-weekly, for 4-months with supplemental home exercise.
61931036|NCT03824106|EXPERIMENTAL|Arm3.Multi-modal Intervention|"Group Exercise/Supplemental Home Exercise: This will be delivered identically to Arm 2.~Nutrition, protein supplementation, and a medication review will also be implemented."
61931037|NCT06067204|EXPERIMENTAL|Automatic ventilation|After the advanced airway is placed, an automatic pneumatic ventilator will be connected and provides ventilation in every 6 seconds.
62132425|NCT01421407|NO_INTERVENTION|Control group|
62691868|NCT01586910|ACTIVE_COMPARATOR|SAVR|Surgical Aortic Valve Replacement (SAVR)
62691869|NCT06062355|EXPERIMENTAL|HRS-9815 injection|
62132426|NCT05165459|EXPERIMENTAL|Cytori Celution System in Chronic Non-Healing venous Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
62132427|NCT01408524|ACTIVE_COMPARATOR|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
62132428|NCT01408524|ACTIVE_COMPARATOR|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
62132429|NCT00611559|EXPERIMENTAL|Infanrix hexa Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
62132430|NCT00611559|ACTIVE_COMPARATOR|Infanrix hexa Preservative-Containing Formulation Group|Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
62132431|NCT00611559|ACTIVE_COMPARATOR|Infanrix penta Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
62483543|NCT03889639|EXPERIMENTAL|Cohort 2: Placebo Then SAR442168 60 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 60 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
62483544|NCT05512650|ACTIVE_COMPARATOR|VR first|At their first visit, subjects will engage in a virtual reality meditation while wearing the VR headset. At their second visit, they will engage in a non-immersive meditation without the 3D VR aspect.
62483545|NCT05512650|ACTIVE_COMPARATOR|VR second|At their first visit, subjects will engage in a non-immersive meditation without the 3D VR aspect. At their second visit, they will engage in a virtual reality meditation while wearing the VR headset.
62483546|NCT02974621|EXPERIMENTAL|Arm A (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62483547|NCT02974621|EXPERIMENTAL|Arm B (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62483548|NCT06093984|EXPERIMENTAL|Dual Stimulation Protocol|Dual stimulations were performed during the follicular and luteal phases in the same cycle.
62483549|NCT06093984|ACTIVE_COMPARATOR|Antagonist Stimulation Protocol|Antagonist stimulations were performed during two consecutive follicular phases in two cycles.
62483550|NCT02479763|NO_INTERVENTION|Conventional loss-of-resistance|
62483551|NCT02479763|EXPERIMENTAL|Waveform-confirmed loss-of-resistance|
62483552|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
62483553|NCT01876992|EXPERIMENTAL|Metformin|"Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of \<60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.~For children \<50kg:~Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.~For children ≥50kg:~Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.~For adults:~Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid."
62691870|NCT06675747||study group|Female patients will be selected from those who present with various maxillofacial muscle pain complaints to the 'Temporomandibular Disorders Clinic' at the Department of Prosthodontics, Istanbul University Faculty of Dentistry. Female patients diagnosed with myofascial pain syndrome and for whom occlusal splint therapy is planned will be included in the study will be selected from this patient group.
62691871|NCT05713110|EXPERIMENTAL|tazemetostat combined with HMP689 open-label treatment arm|"Dose Escalation Phase (Phase IIa):~patients with relapsed or refractory lymphoma who have failed standard treatment and have no standard treatment options~Dose Expansion Phase (Phase IIb):~Cohort 1 (DLBCL, FL 3b): Histologically confirmed DLBCL, FL 3b (including primary mediastinal B-cell lymphoma) with relapsed/refractory disease ；~Cohort 2 (FL) patients with histologically confirmed R/R FL (Grade 1, 2, 3a)；~Cohort 3 (MCL): Patients with R/R MCL who had prior therapies ；~Cohort 4 (PTCL): Patients with histologically confirmed R/R PTCL who have failed or cannot tolerate standard therapy"
62691872|NCT01277198||surgery without using a flexible cystoscopy|surgery without using a flexible cystoscopy: patients who did not undergo a flexible cystoscopy during laparoscopic stone surgery
61931038|NCT06067204|ACTIVE_COMPARATOR|Manual ventilation|After the advanced airway is placed, a bag valve mask resuscitator will be connected and provides ventilation in every 6 seconds by the emergency medical technician.
62483554|NCT01876992|NO_INTERVENTION|Obese Controls|"Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.~There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn."
61931039|NCT05281016|EXPERIMENTAL|Delayed Intervention Control Group|Participants randomised to the Control Group will be offered standard care and will be introduced to 6 month delayed intervention which consists of the online community LITE programme.
61931040|NCT05281016|EXPERIMENTAL|Intervention Group|Participants randomised to the Intervention Group will receive standard care plus invitation to participate in the online community LITE programme for 4-5 months.
61931041|NCT05497518||People with chronic kidney disease|No interventions will be administered as part of this registry.
61931042|NCT05337293|EXPERIMENTAL|COPE-HF Partnership Intervention|Working with a trained registered nurse interventionist, participants in this arm were trained to use a 4-step problem-solving process to manage identified problems related to heart failure. Heart failure self-care education and materials were provided as indicated based on specific identified problems.
61931043|NCT05337293|SHAM_COMPARATOR|Attention|Participants in this arm received telephone calls from a trained research assistant on the same schedule as the intervention group. During these calls basic data were collected on several key areas of heart failure self-care. No intervention or patient education took place during these calls.
62132432|NCT03498196|EXPERIMENTAL|Avelumab|Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
62132433|NCT02885636|EXPERIMENTAL|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
62483555|NCT01326494|ACTIVE_COMPARATOR|Arm 1 Oral Cortico Steroid|A filled prescription will be given to be used upon early onset of symptoms.
62483556|NCT01326494|NO_INTERVENTION|Usual care for Asthma treatment|monitor the readmission of URTI induced asthma in children over a 12 month period
62483557|NCT02275143||CT TAP scan|Suitable patients will be identified after consultant radiologists have approved a request for cancer routine CT TAP scan.
61931044|NCT05337293|NO_INTERVENTION|Usual Care|Participants in this arm received usual care from their healthcare providers and facility designated heart failure discharge education only.
62132434|NCT02885636|PLACEBO_COMPARATOR|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
62483558|NCT06386094||NAFLD|"Non invasive tests like APRI, FIB-4, , FAST scan and VCTE in the form of Fibroscan will be done and recorded.~Liver biopsy would be done as per the clinical indication. Diagnosis of NAFLD will be based on history, physical examination, laboratory investigations, upper gastrointestinal endoscopy, imaging studies (ultrasonography and Doppler of spleno portal venous axis, VCTE) and liver biopsy where available."
62483559|NCT02993562||Hypothyroid patients|Hypothyroid patients treated with Levothyroxine as part of normal treatment.
62483560|NCT02993562||Healthy volunteers|Matched on age and BMI. 18 Persons.
62691873|NCT01277198||surgery with using a flexible cystoscopy|surgery with using a flexible cystoscopy: patients who underwent a flexible cystoscopy during laparoscopic stone surgery
62691874|NCT05589597|EXPERIMENTAL|Cohort 1|E04010 Monotherapy
62691875|NCT05589597|EXPERIMENTAL|Cohort 2|E04010 in combination with nivolumab
62324606|NCT04200170|NO_INTERVENTION|Waitlist Control Arm|The participants in the waitlist control arm served as controls for the study. They completed the pre-pilot and post-pilot assessments only. The waitlist participants continued their standard care and were offered entrance to the intervention arm at the end of the study period or earlier if patients in the intervention arm dropped out mid-study. During their time on the waitlist, participants could reach out to study personnel if they needed assistance with their psychiatric care.
62691876|NCT05589597|EXPERIMENTAL|Cohort 3|E04010 in combination with nivolumab and/or bevacizumab
62324607|NCT03238092|ACTIVE_COMPARATOR|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
62324608|NCT03238092|NO_INTERVENTION|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
62324609|NCT03238092|EXPERIMENTAL|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
62324610|NCT03476018|PLACEBO_COMPARATOR|Placebo|
62324611|NCT03476018|EXPERIMENTAL|0.2 microgram Z-100|
62324612|NCT03476018|EXPERIMENTAL|2 microgram Z-100|
62324613|NCT03476018|EXPERIMENTAL|20 microgram Z-100|
62324614|NCT06692439||acute heart failure|"The presence or absence of acute left heart failure (gold standard) was determined through diagnosis by two experts (a cardiologist and an emergency physician) based on:~1. Data collected in the ED and during hospitalization: Clinical examination and history, Current medications, Hemodynamic parameters, ECG, Chest X-ray, Emergency interventions, Clinical and paraclinical findings during hospitalization~2. Biological assays (excluding NT-proBNP)~3. Echocardiography performed by a cardiologist within 24 hours of admission, including: Left Ventricular Ejection Fraction, Segmental wall motion, Presence of valvular disease, Transmitral flow, Tissue Doppler E' velocity~anticipated, n = 185/450 (41%)"
62324615|NCT06692439||no acute heart failure|"The presence or absence of acute left heart failure (gold standard) was determined through diagnosis by two experts (a cardiologist and an emergency physician) based on:~1. Data collected in the ED and during hospitalization: Clinical examination and history, Current medications, Hemodynamic parameters, ECG, Chest X-ray, Emergency interventions, Clinical and paraclinical findings during hospitalization~2. Biological assays (excluding NT-proBNP)~3. Echocardiography performed by a cardiologist within 24 hours of admission, including: Left Ventricular Ejection Fraction, Segmental wall motion, Presence of valvular disease, Transmitral flow, Tissue Doppler E' velocity~anticipated, n = 265/450 (59%)"
62324616|NCT04249141||ICU providers|Surveys and a concept mapping exercise will be administered to ICU providers who participated in the ICU Liberation Collaborative
62324617|NCT04249141||Secondary Data Analysis|Secondary data analysis will used information on patients and providers who participated in the ICU Liberation Collaborative
62324618|NCT06098261|EXPERIMENTAL|Test (T)-Reference (R)|In this trial, 40 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group A: Test (T)-Reference (R), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
62324619|NCT06098261|EXPERIMENTAL|Reference (R)-Test (T)|In this trial, 40 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group B: Reference (R)-Test (T), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
62324620|NCT05984381|ACTIVE_COMPARATOR|Prednisolone and Methotrexate (Control Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) and Methotrexate 15 mg weekly for 16 weeks.
62324621|NCT05984381|EXPERIMENTAL|Prednisolone and Dapsone (Test Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) and Dapsone 100 mg/day for 16 weeks
62324622|NCT05454176|EXPERIMENTAL|Libre 2|"Half of patients will be randomized to wear an unblinded FreeStyle Libre 2 CGM for 12 months. Sensor glucose data will be continuously available to patients and their providers.~Primary outcome measurement occurs at 6 months."
62324623|NCT05454176|PLACEBO_COMPARATOR|SMBG levels 3x/daily (standard diabetes management)|Half of subjects will be given sufficient test strips to test 3x per day for the first 6 months of the study, as is usual clinical practice. They wear a blinded FreeStyle Libre Pro CGM monthly during this time-the blinded device is simply to collect study data, the data will not be available to the patient or their provider for clinical use. They will use the 3x daily SMBG data for insulin adjustment, as per usual standard of care. For the final 6 months (7-12), this group will switch to unblinded CGM patients and providers will have full access to CGM data.
62324624|NCT05889130|ACTIVE_COMPARATOR|first two hours of exercise group|This is the group that will do resistance exercise in the first two hours of the hemodialysis session.
62324625|NCT05889130|ACTIVE_COMPARATOR|last two hours of exercise group|This is the group that will do resistance exercise in the last two hours of the hemodialysis session.
62483561|NCT01310257||Knee osteoarthritis|Patients will have osteoarthritis (OA) of the knee defined and scored radiologically in Study 1. Patients in Study 2 will also have OA of the knee, but a clinical diagnosis will suffice. All patients will report knee pain.
62483562|NCT06115317|OTHER|Prism followed by sham|
62483563|NCT06115317|OTHER|Sham followed by prism|
62132435|NCT06220994||Chronic limb-threatening ischemia|Resting pain for at least 2 weeks with at least one hemodynamic index: ABI\<0.4,AP\<50mmHg, TP or TCPO2\<30mmHg. Tissue defects (ulceration or gangrene) persisted for at least 2 weeks with at least one significant PAD objective evidence: ABI\<0.8, AP\<100mmHg, TP or TCPO2\<60mmHg.
62132436|NCT06220994||health control|sex - and age-matched healthy people (without history of atherosclerotic plaque, coronary heart disease or stroke).
62132437|NCT04177147|EXPERIMENTAL|Clinical decision support via alert tool|Clinicians received access to the electronic alert tool, which automatically displayed patients' risk of hypoglycemia.
62132438|NCT04177147|NO_INTERVENTION|Usual care|Clinicians did not receive access to the electronic alert tool.
62132439|NCT01189149|EXPERIMENTAL|IV fluids|Infants will get IV fluids whem indicated until able to tolerate full oral feedings
62132440|NCT01189149|EXPERIMENTAL|Oro/naso gastric tube feeding|Infants will get oro/naso gastric tube feeding whem indicated until able to tolerate full oral feedings
62132441|NCT06510595|EXPERIMENTAL|Active Treatment Arm|The child will receive active elbow flexion exercise with electrotherapy.
62132442|NCT06510595|ACTIVE_COMPARATOR|Control Treatment Arm|The child will be managed with conservative treatment using a brace only.
62324626|NCT06405490|EXPERIMENTAL|NALIRI-XELOX+AK104|"Every 2 weeks as a cycle:~1. Nanoliposomal Irinotecan: 47.1mg/m2, iv, d1;~2. Cadonilimab: 6mg/kg, iv, d3;~3. Oxaliplatin: 70mg/m2, iv, d1;~4. Capecitabine: 1000mg/m2, bid, po, d1-d7; Re-evaluate patients every three cycles. If the patient has been treated for more than 9 cycles, they will enter maintenance therapy, and the regimen is capecitabine +Cadonilimab."
62324627|NCT06156384||Patients|Patients aged ≥12 years with congenital or acquired lower limb discrepancy, greater than 30mm
62324628|NCT05643560||Hemophilia A patients|Hemophilia patients who had initiated damoctocog alfa pegol treatment .
62324629|NCT00428987||lean|Normal weight men and women over the age of 18 years with BMI greater than 18.5 and less than 25, who are reasonably healthy
62324630|NCT00428987||obese|Obese men and women over the age of 18 years with BMI greater than 30, who are reasonably healthy
62324631|NCT00428987||overweight|Overweight men and women over the age of 18 years with BMI greater than 25 and less than 30, who are reasonably healthy
62324632|NCT03664609||Parkinson's Disease|Subjects with Parkinson's disease, implanted with a Boston Scientific Deep Brain Stimulation System
62324633|NCT03664609||Essential Tremor|Subjects with Essential Tremor, implanted with a Boston Scientific Deep Brain Stimulation System
62132443|NCT05208125|EXPERIMENTAL|CSSMS|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
62132444|NCT05208125|PLACEBO_COMPARATOR|PPPPP|Normal saline solution at weeks 0, 4, 12, 22, and 28 (PPPPP).
62132445|NCT00894543|ACTIVE_COMPARATOR|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
62324634|NCT03664609||Dystonia|Subjects with dystonia, implanted with a Boston Scientific Deep Brain Stimulation System
62324635|NCT05579314|ACTIVE_COMPARATOR|SAD Cohort A - XW014|Single oral XW014 administration
62324636|NCT05579314|PLACEBO_COMPARATOR|SAD Cohort A - Placebo|Single oral placebo administration
62324637|NCT05579314|ACTIVE_COMPARATOR|MAD Cohort B - XW014|MAD in Healthy Subjects with Elevated BMI
62324638|NCT05579314|PLACEBO_COMPARATOR|MAD Cohort B - Placebo|MAD in Healthy Subjects with Elevated BMI
62324639|NCT05579314|ACTIVE_COMPARATOR|MAD Cohort C - XW014|MAD in Patients with T2DM
62324640|NCT05579314|PLACEBO_COMPARATOR|MAD Cohort C - Placebo|MAD in Patients with T2DM
62324641|NCT05579314|ACTIVE_COMPARATOR|MAD Cohort B-EXT - XW014|MAD in Healthy Subjects with Elevated BMI
62324642|NCT05579314|ACTIVE_COMPARATOR|MAD Cohort B-EXT - Placebo|MAD in Healthy Subjects with Elevated BMI
62324643|NCT05617599||Coronary Artery Disease (CAD)|
62324644|NCT02369731||Translarna|Participants with nmDMD receiving Translarna will be followed for at least 5 years from their date of enrollment, or until participant withdrawal of consent or death, whichever occurs first.
62324645|NCT04078152|EXPERIMENTAL|Treatment|Durvalumab Monotherapy
62132446|NCT00894543|PLACEBO_COMPARATOR|Placebo|Inactive pill
62132447|NCT04062396|ACTIVE_COMPARATOR|Eurosets REMOWELL 2 oxygenator|
62132448|NCT04062396|ACTIVE_COMPARATOR|LivaNova INSPIRE oxygenator|
62132449|NCT03754036|EXPERIMENTAL|Sleep Extension|Increase in time in bed of 1.5 hours per night for one week
62132450|NCT03754036|EXPERIMENTAL|Sleep Restriction|Decrease in time in bed of 1.5 hours per night for one week
62132451|NCT02358616||Former VOICE (MTN-003) participants|Qualitative interviews and focus group discussions conducted on former VOICE participants. All participants to receive interviews.
62324646|NCT04078152|NO_INTERVENTION|Off Treatment|Follow up Only
62324647|NCT05884073|EXPERIMENTAL|Circuit-based resistance exercise|12-week, supervised circuit-based resistance training program (2-3 times/week).
62324648|NCT05884073|ACTIVE_COMPARATOR|Nature Walking|12-weeks self-paced walking in nature (2-3 times/week).
62324649|NCT06525649|PLACEBO_COMPARATOR|Placebo|Matching placebo for active comparator.
62324650|NCT06525649|ACTIVE_COMPARATOR|NPT 2042 160mg|NPT 2042
62324651|NCT06525649|ACTIVE_COMPARATOR|NPT 2042 240mg|NPT 2042
62324652|NCT03897075|EXPERIMENTAL|Arm A|
62324653|NCT03897075|PLACEBO_COMPARATOR|Arm B|
62324654|NCT05998824|OTHER|Adults With Sickle Cell Disease|Age 18 years or older
62324655|NCT06553625||Boston Scientific Radiofrequency Ablation Systems|Subjects treated with Boston Scientific commercially approved radiofrequency (RF) ablation systems in the central nervous system (CNS).
62324656|NCT06054893|EXPERIMENTAL|Part 1 and 2: Cohort A1|Cohort A1 will contain participants ≥12 to \<16 years of age. Participants will receive a single oral dose of omaveloxolone 150 milligrams (mg), capsule, on Day 1 of the treatment period of part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian population pharmacokinetics (popPK) analyses.
62339918|NCT03661489|EXPERIMENTAL|Intravenous Remimazolam 50 mg|"For induction of general anesthesia, remimazolam is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia remimazolam is titrated to effect. Administration of boluses of remimazolam is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
62483564|NCT01746472|EXPERIMENTAL|2 - B-passive|
62483565|NCT01746472|EXPERIMENTAL|3 - B-active|
62483566|NCT01746472|EXPERIMENTAL|4 - B-active, B-passive|
62483567|NCT01746472|EXPERIMENTAL|6 - z, B-passive|
62483568|NCT01746472|EXPERIMENTAL|7 - z, B-active|
62483569|NCT01746472|EXPERIMENTAL|8 - z, B-active, B-passive|
62483570|NCT01746472|EXPERIMENTAL|10 - t, B-passive|
62483571|NCT01746472|EXPERIMENTAL|11 - t, B-active|
62483572|NCT01746472|EXPERIMENTAL|12 - t, B-active, B-passive|
62483573|NCT01746472|EXPERIMENTAL|14 - t, z|
62483574|NCT01746472|EXPERIMENTAL|15 - t, z, B-active|
62483575|NCT01746472|EXPERIMENTAL|16 - t, z, B-active, B-passive|
62483576|NCT03675633||FEUrea in decompensated liver cirrhosis|FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS
62691877|NCT06641544|ACTIVE_COMPARATOR|A Group|"Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pertuzumab：was administered as an intravenous (IV) loading dose of 840mg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420mg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Chemotherapy regimen chosen by the physician"
62132452|NCT03036176|OTHER|SAM intervention group|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
62132453|NCT03036176|OTHER|SAM control Group|The control children received routine medical treatment and nutritional rehabilitation services in hospital. Though they had access to playground facilities neither the control children nor their caregivers had access to the playroom materials and the basic orientation on child care, feeding and stimulation.
62691878|NCT06641544|EXPERIMENTAL|B Group|"Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pyrotinib：400 mg once daily orally within 30 minutes after a meal at the same time each day.~Chemotherapy regimen chosen by the physician"
62691879|NCT06186284|OTHER|patient|Rehabilitation patients using a technical walking aid will be followed up for development of carpal tunnel syndrome
62691880|NCT06642792|EXPERIMENTAL|AK129|Phase Ia: Subjects will receive AK129: different doses on every 2 weeks.
62691881|NCT06642792|EXPERIMENTAL|AK129+AK117|"Phase Ib: Subjects will receive: AK129: different doses on every 2 weeks, AK117: 30mg/kg on every 2 weeks.~Phase II: Subjects will receive: AK129: recommended phase II dose (RP2D) from phase Ib on every 2 weeks, AK117: 30mg/kg on every 2 weeks."
62691882|NCT04275518|EXPERIMENTAL|APG-115/APG-115+Cytarabine in Relapse/Refractory AML|
62132454|NCT05398861|EXPERIMENTAL|HER-2 Negative Advanced Breast Cancer|Utidelone Combined with Bevacizumab
62483577|NCT03115957|EXPERIMENTAL|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
62483578|NCT03115957|EXPERIMENTAL|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
62483579|NCT06503900|EXPERIMENTAL|Simultaneous Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine and IIV at Visit 1.
62483580|NCT06503900|EXPERIMENTAL|Sequential Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine at Visit 2 and a dose of IIV at Visit 2.
62483581|NCT05370807|EXPERIMENTAL|Cohort A|Patients take 2 oral tablets of 40mg of Regorafenib daily.
62483582|NCT05370807|EXPERIMENTAL|Cohort B|Patients take 1 oral tablets of 40mg of Regorafenib daily in combination with BRAF- /MEK- inhibitors dabrafenib/trametinib or encorafenib/binimetinib at the dose they were already taking them.
62483583|NCT05370807|EXPERIMENTAL|Cohort C|Patients take 1 oral tablets of 40mg of Regorafenib daily in combination with encorafenib/binimetinib at the standard dose.
62483584|NCT05249257||No Treatment - previously treated in parent study|Participants who completed the parent study EN3835-224 (NCT04580303) will be eligible for this study.
62483585|NCT00932841|PLACEBO_COMPARATOR|Placebo|
62483586|NCT00932841|ACTIVE_COMPARATOR|VSL#3 90 billion bacteria|
62483587|NCT00932841|ACTIVE_COMPARATOR|VSL#3 900 billion bacteria|
62483588|NCT03407963|EXPERIMENTAL|Prostate cancer patients|
62483589|NCT05226702|EXPERIMENTAL|COVAC-2 10 µg group|20 healthy adults ≥18 years of age receive the vaccine on Day 0.
62483590|NCT05226702|EXPERIMENTAL|COVAC-2 25 µg group|20 healthy adults ≥18 years of age receive the vaccine on Day 0
62483591|NCT05226702|PLACEBO_COMPARATOR|Placebo Control|20 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
62483592|NCT05316454|EXPERIMENTAL|Experimental|Patients with hypertension benefit from self-efficacy support in terms of medication adherence and self-efficacy.
62483593|NCT05316454|NO_INTERVENTION|Control|No change.
62483594|NCT05024682|EXPERIMENTAL|conventional pulsed radiofrequency|
62483595|NCT05024682|EXPERIMENTAL|pulse dosed pulsed radiofrequency|
62483596|NCT01945307||Healthy adults|Healthy adults aged 18 to 70 years
62483597|NCT01366963||Normal Controls / Healthy Volunteers|Age and gender matched individuals without postural orthostatic tachycardia syndrome
62483598|NCT01366963||Patients with Postural Tachycardia Syndrome (POTS)|Individuals with Postural Tachycardia Syndrome
62483599|NCT02611440|EXPERIMENTAL|Pharmacist Intervention|It will be a semi -structured interviews with patient and pharmacist over various time after the stroke (at Month0, M3, M6, M9) combined with patient's therapeutic follow-up from various healthcare professionals.
62483600|NCT02611440|NO_INTERVENTION|Control|No pharmacist intervention planned.
61931045|NCT04910256|EXPERIMENTAL|HuaTuo ZaiZao group|"In this arm, patients take 8g of HuatuoZaizao pill three times a day. Besides，participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
61931046|NCT04910256|SHAM_COMPARATOR|Control group|"participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
61931047|NCT00135733|ACTIVE_COMPARATOR|A|Amevive
61931048|NCT00135733|PLACEBO_COMPARATOR|B|Placebo
62324657|NCT06054893|EXPERIMENTAL|Part 1 and 2: Cohort A2|Cohort A2 will contain participants ≥12 to \<16 years of age. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from Cohort A1 to select the dose in part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses.
62324658|NCT06054893|EXPERIMENTAL|Part 1 and 2: Cohort B|Cohort B will contain participants ≥6 to \<12 years of age and will initiate in parallel with Cohort A2. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from Cohort A1 to select the dose in part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses.
62324659|NCT06054893|EXPERIMENTAL|Part 1 and 2: Cohort C|Cohort C will contain participants ≥2 to \<6 years of age. Participants will receive a single oral dose of omaveloxolone at a dosage level determined by a Bayesian popPK analysis using the data from cohorts A1, A2, and B to select the dose in part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses.
62691883|NCT04275518|EXPERIMENTAL|APG-115/APG-115+Aza in relapsed/progressed high risk MDS|
61931049|NCT05612022||Group 1. Patients with AVF as first line HD access option.|24 consecutive patients in need of AVF enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.
61931050|NCT05612022||Group 2. Patients with AVG as first line HD access option.|20 consecutive patients in need of AVG enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.
62132455|NCT04664270|EXPERIMENTAL|e-Psychotherapy|Group will receive 8-week online program including CBT in combination with mindfulness and problem-based therapy in addition to treatment as usual. The content will reflect challenges cancer and palliative patients face through the course of treatment and developed into interactive and engaging therapy modules. All online sessions and interactions will occur through a secure online platform. Pre-designed therapy modules are assigned to the patients, accessible to them at any time throughout the week. Each module consists of approximately 30 slides, which take 45-50 minutes to complete. Each module highlights a different topic and includes general information, an overview of skills, and homework that is to be completed within that week. This homework can be directly submitted through the platform to the clinician who will then provide personalized feed-back to the patient. The average time spent per week by a clinician with a particular patient is about 15 minutes.
62132456|NCT04664270|NO_INTERVENTION|Treatment as Usual|The control group will receive treatment as usual in the first 8 weeks; if still significantly symptomatic (less than 50% response to treatment from baseline), they will then be offered the 8-week e-psychotherapy program. They will be instructed to continue with any lifestyle activities (i.e., diet, exercise, medication, etc.)
62324660|NCT05846334|EXPERIMENTAL|Intervention group|
62691884|NCT06673810|EXPERIMENTAL|Group A|Ankle Weighted Cuffs Training Along with Routine Physical Therapy Exercises
61931051|NCT06238661|EXPERIMENTAL|Subjects with PSA ≥ 3 ng/ml|"* Urologic examination~* Risk calculation (ERSPC no.6)~* Magnetic resonance imaging~* (optional) biopsy"
61931052|NCT04637906|EXPERIMENTAL|L-arginine|Bioarginina®, 2 orally administered vials per day
61931053|NCT04637906|PLACEBO_COMPARATOR|Placebo|2 orally administered vials per day of Bioarginina® without L-arginine
61931054|NCT04544189|EXPERIMENTAL|Alpelisib+Fulvestrant (randomized cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular \[as two 250mg/5 ml injections\] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
61931055|NCT04544189|PLACEBO_COMPARATOR|Placebo+Fulvestrant (randomized cohort)|Placebo (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular \[as two 250mg/5 ml injections\] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
61931056|NCT04544189|EXPERIMENTAL|PK cohort (open label cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular \[as two 250mg/5 ml injections\] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
61931057|NCT00089284|EXPERIMENTAL|Rituxan and 90Yttrium-Zevalin plus MGd|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
61931058|NCT02328911|EXPERIMENTAL|Laser treatment|Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
62132457|NCT01483066|EXPERIMENTAL|ShapeMatch Instrumentation|
62132458|NCT01483066|ACTIVE_COMPARATOR|Usual Instrumentation|
62324661|NCT05846334|NO_INTERVENTION|Control group|
62324662|NCT05777993|EXPERIMENTAL|Mitapivat|Participants will receive mitapivat of 5, 20 or 50 milligrams (mg), orally, twice daily (BID), based on the last dose received by the participants in the antecedent study. Mitapivat will be administered from Day 1 up to end of treatment period of this study.
62324663|NCT06077864|EXPERIMENTAL|survodutide 3.6 mg|
62324664|NCT06077864|EXPERIMENTAL|survodutide 6.0 mg|
62691885|NCT06673810|OTHER|Control Group|Routine Physical Therapy Exercises
62691886|NCT05841771|EXPERIMENTAL|AZA-VEN maintenance|hypomethylating agents (azacytidine 32mg/m2 or decitabine 5mg/m2) for 5 days and venetoclax 400mg/d for 7 days, repeated every 28 days until up to 1-year posttransplant.
62691887|NCT06499350|EXPERIMENTAL|FC084CSA+Tislelizumab|This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of FC084CSA in combination with Tislelizumab. Increasing dose levels of FC084CSA with fixed dose of Tislelizumab. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level. Following the definition of the recommended Phase 2 Dose (RP2D) of FC084CSA in dose escalation phase, NSCLC dose expansion cohort is planned to perform a preliminary assessment of the anti-tumour efficacy and to further establish the safety profile of the RP2D of FC084CSA in combination with Tislelizumab.
62691888|NCT06639945|EXPERIMENTAL|Verum stimulation followed by Sham stimulation|
62324665|NCT06077864|PLACEBO_COMPARATOR|Placebo|
62691889|NCT06639945|EXPERIMENTAL|Sham stimulation followed by Verum stimulation|
62691890|NCT06563596|EXPERIMENTAL|Rituxam + Zanubrutinib + Epcoritamab|"Enrolled participants will complete:~* Baseline visit with imaging and bone marrow biopsy~* Imaging on cycles 3, 6, 9, 13, and 19~* Up to 2 years of treatment with study drugs~* End of Treatment visit with imaging and bone marrow biopsy~* Follow up visits every 6 months for up to 10 years"
62691891|NCT05080790|EXPERIMENTAL|5 cycles (Q5W) of dinutuximab beta, interleukin-2 and zoledronic acid|5 cycles (Q5W) of dinutuximab beta, 20mg/m2/day, interleukin-2, 5.4x10\^6, and zoledronic acid, 4 mg
62691892|NCT01225224|EXPERIMENTAL|ASP015K Single Japanese Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
61931059|NCT02328911|SHAM_COMPARATOR|Sham treatment|Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
61931060|NCT05531201|EXPERIMENTAL|Interventional|Trainig of GP and physiotherapist at collaborative coordinated care pathway
61931061|NCT05531201|NO_INTERVENTION|Control|without modification of the usual follow-up
61931062|NCT06709027|EXPERIMENTAL|Intervention Group (Mobile Health Management Intervention)|Participants in this group will receive a mobile health management intervention over a period of 12 weeks. This intervention includes the use of a mobile application designed for health management, psychological support, and monitoring，et al, with the aim of improving the mental health status of elderly patients with depression.
61931063|NCT06709027|NO_INTERVENTION|Control Group (Standard Care)|Participants in this group will receive standard care during the same 12-week period. This includes routine medical services and psychological support, but does not involve any specific mobile health intervention.
61931064|NCT06697847||Healthy volunteers|Adults with no mood disorder and who have not been diagnosed with or had treatment for a mood disorder in the last 6 months.
61931065|NCT06161441|EXPERIMENTAL|Arm A|"Randomized 1:1:1~Neoadjuvant period:~placebo + cemiplimab + platinum doublet chemotherapy~Adjuvant period:~placebo + cemiplimab"
62132459|NCT00995904|EXPERIMENTAL|Treatment A, then Treatment B, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
62132460|NCT00995904|EXPERIMENTAL|Treatment A, then Treatment C, then Treatment B|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
62324666|NCT02710734|EXPERIMENTAL|CRT|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3
61931066|NCT06161441|EXPERIMENTAL|Arm B|"Randomized 1:1:1~Neoadjuvant period:~fianlimab high dose + cemiplimab + platinum doublet chemotherapy~Adjuvant period:~fianlimab high dose + cemiplimab"
62324667|NCT02710734|EXPERIMENTAL|Surveillance|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance
62324668|NCT02710734|EXPERIMENTAL|Intravesicle therapy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3
62691893|NCT01225224|EXPERIMENTAL|ASP015K Single Caucasian Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
61931067|NCT06161441|EXPERIMENTAL|Arm C|"Randomized 1:1:1~Neoadjuvant period:~fianlimab low dose + cemiplimab + platinum doublet chemotherapy~Adjuvant Period:~fianlimab low dose + cemiplimab"
61931068|NCT00053365|EXPERIMENTAL|Treatment (irofulven)|Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
61931069|NCT04815031||COMIRNATY|COVID-19 mRNA vaccine (nucleoside-modified)
61944572|NCT05290792|OTHER|Intra-individual changes of physiological and activity parameters|"Participants will be administered FluMist (live attenuated influenza vaccine) to induce a low grade VRTI (Day 0). Participants will be monitored in the 7 days prior and 7 days after vaccination via symptom questionnaires, blood draws, stair tests and vital sign monitoring from wearable sensors.~Each participant will serve as their own control, relying on the baseline measurements obtained over the 7-day period prior to inoculation."
61944573|NCT00566111|ACTIVE_COMPARATOR|A|
61944574|NCT00566111|PLACEBO_COMPARATOR|P|
61944575|NCT02436252|EXPERIMENTAL|DSP-7888|
61944576|NCT04216498||Pre-Transfer Patients aged 10-16 years|
62324669|NCT02710734|EXPERIMENTAL|Radical Cystectomy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy
62324670|NCT00475761||Breast Cohort|Primary clinical- patients referred to diagnostic breast biopsy
62324671|NCT06115252|EXPERIMENTAL|Motivational Interviewing (MI)|
61944577|NCT04216498||Post-Transfer Patients aged 16-25 years|
62324672|NCT05168423|EXPERIMENTAL|Dose Level 1|Cohort 1 (N = 3-6): will receive a single fixed dose of 1x10\^7 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
62324673|NCT05168423|EXPERIMENTAL|Dose Level -1|Cohort-1 (N = 3-6): will receive a single fixed dose of 5x10\^6 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
62132461|NCT00995904|EXPERIMENTAL|Treatment B, then Treatment A, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
61931070|NCT06511882|OTHER|Consolidation and Discontinuation|"Consolidation: Patient will receive HMA (azacitidine or decitabine)/VEN (venetoclax) as part of standard of care treatment.~At the conclusion of consolidation, if the results of the bone marrow biopsy are a negative Measurable Residual Disease (MRD), patient will continue to Discontinuation.~Discontinuation:~Monthly clinic visits with laboratory assessment and bone marrow biopsies (BMBs) with MRD testing every 3 months to closely monitor disease status. At any point of the study if molecular relapse (including MRD emergence), or morphologic relapse, therapy will be reinitiated.~If only molecular relapse, HMA (azacitidine or decitabine)/VEN (venetoclax) will be reinitiated with the same monitoring schedule as before.~If morphologic relapse, HMA (azacitidine or decitabine)/VEN (venetoclax) will be reinitiated for 2 cycles.~If no response (NR), patient will be taken off Study."
62691894|NCT01225224|PLACEBO_COMPARATOR|Placebo Single Japanese Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
62691895|NCT01225224|PLACEBO_COMPARATOR|Placebo Single Caucasian Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
62691896|NCT01225224|EXPERIMENTAL|ASP015K Multiple Group|Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level. ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.
62691897|NCT01225224|PLACEBO_COMPARATOR|Placebo Multiple Group|Participants will receive placebo in three stages, each stage corresponding to a different dosage level. Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.
61931071|NCT03967977|ACTIVE_COMPARATOR|Tislelizumab in combination with chemotherapy|Tislelizumab: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
61931072|NCT03967977|PLACEBO_COMPARATOR|Placebo in combination with chemotherapy|Placebo: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
62132462|NCT00995904|EXPERIMENTAL|Treatment B, then Treatment C, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
62691898|NCT03410745|EXPERIMENTAL|Exercise group|
62691899|NCT03410745|NO_INTERVENTION|Control group|
62691900|NCT01203137||tricuspid regurgitation, severe|To be included in the present study, the following 3 criteria for severe TR should be met based on the preoperative echocardiography: (1) TR jet \> 30% of right atrial area, (2) inadequate cusp coaptation, and (3) systolic flow reversal in the hepatic vein.
62691901|NCT04925375|EXPERIMENTAL|Abatacept|"Pediatric subjects weighing \<50 kg will be placed in an single arm with abatacept with dosing based on weight. Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26.~Pediatric dosing:~Abatacept subcutaneous every week:~10-25 kg: 50 mg; 25-50 kg: 87.5 mg; \>50 kg: 125 mg~Adult dosing:~Abatacept: 125 mg subcutaneous every week"
62691902|NCT04925375|PLACEBO_COMPARATOR|Placebo|Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26. The composition of the placebo is the same as the active study drug without the abatacept. To maintain the blind, injection volumes will be the same as the active treatment.
62691903|NCT05703126|OTHER|The study group|The study group will include patients with acute myeloid leukemia receiving chemotherapy, aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before the start of polychemotherapy, in whom in the course of chemotherapy treatment after the next course of treatment a decrease in global longitudinal strain of 15% or more relative to the initial values will be revealed.
62691904|NCT05703126|OTHER|The control group|The control group will consist of patients with acute myeloid leukemia receiving chemotherapy, aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before the start of polychemotherapy, in whom no signs of myocardial disease will be detected during chemotherapy. and endothelial dysfunction.
62691905|NCT03235986|EXPERIMENTAL|nCPAP+ Nebulised Curosurf®|Curosurf® administered through nebulization
62691906|NCT03235986|OTHER|nCPAP alone (control)|Standard of care, respiratory support used also during experimental arms
62691907|NCT05442047|EXPERIMENTAL|NNC6019-0001, Dose 1|Participants will receive dose 1 intravenous (i.v.) infusion of NNC6019-0001 every 4 weeks (Q4W) added to standard of care until week 52.
62691908|NCT05442047|EXPERIMENTAL|NNC6019-0001, Dose 2|Participants will receive dose 2 i.v. infusion of NNC6019-0001 Q4W added to standard of care until week 52.
62691909|NCT05442047|PLACEBO_COMPARATOR|Placebo|Participants will receive i.v. infusion of placebo (NNC6019-0001) Q4W added to standard of care until week 52.
62691910|NCT01687062|ACTIVE_COMPARATOR|FeSO4 + high phytate|injera test meal 1 labeled with a 4 mg staple iron isotope tag
62691911|NCT01687062|EXPERIMENTAL|FeSO4 + medium phytate|injera test meal 2 labeled with a 4 mg staple iron isotope tag
62691912|NCT01687062|EXPERIMENTAL|FeSO4 + low phytate|injera test meal 3 labeled with a 4 mg staple iron isotope tag
61944578|NCT04216498||Parents/Guardians of Pre-Transfer Patients|
61944579|NCT01685866|OTHER|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
62691913|NCT01687062|EXPERIMENTAL|FeSO4 + NaFeEDTA (1:1) + high phytate|injera test meal 4 labeled with a 4 mg staple iron isotope tag
62691914|NCT01687062|EXPERIMENTAL|FeSO4 + NaFeEDTA (1:3) + high phytate|injera test meal 5 labeled with a 4 mg staple iron isotope tag
62691915|NCT04148911|EXPERIMENTAL|Atezolizumab plus Nab-Paclitaxel|Participants will receive Atezolizumab via intravenous (IV) infusion on Days 1 and 15 of every 28-day cycle in combination with Nab-Paclitaxel on Days 1, 8, and 15 (individually selected by the investigator) until disease progression, or unacceptable toxicity, additionally until loss of clinical benefit as determined by the investigator or participant decision to discontinue treatment.
62691916|NCT05294146|EXPERIMENTAL|Loading dose Clofazimine|All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine (CFZ) once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.
62691917|NCT06644001|EXPERIMENTAL|Probiotic|Bacillus coagulans
62691918|NCT06644001|PLACEBO_COMPARATOR|Placebo|Placebo
62691919|NCT06073119|EXPERIMENTAL|SAR441566 dose regimen A|Participants will receive dose regimen A of SAR441566
62691920|NCT06073119|EXPERIMENTAL|SAR441566 dose regimen B|Participants will receive dose regimen B of SAR441566
62691921|NCT06073119|EXPERIMENTAL|SAR441566 dose regimen C|Participants will receive dose regimen C of SAR441566
61931073|NCT06707649|EXPERIMENTAL|Education+Telephone Follow-up|Patients in this group will receive self-management education during the 3 days when they are in the hospital. On the first day of the training, COPD disease, causes of the disease, symptoms, reasons for alleviating complaints, practical information for living comfortably with COPD will be given. On the second day, emergency situations in COPD, what is an exacerbation and prevention suggestions and diaphragmatic breathing-cough exercises will be taught. On the last day, training will be given on pursed lip breathing, medication use, oxygen and nebulizer treatments. Patients will receive their first call one week after discharge. The calls will be scheduled weekly during the first month, biweekly in the second month, and monthly starting from the third month. During the calls, it is planned to repeat the educational content and answer the patient's questions. All scales are planned to be re-administered at 1, 3, and 6 months.
61931074|NCT06707649|EXPERIMENTAL|Education|Patients in this group will receive self-management education during the 3 days when they are in the hospital. On the first day of the training, COPD disease, causes of the disease, symptoms, reasons for alleviating complaints, practical information for living comfortably with COPD will be given. On the second day, emergency situations in COPD, what is an exacerbation and prevention suggestions and diaphragmatic breathing-cough exercises will be taught. On the last day, training will be given on puckered lip breathing, medication use, oxygen and nebulizer treatments. Patients in this group will not receive telephone follow-up. All scales are planned to be re-administered at 1, 3, and 6 months.
61931075|NCT06707649|ACTIVE_COMPARATOR|Standard Care|Patients in this group will receive standard care. Education and telephone follow-up will not be applied. All scales are planned to be re-administered at 1, 3, and 6 months.
61931076|NCT05224349||Group A|Participants with stable oral anti-spasticity treatment for at least 4 weeks prior to study entry
61931077|NCT05224349||Group B|Participants with no anti-spasticity therapy for at least 4 weeks prior to study entry
61931078|NCT02319837|EXPERIMENTAL|Enzalutamide plus leuprolide|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as as a single intramuscular or subcutaneous injection once every 12 weeks
61931079|NCT02319837|EXPERIMENTAL|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
61931080|NCT02319837|ACTIVE_COMPARATOR|Leuprolide plus placebo|"Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks.~The randomized blinded portion of the study has concluded following primary endpoint analyses. In the Open Label Period the placebo is no longer applicable in this study arm, and patients continue to receive leuprolide alone."
62132463|NCT00995904|EXPERIMENTAL|Treatment C, then Treatment A, then Treatment B|"Study visits were separated by 3-7 day intervals.~Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4"
62132464|NCT00995904|EXPERIMENTAL|Treatment C, then Treatment B, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
62132465|NCT03102853|ACTIVE_COMPARATOR|Nordic diet|
62132466|NCT03102853|OTHER|Control diet|
62324674|NCT05168423|EXPERIMENTAL|Dose Level 2|Cohort 2 (N = 3-6): will receive a single fixed dose of 2.5x10\^7 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
62691922|NCT06073119|EXPERIMENTAL|SAR441566 dose regimen D|Participants will receive dose regimen D of SAR441566
62691923|NCT06073119|EXPERIMENTAL|SAR441566 dose regimen E|Participants will receive dose regimen E of SAR441566
61931081|NCT02860377|ACTIVE_COMPARATOR|stranger's voice|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
61944580|NCT01685866|NO_INTERVENTION|no medical device|in the second arm, we use no medical device
62132467|NCT04138316||Migraine patients|
62324675|NCT05168423|EXPERIMENTAL|Dose Level 3|Cohort 3 (N = 3-6): will receive a single fixed dose of 5x10\^7 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
62324676|NCT06636656|EXPERIMENTAL|All participants|All participants will receive an intravenous dose of BI 3032950 in Part A followed by a subcutaneous dose of BI 3032950 in Part B.
62691924|NCT06073119|PLACEBO_COMPARATOR|Placebo|Participants will receive SAR441566 matching placebo
62691925|NCT00380146|EXPERIMENTAL|SP plus artesunate|SP (Fansidar®, Roche South Africa) at a dose of 25/1.25mg/kg of sulfadoxine/pyrimethamine respectively on day 0 only, and artesunate (Arsumax®, Sanofi-Aventis, South Africa) at a dose of 4mg/kg on days 0, 1, and 2
62691926|NCT05878093|EXPERIMENTAL|Dupilumab|Dupilumab every 2 weeks (Q2W) via SC injection
62691927|NCT05878093|PLACEBO_COMPARATOR|Placebo|Placebo matching dupilumab Q2W via SC injection
62691928|NCT04437745|EXPERIMENTAL|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
62691929|NCT04437745|NO_INTERVENTION|Control|No Intervention
62483601|NCT06324864|ACTIVE_COMPARATOR|START NOW Adapted|"The intervention group will receive a culturally adapted version of the yet well-validated START NOW training. The skills taught within START NOW aim to change dysfunctional negative attitudes and behaviour, improve emotion regulation capacities and enhance the ability to achieve individual goals by addressing key aspects of mental health and resilience. The training includes 10 group sessions including exercises and discussion.~The sessions will be held by a trained facilitator (staff member of institution, social worker, or else) with the same cultural background in the respective language (depending on group constellation) and supervised by a certified START NOW trainer from the START NOW team."
62483602|NCT06324864|NO_INTERVENTION|Treatment as Usual|The control group will receive treatment as usual.
62483603|NCT05374057|EXPERIMENTAL|Chiropractic Spinal Manipulative Therapy (CSMT)|A specific contact, high-velocity, low-amplitude, spinal thrust manipulation directed to spinal biomechanical dysfunction in the cervical and/or thoracic spinal column, as diagnosed by standard chiropractic tests, in accordance with their clinical judgment.
62483604|NCT05374057|SHAM_COMPARATOR|CSMT sham manipulation|A broad non-specific contact, low-velocity, low-amplitude sham push manoeuvre in a non-therapeutic directional line.
62483605|NCT05374057|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 600mg, 3 times daily for 12 days.
62483606|NCT05374057|SHAM_COMPARATOR|Placebo medication|Placebo medication, x 3 times daily for 12 days.
62483607|NCT04739358|EXPERIMENTAL|Monotherapy|"* Dose Escalation Phase for participants with MET-driven NSCLC.~* Dose Expansion Phase: CNS Efficacy Dose Expansion Cohort for participants with MET-driven NSCLC and measurable CNS disease."
62132468|NCT05102500||Retrospective Chart Review Patients|The PI will conduct a retrospective chart review of breast cancer, colorectal cancer, and pancreatic cancer patients to better understand the patient, disease, and treatment characteristics that play a role in second opinion retention rates.
62132469|NCT05102500||Semi-structure Interview Patients|The PI will conduct semi-structured interviews with breast cancer, colorectal cancer and pancreatic cancer patients to better understand the decision-making process that goes into continued care with their primary or second opinion physician.
62132470|NCT04559126|EXPERIMENTAL|EDP-297 SAD Cohorts|EDP-297 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral solution, once daily in one single administration
62483608|NCT04739358|EXPERIMENTAL|Combination Therapy|"* Dose Escalation Phase for participants with evidence of MET-driven acquired -resistance.~* Dose Expansion Phase for participants with evidence of MET-driven acquired -resistance with or without measurable CNS disease."
62483609|NCT05746104|EXPERIMENTAL|SWIG Arm|This is the only arm for the study and will be experimental. All patients will receive the appropriate dosage of the study drug, which will then be used for visualization of the tumor intraoperatively.
62691930|NCT03527979|ACTIVE_COMPARATOR|PCOS women with history of LOD before IVF/ICSI|
61931082|NCT02860377|EXPERIMENTAL|maternal voice|At the end of surgery, patients were stimulated to wake up by recorded maternal voice, which was recorded before the operation.
61931083|NCT03213600|ACTIVE_COMPARATOR|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
61931084|NCT03213600|SHAM_COMPARATOR|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
61931085|NCT05489211|EXPERIMENTAL|Substudy-1A|Dato-DXd will be evaluated as monotherapy
61931086|NCT05489211|EXPERIMENTAL|Substudy-2A|Dato-DXd in combination with capecitabine will be evaluated
61931087|NCT05489211|EXPERIMENTAL|Substudy-2B|Dato-DXd in combination with 5-FU will be evaluated
61931088|NCT05489211|EXPERIMENTAL|Substudy-3A|Dato-DXd will be evaluated as monotherapy
61931089|NCT05489211|EXPERIMENTAL|Substudy-3C|Dato-DXd will be evaluated in combination with prednisone/prednisolone
62483610|NCT04920279||The patients with diabetes mellitus|When patients with diabetes mellitus admitted to our outpatient clinic if they have inclusion criteria, we have used the ABC questionnaire. And we have done perform Time Up And Go Test twice respectively.
62483611|NCT06627530|EXPERIMENTAL|Darolutamide + ADT leuprorelin|
62483612|NCT06627530|ACTIVE_COMPARATOR|Darolutamide|
62483613|NCT06627530|ACTIVE_COMPARATOR|Leuprorelin|
62483614|NCT03721471||Frail, non-frail|"Frail Group: Those individuals identified as frail by low hand-grip-strength and/or the Clinical Frailty Scale.~Non-frail Group: Those individuals identified as not frail by hand-grip-strength and/or the Clinical Frailty Scale."
62483615|NCT02045849|EXPERIMENTAL|Part 1|Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
62691931|NCT03527979|ACTIVE_COMPARATOR|PCOS women without history of drilling|
62691932|NCT01254929||F-18 PET bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo an F-18 PET bone scan for diagnostic imaging.
61931090|NCT05489211|EXPERIMENTAL|Substudy-4A|Dato-DXd will be evaluated as monotherapy
61931091|NCT05489211|EXPERIMENTAL|Substudy-4C|Dato-DXd in combination with carboplatin + bevacizumab followed by Dato-DXd + bevacizumab will be evaluated
61931092|NCT05489211|EXPERIMENTAL|Substudy-5A|Dato-DXd will be evaluated as monotherapy
61931093|NCT05489211|EXPERIMENTAL|Substudy-5B|Dato-DXd + 5-FU + LV + bevacizumab OR Dato-DXd + capecitabine + bevacizumab will be evaluated
61931094|NCT05489211|EXPERIMENTAL|Substudy-6A|Dato-DXd in combination with volrustomig (MEDI5752) will be evaluated
61931095|NCT05489211|EXPERIMENTAL|Substudy-6B|Data-DXd in combination with rilvegostomig (AZD2936) will be evaluated
61931096|NCT05489211|EXPERIMENTAL|Substudy-6C|Dato-DXd will be evaluated as monotherapy
61931097|NCT05489211|EXPERIMENTAL|Substudy-6D|Dato-DXd in combination with carboplatin or cisplatin will be evaluated
61931098|NCT05489211|EXPERIMENTAL|Substudy-7A|Dato-DXd will be evaluated as monotherapy
61944581|NCT04898387|EXPERIMENTAL|T4030 Group|
61944582|NCT04898387|ACTIVE_COMPARATOR|Ganfort Group|
62132471|NCT04559126|EXPERIMENTAL|EDP-297 MAD Cohorts|EDP-297 Dose 1, Dose 2 and Dose 3 oral solution, once daily for 14 days
62483616|NCT02045849|EXPERIMENTAL|Part 2|Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
62483617|NCT02045849|EXPERIMENTAL|Part 3|Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.
62324677|NCT05216835|EXPERIMENTAL|Cohort A: Dose Escalation|Patients with anti-PD-1/PD-L1 exposed r/r cHL will receive sabestomig to determine the recommended phase 2 dose (RP2D).
62324678|NCT05216835|EXPERIMENTAL|Cohort B1: Dose Expansion|Patients with anti-PD-1/PD-L1 exposed r/r cHL will receive sabestomig once the RP2D has been determined.
62324679|NCT05216835|EXPERIMENTAL|Cohort B2: Dose Expansion|Patients with anti-PD-1/PD-L1 naïve r/r cHL will receive sabestomig once the RP2D has been determined.
62324680|NCT05415215|OTHER|Arm A: Pertuzumab IV and Trastuzumab IV Plus Investigator's Choice of Chemotherapy|During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with pertuzumab and trastuzumab intravenously (PH IV) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH IV will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH IV will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
62483618|NCT05986188||Implementing Schools|Implementing schools are public K-12 schools in the State of Michigan that participated in the Pathways to Potential program in a given year (from 2012 to 2024).
62691933|NCT01254929||Tc-99m MDP bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo a Tc-99m MDP bone scan for diagnostic imaging.
62691934|NCT06192966|EXPERIMENTAL|Experimental|Probiotic formulation comprising Lactobacillus plantarum CECT8675 and CECT8677 in combination with cranberry, and vitamine C in a capsule format. Probiotic strains have Qualified Presumption of Safety (QPS) sttus by European Food Safety Authority.
62691935|NCT06192966|PLACEBO_COMPARATOR|Placebo|Placebo composed of maltodextrin
61931099|NCT03051854|EXPERIMENTAL|ICC-T|Intervention: Interaction Competencies with children - for teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
61931100|NCT03051854|NO_INTERVENTION|Control schools|The control school do not receive any intervention.
61931101|NCT04868058|EXPERIMENTAL|1 AF SAPB|Atrial fibrillation. Serratus anterior plane block
61931102|NCT04868058|EXPERIMENTAL|2 AF ESPB|Atrial fibrillation. Erector spinae plane block
61931103|NCT04868058|EXPERIMENTAL|3 VT SAPB|Ventricular Tachycardia.Serratus anterior plane block
61931104|NCT04868058|EXPERIMENTAL|4 VT ESPB|Ventricular Tachycardia. Erector spinae plane block
61931105|NCT04868058|EXPERIMENTAL|5 ISNT SAPB|Inappropriate Sinus node tachycardia. Serratus anterior plane block
61931106|NCT04868058|EXPERIMENTAL|6 ISNT ESPB|Inappropriate Sinus node tachycardia. Erector spinae plane block
61931107|NCT05437211|EXPERIMENTAL|VR-based Experimental Group|Participants will receive Factor VIII or Factor IX infusion using a VR-based solution. The VR-based solution will be provided in a medical device CE marked and specifically developed by Deepsen, a French company specializing in e-health solutions to reduce pain. It includes both a mobile phone application (for an explanation on infusions) and a 3D mask to be used during infusions.
62483619|NCT05986188||Non-implementing schools|Non-implementing schools are public K-12 schools in the State of Michigan that DID NOT participate in the Pathways to Potential program in a given year (from 2012 to 2024).
61931108|NCT05956821|EXPERIMENTAL|SIACI of cetuximab and bevacizumab|Participants in this group will receive Cetuximab and Bevacizumab infusion into an artery each month for up to approximately one year.
61931109|NCT03335111|EXPERIMENTAL|ACI with BAIPC|Beside of routine treatment for Anterior circulation infarction(ACI) patients, BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
61944583|NCT01632917|EXPERIMENTAL|ATX-101 - EU|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
62483620|NCT02649647|ACTIVE_COMPARATOR|Conventional Resection|Patients receive conventional resection with standard proximal excision margin. The sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
62691936|NCT06458998|ACTIVE_COMPARATOR|Patient Navigation (PN)|Half of the HCC sites and half of the CRC sites will be randomized to PN delivered by Clinical Resource Hub navigators.
62691937|NCT06458998|ACTIVE_COMPARATOR|Implementation Facilitation (IF)|Half of the HCC sites and half of the CRC sites will be randomized to IF delivered by 2 facilitators (one clinical and one evaluation expert) per site.
62691938|NCT02832531|EXPERIMENTAL|Rivaroxaban (15 mg)|Rivaroxaban 15 mg od (n \~ 1000)
62691939|NCT02832531|ACTIVE_COMPARATOR|Aspirin (ASA)|Aspirin 100 mg od (n\~1000)
62691940|NCT04379921|NO_INTERVENTION|Control|Participants will receive standard care.
62691941|NCT04379921|EXPERIMENTAL|Apple Watch and App|Participants will receive standard care, and an Apple Watch to record activity through the App.
62691942|NCT05440565|PLACEBO_COMPARATOR|Risk score|
62691943|NCT05440565|ACTIVE_COMPARATOR|Fecal immunochemical test|
62691944|NCT06638944|EXPERIMENTAL|IN-person i-Phagia|The treatment group assigned to the IN-PERSON i-Phagia service delivery will use the system to complete a standardized swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions in the clinic and 3 days of home practice per week.
62483621|NCT02649647|EXPERIMENTAL|Proximally Extended Resection|Patients receive proximally extended resection. The whole sigmoid colon and rectum proximal to the tumor is removed, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
62483622|NCT00367133|ACTIVE_COMPARATOR|1|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
62483623|NCT00367133|EXPERIMENTAL|2|Intravitreal injection of 1mg of triamcinolone acetonide
62483624|NCT00367133|EXPERIMENTAL|3|Intravitreal injection of 4mg of triamcinolone acetonide
62483625|NCT05069688|EXPERIMENTAL|Dolutegravir PK during standard and high-dose rifampicin|This is a single arm study: all patients are started on HIV/TB cotreatment considered standard of care and then for two weeks (study weeks 20-21) high-dose rifampicin is given during which safety and pharmacokinetics are examined.
62483626|NCT02153203|EXPERIMENTAL|Behavioral approach|The Prevent-Teach-Reinforce Model will be implemented with families in their home settings.
62483627|NCT02153203|ACTIVE_COMPARATOR|Educational approach|Each child's parent will participate in one 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior in children with autism spectrum disorders.
62691945|NCT06638944|ACTIVE_COMPARATOR|Remote i-Phagia|The treatment group assigned to the REMOTE i-Phagia service delivery will use the i-Phagia system to complete a standardized swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions completed remotely (via telehealth) and 3 days of home practice per week.
62691946|NCT06638944|OTHER|Standard-of-Care (SOC) Swallow Treatment|The treatment group assigned to the SOC service delivery will complete the same standardized swallowing rehabilitation protocol and in the same frequency as the i-Phagia groups but without the device. That is, they will complete the protocol for 12 weeks with weekly (once per week) treatment sessions completed in-person and 3 days of home practice per week.
62691947|NCT06437457||CEUS|The patients who underwent CEUS before liver resection
62324681|NCT05415215|OTHER|Arm B: PH FDC SC Plus Investigator's Choice of Chemotherapy|During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with the fixed dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH FDC SC will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH FDC SC will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
62324682|NCT05415215|EXPERIMENTAL|Arm C: Adjuvant PH FDC SC in Hospital, Then at Home|During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm C will receive 3 cycles of PH FDC SC in the hospital and then 3 cycles of PH FDC SC in the home setting. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
62339919|NCT03661489|ACTIVE_COMPARATOR|Intravenous Propofol 2%|"For induction of general anesthesia, propofol is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia propofol is titrated to effect. Administration of boluses of propofol is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
62483628|NCT04722198|EXPERIMENTAL|PS128|Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
62483629|NCT02394860||blood and cardiological examination|
62691948|NCT06437457||CE-MRI|The patients who underwent CE-MRI before liver resection
62691949|NCT04342546|EXPERIMENTAL|Toxicity test|"For all patients, the NovaGray RILA Breast® test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection) and in the case of adjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection).~The test consists of a blood sample of 2x4 mL"
62339920|NCT02321137|ACTIVE_COMPARATOR|BioAVR with surgical closure of LAA|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage
62339921|NCT02321137|PLACEBO_COMPARATOR|BioAVR alone|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
62483630|NCT03614039|ACTIVE_COMPARATOR|probiotic-smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
62483631|NCT03614039|PLACEBO_COMPARATOR|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
62483632|NCT04651335|ACTIVE_COMPARATOR|Concentric|uses an afferent virtual reality program
62483633|NCT04651335|ACTIVE_COMPARATOR|Eccentric|uses an efferent virtual reality program
62483634|NCT05133180|EXPERIMENTAL|Oxervate|One drop of cenegermin 20 mcg/mL (rhNGF 20 mcg/mL) in the pharmaceutical form of ophthalmic sterile solution was instilled in both eyes three times daily (TID), every six hours.
62483635|NCT05133180|PLACEBO_COMPARATOR|Vehicle|One drop of vehicle ophthalmic solution was instilled in both eyes TID (every six hours).
62483636|NCT01075282|EXPERIMENTAL|LY2189265 1.5 mg|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
62483637|NCT01075282|EXPERIMENTAL|LY2189265 0.75 mg|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
62483638|NCT01075282|ACTIVE_COMPARATOR|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
62132472|NCT04559126|PLACEBO_COMPARATOR|EDP-297 SAD Placebo Cohort|Matching placebo, oral solution, once daily in one single administration
62483639|NCT01161420|EXPERIMENTAL|Inspire Therapy|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
62483640|NCT03155503|ACTIVE_COMPARATOR|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
62483641|NCT03155503|ACTIVE_COMPARATOR|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
62483642|NCT04353362|EXPERIMENTAL|Ofloxacin group|
62483643|NCT04353362|ACTIVE_COMPARATOR|Amoxicillin plus Metronidazole group|
62324683|NCT05415215|EXPERIMENTAL|Arm D: Adjuvant PH FDC SC at Home, Then in Hospital|During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm D will receive 3 cycles of PH FDC SC in the home setting and then 3 cycles of PH FDC SC in the hospital. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
62691950|NCT02928835|EXPERIMENTAL|Dynasplint group|The experimental group received standardized physical therapy intervention and used the knee flexion Dynasplint orthosis six hours daily during one month, starting at day seven after total knee arthroplasty surgery.
62691951|NCT02928835|NO_INTERVENTION|Control group|Control group received standardized physical therapy intervention.
61931110|NCT03335111|SHAM_COMPARATOR|ACI without BAIPC|ACI patients in this group only recieve routine treatment for ischemic stroke and are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
62132473|NCT04559126|PLACEBO_COMPARATOR|EDP-297 MAD Placebo Cohort|Matching placebo, oral solution, once daily for 14 days
62324684|NCT05415215|OTHER|Arm E: Adjuvant Trastuzumab Emtansine|Participants with pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy and surgery will enter Arm E to receive trastuzumab emtansine for 14 cycles. Trastuzumab emtansine will be administered IV in the hospital as per prescribing information.
62483644|NCT04828122||Arm 1: MCI amyloid positive|"1. Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~2. Positive amyloid PET or amyloid CSF status.~3. MMSE 23-30 (inclusive)"
62483645|NCT04828122||Arm 2: MCI amyloid negative|"1. Non-AD Mild Cognitive Impairment (MCI)~2. Negative amyloid PET or amyloid CSF status.~3. MMSE 23-30 (inclusive)"
62483646|NCT04828122||Arm 3: CN amyloid positive|"1. Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~2. Positive amyloid PET or amyloid CSF status.~3. MMSE 26-30 (inclusive)"
62483647|NCT04828122||Arm 4: CN amyloid negative|"1. Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~2. Negative amyloid PET or amyloid CSF status.~3. MMSE 26-30 (inclusive)"
62483648|NCT03024086|EXPERIMENTAL|DWJ1252|DWJ1252 + Placebo of Gasmotin
62483649|NCT03024086|ACTIVE_COMPARATOR|Gasmotin|Gasmotin + Placebo of DWJ1252
62483650|NCT04728542||Origine|70 subjects with the ORIGIN PS System
62483651|NCT04728542||Vanguard|70 subjects with the VANGUARD System
62483652|NCT04467151|EXPERIMENTAL|anti-SARS-CoV-2 plasma|Patients receive one dose (250-300ml) of anti-SARS-CoV-2 convalescent plasma
62691952|NCT06674889|NO_INTERVENTION|Standard|Subjects will receive standard of care.
62691953|NCT06674889|EXPERIMENTAL|Rehabilitation|Subjects will be assessed for rehabilitation and a rehabilitation plan will be generated.
62691954|NCT02256033|EXPERIMENTAL|Istradefylline|One 40-mg tablet of istradefylline administered on Day 1.
61931111|NCT03337607|ACTIVE_COMPARATOR|rESWT plus C-E drugs|Patients will receive rESWT, Celecoxib and Eperisone
62132474|NCT04132141|OTHER|VR intervention|each subject will be own control. subjects breaks will be randomly assigned to VR or WT until they complete 3 for each type or a total of 6
62324685|NCT05485779|EXPERIMENTAL|Part A (SAD): Group A1|Single dose of AQ280, 3 mg or placebo
62324686|NCT05485779|EXPERIMENTAL|Part A (SAD): Group A2|Single dose of AQ280, dose to be determined (TBD) or placebo
62324687|NCT05485779|EXPERIMENTAL|Part A (SAD): Group A3|Single dose of AQ280, dose TBD or placebo
62324688|NCT05485779|EXPERIMENTAL|Part A (SAD): Group A4|Single dose of AQ280, dose TBD or placebo
62324689|NCT05485779|EXPERIMENTAL|Part A (SAD): Group A5|Single dose of AQ280, dose TBD or placebo
62483653|NCT04467151|PLACEBO_COMPARATOR|Placebo|Patients receive one dose (250-300ml) of placebo (albumin 5%)
62483654|NCT05393050|ACTIVE_COMPARATOR|Colquhounia Root Tablet plus methotrexate (MTX)|Colquhounia Root Tablet 0.9g tid and methotrexate (MTX) 10 mg oncea week for the first 12 weeks，Colquhounia Root Tablet 0.54g tid and methotrexate (MTX) 10 mg once a week for the after 12 weeks.
62483655|NCT05393050|PLACEBO_COMPARATOR|placedo of Colquhounia Root Tablet plus methotrexate (MTX)|placedo of Colquhounia Root Tablet 0.9g tid and methotrexate (MTX) 10 mg oncea week for the first 12 weeks，placedo of Colquhounia Root Tablet 0.54g tid and methotrexate (MTX) 10 mg once a week for the after 12 weeks.
62483656|NCT04492540|OTHER|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be 60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
61931112|NCT03337607|ACTIVE_COMPARATOR|rESWT alone|Patients will receive rESWT
62324690|NCT05485779|EXPERIMENTAL|Part B (MAD): Group B1|AQ280 dose TBD or placebo, once daily (QD) for seven days
62324691|NCT05485779|EXPERIMENTAL|Part B (MAD): Group B2|AQ280 dose TBD or placebo, once daily (QD) for seven days
62324692|NCT05485779|EXPERIMENTAL|Part B (MAD): Group B3|AQ280 dose TBD or placebo, once daily (QD) for seven days
62324693|NCT05345171|EXPERIMENTAL|DTX301, Then Placebo|Participants receive single peripheral intravenous (IV) infusion of DTX301 in solution. At week 64, participants receive single peripheral IV infusion of placebo.
62324694|NCT05345171|EXPERIMENTAL|Placebo, Then DTX301|Participants receive single peripheral IV infusion of placebo. At week 64, participants receive single peripheral IV infusion of DTX301 in solution.
62324695|NCT04417062|EXPERIMENTAL|Olaparib-Ceralasertib|"Unresectable disease (can not be surgically removed) will be enrolled into Cohort 1 and Resectable disease (can be surgically removed) which is limited only to the lung parenchyma will be enrolled into Cohort 2.~* Olaparib at a predetermined dose orally 2 times a day on days 1-28~* Ceralasertib will be given at a predetermined dose orally 2 times a day on days 1-14 in 28-day study cycles.~Patients can remain on treatment for up to 2 years if disease progression has not occurred."
62324696|NCT04467411||Breast Cancer Group|Breast Cancer Group
62324697|NCT04467411||Healthy Volunteer|Healthy Volunteer Group
62324698|NCT06643455|EXPERIMENTAL|Arm A (MIND program)|Patients participate in the MIND program consisting of self-paced online education on nutrition, chef demo skills-building cooking, and mindfulness practice over 4 hours weekly for 6 weeks.
62324699|NCT06643455|ACTIVE_COMPARATOR|Arm B (waitlist control)|Patients participate in SOC for 6 weeks. Patients may optionally receive access to the MIND program following the initial 6-week study period.
62324700|NCT04610788||SSc-PAH Group|Scleroderma patients referred for a clinically indicated right heart catheterization (RHC).
62483657|NCT04492540|OTHER|The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet program|the control group will receive MIND diet program for 12 weeks
62483658|NCT04890353|EXPERIMENTAL|standard management plus Dimethyl Fumarate|
62483659|NCT04890353|NO_INTERVENTION|standard management|
62324701|NCT04610788||IPAH Group|Presumed/known IPAH patients referred for a clinically indicated right heart catheterization (RHC).
62324702|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
62324703|NCT05500508|EXPERIMENTAL|Escalation|"Dose escalation of DFMO with AMXT1501 fixed dose will follow a 3 + 3 dose escalation design.~The AMXT 1501 starting dose administered in the first cohort will be 1200mg total daily dose (200 mg capsules; 3 capsules in morning; 3 capsules in evening) along with IV DFMO administered in continuous infusion at 2mL/hr over a 28 days per cycle. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of DFMO alone will increase per cohort."
62483660|NCT05231603|ACTIVE_COMPARATOR|Treatment group:|Ivermectin 0.4 mg/kg/day (maximum 24 mg)
62483661|NCT05231603|PLACEBO_COMPARATOR|Control group|Placebo-inactive substance
62483662|NCT02408367||Exercise|30 minutes of active training at 75% of the Maximum heart rate achieved in a cardiopulmonary exercise test
61931113|NCT03337607|ACTIVE_COMPARATOR|C-E drugs alone|Patients will receive Celecoxib and Eperisone
62324704|NCT05500508|EXPERIMENTAL|Expansion|The expansion cohort will include up to 40 evaluable patients at a proposed RP2D level of AMXT1501 and DFMO defined by AMXT1501-101A study to further characterize safety at proposed RP2D dose level with repeat dosing, and characterize early anti-tumor activity.
62324705|NCT05325632|EXPERIMENTAL|Lead In - Dose level 1|Six participants will be treated at dose level 1: DC vaccine given at the dose of 50 million once per week for 6 weeks
62324706|NCT05325632|EXPERIMENTAL|Lead In: Dose Level 2|Six participants will be treated at dose level 2: DC vaccine given at the dose of 100 million once per week for 6 weeks
62324707|NCT05325632|EXPERIMENTAL|Expansion -Estrogen Receptor (ER) positive|An additional 24 participants will be enrolled at dose level 2 if determined to be safe in lead in phase to have a total of 28 evaluable participants for pathologic response assessment (including 6 pts from the lead in phase).
62324708|NCT05325632|EXPERIMENTAL|Expansion -Estrogen Receptor (ER) negative|An additional 23 participants will be enrolled at dose level 2 if determined to be safe in lead in phase to have a total of 28 evaluable participants for pathologic response assessment (including 6 pts from the lead in phase).
62324709|NCT05849259|EXPERIMENTAL|Dementia Care Quality at Home|Each HBPC practice will receive the Dementia Care Quality at Home intervention.
62339922|NCT05065996||Different 4D flow MRI parameters in aortic dilatation and controls|Patients with aortic dilatation (n=20) scheduled for aortic MRI and healthy controls (n=20) without aortic dilatation. One time aortic MRI with 4D flow imaging.
62339923|NCT05065996||Value of aortic 4D flow MRI parameters to predict aortic dilatation in 5 years follow up|Patients with aortic dilatation (n=100) scheduled for aortic MRI follow up in Kuopio University Hospital. Aortic 4D flow MRI will be done yearly for 5 years and flow parameters predicting aortic dilatation will be analysed.
62483663|NCT02408367||Relaxation|30 Minutes of passive relaxation
61931114|NCT05280093|EXPERIMENTAL|Hybrid sinus node sparing ablation procedure|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
61931115|NCT03654443|EXPERIMENTAL|Group Painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a painful stimulus (IT0), during the painful stimulus (IT1) and soon afterwards (IT2)
61931116|NCT03654443|EXPERIMENTAL|Group Non-painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a non-painful stimulus (IIT0), during the painful stimulus (IIT1) and soon afterwards (IIT2)
62483664|NCT02286362||Cohort|
62483665|NCT01870453||Isoflurane Anesthesia|Recruited subjects that were anesthetized with isoflurane for their surgery.
62483666|NCT01870453||Sevoflurane Anesthesia|Recruited subjects that were anesthetized with sevoflurane for their surgery.
62483667|NCT01870453||Desflurane Anesthesia|Recruited subjects that were anesthetized with desflurane for their surgery.
62691955|NCT00692328|ACTIVE_COMPARATOR|1|The subjects will be told they receive levodopa or acupuncture.
62324710|NCT06644560|EXPERIMENTAL|Prehabilitation Intervention|This is a single-arm, pre-post, window of opportunity trial. The tailored prehab program will be implemented for AI cancer patients preparing for cancer surgery for a 3-week duration in the preoperative window of opportunity. The prehab intervention is designed to modify inﬂammatory biomarkers in paired pre/post-intervention blood and tissue samples. 30 individuals who are 18-80 years old with a diagnosis of obesity-related solid tumor cancer, scheduled at least 3 weeks out from cancer surgery who are enrolled tribal members will be recruited over the duration of the study. Blood samples will be collected before and after the prehab, and inflammatory biomarkers will be measured in the paired pre/post blood sample. Unstained slides from the diagnostic biopsy and resected tumor specimen will be requested, and inflammatory biomarkers will be measured in the paired pre/post tissue sample.
62483668|NCT01870453||Propofol Anesthesia|Recruited subjects that were anesthetized with propofol for their surgery.
62483669|NCT04193241|ACTIVE_COMPARATOR|Conventional purse-string suture closure|A common-place conventional method of closure of chest tube or thoracostomy wound using a Prolene 1 purse-string suture (also known as U-suturing), at the time of chest tube removal.
62483670|NCT04193241|EXPERIMENTAL|Suture-less occlusive-absorbent dressing closure|Unconventional method of closing chest tube or thoracostomy wounds using Occlusive adhesive-absorbent dressing material (Primapore\*) application i.e. Un-reapproximated wound edges, at time of chest tube removal
62483671|NCT04286074|EXPERIMENTAL|Experimental group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the muscle training technique will be performed against a resistance of 50% of the maximum inspiratory pressure of each athlete"
62483672|NCT04286074|ACTIVE_COMPARATOR|Control group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the muscle training technique will be performed against a resistance of 10% of the maximum inspiratory pressure of each athlete"
62691956|NCT00692328|PLACEBO_COMPARATOR|2|The subjects will be told they receive placebo/sham levodopa or acupuncture.
62691957|NCT00692328|EXPERIMENTAL|3|The subjects will be told they have 50% chance of receiving real or placebo/sham levodopa or acupuncture.
62324711|NCT04544436|EXPERIMENTAL|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses based on their body weight at baseline: 1200 mg (participant's body weight \<75 kilograms \[kg\]) or 1800 mg (participant's body weight ≥ 75 kg) of ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
62691958|NCT04650893|PLACEBO_COMPARATOR|Control|no steroid or non steroidal anti-inflammatory
62691959|NCT04650893|ACTIVE_COMPARATOR|Ketorolac|one time dose of 30mg of IV Ketorolac at time of closure
62691960|NCT04650893|ACTIVE_COMPARATOR|dexamethasone|one time dose of 10mg of IV dexamethasone at the time of closure
62691961|NCT04516213|EXPERIMENTAL|Enteral formula tube feeding|Enterally fed children, ages 1-4, with established enteral feeding access
62691962|NCT06571474||Lean Individuals|No intervention will be administered.
62691963|NCT06571474||Metabolically abnormal obese Individuals|Obesity with normoglycemia and abnormal liver fat content
62691964|NCT06571474||Metabolically normal obese Individuals|Obesity with normoglycemia and normal liver fat content
62691965|NCT06571474||Individuals with Type 2 Diabetes Mellitus|Pre-Diagnosed type 2 diabetics
62691966|NCT03288857|NO_INTERVENTION|Bulb Aspirator|If randomized to the bulb aspirator group, the patient will be sent home with a bulb aspirator to use for home nasal secretion management
62691967|NCT03288857|EXPERIMENTAL|Nasal Oral Aspirator (NeilMed Naspira)|If randomized to the nasal oral aspirator group, patient will be sent home with a nasal oral aspirator to use for home nasal secretion management
62691968|NCT06639204|EXPERIMENTAL|Electrical Stimulation|Electric current will be applied in this group of patients using a removable device.
62691969|NCT06639204|ACTIVE_COMPARATOR|Conventional treatment with no stimulation|No acceleration method will be performed in this group
62691970|NCT03093415|ACTIVE_COMPARATOR|Old Town Clinic, Medication Assisted Therapy group|25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
62691971|NCT03093415|ACTIVE_COMPARATOR|Outside In Clinic, Needle Exchange Program|25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
62691972|NCT03093415|OTHER|OHSU Hepatology Clinic, Academic center Retrospective Cohort|50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health \& Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
62691973|NCT05725434|EXPERIMENTAL|CT-P47 SC (tocilizumab)|CT-P47 (tocilizumab) by subcutaneous (SC) injection
62691974|NCT05215626||Patients implanted with the Zimmer Reconstruction System|
62691975|NCT06292507|EXPERIMENTAL|EFFECTS OF MYOFASCIAL STRETCH|This group will receive Myofascial stretch Group.
62691976|NCT06292507|EXPERIMENTAL|CONTRACT-RELAX TECHNIQUE ON TONE|This group will receive Contract-Relax technique Group
62691977|NCT05272605|EXPERIMENTAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 5mcg + MF59|DoCo-Pro-RBD-1 antigen 5mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
62691978|NCT05272605|EXPERIMENTAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1)15mcg + MF59|DoCo-Pro-RBD-1 antigen 15mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
62691979|NCT05272605|EXPERIMENTAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 45mcg + MF59|DoCo-Pro-RBD-1 antigen 45mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
62691980|NCT05272605|EXPERIMENTAL|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 10mcg|MIPSCo-mRNA-RBD-1 antigen 10mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
62324712|NCT04544436|ACTIVE_COMPARATOR|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
61931117|NCT04644445|NO_INTERVENTION|Control|Standard bariatric clear liquid diet to be started 4 hours after surgery
61931118|NCT04644445|EXPERIMENTAL|Intervention|Bariatric full liquid diet (clear liquid diet + protein shakes) to be started 4 hours after surgery
61931119|NCT00880373|ACTIVE_COMPARATOR|1|Diamorphine or Morphine by PCA and oral ibuprofen
61931120|NCT00880373|PLACEBO_COMPARATOR|2|Diamorphine or Morphine by PCA and oral placebo
61931121|NCT06414096|ACTIVE_COMPARATOR|Conventional Subcutaneous FSH Dosing|A daily gonadotropin dose (typically 75-450 IU) will be assigned and adjusted, based on clinical criteria and, if known, past response to hormones. Recombinant human FSH (rhFSH) will be given as a daily subcutaneous injection, as is performed, by patients at home, in routine clinical practice.
61931122|NCT06414096|EXPERIMENTAL|Pulsatile IV FSH Dosing|participants will receive the same daily rhFSH dose (based on clinical practice criteria); however, it will be delivered via a portable infusion pump with reservoir (Avocet Infusion Pump, Eitan Medical LTD) that will provide an IV bolus (100-500 µl) every 90 minutes, a frequency that has previously been shown to result in physiologic ovulatory cycles in GnRH deficient women (Martin). The total gonadotropin dose delivered over a 24 hour period will be typically 75-450 IU, assigned based on standard of care clinical criteria (max dose is 900IU per clinical care guidelines). Participants will be provided with a 100mL preloaded reservoir, calibrated to deliver the approved standard of care dosing, in 16 boluses (100-500µl) over 24 hours (q 90min), for 7-12 days. Each 100 ml reservoir has capacity for 200 doses if the volume is 500 µl, which is sufficient for the typical 7- 12-day protocol.
61931123|NCT06274788||Single arm OMEGAVEN® (fish oil triglycerides; injectable emulsion)|The dose of investigational drug (study treatment), as well as all other components of the overall nutritional regimen is solely at the discretion of the Investigator. It is assumed the Investigator will use sound medical judgement, follow institutional standards of care regarding the nutrition provided to each patient, and review applicable prescribing information indicating the maximum and recommended dose of Omegaven of 1 g/kg/day infused intravenously over 8 to 24 hours as long as the infusion rate does not exceed 1.5 mL/kg/hour.
61931124|NCT04893226|NO_INTERVENTION|Control|Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). There will be no intervention.
61931125|NCT04893226|EXPERIMENTAL|Time-Restricted Feeding (TRF) Group|Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). Subjects in this group will be educated about the health benefits of time-restricted feeding (TRF). Then each subject in the TRF group will self-select a 10-h window during which she will consume all daily calories for 16 weeks.
61931126|NCT06707545||Asqelio EDOF|Patients submitted to cataract surgery and implanted with the extended depth-of-focus intraocular lens Asqelio EDOF Toric
61931127|NCT06707545||Monofocal IOL|Patients submitted to cataract surgery and implanted with the TECNIS 1-Piece monofocal intraocular lens
61931128|NCT05421923|EXPERIMENTAL|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
61931129|NCT05421923|PLACEBO_COMPARATOR|Placebo|Ascending single and multiple doses of SR1375 placebo orally
61931130|NCT05983198|EXPERIMENTAL|Group-1 (mCRPC/ post-177Lu)|"1. Dose Escalation: All eligible participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have received anti-cancer treatment (post-Androgen Receptor Pathway Inhibitors (ARPI), post-taxane based chemotherapy and heavily pre-treated and having already received prior 177Lu-labelled Prostate Specific Membrane Antigen (PSMA)-targeting Radioligand Therapy (RLT) will receive the starting dose of 7 Megabecquerel (MBq) of 225Ac-PSMA-R2 to determine the Maximum Tolerated Dose/Recommended Dose for Expansion (MTD/RDE) of Group 1.~2. Dose Expansion: Once RDE is determined for Group 1, participants who have previously received 177Lu-PSMA-RLT will be enrolled in Group 1 dose expansion."
61931131|NCT05983198|EXPERIMENTAL|Group-2 (mCRPC/ pre-177Lu)|"1. Dose Escalation: All eligible participants with mCRPC who have received anti-cancer treatment (post-Androgen Receptor Pathway Inhibitors (ARPI), prior taxane-based chemotherapy is not required, but have never been treated with 177Lu-labelled PSMA-targeted RLT (177Lu-labelled PSMA-targeted RLT treatment naïve) will receive the starting dose of 7 Megabecquerel (MBq) of 225Ac-PSMA-R2 to determine the Maximum Tolerated Dose/Recommended Dose for Expansion (MTD/RDE) of Group 2.~2. Dose Expansion: Once RDE is determined for Group 2, participants naïve to 177Lu-labelled PSMA-targeted Radioligand Therapy (RLT) will be enrolled in Group 2 dose expansion."
61944584|NCT01632917|EXPERIMENTAL|ATX-101 - US|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
61944585|NCT04612439|EXPERIMENTAL|VABB Elite 10G|Vacuum-assisted Elite 10G
61944586|NCT04612439|ACTIVE_COMPARATOR|BARD 14G CNB|BARD 14G Core needle
62324713|NCT01434368||children age 8-17 years admitted to pilot brain imaging studies|children age 8-17 years admitted to pilot brain imaging studies
62324714|NCT01434368||healthy adults|healthy adults ages 25 - 35 years at the time of enrollment
62324715|NCT01434368||typically developing children (with evidence of advanced bone age|typically developing children (with evidence of advanced bone age relative to chronologic age); age 8 or ages 12-13
62324716|NCT01434368||typically developing children ages 12/13 17 years|typically developing children ages 12 or 13 - 17 years
62324717|NCT01434368||typically developing children ages 8 17 years|typically developing children ages 8 - 17 years
62324718|NCT06383403|EXPERIMENTAL|Elafibranor 80 mg|Participants will take 1 tablet of elafibranor 80 mg per day orally before breakfast with a glass of water at approximately the same time each morning.
62324719|NCT06383403|PLACEBO_COMPARATOR|Placebo|Participants will take 1 placebo tablet per day orally before breakfast with a glass of water at approximately the same time each morning.
61931132|NCT05983198|EXPERIMENTAL|Group 3 (mHSPC/ pre-177Lu)|"1. Dose Escalation: All eligible participants with mHSPC (177Lu-labelled PSMA-targeted RLT treatment naïve), who are treatment naive or minimally treated with a) luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or bilateral orchiectomy with or without first generation antiandrogen (e.g. bicalutamide, flutamide) b) CYP17 inhibitor or ARDT exposure. Patient in this group will start treatment with 225Ac-PSMA-R2 after group 1 and group 2 patients.~2. Dose Expansion: Once RDE is determined for Group 3, participants will be enrolled in Group 3 dose expansion."
61931133|NCT02638090|EXPERIMENTAL|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
61931134|NCT02638090|EXPERIMENTAL|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.~Level 1: Maximum Tolerated Dose (MTD)"
61931135|NCT02638090|ACTIVE_COMPARATOR|Arm A: Pembrolizumab|"Pembrolizumab treatment only.~Level 1: Pembrolizumab 200 mg Q3 wks"
61931136|NCT02638090|ACTIVE_COMPARATOR|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.~Level 1: MTD"
61931137|NCT02254278|EXPERIMENTAL|IMRT 6 weeks + cisplatin|IMRT 6 weeks with concurrent cisplatin
61931138|NCT02254278|EXPERIMENTAL|IMRT 5 weeks|IMRT 5 weeks
61931139|NCT06706661|EXPERIMENTAL|Nutritional treament|At day 4 after discharge, the intervention group (IG) receives dietetic counselling including a recommendation of daily exercise, an individual nutrition plan and a package containing foods and drinks covering dietary requirements for the next 24 h. Further, a goodie-bag containing samples of protein-rich milk-based drinks is provided. Information regarding recommendations of nutritional therapy after discharge is systematically and electronically communicated to the municipality. The dietician performes telephone follow-ups on day 30 and a home visit at 12 weeks
61931140|NCT05702866||Patients Suspected of Having Thoracic Outlet Syndrome|Patients who came for the diagnosis of TOS
61931141|NCT06626711|EXPERIMENTAL|Propofol-based total venous anesthesia group|These patients will receive total venous anethesia where propofol is used as a hypnotic drug.
61931142|NCT06626711|EXPERIMENTAL|Sevoflurane-based inhalational anesthesia group|These patients will receive inhalational anethesia where sevoflurane is used as a hypnotic drug.
61931143|NCT06629779|EXPERIMENTAL|Arm A|Participants will receive PF-06821497 (875 mg) BID (twice daily) + enzalutamide 160 mg QD (once daily)
61931144|NCT06629779|ACTIVE_COMPARATOR|Arm B|Participants will receive Placebo BID (twice daily) + enzalutamide 160 mg QD (once daily)
61931145|NCT04631445|EXPERIMENTAL|Ketogenic (KD) + Triplet|Ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
61931146|NCT04631445|NO_INTERVENTION|Non-ketogenic + Triplet|Non-ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
61931147|NCT01250288||Consumers|Consumers (patients or their designated proxies) who have registered to use the personal health management technology platform offered by the Brooklyn Health Information Xchange (BHIX) or Long Island Patient Information Xchange (LIPIX).
61931148|NCT01250288||Providers|Providers who are authorized to view the data entered by consumers in either (1) BHIX's personal health management system, along with BHIX health information exchange data; OR LIPIX's secure messaging system (SMS), along with LIPIX health information exchange data.
61931149|NCT05473884||lesion preparation with POBA in femoropopliteal Artery occlusion|Patients with femoropopliteal artery occlusion were treated by plain old balloon angioplasty followed with DCB.
61931150|NCT05473884||lesion preparation with debulking devices in femoropopliteal Artery occlusion|Patients with femoropopliteal artery occlusion were treated by other lesion preparation devices, like Chocolate balloon, Shockwave balloon, TurboHawk, Jetstream and Rotarex and then followed by DCB.
61931151|NCT06333067|EXPERIMENTAL|lax tissue|
61931152|NCT05910814|EXPERIMENTAL|PP (physical practice)|Acquired the motor sequence physically
61931153|NCT05910814|EXPERIMENTAL|MI (motor imagery)|Acquired the motor sequence mentally during training
61931154|NCT05910814|EXPERIMENTAL|MI+HIIE (motor imagery + high-intensity interval physical exercise)|Acquired the motor sequence mentally and achieve a HIIE before the consolidation
62324720|NCT06462404|EXPERIMENTAL|Sequence 1, ABECD: Placebo + E2086 Dose 1 + Active Comparator + E2086 Dose 2 + E2086 Dose 3|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324721|NCT06462404|EXPERIMENTAL|Sequence 2, BCADE: E2086 Dose 1 + E2086 Dose 2 + Placebo + E2086 Dose 3 + Active Comparator|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
61931155|NCT05910814|EXPERIMENTAL|PP+HIIE (physical practice + motor imagery + high-intensity interval physical exercise)|Acquired the motor sequence physically and achieve a HIIE before the consolidation
61931156|NCT05910814|EXPERIMENTAL|SD + PP (sleep deprivation + physical practice)|One night of sleep deprivation prior physical motor acquisition with PP and consolidation
61931157|NCT05910814|EXPERIMENTAL|SD+PP+HIIE (sleep deprivation + physical practice + high-intensity interval physical exercise)|One night of sleep deprivation prior physical motor acquisition and HIIE before consolidation
61931158|NCT05468463|ACTIVE_COMPARATOR|Living Donor Navigator Program In-person|The LDN program is designed to help transplant candidates find potential donors, and guide potential living donors through the evaluation/ donation process. The LDN program consists of four educational sessions, with each session building on the last. Each educational session lasts approximately 2 hours and is held once every other week for two months. Each LDN session will be conducted by a living donor navigator. As potential living donors are identified, the living donor navigators will work closely with the potential donors to guide them through each step of the evaluation/donation process to ensure streamlined medical services and a personalized experience. Individuals randomized to LDN in-person will receive the program locally at the transplant center.
62324722|NCT06462404|EXPERIMENTAL|Sequence 3, CDBEA: E2086 Dose 2 + E2086 Dose 3 + E2086 Dose 1 + Active Comparator + Placebo|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62691981|NCT05272605|EXPERIMENTAL|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 20mcg|MIPSCo-mRNA-RBD-1 antigen 20mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
62691982|NCT05272605|EXPERIMENTAL|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 50mcg|MIPSCo-mRNA-RBD-1 antigen 50mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
61931159|NCT05468463|ACTIVE_COMPARATOR|Living Donor Navigator Program Tele-health|The LDN program is designed to help transplant candidates find potential donors, and guide potential living donors through the evaluation/ donation process. The LDN program consists of four educational sessions, with each session building on the last. Each educational session lasts approximately 2 hours and is held once every other week for two months. Each LDN session will be conducted by a living donor navigator. As potential living donors are identified, the living donor navigators will work closely with the potential donors to guide them through each step of the evaluation/donation process to ensure streamlined medical services and a personalized experience. Individuals randomized to LDN tele-health will receive the program virtually at a local health department within the Alabama Department of Public Health's tele-health network.
62324723|NCT06462404|EXPERIMENTAL|Sequence 4, DECAB: E2086 Dose 3 + Active Comparator + E2086 Dose 2 + Placebo + E2086 Dose 1|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324724|NCT06462404|EXPERIMENTAL|Sequence 5, EADBC: Active Comparator + Placebo + E2086 Dose 3 + E2086 Dose 1 + E2086 Dose 2|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324725|NCT06462404|EXPERIMENTAL|Sequence 6, DCEBA: E2086 Dose 3 + E2086 Dose 2 + Active Comparator + E2086 Dose 1 + Placebo|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324726|NCT06462404|EXPERIMENTAL|Sequence 7, EDACB: Active Comparator + E2086 Dose 3 + Placebo + E2086 Dose 2 + E2086 Dose 1|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324727|NCT06462404|EXPERIMENTAL|Sequence 8, AEBDC: Placebo + Active Comparator + E2086 Dose 1 + E2086 Dose 3 + E2086 Dose 2|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324728|NCT06462404|EXPERIMENTAL|Sequence 9, BACED: E2086 Dose 1 + Placebo + E2086 Dose 2 + Active Comparator + E2086 Dose 3|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324729|NCT06462404|EXPERIMENTAL|Sequence 10, CBDAE: E2086 Dose 2 + E2086 Dose 1 + E2086 Dose 3 + Placebo + Active Comparator|Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
62324730|NCT06176352|EXPERIMENTAL|Arm A: Faricimab|All participants randomly assigned to Arm A will receive faricimab 6 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with faricimab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.
62324731|NCT06176352|ACTIVE_COMPARATOR|Arm B: Ranibizumab|All participants randomly assigned to Arm B will receive ranibizumab 0.5 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with ranibizumab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.
62324732|NCT06195241|EXPERIMENTAL|Benign Essential Blepharospasm or Hemifacial Spasm|Patients with either Benign Essential Blepharospasms or Hemifacial Spasms
62324733|NCT05543915|EXPERIMENTAL|Group with tDCS-MRI|Participants will have a cognitive assessment, an optional gait assessment, and a 1-hour MRI brain scan combined with 20 minutes of simultaneous tDCS. Participants may also complete the MRI on a separate visit.
61931160|NCT02010827||Patients|Patients
61931161|NCT02010827||healthy controls|healthy controls
61931162|NCT05215990|ACTIVE_COMPARATOR|Patient receive metformin with pulmonary tuberculosis standard treatment.|Patient receive pulmonary tuberculosis standard treatment: isoniazid, rifampicin, pyrazinamide, and ethambutol in first and second month(weight adjusted dose), then in third to sixth month switch tuberculosis standard treatment to isoniazid and rifampicin(weight adjusted dose). In all 6 months, patient receive metformin (500 mg) 1 tablet simultaneously.
61931163|NCT05215990|PLACEBO_COMPARATOR|Patient receive placebo drug with pulmonary tuberculosis standard treatment.|Patient receive pulmonary tuberculosis standard treatment: isoniazid, rifampicin, pyrazinamide, and ethambutol in first and second month(weight adjusted dose), then in third to sixth month switch tuberculosis standard treatment to isoniazid and rifampicin(weight adjusted dose). In all 6 months, patient receive placebo drug 1 tablet simultaneously.
62132475|NCT04602975|EXPERIMENTAL|Adults cohort 1 vaccinees|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.
62132476|NCT04602975|PLACEBO_COMPARATOR|Adults cohort 1 placebo recipients|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.
62324734|NCT05543915|NO_INTERVENTION|Group without tDCS- MRI|Participants will have include a cognitive assessment and an optional gait assessment
62691983|NCT05272605|PLACEBO_COMPARATOR|Normal saline (0.9%)|Normal saline (0.9%) administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
62691984|NCT04833738|ACTIVE_COMPARATOR|Electrotherapy|
62691985|NCT04833738|ACTIVE_COMPARATOR|corticosteroid|
61931164|NCT05605431||COPD associated with OSA|
61931165|NCT05605431||COPD without OSA|
62691986|NCT04833738|ACTIVE_COMPARATOR|hyaluronic acid|
62691987|NCT06570382|ACTIVE_COMPARATOR|Taste video participants (n=500)|Participants in this arm will only watch taste focused messaging videos
62691988|NCT06570382|ACTIVE_COMPARATOR|Health video participants (n=500)|Participants in this arm will only watch health focused messaging videos.
62691989|NCT02302222|ACTIVE_COMPARATOR|Standard of Care|dry sterile dressing/gauze and steristrips
62691990|NCT02302222|EXPERIMENTAL|Customizable|Prevena Customizable Dressing with ActiV.A.C. Therapy Unit
62691991|NCT03079778|ACTIVE_COMPARATOR|TACE alone|Transarterial chemoembolization (TACE)
62691992|NCT03079778|EXPERIMENTAL|TACE plus RT|Combination of transarterial chemoembolization and radiation (TACERT)
62132477|NCT04602975|EXPERIMENTAL|Children cohort 2 vaccinees|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.
62483673|NCT05091151|ACTIVE_COMPARATOR|Intranasal dexmedetomidine at dose of 2 mcg/kg|Subjects in IND 2 group received Intranasal dexmedetomidine at dose of 2 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe. Patient was maintained in supine position for 1-2 minutes to maximize absorption.
62483674|NCT05091151|ACTIVE_COMPARATOR|Intranasal dexmedetomidine at dose of 4 mcg/kg.|Subjects in IND 4 group received Intranasal dexmedetomidine at dose of 4 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe. Patient was maintained in supine position for 1-2 minutes to maximize absorption.
62483675|NCT03488147|EXPERIMENTAL|Esomeprazole Only|Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study
61931166|NCT01723137||In pain|Patients who report pain greater than or equal to 3 out of 10 are eligible for this study.
61931167|NCT03865134||Laser Group|Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
61931168|NCT03865134||Anti-VEGF Group|Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
62324735|NCT04677569|EXPERIMENTAL|ALIS + Background Regimen|Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg, once daily.
62324736|NCT04677569|PLACEBO_COMPARATOR|ELC + Background Regimen|Participants will be administered ELC (empty liposome control), a visually matching placebo to ALIS (amikacin liposome inhalation suspension), once daily. Participants will also be administered azithromycin 250 mg and ETH (ethambutol) 15 mg/kg, once daily.
62324737|NCT05774756|EXPERIMENTAL|Setemelanotide|Randomized 2:1 (Setmelanotide: Placebo)
62324738|NCT05774756|PLACEBO_COMPARATOR|Placebo|Randomized 2:1 (Setmelanotide: Placebo)
62324739|NCT06339177||sHLH|Hemophagocytic lymphohistiocytosis (HLH) represents a clinical condition of persistent, dysregulated immune activation with unrelenting fevers, hyperferritinemia, and cytopenias, which lead to multiorgan failure and death.
62324740|NCT06533540|EXPERIMENTAL|low dose|
62324741|NCT06533540|EXPERIMENTAL|middle dose|
62324742|NCT06533540|EXPERIMENTAL|high dose|
62324743|NCT04352166|EXPERIMENTAL|extended-release buprenorphine (BXR)|Three extended-release buprenorphine (BXR) injections to be administered roughly 28 days apart. The first and second injection will be 300 mg and the third will be 100 mg.
62324744|NCT04352166|ACTIVE_COMPARATOR|sublingual buprenorphine (BSL)|sublingual buprenorphine (BSL) up to 24 mg will be administered once daily for 12 weeks or length of study participation.
62324745|NCT04928846|EXPERIMENTAL|Telisotuzumab Vedotin|Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
62324746|NCT04928846|ACTIVE_COMPARATOR|Docetaxel|Participants will receive docetaxel every 3 weeks until meeting study drug discontinuation criteria.
62324747|NCT05649722|EXPERIMENTAL|Treprostinil Palmitil Inhalation Powder|"Participants who are not transitioning immediately from INS1009-211 and other lead-in studies, will be administered TPIP, once daily (QD), during 3-week titration period.~Participants who are transitioning immediately from a randomized blinded lead-in TPIP study and who previously received:~1. TPIP- will be administered placebo QD along with the maximum tolerated dose (MTS) TPIP dose from lead-in study in a blinded manner during 3-week titration period.~2. Placebo- will be administered TPIP QD along with the achieved placebo dose from lead-in study in a blinded manner during 3-week titration period.~The overall treatment period will be 24 months."
62324748|NCT06045507|EXPERIMENTAL|MK-8527 Low Dose QM|Participants receive oral MK-8527 low dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
62324749|NCT06045507|EXPERIMENTAL|MK-8527 Medium Dose QM|Participants receive oral MK-8527 medium dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
62324750|NCT06045507|EXPERIMENTAL|MK-8527 High Dose QM|Participants receive oral MK-8527 high dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
62483676|NCT03488147|ACTIVE_COMPARATOR|Esomeprazole and Placebo Oral Tablet|Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling an esomeprazole tablet 20 mg ) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.
62324751|NCT06045507|PLACEBO_COMPARATOR|Placebo to MK-8527|Participants receive oral placebo matched to MK-8527 QM for 6 months, followed by an 8-week blinded safety follow-up period.
62324752|NCT02789228|EXPERIMENTAL|Group A|"Group A includes patients who have undergone an allogeneic hematopoietic stem cell transplant (HSCT) as part of their prior therapy.~Group A patients (post allogeneic HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first."
62324753|NCT02789228|EXPERIMENTAL|Group B|"Group B includes patients who have undergone conventional (standard) therapy which does not include an allogeneic HSCT. Within group B, a cohort of patients with relapsed or refractory Wilms tumor will be enrolled and receive a lymphodepleting chemotherapy regimen followed by TAA-T.~Group B patients (no prior allogeneic HSCT): TAA-T will be infused any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. Patients receiving lymphodepletion will be \>2 weeks from most recent course of conventional therapy and have nadired and recovered before beginning protocol therapy."
62324754|NCT05110157|PLACEBO_COMPARATOR|Placebo|Placebo once daily.
62132478|NCT04602975|PLACEBO_COMPARATOR|Children cohort 2 placebo recipients|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.
62324755|NCT05110157|EXPERIMENTAL|Vesicular monoamine transporter 2 (VMAT2) inhibitor|Valbenazine once daily
61931169|NCT03865134||Regrese Group|Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
61931170|NCT04418440|NO_INTERVENTION|Control|Routine NHS care following traumatic brain injury
61931171|NCT04418440|EXPERIMENTAL|Treatment|Routine NHS care following traumatic brain injury plus daily dose of test compound (oral nutritional supplement)
61931172|NCT06709495|EXPERIMENTAL|Phase 1: Dose Escalation PEEL-224 Dose Level 0|"Up to 15 participants will be enrolled using a Bayesian design, the Continual Reassessment Method (CRM), to determine the maximum tolerated dose of PEEL-224 and starting at Dose Level 0. Transition to a lower dose level will be determined by types of dose-limiting toxicities observed per the protocol.~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931173|NCT06709495|EXPERIMENTAL|Phase 1: Dose Escalation PEEL-224 Dose Level -1A|"Transition to a lower dose level will be determined by types of dose-limiting toxicities observed per the protocol, otherwise establishment of the MTD/RP2D will be according to the CRM model.~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931174|NCT06709495|EXPERIMENTAL|Phase 1: Dose Escalation PEEL-224 Dose Level -1B|"Transition to a lower dose level will be determined by types of dose-limiting toxicities observed per the protocol, otherwise establishment of the MTD/RP2D will be according to the CRM model.~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931175|NCT06709495|EXPERIMENTAL|Phase 1: Dose Escalation PEEL-224 Dose Level -2|"Establishment of the MTD/RP2D will be according to the CRM design.~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931176|NCT06709495|EXPERIMENTAL|Phase 1: Dose Escalation PEEL-224 Dose Level 1|"Escalation to Dose Level 2 or establishment of the MTD/RP2D will be determined by the CRM design.~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931177|NCT06709495|EXPERIMENTAL|Phase 1: Dose Escalation PEEL-224 Dose Level 2|"Establishment of the MTD/RP2D will be determined by the CRM design.~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
62132479|NCT04602975|EXPERIMENTAL|Infants cohort 3A vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
62132480|NCT04602975|PLACEBO_COMPARATOR|Infants cohort 3A placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
62324756|NCT03569176|EXPERIMENTAL|Autism Glass Intervention|Participants in the experimental group will receive the autism glass for 6 weeks once they are assigned to the experimental condition. Participants will be asked to use the glasses at least 3 times a week for 20 minutes sessions in addition to continuing Applied Behavior Analysis (ABA) therapy.
62324757|NCT03569176|OTHER|Crossover Control for Autism Glass|Participants randomized to the control arm, will continue treatment as usual (receiving ABA twice a week) while the intervention participants will receive the Autism Glass intervention (while continuing to receive ABA therapy). After 6 weeks, control participants will receive the Autism Glass intervention after which, they will be asked to come in for a second round of follow-up testing following 6 weeks of use (at week 18).
61931178|NCT06709495|EXPERIMENTAL|Phase 2: Dose Expansion Ewing Sarcoma|"Administration of PEEL-224 will be at the RP2D, and safety monitoring rules will be applied for the occurrence of dose-limiting toxicities. 15 participants will be enrolled and will complete:~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931179|NCT06709495|EXPERIMENTAL|Phase 2: Dose Expansion DSRCT|"Administration of PEEL-224 will be at the RP2D, and safety monitoring rules will be applied for the occurrence of dose-limiting toxicities. 15 participants will be enrolled and will complete:~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931180|NCT06709495|EXPERIMENTAL|Phase 2: Dose Expansion Other Sarcoma|"Administration of PEEL-224 will be at the RP2D, and safety monitoring rules will be applied for the occurrence of dose-limiting toxicities. 15 participants will be enrolled and will complete:~* Baseline visit with assessments and imaging~* Cycle 1 (21 day cycle):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~ * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily~* Cycle 2 through End of Treatment (21 day cycles):~  * Days 1 through 5: Predetermined dose of Temozolomide 1x daily~ * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily~* Imaging every 2 cycles until Cycle 6 and then every 3 cycles~* End of study visit"
61931181|NCT06708273|EXPERIMENTAL|group 1 received constraint induced movement therapy + traditional treatment|group 1 received constraint induced movement therapy + traditional treatment we will constraint affected hand and enforce patient to use affected side
61931182|NCT06708273|ACTIVE_COMPARATOR|traditional treatment for hand burn positioning - RANGE OF MOTION|traditional treatment for hand burn positioning - RANGE OF MOTION
61931183|NCT01681797|EXPERIMENTAL|add-on fluorescence angiography|"The surgeon will prescribe the usual morphological assessment of the proposed flap:~* CT angiography for an anterolateral thigh flap or an epigastric inferior flap~* A Doppler ultrasonography for a fibula flap.~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days."
61931184|NCT06457269|OTHER|Cross-comparison group(the disease diagnosis section)|Cross-comparison group (including human doctor controls and all LLMs)
61931185|NCT06457269|OTHER|Cross-comparison group(the medical explanation section)|Cross-comparison group (including human doctor controls and all LLMs)
61931186|NCT02684487|ACTIVE_COMPARATOR|vitamin D3|Patients will be given single dose of vitamin D3 within 24 hours of new-onset severe sepsis, followed by weekly doses of vitD3 (25,000 IU) up to 90 days to assess clinical outcomes and key biomarkers.
61931187|NCT02684487|SHAM_COMPARATOR|Placebo|Patients will be given placebo intervention within 24 hours of new onset severe sepsis followed by or placebo for up to 90 days to assess clinical outcomes and key biomarkers.
62132481|NCT04602975|EXPERIMENTAL|Infants cohort 3A vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
62132482|NCT04602975|PLACEBO_COMPARATOR|Infants cohort 3A placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
62132483|NCT04602975|EXPERIMENTAL|Infants cohort 3B vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
62132484|NCT04602975|PLACEBO_COMPARATOR|Infants cohort 3B placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
62132485|NCT04602975|EXPERIMENTAL|Infants cohort 3B vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
62132486|NCT04602975|PLACEBO_COMPARATOR|Infants cohort 3B placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
62132487|NCT05951140|EXPERIMENTAL|Start-Group|The Start-Group starts with the Protein-Application and wereables for 3 Months and afterwards uses only wereables for 6 Weeks.
62132488|NCT05951140|EXPERIMENTAL|Wait-Group|The Wait-Group starts with 6 Weeks of using only wereables and afterwards adds the usage of the Protein-Application.
62132489|NCT05736094|OTHER|Dual-frequency ultrasound|Dual-frequency ultrasound for detection of prostate cancer
62132490|NCT04325685|PLACEBO_COMPARATOR|Control group|
62132491|NCT04325685|ACTIVE_COMPARATOR|Antiseptic (Octenisept) group|
62132492|NCT04325685|EXPERIMENTAL|Bacteriophage (Sextaphag) group|
62132493|NCT00826475|EXPERIMENTAL|Mindfulness|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
62132494|NCT00826475|ACTIVE_COMPARATOR|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
62132495|NCT01895582||Active TB-infected patients|TB-infected patients with bacteriological and histological evidences
62132496|NCT01895582||Non active TB-infected patients (already met TB)|some of elders have already met M tuberculosis before active antibiotherapy exists
62132497|NCT01895582||Non active TB-infected patients (other diagnosis)|same symptoms than two others groups but an other diagnosis
62132498|NCT03307278|EXPERIMENTAL|Steroid resistance in HDM allergic patients|
62132499|NCT03307278|EXPERIMENTAL|Steroid resistance in non HDM allergic subjects|
61931188|NCT04592744|EXPERIMENTAL|Intervention|Patients assigned to the study group will receive Ang 2 infusion in addition to standard vasopressor regimen. Ang 2 is currently approved at UCLA as a second line vasopressor and will be used as such for the purposes of our study. Hemodynamic goals will be established at the beginning of the case by the anesthesiology and surgical teams. Ang 2 will be started as a second vasopressor once the norepinephrine dose has reached 0.05mcg/kg/min. Ang 2 will be initiated at a starting dose of 5ng/kg/min. That dose will be up titrated one time to 10ng/kg/min as vasopressor requirements escalate. Once a patient is on the 10ng/kg/min dose of ang 2, no additional up titration will be performed. Hemodynamic management will continue throughout the case with titration of other vasopressors as needed. Ang 2 will be continued throughout the intraoperative period but will be weaned off prior to leaving the operating room.
61931189|NCT04592744|ACTIVE_COMPARATOR|Control|Patients assigned to the control group will undergo intraoperative management with a standard vasopressor regimen composed of norepinephrine, vasopressin and epinephrine based on hemodynamic goals established by the surgical and anesthesia teams prior to surgery.
61931190|NCT05411614|EXPERIMENTAL|Convergent Hybrid Ablation with Left Atrial Appendage Exclusion|"Staged Convergent Hybrid Ablation Procedure~Stage 1 - Minimally-Invasive Surgical Epicardial Ablation Procedure +/- concomitant LAA exclusion.~Stage 2 - Endocardial Catheter Ablation"
61931191|NCT05411614|ACTIVE_COMPARATOR|Standard Endocardial Catheter Ablation|Standard endocardial catheter ablation
62132500|NCT01156155||Participants with Rheumatoid Arthritis|Rheumatoid arthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination Bilateral digital xray of hands
62132501|NCT01156155||Osteoarthritis|Osteoarthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination
62132502|NCT00996749|EXPERIMENTAL|Treatment (omega-3 fatty acid)|Patients receive long-term omega-3 PUFA supplementation PO.
62132503|NCT05018013|ACTIVE_COMPARATOR|Duloxetine group|The eligible subjects will receive duloxetine hydrochloride enteric-coated capsules plus placebo to Ammoxetine.
62324758|NCT00004850||HBV positive|HBV positive subjects
62324759|NCT00004850||HCV positive partners|HCV positive partner subjects
62132504|NCT05018013|PLACEBO_COMPARATOR|Placebo group|The eligible subjects will receive placebo to Ammoxetine and placebo to Duloxetine.
62132505|NCT05018013|EXPERIMENTAL|Ammoxetine group-cohort 1|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
62132506|NCT05018013|EXPERIMENTAL|Ammoxetine group-cohort 2|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
62132507|NCT05018013|EXPERIMENTAL|Ammoxetine group-cohort 3|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
62132508|NCT05018013|EXPERIMENTAL|Ammoxetine group-cohort 4|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
62324760|NCT00004850||HCV postive|HCV positive subjects
62324761|NCT04756063|EXPERIMENTAL|Ascorbic Acid (AA)|The first intravenous dosage of 1500mg of AA in 100mL of normal saline (NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
62324762|NCT04756063|PLACEBO_COMPARATOR|Placebo|The first intravenous dosage of placebo (100 mL of NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
62324763|NCT00001168||Dyslipidemia|Dyslipidemia
62324764|NCT05355311|EXPERIMENTAL|L-Carnitine|L-carnitine is a nutritional supplement and emerging research shows it has neuroprotective properties and may help treat alcohol use disorder and depression, 2.97 g daily for 6 weeks
62324765|NCT06640933|EXPERIMENTAL|BIIB091 IR|Participants will receive BIIB091 IR tablets on Day 1 of its respective period, with food.
62324766|NCT06640933|EXPERIMENTAL|BIIB091 GR-slow|Participants will receive BIIB091 GR-slow tablets on Day 1 of its respective period, with food.
61931192|NCT01583543|EXPERIMENTAL|Olaparib|400mg PO BID Continuous
62132509|NCT02413866|EXPERIMENTAL|Calorie Restriction Only|Participants in this group will be decreasing their caloric intake to approximately 95% of their resting metabolic rate. We will provide one meal for 4 days of the week, and participants will be required to keep an accurate dietary record of all food and drink. Participants assigned to this group will be instructed to keep a fixed sleep schedule based on their own sleep/napping habits.
62324767|NCT06640933|EXPERIMENTAL|BIIB091 GR-fast|Participants will receive BIIB091 GR-fast tablets on Day 1 of its respective period, with food.
62324768|NCT06640933|EXPERIMENTAL|BIIB091 ER-slow|Participants will receive BIIB091 ER-slow tablets on Day 1 of its respective period, with food.
62324769|NCT06640933|EXPERIMENTAL|BIIB091 ER-fast|Participants will receive BIIB091 ER-fast tablets on Day 1 of its respective period, with food.
62324770|NCT06640933|EXPERIMENTAL|BIIB091 ER-slow Fasted|Participants will receive BIIB091 ER-slow tablets on Day 1 of its respective period, without food.
62324771|NCT05046314|EXPERIMENTAL|TK216+Vincristin|
62324772|NCT05658510|EXPERIMENTAL|Part 1: 60 mcg of BXCL501|Sublingual film containing 60 Micrograms Dexmedetomidine
62324773|NCT05658510|PLACEBO_COMPARATOR|Part 1: Matching Placebo|Sublingual Placebo film
62324774|NCT05658510|EXPERIMENTAL|Part 2: 120 mcg of BXCL501|Sublingual film containing 120 Micrograms Dexmedetomidine
62324775|NCT05658510|PLACEBO_COMPARATOR|Part 2: Matching Placebo|Sublingual Placebo film
62324776|NCT05087875|EXPERIMENTAL|TRAC: Tracking and Reducing Alcohol Consumption|"The TRAC intervention focuses on increasing motivation and building skills to reduce alcohol use and involves 4, 30-minute sessions with an interventionist done via video chat or phone.~Participants will complete smartphone-based self-monitoring of alcohol use. Each morning, participants complete a mobile survey indicating if they drank the previous day and if so, how many drinks they had. Surveys will be programmed using REDcap and sent via a link in the reminder text message. Additionally, participants will be prompted each evening and asked to complete a breathalyzer reading using a mobile app to determine blood alcohol content (BAC). If safety concerns are identified (e.g., BAC ≥0.30; blackouts), the interventionist will refer the AYA to a licensed provider with expertise in substance use treatment."
62483677|NCT03488147|PLACEBO_COMPARATOR|Placebo Oral Tablet Only|Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study
61931193|NCT05702749|ACTIVE_COMPARATOR|Intervention: PREHAB and Surgery|PREHAB exercises will be determined during the physical therapy visit (1x/week) and completed daily with varying frequency for three weeks. Subjects will undergo microsurgical resection of VS.
61931194|NCT05702749|PLACEBO_COMPARATOR|Control: Surgery (No PREHAB)|Subjects will undergo microsurgical resection of VS.
61931195|NCT05702749|ACTIVE_COMPARATOR|Intervention: PREHAB and SRS|PREHAB exercises will be determined during the physical therapy visit (1x/week) and completed daily with varying frequency for three weeks. Subjects will undergo stereotactic radiosurgery.
62132510|NCT02413866|EXPERIMENTAL|Sleep & Calorie Restriction|Participants in this group will decrease their caloric intake to approximately 95% of their resting metabolic rate in addition to reducing their total time in bed by 90 minutes 5 days a week.
62132511|NCT00961831|EXPERIMENTAL|Arm 1|
62132512|NCT00961831|EXPERIMENTAL|Arm 2|
62132513|NCT02355236|EXPERIMENTAL|Test Group|Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks
62132514|NCT02355236|ACTIVE_COMPARATOR|Comparator Group|Celecoxib 200mg and Naxozol-Placebo for 12 weeks
62132515|NCT05115058|OTHER|ReLex Smile module|"VisuMax femtosecond laser created the stromal pocket with a diameter 7.60 mm and cap thickness set to 120 μm from corneal surface and with a small opening - 2 mm superior incision at 90° and side cut angle 50°. The pocket was dissected using a blunt spatula.~The patients were followed up for one year with distance, intermediate, and near visual acuity, slit lamp, corneal topography, anterior segment optical coherence tomography. Uncorrected near visual acuity at 35 cm increased from J7 to J2 in 8 eyes operated on, from J8 to J2 in 7 eyes, and from J6 to J2 in 6 eyes. Uncorrected intermediate visual acuity ranged from J4 to J5 at 70 cm, and uncorrected distance visual acuity remained binocular at 20/20. The patients reported satisfaction while reading a book, looking at the phone, and using a computer. No discomfort was observed from the lights while driving at night."
62132516|NCT04785950||Women with IUS|Women aged 18 to 35 years from Spain who chose to use any low-dose LNG-IUS marketed in Spain for the first time during routine clinical practice
62132517|NCT03358446||A group|"Based on the presence of non-overlapping range between femoral artery and vein from the initial observation, the patients were divided into following two groups.~A group is the patients with non-overlapping range"
62132518|NCT03358446||S group|S group is the patients without non-overlapping range
62132519|NCT04131907|EXPERIMENTAL|Optilume™ BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
62132520|NCT04131907|SHAM_COMPARATOR|Sham Device|The Sham Device is a 21 Fr Optilume BPH, Prostatic Pre-dilation Catheter within the sheath.
62132521|NCT04131907|EXPERIMENTAL|Pharmacokinetics Optilume Arm|A single arm of 15 non-randomized subjects will be treated in the pharmacokinetics (PK) arm. These subjects will be treated with the Optilume BPH Catheter System
62132522|NCT03778541|EXPERIMENTAL|CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
62132523|NCT03778541|ACTIVE_COMPARATOR|RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
62132524|NCT01367405|EXPERIMENTAL|surgical decompression|surgical decompression within 24 hours post-injury
62132525|NCT01367405|ACTIVE_COMPARATOR|Conservative treatment|Normal conservative treatment without surgical intervention
62132526|NCT01506934|EXPERIMENTAL|linifanib|Single Doses
62132527|NCT02182336|EXPERIMENTAL|BI 201335 NA|
62132528|NCT04093895|EXPERIMENTAL|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept® drug administration
62132529|NCT03394885|EXPERIMENTAL|Atezolizumab, Carboplatin, Paclitaxel (+Optional Bevacizumab)|"1. Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by~2. Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by~3. Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing).~4. (Optional, Physician choice) Bevacizumab IV maintenance administered starting at cycle 5 of chemotherapy over 30-90 minutes. For those who receive bevacizumab, it will be given for a total duration of 16 cycles"
62132530|NCT01334489|NO_INTERVENTION|Usual management|Usual management of monochorionic pregnancy without the pessary placement
62132531|NCT01334489|OTHER|Arabin Cervical Pessary|"The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.~The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs."
61931196|NCT05702749|PLACEBO_COMPARATOR|Control: SRS (No PREHAB)|Subjects will undergo stereotactic radiosurgery.
62132532|NCT01006577|OTHER|colon j pouch|Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
62324777|NCT05087875|ACTIVE_COMPARATOR|Control|Participants in the control group will receive educational materials regarding alcohol consumption and its link to cancer . They will also participate in smartphone monitoring of alcohol use on the same schedule as participants in the intervention group. This will allow us to compare daily alcohol use data between the two conditions and evaluate the added component of weekly counseling in TRAC.
62324778|NCT05270668|EXPERIMENTAL|Tulisokibart|Tulisokibart IV administered by IV infusion
62324779|NCT05270668|PLACEBO_COMPARATOR|Placebo|Placebo administered by IV infusion
62691993|NCT06638723|EXPERIMENTAL|Amputee peers|"This research uses a cross-over design to expose the participants with lower limb loss to the two training conditions (observing amputee peers vs. non-amputees) in random order, with a 4-week washout period between conditions. In this arm, participants are instructed to learn from video demonstrations by amputee peers. The videos will show balance and fall recovery movement tasks performed by the models, 15-30 seconds in length. The instruction to the participants is: Please watch and learn the tasks as performed by the demonstrator. You (the participant) will be asked to perform these tasks later."
61931197|NCT06706869|EXPERIMENTAL|Period 1|A single oral dose of PF-07258669 on Study Day 1
61931198|NCT06706869|EXPERIMENTAL|Period 2|Itraconazole QD orally on Study Days 4 to 11. PF-07258669 will be co administered on Study Day 7.
61931199|NCT01740739||Cardiac Risk|Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.
61931200|NCT03983837|EXPERIMENTAL|1|Participants will be on this diet for 4 weeks. The amount per serving will be determined on the basis of the participant s weight and caloric needs, as determined by a staff dietician.
61931201|NCT06660433|EXPERIMENTAL|Point-of-Care Polymerase Chain Reaction Testing Platform|
62132533|NCT01006577|EXPERIMENTAL|side-to-end anastomosis (STE)|Experimental intervention: Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon is closed with a linear stapler. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
62132534|NCT02338024|EXPERIMENTAL|MARTAS intervention|Structured motivational sessions and further communication between linkage coordinators and HIV-positive patients focused on engagement in HIV medical care.
62132535|NCT02338024|NO_INTERVENTION|Standard of care|"Oral referrals to a network of government AIDS Centers or their departments (Trust offices) located in each study region."
62132536|NCT04303325|PLACEBO_COMPARATOR|Control|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
62324780|NCT03150914|PLACEBO_COMPARATOR|Placebo|Overencapsulated matrix
62324781|NCT03150914|ACTIVE_COMPARATOR|Treatment|Over-encapsulated 1 mg sirolimus tablet
62324782|NCT06130540|EXPERIMENTAL|Secukinumab: Giant Cell Arteritis (GCA)|
62483678|NCT04159285|EXPERIMENTAL|Group CBT|15-week group CBT with a focus on improvement of social interactions by cognitive re-modelling and role plays. Patients may simultaneously receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
62483679|NCT04159285|EXPERIMENTAL|Treatment as Usual|Patients may receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
62483680|NCT03681470|EXPERIMENTAL|Patients with Acne Vulgaris|Acne Vulgaris in Patients With Skin of Color
61931202|NCT06660433|ACTIVE_COMPARATOR|Existing Testing Platform for Respiratory Viruses|
61931203|NCT04176705|EXPERIMENTAL|Laser|Split person design. Each participant had a skin burn area that was treated with the laser and a skin burn area that was not treated with the laser.
61931204|NCT04176705|PLACEBO_COMPARATOR|No laser|Split person design. Each participant had a skin burn area that was treated with the laser and a skin burn area that was not treated with the laser.
61931205|NCT06283459|EXPERIMENTAL|IMNN-101|"Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle.~IMNN-101 is for intramuscular injection only."
62132537|NCT04303325|ACTIVE_COMPARATOR|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine.
62132538|NCT01522573||EUS guided ERCP procedure group|Subjects who will undergo Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP) procedures for their pancreatico-biliary conditions.
62132539|NCT03237416|EXPERIMENTAL|BAY1841788/Healthy subjects|Period 1: intake of Midazolam and Dabigatran etexilate at day 1 followed by Period 2: intake of Darolutamide at days 1-11 (twice daily), intake of dabigatran etexilate at days 3 and 9, intake of Midazolam at day 9
62132540|NCT02006758||Uncontrolled hypertension patients|The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN™ Renal Denervation System') for the treatment of their uncontrolled hypertension.
62132541|NCT02139436|EXPERIMENTAL|FES-row-training|Subjects will perform 6 months of FES-row-training.
62132542|NCT02139436|OTHER|Wait-list time control|Subjects perform 6 months of their standard of care
62132543|NCT02139436|ACTIVE_COMPARATOR|Arms-only-row-training|Subjects will perform 6 months of arms-only row training
62132544|NCT05815030|EXPERIMENTAL|Group A|experimental group, receiving 3 exposures to the kink-focused video intervention
62132545|NCT05815030|OTHER|Group B|control group, receiving no exposure to the kink-focused video, but seeing the generic / standard video
62324783|NCT06130540|EXPERIMENTAL|Secukinumab: Polymyalgia Rheumatica (PMR)|
62324784|NCT06191315|EXPERIMENTAL|Dupilumab (double-blind period)|Dupilumab subcutaneous injection as per protocol
62324785|NCT06191315|PLACEBO_COMPARATOR|Placebo|Placebo matching dupilumab subcutaneous injection as per protocol
62324786|NCT03172624|EXPERIMENTAL|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
62324787|NCT03172624|EXPERIMENTAL|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
62483681|NCT01147939|EXPERIMENTAL|Elacytarabine|
62483682|NCT01147939|ACTIVE_COMPARATOR|Investigator's Choice|
62691994|NCT06638723|EXPERIMENTAL|Non-amputees|"In this arm, participants with lower limb loss are instructed to learn from video demonstrations by non-amputees. The videos will show balance and fall recovery movement tasks performed by the models, 15-30 seconds in length. The instruction to the participants is: Please watch and learn the tasks as performed by the demonstrator. You (the participant) will be asked to perform these tasks later."
62691995|NCT05932914||Participants|Those who meet the Eligibility Criteria
61931206|NCT01370668|EXPERIMENTAL|Functional remediation|"Patients assigned to the experimental treatment will receive standard psychiatric care and will be enrolled in the neurocognitive intervention program composed of 21 sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 8-to-10 patient group conducted by 2 experienced neuropsychologists. with previous experience with bipolar patients (at least 3 years) and specific training on patients' group management."
61931207|NCT01370668|ACTIVE_COMPARATOR|Psychoeducation|The group psychoeducation is a tested (Colom et al, 2003) and manualized intervention (Vieta and Colom, 2006) consisting on 21 sessions of 90 minutes, aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences and lifestyle regularity. The program will be performed in an 8-10 patient group conducted by 2 experienced psychologists with previous experience with bipolar patients and specific training on patients' group management. The structure of each session consists of a 30 to 40 minute speech on the topic of the day, followed by an exercise related to the issue (eg. drawing a life chart, writing a list of potential triggering factors) and a discussion.
62339924|NCT05065996||Histology, molecular biology and genetics behind aortic dilatation|Patients scheduled for aortic operation (n=20+100) in Kuopio University Hospital. Aortic tissue samples and blood will be collected for analysis and compared to 4D flow MRI parameters. Control samples will be collected from healthy organ donors (n=5+5) operated in Kuopio University Hospital.
61931208|NCT01370668|ACTIVE_COMPARATOR|Treatment as Usual|This arm will not receive any sort of add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
61931209|NCT06210282|ACTIVE_COMPARATOR|Usual Care|Participants assigned to the usual care group will receive the general practitoner's usual care of adults (≥ 18 years) presenting with symptoms of an acute lower respiratory tract infection (LRTI) where the GP suspects community-acquired pneumonia. Usual care will be used as a pragmatic comparator to reflect the current standard examinations and care of this patient population in general practices in Denmark. Usual care is recommended to follow applicable guidelines from the Danish Society of General Practitioners and The Doctor's Handbook. Focused lung ultrasound (FLUS) is currently not standard or even a common examination in Danish general practices. Even for GPs already using point-of-care ultrasound on a weekly basis, FLUS is not part of usual care for adults presenting with symptoms of an acute LRTI
61931210|NCT06210282|EXPERIMENTAL|Usual Care + Focused lung ultrasound (FLUS)|Participants assigned to the intervention group will receive a focused lung ultrasound examination (FLUS) during the index consultation (day 0) as an addition to usual care.
61931211|NCT04594954|EXPERIMENTAL|Diet + Exercise + FMT|
61931212|NCT04594954|ACTIVE_COMPARATOR|Diet+Exercise|
61931213|NCT02464371||ICU acquired muscle weakness (IAMW) group +|"The Medical Research Council score (MRC score) is lower than 48, defining an ICU acquired muscle weakness (IAMW).~Kinetic of microRNAs is measured"
61931214|NCT02464371||ICU acquired muscle weakness (IAMW) group -|The Medical Research Council score (MRC score) is higher than 48. Kinetic of microRNAs is measured
61931215|NCT04060017|EXPERIMENTAL|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
61931216|NCT04060017|PLACEBO_COMPARATOR|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
61931217|NCT06395688|EXPERIMENTAL|AEF0117|Participant will be administered once daily 2 placebo capsules for 1 day and 2 AEF0117 capsules for 7days
61931218|NCT06395688|PLACEBO_COMPARATOR|Placebo|Participant will be administered once daily 2 placebo capsules for 8 days.
61931219|NCT01897480|EXPERIMENTAL|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
61931220|NCT01897480|ACTIVE_COMPARATOR|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
61931221|NCT06706778|EXPERIMENTAL|Music group|Based on the NIH toolkit and MBIs reporting guidelines, the engagement in this pilot study will be receptive by providing participants with prerecorded, preselected playlists. Participants will also receive a guided video on maximizing music's therapeutic benefits. The playlists will be purely instrumental, with a 60-80 bpm tempo, and feature melodies and harmonies designed for stress relief, including soothing, grounding, meditation, emotional release, etc. This approach is resource-efficient and easily accessible, allowing participants to integrate it into daily pain self-management strategies. Participants will be asked to engage in the MBI in the morning and at night for 30 minutes each, wearing the abdominal belt and smartwatch.
61931222|NCT06369623|EXPERIMENTAL|Whole sample|All enrolled subjects will complete a standard Monetary Incentive Delay Task if able. Inclusion of this task meets criteria for Basic Experimental Studies Involving Humans (BESH)
61931223|NCT06230328||Cohort 1|Patients with early tumors at diagnosis (BCLC 0, A or B)
61931224|NCT06230328||Cohort 2|Pacientes com tumores avançados ao diagnóstico (BCLC C ou D)
61931225|NCT06036056||Acute Respiratory Distress Syndrome|Mild Acute Respiratory Distress Syndrome
61931226|NCT06036056||Healthy|Healthy volunteer
61931227|NCT01091337|EXPERIMENTAL|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
61931228|NCT01091337|ACTIVE_COMPARATOR|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
61931229|NCT06622070|EXPERIMENTAL|SAD Cohorts, Experimental Arm|Participants will receive a single dose of SPY002-072 in a dose escalation format
62132546|NCT05815030|OTHER|Group C|group that receives 1 exposure to the generic / standard video, and later 2 exposures to the kink-focused video
62339925|NCT06156514|EXPERIMENTAL|A (Gemcitanine)|To receive concomitant chemotherapy based on gemcitabine at 300 mg / m2 weekly
62132547|NCT05815030|OTHER|Group D|group that receives 2 exposures to the generic / standard video, and later 1 exposure to the kink-focused video
62691996|NCT05543174|EXPERIMENTAL|TAK-625|TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1.
61931230|NCT06622070|PLACEBO_COMPARATOR|SAD Cohorts, Placebo Arm|Participants will receive a single dose of placebo
61931231|NCT02466373|NO_INTERVENTION|No clonidine|No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
61931232|NCT02466373|EXPERIMENTAL|Clonidine 600mcg|4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
61931233|NCT02466373|EXPERIMENTAL|Clonidine 1200mcg|"* 4 patients receive 1200 µg/day of clonidine without loading schedule.~* 4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h."
61931234|NCT02466373|EXPERIMENTAL|Clonidine 1800mcg|"* 4 patients receive 1800 µg/day of clonidine without loading schedule.~* 4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h."
61931235|NCT05454904|ACTIVE_COMPARATOR|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the pre-specified nutritional criteria.
61931236|NCT05454904|ACTIVE_COMPARATOR|Mediterranean diet alone|The Mediterranean group will receive indications to consume a locally adapted and feasible dietary pattern including characteristic Mediterranean foods based on Chilean food availability.
62132548|NCT06435650|EXPERIMENTAL|Mindful-compassion group|Online mindful-compassion weekly for four weeks
62132549|NCT06435650|EXPERIMENTAL|Mindful-compassion and Cannabis suppository|"Participants were not prescribed cannabis as part of this study. Participants had been for at least one month before participating in the study. Participants used cannabis suppositories each time they engaged in anal intercourse (recipient). The average dose, based on participant reports, was approximately 500mg.~Online mindful-compassion weekly for four weeks"
62132550|NCT02446340|EXPERIMENTAL|dalazatide 5ug|8 subjects, 6 given active agent and 2 given placebo
62132551|NCT02446340|EXPERIMENTAL|dalazatide 15ug|8 subjects, 6 given active agent and 2 given placebo
62132552|NCT02446340|EXPERIMENTAL|dalazatide 30ug|8 subjects, 6 given active agent and 2 given placebo
62132553|NCT02446340|EXPERIMENTAL|dalazatide 60ug|8 subjects, 6 given active agent and 2 given placebo
62132554|NCT06045208|ACTIVE_COMPARATOR|Foot Exercise Group (FEG)|
62132555|NCT06045208|ACTIVE_COMPARATOR|Lower Extremity Exercise Group (LEEG)|
62132556|NCT06045208|NO_INTERVENTION|Control Group (CG)|
62132557|NCT03032458|ACTIVE_COMPARATOR|Pethidine|Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)
62132558|NCT03032458|ACTIVE_COMPARATOR|Ketorolac|Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
62132559|NCT03032458|ACTIVE_COMPARATOR|Xylocaine Gel|Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)
62339926|NCT06156514|ACTIVE_COMPARATOR|B (Cisplatin)|To receive concomitant chemotherapy based on cisplatin 40 mg / m2 weekly
62691997|NCT04875754|EXPERIMENTAL|Group 1: ICM-203 (Low dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e12 vg (n=6) or placebo (n=2) into the target knee at Day 1
61931237|NCT05454904|ACTIVE_COMPARATOR|Mediterranean diet plus psychological well-being support|The Mediterranean diet + well-being intervention group will be subject to intake a locally adapted and feasible pattern of Mediterranean foods available in Chile in combination with a psychological well-being theory-based intervention.
61931238|NCT06710691|EXPERIMENTAL|Before-school high-resistance circuit training group|Participants conducted circuit-based training before school at submaximal intensities (6, 7 and 8 RPE) with limited rest between exercises.
61931239|NCT06710691|ACTIVE_COMPARATOR|Before-school strength training group|Participants conducted strength training before school at submaximal intensities (6, 7 and 8 RPE) with 1 min rest between exercises.
61931240|NCT06710691|EXPERIMENTAL|After-school high-resistance circuit training group|Participants conducted circuit-based training after school at submaximal intensities (6, 7 and 8 RPE) with limited rest between exercises.
61931241|NCT06710691|ACTIVE_COMPARATOR|After-school strength training group|Participants conducted strength training after school at submaximal intensities (6, 7 and 8 RPE) with 1 min rest between exercises.
61931242|NCT04406285|ACTIVE_COMPARATOR|Leukemia Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
61931243|NCT04406285|EXPERIMENTAL|Leukemia Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
61931244|NCT04406285|ACTIVE_COMPARATOR|Lymphoma Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
62132560|NCT01446497|ACTIVE_COMPARATOR|Timolol|non selective beta blocker, aqueous humor suppressant ophthalmic solution
62132561|NCT01446497|ACTIVE_COMPARATOR|Combigan (Timolol/Brimonidine) combination drug|Brimonidine: alpha-2 agonist
62132562|NCT00993460||Normal body weight|Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.
62132563|NCT00993460||Roux-en-Y gastric bypass|Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.
62132564|NCT02987816|SHAM_COMPARATOR|Sham tDCS|Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
62132565|NCT02987816|EXPERIMENTAL|Anodal tDCS|Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
62132566|NCT03631238||Apparently normal participants|Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment.
62132567|NCT01471756|EXPERIMENTAL|iSnare with Gonak solution|
62132568|NCT01471756|EXPERIMENTAL|Snaremaster braided snare with Gonak solution|
62691998|NCT04875754|EXPERIMENTAL|Group 2: ICM-203 (Medium dose) vs Placebo|4 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 2x10e13 vg (n=3) or placebo (n=1) into the target knee at Day 1
61931245|NCT04406285|EXPERIMENTAL|Lymphoma Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
62132569|NCT01471756|EXPERIMENTAL|iSnare with saline solution|
62132570|NCT01471756|EXPERIMENTAL|Snaremaster braided snare with saline solution|
62132571|NCT04919057|EXPERIMENTAL|Robotic perineal radical prostatectomy|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
62691999|NCT04875754|EXPERIMENTAL|Group 3: ICM-203 (High dose) vs Placebo (Optional)|4 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e13 vg (n=3) or placebo (n=1) into the target knee at Day 1
62692000|NCT03757949|EXPERIMENTAL|Arm I (SIM)|Patients receive SIM PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
62692001|NCT03757949|PLACEBO_COMPARATOR|Arm II (placebo)|ARM II: Patients receive placebo PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
62692002|NCT04658680|EXPERIMENTAL|BCG available at first health facility contact|Infants living in catchment areas of HFs randomized to opening of BCG vial if just 1 eligible child is present.
62132572|NCT05397275|EXPERIMENTAL|experimental group|progressive muscle relaxation exercises + breathing exercise
62132573|NCT05397275|EXPERIMENTAL|control group|only breathing exercise
62132574|NCT01790672|PLACEBO_COMPARATOR|Water|Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
61931246|NCT04349514||Friedreich ataxia|Individuals with a diagnosis of Friedreich ataxia.
61931247|NCT04349514||Control|Individuals without a diagnosis of Friedreich ataxia.
61931248|NCT06686316|EXPERIMENTAL|Intervention group|The EG (Experimental Group) will undergo a 6-week intervention protocol with three weekly sessions (Monday, Wednesday, and Friday) of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
61931249|NCT06686316|SHAM_COMPARATOR|Control group|The Sham Group (SG) will follow a 6-week sham intervention protocol with three weekly sessions (Monday, Wednesday, and Friday) of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
61931250|NCT04429243||GORE® VIABAHN® Stent Graft|Participants will be examined 1, 3, 6, 12 and 24 months following the GORE® VIABAHN® Stent Graft installation.
61931251|NCT06709365|ACTIVE_COMPARATOR|Fusion group|
61931252|NCT06709365|ACTIVE_COMPARATOR|Open reduction and internal fixation group|
61931253|NCT05083468|EXPERIMENTAL|SR750 tablet|Ascending single and multiple doses of SR750 tablets orally
61931254|NCT05083468|PLACEBO_COMPARATOR|matching placebo|Ascending single and multiple doses of matching placebo orally
62132575|NCT01790672|ACTIVE_COMPARATOR|Alcoholized wine|"Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.~Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol."
62132576|NCT01790672|PLACEBO_COMPARATOR|De-alcoholized wine|Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
62692003|NCT04658680|NO_INTERVENTION|Usual availability of BCG at health facilities|Infants living in catchment areas of HFs randomized to BCG availability according to the per usual restricted vial opening policy aiming at reducing vaccine wastage. This entails that BCG vaccination is commonly only available on specific predefined days where a BCG vial will only be opened if several children are present.
62692004|NCT02192476|ACTIVE_COMPARATOR|conventional|15 participants are allotted in this arm and each participants received conventional neuro rehabilitation programme 5 days a week for 6 weeks.
62132577|NCT01790672|ACTIVE_COMPARATOR|Ethanol|"Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.~Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.~Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water."
62132578|NCT04221828|EXPERIMENTAL|NanoPac|Direct injection of NanoPac at 15 mg/mL at a volume not to exceed the volume of the prostate cancer lesion (no more than 10% of total prostate volume). NanoPac will be administered on up to three occasions, with at least 28 days between each dose.
62132579|NCT02479217||Adjuvant therapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
62132580|NCT02479217||Combination Therapy|Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression
62132581|NCT02479217||Monotherapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
62692005|NCT02192476|EXPERIMENTAL|intervention|15 participants allotted in this arm and each participants received California tri-pull taping method along with conventional neuro rehabilitation was given 5 days a week for 6 weeks
62692006|NCT03412591|OTHER|Open label trial of suvorexant in individuals with opioid use disorder|It is an open label trial to study the efficacy of suvorexant in a group of patients with opioid use disorder.
62692007|NCT03412591|OTHER|Open label trial of suvorexant in individuals with alcohol use disorder|It is an open label trial to study the efficacy of suvorexant in a group of patients with alcohol use disorder.
62692008|NCT05501522|EXPERIMENTAL|Primary series of mRNA-1273 manufactured by ModernaTX, Inc.|participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
62692009|NCT05501522|PLACEBO_COMPARATOR|Primary series of mRNA-1273 manufactured by ModernaTX, Inc. (Placebo)|participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
62692010|NCT05501522|EXPERIMENTAL|Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca or S.I of India Pvt., Ltd.|participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
61931255|NCT06710600|ACTIVE_COMPARATOR|Group 1|"single oral dose of following medications, including 7 days wash-out phase respectively:~1. diclofenac~2. voriconazole~3. hydrochlorothiazide~4. pantoprazole~5. amiodarone"
61931256|NCT06710600|ACTIVE_COMPARATOR|Group 2|"single oral dose of following medications, including 7 days wash-out phase respectively:~1. acetylsalicylic acid~2. verapamil~3. doxycycline~4. furosemide~5. enalapril"
61931257|NCT00602667|EXPERIMENTAL|Low-Risk Patients|"Patients with GTR/M0 medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.~Note: Accrual to the low-risk medulloblastoma cohort is closed as of 12/2/2015. Accrual to the low-risk high grade glioma remains open."
61931258|NCT00602667|EXPERIMENTAL|High-Risk Patients|Patients with CNS metastatic disease will receive induction chemotherapy and high-risk therapy.
61931259|NCT00602667|EXPERIMENTAL|Intermediate-Risk Therapy|Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
61931260|NCT05502341|EXPERIMENTAL|Phase 2: Bictegravir (BIC) 75 mg + Lenacapavir (LEN) 25 mg|"Participants will switch from their stable baseline regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1 up to the end of randomized treatment (ERT) visit, participants will be treated for at least 24 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg fixed dose combination (FDC)."
61931261|NCT05502341|EXPERIMENTAL|Phase 2: BIC 75 mg + LEN 50 mg|"Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1 up to the ERT visit, participants will be treated for at least 24 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
61931262|NCT05502341|ACTIVE_COMPARATOR|Phase 2: Stable Baseline Regimen (SBR)|"Participants will continue with their SBR per prescription for up to the ERT visit, participants will be treated for at least 24 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
61931263|NCT05502341|EXPERIMENTAL|Phase 3: BIC/LEN 75 mg/50 mg Fixed-dose Combination (FDC)|"Participants will switch from their SBR to a regimen of BIC/LEN 75 mg/50 mg FDC. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1 up to the ERT visit, participants will be treated for at least 48 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
61931264|NCT05502341|ACTIVE_COMPARATOR|Phase 3: Stable Baseline Regimen|"Participants will continue with their SBR per prescription for up to the ERT visit, participants will be treated for at least 48 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
61931265|NCT00405327|EXPERIMENTAL|DC vaccine therapy|Tumor lysate-pulsed dendritic cell (DC) vaccine following HSCT
61931266|NCT02778971||Qualifying participants|All consented participants referred by a dementia expert physician to receive an amyloid PET scan with \[18F\]Flutametamol and meeting eligibility criteria will have visual and semi-quantitative software aided scan interpretation, complete care partner questionnaires and providers will document diagnosis, diagnostic confidence, and management plan before and after the scan.
61931267|NCT02389075||Ankylosing Spondylitis|Subjects with a diagnosis of ankylosing spondylitis undergoing routine colonoscopy or willing to undergo a flexible sigmoidoscopy for research purposes only. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
61931268|NCT02389075||Inflammatory Bowel Disease|Subjects with a diagnosis of inflammatory bowel disease undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
61931269|NCT02389075||Healthy Controls|Subjects without any major autoimmune diseases or pathologies undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
61931270|NCT04890431|EXPERIMENTAL|Oxygen|
61931271|NCT04890431|PLACEBO_COMPARATOR|Placebo|
61931272|NCT05467800|EXPERIMENTAL|Canakinumab|Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.
61931273|NCT02143466|EXPERIMENTAL|AZD6094|AZD9291 in combination with AZD6094
61931274|NCT02143466|EXPERIMENTAL|Selumetinib|AZD9291 in combination with selumetinib
62339927|NCT06067412|ACTIVE_COMPARATOR|levetiracetam|"levetiracetam at a dose of 30 mg/kg diluted in 50 ml of normal saline in 15 minutes followed by a maintenance dose of 30mg/kg/day divided in two doses 12 hours apart after initial loading dose.~if seizures recurred after the first loading dose an additional 10mg/kg of the same drug was given over 10 minutes. If seizures recurred, the patients were loaded with sodium valporate 30 mg/kg diluted in 50 ml normal saline in 15 minutes."
62692011|NCT05501522|PLACEBO_COMPARATOR|Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca or S.I of India Pvt., Ltd. (Placebo)|participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
61931275|NCT02143466|EXPERIMENTAL|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
61931276|NCT02143466|EXPERIMENTAL|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
61931277|NCT06598059|EXPERIMENTAL|Drug-eluting electrode array (CI632D)|Participants will be implanted with the slim modiolar dexamethasone-eluting electrode array.
62132582|NCT03039244|EXPERIMENTAL|Test Group|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
62483683|NCT03311061|EXPERIMENTAL|DREAMS|"The experimental group will be exposed to the DREAMS curriculum including the supplemental technology based application.It is composed of 10 modules: Introduction; Self Exploration; Healthy Relationships; Adolescent Sexuality; Attitudes and Adolescent Sexual Activity; Consequences of Sex - HIV/STI; Consequences of Sex - Pregnancy; Managing Pressure to Engage in Sexual Activity through the Lens of Social Media; Financial Literacy; Careers; Post secondary Education; Wrap up and Close Out.~The technology app will include curriculum support and additional resources.~Students will have access to the mobile app after the in school programming ends. The intent is for students to have access to portions of the app that deal with self developed goals and progress monitoring for goals, and resource material. This is similar to a student having continued access to a textbook/other class materials."
62692012|NCT05501522|EXPERIMENTAL|A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & Johnson|participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
62692013|NCT05501522|PLACEBO_COMPARATOR|A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/J&J (Placebo)|participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive Placebo.
61931278|NCT00057876|ACTIVE_COMPARATOR|Gemcitabine|
61931279|NCT00057876|EXPERIMENTAL|Gemcitabine + Radiation|
61931280|NCT04333537|EXPERIMENTAL|Sentinel Lymph Node (SLN) Biopsy|Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy.
61931281|NCT04333537|ACTIVE_COMPARATOR|Elective Neck Dissection (END)|Patients undergo standard END.
61931282|NCT02718001|EXPERIMENTAL|Treatment|Treatment with the Edwards EVOQUE Eos mitral valve replacement system
61931283|NCT04804644|EXPERIMENTAL|Arm I (SRS)|Patients undergo SRS over 1 day (in some cases several days).
61931284|NCT04804644|ACTIVE_COMPARATOR|Arm II (HA-WBRT, memantine)|Patients also undergo HA-WBRT QD for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients will also receive memantine PO QD or BID for up to 24 weeks in the absence of disease progression or unacceptable toxicity.
61931285|NCT03690011|EXPERIMENTAL|CD7.CAR/28zeta CAR T Cells|Four dose levels will be evaluated. The T cells will be administered following lymphodepleting chemotherapy with cyclophosphamide and fludarabine.
61931286|NCT05088863|OTHER|Implementation of health claim|Participants will have 2 weeks to incorporate 40g of flaxseed per day into their diet
61931287|NCT00900198||1/Standard|Standard
61931288|NCT00900198||2/Standard and Preclinical Models|Standard and Preclinical Models
61931289|NCT00900198||3/Preclinical Models|Preclinical Models
61931290|NCT00900198||4/Preclinical Models, Pediatric|Preclinical Models, Pediatric
61931291|NCT05554523||Vitiligo|
61931292|NCT05554523||Fitzpatrick Type 1|
61931293|NCT05554523||Fitzpatrick Type 2|
61931294|NCT05554523||Fitzpatrick Type 3|
61931295|NCT05554523||Fitzpatrick Type 4|
61931296|NCT05554523||Fitzpatrick Type 5|
61931297|NCT05554523||Fitzpatrick Type 6|
61931298|NCT02694523|ACTIVE_COMPARATOR|Adalimumab (Part A)|Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).
61931299|NCT02694523|EXPERIMENTAL|Risankizumab (Part A)|Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).
61931300|NCT02970318|EXPERIMENTAL|Acalabrutinib (ACP-196)|Acalabrutinib (ACP-196) Monotherapy
61931301|NCT02970318|ACTIVE_COMPARATOR|Rituximab Plus Idelalisib or Bendamustine|Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
61931302|NCT04878887|OTHER|IP-DRA|In plane distal radial artery catherterization
61931303|NCT04878887|OTHER|IP-PRA|In plane proximal radial artery catherterization
61931304|NCT06709937||Patients with metastatic breast carcinoma|In patients with metastatic breast carcinoma, the skin is affected in 5-30% of cases. Although constituting a relatively rare event in absolute terms, the onset of cutaneous metastases generally represents an unfavorable prognostic factor (due to synchronous progression of disease in other sites), as well as a condition of difficult therapeutic management. Even in the most favorable cases, cutaneous metastases often lead to a deterioration in the quality of life of patients, linked to their psychological impact and associated symptoms. It is crucial that patients receive timely and effective treatment. In these cases, various therapeutic options are discussed by a multidisciplinary team, and the patient is typically evaluated for systemic treatment (chemotherapy, endocrine therapy, targeted therapy).
61931305|NCT06469788|EXPERIMENTAL|"Storytelling video including patient narratives, brochure and patient navigation"|Participants will review video with narratives on COVID-19 vaccination in patients with AIRD, receive brochure on the same topic; and interact with patient navigators.
61931306|NCT06469788|ACTIVE_COMPARATOR|"Attention Control: Oral Health video and Oral Health brochure"|Participants will review video on the importance of oral health in patients with AIRD and receive brochure on the same topic.
61931307|NCT06560619|EXPERIMENTAL|MENTOR Wellness Program|MENTOR is an 8-week group program conducted via videoconferencing, designed for individuals with physical disabilities in the United States to enhance their health and well-being. The program includes 1 hour per week of mindfulness training, 2 hours per week of exercise, and 1 hour per week of nutrition education. Participants will also receive personalized health coaching and have access to a fitness instructor, registered dietician, and mindfulness coach. Additionally, participants will receive information on 8 other areas, including self-care skills, core values, outdoor time in nature, rest/relaxation, contributing to others, arts and leisure, relationships, and spiritual practice, all taught by a trained health coach over the 8-week period.
61931308|NCT05777018|ACTIVE_COMPARATOR|conventional|
61931309|NCT05777018|ACTIVE_COMPARATOR|ultrasound-guided|
61931310|NCT06518564|EXPERIMENTAL|Avelumab and M1774|"25 participants will be enrolled and complete study procedures. The first 6 participants enrolled will take part in a lead-in phase with a dose de-escalation plan for M1744, starting at Dose Level 0 and decreasing to Dose Level -1 and then -2 if applicable per the protocol depending on the occurrence of dose-limiting toxicities. Participants will complete:~* Baseline visit with assessments and CT or MRI scan.~* CT or MRI scans every 12 weeks~* Cycle 1 through End of Treatment:~  * Days 1 - 14 and 22 - 35 of 42-day Cycle: Predetermined dose of M1774 1x daily.~ * Days 1, 15, 29 of 42-day Cycle: Predetermined dose of Avelumab 1x daily.~* End of Treatment visit with with CT or MRI scan~* 30 day post-treatment follow up visit~* 90 day post-treatment follow up~* Long term follow up every 6 months for 3 years."
61931311|NCT05548010||Subjects|Patients \>18years old with scheduled operation
61931312|NCT05548010||Healthcare Professionals (HCP)|HCP of the enrolled subjects
61931313|NCT06707766|EXPERIMENTAL|oculomotor exercises along with conventional therapy|oculomotor exercises along with conventional therapy
62132583|NCT03039244|SHAM_COMPARATOR|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
62692014|NCT05501522|ACTIVE_COMPARATOR|Primary series of BNT162b2 manufactured by Pfizer/BioNTech|participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
61931314|NCT06707766|EXPERIMENTAL|sub-occipital muscle energy technique along with Conventional Therapy|"Sub-occipital muscle energy technique (PIR) 3 reps \* 1 set conventional therapy: Hot pack 20 minutes~Kendall exercises were performed as follows:~strengthening exercise: 12 repetitions\* 3 sets, 2-8 sec hold stretching exercise was: 3 reps\* 30 seconds' hold~1. Strengthening the deep cervical flexors~2. Stretching the cervical extensors~3. Strengthening shoulder retraction~4. Stretching of the pectoralis major muscle"
61931315|NCT03936322|EXPERIMENTAL|Pregnant women diagnosed with fetal myelomeningocele|Women subjects who are pregnant and diagnosed with myelomeningocele (MMC), also known as fetal spina bifida or neural tube defect, will undergo a minimally invasive fetoscopic repair of MMC.
61931316|NCT06025851|EXPERIMENTAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) Four (4) treatment groups (0.75 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10 mg/kg)
61931317|NCT06025851|PLACEBO_COMPARATOR|Placebo|Placebo - intravenous infusion
61931318|NCT04015622|EXPERIMENTAL|A: Biomarker directed Therapy (BT)|ctDNA fraction \<2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
61931319|NCT04015622|ACTIVE_COMPARATOR|B: Clinician's Choice (CC)|Enzalutamide or docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
62132584|NCT05092113|EXPERIMENTAL|Group A|a compound glutamine capsule was taken orally in the first cycle of chemotherapy, and a compound glutamine capsule simulated placebo was taken in the second cycle of chemotherapy. All patients take drugs orally on the first day of each cycle of chemotherapy, 3 tablets 3 times a day, and the course of the treatment was 3 weeks.
62132585|NCT05092113|EXPERIMENTAL|Group B|in the first cycle of chemotherapy, a compound glutamine capsule simulated placebo was given ,and in the second cycle, a compound glutamine capsule was taken at the same time of chemotherapy. All patients take orally from the first day of chemotherapy, 3 times a day after meals, 3 tablets each time, and the course of treatment was 3 weeks.
62132586|NCT05364216|OTHER|Group C|The general anesthesia was used.In this group, cognitive function was evaluated by MMSE and MoCA scale on one day before surgery, one day after surgery, and three months after surgery. Acute postoperative pain was was evaluated by VAS after extubation , one day after surgery, Chronic postsurgical pain was evaluated by VAS on three months after surgery.
62132587|NCT05364216|EXPERIMENTAL|Group T|Group T received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction.
62132588|NCT05364216|OTHER|Non-surgical controls|Age and sex-matched community people are included for three sessions of MMSE test evaluation for calculation of POD incidence as normal control to in Z value calculation of POD incidence to rule out learning effect.
62324788|NCT06500533|EXPERIMENTAL|Study's single arm|"Patients will be receiving rTMS/tDCS combined 30-session protocol, consisting of 15 rTMS sessions every other day alternating with 15 tDCS at-home treatments.~The rTMS protocol used in the study will be intermittent Theta Burst Stimulation (iTBS) on the left dorsolateral prefrontal cortex given for 3 minutes and 9 seconds, every other day 5 weeks. iTBS is delivered in 2s bursts consisting of three pulses at a frequency of 50 Hz, with an inter-burst interval of 200 ms (i.e., 5 Hz). Stimulation intensity will be 120% of resting motor threshold.~Each of the 15 tDCS sessions will be lasting 30 minutes with a stimulation intensity of 2mA. The electrodes will be positioned bilaterally over the dorsolateral prefrontal cortex. The device chosen for the study is specifically designed for home use. The device is controlled via an app that walks the participant through correct usage and dosage with the device to minimize non-compliance."
62324789|NCT05943626|NO_INTERVENTION|Control Group|Provided with general health information on diet and physical activity.
62324790|NCT05943626|EXPERIMENTAL|Intervention Group|Circadian-based intervention focused on timing of light exposure and food intake.
62692015|NCT05501522|PLACEBO_COMPARATOR|Primary series of BNT162b2 manufactured by Pfizer/BioNTech (Placebo)|participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
62692016|NCT05501522|EXPERIMENTAL|Primary series of BBIBP-CorV manufactured by Sinopharm|participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
62692017|NCT05501522|PLACEBO_COMPARATOR|Primary series of BBIBP-CorV manufactured by Sinopharm (Placebo)|participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo
62692018|NCT05501522|ACTIVE_COMPARATOR|Primary series of CoronaVac|participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
62132589|NCT01102673|EXPERIMENTAL|PF-04991532|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
62132590|NCT01102673|PLACEBO_COMPARATOR|Placebo|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
62132591|NCT02564744|EXPERIMENTAL|Part 1: Safety Run-in|Participants with a diagnosis of relapsed and/or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), and with non-Hodgkin's lymphoma (NHL) including follicular lymphoma (FL), marginal zone lymphoma/mucosa-associated lymphoid tissue (MZL/MALT), mantle cell lymphoma (MCL) or other NHL with the Sponsor's approval received Debio 1562 0.7 mg/kg, intravenous (IV) infusion followed by rituximab 375 mg/m\^2 IV infusion, once on Day 1 of 21-day cycles until the study discontinuation criteria were met (until they develop disease progression, death, unacceptable toxicity, withdraw consent, start new anti-lymphoma treatment or the Sponsor terminates the study).
62132592|NCT02564744|EXPERIMENTAL|Part 1: Cohort 1|Participants with R/R DLBCL received Debio 1562 0.7 mg/kg, IV infusion followed by rituximab 375 mg/m\^2 IV infusion, once on Day 1 of 21-day cycles until the study discontinuation criteria were met (until they develop disease progression, death, unacceptable toxicity, withdraw consent, start new anti-lymphoma treatment or the Sponsor terminates the study).
62132593|NCT02564744|EXPERIMENTAL|Part 1: Cohort 2|Participants with R/R, FL, MZL/MALT, MCL or other NHL with the Sponsor's approval received Debio 1562 0.7 mg/kg, IV infusion followed by rituximab 375 mg/m\^2 IV infusion, once on Day 1 of 21-day cycles until the study discontinuation criteria were met (until they develop disease progression, death, unacceptable toxicity, withdraw consent, start new anti-lymphoma treatment or the Sponsor terminates the study).
62132594|NCT02564744|EXPERIMENTAL|Part 2/3: Cohort A|Participants with relapsed DLBCL received Debio 1562 0.7 mg/kg, IV infusion followed by rituximab 375 mg/m\^2 IV infusion, once on Day 1 of a 21-day cycle for at least 6 cycles and/or until the study discontinuation criteria were met (until they develop disease progression, death, unacceptable toxicity, withdraw consent, start new anti-lymphoma treatment or the Sponsor terminates the study).
62132595|NCT02564744|EXPERIMENTAL|Part 2/3: Cohort B|Participants with relapsed DLBCL received Debio 1562 0.4 mg/kg IV infusion followed by rituximab 375 mg/m\^2 IV infusion on Day 1, then Debio 1562 0.2 mg/kg IV infusion on Days 8 and 15 of a 21-day cycle for at least 6 cycles and/or until the study discontinuation criteria were met (until they develop disease progression, death, unacceptable toxicity, withdraw consent, start new anti-lymphoma treatment or the Sponsor terminates the study).
62132596|NCT00212251|EXPERIMENTAL|Lifestyle counseling|10 ActiveMoms classes, 8 Moms Time Out nutrition classes, 6 coaching calls, supportive materials
62132597|NCT01086813|EXPERIMENTAL|1|
62132598|NCT03002428|EXPERIMENTAL|Teriparatide (PF708)|PF708 20 mcg once-daily subcutaneous injection for 24 weeks
62132599|NCT03002428|ACTIVE_COMPARATOR|Teriparatide (Forteo)|Forteo 20 mcg once-daily subcutaneous injection for 24 weeks
62132600|NCT02867254||Groups1|15 patients with type 2 diabetes mellitus with periodontal endodontic lesions
62132601|NCT02867254||Groups 2|15 non-diabetics with periodontal endodontic lesions
62692019|NCT05501522|PLACEBO_COMPARATOR|Primary series of CoronaVac (Placebo)|participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose Placebo
62692020|NCT01601561|EXPERIMENTAL|High-dose insulin|
62692021|NCT01601561|NO_INTERVENTION|Control|
62692022|NCT05692011||blood purification(AN69ST)|
62132602|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
62132603|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
62132604|NCT04434742|EXPERIMENTAL|Intervention group|The subjects in this group receive complex interventions, including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team.
62324791|NCT06472973|EXPERIMENTAL|Interventional group|Patients randomized into the interventional arm will participate in an addiction consultation during their hospital stay following LT. The participant's addiction treatment will be based on the number of risk factors identified.
62692023|NCT05692011||blood purification(PS)|
62692024|NCT05887336|ACTIVE_COMPARATOR|Investigational device treament and standard treatment|After an initial demonstration of the device, study subjects will be given the device to be used for self-administration at home, 10 minutes per day in each nasal cavity, 3 days a week, for a total treatment period of six weeks.
62483684|NCT03311061|ACTIVE_COMPARATOR|Non DREAMS|The control group experience will include health curriculum already adopted by the school district. Continued services as usual. The control group schools, for the most part, lack any formal pregnancy prevention services. All schools claim that lessons developed by the teachers meet the Texas Essential Knowledge Standards (TEKS). No outside services are provided to students and school based services are limited. The services offered at the schools is predominately abstinence based. Students attending the schools would need to initiate any services that are available within the community. The control group will not have access to the DREAMS curriculum or the technology-based application to enhance the DREAMS curriculum. The technology-based application will be a closed, password protected, system during the research trial.
62483685|NCT03711760|EXPERIMENTAL|intervention|telepsychology treatment
62132605|NCT04434742|OTHER|Control group|The control group received usual discharge care and community resources that were made available to them as appropriate. A monthly social call was made to each client in the control group in order to exclude social effects. The contents of the social call, such as asking about entertainment and clients' hobbies, were set in the protocol.
62483686|NCT03711760|NO_INTERVENTION|usual care|standard of care
62483687|NCT05909358|EXPERIMENTAL|Candidate vaccine 1|One injection of cAd3 will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
62483688|NCT05909358|EXPERIMENTAL|Candidate vaccine 2|One injection of chAdOx1 will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
62483689|NCT05909358|EXPERIMENTAL|Candidate vaccine 3|One injection of rVSV-SUDV will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
62692025|NCT05887336|SHAM_COMPARATOR|Sham device treatment and standard treatment|After an initial demonstration of the device, study subjects will be given the device to be used for self-administration at home, 10 minutes per day in each nasal cavity, 3 days a week, for a total treatment period of six weeks.
62132606|NCT03578536|EXPERIMENTAL|CIT with Recovery Rapids|"This project will develop a therapeutic model that promotes use of the impaired arm and hand. Researchers often call this type of therapy constraint induced therapy. In this study, participants focus on using the impaired limb rather than the unaffected limb. Study participants will only be able to play the game using the impaired limb.~A small group of patients will participate in a question and answer session about preferences for activities which make up transfer tasks. Patients will also receive automated reminders to use the impaired arm throughout the day. Twelve (12) Veterans will be recruited annually from the inpatient Stroke Specialty Program. Six (6) patients will be assigned to the Treatment group and receive the intervention. The remaining six (6) will receive the current standard of care. Outcome measures will include motor function tests that evaluate upper extremity function."
62132607|NCT05588817|ACTIVE_COMPARATOR|Group 1|Normal control
62132608|NCT05588817|ACTIVE_COMPARATOR|Group 2|Diagnosed Rhomatoid arthritis patients
62339928|NCT06067412|ACTIVE_COMPARATOR|phenytoin|"I/V phenytoin at 20 mg/kg diluted in 50ml normal saline in 15 minutes followed by maintenance dose of 5 mg/kg/day divided in two doses 12 hours apart.~if seizures recurred after the first loading dose an additional 10mg/kg of the same drug was given over 10 minutes. If seizures recurred, the patients were loaded with sodium valporate 30 mg/kg diluted in 50 ml normal saline in 15 minutes."
62339929|NCT02490319||Group 1|Lung cancer patients treated with thoracic radiation therapy
62483690|NCT05909358|PLACEBO_COMPARATOR|Control|One injection of placebo will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
62483691|NCT03135236|EXPERIMENTAL|Parent training|All registered participants will participate in a series of trainings (3 separate) on sexuality education.
62483692|NCT02336087|EXPERIMENTAL|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62483693|NCT04356508|EXPERIMENTAL|Intervention (n=10)|Nivolumab + best supportive care
62483694|NCT04356508|NO_INTERVENTION|Non-intervention (n=5)|Best supportive care
62483695|NCT04099758|EXPERIMENTAL|Mindfulness of the breath meditation|10 minute mindfulness of the breath meditation practice delivered online via audio-recording.
62483696|NCT04099758|PLACEBO_COMPARATOR|Audio-recording control|10 minute non-fiction audio-recording delivered online
62483697|NCT02673762||Normal glucose metabolism|Normal fasting blood glucose, 2 hour post prandial glucose, hemoglobin A1c and HOMA IR
62483698|NCT02673762||Pre-diabetes|Abnormal glucose tolerance tests and/or insulin resistance with fating blood glucose and hemoglobin A1c below type II diabetes levels
62483699|NCT02673762||Type II diabetes|Hemoglobin A1c 6.5% or greater, fasting blood glucose \>125 mg/dl or 2 hour post-prandial blood glucose 200 mg/ml or greater
62483700|NCT05550064|EXPERIMENTAL|Intervention arm|"Evidence-based intervention for SCC, previously evaluated in a cluster randomized trial (doi:10.1111/1471-0528.16754) The intervention for prepartum SCC will consist of four different parts, adjusted to suit pregnant women with emphasis on immediate start when applicable:~1. An educational video presenting available contraceptive methods~2. 4 Key questions concerning how to deal with a new pregnancy, reproductive life plan, and additional health benefits from using contraception.~3. A tiered effectiveness chart of available contraceptives~4. A box of contraceptive models"
62483701|NCT05219864|EXPERIMENTAL|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
62692026|NCT06564987|EXPERIMENTAL|Articaine|Inferior Alveolar Nerve block using Articaine 4% with 1:200,000 epinephrine local anesthetic
62692027|NCT06564987|ACTIVE_COMPARATOR|Lidocaine|Inferior Alveolar Nerve block using 2% lidocaine with 1:100,000 epinephrine local anesthetic
62692028|NCT06183567|ACTIVE_COMPARATOR|Sedoanalgesia (SA) group|The aim was to achieve a moderate level of sedoanalgesia (previously called conscious sedation) that would reduce agitation, anxiety and mobility but allow communication with the patient. Sedation was maintained at a level where cardiovascular function was preserved and no intervention was required to protect the airway in spontaneous breathing. Fentanyl iv 25-50 µg bolus was administered to each patient undergoing sedoanalgesia. For maintenance of sedoanalgesia, propofol iv infusion was started at doses of 1-2 mg kg-1 hour. It was titrated according to BIS level. In case of patient noncompliance, propofol iv 0.5 mg kg-1 was intervened.
62132609|NCT04523922|EXPERIMENTAL|Oxytocin Treatment Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.~40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session."
62132610|NCT04523922|ACTIVE_COMPARATOR|Placebo Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray).~Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session."
62132611|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
62132612|NCT06257680|EXPERIMENTAL|ReT01 ACT|
62132613|NCT01407458|ACTIVE_COMPARATOR|Experimental Group|Children doing additional exercises with upper limbs in physical education class
62324792|NCT06472973|NO_INTERVENTION|Control group|"Participants randomized into the control arm will benefit from routine LT follow-up organized by the doctors and/or surgeons of the LT center during the post-transplant follow-up period. Usually, the patients have monthly outpatient visit with their physician during the first year after LT, then bi-monthly during the second year. At present, each center has a very different way of supporting transplant recipients, there is no systematic follow-up by an addictologist. Routine care at each center will be identified before the study set up. The different centers refer patients only after return to alcohol use is perceived in routine consultation or identified through biological alcohol markers. In this case, the alcohol relapse event will be noted and patients will be transferred to the addictologic center."
62324793|NCT06091332|EXPERIMENTAL|High-dose sirolimus group|Participants will receive oral sirolimus with a target blood concentration of 9-15ng/ml continuously for 12 months.
62324794|NCT06091332|EXPERIMENTAL|Low-dose sirolimus group|Participants will receive oral sirolimus with a target blood concentration of 3-7ng/ml continuously for 12 months
62324795|NCT06091332|PLACEBO_COMPARATOR|Placebo control group|Participants will receive oral placebo(starch formulation) for 12 months.
62692029|NCT06183567|ACTIVE_COMPARATOR|General anesthesia (GA) group|Anesthesia induction was performed with lidocaine iv 0.5 mg kg-1, propofol iv 1-2 mg kg-1, fentanyl iv 25-50 µg. After providing adequate ventilation with a mask, rocuronium iv 0.45-0.6 mg kg-1 is administered and endotracheal intubation is performed. After intubation is confirmed with end-tidal CO2 monitoring, tidal volume is set to 6-8 ml kg-1 and respiratory frequency to 12/min in CMV mode. In order to maintain cerebral perfusion, PaCO2: 35-40 mmHg is aimed to be maintained. Sevoflurane MAC 0.8 and remifentanil infusion 0.03 µg kg-1 min iv were used for maintenance of anesthesia. At the end of the procedure, sugammadex iv 2mg kg-1 was administered for extubation.
62692030|NCT01821872|ACTIVE_COMPARATOR|Sampling at approx 15 minutes|Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol
61931320|NCT06709859|EXPERIMENTAL|Afatinib plus chemotherapy|Patients with unresectable EGFR sensitive mutation-positive stage III NSCLC will receive 3-4 cycles of afatinib plus chemotherapy as the conversion treatment (afatinib 40mg qd; carboplatin (AUC 5) on day 1, and pemetrexed (500 mg/m2 for non-squamous carcinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma) d1 q3w), and then surgery will be provided for patients who are suitable for primary tumor resection. Maintenance treatment with afatinib 40mg qd will continue up to 2 years or disease progression after surgery.
61931321|NCT02323932|ACTIVE_COMPARATOR|Bilateral Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: each of the CI alone and bilateral (CI/CI) conditions.
62132614|NCT01407458|ACTIVE_COMPARATOR|Control Group|Children doing normal physical education exercises
62132615|NCT03639896|EXPERIMENTAL|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
62132616|NCT03639896|PLACEBO_COMPARATOR|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
62132617|NCT04870749||lower urinart tract syptoms|Lower urinary tract symptoms (LUTS) are common in older men and one of the main reasons for this is the enlargement in prostate gland volume caused by hormonal changes.
62132618|NCT01932970|EXPERIMENTAL|Etelcalcetide|Participants were treated with 5 mg etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times per week (TIW) for 4 weeks.
62132619|NCT02291913|EXPERIMENTAL|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
62324796|NCT05626114|EXPERIMENTAL|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
62324797|NCT05988749|EXPERIMENTAL|Device|Participants will receive usual care or usual care plus the American Heart Association's Digital Solution in patients with HFrEF. The Solution is a combination of the AHA/CHTI HF CarePlans and Education Content, delivered through and combined with the Biofourmis Platform.
62324798|NCT05988749|NO_INTERVENTION|Routine Care|Routine care for heart failure management
62483702|NCT05219864|PLACEBO_COMPARATOR|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
62483703|NCT06331715|EXPERIMENTAL|TR|Subject will receive Test product palbociclib (125 mg Iclos) followed by reference product (Ibrance Pfizer 125 mg capsules) after 14 days washout
62483704|NCT06331715|EXPERIMENTAL|RT|Subject will receive reference product (Ibrance Pfizer 125 mg capsules) followed by Test product palbociclib (125 mg Iclos) after 14 days washout
62483705|NCT03575650||Cardiac imaging modalities|Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.
62483706|NCT00705003|EXPERIMENTAL|Active Drug Combination|BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
62132620|NCT01109498|EXPERIMENTAL|Dose cohort 3 x 10^11gc/kg|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
62324799|NCT05556616|EXPERIMENTAL|Group 1 (MM Maintenance) Arm 1: Modakafusp alfa + Lenalidomide|Modakafusp alfa, infusion intravenously (IV), once on Day 1, once every 4 weeks (Q4W), in combination with Lenalidomide capsules orally once daily continuously on Days 1 to 28, in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or to a maximum of 2 years for MRD \[-\] negative participants, whichever occurs first. Participants who remain MRD positive with demonstrated clinical benefit after 2 years of maintenance therapy may continue treatment beyond 2 years with agreement of the sponsor/designee.
62483707|NCT00705003|ACTIVE_COMPARATOR|BCI-024 (Buspirone)|BCI-024: over-encapsulated Buspirone 15 mg QD
61931322|NCT02323932|ACTIVE_COMPARATOR|Bimodal Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: CI alone, HA alone and bimodal (CI/HA) conditions.
61931323|NCT03461822||SRT in primary-inoperable solid tumors|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in primary-inoperable solid tumors
62324800|NCT05556616|EXPERIMENTAL|Group 2 (RRMM Doublets) Arm 2: Modakafusp alfa + Pomalidomide|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
62324801|NCT05556616|EXPERIMENTAL|Group 2 (RRMM Doublets) Arm 3: Modakafusp alfa + Bortezomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Bortezomib injection subcutaneously on Days 8, 15, and 22 for the first 8 cycles and subsequently on Days 8 and 22 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
62324802|NCT05556616|EXPERIMENTAL|Group 2 (RRMM Doublets) Arm 4: Modakafusp alfa + Carfilzomib|"Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Carfilzomib IV, on Day 1, 8 and 15 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~This arm is closed for enrollment after 3 participants were enrolled."
62324803|NCT05556616|EXPERIMENTAL|Group 3 (RRMM Triplets) Arm A: Modakafusp alfa + Pomalidomide + Bortezomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle along with Bortezomib injection subcutaneously on Days 8, 15 and 22 for the first 8 cycles and subsequently on Days 8 and 22 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
62324804|NCT05556616|EXPERIMENTAL|Group 3 (RRMM Triplets) Arm D: Modakafusp alfa + Daratumumab + Pomalidomide|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Daratumumab injection subcutaneously on Days 1, 8, 15 and 22 of Cycles 1 and 2, further followed by on Days 1 and 15 of Cycles 3 to 6, thereafter on Day 1 on a 28-day (4-week) treatment cycle along with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
62324805|NCT05925803|EXPERIMENTAL|Anifrolumab (subcutaneous weekly injection)|Anifrolumab subcutaneous injection once weekly
62324806|NCT05925803|PLACEBO_COMPARATOR|matched placebo control (subcutaneous weekly injection)|matched placebo control subcutaneous injection once weekly
62483708|NCT00705003|PLACEBO_COMPARATOR|Matching placebo|Placebo: 1 capsule QD
62692031|NCT01821872|ACTIVE_COMPARATOR|Sampling at approx 30 minutes|Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol
62692032|NCT01821872|ACTIVE_COMPARATOR|Sampling at approx 120minutes|Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol
62692033|NCT06637280|ACTIVE_COMPARATOR|Standard nasal cannula 6l/min, 100% O2|Standard procedure during EBUS bronchoscopy
61931324|NCT03461822||Classic radiotherapy in primary-inoperable solid tumors|Classic radiotherapy in 1.8-2.0 Gy per fraction in primary-inoperable solid tumors
61931325|NCT03461822||SRT in oligometastatic cancer|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in oligometastatic cancer
61931326|NCT03461822||Classic radiotherapy in oligometastatic cancer|Classic radiotherapy in 1.8-2.0 Gy per fraction in oligometastatic cancer
62132621|NCT01109498|EXPERIMENTAL|Alipogene Tiparvovec, Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
62692034|NCT06637280|EXPERIMENTAL|High - flow nasal cannula 60l/min, 45% O2|The new method
62697520|NCT06482034|EXPERIMENTAL|Group 3|Arm 3 Intervention Type: Combination Product Intervention Name: N-acetylcysteine (NAC) and zinc sulfate Other Intervention Names: NAC and Zinc Intervention Description: Patients will receive N-acetylcysteine sachets (600mg) twice daily and zinc sulfate capsules (25mg) thrice daily. They will dissolve the NAC sachet in a cup of water, gargle for 60 seconds, and swallow it. The treatment will start 3 days before the beginning of radiotherapy and continue for 2 weeks after the completion of the radiotherapy schedule.
62697521|NCT06482034|EXPERIMENTAL|Group 4|Intervention Type: Combination Product Intervention Name: N-acetylcysteine (NAC) and zinc sulfate after mucositis onset Other Intervention Names: NAC and Zinc post-mucositis Intervention Description: Patients who already began their radiotherapy and developed oral mucositis will receive N-acetylcysteine sachets (600mg) twice daily and zinc sulfate capsules (25mg) thrice daily. They will dissolve the NAC sachet in a cup of water, gargle for 60 seconds, and swallow it. The treatment will continue for 2 weeks after the completion of the radiotherapy schedule.
61931327|NCT03880604|ACTIVE_COMPARATOR|Triple tourniquets plus TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus1-gram tranexamic acid (10 ml) in 100 ml saline infusion
61931328|NCT03880604|ACTIVE_COMPARATOR|Triple tourniquets plus placebo to TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
61931329|NCT05653024|EXPERIMENTAL|Inhaled salbutamol|8 puffs of 100 mcg of inhaled salbutamol once
61931330|NCT05653024|PLACEBO_COMPARATOR|Placebo|8 puffs of inhaled placebo once
61931331|NCT01242059|EXPERIMENTAL|Control Tomato Soup|
61931332|NCT01242059|EXPERIMENTAL|10 g of yellow pea fiber|
61931333|NCT01242059|EXPERIMENTAL|20 g of yellow pea fiber|
61931334|NCT01242059|EXPERIMENTAL|10 g of yellow pea protein|
61931335|NCT01242059|EXPERIMENTAL|20 g of yellow pea protein|
61931336|NCT05343013|EXPERIMENTAL|TAS-102|TAS-102 should be taken by mouth 2 times a day, within 1 hour after your morning and evening meals (about 12 hours apart).
61931337|NCT06710236|EXPERIMENTAL|Hearing Aid Users|Participants will wear hearing instruments for the duration of the study period. They will be asked to complete questionnaires about their environment and experience.
61931338|NCT03120442|EXPERIMENTAL|Propofol-fentanyl|Fentanyl 0.5 mcg/kg Propofol Target-controlled infusion to achieve MOAA/S 3-4 as end point of sedation Bispectral index (BIS) monitoring
61931339|NCT03120442|EXPERIMENTAL|Dexmedetomidine|Fentanyl 0.5 mcg/kg Dexmedetomidine in incremental titrated dose for moderate sedation to achieve MOAA/S 3-4 as end-point of titration Bispectral index (BIS) monitoring
61931340|NCT03120442|EXPERIMENTAL|Fentanyl|Fentanyl 0.5 mcg/kg Supplemental dosage of fentanyl for intraoperative anxiolysis
61931341|NCT06345846|EXPERIMENTAL|IFIOL|Patients with an implanted IFIOL
61931342|NCT06345846|EXPERIMENTAL|SFIOL|Patients with an implanted SFIOL
62339930|NCT02621879|EXPERIMENTAL|Bilateral Gluteal Advancement Flap|Advancement of both gluteal muscles to the midline after release incisions in their fascia.
62339931|NCT05900193|EXPERIMENTAL|Participants receiving oral glucose tolerane tests with TAS1R agonists|Participants received a standard oral glucose tolerance test alone and with the addition of the TAS1R2/3 agonist sucralose in admixture
61931343|NCT04173234|EXPERIMENTAL|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
61931344|NCT04173234|ACTIVE_COMPARATOR|Control Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 5 days a week.
61931345|NCT03053271|EXPERIMENTAL|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
61931346|NCT03053271|PLACEBO_COMPARATOR|Placebo|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
62132622|NCT01109498|EXPERIMENTAL|Alipogene Tiparvovec, Human LPL [S447X], 1xE12 gc/kg|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
62132623|NCT02076568|EXPERIMENTAL|Education - Diabetes and Partnership|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Partnership"
62132624|NCT02076568|NO_INTERVENTION|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
62132625|NCT03872310|ACTIVE_COMPARATOR|Active comparator|Within group
62132626|NCT03872310|SHAM_COMPARATOR|Sham comparator|Within group
62132627|NCT04037813|ACTIVE_COMPARATOR|Laparoscopic tubal occlusion|54 patients will undergo laparoscopic tubal occlusion.
62132628|NCT04037813|ACTIVE_COMPARATOR|Hysteroscopic tubal occlusion|54 patients will undergo hysteroscopic tubal occlusion.
62132629|NCT03628885|NO_INTERVENTION|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
62132630|NCT03628885|EXPERIMENTAL|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (\< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
62132631|NCT03628885|EXPERIMENTAL|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (\< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
62483709|NCT01464450|ACTIVE_COMPARATOR|Sequence 1: Treatment A - B - C|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
62483710|NCT01464450|ACTIVE_COMPARATOR|Sequence 2: Treatment A - C - B|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
62483711|NCT01464450|ACTIVE_COMPARATOR|Sequence 3: Treatment B - C - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
62483712|NCT01464450|ACTIVE_COMPARATOR|Sequence 4: Treatment B - A - C|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
61931347|NCT06536608|EXPERIMENTAL|Massage Group|Pregnant women who meet the inclusion criteria assigned to the Oketani Massage group will be informed about the study and their written and verbal consent will be obtained. Pregnant women will be asked to fill out the 'Introductory Characteristics Information Form' and 'Prenatal Breastfeeding Self-Efficacy Scale Short Form' at the first meeting before the training and then they will be given breastfeeding training and massage prepared with the Oketani method. 2 weeks after the training, the researcher will apply Oketani breast massage twice before the mother enters the operating room and once before the mother's first breastfeeding in the operating room or in the ward. One day after birth, they will be asked to answer the Postpartum Breastfeeding Self-Efficacy Scale Short Form, LACTH and Visual Comparison Scale Satisfaction (VAS-S) scale.
62132632|NCT05512182|EXPERIMENTAL|Chemotherapy|
62132633|NCT05527613|EXPERIMENTAL|Conventional bracket bonding with instructions by WhatsApp|will receive the WhatsApp application, through which oral hygiene reminders will be sent through images and videos with the necessary information, and at the same time they will receive verbal oral hygiene instructions
62324807|NCT05139069|EXPERIMENTAL|Trauma-Informed Pre-Exposure Prophylaxis Implementation Toolkit|The Toolkit to be developed in the proposed study includes components from the women-specific Pre-Exposure Prophylaxis care continuum theoretical model and implementation challenges, and is adapted to identify and provide care to women experiencing intimate partner violence. Overall, the Toolkit is designed to create culturally-congruent, intimate partner violence-informed clinical settings; and equip clinical staff with the knowledge and skills they need to address HIV prevention for African American women; and integrate intimate partner violence into Pre-Exposure Prophylaxis care services.
62324808|NCT04903314|EXPERIMENTAL|Cohort I|Xcopri to be administered to ages 12 to \< 18 years not to exceed 400 mg/day.
62324809|NCT04903314|EXPERIMENTAL|Cohort IIa|Xcopri to be administered to ages 6 to \< 12 years not to exceed 400 mg/day.
62132634|NCT05527613|ACTIVE_COMPARATOR|Conventional bracket bonding without instructions by whatsapp|receive verbal instructions on oral hygiene
62132635|NCT06037993|EXPERIMENTAL|PEA arm|Palmitoylethanolamide (PEA)-treated patients
62132636|NCT01837238|EXPERIMENTAL|beta-hydroxy beta-methylbutyrate|Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
62132637|NCT01837238|PLACEBO_COMPARATOR|Placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
62324810|NCT04903314|EXPERIMENTAL|Cohort IIb|Xcopri to be administered to ages 4 to \< 6 years not to exceed 400 mg/day.
62324811|NCT04903314|EXPERIMENTAL|Cohort III|Xcopri to be administered to ages 2 to \< 4 years not to exceed 400 mg/day.
61931348|NCT06536608|NO_INTERVENTION|Control Group|Pregnant women who meet the inclusion criteria and who are assigned to the control group will be informed about the study and their written and verbal consent will be obtained. Pregnant women will be asked to fill out the 'Introductory Characteristics Information Form' and 'Prenatal Breastfeeding Self-Efficacy Scale Short Form' at the first meeting. One day after birth, they will be asked to answer the Postpartum Breastfeeding Self-Efficacy Scale Short Form and LACTH.
62692035|NCT05832047|EXPERIMENTAL|Plasma solution|"Plasma solution (HK inno.N Corp., Seoul, Republic of Korea) is a balanced crystalloid solution that contains the same ingredients as Plasma-Lyte A (Baxter International, Deer field, Ill) .~Preprocedure hydration begins 30-90 min before ERCP with an infusion rate of 10 mL/kg. All the ERCP procedures are performed under sedation with balanced propofol sedation (incremental dose of propofol in combination with fixed doses of fentanyl and midazolam), without general anaesthesia. The infusion rate during ERCP and 30-60 min after ERCP is 3 mL/kg/hour and 10 mL/kg, respectively (in the case of a 10 mL/kg injection after the procedure, the injection should be stopped at the point where it is necessary to move from the endoscopy room to the ward after the procedure, and the injection rate can be changed to 3 mL/kg/hour)."
61931349|NCT06168058|SHAM_COMPARATOR|Transcatheter Venography|
61931350|NCT06168058|EXPERIMENTAL|Bilateral Ovarian Vein Embolization|Transcatheter Venography plus Bilateral Ovarian Vein Embolization.
61931351|NCT03350620|EXPERIMENTAL|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
62132638|NCT02329639||case group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy with bevacizumab
62132639|NCT02329639||control group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy without bevacizumab
62132640|NCT03002675|EXPERIMENTAL|exenatide|Participants will receive exenatide (Bydureon, 2mg s.c. 1x/wk, AstraZeneca) during 12 weeks
62132641|NCT03739918||patients with adrenal masses|patients with adrenal mass managed by adrenalectomy
62132642|NCT04816175|EXPERIMENTAL|Treatment Intervention|All children will receive 3-5 weeks of intensive neuromotor Acquire therapy, an operant conditioning, play based therapy that maximizes therapeutic movements, attention, and engagement.
62132643|NCT03244813|EXPERIMENTAL|Adapted physical activity|
62132644|NCT03244813|NO_INTERVENTION|Standard care|
62132645|NCT00174252|EXPERIMENTAL|Genotonorm (Somatropin)|
62324812|NCT00001248||healthy volunteers|Healthy volunteers for technique development and comparison with the patient populations.
62324813|NCT00001248||MS/CIS/RIS population|Patients with a diagnosis of MS or who have typical imaging abnormalities associated with MS.
62324814|NCT00001248||Non-MS comparison population|Patients with disorders of the CNS, to include patients with diseases that share mechanisms of tissue damage with MS
62324815|NCT04112316|ACTIVE_COMPARATOR|Liothyronine (LT3), then placebo|Participants received liothyronine first, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive placebo for 8 weeks.
62324816|NCT04112316|PLACEBO_COMPARATOR|Placebo, then liothyronine|Participants received placebo first, with weekly sham titration for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive LT3 for 8 weeks.
62324817|NCT05400213|ACTIVE_COMPARATOR|Group 1 Vallos|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
62324818|NCT05400213|ACTIVE_COMPARATOR|Group 2 Vallomix|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
62324819|NCT05400213|ACTIVE_COMPARATOR|Group 3 Vallos-F|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
62324820|NCT05400213|ACTIVE_COMPARATOR|Group 4 Vallomix-F|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
62324821|NCT04817462|EXPERIMENTAL|Liver Biopsy|All patients undergo a liver biopsy only
62324822|NCT05984784|EXPERIMENTAL|Cohort 1 IMG-007 Dose 1|IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks
62324823|NCT05984784|EXPERIMENTAL|Cohort 2 IMG-007 Dose 2|IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks
62324824|NCT05984784|PLACEBO_COMPARATOR|Placebo|Placebo will be administered intravenously 3 times over 4 weeks
61931352|NCT03350620|EXPERIMENTAL|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
61931353|NCT03350620|PLACEBO_COMPARATOR|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
61931354|NCT06693960|EXPERIMENTAL|Arm 1: oregano alone|6 participants will be administered 180 mg of a well-characterized oregano product. Blood will be drawn via an indwelling venous catheter immediately before and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after administration of oregano. Urine will be collected in multiple jugs for 24 hours.
61931355|NCT06693960|EXPERIMENTAL|Arm 2: drug cocktail alone|16 participants, which may or may not include any number of the original 6 from Arm 1, will be administered an oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg). Blood and urine will be collected in the same manner described in Arm 1.
62132646|NCT01327664|EXPERIMENTAL|AIN457 300mg s.c every 2 weeks|
62132647|NCT00684242|EXPERIMENTAL|Lenalidomide|10 mg by mouth daily
62132648|NCT06519617|SHAM_COMPARATOR|conventional program group|Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
62132649|NCT06519617|ACTIVE_COMPARATOR|optimized program combining Chinese and Western medicine for pSS glandular damage|The herbal prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
62483713|NCT01464450|ACTIVE_COMPARATOR|Sequence 5: Treatment C - A - B|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
62692036|NCT05832047|ACTIVE_COMPARATOR|Lactated Ringer's solution|Preprocedure hydration begins 30-90 min before ERCP with an infusion rate of 10 mL/kg. All the ERCP procedures are performed under sedation with balanced propofol sedation (incremental dose of propofol in combination with fixed doses of fentanyl and midazolam), without general anaesthesia. The infusion rate during ERCP and 30-60 min after ERCP is 3 mL/kg/hour and 10 mL/kg, respectively (in the case of a 10 mL/kg injection after the procedure, the injection should be stopped at the point where it is necessary to move from the endoscopy room to the ward after the procedure, and the injection rate can be changed to 3 mL/kg/hour).
62132650|NCT00790413|EXPERIMENTAL|High-dose MIBG with haploidentical stem cell transplantation|High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft
62132651|NCT02316301|EXPERIMENTAL|Long interval misoprostol|A small envelope including two labeled plastic bags (A \& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
62324825|NCT04700124|EXPERIMENTAL|Arm A: Perioperative EV+ Pembrolizumab and RC + PLND|Participants receive 4 cycles (each cycle length = 21 days) of EV intravenous (IV) infusion plus pembrolizumab IV infusion preoperatively, followed by RC + PLND, followed by 5 cycles of adjuvant EV IV infusion plus 13 cycles of adjuvant pembrolizumab IV infusion postoperatively. The total treatment duration is up to approximately 1 year.
62324826|NCT04700124|ACTIVE_COMPARATOR|Arm B: Standard of Care (SOC)-Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND|Participants receive 4 cycles (each cycle length = 21 days) of standard of care (SOC) chemotherapy (gemcitabine IV infusion plus cisplatin IV infusion) preoperatively, followed by RC + PLND. The total treatment duration is up to approximately 3 months.
62324827|NCT04184050|EXPERIMENTAL|MK-4002 monotherapy dose escalation|MK-4002 is intravenously (IV) administered once weekly in escalating doses.
62324828|NCT04184050|EXPERIMENTAL|MK-4002 dose escalation with extended dosing intervals|MK-4002 is IV administered once every 2 weeks.
62324829|NCT06062030|EXPERIMENTAL|test group|"Investigational Products (DWJ1609) Number of tablets: 20 tablets in total Drinking water: 2,550 mL in total~The day before the colonoscopy \[Day 1\] ▶ Common: Eat a light breakfast the day before the examination, or take only clear fluids.~Take 10 tablets of DWJ1609 with 425 mL of water in the early evening (18:00-20:00) the day before the test, followed by 2 more doses of 425 mL of water for 1 hour (takes a total of 1,275 mL of water).~On the day of colonoscopy \[Day 2\]~▶ Common: On the day of the examination, only clear liquids should be taken before the examination. Complete the clinical trial medication and additional water intake at least 2 hours prior to the test or at the time indicated by the tester In the evening before the test, take 10 additional DWJ1609 tablets with 425 mL of water in the morning (04:00\~08:00), 10 to 12 hours after taking DWJ1609, followed by 2 more doses of 425 mL of water for 1 hour (Total 1,275 mL of water)."
62324830|NCT06062030|ACTIVE_COMPARATOR|control group|"Control Products (DWC202304) Number of tablets: 28 tablets in total Drinking water: 2,550 mL in total~The day before the colonoscopy \[Day 1\] Take 14 tablets of DWC202304 with 425 mL of water in the early evening (18:00 to 20:00) the day before the test, followed by 2 more doses of 425 mL of water for 1 hour (takes a total of 1,275 mL of water).~On the day of colonoscopy \[Day 2\]~▶ Common: On the day of the examination, only clear liquids should be taken before the examination. Complete the clinical trial medication and additional water intake at least 2 hours prior to the test or at the time indicated by the tester In the evening before the test, take 14 additional DWC202304 tablets with 425 mL of water in the morning of the test (04:00\~08:00), 10 to 12 hours after taking DWC202304, and then take 425 mL of water twice for 1 hour (total 1,275 mL of water)."
62324831|NCT05667142|EXPERIMENTAL|XEN1101 25 mg/day|XEN1101 25 mg/day
62324832|NCT05667142|PLACEBO_COMPARATOR|Placebo|Placebo
62324833|NCT05667142|EXPERIMENTAL|XEN1101 15 mg/day|XEN1101 15 mg/day
62324834|NCT06004050|EXPERIMENTAL|Double-Blind Period: Twice-Daily Delgocitinib Cream|20 mg/g twice daily
62324835|NCT06004050|PLACEBO_COMPARATOR|Double-Blind Period: Twice-Daily Vehicle Cream|20 mg/g twice daily
62324836|NCT06004050|EXPERIMENTAL|Open Label Period: Twice-Daily Delgocitinib|20 mg/g twice daily
62324837|NCT02567201|EXPERIMENTAL|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
62324838|NCT02567201|EXPERIMENTAL|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
62324839|NCT05748834|EXPERIMENTAL|Tucatinib Experimental Treatment Arm|Participants will receive tucatinib 300mg by mouth twice daily continuously in combination with Doxil 40mg/m2 given intravenously on day 1 of each cycle. Cycles will be 28 days. Up to 36 participants will be enrolled in this Phase 2 study.
62339932|NCT05900193|EXPERIMENTAL|Participants receiving oral glucose tolerane tests with TAS1R antagonists|Participants received a standard oral glucose tolerance test alone and with the addition of the the TAS1R2/3 antagonist lactisole in admixture
62692037|NCT06640842||Hypertensive disorder of pregnancy|Women who were diagnosed with a hypertensive disorder of pregnancy during the ADORE study participation.
62692038|NCT06640842||Healthy pregnancy|Women who participated in the ADORE study and had a healthy pregnancy during their participation.
61931356|NCT06693960|EXPERIMENTAL|Arm 3: acute oregano + cocktail|The same 16 participants will be administered the oregano product and the drug cocktail. Blood and urine will be collected in the same manner described in Arm 1.
61931357|NCT06693960|EXPERIMENTAL|Arm 4: chronic oregano + cocktail|The same 16 participants will self-administer the oregano product at home for 5 consecutive days. On day 6, participants will return to the study setting, where the procedure described in Arm 3 will be repeated.
61931358|NCT03878342|ACTIVE_COMPARATOR|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
62483714|NCT01464450|ACTIVE_COMPARATOR|Sequence 6: Treatment C - B - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
62483715|NCT01111448|EXPERIMENTAL|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle
62483716|NCT03914365|ACTIVE_COMPARATOR|Ultrasound-guided pudendal nerve block (PNB)|"Standard circumcision under general anaesthesia with ultrasound-guided pudendal nerve block.Pudendal nerve block patients will be positioned dorsally with the legs in the  frog  position (hips in abduction, knees flexed, sole of the feet together). An ultrasound-guided technique will be used as described previously. A linear probe will be positioned horizontally between the ischiatic tuberosity and the rectum. The ischiorectal fossa is then located between these two landmarks. Using a sterile tech-nique, an echogenic 22 gauge, 50 mm block needle will be inserted out of plane on the superior edge of the probe, midline between the ischiatic tuberosity and the rectum. After feeling two distinct fascial  clics  and confirmation of correct needle posi-tioning in the ischiorectal fossa under ultrasound, 0,2 mL/kg (max 10mL) of ropiva-caine 0,25% will be injected under real-time ultrasound-guidance after negative aspiration. The same technique will be repeated on the contralateral side."
62483717|NCT03914365|ACTIVE_COMPARATOR|Ultrasound-guided penile nerve block (DPNB)|Standard circumcision under general anaes-thesia with ultrasound-guided penile nerve block.Penile nerve block patients will be positioned in the supine position. An ultrasound-guided technique will be used as described previously. A linear probe will be placed transversely at the base of the penis while an assistant applies caudal traction to the penis. The penile neurovascular sheath is then located just above the corpus cavernosum. The dorsal penile nerve, dorsal penile artery and penile deep dorsal vein are visualized deep to Buck's fascia. Using a sterile technique, a 25 gauge, 1,5 inch needle will be inserted in-plane from lateral to medial so that the needle tip is placed into the penile neurovascular sheath, 0,1 mL/kg (max 4 mL) of ropivacaine 0,25% will be injected under real-time ultrasound guidance while retracting the needle so that the local anaesthetic solution spreads bilaterally filling the neurovascular space.
62483718|NCT05698589|EXPERIMENTAL|Compassion Focused Therapy|
62483719|NCT05698589|ACTIVE_COMPARATOR|Ending Self Stigma|
62483720|NCT05698589|NO_INTERVENTION|Treatment As Usual|
62483721|NCT03810963|EXPERIMENTAL|FES Cycling and Nutrition Counseling|"Device:~HIIT-FES cycling will be performed 30 minutes per session, 3 times per week for 3 weeks combined with~Behavior:~Nutrition counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
62483722|NCT03810963|OTHER|Nutritional Counseling Only|"Behavior:~Nutritional counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
62483723|NCT05504902|EXPERIMENTAL|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
61931359|NCT03878342|EXPERIMENTAL|No Radiotherapy|No Irradiation- Active surveillance
61931360|NCT03304821|EXPERIMENTAL|GM-CSF|Participants receiving 500µg of granulocyte-macrophage colony stimulating factor (GM-CSF), administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
61931361|NCT03304821|PLACEBO_COMPARATOR|Placebo|Participants receiving 500µg of a placebo, administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
61931362|NCT05014828|EXPERIMENTAL|Safety Run in Stage and Combination Assessment|lenvatinib + tislelizumab
61931363|NCT06451263|EXPERIMENTAL|Nudge|The study consists of one intervention, a clinician nudge to gynecologic oncology referral.
62324840|NCT03367572|EXPERIMENTAL|Group I (netupitant/palonosetron hydrochloride, dexamethasone|Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.
61931364|NCT03783091|EXPERIMENTAL|Hydroxocobalamin|Single IV infusion administered over a 10-15 minute period
61931365|NCT03783091|PLACEBO_COMPARATOR|Saline Placebo|Single IV saline administered over a 10-15 minute period.
61931366|NCT06512545|EXPERIMENTAL|intervention arm|second haploidentical stem cell transplantation
62324841|NCT03367572|EXPERIMENTAL|Group II (net/pal hydro, dexa, prochlorperazine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on days 1-4.
62324842|NCT03367572|EXPERIMENTAL|Group III (net/pal hydro, dexa, olanzapine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days 1-4.
62483724|NCT02193763|EXPERIMENTAL|90 days and under--Interventional|Neonates aged 90 days and under randomized to ultrasound assisted lumbar puncture
61931367|NCT06488547|EXPERIMENTAL|Stress Managemenet Group|"Participants will be instructed and trained with two stress management techniques (Diaphragmatic Breathing- DB and Progressive Muscle Relaxation-PMR), along with biofeedback training in diaphragmatic breathing.~During the eight weeks of the program, participants in the intervention group will receive information regarding stress, work-related stress factors, musculoskeletal health and disorders, the Medically Unexplained Symptoms-MUS, occupational psychosocial hazards, lifestyle habits (healthy diet, sedentary life, sleep, hygiene).~Moreover, participants will be informed about how to manage stress related factors at the workplace, and its symptoms, through lifestyle modifications along with ergonomic guidance at work and in relation with their musculoskeletal health, the psychosocial hazards at work and their body response to work-related stress."
61931368|NCT06488547|NO_INTERVENTION|Control Group-CG|Participants will receive only information regarding ergonomic practices and tips able to be appilied at the workplace.
61931369|NCT06706973||patient with head and neck SCC|Anatomic location: oral cavity, larynx, oropharynx
61931370|NCT06406777|ACTIVE_COMPARATOR|Healthy Normal Subjects|Healthy subjects, with no lung diagnosis, who are non-smokers.
61931371|NCT06406777|EXPERIMENTAL|Post Lung Transplant with normal functioning|Subjects who have had a lung transplant and now have normal lung function
61931372|NCT06406777|EXPERIMENTAL|Post Lung Transplant with Chronic Lung Allograft Dysfunction (CLAD)|Subjects who have had a lung transplant that now have CLAD
61931373|NCT04593849|ACTIVE_COMPARATOR|group A (Ru-Yih-Jin- Huang-Saan group)|Herbal medicine(Ru-Yih-Jin- Huang-Saan) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
61931374|NCT04593849|EXPERIMENTAL|group B (Wan-Yin-Gao-Jia-Jean-Wey group)|Herbal medicine (Wan-Yin-Gao-Jia-Jean-Wey) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
61931375|NCT04593849|PLACEBO_COMPARATOR|placebo group( topical agent without therapeutic effects)|topical agent without therapeutic effects will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
61931376|NCT04593849|NO_INTERVENTION|control group|only oral analgesics will be applied to patients
61931377|NCT06136247||Healthy controls|Healthy controls, people not living with opioid use disorder or on medication assisted therapy for such.
61931378|NCT06136247||Patients living with Opioid Use Disorder|Individuals with opioid use disorder who have been on a stable dose of medication assisted therapy for at least a week.
61931379|NCT06638307|EXPERIMENTAL|MEN2312: Monotherapy|Participants will receive MEN2312.
61931380|NCT06638307|EXPERIMENTAL|MEN2312: Combination Therapy (Elacestrant)|Participants will receive MEN2312 in combination with elacestrant.
62132652|NCT02316301|ACTIVE_COMPARATOR|Short interval misoprostol|A small envelope including two labeled plastic bags (A\& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
62132653|NCT00426829|EXPERIMENTAL|Proton Therapy + Bevacizumab|Proton Therapy + Bevacizumab
62483725|NCT02193763|NO_INTERVENTION|90 days and under--control|Neonates aged 90 days and under randomized to lumbar puncture using the anatomical landmark approach
62483726|NCT02193763|EXPERIMENTAL|Over 90 days--Interventional|Neonates aged over 90 days randomized to ultrasound assisted lumbar puncture
62483727|NCT02193763|NO_INTERVENTION|Over 90 days--Control|Neonates aged over 90 days randomized to lumbar puncture using the anatomical landmark approach
61931381|NCT03088215|EXPERIMENTAL|A / Shock-waves|Will receive shock-waves
62132654|NCT03415360|OTHER|cryoablation|peripheral nerve cryoablation
62132655|NCT05461313|OTHER|Constrained Liner|
62132656|NCT05461313|OTHER|Dual Mobility Cup|
62132657|NCT03484910|EXPERIMENTAL|BFB group|Exercise therapy - Six-week training program of stationary cycling with a real-time visual EMG biofeedback
62132658|NCT03484910|ACTIVE_COMPARATOR|CON group|Exercise therapy - Six-week training program of stationary cycling without EMG biofeedback
62132659|NCT00468156|ACTIVE_COMPARATOR|1|written materials only
62132660|NCT00468156|EXPERIMENTAL|2|written materials plus asked to form implementation intentions
62132661|NCT00468156|EXPERIMENTAL|3|same as arm 2 plus telephone support
62132662|NCT01754636||Elderly patients|patients aged 65 years old or older : no intervention
61931382|NCT03088215|NO_INTERVENTION|B / Nothing|Will not receive shock-waves
62132663|NCT01754636||"Young patients"|patients aged 18-64 years (added by amendment n°3 -02/2014) : no intervention
62132664|NCT05114967||Patients undergoing surgery|Patients undergoing surgery during the 4th wave of the pandemic for 1 month duration in the University Hospital of Larissa
62132665|NCT03465813|EXPERIMENTAL|CaringGuidance Intervention|Three months of web-based CaringGuidance psychoeducational program use, independently on home computer in addition to usual care.
62132666|NCT03465813|NO_INTERVENTION|Usual Care|Three months of care as usual from subjects' clinics and community as the subject chooses.
62132667|NCT04338399|EXPERIMENTAL|Buparlisib & Weekly Paclitaxel|"Drug: Patients will receive 100 mg (2 x 50 mg) buparlisib hard gel capsule administered orally, once daily starting on Day 1 of Treatment Cycle 1, Drug: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle.~Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason."
62132668|NCT04338399|ACTIVE_COMPARATOR|Weekly Paclitaxel|Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
62692039|NCT06561126|EXPERIMENTAL|Participatory, Learning and Action (PLA) Based Intervention|Community mobilization will be done via male and female community groups using a PLA Cycle whereby groups themselves identify and priorities problems associated with diabetes and the risk of developing diabetes.Lay facilitators will convene the groups monthly over a period of 18 months, with one meeting per month. A total of 64 groups will be established in each district, each comprising approximately 20-30 participants, covering an eligible population of 250 to 300 individuals. The total number of participants exposed to the intervention, adapted from the DMagic trial in Bangladesh, will be determined based on random selection from the community. The intervention will focus on participatory groups, with separate groups for males and females to ensure inclusivity and encourage participation from high-risk individuals and those with TIIDM.
62132669|NCT04019444|EXPERIMENTAL|Arm A|One dose (1 ml (5x10\^10 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
62132670|NCT04019444|EXPERIMENTAL|Arm B|One dose (1 ml (1x10\^11 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
62132671|NCT04019444|EXPERIMENTAL|Arm C|Two doses (1 ml (1x10\^11 vp) each) of ChAd155-RG vaccine administered intramuscularly on Day 1 (first dose) and Day 15 (second dose), and 1 ml of matching placebo administered intramuscularly on Days 8 and 22. N=10
62132672|NCT04019444|ACTIVE_COMPARATOR|Arm D|Three doses (1 ml each) of RABAVERT vaccine administered intramuscularly on Day 1 (first dose), Day 8 (second dose), and Day 22 (third dose), and 1 ml of matching placebo administered intramuscularly on Day 15. N=12 (2 sentinel, 10 non-sentinel)
62132673|NCT05602207|EXPERIMENTAL|Abrocitinib 100 mg tablet (marketed drug)|
62324843|NCT05357482|EXPERIMENTAL|briquilimab in stem cell transplant recipients for SCD|Affected SCD and beta-thal subjects will receive briquilimab
62483728|NCT05457985|EXPERIMENTAL|Prolonged Exposure for Primary Care (PE-PC) then continue as early responder|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage (for 8 weeks).
62483729|NCT05457985|EXPERIMENTAL|Clinician Supported (CS) PTSD Coach App then continue as early responder|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first). Early responders will be encouraged to continue app use but will discontinue clinician support sessions for 8 weeks.
62483730|NCT05457985|EXPERIMENTAL|Prolonged Exposure for Primary Care (PE-PC) then full PE|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
62483731|NCT05457985|EXPERIMENTAL|Clinician Supported PTSD Coach App then full PE|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
62132674|NCT00939510|EXPERIMENTAL|Lenalidomide (RevlimidTM ) and GM-CSF|
62483732|NCT05457985|EXPERIMENTAL|Prolonged Exposure for Primary Care (PE-PC) then continued PE-PC|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), slow responders that are then randomized to continue with PE-PC (medium intensity) will continue weekly sessions for 8 weeks.
62483733|NCT05457985|EXPERIMENTAL|Clinician Supported PTSD Coach App then continued CS PTSD Coach App|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first), slow responders that are then randomized to continue this treatment will have the frequency reduced to twice monthly.
62483734|NCT06249139|EXPERIMENTAL|Compass for Care (Well-being intervention)|Participants receive 12 weekly modules containing interactive activities and static content and tailored messages delivered via text message or email. The intervention focuses on five self-care behaviors critical to ADRD caregiver well-being: 1) taking time to recharge; 2) finding information about your loved one's diagnosis and needs; 3) discovering your strengths and limits; 4) exploring outside help; and 5) seeking emotional support.
62483735|NCT06249139|ACTIVE_COMPARATOR|Compass for Care (Safety intervention)|Participants receive 12 weekly modules and tailored messages delivered via text message or email. The intervention focuses on safety behaviors (e.g., weather safety, first aid, home safety, etc.)
62483736|NCT00729976|EXPERIMENTAL|1|Ibuprofen Suppository
61931383|NCT05683223|EXPERIMENTAL|Responders|The experimental arm involves EEG + MRI before and after exposure therapy for social anxiety disorder.
62132675|NCT00984048||FOLFOX, XELOX or FOLFIRI +/- bevacizumab|Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.
62132676|NCT03492866|ACTIVE_COMPARATOR|Gentamicin Sulfate|All subjects will be treated with topical gentamycin applied twice daily (1 fingertip unit (FTU)) to the right half of the scalp. Total study period: 6 months.
62132677|NCT03492866|NO_INTERVENTION|No treatment|The medication won't be applied to the left half of the scalp.
62132678|NCT02966275|EXPERIMENTAL|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
62132679|NCT02966275|PLACEBO_COMPARATOR|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
62324844|NCT05357482|NO_INTERVENTION|Stem cell Donors of Recipients undergoing stem cell transplant|Participants donate stem cells for recipient to undergo stem cell transplant
62132680|NCT03602950|NO_INTERVENTION|Control group|50 diabetic ladies at full term will undergo elective CS and will receive the usual surgical care routinely done at our hospital
62132681|NCT03602950|ACTIVE_COMPARATOR|study group|50 diabetic ladies will undergo elective CS at full term and autologous PRP will be injected subcutaneously before skin closure.
62483737|NCT00729976|ACTIVE_COMPARATOR|2|Ibuprofen suspension
62483738|NCT02172781|EXPERIMENTAL|Ipratropium - unit dose vial|
62483739|NCT02172781|EXPERIMENTAL|Tiotropium - inhalation capsule - low dose|
62483740|NCT02172781|PLACEBO_COMPARATOR|Placebo matching tiotropium - inhalation capsule|
62483741|NCT02172781|PLACEBO_COMPARATOR|Placebo matching to ipratropium - unit dose vial|
62483742|NCT02172781|EXPERIMENTAL|Tiotropium - inhalation capsule - high dose|
62692040|NCT06561126|NO_INTERVENTION|Usual Care|The Control Group will not receive the PLA (Participatory Learning and Action) intervention. Study participants in the control group would not be exposed to the training and would be kept in the control group. They would be a group that would receive usual care and routine awareness. However, they will still benefit from the study in several ways. Information about the trial and guidance on who to contact in case of hyperglycemia or intermediate hyperglycemia will be provided. The disease burden in the control area will be monitored, and findings will be included in national and international advocacy and dissemination efforts.
62692041|NCT00751985|EXPERIMENTAL|1|Personalized normative feedback (PFI). The PFI was a single-session intervention; it was displayed in a single screenshot and addressed the participant by name. It consisted of a summary of the participant's weekly consumption, a comparison with maximum drinking limits and a graphical comparison of the participant's consumption to the average level in the municipality (gender-specific), followed by information about health and social risks of heavy drinking as well as links for further self-help material and a local alcohol treatment facility.
62692042|NCT00751985|EXPERIMENTAL|2|Self-help material (SHM). The SHM was a single-session intervention and was displayed in a single screenshot. It consisted of information about maximum drinking limits, followed by information about health and social risks of heavy drinking as well as links for further standardized self-help material and a local alcohol treatment facility.
62692043|NCT00751985|PLACEBO_COMPARATOR|3|Control
62692044|NCT04305756|EXPERIMENTAL|Weight-based LMWH|"Participants will receive a weight-based dose of prophylactic enoxaparin.~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours"
61931384|NCT05683223|EXPERIMENTAL|Non-Responders|The experimental arm involves EEG + MRI before and after exposure therapy for social anxiety disorder. Non-responders to initial exposure therapy will receive sertraline and additional exposure therapy prior to final EEG and MRI.
62692045|NCT04305756|ACTIVE_COMPARATOR|Fixed LMWH|"Participants will receive a fixed dose of prophylactic enoxaparin.~* For BMI \<40: 40mg injected subcutaneously every 24 hours~* For BMI \> or = to 40: 40mg injected subcutaneously every 12 hours"
61931385|NCT05683223|NO_INTERVENTION|Controls|Controls will receive baseline EEG and MRI, screening questionnaires and intake interview. They will not participate in therapy but complete weekly symptom measures and a second EEG/MRI session 12 weeks after baseline. Control participants will be compared with social anxiety participants to determine differences in neuro-markers at baseline and over follow-up.
61931386|NCT02983396|EXPERIMENTAL|no transmural ischemia (NTI) and transmural ischemia (TI)|"Case cross-over from no transmural ischemia (NTI) to transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)~Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia."
61931387|NCT05135663|EXPERIMENTAL|NS-089/NCNP-02 40 mg/kg|
61931388|NCT05135663|EXPERIMENTAL|NS-089/NCNP-02 80 mg/kg|
61931389|NCT01799031|EXPERIMENTAL|Arm I (WISE)|Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
61931390|NCT01799031|ACTIVE_COMPARATOR|Arm II (control)|Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
61931391|NCT06698601|EXPERIMENTAL|Intervention group|wild blueberry
62483743|NCT00919737|EXPERIMENTAL|NPC-08|
62483744|NCT05119504|EXPERIMENTAL|Acceptance-based|This 90-minute one-on-one intervention will provide psychoeducation and experiential training on the use of acceptance-based strategies for physical activity.
62483745|NCT05119504|SHAM_COMPARATOR|Multi Health Behavior|This 90-minute one-on-one intervention will provide psychoeducation on physical activity as one of several interconnected health behaviors.
62483746|NCT00829309|EXPERIMENTAL|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
62483747|NCT00829309|ACTIVE_COMPARATOR|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
61931392|NCT06698601|OTHER|Control group|No wild blueberry
62132682|NCT05960994|EXPERIMENTAL|Sequence 1|Sequence 1 will consist of a 3-month control period, followed by a 3-month transition period, and finally, a 19-month intervention period. The total duration of sequence 1 will be 25 months.
62483748|NCT05609981|OTHER|Intervention|The intervention at t=0 consists of a 5-step patient-centred CMR focused on deprescribing supported by a toolbox provided to the pharmacists
62483749|NCT05609981|NO_INTERVENTION|Control|Usual care.
62483750|NCT05125315||low-hemosynamics|
62483751|NCT05125315||high-hemodynamics|
62483752|NCT01366781|EXPERIMENTAL|Healthy males|Meal ingestion in healthy males
61931393|NCT01954342||Pregnant|Obese pregnant women
61931394|NCT03143322|EXPERIMENTAL|Systemic treatment + SBRT|Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
62132683|NCT05960994|EXPERIMENTAL|Sequence 2|Sequence 2 will consist of a 7-month control period, followed by a 3-month transition period, and finally, a 15-month intervention period. The total duration of sequence 2 will be 25 months.
62324845|NCT06637254|EXPERIMENTAL|HSK31858 20mg|multiple oral doses: 20mg/d for 48w
62483753|NCT01366781|EXPERIMENTAL|Healthy females|Meal ingestion in healthy females
62324846|NCT06637254|EXPERIMENTAL|HSK31858 40mg|multiple oral doses: 40mg/d for 48w
62324847|NCT06637254|PLACEBO_COMPARATOR|placebo|multiple oral doses for 48w
62324848|NCT06376669|EXPERIMENTAL|Proton Stereotactic Body Radiation Therapy (SBRT)|The SBRT group is the single arm of this study.
62324849|NCT04585477|EXPERIMENTAL|Cohort 1 minimal residue disease positive(MRD+)|"Subjects with detectable ctDNA (MRD+) will receive up to 12 cycles of durvalumab (1500mg dose by intravenous (by vein) injection every 28 days). ctDNA will be re checked following 2 cycles (8 weeks) of durvalumab and compared to baseline levels. In the absence of progression or toxicity after 2 cycles, subject will continue with durvalumab to complete 1 year of treatment about 10 additional cycles).~Subjects will be monitored for secondary endpoints of progression free survival (PFS) and overall survival (OS)."
62324850|NCT04585477|ACTIVE_COMPARATOR|Cohort 2 minimal residue disease negative (MRD-)|Subjects with undetectable ctDNA (MRD) will receive Standard of care and no treatment
62483754|NCT06558955|EXPERIMENTAL|Technology-enabled anticipatory guidance and peer support|Participants (mothers) will join online parent empowerment sessions for about 4 times (around 3, 6, 12, and 18 months of child's age, around 45 - 60 minutes each), and receive additional information and push notifications via a mobile phone app.
62483755|NCT06558955|ACTIVE_COMPARATOR|Conventional oral health education|Participants (mothers) will receive child oral health information for about 4 times (around 3, 6, 12, and 18 months of child's age).
61931395|NCT03143322|NO_INTERVENTION|Systemic treatment|Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression...)
61931396|NCT04729387|EXPERIMENTAL|Alpelisib+olaparib|Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule.
61931397|NCT04729387|ACTIVE_COMPARATOR|Paclitaxel or PLD|Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days.
61931398|NCT06661850||Blinded-to-NOCISCAN|NOCISCAN completed pre-operatively. Investigator will not have access to NOCISCAN result.
61931399|NCT06661850||Unblinded-to-NOCISCAN|NOCISCAN completed pre-operatively. Investigator will have access to the NOCISCAN result after completing initial treatment plan but before treatment.
61931400|NCT06681688|EXPERIMENTAL|Study Arm (OMIDRIA)|"* Pre-op, 1 drop ketorolac (0.5%) {Toradol}, 1 drop moxifloxacin (0.5%) {Avelox}~* Prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Concl. of surgery while still in the OR: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%) {Pred Forte}~* Post-op recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%).~Intraoperative interventions: intracameral phenylephrine {Sudafed} 1.0%/ketorolac 0.3%, {OMIDRIA} intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10 mg/mL) {Kenalog}.~In-office drops administered by study staff at the end of the 1-day visit: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%).~Rescue therapy will be allowed, if necessary, at the discretion of the evaluating physician and will consist of prednisolone acetate (1%) QID (taper also at the discretion of the evaluating physician)."
61931401|NCT06681688|ACTIVE_COMPARATOR|Control Arm (Standard of Care)|"Self-administration of:~Ketorolac (0.5%) {Toradol} four times daily (QID) x 1 day and moxifloxacin (0.5%) {Avelox} drops three times daily (TID) x 1 day before SX.~On the Day of SX, eyes will receive in-office drops administered by study staff according to the following:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to SX: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of SX while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%) Pred Forte}~* Any time in post-op recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%).~Eyes will then self-administer the following postoperative interventions: ketorolac drops QID x 1 month. Prednisolone acetate tapering QID x1 week, TID x 1 week, twice daily (BID) x 1 week, and once daily (QD) x 1 week; and moxifloxacin drops TID x 1 week."
61931402|NCT06709742|EXPERIMENTAL|Intervention Group|The Intervention based on GMFM-88 items will be given 3 times per week for a duration of 40-45 minutes for each session for 16 weeks.
61931403|NCT05475613|EXPERIMENTAL|Downstaging group|Eligible patients (See inclusion and exclusion criteria) will undergo downstaging treatment containing Anti-PD-1 inhibitor (tislelizumab, pembrolizumab, nivolumab et al). Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously. Other combination regimens, such as locoregional therapies and targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers. Patients that have reached the Criteria for Successful Downstage within 12 cycles of downstaging treatment will proceed to the observation phase, while those who fail to meet the Criteria for Successful Downstage after the maximum length of downstaging procedures will drop out from the study.
61944587|NCT05909683|SHAM_COMPARATOR|Standard-of-care|These patients will receive antibiotics according to standard practice of the attending physicians. The central lab will feedback to attending physicians and investigators the results of the conventional blood cultures and AST according to the routine SOP. The attending physicians and investigators will be allowed to decide for any change of antimicrobial treatment based on the results of conventional blood cultures provided to them by the central lab or any other culture provided to them by their hospital. Antibiotics will be stopped according to the local standard practice. BCID2, Reveal Rapid AST and PCT will be performed in the samples of these patients, attending physicians will not be provided such information.
62324851|NCT04437511|EXPERIMENTAL|Donanemab|Participants received 700 milligram (mg) Donanemab every 4 weeks (Q4W) x 3 doses, then 1400 mg Q4W given intravenously (IV) for up to 72 weeks
62324852|NCT04437511|PLACEBO_COMPARATOR|Placebo|Participants received placebo given IV.
62339933|NCT05834907|EXPERIMENTAL|Circle of Security Parenting (COS-P)|These participants will receive the Circle of Security Parenting (COS-P) intervention, an attachment-based, manualized, 8-session (90 minutes/session), home visiting intervention.
62483756|NCT03420053|EXPERIMENTAL|Group 1 HIV- vaccine recipients|"Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10\^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine.~Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
62692046|NCT01644591|EXPERIMENTAL|Treatment (SRS)|Patients undergo SRS on day 1.
62483757|NCT03420053|PLACEBO_COMPARATOR|Group 1 HIV- NS controls|"Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
62483758|NCT03420053|EXPERIMENTAL|Group 2a HIV+ vaccine sentinels|Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10\^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.
62483759|NCT03420053|EXPERIMENTAL|Group 2b HIV+ vaccine recipients|"Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10\^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
62483760|NCT03420053|PLACEBO_COMPARATOR|Group 2b HIV+ placebo controls|"Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
62483761|NCT01726491||Insulin resistance epigenetics|"This experiment will use the Infinium methylation assay to perform epigenome mapping and define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. We will test the hypotheses that~(1) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (2) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (3) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance."
62132684|NCT05960994|EXPERIMENTAL|Sequence 3|Sequence 3 will consist of a 11-month control period, followed by a 3-month transition period, and finally, a 9-month intervention period. The total duration of sequence 3 will be 25 months.
62132685|NCT05960994|EXPERIMENTAL|Sequence 4|Sequence 4 will consist of a 15-month control period, followed by a 3-month transition period, and finally, a 7-month intervention period. The total duration of sequence 4 will be 25 months.
62132686|NCT05960994|EXPERIMENTAL|Sequence 5|Sequence 5 will consist of a 19-month control period, followed by a 3-month transition period, and finally, a 3-month intervention period. The total duration of sequence 5 will be 25 months.
62324853|NCT05903131|EXPERIMENTAL|Arm 1: Levonorgestrel-releasing IUD (LNG-IUD) + Behavioral Weight Loss Intervention|"* The levonorgestrel-releasing IUD is used in this study as per standard care.~* The behavioral weight loss intervention consists of a telemedicine cognitive behavioral coaching program. At each session, patients will self-report weight, number of days they kept a food journal during the past week, average daily caloric intake for the week, number of days exercised for the week, total number of minutes of moderate physical activity, and average number of steps per day for the week."
62324854|NCT05903131|ACTIVE_COMPARATOR|Arm 2: Levonorgestrel-releasing IUD (LNG-IUD) + Enhanced Usual Care|"* The levonorgestrel-releasing IUD is used in this study as per standard care.~* Participants will be provided with 1- to 3-page handouts on topics including healthy eating, exercise, and behavioral eating strategies from materials provided on the American Cancer Society, Society of Gynecologic Oncology, and WebMD Nourish websites. These materials encourage weight loss through calorie counting, recording dietary intake, engaging in exercise programs, and using portion control strategies.~* The participants randomized to this arm will cross over to the behavioral weight loss intervention arm at 12 months if they have not achieved resolution of AEH or grade 1 endometrial cancer."
62324855|NCT05999123||All Participants|Up to 150 participants will be enrolled at one or more clinical research sites in the United States. Participants will be healthy, menstruating individuals between 18 to 42 years of age who meet all eligibility criteria.
62324856|NCT05711615|EXPERIMENTAL|Treatment (peposertib, liposomal doxorubicin)|Patients receive peposertib PO BID and pegylated liposomal doxorubicin hydrochloride IV QD during treatment cycles on study. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection and tissue biopsy during screening and on the trial.
62324857|NCT02955784|EXPERIMENTAL|Sinasprite Mobile App|Mobile App
62324858|NCT05622708|EXPERIMENTAL|Treatment Period 1|Open-label Secukinumab PFS (prefilled syringe) labeled as AIN457 150mg/1mL
62324859|NCT05622708|EXPERIMENTAL|Treatment Period 2|Double-blind Secukinumab and Placebo PFS labeled as AIN457 150mg/1mL/Placebo
61931404|NCT04365257|EXPERIMENTAL|Prazosin|"1. Prazosin 1mg given to observe if medication is tolerated or if signs or symptoms of hypotension develop (e.g. dizziness, lightheadedness).~2. If the patient remains asymptomatic and BP \>110/60 mmHg, prazosin is continued at 1mg every 8 hours (q8h).~3. Day 3: If the patient remains asymptomatic and BP \>110/60 mmHg, increase dose to 2mg q8h.~4. Day 6: If the patient remains asymptomatic and BP \>110/60 mmHg, increase dose to 5mg q8h.~5. If the BP is \<100/60 mmHg at any time, the next dose should be held, and patient continues with the highest previously tolerated dose 8 hours later.~6. If the patient did not tolerate dose escalation to 5mg q8h, one attempt is made to increase dose to 3mg q8h. If this is not tolerated, the patient continues with the highest previously tolerated dose 8 hours later.~If BP monitoring is not available, repeated occurrences of postural dizziness should trigger drug dose reduction or BP monitoring."
61931405|NCT04365257|ACTIVE_COMPARATOR|Standard of care|Subjects randomized to this arm will receive standard of care.
62132687|NCT02320370|EXPERIMENTAL|Treatment 1|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
62324860|NCT06554522|NO_INTERVENTION|Non-LISA Group|Preterm infants with respiratory distress syndrome who are on continuous positive airway pressure support and being treated with caffeine citrate.
62132688|NCT02320370|EXPERIMENTAL|Treatment 2|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
62132689|NCT02496325|OTHER|perineal technic|
62132690|NCT06282107|EXPERIMENTAL|Bilateral superselective adrenal arterial embolization|Selectively injects 1.5-2.5 mL ethanol into bilateral adrenal artery to ablate part of the adrenal gland; irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
61931406|NCT06704503||Group A was 20-40 years old|They were divided into three groups according to age: A, B, and C.Group A was 20-40 years old.
61931407|NCT06704503||Group B was 40-60 years old|They were divided into three groups according to age: A, B, and C. Group B was 40-60 years old.
61931408|NCT06704503||Group C was 60-80 years old|They were divided into three groups according to age: A, B, and C. Group C was 60-80 years old.
61931409|NCT05468138|ACTIVE_COMPARATOR|Adjuvant chemotherapy(SOX or XELOX )|"8 cycles of adjuvant SOX or XELOX should be performed within 8 weeks after receiving standard gastrectomy with D2 lymphadenectomy.~SOX: S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months) XELOX: capecitabine：1000 mg/m2 ，bid, d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
61931410|NCT05468138|EXPERIMENTAL|Observation|After receiving standard gastrectomy with D2 lymphadenectomy, regular follow-up every 3 months alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
61931411|NCT05468138|EXPERIMENTAL|PD-1 immunotherapy|"Adjuvant treatment with PD-1 antibody every 3 weeks(maximum 1 years) should be performed within 8 weeks after receiving standard gastrectomy with D2 lymphadenectomy.~PD-1 antibody: Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles"
61931412|NCT05866237|EXPERIMENTAL|Intervention group|Individuals allocated to this group will be receiving care from their GP as well as the patient engagement tool (intervention). This will include messages being sent to patients in regards to vaccine information and uptake at different time points (three times).
61931413|NCT05866237|NO_INTERVENTION|Control Group|The individuals in this group will receive standard care from their GP and nothing additional to this.
62132691|NCT06282107|ACTIVE_COMPARATOR|traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
62324861|NCT06554522|EXPERIMENTAL|LISA Group|Preterm infants with respiratory distress syndrome, who are on continuous positive airway pressure support are treated with caffeine citrate and surfactant through the less invasive surfactant administration technique.
62324862|NCT06188286|ACTIVE_COMPARATOR|TEAS|transcutaneous acupoint electrical stimulation was performed at the bilateral Hegu and Waiguan acupoints for 30 minutes, and then transcutaneous acupoint electrical stimulation was performed at the Sanyinjiao and Zusanli acupoints of the bilateral lower limbs for 30 minutes.
62324863|NCT06188286|PLACEBO_COMPARATOR|sham TEAS|Except for the transcutaneous acupoint electrical stimulator, which has no current output, the other operations are the same as TEAS group
62324864|NCT04719988|EXPERIMENTAL|Experimental|"Induction treatment~* Modified DCF: every 2 weeks for 8 cycles Docetaxel (40 mg/m², day 1), Cisplatin (40 mg/m², day 1) , 5-FU (1200 mg/m²/day for 2 days)~* Ezabenlimab: 240 mg intravenous, every 3 weeks for 3 cycles~In case of tumor response:~* Two additional cycles of mDCF and one additional cycle of Ezabenlimab (Q3W).~* Hypofractionated radiotherapy~* Ezabenlimab: 240 mg intravenous, every 3 weeks for 7 cycles~In absence of tumor response:~o Chemoradiotherapy (Intensity-Modulated Radiation Therapy \[IMRT\]) treatment: Chemoradiotherapy using IMRT will begin 3-4 weeks following the last cycle of induction phase, in the absence of toxicities of grade 1 and/or management of toxicities. It will last 7 weeks and will consist of:~• Standard dose of 45 Gy in 25 fractions over 5 weeks followed by a sequential boost of 14.4 Gy in 8 sessions,~Concomitantly given with:~* Capecitabine (825 mg/m²/orally twice daily) from Monday to Friday,~* Mitomycin C (10 mg/m² Day 1)"
62132692|NCT00186849|OTHER|1|
62132693|NCT01311622|EXPERIMENTAL|warfarin|
62132694|NCT01311622|EXPERIMENTAL|warfarin and fostamatinib|
62132695|NCT02612233|ACTIVE_COMPARATOR|Pregabalin|Pregabalin 150mg ON week 1 increased to Pregabalin 300mg ON weeks 2-11 then decrease to Pregabalin 150mg ON week 12 then STOP
62324865|NCT05866211||Case|Individuals with impaired lung function, according to spirometry results (FVC ≤ LLN and FEV1/FVC ≥ LLN).
62324866|NCT05866211||Control|Individuals with normal lung function
62324867|NCT02107989||healthy volunteers|healthy volunteers
62324868|NCT02107989||Patients|Patients
62324869|NCT05011266|EXPERIMENTAL|Buprenorphine-naloxone|Buprenorphine/naloxone 5.7 mg /1.4 mg/day sub-lingual tablets
61931414|NCT04021563|EXPERIMENTAL|SR419|Ascending single and multiple doses of SR419 orally
62324870|NCT05011266|PLACEBO_COMPARATOR|Placebo|placebo sub-lingual tablet
61931415|NCT04021563|PLACEBO_COMPARATOR|Placebo|Ascending single and multiple doses of placebo orally
62132696|NCT02612233|ACTIVE_COMPARATOR|Duloxetine|Duloxetine 30mg ON week 1 increase to Duloxetine 60mg weeks 2-11 then decrease to Duloxetine 30mg ON week 12 then STOP
62132697|NCT02612233|PLACEBO_COMPARATOR|Placebo|1 capsule ON week 1- increase to 2 capsules ON week 2-11 then decrease to 1 capsule ON week 12 then STOP.
62132698|NCT05490524|NO_INTERVENTION|Control group|"The Control group will receive standard health care with no technical support, where the intervention groups will receive platform and device services provided to each user. In that respect, Intervention Group 1 will receive no real-time feedback, where Intervention Group 2 will unhand with real data and notifications.~A control group is defined as a group of clinical trial participants who will not be provided any digital devices as part of the trial and will receive care as usual by PASYKAF and AMEN."
62132699|NCT05490524|EXPERIMENTAL|Intervention group 1 (limited technology)|Intervention Group 1 - platform/devices (no real feedback provided (limited technology group) A limited technology group is defined as a group of clinical trial participants who receive the digital devices but not the automated interventions through the devices (prompts, messages).
62132700|NCT05490524|EXPERIMENTAL|Intervention group 2 (full technology)|Intervention Group 2 -platform/devices (with real feedback provided) (full technology group) A full technology group is defined as a group of clinical trial participants who receive the digital devices as part of the trial and healthcare professionals receive the patients' data.
61931416|NCT05659966|EXPERIMENTAL|Intervention|The intervention condition participants will be instructed to follow a plant-based diet. The intervention participants will receive weekly group classes for 3 months at a local restaurant and will receive guidance on how to choose foods to meet their nutrient needs that fit within the vegan diet. The intervention participants will receive a voucher each week for a free plant-based meal at the restaurant.
62132701|NCT03172234|ACTIVE_COMPARATOR|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
62324871|NCT06138093|EXPERIMENTAL|Sealed / closed tracheostomy|Sealing of the tracheostomy wound using a sealing device.
62483762|NCT01726491||Single bout of exercise|"This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~1. Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and~2. Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise."
62483763|NCT01726491||Eight weeks of exercise|"This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~1. There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes,~2. There is altered methylation of genes involved in inflammation and cytoskeletal structure."
62324872|NCT05364944|EXPERIMENTAL|Cohort A: Participants With Acromegaly|Participants will receive Sandostatin Long-acting repeatable (LAR) or Somatuline Autogel (ATG) (or equivalent formulations of octreotide/lanreotide) in Run-in Period and further will receive Debio 4126 in this group.
62324873|NCT05364944|EXPERIMENTAL|Cohort B: Participants With GEP-NET|Participants will receive Sandostatin LAR or Somatuline ATG (or equivalent formulations of octreotide/lanreotide) in Run-in Period and further will receive Debio 4126 in this group.
62483764|NCT00443391|EXPERIMENTAL|1|
62483765|NCT01923909|ACTIVE_COMPARATOR|Intra-articular corticosteroid|Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
62483766|NCT01923909|EXPERIMENTAL|Intra-articular platelet-rich plasma|IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
62324874|NCT05583526|EXPERIMENTAL|Ritlecitinib 50 mg|Ritlecitinib 50 mg QD (ritilecitinib 50 mg QD arm; approximately 400 participants)
62692047|NCT05479227||Patients with bile duct injuries during laparoscopic cholecystectomy|The data concerning 241 patients´ BDI emergence, severity, management, and outcomes was analyzed
62692048|NCT01182246|EXPERIMENTAL|AXP107-11|
61931417|NCT05659966|ACTIVE_COMPARATOR|Control|Participants in the active control condition will receive meal vouchers to the restaurant. The active control condition participants will not receive any instruction to follow a particular diet or support. Participants in this condition will receive all intervention material and attend a class at the end of the study to learn about the intervention diet.
62324875|NCT05583526|PLACEBO_COMPARATOR|Placebo|Placebo (placebo arm; approximately 200 participants)
62324876|NCT06362798|EXPERIMENTAL|Financial Transfers|"Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a CuddleCard debit-card with a one- time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age."
62483767|NCT02442687|ACTIVE_COMPARATOR|A|JKB 121, 5 mg twice daily
62483768|NCT02442687|ACTIVE_COMPARATOR|B|JKB 121, 10 mg twice daily
62483769|NCT02442687|PLACEBO_COMPARATOR|C|Identical appearing placebo
62692049|NCT05548361|EXPERIMENTAL|Active Chx|This group will receive active chlorhexidine and placebo probiotics
62692050|NCT05548361|EXPERIMENTAL|Active probiotics|This group will receive placeo chlorhexidine and active probiotics
62132702|NCT03172234|ACTIVE_COMPARATOR|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
62132703|NCT03172234|PLACEBO_COMPARATOR|control group (group C)|the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.
62132704|NCT03636334|EXPERIMENTAL|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
62132705|NCT03636334|NO_INTERVENTION|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
62692051|NCT05548361|EXPERIMENTAL|Active Chx & probiotics|This group will receive active chlorhexidine and active probiotics
62692052|NCT06088914|EXPERIMENTAL|Anodal tDCS group|Participants will receive anodal tDCS applied to the ipsilesional primary motor cortex.
62692053|NCT06088914|SHAM_COMPARATOR|Sham tDCS|Participants will receive sham tDCS applied to the ipsilesional primary motor cortex
62132706|NCT06495359|EXPERIMENTAL|Experimental group|Researchers will administer the immunization education program to parents.
62692054|NCT04347538|NO_INTERVENTION|Control Group, No intervention|control group, no nasal irrigation
62692055|NCT04347538|EXPERIMENTAL|Saline Nasal Irrigation|Nasal irrigation BID with normal saline
62692056|NCT04347538|EXPERIMENTAL|Saline with Baby Shampoo Nasal Irrigation|Nasal irrigation BID with normal saline and 1/2 teaspoon baby shampoo
62132707|NCT06495359|NO_INTERVENTION|Control group|No intervention
62324877|NCT06362798|NO_INTERVENTION|Usual Care|
62324878|NCT04955730|EXPERIMENTAL|NPWT - Negative Pressure Wound Therapy|Participants will receive Negative Pressure Wound Therapy (NPWT) after surgery and wear the NPWT until postop day 3. NPWT dressing will be removed and a new NPWT will be replaced until Postop day 7, where NPWT dressing will be removed.
62324879|NCT04955730|NO_INTERVENTION|Standard of Care Wound Therapy|Participants will receive standard of care wound therapy after surgery. Postop day 3, dressings will be removed and new sterile dressings will be applied if needed.
62324880|NCT06635915|EXPERIMENTAL|Patients with nasogastric tube placed during the intraoperative period.|Ultrasound will be performed during the postoperative period to assess the normoposition of nasogastric tube.
62483770|NCT06627062||subluxated lens extraction|This research cohort consists of patients with moderate to severe subluxation who have successfully undergone lens extraction using an improved scleral fixation standard tension ring technique.
61931418|NCT06613893|ACTIVE_COMPARATOR|Group A will receive total inravenous anesthesia (TIVA)|patients in this group will receive total intravenous anesthesia using propofol infusion after induction of anesthesia, tested variables will be measured according to the protocol
61931419|NCT06613893|ACTIVE_COMPARATOR|Group B will receive inhalational anesthesia (IHA)|patients in this group will receive inhalational anesthesia using isoflurane, tested variables will be measured according to the protocol
61931420|NCT05442190|EXPERIMENTAL|SGX302 Ointment (0.25 % Hypericin)|SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
61931421|NCT05442190|PLACEBO_COMPARATOR|Placebo (Ointment without Hypericin)|Placebo ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
61931422|NCT05442190|EXPERIMENTAL|SGX302 Gel (0.25 % hypericin)|SGX302 (0.25 % hypericin) gelt will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
61931423|NCT05624996|ACTIVE_COMPARATOR|Arm I (image guided RT, chemotherapy, immunotherapy)|Patients undergo conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel IV and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or PET/CT during follow up.
61931424|NCT05624996|EXPERIMENTAL|Arm II (SBRT, image guided RT, chemotherapy, immunotherapy)|Patients undergo SBRT and conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel IV and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or PET/CT during follow up.
61931425|NCT05114538|EXPERIMENTAL|RIT Training Group|Providers in the RIT group (n=80) will receive intensive training (online tutorial, 2-day workshop, and virtual coaching and feedback in the field) in RIT and parent coaching and will be required to achieve fidelity prior to enrolling families from their caseload. They will then be asked to use the intervention with enrolled families for a minimum of 3 months. One intervention session per month for each enrolled family will be videotaped and scored for fidelity. Providers will receive monthly consultation from RIT trainers while these families are in the active treatment phase.
61931426|NCT05114538|NO_INTERVENTION|Treatment as Usual|Providers in the TAU group (n=80) will have three sessions videotaped and scored for each enrolled family to assess treatment differentiation. To incentivize agency participation, RIT training will be provided to the TAU group and other providers when data collection is complete.
61931427|NCT06708260|EXPERIMENTAL|ENN0403 low dose treatment arm|
61931428|NCT06708260|EXPERIMENTAL|ENN0403 high dose treatment arm|
61931429|NCT00412568|ACTIVE_COMPARATOR|1|PRK control group
61931430|NCT04447378|EXPERIMENTAL|Fondaparinux|Subcutaneous injection of fondaparinux 2.5 mg once daily would be given over 10 days for post partum thromboprophylaxis
61931431|NCT05758415|EXPERIMENTAL|Secukinumab|"* Name and Strength: 2 X Secukinumab 150 mg / 1 mL~* Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~* Randomized in a 1:1 ratio"
61931432|NCT05758415|PLACEBO_COMPARATOR|Placebo|"* Name and Strength: 2 X Placebo / 1 mL~* Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~* Randomized in a 1:1 ratio"
61931433|NCT02395510|OTHER|Flexible, open label dosing|Flexible dosing 5-20mg
61931434|NCT01284530|EXPERIMENTAL|Conversion-25|25 mg
61931435|NCT01284530|EXPERIMENTAL|Conversion-50|50 mg
61931436|NCT01284530|EXPERIMENTAL|Conversion-100|100 mg
61931437|NCT01284530|EXPERIMENTAL|Conversion-200|200 mg
62324881|NCT06635915|ACTIVE_COMPARATOR|Patients without nasogastric tube placed during the intraoperative period.|Ultrasound will be performed during the postoperative period to assess the absence of nasogastric tube.
62324882|NCT05359939|OTHER|Head-to-head comparison of two tracers: 18F-FDGal PET/CT, 18F-choline PET/CT|Diagnostic scan
62339934|NCT05834907|ACTIVE_COMPARATOR|Little Talks|These participants will receive the Little Talks intervention, a manualized, 8-session (90 minutes/session) early literacy home visiting intervention.
62692057|NCT02593214|EXPERIMENTAL|Wondaleaf Arm|This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only.
61931438|NCT05269732|EXPERIMENTAL|Treatment (9-week online CBT group)|Participants assigned to the treatment group will continue to receive any healthcare they might already be receiving (e.g. family doctor, midwife, Obstetrician/Gynecologist, etc.) and participate in a 9-week group Cognitive Behavioral Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists, social workers, nurses, and/or psychiatrists.
61931439|NCT05269732|NO_INTERVENTION|Control (treatment as usual)|The control group will receive standard postnatal care from their obstetrician, midwife, and/or family physician
61931440|NCT06708364|EXPERIMENTAL|Virtual Reality Training|Virtual reality training (X-BOX) for 6 weeks
61931441|NCT06708364|ACTIVE_COMPARATOR|Cycle Ergometer|Aerobic activity on cycle ergometer for 6 weeks
61931442|NCT05294913|EXPERIMENTAL|Intervention group|
61931443|NCT05294913|PLACEBO_COMPARATOR|Placebo control group|
62132708|NCT04024176|EXPERIMENTAL|Moderate hemophiliac patients|Each participant will perform a gait analysis and clinical examination
62132709|NCT00809068|ACTIVE_COMPARATOR|1|fenofibrate and tibolone
62132710|NCT00809068|SHAM_COMPARATOR|2|tibolone
62132711|NCT04091178|EXPERIMENTAL|VITAMIN D SUPPLEMENTATION ARM|"On day 1 of every chemotherapy cycle, the patient will be receive an oral solution of vitamin D (UVEDOSE/calciferol).~In parallel,a calcium supplementation is prescribed."
62132712|NCT05631860||DanFunD baseline|The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).
62483771|NCT06183788|EXPERIMENTAL|Anti-NMDARe patients with remote cognitive rehabilitation|Participants of a prospective cohort in post-acute phase of the Antibody-mediated NMDA Receptor Encephalitis that will received a behavioral treatment.
62483772|NCT00918645|EXPERIMENTAL|41 Ca|
62132713|NCT05631860||DanFunD 5-years follow-up investigation|The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).
62324883|NCT01399385|EXPERIMENTAL|Group 1|Group 1 will consist of subjects with a 10-year total CHD risk \<10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
62324884|NCT01399385|EXPERIMENTAL|Group 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
62324885|NCT01399385|EXPERIMENTAL|Group 3|Group 3 will consist of subjects with a 10-year total CHD risk \>20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
62324886|NCT01399385|EXPERIMENTAL|Group 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
62324887|NCT05818423|EXPERIMENTAL|Brain Health Academy|Participant in this arm will watch expert videos on a wide range of brain health topics and will complete quizzes for 2.5 hours a week for 12 weeks (30 hours total)
62324888|NCT05818423|EXPERIMENTAL|Brain Health Together|Participants in this arm will participate in online, live-streaming Moving Together classes (1 hour a week) and group brain health classes (1 hour a week) and will work 1-on-1 with a brain health coach to set personalized risk reduction goals (0.5 hours a week) for 12 weeks (30 hours total)
62324889|NCT05818423|EXPERIMENTAL|Maintain Brain Health Together|Participants in this arm will participate in the full Brain Health Together program for 12 weeks (30 hours) followed by weekly group classes and six 1-on-1 coaching sessions for another 12 weeks (additional 15 hours; 45 hours total)
62324890|NCT06512194|EXPERIMENTAL|Group 1: Psilocybin + Treatment as Usual + taVNS|Post-psilocybin dosing, Group 1 will receive twice-daily taVNS paired with psychedelic session contextual cues for 7 consecutive days. They will also receive treatment as usual (TAU) comprised of an integration session 1-day, 1-week, and 2-weeks post-psilocybin dosing.
62483773|NCT02332967|ACTIVE_COMPARATOR|Whey predominant starter formula|Whey predominant starter formula
62692058|NCT06638957||patients with colorectal cancer who underwent surgical treatment from 2018 to 2020|The pre-COVID-19 period extended from 2018 to February 2020
61931444|NCT06191978|EXPERIMENTAL|ASTX727/venetoclax|"On Days 1-5 of Cycle 1, you will take ASTX727 by mouth with a glass of water. Participants must fast (not eat or drink anything but water, black coffee, or tea) for at least 2 hours before and for 2 hours after taking ASTX727. For 4 hours before dosing and 4 hours after dosing, participants should not take antacids or any other medicine that can change the amount of acid in your stomach.~Days 1-21 or 1-28 depending on dose level, of all cycles beginning with Cycle 2. The study doctor will tell participants which of these schedules participants will follow. Venetoclax should be taken with water and a meal at around the same time each day."
62132714|NCT01939691|EXPERIMENTAL|Difluprednate|Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
62324891|NCT06512194|SHAM_COMPARATOR|Group 2: Psilocybin + Treatment as Usual + Sham taVNS|Post-psilocybin dosing, Group 2 will receive twice-daily sham taVNS paired with psychedelic session contextual cues for 7 days. They will also receive treatment as usual (TAU) comprised of an integration session 1-day, 1-week, and 2-weeks post-psilocybin dosing.
62324892|NCT06512194|ACTIVE_COMPARATOR|Group 3: Psilocybin + Treatment as Usual|Post-psilocybin dosing, Group 3 will receive treatment as usual (TAU), comprised of an integration session 1 day, 1-week and 2-weeks post-psilocybin dosing.
62324893|NCT04451590|EXPERIMENTAL|VR-based Simulation (Intervention)|Students will receive training on traumatic airway management using VR-based simulation.
62324894|NCT04451590|OTHER|Mannequin-based Simulation (Control)|Students will receive training on traumatic airway management using mannequin-based simulation.
62324895|NCT01226316|EXPERIMENTAL|Part A and B Schedule 1, Continuous dosing|Part A: Ascending doses of AZD5363 administered orally, every day to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A.
62483774|NCT02332967|EXPERIMENTAL|Whey predominant starter formula + 40% palmitic acid|Whey predominant starter formula + 40% palmitic acid in sn-2 position
62483775|NCT02332967|EXPERIMENTAL|Whey predominant starter formula + 50% palmitic acid|Whey predominant starter formula + 50% palmitic acid in sn-2 position
62483776|NCT01776138||Bladder Cancer Patients|Patients diagnoses with bladder cancer who are eligible to undergo treatment.
62483777|NCT03257956|EXPERIMENTAL|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
62483778|NCT03257956|ACTIVE_COMPARATOR|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
62483779|NCT02258074|EXPERIMENTAL|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
62483780|NCT02258074|PLACEBO_COMPARATOR|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
62692059|NCT06638957||patients with colorectal cancer who underwent surgical treatment from 2020|the COVID-19 period began in March 2020 to December 2020
62692060|NCT06636851|ACTIVE_COMPARATOR|RV Apical pacing|Patient with the pacemaker RV lead located at the RV apex
62692061|NCT06636851|ACTIVE_COMPARATOR|RV Septal pacing|Patient with the pacemaker RV lead located at the RV septum.
62483781|NCT02258074|ACTIVE_COMPARATOR|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
62483782|NCT02258074|PLACEBO_COMPARATOR|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
62483783|NCT02653664|EXPERIMENTAL|Condition #1: PsychoEducation (ED)|Condition #1 will include 8 90-minute group sessions that will educate the subject about chronic pain, discuss the impact of pain, and inform the subject of different ways to manage it in hopes of decreasing pain and its impact on the subject's life. Participants in this condition will be given pre-recorded audio recordings of the content of the sessions to listen to.
62483784|NCT02653664|EXPERIMENTAL|Condition #2:Self-Hypnosis Training (HYP)|In condition #2, the facilitator will perform a standard hypnotic short induction followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the clinician read a standardized hypnotic script that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
61931445|NCT05901792|EXPERIMENTAL|Virtual Reality Games|VRGs group will receive games that focus on changing the position of the body center of gravity and improving balance levels.
61931446|NCT05901792|OTHER|Control group|As the control group, the cases on the waiting list will be evaluated.
62132715|NCT01939691|EXPERIMENTAL|Nepafenac plus Prednisolone acetate|Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
62483785|NCT02653664|EXPERIMENTAL|Condition #3: Mindfulness Meditation (MM)|In condition #3, the facilitator will teach participants Vipassana meditation, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Time will also be devoted to problem solving around any difficulties with MM practice.
62483786|NCT04418297|EXPERIMENTAL|CT-G20|
62483787|NCT04418297|PLACEBO_COMPARATOR|Placebo|
62483788|NCT06133816|EXPERIMENTAL|Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive)|Participants will receive two framed messages (AA) plus an incentive
62483789|NCT06133816|EXPERIMENTAL|Arm 2 (Introductory Message A + Tobacco Use Message A)|Participants will receive two framed messages (AA)
62483790|NCT06133816|EXPERIMENTAL|Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive)|Participants will receive two framed messages (AB) plus an incentive
62483791|NCT06133816|EXPERIMENTAL|Arm 4 (Introductory Message A + Tobacco Use Message B)|Participants will receive two framed messages (AB)
62483792|NCT06133816|EXPERIMENTAL|Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive)|Participants will receive two framed messages (BA) plus an incentive
61931447|NCT06226467|EXPERIMENTAL|N-ACT without delay|"After a baseline in-person assessment session (Week 1), participants randomly assigned to the experimental condition (i.e., N-ACT without delay) will complete one week of pre-intervention ecological momentary assessment (EMA; Week 2), then the intervention (Weeks 3-10), followed by a post-treatment in-person assessment session with comparable measures to baseline (Week 11) and a second week of (post-intervention) EMA (Week 12)."
61931448|NCT06226467|OTHER|Waitlist control|"Participants randomly assigned to the two-month waitlist control condition will be recontacted approximately 10 weeks after the baseline in-person assessment session (Week 1) to complete a second assessment session (with comparable measures) post-waitlist, prior to starting the N-ACT program. The post-waitlist assessment session (Week 11) after the waitlist period (Weeks 2-10) will precede a series of procedures equivalent to the experimental (N-ACT without delay) arm: One subsequent week of pre-intervention (post-waitlist) ecological momentary assessment (EMA; Week 12), then eight weeks of N-ACT (Weeks 13-20), followed by a third and final in-person (post-intervention) assessment (Week 21) with parallel procedures to the baseline and post-waitlist sessions, as well as a second week of EMA (Week 22). All study procedures are identical between the two trial arms, with the exception of an added eight-week waitlist and post-waitlist assessment for participants in the control condition."
61931449|NCT06708676|EXPERIMENTAL|Washed Microbiota Transplantation(WMT)|
61931450|NCT06708676|NO_INTERVENTION|Basic Treatment|
62339935|NCT06365671|EXPERIMENTAL|CAR-T following ASCT|Participants will receive high-dose chemotherapy followed by stem-cell infusion, and a fixed dose of CAR-T cells will be infused.
62483793|NCT06133816|EXPERIMENTAL|Arm 6 (Introductory Message B + Tobacco Use Message A)|Participants will receive two framed messages (BA)
62483794|NCT06133816|EXPERIMENTAL|Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive)|Participants will receive two framed messages (BB) plus an incentive
62483795|NCT06133816|EXPERIMENTAL|Arm 8 (Introductory Message B + Tobacco Use Message B)|Participants will receive two framed messages (BB)
61931451|NCT01583920|EXPERIMENTAL|Focal salvage HDR prostate brachytherapy|
61931452|NCT06253546|EXPERIMENTAL|Olanzapine Dose 1|"Period 1: Participants will receive oral olanzapine daily~Period 2: Participants will receive subcutaneous (sc) injection of TV-44749"
61931453|NCT06253546|EXPERIMENTAL|Olanzapine Dose 2|"Period 1: Participants will receive oral olanzapine daily~Period 2: Participants will receive sc injection of TV-44749"
62339936|NCT04296526|EXPERIMENTAL|Precontemplation|
62339937|NCT04296526|EXPERIMENTAL|Contemplation|
62339938|NCT04296526|EXPERIMENTAL|Preparation|
62692062|NCT06570070|EXPERIMENTAL|AI support group|AI-powered chatbot support+ 5A's/5R's advice + health warning leaflet+ Self-help booklet
62692063|NCT06570070|EXPERIMENTAL|Counselor support group|Counselor individual support+ 5A's/5R's advice + health warning leaflet+ Self-help booklet
62692064|NCT06570070|ACTIVE_COMPARATOR|Control group|5A's/5R's advice + health warning leaflet+ Self-help booklet
61931454|NCT06253546|EXPERIMENTAL|Olanzapine Dose 3|"Period 1: Participants will receive oral olanzapine daily~Period 2: Participants will receive sc injection of TV-44749"
62132716|NCT01939691|EXPERIMENTAL|Difluprednate plus Nepafenac|Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
62483796|NCT06133816|EXPERIMENTAL|Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive)|Participants will receive two framed messages (CA) plus an incentive
62483797|NCT06133816|EXPERIMENTAL|Arm 10 (Introductory Message C + Tobacco Use Message A)|Participants will receive two framed message (CA)
62132717|NCT05294393|PLACEBO_COMPARATOR|N/S 0.9%|Wound infiltration with 12 ml of N/S 0.9% at the end of surgery before wound closure
62339939|NCT01273415||hormone receptor-positive breast cancer|postoperative hormone receptor-positive breast cancer
62339940|NCT04305886|EXPERIMENTAL|Intervention|Providers were placed in small groups and given the intervention of a discussion guide to facilitate discussion.
62483798|NCT06133816|EXPERIMENTAL|Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive)|Participants will receive two framed messages (CB) plus an incentive
62483799|NCT06133816|EXPERIMENTAL|Arm 12 (Introductory Message C + Tobacco Use Message B)|Participants will receive two framed messages (CB)
62483800|NCT05073380|EXPERIMENTAL|Control|Outdoor play is an essential component of childhood development, including supporting children's cognitive, physical, emotional, and social growth. Currently, the YMCA early learning and child care centres (ELCCs) host children within childcare settings, with outdoor playtime governed by institutional regulations.
62483801|NCT05073380|SHAM_COMPARATOR|Intervention|"The PRO-ECO intervention to increase the quality of outdoor play involves four primary components:~1. Modifying YMCA GV's outdoor play policies The ELCC policy on outdoor play requirements and procedures will be modified in conjunction with YMCA management.~2. ECE training ECEs will undergo training delivered by YMCA of Southwestern Ontario that includes the importance of outdoor risky play, along with other online training tools along with resources on supporting outdoor play. There will also be ongoing as-needed supportive training and mentorship provided by YMCA senior managers and research team, along with peer mentorship and support.~3. ELCC outdoor space modification This includes designing and implementing tailored modifications for each centre's outdoor play space developed by landscape architecture students.~4. Parent engagement We will host parent-engagement events and opportunities to increase knowledge of the importance of outdoor play."
62483802|NCT03169062|EXPERIMENTAL|All patients|Gated Stationary Chest Tomosynthesis
62483803|NCT06531122|ACTIVE_COMPARATOR|apixaban|100 CVT patients will receive apixaban 5mg Bid for 6 months
62483804|NCT06531122|ACTIVE_COMPARATOR|rivaroxaban|100 CVT patients will receive rivaroxaban 20mg daily for 6 months
62483805|NCT01897207|EXPERIMENTAL|Dendritic cell application|
62483806|NCT06360887||Conservative|Participants allocated to conservative management will receive an orthosis (Gilchrist) for a minimum of four weeks. Using Gilchrist, the upper arm of the injured side is secured in abduction and internal rotation with the weight of the arm held by a ring around the patient's neck. At four weeks, plain radiographs of the shoulder will be conducted to ascertain the presence of the bony callous. If a bony callous is not present, the patient will maintain Gilchrist and plain radiographs of the shoulder will be conducted on a biweekly basis until a bony callous will be evident. If a bony callous is present, the patient will start a structured program of rehabilitation.
62483807|NCT06360887||Open Reduction Internal Fixation|Participants allocated to ORIF will undergo surgery within 72 hours from the diagnosis using a standard deltopectoral approach. An angular stable plate is used in all patients following manufacturer instructions. No drains will be used.
62132718|NCT05294393|ACTIVE_COMPARATOR|Ropivacaine 10%|Wound infiltration with 12 ml solution of 100mg ropivacaine at the end of surgery before wound closure
61931455|NCT06710340|OTHER|Nuts in the first meeting|"In the first session, after a 10-hour fasting, a high saturated fat meal with 30g of nuts will be offered.~In the second session, after a 10-hour fasting, a high saturated fat meal without 30g of nuts will be offered."
61931456|NCT06710340|PLACEBO_COMPARATOR|Nuts in the second meeting|"In the first session, after a 10-hour fasting, a high saturated fat meal without 30g of nuts will be offered.~In the second session, after a 10-hour fasting, a high saturated fat meal with 30g of nuts will be offered."
61931457|NCT02049320||Remifentanil|Patients sedated using Remifentanil
62132719|NCT05294393|EXPERIMENTAL|Ropivacaine 10% magnesium sulphate 10mg/kg|Wound infiltration with 12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery before wound closure
62132720|NCT01762059|EXPERIMENTAL|Bi-homonal Bionic Pancreas|Closed-loop blood glucose control with a bi-hormonal bionic endocrine pancreas designed by Edward Damiano and Firas El-Khatib of Boston University. The device will deliver insulin lispro (Humalog) and glucagon based on blood glucose levels estimated by a continuous glucose monitoring device (Dexcom G4 Platinum) and a proprietary dosing algorithm. Blood glucose control will be automated for 5 days during which volunteers will sleep in a hotel and roam freely in downtown Boston during the day. There will be no restrictions on diet or exercise.
62132721|NCT01762059|ACTIVE_COMPARATOR|Usual Care|Usual care for 5 days (insulin pump therapy according to usual practice), volunteers will sleep at home and maintain their usual schedule during the day, there will be no restrictions on diet or exercise, they will wear a blinded CGM
62132722|NCT03177824|EXPERIMENTAL|S|Sildenafil citrate (25mg)
62132723|NCT03177824|PLACEBO_COMPARATOR|P|placebo oral tablet
62132724|NCT06111586|EXPERIMENTAL|Frexalimab Dose 1|
62132725|NCT06111586|EXPERIMENTAL|Frexalimab Dose 2|
62132726|NCT06111586|EXPERIMENTAL|Frexalimab Dose 3|
62132727|NCT06111586|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62132728|NCT05783843|EXPERIMENTAL|Pictorial Warnings|Waterpipe tobacco packages shown with pictorial warnings about health harms of waterpipe smoking
62132729|NCT05783843|EXPERIMENTAL|Text Warnings|Waterpipe tobacco packages shown with text-only warning about health harms of waterpipe smoking
62132730|NCT05783843|EXPERIMENTAL|No Warnings (Control)|Waterpipe tobacco package shown without a warning
62132731|NCT01422603|EXPERIMENTAL|Clofarabine and Full intensity SCT|Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned allogeneic stem cell transplant (SCT).
62132732|NCT01422603|EXPERIMENTAL|Clofarabine and Reduced intensity SCT|Cohort 2: Patients not suitable for a full intensity TBI-based transplant due to age or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and Campath 1H.
62132733|NCT06152640|EXPERIMENTAL|dTMS treatment group|dTMS treatment group has 40 patients with dTMS intervention using real coils, targeting ACC, given once per day, for 28 days, with a total of 28 treatments.
61931458|NCT05625503|ACTIVE_COMPARATOR|Verapamil|Intra-arterial Verapamil 5 mg (2mL) diluted with 8 mL of normal saline
61931459|NCT05625503|PLACEBO_COMPARATOR|Nicardipine|Intra-arterial Nicardipine 400 mcg undiluted (8mL)
61931460|NCT01264016|EXPERIMENTAL|Intended Users of the Monitoring System|Untrained subjects with diabetes use an investigational blood glucose monitoring system.
61931461|NCT00861536|EXPERIMENTAL|ATG Fresenius|
61931462|NCT00861536|ACTIVE_COMPARATOR|Thymoglobuline Genzyme|
61931463|NCT04886284|EXPERIMENTAL|Ertapenem|Ertapenem 1g IV daily infused over 2 hours x 5 days
61931464|NCT04886284|PLACEBO_COMPARATOR|Placebo|Saline placebo infused daily over 2 hours x 5 days
61931465|NCT05861310|EXPERIMENTAL|Metronidazole 1% Group|Metronidazole 1% cream is applied to the entire face twice a day. Giving cream in the morning and at night. Evaluation will be carried out on days 28 and 56.
61931466|NCT05861310|EXPERIMENTAL|Placebo Group|Placebo cream (without the drug substance) is applied to the entire face twice a day. Giving cream in the morning and at night. Evaluation will be carried out on days 28 and 56.
61931467|NCT06373250|ACTIVE_COMPARATOR|Membrane stripping group|Participants in the membrane stripping group will be stripped at least once during labour. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the visual analogue scale and Bishop scores obtained during the vaginal examinations is taken. Bleeding will be assessed by weighing the pads at four hours postpartum. You will also be asked to complete the short form of the Birth Satisfaction Scale.
62132734|NCT06152640|SHAM_COMPARATOR|pseudo-stimulation group|Pseudo-stimulation group has 40 patients with dTMS intervention using sham coils (with the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field). It is given once per day, for 28 days, with a total of 28 treatments.
62132735|NCT05422846|EXPERIMENTAL|exercise protocol group|The group that applied progressive exercise according to the motivation of patients and healing status of ulcers.
62132736|NCT05422846|EXPERIMENTAL|aerobic exercise group|The group performing aerobic exercise with a bicycle ergometer
62132737|NCT05422846|EXPERIMENTAL|control group|The group to which standard applications of DFU treatment will be applied
62132738|NCT03716336|OTHER|aerobic exercise|walking on treadmill
62132739|NCT03716336|OTHER|resistive exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs
62132740|NCT04185636||Skin Graft Patients|There will only be 1 group, patients receiving a skin graft and MolecuLight i:X imaging
62132741|NCT01102725||Colorectal Surgery|Subject who are undergoing a colon or rectal resection
62132742|NCT05043272||Overweight population with basic diseases|Basic diseases include diabetes, hypertension.
62132743|NCT05043272||Overweight population with chronic liver diseases|Chronic liver diseases include chronic hepatitis ,liver cirrhosis, primary hepatocellular carcinoma.
61931468|NCT06373250|ACTIVE_COMPARATOR|Control group|Participants in the control group will not undergo any membrane stripping or other cervical interventions during labour, and other routine procedures will be carried out. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the visual analogue scale and Bishop scores obtained during the vaginal examinations is taken. Bleeding will be assessed by weighing the pads at four hours postpartum. You will also be asked to complete the short form of the Birth Satisfaction Scale.
61931469|NCT06296212|EXPERIMENTAL|TAD® 600 mg/4 mL Solution for Injection|TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
61931470|NCT06296212|PLACEBO_COMPARATOR|Saline solution of 0.9% sodium chloride|Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
61931471|NCT04234386|ACTIVE_COMPARATOR|Dose Level 1: 21 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
61931472|NCT04234386|ACTIVE_COMPARATOR|Dose Level 2: 24 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
61931473|NCT04234386|ACTIVE_COMPARATOR|Dose Level 3: 27 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
61931474|NCT04234386|ACTIVE_COMPARATOR|Dose Level 4: 30 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
61931475|NCT03645031|EXPERIMENTAL|ALS Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
62132744|NCT05043272||Healthy population|Control group
62339941|NCT04305886|NO_INTERVENTION|Control|Providers were placed in small groups and not given a discussion guide to facilitate discussion.
62697522|NCT06482034|ACTIVE_COMPARATOR|Group 5|Intervention Type: Other Intervention Name: Standard care (normal saline mouthwash) Other Intervention Names: Saline mouthwash Intervention Description: Patients will receive the institutional standard care, which is a normal saline mouthwash. The treatment will start 3 days before the beginning of radiotherapy and continue for 2 weeks after the completion of the radiotherapy schedule. Patients who develop any grade of oral mucositis will be treated according to the institutional standard treatment protocol.
61931476|NCT03645031|EXPERIMENTAL|Healthy Control Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
61931477|NCT05579691|EXPERIMENTAL|CTI-160l|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
61931478|NCT05579691|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62132745|NCT03312322|EXPERIMENTAL|CWT with high-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
62132746|NCT03312322|EXPERIMENTAL|CWT with low-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
62324896|NCT01226316|EXPERIMENTAL|Parts A,B,C,D Schedule 2, Intermittent dosing|Part A: Ascending doses of AZD5363 administered orally, twice daily, on a 7-day repeating regimen (4 days on, 3 days off and 2 days on, 5 days off), to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A (4 days on, 3 days off and 2 days on, 5 days off). Part C and D: AZD5363 orally, twice daily on an intermittent regimen (4 days on, 3 days off).
62324897|NCT01226316|EXPERIMENTAL|Parts A and B Schedule 3, Intermittent dosing.|"Part A: Ascending doses of AZD5363 administered orally, twice daily, on an alternative weekly regimen. Initiation of Schedule 3 is dependant on emerging clinical data.~Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A"
62324898|NCT01226316|EXPERIMENTAL|Parts E and F, Intermittent dosing with Fulvestrant|Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment to cessation of therapy combined with background therapy of fulvestrant at its licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter to cessation of therapy.
62324899|NCT05639751|EXPERIMENTAL|PRT3789 Monotherapy|PRT3789 will be administered by intravenous infusion
62324900|NCT05639751|EXPERIMENTAL|PRT3789/Docetaxel Combination|PRT3789 and Docetaxel will be administered by intravenous infusions
62324901|NCT04589845|EXPERIMENTAL|Cohort A: ROS1 Fusion-positive tumors (excluding NSCLC)|Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) \>/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA\<1.51 m2 will be lower.
62697523|NCT05882370|EXPERIMENTAL|SCALE|TIPS plus Cadonilimab
61931479|NCT00590798|EXPERIMENTAL|1|Patients are asked to walk within 30 minutes after implantation of the Star- Close vascular closure system.
61931480|NCT05432297|EXPERIMENTAL|Physical exercise intervention|The physical activity intervention is based on national guidelines of physical activity in cancer rehabilitation. A physiotherapist together with each patient will develop individual adaptations to the exercise protocol, with suggestions on which type of exercise the participant is able to perform depending on their daily condition. Suggestions on physical activity for good, bad and in-between-days will be listed in collaboration with the participant, and the participant will report number of minutes/day in each of the 3 physical activity levels stated.
61931481|NCT05432297|NO_INTERVENTION|Control|The control group will receive general advice on the importance of physical activity during oncologic treatment, according to local clinical standard.
61931482|NCT03851133||All Participants|Blood samples, tumor samples and data will be collected from all participants as applicable.
62132747|NCT03312322|EXPERIMENTAL|CWT with sham electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
62132748|NCT06214442||Physically active eumenorrheic women with regular menstrual cycle|Women who practice physical exercise and have regular menstruation ranging from 25 to 38 days.
62324902|NCT04589845|EXPERIMENTAL|Cohort B: NTRK1/2/3 fusion-positive tumors|Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA \>/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA\<1.51 m2 will be lower.
62324903|NCT04589845|EXPERIMENTAL|Cohort C: ALK fusion-positive tumors (excluding NSCLC)|Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.
62339942|NCT05597059||Shortness of breath|
62339943|NCT05597059||Extremity pathologies|
62339944|NCT05597059||Abdominal pain|
61931483|NCT00992329|EXPERIMENTAL|ciprofloxacin tab1|formulation 1
61931484|NCT00992329|EXPERIMENTAL|ciprofloxacin tab2|formulation 2
61931485|NCT00992329|EXPERIMENTAL|ciprofloxacin tab 3|formulation 3
61931486|NCT00992329|ACTIVE_COMPARATOR|ciprofloxacin reference|reference product
61931487|NCT05144204|EXPERIMENTAL|Irritable Bowel Syndrome Patients|
61931488|NCT05578872|EXPERIMENTAL|ANV419 single agent, dose 1, Q2W|
61931489|NCT05578872|EXPERIMENTAL|ANV419 single agent, dose 2, Q2W|
61931490|NCT05578872|OTHER|ANV419 + Pembrolizumab, Q3W|
61931491|NCT05578872|OTHER|ANV419 + Ipilimumab, Q3W|
61931492|NCT03034200|EXPERIMENTAL|Arm A: Metastatic PC-PG|625mg ONC201 will be given once weekly
61931493|NCT03034200|EXPERIMENTAL|Arm B: Other NETs|625mg ONC201 will be given once weekly
61931494|NCT03034200|EXPERIMENTAL|Arm C: PC-PG + other NETs|625mg ONC201 will be given on day 1 and day 2 of each week
61931495|NCT01743456|NO_INTERVENTION|Current practice (BIS and rSO2 blinded)|
61931496|NCT01743456|EXPERIMENTAL|Targeted intra-operative depth of anaesthesia|
61931497|NCT02035475|ACTIVE_COMPARATOR|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
61931498|NCT02035475|ACTIVE_COMPARATOR|Maryland Bipolar Cautery|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
61931499|NCT04738851|EXPERIMENTAL|healthy volunteers|Virtual mirror therapy task : TMV Classic mirror therapy task : TMC Control task :TC
61931500|NCT06019429|EXPERIMENTAL|HiRO plus judo|In this condition, students receive weekly classes aimed to promote social-emotional development. In addition, they will receive 6 judo classes.
61931501|NCT06019429|EXPERIMENTAL|HiRO|In this condition, students receive weekly classes aimed to promote social-emotional development.
61931502|NCT06019429|ACTIVE_COMPARATOR|School as usual|In this condition, students receive any amount of classes organized by their school to promote social-emotional development.
61931503|NCT06252636|ACTIVE_COMPARATOR|A2 Milk|A2 milk, 275 mL, twice daily after meal (550 mL/day)
61931504|NCT06252636|PLACEBO_COMPARATOR|A1/A2 Milk|A1/A2 milk, 275 mL, twice daily after meal (550 mL/day)
61931505|NCT06710392|EXPERIMENTAL|Digestive Enzyme Cocktail A|Arm receiving investigational product A
61931506|NCT06710392|EXPERIMENTAL|Digestive Enzyme Cocktail B|Arm receiving investigational product B
61931507|NCT06710392|PLACEBO_COMPARATOR|Placebo A|Arm receiving placebo A
61931508|NCT06710392|PLACEBO_COMPARATOR|Placebo B|Arm receiving Placebo B
61931509|NCT06701682|EXPERIMENTAL|Cohort A: vilobelimab|
61931510|NCT06701682|PLACEBO_COMPARATOR|Cohort A: placebo|
61931511|NCT02160353|EXPERIMENTAL|Combined hormonal therapy|Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day) for 126 days Prednisolone; 5mg/day (1 tablet orally once a day, concomitant to abiraterone acetate) for 126 days GnRh agonist for 4 injections (at 28 day intervals)
61931512|NCT06707090|EXPERIMENTAL|TR987 0.1% gel + Standard of Care|Participants will receive up to 16 weeks of TR987 0.1% gel topically + Standard of Care (wound cleansing/dressings and compression bandaging). Treatment will be twice weekly for the first four weeks then weekly for the remaining 12 weeks.
61931513|NCT06707090|OTHER|Standard of Care|
61931514|NCT06598800|EXPERIMENTAL|Phase 1a: Part A: Monotherapy Dose Escalation|Sequential cohorts of increasing dose levels of BG-T187 will be evaluated as monotherapy.
61931515|NCT06598800|EXPERIMENTAL|Phase 1a: Part B: Monotherapy Safety Expansion|BG-T187 dose levels that have been determined to be safe and tolerable in Part A will be investigated.
61931516|NCT06598800|EXPERIMENTAL|Phase 1b: Monotherapy Dose Expansion|The monotherapy dose expansion phase will begin once the BG-T187 monotherapy recommended dose for expansion (RDFE) and dosing schedule have been determined from Parts A and B in Phase 1a.
61931517|NCT06707948||Conservative treatment group|Non-steroidal anti-inflammatory and analgesic drugs
62697524|NCT05130801|EXPERIMENTAL|MRI and pHLIP® ICG|All study participants in Phase I will receive pre-operative MRI and mpMRI scans, a pre-operative injection of pHLIP ICG, and NIRF imaging during surgery (intra-operatively). During phase IIa of the study, if pHLIP® ICG NIRF imaging indicates tumor in areas outside of the planned resection area, biopsy samples will be taken from these areas and submitted for pathological analysis.
62697525|NCT00781261|PLACEBO_COMPARATOR|Control|Subjects in the control group will receive a placebo drug for a 1 year period
61931518|NCT06707948||Arthroscopic partial meniscectomy group|Arthroscopically, the damaged free meniscus is trimmed, ground, and partially resected;
61931519|NCT06707948||Arthroscopic meniscus suture repair group|Arthroscopic download of the posterior meniscus root injury, placement of sutures through the bone tunnel to fix the meniscus, and then cutting it with a knot to complete the meniscus suture repair.
61931520|NCT05557435|EXPERIMENTAL|Breast milk odor|Participants received breast milk odor before and during heel stick.
61931521|NCT05557435|PLACEBO_COMPARATOR|Placebo|Participants received placebo before and during heel stick.
61931522|NCT06709391|ACTIVE_COMPARATOR|Fusion surgery|Fusion surgery with implants
61931523|NCT06709391|SHAM_COMPARATOR|Non-fusion surgery|No fusion is performed. No implants are placed.
61931524|NCT03040973|EXPERIMENTAL|Capmatinib|Starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
61931525|NCT03040973|EXPERIMENTAL|Capmatinib + Nazartinib|Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
61931526|NCT03040973|EXPERIMENTAL|Capmatinib + Gefitinib|Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
61931527|NCT03040973|EXPERIMENTAL|Capmatinib + Osimertinib|Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
61931528|NCT06283394|NO_INTERVENTION|Usual Care|Participants in the usual care arm will not receive weekly subsidies on Instacart, and they will not receive any modifications to the virtual storefront on Instacart. They will have access to the standard Instacart platform and Instacart + memberships with a $5 per week to cover service and delivery fees and coverage of delivery tips for 3 months.
61931529|NCT06283394|EXPERIMENTAL|Non Choice Architecture (Arm A)|Arm A will receive a $160 subsidy per month for 3 months to be used on healthy foods (fruits and vegetables, whole grains, etc.). They will see the Instacart storefront without choice architecture manipulation and will see the discount applied at checkout. They will have Instacart + memberships for 3 months.
61931530|NCT06283394|EXPERIMENTAL|Choice Architecture (Arm B)|Arm B will receive a $160 subsidy per month for 3 months to be used on healthy foods (fruits and vegetables, whole grains, etc.). They will see a storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible) and will see the discount applied at checkout. They will have Instacart + memberships for 3 months.
62339945|NCT05597059||Urological pathologies|
62339946|NCT05597059||Chest pain|
62339947|NCT05597059||Back pain|
61931531|NCT06283394|EXPERIMENTAL|Non Choice Architecture + Loss Framing (Arm C)|Arm C will receive a $160 subsidy per month for 3 months to be used on produce.They will see the usual Instacart storefront and will see the discount applied at checkout. They will also receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following the end of the month). They will have Instacart + memberships.
61931532|NCT06283394|EXPERIMENTAL|Choice Architecture + Loss Framing (Arm D)|Arm D will receive a $160 subsidy per month for 3 months to be used on produce. They will see a storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible) and will see the discount applied at checkout. They will also receive text messages detailing how much of their $160 subsidy is left (as in arm C). They will have Instacart + memberships.
61931533|NCT03377114|ACTIVE_COMPARATOR|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
61931534|NCT03377114|EXPERIMENTAL|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
61931535|NCT05803382|EXPERIMENTAL|Treatment (ZEN003694, capecitabine)|Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.
61931536|NCT01054807|OTHER|GalyfilconHL/Galyfilcon8.7/Galyfilcon8.3|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)
61931537|NCT01054807|OTHER|Galyfilcon8.7/Galyfilcon8.3/GalyfilconHL|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
62324904|NCT04589845|EXPERIMENTAL|Cohort D: TMB-high tumors|"Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged \>/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \< 18 years on Day 1 of each 21-day cycle.~Note: Cohort D has been closed for enrollment"
62324905|NCT04589845|EXPERIMENTAL|Cohort E: AKT1/2/3 mutant-positive tumors|"Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \<35 kg, 300 mg for participants \>/= 35 and \<45 kg, 400 mg for those \>/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent.~Note: Cohort E has been closed for enrollment"
62324906|NCT04589845|EXPERIMENTAL|Cohort F: HER2 mutant-positive tumors|"Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.~Note: Cohort F has been closed for enrollment"
61931538|NCT01054807|OTHER|GalyfilconHL/Galyfilcon8.3/Galyfilcon8.7|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)
61931539|NCT01054807|OTHER|Galyfilcon 8.7/Galyfilcon HL/Galyfilcon 8.3|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator) /Galyfilcon A 8.3 BC (Experimental)
61931540|NCT01054807|OTHER|Galyfilcon8.3/GalyfilconHL/Galyfilcon8.7|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)
61931541|NCT01054807|OTHER|Galyfilcon8.3/Galyfilcon8.7/GalyfilconHL|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
61931542|NCT06683222|OTHER|Sub-group of 280 patients derived from the MONIKA study|
61931543|NCT03976245|ACTIVE_COMPARATOR|etanercept|etanercept 50 mg subcutaneously injected per week
61931544|NCT03976245|ACTIVE_COMPARATOR|tofacitinib|tofacitinib 5 mg orally daily
61931545|NCT04048200|OTHER|Control group|Anesthesia will be induced by fentanyl 1 ug/kg, propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The patients in this group will be connected to a syringe pump before induction of anesthesia that was prepared by anesthesia resident not participating in the study and contain normal saline and adjusted at a rate of 1 ml/kg/hr till the end of the surgery.
61931546|NCT04048200|EXPERIMENTAL|Opioid free anesthesia group|A syringe 50 ml was prepared by anesthesia resident not participating in the study and contain 100 ug of dexmedetomidine (2 ug/ml) and 25 mg ketamine 90.5 mg/ml) and 200 mg lidocaine (4 mg/ml). The syringe will be connected to the patients before induction of anesthesia at a rate of 0.1 ml/kg/hr according to the ideal body weight. Anesthesia will be induced by propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The syringe infusion will be continued till the end of peritoneal manipulation. Patients in this group will receive magnesium sulphate preload at a dose of 40 mg/kg ideal body weight followed by maintenance infusion of 10 mg/kg/hr.
62324907|NCT04589845|EXPERIMENTAL|Cohort G: MDM2-amplified, TP53 wild-type tumors|"Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle.~Note: Cohort G has been closed for enrollment"
62697526|NCT00781261|ACTIVE_COMPARATOR|Zoledronic Acid|Subjects in this intervention group will be given 5mg Zoledronic acid as a single injection
62324908|NCT04589845|EXPERIMENTAL|Cohort H: PIK3CA multiple mutant-positive tumors|"Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.~Note: Cohort H has been closed for enrollment"
62339948|NCT03348111|EXPERIMENTAL|Air-polishing device|Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®
61931547|NCT05889416|NO_INTERVENTION|Usual care|Implementation of national guidelines on secondary prevention according to local plan and preferences
62324909|NCT04589845|EXPERIMENTAL|Cohort I: BRAF class II mutant or fusion-positive tumors|"Participants with BRAF class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.~Note: Cohort I has been closed for enrollment"
62324910|NCT04589845|EXPERIMENTAL|Cohort J: BRAF class III mutant-positive tumors|"Participants with BRAF class III mutant-positive tumors(adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.~Note: Cohort J has been closed for enrollment"
62324911|NCT04589845|EXPERIMENTAL|Cohort K: RET fusion-positive tumors (excluding NSCLC)|"Participants with RET fusion-positive tumors will self-administer Pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).~Note: Cohort K has been closed for enrollment"
62324912|NCT04589845|EXPERIMENTAL|Cohort L: KRAS G12C-positive tumors (excluding NSCLC and CRC)|Participants with KRAS G12C-positive tumors will self-administer GDC-6036 orally at home (except on clinic days).
61931548|NCT05889416|ACTIVE_COMPARATOR|Audit and feedback|Audit and feedback on implementation of national guidelines on secondary prevention through the national quality registry SWEDEHEART
61931549|NCT05889416|ACTIVE_COMPARATOR|Implementation support|Audit and feedback through the national quality registry SWEDEHEART and structured implementation support for implementation of national guidelines on secondary prevention
61931550|NCT05050084|EXPERIMENTAL|Arm I (RT)|Patients undergo RT using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity.
61931551|NCT05050084|EXPERIMENTAL|Arm II (RT, ADT)|Patients undergo RT as Arm I. Patients also receive ADT consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days.
61931552|NCT05050084|EXPERIMENTAL|Arm III (RT, ADT)|Patients receive treatment as in Arm II.
61931553|NCT05050084|EXPERIMENTAL|Arm IV (RT, ADT, darolutamide)|Patients receive RT and ADT as in Arm II. Patients also receive darolutamide PO BID on days 1-90. Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
61931554|NCT01387399|EXPERIMENTAL|Cisplatin as HIPEC|Phase I dose escalating study of cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
61931555|NCT04718103|EXPERIMENTAL|GSK3511294|Participants received a 100 milligram (mg) dose of GSK3511294 subcutaneous (SC) injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.
61931556|NCT04718103|PLACEBO_COMPARATOR|Placebo|Participants received placebo SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma SOC treatment throughout the study.
61931557|NCT04981067|OTHER|Sciatic nerve block using same or decreased concentration of local anesthetic|If the sciatic nerve block in the previous participant was successful, the concentration of local anesthetic would be maintained or decreased 0.05% in the next patient based on a random assignment.
61931558|NCT04981067|OTHER|Sciatic nerve block using increased concentration of local anesthetic|If the sciatic nerve block in the previous participant was not successful, the concentration of local anesthetic would be increased 0.05% in the next patient.
61931559|NCT00365144|EXPERIMENTAL|Bevacizumab Plus Erlotinib Hydrochloride|"A treatment cycle is 21 days:~bevacizumab 15 mg/kg as a 60-90 min infusion once every 21 days, with erlotinib hydrochloride 150 mg by mouth daily"
61931560|NCT05484908|EXPERIMENTAL|DPMAS+LPE group|30 patients receive treatment of DPMAS, LPE, and comprehensive internal medical treatment.
61931561|NCT05484908|ACTIVE_COMPARATOR|PE group|30 patients receive treatment of PE and comprehensive internal medical treatment.
61931562|NCT06369467|EXPERIMENTAL|Severe IgE-mediated food allergy|
61931563|NCT05368090|EXPERIMENTAL|EUS-RFA of PA with AVS-verified left lateralisation|PA patients with AVS-confirmed lateralisation to the left adrenal and signed study consent will be included in this study group. EUS will be performed. If EUS identifies an adrenal nodule in the left adrenal, EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure will be performed. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.
62132749|NCT06214442||Sedentary eumenorrheic women with regular menstrual cycle|Women who do not practice physical exercise and have regular menstruation ranging from 25 to 38 days.
62132750|NCT06214442||Physically active women using hormonal contraceptives|Physically active women using oral hormonal contraception combined with estrogen and progesterone within the last six months.
62132751|NCT06214442||Sedentary women who use hormonal contraception|Sedentary women using oral hormonal contraception combined with estrogen and progesterone within the last six months.
62324913|NCT04589845|EXPERIMENTAL|Cohort M: ATM Loss of Function tumors|Participants with ATM Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).
62324914|NCT04589845|EXPERIMENTAL|Cohort N: SETD2 Loss of Function tumors|Participants with SETD2 Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).
62324915|NCT04567238|EXPERIMENTAL|Reduced Use Condition|Participants in the reduced use condition will be provided mobile contingency management, in which they are paid to provide marijuana saliva readings that suggest they have been abstinent from marijuana use.
62324916|NCT04567238|NO_INTERVENTION|Control Condition|Participants in the control condition will be asked to provide marijuana saliva readings, but they are not paid for abstinent readings. Instead, their payments are yoked to the average amount of payment made by two participants in the reduced use condition.
62483808|NCT06360887||Closed Reduction Percutaneous Pinning|Participants allocated to CRPP will be positioned in a beach chair under total anesthesia. The fracture is repositioned under fluoroscopic guidance using manual traction. The osteosynthesis is then done using Kirschner wires.The arm is placed into a Gilchrist for four weeks. At four weeks, plain radiographs of the shoulder will be conducted to ascertain the presence of the bony callous. If a bony callous is not present, the patient will maintain Gilchrist and plain radiographs of the shoulder will be conducted on a biweekly basis until a bony callous will be evident. If a bony callous is present, the Kirschner wires will be removed and the patient will start a structured program of rehabilitation.
62483809|NCT03740295|PLACEBO_COMPARATOR|Control Multiple Sclerosis|
62483810|NCT03740295|EXPERIMENTAL|Intervention Multiple Sclerosis|
62483811|NCT06560567||Prosthetics and Orthotics Professionals|A total of 131 participants, 29 female and 102 male, aged at least 18 and at most 65 years old, completed the survey. The inclusion criteria for the participants were determined as working in an Orthosis and Prosthesis Application Center and being 18 years of age or older.
62483812|NCT05054777||oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques
62483813|NCT05054777||conventional breast-conserving surgery|The conventional breast-conserving surgery were performed without any oncoplastic operations
62483814|NCT05646823|PLACEBO_COMPARATOR|Placebo|vehicle only - Maltodextrin gluten free
62483815|NCT05646823|EXPERIMENTAL|Treatment|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
62483816|NCT06627712|EXPERIMENTAL|SBRT+PD-1 Inhibitor + Chemotherapy|"Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
61931564|NCT05368090|EXPERIMENTAL|"EUS-RFA of PA without verified left lateralisation, for aldosterone debulking"|PA patients with suspicion of aldosterone overproduction in their left adrenal, but without fulfilling the strict AVS lateralization criteria, either due to a non-representative AVS, or a representative AVS but without significant left-sided lateralization (LI \< 4), and where the study investigators consider EUS-RFA treatment as an aldosterone-reducing procedure to be of high potential clinical and biochemical benefit for the patient, will be included in this study group after signed consent. EUS will be performed. If EUS identifies an adrenal nodule in the left adrenal, an EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.
61931565|NCT05368090|EXPERIMENTAL|EUS-RFA of MACS with left lateralisation and left adrenal tumour|MACS patients with AVS-confirmed lateralisation the left adrenal gland and CT showing left-sided tumour will be included in this study group after signed consent. EUS will be performed, and a EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.
61931566|NCT05368090|EXPERIMENTAL|EUS-RFA of MACS with bilateral cortisol overproduction and bilateral tumours|MACS patients with AVS-confirmed bilateral cortisol overproduction and bilateral tumours will be included in this study group after signed study consent. EUS will be performed, and EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.
61931567|NCT05948930|EXPERIMENTAL|Aerobic Exercise|Progressive aerobic exercise 3x/week for 12 weeks.
62324917|NCT06118515|EXPERIMENTAL|Group 1|Neonates (\</= 21 days) with symptomatic congenital Cytomegalovirus (CMV) disease will receive one dose of oral letermovir, using weight dose banding. All subjects also will receive valganciclovir as standard of care. A dose safety evaluation will occur to ensure the safety data support subjects proceeding. If the observed letermovir exposure is \</= 100,000 ngxhr/mL, the subject will initiate a 14-day course of once-daily oral letermovir at the same dose as utilized on the Dose Finding Day. If the observed letermovir exposure of the subject is \> 100,000 ngxhr/mL, the once-daily oral letermovir dose that will be used will be adjusted down in 2.5 mg increments from the dose utilized on the Dose Finding Day. N = 4
62324918|NCT06118515|EXPERIMENTAL|Group 2|Neonates (\</= 28 days) with symptomatic congenital Cytomegalovirus (CMV) disease will initiate a 14-day course of once-daily oral letermovir, using weight dose banding. All subjects also will receive valganciclovir as standard of care. A dose escalation safety evaluation will occur to ensure the safety data support subjects proceeding. If the median of observed letermovir exposures of subjects in Group 1 is below 34,400 ngxhr/mL (or above 100,000 ngxhr/mL), then the subjects enrolled in Group 2 will receive once-daily oral letermovir at a dose that has been adjusted upward (or downward) in 2.5 mg increments. N=8
62324919|NCT05926739|OTHER|Standard of care plus additional questionaire|As part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an endof- life visit and validated questionnaires assessing functional deficiencies and impact on daily life.
62324920|NCT06201689|PLACEBO_COMPARATOR|Placebo Control 1|Energy Product Form 1 - control
62483817|NCT06627712|PLACEBO_COMPARATOR|PD-1 Inhibitor + Chemotherapy|"Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
62483818|NCT06559202||CT group|Participants who underwent chest and abdominopelvic computed tomography on the same day for health screening purposes
62483819|NCT00669721|EXPERIMENTAL|A|This patients start a run in period with LMWH schedule as hemodialysis circuit anticoagulation. Then they'll undergo hemodialysis with LMWH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to UFH schedule. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
61931568|NCT05948930|EXPERIMENTAL|Cognitive Training|Adaptive cognitive training on Cogmed 5x/week for a total of 25 sessions in 5-8 weeks.
61931569|NCT05948930|EXPERIMENTAL|Combined Cognitive and Aerobic Exercise|Combined progressive aerobic exercise 3x/week for 12 weeks and adaptive cognitive training on Cogmed 5x/week for a total of 25 sessions in 5-8 weeks simultaneously.
62692065|NCT04498767|ACTIVE_COMPARATOR|Arm 1: Standard of Care + palliative RT|"Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).~Systemic therapy will be pre-specified based on the standard of care approach for that patient, and it may include cytotoxic, targeted, hormonal, or immunotherapy."
61931570|NCT02111941|EXPERIMENTAL|Treatment (vaccine therapy)|"INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity."
61931571|NCT06708884|EXPERIMENTAL|Group 1: TR Group|TR: telerehabilitation. During the follow-up period, a standard exercise programme will be applied to the TR group via videoconference-based telerehabilitation.
61931572|NCT06708884|EXPERIMENTAL|Group 1: F2F Group|F2F: face to face. During the follow-up period, a standard exercise programme will be applied to the F2F group via face to face rehabilitation.
61931573|NCT05760612|ACTIVE_COMPARATOR|Trastuzumab combined with Parstuzumab|Trastuzumab（6mg/KG） and Parstuzumab（420mg/ONCE），once every three weeks，18 times in total with preoperative treatment
61931574|NCT05760612|EXPERIMENTAL|Trastuzumab combined with nelatinib|Trastuzumab（6mg/KG), once every three weeks, 18 times in total with preoperative treatment, during Trastuzumab treatment, take nelatinib（240mg） per day during treatment.
61931575|NCT02617784|EXPERIMENTAL|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
61931576|NCT02617784|EXPERIMENTAL|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
61931577|NCT06323707|EXPERIMENTAL|Exercise & Self-Management|
61931578|NCT06323707|EXPERIMENTAL|Self-Management Only|
61931579|NCT06323707|NO_INTERVENTION|Usual Care|
61931580|NCT06581796||Study group|pregnant women with hyperemesis gravidarum
61931581|NCT06581796||Control group|pregnant women without hyperemesis gravidarum
61931582|NCT04648254|EXPERIMENTAL|Dose escalation (Q702)|Participants will receive escalating doses of Q702
61931583|NCT03126877|EXPERIMENTAL|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
62692066|NCT04498767|EXPERIMENTAL|Arm 2: Standard of Care + SBRT|"The experimental arm consists of SBRT (and standard of care systemic therapy). Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.~Patients treated with prior or concomitant systemic therapy are eligible for this study. Use of chemotherapy regimens, targeted therapy or immunotherapy containing potent enhancers of radiation damage (e.g. gemcitabine, doxorubicin) can be postponed or interrupted for a duration of one month after radiation."
61931584|NCT03126877|ACTIVE_COMPARATOR|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
61931585|NCT06619080|ACTIVE_COMPARATOR|Group 1: Block with 0.5% bupivacaine and corticosteroid (triamcinolone).|Injection Doses: 2.5 mL of 0.5% bupivacaine + 20 mg of triamcinolone.
62692067|NCT06643013|EXPERIMENTAL|XBD173 then Placebo|
62692068|NCT06643013|EXPERIMENTAL|Placebo then XBD173|
62132752|NCT04413838|EXPERIMENTAL|NIVOLUMAB on top of routine standard of care|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin \< 9.2 g/dl AND a blood platelets \< 110000/mm3 AND aspartate aminotransferase (AST) \> 30 U/l AND ferritin \> 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a NIVOLUMAB treatment and routine standard of care for COVID-19 infection at the time of study inclusion
62692069|NCT00962338||lap. inguinal herniorrhaphy|Patients undergoing planned lap. inguinal herniorrhaphy
61931586|NCT06619080|ACTIVE_COMPARATOR|Group 2: Block with 0.5% bupivacaine.|Injection Doses: 2.5 mL of 0.5% bupivacaine.
61931587|NCT06619080|PLACEBO_COMPARATOR|Group 3 (Control): Block with saline solution.|Injection Doses: 2.5 mL of saline solution.
62324921|NCT06201689|EXPERIMENTAL|Active Product 1.1|Energy Product Form 1 - active product 1
62324922|NCT06201689|EXPERIMENTAL|Active Product 1.2|Energy Product Form 1 - active product 2
62324923|NCT06201689|PLACEBO_COMPARATOR|Placebo Control 2|Energy Product Form 2 - control
62692070|NCT06641934||Chemotherapy-Related Myelosuppression|Chemotherapy-Related Myelosuppression Clinical Management
61931588|NCT05672108|EXPERIMENTAL|Lung chemoembolization|Patients receive lipiodol intra-arterially (IA), mitomycin IA, and embospheres IA and undergo TACE on study. Patients also undergo angiography and computed tomography (CT) at baseline and follow up.
61931589|NCT05177211|EXPERIMENTAL|Treatment with Fedratinib|Participants will taken Fedratinib by mouth once a day every day of each 28 day cycle.
61931590|NCT06236425|OTHER|TIL Harvest/Standard of care Treatment Phase|Participants will undergo tumor harvest for TIL and then receive 2 to 3 cycles of pembrolizumab or pembrolizumab/platinum chemotherapy (cisplatin or carboplatin / 5-FU) as per standard of care.
61931591|NCT06236425|EXPERIMENTAL|TBio-4101 Treatment|Participants without radiographic response (progressive disease) after pembrolizumab or pembrolizumab/platinum chemotherapy, and who meet eligibility requirements, will transition to receive TBio-4101. Participants will receive TBio-4101 infusion and after completion of TBio-4101 infusion, IL-2 will be administered every 8 hours, for up to 6 doses. Finally, pembrolizumab will be administered on Day 14, Day 35, and Day 56 and Q6W (beginning Week 12) thereafter for up to 2 years until discontinuation.
61931592|NCT06710119|NO_INTERVENTION|No Visual Feedback|Participants will receive typical accommodation training after being prescribed the CDO.
61931593|NCT06710119|ACTIVE_COMPARATOR|Provided Visual Feedback|Participants will receive typical accommodation training with additional visual feedback after being prescribed the CDO.
61931594|NCT02754544|EXPERIMENTAL|Diagnostic (electrocorticography)|Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.
61931595|NCT05169073|EXPERIMENTAL|Virtual Reality MRCP|The MRCP images will be transferred into a 3D VR rendering software (Specto VR TM) for each patient. Residents will have the opportunity to use the virtual reality environment the day before surgery until a sufficient understanding of the anatomy is achieved.
61931596|NCT05169073|ACTIVE_COMPARATOR|Conventional MRCP|Controls will have regular access to the conventional MRCP images.
61931597|NCT05793437|EXPERIMENTAL|permissive hypercapnia|Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
61931598|NCT05793437|ACTIVE_COMPARATOR|normocapnia|Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
61931599|NCT03476668|ACTIVE_COMPARATOR|RPD PD patients|Right-side affected PD patients. Intervention: MIRT
61931600|NCT03476668|ACTIVE_COMPARATOR|LPD PD patients|Left-side affected (LPD) PD patients. Intervention: MIRT
61931601|NCT01580514|ACTIVE_COMPARATOR|Exenatide|"Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
62692071|NCT06641934||Chemotherapy-related myelosuppression, primary prevention, treatment rate and clinical management|Chemotherapy-related myelosuppression, primary prevention, treatment rate and clinical management
61931602|NCT01580514|PLACEBO_COMPARATOR|Saline|"Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
61931603|NCT06370091|EXPERIMENTAL|G1: Gum of Xylitol|They will consume chewing gum with xylitol (Xylichew), and stimulated saliva will be collected at three time intervals: T2 from 5 to 10 minutes, T3 from 15 to 20 minutes, and T4 from 25 to 30 minutes after the start of chewing gum consumption
61931604|NCT06370091|ACTIVE_COMPARATOR|G2: Gum of sugar free|They will consume sugar-free chewing gum (Trident), and stimulated saliva will be collected at three time intervals: T2 from 5 to 10 minutes, T3 from 15 to 20 minutes, and T4 from 25 to 30 minutes after the start of chewing gum consumption
61931605|NCT06370091|ACTIVE_COMPARATOR|G3: Gum of sugar|Formed by participants who will chew sugared gum (Agogó), and stimulated saliva will be collected at three time intervals: T2 from 5 to 10 minutes, T3 from 15 to 20 minutes, and T4 from 25 to 30 minutes after the start of chewing gum consumption
62692072|NCT06641934||Chemotherapy-induced myelosuppression, secondary prevention, treatment rates, and clinical managemen|no intervention
61931606|NCT06370091|PLACEBO_COMPARATOR|G4: paraffin wax|The control group will chew paraffin wax (Dentek), and stimulated saliva will be collected at three time intervals: T2 from 5 to 10 minutes, T3 from 15 to 20 minutes, and T4 from 25 to 30 minutes after the start of chewing paraffin wax
62324924|NCT06201689|EXPERIMENTAL|Active Product 2.1|Energy Product Form 2 - active product 1
62692073|NCT06328569|EXPERIMENTAL|Virtual Reality group|conventional dysphagia treatment and Virtual Reality Therapy are provided
62692074|NCT06328569|ACTIVE_COMPARATOR|conventional dysphagia treatment group|conventional dysphagia treatment is provided
62692075|NCT06405581||Edmonton frailty scale ≥ 7|"The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile"
62692076|NCT06405581||Edmonton frailty scale below 7|"The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile"
62692077|NCT01344655|EXPERIMENTAL|Formoterol 12 μg pMDI (Atimos®)|
62692078|NCT01344655|ACTIVE_COMPARATOR|Salmeterol 25 µg pMDI HFA (Serevent™)|
61931607|NCT05156073|EXPERIMENTAL|Intervention|"The intervention consists of providing educational materials on deprescribing to:~1. Patient and care partner cohort~2. Primary care physician cohort"
61931608|NCT04866771|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|Facilitatory transcranial direct current stimulation (tDCS)
61931609|NCT04866771|SHAM_COMPARATOR|Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group|Sham tDCS followed by a switch to anodal tDCS.
62324925|NCT06201689|PLACEBO_COMPARATOR|Placebo Control 3|Energy Product Form 3 - control
62324926|NCT06201689|EXPERIMENTAL|Active Product 3.1|Energy Product Form 3 - active product 1
62324927|NCT06201689|PLACEBO_COMPARATOR|Placebo Control 4|Energy Product Form 4 - control
61931610|NCT06708897|EXPERIMENTAL|ZE50-0134 Dose Level -1|Optional and would only be performed Dose Level 1 is poorly tolerated
61931611|NCT06708897|EXPERIMENTAL|ZE50-0134 Dose Level 1|
61931612|NCT06708897|EXPERIMENTAL|ZE50-0134 Dose Level 2|
61931613|NCT06708897|EXPERIMENTAL|ZE50-0134 Dose Level 3|
62324928|NCT06201689|EXPERIMENTAL|Active Product 4.1|Energy Product Form 4 - active product 1
62324929|NCT06201689|EXPERIMENTAL|Active Product 4.2|Energy Product Form 4 - active product 2
61931614|NCT06708897|EXPERIMENTAL|ZE50-0134 Dose Level 4|
61931615|NCT06708897|EXPERIMENTAL|ZE50-0134 Dose Level 5|
61931616|NCT06708897|EXPERIMENTAL|ZE50-0134 Selected dose 1|The doses used in Part 2 of the study will be determined based on the data from Part 1 of the study
61931617|NCT06708897|EXPERIMENTAL|ZE50-0134 Selected dose 2|The doses used in Part 2 of the study will be determined based on the data from Part 1 of the study
61931618|NCT05270213|EXPERIMENTAL|Treatment Group A-1|For Treatment Group A-1, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418. Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
61931619|NCT05270213|EXPERIMENTAL|Treatment Group A-2|For Treatment Group A-2, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418 in combination with pembrolizumab 200 mg IV (administered on Day 1 and every 3 weeks). Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
61931620|NCT05270213|EXPERIMENTAL|Treatment Group B|After dose escalation phase is completed in both monotherapy and combination therapy setting (A-1 and A-2), an expansion treatment group will be enrolled, and subjects (n=20- 40) will be treated with a fixed dose of RBS2418 to be selected by the Sponsor in consultation with the SRC and after reviewing the totality of the dose escalation data both as monotherapy and combination therapy.
61931621|NCT06496503|EXPERIMENTAL|Experimental group|The children included in the experimental group will undergo 12 weeks of physical activity sessions, and it is mandatory that all children complete a minimum of two weekly sessions of physical activity for 50-60 minutes. The activities will consist of content such as motor and cognitive games, sports, dance, and gymnastics. The intensity of the sessions will be checked using accelerometry. The physical activity protocol is adapted from a previously described protocol (CMSP, 2021; Klem, Filha, Monteiro, 2017; Mazzoccante et al.; 2020; Paiano, 2019; Rodrigues, 2018; Rosini et al., 2014). Acceptance of the exercise program in the pediatric population has been previously observed in a pilot study.
61931622|NCT06496503|NO_INTERVENTION|Control group|The children will follow their usual school routines, including Physical Education classes as part of the curriculum
62132753|NCT04413838|OTHER|Standard of care for COVID-19 infection|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin \< 9.2 g/dl AND a blood platelets \< 110000/mm3 AND AST \> 30 U/l AND ferritin \> 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a routine standard of care for COVID-19 infection at the time of study inclusion
62132754|NCT00818246|SHAM_COMPARATOR|Sham light|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with a Sham light on the experimental periorbital area
62132755|NCT00818246|EXPERIMENTAL|LED-treated|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with 660 nm Light emitting diode (LED) on the experimental periorbital area
62324930|NCT06201689|EXPERIMENTAL|Active Product 4.3|Energy Product Form 4 - active product 3
62324931|NCT06201689|EXPERIMENTAL|Active Product 5.1.0|Energy Product Form 5.0 - active product 1
62324932|NCT06201689|PLACEBO_COMPARATOR|Placebo Control 5.1.1|Energy Product Form 5.1 - control
62483820|NCT00669721|ACTIVE_COMPARATOR|B|The patients randomized to receive UFH will start a run in period with this heparin schedule. Then they'll undergo hemodialysis with UFH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to LMWH. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
62324933|NCT04533750|EXPERIMENTAL|Treatment (peposertib, IMRT)|Beginning 60-90 minutes before each radiation treatment, patients receive peposertib PO QD and undergo IMRT daily Monday-Friday for 7 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, or 18F-FDG PET/CT during screening and follow-up.
62324934|NCT04300920|EXPERIMENTAL|N-acetylcysteine|600 mg oral N-acetylcysteine (NAC) three times daily for 24 months.
62483821|NCT01634139|EXPERIMENTAL|Tiotropium high dose QD|
62692079|NCT01344655|PLACEBO_COMPARATOR|Matched Placebo|
61931623|NCT02722525|EXPERIMENTAL|Diagnostic (cardiac MRI, skeletal muscle PMRS)|Patients undergo a treadmill stress CMR focused on cardiac muscle comprised of resting MRI over 10-15 minutes followed by treadmill exercise until peak stress. Patients then undergo MRI and gadopentetate dimeglumine perfusion imaging immediately after exercise and after a 6-8 minute recovery period. Within 24 hours of treadmill CMR exam, patients also undergo skeletal muscle PMRS while at rest, during, and in the recovery phase of resistive lower extremity exercise which patients complete over 30 seconds. Both procedures are performed before initiation of ADT treatment (baseline) and 4-7 months after initiation of ADT treatment.
62483822|NCT01634139|EXPERIMENTAL|Tiotropium low dose QD|
62132756|NCT02492516|EXPERIMENTAL|Stem cell|The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell.
62324935|NCT04300920|PLACEBO_COMPARATOR|Placebo|Placebo tablet three times daily for 24 months.
62324936|NCT06094062|EXPERIMENTAL|Intervention Group|
62324937|NCT06064097|EXPERIMENTAL|Treatment (nivolumab, gemcitabine, cisplatin, radiattion)|See Detailed Description
62324938|NCT05827016|EXPERIMENTAL|Arm A1: Iberdomide Dose 1|
62324939|NCT05827016|EXPERIMENTAL|Arm A2: Iberdomide Dose 2|
62324940|NCT05827016|EXPERIMENTAL|Arm A3: Iberdomide Dose 3|
62324941|NCT05827016|ACTIVE_COMPARATOR|Arm B: Lenalidomide|
62483823|NCT01634139|EXPERIMENTAL|Placebo QD|
62483824|NCT01488435|PLACEBO_COMPARATOR|Cow's Milk|Powdered whole cow's milk
62483825|NCT01488435|EXPERIMENTAL|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
62692080|NCT06501976|EXPERIMENTAL|Experimental Treatment: Lurbinectedin combined with Thoracic Radiotherapy|Patients receive 2 cycles of lurbinectedin 2.6 mg/m2 combined with thoracic radiotherapy followed by 2 cycles of lurbinectedin 2.6 mg/m2 alone. Patients receive lurbinectedin intravenously (IV) over 1 hour on day 1 of each cycle.
62692081|NCT06644521||Group 1: COVID-19 group|
62692082|NCT06644521||Group 2: Control|
62324942|NCT06269367|EXPERIMENTAL|NewGait|Participants will put on the NewGait device and walk on the treadmill and overground. Participants may receive biofeedback of their gait patterns to engage them in the training.
62692083|NCT01327729|ACTIVE_COMPARATOR|YPEG-IFN α-2a one week|this arm will be treated with: YPEG-IFN α-2a 180mcg/ week for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
61931624|NCT00562627|EXPERIMENTAL|LIA IV|Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine
61931625|NCT00562627|EXPERIMENTAL|LIA IA|Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine
61931626|NCT00562627|ACTIVE_COMPARATOR|EDA|standard continuous epidural analgesia
61931627|NCT02210273|EXPERIMENTAL|Treatment|Subjects undergoing treatment with the Solace Bladder Control (Vesair) Balloon on day 0
61931628|NCT02210273|SHAM_COMPARATOR|Solace Sham Treatment|Subjects undergoing sham treatment on day 0, and treatment with the Solace Bladder Control (Vesair) Balloon at 3 months
61931629|NCT03584152|ACTIVE_COMPARATOR|Drug Arm A|Norco 5mg-325 mg Tablet, administered orally every 4 hours for 5 days total
61931630|NCT03584152|ACTIVE_COMPARATOR|Drug Arm B|Tylenol 325 mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
61931631|NCT06201416|EXPERIMENTAL|SBT777101 Dose 1|Low dose SBT777101
61931632|NCT06201416|EXPERIMENTAL|SBT777101 Dose 2|Mid dose SBT777101
61931633|NCT06201416|EXPERIMENTAL|SBT777101 Dose 3|High dose SBT777101
62692084|NCT01327729|ACTIVE_COMPARATOR|YPEG-IFN α-2a Ten days|this arm will be treated with: YPEG-IFN α-2a 180mcg/10 days for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
61931634|NCT06115668|ACTIVE_COMPARATOR|Positive end-expiratory pressure 5 (PEEP 5)|Patients will receive fixed positive end-expiratory pressure(= 5 cmH2O) as a control group
61931635|NCT06115668|EXPERIMENTAL|Individualized positive end-expiratory pressure (PEEPIND)|Patients who will receive the individualized positive end-expiratory pressure.
61931636|NCT06225817|EXPERIMENTAL|Open label placebo arm|Participants who are assigned to the OLP group will be given a bottle of OLP pills. They will be asked to take one pill per day for 45 days. They will be introduced to placebo effects and the therapeutic potential of using open-label placebo for chronic pain management and sleep improvement.
61931637|NCT06225817|NO_INTERVENTION|Wait-list arm|Participants in the wait-list group will not receive OLP pills until the end of the 45-day monitoring period. Therefore, the 45 days without OLP will serve as an no intervention comparators relative to the OLP group.
61931638|NCT06706895|EXPERIMENTAL|Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules|"Fruquintinib Capsules：4 mg / day, orally once daily on days 1-14 in 21-day cycles. If the patient has AE of grade 3 or above, the dose of fruquintinib capsules is reduced to 3 mg / day(dose discontinuation to dose reduction).~Paclitaxel Polymeric Micelles for Injection：150mg / m2 intravenously over 3 hours on Days1,8 of each 21-day cycle. Do not need special infusion device.~Paclitaxel Polymeric Micelles for Injection and Fruquintinib Capsules are used for 6 cycles. Subsequently, dual-drug or single-drug maintenance therapy was selected according to the tolerance of the patients. Subsequently, Paclitaxel Polymeric Micelles for Injection ( 120mg / m2, if the patient is intolerable, the dose can be reduced to 100mg / m2 ), until occur the disease progress, the intolerant toxicity or the patient withdrawal."
61931639|NCT06040528||Patients discharged on the Early Discharge Pathway at Barts Heart Centre|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with acute coronary syndrome who are admitted to Barts Heart Centre and are discharged via the early discharge pathway.
61931640|NCT05907122|EXPERIMENTAL|ABP 206|Subjects will receive Dose A of ABP 206 via intravenous (IV) infusion.
61931641|NCT05907122|ACTIVE_COMPARATOR|FDA-licensed Nivolumab|Subjects will receive Dose A of FDA-licensed Nivolumab via IV infusion.
62324943|NCT06269367|OTHER|Control|Participants will put on the Control device and walk on the treadmill and over ground. Participants may receive biofeedback of their gait patterns to engage them in the training.
62324944|NCT01323322||HANDLS|A fixed cohort as an area probability sample of Baltimore City from August 2004 through November 2009.
62339949|NCT03573128|EXPERIMENTAL|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
62339950|NCT03573128|ACTIVE_COMPARATOR|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
61931642|NCT05907122|ACTIVE_COMPARATOR|EU-authorized Nivolumab|Subjects will receive Dose A of EU-authorized Nivolumab via IV infusion.
61931643|NCT04938349|EXPERIMENTAL|Single session dual task perturbation training-OAwMCI|Participants will receive single session training of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
61931644|NCT04938349|EXPERIMENTAL|Multiple session dual task perturbation training-OAwMCI|All participants will undergo stance and walking perturbation training for 4 weeks. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
62339951|NCT05755334|ACTIVE_COMPARATOR|Ropivacaine 0.1%|Erector spinae plane block with 2 ml/kg of ropivacaine 0.1%.
62339952|NCT05755334|EXPERIMENTAL|Ropivacaine 0.2%|Erector spinae plane block with 1 ml/kg of ropivacaine 0.2%.
62692085|NCT01327729|ACTIVE_COMPARATOR|YPEG-IFN α-2a two weeks|"The third group will be treated with:~YPEG-IFN α-2a 180mcg/ 2 weeks for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks."
62132757|NCT02632071|ACTIVE_COMPARATOR|80 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
62324945|NCT04994132|EXPERIMENTAL|Arm A (VAC, VINO-CPO)|"Patients receive vincristine sulfate IV on days 1, 8 and 15 of cycles 1-4, 7, 8, 11, and 12, and day 1 of cycles 5, 6, 9, 10, 13, and 14. Patients also receive dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5, 8-10, and 11-14, and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.~MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated."
62692086|NCT06569446||Focused Group Sessions|This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).
62132758|NCT02632071|ACTIVE_COMPARATOR|120 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
62132759|NCT02632071|ACTIVE_COMPARATOR|180 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
62132760|NCT02632071|ACTIVE_COMPARATOR|240 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
62132761|NCT04778670|ACTIVE_COMPARATOR|Standard of Care|Standard of Care means all examinations will receive a flagging decision by: first reader and second reader radiologist as usual. However, in this paired design all participants will belong to both arms.
62132762|NCT04778670|EXPERIMENTAL|AI CAD combination|AI CAD combination in the primary end-point means the combination of the flagging decision of the first reader and AI CAD; in the secondary end-points it means any combination of AI alone, or AI in combination with first, second and both readers.
62132763|NCT02198469|EXPERIMENTAL|Er:YAG AFL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
62132764|NCT02198469|ACTIVE_COMPARATOR|MAL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
62132765|NCT04005287|PLACEBO_COMPARATOR|WST-057 Matching placebo 2 mL volume|
62483826|NCT04621851||Retrospective cohort|Patients who discontinued before the opening of this study will contribute to the retrospective cohort.
62483827|NCT04621851||Prospective cohort|Patients who will discontinue after it will contribute to the prospective cohort.
62132766|NCT04005287|PLACEBO_COMPARATOR|WST-057 Matching placebo 4mL volume|
62132767|NCT04005287|ACTIVE_COMPARATOR|WST-057 (4% pirenzepine) 2mL volume|
62132768|NCT04005287|ACTIVE_COMPARATOR|WST-057 (4% pirenzepine) 4mL volume|
62132769|NCT01514149|EXPERIMENTAL|Arm 1 - Weekly CJC-1134-PC|
62132770|NCT01514149|EXPERIMENTAL|Arm 2 - Weekly CJC-1134-PC|
62132771|NCT01514149|EXPERIMENTAL|Arm 3 - Weekly CJC-1134-PC|
62132772|NCT01514149|EXPERIMENTAL|Arm 4 - Weekly CJC-1134-PC|
62132773|NCT01514149|PLACEBO_COMPARATOR|Arm 5 - Weekly Placebo|
62132774|NCT04762758|EXPERIMENTAL|PXT3003|Liquid oral solution, 10 mL twice a day, morning and evening with food
62132775|NCT04762758|PLACEBO_COMPARATOR|Placebo|Liquid oral solution, 10 mL twice a day, morning and evening with food
62132776|NCT01324713||Males|
62132777|NCT01324713||Females|
62132778|NCT02008916|EXPERIMENTAL|Secukinumab 10 mg/kg i.v. / 300 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
62132779|NCT02008916|EXPERIMENTAL|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
62132780|NCT02008916|PLACEBO_COMPARATOR|Placebo i.v. and s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients were re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.
62132781|NCT03060317||Validation group DOC|Examination with neurological scales.
62132782|NCT06302920|ACTIVE_COMPARATOR|Kinesiotaping group|Patients will be divided into 2 groups according to the random numbers table, and both groups will receive a conventional physical therapy and rehabilitation program and nutritional support. Afterwards, edema-reducing kinesiotaping will be applied to one group.
62132783|NCT06302920|NO_INTERVENTION|Control group|Patients will be divided into 2 groups according to the random numbers table, and both groups will receive a conventional physical therapy and rehabilitation program and nutritional support.
62132784|NCT04620421|EXPERIMENTAL|Training group (Rhythm-based multitask training)|Randomized to participate in the rhythm-based multitask training intervention
62132785|NCT04620421|NO_INTERVENTION|Control group (Continuation of regular activity schedule)|Randomized to the control group who is encouraged to continue their regular everyday routines, which may include self-administrated training exercises.
62132786|NCT01643499|EXPERIMENTAL|Treatment (mFOLFIRINOX)|Patients receive oxaliplatin IV over 2 hours on, irinotecan hydrochloride IV over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62339953|NCT04136613|EXPERIMENTAL|Post placental intra uterine device insertion|There was immediate post-partum insertion of CuT 380 A intrauterine device after delivery of placenta during cesarean delivery. To overcome the considerable expulsion rate in the previous studies, we stabilize the IUD in place at the fundus be an absorbable suture; vicryl 0 that was introduced through the fundus, held the needle with sponge holder that was introduce up the fundus and taken out the vicryl through the lower uterine inscion, cutting the needle, hold the vicryl around the the T arm of the IUD and withdrawn back to be placed inside the fundus. Before closing the uterine incision, the threads were placed in the lower uterine segment, then the uterine incision was then closed routinely.
62692087|NCT06569446||Cognitive Interviews|This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer.
62697527|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
61931645|NCT04938349|ACTIVE_COMPARATOR|Single session dual task perturbation training-CIOA|All participants will receive only one training session of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
61931646|NCT04756869||Health Care Workers at Risk for COVID-19|Health care workers at risk for COVID-19 will be monitored using wearing sensors and smartphone technology.
61931647|NCT04166149||University of Maryland|Pancreas and pancreas kidney patients enrolled at University of Maryland. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
61931648|NCT04166149||University of Wisconsin|Pancreas and pancreas kidney patients enrolled at University of Wisconsin. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
61931649|NCT04166149||Georgetown University|Pancreas and pancreas kidney patients enrolled at Georgetown University. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
61931650|NCT06708585|EXPERIMENTAL|Experimental group|Each pregnant woman who meets the inclusion criteria will be interviewed individually for approximately 15-20 minutes on the day of surgery and data collection forms will be applied. Then, each woman will be given progressive relaxation exercises individually. Exercises will begin two hours before surgery and will be repeated four times. Each exercise will last approximately 20 minutes. Data collection forms will be applied two hours after the completion of the exercise and at the end of surgery.
61931651|NCT06708585|NO_INTERVENTION|control group|Each pregnant woman in the control group will be administered the individual information form, State Anxiety Scale, and Surgical Fear Scale data collection tools two hours before the surgery and will be released to the routine care of the institution. After two hours, the State Anxiety Scale and Surgical Fear Scale will be administered again. 6 hours after the cesarean section, the woman's pain will be assessed with the VAS pain scale and 24 hours later, the postpartum comfort scale will be administered.
61931652|NCT00756639|EXPERIMENTAL|Radiation|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks. On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
61931653|NCT00892242|EXPERIMENTAL|Neoadjuvant Zoledronic Acid|"Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)~Pancreatic resection~Zoledronic acid 4 mg IV monthly for two additional doses"
61931654|NCT02072239|EXPERIMENTAL|Device Applied|All participants will be treated with the Angioshield
62132787|NCT01951807|EXPERIMENTAL|Coping & Communication Skills|The CCI intervention focuses on bolstering stress management and problem solving abilities, identifying and expressing support needs constructively, facilitating the ability to cope with unchangeable issues, cognitive restructuring, and dealing effectively with body image and sexuality issues over seven weekly 60 minute sessions.
62132788|NCT01951807|EXPERIMENTAL|Supportive Counseling (SC)|The SC intervention incorporates a supportive, non-directive counseling approach in seven weekly 60 minute sessions
62132789|NCT01951807|NO_INTERVENTION|Usual Care (UC)|Patients receive standard psychological and emotional care (usual care \[UC\]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
61931655|NCT02653092|ACTIVE_COMPARATOR|Aim 1-Administration of FFA in an acute model|"Reproduction of the reproductive phenotype of obesity in Normal Weight Women (NWW) by:~1) infusing insulin and free fatty acids (FFAs) in short term experiments and measuring gonadotropin pulsatility and pituitary GnRH response Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production."
62132790|NCT06345170|EXPERIMENTAL|Intervention Group|The group in which the Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) training program will be applied in addition to the DIR/Floortime™ therapy program
62132791|NCT06345170|ACTIVE_COMPARATOR|Control Group|The group in which the DIR/Floortime™ therapy program will be applied
62132792|NCT04857294|EXPERIMENTAL|Discectomy|Unilateral Discectomy
61931656|NCT02653092|EXPERIMENTAL|Aim 2-Hyperinsulinemic Euglycemic Clamp after a chronic administration of a diet|"Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production.~Inducing a chronic model of the reprometabolic syndrome by administering a eucaloric diet that is relatively high in pro-inflammatory omega-6 fatty acids and low in anti-inflammatory omega-3 fatty acids (high fat diet; HFD) for one month while monitoring gonadotropin pulsatility and daily urinary reproductive hormone excretion."
62132793|NCT02419703||Patients receiving Targeted Radiofrequency Ablation (t-RFA)|
61931657|NCT03402659|EXPERIMENTAL|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
62132794|NCT03128359|EXPERIMENTAL|Regimen A (fludarabine, melphalan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
62132795|NCT03128359|EXPERIMENTAL|Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
62132796|NCT03128359|EXPERIMENTAL|Regimen C (fludarabine, TBI, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
62132797|NCT03809936|ACTIVE_COMPARATOR|real tDCS|real tDCS:anodal transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
62132798|NCT03809936|SHAM_COMPARATOR|sham tDCS|sham tDCS:sham transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
62132799|NCT01655563|ACTIVE_COMPARATOR|Standard Dosing Arm|Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
62132800|NCT01655563|EXPERIMENTAL|Pharmacogenetic Arm|"Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.~CYP3A5 non-expressor starting dose:~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours~CYP3A5 expressor starting dose:~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours"
62132801|NCT02752659|EXPERIMENTAL|Women with breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
62132802|NCT02752659|EXPERIMENTAL|Women at risk of breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
62132803|NCT03793413|EXPERIMENTAL|Surgical group|
62132804|NCT03793413|NO_INTERVENTION|Observation group|
62132805|NCT00642850|EXPERIMENTAL|1|
62132806|NCT01765231|EXPERIMENTAL|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
62132807|NCT01765231|ACTIVE_COMPARATOR|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
62132808|NCT06180889|ACTIVE_COMPARATOR|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days post-surgery.
62132809|NCT06180889|EXPERIMENTAL|KN060 Low (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 low dose once post-surgery.
62132810|NCT06180889|EXPERIMENTAL|KN060 Middle (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 middle dose once post-surgery.
62132811|NCT06180889|EXPERIMENTAL|KN060 Hight (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 hight dose once post-surgery.
62132812|NCT01541059|PLACEBO_COMPARATOR|Placebo|Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
62697528|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
61931658|NCT03402659|PLACEBO_COMPARATOR|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
62132813|NCT01541059|EXPERIMENTAL|Ropivacaine|Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.
62132814|NCT00077675|EXPERIMENTAL|Telavancin|
62132815|NCT00077675|ACTIVE_COMPARATOR|Standard of care for cSSSI|cSSSI - comlicated skin and skin structure infections
62132816|NCT02084420|EXPERIMENTAL|Ilaprazole or Pantoprazole placebo|Ilaprazole 10mg, Pantoprazole 40mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day, PO
62132817|NCT02084420|ACTIVE_COMPARATOR|Ilaprazole placebo or Pantoprazole|Pantoprazole 40mg, Ilaprazole 10mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day,PO
62132818|NCT00976105|ACTIVE_COMPARATOR|Part A: Zolpidem or placebo|This part is designed to examine the acute effects of up to 10mg of a known hypnotic sedative drug (Zolpidem) on cognitive and mood changes sensitve to sedation and tiredess.
61931659|NCT04559360|ACTIVE_COMPARATOR|Active group - PRESTOapp users|Once users are recruited, an independent researcher will randomize the participants using a 1:1 sequential method in two groups of 76 individuals and will assign a 6-digit identification code (IC) to each participant. The IC will be given to the participant on a reminder card and will be used to access the app guaranteeing its confidentiality. The name of the subjects and their respective code will be stored in independent servers for methodological, security and legal reasons. The intervention group will be asked to use the app for a period of 2 months. The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
61931660|NCT04559360|NO_INTERVENTION|Control group|The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
61931661|NCT00721266|EXPERIMENTAL|1|
61931662|NCT04196972|EXPERIMENTAL|Arm A (ECHO telementoring)|Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
61931663|NCT04196972|EXPERIMENTAL|Arm B (wait-list, ECHO telementoring)|Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
61931664|NCT04453228||2017-2018 snow season|Injured skiers in the 2017-2018 snow season
61931665|NCT04453228||2018-2019 snow season|Injured skiers in the 2018-2019 snow season
61931666|NCT04151199|NO_INTERVENTION|No Intervention Control|The control group is randomized but does not participate in the intervention but does complete the acute test and biospecimen collection following the intervention period.
61931667|NCT04151199|ACTIVE_COMPARATOR|Endurance Exercise|Participants randomized to EE participate in the intervention and complete the acute test and biospecimen collection following the intervention period.
61931668|NCT04151199|NO_INTERVENTION|Cross Sectional HA|Do not participate in intervention after single acute exercise test of Endurance Exercise.
61931669|NCT04151199|NO_INTERVENTION|Cross Sectional LA|Do not participate in intervention after single acute exercise test of Endurance Exercise.
61931670|NCT02670174|ACTIVE_COMPARATOR|Traditional training|A home exercise program consisting of rotator cuff and scapular muscle training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
61931671|NCT02670174|EXPERIMENTAL|Separate kinetic chain training|A home exercise program consisting of traditional training exercises as well as separate exercises focusing on core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
61931672|NCT02670174|EXPERIMENTAL|Integrated kinetic chain training|A home exercise program consisting of traditional training exercises while integrating core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
61931673|NCT04895709|EXPERIMENTAL|Part 1A: BMS-986340 Dose Escalation|
61931674|NCT04895709|EXPERIMENTAL|Part 2A: BMS-986340 Dose Expansion|
61931675|NCT04895709|EXPERIMENTAL|Part 1B: BMS-986340 + Nivolumab Dose Escalation|
61931676|NCT04895709|EXPERIMENTAL|Part 2B: BMS-986340 + Nivolumab Dose Expansion|
62483828|NCT04621851||Retrospective/Prospective cohort|Patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts.
61931677|NCT04895709|EXPERIMENTAL|Part 1C: BMS-986340 + Docetaxel Dose Escalation|
61931678|NCT06404775|EXPERIMENTAL|external mastalgia-oil plus oral tamoxifen placebo|
62483829|NCT04547309|EXPERIMENTAL|68Ga/18F-HER2 Affibody PET/CT scan|
62697529|NCT06194656|EXPERIMENTAL|Group A|Experimental group in Ⅱa (part one). It will be the dose A of SIBP-03. It will determine whether the dose A is the optimal recommended dosage (RP2D) based on actual study results.
62697530|NCT06194656|EXPERIMENTAL|Group B|Experimental group in Ⅱa (part one). It will be the dose B of SIBP-03. It will determine whether the dose B is the RP2D based on actual study results.
61931679|NCT06404775|ACTIVE_COMPARATOR|oral tamoxifen plus external mastalgia-oil placebo|
61931680|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 1|4 Subjects will receive one dose of 10 mg and 2 subjects will receive one dose of placebo
61931681|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 2|4 Subjects will receive one dose of 25 mg and 2 subjects will receive one dose of placebo
62132819|NCT00976105|EXPERIMENTAL|Part B: GSK1521498 or placebo|At least 15 hours after Part A is completed subjects will enter Part B of the study.
62483830|NCT04188392|EXPERIMENTAL|open-label treatment|pimavanserin 34mg at bedtime for 6 weeks
62483831|NCT02191059|EXPERIMENTAL|Intermittent High Dose of Icotinib|"Intermittent High Dose of Icotinib in Combination With Docetaxel:~Icotinib 625mg tablet b ymouth three times per day for day1-2, Docetaxel 75mg/m2 injection intravenous drip for day 3, 3 weeks as 1 cycle"
62483832|NCT02169323|EXPERIMENTAL|Step-down|Step-down of the inhaled corticosteroid (ICS) dose
62483833|NCT02535923|EXPERIMENTAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
62697531|NCT06194656|EXPERIMENTAL|Group C|Experimental group in Ⅱa (part two). It will be the dose C of SIBP-03. It will determine whether the dose C is the RP2D based on actual study results.
62697532|NCT06194656|EXPERIMENTAL|Group D|Experimental group in Ⅱb. It will be the RP2D of SIBP-03.
61931682|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 3|4 Subjects will receive one dose of 50 mg and 2 subjects will receive one dose of placebo
61931683|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 4|4 Subjects will receive one dose of 100 mg and 2 subjects will receive one dose of placebo
61931684|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 5|4 Subjects will receive one dose of 200 mg and 2 subjects will receive one dose of placebo
61931685|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 6|4 Subjects will receive one dose of 300 mg and 2 subjects will receive one dose of placebo
62692088|NCT05559385|EXPERIMENTAL|Robotic Rehabilitation Group|"The standardized ITR program was applied to both groups for 60 minutes a day, five days a week, for six weeks. The ITR program included exercises of abdominal strengthening, controlled pelvic movements, bridging, trunk lateral flexion and rotation, reaching forward, and push-ups with a Swiss Ball. This group received a robotic rehabilitation program for the upper extremity with a Houston Bionics ExoRehab X brand/model device. This device has no motor force of repulsion or attraction. Patients initiate and maintain their movements during the exercise. The device supports the patient's active movement and allows extensive movement repetition.~Before starting robotic rehabilitation, the patient was seated upright on the platform. The games were projected onto a 43-inch television screen. The exercise program was planned to include upper extremity movements in all directions."
61931686|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 7|4 Subjects will receive one dose of 400 mg and 2 subjects will receive one dose of placebo
61931687|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 8|4 Subjects will receive one dose of 800 mg and 2 subjects will receive one dose of placebo
61931688|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 9|4 Subjects will receive one dose of 1200 mg and 2 subjects will receive one dose of placebo
61931689|NCT04505397|EXPERIMENTAL|Single Ascending Dose Level 10|4 Subjects will receive one dose on the outcome of preceding dose levels and 2 subjects will receive one dose of placebo
61931690|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 1|6 Subjects will receive one dose of 50 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose).
61931691|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 2|6 Subjects will receive one dose of 200 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
61931692|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 3|6 Subjects will receive one dose of 400 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
61931693|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 4|6 Subjects will receive one dose of 800 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
61931694|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 5|6 Subjects will receive one dose of 1200 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
61931695|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 6|"6 Subjects will receive one dose of 1200 mg each day (using tablet formulation instead of capsule formulation\*) for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).~\*Tablet formulation is utilized, instead of capsule formulation, in the marked dose levels."
61931696|NCT04505397|EXPERIMENTAL|Food Effect Cohort|After completing the fasting Single Ascending Dose escalation, the same 6 subjects who received one dose of 50 mg under fasting conditions will return to the clinic after a washout period for a second confinement to receive a second dose (same as fasting) under fed conditions.
61931697|NCT04505397|EXPERIMENTAL|Gender Effect Cohort|6 female subjects of non-childbearing potential will receive one dose of 50 mg under fasting conditions.
61931698|NCT04505397|EXPERIMENTAL|Optional Food Effect Cohort|Up to 12 male subjects will undergo an open-label, two period, two-sequence crossover design at the maximum daily dose tested in Part A.
61931699|NCT04505397|EXPERIMENTAL|Optional Formulation Effect Cohort|Up to 12 male subjects will be treated with the maximum daily dose tested in Part A using open-label, two period, two-sequence crossover design.
62697533|NCT06194656|PLACEBO_COMPARATOR|Group E|Placebo of SIBP-03 (SIBP-03 solvent without HER3 antibody), and the dose will be the same with group D.
61931700|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 7|"6 Subjects will receive one dose of 2000 mg each day (using tablet formulation instead of capsule formulation\*) for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).~\*Tablet formulation is utilized, instead of capsule formulation, in the marked dose levels."
61931701|NCT04505397|EXPERIMENTAL|Multiple Ascending Dose Level 8|"6 Subjects will receive one dose each day (using tablet formulation instead of capsule formulation\*) for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).~\*Tablet formulation is utilized, instead of capsule formulation, in the marked dose levels."
61931702|NCT02777736|EXPERIMENTAL|Arm A - Methotrexate i.v.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive 2 cycles of methotrexate 3g/m2 i.v. after the 3rd and 6th cycle of systemic chemotherapy (R CHOP or DA EPOCH R).
61931703|NCT02777736|ACTIVE_COMPARATOR|Arm B - Methotrexate i.t.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive intrathecal methotrexate 12mg in each cycle of systemic chemotherapy (6x).
61931704|NCT02777736|NO_INTERVENTION|Arm C - no Methotrexate|Patients with 0-1 risk factor for CNS relapse will not receive CNS prophylaxis.
61931705|NCT06690281|EXPERIMENTAL|1/ TCR T-cells and aldesleukin|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + TCR T cells + aldesleukin
61931706|NCT06690281|NO_INTERVENTION|2/ No cellular therapy|Surveillance and follow-up
61931707|NCT05405114|EXPERIMENTAL|HU-non-eligible - NDec plus placebo|HU-non eligible patients randomised to treatment with NDec on one day and placebo on the other day
61931708|NCT05405114|EXPERIMENTAL|HU-non-eligible - NDec plus NDec|HU-non eligible patients randomised to treatment with NDec on both days
61931709|NCT05405114|PLACEBO_COMPARATOR|HU-non-eligible - Placebo plus placebo|HU-non eligible patients randomised to treatment with placebo on both days
61931710|NCT05405114|EXPERIMENTAL|HU-active - NDec plus placebo|HU-active patients randomised to treatment with NDec on one day and placebo on the other day
61931711|NCT05405114|EXPERIMENTAL|HU-active - NDec plus NDec|HU-active patients randomised to treatment with NDec on both days
62483834|NCT02535923|ACTIVE_COMPARATOR|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
61931712|NCT05405114|ACTIVE_COMPARATOR|HU-active - HU|HU-active patients randomised to continue on open-label HU treatment
61931713|NCT02479360||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the 10 metre walk test, the timed up and go test, the functional reach test and the nine-hole peg test. A physiotherapist will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF1 consultants and one NF1 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy.
61931714|NCT06426719|EXPERIMENTAL|intervention group osseodensification|the group in which alveloalr ridge widening is done using densah burs, it is the study group
61931715|NCT06426719|ACTIVE_COMPARATOR|conventional osteotome group|the group in which alveolar ridge expansion is done using hand driven osteotomes . it is the conventional froup
61931716|NCT03659786|EXPERIMENTAL|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
62483835|NCT06396858|ACTIVE_COMPARATOR|Group 1|rivaroxaban 2.5 mg Twice a day (BID) + colchicine 0.5 mg once daily (QD)
62324946|NCT04994132|EXPERIMENTAL|Arm B (vinorelbine, VAC, VINO-CPO)|"Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8, vincristine sulfate IV on day 15, dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5 and 8-14, and cyclophosphamide IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.~MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated."
62324947|NCT00006518||1|Participants with HIV infection, KSHV infection, or with cancer
62324948|NCT06457503|EXPERIMENTAL|Toripalimab + cisplatin (or carboplatin) + gemcitabine|Participants will receive the triple combination of cisplatin, gemcitabine and toripalimab (Chemotherapy-based treatment phase) followed by single-agent toripalimab (Maintenance treatment phase). The use of cisplatin can be substituted with carboplatin from cycle 2 onwards.
62324949|NCT06269679|NO_INTERVENTION|OPT|Orthopantomogram = current recommended clinical examination approach (comparator procedure)
62324950|NCT06269679|EXPERIMENTAL|CBCT|Cone Beam Computed Tomography = experimental clinical examination approach (procedure under evaluation)
62483836|NCT06396858|ACTIVE_COMPARATOR|Group 2|rivaroxaban 2.5 mg BID + colchicine placebo QD
61931717|NCT03659786|NO_INTERVENTION|Day 3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo)
61931718|NCT03659786|NO_INTERVENTION|Day 5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo)
61931719|NCT03693170|EXPERIMENTAL|1 Arm|encorafenib plus binimetinib plus cetuximab
62324951|NCT03967158||Consecutive percutaneous coronary intervention|
62324952|NCT02511028|EXPERIMENTAL|ferumoxytol|A 510 mg dose (17 mL) of ferumoxytol diluted in 50 mL of 0.9% normal saline will be intravenously infused over 17 minutes
62324953|NCT05769218|EXPERIMENTAL|CHORUS+|The baseline questionnaire for participants in this arm will be followed by a 30-minute motivational interviewing (MI) session with the peer recovery coach (PRC), and will assess readiness for change and provide information about PrEP. The PRC will also assess readiness for MOUD, and this will be further explored during subsequent visits.
62483837|NCT06396858|ACTIVE_COMPARATOR|Group 3|rivaroxaban placebo BID + colchicine 0.5 mg QD
62483838|NCT06396858|PLACEBO_COMPARATOR|Group 4|rivaroxaban placebo BID + colchicine placebo QD
62483839|NCT01901263||patient with alzheimer's disease|"Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)~Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate"
61931720|NCT06475183|EXPERIMENTAL|Probioitic consumption|All pariticpants will consume Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum in a quantity of 10 billium CFUs daily
61931721|NCT01187199|EXPERIMENTAL|Carboplatin Group|Carboplatin: Starting dose AUC 2 by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
61931722|NCT01187199|EXPERIMENTAL|Paclitaxel Group|Paclitaxel: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
62483840|NCT05445180|EXPERIMENTAL|Psychosis patients with cannabis use (Abstinent)|Psychosis patients with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
62483841|NCT05445180|NO_INTERVENTION|Psychosis patients with cannabis use (Non-abstinent)|Psychosis Patients with cannabis use who will continue to use cannabis as usual
62324954|NCT05769218|ACTIVE_COMPARATOR|Usual care- control|Participants in this arm will receive passive referral for care. there will be no PRC MI session and they will not be offered PrEP or MOUD.
62324955|NCT05948540|EXPERIMENTAL|Intervention C Daridorexant|
62692089|NCT05559385|ACTIVE_COMPARATOR|Conventional Rehabilitation Group|"The standardized ITR program was applied to both groups for 60 minutes a day, five days a week, for six weeks. During this period, lower extremity rehabilitation was added if needed in addition to trunk rehabilitation. Exercises for the lower extremities were applied according to the patient's individual needs. The ITR program included exercises of abdominal strengthening, controlled pelvic movements, bridging, trunk lateral flexion and rotation, reaching forward and sideways, and push-ups with a Swiss Ball.~CR applied after the ITR program consisted of an individualized rehabilitation program for the upper extremities. These rehabilitation programs generally included activities for functional purposes (dressing, object manipulation, reaching, cup holding, range of motion, strengthening, weight-bearing, etc.). The treatment program was applied five days a week for six weeks, with the session duration limited to 60 minutes."
62692090|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
61931723|NCT01187199|EXPERIMENTAL|Sorafenib Group|Sorafenib: Starting dose 200 mg by mouth daily for a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
61931724|NCT06298890||Patients who will be using artificial tears before and after cataract surgery|Patients will receive artificial tears 7 days before the cataract surgery and continue to use them for 3 months after the surgery.
61931725|NCT06298890||Patients who will not be using any artificial tears neither before nor after the cataract surgery.|Patients will not receive any artificial tears neither before nor after the cataract surgery.
62324956|NCT05948540|PLACEBO_COMPARATOR|Intervention C Placebo|
62324957|NCT06553612|EXPERIMENTAL|Experimental group|Delivery of personalized post-cancer plan with multidisciplinary assessment of oncology support care needs in a day hospital
62324958|NCT06553612|ACTIVE_COMPARATOR|Control group|Delivery of a personalized post-cancer plan without a day hospital
62324959|NCT06553612|OTHER|Cohort|Follow-up as part of an observational cohort
62483842|NCT05445180|EXPERIMENTAL|Non-Psychiatric controls with cannabis use (Abstinent)|Non-Psychiatric controls with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
61931726|NCT05379725|EXPERIMENTAL|Mediterranean diet|Participants will receive diet education on adherence to a Mediterranean dietary pattern.
61931727|NCT05379725|EXPERIMENTAL|Fermented food|Participants will receive diet education on adherence to a high fermented food dietary pattern.
61931728|NCT02659956||Individuals without known CNS disease|Family members of patient participants
62324960|NCT02637687|EXPERIMENTAL|Phase 1 dose escalation|"Patients will receive the different levels of dose on Day 1 (BID in accordance with the cohort assignment). Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation. (arm closed)"
62324961|NCT02637687|EXPERIMENTAL|Phase 1 dose expansion|"Patients who are enrolled in the expansion cohort, following the formal dose escalation phase of the study.~Distinct from the Phase 1 dose escalation cohort, the Phase 1 expansion cohort will enroll pediatric patients with advanced solid or primary CNS tumors with a documented NTRK gene fusion, or in the case of IFS, CMN or SBC with documented ETV6 rearrangement by FISH or RT-PCR or a documented NTRK fusion by NGS.~This expansion cohort will follow the same schedule of assessments as the dose escalation cohorts. (arm closed)"
62132820|NCT02297919|EXPERIMENTAL|web based intervention|Web based intervention: Students will have access to the educational content through the learning management system on the web site (genc-e-saglik) created for this project.
62324962|NCT02637687|EXPERIMENTAL|Phase 2: Patients with tumors bearing NTRK fusions (IFS)_Cohort 1|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation. (arm closed)"
62324963|NCT02637687|EXPERIMENTAL|Phase 2: Other extra-cranial solid tumors_Cohort 2|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation. (arm closed)"
62324964|NCT02637687|EXPERIMENTAL|Phase 2: Primary CNS tumors_Cohort 3|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation."
62483843|NCT05445180|NO_INTERVENTION|Non-Psychiatric controls with cannabis use (Non-abstinent)|Non-Psychiatric Controls with cannabis use will continue to use cannabis as usual
62483844|NCT05445180|NO_INTERVENTION|Non-Psychiatric Controls without cannabis use|Non-Psychiatric controls without cannabis use
62483845|NCT06627257|EXPERIMENTAL|LepVax|Participants will be randomized within each Group to receive three doses of vaccine administered IM on Days 0, 28, and 56. Participants will be monitored for one year following the last study injection, including safety laboratory analyses 7 days following each study injection. Blood samples will be obtained for immunological assays at Days 0, 35, 63, and 168.
62697534|NCT04967456|ACTIVE_COMPARATOR|Measurement of pulpal blood flow of traumatised tooth|In the split-mouth design, the traumatised maxillary incisor will be investigated using Laser Doppler flowmetry.
62697535|NCT04967456|OTHER|Measurement of pulpal blood flow of non-traumatised tooth|In the split-mouth design, this arm - the non-traumatised maxillary incisor, contralateral tooth, will be investigated using Laser Doppler flowmetry as a control tooth.
62483846|NCT06627257|PLACEBO_COMPARATOR|Placebo groups|Participants will be randomized within each Group to receive three doses of placebo administered IM on Days 0, 28, and 56. Participants will be monitored for one year following the last study injection, including safety laboratory analyses 7 days following each study injection. Blood samples will be obtained for immunological assays at Days 0, 35, 63, and 168.
62483847|NCT01167829|EXPERIMENTAL|Acyline and oral testosterone|
62483848|NCT01803594|PLACEBO_COMPARATOR|Control Shake|Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
62483849|NCT01803594|ACTIVE_COMPARATOR|PC700, Krill Oil, and Lutein|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)"
62483850|NCT01803594|ACTIVE_COMPARATOR|PC700, Krill Oil, Lutein, and Niacin|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)"
62483851|NCT01826838|EXPERIMENTAL|Dasatinib|Three dasatinib dose levels will be evaluated, 50 mg/day, 70 mg/day and 100 mg/day. Dasatinib will begin with day #1 of radiation and will be discontinued once radiation is completed.
62483852|NCT03552484|ACTIVE_COMPARATOR|Home Visit Arm|"Participants and their caregivers, when available, will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~\[Completion of Home Visit Program\]"
62692091|NCT05811832||Fragile elderly individuals with COPD|"Patient evaluation form and socio-demographic form of all individuals participating in the study.~properties will be questioned.To assess pulmonary functions at the assessment stage for all individuals pulmonary function test,Modified Medical Questionnaire to assess dyspnea research Council, to assess health-related quality of life, Saint George Respiratory Two Minute Walk Test to assess exercise capacity, frailty Frail fragility scale to detect fragility, Prisma-7 Vulnerability scale to assess fragility The scale is Pase to assess physical activity, Berg balance to assess balance. scale, digital hand dynamometer to evaluate quadriceps muscle strength, hand grip strength hand dynamometer to assess fatigue levels Fatigue Severity Scale will be used."
62692092|NCT05811832||Non-fragile elderly individuals with COPD|"Patient evaluation form and socio-demographic form of all individuals participating in the study.~properties will be questioned.To assess pulmonary functions at the assessment stage for all individuals pulmonary function test,Modified Medical Questionnaire to assess dyspnea research Council, to assess health-related quality of life, Saint George Respiratory Two Minute Walk Test to assess exercise capacity, frailty Frail fragility scale to detect fragility, Prisma-7 Vulnerability scale to assess fragility The scale is Pase to assess physical activity, Berg balance to assess balance. scale, digital hand dynamometer to evaluate quadriceps muscle strength, hand grip strength hand dynamometer to assess fatigue levels Fatigue Severity Scale will be used."
62697536|NCT00496119|EXPERIMENTAL|70 Gray (Gy) Proton Beam Therapy|Participants treated to 70 cobalt Gray equivalent (CGE) only (the standard treatment).
62132821|NCT02297919|ACTIVE_COMPARATOR|classic preprepared lesson|Training at the control group,lectures will be presented on the basis of the classic preprepared lesson by educator and at the end of the training, will be answered student's questions.
62324965|NCT02637687|EXPERIMENTAL|Phase 2: Bone health assessment_sub-cohort|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation.~Patients in this group will undergo bone health assessments in addition to all other efficacy and safety assessments."
62324966|NCT03869996|ACTIVE_COMPARATOR|fast track total knee arthroplasties|patients treated using fast track care protocol
62324967|NCT03869996|ACTIVE_COMPARATOR|standard care total knee arthroplasties|patients treated using standard care protocol
62324968|NCT06563609|ACTIVE_COMPARATOR|Integrated Physical Therapy and Nutritional Support with Probiotic Saccharomyces boulardii|Intensive physical therapy + individualised nutritional support + administration of probiotic yeast saccharomyces boulardii
62132822|NCT04185961|EXPERIMENTAL|EVERA-RAPHA with 60mmHG|EVERA-RAPHA apply 15 minutes with 60mmHG every day for 4 weeks
62132823|NCT04185961|EXPERIMENTAL|EVERA-RAPHA with 100mmHG|EVERA-RAPHA apply 15 minutes with 100mmHG every day for 4 weeks
62132824|NCT04080141||PD+|Subjects with personality disorder
62132825|NCT04080141||PD-|Subjects without personality disorder
62132826|NCT01095796|EXPERIMENTAL|Stribild|Stribild plus placebo to match Atripla
62132827|NCT01095796|ACTIVE_COMPARATOR|Atripla|Atripla plus placebo to match Stribild
62132828|NCT00976495|EXPERIMENTAL|Dapagliflozin|
62132829|NCT00976495|ACTIVE_COMPARATOR|Hydrochlorothiazide|
62132830|NCT01782846|ACTIVE_COMPARATOR|Ixprim®|2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)
62324969|NCT06563609|ACTIVE_COMPARATOR|A combined Intensive physical Therapy and individualised Nutritional Support intervention|Intensive physical Therapy + Individualised Nutritional Support
62324970|NCT06563609|ACTIVE_COMPARATOR|Administration of probiotic yeast Saccharomyces boulardii|Administration of probiotic yeast Saccharomyces boulardii
62324971|NCT06563609|PLACEBO_COMPARATOR|Control group|Standard hospital care
62324972|NCT01496625||Cohort 1|Participants with age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases.
62324973|NCT01496625||Cohort 2|Participants without any retinal diseases.
62324974|NCT03478839||CRF completion|Individuals with a diagnosis of GACI or ARHR2 with sufficient chart data to be included in the study will be eligible for enrollment, as well as all their siblings and parents.
62483853|NCT03552484|ACTIVE_COMPARATOR|Usual Care Arm|"Participants and their caregivers, when available, will be asked to complete an initial online survey. Twelve months later, patients (and caregivers, if available) will be asked to complete an online follow-up survey.~\[Completion of Usual Care/Online Survey\]"
62324975|NCT01900132|EXPERIMENTAL|1/All Subjects|Healthy Volunteers and patients
62483854|NCT06130215|EXPERIMENTAL|Fix meal annoucement with three presets of carbohydrates|simple meal management
62324976|NCT06385275|EXPERIMENTAL|Vitamin K1 500 µg|Participants randomized to this arm will take one Vitamin K1 500 µg pill daily for 4 weeks.
62324977|NCT06385275|EXPERIMENTAL|Vitamin K1 1000 µg|Participants randomized to this arm will take one Vitamin K1 1000 µg pill daily for 4 weeks.
62324978|NCT06385275|EXPERIMENTAL|Vitamin K2 (MK-7) 300 µg|Participants randomized to this arm will take one Vitamin K2 (MK-7) 300 µg pill daily for 4 weeks.
62324979|NCT06385275|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will take 1 placebo pill daily for 4 weeks.
62324980|NCT03623321|EXPERIMENTAL|Drug - pimavanserin|Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
62324981|NCT06450366|EXPERIMENTAL|Enlicitide Decanoate|Participants receive enlicitide decanoate 20mg, ezetimibe-matching placebo, and bempedoic acid-matching placebo once daily (QD) orally up to approximately 56 days.
62324982|NCT06450366|ACTIVE_COMPARATOR|Ezetimibe|Participants receive ezetimibe 10mg, enlicitide decanoate-matching placebo, and bempedoic acid-matching placebo QD orally up to approximately 56 days.
62324983|NCT06450366|ACTIVE_COMPARATOR|Bempedoic Acid|Participants receive bempedoic acid 180mg, ezetimibe-matching placebo, and enlicitide decanoate-matching placebo QD orally up to approximately 56 days.
62324984|NCT06450366|ACTIVE_COMPARATOR|Ezetimibe + Bempedoic Acid|Participants receive ezetimibe 10 mg, bempedoic acid 180mg, enlicitide decanoate-matching placebo orally QD for approximately 56 days.
62324985|NCT04851964|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection, in an accessorized pre-filled syringe.
62324986|NCT04851964|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection, in an accessorized pre-filled syringe.
62324987|NCT06091254|EXPERIMENTAL|Odronextamab|"Part 1 is a safety run-in. All participants will receive odronextamab.~In part 2 participants will be randomly assigned in a 1:1 ratio to receive odronextamab followed by odronextamab maintenance."
62324988|NCT06091254|ACTIVE_COMPARATOR|Rituximab + Investigator's Choice Chemotherapy|Part 2 only, participants will be randomized 1:1 to receive rituximab in combination with chemotherapy followed by rituximab maintenance.
62483855|NCT06130215|ACTIVE_COMPARATOR|Flex meal annoucement with precise carbohydrate counting|precise meal management
62692093|NCT04114825|EXPERIMENTAL|RV001V|Total of 12 SC vaccinations with RV001V. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
62324989|NCT03374215||Adult AA with primary aldosteronism|Adult individuals (age 18 or older) with HTN and discrete adrenal masses or bilateral hyperplasia of the adrenal glands, with outpatient positive ARR or string clinical suspicion for PA
62324990|NCT03374215||Family members age >= 7 of participants|DNA from relatives of patients (age 7 or older)
62692094|NCT04114825|PLACEBO_COMPARATOR|Placebo|Total of 12 SC vaccinations with placebo. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
62692095|NCT06669702|NO_INTERVENTION|Control|Healthy controls
62324991|NCT06012240|EXPERIMENTAL|Study 1: Group 1 Upadacitinib Dose A|Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.
62483856|NCT04056338||Delirium|Patients with delirium as assessed by the bedside nurse using Confusion Assessment Method for the ICU.
62483857|NCT04056338||Non-delirium|Patients without delirium.
62483858|NCT06194877|EXPERIMENTAL|Part 1: Dose Finding Part|Participants with advanced or metastatic CRC and with known mutation status and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS and with documented disease progression by RECIST during or after at least 1 line of prior therapy will be enrolled into 4 planned sequentially run cohorts. Participants will receive escalating doses of BGB-3245 in combination with panitumumab to establish the MTD and RP2D by assessing the safety, tolerability, preliminary antitumor activity, and pharmacokinetics (PK) for the combination of BGB-3245 with panitumumab.
62692096|NCT06669702|EXPERIMENTAL|Exercise|12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week.
62324992|NCT06012240|EXPERIMENTAL|Study 1: Group 2 Upadacitinib Dose B|Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.
62324993|NCT06012240|EXPERIMENTAL|Study 1: Group 3 Placebo|Participants will receive matching placebo once daily for 24 weeks in Period A.
62324994|NCT06012240|EXPERIMENTAL|Study 1: Group 4 Upadacitinib Dose A|Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.
62324995|NCT06012240|EXPERIMENTAL|Study 1: Group 5 Upadacitinib Dose B|Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.
62324996|NCT06012240|EXPERIMENTAL|Study 1: Group 6 Placebo|Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.
62324997|NCT06012240|EXPERIMENTAL|Study 2: Group 1 Upadacitinib Dose A|Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.
62324998|NCT06012240|EXPERIMENTAL|Study 2: Group 2 Upadacitinib Dose B|Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.
62483859|NCT06194877|EXPERIMENTAL|Part 2: Dose Expansion Part, Group 1|Participants with advanced or metastatic CRC that harbors KRAS or NRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
62692097|NCT06669702|EXPERIMENTAL|Routine care|Routine care
62692098|NCT03436849|EXPERIMENTAL|ESN364 dose-1 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
62692099|NCT03436849|EXPERIMENTAL|ESN364 dose-2 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
62132831|NCT01782846|ACTIVE_COMPARATOR|Dafalgan Codeine®|Two capsules of Dafalgan Codeine® given orally (1000 mg Paracetamol + 46.8 mg Codeine)
62132832|NCT01404585|PLACEBO_COMPARATOR|Arm 1: Placebo|
62324999|NCT06012240|EXPERIMENTAL|Study 2: Group 3 Placebo|Participants will receive matching placebo once daily for 24 weeks in Period A.
61931729|NCT02659956||Patient controls|a target population of 50 patient controls will also be enrolled. These individuals will have diseases that share clinical, imaging, or biological features with MS.
61931730|NCT02659956||Patients with multiple sclerosis|Up to 150 adults (age \>= 18) with MS, diagnosed by applicable consensus criteria, and by the best judgment of the investigators, at the time of enrollment.
62132833|NCT01404585|EXPERIMENTAL|Arm 2: BMS-817399 (200 mg)|
62132834|NCT01404585|EXPERIMENTAL|Arm 3: BMS-817399 (400 mg)|
62325000|NCT06012240|EXPERIMENTAL|Study 2: Group 4 Upadacitinib Dose A|Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.
62325001|NCT06012240|EXPERIMENTAL|Study 2: Group 5 Upadacitinib Dose B|Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.
62325002|NCT06012240|EXPERIMENTAL|Study 2: Group 6 Placebo|Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.
62325003|NCT06012240|EXPERIMENTAL|Study 3: Group 1 Upadacitinib Dose B (SALT > 20)|Participants receiving upadacitinib Dose A with a SALT score \> 20 at Week 52 (end of Period B) of Study 1 or Study 2 will dose escalate to upadacitinib Dose B once daily for 108 weeks.
62325004|NCT06012240|EXPERIMENTAL|Study 3: Group 2 Upadacitinib Dose A (SALT ≤ 20)|Participants receiving upadacitinib Dose A with a SALT score ≤ 20 at Week 52 (end of Period B) of Study 1 or Study 2 will remain on upadacitinib Dose A once daily for 108 weeks.
62325005|NCT06012240|EXPERIMENTAL|Study 3: Group 3 Upadacitinib Dose B (Non-Sustained)|Participants who end Period B on upadacitinib Dose B with a with a SALT score \> 20 at Week 40 or Week 52 of Study 1 or Study 2 will remain on upadacitinib Dose B once daily for 108 weeks.
62325006|NCT06012240|EXPERIMENTAL|Study 3: Group 4 Upadacitinib Dose B (Sustained)|Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose B once daily for 108 weeks.
62325007|NCT06012240|EXPERIMENTAL|Study 3: Group 5 Upadacitinib Dose A (Sustained)|Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose A once daily for 108 weeks.
62325008|NCT06153563||Mitral valve prolapse|Patients with mitral valve prolapse
62325009|NCT06153563||Restrictive ischemic mitral valve|Patients with restrictive ischemic mitral valve
62483860|NCT06194877|EXPERIMENTAL|Part 2: Dose Expansion Part, Group 2|Participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that harbors KRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
62483861|NCT03123094|EXPERIMENTAL|Spesolimab low dose group (intravenous)|
62483862|NCT03123094|EXPERIMENTAL|Spesolimab medium dose group (intravenous)|
62483863|NCT03123094|EXPERIMENTAL|Spesolimab high dose group (intravenous)|
62483864|NCT03123094|EXPERIMENTAL|Spesolimab low dose group (subcutaneous)|
62132835|NCT01763853|OTHER|albumin|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
62483865|NCT03123094|PLACEBO_COMPARATOR|Placebo matching to spesolimab|
62692100|NCT03436849|PLACEBO_COMPARATOR|Placebo group in Part 1|Healthy male subjects will receive a single dose of Placebo.
62132836|NCT01763853|OTHER|crystalloid|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
62132837|NCT05654467|EXPERIMENTAL|Group 1: Young Children, nOPV3 10^5.5 CCID50|48 young children aged 1 to \<5 years will receive 2 doses of nOPV3 at a dose level of 10\^5.5 CCID50 on Day 1 and Day 29
62325010|NCT05452239|EXPERIMENTAL|Eptinezumab|Participants will receive an intravenous (IV) infusion of eptinezumab at Week 0 and Week 12.
62692101|NCT03436849|EXPERIMENTAL|Male ESN364 group in Part 2|Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
62692102|NCT03436849|EXPERIMENTAL|Pre-menopausal female ESN364 group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
62692103|NCT03436849|EXPERIMENTAL|Post-menopausal female ESN364 group in Part 2|Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
62697537|NCT00496119|EXPERIMENTAL|Photon Beam Therapy|Proton beam therapy combined with photon radiation therapy where combination improves final dose distribution.
61931731|NCT04960410||Low air pollution|
61931732|NCT04960410||High air pollution|
61931733|NCT03313778|EXPERIMENTAL|Part A: Dose Escalation and Dose Expansion|Participants will receive mRNA-4157 via an intramuscular (IM) injection on Day 1 of each 21-day cycle for up to 9 cycles.
62692104|NCT03436849|PLACEBO_COMPARATOR|Male placebo group in Part 2|Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
61931734|NCT03313778|EXPERIMENTAL|Part B: Dose Escalation and Dose Expansion|Participants will receive mRNA-4157 via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
61931735|NCT03313778|EXPERIMENTAL|Part A2: Dose Expansion|Participants will receive mRNA-4157 via an IM injection on Day 1 of each 21-day cycle and a SoC treatment every 2 weeks (Q2W) on Day 1 of each 21-day cycle starting from Cycle 5 of mRNA-4157 for up to 12 cycles.
61931736|NCT03313778|EXPERIMENTAL|Part C: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
61931737|NCT03313778|EXPERIMENTAL|Part D: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 18 cycles (approximately 1 year of treatment), whichever is sooner.
61931738|NCT03313778|EXPERIMENTAL|Part E1: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab every 6 weeks (Q6W) via IV infusion, and SoC chemotherapy every 3 weeks (Q3W) for up to 4 cycles during the perioperative and adjuvant phases.
61931739|NCT03313778|EXPERIMENTAL|Part E2: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab Q6W via IV infusion, and SoC chemotherapy Q3W for up to 4 cycles during the perioperative and adjuvant phases.
62325011|NCT05452239|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV infusion of matching placebo to eptinezumab at Week 0. Then, all participants will receive a single IV infusion of eptinezumab at Week 12.
62325012|NCT06153251|EXPERIMENTAL|Administration of BMS-986453|
62325013|NCT04849416|EXPERIMENTAL|LOXO-305|Participants received 200 mg of LOXO-305 administered orally once daily (QD) on Days 1 through 28 of a 28-day cycle. The treatment was continued until progressive disease, a discontinuation criterion, or unacceptable toxicity.
62325014|NCT05434078|ACTIVE_COMPARATOR|Group AB|Group AB will be started with 6-week Intervention A (OrthoFeet) and then switched to 6-week intervention B (own shoes)
62325015|NCT05434078|NO_INTERVENTION|Group BA|Group BA will be started with B (own shoes) for 6 weeks and then switched to Intervention A (OrthoFeet) for the same duration
62325016|NCT03570892|EXPERIMENTAL|Tisagenlecleucel treatment strategy|Patients received investigator's choice of optional platinum-based immunochemotherapy followed by lymphodepleting chemotherapy and a single dose of tisagenlecleucel
62325017|NCT03570892|ACTIVE_COMPARATOR|Standard of care treatment strategy|Patients received investigator's choice of platinum-based immunochemotherapy followed in responding patients by high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
62325018|NCT05829265||Intervention group in the feasibility study.|There will only be one group in the feasibility study (i.e. all 50 patients recruited will receive the intervention).
62325019|NCT03496402|EXPERIMENTAL|High risk Cohorts|Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
62692105|NCT03436849|PLACEBO_COMPARATOR|Pre-menopausal female placebo group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
62692106|NCT03436849|PLACEBO_COMPARATOR|Post-menopausal female placebo group in Part 2|Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
62697538|NCT06436781|EXPERIMENTAL|Maolactin|2 capsules containing a total of 500 mg/day active proteins taken once daily before the morning meal
62697539|NCT06436781|PLACEBO_COMPARATOR|Maltodextrin|2 capsules containing maltodextrin (0mg/day active proteins) taken once daily before the morning meal
61931740|NCT03313778|EXPERIMENTAL|Part E3: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab Q3W via IV infusion, and SoC chemotherapy Q2W or Q3W for up to 4 cycles during the perioperative and adjuvant phases.
61931741|NCT04418284||Veterinary Medical students|Veterinary Medical students who are studying anatomy during COVID-19 pandemic lockdown
61931742|NCT04478123|EXPERIMENTAL|romiplostim|"Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.~Regardless of the conditioning regimen received, all patients will receive romiplostim 3.0 mcg/kg SC on Day +1 and romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. No patient will receive more than six doses of romiplostim, even if platelets have not corrected by Day +42."
61931743|NCT06630143|EXPERIMENTAL|Combined Virtual and Clinical Simulation Arm|Participants in this arm will receive a combination of virtual simulation using the vSim® platform and clinical simulation with a high-fidelity manikin. The virtual simulation focuses on the management of a preeclampsia case, which will be followed by a hands-on clinical simulation replicating the same scenario. This arm aims to assess whether combining both educational strategies enhances theoretical knowledge and clinical judgment more effectively than either method alone.
62132838|NCT05654467|EXPERIMENTAL|Group 3: Young Children, nOPV3 10^6.0 CCID50|48 young children aged 1 to \<5 years will receive 2 doses of nOPV3 at a dose level of 10\^6.0 CCID50 on Day 1 and Day 29
62483866|NCT00767260|EXPERIMENTAL|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
62483867|NCT00767260|EXPERIMENTAL|BM-MNC|Autologous Bone Marrow mononuclear cell Infusion
62483868|NCT00767260|EXPERIMENTAL|HOT|hyperbaric oxygen therapy
62483869|NCT00767260|ACTIVE_COMPARATOR|Control|stand medical therapy (enhanced hemoglucose monitor, health and diet counseling and insulin injection)
62483870|NCT03923192|OTHER|ICDAS II|Visual tactile examination based on ICDASII scoring system
62483871|NCT04221113|ACTIVE_COMPARATOR|Group A ( Immobilization protocol)|Group A patients will receive static splints.By the end of 4 weeks the splint will be modified and patients will start doing physiotherapy. Movement at MCPJ will be from 0 to 45 degrees.
62483872|NCT04221113|ACTIVE_COMPARATOR|Group B( early active mobilization protocol).|Group B patients will receive splints in such a way that from 3rd post operative day patients will be instructed to do physiotherapy. Initially MCPJ movement will be from 0 to 30 degrees.
62692107|NCT06046378|ACTIVE_COMPARATOR|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to."
62692108|NCT06046378|ACTIVE_COMPARATOR|Control|The students in the control group will listen to the Normal Birth and Postpartum term course face-to-face with the classical education approach. The knowledge level of the students will be measured with the knowledge tests.
61931744|NCT06630143|ACTIVE_COMPARATOR|Virtual Simulation Arm|Participants in this arm will undergo a virtual simulation using the vSim® platform, which focuses on a preeclampsia case. This intervention will help participants develop clinical reasoning and decision-making skills in a virtual environment. The objective is to measure the effectiveness of virtual simulation alone on theoretical knowledge and clinical judgment.
62325020|NCT03496402|EXPERIMENTAL|Low risk Cohort|Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
61931745|NCT06684106|EXPERIMENTAL|Ursodeoxycholic acid group|Ursodeoxycholic acid (UDCA) 500 mg: This group of participants receive UDCA 500mg per day.
62325021|NCT06018454|NO_INTERVENTION|Provider counseling with pre-test|Counseling regarding PGT-A only with a provider(current standard of care), pre-test provided.
62325022|NCT06018454|EXPERIMENTAL|Handout on PGT-A and provider counseling with pre-test|Counseling regarding PGT-A with a provider and review of a handout(educational intervention), pre-test provided.
62325023|NCT06018454|EXPERIMENTAL|Handout on PGT-A, provider counseling and brief genetic counselor counseling with pre-test|Counseling regarding PGT-A only with a provider, review of a handout(educational intervention) and genetic counseling (counseling intervention), pre-test provided.
62325024|NCT03530774|EXPERIMENTAL|Egg while protein supplement|25 g of powdered egg white protein supplement daily for 6 months. Total of 20.6 g of protein in 25 g of supplement.
62325025|NCT03530774|PLACEBO_COMPARATOR|Maltodextrin supplement|25 g of powdered maltodextrin supplement daily for 6 months. Total 23.5 g of carbohydrate in 25 g of supplement.
62483873|NCT02376114|OTHER|Ginkgo-Placebo|Patients receive Ginkgo biloba and then placebo afterwards.
62483874|NCT02376114|OTHER|Placebo-Ginkgo|Patients receive placebo and then Ginkgo biloba afterwards.
62483875|NCT01354886|EXPERIMENTAL|FSH-GEX 25 IU|25 IU single dose
62483876|NCT01354886|EXPERIMENTAL|FSH-GEX 75 IU|75 IU single dose
62483877|NCT01354886|EXPERIMENTAL|FSH-GEX 150 IU|150 IU single dose
62483878|NCT01354886|EXPERIMENTAL|FSH-GEX 300 IU|300 IU single dose
62483879|NCT01354886|ACTIVE_COMPARATOR|Gonal-f|150 IU single dose
61931746|NCT06684106|PLACEBO_COMPARATOR|placebo group|This group of participants receive placebo.
61931747|NCT03779360|ACTIVE_COMPARATOR|Subjects 1-6|7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
62483880|NCT01354886|ACTIVE_COMPARATOR|Bravelle|150 IU single dose
62483881|NCT01354886|PLACEBO_COMPARATOR|Placebo|single dose
62483882|NCT00776763|EXPERIMENTAL|Avastin|
62483883|NCT06258421||Desmoid Tumor Patients|People who have been diagnosed with a desmoid tumor after the age of 18
62483884|NCT00869193|ACTIVE_COMPARATOR|Grape seed|Grape seed extract
62325026|NCT05381597|EXPERIMENTAL|Combination cream of 5-fluorouracil and calcipotriene|Participants randomized to this group will receive treatment with the combination cream consisting of 5-fluorouracil and calcipotriene twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
62325027|NCT05381597|ACTIVE_COMPARATOR|5-fluorouracil cream|Participants randomized to this group will receive treatment with 5-fluorouracil cream twice a day for 28 days.
62325028|NCT06386874|SHAM_COMPARATOR|BQ 3.0 Sham Stimulation Group|"Q Therapeutic System (BQ 3.0) sham stimulation group:~Device used: Q Therapeutic System (BQ 3.0)~In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 3.0 (frequency and intensity parameters will be set to zero so that no stimulation is delivered) including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention."
62325029|NCT06386874|ACTIVE_COMPARATOR|BQ 3.0 Active Stimulation Group|"Q Therapeutic System (BQ 3.0) active stimulation group:~Device used: Q Therapeutic System (BQ 3.0)~In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention."
62325030|NCT00055029||Affected males and family members|Up to 500 participants, including a minimum of 150 males diagnosed with XLRS
62483885|NCT00869193|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose
62692109|NCT00087035|EXPERIMENTAL|Taxotere plus Tarceva|"Patients receive Tarceva 150 mg daily for 21 consecutive days (one treatment cycle). In addition, all patients will receive single agent Taxotere 60 mg/m2 IV over 1 hour infusion every 21 ± 2 days and have it administered on day 1.~Taxotere + Tarceva to be taken for three cycles past maximal response or until one of the following occurs: 1) a drug-related toxicity requiring discontinuation, 2) disease progression, or 3) for a maximum of 9 cycles.~Upon completion of 9 cycles of Taxotere plus Tarceva, patients showing evidence of objective response (CR, PR or stable disease) may continue in the extension phase of the study and receive treatment with Tarceva alone. Treatment response evaluated after four cycles of Tarceva treatment(immediately prior to cycle 14). Patients with progression of disease will be taken off study. Responding and stable disease patients will remain on study for up to 8 extension-phase cycles for a total of 17 cycles."
61931748|NCT03779360|EXPERIMENTAL|Subjects 7-24|7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
61931749|NCT03779360|ACTIVE_COMPARATOR|Subjects 25-30|0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
61931750|NCT00772083|EXPERIMENTAL|1|
61931751|NCT00772083|ACTIVE_COMPARATOR|2|standard approach currently being used
62325031|NCT01306019|OTHER|cohort a|First 8 Patients Treated
61931752|NCT06235632|EXPERIMENTAL|Policy and Training Intervention|This intervention includes the combination of a 2-hour policy meeting held by the Oregon Liquor and Cannabis Commission to teach the current laws around selling recreational marijuana as well as access to the TrainToTend program which contains 5 modules: The Laws, ID Checking, Health Effects, Customer Service, and Rules of the Trade
61931753|NCT06235632|ACTIVE_COMPARATOR|Usual and Customary Policy and Training (UC-PT) (Control) Condition|This is basic Responsible Marijuana Vendor training currently provided by the Oregon Liquor and Cannabis Commission and includes reading a booklet on selling recreational marijuana responsibly and passing and exam
61931754|NCT06583239|EXPERIMENTAL|Engagement Navigator Service (ENS)|ENS will be a centralized service, staffed by dedicated professional to (1) receive and organize referrals, (2) complete ongoing specialized training in engagement science and evidence-based strategies, (3) provide unbiased support when participants' and/or families' relationships with a CSC program are poor, (4) re-engage participants in CSC or actively connect them with other services if preferred, and (5) continue contact with those who refuse treatment in case they reconsider.
61931755|NCT06583239|NO_INTERVENTION|No ENS|Those who do not participate in ENS will comprise the no intervention arm.
61931756|NCT04343729|ACTIVE_COMPARATOR|Methylprednisolone|0.5mg/kg injectable methylprednisolone sodium succinate, twice daily, for 5 days.
61931757|NCT04343729|PLACEBO_COMPARATOR|Placebo|Saline solution, twice daily, for 5 days. Injectable.
61931758|NCT05941897|EXPERIMENTAL|Group A|Ceralasertib plus durvalumab combination therapy Participants will be administered orally ceralasertib followed by IV durvalumab each 28 days cycle.
61931759|NCT00815243|EXPERIMENTAL|Telemed|Group of trauma\&orthopedic patients - for determination of clinical strategy and treatment plan telemedicine will be used
61931760|NCT00815243|ACTIVE_COMPARATOR|InternalControl|Group of trauma\&orthopedic patients from 3rd level trauma center - for determination of clinical strategy and treatment plan usual clinical approaches will be used
61931761|NCT00815243|ACTIVE_COMPARATOR|ExternalControl|Group of trauma\&orthopedic patients from 1-2rd level trauma centers (in rural and small municipal hospitals) - for determination of clinical strategy and treatment plan personal arriving of the expert by the car (so-called Urgent Expert Care) will be used
61931762|NCT02705027|ACTIVE_COMPARATOR|Standard|"After randomization one half of the patients receive a Freka®-Trilumina probe, which is inserted in nasogastric route an then pushed  using a small forceps which is inserted through the endoscope into the small intestine."
61931763|NCT02705027|EXPERIMENTAL|Freka®-EasyIn|The other half of the patients will receive a Freka®-EasyIn probe which is directly placed in the small intestine inserted over the endoscope, after endoscopy was initially pushed - as far as possible - into the small intestine.
62692110|NCT02034565|EXPERIMENTAL|Treatment A: Apixaban tablet|Apixaban Film coated Tablet Single dose 10 mg orally
62692111|NCT02034565|EXPERIMENTAL|Treatment B: Apixaban oral solution|Apixaban Solution Single dose 10 mg orally
61931764|NCT00745173|OTHER|1|
61931765|NCT06533735|EXPERIMENTAL|Experimental: Immediate Intervention Group|The immediate intervention group will take part in the online parent training program called the Parent Web (PW), with pre and post testing (before and after intervention).
61931766|NCT06533735|OTHER|Wait-List Control Group|This is a group of parents who are in a wait-list control group and will receive the Parent Web, after pre and post testing.
61931767|NCT04177433|EXPERIMENTAL|Corticosteroid Injection|Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
61931768|NCT04177433|PLACEBO_COMPARATOR|Saline|Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
61931769|NCT06070714|ACTIVE_COMPARATOR|Holmium laser with pulse modulation|
61931770|NCT06070714|ACTIVE_COMPARATOR|Thulium fiber laser|
61931771|NCT06259708|EXPERIMENTAL|Vim first|Participants assigned to this arm get LIFU stimulation in the Vim before the ZI.
61931772|NCT06259708|EXPERIMENTAL|ZI first|Participants assigned to this arm get LIFU stimulation in the Vim before the ZI.
61931773|NCT03622359|EXPERIMENTAL|SPECT/CT perfusion imaging|Patients with peripheral artery disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo SPECT/CT imaging as part of the research protocol.
62325032|NCT01306019|OTHER|cohort b|Patients 9 and Beyond
62325033|NCT04492722|EXPERIMENTAL|AZD5718 Dose 1 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 1 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
62483886|NCT06562127|EXPERIMENTAL|TRAIN-Vets|TRAIN-Vets is an 8-month intervention with aquatic-based exercise training and cognitive training combined with lifestyle coaching related to cognitive impairment risk factors. This intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in monthly lifestyle coaching based at SFVAHCS focused on other risk factors and symptoms.
62483887|NCT06562127|OTHER|Health Education Control|The Health Education Control (HEC) receives mailed educational materials about brain health and healthy lifestyles over 8 months, as well as regular contact with study staff.
62483888|NCT00833209|EXPERIMENTAL|1|Patients with Medication Overuse Headache (MOH)
62483889|NCT00833209|SHAM_COMPARATOR|2|controls suffering from migraine
62692112|NCT05379946|EXPERIMENTAL|Phase 1b Dose escalation of D-1553 plus IN10018|Phase 1b will evaluate up sequential cohorts with different doses of IN10018 together with D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
62325034|NCT04492722|EXPERIMENTAL|AZD5718 Dose 2 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 2 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
62325035|NCT04492722|EXPERIMENTAL|AZD5718 Dose 3 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 3 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
62325036|NCT04492722|PLACEBO_COMPARATOR|Placebo + Dapagliflozin 10 mg|Participants will receive once daily oral dose of placebo matched to AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
62325037|NCT06032546|PLACEBO_COMPARATOR|Arm A: Placebo|Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8.
62325038|NCT06032546|EXPERIMENTAL|Arm B: Budigalimab Dose A|Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8.
62325039|NCT06032546|EXPERIMENTAL|Arm C: ABBV-382 Dose A|Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.
62325040|NCT06032546|EXPERIMENTAL|Arm D: Budigalimab Dose A + ABBV-382 Dose B|Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8.
62325041|NCT06032546|EXPERIMENTAL|Arm E: Budigalimab Dose A + ABBV-382 Dose A|Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.
62325042|NCT06032546|EXPERIMENTAL|Arm F: Budigalimab Dose B|Participants will receive open-label budigalimab Dose B on Day 1 and Weeks 2, 4, and 6 (Note, no ABBV-382 or placebo will be administered).
62325043|NCT06089291||Persona IQ Cohort|"The study device is intended to relieve pain and restore function in patients with adequate quality and quantity of bone stock to support the prosthesis.~The device is indicated for use in patients undergoing a cemented TKA procedure that are normally indicated for at least a 58mm sized tibial stem extension.~To qualify to receive the CTE with CHIRP System, the Patient must meet the following requirements in addition to any requirements for TKA surgery as determined by the patient's Health Care Professionals (HCPs):~1. The Patient's anatomy must be capable of accepting the Zimmer Biomet Persona Tibia Baseplate with canturio™te construct sizing. This assessment will be conducted pre-operatively by the HCP using a CTE Template supplied by Canary Medical.~2. The patient must have access to a computer with a USB connection to set up their Home Base Station.~3. The Patient must have wireless internet in their domicile."
62325044|NCT06150898|EXPERIMENTAL|No pre-operative treatment|"Control group: Standard of care~Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
62325045|NCT06150898|EXPERIMENTAL|Pre-operative ketorolac|"Investigational Medicinal Product (IMP): Ketorolac~Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
62325046|NCT06150898|EXPERIMENTAL|Pre-operative pregabalin|"Investigational Medicinal Product (IMP): Pregabalin~Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
62325047|NCT06150898|EXPERIMENTAL|Pre-operative ketorolac and pregabalin|"Investigational Medicinal Products (IMPs): Ketorolac and pregabalin~Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
62325048|NCT05064410|EXPERIMENTAL|Educational Intervention and Referral for Fecal Immunochemical Test (FIT) Kit or Colonoscopy|The Community Health Educator (CHE) will provide online, phone or in-person colorectal cancer (CRC) early detection, prevention, and screening education to increase knowledge of CRC and the importance of screening. These sessions will be conducted in small in-person sessions, virtually within a group, virtually via a self-paced/self-directed online learning module, or one-on-one via phone. Additionally, the CHE will provide information regarding FIT kit and colonoscopy screening and the screening process for attendees. The CHE and research assistant will be prepared to provide access to screening resources and services through participants' existing coverage. Those participants who do not have a primary care provider will be provided information on obtaining FIT kits through the mechanisms of the Federally Qualified Health Center (FQHC) and/or a colonoscopy through the cancer center on a case by case basis.
62325049|NCT04874116|EXPERIMENTAL|Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging|Participants receive Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging for 12 months.
62325050|NCT04874116|ACTIVE_COMPARATOR|Mobile phone text messaging|Participants receive mobile phone text messaging alone for 12 months.
62325051|NCT05543681|ACTIVE_COMPARATOR|Active Comparator: IGC-AD1Active|IGC-AD1 Active Treatment THC plus another API plus excipients.
61931774|NCT03622359|EXPERIMENTAL|PET/CT perfusion imaging|Patients with peripheral artery disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo PET/CT imaging as part of the research protocol.
62483890|NCT00833209|SHAM_COMPARATOR|3|controls without any neurological disease
62483891|NCT00585286|EXPERIMENTAL|Fractional carbon dioxide laser system|Thirty total healthy subjects from two research centers with skin type I-IV of moderate to severe acne scarring received treatment with the 10,600 nm fractional carbon dioxide laser system.
62483892|NCT06560866|EXPERIMENTAL|Just Care for Families|Parents receiving Just Care for Families
61931775|NCT06332248|EXPERIMENTAL|Magnesium 375 mg|375 mg dietary supplement magnesium, one pill daily for up to 3 months.
62325052|NCT05543681|PLACEBO_COMPARATOR|Placebo Comparator: IGC-AD1 Placebo|IGC-AD1 Placebo, similar to Active in color, taste, and texture, with excipients but without APIs.
62325053|NCT04438213|EXPERIMENTAL|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
62325054|NCT04438213|EXPERIMENTAL|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
62483893|NCT02284035|EXPERIMENTAL|Group 1 Raltegravir / 3TC (MK0518B|Raltegravir / 3TC (MK0518B ) (50 patients)
62483894|NCT02284035|ACTIVE_COMPARATOR|Group 2 standard combination therapy|"NNRTI-Based Regimen:~• EFV/TDF/FTC~PI-Based Regimens:~ATV/r + TDF/FTC or DRV/r + TDF/FTC~INSTI-Based Regimens:~DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC~NNRTI-Based Regimens:~EFV plus ABC/3TC or RPV/TDF/FTC~PI-Based Regimen:~ATV/r plus ABC/3TC~PI-Based Regimens:~DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC~INSTI-Based Regimen:~RAL plus ABC/3TC~And other ART regimens"
62483895|NCT06626867|PLACEBO_COMPARATOR|placebo|Ingest maltodextrin
62483896|NCT06626867|EXPERIMENTAL|dietary fiber|Ingest indigestible dextrin supplementation
62483897|NCT04018768||Ibuprofen + Percocet|
62483898|NCT04018768||Percocet|
62483899|NCT06284941|NO_INTERVENTION|0.25% ropivacaine 30ml for iliac fascia block|
61931776|NCT06332248|PLACEBO_COMPARATOR|Placebo|Placebo (rice powder), one pill daily for up to 3 months. Identical appearance as the magnesium pill.
61931777|NCT05103527|EXPERIMENTAL|Non-operated Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with no history of knee surgery
61931778|NCT05103527|EXPERIMENTAL|Surgically Repaired Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with history of surgical repair of the knee
61931779|NCT04704219|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
62325055|NCT04438213|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
62325056|NCT03358810|ACTIVE_COMPARATOR|Active group|patients randomized to receive active PES
62325057|NCT03358810|SHAM_COMPARATOR|Sham treatmment|Patients randomized to sham will not receive any PES.
61931780|NCT03732690|OTHER|Diet High Protein (HP)|Diet High Protein (HP) : 30% protein, 40% carbohydrate and 30% fat
61931781|NCT03732690|OTHER|Diet Low Protein (LP)|Diet Low Protein (LP) : 10% protein, 55% carbohydrate and 35% fat
62325058|NCT04316546|EXPERIMENTAL|MK-7075 (miransertib)|This is a single-arm study. All study participants will be taking the experimental drug, MK-7075 (miransertib).
62325059|NCT02417714||Body CT group|100 subjects for a body CT
62325060|NCT02417714||Chest Ct Group|115 subjects for a chest CT
62325061|NCT01036685||379-bench-control|healthy control who will only do behavioral tasks
62325062|NCT01036685||379-bench-other-psych-diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who will only do behavioral tasks
62325063|NCT01036685||379-bench-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts) who will only do behavioral tasks
61931782|NCT05251311|EXPERIMENTAL|Social Risk Screening + Resource Map|Participants randomized to the experimental arm will receive a social risk assessment tool followed by an electronic resource map
61931783|NCT05251311|ACTIVE_COMPARATOR|Resource Map|Participants randomized to the active comparator group will receive only an electronic resource map
61931784|NCT05251311|EXPERIMENTAL|Resource Menu + Resource Map|Participants randomized to this experimental arm will receive a social resource menu tool followed by an electronic resource map.
62325064|NCT01036685||379-bench-user|someone with a DSM-V substance use disorder on a substance other than nicotine who will only do behavioral tasks
62325065|NCT01036685||379-control|healthy control who can do MRI
62325066|NCT01036685||379-other-psych -diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who can do MRI
62483900|NCT06284941|EXPERIMENTAL|0.25% ropivacaine+0.05% methylene blue 30ml for iliac fascia block|
62483901|NCT04939571||Preterm born infants treated for ROP|
62483902|NCT03446768|ACTIVE_COMPARATOR|Reactive Care (RC)|Participants in the RC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support.
62483903|NCT03446768|ACTIVE_COMPARATOR|Proactive Care (PC)|Participants in the PC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support. Additionally, the PC group will also receive access to an online study portal which houses an educational health curriculum covering topics related to COPD and OSA. The portal allows participants to send online messages to peer coaches and respiratory therapist coaches. PC group will also receive weekly updates.
62483904|NCT06410638||Healthy subjects|
62325067|NCT01036685||379-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts) who can do MRI
62325068|NCT01036685||379-user|someone with a DSM-V substance use disorder on a substance other than nicotine who can do MRI
62325069|NCT03484039|EXPERIMENTAL|Epilepsy Patients|The group will receive the module (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management) right after a baseline assessment. A post assessment and delayed post assessment will be conducted after the module is administered.
62483905|NCT05629728|EXPERIMENTAL|frail elderly-TC|Tai Chi group received 12 weeks of Tai Chi exercise program with 12 week follow-up, twice a week, 60 min per session led by a trained Tai Chi instructor
62483906|NCT05629728|NO_INTERVENTION|frail elderly-WC|control group received no intervention for 12 weeks, and will be provided the chance to participate in Tai Chi program if they choose.
62483907|NCT05770076|ACTIVE_COMPARATOR|Probiotic lysate (postbiotic and metabiotic) group|oral, 2 capsules per day (BID) for 3 month treatment
62483908|NCT05770076|PLACEBO_COMPARATOR|Placebo group|placebo, oral, 2 capsules per day (BID) for 3 month treatment
62483909|NCT06464549||Patients with severe acquired brain injury|Patients' inclusion criteria: (i) age≥18 years; (ii) time post-injury≥28 days. Exclusion criteria will be: (i) large craniectomy interfering with EEG recording; (ii) unstable clinical conditions; (iii) presence of ophthalmic disorders, or central or peripheral impairments in eyelid motility on clinical evaluation; (iv) administration of sedative medication in the previous 24h; (v) previous history of neurological or psychiatric diseases; (vi) written informed consent by patient or, where necessary, by primary caregiver.
62483910|NCT06464549||Benchmark sample|i) age≥18 years; ii) normal or corrected-to-normal vision excluding contact lenses; iii) a total score \>22.23 at the Montreal Cognitive Assessment (Santangelo et al., 2015); iv) written informed consent. Exclusion criteria: i) presence of ophthalmic disorders, or central or peripheral impairments in eyelid motility on clinical evaluation; ii) consumption of drugs acting on the central nervous system; iii) previous history of neurologic or psychiatric diseases.
62483911|NCT04626245|EXPERIMENTAL|Mindfulness training|Phone-delivered mindfulness training
62483912|NCT04626245|OTHER|Treatment as usual|Prenatal care
62483913|NCT05444647||HER2-positive|patients with newly diagnosed early stage HER2-positive breast cancer with an indication for standard trastuzumab-containing neoadjuvant treatment.
62692113|NCT05379946|EXPERIMENTAL|Phase 2 Doseexpansion of D-1553 plus IN10018|Phase 2 will include more subjects to further evaluate the safety and efficacy of D-1553 in combination with IN10018 in patients with solid tumors with KRasG12C mutation.
62692114|NCT06346119|NO_INTERVENTION|control|this arm will not received relaxing touch. It's a control arm
62325070|NCT05802056|EXPERIMENTAL|Treatment (aldesleukin, nivolumab, chemotherapy)|Patients receive aldesleukin IP over at least 40 minutes on days 1 and 8 of each cycle. Patients also receive standard of care nivolumab IV over 30 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, oxaliplatin IV over 2 hours on day 1, and flurouracil IV continuously over 46 hours on days 1-3 for each cycle. Cycles repeat every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo diagnostic laparoscopy with biopsy, PET/CT or PET/MRI, and collection of blood and tissue samples throughout the trial.
62325071|NCT06157580|OTHER|History of a preeclampsia|Women who had preeclampsia in their most recent pregnancy
62325072|NCT06157580|OTHER|History of a healthy pregnancy|Women who had an uncomplicated pregnancy
62325073|NCT03429036||1|Subjects must be diagnosed with a disorder of the head and neck region
62325074|NCT06449183|EXPERIMENTAL|Subjects with Mild Traumatic Brain injury|Subjects presenting to the ED within 12 hours of suspected mild head trauma and a Glasgow Score of 13-15 undergo to blood collection for VIDAS® TBI \[GFAP, UCH-L1\] testing.
62325075|NCT06171750|EXPERIMENTAL|ANK-101 IT Injection in Superficial Lesions|IT injections of ANK-101 once every 3 weeks into superficial lesions
62325076|NCT06171750|EXPERIMENTAL|ANK-101 IT Injection in Visceral Lesions|IT injections of ANK-101 once every 3 weeks into visceral lesions
62325077|NCT06171750|EXPERIMENTAL|ANK-101 IT Injection in Combination with Cemiplimab|IT injections of ANK-101 once every 3 weeks in combination with Cemiplimab into patients with high-risk locally advanced or metastatic CSCC that have superficial lesions
62325078|NCT06341712|EXPERIMENTAL|Arm A: Cabozantinib+ Best supportive care (BSC)|Participants will receive cabozantinib and BSC.
62325079|NCT06341712|OTHER|Arm B: Best supportive care (BSC)|Participants will receive BSC alone administered per investigator's discretion and institutional guidelines.
62325080|NCT06648668|EXPERIMENTAL|TMP-301|Once daily \[QD\] × 14 days
62325081|NCT06648668|PLACEBO_COMPARATOR|Placebo|Once daily \[QD\] × 14 days
62325082|NCT05464030|EXPERIMENTAL|Part 1: M9140|
62325083|NCT05464030|EXPERIMENTAL|Part 2A: M9140|
62483914|NCT02464657|EXPERIMENTAL|Ph 1 Nivolumab (1mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
62483915|NCT02464657|EXPERIMENTAL|Ph 1 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
62692115|NCT06346119|EXPERIMENTAL|Experimental|this arm will received relaxing touch twice a day
62692116|NCT06671626|EXPERIMENTAL|Parkinson's disease patients|This group consists of Parkinson's disease patients who are undergoing deep brain stimulation surgery for treatment of their movement disorder. Participants will complete behavioral assessments while receiving subcortical DBS stimulation.
62692117|NCT04464538|PLACEBO_COMPARATOR|Health information|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
62325084|NCT05464030|EXPERIMENTAL|Part 2B: M9140|
62325085|NCT05464030|EXPERIMENTAL|Part 2C: M9140 + Bevacizumab +/-Capecitabine|
62325086|NCT05464030|EXPERIMENTAL|Part 2D: M9140 + 5-fluorouracil + Folinic acid + Bevacizumab|
62325087|NCT06545331|EXPERIMENTAL|XB010 Single-Agent Dose Escalation Cohorts|XB010 will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects
62325088|NCT06545331|EXPERIMENTAL|XB010 + Pembrolizumab Dose Escalation Cohorts|XB010+Pembrolizumab will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects
62692118|NCT04464538|EXPERIMENTAL|Group education session and individualised coaching (online)|Participants assigned to the WALC-R intervention will attend a virtual baseline educational group session which will include a maximum of five people. The aim of the sessions will be to introduce the basics of the benefits of walking for exercise and why exercise is beneficial, as well as to give information, support and motivation to help participants to independently walk more in their daily routines.The group session will also include goal setting, in which participants will be encouraged to set their own daily walking targets to increase their habitual levels of walking. All participants will be given a pedometer to self-monitor how far they walk and a diary to record activity context throughout the intervention daily. Participants will meet briefly (20-30 minutes) via the internet with an assigned coach every 2 weeks.
61931785|NCT04974528|EXPERIMENTAL|Afrezza (Technosphere Insulin) + Basal Insulin|"Individualized dose of Afrezza (Technosphere Insulin) for each patient before each meal (breakfast, lunch, and dinner) for 26 weeks.~Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient."
62132839|NCT05654467|EXPERIMENTAL|Group 5: Young Children, nOPV3 10^6.5 CCID50|48 young children aged 1 to \<5 years will receive 2 doses of nOPV3 at a dose level of 10\^6.5 CCID50 on Day 1 and Day 29
62132840|NCT05654467|ACTIVE_COMPARATOR|Groups 2, 4 and 6: Young Children, mOPV3|48 young children aged 1 to \<5 years will receive 2 doses of mOPV3 at a dose level of ≥ 10\^5.8 CCID50 on Day 1 and Day 29
62325089|NCT06545331|EXPERIMENTAL|XB010 Single-Agent Dose Expansion Cohorts|XB010 will be administered at the recommended dose for expansion (RDE) every 3 weeks in the following tumor-specific cohorts: non-small cell lung cancer (NSCLC), hormone-receptor-positive breast cancer (HR+BC), head and neck squamous cell cancer (HNSCC), pancreatic ductal adenocarcinoma (PDAC), endometrial cancer (EC) and triple-negative breast cancer (TNBC)
62325090|NCT06579105|EXPERIMENTAL|Arm 1|Participants will receive xx mg once daily dose of AZD5004
62325091|NCT06579105|EXPERIMENTAL|Arm 2|Participants will receive xx mg once daily dose of AZD5004
62325092|NCT06579105|EXPERIMENTAL|Arm 3|Participants will receive xx mg once daily dose of AZD5004
62325093|NCT06579105|EXPERIMENTAL|Arm 4|Participants will receive xx mg once daily dose of AZD5004
62325094|NCT06579105|EXPERIMENTAL|Arm 5|Participants will receive xx mg once daily dose of AZD5004
62325095|NCT06579105|EXPERIMENTAL|Arm 6|Participants will receive xx mg once daily dose of AZD5004
62325096|NCT06579105|ACTIVE_COMPARATOR|Arm 7|Participants will receive once daily dose of Semaglutide as active comparator
62325097|NCT06579105|PLACEBO_COMPARATOR|Arm 8|Participants will receive matching placebo for each AZD5004 arm
62325098|NCT06400511|ACTIVE_COMPARATOR|Pimecrolimus 0.3% Ophthalmic Ointment|Study Drug
62325099|NCT06400511|PLACEBO_COMPARATOR|Placebo Ophthalmic Ointment|Placebo
62325100|NCT05711394|EXPERIMENTAL|Open-Label PK Substudy: Atogepant Dose A (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of atogepant Dose A to determine appropriate dose for the 6-11 year old group in double-blind treatment period.
62325101|NCT05711394|EXPERIMENTAL|Open-Label PK Substudy: Atogepant Dose B (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of atogepant Dose B to determine appropriate dose for the 6-11 year old group in double-blind treatment period.
62325102|NCT05711394|EXPERIMENTAL|Double-Blind Treatment Period: High Dose Atogepant (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of high dose atogepant once a day for 12 weeks.
62325103|NCT05711394|EXPERIMENTAL|Double-Blind Treatment Period: Placebo (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.
62132841|NCT05654467|EXPERIMENTAL|Group 7: Infants, nOPV3 10^5.5 CCID50|240 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV3 at a dose level of 10\^5.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
62325104|NCT05711394|EXPERIMENTAL|Double-Blind Treatment Period: Low Dose Atogepant (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of low dose atogepant once a day for 12 weeks.
62325105|NCT05711394|EXPERIMENTAL|Double-Blind Treatment Period: High Dose Atogepant (6-11 yrs)|Participants aged 6-11 will receive oral tablets of high dose atogepant once a day for 12 weeks.
62325106|NCT05711394|EXPERIMENTAL|Double-Blind Treatment Period: Placebo (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.
62325107|NCT05711394|EXPERIMENTAL|Double-Blind Treatment Period: Low Dose Atogepant (6-11 yrs)|Participants aged 6-11 will receive oral tablets of low dose atogepant once a day for 12 weeks.
62325108|NCT03949647||1|Healthy males and females aged 18 years and older
62325109|NCT04530110|EXPERIMENTAL|Fremanezumab|The dose of Fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
61931786|NCT04974528|ACTIVE_COMPARATOR|RAA Injection + Basal Insulin|"Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks.~Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient."
61931787|NCT06668155|ACTIVE_COMPARATOR|Assignment 0|
61931788|NCT06668155|ACTIVE_COMPARATOR|Assignment 1|
62132842|NCT05654467|EXPERIMENTAL|Group 9: Infants, nOPV3 10^5.5 CCID50|240 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV3 at a dose level of 10\^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
62132843|NCT05654467|EXPERIMENTAL|Group 11: Infants, nOPV3 10^6.5 CCID50|140 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV3 at a dose level of 10\^6.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
62325110|NCT05648500|EXPERIMENTAL|Cenerimod 4 mg|Participants will receive cenerimod once daily in addition to background SLE therapy.
62325111|NCT05648500|PLACEBO_COMPARATOR|Matching placebo|Participants will receive matching placebo once daily in addition to background SLE therapy.
62325112|NCT04014673|OTHER|Patients with a PGRN gene mutation|Symptomatic patients with a PGRN gene mutation
62325113|NCT04014673|OTHER|Presymptomatic individuals|Asymptomatic 'At-risk' individuals with a PGRN gene mutation
62325114|NCT04014673|OTHER|healthy volunteers|'At-risk' individuals without a PGRN gene mutation
62325115|NCT06052072|EXPERIMENTAL|PADN with Gradient Denervation System|Procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
61931789|NCT06415734|EXPERIMENTAL|rTMS|Subjects were treated with transcranial magnetic stimulation with the addition of a figure-of-eight coil on top of conventional western medicine treatment, and the treatment modalities were all LF-rTMS 20 min, 1200 pulses, 120% RMT in M1 contralateral to the brain lesion, with a treatment cycle of 5 days. And subjects will be assessed on the relevant scales on Day 1 and Day 5 of treatment and will be tested using a near infrared functional brain imaging device before, during and after treatment on that day.
61931790|NCT06415734|NO_INTERVENTION|control|Patients received only conventional Western medications. And subjects will be assessed on the relevant scales on Day 1 and Day 5 of treatment and will be tested using a near infrared functional brain imaging device before, during and after treatment on that day.
61931791|NCT06710678|EXPERIMENTAL|Social Media Study Break|Medical students will engage in a 10 minute social media study break
62692119|NCT05902975|EXPERIMENTAL|Fiber reinforced composite space maintainer|12 children received fiber reinforced composite (FRC) space maintainer without silver nanoparticle.
62692120|NCT05902975|EXPERIMENTAL|Fiber reinforced space maintainer with silver nano particles|12 children received fiber reinforced composite (FRC) space maintainers modified with silver nanoparticles.
61931792|NCT06710678|ACTIVE_COMPARATOR|Physical Activity Study Break|Medical student will engage in a 10 minute light physical activity study break
61931793|NCT06710678|NO_INTERVENTION|No study break|Medical students will continue to study instead of a break
61931794|NCT06662357|ACTIVE_COMPARATOR|Active Comparator: Family Connections Intervention|
61931795|NCT06662357|NO_INTERVENTION|Treatment as Usual|
61931796|NCT01590992|EXPERIMENTAL|Exposure-based Psychotherapy for Somatic Symptoms|First: 1-2 months waiting period; followed by: exposure-based psychotherapy
61931797|NCT01590992|ACTIVE_COMPARATOR|Relaxation Therapy|First: 1-2 months waiting period; followed by: relaxation therapy
61931798|NCT06608472|EXPERIMENTAL|N0877|in the test group will be required to take 1 tablet of the test drug N0877. 1 tablet a day for 56 days +/- 4 days.
61931799|NCT06608472|ACTIVE_COMPARATOR|Benicar HCT®|in the test group will be required to take 1 tablet of the Benicar HCT®. 1 tablet a day for 56 days +/- 4 days.
62325116|NCT06560281|EXPERIMENTAL|Motion Minder Group|Children in this arm receives a structured motion minder therapy protocol designed to improve fine motor skills in children with spastic hemiplegic cerebral palsy through targeted activities.
62692121|NCT05040932|EXPERIMENTAL|YH004|The dose escalation phase includes 7 dose levels of YH004, and the highest dose is up to 10mg/kg. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 16 cycles if patients receive benefits.
61931800|NCT06710951|EXPERIMENTAL|Povidone-iodine 1%|Povidone-iodine 1% was used as antiseptic during anti-VEGF intravitreal injection
61931801|NCT06710951|ACTIVE_COMPARATOR|Povidone-iodine 5%|Povidone-iodine 5% was used as antiseptic during anti-VEGF intravitreal injection
61931802|NCT02834377|EXPERIMENTAL|Treatment algorithm|Patients allocated to the study group will be connected to a cardiac output monitor. An initial haemodynamic assessment will be performed at the beginning of surgery and at regular time intervals (every 15 minutes) during surgery. The personal cardiac output value is targeted.
61931803|NCT02834377|NO_INTERVENTION|Standard of Care|Patients allocated to the control group will receive the standard care of the hospital.
61931804|NCT05682235|EXPERIMENTAL|Therapeutic Exercise AND Pain Neurophysiology Education|"Therapeutic exercise:~Therapeutic exercise is the systematic and planned execution of posture movements and physical activities to correct or prevent alterations, improve or enhance physical functioning, prevent risk factors for solid and optimize overall health status.~Pain Neurophysiology Education:~Education in pain neurophysiology consists in describing to the patient the neurobiology and neurophysiology of his nervous system pain to improve the processing of it and diminish the threatening meaning of pain."
61931805|NCT05682235|SHAM_COMPARATOR|Sham Comparator|Talks about healthy habits
61931806|NCT04920136|EXPERIMENTAL|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|"A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.~A strip of a free gingival graft is then harvested from the patient's palate. This strip is only 2 to 3 mm wide ,1 to 1.5 mm thick and has an appropriate length to cover the full apical extension of the recipient site. The strip is sutured immediately with 6-0 monocryl sutures. Coronal to the strip, the periosteal bed is covered with ADM, which is already rehydrated in sterile saline for 10 min, trimmed and customized to fit the available space. The ADM is then stabilized on the periosteal bed with the epithelium side facing upward. The ADM is fixed on the recipient bed by periosteal 6-0 monocryl sutures."
61931807|NCT04920136|ACTIVE_COMPARATOR|Free gingival graft.|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area will be sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
61931808|NCT04990336|EXPERIMENTAL|DDC(Dachaihu decoction compound) Group|Treated with Dachaihu decoction compound and regular therapies
61931809|NCT04990336|ACTIVE_COMPARATOR|RSM(rhubarb single medicine) Group|Treated with rhubarb single medicine and regular therapies
62692122|NCT05912400||NF1 Group|This study will look to enroll 40 to 45 adults over 18 years old diagnosed with NF1.
61931810|NCT04990336|OTHER|N Group|Treated with regular therapies and without traditional Chinese medicine
61931811|NCT01814618|NO_INTERVENTION|Observation|These subjects did not have improved sense of smell after surgery and were randomized to this observation group or treatment group. These patients will be observed post-operatively but will not receive the trial medication.
62692123|NCT05912400||Control Group|This study will look to enroll 10 to 15 adults over 18 years old without NF1.
62692124|NCT01854762|EXPERIMENTAL|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
62692125|NCT01854762|ACTIVE_COMPARATOR|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
61931812|NCT01814618|EXPERIMENTAL|Treatment|"These subjects did not have improved sense of smell after surgery and were randomized to this treatment group or the observation. These patients will be observed post-operatively and will receive a 3-month course of topical nasal steroids(budesonide respules).~Drug: Budesonide Respules~Other Names:~Pulmicort respules~Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months."
61931813|NCT04095390|EXPERIMENTAL|Arm A|Hormone receptor positive,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Letrozole until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
61931814|NCT04095390|EXPERIMENTAL|Arm B|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Capecitabine until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
61931815|NCT04095390|EXPERIMENTAL|Arm C|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
61931816|NCT05470985|EXPERIMENTAL|Ozanimod Dose Level 1|
61931817|NCT05470985|EXPERIMENTAL|Ozanimod Dose Level 2|
61931818|NCT01003444|EXPERIMENTAL|Cohort 1|Muscle biopsy in healthy volunteers
61931819|NCT03366779|OTHER|Surgery with 6mm ACD|ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
62692126|NCT06628960|EXPERIMENTAL|su jok therapy;|su jok therapy; application of seeds placed at certain points on the palm of the hand every day for the first ten days after birth, every day to be kept in the hand for 2 hours.
61931820|NCT03827837|EXPERIMENTAL|SHR-1210 combined with Famitinb|SHR-1210 + Famitinib
61931821|NCT03180268|OTHER|Arm I (Clinical Observation)|Patients undergo observation after gross total resection.
61931822|NCT03180268|EXPERIMENTAL|Arm II (Radiation Therapy)|Patients undergo radiation therapy 5 days a week over 6.5-7 weeks for a total of 33 fractions after gross total resection.
61931823|NCT01329484|EXPERIMENTAL|Cognitive training|
61931824|NCT01329484|EXPERIMENTAL|Reminiscence therapy|
61931825|NCT01329484|OTHER|Control|This group will receive neither of the above interventions or any other similar interventions
62132844|NCT05654467|ACTIVE_COMPARATOR|Groups 8, 10 and 12: Infants, mOPV3|240 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of mOPV3 at a dose level of ≥ 10\^5.8 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
61931826|NCT05061745|ACTIVE_COMPARATOR|Guided Meditation VR for Wellness|Selected modules of commercially available meditation VR
61931827|NCT05061745|ACTIVE_COMPARATOR|Accelerated Transcranial Magnetic Stimulation: Treatment A|Intermittent theta-burst over dlPFC
61931828|NCT05061745|ACTIVE_COMPARATOR|Accelerated Transcranial Magnetic Stimulation: Treatment B|Intermittent theta-primed 10Hz over mPFC
61931829|NCT04290312|OTHER|Mastiha oil|As a control to the experimental design, timepoint 0 was considered.
61931830|NCT04749667|EXPERIMENTAL|Arm A - Crossover with MSCs at baseline and placebo at 6 months|Receives mesenchymal stem cells at baseline and placebo at 6 months
61931831|NCT04749667|EXPERIMENTAL|Arm B - Crossover with placebo at baseline and MSCs at 6 months|Receives placebo at baseline and mesenchymal stem cells at 6 months
61931832|NCT03509610|ACTIVE_COMPARATOR|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
61931833|NCT03509610|EXPERIMENTAL|LOW SUG|Diet consisting of 50% carbohydrate (\<5% sugar), 15% protein, 35% fat
61931834|NCT03509610|EXPERIMENTAL|LOW CHO|Diet consisting of \<8% carbohydrate (\<5% sugar), 15% protein, \>77% fat
61931835|NCT04219904|EXPERIMENTAL|Diagnostic (PET/MRI)|Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.
61931836|NCT01369615|EXPERIMENTAL|Oxycodone HCl controlled-release|Oxycodone hydrochloride controlled-release tablets
61931837|NCT01226043|EXPERIMENTAL|Lantus (insulin glargine) vial & syringe|10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
61931838|NCT01226043|EXPERIMENTAL|Lantus (insulin glargine) SoloSTAR pen|3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
62132845|NCT05654467|EXPERIMENTAL|Group 13: Neonates, nOPV3 10^5.5 CCID50|120 neonates (day of birth + 3 days) will receive 2 doses of nOPV3 at a dose level of 10\^5.5 CCID50 on Day 1 and Day 29.
62132846|NCT05654467|EXPERIMENTAL|Group 15: Neonates, nOPV3 10^6.0 CCID50|120 neonates (day of birth + 3 days) will receive 2 doses of nOPV3 at a dose level of 10\^6.0 CCID50 on Day 1 and Day 29.
62325117|NCT05985395|EXPERIMENTAL|HEART Camp Connect|Participants will have access to a virtual exercise platform or membership to a medical exercise facility. Participants will meet with a virtual exercise coach via Zoom on a weekly basis.
62692127|NCT06628960|NO_INTERVENTION|control group|control group, Su Jok will not be applied
62692128|NCT02333292||IFN|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing pegylated interferon in combination with any DAA
62692129|NCT02333292||IFN-free|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing one or more DAA
62692130|NCT03775109|ACTIVE_COMPARATOR|Canakinumab 150mg/ml solution for injection|150mg/ml solution for injection
61931839|NCT06135207||COVID-19 Group|Patients with a history of COVID-19 infection and experiencing symptoms of dysphagia.
61931840|NCT06135207||Non-COVID-19 Group|Patients who do not have a history of COVID-19 infection but experience symptoms of dysphagia.
61931841|NCT03387150|EXPERIMENTAL|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
61931842|NCT03387150|EXPERIMENTAL|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
61931843|NCT03387150|EXPERIMENTAL|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
61931844|NCT03387150|EXPERIMENTAL|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
61931845|NCT03387150|EXPERIMENTAL|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
62483916|NCT02464657|EXPERIMENTAL|Ph 2 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase II dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
62692131|NCT03775109|PLACEBO_COMPARATOR|Dextrose|
62325118|NCT05985395|NO_INTERVENTION|Usual Care|Participants will have access to a virtual exercise platform or membership to a medical exercise facility.
62325119|NCT05020678|EXPERIMENTAL|NKX019 - CAR NK cell therapy|All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 weekly doses of NKX019 on Day 0, 7, and 14 of a 28-day cycle. Combination cohorts (if opened) will additionally receive rituximab with each cycle.
62692132|NCT01610401|ACTIVE_COMPARATOR|Pretreatment with metformin|Pretreatment with metformin 500 mg three times a day for 3 days.
62692133|NCT01610401|NO_INTERVENTION|No pretreatment.|no intervention
61931846|NCT03387150|EXPERIMENTAL|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
61931847|NCT03387150|PLACEBO_COMPARATOR|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
61931848|NCT06674031||Chronic kidney disease|
61931849|NCT06674031||Healthy individuals|
61931850|NCT00116168|EXPERIMENTAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
61931851|NCT00116168|EXPERIMENTAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
61931852|NCT00116168|EXPERIMENTAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
61931853|NCT00116168|EXPERIMENTAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
61931854|NCT03861923|EXPERIMENTAL|Dry needling and exercise|
61931855|NCT03861923|SHAM_COMPARATOR|Sham dry needling and exercise|
62325120|NCT03493425|ACTIVE_COMPARATOR|Arm A (surgery, IMRT, cisplatin, carboplatin)|Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
62483917|NCT05164354|EXPERIMENTAL|Aromatherapy|Aromatherapy will be done in the form of a 20-minute application period for three days.
61931856|NCT03300323|ACTIVE_COMPARATOR|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
61931857|NCT03300323|ACTIVE_COMPARATOR|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
61931858|NCT03803683|EXPERIMENTAL|mLab App Intervention|Youth randomized to the intervention arm (arm 1) will be provided with the mLab App, 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at their 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
61931859|NCT03803683|ACTIVE_COMPARATOR|Standard of Care HIV Information Control Arm|Youth randomized to the Standard of Care HIV information control arm (arm 2) will receive standard-of-care HIV/STI testing-related risk reduction counseling, a box of condoms, PrEP assessment, and referral information for clinics that provide PrEP during their first visit. Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including pre-exposure prophylaxis (PrEP) and HIV testing information that is found on the CDC website.They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
61931860|NCT03803683|ACTIVE_COMPARATOR|HIV Home Tests|Youth randomized to the HIV home testing arm (arm 3) will be provided with the 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at the 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
61931861|NCT05355298|EXPERIMENTAL|AMP945|Part A: AMP945 administered in dose escalating cohorts Part B: AMP945 recommended phase 2 dose
61931862|NCT06707233|EXPERIMENTAL|SIRT|Patients will receive SIRT treatment
61931863|NCT06166082|EXPERIMENTAL|Active iTBS-DLPFC|The active group will receive active iTBS. Treat 10 times a day with 1800 pulses per day for consecutive 5 days, with 50 minutes inter-session intervals.
62483918|NCT05164354|EXPERIMENTAL|music concert|"Music concert will be performed in the form of a 20 minute daily practice period for three days."
61931864|NCT06166082|SHAM_COMPARATOR|Sham iTBS-DLPFC|The sham group will receive sham iTBS. Treat 10 times a day with 1800 pulses per day for consecutive 5 days, with 50 minutes inter-session intervals.
61931865|NCT04266223|EXPERIMENTAL|Mask-free surface monitoring|Lay in treatment position for 20 minutes with surface monitoring technology activated
61931866|NCT05843760||undergraduate students|Hacettepe University Faculty of Physical Therapy and Rehabilitation undergraduate students
62692134|NCT01610401|ACTIVE_COMPARATOR|Pretreatment with Metformin/caffeine|to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion
62692135|NCT01610401|OTHER|No metformin, only pretreatment with caffeine|No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).
62692136|NCT01257243|EXPERIMENTAL|DRUG 1|Syrup of oxomemazine, guaifenesin and potassium iodate
62692137|NCT01257243|ACTIVE_COMPARATOR|DRUG 2|Syrup of guaifenesin
62692138|NCT05064423|EXPERIMENTAL|Clinical Trials Education|Community Health Educators (CHE) will provide Clinical Trial Education to increase knowledge of Clinical Trials and the importance of Clinical Trial participation.
61931867|NCT04203381|OTHER|Transgender Participant|Transgender children at Tanner stage II or early Tanner stage III between the ages of 9 and 14. Must be a current patient at a gender patient and within 6 weeks of initiating pubertal blockade treatment
61931868|NCT04203381|NO_INTERVENTION|Cisgender Control Participant|Cisgender children Tanner II or early Tanner III between 9 and 14 matched by race, age, and BMI.
61931869|NCT06470867|EXPERIMENTAL|Intervention|VA S.A.V.E. Training
61931870|NCT06470867|SHAM_COMPARATOR|Control|Myths and Facts of Wounded Warriors
61931871|NCT04968379|EXPERIMENTAL|Ferric Carboxymaltose|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 5.0 mg/kg dose of FCM
61931872|NCT04968379|EXPERIMENTAL|Injectafer|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 7.5 mg/kg dose dose of FCM.
61931873|NCT04069078|ACTIVE_COMPARATOR|Hyoscine butylbromide|
61931874|NCT04069078|PLACEBO_COMPARATOR|Control|
61931875|NCT04307914|ACTIVE_COMPARATOR|External Beam Radiotherapy|In the control arm, patients will undergo standard radiotherapy for painful bone metastases.The radiation schedule is at the discretion of the treating radiation oncologist.
61931876|NCT04307914|EXPERIMENTAL|MR-HIFU|In the intervention arm, patients will be offered MR-HIFU treatment instead of standard radiotherapy. Treatment will be given following the international guidelines for MR-HIFU.
61931877|NCT04307914|EXPERIMENTAL|Combination EBRT + MR-HIFU|In the combination arm, patients will undergo standard radiotherapy followed by MR-HIFU in a short timeframe.
61931878|NCT04147585|EXPERIMENTAL|Intervention Arm|Three cycles of a 5-day Intermittent Reduced Calorie Diet
61931879|NCT04147585|NO_INTERVENTION|Control Arm|Regular Diet
61931880|NCT03514017|EXPERIMENTAL|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
61931881|NCT06259084|EXPERIMENTAL|Measurement|Intrauterine biomarker will be measured twice in all enrolled patients during the frozen embryo transfer cycle: on the day before embryo transfer and on the day of embryo transfer.
61931882|NCT05994560|OTHER|without temporary occlusion|Without temporary occlusion: No occlusion of uterine or útero-ovarian ligaments during laparoscopy myomectomy
62692139|NCT00434811|EXPERIMENTAL|Islet Transplantation|Participants will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG), sirolimus, and low-dose tacrolimus.
61931883|NCT05994560|ACTIVE_COMPARATOR|With temporary occlusion|Temporary occlusion of the uterine arteries and utero-ovarian ligaments during laparoscopic myomectomy
61931884|NCT06710418|EXPERIMENTAL|Arm I (restrictive threshold)|Patients undergo PRBC transfusion if at any point their hemoglobin level is 7 gm/dL or less, starting the day after SOC chemotherapy/stem cell infusion is complete and continuing for up to 42 days. Patients also undergo collection of blood samples on study.
61931885|NCT06710418|EXPERIMENTAL|Arm II (liberal threshold)|Patients undergo PRBC transfusion if at any point their hemoglobin level is 9 gm/dL or less, starting the day after SOC chemotherapy/stem cell infusion is complete and continuing for up to 42 days. Patients also undergo collection of blood samples on study.
61931886|NCT06704087||Telemonitoring|patients with chronic wounds of the lower limb benefiting from the digital solution for remote monitoring of healing.
61931887|NCT02420977|EXPERIMENTAL|DCFPyL PET-MRI fusion or PET/MRI|"* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
62339954|NCT02303951|EXPERIMENTAL|vemurafenib + cobimetinib + atezolizumab|"Run-In (week 1-4):~* Day 1-21: vemurafenib 960 mg bid orally + cobimetinib 60 mg od orally~* Day 22-28: vemurafenib 720 mg bid orally~Triple-Treatment (week 5 ongoing):~atezolizumab 840 mg Q2W i.v. + vemurafenib 720 mg bid orally + cobimetinib 60 mg od 21/7 orally (vemurafenib: daily intake; cobimetinib: 3 weeks on drug, 1 week off)"
61931888|NCT03694912||Aggressive RCC Group|RCC with synchronous metastasis, recurrence, or cancer-specific death
61931889|NCT03694912||Non-aggressive RCC Group|RCC without synchronous metastasis, recurrence, or cancer-specific death
61931890|NCT03671018|EXPERIMENTAL|Dose Finding|Participants will receive mosunetuzumab in combination with polatuzumab vedotin. Dose finding will be guided by the observed incidence of dose-limiting toxicities (DLTs) at each dose level.
61931891|NCT03671018|EXPERIMENTAL|Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL|Participants with at least one line of prior therapy (2L+) and that have relapsed or refractory (R/R) follicular lymphoma (FL) will receive mosunetuzumab + polatuzumab vedotin.
62339955|NCT00074724|ACTIVE_COMPARATOR|Medical Therapy|All medical interventions know to improve outcomes in patients with ischemic left ventricular dysfunction.
62692140|NCT06305403||1|Patients with sepsis who develop AKI
62692141|NCT06305403||2|Patients with sepsis who not develop AKI
62692142|NCT04427670|OTHER|Regular speech therapy|Regular speech therapy will be provided to the controlled group.
62692143|NCT04427670|OTHER|Group intervention|Group intervention will be provided to the experimental group.
61931892|NCT03671018|EXPERIMENTAL|Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL|2L+ participants with R/R diffuse large B-cell lymphoma will receive mosunetuzumab + polatuzumab vedotin.
61931893|NCT03671018|EXPERIMENTAL|Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL|Participants with at least 2 lines of prior therapy (3L+) will receive subcutaneous (SC) mosunetuzumab + polatuzumab vedotin.
61931894|NCT03671018|EXPERIMENTAL|Mosunetuzumab SC + Polatuzumab Vedotin 2L+R/R DLBCL|2L+ participants with R/R DLBCL will receive SC mosunetuzumab and polatuzumab vedotin.
61931895|NCT06709625|ACTIVE_COMPARATOR|Group of patients who underwent erector spinae plane block|20 ml %0.25 bupivacaine solution will be given under the erector spinae muscle under USG guidance in the prone position and intraoperative and postoperative data will be recorded.
61931896|NCT06709625|ACTIVE_COMPARATOR|Group of patients who undervent transversus thoracic plane block|20ml %0.25 bupivacaine solution will be given between the transversus thoracis muscle and the internal intercostal muscle under USG guidance in the supin position and intraoperative and postoperative data will be recorded.
62483919|NCT03262103|EXPERIMENTAL|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
62692144|NCT05494619|EXPERIMENTAL|Crovalimab|Participants will receive a single intravenous (IV) infusion of crovalimab on Day 1 based on body weight, followed by crovalimab subcutaneous (SC) injection on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.
61931897|NCT05942053|PLACEBO_COMPARATOR|Group 1: Control group|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b). Patients will be treated with ramipril 10 mg/day and a placebo match vitamin K2 capsules once per day. The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
61931898|NCT05942053|ACTIVE_COMPARATOR|Vitamin K2 (menaquinone-7)|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b).Patients will be treated with ramipril 10 mg/day and vitamin K2 capsules (menaquinone-7) 90 mcg/day. The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
61931899|NCT04508140|EXPERIMENTAL|Cohort A|Cohort A consisted of 11 patients with CRC (microsatellite stable \[MSS\]) with nonresectable liver metastases suitable for IT injection and who had received at least 2 prior standard of care systemic anticancer therapies for advanced/metastatic disease. Patients who had resection of hepatic metastases and had hepatic recurrence, needed to have 1 or more prior standard of care systemic anticancer therapies in order to be eligible for this study. BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
61931900|NCT04508140|EXPERIMENTAL|Cohort B|Cohort B consisted of 7 patients with gastric or GC/GEJ with nonresectable liver metastases suitable for IT injection and who had received at least 1 prior standard of care systemic anticancer therapy for advanced/metastatic disease. BO-112 was administered in the liver metastasis at the dose of 1 mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
61931901|NCT04953052|EXPERIMENTAL|Intravenous Imatinib Mesylate|Intravenous Imatinib Mesylate solution- 200mg as an 8mg/ml solution, administered twice daily (400mg total daily dose). Each dose administered in a 25ml solution over a two-hour infusion period.
61931902|NCT04953052|PLACEBO_COMPARATOR|Intravenous Placebo|Intravenous Placebo matched solution- administered 25ml solution, twice daily over a two-hour infusion period
62325121|NCT03493425|EXPERIMENTAL|Arm B (docetaxel, cisplatin, carboplatin, surgery, IMRT)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV or carboplatin IV weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
62325122|NCT06382948|EXPERIMENTAL|Interventional Arm 1|"Patients will receive 345 mg of elacestrant and 7.5 mg of everolimus orally once daily.~Patients will remain in treatment until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first."
62325123|NCT06382948|ACTIVE_COMPARATOR|Control Arm 2|"Patients will receive elacestrant at (345 mg orally once daily) plus matched everolimus placebo.~Patients will remain in treatment until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first."
62325124|NCT06267911|EXPERIMENTAL|Cognitive stimulation and psychological support (RGS-ICU)|
62325125|NCT06267911|NO_INTERVENTION|Treatment as usual (TAU)|
62325126|NCT05840159|EXPERIMENTAL|Arm 1|100 mg of doxycycline orally administered twice daily for 3 days and 4 days of placebo to assigned female at birth (AFAB) participants \>/= 16 years old with confirmed urogenital Chlamydia trachomatis (CT). N=166.
62325127|NCT05840159|ACTIVE_COMPARATOR|Arm 2|100 mg of doxycycline orally administered twice daily for 7 days to assigned female at birth (AFAB) participants \>/= 16 years old with confirmed urogenital Chlamydia trachomatis (CT). N=166.
62325128|NCT05840159|EXPERIMENTAL|Arm 3|100 mg of doxycycline orally administered twice daily for 3 and 4 days of placebo days to assigned male at birth (AMAB) participants \>/= 16 years old with confirmed rectal Chlamydia trachomatis (CT). N=166.
62325129|NCT05840159|ACTIVE_COMPARATOR|Arm 4|100 mg of doxycycline orally administered twice daily for 7 days to assigned male at birth (AMAB) participants \>/= 16 years old with confirmed rectal Chlamydia trachomatis (CT). N=166.
62325130|NCT06331598|EXPERIMENTAL|Atezolizumab|Participants will be treated with atezolizumab every 4 weeks (Q4W) for 12 cycles (cycle = 28 days). After study treatment discontinuation participants will be followed until disease progression and afterwards, survival follow-up and new anti-cancer therapy will be collected until death (unless the participant withdraws consent, is lost to follow-up or the Sponsor terminates the study).
62325131|NCT06331598|EXPERIMENTAL|Atezolizumab + Tiragolumab|Participants will be treated with atezolizumab and tiragolumab Q4W for 12 cycles (cycle = 28 days). After study treatment discontinuation participants will be followed until disease progression and afterwards, information on survival follow-up and new anti-cancer therapy will be collected until death (unless the participant withdraws consent, is lost to follow-up or the Sponsor terminates the study).
62339956|NCT00074724|ACTIVE_COMPARATOR|CABG|Surgical revascularization in conjunction with optimal medical therapy.
62483920|NCT03262103|EXPERIMENTAL|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
62483921|NCT03262103|EXPERIMENTAL|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
62483922|NCT03262103|EXPERIMENTAL|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
62483923|NCT03033810||Consecutive patients with FFR and iFR|Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
62483924|NCT04200586|EXPERIMENTAL|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground
62325132|NCT05371093|EXPERIMENTAL|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV lymphodepleting chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered.
62325133|NCT05371093|ACTIVE_COMPARATOR|Standard of Care Therapy|"Participants will receive the investigator's choice of one of the following therapies/dosing schedules:~* Rituximab plus lenalidomide (R\^2) for 12 cycles (28-day cycle)~  * Cycle 1: lenalidomide 20 mg/day on Day 1 through Day 21; rituximab 375 mg/m\^2 on Day 1, Day 8, Day 15, and Day 22~ * Cycle 2 through Cycle 5: lenalidomide 20 mg/day on Day 1 through Day 21; Rituximab 375 mg/m2 on Day 1~ * Cycle 6 through Cycle 12: lenalidomide 20 mg/day on Day 1 through Day 21~* Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 6 cycles (21-day cycle)~  * rituximab 375 mg/m\^2 on Day 1~ * cyclophosphamide 750 mg/m\^2 on Day 1~ * doxorubicin 50 mg/m\^2 on Day 1~ * vincristine 1.4 mg/m\^2 (maximum 2 mg) on Day 1~ * prednisone 40 mg/m\^2 on Day 1 through Day 5~* Rituximab plus bendamustine (BR) for 6 cycles (28-day cycle)~  * rituximab 375 mg/m\^2 on Day 1~ * bendamustine 90 mg/m\^2 on Day 1 and Day 2"
62483925|NCT02376881|EXPERIMENTAL|EPO|20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days
61931903|NCT06709001||Quantitative - Children assessed for Malnutrition Risk|Children living in under-resourced communities
61931904|NCT06709001||Qualitative - NGOs, Caregivers, CHWs, and PHPs|Involved in the study as a staff or caregiver or have experience with pediatric malnutrition
61931905|NCT04387721||Trifocal IOL(Finevision IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted First group: FineVision
61931906|NCT04387721||Trifocal toric IOL (Finevision Toric IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted: Second group: FineVisionToric
61931907|NCT03646643|ACTIVE_COMPARATOR|PVI, non-PV triggers|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
62325134|NCT05624554|EXPERIMENTAL|Nemtabrutinib|Administered daily via oral tablet.
62325135|NCT05624554|ACTIVE_COMPARATOR|FCR or BR|Investigator's choice of fludarabine plus cyclophosphamide plus rituximab (FCR) OR bendamustine plus rituximab (BR). Participants will receive either rituximab or specified approved rituximab biosimilar.
62325136|NCT04221438|EXPERIMENTAL|Treatment (18F-FLT, PET/CT, encorafenib, binimetinib, surgery)|"NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.~SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.~ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity."
62339957|NCT00028561|EXPERIMENTAL|Treatment (ixabepilone, carboplatin)|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
62483926|NCT02376881|PLACEBO_COMPARATOR|control group|100 ml normal saline in 2 hr for 3 successive days
61931908|NCT03646643|ACTIVE_COMPARATOR|PVI, non-PV triggers & CS-LA connection|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.
61931909|NCT06612853||Pilot testing|A sample of n=20 Italian-speaking spine patients will complete the pre-final Italian version of the SQS and then be interviewed to discuss linguistic clarity and relevance. The same process will be performed with native German speakers for the German versions of the SQS
61931910|NCT06612853||Field testing|A sample of n=100 Italian-speaking spine patients will complete the final translated Italian version of the SQS, together with the PSQI. The same process will be performed for n=100 German-speaking patients.
62483927|NCT02579733|ACTIVE_COMPARATOR|Azathioprine|Azathioprine (1.5mg/kg) po for 1 year
62483928|NCT02579733|PLACEBO_COMPARATOR|Sugar pill|Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
62483929|NCT00974558|EXPERIMENTAL|fan directed to cheeks|Blow draft of air generated by fan across cheeks
62483930|NCT05643677|EXPERIMENTAL|Fruquintinib combined with irinotecan|Fruquintinib combined with irinotecan as a second-line treatment for advanced gastric cancer
62483931|NCT01267162||TDF Treatment|
62483932|NCT05418374|ACTIVE_COMPARATOR|Group A|18G epidural needle will be inserted intrathecally at the level of L4-L5. After insertion of the Tuohy needle, the subarachnoid space is found and the bevel is directed downward, and the spinal catheter is passed 2-3 cm into the subarachnoid space. After confirmation of aspiration cerebral spinal fluid through the catheter, an initial dose 2.5 mg (0.5 ml) of plain bupivacaine 0.5%(manufactured by sunny medical ) will be injected.
61931911|NCT03219918|ACTIVE_COMPARATOR|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
61931912|NCT03219918|NO_INTERVENTION|NO EndoRings|Colonoscopy is performed conventionally without any caps
62483933|NCT05418374|NO_INTERVENTION|Control group|traditional spinal anesthesia will be done with a 25G pencil point spinal needle at the level of L4-L5 with injection of 12.5 mg (2.5ml) of bupivacaine 0.5%. By adjusting the head level, T10 sensory block will be targeted
62483934|NCT03591458|EXPERIMENTAL|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
61931913|NCT03457688|ACTIVE_COMPARATOR|prebiotic inulin-type fructans|
61931914|NCT03457688|PLACEBO_COMPARATOR|placebo maltodextrin|
61931915|NCT03602729|NO_INTERVENTION|Group 1|No study related education given
61931916|NCT03602729|EXPERIMENTAL|Group 2|Written BF education
61931917|NCT03602729|EXPERIMENTAL|Group 3|Verbal BF education
61931918|NCT03602729|EXPERIMENTAL|Group 4|Video BF education
61931919|NCT00191646|EXPERIMENTAL|Gemcitabine/Carboplatin|Gemcitabine 1000 milligrams per meter square (mg/m\^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles
61931920|NCT00191646|ACTIVE_COMPARATOR|Paclitaxel/Carboplatin|Paclitaxel 175 milligrams per meter square (mg/m\^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles
61931921|NCT06190353|EXPERIMENTAL|Intervention|The experimental group which will have an immediate access to web-based psychotherapy.
61931922|NCT06190353|NO_INTERVENTION|Control|A wait-list control group which have one month delayed access to intervention program.
61931923|NCT00850161|EXPERIMENTAL|Nasulin™|Intranasal insulin spray
61931924|NCT00850161|ACTIVE_COMPARATOR|aspart|Subcutaneous administration
61931925|NCT03306706|EXPERIMENTAL|whole yellow pea|2 muffins containing 25g available carbohydrate from whole yellow peas. Intervention: Whole pea muffins
61931926|NCT03306706|EXPERIMENTAL|split yellow pea|2 muffins containing 25g available carbohydrate from split yellow peas. Intervention: Split pea muffins
61931927|NCT03306706|PLACEBO_COMPARATOR|wheat-PPGR|2 muffins containing 25g available carbohydrate from wheat flour. Intervention: Wheat muffins
61931928|NCT03306706|PLACEBO_COMPARATOR|wheat-satiety|"2 muffins containing wheat flour to match the calories in the whole and split pea muffins.~Intervention: Wheat muffins"
61931929|NCT00704912|ACTIVE_COMPARATOR|Lifestyle intervention|Orlistat/Meal Replacement/Lifestyle Modification
61931930|NCT00704912|ACTIVE_COMPARATOR|Oral Contraceptives (OCP)|Loestrin 1/20
61931931|NCT00704912|ACTIVE_COMPARATOR|Lifestyle/OCP Combined|Combination of treatments
61931932|NCT06500455|ACTIVE_COMPARATOR|ARM I (SRS)|Patients undergo SRS over 30-90 minutes for 1 fraction on study. Additionally, patients undergo CT and MRI on study.
61931933|NCT06500455|EXPERIMENTAL|ARM II (FSRS)|Patients undergo FSRS over 30-90 minutes for 3 fractions on study. Additionally, patients undergo CT and MRI on study.
61931934|NCT05386485||Group A (asymptomatic infection)|Absence of clinical manifestation during the acute phase of SARS-CoV-2 infection until discharge.
62325137|NCT05282927|ACTIVE_COMPARATOR|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
62339958|NCT01453309|ACTIVE_COMPARATOR|Cell Saver|Patients will have the use of a cell-saver during surgery
62339959|NCT01453309|PLACEBO_COMPARATOR|No Cell saver|Patient will not have cell saver available during surgery.
61931935|NCT05386485||Group B1 (mild symptomatic infection)|Clinical manifestation of the infection without severity signs (respiratory rate \< 30/minute; peripheral oxygen saturation (SpO2) \>94%) and no radiological evidence of pneumonia
61931936|NCT05386485||Group B2 (moderate symptomatic infection)|Clinical manifestation of the infection without severity signs (respiratory rate \< 30/minute; peripheral oxygen saturation (SpO2) \>94%) and radiological evidence of pneumonia
61931937|NCT05386485||Group B3 (severe symptomatic infection)|Clinical manifestation of the infection with severity signs (respiratory rate \> 30/minute; peripheral oxygen saturation (SpO2) \<94%) and radiological evidence of pneumonia
61931938|NCT05386485||Group B4 (critical symptomatic infection)|"Clinical manifestation of the infection with severity signs (respiratory rate \> 30/minute; peripheral oxygen saturation (SpO2) \<94%) and at least one of the following:~I) Acute Respiratory Distress Syndrome: defined under Berlin Criteria mostly defined by a PaFi\<200, II) Shock: Patient diagnosed with sepsis that despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial pressure ≥65 mmHg and lactate values \>2 mmol/L (\>18 mg/dL) or III) Organ dysfunction that requires ICU admission"
61931939|NCT06642454|EXPERIMENTAL|25 Hz non-expiratory gated taVNS|25 Hz non-expiratory gated transcutaneous auricular vagus nerve stimulation
61931940|NCT06642454|EXPERIMENTAL|25 Hz expiratory gated taVNS|25 Hz expiratory gated transcutaneous auricular vagus nerve stimulation
62132847|NCT05654467|EXPERIMENTAL|Group 17: Neonates, nOPV3 10^6.5 CCID50|120 neonates (day of birth + 3 days) will receive 2 doses of nOPV3 at a dose level of 10\^6.5 CCID50 on Day 1 and Day 29.
61931941|NCT06642454|EXPERIMENTAL|100 Hz expiratory gated taVNS|100 Hz expiratory gated transcutaneous auricular vagus nerve stimulation
61931942|NCT05991349|EXPERIMENTAL|IBI129|IBI129
61931943|NCT05798780|EXPERIMENTAL|ENHANCE Intervention Diet and Excerise|Participants will participate in 2 in-person supervised resistance training sessions every week for the 7 weeks (during radiation), followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks (after radiation). During radiation, participants will be provided 15 meals each week for 7 weeks. Participants will also attend weekly dietary coaching sessions. Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.
62132848|NCT05654467|ACTIVE_COMPARATOR|Groups 14, 16 and 18: Neonates, mOPV|120 neonates (day of birth + 3 days) will receive 2 doses of mOPV3 at a dose level of ≥ 10\^5.8 CCID50 on Day 1 and Day 29
62339960|NCT04448808|EXPERIMENTAL|BX-1 (dronabinol)|BX-1
62339961|NCT04448808|PLACEBO_COMPARATOR|Placebo|Placebo of BX-1
62692145|NCT05494619|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV infusion of placebo on Day 1 based on body weight, followed by placebo SC injections on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, IVIg background therapy will be administered QD for 5 days.
61931944|NCT05798780|EXPERIMENTAL|ENHANCE Intervention Diet Only|Participants will be provided 15 meals each week for 7 weeks that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals. Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.
61931945|NCT05798780|NO_INTERVENTION|Usual Care + Fitbit|Participants will receive handouts with diet and exercise education. Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.
61931946|NCT05471557|EXPERIMENTAL|Pain Stimulus|Capsaicin combined with heat applied to intact skin
61931947|NCT05471557|NO_INTERVENTION|No Stimulus|Nothing applied to skin
61931948|NCT01512056|EXPERIMENTAL|the immunogenicity profiles of the AdimFlu-S|"Experimental group: to receive either only one dose of influenza vaccine at day 0 or one more booster vaccination 3 weeks later.~Negative control group: dialysis patients who refused to receive influenza vaccination."
61931949|NCT01512056|NO_INTERVENTION|The safety outcome of the vaccine|Any adverse effect, including systemic or local site, will be recorded during the study period.
61931950|NCT05174884|EXPERIMENTAL|Single Casea S pellet|In Part 1 of this study, four women will each have a single Casea S pellet (22.2 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
61931951|NCT05174884|EXPERIMENTAL|Two Casea S pellets|In Part 2 of this study, sixteen women will each have two Casea S pellets (44.4 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
62132849|NCT02262767|EXPERIMENTAL|Single Ascending Doses Cohort 1|Single doses, given by oral solution, starting at 0.75 mg up to a possible maximum of 3.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
62692146|NCT06629961|EXPERIMENTAL|Abutment Group|"The patients in this group will undergo implant placement surgery using the conventional technique, which will include a full-thickness flap, biological drilling, and sub-crestal implant placement at 2 mm below the crest level. Since this is the Pilar group (Galimplant aesthetic straight abutment, NUEVAGALIMPANT), a 3 mm abutment will be placed during the same procedure, secured with a torque of 30 N. A healing cap will be applied and maintained until the osseointegration process is completed after three months.~After three months, this group will receive a cement-retained and screw-retained zirconia prosthesis, which will be placed over the previously installed abutment. The crown screw will be torqued to 25 N."
62692147|NCT06629961|EXPERIMENTAL|ti-base Group|"The patients in this group will undergo implant placement surgery using the conventional technique, which will include a full-thickness flap, biological drilling, and sub-crestal implant placement at 2 mm below the crest level. Since this is the Tibase group (3 mm Tibase from Galimplant, NUEVAGALIMPANT), submerged healing will be performed with a healing cap connected to the implant, which will remain in place until the osseointegration process is completed after three months.~After three months of osseointegration, a prosthesis will be placed directly connected to the implant platform via the 3 mm Tibase. The screw will be tightened to 30 N."
62692148|NCT05620134|EXPERIMENTAL|Dose Escalation|Escalating repeated doses of JK08 administered as a subcutaneous injection. A cycle of treatment is defined as 21 days, in which three doses of JK08 will be planned for administration.
61931952|NCT03564873|EXPERIMENTAL|Phase I|Up to 18 patients will be enrolled to one of three cohorts to receive various doses of omacetaxine over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
61931953|NCT03564873|EXPERIMENTAL|Phase II|Up to 33 patients will be enrolled to receive the maximum tolerated dose (determined in phase I) over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
61931954|NCT06704269|EXPERIMENTAL|YTB323|YTB323 single intravenous (i.v.) infusion
61931955|NCT03475693|EXPERIMENTAL|Treatment arm|Patients will receive PO magnesium 400 mg, Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID and 400 mg MagOx tablets BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
61931956|NCT03475693|PLACEBO_COMPARATOR|Placebo arm|Patients will receive PO Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
61931957|NCT06647498|EXPERIMENTAL|Stage 1: Remternetug|Active Remternetug- blinded
61931958|NCT06647498|PLACEBO_COMPARATOR|Stage 1: Matching placebo (Remternetug)|Matching placebo
61931959|NCT06647498|ACTIVE_COMPARATOR|Stage 2: Remternetug Open Label|Open label will start after last dose of Stage 1
61931960|NCT06492304|EXPERIMENTAL|CTX131|Administered by IV infusion following lymphodepleting chemotherapy
61931961|NCT04185883|EXPERIMENTAL|Sotorasib + trametinib + panitumumab|"Experimental: Sotorasib + trametinib + panitumumab Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
61931962|NCT04185883|EXPERIMENTAL|Sotorasib + RMC-4630|"Experimental: Sotorasib + RMC-4630 Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants, with KRAS p.G12C mutant advanced solid tumors."
61931963|NCT04185883|EXPERIMENTAL|Sotorasib + afatinib|"Experimental: Sotorasib + afatinib Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
62483935|NCT03591458|PLACEBO_COMPARATOR|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
62483936|NCT06402695||retrospective cohort|GEP- and Pulm- NET patients referred to the U.O.C. of Medical Oncology of the FPG - IRCCS since 01/01/2010 up to the date of approval of the study.
62483937|NCT06402695||prospective cohort|GEP- and Pulm- NET patients referred to the U.O.C. of Medical Oncology of the FPG - IRCCS starting from the date of approval of the study for the following 36 months.
62483938|NCT04345653|EXPERIMENTAL|Study arm - Hydroxychloroquine Sulfate (HCQ)|HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth
62483939|NCT04101396|OTHER|4 points blood glucose monitoring|4 points of self monitoring blood glucose which comprises of fasting, 1 hour post breakfast, 1 hour post lunch and 1 hour post dinner
62483940|NCT04101396|OTHER|7 points blood glucose monitoring|7 points of self monitoring blood glucose which comprises of fasting,1 hour post breakfast, 1 hour pre and post lunch, 1 hour pre and post dinner, pre bed at 10 pm
62483941|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
62483942|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
62483943|NCT03641222|EXPERIMENTAL|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
62483944|NCT03641222|ACTIVE_COMPARATOR|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
62692149|NCT05620134|EXPERIMENTAL|Dose Expansion Pembrolizumab Combination Cohort - Non-Small Cell Lung Cancer|JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with a mix of solid tumors. Pembrolizumab will be given IV per standard institutional practice
62692150|NCT05620134|EXPERIMENTAL|Dose Expansion Pembrolizumab Combination Cohort - Colorectal Cancer|JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with a mix of solid tumors. Pembrolizumab will be given IV per standard institutional practice
62692151|NCT05620134|EXPERIMENTAL|Dose Expansion Lenvatinib Combination Cohort - Hepatocellular Cancer|JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with a mix of solid tumors. Lenvatinib will be given orally per standard institutional practice
62692152|NCT05798585|EXPERIMENTAL|US-guided ESP block + sham US-guided TPV block|ESP block will be performed with local anesthetic under US guide; instead TPV block with physiological solution
61931964|NCT04185883|EXPERIMENTAL|Sotorasib + panitumumab +/- chemotherapy|"Experimental: Sotorasib + panitumumab +/- chemotherapy Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
62692153|NCT05798585|SHAM_COMPARATOR|sham US-guided ESP block + US-guided TPV block|ESP block will be performed with physiological solution under US guide; instead TPV block with local anesthetic
62692154|NCT03020316|NO_INTERVENTION|Usual Care|"Subjects will be encouraged to follow-up with their primary physicians.~Subjects will be informed that they will be periodically contacted by telephone and/or email by the research team for future assessments."
61931965|NCT04185883|EXPERIMENTAL|Sotorasib + atezolizumab|"Experimental: Sotorasib + atezolizumab Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
61931966|NCT04185883|EXPERIMENTAL|Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab|"Experimental: Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
62325138|NCT05282927|EXPERIMENTAL|Enhanced REP|EnREP begins with the same activities as foundational REP. Sites that do not meet EBP-specific a priori benchmarks reflecting adoption within 6 months will continue with foundational REP and will receive higher intensity support for a period of 6 months (enREP). Additionally, sites randomized to enREP that met adoption benchmarks but did do not meet the sustainment benchmark, will also receive intensified implementation support for the remainder of the study period (3 months). The higher intensity support will include one-on-one calls approximately every 3 to 4 weeks between site implementation teams and a trained practice facilitator (from Function QUERI team). The facilitator will coach individual sites using techniques, processes, and activities to help teams make decisions and identify and solve problems. Facilitators' actions will depend on each site's needs and clinical context.
62325139|NCT06321302|EXPERIMENTAL|BI 764524|BI 764524
62325140|NCT06321302|SHAM_COMPARATOR|Sham comparator to BI 764524|Sham comparator to BI 764524
62692155|NCT03020316|ACTIVE_COMPARATOR|Peer Mentor & Transcendental Meditation|"Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments.~In addition to the peer mentor, subjects will be instructed in transcendental meditation (TM) in the standard manner by a trained TM instructor."
61931967|NCT04185883|EXPERIMENTAL|Sotorasib Monotherapy|"Experimental: Sotorasib only Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer with brain metastases.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer with brain metastases."
61931968|NCT04185883|EXPERIMENTAL|Sotorasib + palbociclib|"Experimental: Sotorasib + palbociclib Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor."
61931969|NCT04185883|EXPERIMENTAL|Sotorasib + pembrolizumab|"Experimental: Sotorasib + pembrolizumab Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant non small cell lung cancer.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS P.G12C mutant non small cell lung cancer."
61931970|NCT04185883|EXPERIMENTAL|Sotorasib + MVASI® (bevacizumab-awwb)+ Chemotherapy|"Experimental: Sotorasib + MVASI® (bevacizumab-awwb)+ chemotherapy Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced colorectal cancer."
61931971|NCT04185883|EXPERIMENTAL|Sotorasib + TNO155|"Experimental: Sotorasib + TNO155 Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
61931972|NCT04185883|EXPERIMENTAL|Sotorasib + BI 1701963|"Experimental: Sotorasib + BI 1701963 Dose Exploration and Dose Expansion~* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~* Upon completion of dose exploration part of the study the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced non-small cell lung cancer and advanced colorectal cancer."
61931973|NCT04185883|EXPERIMENTAL|Sotorasib + AMG 404|Experimental: Sotorasib + AMG 404 Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors
61931974|NCT04185883|EXPERIMENTAL|Sotorasib + everolimus|Experimental: Sotorasib + everolimus Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.
61931975|NCT02927262|EXPERIMENTAL|Gilteritinib|Participants received gilteritinib 120 mg (three tablets of 40 mg) orally, once daily (QD) for up to 2 years or until a protocol-specified discontinuation criterion was met.
61931976|NCT02927262|PLACEBO_COMPARATOR|Placebo|Participants received gilteritinib matching placebo orally, QD for up to 2 years or until a protocol-specified discontinuation criterion was met.
61931977|NCT04444349|EXPERIMENTAL|Coenzyme Q10 group|Participants in the experimental group will be given 10mg of Coenzyme Q10 each time (3 times a day).
61931978|NCT04444349|SHAM_COMPARATOR|Control|patients only receive standard medical therapy.
61931979|NCT04310787||HBV-ACLF|To investigate the clinical events and prognosis of patients with hepatitis b associated acute on-chronic liver failure
61931980|NCT03384693|EXPERIMENTAL|Prophylactic Defibrotide|6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.
62325141|NCT06321302|ACTIVE_COMPARATOR|Aflibercept (Eylea®) - US only|Aflibercept (Eylea®) - US only
62692156|NCT03020316|ACTIVE_COMPARATOR|Peer Mentor|"We are no longer recruiting in this arm.~Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments."
62692157|NCT06641804|ACTIVE_COMPARATOR|Silicon ring pessary|Change to silicon ring pessary of nearest size
62692158|NCT06641804|PLACEBO_COMPARATOR|PVC ring pessary|Change of same PVC ring pessary
62692159|NCT06641583|EXPERIMENTAL|Exprimental|Experimental Group: This group will consist of children aged 10-14 diagnosed with high-functioning Autism Spectrum Disorder (ASD). These children will participate in LEGO therapy sessions once a week for 90 minutes over the course of 3 months (12 sessions total). The goal is to evaluate how LEGO therapy influences their social skills and behavior.
62325142|NCT06100289|EXPERIMENTAL|Induction Period: Participants ≥30 kg, Vedolizumab (High Dose) IV|Participants weighing ≥30 kg will receive vedolizumab (High Dose) IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.
62692160|NCT06641583|ACTIVE_COMPARATOR|Control|Control Group: This group will also consist of children aged 10-14 diagnosed with high-functioning ASD. However, these children will not receive LEGO therapy. Instead, they will continue their usual treatments in their local settings without participating in the LEGO therapy sessions. This group's outcomes will be compared with the experimental group to assess the effectiveness of LEGO therapy.
62692161|NCT06127303|EXPERIMENTAL|Toripalimab Combined with Cryoablation|Patients with oligometastatic driver-negative advanced NSCLC after first-line immunotherapy progress would be treated with Toripalimab Combined with Cryoablation.
62692162|NCT05358223|NO_INTERVENTION|Prostatic block|Patients who will be treated with periprostatic block
62132850|NCT02262767|EXPERIMENTAL|Single Ascending Doses Cohort 2|Single doses, given by oral solution, starting at 4.5 mg up to a possible maximum of 9.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
61931981|NCT00402142|ACTIVE_COMPARATOR|Pulsed dendritic cells untreated patients|Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
61931982|NCT00402142|PLACEBO_COMPARATOR|non pulsed dendritic cells untreated patients|
61931983|NCT00402142|ACTIVE_COMPARATOR|pulsed dendritic cell treated patient|treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
61931984|NCT00402142|ACTIVE_COMPARATOR|pulsed dendritic cell in treated patients|patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
61931985|NCT00402142|PLACEBO_COMPARATOR|non pulsed dendritic cells|
61931986|NCT01946854|OTHER|Observation Arm|Patients observed for 6 months, then will receive chemotherapy for 6 months.
61931987|NCT01946854|ACTIVE_COMPARATOR|Chemotherapy Group|Patients receive chemotherapy for 6 months, then observed for 6 months. The exact type of fluoropyrimidine-based chemotherapy is not mandated and final treatment decisions will be left to the medical oncologist who is administering the chemotherapy. All chemotherapy adjustments will be done by the treating medical oncologist according to standard of care.
61931988|NCT03819101|NO_INTERVENTION|Arm A|Standard of Care (SOC) for CRPC
61931989|NCT03819101|EXPERIMENTAL|Arm B|SOC + acetylsalicylic acid 100 mg daily
61931990|NCT03819101|EXPERIMENTAL|Arm C|SOC + atorvastatin 80 mg daily
61931991|NCT03819101|EXPERIMENTAL|Arm D|SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8
61931992|NCT02675114|ACTIVE_COMPARATOR|Surgical aortic valve replacement (SAVR)|
61931993|NCT02675114|EXPERIMENTAL|Transcatheter aortic valve replacement (TAVR)|
61931994|NCT06602102||Low Vision|Participants with Low Vision
61931995|NCT00990938|PLACEBO_COMPARATOR|Saline|If randomized to placebo the patient will receive a subcutaneous injection once per week for 4 weeks
62132851|NCT00593489|EXPERIMENTAL|Basal Insulin Initiation Strategy|"Basal Insulin Initiation Strategy which includes:~1. support by community pharmacist~2. support by diabetes specialist"
62692163|NCT05358223|ACTIVE_COMPARATOR|Prostatic block+Music|Patients who will be treated with periprostatic block and who will be simultaneously listened to music
61931996|NCT00990938|EXPERIMENTAL|IMO-2125|If randomized to receive the experimental treatment, IMO-2125, the patient will receive a subcutaneous injection once per week for 4 weeks
61931997|NCT06548165|EXPERIMENTAL|Wearables|Participants will wear at least three sensors for the measurement of different physiological outcomes (heat rate variability, skin conductance, pulserate) for two weeks. Women can use a fourth sensor to measure the body core temperature intravaginally. Food intake will be assessed via photos.
62692164|NCT05358223|ACTIVE_COMPARATOR|Prostatic block+Tens|Patients who will undergo periprostatic block and concomitant TENS
61931998|NCT02252887|EXPERIMENTAL|Gemcitabine, Trastuzumab, and Pertuzuma|The regimen will consist of gemcitabine at 1000mg/m\^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it \< 6 weeks prior to Cycle 1 Day 1.
61931999|NCT06596291|EXPERIMENTAL|EG110A (low dose)|Patients who Received EG110A (low dose)
61932000|NCT06596291|EXPERIMENTAL|EG110A (Middle Dose)|Patients who Received EG110A (middle dose)
61932001|NCT06596291|EXPERIMENTAL|EG110A (High Dose)|Patients who Received EG110A (high dose)
62692165|NCT05358223|ACTIVE_COMPARATOR|Music|Patients who will only listen to music without periprostatic block
62692166|NCT05358223|ACTIVE_COMPARATOR|Tens|Patients who will only be treated with TENS without periprostatic block
61932002|NCT04867239|OTHER|A two-day education program|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise for metabolic syndrome. Participants visited at 3- and 6-month after camp for follow-up.
61932003|NCT01289457|EXPERIMENTAL|Clofarabine + Idarubicin + Cytarabine|Phase I: Clofarabine Starting dose 15 mg/m2 by vein for 5 days (days 1-5) + Idarubicin 10 mg/m2 by vein on day 1-3 + Cytarabine 1 g/m2 by vein on day 1-5.
61932004|NCT01289457|EXPERIMENTAL|Group 1 CIA|Phase II, Group 1 CIA (Clofarabine + Idarubicin + Cytarabine): Clofarabine Maximum Tolerated Dose (MTD) based on Phase I by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
61932005|NCT01289457|EXPERIMENTAL|Group 2 FLAI|Phase II, Group 2 FLAI (Fludarabine + Idarubicin + Cytarabine): Fludarabine 30 mg/m2 by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
61932006|NCT05914116|EXPERIMENTAL|DB-1311 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 1 on Day 1 of each cycle Q3W
61932007|NCT05914116|EXPERIMENTAL|DB-1311 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 2 on Day 1 of each cycle Q3W
62132852|NCT00593489|NO_INTERVENTION|Usual Practice|The physicians randomized to this group proceeded with their usual practice
62132853|NCT02212496||Cancer-associated stroke|Cryptogenic embolic stroke with active cancer
62132854|NCT02212496||Cryptogenic embolic stroke|Cryptogenic embolic stroke without active cancer
62692167|NCT04684862|EXPERIMENTAL|Hepatic Artery Infusion (HAI) Therapy|Eligible patients will be implanted with a device that combines components of two commercially available drug delivery pumps to administer regional chemotherapy (FUDR) to the liver. Specifically, a Medtronic pump is being used with an Intera tapered catheter, instead of the Medtronic catheter.
61932008|NCT05914116|EXPERIMENTAL|DB-1311 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 3 on Day 1 of each cycle Q3W
61932009|NCT05914116|EXPERIMENTAL|DB-1311 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 4 on Day 1 of each cycle Q3W
62483945|NCT06258681|ACTIVE_COMPARATOR|Incentive spirometry group|The incentive spirometry group will continue the 8-week training with Volumetric Triflo. Individuals will be expected to exhale normally and hold their breath for at least 3 seconds after taking as deep a breath as possible. In the first week after surgery, the individual will be asked to work with an incentive spirometry in 10 repetitions every hour when awake. The group also followed standard program which includes phases of chest physiotherapy (modified postural drainage and assisted coughing techniques) and early progressive mobilization (gradually increasing walking distance in the corridor depending on patient tolerance). Participants in both groups will continue aerobic exercise training in the clinic until the end of the 8th week after discharge. Aerobic exercise training includes a bicycle ergometer, two days a week, 20-30 minutes, and perceived effort in the range of 60-70% of the maximal heart rate, in the range of 4-6 according to the Modified Borg Scale.
62692168|NCT04758988|OTHER|Group A|This group will receive access to the AI augmented digital online educational system and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
61932010|NCT05914116|EXPERIMENTAL|DB-1311 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 5 on Day 1 of each cycle Q3W
61932011|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 1|Subjects with advanced/unresectable, or metastatic SCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
61932012|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 2|Subjects with advanced/unresectable, or metastatic NSCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
61932013|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 3|Subjects with advanced/unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
61932014|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 4|Subjects with advanced/unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
61932015|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 5|Subjects with advanced/unresectable, or metastatic melanoma who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
61932016|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 6|Subjects with advanced/unresectable, or metastatic HCC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
62325143|NCT06100289|EXPERIMENTAL|Induction Period: Participants >15 to <30 kg, Vedolizumab (Medium Dose) IV|Participants weighing \>15 to \<30 kg will receive vedolizumab (Medium Dose), IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.
62325144|NCT06100289|EXPERIMENTAL|Induction Period: Participants ≥10 to ≤15 kg, Vedolizumab (Low Dose) IV|Participants weighing ≥10 to ≤15 kg will receive vedolizumab (Low Dose), IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.
62325145|NCT06100289|EXPERIMENTAL|Maintenance Period: Participants ≥30 kg, Vedolizumab 108 mg SC Q2W|Participants with clinical response at Week 14 weighing ≥30 kg will receive vedolizumab 108 mg, SC injection, Q2W from Week 14 to Week 32 in the Maintenance Period.
62325146|NCT06100289|EXPERIMENTAL|Maintenance Period: Participants ≥10 to <30 kg, Vedolizumab 108 mg SC Q4W|Participants with clinical response at Week 14 weighing ≥10 to \<30 kg will receive vedolizumab 108 mg, SC injection, Q4W from Week 14 to Week 30 in the Maintenance Period.
62325147|NCT05150990|EXPERIMENTAL|Virtual Reality|Weekly activities using virtual reality (Rendever)
62325148|NCT05150990|ACTIVE_COMPARATOR|Video Chat|Weekly activities using video conference (Zoom)
62325149|NCT06242821|PLACEBO_COMPARATOR|Observation|Patients who select to be part of the trial, but not partake in either yoga or physical therapy (PT), choosing to be part of an observation group.
62325150|NCT06242821|ACTIVE_COMPARATOR|Physical Therapy|Patients who select or are randomized into the Physical Therapy group will partake in PT as per non-surgical AIS standard of care.
62325151|NCT06242821|ACTIVE_COMPARATOR|Yoga|Patients who select or are randomized into the yoga group will partake in an online 20 min yoga class 2 days per week for 6 months, consisting of a set protocol.
62325152|NCT06280235|EXPERIMENTAL|BI 1569912 low dose group|
62325153|NCT06280235|EXPERIMENTAL|BI 1569912 medium dose group|
62325154|NCT06280235|EXPERIMENTAL|BI 1569912 high dose group|
62325155|NCT06280235|PLACEBO_COMPARATOR|Placebo group|
62325156|NCT05065216|EXPERIMENTAL|DM199|DM199 administered by a single intravenous (IV) dose followed by a subcutaneous (SC) dose within 12 hours and then 2 times a week for three weeks (until Day 21).
62325157|NCT05065216|PLACEBO_COMPARATOR|Placebo|Placebo administered by a single intravenous (IV) dose followed by a subcutaneous (SC) dose within 12 hours and then 2 times a week for three weeks (until Day 21).
62325158|NCT05554380|EXPERIMENTAL|Treatment (paclitaxel, ipatasertib)|Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.
62325159|NCT04603807|EXPERIMENTAL|Entrectinib|Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
62325160|NCT04603807|ACTIVE_COMPARATOR|Crizotinib|Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
62325161|NCT06523595|EXPERIMENTAL|VX-993 and Metformin|Metformin will be administered to participants as a single oral dose on Day 1 and then co-administered with VX-993 on Day 10. VX-993 dose will be administered every 12 hours (q12h) from Day 5 through Day 14.
62325162|NCT06276335|EXPERIMENTAL|Immediate implant placement and conventional loading (Test)|In this group, a dental implant will be placed on the same day as tooth extraction and loaded after 3 months
62483946|NCT06258681|EXPERIMENTAL|Individualized respiratory training group|In the first week after surgery, the personalized breathing exercise device will be adjusted to the resistance level corresponding to 40% of the initial pressure load, MIP, and MEP measurements. Participants will be asked to rest and repeat the training for ten sets following five breathing cycles. In each set, there will be a one-minute rest break between repetitions. Participants can practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. As the progression progresses, the perceived exertion level will be increased by 5-10% every week to a range of 4-6 according to the Modified Borg Scale. The training will continue for eight weeks.
61932017|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 7|Subjects with advanced/unresectable, or metastatic cervical cancer who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
62132855|NCT03017469|EXPERIMENTAL|ARISE Intervention|Nurses who participate in the 1.5 day ARISE Intervention
62132856|NCT03017469|NO_INTERVENTION|Control Group|Nurses who do not participate in the ARISE Intervention
62325163|NCT06276335|ACTIVE_COMPARATOR|Late implant placement and conventional loading (Control)|In this group, a dental implant will be placed after complete bone healing (4 - 6 months after tooth extraction) and loaded after 3 months
62325164|NCT05487599|EXPERIMENTAL|LY3884961|LY3884961 is an advanced therapy investigational medicinal product administered as a single intravenous infusion.
62325165|NCT04458883|EXPERIMENTAL|Myocardial Infarction Group|Patients diagnosed with a myocardial infarction
62325166|NCT04458883|EXPERIMENTAL|Healthy Volunteers|Healthy Volunteers
62325167|NCT06433219|EXPERIMENTAL|Tuvusertib with Niraparib|
62325168|NCT06433219|EXPERIMENTAL|Tuvusertib with Lartesertib|
62325169|NCT06379217|EXPERIMENTAL|PSMA-predominant NEPC|
62483947|NCT00949143|EXPERIMENTAL|forward position|
62483948|NCT00949143|EXPERIMENTAL|rear position|
62483949|NCT01837914|EXPERIMENTAL|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
62483950|NCT01837914|ACTIVE_COMPARATOR|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
62483951|NCT05602766||NGENLA (Somatrogon)|Patients with GHD without epiphyseal closure who received NGENLA (Somatrogon)
62483952|NCT03811418|EXPERIMENTAL|Kanjinti/Pertuzumab plus Vinorelbine|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus vinorelbine.
61932018|NCT05914116|EXPERIMENTAL|DB-1311 Dose Expansion 8|Subjects with other advanced or metastatic solid tumors who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
61932019|NCT01786265|ACTIVE_COMPARATOR|Arm A (finite androgen ablation)|Participants receive either leuprolide acetate via injection every month or every 4 months, goserelin acetate via injection every month, or degarelix via injection every month for 8 months. Patients also receive bicalutamide PO QD, flutamide PO TID, or nilutamide PO QD. Patients may crossover to Arm B with disease progression after 8 months.
61932020|NCT01786265|EXPERIMENTAL|Arm B (finite androgen ablation, abiraterone, prednisone)|Participants receive leuprolide acetate, goserelin acetate, degarelix, bicalutamide, flutamide, or nilutamide as in Arm A. Patients also receive abiraterone acetate PO daily for 8 months and prednisone daily. Patients may crossover to Arm A with disease progression after 8 months.
62132857|NCT05966350||Sensory neuronopathies (SNN)|Patients with Sensory neuronopathies (SNN) will be included.
62325170|NCT06379217|EXPERIMENTAL|SSTR2-predominant NEPC|
62483953|NCT03811418|ACTIVE_COMPARATOR|Kanjinti/Pertuzumab plus Docetaxel|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus docetaxel.
62483954|NCT05724784|EXPERIMENTAL|Flourish|Participants will be onboarded to Flourish by a research study clinician, following which they will receive a text messaging program for 4 weeks as well as an accompanying resources website.
62132858|NCT05966350||another peripheral neuropathy|Patients with small fiber neuropathy, chronic polyradiculoneuritis or other axonal neuropathy) will be included.
62132859|NCT05966350||dysimmune context without associated neuropathy.|Patient with dysimmune context without associated neuropathy will be included.
62132860|NCT01203306|EXPERIMENTAL|Drugs: bevacizumab + octreotide LAR + capecitabine|bevacizumab + octreotide + metronomic capecitabine
62132861|NCT05897632|OTHER|Outpatient Evaluation|Patients randomized to this arm are discharged and receive outpatient evaluation, or cardiovascular ambulatory rapid evaluation (CARE), focused on medical management for cardiovascular risk factors (e.g. hypertension) within 72 hours of Emergency Department discharge.
62132862|NCT05897632|OTHER|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
62325171|NCT06379217|EXPERIMENTAL|GRPR-predominant NEPC|
62325172|NCT06022822|EXPERIMENTAL|Arm I (urolithin A)|Patients receive urolithin A PO BID for 3-6 weeks prior to SOC RP. Patients also undergo biopsy at time of surgery and collection of blood samples during screening and on study.
62325173|NCT06022822|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 3-6 weeks prior to SOC RP. Patients also undergo biopsy at time of surgery and collection of blood samples during screening and on study.
62325174|NCT05420064|ACTIVE_COMPARATOR|Proband-Mediated Cascade Genetic Testing|Control arm- Behavioral: As per standard of care, probands will be given a Family Letter by their genetic counselor that they will be instructed to share with their at-risk relatives (ARR). In addition to the recommendation that ARR undergo genetic counseling and a list of local genetics clinics, this letter will include a link to the eDGP through which control ARR can enroll onto the present study. For these ARR, the eDGP will only be used to obtain study e-consent and to administer study surveys.
62325175|NCT05420064|EXPERIMENTAL|EfFORT Trial Intervention Arm: Provider-Facilitated Cascade Genetic Testing|Intervention arm-: Behavioral: Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
61932021|NCT03553836|EXPERIMENTAL|Pembrolizumab|Participants receive 200 mg pembrolizumab (2 mg/kg for a maximum of 200 mg in pediatric participants) by intravenous (IV) infusion once every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to \~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of pembrolizumab and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2.
62325176|NCT05420064|ACTIVE_COMPARATOR|STRIVE Trial Control Arm: Patient-Led VUS Follow-Up|Patients will receive standard of care post-test genetic counseling and discussion of implications for relatives, if any. Consistent with standard practice, most patients will likely be recommended against telling their relatives to seek genetic testing for the Variant of uncertain significance/VUS because it is not clinically useful. All participants with a VUS will be recommended to re-contact the MSK CGS in 1-2 years for updated information related to the VUS result
62325177|NCT05420064|EXPERIMENTAL|STRIVE Trial Intervention Arm: Digitally-Facilitated VUS Follow-Up|Following standard of care post-test genetic counseling, patients will be provided access to the MyGene Portal. Through this portal, participants will be able to continuously engage with interactive educational materials including information about Variant of uncertain significance/VUS results and recommendations, access tools for participants to communicate with the CGS team, access the interactive pedigree (FamGenix) to provide updates about personal/family medical history, receive notifications about VUS reclassification, and receive reminders to self-schedule a follow-up clinical visit to discuss updates. In this way, participants will have a transparent, ongoing, and structured follow-up plan for their VUS management.
62325178|NCT05420064|NO_INTERVENTION|EfFORT Trial De-Identified Non-Randomized Control Arm|This control arm is comparable to true standard of care.
61932022|NCT03553836|PLACEBO_COMPARATOR|Placebo|Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to \~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2.
61932023|NCT00730197|EXPERIMENTAL|1|NISOLDIPINE EXTENDED-RELEASE TABLETS, 40 MG
61932024|NCT00730197|ACTIVE_COMPARATOR|2|Sular® Extended Release 40 mg tablets
61932025|NCT06708390||SILC|single-incision laparoscopic cholecystectomy
61932026|NCT06708390||CLC|conventional laparoscopic cholecystectomy
61932027|NCT05940012|EXPERIMENTAL|Manual therapy treatment|Manual therapy treatments will consist of global soft tissue stretching of the upper trapezius, occipital muscles, levator scapula, and scalene muscles as the patient lies in supine. Non-thrust manipulation will consist of unilateral or central posterior-anterior accessory movements (PAIVMs) to the cervical and upper thoracic segments (in prone) at the most symptomatic levels. Passive physiological intervertebral movements of rotation will be performed in supine, as a mechanism to reduce pain and increase range of motion. Individuals with chronic neck pain randomized to the manual therapy arm, will be assigned a HEP twice daily that will consist of cervical rotations with belt or equivalent, side flexion with belt or equivalent, self-stretching exercises that are designed to target the upper thoracic musculature, and corner wall stretches.
61932028|NCT05940012|ACTIVE_COMPARATOR|Resisted exercise treatment|"In-clinic exercises will consist of chin retractions in sitting, supine clock isometric resistance, supine anterior neck flexion exercises that target the deep neck flexors, prone neck extensor exercises (with concurrent chin retraction), and lateral neck raises (bilaterally). The study team will also target the mid and upper thoracic region by performing upright rows, supine chest raises that target the mid-scapular muscles and the paraspinal muscles, prone I, T, and Y exercises, and proprioceptive neuromuscular facilitation exercises using a bar or a cane. Individuals randomized to the resistance exercise arm will be assigned a HEP twice daily that will consist of chin retractions in sitting, supine anterior neck flexion exercises, and elastic band rows that replicate the upright rows performed in the clinic."
61932029|NCT06129942|PLACEBO_COMPARATOR|Dim light group|treated with the placebo device which operates with one intensity of 300 lux \* 1 month
61932030|NCT06129942|EXPERIMENTAL|Bright light group|treated with the experimental device which operates with one intensity of 10,000 lux \* 1 month
61932031|NCT06080048|EXPERIMENTAL|Part 3 SOR102 QD|SOR102 once a day for 6 weeks SOR102 oral capsules
61932032|NCT06080048|EXPERIMENTAL|Part 3 SOR102 BID|SOR102 twice a day for 6 weeks SOR102 oral capsules
61932033|NCT06080048|PLACEBO_COMPARATOR|Part 3 Placebo|Placebo for twice a day for 6 weeks Placebo oral capsules
61932034|NCT05041517|NO_INTERVENTION|Control|No intervention
61932035|NCT05041517|EXPERIMENTAL|BOLT + 1 PTC|BOLT Training + 1 PTC Call
61932036|NCT05041517|EXPERIMENTAL|BOLT + 2 PTC|BOLT Training + 2 PTC Calls
61932037|NCT05041517|EXPERIMENTAL|BOLT + 4 PTC|BOLT Training + 4 PTC Calls
61932038|NCT04776031|EXPERIMENTAL|Laser Treatment|Laser treatment using the R:GEN Laser System on Day 1 and at Week 24
61932039|NCT05854199|EXPERIMENTAL|Telehealth solution|Telehealth solution offered
62483955|NCT02343926|EXPERIMENTAL|Gemigliptin|GEMIGLIPTIN LS15-0444 administered once a day for 24 weeks as add-on therapy to metformin
62483956|NCT02343926|ACTIVE_COMPARATOR|Vildagliptin|Vildagliptin administered twice a day for 24 weeks as add-on therapy to metformin
62483957|NCT02933658|EXPERIMENTAL|Reference1|single(Reference1) -\> combination(Reference1+Reference2)
61932040|NCT05854199|NO_INTERVENTION|Usual care|Control
61932041|NCT06186856||Patients|
61932042|NCT06706830||Hypoxemic|Patients whose partial oxygen levels are low
61932043|NCT02724150|ACTIVE_COMPARATOR|Omeprazole High dose|Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days
61932044|NCT02724150|EXPERIMENTAL|Omeprazole Low Dose|Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days
61932045|NCT06048250|EXPERIMENTAL|Treatment (mezigdomide)|Starting between 30 and 90 days after infusion of idecabtagene vicleucel, patients receive mezigdomide PO on days 1-21 or days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT during screening. Patients also undergo bone marrow aspiration and blood sample collection throughout the study.
61932046|NCT06498505|ACTIVE_COMPARATOR|WOMEN - ACETAZOLAMIDE oral capsule|Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m
62483958|NCT02933658|EXPERIMENTAL|Reference2|single(Reference2) -\> combination(Reference1+Reference2)
62325179|NCT04548999|EXPERIMENTAL|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses based on their body weight at baseline: 1200 mg (participant's body weight \<75 kilograms \[kg\]) or 1800 mg (participant's body weight ≥ 75 kg) of ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
62483959|NCT03541538|ACTIVE_COMPARATOR|Global manipulation|Manual therapy performed in the cervical region in a non-specific way.
62483960|NCT03541538|EXPERIMENTAL|Especific manipulation|manual therapy performed specifically on the C6-7 segment
62483961|NCT05800262|EXPERIMENTAL|Dynamic stability exercise|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
62483962|NCT00241020|EXPERIMENTAL|Octreotide|
61932047|NCT06498505|ACTIVE_COMPARATOR|MEN - ACETAZOLAMIDE oral capsule|Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m
61932048|NCT06498505|PLACEBO_COMPARATOR|WOMEN - PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
61932049|NCT06498505|PLACEBO_COMPARATOR|MEN - PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
61932050|NCT05271162|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin, 10 mg q.d; p.o
61932051|NCT05271162|PLACEBO_COMPARATOR|Placebo|Placebo 1 tabl q.d; p.o
61932052|NCT05517993|EXPERIMENTAL|Group A|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) 3g orally twice daily for 12 weeks.
61932053|NCT05517993|NO_INTERVENTION|Group B|No intervention.
61932054|NCT03583073|ACTIVE_COMPARATOR|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
61932055|NCT03583073|EXPERIMENTAL|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
61932056|NCT06048536|EXPERIMENTAL|Norelgestromin low dose 2.43mg 28/0 regimen non-Obese|
61932057|NCT06048536|EXPERIMENTAL|Norelgestromin mid dose 3.64mg 28/0 regimen non-Obese|
61932058|NCT06048536|EXPERIMENTAL|Norelgestromin high dose 4.86mg 28/0 regimen non-Obese|
62483963|NCT00373256|EXPERIMENTAL|A|
62483964|NCT00373256|ACTIVE_COMPARATOR|B|
62483965|NCT04674072|EXPERIMENTAL|Intervention group|The intervention group will be instructed to include the reverse Nordic curl exercise into their warm up 15 to 20 mins before training session (3 times per week) during one season (6 months).
62483966|NCT04674072|ACTIVE_COMPARATOR|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions
61932059|NCT06048536|EXPERIMENTAL|Norelgestromin high dose 4.86mg 21/7 regimen non-Obese|
61932060|NCT06048536|EXPERIMENTAL|Norelgestromin mid dose 3.64mg 28/0 regimen Obese|
61932061|NCT06048536|EXPERIMENTAL|Norelgestromin high dose 4.86mg 28/0 regimen Obese|
61932062|NCT06048536|EXPERIMENTAL|Norelgestromin high dose 4.86mg 21/7 regimen Obese|
61932063|NCT06710223|EXPERIMENTAL|SD-101|Participants will be treated with cryoablation and intrahepatic artery infusion of SD-101. This treatment will be followed by administration of the immune checkpoint inhibitors Tremelimumab and Durvalumab (STRIDE regimen). Tremelimumab 300mg will be given intravenously once, 7-10 days after cryoablation + SD-101. Durvalumab 1500mg will be given intravenously at the same time as Tremelimumab, and then every 28 days (on day 1 of every subsequent cycle).
61932064|NCT06678620|EXPERIMENTAL|Experimental group 1|248 participants will be randomized to receive Reinovax PCV24 formulation 1. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
61932065|NCT06678620|EXPERIMENTAL|Experimental group 2|248 participants will be randomized to receive Reinovax PCV24 formulation 2. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
61932066|NCT06678620|EXPERIMENTAL|Experimental group 3|248 participants will be randomized to receive Reinovax PCV24 formulation 3. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
61932067|NCT06678620|ACTIVE_COMPARATOR|Active control group|248 participants will be randomized to receive PPSV23. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
61932068|NCT06330051|EXPERIMENTAL|Improvement intervention|receive the following continuous improvement intervention for 6 months
62483967|NCT03600883|EXPERIMENTAL|Phase 1 Dose Exploration Part 1 monotherapy|"Cohorts with food effect and alternative dosing regimens~Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort"
62483968|NCT03600883|EXPERIMENTAL|Phase 1 Dose Expansion Part 2 monotherapy|Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently
62483969|NCT03600883|EXPERIMENTAL|Phase 1 combination arm with sotorasib and anti PD-1/L1|Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)
61932069|NCT06330051|NO_INTERVENTION|Control group|Only information will be collected.
61932070|NCT05633797|EXPERIMENTAL|Totally endoscopic cardiac surgery|Patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative.
61932071|NCT00729924|EXPERIMENTAL|Open label oral raltegravir|Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
61932072|NCT06492590|EXPERIMENTAL|Intervention group|A multicomponent intervention: The psycho-education will consist of 9 sessions of 90 minutes, one per week, in groups of a maximum of 16 participants.The topics that will be covered during the sessions with a specialized therapist will be: (1) education in neuroscience of the symptomatology of the Long COVID; (2) Mindfulness; (3) Cognitive-Behavioral Therapy; and (4) Strategies of self-healing. Physical rehabilitation will consist of 9 sessions of 60 minutes, one per week, in groups of a maximum of 16 participants, conducted by an expert physiotherapist. Each session will work on the following 4 blocks in a progressive approach: (1) warm-up and aerobic exercises (25 minutes); (2) functional and muscle strengthening exercises (10 minutes); (3) Proprioception exercises (10 minutes); and (4) breathing exercises (10 minutes). Answering the assessment questionnaires pre, post and 24 weeks of intervention follow-up
61932073|NCT06492590|NO_INTERVENTION|Control group|"Participants in the control group will complete the same research questionnaires as the intervention group and for the same period.~Participants in the control group will be placed on a waiting list for the intervention once its efficacy has been demonstrated."
61932074|NCT04842422|EXPERIMENTAL|Earliest Stage Treatment of Aktinic Keratosis|
62692169|NCT04758988|NO_INTERVENTION|Group B|"This group is withheld their access to the AI augmented digital online educational system for 2 months.~After the 2 months delay, the subjects in the group are given the same access as the participants in Group A."
62692170|NCT03403790||Patients with depression in bipolar disorder|Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
62692171|NCT01040026|EXPERIMENTAL|NK cell infusions|10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells
62692172|NCT06644248||Self reported uterine distress undergoing colposcopic evaluation|The study group consists of women undergoing cervical cancer screening. This includes those with suspected cervical abnormalities identified through initial cytology or HPV tests and referred for colposcopy. The study group also includes women without apparent cervical abnormalities to ensure a comprehensive dataset. The aim is to develop an AI model capable of accurately diagnosing cervical cancer and identifying transformation zones in colposcopic images. This diverse group allows for the evaluation of the AI model across a wide range of conditions and exposures, enhancing its generalizability and clinical utility.
61932075|NCT01409395|EXPERIMENTAL|Metformin|Subjects will be dosed with Metformin alone (850 mg)
61932076|NCT01409395|EXPERIMENTAL|Metformin and Nizatidine|Subjects will be dosed with metformin in conjunction with nizatidine
61932077|NCT05095376|ACTIVE_COMPARATOR|Arm I (radiation therapy, temozolomide)|Patients undergo radiation therapy 5 days per week and receive temozolomide PO QD for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
61932078|NCT05095376|EXPERIMENTAL|ARM II (radiation therapy, temozolomide, lomustine)|Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 and temozolomide PO QD on days 2-6. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
61932079|NCT04623398|EXPERIMENTAL|Lithium|"Li+ is an FDA (NDA: 016834) and ANSM (AMM 3400931376339) approved drug. There are two lithium salts that are marketed in France, Teralithe LI (cp 250mg) and Teralithe LP (cp 400mg).~The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials."
61932080|NCT04623398|PLACEBO_COMPARATOR|Placebo|"Capsules containing lactose monohydrate in all points resembling the capsules of active ingredients.~Capsules of pla62.5 mg, pla125 mg and pla250 mg (pla=placebo)"
61932081|NCT00666874|EXPERIMENTAL|1|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
61932082|NCT00666874|ACTIVE_COMPARATOR|2|General information about healthy food choices and exercise
61932083|NCT05204550|EXPERIMENTAL|intranasal heparin|"Unfractionated heparin (UFH) 1400u each nostril (as heparin solution 5,000u/ml, 140 microL/actuation, Two actuations each nostril) Three times daily via a plastic nasal inhalator device (APTAR, UK) for 10 days.~This is a maximal dose per day of UFH of 8400u. ie 700 x 2 actuations per nostril (1400 x2) 3 times per day (1400x2x3 = 8400u)"
61932084|NCT05204550|PLACEBO_COMPARATOR|intranasal saline|Comparator 0.9% saline (as saline solution, 140 microlitres/actuation, Two actuations each nostril) Three times daily via a plastic nasal inhalator device(APTAR, UK) for 10 days.
61932085|NCT04167722||Obese patients|BMI \> 25
61932086|NCT04167722||Lean patients|BMI \< or = 25
61932087|NCT06153316||Exposure Schools|From the dataset that matches study criteria, randomly select three K-12 schools that have recently experienced mass violence or attempted mass violence (\< two years prior) and three K-12 schools that have experienced mass violence or attempted mass violence less recently (\> two years ago). Students, teachers and principals of these schools will be eligible to participate.
61932088|NCT06153316||Non-exposure schools|For the study, the non-exposure schools will be matched to exposure schools on five key variables: state, urban/non-urban, school type (public/private), school level (elementary/middle/high), and school size, and selected from the complete database of K-12 schools across the United states. Students, teachers and principals of these schools will be eligible to participate.
61932089|NCT06708221|EXPERIMENTAL|Real-Time IGRT|Real-Time IGRT
61932090|NCT05473897|EXPERIMENTAL|Catalyst Cryohelmet intervention with symptomatic care|The treatment arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg) along with 30 minutes of head-neck cooling in the emergency department while being monitored for side effects.
62692173|NCT00831883|EXPERIMENTAL|Partner Specific IMB|partner-specific HIV risk reduction intervention
62692174|NCT00831883|PLACEBO_COMPARATOR|HLS|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
62132863|NCT05879419|ACTIVE_COMPARATOR|Subproject A: Patients with ARDs who received the vaccine at study entry (P1)|Patients with ARDs who received the vaccine at study entry (P1) (n = 590). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
62483970|NCT03600883|EXPERIMENTAL|Phase 1 monotherapy treatment naive advanced NSCLC|Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.
62483971|NCT03600883|EXPERIMENTAL|Phase 2 monotherapy dose comparison|Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy
62325180|NCT04548999|ACTIVE_COMPARATOR|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
62483972|NCT03600883|EXPERIMENTAL|Phase 1 Does escalation and Expansion monotherapy BID|BID 2L+solid tumors (fed state)
61932091|NCT05473897|NO_INTERVENTION|Control: symptomatic care arm|The control arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg). They will not wear any helmets.
62132864|NCT05879419|PLACEBO_COMPARATOR|Subproject A: Patients with ARDs who received the placebo at study entry (P2)|"Subproject A: Patients with ARDs who received the placebo at study entry (P2) (n = 590).~ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126."
62325181|NCT04773353|EXPERIMENTAL|Follitropin Delta (FE 999049)|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
62692175|NCT06459583|EXPERIMENTAL|eHealth platform|The eHealth platform consists of the self-directed web-portal (ADWebPortal) and chatbot (ADChatbot) to receive their Alzheimer's-related test results. Participants randomized to this arm can switch between the two or schedule a virtual appointment with a healthcare provider.
62692176|NCT06459583|ACTIVE_COMPARATOR|Videoconference telehealth|The videoconference telehealth platform consists of remote visit(s) with a healthcare provider to receive their Alzheimer's-related test results.
62132865|NCT05879419|ACTIVE_COMPARATOR|Subproject A: Control group of non-immunosuppressed individuals (CG)|Subproject A: Control group of non-immunosuppressed individuals (CG) (n = 393). The control group of non-immunosuppressed individuals (CG) (≥50 years old) will be invited to receive the vaccine at study entry (3 patients:1 control).
62132866|NCT05879419|ACTIVE_COMPARATOR|Subproject B: MTX-withhold|Subproject B: MTX-withhold (n = 101). Patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab, to be randomized into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
62132867|NCT05879419|ACTIVE_COMPARATOR|Subproject B: MTX-maintain|Subproject B: MTX-maintain (n = 101). Patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab, to be randomized into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
62132868|NCT05879419|ACTIVE_COMPARATOR|Subproject B: MMF-withhold|Subproject B: MMF-withhold (n = 115). Patients with ARDs using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for one week after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
62132869|NCT05879419|ACTIVE_COMPARATOR|Subproject B: MMF-maintain|Subproject B: MMF-maintain (n = 115). Patients with ARDs using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for one week after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
62132870|NCT04121546|EXPERIMENTAL|Intervention Arm|Patients will receive the telecare intervention.
62132871|NCT04121546|NO_INTERVENTION|Usual Care Arm|Patients will receive usual care.
62132872|NCT00710567|OTHER|Historical Data|"DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients"
62132873|NCT00202436|ACTIVE_COMPARATOR|1|Phlebotomy
62132874|NCT00202436|ACTIVE_COMPARATOR|2|Erythrocytapheresis
62132875|NCT04638816|EXPERIMENTAL|Restylane Volyme|Hyaluronic Acid
62325182|NCT04773353|EXPERIMENTAL|Follitropin Alfa (GONAL-F)|rFSH. Follitropin alfa for subcutaneous injection
62325183|NCT05881408|EXPERIMENTAL|Delandistrogene Moxeparvovec followed by Placebo|Participants will receive single IV infusion of delandistrogene moxeparvovec on Day 1. Then, participants will receive a single IV infusion of matching placebo at approximately 72 weeks.
62325184|NCT05881408|PLACEBO_COMPARATOR|Placebo followed by Delandistrogene Moxeparvovec|Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of delandistrogene moxeparvovec at approximately 72 weeks.
62483973|NCT06558786||Esophageal and Gastroesophageal Junction Cancer|Patients will undergo assessment with the EORTC QLQ-C30 and QLQ-OGS25 questionnaires. Those patients who undergo local therapy will occur at baseline, months 7-9 within 45 days of local therapy, and one year/time of progression. Those patients who do not undergo local therapy will undergo assessment at baseline, at 6 months, and at one year.
62483974|NCT02164435|OTHER|Renal Denervation|
62483975|NCT01118598|PLACEBO_COMPARATOR|placebo arm|this group will receive placebo as per protocol
62483976|NCT01118598|ACTIVE_COMPARATOR|tredaptive|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
62483977|NCT05244720|EXPERIMENTAL|Intervention|"Baseline questionnaire filled out at recruitment. Invited to an examination of the liver, by fibroscan and blood samples, shortly after recruitment.~Follow-up by phone after 6 months."
62483978|NCT05244720|OTHER|Control|Baseline questionnaire filled out at recruitment. Follow-up by phone after 6 months. Invited to an optional examination of the liver, by fibroscan and blood samples, after 6 months.
61932092|NCT03137030|EXPERIMENTAL|GRT7014 - 1 Tablet (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
62325185|NCT05972135|EXPERIMENTAL|Teclistamab|Participants will receive step up dosing of Teclistamab following the recommended dosage of TECVAYLI™ USPI followed by weekly dosing for twelve 28-day cycles, until disease progression, unacceptable toxicity, or the EOT (end of Cycle 12). Teclistamab dosing may be reduced to once every 2 weeks for participants who achieve partial response (PR) or better after 6 months of therapy.
62325186|NCT05972135|EXPERIMENTAL|Talquetamab|Participants will receive step up dosing of Talquetamab following the recommended dosage of TALVEY™ USPI followed by every 2 week dosing for six 28-day cycles, until disease progression, unacceptable toxicity, or the EOT (end of Cycle 6). Talquetamab dosing may be reduced to once every 4 weeks for participants who achieve very good partial response (VGPR) or better after Cycle 4
62325187|NCT06291376|EXPERIMENTAL|Ravulizumab IV q8w|"Participants will receive a weight-based loading dose on Day 1 followed by weight-based maintenance dosing initiated on Day 15, and then administered every 8 weeks (q8w).~Participants in the exploratory group will receive open-label weight based loading dose on Day 1 followed by open label weight based maintenance dose on Day 15 and q8weeks after."
62325188|NCT06291376|PLACEBO_COMPARATOR|Placebo IV q8w|Participants will receive a weight-based loading dose on Day 1 followed by weight-based maintenance dosing initiated on Day 15, and then administered q8w.
62325189|NCT03616587|EXPERIMENTAL|AZD9833 monotherapy dose escalation|
62325190|NCT03616587|EXPERIMENTAL|AZD9833 monotherapy dose expansion|
62325191|NCT03616587|EXPERIMENTAL|AZD9833 with palbociclib dose escalation|
62325192|NCT03616587|EXPERIMENTAL|AZD9833 with palbociclib dose expansion|
62483979|NCT02104479||Immunocompromised Patients|Immunocompromised patients with suspected IPA who have Pleural effusions act as the observed study population
62483980|NCT02104479||Control Group|Patients without Immunosuppression with pleural effusions
62483981|NCT06603532|EXPERIMENTAL|low-load blood flow restriction (BFR) resistance training|Group of patients that performed the experimental exercise training against low mechanical resistance (workload) with blood flow restriction (BFR) in the active thigh muscles.
62483982|NCT06603532|SHAM_COMPARATOR|low-load resistance training|Group of patients that performed exercise training against low mechanical resistance (workload) with sham blood flow restriction (SHAM-BFR) in the active thigh muscles.
62483983|NCT03151577|OTHER|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
62483984|NCT01429363|EXPERIMENTAL|Targeted disc decompression|
62483985|NCT05127057|EXPERIMENTAL|PRIME Parkinson Care|PRIME Parkinson Care is a multi-component model of care comprising individual components: a) Case management b) Empowerment of patients and care givers c) Empowerment of healthcare professionals d) IT infrastructure.
62483986|NCT05127057|PLACEBO_COMPARATOR|Usual care|Usual care provided by NHS
61932093|NCT03137030|EXPERIMENTAL|GRT7014 - 10 Tablets (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
62325193|NCT03616587|EXPERIMENTAL|AZD9833 with everolimus dose expansion|
62325194|NCT03616587|EXPERIMENTAL|AZD9833 with everolimus dose escalation|
62325195|NCT03616587|EXPERIMENTAL|AZD9833 with abemaciclib (± anastrozole) dose escalation|
62325196|NCT03616587|EXPERIMENTAL|AZD9833 with abemaciclib (± anastrozole)dose expansion|
62325197|NCT03616587|EXPERIMENTAL|AZD9833 with capivasertib dose escalation|
62325198|NCT03616587|EXPERIMENTAL|AZD9833 with capivasertib dose expansion|
62325199|NCT03616587|EXPERIMENTAL|AZD9833 with ribociclib (± anastrozole) dose escalation|
62325200|NCT03616587|EXPERIMENTAL|AZD9833 with ribociclib (± anastrozole) dose expansion|
62325201|NCT03616587|EXPERIMENTAL|AZD9833 with anastrozole dose escalation|
62325202|NCT03616587|EXPERIMENTAL|AZD9833 with anastrozole dose expansion|
62325203|NCT04646460|EXPERIMENTAL|Observed Success - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
62483987|NCT06562088|EXPERIMENTAL|Cohort 1: HDM1002 and rifampicin|"Part 1: Single dose of HDM1002~Part 2: Once daily dose of rifampicin with single dose of HDM1002"
62483988|NCT06562088|EXPERIMENTAL|Cohort 2: HDM1002 and itraconazole|"Part 1: Single dose of HDM1002~Part 2: Once daily dose of itraconazole with single dose of HDM1002"
62483989|NCT06558240||Experimental: HERADERM Hydrogel Wound Dressing (Sterile)|"Eligible subjects will use experimental dressings for postoperative wound care after caesarean section. The subjects received dressing change on the second day after surgery and on the day of discharge. After discharge, subjects will take home 2 pieces of experimental dressings and change by themselves.~(Timing to change dressing after discharge: the area of exudate exceeds two-thirds of the dressing area)"
62483990|NCT03425344|OTHER|Diagnostic|All participants will be exposed to shoulder- MRI, ultrasound and sonoelastography.
62483991|NCT01309763|ACTIVE_COMPARATOR|AFFITOPE AD03|s.c. injection
62483992|NCT01309763|EXPERIMENTAL|AFFITOPE AD03 + Alum|s.c. injection
62483993|NCT04767347|EXPERIMENTAL|Fixed Work Rate|Participants will walk on a treadmill at 3 mph and the grade will be adjusted to elicit 430 W of metabolic heat production (the most common work intensity). This study will systematically examine the NIOSH recommendations for prescribing work-to-rest ratios with increasing environmental heat stress (defined as Wet Bulb Globe Temperature, WBGT) at this fixed rate of metabolic heat production on kidney function.
62483994|NCT04767347|EXPERIMENTAL|Fixed work-to-rest ratio|This study will systematically examine the NIOSH recommendations on changes in kidney function when the work-to-rest ratio is fixed at 30 min per hour (the most commonly prescribed work-to-rest ratio), but the rate of metabolic heat production and environmental heat stress differs (Figure 2). As described in Study 1, the appropriate rate of metabolic heat production will be elicited by having participants walk on a treadmill at 3 mph and the grade will be adjusted accordingly.
62483995|NCT05569291|EXPERIMENTAL|Automated Coaching Program (ACP)|The ACP will use the application as developed for patients with COPD and tested to be effective in this population (Demeyer et al., 2017). The program includes 1) one-to-one semi-structured interview (V1) with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favorite activities and (coping) strategies to become more active resulting in an individual action plan; 2) step counter (Fitbit; wrist or waist worn) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention; 3) smartphone coaching application, installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient. 4) phone calls by the coaches initiated in pre-defined situations.
62483996|NCT05569291|EXPERIMENTAL|Manual Coaching Program (MCP)|The MCP includes 1) one-to-one semi-structured interview (V1) with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favorite activities and (coping) strategies to become more active resulting in an individual action plan; 2) step counter (Fitbit, wrist or waist worn), that will be linked with a smartphone using the Fitbit application providing direct feedback. Patients can access the Fitbit application if they want to, but they will not receive personal feedback; 3) weekly phone calls by the coaches, interviewing patients on their progress, performance (steps) and feedback. The first goal is based on the physical activity level at the beginning of the coaching intervention (median of 4 days). The individual activity goal (expressed as daily step count) will be revised based on the patient's willingness to increase.
62483997|NCT05745363|EXPERIMENTAL|AL2846 capsule|AL2846 capsules monotherapy, 28 days as a treatment cycle.
62483998|NCT03658954|ACTIVE_COMPARATOR|Advice|Participants receive only web-based sleep health advice
62483999|NCT03658954|EXPERIMENTAL|Advice + Self-monitoring|Participants receive web-based sleep health advice + sleep/alcohol diary self-monitoring
62484000|NCT03658954|EXPERIMENTAL|Advice + Self-monitoring + Feedback|Participants receive web-based sleep health advice + sleep/alcohol diary self-monitoring + sleep/alcohol data feedback \& tailored coaching
62484001|NCT02597374|EXPERIMENTAL|Experimental|A 45 mn EEG for all the participants.
62484002|NCT00938795|OTHER|Uncertainty Management Intervention|The Uncertainty Management Intervention will consist of six 30-minute phone calls with a study educator to discuss issues of psychological distress, uncertainty management, symptom control, self efficacy for symptom management, and quality of life.
62484003|NCT00938795|OTHER|Comparison Conditions for Liver Disease|Six 30-minute telephone calls that provide structured education about liver disease.
62484004|NCT01824940|PLACEBO_COMPARATOR|Standard of Care|The Standard of Care interventions are the blanket interventions.
62484005|NCT01824940|ACTIVE_COMPARATOR|WASH|"One of two active interventions to be studied in this 2X2 (two by two) Factorial trial:~Intervention 1: a package of interventions to improve household sanitation and hygiene (WASH)"
62484006|NCT01824940|ACTIVE_COMPARATOR|Nutrition|"One of two active interventions to be studied in this 2X2 Factorial trial:~Intervention 2: a package of interventions to improve infant and young child feeding (IYCF)"
62484007|NCT01824940|ACTIVE_COMPARATOR|WASH and Nutrition|This arm receives a combination of all standard care interventions, all WASH and all IYCF interventions.
62484008|NCT05370417|SHAM_COMPARATOR|Control Group|Participants in this group received toothpaste with fluoride concentration ≥ 1000 ppm (Parts Per Million), glass ionomer sealant and simulated low-level laser.
62484009|NCT05370417|ACTIVE_COMPARATOR|Study Group|Participants in this group received toothpaste with fluoride concentration ≥ 1000 ppm (Parts Per Million), glass ionomer sealant and active low-level laser.
62484010|NCT00573313|EXPERIMENTAL|S-adenosylmethionine (SAMe)|Alcoholic liver disease patients receiving S-adenosylmethionine (SAMe)at 400 mg capsule three times daily for 24 weeks
62484011|NCT00573313|PLACEBO_COMPARATOR|Sugar pill|ALD subjects receiving Placebo three times daily for 24 weeks.
61932094|NCT03137030|ACTIVE_COMPARATOR|Norco - 1 Tablet (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
61932095|NCT03137030|ACTIVE_COMPARATOR|Norco - 10 Tablets (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
61932096|NCT03137030|EXPERIMENTAL|GRT7014 - 5 Tablets (Optional Part 2)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
61932097|NCT03137030|ACTIVE_COMPARATOR|Norco - 5 Tablets (Optional Part 2)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
61932098|NCT05370391|EXPERIMENTAL|Comprehensive Behavioral Intervention for Tics (CBIT)|"Experimental: Comprehensive Behavioral Intervention for Tics (CBIT) Group~Participants in this group will receive the CBIT intervention for up to 6 weeks."
61932099|NCT05136690|EXPERIMENTAL|Panel A: Healthy Control Participants|In Part 1, HC participants receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), HC participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.
62132876|NCT04638816|EXPERIMENTAL|Restylane Lyft Lidocaine|Hyaluronic Acid
62132877|NCT00402896|EXPERIMENTAL|ZD6474|300 mg/day orally for 10 weeks.
62484012|NCT00031434|EXPERIMENTAL|1|All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
61932100|NCT05136690|EXPERIMENTAL|Panel B: Participants with Mild-to-Moderate SZ|In Part 1, participants with mild-to-moderate SZ receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), SZ participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.
61932101|NCT06248515|EXPERIMENTAL|Sacituzumab|
61932102|NCT06707428|EXPERIMENTAL|Compression stocking using group|Wearing varicose vein stockhing is a routine operation preparation
61932103|NCT06707428|NO_INTERVENTION|Control Group|Routine opreration preparation
61932104|NCT06701669|EXPERIMENTAL|Cohort B: paridiprubart|
61932105|NCT06701669|PLACEBO_COMPARATOR|Cohort B: placebo|
61932106|NCT06708013|EXPERIMENTAL|Transcranial Magnetic Stimualtion Treatment Arm|"Experimental: Treatment resistant depression group Participants will be treated with TMS using the MagVenture™ MagProX100™ device. The treatment includes 20 sessions over 4 weeks, delivering 18000 pulses in total. The stimulation targets the left dorsolateral prefrontal cortex, with parameters set to achieve optimal therapeutic effects without inducing adverse side effects. Motor threshold measurements are conducted prior to the initiation of treatment and adjusted weekly to maintain consistent treatment intensity.~Comprehensive ophthalmologic examinations will be performed on all participants both before and after the completion of the TMS treatment. These examinations will include assessments of retinal vasculature using OCTA. The PHQ-9 and Hamilton Depression Rating Scale 17 will be conducted to evaluate changes in the severity of depressive symptoms."
61932107|NCT06311721|EXPERIMENTAL|ABP 234|Part 1: Participants will receive ABP 234 followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive ABP 234 followed by pemetrexed.
61932108|NCT06311721|EXPERIMENTAL|Pembrolizumab (US)|Part 1: Participants will receive FDA-licensed pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive FDA-licensed pembrolizumab followed by pemetrexed.
61932109|NCT06311721|EXPERIMENTAL|Pembrolizumab (EU)|Part 1: Participants will receive EU-approved pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive EU-approved pembrolizumab followed by pemetrexed.
61932110|NCT02314234||Control group|did not receive muscle relaxant during anesthesia
61932111|NCT02314234||Sugammadex group|received single dose of rocuronium for anesthesia and sugammadex at skin incision
61932112|NCT06708403|EXPERIMENTAL|Judo-Specific Injury Prevention Exercise Program|"18 participants will be in the experimental group, following a judo-specific injury prevention exercise protocol for six weeks (three sessions per week).~Baseline and post-intervention measurements will evaluate judo-specific skills, agility, balance, and overall performance.~The intervention will include:~Warm-up exercises tailored for injury prevention Strength and conditioning exercises specific to judo movements Drills focusing on balance, agility, and coordination Gradually progressive intensity over six weeks"
61932113|NCT06708403|NO_INTERVENTION|Regular Judo Training|"18 participants will be in the control group, continuing their regular judo training sessions without any additional intervention.~The same performance metrics will be measured at baseline and post-intervention.~The control group will continue their regular training sessions as guided by their judo coaches, with no alterations."
61932114|NCT05527184|EXPERIMENTAL|IMGN151|IMGN151 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 every 3-week cycle (Q3W).
61932115|NCT01546012|EXPERIMENTAL|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
61932116|NCT01546012|ACTIVE_COMPARATOR|HYLO-COMOD®:|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
61932117|NCT02260362||HTAP of Congenital Heart Disease|
61932118|NCT06347133|EXPERIMENTAL|Plozasiran Injection|4 doses of plozasiran by subcutaneous (sc) injection
62325204|NCT04646460|EXPERIMENTAL|Observed Failure - Experienced Failure|"This participant group (N=30) will witness a failed placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
61932119|NCT06347133|PLACEBO_COMPARATOR|Placebo|calculated volume to match active treatment by sc injection
61932120|NCT05570825|EXPERIMENTAL|Treatment (SX-682, pembrolizumab)|Patients receive SX-682 PO BID, starting 7 days prior to the start of pembrolizumab, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and PET/CT or CT at screening and on study and undergo MRI and collection of blood samples at screening, throughout the study, and during follow up.
61932121|NCT05249465|EXPERIMENTAL|Condition 1|Core Only
61932122|NCT05249465|EXPERIMENTAL|Condition 2|Core + Track Weight
61932123|NCT05249465|EXPERIMENTAL|Condition 3|Core + Track Steps
61932124|NCT05249465|EXPERIMENTAL|Condition 4|Core + Track Diet
61932125|NCT05249465|EXPERIMENTAL|Condition 5|Core + Track Weight + Track Steps
61932126|NCT05249465|EXPERIMENTAL|Condition 6|Core + Track Weight + Track Diet
61932127|NCT05249465|EXPERIMENTAL|Condition 7|Core + Track Steps + Track Diet
61932128|NCT05249465|EXPERIMENTAL|Condition 8|Core + Track Weight + Track Steps + Track Diet
61932129|NCT06560424||Personal History of Cardiovascular or Metabolic Diseases|Persons who have a diagnosis of a cardiovascular or metabolic disease. Examples of cardiovascular diseases are: heart failure, arrhythmias, high cholesterol, coronary artery disease, heart attack, and stroke. Examples of metabolic diseases are: diabetes, metabolic syndrome, and hemochromatosis.
62132878|NCT05296889||Ennovate® Cervical|Alll patients which were treated with the Ennovate® Cervical system in accordance with the indications given in the instructions for use
62484013|NCT04964440||PURE EP Guided Procedures|Redo AF procedures guided by Pure EP System during an AF Ablation
62484014|NCT04964440||Standard Recording System Guided Procedures|Redo AF procedures guided by the Standard Recording System during an AF Ablation
62484015|NCT02949167|EXPERIMENTAL|MyHealth intervention arm|Nurse-led follow-up
62484016|NCT02949167|NO_INTERVENTION|MyHealth Control condition|Physician-led follow-up
62132879|NCT04129203|EXPERIMENTAL|Trial arm|Mechanical thrombectomy using Versi Retriever
62325205|NCT04646460|EXPERIMENTAL|Observed Success - Experienced Failure|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
62484017|NCT04403347|EXPERIMENTAL|Innovative Dietary Formulation|In addition to regular diets and usual care of hypertension, additional innovative dietary formulation will be orally taken 3 times per day.
61932130|NCT06560424||Family History of Cardiovascular or Metabolic Diseases|Persons without a personal diagnosis of any cardiovascular or metabolic disease but with a family history in a first-degree relative of one of those diseases.
61932131|NCT06560424||Healthy Controls|No personal or family (first-degree relative) history of cardiovascular or metabolic diseases.
61932132|NCT04594642|EXPERIMENTAL|AZD0486 Monotherapy Dose Escalation in Subjects with RR B-NHL|AZD0486 monotherapy will be administered intravenously on day 1 and 15 of 28 day cycles for a maximum of 2 years or until discontinuation criteria are met. Depending on cohort, subjects may receive priming or step-up dosing during cycle 1 before reaching the target dose. While on study, subjects will be monitored for safety and efficacy with periodic disease assessment with PET/CT. If subject achieves two consecutive CRs after completing C6, then they may be eligible for monthly dosing
61932133|NCT03824171|EXPERIMENTAL|Raloxifene 60mg/Cholecalciferol 800IU to AD-102|Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
61932134|NCT03824171|EXPERIMENTAL|AD-102 to Raloxifene 60mg/Cholecalciferol 800IU|Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
61932135|NCT01986907|EXPERIMENTAL|Ranibizumab|Administered as an Intravitreal injection
61932136|NCT05034133|EXPERIMENTAL|Study arm|Patients with limited stage small cell lung cancer receive durvalumab with chemotherapy (Etoposide and Cisplatin) for receive 6 cycles, and then receive thoracic radiotherapy.
61932137|NCT06710145||Attention App Users|Soldiers who used the App and completed at least one training session
62325206|NCT04646460|EXPERIMENTAL|Observed Failure - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
62325207|NCT05345223||TGCV|Patients who have been confirmed as TGCV by a cardiologist.
61932138|NCT06710145||Non Users|Soldiers matched on age, sex, and specialty to the Attention App Users group who never used the App
61932139|NCT01545453|EXPERIMENTAL|lebrikizumab - highest dose|
61932140|NCT01545453|EXPERIMENTAL|lebrikizumab - lowest dose|
61932141|NCT01545453|EXPERIMENTAL|lebrikizumab - middle dose|
61932142|NCT01545453|PLACEBO_COMPARATOR|placebo|
61932143|NCT01640626|ACTIVE_COMPARATOR|Health Education|Deworming will be conducted in both schools. A health education package will be introduced to schoolchildren in the intervention school (School A) only. Both schools will be followed up for 6 months.
61932144|NCT01640626|NO_INTERVENTION|Control|Schoolchildren in school B will serve as a control group. No intervention (Health education package) will be given after complete deworming at baseline.
61932145|NCT03361267|ACTIVE_COMPARATOR|Bismuth containing quadruple therapy|If CLO test is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days If CLO test is negative, no intervention is needed
61932146|NCT03361267|EXPERIMENTAL|tailored therapy|If H. pylori PCR is negative, no intervention is needed If H. pylori PCR is positive and mutation is negative, triple regimen (rabeprazole 20 mg bid, amoxacillin 1000 mg bid, clarithromycin 500mg bid) are prescribed for 7 days is given If H. pylori PCR is positive and mutation is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days is given
61932147|NCT06707805|EXPERIMENTAL|lumber SNAGS|A sustained natural apophyseal glide (SNAG) is a mobilization technique commonly used in the treatment of painful movement restrictions of the spine.Studing the effect of Lumber SNAGs in lower cross syndrome hold significance due to its potential to correct pain, hypomobility and biomechanical changes i.e hyperlordotic curve and anterior pelvic tilting caused by lower cross syndrome
61932148|NCT06707805|OTHER|Conventional group|Exercises ,Tens and hotpack
62132880|NCT03642106|ACTIVE_COMPARATOR|Unidos Se Puede|Unidos Se Puede: consists of 5-weekly Family Workshops, 6 monthly booster sessions, 10-months success coaching, adolescent group activities and will be compared to an attention placebo control.
62325208|NCT05951166|EXPERIMENTAL|PADN with Gradient Denervation System|
62325209|NCT06475742|EXPERIMENTAL|Cenerimod 4 mg|Participants will receive oral cenerimod once daily in addition to background systemic lupus erythematosus therapy, for at least 1 year and up to a maximum of 3 years.
62325210|NCT06320756|EXPERIMENTAL|Intervention arm: Wysa in Hindi + usual care|"The intervention arm will receive Wysa in Hindi and the usual care. Wysa in Hindi is a digital mental health intervention that combines Artificial Intelligence-led conversational chatbot support and human therapy in the Hindi language. The Artificial Intelligence (AI) chatbot acts as a companion, and understands, empathizes, and guides users through exercises grounded in cognitive behavioral therapy (CBT) techniques, written by qualified psychologists and clinicians.~Usual care includes access to individual and bi-weekly group sessions focused on building coping, wellbeing, and motivation by the diabetes educator team."
62325211|NCT06320756|ACTIVE_COMPARATOR|Usual care arm|Participants in the control group will only have access to usual care (which will remain the same as that for the intervention arm). This includes access to individual sessions and bi-weekly group sessions with the diabetes education team on motivation, wellbeing, and coping.
62325212|NCT05611801|EXPERIMENTAL|marstacimab (PF-06741086)|Weekly subcutaneous injections.
62484018|NCT04403347|ACTIVE_COMPARATOR|Antihypertensive Medication|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
62484019|NCT04403347|NO_INTERVENTION|Usual Care|Usual Care (Guideline-based patient education and lifestyle recommendations)
61932149|NCT03408314|EXPERIMENTAL|PediQUEST Response|"* Weekly PediQUEST surveys are automatically assigned to parents and children (if 5 years old or older) and sent 48 hours prior to participant's usual clinic day~* Once a PediQUEST survey is assigned, automated email reminders/app notifications are sent daily for two days~* After 48 hours, unanswered or incomplete surveys are auto-submitted~* PQ-feedback report generated automatically after a PQ Survey is answered~* A pdf of the report is automatically emailed/available on mobile App to designated recipients~* Will also receive oncology-PC integrated care through the Response team~* Duration of follow-up: 18 weeks (2-week run-in period, followed by a 16-week post-randomization follow-up)"
61932150|NCT03408314|OTHER|Usual Cancer Care|"* Will receive the usual cancer care provided at the participating sites~* Will complete weekly PQ-Surveys (no feedback reports will be generated)~* Can receive regular palliative care consultations following the site's usual referral procedures~* Same follow-up (18 weeks)"
61932151|NCT05768919|EXPERIMENTAL|Tolerability, Safety, and Efficacy of LC in Combination with RT and TMZ|Define the MTD/recommended Phase 2 dose (RP2D) of LC, administered IV weekly in combination with standard CRT (60 Gy in 30-33 fractions M-F, and daily oral TMZ 75 mg/m2), in patients with high grade malignant gliomas. This study seeks the MTD/RP2D of LC when added to TMZ during concurrent RT and adjuvant TMZ after RT. The study will evaluate escalating doses of LC delivered by IV infusion weekly as a gravity infusion (without infusion pump). Within each cohort, the dose will remain the same. In the first cohort, dosing will begin at Level 1 (300 mg/m2). The infusion of LC will begin at the start of CRT. Patients will be evaluable for the cohort if they have completed 80% of the planned doses of LC, 80% of RT and 60% of TMZ within the first 10 weeks of treatment. Patients who experience a dose-limiting toxicity (DLT) will be evaluable for the cohort if they have received at least 1 dose of LC.
61932152|NCT06597760|EXPERIMENTAL|Sequence 1: 0.25mg Digoxin-->0.25mg Digoxin plus 20mg enlicitide/180mg Sodium Caprate|Participants will receive 1 tablet of 0.25mg Digoxin on Day 1 of period 1 and 1 tablet of 0.25mg Digoxin coadministered with 1 tablet of 20 mg enlicitide/180 mg sodium caprate on Day 1 of Period 2.
61932153|NCT06597760|EXPERIMENTAL|Sequence 2: 0.25mg Digoxin plus 20mg enlicitide/180mg Sodium Caprate-->0.25mg Digoxin|Participants will receive 1 tablet of 0.25mg Digoxin coadministered with 1 tablet of 20 mg enlicitide/180 mg sodium caprate on Day 1 of Period 1 and will receive 1 tablet of 0.25mg Digoxin on Day 1 of period 2.
61932154|NCT01554397|ACTIVE_COMPARATOR|IMRT with concurrent cisplatin 40 mg/m2|Intensity-modulated Radiation Therapy (IMRT) with concurrent cisplatin 40 mg/m2
61932155|NCT01554397|EXPERIMENTAL|PET-guided Bone Marrow-Sparing IMRT|PET-guided Bone Marrow-Sparing IMRT with concurrent cisplatin 40 mg/m2
61932156|NCT04764162|EXPERIMENTAL|Choline, then Placebo|Participants will consume 1000 mg (2 x 500 mg) of choline supplement per day for 4 weeks, including post-testing sessions. A 2-week washout period will follow the first intervention. Then the participants will consume 1000 mg (2 x 500 mg) of placebo per day for 4 weeks, including post-testing sessions.
61932157|NCT04764162|EXPERIMENTAL|Placebo, then Choline|Participants will consume 1000 mg (2 x 500 mg) of placebo per day for 4 weeks, including post-testing sessions. A 2-week washout period will follow the first intervention. Then the participants will consume 1000 mg (2 x 500 mg) of choline supplement per day for 4 weeks, including post-testing sessions.
61932158|NCT06709144|EXPERIMENTAL|Group SMA|The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA).
61932159|NCT06709144|ACTIVE_COMPARATOR|Group SMV|The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
61932160|NCT04847622||Target Population|Adults with COVID-19 diagnosed and treated with Remdesivir after Aug 31st2020.
61932161|NCT04903197|EXPERIMENTAL|Arm 1A|VAY736 single agent dose escalation in patients with NHL subtypes of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)
61932162|NCT04903197|EXPERIMENTAL|Arm 1B|VAY736 single agent dose expansion in patients with DLBCL
61932163|NCT04903197|EXPERIMENTAL|Arm 2A|VAY736 + lenalidomide dose escalation in patients with DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). Enrollment has been halted in this arm.
61932164|NCT04903197|EXPERIMENTAL|Arm 2B|VAY736 + lenalidomide dose expansion in patients with DLBCL. This arm will not be conducted.
61932165|NCT05065528|PLACEBO_COMPARATOR|Control|placebo pill twice daily for 3 days ondansetron 4mg twice daily for 3 days acetaminophen 500mg twice daily for 3 days
61932166|NCT05065528|EXPERIMENTAL|Intervention|Magnesium 500mg twice daily for 3 days ondansetron 4mg twice daily for 3 days acetaminophen 500mg twice daily for 3 days
61932167|NCT01157468||Cases|"The Case group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2:~* 30 patients with a quiescent lupus~* 30 patients with an active lupus"
61932168|NCT01157468||Controles|"The Control group is constituted by people coming to give blood to the French Blood Establishment of Martinique."
61932169|NCT06708455|EXPERIMENTAL|Administration of RAPA-201 cells|RAPA-201 cells will be administered at a target flat dose between 80 and 400 x 10\^6 cells per infusion.
62484020|NCT04532684|ACTIVE_COMPARATOR|Duloxetine|33 patients received 60 mg/day of duloxetine HCL orally for 12 weeks
62484021|NCT04532684|ACTIVE_COMPARATOR|Pregabalin|33 patients received 300 mg/day of pregabalin orally for 12 weeks
61932170|NCT06462547|EXPERIMENTAL|INZ-701|"INZ-701 will be administered by subcutaneous injection on a once-weekly basis as follows:~* Study participants from 1 year to \<13 years of age will receive a dose of 2.4 mg/kg~* Study participants ≥13 years will either receive a 1.8 mg/kg dose or a 150 mg flat dose of INZ-701"
61932171|NCT05670847|EXPERIMENTAL|Study group|Children receiving exogenous ketone esters + standard of care
61932172|NCT05670847|NO_INTERVENTION|Control group|Children receiving only standard of care
61932173|NCT00956956|EXPERIMENTAL|PF-04455242 treatment|
61932174|NCT00956956|PLACEBO_COMPARATOR|Placebo|
62132881|NCT03642106|PLACEBO_COMPARATOR|Attention placebo control|Placebo consists of after school club for youth.
62132882|NCT05973279||Hemiplegic patients|
62132883|NCT01521169|ACTIVE_COMPARATOR|1 = Tested product dose 1|
62484022|NCT01262001|EXPERIMENTAL|Cohort 1/1-EX|Subjects with moderate to severe idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
62484023|NCT01262001|EXPERIMENTAL|Cohort 2/2-EX|Subjects with mild to moderate idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
61932175|NCT03598244|EXPERIMENTAL|Treatment (volitinib)|Patients receive volitinib PO QD. Treatment repeats every 28 days for up to 39 courses in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, X-ray imaging, and MRI scans throughout study.
61932176|NCT02892032|EXPERIMENTAL|Attention Modification Training|ABMT is a newly emerging intervention that trains patients to override their tendency to focus on threatening aspects of an event and to interpret events as more neutral and therefore less stressful
61932177|NCT02892032|PLACEBO_COMPARATOR|No Attention Modification Training|There is no disengagement of attention from a target stimulus. Attention is divided equally between two stimuli on the screen.
61932178|NCT03703050|EXPERIMENTAL|Cohort 1|Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
61932179|NCT03703050|EXPERIMENTAL|Cohort 2|Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
61932180|NCT04956094||First Trimester Prenatal Visit|Women attending an initial first trimester prenatal visit who will be undergoing a standard blood draw.
61932181|NCT04570579||Observational cohort|"This is a prospective, nonrandomized study of patients undergoing bilateral cataract surgery with implantation of the spherical Vivity and/or Vivity toric IOL. Preoperative patient data such as age, sex, prior ocular history, medical history, and intraocular lens calculations/formulae used will be recorded. Uncorrected and best-corrected visual acuity will be measured at distance (4m), intermediate (60cm) and near (40cm). All 3 surveys will be administered prior to surgery (at baseline) and at 3 months postoperative, regarding spectacle independence, visual disturbances, and visual quality. A proper perioperative record will be maintained, documenting planned IOL implantation, actual IOL implant used, use of femtosecond laser, use of intraoperative aberrometry, and use of pupillary expansion devices. Patients will be examined 1 day (postoperative day 1), 1 week (postoperative week 1), 1 month (postoperative month 1) and 3 months (postoperative month 3) following surgery."
61932182|NCT06102304|PLACEBO_COMPARATOR|Sham Extracorpeal Shock Wave|Control group (GA) Patients in (GA) will be treated by a designed physiotherapy program consisted of Myo-fascial release, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Median nerve neural glide techniques, Graduated strengthening exercises for the upper limb in addition to sham shockwave on the upper trapezius.
61932183|NCT06102304|EXPERIMENTAL|Focused Extracorpeal Shock wave|Patients in (GB) will be treated by Focused Extracorpeal shockwave on the trigger points of upper trapezius in addition to the same physiotherapy program as GA.
61932184|NCT01920009|ACTIVE_COMPARATOR|Pharmacy care group|patients in this group will receive two counseling sessions with a motivational interview.
61932185|NCT01920009|NO_INTERVENTION|Controlgroup|patients in this group will receive usual care by pharmacists
61932186|NCT05577858|OTHER|Meat based|Animal protein-based dietary intervention
61932187|NCT05577858|EXPERIMENTAL|Pulse based|Pulse-protein-based dietary intervention
61932188|NCT06709573|EXPERIMENTAL|Early Vasopressin Initiation|Patients randomized to this arm will have a provider BPA fire prompting vasopressin initiation when the norepinephrine dose is between 10-20 mcg/min
61932189|NCT06709573|ACTIVE_COMPARATOR|Standard of Care Vasopressin Initiation|Patients randomized to this arm will have a provider BPA fire prompting vasopressin initiation when the norepinephrine dose is between 20-35 mcg/min
62325213|NCT05422794|EXPERIMENTAL|Dose Escalation (ZEN003694, nab-paclitaxel, pembrolizumab)|Patients receive ZEN003694 PO QD on days 1-21, nab-paclitaxel IV over 30 minutes on day 1, 8, and 15, and pembrolizumab IV over 30 minutes every 21 days of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity with a maximum of 35 doses of pembrolizumab administered. Patients also undergo CT or MRI scan and collection of blood samples throughout the trial.
62484024|NCT01108445|ACTIVE_COMPARATOR|RAD001|Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
62484025|NCT01108445|ACTIVE_COMPARATOR|Sunitinib|Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
61932190|NCT01669096|EXPERIMENTAL|GSK 692342 Group|Healthy male and female subjects, between and including 18 to 50 years of age, who received 2 doses of GSK 692342 vaccine administered intramuscularly in the deltoid region of the arm, at Days 0 and 30.
61932191|NCT04093349|EXPERIMENTAL|SPK-3006|All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.
61932192|NCT02497300|EXPERIMENTAL|Spironolactone|Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.
61932193|NCT02497300|ACTIVE_COMPARATOR|Amiloride|Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.
61932194|NCT06533397|EXPERIMENTAL|3-month healing period|Staged SFE is performed; following a 3-month-long healing period, bone core biopsy samples are harvested from the augmented bone, and dental implants are placed.
61932195|NCT06533397|EXPERIMENTAL|6-month healing period|Staged SFE is performed; following a 6-month-long healing period, bone core biopsy samples are harvested from the augmented bone, and dental implants are placed.
61932196|NCT05012761|EXPERIMENTAL|SR419 capsules|Ascending single and multiple doses of SR419 orally
61932197|NCT05012761|PLACEBO_COMPARATOR|Placebo|Ascending single and multiple doses of SR419 placebo orally
61932198|NCT05220800|EXPERIMENTAL|Iron(III)isomaltoside 1000|Weight-dependent one-time dosage of intravenous administration of iron(III)isomaltoside given prior to surgery. Dosage: \<50 kg body weight = 500 mg, 50-59 kg body weight = 600 mg, 60-59 kg body weight = 700 mg, 70-79 kg body weight = 800 mg, 80-89 kg body weight = 900 mg, and 90+ kg body weight = 1000 mg.
61932199|NCT05220800|PLACEBO_COMPARATOR|Placebo|500 ml isotonic saline infusion fluid
61932200|NCT01822678|EXPERIMENTAL|Group 1|Group 1: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
61932201|NCT01822678|EXPERIMENTAL|Group 2|Group 2: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
61932202|NCT01822678|PLACEBO_COMPARATOR|Group 3|Group 3: Placebo (change in daily number of tablets administered, according to clinical response).
62484026|NCT03717805|EXPERIMENTAL|Intervention group|Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
62484027|NCT03717805|NO_INTERVENTION|Control group|Participating couples of the control group will receive care as usual (as will participating couples of the intervention group) and will not get access to the preparatory information movie on oocyte aspiration (POAM).
62484028|NCT01730846|EXPERIMENTAL|Doxazosin 4mg/day|doxazosin 4mg/day
62484029|NCT01730846|PLACEBO_COMPARATOR|Placebo|placebo control
62484030|NCT01730846|EXPERIMENTAL|Doxazosin 8mg/day|doxazosin 8mg/day
62484031|NCT06561061|EXPERIMENTAL|Zinc|Dispersible zinc sulfate tablet (20 mg)
62484032|NCT06561061|PLACEBO_COMPARATOR|Placebo|Dispersible identical placebo tablet
62484033|NCT01861535|EXPERIMENTAL|Primary Imiquimod|Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
62484034|NCT01861535|ACTIVE_COMPARATOR|Primary surgery|The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.
62484035|NCT03214588|PLACEBO_COMPARATOR|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
62484036|NCT03214588|EXPERIMENTAL|TAK-831 75 mg|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
62484037|NCT03214588|EXPERIMENTAL|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
62484038|NCT06562231||questionnaire group|The patient will fill out the questionnaire form with the diagnosis of isthmocele.
62484039|NCT04410380|EXPERIMENTAL|Electronic tablet|Spanish-speaking parents receive electronic tablet and teaching about use
62484040|NCT05189106|EXPERIMENTAL|Baricitinib|Baricitinib 2mg administered by mouth once daily for the first 8 weeks, followed by baricitinib 4mg administered by mouth once daily for 16 weeks.
62325214|NCT05422794|EXPERIMENTAL|Dose Expansion (ZEN003694, nab-paclitaxel, pembrolizumab)|Patients receive ZEN003694 PO QD on days 1-7 prior to combination therapy. Patients then receive ZEN003694 PO QD on days 1-21, nab-paclitaxel IV over 30 minutes on days 1, 8, and 15, and pembrolizumab IV over 30 minutes every 21 days of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity with a maximum of 35 doses of pembrolizumab administered. Patients also undergo biopsies on study, and CT or MRI scans and collection of blood samples throughout the trial.
62325215|NCT02166463|ACTIVE_COMPARATOR|Arm I (ABVE-PC)|Patients receive doxorubicin hydrochloride IV over on days 1-2, bleomycin sulfate IV or SC on days 1 and 8, vincristine sulfate IV on days 1 and 8, etoposide IV on days 1-3, prednisone orally PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
62484041|NCT04946708|EXPERIMENTAL|Small group zoom meeting|Group one: will be asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants e.g. questions, perceptions, etc.).
62484042|NCT04946708|EXPERIMENTAL|YouTube pre-recorded video|Group two: will be asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
62484043|NCT05336422|EXPERIMENTAL|training on the risks associated with sun exposure|power point on the risks associated with sun exposure
62484044|NCT06003335|EXPERIMENTAL|IG|The intervention group will receive personalised motivational messages (according to their physical activity levels and preferences screened during the baseline measurement) using instant messaging applications (e.g., WhatsApp). They will be equipped with a wearable activity tracker for 3 months to monitor their physical activity level. In accordance with the guidelines for mobile instant messageing development, we will develop a message content library and protocol for intervention delivery.
62484045|NCT06003335|ACTIVE_COMPARATOR|CG 1|Control group 1 will receive regular message delivery (as mentioned in the intervention) without personalised motivational messaging for better evaluation of the effect of personalized motivational messaging.
62692177|NCT04098146||Mandibular Reconstruction|Patients undergoing segmental mandibular defect reconstruction. The decision of one stage or two stage reconstruction is done according to the patient and treating surgeon preferences following the local standard of care
62325216|NCT02166463|EXPERIMENTAL|ARM II (Bv-AVEPC)|Patients receive brentuximab vedotin IV on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
62484046|NCT06003335|NO_INTERVENTION|CG 2|Control group 2 (self-management) will only receive a leaflet containing basic information about CRCI distributed during the recruitment process and text message reminders for follow-up surveys. Regular and real-time support (i.e., chat-type) messages will not be made available to the control group.
62484047|NCT02342535|OTHER|Physical activity intervention|"Participants will attend bi weekly exercise classes for a total of 16 weeks, led by certified, and trained instructors.~The participant's children between the ages of 6 and 14 years will participate in the martial arts class with the mothers."
62692178|NCT06477029|EXPERIMENTAL|VS tFUS/Sham tFUS|VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
62692179|NCT06477029|EXPERIMENTAL|Sham tFUS/VS tFUS|VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
62692180|NCT02167126|EXPERIMENTAL|Kinesio Taping|Kinesio Taping was applied as experimental group.
62692181|NCT02167126|PLACEBO_COMPARATOR|Micropore|Micropore Tape was used as placebo tape
62132884|NCT01521169|ACTIVE_COMPARATOR|2 = Tested product dose 2|
62132885|NCT01521169|SHAM_COMPARATOR|3 = Control product|
62132886|NCT02538900|EXPERIMENTAL|Group 1|Low-intensity, self-paced walking exercise. Home based exercise.
62484048|NCT04405102|EXPERIMENTAL|Ozanimod + standard of care|During hospitalization, the experiment treatment of Ozanimod will be given with the standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data.).
61932203|NCT06479876|EXPERIMENTAL|Home-based cardiac rehabilitation mobile health intervention|Home-based cardiac rehabilitation with mobile application and periodic video calls with exercise physiologist + AHA Life's Essential 8 sheets.
61932204|NCT06479876|NO_INTERVENTION|Control|Standard of care course for an individual not participating in center based cardiac rehabilitation. AHA Life's Essential 8 Fact Sheets are provided to promote healthy living.
62132887|NCT02538900|EXPERIMENTAL|Group 2|Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.
62132888|NCT02538900|ACTIVE_COMPARATOR|Group 3|Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.
62132889|NCT00589875|EXPERIMENTAL|Single arm|This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.
62132890|NCT01074294|EXPERIMENTAL|Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant|Participants received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for 5 weeks. Once assigned to a stimulant by the investigator, participants remained on the same stimulant for the duration of the trial. Participants who met eligibility criteria i.e., who received prior treatment for adult ADHD and treatment-naïve participants were included in this arm group. Participants with incomplete response at the end of Phase A (Week 5) entered Phase B and rest of the participants continued to Phase A+.
62132891|NCT01074294|EXPERIMENTAL|Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant|Participants with incomplete response (with a \> 0% and \< 30% reduction in ADHD Symptoms Total Score {18 items} between the baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV { Conners' Adult ADHD Rating Scale-Observer: Screening Version}, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a clinical global impression - improvement scale (CGI-I) score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received Brexpiprazole 2 milligram (mg) tablet along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
62325217|NCT06208267|ACTIVE_COMPARATOR|1)Standard care: 1G TXA IV|1 gm TA IV given prior to incision and 1G TXA IV during cementation or closure
62325218|NCT06208267|ACTIVE_COMPARATOR|2) Standard + 1G oral TXA - 0 and 8 hours post-operatively|Standard + 1G oral TXA given at 0 and 8 hours post-operatively
62325219|NCT06208267|ACTIVE_COMPARATOR|3) Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively|Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively
62132892|NCT01074294|PLACEBO_COMPARATOR|Phase B (Double-blind Randomization Phase): Placebo + Stimulant|Participants with incomplete response (with a \> 0% and \< 30% reduction in ADHD Symptoms Total Score {18 items} between the Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a CGI-I score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received matching-placebo tablets along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
62325220|NCT05142618|ACTIVE_COMPARATOR|Standard Post-operative Instructions|Participants in the control group will be told upon post-operative discharge that they should follow the post-operative instructions.
62325221|NCT05142618|EXPERIMENTAL|Supervised Physical Therapy|Participants in the physical therapy group will be scheduled for visits to the physical therapy clinic beginning two weeks after surgery, and will undergo supervised physical therapy treatments approximately twice per week for eight weeks according to a standardized evidence-based post-operative abdominal core surgery rehabilitation program.
62325222|NCT01903811|EXPERIMENTAL|Arm I (dexamethasone, low-dose carfilzomib)|Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.
62325223|NCT01903811|EXPERIMENTAL|Arm II (dexamethasone, high-dose carfilzomib)|Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
61932205|NCT05951257|EXPERIMENTAL|Personalized multimodal intervention involving hypnosis and/or music|"This arm will receive a personalized multimodal intervention involving (a) hypnosis, (b) music or (c) hypnosis and music.~Note that the objective of the research is not to compare the effect of the different intervention modalities between them, but to consider these three modalities as a multimodal intervention taking into consideration patients' preferences, that we compare to the control."
62325224|NCT04922268|ACTIVE_COMPARATOR|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
62484049|NCT04405102|ACTIVE_COMPARATOR|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
61932206|NCT05951257|NO_INTERVENTION|Control/Waiting list|The participants of the control group will carry out its their daily activities and will be assessed using the same measures, at the beginning of each session and after a delay comparable to the duration of the intervention administered in the experimental group.
61932207|NCT05917769|EXPERIMENTAL|Group A (Rocabdo exercises)|The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day. It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction.
61932208|NCT05917769|EXPERIMENTAL|Group B (Postural correction exercises)|This group will perform posture correction exercises for six days and six times per day. Posture correction exercises include chest stretch , wall stretch , chin tuck in and face down arm lifts.
61932209|NCT05123911|EXPERIMENTAL|Product Kit: Shampoo, Conditioner and Combining Cream (Investigational Products [IPs])|The parents/legally acceptable representative (LAR) of the participants will receive a product kit containing the 3 investigational products (shampoo, conditioner and combining cream) and will bathe the child participant with shampoo followed by conditioner and then apply combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
61932210|NCT06648681|EXPERIMENTAL|Intervention|The intervention arm will receive the study drug, Lemborexant 5mg, daily for 7 days post-operatively while in hospital.
61932211|NCT06648681|PLACEBO_COMPARATOR|Control|The Control arm will receive the placebo study drug daily for 7 days post-operatively while in hospital.
61932212|NCT06310525||Fatal drowning|Drowning incidents where the patient died within 30 days after the incident as a consequence of the submersion injury
61932213|NCT06310525||Non-fatal drowning|Drowning incidents where the patient survived to 30 days
61932214|NCT06707376|EXPERIMENTAL|Early Kangaroo Mother Care Group|"Early Kangaroo Mother Care Group:~* Initiation of KMC within 24 hours of birth.~* Continuous skin-to-skin contact for at least 8 hours per day, with gradual increase based on infant tolerance.~* Support for exclusive breastfeeding or expressed breast milk feeding.~* Ongoing assessment and support from trained neonatal nurses and lactation consultants."
61932215|NCT06707376|NO_INTERVENTION|Control Group|"Control Group:~* Standard neonatal nursing practices, including incubator care, intermittent holding, and feeding as per clinical guidelines.~* Respiratory support as needed based on the severity of respiratory distress."
61932216|NCT04967664|EXPERIMENTAL|Qutenza (capsaicin) 8% topical system|Qutenza (capsaicin 8% topical system, containing capsaicin 179 mg or capsaicin 640 µg/cm2 of topical system)
61932217|NCT04967664|ACTIVE_COMPARATOR|Low-dose capsaicin control|capsaicin 0.04% topical system
61932218|NCT04815746|EXPERIMENTAL|Psychosocial Symptom Management Intervention (PSMI) Experimental Condition Arm|Participants in this group will receive the Cognitive Behavioral Therapy (CBT)-based skills over a 10-week period.
61932219|NCT04815746|ACTIVE_COMPARATOR|Usual Clinical Care Control Arm|Participants in this group will receive standard education.
61932220|NCT05880654|ACTIVE_COMPARATOR|Systemically healthy periodontitis|Non Surgical Periodontal therapy ( Scaling \& Root planning)
61932221|NCT05880654|ACTIVE_COMPARATOR|Diabetic & Periodontitis|Non surgical periodontal therapy ( scaling \& root planning)
61932222|NCT05880654|NO_INTERVENTION|Control|Healthy group with neither Diabetes nor Periodontitis
62325225|NCT04922268|EXPERIMENTAL|External focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
62325226|NCT04869436|EXPERIMENTAL|Dupilumab group|Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.
62325227|NCT05921032|OTHER|Lumbar stabilisation exercise (LSE)|Lumbar stabilisation exercise (LSE) group will perform eight weeks exercise intervention for two sessions in a week. Each session took about 45 minutes to complete. The total exercise sessions were 16 sessions. LSE group will be focused on strengthening the deep trunk stabilising muscles (i.e., transverse abdominal, internal oblique and lumbar multifidus) and control pelvis muscles.
62484050|NCT02375477|EXPERIMENTAL|Health services research (isolation protocol education)|Residents and nurses are given an educational intervention on isolation protocols for diarrhea and enteric pathogens approved by Infection Control and covering their recommendations.
62484051|NCT03979768|EXPERIMENTAL|Risk Assessment Only pharmacies (RTO-group)|Offered a diabetes risk assessment service without any blood sample testing.
62484052|NCT03979768|EXPERIMENTAL|HbA1c-group /pharmacies|Offered a diabetes risk assessment service including a measurement of Haemoglobin A1c (HbA1c) to the people with a high risk of developing type 2 diabetes on the risk assessment form (The Finnish Diabetes Risc Score (FINDRISC) to those with a western background, and Leicester Risk Assessment (LRA) form for those with a non-western background.
61932223|NCT03183778|EXPERIMENTAL|Patiromer + Research Diet|"During the first phase (week 2), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (less than or equal to 1 serving/day), and eliminates high-potassium fruits and vegetables.~During the second phase (weeks 3 and 4), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources."
62484053|NCT06455137|EXPERIMENTAL|Epidural Stimulator|Participants will have a 16-electrode epidural array implanted in the C4-C7 and T11-L2 areas of the spinal cord. Following a 2 weeks recovery period, patients will engage in a structured training of physical rehabilitation and electrical stimulation.
62484054|NCT01344590|ACTIVE_COMPARATOR|saline lock maintenance|Standard saline lock maintenance
62484055|NCT01344590|EXPERIMENTAL|ethanol maintenance|Instillation of 70% pharmaceutical grade ethanol solution into the central line in a volume calculated to fill the catheter lumen and hub.
62484056|NCT06234423|EXPERIMENTAL|Monotherapy Dose Finding - Phase 1a|
62484057|NCT06234423|EXPERIMENTAL|Expansion as Monotherapy - Phase 1b|
62484058|NCT06626659||Elevated Lp(a)|Individuals with an Lp(a) level greater than or equal to 100 nmol/L
62484059|NCT06626659||Non-elevated Lp(a)|Individuals with an Lp(a) level less than 100 nmol/L
62484060|NCT02651506|EXPERIMENTAL|Electromagnetic Navigation Bronchoscopy|
61932224|NCT05807763|NO_INTERVENTION|Control Group|Fundoplication
61932225|NCT05807763|EXPERIMENTAL|Study Group|No Fundoplication
62325228|NCT05921032|OTHER|Lumbar muscle strengthening exercise (LMSE)|Lumbar muscle strengthening exercise (LMSE) group will perform eight weeks exercise intervention for two sessions in a week. Each session took about 45 minutes to complete. The total exercise sessions were 16 sessions. LMSE group aims to strengthen the trunk flexor and extensor muscles.
62325229|NCT05921032|NO_INTERVENTION|Control group|The control group will be given a diary to record their daily activities which consist of their 24 hours diet recall for 8 weeks and involvement of any physical activity throughout the 8 weeks. This diary will be collected during follow up (1 month after post-intervention). Upon completion of the trial, participants in the control group will receive either LSE or LMSE or combination of both exercises depending on their preference.
62484061|NCT02651506|ACTIVE_COMPARATOR|Transthoracic Needle Biopsy|
62484062|NCT06253260|ACTIVE_COMPARATOR|(Group A): rapid sequential group|
62484063|NCT06253260|ACTIVE_COMPARATOR|(Group B): normal sequential group|
62484064|NCT01910753|EXPERIMENTAL|APA|Patient with neck cancer and accepting the physical activity program .
62484065|NCT04802057|EXPERIMENTAL|SAR445088|Repeat dose of SAR445088
62484066|NCT06592222||Elranatamab|Patients treated with elranatamab from the MagnetisMM-3 trial
62484067|NCT06592222||Standard of care|Patients treated with standard-of-care therapies from real-world data sources
62484068|NCT01028183||Extremely Premature Infants|\< 30 weeks gestation (N=5000)
62484069|NCT01028183||Premature Infants|30-36 weeks gestation (N=2000)
62484070|NCT01028183||Hospitalized Term Infants|\>=37 weeks gestation (N=2000)
62484071|NCT01028183||Healthy Term Infants|\>=37 weeks gestation (N=1000)
62484072|NCT00404183|EXPERIMENTAL|hydrocodone/acetaminophen extended release|
62484073|NCT00404183|PLACEBO_COMPARATOR|Placebo|
62484074|NCT06626893|OTHER|Relapsed Refractory Acute Leukemias|Functional and genomics analyses will be performed on primary sample from each enrolled patient (biological preclinical study)
62484075|NCT04474405|EXPERIMENTAL|Brain flortaucipir PET scan|Subjects receiving a brain PET scan after flortaucipir administration
62484076|NCT04474405|EXPERIMENTAL|Whole body flortaucipir PET scan|Subjects receiving a whole body PET scan after flortaucipir administration
62484077|NCT04474405|OTHER|MRI and Amyloid Extension Cohort|Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)
62484078|NCT05439707|EXPERIMENTAL|Experimental group|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
62484079|NCT05439707|SHAM_COMPARATOR|Control group|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
62484080|NCT04170452||Chronic Hepatitis Delta patients|Patients infected with delta virus
62484081|NCT03058614|ACTIVE_COMPARATOR|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
62132893|NCT01074294|EXPERIMENTAL|Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant|Participants with response (with a ≥ 30% reduction in ADHD Symptoms Total Score {18 items} between Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, or a CAARS-O:SV ADHD Symptoms Total Score {18 items} of \< 24 at Week 5, or a CGI-I score of \< 3 at Week 5) and non-response (with deterioration or no change in ADHD symptoms at Week 5) at the end of Phase A (Week 5), received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for an additional 6 weeks (up to Week 11).
62132894|NCT04894851|EXPERIMENTAL|Contingency Management|Receives contingency payments each month based on decluttering scores
61932226|NCT06518525|EXPERIMENTAL|pilates-based tele-exercises|Participants in the primary dysmenorrhea study group will be given a general introduction to Pilates-based tele-exercises, and they will be taught five essential elements that they should continuously practice during the exercise process. These elements will be control, breathing, fluidity, precision, and centering. They will be instructed on how to activate the core muscles, including the transverse abdominis, pelvic floor, and multifidus muscles, through isometric contractions while exhaling (centering). The exercises will be conducted over 6 weeks, twice a week, with each session lasting 50 minutes. The exercises, predetermined by the researcher, will be performed under the supervision of a physiotherapist. Each session will be structured into warm-up exercises, main exercises, and cool-down exercises. .
61932227|NCT06518525|NO_INTERVENTION|control group|control group
61932228|NCT05274685|EXPERIMENTAL|covid positive with acute kidney injury receiving early renal replacement|
61932229|NCT05274685|EXPERIMENTAL|covid positive with acute kidney injury under conservative management|
61932230|NCT02892123|EXPERIMENTAL|ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy|
61932231|NCT06710626|OTHER|Single|
61932232|NCT04147533|EXPERIMENTAL|initially treated patients|The dose of tyrosin kinase inhibitors (imatinib, or nilotinib, or dasatinib) in patients meeting all of the inclusion criteria and none of the exclusion criteria will be reduced in two consequent steps, during the first 6 months after study entry by 50%, during the second 6 months by 50% again; the medication is discontinued then and the patients are followed each month in the first 6 months after withdrawal, each 1,5 month in the next 6 months, and each 3 months in the next 12 months.
61932233|NCT01229397|ACTIVE_COMPARATOR|Inflexal V 0.25 mL x 2|
61932234|NCT01229397|EXPERIMENTAL|Inflexal V 0.5 mL x 1|
61932235|NCT06708065|EXPERIMENTAL|ARMEO group|The intervention group consisted of 42 patients who received standard physical therapy and occupational therapy for 90 minutes per day, five days per week. Additionally, these patients underwent training with the ArmeoPower robotic system for 45 minutes per day, five days per week.
61932236|NCT06708065|ACTIVE_COMPARATOR|Control group|The control group comprised 42 patients who participated in standard physical therapy and occupational therapy for 90 minutes per day, five days per week. In addition, these patients were instructed to engage in home-based practice for 45 minutes per day, five days per week, guided by direct instructions and exercise leaflets provided by the therapists.
61932237|NCT06709599||MMA athletes|Healthy, trained athletes
61932238|NCT04331236|EXPERIMENTAL|Patient and Caregiver Intervention|Patient and Caregivers receive both cognitive behavioral intervention and yoga interventions each week, for 7 weeks.
61932239|NCT03162731|EXPERIMENTAL|Treatment ( nivolumab, ipilimumab, radiation therapy)|Patients receive nivolumab IV over at least 30 minutes every 2 weeks and ipilimumab IV over at least 90 minutes every 6 weeks. Beginning week 3, patients undergo simultaneous integrated boost intensity modulated radiation therapy or volumetric modulated arc therapy for 5 days per week over 7 weeks. Patients continue nivolumab every 2 weeks for 12 doses and ipilimumab every 6 weeks for 4 doses. Courses repeat for up to 23 weeks in the absence of disease progression or unacceptable toxicity.
61932240|NCT06707532|ACTIVE_COMPARATOR|Group I (no muscular relaxant)|Group I - 16 patients undergoing general anaesthesia with endotracheal intubation, during the induction of anaesthesia, the patients will be administered a muscle relaxant from the depolarising group (Chlorsuccilin®) for the endotracheal intubation procedure (using precurarisation). This is a method of pharmacologically preventing the muscle fasciculations characteristic of depolarising agents. For this purpose, a low-dose muscle relaxant from the non-depolarising group - (rocuronium, Esmeron®) will be administered just before the actual dose of the depolarising agent. No muscle relaxant will be used during the actual procedure, but the level of muscle relaxation will be continuously monitored through the use of the NMT - TOF % technique (a method of measuring neuromuscular excitability that allows real-time assessment of muscle strength).
62132895|NCT03746938|EXPERIMENTAL|VB-C01|Surgical technique: Via left lateral thoracotomy, the heart is lifted and supported on two deep pericardial points with 4-0 or 5-0 Prolene double arrmed suture. Each suture is passed through the reinforced frame of the collagen membrane containing the stem cells (VB-C01) and then tied, while the upper part of the patch is held with forceps. After securing the lower part of the pericardial layer, the heart is allowed to slowly recover its position with the pericardial cavity while the collagen membrane is mobilized to cover all of the target area. If necessary, some sutures can be used to fix the patch VB-C01 to the epicardial surface of the heart. Each suture is likewise passed through the reinforced frame of the membrane.
62132896|NCT02061501|ACTIVE_COMPARATOR|Speech therapy|Speech therapy (30 min per week) alone for the 6 first months. Then speech therapy (30 min per week) and optometric therapy (30 min per week) for the 6 last months.
62132897|NCT02061501|EXPERIMENTAL|Speech therapy and optometric therapy|Speech therapy (30 min per week) and optometric therapy (30 min per week) for 12 months.
62132898|NCT03335397|EXPERIMENTAL|M-learning group|Participants receive mobile app (m-learning application) with interactive content (quiz).
62132899|NCT03335397|OTHER|Control group|Participants receive traditional learning process (books, journals available in the University library).
62325230|NCT04934527|EXPERIMENTAL|Experimental|Patients with positive CMV serology at transplantation will receive 6 infusions of Cytotect every 15 days with the first injection on the day of transplantation. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
62325231|NCT06416072||Group A|Approximately 500 participants who screen failed from the AHEAD study that were plasma positive / PET negative
62325232|NCT06416072||Group B|Approximately 250 participants who screen failed from the AHEAD study that were plasma negative / PET negative
61932241|NCT06707532|ACTIVE_COMPARATOR|Group II (muscular relaxant)|Group II -16 patients undergoing general anaesthesia with endotracheal intubation, during the induction of anaesthesia the patients will be administered a muscle relaxant from the depolarising group (rocuronium, Esmeron®) for the endotracheal intubation procedure (using precurarisation). This is a method of pharmacological prevention of muscle fasciculation, characteristic of depolarising agents. For this purpose, a low-dose muscle relaxant from the non-depolarising group (rocuronium, Esmeron®) will be administered just before the actual dose of the depolarising agent. During the procedure itself, the level of relaxation will be continuously monitored by using the NMT - TOF % technique (a method of measuring neuromuscular excitability that allows real-time assessment of muscle strength). During the ablation performed, the patient will be under the influence of a muscle relaxant from the non-depolarising group (rocuronium, Esmeron®).
61932242|NCT04512287|EXPERIMENTAL|Experimental: Autologous PRP followed by Placebo Group|Participants in this group will receive the autologous intervention first, followed by the placebo intervention 3 months later.
61932243|NCT04512287|EXPERIMENTAL|Experimental: Placebo followed by Autologous PRP Group|Participants in this group will receive the placebo intervention first, followed by the Autologous PRP intervention 3 months later.
61932244|NCT06587308|EXPERIMENTAL|Dorsal-Double-Layered 10% Circumferential Reduction (DD-10) Pressure Garment|A custom-fabricated finger-to-above-elbow (long glove) pressure garment with 10% of stress. The design is similar to S-10 except it has an extra layer of fabric on the dorsal aspect that gives stronger compression
61932245|NCT06587308|ACTIVE_COMPARATOR|Single-Layered 10% Circumferential Reduction (S-10) Pressure Garment|A custom-fabricated single-layered finger-to-above-elbow (long glove) pressure garment with 10% of stress.
61932246|NCT06587308|PLACEBO_COMPARATOR|Single-Layered No Circumferential Reduction (S-0) Pressure Garment|A custom-fabricated single-layered finger-to-above-elbow (long glove) pressure garment with 0% of stress
61932247|NCT05569473|EXPERIMENTAL|Test group|Intrabony defect filled with VCMX after along with open flap debridement \[OFD+VCMX\])
61932248|NCT05569473|EXPERIMENTAL|control group|OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
61932249|NCT03370614||IBS Group|Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
61932250|NCT03370614||Healthy Control Group|Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
61932251|NCT01070043|EXPERIMENTAL|Amlodipine 5mg/Valsartan 80 mg|During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.
61932252|NCT01070043|ACTIVE_COMPARATOR|Valsartan 160 mg|In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.
61932253|NCT01070043|OTHER|Run-In Valsartan 80 mg|During run-in period, oral valsartan 80 mg once daily for 4 weeks.
61932254|NCT05049369|EXPERIMENTAL|Polysomnography for all participants of the study|Polysomnography device is used to measure certain variables overnight when a participant is sleeping
61932255|NCT04266769|EXPERIMENTAL|Patients with Malocclusion|
61932256|NCT05751642|EXPERIMENTAL|Cohort 1|Participants will receive a single dose of ALXN1920.
61932257|NCT05751642|EXPERIMENTAL|Cohort 2|Participants will receive a single dose of ALXN1920.
61932258|NCT05751642|EXPERIMENTAL|Cohort 3|Participants will receive a single dose of ALXN1920.
61932259|NCT05751642|EXPERIMENTAL|Cohort 4|Participants will receive a single dose of ALXN1920.
61932260|NCT05751642|EXPERIMENTAL|Cohort 5|Participants will receive a single dose of ALXN1920.
61932261|NCT05751642|EXPERIMENTAL|Cohort 6: Japanese Cohort|Japanese participants will receive a single dose of ALXN1920.
61932262|NCT05751642|PLACEBO_COMPARATOR|Pooled Placebo|Participants will receive Placebo.
61932263|NCT06350474|EXPERIMENTAL|Dnase - Discontinue|Discontinuation of current dornase alfa (dnase) therapy
62132900|NCT02014831|ACTIVE_COMPARATOR|TIP|"Reference arm; Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment)"
62132901|NCT02014831|EXPERIMENTAL|Cetuximab + TIP|"Experimental arm: Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment) and weekly infusion of Cetuximab."
61932264|NCT06350474|ACTIVE_COMPARATOR|Dnase - Continue|Continuation of current dornase alfa (dnase) therapy
61932265|NCT06708780|EXPERIMENTAL|Treg Group|Participants in this group are transplanted with expanded autologous Tregs in addition to routine therapy for T1DM.
61932266|NCT06708780|OTHER|Control Group|Participants in this group receive only routine therapy for T1DM.
61932267|NCT01717144|NO_INTERVENTION|traditional medical care|patients benefiting of a traditional medical care
61932268|NCT01717144|EXPERIMENTAL|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
61932269|NCT04110262|EXPERIMENTAL|High-low dietary sodium|High sodium diet (3400 mg/day) feeding period followed by low sodium diet (2300 mg/day) feeding period
61932270|NCT04110262|EXPERIMENTAL|Low-high dietary sodium|Low sodium diet (2300 mg/day) feeding period followed by high sodium diet (3400 mg/day) feeding period
62132902|NCT01245400|EXPERIMENTAL|Z-Lig|Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) graft implantation performed under anesthesia during an arthroscopic procedure.
62132903|NCT01245400|ACTIVE_COMPARATOR|Allograft|Allograft bone/tendon graft implantation performed under anesthesia during an arthroscopic procedure.
62132904|NCT04352400|ACTIVE_COMPARATOR|Nafamostat|Nafamostat mesylate on top of best standard of care.
62132905|NCT04352400|PLACEBO_COMPARATOR|Placebo|Placebo on top of best standard of care.
62132906|NCT02132559||DHEA administration,no treatment|The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
62132907|NCT01236846|PLACEBO_COMPARATOR|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
62132908|NCT01236846|EXPERIMENTAL|VDR Genotype (aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
62692182|NCT02624687|ACTIVE_COMPARATOR|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
62692183|NCT02624687|PLACEBO_COMPARATOR|Control|These subjects will receive no intervention.
61932271|NCT05007717|EXPERIMENTAL|Data-informed Stepped Care (DiSC) arm|At intervention sites, HCW will assign ALHIV to different levels or intensity of HIV services depending on their current and anticipated health care needs. The stepped care framework is designed to be flexible, to accommodate variable individual and social support services available at each facility.
61932272|NCT05007717|NO_INTERVENTION|Standard of care|Sites randomized to the control arm will continue with standard of care approaches for adolescent clinic visits (usually 1-3 monthly visits) regardless of health care needs and additional support as needed.
61932273|NCT02045173|OTHER|Apneascan TM|autoscoring algorithms of the Apneascan TM compared to the polysomnography or polygraphy
61932274|NCT06016907|OTHER|Stepped care|Participants will receive up to two courses of treatment. All participants in stepped care will receive internet-delivered cognitive behavioral therapy (ICBT) in the first course (A). Participants with an insufficient treatment response will then be offered in-person cognitive behavioral therapy (CBT) in the second course (B). Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments.
61932275|NCT06016907|OTHER|Stratified care|Participants will receive up to two courses of treatment. In stratified care, in treatment course A, the investigators aim to offer around half of the participants ICBT and the other half in-person CBT (based on their risk of non-response). All participants in stratified care who do not sufficiently respond to treatment in course A will be offered personalized in-person CBT in course B. Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments.
61932276|NCT03128645||Group 1|Standard method group
61932277|NCT03128645||Group 2|Abdominal corset group
61932278|NCT06707064|EXPERIMENTAL|SFEE Diet Management Group ( Experimental Arm)|"Participants in this group received the Self-Family-Environment Empowerment (SFEE) diet management intervention, which included:~Self-empowerment: Goal-setting, dietary planning, and evaluation. Family empowerment: Emotional support and supervision of dietary practices. Environmental empowerment: Peer group interaction, education, and support through WeChat groups.~Routine nursing care was also provided alongside the intervention."
61932279|NCT06707064|ACTIVE_COMPARATOR|Control Group|"Participants in this group received routine nursing care for gestational diabetes management, including:~Medication guidance, dietary education using guidance charts, exercise plans, and self-monitoring.~Dietary plans were customized based on individual patient needs, but no additional empowerment strategies (e.g., SFEE) were implemented."
61932280|NCT02353754|ACTIVE_COMPARATOR|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
61932281|NCT02353754|EXPERIMENTAL|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
61932282|NCT04263363|EXPERIMENTAL|CDS pathway|When the anesthesiologist completes the preoperative evaluation for a patient who is flagged as having either respiratory disease or OSA and will receive general anesthesia, the anesthesiologist will receive a pop-up window reminding them of the best practice guidelines for pulmonary management in high-risk patients. We anticipate that the pathway will suggest 1) use of sugammadex to reverse neuromuscular blockade if rocuronium was used 2) use of objective train of four monitoring throughout the case and to confirm reversal 3) use of a tidal volume of 6-8 cc/kg 4) use of at least 5 cmH2O of PEEP
61932283|NCT06145607|EXPERIMENTAL|Period 1, 2 and 3 ABBV-CLS-7262|"* Participants will receive ABBV-CLS-7262 administered under fasted conditions.~* Participants will receive ABBV-CLS-7262 administered under fed conditions (high-fat/high-calorie breakfast).~* Participants will receive ABBV-CLS-7262 administered with applesauce."
61932284|NCT05407610|ACTIVE_COMPARATOR|Conventional Radiofrequency of the genicular nerves|In the conventional radiofrequency group a intervention of 80°C at the tip is applied during 90 seconds at each nerve (superolateral, superomedial and inferomedial genicular nerves). The probe stays in place for 150 seconds at each nerve so that the time needed for each procedure is similar.
61932285|NCT05407610|ACTIVE_COMPARATOR|Cooled Radiofrequency of the genicular nerves|In the cooled radiofrequency group a intervention of 60°C measured at the tip and on average 80°C in the targeted tissue is applied for 150 seconds using the Cooled RF system at each nerve (superolateral, superomedial and inferomedial genicular nerves).
61932286|NCT05407610|SHAM_COMPARATOR|Sham procedure|In the sham group a 18 gauge introducer and probe will be placed but no RF intervention will be applied. The generator will be turned on without connection to the probe for 150 seconds and the sound of the generator will be mimicked with a recording. The position of the needle will not be checked by fluoroscopy; however, the intervention team will position the fluoroscopy arm and mention the acquisition of the fluoroscopic image to the patient. This way no unnecessary radiation is used.
61932287|NCT06546670|EXPERIMENTAL|Part 1A|Part 1A in healthy participants
61932288|NCT06546670|EXPERIMENTAL|Part 1B|Part 1B in healthy participants
61932289|NCT06546670|EXPERIMENTAL|Part 1C|Part 1C in healthy participants
61932290|NCT06546670|EXPERIMENTAL|Part 2|Part 2 in patients with sickle cell disease
62692184|NCT05475002|EXPERIMENTAL|Intervention group|care empowerment program
62692185|NCT05475002|ACTIVE_COMPARATOR|Control group|dementia education
62692186|NCT01986023|EXPERIMENTAL|SMS Short Message Service Arm plus Prescription|"Intervention is as follows: Drug reminder SMS will be sent to the participants in the intervention arm customised to their stroke prescription. These SMS will be interactive in a way that the participants will have to answer back if they have taken their medicine or not in a Yes/No format. Moreover behaviour change SMS will also be sent to the intervention arm twice weekly. In addition , Participants will be encouraged to take medication using a taxonomy of behavioral change intervention techniques."
62132909|NCT01236846|EXPERIMENTAL|VDR Genotype (AA)|Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
62484082|NCT03058614|ACTIVE_COMPARATOR|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
62484083|NCT05633862|EXPERIMENTAL|BI 1015550 low dose|
62484084|NCT05633862|EXPERIMENTAL|BI 1015550 high dose|
62132910|NCT01236846|EXPERIMENTAL|VDR genotype (Aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
62132911|NCT05447936|ACTIVE_COMPARATOR|Female arm|Ten healthy active female XCS past the age of 18 years were included. The duration of the study was 12 weeks divided in three dose-escalation periods of four weeks. In the first 4-week period all the participants was given 47gram Jarlsberg cheese daily. Based on the change in serum Osteocalcin level, the daily intake of Jarlsberg cheese for the next 4-week periode was desided in accordance with the RSP procedure
62325233|NCT06416072||Group C|Approximately 250 participants who screen failed prior to PET imaging will undergo amyloid PET imaging with NAV4694 injection.
62692187|NCT01986023|NO_INTERVENTION|Standard Prescriptions and Counselling|The usual care arm will undergo standard treatment and counselling regarding their treatment and the education regarding their medication as per standard of care. They will receive a standard written prescription and no SMS
62325234|NCT06274515|EXPERIMENTAL|Mechanisms of Acquired Resistance|Participants with breast cancer who have a newly appearing or recurrent metastatic lesion while on anti-cancer therapy will be assigned to one of 3 cohorts.
62325235|NCT06274515|EXPERIMENTAL|Mechanisms of Primary Resistance|Participants with breast cancer who have a progressing tumor lesion while on anti-cancer therapy will be assigned to one of 2 cohorts.
62325236|NCT06033196|EXPERIMENTAL|Tocilizumab Group|Subject in this group will receive ACTEMRA(R) (Tocilizumab) ,(six injections over 20 weeks) plus standard triple maintenance immunosuppression of Tacrolimus, Mycophenolate Mofetil, corticosteroids
62325237|NCT06033196|PLACEBO_COMPARATOR|Placebo Group|Subject in this group will receive placebo for Tocilizumab (sterile normal saline) plus standard triple maintenance immunosuppression of Tacrolimus, Mycophenolate Mofetil, corticosteroids
62325238|NCT06384157|EXPERIMENTAL|100 mg INDV-2000 QD dosed by two 50 mg extended-release tablets|
62325239|NCT06384157|EXPERIMENTAL|200 mg INDV-2000 QD dosed by two 100 mg extended-release tablets|
62325240|NCT06384157|EXPERIMENTAL|400 mg INDV-2000 QD dosed by two 200 mg extended-release tablets|
62325241|NCT06384157|PLACEBO_COMPARATOR|Placebo dose|
62325242|NCT06493851|ACTIVE_COMPARATOR|hyperbaric oxygen therapy (HBOT) active treatment|The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.
62325243|NCT06493851|SHAM_COMPARATOR|hyperbaric oxygen therapy (HBOT) Sham treatment|The sham HBOT protocol consists of 6 weeks protocol including 5 daily sham HBOT sessions per week (total of 30), each session includes breathing 21% oxygen by mask in a sham multiplace chamber. Sham pressure will go up to 1.2 ATA during the first five minutes of the session (to stimulate the pressure sensation in the ears), and then decrease during the next 5 minutes to 1.03 ATA for 90 minutes with 5-minute air breaks every 20 minutes.
62325244|NCT05800574|EXPERIMENTAL|Cohort A (>N1 or single node > 3cm )|More extensive neck involvement or proximity to the midline can qualify a patient in cohort A. Cohort A will have patients with either more than one lymph node adenopathy or 1 lymph node that is large (\>3cm).
62325245|NCT05800574|EXPERIMENTAL|Cohort B (N0 or N1 <3cm)|For Cohort B patients need to have either no lymph nodes or only one lymph node adenopathy, provided it is smaller than 3cm.
62325246|NCT03850574|EXPERIMENTAL|Part A Dose Escalation [COMPLETED]|Part A dose escalation of tuspetinib as a single agent is planned for up to 6 dose levels. If a study participant in dose escalation at any dose level achieves clinical response, then the dose level will continue to enroll in Part B. If one DLT or less is observed in the 6 participants (\<1/6 DLT observed) in Part A, up to 20 evaluable participants can be enrolled in Part B at that dose level.
62325247|NCT03850574|EXPERIMENTAL|Part B Dose Exploration [ACTIVE, NOT RECRUITING]|Part B dose exploration of tuspetinib as a single agent is planned for up to 4 dose levels.
62325248|NCT03850574|EXPERIMENTAL|Part C Dose Expansion (tuspetinib as a single agent) [COMPLETE]|Part C dose expansion of tuspetinib as a single agent is planned for 2 dose levels. Study participants will be randomly assigned to either arm based on the number of slots available. The initial tuspetinib dose will be 120 mg.
62325249|NCT03850574|EXPERIMENTAL|Part C Dose Expansion (tuspetinib plus venetoclax) [COMPLETE]|Part C dose expansion of tuspetinib in combination with venetoclax is planned for 2 dose levels. The initial tuspetinib dose will be 80 mg.
62325250|NCT03850574|EXPERIMENTAL|Part D Dose Exploration (tuspetinib plus venetoclax and azacitidine) [ACTIVE, RECRUITING - US Sites]|Part D dose exploration of tuspetinib in combination with venetoclax and azacitidine is planned for up to 6 dose levels. The initial tuspetinib dose will be 40 mg.
62325251|NCT04913870|EXPERIMENTAL|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers will be given orally once a day for 2 years.
62325252|NCT04913870|PLACEBO_COMPARATOR|Placebo|Participants will receive a matched placebo orally once a day for 2 years.
61932291|NCT03805646|NO_INTERVENTION|No Mobile Phone-administered Triage Tool|"For each hospital site: Baseline data will be collected for six months.~\*\*This extended beyond 6 months due to the COVID pandemic\*\*\*"
62325253|NCT06276465|ACTIVE_COMPARATOR|ADT + darolutamide|Up to 5 years of treatment
62325254|NCT06276465|EXPERIMENTAL|ADT + darolutamide + SBRT|Up to 5 years of treatment
62325255|NCT04691323|OTHER|HU-Go app intervention arm|Participants will use the HU-Go app intervention arm for 12 months.
62325256|NCT06260228|OTHER|PD Participant with Cognitive Dysfunction|"Participants will receive the HOBSCOTCH-PD intervention consisting of 1:1 sessions delivered once per week including:~* 1 pre-HOBSCOTCH Session (on webcam or by phone)~* 1 educational session (on webcam)~* 6 HOBSCOTCH intervention sessions (webcam or phone)~* 1 wrap-up session (webcam or phone)"
62692188|NCT05639725|EXPERIMENTAL|EXTRACTION OF MAXILLARY IST PREMOLARS|Experimental: EXTRACTION treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
62692189|NCT05639725|EXPERIMENTAL|DISTALIZATION|Experimental: DISTALIZATION treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
61932292|NCT03805646|EXPERIMENTAL|Mobile Phone-administered Triage Tool|"For each hospital site: After the first six months of baseline data collection, the mobile phone-administered triage tool (or Mobile Phone-based Triage Tool) will be implemented for a year.~\*\*This extended beyond 1 year due to the COVID pandemic\*\*\*"
61932293|NCT00812747||1|
61932294|NCT04629547|EXPERIMENTAL|Poor sleep treatment group|100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
61932295|NCT04629547|PLACEBO_COMPARATOR|Poor sleep control grop|100 participants will be randomized to take placebo daily at h.s. for two years.
61932296|NCT01954732|NO_INTERVENTION|Group I (observation)|Patients undergo observation.
61932297|NCT01954732|EXPERIMENTAL|Group II (metformin hydrochloride)|Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity.
61932298|NCT01954732|EXPERIMENTAL|Group III (metformin hydrochloride)|Patients receive metformin hydrochloride as in Group II.
61932299|NCT05385185|EXPERIMENTAL|Leptomeningeal metastases received PD-1 inhibitor and recombinant human endostatin|Camrelizumab 200mg intravenously, once every 21 days or envafolimab 150mg subcutaneous injection,once a week Endostatin 30mg/d was administered intravenously for 7 days (d1-d7). The interval between Endostatin and next was 2 weeks.
61932300|NCT06710431|PLACEBO_COMPARATOR|AFA-281 placebo control|AFA-281 placebo control group
61932301|NCT06710431|ACTIVE_COMPARATOR|Low dose of AFA-281|AFA-281 at 60 mg per day
61932302|NCT06710431|ACTIVE_COMPARATOR|High dose AFA-281|AFA-281 at 120 mg per day
61932303|NCT05794230|EXPERIMENTAL|Groups 1a, 1b and 1c Cohort Ia (India)|2 injections of MenACYW conjugate vaccine: at 6 months of age and second dose at 12 months of age (group 1a) or at 15 months of age (group 1b) or at 16 months of age (group 1c) + co-administered routine pediatric vaccines
61932304|NCT05794230|ACTIVE_COMPARATOR|Group 2 Cohort Ia (India)|2 injections of Menactra vaccine: at 9 months of age and second dose at 16 months of age + co-administered routine pediatric vaccines
61932305|NCT05794230|EXPERIMENTAL|Groups 3 Cohort Ib (RSA)|2 injections of MenACYW conjugate vaccine: at 6 months of age and second dose between 12 and 16 months of age + co-administered routine pediatric vaccines
61932306|NCT05794230|ACTIVE_COMPARATOR|Group 4 Cohort Ib (RSA)|2 injections of Menactra vaccine: at 9 months of age and second dose between 12 and 16 months of age + co-administered routine pediatric vaccines
61932307|NCT05794230|EXPERIMENTAL|Groups 5a and 5b Cohort IIa (India)|3 injections of MenACYW conjugate vaccine: at 6-8 weeks of age and second dose at 14-16 weeks of age with a booster dose administered at 12 months of age (group 5a) or at 15 months of age (group 5b) + co-administered routine pediatric vaccines
61932308|NCT05794230|OTHER|Group 6 Cohort IIa (India)|routine pediatric vaccines only
61932309|NCT05794230|EXPERIMENTAL|Group 7 Cohort IIb (RSA)|3 injections of MenACYW conjugate vaccine: at 6-8 weeks of age and second dose at 14-16 weeks of age with a booster dose administered between 12 and 15 months of age + co-administered routine pediatric vaccines
61932310|NCT05794230|OTHER|Group 8 Cohort IIb (RSA)|routine pediatric vaccines only
61932311|NCT01721070|EXPERIMENTAL|SUF NT 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.
61932312|NCT01721070|EXPERIMENTAL|Ketoconazole 400 mg, SUF NT 15 mcg|"Ketoconazole 400 mg administered once daily for three days. One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.~Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
61932313|NCT01539798|EXPERIMENTAL|Oral Saline|Ingestion of 0.9% saline solution
61932314|NCT01539798|ACTIVE_COMPARATOR|Intravenous Saline|Intravenous infusion of 0.9% saline solution
61932315|NCT06311188|EXPERIMENTAL|ITR Healing Intervention|This is a single arm nonrandomized test of the culturally adapted ITR healing intervention.
62132912|NCT05447936|ACTIVE_COMPARATOR|Male arm|Ten healthy active male XCS past the age of 18 years were included. The duration of the study was 12 weeks divided in three dose-escalation periods of four weeks. In the first 4-week period all the participants was given 47gram Jarlsberg cheese daily. Based on the change in serum Osteocalcin level, the daily intake of Jarlsberg cheese for the next 4-week periode was desided in accordance with the RSP procedure
62132913|NCT00589277|EXPERIMENTAL|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
62484085|NCT00951457|EXPERIMENTAL|Overall study|"Dose escalation phase:~Days -3, -2, -1: 3 - 10 - 30 mg Alemtuzumab s.c.~Treatment phase:~Bendamustine 70 mg/m2 i.v. on d1 + d2 repeat every 28 days for 4 cycles~Alemtuzumab 30 mg s.c. 3x per week (days 1, 3, 5) continuously in parallel with chemotherapy cycles for a maximum of 16 weeks"
62484086|NCT01955200|EXPERIMENTAL|CLOP-150|clopidogrel 150mg once daily
62484087|NCT01955200|EXPERIMENTAL|CLOP+CILOST|clopidogrel 75mg once daily plus cilostazol 100mg twice daily
61932316|NCT04912011|EXPERIMENTAL|Canrenoate potassium|Administration of 200 mg of potassium Canrenoate potassium dissolved in 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
61932317|NCT04912011|PLACEBO_COMPARATOR|Placebo|Administration of 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
61932318|NCT04680676|EXPERIMENTAL|BI 730357 - low dose|
61932319|NCT04680676|EXPERIMENTAL|BI 730357 - medium dose|
61932320|NCT04680676|EXPERIMENTAL|BI 730357 - high dose|
61932321|NCT04680676|PLACEBO_COMPARATOR|Placebo|
61932322|NCT06708858|EXPERIMENTAL|GC+IO+Surufatinib|Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab
61932323|NCT03756480||Case Group|"Clinical or surgical diagnosis of Endometriosis, patients undergoing surgical management~100 participants"
61932324|NCT03756480||Control Group|"No diagnosis of Endometriosis, Patients undergoing Laparoscopic Tubal Ligation~35 participants"
61932325|NCT03861611|EXPERIMENTAL|Ketorolac + Educational Intervention|Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
61932326|NCT03861611|EXPERIMENTAL|Ibuprofen + Educational Intervention|Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
62484088|NCT01955200|EXPERIMENTAL|TICAG|ticagrelor 90mg twice daily
62484089|NCT01955200|ACTIVE_COMPARATOR|CON(conventional DAPT)|clopidogrel 75mg once daily
62484090|NCT01955200|ACTIVE_COMPARATOR|Non-HOPR|clopidogrel 75mg once daily
62484091|NCT02380794|ACTIVE_COMPARATOR|Danshen Gegen Capsule|3 capsules (500 mg per capsule) twice daily for 24 weeks
62132914|NCT00589277|PLACEBO_COMPARATOR|Standard care counseling + standard materials|Standard care counseling + standard care print information
62325257|NCT06561321|EXPERIMENTAL|Tapinarof Drug Treatment|Subjects in this arm will apply Tapinarof 1% cream topically once daily for a 16-week open-label treatment period. Participants who achieve disease clearance after 16 weeks may discontinue treatment and will be monitored for sustained response up to 52 weeks. Those who do not achieve clearance will continue the treatment during an extension period for up to 36 additional weeks or until clearance is achieved, whichever comes first. Regular follow-up visits will assess the duration of disease clearance and monitor for any potential recurrence of keratoderma.
62325258|NCT05629936|OTHER|Digital intervention|Digital intervention
62325259|NCT00453505|EXPERIMENTAL|1|Healthy Volunteers
62325260|NCT00453505|SHAM_COMPARATOR|1a|Healthy Volunteers
62325261|NCT00453505|EXPERIMENTAL|2|Healthy Volunteers
62484092|NCT02380794|PLACEBO_COMPARATOR|Placebo|3 capsules (500 mg per capsule) twice daily for 24 weeks
62484093|NCT05859984|EXPERIMENTAL|Low dose group|1 bottle of recombinant human interferon ω spray and 1 bottle of placebo（recombinant human interferon ω spray mimics）+base drugs（Xiao'er Changui Tuire granules and Xiao'er Feire Kechuan granules). Each bottle of medication is sprayed once, twice a day. After using the medication, no food or water can be consumed for 20 minutes. Follow the doctor's instructions for use of the base drugs. This treatment course can last up to 7 days.
62484094|NCT05859984|EXPERIMENTAL|High dose group|2 bottle of recombinant human interferon ω spray +base drugs（Xiao'er Changui Tuire granules and Xiao'er Feire Kechuan granules). Each bottle of medication is sprayed once, twice a day. After using the medication, no food or water can be consumed for 20 minutes. Follow the doctor's instructions for use of the base drugs. This treatment course can last up to 7 days.
62484095|NCT05859984|PLACEBO_COMPARATOR|Placebo group|2 bottle of placebo（recombinant human interferon ω spray mimics）+base drugs（Xiao'er Changui Tuire granules and Xiao'er Feire Kechuan granules). Each bottle of medication is sprayed once, twice a day. After using the medication, no food or water can be consumed for 20 minutes. Follow the doctor's instructions for use of the base drugs. This treatment course can last up to 7 days.
62484096|NCT05973513||Immediate Enrollment|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
62484097|NCT04538677||F2F-Group|Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic.
62484098|NCT04538677||VC-group|Patients who preferred a video consult were seen over a video connection.
62484099|NCT02197741||opiate without bolus|continuous opiate administration without bolus application
62484100|NCT02197741||opiate with bolus|continuous opiate administration with additional bolus application
62484101|NCT02047305|EXPERIMENTAL|Radiofrequency ablation|To study the safety and effectiveness of radiofrequency ablation (RFA) using the HALO ablation system in completely eradicating the diseased epithelium in patients with ESCN
62484102|NCT05329922|EXPERIMENTAL|ALICE (experienced hearing aid/cochlear implant users)|Clients participating in this arm are asked to train their listening and communication skills using the ALICE app on their personal smart device for 8 weeks.
62484103|NCT05329922|NO_INTERVENTION|Control (experienced hearing aid/cochlear implant users)|This arm will receive the standard of care given to the client. Persons with a moderate to profound hearing loss are provided with a hearing aid. Persons with a profound to severe HI are provided with a cochlear implant and concomitant rehabilitation. Most persons with a cochlear implant receive intensive rehabilitation during the first 6 months after their implantation. Afterwards, they mainly return for mapping of the device but not for listening training therapy.
62484104|NCT05329922|EXPERIMENTAL|ALICE (new hearing aid users)|Clients participating in this arm are asked to train their listening and communication skills using the ALICE app on their personal smart device during the hearing aid trial period (4-6 weeks on average).
62484105|NCT05329922|NO_INTERVENTION|Control (new hearing aid users)|This arm will receive the standard of care given to the client during the hearing aid trial period.
62484106|NCT00838188||1|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
62484107|NCT00838188||2|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
62484108|NCT00838188||Breast - feeding first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
62484109|NCT00838188||Bottle first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
62484110|NCT00838188||Way of feeding|Each infant is evaluated twice, once after breastfeeding and once after bottle feeding of breast milk using a Premature Nipple \& Ring (Ross Products Division, Columbus OH, USA). In this way, each infant serves as its own control. REE is recorded for 20 minutes after each meal
62132915|NCT01130194|EXPERIMENTAL|Experimental|C-MOPP-R chemotherapy, 6 cycles Peripheral blood stem cell mobilization Radioimmunotherapy Autologous Hematopoietic Stem Cell Transplantation
62132916|NCT06321224|EXPERIMENTAL|Exercise group|The exercise group will be given breathing exercises
62132917|NCT06321224|OTHER|Control group|The control group will be asked to continue their routine lives.
62132918|NCT00476385|EXPERIMENTAL|somatropine|
62132919|NCT03563690|EXPERIMENTAL|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
62325262|NCT00453505|SHAM_COMPARATOR|2a|Healthy Volunteers
62325263|NCT00453505|EXPERIMENTAL|3|Healthy Volunteers
62325264|NCT00453505|SHAM_COMPARATOR|3a|Healthy Volunteers
62325265|NCT00453505|EXPERIMENTAL|4|Healthy Volunteers
62325266|NCT00453505|SHAM_COMPARATOR|4a|Healthy Volunteers
62325267|NCT06176300|EXPERIMENTAL|Community A|
62325268|NCT06176300|EXPERIMENTAL|Community B|
62325269|NCT06176300|NO_INTERVENTION|Community C|
61932327|NCT03861611|EXPERIMENTAL|Diclofenac + Educational Intervention|Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
61932328|NCT04949685||symptomatic plantar plate rupture|plantar plate repair operation for symptomatic lesser metatarsophalangeal joint instability
62692190|NCT03511287|EXPERIMENTAL|IMT group|"Group intervention: home-based interval inspiratory muscle training:~* during 8 weeks (two sessions per day, daily)~* two times 30 breaths with one-minute rest between them in each session~* training resistance set to the highest tolerable load according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher adjusted in the supervised weekly session"
61932329|NCT01994928|ACTIVE_COMPARATOR|Nose-mouth mask|Performance of intubation after preoxygenation using a nose-mouth mask.
61932330|NCT01994928|EXPERIMENTAL|High flow nasal cannula oxygen|Performance of intubation after preoxygenation using high flow nasal cannula oxygen.
61932331|NCT06709807|EXPERIMENTAL|Fast-Fed|Period 1: A single oral dose of 1 tablet under fasting condition, Period 2: A single oral dose of 1 tablet under fed condition
61932332|NCT06709807|EXPERIMENTAL|Fed-Fast|Period 1: A single oral dose of 1 tablet under fed condition, Period 2: A single oral dose of 1 tablet under fasting condition
61932333|NCT05808309||PRp|Patients with a diagnostic of rheumatoid arthritis with an age of onset before 60 years
61932334|NCT05808309||PRt|Patients with a diagnostic of rheumatoid arthritis with an age of onset from 65 years
61932335|NCT05808309||Tem|Patients with a diagnostic of osteoarthritis without RA
61932336|NCT05808309||Ap|Relatives to PRt, with RA (with any age of onset) or without RA
61932337|NCT06534125|EXPERIMENTAL|Arm I (acupuncture, AI therapy)|Patients undergo acupuncture therapy in-person over 1 hour twice weekly for the first 6 weeks and then once weekly for 6 weeks and receive standard of care (SOC) aromatase inhibitor (AI) therapy.
61932338|NCT06534125|EXPERIMENTAL|Arm II (acupressure, AI therapy)|Patients undergo self-administered acupressure therapy virtually over 1 hour twice weekly for the first 6 weeks and then once weekly for 6 weeks and receive SOC AI therapy.
61932339|NCT06534125|ACTIVE_COMPARATOR|Arm III (AI therapy)|Patients receive SOC AI therapy.
61932340|NCT06255834|EXPERIMENTAL|Cohort 1 (SAD - 0.5 mg)|4 subjects in this cohort will receive a single dose of IPG11406 0.5 mg qd and 2 subjects will receive a single dose of placebo 0.5 mg qd orally.
61932341|NCT06255834|EXPERIMENTAL|Cohort 2 (SAD - 2 mg)|4 subjects in this cohort will receive a single dose of IPG11406 2 mg qd and 2 subjects will receive a single dose of placebo 2 mg qd orally.
61932342|NCT06255834|EXPERIMENTAL|Cohort 3 (SAD - 6 mg)|4 subjects in this cohort will receive a single dose of IPG11406 6 mg qd and 2 subjects will receive a single dose of placebo 6 mg qd orally.
61932343|NCT06255834|EXPERIMENTAL|Cohort 4 (SAD - 20 mg)|6 subjects in this cohort will receive a single dose of IPG11406 20 mg qd and 2 subjects will receive a single dose of placebo 20 mg qd orally.
61932344|NCT06255834|EXPERIMENTAL|Cohort 5 (SAD - 40 mg)|6 subjects in this cohort will receive a single dose of IPG11406 40 mg qd and 2 subjects will receive a single dose of placebo 40 mg qd orally.
61932345|NCT06255834|EXPERIMENTAL|Cohort 6 (SAD - 80 mg)|6 subjects in this cohort will receive a single dose of IPG11406 80 mg qd and 2 subjects will receive a single dose of placebo 80 mg qd orally.
61932346|NCT06255834|EXPERIMENTAL|Cohort 7 (MAD - 10 mg)|6 subjects in this cohort will receive a dose of IPG11406 10 mg qd and 2 subjects will receive a dose of placebo 10 mg qd orally from Day 1 to 10-day.
61932347|NCT06255834|EXPERIMENTAL|Cohort 8 (MAD - 20 mg)|6 subjects in this cohort will receive a dose of IPG11406 20 mg qd and 2 subjects will receive a dose of placebo 20 mg qd orally from Day 1 to 10-day.
62325270|NCT06047080|EXPERIMENTAL|Glofitamab + Pola-R-CHP|Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP).
61932348|NCT06255834|EXPERIMENTAL|Cohort 9 (MAD - 40 mg)|6 subjects in this cohort will receive a dose of IPG11406 40 mg qd and 2 subjects will receive a dose of placebo 40 mg qd orally from Day 1 to 10-day.
61932349|NCT04893096|EXPERIMENTAL|MOR202 (felzartamab) infusion|Participants will receive active treatment for a total of nine doses during 24 weeks.
61932350|NCT05578690|EXPERIMENTAL|Lifestyle group|A tailored multifactorial lifestyle intervention consisting of diet, exercise and mentorship in women with overweight or obesity to obtain a healthy lifestyle before and during pregnancy.
61932351|NCT05578690|NO_INTERVENTION|Standard of care group|The standard of care group will receive no active intervention but are encouraged to seek any possible guidance from the general practitioner for management of pre-pregnancy obesity according to current guidelines.
61932352|NCT01553032|ACTIVE_COMPARATOR|Erbitux®|
61932353|NCT01553032|ACTIVE_COMPARATOR|Fractionated Radiotherapy|
61932354|NCT00856648||Group 1|SCI
61932355|NCT00856648||Group 2|Able-bodied
62325271|NCT06047080|ACTIVE_COMPARATOR|Pola-R-CHP|Participants will receive Pola-R-CHP.
62692191|NCT06281769|OTHER|Diagnostic evaluation of prostate cancer|
61932356|NCT03381183|EXPERIMENTAL|Phase 1 - Dose Escalation|Six patients will be enrolled at Dose Level 1 with IRX-2 230 units/day in combination with cyclophosphamide and durvalumab and treated sequentially at least 1 week apart. If less than 2 out of 6 patients have DLTs in Dose Level 1, the dose will be escalated to administration of IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab as Dose Level 2. If 2 of 6 patients have DLTs, stop accrual and re-evaluate. In the next safety phase, six patients at IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab will be enrolled and treated sequentially (at least 1 week apart). If DLT occurs in less than 2 of 6 patients during the first 6 weeks of treatment, enrollment can continue in the dose expansion phase at Dose Level 2. If DLT is observed in 2 of 6 patients, accrual will be stopped and Dose Level 1 will resume in the dose expansion phase.
62325272|NCT06470048|EXPERIMENTAL|VAY736 (Ianalumab)|"Treatment Period 1:~Ianalumab subcutaneous (s.c.) injection as defined in the protocol~Treatment Period 2:~Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol"
62484111|NCT04618900|EXPERIMENTAL|Osteotome-mediated sinus floor elevation with Bio-Oss collagen|Sinus floor elevation with a grafting material (Bio-Oss collagen)
62132920|NCT03563690|EXPERIMENTAL|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
62325273|NCT06470048|PLACEBO_COMPARATOR|Placebo|"Treatment Period 1:~Placebo to Ianalumab subcutaneous (s.c.) injection as defined in the protocol~Treatment Period 2:~Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol"
62484112|NCT04618900|PLACEBO_COMPARATOR|Osteotome-mediated sinus floor elevation with no grafting material|Sinus floor elevation with no grafting material
62484113|NCT03935815|ACTIVE_COMPARATOR|Intervention|"Standard of care pain management plus quadratus lumborum nerve block.~Ropivicaine 0.25% 60 mL will be injected in the fascial plane between the quadratus lumborum muscle and transverses abdominus muscle."
62484114|NCT03935815|SHAM_COMPARATOR|Control|Standard of care pain management plus a sham procedure.
62325274|NCT04686305|EXPERIMENTAL|Arm 1A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
62325275|NCT04686305|EXPERIMENTAL|Arm 1B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
62325276|NCT04686305|EXPERIMENTAL|Arm 1C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed (Arm not initiated)
62325277|NCT04686305|EXPERIMENTAL|Arm 1D: T-DXd|T-DXd
62484115|NCT03259139|EXPERIMENTAL|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
62484116|NCT03259139|EXPERIMENTAL|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
62484117|NCT03259139|OTHER|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
62697540|NCT03483701|EXPERIMENTAL|Cognitive Remediation Therapy|Participants in the experimental group will continue to receive IPS services, which is part of their standard care. In addition, they will be required to complete up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer, on their own schedule. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
62132921|NCT03563690|EXPERIMENTAL|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
62325278|NCT04686305|EXPERIMENTAL|Arm 3A: T-DXd and Volrustomig|Drug: T-DXd and Volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig
62325279|NCT04686305|EXPERIMENTAL|Arm 3B: T-DXd, Volrustomig and Carboplatin|Drug: T-DXd, Volrustomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig Drug: Carboplatin Carboplatin: administered as an IV infusion
62325280|NCT04686305|EXPERIMENTAL|Arm 4A: T-DXd and Rilvegostomig|T-DXd and Rilvegostomig Drug: T-DXd, Rilvegostomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936
62325281|NCT04686305|EXPERIMENTAL|Arm 4B T-DXd and Rilvegostomig with Carboplatin|Drug: T-DXd, Rilvegostomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936 Drug: Carboplatin Carboplatin: administered as an IV infusion
62325282|NCT06266416|EXPERIMENTAL|Experimental (IMAGE) Group|The IMAGE group will receive an 8-10-hour HIV/STI group-based (6-8 dyads) prevention program delivered to Black male caregivers and girls over 2-days.
62325283|NCT06266416|ACTIVE_COMPARATOR|Control (FUEL) Group|The FUEL group will receive a caregiver-adolescent general health promotion program identical in length and intensity to IMAGE.
62325284|NCT05292404|EXPERIMENTAL|Early PCSK9 inhibitor treatment group|
62325285|NCT05292404|OTHER|conventional treatment group|
62484118|NCT01203891||Healthy brain subjects|The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
62484119|NCT05615909||Online MR-guided radiotherapy|Prostate cancer patients treated with online MR-guided radiotherapy in the Unity MR-linac.
62484120|NCT05615909||CT-guided radiotherapy|Prostate cancer patients treated with CT-guided radiotherapy (VMAT) in linear accerelators.
62484121|NCT06501222|EXPERIMENTAL|RIC group|The RIC protocol involves five cycles of alternating inflation of both upper arms, utilizing an automated device to alternately inflate to 200 mmHg for 5 minutes and deflate for 5 minutes.
62484122|NCT06501222|SHAM_COMPARATOR|sham-RIC group|The sham-RIC protocol involves five cycles of alternating inflation of both upper arms, utilizing an automated device to alternately inflate to 60 mmHg for 5 minutes and deflate for 5 minutes.
62484123|NCT06627673|EXPERIMENTAL|Treatment arm utilizing primary TKA with PEEK femoral component|This study is a single arm, multi-center, prospective IDE trial. Two hundred (200) patients recruited and consented will receive the PEEK-OPTIMA™ Femoral Component and results will be compared to matched historic controls from the Maxx Orthopedics Freedom Total Knee System product registry (PK-00002 REV-01, WCG IRB# 20241890). Male and female patients 18 years of age or older with Knee Society Score (KSS) of \>25 and \<75 will be eligible for enrollment.
62484124|NCT01198964||Epileptic Patients|The population of patients with medically refractory epilepsy will already have been recommended clinically for electrode grid placement on the brain and high-level stimulation to map brain function.
62484125|NCT04702685|EXPERIMENTAL|Ropivacaine|Ropivacaine 0.5% - 20 ml will be administered as erector spinae plane block under ultrasound guidance
62484126|NCT04702685|PLACEBO_COMPARATOR|Placebo|No injection. Bandage will be placed over the presumed site of injection
62325286|NCT04231760|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease|Mild \& Moderate COPD to receive either placebo or inhaled nitric oxide (40ppm)
62325287|NCT04231760|ACTIVE_COMPARATOR|Healthy Controls|Control group to receive either placebo or inhaled nitric oxide (40ppm)
62325288|NCT05947058|EXPERIMENTAL|Arthroplasty|A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. We recommend surgeons consider a total hip arthroplasty for younger active, independent participants; conversely, a hemiarthroplasty is recommended for more frail, lower-demand participants. Similarly, cemented arthroplasty for older adult participants is also recommended. The surgical approach and the use of post-operative hip precautions will be determined by the treating surgeon.
62484127|NCT02441686|EXPERIMENTAL|Lenalidomide, subcutaneous Bortezomib, Dexamethasone|"Lenalidomide (R): 25 mg on days 1-14 orally Subcutaneous Bortezomib (sqV): 1.3 mg/m\^2 on days 1, 4, 8 and 11 Dexamethasone (d): 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 Stem cell mobilization occurs at the end of Cycle 4. Participants may elect to stop treatment at the end of Induction Cycle 4 and proceed to autologous stem cell transplant (ASCT) with melphalan 200 mg/m\^2 conditioning, or receive a full 8 cycles of RsqVd induction therapy. RsqVd cycle duration is 21-days.~Maintenance follows with the specific regimen determined by risk category. High-risk participants defined as those with International Staging System (ISS) stage II or stage III disease and/or high-risk cytogenetics including t(4;14), t(4; 16), del(17p) receive sqV of 1.3 mg/m\^2 on days 1 and 15 in addition to R 10mg (15mg after cycle 3 if tolerated) on days 1-21 of 28-day cycle. Standard-risk participants receive R monotherapy."
62692192|NCT04759404|ACTIVE_COMPARATOR|Deep Oscillation Group|Individuals in the deep oscillation group will be treated by the researcher. During the application, individuals will be positioned face down on the stretcher. After the powder is applied to the lumbar region, deep oscillation treatment with a frequency of 80% -100% with a frequency of 145-150 Hz for the first 10 minutes and 55-60 Hz for 5 minutes will be applied with the Physiomed Deep Oscilation device. Each individual will be given a home exercise program (stretching and strengthening for waist, back and abdominal) consisting of stretching and strengthening. Individuals will be asked to come to the center where the research will take place, for a total of six sessions for two weeks, three times a week.
62692193|NCT04759404|ACTIVE_COMPARATOR|Myofascial Release Group|Individuals in the myofascial relaxation group will be treated by the researcher. During the application, individuals will lie face down on the stretcher. Myofascial release therapy will be applied in the lumbar region and each individual will be given home exercise (stretching and strengthening for waist, back and abdominal). Individuals will be asked to come to the center where the research will be conducted for a total of six sessions for two weeks, three times a week.
61932357|NCT03381183|EXPERIMENTAL|Phase 2 - Dose Expansion|14 patients will be enrolled at the recommended dose level from the dose finding phase for a total enrollment of 20 patients; however, investigators will replace patients with any missing tumor sample collection and continue enrollment until there are at least 20 pre- and post-treatment paired tumors (i.e. minimum 2 of 3 tumors per patient). The 6 patients treated at the recommended dose in the dose finding phase of the study will be counted as a part of the dose expansion patient population,
61932358|NCT05568472|EXPERIMENTAL|ARM I (ET, health education, symptom assessment)|Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients are asked 6 brief questions about symptoms weekly by email, text, or phone call for the first 6 months, then every 4 weeks for 12 months. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at baseline, 3, 12, and 18 months.
61932359|NCT05568472|ACTIVE_COMPARATOR|ARM II (ET, health education)|Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at 3, 12, and 18 months.
61932360|NCT06709963|SHAM_COMPARATOR|Sham|
61932361|NCT06709963|EXPERIMENTAL|Left DLPFC|
61932362|NCT03307057|EXPERIMENTAL|Social Communication Growth Charts (SCGC) in Stage 1 Plus SCGC in Stage 2|"This arm includes infant participants who did not show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD, were randomized to receive the Social Communication Growth Charts (SCGC) intervention for 6 months.~In stage 2, infants at 12 months of age who are not showing early signs of ASD were re-randomized to receive the Social Communication Growth Charts (SCGC) intervention from 12 to 21 months of age."
61932363|NCT03307057|EXPERIMENTAL|Social Communication Growth Charts (SCGC) in Stage 1 Plus Usual Care in Stage 2|"This arm includes participants who did not show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD were randomized to receive the Social Communication Growth Charts (SCGC) intervention for 6 months.~In stage 2, infants at 12 months of age who are not showing early signs of ASD were re-randomized to receive usual care from 12 to 21 months of age."
61932364|NCT03307057|EXPERIMENTAL|SCGC in Stage 1 Plus Parent-Implemented (P-I) Condition in Stage 2|"This arm includes infant participants who show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD, were randomized to receive the Social Communication Growth Charts (SCGC) intervention for 6 months.~In stage 2, infants at 12 months of age showing early signs of ASD were randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) from 12 to 21 months of age."
61932365|NCT03307057|EXPERIMENTAL|SCGC in Stage 1 Plus Clinician-Implemented (C-I) Condition in Stage 2|"This arm includes infant participants who show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD, were randomized to receive the Social Communication Growth Charts (SCGC) intervention for 6 months.~In stage 2, infants at 12 months of age showing early signs of ASD were randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model from 12 to 21 months of age."
62132922|NCT03563690|EXPERIMENTAL|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
62325289|NCT05947058|ACTIVE_COMPARATOR|Internal Fixation|Based on the fracture displacement eligibility criteria, minimal or no reduction is expected during the surgical procedure. However, the treating surgeon will be allowed to perform fracture reduction maneuvers if desired. Fixed angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. If using multiple cancellous screws, an inverted triangle or similar screw pattern is recommended. Fixed angle devices, such as a sliding hip screw (with or without an anti-rotation screw) or newer multi-screw fixed angle devices will also be permitted. Internal fixation constructs combining cancellous screws and fixed angle devices will be permitted.
62325290|NCT05147636|EXPERIMENTAL|PEEP Extubation With Positive End-Expiratory Pressure|endo-tracheal aspiration followed by the application of PEEP = 10 cm of H2O, maintained for 3 minutes (reventilation and rest time) and continued until the end of the procedure removal of the extubation
62484128|NCT04336605||Young-HUNT|The young-HUNT study is a renowned, representative, population-based study where all adolescents living in the Nord-Trøndelag county have been invited to participate in four subsequent waves, from 1995 to 2019. Information about the study can be found here: https://www.ntnu.edu/hunt/young-hunt. In this study data from the Young-HUNT1-4 studies (1995-2019) will be linked to longitudinal, individual data from the Norwegian prescription Database (NorPD) (2004-2020), providing a unique, longitudinal dataset in which research questions will be explored. To obtain good, reliable follow-up data and outcome measures for the young-HUNT3 participants (2006-2008) the investigators will additionally include longitudinal data from the HUNT4 study of young adults (2017-2019); applicable for those participating in both the YoungHUNT3 and the YoungHUNT4.
62484129|NCT01857947|NO_INTERVENTION|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
62484130|NCT05911711||Sepsis patient in Medical ICU|"Eligibility Criteria:~adults over the age of 19 a sepsis patient in Medical ICU~Patients are excluded from the study :~If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a Do not resuscitation (DNR) patient"
62484131|NCT03072030|EXPERIMENTAL|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
62484132|NCT03072030|PLACEBO_COMPARATOR|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
62484133|NCT05452707||Patients|"Patients will be observed during their active training sessions.~Patients will be asked questions about:~* fatigue~* physical fatigue~* pain~* the difficulty of the session~* motivation"
62484134|NCT05452707||Therapists|"Therapists will be asked questions about the observed training sessions of the patients. The questions will be about:~* Estimation of active training time~* Estimation of patient's fatigue~* Estimation of the patient's perceived difficulty of the session~* Estimation of the patient's perceived physical fatigue of the session~* Estimation of the patient's perceived motivation for the session"
61932366|NCT03307057|EXPERIMENTAL|Usual Care in Stage 1 Plus SCGC in Stage 2|"This arm includes infant participants who did not show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD, were randomized to receive usual care for 6 months.~In stage 2, infants at 12 months of age who are not showing early signs of ASD were re-randomized to receive the Social Communication Growth Charts (SCGC) intervention from 12 to 21 months of age."
61932367|NCT03307057|ACTIVE_COMPARATOR|Usual Care in Stage 1 Plus Usual Care in Stage 2|"This arm includes infant participants who did not show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD, were randomized to receive usual care for 6 months.~In stage 2, infants at 12 months of age who are not showing early signs of ASD were re-randomized to receive usual care from 12 to 21 months of age."
61932368|NCT03307057|EXPERIMENTAL|Usual Care in Stage 1 Plus Parent-Implemented (P-I) Condition in Stage 2|"This arm includes infant participants who show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD, were randomized to receive usual care for 6 months.~In stage 2, infants at 12 months of age showing early signs of ASD were randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) from 12 to 21 months of age."
61932369|NCT03307057|EXPERIMENTAL|Usual Care in Stage 1 Plus Clinician-Implemented (C-I) Condition in Stage 2|"This arm includes infant participants who show early signs of ASD at 12 months of age, following stage 1.~In stage 1, infants at 6 months of age with a sibling who is diagnosed with ASD, were randomized to receive usual care for 6 months.~In stage 2, infants at 12 months of age showing early signs of ASD were randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model from 12 to 21 months of age."
61932370|NCT06709235||AML patients treated with intensive chemotherapy|Patients diagnosed with acute myeloid leukemia treated in our center with 3+7 based induction chemotherapy regimen
61932371|NCT06708650|EXPERIMENTAL|Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma|Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
62132923|NCT03563690|SHAM_COMPARATOR|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
62325291|NCT05147636|ACTIVE_COMPARATOR|Aspiration Extubation With SUctioning|endo-tracheal aspiration concomitant with removal of extubation. Suction is maintained throughout the intubation tube ablation procedure
62325292|NCT06294925||Patients receiving etrasimod for ulcerative colitis|
62484135|NCT02286479|ACTIVE_COMPARATOR|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
62484136|NCT02286479|EXPERIMENTAL|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
62484137|NCT01133535||Pancreatitis, acute, recurrent|Patients with acute recurrent pancreatitis where the cause is unknown
61932372|NCT04559919||Adults with epilepsy|"Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in VGR at the time of inclusion. Languages available: Swedish, English, Arabic.~Based on the clinical information, patients can be categorized into relevant groups; single seizure, seizure-free with epilepsy, and drug-resistant epilepsy. Subgroups may also be selected based on age, sex, epilepsy sub-diagnosis, cause of epilepsy, use of a particular antiepileptic drug, or experience of a particular side effect."
62325293|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
62325294|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
62325295|NCT03640858|EXPERIMENTAL|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
62325296|NCT05780983|OTHER|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
62325297|NCT06246799|EXPERIMENTAL|Group IC|Tirzepatide starting at 2.5mg weekly titrated to 15mg weekly (2.5 month 1, 5mg month 2, 10mg month 3 and 15mg at month 4) with Pioglitazone beginning at 15mg daily and ending at 45mg daily (15mg month 1, 30mg month 2 and 45mg at month 3 onwards).
62325298|NCT06246799|ACTIVE_COMPARATOR|Group II|Metformin starting at 1000mg XR daily and Sitagliptin 100mg daily at week 4, Metformin will be increased to 200mg.
62325299|NCT06246799|ACTIVE_COMPARATOR|Group IA|Tirzepatide will be started at 2.5mg and increased to 15mg by month 4. At month 6, Pioglitazone will be added to the Tirzepatide, 15 mg daily.
62325300|NCT06246799|ACTIVE_COMPARATOR|Group 1B|Pioglitazone will be started at 15mg and increased to 45 mg by month 3. At month 6, tirzepatide 2.5mg will be started and increased weekly as tolerated.
62325301|NCT02262832|OTHER|Leptin study drug|Administration of study drug SQ BID
62325302|NCT05973630|EXPERIMENTAL|Cohort 1|ATA-200 Dose level 1: 1.0E+14 vg/Kg, solution for injection, single IV infusion over 2h
62325303|NCT05973630|EXPERIMENTAL|Cohort 2|ATA-200 Dose level 2: 3.0E+14 vg/Kg, solution for injection, single IV infusion over 2h
62325304|NCT00804154|EXPERIMENTAL|Single Arm|advanced cancer patients with pain
62325305|NCT05941377|EXPERIMENTAL|standard blood pressure lowering (SBPL) group|
62325306|NCT05941377|EXPERIMENTAL|enhanced blood pressure lowering (EBPL) group|
62325307|NCT03639883|EXPERIMENTAL|0.033% versus Vehicle|One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
62325308|NCT03639883|EXPERIMENTAL|0.1% versus Vehicle|One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
62325309|NCT03639883|EXPERIMENTAL|0.3% versus Vehicle|One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
62484138|NCT04935554|ACTIVE_COMPARATOR|Intervention|"Baseline testing with blood samples, blood pressure and 6 minute walking test. After answering a comprehensive screening tool questionnaire and a conversation with a resource person about What is important to you, the study participant will chose one or several of the following interventions: physical activity, nutrition, motivation, health competence, psychosocial."
61932373|NCT04664244|EXPERIMENTAL|All eligible patients|All eligible patients enrolled
62325310|NCT03639883|EXPERIMENTAL|1% versus Vehicle|One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
62325311|NCT04145440|EXPERIMENTAL|Cohort 1 (newly diagnosed or relapsed participants)|Participants with newly diagnosed or relapsed membranous nephropathy received MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occurred weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
62325312|NCT04145440|EXPERIMENTAL|Cohort 2 (refractory participants)|Participants with membranous nephropathy refractory to immunosuppressive treatment received MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occurred weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
62325313|NCT06111027|EXPERIMENTAL|Intervention|Will use the device, single group
62325314|NCT06262477|EXPERIMENTAL|BIIB800|Participants will receive a single dose of BIIB800 via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.
62325315|NCT06262477|EXPERIMENTAL|Actemra|Participants will receive a single dose of Actemra via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.
62325316|NCT06057948|EXPERIMENTAL|Group 1|Participants will receive oral β-glucan (40 mg/kg/day) for 14 days on, and 14 days off, beginning with vaccination #1 and continuing until vaccination #5 (\~20 weeks), then only one 14-day cycle with each of vaccinations #6-#10.
62325317|NCT06057948|EXPERIMENTAL|Group 2|Participants will receive oral β-glucan (40 mg/kg/day) for 14 days on, and 14 days off, beginning with vaccination #1 and continuing until vaccination #7 (\~52 weeks), then only one 14-day cycle with each of vaccinations #8-#10.
62325318|NCT05092386|EXPERIMENTAL|Experimental Group of One Dose|110 Participants (including 20 subjects aged 18\~49 years, 20 subjects aged 6\~17 years , 30 subjects aged2-5 years) will receive one dose of experimental vaccine
62325319|NCT05092386|EXPERIMENTAL|Experimental Group of Two Doses|30 Participants aged 12\~23 months will receive two doses of experimental vaccine on the schedule of month 0,2.
61932374|NCT06517836|EXPERIMENTAL|eROP data|
61932375|NCT05320809|EXPERIMENTAL|3D189|
61932376|NCT06314308|EXPERIMENTAL|Intervention|Task Specific Training Task-Specific Training (TST) which is the repeated, active practice of a motor skill or activity that is meaningful to an individual with the goal of skill acquisition and retention will be provided over 5 sessions after initial an initial assessment by a physical therapist. Cognitive Behavioral Therapy (CBT) with exposure is a psychotherapeutic intervention that focuses on modifying individuals' thoughts and behavior guided through graded exposure will be guided by a psychologist.
62325320|NCT05092386|EXPERIMENTAL|Experimental Group of Three Doses|30 Participants aged 7\~11 months will receive two doses of experimental vaccine on the primary immunization schedule of month 0,2 and one dose of booster immunization during the participants aged 12\~15 months .
61932377|NCT01602380|EXPERIMENTAL|faslodex+placebo|Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
61932378|NCT01602380|ACTIVE_COMPARATOR|arimidex +placebo|Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
61932379|NCT04844775|EXPERIMENTAL|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"0.1mL of DREP-HIV-PT1 will be diluted with saline (Sodium Chloride for Injection, 0.9%) and administered intramuscularly (total volume of 0.5mL) in the LEFT deltoid muscle using a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
61932380|NCT04844775|EXPERIMENTAL|Drep-HIV-PT1 1.0mg and CN54gp140/MPLA-L|"0.5mL of DREP-HIV-PT1 will be administered intramuscularly in the LEFT deltoid muscle using the a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
61932381|NCT04844775|EXPERIMENTAL|DNA HIV PT123 4mg and CN54gp140/MPLA-L|"1ml of DNA-HIV-PT123 will be injected into the LEFT deltoid muscle using a needle and syringe.~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
61932382|NCT06686238|EXPERIMENTAL|Hypoxic-Hyperoxic group|"The EG (Experimental Group) will undergo a single session of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI.~Participants will be asked to sit and breath normally in each exposure.~An attendance checklist will be used to monitor compliance with the intervention"
61932383|NCT06686238|SHAM_COMPARATOR|Sham Hypoxic-Hyperoxic Group|"The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany).~Participants will be asked to sit and breath normally in each exposure.~An attendance checklist will be used to monitor compliance with the placebo intervention."
61932384|NCT05353985|PLACEBO_COMPARATOR|Cohort 1: TAK-062 Placebo + SIGE Gluten-Bar|TAK-062 placebo-matching 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
62325321|NCT05092386|EXPERIMENTAL|Experimental Group of Four Doses|30 Participants aged 3 months will receive three doses of experimental vaccine on the primary immunization schedule of month 0,1,2 and one dose of booster immunization during the participants aged 12\~15 months ; 30 Participants aged 2 months will receive three doses of experimental vaccine on the primary immunization schedule of month 0,2,4 and one dose of booster immunization during the participants aged 12\~15 months
62325322|NCT05092386|ACTIVE_COMPARATOR|Control Group of One Dose With WALVAX PCV13|30 Participants aged 2-5 years will receive one dose of control vaccine (WALVAX PCV13)
62484139|NCT04935554|NO_INTERVENTION|Control|Baseline testing with blood samples, blood pressure, 6 minute walking test and screening tool questionnaire.
62692194|NCT04759404|NO_INTERVENTION|Control Group|
62692195|NCT06637761|EXPERIMENTAL|Group I|"NeoMTA 2~Manipulation and mixing will be done according to manufacturer instructions:~* 1 scoop (0.1gm) of NeoMTA 2 Powder will be dispensed on a glass slab. Then two drops of NeoMTA 2 Gel will be dispensed next to the powder.~* Gradually as much Gel as necessary will be added to the Powder to achieve the desired consistency. The Gel will be incorporated by spatula-ting the Powder/Gel mixture firmly against the glass slab to ensure all of the Powder is thoroughly witted by the Gel."
62692196|NCT06637761|ACTIVE_COMPARATOR|Group II|"White mineral trioxide aggregate~* One spoon of powder and one drop of distilled water are dispensed on a sterile glass slab.~* A metal spatula will be used to gradually mix the liquid and powder together for 30 seconds to ensure full wetting of the powder particles and to obtain a consistency similar to wet sand.~* 3-4 mm of white MTA will be placed over the clot carefully by using an amalgam carrier.~The mix will be placed over the collagen matrix 2mm beneath the clinical cement-enamel junction."
61932385|NCT05353985|EXPERIMENTAL|Cohort 1: TAK-062 Dose 1 + SIGE Gluten-Bar|TAK-062 Dose 1, 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
61932386|NCT05353985|PLACEBO_COMPARATOR|Cohort 2: TAK-062 Placebo + SIGE Gluten-Bar|TAK-062 placebo-matching 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
62325323|NCT05092386|ACTIVE_COMPARATOR|Control Group of Two Doses With WALVAX PCV13|30 Participants aged 12\~23 months will receive two doses of control vaccine(WALVAX PCV13) on the schedule of month 0,2.
62484140|NCT03747276|OTHER|Clinical Trial Kiosk|
62692197|NCT05949892|EXPERIMENTAL|A healthy diet|"This arm will focus on the following:~Eating lots of vegetables and fruit Choosing whole grain foods Eating protein foods Limiting highly and ultra-processed foods Highly processed foods Making water your drink of choice Salt, sodium and potassium Refraining from added sugars"
62692198|NCT05949892|EXPERIMENTAL|Healthy Weight Management|"This arm will focus on the following:~Physical Activity for a Healthy Weight Preventing Weight Gain Choosing an Eating Plan to Prevent Weight Gain Balancing Food and Activity for Healthy Weight"
62692199|NCT05949892|EXPERIMENTAL|Physical Activity|"This arm will focus on the following:~Step 1: Make a commitment Step 2: Take stock of where you are Step 3: Set realistic goals Step 4: Identify resources for information and support Step 5: Continually check in with yourself to monitor your progress. Revisit the goals you set for yourself in Step 3 and evaluate your progress regularly"
62692200|NCT05949892|EXPERIMENTAL|Stress management|"This arm will focus on the following:~Stress relief Relaxation techniques Meditation Mindfulness exercises"
62484141|NCT04155450|EXPERIMENTAL|McKenzie Extension with External Limb Loading Protocol|"Moist Heat Pack for 10 mins~McKenzie Extension Exercise Protocol~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing~Limb loading for basic stabilization progression of the lumbar extensors. Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity"
62325324|NCT05092386|ACTIVE_COMPARATOR|Control Group of Three Doses With WALVAX PCV13|30 Participants aged 7\~11 months will receive two doses of control vaccine(WALVAX PCV13) on the primary immunization schedule of month 0,2 and one dose of booster immunization during the participants aged 12\~15 months .
62325325|NCT05092386|ACTIVE_COMPARATOR|Control Group of Three Doses With Pfizer PCV13|30 Participants aged 2 months will receive three doses of control vaccine(Pfizer PCV13 on the primary immunization schedule of month 0,2,4 and one dose of booster immunization during the participants aged 12\~15 months
62325326|NCT04164641|EXPERIMENTAL|Noraxon myoRESEARCH™ Software|All participants will be assigned to this group to receive study intervention.
62132924|NCT03563690|ACTIVE_COMPARATOR|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
62132925|NCT06516705|EXPERIMENTAL|Multimedia hypoglycemia health education|The multimedia educational content included an introduction to blood glucose, symptoms and management of hypoglycemia (the 15-rule), prevention of hypoglycemia (diet and exercise), and medication therapy.
62132926|NCT06516705|ACTIVE_COMPARATOR|Conventional hypoglycemia education|The verbal educational content provided by the health educators included an introduction to blood glucose, symptoms and management of hypoglycemia (the 15-rule), prevention of hypoglycemia (diet and exercise), and medication therapy.
62325327|NCT05217888||TAVR|Undergoing transcatheter aortic valve replacement patients
62325328|NCT01747213|EXPERIMENTAL|BNC|Bisnorcymserine tartrate
62325329|NCT01747213|PLACEBO_COMPARATOR|Placebo|microcrystalline celluose
62325330|NCT06176664|NO_INTERVENTION|Standard of Care|Participants will receive pneumonia care per World Health Organization guidelines. If their oxygen saturation falls below 90% after enrollment, they will be treated with low-flow oxygen.
62325331|NCT06176664|EXPERIMENTAL|Low-flow Oxygen|Participants will be treated with low-flow oxygen to achieve a goal oxygen saturation above 94%
62325332|NCT06176664|EXPERIMENTAL|High-flow Nasal Cannula Oxygen|Participants will be treated with high-flow nasal cannula oxygen to achieve a goal oxygen saturation above 94%.
62325333|NCT05343572|EXPERIMENTAL|Endometrial Disorders|"Three groups of patients, with 10 subjects per group:~1. Asherman's syndrome, as classified by the American Society of Reproductive Medicine (ASRM) by extent of uterine cavity involvement and adhesion type. Specifically, refractory Asherman's syndrome: patients who have had at least one operative hysteroscopy which was unsuccessful.~2. Atrophic endometrium, as defined by maximal endometrial lining thickness ≤6mm documented in at least 2 cycles on either:~   * Day of luteinizing hormone (LH) surge in natural cycle~  * Day of human chorionic gonadotropin (hCG) trigger in the setting of fresh IVF cycle~  * Day 14 of estradiol in the setting of frozen embryo transfer things (FET) cycles~3. Recurrent implantation failure, defined as failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen transfer cycles in a woman under 40 years"
62325334|NCT06158724||Simplified PPE group|Surgical mask, standard non sealing goggles, use of protective gown while in direct contact with patients.
62325335|NCT06158724||Standard COVID-19 PPE|"FFP2 mask, goggles and face shield, protective gown for COVID-19 ward.~FFP 3 mask or filter gas mask, sealing goggles, face shield or hazmat suit, protective gown, gloves and surgical cap."
61932387|NCT05353985|EXPERIMENTAL|Cohort 2: TAK-062 Dose 2 + SIGE Gluten-Bar|TAK-062 Dose 2, 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
61932388|NCT05353985|EXPERIMENTAL|Cohort 2: TAK-062 Dose 3 + SIGE Gluten-Bar|TAK-062 Dose 3, 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
62325336|NCT05849090|ACTIVE_COMPARATOR|Standard of care prophylactic antibiotics|"Standard irrigation and IV, cephalosporin, 2-grams, intravenous (IV),~* or standard irrigation and IV, clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV) for patients with cephalosporin allergies."
62325337|NCT05849090|EXPERIMENTAL|Vancomycin and Tobramycin|One-time dosage of topical vancomycin (1 gram) and tobramycin (1.2 grams) powder.
62325338|NCT03710603|ACTIVE_COMPARATOR|Velcade Lenalidomide dexamethasone (VRd)|VRd: subjects will receive VRd for induction and consolidation, followed by lenalidomide (R) maintenance until disease progression or unacceptable toxicity.
62484142|NCT04155450|ACTIVE_COMPARATOR|McKenzie Extension Group|"Moist Heat Pack for 10 mins~McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
62484143|NCT01016782|EXPERIMENTAL|Test|Test product that contains active pharmaceutical ingredient
62132927|NCT02337036|EXPERIMENTAL|Arm 1: Pharmacokinetic and Pharmacogenetic|Liver Transplant Children treated with tacrolimus
62132928|NCT01881412|EXPERIMENTAL|Inhaled corticosteroid (fluticasone)|Child receives: 1) standardized asthma discharge instructions, and the intervention which is 2) inhaled corticosteroid prescription with accompanying instructions.
62132929|NCT01881412|PLACEBO_COMPARATOR|Routine Asthma Care|Child receives: 1) Standard Asthma Discharge Instructions. No intervention in this arm (placebo controlled)
62132930|NCT00766649|EXPERIMENTAL|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
62132931|NCT00622856|EXPERIMENTAL|1|Psychological intervention for strengthening parental authority
62325339|NCT03710603|EXPERIMENTAL|Daratumumab + VRd (D-VRd)|D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
62325340|NCT06079281|PLACEBO_COMPARATOR|Placebo Group|During the Randomized Evaluation Period, the placebo group will receive placebo on Day 1, followed by once every 2 weeks (q2w) via SC injection for 24 weeks. Participants will enter the OLE Period and receive bodyweight dependent doses of either 20mg, 35mg, or 50mg of ALXN1850 and continue q2w dosing with ALXN1850 for up to 132 weeks.
62325341|NCT06079281|EXPERIMENTAL|ALXN1850 Group|Starting at Day 1 of the Randomized Evaluation Period, the ALXN1850 group will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once q2w via SC injection, for 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.
62325342|NCT04196712||Coronary angiography arm|Patient undergoing invasive coronary angiography
62484144|NCT01016782|ACTIVE_COMPARATOR|Reference|Reference product that contains active pharmaceutical ingredient
62484145|NCT01016782|PLACEBO_COMPARATOR|Vehicle|Placebo that contains no active pharmaceutical ingredient
61932389|NCT05353985|PLACEBO_COMPARATOR|Cohort 2: TAK-062 Placebo + Gluten-free SIGE Bar|TAK-062 placebo-matching 4 tablets, orally, taken within pre-determined time before the start of a meal and gluten-free SIGE bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
61932390|NCT05353985|EXPERIMENTAL|Cohort 2: TAK-062 Dose 1 + Gluten-free SIGE Bar|TAK-062 Dose 1, 4 tablets, orally, taken within pre-determined time before the start of a meal and gluten-free SIGE bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
61932391|NCT05353985|EXPERIMENTAL|Cohort 2: TAK-062 Dose 2 + Gluten-free SIGE Bar|TAK-062 4 tablets, orally, taken within pre-determined time before the start of a meal and gluten-free SIGE bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
61932392|NCT04090723|EXPERIMENTAL|Computer-delivered brief alcohol intervention (CBI-CC)|Participants will be offered only the Computer-delivered brief alcohol intervention with peer navigation from beginning of study to the end.
61932393|NCT03447184||Androgen priming|Eight weeks prior to stimulation for IVF - at the onset of menses, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor will commence, concomitantly with GnRHa down-regulation with a depot GnRHa (28days). After 8 weeks, a standard rFSH stimulation with either 300 IU rFSH or 300 IU rFSH+rLH will start. The androgen priming (hCG and aromatase inhibitor) will stop on the first day of stimulation.
61932394|NCT03772678|PLACEBO_COMPARATOR|Placebo|0.9% Saline For SAD and MAD arms.
61932395|NCT03772678|EXPERIMENTAL|Single Ascending Dose - Low Dose|LSALT peptide (1mg/mL in 0.9% saline) Single escalating dose - 0.01mg, 0.1mg, 0.3mg, 0.5mg intravenously Escalation to 2.5mg and 5mg doses in next cohorts if no adverse effects are seen after 10-14 days.
61932396|NCT03772678|EXPERIMENTAL|Single Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Single dose - 1mg intravenously over 2h Escalation to next dose in next participant every 72h if no adverse effects are seen.
61932397|NCT03772678|EXPERIMENTAL|Multiple Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Dose will be determined based on results of SAD arm. LSALT will be administered intravenously once or twice daily for 3 days.
61932398|NCT05375747|EXPERIMENTAL|Remimazolam based total intravenous anesthesia|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
61932399|NCT05375747|ACTIVE_COMPARATOR|Propofol based total intravenous anesthesia|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
61932400|NCT05722938|EXPERIMENTAL|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
61932401|NCT05722938|PLACEBO_COMPARATOR|Placebo|Human albumin 1%
61932402|NCT06655909|OTHER|mothers|healthy volunteers
61932403|NCT06655909|OTHER|preschool children|healthy volunteers
61932404|NCT06045650||Cases|Participants with borderline personality disorder who meet the inclusion criteria
61932405|NCT06045650||Controls|Participants without borderline personality disorder, who meet the inclusion criteria
62484146|NCT03432663|EXPERIMENTAL|24h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)
62692201|NCT05949892|EXPERIMENTAL|Smoking Cessation and Avoidance|"This arm will focus on the following:~Second-hand smoke Offering option to avoid secondhand smoke"
62692202|NCT00057512|EXPERIMENTAL|Intratumoral M4N|The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.
61932406|NCT03393884|EXPERIMENTAL|NACT + IMNN-001|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. IMNN-001 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
61932407|NCT03393884|ACTIVE_COMPARATOR|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
61932408|NCT06708975|EXPERIMENTAL|Group A|subjects will receive Phonophoresis Insulin Therapy, hyperpolarized light therapy and Standard wound cleaning and dressing.
61932409|NCT06708975|SHAM_COMPARATOR|Group B|subjects will receive hyperpolarized light therapy and Standard wound cleaning and dressing
61932410|NCT06708936|EXPERIMENTAL|KSD-201|Biological: Dendritic Cell Vaccine.Autologous monocyte-derived DCs pulsed with clear cell renal cell carcinoma-associated antigen.
61932411|NCT05398926|EXPERIMENTAL|Experimental group 1 (3-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (3-month interval）.
61932412|NCT05398926|EXPERIMENTAL|Experimental group 2 (4-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (4-month interval）.
61932413|NCT05398926|EXPERIMENTAL|Experimental group 3 (5-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (5-month interval）.
61932414|NCT05398926|EXPERIMENTAL|Experimental group 4 (6-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (6-month interval）.
62484147|NCT03432663|EXPERIMENTAL|72h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)
61932415|NCT06710015||BRCA1 and BRCA2 carriers|"Inclusion criteria:~* age \> 18 years~* presence of a pathogenic variant in the BRCA genes~* signed informed consent for study participation"
61932416|NCT06710015||Control cohort|"* \>18 y.o~* Relatives up to the third degree of kinship from cohort 1 who tested negative on predictive testing for the familial pathogenic variant in the BRCA genes, matched for age where possible."
61932417|NCT06709118||3.8mm Group|Orotracheal intubation was performed with a 3.8 millimeter outer diameter fiberoptic
62325343|NCT06539247|EXPERIMENTAL|Motor Relearning Approach with EMS (MRA + EMS)|"This arm received a 30-minute motor relearning program focused on improving foot drop and gait patterns. The program consisted of:~Motor Relearning Practice (20 minutes): Participants practiced walking, starting with individual components and gradually progressing to full walking sequences. The unaffected leg initiates each step, with the physiotherapist providing support as needed (Singh, 2017).~Electrical Muscle Stimulation (EMS) for Targeted Activation (10 minutes): EMS applied to the affected ankle dorsiflexors for 10 minutes to stimulate muscle activation. The parameters were:~Pulse amplitude: 40 mA (default) Pulse duration: adjusted to achieve balanced maximum ankle dorsiflexion Mode: adaptive, considering both intensity and duration for safe foot lift during walking Electrode placement: on the affected ankle dorsiflexors Intensity: set to a comfortable level for the participant (Knutson \& Chae, 2010)"
61932418|NCT06709118||2.8 mm group|Orotracheal intubation was performed with a 2.8 millimeter outer diameter fiberoptic
61932419|NCT06709118||4.8mm group|Orotracheal intubation was performed with a 4.8 millimeter outer diameter fiberoptic
61932420|NCT06272669|EXPERIMENTAL|Active-tDCS vs Sham-tDCS|"During the active- and sham-tDCS conditions, the participants will receive current with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, the tasks will be initiated five minutes subsequent to the stimulation mode and terminated prior to its end for active-tDCS condition. Whereas, the sham condition with the same placement and intensity will only receive 30s initial stimulation and then discontinue. Throughout the active / sham-tDCS condition, participants are required to sit still and focus their attention on a + displayed on a computer monitor during the five-minute rest. After that, they will undergo active-tDCS (1mA, 20 min) to the left DLPFC or sham stimulation over 10 sessions in 2 weeks, while performing the executive function training tasks."
61932421|NCT06272669|OTHER|Crossover trial|Participants in the sham-tDCS group will receive 10-day active tDCS and assessments will be performed before and after the 10-tDCS session.
62325344|NCT06539247|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation with EMS (PNF + EMS)|"This arm received a 30-minute intervention combining Proprioceptive Neuromuscular Facilitation (PNF) techniques and EMS. The program consisted of:~PNF Techniques for Neuromuscular Facilitation (20 minutes) in side-lying position with the affected leg uppermost. The sequence involved rhythmic initiation movements, measured using an alarm clock (Singh, 2017).~Electrical Muscle Stimulation (EMS) for Muscle Response Enhancement (10 minutes): Similar to Arm 1, EMS applied to the affected ankle dorsiflexors for 10 minutes with the same parameters:~Pulse amplitude: 40 mA (default) Pulse duration: adjusted to achieve balanced maximum ankle dorsiflexion Mode: adaptive, considering both intensity and duration for safe foot lift during walking Electrode placement: on the affected ankle dorsiflexors Intensity: set to a comfortable level for the participant (Knutson \& Chae, 2010)"
62484148|NCT02412553|ACTIVE_COMPARATOR|Specific carbohydrate arm|The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient.
62484149|NCT02412553|ACTIVE_COMPARATOR|Elemental diet arm|The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet
62692203|NCT06674174|EXPERIMENTAL|lower limb strength training|Experimental group will receive lower limb strength training
62692204|NCT06674174|OTHER|endurance training|control group will receive endurance training.
61932422|NCT06272669|EXPERIMENTAL|Booster effect|All tDCS responders (\>10% reduction in SRS scores) will enrol on a 6 months follow-up phase in which they will be randomized to receive either bimonthly 20-minute booster tDCS sessions, or bimonthly 20-minute booster sham tDCS sessions for 3 months, followed by monthly 20-minute booster tDCS, monthly 20-minute booster sham tDCS, for another 3 months, with a maximum of 9 (sham) tDCS booster sessions.
61932423|NCT04722549|PLACEBO_COMPARATOR|Placebo|Placebo (cellulose)
61932424|NCT04722549|ACTIVE_COMPARATOR|Butyrate|Sodium butyrate
61932425|NCT03104374|EXPERIMENTAL|ABT-494 Dose A|It is administered once daily.
61932426|NCT03104374|PLACEBO_COMPARATOR|Placebo followed by ABT-494 Dose B|It is administered once daily.
61932427|NCT03104374|EXPERIMENTAL|ABT-494 Dose B|It is administered once daily.
61932428|NCT03104374|PLACEBO_COMPARATOR|Placebo followed by ABT-494 Dose A|It is administered once daily.
61932429|NCT02469207||Deceased organ donors|Patients with consent for organ donation towards transplantation and research. Organs not used for transplantation will be used for this study if determined appropriate and necessary.
61932430|NCT05642507|EXPERIMENTAL|Active (AC01) Microtablets|Escalating doses of AC01
61932431|NCT05642507|PLACEBO_COMPARATOR|Placebo Microtablets|Matching placebo tablets
61932432|NCT04060030|EXPERIMENTAL|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
62484150|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
62484151|NCT02450539|EXPERIMENTAL|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62484152|NCT02450539|ACTIVE_COMPARATOR|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62484153|NCT01437761||2008 Sorbent system|Hemodialysis with the 2008 Sorbent system
62484154|NCT06350240|EXPERIMENTAL|Control group|Exercise group
62484155|NCT06350240|EXPERIMENTAL|Intervention group|Exercise and use of textured insoles group
62484156|NCT05312554|EXPERIMENTAL|Intervention arm|Patients with cryptogenic stroke complicated with patent foramen ovale,and passed the screening and signed the informed consent form
62325345|NCT06334042||Intensive Care Patients|
62325346|NCT06365385|EXPERIMENTAL|CL - CF|"The interventions (carbohydrate-last meal pattern (CL) or carbohydrate-first meal pattern (CF)) will be delivered in random order at two study visits, separated by a wash-out period of 7 days. If participants are allocated to this study arm, they will receive the CL on the first visit and the CF on the second visit.~The nutritional composition of the test-meal will comply to the current sports nutrition guidelines for the pre-exercise meal (i.e., 1-4 g of CHO/kg of body mass, moderate amounts of protein, low-fat and fibre content, 5-10 mL/kg of body mass of fluids) (Thomas et al., 2016). Participants will be encouraged to consume the meal in full within 15 minutes, at a comfortable pace, to mimic real eating circumstances."
62325347|NCT06365385|ACTIVE_COMPARATOR|CF - CL|"The interventions (carbohydrate-last meal pattern (CL) or carbohydrate-first meal pattern (CF)) will be delivered in random order at two study visits, separated by a wash-out period of 7 days. If participants are allocated to this study arm, they will receive the CF on the first visit and the CL on the second visit.~The test-meal will be identical and isocaloric in both interventions of the study."
62484157|NCT05815394|EXPERIMENTAL|177Lu-Anti-PSMA mAbs|
62484158|NCT05329311||ERATS protocol applied|Inflammatory parameters of the operated patients by applying the ERATS protocol will be investigated.
62484159|NCT05329311||ERATS protocol not applied|Inflammatory parameters of patients who were operated without the ERATS protocol will be investigated.
62484160|NCT02915445|EXPERIMENTAL|EpCAM CAR-T cells|Autologous T cells from patient are engineered to expressing a special chimeric antigen receptor to recognizing EpCAM by lentiviral vector. The engineered T cells were then endowed cytotoxicity to the tumor cells and hold the potential to inhibit the advance of tumors.
61932433|NCT04060030|PLACEBO_COMPARATOR|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
61932434|NCT05672121|EXPERIMENTAL|KH631 Dose 1|dose1:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
62484161|NCT05786118||SIJ Group|Individuals with sacroiliac joint dysfunction: Participants will be grouped as positive sacroiliac joint dysfunction according to Laslett's algorithm using provocation tests to detect sacroiliac joint dysfunction.
62692205|NCT06349837|EXPERIMENTAL|LDRT+SBRT + Tislelizumab|This is a dose escalation study, low Dose Radiotherapy (LDRT) dose was 6Gy/3f, Stereotactic Ablative Radiotherapy (SBRT) dose was 24Gy/3f , 30Gy/3f and 45 Gy/3f, the dose of Tislelizumab was recommended in the instruction manual.
62325348|NCT04921501|EXPERIMENTAL|Proven or suspected arrhythmias group|
62325349|NCT06241456|EXPERIMENTAL|Regimen A: FT825|Participants with advanced HER2-expressing solid tumors receive FT825 following chemotherapy in Cycle 1 (each cycle is approximately 61 days). Based on the safety, tolerability, and radiographically confirmed clinical benefit to treatment in Cycle 1, participants may be considered for an additional treatment cycle (Cycle 2 retreatment).
62484162|NCT05786118||Control Group|Individuals with no sacroiliac joint dysfunction: Individuals with sacroiliac joint dysfunction: Participants will be grouped as negative sacroiliac joint dysfunction according to Laslett's algorithm using provocation tests to detect sacroiliac joint dysfunction.
62484163|NCT05460520|SHAM_COMPARATOR|Group 1: VOR readaptation with full-field OKS|This group to undergo VOR readaptation with full-field OKS. Groups 1 will be treated with stationary OKS (sham). (Group 1, n=50).
62484164|NCT05460520|SHAM_COMPARATOR|Group 2: VOR readaptation with VR googles|This group to undergo VOR readaptation with VR googles. Groups 2 will be treated with stationary OKS (sham). (Group 2, n=50)
62484165|NCT05460520|ACTIVE_COMPARATOR|Group 3: Supplemental VOR habituation|This group to undergo VOR readaptation with full-field OKS combined with a habituation protocol. (Group 3, n=30)
62692206|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference \<80 cm and fasting glucose levels \<6.1 mmol/L.
61932435|NCT05672121|EXPERIMENTAL|KH631 Dose 2|dose2:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
61932436|NCT05672121|EXPERIMENTAL|KH631 Dose 3|dose3:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
62484166|NCT05460520|ACTIVE_COMPARATOR|Group 4: Visual desensitization treatment|This group to undergo VOR readaptation with full-field OKS combined with visual desensitization protocol. (Group 4, n=30)
62484167|NCT05460520|ACTIVE_COMPARATOR|Group 5: Treatment of gravitational pull with OKS with full-field setting|This group with phantom sensation dominated by gravity pull. This group will undergo OKS in a full-field (Group 5, n=20) .
62692207|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference \>88 cm and fasting glucose levels \>=6.1 and \<7.5 mmol/L
61932437|NCT05672121|EXPERIMENTAL|KH631 Dose 4|dose4:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
62692208|NCT02694263|EXPERIMENTAL|Canagliflozin + Metformin|Canagliflozin + metformin (using the participant's current dose, or dose recommended by the study clinician). An initial dose of 100mg once daily of Canagliflozin will be prescribed, and this will be titrated up to a maximum of 300mg once daily.
62484168|NCT05460520|ACTIVE_COMPARATOR|Group 6: Treatment of gravitational pull with OKS with VR setting|This group with phantom sensation dominated by gravity pull. This group will undergo OKS in a VR setting (Group 6, n=20).
62692209|NCT02694263|ACTIVE_COMPARATOR|Repaglinide + Metformin|Repaglinide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). An initial dose of 0.5mg once daily where no prior treatment has been given will be prescribed. However, where prior treatment has been in place, an initial dose of 1-2mg once daily will be started and this will be titrated up to a maximum dose of 4mg daily.
62692210|NCT02694263|ACTIVE_COMPARATOR|Pioglitazone + Metformin|Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
61932438|NCT05672121|EXPERIMENTAL|KH631 Dose 5|dose5:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
62692211|NCT02694263|ACTIVE_COMPARATOR|Gliclazide + Metformin|Gliclazide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Gliclazide dose will initially be 40-80 mg once daily, up to maximum dose of 160mg twice daily..
62692212|NCT02694263|ACTIVE_COMPARATOR|Glimepiride + Metformin|Glimepiride + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). Glimepiride will initially be administered as 1mg once daily, up to a maximum dose of 4mg once daily.
61932439|NCT03306927|EXPERIMENTAL|Whole yellow pea|Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili
61932440|NCT03306927|EXPERIMENTAL|Split yellow pea|Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili
61932441|NCT03306927|PLACEBO_COMPARATOR|Rice-PPGR|Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili
61932442|NCT03306927|PLACEBO_COMPARATOR|Rice-Satiety|Rice chili with the same calories as the pea chili. Intervention: Rice chili
61932443|NCT05929859|EXPERIMENTAL|Intensive Treatment|Speech Motor Chaining will be delivered in an intensive fashion. Week 1: 8 sessions (2 sessions per day on 4 different days) Week 2: 3 sessions (1 per day on 3 different days) Week 3: 3 sessions (1 per day on 3 different days) Week 4: 2 sessions (1 per day on 2 different days)
61932444|NCT05929859|EXPERIMENTAL|Distributed Treatment|Speech Motor Chaining will be delivered twice weekly for 8 weeks
61932445|NCT06577116|EXPERIMENTAL|720mg of AK006 IV|Subjects in this arm will receive 4 doses of 720mg of AK006 via intravenous infusion every 4 weeks.
61932446|NCT05442216|EXPERIMENTAL|Experimental Group|"During Cycle 1 and Cycle 2:~Tagraxofusp will be administered intravenously (12 mcg/kg) on days 1-5 of Cycle 1-2 (Cycle is 21 days)~During Cycles 3-12:~Subjects with a marrow CR after Cycle 2 will continue tagraxofusp ONLY for Cycles 3-12 (up to a year of treatment) on Days 1-5 of a 28 day cycle.~For subjects without a marrow CR, azacitidine will be administered intravenously (75 mg/m2) on days 1-7 of Cycle 3-12 (Cycle is 28 days) and tagraxofusp will be administered intravenously (12 mcg/kg) on days 1-3 of Cycle 3-12 (Cycle is 28 days).~Subjects who achieve a marrow CR receiving tagraxofusp only after Cycle 4, will continue tagraxofusp at 12 mcg/kg IV for 5 consecutive days every 28 days until Cycle 12. Subjects who continue to achieve an overall response (CR, CRi, PR, MLFS, marrow CR) receiving tagraxofusp and azacitidine will continue tagraxofusp at 12 mcg/kg IV for 3 consecutive days and azacitidine 75 mg/m2 SQ or IV on Days 1-7 every 28 days until Cycle 12."
61932447|NCT01607268||Pure Autonomic Failure|Pure autonomic failure is a type of primary autonomic failure characterized by peripheral autonomic nervous system impairment.
61932448|NCT01607268||Multiple System Atrophy|Multiple system atrophy is a type of primary autonomic failure characterized by central autonomic nervous system impairment.
61932449|NCT01180166|EXPERIMENTAL|nimotuzumab|Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
61932450|NCT05780606|OTHER|Voluntary|
61932451|NCT05055453|EXPERIMENTAL|Experimental Study Group|Participants age 8-17 with bilateral hearing loss will be fit with Phonak BTE hearing aids and given access to the Phonak hearing app. The participants will use the app to adjust the hearing aid microphone and noise reduction settings.
61932452|NCT06424834|EXPERIMENTAL|Targeted medical therapy|"1. Epicardial or microvascular coronary spasm: Amlodipine 2.5mg initial dose, 10mg max dose~2. Coronary microvascular dysfunction: Nebivolol 5mg initial dose, 20mg max dose~3. Myocardial Bridge: Nebivolol 5mg initial dose, 20mg max dose~4. Mixed epicardial/microvascular spasm and coronary microvascular dysfunction/myocardial bridge: Amlodipine 2.5mg initial dose, 10mg max dose; PLUS Nebivolol 5mg initial dose, 20mg max dose~Participants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 1-3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for an additional 4 weeks to the conclusion of the study."
61932453|NCT06424834|PLACEBO_COMPARATOR|Placebo|"1. Epicardial or microvascular coronary spasm: Placebo~2. Coronary microvascular dysfunction: Placebo~3. Myocardial Bridge: Placebo~4. Mixed epicardial/microvascular spasm and coronary microvascular dysfunction/myocardial bridge: Placebo~Participants will take their assigned therapy after randomization. Weekly person via in-person visit or telephone is performed to uptitrate therapy to the maximally tolerated dose. After 1-3 weeks, the initial drug titration phase is completed and a final dose reached. Participants are then instructed to take the maximally tolerated dose for an additional 4 weeks to the conclusion of the study."
61932454|NCT00696683||A|Patients from the identified scorpion envenomation cases, who met inclusion/exclusion criteria.
62692213|NCT04030650||healthy volunteers|
62692214|NCT04030650||patients|patients with lower limb amputations
62132932|NCT00622856|ACTIVE_COMPARATOR|2|Diabetes education- 5 sessions with diabetes nurse, taking place once a week
62132933|NCT00622856|NO_INTERVENTION|3|Control group- regular treatment without any intervention
62484169|NCT03190239|EXPERIMENTAL|Apatinib XQonc-0007|Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd
62484170|NCT06218524|PLACEBO_COMPARATOR|TMZ single|Single oral Temozolomide
62484171|NCT06218524|EXPERIMENTAL|TMZ and Haloperidol|Oral Temozolomide and Haloperidol
62484172|NCT03560843|EXPERIMENTAL|MBSR treatment|MBSR will be administered over 8 week period.
62484173|NCT03560843|NO_INTERVENTION|Control group|Usual care will continue for this group.
62692215|NCT06642181|EXPERIMENTAL|Combined Group|Will receive both Guanfacine pharmacotherapy and MORE intervention
61932455|NCT03722199|EXPERIMENTAL|Healthy persons|In this interventional study the investigators ask the patient (healthy persons) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
61932456|NCT03722199|EXPERIMENTAL|Persons with essential hypertension|In this interventional study the investigators ask the patient (persons with essential hypertension) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
61932457|NCT03722199|EXPERIMENTAL|Persons with type 2 diabetes|In this interventional study the investigators ask the patient (persons with type 2 diabetes) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
61932458|NCT06591286|EXPERIMENTAL|Intervention group|The intervention group (75 cases) will wear real-time CGM to monitor blood glucose for 12 weeks, followed by 36 weeks of follow-up.
61932459|NCT06591286|OTHER|Control group|The control group (75 cases) is self-monitored by traditional SMBG for 12 weeks at a frequency of no less than 4 times a week, followed by 36 weeks of follow-up.
61932460|NCT06310044|EXPERIMENTAL|Commiphora Myrrh|50% Commiphora Myrrh
61932461|NCT06310044|ACTIVE_COMPARATOR|Sodium hypochlorite|2.5% NaOCl
61932462|NCT02532530|OTHER|Study group|Adult patients (age ≥ 70 years) undergoing elective on-pump cardiac surgery (i.e. valve replacement with or without 'Coronary Artery Bypass Graft' (CABG) surgery)
61932463|NCT06617832|ACTIVE_COMPARATOR|Active group|Active drug
61932464|NCT06617832|PLACEBO_COMPARATOR|Placebo group|Inactive placebo
61932465|NCT03690453|EXPERIMENTAL|Healthy volunteer for Clinical Trial|
61932466|NCT03690453|NO_INTERVENTION|Healthy volunteer for blood donor|
62692216|NCT06642181|EXPERIMENTAL|MORE Group|Will receive MORE intervention and placebo medication
62692217|NCT06642181|EXPERIMENTAL|Guanfacine Group|Will receive Guanfacine intervention and Support group control (non-mindfulness) intervention
62692218|NCT06642181|NO_INTERVENTION|Control Group|Will receive placebo and support group control (non-mindfulness)
61932467|NCT06010030|EXPERIMENTAL|HD-tDCS|Participants will be randomized to receive either anodal HD-tDCS or sham-tDCS.
61932468|NCT06010030|EXPERIMENTAL|Speech Therapy|Participants will be randomized to receive either phonologic-focused speech therapy or semantic-focused speech therapy
62484174|NCT04259476|ACTIVE_COMPARATOR|group A|WIll be given low dose perioperative ketamine infusion, as well as a ketamine bolus at start of surgery.
61932469|NCT03773211|EXPERIMENTAL|Renaparin|Solution administered once to kidney ex-vivo
61932470|NCT03773211|PLACEBO_COMPARATOR|Placebo|Placebo administered once to kidney ex-vivo
61932471|NCT05307978|EXPERIMENTAL|Cohort 1|Participants will receive a single dose of 5 mg of ALXN1910 IV or Placebo IV.
61932472|NCT05307978|EXPERIMENTAL|Cohort 2|Participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
61932473|NCT05307978|EXPERIMENTAL|Cohort 3|Participant will receive a single dose of 15 mg of ALXN1910 IV or Placebo IV.
61932474|NCT05307978|EXPERIMENTAL|Cohort 4|Japanese participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
61932475|NCT05307978|EXPERIMENTAL|Cohort 5|Participants will receive a single dose of 45 mg of ALXN1910 SC or Placebo SC.
61932476|NCT05307978|EXPERIMENTAL|Cohort 6|Participants will receive a single dose of 135 mg of ALXN1910 SC or Placebo SC.
61932477|NCT05907096|EXPERIMENTAL|ARGX-117|Patients receiving ARGX-117 intravenous infusions
61932478|NCT05907096|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo intravenous infusions
61932479|NCT02126358|PLACEBO_COMPARATOR|Gemigliptin|only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)
61932480|NCT02126358|PLACEBO_COMPARATOR|Rosuvastatin|only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)
61932481|NCT02126358|EXPERIMENTAL|FDC|Gemigliptin \& Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)
61932482|NCT06541314|EXPERIMENTAL|Fluzoparib neoadjuvant therapy|
61932483|NCT05892653|EXPERIMENTAL|Dose Escalation and Dose Expansion|"During the dose escalation stage, a classic 3+3 design will be used to guide dose escalation to determine MTD and RP2D. Three to six subjects are expected to be enrolled in each dose group and at least 6 subjects are enrolled in the MTD/highest dose group. The total number of subjects enrolled during the dose escalation stage will depend on the amount of DLT and the total number of dose levels explored. If DLT is not observed in the first 3 subjects enrolled for each dose level, the Safety Monitoring Committee (SMC) will review the cumulative safety data of subjects at each dose level and decide whether to proceed with dose escalation upon the completion of study treatment at least for the DLT evaluation period (28 days of Cycle 1). The dose expansion stage in this study will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level (MTD or the optimal dose needs to be reviewed by the SMC and subjects are safe and tolerable at that dose level)."
62132934|NCT00933257|EXPERIMENTAL|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
62484175|NCT04259476|PLACEBO_COMPARATOR|group B|will be given normal saline infusion and bolus at start of surgery.
62484176|NCT05616728|EXPERIMENTAL|EDP-235 200mg|Once a day orally for 5 days
62484177|NCT05616728|EXPERIMENTAL|EDP-235 400mg|Once a day orally for 5 days
62484178|NCT05616728|PLACEBO_COMPARATOR|Placebo|Once a day orally for 5 days
62692219|NCT06511648|EXPERIMENTAL|Erdafitinib (ERDA) monotherapy|Patients will receive treatment neoadjuvant with erdafitinib alone (cohort 1: Erdafitinib) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment)
62692220|NCT06511648|EXPERIMENTAL|Erdafitinib (ERDA) and Cetrelimab (CET) combination|Patients will receive treatment neoadjuvant with erdafitinib + cetrelimab (cohort 2: Erdafitinib + Cetrelimab) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment)
62697541|NCT03483701|NO_INTERVENTION|Treatment as Usual|Participants in the control condition will continue to receive IPS services as usual.
61932484|NCT04334525|NO_INTERVENTION|Generic placemats and frequent diner cards|Participants will receive generic placemats listing all of the restaurant's kids' meals. Families will also receive a generic frequent diner card, which after purchasing (any) kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
62325350|NCT06241456|EXPERIMENTAL|Regimen B: FT825 + Cetuximab|Participants with advanced epidermal growth factor receptor (EGFR)-expressing solid tumors receive FT825 in combination with cetuximab following chemotherapy in Cycle 1 (each cycle is approximately 61 days). Based on the safety, tolerability, and radiographically confirmed clinical benefit to treatment in Cycle 1, participants may be considered for an additional treatment cycle (Cycle 2 retreatment).
62325351|NCT05614063|EXPERIMENTAL|XEN1101 25 mg/day|XEN1101 25 mg/day
62692221|NCT03135067|EXPERIMENTAL|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
62692222|NCT03135067|NO_INTERVENTION|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling \& testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
62692223|NCT02367885|EXPERIMENTAL|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
61932485|NCT04334525|EXPERIMENTAL|Placemats and frequent diner cards promoting healthier meals|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
61932486|NCT02063880|EXPERIMENTAL|Urgent ART|"Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.~Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health."
61932487|NCT02063880|ACTIVE_COMPARATOR|Early ART|Initiation of HAART 7-14 days after enrollment.
61932488|NCT00266773|NO_INTERVENTION|1|Control - standard care only
61932489|NCT00266773|EXPERIMENTAL|2|Attention Control - standard care plus 6 months TIVR receiving minimal monthly feedback
61932490|NCT00266773|EXPERIMENTAL|3|Standard care plus 6 months TIVR receiving detailed monthly feedback
61932491|NCT03698552|EXPERIMENTAL|ADCT-602|Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
61932492|NCT06517823|EXPERIMENTAL|Etoricoxib+Cyanocobalamin|Administered orally, 1 tablet a day for 7 days.
61932493|NCT06517823|ACTIVE_COMPARATOR|Etoricoxib|Administered orally, 1 pill a day for 7 days.
61932494|NCT04069572|EXPERIMENTAL|Vibrotactile Stimulation|
61932495|NCT04069572|SHAM_COMPARATOR|Sham Stimulation|
61932496|NCT03875118|EXPERIMENTAL|The intervention group|Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
61932497|NCT03875118|ACTIVE_COMPARATOR|The control group|Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
62325352|NCT05614063|EXPERIMENTAL|XEN1101 15 mg/day|XEN1101 15 mg/day
62325353|NCT05614063|PLACEBO_COMPARATOR|Placebo|Placebo
62325354|NCT04895436|EXPERIMENTAL|Cohort 1 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.
61932498|NCT04580225|ACTIVE_COMPARATOR|Group A: Partial Wrist Arthrodesis without Triquetral Excision|Four-Corner Arthrodesis
61932499|NCT04580225|ACTIVE_COMPARATOR|Group B: Partial Wrist Arthrodesis with Triquetral Excision|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision
61932500|NCT06710782|EXPERIMENTAL|Hyaluronic Acid group|Patients underwent intra-articular hyaluronic acid injection.
61932501|NCT06710782|EXPERIMENTAL|Transcutaneous pulsed radiofrequency group|Patients underwent transcutaneous pulsed radiofrequency application plus genicular nerve block.
61932502|NCT04465214||1/Cohort 1|Participants with a diagnosis of cancer who are under active treatment on a protocol at NIH
61932503|NCT02088242|PLACEBO_COMPARATOR|Placebo|Subjects receiving placebo will be asked to ingest 3 capsules identical in shape, colour and size to the Astaxanthin capsules, and will contain only the inactive ingredients of the same formulation.
61932504|NCT02088242|EXPERIMENTAL|Astaxanthin|Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
62325355|NCT04895436|EXPERIMENTAL|Cohort 2 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.
62325356|NCT00361829||Ecologic/Community|Married women, infants, caregivers, Japanese-American, Argentine-American
62325357|NCT05600088|EXPERIMENTAL|CTS Treatment Arm|active cryotherapy of a single suitable high-risk coronary plaque lesion with CTS device
62325358|NCT03598608|EXPERIMENTAL|Part A: Favezelimab Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62484179|NCT05730920|ACTIVE_COMPARATOR|Intravenous (IV) Methadone|Subjects will receive IV methadone 0.2 mg/kg (maximum dose 20mg) via an infusion pump over 15 minutes while undergoing continuous monitoring. Additional IV methadone may be given during the case per the anesthesiologist's discretion, but the total dose may not exceed 20mg.
62325359|NCT03598608|EXPERIMENTAL|Part A: Favezelimab Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62325360|NCT03598608|EXPERIMENTAL|Part A: Favezelimab Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62484180|NCT05730920|EXPERIMENTAL|Liposomal Bupivacaine (LB, Exparel)|Subjects will receive four-point ESPB with an admixture of LB and 0.25% bupivacaine hydrochloride. The total LB dose will be 4mg/kg, max dose of 266mg, while the total dose of bupivacaine hydrochloride will be 2mg/kg.
62484181|NCT05651958|EXPERIMENTAL|Pranayma Breathing Technique|Pranayma Breathing Technique protocol includes 15 breaths in the morning and 15 breaths in evening for atleast weeks.
62325361|NCT03598608|EXPERIMENTAL|Part B: cHL-Combination Therapy|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the recommended Phase 2 dose (RP2D) of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62325362|NCT03598608|EXPERIMENTAL|Part B: DLBCL-Combination Therapy|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62484182|NCT05651958|ACTIVE_COMPARATOR|Conventional Treatment|Long-acting beta-2 agonist, nebulizers and long acting anti-mucosic drugs.
61932505|NCT00542568|EXPERIMENTAL|1|Cohort 1 (Low Dose group) 18-25 IU/kg/day
61932506|NCT00542568|EXPERIMENTAL|2|Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
61932507|NCT00542568|EXPERIMENTAL|3|Cohort 3 (High Dose group): 55-65 IU/kg/day
62325363|NCT03598608|EXPERIMENTAL|Part B: iNHL-Combination Therapy|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
62325364|NCT03598608|EXPERIMENTAL|Part B: Randomized cHL-Monotherapy|Participants with cHL receive either pembrolizumab by IV infusion or the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to approximately 2 years).
62325365|NCT06540911|EXPERIMENTAL|Personalized physical back training program|4-week personalized physical back training program
62325366|NCT06540911|ACTIVE_COMPARATOR|Non-personalized physical back training program|4-week non-personalized physical back training program
62484183|NCT02287844|EXPERIMENTAL|XOS group|Subjects consumed 6.64 g of a XOS-enriched compound derived from wheat arabinoxylans (5 g of XOS) everyday for 4 weeks.
62484184|NCT02287844|EXPERIMENTAL|INU-XOS group|Subjects consumed 6.64 g of a mixture containing inulin-type fructans, XOS and maltodextrins (3 g of inulin and 1 g of XOS) everyday for 4 weeks.
62484185|NCT02287844|ACTIVE_COMPARATOR|Placebo|Subjects consumed 6.64 g of wheat maltodextrins everyday for 4 weeks.
62484186|NCT05812118|NO_INTERVENTION|Control group|Control group
62484187|NCT05812118|EXPERIMENTAL|Experimental group|Physical active learning intervention
61932508|NCT01532973|EXPERIMENTAL|GT1 HCV 10-mg Elbasvir (Panel A)|Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
61932509|NCT01532973|EXPERIMENTAL|GTI HCV 50-g Elbasvir (Panel B)|Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
61932510|NCT01532973|EXPERIMENTAL|GT1 HCV 5-mg Elbavir (Panel C)|Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
61932511|NCT01532973|EXPERIMENTAL|GT1 HCV 200-mg Elbasvir (Panel D)|Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
61932512|NCT01532973|EXPERIMENTAL|GT3 HCV 10-mg Elbasvir (Panel E)|Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
61932513|NCT01532973|EXPERIMENTAL|GT3 HCV 50-mg Elbasvir (Panel F)|Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
62484188|NCT06627452|EXPERIMENTAL|Study Group|Participants in Dynamic Neuromuscular Stabilization(DNS) will perform exercises with a physiotherapist twice a week and at home three days a week. The sessions will last approximately 30 minutes and will be conducted five days a week for 12 weeks.
62692224|NCT02367885|EXPERIMENTAL|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
62692225|NCT02367885|EXPERIMENTAL|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
61932514|NCT01532973|EXPERIMENTAL|GT3 HCV 100-mg Elbasvir (Panel G)|Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
61932515|NCT01532973|EXPERIMENTAL|GT3 HCV 200-mg Elbasvir (Panel H)|Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
61932516|NCT01532973|EXPERIMENTAL|GT1a HCV 10-mg Elbasvir (Panel I)|Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
62325367|NCT04107857||Smoking Cessation|"* Patients enter the program through clinic appointments or community outreach programs.~* Patients will be given brief advice to quit smoking and referral options to receive evidence-based treatment through Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov dependent on the patient's preference for counseling~* Patient can also be prescribed smoking cessation pharmacotherapy"
62325368|NCT06353386|EXPERIMENTAL|Arm A1: Opevesostat|Participants receive 5 mg of opevesostat twice daily (BID) via oral tablet plus dexamethasone 1.5 mg by oral tablets once daily (QD) and 0.1 mg fludrocortisone acetate by oral tablet QD until progression or discontinuation.
62325369|NCT06353386|EXPERIMENTAL|Arm A2: Olaparib + Opevesostat|Participants receive 5 mg of opevesostat BID via oral tablet plus dexamethasone 1.5 mg by oral tablets QD and 0.1 mg fludrocortisone acetate by oral tablet QD, PLUS 300 mg of olaparib BID via oral tablet until progressive disease or discontinuation.
62484189|NCT06627452|ACTIVE_COMPARATOR|Control Group|Participants in Pelvic Floor Muscle Training (PFMT) will be taught pelvic floor exercises through vaginal palpation. They will perform the exercises with a physiotherapist two days a week and at home three days a week. The sessions will last approximately 30 minutes and will be conducted five days a week for 12 weeks.
62692226|NCT06629740|EXPERIMENTAL|Cannabinoid|A single administration of cannabinoid where a CE-marked eHealth system will be used before and after intake.
62484190|NCT03873363|EXPERIMENTAL|PS|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
62484191|NCT03873363|ACTIVE_COMPARATOR|CR|Implantation of a cruciate retaining Total Knee Arthroplasty.
62484192|NCT04694963||Subaute Cough|N=500
62484193|NCT05795621|PLACEBO_COMPARATOR|Placebo|Participants with TED will be randomized to receive 4 intravenous infusions of Placebo with an interval of 3 weeks for phase II and 8 intravenous infusions of Placebo with an interval of 3 weeks for phase III.
62484194|NCT05795621|ACTIVE_COMPARATOR|IBI311|Participants with TED will be randomized to receive 4/8 intravenous infusions of IBI311 with an interval of 3 weeks for phase II/III.
62692227|NCT06629740|EXPERIMENTAL|Phenethylamine|A single administration of phenethylamine where a CE-marked eHealth system will be used before and after intake.
62692228|NCT01430715|EXPERIMENTAL|Outside play|
62692229|NCT01430715|EXPERIMENTAL|Active video game|
62132935|NCT05384470|OTHER|Exhaled Breath Samples|Quantitative detection of marijuana, morphine or fentanyl through exhaled breath
62132936|NCT04432142||Proton|Patients receiving proton therapy
62132937|NCT04432142||Photon|Patients receiving photon therapy in 4 fractions or less
62325370|NCT06353386|EXPERIMENTAL|Arm A3: Docetaxel + Opevesostat|Participants receive 5 mg of opevesostat BID via oral tablet plus dexamethasone 1.5 mg by oral tablets QD and 0.1 mg fludrocortisone acetate by oral tablet QD, PLUS 75 mg/m\^2 of docetaxel once every 3 weeks (Q3W) via IV infusion, plus prednisone per approved product label BID by oral tablets until progressive disease or discontinuation.
62325371|NCT06353386|EXPERIMENTAL|Arm A4: Cabazitaxel + Opevesostat|Participants receive 5 mg of opevesostat BID via oral tablet plus dexamethasone 1.5 mg by oral tablets QD and 0.1 mg fludrocortisone acetate by oral tablet QD, PLUS 20 mg/m\^2 of cabazitaxel Q3W via IV infusion, plus prednisone per approved product label BID by oral tablets until progressive disease or discontinuation.
62692230|NCT02895984|EXPERIMENTAL|Brief Motivational Intervention (BMI)|The intervention recipients in the BMI group will receive a 1-hour single-session alcohol intervention (BMI) with personalized normative feedback.
62692231|NCT02895984|NO_INTERVENTION|Natural History Control (NHC)|Students in the NHC group will receive no contact.
62692232|NCT03653546|EXPERIMENTAL|AZD3759 Group|AZD3759 group will receive a 200 mg twice daily dose of AZD3759
62692233|NCT03653546|ACTIVE_COMPARATOR|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
62132938|NCT04431375|EXPERIMENTAL|plasma Exchange+Tenofovir+FMT|Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
62132939|NCT04431375|ACTIVE_COMPARATOR|Tenofovir|TabletTenofovir \[antiviral\] 300mg per oral once a day
62692234|NCT06220318|EXPERIMENTAL|C019199 plus Sintilimab|Patients with selected tumors will received oral C019199 at a starting dose of 100mg once daily in combination with intravenous Sintilimab 200mg every 3 weeks ( Q3W ) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, or withdrawal of consent .
62692235|NCT05001113|EXPERIMENTAL|the subxiphoid approach thoracoscopic thymectomy|The subxiphoid approach thoracoscopic thymectomy is performed in enrolled patients.
62132940|NCT00774397|EXPERIMENTAL|240 mg QD TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
62132941|NCT00774397|EXPERIMENTAL|240 mg QD / LI-TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
62132942|NCT00774397|PLACEBO_COMPARATOR|Placebo|Placebo once daily combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
62132943|NCT00774397|EXPERIMENTAL|120 mg QD / LI-TN|120 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in (LI) phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), followed by an additional 24 weeks of PegIFN/RBV in treatment naive (TN) patients
62325372|NCT03056755|EXPERIMENTAL|Cohort A: Pre-treated with CDK 4/6i + AI|Participants who received any Cyclin-Dependent Kinases 4 and 6 inhibitor (CDK 4/6i) plus aromatase inhibitor (AI) as immediate prior treatment will receive alpelisib + fulvestrant
62484195|NCT04917419|EXPERIMENTAL|Luminotherapy and Psychoeducation Program|
62484196|NCT04917419|ACTIVE_COMPARATOR|Psychoeducation Program|
62484197|NCT01889407||IA regimen|IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
62484198|NCT01889407||DA regimen|Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
62484199|NCT06623162|EXPERIMENTAL|Neoadjuvant|4 cycles of gemcitabine plus cisplatin
62484200|NCT01735994|EXPERIMENTAL|Healthy Weight Intervention|Eating Disorder Prevention Program
62484201|NCT01735994|OTHER|Brochure wait list|Brochure wait list control group
62484202|NCT02083328|ACTIVE_COMPARATOR|Caffeine|Caffeine will be administrated at a dosage of 6mg/kg of body mass. It is ingested once, one hour before the exercise performance test.
62484203|NCT02083328|PLACEBO_COMPARATOR|Mannitol (Placebo)|Placebo capsules will be administrated one hour before the exercise performance test. The subject gets exactly the same number of capsules as for the caffeine dosage. Caffeine and placebo capsules look the same.
62484204|NCT05740098|EXPERIMENTAL|Best practices|Participants will receive the Five As plus a referral to a quit line.
62692236|NCT05001113|ACTIVE_COMPARATOR|the lateral intercostal approach thoracoscopic thymectomy|The lateral intercostal approach thoracoscopic thymectomy is performed in enrolled patients.
62484205|NCT05740098|EXPERIMENTAL|Best practices and financial incentives|Participants will receive the Five As, a referral to a quit line, and financial incentives contingent on biochemically confirmed smoking abstinence
62325373|NCT03056755|EXPERIMENTAL|Cohort B: Pre-treated with CDK 4/6i + fulvestrant|Patients who received any CDK 4/6i plus fulvestrant as immediate prior treatment will receive alpelisib + letrozole
62325374|NCT03056755|EXPERIMENTAL|Cohort C: Pre-treated with systemic chemotherapy or ET|Participants who received systemic chemotherapy or endocrine therapy (ET) (as monotherapy or in combination with targeted treatment except CDK 4/6i + AI) as immediate prior treatment will receive alpelisib + fulvestrant.
62484206|NCT05740098|EXPERIMENTAL|Best practices, financial incentives, and NRT|Participants will receive the Five As, a referral to a quit line, financial incentives contingent on biochemically confirmed smoking abstinence, and nicotine replacement therapy (NRT) provided in the form of both nicotine patches and gum/lozenge for dual therapy.
62484207|NCT03140631|NO_INTERVENTION|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of \<200s or return to pre-procedural baseline prior to sheath removal.
62484208|NCT03140631|ACTIVE_COMPARATOR|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of \<200s or return to preprocedural baseline prior to removal of vascular sheaths.
62484209|NCT06080451|EXPERIMENTAL|HEARTS implementation - Patients|A trial for 6 months will be carried out in 11 Ministry of Health primary care facilities starting in October 2023. This arm consists of the patients whose health markers will be monitored through the study.
62484210|NCT06080451|EXPERIMENTAL|HEARTS implementation - Providers|A trial for 6 months will be carried out in 11 Ministry of Health primary care facilities starting in October 2023. This arm consists of the health care providers who will be administering care to the patient participants.
62692237|NCT06570720|EXPERIMENTAL|ASSIST|Participants in this arm will receive online survey assessments as well as the behavioral intervention, ASSIST.
62484211|NCT02012335|PLACEBO_COMPARATOR|ECT + saline|Brief pulse ECT with saline as placebo in each session
62484212|NCT02012335|EXPERIMENTAL|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
62484213|NCT02327559|EXPERIMENTAL|Mind in Labor (MIL)|Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.
62484214|NCT02327559|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment As Usual (TAU) refers to standard hospital- and community-based childbirth preparation courses (high quality childbirth education that excludes a mindfulness or mind/body stress reduction focus).
62484215|NCT03320863|ACTIVE_COMPARATOR|Active or Enso Group|Active Enso device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
62484216|NCT03320863|NO_INTERVENTION|Sham Group|Sham device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
62692238|NCT06570720|NO_INTERVENTION|Assessment-Only|Participants in this arm will only receive online survey assessments.
62692239|NCT03828526|EXPERIMENTAL|High Fidelity Simulation|"Students will be exposed to the intensive care setting where they will have to solve issues related to general nursing care, including the stages of the medication process that involve the nurses' performance and their complexity.~During the experience of the scenario will be provoked external factors, such as telephone ringing, visit of the professional of the infection commission, to evaluate the reactions of the student and the strategies adopted to minimize the occurrence of adverse events against such external factors.~Subsequently, they will participate in the debriefing, where they will be reflected on the positives and those that should be adjusted to promote safer nursing care related to drug administration."
62692240|NCT03828526|ACTIVE_COMPARATOR|Traditional teaching strategy|Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
62692241|NCT06596525|SHAM_COMPARATOR|Group 1: Conventional physical therapy (PT) + WBVTsh (sham)|"Group 1 will receive a sham WBVT in addition to conventional physical therapy. Over a period of 4 weeks, 3 days per week for 30 minutes each session, participants will engage in conventional physical therapy program."
61932517|NCT01532973|EXPERIMENTAL|GT1a HCV 50-mg Elbasvir (Panel J)|Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
62325375|NCT05153226|EXPERIMENTAL|Cyclophosphamide|Cyclophosphamide 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
62325376|NCT05153226|ACTIVE_COMPARATOR|ATG|ATG Grafalon 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
62325377|NCT06107413|EXPERIMENTAL|ABBV-400+Fluorouracil, Folinic Acid, and Bevacizumab (FFB) A|Participants will receive escalating ABBV-400 in combination with FFB on dose schedule A as part of the safety lead in, during the 3 year study duration.
62325378|NCT06107413|EXPERIMENTAL|ABBV-400+FFB B|Participants will receive escalating ABBV-400 in combination with FFB on dose schedule B as part of the safety lead in, during the 3 year study duration.
61932518|NCT06136312|EXPERIMENTAL|Multi4 procedure|Complete TURBT procedure performed in local anesthesia with Multi4 instrument via flexible cystoscopy
61932519|NCT05936970||Adults diagnosed with RA|Adults diagnosed with RA who are planning to initiate a new bDMARD +/- csDMARD or tsDMARD +/- csDMARD treatment
62325379|NCT06107413|EXPERIMENTAL|ABBV-400+FFB A Low|Participants will receive ABBV-400 in combination with FFB at the low dose determined in the safety lead in on dose schedule A as part of the dose optimization, during the 3 year study duration.
62325380|NCT06107413|EXPERIMENTAL|ABBV-400+FFB A High|Participants will receive ABBV-400 in combination with FFB at the high dose determined in the safety lead in on dose schedule A as part of the dose optimization, during the 3 year study duration.
61932520|NCT04211168|EXPERIMENTAL|Toripalimab Plus Lenvatinib|"Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
61932521|NCT06645132|EXPERIMENTAL|Reminders to exercise through cues provided by wearable device + custom smartphone application|"Each participant receives 2 wearable devices and custom smartphone application. Participants will wear an activity monitor on their non-dominant wrist and contralateral ankle. Post-transplant inpatient days \~3-10, participants will schedule three cued exercise sessions each day using the smartphone application. At the scheduled time, the wearable devices will vibrate to indicate time to exercise and participants are encouraged to complete an exercise task for 15 minutes. Post-transplant inpatient hospital days \~1-2 and post-transplant inpatient hospital days \~11 until discharge patients will wear the devices but will not receive any cues. During these days, the monitors will only be measuring their movement without any intervention."
62325381|NCT06107413|EXPERIMENTAL|ABBV-400+FFB B Low|Participants will receive ABBV-400 in combination with FFB at the low dose determined in the safety lead in on dose schedule B as part of the dose optimization , during the 3 year study duration.
61932522|NCT00488072|EXPERIMENTAL|Mirtazapine|Mirtazapine 15 mg by mouth (PO) daily for 15 days; Day 22-29, increased to 30 mg PO daily.
61932523|NCT00488072|PLACEBO_COMPARATOR|Placebo|One placebo tablet by mouth daily.
61932524|NCT06387537|ACTIVE_COMPARATOR|Group A (Conventional Physical Therapy )|"Patients in this group will receive conventional physical therapy including Hot pack for 10 to 15 minutes, ROM exercises such as Internal \& external rotation, Extension in standing, Pulley for elevation in sitting or standing, Forward flexion in supine using own head, pendulum (1min clockwise, 1 min anti clock wise),these are Low intensity, short duration, 1-5 sec, 2-3 times/day, pain free passive, AAROM.~GH mobilization: kaltenborn low grade mobilization (grade I or II) for (1 minute), Then mobilization with movement 3 sets of 10 reps with 1 minute rest in between will be given.Strengthening exercises include Isometric in all planes, 5 second holds, 1 set of 10 each direction, against wall. Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 weeks."
61932525|NCT06387537|EXPERIMENTAL|Group B (Conventional physical therapy and Scapular mobilization)|"Patients will receive scapular mobilization in addition to conventional physical therapy including Hot pack for 10 to 15 minutes , ROM exercises such as Internal \& external rotation, Extension in standing, Pulley for elevation in sitting or standing, Forward flexion in supine using own head, pendulum (1min clockwise, 1 min anti clock wise),these are Low intensity, short duration, 1-5 sec, 2-3 times/day, pain free passive, AAROM. GH mobilization: kaltenborn low grade mobilization (grade I or II) for (1 minute), Then mobilization with movement 3 sets of 10 reps with 1 minute rest in between will be given. Strengthening exercises include Isometric in all planes, 5 second holds, 1 set of 10 each direction, against wall.~Scapular Mobilizations Glides- superior, inferior, distraction, upward and downward rotation (5 sets, 10 reps, 30 sec break in 1 session).Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 consecutive weeks."
61932526|NCT05613803|ACTIVE_COMPARATOR|Fish oil|6g of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) in a 1.3:1 ratio; respectively, as six Omacor capsules, taken once daily, or in divided doses, with food.
61932527|NCT05613803|PLACEBO_COMPARATOR|Placebo|Matched capsules (six) containing palm olein IV 56 taken once daily, or in divided doses, with food.
61932528|NCT03767101|EXPERIMENTAL|TAU + Positive mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented positive mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a happy, positive situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities and feelings in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
61932529|NCT03767101|ACTIVE_COMPARATOR|TAU + Neutral mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented neutral mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a all-day, non-emotional provoking situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
62132944|NCT00774397|EXPERIMENTAL|240 mg QD TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment experienced (TE) patients
62132945|NCT00774397|EXPERIMENTAL|240 mg QD / LI-TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-experienced (TE) patients
62325382|NCT06107413|EXPERIMENTAL|ABBV-400+FFB B High|Participants will receive ABBV-400 in combination with FFB at the high dose determined in the safety lead in on dose schedule B as part of the dose optimization, during the 3 year study duration.
62325383|NCT06107413|EXPERIMENTAL|FFB+Irinotecan (Standard of Care [SOC])|Participants will receive SOC during the 3 year study duration.
62325384|NCT06450197|EXPERIMENTAL|AZD7798|AZD7798
62325385|NCT06450197|PLACEBO_COMPARATOR|Placebo|Placebo
62697542|NCT01661595|ACTIVE_COMPARATOR|Sildenafil / Placebo|50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
62697543|NCT01661595|ACTIVE_COMPARATOR|Tadalafil / Placebo|10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
62692242|NCT06596525|EXPERIMENTAL|Group 2: Conventional physical therapy (PT) + WBVTs (shod)|"Over a period of 4 weeks, in addition to conventional physical therapy program, the participants will engage in WBVT on commercially available ThinningPlate vibration platform, 3 days per week for 15 minutes each session. Group 2 will wear everyday sports shoes during WBVT."
61932530|NCT03767101|OTHER|Treatment as usual|In all conditions the first eight sessions of treatment are focused. No additional intervention is conducted at the start of therapy sessions. Standard cognitive behavioral therapy is conducted during the whole treatment sessions.
61932531|NCT05725668|EXPERIMENTAL|Dual-task taj ji quan|This intervention includes training of (a) symmetrical postural tai ji quan forms/movements synchronized with breathing, (b) controlled displacement (weight-shifting) of the body's center of mass over the base of support, (c) dynamic eye-hand movements during whole-body motion, (d) multidirectional (anterior-posterior and medial-lateral) stepping, and (e) rotational ankle sway and self-induced reactive postural recovery actions. The training practices are integrated, gradually over time, with a mix of interactive, cognitively stimulating, dual-task exercises that challenge attention control, working memory, verbalization, response inhibition, processing speed, dual tasking, task switching/prioritization, and spatial orientation and postural awareness.
61932532|NCT05725668|EXPERIMENTAL|Standard tai ji quan|This intervention includes training of tai ji quan forms with synchronized breathing, supplemented by a set of mini-therapeutic exercises. The training involves repeated practice of (a) symmetrical, coordinated, trunk-driven tai ji quan form movements, (b) controlled displacement (weight-shifting) of the body's center of mass over varying sizes of the base of support, (c) dynamic eye-hand movements during whole-body motion, and (d) multidirectional (anterior-posterior and medial-lateral) stepping. As a balance training therapy, movement practices emphasize a dynamic interplay of stabilizing and self-induced destabilizing postural actions and balance exercises that target mobility, stability limits, and sensory integration.
62132946|NCT00774397|EXPERIMENTAL|240 mg BID / LI-TE|240mg BI 201335 NA (Faldaprevir) twice daily combined with PegIFN/RBV for 24 or 48 weeks, with 3-day lead-in phase of PegIFN/RBV, in treatment-experienced patients
62325386|NCT00006150||Affected adults and children|Confirmed or suspected history of a Hyper IgE syndrome
62132947|NCT01798667|PLACEBO_COMPARATOR|Placebo|PO administration
62325387|NCT00006150||Relatives|Family members of subjects with confirmed or suspected history of a Hyper IgE syndrome
62325388|NCT00001405||Healthy Volunteers|Healthy Adult Volunteers
62325389|NCT00001405||Patients|Pts with PID or other blood disorder or clinical history consistent with PID or other blood disorder. Pts are able to volunteer as patient for research collection only per PI discretion.
62325390|NCT01661010||Control|Family members can serve as control group
62325391|NCT01661010||Sex-linked genes|Patients previously identified through outside research or diagnostic labs as having sex-chromosome variants causing deletion/duplication of sex-linked genes or entire sex chromosomes.
62325392|NCT06380751|EXPERIMENTAL|Arm 1: saruparib (AZD5305) plus camizestrant|participants will receive saruparib (AZD5305) orally and camizestrant orally
62325393|NCT06380751|ACTIVE_COMPARATOR|Arm 2: Physician's choice CDK4/6i plus physician's choice ET|"agents are indicated below and should follow local guidelines:~* Physician's Choice CDK4/6i:~  * abemaciclib orally, or~ * ribociclib orally, or~ * palbociclib orally.~* Physician's Choice ET:~  * fulvestrant intramuscularly, or~ * One of the following AIs:~    * letrozole orally, or~   * anastrozole orally, or~   * exemestane orally"
62325394|NCT06380751|EXPERIMENTAL|Arm 3: Physician's choice CDK4/6i plus camizestrant|participants will receive camizestrant orally. Agents for CDK4/6i treatment are indicated above and should follow local guidelines
62325395|NCT05411081|ACTIVE_COMPARATOR|Arm I (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI and blood and urine sample collection throughout the trial. Patients may also undergo bone scan throughout the trial.
62325396|NCT05411081|EXPERIMENTAL|Arm II (cabozantinib S-malate, atezolizumab)|Patients receive cabozantinib S-malate PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI and blood and urine sample collection throughout the trial. Patients may also undergo bone scan throughout the trial.
62325397|NCT06029114||Healthy Control Group|Subjects will have a magnetic resonance elastography (MRE) performed.
62325398|NCT06029114||Alzheimer's Disease Group|Subjects will have a magnetic resonance elastography (MRE) performed.
62132948|NCT01798667|EXPERIMENTAL|DA-8031 dose 1|PO administration
62132949|NCT01798667|EXPERIMENTAL|DA-8031 dose 2|PO administration
62132950|NCT01798667|EXPERIMENTAL|DA-8031 dose 3|PO administration
62132951|NCT02356341||NovaTears®|
62132952|NCT04554108|ACTIVE_COMPARATOR|Intravenous antibiotic treatment|Intravenous antibiotic treatment started during an initial hospitalization of 3 days, with continuation of oral antibiotic therapy at home for a total duration of antibiotic therapy of 3 weeks
62325399|NCT06029114||Mild Cognitive Impairment Group|Subjects will have a magnetic resonance elastography (MRE) performed.
62325400|NCT04443530||Coronary artery stenosis|Patients with coronary artery disease
62325401|NCT06305247|EXPERIMENTAL|Phase I (Dose Escalation with Backfilling)|Nine dose levels are planned to be tested.
62325402|NCT06305247|EXPERIMENTAL|Phase IIa (Cohort Expansion)|Study intervention will be administered at one of two doses of interest determined at the end of Phase I.
62692243|NCT06596525|EXPERIMENTAL|Group 3: Conventional physical therapy (PT) + WBVTb (barefoot)|"Over a period of 4 weeks, in addition to conventional physical therapy program, the participants will engage in WBVT on commercially available ThinningPlate vibration platform, 3 days per week for 15 minutes each session. Group 3 will be barefoot during WBVT."
62697544|NCT01661595|ACTIVE_COMPARATOR|Placebo / Sildenafil|Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
62325403|NCT04545866|EXPERIMENTAL|budesonide with surfactant|Infants randomized to the intervention arm receive a dose of surfactant (poractant alfa; Curosurf) mixed with budesonide (Pulmicort nebulizing suspension) within 50 hours of birth and administered via endotracheal tube.
62325404|NCT04545866|ACTIVE_COMPARATOR|surfactant alone|Infants randomized to the active control arm receive a dose of surfactant (poractant alfa; Curosurf).
62325405|NCT05641948||Low Back Pain|In this prospective observational study, patients with chronic low back pain, scheduled for possible treatment with radiofrequency denervation (RFD), will be recruited from the NHS Grampian pain clinic. In the clinical pathway, patients will undergo a diagnostic medial branch nerve block (MBB). The outcome of this test determines if they are suitable for RFD. For this study, patients will be recruited from the clinics before the MBB. They will have both clinical assessments of pain levels and quality of life and a brain scan at three time intervals - baseline before the diagnostic nerve block, after diagnostic nerve block and 3 months after RFD. The final eligibility for the study is confirmed after the diagnostic block.
62484217|NCT03913676|EXPERIMENTAL|Velibra|All treatment will be provided via the Velibra website: https://velibra.broca.io/en/registration/voucher. While the Velibra treatment is only six weeks long, participants will have free access to the program for 24 weeks. They can access this website as often as they would like. The Velibra program is self-guided, so participants determine how often they access the material (the program encourages participants to complete one of six sessions per week for six weeks).
62484218|NCT01608360|ACTIVE_COMPARATOR|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
62484219|NCT01608360|PLACEBO_COMPARATOR|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
62692244|NCT06638346|EXPERIMENTAL|[Part 1 of study]: Shortened FIFA 11+ Intervention Group|The intervention group will complete a shortened FIFA11+ pre-activation training, incorporating 5 exercises from FIFA11+. The program will be performed twice a week for 12 weeks. The program lasts approximately 7 minutes.
62692245|NCT06638346|ACTIVE_COMPARATOR|[Part 1 study]: Control Group (Standard warm-up)|The control group will engage in a Brazilian warm-up, lasting approximately 7 minutes, 2 times a week for 3 months. Brazilian warm-ups are typically performed the usual warm-up routine at Soccer Montréal. A standardized version of the warm-up will be given so that all participants in the control group will undergo the same program.
62692246|NCT00609349|OTHER|connective tissue disease|all patients suffer from a connective tissue disease representing a risk for the development of pulmonary hypertension
61932533|NCT05725668|EXPERIMENTAL|Stretching exercise|This active control intervention includes light activities that consist of breathing, stretching, and relaxation exercises. Each exercise session encompasses a variety of light and static stretches for joints and muscles, performed in a seated or standing position. Exercise involves the upper body (arms, neck, upper back, shoulder, back, and chest), lower extremities (quadriceps, hamstrings/calfs, and hips), and gentle and slow trunk rotations. Also included are intermittent light walking, deep abdominal breathing exercises that emphasize inhaling and exhaling to maximum capacity, and progressive relaxation of major muscle groups.
62132953|NCT04554108|EXPERIMENTAL|oral antibiotic treatment|Oral antibiotic treatment started in hospital then continued at home for a total duration of 3 weeks of antibiotic therapy
62132954|NCT05634382|EXPERIMENTAL|Intravenous thrombolysis bridging with endovascular thrombectomy|
62132955|NCT05634382|ACTIVE_COMPARATOR|Direct endovascular thrombectomy without intravenous thrombolysis|
62132956|NCT03577223|EXPERIMENTAL|Whole Eggs|
62325406|NCT05742802|EXPERIMENTAL|Tozorakimab Dose 1|Injection subcutaneously Tozorakimab via pre-filled syringe.
62325407|NCT05742802|EXPERIMENTAL|Tozorakimab Dose 2|Injection subcutaneously Tozorakimab via pre-filled syringe.
62325408|NCT05742802|PLACEBO_COMPARATOR|Placebo|Injection subcutaneously with equivalent volume to Tozorakimab via pre-filled syringe.
62325409|NCT04905069|NO_INTERVENTION|No-Spacer Control|Subjects will receive radiotherapy without the use of the SpaceOAR Vue.
62325410|NCT04905069|EXPERIMENTAL|SpaceOAR Vue|Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel.
62325411|NCT06309719|EXPERIMENTAL|Test|Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)
62325412|NCT06309719|ACTIVE_COMPARATOR|Control|Periodontal Access Flap (AF)
62325413|NCT05392946|EXPERIMENTAL|Treatment (iberdomide, bortezomib, dexamethasone, daratumumab)|"INDUCTION PHASE: Patients receive iberdomide PO QD on days 1-21, bortezomib SC on days, 1, 8, 15, and 22, and dexamethasone PO on days 1, 8, 15, 22. Patients also receive daratumumab SC on days 1, 8, 15, 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~CYCLES 13-36 CYCLES: Patients receive iberdomide PO QD on days 1-21. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity."
62132957|NCT03577223|ACTIVE_COMPARATOR|Egg White-Based Egg Substitute|
62484220|NCT02518360|EXPERIMENTAL|OSTEOPATHIC PROTOCOL|"Physiotherapist applies an osteopathic treatment in non-specific low back pain patients.~The experimental group is treated with osteopathy, three sessions (20 minutes/session) and a frequency one session/week. Osteopathic treatment osteopathic is a body adjustment protocol. This protocol adjusts the musculoskeletal disorders since neck to lower limbs in the experimental group. Before treatment, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry."
62132958|NCT03556449||Patients|High resolution ultrasound
62484221|NCT02518360|ACTIVE_COMPARATOR|Auto Stretching|The patients realizes stretching protocol: two stretching global postures once a week (10 minutes for each posture) for three weeks: the first is for the anterior muscular chain and the second posture to stretch the posterior muscle chain. Before three stretching, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry.
62484222|NCT00844922|EXPERIMENTAL|Org 34517|Org 34517 titrated to 900 mg daily for 2 weeks
62484223|NCT00844922|PLACEBO_COMPARATOR|Placebo|
62484224|NCT03261167|EXPERIMENTAL|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
62692247|NCT02759510|ACTIVE_COMPARATOR|phenylephrine|phenylejphrine (one bolus for 40 ug/ml)
62692248|NCT02759510|EXPERIMENTAL|norepinephrine|norepinephrine (one bolus for 2 ug/ml)
62692249|NCT01450631|ACTIVE_COMPARATOR|Standard Dressing|Standard-of-care includes coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™) consistent with the national standard for dressing Cesarean section incisions.
62484225|NCT03261167|ACTIVE_COMPARATOR|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
62484226|NCT03261167|EXPERIMENTAL|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
62325414|NCT03215030|EXPERIMENTAL|Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg|Modakafusp alfa 0.001 up to 14 milligram per kilogram (mg/kg), infusion, intravenously (IV), once every week (Q1W) on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by once on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by once on Day 1 of each 28-day treatment cycle until treatment discontinuation.
62484227|NCT04942535|EXPERIMENTAL|Social Incentive Gamification|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Incentive Gamification intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
62484228|NCT04942535|EXPERIMENTAL|Social Goals through Incentives to Charity|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Goals through Incentives to Charity intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
62325415|NCT03215030|EXPERIMENTAL|Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 2 weeks (Q2W) on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
62325416|NCT03215030|EXPERIMENTAL|Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
62484229|NCT04942535|ACTIVE_COMPARATOR|Control|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive Daily Performance Feedback during the 12 month intervention and 6 month follow up."
62692250|NCT01450631|EXPERIMENTAL|Prevena™ (PIMS)|PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period.
62692251|NCT03792737|EXPERIMENTAL|Investigational group 1|Investigational group 1: Use the study device Spiral PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and MONOCRYL Plus for continuous subcuticular suture.
62132959|NCT03556449||Healthy subjects|High resolution ultrasound
62325417|NCT03215030|EXPERIMENTAL|Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
62325418|NCT03215030|EXPERIMENTAL|Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg|Dose(s) for Phase 2 will be based on safety and tolerability results from the preceding Phase 1 dose escalation cohorts. Participants in Phase 2 cohorts will receive modakafusp alfa TBD as a single agent. Participants in at least 1 cohort will receive modakafusp alfa TBD and modakafusp alfa TBD and dexamethasone 40 mg, orally, once weekly of each 28-day treatment cycle until treatment discontinuation.
62325419|NCT03215030|EXPERIMENTAL|Part 3 (Dose Extension): Modakafusp alfa 120 mg|Participants will receive modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
62325420|NCT03215030|EXPERIMENTAL|Part 3 (Dose Extension): Modakafusp alfa 240 mg|Participants will receive modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
62325421|NCT06369285|EXPERIMENTAL|Alisertib 50 mg|Alisertib with selected endocrine therapy
62325422|NCT06369285|EXPERIMENTAL|Alisertib 40 mg|Alisertib with selected endocrine therapy
62325423|NCT06369285|EXPERIMENTAL|Alisertib 30 mg|Alisertib with selected endocrine therapy
62484230|NCT00815087|EXPERIMENTAL|Functional Electrical Stimulation (FES)|Functional electrical stimulation: Experimental
62484231|NCT00815087|ACTIVE_COMPARATOR|Home Rehabilitation Program (HRP)|Exercise home program
62692252|NCT03792737|EXPERIMENTAL|Investigational group 2|Investigational group 2: Use PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the study device Spiral MONOCRYL Plus for continuous subcuticular suture.
62692253|NCT03792737|ACTIVE_COMPARATOR|Control group|Control group: Use the control device PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the control device MONOCRYL Plus continuous subcuticular suture.
62692254|NCT04724252|ACTIVE_COMPARATOR|Gabapentin Treatment|Given at a dose of 10mg/kg (max 600mg) perioperatively (immediately prior to surgery) followed by 3mg/kg/dose TID with first dose to be given starting at 8 hours post perioperative dose.
62692255|NCT04724252|PLACEBO_COMPARATOR|Control Group|Given placebo which coincides with the active treatment group
62692256|NCT03657485|EXPERIMENTAL|interventional|In the interventional group we supplemented the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFbaby, IBSS Biomed SA, Poland) orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
62692257|NCT03657485|NO_INTERVENTION|control|No intervention. Feeding with mother milk
62692258|NCT03657485|NO_INTERVENTION|comperative|Comparing stool composition of vaginally born newborns
62692259|NCT06582732|EXPERIMENTAL|Cohort 1 (12-month exchange)|Travoprost Intracameral Implant Exchanged at Month 12
62132960|NCT04422236||Obese patients eligible for laparoscopic bariatric surgery|
62325424|NCT03538652|PLACEBO_COMPARATOR|EMA only|randomized control group undergoing mobile assessment without JITAI
62325425|NCT03538652|NO_INTERVENTION|Formative Interviews|First stage, before content of mobile intervention is finalized
62325426|NCT03538652|ACTIVE_COMPARATOR|JITAI|group receiving microrandomized active intervention: JITAI with both CBT and ACT
62484232|NCT03170219|EXPERIMENTAL|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
62692260|NCT06582732|EXPERIMENTAL|Cohort 2 (3-month exchange)|Travoprost Intracameral Implant Exchanged at Month 3
61932534|NCT05000697|EXPERIMENTAL|Arm 1 - 5FU + Oxaliplatin|1) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by mFOLFOX6 or XELOX for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
61932535|NCT05000697|ACTIVE_COMPARATOR|Arm 2 - 5FU Only|2) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by capecitabine 2000mg/m2/day for 14 days in a 21 days cycle for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
61932536|NCT02702063|OTHER|TTE vs. EC + calibration group|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial."
61932537|NCT02702063|OTHER|Right heart catheterisation|Twenty five patients undergoing routine right heart catheterization (RHC) at the department of cardiology for the evaluation of suspected pulmonary hypertension or heart failure will be included in this trial. EC measurements will be obtained during RHC, and a TTE (for measuring LVOT-area) will be performed immediately before undergoing RHC. Inclusion and exclusion criteria are similar as described above.
61932538|NCT02702063|OTHER|Passive leg raising test|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial.~SV and CO will be measured using TTE and EC. Patient's legs will then be raised by 45degree, and SV and CO measurements will be repeated after 1 minute. Changes in SV and CO observed with both methods will be compared."
61932539|NCT02860455|OTHER|SpCO and COHb measurement|"SpCO measurement (Experimental) : Non invasive pulse CO-oximetry will be carried out in all patients simultaneously with venous blood sampling for standard laboratory blood gas analysis, at time of prehospital management by emergency medical services~COHb measurement (Active comparator) : Blood carboxyhemoglobin testing will be carried out in all patients"
61932540|NCT05398263|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection, in an accessorised pre-filled syringe.
61932541|NCT05398263|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection, in an accessorised pre-filled syringe.
61932542|NCT05417243|EXPERIMENTAL|Advanced Trauma Life Support (ATLS)|Training in ATLS for residents providing trauma care.
61932543|NCT05417243|EXPERIMENTAL|Primary Trauma Care (PTC)|Training in PTC for residents providing trauma care.
61932544|NCT05417243|NO_INTERVENTION|Standard Care|Trauma care according to the current standard with no intervention.
61932545|NCT01163266|PLACEBO_COMPARATOR|Placebo|Placebo-matching capsules, orally, once daily for up to 8 weeks.
61932546|NCT01163266|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
61932547|NCT01163266|EXPERIMENTAL|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
61932548|NCT01266577|OTHER|One Arm|Subjects receive the same scan
61932549|NCT01434485||Nexium|
61932550|NCT03528694|EXPERIMENTAL|Durvalumab plus BCG (induction + maintenance)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
61932551|NCT03528694|EXPERIMENTAL|Durvalumab plus BCG (induction only)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
61932552|NCT03528694|ACTIVE_COMPARATOR|BCG treatment (Standard of care therapy)|Bacillus Calmette-Guerrin (BCG) standard of care treatment
61932553|NCT05647096|EXPERIMENTAL|NucleoCapture Treatment|Participants in the NucleoCapture treatment arm will receive Standard of Care plus three treatment sessions with the NucleoCapture treatment device. The device consists of 100ml NucleoCapture selective adsorber.
61932554|NCT05647096|NO_INTERVENTION|Standard of Care|Participants in the Standard of Care arm will receive standard medical care alone.
61932555|NCT01483768|EXPERIMENTAL|Arm A:|Sleeve gastrectomy for morbid obesity
61932556|NCT06707740||Group 1 AcrySof IQ(SN6AT) implantation after cataract surgery.|
62692261|NCT06582732|EXPERIMENTAL|Cohort 3 (6-month exchange)|Travoprost Intracameral Implant Exchanged at Month 6
62692262|NCT06582732|EXPERIMENTAL|Cohort 4 (24-month exchange)|Travoprost Intracameral Implant Exchanged at Month 24
62692263|NCT06582732|EXPERIMENTAL|Cohort 5 (21-month exchange)|Travoprost Intracameral Implant Exchanged at Month 21
61932557|NCT06707740||Group 2TECNIS（ZCU） implantation after cataract surgery.|
61932558|NCT05396157||Patients with an active hematological malignancy admitted to ICU|"All patients 18 years and older admitted to an adult intensive care unit during the current admission episode and that also had an active HM / HCT diagnosis.~We plan to the analyze patients outcomes according to:~1. Thrombocytopenia We will analyze bleeding and thrombosis risk taking into account platelets levels.~2. Patients receiving thromboprophylaxis (VTE vs Bleeding)"
61932559|NCT05265052|EXPERIMENTAL|3D1002 50 mg group (Phase IIa)|3D1002 is given 50 mg twice a day for 2 weeks.
61932560|NCT05265052|EXPERIMENTAL|3D1002 100 mg group (Phase IIa)|3D1002 is given 100 mg twice a day for 2 weeks.
61932561|NCT05265052|EXPERIMENTAL|3D1002 150 mg group (Phase IIa)|3D1002 is given 150 mg twice a day for 2 weeks.
61932562|NCT05265052|EXPERIMENTAL|3D1002 monotherapy group (Phase IIb)|3D1002 at recommended dose plus mimic OxyContin tables, will be given twice a day for 2 weeks.
62325427|NCT03394066|EXPERIMENTAL|TMS|All participants will receive TMS to investigate acute modulations of brain activity by TMS
62325428|NCT04519619||Aflibercept (Eylea, BAY86-5321)|Decision of Eylea treatment is made by attending investigators according to the Japanese Package Insert
62692264|NCT06582732|EXPERIMENTAL|Cohort 6 (18-month exchange)|Travoprost Intracameral Implant Exchanged at Month 18
61932563|NCT05265052|EXPERIMENTAL|OxyContin monotherapy group (Phase IIb)|OxyContin initiating at 10mg per dose plus mimic 3D1002 tablets, will be given twice a day for 2 weeks.
61932564|NCT05265052|EXPERIMENTAL|3D1002 + OxyContin group (Phase IIb)|3D1002 at recommended dose plus OxyContin initiating at 10 mg per dose, will be given twice a day for 2 weeks.
61932565|NCT05323110|EXPERIMENTAL|Part A - Cohort 1A|Single dose cohort
61932566|NCT05323110|EXPERIMENTAL|Part A - Cohort 2A|Single dose cohort
61932567|NCT05323110|EXPERIMENTAL|Part A - Cohort 3A|Single dose cohort
61932568|NCT05323110|EXPERIMENTAL|Part A - Cohort 4A|Single dose cohort
61932569|NCT05323110|EXPERIMENTAL|Part A - Cohort 5A|Single dose cohort
61932570|NCT05323110|EXPERIMENTAL|Part A - Cohort 6A|Single dose cohort
61932571|NCT05323110|EXPERIMENTAL|Part A - Cohort 7A|Single dose cohort
61932572|NCT05323110|EXPERIMENTAL|Part A - Cohort 8A|Single dose cohort
61932573|NCT05323110|EXPERIMENTAL|Part B - Cohort 1B|Multiple dose cohort
61932574|NCT05323110|EXPERIMENTAL|Part B - Cohort 2B|Multiple dose cohort
62132961|NCT05607823|EXPERIMENTAL|CST Group|The core stabilization group. Participants in this group will be received core stabilization training, orofacial manuel therapy and conventional physiotherapy (Home exercise program and patient education) as treatment. The number of participants is planned to be 15.
62132962|NCT05607823|EXPERIMENTAL|OMT Group|The orofacial manuel therapy group. Participants in this group will be received orofacial manuel therapy and conventional physiotherapy (Home exercise program and patient education) as treatment. The number of participants is planned to be 15.
62132963|NCT05607823|EXPERIMENTAL|Control Group|Participants in this group will be received only conventional physiotherapy (Home exercise program and patient education) as treatment. The number of participants is planned to be 15.
62132964|NCT03285542|ACTIVE_COMPARATOR|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
62132965|NCT03285542|PLACEBO_COMPARATOR|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
62132966|NCT02695264|EXPERIMENTAL|HS-1000 recording|ICP readings will be recorded from both the invasive and HeadSense non-invasive ICP monitor for an aggregate of 30 minutes. During the recording sessions, a webcam will take periodic snapshots of the ICP monitor and/or bedside monitor picturing the ICP values and other clinical parameters that are displayed on screen, with a focus on blood pressure and heart rate (HR). Recording sessions will be done until an aggregate of at least 30 minutes of data are collected, depending on the patient's clinical condition. Recording sessions may be repeated over several days until the 30 minute target is reached.
62325429|NCT03802799|EXPERIMENTAL|ZYN002|ZYN002 - cannabidiol Transdermal Gel
62325430|NCT05672576|EXPERIMENTAL|Cenerimod 4 mg|Participants will receive cenerimod once daily in addition to background SLE therapy.
62325431|NCT05672576|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo once daily in addition to background SLE therapy.
62325432|NCT06456463|EXPERIMENTAL|Part 1 - Tagraxofusp (9 μg/kg/day)|Participants will receive tagraxofusp in combination with venetoclax and azacitidine.
62325433|NCT06456463|EXPERIMENTAL|Part 1 - Tagraxofusp (12 μg/kg/day)|Participants will receive tagraxofusp in combination with venetoclax and azacitidine.
62325434|NCT06456463|EXPERIMENTAL|Part 2 - Tagraxofusp (Selected Dose) and TP53 Wild Type|Participants (TP53 wild type) will receive tagraxofusp in combination with venetoclax and azacitidine.
62325435|NCT06456463|EXPERIMENTAL|Part 2 - Tagraxofusp (Selected Dose) and TP53 Mutated|Participants (TP53 mutated) will receive tagraxofusp in combination with venetoclax and azacitidine.
61932575|NCT05323110|EXPERIMENTAL|Part A - Cohort 3B|Multiple dose cohort
61932576|NCT05726591|EXPERIMENTAL|Group A|12 weeks-study intervention
61932577|NCT05726591|NO_INTERVENTION|Group B|12 weeks the control first.
61932578|NCT05590624|EXPERIMENTAL|Mediterranean-type Diet(s)-Arm 1|Diet randomization occurs two weeks prior to the Standard of Care (SOC) diagnostic biopsy. If patient is randomized to Arm 1, they will receive Low Fat (LF) Mediterranean Diet first. The results of the diagnostic biopsy determines how the patient will proceed on the trial. If there is a confirmed Prostate Cancer (PCa) diagnosis AND is a candidate for Active Surveillance (AS) per SOC, then patient will undergo a washout period and cross-over to the Lower Carbohydrate (LC) Mediterranean Diet two weeks prior to the SOC confirmatory biopsy. A long-term follow-up (LTFU) visit will occur 3 months after the second dietary intervention has concluded. If patient does not have PCa or is not placed on AS, then they will only have the first dietary intervention and a LTFU visit 3 months after
61932579|NCT05590624|EXPERIMENTAL|Mediterranean-type Diet(s)-Arm 2|Diet randomization occurs two weeks prior to the Standard of Care (SOC) diagnostic biopsy. If patient is randomized to Arm 2, they will receive Lower Carbohydrate (LC) Mediterranean Diet first. The results of the diagnostic biopsy determines how the patient will proceed on the trial. If there is a confirmed Prostate Cancer (PCa) diagnosis AND is a candidate for Active Surveillance (AS) per SOC, then patient will undergo a washout period and cross-over to the Low Fat (LF) Mediterranean Diet two weeks prior to the SOC confirmatory biopsy. A long-term follow-up (LTFU) visit will occur 3 months after the second dietary intervention has concluded. If patient does not have PCa or is not placed on AS, then they will only have the first dietary intervention and a LTFU visit 3 months after.
61932580|NCT05389423|EXPERIMENTAL|1/Dose Escalation|Pomalidomide (escalating doses) + Prednisone, Etoposide, Doxorubicin, Vincristin
61932581|NCT05389423|EXPERIMENTAL|2/Dose Expansion|Pomalidomide (at the MTD) + Prednisone, Etoposide, Doxorubicin, Vincristine and
62484233|NCT03170219|NO_INTERVENTION|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
61932582|NCT06451029||face-to-face interviews|The group that will carry out the psychological counselling in the presence will have 6 meetings (spread over 6 months) with a psychologist at the anti-smoking center in the hospital and a final phone call 12 months after the first meeting to verify the maintenance of abstinence.
62484234|NCT03419403|EXPERIMENTAL|Standard Steroids|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days
62484235|NCT03419403|EXPERIMENTAL|Standard Steroids + Vasoconstrictor + Cold Compress|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).
62484236|NCT03419403|EXPERIMENTAL|Enhanced Steroids + Vasoconstrictor + Cold Compress|Enhanced steroid eye drops: 1 drop each eye, 6 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Ophthalmic Steroid Ointment; applied to each eye once daily before sleep, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. Cold compress was to be applied in increments no longer than 30 min (could be shorter if the patient is uncomfortable).
62484237|NCT06626802|EXPERIMENTAL|Group A: Mitomycin|Patients in Group A will be treated with esophageal dilation with a CRE balloon. After adequate dilation of stricture, injection Mitomycin will be applied to the narrowest portion of the stricture. It will be applied in a dose of 1ml (0.4mg/ml); after dividing in to four aliquots, each aliquot will be applied to to one of the four quadrants.
62325436|NCT03997968|EXPERIMENTAL|CYT-0851 dose escalation|Part A: CYT-0851 administered orally in rising doses QD or BID for 28 day cycles
62325437|NCT03997968|EXPERIMENTAL|CYT-0851 dose expansion|Part B: CYT-0851 administered orally at the selected Phase 2 dose for 28 day cycles
62325438|NCT03997968|EXPERIMENTAL|CYT-0851 and rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab on Day 1 and bendamustine on Days 1 and 2 of each 28 day cycle
62325439|NCT03997968|EXPERIMENTAL|CYT-0851 and gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine on Day 1, 8 and 15 of each 28 day cycle
62325440|NCT03997968|EXPERIMENTAL|CYT-0851 and capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine on Days to 14 of each 21 day cycle
62484238|NCT06626802|EXPERIMENTAL|Group B: Triamcinolone|Patients in Group B will be treated with esophageal dilation with a CRE balloon. After adequate dilation of stricture, Triamcinolone injection will be injected into the narrowest portion of the stricture, using a sclerotherapy injector. Injection triamcinolone will be used in a dose of 1ml (40mg/ml). It will be divided in to four aliquots; each aliquot will be injected in to each of the four quadrants.
62692265|NCT06582732|EXPERIMENTAL|Cohort 7 (15-month exchange)|Travoprost Intracameral Implant Exchanged at Month 15
62692266|NCT04211948|EXPERIMENTAL|robotic pancreatectomy|robotic pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
62692267|NCT04211948|ACTIVE_COMPARATOR|open surgery|open pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
62692268|NCT05715762||Ventilation in supine position|Patients are ventilated in supine position.
61932583|NCT06451029||video interviews|The group that will be followed in remote mode will carry out the same number of interviews as the group described above and a 12-months call will also be made to them to check the state of abstinence.
61932584|NCT06707181|ACTIVE_COMPARATOR|Group A|Group A treated by silodosin 8mg.
62325441|NCT05543252|EXPERIMENTAL|Minzasolmin (UCB0599) High Dose Arm|Participants will receive a predefined high dosage of minzasolmin (UCB0599) during the Treatment Period.
62325442|NCT05543252|EXPERIMENTAL|Minzasolmin (UCB0599) Low Dose Arm|Participants will receive a predefined low dosage of minzasolmin (UCB0599) during the Treatment Period.
62325443|NCT06419634|EXPERIMENTAL|Part 1: Dose Escalation BMS-986497|
62325444|NCT06419634|EXPERIMENTAL|Part 2: Dose Expansion BMS-986497|
62325445|NCT05537740|EXPERIMENTAL|Dose escalation - Arm 1A|Dose escalation of BAY3375968 as monotherapy
62325446|NCT05537740|EXPERIMENTAL|Dose escalation - Arm 1B|Dose escalation of BAY 3375968 in combination with pembrolizumab
62325447|NCT05537740|EXPERIMENTAL|Dose expansion - Arm 2A|BAY3375968 monotherapy-mode-of-action (monotherapy-MoA) expansion in subjects with one of the following tumor types: NSCLC, TNBC, HNSCC, or melanoma. The tumors should have primary (ICI-refractory) or secondary (ICI-relapsed) resistance to prior ICI-therapy. The final decision on the enrolled tumor type is at the discretion of the Sponsor.
61932585|NCT06707181|ACTIVE_COMPARATOR|Group B|Group B treated by a tamsulosin 0.4 mg .
62325448|NCT05537740|EXPERIMENTAL|Dose expansion - Arm 2B|Disease-specific combination expansion with separate cohorts in ICI-relapsed tumor types (NSCLC, TNBC, HNSCC, gastric cancer, or melanoma)
62484239|NCT05271890|EXPERIMENTAL|Immediate periodontal treatment|Subjects assigned to this group were receiving non-surgical periodontal treatment as well as oral hygiene instructions immediately after their inclusion. All subjects were undergone full periodontal and rheumatologic clinical examinations both at baseline and 90 days after the completion of the treatment. Blood collection for the analysis of the serum concentration of CRP, ESR, Fibrinogen, IL-6 and TNF-α was also performed at baseline and 90 days after periodontal treatment.
62484240|NCT05271890|NO_INTERVENTION|Delayed periodontal treatment|Subjects assigned to this group were receiving non-surgical periodontal treatment 90 days after baseline evaluation. All subjects were undergone full periodontal and rheumatologic clinical examinations both at baseline and 90 days after. Blood collection for the analysis of the serum concentration of CRP, ESR, Fibrinogen, IL-6 and TNF-α was also performed at baseline and 90 days after.
62484241|NCT03822754|EXPERIMENTAL|Experimental Group|sIPV-bOPV-bOPV vaccination schedule
62484242|NCT03822754|ACTIVE_COMPARATOR|Control Group|wIPV-bOPV-bOPV vaccination schedule
61932586|NCT06707181|ACTIVE_COMPARATOR|Group C|Group C was treated with a combination of silodosin 8 mg and tadalafil 5 mg .
61932587|NCT06707181|ACTIVE_COMPARATOR|Group D|Group D treated by a combination of tamsulosin 0.4 mg and tadalafil 5 mg.
61932588|NCT06084078||Telehealth cohort|Individuals who opt to do the screening using telehealth. Telehealth using video assisted techniques or using telephone.
61932589|NCT06084078||In-person cohort|Individuals who are willing to travel to the hospital for in-person screening and follow-up
61932590|NCT06104527|OTHER|1.3 g/kg/day followed by 2.0 g/kg/day|Patients in this arm will, on their first test day, receive enteral nutrition containing 1.3 grams of protein per kg of body weight per day followed by 2.0 grams of protein per kg of body weight per day on their second test day.
61932591|NCT06104527|OTHER|2.0 g/kg/day followed by 1.3 g/kg/day|Patients in this arm will, on their first test day, receive enteral nutrition containing 2.0 grams of protein per kg of body weight per day followed by 1.3 grams of protein per kg of body weight per day on their second test day.
62325449|NCT00787423||COHORT 1|Individuals from 18 to 75 years of age who are current heroin users seeking treatment for addiction and who spend most of their time in Baltimore city.
61932592|NCT01678027|PLACEBO_COMPARATOR|Placebo|Placebo for LAC triple therapy
61932593|NCT01678027|ACTIVE_COMPARATOR|LAC triple therapy|PPI (Lansoprazole), Clarithromycin, Amoxicilline
61932594|NCT06705062|EXPERIMENTAL|Reduced dose of post-transplantation cyclophosphamide|study group
62325450|NCT03837821|EXPERIMENTAL|All Subjects|Abemaciclib 200 mg oral, every 12 hours
62325451|NCT04252573|EXPERIMENTAL|ChEVAS System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
61932595|NCT06705062|ACTIVE_COMPARATOR|Standard-dose PTCy|Patients receiving standard dose of post-transplantation cyclophosphamide
62325452|NCT06205095|EXPERIMENTAL|pdVWF:FVIII concentrate (Wilate®) Treatment and Standard Care|Wilate® at a dose of 30-60 IU VWF:RCo/kg for the two anticipated heaviest days of bleeding every 24-48 hours within the first 4 days of menstruation will be provided. Additional two optional doses 24-48 hours from the last can be provided. A minimum of 2 doses must be provided.
62325453|NCT06205095|PLACEBO_COMPARATOR|Placebo and Standard Care|Patients randomized to the placebo arm will receive intravenous placebo (normal saline) at the same approximate volume and frequency as the study drug.
62325454|NCT04529044|EXPERIMENTAL|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30-40 minutes during weeks 1, 8, 16, and 24 in the absence of disease progression or unacceptable toxicity. Patients also receive Ga 68-DOTATATE and undergo PET/CT during screening, biopsy as clinically-indicated as well as CT and/or MRI and collection of blood samples throughout the study.
62325455|NCT01276470||Antisynthetase Negative|Subjects with myositis without antisynthetase syndrome
62325456|NCT01276470||Antisynthetase Positive|Subject with myositis with antisynthetase syndrome
62325457|NCT01276470||Healthy Control|Subjects without autoimmune disease
62325458|NCT03485729|EXPERIMENTAL|Arm A|Patients received 625 mg dordaviprone (ONC201) once weekly on Days 1, 8, and 15 of each 3-week cycle. Patients were required to undergo a biopsy of their tumor one day after their second dose of dordaviprone (ONC201) on Cycle 1, Day 9.
62325459|NCT03485729|EXPERIMENTAL|Arm B|Patients received 625 mg dordaviprone (ONC201) once weekly on Days 1, 8, and 15 of each 3-week cycle. Patients were not required to undergo a biopsy of their tumor.
62484243|NCT00343681|EXPERIMENTAL|1|
62484244|NCT02727725|EXPERIMENTAL|Traminer MRI Sequence|The TRAMINER MRI sequence implementation to be tested allows the acquisition of high resolution MR images in the free-breathing patient, by combining multiple averages and motion correction with the TRAMINER preparation.
62692269|NCT05715762||Ventilation in supine position and NO inhalation|Patients are ventilated in supine position with NO inhalation for 1 hour.
61932596|NCT02016430|EXPERIMENTAL|MeLT Dietary intervention|Mediterranean Low-TMAO (MeLT) diet. Used in cohorts 1, 2 and 3.
61932597|NCT02016430|EXPERIMENTAL|TLC Dietary intervention|Therapeutic Lifestyle Changes (TLC) diet. Used in cohorts 1, 2 and 3.
61932598|NCT02016430|EXPERIMENTAL|MeLT dietary intervention with TMAO|Mediterranean Low TMAO diet with TMAO levels reported. Used in cohort 1 only.
61932599|NCT06695312|OTHER|study group|the study group received the selected exercise program in addition to High Tone Power Therapy
61932600|NCT06695312|OTHER|control group|therapeutic ultrasound, Static neck exercise,
61932601|NCT05691907|EXPERIMENTAL|Directional Preference Exercises|Directional Preference Exercises will be provided, also known as Mckenzie's extension exercises
61932602|NCT05691907|EXPERIMENTAL|Motor Control Exercises|Motor Control Exercises consisting of extension bias external limb loading protocol.
62132967|NCT02639637|OTHER|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
62132968|NCT02639637|OTHER|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
62484245|NCT00720395||1|Women with bipolar disorder who are preconception or pregnant. Primary focus on predictors of postpartum bipolar disorder relapse and burden of illness through first six months postpartum
62132969|NCT02639637|PLACEBO_COMPARATOR|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
62132970|NCT02639637|PLACEBO_COMPARATOR|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
62325460|NCT03485729|EXPERIMENTAL|Arm C|Patients received 625 mg dordaviprone (ONC201) twice weekly on consecutive days on Days 1, 2, 8, 9, 15, and 16 of each 3-week cycle. Patients were required to undergo a biopsy of their tumor one day after their fourth dose of dordaviprone (ONC201) on Cycle 1, Day 10.
62325461|NCT06163482||Healthy controls|No cystic fibrosis (CF)
62325462|NCT06163482||Pancreatic sufficient CF|cystic fibrosis, but not pancreatic insufficient
62325463|NCT06163482||Pancreatic insufficient CF|cystic fibrosis and pancreatic insufficient
62484246|NCT05360394|ACTIVE_COMPARATOR|PCB Only|Cephalic arch stenosis is first treated with conventional plain balloon angioplasty. Once treated adequately (\<30% residual stenosis), CAS will be treated with PCB angioplasty.
62132971|NCT06363149||Septic shock|Adult ICU patients having septic shock as defined by Sepsis -3 definition requiring vasopressor for at least 12 hours duration will be considered for inclusion in this observational study..
62132972|NCT03908775|ACTIVE_COMPARATOR|Group VL|C-MAC Videolaryngoscope Patients intubated with C-MAC Videolaryngoscope
62132973|NCT03908775|ACTIVE_COMPARATOR|Group DL|Direct Laryngoscope Patients intubated with Direct laryngoscope
62325464|NCT06163482||CF-related diabetes|cystic fibrosis and diabetes
62325465|NCT04251806||Prenatal Repair|This group received prenatal myelomeningocele repair.
62325466|NCT04251806||Postnatal Repair|This group received postnatal myelomeningocele repair.
62325467|NCT00887939||1|Affected physical urticaria
62325468|NCT00887939||2|Healthy volunteer
62484247|NCT05360394|EXPERIMENTAL|Stent Graft and PCB angioplasty of stent edges|CAS is first treated with conventional plain balloon angioplasty. Once treated adequately (\<30% residual stenosis), CAS will be treated with PCB first to avoid geographical miss. After which, stent graft will be deployed. Length of PCB shall be long enough to cover stent edges.
62484248|NCT03049215|ACTIVE_COMPARATOR|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
62484249|NCT03049215|ACTIVE_COMPARATOR|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
62484250|NCT01745679|EXPERIMENTAL|Ceftriaxone treatment|ceftriaxone will be administered à high dose : \> or equal to 75mg/kg/day or 4 gr/day
62692270|NCT05715762||Ventilation in prone position for 1 hour|Patients are ventilated in prone position for 1 hour.
62132974|NCT06349655||Azvudine|COVID-19 patients with Azvudine treatment
62132975|NCT06349655||Paxlovid|COVID-19 patients with Paxlovid treatment
62132976|NCT06349655||Control|COVID-19 Patients who have not been treated with Azvudine or Paxlovid
62132977|NCT05564611|EXPERIMENTAL|ADL-018|150 mg single dose Lyophilized vial
62132978|NCT05564611|ACTIVE_COMPARATOR|US-Licensed XOLAIR|150 mg single dose Lyophilized vial
62132979|NCT06178588|EXPERIMENTAL|Treatment (Sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy, PET/CT or MRI scans, and blood sample collection throughout the study.
62325469|NCT00887939||3|Unaffected relative
62325470|NCT05614089|EXPERIMENTAL|Glargine|Insulin glargine (long-acting insulin analogue)
62325471|NCT05614089|ACTIVE_COMPARATOR|NPH or premixed 70/30 (human insulin)|NPH or premixed 70/30 (human insulin)
62325472|NCT04126018||Mitral Valve Regurgitation|Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam.
62325473|NCT04126018||Aortic Valve Regurgitation|Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam.
62325474|NCT04126018||Aortic Stenosis|Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam.
62325475|NCT04126018||Patients referred for CRT Implantation|Patients who meet clinical guideline criteria for CRT implantation with EF \< 40%
62325476|NCT05085366|EXPERIMENTAL|mRNA-1647|Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 1, Day 57, and Day 169.
62325477|NCT05085366|PLACEBO_COMPARATOR|Placebo|Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 1, Day 57, and Day 169.
62325478|NCT05733598|EXPERIMENTAL|RP2+Bevacizumab and Atezolizumab|Patients with locally advanced unresectable, recurrent and/or metastatic HCC who have progressed on 1 prior systemic treatment, which must have included anti-programmed cell death 1 (PD-1)/anti-PD-L1 therapy. Patients will receive atezolizumab plus bevacizumab therapy combined with RP2.
62484251|NCT03302832|ACTIVE_COMPARATOR|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
62484252|NCT03302832|EXPERIMENTAL|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
62484253|NCT01269658|EXPERIMENTAL|Azithromycin ophthalmic solution, 1%|
62484254|NCT01269658|PLACEBO_COMPARATOR|Vehicle|
62484255|NCT01406353|ACTIVE_COMPARATOR|Early Percutaneous Mitral Intervention|early elective percutaneous mitral commissurotomy within 3 months of enrollment
62484256|NCT01406353|NO_INTERVENTION|Conventional Treatment|All patients in the conventional treatment group regularly visit their attending physicians at 3 monthly interval for maintenance of anticoagulation therapy or every year for annual re-evaluation. Patients who become symptomatic during follow-up are referred for percutaneous mitral commissurotomy or mitral valve surgery.
62484257|NCT00551863|ACTIVE_COMPARATOR|IVPT|Intervention based on Motivational Interviewing and CBT
62484258|NCT06627777|OTHER|Emotion regulation observation in early adolescence|All children will experience brief standardized laboratory tasks according to the same protocol.
62484259|NCT01497587|EXPERIMENTAL|Insulin detemir|
62484260|NCT02939703|ACTIVE_COMPARATOR|Control Western diet|Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
61932603|NCT06709040||Participants with Growth Hormone Deficieny|The study is non-interventional as there are no interventions involved and decision to treat participants with commerically available somapacitan will be made at the treating physician's discretion prior to, and independently from, the decision to include the participants in the GLoBE-Reg registry. Novo Nordisk will not provide any products for included participants during the conduct of the study.
61932604|NCT06161610|EXPERIMENTAL|LITT|LITT+potential other treatment
61932605|NCT06161610|ACTIVE_COMPARATOR|Control|Best medical management under guidelines
61932606|NCT06710730||Health care professionals working at Department of Cardiothoracic surgery|Longitudinal 3-year study. Data collection 2024 - 2026
61932607|NCT04932512|EXPERIMENTAL|ION224|Multiple doses of ION224 will be administered by SC injection once every 4 weeks for up to 49 weeks.
62325479|NCT04395001|EXPERIMENTAL|behavioral intervention, nurse support plus medication|Subjects randomized to this arm will receive duloxetine, web-based Cognitive Behavioral Therapy (CBT) and nurse support.
61932608|NCT04932512|PLACEBO_COMPARATOR|Placebo|Multiple doses of matching placebo will be administered by SC injection once every 4 weeks for up to 49 weeks.
61932609|NCT06680934||CABP2 participant group|Individuals with hearing impairment who have a molecular genetic diagnosis involving CABP2
61932610|NCT06706791|EXPERIMENTAL|experimental arm, Palcebo controlled group|Experimental arm, taking empagliflozin 10mg once daily along with standard treatment.
61932611|NCT06706791|PLACEBO_COMPARATOR|Palcebo controlled group|Palcebo controlled group patient receiving placebo to compare with empagliflozin along with standard treatment.
61932612|NCT05182125|EXPERIMENTAL|Part A, Group 1: AdC6-HIVgp140|Participants will receive 1 x 10\^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
61932613|NCT05182125|EXPERIMENTAL|Part A, Group 2: AdC7-HIVgp140|Participants will receive 1 x 10\^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
62325480|NCT04395001|EXPERIMENTAL|behavioral intervention plus medication|Subjects randomized to this arm will receive duloxetine and web-based Cognitive Behavioral Therapy (CBT).
62325481|NCT04395001|ACTIVE_COMPARATOR|medication only|Subjects randomized to this arm will receive duloxetine only.
62325482|NCT05970640|EXPERIMENTAL|BI 3006337 dose group 1 or placebo|
62325483|NCT05970640|EXPERIMENTAL|BI 3006337 dose group 2 or placebo|
62325484|NCT05970640|EXPERIMENTAL|BI 3006337 dose group 3 or placebo|
62325485|NCT05970640|EXPERIMENTAL|BI 3006337 dose group 4|
62325486|NCT05882058|EXPERIMENTAL|Dose group 1|
62325487|NCT05882058|EXPERIMENTAL|Dose group 2|
62325488|NCT05007782|EXPERIMENTAL|Part A - Denikitug Dose Escalation|
62325489|NCT05007782|EXPERIMENTAL|Part B - Mandatory Paired Tumor Biopsy|
62325490|NCT05007782|EXPERIMENTAL|Part C: Denikitug + Zimberelimab Dose Escalation|
62325491|NCT05007782|EXPERIMENTAL|Part D: Denikitug + Zimberelimab Dose Expansion|
62325492|NCT05007782|EXPERIMENTAL|Part E: Denikitug Monotherapy Dose Expansion|
62325493|NCT05007782|EXPERIMENTAL|Part F: Denikitug Monotherapy and In Combination With Zimberelimab In Select Dose and Schedule|
62325494|NCT06448286|ACTIVE_COMPARATOR|Group I (standard of care surgical resection)|Patients undergo surgical resection with standard intraoperative guidance using contrast-enhanced MRI. Patients also undergo post operative standard of care radiation therapy over 30 fractions and receive standard of care temozolomide PO for 6 weeks. Additionally, patients undergo MRI during follow up.
62325495|NCT06448286|EXPERIMENTAL|Group II (CEST MRI based surgical resection)|Patients undergo surgical resection with intraoperative guidance using CEST MRI. Patients also undergo post operative standard of care radiation therapy over 30 fractions and receive standard of care temozolomide PO for 6 weeks. Additionally, patients undergo MRI during follow up.
62325496|NCT03603600|EXPERIMENTAL|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
62325497|NCT03603600|ACTIVE_COMPARATOR|enVista MX60E|enVista MX60E monofocal IOL
62325498|NCT04725006||Stimulation in individuals with implanted stimulation systems|During psychophysical stimulation trials, an external stimulator will be connected to the SCS lead, a volley of stimulation will be performed, and the subject will be asked to respond to standard psychophysical questions, as well as to provide any additional comments.
62484261|NCT02939703|EXPERIMENTAL|Microbiome Enhancer diet|Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
62325499|NCT04463576||Experimental|A total of 5 676 hospital discharge prescriptions, defined as the list of medications prescribed at discharge from hospital or after a hospital visit, whether new or renewed, will be selected.
62325500|NCT06442423|OTHER|Open-label|Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.
62325501|NCT04923178||1 / Urothelial cancer|Participants with urothelial cancer.
62325502|NCT04923178||2 / Rare Bladder or Urinary Tract Histology|Participants with small cell carcinoma, adenocarcinoma, urachal squamous cell carcinoma, or pure sarcomatoid carcinoma. These pure histologies can occur in the bladder and/or urinary tract.
62325503|NCT04923178||3 / Urothelial Carcinoma Variants|Participants diagnosed with a urothelial variant histologies at any stage.
62325504|NCT04923178||4 / Rare GU Tumors|Participants with renal medullary carcinoma, testicular Sertoli or Leydig cell tumors, penile cancer, refractory germ cell tumors.
62325505|NCT04706663||Cohort 1|Subjects with histologically confirmed prostate cancer and genomic testing results
62325506|NCT04706663||Cohort 2|Subjects with histologically confirmed prostate cancer who deemed to be an exceptional responder with or without genomic testing results
62325507|NCT05603143|EXPERIMENTAL|Obeldesivir|Participants will receive obeldesivir 350 mg orally twice daily for 5 days.
62325508|NCT05603143|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo-to-match obeldesivir orally twice daily for 5 days.
62325509|NCT03639753|EXPERIMENTAL|Parent-Teen Intervention|Parent health coaching session and supportive materials, teen on road driver assessment with feedback.
61932614|NCT05182125|PLACEBO_COMPARATOR|Part A, Group 3: Placebo|Participants will receive placebo for AdC6-HIVgp140 or AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
62325510|NCT03639753|OTHER|Usual Practice|
62325511|NCT01550575||Patients eligible for SCS, RF or other treatment approaches|Patients who have previously been implanted with, or are eligible for implantation with a spinal cord stimulation system or various other treatment approaches such as RF, IDS, etc.
61932615|NCT05182125|EXPERIMENTAL|Part B, Group 4: AdC6-HIVgp140 + AdC7-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10\^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10\^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
61932616|NCT05182125|EXPERIMENTAL|Part B, Group 5: AdC7-HIVgp140 + AdC6-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10\^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10\^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
61932617|NCT05182125|PLACEBO_COMPARATOR|Part B, Group 6: Placebo + Placebo + Placebo|Participants will receive placebo for AdC6-HIVgp140and AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0 and 3. Placebo for CH505TF/GLA-SE (labeled as Sodium Chloride for Injection, 0.9% ) to be administered as 1 mL IM injection into either thigh at month 6.
62325512|NCT01550575||Patients Eligible for treatment options with prior treatment|Patients who have previously been implanted with a spinal cord stimulation system or other various treatments, and have thereafter received a different form of chronic pain treatment such as a different SCS system, RF, IDS etc.
62325513|NCT05569174|EXPERIMENTAL|secukinumab|AIN457 300 mg subcutaneously (s.c.) for 12 weeks
62325514|NCT05569174|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneously for 12 weeks
62325515|NCT06654739|SHAM_COMPARATOR|Treatment arm 1|Sham laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol
62325516|NCT06654739|ACTIVE_COMPARATOR|Treatment arm 2|Laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol
62325517|NCT06550024|EXPERIMENTAL|Genicular Artery Embolization (GAE)|Temporary Embolization of Genicular Arteries using Resorbable Microspheres
62692271|NCT05715762||Ventilation in prone position for 2 hours plus NO inhalation for 1 hour|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour.
62325518|NCT06550024|ACTIVE_COMPARATOR|Corticosteroid Injection|Corticosteroid injection in the knee
62325519|NCT06654713||Commercial AID system|Pregnant individuals with type 1 diabetes (T1D) using commercially available automated insulin delivery (AID) systems for glycemic management in pregnancy
62325520|NCT06654713||Open source AID system|Pregnant individuals with type 1 diabetes T1D) using open source automated insulin delivery (AID) systems (also known as do-it-yourself AID systems or hacked AID systems) for glycemic management in pregnancy
62325521|NCT05070403|EXPERIMENTAL|Afatinib Intervention|Participants will receive afatinib 40 mg once a day. Each cycle is 4 weeks. They will have CT imaging (and/or digital photography) done at baseline and every 8 weeks while on treatment. Participants will have a baseline and on-treatment (at 4 weeks) tumor biopsy, and a biopsy at disease progression if feasible. Patients may remain on treatment as long as they are deriving clinical benefit, until disease progression or intolerable toxicity.
62325522|NCT04711252|EXPERIMENTAL|AZD9833 + palbociclib|The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (1 mg, PO, once daily)
62325523|NCT04711252|ACTIVE_COMPARATOR|Anastrozole + palbociclib|The patients will recieve Anastrozole (1 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)
62484262|NCT03965598||Ultra-high risk for psychosis (UHP)|"Ultra-high risk for psychosis (UHP) is defined as individuals at the prodromal stage of schizophrenia.~Inclusion Criteria: age of 13-30 years; meet the diagnostic criteria of COPS prodromal syndrome by SIPS clinical interviews; have not received any psychiatric medication; be in good health, without major mental illness or physical illness; normal intelligence, can be operated on a clinical scale; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: exclusion of current or previous psychiatric disorders by SCID interview; meet the diagnostic criteria for substance abuse and substance dependence in DSM-IV; contraindications for MRI; pregnant or lactating women."
61932618|NCT05298306|EXPERIMENTAL|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion on separate days at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, LAT8881 will be given as a single intravenous infusion. The dose will be determined from the results of Part A."
61932619|NCT05298306|PLACEBO_COMPARATOR|Placebo|Matching placebo will be given as a single intravenous infusion in Part A and Part B
61932620|NCT05959200|OTHER|LID226397, then AOfAHP|Serafilcon A toric contact lenses worn in Period 1, with senofilcon A toric contact lenses worn in Period 2. Each product will be worn bilaterally (in both eyes) during waking hours for approximately 14 days. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
61932621|NCT05959200|OTHER|AOfAHP, then LID226397|Senofilcon A toric contact lenses worn in Period 1, with serafilcon A toric contact lenses worn in Period 2. Each product will be worn bilaterally (in both eyes) during waking hours for approximately 14 days. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
61932622|NCT01798680|EXPERIMENTAL|Vitamin D3 (cholecalciferol)|
61932623|NCT01798680|PLACEBO_COMPARATOR|Placebo|
61932624|NCT03301506|EXPERIMENTAL|Seladelpar 5 mg Capsules|
61932625|NCT03301506|EXPERIMENTAL|Seladelpar 10 mg Capsule|
61932626|NCT05227144|EXPERIMENTAL|Dose Escalation|ORIC-533 dosed orally, once per day of each consecutive 28-day cycle.
62325524|NCT06590610|EXPERIMENTAL|electrotherapy|All the selected 20 healthy subjects will undergo the radial pressure waves treatment on one leg at the Gastrocnemius, left or right leg as per randomization. Afterwards each patient will undergo NMES electrostimulation treatment on the opposite leg at the Gastrocnemius.
62325525|NCT05649748|EXPERIMENTAL|Treprostinil Palmitil Inhalation Powder (TPIP)|"Participants who are not transitioning immediately from other TPIP studies:INS1009-201(NCT04791514), INS1009-202(NCT05147805) and other lead-in studies, will be given TPIP, once daily (QD), starting with 80 micrograms (μg), up-titrated to highest tolerated dose between 80 μg and 640 μg during 3-week titration period that maybe increased upto maximum dose of 1280 μg QD post initial titration, per investigator's assessment. Overall treatment period=24 months.~Participants transitioning immediately from randomized blinded lead-in TPIP study and who previously received:~1. TPIP- will be given placebo QD(80 μg upto achieved TPIP dose from previous study)along with achieved TPIP dose from previous study in blinded manner during 3-week titration period.~2. Placebo- will be given TPIP QD (80 μg up to achieved placebo dose from previous study)along with achieved placebo dose from previous study in blinded manner during 3-week titration period.Overall treatment period=24 months."
62325526|NCT06655415||Individuals who have a parent, sibling, or child with IBD but who do not have IBD themselves|Adult and adolescent (greater than 14 years of age) first-degree relatives (parents, siblings, or children) of patients with inflammatory bowel disease (including Crohn's disease, ulcerative colitis, or inflammatory bowel disease-unclassified/indeterminate colitis) but who do not have inflammatory bowel disease themselves.
62325527|NCT04928287|ACTIVE_COMPARATOR|HB-adMSCs|Autologous Hope Biosciences adipose derived mesenchymal stem cells.
62325528|NCT04928287|PLACEBO_COMPARATOR|Placebo|Sterile Saline Solution 0.9%
62325529|NCT06592248|EXPERIMENTAL|CocKnee|Implementation of CocKnee
62325530|NCT06658912|OTHER|TOPS Classes|
62325531|NCT04991324|EXPERIMENTAL|weekly supplementation|Weekly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 3500 IU per day, as comedication to the usual treatment during 6 months.
62325532|NCT04991324|ACTIVE_COMPARATOR|monthly supplementation|Monthly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 800 IU per day, as comedication to the usual treatment during 6 months.
62325533|NCT04991324|NO_INTERVENTION|control group|Usual treatment without vitamin D supplementation.
62692272|NCT05715762||Ventilation in prone position for 3 hours|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 1 hour.
62692273|NCT05715762||Ventilation in prone position for 16 hours|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 14 hours.
62692274|NCT05715762||Ventilation in re-supine position for 3 hours|Patients are ventilated in supine position for 3 hours followed by ventilation in prone position for 16 hours.
61932627|NCT05227144|EXPERIMENTAL|Dose Expansion|RP2D dose
61932628|NCT05147428|EXPERIMENTAL|Patient-Provider|Both patients and providers will receive educational materials on inappropriate prescribing and deprescribing.
61932629|NCT05147428|EXPERIMENTAL|Provider Only|Only providers will receive educational materials on inappropriate prescribing and deprescribing.
61932630|NCT05147428|NO_INTERVENTION|Usual Care|
61932631|NCT03730012|EXPERIMENTAL|Gilteritinib 120 mg + Atezolizumab 420 mg|Participants received 120 milligrams (mg) giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 420 mg adminstered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab).
61932632|NCT03730012|EXPERIMENTAL|Gilteritinib 120 mg + Atezolizumab 840 mg|Participants received 120 mg giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 840 mg administered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 126 days for gilteritinib and 70 days for atezolizumab).
62325534|NCT06600711|EXPERIMENTAL|Nitazoxanide|
62484263|NCT03965598||Healthy controls|"Inclusion Criteria: the gender, age, and education level of the group are matched with the Ultra-high risk group; 13 to 30 years old; right-handed; no history of mental illness; no mental disorder consistent with DSM-IV diagnostic criteria within two or three generations; No contraindications for MRI; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: history of disturbance of consciousness over 5 minutes; history of brain organic disease or head injury; history of alcohol and drug dependence; history of coma; history of endocrine disease; abnormity in examination of blood, heart, liver, or renal function; pregnant or lactating women."
62484264|NCT05314257|ACTIVE_COMPARATOR|Group G|IV granisetron 1mg
62484265|NCT05314257|PLACEBO_COMPARATOR|Group C|IV 5ml of 0.9% normal saline
62484266|NCT01032863||Young healthy Indian adults|Persons aged between 25 and 40 years of age who are relatives of patients being treated in Amrita Institute of Medical Sciences (Inpatient or Outpatient) and voluntary blood donors at the same institute who are willing to participate in the study.
62484267|NCT00274781|EXPERIMENTAL|ATO + GO|Arsenic Trioxide 0.25 mg/kg D1-5 Week 1/Twice Weekly W2-12 + Gemtuzumab Ozogamicin 3 mg/m\^2 D8 for 1 or 2 Cycles of 12 Weeks each
62484268|NCT00840398|EXPERIMENTAL|1|
62325535|NCT06600711|PLACEBO_COMPARATOR|Placebo|
62325536|NCT06662019|EXPERIMENTAL|Dosing arm|
62484269|NCT00840398|ACTIVE_COMPARATOR|2|
62484270|NCT06562504|EXPERIMENTAL|Anodal group|In the anodal group, the anode was placed over the left DLPFC (F3), and the cathode was placed over the contralateral supraorbital area (FP2). A direct current of 2mA was applied for 20 minutes during each stimulation session.
61932633|NCT04180722|EXPERIMENTAL|Intervention|Participants will receive multi-component Virtual Transition Intervention facilitated through the aTouchAway™ platform including the usual care provided by specialist HMV programs.
62325537|NCT06662019|PLACEBO_COMPARATOR|Control|Nebulized treatment consisting of 0.9% saline solution.
62325538|NCT05856227|EXPERIMENTAL|Treatment Arm: Ceftobiprole|Ceftobiprole medocaril: 7.5 mg/kg to 15 mg/kg
62325539|NCT04889066|ACTIVE_COMPARATOR|Durvalumab and standard fSRT|Fractionated stereotactic radiotherapy (fSRT) will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 fractions total, delivered every other day (\~2 times/week) with first cycle of Durvalumab.
62325540|NCT04889066|EXPERIMENTAL|Durvalumab and PULSAR|"Personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR), will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 pulses of radiation total, delivered one pulse monthly with each cycle of Durvalumab."
62325541|NCT05132296|EXPERIMENTAL|GROUP I (CLIP)|Patients undergo 60 minute sessions of nutrition education for 12 weeks and behavioral intervention 26 weeks. Patients receive FitBit and undergo physical activity for 30-60 minutes 5 days a week (aerobic activity) and 2 days a week (resistance training).
62325542|NCT05132296|ACTIVE_COMPARATOR|GROUP II (usual care)|Patients have access to all usual care supportive services.
62325543|NCT04005339|EXPERIMENTAL|Single Arm|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.
62484271|NCT06562504|SHAM_COMPARATOR|Sham group|In the sham group, the stimulation parameters, including the stimulation site and duration, were identical to those of the anodal group. However, during the 10-second ramp-up and ramp-down periods before and after stimulation, patients were unaware that the current was turned off.
62484272|NCT06562504|EXPERIMENTAL|tACS group|In the transcranial alternating current stimulation (tACS) group, the anode was placed in the left DLPFC (F3) and the cathode was placed in the contralateral supraorbital region (FP2). A direct current of 1.5 mA was applied for 20 minutes during each stimulation, theta rhythm, 6 HZ.
62484273|NCT03546738|EXPERIMENTAL|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
62484274|NCT03546738|SHAM_COMPARATOR|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
62484275|NCT00789308|ACTIVE_COMPARATOR|Standard of Care|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) without LMW-DS
62692275|NCT06463730|EXPERIMENTAL|Self-paced first, non-custom first|Order of interventions: self-paced non-custom games, self-paced custom games, game-paced non-custom games, game-paced custom games
62484276|NCT00789308|EXPERIMENTAL|LMW-DS|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) and LMW-DS
62484277|NCT05241639||group 1|of RA in the remission state
62484278|NCT05241639||group 2|of RA in the active state
61932634|NCT04180722|NO_INTERVENTION|Control|Usual care will be delivered in accordance with the Canadian Thoracic Society (CTS) clinical practice guidelines and includes scheduled face-to-face clinic visits with the ventilator team with the ventilator team within the first month of starting HMV and then every 3, 6, or 12 months depending on medical stability with additional telephone calls/email contact for equipment trouble shooting and management of intercurrent illnesses as needed.
61932635|NCT05942859||Retrospective Cohort|Patients who have previously been seen by the local Pulmonary Hypertension service, between 2007 and June 2023, for a suspected diagnosis of pulmonary hypertension, and undergone Right Heart Catheterisation (RHC) will be invited to participate in the study by a member of the direct clinical care team. Their ECG will be analysed using AI technology to develop an algorithm to aid the diagnosis of PH.
62325544|NCT06614192|EXPERIMENTAL|Stage 1: ABBV-400 Dose A|Participants will receive ABBV-400 dose A, as part of the approximately 4 year study duration.
62325545|NCT06614192|EXPERIMENTAL|Stage 1: ABBV-400 Dose B|Participants will receive ABBV-400 dose B, as part of the approximately 4 year study duration.
62325546|NCT06614192|EXPERIMENTAL|Stage 2: ABBV-400 Optimal Dose|Participants will receive the optimal dose of ABBV-400, as part of the approximately 4 year study duration.
62325547|NCT06614192|EXPERIMENTAL|Stage 2: Standard of Care (SOC)|Participants will receive the SOC, as part of the approximately 4 year study duration.
62325548|NCT00923221||1/Participant samples|Blood samples from participants with diagnosed prostate cancer
62325549|NCT06667453|EXPERIMENTAL|PGN-EDODM1|Participants will be randomized to receive ascending doses of PGN-EDODM1, once every 4 weeks (Q4W) for 12 weeks
62325550|NCT06667453|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive doses of saline (0.9% NaCl), once every 4 weeks (Q4W) for 12 weeks
62325551|NCT04466865|EXPERIMENTAL|Best Case/Worst Case communication tool|The participant's enrolled nephrologist will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the participant.
62325552|NCT04466865|NO_INTERVENTION|Usual Care|"Usual care conversations are typically focused on mode and timing of dialysis, management of electrolytes and scheduling of laboratory testing. Conservative management or a treatment option of no dialysis is rarely mentioned."
62325553|NCT06376695|PLACEBO_COMPARATOR|Placebo Control 1.1|GI Health Product Form 1 - control
62325554|NCT06376695|EXPERIMENTAL|Active Product 1.1|GI Health Product Form 1 - active product 1
62484279|NCT05241639||Group 3|120 eyes of healthy controls.
62484280|NCT00624286|EXPERIMENTAL|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62484281|NCT00624286|PLACEBO_COMPARATOR|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
61932636|NCT05942859||Prospective Cohort|Patients who are referred to the local PH service, from July 2023, with a suspected diagnosis of pulmonary hypertension, and undergo Right Heart Catheterisation will be invited to participate in the study by a member of the direct clinical care team. Their ECG will be analysed using AI technology to develop an algorithm to aid the diagnosis of PH.
61932637|NCT05560204|ACTIVE_COMPARATOR|Watchman Flx|Watchman Flx device to be used for LAAO
61932638|NCT05560204|ACTIVE_COMPARATOR|Amulet|Amulet device to be used for LAAO
61932639|NCT01587352|EXPERIMENTAL|Treatment (vorinostat)|Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62325555|NCT06376695|PLACEBO_COMPARATOR|Placebo Control 2|GI Health Product Form 2 - control
62325556|NCT06376695|EXPERIMENTAL|Active Product 2.1|GI Health Product Form 2 - active product 1
62325557|NCT06376695|PLACEBO_COMPARATOR|Placebo Control 3|GI Health Product Form 3 - control
62325558|NCT06376695|EXPERIMENTAL|Active Product 3.1|GI Health Product Form 3 - active product 1
62325559|NCT06376695|PLACEBO_COMPARATOR|Placebo Control 4|GI Health Product Form 4 - control
62484282|NCT02440607|EXPERIMENTAL|Electronic aid|The dynamic aid will consist of a centralized electronic aid embedded within a simulated EMR.
62325560|NCT06376695|EXPERIMENTAL|Active Product 4.1|GI Health Product Form 4 - active product 1
62325561|NCT06376695|PLACEBO_COMPARATOR|Placebo Control 5|GI Health Product Form 5 - control
62325562|NCT06376695|EXPERIMENTAL|Active Product 5.1|GI Health Product Form 5 - active product 1
62484283|NCT02440607|ACTIVE_COMPARATOR|Static Cognitive aid|The static aid represents the standard algorithm put forth by a leading clinical care organization.
62484284|NCT06624735|ACTIVE_COMPARATOR|cases group|Children aged 4-12 years Confirmed diagnosed as asthma
62484285|NCT06624735|ACTIVE_COMPARATOR|control group|Children below age of 4 years and aboveage of 12 years . not Diagnosed with any other chronic medical conditions
62484286|NCT03649763|ACTIVE_COMPARATOR|Lidocaine distal forearm|Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
62484287|NCT03649763|ACTIVE_COMPARATOR|Bupivacaine distal forearm|Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
62697545|NCT01661595|ACTIVE_COMPARATOR|Placebo / Tadalafil|Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
62325563|NCT06376695|PLACEBO_COMPARATOR|Placebo Control 7.1.0|GI Health Product Form 7.1- control
62325564|NCT06376695|EXPERIMENTAL|Active Product 7.1.1|GI Health Product Form 7.1 - active product 1
62325565|NCT00026650||1/Cohort 1|Patients who have received radiotherapy in the ROB and may or may not be officially entered on a clinical protocol.
61932640|NCT04870034|EXPERIMENTAL|Treatment (palbociclib, binimetinib)|Patients receive palbociclib PO QD and binimetinib PO BID for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week after last dose of study medication, patients undergo surgery.
61932641|NCT00430430|EXPERIMENTAL|High MUFA|high monounsaturated fat background diet to portfolio diet
62325566|NCT02619838||Aptus CCS 5.0 or/and 7.0 screws|Procedure/Surgery: Subtalar, Double or Triple Arthrodesis of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint of the foot with the Aptus CCS 5.0 or/and 7.0 screws
62484288|NCT03649763|ACTIVE_COMPARATOR|Lidocaine distal and proximal forearm|Lidocaine 1%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Lidocaine 1%. Volume injected is 3 mL/nerve; 12 mL total
62484289|NCT03649763|ACTIVE_COMPARATOR|Bupivacaine distal and proximal forearm|Bupivacaine 0.5%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Bupivacaine 0.5 %. Volume injected is 3 mL/nerve; 12 mL total.
62692276|NCT06463730|EXPERIMENTAL|Self-paced first, custom first|Order of interventions: self-paced custom games, self-paced non-custom games, game-paced custom games, game-paced non-custom games
62692277|NCT06463730|EXPERIMENTAL|Game-paced first, non-custom first|Order of interventions: game-paced non-custom games, gam-paced custom games, self-paced non-custom games, self-paced custom games
62692278|NCT06463730|EXPERIMENTAL|Game-paced first, custom first|Order of interventions: game-paced custom games, game-paced non-custom games, self-paced custom games, self-paced non-custom games
62692279|NCT04246749|EXPERIMENTAL|Part A: [14C]-CRN00808 Oral Solution|Single oral dose of CRN00808 containing \[14C\]-CRN00808
62692280|NCT04246749|EXPERIMENTAL|Part B: CRN00808 Oral Capsule w/ [14C]-CRN00808 IV microtracer|Single oral dose of CRN00808 followed by \[14C\]-CRN00808 IV microtracer injection
61932642|NCT00430430|ACTIVE_COMPARATOR|Low MUFA|low monounsaturated fat background diet to portfolio diet
61932643|NCT02484690|ACTIVE_COMPARATOR|Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
62692281|NCT03213951||Prostate cancer|Gleason grade group 1-5 on prostate biopsy or prostate cancer recurrence.
61932644|NCT02484690|EXPERIMENTAL|Arm B: Faricimab, 1.5 mg Q4W|Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
61932645|NCT02484690|EXPERIMENTAL|Arm C: Faricimab, 6 mg Q4W|Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
61932646|NCT02484690|EXPERIMENTAL|Arm D: Faricimab, 6 mg Every 4-8 weeks|Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
61932647|NCT02484690|EXPERIMENTAL|Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
61932648|NCT03191240|EXPERIMENTAL|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
61932649|NCT03191240|PLACEBO_COMPARATOR|Normal saline|Additional normal saline intravenous injection for 2 times
61932650|NCT03605927|EXPERIMENTAL|Combination Therapy|"BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.~Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care."
61932651|NCT06190951|ACTIVE_COMPARATOR|cemiplimab|Phase 2 Randomized 1:1:1
61932652|NCT06190951|EXPERIMENTAL|cemiplimab+fianlimab HD|Phase 2 fianlimab HD Randomized 1:1:1 Phase 3 fianlimab ((if HD chosen for phase 3) Randomized 1:1
61932653|NCT06190951|EXPERIMENTAL|cemiplimab+fianlimab LD|Phase 2 fianlimab LD Randomized 1:1:1 Phase 3 fianlimab (if LD chosen for Phase 3) Randomized 1:1
61932654|NCT06190951|ACTIVE_COMPARATOR|pembrolizumab|Phase 3 Randomized 1:1
61932655|NCT03274687|ACTIVE_COMPARATOR|Conventional radiation therapy|Conventional post-prostatectomy radiation therapy (COPORT) over 7 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
62692282|NCT04783571|EXPERIMENTAL|Schizophrenia|Adult outpatients with a diagnosis of schizophrenia.
62325567|NCT04159610|EXPERIMENTAL|WO 3970|Formulation containing WO 3970 for topical application
62325568|NCT04159610|ACTIVE_COMPARATOR|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
62325569|NCT05387551|EXPERIMENTAL|CGM intervention|Continuous glucose monitoring with real-time glucose data using Dexcom G6.
62325570|NCT03957681|EXPERIMENTAL|KHK4827|
62325571|NCT03957681|PLACEBO_COMPARATOR|Placebo|
62325572|NCT05836324|EXPERIMENTAL|Part 1a - Dose Escalation|INCA33890 will be administered at a protocol defined starting regimen intravenously. Subsequent dose regimens will be determined during study conduct.
62692283|NCT04783571|EXPERIMENTAL|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use.
62692284|NCT03713411|NO_INTERVENTION|No-catheter|after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones, patients in whom a urethral catheter wasn't placed
62692285|NCT03713411|ACTIVE_COMPARATOR|Catheter|urethral catheter placement after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones
62692286|NCT06643624|ACTIVE_COMPARATOR|Control Group|The athletes in the control group continued their routine training program. no vision training program was applied to the athletes in this group.
61932656|NCT03274687|EXPERIMENTAL|Hypofractionated radiation therapy|Hypofractionated post-prostatectomy radiation therapy (HYPORT) over 5 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
61932657|NCT01843595|EXPERIMENTAL|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
61932658|NCT01843595|NO_INTERVENTION|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
61932659|NCT06378125|EXPERIMENTAL|healthy subjects healthy subjects|single-ascending and multipleascending doses (SAD/MAD)
62484290|NCT05277896|ACTIVE_COMPARATOR|Ketamine Group|Patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
62325573|NCT05836324|EXPERIMENTAL|Part 1b-Dose Expansion|INCA33890 will be administered at the recommended dose(s) for expansion (RDE\[s\]) in participants with advanced or metastatic ICI sensitive or ICI non sensitive tumor types
62692287|NCT06643624|EXPERIMENTAL|Vision Training Group|In addition to their routine training program, the athletes in the vision training group were subjected to a vision training program administered by a physiotherapist, which gradually increased in duration over 8 weeks.
62132980|NCT04336436|EXPERIMENTAL|Mindfulness Training and Nutrition Counseling|"Baseline and 3-6 month follow up visits will be arranged for all participants.~Visits will be conducted at baseline prior to initiation of mindfulness training and nutrition counseling, and at the 3-6 month follow up. Clinical and laboratory assessments will be obtained at each visit."
62325574|NCT04543201|EXPERIMENTAL|Early STructured Advanced care Referrals by Telehealth|"Early START visit using checklist over telephone or zoom:~A telehealth visit conducted within 4 months of patient diagnosis, with the goal of encouraging patients to discuss and document their end-of-life wishes prior to the onset of cognitive impediments common among patients with late-stage high grade glioma."
62325575|NCT06360094|PLACEBO_COMPARATOR|Phase IIa/IIb, IPF cohort: Placebo|
62325576|NCT06360094|EXPERIMENTAL|Phase IIa/IIb, IPF cohort: BI 1839100 low dose|
62325577|NCT06360094|EXPERIMENTAL|Phase IIa/IIb, IPF cohort: BI 1839100 medium dose|
62132981|NCT03118323||Patients in need of endodontic treatment|n = 200
62325578|NCT06360094|EXPERIMENTAL|Phase IIa/IIb, IPF cohort: BI 1839100 high dose|
62325579|NCT06360094|PLACEBO_COMPARATOR|Phase IIb, PPF cohort: Placebo|
62325580|NCT06360094|EXPERIMENTAL|Phase IIb, PPF cohort: BI 1839100 high dose|
62325581|NCT03995979|EXPERIMENTAL|Protein Restriction Group|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided.
62325582|NCT01251900||Patients|Hispanic women, over the age of 18, with breast cancer will be eligible.
62325583|NCT01191853||Healthy volunteers|Healthy volunteers will have blood drawn before and after seasonal flu vaccination
62325584|NCT05561842||Participants with a solid mass on breast ultrasound|Participants will have a solid mass on breast ultrasound that is suspicious for breast cancer.
62325585|NCT03298178||all aortic stenosis|
62325586|NCT06479135|EXPERIMENTAL|Arm 1|Navtemadlin administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
62325587|NCT06479135|ACTIVE_COMPARATOR|Arm 2|Navtemadlin placebo administered orally once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles. Ruxolitinib administered orally twice a day.
62692288|NCT05187650|EXPERIMENTAL|Ekso and FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton combined with gait-synchronized FES using the FES RehaMove2.
62132982|NCT04386772|EXPERIMENTAL|PVE with coils plus TAGM|PVE with coils proximally plus TAGM distally and subsequent major hepatectomy
62132983|NCT04386772|ACTIVE_COMPARATOR|PVE with multiple coils|PVE with multiple coils and subsequent major hepatectomy
62325588|NCT06453213|EXPERIMENTAL|Cenobamate|All enrolled subjects will automatically participate in the Cenobamate arm since this is a single-arm study.
62325589|NCT06589674||General Anesthesia Group|This group includes all study patients who underwent elective lumbar spine surgery under general anesthesia. In these patients, both PVI and DSI measurements will be performed before and during anesthesia induction.
62132984|NCT02776475|OTHER|Sacral neuromodulation device turned off|Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.
62132985|NCT05680649|EXPERIMENTAL|Intervention|Breathing exercise
62325590|NCT01660984||Parents/caregivers|Parents or caregivers of study patients to assess their psychosocial experiences and needs.
62325591|NCT01660984||Patients|Children and adults with MTC and MEN2B, other non-tumor manifestations of MEN2, and patients with MEN2 who do not demonstrate MTC. Characterize the biology and manifestations of their disease.
62484291|NCT05277896|ACTIVE_COMPARATOR|Etomidate Group|Patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
62132986|NCT05680649|NO_INTERVENTION|Control|Standard practice
62484292|NCT05668689|OTHER|Preliminary testing (Phase 3)|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants.
62484293|NCT05668689|OTHER|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained).
62484294|NCT06223139||COPD|COPD patients aged 40 years or older with a post-bronchodilator ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) \<0.7.
62692289|NCT05187650|ACTIVE_COMPARATOR|Ekso without FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton without applying FES.
62692290|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
62692291|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (\~2010) to 2013
62692292|NCT05535972|EXPERIMENTAL|Participants receiving TRELEGY ELLIPTA|Participants will receive FF/UMEC/VI, inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) for 12 weeks.
62132987|NCT04992585|EXPERIMENTAL|PTBD with primary metal stent implantation|PTBD with primary metal stent implantation is performed in the same session as a one step-procedure
62132988|NCT04992585|ACTIVE_COMPARATOR|PTBD with secondary metal stent implantation|PTBD with secondary metal stent implantation is performed as a two step-procedure with metal stent implantation 3 to 7 days after previous percutaneous transhepatic biliary drainage and insertion of a plastic catheter
62132989|NCT02462759|EXPERIMENTAL|Nusinersen|Administered by intrathecal injection.
62132990|NCT02462759|SHAM_COMPARATOR|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
62132991|NCT02586090|ACTIVE_COMPARATOR|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
62325592|NCT02520609||Healthy volunteers|Healthy volunteers
62325593|NCT02520609||Patients with metabolic syndrome without NAFLD|Patients with metabolic syndrome without NAFLD
62325594|NCT02520609||Patients with NAFLD|Patients with NAFLD
62325595|NCT06307665|EXPERIMENTAL|Budesonide/albuterol metered -dose inhaler (BDA MDI)|Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed.
62325596|NCT06307665|ACTIVE_COMPARATOR|Albuterol sulfate metered-dose inhaler (AS MDI)|Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed.
62325597|NCT05819398|EXPERIMENTAL|Part I: Low dose group|
62692293|NCT05129735|EXPERIMENTAL|Meal replacement shake|Teatis meal replacement shake
62692294|NCT05544409|EXPERIMENTAL|MAKv1|The MAKv1 group will receive 1 hour of MAKv1 rehabilitation, thrice per week during 1 month
62325598|NCT05819398|EXPERIMENTAL|Part I: Medium dose group|
62325599|NCT05819398|EXPERIMENTAL|Part I: High dose group|
61932660|NCT06378125|EXPERIMENTAL|subjects with prediabetes|multiple dose (MD)
62325600|NCT05819398|PLACEBO_COMPARATOR|Part I: Placebo group|
62325601|NCT05819398|EXPERIMENTAL|Part II: Active (treatment) group|
62325602|NCT05819398|PLACEBO_COMPARATOR|Part II: Placebo group|
62325603|NCT06378801|PLACEBO_COMPARATOR|Placebo Control 1|Relaxation Product Form 1 - control
62325604|NCT06378801|EXPERIMENTAL|Active Product 1.1|Relaxation Product Form 1 - active product 1
62325605|NCT06378801|PLACEBO_COMPARATOR|Placebo Control 2|Relaxation Product Form 2 - control
62325606|NCT06378801|EXPERIMENTAL|Active Product 2.1|Relaxation Product Form 2 - active product 1
62325607|NCT06378801|PLACEBO_COMPARATOR|Placebo Control 3|Relaxation Product Form 3 - control
62325608|NCT06378801|EXPERIMENTAL|Active Product 3.1|Relaxation Product Form 3 - active product 1
62325609|NCT06378801|PLACEBO_COMPARATOR|Placebo Control 4|Relaxation Product Form 4 - control
62325610|NCT06378801|EXPERIMENTAL|Active Product 4.1|Relaxation Product Form 4 - active product 1
62325611|NCT06378801|EXPERIMENTAL|Active Product 4.2|Relaxation Product Form 4 - active product 2
62484295|NCT05429463|EXPERIMENTAL|Arm A(3 cycles of neoadjuvant therapy)|"Neoadjuvant: Prior to surgery, participants receive up to 3 cycles (cycle length: 3 weeks) of sintilimab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel \[260 mg/m\^2, IV; given on cycle day 1\] and carboplatin \[AUC 5- 6mg/mL/min, IV; given on cycle day 1 \] .~Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab \[200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks\] may be selected upon subject request for up to 1 year."
62484296|NCT05429463|EXPERIMENTAL|Arm B(4 cycles of neoadjuvant therapy)|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of sintilimab \[200 mg, intravenous (IV); given on cycle day 1\] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel \[260 mg/m\^2, IV; given on cycle day 1\] and carboplatin \[AUC 5- 6mg/mL/min, IV; given on cycle day 1 \] .~Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab \[200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks\] may be selected upon subject request for up to 1 year."
62484297|NCT02225782|ACTIVE_COMPARATOR|1.0 mg alteplase (tPA)|1.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
62484298|NCT02225782|EXPERIMENTAL|2.0 mg alteplase (tPA)|2.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
62484299|NCT04159103|EXPERIMENTAL|Part 1 (Dose Optimization), Part 2 (Dose Expansion), and Part 3 (Infants)|"Part 1 (Dose Optimization): Participants (≥1 year of age) will receive single dose of mRNA-3927 by intravenous (IV) infusion every 2 weeks (Q2W) or every 3 weeks (Q3W) for up to 10 doses.~Part 2 (Dose Expansion): Participants (≥1 year of age) will receive single dose of mRNA-3927 (identified during Dose Optimization Phase) by IV infusion Q2W for up to 12 months. Part 3: Participants (\<1 year of age) will receive single dose of mRNA-3927 (identified during Dose Optimization Phase) by IV infusion Q2W for up to 12 months."
62484300|NCT00081653|EXPERIMENTAL|1|
62484301|NCT00081653|ACTIVE_COMPARATOR|2|
62484302|NCT04994535|EXPERIMENTAL|BOTOX|BOTOX (OnabotulinumtoxinA) will be injected into the platysma muscle on Day 1
62484303|NCT04994535|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the platysma muscle on Day 1
61932661|NCT02210468|EXPERIMENTAL|APIC-CF 4cc,|APIC-CF 4cc, once at first day
62132992|NCT02586090|EXPERIMENTAL|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
62132993|NCT04351828||Celiac patients compliant to gluten-free diet (GFD)|People with celiac disease who compliant to gluten-free diet (GFD) when they accepted in the study
62132994|NCT04351828||Celiac patients non-compliant to gluten-free diet(NGFD)|People with celiac disease who noncompliant to the gluten-free diet (NGFD) group when they accepted in the study
62132995|NCT00679770|EXPERIMENTAL|Group 1|AN2690 Solution: 2.5%
62132996|NCT00679770|EXPERIMENTAL|Group 2|AN2690 Solution: 5%
62132997|NCT00679770|EXPERIMENTAL|Group 3|AN2690 Solution: 7.5%
62484304|NCT03893123||Firefighters|
62484305|NCT04982523|EXPERIMENTAL|Online Mental Health Program Group|The online mental health program of 8 sessions is provided. Data collection was collected pre-, post-, and one month after the program.
62484306|NCT04982523|NO_INTERVENTION|Control Group|"Data collection was collected three times for three months. No intervention was provided during the study.~If they wanted, they were provided the online mental health program same as the experimental group after data collection."
62484307|NCT03774862||Medullary carcinoma of colorectal cancers|
62484308|NCT03774862||non-medullary carcinomas of the colorectal cancers|
62484309|NCT04505163|ACTIVE_COMPARATOR|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Standard cryoballoon pulmonary vein isolation alone using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
61932662|NCT02210468|EXPERIMENTAL|APIC-CF, 2cc|APIC-CF, 2cc, one at first day
61932663|NCT02210468|PLACEBO_COMPARATOR|Saline|
62132998|NCT00679770|PLACEBO_COMPARATOR|Group 4|AN2690 Solution Vehicle
62132999|NCT00366249|ACTIVE_COMPARATOR|A|
62133000|NCT00366249|ACTIVE_COMPARATOR|B|
62133001|NCT00249769|EXPERIMENTAL|LJEV then MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.
62133002|NCT00249769|EXPERIMENTAL|LJEV and MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.
62325612|NCT04114877|EXPERIMENTAL|attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. Attentional retraining (AR) is the most commonly used CBM intervention in the study of addiction-related attentional bias.
62325613|NCT04114877|ACTIVE_COMPARATOR|visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues.
62692295|NCT02584647|EXPERIMENTAL|Phase 1: PLX3397 and Sirolimus|Cohort 1 (Phase 1): Subjects with unresectable or metastatic sarcoma will take orally PLX3397 (600 - 1000mg) in combination with Sirolimus (2-6mg) daily .
62325614|NCT05624749|EXPERIMENTAL|ianalumab s.c. monthly|ianalumab s.c. monthly
62325615|NCT05624749|PLACEBO_COMPARATOR|placebo s.c. monthly|placebo s.c. monthly
62325616|NCT05376800|EXPERIMENTAL|Phase 0 Part: BI 907828 (Brigimadlin)|
62325617|NCT05376800|EXPERIMENTAL|Phase Ia Part: BI 907828 (Brigimadlin)|
61932664|NCT02774746|ACTIVE_COMPARATOR|35-week delivery group|Subjects to be delivered at 35 0/7 weeks through 35 6/7 weeks.
61932665|NCT02774746|ACTIVE_COMPARATOR|38-week delivery group|Subjects to be expectantly managed to spontaneous delivery, delivered by 38 0/7 weeks through 38 6/7 weeks.
62133003|NCT00249769|EXPERIMENTAL|MV then LJEV|Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.
62133004|NCT05283408|EXPERIMENTAL|Dexmedetomidine infusion on recovey quality with radical mastectomy|Drug: Dexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
62133005|NCT05283408|EXPERIMENTAL|Co-administration dexmedetomidine and low-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
62133006|NCT05283408|EXPERIMENTAL|Combined dexmedetomidine and high-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
62133007|NCT02035631|EXPERIMENTAL|Intervention|Lifestyle intervention combining weight control, diet and physical activity
62133008|NCT02035631|SHAM_COMPARATOR|Minimal intervention|Minimal diet intervention and minimal physical activity intervention
62133009|NCT02129595|ACTIVE_COMPARATOR|resveratrol|resveratrol will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
62325618|NCT04101851|EXPERIMENTAL|No axillary SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery. Approximately 80% of these patients will be assigned to the single study arm (no axillary SLNB) due to breast pCR (ypT0/ypTis) at the final pathology of lumpectomy.
62325619|NCT05738148|ACTIVE_COMPARATOR|Epinephrine|"Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC."
62325620|NCT05738148|EXPERIMENTAL|Vasopressin|"Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC \[2,3\] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing."
62325621|NCT03797716|NO_INTERVENTION|Standard Care arm|"Participants will receive standard of care from the pre-assessment clinic until discharge.~A typical preparatory National Health Service pathway would include: meeting a specialist nurse in the preoperative assessment clinic; a preoperative anaesthetic and surgical consultation; interaction with health play specialists on the day of surgery; and distraction interventions such as hand-held tablets during induction of anaesthesia. Participants may have inhalation or intravenous induction depending on the primary management plan of the anaesthetist in charge.~Participants in the standard care arm will also receive a virtual reality cardboard headset, which can be taken home, personalised and decorated before use with virtual reality apps available to download from the app stores."
62692296|NCT02584647|EXPERIMENTAL|Phase 2: PLX3397 and Sirolimus|Cohort 2 (Phase 2): Subjects with unresectable or metastatic Malignant Peripheral Nerve Sheath Tumors (MPNSTs) will take PLX3397 and Sirolimus at the recommended Phase 2 dose (RP2D).
62692297|NCT06405529|NO_INTERVENTION|Control group|During hospitalization in the ICU and ward, this group will perform a maximum of 10 minutes of exercises of the casual care per day.
61932666|NCT06703281|EXPERIMENTAL|Interscalene brachial plexus block|Patients who underwent shoulder arthroscopic surgery and recieved interscalene brachial plexus block for anesthesia before surgery
61932667|NCT06703281|EXPERIMENTAL|Superior trunk brachial plexus block|Patients who underwent shoulder arthroscopic surgery and recieved superior trunk brachial plexus block for anesthesia before surgery
61932668|NCT03858478|EXPERIMENTAL|Biktarvy arm|one tablet of BIKTARVY including \[TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) \] one tablet once a day for 48 weeks
61932669|NCT05967143||Patients with unresectable HCC or unresectable liver metastases from mCRC|This cohort will include patients with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, who have been prescribed selective internal radiation therapy (SIRT) with SIR-Spheres per medical decision.
61932670|NCT06475118|EXPERIMENTAL|Patients with hepatocellular carcinoma|
61932671|NCT02647437|EXPERIMENTAL|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
61932672|NCT02647437|EXPERIMENTAL|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
62484310|NCT04505163|EXPERIMENTAL|Cryoballoon PVI + Posterior Wall Isolation|Cryoballoon pulmonary vein isolation in conjunction with posterior wall isolation using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
62484311|NCT00907387|ACTIVE_COMPARATOR|Dose A|Dose A RT001
62484312|NCT00907387|ACTIVE_COMPARATOR|Dose B|Dose B RT001
62484313|NCT00907387|PLACEBO_COMPARATOR|Dose C|Dose C Placebo
62484314|NCT01521780|EXPERIMENTAL|Imaging|Magnetic resonance imaging (MRI) of HCC tumor.
62484315|NCT01521780|EXPERIMENTAL|Pathology|Pathology samples from surgical resection of HCC tumor and adjacent liver.
62484316|NCT01521780|EXPERIMENTAL|Imaging/Pathology|MRI of HCC tumor, followed by pathology samples from surgical resection of HCC tumor and adjacent liver.
61932673|NCT06521658|NO_INTERVENTION|loop first|Those will have the retroflexion/looping of the colonoscope performed as the first part of the colonoscopy
62325622|NCT03797716|EXPERIMENTAL|Intervention arm|Participants allocated to the intervention arm will receive the same peri-operative management as the standard care arm and will also receive an access code enabling them to use the Little Journey app in the weeks leading up to their operation. We suggest the Little Journey app is used in the days to weeks leading up to the child's operation depending on their age. On downloading the app, if parents/carers insert the age of the child and date of surgery into the Little Journey app they will be sent a push notifications reminding them when to use it according to their child's age. However, it can be used as frequently as the child and/or their parents or carers wish before the operation.
62325623|NCT03105102|PLACEBO_COMPARATOR|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
62325624|NCT03105102|EXPERIMENTAL|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
62325625|NCT03105102|EXPERIMENTAL|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
62325626|NCT03105102|EXPERIMENTAL|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants will receive double-blind subcutaneous (SC)risankizumab dose 1 and intravenous placebo at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
62325627|NCT03105102|EXPERIMENTAL|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants will receive double-blind subcutaneous placebo and intravenous risankizumab dose 3 at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
62325628|NCT03105102|EXPERIMENTAL|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or other AbbVie risankizumab Crohn's disease study or M16-006 or M15-991 without endoscopy will receive open-label risankizumab dose 1 or dose 2 depending on their preceding study beginning at Week 56.
62325629|NCT03105102|EXPERIMENTAL|Risankizumab On-Body Injector and Open Label (Sub-Study 4)|Participants in Sub-study 3 who meet eligible criteria for Sub-study 4 will receive risankizumab dose 1 or dose 2 via on-body injectors on Weeks 0,8 and 16. Beginning Week 24, participants will receive risankizumab dose 1 or dose 2 via pre-filled syringes Q8W.
62325630|NCT03105102|EXPERIMENTAL|CTE: Open Label Continuous Treatment Extension|Participants who tolerate and derive benefit from receiving risankizumab and complete Sub-study 3 or Sub-study 4 will receive risankizumab dose 1 or dose 2 Q8W.
62484317|NCT04084613||Patients with uncontrolled severe eosinophilic asthma|Asthmatic patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants.
62484318|NCT01703754|EXPERIMENTAL|Ad-RTS-hIL-12 and veledimex|Experimental study drug monotherapy arm (A)
62484319|NCT01703754|EXPERIMENTAL|Ad-RTS-hIL-12 and Palifosfamide|Study drug combination therapy arm (C)
62325631|NCT06587139|EXPERIMENTAL|Treatment|The Teen Connection Project (TCP) is theoretically grounded, and follows best practices for effective health behavior prevention. It includes seven 90-minute sessions with group and one-on-one mentoring components. The intervention is facilitated by transgender and/or gender minority adults (i.e., any identity other than cisgender).
62325632|NCT06587139|NO_INTERVENTION|Waitlist control|Provide check-ins, provide resources, and offer program after intervention and measurement has been completed.
62325633|NCT06587139|NO_INTERVENTION|Mentors|Mentors complete a two-day training and post-training survey, facilitate programming, and complete post-session surveys. A subset of the mentors will complete exit interviews.
62325634|NCT06635226|EXPERIMENTAL|Cohort 1|Cohort 1 will consist of 12 healthy subjects, randomly assigned to ID110521156 (10 patients) or its placebo (2 patients)
62484320|NCT06561763|EXPERIMENTAL|TPC+Triprolizumab+Nimotuzumab|
62484321|NCT06561763|ACTIVE_COMPARATOR|GP+Triprolizumab+Nimotuzumab|
62484322|NCT06328829|EXPERIMENTAL|Conventional Care+Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
62484323|NCT06328829|ACTIVE_COMPARATOR|Conventional Care+Nasogastric tube|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The control group receives Nasogastric Tube Feeding for enteral nutrition support
62484324|NCT06345053|EXPERIMENTAL|Trauma fit inclusion / accept participation in DBT-SUD skills NET|All patients with relevant will be offered to participate in DBT-SUD skills training and or NET.
62692298|NCT06405529|EXPERIMENTAL|Intervention Group|During hospitalization in the ICU and ward, this group will perform 30 to 60 minutes of exercises per day, according to the IMS scale and the intensive mobilization protocol.
61932674|NCT06521658|EXPERIMENTAL|loop last|Those will have the retroflexion/looping of the colonoscope performed as the last part of the colonoscopy
61932675|NCT05941559|OTHER|Shortest baseline length|Intervention starting points are at day 15, 16, 17, 18 or 19.
62325635|NCT06635226|EXPERIMENTAL|Cohort 2|Cohort 2 will consist of 12 healthy subjects, randomly assigned to ID110521156 (10 patients) or its placebo (2 patients)
62484325|NCT01099007|ACTIVE_COMPARATOR|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
62133010|NCT02129595|PLACEBO_COMPARATOR|placebo|A placebo will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
61932676|NCT05941559|OTHER|Medium baseline length|Intervention starting points are at day 20, 21, 22, 23, and 24.
61932677|NCT05941559|OTHER|Longest baseline length|Intervention starting points are at day 25, 26, 27, 28, or 29.
61932678|NCT06431373|EXPERIMENTAL|Arm 1|
62133011|NCT05792488|OTHER|Standard of care|
62133012|NCT05792488|EXPERIMENTAL|Lifestyle coach|
62133013|NCT05792488|EXPERIMENTAL|App|
62133014|NCT05295342|EXPERIMENTAL|Girls-only intervention arm|Schools in this arm will receive only the girls intervention.
62133015|NCT05295342|EXPERIMENTAL|Girls and Boys intervention arm|Schools in this arm will receive both the girls and boys intervention.
62325636|NCT06635226|EXPERIMENTAL|Cohort 3|Cohort 3 will consist of 12 healthy subjects, randomly assigned to ID110521156 (10 patients) or its placebo (2 patients)
62325637|NCT04660812|EXPERIMENTAL|Etrumadenant + Zimberelimab + mFOLFOX-6 +/- Bevacizumab|Participants will receive oral etrumadenant in combination with zimberelimab +mFOLFOX-6 +/-bevacizumab by IV infusion.
62325638|NCT04660812|ACTIVE_COMPARATOR|mFOLFOX-6 +/- Bevacizumab|Participants will receive mFOLFOX-6 +/- bevacizumab by IV infusion.
62325639|NCT04660812|ACTIVE_COMPARATOR|Regorafenib|Participants will receive oral regorafenib
62325640|NCT04660812|EXPERIMENTAL|AB680 + Etrumadent+ Zimberelimab|Participants will receive oral etrmadenant in combination with AB680 + zimberelimab by IV infusion.
62325641|NCT03951194|EXPERIMENTAL|Participants receiving PRP treatment|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
62325642|NCT03951194|PLACEBO_COMPARATOR|Participants receiving Platelet Free Plasma (PFP)|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
62325643|NCT03366168||Group 1|Ages 18-39 years
62325644|NCT03366168||Group 2|Ages 40-59 years
62325645|NCT03366168||Group 3|Ages 60 years old or older
62325646|NCT06337032|EXPERIMENTAL|Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAF|"Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent.~Participants may switch to B/F/TAF, at a dose based on participant's weight."
62325647|NCT06337032|EXPERIMENTAL|Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAF|"Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg.~Participants may switch to B/F/TAF at a dose based on participant's weight."
62133016|NCT05295342|ACTIVE_COMPARATOR|Control|The control arm will receive the standard school-based Life Orientation curriculum.
62325648|NCT06337032|EXPERIMENTAL|Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAF|"Participants will continue to take the following study drugs they were taking in the parent study:~* Cobicistat (COBI) + DRV + NRTI backbone~* COBI + ATV + NRTI backbone~* F/TAF + DRV+ COBI~* F/TAF + ATV+ COBI~* F/TAF + LPV/r~* F/TAF + 3rd unboosted agent~The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily.~Participants may switch to B/F/TAF at a dose based on participant's weight."
62325649|NCT06337032|EXPERIMENTAL|Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)|Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant.
62325650|NCT06636383||Group 1: DTX401 in Prior Clinical Study|Patients administered DTX401 (full or partial dose) in prior clinical study involving DTX401
61932679|NCT06431373|PLACEBO_COMPARATOR|Arm 2|
61932680|NCT06623656|EXPERIMENTAL|Cemiplimab with chemotherapy (Arm A)|"Before lung cancer surgery:~1. Cemiplimab 350 mg intravenously every 3 weeks up to 3 cycles.~2. Platinum-based chemotherapy intravenously every 3 weeks up to 3 cycles.~After lung cancer surgery, cemiplimab 350 mg intravenously every 3 weeks for 4 treatments followed by 700 mg every 6 weeks for one year (11 treatments)."
62133017|NCT03311516|EXPERIMENTAL|Group A|Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
62133018|NCT03311516|OTHER|Group B|Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
62133019|NCT01082575||Major Surgery|Oxygen Monitoring
62133020|NCT05656053||Patients undergoing glioma removal surgery|Patients will undergo magnetic resonance examination before surgery, followed by rapid ultrasound acquisition of the tumor section by the surgeon during surgery and the resection of the tumor tissue for cryopreservation. After surgery, the tissue sample will be used for genetic sequencing and mass spectrometry to obtain molecular information. The data involved in the overall surgical procedure will be saved and used in this observational study.
62133021|NCT05177939|EXPERIMENTAL|NPB-01|Intravenous immunoglobulin
62133022|NCT05177939|ACTIVE_COMPARATOR|NPB-01-ME|methylprednisolone sodium succinate
62133023|NCT02402569|EXPERIMENTAL|Multi-electrodes / single electrode|Multi stimulation / single stimulation
62133024|NCT02402569|EXPERIMENTAL|Single-electrode / Multi electrodes|Single stimulation / Multi stimulation
62133025|NCT02740491||The study population|The study population consists of adult patients diagnosed with localized breast cancer who have completed adjuvant treatment (chemotherapy, radiotherapy) and who are cared for in the Medical Oncology department of the Nîmes University Hospital.
62133026|NCT03230903|EXPERIMENTAL|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
62133027|NCT03230903|SHAM_COMPARATOR|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
62484326|NCT01099007|EXPERIMENTAL|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
62484327|NCT04716582|EXPERIMENTAL|SIT group|participants will sitting 4 hours continuously.
62484328|NCT04716582|EXPERIMENTAL|INTERRUPT group|participants will sitting 25 minutes with 5 minutes walking per half hour,40minutes walking in total
62484329|NCT04716582|EXPERIMENTAL|COGN group|participants will perform GED test as cognitive loading task during 4-hour sitting
62484330|NCT05381727||Patients with Post COVID-19|"That group consists from patients who had diagnosed with COVID-19 by doctors.~Oxygen consumption using cardiopulmonary exercise test, physical activity level using multi-sensor activity monitor, pulmonary function using spirometer, functional exercise capacity with six minute walk test, respiratory muscle strength using mouth pressure device, peripheral muscle strength with hand held dynamometer, inspiratory muscle endurance using incremental threshold loading test, dyspnea with 'Turkish version of London Chest Daily Living Activity Scale', fatigue with 'Turkish version of Fatigue Severity Scale' and quality of life with 'Turkish version of Saint George Respiratory Questionnaire' will be evaluated in patient with post COVID-19. Chronotropic response will be assessed according to results of maximal exercise test. Besides, functional statu of patients will be evaluated with Turkish version of 'Post COVID-19 Functional Status Scale'."
62484331|NCT05381727||Healthy Group|"That group consists from people who do not have any diagnosed disease.~Oxygen consumption using cardiopulmonary exercise test, physical activity level using multi-sensor activity monitor, pulmonary function using spirometer, functional exercise capacity with six minute walk test, respiratory muscle strength using mouth pressure device, peripheral muscle strength with hand held dynamometer, inspiratory muscle endurance using incremental threshold loading test, dyspnea with 'Turkish version of London Chest Daily Living Activity Scale', fatigue with 'Turkish version of Fatigue Severity Scale' and quality of life with 'Turkish version of Saint George Respiratory Questionnaire' will be evaluated in healthy controls."
62484332|NCT06397339|EXPERIMENTAL|Intervention|"The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program"
62692299|NCT06405529|NO_INTERVENTION|Guidance Group|After hospital discharge, this group will not participate in any supervised exercise session, they will only be instructed by the therapists and receive the exercise booklet from the Rehabilitation Center.
62133028|NCT05848609|OTHER|Older patients with colorectal cancer|Patients undergo geriatric assessment including evaluation of cognitive function, functional status and quality of life
62133029|NCT01355549|EXPERIMENTAL|Platelet-rich plasma therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
62325651|NCT06636383||Group 2: DTX401 in Post-Marketing Setting|Patients administered prescribed DTX401(full or partial dose) in a post-marketing setting
62325652|NCT06029270|ACTIVE_COMPARATOR|Arm I (Nivolumab)|Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.
62325653|NCT06029270|EXPERIMENTAL|Arm II (Nivolumab, relatlimab)|Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.
62325654|NCT06029270|EXPERIMENTAL|Induction therapy (Platinum-gemcitabine-nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection during screening and on study.
62325655|NCT06293365|EXPERIMENTAL|Cohort 1: Sequence 1 + Thigh|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) AI in TP2 in Thigh~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
62325656|NCT06293365|EXPERIMENTAL|Cohort 1: Sequence 1 + Abdomen|"Patients randomized to receive injection~1. X 2 mL) AI in TP1 in Abdomen~2. x 1 mL) PFS in TP2 in Abdomen~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
62325657|NCT06293365|EXPERIMENTAL|Cohort 1: Sequence 2 + Thigh|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) AI in TP2 in Thigh~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
62325658|NCT06293365|EXPERIMENTAL|Cohort 1: Sequence 2 + Abdomen|"Patients randomized to receive injection~1. X 2 mL) AI in TP1 in Abdomen~2. x 1 mL) PFS in TP2 in Abdomen~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
62325659|NCT06293365|EXPERIMENTAL|Cohort 2: Sequence 1 + Thigh|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) PFS in TP2 in Thigh~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
62484333|NCT06397339|OTHER|Waitlist|"The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program"
62484334|NCT03342846|ACTIVE_COMPARATOR|High Frequency rTMS in PD|The first group received 20 Hz rTMS on M1 daily for 10 days 5 sessions every week.
62484335|NCT03342846|ACTIVE_COMPARATOR|Low Frequency rTMS in PD|The second group received 1 Hz rTMS on M1 daily for 10 days 5 sessions every week.
62484336|NCT01169753|PLACEBO_COMPARATOR|Placebo|Patients randomized to nonintervention will take a placebo every morning for 2 weeks.
62484337|NCT01169753|EXPERIMENTAL|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
62484338|NCT06128967|PLACEBO_COMPARATOR|Placebo|Placebo talc pills of same shape, color, weight dispensed in coded bottles. Each bottle contains 120 pills
61932681|NCT06623656|EXPERIMENTAL|Cemiplimab with SBRT (Arm B)|"Before lung cancer surgery:~1. Cemiplimab 350 mg intravenously every 3 weeks up to 3 cycles.~2. SBRT on days 1, 2, and 3.~After lung cancer surgery, cemiplimab 350 mg intravenously every 3 weeks for 4 treatments followed by 700 mg every 6 weeks for one year (11 treatments)."
61932682|NCT06709781|EXPERIMENTAL|Non-Burned Individuals|Non-burned individuals will exercise for 60 minutes in the heat while being exposed to either no cooling and cooling via a combination of a fan and skin wetting (two trials).
61932683|NCT06709781|EXPERIMENTAL|Burn Survivors (20% or more Burn Surface Area burn-injured)|Burn survivors with 20% or more BSA (burn surface area) burn-injured will exercise for 60 in the heat while being exposed to either no cooling and cooling via a combination of a fan and skin wetting (two trials).
61932684|NCT02891161|EXPERIMENTAL|Arm A: Safety Run In Phase Ib|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
61932685|NCT02891161|EXPERIMENTAL|Arm B: Investigational Treatment Phase II|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
61932686|NCT01413477|ACTIVE_COMPARATOR|Calcipotriol ointment|
61932687|NCT01413477|ACTIVE_COMPARATOR|Betamethasone dipropionate ointment|
61932688|NCT01413477|ACTIVE_COMPARATOR|Calcipotriol and betamethasone ointment|
61932689|NCT01413477|PLACEBO_COMPARATOR|Vaseline Petroleum Jelly|
62133030|NCT03727958|ACTIVE_COMPARATOR|Lung and coronary CT assessment|Subjects will undergo simultaneous CT assessment of both coronary arteries and thoracic area
62325660|NCT06293365|EXPERIMENTAL|Cohort 2: Sequence 1 + Abdomen|"Patients randomized to receive injection~1. X 2 mL) PFS in TP1 in Abdomen~2. x 1 mL) PFS in TP2 in Abdomen~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
62325661|NCT06293365|EXPERIMENTAL|Cohort 2: Sequence 1 + Upper Arm|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Upper Arm (1 X 2 mL) PFS in TP2 in Upper Arm~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
62325662|NCT06293365|EXPERIMENTAL|Cohort 2: Sequence 2 + Thigh|"Patients randomized to receive injection~1. X 2 mL) PFS in TP1 in Thigh~2. x 1 mL) PFS in TP2 in Thigh~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
62484339|NCT06128967|ACTIVE_COMPARATOR|Fluvoxamine 100 mg|Fluvoxamine maleate 100 mg pills dispensed in coded bottles. Each bottle contains 120 pills
62484340|NCT06128967|ACTIVE_COMPARATOR|Metformin XR 750 mg|Metformin 750 mg Extended release pills dispensed in coded bottles. Each bottle contains 120 pills
62484341|NCT01098903||Sunitinib|Patients with a malignancy treated with sunitinib
62484342|NCT03724890|EXPERIMENTAL|Part A: M3814 + Avelumab|
61932690|NCT05554939|EXPERIMENTAL|Patients with refractory or relapsed B-cell NHL|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, allogenic targeting CD19 chimeric antigen receptor γδT cells.
62133031|NCT03727958|ACTIVE_COMPARATOR|Coronary CT assessment|Subjects will undergo CT assessment of coronary arteries only
62133032|NCT03248505|PLACEBO_COMPARATOR|Placebo TENS|TENS unit turned on, but with zero amplitude.
62133033|NCT03248505|EXPERIMENTAL|Conventional TENS|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude.
62133034|NCT03248505|EXPERIMENTAL|Burst TENS|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
62325663|NCT06293365|EXPERIMENTAL|Cohort 2: Sequence 2 + Abdomen|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Abdomen (1 X 2 mL) PFS in TP2 in Abdomen~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
62325664|NCT06293365|EXPERIMENTAL|Cohort 2: Sequence 2 + Upper Arm|"Patients randomized to receive injection~1. X 2 mL) PFS in TP1 in Upper Arm~2. x 1 mL) PFS in TP2 in Upper Arm~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
62325665|NCT06286033|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Participants will receive a range of doses of AG-181 or placebo, orally, once on Day 1. AG-181 will be given under fasted conditions.
62325666|NCT06286033|EXPERIMENTAL|Part 2: Multiple Ascending Dose (MAD)|Participants will receive a range of doses of AG-181 or placebo twice daily (BID) for 13 days and a single dose on Day 14 under fasted conditions.
62484343|NCT03724890|EXPERIMENTAL|Part B: M3814 + Avelumab + Radiotherapy (RT)|
62484344|NCT03724890|EXPERIMENTAL|Part FE: M3814 + Avelumab (fasted/fed state)|
62484345|NCT02336074|ACTIVE_COMPARATOR|Control|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)
62484346|NCT02336074|EXPERIMENTAL|Intervention|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).
62133035|NCT03248505|EXPERIMENTAL|Cryotherapy|1,5 Kg crushed ice pack
62484347|NCT04577651|EXPERIMENTAL|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with a 16-contact Directional Lead
62484348|NCT00101439|EXPERIMENTAL|Ezetimibe→Placebo|After a 2-week single- blind placebo run-in, participants will receive ezetimibe 10 mg once daily for 4 weeks and then receive placebo once daily for 4 weeks.
62484349|NCT00101439|EXPERIMENTAL|Placebo→ Ezetimibe|After a 2-week single- blind placebo run-in, participants will receive placebo once daily for 4 weeks and then receive ezetimibe10 mg once daily for 4 weeks.
62484350|NCT06560502|ACTIVE_COMPARATOR|Standard of Care-DFU|Debridement, reduction of bacterial burden, and proper moisture balance using dressings provided by SerenaGroup. Off-loading using the off-loading boot or total contact cast (TCC) provided by SerenaGroup.
62484351|NCT06560502|EXPERIMENTAL|AmnioCore - DFU|Dual layer, amniotic membrane allograft.
62484352|NCT06560502|EXPERIMENTAL|Amnio Quad-Core - DFU|Four layer, amniotic membrane allograft.
62484353|NCT06560502|EXPERIMENTAL|Amniocore Pro + - DFU|Dual layer, amnion/chorion membrane allograft.
62692300|NCT06405529|EXPERIMENTAL|Rehabilitation Group|After hospital discharge, this group will participate in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center.
62692301|NCT00708981|ACTIVE_COMPARATOR|Study Group|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL \> 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
62692302|NCT00708981|NO_INTERVENTION|Control Group|Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management.
62484354|NCT06560502|ACTIVE_COMPARATOR|Standard of Care-VLU|Debridement, reduction of bacterial burden, and proper moisture balance using dressings provided by SerenaGroup. Compression using multilayer compression wraps provided by SerenaGroup.
62484355|NCT06560502|EXPERIMENTAL|Amnio Tri-Core - VLU|Three layer, amniotic membrane allograft.
62484356|NCT06560502|EXPERIMENTAL|AmnioCore Pro - VLU|Three layer, amnion/chorion/amnion membrane allograft.
62484357|NCT00955838|EXPERIMENTAL|Manus|
62133036|NCT03248505|EXPERIMENTAL|Burst TENS + Cryotherapy|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus an ice pack of 1,5 Kg.
62133037|NCT03248505|EXPERIMENTAL|Conventional TENS + Cryotherapy|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude plus an ice pack of 1,5 Kg.
62484358|NCT00955838|EXPERIMENTAL|BCI_Manus|
62692303|NCT04584008|EXPERIMENTAL|Matched Targeted Agent|Matched Targeted Agent
62692304|NCT04584008|ACTIVE_COMPARATOR|Unmatched Therapy|Unmatched Therapy
62692305|NCT03777020|EXPERIMENTAL|Service Dog Training Program (SDTP)|Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
62133038|NCT03649243||Propolis group|The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
62133039|NCT03649243||control group|the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
62133040|NCT02517892|EXPERIMENTAL|Patients with metastatic oncogen-driven cancer|
62133041|NCT01696916|EXPERIMENTAL|exercise testing|6-minute walking test with pCO2 and pO2 measurement
62133042|NCT02291094|ACTIVE_COMPARATOR|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
62133043|NCT02291094|ACTIVE_COMPARATOR|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
62133044|NCT03949101|EXPERIMENTAL|combined use of 1% atropine and 0.01% atropine|first week, use atropine sulfate 1% ophthalmic ointment every night before sleep; then use atropine sulfate 1% ophthalmic ointment once every week(Friday night before sleep is recommended) for half a year; then use atropine sulfate 0.01% eye drop every night before sleep for one year and a half.
62133045|NCT03949101|ACTIVE_COMPARATOR|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years.
62133046|NCT01254916||Patients with chronic rhinosinusitis|
62133047|NCT04924218|ACTIVE_COMPARATOR|rigid cystoscopy|Group undergoing endoscopic urethral procedure with rigid cystoscopy after radical prostatectomy
62133048|NCT04924218|ACTIVE_COMPARATOR|flexible cystoscopy|Group undergoing endoscopic urethral procedure with flexible cystoscopy after radical prostatectomy
62133049|NCT04924218|ACTIVE_COMPARATOR|semi-rigid ureterorenoscopy|Group undergoing endoscopic urethral procedure with semi-rigid ureterorenoscopy after radical prostatectomy
62133050|NCT02378779|OTHER|Interventional GP : GP trainned in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize)."
62484359|NCT05921981|EXPERIMENTAL|Multisensorial Stimulation Group|The group to which multi-sensory stimulation will be applied during the retinopathy examination.
62484360|NCT05921981|ACTIVE_COMPARATOR|White Noise Group|The group to which White Noise will be applied during the retinopathy examination.
62484361|NCT05921981|NO_INTERVENTION|Control Group|The group that will receive routine care during the retinopathy examination
62484362|NCT06547294|EXPERIMENTAL|Osprey IV|Subjects enrolled will receive the study device as part of their routine medical care.
62484363|NCT01661803||group-A and group-B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for \>15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for \>15 with 1 mcg/kg preservative free clonidine).
61932691|NCT06333821|EXPERIMENTAL|Nimotuzumab+chemoradiotherapy|Participants receive Nimotuzumab 400 mg intravenously (IV) on Day 1 of each week cycle (QW) for 7-8 cycles followed by Nimotuzumab 400 mg IV on Day 1 of each 2-week cycle (Q2W) for an additional 12 cycles. During the QW dosing period of Nimotuzumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once or divides into 3 times per week (QW) for 4 or 5 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80-85 Gray Units (Gy) for volume-directed given with the total duration of radiation treatment not to exceed 8 weeks .
61932692|NCT06333821|EXPERIMENTAL|placebo for Nimotuzumab+chemoradiotherapy|Participants receive placebo for Nimotuzumab 400 mg intravenously (IV) on Day 1 of each week cycle (QW) for 7-8 cycles followed by placebo 400 mg IV on Day 1 of each 2-week cycle (Q2W) for an additional 12 cycles. During the QW dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once or divides into 3 times per week (QW) for 4 or 5 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80-85 Gray Units (Gy) for volume-directed given with the total duration of radiation treatment not to exceed 8 weeks .
61932693|NCT05684939||cancer patients and cancer survivors|answer to an online questionnaire
61932694|NCT02690883|ACTIVE_COMPARATOR|Lispro|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG \<7.2mmol/L and \>4.4mmol/L.
61932695|NCT02690883|EXPERIMENTAL|Exenatide|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG \<7.2mmol/L and \>4.4mmol/L.
61932696|NCT06330129|EXPERIMENTAL|Healthy subjects|30 healthy subjects undergo trunk muscle strength assessement using the Pegasus device, with repeated measurements to evaluate repeatability and correlation with both surface electromyography (EMG) and MRI scans of trunk muscles.
61932697|NCT05591131|EXPERIMENTAL|Study Time and Events Table|"Study Procedures are as followed:~On Day 1 Surgery/biopsy will be performed to obtain ovarian and endometrial samples. Day 14 will include Informed consent, demographics collection and Blood samples will be obtained. Subjects will complete a survey about knowledge of, attitudes towards, and awareness of genetic testing use over 30 minutes on Day 14. Days 14-21 Tumor/blood DNA preparation. On Day 42 Genetic test results will be released and uploaded in the EMR. If the genetic testing is positive, genetic counseling will be scheduled."
61932698|NCT02296918|EXPERIMENTAL|Cohort 1: Acalabrutinib+Obinutuzumab (R/R)|Dose-escalation and dose-expansion phases will be conducted for relapsed/refractory (R/R) participants with CLL. In dose-escalation phase, participants will receive oral acalabrutinib Dose 1 once daily (QD), later the dose was switched to Dose 2 twice daily (BID) per Amendment 02. In dose- expansion phase, participants will receive oral acalabrutinib Dose 2 BID in 28-day continuous cycles; and will receive intravenous (IV) infusion of obinutuzumab for total 6 cycles (from Cycles 2 to 7) as on Cycle 2 Day 1 participants will receive Dose 1, on Cycle 2 Day 2 participants will receive Dose 2, on Cycle 2 Days 8 and 15 participants will receive Dose 3, and on Day 1 of Cycles 3 to 7 participants will receive Dose 3. Participants will continue to receive acalabrutinib Dose 2 BID until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first.
61932699|NCT02296918|EXPERIMENTAL|Cohort 2: Acalabrutinib+Obinutuzumab (Treatment-naive)|Dose-escalation and dose-expansion phases will be conducted for treatment-naïve participants with CLL/ small lymphocytic lymphoma (SLL). In dose-escalation phase, participants will receive oral acalabrutinib Dose 2 BID in first cycle (28-day cycle). In dose- expansion phase, participants will receive oral acalabrutinib Dose 2 BID in 28-day continuous cycles; and will receive IV infusion of obinutuzumab for total 6 cycles (from Cycles 2 to 7) as on Cycle 2 Day 1 participants will receive Dose 1, on Cycle 2 Day 2 participants will receive Dose 2, on Cycle 2 Days 8 and 15 participants will receive Dose 3, and on Day 1 of Cycles 3 to 7 participants will receive Dose 3. Participants will continue to receive acalabrutinib Dose 2 BID until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first.
62133051|NCT02378779|OTHER|Usual care : GP did not trainnd in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about"
62484364|NCT01661803||group-A and group--B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for \>15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for \>15 with 1 mcg/kg preservative free clonidine).
62484365|NCT01148186|EXPERIMENTAL|Educational intervention|Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
62484366|NCT01148186|NO_INTERVENTION|Wait-list group|
62484367|NCT00876967|EXPERIMENTAL|1|metallic single use blade
62484368|NCT00876967|EXPERIMENTAL|2|plastic single use blade
62484369|NCT00876967|ACTIVE_COMPARATOR|3|metallic reusable blade
61932700|NCT02296918|EXPERIMENTAL|Cohort 3: Acalabrutinib+Rituximab+Venetoclax (R/R)|The R/R participants with CLL will receive oral acalabrutinib, IV infusion of rituximab, and oral venetoclax. Participants will receive acalabrutinib Dose 2 BID in 28-day continuous cycles until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first. Participants will receive rituximab for total 6 cycles (from Cycles 2 to 7) as Dose 1 on Cycle 2 Day 1, followed by Dose 1 every 3 weeks (Q3W) for 3 doses, then every 4 weeks (Q4W) for 5 doses (total 9 infusions through the end of Cycle 7). Participants will receive venetoclax weekly ramp-up schedule over 5 weeks from Cycles 3 to 15, Dose 1 QD for 1 week on Cycle 3 Day 1, Dose 2 QD for 1 week on Cycle 3 Day 8, Dose 3 QD for 1 week on Cycle 3 Day 15, Dose 4 QD for 1 week on Cycle 3 Day 22, and Dose 5 QD from Cycle 4 Day 1 until completion of Cycle 15.
62133052|NCT05360901|OTHER|IntelliCare with automated motivational messaging|Digital mental health intervention with micro-randomized automated motivational messaging delivery
62325667|NCT06286033|EXPERIMENTAL|Part 3: Food Effect - Sequence 1: AB|Participants will receive single oral dose of AG-181 on Day 1 of Period 1 under fasted condition (A) followed by single oral dose of AG-181 on Day 1 of Period 2 under fed (high fat meal) condition (B). Each period will be separated by a washout period of 72 hours.
62325668|NCT06286033|EXPERIMENTAL|Part 3: Food Effect - Sequence 2: BA|Participants will receive a single oral dose of AG-181 on Day 1 of Period 1 under fed (high fat meal) condition (B) followed by single oral dose of AG-181 on Day 1 of Period 2 under fasted condition (A). Each period will be separated by a washout period of 72 hours.
62484370|NCT03921879|EXPERIMENTAL|Stage 1 Dose Escalation|The dose escalation arm will use a modified 3+3 design to determine the maximum tolerated dose. or maximum tested dose.
62484371|NCT03921879|EXPERIMENTAL|Stage 2 Dose Expansion|The dose expansion arm will use the maximum tolerated dose to determine preliminary efficacy.
62484372|NCT00594035|EXPERIMENTAL|1|Spinal Sealant
62484373|NCT00594035|ACTIVE_COMPARATOR|2|Standard of care
62133053|NCT03953859||Gamete donors|healthy male and female game donors to undergo routine gamete donation process
62133054|NCT03953859||Infertile Couple|Couples undergoing routine IVF to treat their infertility
62133055|NCT03890848|EXPERIMENTAL|Wechat application intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
62133056|NCT03890848|ACTIVE_COMPARATOR|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
62484374|NCT04295486|EXPERIMENTAL|Treatment Once Daily|Participant receives 81 mg aspirin taken once daily beginning the night before surgery and up to 28 days post surgery.
62484375|NCT04295486|ACTIVE_COMPARATOR|Treatment Twice Daily|Participant receives 81 mg aspirin taken twice daily (one in the morning and one at night) beginning at the night before surgery and up to 28 days post surgery.
62484376|NCT01103713|EXPERIMENTAL|AZCQ|Azithromycin/Chloroquine
62484377|NCT06391450|EXPERIMENTAL|Empagliflozin 10 milligram (MG)|
62484378|NCT06391450|PLACEBO_COMPARATOR|Placebo|
62484379|NCT05946486|NO_INTERVENTION|control group|continuation of ongoing psychiatric care (with or without standard treatment as usual (i.e. antipsychotics, mood stabilisers, antidepressants and/or anxiolytics)).
62484380|NCT05946486|EXPERIMENTAL|experimental group|immunomodulatory treatment by rituximab, 1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days), added to stable ongoing psychiatric care (with or without standard treatment as usual ( i.e. antipsychotic, mood stabiliser, antidepressant and/or anxiolytic)). The rituximab is the best immunomodulatory treatment recommended for neurologic encephalitis.
62484381|NCT02247362|EXPERIMENTAL|Vaccine Dose Group 12 mcg|VAX2012Q, 12 mcg dose
62484382|NCT02247362|EXPERIMENTAL|Vaccine Dose Group 20 mcg|VAX2012Q, 20 mcg dose
62484383|NCT02247362|EXPERIMENTAL|Vaccine Dose Group 16 mcg|VAX2012Q; 16 mcg dose
62484384|NCT02247362|PLACEBO_COMPARATOR|Vaccine Diluent|Vaccine Diluent, F147, as placebo control
62484385|NCT05854784|EXPERIMENTAL|Afamelanotide|
62484386|NCT04343794|EXPERIMENTAL|Biovitals|Continuous physiological monitoring using Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
62484387|NCT04343794|NO_INTERVENTION|Control|Usual standard care
62484388|NCT03911037|ACTIVE_COMPARATOR|Standard Medical Therapy + G CSF Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required). G-CSF ( prefilled syringe) at the dosage of 5 μg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
62133057|NCT02778659|EXPERIMENTAL|Zolpidem Normoxia|Acute zolpidem intake at sea level
62133058|NCT02778659|SHAM_COMPARATOR|Placebo Normoxia|Acute placebo intake at sea level
62133059|NCT02778659|EXPERIMENTAL|Zolpidem Hypoxia|Acute zolpidem intake at high altitude
62133060|NCT02778659|SHAM_COMPARATOR|Placebo Hypoxia|Acute placebo intake at high altitude
62133061|NCT03117582||Patients with C.diff infection|Patients with C.diff infection not responding to antibiotics who are now scheduled for the FMT procedure for routine care of their condition.
62133062|NCT05985590|EXPERIMENTAL|Treatment A: DRSP/EE|
62133063|NCT05985590|EXPERIMENTAL|Treatment B: BMS-986278/DRSP/EE|
62133064|NCT00630487|PLACEBO_COMPARATOR|Placebo|
62133065|NCT00630487|ACTIVE_COMPARATOR|Verum|
62133066|NCT03208491|EXPERIMENTAL|serious games|
62133067|NCT03208491|ACTIVE_COMPARATOR|usual care|
62133068|NCT06061744||Open approach|Gallbladder cancer with hepatectomy and lymphadenectomy which underwent surgery by classical open approach
62133069|NCT06061744||Robotic approach|Gallbladder cancer with hepatectomy and lymphadenectomy which underwent surgery by any type of robotic surgical device approach
62133070|NCT06061744||Laparoscopic approach|Gallbladder cancer with hepatectomy and lymphadenectomy which underwent surgery by laparoscopic approach
62133071|NCT04408872|ACTIVE_COMPARATOR|EGD|SUBJECT WILL UNDERGO ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)
62133072|NCT04408872|EXPERIMENTAL|EUS|SUBJECT WILL UNDERGO ENDOSCOPIC ULTRASOUND (EUS)
61932701|NCT02296918|EXPERIMENTAL|Cohort 4: Acalabrutinib+Obinutuzumab+Venetoclax (Treatment-naive)|The treatment-naïve participants with CLL will receive oral acalabrutinib, IV infusion of obinutuzumab, and oral venetoclax. Participants will receive acalabrutinib Dose 2 BID in 28-day continuous cycles until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first. Participants will receive obinutuzumab for total 6 cycles (from Cycles 2 to 7) as Dose 1 on Cycle 2 Day 1, Dose 2 on Cycle 2 Day 2, Dose 3 on Cycle 2 Days 8 and 15, and Dose 3 on Day 1 of Cycles 3 to 7. Participants will receive venetoclax weekly ramp-up schedule over 5 weeks from Cycles 3 to 15 as Dose 1 QD for 1 week on Cycle 3 Day 1, Dose 2 QD for 1 week on Cycle 3 Day 8, Dose 3 QD for 1 week on Cycle 3 Day 15, Dose 4 QD for 1 week on Cycle 3 Day 22, and from Cycle 4 Day 1 participants will receive Dose 5 QD until completion of Cycle 15.
62133073|NCT00988858|EXPERIMENTAL|LY2603618 and Pemetrexed|
62325669|NCT03006172|EXPERIMENTAL|Stage I Arm A: Inavolisib Single Agent|Participants will receive inavolisib in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of inavolisib on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325670|NCT03006172|EXPERIMENTAL|Stage I Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325671|NCT03006172|EXPERIMENTAL|Stage I Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of inavolisib will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325672|NCT03006172|EXPERIMENTAL|Stage II Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325673|NCT03006172|EXPERIMENTAL|Stage II Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325674|NCT03006172|EXPERIMENTAL|Stage II Arm D: Inavolisib + Fulvestrant|Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325675|NCT03006172|EXPERIMENTAL|Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325676|NCT03006172|EXPERIMENTAL|Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62484389|NCT03911037|PLACEBO_COMPARATOR|Standard Medical Therapy + Placebo|"Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required).~Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered."
62133074|NCT05082636||case|54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital,
62133075|NCT05082636||control|besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).
62133076|NCT01619410|ACTIVE_COMPARATOR|linezolid|
62133077|NCT01619410|ACTIVE_COMPARATOR|Clindamycin|
62133078|NCT02426996|EXPERIMENTAL|Study population|"The patients included have been operated for chronic anterior shoulder instability by a Latarjet-type bone block procedure using the SEM (Science Et Medecine) positioning tool within the past 3 months.~Intervention: Scan of shoulder"
62133079|NCT02292329|ACTIVE_COMPARATOR|150g of acai fruit|150g of acai fruit in fruit smoothie form
62133080|NCT02292329|PLACEBO_COMPARATOR|Placebo control|The control will be a smoothie-like drink matched for major macro- and micro-nutrients
62133081|NCT04164316|SHAM_COMPARATOR|Kinesio Tape No Tension|Kinesio Tape No Tension
62133082|NCT04164316|ACTIVE_COMPARATOR|Kinesio Tape with Tension|Kinesio Tape with Tension
62133083|NCT02652091||Interferon beta-1b|Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are injecting Betaseron via the Betaconnect device.
62133084|NCT03941119|EXPERIMENTAL|Intervention|The intervention arm will receive a VR-therapy session every 24-72 hours of their stay in the hospital. Participants will view specially designed 360-degree VR films using a Virtual Reality head mounted display for a maximum of 20 minutes per session.
62133085|NCT03941119|NO_INTERVENTION|Control|The control arm will not receive any VR-therapy sessions during their hospital stay.
62133086|NCT04877340|OTHER|Standard FNA 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a standard FNA 22G needle
62133087|NCT04877340|EXPERIMENTAL|Franseen 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a FNB 22G needle. The sequence of the use of needles will be randomized.
62484390|NCT00052377|EXPERIMENTAL|Treatment (aldesleukin, recombinant interleukin-12)|"Patients receive IL-12 SC twice weekly for 24 weeks.~Disease is assessed at 13 weeks. Patients who do not have progressive disease also receive IL-2 SC 3 consecutive days a week during weeks 13-24. Patients with progressive disease at week 13 receive IL-2 SC at a fixed dose during weeks 13-24.~Patients with responding disease after week 24 may continue to receive IL-2 and IL-12 for another 12 weeks.~Cohorts of 3-6 patients receive escalating doses of IL-2 until the MTD is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RD is the dose preceding the MTD. Additional patients are treated at the RD."
62484391|NCT00870558|EXPERIMENTAL|Arm I|Patients receive an intra-arterial infusion of iodine I 131 ethiodized oil.
62484392|NCT00870558|PLACEBO_COMPARATOR|Arm II|Patients receive an intra-arterial infusion of unlabeled ethiodized oil.
62484393|NCT02770222|EXPERIMENTAL|Part 1, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. There is a washout period of 14 to 21 days between the two periods.
62692306|NCT03777020|OTHER|Dog Training Education|Veterans randomized to Dog Training Education will participate in one hour online SD training modules (https://e-trainingfordogs.com) scheduled once a week for 8 weeks. The online training modules are delivered by experienced SD trainers and will employ parallel content to the WCC SDTP. Participants will come to the WCC site for all the weekly online training modules. Members of the WLCI group will have education about dog training, but NO interaction with a SD. The online training modules for the DTE group are intended to keep the veterans who are not immediately assigned to the SDTP engaged in the study. They will participate in the SDTP after conclusion of participation in the 8 week study.
62692307|NCT03755401|EXPERIMENTAL|TFPP|TFPP is a manualized 16-24 session psychodynamic psychotherapy targeted on trauma symptoms of PTSD
62692308|NCT03755401|ACTIVE_COMPARATOR|TAU|TAU in this study is treatment for PTSD as currently delivered at the VA
61932702|NCT03710772|EXPERIMENTAL|Group I (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as described in part I.~COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone PO or IV on days 1-4, cyclophosphamide IV over 3 hours BID on days 2-4, and doxorubicin hydrochloride IV over 24 hours and vincristine sulfate IV over 15-30 minutes on day 5 of odd-numbered cycles (1 and 3). Patients also receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4 of even-numbered cycles (2 and 4). Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and rituximab IV over 4-8 hours on day 1 of every other month. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
61932703|NCT03710772|EXPERIMENTAL|Group II (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as in part I.~Patients receive combination chemotherapy as in group I. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive maintenance therapy as in group I."
61932704|NCT03710772|EXPERIMENTAL|Group III (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib, rituximab, venetoclax as in part I. Patients then receive maintenance therapy as in group I.
61932705|NCT06455085|ACTIVE_COMPARATOR|Enhanced Usual Care Arm|Participants will be mailed education materials and encouraged to follow up with their primary care physician.
62133088|NCT03305445|EXPERIMENTAL|Pts with Diffuse Large B Cell Lymphoma|"Patients with DLBCL not eligible for autologous stem cell transplant. All patients will receive dual checkpoint blocking antibody (DCBA) therapy of ipilimumab and nivolumab given at three week intervals, two times before, and two times following immunotransplant in which T cells (in whole PBMCs) are cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting chemotherapy regimen, currently being employed in adoptive T cell therapies."
62133089|NCT02809794|EXPERIMENTAL|Investigational CPAP device|Fisher \& Paykel Healthcare CPAP Device
62133090|NCT00083551|ACTIVE_COMPARATOR|Thalidomide|Thalidomide 400 qod during induction.100 mg qd between transplants, post transplant pat. 200 mg qd. During year one of maintenance therapy pt will take 100mg of Thal qod and 50 mg of thal qod during second year of maintenance
62325677|NCT03006172|EXPERIMENTAL|Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab|Participants will receive inavolisib in combination with trastuzumab and pertuzumab (Days 1-21). Dose of inavolisib will be determined from the results of Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
62325678|NCT04368403|EXPERIMENTAL|KHK4827|
62325679|NCT06490822|OTHER|Single arm study|A single 3 mm-diameter punch skin biopsy will be obtained from FTLD patients and healthy volunteers at the C8 paravertebral under local anesthesia to analyze cutaneous innervation
62325680|NCT06442592|OTHER|CATAMARAN - Pediatrics - Nantes|The study population will consist of 201 children aged 3 to 11 and their two parents.
62325681|NCT06442592|OTHER|CATAMARAN - Pediatrics - Associated centers (excluding Nantes)|The study population will consist of 201 children aged 3 to 11 and their two parents.
62325682|NCT06049927|EXPERIMENTAL|Experimental Group of quadrivalent influenza vaccine(0.25ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.25ml) according to the immunization schedule of day 0,28
62325683|NCT06049927|EXPERIMENTAL|Experimental Group of quadrivalent influenza vaccine(0.5ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.5ml) according to the immunization schedule of day 0,28
62325684|NCT06049927|ACTIVE_COMPARATOR|Control Group of trivalent influenza vaccine(BV)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BV) according to the immunization schedule of day 0,28.
62325685|NCT06049927|ACTIVE_COMPARATOR|Control Group of trivalent influenza vaccine(BY)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BY) according to the immunization schedule of day 0,28.
62484394|NCT02770222|EXPERIMENTAL|Part 1, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. They also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. During the second period (Treatment A) they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
62133091|NCT00083551|ACTIVE_COMPARATOR|No Thalidomide|During induction, consolidation, and maintenance steps patient receives no thalidamide
62133092|NCT04595474||Study Cohort|533 adult subjects with type 1 diabetes with no secondary causes of fatty liver
62692309|NCT02255656|EXPERIMENTAL|Alemtuzumab|All Participants who completed the study CAMMS03409 (extension study of CAMMS223 \[NCT00050778\], CAMMS323 \[NCT00530348\], or CAMMS324 \[NCT00548405\]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649).
62692310|NCT05544760|NO_INTERVENTION|Control|"Placement into the intervention vs. control group is random, but dependent upon multisensory integration performance. Meaning, older adults who are enrolled and screened with good integration abilities on the CatchU test (aka: VSI + (good) integrators), (VSI = visual-somatosensory integration) will not be placed in either the intervention or control group since better visual-somatosensory integration performance has been linked to better cognitive and motor outcomes. These participants will be included in examination of additional study aims not related to the intervention.~VSI - (poor) integrators, will be randomly assigned into either the intervention or control group to test the beneficial effect of the CatchU intervention.~Participants in the Control arm will be monitored every two months via telephone surveys to determine falls history, but will not receive the CatchU intervention."
62133093|NCT06096831||Post-Stroke patients at chronic phase living in the community|The data will be extracted from medical records of all people who are at least one year after a stroke, live in the community and are insured by Health maintenence Organization (HMO).In the first part we expect to extract data of approximately 40,000 patients . In the second part, a sub sample of 240 patients will be recruited to answer standardized questionnaires. In the third part, a sub-sample from part 2, of 20 people will be interviewed.
62325686|NCT04410042|EXPERIMENTAL|Tranexamic Acid|At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
62692311|NCT05544760|EXPERIMENTAL|CatchU Intervention|"Placement into the intervention vs. control group is random, but dependent upon multisensory integration performance.~VSI - (poor) integrators, will be randomly assigned into either the intervention or control group to test the beneficial effect of the CatchU intervention. Participants in the Intervention arm will be monitored every two months to determine falls history, but will also receive the CatchU intervention which consists of physicians relaying individualized recommendations from the CatchU physician report to the participant, as well as providing the participant with falls intervention referrals and falls counseling."
62692312|NCT00373360|EXPERIMENTAL|1|
61932706|NCT06455085|EXPERIMENTAL|Augmented-Fracture Liaison Service Arm|Participants will be mailed education materials. Participants will also be contacted by patient navigators who will guide participants through the process of getting a Bone Health Clinician appointment.
62325687|NCT04410042|PLACEBO_COMPARATOR|Placebo|At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
62325688|NCT04886804|EXPERIMENTAL|Phase Ia - Dose escalation part|Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.
62133094|NCT01616888|ACTIVE_COMPARATOR|Treatment arm|SFA angioplasty with In.Pact Admiral drug eluting balloon
62133095|NCT04589520|EXPERIMENTAL|HeartBot Group|The HeartBot group downloaded the app and used it daily for 21 days based on a calendar that provided them with step by step outlines of the tools for each day.
62133096|NCT04589520|NO_INTERVENTION|Control Group|The control group did not download the app and experienced no change to their daily routines.
62133097|NCT00867256|EXPERIMENTAL|Large Diameter Metal on Metal|
62133098|NCT06389435|EXPERIMENTAL|RTKR|Robotic assisted total knee replacement (RTKR)
62133099|NCT06389435|ACTIVE_COMPARATOR|TKR|Standard total knee replacement (TKR)
62133100|NCT02059616|EXPERIMENTAL|AML 5mg|Amlodipine 5 mg, once a day for 8 weeks
62325689|NCT04886804|EXPERIMENTAL|Phase Ib - Dose expansion part: Cohort 1|
62325690|NCT04886804|EXPERIMENTAL|Phase Ib - Dose expansion part: Cohort 2|
62325691|NCT04886804|EXPERIMENTAL|Phase Ib - Dose expansion part: Cohort 3|
62133101|NCT02059616|EXPERIMENTAL|AML 10mg|Amlodipine 10 mg, once a day for 8 weeks
62133102|NCT02059616|EXPERIMENTAL|CC 8mg|Candesartan Cilexetil 8 mg, once a day for 8 weeks
62133103|NCT02059616|EXPERIMENTAL|CC 16mg|Candesartan Cilexetil 16 mg, once a day for 8 weeks
62133104|NCT02059616|EXPERIMENTAL|AML 5mg/CC 8mg|Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks
62133105|NCT02059616|EXPERIMENTAL|AML 5mg/CC16mg|Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
62133106|NCT02059616|EXPERIMENTAL|AML 10mg/CC 8mg|Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks
61932707|NCT05350592|ACTIVE_COMPARATOR|Tocilizumab + Dobutamine|Tocilizumab IV 280 mg (100mL/hour, 1 hour) Dobutamine IV 5 micrograms/kg/minute (5mL/hour, 24 hours)
61932708|NCT05350592|ACTIVE_COMPARATOR|Tocilizumab + Placebo|Tocilizumab IV 280 mg (100mL/hour, 1 hour) NaCl 0,9% IV (5mL/hour, 24 hours)
62133107|NCT02059616|EXPERIMENTAL|AML 10mg/CC 16mg|Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
62692313|NCT05703165|EXPERIMENTAL|subjects with stress burden and animal-assisted intervention|The 20-minute horse-assisted intervention takes place in compliance with basic safety precautions (safety bar between horse and participant) and after safety instruction in handling the therapy horse. The horse can be touched or stroked more or less intensively, depending on the needs and current state of mind of the study participant.
61932709|NCT05350592|ACTIVE_COMPARATOR|Placebo + Dobutamine|NaCl 0,9% IV (100mL/hour, 1 hour) Dobutamine IV 5 micrograms/kg/minute (5mL/hour, 24 hours)
61932710|NCT05350592|PLACEBO_COMPARATOR|Placebo + Placebo|NaCl 0,9% IV (100mL/hour, 1 hour) NaCl 0,9% IV (5mL/hour, 24 hours)
61932711|NCT00773929|EXPERIMENTAL|1|3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort
61932712|NCT04609072||Healthy volunteers|Up to 200,000 men and women aged 30 to 70 years, with no personal history of cancer, and patients or members of participating integrated health care systems.
61932713|NCT04469426|EXPERIMENTAL|Informational online app group|Participants will have access to an interactive online peer support app developed by the research team.
61932714|NCT04469426|NO_INTERVENTION|Booklet only|Participants will only have access to the educational booklet on LARS developed by the colorectal research team.
61932715|NCT06525311|EXPERIMENTAL|PBC w/o CIRR|K-808 single dose followed by multiple-dose treatment period.
61932716|NCT06525311|EXPERIMENTAL|PBC w/ CIRR CP-A|K-808 single dose followed by optional multiple-dose treatment period.
61932717|NCT05026008|EXPERIMENTAL|SR1375 Capsule|Ascending single and multiple doses of SR1375 capsules orally
61932718|NCT05026008|EXPERIMENTAL|Matching placebo|Ascending single and multiple doses of placebo capsules orally
61932719|NCT06686056|EXPERIMENTAL|AIM-CHD Mobile Health Intervention Group|Participants in the intervention group will be trained to use the AIM-CHD for post-discharge care，while also receiving post-discharge usual care.
61932720|NCT06686056|ACTIVE_COMPARATOR|Standard Post-Discharge Care Group|Participants in the control group will receive usual post-discharge care, which includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.
61932721|NCT01454427||healthy volunteers|
61932722|NCT05919043|EXPERIMENTAL|Upper limb-based movement priming (UL-priming)|The upper limb priming task will include rhythmic, bilateral priming involving the movement of at least one major joint in the upper limbs (shoulder, elbow, wrist).
62692314|NCT05703165|ACTIVE_COMPARATOR|subjects with stress burden and without animal-assisted intervention|Study participants only observe the natural environment.
62692315|NCT05703165|ACTIVE_COMPARATOR|subjects without stress burden and with animal-assisted intervention|The 20-minute horse-assisted intervention takes place in compliance with basic safety precautions (safety bar between horse and participant) and after safety instruction in handling the therapy horse. The horse can be touched or stroked more or less intensively, depending on the needs and current state of mind of the study participant.
61932723|NCT05919043|ACTIVE_COMPARATOR|Lower limb-based movement priming (LL-priming)|Participants will perform rhythmic, symmetric, bilateral plantarflexion and dorsiflexion movements.
61932724|NCT05919043|SHAM_COMPARATOR|Sham priming|Participants will listen to a 1 Hz metronome for 20 minutes as a form of auditory stimulation during the sham priming session.
61932725|NCT03152032|EXPERIMENTAL|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
61932726|NCT04704843|EXPERIMENTAL|Module A (Without Gluten-Challenge): Guselkumab or Placebo|Participants in Module A (without gluten-challenge) will receive intravenous (IV) infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by subcutaneous (SC) injection of guselkumab or matching placebo at Week 12.
61932727|NCT04704843|EXPERIMENTAL|Module B (With Gluten-Challenge): Guselkumab or Placebo|Participants in Module B (with gluten-challenge) will receive IV infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by SC injection of guselkumab or matching placebo at Week 12.
61932728|NCT06273631|EXPERIMENTAL|diverse carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 45\~50% of carbohydrate supply sources are refined grains, 45\~50% of carbohydrate supply sources are whole grains or beans.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
61932729|NCT06273631|OTHER|middle carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25\~35%. 90\~95% of the carbohydrate supply comes from refined grains.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
61932730|NCT06144697|EXPERIMENTAL|Part A: Single Ascending Dose (SAD) [BMS-986465 or placebo]|
61932731|NCT06144697|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD) [BMS-986465 or placebo, Pegasys]|
61932732|NCT06144697|EXPERIMENTAL|Part C: MAD in Japanese ethnicity [BMS-986465 or placebo]|
61932733|NCT06144697|EXPERIMENTAL|Part D: Food/Formulation/pH Effects [BMS-986465, Famotidine]|
61932734|NCT06142383|PLACEBO_COMPARATOR|Arm 1|Placebo Treatment
61932735|NCT06142383|EXPERIMENTAL|Arm 2|XXB750 Low Dose
61932736|NCT06142383|EXPERIMENTAL|Arm 3|XXB750 Medium Dose
61932737|NCT06142383|EXPERIMENTAL|Arm 4|XXB750 High Dose
61932738|NCT06142383|ACTIVE_COMPARATOR|Arm 5|Sacubitril/valsartan, open label tablet
61932739|NCT02534818|EXPERIMENTAL|Group 1|lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia
62325692|NCT04886804|EXPERIMENTAL|Phase Ib - Dose expansion part: Cohort 4|
61932740|NCT02534818|ACTIVE_COMPARATOR|Group 2|conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia
61932741|NCT05338294|EXPERIMENTAL|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
62692316|NCT05949320|EXPERIMENTAL|e-MI intervention group|1200 participations are randomized to the e-MI group. They are asked to download the e-MI app and exposed to the related content for 90 days.
62692317|NCT05949320|NO_INTERVENTION|Waiting list control group|400 participants are randomized to the waiting list control group. They will commence the e-MI intervention after the completion of the e-MI group.
62692318|NCT05931822|ACTIVE_COMPARATOR|Silver Diamine fluoride modified glass ionomer restoration|
62692319|NCT05931822|ACTIVE_COMPARATOR|fluoride varnish and glass ionomer restoration|
62692320|NCT03202303|EXPERIMENTAL|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
61932742|NCT05374460|SHAM_COMPARATOR|Conscious awareness: No information|Told nothing about the visuo-proprioceptive mismatch. Hand remains hidden beneath mirror that shows visual display. (control)
61932743|NCT05374460|EXPERIMENTAL|Conscious awareness: Explanatory diagram|Told in advance about the visuo-proprioceptive mismatch, which will be explained with a diagram. Hand remains hidden.
61932744|NCT05374460|EXPERIMENTAL|Conscious awareness: Direct vision of hand|Foamboard under mirror removed, making the mirror see-through and the hand directly visible.
61932745|NCT05374460|SHAM_COMPARATOR|Movement feedback: No feedback|No movement feedback (control)
62692321|NCT03202303|PLACEBO_COMPARATOR|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
61932746|NCT05374460|EXPERIMENTAL|Movement feedback: Target hand|Movement feedback about the target hand.
61932747|NCT05374460|EXPERIMENTAL|Movement feedback: Pointing hand|Movement feedback about the pointing hand.
61932748|NCT05395663|ACTIVE_COMPARATOR|Arm 1: Usual practice|People will receive a free well water test kit that is delivered by mail and the results from this water test. They will also be mailed material that is provided by the Oregon Health Authority's Domestic Well Stewardship Program which is the Water Well Owner's Handbook(in English or Spanish) and contaminant guides.
61932749|NCT05395663|EXPERIMENTAL|Arm 2: Health navigator|"People will receive a free well water test kit that is delivered by mail and the results from this water test. They will also be mailed material that is provided by the Oregon Health Authority's Domestic Well Stewardship Program which is the Water Well Owner's Handbook(in English or Spanish) and contaminant guides. In addition, a trained health navigator will meet with the homeowner three times to assist the homeowner's decision-making.~Activities include: i) Interpreting results, ii) Improving health literacy and numeracy through teach-back moments, iii) Assessment of household risk for contaminants from well and septic, iv) Assessment of risk to family members, pets, livestock, etc v) Coaching to resolve ambivalence or lack of motivation and other barriers using elicit-provide-elicit motivational interviewing; vi) Assistance with decision-making and weighing financial options, and vii) Goal-setting and action plans."
61932750|NCT06708806|OTHER|Toric vs Monofocal IOL|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive a monofocal IOL (XY1) vs. an toric IOL (XY1A)
61932751|NCT05936385|EXPERIMENTAL|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
61932752|NCT05936385|ACTIVE_COMPARATOR|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
61932753|NCT06145906||Paroxysmal AF group|AF that terminates spontaneously or with intervention within 7 days of onset
61932754|NCT06145906||Persistent AF group|AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion) after ≥7 days
61932755|NCT03989414|EXPERIMENTAL|Cohort A: CC-92480 with bortezomib and dexamethasone|
61932756|NCT03989414|EXPERIMENTAL|Cohort C: CC-92480 with carfilzomib and dexamethasone|
61932757|NCT03989414|EXPERIMENTAL|Cohort H: CC-92480 with elotuzumab and dexamethasone|
61932758|NCT03989414|EXPERIMENTAL|Cohort I: CC-92480 with isatuximab and dexamethasone|
61932759|NCT03989414|EXPERIMENTAL|Cohort D: CC-92480 with bortezomib and dexamethasone|
61932760|NCT03989414|EXPERIMENTAL|Cohort F: CC-92480 with carfilzomib and dexamethasone|
62692322|NCT03129997|ACTIVE_COMPARATOR|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
62692323|NCT03129997|PLACEBO_COMPARATOR|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
62692324|NCT06569459|EXPERIMENTAL|Experimental group|Trilaciclib 240mg/m2；Radiation therapy：50.4Gy/28/1.8；Paclitaxel: 135mg/m2, d1, Q3W, 4 cycles；Carboplatin: AUC=5, d2, Q3W, 4 cycles（or nedaplatin 75 mg/m2, d2, Q3W, 4 cycles）;Immune inhibitors (by choice) : d1, Q3W, treatment + maintain phase, continuous dosing, until disease progression or not tolerated toxicity.
61932761|NCT03989414|EXPERIMENTAL|Cohort J: CC-92480 with elotuzumab and dexamethasone|
61932762|NCT03989414|EXPERIMENTAL|Cohort K: CC-92480 with isatuximab and dexamethasone|
61932763|NCT03989414|EXPERIMENTAL|Cohort G: CC-92480 with bortezomib and dexamethasone|
61932764|NCT03989414|EXPERIMENTAL|Subcohort B1: CC-92480 with daratumumab and dexamethasone|
61932765|NCT03989414|EXPERIMENTAL|Subcohort B2: CC-92480 with daratumumab and dexamethasone|
61932766|NCT03989414|EXPERIMENTAL|Subcohort B3: CC-92480 with daratumumab and dexamethasone|
61932767|NCT03989414|EXPERIMENTAL|Subcohort E1: CC-92480 with daratumumab and dexamethasone|
61932768|NCT03989414|EXPERIMENTAL|Subcohort E2: CC-92480 with daratumumab and dexamethasone|
61932769|NCT03989414|EXPERIMENTAL|Subcohort E3: CC-92480 with daratumumab and dexamethasone|
61932770|NCT04245462||Participants|Older aged (\>60 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco, Mexico).
62133108|NCT05051982|EXPERIMENTAL|Study Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the study group, the monitor will be in full view of the anesthesiologist administering the anesthetic.
62325693|NCT04886804|EXPERIMENTAL|Phase Ib - Dose expansion part: Cohort 5|
62692325|NCT06569459|SHAM_COMPARATOR|Control group|Radiation therapy：50.4Gy/28/1.8；Paclitaxel: 135mg/m2, d1, Q3W, 4 cycles；Carboplatin: AUC=5, d2, Q3W, 4 cycles（or nedaplatin 75 mg/m2, d2, Q3W, 4 cycles）;Immune inhibitors (by choice) : d1, Q3W, treatment + maintain phase, continuous dosing, until disease progression or not tolerated toxicity.
62325694|NCT04886804|EXPERIMENTAL|Phase Ib - Dose expansion part: Cohort 6|Cohort only in the United States of America (USA)
62692326|NCT06642051|EXPERIMENTAL|Prospective observational|Patients that have undergone high intensity focused ultrasound ablation of incompetent veins of the periphery
62692327|NCT02412982|NO_INTERVENTION|Serum anti-Xa >= 0.1 IU/mL|Patients with serum anti-Xa level \>= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
62692328|NCT02412982|ACTIVE_COMPARATOR|Anti-Xa <0.1 IU/mL:enoxaparin 40 mg q12h|Patients with serum anti-Xa level \< 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
62692329|NCT02412982|ACTIVE_COMPARATOR|Anti-Xa <0.1 IU/mL:enoxaparin 30 mg q8h|Patients with serum anti-Xa level \< 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours
62692330|NCT02412982|NO_INTERVENTION|Serum anti-Xa < 0.1 IU/mL|Patients with serum anti-Xa level \< 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
62692331|NCT05580679|EXPERIMENTAL|Abdominal massage group|Abdominal massage using for evaluation of constipation.
62692332|NCT05580679|NO_INTERVENTION|Standart care group|No intervention palliative care patient
62692333|NCT05788991|EXPERIMENTAL|Dequalinium chloride|Dequalinium chloride 10 mg vaginal tablets
62692334|NCT05788991|ACTIVE_COMPARATOR|Metronidazole|Metronidazole 500 mg oral tablets
62692335|NCT03333889|ACTIVE_COMPARATOR|E-max hybrid crown|E-max hybrid crown Lithium Disilicate based ceramic which is characterized by high strength and optimum esthetics and considered a gold standard in anterior restorations
61932771|NCT06044311|EXPERIMENTAL|Vactosertib + Chemoradiotherapy|Vactosertib orally, 200 mg twice daily for five days a week for 2 weeks, followed by standard of care chemoradiotherapy, followed by Vactosertib for 4 weeks after standard of care chemoradiotherapy
62325695|NCT04886804|EXPERIMENTAL|Phase Ib - Dose expansion part: Cohort 7|Cohort only in Japan
61932772|NCT05625893|EXPERIMENTAL|PBT arm|
61932773|NCT06080412||Blueprint Mixed Reality HOLOBLUEPRINT™ in Reversed Shoulder replacement|One single cohort of patients receiving a reversed shoulder arthroplasty with the use of Blueprint Mixed Reality HOLOBLUEPRINT™ as per standard of care.
61932774|NCT06097299|EXPERIMENTAL|Part A and Part B: Cohort 1 (2 to <5 Years of Age)|Part A: Participants 2 to \<5 years of age will receive either a single intramuscular (IM) injection of mRNA-1345 or placebo on Day 1. Part B: Participants will have the option to be re-enrolled into a 6-month safety-follow up period.
61932775|NCT06097299|EXPERIMENTAL|Part A: Cohort 2 (5 to <18 Years of Age)|Participants 5 to \<18 years of age will receive a single IM injection of mRNA-1345 on Day 1.
61932776|NCT05976347|EXPERIMENTAL|Selective serotonin reuptake inhibitors (SSRI)|Fluoxetine, 20mg once daily
61932777|NCT05976347|EXPERIMENTAL|serotonin and norepinephrine reuptake inhibitors (SNRI)|Duloxetine, 30mg once daily
61932778|NCT05976347|OTHER|Observational|Referral to behavioral health per standard practice and provision of resources for strategices to address depressive symptoms.
61932779|NCT04180085|EXPERIMENTAL|BELATACEPT|
61932780|NCT06624358|EXPERIMENTAL|Fixed step goal only|This intervention designed to test if fixed step goals improve physical activity participation.
61932781|NCT06624358|EXPERIMENTAL|Fixed step goal with feedback|This intervention designed to test if fixed step goals and/or daily feed back improve physical activity participation.
61932782|NCT06624358|EXPERIMENTAL|Fixed step goal with financial incentives|This intervention designed to test if fixed step goals and/or financial incentives improve physical activity participation.
62325696|NCT05126277|EXPERIMENTAL|Arm 1 - ianalumab s.c. q4w|ianalumab s.c. q4w in addition to standard of care (SoC)
62325697|NCT05126277|EXPERIMENTAL|Arm 2 - ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
62325698|NCT05126277|PLACEBO_COMPARATOR|Arm 3 - placebo s.c. q4w|Placebo s.c. q4w in addition to SoC
61932783|NCT06624358|EXPERIMENTAL|Fixed step goal with financial incentive and feedback|This intervention designed to test if fixed step goals and/or financial incentives and/or daily feedback improve physical activity participation.
61932784|NCT06624358|EXPERIMENTAL|Ramped Step goals|This intervention designed to test if ramped step goals improve physical activity participation.
61932785|NCT06624358|EXPERIMENTAL|Ramped step goals with feedback|This intervention designed to test if ramped step goals and/or daily feedback improve physical activity participation.
61932786|NCT06624358|EXPERIMENTAL|Ramped step goal with financial incentive|This intervention designed to test if ramped step goals and/or financial incentive improve physical activity participation.
62325699|NCT03885518|ACTIVE_COMPARATOR|Intervention|Participants attending the childcare centers randomized to this arm will receive the stencil activities after baseline assessments have been completed. We will follow-up with assessments after 6-8 weeks
62325700|NCT03885518|PLACEBO_COMPARATOR|Wait-List|Participants attending the childcare centers randomized to this arm will receive the stencil activities approximately 8 weeks after enrolling, after baseline and follow-up assessments have been completed.
62325701|NCT06042478|EXPERIMENTAL|Remibrutinib|Participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 52 weeks.
62692336|NCT03333889|EXPERIMENTAL|Vita Enamic hybrid crown|Vita Enamic hybrid crown polymer infilltrated ceramic network(hybrid ceramic) characterized by low modulus of elasticity that acts as cushion on implants.
62692337|NCT01713244|ACTIVE_COMPARATOR|Hepatectomy|Using Hepatectomy for the treatment of advanced HCC
62692338|NCT01713244|EXPERIMENTAL|RFA assisted Hepatectomy|Ablating the liver tissue around the tumor before hepatectomy.
62692339|NCT05151731|EXPERIMENTAL|Arm A: 0.25 mg Vamikibart Q8W|Participants will receive vamikibart 0.25 milligrams (mg), by intravitreal (IVT) injection, on Day 1 and every 8th week (Q8W), up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
62484395|NCT02770222|EXPERIMENTAL|Part 2, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods.
62484396|NCT02770222|EXPERIMENTAL|Part 2, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin. During the second period (Treatment A), they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
62692340|NCT05151731|EXPERIMENTAL|Arm B: 1.0 mg Vamikibart Q8W|Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and Q8W, up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
62325702|NCT06042478|PLACEBO_COMPARATOR|Placebo to remibrutinib|Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w.
62692341|NCT05151731|EXPERIMENTAL|Arm C: 1.0 mg Vamikibart Q4W|Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and every 4th week (Q4W), up to Week 44 for a total of 12 injections.
61932787|NCT06624358|EXPERIMENTAL|Ramped step goal with financial incentive and feedback|This intervention designed to test if ramped step goals and/or financial incentive and/or daily feedback improve physical activity participation.
61932788|NCT06624358|EXPERIMENTAL|Personalized plan with fixed step goal|This intervention designed to test if personalized exercise plan and/or fixed step goal improves physical activity participation.
61932789|NCT06624358|EXPERIMENTAL|Personalized plan with fixed step goal and feedback|This intervention designed to test if personalized exercise plan and/or fixed step goal and/or daily feedback improves physical activity participation.
61932790|NCT06624358|EXPERIMENTAL|Personalized plan with fixed step goal and financial incentive|This intervention designed to test if personalized exercise plan and/or fixed step goal and/or financial incentive improves physical activity participation.
61932791|NCT06624358|EXPERIMENTAL|Personalized plan with fixed step goal and financial incentive and feedback|This intervention designed to test if personalized exercise plan and/or fixed step goal and/or financial incentive and/or daily feedback improves physical activity participation.
62325703|NCT06042478|PLACEBO_COMPARATOR|Placebo to omalizumab|Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d.
62325704|NCT06042478|ACTIVE_COMPARATOR|Omalizumab|participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d. for 52 weeks.
62325705|NCT04613596|EXPERIMENTAL|Phase 2 Cohort 1a: PD-L1 TPS <1%|Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab
61932792|NCT06624358|EXPERIMENTAL|Personalized plan with ramped step goal|This intervention designed to test if personalized exercise plan and/or fixed step goal improves physical activity participation.
61932793|NCT06624358|EXPERIMENTAL|Personalized plan with ramped step goal and feedback|This intervention designed to test if personalized exercise plan and/or fixed step goal and/or daily feedback improves physical activity participation.
61932794|NCT06624358|EXPERIMENTAL|Personalized plan with ramped step goal and financial incentive|This intervention designed to test if personalized exercise plan and/or fixed step goal and/or financial incentive improves physical activity participation.
62133109|NCT05051982|NO_INTERVENTION|Control Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the control group, an apparatus will be placed over the monitor will not be in view of the anesthesiologist. The
62325706|NCT04613596|EXPERIMENTAL|Phase 2 Cohort 1b: PD-L1 TPS <1%|Cohort 1b: Adagrasib BID monotherapy
62325707|NCT04613596|EXPERIMENTAL|Phase 2 Cohort 2: PD-L1 TPS ≥1%|Cohort 2: Adagrasib BID in combination with pembrolizumab
62325708|NCT04613596|EXPERIMENTAL|Phase 3 Cohort 3 Investigational Arm|Adagrasib BID in combination with pembrolizumab
62692342|NCT05151731|ACTIVE_COMPARATOR|Arm D: 0.5 mg Ranibizumab Q4W|Participants will receive ranibizumab 0.5 mg, by IVT injection, on Day 1 and Q4W, up to Week 44 for a total of 12 injections.
62692343|NCT02909114|EXPERIMENTAL|Experimental group|SBRT for oligometastatases from colorectal cancer objectives
61932795|NCT06624358|EXPERIMENTAL|Personalized plan with ramped step goal and financial incentive and feedback|This intervention designed to test if personalized exercise plan and/or fixed step goal and/or financial incentive and/or daily feedback improves physical activity participation.
61932796|NCT06535919||RUP|Individuals receiving TAU from RUP
62133110|NCT05747716|EXPERIMENTAL|SBRT, Fruquintinib, Cadonilimab|
62133111|NCT02755259|EXPERIMENTAL|Acetazolamide|Diamox 500mg i.v. (1x)
62133112|NCT02755259|PLACEBO_COMPARATOR|Placebo|Placebo Saline injection (1x)
62133113|NCT01869179|EXPERIMENTAL|Community of Voices choir program|Participants will receive the 12 month choir program as soon as possible after study enrollment.
62133114|NCT01869179|EXPERIMENTAL|Wait-list control group|Waits six months, and at the end of the six months is offered the option of participating in the 12 month choir program.
62133115|NCT04613375||All participants|
62133116|NCT00805844||1|Spine surgery with Motor Evoked Potential monitoring without SedLine monitoring visible.
62133117|NCT00805844||2|Spine surgery with Motor Evoked Potential Monitoring with SedLine monitoring visible.
62133118|NCT04790357|OTHER|Reference strategy|correspond to the reference techniques according to the current guidelines in the etiological work up of ischemic strokes and TIA
62133119|NCT04790357|OTHER|Evaluated strategy|correspond to perform the cci-MR: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
62133120|NCT04605731|EXPERIMENTAL|Treatment (durvalumab, tremelimumab)|Patients undergo standard of care radioembolization with Yttrium-90 SIR-spheres intra-arterially over 60-90 minutes on day -14. Patients then receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on day 1. Cycles with durvalumab repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
62484397|NCT03317444|EXPERIMENTAL|TRC101|Administered once daily (QD) for 12 weeks
62484398|NCT03317444|PLACEBO_COMPARATOR|Placebo|Administered once daily (QD) for 12 weeks
62484399|NCT02531620|EXPERIMENTAL|Physiatry|Pre-operative Physiatry assessment and intervention
62484400|NCT02531620|OTHER|Routine Care|Patients will receive routine pre-operative care, this study arm does not have an intervention.
62484401|NCT01443195|EXPERIMENTAL|Iron suplementation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal
62484402|NCT02563379||Dippers|"Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.~Extreme dipping is marked nocturnal systolic and/or diastolic BP fall\>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio \<0.8.~Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects."
62484403|NCT02563379||Non-dippers|"Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.~In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects."
62484404|NCT02563379||Morning Hypertensives|"It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.~Patients in this group will have morning hypertension that is classified into two types:~the morning-surge type, characterized by a marked increase in blood pressure in the early morning, and the nocturnal-hypertension type, characterized by high blood pressure that persists from nighttime until early morning.~In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects."
62484405|NCT01651845||Image Guided Intervention|Standard of care white light visual wound assessment followed by fluorescence image-guided wound assessment
62692344|NCT04784143|ACTIVE_COMPARATOR|Two sessions of MDMA-assisted therapy|Two experimental sessions of MDMA-assisted therapy
62133121|NCT04328155|EXPERIMENTAL|Hotpack Group|Group I (15 subjects) received 18 sessions hotpack to hamstring muscles and self stretching exercise3 times per week.
62133122|NCT04328155|EXPERIMENTAL|Infrared Group|Group II (15 subjects) received 18 sessions infrared to hamstring muscles and self stretching exercise3 times per week.
62484406|NCT06000085|EXPERIMENTAL|Flowable Giomer Beautifil flow plus x|injectable flowable restorative material
62484407|NCT06000085|ACTIVE_COMPARATOR|Glass-hybrid-added HVGIC Equia Forte|Glass-hybrid-added Highly viscous glass ionomer cement
62484408|NCT06254014|EXPERIMENTAL|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg,Subcutaneous injection in the abdomen,Bi-weekly for 54 weeks.
62692345|NCT04784143|ACTIVE_COMPARATOR|Three sessions of MDMA-assisted therapy|Three experimental sessions of MDMA-assisted therapy
62692346|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function (\[24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
62692347|NCT04667572|EXPERIMENTAL|Pulsed 5mW/cm2|5mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 36 minute total treatment time
62692348|NCT04667572|EXPERIMENTAL|Pulsed 8mW/cm2|8mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 22 minute and 30 seconds total treatment time
62133123|NCT04328155|EXPERIMENTAL|Ultrasound Group|Group III (15 subjects) received 18 sessions ultrasound to hamstring muscles and self stretching exercise 3 times per week.
62133124|NCT04328155|ACTIVE_COMPARATOR|Control|Group IV (15 subjects) received 18 sessions self stretching exercise 3 times per week.
62133125|NCT02634450|NO_INTERVENTION|Control|Current practice of Early Infant Diagnosis in Mozambique: using conventional system of collecting blood on Dried Blood Spot and sending it to central laboratory for PCR processing and receiving result by SMS printer.
62325709|NCT04613596|ACTIVE_COMPARATOR|Phase 3 Cohort 4 Comparator Arm|Pembrolizumab
61932797|NCT04175054|ACTIVE_COMPARATOR|Low Intensity Group|Less than 40% Heart Rate Reserve
61932798|NCT04175054|EXPERIMENTAL|Vigorous Intensity Group|More than 60% Heart Rate Reserve
62325710|NCT05578612|EXPERIMENTAL|Bridge Plate Removal at 6-8 Weeks Postoperatively|Participants will undergo dorsal spanning bridge plate fixation per standard technique. Patients in the experimental group will return to the operative room for removal of the bridge plate at Week 6-8. Patients will begin the standardized postoperative rehabilitation protocol immediately following bridge plate removal on Week 6-8.
62325711|NCT05578612|ACTIVE_COMPARATOR|Bridge Plate Removal at 12-14 Weeks Postoperatively|Participants will undergo dorsal spanning bridge plate fixation per standard technique. Patients in the control group will return to the operating room for removal of the bridge plate at Week 12-14. Patients will begin the standardized postoperative rehabilitation protocol immediately following bridge plate removal on Week 12-14.
62325712|NCT06075147||naïve nAMD|Treatment-naive patients with nAMD
62325713|NCT06075147||pretreated nAMD|Pretreated patients with nAMD
62325714|NCT06075147||naïve DME|Treatment-naïve patients with DME
62325715|NCT06075147||pretreated DME|Pretreated patients with DME
62325716|NCT05724108|EXPERIMENTAL|Arm 1 (triapine, lutetium Lu 177 dotatate)|Patients receive triapine PO QD on days 1-14 of each cycle and lutetium Lu 177 dotatate IV over 30 minutes on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
62325717|NCT05724108|ACTIVE_COMPARATOR|Arm 2 (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
62325718|NCT03841617|ACTIVE_COMPARATOR|124I PET/CT scan after rhTSH|124I PET/CT scan after preparation with human recombinant TSH
62484409|NCT06254014|EXPERIMENTAL|Exendin-4 Fc fusion protein injection(2.4mg）|The first dose of 1.2 mg of JY09 injection was administered, the dose was adjusted to 2.4 mg after two weeks, after which 2.4 mg was maintained to continue subcutaneous injection in the abdomen, bi-weekly treatment for 52 weeks.
62484410|NCT06254014|PLACEBO_COMPARATOR|placebo(0.6ml）|JY09 placebo injection 0.6 ml, biweekly abdominal subcutaneous injection for 26 weeks, followed by randomization in a 1:1 ratio into JY09 (1.2 mg) and JY09 (2.4 mg) for 28 weeks, biweekly subcutaneous injections.
62484411|NCT05813847|EXPERIMENTAL|CPL-01|Local infiltration of CPL-01
62484412|NCT05813847|ACTIVE_COMPARATOR|Ropivacaine HCl|Local infiltration of Naropin
62484413|NCT05813847|PLACEBO_COMPARATOR|Placebo|Local infiltration of Saline Placebo
62484414|NCT06262295||Implantation of the pacemaker without lead AVEIR VR LP|
62484415|NCT03542669|EXPERIMENTAL|6B11-OCIK injection|
62484416|NCT05606458|NO_INTERVENTION|Control Group|The baby who met the inclusion and exclusion criteria underwent routine heel blood sampling at the hospital. First of all, the foot of the baby, who was taken to an open bed under a radiant heater, was warmed in the nurse's hand for one minute, the area where the baby's heel blood would be taken was determined, the baby's heel was wiped with 70% alcohol with the help of a sponge and waited for it to dry, then heel lance was performed. The procedure was completed after the relevant sections on the pre-prepared heel blood sheet were filled with blood. A light touch was provided if necessary for routine comfort of the infant for ethical reasons.
62484417|NCT05606458|EXPERIMENTAL|İntervention Group|"Their mothers gave a multisensory stimulus to the newborns in the mother's room.~1. Stimulus: Breast milk, breastfeeding (sense of taste)~2. Stimulus : Maternal touch (sense of touch)~3. Stimulus: Mother's voice (hearing sense)~4. Stimulus: Maternal eye contact (sense of sight)~5. Stimulus: Mother skin smell (sense of smell)"
62484418|NCT05026138||Biological relatives without HPV|Biological relatives without current HPV disease serving as controls to be compared with those from affected participants for evaluation of the differences between people with HPV and without.
62484419|NCT05026138||Participants with HPV|Patients with recurrent HPV related diseases refractory to standard-of-care medical or surgical interventions.
62484420|NCT01207479|EXPERIMENTAL|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
62484421|NCT02911025||Patients Treated With Clobazam|Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.
62484422|NCT05755113|EXPERIMENTAL|Single Arm, Open Label|Single or multiple Intratumoural injections of tigilanol tiglate at up to a fixed dose of 3.6 mg/m2 (Body Surface Area \[BSA\]) per treatment.
62484423|NCT00848536|EXPERIMENTAL|TRAVATAN APS|One drop once daily in the evening for 3 months
62484424|NCT00848536|ACTIVE_COMPARATOR|TRAVATAN|One drop once daily in the evening for 3 months
62484425|NCT02566122||muscle strength ,muscle mass|
62484426|NCT05795504|EXPERIMENTAL|resistive exercises|Premenopausal women in group A will perform resistive exercise for upper and lower limbs, three times per week in addition to calcium and vitamin d supplementations.
61932799|NCT05271630||Single Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving single maintenance therapy with an immunomodulatory drug after Autologous Stem Cell Transplant for Multiple Myeloma
62133126|NCT02634450|ACTIVE_COMPARATOR|Intervention|Point Of Care Device (Alere q) is used for Early Infant Diagnosis, with the sample collected and processed in the consultation room with the device
62133127|NCT00775294|EXPERIMENTAL|maraviroc|Single arm trial looking at the pharmacokinetics of maraviroc in healthy volunteers.
62133128|NCT04749784|EXPERIMENTAL|High dose IP|Two tablets IP daily for 12 weeks
62484427|NCT05795504|EXPERIMENTAL|high intensity interval training|Premenopausal women in group B will receive high intensity interval training for three times per week in addition to calcium and vitamin D supplementations
62484428|NCT05795504|ACTIVE_COMPARATOR|conventional therapy|Premenopausal women in group C will receive calcium and vitamin D supplementations only.
62484429|NCT04332445|EXPERIMENTAL|Experimental|subjects, 18-70 y, healthy
62484430|NCT01910038|EXPERIMENTAL|Prednisone+Tocilizumab|Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).
62484431|NCT04863560||Hoehn & Yahr stage I (H&YI)|- 20 Hoehn \& Yahr stage I (early disease, minimal symptoms)
62484432|NCT04863560||Hoehn & Yahr stage II (H&YII)|- 30 Hoehn \& Yahr stage II (mild disease, no balance issues)
62484433|NCT04863560||Hoehn & Yahr stage III (H&YIII)|- 30 Hoehn \& Yahr stage III (moderate disease, balance issues)
62484434|NCT05488158|ACTIVE_COMPARATOR|MD|Allopathic physicians in one arm of the study were treated with OMT to alleviate pain and somatic disfunction. The amount of pain they were experiencing before treatment was recorded using a Likert pain scale.
62484435|NCT05488158|ACTIVE_COMPARATOR|DO|Osteopathic physicians in one arm of the study were treated with OMT to alleviate pain and somatic disfunction. The amount of pain they were experiencing before treatment was recorded using a Likert pain scale.
62484436|NCT04631562|EXPERIMENTAL|ALXN1820|Participants will receive ALXN1820 SC or ALXN1820 IV according to their assigned cohort. ALXN1820 SC will be evaluated in single and multiple ascending doses while ALXN1820 IV will be evaluated in a single dose cohort only.
62484437|NCT04631562|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
61932800|NCT05271630||Double Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving double maintenance therapy with the combination of an immunomodulatory drug and a proteasome inhibitor after Autologous Stem Cell Transplant for Multiple Myeloma.
62133129|NCT04749784|EXPERIMENTAL|Low dose IP|One tablet IP + one tablet placebo daily for 12 weeks
62133130|NCT04749784|PLACEBO_COMPARATOR|Placebo|Two tablets placebo daily for 12 weeks
62133131|NCT05821569||standard position during breastfeeding|Women who adopted, according to their preference and/or to the professional advice and support of the nursing staff the standard position (derived from UNICEF guidelines) to breastfeed
62133132|NCT05821569||biological nurturing|Women who adopted, according to their preference and/or to the professional advice and support of the nursing staff, the biological nurturing approach to breastfeed
62484438|NCT02343796|EXPERIMENTAL|Fibre-reinforced composite|Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
61932801|NCT04926831|EXPERIMENTAL|Cohort A|Participants with NSCLC with MET exon 14 skipping mutations, irrespective of MET gene copy number (GCN) will take 400 mg tablet orally twice per day
61932802|NCT04926831|EXPERIMENTAL|Cohort B|Participants with NSCLC with high level MET amplification will take 400 mg tablet orally twice per day
61932803|NCT03708185|EXPERIMENTAL|HIIT + beta-alanine|Participants will ingest an active supplement containing beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
61932804|NCT03708185|EXPERIMENTAL|HIIT + placebo|Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
61932805|NCT04078178|EXPERIMENTAL|Sequence 1: Active Niagen, Placebo|Subjects received 1000 mg Niagen and PBO dispensed in randomized blocks. Participants in Sequence 1 took Niagen daily for 8 weeks, followed by Placebo daily for 8 weeks.
61932806|NCT04078178|EXPERIMENTAL|Sequence 2: Placebo, Active Niagen|Subjects received 1000 mg Niagen and PBO dispensed in randomized blocks. Participants in Sequence 2 took Placebo daily for 8 weeks, followed by Active Niagen daily for 8 weeks.
61932807|NCT03564691|EXPERIMENTAL|Dose Escalation, Part A: MK-4830 Monotherapy|MK-4830 monotherapy (with MK-4830 doses determined by an accelerated titration design \[ATD\]) will be administered intravenously (IV), every 3 weeks (Q3W), starting with Cycle 1, Day 1, for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pancreatic adenocarcinoma.
61932808|NCT03564691|EXPERIMENTAL|Dose Escalation, Part B: MK-4830 Monotherapy|MK-4830 monotherapy (with MK 4830 doses determined by a modified toxicity probability interval \[mTPI\] method) will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes.
61932809|NCT03564691|EXPERIMENTAL|Dose Escalation, Part C: MK-4830 and Pembrolizumab|Combination therapy with MK-4830 and pembrolizumab (with MK-4830 doses determined by an mTPI design). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
61932810|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm A: Pancreatic Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed pancreatic adenocarcinoma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
62325719|NCT03841617|ACTIVE_COMPARATOR|124I PET/CT scan after thyroid hormone withdrawal|124I PET/CT scan after preparation with thyroid hormone withdrawal
62325720|NCT06402331|EXPERIMENTAL|FPI-2265 50 kBq/kg|Arm 1: FPI-2265 administered by IV injection every four weeks; up to 9 doses.
62325721|NCT06402331|EXPERIMENTAL|FPI-2265 75 kBq/kg|Arm 2: FPI-2265 administered by IV injection every six weeks; up to 6 doses.
62325722|NCT06402331|EXPERIMENTAL|FPI-2265 100 kBq/kg|Arm 3: FPI-2265 administered by IV injection every eight weeks; up to 4 doses.
62325723|NCT06495970|EXPERIMENTAL|PADN with Gradient Denervation System|
62325724|NCT03606967|EXPERIMENTAL|Arm I (neoantigen vaccine, durvalumab, nab-paclitaxel)|See Detailed Description.
62325725|NCT03606967|ACTIVE_COMPARATOR|Arm II (durvalumab, nab-paclitaxel)|See Detailed Description.
62325726|NCT05623007|EXPERIMENTAL|Intervention|220 overweight/obese adolescents will be given Probiotics and counselling on healthy eating, physical activity, and psychosocial stimulation.
62325727|NCT05623007|PLACEBO_COMPARATOR|Control|220 overweight/obese adolescents will be given placebo probiotics and counselling on healthy eating, physical activity, and psychosocial stimulation.
62325728|NCT00046059||ADHD|Children aged 7-17 with ADHD and their families.
62325729|NCT06603298||Medical therapy alone|It includes patients with Crohn's disease who were only treated with biological therapy for clinically significant intestinal stenosis. These patients underwent drug treatment without any endoscopic procedure.
62325730|NCT06603298||Medical therapy + endoscopic dilatation|It includes patients who received both endoscopic dilatation (ED) with a balloon and biological therapy. This cohort underwent combined treatment for intestinal stenosis, integrating mechanical and pharmacological intervention.
62325731|NCT06600074|ACTIVE_COMPARATOR|Back care advice + Postural correction exercises|It will include 18 postpartum women who will receive back care advice and postural correction exercises.
62325732|NCT06600074|EXPERIMENTAL|Back care advice + Postural correction exercises + Retro-walking|It will include 18 postpartum women who will receive the same back care advice and postural correction exercises, in addition to retro-walking.
62325733|NCT05716100|EXPERIMENTAL|XEN1101 25 mg/day|XEN1101 25 mg/day
62325734|NCT05716100|EXPERIMENTAL|XEN1101 15 mg/day|XEN1101 15 mg/day
62325735|NCT05716100|PLACEBO_COMPARATOR|Placebo|Placebo
62325736|NCT06135870||Women with fibroids undergoing elective hysterectomy or myomectomy|Women between the age of 18-55 with fibroids undergoing elective hysterectomy or myomectomy
62325737|NCT06608927|EXPERIMENTAL|Arm A (Experimental Arm)|Quemliclustat, nab-paclitaxel and gemcitabine will be administered by IV infusion
62325738|NCT06608927|PLACEBO_COMPARATOR|Arm B (Comparator Arm)|Placebo, nab-paclitaxel and gemcitabine will be administered by IV infusion
62325739|NCT06660225|EXPERIMENTAL|Sham Control stimulation, then Therapeutic stimulation|"Subject randomized to this arm are initially OFF DBS (Deep Brain Stimulation) prior to the open label period for 16 weeks and then ON DBS for the next 16 weeks. This is then followed by an open-label period of DBS stimulation."
62484439|NCT01160796|EXPERIMENTAL|Lcr35®|
62484440|NCT01160796|PLACEBO_COMPARATOR|placebo|
62484441|NCT03168659|OTHER|Treatment|Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
62484442|NCT04762966||Therapeutic|Patients with metformin blood concentration in the therapeutic ranges.
62484443|NCT04762966||Supratherapeutic|Patients with metformin blood concentration above the therapeutic ranges.
62692349|NCT02298946|EXPERIMENTAL|DL1 - CTX, SBRTx1 day, & AMP-224|Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0. Stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days for a total of 6 doses
62692350|NCT02298946|EXPERIMENTAL|DL2 - CTX, SBRTx3 days, and AMP-224|Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.
61932811|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm B: Glioblastoma (GBM)|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed GBM. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
62484444|NCT04872075|EXPERIMENTAL|Experimental|People at the concert
62484445|NCT04872075|ACTIVE_COMPARATOR|Control|People staying at home
61932812|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm C: R/M HNSCC|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease progressed on an anti-programmed cell death 1/programmed cell death ligand 1 (PD1/L1) therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
62692351|NCT06641336|EXPERIMENTAL|RehAtt|Each patient was included in the introduction session (performed by a psychologist), three sessions of occupational therapy and three sessions of physiotherapy. Each session lasted for 30 minutes. Occupational-therapy training was focused on activities aimed at improving upper limb function; physiotherapy training was focused on balance, walking and standing.
62692352|NCT00194311||pregnancy complications|prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR).
61932813|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm D: PD-L1 positive HNSCC, Dose A|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed advanced programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma (HNSCC). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
61932814|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm E: First-Line Advanced NSCLC, Dose A|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
61932815|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm F: First-Line Advanced NSCLC, Dose B|Combination therapy with the preliminary RP2D B of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
62133133|NCT02891915|ACTIVE_COMPARATOR|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
62133134|NCT02891915|ACTIVE_COMPARATOR|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
62133135|NCT00515814|EXPERIMENTAL|1, 2|During measurement/test periods, investigator sets implant into ON or OFF condition without subjects knowledge of when device is active.
62325740|NCT06660225|EXPERIMENTAL|Therapeutic stimulation, then Sham Control stimulation|"Subjects randomized to this arm are initially ON DBS prior to the open label period for 16 weeks and then OFF DBS for the next 16 weeks. This is followed by an open-label stimulation period."
62484446|NCT03887884|EXPERIMENTAL|CVT-301|Single inhaled dose of CVT-301 84 mg
62484447|NCT03887884|ACTIVE_COMPARATOR|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
62484448|NCT03243786|ACTIVE_COMPARATOR|"12-week Stay on Track intervention"|The study intervention includes three personal exercise training sessions, three dietary counseling sessions, use of a physical activity tracking device, and approximately three weekly text messaging
62484449|NCT03243786|ACTIVE_COMPARATOR|12-week self-guided control|The self guided group does not receive the study intervention, but is offered a Nutrition and wellness guide at the end of 6 months
62484450|NCT00725322|EXPERIMENTAL|Placebo then Botox|
62484451|NCT00725322|EXPERIMENTAL|Botox then Placebo|
62484452|NCT01853722|EXPERIMENTAL|DCN01|
62484453|NCT01853722|PLACEBO_COMPARATOR|Unisol|
62484454|NCT05272813|EXPERIMENTAL|MS-553 Low Dose|MS-553 Low Dose PO BID
62484455|NCT05272813|EXPERIMENTAL|MS-553 Mid Dose-1|MS-553 Mid Dose-1 PO BID
62484456|NCT05272813|EXPERIMENTAL|MS-553 Mid Dose-2|MS-553 Mid Dose-2 PO BID
62484457|NCT05272813|EXPERIMENTAL|MS-553 High Dose|MS-553 High Dose PO BID
62484458|NCT03734263|EXPERIMENTAL|open label|sodium phenylbutyrate
62484459|NCT00178178|EXPERIMENTAL|Drug: Bupivicaine 0.5% Intraaticulary Only|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Intraaticular Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter"
62692353|NCT04573478|EXPERIMENTAL|Atrasentan|"Double-blind Period: Once daily oral administration of 0.75 mg atrasentan for 132 weeks.~Open-label Extension Period: Once daily oral administration of 0.75 mg atrasentan for 48 weeks after completion of 132 weeks on atrasentan or placebo."
62692354|NCT04573478|PLACEBO_COMPARATOR|Placebo|Double-blind Period: Once daily oral administration of placebo for 132 weeks
62692355|NCT01854775|EXPERIMENTAL|Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg|HIV-infected, ARV treatment-naive adolescents (12 to \< 18 years of age weighing ≥ 35 kg) will receive E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
61932816|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm G: NSCLC, +Carboplatin/Pemetrexed|Combination therapy with the preliminary RP2D A of MK-4830, pembrolizumab, and carboplatin/pemetrexed in participants with advanced non-squamous non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Carboplatin and pemetrexed will be administered IV Q3W, starting with Cycle 1, Day 1, for 4 cycles, followed by pemetrexed Q3W continuous with MK-4830 and pembrolizumab, up to 35 cycles. Each cycle is 21 days (up to approximately 2 years).
61932817|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm H: RCC, +Lenvatinib|Combination therapy with the preliminary RP2D A of MK-4830, pembrolizumab, and lenvatinib in participants with advanced renal cell carcinoma (RCC). MK-4830 will be administered IV, Q3W, starting with Cycle 1 following pembrolizumab infusion, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years). Lenvatinib will be administered orally once daily for up to 35 cycles of 21 days (up to approximately 2 years).
61932818|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm I: R/M Gastric/GE Junction Adenocarcinoma|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic (R/M) gastric or gastroesophageal (GE) junction adenocarcinoma and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
61932819|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm J: Ovarian Cancer|Triple combination therapy with pembrolizumab plus preliminary RP2D A of MK-4830 plus paclitaxel in participants who have histologically confirmed, ovarian cancer. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Paclitaxel will be administered by IV, once every week (QW) on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity.
62325741|NCT06660225|EXPERIMENTAL|Therapeutic stimulation|All participants will transition to an open label stimulation phase for chronic therapy after the cross-over portion of this trial
62325742|NCT03332940|EXPERIMENTAL|NASH subjects|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
62325743|NCT03332940|EXPERIMENTAL|Healthy controls|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
62325744|NCT06331312|EXPERIMENTAL|Secukinumab 300mg|All eligible participants will receive secukinumab 300 mg s.c. (2 x 150mg/1mL PFS secukinumab) from baseline and every 4 weeks up to 2 years. The study medication may be modified/adjusted after the initial doses of 300mg s.c. (decreased to 150mg s.c. q4w or increased again from 150mg s.c. q4w to 300mg s.c. q4w) if deemed appropriate by the investigator. Dose modification/adjustment may only occur from Week 24 visit onwards. The modification/adjustment of the study medication will be determined at a site visit.
62325745|NCT06588101|EXPERIMENTAL|Both recruitment strategies|Consent form with Infographic + Large compensation
62325746|NCT06588101|NO_INTERVENTION|Neither recruitment strategy|Consent form + No compensation
62325747|NCT06588101|EXPERIMENTAL|One recruitment strategy - Infographic|Consent form with Infographic + No compensation
62325748|NCT06588101|EXPERIMENTAL|One recruitment strategy - Compensation|Consent form + Large compensation
62484460|NCT00178178|EXPERIMENTAL|Drug: Bupivicaine 0.5% Patellar Tendon Site|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Patellar Tendon Site Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter"
62484461|NCT00178178|EXPERIMENTAL|Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%; Intraarticular and Patellar Tendon Sites~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter"
62484462|NCT00178178|PLACEBO_COMPARATOR|Drug: Placebo|"Breg Pain Care 3000 Catheter with Placebo~Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter"
62484463|NCT06628141|EXPERIMENTAL|Nutritional support tool|
62325749|NCT06001268|EXPERIMENTAL|STRONG-PCS Intervention|Participants will receive an initial in-person consultation with a dietician within 2 weeks of hospital discharge. Then participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing their data with a dietician.
62325750|NCT06001268|ACTIVE_COMPARATOR|Usual Care|Participants will be referred for nutrition counseling from a dietitian based on clinical discretion.
62325751|NCT06586541|NO_INTERVENTION|Phase 1 (Control group)|Participants will be able to engage in care as per current family engagement practices. Family members in the usual care group will not participate in daily ICU rounds. In-person or virtual family participation in rounds is not routinely performed at any of the trial sites.
62325752|NCT06586541|EXPERIMENTAL|Phase 2 (Intervention)|Participants in the Intervention group will be invited to participate in attending team rounds.
62325753|NCT06658496||Neonates with PDA|
62325754|NCT06657833|OTHER|Drug Eluting Balloon (DEB)|
62325755|NCT06657833|OTHER|Drug Eluting Stent (DES)|
62325756|NCT05955378|EXPERIMENTAL|DSR Ankle|The DSR Ankle is a novel microprocessor-controlled ankle prosthesis that is able to provide enhanced mobility and stability to individuals with lower limb amputation. It interfaces to the user by attaching to their socket via an industry-standard pyramid connector.
62325757|NCT05955378|ACTIVE_COMPARATOR|Predicate Ankle|The predicate ankle is the user's prescribed prosthesis worn for the activities of daily living.
62325758|NCT04227301||Hyponatremic patients|Patients hospitalized at the University Hospital of Basel and presenting with hyponatremia will be screened for the study
62325759|NCT06585774|EXPERIMENTAL|Axatilimab + Corticosteroids|Axatilimab and Corticosteroids at the protocol-defined dose.
62325760|NCT06585774|EXPERIMENTAL|Placebo + Corticosteroids|Matching placebo and Corticosteroids at the protocol-defined dose.
62325761|NCT06586528|NO_INTERVENTION|Control Group: Usual Care|Participants in the control group will not receive access to the NGAGE tool. Participants will be able to engage in care as per current family engagement practices at each site.
62325762|NCT06586528|EXPERIMENTAL|Intervention Group: Access to NGAGE Tool|Participants in the intervention group will be provided access to the NGAGE tool.
62325763|NCT04169568||OI manual cuff BP|Patients with diagnosis of Osteogenesis Imperfecta from ages 1 to 35 who are admitted to our institution to the inpatient, non-ICU setting, following orthopedic surgery for spine surgery, upper or lower extremity realignment and IM rodding
62325764|NCT06662123|EXPERIMENTAL|Subcutaneous|
62325765|NCT06662123|EXPERIMENTAL|Intravenous|
62325766|NCT05620407|EXPERIMENTAL|Arm 1: Deucravacitinib|
62325767|NCT05620407|PLACEBO_COMPARATOR|Arm 2: Placebo|
62325768|NCT05541354||Stakeholder Interviews|Semi-structured, open-ended interviews will be conducted via Zoom with a purposive sample of surgeons, anesthesiologists and OR nurses and trainees to identify perceived OR ergonomics issues among stakeholders
62325769|NCT05541354||OR Observations|Live observation of OR teams by teams of two observers (an anthropologist and an ergonomics expert, such as a chiropractor or physiotherapist). This will be done, in addition to the interview studies, to identify unperceived and misperceived needs using an observation data collection tool. Each of the following 4 phases of surgery will be assessed individually: 1) OR preparation (team arrival to wheels-in), 2) wheels-in to incision, 3) incision to closure, and 4) closure to wheels-out.
62325770|NCT05541354||Curriculum Piloting|Participating OR teams will take part in piloting sessions of the developed simulation curriculum to determine if it meets the proposed content objectives and ensure environmental validity.
62325771|NCT04159012|EXPERIMENTAL|Active transcranial direct current stimulation|Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
62325772|NCT04159012|SHAM_COMPARATOR|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
62325773|NCT03582033|EXPERIMENTAL|Parts A and B: SEA-BCMA Monotherapy|SEA-BCMA
62325774|NCT03582033|EXPERIMENTAL|Part C: SEA-BCMA + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone
62325775|NCT03582033|EXPERIMENTAL|Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone + pomalidomide
62325776|NCT06581198|EXPERIMENTAL|Regimen 1|rapcabtagene autoleucel Regimen 1
62325777|NCT06581198|EXPERIMENTAL|Regimen 2|rapcabtagene autoleucel Regimen 2
62325778|NCT06581198|ACTIVE_COMPARATOR|Standard of Care|The treatment regimen must be in line with Kidney Disease Improving Global Outcomes (KDIGO) guidelines for treatment of class III/IV LN.
62325779|NCT05630066|EXPERIMENTAL|Part 1 Adult Alogabat High Dose (aged 15-17)|In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat
62325780|NCT05630066|EXPERIMENTAL|Part 1 Age adjusted high dose (age 10-14)|In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat.
62325781|NCT05630066|EXPERIMENTAL|Part 1 Age Adjusted Low Dose (age 5-9)|In Part 1 of the study, participants will receive age-adjusted dose 20 mg QD alogabat.
62325782|NCT05630066|EXPERIMENTAL|Part 2 Cohort 1|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
62325783|NCT05630066|EXPERIMENTAL|Part 2 Cohort 2|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
62484464|NCT01096329|ACTIVE_COMPARATOR|Cohort 2|Testosterone Spray (5%) vs Intrinsa® Patch
62484465|NCT01096329|ACTIVE_COMPARATOR|Cohort 3|Testosterone Spray (1%) vs Intrinsa® Patch
62325784|NCT05630066|EXPERIMENTAL|Part 1 Optional Cohort|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, additional participants may be recruited in any of the of the 3 age-groups in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."
62484466|NCT01096329|ACTIVE_COMPARATOR|Cohort 1|Testosterone Spray (5%) vs Testosterone Spray (1%)
62484467|NCT06015035|EXPERIMENTAL|anlotinib for anti-angiogenesis and sintilimab and chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles.
62484468|NCT00091871||Affected family members|Family members with peripheral blood eosinophilia
62484469|NCT00091871||Unaffected family members|Family members without peripheral blood eosinophilia
62484470|NCT02112123|PLACEBO_COMPARATOR|Placebo|Matching placebo given for 5 days (qd po)
62133136|NCT06058767|ACTIVE_COMPARATOR|Two-stage PTA+OAE hearing screening (TS-PO)|"Children initially undergo a PTA screening test, recommended by the American Academy of Audiology and supported by published evidence. This screening assesses their hearing ability through conditioned-play responses to 25 dB HL pure tones at 1000, 2000, and 4000 Hz, yielding results of PASS, REFER, or UNABLE to test. Those UNABLE to be tested will receive a second OAE screening. Children who REFER either the PTA or OAE test, or are UNABLE to be tested by both, are referred to their pediatrician for further evaluation and management.~All children will undergo both PTA and OAE screening and the group allocation will be determined post hoc."
62484471|NCT02112123|ACTIVE_COMPARATOR|Icariin - 100 mg/day|Icariin given at 100 mg/day (qd po) for 5 days
62484472|NCT02112123|ACTIVE_COMPARATOR|Icariin - 200 mg/day|Icariin given at 200 mg/day (qd po) for 5 days
62484473|NCT02112123|ACTIVE_COMPARATOR|Icariin - 400 mg/day|Icariin given at 400 mg/day (qd po) for 5 days
62484474|NCT02112123|ACTIVE_COMPARATOR|Icariin - 840 mg/day|Icariin given at 840 mg/day (qd po) for 5 days
62484475|NCT02112123|ACTIVE_COMPARATOR|Icariin - 1680 mg/day|Icariin given at 1680 mg/day (qd po) for 5 days
62484476|NCT03972163|EXPERIMENTAL|SPECTORx Educational Intervention|The program intervention is based on a combination of 3 existing, complementary, educational programs that, together, equip hospice staff to create a comprehensive, patient-centered, medication management care plan.
62484477|NCT03972163|ACTIVE_COMPARATOR|Attention Control|"As the attention control, we will refer staff in control offices to the National Institute of Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
62133137|NCT06058767|ACTIVE_COMPARATOR|Single-Stage OAE hearing screening (SS-O)|"Children undergo only screening with OAEs, detecting distortion-product OAEs in response to tone pairs centered at 2000, 3000, 4000, and 5000 Hz. If they PASSED the OAE, they would be assigned a PASS for the SS-O Hearing Screen outcome; if they REFERRED or were UNABLE to test, they would be assigned a REFER.~All children will undergo both PTA and OAE screening and the group allocation will be determined post hoc."
62133138|NCT04884165|EXPERIMENTAL|Intervention|Remote monitoring using SRETT (CE marked device) + home mechanical ventilation (non-invasive ventilation, NIV) and usual care.
62133139|NCT04884165|ACTIVE_COMPARATOR|Control|Home mechanical ventilation (non-invasive ventilation, NIV) with usual care.
62325785|NCT05630066|EXPERIMENTAL|Part 2 Optional Cohort|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, participants from any of the 3 age-groups may enroll in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."
62133140|NCT04174768|EXPERIMENTAL|Bariatric surgery patients|Bariatric patients undergoing sleeve gastrectomy or Roux-en-Y gastric bypass
62133141|NCT00764335||unilateral normal|total hip arthroplasty one side, normal offset of medial femoral head
62133142|NCT00764335||bilateral normal|total hip arthroplasty both sides, normal offset of medial femoral head
62133143|NCT00764335||bilateral abnormal offset|total hip arthroplasty both sides, abnormal offset of medial femoral head
62325786|NCT06655896|EXPERIMENTAL|rapcabtagene autoleucel arm|rapcabtagene autoleucel
62325787|NCT06655896|ACTIVE_COMPARATOR|rituximab arm|rituximab
62325788|NCT05375812||GWI|Gulf War Veterans
62325789|NCT05375812||HVC|Healthy Volunteer Controls
62484478|NCT04511039|EXPERIMENTAL|Treatment Arm|Patients receive trifluridine/tipiracil PO BID and talazoparib tosylate PO QD on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62484479|NCT03978442|EXPERIMENTAL|CPT-SMART|COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) - an intervention that combines evidence-based PTSD treatment with guideline-concordant cognitive-behavioral smoking cessation counseling, bupropion, and intensive behavioral therapy through CM.
62484480|NCT03978442|ACTIVE_COMPARATOR|Combined Contact Yoked Control|COMBINED CONTACT YOKED CONTROL (CCYC) - an intervention that is identical to CPT-SMART for PTSD and smoking treatment, except for using non-contingent payment (i.e., yoked CM) to control for compensation and monitoring.
62484481|NCT06415903|EXPERIMENTAL|TQB3117 tablets|TQB3117 tables is administered as a single dose or multiple dose, ranging from 20 to 180 mg once daily. Oral administration on fast condition, with each cycle lasting 21 days.
62484482|NCT03785262|SHAM_COMPARATOR|Sham|Inactive uroshield device
62484483|NCT03785262|EXPERIMENTAL|Active Uroshield|Active uroshield device
62484484|NCT03653299|EXPERIMENTAL|Group A - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy A will receive the programs in the following order 1, 2, 3 and 4, before the tests."
62484485|NCT03653299|EXPERIMENTAL|Group B - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy B will receive the programs in the following order 2, 3, 4 and 1, before the tests."
62484486|NCT03653299|EXPERIMENTAL|Group C - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy C will receive the programs in the following order 3, 4, 1 and 2, before the tests."
62484487|NCT03653299|EXPERIMENTAL|Group D - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy D will receive the programs in the following order 4, 1, 2 and 3, before the tests."
62484488|NCT01934205|EXPERIMENTAL|Part A(Cohort1)|Study BTZ116666 has two parts. Each part will consist of a maximum of 6 cohorts. Part A will be initiated with 4 initial cohorts/timepoints in order to minimize the number of healthy volunteers that undergo bronchoscopy in this study. After review of data from Cohorts 1 through 4 of Part A, the study team will determine if additional cohorts are needed to be studied in Part A and/ or if Part B is needed. If the study team determines that additional cohorts are needed, then only the necessary cohorts in Parts A and/or B will be executed. In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 2 hours x 1 dose
62484489|NCT01934205|EXPERIMENTAL|Part A (Cohort2)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 4 hours x 1 dose
62484490|NCT01934205|EXPERIMENTAL|Part A (Cohort3)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 8 hours x 1 dose
62484491|NCT01934205|EXPERIMENTAL|Part A (Cohort4)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 12 hours x 1 dose
62484492|NCT01934205|EXPERIMENTAL|Part A (Cohort5)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
62484493|NCT01934205|EXPERIMENTAL|Part A (Cohort6)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
61932820|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm K: Triple negative Breast Cancer (TNBC)|Triple combination therapy with pembrolizumab plus preliminary RP2D A of MK-4830 plus paclitaxel in participants who have histologically confirmed TNBC. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Paclitaxel will be administered by IV on Days 1, 8, and 15 every 4 weeks (Q4W) until disease progression or prohibitive toxicity.
61932821|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm L: Mesothelioma|Triple combination therapy with pembrolizumab plus preliminary RP2D A of MK-4830 plus pemetrexed plus cisplatin in participants who have histologically confirmed advanced mesothelioma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Pemetrexed will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days. Cisplatin will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days.
61932822|NCT03564691|EXPERIMENTAL|Dose Expansion, Arm M: Advanced Solid Tumor in Chinese Participants In China|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in Chinese participants, who reside in China, have histologically or cytologically-confirmed advanced/metastatic solid tumor, and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
62325790|NCT06156943|EXPERIMENTAL|Optimized group managed by the Starling device|In the optimized group, patients will be managed intraoperatively with the Starling device according to the Société Française d'Anesthésie Réanimation 2024 GDFT protocol (Alter C. https://sfar.org/optimisation-hemodynamique-perioperatoire-adulte-dont-obstetrique/). It is a non-invasive fluid management monitoring system provides continuous hemodynamic monitoring and empowers fluid management across the continuum of care. Thanks to this device, patients will be managed according to the following protocol: fluid responsiveness will be systematically assessed after anesthetic induction and throughout the procedure as soon as the basal SV monitored by the Starling device decrease by at least 10%. To do so, repetitive fluid challenges (200 ± 50 ml of cristalloids) will be quickly delivered until SV stops to increase by 10% or more. Vasoactive and/or inotropic agents will be used at the discretion of the attending anesthesiologists in case of fluid unresponsiveness.
62325791|NCT06156943|OTHER|Control group managed by standard of care|In the control group, patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols (i.e. fluids and/or vasoactive agents are given to maintain mean arterial pressure ≥ 65 mmHg).
62325792|NCT05640752|EXPERIMENTAL|ESC strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL \<15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
62133144|NCT00764335||controls|Healthy, age-matched control group
62484494|NCT01934205|EXPERIMENTAL|Part B (Cohort1)|In Part B, participants will receive GSK2140944 1000 mg IV infusion, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
62484495|NCT01934205|EXPERIMENTAL|Part B (Cohort2)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
62484496|NCT01934205|EXPERIMENTAL|Part B (Cohort3)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
62484497|NCT01934205|EXPERIMENTAL|Part B (Cohort4)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
62484498|NCT01934205|EXPERIMENTAL|Part B (Cohort5)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
62484499|NCT01934205|EXPERIMENTAL|Part B (Cohort6)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
62484500|NCT06603597||HER2-positive breast cancer|Patients with stage I-IV HER2-positive breast cancer
62484501|NCT03442491||Hayman's Haemostatic Suture|Women that had major Post-partum Haemorrhage, defined as postpartum blood loss in excess of 2000 ml, resistant to pharmacologic treatment and that underwent Hayman's Haemostatic Suture.
62484502|NCT02728999|OTHER|Group A|Steep Trendelenburg
62484503|NCT02728999|EXPERIMENTAL|Group B|Decreased Trendelenburg
62325793|NCT05640752|EXPERIMENTAL|NICE strategy|According to NICE strategy, subjects with nonanginal chest pain and normal ECG are classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG are classified into high risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
62484504|NCT05766150||Patients with no oral malignant disease|
62484505|NCT05766150||Patients with oral premalignant disease|
62484506|NCT05766150||Patients with oral malignant disease|
62484507|NCT05216562|EXPERIMENTAL|Intervention group|Group participants who receive injection of EXOSOME-MSC as adjuvant
62484508|NCT05216562|PLACEBO_COMPARATOR|Control group|Group participants who receive injection of Placebo (NaCL) as adjuvant
62484509|NCT01203215|EXPERIMENTAL|JumpStart|
62484510|NCT01203215|EXPERIMENTAL|Choose to Move|
62484511|NCT01203215|ACTIVE_COMPARATOR|Wellness|
62484512|NCT03218787|EXPERIMENTAL|XIENCE|Subjects will receive XIENCE family stents and if a subject was DAPT compliant and event free, then took 3 month DAPT, following with aspirin mono-therapy until 12 month
62133145|NCT05307536|EXPERIMENTAL|Autologous BMMNCs infusion combined with educational intervention|"Bone marrows are harvested from the patient's iliac depending on the patient's body weight as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) × 7 ml\] for patients above 10 kg. Mononuclear cells from collected bone marrow are infused intrathecally through a space between number vertebrae 4th and 5th. Two transplantations will be conducted at an interval of 6 months. The educational intervention will be developed based on the Early Start Denver Model for 6 months after the first infusion.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), and Clinical Global Impression (CGI). In addition, Health-related quality of life (HRQoL) in patients will be evaluated at baseline, two months, six months, and 12 months with those in the control group (educational intervention only) using the Pediatric Quality of Life Inventory (PedsQL)"
62484513|NCT02792816||Kawthaung Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Kawthaung is one of the sentinel site and located at the Southern Myanmar.
62484514|NCT02792816||Myawaddy Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Myawaddy is one of the sentinel site and located at the northern part of the Southern Myanmar.
62484515|NCT02792816||Thanbyuzayat Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Thanbyuzayat is one of the sentinel site and located at the northern part of the Southern Myanmar.
62484516|NCT02792816||Shwegyin Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Shwegyin is one of the sentinel site and located at the southern part of the central Myanmar.
62484517|NCT02792816||Magway Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Magway is one of the sentinel site and located at the middle part of the central Myanmar.
62484518|NCT02792816||Rakhine Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Rakhine is one of the sentinel site and located at the western Myanmar.
62484519|NCT03683667|PLACEBO_COMPARATOR|Placebo & Control|Placebo / Nutrition education
62484520|NCT03683667|EXPERIMENTAL|Placebo & Protein Supplement|Placebo / Protein-rich blended food / Nutrition education
62484521|NCT03683667|PLACEBO_COMPARATOR|Placebo & Isocaloric Supplement|Placebo / Isocaloric blended food / Nutrition education
62484522|NCT03683667|EXPERIMENTAL|Placebo & Egg|Placebo / Egg / Nutrition education
62325794|NCT06346262|EXPERIMENTAL|SMART RM|The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE). The intervention will be remotely delivered in a web-based format using a secure web teleconferencing system (such as Zoom) that will allow us to set up a virtual meeting room. Following the group-session series, participants will have 3 monthly telephone maintenance sessions lasting around 15 minutes. Maintenance session web/telephone calls will be made to study participants by a NE with experience in epilepsy and/or chronic health condition management.
62325795|NCT06478173|ACTIVE_COMPARATOR|Exercise training|Patients in the exercise group will engage in supervised soccer training 3 times a week for 14 weeks.
62484523|NCT03683667|EXPERIMENTAL|Azithromycin & Control|Azithromycin / Nutrition education
62484524|NCT03683667|EXPERIMENTAL|Azithromycin & Protein Supplement|Azithromycin / Protein-rich blended food / Nutrition education
61932823|NCT03564691|EXPERIMENTAL|Coformulation Phase, Arm N: MK-4830A (Coformulation of MK-4830 + pembrolizumab)|Monotherapy with MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, in participants with histologically or cytologically-confirmed advanced/metastatic solid tumor, and who and have received, been intolerant to, been ineligible for, or refused all treatment known to confer clinical benefit. MK-4830A will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days.
61932824|NCT01225107|PLACEBO_COMPARATOR|Inert Placebo Capsule|
61932825|NCT01225107|EXPERIMENTAL|Cranberry Extract|
61932826|NCT06707116||Study group|
62325796|NCT06478173|NO_INTERVENTION|Control|Patients in the control group will receive standard treatment and be instructed to maintain habitual activity levels at the same level as before enrollment in the study.
62325797|NCT05281276|EXPERIMENTAL|chidamide (20 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (20 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
62325798|NCT05281276|EXPERIMENTAL|chidamide(30 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (30 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
62325799|NCT05345327|EXPERIMENTAL|Dapagliflozin 10mg|1x over-encapsulated Dapagliflozin 10mg tablet and 2x Metformin placebo tablets, taken orally once daily for 2 years
62325800|NCT05345327|ACTIVE_COMPARATOR|Metformin XR 2000mg|2x Metformin XR 1000mg tablets and 1x over-encapsulated Dapagliflozin placebo, taken orally once daily for 2 years
62325801|NCT05145127|EXPERIMENTAL|PF-06741086|"For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria."
62325802|NCT05743699|EXPERIMENTAL|Case management + Bright Horizons|Participants enrolled into the Bright Horizons intervention group will receive one 2-4 hour long session with an Research Program Assistant.
62325803|NCT05743699|PLACEBO_COMPARATOR|Case management|Participants in the control group will receive standard case management via the White Mountain Apache suicide and self-harm surveillance system.
61932827|NCT03282565|EXPERIMENTAL|Functional Resistance Training with a Brace|Participants will receive functional resistance training via a knee brace while walking on a treadmill 2-3 times a week for about 8 weeks.
61932828|NCT03282565|EXPERIMENTAL|Functional Resistance Training with Elastic Band|Participants will receive functional resistance training via an elastic band attached at the ankle while walking on a treadmill 2-3 times a week for about 8 weeks.
61932829|NCT03282565|SHAM_COMPARATOR|Control|Participants will while on a treadmill without an applied resistance 2-3 times a week for about 8 weeks.
62484525|NCT03683667|EXPERIMENTAL|Azithromycin & Isocaloric Supplement|Azithromycin Isocaloric blended food Nutrition education
62484526|NCT03683667|EXPERIMENTAL|Azithromycin and Egg|Azithromycin Egg Nutrition education
61932830|NCT04755244|EXPERIMENTAL|evorpacept (ALX148) + venetoclax + azacitidine|"Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine~Phase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine."
61932831|NCT05396807|OTHER|All subjects|mCRC subjects with WT (wild type) and RAS (matated)
61932832|NCT04401605|EXPERIMENTAL|Fermented Food-Supplemented Diet|Patients in this arm will supplement their regular diet by an increasing number of daily servings of fermented food over a period of 10 weeks.
62484527|NCT04366544|OTHER|Time Point 1: Baseline/Pre-preparatory Samyama|"* Survey link for participant~* Survey link for spouse/ control~* Stool collection from home~* Blood sample at home provided by at home phlebotomy services or at Isha Center group meditation by study personnel."
62484528|NCT04366544|OTHER|Time point 2: Post-Preparatory/Pre-Samyama|"* Online Surveys~  * Participant~ * Spouse~* Stool collection from IIIS/home~* Blood sample collection: on site at IIIS/home EEG and fMRI"
61932833|NCT04401605|PLACEBO_COMPARATOR|Regular Diet Control Arm|Patients in this arm will continue their regular diet throughout the 10 weeks of study with a maximum of 1 serving of fermented foods per day.
61932834|NCT03965208|ACTIVE_COMPARATOR|Unfractionated heparin|Patients randomized to this group will receive anticoagulation with unfractionated heparin
61932835|NCT03965208|EXPERIMENTAL|Bivalirudin|Patients randomized to this group will receive anticoagulation with bivalirudin
62325804|NCT06587516|EXPERIMENTAL|Experimental|badminton players who plays badminton socially once a week with minimum experience of three years
62325805|NCT06587516|ACTIVE_COMPARATOR|Control|badminton players who plays badminton socially once a week with minimum experience of three years
62325806|NCT06150534||Adult Patients with PID|Adult patients with PID who recently started or will soon begin to complete SCIG (HyQvia or Cuvitru) infusions independently will be interviewed before and/or after the use of Alexa Skill.
62325807|NCT06150534||Caregivers of Patients with a Self-reported Diagnosis of PID|Caregivers who recently started or will soon begin infusing SCIG (HyQvia or Cuvitru) for patients with a self-reported diagnosis of PID will be interviewed before and/or after the use of Alexa Skill.
62325808|NCT06150534||Healthcare Professionals (HCPs)|HCPs, specifically, clinical immunologists who prescribe SCIG for the treatment of PID and nurses who have experience administering SCIG will be interviewed after the use of Alexa Skill.
62325809|NCT05435014|EXPERIMENTAL|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil.
62325810|NCT05435014|ACTIVE_COMPARATOR|Lipiodol|TAE/TACE treatment was performed with Lipiodol.
62325811|NCT06454240|PLACEBO_COMPARATOR|Arm 1|Participant will receive placebo subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.
62325812|NCT06454240|EXPERIMENTAL|Arm 2|Participant will receive lunsekimig subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.
62325813|NCT05771480|EXPERIMENTAL|Durvalumab + Gemcitabine based chemotherapy|"Participants will receive durvalumab 1500mg every 3 or 4 weeks, in combination with continuation of all or some of the original background gemcitabine based chemotherapy every 3 or 2 weeks for up to a maximum of 8 cycles of chemotherapy. Durvalumab 1500mg is given as a 60-minute IV infusion in the first cycle (Day 1) and as a 30-minute IV infusion in following cycles.~Upon completing 8 cycles of background gemcitabine-chemotherapy, or after discontinuing any of the combination chemotherapies due to toxicity before completing 8 cycles, participants are eligible to continue receiving durvalumab 1500 mg IV every 4 weeks either alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), as per investigator's discretion."
62325814|NCT06655974|EXPERIMENTAL|Decision support intervention group|Adult ED patients seeking care the ED site with the health-related social needs decision support system live.
62325815|NCT06655974|NO_INTERVENTION|Comparison group|Adult ED patients created using statistical matching from ED sites in the same metropolitan area.
62325816|NCT06041217|EXPERIMENTAL|Semaglutide 2.4 milligram (mg)|Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.
62325817|NCT06041217|PLACEBO_COMPARATOR|Placebo|Participants will receive once-weekly subcutaneous (s.c) injection of placebo for 44 weeks.
62325818|NCT06605560|NO_INTERVENTION|Aspiration group|The existing Baker's cyst of patients in this group will be aspirated under ultrasonographic guidance.
62325819|NCT06605560|EXPERIMENTAL|PRP+Aspiration group|The existing Baker's cyst of patients in this group will be aspirated under ultrasonography guidance and PRP injection will be administered into the cyst.
62325820|NCT06654401|EXPERIMENTAL|Radiofrequency pulmonary vein isolation in patients with previous electrical cardioversion|Depending on the duration of atrial fibrillation and anatomic parameters of the left atrium (according to heart ultrasound), patients will undergo electric cardioversion before the primary radiofrequency catether pulmonary veins' isolation. The experimental group will be subdivided into a persistent AF patients who were successfully cardioverted in sinus rhythm and persistent AF patients who failed to restore sinus rhythm during DC at the time of catheter ablation.
62325821|NCT06654401|ACTIVE_COMPARATOR|Radiofrequency pulmonary vein isolation in patients without previous electrical cardioversion|Primary interventional treatment is performed without restoration of the sinus rhythm.
62325822|NCT05701228||day 0 of transplantation|This cohort will include 450 patients at the time of transplantation. The following number of participants will be enrolled in the cohort according to strata defined by organ-transplanted type and baseline immune status.
62692356|NCT01854775|EXPERIMENTAL|Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg|Virologically suppressed HIV-infected children (6 to \< 12 years of age weighing ≥ 25 kg) will receive E/C/F/TAF (150/150/200/10 mg) FDC once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
62325823|NCT05701228||day 0 of infection|This cohort will include 150 patients at the time of the infection: Approximatively 75 patients will be drawn from the cohort of solid-organ transplant recipients included at day 0 of transplantation. Additional 75 patients developing a CMV infection will be also included.
62325824|NCT06268886|PLACEBO_COMPARATOR|Placebo|
62325825|NCT06268886|EXPERIMENTAL|BMS-986446 Dose A|
62325826|NCT06268886|EXPERIMENTAL|BMS-986446 Dose B|
62325827|NCT03480061|ACTIVE_COMPARATOR|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
62325828|NCT03480061|NO_INTERVENTION|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
61932836|NCT04662580|EXPERIMENTAL|ARX517|ARX517 will be administered via intravenous (IV) infusion, with the initial treatment regimen by weight-based infusion at an interval of every 3 weeks. Other treatment regimen may be explored.
61932837|NCT04662580|EXPERIMENTAL|ARX517+Apalutamide|ARX517 and apalutamide
62484529|NCT04366544|OTHER|Timepoint 3: Immediate Post-Samyama|"* Online survey to be completed~* Survey link for participant~* Survey link for spouse~* Blood sample collection: on site at IIIS o Participant only - Not spouse/significant other. EEG and fMRI"
62484530|NCT04366544|OTHER|Timepoint 4: 3 months Post Samyama|"* Blood draw at home by at home phlebotomist~* Post program online survey follow up to be completed~* Survey link for participant~* Survey link for spouse: https~* Stool collection from home"
62692357|NCT01854775|EXPERIMENTAL|Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg|Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to \< 25 kg) will receive E/C/F/TAF (90/90/120/6 mg) FDC once daily for 48 weeks. Participants who attain a weight of ≥ 25 kg during the course of the study will switch to adult E/C/F/TAF (150/150/200/10 mg) tablets. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
62692358|NCT02821650|EXPERIMENTAL|Intervention|Intervention arm will be administered with improved cook stoves (TEJ- Traditional stove to Efficient stove in Jhuggi).
61932838|NCT04662580|EXPERIMENTAL|ARX517+AAP|ARX517 and abiraterone acetate plus prednisone(AAP)
61932839|NCT04191395||Inflammatory bowel disease|
61932840|NCT04191395||Chronic inflammatory rheumatic disease|
61932841|NCT04191395||Chronic inflammatory skin diseases|
61932842|NCT02723994|EXPERIMENTAL|Ruxolitinib in combination with chemotherapy|
61932843|NCT06324630|ACTIVE_COMPARATOR|Produce Prescription Mobile Market|Usual care control is a produce prescription model prescribed by a clinician, providing funds to purchase 21 servings of fruit and vegetables per person at designated mobile market provider(s).
61932844|NCT06324630|EXPERIMENTAL|Produce Prescription Delivery|Intervention arm 1 is a healthy food delivery model, wherein the participant receives a customizable produce box providing 21 servings of fruits and vegetables per person.
61932845|NCT06324630|EXPERIMENTAL|Healthy Meal Kit Delivery|Intervention arm 2 is a healthy meal kit delivery model providing all ingredients to make 3+ meals with 21 servings of fruits and vegetables, with 6-9 meal options to choose from each week.
61932846|NCT00975520|ACTIVE_COMPARATOR|Radiation Therapy|Investigational Treatment
61932847|NCT00975520|OTHER|Observation|Observation
61932848|NCT06706934||Patients|Patients group with intellectual disability
61932849|NCT06706934||Control|Control group without intellectual disability
61932850|NCT06701630||Neurologically unimpaired participants|i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities; iii) Normal performance on the Mini Mental State Examination (Folstein et al. 1975; Foderaro et al., 2022).
61932851|NCT06701630||Subjective Cognitive Decline (SCD)|"i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities.~iii) Conditions consistent with Subjective Cognitive Decline according to Jessen et al. (2014)"
61932852|NCT06701630||Mild Cognitive Impairment (MCI)|"i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities.~iii) Conditions consistent with Mild Cognitive Impairment according to Winblad et al. (2004)"
61932853|NCT06701630||Major Neurocognitive Disorder|i) Age ≥ 60 years; ii) Availability of an informant/caregiver, able to judge their functional abilities iii) Conditions consistent with a Mild Major Neurocognitive Disorder according to DSM-5-TR (APA, 2022).
62133146|NCT05307536|ACTIVE_COMPARATOR|Educational intervention (controlled group)|"The educational intervention will be developed based on the Early Start Denver Model for six months after enrollment.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), and Clinical Global Impression (CGI). In addition, Health-related quality of life (HRQoL) in patients will be evaluated at baseline, two months, six months, and 12 months with those in the control group (educational intervention only) using the Pediatric Quality of Life Inventory (PedsQL)"
62133147|NCT03094169|EXPERIMENTAL|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
61932854|NCT06710496||AFAB TG|assigned female at birth transgender people undergoing gender affirming surgery during testosterone therapy
61932855|NCT01690637|ACTIVE_COMPARATOR|Oseltamivir phosphate suspension|Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
62133148|NCT03094169|EXPERIMENTAL|Phase 2a Triple Negative Breast Cancer|Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
62325829|NCT00092222|ACTIVE_COMPARATOR|Active Treament 3|Patients not responding to high- dose zidovudine and valganciclovir alone may be treated with botezomib plus high- dose zidovudine and valganciclovir
61932856|NCT01690637|PLACEBO_COMPARATOR|Placebo|
62325830|NCT00092222|ACTIVE_COMPARATOR|Active Treatment 1|Single agent sirolimus for patients where targeted oncolytic virotherapy seems suboptimal
62484531|NCT00587730|ACTIVE_COMPARATOR|Clinical SPECT|GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.
62692359|NCT02821650|NO_INTERVENTION|control|control arm will continue using traditional cook stoves (chulha) or a combination of the traditional stove and the kerosene/diesel stove.
62692360|NCT05115825|EXPERIMENTAL|Supportive care (Mobile Pain Coping Skills Training)|Patients attend 5 sessions of Mobile Pain Coping Skills Training for 45 minutes each over 8 weeks.
62692361|NCT06641895|EXPERIMENTAL|Single dose intravenous injection of BBM-D101|
61932857|NCT06706804|NO_INTERVENTION|Control Group:|Pregnant women in the control group will be subjected to the routine hospital protocol and will not be subjected to any other intervention. In the pregnancy schools of the hospitals, they are verbally told not to wash and wipe their babies before the umbilical cord falls off. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
62325831|NCT00092222|ACTIVE_COMPARATOR|Active Treatment 2|EPOCH chemotherapy with rituximab may be utilized to rescue such patients, with the intent of stabilizing suchpatients
62133149|NCT03094169|EXPERIMENTAL|Phase 2a Head and Neck Carcinoma|Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
62133150|NCT03094169|EXPERIMENTAL|Phase 2a Non-Small Cell Lung Carcinoma|Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
62133151|NCT03610789||REDAPT Revision Femoral System|REDAPT Revision Femoral System Monolithic Sleeveless Stems, monolithic sleeved stems and/or Acetabular Components or modular shells and/or augments
62133152|NCT03055689|EXPERIMENTAL|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
62133153|NCT03055689|ACTIVE_COMPARATOR|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
62325832|NCT00092222|ACTIVE_COMPARATOR|Active Treatment 4|Rituximab with liposomal doxorubicin (R-Dox) followed by consolidation or lmaintenancel therapy with dose escalating interferon-alpha
62325833|NCT00092222|ACTIVE_COMPARATOR|Active Treatment 5|High dose zidovudin and valganciclovir
62325834|NCT00092222|ACTIVE_COMPARATOR|Natural History|Observation Only
62325835|NCT03671629|EXPERIMENTAL|Intervention group|In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital.
62133154|NCT00117026|EXPERIMENTAL|Benfotiamine|Benfotiamine 300mg/day
62133155|NCT00117026|PLACEBO_COMPARATOR|Placebo|Placebo for benfotiamine
62133156|NCT06440642||steep trendelenburg|Patients Undergoing Laparoscopic Hysterectomy
62133157|NCT00909649|ACTIVE_COMPARATOR|1 fibrin glue|8 ml of fibrin glue was sprayed on the surgical area with Y canula ( doubleject application system).One milliliter of fibrin glue contains 70-100 mg. fibrinogen, 10-50 u factor 8 aprotinin 3000k iu/ml, 2-9 mg fibronectin,40-120 ug plasminogen ,4 Iu/ml thrombin, 40 mmol cocl2/L (immuno AG/austrial)
62133158|NCT00909649|NO_INTERVENTION|2 non fibrin glue|after good haemostasis the same sized drain was applied in axillary and breast area and incision was closed. Followed by external compression for 10 minutes in both groups. Drains were left in places until the drainage for the preceding 24 h was less than 20 ml.
62133159|NCT03104036|ACTIVE_COMPARATOR|Mesalazine enema|Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.
62133160|NCT03104036|EXPERIMENTAL|Faecal bacterial transplantation enema|Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.
62133161|NCT03513367||Boys with Muscular Duchenne Dystrophy|"105 boys with Muscular Duchenne Dystrophy (DMD) distributed as follows: 35 patients with Duchenne muscular dystrophy by age category, 8-12 years old and 13-18 years old.~Children will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of his parents"
62325836|NCT03671629|NO_INTERVENTION|Control group|This group receives standard care, which might include a medication review at the hospital.
62325837|NCT06588686|EXPERIMENTAL|Buloxibutid 100 mg BID|For 52 weeks.
62325838|NCT06588686|EXPERIMENTAL|Buloxibutid 50 mg BID|For 52 weeks.
62325839|NCT06588686|PLACEBO_COMPARATOR|Placebo BID|For 52 weeks.
62325840|NCT05839600|EXPERIMENTAL|BI 1821736: Dose escalation cohort|
62325841|NCT04513054|OTHER|Takotsubo Case Arm|A patient that has been diagnosed with Takotsubo Cardiomyopathy from 2010 onwards.
62325842|NCT04638647|EXPERIMENTAL|Secukinumab s.c.|Participants will be started on 75 mg, 150 mg or 300 mg s.c. Q4W depending on what dose the participant was receiving in the parent trial (for trials with i.v. formulation the starting dose will be 300 mg s.c.). The study medication dose may be modified basedu pon clinical need, the judgement of the investigator and health authority guidelines (if applicable). For pediatric participants, the dose should not be increased beyond the maximum dose evaluated in the respective weight category in the parent protocol.
62325843|NCT05375643|EXPERIMENTAL|Arm B (informational video)|"Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to the SURGE intervention where they will receive:~* Informational Video"
62133162|NCT03513367||Parents of boys with Muscular Duchenne Dystrophy|105 parents of boys with Muscular Duchenne Dystrophy For the 5-7 age group, only parents answer the questionnaire but medical data are collected : 35 by age category (5-7; 8-12; 13-18) Parents will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of their children
62133163|NCT05395403|EXPERIMENTAL|Office Blood Pressure Measurement (OBPM)|Traditional office blood pressure monitoring in the primary care clinical environment.
62133164|NCT05395403|EXPERIMENTAL|Automated Office Blood Pressure Measurement (AOBPM)|Blood pressure measurement using a validated BpTRU device
62325844|NCT05375643|NO_INTERVENTION|Arm A (standard of care)|"Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to Standard of Care (SOC) and receive:~* Standard of Care"
62325845|NCT05375643|EXPERIMENTAL|Arm C (informational video and patient navigation)|"Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to the SURGE intervention where they will receive:~* Informational Video and Patient Navigation"
62325846|NCT04417621|EXPERIMENTAL|LXH254 + LTT462|
62325847|NCT04417621|EXPERIMENTAL|LXH254 + trametinib|
62325848|NCT04417621|EXPERIMENTAL|LXH254 + ribociclib|
62325849|NCT05976646|PLACEBO_COMPARATOR|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
62692362|NCT01715870||"Population of the Epidemiological study on AMD."|
62325850|NCT05976646|EXPERIMENTAL|Auvelity|Orally-administered combination of dextromethorphan with Bupropion (trade name Auvelity)
62325851|NCT05102942|EXPERIMENTAL|Group A: a gamified AACTP smartphone application + treatment as usual (TAU)|
61932858|NCT06706804|EXPERIMENTAL|Wipe Bathing|In groups of 2-3 pregnant women in this group, the researcher will explain the stages of newborn wiping bath application on the newborn model, and then the pregnant women will individually apply the bath on the model. The trainings will be held in the pregnant school at the appropriate hours, or in an empty room determined by the hospital administration if there is another planned training in the pregnant school. In the wiping bath training, for genital area cleaning based on the gender of newborns, women will be provided to perform the procedure on the model appropriate to the gender of their babies. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
62133165|NCT05395403|EXPERIMENTAL|Home Blood Pressure Measurement (HBPM)|Blood pressure measurement at patient's home using home monitoring device.
62692363|NCT06146062|EXPERIMENTAL|Intervention|"Final product is a MSC solution at the concentration of 2.10\^6/kg in 150 mL of NaCl 0.9% and human albumin 0.5%, conditioned aseptically and identified for IV administration.~3 injections one week apart."
62692364|NCT06146062|PLACEBO_COMPARATOR|control|The placebo will be a solution of NaCl 0.9% 3 injections one week apart.
62692365|NCT06446648|NO_INTERVENTION|SOC group|Robot-Assisted Radical Prostatectomy will be performed as a standard procedure.
62692366|NCT06446648|EXPERIMENTAL|ICG group|Robot-Assisted Radical Prostatectomy using ICG
62133166|NCT03196882|ACTIVE_COMPARATOR|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
62133167|NCT03196882|EXPERIMENTAL|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
62133168|NCT03196882|ACTIVE_COMPARATOR|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are \>130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
62133169|NCT03196882|EXPERIMENTAL|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are \>130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
62133170|NCT00792636|EXPERIMENTAL|sumatriptan and naproxen sodium combination|
62133171|NCT00792636|ACTIVE_COMPARATOR|sumatriptan|
62133172|NCT00792636|ACTIVE_COMPARATOR|naproxen sodium|
62133173|NCT04699786|ACTIVE_COMPARATOR|Arm A|Participants randomized to Arm A will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document. Arm A is a neuroimaging arm.
62133174|NCT04699786|ACTIVE_COMPARATOR|Arm B|Participants randomized to Arm B will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document. Arm B is a neuroimaging arm.
62133175|NCT04699786|ACTIVE_COMPARATOR|Arm C|Participants randomized to Arm C will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document. Arm C is a plasma amyloid arm.
62133176|NCT04699786|ACTIVE_COMPARATOR|Arm D|Participants randomized to Arm D will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document. Arm D is a plasma amyloid arm.
62133177|NCT05065203||Postpartum patients|Women booked and have delivery of their child(ren) at Lucile Packard Children's Hospital
62133178|NCT05090631||Experimental group:|Patients with atopic dermatitis
62133179|NCT05090631||Control group|Patients without atopic dermatitis
62133180|NCT05176054|EXPERIMENTAL|Experimental group|Researchers will conduct the health service program for the experimental group.
62133181|NCT05176054|NO_INTERVENTION|Contrast group|The contrast group will be receiving the routine care only.
62133182|NCT03951805|EXPERIMENTAL|Insulin 287 algorithm A|Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
62133183|NCT03951805|EXPERIMENTAL|Insulin 287 algorithm B|Controlled on metformin with or without DPP4i and with or without SGLT2i.
62133184|NCT03951805|EXPERIMENTAL|Insulin 287 algorithm C|Controlled on metformin with or without DPP4i and with or without SGLT2i.
62133185|NCT03951805|ACTIVE_COMPARATOR|Insulin Glargine algorithm D|Controlled on metformin with or without DPP4i and with or without SGLT2i.
62325852|NCT05102942|PLACEBO_COMPARATOR|Group B: a gamified AACTP sham-control application + TAU|
62325853|NCT06564207|PLACEBO_COMPARATOR|Standard of Care (SOC) + Placebo (BID for 14 Days)|Participants randomized to this arm will receive standard of care (SOC) treatment plus placebo given twice daily for 14 days
62692367|NCT02887794|EXPERIMENTAL|30 patients with schizophrenia|Measure the correlation between the score on the scale psychometric AHRS (Auditory Hallucination Rating Scale) to measure HAV and performance scores discrimination test psychoacoustic Tone Matching Task in subjects suffering from schizophrenia and HAV.
62133186|NCT02484599|EXPERIMENTAL|CAT active attention bias modification|Active computerized attention training (CAT). Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements intended to direct attention towards food stimuli using pictorial food and non-food stimuli (see Werthmann, Field, Roefs, Nederkoorn, \& Jansen, 2014).
62325854|NCT06564207|EXPERIMENTAL|Standard of Care (SOC) + Fostamatinib 150mg (BID for 14 Days)|Participants randomized to this arm will receive standard of care (SOC) treatment plus fostamatinib 150mg given twice daily for 14 days
62484532|NCT03076437|EXPERIMENTAL|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.~Interventions:~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
62484533|NCT02928185||HSCT patients|Individual/dyadic semi-structured interviews between Day +100 to +130
62484534|NCT02928185||HSCT care givers|Individual/dyadic semi-structured interviews between Day +100 to +130
62692368|NCT02732496|EXPERIMENTAL|Cognitive Training|Targeted Cognitive Training (TCT)
62325855|NCT03318159|OTHER|posaconazole prophylaxis group|aplastic anemia / hypoplastic myelodysplastic syndrome patients undergoing antithymocyte globulin treatment and receiving posaconazole as prophylaxis antifungal agent
62325856|NCT06567925|EXPERIMENTAL|Gradual sleep extension strategy|Demonstrate the feasibility of a gradual sleep extension strategy combined with sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy
62325857|NCT06011551|EXPERIMENTAL|Treatment Arm|"Group A: continued non-surgical conservative medical management plus a percutaneous hydrogel spinal implant delivered via the HYDRAFIL System (the HYDRAFIL implant) (the Treatment Arm)"
62325858|NCT06011551|SHAM_COMPARATOR|Control Arm|"Group B: continued non-surgical conservative medical management plus advancement of the HYDRAFIL System delivery needle to inside the skin in the direction of the target disc(s) but without contacting the muscle layer or deeper (the Control Arm)"
62325859|NCT06480786|EXPERIMENTAL|Active Spinal Cord Stimulation|Therapeutic spinal cord stimulation titrated at 12 weeks post operative at standard clinical practice.
62325860|NCT06480786|SHAM_COMPARATOR|Sham Stimulation|Sub-threshold low frequency spinal cord stimulation to provide no analgesic benefit but serve as a sham control.
62325861|NCT06638996|PLACEBO_COMPARATOR|Placebo Arm|Participants in this arm will receive a placebo
62325862|NCT06638996|EXPERIMENTAL|CBG Arm|Participants in this arm will receive CBG
62325863|NCT04926766|EXPERIMENTAL|SHF-WBI|Patients with an indication for whole breast irradiation will receive 5.2 Gy in 5 fractions to whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
62325864|NCT06264180|EXPERIMENTAL|VO + nivolumab|
62325865|NCT06264180|ACTIVE_COMPARATOR|Physicians Choice|"Choosing from 1 of the following (to be consistent with approved label and/or applicable local clinical guidelines):~* Nivolumab + relatlimab (as Opdualag)~* Anti-PD-1 monotherapy (nivolumab or pembrolizumab)~* Single-agent chemotherapy (dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel)"
62692369|NCT02732496|PLACEBO_COMPARATOR|Youth Appropriate Online Games|Engaging games not designed to improve cognition
61932859|NCT06707662|ACTIVE_COMPARATOR|Right Ventricle Apical Pacing|Standard location for any pacing lead in the right ventricle
62325866|NCT03337698|ACTIVE_COMPARATOR|Stage 1: Cohort 1: Atezolizumab|"Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria."
62325867|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 1: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62325868|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 1: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62325869|NCT03337698|ACTIVE_COMPARATOR|Stage 1: Cohort 2: Docetaxel|"Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62692370|NCT00802503|EXPERIMENTAL|SPN group|"experimental arm: Supplemental Parenteral Nutrition (SPN) is added to enteral nutrition (EN) to reach 100% of their predicted energy needs from ICU day 4.~In the treated group, SPN is started if at day 4 energy input by EN is \< 60% of energy target in order to reach 100% of energy target by peripheral or central line. Nutritional products as currently used in our institution. SPN is composed of EN and PN, both techniques being currently used in our institution."
62692371|NCT00802503|NO_INTERVENTION|Control gr|EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
62325870|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62484535|NCT02928185||HSCT dyads|Individual/dyadic semi-structured interviews between Day +100 to +130
62484536|NCT02928185||HSCT Clinicians|Can include: MD, RN, SW, PharmD and Nutritionist. Individual semi-structured interviews after 14 days to review the Coping Together manuals
62484537|NCT05113043||Ischemic stroke|Young patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
62484538|NCT05113043||Hemorrhagic stroke|Young patients who suffered from acute hemorrhagic stroke within 12 hours for the first time before entry into the study.
62484539|NCT05113043||Healthy Controls|Healthy young people
62484540|NCT03723044|EXPERIMENTAL|healthy volunteers|
62484541|NCT02052895||Sepsis/SIRS|Patients with sepsis or SIRS
62484542|NCT02052895||Control|Patients without SIRS, sepsis, or end stage renal disease
62484543|NCT02052895||End Stage Renal Disease|Patients with end stage renal disease, without SIRS or sepsis
62484544|NCT04996316||Clinical staff (interview, training, survey)|Before implementation, some participants will complete usability testing of the interface in the electronic health record and MammoScreen. Participants undergo training sessions over 20 minutes and participate in interviews over 30 minutes at baseline, prior to MammoScreen launch. Clinical staff also participate in interviews over 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the maintenance phase, about six months after the last reminders are sent.
61932860|NCT06707662|EXPERIMENTAL|Left bundle branch pacing|Stimulation in the Conduction System (righ ventricle) capturing the left budle branch
61932861|NCT06707662|EXPERIMENTAL|Left septal pacing|Stimulation in the Conduction System (righ ventricle) without capturing the left budle branch
61932862|NCT06543615||Patients undergoing laparoscopic cholecystectomy with history of sleeve gastrectomy|Gastric residual volume will be assessed after 8 hours of fasting preoperatively using ultrasonography in patients undergoing laparoscopic cholecystectomy with history of sleeve gastrectomy
61932863|NCT06543615||Patients undergoing laparoscopic cholecystectomy with no history of bariatric surgeries|Gastric residual volume will be assessed after 8 hours of fasting preoperatively using ultrasonography in patients undergoing laparoscopic cholecystectomy with No history of bariatric surgeries
61932864|NCT05452772|ACTIVE_COMPARATOR|Psilocybin|30 mg in session 1 and either 30 mg or 40 mg in session 2, with sessions 1 week apart. Dosing will be based on participants' responses to the Mystical Experiences Questionnaire (MEQ30), taken at the end of their first session. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 30 mg of psilocybin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 40 mg for the second session.
61932865|NCT05452772|ACTIVE_COMPARATOR|Niacin|150 mg in session 1 and either 150 mg or 200 mg in session 2, with sessions 1 week apart. Dosing will be based on participants' responses to the Mystical Experiences Questionnaire (MEQ30), taken at the end of their first session. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 150 mg niacin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 200 mg niacin for the second session.
62325871|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + CPI-444|"Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62325872|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62325873|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Ipatasertib|"Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62325874|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Docetaxel|"Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62325875|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Bevacizumab|"Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
62325876|NCT03337698|EXPERIMENTAL|Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin|Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325877|NCT03337698|EXPERIMENTAL|Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin|Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325878|NCT03337698|EXPERIMENTAL|Stage 2: Cohort 2: Atezolizumab + RO6958688|Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325879|NCT03337698|EXPERIMENTAL|Stage 2: Cohort 2: Atezolizumab + Docetaxel|"Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2."
62484545|NCT04996316||Patients (interview, MammoScreen)|Patients participate in interviews up to 1 hour. Patients medical records are reviewed. Patients use the MammoScreen at enrollment. Some Patients will also participate in interviews up to 1 hour, each during years 3-5.
62484546|NCT00730691|PLACEBO_COMPARATOR|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
62484547|NCT00730691|EXPERIMENTAL|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
62484548|NCT00730691|EXPERIMENTAL|Vortioxetine 5 mg|Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
62484549|NCT00730691|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
62692372|NCT06549816|EXPERIMENTAL|sigvotatug vedotin|sigvotatug vedotin monotherapy 1.8 mg/kg adjusted ideal body weight intravenous administration on Days 1 and 15 of a 28-day cycle.
61932866|NCT06143774|EXPERIMENTAL|TRX-920 Oral Gel|Dose escalation (escalation from 1, 2, 4, 8, 16, 30, 60, 90 mg TRX-920 Oral Gel)
62484550|NCT00730691|ACTIVE_COMPARATOR|Duloxetine 60 mg|Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
62484551|NCT02278809|NO_INTERVENTION|waitlist control group|The waitlist control group parents received the online videos when the intervention period was over.
62484552|NCT02278809|EXPERIMENTAL|intervention group|
62692373|NCT06674902|EXPERIMENTAL|Experimental 1: Electrolysis with 4 mA|A charge of 24 mC will be delivered at 4 mA for 6 seconds, followed by a 54-second pause.
62692374|NCT06674902|EXPERIMENTAL|Experimental 2: Electrolysis with 400 μA|A charge of 24 mC will be delivered at 400 µA for 60 seconds.
62325880|NCT03337698|EXPERIMENTAL|Stage 2: Cohort 2: Atezolizumab + Linagliptin|Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325881|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan|Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325882|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy|Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325883|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Evolocumab|Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
62325884|NCT03337698|ACTIVE_COMPARATOR|Stage 1: Cohort 1: Atezolizumab + Tiragolumab|Participants in the Atezolizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325885|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 1: Atezolizumab + Tiragolumab + XL092 (Zanzalintinib)|Participants in the Atezolizumab + Tiragolumab + XL092 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325886|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Camonsertib|Participants in the Atezolizumab + Camonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325887|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Camonsertib|Participants in the Atezolizumab + Bevacizumab + Comonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325888|NCT03337698|EXPERIMENTAL|Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Tiragolumab|Participants in the Atezolizumab + Bevacizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
62325889|NCT06168019||Influenza & COVID-19 Obstetric and Perinatal Epidemiology (ICOPE)|Pregnant women in their first trimester of pregnancy who present to the outpatient antenatal care clinic at Government Medical College Hospital in Nagpur, India.
62325890|NCT06645678|EXPERIMENTAL|Treatment arm|"Participants will receive elranatamab, mezigdomide and dexamethasone.~Part 1 (safety cohort): approximately 12 participants to select the optimal RP2D and to assess the safety, tolerability, and preliminary efficacy. Every cycle consists of 28 days.~Part 2 (expansion cohort): approximately 63 participants will be enrolled. The primary objective of Part 2 is to determine the overall response rate per IMWG criteria at 24 months after enrollment."
62325891|NCT06474377|EXPERIMENTAL|Experimental group 1|48 participants will be randomized to receive Sinovac PCV24 formulation 1. Route of administration is intramuscular injection at deltoid muscle of upper arm. Immunization schedule is 1 dose.
62325892|NCT06474377|EXPERIMENTAL|Experimental group 2|48 participants will be randomized to receive Sinovac PCV24 formulation 2. Route of administration is intramuscular injection at deltoid muscle of upper arm. Immunization schedule is 1 dose.
62325893|NCT06474377|ACTIVE_COMPARATOR|Active control group|48 participants will be randomized to receive Pneumovax®. Route of administration is intramuscular injection at deltoid muscle of upper arm. Immunization schedule is 1 dose.
62325894|NCT06474377|PLACEBO_COMPARATOR|Placebo group|24 participants will be randomized to receive placebo. Route of administration is intramuscular injection at deltoid muscle of upper arm. Immunization schedule is 1 dose.
62325895|NCT05917587|ACTIVE_COMPARATOR|metformin|
62325896|NCT05917587|PLACEBO_COMPARATOR|placebo|
62325897|NCT04768322|EXPERIMENTAL|Early Left Ventricular Assist Device and Guideline Directed Medical Therapy|The intervention group will receive an early left ventricular assist device implantation (bridge to transplantation, bridge to candidacy or destination therapy) in addition to guideline directed medical therapy within 21 days of randomization.
62325898|NCT04768322|OTHER|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
62484553|NCT00959790|EXPERIMENTAL|High vegetable dose|Consumption of 200 grams of vegetables daily, for four weeks.
62484554|NCT00959790|EXPERIMENTAL|Low vegetable dose|Consumption of 50 grams of vegetables daily, for four weeks.
62692375|NCT06674902|EXPERIMENTAL|Experimental 3: Electrolysis with 600 μA|A charge of 36 mC will be delivered at 600 µA for 60 seconds.
62692376|NCT05407636|EXPERIMENTAL|ABBV-RGX-314 Dose 1|ABBV-RGX-314 Dose 1 administered via subretinal delivery one time.
62484555|NCT00959790|ACTIVE_COMPARATOR|Weight loss interventio|Consumption of - 1000 kcal daily, for four weeks to be used as a positive control for the vegetables interventions.
62484556|NCT01876667|ACTIVE_COMPARATOR|Intervention (CPCRS) Group|CPCRS will ensure patients have regular laboratory monitoring and blood pressure measures, appropriate lipid-lowering and antihypertensive medications, and receive follow-up in a timely manner.
62484557|NCT01876667|PLACEBO_COMPARATOR|Usual Care|Usual Care: Patients randomized to Usual Care will continue to receive interventions/procedures they normally receive according to standard/usual care practices
61932867|NCT06513624|EXPERIMENTAL|ETC-159|Patients will undergo screening prior to the initial administration of ETC-159 in combination with pembrolizumab. ETC-159 in combination with pembrolizumab will be administered in 21-day cycles. ETC-159 will be dosed every other day while Pembrolizumab will be dosed at IV Q3W along with bone protective treatment (Denosumab or Zoledronic Acid)
62692377|NCT05407636|EXPERIMENTAL|ABBV-RGX-314 Dose 2|ABBV-RGX-314 Dose 2 administered via subretinal delivery one time.
62133187|NCT02484599|PLACEBO_COMPARATOR|CAT sham bias modification|Sham computerized attention training. Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements not intended to change attention processing of food stimuli using pictures of two different non-food stimuli categories (e.g. household and musical instruments).
62133188|NCT03261908||wild genotype|Through next generation sequencing, distinguish wild genotype of simvastatin
62133189|NCT03261908||mutant genotype|Through next generation sequencing, distinguish mutant genotype of simvastatin
62133190|NCT04761016|ACTIVE_COMPARATOR|Control|Control group participants will receive access to the same I-POP Health resources without CHW navigation until the end of 10-months (delayed CHW navigation). The current usual care model is outlined. Participants will complete study measures at baseline, 6-months, and 10-months timepoints. Upon completion of 10-months measures, these individuals will be assigned a CHW and receive delayed navigation.
62325899|NCT05848011|EXPERIMENTAL|Lorigerlimab + Docetaxel and Prednisone|Lorigerlimab 6 mg/kg IV (up to 2 years) and docetaxel 75 mg/m\^2 IV every 3 weeks (up to 7 months) and prednisone 5 mg orally twice daily (up to 7 months).
62325900|NCT05848011|OTHER|Standard of care docetaxel and prednisone|Docetaxel 75 mg/m\^2 IV every 3 weeks and prednisone 5 mg orally twice daily.(up to 7 months)
62325901|NCT05211895|EXPERIMENTAL|Arm A: Durvalumab + Domvanalimab|Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months
62325902|NCT05211895|ACTIVE_COMPARATOR|Arm B: Durvalumab + Placebo|Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months
62325903|NCT05861999|EXPERIMENTAL|Risdiplam|Participants will receive risdiplam orally once daily for 72 weeks (Treatment Period). The Treatment Period will be followed by a 1-year Treatment Extension Period for a total study duration of 120 weeks (approximately 2.5 years) for each participant enrolled.
62325904|NCT03886766|EXPERIMENTAL|Sequence 1,2,3|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period C/ Visit 10: Efavirenz solution, 3 mg, oral administration (product 3)
62325905|NCT03886766|EXPERIMENTAL|Sequence 2,3,1|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period B/ Visit 6: Efavirenz solution, 3 mg, oral administration (product 3) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
62325906|NCT03886766|EXPERIMENTAL|Sequence 3,1,2|Period A/ Visit 2: Efavirenz solution, 3 mg, oral administration (product 3) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
62325907|NCT05723055|EXPERIMENTAL|Treatment: All Patients|"Nivolumab 480 mg IV Q4 weeks Axatilimab (SNDX 6532) dose (3mg/kg IV) Q4 weeks. If DLT criteria are met, Axatilimab dosing will be reduced to 2mg/kg IV Q4W for the remainder of patients on the study.~The combination will be continued until progression/toxicity up to a maximum of 12 cycles."
62325908|NCT03634540|EXPERIMENTAL|Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)|Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.
62325909|NCT03634540|EXPERIMENTAL|Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)|Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.
62325910|NCT05782907|EXPERIMENTAL|Period 1- Open Label Induction Phase|All participants in open label induction phase of Period 1 will receive upadacitinib Dose A for 8 weeks based on body weight.
62325911|NCT05782907|EXPERIMENTAL|Period 1- Double Blind Maintenance Phase|Clinical responders at the end of open label induction phase of Period 1 will be randomly assigned to receive either upadacitinib Dose B or Dose C for 44 weeks based on body weight.
62325912|NCT05782907|EXPERIMENTAL|Period 2- Open Label Long Term Extension Phase Arm A|Clinical non-responders outside of US after Period 1 induction phase will receive upadacitinib Dose A daily for 8 week extended induction phase in open label long term extension (OLE) Period 2. Clinical responders from extended induction phase in OLE will receive upadacitinib Dose B daily for up to 252 weeks in OLE period 2.
62325913|NCT05782907|EXPERIMENTAL|Period 2- Open Label Long Term Extension Phase Arm B|Clinical non-responders in US after Period 1 induction phase or clinical responders with loss of response during maintenance phase will receive upadacitinib Dose B daily for up to 260 weeks in OLE Period 2.
62325914|NCT05782907|EXPERIMENTAL|Period 2- Long Term Extension Phase Arm C|Clinical responders who complete Period 1 through Week 52 will receive upadacitinib Dose C daily for up to 260 weeks in OLE Period 2.
62325915|NCT05695027|EXPERIMENTAL|Nicotinamide and Pyruvate|The N\&P group will receive nicotinamide and pyruvate for 87 weeks (20 months).
62325916|NCT05695027|PLACEBO_COMPARATOR|Placebo|The placebo group will receive placebo for 87 weeks (20 months).
62325917|NCT05576350|EXPERIMENTAL|SAM-Only Comparison Group|Participants in this group will engage only in smartphone-based alcohol monitoring.
62325918|NCT05576350|EXPERIMENTAL|TRAC plus SAM|Participants in this group will receive the Tracking and Reducing Alcohol Consumption (TRAC) intervention and smartphone-based alcohol monitoring.
62325919|NCT05576350|EXPERIMENTAL|TRAC-ER plus SAM|Participants in this group will receive the Tracking and Reducing Alcohol Consumption (TRAC) intervention combined with GPS-based ecological momentary interventions (EMI) and smartphone-based alcohol monitoring.
62325920|NCT06237257|EXPERIMENTAL|SHR-1316 plus concurrent chemoradiotherapy|
62325921|NCT05982171|EXPERIMENTAL|Exoskeleton+Transcutaneous Spinal Cord Stimulation|Treatment in this group will involve walking overground using the assistance of an exoskeleton while receiving a therapeutic level of transcutaneous spinal cord stimulation (TSCS) thoracolumbar spinal cord areas. Focus will be on stepping at a high intensity throughout the session as measured by heart rate.
62325922|NCT05982171|SHAM_COMPARATOR|Exoskeleton+Sham Stimluation|Treatment in this group will involve walking overground using the assistance of an exoskeleton while receiving a non-therapeutic level of stimulation (considered to be a sham). Focus will be on stepping at a high intensity throughout the session as measured by heart rate.
62325923|NCT05458011|EXPERIMENTAL|Fremanezumab Monthly|"Double Blind (DB) Period: Participants will receive fremanezumab once a month (approximately every 4 weeks). Participants will receive a single injection of fremanezumab and two placebo injections on Day 1, and a single injection of fremanezumab on Days 29 and 57.~Open Label (OL) Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141."
62692378|NCT05407636|ACTIVE_COMPARATOR|Control Arm|Aflibercept administered via intravitreal injection approximately every 8 weeks
62692379|NCT04854473|EXPERIMENTAL|Impedance measurement|Subjects with Exero's Smart Drain Device Attached This arm contains subjects which will have Exero's leak detection Device used: Exero Smart Drain is placed on their large bowel during colonic resection surgery (either open, laparoscopic or robotic). The study aims to demonstrate that the parameters measured by the device in in-vivo, non-disrupted tissue are different than parameters measured in ischemic tissue. Once this data is collected a detection algorithm can be trained. This procedure will add no more than 20 minutes to the existing procedure that is performed per hospital standard overall and will enable collection of control vs. ischemia induced clinical data, essential to developing the detection algorithms.
62692380|NCT06561243||Ibrutinib|Adult patients with a chronic B-cell malignancy exposed to ibrutinib
62325924|NCT05458011|EXPERIMENTAL|Fremanezumab Quarterly|"DB Period: Participants will receive fremanezumab once a quarter (once at the beginning of the 12-week double-blind treatment period). Participants will receive 3 injections of fremanezumab on Day 1, and a single placebo injection on Days 29 and 57.~OL Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141."
62325925|NCT05458011|PLACEBO_COMPARATOR|Placebo|"DB Period: Participants will receive placebo once a month (approximately every 4 weeks). Participants will receive 3 placebo injections on Day 1, and a single injection of placebo on Days 29 and 57.~OL Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141."
62692381|NCT06561243||Acalabrutinib|Adult patients with a chronic B-cell malignancy exposed to acalabrutinib
62692382|NCT03977155|EXPERIMENTAL|High dose of BOS-589|Participants will receive a high dose of BOS-589 orally twice a day (BID).
61932868|NCT02325310|EXPERIMENTAL|Breastfeeding women|70 breastfeeding women meeting all the inclusion criteria and none of the exclusion criteria will be immunized with MMR vaccine in postpartum (before the exit of the maternity)
61932869|NCT06710756|EXPERIMENTAL|Dose Escalation|"* Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers.~* Enrolled subjects are administered \[212Pb\]Pb-PSV359 (starting at 2.5 mCi upto 10 mCi) for treatment of FAP-expressing cancers and for determining Recommended Phase 2 Dose (RP2D)"
61932870|NCT06710756|EXPERIMENTAL|Dose Expansion|"* Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers.~* Enrolled subjects are administered \[212Pb\]Pb-PSV359 (RP2D determined previously) for treatment of FAP-expressing cancers"
61932871|NCT06710483|EXPERIMENTAL|Pre-Dental Visit Telehealth Interview|Participants randomized into this arm will receive a scripted telehealth interview before the scheduled dental visit.The participant's' caregiver and dentist will complete a survey within a week of the dental visit.
61932872|NCT06710483|NO_INTERVENTION|Routine Dental Visit|Participants randomized into this arm will receive standard of care dental visit. The participant's' caregiver and dentist will complete a survey within a week of the dental visit.
61932873|NCT06626243||Robotic Approach|Adult patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent robotic lung resection
62325926|NCT05973851|EXPERIMENTAL|Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray|"Major depressive disorder randomized to EIPT: Switch to second-line antidepressant + esketamine nasal spray or (es)ketamine infusion. Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).~Esketamine nasal spray: 2 times per week for 4 weeks. Initial dose 28 mg, after that increases can be made with 28 mg per increase (up to 84 mg per week). This decision is up to the investigator's discretion (in accordance with SmPC).~(Es)ketamine infusion: performed twice weekly for 4 weeks. Compound, brand up to the investigator's discretion (in accordance with SmPC)."
62692383|NCT03977155|EXPERIMENTAL|Low dose of BOS-589|Participants will receive a low dose of BOS-589 orally BID.
62692384|NCT03977155|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally BID.
62692385|NCT04005833||COPD exacerbation|COPD exacerbation, compared according to blood fibrocytes level measured during the suspected exacerbation (Day 1)
62692386|NCT00860496|OTHER|1|Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
62692387|NCT00860496|OTHER|2|Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.
62692388|NCT04974398|EXPERIMENTAL|Group A|Group A (study group): Penpulimab plus cisplatin and gemcitabine
61932874|NCT06626243||video-assisted thoracoscopic surgery (VATS) Approach|Adult patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent video-assisted thoracoscopic surgery (VATS) lung resection
61932875|NCT06626243||Open Approach|Adult patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent open lung resection
61932876|NCT05293964|EXPERIMENTAL|SIM0270|Phase Ia SIM0270 monotherapy dose escalation and expansion
61932877|NCT05293964|EXPERIMENTAL|SIM0270+palbociclib|Phase Ib SIM0270 with palbociclib dose escalation and expansion
62692389|NCT04974398|PLACEBO_COMPARATOR|Group B|Group B (control group): Placebo plus cisplatin and gemcitabine
62692390|NCT04952519|EXPERIMENTAL|Amantadine|
62692391|NCT04952519|PLACEBO_COMPARATOR|Placebo|
62692392|NCT05646693|EXPERIMENTAL|Drusen Mega® + Sertraline|It will consist of 29 patients with Chronic Subjetive Endotic Tinnitus. Patients will eat one capsule of antioxidant therapy (Drusen Mega®) and one capsule of sertraline per day in the night for 3 months.
62692393|NCT05646693|PLACEBO_COMPARATOR|Placebo + Sertraline|It will consist of 29 patients with Chronic Subjetive Endotic Tinnitus. Patients will eat one capsule of placebo (Magnesium Oxide 100mg) per day in the morning and one capsule of sertraline per day in the night for 3 months.
62692394|NCT00398879|EXPERIMENTAL|Arm 1: Perifosine + Capecitabine|Perifosine 50 mg/d qd + Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks until progression
61932878|NCT05293964|EXPERIMENTAL|SIM0270+everolimus|Phase Ib SIM0270 with everolimus dose escalation and expansion
62133191|NCT04761016|EXPERIMENTAL|I-POP CHW Intervention|I-POP+CHW participants will be paired with a CHW at baseline to assist with navigation for 10-months between health and wellness services in the selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227. Participants will receive a multi-level intervention utilizing the current I-POP Health model that includes: 1) Access to health services (including oral health), 2) Access to clinical prevention services, 3) Access to education and facilities to increase physical activity and improved nutrition choices, and 4) Scheduled visits with CHWs for education and navigation. Individuals will complete study measures at baseline, 6-months, and 10-months.
62325927|NCT05973851|ACTIVE_COMPARATOR|Major Depressive Disorder TAU: second-line antidepressant|Subject with major depressive disorder, randomized to TAU: switch to second-line antidepressant. When randomized to second-line anti-depressants, this means participants will receive treatment as usual. The physician has the choice to administer any second-line anti-depressant. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
62325928|NCT04350138|EXPERIMENTAL|Group 1|Bexsero vaccine will be administered as an intramuscular injection in 1 mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
62325929|NCT04350138|PLACEBO_COMPARATOR|Group 2|Placebo will be administered as an intramuscular injection in single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
62325930|NCT06431074|PLACEBO_COMPARATOR|Placebo Control 1|Calm Product Form 1 - control
62325931|NCT06431074|EXPERIMENTAL|Active Product 1.1|Calm Product Form 1 - active product 1
62325932|NCT05091112||Active group|Patients who are scheduled to undergo lumbar spinal surgery and fulfill the inclusion and exclusion criteria
61932879|NCT06683339||Children with chronic kidney disease|
61932880|NCT06708169|NO_INTERVENTION|Patients without preoperative education by anesthesiologists|Patients get minimal information about the surgical process and their questions will be answered by obstetrician.
61932881|NCT06708169|EXPERIMENTAL|Patients with preoperative education by anesthesiologists|Patients get preemptive education about the whole process from anesthesia to recovery stage within 15 minute by anesthesiologists.
61932882|NCT06688058|EXPERIMENTAL|V540D|Participants will receive vaccinations with V540D.
61932883|NCT06688058|ACTIVE_COMPARATOR|GARDASIL®9|Participants will receive vaccinations with GARDASIL®9.
61932884|NCT04568993|EXPERIMENTAL|proximal phalangeal level|injection in the the tendon sheet over proximal phalanx of finger
61932885|NCT04568993|ACTIVE_COMPARATOR|volar MCP level|injection above the A1 pulley volar to the MCP joint
61932886|NCT03511196|EXPERIMENTAL|Adaptive ADT+ Standard of Care|Participants will undergo 12-16 weeks of GnRH analog, along with 8-12 weeks of combinational therapy with GnRH analog and abiraterone plus prednisone. 14 participants who achieve \>75% PSA decline after the run-in period will be enrolled. GnRH analog and abiraterone will be stopped after study enrollment. PSA and testosterone level will be measured every 4 weeks during the run-in period, then every 6 weeks after study enrollment. Imaging studies with CT and bone scan will be performed at the time of study enrollment and these will be considered baseline scans. Study treatment will be restarted if participant's PSA reaches 2 fold or higher of his baseline PSA. Selection of treatment will be based on participant's testosterone level.
61932887|NCT02213926|EXPERIMENTAL|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
61932888|NCT05970718|EXPERIMENTAL|IV Dose Level 1|Randomized 6:2 for single ascending IV dose
61932889|NCT05970718|EXPERIMENTAL|IV Dose Level 2|Randomized 6:2 for single ascending IV dose
61932890|NCT05970718|EXPERIMENTAL|IV Dose Level 3|Randomized 6:2 for single ascending IV dose
61932891|NCT05970718|EXPERIMENTAL|IV Dose Level 4|Randomized 6:2 for single ascending IV dose
62325933|NCT04032470||Essential Tremor|Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems
62325934|NCT05616130||Trauma|Data collection from medical records; bone marrow collection at time of surgical intervention; serial blood sampling; serial interviews to complete surveys and questionnaires which assess overall health, quality of life, daily living activities and mobility; serial physical function tests - hand grip strength measurement and short physical performance battery and telephone follow up call
62325935|NCT05616130||Elective Hip Repair|Data collection from medical records; bone marrow collection at time of surgical intervention; serial blood sampling; serial interviews to complete surveys and questionnaires which assess overall health, quality of life, daily living activities and mobility; serial physical function tests - hand grip strength measurement and short physical performance battery and telephone follow up call
61932892|NCT05970718|EXPERIMENTAL|IV Dose Level 5|Randomized 6:2 for single ascending IV dose
61932893|NCT05970718|EXPERIMENTAL|IV Dose Level 6|Randomized 6:2 for single ascending IV dose
62325936|NCT03952559|EXPERIMENTAL|Baricitinib Open Label High Dose (PK Lead-in)|"Participants 10 to \< 18 years received Baricitinib high dose (4 mg) administered orally in tablet form QD.~Participants 2 to \< 10 years received Baricitinib high dose (2 mg) administered as oral suspension (1 mL) QD."
62692395|NCT00398879|PLACEBO_COMPARATOR|Arm 2: Perifosine Placebo + Capecitabine|Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks until progression
61932894|NCT05970718|EXPERIMENTAL|SC Dose Level 1|Randomized 6:2 for single ascending SC dose
61932895|NCT05970718|EXPERIMENTAL|SC Dose Level 2|Randomized 6:2 for single ascending SC dose
61932896|NCT05970718|EXPERIMENTAL|SC Dose Level 3|Randomized 6:2 for single ascending SC dose
61932897|NCT05970718|EXPERIMENTAL|Optional Cohort 1|Randomized 6:2 for single ascending dose This is an optional cohort, that may be IV or SC and will not exceed highest dose level
61932898|NCT05970718|EXPERIMENTAL|Optional Cohort 2|Randomized 6:2 Randomized 6:2 for single ascending dose This is an optional cohort, that may be IV o SC and will not exceed highest dose level
61932899|NCT05482542|OTHER|Cyclophosphamide/ATG Conditioning Regimen|Cyclophosphamide (200 mg /kg) / rabbit antithymocyte globulin (6.0 mg/kg)
61932900|NCT05482542|OTHER|Cyclophosphamide/Rituximab Conditioning Regimen|Cyclophosphamide (200 mg/kg) / rituximab (1000 mg).
62325937|NCT03952559|EXPERIMENTAL|Baricitinib High Dose|"Participants 10 to \< 18 years received Baricitinib high dose (4 mg) and placebo to maintain the blind, administered orally in tablet form QD.~Participants 2 to \< 10 years received Baricitinib high dose (2 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind."
62325938|NCT03952559|EXPERIMENTAL|Baricitinib Medium Dose|"Participants 10 to \< 18 years received Baricitinib low dose (1 mg) and placebo to maintain the blind, administered orally in tablet form QD.~Participants 2 to \< 10 years received Baricitinib low dose (0.5 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind."
62325939|NCT03952559|EXPERIMENTAL|Baricitinib Low Dose|"Participants 10 to \< 18 years received Baricitinib low dose (1 mg) and placebo to maintain the blind, administered orally in tablet form QD.~Participants 2 to \< 10 years received Baricitinib low dose (0.5 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind."
62133192|NCT01006434||Thrombolysis group (Pilot phase)|Patients receiving intravenous thrombolysis for acute ischemic stroke. Pilot phase (100 Patients).
62325940|NCT03952559|PLACEBO_COMPARATOR|Placebo|Participants 10 to \< 18 years received placebo tablets. Participants 2 to \< 10 years received placebo as oral suspension.
62325941|NCT04349436|EXPERIMENTAL|RP1, intra-tumoral injection, oncolytic virus|RP1 administered as an intra-tumoral injection every 2 weeks.
62325942|NCT05877599|EXPERIMENTAL|Dose Escalation and Expansion|Dose Escalation of TCR T cell product
62692396|NCT06335706||Frequently worn underpants during daytime|It will be divided into two groups based on the type of underwear worn: loose-fit, which includes boxers and tight-fit, which includes all other types.
62133193|NCT01006434||Thrombolysis group|Patients receiving intravenous thrombolysis for acute ischemic stroke.
62133194|NCT05850975|EXPERIMENTAL|mindful breathing|
62133195|NCT05850975|EXPERIMENTAL|deep breathing|
62133196|NCT05850975|EXPERIMENTAL|cognitive therapy|
62133197|NCT05850975|EXPERIMENTAL|dare response|
62133198|NCT05850975|EXPERIMENTAL|defusion|
62133199|NCT05850975|EXPERIMENTAL|in flow with fear|
62133200|NCT05850975|EXPERIMENTAL|gratitude practice|
62133201|NCT05850975|EXPERIMENTAL|guided mindfulness|
62133202|NCT05850975|EXPERIMENTAL|muscle relaxation|
62133203|NCT05850975|EXPERIMENTAL|reframe your fears|
62133204|NCT05850975|EXPERIMENTAL|calming visualization|
62692397|NCT06335706||Frequently worn underpants at nighttime|It will be divided into two groups based on the type of underwear worn: loose-fit, which includes boxers or none, and tight-fit, which includes all other types.
62133205|NCT05850975|EXPERIMENTAL|reflective writing|
62133206|NCT05850975|PLACEBO_COMPARATOR|reading about anxiety|
62133207|NCT05850975|NO_INTERVENTION|do what you would usually do|
62325943|NCT05877599|EXPERIMENTAL|Part 1: Disease Histology Evaluation|TCR T Cell Product at the MTD
62325944|NCT05877599|EXPERIMENTAL|Part 2: Disease Cohort Expansion|TCR T Cell Product at the RP2D
62325945|NCT04475939|EXPERIMENTAL|Participants receiving niraparib plus pembrolizumab|Eligible participants will receive niraparib along with pembrolizumab.
62325946|NCT04475939|PLACEBO_COMPARATOR|Participants receiving placebo plus pembrolizumab|Eligible participants will receive matching placebo along with pembrolizumab.
62325947|NCT05139862|EXPERIMENTAL|Active iTBS|Active intermittent theta-burst stimulation (iTBS) rTMS session on the left dorsolateral prefrontal cortex (L-DLPFC)
62692398|NCT06289582|EXPERIMENTAL|Prodromal and manifest (PD) participants|
61932901|NCT06710821|EXPERIMENTAL|VIT|Vincristine: 1.5 mg/m², iv, d1. l Temozolomide 150 mg/m²/d, iv drip, d1-5. l Irinotecan liposomal RP dose, iv infusion over 90 min, d1.
61932902|NCT03594435|EXPERIMENTAL|Ibudilast|10mg delayed-release capsules, target dose 50mg twice daily (5 x 10mg capsules twice daily) for 12 weeks
61932903|NCT03594435|PLACEBO_COMPARATOR|Placebo Oral Capsule|matched to experimental drug
62133208|NCT00772044|ACTIVE_COMPARATOR|Provent|Those receiving the active device
62133209|NCT00772044|SHAM_COMPARATOR|Sham|Those receiving sham device
62133210|NCT02343913|EXPERIMENTAL|PAC checklist|Pictorial checklist which illustrates these signs and symptoms
62133211|NCT01866215|EXPERIMENTAL|Study1a|exercice performed 90 min before 13C fructose meal ingestion
62133212|NCT01866215|EXPERIMENTAL|study 1b|exercise performed 90 min after 13C fructose meal ingestion
62133213|NCT01866215|NO_INTERVENTION|study 1c|no exercise
62133214|NCT01866215|EXPERIMENTAL|study 2a|meals containing fructose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
62133215|NCT01866215|ACTIVE_COMPARATOR|study 2b|meals containing glucose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
62133216|NCT06222983||CEA group|CEA for atherosclerosis
62133217|NCT06222983||CAS group|CEA for atherosclerosis
62133218|NCT06270628|EXPERIMENTAL|Exercise group|Participants will be offered three live-remote exercise training sessions per week. Each participant in the trial will be provided with the base module twice a week, which will involve a personalized training intensity. This module aims at targeting the participants' HRQOL, which is the first primary endpoint of the trial. Additionally, each participant will receive one out of four specific modules once a week to address their individual main side-effect (based on shared decision-making (SDM)) (second primary outcome). The intervention also includes an educational component about exercise and cancer.
62133219|NCT06270628|NO_INTERVENTION|Wait list control group|Regular care The control group will receive the same exercise program after the 12 weeks intervention period
62133220|NCT04564365||with beta-blocker|
62133221|NCT04564365||without beta-blocker|
62133222|NCT05296772|OTHER|Dose escalation|A open-label single arm of JS014 alone or in combination with pembrolizumab
62133223|NCT00533494|ACTIVE_COMPARATOR|B|Feedback to physicians + reminder letters to patients
62133224|NCT00533494|ACTIVE_COMPARATOR|A|Feedback information to physicians
62325948|NCT04167761|EXPERIMENTAL|Ertugliflozin (treated tissue)|Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. Tissue samples were incubated with Ertugliflozin to evaluate its effects on lipolysis, inflammation, and gene expression in epicardial, pericardial, and subcutaneous adipose tissues
62692399|NCT06289582|EXPERIMENTAL|Healthy participants|
62484558|NCT03426657|EXPERIMENTAL|Durvalumab + Tremelimumab + RT|Durvalumab (1500 mg,q4W) + Tremelimumab (75 mg, q4W / since Amendment 3: 300 mg absolute dose d5) for up to a maximum of 4 doses/cycles combined with radiotherapy (35 x 2.0/1.8/1.6 Gy) followed by durvalumab monotherapy 1500mg via IV infusion q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 8 additional durvalumab doses.
62484559|NCT05657587||PNS Group|All subjects will receive the PNS device. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
62484560|NCT00540423|EXPERIMENTAL|SB-497115-GR group|Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
62484561|NCT00540423|PLACEBO_COMPARATOR|placebo group|Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
62484562|NCT01983501|EXPERIMENTAL|Tucatinib (ONT-380) in combination with T-DM1|
62484563|NCT04942496|ACTIVE_COMPARATOR|Test Product 1 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484564|NCT04942496|ACTIVE_COMPARATOR|Test Product 2 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484565|NCT04942496|ACTIVE_COMPARATOR|Test Product 3 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484566|NCT04942496|ACTIVE_COMPARATOR|Test Product 4 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484567|NCT04942496|ACTIVE_COMPARATOR|Test Product 5 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484568|NCT04942496|ACTIVE_COMPARATOR|Test Product 6 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484569|NCT04942496|ACTIVE_COMPARATOR|Test Product 7 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484570|NCT04942496|ACTIVE_COMPARATOR|Test Product 8 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484571|NCT04942496|ACTIVE_COMPARATOR|Test Product 9 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
62484572|NCT04942496|PLACEBO_COMPARATOR|0.1% Sodium Lauryl Sulfate|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product with known irritancy potential.
62325949|NCT05616026|EXPERIMENTAL|Intervention|The intervention (INT) will include 6 months of DM management support via SMS texts including reminders for medication adherence, appointments, and DM self-care activities as well as education, and support.
62325950|NCT05616026|PLACEBO_COMPARATOR|Control|The control (CL) will receive 6 months of texts for general health promotion.
62325951|NCT06571552|ACTIVE_COMPARATOR|Patients benefitting from Single Plasma Exchange followed by Double Filtration Plasmapheresis|For the patients in this group, the first cycle (T1) will consist of Single Plasma Exchange and the second cycle (T2) of Double Filtration Plasmapheresis.
62484573|NCT04942496|PLACEBO_COMPARATOR|Distilled Water|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product known not to cause irritancy
62484574|NCT03693014|EXPERIMENTAL|Stereotactic Body Radiotherapy|Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions) to 1-3 lesions. Treatment with the checkpoint inhibitor will continue until progression at the discretion of the treating physician or unacceptable toxicity.
62484575|NCT04866979|EXPERIMENTAL|Combination of continuous TBS plus cognitive training (cTBS + CT)|Continuous mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
62484576|NCT04866979|EXPERIMENTAL|Combination of intermittent TBS plus cognitive training (iTBS + CT)|Intermittent mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
62325952|NCT06571552|ACTIVE_COMPARATOR|Patients benefitting from Double Filtration Plasmapheresis followed by Single Plasma Exchange|For the patients in this group, the first cycle (T1) will consist of Double Filtration Plasmapheresis and the second cycle (T2) of Single Plasma Exchange.
62325953|NCT06159608|OTHER|Healthy Young Women|Young women who do not use e-cigarettes
62325954|NCT06159608|OTHER|Healthy Young Men|Young men who do not use e-cigarettes
62325955|NCT06159608|OTHER|Young Women using E-cigarettes|Young women chronically use e-cigarettes
62325956|NCT06159608|OTHER|Young Men using E-cigarettes|Young men chronically use e-cigarettes
62484577|NCT04866979|EXPERIMENTAL|Continuous TBS only (cTBS)|TBS in continuous mode application, only (without cognitive training).
62484578|NCT04866979|EXPERIMENTAL|Intermittent TBS only (iTBS)|TBS in intermittent mode application, only (without cognitive training).
62484579|NCT04866979|ACTIVE_COMPARATOR|Cognitive training only (with sham TBS) (CT).|"TBS Sham will be implemented using the same set-up as a true TBS protocol but with sham stimulation. Directly following sham stimulation (as in the true combination of stimulation + cognitive training protocols), patients will undergo 25 minutes of cognitive training."
62484580|NCT01215279|EXPERIMENTAL|AZD2423|AZD2423 Oral Treatment for 28 days
62484581|NCT01215279|PLACEBO_COMPARATOR|Placebo|Oral treatment for 28 days
62484582|NCT03961204|OTHER|Cohort A|The participants previously enrolled in parent studies CLARITY (NCT00213135), CLARITY-EXT (NCT00641537), ORACLE (NCT00725985) and had received Cladribine tablet and Placebo were invited up to 2 visit for follow-up/data collection.
62692400|NCT06497088|EXPERIMENTAL|Nasotrak System|
62692401|NCT04725513|ACTIVE_COMPARATOR|Physical Therapy Only|
62692402|NCT04725513|EXPERIMENTAL|Shockwave Therapy and Physical Therapy|
62692403|NCT04725513|EXPERIMENTAL|Photobiomodulation, Shockwave Therapy and Physical Therapy|
62325957|NCT06570525|EXPERIMENTAL|NurseNET-Narrative Exposure Therapy|"Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding."
62484583|NCT05999253||Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~* Patients will be induced with standard general anesthesia and turned to the prone position.~* Before the surgical incision, 20 ml of 0.25% bupivacaine 0.25% will be administered bilaterally under ultrasound guidance only once.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* Plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
62484584|NCT05999253||Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~* Patients will be induced with standard general anesthesia and turned to the prone position.~* Before the surgical incision, 20 ml of 0.25% bupivacaine will be administered bilaterally under ultrasound guidance only once.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* Plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
62325958|NCT06570525|ACTIVE_COMPARATOR|PAL: Peer Active Listening|"Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control)."
62325959|NCT06021600|EXPERIMENTAL|Cohort 1 (Pilot)|Participants will only receive 1 dose of oral cladribine, followed by 4 daily doses of cladribine by vein
62325960|NCT06021600|EXPERIMENTAL|Cohort 2 (PK)|Participants will only receive 1 dose of oral cladribine, followed by 4 daily doses of cladribine by vein
62325961|NCT06021600|EXPERIMENTAL|Cohort 3 (All-Oral HCL)|Participants will all receive the same dose of oral cladribine over the course of 5 days.
62692404|NCT03829488|EXPERIMENTAL|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
62692405|NCT03829488|ACTIVE_COMPARATOR|0.9% SODIUM CHLORIDE 9g/L injection BP|0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
61932904|NCT04317105|EXPERIMENTAL|Trial I (copanlisib, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray and/or CT scan during screening and every 8 weeks, as well as a tumor biopsy at baseline, cycle 1 day 15, cycle 2 day 15, and every 3 weeks thereafter, and at disease progression. Patients also undergo blood sample collection at baseline, cycle 1 days 8 and 15, cycle 2 day 15, cycle 4 day 1 and disease progression. Patients undergo ECHO during screening and as clinically indicated on study.
61932905|NCT04317105|EXPERIMENTAL|Trial II (copanlisib, nivolumab, ipilimumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1 and ipilimumab IV over 90 minutes every 8 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray and/or CT scan during screening and every 8 weeks, as well as a tumor biopsy at baseline, cycle 1 day 15, cycle 2 day 15, and every 3 weeks thereafter, and at disease progression. Patients also undergo blood sample collection at baseline, cycle 1 days 8 and 15, cycle 2 day 15, cycle 4 day 1 and disease progression. Patients undergo ECHO during screening and as clinically indicated on study.
61932906|NCT06310213|ACTIVE_COMPARATOR|Aim 1 Control|Intervention at single time point not to interfere with standard of care procedures
61932907|NCT06310213|EXPERIMENTAL|Aim 1 Hydrocephalus|Intervention at single time point during standard of care hydrocephalus evaluation (anterior fontanelle assessment and measurement of head circumference), unless further assigned to supplemental arm following standard of care surgical procedure
61932908|NCT06310213|EXPERIMENTAL|Aim 2 Hydrocephalus, Shunt surgery|Intervention pre- and post-operatively
61932909|NCT06310213|EXPERIMENTAL|Aim 3 Hydrocephalus, EVD ICP monitor|Intervention during standard of care monitoring of EVD ICP reading(s)/hydrocephalus evaluation (anterior fontanelle assessment and measurement of head circumference)
62325962|NCT03818880|EXPERIMENTAL|Treatment|Subjects wearing novel spectacle lenses will be assessed
62325963|NCT03992430|EXPERIMENTAL|Part 1: Eteplirsen|Participants will receive eteplirsen 100 mg/kg once weekly for at least 4 weeks, followed by eteplirsen 200 mg/kg once weekly for at least 4 weeks.
62325964|NCT03992430|ACTIVE_COMPARATOR|Part 2: Eteplirsen 30 mg/kg|Randomized participants will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.
62325965|NCT03992430|EXPERIMENTAL|Part 2: Eteplirsen 100 mg/kg|Randomized participants will receive eteplirsen 100 mg/kg once weekly for up to 144 weeks.
61932910|NCT06310213|EXPERIMENTAL|Aim 4 Hydrocephalus, Reservoir surgery|Intervention pre- and post- ventricular reservoir tap(s)
61932911|NCT06708026|EXPERIMENTAL|Intervention group|For each session, participants will be required to conduct a ten-minute basic wheelchair exercise followed by a twenty-minute AOMI training at home. The whole intervention will last for eight weeks, three times a week.
61932912|NCT06708026|ACTIVE_COMPARATOR|Control group|For each session, participants will be required to conduct a ten-minute basic wheelchair exercise at home. The whole intervention will last for eight weeks, three times a week.
61932913|NCT06705907|EXPERIMENTAL|Achieving Independence & Mastery in School (AIMS)|AIMS targets executive functioning skills using evidence-based strategies for youth with ASD to promote increased independence related to academics. Each session involves a review of a real world practice assignment and a didactic component illustrating key concepts followed by an in-session practice of the key concepts and strategies with coaching from a therapist. A behavior agreement is used to identify specific goals for adolescents to work on in collaboration with their caregivers and specific rewards earned for meeting their goals. Adolescents are assigned a real world practice assignment each session that consists of additional practice of strategies to further build and generalize skills between sessions.
62484585|NCT02942823|EXPERIMENTAL|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). Additionally, the intervention group will take the game home on a tablet computer to play it with their parents in between session 1 and 2. The game equips the children and their parents with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
62484586|NCT02942823|NO_INTERVENTION|Control|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors. The parents are not involved.
62484587|NCT00582179|ACTIVE_COMPARATOR|1, A|Group A patients will be treated with a pressure dressing and observation.
61932914|NCT06705907|ACTIVE_COMPARATOR|Building Essential Social Skills for Teens (BESST)|BESST targets social skills using evidence-based strategies and includes sessions related to starting, joining, maintaining, and ending conversations and making, maintaining, and deepening friendships. Each skill will be introduced in a didactic lesson which includes modeling of the targeted skill by a therapist. Adolescents will role-play new skills during the session before receiving a homework assignment to practice the skill at home. Caregivers will receive training in social-communication difficulties in ASD and suggestions for supporting development of these skills. The sessions are specifically focused on generalizing newly learned skills to both home and school.
61932915|NCT06508489|EXPERIMENTAL|Substudy 01: SAR443579 + azacitidine + venetoclax|Part 1: Safety run-in: SAR443579 treatment will begin with an identified starting dose. Safety run-in will proceed according to the incidence of DLTs.
61932916|NCT03003611||Hypnose|the group of patient who's operated under hypnose sedation
61932917|NCT03003611||traditional anesthesia|The match is realized with a patient operated in the same period as the patient in the hypnose group and it's need a comparative type of surgery.
61932918|NCT04728867|ACTIVE_COMPARATOR|Surgical textbook|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be a textbook chapter explaining the details for laparoscopic rectal surgery.
61932919|NCT04728867|ACTIVE_COMPARATOR|3D animation|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational animation video showing laparoscopic rectal surgery.
62325966|NCT03992430|EXPERIMENTAL|Part 2: Eteplirsen 200 mg/kg|Randomized participants will receive eteplirsen 200 mg/kg once weekly for up to 144 weeks.
62692406|NCT06639152|EXPERIMENTAL|oil-based contrast medium|oil-based contrast medium: ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml)
62692407|NCT06639152|ACTIVE_COMPARATOR|warer-based contrast medium|water-based contrast medium: Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml)
62692408|NCT06525727||Patients aged 65 years and over|Patients aged 65 years and over who came to the emergency department with a fall on level ground ((either inside or outside), off a chair, toilet seat or out of bed) within the last 48 hours
62692409|NCT03238053|ACTIVE_COMPARATOR|Menopausal Laser|20 women with vaginal laser treatment
62692410|NCT03238053|SHAM_COMPARATOR|Menopausal sham|20 women with probe, no active laser ray
61932920|NCT04728867|ACTIVE_COMPARATOR|Cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational cadaveric dissection video showing laparoscopic rectal surgery.
62325967|NCT00895271||Healthy Volunteers|Up to 50 subjects as healthy controls
62325968|NCT00895271||Immunodeficiency|Up to 150 subjects with poorly defined, rare inherited immunodeficiency or immunodysregulation disorders
62325969|NCT00025935||Children/adolescents with ADHD|Children/adolescents with ADHD
62325970|NCT00025935||Children/Adolescents with DMDD or subthreshold DMDD|Children/Adolescents with DMDD or subthreshold DMDD
62325971|NCT00025935||Children/adolescents with MDD|Children/adolescents with MDD
62325972|NCT00025935||Healthy volunteer adults|Healthy volunteer adults
62325973|NCT00025935||Healthy volunteer children/adolescents|Healthy volunteer children/adolescents
62325974|NCT00025935||Parents of children/adolescents with DMDD or subthreshold DMDD|Parents of children/adolescents with DMDD or subthresdhold DMDD
62325975|NCT06310967|OTHER|Cohort A (0.25 g tablets)|"Cohort A will have 10 eligible patients. 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort.~Dose shall be at 0.25 g tablets. Single-dose initial treatment phase: D1\~D3. Subject will receive a single dose of IG3018 or the placebo on Day 1. The predetermined information shall be collected in the form of blood and urine samples for PK analyses, whilst efficacy and safety assessment data will be collected within 48 hours after the single dose of study drug administration (IG3018 or placebo).~Maintenance treatment on daily basis phase: 4 weeks. Subjects in this maintenance treatment phase shall receive the study drug IG3018 in twice daily dosing for 28 days from Day 4 to Day 31, and will be given IG3018 once on the morning of D32."
62325976|NCT06310967|OTHER|Cohort B (0.5 g tablets)|"Cohort B will have 10 eligible patients. 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort.~Dose shall be at 0.5 g tablets. Single-dose initial treatment phase: D1\~D3. Subject will receive a single dose of IG3018 or the placebo on Day 1. The predetermined information shall be collected in the form of blood and urine samples for PK analyses, whilst efficacy and safety assessment data will be collected within 48 hours after the single dose of study drug administration (IG3018 or placebo).~Maintenance treatment on daily basis phase: 4 weeks. Subjects in this maintenance treatment phase shall receive the study drug IG3018 in twice daily dosing for 28 days from Day 4 to Day 31, and will be given IG3018 once on the morning of D32."
62325977|NCT06310967|OTHER|Cohort C (1.0 g tablets)|"Cohort C will have 10 eligible patients. 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort.~Dose shall be at 1.0 g tablets. Single-dose initial treatment phase: D1\~D3. Subject will receive a single dose of IG3018 or the placebo on Day 1. The predetermined information shall be collected in the form of blood and urine samples for PK analyses, whilst efficacy and safety assessment data will be collected within 48 hours after the single dose of study drug administration (IG3018 or placebo).~Maintenance treatment on daily basis phase: 4 weeks. Subjects in this maintenance treatment phase shall receive the study drug IG3018 in twice daily dosing for 28 days from Day 4 to Day 31, and will be given IG3018 once on the morning of D32."
62325978|NCT06310967|OTHER|Cohort D (0.5 g BID IG3018)|5 to 8 hyperuricemia subjects with advanced CKD will be enrolled in Cohort D and will receive 0.5 g IG3018 twice daily (BID) for 4 weeks.
62325979|NCT06310967|OTHER|Cohort E (1.0 g BID IG3018)|5 to 8 hyperuricemia subjects with advanced CKD will be enrolled in Cohort E and will receive 1.0 g IG3018 twice daily (BID) for 4 weeks.
62325980|NCT04009499|EXPERIMENTAL|Bimekzumab dosage regimen|Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.
62325981|NCT03180034|EXPERIMENTAL|Arm I (Gardasil, DTaP)|Participants receive Gardasil IM at month 0 and DTaP IM at month 6.
62325982|NCT03180034|EXPERIMENTAL|Arm II (Cervarix, DTaP)|Participants receive Cervarix IM at month 0 and DTaP IM at month 6.
62325983|NCT03180034|ACTIVE_COMPARATOR|Arm III (Gardasil)|Participants receive Gardasil IM at month 0 and 6.
62325984|NCT03180034|ACTIVE_COMPARATOR|Arm IV (Cervarix)|Participants receive Cervarix IM at month 0 and 6.
62325985|NCT03180034|NO_INTERVENTION|Arm V (epidemiologic survey)|A concurrent epidemiologic survey for HPV status among two groups of unvaccinated women. Survey participants are followed for two study visits six months apart to determine their HPV DNA status, with no further follow-up. These women will be offered HPV vaccination (Cervarix) at the two study visits.
62325986|NCT05842122|ACTIVE_COMPARATOR|Client-sustained delivery of pharmacy PrEP/PEP|Pharmacy providers offer clients PrEP and PEP services for a fee of 250 Kenyan Shillings (KES) per visit (study team compensates pharmacy providers 0 KES per visit).
62325987|NCT05842122|ACTIVE_COMPARATOR|Implementor-sustained delivery of pharmacy PrEP/PEP|Pharmacy providers offer clients PrEP and PEP services for a fee of 0 KES per visit (study team compensates pharmacy providers 250 KES per visit).
62325988|NCT05842122|ACTIVE_COMPARATOR|Counselor-supported delivery of pharmacy PrEP/PEP|HIV testing service (HTS) counselors support pharmacy providers in offering clients PrEP and PEP services for a fee of 0 KES per visit (study team compensates pharmacy providers 100 KES per visit).
62325989|NCT05842122|ACTIVE_COMPARATOR|Referral to clinic-based PrEP/PEP|Pharmacy providers offer clients referral to PrEP and PEP services at nearby public clinics for a fee of 0 KES per referral (study team compensates pharmacy providers 100 KES per referral).
62325990|NCT00001456||HPS|HPS patients of any gender and ethnicity age 1-80 years
62325991|NCT00001456||HPS Symptom Questionnaire|Includes both patients and family members or caregivers.
62325992|NCT05835986|EXPERIMENTAL|Part 1: SAD: RO7507062|Participants will receive RO7507062 at an assigned dose as subcutaneous (SC) injection on Day 1.
62325993|NCT05835986|EXPERIMENTAL|Part 2: Dose Escalation with Fractionated Dosing: RO7507062|Participants will receive RO7507062 as SC injection at the dose determined in Part 1, on Day 1 and at an escalated dose, based on emergent safety data, on Day 8.
62325994|NCT06425133|ACTIVE_COMPARATOR|Regorafenib|"• Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : no regorafenib~For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
62325995|NCT06425133|EXPERIMENTAL|Regorafenib+ metronomic chemotherapy + aspirin|"• Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg daily week 2: 120 mg daily week 3: 160 mg daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.~* Metronomic chemotherapy will be administrated as following:Cyclophosphamide: 50 mg per os, daily, for 6 months,Capecitabine: 625mg/m²/orally twice daily, for 6 months.~* Low-dose Aspirin: 75 mg orally, daily, until progression."
62325996|NCT03650712|OTHER|frequently sampled oral glucose tolerance testing|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit
62692411|NCT03238053|ACTIVE_COMPARATOR|breast cancer laser|20 women with breast cancer with vaginal laser treatment
62325997|NCT03650712|OTHER|Frequently sampled oral glucose tolerance testing anc CGM|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back
62325998|NCT03650712|OTHER|frequently sampled oral glucose tolerance testing and DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + a DXA scan will be done at the same visit
62484588|NCT00582179|ACTIVE_COMPARATOR|2, B|Group B patients will be treated with a Vacuum Assisted Closure device (VAC).
62692412|NCT03238053|SHAM_COMPARATOR|breast cancer sham|20 women with breast cancer with vaginal probe, no active laser rays
62692413|NCT03238053|ACTIVE_COMPARATOR|endometrial cancer laser|20 women with endometrial cancer with vaginal laser treatment
61932921|NCT04728867|ACTIVE_COMPARATOR|Both 3D animation + cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be both animation and educational cadaveric dissection video showing laparoscopic rectal surgery.
61932922|NCT02394678|EXPERIMENTAL|Intervention - clot removal|Patients will undergo rheolytic thrombectomy for intraventricular hemorrhage
61932923|NCT00132353||Healthy volunteers|For normative data
61932924|NCT00132353||Patients with neurological disorders|For teaching fellows electrodiagnostic techniques
61932925|NCT06509334|EXPERIMENTAL|JYB1904: Dose-1|
61932926|NCT06509334|EXPERIMENTAL|JYB1904: Dose-2|
61932927|NCT06509334|ACTIVE_COMPARATOR|Omalizumab|
61932928|NCT05231668|EXPERIMENTAL|SAR439459|Participants will receive a single dose of SAR439459
62484589|NCT00611676|EXPERIMENTAL|A|All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
62484590|NCT06545474|EXPERIMENTAL|theta burst stimulation (TBS)|In Stage I, participants receive 4-week bilateral theta burst stimulation. Bilateral TBS consists of 20 sessions that are conducted daily from Monday to Friday over a period of 4 weeks. The target regions are the right and left dorsolateral prefrontal cortex (dlPFC). On the left hemisphere, intermittent TBS (iTBS) is applied, which has a stimulating effect on the target region similar to 10 Hz rTMS. On the right dlPFC, continuous TBS (cTBS) is applied, which has an inhibitory effect similar to 1 Hz rTMS.
62692414|NCT03238053|SHAM_COMPARATOR|endometrial cancer sham|20 women with endometrial cancer with vaginal probe, no active laser rays
61932929|NCT05231668|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo
61932930|NCT06710717|EXPERIMENTAL|autologous CD19 CAR T-cells|Single Infusion of autologous CD19 CAR T- cells
61932931|NCT01588249|EXPERIMENTAL|Novel formulation of pasteurized maple cough syrup|
62325999|NCT03650712|OTHER|frequently sampled oral glucose tolerance testing, CGM & DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back + a DXA scan will be done at the same visit
62326000|NCT06651281|EXPERIMENTAL|Group 1: Low Dose Unblinded|Participants receive a low dose subcutaneous (SC) tulisokibart regimen.
62326001|NCT06651281|EXPERIMENTAL|Group 2: High Dose Unblinded|Participants receive a high dose SC tulisokibart regimen.
62326002|NCT06651281|EXPERIMENTAL|Group 3: High Dose Blinded|Participants receive a blinded high dose SC tulisokibart regimen.
62326003|NCT06651281|EXPERIMENTAL|Group 4: Low Dose Blinded|Participants receive a blinded low dose SC tulisokibart regimen.
62326004|NCT06361251|EXPERIMENTAL|(EC14_4osc)|(EC14_4osc) 1 application every week for a total of 6 applications
62326005|NCT06361251|EXPERIMENTAL|(EC-05_1osc)|(EC-05_1osc) 1 application every two weeks for a total of 6 applications
61932932|NCT01588249|PLACEBO_COMPARATOR|Placebo|
61932933|NCT05515471|EXPERIMENTAL|Treatment group A: SHR8058 eye drops|
62692415|NCT03238053|ACTIVE_COMPARATOR|overactive bladder laser|20 women with overactive bladder with vaginal laser treatment
61932934|NCT05515471|PLACEBO_COMPARATOR|Treatment group B: saline eye drops|
61932935|NCT06085547|ACTIVE_COMPARATOR|White Rural: General|"White rural participants receive general consumption video information about SARS-CoV-2 antibody testing."
61932936|NCT06085547|EXPERIMENTAL|White Rural: Rural-Targeted|White rural participants receive rural-targeted video information about SARS-CoV-2 antibody testing.
61932937|NCT03810339|EXPERIMENTAL|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
61932938|NCT05650567|EXPERIMENTAL|Double-blind Placebo Controlled (DBPC) Period: M5049 high dose|
61932939|NCT05650567|PLACEBO_COMPARATOR|DBPC Period: Placebo|
61932940|NCT05650567|EXPERIMENTAL|Open Label Extension (OLE) Period: M5049 high dose|
61932941|NCT03471065|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR)|
61932942|NCT05736783|EXPERIMENTAL|plyometric exercises|performing plyometric exercises for 6 weeks
61932943|NCT05736783|EXPERIMENTAL|strenghtening of quadriceps and hamstring|performing strengthening of quadriceps and hamstring for 6 weeks
61932944|NCT02169973|EXPERIMENTAL|Part A|3 to 5 participants will undergo Positron Emission Tomography (PET)/computed tomography scan after administration of 11C-MK-3168 on Day 1.
61932945|NCT02169973|EXPERIMENTAL|Part B|3 to 12 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive 2 single doses of JNJ-42165279: 100 mg on Days 1 and up to 250 mg on Day 8. Participants will undergo PET scans after 1 hour of each administration of JNJ-42165279 on Days 1 and 8, with 11C-MK-3168 administration.
61932946|NCT02169973|EXPERIMENTAL|Part C|4 to 8 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive once daily dose of JNJ-42165279 (up to 100 mg) from Day 1 to Day 7. Participants will undergo PET scans after 24 hour of administration of JNJ-42165279 on Days 1 and 7, with 11C-MK-3168 administration.
61932947|NCT00606944|EXPERIMENTAL|ERP group|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
61932948|NCT00606944|NO_INTERVENTION|control group|traditional, conventional care group
61932949|NCT06614829|NO_INTERVENTION|Control|This group would be receiving the standard of care.
61932950|NCT06614829|ACTIVE_COMPARATOR|Bundled C-section Wound Closure|Surgeons in this arm will complete elective C-section wound closure with Stratafix Sutures and the Dermabond PRINEO wound dressing.
61932951|NCT06660277|EXPERIMENTAL|Expanded Hemodialysis|Participants will receive their regularly scheduled hemodialysis treatments using a super high-flux dialyzer (Nipro Elisio HX).
62326006|NCT04499053|EXPERIMENTAL|durvalumab (MEDI4736) and tremelimumab|Durvalumab in combination with tremelimumab and platinum-based doublet chemotherapy. Only subjects who achieve stable disease or better radiological response after 4 cycles of induction treatment will be eligible to continue study treatment with durvalumab in maintenance.
62326007|NCT00340405||Tin Miners in China at risk of lung cancer|Tin Miners in China at risk of lung cancer
62326008|NCT00340028||Women in Early Pregnancy|Women enrolled in the University of North Carolina's Right from the Start study are followed while trying to become pregnant and through 9 weeks of pregnancy
62326009|NCT05581485|NO_INTERVENTION|Intubated general anesthesia LMS|The patients received a LMS with intubated general anesthesia.
61932952|NCT06660277|ACTIVE_COMPARATOR|Conventional Hemodialysis|Participants will receive their regularly scheduled hemodialysis treatments using a high-flux dialyzer (as prescribed in routine care).
62326010|NCT05581485|EXPERIMENTAL|Non-intubated LMS with spontaneous breathing|The patients received a non-intubated LMS optiflow(HFNO) device and maintained spontaneous breathing.
62133225|NCT04523701|EXPERIMENTAL|Experimental Intervention (treatment)|"Open bile ducts are identified by visual control of the liver resection surface combined with the direct injection in the cystic stump of 20-40ml of SMOFlipid 20% Fresenius Kabi Canada Ltd.; authorization number: 57231 (Swissmedic).~SMOFlipid is a white oily emulsion containing soya oil and medium chain triglycerides as main active components, normally used as parenteral nutrition as complement for essential fat acids supplementation. In this study the white test (= the administration of SMOFlipid retrograde through the cystic duct) is made by injection of one or two 20cc syringes full of lipidic solution (SMOFlipid 20%) in the cystic stump, directing the flow to the intrahepatic ducts. Residual fat emulsion is washed out from the biliary tract by a low pressure infusion of 20 to 50 ml of saline solution."
62133226|NCT04523701|NO_INTERVENTION|Control Intervention|Open bile ducts are identified in the control group by visual control of the liver resection surface combined with the use of white gauzes (standard procedure)
62326011|NCT05581485|EXPERIMENTAL|Non-intubated LMS with dexmedetomidine|The patient received a non-intubated LMS optiflow (HFNO) device and was administered dexmedetomidine.
62326012|NCT05532137|NO_INTERVENTION|Control group|This arm uses the 'non-feedback' e-12HR. This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index.
62326013|NCT05532137|EXPERIMENTAL|Intervention group|This arm uses the 'feedback' e-12HR. This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet.
62133227|NCT02966938||Nut allergic patients|Allergic patient and their family with allergy to peanut or other tree nuts that are in elimination diet.
62326014|NCT06253845|EXPERIMENTAL|CG0070|CG0070 is a conditionally replicating oncolytic adenovirus (serotype 5) designed to preferentially replicate in and kill cancer cells.
62484591|NCT06545474|ACTIVE_COMPARATOR|SSRI treatment|In Stage I, participants receive escitalopram (10mg/day) as standard medication for 4 weeks. In justified individual cases and according to the decision of the study physician, a higher dose or another SSRI can be administered.
62692416|NCT03238053|SHAM_COMPARATOR|Overactive bladder sham|20 women with overactive bladder with vaginal probe, no active laser rays
62326015|NCT03888105|EXPERIMENTAL|FL|Follicular lymphoma grade 1-3a cohort
61932953|NCT05581953|EXPERIMENTAL|Omnivorous|Animal protein-lean pork
62326016|NCT03888105|EXPERIMENTAL|DLBCL|Diffuse large B-cell lymphoma cohort
62326017|NCT03888105|EXPERIMENTAL|MCL|Mantle Cell Lymphoma cohort
62326018|NCT03888105|EXPERIMENTAL|MZL|Marginal Zone Lymphoma cohort
62326019|NCT03888105|EXPERIMENTAL|Other B-NHL|Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia \[WM\]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed
62326020|NCT04600804||All patients registered in the MCL0208 trial|"About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.~In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only."
62326021|NCT06486441|EXPERIMENTAL|Sacituzumab Govitecan (SG)|Participants will receive SG at a dose of 10 mg/kg on Days 1 and 8 of a 21-day cycle.
62326022|NCT06486441|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|"Participants will receive one of the following TPC, regimens determined prior to randomization.~* Doxorubicin 60 mg/m\^2 IV on Day 1 of a 21-day cycle~* Paclitaxel 80 mg/m\^2 IV on Days 1, 8, and 15 of a 28-day cycle"
62326023|NCT06470295|PLACEBO_COMPARATOR|Healthy Control- Saline|Saline will be infused in healthy control subjects during insulin-induced hypoglycemia
62326024|NCT06470295|ACTIVE_COMPARATOR|Healthy Control- C-peptide|C-peptide will be infused in healthy control subjects during insulin-induced hypoglycemia
62326025|NCT06470295|PLACEBO_COMPARATOR|T1D- Saline|Saline will be infused in T1D subjects during insulin-induced hypoglycemia
62326026|NCT06470295|ACTIVE_COMPARATOR|T1D- C-peptide|C-peptide will be infused in T1D subjects during insulin-induced hypoglycemia
62484592|NCT05009212|EXPERIMENTAL|ESt group|Endoscopic stricturotomy
62484593|NCT05009212|ACTIVE_COMPARATOR|EBD group|Endoscopic balloon dilatation
62484594|NCT02374710|EXPERIMENTAL|ACL Reconstruction: Anterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed anterior (in front) of the 35% line.
61932954|NCT05581953|OTHER|Vegetarian|Lacto-ovo-vegetarian without any meat
61932955|NCT04250155|EXPERIMENTAL|Phase 1a Dose Escalation|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
61932956|NCT04250155|EXPERIMENTAL|Phase 1a Dose Expansion|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
61932957|NCT04250155|EXPERIMENTAL|Phase 1b Dose Escalation|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
61932958|NCT04250155|EXPERIMENTAL|Phase 1b Dose Expansion|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
62326027|NCT02108080||Inpatient AUD|This group includes individuals who are in the alcohol use treatment.
62326028|NCT02108080||Outpatient|This group includes individuals who are not seeking treatment for alcohol use disorder.
62326029|NCT03052608|EXPERIMENTAL|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
61932959|NCT06099782|EXPERIMENTAL|Arm A: MK-3475A SC →Pembrolizumab IV|In the treatment crossover period, participants will receive MK-3475A SC followed by pembrolizumab IV. After completion of the treatment crossover period, participants will enter the treatment continuation period, where they will receive their preferred intervention for up to \~1 year for renal cell carcinoma (RCC) and melanoma and for up to \~2 years for non-small cell lung cancer (NSCLC).
61932960|NCT06099782|ACTIVE_COMPARATOR|Arm B: Pembrolizumab IV→MK-3475A SC|In the treatment crossover period, participants will receive pembrolizumab IV followed by MK-3475A SC. After completion of the treatment crossover period, participants will enter the treatment continuation period, where they will receive their preferred intervention for up to \~1 year for RCC and melanoma and for up to \~2 years for NSCLC.
61932961|NCT03436810|EXPERIMENTAL|Experimental group|The experimental group will receive training programs of Motor imagery (MI) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration of program session will be 90 minutes. Training for 3 times a week over duration of 4 weeks.
61932962|NCT03436810|ACTIVE_COMPARATOR|Control group|The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
61932963|NCT05217927|EXPERIMENTAL|Rimegepant 75mg Orally Disitegrating Tablet (ODT)daily dosing|"Double-blind Treatment Phase: Rimegepant 75 mg ODT dosed daily~Open-Label Extension Phase:~Rimegepant 75 mg ODT dosed daily"
61932964|NCT05217927|EXPERIMENTAL|Rimegepant 75mg Orally Disintegrating Tablet (ODT)every other day dosing|Double-blind Treatment Phase: Rimegepant 75 mg ODT every other day dosing alternating with matching placebo
61932965|NCT05217927|PLACEBO_COMPARATOR|Placebo comparator dosing|Double-blind Treatment Phase: matching placebo dosed daily
61932966|NCT05957367|EXPERIMENTAL|Dose Escalation (Part 1, Module A)|Escalation Module A Part 1 DCC-3116 combination closed on January 8, 2024, with no participants enrolled.
61932967|NCT05957367|EXPERIMENTAL|Expansion (Part 2, Module A)|Expansion Module A Part 2 DCC-3116 combination closed on January 8, 2024, with no participants enrolled.
61932968|NCT05957367|EXPERIMENTAL|Dose Escalation (Part 1, Module B)|DCC-3116 tablets in escalating dose cohorts in 28-day cycles will be administered in combination with ripretinib once daily (QD).
61932969|NCT05957367|EXPERIMENTAL|Expansion (Part 2, Module B)|DCC-3116 tablets will be administered in combination with ripretinib in 28-day cycles to evaluate preliminary efficacy in participants with 2nd-line advanced gastrointestinal stromal tumor (GIST).
62484595|NCT02374710|ACTIVE_COMPARATOR|ACL Reconstruction: Posterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed posterior (in back) of the 35% line.
61932970|NCT05628883|EXPERIMENTAL|Infusion of TBio-4101 TIL|"TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product: participants tumor tissue is surgically removed and immune T-cells are taken out of the tumor and multiplied, or grown, in the laboratory. TIL product infused intravenously over 20 to 30 minutes within 2 to 4 days after the last dose of fludarabine~Participants will also receive:~* Cyclophosphamide dose 60 mg/kg/day for 2 days administered IV in 250 mL dextrose 5% in water infused simultaneously with Mesna 15 mg/kg/day delivered over 1 hour per day for 2 days. Fludarabine 25 mg/m2/day is delivered by intravenous piggyback daily over 15-30 minutes for 5 days.~* Interleukin-2 (IL-2)- will be given to participants through IV after they receive the infusion of the TIL. IL-2 is administered at a dose of 600,000 IU/kg (based on actual body weight) IV every 8-12 hours beginning within 24 hours of TIL infusion for a maximum of 6 doses."
61932971|NCT05086978||Heart Failure out-patients|Subjects with heart failure of any etiology
62326030|NCT03052608|ACTIVE_COMPARATOR|Crizotinib|Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
62326031|NCT05182476|PLACEBO_COMPARATOR|Placebo|Placebo daily
62326032|NCT05182476|EXPERIMENTAL|Luvadaxistat treatment schedule 1|Luvadaxistat daily
62326033|NCT05182476|EXPERIMENTAL|Luvadaxistat treatment schedule 2|Luvadaxistat daily
62326034|NCT03804905|EXPERIMENTAL|No-cost Medications|Eligible patients of physicians allocated to the no-cost medications arm will receive free medications through Trillium Health Partners outpatient pharmacy.
62692417|NCT05074381|EXPERIMENTAL|Dry needling|A single dry needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into skin surface, fascia,into the muscle tissue at the MTrP location of the M. Obliquus Capitis Inferior, and will move the needle up and down to elicit local twitch responses.In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
61932972|NCT05086978||Heart Failure in-patients|Subjects with heart failure of any etiology
62326035|NCT03804905|NO_INTERVENTION|Usual care|Eligible patients of physicians allocated to the usual care arm will continue to access their medications through self-pay or other mechanisms.
62326036|NCT03394079|EXPERIMENTAL|OCT-guided|
62326037|NCT03394079|ACTIVE_COMPARATOR|IVUS-guided|
62326038|NCT04749446||Breast sarcoma|This cohort include patients affected by breast sarcoma, referred to participating Institutions between January 2000 and June 2020.
62326039|NCT05512377|EXPERIMENTAL|brigimadlin (BI 907828) treatment arm|
62326040|NCT04801771|EXPERIMENTAL|Subjects implanted with Inspire UAS System|Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.
62326041|NCT04509427|ACTIVE_COMPARATOR|Handouts Only (HO) group|The HO only group will receive program instructions via handouts and videoconferencing with a physical therapist who will provide intervention instruction, assist with program progression, and monitor participant quality of movement and safety.
62326042|NCT04509427|ACTIVE_COMPARATOR|Handouts plus web-based video (HO+) group|The HO+ group will receive the same intervention as the HO group but they will also have access to web-based videos that will lead them through all exercise/posture routines like a commercial exercise video.
62326043|NCT03543189|EXPERIMENTAL|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
62326044|NCT06507254|EXPERIMENTAL|Polyphenol Supplement|Juice Plus Essentials, Berry Blend Capsules
62326045|NCT06507254|PLACEBO_COMPARATOR|Placebo Supplement|
62326046|NCT06646276|EXPERIMENTAL|Arm A|
62484596|NCT06406257|NO_INTERVENTION|Group C|Patients in Group C will be covered with a bedsheet intraoperatively without active warming methods employed.
62326047|NCT06646276|ACTIVE_COMPARATOR|Arm B|
62326048|NCT06132568|EXPERIMENTAL|High Risk PCI Patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions
62484597|NCT06406257|EXPERIMENTAL|Group W|Patients in Group W will have a 37°C forced-air warming blanket initiated upon entering the operating room to maintain their body temperature between 36-37 degrees Celsius.
62484598|NCT03388905|EXPERIMENTAL|Wearable Cardioverter Defibrillator group|
62484599|NCT03480763|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
62484600|NCT03480763|ACTIVE_COMPARATOR|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
62484601|NCT06559605|ACTIVE_COMPARATOR|zirconia barrier|Zirconia will be used as a barrier material because it has interesting features and, if compared to titanium, it induces a better fibroblast response. It also shows less biofilm adhesion and less inflammatory response. From the pre-operative CBCT a 3D model of the alveolar jaw bone will be created. A 0.4-0.5 mm-thick barrier will then be designed. It will be designed to cover the planned bone graft and extended a few millimeters wider than the graft perimeter.
62484602|NCT06559605|PLACEBO_COMPARATOR|titanium mesh|Titanium mesh in particular, its clinical suitability for GBR procedures is unmatched by other GBR membranes, due to their exceptional volume stability, titanium meshes are indispensable in the management of vertical or large horizontal bone defects. Titanium meshes not only demonstrate high strength and stiffness but also exhibit good plasticity, allowing them to be perfectly adapted to various bone defects through bending and shaping. Due to titanium mesh's stiffness and sharp edges from cutting and bending, mucosal flaps may be adversely stimulated, leading to mucosal rupture and subsequent mesh exposure
62326049|NCT04784494|EXPERIMENTAL|Magnetic Seizure Therapy|MST treatments will be administered using the MagPro XP MST with Cool TwinCoil.
62484603|NCT03069963|EXPERIMENTAL|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
62484604|NCT03069963|EXPERIMENTAL|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
61932973|NCT03956056|EXPERIMENTAL|Neoantigen Peptide Vaccine|The schedule for vaccination will be Days 1, 4, 8, 15, and 22 (delays of up to 96 hours are allowed for each dose based on the adverse events experienced). Additional vaccinations will be given on Days 50 and 78 (+/- 2 weeks). The first vaccine dose may be administered following confirmation of disease-free status and within 90 days following date of repeat imaging. All study injections will be given subcutaneously and co-administered with poly-ICLC by a trained healthcare provider.
61932974|NCT06596005|EXPERIMENTAL|TJ0113|subjects will receive 200 mg or 400 mg of TJ0113 capsules for 12 consecutive weeks
62133228|NCT02477813|EXPERIMENTAL|Temozolomide|oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
62484605|NCT02742558|EXPERIMENTAL|cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
62484606|NCT02742558|ACTIVE_COMPARATOR|shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
62484607|NCT02269592||Specimen Collection|Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol
62692418|NCT05074381|SHAM_COMPARATOR|Sham needling|A single sham needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
62692419|NCT06638203|EXPERIMENTAL|Intervention Group|Participants who will complete the leadership course and then engage in the leadership game
62692420|NCT06638203|ACTIVE_COMPARATOR|Control Group|Participants who will complete the leadership course only.
62692421|NCT02108808|ACTIVE_COMPARATOR|Prasugrel or Clopidogrel|Prasugrel 60mg or Clopidogrel 600mg loading dose, as clinically indicated
62692422|NCT02108808|EXPERIMENTAL|Ticagrelor|Ticagrelor 180mg loading dose
62692423|NCT01014780||Normal (non-dry) dry eye subjects|These are healthy individuals, age 18 and above, who do not exhibit dry eyes by signs and symptoms
61932975|NCT06596005|PLACEBO_COMPARATOR|Placebo|subjects will receive 200 mg or 400 mg of placebo for 12 consecutive weeks
61932976|NCT04371315||Positive COVID-19|"Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected~Monthly follow-up until Covid-19 is negative: Respiratory and Whole Blood Samples Collected"
61932977|NCT04371315||Negative COVID-19|Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
61932978|NCT06647849|EXPERIMENTAL|"Arm with training"|"Arm with training: centers whose interns receive simulation training in the announcement of early spontaneous miscarriage between the 2 inclusion phases."
62133229|NCT00073749|EXPERIMENTAL|Inotuzumab ozogamicin|Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2
62133230|NCT04264013|PLACEBO_COMPARATOR|Exercise|Exercise
62133231|NCT04264013|ACTIVE_COMPARATOR|Exercise + Diet|Exercise + eggs
62326050|NCT06239116|EXPERIMENTAL|RM-718 (Cohort A1)|Single dose of RM-718 (4) or placebo (2)
62326051|NCT06239116|EXPERIMENTAL|RM-718 (Cohort A2)|Single dose of RM-718 (4) or placebo (2)
62326052|NCT06239116|EXPERIMENTAL|RM-718 (Cohort A3)|Single dose of RM-718 (4) or placebo (2)
62326053|NCT06239116|EXPERIMENTAL|RM-718 (Cohort A4)|Single dose of RM-718 (4) or placebo (2)
62326054|NCT06239116|EXPERIMENTAL|RM-718 (Cohort A5)|Single dose of RM-718 (4) or placebo (2)
62326055|NCT06239116|EXPERIMENTAL|RM-718 (Cohort A6)|Single dose of RM-718 (4) or placebo (2)
62326056|NCT06239116|EXPERIMENTAL|RM-718 (Cohort B1)|Multiple doses of RM-718 (4) or placebo (2)
62326057|NCT06239116|EXPERIMENTAL|RM-718 (Cohort B2)|Multiple ascending doses of RM-718 (4) or placebo (2)
62326058|NCT06239116|EXPERIMENTAL|RM-718 (Cohort B3)|Multiple ascending doses of RM-718 (4) or placebo (2)
62326059|NCT06239116|EXPERIMENTAL|RM-718 (Cohort B4)|Multiple ascending doses of RM-718 (4) or placebo (2)
62326060|NCT06239116|EXPERIMENTAL|RM-718 (Cohort B5)|Multiple ascending doses of RM-718 (4) or placebo (2)
62326061|NCT06239116|EXPERIMENTAL|RM-718 (Cohort C1)|Multiple ascending doses of RM-718 (8)
62326062|NCT06239116|EXPERIMENTAL|RM-718 (Cohort C2)|Multiple ascending doses of RM-718 (8)
62326063|NCT06239116|EXPERIMENTAL|RM-718 (Cohort C3)|Multiple ascending doses of RM-718 (8)
62326064|NCT06381258||Patients with preeclampsia|"Fetal ultrasound( echocardiography).Measurements will be performed using conventional pulsed-wave Doppler and M mode cross sectional image of the fetal thorax at the level of the 4-chamber view with an apical projection of the heart is obtained. Measurements of the ventricle at diastole and systole are obtained, and using the relationship between these measurements, calculations are performed to determine the ejection fraction (EF) (\[diastole measurement-systole measurement\]/diastole) measurement and shortening fraction ( SF) for both right \& left ventricles.~Assessment of ventricular diastolic function through measuring E-wave (early ventricular filling) and A wave (active atrial contraction - late ventricular filling) peak velocities and the ratio between them (E/A ratio) as an index will be performed for both mitral valve (MV) and tricuspid valve (TV)"
62326065|NCT06381258||Patients without preeclampsia|"Fetal ultrasound (echocardiography).Measurements will be performed using conventional pulsed-wave Doppler and M mode cross sectional image of the fetal thorax at the level of the 4-chamber view with an apical projection of the heart is obtained. Measurements of the ventricle at diastole and systole are obtained, and using the relationship between these measurements, calculations are performed to determine the ejection fraction (EF) (\[diastole measurement-systole measurement\]/diastole) measurement and shortening fraction ( SF) for both right \& left ventricles.~Assessment of ventricular diastolic function through measuring E-wave (early ventricular filling) and A wave (active atrial contraction - late ventricular filling) peak velocities and the ratio between them (E/A ratio) as an index will be performed for both MV and TV"
62326066|NCT01633021||Diabetes|Self/Family member affected by type-2 diabetes (plus self-referred family-members)
62326067|NCT01633021||Heritable Cancer Screen-Positive|Person who has screened-positive for heritable cancers on genetic tests (plus referred family-members)
62326068|NCT01633021||Sickle Cell (Trait/Disease/Related)|Self/Family member affected by Sickle Cell Trait or Sickle Cell Disease (plus self-referred family-members)
62326069|NCT05536141|EXPERIMENTAL|Dose Escalation Cohort 1|Participants will receive casdatifan orally once daily
62484608|NCT03828708|EXPERIMENTAL|Standard iron arm|Participants randomized to this arm will consume infant formula containing 12 mg/L of iron, equivalent to the standard iron content in U.S. infant formula
62484609|NCT03828708|EXPERIMENTAL|Low iron arm|Participants randomized to this arm will consume infant formula containing 5 mg/L of iron, equivalent to the standard iron content in European infant formula
62484610|NCT04732325|EXPERIMENTAL|Burst / kHz / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
62484611|NCT04732325|EXPERIMENTAL|Burst / Sham / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
62484612|NCT04732325|EXPERIMENTAL|kHz / Sham / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
61932979|NCT06647849|OTHER|"Untrained arm"|"Untrained arm: centers with standard in-house management of spontaneous miscarriage/pregnancy arrested in the emergency department."
61932980|NCT02459652|EXPERIMENTAL|Neoadjuvant S-1/RT|This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
62326070|NCT05536141|EXPERIMENTAL|Dose Escalation Cohort 2|Participants will receive casdatifan orally once daily
61932981|NCT01764425|ACTIVE_COMPARATOR|P7435|Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
62326071|NCT05536141|EXPERIMENTAL|Dose Escalation Cohort 3|Participants will receive casdatifan orally twice daily
62326072|NCT05536141|EXPERIMENTAL|Dose Escalation Cohort 4|Participants will receive casdatifan orally
62326073|NCT05536141|EXPERIMENTAL|Dose Escalation Cohort 5|Participants will receive casdatifan orally
62326074|NCT05536141|EXPERIMENTAL|Dose Expansion Cohort 1|Participants will receive casdatifan orally
62326075|NCT05536141|EXPERIMENTAL|Dose Expansion Cohort 2|Participants will receive casdatifan orally
62326076|NCT05536141|EXPERIMENTAL|Dose Expansion Cohort 3|Participants will receive casdatifan orally
62326077|NCT05536141|EXPERIMENTAL|Dose Expansion Cohort 4|Participants will receive casdatifan orally with Cabozantinib
62326078|NCT04513132|ACTIVE_COMPARATOR|active-CHR|Participants will be intervened with deep transcranial magnetic stimulation (dTMS).
62326079|NCT04513132|SHAM_COMPARATOR|sham-CHR|Participants, as a control group, will receive sham stimulation.
62326080|NCT04513132|ACTIVE_COMPARATOR|active-FES|Patients with first-episode schizophrenia will be intervened with deep transcranial magnetic stimulation (dTMS).
62326081|NCT04513132|SHAM_COMPARATOR|sham-FES|Patients with first-episode schizophrenia, as a control group, will receive sham stimulation.
62326082|NCT05639543|ACTIVE_COMPARATOR|INT-787|Participants will be randomized to receive INT-787 (escalating doses through the cohorts)
62326083|NCT05639543|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive matching placebo
61932982|NCT01764425|PLACEBO_COMPARATOR|Placebo|Placebo tablets for oral administration
62484613|NCT04732325|EXPERIMENTAL|kHz / Burst / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
62692424|NCT01014780||Dry eye subjects|These are subjects, age 18 years and above, who do exhibit signs and symptoms of dry eye.
62326084|NCT06551311|NO_INTERVENTION|Control group|Receive regular health care
62326085|NCT06551311|EXPERIMENTAL|The concentric cycling exercise training group|Over eight weeks, participants completed 24 exercise sessions, three times per week, with each session lasting between 20 and 30 minutes under concentric cycling exercise training.
62326086|NCT06551311|EXPERIMENTAL|The eccentric cycling exercise training group|Over eight weeks, participants completed 24 exercise sessions, three times per week, with each session lasting between 20 and 30 minutes under eccentric cycling exercise training.
62692425|NCT04090606||FTC Method|
62484614|NCT04732325|EXPERIMENTAL|Sham / Burst / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
61932983|NCT06709638|EXPERIMENTAL|Zhilong Huoxue Tongyu capsule|
62692426|NCT04090606||Massachusetts Method|
61932984|NCT06709638|PLACEBO_COMPARATOR|Placebo Comparator|
61932985|NCT04548648|OTHER|Open-label, single-arm|A multicenter open-label, single-arm, phase 2 study designed to investigate the antitumor effects of acalabrutinib in subjects with relapsed primary central nervous system lymphoma (PCNSL), and relapsed secondary CNS lymphoma (SCNSL) with no evidence of current systemic disease. Subjects will receive acalabrutinib at the dose of 100 mg every 12 hours.
61932986|NCT06572241|ACTIVE_COMPARATOR|Morphine|0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with morphine 100 mcg (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).
61932987|NCT06572241|PLACEBO_COMPARATOR|Placebo|0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with normal saline 0.2 ml (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).
61932988|NCT06091579|EXPERIMENTAL|Part A (SAD Cohort 1): TPIP|Participants in the single ascending dose (SAD) Cohort 1 received a single dose of TPIP at Dose A, Dose B, or Dose C by oral inhalation on Day 1.
61932989|NCT06091579|EXPERIMENTAL|Part A (SAD Cohort 2): TPIP or Placebo|Participants in SAD Cohort 2 received a single dose of TPIP at Dose D or matching placebo by oral inhalation on Day 1.
61932990|NCT06091579|EXPERIMENTAL|Part A (SAD Cohort 3): TPIP or Placebo|Participants in SAD Cohort 3 received a single dose of TPIP at Dose E or matching placebo by oral inhalation on Day 1.
61932991|NCT06091579|EXPERIMENTAL|Part B (MAD Cohort 1): TPIP or Placebo|Participants in the multiple ascending dose (MAD) Cohort 1 received TPIP at Dose B, Dose C or matching placebo, once daily (QD) by oral inhalation on Days 1 through 7.
61932992|NCT06091579|EXPERIMENTAL|Part B (MAD Cohort 2): TPIP or Placebo|Participants in MAD Cohort 2 received TPIP up to Dose D or matching placebo, QD by oral inhalation on Days 1 through 7.
62326087|NCT05031507||1|Subjects with rare skeletal disorders
62326088|NCT03391466|EXPERIMENTAL|Axicabtagene Ciloleucel Treatment|Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation antigen (CD) 19 CAR transduced autologous T cells/kg on Day 0.
62484615|NCT04732325|EXPERIMENTAL|Sham / kHz / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
62484616|NCT03807037|EXPERIMENTAL|Treatment|Mixed tocotrienols 200mg, twice daily (400mg/day)
61932993|NCT00089323|OTHER|1: Bone Marrow Aspiration|
61932994|NCT02545075|EXPERIMENTAL|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
61932995|NCT02545075|EXPERIMENTAL|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
61932996|NCT00573248|EXPERIMENTAL|4|
62692427|NCT04090606||Health Canada Intense Method|
62692428|NCT03906071|EXPERIMENTAL|Nivolumab and Sitravatinib|Nivolumab will be administered by intravenous infusion over 30 minutes at 240 mg every 2 weeks or at 480 mg every 4 weeks. Sitravatinib capsules will be administered orally, once daily.
62692429|NCT03906071|ACTIVE_COMPARATOR|Docetaxel|Docetaxel will be administered by intravenous infusion at 75 mg/m2 over 1 hour every 3 weeks.
61932997|NCT03448055|OTHER|Interventional|Immunocal 20gm daily
61932998|NCT03988413|EXPERIMENTAL|25mg|Tablets, Oral, 25mg, single dose
61932999|NCT03988413|EXPERIMENTAL|50mg|Tablets, Oral, 50mg, single dose
61933000|NCT03988413|EXPERIMENTAL|100mg|Tablets, Oral, 100mg, single dose
61933001|NCT03988413|EXPERIMENTAL|200mg|Tablets, Oral, 200mg, single dose
61933002|NCT03988413|EXPERIMENTAL|400mg|Tablets, Oral, 400mg, single dose
61933003|NCT03988413|EXPERIMENTAL|800mg|Tablets, Oral, 800mg, single dose
61933004|NCT04962646|EXPERIMENTAL|Intervention|Once the thoracic cavity os opened during surgery, carbon dioxide flooding using a diffusor will be instigated with a flow of 5L/min. The flooding will be terminated once the aorta and the heart have no open contact with surrounding air.
61933005|NCT04962646|NO_INTERVENTION|Control|No intervention. No sham will be used as the staff performing the surgery would have been able to detect the lack of carbon dioxide in the surgical wound.
62692430|NCT06041880|EXPERIMENTAL|4-weeks of passive calf stretching for 30 minutes 5 days a week|A modified plantar fasciitis ankle splint will be used to passively stretch the calf muscle.
62692431|NCT06041880|NO_INTERVENTION|4-weeks of no-stretching|No device will be used to stretch the calf muscle. Participants will go about their normal daily activity for 4-weeks.
62692432|NCT06638918||Virtual Reality Group|These participants will receive the virtual reality intervention for at least 20 minutes daily for approximately seventeen sessions, or as long as they are able.
62692433|NCT00237159|EXPERIMENTAL|ZOL446|
62692434|NCT06673264|EXPERIMENTAL|Receives soft neural probe device insertion|
62326089|NCT03391466|ACTIVE_COMPARATOR|Standard of Care Therapy|Participants will receive 2 or 3 21-day cycles of second-line chemotherapy regimen; R-ICE: rituximab 375 mg/m\^2 before chemotherapy,ifosfamide 5 g/m\^2 24hour(hr) infusion on Day 2+mesna,carboplatin area under the curve (AUC) 5 on Day 2, maximum dose 800 mg,etoposide 100 mg/ m\^2/day on Days 1-3; R-ESHAP: rituximab 375 mg/m\^2 Day 1,etoposide 40 mg/m\^2/day IV on Days 1-4,methylprednisolone 500 mg/day IV on Days 1-4 or 5,cisplatin at 25 mg/m\^2/day Days 1-4,cytarabine 2 g/m\^2 on Day 5; R-GDP: rituximab 375 mg/m\^2 Day 1(or Day 8),gemcitabine 1g/m\^2 on Days 1 and 8,dexamethasone 40 mg on Days 1-4,cisplatin 75mg/m\^2 on Day 1 or carboplatin AUC=5; or R-DHAP: Rituximab 375 mg/ m\^2 before chemotherapy,dexamethasone 40 mg/day on Days 1-4,highdose cytarabine 2 g/m\^2 every 12 hours for 2 doses on Day 2 following/platinum,cisplatin 100 mg/m\^2 24hr infusion on Day 1 or oxaliplatin 100 mg/m\^2. Participants who will respond will get high dose therapy and autologous stem cell transplant.
62484617|NCT03807037|PLACEBO_COMPARATOR|Control|Matching Placebo (Placebo oral capsule)
62484618|NCT01065857|EXPERIMENTAL|Citrafleet|The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
62484619|NCT01065857|ACTIVE_COMPARATOR|Klean Prep|The day prior to the colonoscopy from 16:00h to 20:00h.
62484620|NCT01065857|EXPERIMENTAL|Citrafleet Exploratory|The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
62484621|NCT02863822|EXPERIMENTAL|Low FODMAP|Subjects will be given dietary education in the low FODMAP diet, which they will continue for 4 weeks. Subjects will then followup with the dietician and subjects with a symptomatic response will be given instructions for reintroduction.
62484622|NCT02863822|ACTIVE_COMPARATOR|Choose My Plate|Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.
61933006|NCT03029273|EXPERIMENTAL|Anti-NY-ESO-1 TCR-transduced T cells|"NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with Cyclophosphamide (250-500mg/m2/day) and Fludarabine (25mg/m2/day) for 3 days.~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject."
61933007|NCT05546918||People with Long COVID|Any people with persisting symptoms related to COVID-19 (With a Long COVID diagnosis or not)
62484623|NCT02331823|EXPERIMENTAL|arm A: super-short retreatment regimen|A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon
62484624|NCT02331823|ACTIVE_COMPARATOR|arm B:standardized retreatment regimen|8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon
62484625|NCT02248051|EXPERIMENTAL|CXA-10|
62692435|NCT06428357|EXPERIMENTAL|Females: Recombinant Bovine Lactoferrin (rbLf), then Bovine milk derived Lactoferrin|After a 2-week run-in period, this arm will begin treatment with recombinant bovine lactoferrin for 4 weeks and following a 2-week washout start bovine milk derived lactoferrin for 4 weeks.
62692436|NCT06428357|ACTIVE_COMPARATOR|Females: Bovine milk derived lactoferrin (cmdLf), then Recombinant bovine lactoferrin|After a 2-week run-in period, this arm will begin treatment with bovine milk derived lactoferrin and then following a 2-week washout start recombinant bovine lactoferrin for 4 weeks.
61933008|NCT05546918||Healthcare Professional|Healthcare professionals in charge of Long COVID patients
62692437|NCT06428357|ACTIVE_COMPARATOR|Males: Recombinant Bovine Lactoferrin (rbLf), then placebo|After a 2-week run-in period, this arm will begin treatment with recombinant bovine lactoferrin for 4 weeks and following a 2-week washout start placebo for 4 weeks.
62692438|NCT06428357|PLACEBO_COMPARATOR|Males: Placebo, then recombinant bovine lactoferrin (rbLf)|After a 2-week run-in period, this arm will begin treatment with placebo for 4 weeks and following a 2-week washout start recombinant bovine lactoferrin for 4 weeks.
62326090|NCT04912869|EXPERIMENTAL|Crovalimab|Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.
62326091|NCT04912869|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV infusion of matching Placebo.
62326092|NCT06409286||Shunted patients undergoing surgery|Patients with an existing implanted ventriculoperitoneal shunt who are experiencing shunt malfunction symptoms and require shunt revision surgery per standard of care shunt evaluation
62692439|NCT05054439|EXPERIMENTAL|SI-B001 combined with paclitaxel|SI-B001 in combination with paclitaxel for the treatment of recurrent metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) with disease progression or intolerance.； The patient had previously received anti-PD-1 mab ± platinum-based chemotherapy； Patients' previous treatment line should be ≤2L.
61933009|NCT03491943|EXPERIMENTAL|Midline group|Preprocedural ultrasound-assisted midline approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
62326093|NCT06008301|EXPERIMENTAL|Consent for the entire study|Participants with a newly diagnosed breast cancer and recommended for enhanced imaging will be randomly assigned to either CEM or MRI and take the State-Trait Anxiety Inventory (STAI) before and after imaging.
62484626|NCT06438640|NO_INTERVENTION|Usual Care|Usual care will be delivered at each site during the pre-intervention phase. Patients treated in this arm will undergo pre-anesthesia care discussions as per existing clinical routine at each site.
62484627|NCT06438640|ACTIVE_COMPARATOR|My Anesthesia Choice- HF|During the intervention and sustainment phases, site clinicians will receive standardized in-personal or virtual training on shared decision making theory and approaches. The My Anesthesia Choice-HF tool will be made available for use during preoperative conversations. Clinicians will receive encouragement to use the tool on study-eligible patients based on their assessment of clinical appropriateness.
61933010|NCT03491943|ACTIVE_COMPARATOR|Paramedian group|Preprocedural ultrasound-assisted paramedian approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
62484628|NCT06149767|EXPERIMENTAL|Adebrelimab Combined With Paclitaxel for Injection,cisplatin and radiotherapy|Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.
62484629|NCT05620862|EXPERIMENTAL|mitoxantrone hydrochloride liposome alone or combined with Irinotecan+Vincristine|In phase Ia, patients with relapsed and refractory lymphoma and solid tumors will receive mitoxantrone hydrochloride liposome alone (at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2, ) or combination of Irinotecan 50mg/ m2，d1-5, Vincristine 1.5mg/ m2，d1 for up to 6 cycles (21 days per cycle). In phase Ib, patients will recive mitoxantrone hydrochloride liposome 24 mg/m2, combination of Irinotecan 50mg/ m2，d1-5, Vincristine 1.5mg/ m2
62692440|NCT03695978||Nuwiq|All patients receiving Nuwiq (recombinant FVIII)
62692441|NCT03695978||Octanate|All patients receiving Octanate (plasma derived FVIII)
62692442|NCT03695978||Wilate|All patients receiving Wilate (plasma derived FVIII/von Willebrand factor \[VWF\])
61933011|NCT02808871|EXPERIMENTAL|Pirfenidone|Pirfenidone 2403 mg/d for 52 weeks
62133232|NCT03298074|EXPERIMENTAL|Apatinib plus Etoposide|Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
62133233|NCT03298074|ACTIVE_COMPARATOR|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
62133234|NCT00942487|EXPERIMENTAL|Nebivolol|
61933012|NCT02808871|PLACEBO_COMPARATOR|Placebo|Placebo for 52 weeks
61933013|NCT01697358|ACTIVE_COMPARATOR|SCS + OMM|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
61933014|NCT01697358|ACTIVE_COMPARATOR|OMM alone|The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan
61933015|NCT04157621|ACTIVE_COMPARATOR|Active taVNS|
61933016|NCT04157621|SHAM_COMPARATOR|Sham Stimulation|
61933017|NCT06261268|EXPERIMENTAL|Strip graft with Mucograft|An apically repositioned flap is prepared then, a free epithelialized gingival strip graft is harvested from the molar area of the palate and sutured to the apical part of the recipient area. A xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) covers the remaining uncovered part of the periosteal bed.
61933018|NCT06261268|ACTIVE_COMPARATOR|Free gingival graft|Apically repositioned flap is prepared. An epithelialized free gingival graft is harvested from the molar area of the palate, and sutured to the recipient area
61933019|NCT01601431|EXPERIMENTAL|Cap Assisted Colonoscopy|Cap Assisted Colonoscopy uses a Cap which is a transparent hood which is attached to the distal end of the colonscope and allows depressing the colon folds in order to visualize hidden polyps behind the folds.
61933020|NCT01601431|ACTIVE_COMPARATOR|Conventional colonoscopy|A conventional colonoscopy does not use a Cap in order to perform the procedure
61933021|NCT05889572|EXPERIMENTAL|MaaT033|"Route of administration: oral (capsule)~Between D-5 to D-1: Bowel preparation with Macrogol and Rifamixin~Between D1 to D28: MaaT033 treatment period 1~Between D28 to D56: MaaT033 treatment period 2"
62133235|NCT00942487|ACTIVE_COMPARATOR|Metoprolol|
62133236|NCT01762475|EXPERIMENTAL|Experimental: Group 1--Symptomatic TBI|"Experimental Group, Group 1, will consist of twenty-four male and female adult participants who have persistent TBI symptoms lasting more than six months.~Participants in the experimental group will be randomized in a 1:1 ratio, assigned to group a or b.~Participants randomized into Group 1a will take placebo twice daily for 8 weeks, followed by 8 weeks of sildenafil 25 mg twice daily with a 2-week washout period between the two 8-week periods.~Participants randomized into Group 1b will take sildenafil 25 mg twice daily for 8 weeks, followed by 8 weeks of placebo twice daily with a 2-week washout period between the two treatment periods."
62133237|NCT01762475|ACTIVE_COMPARATOR|Active Comparator: Group 2--Healthy Controls|Group 2 will be comprised of twenty male and female adult participants who have never experienced a TBI or concussion to serve as age and gender-matched healthy controls. Participants in Group 2 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
62326094|NCT06008301|ACTIVE_COMPARATOR|Consent only for the STAI|Participants with a newly diagnosed breast cancer and recommended for enhanced imaging but who cannot or choose not to be randomly assigned to CEM or MRI but they consent to take the State-Trait Anxiety Inventory (STAI) before and after imaging.
62326095|NCT04712097|EXPERIMENTAL|M + Len (Arm A)|Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
62484630|NCT00761163|EXPERIMENTAL|1|
62326096|NCT04712097|EXPERIMENTAL|R + Len (Arm B)|Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
62326097|NCT04712097|EXPERIMENTAL|M + Len (US Extension Arm C)|Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
62326098|NCT04759586|ACTIVE_COMPARATOR|Arm A (DA-EPOCH-R)|See Detailed Description
62484631|NCT00761163|EXPERIMENTAL|2|
62484632|NCT00761163|EXPERIMENTAL|3|
62484633|NCT03668015|EXPERIMENTAL|Group A (Xylitol then sorbitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol"
62484634|NCT03668015|EXPERIMENTAL|Group B (Sorbitol then xylitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol"
62692443|NCT00979758|SHAM_COMPARATOR|Atorvastatin|Atorvastatin routine dose
62692444|NCT00979758|PLACEBO_COMPARATOR|Intensive Atorvastatin|Atorvastatin Intensive dose
62692445|NCT00979758|ACTIVE_COMPARATOR|Atorvastatin+Transplantation|Atorvastatin routine dose+ Mononuclear cells Transplantation
62692446|NCT00979758|EXPERIMENTAL|Intensive Atorvastatin+Transplantation|Atorvastatin intensive dose+ Mononuclear cells Transplantation
62133238|NCT01762475|ACTIVE_COMPARATOR|Group 3--Recovered TBI|Group 3 will be comprised of twenty male and female adult participants who have experienced a TBI, have recovered, and are asymptomatic at the time of screening, to serve as age and gender-matched asymptomatic TBI controls. Participants in Group 3 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
62326099|NCT04759586|EXPERIMENTAL|Arm B (DA-EPOCH-R, nivolumab)|Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and LP for CSF collection during screening. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
62326100|NCT04759586|ACTIVE_COMPARATOR|Arm C (R-CHOP)|Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
62326101|NCT04759586|EXPERIMENTAL|Arm D (R-CHOP, nivolumab)|Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
62484635|NCT03349567|EXPERIMENTAL|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
62484636|NCT03349567|NO_INTERVENTION|Control|The control arm will consist of providers who do not receive the intervention.
62484637|NCT03592420|EXPERIMENTAL|Interdisciplinary interventions|"Multicomponent interventions~* On-site supervised group exercise program (11 weeks)~* Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)~* Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards~* Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
62484638|NCT03592420|ACTIVE_COMPARATOR|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
62484639|NCT05476588|ACTIVE_COMPARATOR|Self-Administration followed by Interviewer-Administered|Screening and validation of assessment tool translated into Spanish
61933022|NCT03052192||FAM group (n=98)|"≥65 years. Acutely admitted medical patients.~Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup.~Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.~If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician.~Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size."
62484640|NCT05476588|ACTIVE_COMPARATOR|Interviewer-Administered followed by Self-Administration|Screening and validation of assessment tool translated into Spanish
61933023|NCT03052192||Control group 1 (n=54)|"≥65 years. No hospital admissions within the past two years.~Matched individually with patients in the FAM group by age, sex, and municipality.~Examined at inclusion and 52 weeks after inclusion.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality."
62133239|NCT03283371|EXPERIMENTAL|Natalizumab 300 mg|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab 300 mg intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will continue to receive natalizumab 300 mg IV infusion every 4 weeks for up to an additional 24 weeks in open label phase.
62133240|NCT03283371|PLACEBO_COMPARATOR|Placebo|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab matching placebo intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will then receive natalizumab 300 mg IV infusion every 4 weeks for 24 weeks in open label phase.
62484641|NCT06596226|EXPERIMENTAL|Pathways with a Mutal Gaze Protocol|12 90-minute sessions (or 15 weeks, whichever comes first) of Pathways manualized Naturalistic Developmental Behavioral Intervention (NDBI) parent-mediated intervention (research version). Pathways uses a coaching model.
62484642|NCT06596226|ACTIVE_COMPARATOR|Pathways without Mutual Gaze Protocol|12 90-minute sessions (or 15 weeks, whichever comes first) of Pathways manualized Naturalistic Developmental Behavioral Intervention (NDBI) parent-mediated intervention (research version) without the Mutual Gaze protocol. Pathways uses a coaching model.
62484643|NCT03757195|EXPERIMENTAL|augmentation by xenograft|xenograft mixed with plasma extracted from blood
62484644|NCT05456594|PLACEBO_COMPARATOR|Conventional bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing their own conventional bra.
62133241|NCT06433102|EXPERIMENTAL|the training group|Participants in this group received visual perceptual training based on the lateral masking paradigm every other day for 35 to 45 minutes, with each cycle consisting of 40 sessions, lasting approximately 3 months. The training began in the hospital during the first week and continued at home using personal computers thereafter. The personal computers were connected to a central server via the internet.
62326102|NCT04759586|ACTIVE_COMPARATOR|Arm E (R-CHOP, radiation therapy)|Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
62326103|NCT04759586|EXPERIMENTAL|Arm F (R-CHOP, nivolumab, radiation therapy)|Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
62484645|NCT05456594|ACTIVE_COMPARATOR|Bounceless bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing provided Bounceless bra.
62484646|NCT05456594|ACTIVE_COMPARATOR|Shefit bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing provided Shefit bra.
62484647|NCT05497063|EXPERIMENTAL|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine|Two dispersible tablets of Sulfadoxine/Pyrimethamine (250 mg sulfadoxine / 12.5 mg pyrimethamine to be given as single dose once under fasting condition
62484648|NCT05497063|ACTIVE_COMPARATOR|G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
62484649|NCT03406156|EXPERIMENTAL|Obinutuzumab|"Obinutuzumab (100 mg on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and Day 1 of Cycle 2; for Cycles 3 - 6 (1000 mg on Day 1) only as needed for participants to achieve low tumor burden) was administered via intravenous infusion during the debulking regimen.~After debulking, obinutuzumab (1000 mg) was administered via intravenous infusion on Day 1 of one 5-week and four 4-week cycles during the obinutuzumab/venetoclax combination part of the regimen. Venetoclax was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg."
62133242|NCT06433102|NO_INTERVENTION|the control group|The control group maintained the original treatment plan without any additional interventions.
62484650|NCT03406156|EXPERIMENTAL|Obinutuzumab/bendamustine|"Obinutuzumab (100 mg on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and Day 1 of Cycle 2; for Cycles 3 - 6 (1000 mg on Day 1) only as needed for participants to achieve low tumor burden) was administered via intravenous infusion during the debulking regimen. Bendamustine (90 mg/m\^2 ) was to be administered to those with nodes or nodal mass \> 10 cm, or with del(11q) and \> 5 cm nodes, or at the discretion of the investigator as above, via intravenous infusion over 10 minutes on Days 1 and 2 (or Days 2 and 3 at the discretion of the investigator during Cycle 1) of each 28-day cycle for up to 6 cycles during the debulking regimen.~After debulking, obinutuzumab (1000 mg) was administered via intravenous infusion on Day 1 of one 5-week and four 4-week cycles during the obinutuzumab/venetoclax combination part of the regimen. Venetoclax was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg."
61933024|NCT03052192||Control group 2 (n=60)|"20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)~Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples."
61933025|NCT01865084|EXPERIMENTAL|Placebo|Placebo taken orally once daily.
61933026|NCT01865084|EXPERIMENTAL|0.3 mg/kg Tadalafil|0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
62484651|NCT04005638||Autoimmune Cytopenia|
62484652|NCT00967135|EXPERIMENTAL|Pregabalin|Study subjects will be randomized to receive on the morning of surgery, at least 30 minutes before induction, a 150 mg oral dose of pregabalin. Patients will then receive a 150 mg oral dose of pregabalin on the evening of the surgery. Subsequently, patients will receive a 150 mg oral dose of pregabalin twice daily on the following four postoperative days.
62484653|NCT00967135|PLACEBO_COMPARATOR|Placebo|Study subjects will be randomized to receive a matching placebo on the morning of surgery, at least 30 minutes before induction. Patients will then receive a placebo on the evening of the surgery. Subsequently, patients will receive a placebo twice daily on the following four postoperative days.
62484654|NCT06043388|EXPERIMENTAL|Group 1|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cell)
62484655|NCT06043388|PLACEBO_COMPARATOR|Group 2|physiological saline
62484656|NCT03049631|ACTIVE_COMPARATOR|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
62484657|NCT03049631|EXPERIMENTAL|Raspberry|Red raspberries (1 cup equivalent)
62692447|NCT06675630|OTHER|Control|Healthy eating advice
62692448|NCT06675630|EXPERIMENTAL|Intervention|Targeted fibre-related education
62692449|NCT04474847|EXPERIMENTAL|Blinded Abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
61933027|NCT01865084|EXPERIMENTAL|0.6 mg/kg Tadalafil|0.6 mg/kg tadalafil taken orally once daily.
61933028|NCT00961766|EXPERIMENTAL|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010 or matching placebo
61933029|NCT00961766|PLACEBO_COMPARATOR|Placebo|Participants may be randomized to escalating doses of BG00010 or matching placebo
61933030|NCT00697073|EXPERIMENTAL|1|high dose Idebenone
61933031|NCT03949985||Estrogenic contraceptive users|
61933032|NCT03949985||Non-estrogenic contraceptive users|
62133243|NCT01644994|EXPERIMENTAL|intracavitary cisplatin-fibrin|single dose local intracavitary cisplatin-fibrin application after pleurectomy/decortication
62133244|NCT03238261|EXPERIMENTAL|Chemotherapy and concomitant radiotherapy|
62133245|NCT03238261|ACTIVE_COMPARATOR|Radiotherapy|
62133246|NCT02035046|OTHER|study's population|
62133247|NCT02333513|EXPERIMENTAL|case group|
62133248|NCT03067142||Cohort 1 (Phase 1): PH1|Cross-Sectional/Observational
62133249|NCT03067142||Cohort 2 (Phase 1): Controls|Cross-Sectional/Observational
62326104|NCT03474107|EXPERIMENTAL|Arm A: Enfortumab Vedotin 1.25 mg/kg|Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
62326105|NCT03474107|ACTIVE_COMPARATOR|Arm B: Chemotherapy|Participants received either 75 milligrams per square meter (mg/m\^2) docetaxel by IV infusion over approximately 1 hour or 320 mg/m\^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m\^2 paclitaxel by IV infusion over approximately 1 hour on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
62133250|NCT03067142||Cohort 3 (Phase 2): PH1|Longitudinal/Observational
62692450|NCT04474847|PLACEBO_COMPARATOR|Blinded Placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
61933033|NCT04460456|EXPERIMENTAL|SBT6050 Monotherapy|Escalating doses of SBT6050 in Part 1 followed by expansion in Part 2 at the recommended dose determined in Part 1.
62133251|NCT03014518||Suicide Attempt Study Group|Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
62133252|NCT03014518||Healthy Control Group|Healthy adolescents with no history of suicide attempt. Clinical assessments and blood samples; no 12mo follow-up.
62133253|NCT00439413|ACTIVE_COMPARATOR|Selegiline Transdermal Patch|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received Selegiline Transdermal System, 6mg -20cm(2) patch, one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
62133254|NCT00439413|PLACEBO_COMPARATOR|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received matched placebo 20cm(2) patch transdermal patch one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
62326106|NCT03474107|EXPERIMENTAL|Cross-over Extension (COE)|Eligible participants from chemotherapy arm who met the criteria for COE will receive 1.25 mg/kg of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle until discontinuation criteria is met.
62326107|NCT06472726|EXPERIMENTAL|IONA Mind app|Participants will be asked to use the IONA Mind app for a 6-week period.
62326108|NCT06515002|EXPERIMENTAL|Phase I: Dose group 1 (low dose)|
62326109|NCT06515002|EXPERIMENTAL|Phase I: Dose group 2 (medium dose)|
62326110|NCT06515002|EXPERIMENTAL|Phase I: Dose group 3 (high dose)|
62326111|NCT06515002|EXPERIMENTAL|Phase II: Dose group 1|
62326112|NCT06515002|EXPERIMENTAL|Phase II: Dose group 2|
62692451|NCT06057623||Group 1|- Group 1: HFpEF patients with diabetes mellitus (HF-T2DM): patients with a diagnosis of diabetes mellitus in optimized drug therapy, documented by values of glycated hemoglobin (HbA1c) between 6% and 9%
62133255|NCT05121467||Patients with Cervical Disc Herniation|Endurance tests were performed for 9 muscles/muscle groups in the cervical and scapular regions, upper limb, and trunk Visual Analogue Scale (VAS) and Neck Disability Index (NDI) Fremantle Neck Awareness Questionnaire (FreNAQ) Tampa Scale of Kinesiophobia (TSK)
62326113|NCT06515002|PLACEBO_COMPARATOR|Phase II: Placebo group|
62326114|NCT06460506|EXPERIMENTAL|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
62326115|NCT03412877|EXPERIMENTAL|1/iTCR|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin
62692452|NCT06057623||Group 2|- Group 2: HFpEF without diabetes mellitus (HF-NotT2DM): patients with HF in absence of diabetes evidenced by values of glycated hemoglobin (HbA1c) \< 6.0%
61933034|NCT04460456|EXPERIMENTAL|SBT6050 and pembrolizumab|Escalating doses of SBT6050 in combination with pembrolizumab in Part 3 followed by expansion in Part 4 at the recommended dose determined in Part 3.
61933035|NCT04460456|EXPERIMENTAL|SBT6050 and cemiplimab|SBT6050 in combination with cemiplimab in Part 5 at the recommended dose determined in Parts 1 and 3.
61933036|NCT05249790|EXPERIMENTAL|'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
61933037|NCT05249790|ACTIVE_COMPARATOR|Usual care|COVID-19 patients treated at home by their family doctors according to their usual clinical practice expected to be in accordance with AIFA recommendations
61933038|NCT04098666|EXPERIMENTAL|metformin users|Extended release metformin 500 mg tablets up to 2,000 mg (4 tablets) a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
61933039|NCT04098666|PLACEBO_COMPARATOR|metformin non-users|Placebo tablets identical to extended release metformin 500 mg tablets up to 4 tablets a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
62692453|NCT03992872|EXPERIMENTAL|Prior Alpha|All study participants received the same Investigational Product according to the same schedule. Participants were prior recipients of experimental alphavirus vaccines.
62692454|NCT03992872|ACTIVE_COMPARATOR|Control: Naïve Alpha|All study participants received the same Investigational Product according to the same schedule. The alphavirus vaccine naïve participants will serve as controls for determining the effect of pre-existing alphavirus immunity on vaccine safety and immunogenicity.
62692455|NCT01564030|OTHER|Empty stomach|Patients have fasted for 8 hours.
62692456|NCT01564030|OTHER|Fluid|Patients have fasted for 8 hours, followed by the consumption of 250mL of apple juice.
62692457|NCT01564030|OTHER|Solid|Patients have fasted for 8 hours, followed by the consumption of their breakfast.
62133256|NCT02362867|NO_INTERVENTION|Total Knee Replacement|Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.
62133257|NCT01340716|ACTIVE_COMPARATOR|stretching exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style.
62326116|NCT03412877|EXPERIMENTAL|2/iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCRTransduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeksfollowing cell infusion
62326117|NCT03453567||TAVR|Transcatheter Aortic Valve Replacement
62326118|NCT03453567||Sutureless AVR|Sutureless Aortic Valve Replacement
62326119|NCT03453567||Conventional AVR|Conventional Aortic Valve Replacement
62326120|NCT05099003|EXPERIMENTAL|Treatment (selinexor and radiation therapy)|"CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a MRI and may undergo a biopsy during screening.~MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up."
62326121|NCT04333576|PLACEBO_COMPARATOR|Double-Blind: Placebo|Participants will receive double-blind placebo on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months.
62326122|NCT04333576|EXPERIMENTAL|Double-Blind: Elagolix|Participants will receive double-blind Elagolix on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months.
62326123|NCT04333576|EXPERIMENTAL|Double-Blind: Elagolix + COC|Participants will receive double-blind elagolix in combination with COC (combined oral contraceptive) on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC for 15 months. Participants will be followed-up for up to 12 months.
62326124|NCT05646862|EXPERIMENTAL|Inavolisib + Fulvestrant|Participants will be administered the treatments as outlined in the interventions section.
62326125|NCT05646862|ACTIVE_COMPARATOR|Alpelisib + Fulvestrant|Participants will be administered the treatments as outlined in the interventions section.
62326126|NCT03092453|EXPERIMENTAL|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
62326127|NCT06095375|EXPERIMENTAL|Cohort A (Adjuvant/Maintenance Phase)|
62326128|NCT06095375|EXPERIMENTAL|Cohort B (Concomitant Phase)|
62692458|NCT05516173||Ambulatory patients|"Patient with a high blood pressure during regular visit will undertake an ambulatory blood pressure monitoring. Before wearing the device , they will be asked to answer to the questionnaire and the investigators will gather their demographic,clinical characteristics and dietary habits data.~Ethical considerations will be undertaken and respected."
62133258|NCT01340716|EXPERIMENTAL|Tai Chi Chuan exercise|patients in this group held weekly classes of two stretching for 12 weeks.
62326129|NCT04400331|EXPERIMENTAL|Valbenazine|Capsule, administered orally once daily.
62326130|NCT00339495||Non-Screening|Participants received their usual care
62326131|NCT00339495||Screening|Participants received trial-provided screening examinations for prostate, lung, colorectal, and ovarian cancer
62326132|NCT00001987||Healthy Volunteers|Healthy Volunteers
62326133|NCT00001987||Patients with severe insulin resistance|patients with severe insulin resistance manifesting with acanthosis nigricans, hyperinsulinemia, type A and B insulin resistance syndromes, and patients with lipodystrophy.
62326134|NCT06493461|EXPERIMENTAL|HS135|Subcutaneous Injection
62326135|NCT04950309|EXPERIMENTAL|OPM Array studies|Testing of a final 49-61 channel OPM MEG system and any interim arrays
62326136|NCT05906589|EXPERIMENTAL|Inulin|The participant will be asked to administer the provided doses of 8g inulin twice daily.
62326137|NCT05906589|EXPERIMENTAL|Inulin + psyllium|The participant will be asked to administer the provided doses of 8g inulin + 3.5g psyllium twice daily.
62326138|NCT05906589|PLACEBO_COMPARATOR|Maltodextrin|The participant will be asked to administer the provided doses of 8g maltodextrin twice daily.
62326139|NCT00001505||1/Single Cohort|Healthy individuals (including employees and other patients) and patients with selected skin or other diseases
62692459|NCT03942653|EXPERIMENTAL|Goserelin Acetate + Pembrolizumab|Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV
62692460|NCT02578537|EXPERIMENTAL|Ticagrelor group|ticagrelor 180mg loading, followed by 90mg bid for 30 days
62692461|NCT02578537|ACTIVE_COMPARATOR|Clopidogrel group|clopidogrel 600mg loading, followed by 75mg/d for 30 days
62692462|NCT06243250||with irAE|Cancer patients who develop irAE after ICIs treatment.
62692463|NCT06243250||without irAE|Cancer patients who do not develop irAE after 3 months of ICIs treatment.
62692464|NCT06243250||healthy volunteer|Healthy volunteer.
61933040|NCT05597670|OTHER|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
62133259|NCT03753984|EXPERIMENTAL|Healthy group|The protocol consists of Low-level laser therapy (LLLT) application in the dominant side brachialis muscle in healthy subjects prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, electromyography associated with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration by means of the lactimeter, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
62133260|NCT03753984|EXPERIMENTAL|Post stroke group|The protocol consists of Low-level laser therapy (LLLT) application in the hemiparetic side brachialis muscle post stroke individuals prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, surface electromyography with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
62133261|NCT00956852||Lung cancer|Non-small cell lung cancer patients undergoing surgical lung resections
62133262|NCT02713126|PLACEBO_COMPARATOR|Placebo|Subjects will undergo cardiac exercise training and receive inhaled or oral placebo three times per day for 12 weeks while wearing an accelerometer
61933041|NCT05597670|EXPERIMENTAL|group B|Patients in this group will receive the same program as group (A) plus proximal stabilization exercise
62326140|NCT05217628|EXPERIMENTAL|Arm A: Basimglurant/NOE-101|"* Period 1 (Run-in: Baseline1 to Week 8): Basimglurant once daily dosing starting dose 1.5mg~* Period 2 (Double blind: Weeks 9 to 20): Participants will receive double-blind treatment with Basimglurant once daily.~* Open-label Extension (OLE): On completion of Period 2, participants will be offered open label treatment with Basimglurant in an open label extension for up to 52 weeks."
61933042|NCT00890266|EXPERIMENTAL|Study Arm|Exploratory
62326141|NCT05217628|PLACEBO_COMPARATOR|Arm B: Placebo|- Period 2 (Double blind: Week 9 to Week 20): Participant randomized to placebo will receive the corresponding number of matching placebo capsules.
62326142|NCT05810870|EXPERIMENTAL|Cohort A|"MEN1611 orally (PO) 48 mg twice daily (BID) (2 intakes of 3x16 mg capsules, for a total daily dose of 96 mg MEN1611 free-base) during each 21-day cycle combined with eribulin mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 when expressed as a free base) administered intravenously (IV) over 2 to 5 minutes on days 1 and 8 of every 21-day cycle (CXD1 and CXD8).~A run-in phase for safety and tolerability of MEN1611 in combination with eribulin will be conducted after the first 2 cycles on the first 3 patients. Upon Steering Committee agreement the cohort A will be expanded up to N=14 (11 additional patients).~Patients will receive treatment until disease progression, unacceptable toxicity, death, discontinuation from the study treatment for any other reason, withdrawal of consent, or study termination."
62326143|NCT05639114|EXPERIMENTAL|Ianalumab s.c. monthly|Ianalumab s.c. monthly
62326144|NCT05639114|EXPERIMENTAL|Ianalumab s.c. quarterly|Ianalumab s.c. quarterly
62326145|NCT05639114|PLACEBO_COMPARATOR|Placebo s.c. monthly|placebo s.c. monthly
62326146|NCT00001979||Patients|Patients with known or suspected immunologically-mediated kidney diseases or immunologically-mediated diseases with potential for kidney disease.
62326147|NCT01712620|EXPERIMENTAL|Group A|Spironolactone
62326148|NCT01712620|PLACEBO_COMPARATOR|Group B|Placebo
62692465|NCT06674863|EXPERIMENTAL|Group I (standard SCP, tailored SCP)|Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.
62692466|NCT06674863|ACTIVE_COMPARATOR|Group II (standard SCP)|Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.
62692467|NCT04221477|EXPERIMENTAL|Obinutuzumab|"Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit.~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
61933043|NCT02526173|EXPERIMENTAL|dHACM|This group will receive RALP using full nerve sparing technique plus dHACM application.
61933044|NCT02526173|OTHER|Control|This group will receive RALP using full nerve sparing technique only.
61933045|NCT01932073|NO_INTERVENTION|Control Group|Receives institutional skin care protocol
61933046|NCT01932073|EXPERIMENTAL|Treatment Group|Receives institutional skin care protocol and, when applicable (if skin reactions develop), Low-Level Laser Therapy
61933047|NCT01133561|ACTIVE_COMPARATOR|actozone A|Pioglitazone 30 mg tablets daily
61933048|NCT01133561|PLACEBO_COMPARATOR|actozone B|placebo
62133263|NCT02713126|ACTIVE_COMPARATOR|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive inhaled or oral sodium nitrite three times per day for 12 weeks while wearing an accelerometer
62133264|NCT03426800|EXPERIMENTAL|Migraine_acupuncture and training|Migraine acupuncture and training
62133265|NCT03426800|EXPERIMENTAL|Migraine training|Migraine training
62133266|NCT03426800|EXPERIMENTAL|Tension_acupuncture and training|Tension headache acupuncture and training
61933049|NCT06602063|EXPERIMENTAL|criteria-fulfilled arm|Patients who meet the inclusion and exclusion criteria will receive secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy with Sintilimab maintenance therapy.
62133267|NCT03426800|EXPERIMENTAL|Tension headache training|Tension headache training
62133268|NCT00937131|NO_INTERVENTION|no comparator|
62692468|NCT04221477|PLACEBO_COMPARATOR|Placebo|"Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone.~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
62692469|NCT04077320|EXPERIMENTAL|Memory Self-Efficacy Training|Memory self-efficacy group training classes.
62692470|NCT04077320|ACTIVE_COMPARATOR|General Education Group|General education group classes (e.g., exercise, diet, sustainability, tc.)
62692471|NCT00745667|ACTIVE_COMPARATOR|1|laparoscopic
61933050|NCT06602063|EXPERIMENTAL|compassionate use arm|Patients who are enrolled under expanded eligibility criteria will receive secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy with Sintilimab maintenance therapy.
61933051|NCT06602063|NO_INTERVENTION|real world arm|Patients who meet the inclusion and exclusion criteria but refuse to participate in the CF and CU arms will receive the physician's therapy of choice.
61933052|NCT06482814|EXPERIMENTAL|Study Sequence AB|Sleep restriction condition in the first period and normal sleep condition in the second period. Each period will consist of a 10-day inpatient visit comprising a 3-day/2-night baseline, followed by a 5-day/5-night experimental phase, and a 2-day/2-night recovery phase.
61933053|NCT06482814|EXPERIMENTAL|Study Sequence BA|Normal sleep condition in the first period and sleep restriction condition in the second period. Each period will consist of a 10-day inpatient visit comprising a 3-day/2-night baseline, followed by a 5-day/5-night experimental phase, and a 2-day/2-night recovery phase.
61933054|NCT05633693|EXPERIMENTAL|Counterpressure Maneuvers|"Counterpressure maneuver (CPM) trials will be performed in front of a neutral wall in silence to ensure that visual or auditory stimuli do not affect movement.~CPM:~* Leg crossing and muscle tensing: Legs are crossed while upright and lower body musculature is isometrically contracted (clinical)~* Crouching: Participant crouches down resting weight on the balls of their feet, pressing calves against the back surface of the thighs (clinical)~* Exaggerated anterior-posterior sway: Participant sways back and forth with feet planted on ground at a pace/amplitude that is comfortable (discrete)~* Gluteal clenching: Participant rhythmically tenses and relaxes the gluteal muscles at a pace/duration that is comfortable (discrete)~Participants serve as their own controls and complete both testing arms."
61933055|NCT05633693|SHAM_COMPARATOR|Baseline Stand|"Participants will perform a sit-stand test, followed by 5-minutes of baseline (quiet) standing trial on a force platform while cardiorespiratory responses are recorded.~Sit-stand test: following 5-minutes of supine rest, the participant will be passively moved into the seated position. They will then be asked to actively move into the standing position.~Baseline stand: immediately following the sit-stand test, the baseline trial will begin. Participants will stand quietly on the force platform for 5-minutes. This trial will be performed in front of a neutral wall in silence to ensure that visual or auditory stimuli do not affect their movement.~Participants serve as their own controls and complete both testing arms."
61933056|NCT06710275||elevated gap CO2 group and low gap CO2 group|Gap CO2 is calculated as PvCO2-PaCO2, using arterial and venous blood gases taken during CPB. Patients will be included in the elevated gap CO2 group when gap CO2 during CPB is \> 6 mmHg
61933057|NCT06699342|EXPERIMENTAL|LBBAP+AVNA arm|Left bundle branch area pacing combined with atrioventricular node ablation.
61933058|NCT06699342|SHAM_COMPARATOR|Control arm|Pharmacologic treatment optimized according to guidelines in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.
61933059|NCT00642473|EXPERIMENTAL|Prevention (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
61933060|NCT00642473|EXPERIMENTAL|Treatment (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
61933061|NCT03274271|EXPERIMENTAL|AP+CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with all three behaviour change techniques of interest: action planning (AP), coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
61933062|NCT03274271|EXPERIMENTAL|AP+CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
62692472|NCT00745667|ACTIVE_COMPARATOR|2|open correction
62692473|NCT04370886|EXPERIMENTAL|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic
62692474|NCT04370886|EXPERIMENTAL|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation
62692475|NCT04370886|EXPERIMENTAL|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation
62692476|NCT04370886|PLACEBO_COMPARATOR|SMS with holiday greeting|SMS content in this group will be about holiday greeting of Labour Day.
62692477|NCT05460286|EXPERIMENTAL|CSMT group|Chiropractic Spinal Manipulative Treatment group
62692478|NCT05460286|EXPERIMENTAL|SD group|Spinal Decompression group
62692479|NCT06634615|EXPERIMENTAL|Education|Patients in the education group will be shown a patient education video about the laparoscopic cholecystectomy operation with virtual reality glasses on the day of hospitalization.
61933063|NCT03274271|EXPERIMENTAL|AP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
61933064|NCT03274271|EXPERIMENTAL|CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
61933065|NCT03274271|EXPERIMENTAL|M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
61933066|NCT03274271|EXPERIMENTAL|CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
61933067|NCT03274271|EXPERIMENTAL|AP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: action planning (AP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
61933068|NCT03274271|ACTIVE_COMPARATOR|Control|Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
61933069|NCT02988154||Arm A: Simulation training cohort|Recruits to Arm A undergo simulation training (computer simulation of the procedure, followed by simulation on a dead animal model), after which they will attempt to perform an EVD procedure on their own, on a 3D-printed skull model that we designed.
61933070|NCT02988154||Arm B: ''See one, do one'' cohort|Recruits to Arm B will witness an EVD placement as performed by an experienced surgeon, after which they will attempt to perform an EVD procedure on their own, using the aforementioned 3D-printed skull model. This mimics the ''see one, do one'' paradigm prevalent in surgical training.
62692480|NCT06634615|EXPERIMENTAL|Education+Interview|Patients in the education+interview group will be shown a patient education video about the laparoscopic cholecystectomy operation with virtual reality glasses on the day of hospitalization. Patients in the education group will be shown a patient education video on laparoscopic cholecystectomy surgery with virtual reality glasses on the day of admission to the hospital. When patients are taken to the operative waiting area, virtual reality glasses will be put on and a 5-minute video family meeting will be initiated with the patient's relative(s).
62692481|NCT06634615|NO_INTERVENTION|Control|
61933071|NCT03364790|EXPERIMENTAL|group1|participant with posterior lumbar interbody fusion(PLIF or PLF)
61933072|NCT03364790|EXPERIMENTAL|group2|participant with total knee arthroplasty (TKA)
61933073|NCT03364790|EXPERIMENTAL|group3|participant with PLIF and TKA on one stage
61933074|NCT03364790|NO_INTERVENTION|group4|participant without operation
62692482|NCT02695186||A/IM alone|Patients with intestinal metaplasia who undergo gastroscopy and blood sample analysis
62692483|NCT02695186||B/IM and MS|Patients with intestinal metaplasia and metabolic syndrome who undergo gastroscopy and blood sample analysis
61933075|NCT04012918|EXPERIMENTAL|A.I. + Capeciabine|Patients will receive Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
61933076|NCT04012918|ACTIVE_COMPARATOR|A.I|Patients will receive aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor.
61933077|NCT02849665|EXPERIMENTAL|Kangaroo Position|The newborn remains in a vertical position, with limbs flexed, dressed in light clothes, maintaining skin-to-skin contact and the face on the adult's thorax.
61933078|NCT02849665|NO_INTERVENTION|Not Kangaroo Position|The newborns will be not placed in the position Kangaroo.
62133269|NCT01262339|ACTIVE_COMPARATOR|Comparator of Hand A intervention vs Hand B|Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
61933079|NCT01981759|PLACEBO_COMPARATOR|Placebo|Participants receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from week 1-12 (12 visits).
62692484|NCT02695186||C/Healthy controls|Healthy controls without intestinal metaplasia or metabolic syndrome who undergo gastroscopy and blood sample analysis
61933080|NCT01981759|EXPERIMENTAL|D-Cycloserine|Participants will receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from weeks 1-2 (2 visits), then a weekly 50 mg dose of D-Cycloserine by mouth one hour before CBT sessions from weeks 3-12 (10 visits).
61933081|NCT05654441|EXPERIMENTAL|Influenza Vaccine|Experimental group given influenza vaccine (Flulaval)
61933082|NCT05654441|PLACEBO_COMPARATOR|Sham Vaccine|The control group given a placebo (saline injection)
62133270|NCT06102616|EXPERIMENTAL|periodontal compromised orthodontic pateints|periodontal compromised adults female patients with sever dental crowding and seeking for orthodontic treatment
62133271|NCT03939312|EXPERIMENTAL|Atogepant 60 mg|Participants received atogepant 60 mg, orally, once daily (QD) for up to 40 weeks.
62133272|NCT02614235|EXPERIMENTAL|Pocket-ECG III System|After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.
61933083|NCT06676488|EXPERIMENTAL|Re-Timer Device (Bright Light Therapy)|Morning bright light therapy will be administrated through a safe wearable device called a Re-timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light. The device emits light at a higher wavelength than the UV range and has a UV filter for added safety. Subjects will be asked to wear the glasses for one hour each morning per day for 7 days a week. They will wear the device for a total of 14 days to receive the full therapeutic effect. Additionally, subjects will be asked to complete the light therapy the first hour of being awake and remain indoors while using the device. Participants will be informed that they can wear the device freely throughout their home or work environment but should avoid activities that could potentially be harmful (i.e., driving, contact sports, operating heavy machinery).
62133273|NCT02614235|ACTIVE_COMPARATOR|Conventional Holter|Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
62484658|NCT02061280|EXPERIMENTAL|MICT Trial Design|"Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily"
62484659|NCT02061280|ACTIVE_COMPARATOR|LASST Trial Design|"Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily."
62692485|NCT04408638|EXPERIMENTAL|Glofit-GemOx|Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
62692486|NCT04408638|EXPERIMENTAL|R-GemOx|Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
62692487|NCT05515224|EXPERIMENTAL|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. Depending on whether the 5-Cog results are normal or abnormal on any one of the 3 tests, appropriate clinical decision support tools are provided to the primary care physicians in electronic medical record. The primary care physicians are not instructed to follow 5-Cog suggestions verbatim but use their clinical judgment.
62692488|NCT05515224|ACTIVE_COMPARATOR|Enhanced usual care|Educational sessions for primary care physicians and clinic staff regarding cognitive detection and medical billing will be conducted. A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
61933084|NCT06676488|PLACEBO_COMPARATOR|Placebo device (non Bright Light Therapy)|Subjects will be asked to wear glasses that do not provide Bright Light Therapy for one hour each morning per day for 7 days a week as recommended by the manufacturer. They will wear the device for a total of 14 days to receive the full therapeutic effect. Additionally, subjects will be asked to complete the light therapy the first hour of being awake and remain indoors while using the device. Participants will be informed that they can wear the device freely throughout their home or work environment but should avoid activities that could potentially be harmful (i.e., driving, contact sports, operating heavy machinery).
61933085|NCT06463574|EXPERIMENTAL|Surefil one bulk-fill composite|Restorative material applied directly to the tooth without adhesive appliaction.
61933086|NCT06463574|ACTIVE_COMPARATOR|Filtek One bulk-fill composite|Restorative material that is applied to the tooth after adhesive application.
62133274|NCT02748317|EXPERIMENTAL|Adults with Spinal Cord Injury|Lactobacillus rhamnosus GG
62133275|NCT03813433|EXPERIMENTAL|Enosequence|3-4 mm of Endosequence will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
62133276|NCT03813433|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|3-4 mm of Mineral Trioxide Aggregate will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
62484660|NCT03911583|ACTIVE_COMPARATOR|Control Group (CG)|Education, modifying diet and light physical activity (LPA)
62484661|NCT03911583|ACTIVE_COMPARATOR|Moderate physical activity group (MPA)|Education, modifying diet and moderate physical activity (MPA)
62484662|NCT03911583|ACTIVE_COMPARATOR|Intense physical activity group (IPA)|Education, modifying diet and intense physical activity (IPA)
61933087|NCT02341105|ACTIVE_COMPARATOR|Medical therapy|Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
61933088|NCT02341105|ACTIVE_COMPARATOR|Catheter ablation|A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )
61933089|NCT00788398|ACTIVE_COMPARATOR|Saline, gravity flow|
61933090|NCT00788398|ACTIVE_COMPARATOR|Saline, Low Pressure|
62692489|NCT05051436|EXPERIMENTAL|Mirabegron (M)|Drug will be administered for 12 weeks after baseline procedures.
62692490|NCT05051436|EXPERIMENTAL|Tadalafil (T)|Drug will be administered for 12 weeks after baseline procedures.
62133277|NCT04850586|EXPERIMENTAL|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
62484663|NCT04198090|OTHER|Sexual & Gender Minority (SGM) Competence Training|Personnel will be trained using a validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for Oncology.
61933091|NCT00788398|ACTIVE_COMPARATOR|Saline, High Pressure|
61933092|NCT00788398|ACTIVE_COMPARATOR|Soap, Gravity Flow|
61933093|NCT00788398|ACTIVE_COMPARATOR|Soap, low pressure|
61933094|NCT00788398|ACTIVE_COMPARATOR|Soap, high pressure|
61933095|NCT05204732|EXPERIMENTAL|Experimental group|"* Speech training: 4 times 1 hour of intonation training for 4 weeks~* Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 2 postmeasurements)"
61933096|NCT05204732|SHAM_COMPARATOR|Control group|"* Speech training: : 4 times 1 hour sham therapy (info sessions + active intervention non-verbal communication) during 4 weeks + 4 times 1 hour intonation training during 4 weeks~* Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 3 postmeasurements)"
61933097|NCT04911413|EXPERIMENTAL|low-dose group,|A bolus of 10 mg/kg Tranexamic Acid followed by a maintenance dose of 10 mg/kg/h Tranexamic Acid until the end of surgery
62692491|NCT05051436|EXPERIMENTAL|Mirabegron and Tadalafil (MT)|Both drugs will be administered for 12 weeks after baseline procedures.
62692492|NCT05051436|PLACEBO_COMPARATOR|Placebo (P)|
61933098|NCT04911413|EXPERIMENTAL|middle-dose group,|A bolus of 20 mg/kg Tranexamic Acid followed by a maintenance dose of 15 mg/kg/h Tranexamic Acid until the end of surgery
61933099|NCT04911413|EXPERIMENTAL|high-dose group|A bolus of 30 mg/kg Tranexamic Acid followed by a maintenance dose of 20 mg/kg/h Tranexamic Acid until the end of surgery
61933100|NCT06710093||Histologically proven melanoma|Unresectable stage III or stage IV disease, with confirmed radiological disease progression within 1 month of recruitment
61933101|NCT05495087|EXPERIMENTAL|IHT Treatment|Exposures to hypoxic air (10% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.
61933102|NCT05495087|PLACEBO_COMPARATOR|Sham-IHT control|Exposures to normoxic air (21% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.
61933103|NCT05230459|EXPERIMENTAL|AB-1003 Cohort 1|
62133278|NCT04850586|NO_INTERVENTION|Control Group|Routine education was given to the patients in the control group. Routine education was administered by a nurse working in the clinic after the patients were admitted to the hospital. The patients in this group were not trained by a multidisciplinary team. In the routine training, patients were only informed about preoperative preparation.
62133279|NCT02664558|EXPERIMENTAL|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
61933104|NCT05230459|EXPERIMENTAL|AB-1003 Cohort 2|
61933105|NCT05230459|PLACEBO_COMPARATOR|Placebo (Cohorts 1 and 2)|
61933106|NCT04493333|EXPERIMENTAL|Vaginal DHEA|Vaginal insert with 6.5 mg vaginal DHEA self-administered once daily at bedtime for 12 weeks
61933107|NCT04493333|ACTIVE_COMPARATOR|Vaginal Polycarbophil Moisturizer|Prefilled vaginal applicator with 2.5 g of polycarbophil vaginal moisturizing gel, self-administered two times per week at night for 12 weeks
61933108|NCT05794971|EXPERIMENTAL|Irinotecan Drug-Eluting Beads combined with regorafenib|
61933109|NCT05794971|ACTIVE_COMPARATOR|regorafenib|
61933110|NCT04253964|EXPERIMENTAL|Performance Status 0-1 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.~PLUS~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:~* Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS~* Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR~* Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
61933111|NCT04253964|EXPERIMENTAL|Performance Status 2 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.~PLUS~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:~* Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS~* Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR~* Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
62133280|NCT02664558|PLACEBO_COMPARATOR|placebo|placebo capsules TID, administered orally for a total of 24 weeks
62133281|NCT04758416||Metastatic breast cancer patients|50 metastatic breast cancer patients
62133282|NCT01797354|EXPERIMENTAL|Cognitive-behavioral therapy and hypnosis group|Patients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
62692493|NCT06441305|NO_INTERVENTION|Standard of Care|"* Register-based household registration (census) by CHP every 12 months~* Some family MUAC of variable and unknown coverage/frequency, national guidance developed.~* Some passive screening using weight-for-height z-score at Health Facility and during outreach during Malezi bora (child health week every 6 months).~* Monthly compilation by CHA (supervisors) of the list of defaulters and non-respondents for transmission to relevant community health promoter (CHP) during monthly in-person meeting."
62692494|NCT06441305|EXPERIMENTAL|SWITCH intervention package|"* Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up."
62692495|NCT06640166|EXPERIMENTAL|encorafenib+cetuximab+FOLFIRI|Encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI)
62133283|NCT01797354|ACTIVE_COMPARATOR|Support group|Patients will receive (in groups of 6) fifteen 120-min support group session.
62692496|NCT04330859|EXPERIMENTAL|Intervention|Parent-driven intervention bundle of 6 evidence-based elements: vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy
62692497|NCT04330859|PLACEBO_COMPARATOR|Routine care|Routine care per unit guidelines
62692498|NCT06538012|EXPERIMENTAL|Biological Tumor Infiltrating Lymphocytes (TIL) Therapy with Immunotherapy|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and TILs IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62692499|NCT04620980||Cases|"Participants will be assessed for disease progression: Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence.~Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
62692500|NCT04620980||controls|"Participants will be assessed for the presence of disease. Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
62692501|NCT03345550|EXPERIMENTAL|Omega-3 Polyunsaturated Fatty Acid Treatment Arm|Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
62692502|NCT03345550|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to this study arm will receive placebo drug for 3 months.
62692503|NCT05179915|EXPERIMENTAL|Experimental Group|The experimental group will be administered 15-minute therapeutic touch focused on sacral region the latent phase and after it finishes, the participating pregnant woman will be asked to rest for 30 minutes.
62692504|NCT05179915|PLACEBO_COMPARATOR|Placebo Group|After the mimic (sham) therapeutic touch focused on sacral region , the pregnant woman will be asked to rest for 30 minutes.
62692505|NCT06300684|EXPERIMENTAL|CBT-i|The CBT-i group consists of participants who will receive Cognitive Behavioral Therapy for Insomnia (CBTi) over 4 weeks (1 session per week). This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
62692506|NCT06300684|NO_INTERVENTION|Sleep Hygiene|The Sleep Hygiene group consists of participants who will not receive any specific therapeutic intervention. Instead, participants in this group will receive basic sleep hygiene education, which includes general recommendations and guidance on healthy sleep habits, which does not involve a structured therapeutic intervention.
62692507|NCT03688763|OTHER|Digital CBTi administered|Participants will receive 6 sessions of digitally administered CBTi using the Sleepio platform over the course of 12 weeks. Each session lasts on average 30-60 minutes, and is tailored to participant's progress and problems. During the treatment phase, between sessions, participants complete the Consensus Sleep Diary to track their progress.
62692508|NCT06549608||Adults participants treated with mavacamten|Participants with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care.
62692509|NCT05052736|EXPERIMENTAL|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62692510|NCT05052736|PLACEBO_COMPARATOR|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
62692511|NCT02113878|EXPERIMENTAL|Dose Level 1|"* 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.~* Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).~* Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
62133284|NCT00629954||I|
62133285|NCT03936023||2nd Generation SUs|Reference Group
62133286|NCT03936023||Saxagliptin|Exposure Group
62133287|NCT01278420|OTHER|Tecnis MF|
62133288|NCT01278420|OTHER|ReSTOR|
62133289|NCT02269475|EXPERIMENTAL|MEDI3250|MEDI3250 Nasal Spray
62692512|NCT02113878|EXPERIMENTAL|Dose Level 2|"* 40 mg BKM120 will be administered orally daily for 45 days.~* Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).~* Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
61933112|NCT03079180|EXPERIMENTAL|Aged & strength training at 80% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~Training programs:~Frequency: 3 training sessions per week. Duration: 12 weeks. Intensity: 80% of one repetition maximum (1RM). The 1RM of the participants in each of the 3 exercises performed in the training program will be reviewed every 2 weeks during training. If 1RM increase, the training load will be adjusted accordingly.~Training exercises: A Warm-up will first be performed on a cycle ergometer during 10min. The training intervention will then consist in performing two sets on each one of the two exercises used for Patellar tendon stress: leg extension and leg press. To stress Achilles tendon, the subjects will perform four (4) sets using a calf raise machine. The subjects will perform 4 to 8 repetitions at 80% 1RM.~All training sessions will take place under appropriate supervision in UTC for the duration of the interventions according to the study design."
61933113|NCT03079180|EXPERIMENTAL|Aged & strength training at 55% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~The training program and training exercises in this group are the same as for the Aged \& strength training at 80% 1RM arm except for the two following parameters.~Training intensity: Intensity of exercises will be 55% of one repetition maximum (1RM).~The subjects will perform 6 to 12 repetitions at 55% 1RM.~The two training programs (55% or 80% of 1RM) are designed to be equal in volume (resistance x repetitions x sets)."
62326149|NCT02677896|EXPERIMENTAL|Enzalutamide + Androgen Deprivation Therapy (ADT)|Participants received 160 mg enzalutamide orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide during double-blind treatment period and provided informed consent to take part in open-label period continued to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
61933114|NCT03079180|EXPERIMENTAL|Young & strength training at 55% 1RM|"Subjects: 20 subjects aged between 18 and 30 years~The training program and training exercises in this group are the same as for the Aged \& strength training at 55% 1RM arm"
61933115|NCT00054717|OTHER|Tipranavir(TPV)/low dose ritonavir(r)|
61933116|NCT00054717|OTHER|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
61933117|NCT03024697|ACTIVE_COMPARATOR|PECs Block|Patients randomised to receive pectoral plane blocks and a sham local anaesthetic infusion wound catheter
61933118|NCT03024697|ACTIVE_COMPARATOR|LA Infusion|Patients randomised to receive a local anaesthetic infusion wound catheter; No sham pectoral plane block performed as patients usually under general anaesthetic at time of block.
61933119|NCT03024697|ACTIVE_COMPARATOR|PECs Block & LA Infusion|Patients randomised to receive pectoral plane blocks and a local anaesthetic infusion wound catheter.
61933120|NCT03952637|EXPERIMENTAL|1|In Stage 1, up to 5 Type II subjects will receive 1.5E13 vg/kg of the gene transfer agent, and two Type II subjects will receive 4.5E13 vg/kg of the gene transfer agent. In Stage 1, up to 3 Type I subjects will receive 1.5E13 of the gene transfer agent (Cohort 1) and then up to 3 subjects will receive 4.5E13 of the gene transfer agent (Cohort 2).
61933121|NCT03952637|EXPERIMENTAL|2|Following the last Stage 1 subject s 6 months visit, data will be reviewed, and Stage 2 dosing and assessments will be determined. If Stage 2 dosing is to proceed, it will be reflected in a protocol amendment.
61933122|NCT03420417|EXPERIMENTAL|Assessement of respiratory mechanics|Measurement of respiratory mechanics characteristics
61933123|NCT06707454||Study group|Patients who will undergo open heart surgery, such as isolated coronary artery bypass grafting (CABG) or combined CABG and valve surgery.
61933124|NCT05417217|ACTIVE_COMPARATOR|Control group|"Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure.~Blood will be drawn:~At baseline: before general anaesthesia, after start of CPB, after clamping the aorta, before unclamping the aorta, after the operation, 5 h after clamping the aorta, 12 hours after clamping the aorta, and 24 hours after aortic clamping"
61933125|NCT05417217|EXPERIMENTAL|Ventilation group|"Ventilation is continued from going on CPB until clamping of the ascending aorta.~Blood will be drawn:~At baseline: before general anaesthesia, after start of CPB, after clamping the aorta, before unclamping the aorta, after the operation, 5 h after clamping the aorta, 12 hours after clamping the aorta, and 24 hours after aortic clamping"
61933126|NCT05708846||Heart Failure patients telemonitored|Patients will be monitored with the vitalera app and platform
61933127|NCT04620655|EXPERIMENTAL|RD13-01 cell infusion|
61933128|NCT02942875|EXPERIMENTAL|Mirror therapy group|MT group subjects will attend training sessions of bilateral upper limb exercise daily in the presence of the mirror.
61933129|NCT02942875|ACTIVE_COMPARATOR|Control therapy group|Control group subjects will undergo the same training sessions of bilateral upper limb exercise daily without mirror.
61933130|NCT00664027|EXPERIMENTAL|25 mg|25 mg RTA 402 (Bardoxolone methyl)/Stratum 1
61933131|NCT00664027|EXPERIMENTAL|75 mg|75 mg RTA 402 (Bardoxolone methyl)/Stratum 1
61933132|NCT00664027|EXPERIMENTAL|150 mg|150 mg RTA 402 (Bardoxolone methyl)/Stratum 1
61933133|NCT00664027|EXPERIMENTAL|25/75 mg|25 mg -\> 75 mg RTA 402 (Bardoxolone methyl)/Stratum 2
61933134|NCT05273970|EXPERIMENTAL|Behavioral testing under intracranial monitoring|Patients will undergo behavioral tasks while being monitored by intercranial electrodes
62133290|NCT02269475|PLACEBO_COMPARATOR|Placebo|Placebo Nasal spray
62326150|NCT02677896|PLACEBO_COMPARATOR|Placebo + Androgen Deprivation Therapy (ADT)|Participants received matching placebo orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
62133291|NCT06605924|EXPERIMENTAL|Tobacco-free|Viewing a static advertisement
62133292|NCT06605924|EXPERIMENTAL|Discrete|Viewing a static advertisement
62326151|NCT02677896|EXPERIMENTAL|Placebo followed by Enzalutamide|Eligible participants who received enzalutamide matching placebo during double-blind treatment period and provided informed consent to take part in open-label period switched to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
62326152|NCT06073093|EXPERIMENTAL|SAR441566 dose regimen A|Participant will receive dose regimen A of SAR441566 for 12 weeks
62326153|NCT06073093|EXPERIMENTAL|SAR441566 dose regimen B|Participant will receive dose regimen B of SAR441566 for 12 weeks
62326154|NCT06073093|EXPERIMENTAL|SAR441566 dose regimen C|Participant will receive dose regimen C of SAR441566 for 12 weeks
62326155|NCT06073093|EXPERIMENTAL|SAR441566 dose regimen D|Participant will receive dose regimen D of SAR441566 for 12 weeks
62326156|NCT06073093|PLACEBO_COMPARATOR|Placebo|Participant will receive SAR441566-matching placebo for 12 weeks
62326157|NCT01878045||American Indians with type 2 diabetes|previously enrolled in OH95-DK-N037
62326158|NCT03053141||All Subjects|All subjects are included in this cohort and are treated with the Rhythmia Mapping System
62326159|NCT05873517|EXPERIMENTAL|Immediate NET+|Receives NET+ immediately
62326160|NCT05873517|ACTIVE_COMPARATOR|Waitlist NET+|Receives NET+ after waitlist
62326161|NCT02504879||Melorheostosis patients|Patients aged \> 18 years with possible and confirmed melorheostosis.
62326162|NCT02504879||Relatives of patients with melorheostosis|Relatives of patients with melorheostosis may be included for genetic testing only.
62326163|NCT00047996||Group1|Clinical Center Patients, Healthy Volunteers
62326164|NCT05170204|EXPERIMENTAL|Cohort A1: ALK-Positive (alectinib arm)|Participants will receive alectinib 600 mg orally twice daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
62326165|NCT05170204|ACTIVE_COMPARATOR|Cohort A1: ALK-positive (durvalumab arm)|Participants will receive 1500 mg of intravenous (IV) durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
62326166|NCT05170204|EXPERIMENTAL|Cohort A2: ROS 1-positive (entrectinib arm)|"Participants will receive entrectinib 600 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first.~Cohort A2 has been closed to enrollment."
62326167|NCT05170204|ACTIVE_COMPARATOR|Cohort A2: ROS 1-positive (durvalumab arm)|"Participants will receive 1500 mg of IV durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first~Cohort A2 has been closed to enrollment."
62326168|NCT02417740||Adult with absence of Portal Hypertension|Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination.
61933135|NCT06552247|EXPERIMENTAL|AI-based fundus picture screening|"Volunteers will performed a full study visit as part of their regular Ophthalmology assessment. This will include a fundus picture, an Optic-disc entered OCT, a Visual Field exam and a clinical examination by a clinical expert.~Fundus picture will be assessed by an AI algorithm (G-Risk) and labelled with referral vs non-referrable and compared with the clinical gold standard"
62326169|NCT02417740||Adult with presence of Portal Hypertension|Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG \>5mmHg).
62326170|NCT02417740||Minors likely to have the absence of Portal Hypertension|Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination.
62326171|NCT02417740||Minors likely to have the presence of Portal Hypertension|Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG \>5).
61933136|NCT03029702|ACTIVE_COMPARATOR|Usual Care|Participants will undergo standard counseling and be prescribed a treatment for their GDM. Treatments include insulin, glyburide, and metformin.
61933137|NCT03029702|ACTIVE_COMPARATOR|Individualized Treatment|Participants will undergo standard counseling and be matched to therapy based on their GDM mechanism. Treatments include insulin, glyburide, and metformin.
61933138|NCT06421207|ACTIVE_COMPARATOR|Cohort 1 Safety Evaluation of Treatment Depths|Each subject will be treated a single time at 4mm, 5mm and 7 mm depths at a minimum of 3 treatment areas. A non-treated control area will also be designated. Histology evaluations for all treatment areas and the control area will occur 30 days after treatment (Day 30).
62133293|NCT06605924|EXPERIMENTAL|Convenient|Viewing a static advertisement
62133294|NCT06605924|NO_INTERVENTION|Control|Viewing a static advertisement - baseline language only
62133295|NCT00558454|PLACEBO_COMPARATOR|1|Placebo
62133296|NCT00558454|EXPERIMENTAL|2|1 mg/kg/day from age 6 weeks to 6 months
62326172|NCT06193902|EXPERIMENTAL|LEU011|Infusion of target dose of LEU011
62326173|NCT05639933|EXPERIMENTAL|Open-Label PK Cohort|Topical treatment with HT-001 2% Gel unblinded.
62326174|NCT05639933|PLACEBO_COMPARATOR|Randomized, Double Blind Cohort|Topical treatment with HT-001 (2%, 1%, or 0.5%) or placebo (HT-001 vehicle), blinded
62326175|NCT05878769|EXPERIMENTAL|Open-Label Extension|Eligible participants from parent studies GB43311 and GB44332 will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W) until the end of the study
62692513|NCT06141993||Men with progressive metastatic castration resistant prostate cancer (mCRPC)|Men with progressive metastatic castration resistant prostate cancer (mCRPC) and starting standard of care therapy with a second androgen receptor (AR) inhibitor (typically enzalutamide or abiraterone acetate) will have blood collected for circulating tumor cell (CTC) assessments and other research assessments at baseline, 12 weeks and upon disease progression.
62133297|NCT00558454|EXPERIMENTAL|3|2 mg/kg/day from age 6 weeks to 6 months
62133298|NCT06358534|NO_INTERVENTION|control groups|No intervention was performed in chronic renal failure patients with eGFH values below 29 ml/dl/1.72m.
62326176|NCT02639325||Patients|Patients who have solitary primary or recurrent brain tumor with associated seizures.
62484664|NCT00582387||nonmuscle invasive bladder cancer|This is a hospital-based cohort study in which subjects with non-muscle invasive bladder cancer diagnosed within the previous 12 months will be evaluated to determine whether candidate genetic variants in patients with superficial bladder cancer can predict the risk of disease recurrence and/or progression, with the goal of modifying surveillance schedules as a function of predicted risk of recurrence or progression. All patients will be treated according to the treatment plan as outlined by their attending physician. The study will not require any deviation from the planned usual treatment.
62484665|NCT00633022|EXPERIMENTAL|LOSMAPIMOD 7.5 MG TWICE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod orally twice daily, each morning and evening for a period of 12 weeks
62692514|NCT03097978|EXPERIMENTAL|RIC arm system with pattern recognition|Subject will be fit with a custom socket and receive training on pattern recognition with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
62692515|NCT03097978|EXPERIMENTAL|RIC arm system with direct control|Subject will be fit with a custom socket and receive training on direct control with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
61933139|NCT06421207|ACTIVE_COMPARATOR|Cohort 2 Multiple Treatment Histology|Each subject will be treated at a specified depth (4mm). Treatment area 1 will have 3 treatments with the study device, each treatment 30 days apart starting on Day 0. Treatment area 2 will have 2 treatments with the study device 30 days apart starting on Day 30. Treatment area 3 will have a single treatment with the study device on Day 60. A non-treated control area will also be designated. Histology evaluations for all treatment areas and the control area will occur 30 days after the area 3 treatment (Day 90).
62326177|NCT06336798|EXPERIMENTAL|Pioglitazone, Then Placebo|Participants will first receive a 30 mg tablet of Pioglitazone once daily for 28 days. After a washout period of 14 days, they will then receive a Placebo tablet (matching Pioglitazone 30 mg tablet) once daily for 28 days.
62326178|NCT06336798|EXPERIMENTAL|Placebo, Then Pioglitazone|Participants will first receive a Placebo for 28 days. After a washout period of 14 days, they will then receive a 30 mg Pioglitazone tablet once daily for 28 days.
62326179|NCT06049654|ACTIVE_COMPARATOR|NVT ALLEGRA System TF|NVT ALLEGRA System TF
62326180|NCT06049654|EXPERIMENTAL|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM
62326181|NCT06284954|EXPERIMENTAL|Empasiprubart|Patients receiving Empasiprubart IV
62326182|NCT06284954|PLACEBO_COMPARATOR|Placebo|Patients receiving Placebo IV
62326183|NCT04967599|NO_INTERVENTION|Control (CONTROL)|Participants do not receive PHEN or GENE.
62326184|NCT04967599|EXPERIMENTAL|Phenotype Feedback (PHEN)|Participants receive the PHEN intervention.
62326185|NCT04967599|EXPERIMENTAL|Phenotype and Genotype Feedback (PHEN+GENE)|Participants receive the PHEN and GENE interventions.
62326186|NCT02809443|EXPERIMENTAL|GLS-5700 at 1 mg|DNA/dose
62326187|NCT02809443|EXPERIMENTAL|GLS-5700 at 2 mg|DNA/dose
62326188|NCT05044273||Coronary Artery Disease|
62326189|NCT06463873||Omnigraft 3 month - 1 year Group 1|Subjects will be enrolled between 2 months and 1 year post Simultaneous Pancreas Kidney (SPK) transplant. Blood sample to test Omnigraft will be collected monthly month or every 3 months depending on the enrollment time, time of rejection, or when a biopsy is done.
62326190|NCT06463873||Omnigraft 1 year - 3 years Group 2|Subjects will be enrolled between 12 months and 3 year post SPK transplant. Blood sample to test Omnigraft will be collected every 3 months, at the time of rejection or when a biopsy is done.
62326191|NCT06463873||Omnigraft 10 years Group 3|Subjects will be enrolled between 3 years to 10 years post SPK transplant. Then, blood samples to test Omnigraft will be collected every 3 months, time of rejection or when a biopsy is done.
62326192|NCT05872763||Retrospective cohort (Cohort 1)|All cases of unresectable stage IIIB/IIIC/IV NSCLC newly diagnosed between January 2020 and the date of the study initiation will be collected. All these participants will be followed up until death or lost-to-follow-up or until 12 months after the last participant is enrolled in cohort 2 in the study.
62326193|NCT05872763||Prospective cohort (Cohort 2)|The prospective enrollment of new cases of unresectable stage IIIB/IIIC/IV NSCLC will end up to 1 year after the first patient is enrolled (FPI) in Cohort 2.
62133299|NCT06358534|EXPERIMENTAL|intervention groups|An 8-session acceptance and commitment therapy-based psychoeducation was applied to chronic renal failure patients with eGFH values below 29 ml/dl/1.72m
62326194|NCT05977998|EXPERIMENTAL|Paclitaxel|Participant will receive paclitaxel every 2 weeks for 6 weeks, and then participants may have a gastrectomy based on what the doctor thinks is in your best interest. You may then receive additional paclitaxel every 2 weeks for 6 weeks.
62326195|NCT03194685|EXPERIMENTAL|Cohort 1: 10 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326196|NCT03194685|EXPERIMENTAL|Cohort 2: 20 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326197|NCT03194685|EXPERIMENTAL|Cohort 3: 35 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326198|NCT03194685|EXPERIMENTAL|Cohort 4: 50 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326199|NCT03194685|EXPERIMENTAL|Cohort 5: 75 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326200|NCT03194685|EXPERIMENTAL|Cohort 6: 100 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326201|NCT03194685|EXPERIMENTAL|Cohort 7: 150 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326202|NCT03194685|EXPERIMENTAL|Cohort 8: 225 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
62326203|NCT05608083|EXPERIMENTAL|HEARTS NOW|Participants in the HEARTS NOW group participants will participate in a weekly six-session online HEARTS class via Zoom about relationships.
62484666|NCT00633022|PLACEBO_COMPARATOR|Placebo|Participants received 1 tablet of placebo matching Losmapimod orally twice daily, each morning and evening for a period of 12 weeks.
62484667|NCT00633022|EXPERIMENTAL|LOSMAPIMOD 7.5 MG ONCE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod each morning once daily and placebo tablet each evening once daily orally for a period of 12 weeks.
62484668|NCT04981704|EXPERIMENTAL|Part 1: Itraconazole/Poziotinib Drug-drug interaction (DDI)|On Day 1 of Treatment period 1, a single oral dose of 8 milligrams (mg) poziotinib will be administered. On Day 1 of Treatment Period 2, 200 mg itraconazole oral solution will be administered twice a day (BID) followed by 200 mg itraconazole oral solution once daily (QD) for 7 consecutive days (Day 2 to Day 8) with a single oral dose of 8 mg poziotinib coadministered on Day 4.
62484669|NCT04981704|EXPERIMENTAL|Part 2: Phenytoin/Poziotinib DDI|On Day 1 of Treatment period 1, a single oral dose of 16 mg poziotinib will be administered. In treatment period 2, an oral dose of 100 mg phenytoin will be administered three times daily (TID) for 17 consecutive days (Day 1 to Day 17) with a single oral dose of 16 mg poziotinib coadministered on Day 14.
62484670|NCT04981704|EXPERIMENTAL|Part 3: Paroxetine/Poziotinib DDI|On Day 1 of Treatment Period 1, a single oral dose of 8 mg poziotinib will be administered. On Day 1 and Day 2 of Treatment Period 2, an oral dose of 20 mg paroxetine will be administered BID followed by 20 mg paroxetine QD for 9 consecutive days (Day 3 to Day 11) with a single oral dose of 8 mg poziotinib coadministered on Day 7.
62484671|NCT05124444|EXPERIMENTAL|Cases (tolerant patients)|
62484672|NCT05124444|EXPERIMENTAL|Controls|
62484673|NCT01664767|EXPERIMENTAL|Thermal water inhalation|Patients will perform 12 days of sulfur thermal water inhalation
62326204|NCT05608083|ACTIVE_COMPARATOR|HEARTS LATER|Participants in the HEARTS LATER group will participate in a six-week online support group via Zoom about relationships. Participants in this arm will have the option of taking the HEARTS class after the study has ended.
62326205|NCT05890976|EXPERIMENTAL|Semaglutide 50 mg|Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 44 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), 25 mg (weeks 13 to 16) and 50 mg (weeks 17 to 44).
62326206|NCT05890976|PLACEBO_COMPARATOR|Semaglutide Placebo|Participants will receive placebo tablets matched to semaglutide orally once daily for 44 weeks.
62326207|NCT06018753||Patients with cancer|No intervention or sample collection is required on the study.
62326208|NCT05319600|EXPERIMENTAL|Intervention|This arm will complete an intervention delivered remotely via an online website and online communication from the research team across the 12-week intervention period. This intervention has two parts, taking place simultaneously over the 12 weeks. First, participants will complete 8 web-delivered online behavior-change skills learning sessions which include reading and activities. Second, participants will be given daily and weekly personalized physical activity goals to meet, which will be tracked via their Garmin activity tracker and weekday text and if indicated video support. They have the opportunity to win money each week for meeting activity goals.
62326209|NCT05319600|NO_INTERVENTION|Treatment as usual - Control|This arm will not complete an intervention. Participants will be instructed to wear a Garmin activity tracker but will be given no other specific instructions, other than to continue to follow their normal daily diabetes care plan.
62326210|NCT06511063|EXPERIMENTAL|Truvada (Tenofovir Disoproxil Fumarate, TDF/FTC, tenofovir disoproxil/emtricitabine)|Participants will take 300mg tenofovir disoproxil fumarate/200 mg emtricitabine, once per day, oral capsule for 90 days.
62326211|NCT06511063|EXPERIMENTAL|Selzentry|Participants will take 300 mg of Selzentry, twice a day, oral capsule for 90 days.
62326212|NCT06511063|PLACEBO_COMPARATOR|Placebo|Participants will take a placebo, once per day, oral capsule for 90 days.
62326213|NCT05610644|ACTIVE_COMPARATOR|TRF of RDA|A time-restricted model of consumption of the RDA of protein/day.
62484674|NCT01664767|PLACEBO_COMPARATOR|Isotonic saline inhalation|Patients will perform 12 days of isotonic saline inhalation
62484675|NCT04542746|EXPERIMENTAL|Minimally invasive surgical technique|The intra-bony defects of subjects allocated in test group were treated with a combination of minimally invasive surgical technique (MIST) and enamel matrix derivative( EMD).
62692516|NCT03097978|EXPERIMENTAL|Commercial system with PR control|Subject will be fit with a custom socket and receive training on pattern recognition with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
62326214|NCT05610644|ACTIVE_COMPARATOR|TRAD of RDA|A typical American dietary ingestion pattern of the RDA of protein/day.
62326215|NCT05610644|EXPERIMENTAL|TRF of 2RDA|A time-restricted model of consumption of twice the RDA of protein/day.
62326216|NCT05610644|EXPERIMENTAL|TRAD of 2RDA|A typical American dietary ingestion pattern of twice the RDA of protein/day.
62484676|NCT04542746|ACTIVE_COMPARATOR|Conventional open flap debridement with papilla preservation|The intra-bony defects of control group were treated using a combination of conventional open flap debridement with papilla preservation (COFD+PP) and EMD.
62484677|NCT03896594|EXPERIMENTAL|HL237 200mg|HL237 100mg 1 tablet twice a day
62484678|NCT03896594|EXPERIMENTAL|HL237 400mg|HL237 100mg 2 tablets twice a day
62484679|NCT03896594|EXPERIMENTAL|HL237 800mg|HL237 400mg 1 tablet twice a day
62484680|NCT05835804|EXPERIMENTAL|Intratumoral chemotherapy|
62484681|NCT00567463|PLACEBO_COMPARATOR|Placebo|Placebo inhalator will be used by subjects in the placebo group(same course as patients in the treated group)
62484682|NCT05312983|EXPERIMENTAL|people over the age of 18 who agree to participate in the research.|They are either people who have a hearing loss about 20 years older than their age and wear a hearing aid (or come in for a hearing aid), or people over the age of 40 with normal hearing for their age.
61933140|NCT03367013|EXPERIMENTAL|Intervention Group|The intervention group will receive a daily dose of 200 mg/kg of bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
61933141|NCT03367013|SHAM_COMPARATOR|Control Group|The control group will receive daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
61933142|NCT03576222|ACTIVE_COMPARATOR|patients with preventive PICO|PICO dressing is used in patients with incisional hernia intraoperatively
62133300|NCT04743440||Physicians|We will include specialists in anaesthesiology who work at the Anaesthesiology Department, Hillerød hospital, during the trial period. It is an inclusion criterion that they take part in the Anaesthesiology Department's specialist in-house on-call rotation (i.e., attending physician). Each of the included physician participants will be responsible for conducting the airway management in four patient participants; two who have been randomised to the i-gelTM LMA, and two to the Ambu® AuraGainTM LMA, respectively.
62326217|NCT05475379|EXPERIMENTAL|Test vaccine group|"300 participants will receive Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)~Trade name: Typhocon®, Incepta Vaccine Ltd."
62326218|NCT05475379|ACTIVE_COMPARATOR|Reference vaccine group|"300 participants will receive Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TCV)~Trade name: Typbar-TCV®, Bharat-Biotech International Limited."
62326219|NCT06414733|EXPERIMENTAL|HER-2 vaccine Breast|
62326220|NCT06414733|EXPERIMENTAL|HER-2 vaccine GI|
62484683|NCT05613972|EXPERIMENTAL|Brief Suicide and Trauma Therapy (BSTT)|This novel suicide intervention integrates Brief Skills for Safer Learning (B-SfSL) with trauma therapy. BSTT incorporates the guiding principles of taking a non-pathologizing approach to treatment, emphasizing safety, attending to the therapeutic relationship, empowering clients, and incorporating solution-focused concepts.
62484684|NCT03373968|EXPERIMENTAL|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
62692517|NCT03097978|EXPERIMENTAL|Commercial system with Direct Control|Subject will be fit with a custom socket and receive training on direct control with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
62692518|NCT04846699||group 1|bulls eye localization
62692519|NCT04846699||group 2|stone targeted technique renal access
62692520|NCT04846699||group 3|triangulation renal access technique
62692521|NCT05314387||SMR TT Hybrid Glenoid without Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid without Cementless Finned Short Stem
62692522|NCT05314387||SMR TT Hybrid Glenoid with Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid with Cementless Finned Short Stem
62692523|NCT06068361||DLB patients|Dementia with Lewy bodies according to the revised criteria of Mc Keith 2017
62692524|NCT06068361||AD patients|Alzheimer's disease according to McKhann et al., 2011 criteria including CSF biomarkers (an abnormal level of beta-amyloid 1-42 protein \[Ab42\] or a pathological Ab42/Ab40 ratio and an abnormal level of phosphorylated tau \[p-tau\])
61933143|NCT03576222|PLACEBO_COMPARATOR|patients with preventive MEPORE|MEPORE dressing is used in patients with incisional hernia intraoperatively
61933144|NCT00764491|EXPERIMENTAL|Optimesh 1500S|OptiMesh 1500S, filled with a mixture of demineralized bone matrix (DBM) and cortico-cancellous bone, placed into the interbody space from the posterior approach and supplemental pedicle screws.
61933145|NCT00764491|ACTIVE_COMPARATOR|Structural Allograft Spacer|Structural Allograft Spacer with pedicle screws.
62133301|NCT01079949|EXPERIMENTAL|r-hLH + r-hFSH|
62133302|NCT01079949|ACTIVE_COMPARATOR|r-hFSH|
62133303|NCT06109493|EXPERIMENTAL|ACT group|8 individual weekly sessions which included ACT methods
62133304|NCT06109493|NO_INTERVENTION|Waiting list|Participants assigned to Waiting List arm waited for 5 months before receiving treatment
62326221|NCT05638295|EXPERIMENTAL|Cohort I Arm A (sotorasib, panitumumab)|Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
62326222|NCT05638295|ACTIVE_COMPARATOR|Cohort I Arm B (sotorasib)|Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
62326223|NCT05638295|EXPERIMENTAL|Cohort II (sotorasib, panitumumab)|Patients receive combination therapy as in Arm A.
62484685|NCT00235027|EXPERIMENTAL|Adverse Drug Event Monitoring|In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
62484686|NCT00235027|NO_INTERVENTION|Care as Usual|In this arm, clinicians did not receive the medication safety alerts.
62484687|NCT00521586|OTHER|1|arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
62484688|NCT00521586|OTHER|2|arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
62484689|NCT01751854|EXPERIMENTAL|SSRI|SSRI alone or with training
62484690|NCT01751854|PLACEBO_COMPARATOR|Placebo|Placebo alone or with training
62484691|NCT05825716||Ifaa Basic|comparison group
62484692|NCT05825716||Ifaa Enhanced|intervention group 1
62484693|NCT05825716||Ifaa Enhanced + Livelihoods|intervention group 2
62692525|NCT06068361||Control|Subjective cognitive complaint, with a normal brain MRI and neurological examination, without any elements in favor of a neurodegenerative disease
62692526|NCT01334567|EXPERIMENTAL|Tenofovir DF|
62692527|NCT03048825|ACTIVE_COMPARATOR|Colchicine + Spironolactone +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
62326224|NCT03908099|EXPERIMENTAL|Fit-For-Fertility program|The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
62326225|NCT03908099|ACTIVE_COMPARATOR|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months.
62326226|NCT05248386|EXPERIMENTAL|RTX-GRT7039|Participants will receive intra-articular injections of RTX-GRT7039 during the 52-week double-blind treatment period.
62326227|NCT05248386|PLACEBO_COMPARATOR|Placebo|Participants will receive intra-articular injections of placebo matching to RTX-GRT7039 during the 52-week double-blind treatment period.
62692528|NCT03048825|ACTIVE_COMPARATOR|Spironolactone +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
61933146|NCT06515522||Schizophrenia|All patients with schizophrenia recruited from 2007 and 2023
61933147|NCT06515522||Mood disorders|All patients with bipolar or major depressive disorders recruited from 2007 and 2023
61933148|NCT06515522||Controls|healthy controls
61933149|NCT02057393|EXPERIMENTAL|Indocyanine Green|Single arm study, each subject receives 0.9ml ICG, methylene blue and technetium 99.
61933150|NCT03376906|EXPERIMENTAL|Obese Subjetcs|The subjects were welcomed for a visit to the Laboratory of Studies of Physical Training Applied to Health, where they performed an evaluation of body composition, maximal ergospirometric exercise test, and three experimental sessions (HIIE 1, HIIE 3 and Control) in a random order, which were performed with a 96 h interval between them.
61933151|NCT06626958|EXPERIMENTAL|Vsisual Analog Scale (VAS)|The VAS scale will be used to evaluate the level of labor pain in the intervention and control groups.
61933152|NCT06626958|EXPERIMENTAL|Labor Comfort Scale|The birth comfort scale will evaluate the birth comfort of women in the intervention and control groups during birth.
61933153|NCT06084468||Cystic Fibrosis|"Adult CF patients (\>/=18 years) at Department of Infectious Diseases, Copenhagen University Hospital, will be invited to participate in this study. Potential participants are invited by their regular CF physician to participate during routine visits at the CF outpatient clinic.~Inclusion criteria:~Diagnosis of CF and age \>/=18 years.~Exclusion criteria:~* Lung transplanted patients~* Inability to cooperate~* Inability to understand and sign informed consent"
61933154|NCT06084468||Control group|The control group will consist of a random sample of age- and sex-matched participants from the general population examined in the 5th Copenhagen City Heart Study, 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
61933155|NCT01788176|PLACEBO_COMPARATOR|Saline|One single intravenous infusion of 100ml of saline (placebo control group).
61933156|NCT01788176|ACTIVE_COMPARATOR|Zoledronic acid|one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
61933157|NCT06339632|EXPERIMENTAL|Transcutaneous electrical phrenic nerve stimulation (TEPNS)|The technique will be performed by applying transcutaneous neuromuscular electrical stimulation to the phrenic nerve pathway in the cervical region.
61933158|NCT06339632|ACTIVE_COMPARATOR|Transcutaneous electrical diaphragm stimulation (TEDS)|The technique will be performed by applying transcutaneous neuromuscular electrical stimulation with the electrodes positioned bilaterally in the parasternal region adjacent to the xiphoid process, and the other electrode placed in the intercostal space.
61933159|NCT01598168|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
61933160|NCT02068456||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved Korean label.
61933161|NCT01086293||Patients exposed to Saxagliptin|
61933162|NCT01086293||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
61933163|NCT03063203|EXPERIMENTAL|Decitabine|"* Cycle 1: All patients will receive decitabine 20 mg/m\^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle~* Cycle 2: Patients with bone marrow blast counts \< 5% may receive decitabine 20 mg/m\^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m\^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.~* Cycle 3 and subsequent cycles: All patients will receive 20 mg/m\^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle"
61933164|NCT02922595|ACTIVE_COMPARATOR|Intubation through ILMA®|The ILMA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. The Intervention will be the intubation through ILMA. We will measure the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
61933165|NCT02922595|EXPERIMENTAL|Intubation through ILTS®|The ILTA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. It will be proceeded to the intubation through ILTS and the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
62692529|NCT03048825|ACTIVE_COMPARATOR|Colchicine +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
61933166|NCT03538431|EXPERIMENTAL|Buspirone|These subjects will receive buspirone prior to engaging in the driving simulation.
61933167|NCT03538431|EXPERIMENTAL|Unmedicated|These subjects will take no medication prior to engaging in the driving simulation
62692530|NCT03048825|PLACEBO_COMPARATOR|Placebo +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
61933168|NCT00596856|ACTIVE_COMPARATOR|1|25 randomly selected pediatric practices that have never participated in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to non-participating practices)
61933169|NCT00596856|EXPERIMENTAL|2|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to participating practices)
62326228|NCT03731234|EXPERIMENTAL|Ibrutinib+R-CHOP|Screening phase for selection of Activated-B-Cell (ABC)-DLBCL Induction phase: R-CHOP21 x 5 cycles in combination with ibrutinib Maintenance phase: maintenance with Ibrutinib for 18 months for patients responding to the induction phase (CR or PR)
62326229|NCT02321501|EXPERIMENTAL|Treatment (ceritinib, everolimus)|Patients receive ceritinib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62326230|NCT05929430|EXPERIMENTAL|Mindfulness-Based Health Care Program (MBHC).|Mindfulness skills will take over a 6-week period. Mindfulness skills will deliver in a weekly group format. Participants will be instructed to follow mindfulness practice at home. The program is focused on cultivating mindfulness of present-moment, cultivating a nonreactive, nonjudgmental attitude toward the experience, and includes specific formal and informal practices aimed at cultivating healthy habits and lifestyle (e.g., activities of daily living such as feeding, bathing, or showering and other occupations such as communication management, health management, etc.; and prosocial components (e.g., kindness and compassion).
62326231|NCT05929430|EXPERIMENTAL|Mindfulness-Based Health Care program with virtual reality (MBHC-VR).|This program combines mindfulness practice with immersion in a virtual environment. The content and objectives of MBHC-VR program are the same that MBHC, with the main difference being that all formal practices of each session will be performed using VR.
62326232|NCT05929430|NO_INTERVENTION|Waiting list control group (WL).|Participants in the WL control group will not receive any intervention during the study. However, for ethical reasons, at the end of the 3-month follow-up assessment, participants of this WL control group will be invited to participate in the MBHC program free of charge.
62326233|NCT05475925|EXPERIMENTAL|Part A Dose Escalation 1 mg/kg of DR-01|Subjects in this arm will initially receive 1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 6 mg/kg) thereafter for up to 25 cycles total.
62326234|NCT05475925|EXPERIMENTAL|Part A Dose Escalation 3 mg/kg of DR-01|Subjects in this arm will initially receive 3 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
62326235|NCT05475925|EXPERIMENTAL|Part A Dose Escalation 6 mg/kg of DR-01|Subjects in this arm will initially receive 6 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
62326236|NCT05475925|EXPERIMENTAL|Part A Dose Escalation 10 mg/kg of DR-01|Subjects in this arm will initially receive 10 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
62326237|NCT05475925|EXPERIMENTAL|Part A Dose De-escalation 0.3 to <1 mg/kg of DR-01|This cohort would only be triggered should a DLT occur at Dose Level 1 or if recommended by the Safety Review Committee. Subjects in this arm would initially receive 0.3 to \<1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 3 mg/kg) thereafter for up to 25 cycles total.
62326238|NCT05475925|EXPERIMENTAL|Part B Dose Expansion (Cohort B1) Optimized Dose/Regimen of DR-01|Subjects in this arm will receive the pharmacologically optimized dose/regimen for LGL leukemia subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
62326239|NCT05475925|EXPERIMENTAL|Part B Dose Expansion (Cohort B2) Optimized Dose/Regimen of DR-01|Subjects in this arm will receive the pharmacologically optimized dose/regimen for cytotoxic lymphoma subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
62326240|NCT06298396|EXPERIMENTAL|MAPs on Cochlear™ Nucleus® 7, Nucleus® 8 and Kanso® 2 Sound Processors|Participants will receive four different MAPs to use during two take-home periods and will then complete hearing assessments using each MAP.
62326241|NCT06223516|EXPERIMENTAL|ABBV-383 Dose A|Participants will receive Dose A of ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusions, during the 151 week study duration.
62692531|NCT04150497|EXPERIMENTAL|Dose Escalation|"Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART22 administered at the RP2D"
62692532|NCT05934396|ACTIVE_COMPARATOR|Enhanced Control|Cognitive Behavioral Therapy (CBT) Worksheets
62692533|NCT05934396|ACTIVE_COMPARATOR|Affect Regulation|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation
62133305|NCT05715437|EXPERIMENTAL|Bupivacaine plus Normal Saline|30 patients will receive bolus shot 20ml of 0.5% of Bupivacaine plus 1ml Normal saline postoperative TKA.
62133306|NCT05715437|EXPERIMENTAL|Bupivacaine and Ketamine|30 patients will receive bolus shot 20ml of 0.5% of Bupivacaine plus 1ml ketamine (50mg) postoperative TKA.
61933170|NCT00596856|EXPERIMENTAL|3|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through an intense in-office intervention. (Intense intervention with participating practices)
62326242|NCT06223516|EXPERIMENTAL|ABBV-383 Dose B|Participants will receive Dose B of ABBV-383 as an SC injection and IV infusions, during the 151 week study duration.
62484694|NCT05928247|EXPERIMENTAL|Functional Analysis Treatment for Harmful Challenging Behavior|If challenging behavior is found to be socially maintained, the investigators will recommend functional communication training (FCT) to teach a functional communication response (FCR) (e.g., touching a card with a picture of the participant consuming the reinforcer), but the investigators will also offer NCR as a potential treatment option to the caregivers. During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. If the parents choose NCR over FCT for socially maintained challenging behavior, the investigators will deliver the functional and competing reinforcers on time-based schedules. If challenging behavior is found to be automatically maintained, the investigators will recommend using NCR with competing items and response blocking for treatment. The investigators will use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of these treatments.
62484695|NCT05928247|EXPERIMENTAL|Functional Analysis Treatment for Milder Challenging Behavior|Caregivers of patients with mild challenging behavior will receive training using the Research Units in Behavioral Intervention (RUBI) protocol informed by the functional analysis conducted as a part of the initial assessment (Bearss et al., 2018). The RUBI protocol includes 11 core modules and 7 optional modules on training caregivers to apply behavior-analytic techniques to help manage challenging behaviors.
62692534|NCT05934396|ACTIVE_COMPARATOR|Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Problem Solving
62692535|NCT05934396|ACTIVE_COMPARATOR|Affect Regulation + Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation; VR Enhanced Problem Solving
62692536|NCT05934396|ACTIVE_COMPARATOR|Cognitive Restructuring|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Cognitive Restructuring
62692537|NCT05934396|ACTIVE_COMPARATOR|Affect Regulation + Cognitive Restructuring|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation; VR Enhanced Cognitive Restructuring
62692538|NCT05934396|ACTIVE_COMPARATOR|Cognitive Restructuring + Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Cognitive Restructuring; VR Enhanced Problem Solving
62692539|NCT05934396|ACTIVE_COMPARATOR|Affect Regulation + Cognitive Restructuring + Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation; VR Enhanced Cognitive Restructuring; VR Enhanced Problem Solving
62692540|NCT06564532|EXPERIMENTAL|Servicemember and partner paired with positive stimuli|Both the servicemember and the partner of the servicemember see their partner paired with positive stimuli
62692541|NCT06564532|EXPERIMENTAL|Servicemember partner paired with positive stimuli, servicemember paired with neutral stimuli|The servicemember sees the partner paired with positive stimuli and the partner sees the servicemember paired with neutral stimuli
62326243|NCT06223516|EXPERIMENTAL|ABBV-383 Expansion|Participants will receive the selected dose from Arm A of ABBV-383 as SC injections, during the 151 week study duration.
62326244|NCT06550830|EXPERIMENTAL|Experimental group 1|"12 participants aged 6-17 years and 30 participants aged 2-5 years will be randomized to receive Sinovac PCV24 formulation 1. Route of administration is intramuscular injection at deltoid muscle of upper arm.~Immunization schedule is 1 dose."
62326245|NCT06550830|EXPERIMENTAL|Experimental group 2|"12 participants aged 6-17 years and 30 participants aged 2-5 years will be randomized to receive Sinovac PCV24 formulation 2. Route of administration is intramuscular injection at deltoid muscle of upper arm.~Immunization schedule is 1 dose."
62326246|NCT06550830|ACTIVE_COMPARATOR|Active control group|"30 participants aged 2-5 years will be randomized to receive Prevenar13®. Route of administration is intramuscular injection at deltoid muscle of upper arm.~Immunization schedule is 1 dose."
62326247|NCT06389136|EXPERIMENTAL|Period 1: Upadacitinib Open Label Treatment|"Participants randomly assigned to receive Upadacitinib Dose A tablet once per day.~Based on clinical response, participants randomized to Upadacitinib Dose A will have their dose increased to Upadacitinib Dose B starting at Week 2."
62326248|NCT06389136|EXPERIMENTAL|Period 1: Dupilumab Open Label Treatment|Participants randomly assigned to receive Dupilumab Dose A SC injection once every other week for 8 weeks.
62326249|NCT06389136|EXPERIMENTAL|Period 2 Open Label: Upadacitinib < EASI 75 response|Participants that were receiving Upadacitinib Dose A or Dose B and completed Period 1, will be allocated or continue to receive oral doses of Upadacitinib Dose B in Period 2 with a clinical response of \< EASI 75 at Week 8
62484696|NCT00835614|EXPERIMENTAL|1|
62484697|NCT00835614|ACTIVE_COMPARATOR|2|
62326250|NCT06389136|EXPERIMENTAL|Period 2 Open Label: Upadacitinib ≥ EASI 75 Response|Participants that were receiving Upadacitinib Dose A or Dose B and completed Period 1, will continue to receive the same oral doses of Upadacitinib in Period 2 with a clinical response of ≥ EASI 75 at Week 8
62692542|NCT06564532|EXPERIMENTAL|Servicemember partner paired with neutral stimuli, servicemember paired with positive stimuli|The servicemember sees the partner paired with neutral stimuli and the partner sees the servicemember paired with positive stimuli
62692543|NCT06564532|NO_INTERVENTION|Servicemember and partner paired with neutral stimuli|Both the servicemember and the partner of the servicemember see their partner paired with neutral stimuli
62692544|NCT06549452|ACTIVE_COMPARATOR|mHealth Intervention|Patients will be randomized to the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
62692545|NCT06549452|OTHER|Usual Care|Routine medical care
61933171|NCT05199740||mtDNA mutation carriers|Carriers of a pathogenic mtDNA mutation
61933172|NCT00723216|ACTIVE_COMPARATOR|1|Enoxaparin
61933173|NCT00723216|OTHER|2|Intermittent Pneumatic Compression (IPC)
61933174|NCT05472324|PLACEBO_COMPARATOR|Placebo|Placebo, subcutaneous administration, 4 weeks as a treatment cycle.
62326251|NCT06389136|EXPERIMENTAL|Period 2 Open Label: Dupilumab ≥ EASI 75 Response|Participants that were receiving Dupilumab Dose A and completed Period 1, will continue to receive Dupilumab Dose A SC injection in Period 2 with a clinical response of ≥ EASI 75 at Week 8
62326252|NCT06389136|EXPERIMENTAL|Period 2 Open Label Period: Dupilumab < EASI 75 Response|Participants that were receiving Dupilumab Dose A and completed Period 1, will receive oral doses of Upadacitinib Dose A in Period 2 with a clinical response of \< EASI 75 at Week 8
62326253|NCT06357130||Transgender|Transgender population in France, male to female and female to male.
62326254|NCT04442425||1DF/NoPain_IV-VI_Female|Worst pain in past month = 0; Skin Type IV-VI, Female
62692546|NCT00626951|EXPERIMENTAL|1|LMA Supreme
61933175|NCT05472324|EXPERIMENTAL|TQC2731 injection 70 mg|TQC2731 injection 70 mg, subcutaneous administration, 4 weeks as a treatment cycle.
61933176|NCT05472324|EXPERIMENTAL|TQC2731 injection 210 mg|TQC2731 injection 210 mg, subcutaneous administration, 4 weeks as a treatment cycle.
62692547|NCT00626951|EXPERIMENTAL|2|LMA ProSeal
62692548|NCT00459550|EXPERIMENTAL|Part A|Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
61933177|NCT05472324|EXPERIMENTAL|TQC2731 injection 420 mg|TQC2731 injection 420 mg, subcutaneous administration, 4 weeks as a treatment cycle.
61933178|NCT06708819||Participants undergoing resection of colorectal disease by segmental resection and anastomosis|"Participants will be having indocyanine green fluorescence angiography (ICGFA) performed during their procedure as per routine practice of the operating surgeon.~Once presented for ICGFA, with the surgeon's confirmation of the level clinically judged appropriate for transection, the segment(s) of interest is positioned in focus and the recording is begun. ICG is administered and the angiography is interpreted by the operating surgeon to guide the site of transection, which is indicated within the same recording.~The video image will be subjected to real-time analysis by the AI model with a representative interpretation of the ICGFA signal generated by the model, however the surgeon will be blinded to this interpretation.~The procedure will then continue and conclude as per routine practice."
61933179|NCT04568889|EXPERIMENTAL|Government/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
61933180|NCT04568889|EXPERIMENTAL|Government/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
61933181|NCT04568889|EXPERIMENTAL|Government/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
61933182|NCT04568889|EXPERIMENTAL|Government/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
62326255|NCT04442425||1DM/NoPain_IV-VI_Male|Worst pain in past month = 0; Skin Type IV-VI, Male
62326256|NCT04442425||1LF/NoPain_I-III_Female|Worst pain in past month = 0; Skin Type I-III, Female
62326257|NCT04442425||1LM/NoPain_I-III_Male|Worst pain in past month = 0; Skin Type I-III, Male
62326258|NCT04442425||2DF/MildPain_IV-VI_Female|Worst pain in past month = 1-3; Skin Type IV-VI, Female
62326259|NCT04442425||2DM/MildPain_IV-VI_Male|Worst pain in past month = 1-3; Skin Type IV-VI, Male
62692549|NCT00459550|EXPERIMENTAL|Part B|"Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:~First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow"
62326260|NCT04442425||2LF/MildPain_I-III_Female|Worst pain in past month = 1-3; Skin Type I-III, Female
62484698|NCT06563258|EXPERIMENTAL|Whole Body Vibration Training in Patients With Knee Osteoarthritis|Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks.
62484699|NCT06563258|EXPERIMENTAL|Biodex Balance Training in Patients With Knee Osteoarthritis|"Group B will receive Biobex training, Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals in addition to traditional exercises,3 sessions per week for four weeks.~-"
62484700|NCT06563258|EXPERIMENTAL|traditional exercises in Patients With Knee Osteoarthritis|Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise.
62484701|NCT01322321|EXPERIMENTAL|ACZ885|
62484702|NCT01322321|PLACEBO_COMPARATOR|Placebo|
62484703|NCT00503789|ACTIVE_COMPARATOR|1|cow-milk based infant formula
62692550|NCT03802851|EXPERIMENTAL|Holmium Laser Enucleation of Prostate (HoLEP)|Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
62692551|NCT03802851|NO_INTERVENTION|Control Arm|Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
62692552|NCT05510934||Shared-care Group|The Shared-care Group will comprise of patients who are receiving long term follow-up care for their condition by their PCP.
62692553|NCT05510934||Control Group|The Control Group will be made of patients who are receiving long term follow-up care for their condition of low-risk DTC at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC).
62326261|NCT04442425||2LM/MildPain_I-III_Male|Worst pain in past month = 1-3; Skin Type I-III, Male
62692554|NCT04054362|EXPERIMENTAL|With Cisplatin|Paclitaxel Protein bound, Cisplatin, and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
62692555|NCT04054362|EXPERIMENTAL|Without Cisplatin|Paclitaxel Protein bound and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
61933183|NCT04568889|EXPERIMENTAL|Researchers/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
61933184|NCT04568889|EXPERIMENTAL|Researchers/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
62326262|NCT04442425||3DF/ModPain_IV-VI_Female|Worst pain in past month = 4-6; Skin Type IV-VI, Female
62326263|NCT04442425||3DM/ModPain_IV-VI_Male|Worst pain in past month = 4-6; Skin Type IV-VI, Male
62326264|NCT04442425||3LF/ModPain_I-III_Female|Worst pain in past month = 4-6; Skin Type I-III, Female
62326265|NCT04442425||3LM/ModPain_I-III_Male|Worst pain in past month = 4-6; Skin Type I-III, Male
62326266|NCT04442425||4DF/SeverePain_IV-VI_Female|Worst pain in past month = 7-10; Skin Type IV-VI, Female
62326267|NCT04442425||4DM/SeverePain_IV-VI_Male|Worst pain in past month = 7-10; Skin Type IV-VI, Male
62326268|NCT04442425||4LF/SeverePain_I-III_Female|Worst pain in past month = 7-10; Skin Type I-III, Female
62326269|NCT04442425||4LM/SeverePain_I-III_Male|Worst pain in past month = 7-10; Skin Type I-III, Male
62326270|NCT04600323|PLACEBO_COMPARATOR|Placebo|Placebo medication will be used at a dose of 0.5 mEq/kg-lean body weight/day
62326271|NCT04600323|EXPERIMENTAL|Sodium bicarbonate|Sodium bicarbonate will be used at a dose of 0.5 mEq/kg-lean body weight/day.
62326272|NCT06180837|NO_INTERVENTION|Control Group|Provided with general health information on diet and physical activity.
62326273|NCT06180837|EXPERIMENTAL|Intervention Group|Sleep extension-based intervention focused on increasing time in bed by 2 hours per night.
62326274|NCT03217422|EXPERIMENTAL|Arm 1|VAY736 Dose 1
62484704|NCT00503789|EXPERIMENTAL|2|cow milk based infant formula with prebiotics
62484705|NCT00503789|OTHER|3|human milk reference group
62484706|NCT01978886||Patient with diabetes|Patients who have been diagnoses with diabetes.
62484707|NCT01978886||Patients without diabetes|Patients who have not previous been diagnosed with diabetes.
62484708|NCT05724394|EXPERIMENTAL|Ca-GBBB arm|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months. Sessions will be delivered weekly and each session will last about 45-50 minutes. All sessions will be delivered by master level psychologist. The manual will be translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios will be incorporated and a consensual view to addressing cultural factors such as gender role, financial difficulties will be taken into consideration. The time and venue of session will be decided prior according to participant convenience.
62484709|NCT05724394|NO_INTERVENTION|Treatment As Usual|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4-month post-randomization.
62326275|NCT03217422|EXPERIMENTAL|Arm 2|VAY736 Dose 2
62326276|NCT03217422|EXPERIMENTAL|Arm 3|VAY736 Dose 3
62326277|NCT03217422|PLACEBO_COMPARATOR|Arm 4|Placebo
62326278|NCT05414136|EXPERIMENTAL|A1/3mg/kg|Dose: 3mg/kg
62326279|NCT05414136|EXPERIMENTAL|A2/6mg/kg|Dose: 6mg/kg
62326280|NCT05414136|EXPERIMENTAL|A3/10mg/kg|Dose: 10mg/kg
62326281|NCT05414136|EXPERIMENTAL|A4/15mg/kg|Dose: 15mg/kg
62326282|NCT05414136|EXPERIMENTAL|A5/20mg/kg|Dose: 20mg/kg
62326283|NCT05109728|EXPERIMENTAL|Group 1 - Newly diagnosed GB|Participants with newly diagnosed glioblastoma will receive \[177Lu\]Lu-DOTA-TATE every 4 weeks +/- 2 days, starting 7 to 10 days prior to initiation of Radiotherapy (RT) and Temozolomide (TMZ)
62326284|NCT05109728|EXPERIMENTAL|Group 3 - Recurrent GB|Participants with recurrent glioblastoma will receive \[177Lu\]Lu-DOTA-TATE as single agent therapy every 3 weeks +/- 2 days
62326285|NCT06202872|EXPERIMENTAL|Active tACS|Gamma (40 Hz) tACS at the precuneus region
62326286|NCT06202872|SHAM_COMPARATOR|Sham tACS|Sham tACS at the precuneus region
62326287|NCT03922529|ACTIVE_COMPARATOR|Usual Care|Care after an acute heart event will be at the discretion of the participants' clinical providers.
62326288|NCT03922529|EXPERIMENTAL|MACRO-I|A coaching intervention that supplements usual care.
62484710|NCT00715442|EXPERIMENTAL|Sunitinib + Nephrectomy|Sunitinib 50 mg by mouth daily for 28 consecutive days. Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
62692556|NCT00847730|EXPERIMENTAL|VAC GranuFoam Bridge Dressing|This is a medical device foam dressing allowing placement away from wound site. It is designed to simplify the bridging application. It is used in combination with the V.A.C. Negative Pressure Wound Therapy System. For each subject, the dressing was applied in compliance with the IFU for 48-72 hours.
62692557|NCT04816721|EXPERIMENTAL|EDP-938|EDP-938, oral suspension, once daily for 5 days
62692558|NCT04816721|PLACEBO_COMPARATOR|Placebo|Matching placebo, orally, once daily for 5 days
62692559|NCT00800345|EXPERIMENTAL|Experimenal|Metronomic oral topotecan and oral pazopanib will be administered by mouth beginning on Cycle 1 Day 1. Patients will be enrolled and observed for dose limiting toxicity (DLT) for 1 cycle of treatment. Dose modification of the combination will depend on the number of patients experiencing DLT(s) at each dose level.
62692560|NCT06639373||R2R Service Access|Individuals with a substance use disorder who access or are admitted to an R2R service
62692561|NCT00242892|EXPERIMENTAL|1|Intra coronary measures of pressure
61933185|NCT04568889|EXPERIMENTAL|Researchers/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
61933186|NCT04568889|EXPERIMENTAL|Researchers/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
61933187|NCT04568889|EXPERIMENTAL|Government/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
61933188|NCT04568889|EXPERIMENTAL|Government/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
61933189|NCT04568889|EXPERIMENTAL|Government/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
61933190|NCT04568889|EXPERIMENTAL|Government/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
61933191|NCT04568889|EXPERIMENTAL|Researchers/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
61933192|NCT04568889|EXPERIMENTAL|Researchers/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
62326289|NCT05382286|EXPERIMENTAL|Sacituzumab Govitecan-hziy (SG) + Pembrolizumab|"Participants will receive SG 10 mg/kg on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg on Day 1 of 21-day cycles~Pembrolizumab will be administered for a maximum of 35 cycles."
62326290|NCT05382286|ACTIVE_COMPARATOR|Pembrolizumab + Treatment of Physician's Choice (TPC)|"Participants will receive pembrolizumab 200 mg on Day 1 of each 21-day cycle (maximum 35 cycles) plus TPC determined prior to randomization from 1 of the 3 allowed regimens:~* Paclitaxel 90 mg/m\^2 on Days 1, 8, and 15 of 28-day cycles~* nab-Paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of 28-day cycles~* Gemcitabine 1000 mg/m\^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of 21-day cycles"
62326291|NCT05875805|EXPERIMENTAL|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
62326292|NCT05875805|OTHER|Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
62484711|NCT04896580|EXPERIMENTAL|Active|Participants will be asked to complete a 12 week exercise program
62692562|NCT06675656||1M. Predictive role of microbiome in male with low grade NMIBC undergoing Gem/Dox.|Predictive role of microbiome in male with low grade non-muscle invasive bladder carcinoma undergoing Gem/Dox.
62692563|NCT06675656||1F. Predictive role of microbiome in female with low grade NMIBC undergoing Gem/Dox.|Predictive role of microbiome in female with low grade non-muscle invasive bladder carcinoma undergoing Gem/Dox.
62692564|NCT06675656||2M. Predictive role of microbiome in male with intermediate grade NMIBC undergoing MMC.|Predictive role of microbiome in male with intermediate grade non-muscle invasive bladder carcinoma undergoing MMC.
62692565|NCT06675656||2F. Predictive role of microbiome in female with intermediate grade NMIBC undergoing MMC.|Predictive role of microbiome in female with intermediate grade non-muscle invasive bladder carcinoma undergoing MMC.
62326293|NCT03949387|EXPERIMENTAL|FES Cycling Exercise|FES cycling will involve systematic, transcutaneous electrical stimulation of the leg muscles to produce leg-cycling movement. The intensity and duration of training will be prescribed based on guidelines for aerobic exercise training for persons with MS and from the American College of Sports Medicine, and will progressively increase across 24 weeks. Participants will be encouraged to actively cycle at a minimum cadence of \~40-50 rpm, at 40-60% VO2peak for between 10-50 minutes. The intensity of stimulation will be adjusted per leg muscle group based on sensory tolerance with the goal of maintaining pedaling action and target heart rate over the entire session. At each session, we will record the distance traveled, energy expended, power output, resistance, heart rate and rating of perceived exertion (RPE).
62326294|NCT03949387|PLACEBO_COMPARATOR|Passive Leg Cycling|Passive leg cycling will involve movement of the participant's legs by the cycle ergometer motor without electrical stimulation. The duration of training will follow the same schedule as the FES cycling condition and the same data will be recorded at each session. The passive cycling condition will include the same exposure with the training facility, the exercise equipment (i.e. RT300 cycles), and the research staff (i.e. social contact and attention) as with the FES cycling condition.
62326295|NCT02627443|EXPERIMENTAL|Treatment (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62326296|NCT00978003||1/Healthy Volunteers|Adults age 18-55.
62326297|NCT05139914|EXPERIMENTAL|Dapagliflozin then Placebo|Participants in this arm will receive dapagliflozin and then placebo with a 2 week wash out period in between.
62326298|NCT05139914|PLACEBO_COMPARATOR|Placebo then dapagliflozin|Participants in this arm will receive placebo and then dapagliflozin with a 2 week wash out period in between.
62326299|NCT04925388|EXPERIMENTAL|multiplex PCR|peritoneal samples will be analysed using Unyvero IAI test and using conventional method
62484712|NCT05553444|EXPERIMENTAL|Self-management intervention|"The intervention is based on the 5 key skills for successful self-management which are;~1. Problem solving~2. Decision-making~3. Utilizing resources~4. Forming partnerships with healthcare providers~5. Taking action. It is important to keep in mind, that not all included patients will necessarily lack all 5 skills. As such, the intervention will be tailored to each participant based on the initial assessment and continuous clinical reasoning."
62484713|NCT03639181|EXPERIMENTAL|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
62484714|NCT06212479||MRI Scan Arm|Whole Body MRI Scan
62484715|NCT01438593|EXPERIMENTAL|HUCB, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
62484716|NCT00704639|EXPERIMENTAL|Single arm|Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
61933193|NCT04568889|EXPERIMENTAL|Researchers/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
62326300|NCT04925388|OTHER|conventional method|peritoneal samples will be analysed using only conventional method
62326301|NCT00001506||Patients|With dermatologic diseases and systemic diseases with cutaneous manifestations
62326302|NCT03076554|EXPERIMENTAL|Arm 1 Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
62692566|NCT06675656||3M. Predictive role of microbiome in male with high grade NMIBC undergoing BCG.|Predictive role of microbiome in male with high grade non-muscle invasive bladder carcinoma undergoing BCG.
61933194|NCT04568889|EXPERIMENTAL|Researchers/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
61933195|NCT03188627|EXPERIMENTAL|Bronchial basal cells|Transplantation of autologous bronchial basal cells
61933196|NCT03188627|NO_INTERVENTION|Control|Conventional treatment
61933197|NCT02155569|ACTIVE_COMPARATOR|Transperitoneal Cesarean|
62326303|NCT06262607|EXPERIMENTAL|CLE-400 (Detomidine topical gel)|Topical CLE-400 gel 0.28% once daily
62326304|NCT06262607|PLACEBO_COMPARATOR|Vehicle|Topical vehicle gel once daily
62326305|NCT04421963|EXPERIMENTAL|Olaparib|Treatment
62326306|NCT03930199|EXPERIMENTAL|Not Meeting Mobility Goals|After the first three months of sensor monitoring, participants not meeting goals will receive an intervention (others will be removed from the study). The intervention assigned is not pre-determined, but will be assigned by an expert panel based on the individual needs determined from the assessment results and monitoring data. The intervention may include prosthetic care, physical therapy, motivational interviewing or other related psychological interventions, or a combination thereof. After three months of intervention, assessments are performed again and if improvement in prosthesis use is determined, participants are monitored for another three months to assess maintenance of prosthesis use (participants showing no improvement are removed from the study before these final three months of monitoring).
62326307|NCT05041257|EXPERIMENTAL|Mirvetuximab Soravtansine|Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)
62692567|NCT06675656||3F. Predictive role of microbiome in female with high grade NMIBC undergoing BCG.|Predictive role of microbiome in female with high grade non-muscle invasive bladder carcinoma undergoing BCG.
62692568|NCT01842347|EXPERIMENTAL|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
62692569|NCT06193681|EXPERIMENTAL|Pedi@ctivity Exercise Mobile Application|
61933198|NCT02155569|ACTIVE_COMPARATOR|Extraperitoneal Cesarean|
61933199|NCT04152707|EXPERIMENTAL|Splendor X|
61933200|NCT00884377|ACTIVE_COMPARATOR|Sodium stibogluconate intravenous|20 mg/kg/day Sodium stibogluconate intravenous
61933201|NCT00884377|EXPERIMENTAL|ThermoMed device|ThermoMed device, single heat treatment at 50 degrees Celsius
61933202|NCT05753618|ACTIVE_COMPARATOR|Receive G-CSF|Receive G-CSF injections (either filgrastim or pegfilgrastim) after each cycle of paclitaxel chemotherapy.
61933203|NCT05753618|EXPERIMENTAL|Omission of G-CSF|Omission of G-CSF injections after each cycle of paclitaxel chemotherapy.
62326308|NCT04549168|EXPERIMENTAL|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
62326309|NCT04549168|PLACEBO_COMPARATOR|Placebo|Participants will receive one placebo matched to lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
62484717|NCT05658393|EXPERIMENTAL|ReLiver-N App Group|"The ReLiver-N App will be introduced to the participants with liver cirrhosis during face-to-face interviews. The ReLiver-N App group will have access to all the contents of the ReLiver-N App, which includes the about us, patient education information about liver cirrhosis , patient activity skills, and measuring tools. During the follow-up period, the participants in the ReLiver-N App group will take WhatsApp messages once a week and be reminded to use the education program. The ReLiver-N App will be asked to use it for three months on daily and weekly inputs their results. During the follow-up period, the participants can contact researcher via the 24/7 on the ReLiver-N App. The clinical researchers of the team will answer the participant' questions via WhatsApp. Participants in the ReLiver-N group will also receive routine patient education and routine hospital follow-ups given by the Gastroenterology team."
62484718|NCT05658393|ACTIVE_COMPARATOR|Active Control Group|"The ReLiver-N App will be introduced to the participants with liver cirrhosis in the active control group during face-to-face interviews. The active control group will have access to only these fields about us, patient activity skills, and measuring tools. Participants in the active control group will also receive routine patient education and routine hospital follow-ups given by the Gastroenterology team during the three-month follow-up period."
62484719|NCT05589753|EXPERIMENTAL|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during non-rapid eye movement sleep (NREM) sleep.
62484720|NCT05589753|EXPERIMENTAL|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 6 days, While on the medication following studies will be performed - experimental night study, experimental day study, polysomnography night study (PSG).
62484721|NCT05917522|NO_INTERVENTION|Observational Study - Full Cohort|"800 adults first kidney transplant recipients will be followed observationally to evaluate HLA-DR/DQ molecular mismatch (mMM) as a risk-stratifying prognostic biomarker.~Donor-recipient HLA-DR/DQ mMM score will be determined at enrollment and recipients will be followed over 24-months post-kidney transplant for primary alloimmune events (i.e., TCMR, DSA, and ABMR).~Standard of care (SOC) therapy will be used to satisfy the FDA requirement to prospectively evaluate the HLA-DR/DQ mMM score as a prognostic biomarker for post-kidney transplant outcomes."
62484722|NCT05917522|EXPERIMENTAL|Nested RCT - Treatment Group (Abatacept)|"Eligible subjects will be re-consented and randomized to the investigational (abatacept/Mycophenolate mofetil (MMF)/Pred) Arm.~Starting with abatacept at a fixed dose (125 mg s.c. weekly) and eliminate Calcineurin Inhibitor (CNI) over \~3 months using serial Tacrolimus (TAC) C0 level targets to taper the dose.~2200 subjects will be followed for 18 months post-randomization, monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM).~Subjects who develop Biopsy Proven Acute Rejection (BPAR) will have concurrent serum/urine/tissue samples collected and stored."
62484723|NCT05917522|ACTIVE_COMPARATOR|Nested RCT - Control Group (SOC)|"Eligible subjects will be re-consented and randomized to the control group (tacrolimus/Mycophenolate mofetil (MMF)/Pred) .~100 subjects will be and followed for 18 months post-randomization, monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM).~Subjects who develop Biopsy Proven Acute Rejection (BPAR) will have concurrent serum/urine/tissue samples collected and stored."
62692570|NCT06193681|EXPERIMENTAL|Supervised Exercise Group|
62692571|NCT04569032|EXPERIMENTAL|CD30-negative Cohort|Participants with CD30 expression level \< 1%
62692572|NCT04569032|EXPERIMENTAL|CD30-positive Cohort|Participants with CD30 expression level ≥1% to \< 10%
62692573|NCT03742726|EXPERIMENTAL|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
62692574|NCT05046730|EXPERIMENTAL|Prospective Evaluation of the SFM Device|This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device
62692575|NCT05046730|ACTIVE_COMPARATOR|Retrospective Chart Review of Historical Controls|In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.
62692576|NCT06363981|EXPERIMENTAL|rTMS over the left DLPFC and over the left DMPFC|Active 10 Herz rTMS with intensity of 120% of the resting motor threshold recorded from the right first dorsal interosseus and the right abductor hallucis will be administered over the left DLPFC and over the left DMPFC respectively. Therapy will include 20 sessions (one session in each of 20 consecutive working days - four weeks in total). In every session ca 1500 magnetic pulses over the left DLPFC and ca 1500 over the left DMPFC will be elicited.
62692577|NCT06363981|ACTIVE_COMPARATOR|rTMS over the left DLPFC|Active 10 Herz rTMS with intensity of 120% of the resting motor threshold recorded from the right first dorsal interosseus will be administered over the left DLPFC. Therapy will include 20 sessions (one session in each of 20 consecutive working days - four weeks in total). In every session 3000 magnetic pulses over the left DLPFC will be elicited.
62326310|NCT00098072|EXPERIMENTAL|Pilot|Pilot
62326311|NCT06058741||Venetoclax + Azacitidine Participants|Participants treated with venetoclax in combination with azacitidine in accordance with approved local label.
62326312|NCT06074614||Parkison's disease|Participants with clinically confirmed Parkinson's disease, Hoehn and Yahr stage 1 to 3.
62326313|NCT06074614||Healthy controls|Participants without Parkinson's disease.
62326314|NCT05876780|EXPERIMENTAL|SRP-9003|Participants will receive single IV infusion of SRP-9003 on Day 1.
62326315|NCT01294332|EXPERIMENTAL|Exercise|Aerobic exercise performed for 12 weeks
62326316|NCT06236438|EXPERIMENTAL|Stage 1 (Cohort 1): Livmoniplimab Dose A|Participants will receive livmoniplimab (dose A)+ budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
62484724|NCT03849651|EXPERIMENTAL|Transplant participants|"Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days.~Cells for infusion are prepared using the CliniMACS system."
62484725|NCT04736303|NO_INTERVENTION|POD without BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery, with CAM and Nu-DESC tools.
62484726|NCT04736303|ACTIVE_COMPARATOR|POD with BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery with the implementation of BIS monitoring, with CAM and Nu-DESC tools.
62484727|NCT03300011|EXPERIMENTAL|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
62484728|NCT03300011|NO_INTERVENTION|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
62484729|NCT03300011|NO_INTERVENTION|OMT|Patients with CTO lesion optimal medicine treatment without PCI
62484730|NCT01899989|EXPERIMENTAL|A) >5cm,Chemo eligible (closed to accrual)|Patients will receive five fractions of either 8, 10, or 12 Gy to the gross tumor only. Following SBRT patients will be evaluated by their medical oncologist for consideration of adjuvant chemotherapy, starting 6-8 weeks post-RT. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy by their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year.
61933204|NCT00208299|EXPERIMENTAL|1|Regadenoson
62484731|NCT01899989|EXPERIMENTAL|B) 3-5cm OR Chemo ineligible|Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in \< 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in \< 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
62484732|NCT01240850|ACTIVE_COMPARATOR|Prednisone|
61933205|NCT00208299|ACTIVE_COMPARATOR|2|Adenoscan
61933206|NCT01550471|EXPERIMENTAL|1 Treatment Sequence-A and O, Q and B, P and P|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
62326317|NCT06236438|EXPERIMENTAL|Stage 1 (Cohort 2): Livmoniplimab Dose B|Participants will receive livmoniplimab (dose B) + budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
62326318|NCT06236438|EXPERIMENTAL|Stage 1 (Cohort 3): Budigalimab|Participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed.
62326319|NCT06236438|EXPERIMENTAL|Stage 1 (Cohort 4): Pembrolizumab|Participants will receive pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed.
62326320|NCT06236438|EXPERIMENTAL|Stage 2 (Arm 1): Livmoniplimab (Dose Optimized)|Participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
62326321|NCT06236438|EXPERIMENTAL|Stage 2 (Arm 2): Placebo|Participants will receive placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed.
62326322|NCT02578875||Sample|Discarded patient samples and autopsy material
62484733|NCT01240850|EXPERIMENTAL|Methotrexate+Prednisone|
62326323|NCT03576989|EXPERIMENTAL|EPA+DHA Group|12 weeks of daily oral therapy with EPA+DHA (three opaque softgels to provide a total daily intake of 1.87 g of EPA + 1.0 g of DHA)
62326324|NCT03576989|PLACEBO_COMPARATOR|Placebo Group|12 weeks of daily oral therapy with placebo (three opaque softgels to provide a total daily intake of 2.5 mL of mineral oil)
62326325|NCT03588481||Coronary stenosis|
62484734|NCT01591564|OTHER|therapy|All participants will receive the intervention.
62484735|NCT00606281|EXPERIMENTAL|1|
62484736|NCT00606281|PLACEBO_COMPARATOR|2|
62484737|NCT03499353|EXPERIMENTAL|TALAZOPARIB|SINGLE ARM, NON-RANDOMIZED
62326326|NCT05603104|EXPERIMENTAL|Schizophrenia EIPT: Switch to clozapine|Schizophrenia randomized to EIPT: Switch to clozapine. Brand, dosage, frequency and duration up to the investigator's discretion
62484738|NCT03850938|EXPERIMENTAL|Conventional Kyphoplasty|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon.
62326327|NCT05603104|ACTIVE_COMPARATOR|Schizophrenia TAU: second-line antispychotic|Schizophrenia randomized to TAU: switch to second-line antispychotic. Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC)
62326328|NCT05603104|EXPERIMENTAL|Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray|"Major depressive disorder randomized to EIPT: Switch to second-line antidepressant + esketamine nasal spray or (es)ketamine infusion. Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).~Esketamine nasal spray: 2 times per week for 4 weeks. Initial dose 28 mg, after that increases can be made with 28 mg per increase (up to 84 mg per week). This decision is up to the investigator's discretion (in accordance with SmPC).~(Es)ketamine infusion: performed twice weekly for 4 weeks. Compound, brand up to the investigator's discretion (in accordance with SmPC)."
62326329|NCT05603104|ACTIVE_COMPARATOR|Major Depressive Disorder TAU: second-line antidepressant|Major depressive disorder randomized to TAU: Switch to second-line antidepressant + esketamine nasal spray or ketamine IV or esketamine IV . Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).
62326330|NCT05603104|EXPERIMENTAL|Bipolar Depression EIPT: Switch to one of the following combinations:|Bipolar Depression randomized to EIPT: Switch to 1. one of the following: escitalopram, sertraline, or venlafaxine plus 2. two of the following: lithium, valproate acid or quetiapine
62326331|NCT05603104|ACTIVE_COMPARATOR|Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine|Bipolar Depression randomized to TAU: Switch to quetiapine plus lithium or valproate acid Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).
62326332|NCT05413304|EXPERIMENTAL|1/Abemaciclib and microdialysis monitoring|Abemaciclib orally BID for 4.5 days followed by resection or biopsy and microdialysis catheter placement with continuous monitoring for 48 hours post-operative and genomic sampling of tissue/blood; followed by abemaciclib+temozolomide maintenance therapy
62484739|NCT03850938|ACTIVE_COMPARATOR|Kyphoplasty with Rotary Cutter|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration, which may induce a cavity with barriers pushed by balloon dilatation. Then, the structure of the cavity is destroyed by a rotary cutter. Finally, the cement is injected, which may effectively interdigitates with the healthy cancellous bone.
62484740|NCT00486187|EXPERIMENTAL|1|"Treatment-naive subjects randomly assigned to rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking metformin before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking glyburide before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day)."
62484741|NCT00486187|ACTIVE_COMPARATOR|2|"Treatment-naive subjects randomly assigned to metformin (250 mg twice per day \[BID\] titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 500 mg BID titrated to 1 g BID if baseline A1C \>8.0%).~Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID titrated to 10 mg BID if baseline A1C \>8.0%).~Subjects taking glyburide before randomization were randomly assigned to the addition of metformin (250 mg BID titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0% or 500 mg BID titrated to 1 g BID if baseline A1C \>8.0%)."
61933207|NCT01550471|EXPERIMENTAL|2 Treatment Sequence-A and O, P and P, Q and B|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
62133307|NCT02421185|EXPERIMENTAL|Part 1: Dose Escalation and Part 2: Dose Expansion|"Part 1: First, participants will receive 8 milligram (mg) (starting dose) tablet of JNJ-42756493 (erdafitinib) orally once daily from Day 1 to 7, then Day 15 to 21 of 28 days cycle or 8 mg orally once daily from Day 1 to 21 of 28 days cycle (intermittent dosing). After recommended Phase 2 dose (RP2D) is identified, enrollment of continuous dosing schedule will be open, starting at 8mg. In this cohort, participants will receive 8mg (starting dose) tablet of JNJ42756493 (erdafitinib) orally once daily from Day 1 to Day 28 in a 28-day cycle. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine RP2D.~Part 2: Participants will receive RP2D JNJ-42756493 (erdafitinib) dose determined in Part 1. Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent."
62133308|NCT03366506||ALS patients|"ALS patients ( suspected, possible, probable or definite per El-Escorial criteria).~Observation"
62133309|NCT03079817|ACTIVE_COMPARATOR|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
62326333|NCT03732898|EXPERIMENTAL|Novel Deep Brain Stimulation (nDBS) program|This arm will include patients receiving stimulation with a novel Deep Brain Stimulation (nDBS) for Parkinson's Disease (PD).
62326334|NCT03732898|ACTIVE_COMPARATOR|Conventional Deep Brain Stimulation (cDBS) program|This arm will include patients receiving stimulation with a conventional Deep Brain Stimulation (cDBS) for Parkinson's Disease (PD).
62326335|NCT06500975||Vestibular Implant|Up to 32 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System (MVI)
61933208|NCT01550471|EXPERIMENTAL|3 Treatment Sequence-Q and B, A and O, P and P|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
62133310|NCT03079817|EXPERIMENTAL|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
62133311|NCT03443661|EXPERIMENTAL|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
62133312|NCT04380558||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
62133313|NCT05623033||infection group|
62133314|NCT05623033||non-infection group|
62133315|NCT05909072|ACTIVE_COMPARATOR|right side of the face|microneedling with tranexamic acid alone on the right side of the face
62133316|NCT05909072|ACTIVE_COMPARATOR|Left side of the face|microneedling with tranexamic acid combined with hyaluronic acid on the left side
62133317|NCT05656560|OTHER|Clinician education only|Online clinician education
62326336|NCT05671185|EXPERIMENTAL|conventional rTMS|"target: left DLPFC~protocol: 10Hz for 4 seconds, 120% motor threshold, 75 trains with 26-second interval, 3000 pulses per session, one session per day, five sessions per week, two weeks in total"
62326337|NCT05671185|EXPERIMENTAL|iTBS|"target: left DLPFC~protocol: 3 pulses at 50Hz, 90% motor threshold, repeated at 5Hz, 60 trains of 10 bursts with 8-second intervals, 1800 pulses per session, one session per day, five sessions per week, two weeks in total"
62326338|NCT05671185|SHAM_COMPARATOR|sham rTMS|"target: left DLPFC~sham probe, the same protocol as active conventional rTMS"
62326339|NCT05671185|SHAM_COMPARATOR|sham iTBS|"target: left DLPFC~sham probe, the same protocol as active iTBS"
62326340|NCT06086171|EXPERIMENTAL|Methadone|Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
62326341|NCT06086171|PLACEBO_COMPARATOR|Placebo|Standard saline solution administered intravenously at the induction of anaesthesia
62326342|NCT00011648||non-SCD|200 Men and Women without a diagnosis of sickle cell disease 18 years of age or older
62326343|NCT00011648||SCD|1000 Men and Women with a diagnosis of sickle cell disease
62326344|NCT04869098|EXPERIMENTAL|Whey protein preload condition|Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.
62326345|NCT04869098|PLACEBO_COMPARATOR|Placebo condition|Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,
62326346|NCT05654519|ACTIVE_COMPARATOR|Group QL Block|A convex transducer will be placed in the transverse plane on the flank cranial to the iliac crest to visualise the transverse process of the 4th lumbar vertebra, erector spina, quadratus lumborum and psoas muscles as a 'Shamrock sign'. The needle will inserted in to the fascial plane between the quadratus lumborum and psoas muscles and 30 ml bupivacaine 0.25% will be administered.
62326347|NCT05654519|ACTIVE_COMPARATOR|Group PENG+LFCN Block|"A linear probe will be placed on the anterior inferior iliac crest in the transverse plane while the patient is in the supine position. After rotating 45 degrees, the pubic ramus, femoral artery and psoas muscle will be visualized. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and the iliopubic eminence After a negative aspiration test, 25 ml bupivacaine 0.25% will be injected.~Then, the lateral femoral cutaneous nerve (LFCN) block was performed using linear US probe (10-18 MHz).The LFCN will be localized, infero-medially to the antero-superior iliac spine, laterally to the sartorius muscle and 5 ml of bupivacaine 0.25% will be carefully injected."
62326348|NCT03808558|EXPERIMENTAL|TVB-2640|Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
62326349|NCT00081523||Patients|Individuals with known or suspected sickle cell disease
62326350|NCT05660980|EXPERIMENTAL|Cohort 1|Cohort 1 will receive Once daily oral CAB + oral RPV through the Week 4b visit, followed by intramuscular injection doses of CAB LA + RPV LA every four weeks (Q4W dosing regimen) or every eight weeks (Q8W dosing regimen)
62326351|NCT05660980|EXPERIMENTAL|Cohort 2A|Cohort 2A: Once daily doses of oral CAB + oral RPV through the Week 4b visit, followed by Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.
62326352|NCT05660980|EXPERIMENTAL|Cohort 2B|Cohort 2B: Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.
62326353|NCT05031780|EXPERIMENTAL|Phase 2: Mitapivat 50 mg BID|Double-blind Period: Mitapivat 50 milligrams (mg) twice daily (BID) for 12 weeks.
62326354|NCT05031780|EXPERIMENTAL|Phase 2: Mitapivat 100 mg BID|Double-blind Period: Mitapivat 100 mg BID for 12 weeks.
62326355|NCT05031780|PLACEBO_COMPARATOR|Phase 2: Placebo|Double-blind Period: Mitapivat-matching placebo for 12 weeks.
62326356|NCT05031780|EXPERIMENTAL|Phase 2: Open-Label Extension Period|"Participants who received mitapivat 50mg BID in the double-blind period may choose to receive mitapivat 50mg BID for 216 weeks after.~Participants who received mitapivat 100mg BID in the double-blind period may choose to receive mitapivat 100 mg BID for 216 weeks after.~Participants who received mitapivat-matching placebo in the double-blind period, may be randomized to receive either mitapivat 50 mg or 100 mg BID for 216 weeks after."
62326357|NCT05031780|EXPERIMENTAL|Phase 3: Mitapivat 100 mg BID|Double-blind Period: Mitapivat 100 mg BID for 52 weeks.
62326358|NCT05031780|PLACEBO_COMPARATOR|Phase 3: Placebo|Double-blind Period: Mitapivat-matching placebo for 52 weeks.
62326359|NCT05031780|EXPERIMENTAL|Phase 3: Open-Label Extension Period|"Participants may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period.~Participants who received mitapivat-matching placebo in the double-blind period, may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period."
62326360|NCT04691648||Xospata|Patients who receive Xospata® 40 mg tablet in routine clinical practice according to the drug label approved at the time of marketing authorization.
62326361|NCT05079464|EXPERIMENTAL|Exercise primed tDCS|Individuals randomized to this group will receive exercise at University Health Network-Toronto Rehabilitation Institute followed by active tDCS.
62326362|NCT05079464|OTHER|Exercise primed Sham stimulation|Individuals randomized to this group will receive exercise at University Health Network-Toronto Rehabilitation Institute followed by sham tDCS.
62326363|NCT05079464|OTHER|Treatment as usual (exercise education) & tDCS|Individuals randomized to this group will receive routine advice about physical activity, and active tDCS.
62326364|NCT05079464|OTHER|Treatment as usual (exercise education) & sham stimulation|Individuals randomized to this group will receive routine advice about physical activity, and sham tDCS.
62326365|NCT05678959|EXPERIMENTAL|Ligelizumab 120 mg|120 mg
62326366|NCT05678959|EXPERIMENTAL|Ligelizumab 240 mg|240 mg
62326367|NCT05891860|EXPERIMENTAL|Intervention|Study participants will be present during daily ICU team rounds by secure video conference.
62326368|NCT06457919|EXPERIMENTAL|Tinengotinib with abiraterone acetate/prednisone|Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily will be administered unless dose de-escalation is required in Phase 1b. Participants will receive tinengotinib in combination with abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID) or enzalutamide 160 mg PO QD.
62484742|NCT04583423|EXPERIMENTAL|MK-3655 50 mg|Following a 2-week placebo run-in, participants will receive MK-3655 50 mg by subcutaneous (SC) injection once every 4 weeks (Q4W) for 52 weeks.
62484743|NCT04583423|EXPERIMENTAL|MK-3655 100 mg|Following a 2-week placebo run-in, participants will receive MK-3655 100 mg by SC injection Q4W for 52 weeks.
62484744|NCT04583423|EXPERIMENTAL|MK-3655 300 mg|Following a 2-week placebo run-in, participants will receive MK-3655 300 mg by SC injection Q4W for 52 weeks.
62484745|NCT04583423|PLACEBO_COMPARATOR|Placebo|Following a 2-week placebo run-in, participants will receive Placebo by SC injection Q4W for 52 weeks.
62692578|NCT06363981|SHAM_COMPARATOR|Sham rTMS|Sham 10 Herz rTMS will be administered over the left DLPFC. Therapy will include 20 sessions (one session in each of 20 consecutive working days - four weeks in total). In every session 3000 magnetic pulses over the left DLPFC or ca 1500 magnetic pulses over the left DLPFC and ca 1500 over the left DMPFC will be elicited. (rTMS protocol will be chosen randomly before the first session).
62133318|NCT05656560|EXPERIMENTAL|Commitment nudge|The commitment nudge will be an EHR alert that is triggered when a clinician renews or orders a qualifying medication in any Epic encounter (including non-face-to-face encounters) for a patient aged 65 or greater who meets criteria for high-risk polypharmacy. When triggered, the commitment nudge will offer the clinician a choice option that sets a reminder to discuss polypharmacy at the patient's next visit date.
62326369|NCT06457919|EXPERIMENTAL|Phase 1b dose of tinengotinib (RP2D) with abiraterone acetate/prednisone or enzalutamide|Phase 1b dose of tinengotinib recommended Phase II dose (RP2D) with abiraterone acetate/prednisone or enzalutamide
62326370|NCT05297396|EXPERIMENTAL|Slow Tapering of Chronic Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will have their opioid medication doses slowly and gradually reduced every 4 weeks.
62326371|NCT05297396|NO_INTERVENTION|Continued Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will stay on the same dose of opioids they are currently using at the beginning of the study for the entire 12-month duration of the study.
62326372|NCT04353661|EXPERIMENTAL|Arm A Open-label: azithromycin + SOC therapy|Participants will receive azithromycin and SOC theraphy for 52 weeks.
62326373|NCT04353661|ACTIVE_COMPARATOR|Arm A Open-label: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
62326374|NCT04353661|ACTIVE_COMPARATOR|Arm B Observational: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
62326375|NCT00071045||1|patients undergoing allogeneic stem cell transplantation
62326376|NCT00071045||2|HLA compatible donors
62326377|NCT00001888||1|Asthmatics
62326378|NCT00001888||2|Research Volunteers
62326379|NCT06072781|EXPERIMENTAL|avutometinib + defactinib|Avutometinib 3.2 mg, PO, twice weekly for 21 days on, 7 days off in a 28-day (4 weeks) cycle in combination with defactinib 200 mg, PO, twice daily for 21 days on, 7 days off in a 28-day(4 week) cycle.
62326380|NCT06072781|ACTIVE_COMPARATOR|Investigator Choice of Treatment (ICT)|"Patients will receive one of the following therapies as determined by the Investigator:~* Pegylated liposomal doxorubicin: 40 mg/m2 IV on Day 1 of each 28-day (4 week) cycle.~* Paclitaxel: 80 mg/m2 IV on Days 1, 8, and 15 of each 28-day (4 week) cycle.~* Anastrozole: 1 mg, PO, once daily of each 28-day (4 week) cycle.~* Letrozole: 2.5 mg, PO, once daily of each 28-day (4 week) cycle."
62326381|NCT04845893||Skeletal Ewing Sarcoma|This cohort include patients affected by Ewing Sarcoma of bone, referred to participating Institutions.
62326382|NCT06013969|EXPERIMENTAL|GPP Patients|Generalized Pustular Psoriasis (GPP) patients with a recurrent flare following initial GPP flare treatment with intravenous (i.v.) spesolimab.
62326383|NCT06121843|EXPERIMENTAL|Arm A: BMS-986393 + Alnuctamab|
62326384|NCT06121843|EXPERIMENTAL|Arm B: BMS-986393 + Mezigdomide|
62484746|NCT05766553|EXPERIMENTAL|Interventional Group|"Patients in this arm will have 6 sessions of virtual reality in a pod (1 session per week).~Patients will then have a visit at day 90 and day 180."
62484747|NCT05766553|ACTIVE_COMPARATOR|Control group|"Patients in this arm will receive the gold standard of treatment for tobacco cessation (nicotine patches and chewing gum) from day 0 (inclusion visit) to day 90.~Patients will then have a visit at day 90 and day 180."
62484748|NCT00538239|EXPERIMENTAL|Ridaforolimus|
62484749|NCT00538239|PLACEBO_COMPARATOR|Placebo|
62484750|NCT01860638|EXPERIMENTAL|First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
62484751|NCT01860638|PLACEBO_COMPARATOR|First-Line Bevacizumab followed by Placebo + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
62484752|NCT01293097|ACTIVE_COMPARATOR|Intensive statin therapy|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
62484753|NCT01293097|OTHER|Usual care|Usual care, but statin dose should not be higher than that described in exclusion criteria.
62692579|NCT06494644|EXPERIMENTAL|AZD6793 and Itraconazole|Participants will receive a single dose of AZD6793 on Day 1. On Day 4, the participant will receive 2 doses of 200 mg itraconazole 12 hours apart followed by a single dose of 200 mg itraconazole from Days 5 to 7. On Day 8, participants will receive a combined dose of AZD6793 and 200 mg itraconazole. On Day 9 and Day 10, the participants will receive a single dose of 200 mg itraconazole.
62692580|NCT03511846|EXPERIMENTAL|Oral capsaicin|
62692581|NCT03511846|SHAM_COMPARATOR|Oral capsaicin and Medical Air|
62692582|NCT03511846|EXPERIMENTAL|Oral Capsaicin and Low Flow Oxygen|
61933209|NCT01550471|EXPERIMENTAL|4 Treatment Sequence-Q and B, P and P, A and O|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
62484754|NCT02225405|EXPERIMENTAL|Treatment (cisplatin, docetaxel, nintedanib)|"RUN-IN PHASE: Patients receive induction therapy comprising cisplatin IV over 2 hours on day 1, docetaxel IV over 1 hour on day 1, and nintedanib PO BID from day 2 of course 1 to day 7 of course 3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~EXPANSION PHASE: Patients receive single-agent nintedanib PO BID on days 1-28. Patients then receive 3 courses of induction chemotherapy and undergo surgery as above. Treatment continues even if patients experience disease progression, unless treatment is judged to be not in the best interest of the patient by the treating physician."
62484755|NCT05275699|EXPERIMENTAL|68Ga-FAPI-04 PET/CT|All patients diagnosed with keloid underwent 68Ga-FAPI PET/CT.
62692583|NCT03511846|EXPERIMENTAL|Oral capsaicin and High Flow Oxygen|
62484756|NCT05603351|EXPERIMENTAL|Preventive prostate examination by bpMRI|"The cohort consists of patients:~* with age 50-69 years~* without any contraindications to MRI or biopsy~* without known status of prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)~* without known BRCA mutation~* without PSA test or prostate MRI in the past 2 years~* without any signs of prostatitis or urinary tract infection in the past 6 months."
62484757|NCT03424915||Regular exercisers and non-exercising groups who have been diagnosed with breast cancer|There is no treatment on this study, it is a onetime assessment. exercisers: ≥120 minutes of vigorous-intensity aerobic exercise;There is no treatment on this study, it is a onetime assessment. non-exercisers: ≤ 30 minutes of moderate-intensity exercise per week.
62484758|NCT03424915||Regular exercisers who are at high risk of developing breast cancer|≥120 minutes of vigorous-intensity aerobic exercise;
62692584|NCT03511846|EXPERIMENTAL|Topical capsaicin|
62692585|NCT03511846|SHAM_COMPARATOR|Topical capsaicin and Medical Air|
62692586|NCT03511846|EXPERIMENTAL|Topical capsaicin and Low Flow Oxygen|
62326385|NCT06121843|EXPERIMENTAL|Arm C: BMS-986393 + Iberdomide|
62326386|NCT06138795|EXPERIMENTAL|Cohort 1: Part A1 - AZD2389 dose 1/placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62692587|NCT03511846|EXPERIMENTAL|Topical capsaicin and High Flow Oxygen|
62692588|NCT03511846|EXPERIMENTAL|Intranasal capsaicin|
62692589|NCT03511846|SHAM_COMPARATOR|Intranasal capsaicin and Medical Air|
62692590|NCT03511846|EXPERIMENTAL|Intranasal capsaicin and Low Flow Oxygen|
62692591|NCT03511846|EXPERIMENTAL|Intranasal capsaicin and High Flow Oxygen|
62692592|NCT03511846|EXPERIMENTAL|Cold water irrigation|
62692593|NCT03511846|SHAM_COMPARATOR|Cold water irrigation and Medical Air|
62692594|NCT03511846|EXPERIMENTAL|Cold water irrigation and Low Flow Oxygen|
62692595|NCT03511846|EXPERIMENTAL|Cold water irrigation and High Flow Oxygen|
62692596|NCT06049160|ACTIVE_COMPARATOR|Pre-operative and post-operative rectal misoprostol|64 participants who will receive combined pre-operative and post-operative rectal misoprostol (400μg rectal misoprostol during urinary catheter insertion just after spinal anesthesia plus 200μg after abdominal closure).
62692597|NCT06049160|ACTIVE_COMPARATOR|Post-operative rectal misoprostol|64 participants who will receive rectal misoprostol post-operative only (600μg of rectal misoprostol after closure of the Cesarean Wound)).
62692598|NCT06352970||Women in labor|Women admitted to labor wards for delivery
62692599|NCT03347669|EXPERIMENTAL|FM patients|50 fibromyalgia patients/50 healthy subjects
62692600|NCT03347669|ACTIVE_COMPARATOR|Healthy subjects|50 fibromyalgia patients/50 healthy subjects
62692601|NCT05454982|EXPERIMENTAL|Low pressure|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and a static pressure of 25 mmHg is applied to the lower limb by the cuff.
62692602|NCT05454982|EXPERIMENTAL|Medium pressure|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and an intermittent pressure of 25-50 mmHg is applied to the lower limb by the cuff.
62692603|NCT05454982|EXPERIMENTAL|High pressure|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and an intermittent pressure of 25-75 mmHg is applied to the lower limb by the cuff.
62692604|NCT06637735|EXPERIMENTAL|Experimental group|Experimental group; pregnant women will receive a 4-week training
62484759|NCT02873845||PATIENT|Patients with colon cancer
62484760|NCT02873845||THE SPOUSE/PARTNER|The spouse/partner of patients with colon cancer
62484761|NCT00041015|ACTIVE_COMPARATOR|oral topotecan plus cisplatin IV|oral topotecan once daily on days 1-5 and cisplatin IV on day 5
62326387|NCT06138795|EXPERIMENTAL|Cohort 2: Part A1 - AZD2389 dose 2/placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62484762|NCT00041015|EXPERIMENTAL|Cisplatin IV plus etoposide IV|Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
62484763|NCT00908999||Controls|The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
62484764|NCT00908999||amnestic Mild Cognitive Impairment|Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
62484765|NCT00908999||Alzheimer's disease|Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.
62484766|NCT01945450|ACTIVE_COMPARATOR|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
62484767|NCT01945450|NO_INTERVENTION|No treatment|No antibiotics
62484768|NCT03811158|EXPERIMENTAL|HHHFNC group|On HHHFNC FiO2 will setting as same as SBT before extubation Flow rate: 50L/min
62484769|NCT03811158|SHAM_COMPARATOR|UHFOM group|On Aerosol mask FiO2 will setting as same as SBT before extubation Flow rate: 15L/min
62484770|NCT00822744|EXPERIMENTAL|SSR411298 10 mg|SSR411298 10 mg, one capsule once daily for 8 weeks
62484771|NCT00822744|EXPERIMENTAL|SSR411298 50 mg|SSR411298 50 mg, one capsule once daily for 8 weeks
62692605|NCT06637735|NO_INTERVENTION|control|No intervention will be made to the control group. Only measurements will be made on parallel dates with the experimental group.
61933210|NCT01550471|EXPERIMENTAL|5 Treatment Sequence-P and P, A and O, Q and B|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
62326388|NCT06138795|EXPERIMENTAL|Cohort 3: Part A1 - AZD2389 dose 3 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62326389|NCT06138795|EXPERIMENTAL|Cohort 4: Part A1 - AZD2389 dose 4 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62326390|NCT06138795|EXPERIMENTAL|Cohort 5: Part A1 - AZD2389 dose 5 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62326391|NCT06138795|EXPERIMENTAL|Cohort 6: Part A1 - AZD2389 dose 6 oral administration|A total of 6 study participants will receive a single dose of AZD2389.
62326392|NCT06138795|EXPERIMENTAL|Cohort 7: Part A2 - AZD2389 dose 7 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62484772|NCT00822744|EXPERIMENTAL|SSR411298 200 mg|SSR411298 200 mg, one capsule once daily for 8 weeks
62326393|NCT06138795|EXPERIMENTAL|Cohort 8: Part A2 - AZD2389 dose 8 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62326394|NCT06138795|EXPERIMENTAL|Cohort 9: Part A2 - AZD2389 dose 9 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62484773|NCT00822744|ACTIVE_COMPARATOR|Escitalopram 10 mg|Escitalopram 10 mg, one capsule once daily for 8 weeks
62484774|NCT00822744|PLACEBO_COMPARATOR|Placebo|Placebo (for SSR411298), one capsule once daily for 8 weeks
62484775|NCT06059625|EXPERIMENTAL|DOUBLE-ROW|rotatori cuff repair with double-row suture bridge technique
62484776|NCT06059625|ACTIVE_COMPARATOR|SINGLE-ROW|rotatori cuff repair with single-row technique
62484777|NCT05806177|EXPERIMENTAL|AD16|AD16 tablets should be administered only in the morning on the day of the first dose and on the ninth day after the first dose. Fasting is required for at least 10 h before administration.Two dosing cohorts received AD16 From the third day to the eighth day, the medicine was administered twice a day, 1 h before breakfast, 1 h before dinner or 2 h after dinner, with a 12 h interval (time window ±1 h).The duration of oral AD16 tablets was nine days.
62484778|NCT05806177|PLACEBO_COMPARATOR|AD16 placebo|AD16 placebo tablets should be administered only in the morning on the day of the first dose and on the ninth day after the first dose. Fasting is required for at least 10 h before administration.Two dosing cohorts received AD16 placebo From the third day to the eighth day, the medicine was administered twice a day, 1 h before breakfast, 1 h before dinner or 2 h after dinner, with a 12 h interval (time window ±1 h).The duration of oral AD16 placebo tablets was nine days.
62484779|NCT02609568||Control Group 1|Children with non-trauma complaints
62484780|NCT02609568||Control Group 2|Children with non TBI and musculoskeletal trauma
62484781|NCT02609568||Cases|Children admitted to hospital with moderate/severe isolatedTBI
62484782|NCT04303221|EXPERIMENTAL|GAJL - Young adult with lymphedema|Women age 35 to 59 years (young adult) with lymphedema - exercise group
62692606|NCT00370084|PLACEBO_COMPARATOR|Placebo|
62692607|NCT00370084|EXPERIMENTAL|Itopride|
62692608|NCT01965951|EXPERIMENTAL|Experimental Treatment|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
62484783|NCT04303221|EXPERIMENTAL|GAJ - Young adult without lymphedema|Women age 35 to 59 years (young adult) without lymphedema - exercise group
62692609|NCT01965951|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
62133319|NCT05656560|EXPERIMENTAL|Justification nudge|The justification nudge will be an EHR alert triggered for patients with high-risk polypharmacy when a clinician begins to renew or newly prescribe a medication that causes a high-risk criterion to be fulfilled (i.e., a medication meeting causing 1 of the 7 high-risk polypharmacy criteria/primary study measures to be met). This alert will inform the clinician of the high-risk nature of the prescription and request a free-text justification for starting or renewing the medication. This written justification will appear in the EHR in a section of that encounter that other EHR users can see.
62326395|NCT06138795|EXPERIMENTAL|Cohort 10: Part A3 - AZD2389 dose 10 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
62326396|NCT06138795|EXPERIMENTAL|Cohort 11: Part B1 - AZD2389 dose 11 /placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
62326397|NCT06138795|EXPERIMENTAL|Cohort 12: Part B1 - AZD2389 dose 12 /placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
62326398|NCT06138795|EXPERIMENTAL|Cohort 13: Part B1 - AZD2389 dose 13 /placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
62326399|NCT06138795|EXPERIMENTAL|Cohort 14: Part B2- AZD2389 dose 14/placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
62326400|NCT05896839|EXPERIMENTAL|Treatment (nivolumab and ipilimumab)|See detailed description
62326401|NCT05568459||Cohort 1|Male participants with hemophilia B on current FIX Replacement Therapy prophylaxis or a documented genotype known to produce severe hemophilia B
62326402|NCT05786066|EXPERIMENTAL|Perampanel + Ketamine|Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day.
62326403|NCT05786066|PLACEBO_COMPARATOR|Placebo + Ketamine|Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day.
62692610|NCT05032352||Treatment Arm|"Treatment Arm 1: 4 cycles of adjuvant treatment with a standard NSCLC cisplatin-based doublet regimen or carboplatin-based regimen of physician choice.~Treatment 1A: other adjuvant therapy or combination of adjuvant therapies (targeted therapy, immunotherapy, or other)"
62133320|NCT05656560|EXPERIMENTAL|Commitment nudge + Justification nudge|This study arm will receive both the commitment nudge and the justification nudge.
62133321|NCT03434587|EXPERIMENTAL|Syndactyly|Syndactyly
62484784|NCT04303221|EXPERIMENTAL|GIL - Elderly with lymphedema|Women aged 60 to 80 years (elderly) with lymphedema - exercise group
62484785|NCT04303221|EXPERIMENTAL|GI - Elderly without lymphedema|Women aged 60 to 80 years (elderly) without lymphedema - exercise group
62692611|NCT05032352||Observation only|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
62692612|NCT04883203|ACTIVE_COMPARATOR|VITD|A single vial of Cholecalciferol (1 ml) (200,000 IU / 1 m), Oral form,
62133322|NCT03434587|ACTIVE_COMPARATOR|Reduction and inmobilization|Closed reduction and splint inmobilization
62326404|NCT04047641|EXPERIMENTAL|Treatment (idarubicin, cladribine, cytarabine, quizartinib)|"INDUCTION: Patients receive idarubicin Intravenous over 1 hours on days 1-3, cladribine intravenous over 1-2 hours on days 1-5, cytarabine Intravenous over 3 hours on days 1-5 (or days 1-3 for patients over age 60), and quizartinib by mouth daily on days 6-19. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR or CRp after Induction receive idarubicin Intravenous over 1 hours on days 1-2, cladribine Intravenous over 1-2 hours on days 1-3, cytarabine Intravenous over 3 hours on days 1-3, and quizartinib by mouth daily on days 4-28. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve CR or CRi/CRh after Consolidation receive quizartinib by mouth daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
62326405|NCT00001351||Immediate family members of patients|immediate family members of patients with inflammatory conditions may be evaluated under this protocol
62326406|NCT00001351||Patients|Inflammatory conditions associated with, but not limited, to acute and chronic infections or presumed infections, and congenital or acquired immunologic disorders
62326407|NCT02911103|EXPERIMENTAL|Active|single arm study
62326408|NCT05469789||Prevalent Cohort A|Prevalent Cohort A will comprise eligible participants with HAE type I or II who have initiated treatment with lanadelumab at any point in time (i.e., all prevalent cases of exposure to lanadelumab). The total follow-up encompasses a 12-month pre-treatment period, and an up-to 24-month post-treatment period.
62326409|NCT05469789||Prevalent Cohort B|Prevalent Cohort B will comprise eligible participants with HAE type I or II who have been treated with lanadelumab for \<12 months (i.e., the subset of participants from Prevalent Cohort A who initiated treatment with lanadelumab within \<12 months). The total follow-up encompasses a 12-month pre-treatment and an up to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.
62326410|NCT05469789||Incident Cohort A|Incident Cohort A will comprise eligible participants with HAE type I or II initiating treatment with lanadelumab at any time within the prospective data collection time period. The total follow-up encompasses a 12-month pre-treatment and an up-to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.
62692613|NCT04883203|PLACEBO_COMPARATOR|Placebo|A single vial of physiological salin Oral form
62692614|NCT02163863|EXPERIMENTAL|BioMimics 3D|The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.
62484786|NCT02091713||Experimental/Functional movement screen|300 subjects from three different combat units will undergo functional movement screening
62484787|NCT06508905|EXPERIMENTAL|Sleep buddy|Children who did not have their own sleeping companion were given a toy selected as a sleeping companion. The toy was introduced to the children and accompanied them for 3 days during their hospitalization.
62484788|NCT06508905|NO_INTERVENTION|control group|After the child in the control group was hospitalized in the clinic, routine hospitalization procedures were performed and no intervention was performed. The child was observed during the three days of hospitalization. It was observed that the children did not have their own toys with them.
62484789|NCT01895764|ACTIVE_COMPARATOR|Adalimumab|adalimumab 40mg every 2 weeks
61933211|NCT01550471|EXPERIMENTAL|6 Treatment Sequence-P and P, Q and B, A and O|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
62326411|NCT01175993|ACTIVE_COMPARATOR|Eliptical training|Home base exercise
62326412|NCT06340568|EXPERIMENTAL|BNT323/DB-1303|
62326413|NCT06340568|ACTIVE_COMPARATOR|Doxorubicin or paclitaxel|Single agent chemotherapy (either doxorubicin or paclitaxel) per investigator's choice
62326414|NCT06531824|OTHER|Part 1: Run-in period (all participants)|Eligible participants will enter a Run-in period during which they will receive placebo matching BI 690517 + empagliflozin.
62326415|NCT06531824|EXPERIMENTAL|Part 2: Randomized treatment, follow-up period, treatment group|
62326416|NCT06531824|PLACEBO_COMPARATOR|Part 2: Follow-up period, placebo group|
62484790|NCT01895764|EXPERIMENTAL|Adalimumab + Methotrexate|adalimumab 40mg every 2 weeks and methotrexate 10mg per week
62484791|NCT05005728|EXPERIMENTAL|Cohort A - AVPCa|
62484792|NCT05005728|EXPERIMENTAL|Cohort B - HRD/CDK12 PARP - Progressors|
62484793|NCT05005728|EXPERIMENTAL|Cohort C - HRD/CDK12 PARP Naïve|
62484794|NCT05005728|EXPERIMENTAL|Cohort D - MSI-H, MMRD or TMB-H|
62484795|NCT05005728|EXPERIMENTAL|Cohort E - No Targetable Mutations|
62484796|NCT03197818|EXPERIMENTAL|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
62484797|NCT03197818|ACTIVE_COMPARATOR|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
62484798|NCT05173792|EXPERIMENTAL|AK119|Subjects will receive escalating doses of AK119 every 2 or 3 weeks.
62692615|NCT02163863|ACTIVE_COMPARATOR|Control|CR Bard LifeStent System, delivering a self-expanding Nitinol stent
62692616|NCT06245655|ACTIVE_COMPARATOR|Active TENS|For the Active TENS group, the device will be set to 80 Hz (hfTENS) and device intensity (0-8) will be titrated to patient comfort, as is the standard protocol for TENS use.
62692617|NCT06245655|PLACEBO_COMPARATOR|Placebo TENS|For the placebo TENS group, setup will be identical, but the device will not be turned on.
62692618|NCT06644950|EXPERIMENTAL|Two cartridges of anesthetic|Two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block.
62133323|NCT03304041|EXPERIMENTAL|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
62133324|NCT03304041|PLACEBO_COMPARATOR|Traditional dietary advice|"Traditional dietary advice (TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~Traditional dietary advice for 3 weeks"
62133325|NCT02837796|ACTIVE_COMPARATOR|inside-outside group|inside-out transobturator tape approach
62133326|NCT02837796|ACTIVE_COMPARATOR|outside-inside group|outside-in transobturator tape approach
62133327|NCT03065569|ACTIVE_COMPARATOR|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
62133328|NCT03065569|EXPERIMENTAL|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
62133329|NCT06094231|EXPERIMENTAL|Interventional Arm|The patients randomized to the interventional Arm will be simultaneously treated with therapeutic carbohydrate restriction and dapagliflozin for a period of three months. During this time repeated measurements of blood ketone levels and a continuous glucose monitoring will be performed.
62133330|NCT06094231|NO_INTERVENTION|Control Arm|The patients randomized to the control arm will continue to receive the standard of care for chronic kidney disease and prediabetes or diabetes, which includes the use of dapagliflozin.
62133331|NCT02928172|OTHER|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
62133332|NCT05398289|EXPERIMENTAL|4-week duration of antibiotic therapy|
62133333|NCT05398289|ACTIVE_COMPARATOR|standard 6-week duration of antibiotic therapy|
62133334|NCT00975585|ACTIVE_COMPARATOR|senofilcon A both eyes|soft contact lens worn daily for 2 weeks, with a 2-week replacement regimen.
62133335|NCT00975585|ACTIVE_COMPARATOR|lotrafilcon B both eyes|soft contact lens worn daily for 4 weeks, with a 4-week replacement regimen
62133336|NCT03832140||Patients with monoclonal gammopathy|
62133337|NCT03832140||patients with a normal plasma protein electrophoresis|
62133338|NCT04965415|ACTIVE_COMPARATOR|Lagged|Businesses in the lagged arm participated in Health Links for one year from their baseline assessment to their first follow-up assessment one year later. They were eligible to participate in the Leadership Training after both assessments were completed.
62133339|NCT04965415|EXPERIMENTAL|Early|Businesses in this arm participated in Health Links + Leadership Training for one year from their baseline assessment to their first follow-up assessment one year later.
62484799|NCT05315297|EXPERIMENTAL|PEMF device|
62484800|NCT05315297|SHAM_COMPARATOR|Sham PEMF device|
62484801|NCT03808376|EXPERIMENTAL|Continuous Glucose Monitoring Device|The Eversense® 180 CGM System
62484802|NCT03649581|EXPERIMENTAL|patient with schizophrenia and periodic catatonia|
62484803|NCT03649581|EXPERIMENTAL|patient with schizophrenia and hebephrenia|
62484804|NCT03649581|ACTIVE_COMPARATOR|healthy volunteers|
62484805|NCT00221299|ACTIVE_COMPARATOR|Group1a-rhPTH&RIS-Placebo(Y1)&RIS(Y2)|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - re-randomized to risedronate (35mg/wk) tablets for second year.
62484806|NCT00221299|ACTIVE_COMPARATOR|Group1b-rhPTH&RisendronatePlacebo|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - continue on risedronate placebo tablets for second year.
62484807|NCT00221299|ACTIVE_COMPARATOR|Group2-rhPTH&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
62484808|NCT00221299|ACTIVE_COMPARATOR|Group3-rhPTH-Placebo&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), placebo SC injections of normal saline daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
62484809|NCT01706757|EXPERIMENTAL|with go-cart|conducts exercises with the help of a go-cart
62484810|NCT01706757|NO_INTERVENTION|without go-cart|conduct exercises without go-cart
62692619|NCT06644950|ACTIVE_COMPARATOR|Single cartridge of anesthetic|In the control group, a single cartridge of anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without needle, in the same area, counting up to 30 seconds.
62692620|NCT02069847|EXPERIMENTAL|Esophageal stricture, Budesonide|Budesonide 1mg twice a day for a total of 8 weeks following endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR)
62692621|NCT02069847|NO_INTERVENTION|Control group|Retrospective collect data for subjects who undergo endoscopic submucosal dissection or endoscopic mucosal resection
62692622|NCT03689179|EXPERIMENTAL|Treatment with Follow-up (Group A)|"Group A received access to the full Time for Living \& Caring (TLC) intervention for 8 weeks (calendar + coaching + resources), followed by an 8-week maintenance period where they could continue to use the TLC intervention. The TLC intervention turned off after 16 weeks of exposure for all participants."
62326417|NCT03111745||1|Retrospective chart review of patients who have underwent hematopoietic stem cell transplantation (HSCT)
62326418|NCT04829240|EXPERIMENTAL|Intervention condition|Modular cognitive-behavioral anxiety intervention tailored to and personalized for Veterans
62326419|NCT04829240|ACTIVE_COMPARATOR|Control condition|Usual care anxiety treatment
62326420|NCT04314778|EXPERIMENTAL|Intervention|Participants in the intervention arm will have a postoperative daily step goal that increases from baseline by 500 steps each day.
62326421|NCT04314778|NO_INTERVENTION|Control|Participants in the control group will have data collected passively via Fitbit.
62326422|NCT04639830||Children with a known risk|Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder.
62326423|NCT04639830||Children with no known risk|Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders.
62326424|NCT05767034|EXPERIMENTAL|Secukinumab 300 mg|randomized in 1:1:1 ratio every 4 weeks
62326425|NCT05767034|EXPERIMENTAL|Secukinumab 150 mg|randomized in 1:1:1 ratio every 4 weeks
62326426|NCT05767034|PLACEBO_COMPARATOR|Placebo to secukinumab|randomized in 1:1:1 ratio every 4 weeks
62326427|NCT05051540|EXPERIMENTAL|Inelastic Compression System Group|Participants in this group will receive the inelastic compression wrap for daily use on their legs for 6 consecutive weeks.
62326428|NCT05187013|EXPERIMENTAL|Hypertension-Specific Education|6 months of mHealth HTN management support via SMS texts including reminders for medication adherence, appointment attendance, and HTN-specific health education and support. Texts will be delivered to support medication adherence and lifestyle changes, and participants will receive appointment reminders before each appointments with a follow-up text and robocall if the appointment is missed.
62326429|NCT05187013|OTHER|General Health Education|6 months of mHealth including basic healthcare and general health promotion via SMS texts. Blood pressure measurements and adherence assessments will be collected at every shelter visit.
62326430|NCT06126224|EXPERIMENTAL|KarXT|Xanomeline and Trospium Chloride Capsules
62326431|NCT06126224|PLACEBO_COMPARATOR|Placebo|Placebo Capsules
62326432|NCT06585449|EXPERIMENTAL|ALN-HTT02|Participants will be administered a single dose of ALN-HTT02 during the Double-blind Part of the study. Participants who received ALN-HTT02 in the Double-blind part of the study will not receive an additional dose during the Open-label part of the study
62326433|NCT06585449|PLACEBO_COMPARATOR|Placebo + ALN-HTT02|Participants will be administered a single dose of placebo during the Double-blind Part of the study. Participants will have the option to receive a single dose of ALN-HTT02 during the Open-Label Part of the study.
62326434|NCT01617408||1|Neurologically normal subjects aged 18 to 50 years old
62484811|NCT04723693||individuals With Haemophilia A and with inhibitors on emicizumab|Qualitative interviews
62484812|NCT02036788||Postsurgical patients sedated and paralized|Patients admitted to ICU after surgery, treated with mechanical ventilation, sedated and paralized
62484813|NCT02036788||Postsurgical patients intubated and breathing spontaneously|
62484814|NCT05957549|EXPERIMENTAL|Speech Sounds|Participants listen to speech sounds while the investigators measure electrical and hemodynamic changes in the brain.
62484815|NCT04820322|PLACEBO_COMPARATOR|control cookie|a sugarsnap cookie baked specifically for this trial
62484816|NCT04820322|ACTIVE_COMPARATOR|Fibersym cookie|a sugarsnap cookie baked using the same methodology for the control cookie but with the resistants starch RS4, Fibersym, added
62484817|NCT02538627|EXPERIMENTAL|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
62484818|NCT02538627|EXPERIMENTAL|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
61933212|NCT00273910|EXPERIMENTAL|Adj-3 A2 gp209(2M) in IFA SQ (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
61933213|NCT00273910|EXPERIMENTAL|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
62692623|NCT03689179|EXPERIMENTAL|Wait-List Control w/Treatment (Group B)|"Group B received 8 weeks of waitlist control (minimal treatment - calendar only) , followed by access to the full Time for Living \& Caring (TLC) intervention for an additional 8 weeks (calendar + coaching + resources). The TLC intervention turned off after 16 weeks of exposure for all participants."
62692624|NCT03014414|EXPERIMENTAL|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
62326435|NCT03692052|EXPERIMENTAL|AG-348|Participants with alpha or beta thalassemia received AG-348 50 mg twice daily (BID), orally up to Week 6. Following Week 6, depending on the participants' safety and hemoglobin (Hb) concentrations, they could undergo one potential dose-level increase from 50 to 100 mg BID. After completion of the Core Period of 24 weeks, participants were eligible to continue to receive AG-348 in the Extension Period which is up to 10 years.
62326436|NCT00341237||polymorphisms|Specimens are available to investigators in coded form to anonymously screen for the presence of single-nucleotide polymorphisms (SNPs) and other mutations in DNA.
62326437|NCT05233605||Exposed to Dexmedetomidine during ICU stay|Dexmedetomidine has been administered in accordance with its MA (at least 24 hours continuously with a starting dose of 0.7 µg/kg/h and then adjusted to sedation scores between 0.4 and 1.1 µg/kg/h), as part of care, prior to inclusion in the protocol
62326438|NCT05233605||Not Exposed to Dexmedetomidine during ICU stay|Standard of care
62326439|NCT06281834|EXPERIMENTAL|Dolutegravir PK during weekly rifapentine/isoniazid for TB prevention|This is a single arm study: all patients are started on standard HIV treatment, with LTBI/TB prevention treatment varying according to age cohorts. Children 2-11 years receive standard weekly rifapentine/isoniazid (3HP) for TB prevention; those \<2 years received a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis.
62326440|NCT00291525|EXPERIMENTAL|AVR Low Risk without warfarin|AVR Low Risk without warfarin
62326441|NCT00291525|ACTIVE_COMPARATOR|AVR low risk with standard warfarin|AVR low risk with standard warfarin
62326442|NCT00291525|EXPERIMENTAL|AVR High risk with lower warfarin|AVR High risk with lower warfarin
62326443|NCT00291525|ACTIVE_COMPARATOR|AVR High Risk with standard warfarin|AVR High Risk with standard warfarin
62326444|NCT00291525|EXPERIMENTAL|MVR with lower warfarin|MVR with lower warfarin
62326445|NCT00291525|ACTIVE_COMPARATOR|MVR with standard warfarin|MVR with standard warfarin
62326446|NCT03871257|ACTIVE_COMPARATOR|Arm I (carboplatin, vincristine)|"INDUCTION: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 and vincristine IV or IV push over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI during screening and on study.~MAINTENANCE: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, and 22 and vincristine IV or IV push over 1 minute on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI on study and during follow-up."
62326447|NCT03871257|EXPERIMENTAL|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment is continuous and repeats every 28 days for 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the trial.
62326448|NCT00001452||1|families with PPNAD and/or Carney complex
62326449|NCT06207032||Cohort 001: KRAS mutated CRC|No intervention.
62692625|NCT03014414|ACTIVE_COMPARATOR|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. \[The study and investigative team have no financial relationship with Weight Watchers\].
61933214|NCT00273910|EXPERIMENTAL|Adj-3 A2 gp209(2M) in saline ID|gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
61933215|NCT00273910|EXPERIMENTAL|Adj-3 A2 gp209(2M) in saline ID + Imiquimod|gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.
62326450|NCT06207032||Cohort 002: KRAS mutated PDAC|No intervention.
62326451|NCT06207032||Cohort 003: KRAS mutated NSCLC|No intervention.
62326452|NCT04998877||Heart Failure with Preserved Ejection Fraction|
62326453|NCT04998877||Healthy Volunteers|
62326454|NCT05224102|EXPERIMENTAL|Main Phase: Faricimab|Participants in the main study phase will receive 6-milligram (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) up to Week 20, followed by 6-mg IVT faricimab injections once every 8 weeks (Q8W) up to Week 52. Participants will return for the Week 56 safety follow-up visit after ≥28 days following their last study treatment.
62326455|NCT05224102|EXPERIMENTAL|Long-Term Extension Phase: Faricimab|Eligible participants in the U.S. who opt to continue into the long-term extension (LTE) phase of this study will receive 6-mg faricimab IVT injections according to the personalized treatment interval (PTI) dosing algorithm. The minimum and maximum PTIs in the LTE are Q4W and once every 24 weeks (Q24W), respectively.
62326456|NCT06163534||Metastatic or unresectable recurrent HNSCC|Up to 500 participants (including primary tumor location of pharynx, larynx, oral cavity and oropharynx) with metastatic or unresectable recurrent HNSCC who are intended for first line immunotherapy or combination therapy. No intervention.
62484819|NCT02538627|EXPERIMENTAL|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
62133340|NCT02463448|EXPERIMENTAL|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
62133341|NCT02147717|EXPERIMENTAL|Laser stimulation|"Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
62326457|NCT04867317|ACTIVE_COMPARATOR|Growth Hormone Replacement Therapy|Recombinant Human Growth Hormone
62326458|NCT04867317|PLACEBO_COMPARATOR|Placebo|Placebo
62484820|NCT02538627|EXPERIMENTAL|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
62133342|NCT02147717|PLACEBO_COMPARATOR|fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
62133343|NCT06108024|ACTIVE_COMPARATOR|SM-020 gel 1.0%|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
62133344|NCT06108024|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
62133345|NCT03746470|EXPERIMENTAL|insertion preserving|ACL reconstruction preserving insertion
62133346|NCT03746470|ACTIVE_COMPARATOR|insertion detaching|ACL reconstruction detaching insertion
62133347|NCT02400931|ACTIVE_COMPARATOR|mask ventilation|Mask ventilation will be performed before the tracheal intubation.
62133348|NCT02400931|EXPERIMENTAL|no mask ventilation|Mask ventilation will not be performed before the tracheal intubation.
62133349|NCT04376567|ACTIVE_COMPARATOR|One stage approach|To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure.
62133350|NCT04376567|ACTIVE_COMPARATOR|Two Stage approach|To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured.
62133351|NCT00761553|EXPERIMENTAL|1|Solid dietary supplements with exercise
62326459|NCT06013241|EXPERIMENTAL|Brensocatib 40 mg|Participants will receive brensocatib 40 mg tablet, orally, QD for 24 weeks along with mometasone furoate nasal spray (MFNS) by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
62326460|NCT06013241|EXPERIMENTAL|Brensocatib 10 mg|Participants will receive brensocatib 10 mg tablet, orally, QD for 24 weeks along with MFNS by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
62484821|NCT02538627|EXPERIMENTAL|Colorectal cancer Expansion|Doses established in part 1 of the study
62484822|NCT02538627|EXPERIMENTAL|Head and neck Expansion|Doses established in part 1 of the study
62484823|NCT04892953|EXPERIMENTAL|Cohort A (oligoprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62484824|NCT04892953|EXPERIMENTAL|Cohort B (polyprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Patients also receive one of the following chemotherapy options: carboplatin and paclitaxel on day 1, carboplatin on day 1 and nab-paclitaxel on days 1, 8, 15, or carboplatin on day 1 and gemcitabine on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous histology receive pemetrexed on day 1 every 21 days for cycles 1-4, pemetrexed and durvalumab IV on day 1 every 28 days in the absence of disease progression or unacceptable toxicity.
62484825|NCT05997108||cases group|
62484826|NCT05997108||control group|
62133352|NCT00761553|EXPERIMENTAL|2|Solid dietary supplements without exercise
62133353|NCT00761553|EXPERIMENTAL|3|Liquid dietary supplements with exercise
62133354|NCT00761553|EXPERIMENTAL|4|Liquid supplements without exercise
62133355|NCT05437653|ACTIVE_COMPARATOR|Control group|Healthy weight group ( same age and sex)
62133356|NCT05437653|ACTIVE_COMPARATOR|Obese group|Obese group
62133357|NCT05641506|EXPERIMENTAL|Arm|Participants received Niraparib 200mg or 300mg QD PO continually combined with Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.
62133358|NCT05048251|EXPERIMENTAL|cTBS|continuous TBS to right MFG
62133359|NCT05048251|EXPERIMENTAL|iTBS|intermittent TBS to right MFG
62133360|NCT05048251|SHAM_COMPARATOR|sham|sham stimulation to right MFG
62133361|NCT06083766||Transmasculine/transfeminine individuals and/or transgender men/women (whom are NOT receiving GAHT)|
62133362|NCT06083766||Transmasculine/transfeminine individuals and/or transgender men/women (whom ARE receiving GAHT)|
62133363|NCT02827474||Patient Participants|Patient participants will participate in two patient interviews.
62133364|NCT02827474||Physician Participants|Provider participants will participate in one provider interview.
62133365|NCT04289324|EXPERIMENTAL|Intervention|lung recruitment maneuvers performed every twelve hours during HFOV
62133366|NCT04289324|NO_INTERVENTION|Control|no regular lung recruitment maneuvers during HFOV
62133367|NCT05249842||Respiratory function 3 months after hospital discharge in critically ill COVID-19 patients|All critically ill adult patients admitted to the ICU with confirmed diagnosis of COVID-19 were submitted at least 3 months after hospital discharge to spirometry (FVC, FEV1, FEV1 /;FVC and FEF 25-75%), the 6-minute walk test (6MWT) and evaluation of the physical component summary (PCS) of the SF-36 quality of life instrument.
62133368|NCT02219568|EXPERIMENTAL|obscure gastrointestinal bleeding|Those patients who developed obscure gastrointestinal bleeding either overt or occult bleeding who will then undergo video capsule endoscopy and CT enterography.
62133369|NCT05643456|ACTIVE_COMPARATOR|group 1 :Two muscle surgery|30 patients will underwent two muscle surgery(bilateral lateral rectus muscle recession)
62133370|NCT05643456|ACTIVE_COMPARATOR|group 2:Three muscle surgery|39 patients underwent three muscle surgery(bilateral lateral rectus muscle recession with unilateral medial rectus muscle tucking)
62133371|NCT01690572|ACTIVE_COMPARATOR|Paclitaxel coated balloon catheter|"Paclitaxel coated balloon catheter IN.PACT Falcon"
62326461|NCT06013241|PLACEBO_COMPARATOR|Placebo|Participants will receive a brensocatib-matching placebo tablet, orally, QD for 24 weeks along with MFNS by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
62484827|NCT03884894||sepsis diagnosis by blood colture/molecular biology|fullterm/ preterm neonates hospitalized in NICU with suspect of sepsis
62484828|NCT02353936|EXPERIMENTAL|afatinib group|
62484829|NCT06467344|EXPERIMENTAL|Low dose of ACDN-01|One time low dose of ACDN-01.
62484830|NCT06467344|EXPERIMENTAL|Mid-dose of ACDN-01|One time mid-dose of ACDN-01.
62484831|NCT06467344|EXPERIMENTAL|High dose of ACDN-01|One time high dose of ACDN-01.
62692626|NCT05604586|EXPERIMENTAL|N-acetylcysteine|Intervention: Dietary Supplement: N-acetylcysteine Participants will undergo two exercise tests and daily supplementation with N-acetylcysteine orally in three doses a day for seven consecutive days.
62692627|NCT05604586|PLACEBO_COMPARATOR|Placebo|Supplement: Placebo Participants will undergo two exercise tests and daily supplementation with placebo orally in three doses a day for seven consecutive days.
62133372|NCT01690572|ACTIVE_COMPARATOR|uncoated balloon catheter|"uncoated balloon catheter sprinter legend"
62133373|NCT03272087|ACTIVE_COMPARATOR|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
62133374|NCT03272087|ACTIVE_COMPARATOR|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
62133375|NCT00421889|EXPERIMENTAL|Single arm|"Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle~Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle"
62133376|NCT02119650|EXPERIMENTAL|Ruxolitinib plus Pemetrexed/Cisplatin|
62133377|NCT02119650|ACTIVE_COMPARATOR|Placebo plus Pemetrexed/Cisplatin|
62133378|NCT01318967|PLACEBO_COMPARATOR|PAH|PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
62133379|NCT01318967|ACTIVE_COMPARATOR|MRI after furosemide|After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
62133380|NCT02894879|EXPERIMENTAL|Modify group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 4 modify techniques and receive cardiac rehabilitation phase 1 in postoperative period.
62133381|NCT02894879|SHAM_COMPARATOR|Conventional group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 3 conventional techniques and receive cardiac rehabilitation phase 1 in postoperative period.
62133382|NCT01595789|PLACEBO_COMPARATOR|Placebo + metformin|
62133383|NCT01595789|ACTIVE_COMPARATOR|Liraglutide + metformin|
62133384|NCT00989469|EXPERIMENTAL|Sorafenib and irinotecan|
62133385|NCT03486574||Gastric cancer|Pathologically proven diseases after upper gastroendoscopy and biopsy. Previous pathological reports and endoscopic image can be used.
62326462|NCT00739362|SHAM_COMPARATOR|1-Sham|Active tDCS stimulation
62326463|NCT00739362|ACTIVE_COMPARATOR|2-Active|Active tDCS stimulation
62326464|NCT00739362|SHAM_COMPARATOR|2-Sham|Sham/no-stimulation
62484832|NCT00996697|ACTIVE_COMPARATOR|Triple therapy|Symbicort and tiotropium
62692628|NCT04502108||Employees|Employees of the Department of Health Professions, Bern University of Applied Sciences
62484833|NCT00996697|PLACEBO_COMPARATOR|Combination therapy|Symbicort and placebo
62484834|NCT02036086|EXPERIMENTAL|Vemurafenib, pill, twice daily|Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily
62692629|NCT04502108||Students|Students of the Department of Health Professions, Bern University of Applied Sciences
61933216|NCT00273910|EXPERIMENTAL|Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
62133386|NCT03486574||non-gastric cnacer|Rull out gastric cancer by upper gastroendoscopy. The results 3 moths before enrollment is available.
62133387|NCT03980613||Spontaneous subarachnoid haemorrhage|Patients with verified spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
62484835|NCT00064038|EXPERIMENTAL|Arm I|Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62484836|NCT00064038|ACTIVE_COMPARATOR|Arm II|Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
62484837|NCT04206267|EXPERIMENTAL|Acceledent group|Patients up to 18 years old who were planned first premolar extractions assigned to study group. AcceleDent Aura appliance was applied for 20 minutes per day. during canine retraction.
62484838|NCT04206267|NO_INTERVENTION|Control group|Patients up to 18 years old who were planned first premolar extractions assigned to control group. The canine retractions were performed without any additional vibrational device.
62484839|NCT01548586|ACTIVE_COMPARATOR|Anodal tDCS|
62484840|NCT01548586|ACTIVE_COMPARATOR|Cathodal tDCS|
62484841|NCT01548586|PLACEBO_COMPARATOR|Placebo type tDCS|
62133388|NCT03980613||Controls|Patients without spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
62133389|NCT02405013|EXPERIMENTAL|Sofosbuvir+Ribavirin|Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
62133390|NCT02405013|EXPERIMENTAL|Sofosbuvir+Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
62133391|NCT03822988||patients accepting to answer to the survey|patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
62326465|NCT00739362|ACTIVE_COMPARATOR|3-Active|Active tDCS stimulation
61933217|NCT00273910|EXPERIMENTAL|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
62133392|NCT01657604|EXPERIMENTAL|Nilotinib+IFN|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with Peginterferon α2b at a starting target dose of 30μg/week.
62133393|NCT01657604|ACTIVE_COMPARATOR|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily.
62133394|NCT00926354|EXPERIMENTAL|AS101 infusion|Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
62326466|NCT00739362|SHAM_COMPARATOR|3-Sham|Sham/no-stimulation
62326467|NCT05575063|EXPERIMENTAL|Investigational Healon EndoCoat|Eligible subjects to be randomly assigned to receive investigational Healon EndoCoat in one eye and control Healon EndoCoat in fellow eye.
62326468|NCT05575063|ACTIVE_COMPARATOR|Control Healon EndoCoat|Eligible subjects to be randomly assigned to receive investigational Healon EndoCoat in one eye and control Healon EndoCoat in fellow eye.
62484842|NCT03218813|NO_INTERVENTION|Control cohort ('before' group)|Control cohort ('before' group): eligible patients will receive treatment as usual (TAU) and will complete all outcome measures.
62484843|NCT03218813|EXPERIMENTAL|Intervention cohort ('after' group)|Eligible patients will receive the pharmacist-led intervention and will complete all outcome measures.
62484844|NCT01159145|EXPERIMENTAL|D961H 10 mg capsule|2 way crossover
62484845|NCT01159145|EXPERIMENTAL|Omeprazole 10 mg tablet|2 way crossover
62484846|NCT03502811||MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR and XTR system
62484847|NCT05163691|EXPERIMENTAL|Group A - 6 mg single-dose|A single, inhaled dose of GH001 6 mg or placebo (randomized as 8 active and 2 placebo subjects)
62484848|NCT05163691|EXPERIMENTAL|Group B - 12 mg single-dose|A single, inhaled dose of GH001 12 mg or placebo (randomized as 8 active and 2 placebo subjects)
62484849|NCT05163691|EXPERIMENTAL|Group C - 18 mg single-dose|A single, inhaled dose of GH001 18 mg or placebo (randomized as 8 active and 2 placebo subjects)
62484850|NCT05163691|EXPERIMENTAL|Group D - Individualized Dosing Regimen, 1-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 1-hour dose interval (8 subjects)
61933218|NCT05379972|EXPERIMENTAL|HR deficient cohort|Pre-identified presence of somatic or germline deleterious mutation, as determined by NGS only, in at least one gene critical to DNA repair through homologous recombination, including but not limited to: ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1, BRCA2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC.
61933219|NCT05379972|EXPERIMENTAL|HR proficient cohort|No identifiable somatic or germline deleterious mutation in DNA Response and Repair pathway
62326469|NCT06394180||Perforation during thrombectomy|The target cohort includes 500 patients where vessel perforation occured during Thrombectomy.
62326470|NCT06394180||No perforation during thrombectomy|The comparison cohort includes 500 patients, matched to the target cohort, where vessel perforation did not occur during Thrombectomy.
62484851|NCT05163691|EXPERIMENTAL|Group E - Individualized Dosing Regimen, 2-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 2-hour dose interval (8 subjects)
62484852|NCT06348329|EXPERIMENTAL|education without co-participation|
62484853|NCT06348329|EXPERIMENTAL|education with co-participation|
61933220|NCT00810381|ACTIVE_COMPARATOR|1|"Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):~0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes"
62484854|NCT06446869|EXPERIMENTAL|Gyntima Menopause|Study treatment
62484855|NCT06446869|PLACEBO_COMPARATOR|Placebo|Placebo comparator arm
62484856|NCT06626750|ACTIVE_COMPARATOR|Traditional School Readiness Parenting Program|Parents will be required to attend a School Readiness Parenting Program for 1.5 to 2 hours weekly. Sessions include behavioral management strategies and school readiness. Behavior management strategies are delivered to the entire group via a Community Parent Education Program (COPE) style modeling problem solving approach; parents contribute to the didactic discussion. The behavioral management content is derived from Parent-Child Interaction Therapy (PCIT).
62484857|NCT06626750|EXPERIMENTAL|School Readiness Parenting Program + Cognitive Behavioral Therapy|For those randomly assigned to the additional parenting stress modules, parents will receive the same SRPP as well as three additional modules to target parenting stress. The modules will incorporate practices based on Cognitive-Behavioral Therapy (CBT).
62484858|NCT00151593|EXPERIMENTAL|1|Celsior preservation solution
62484859|NCT01814904|EXPERIMENTAL|MCI-196-L|MCI-196 BSA eq 3g
62484860|NCT01814904|EXPERIMENTAL|MCI-196-M|MCI-196 BSA eq 6g
62484861|NCT01814904|EXPERIMENTAL|MCI-196-H|MCI-196 BSA eq 9g
62692630|NCT06371352|ACTIVE_COMPARATOR|iTBS over the left DLPFC|Active iTBS with intensity of 120% of the resting motor threshold recorded from the right first dorsal interosseus will be administered over the left DLPFC. Therapy will include 90 sessions (three sessions in each of 20 consecutive working days - four weeks in total). In every session 900 magnetic pulses will be elicited.
61933221|NCT00810381|ACTIVE_COMPARATOR|2|"Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):~0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes"
61933222|NCT00810381|ACTIVE_COMPARATOR|3|"Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):~0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes"
61933223|NCT00810381|PLACEBO_COMPARATOR|4|Physiologic saline solution
61933224|NCT04533880|PLACEBO_COMPARATOR|Control|The control group will receive autologous bone obtained from the BTBPB graft harvest
61933225|NCT04533880|ACTIVE_COMPARATOR|Autologous Bone + DBM|Autologous bone plus demineralized bone matrix
61933226|NCT04533880|ACTIVE_COMPARATOR|Autologous Bone + Calcium Phosphate Cement|Autologous bone plus calcium phosphate cement
62133395|NCT00926354|NO_INTERVENTION|Control group|Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly.
62484862|NCT01814904|ACTIVE_COMPARATOR|CBPB|Calcium-based P binder
62484863|NCT03922555|EXPERIMENTAL|ASTX727 (Cedazuridine + Cytidine Antimetabolite Decitabine)|-ASTX727 administered orally for 5 or 6 consecutive days every 28d cycle and will de-escalate to 4 consecutive days every 28 d cycle.
62484864|NCT03922555|EXPERIMENTAL|Expansion Cohort|"* Oral ASTX727 will be administered daily for 4, 5 or 6 consecutive days~* Surgical resection will take place 12 days (+/- 1 day) after initiation of treatment"
62484865|NCT01674907||Cohort|
62484866|NCT01002963|EXPERIMENTAL|PF-04418948 30 mg|
62484867|NCT01002963|EXPERIMENTAL|PF-04418948 100 mg|
62692631|NCT06371352|EXPERIMENTAL|cTBS over the right DLPFC|Active cTBS with intensity of 120% of the resting motor threshold recorded from the left first dorsal interosseus will be administered over the right DLPFC. Therapy will include 90 sessions (three sessions in each of 20 consecutive working days - four weeks in total). In every session 1200 magnetic pulses will be elicited.
62484868|NCT01002963|EXPERIMENTAL|PF-04418948 300 mg|
62484869|NCT01002963|EXPERIMENTAL|PF-04418948 1000 mg|
62484870|NCT01002963|EXPERIMENTAL|PF-04418948 3000 mg|
62484871|NCT01002963|EXPERIMENTAL|PF-04418948 4500 mg|
62484872|NCT01002963|EXPERIMENTAL|PF-04418948 6000 mg|
62484873|NCT04972578|ACTIVE_COMPARATOR|Screw Fixation|Traditional fixation method of placing one or two screws across the syndesmosis.
62484874|NCT04972578|ACTIVE_COMPARATOR|Suture Button|Suture button implants which use a suture and anchor to repair the syndesmosis
62484875|NCT00978536|OTHER|group 1|MS with cortical cognitive troubles
62484876|NCT00978536|OTHER|group 2|MS with subcortical cognitive troubles
61933227|NCT04885946|EXPERIMENTAL|Vancomycin 125 x 4 for 10 days + 2 Fecal Microbota Transplantation|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, FMT.
61933228|NCT04885946|PLACEBO_COMPARATOR|Vancomycin 125 x 4 for 10 days + 2 Placebo|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, placebo.
61933229|NCT04885946|OTHER|Open-label for screened, but not randomized patients with fulminant CDI|This arm exists for patients with fulminant CDI and for randomization to placebo may be considered unethical.
61933230|NCT04473846|EXPERIMENTAL|PF group|The first group will undergo general anesthesia using Fentanyl and Propofol.
61933231|NCT04473846|EXPERIMENTAL|PFK group|The second group will receive a mixture that consists of Fentanyl, Propofol, and Ketamine. In addition, Lidocaine will be added to reduce the pain on injection caused by Propofol.
62326471|NCT04846881|EXPERIMENTAL|Iclepertin|
62484877|NCT00978536|OTHER|group 3|MS in the early stage of the disease when cognitive troubles are absent or inconspicuous
62484878|NCT01934816|EXPERIMENTAL|Glimepiride|4mg of Glimepiride once only before vascular testing and intradermal injections of GLP-1 and its analogues
62484879|NCT01934816|PLACEBO_COMPARATOR|Placebo tablet|Placebo tablet is given in the morning of the intradermal injections of GLP-1 and its analogues
62484880|NCT01934816|ACTIVE_COMPARATOR|Glyburide|10mg of Glyburide before study visit and intradermal injections of GLP-1 and its analogues
62692632|NCT06371352|SHAM_COMPARATOR|Sham stimulation|Active iTBS or cTBS will be administered over the left or right DLPFC respectively with sham coil. Therapy will include 90 sessions (three sessions in each of 20 consecutive working days - four weeks in total). In every session 900 or 1200 magnetic pulses will be elicited.
62692633|NCT06643195|EXPERIMENTAL|Disease control group|1.patients proceeded to allogeneic HSCT as soon as possible..
62326472|NCT04846881|PLACEBO_COMPARATOR|Placebo|
62484881|NCT04703504|EXPERIMENTAL|multi-intervention|"* Automatic creation of discharge prescription (personalized checklist of possible therapeutic optimizations generated from clinical data entered into the platform. This checklist will comply with the recommendations on altered left ventricular ejection fraction from European Society of Cardiology 2016.~* Automatic creation of documents for patient:~  * Reminder letter to make an appointment with his general practitioner (at 7 days) and cardiologist (1 month) and to report the prescribed blood test.~ * Drug prescription.~ * Prescription for blood tests (5 days and 25 days before seeing the general practitioner and cardiologist).~ * Therapeutic education documents~* Patients will receive numerous messages (SMS / e-mail) in order to 1 / not forget their medical appointments, 2 / not to forget to make and bring back their blood test for the consultation, 3 / to perfect the therapeutic education advice provided previously"
62484882|NCT04703504|NO_INTERVENTION|Control|Discharge prescription according to the investigator's habits.
62484883|NCT00833300|ACTIVE_COMPARATOR|1|Haloperidol
62133396|NCT01635712|EXPERIMENTAL|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days on a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level
62133397|NCT00001258||1|Patients with schizophrenia spectrum disorder
62326473|NCT06745908|EXPERIMENTAL|Experimental Arm|Treatment regimen will consist of 2, 3-week cycles followed by repeated 2-week cycles with a ± 3-day window for each visit. Agents are to be administered in the order listed (eg, on day 1 experimental arm \[cycles 1 and 2\], administer ANKTIVA, followed by nivolumab and then followed by docetaxel).
62326474|NCT06745908|OTHER|Control Arm|The control arm treatment regimen will consist of repeated 3-week cycles with a ± 3-day window for each visit of Docetaxel 75 mg/m2 IV.
62326475|NCT06617715|EXPERIMENTAL|Experimental Group|Participants aged 6 weeks-5 years will receive 4 doses of Sinovac PCV13 according to different immunization schedules.
62326476|NCT06617715|ACTIVE_COMPARATOR|Active Comparator Group|Participants aged 6 weeks-5 years will receive 4 doses of Prevnar 13® according to different immunization schedules.
62326477|NCT06741228|PLACEBO_COMPARATOR|Arm 1 - Placebo|A substance that is designed to have no therapeutic value
62484884|NCT00833300|ACTIVE_COMPARATOR|2|Olanzapine
62692634|NCT06643195|EXPERIMENTAL|Retreatment group|2. Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
62133398|NCT00001258||2|normal volunteers
62133399|NCT04803409|EXPERIMENTAL|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
62133400|NCT04803409|NO_INTERVENTION|Control Group|Control Group
62133401|NCT05783791||Participants with Angelman Syndrome (AS)|AS confirmed by molecular testing
62484885|NCT01506622|ACTIVE_COMPARATOR|Propofol group|intravenous administration of propofol 1 mg/kg at the end of anesthesia
62484886|NCT01506622|ACTIVE_COMPARATOR|Fentanyl group|intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia
62484887|NCT01506622|ACTIVE_COMPARATOR|Control group|intravenous administration of saline at the end of anesthesia
62133402|NCT05783791||Participants with Prader-Willi Syndrome (PWS)|PWS confirmed by molecular testing
62133403|NCT05783791||Healthy Controls|
62133404|NCT01294956|EXPERIMENTAL|FID 115958D|Lubricant Eye Drop
62133405|NCT01294956|ACTIVE_COMPARATOR|Refresh Liquigel|Lubricant Eye Drop
62326478|NCT06741228|EXPERIMENTAL|Arm 2 - 100µg MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
62326479|NCT03438552|EXPERIMENTAL|SBRT at a total dose of 30 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30 Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
62326480|NCT03438552|EXPERIMENTAL|SBRT at a total dose of 25 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
62326481|NCT03438552|EXPERIMENTAL|SBRT at a total dose of 36 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
62326482|NCT00001481|PLACEBO_COMPARATOR|Group 1, Hormone and Placebo Group|8 weeks of hormonal addback plus 4 weeks of placebo
62326483|NCT00001481|ACTIVE_COMPARATOR|Group 2, Continued Replacement Group|12 weeks of hormone addback
62326484|NCT06707688|EXPERIMENTAL|Amulet™ 2 Left Atrial Appendage (LAA) Occluder|Transcatheter left atrial appendage (LAA) occluder
62326485|NCT05864846|EXPERIMENTAL|Cannabidiol Oral Solution|Participants who will receive the Cannabidiol Oral Solution (CBD-OS) titrated up to a dose of 12.5 mg/kg administered twice daily for a total dose of up to 25 mg/kg/day for 26 consecutive weeks. Participants will have the option to continue receiving the CBD-OS for an additional 26 weeks, for a total of 52 weeks.
62326486|NCT06724718|EXPERIMENTAL|Smartwatch group|Experimental intervention using smartwatches for rhythm monitoring.
62326487|NCT06724718|ACTIVE_COMPARATOR|Control group|Standard care without smartwatch monitoring
62484888|NCT03632031||Patients with chronic non-healing wounds|Patients with chronic non-healing wounds with planned use of OASIS Extracellular Wound Matrix
62692635|NCT06644885||Patients with TIVAD|
62133406|NCT04595305|OTHER|Treatment Arm - Standard of Care|Implantation of CRT-P or CRT-D for a clinical indication as per standard of care.
62326488|NCT06743308||Information needs, preferences, and understanding trial (INPUT)|"Participants are expected to be in this research study for about 6 months. Participants will be asked answer questionnaires about your perception of curability, your overall illness understanding, anxiety, depression, quality of life, quality of communication, feelings of being heard and understood, symptom burden, and goals of care at three total visits: initial, 3-month and 6-month follow-up visits. The questionnaires should take about 30 minutes to complete.~Participants may be asked to complete a brief screening questionnaire at each visit with your oncology team during the study period. This questionnaire includes questions about illness understanding, information needs and preferences regarding your illness. It should take about 5 minutes to complete."
62326489|NCT06624670|EXPERIMENTAL|Spesolimab|
62326490|NCT06624670|PLACEBO_COMPARATOR|Placebo|
62484889|NCT04548258|EXPERIMENTAL|electric welded metal framework|using electric welding device to intraorally join metal framework where the study aim to save time and cost and eliminate lab errors
62692636|NCT06640712|EXPERIMENTAL|Arm 1: Methamphetamine Use Group|This group consists of individuals diagnosed with Methamphetamine Use Disorder. Diagnoses were conducted by the same psychiatrist for all participants. Following psychiatric evaluation, participants underwent a clinical oral health examination to assess their dental health status, with the Decayed, Missing, and Filled Teeth (DMFT) index being calculated afterward. This group is included to investigate the impact of methamphetamine use on oral health.
62692637|NCT06640712|EXPERIMENTAL|Arm 2: Cannabis Use Group|This group consists of individuals diagnosed with Cannabis Use Disorder. Diagnoses were performed by the same psychiatrist for consistency. After the psychiatric assessment, participants received a clinical oral health examination to determine their dental health status, and the DMFT index was calculated subsequently. This group aims to assess the effects of cannabis use on oral health.
62692638|NCT06640712|EXPERIMENTAL|Arm 3: Polysubstance Use Group|This group includes individuals who use multiple substances (polysubstance use disorder). All participants were evaluated by the same psychiatrist to ensure diagnostic accuracy. Following their psychiatric evaluation, participants had a clinical oral health examination, during which the DMFT index was calculated to assess dental health. This group is included to examine the impact of polysubstance use on oral health.
61933232|NCT04372797|EXPERIMENTAL|Mild Traumatic Brain Injury Participants|Males and females from 18-50 years of age who present to a recruitment site within 10 days of injury with a diagnosed concussion that meets all of the following criteria: 1) clear mechanism of injury (i.e., direct or indirect impact to head), 2) Glasgow Coma Scale= 13-15, 3) observed or reported signs (e.g., loss of consciousness, amnesia, or confusion) or symptoms (e.g., headache, dizziness, nausea), and 3) neurosensory symptoms.
62133407|NCT01778907|NO_INTERVENTION|Normal genotype- control (NG-C)|In the external control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice. Allocation to this arm is not based on randomization.
62326491|NCT04194216|ACTIVE_COMPARATOR|Treatment arm A|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."
62692639|NCT06640712|OTHER|Arm 4: Control Group|Healthy, non-substance-using individuals This group consists of healthy individuals with no history of substance use, systemic medical conditions, or regular medication use. Diagnoses were confirmed by the same psychiatrist. Afterward, participants underwent a clinical oral health examination, and the DMFT index was calculated to provide a baseline for comparison with substance-using groups. This group serves as the control group to compare the dental health outcomes of non-substance-using individuals.
62692640|NCT01657331|EXPERIMENTAL|Brentuximab Vedotin / Bendamustine|Subjects with relapsed or refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma will receive Brentuximab Vedotin in combination with Bendamustine, and prophylactic Neulasta
62326492|NCT04194216|ACTIVE_COMPARATOR|Treatment arm B|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg every 4 hours or clindamycin 150mg every 6 hours, for a duration of three days."
62326493|NCT06706336|ACTIVE_COMPARATOR|Active Radon Mitigation|Active radon mitigation system
62326494|NCT06706336|SHAM_COMPARATOR|Inactive radon mitigation system control( sham)|Inactive radon mitigation system looks and sounds like active but doesn't reduce radon ( sham)
62326495|NCT02311959|EXPERIMENTAL|Invasive or in situ breast carcinoma.|
62326496|NCT06737627||Intellectual disability|
62326497|NCT06686147||Low Back Pain Patient Group|
62326498|NCT06686147||Healthy Control Group|
62326499|NCT06748053|EXPERIMENTAL|Part A: Dose Finding - GSK5784283|
62326500|NCT06748053|EXPERIMENTAL|Part A: Dose Finding - Placebo|
62326501|NCT06748053|EXPERIMENTAL|Part B: Extended Dosing - GSK5784283|
62326502|NCT06748053|EXPERIMENTAL|Part B: Extended Dosing - Placebo|
62484890|NCT04548258|EXPERIMENTAL|conventional cast metal technique|using the conventional casting technique to join metal framework and compare it with the electric welding technique
62484891|NCT05972759|EXPERIMENTAL|Experimental Arm|Two modes of high intensity exercise.
62484892|NCT01080703|EXPERIMENTAL|Lower extremity strengthening|
62326503|NCT06747299||patients diagnosis of T-NK cell lymphoma|
62484893|NCT04379739|EXPERIMENTAL|camrelizumab + apatinib|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; apatinib 250 mg, qd, p.o. 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
62133408|NCT01778907|NO_INTERVENTION|Deviating genotype -control (DG-C)|In the internal control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice
62326504|NCT06732037|ACTIVE_COMPARATOR|Conventional physical therapy program|It consists of thirty patients with cervical radiculopathy. They will receive conventional physical therapy program.
62326505|NCT06732037|EXPERIMENTAL|Conventional physical therapy program + Kinetic control training|It consists of thirty patients with cervical radiculopathy. They will receive conventional physical therapy program plus kinetic control training.
62326506|NCT03788369||Multivessel coronary artery disease|must include left anterior descending artery
62484894|NCT04379739|EXPERIMENTAL|camrelizumab + platinum-based chemotherapy|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (squamous: carboplatin AUC5, gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
62484895|NCT00433719|EXPERIMENTAL|1|Combivir, efavirenz for 12 months
62484896|NCT00433719|PLACEBO_COMPARATOR|2|Placebo for 2 months followed by Combivir and efavirenz for 10 months
62484897|NCT03185208|EXPERIMENTAL|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
62133409|NCT01778907|EXPERIMENTAL|Deviating genotype (DG-I)|In the intervention group, genotype information accompanied by a drug dosing advice will be given to the treating physician. Blood level of the drug will be communicated by a dedicated research team to the treating physician according to daily practice.
62692641|NCT05509660|EXPERIMENTAL|Therapist-guided internet-based CBT treatment with increased therapist support|"Intervention/treatment: Behavioral: 'PUMA+'~8-week transdiagnostic CBT with therapist-support. One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules (acceptance; maintenance of skills learned). From mid-treatment onwards, participants will be offered increased therapist support."
62133410|NCT03438903||Normal group|Healthy subjects without any ocular problems Repeat exams of OCT device (SD and SS-OCT)
62133411|NCT03438903||Retinal diseases group|Patients with various macular diseases Repeat exams of OCT device (SD and SS-OCT)
62133412|NCT03721913|EXPERIMENTAL|Intervention group|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
62133413|NCT03721913|NO_INTERVENTION|Control group|The control group will not receive the intervention during the study.
62133414|NCT04601974|EXPERIMENTAL|lentiviral gene therapy treatment (Intervention Arm)|Patients will receive a single dose of lentiviral gene therapy treatment administered once intracranially
62133415|NCT06092255|EXPERIMENTAL|Preventive radiotherapy irradiation SVZ group|GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
62133416|NCT06004765|EXPERIMENTAL|lenalidomide and sequential azacitidine|Lenalidomide (10mg/d \*21 days, 28 days for 1 course), at least 2 courses. If effective, continue to use lenalidomide until ineffective or intolerant. Patients receive azacitidine (75mg/m2/d\*5 days, 28 days for 1 course). Until progression or intolerance. At least 2 sessions of treatment are needed.
62133417|NCT06004765|EXPERIMENTAL|azacitidine|Azacitidine (75mg/m2/d\*5 days, 28 days for 1 course) for at least 4 courses
62326507|NCT06719011|EXPERIMENTAL|Part A: NNC0174-1213 (SD1-SD5)|Part A: Single ascending dose (SAD) of NNC0174-1213 will be administered in cohorts 1-5.
62326508|NCT06719011|EXPERIMENTAL|Part A: Cagrilintide (SDA and SDB)|"Part A: Single ascending dose (SAD): Cagrilintide SDA will be administered in cohort 1 and 2.~Cagrilintide SDB will be administered in cohort 3 and 4."
62326509|NCT06719011|EXPERIMENTAL|Part A: Placebo|Part A: Single ascending dose (SAD) of placebo will be administered to cohorts 1-5.
62326510|NCT06719011|EXPERIMENTAL|Part B: NNC0174-1213 (MD1-MD5)|Part B: Multiple ascending doses (MAD) of NNC0174-1213 will be administered to cohorts 1-5.
62326511|NCT06719011|EXPERIMENTAL|Part B: Cagrilintide (MDA)|Part B: Multiple ascending doses (SAD) of Cagrilintide MDA will be administered to cohorts 1-5.
62326512|NCT06719011|EXPERIMENTAL|Part B: Placebo|Part B: Multiple ascending doses (MAD) of placebo will be administered to cohorts 1-5.
62326513|NCT06694311|EXPERIMENTAL|CPAP|CPAP 12 cmH2O
62326514|NCT06694311|ACTIVE_COMPARATOR|HFNO|HFNO 50 L/min.
62133418|NCT03728764|OTHER|single arm|
62484898|NCT03185208|PLACEBO_COMPARATOR|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
62484899|NCT06237322||Healthy|"Blood Pressure, Heart Rate and Respiration Rate Measurements:~Observations will be made using a medically approved blood pressure monitor, Heart Rate Monitor, Respiration Rate Monitor.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Measurement:~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
62326515|NCT06715488||Inflammatory arthritis|Patients with inflammatory arthritis regardless of etiology including rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosis and viral arthritis
62326516|NCT06746272|ACTIVE_COMPARATOR|SAPB group|Ultrasound guided Serratus anterior block will be performed according to the analgetic standard in our department.
62692642|NCT05509660|ACTIVE_COMPARATOR|Therapist-guided internet-based CBT treatment with standard therapist-support|"Intervention/treatment: Behavioral: 'PUMA' Intervention/treatment: Behavioral: 'PUMA'~8-week transdiagnostic CBT with therapist support. One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules (acceptance; maintenance of skills learned)."
62133419|NCT03750968|EXPERIMENTAL|Carotenoid group|The Carotenoid group will receive a commercially available prenatal vitamin/mineral/Docosahexaenoic acid (DHA) softgel plus a softgel containing lutein/zeaxanthin in safflower oil.
62326517|NCT06746272|NO_INTERVENTION|Standard i.v. analgesia group|A sterile plaster will be placed on an appropriate site to blind ICU and PACU personnel of the intervention. Patients will receive i.v. analgesia according to the analgesic standard of care in our department.
62692643|NCT05406726|EXPERIMENTAL|palmitoylethanolamide (PEA)|Palmitoylethanolamide (PEA) is a lipid based endocannabinoid dietary supplement currently marketed.
62692644|NCT05406726|PLACEBO_COMPARATOR|Placebo|A similar size and shaped capsule containing maltodextrin will be used as a placebo comparator.
62692645|NCT03809533|EXPERIMENTAL|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Kidney recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
61933233|NCT04372797|ACTIVE_COMPARATOR|Control Participants|Age- and sex-matched control subjects with minor, non-surgical injuries (e.g., sprains, strains) not requiring hospital admission and no history of mild traumatic brain injury will be recruited from the same study sites.
62326518|NCT06746909|ACTIVE_COMPARATOR|MCI training|After baseline assessment the MCI-training group will receive a 7 months-long multidomain training, including cognitive, physical exercise and music therapy; Enrolled subjects will be assigned to mixed-gender classes of maximum 10 subjects each and given 2 sessions of 60 minutes supervised cognitive training per day, 3 times a week, and one of 60 minutes supervised aerobic physical activity per day, 3 times a week for 7 months.
62326519|NCT06746909|NO_INTERVENTION|MCI no-training|Follow up of natural history of subjects after 7 months
62326520|NCT06746909|NO_INTERVENTION|healthy subjects|Follow up of natural history of subjects after 7 months
62326521|NCT06746909|NO_INTERVENTION|SCD|Follow up of natural history of subjects after 28 months
62326522|NCT06746909|ACTIVE_COMPARATOR|SCD training|After baseline assessment the MCI-training group will receive a 7 months-long multidomain training, including cognitive, physical exercise and music therapy; Enrolled subjects will be assigned to mixed-gender classes of maximum 10 subjects each and given 2 sessions of 60 minutes supervised cognitive training per day, 3 times a week, and one of 60 minutes supervised aerobic physical activity per day, 3 times a week for 7 months.
62326523|NCT06746909|NO_INTERVENTION|SCD no-training|Follow up of natural history of subjects after 7 months
62326524|NCT04890314||Active Surveillance (AS)|Doctor will monitor the patient without directly treating the cancer.
62326525|NCT04890314||Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment of prostate cancer requiring less than 2 weeks of treatment.
62326526|NCT04890314||Intensity-Modulated Radiation Therapy (IMRT)|Radiation treatment of prostate cancer requiring more than 2 weeks of treatment.
62326527|NCT04890314||Partial Gland Ablation (PGA)|Prostate cancer treatment that involves only treating part of the prostate that has cancer. Examples include, but are not limited to, high intensity focused ultrasound (HIFU) and cryotherapy.
62326528|NCT04890314||Radical Prostatectomy (RP)|Prostate surgery that removes the whole prostate.
62326529|NCT06726889||Standard Care + DSS + Reminders + Feedback|Patients will receive educational material through a web-page, personalized reminders and feedback messages by physician
62326530|NCT06726889||Standard Care + DSS + Reminders|Patients will receive educational material through a web-page and personalized reminders
62326531|NCT06726889||Standard Care + DSS + Feedback|Patients will receive educational material through a web-page and feedback messages by physician
62326532|NCT06726889||Standard Care + DSS|Patients will receive educational material through a web-page
62326533|NCT06726889||Standard Care + Reminders + Feedback|Patients will receive personalized reminders and feedback messages by physician
62326534|NCT06726889||Standard Care + Reminders|Patients will receive personalized reminders
62326535|NCT06726889||Standard Care + Feedback|Patients will receive feedback messages by physician
62326536|NCT06726889||Standard Care|Patient will not receive any additional interventions
62326537|NCT06742047|EXPERIMENTAL|Participating in the Professional development program (ProDeveloP)|The group received the intervention of the Professional Development Programme (ProDeveloP). The planning of the ProDeveloP has been done in close collaboration with stakeholders within the hospital setting where the programme will be implemented. The programme includes face-to-face approaches from peer learning and e-learning modalities.
62692646|NCT03809533|EXPERIMENTAL|HCV seropositive viremic (HCV Ab+/NAT+) donor|Starting post-operative day 1, kidney recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
62692647|NCT06673615||Stages of Heart Failure in a Community-based Cohort China|A community-based cohort on stage A (at risk for HF), stage B (pre-HF) or stage C (symptomatic HF) of heart failure in China elderly people
62692648|NCT06527937|EXPERIMENTAL|Single Doses of DESF and Intramuscular Manual Injection|Single dose of DESF (12 mg) administered after allergen challenge (Treatment Period 1), followed by a single dose of intramuscular (IM) manual injection (0.3 mg) without allergen challenge after a 24-hour washout period (Treatment Period 2), followed by a single dose of DESF (12 mg) without allergen challenge after a 14-day washout period from Treatment Period 1.
61933234|NCT01677637||All measurements|Total measured population
61933235|NCT03411915|EXPERIMENTAL|XmAb18087|XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles
62326538|NCT06742047|NO_INTERVENTION|Control group prior the intervention in 2022|The group did not receive the intervention
62326539|NCT06411860|PLACEBO_COMPARATOR|Treatment A|"All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule:~Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin"
62326540|NCT06411860|EXPERIMENTAL|Treatment B|"All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule:~Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin"
62326541|NCT06411860|EXPERIMENTAL|Treatment C|"All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule:~Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin"
62692649|NCT06527937|EXPERIMENTAL|Repeat Doses of DESF and Intramuscular Manual Injection|Repeat dose of DESF (24 mg \[12 mg x 2\]) administered after allergen challenge (Treatment Period 1), followed by a repeat dose of IM manual injection (0.6 mg \[0.3 mg x 2\]) without allergen challenge after a 24-hour washout period (Treatment Period 2), followed by a repeat dose of DESF (24 mg \[12 mg x 2\]) without allergen challenge after a 14-day washout period from Treatment Period 1.
61933236|NCT03036306|EXPERIMENTAL|1.0 % SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 1.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
61933237|NCT03036306|EXPERIMENTAL|3.0% SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 3.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
61933238|NCT03036306|PLACEBO_COMPARATOR|Placebo cream|Subjects randomized to this arm will have both lateral hip wounds treated with Placebo cream. Intra-subject hip wound treatment is randomly allocated
61933239|NCT05674175|EXPERIMENTAL|Dose Finding Arm|Phase 1 will evaluate the safety of co-administration of CART22-65s with huCART19 in patients who experienced a disease relapse after prior CAR T cell therapy. There is no planned dose escalation but a dose-deescalation will be made based on the incidence of Dose Limiting Toxicities
61933240|NCT05674175|EXPERIMENTAL|Expansion Arm|If at least one dose level of phase 1 is determined to be safe, the phase 2 dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of CART 22-65s and huCART19 cells that were determined to be safe. 2 cohorts are planned: Cohort A (relapsed/refractory, CAR T cell naïve) \& Cohort B (prior treatment with a prior CAR T cell product).
61933241|NCT03923738|EXPERIMENTAL|TCZ IV Q4W|Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.
61933242|NCT06120491|EXPERIMENTAL|Arm 1: Saruparib (AZD5305) + Physician's Choice NHA|Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)
61933243|NCT06120491|PLACEBO_COMPARATOR|Arm 2: Placebo + Physician's Choice NHA|Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)
61933244|NCT01143207|EXPERIMENTAL|Medroxyprogesterone acetate|Single injection of Medroxyprogesterone acetate (hormonal contraceptive)
61933245|NCT05383885||Observational cohort|"The study is an observational study on a single cohort of consecutive out-of-hospital cardiac arrest patients.~All patients in the cohort will be monitored with a non-invasive pletismograph. No intervention will be administered to any patient and no decision on treatment will be based on the collected informations. Treating physicians will be blinded to collected values of perfusion index during the study"
61933246|NCT01428362|EXPERIMENTAL|Placebo/VI-1121|Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.
61933247|NCT01428362|EXPERIMENTAL|VI-1121/Placebo|Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.
61933248|NCT02101203|EXPERIMENTAL|Placebo|40 subjects administered placebo
61933249|NCT02101203|EXPERIMENTAL|Testosterone + Buspirone|40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride
61933250|NCT00736671||Observational Parkinson's Disease|Observational study of subjects with Parkinson disease
61933251|NCT00736671||Observational Normal Control aubjects|Observational study of normal control subjects
61933252|NCT06214507||Prospective|
61933253|NCT06214507||Retrospective only|
61933254|NCT01454115|EXPERIMENTAL|Panel 1: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
61933255|NCT01454115|EXPERIMENTAL|Panel 2: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
61933256|NCT01454115|EXPERIMENTAL|Panel 3: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
61933257|NCT01454115|EXPERIMENTAL|Panel 4: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
61933258|NCT01454115|EXPERIMENTAL|Panel 5: BMS-708163 or Placebo|"Healthy male subjects (age: 18 to 45 years).~In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.~In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1"
61933259|NCT01454115|EXPERIMENTAL|Panel 6: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
61933260|NCT01454115|EXPERIMENTAL|Panel 7: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
61933261|NCT01454115|EXPERIMENTAL|Panel 8: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
61933262|NCT01454115|EXPERIMENTAL|Panel 9: BMS-708163 or Placebo|Healthy, elderly male subjects (age: 60 years and greater)
61933263|NCT01454115|EXPERIMENTAL|Panel 10: BMS-708163 or Placebo|Healthy, elderly female subjects (age: 60 years and greater)
61933264|NCT01454115|EXPERIMENTAL|Panel 11: BMS-708163 or Placebo|Healthy male subjects (age: between 46 to 59 years)
61933265|NCT01454115|EXPERIMENTAL|Panel 12: BMS-708163 or Placebo|Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
61933266|NCT01454115|EXPERIMENTAL|Panel 13: BMS-708163 or Placebo|Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
61933267|NCT01454115|EXPERIMENTAL|Panel 15: BMS-708163 or Placebo|Healthy young male subjects
61933268|NCT06238362|EXPERIMENTAL|TPAP - Experimental Therapy|Experimental therapy in which pressure is reduced during inspiration and the reduction is carried through part of expiration such that the pressure is increased near the end of expiration.
61933269|NCT06238362|ACTIVE_COMPARATOR|CPAP - Traditional OSA Therapy|Standard OSA therapy to which the TPAP therapy will be compared for efficacy.
61933270|NCT00853073|ACTIVE_COMPARATOR|Bevacizumab|subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
61933271|NCT00853073|PLACEBO_COMPARATOR|balanced salt solution|patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
61933272|NCT04684290|ACTIVE_COMPARATOR|Alcohol Septal Ablation|
62133420|NCT03750968|ACTIVE_COMPARATOR|Control group|The Control group will receive the same prenatal vitamin/mineral/Docosahexaenoic acid (DHA) softgel plus a softgel containing only safflower oil.
62133421|NCT05101954|EXPERIMENTAL|Group A|
62133422|NCT05101954|ACTIVE_COMPARATOR|Group B|
62133423|NCT01238146|EXPERIMENTAL|Arm I|Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.
62133424|NCT01238146|EXPERIMENTAL|Arm II|Patients receive rituximab and bendamustine hydrochloride as in arm I.
62133425|NCT00586313|EXPERIMENTAL|a1: Tru-Cut biopsy for liver|Tru-Cut Biospy.
62326542|NCT06411860|ACTIVE_COMPARATOR|Treatment D|"All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule:~Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin"
62326543|NCT06544655|EXPERIMENTAL|Part 1A: BMS-986484 Dose Escalation|
62326544|NCT06544655|EXPERIMENTAL|Part 1B: BMS-986484 + Nivolumab Dose Escalation|
62692650|NCT06397612|EXPERIMENTAL|Group I|"The intervention protocol for Group I peripheral nerve electrostimulation will have the following parameters:~Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient."
62692651|NCT03755336|EXPERIMENTAL|Slipping Perturbations|The intervention involves exposing participants to a series of 12 unannounced slip perturbations while walking overground. These perturbations will be delivered at 3 different times within the gait cycle - early phase, middle phase, and late phase.
62692652|NCT04378790|ACTIVE_COMPARATOR|Sequential treatment|full-time spectacle correction first, with subsequent patching for 2 hours per day/7 days per week only if needed (no improvement (stable/worsening) and residual)
62692653|NCT04378790|EXPERIMENTAL|Simultaneous treatment|full-time spectacle correction and part-time patching for 2 hours per day/7 days per week
62692654|NCT06334146|EXPERIMENTAL|Tap dance program|Participants undertake tap dance program.
61933273|NCT04684290|ACTIVE_COMPARATOR|Surgical Septal Myectomy|
61933274|NCT00814151||MicroPhage|Blood Culture positive specimens available within 24 hours of alarm.
61933275|NCT00814151||Standard of Care|Blood Culture positive specimens.
61933276|NCT04504773|EXPERIMENTAL|Virtual Reality Exposure Therapy|Participants will receive a single session of exposure therapy to address specific phobia that includes the use of virtual reality exposures.
61933277|NCT06707493|EXPERIMENTAL|Ivosidenib|After screening and standard of care hematopoietic stem cell transplantation (HCT) and any standard treatment before and after the HSCT, Ivosidenib will be given orally (PO) once daily (QD) in 28-day continuous cycles. Ivosidenib is administered at a pre-determined dose with a goal of 500mg daily. Participants begin study treatment 45 to 90 days after HCT, and treatment will continue for up to 24 months. Study visits and assessments occur throughout study treatment and in follow-up. After the 24-month treatment period, participants are followed for up to 12 additional months.
61933278|NCT06707493|PLACEBO_COMPARATOR|Placebo|After screening and standard of care hematopoietic stem cell transplantation (HCT) and any standard treatment before and after the HSCT, Placebo will be given orally (PO) once daily (QD) in 28-day continuous cycles. Participants begin study treatment (placebo) 45 to 90 days after HCT, and treatment (placebo) will continue for up to 24 months. Study visits and assessments occur throughout study treatment period and in follow-up. After the 24-month treatment period, participants are followed for up to 12 additional months.
61933279|NCT06589830|EXPERIMENTAL|TL938-Trastuzumab combination|TL938-Trastuzumab combination receives TL938 capsules by mouth once daily. Trastuzumab given intravenously on Day 1 of each Cycle. Cycle length is 21 days
61933280|NCT06589830|EXPERIMENTAL|TL938|TL938 monotherapy receives TL938 capsules by mouth once daily. Cycle length is 21 days.
62133426|NCT01074359|EXPERIMENTAL|A0001|A0001 (0.75 g BID)
62133427|NCT01074359|PLACEBO_COMPARATOR|Placebo|Placebo
62133428|NCT01011582||Novel H1N1 influenza|
62326545|NCT06544655|EXPERIMENTAL|Part 2A: BMS-986484 Dose Expansion|
62326546|NCT06544655|EXPERIMENTAL|Part 2B: BMS-986484 + Nivolumab Dose Expansion|
62326547|NCT05640843|EXPERIMENTAL|Daily Harvest weekly|For 12 weeks, on the Daily Harvest weekly arm, patients will receive two premade meals per day, for lunch and dinner for 6 days weekly, prepared and shipped by U.S.-based company Daily Harvest weekly.
62326548|NCT05640843|EXPERIMENTAL|Supplements|For 12 weeks on the supplement arm, patients will be given algae omega 3 supplements (QWell pharmaceuticals) and curcumin supplements (Sabinsa pharmaceuticals) twice daily.
62326549|NCT05640843|PLACEBO_COMPARATOR|Placebo|For 12 weeks on the placebo arm, patients will be given placebo supplements twice daily (QWell and Sabinsa pharmaceuticals).
62326550|NCT02576431|EXPERIMENTAL|Arm 1_NSCLC|Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed)
62326551|NCT02576431|EXPERIMENTAL|Arm 2_Thyroid|Patients with solid thyroid tumors harboring NTRK fusions (arm closed)
62133429|NCT01011582||Seasonal influenza|
62326552|NCT02576431|EXPERIMENTAL|Arm 3_Sarcoma|Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed)
62326553|NCT02576431|EXPERIMENTAL|Arm 4_Colorectal|Patients with solid colorectal tumors harboring NTRK fusions (arm closed)
62326554|NCT02576431|EXPERIMENTAL|Arm 5_Salivary|Patients with solid salivary tumors harboring NTRK fusions (arm closed)
62133430|NCT01241370||Lean healthy subjects|Homeostasis Model Assessment score (HOMAs) ≤ 2, Body Mass Index (BMI) ≤ 28 kg/m2
62133431|NCT01241370||Insulin-resistnat subjects|HOMAs \> 2, BMI \> 28 kg/m2
62133432|NCT01241370||Type 2 diabetic patients|
62326555|NCT02576431|EXPERIMENTAL|Arm 6_Biliary|Patients with solid biliary tumors harboring NTRK fusions (arm closed)
62326556|NCT02576431|EXPERIMENTAL|Arm 7_Primary CNS|Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed)
62326557|NCT02576431|EXPERIMENTAL|Arm 8_Other tumors|Patients with e.g. kidney cancer, squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions (arm closed)
62326558|NCT02576431|EXPERIMENTAL|Arm 9_Solid tumors without confirmed NTRK fusion|Patients eligible for arms 1 to 8, but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed)
62484900|NCT06237322||Cardio vascular diseases|"Blood Pressure, Heart Rate and Respiration Rate Measurements:~Observations will be made using a medically approved blood pressure monitor, Heart Rate Monitor, Respiration Rate Monitor.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Measurement:~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
62484901|NCT06237322||Pre-Diabetes|"Blood Glucose Measurement:~Participants will use a medically approved glucometer to measure their blood glucose levels.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~PPG Data Collection with Mobile App:~Before each blood glucose measurement, participants will use the RE.DOCTOR Vitals mobile app to collect raw PPG signals.~Then without closing the app, they use medical device and enter blood glucose data from the glucometer into the app after each measurement.~Data collection will be initiated by participants clicking the collect data button on the mobile app.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
62484902|NCT06237322||Diabetes I|"Blood Glucose Measurement:~Participants will use a medically approved glucometer to measure their blood glucose levels.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~PPG Data Collection with Mobile App:~Before each blood glucose measurement, participants will use the RE.DOCTOR Vitals mobile app to collect raw PPG signals.~Then without closing the app, they use medical device and enter blood glucose data from the glucometer into the app after each measurement.~Data collection will be initiated by participants clicking the collect data button on the mobile app.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
62484903|NCT06237322||Diabetes II|"Blood Glucose Measurement:~Participants will use a medically approved glucometer to measure their blood glucose levels.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~PPG Data Collection with Mobile App:~Before each blood glucose measurement, participants will use the RE.DOCTOR Vitals mobile app to collect raw PPG signals.~Then without closing the app, they use medical device and enter blood glucose data from the glucometer into the app after each measurement.~Data collection will be initiated by participants clicking the collect data button on the mobile app.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
62484904|NCT01412827|OTHER|Comparison of radioisotope dosing|
62484905|NCT06245928|EXPERIMENTAL|Experimental Group|The individuals in the experimental group will be trained with an individualized respiratory exercise device for 5 days a week for 8 weeks. The initial pressure load will be set to the resistance level corresponding to 40% of the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements. Participants will be asked to rest following 6 breathing cycles and repeat a total of 36 breathing cycles (6 sets) in each session. Participants will be able to practice both inspiratory and expiratory respiratory muscle training in one breathing cycle. Progression will be increased by 5-10% weekly, with the perceived exertion level being in the range of 4-6 according to the Modified Borg Scale. In addition, physical activity will be recommended.
62133433|NCT01964300|EXPERIMENTAL|Treatment (peginterferon alfa-2b)|Patients receive peginterferon alfa-2b subcutaneously (SC) weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
62133434|NCT04082624|ACTIVE_COMPARATOR|Nutrition condition|Received nutrition information such as the comparison of nutritional information between orange juice and soda pop. Received intervention following measurements at baseline, week 4, and week 8.
62484906|NCT06245928|ACTIVE_COMPARATOR|Control Group|The individuals in the control group will be trained with Threshold® IMT + Threshold™ PEP training for 5 days a week for 8 weeks. Respiratory muscle training will be performed with Threshold® IMT and Threshold™ PEP devices. The training intensity will be set to 40% of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements in the first week. Participants will be asked to perform 6 sets of 6 repetitions for inspiratory and expiratory muscle training separately for a total of 36 repetitions each. Progression will be increased by 5-10% weekly so that the perceived exertion level will be in the range of 4-6 according to the Modified Borg Scale. If the training threshold exceeds the upper-pressure limits of the Threshold® IMT + Threshold™ PEP devices, the training intensity will be continued at the highest limit. In addition, physical activity will be recommended.
62692655|NCT00052897|EXPERIMENTAL|Arm I|"Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity."
62692656|NCT02522221|EXPERIMENTAL|Tecarfarin|Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
61933281|NCT04069299||Participants receiving PET scan|Participants with metastatic poorly-differentiated neuroendocrine carcinomas of the GI tract
61933282|NCT02135159|EXPERIMENTAL|TDM1 concommitant with RT|T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22.
61933283|NCT02135159|EXPERIMENTAL|TDM1 during and after RT|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36.
62133435|NCT04082624|EXPERIMENTAL|Affective condition|Learned about the affective benefits (e.g., less depression) of reduced office sitting time through taking active breaks. Received intervention following measurements at baseline, week 4, and week 8.
62133436|NCT04082624|EXPERIMENTAL|Instrumental condition|Learned about instrumental benefits such as the relationship between sitting and cardiovascular disease and absenteeism at work. Received intervention following measurements at baseline, week 4, and week 8.
62326559|NCT02576431|EXPERIMENTAL|Arm 10_Prospective cohort|Patients with melanoma, non secretory breast and colorectal cancer or other tumor types harboring NTRK fusions, except soft tissue sarcoma, salivary gland and thyroid cancer (arm closed)
61933284|NCT02135159|EXPERIMENTAL|RT before TDM1|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43.
61933285|NCT02135159|EXPERIMENTAL|TDM1 before RT|T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22.
61933286|NCT04400942||Women with uterine myomas undergoing hysteroscopic myomectomy|
61933287|NCT06076707|EXPERIMENTAL|Tramadol (T) group|Participants will be infiltrated with only 200mg tramadol around the wound.
61933288|NCT06076707|PLACEBO_COMPARATOR|Bupivacain (B) group|participants will be infiltrated with only bupivacaine around the wound
61933289|NCT06076707|EXPERIMENTAL|Tramadol + bupivacain ( T+B) group|The participants will be infiltrated with tramadol and bupivacaine which are mixed together in the same syringe.
61933290|NCT06516484|EXPERIMENTAL|Romiplostim group|Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
61933291|NCT02758756|ACTIVE_COMPARATOR|Massage|Subjects assigned to Arm 1 will receive two massage treatments approximately two weeks apart.
61933292|NCT02758756|EXPERIMENTAL|Two Reiki Tx|Subjects assigned to Arm 2 will receive two Reiki treatments approximately two weeks apart.
61933293|NCT02758756|EXPERIMENTAL|Four Reiki Tx|Subjects assigned to Arm 3 will receive four Reiki treatments approximately 1 week apart.
61933294|NCT06653153|EXPERIMENTAL|Remternetug|Remternetug administered subcutaneously (SC).
61933295|NCT06653153|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
61933296|NCT04723758|EXPERIMENTAL|GI Genius-assisted colonoscopy (GGC)|In the GGC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure, except that at some point prior to commencing withdrawal of the colonoscope, a member of the endoscopy staff will turn on the GI Genius machine. This will remain operational from the time it is switched on until the end of the procedure.
61933297|NCT04723758|ACTIVE_COMPARATOR|Standard Colonoscopy (SC)|In the SC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure.
61933298|NCT06485674||Tulip Trial Group|Patients who initiated 300 mg of anifrolumab in TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway)-1 or -2.
61933299|NCT06485674||Toronto Lupus Cohort Group|Participants who received RW Standard Of Care for SLE from the University of Toronto Lupus Clinic (UTLC) registry.
61933300|NCT06281288|EXPERIMENTAL|cognitive therapy with regular exercise|In the form of regular exercise where each participant perform exercise training approximately 60-min 3 times per week for 12 weeks, each session includes a combination of moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities, with additional time for warm-up (5 min; 10% HRmax) and cool down (5 min).
62692657|NCT02522221|ACTIVE_COMPARATOR|Warfarin|Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
61933301|NCT06281288|EXPERIMENTAL|cognitive therapy with irregular exercise|in form of irregular exercise training approximately 60-min once a week for 12 weeks, each session include a combination of moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities, with additional time for warm-up (5 min; 10% HRmax) and cool down (5 min).
61933302|NCT06281288|EXPERIMENTAL|cognitive therapy only|Cognitive behavioral therapy) CBT (techniques is co facilitated by a psychiatrist where participants attend 12 sessions during the 12 weeks of treatment. The intervention is 60-min weekly in group sessions
61933303|NCT00460369|ACTIVE_COMPARATOR|1|sulfadoxine-pyrimethamine
61933304|NCT00460369|ACTIVE_COMPARATOR|2|artemether-lumefantrine
61933305|NCT00460369|ACTIVE_COMPARATOR|3|amodiaquine-artesunate coformulation
61933306|NCT04366973||Participants with Hepatitis C Virus With or Without Treatment|"This study includes 3 populations for analysis:~Target Population (TP): Defined as all participants enrolled in the study regardless of whether treated for HCV or not.~Core Population (CP): Defined as all participants of the TP who have been prescribed glecaprevir/pibrentasvir (G/P) and started treatment.~Safety Population (SP): Defined as all participants who received at least one dose of G/P."
61933307|NCT06708741|EXPERIMENTAL|Vitamin D supplementation|High dose oral vitamin D supplementation (50,000 IU/once a month)
61933308|NCT06708741|NO_INTERVENTION|Standard-of-care Arm|standard of care arm where vitamin D levels are not actively acted upon
61933309|NCT04407481||Adults with autosomal dominant polycystic kidney disease|All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
61933310|NCT04407481||Healthy Controls|Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).
61933311|NCT04340193|EXPERIMENTAL|Nivolumab + Ipilimumab + TACE|TACE (Trans-arterial ChemoEmbolization)
61933312|NCT04340193|EXPERIMENTAL|Nivolumab + TACE|
61933313|NCT04340193|ACTIVE_COMPARATOR|TACE|
61933314|NCT03647332|ACTIVE_COMPARATOR|Cooled RFA treatment|
61933315|NCT03647332|ACTIVE_COMPARATOR|Steroid injection|
61933316|NCT05584371|EXPERIMENTAL|Exogenous ketosis|Intake of 10 grams of beta-hydroxybutyrate free of alcohol and salt.
61933317|NCT03467607|ACTIVE_COMPARATOR|3ml/kg|15 patients ventilated with 3ml/kg ideal body weight while on one lung ventilation
61933318|NCT03467607|ACTIVE_COMPARATOR|4ml/kg|15 patients ventilated with 4ml/kg ideal body weight while on one lung ventilation
61933319|NCT03467607|ACTIVE_COMPARATOR|control|15 patients ventilated using the anaesthetists usual ventilation strategy
62692658|NCT03151668|EXPERIMENTAL|Dexmedetomidin|
62692659|NCT03151668|NO_INTERVENTION|Midazolam|
62692660|NCT05116345|EXPERIMENTAL|DEXTENZA|a single intracanalicular dexamethasone (0.4 mg) insert
62484907|NCT06179173|EXPERIMENTAL|HIIT-RCE|All participants will receive conventional physiotherapy for half an hour thrice weekly for six weeks. Conventional physiotherapy will be followed by a 15 min rest period, then the HIIT on a semi-recumbent cycle SOLE R92 (HIIT-RCE) will be performed.Each HIIT-RCE session will be preceded by 3-min of unloaded cycling as a warm-up and ended with 3-min of stretching. The HIIT-RCE procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload for weeks 1-2 (4 repetitions for 20 min) and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (6 repetitions). The training intensity will progress similarly by 5% peak work rate two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5. The cycle frequency will be at least 50 rpm.
62484908|NCT06179173|ACTIVE_COMPARATOR|Conventional physiotherapy|The group will receive conventional physiotherapy that will consist primarily of passive movement, stretching, balance training, strengthening, and lower intensity overground walking for 30 minutes. This will be followed by a 15-minute rest period. Then an unloaded cycling session on a semi-recumbent cycle ergometer with preferred cadence until to get equal energy expenditure per session between groups by case-matching.
62484909|NCT05794685|ACTIVE_COMPARATOR|adductor canal block|adductor canal block : patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle
62484910|NCT05794685|ACTIVE_COMPARATOR|4 in one block|4 in one block : patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery .
62484911|NCT01299935|EXPERIMENTAL|Stress reduction|Stress reduction program utilizing the Transcendental Meditation (TM) technique
62484912|NCT01299935|ACTIVE_COMPARATOR|health education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
62484913|NCT05884957|ACTIVE_COMPARATOR|Patients Group (Nitric oxide Assesment)|Assessment of nitric oxide synthase gene polymorphism in diabetic patients with erectile dysfunction in 30 patients
62484914|NCT05884957|PLACEBO_COMPARATOR|Control Group|10 healthy people without erectile dysfunction
62484915|NCT05709496|EXPERIMENTAL|De-escalated radiotherapy to the prostate|De-escalated radiotherapy to the prostate with an intra-prostatic boost to the dominant .
62484916|NCT04341337||expert|interviews of expert of pipac about ethical issues
62484917|NCT01665508|EXPERIMENTAL|Nebivolol|Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
62484918|NCT01822119|EXPERIMENTAL|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~* One implant magnet~* One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
62692661|NCT05116345|ACTIVE_COMPARATOR|Topical Dexamethasone Treatment|"Standard of care topical dexamethasone treatment through Month 2 dosing and tapering following:~6x/day week 1 4x/day weeks 2-4 2x/day weeks 5-8 Day of surgery dexamethasone ointment and patch will be applied post-surgically for overnight treatment and removed at post-operative day 1 visit in Group B eyes."
62692662|NCT05548296|EXPERIMENTAL|OncoSignature Positive Tumors|In Arm 1, participants with an OncoSignature Positive test will enter a Phase 2 Simon 2-Stage Study that will assess the efficacy of ACR-368 as monotherapy in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
62692663|NCT05548296|EXPERIMENTAL|OncoSignature Negative|In Arm 2, participants with an OncoSignature Negative will receive the combination of ACR-368 and ultralow Dose Gemcitabine (ULDG). The Phase 1b/2 portion will only enroll participants with OncoSignature Negative tumors. Unevaluable tumors will not be able to participate. A Phase 1b Study will assess the safety of the combination of ACR-368 and escalating doses of ULDG in participants with any of the 3 tumor types (ovarian, endometrial, and urothelial). The Phase 1b Study will determine the recommended Phase 2 dose (RP2D) of ULDG. A Phase 2 Exploratory Study will assess the efficacy and safety of the combination of ACR-368 and the RP2D of ULDG in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
61933320|NCT03300310|EXPERIMENTAL|with nursing visit|a nurse visit is scheduled twice a week during 3 months at patient home.
61933321|NCT03300310|EXPERIMENTAL|without nursing visit|no nursing visit
62133437|NCT04082624|EXPERIMENTAL|Self-regulation condition|Learned how to self-monitor their sedentary behavior and active breaks. They also learned how to create prompts/cues (e.g., sticky note reminder), problem solve to overcome barriers, action plan (i.e., specifying when, where, and how to do the behavior), and set goals in order to be less sedentary according to SMART (i.e., specific, measurable, attainable, relevant, time-oriented) principles. Received intervention following measurements at baseline, week 4, and week 8.
61933322|NCT02568137|EXPERIMENTAL|Behavioral|Nurse-directed mobile health technology using smart phones to promote adherence to antihypertensive medication.
61933323|NCT02568137|NO_INTERVENTION|Usual background care|Standard care
61933324|NCT06039384|EXPERIMENTAL|Part 1: Dose Finding|INCB099280 administered in combination with adagrasib in participants with previously treated KRAS glutamine to cysteine mutation at codon 12 (KRASG12C) mutant advanced solid tumors, will be evaluated to identify dose(s) for further evaluation in the dose expansion phase of the study.
61933325|NCT06039384|EXPERIMENTAL|Part 2: Dose Expansion|Up to 80 participants will be enrolled in 1 of 2 disease-specific cohorts: Cohort A: previously treated KRASG12C mutated non-small cell lung cancer (NSCLC) Cohort B: previously treated KRASG12C-mutated colorectal cancer (CRC). Up to 3 doses may be selected from Part 1: Dose Finding for the Part 2: Dose Expansion.
62133438|NCT05050383|OTHER|Drug-Induced Sleep Endoscopy|Drug-Induced Sleep Endoscopy
62484919|NCT05291819|OTHER|Conventional treat-to-target|Conventional treat-to-target follow-up strategy with structured clinical assessment of disease activity
62484920|NCT05291819|EXPERIMENTAL|Imaging informed treat-to-target|Imaging informed treat-to-target follow-up strategy with both structured clinical assessment of disease activity and structured imaging assessment of disease activity.
62484921|NCT04039451||people who live in rural areas in Assuit governorate|The study will performed on people who live in rural areas in Assuit governorate (all households) regardless of sex or age.
62484922|NCT05281120|ACTIVE_COMPARATOR|mechanical intervention group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the active platform (inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
62484923|NCT05281120|PLACEBO_COMPARATOR|mechanical placebo group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the placebo platform (not inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
62484924|NCT04066088|SHAM_COMPARATOR|Placebo|
62484925|NCT04066088|EXPERIMENTAL|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
62484926|NCT00240032|ACTIVE_COMPARATOR|Copaxone® with Zyrtec|
62484927|NCT00240032|EXPERIMENTAL|Copaxone® with placebo|
62484928|NCT01808651|EXPERIMENTAL|Fluoxetine|Flexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks
62484929|NCT04096664|EXPERIMENTAL|SIMEOX|Use the device for 3 months in addition to usual care
62484930|NCT04096664|NO_INTERVENTION|Control|Usual care
62484931|NCT01710748|ACTIVE_COMPARATOR|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
62484932|NCT01710748|EXPERIMENTAL|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
62484933|NCT02184936||acute ischemic stroke|
62484934|NCT05848115|EXPERIMENTAL|BiPAP|Patients randomized to the study group (BiPAP) will receive continuous nebulized albuterol through the FDA approved Respironics Trilogy BiPAP machine as per routine practice and institutional guidelines for albuterol dosing. Participants will receive BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician.
62484935|NCT05848115|SHAM_COMPARATOR|Control|Patients randomized to the control group (sham BiPAP) will receive continuous nebulized albuterol through the same set-up as the study group and institutional guidelines for albuterol dosing. Participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy per the treating clinician.
62484936|NCT02658487|EXPERIMENTAL|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
62484937|NCT04183335|EXPERIMENTAL|Dupilumab|Participants received dupilumab at a loading dose of 600 milligrams (mg), subcutaneously (SC) on Day 1 followed by dupilumab 300 mg once every 2 weeks (q2w) for 24 weeks added to background therapy of topical corticosteroids/topical calcineurin inhibitors (TCS/TCI) at stable dose.
62484938|NCT04183335|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to dupilumab 600 mg (loading dose), SC on Day 1 followed by placebo matched to dupilumab 300 mg q2w for 24 weeks added to background therapy of TCS/TCI at stable dose.
62484939|NCT04922827|EXPERIMENTAL|Infliximab + Standard of Care|
62484940|NCT04922827|ACTIVE_COMPARATOR|Standard of Care|
61933326|NCT05879835|EXPERIMENTAL|KiteLock 4% Sterile Catheter Lock Solution|4% Tetrasodium EDTA lock solution (KiteLock 4% Sterile Catheter Lock Solution; SterileCare Inc., Canada) will be administered 4-24 hours daily while the patient is cycled off their PN, as per site standard operating procedures.
62133439|NCT06127602|EXPERIMENTAL|REACT-NMES: Intervention condition|"The REACT-NMES group will undergo 6 weeks of reactive balance training with NMES involving 12 one-hour sessions (twice a week). Each session will begin with NMES parameter setup where the current amplitude will be customized to individual maximal tolerable levels for a strong yet comfortable experience. NMES settings will include moderate to high intensity (30-50mA) and low frequency (20-45Hz) to target motor nerve thresholds. The REACT-NMES group will wear a footswitch on their paretic shoe for triggering the slips during walking and for NMES synchronization. NMES will be delivered to the paretic limb quadriceps muscles for 500 milliseconds after slip onset."
62484941|NCT04892615||Cohort A|The drainage tube was removed on the 5th day after surgery.
62484942|NCT04892615||Cohort B|The drainage tube was removed on the 7th day after surgery.
62484943|NCT04428307|NO_INTERVENTION|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
62484944|NCT04428307|EXPERIMENTAL|Arm 2 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
62484945|NCT04428307|EXPERIMENTAL|Arm 3 (client-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
61933327|NCT05879835|ACTIVE_COMPARATOR|Heparin Lock Solution|Heparin lock solution will be administered daily per investigator judgement, given its significant clinical risk in the youngest/smallest/vulnerable subjects.
61933328|NCT03881410|EXPERIMENTAL|Shear-wave elastography-guided|Shear-wave elastography-guided bipsy
61933329|NCT03881410|ACTIVE_COMPARATOR|Convention ultrasound-guided|Convention ultrasound-guided biopsy
62484946|NCT04322344|EXPERIMENTAL|oral escin group|Standard therapy+Escin tablet 40mg\*3, os for 12 days
61933330|NCT00781508|EXPERIMENTAL|sildenafil|Effect of oral administration of a single dose of sildenafil 50 mg on left ventricular filling pressures as evaluated 1 hr after sildenafil administration in patients with heart failure
61933331|NCT00781508|PLACEBO_COMPARATOR|placebo|Inactive placebo prepared to mimic the appearance of sildenafil.
62484947|NCT04322344|SHAM_COMPARATOR|control group|standard therapy
62484948|NCT04322344|EXPERIMENTAL|parenteral escin group|standard treatment + sodium Escinate 20mg iv/day for 12 days
62484949|NCT05777005|EXPERIMENTAL|Intervention group|5A's/5R's advice+ Chatbot-led group support+ Counselor-led individual support+ health warning leaflet+ Self-help booklet
62484950|NCT05777005|ACTIVE_COMPARATOR|Control group|5A's/5R's advice+ Chatbot-led group support+ health warning leaflet+ Self-help booklet
62484951|NCT03115697|ACTIVE_COMPARATOR|Lactulose with Rifaximin|
62484952|NCT03115697|EXPERIMENTAL|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
62326560|NCT02576431|EXPERIMENTAL|Arm 11_Bone health cohort|Patients with all tumor types harboring NTRK fusions, not eligible for the main prospective cohort, including patients with non-measurable disease
62484953|NCT04635007|EXPERIMENTAL|Group 1: Tranexamic acid group|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
62484954|NCT04635007|EXPERIMENTAL|Group 2: Misoprostol group|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
62484955|NCT03979664|ACTIVE_COMPARATOR|Active Iontophoresis|One active iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
62484956|NCT03979664|SHAM_COMPARATOR|Inactive Iontophoresis|One inactive iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
62484957|NCT01515891|EXPERIMENTAL|BIA 9-1067|90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
62484958|NCT05395052|EXPERIMENTAL|Cohort A/A2/AA/AA2: FT536 Monotherapy|FT536 monotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC), ovarian cancer, or pancreatic cancer.
62484959|NCT05395052|EXPERIMENTAL|Cohort B/B2/BB/BB2: FT536 + Avelumab|FT536 + avelumab combination therapy in participants with locally advanced or metastatic solid tumor indications with documented PD-L1 expression.
62484960|NCT05395052|EXPERIMENTAL|Cohort C/C2/CC/CC2: FT536 + Pembrolizumab, Nivolumab, or Atezolizumab|FT536 + pembrolizumab, nivolumab, or atezolizumab in participants with locally advanced or metastatic solid tumor indications with documented PD-L1 expression.
62484961|NCT05395052|EXPERIMENTAL|Cohort D/D2/DD/DD2: FT536 + Trastuzumab|FT536 + trastuzumab in participants with locally advanced or metastatic documented human epidermal growth factor receptor 2 (HER2+) expressing tumors
62484962|NCT05395052|EXPERIMENTAL|Cohort E/E2/EE/EE2: FT536 + Cetuximab|FT536 + cetuximab in participants with locally advanced or metastatic squamous NSCLC, CRC, or head and neck cancer.
62484963|NCT05395052|EXPERIMENTAL|Cohort F/F2/FF/FF2: FT536 + Amivantamab|FT536 + amivantamab in participants with locally advanced or metastatic NSCLC.
62484964|NCT05288686|EXPERIMENTAL|SPIO arm|Superparamagnetic iron oxide guided sentinel lymph node mapping
62484965|NCT05288686|ACTIVE_COMPARATOR|Control arm|Conventional radioisotope and blue dye guided sentinel lymph node mapping
62692664|NCT03478488|EXPERIMENTAL|KN035|"KN035 plus Gemcitabine \& oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.~Gemcitabine 1000 mg/m\^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m\^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
62692665|NCT03478488|ACTIVE_COMPARATOR|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m\^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m\^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
62692666|NCT05973045|ACTIVE_COMPARATOR|24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
62326561|NCT06746337|EXPERIMENTAL|IMAGINE|The intervention is a digital adaptation of the evidence-based Mothers and Babies program, delivered interactively to groups of perinatal people and facilitated by a mental health provider.
62326562|NCT06746337|NO_INTERVENTION|Control|Control participants will be provided with standardized information about signs and symptoms of perinatal depression and will continue to receive standard healthcare.
62484966|NCT05312216|EXPERIMENTAL|Durvalumab plus Lenvatinib|"Durvalumab is a human IgG1 κ monoclonal antibody that inhibits binding of PD-L1 to its receptors PD-1 and CD80.~Lenvatinib is a multi- kinase inhibitor of VEGF receptors 1 to 3, FGF receptors 1 to 4, PDGFRa, RET, and KIT."
62484967|NCT01177462||hemineglect stroke patients|Stroke patients with hemineglect
62484968|NCT01177462||Control stroke patients|Stroke patients without hemineglect
62484969|NCT01177462||Normal control|Normal subjects
62484970|NCT04089553|EXPERIMENTAL|Module 1 (AZD4635 75 mg + Durvalumab 1500 mg)|Participants will receive monotherapy of AZD4635 75 mg orally once daily (QD) for first 14 days and thereafter will continue to receive 75 mg orally QD in combination with durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W) until will derive clinical benefit as judged by the investigator, confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
62484971|NCT04089553|EXPERIMENTAL|Module 2 (AZD4635 50 / 75 mg + Oleclumab 1500 mg)|Participants will receive combination therapy of AZD4635 (50 mg / 75 mg orally QD) and oleclumab 1500 mg IV (every 2 weeks of 28-day cycle for the first 4 doses and Q4W thereafter) until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
62484972|NCT04422457|EXPERIMENTAL|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans
62484973|NCT03890237|NO_INTERVENTION|Control|Business as usual, no intervention
62484974|NCT03890237|EXPERIMENTAL|Her Spaces|Starts in year 1; intervention package with 11-13 year old girls for 10 months; standard parental and community engagement. All programming ends after 10 months.
62484975|NCT03890237|EXPERIMENTAL|Act With Her|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
62692667|NCT05973045|ACTIVE_COMPARATOR|37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
62133440|NCT06127602|ACTIVE_COMPARATOR|REACT: Control condition|The REACT group will undergo 6 weeks involving 12 one-hour sessions (twice a week) of reactive balance training with ShamNMES. To prevent psychological bias and unblinding, sub-sensory stimulation will be used. ShamNMES will employ low intensity (0-10mA) and high frequency (50-100Hz), staying 20% below the sensory nerve threshold without inducing muscle contraction. The REACT group will wear a footswitch on their paretic shoe for triggering the slips during walking and for ShamNMES synchronization. ShamNMES (control) will be delivered after compensatory step touchdown to avoid interference with balance recovery.
62133441|NCT03111537|EXPERIMENTAL|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
62133442|NCT03111537|EXPERIMENTAL|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
62133443|NCT03111537|EXPERIMENTAL|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
62133444|NCT03111537|EXPERIMENTAL|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
62484976|NCT03890237|EXPERIMENTAL|Act With Her + Asset Transfer|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; asset transfer for girls over 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
62484977|NCT03890237|EXPERIMENTAL|Act With Her (simple)|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; does not include community-level systems strengthening. All programming ends after 10 months.
61933332|NCT00181623|EXPERIMENTAL|recombinant human prolactin treatment|Open label twice daily recombinant human prolactin
61933333|NCT02126371|OTHER|Active|LEO32731
61933334|NCT04515927|EXPERIMENTAL|subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.|
61933335|NCT06709092|EXPERIMENTAL|Allergic rhinitis|For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.
61933336|NCT04092270|EXPERIMENTAL|Treatment (peposertib, PLD)|Patients receive peposertib PO BID on days 1-21, days 1-28, or days 1-7 (depending on dose level) and pegylated liposomal doxorubicin hydrochloride IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI during screening and every 8 weeks and after 6 months of study treatment, every 12 weeks. Patients undergo ECHO during screening and every 6 months. Starting in cycle 13, patients undergo ECHO or MUGA scan every 2 cycles. Additionally, patients undergo blood sample collection throughout the study.
61933337|NCT02378623|ACTIVE_COMPARATOR|Apixaban|Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5 mg/dL). Planned treatment duration is 2 years
61933338|NCT02378623|PLACEBO_COMPARATOR|Placebo|Control group: Matched placebo by mouth two times daily in addition to usual medical therapy. Planned treatment duration is 2 years.
61933339|NCT00096954|EXPERIMENTAL|Omalizumab|Omalizumab (Xolair) administered in this study was either a minimum of 0.008 mg/kg/IgE \[IU/mL\] every 2 weeks or a minimum of 0.016 mg/kg/IgE \[IU/mL\] every 4 weeks.
61933340|NCT00096954|PLACEBO_COMPARATOR|Placebo|Placebo administered in this study was either a minimum of 0.008 mg/kg/IgE \[IU/mL\] every 2 weeks or a minimum of 0.016 mg/kg/IgE \[IU/mL\] every 4 weeks.
61933341|NCT04047862|EXPERIMENTAL|Phase 1|"Cycle 1 (28 Days): A flat dose of ociperlimab as a single agent on Day 1. In the first cycle, 200 mg tislelizumab will be administered on Day 8.~If ociperlamib is tolerated in Cycle 1, participants will receive tislelizumab + ociperlimab sequentially on Day 29 and every 21 days for up to 8 months."
61933342|NCT04047862|EXPERIMENTAL|Phase 1b Cohort 1|Participants with metastatic squamous NSCLC will receive ociperlamib + tislelizumab + paclitaxel/nab-paclitaxel + Carbo once every 3 weeks (Q3W) for 4 to 6 cycles (21 days each) followed by ociperlimab + tislelizumab Q3W)
61933343|NCT04047862|EXPERIMENTAL|Phase 1b Cohort 2|Participants with metastatic squamous NSCLC will receive ociperlimab + tislelizumab + pemetrexed + Cis/Carbo Q3W for 4 to 6 cycles (21 days each) followed by ociperlamib+tislelizumab Q3W)
61933344|NCT04047862|EXPERIMENTAL|Phase 1b Cohort 3|Participants with metastatic NSCLC (PD-L1 positive, \[TC\] ≥ 1%) will be treated with ociperlimab + tislelizumab
61933345|NCT04047862|EXPERIMENTAL|Phase 1b Cohort 4|Patients with extensive stage SCLC will be treated with ociperlimab + tislelizumab + etoposide + Cis/Carbo Q3W for up to 6 to 8 cycles followed by ociperlamib+tislelizumab Q3W
61933346|NCT04047862|EXPERIMENTAL|Phase 1b Cohort 5|Checkpoint inhibitor (CPI)-experienced NSCLC patients will be treated with ociperlimab plus tislelizumab
61933347|NCT04047862|EXPERIMENTAL|Phase1b Cohort 6|Patients with metastatic ESCC will be treated with ociperlimab + tislelizumab + cisplatin + 5-fluorouracil /paclitaxel Q3W for 6 cycles followed by ociperlamib+tislelizumab Q3W
61933348|NCT04047862|EXPERIMENTAL|Phase1b Cohort 7|Patients with metastatic EAC will be treated with ociperlimab + tislelizumab + cisplatin + 5-fluorouracil or paclitaxel Q3W for 6 cycles followed by ociperlamib+tislelizumab Q3W
62133445|NCT05917275|EXPERIMENTAL|4 weeks of Amlodipine|
62133446|NCT05917275|EXPERIMENTAL|4 weeks of Olmesartan|
62326563|NCT06747364|EXPERIMENTAL|In Lab alcohol consumption followed by 10 days of abstinence|Up to 40 Healthy volunteers will consume alcohol in the lab designed to produce a peak blood alcohol concentration of 0.06% and have blood collected over 6 hours. Followed by 10 days of abstinence and 4 visits to provide 1 blood sample each time.
62326564|NCT06747364|NO_INTERVENTION|Naturalistic Drinking Period Group|These volunteers will then consume alcohol as usual outside the laboratory for 28 days and blood will be collected weekly (Day 0, Day 7, Day 14, 21 and 28).
62326565|NCT06747364|NO_INTERVENTION|Post Algorithm Naturalistic Drinking Group|An algorithm will be developed, then tested and refined in a 2nd cohort of up to 40 volunteers
62326566|NCT06748014|PLACEBO_COMPARATOR|MPFF + Placebo|Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + placebo
61933349|NCT04047862|EXPERIMENTAL|Phase1b Cohort 8|Patients with recurrent or metastatic HNSCC (PD-L1 positive, vCPS≥ 1%) will be treated with ociperlimab + tislelizumab Q3W
61933350|NCT04047862|EXPERIMENTAL|Phase1b Cohort 9|Patients with metastatic G/GEJ carcinoma will be treated with ociperlimab + tislelizumab + \[oxalipatin + capecitabine\] or \[cisplatin + 5-fluorouracil\] Q3W for 6 cycles followed by ociperlamib+tislelizumab + capecitabine Q3W
61933351|NCT04047862|EXPERIMENTAL|Phase 1b Cohort10|Patients with metastatic NSCLC (PD-L1 positive, \[TC\] ≥ 1%) will be treated with tislelizumab in combination with ociperlimab 450mg, 900mg or 1800mg Q3W.
61933352|NCT03579576||HCV infected patients|All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
61933353|NCT04396496|EXPERIMENTAL|Daratumumab Injection|"Up to 12 four-week cycles of Daratumumab (DARA), in combination with the immunomodulatory drug (IMiD) lenalidomide.~DARA is injected. Dosage calculated by weight.On Cycles 1 and 2, DARA is given on Days 1, 8,15 and 22. On Cycles 3-6,DARA is given on Days 1 and 15. On Cycles 7-12, DARA is given on Day 1.~Lenalidomide is taken by mouth. 15 mg on Days 1-21 of each cycle."
61933354|NCT04309812|ACTIVE_COMPARATOR|Short Stimulation|1 minute duration of stimulation per day for 30 days
61933355|NCT04309812|EXPERIMENTAL|Long Stimulation|30 minutes duration of stimulation per day for 30 days
61933356|NCT01502280|EXPERIMENTAL|5-ALA/Gliolan® /5-Aminolevulinic acid|Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)
61933357|NCT01502280|PLACEBO_COMPARATOR|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
61933358|NCT01206868|ACTIVE_COMPARATOR|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
62133447|NCT05917275|EXPERIMENTAL|4 weeks of Hydrochlorothiazide|
62326567|NCT06748014|ACTIVE_COMPARATOR|MPFF + Aescin|Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + Aescin 60 mg for 2 month
61933359|NCT01206868|SHAM_COMPARATOR|Control|Standard kidney transplantation
61933360|NCT00935051|EXPERIMENTAL|Arm 1|There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
61933361|NCT04081233|EXPERIMENTAL|Early surgical stabilization|This arm will include early surgical stabilization (within 72 hours of admission) in addition to the usual care received for patients with multiple rib fractures. Usual care will involve pain management.
61933362|NCT04081233|ACTIVE_COMPARATOR|Usual care|This arm will be usual care only. Usual care will include pain managment.
61933363|NCT06053463|EXPERIMENTAL|Lens wear experience|Subject will wear contact lenses for about a month during the day.
61933364|NCT05523206||Cohort 1|Participants with MPS IIIA
61933365|NCT06661694|EXPERIMENTAL|Sequence 1|Participants will receive a single 875 mg dose of Treatment A on Day 1 of Period 1, followed by a single 875 mg dose of Treatment B on Day 1 of Period 2, followed by a single 875 mg dose of Treatment C on Day 1 of Period 3, followed by a single 875 mg dose of Treatment D on Day 1 of Period 4.
61933366|NCT06661694|EXPERIMENTAL|Sequence 2|Participants will receive a single 875 mg dose of Treatment B on Day 1 of Period 1, followed by a single 875 mg dose of Treatment D on Day 1 of Period 2, followed by a single 875 mg dose of Treatment A on Day 1 of Period 3, followed by a single 875 mg dose of Treatment C on Day 1 of Period 4.
61933367|NCT06661694|EXPERIMENTAL|Sequence 3|Participants will receive a single 875 mg dose of Treatment C on Day 1 of Period 1, followed by a single 875 mg dose of Treatment A on Day 1 of Period 2, followed by a single 875 mg dose of Treatment D on Day 1 of Period 3, followed by a single 875 mg dose of Treatment B on Day 1 of Period 4.
62133448|NCT05917275|EXPERIMENTAL|4 weeks of Amlodipine/Olmesartan|
62326568|NCT06743074|EXPERIMENTAL|foot Exercise|foot exercise
62484978|NCT06212492|EXPERIMENTAL|Prone Positioning and NMBAs (PP-NMBAs)|Early and systematic use of Prone positioning and NMBAs
61933368|NCT06661694|EXPERIMENTAL|Sequence 4|Participants will receive a single 875 mg dose of Treatment D on Day 1 of Period 1, followed by a single 875 mg dose of Treatment C on Day 1 of Period 2, followed by a single 875 mg dose of Treatment B on Day 1 of Period 3, followed by a single 875 mg dose of Treatment A on Day 1 of Period 4.
61933369|NCT04634890|OTHER|Type 2 Diabetes|Subjects with type 2 diabetes, diagnosed within the last 3-5 years, treated with metformin only as an anti-diabetic drug
61933370|NCT04634890|OTHER|Prediabetes|Subjects with prediabetes, defined as impaired fasting glucose or/and impaired glucose tolerance
61933371|NCT04634890|OTHER|Normoglycemia|Subjects with normal fasting glucose and normal glucose tolerance
61933372|NCT05374668|EXPERIMENTAL|Video-based Yoga|video-based yoga (n=40) given for patients in post-covid-19 status for 8 weeks
61933373|NCT05374668|EXPERIMENTAL|Home-based postur exercises|Home exzercises were given for 8 weeks
61933374|NCT01296360|ACTIVE_COMPARATOR|>14 months to <2 years|IXIARO 0.25 ml i.m. (milliliter, intramuscular)
61933375|NCT01296360|ACTIVE_COMPARATOR|>3 years - <18 years|IXIARO 0.5 ml i.m (milliliter, intramuscular)
61933376|NCT06707896|EXPERIMENTAL|Dose Level 1|After lymphodepleting chemotheerapy subjects will recieve a dose of 3 x 10(8) TCR1020-CD8 T cells
62133449|NCT04736485|EXPERIMENTAL|FLOT regimen plus Spartalizumab|"Standard FLOT regimen~* Docetaxel 50 mg/m² IV infusion on D1~* Oxaliplatine 85 mg/m² IV infusion on D1~* Leucovorin 200 mg/m² IV infusion on D1~* Fluorouracile 2600 mg/m² 24 h IV infusion on D1~with Spartalizumab PDR001 Patients will received the fixed dose of 400 mg per IV infusion on D1 every four weeks (q4w) for 2 pre-operative cycles (8 weeks) and 2 post-operative cycles (8 weeks)"
62133450|NCT01074788|EXPERIMENTAL|mind body intervention group|
62133451|NCT00706875||1|30 patients survived GTD post treatment for 0 - 5 years.
62326569|NCT06743074|EXPERIMENTAL|hip exercise|hip exercise
62326570|NCT06743074|OTHER|control group|other
62484979|NCT06212492|ACTIVE_COMPARATOR|Prone Positioning (PP)|Early and systematic use of prone positioning with NMBAs indicated ONLY as rescue
62484980|NCT05163886|EXPERIMENTAL|LAM-002A|LAM-002A will be administered orally in five 25 mg capsules twice a day (250 mg total daily dose).
62484981|NCT05163886|PLACEBO_COMPARATOR|Placebo|Placebo matching LAM-002A will be administered orally in 5 capsules twice a day.
61933377|NCT06707896|EXPERIMENTAL|Dose Level -1|After lymphodepleting chemotheerapy subjects will recieve a dose 1 x 10(8) TCR1020-CD8 T cells
61933378|NCT06707896|EXPERIMENTAL|Dose Level 2|After lymphodepleting chemotheerapy subjects will recieve a dose 1 x 10(9) TCR1020-CD8 T cells
62133452|NCT00706875||2|30 patients survived GTD post treatment 6 - 10+ years.
62133453|NCT05119491||cases ultra sound and spirometry|observation by ultra sound and spirometry for cases
62133454|NCT05119491||heathy subjects ultra sound and spirometry|observation ultra sound and spirometry for control heathy subjects
62133455|NCT00274469|EXPERIMENTAL|1|Fulvestrant
62133456|NCT00274469|ACTIVE_COMPARATOR|2|Anastrozole
62133457|NCT04310514|ACTIVE_COMPARATOR|Experimental: glucose - fructose - xylitol - saccharose|"* glucose 35 g (500ml of 7% solution);~* fructose 35 g (500ml of 7% solution);~* xylitol 35 g (500ml of 7% solution);~* saccharose 35 g (500ml of 7% solution)"
62133458|NCT04310514|ACTIVE_COMPARATOR|Experimental: fructose - glucose - saccharose - xylitol|"* glucose 35 g (500ml of 7% solution);~* fructose 35 g (500ml of 7% solution);~* xylitol 35 g (500ml of 7% solution);~* saccharose 35 g (500ml of 7% solution)"
62133459|NCT04310514|ACTIVE_COMPARATOR|Experimental: xylitol - saccharose - glucose - fructose|"* glucose 35 g (500ml of 7% solution);~* fructose 35 g (500ml of 7% solution);~* xylitol 35 g (500ml of 7% solution);~* saccharose 35 g (500ml of 7% solution)"
62484982|NCT03703258|EXPERIMENTAL|Intervention|"The THRIVE app involves 3 weeks of daily activities. Day 1 involves identification of activities to add to a self-care activity list with guidance around selecting activities that increase social contact, reduce alcohol use, and reduce avoidance. They will also complete an active-learning exercise about cognitive distortions and create a stuck point to-do list consisting of their cognitive distortions. In subsequent days, participants will be prompted to complete activities from both lists. They will also have access optional activities on topics such as asking for help, preventing isolation, deciding whether to disclose an assault, coping with negative reactions to disclosure, and thinking in helpful ways about social support. They will be prompted to complete brief daily surveys in the app, which will populate a symptom tracker. Participants in will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use."
61933379|NCT06707896|EXPERIMENTAL|Dose Level 3|After lymphodepleting chemotheerapy subjects will recieve a dose 3 x 10(9) TCR1020-CD8 T cells
61933380|NCT04285099|EXPERIMENTAL|PD patients with FOG after STN-DBS[A]|Initially started by A setting
61933381|NCT04285099|EXPERIMENTAL|PD patients with FOG after STN-DBS[B]|Initially started by B setting
61933382|NCT00438451|ACTIVE_COMPARATOR|Levetiracetam|Levetiracetam
61933383|NCT00438451|ACTIVE_COMPARATOR|Carbamazepine|Carbamazepine
61933384|NCT00438451|ACTIVE_COMPARATOR|Lamotrigine|Lamotrigine
61933385|NCT02695875|EXPERIMENTAL|Aquatic therapy|Aquatic therapy is the experimental group. This therapy will take place in a warm pool which is located in Rialta's Sports Complex. Aquatic therapy session will be conducted by the main researcher with the help of an assistant. Because the number of patients (n=17), they will be subdivided into two subgroups of 8 and 9 people respectively in order to ensure the safety and care of patients. The intervention will last for one hour: Warming (15 minutes); exercises to train the static and dynamic balance (25 minutes); stretching (10 minutes); relaxation (10 minutes). Over 12 weeks of treatment, difficulty in performing exercises to train balance will increase progressively.
61933386|NCT02695875|OTHER|Land-based therapy|"The description is the same as aquatic therapy. The difference is land-based therapy sessions will be made at Faculty of Physiotherapy at University of A Coruña."
61933387|NCT02245178||Obervational - CARDIA participants|CARDIA study participants will undergo lung function testing and have existing thoracic CT scans analyzed for lung structure.
61933388|NCT06708689||Case / patients|"Pediatric patients requiring a long-term central line for home parenteral nutrition:~* home parenteral nutrition patients~* diagnosed with at least on episode of botriomycoma on their central line~* 0 to 18 years of age at diagnosis of botriomycoma"
62133460|NCT04310514|ACTIVE_COMPARATOR|Experimental: saccharose - xylitol - fructose - glucose|"* glucose 35 g (500ml of 7% solution);~* fructose 35 g (500ml of 7% solution);~* xylitol 35 g (500ml of 7% solution);~* saccharose 35 g (500ml of 7% solution)"
62133461|NCT00620698||ALS patients|Patients with clinically established amyotrophic lateral sclerosis
62133462|NCT04195113||Direct Oral Anticoagulants (DOACs)|In this study, DOACs include apixaban, dabigatran, edoxaban and/or rivaroxaban.
62133463|NCT04195113||Vitamin K Antagonist (VKA)|In this study, the VKA is warfarin.
62133464|NCT00585624|EXPERIMENTAL|1|Supplement: 3 servings/day of Impact Advanced Recovery in addition to regular food or any other supplements recommended or desired by patient or primary care/surgical team.
62133465|NCT00585624|PLACEBO_COMPARATOR|2|Standard Care: Food, beverages, or supplements as recommended or desired by patient or primary care/surgical team.
62133466|NCT02999763|EXPERIMENTAL|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
62133467|NCT03821636|SHAM_COMPARATOR|Standard Roux-en-Y|
62133468|NCT03821636|ACTIVE_COMPARATOR|Long alimentary limb Roux-en-Y|
62133469|NCT00550823|EXPERIMENTAL|A,1|
62133470|NCT04649996||Pandemic period|patients admitted in hospital for acute appendicitis
62133471|NCT04649996||control period|patients admitted in hospital for acute appendicitis
62133472|NCT01158417|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62133473|NCT01158417|EXPERIMENTAL|Resveratrol 40 mg oral three times a day|Resveratrol
62133474|NCT01158417|EXPERIMENTAL|resveratrol 500 mg oral once daily.|Resveratrol
61933389|NCT06708689||Control|"Pediatric patients requiring a long-term central line for home parenteral nutrition:~* home parenteral nutrition patients~* never diagnosed with an episode of botriomycoma on their central line~* 0 to 18 years of age at diagnosis"
62484983|NCT03703258|NO_INTERVENTION|Assessment-only control|The assessment-only control condition will involve access to a version of the app that includes daily surveys and a symptom tracker populated by these surveys, but without any of the other exercises included in the experimental version of the app. Participants in the control condition will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use.
62484984|NCT04423835||lateral closing osteotomy for cubitus varus deformity|The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs.
62484985|NCT04215705|ACTIVE_COMPARATOR|Group Q|Patients in this group receive Quadratus Lumborum Block with 20 ml bupivacaine 0.5%
62484986|NCT04215705|ACTIVE_COMPARATOR|Group L|Patients in this group receive peritubal local infiltration at 6 and 12 o'clock position with 20ml bupivacaine 0.5%
62484987|NCT02681939|EXPERIMENTAL|Tulsi|One capsule of Tulsi (Ocimum sanctum) orally, every morning and evening in empty stomach for 60 days regularly.
62133475|NCT02115828|EXPERIMENTAL|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
62484988|NCT02681939|NO_INTERVENTION|No Tulsi|No intervention
62484989|NCT03815903|ACTIVE_COMPARATOR|A - induction chemotherapy|
62484990|NCT03815903|EXPERIMENTAL|B - chemoradiotherapy|
62484991|NCT03334058|EXPERIMENTAL|ARGX-113|
62484992|NCT05888311|EXPERIMENTAL|Liquid bandage|The liquid bandage will be applied after the tape strriping procedure and will be reapplied after 12 hours.
62692668|NCT05629572||Prospective subjects in Emergency Department (ED) with symptoms of acute coronary syndrome (ACS).|"Prospectively collected whole blood specimens from subjects presenting to the emergency department (ED) with chest discomfort or equivalent ischemic symptoms suggestive of acute coronary syndrome (ACS).~For this study's MI adjudication, a minimum of 2 samples are to be tested on the site's standard of care (SOC) instrument, one at baseline and one at another time point (T1, T2, T3). For each of the SOC test results, a corresponding research draw for testing on the i-STAT hs-TnI cartridge should be attempted, if feasible. For research, a minimum of 2 samples are to be tested on i-STAT instruments, one at baseline and one at an additional timepoint. Enrollment will be monitored throughout the clinical study."
62692669|NCT05995600|EXPERIMENTAL|Clopidogrel-based antiplatelet therapy group|"Clopidogrel 75 mg daily~Patients assigned to this group will be permitted to use additional antiplatelet drugs other than clopidogrel at the investigator's discretion."
62692670|NCT05995600|ACTIVE_COMPARATOR|Warfarin group|Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
62133476|NCT05713526|EXPERIMENTAL|Telehealth group|The group in which telehealth services for childhood vaccines will be implemented.
62133477|NCT05713526|NO_INTERVENTION|Control group|The group in which telehealth services for childhood vaccines will not be implemented.
62484993|NCT05888311|NO_INTERVENTION|Control area|
62484994|NCT00973219|ACTIVE_COMPARATOR|Peg-Interferon alfa 2a + Adefovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Adefovir for a period of 48 weeks.
62484995|NCT00973219|ACTIVE_COMPARATOR|Peg-Interferon alfa 2a + Tenofovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Tenofovir for a period of 48 weeks.
62484996|NCT00973219|NO_INTERVENTION|no treatment|50 HBeAg negative chronic hepatitis B patients with low viral load will not receive treatment during a period of 48 weeks
62484997|NCT05444296|EXPERIMENTAL|Dry Needling|Experimental group
62484998|NCT05444296|ACTIVE_COMPARATOR|Upper Cervical Mobilizations|Active control
62484999|NCT02243982|EXPERIMENTAL|[F18]-FDDNP|2-(1-{6-\[(2-\[fluorine-18\]fluoroethyl)(methyl)amino\]-2-naphthyl}-ethylidene)malononitrile. Radiopharmaceutical tracer
62485000|NCT06114836|NO_INTERVENTION|Natural maturation|Allows for time for infant maturation without treatment.
62485001|NCT06114836|ACTIVE_COMPARATOR|Proton Pump Inhibitor (PPI)|Omeprazole will be prescribed for 4 weeks using the dose of 1.5mg/kg/dose daily.
62485002|NCT06114836|ACTIVE_COMPARATOR|Added Rice (AR) Formula|Added rice formula will be ordered as the infant diet for the 4-week treatment period.
62485003|NCT06559553|EXPERIMENTAL|Selinexor+pegaspargase+dexamethasone|Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
62485004|NCT03889860||Uveitis group|
62485005|NCT03889860||Control group|age and sex matched group to the uveitis group
61933390|NCT05712876|EXPERIMENTAL|Single ascending dose (SAD) CK-0045 Dose level 1 to 5|At each dose level 6 healthy participants will receive a single dose of CK-0045 by s.c. administration
62133478|NCT00623194|EXPERIMENTAL|insulin detemir|Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
62133479|NCT04863677|EXPERIMENTAL|High Intensity Interval Training(HIIT)|The HIIT sessions include brief, intermittent bouts of high-intensity exercise interspersed with periods of low-intensity exercise (active recovery).HIIT include 20 intervals of high-intensity (30-60s at rating of perceived exertion (RPE; Borg scale of 6-20) of 15 to 17) and low-intensity (1min at RPE \<10 or totally rest). The whole exercise cycle takes around 40-50 minutes.
62485006|NCT04791813||Exposure group|group of surgically treated unilateral cleft lip and palate Egyptian children aged 9_12years
62485007|NCT04791813||Control group|group of healthy Egyptian children aged 9_12years
62485008|NCT05104723|EXPERIMENTAL|XELJANZ (tofacitinib)|Tofacitinib is self-administered orally at 5 mg twice per day or 11 mg once per day for 3 months.
62133480|NCT04863677|EXPERIMENTAL|Moderate Intensity Continuous Training(MICT)|Patients perform 40-50 minutes at a RPE of 12 to 14(a total of 4 groups, each group 5-8 min, interspersed with 2-minute rest)
61933391|NCT05712876|PLACEBO_COMPARATOR|SAD placebo|At each dose level 2 healthy participants will receive a single dose of matching placebo by s.c. administration
61933392|NCT05712876|EXPERIMENTAL|Multiple ascending dose (MAD) CK-0045 Dose level 1 to 3|At each dose level 9 otherwise healthy participants with obesity will receive a loading dose of CK-0045 on Day 1 followed by a dose on Day 8, Day 15, Day 22, Day 29 and Day 36 of CK-0045 by s.c. administration
61933393|NCT05712876|PLACEBO_COMPARATOR|MAD placebo|At each dose level 3 otherwise healthy participants with obesity will receive matching placebo on Day 1, Day 8 , Day 15, Day 22, Day 29 and Day 36 by s.c. administration
61933394|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
61933395|NCT06707103|EXPERIMENTAL|TR987 0.1% gel + Standard of Care|Participants will receive up to 16 weeks of TR987 0.1% gel topically + Standard of Care (wound cleansing/dressings and compression bandaging). Treatment will be twice weekly for the first four weeks then weekly for the remaining 12 weeks.
61933396|NCT06707103|OTHER|Standard of Care|Participants will receive Standard of Care (wound cleansing/dressings and compression bandaging). Treatment will be twice weekly for the first four weeks then weekly for the remaining 12 weeks.
61933397|NCT01737450|EXPERIMENTAL|BKM120|Full dose=100 mg/day (oral route) One study cycle equals 28 days. Patients will be treated until disease progression, unacceptable toxicity, or willingness to stop.
62485009|NCT06562400||NON-Responders|Patients with high frequency episodic or chronic migraine who obtained a reduction in monthly migraine days \< 50% after three months of mAbs treatment compared to pre-treatment values.
62485010|NCT06562400||Partial-Responders|Patients with high frequency episodic or chronic migraine who obtained a reduction in monthly migraine days \> or equal to 50% after six months of mAbs treatment compared to pre-treatment values but still present more than 5 MMDs.
61933398|NCT00503438||Salto Talaris Ankle|This is an Implant Registry of the approved Salto Talaris Ankle replacement device
61933399|NCT04733144|ACTIVE_COMPARATOR|Prednisolone-Dexamethasone|Participants will receive 1 week of low dose (7,5 mg) prednisolone directly followed by 1 week of high dose prednisolone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose dexamethasone (1,125 mg) directly followed by 1 week of high dose dexamethasone (4,5 mg).
61933400|NCT04733144|ACTIVE_COMPARATOR|Dexamethasone-Prednisolone|Participants will receive 1 week of low dose (1,125 mg) dexamethasone directly followed by 1 week of high dose dexamethasone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose prednisolone (7,5 mg) directly followed by 1 week of high dose prednisolone (30 mg).
61933401|NCT03866031|EXPERIMENTAL|M:2.75|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 2.75 mm
61933402|NCT03866031|EXPERIMENTAL|M3.25|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 3.25 mm
61933403|NCT03866031|EXPERIMENTAL|S3.75|12 Patients will be provided with 2 standard sized implant-supported mandibular overdentures d: 3.75 mm
61933404|NCT06072248|PLACEBO_COMPARATOR|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
61933405|NCT06072248|ACTIVE_COMPARATOR|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
61933406|NCT04292392|EXPERIMENTAL|A - ACB + Periarticular Block|Group A: patient will receive a preop ACB, followed by Intra-articular block during TKA surgery
61933407|NCT04292392|EXPERIMENTAL|B - ACB + IPACK Block|Group B: patient will receive a preop ACB+IPACK block before TKA surgery only
61933408|NCT04292392|EXPERIMENTAL|C - ACB + IPACK + Periarticular Block|Group C: patient will receive a preop ACB+IPACK block, followed by Intra-articular block during TKA surgery
61933409|NCT02806973|EXPERIMENTAL|Nasal Glucagon (NG) - Treatment 1|One dose of 3 milligram (mg) NG administered in one of four study periods.
61933410|NCT02806973|EXPERIMENTAL|NG - Treatment 2|Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods.
62692671|NCT05860751|EXPERIMENTAL|Dry needling with electrical stimulation|Participants with restless legs syndrome will receive dry needling with electrical stimulation to the lower extremities
61933411|NCT02806973|EXPERIMENTAL|NG - Treatment 3|Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods.
61933412|NCT02806973|EXPERIMENTAL|NG - Treatment 4|Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.
61933413|NCT05748444||Children with cystic fibrosis|Voluntary children with cystic fibrosis aged 6-18 years with normal glucose tolerance will be included in the study.
61933414|NCT05400122|EXPERIMENTAL|Experimental Infusion|"Preparative Regimen Administration:~* Fludarabine will be given at a dose of 30mg/m2 intravenously daily~* Cyclophosphamide will be given at a dose of 500mg/m2 intravenously daily~Investigational Agent Administration:~* NK Cell Product will be given per institutional standard of care (at a rate no faster than 250mL per hour or 3-4 ml per minute) as two doses by intravenous infusion on Days 0 (+2 days acceptable) and 14 (+/- 3 days acceptable)~* IL-2 will be administered at a flat dose of 2.2 million IU subcutaneously starting on the same day as the first NK cell infusion and will be administered three times weekly (dose level 1) or twice weekly (dose level -1) for up to four weeks total~* Vactosertib will be administered at a dose of 200mg once daily for 5 consecutive days per week, for up to four weeks total."
61933415|NCT02199860|EXPERIMENTAL|SD I - single rising doses|
61933416|NCT02199860|EXPERIMENTAL|SD II - single rising doses|
61933417|NCT02199860|EXPERIMENTAL|SD II - single rising doses + Placebo|
61933418|NCT02199860|PLACEBO_COMPARATOR|Placebo|
61933419|NCT01612949||easy to intubate, model derivation|easy to intubate, model derivation. photographing head and neck
61933420|NCT01612949||difficult to intubate, model derivation|difficult to intubate, model derivation.photographing head and neck
61933421|NCT01612949||easy to intubate, model validation|easy to intubate, model validation. photographing head and neck
62485011|NCT04888338||Observational (data collection)|Patients medical records are reviewed for details about CAR-T and RT treatment and acute and late toxicities, disease outcomes such as any events related to local or distant disease progression, survival, and cause of death if available. Patients' imaging scan data is collected at baseline, within 2 months of the first treatment of RT or CAR-T, and at 3, 6, 12 months, and then annually for 5 years after RT completion.
62485012|NCT01262235|EXPERIMENTAL|TKM-080301|
61933422|NCT01612949||difficult to intubate, model validation|difficult to intubate, model validation. photographing head and neck
61933423|NCT01612949||Test|A group of unlabeled subjects (mix of easy and difficult intubations) to test the reproducibility of the derived and validated model(s)
61933424|NCT03031236|ACTIVE_COMPARATOR|ECD+|Behavioral: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
61933425|NCT03031236|NO_INTERVENTION|Only regular health messages|Only regular health message from government health services
61933426|NCT01012076|ACTIVE_COMPARATOR|Active Control|The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning. Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to improve the parent's ability to successfully promote the child's social and emotional competency.
61933427|NCT01012076|EXPERIMENTAL|Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to promote the ability of the parent-child dyad to successfully manage shared toy play.
61933428|NCT02193451|EXPERIMENTAL|Urodynamics|Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
62326571|NCT06747039||Patients with a diagnosis of FM after failure and/or intolerance of first- and second-line treatment|Patients with a diagnosis of FM according to 2016 American College of Rheumatology Criteria, aged 18 years and older, able to fully understand and fill questionnaires and to provide fully informed consent, who failed and/or were intolerant of first- or second-line treatment.
62326572|NCT06746532|NO_INTERVENTION|Control|Standard care for moderate or severe hypoxic-ischemic encephalopathy with hypothermia.
62326573|NCT06746532|EXPERIMENTAL|Intranasal breast milk|Fresh own mother's breast milk expressed within 4 hours, will be administered 2 times daily, 0.4 ml in each nostril for 28 days.
62326574|NCT06747793|NO_INTERVENTION|Control group:|Standard intensive care unit care without virtual reality stimulation.
62326575|NCT06747793|EXPERIMENTAL|Interventional group:|Standard intensive care unit care and 30 minutes of virtual reality stimulation two times per day.
62326576|NCT03816319|EXPERIMENTAL|Treatment (TAK-243)|Patients receive TAK-243 IV over 30 minutes on days 1, 4, 8, and 11 of each cycle. Cycles repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo urine sample collection, bone marrow aspiration and bone marrow biopsy, MUGA and ECHO during screening and on study, and blood sample collection throughout the trial.
62326577|NCT06747650|EXPERIMENTAL|Active DBT-A Intervention Arm|A single cohort of teens with FASD will be administered DBT-A for the purpose of feasibility testing.
62326578|NCT03801434|EXPERIMENTAL|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.
62485013|NCT01834183|EXPERIMENTAL|Tivozanib/Gemcitabine|Segment 1: Tivozanib, taken orally days 1-21 of each 28 day cycle. Segment 2: Tivozanib, taken orally days 1-21 of each 28 day cycle. Gemcitabine, taken intravenously, Days 1 and 8 of each 28 day cycle.
62485014|NCT05799677|EXPERIMENTAL|Reflexology|Additive treatment with reflexology
62485015|NCT05799677|NO_INTERVENTION|Control|No treatment with reflexology
62485016|NCT00245882|ACTIVE_COMPARATOR|Care Coordination|Care Coordination with monthly follow-up by a diabetes nurse educator
62485017|NCT00245882|ACTIVE_COMPARATOR|Home Telemedicine|Active Care Management with Home Telemedicine
62485018|NCT04794816||Observational (questionnaire administration)|Participants complete an online questionnaire over 5 minutes regarding information on patient demographics and preferences for receiving real-time appointment imaging results.
62326579|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm S)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S.~Rimiducid may be administered as indicated."
62326580|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm F)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen F.~Rimiducid may be administered as indicated."
62326581|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm N)|Single weight-based IV administration of P-BCMA-ALLO1. Rimiducid may be administered as indicated.
62326582|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm P1)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1.~Rimiducid may be administered as indicated."
62326583|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm P2)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P2.~Rimiducid may be administered as indicated."
62326584|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm R)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen R.~Rimiducid may be administered as indicated."
62485019|NCT03345043|EXPERIMENTAL|VAL-339851|
62133481|NCT04863677|NO_INTERVENTION|Control Group|No additional rehabilitation treatment or physical exercise was added in Control Group.
61933429|NCT02193451|ACTIVE_COMPARATOR|Usual care|Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary
61933430|NCT06710769|OTHER|girls facing possible infertility|"Newly diagnosed female or relapsed malignancy who is 1-25 years of age with proposed treatment regimen containing at least ONE (1) of the following:~whole abdomen or pelvic irradiation total body irradiation~Proposed treatment regimen to include any of the following:~cyclophosphamide equivalent dose (CED, see Green et al 2014) ≥7.5 g/m2 any treatment regimen containing procarbazine bone marrow transplant conditioning regimen containing alkylator OR health condition or malignancy that requires removal of one or both ovaries"
62133482|NCT02454283|EXPERIMENTAL|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
62133483|NCT02454283|PLACEBO_COMPARATOR|Placebo|identically matching placebo capsules, orally, single-dose
62133484|NCT06278870|EXPERIMENTAL|disitamab vedotin in combination with pyrotinib|disitamab vedotin 2mg/kg IV every 14 days + Pyrotinib 400mg PO daily, with each 28-day cycle. After 6-8 cycles, adding Trastuzumab initially at 8mg/kg IV followed by 6mg/kg IV every 21 days + Pyrotinib 400mg PO daily for maintenance.
62133485|NCT06278870|ACTIVE_COMPARATOR|taxane drug in combination with trastuzumab and pertuzumab|taxane drug (Docetaxel/Paclitaxel/Albumin Paclitaxel/Liposomal Paclitaxel, dosing and administration per latest National Comprehensive Cancer Network(NCCN) and Chinese Society of Clinical Oncology(CSCO) breast cancer guidelines) + Trastuzumab initially at 8mg/kg IV followed by 6mg/kg IV every 21 days + Pertuzumab initially at 840mg IV followed by 420mg IV every 21 days, with each 21-day cycle. After 6-8 cycles, continuing with Trastuzumab at 6mg/kg IV every 21 days + Pertuzumab at 420mg IV every 21 days for maintenance.
62133486|NCT05629845|ACTIVE_COMPARATOR|EUS-guided therapy group|EUS would be performed with a curvilinear echoendoscope based on protocol described in our prior study. Because EUS-guided glue injection can be applied to both EV and GV and is less technically demanding than coiling or the combination approach, it is chosen as the EUS guided intervention in our study. The target EV or GV size will be measured by the caliper function on the EUS machine. After confirmation of blood flow in the target varix by Doppler, EUS-guided glue injection would be performed for EV or GV ≥ 3mm in diameter using a standard 19G needle. Each injection will contain a 1.2ml mixture of 0.5ml glue (Histoacryl, n-butyl-2-cyanoacrylate, B. Braun Surgical, Germany) + 0.7ml lipiodol. Flow obliteration in the treated varix will be confirmed on EUS Doppler. If blood flow is still observed on Doppler after the first injection, additional injection of glue-lipiodol mixture would be repeated (up to 4 doses) until flow obliteration is achieved.
62133487|NCT05629845|ACTIVE_COMPARATOR|Conventional endoscopic therapy group|In patients with prior EV bleeding, EV with high-risk stigmata (regardless of size) or EV of medium or large size detected on study EGD will be treated with VBL using a multi-band ligator fitted on the gastroscope for secondary prevention. In patients with prior GV bleeding, if compressible GV suggestive of incomplete obliteration from prior glue treatment is noted on study EGD, cyanoacrylate glue injection using a 1.2ml mixture of 0.5ml glue (Histoacryl, n-butyl-2-cyanoacrylate, B. Braun Surgical, Germany) + 0.7ml lipiodol will be performed for secondary prevention.
62133488|NCT05152992|EXPERIMENTAL|Video and stimulation-based induction of emotion|Participants viewed visual stimuli while undergoing stimulation of brain regions involved in emotion during their inpatient hospitalization at the University of California, San Francisco (UCSF).
62133489|NCT03743649|EXPERIMENTAL|Group I (haloperidol, placebo)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
62133490|NCT03743649|EXPERIMENTAL|Group II (lorazepam, placebo)|Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
62133491|NCT03743649|EXPERIMENTAL|Group III (haloperidol, lorazepam)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.
62133492|NCT03743649|EXPERIMENTAL|Group IV (placebo, lorazepam)|Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.
62133493|NCT03488394|EXPERIMENTAL|Treatment|Gene therapy (autologous, CD34+ cell enriched cells fraction containing HSCs, transduced with the IDUA LV encoding for the human IDUA gene and cryopreserved in cryoformulation medium)
62133494|NCT00799552|PLACEBO_COMPARATOR|Placebo|
62133495|NCT00799552|EXPERIMENTAL|RX-10045|
62133496|NCT06518772|EXPERIMENTAL|Intervention|The application procedure started with the application of hot gel packets at a temperature of 40-42°C to the soles of the feet of the women in the intervention group for 20 minutes when cervical dilation reaches 5 cm.The first Visual Analog Scale (VAS) evaluation was conducted after the application. Conduction is followed by more evaluations at the 25th (5 minutes after the application), 35th (15 minutes after the application), and 50th minute (30 minutes after the application). These applications were repeated every hour until cervical dilation reached 10 cm. The applicatilon procedure has been stopped after cervical dilation reached 10 cm.
62485020|NCT03345043|PLACEBO_COMPARATOR|Placebo|
61933431|NCT01461278|EXPERIMENTAL|Cataract surgery plus iStent supra|
61933432|NCT01461278|ACTIVE_COMPARATOR|Cataract surgery|
61933433|NCT01837732|EXPERIMENTAL|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
61933434|NCT01837732|ACTIVE_COMPARATOR|B: relational|Relational: 10 mn verbal patient's centered exchanges
61933435|NCT06708702|EXPERIMENTAL|Copaíba|
62133497|NCT06518772|NO_INTERVENTION|Control|The control group received routine service and VAS at the same times.
62133498|NCT05698758|EXPERIMENTAL|dextrometropine group|Approximately 45 - 60 minutes before cataract surgery, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1).
62485021|NCT02965261|EXPERIMENTAL|Test|Torrent's Fluoxetine Tablets 20 mg
62485022|NCT02965261|ACTIVE_COMPARATOR|Reference|Warner Chilcott LLC's Sarafem® Tablet 20 mg
62485023|NCT05034874|EXPERIMENTAL|IXT-m200|Anti-methamphetamine monoclonal antibody, dose levels of 1.5 and 3 g
62485024|NCT05034874|PLACEBO_COMPARATOR|Placebo|Saline
62485025|NCT00531180|EXPERIMENTAL|4-DCT Ventilation Validation|
62485026|NCT05693623|EXPERIMENTAL|Cold Application to the Sacral Area|
62485027|NCT05693623|NO_INTERVENTION|control group|
62133499|NCT05698758|PLACEBO_COMPARATOR|placebo group|Approximately 45 - 60 minutes before cataract surgery, patients in the placebo group were given 0.9% sodium chloride solution (1.0μg.kg-1).
62133500|NCT01739244|EXPERIMENTAL|SYL040012 eye drops dose A|Ocular topical administration of SYL040012 eye drops dose A
62133501|NCT01739244|EXPERIMENTAL|SYL040012 eye drops dose B|Ocular topical administration of SYL040012 eye drops dose B
62133502|NCT01739244|EXPERIMENTAL|SYL040012 eye drops dose C|Ocular topical administration of SYL040012 eye drops dose C
62485028|NCT01565447||Children with ALL or LL|Children diagnosed with ALL or LL will be recruited for this study
62485029|NCT02105272|EXPERIMENTAL|OPC-1085EL ophthalmic solution|Once daily
62485030|NCT02105272|ACTIVE_COMPARATOR|Latanoprost ophthalmic solution|Once daily
62485031|NCT02601963|EXPERIMENTAL|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
62692672|NCT02193191|EXPERIMENTAL|Plerixafor|Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
61933436|NCT06708702|PLACEBO_COMPARATOR|Placebo|
62133503|NCT01739244|PLACEBO_COMPARATOR|Placebo|Ocular topical administration of placebo eye drops
62133504|NCT00578916|EXPERIMENTAL|1|
62133505|NCT01952366||Depressed patients|Patients admitted to specialist health care service of old age psychiatry
62133506|NCT05335642||Patients that had secondary interventions after EVAR|
62133507|NCT05335642||Patients without secondary interventions after EVAR|
62485032|NCT02601963|EXPERIMENTAL|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
62485033|NCT02601963|PLACEBO_COMPARATOR|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
62692673|NCT01822327|EXPERIMENTAL|Contingent Vouchers Unmatched|CRA therapy plus Voucher incentives contingent on cocaine abstinence with monetary values set at usual monetary values across all patients.
62692674|NCT01822327|EXPERIMENTAL|Contingent Vouchers, Matched|CRA therapy plus Vouchers contingent on cocaine abstinence, with more severe patients receiving twice the usual voucher monetary values.
62692675|NCT01822327|ACTIVE_COMPARATOR|Non-Contingent Vouchers control|CRA therapy plus Vouchers earned independent of drug use
62692676|NCT01400412|EXPERIMENTAL|MVC Arm: DRV/r + MVC + FTC + TDF placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Maraviroc 150 mg PO QD + Emtricitabine 200 mg PO QD + Placebo for Tenofovir disoproxil fumarate PO QD
62133508|NCT04147494|EXPERIMENTAL|Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable). Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a separate day (for volunteer patients only, PSMA PET/CT is optional and not required).
62133509|NCT05570838|EXPERIMENTAL|FES + conventional treatment|60 minutes per session, 5 sessions per week with 30 minutes of task-specific training using Functional Electrical Stimulation applyed by Fesia Grasp device and 30 minutes of Robotic-Assisted Therapy using Amadeo robot for hand rehabilitation
62133510|NCT05570838|ACTIVE_COMPARATOR|Conventional treatment|60 minutes per session, 5 sessions per week with 30 minutes of task-specific training and 30 minutes of Robotic-Assisted Therapy using Amadeo robot for hand rehabilitation
62485034|NCT00341458||Cancer Cases|Women 20-74 years old, residents of Warsaw and Lodz that were newly diagnosed with confirmed in situ or invasive breast cancer or ovarian or endometrial cancer
62485035|NCT03676634|EXPERIMENTAL|Vaccine|rBV A/B
62485036|NCT01946477|EXPERIMENTAL|Pomalidomide + dexamethasone|Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (\< 75 years old) or 20 mg/day (\>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
62692677|NCT01400412|EXPERIMENTAL|TDF Arm: DRV/r + TDF + FTC + MVC placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Emtricitabine 200 mg PO QD + Tenofovir disoproxil fumarate 300 mg PO QD + Placebo for Maraviroc PO QD
61933437|NCT04155489|ACTIVE_COMPARATOR|restrictive|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started.
61933438|NCT04155489|EXPERIMENTAL|Liberal|In the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
62133511|NCT04505358|EXPERIMENTAL|30 mg PU AD 3:2 ratio|will be administered orally, as 30 mg active dose strength tablets qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
62485037|NCT01946477|EXPERIMENTAL|Pomalidomide + Dexamethasone + Daratumumab|"Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (\< 75 years old) or 20 mg/ day (\>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle and daratumumab administered intravenously (IV) at a starting dose of 16 mg/kg at following schedule:~* Days 1, 8, 15, and 22 of a 28-day cycle for Cycle 1 and Cycle 2~* Days 1 and 15 for Cycle 3 through Cycle 6~* Day 1 for Cycle 7 and each cycle thereafter until disease progression"
62485038|NCT03867760|EXPERIMENTAL|Intervention Group|Participants will use the recorded hypnosis intervention (RHI) at home for 28 days.
62485039|NCT03867760|ACTIVE_COMPARATOR|Attention Control Group|Participants will use a recorded relaxation intervention at home for 28 days.
62485040|NCT05764096||COVID-19 patients|38 patients admitted to the intensive care unit due to COVID-19 contagion
62485041|NCT05764096||Healthy control participants|An age- and education-matched group of 38 healthy individuals who did not report a previous COVID-19 contagion
62485042|NCT00922896|EXPERIMENTAL|GPE|Gemcitabine-Cisplatin-Erlotinib
62692678|NCT05726370|EXPERIMENTAL|Pre-Operative Treatment + Salvage Surgery + Adjuvant Treatment|"Participants will complete study procedures as outlined:~Preoperative Phase:~* Mandatory biopsy at baseline.~* Neoadjuvant treatment (2 cycles):~  * Cycles 1 - 2 ---Day 1 of 21-day Cycle: Predetermined doses of Pembrolizumab, Cisplatin (or Carboplatin) and Docetaxel.~Salvage Surgery:~-Primary tumor resection and/or lymph node dissection surgery 3-6 weeks from cycle 2 day 1~Adjuvant Phase:~-3-8 weeks post-surgery and upto a total of 15 cycles~--Cycles 3 - 17~---Day 1 of 21-day cycle: Predetermined dose of Pembrolizumab~Follow up appointments"
62692679|NCT06290323|OTHER|Placebo|Patients in the first group are the control group, and after spinal anesthesia, the sensory block is formed, and the lithotomy position will be taken for the surgical procedure. Patients will be monitored for 48 hours for postoperative pain (Numarating Raiting Scala: NRS) and side effects. On the postoperative 7th day, the patient's pain level will be NRS, and the DJS-connected sub-urinary system symptoms assessed will be evaluated with the ureteral stent discomfort questionnaire (with the stent inserted). In our clinic, approximately one month after URS operations, control cystoscopy is performed and ureteral stents are removed. After five days of removal of the ureteral stent, the lower urinary system symptoms will be questioned with the ureteral stent discomfort questionnaire (after removal of the stent).
62692680|NCT06290323|ACTIVE_COMPARATOR|Quadratus lumborum|After the posterior quadratus lumborum block was made in the lateral decubitus position, the patient was taken to the lithotomy position for surgery. Patients will be monitored for 48 hours for postoperative pain (Numarating Raiting Scala: NRS) and side effects. On the postoperative 7th day, the patient's pain level will be NRS and the DJS-connected sub-urinary system symptoms will be assessed and evaluated using the ureteral stent discomfort questionnaire (with the stent inserted). In our clinic, approximately one month after URS operations, a control cystoscopy is performed, and ureteral stents are removed. After five days of removal of the ureteral stent, the lower urinary system symptoms will be questioned with the ureteral stent discomfort questionnaire (after removal of the stent).
62692681|NCT02132260|EXPERIMENTAL|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)
62692682|NCT02132260|ACTIVE_COMPARATOR|Naftin® Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2%
62692683|NCT02132260|PLACEBO_COMPARATOR|Placebo Topical Cream|Placebo Topical Cream
61933439|NCT05438212|ACTIVE_COMPARATOR|Arm I (surgery, stereotactic radiosurgery)|Patients undergo surgery per standard of care. Within 10-30 days after surgery, patients undergo stereotactic radiosurgery for 1 fraction.
61933440|NCT05438212|EXPERIMENTAL|Arm II (stereotactic radiosurgery, surgery)|Within 7 days before surgery, patients undergo stereotactic radiosurgery for 1 fraction. Patients undergo surgery per standard of care.
61933441|NCT03765879|EXPERIMENTAL|Verum VGAIT Group|Participants in this group will receive verum (real) acupuncture and verum video-guided acupuncture imagery treatment (VGAIT).
61933442|NCT03765879|PLACEBO_COMPARATOR|Sham VGAIT Group|Participants in this group will receive sham acupuncture and sham VGAIT.
62133512|NCT04505358|PLACEBO_COMPARATOR|30 mg Placebo 3:2 ratio|will be administered orally, as 30 mg placebo tablets (placebo has no active ingredients) qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
62133513|NCT02310113||Hematologic outpatients|Chronic anaemic outpatients who are planed to get transfusion RBC
62133514|NCT00032435|EXPERIMENTAL|1|PAL-40 Active
62692684|NCT06624345|EXPERIMENTAL|Inspiratory Muscle Training|Subjects participated in a combination of inspiratory muscle training and aerobic exercise for approximately 30 minutes per day over a period of six weeks.
61933443|NCT05277961|EXPERIMENTAL|UVR Dose 1x3SED|UVR Dose 1x3 standard erytheme dose (SED)
61933444|NCT05277961|EXPERIMENTAL|UVR dose 3x1SED|UVR dose 3x1 standard erythema dose (SED)
61933445|NCT03423134|EXPERIMENTAL|Test of new adhesive strip|A new adhesive strip will be tested in this investigation
61933446|NCT01046370|EXPERIMENTAL|ARP intervention|
62485043|NCT06626139|EXPERIMENTAL|Psilocybin C1|Following screening and a baseline assessment visit, healthy volunteers will receive one dose of up to 25mg psilocybin in a context (Context 1) that is hypothesized to modulate acute and post-acute drug effects.
62485044|NCT06626139|EXPERIMENTAL|Psilocybin C2|Following screening and a baseline assessment visit, healthy volunteers will receive one dose of up to 25mg psilocybin in a context (Context 2) that is hypothesized to modulate acute and post-acute drug effects.
62485045|NCT06626139|PLACEBO_COMPARATOR|Placebo C1|Following screening and a baseline assessment visit, healthy volunteers will receive one dose of an inactive placebo in a context (Context 1) that is hypothesized to modulate acute and post-acute drug effects.
61933447|NCT01046370|NO_INTERVENTION|No intervention|
61933448|NCT03530566||Pnk group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
61933449|NCT03530566||Control group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
61933450|NCT00686179|EXPERIMENTAL|1|Escalating doses of AZD3480 during 6 days
61933451|NCT00686179|EXPERIMENTAL|2|Repeated doses of AZD3480 during 6 days
61933452|NCT00686179|PLACEBO_COMPARATOR|3|Placebo during 6 days
61933453|NCT00686179|ACTIVE_COMPARATOR|4|Placebo during 5 days, active day 6
62133515|NCT00032435|PLACEBO_COMPARATOR|2|PAL-40 Placebo
62133516|NCT02230137|EXPERIMENTAL|Text message arm|
62133517|NCT02230137|NO_INTERVENTION|No text message arm|
62326585|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm RS)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RS.~Rimiducid may be administered as indicated."
61933454|NCT04259281|EXPERIMENTAL|GTX-102 Cohort 1|3.3 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to \<17 years of age)
61933455|NCT04259281|EXPERIMENTAL|GTX-102 Cohort 2|10 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to \<17 years of age)
61933456|NCT04259281|EXPERIMENTAL|GTX-102 Cohort 3|20 mg starting dose followed by intra-patient dose escalation up to 55 mg and then a maintenance phase (in U.S participants 4 to \<17 years of age)
61933457|NCT04259281|EXPERIMENTAL|GTX-102 Cohort 4|3.3 mg starting dose followed by slow intra-patient dose escalation up to 5 mg and then a maintenance phase (in Ex-U.S participants 4 to \<8 years of age)
61933458|NCT04259281|EXPERIMENTAL|GTX-102 Cohort 5|5 mg starting dose followed by slow intra-patient dose escalation up to 7.5 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
61933459|NCT04259281|EXPERIMENTAL|GTX-102 Cohort 6|7.5 mg starting dose followed by slow intra-patient dose escalation up to 10 mg and then a maintenance phase (in Ex-U.S participants 4 to \<8 years of age)
61933460|NCT04259281|EXPERIMENTAL|GTX-102 Cohort 7|10 mg starting dose followed by slow intra-patient dose escalation up to 12 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
61933461|NCT04259281|EXPERIMENTAL|GTX-102 Cohort US|2 mg for 4 monthly doses followed by a quarterly maintenance regimen
61933462|NCT04259281|EXPERIMENTAL|GTX-102 Expanded Enrollment Cohort A|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants 4 to \<8 years of age)
61933463|NCT04259281|EXPERIMENTAL|GTX-102 Expanded Enrollment Cohort B|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
61933464|NCT04259281|EXPERIMENTAL|GTX-102 Expanded Enrollment Cohort C|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants 4 to \<8 years of age)
61933465|NCT04259281|EXPERIMENTAL|GTX-102 Expanded Enrollment Cohort D|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants ≥ 8 to 17 years of age)
62326586|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm C)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen C.~Rimiducid may be administered as indicated."
62326587|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm160)|"Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2.~Rimiducid may be administered as indicated."
61933466|NCT04259281|EXPERIMENTAL|GTX-102 Cohort E|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in participants that transition from GTX-102 US Cohort only)
62326588|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm480)|"Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2.~Rimiducid may be administered as indicated."
62326589|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm P1.5)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1.5.~Rimiducid may be administered as indicated."
62326590|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm RP1)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1.~Rimiducid may be administered as indicated."
62326591|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm RP1.5)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1.5.~Rimiducid may be administered as indicated."
62326592|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm RP2)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP2.~Rimiducid may be administered as indicated."
62326593|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm CP1)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1.~Rimiducid may be administered as indicated."
62326594|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm CP1.5)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1.5.~Rimiducid may be administered as indicated."
62326595|NCT04960579|EXPERIMENTAL|P-BCMA-ALLO1 CAR-T cells (Arm CP2)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP2.~Rimiducid may be administered as indicated."
62326596|NCT06027996|EXPERIMENTAL|Treatment|Tissue expander implantation with the Melodi Matrix
62326597|NCT06027996|NO_INTERVENTION|Control|Tissue expander implantation without a matrix
62326598|NCT06746142|EXPERIMENTAL|Arm A: FB RT arm|Participants will be treated with 40.05 Gy radiation, at 2.67 Gy daily single fraction, 5 days a week, for 3 weeks by IMRT in free breathing technique.
62326599|NCT06746142|EXPERIMENTAL|Arm B: DIBH RT arm|Participants will be treated with 40.05 Gy radiation, at 2.67 Gy daily single fraction, 5 days a week, for 3 weeks by IMRT in DIBH technique.
62485046|NCT06626139|PLACEBO_COMPARATOR|Placebo C2|Following screening and a baseline assessment visit, healthy volunteers will receive one dose of an inactive placebo in a context (Context 2) that is hypothesized to modulate acute and post-acute drug effects.
61933467|NCT06708533|EXPERIMENTAL|12-week physical activity programme|Participants in this arm will engage in a structured 12-week walking program. They will complete sub-maximal fitness assessments and provide biological samples during visits to the university at baseline, week 6, and week 12. They will also complete questionnaires assessing IBS symptoms, quality of life (QoL), anxiety, depression, and other factors.
61933468|NCT06708533|NO_INTERVENTION|No intervention control group|Participants in this arm will not receive any intervention and will continue their usual lifestyle for the study duration. They will complete the same assessments as the intervention arm, including providing biological samples, undergoing sub-maximal fitness tests, and completing questionnaires at baseline, week 6, and week 12. This arm serves as a comparison group to evaluate the effects of the walking program.
61933469|NCT03656835|EXPERIMENTAL|Diagnostic (ILN biochip testing)|Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
61933470|NCT00600444|ACTIVE_COMPARATOR|A|Venae Sectio technique will be used to insert totally implantable access port (TIAP) by a surgeon
61933471|NCT00600444|EXPERIMENTAL|B|Punction of Vena Subclavia will be used to insert totally implantable access port (TIAP) by a radiologist.
61933472|NCT06706921|EXPERIMENTAL|18F-Fluciclovine PET/CT|Subjects receive 18F-Fluciclovine PET/CT scans.
61933473|NCT04703218|EXPERIMENTAL|Patients with stroke and olfaction disorder benefiting from specific olfaction training.|
61933474|NCT04703218|NO_INTERVENTION|Patients with stroke and olfactory disorder benefiting from standard post-stroke rehabilitation|
61933475|NCT01942473|EXPERIMENTAL|Automated FiO2 control|Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Avea, Carefusion 234 GmbH Hoechberg, Germany), which is capable to automatically adjust the FiO2 based on readings of an incorporated SpO2 monitoring device. Infants will be allowed to adjust for at least 2h using the ventilator settings as chosen by the clinical team responsible. Thereafter, data will be recorded for 24h experimental time.
61933476|NCT01942473|PLACEBO_COMPARATOR|Manual Adjustment|Infants will be exposed to the first study phase (clinical routine or automated FiO2 adjustment) for 24 h and then will be switched to the alternate mode (automated FiO2 adjustment or clinical routine) for another 24 h.
61933477|NCT06576427|EXPERIMENTAL|Vertex Pulmonary Embolectomy System|Patients presenting with clinical signs and symptoms of acute PE and who meet the study criteria will be treated with the Vertex Pulmonary Embolectomy System
61933478|NCT06709950|EXPERIMENTAL|Art Therapy|
61933479|NCT06709950|ACTIVE_COMPARATOR|Regular therapy|
61933480|NCT05109052|EXPERIMENTAL|Experimental|"Open label safety and tolerability assessment of PXS-5505:~(PXS-5505) 100-200mg BID (Atezolizumab) 1200mg every 3 weeks (Bevacizumab) 15mg/kg every 3 weeks"
62326600|NCT06747910||Pediatric Childhood Cancer Survivors|"Survivors from the SJLIFE cohort previously treated for ALL, HL, and Non-HL diagnostic groups~Participants will complete a standardized clinical AD assessment during a scheduled on-campus SJLIFE visit. Participants will be asked to wear a heart rate variability monitor for 7 days after the on-campus visit. An AD symptom questionnaire will be completed, either before or after the standardized clinical AD assessment."
62326601|NCT06743529|ACTIVE_COMPARATOR|Immediate strategy|Usual Care
62692685|NCT06624345|SHAM_COMPARATOR|Control group|Subjects received routine care.
62692686|NCT06260774|EXPERIMENTAL|Dose level 1|0.4 mg/kg of TTX-MC138
61933481|NCT04190173|EXPERIMENTAL|Prucalopride|Prucalopride (Trade name: Resolor) 2 mg oral or tube feeding once daily 5 consecutive days Decrease dose to 1 mg once daily in patient with end stage kidney disease or Cirrhosis Child Pugh C
61933482|NCT04190173|PLACEBO_COMPARATOR|Placebo|Placebo tablet to mimic Prucalopride made by starch
61933483|NCT00292318|ACTIVE_COMPARATOR|Arm 1|Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
61933484|NCT00292318|EXPERIMENTAL|Arm 2|Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
61933485|NCT05213572||subjects w sickle cell disease|to evaluate heart, lung, liver, kidney, brain, and neurocognitive function post-hematopoietic stem cell transplant (HSCT) in subjects with sickle cell disease (SCD) who undergo curative therapies
61933486|NCT00620464|ACTIVE_COMPARATOR|Radiopaque Implanon (ro imp)|The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
61933487|NCT00620464|ACTIVE_COMPARATOR|Implanon (imp)|"Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year."
61933488|NCT06587750|EXPERIMENTAL|CMR intervention|Participants receive CMR intervention delivered by a treatment partner in a home enviornment
61933489|NCT03768973||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
61933490|NCT03768973||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
61933491|NCT02938845|EXPERIMENTAL|total laparoscopic hysterectomy(TLH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
61933492|NCT02938845|EXPERIMENTAL|total abdominal hysterectomy(TAH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
61933493|NCT06708143|EXPERIMENTAL|Temporal Interference|The investigators perform temporal interference (TI) stimulation to patients with drug-resistant epilepsy. They observe clinical manifestations before, during, and after stimulation to investigate the efficiency of TI.
61933494|NCT05665179|EXPERIMENTAL|Treatment|Receives tutorial for free online legal resolution at treatment center
61933495|NCT05665179|NO_INTERVENTION|Control|The control group is not provided the experimental intervention.
61933496|NCT06704997||Patients with tertiary neurological rehabilitation|Patients with confirmed diagnosis of stroke, acquired brain injuries, traumatic brain injuries, brain tumours, central nervous system infections and polytrauma from acute neurological or neurosurgical units in Singapore. The cohort will be selected from the TTSH Rehabilitation Centre (TTSH RC) admissions from year 2016 to the present.
62326602|NCT06743529|EXPERIMENTAL|Conservative strategy|Conservative strategy
62326603|NCT06747000||Individuals with lipid disorders|Individuals with lipid disorders (elevated HDL and LDL)
62326604|NCT06747000||Healthy individuals|Healthy individuals with normal lipid values and without lipid-related diseases
62692687|NCT06260774|EXPERIMENTAL|Dose level 2|0.8 mg/kg of TTX-MC138
62692688|NCT06260774|EXPERIMENTAL|Dose level 3|3.2 mg/kg of TTX-MC138
62692689|NCT06445439|EXPERIMENTAL|60 bpm, then 80 bpm|Pacing rate of 60 bpm for the first 3 months, then switch to 80 bpm for the next 3 months.
62692690|NCT06445439|EXPERIMENTAL|80 bpm, then 60 bpm|Pacing rate of 80 bpm for the first 3 months, then switch to 60 bpm for the next 3 months.
62692691|NCT03342222|EXPERIMENTAL|PEEK Interference Screws|PEEK Interference Screws provided by Ruijin Hangzhou Martins Medical Equipment Co., Ltd.
62692692|NCT03342222|ACTIVE_COMPARATOR|Biosure PK interference screw|Biosure PK interference screw from Smith \& Nephew plc.
62692693|NCT05421494|EXPERIMENTAL|study2: WET-R|
62692694|NCT05421494|PLACEBO_COMPARATOR|study 2: MCC|
62326605|NCT06747221|ACTIVE_COMPARATOR|Standard care|Facilities in the control arm will receive regular standard program oversight by county department of health personnel but no further interventions related to the SAIA implementation stratgey.
62326606|NCT05278104|EXPERIMENTAL|Atomoxetine|
62326607|NCT05278104|PLACEBO_COMPARATOR|Placebo|
62326608|NCT05131022|EXPERIMENTAL|Phase 1a Dose Escalation|Multiple dose levels of NX-5948 to be evaluated; determination of Maximum Tolerated Dose/Phase 1b recommended dose(s)
62692695|NCT05421494|EXPERIMENTAL|study 1: WET|Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
61933497|NCT03036319|EXPERIMENTAL|Active TES|"Participants will receive real tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions."
61933498|NCT03036319|PLACEBO_COMPARATOR|Sham TES|Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 260 sessions.
61933499|NCT03036319|EXPERIMENTAL|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
61933500|NCT03036319|EXPERIMENTAL|Active TES + Cognitively based intervention|This condition combines active TES and cognitively based interventions for some or all of the study sessions
61933501|NCT03036319|EXPERIMENTAL|Sham TES + Cognitively based intervention|This condition combines sham TES and cognitively based interventions for some or all of the study sessions
61933502|NCT03036319|EXPERIMENTAL|Active TES, Sham TES, Cognitively based interventions|This condition combines active and sham TES with cognitively based interventions using a cross-over design
61933503|NCT03036319|EXPERIMENTAL|Active and Sham TES|Participants will receive active and sham TES
61933504|NCT01420653|EXPERIMENTAL|Maxigesic 325|Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
61933505|NCT01420653|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
61933506|NCT01420653|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
61933507|NCT01420653|PLACEBO_COMPARATOR|Placebo|Placebo tablets, every 6 hours, orally
61933508|NCT02929173|ACTIVE_COMPARATOR|Group 2|E-max is un allceram crown
61933509|NCT02929173|EXPERIMENTAL|Group 1|Bio HPP crown is a hybrid crown
61933510|NCT06702111||All patients receiving allogeneic HSCT at Queen Mary Hospital, Hong Kong|
61933511|NCT02195206||Healthy|Adult
61933512|NCT04966052||COPD combined with TB group|COPD combined with pulmonary TB infection
61933513|NCT04966052||COPD non-TB control group|COPD combined without pulmonary TB infection
61933514|NCT04966052||TB non-COPD control group|pulmonary TB infection without COPD
61933515|NCT04966052||Non-smoking non-TB control group|Non-smoking without pulmonary TB infection
61933516|NCT03766685|EXPERIMENTAL|Bimekizumab-SS|Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
61933517|NCT03766685|EXPERIMENTAL|Bimekizumab-AI|Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).
61933518|NCT00410202|ACTIVE_COMPARATOR|Entecavir|With the option of adding tenofovir at week 48. (This does not apply to Korea)
61933519|NCT00410202|ACTIVE_COMPARATOR|Adefovir + Lamivudine|
61933520|NCT00410202|ACTIVE_COMPARATOR|Entecavir + Adefovir|
61933521|NCT01516528||All|All subjects enrolled in the study
61933522|NCT06679842|EXPERIMENTAL|one arm|
61933523|NCT06709768|EXPERIMENTAL|Intervention Group|Individuals randomized to the intervention group will receive the MAPSS-MS virtually over an 8 week time period. The Virtual MAPSS-MS has two components: (1) group sessions via Microsoft teams with an expert facilitator focused on providing information and building efficacy for use of cognitive strategies, and (2) computer assisted cognitive training (Brain HQ).
61933524|NCT06709768|NO_INTERVENTION|Wait List Control|Participants in this arm will complete data collection at the same time and intervals as the experimental arm. When all three data collections have been completed, they will be offered the opportunity to participate in the intervention - no additional data will be collected following the intervention.
61933525|NCT01406925|PLACEBO_COMPARATOR|Control|Placebo control
61933526|NCT01406925|EXPERIMENTAL|Low dose NRL001|0.5% NRL001 cream
61933527|NCT01406925|EXPERIMENTAL|Intermediate dose NRL001|0.75% NRL001 cream
61933528|NCT01406925|EXPERIMENTAL|High dose NRL001|1.0% NRL001 cream
62326609|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 1 in CLL or SLL with prior BTKi and BCL2i|CLL or SLL with prior exposure to both a Bruton's tyrosine kinase inhibitor (BTKi) and BCL-2 inhibitor, unless previously deemed ineligible for a BCL-2i. Patients enrolled in CLL/SLL arm will be randomized to one of two dose levels.
62326610|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 2 in CLL/SLL with non-C481S BTK mutations|Prior exposure to both BTKi and BCL-2i (unless deemed ineligible for BCL-2i by Investigator at the time of study enrollment) and documented BTK mutation other than C481S within 6 months prior to study entry
62326611|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 3 in CLL/SLL with prior non-covalent BTKi|CLL/SLL with prior exposure to ncBTKi and BCL-2i naïve.
62326612|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 4 in CLL/SLL with TP53 or 17p deletion, 2L, prior BTKi|Patients with documented TP53 mutation or 17p deletion and 1 prior line of therapy that included a BTKi and BCL-2i naïve.
62133518|NCT03882450|NO_INTERVENTION|Neonates with congenital cardiac disease (retrospective)|Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
62485047|NCT04681391||anodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During anodal tDCS, the anode was placed over right temporoparietal junction, and the cathode was placed over left supraorbital area.
62485048|NCT04681391||cathodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During cathodal tDCS, the cathode was placed over right temporoparietal junction, and the anode was placed over left supraorbital area.
62485049|NCT04681391||sham (as a control condition)|same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds.
62485050|NCT04880616|EXPERIMENTAL|Sequence 1|In treatment period 1 participants will receive increasing doses of NBI-827104 for 28 days. After a 14-day washout period, participants will receive matching placebo for 28 days in treatment period 2.
62485051|NCT04880616|EXPERIMENTAL|Sequence 2|In treatment period 1 participants will receive matching placebo for 28 days. After a 14-day washout period, participants will receive increasing doses of NBI-827104 for 28 days in treatment period 2.
61933529|NCT04421573|EXPERIMENTAL|BCPHD-D5W with usual care|"Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, and 8 weeks.~All helpful treatment methods already underway are continued. Other new treatment methods are discouraged."
62326613|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 5 in CLL/SLL with 2L+, prior BTKi|Patients with at least 1 prior line of therapy that included a BTKi and BCL-2i naïve.
62326614|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 6 in MCL|Non-blastoid MCL with prior exposure to a BTKi and an anti-CD20 monoclonal antibody (mAb)-based chemoimmunotherapy regimen
62133519|NCT03882450|ACTIVE_COMPARATOR|Neonates with congenital cardiac disease (prospective)|Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
62133520|NCT05766540|EXPERIMENTAL|Aripiprazole|This group will receive Aripiprazole 10 mg/day for 6 months along with Clozapine and Metformin
62133521|NCT05766540|PLACEBO_COMPARATOR|Treatment as usual|This group will receive Clozapine and Metformin.
62133522|NCT00588471|ACTIVE_COMPARATOR|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
62133523|NCT00588471|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
62133524|NCT01742169|EXPERIMENTAL|Outreach and Reminder Intervention|Participants randomized to this arm will receive the Outreach and Reminder intervention.
62133525|NCT01742169|NO_INTERVENTION|Usual Care|Patients assigned to this arm will receive usual care.
62133526|NCT00291954|EXPERIMENTAL|1|Henogen hepatitis B vaccine
62133527|NCT00291954|ACTIVE_COMPARATOR|2|HBVAXPRO hepatitis B vaccine
62133528|NCT00570466|EXPERIMENTAL|Video games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.
62133529|NCT00570466|PLACEBO_COMPARATOR|Web and DVD knowledge|Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.
62133530|NCT03631433|ACTIVE_COMPARATOR|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
62326615|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 7 in MZL|MZL (EMZL, MALT, NMZL, SMZL) with prior exposure to an anti-CD20 mAb-based chemo-immunotherapy regimen and an additional line of therapy
62485052|NCT04180969|PLACEBO_COMPARATOR|placebo stressor, sham rTMS|placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil
62485053|NCT04180969|EXPERIMENTAL|placebo stressor, active rTMS|placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
62485054|NCT04180969|EXPERIMENTAL|active stress, sham rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil
61933530|NCT04421573|ACTIVE_COMPARATOR|Waiting period with usual care|All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
61933531|NCT02313324|EXPERIMENTAL|ESWT group|The patients were randomly assigned to the extracorporeal shock wave therapy (ESWT) group.
62326616|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 8 in WM (3L+)|WM with prior exposure to a BTKi and at least an additional line of therapy
62326617|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 9 in WM (2L)|WM following upfront therapy with a BTKi
62326618|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 10 in DLBCL|DLBCL which transformed from indolent lymphoma or Richters transformation with prior exposure to an anthracycline (unless previously deemed ineligible to receive), an anti-CD20 mAb-based chemoimmunotherapy regimen, and an additional line of therapy
62326619|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 11 in FL|FL (grade 1-3a) with prior exposure to an anti-CD20 mAb-based chemoimmunotherapy regimen and an additional line of therapy
61933532|NCT02313324|ACTIVE_COMPARATOR|SWD combined IFC group|The patients were randomly assigned to the SIT group. The patients received combined therapy with shortwave diathermy (SWD) and interferential current (IFC) performed by the same physiotherapist at each treatment session.
62133531|NCT03631433|EXPERIMENTAL|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
62133532|NCT06321952|ACTIVE_COMPARATOR|ROSA robotic assist TKA|ROSA robotic assist TKA
62133533|NCT06321952|ACTIVE_COMPARATOR|iassist TKA|iassist TKA
62485055|NCT04180969|EXPERIMENTAL|active stress, active rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
62485056|NCT04624360|EXPERIMENTAL|Study Drug A|Dexamethasone 8mg intravenous administration stat dose post clamping of the umbilical cord
62485057|NCT04624360|PLACEBO_COMPARATOR|Study Drug B|Normal saline 2cc intravenous stat dose administered after clamping of the umbilical cord
61933533|NCT05564793|ACTIVE_COMPARATOR|Control|"The CRT device is implanted according to clinical practice, without pre-implantation planning. The outcome of the procedure is assessed via echography as per clinical practice.~In addition to clinical practice, the subjects are required to fill in a quality-of-life questionnaire and are subject to an ECG mapping procedure with the Amycard 01C device, including non-contrast CT, to assess the distance between left ventricular lead placement and the latest electrical activation site in the absence of planning information."
61933534|NCT05564793|EXPERIMENTAL|Active|A pre-implantation ECG mapping with the Amycard 01C device, including CT, is performed prior to the CRT device implantation. The resulting target area for the left ventricular lead placement is communicated to the implanting physician, who will attempt to reach a point close to the target, using the available venous access. At six-month follow-up, response to the therapy is assessed using echocardiography, and a second ECG mapping with Amycard 01C is performed, to assess the distance between actual implantation site and target in the presence of pre-implantation planning information.
61933535|NCT05436223|EXPERIMENTAL|Human CD19 Targeted T Cells Injection|Single administration：2.0×10\^6 CAR+T/kg
61933536|NCT02869997|EXPERIMENTAL|Single arm|arm wherein all patients Suppression Ratio evaluated by BIS will be collected
61933537|NCT05176509|EXPERIMENTAL|Intervention/treatment|
61933538|NCT01969552||Thyroid testing|Adult subjects presenting for thyroid testing or treatment
61933539|NCT01539642|EXPERIMENTAL|Sufentanil NanoTab PCA System/15 mcg|
61933540|NCT01539642|PLACEBO_COMPARATOR|Placebo Sufentanil NanoTab PCA System|
61933541|NCT06708546|NO_INTERVENTION|Control group|(n=490): children eating normally (not using Oral Nutritional Supplementation) during 4 months of intervention. After the end, the product will be used for the following 4 months.
61933542|NCT06708546|EXPERIMENTAL|Intervention group|"(n=491): Children eating normally, with 2 boxes of Oral Nutritional Supplementation (180 ml x 2 times/day) as a snack meal.~The product will be provided for subjects at school 7 days per week (From Monday to Sunday) and at home or school. Children use Oral Nutritional Supplementation twice per day, the first time at 9 am, and the second at 3 pm."
61933543|NCT04679844|EXPERIMENTAL|MagnetOs Easypack Putty|"Interventions~* Procedure: Instrumented posterolateral spine fusion~* Device; MagnetOs Easypack Putty"
61933544|NCT04679844|ACTIVE_COMPARATOR|Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed with local autograft bone|"Interventions~* Procedure: Instrumented posterolateral spine fusion~* Device: Demineralized Bone Matrix or Fibers mixed with local autograft bone"
61933545|NCT04538573|EXPERIMENTAL|Virtual Reality Distraction|Use of virtual reality (VR) during during burn treatment, dressing changes and hydrotherapy.
61933546|NCT04538573|ACTIVE_COMPARATOR|Standard Treatment|Standard treatment during burn treatment, dressing changes and hydrotherapy.
61933547|NCT03517124|EXPERIMENTAL|Zirconia restorations|Dental restorations in surface modified zirconia bonded to tooth substance by dual cure resin cement
61933548|NCT03517124|ACTIVE_COMPARATOR|e.max|Restorations in e.max bonded to tooth substance by dual cure resin cement
61933549|NCT02866994|EXPERIMENTAL|Project Connect Online (PCO)|Creation of personal website to share breast cancer experience with friends and family
62133534|NCT02253459|EXPERIMENTAL|UTD1 Injection plus capecitabine|"UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
62133535|NCT02253459|ACTIVE_COMPARATOR|capecitabine|"Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
62133536|NCT03190603|EXPERIMENTAL|Celecoxib arm|Axial Spondyloarthritis patients who takes celecoxib 400mg for day
61933550|NCT02866994|EXPERIMENTAL|PCO PLUS|Creation of personal website to share breast cancer experience with friends and family, as well as other women diagnosed with breast cancer
61933551|NCT00234273|EXPERIMENTAL|Therapeutic education combining dietary and rehabilitation|Therapeutic education combining dietary and rehabilitation (APA)
61933552|NCT00234273|ACTIVE_COMPARATOR|Therapeutic education primarily focused on dietary|Therapeutic education primarily focused on dietary
61933553|NCT04953429||nurses|nurses in a third-grade hospital in Beijing
61933554|NCT03497793|EXPERIMENTAL|Skin-to-skin care with SNUBY|Mothers providing skin-to-skin care with the use of SNUBY
61933555|NCT05283928|EXPERIMENTAL|OsseoDensification (OD) protocol|
62133537|NCT03771313|OTHER|PK/PD|Open-label prospective study with participants receiving treating physician-approved intravenous ceftaroline, dosed according to current recommendations. Blood samples collected at baseline, 1 hour, 1.5 hours, 3 hours, and 6 hours after infusion.
62692696|NCT05421494|EXPERIMENTAL|study 1: WET+MBA|"WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation."
62692697|NCT05421494|PLACEBO_COMPARATOR|study 1: MCC|MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
62133538|NCT03804580|EXPERIMENTAL|osimertinib|All patients recieve osimertinib
62326620|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 12 in PCNSL/SCNSL|PCNSL following at least 1 prior line of therapy that included a BTKi (2L+) or following 2 or more prior lines of therapy (3L+), or SCNSL patients meeting criteria for a cohort enrolling that disease with secondary CNS involvement of lymphoma
62326621|NCT05131022|EXPERIMENTAL|Phase 1b Part 1 Cohort 13 in PCNSL|PCNSL following upfront therapy and with no prior exposure to a BTKi (2L).
62326622|NCT05131022|EXPERIMENTAL|Phase 1b Part 2 in CLL or SLL with prior BTKi and BCL-2i|CLL or SLL with prior exposure to both a Bruton's tyrosine kinase inhibitor (BTKi) and BCL-2 inhibitor
62326623|NCT06689540|EXPERIMENTAL|dose level #1|Starting dose, 0.05 ug/kg
62326624|NCT06689540|EXPERIMENTAL|dose level #2|dose escalation, 0.5 ug/kg
62326625|NCT06689540|EXPERIMENTAL|dose level #3|dose escalation, 3.0 ug/kg
62133539|NCT03947346||survivors of neuroblastoma treated with nephrotoxic therapy|Upon enrollment, all subjects will receive a urine collection kit by mail. Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.
62133540|NCT03594500|EXPERIMENTAL|Intervention: PockeTalker|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
62133541|NCT03594500|OTHER|Control: No PockeTalker|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
62133542|NCT00882934|EXPERIMENTAL|A1|Arm 1 received an informative letter explaining that they were allocated to receive a substance for Erectile Dysfunction treatment.
61933556|NCT05283928|ACTIVE_COMPARATOR|standard drilling (SD) protocol|
61933557|NCT03456440||hepatitis C child pugh's class A|patients are examined with MRI
62133543|NCT00882934|PLACEBO_COMPARATOR|A2|Arm 2 (A2) was written informed that they could or could not receive an active drug for ED treatment.
62133544|NCT00882934|EXPERIMENTAL|A3|Arm 3 (A3) was properly written informed to be using no effective drug for ED treatment.
62326626|NCT06689540|EXPERIMENTAL|dose level #4|dose escalation, 15.0 ug/kg
62326627|NCT06689540|EXPERIMENTAL|dose level #5|dose escalation, 30.0 ug/kg
62326628|NCT06689540|EXPERIMENTAL|dose level #6|dose escalation, 45.0 ug/kg
62326629|NCT06747702|EXPERIMENTAL|Experimental Group: Participants in this group will undergo the intervention|Participants for the injury prevention program
62326630|NCT06747702|NO_INTERVENTION|Control group|Participant with same training program that will not be involved in the intervention although they will follow same specific sport practice
62326631|NCT04597125|EXPERIMENTAL|Arm A|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive radium-223 dichloride
62326632|NCT04597125|ACTIVE_COMPARATOR|Arm B|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive second novel anti-hormonal therapy (NAH)
62326633|NCT05190341|EXPERIMENTAL|Ibuprofen|Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 800mg ibuprofen 1 hour before HSG.
62326634|NCT05190341|EXPERIMENTAL|Ketorolac|Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 30mg ketorolac 1 hour before HSG.
62326635|NCT06747728|EXPERIMENTAL|Bevacizumab group|Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
62326636|NCT06747936|EXPERIMENTAL|AD-2281 + AD-2282|
62326637|NCT06747936|ACTIVE_COMPARATOR|AD-2281 + Placebo of AD-2282|
62326638|NCT06746129|ACTIVE_COMPARATOR|cleavage-stage embryo transfer|embryo(s) will be transferred on day 3 of embryo development (cleavage-stage embryo)
61933558|NCT03456440||normal individuals|controls cases are examined with MRI
61933559|NCT03975062|EXPERIMENTAL|Abbreviated course group (ACG)|The patients receiving 3-days course of dabigatran etexilate during pre-cardioversion period. After cardioversion has been performed the patients continue with dabigatran etexilate until 30 days after cardioversion
61933560|NCT03975062|ACTIVE_COMPARATOR|Conventional course group (CCG)|The patients receiving 3-weeks course of dabigatran etexilate before cardioversion of AF. After cardioversion has been performed the patients will continue with dabigatran etexilate until 30 days after cardioversion
62326639|NCT06746129|ACTIVE_COMPARATOR|blastocyst embryo transfer|embryo(s) will be transferred on day 5-7 of embryo development (blastocyst-stage embryo)
62326640|NCT06737484|EXPERIMENTAL|Experimental group|Hemodialysis patient with pruritus who will be treated with olive oil
62326641|NCT06737484|NO_INTERVENTION|Control group|Hemodialysis patient with pruritus who will not undergo any intervention
62326642|NCT06746701||Peg-IFNα-2b combined with NA|
62326643|NCT06746701||NA monotherapy|
62485058|NCT02035163|ACTIVE_COMPARATOR|Two sites cryoablation group|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
62485059|NCT02035163|NO_INTERVENTION|Control group|No Intervention group
62692698|NCT05941429|ACTIVE_COMPARATOR|Silver Diamine Fluoride|"38% Silver Diamine Fluoride varnish~1. the affected tooth will be cleaned by a disposable micro-brush for 30 seconds and then will be dried using cotton gauze sponges.~2. No excavation will be done to the infected dentin tissue prior to the application of the agent.~3. Gum will be protected with petroleum jelly, and isolation will be achieved by using cotton rolls.~4. After isolation, a single drop SDF will be applied into the cavity by using a disposable micro-brush for at least two minutes. Then site of application will be covered with petroleum jelly.~5. Finally, parents will be instructed that children participating in the trial are not allowed to eat or drink for one hour after application of the agent"
62692699|NCT05941429|EXPERIMENTAL|Nano-Silver Fluoride|"Nano-Silver fluoride varnish preparation~1. the affected tooth will be cleaned by a disposable micro-brush for 30 seconds and then will be dried using cotton gauze sponges.~2. No excavation will be done to the infected dentin tissue prior to the application of the agent.~3. Gum will be protected with petroleum jelly, and isolation will be achieved by using cotton rolls.~4. After isolation, a single drop NSF will be applied into the cavity by using a disposable micro-brush for at least two minutes. Then site of application will be covered with petroleum jelly.~5. Finally, parents will be instructed that children participating in the trial are not allowed to eat or drink for one hour after application of the agent"
62692700|NCT01585532||TB suspects with alternative final diagnosis|
62692701|NCT01585532||Confirmed tuberculosis patients|
62326644|NCT06746168|ACTIVE_COMPARATOR|iPACK with Femoral Triangle Block (FTB)|Patients undergoing an unillateral total kneearthroplasty will receive the anesthetic combination iPACK with FTB.
62326645|NCT06746168|ACTIVE_COMPARATOR|Surgical Local Infiltration Analgesia (LIA)|Patients undergoing an unillateral total kneearthroplasty will receive the surgical LIA.
62692702|NCT06636916|EXPERIMENTAL|short intervals|This group will perform the hiit by doing short intervals
62692703|NCT06636916|EXPERIMENTAL|long intervals|This group will perform the hiit by doing long intervals
61933561|NCT06709170|EXPERIMENTAL|Novel asymmetrical linear stapler|Rectal cancer patients randomized to this group will use the novel asymmetrical linear stapler for distal rectum transection, and with 2 rows of stapler lines instead of 3, sufficient tissue is left on the specimen side to harvest the true distal margin for accurate pathological evaluation.
62326646|NCT04874428|EXPERIMENTAL|Rivaroxaban|Pharmacokinetics and pharmacodynamics of rivaroxaban
62485060|NCT03684928|ACTIVE_COMPARATOR|Comfilcon A (test)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
62485061|NCT03684928|ACTIVE_COMPARATOR|Senofilcon C (control)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
62485062|NCT06123689|EXPERIMENTAL|AMT-Regenera activa|All the patients of the group will be treated with one unique articular injection of autologous micrografts obtained through the Rigenera® Technology
62692704|NCT06124924|NO_INTERVENTION|control|usual care. no medication will be prescribed by Dr. Murphy. Only a basic metabolic panel lab test will be ordered in EPIC for the study participant to be done approximately 2 weeks after discharge and the results of which are to be routed to Dr. Murphy. A post-AKI / post-discharge basic metabolic panel lab test is a usual care lab test, and Dr. Murphy reviews such lab test results in his usual clinical practice.
62692705|NCT06124924|EXPERIMENTAL|Experimental group|randomized to SGLT2i
61933562|NCT06709170|ACTIVE_COMPARATOR|Control|Rectal cancer patients in the control group will use the conventional Signia™ stapler (Medtronic co.) as routinely used in the centers involved with the study, which has triple stapling technology (3 rows of stapler lines on both sides of transection)
61933563|NCT04576624|EXPERIMENTAL|Lifestyle Intervention|Subjects in the Lifestyle Intervention group will, in six months, receive sixteen group sessions and six individualized treatment sessions.
61933564|NCT04576624|SHAM_COMPARATOR|Social Activities|Social Activities Group will receive twenty-two group sessions
62326647|NCT04874428|EXPERIMENTAL|Apixaban|Pharmacokinetics and pharmacodynamics of apixaban
62326648|NCT06675929|EXPERIMENTAL|BI 770371|
62326649|NCT06675929|PLACEBO_COMPARATOR|Placebo for BI 770371|
62326650|NCT06734325|EXPERIMENTAL|Mobile Oral Health Intervention|Mobile oral health intervention in addition to oral hygiene instructions
62326651|NCT06734325|NO_INTERVENTION|Control|oral hygiene instructions only
62692706|NCT06644352|EXPERIMENTAL|Right thoracic approach|Neoadjuvant therapy+surgery+adjuvant therapy. Neoadjuvant therapy: chemotherapy with 2-4 cycles； Surgery: dissociate the stomach and operate the gastroesophagostomy and lower mediastinal lymphadenectomy by the right thoracic approach (right thoracic incision); Adjuvant therapy: perioperative chemotherapy with total 8 cycles (including neoadjuvant chemotherapy).
61933565|NCT04576624|NO_INTERVENTION|Passive Control|Control group will receive patient education materials with each assessment
61933566|NCT00895856||Old-aged people|
62326652|NCT06718101|EXPERIMENTAL|Sub-Study 1: Lutikizumab Monotherapy|In Period 1, participants will be receive lutikizumab Dose A at Baseline randomization, followed by Dose B every other week starting at Week 2 for 16 weeks. participants will continue into Period 2 at Week 16 with Dose C every other week until Week 52.
62485063|NCT06123689|ACTIVE_COMPARATOR|Hyalubrix|All the patients of the group will be treated with one unique articular injection of Sodium Hyaluronate (Hyalubrix 60 -1,5%-2ml vial)
62485064|NCT03459235|EXPERIMENTAL|population from registry data|the intervention involves completing several quality of life questionnaires validated in the medical literature (LARS score, FSFI, USP, IIEF, IPPS, QLQ C-30, QLQ-CR29)
62485065|NCT05797207|EXPERIMENTAL|Colonoscopy|Fecal samples will be obtained from patients who are enrolled for colonoscopy procedure for the suspicion of inflammatory bowel disease
62485066|NCT01943695|EXPERIMENTAL|Aerobic Training During Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training an intensity of at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy. VO2peak will be determined by the CPET performed at baseline. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
62485067|NCT01943695|EXPERIMENTAL|Aerobic Training After Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training at an intensity 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy. VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients. For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
62485068|NCT01943695|EXPERIMENTAL|Continuous Aerobic Training|The ultimate goal is for participants to complete 3 exercise sessions week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy. For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
62485069|NCT01943695|EXPERIMENTAL|General Physical Activity Group|Patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, consultation with a staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to record type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress, and answer questions.
62485070|NCT00537095|EXPERIMENTAL|vandetanib (ZD6474)|vandetanib (ZD6474) 300 mg per os once daily
62485071|NCT00537095|PLACEBO_COMPARATOR|Placebo|Placebo
62485072|NCT03837587||Patients group|Patients with temporomandibular disorders
62485073|NCT06467513|NO_INTERVENTION|blank control group|In the blank control group, no intervention was used during the operation, and normal saline was pumped according to the participant's body weight until the end of the operation.
62485074|NCT06467513|EXPERIMENTAL|Low dose esketamine hydrochloride injection group|In the low-dose ESketamine hydrochloride injection group, 50mg of Esketamine hydrochloride injection was diluted with normal saline into a 50ml syringe, which was wrapped with light-proof paper and pumped continuously from the beginning of anesthesia to the end of surgery. The dosage was calculated as 0.2mg/kg.h.
62485075|NCT06467513|EXPERIMENTAL|High dose esketamine hydrochloride injection group|In the high-dose ESketamine hydrochloride injection group, 50mg of Esketamine hydrochloride injection was diluted with normal saline into a 50ml syringe, which was wrapped with light-resistant paper and pumped continuously from the beginning of anesthesia to the end of surgery. Dosage was calculated as 0.4mg/kg.h.
62485076|NCT04125186||Pilot Part|After providing consent, participants with nocturia will complete web-based baseline EpiNP survey followed by 3-day bladder diary and then a qualitative interview.
62485077|NCT04125186||Main Part|After providing consent, participants will complete web-based baseline EpiNP survey. All respondents who report greater than equal to (≥)2 voids/night, and a randomly selected cohort of respondents reporting 0 and 1 void/night will use the EpiNP 3-day web-based bladder diary.
62692707|NCT06644352|ACTIVE_COMPARATOR|Left thoracic approach|Neoadjuvant therapy+surgery+adjuvant therapy. Neoadjuvant therapy: chemotherapy with 2-4 cycles； Surgery: dissociate the stomach and operate the gastroesophagostomy and lower mediastinal lymphadenectomy by the left thoracic approach (including right thoracic and abdominal incision); Adjuvant therapy: perioperative chemotherapy with total 8 cycles (including neoadjuvant chemotherapy).
62692708|NCT06674629||Healthy Adult Volunteers|Healthy adult volunteers, all above 18 years of age, who provide informed consent.
62692709|NCT06275074|EXPERIMENTAL|Dry Needling and Therapeutic Exercise|
62692710|NCT06275074|ACTIVE_COMPARATOR|Therapeutic Exercise Alone|
62692711|NCT00736151|EXPERIMENTAL|1|Ralfinamide administered orally at rising doses of 80 - 320 mg/day
62692712|NCT00736151|ACTIVE_COMPARATOR|2|Placebo controlled with randomization of 2:1
62692713|NCT01743144|ACTIVE_COMPARATOR|Magnesium sulphate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
62485078|NCT05839262|EXPERIMENTAL|Experimental group|Conventional physical rehabilitation plus Active video games (CPR+AVG)
62485079|NCT05839262|ACTIVE_COMPARATOR|Control group|Conventional physical rehabilitation alone (CPR)
62485080|NCT02189226|EXPERIMENTAL|probe-based confocal laser endomicroscopy (pCLE) group|
62485081|NCT02189226|ACTIVE_COMPARATOR|chromoendoscopy (CE) group|
62485082|NCT01620957||Coma patients|
62485083|NCT04525027||survivors|
62485084|NCT04525027||non survivors|
62485085|NCT06557551|EXPERIMENTAL|Thin catheter surfactant|At or after 5 minutes of life, participants will have a thin endotracheal catheter (Surfcath, Vygon, Ecouen, France) inserted under video laryngoscopy (C-MAC, Karl Storz, Tuttlingen, Germany), through which they will receive surfactant (Curosurf, Chiesi Farmaceutici, Parma, Italy - 120mg for infants \< 26 weeks, 240mg for infants 26 - 27+6 weeks). The catheter will then be removed, and they will continue on face mask breathing support.
62485086|NCT06557551|NO_INTERVENTION|Standard care|Participants will continue on face mask breathing support.
62485087|NCT00548522||1|Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
61933567|NCT06498960|EXPERIMENTAL|eShunt System|Endovascular placement of the eShunt Implant
61933568|NCT06498960|ACTIVE_COMPARATOR|VP Shunt|Surgical ventriculo-peritoneal shunt procedure
61933569|NCT04686123|EXPERIMENTAL|Group A|Group A performed active Stretching of Pectoralis Minor (PMi) muscle along with the strengthening of Lower Trapezius muscle under the supervision of a physiotherapist
61933570|NCT04686123|ACTIVE_COMPARATOR|Group B|Group B performed active Stretching of the Pectoralis Minor (PMi) muscle only under the supervision of a physiotherapist.
61933571|NCT06709703|ACTIVE_COMPARATOR|Kinematic knee replacement with traditional instruments|Patients will undergo kinematic aligned knee replacement done using traditional instruments and cut guides
61933572|NCT06709703|EXPERIMENTAL|Robotic-assisted kinematic knee replacement|Patients will undergo kinematic aligned knee replacement done using robotic assistance
61933573|NCT03304418|EXPERIMENTAL|Radium Ra 223 dichloride and radiation, all patients|
61933574|NCT06663852||Gastric Neuroendocrine Carcinoma (G-NEC) Patients|This study focuses on patients diagnosed with gastric neuroendocrine carcinoma (G-NEC) who have undergone radical surgery. The cohort includes adult patients (≥18 years) treated at 38 tertiary hospitals in China between January 2006 and December 2020. Patients are divided into three groups based on their postoperative adjuvant treatment: no adjuvant chemotherapy, etoposide and platinum derivatives-based chemotherapy, and fluorouracil-based chemotherapy. The study aims to develop and validate a machine learning-based decision support model to optimize individualized adjuvant therapy strategies for G-NEC patients, with the primary outcome being disease-free survival (DFS).
61933575|NCT04865640||Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
61933576|NCT04865640||Pathologic Cohort|The target population for this cohort is adult patients who have been diagnosed with cardiopulmonary conditions. These can include chronic pulmonary conditions, chronic cardiac conditions, and those who are taking diuretic medications, living with heart failure, Chronic Obstructive Pulmonary Disorder (COPD), or recovering from coronary-artery disease-related events. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders as well as conditions outlined above (e.g. at least 5 each of COPD, HF, recovering from a coronary artery disease-related event, and taking diuretic medication)
61933577|NCT00261118|ACTIVE_COMPARATOR|1 (i)|Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
61933578|NCT00261118|PLACEBO_COMPARATOR|2 (ii)|500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
61933579|NCT02450188|ACTIVE_COMPARATOR|vardenafil|The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
61933580|NCT02450188|ACTIVE_COMPARATOR|vardenafil+cbst|"The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings."
61933581|NCT03631693|ACTIVE_COMPARATOR|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
61933582|NCT03631693|ACTIVE_COMPARATOR|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
61933583|NCT01624051|ACTIVE_COMPARATOR|Body Surface Area Dosing|Standard dosing arm based on body surface area
61933584|NCT01624051|EXPERIMENTAL|Lean Body Mass Dosing|Experimental dosing arm based on individual lean body mass
61933585|NCT01129674|ACTIVE_COMPARATOR|Standard of Care|
62485088|NCT00548522||2|Pregnant women (34-38 wks gestation) with Type 1 diabetes
62485089|NCT00548522||3|Post partum women with Type 1 diabetes
62485090|NCT00548522||4|Non pregnant women with Type 1 diabetes
62485091|NCT04483921|EXPERIMENTAL|Exercise|Participants will complete a prescribed exercise bout.
62692714|NCT01743144|PLACEBO_COMPARATOR|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
62692715|NCT06640582|EXPERIMENTAL|Biological Tumor Infiltrating Lymphocytes (TIL) Therapy with Immunotherapy|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and TILs IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
62692716|NCT02786329|ACTIVE_COMPARATOR|TIVA + lidocaine|"TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.~Interventions: TIVA+lidocaine"
62692717|NCT02786329|PLACEBO_COMPARATOR|TIVA+placebo|TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)
62692718|NCT02786329|PLACEBO_COMPARATOR|Sevoflurane+placebo|"Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).~Intervention: sevoflurane anesthesia +placebo (saline infusion)"
62692719|NCT02786329|ACTIVE_COMPARATOR|Sevoflurane+lidocaine|"Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.~Intervention: sevoflurane anesthesia+ lidocaine infusion"
62692720|NCT05609253|ACTIVE_COMPARATOR|Itraconazole in capsule form|Participants in this arm will receive the capsule form of itraconazole
62692721|NCT05609253|ACTIVE_COMPARATOR|Itraconazole in solution form|Participants in this arm will receive the solution form of itraconazole
62326653|NCT06718101|EXPERIMENTAL|Sub-Study 1: Placebo to Lutikizumab|In Period 1, participants will be receive a matching placebo Dose A at Baseline randomization, followed by matching placebo Dose B every other week starting at Week 2 for 16 weeks. At Week 16, participants that were assigned placebo will then enter Period 2 and receive open-label lutikizumab Dose A , followed by lutikizumab Dose B every other week starting at Week 18, and lutikizumab Dose C every other week starting at Week 32 until Week 52.
62326654|NCT06733441|EXPERIMENTAL|Cohort 1: TLN-254 Single Agent|
62326655|NCT06733441|EXPERIMENTAL|Cohort 2: TLN-254 Single Agent|
61933586|NCT01129674|EXPERIMENTAL|LY2140023|"20mg, 40mg or 80mg~After 104 weeks, patients have the option to continue on treatment until the end of the study"
62326656|NCT06747468|EXPERIMENTAL|AVEXITIDE|Avexitide (90 mg via subcutaneous \[SC\] injection) will be taken once per day, in the morning at least 60 minutes before the morning meal, through the duration of the treatment and OLE periods.
62692722|NCT02687620||AS patients receiving Anti-TNF treatment|Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria for the classification of AS (5), and with a new anti-TNF agent prescription (either for the first time or switched) in the last two weeks period will be included. Treatment with anti-TNF agents will be in accordance with the regulations of Turkish Social Security Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as ASAS/EULAR recommendations for the management of AS (29, 30).
61933587|NCT06679075|EXPERIMENTAL|Propolis + Bioceramic putty|Adult permanent molars diagnosed with irreversible pulpitis to be treated with full pulpotomy using propolis as a hemostatic agent and bioceramic putty as a dressing material.
61933588|NCT06679075|EXPERIMENTAL|Propolis + MTA|Adult permanent molars diagnosed with irreversible pulpitis to be treated with full pulpotomy using propolis as a hemostatic agent and MTA as a dressing material.
61933589|NCT06679075|EXPERIMENTAL|Sodium hypochlorite + bioceramic putty|Adult permanent molars diagnosed with irreversible pulpitis to be treated with full pulpotomy using sodium hypochlorite (NaOCl) as a hemostatic agent and bioceramic putty as a dressing material.
61933590|NCT06679075|ACTIVE_COMPARATOR|Sodium hypochlorite + MTA|Adult permanent molars diagnosed with irreversible pulpitis to be treated with full pulpotomy using sodium hypochlorite (NaOCl) as a hemostatic agent and MTA as a dressing material
61933591|NCT06585033|SHAM_COMPARATOR|No stimulation|
61933592|NCT06585033|ACTIVE_COMPARATOR|Stimulation|
61933593|NCT02832843||NTM lung disease|Patients with NTM lung disease satisfying American Thoracic Society guidelines
61933594|NCT02832843||Healthy control|The age-, sex-matched control subjects without pulmonary diseases
61933595|NCT01600807|EXPERIMENTAL|Gemcitabine, Erlotinib, OSI-906|Experimental treatment arm
61933596|NCT01600807|ACTIVE_COMPARATOR|Gemcitabine, Erlotinib|Standard treatment arm
61933597|NCT04234360|EXPERIMENTAL|Eosinophil count > 2%; corticotherapy|Eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
61933598|NCT04234360|EXPERIMENTAL|Eosinophil count <= 2%; corticotherapy|Non-eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
61933599|NCT04234360|PLACEBO_COMPARATOR|Eosinophil count > 2%; placebo|Eosinophilic patients randomized to this arm will receive 5 days of placebo.
61933600|NCT04234360|PLACEBO_COMPARATOR|Eosinophil count <= 2%; placebo|Non-eosinophilic patients randomized to this arm will receive 5 days of placebo.
61933601|NCT01350154|EXPERIMENTAL|Sildenafil (Revation) 20 mg|This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
61933602|NCT01350154|EXPERIMENTAL|Placebo|This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
61933603|NCT01516073|EXPERIMENTAL|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
61933604|NCT01516073|EXPERIMENTAL|Fluticasone propionate (FP) - arm 2|FP BID
61933605|NCT01516073|EXPERIMENTAL|Fluticasone Propionate (FP) - arm 3|FP BID
61933606|NCT01516073|EXPERIMENTAL|FLuticasone Propionate (FP) - Arm 4|FP BID
61933607|NCT01516073|EXPERIMENTAL|Fluticasone Propionate (FP) - Arm 5|FP BID
61933608|NCT01516073|PLACEBO_COMPARATOR|Placebo - Arm 6|Placebo inhalation solution 2mL
61933609|NCT03894956||Participants with Hidradenitis Suppurativa (HS)|Participants who along with their treating physician have elected for treatment with Humira as per routine clinical practice for the treatment of HS
61933610|NCT03090412|EXPERIMENTAL|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
61933611|NCT03090412|EXPERIMENTAL|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
61933612|NCT06487078|EXPERIMENTAL|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
61933613|NCT00514566|ACTIVE_COMPARATOR|1|Surgical Patient undergoing midline laparotomy closure
61933614|NCT05550649|EXPERIMENTAL|Prophylic Embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
61933615|NCT05550649|SHAM_COMPARATOR|Sham Embolization|After the angiography was completed, no embolization was performed, the catheter was withdrawn, the vascular sheath was removed, and symptomatic and supportive treatments such as acid suppression, hemostasis, blood transfusion, and fluid replacement were given.
61933616|NCT02685514|EXPERIMENTAL|HIFU Graves|Applying the High intensity Focused Ultrasound treatment to the relapsed Graves' disease Patients.
62326657|NCT06747468|PLACEBO_COMPARATOR|PLACEBO|"Placebo will be taken once per day, via subcutaneous \[SC\] injection, in the morning at least 60 minutes before the morning meal, through the duration of the treatment period.~Participants receiving Placebo in the double-blind treatment period will transition to Avexitide 90 mg (via subcutaneous \[SC\] injection) in the open-label extension (OLE) period."
62326658|NCT06625060|EXPERIMENTAL|Step 1 - Cohort 1- IPN10200|Participants will receive IPN10200 dose A through injections at Day 1.
62326659|NCT06625060|PLACEBO_COMPARATOR|Step 1 - Cohort 1 - Placebo|Participants will receive placebo through injections at Day 1.
62133545|NCT04059042|EXPERIMENTAL|Music|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (\~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear music.~The musical selections will be professional recordings of instrumental Classical music selected by the researcher. All participants will hear the same pieces in the same order. Instrumentation ranges from piano solo to full orchestra, but they are without lyrics or heavy percussion. Pitch ranges across the pieces, but is standard across participants and not controlled by either the participant or the researcher. Tempo for all of the pieces is slow (\~60 beats per minute). The pieces are in either major keys or minor keys, but all consist primarily of consonant harmonies and sustained melodic phrases. Participants will control the volume to their individual comfort level."
62133546|NCT04059042|PLACEBO_COMPARATOR|Nature Sounds|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (\~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear nature sounds.~Professional recordings of nature sounds selected by the researcher without added music will be used as the active placebo control condition. All participants will hear the same recording. This active control condition will allow for non-musical analgesic effects, such as distraction, to be controlled in the experimental design. Participants will control the volume to their individual comfort level."
62133547|NCT03664635|EXPERIMENTAL|Phase I - Safety Dose Level|In phase I three (3) + 3 patients will be treated with 1x10\^5 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the preceding safety dose level
62133548|NCT03664635|EXPERIMENTAL|Phase I - Dose Level 1|In phase I six (6) + 3 patients will be treated with 1x10\^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 1
62133549|NCT03664635|EXPERIMENTAL|Phase I - Dose Level 2|In phase I six (6) + 3 patients will be treated with 3x10\^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 2
62133550|NCT03664635|EXPERIMENTAL|Phase II|The number of additional patients who will be treated with MB-CART20.1 cells in Phase II is depending on the number of evaluable patients treated with the maximum tolerated dose (MTD) level and the results in Part I
62133551|NCT02932579|ACTIVE_COMPARATOR|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
62133552|NCT02932579|EXPERIMENTAL|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
62133553|NCT03042039||Study group 'New Care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
62133554|NCT03329482|EXPERIMENTAL|Pulse Ultrasound Group A|This is the Pulse Ultrasound group. Twenty five patients will be in this group.
62133555|NCT03329482|EXPERIMENTAL|Kneading Massage Group B|This is kneading massage group . Also 25 patients will be in this group.
62133556|NCT03960606|EXPERIMENTAL|10 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
62133557|NCT03960606|EXPERIMENTAL|20 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
62133558|NCT03960606|EXPERIMENTAL|35 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
62133559|NCT03960606|PLACEBO_COMPARATOR|Placebo|Placebo
62133560|NCT05949359|EXPERIMENTAL|Nintendo RingFit exercise group|Participants in the Nintendo RingFit exercise group received an 8-week, twice-weekly exercise program focusing on improving balance and lower limb muscle strength using Nintendo RingFit device.
62133561|NCT05949359|NO_INTERVENTION|Control group|Usual care was received by the control group participants.
62133562|NCT00574834|ACTIVE_COMPARATOR|Ramipril|Patients randomized to 6 months treatment of Ramipril.
62133563|NCT00574834|ACTIVE_COMPARATOR|HCTZ|PAtients randomized to 6 months treatment of HCTZ.
62133564|NCT00574834|ACTIVE_COMPARATOR|Ramipril+HCTZ|Patients randomized to 6 months treatment of Ramipril+HCTZ.
62133565|NCT03788200|ACTIVE_COMPARATOR|post-injury bracing with rigid cervical collar|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
62133566|NCT03788200|ACTIVE_COMPARATOR|posterior C1-2 instrumented fusion|Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
62133567|NCT05297175|OTHER|Single arm|Implantation of a medial meniscus prosthesis in the medial knee compartment of a post medial meniscectomy knee.
62326660|NCT06625060|EXPERIMENTAL|Step 1 - Cohort 2 - IPN10200|Participants will receive IPN10200 dose B through injections at Day 1.
61933617|NCT03747419|EXPERIMENTAL|Avelumab and Bladder-Directed Radiation|"* Avelumab will be administered every 2 weeks intravenously for 6 doses unless there is unacceptable toxicity~* Two radiation dose regimens are allowed, and the regimen selected is at the discretion of the treating radiation oncologist"
61933618|NCT04914923|EXPERIMENTAL|Cognitive Behaviour Therapy|This study arm will receive 12 weeks of cognitive behaviour therapy as an intervention.
61933619|NCT04914923|EXPERIMENTAL|Mindfulness-based Cognitive Therapy|This study arm will receive 12 weeks of a mindfulness-based cognitive therapy intervention, along with open mindfulness sessions via an EEG headset.
61933620|NCT04914923|NO_INTERVENTION|Waitlist|This study arm will not receive an intervention for 12 weeks.
61933621|NCT01415544||Type 2 Diabetes|Those previously diagnosed with type 2 diabetes
61933622|NCT01415544||Type 1 Diabetes|Those previously diagnosed with type 1 diabetes
61933623|NCT01415544||Gestational Diabetes|Those that are currently diagnosed with gestational diabetes
62485092|NCT04483921|NO_INTERVENTION|Sedentary|Participants will rest quietly in a seated position for the equivalent amount of time prescribed for the exercise condition.
62485093|NCT03865563|EXPERIMENTAL|Pancreatic adenocarcinoma|Participants with resectable, borderline-resectable or locally-advanced pancreatic adenocarcinoma will receive pancreatic retrograde venous infusion of gemcitabine/lipiodol
62485094|NCT06409377|EXPERIMENTAL|The Dexmedetomidine Group (D)|Patients received dexmedetomidine (1.5 μg/kg), propofol (2mg/kg), and fentanyl (1 μg/kg).
62692723|NCT05712395|EXPERIMENTAL|Non-Ischemic Exercise (NICE) exercise program|Patients will perform supervised treadmill walking for 3 months. Patients randomized to the NICE program will walk intermittently at a slow speed of approximately 1.4 mph for only 2-3 minute bouts that do not elicit claudication pain.
62692724|NCT05712395|ACTIVE_COMPARATOR|Standard exercise program|Patients will perform supervised treadmill walking for 3 months. Patients randomized to the Standard program will walk intermittently at a speed of approximately two mph to near maximal claudication pain.
62692725|NCT06570538|EXPERIMENTAL|ESPB Group|The drug composition of the analgesic pump for erector spinae block was 300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
62692726|NCT06570538|ACTIVE_COMPARATOR|Convention group|Intravenous analgesic is sufentanil ( 2.0 μg/kg), 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
62133568|NCT01477255||Cancer patient|Patient participants will include children and adolescents between the ages of 8-17 years who have been recently diagnosed with cancer. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
62326661|NCT06625060|PLACEBO_COMPARATOR|Step 1 - Cohort 2 - Placebo|Participants will receive placebo through injections at Day 1.
62326662|NCT06625060|EXPERIMENTAL|Step 2- EM group IPN10200 Dose A|Dose A will be administered to the participants in a single treatment cycle.
62133569|NCT01477255||Control|For each pediatric patient enrolled, a child without a history of a serious medical illness will be recruited from the larger community who is matched on variables of age, race/ethnicity, gender, and socioeconomic status. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
62133570|NCT02035605|ACTIVE_COMPARATOR|ALN-AT3SC|
62133571|NCT02035605|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62133572|NCT04351932|ACTIVE_COMPARATOR|bone marrow mesenchymal stem cell|Bone marrow mesenchymal stem cells 10 cc by intra articular injection once
62326663|NCT06625060|EXPERIMENTAL|Step 2- EM group IPN10200 Dose B|Dose B will be administered to the participants in a single treatment cycle
62326664|NCT06625060|PLACEBO_COMPARATOR|Step 2- EM group placebo|Placebo will be administered to the participants in a single treatment cycle
62326665|NCT06625060|EXPERIMENTAL|Step 2- CM group IPN10200 Dose A|Dose A will be administered to the participants in a single treatment cycle
62326666|NCT06625060|EXPERIMENTAL|Step 2- CM group IPN10200 Dose B|Dose B will be administered to the participants in a single treatment cycle
62485095|NCT06409377|PLACEBO_COMPARATOR|The Control Group (C)|Patients received normal saline of volume over 10 minutes.
62485096|NCT06560593|EXPERIMENTAL|single ascending dose|single ascending dose, randomized, double-blind study
62485097|NCT06560593|EXPERIMENTAL|multiple ascending dose|multiple ascending dose, randomized, double-blind study
62485098|NCT05590039|EXPERIMENTAL|Treatment for MyEllevate Procedure|The subjects were treated with the MyEllevate procedure.
61933624|NCT01415544||Healthy Human Volunteers|Those that have not been diagnosed with any type of diabetes
61933625|NCT06490731|ACTIVE_COMPARATOR|Patients will receive dexmedetomidine|Patients will receive dexmedetomidine (Precedex®; 200 µg/2 ml; at one µg/kg loading dose over 10 minutes followed by a 0.5 µg/kg/hr. maintenance dose for 48 hours Dexmedetomidine will be diluted in normal saline at a 4 µg/ ml concentration
61933626|NCT06490731|ACTIVE_COMPARATOR|Patients will receive ketamine|Patients will receive ketamine at one mg/kg IV loading dose over 10 minutes, then a continuous infusion starting at 300 µg /kg/hr over 48 hours
61933627|NCT03768570|NO_INTERVENTION|Surveillance|
61933628|NCT03768570|ACTIVE_COMPARATOR|Durvalumab|
61933629|NCT04126551||Lean, healthy control|Lean, healthy control subjects. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
61933630|NCT04126551||Overweight/obese nondiabetic|Overweight/Obese nondiabetic subjects. Overweight and obesity will be defined using the standard body mass index cutoffs. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
61933631|NCT04126551||Type 2 diabetes|Participants with type 2 diabetes will be diagnosed accordingly to ADA criteria. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
61933632|NCT05352490||HF-group|patients with AECOPD and acute heart failure
61933633|NCT05352490||non HF-group|patients with AECOPD without acute heart failure
61933634|NCT01225796|EXPERIMENTAL|Sodium bicarbonate|This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.
61933635|NCT01225796|NO_INTERVENTION|Control|This group will not receive any sodium bicarbonate.
62326667|NCT06625060|PLACEBO_COMPARATOR|Step 2- CM group placebo|Placebo will be administered to the participants in a single treatment cycle
62326668|NCT05016245|EXPERIMENTAL|TheraSphere™ Yttrium-90 Glass Microspheres|
62326669|NCT05016245|ACTIVE_COMPARATOR|conventional Transarterial Chemoembolization(cTACE)|
62485099|NCT02939573|EXPERIMENTAL|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
62326670|NCT05677451|EXPERIMENTAL|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks.
62485100|NCT02939573|EXPERIMENTAL|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
62485101|NCT04598763|OTHER|classic group|"the classic group receives classic olfactory rehabilitation using 4 scents most used in the literature (rose, eucalyptus, lemon, clove)"
62485102|NCT04598763|OTHER|intensive|"the intensive group receiving olfactory rehabilitation using 8 scents (rose, eucalyptus, lemon, cloves, strawberries, cut grass, lavender, spruce)."
62485103|NCT05435638|EXPERIMENTAL|KM-001 1% cream 12 weeks treatment|"KM-001 1% cream will be applied to the affected area, twice daily for 12 consecutive weeks.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
62485104|NCT05435638|EXPERIMENTAL|KM-001 1% cream 16 weeks treatment|"KM-001 1% cream will be applied to the affected area, twice daily for 16 consecutive weeks.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
62485105|NCT04005222|OTHER|SELENIUM|The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
62133573|NCT04351932|ACTIVE_COMPARATOR|adipose mesenchymal stem cells|Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once
62326671|NCT05677451|PLACEBO_COMPARATOR|Arm 2: LOU064 placebo (blinded)|LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2)
62485106|NCT04005222|OTHER|MELATONIN|The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.
61933636|NCT06575894|NO_INTERVENTION|HV Supervisor Refused|Home visitors outside the trial will receive no implementation support from their supervisors with respect to the Mothers and Babies intervention.
61933637|NCT06575894|ACTIVE_COMPARATOR|Standard Implementation|Control arm home visitors will receive standard Mothers and Babies implementation support from their supervisors.
61933638|NCT06575894|EXPERIMENTAL|Adapted Facilitation|Home visitors in the adapted facilitation group will receive standard Mothers and Babies support plus adapted facilitation delivered by home visiting supervisors trained in adapted implementation facilitation.
61933639|NCT02603328|ACTIVE_COMPARATOR|Treatment|Atorvastatin 80mg OD (optimal dose). Treatment dose will be de-escalated to 40mg based on reported adverse events.
62133574|NCT04351932|ACTIVE_COMPARATOR|Bone marrow and Adipose mesenchymal stem cells|Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once.
62133575|NCT03428698|EXPERIMENTAL|experimental device|The extraction was completed, the socket was filled with a topical amino acid + sodium hyaluronate gel (Aminogam®, sterile syringe 2 ml).
62133576|NCT03428698|PLACEBO_COMPARATOR|control no device|The extraction was completed, socket was flushed, using a 2ml sterile syringe similar to one utilized to apply the gel, with sterile physiological solution.
62133577|NCT03717467|PLACEBO_COMPARATOR|S group|Isotonic saline as placebo will be given.
62133578|NCT03717467|ACTIVE_COMPARATOR|M group|Magnesium sulfate will be given
62133579|NCT01078285||Control|
62133580|NCT01078285||Intervention Arm|
62133581|NCT02476435|ACTIVE_COMPARATOR|Experimental = Active rTMS|Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
62133582|NCT02476435|PLACEBO_COMPARATOR|Sham Comparator = Sham rTMS|Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
62133583|NCT02263573|EXPERIMENTAL|PEP'C-R|Subjects will benefit from one preliminary session and 18 sessions of PEP'C-R, (2 sessions per week for 9.5 weeks).
62133584|NCT02263573|ACTIVE_COMPARATOR|Control group|Subjects do not participate in the program PEP'C-R and continue their usual activities at home for 9.5 weeks.
62133585|NCT06161415|EXPERIMENTAL|Group 1|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops once a day (0.6mg per day) in the study eye for 14 days before the surgery.
62133586|NCT06161415|EXPERIMENTAL|Group 2|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops twice a day (1.2mg per day) in the study eye for 14 days before the surgery
62133587|NCT06161415|EXPERIMENTAL|Group 3|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops three times a day(1.8 mg per day) for 14 days before the surgery.
62133588|NCT06161415|EXPERIMENTAL|Stage 2 Comparison Group A|(3 to 6 participants): Participants will receive a dose of Laquinimod eye drops in the study eye for 14 days before the surgery. Frequency to be decided at the end of stage 1.
62326672|NCT01422694||Healthy control|Healthy volunteers will be recruited to serve as controls
62326673|NCT01422694||Other Inflammatory Diseases|Subjects with Other Inflammatory Diseases
62326674|NCT01422694||Patients with Spondyloarthritis|Subjects with confirmed or probable SpA will be identified predominantly by physician referral.
62326675|NCT01736293||Affected Participants|Participants with ABCA4-related retinopathies.
62326676|NCT04147884|EXPERIMENTAL|Mitral Valve Repair|All subjects will receive mitral valve repair using the Millipede System
62326677|NCT06687967|EXPERIMENTAL|Dupilumab|Dupilumab subcutaneous injection as per protocol
62485107|NCT04823832|ACTIVE_COMPARATOR|ERCP group|endoscopic retrograde cholangiopancreaticography with plastic stent insertion
62485108|NCT04823832|ACTIVE_COMPARATOR|PTD group|ultrasound guided percutaneous transhepatic catheter insertion
62692727|NCT02998866|OTHER|Multi-center, prospective outcomes registry|The study is a multi-center, prospective outcomes registry
62326678|NCT06687967|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection as per protocol
62326679|NCT06708299|ACTIVE_COMPARATOR|CardiolRx|"* Initial starting dose (Day 1, evening dose to Day 3, morning dose):~  5 mg/kg of body weight CardiolRx b.i.d.~* Day 3, evening dose to Day 10, morning dose: 7.5 mg/kg of body weight CardiolRx b.i.d.~* Day 10, evening dose to morning dose of the Week 24 Visit:~  10 mg/kg of body weight CardiolRx b.i.d."
62326680|NCT06708299|PLACEBO_COMPARATOR|Placebo|"* Initial starting dose (Day 1, evening dose to Day 3, morning dose):~  5 mg/kg of body weight matching placebo b.i.d.~* Day 3, evening dose to Day 10, morning dose: 7.5 mg/kg of body weight matching placebo b.i.d.~* Day 10, evening dose to morning dose of the Week 24 Visit:~  10 mg/kg of body weight matching placebo b.i.d."
62485109|NCT01447511|OTHER|CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9\*1/\*1 genotype have two \*1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
62485110|NCT01447511|OTHER|CYP2C9*1B/*1B Haplotype|Individuals with the CYP2C9\*1B/\*1B haplotype have two CYP2C9\*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
62485111|NCT01447511|OTHER|CYP2C9*1/*3 Genotype|Individuals with the CYP2C9\*1/\*3 genotype have one \*1 allele and one \*3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
62485112|NCT01447511|OTHER|CYP2C9*2/*3 Genotype|Individuals with the CYP2C9\*2/\*3 genotype have one \*2 and one \*3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
62485113|NCT01447511|OTHER|CYP2C9*3/*3 Genotype|Individuals with the CYP2C9\*3/\*3 genotype have two \*3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
62326681|NCT05410860|EXPERIMENTAL|Etripamil NS 70 mg with Optional Second Dose|Dosing regimen that permits a second dose of Etripamil NS 70 mg
62326682|NCT05410860|EXPERIMENTAL|Placebo with Optional Second Dose|Dosing regimen that permits a second dose of placebo
62485114|NCT01268007||Normal ECG measurements|Observational, un-blinded, non-interventional study designed to collect ECG data on at least one (1) male patient in an outpatient setting.
61933640|NCT02603328|PLACEBO_COMPARATOR|Placebo|Identically looking capsules containing no active ingredient
62326683|NCT06723821|EXPERIMENTAL|Neuromodulation experimental group|"The total number of sessions to be carried out on each patient will be 12 sessions, spread over 4 weeks.~The frequency will be 3 times a week. Each session with NESA microcurrents will last 60 minutes."
62326684|NCT06723821|SHAM_COMPARATOR|Neuromodulation sham group|"The total number of sessions to be carried out on each patient will be 12 sessions, spread over 4 weeks.~The frequency will be 3 times a week. Each session with NESA microcurrents will last 60 minutes.The treatment will be applied with a placebo device that does not emit microcurrent but that has the same function"
62326685|NCT03117972|EXPERIMENTAL|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
62326686|NCT03117972|ACTIVE_COMPARATOR|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
62326687|NCT06695754||Manual massage <90% over colon|Patients received a manual massage or treatment that reachs the ascending and descending colon for less than 90% of the total time of the treatment duration
62326688|NCT06695754||Manual massage >90% over colon|Patients received a manual massage or treatment that reachs the ascending and descending colon for 90% or more of the total time of treatment duration
62326689|NCT06695754||Automatic massage|Patients received a massage or treatment delivered with a medical device, that reachs the ascending and descending colon for 90% or more of the total time of treatment duration
62326690|NCT06746714|EXPERIMENTAL|Intervention group|"Intervention group, receiving protocol-driven outreach by a clinical pharmacist (the hypoglycemia champion, or HC) to hypoglycemia-prone patients with T2D"
62326691|NCT06746714|ACTIVE_COMPARATOR|Usual care group|Usual care, after system-wide dissemination of HOAP
62485115|NCT03599362|EXPERIMENTAL|Multi Agent Chemotherapy Cancer Patients|Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.
62485116|NCT02587663|ACTIVE_COMPARATOR|Group 1 (standard of care)|Patients undergo standard of care diagnostic imaging comprising bilateral mammography and targeted breast ultrasound.
62326692|NCT05395351||Acute ischemic stroke (AIS) patients aged >80 years who received IV rt-PA (Alteplase)|Group 1: Acute ischemic stroke (AIS) patients aged \>80 years who received intravenous recombinant tissue plasminogen activator (IV rt-PA) (Alteplase) within 4.5 hours of symptom onset.
62326693|NCT05395351||Acute ischemic stroke (AIS) patients aged 18 to 80 years who received IV rt-PA (Alteplase)|Group 2: Acute ischemic stroke (AIS) patients aged 18 to 80 years who received intravenous recombinant tissue plasminogen activator (IV rt-PA) (Alteplase) within 4.5 hours of symptom onset.
62326694|NCT05395351||Acute ischemic stroke (AIS) patients aged >80 years without thrombolysis treatment|Group 3: Acute ischemic stroke (AIS) patients aged \>80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive thrombolysis treatment.
62326695|NCT05395351||Acute ischemic stroke (AIS) patients aged 18 to 80 years without thrombolysis treatment|Group 4: Acute ischemic stroke (AIS) patients aged 18 to 80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive thrombolysis treatment.
62326696|NCT05902663||Patients diagnosed with Netherton Syndrome|
62326697|NCT06669091|OTHER|Dosed in fasted state|Ecopipam will be taken in the morning in a fasted state
62485117|NCT02587663|EXPERIMENTAL|Group 2 (bilateral whole-breast ultrasound)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral whole-breast ultrasound.
62485118|NCT02587663|EXPERIMENTAL|Group 3 (bilateral breast contrast-enhanced MRI)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral breast contrast-enhanced MRI.
62485119|NCT02551640|EXPERIMENTAL|Group A|"* Receive a Samsung smartphone~* Receive the FeatForward app~* Receive a Samsung smartwatch~* Continue to receive medical care as usual"
61933641|NCT02788929|ACTIVE_COMPARATOR|Fitbit Charge HR|"Use of the Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.~All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback."
62326698|NCT06669091|OTHER|Dosed in fed state|Ecopipam will be taken in the morning after a standard high-fat breakfast
62485120|NCT02551640|NO_INTERVENTION|Group B|"* Receive a Samsung smartphone~* Receive a Samsung smartwatch~* Continue to receive medical care as usual"
62485121|NCT04029545|EXPERIMENTAL|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. The study device will be provided by the Sponsor.
62485122|NCT04029545|ACTIVE_COMPARATOR|RV001 with lidocaine cream|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used with LMX4, a topical lidocaine. The study device will be provided by the Sponsor. LMX4 will be provided in commercial stock packaging by the Sponsor
62485123|NCT04029545|EXPERIMENTAL|RV001|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used alone. The study device will be provided by the Sponsor.
62485124|NCT01051349|EXPERIMENTAL|BIIB019|Participants received BIIB019, 150 mg subcutaneous injection every 4 weeks up to Week 288.
62485125|NCT02458664||Colo-rectal cancer|All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
62485126|NCT01724515|EXPERIMENTAL|Obese Non-Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
62326699|NCT06523166|EXPERIMENTAL|Left Atrial Appendage Occlusion (LAAC) with Watchman FLX.|Patients who are status post LAAC using the Watchman FLX.
62326700|NCT05681351|EXPERIMENTAL|Olezarsen|Participants who completed either ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326) study would be enrolled to receive olezarsen, subcutaneous (SC) injection, once every 4 weeks from Week 1 through Week 49.
62326701|NCT06619509|EXPERIMENTAL|Brigimadlin|
62485127|NCT01724515|EXPERIMENTAL|Type 2 Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
62326702|NCT06693921|EXPERIMENTAL|allogenic dentin block|Participants will receive allogenic dentin block for reconstruction of combined vertical and horizontal ridge defects with simultaneous implant placement in the maxillary esthetic zone.
62326703|NCT06693921|EXPERIMENTAL|allogenic dentin shell|Participants will receive allogenic dentin shell for reconstruction of combined vertical and horizontal ridge defects with simultaneous implant placement in the maxillary esthetic zone.
62485128|NCT01724515|EXPERIMENTAL|Healthy Control Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
62485129|NCT05356091|ACTIVE_COMPARATOR|Sevoflurane|General anesthesia using sevoflurane
62485130|NCT05356091|EXPERIMENTAL|Remimazolam|General anesthesia using remimazolam
62485131|NCT02890069|EXPERIMENTAL|CRC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
62485132|NCT02890069|EXPERIMENTAL|NSCLC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
62485133|NCT02890069|EXPERIMENTAL|TNBC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
62485134|NCT02890069|EXPERIMENTAL|CRC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
62485135|NCT02890069|EXPERIMENTAL|NSCLC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
62485136|NCT02890069|EXPERIMENTAL|TNBC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
62485137|NCT02890069|EXPERIMENTAL|CRC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
62485138|NCT02890069|EXPERIMENTAL|NSCLC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
62485139|NCT02890069|EXPERIMENTAL|TNBC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
62485140|NCT02890069|EXPERIMENTAL|CRC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
62692728|NCT03231735|OTHER|Mid frequency ventilation|Mid frequency ventilation delivered at rates \> 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
62485141|NCT02890069|EXPERIMENTAL|TNBC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
62485142|NCT02890069|EXPERIMENTAL|NSCLC- PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
62692729|NCT03231735|OTHER|Standard frequency ventilation|Standard frequency ventilation delivered at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
61933642|NCT02788929|NO_INTERVENTION|No Device|No Fitbit used and no feedback on exercise goal adherence. All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback.
62326704|NCT01897441|EXPERIMENTAL|Stratum A: HER2-positive|Patients receive Paclitaxel 80 mg/m\^2 IV infusion over 1 hour for 12 weeks and Trastuzumab 8 mg/kg IV loading dose over 90 minutes, then 6 mg/kg IV every three weeks (after Paclitaxel when given concurrently) for a total of 17 doses over 51 weeks. Beginning 2-3 weeks after the last dose of Paclitaxel, patients receive Doxorubicin hydrochloride 60 mg/m\^2 IV over 5-10 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes every 2 weeks for 8 weeks.
62326705|NCT01897441|EXPERIMENTAL|Stratum B: HER2-negative|Patients receive sequential Paclitaxel followed by Doxorubicin hydrochloride and Cyclophosphamide (AC) as described in Stratum A.
62326706|NCT01897441|EXPERIMENTAL|Stratum C: HER2-negative|Patients receive sequential Doxorubicin hydrochloride and Cyclophosphamide (AC) followed by Paclitaxel. Patients receive Doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.
62326707|NCT01897441|EXPERIMENTAL|Stratum I: HER2-negative|Patients receive Paclitaxel 80 mg/m\^2 IV infusion over 1 hour for 12 weeks followed by Doxorubicin hydrochloride and Cyclophosphamide (AC). Patients receive Doxorubicin hydrochloride 60 mg/m\^2 IV over 5-10 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes every 2 weeks for 8 weeks.
62326708|NCT01897441|EXPERIMENTAL|Stratum II: HER2-positive|Patients receive Paclitaxel 80 mg/m\^2 IV infusion over 1 hour for 12 weeks and Trastuzumab 8 mg/kg IV loading dose over 90 minutes, then 6 mg/kg IV every three weeks (after Paclitaxel when given concurrently) for a total of 17 doses over 51 weeks. Beginning 2-3 weeks after the last dose of Paclitaxel, patients receive Doxorubicin hydrochloride 60 mg/m\^2 IV over 5-10 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes every 2 weeks for 8 weeks.
62326709|NCT01897441|EXPERIMENTAL|Stratum III: ER2-positive, HER2-negative|Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
62485143|NCT02890069|EXPERIMENTAL|CRC - PDR001 + HDM201|Dose escalation completed, expansion arm.
61933643|NCT02891811|EXPERIMENTAL|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
61933644|NCT02891811|ACTIVE_COMPARATOR|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
61933645|NCT02747654|NO_INTERVENTION|standard dosing|a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight
61933646|NCT02747654|EXPERIMENTAL|Genotype-guided dosing|INH dose determined based on developed model
61933647|NCT02537782|OTHER|Cardiac resynchronisation therapy implantation|Patients with current guideline-based indication for CRT implantation.
62133589|NCT06161415|EXPERIMENTAL|Stage 2 Comparison Group B|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops in the study eye for 14 days before the surgery. Frequency to be decided at the end of stage 1.
62133590|NCT02582424|EXPERIMENTAL|PDL-0101|EPA +astaxanthin
62133591|NCT02582424|PLACEBO_COMPARATOR|placebo|olive oil
62133592|NCT03592602|EXPERIMENTAL|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
62133593|NCT06461390|EXPERIMENTAL|Norepinephrine Group (Fluid loading with early norepinephrine administration group)|"NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/ minute until MAP\>5 percentile.~Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group"
62692730|NCT06563804|EXPERIMENTAL|Dose Escalation - Arm A|S227928 as a single agent
62692731|NCT06563804|EXPERIMENTAL|Dose Escalation - Arm B|S227928 in combination with venetoclax
62692732|NCT06563804|EXPERIMENTAL|Dose Expansion - Cohort 1|For participants with R/R AML and MDS/AML. S227928 in combination with venetoclax at RP2D
62692733|NCT06563804|EXPERIMENTAL|Dose Expansion - Cohort 2|For participants with CMML. S227928 in combination with venetoclax at RP2D
62692734|NCT04448847|PLACEBO_COMPARATOR|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
62692735|NCT04448847|EXPERIMENTAL|Bif195 arm|Active trial product with minimum 100 billion CFU daily dose
61933648|NCT05650060||Secukinumab|all patients with psoriasis who received secukinumab
62133594|NCT06461390|ACTIVE_COMPARATOR|Ringer's lactate Group|The Fluid Group will receive only ringer lactate bolus 20 ml/kg. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed.
62133595|NCT05361733|ACTIVE_COMPARATOR|XFB-19|"Part A: XFB-19 SC injection at the following dose levels:~* Cohort 1: 5 mg~* Cohort 2: 10 mg~* Cohort 3: 20 mg~Part B: XFB-19 SC injection at the 2 highest acceptable dose levels from Part A:~* Cohort 4: second highest acceptable dose level from Part A~* Cohort 5: highest acceptable dose level from Part A"
62133596|NCT05361733|PLACEBO_COMPARATOR|Placebo|10 healthy volunteers will be randomized and assigned to the Placebo arm in Part A (Cohorts 1, 2 and 3) and Part B (Cohorts 4 and 5).
62133597|NCT06590441||Myopia control spectacle wearers|Established (use of ≥3 months) juvenile myopia control spectacle wearers
62133598|NCT04829604|EXPERIMENTAL|ARX788|The investigational medicinal product (IMP), ARX788, will be administered every 3 weeks (Q3W) by intravenous (IV) infusion.
62326710|NCT05147662|EXPERIMENTAL|Main study (Part A) and the extension study (Part B)|Part A will last for 6 months. After completing Part A participants will continue in the extension study for another 18 months.
62326711|NCT06682572|EXPERIMENTAL|avutometinib + defactinib|Avutometinib 3.2mg, PO, twice weekly for 21 days on, 7 days off in a 28-day (4 weeks) cycle in combination with defactinib 200 mg, PO, twice daily for 21 days on, 7 days off in a 28-day (4 week) cycle.
62133599|NCT00545519|EXPERIMENTAL|Dose Level 1|Thymoglobulin 2.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
62133600|NCT00545519|EXPERIMENTAL|Dose Level 2|Thymoglobulin 3.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
62133601|NCT00545519|EXPERIMENTAL|Dose Level 3|Thymoglobulin 4.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
62133602|NCT01286064|EXPERIMENTAL|patient with colo-rectal cancer|fluorescence spectra will be mainly characterized by the presence of an emission peaking at 620-630 nm
62133603|NCT01286064|ACTIVE_COMPARATOR|patient without colo-rectal cancer|fluorescence spectra will be characterized by the absence of an emission peaking at 620-630 nm
62133604|NCT04707001|ACTIVE_COMPARATOR|Ultrasound monitoring group|In the ultrasound group, urinary retention is monitored, according to current practice, with an ultrasound scanner and the patient is catheterized if necessary, if residual urine exceeds 800 ml, or if the patient is symptomatic.
62133605|NCT04707001|ACTIVE_COMPARATOR|Symptoms alone group|Urination is monitored by asking at regular intervals about the onset of spontaneous urination and the patient is catheterized only on a symptomatic basis.
62133606|NCT04762238|EXPERIMENTAL|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
62326712|NCT04575883|EXPERIMENTAL|MedBIKE HIIT|MedBIKE HIIT Exercise Program
62326713|NCT01909453|EXPERIMENTAL|LGX818 450 mg + MEK162|LGX818 450 mg QD + MEK162 45 mg BID
61933649|NCT00664469|EXPERIMENTAL|EZE+statin|ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
62133607|NCT04762238|SHAM_COMPARATOR|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
62133608|NCT06350812|EXPERIMENTAL|PB-119|PB-119 administered on the first day of week 1-20 according to the dose-escalation design
62326714|NCT01909453|ACTIVE_COMPARATOR|Vemurafenib|Vemurafenib 960 mg BID
62326715|NCT01909453|EXPERIMENTAL|LGX818 300 mg + MEK162|LGX818 300 mg QD + MEK162 45 mg BID
62326716|NCT01909453|EXPERIMENTAL|LGX818|LGX818 300 mg QD
62326717|NCT05987332|EXPERIMENTAL|Phase 2a Dose Optimization of IDE196 + crizotinib|Multiple doses of IDE196 will be tested in combination with fixed dose of crizotinib to identify the optimal combination dose.
61933650|NCT00664469|ACTIVE_COMPARATOR|Stat2|patients on statins has their dose doubled for 6 weeks followed by another 6 weeks in which ezetimibe is added or the statin dose is doubled again.
61933651|NCT06643845|EXPERIMENTAL|Multimodal medical care arm|In the medical care arm, rheumatologists will list previous treatment, ongoing treatment and then order validated treatment (corticosteroid or hyaluronic acid joint injection if necessary, physical activity and weight loss in the event of obesity, other non-drug treatments (insole, orthosis) as well as other drug treatments (pain killers or non steroidal anti-inflammatory drugs) including validated tools (personalized program, filmed sessions and digital exercise media for regular practice at home, motivational e-mails). At least one modification will be discussed in each domain (physical activity, weight loss, insole, orthosis, assistive device when walking, joint injection, pills -pain killer acetaminophen and opioids- nonsteroidal anti inflammatory drugs -with classical rules - and others)
61933652|NCT06643845|ACTIVE_COMPARATOR|Surgery arm|In the surgery arm, patients will have to plan, as initially suggested, their surgery (total knee arthroplasty)
61933653|NCT00551044|ACTIVE_COMPARATOR|Bicalutamide|Osteoporotic patients (T score ≤ -2.5) on bicalutamide
61933654|NCT02703623|EXPERIMENTAL|Arm 2A (abiraterone acetate, prednisone, apalutamide)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.
61933655|NCT02703623|EXPERIMENTAL|Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
61933656|NCT02703623|ACTIVE_COMPARATOR|Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
61933657|NCT01462227|EXPERIMENTAL|Naltrexone (higher dose)|Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
61933658|NCT01462227|EXPERIMENTAL|Naltrexone (lower dose)|Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
61933659|NCT06692686|EXPERIMENTAL|Custom-fit|These pre-manufactured orthoses are customized to fit each patient. These devices can help to distribute weight evenly along the foot, but do not offer much opportunity for adjustment to a patient's specific needs. These AFOs achieve ankle motion through material deflection and lack a single point of articulation.
62133609|NCT06350812|PLACEBO_COMPARATOR|Placebo|Matched placebo administered on the first day of week 1-20 according to the dose-escalation design
62133610|NCT04319913|EXPERIMENTAL|ANI-guided|ANI-guided narcotics use to maintain ANI value between 50 to 70
62326718|NCT05987332|EXPERIMENTAL|Phase 2b / 3 Chosen Combination dose of IDE196 + crizotinib|Chosen combination dose of IDE196 + crizotinib will be tested in additional participants.
62326719|NCT05987332|ACTIVE_COMPARATOR|Phase 2a / 2b / 3 Comparator Arm|Participants will receive investigator's choice of Pembrolizumab, Ipilimumab + Nivolumab, or Dacarbazine.
62692736|NCT04421001|EXPERIMENTAL|I-Port™*(Medtronic) use Arm|Patients will administer insulin via iport system. I-Port™\* (Medtronic), infusion set, dedicated for insulin deliery for 72 hours.
62692737|NCT04421001|ACTIVE_COMPARATOR|Insulin Pen Injections|Patients will administer insulin via injections as usual
62692738|NCT03795519|EXPERIMENTAL|Healthy Male Volunteers|Single oral dose of \[14C\]-olinciguat
62692739|NCT00660231|EXPERIMENTAL|GemBex|Gemcitabine days 1 and 8 of a 3 week cycle (4 cycles total - 12 weeks) Bexarotene daily: in combination with Gemcitabine during first 12 weeks, then Bexarotene maintenance until disease progression.
62692740|NCT06641492|EXPERIMENTAL|Intervention|The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
62692741|NCT06641492|ACTIVE_COMPARATOR|Control|The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
62692742|NCT05665452|ACTIVE_COMPARATOR|Group (1)|patients will receive stretch and strength exercises
62133611|NCT04319913|NO_INTERVENTION|Control|narcotics use guided by clinical experience, ANI is still recorded but would be covered up intraoperatively
62133612|NCT02398487|ACTIVE_COMPARATOR|Personal Vaporizer|Personal Vaporizer loaded with nicotine
62133613|NCT02398487|ACTIVE_COMPARATOR|Cigalike|Cigalike loaded with nicotine
62133614|NCT02398487|NO_INTERVENTION|Usual smoking|
62133615|NCT03257644|EXPERIMENTAL|Cohort 1|Ruxolitinib phosphate cream 0.5%.
62133616|NCT03257644|EXPERIMENTAL|Cohort 2|Ruxolitinib phosphate cream 1.5%.
62692743|NCT05665452|EXPERIMENTAL|Group (2)|patients will receive stretch, strength, patellar mobilization, retinacula release and deep friction message
62692744|NCT05972785||No AHT|Women with HTN with no AHT use
62133617|NCT03257644|EXPERIMENTAL|Cohort 3|Ruxolitinib phosphate cream 0.75%.
62133618|NCT03257644|EXPERIMENTAL|Cohort 4|Ruxolitinib phosphate cream 1.5%.
62133619|NCT03257644|EXPERIMENTAL|Cohort 5|Ruxolitinib phosphate cream 0.75%.
62133620|NCT03257644|EXPERIMENTAL|Cohort 6|Ruxolitinib phosphate cream 1.5%.
62133621|NCT01488734|EXPERIMENTAL|Mushroom with 600 IU vitamin D2|Mushroom with 600 IU of vitamin D2 daily and placebo tablet
62326720|NCT06719089|ACTIVE_COMPARATOR|Rocamed RocaJJ Soft|
62326721|NCT06719089|EXPERIMENTAL|Hydrustent®|
62326722|NCT04880031|EXPERIMENTAL|Cohort A1: Efimosfermin Dose 1 or placebo (PBO)|
62326723|NCT04880031|EXPERIMENTAL|Cohort A2: Efimosfermin Dose 2 or PBO|
62692745|NCT05972785||AHT but non-CCB|Women with HTN exposed to other antihypertensive medicines but not exposed to calcium channel blockers
62692746|NCT05972785||CCB only|Women with HTN exposed to calcium channel blockers but not exposed to other antihypertensive medicines
62692747|NCT05972785||Both CCB and non-CCB|Women with HTN exposed to both calcium channel blockers and other antihypertensive medicines.
62692748|NCT00002759|EXPERIMENTAL|Arm I|See detailed description.
62692749|NCT05272488|EXPERIMENTAL|Manual therapy and nervous vagus stimulation|Subjects will received manual therapy combined with nerve vagus stimulation.
62692750|NCT05272488|ACTIVE_COMPARATOR|Manual therapy|Subjects will received isolated manual therapy techniques.
62692751|NCT06231264|EXPERIMENTAL|treatment group|Subjects will be trained to use the devices at the treatment sites and receive treatment twice a day for 8 weeks.
62692752|NCT06231264|PLACEBO_COMPARATOR|shame group|Subjects will be trained to use the devices at the sham sites and receive sham treatment twice a day for 8 weeks.
61933660|NCT06692686|EXPERIMENTAL|Custom fabricated-solid ankle|These AFO designs are built from a custom mold of the patient's affected limb for a more individualized fit. They achieve ankle motion through material deflection and lack a single point of articulation.
61933661|NCT06692686|EXPERIMENTAL|Custom fabricated-articulating|These AFO designs are also built from a custom mold of the patient's affected limb, but these orthoses have a true articulation at the ankle to provide controlled ankle movement in a range determined appropriate by the orthotist through gait analysis.
62133622|NCT01488734|EXPERIMENTAL|Mushroom with 4000 IU Vitamin D2|Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
62133623|NCT01488734|ACTIVE_COMPARATOR|600 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
62133624|NCT01488734|ACTIVE_COMPARATOR|4000 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
62133625|NCT00769353|EXPERIMENTAL|Cognitive Behavioral Therapy-PASCET|Primary and Secondary Coping Enhancement Training (PASCET)
62133626|NCT00769353|ACTIVE_COMPARATOR|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy (SNDT)
62133627|NCT01113931|EXPERIMENTAL|Doxycycline Hyclate 200 mg tablet|Once daily
62133628|NCT01113931|ACTIVE_COMPARATOR|Vibramycin 100 mg capsule|Twice daily
62133629|NCT04547764|EXPERIMENTAL|TAP group|
62133630|NCT04547764|ACTIVE_COMPARATOR|Vitapex group|
62326724|NCT04880031|EXPERIMENTAL|Cohort A3: Efimosfermin Dose 3 or PBO|
62326725|NCT04880031|EXPERIMENTAL|Cohort A4: Efimosfermin Dose 4 or PBO|
62133631|NCT00754000||Cohort 1|All patients in study
62133632|NCT03619642|OTHER|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
62326726|NCT04880031|EXPERIMENTAL|Cohort A5: Efimosfermin Dose 5 or PBO|
62326727|NCT04880031|EXPERIMENTAL|Part B: Efimosfermin Dose 1 or PBO|
62326728|NCT04880031|EXPERIMENTAL|Part C: Efimosfermin Dose 1|
62326729|NCT04880031|EXPERIMENTAL|Part D: Efimosfermin Dose 6 or PBO|
62326730|NCT04880031|EXPERIMENTAL|Part D: Efimosfermin Dose 1 or PBO|
62326731|NCT06603844|EXPERIMENTAL|Part A: Dose 1 CRB-601 monotherapy|Dose 1 of CRB-601 (3mg/Kg) administered intravenously every two weeks
62326732|NCT06603844|EXPERIMENTAL|Part A: Dose 2 of CRB-601 monotherapy|Dose 2 of CRB-601 (10mg/Kg) administered intravenously every two weeks
62692753|NCT04428905|EXPERIMENTAL|Arm I (personalized care plan, telehealth sessions)|Patients receive a personalized care plan/resource manual. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) about self-management skills building, then 3 maintenance telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) for additional self-management skills building support. A copy of patient's care plan is also sent to their PCP.
62692754|NCT04428905|ACTIVE_COMPARATOR|Arm II (ASCO care plan, telehealth sessions)|Patients receive an ASCO care plan. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) to answer questions on a handbook about life after cancer treatment, then 3 monthly telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) to answer questions about the handbook. A copy of the ASCO care plan is also sent to their PCP.
62692755|NCT04722809|EXPERIMENTAL|Symptomatic patients in the context of bruxism|
62133633|NCT03619642|OTHER|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
62133634|NCT03619642|OTHER|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
62133635|NCT05646004|EXPERIMENTAL|621|
62133636|NCT00861770|OTHER|1 - Control|All subjects will receive blood volume measurement immediately before and 30 minutes after ultrafiltration is completed. In the control group, the treating physician will not see the blood volume measurement results and treat according to standard of care.
62133637|NCT00861770|EXPERIMENTAL|2 - BVM|Ultrafiltration will be guided by blood volume measurement results.
62133638|NCT02611609|EXPERIMENTAL|Cohort 1|Low dose MultiStem
62133639|NCT02611609|EXPERIMENTAL|Cohort 2|High dose MultiStem
62133640|NCT02611609|EXPERIMENTAL|Cohort 3|Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo
62326733|NCT06603844|EXPERIMENTAL|Part A: Dose 3 of CRB-601 monotherapy|Dose 3 of CRB-601 (30mg/Kg) administered intravenously every two weeks
62326734|NCT06603844|EXPERIMENTAL|Part B/Cohort 1: Dose level (low) CRB-601 monotherapy in combination with anti-PD(L)-1|Dose (defined in Part A) of CRB-601 administered intravenously in combination with anti-PD(L)-1 therapy dosed as per label.
62326735|NCT06603844|EXPERIMENTAL|Part B/Cohort 1: Dose level (high) CRB-601 monotherapy in combination with anti-PD(L)-1|High dose CRB-601 (defined in Part A) of CRB-601 administered intravenously in combination with anti-PD(L)-1 therapy dosed per label.
62326736|NCT06603844|EXPERIMENTAL|Part B/Cohort 2 low dose CRB-601, anti-PD(L)-1 therapy and SBRT|Participants will received a low dose of CRB-601(defined in Part A), standard of care dose of anti-PD(L)-1 therapy and 3 x 8gy doses of immune priming SBRT focused on a single lesion.
61933662|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
61933663|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
61933664|NCT04895748|EXPERIMENTAL|Arm 1 Dose Escalation DFF332|DFF332 Single Agent
61933665|NCT04895748|EXPERIMENTAL|Arm 2 Dose Escalation DFF332 + Everolimus|Combination treatment DFF332 + Everolimus. This arm will not open.
61933666|NCT04895748|EXPERIMENTAL|Arm 3 Dose Escalation DFF332 + Spartalizumab + Taminadenant|Combination treatment DFF332 + Spartalizumab + Taminadenant. This arm will not open.
61933667|NCT04895748|EXPERIMENTAL|Arm 1a Dose Expansion DFF332 in ccRCC|DFF332 Single Agent in patients with ccRCC (age 18 years old and above). This arm will not open.
61933668|NCT04895748|EXPERIMENTAL|Arm 1b Dose Expansion DFF332 in HIF stabilizing malignancies|DFF332 Single Agent in patients with HIF stabilizing malignancies (age 12 years old and above). This arm will not open.
61933669|NCT04895748|EXPERIMENTAL|Arm 2a Dose Expansion DFF332 + Everolimus in ccRCC|Combination treatment DFF332 + Everolimus in patients with ccRCC (age 18 years old and above). This arm will not open.
61933670|NCT04895748|EXPERIMENTAL|Arm 3a Dose Expansion DFF332 + Spartalizumab + Taminadenant in ccRCC|Combination treatment DFF332 + Spartalizumab + Taminadenant in patients with ccRCC (age 18 years old and above). This arm will not open.
61933671|NCT05548738|ACTIVE_COMPARATOR|Steroid group (Group S)|This group will receive ultrasound and fluoroscopy-guided caudal epidural steroid injection
61933672|NCT05548738|EXPERIMENTAL|Prolotherapy group (Group P)|This group will receive ultrasound and fluoroscopy-guided caudal epidural prolotherapy injection
61933673|NCT01248481||Group 1|
61933674|NCT01308931||Tubal ligation|Patients who elect to have tubal ligation
61933675|NCT01308931||Essure|Group that elects to have Essure placement
61933676|NCT01308931||Levonorgestrel IUD|Patients that elect to have a levonorgestrel intra-uterine device placement
62326737|NCT06603844|EXPERIMENTAL|Part B/Cohort 2 high dose CRB-601, anti-PD(L)-1 therapy and SBRT|Participants will received a high dose of CRB-601(defined in Part A), standard of care dose of anti-PD(L)-1 therapy and 3 x 8gy doses of immune priming SBRT focused on a single lesion.
62326738|NCT06603844|EXPERIMENTAL|Part C - Low dose CRB-601, anti-PD(L)-1 with or without SBRT|Participants will received a low dose of CRB-601(defined in Part A \& B), standard of care dose of anti-PD(L)-1 therapy with or without 3 x 8gy doses of immune priming SBRT focused on a single lesion (as determined in Part B).
62326739|NCT06603844|EXPERIMENTAL|Part C - High dose CRB-601, anti-PD(L)-1 with or without SBRT|Participants will received a high dose of CRB-601(defined in Part A \& B), standard of care dose of anti-PD(L)-1 therapy with or without 3 x 8gy doses of immune priming SBRT focused on a single lesion (as determined in Part B).
61933677|NCT06654791|OTHER|[14C]SIM0270 group|Single arm study
61933678|NCT05946213|EXPERIMENTAL|Arm I (SBRT)|Patients undergo SBRT for a total of 5 treatments over 2 weeks.
61933679|NCT05946213|ACTIVE_COMPARATOR|Arm II (EBRT)|Patients undergo EBRT for 20 to 45 treatments over 4 to 9 weeks.
61933680|NCT01419743||patients with Vit D level of < 20ng/mL: Group 1|randomized to receive 400 IU of vitamin D per day
61933681|NCT01419743||patients with Vit D levels <20ng/mL: Group 2|Randomized to receive 2000IU of Vitamin D per day
61933682|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 3|Randomized to receiving placebo
61933683|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 4|Randomized to receive 400IU of vitamin D per day
62326740|NCT06718491|EXPERIMENTAL|Managing Physical Reactions to Overwhelming Emotions (IMPROVE)|In this arm, participants will receive the IMPROVE intervention, a clinician-delivered protocol targeting anxiety and uncertainty.
62326741|NCT06718491|ACTIVE_COMPARATOR|Health Education Training (HET)|In this arm, participants will receive a clinician-delivered protocol with a digital component, called HET. HET focuses on healthy living more broadly and does not include information about anxiety or uncertainty.
62485144|NCT02890069|EXPERIMENTAL|RCC - PDR001 + HDM201|Dose escalation completed, expansion arm.
61933684|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 5|Randomized to receive 2000IU of vitamin D per day
61933685|NCT01419743||patients with vit D levels > 30ng/mL: Group 6|No treatment
61933686|NCT01729260|EXPERIMENTAL|Mebendazole|All study participants will receive study drug; Mebendazole.
61933687|NCT01833546|EXPERIMENTAL|Evofosfamide 240 mg|
61933688|NCT01833546|EXPERIMENTAL|Evofosfamide 340 mg|
61933689|NCT01833546|EXPERIMENTAL|Evofosfamide 480 mg|
61933690|NCT01833546|EXPERIMENTAL|Evofosfamide 340 mg + Gemcitabine|
61933691|NCT00810524|EXPERIMENTAL|A|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
61933692|NCT00810524|ACTIVE_COMPARATOR|B|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
61933693|NCT00810524|EXPERIMENTAL|C|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
61933694|NCT00810524|ACTIVE_COMPARATOR|D|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
61933695|NCT06710353|EXPERIMENTAL|Albumin group|A 20% albumin solution is administered over a period of one hour, starting at the time of anesthesia induction.
61933696|NCT06710353|PLACEBO_COMPARATOR|Control group|The same volume of crystalloid solution as the administered albumin is infused.
61933697|NCT03252938|EXPERIMENTAL|Solid tumors|Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy (intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas) are not allowed)
62326742|NCT06709521|EXPERIMENTAL|Arm 1|Adult patients in the ICU receiving either meropenem or cefepime as part of their clinical management will receive one dose of IV iohexol 1500 mgI (5 mL) via slow push administration on Study Days 1 and 2 prior to the start of first or second daily meropenem or cefepime dose.
62326743|NCT06730061|EXPERIMENTAL|Elafibranor|Participants will take the study intervention by mouth (swallow whole) once daily
62326744|NCT06731647|EXPERIMENTAL|Interventional group|one intravenous dose of ketoprofen 100 mg followed by 5 doses every 12 h of ketoprofen LP 100 mg (a total regimen of 6 doses of ketoprofen every 12 h for 72h)
62326745|NCT06731647|PLACEBO_COMPARATOR|Control group|placebo of ketoprofen with the schema of administration consisting in the administration of one intravenous dose of 100 ml of NaCl 0.9% following 6 oral intakes of a placebo pill every 12h (a total regimen of 6 doses of placebo of NSAID every 12 h for 72h)
62133641|NCT01813773|EXPERIMENTAL|Group A - IAI every 4 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.
62326746|NCT06695845|EXPERIMENTAL|Zanidatamab treatment arm|Eligible participants receiving zanidatamab treatment
62133642|NCT01813773|EXPERIMENTAL|Group B - IAI every 8 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will receive IAI every 8 weeks, beginning week 24, through week 48.
62326747|NCT06746402|EXPERIMENTAL|Part A|
62326748|NCT06746402|EXPERIMENTAL|Part B1/B2 Treatment A|
62326749|NCT06746402|EXPERIMENTAL|Part B1/B2 Treatment B|
62326750|NCT06746402|EXPERIMENTAL|Part B1/B2 Treatment C|
62326751|NCT06746402|EXPERIMENTAL|Part B1/B2 Treatment D|
62326752|NCT06746402|EXPERIMENTAL|Part B3 Treatment A|
62326753|NCT06746402|EXPERIMENTAL|Part B3 Treatment B|
62326754|NCT06746402|EXPERIMENTAL|Part B3 Treatment C|
62326755|NCT06746402|EXPERIMENTAL|Part B3 Treatment D|
62326756|NCT06743360||Test group|Patients seeking for orthodontic treatment with the need of use of the mini-implants
62326757|NCT06739122|EXPERIMENTAL|Dulaglutide|Participants will receive dulaglutide subcutaneously (SC)
62485145|NCT04225715|ACTIVE_COMPARATOR|Nucleos(t)ide (NUC) Control Arm|Participants will continue their background NUC therapy for the 48-week treatment period. At the end of the treatment period, in line with current CHB treatment guidelines, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485146|NCT04225715|EXPERIMENTAL|Core Protein Allosteric Modulator (CpAM; RO7049389) + Toll-like Receptor 7 (TLR7;RO7020531) + NUC|Participants will receive RO7049389 (600 mg once daily \[QD\]) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg once every other day \[QOD\]) will be administered during Weeks 1-12 and Weeks 25-36. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485147|NCT04225715|EXPERIMENTAL|Short Interfering Ribonucleic acid (siRNA; RO7445482) (Dose1) + NUC|Participants will receive RO7445482 (Dose 1) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485148|NCT04225715|EXPERIMENTAL|siRNA (RO7445482) (Dose 2) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485149|NCT04225715|EXPERIMENTAL|siRNA (RO7445482) + Pegylated Interferon (PEG-IFN) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. PEG-IFN will be administered at a dose of 180 μg once weekly (QW) for 48 weeks. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485150|NCT04225715|EXPERIMENTAL|siRNA (RO7445482) + CpAM (RO7049389) + NUC|Participants will receive RO7445482 (Dose 2) and RO7049389 (600 mg QD) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62692756|NCT05698498|ACTIVE_COMPARATOR|Usual Care|Participants in the active comparator control group will receive usual care, which includes usual public benefit, assistance and social service programs that are available at the local, county, state, and federal levels to all residents of Santa Clara County. They will also be offered the option to attend a Public Benefits Information Session.
62692757|NCT05698498|EXPERIMENTAL|Guaranteed Income|Participants in the intervention group will receive guaranteed income gift payments equivalent to $1,000/month for a total of 24 months in addition to usual care. They will also have the option to attend the same Public Benefits Information Session being offered to the control group as above.
62692758|NCT03926247|OTHER|Immigrant Well-being Project Intervention|Intervention
62692759|NCT06643650||1st group: 3 months intake of cholecalciferol supplementation (therapeutic dose)|
62133643|NCT02652442|EXPERIMENTAL|Centrifugation Parameters|Three experiments were performed to identify optimal centrifugation parameters: (1) distance off-axis (3.5 vs 7 cm); (2) duration (1 min vs 3 mins); (3) schedule (daily vs biweekly). The comparisons were all within subjects; i.e., each subject was tested systematically for each centrifugation parameter under both conditions. The change in the outcome measure SVV (from pre- to post-off-axis rotation) for each condition (e.g., 3.5 vs 7 cm) within a parameter was compared.
62133644|NCT04801199|EXPERIMENTAL|CPL-2009-0031 140 mg|Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks
62326758|NCT06746623|OTHER|This is a single arm study. Participants will complete 2 diagnostic tests: Esocheck and EGD.|Patients without history of GERD receiving care in Wade Park VA will be approached regarding BE screening. Reasons for refusal of screening will be recorded. Adult subjects without history of gastroesophageal reflux with three or more risk factors- white race, male gender, obesity (BMI \> 30), smoking, or family history will be included. Only those patients who have not had prior EGD will be candidates for Esocheck screening. Distal esophageal samples will be assayed for mVIM + mCCNA1 (Esoguard assay). All patients will be offered upper endoscopy.
62326759|NCT06536504|EXPERIMENTAL|Patients: Simulated Live Music|Patients will be screened for eligibility, enrolled in the study and randomized 1:1:1.
62326760|NCT06536504|EXPERIMENTAL|Patients: Recorded Music|Patients will be screened for eligibility, enrolled in the study and randomized 1:1:1.
62326761|NCT06536504|EXPERIMENTAL|Patients: Control: No Music|Patients will be screened for eligibility, enrolled in the study and randomized 1:1:1.
62133645|NCT04801199|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks
62133646|NCT01013584|ACTIVE_COMPARATOR|1,000 IU|1,000 IU/day of vitamin D3
62133647|NCT01013584|ACTIVE_COMPARATOR|5,000 IU|5,000 IU/day of vitamin D3
62133648|NCT01013584|ACTIVE_COMPARATOR|10,000 IU|10,000 IU/day of vitamin D3
62133649|NCT02357472|EXPERIMENTAL|High dose group|dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
62133650|NCT02357472|EXPERIMENTAL|Standard dose group|dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
62692760|NCT06643650||2nd group: 3 months therapeutic and 3 months prophylactic dose intake of cholecalciferol|
62692761|NCT05644301|ACTIVE_COMPARATOR|High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Minocyclin + Treatment As Usual (TAU)|
62692762|NCT05644301|ACTIVE_COMPARATOR|High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Celecoxib + Treatment As Usual (TAU)|
62692763|NCT05644301|PLACEBO_COMPARATOR|High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Placebo + Treatment As Usual (TAU)|
62692764|NCT05644301|ACTIVE_COMPARATOR|High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Minocyclin + Treatment As Usual (TAU)|
62133651|NCT01567813||Regimen Initiators|Any male health plan member who receives at least one dose of GARDASIL™
62133652|NCT01567813||Regimen Completers|Regimen Initiators who complete the 3-dose vaccination regimen within 12 months
62133653|NCT01567813||Autoimmune cohort|Regimen Initiators who were members of the health plan during the 12-month period prior to their first dose of GARDASIL™
62326762|NCT06667596||anxiety|Patients aged 18-65 years, ASA-I-II-III, oriented and cooperative, who agreed to participate in the survey, undergoing upper extremity surgery under regional or general anesthesia.
62326763|NCT04106830||NMOSD|Patients with neuromyelitis optica spectrum disorders
62326764|NCT04106830||Multiple sclerosis(MS)|Patients with multiple sclerosis
62485151|NCT04225715|EXPERIMENTAL|siRNA (RO7445482) + TLR7 (RO7020531) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg QOD) will be administered during Weeks 13-24 and Weeks 37-48 (i.e., 2 treatment cycles of 12 weeks' duration each and 42 doses of RO7020531 for each cycle). At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485152|NCT04225715|EXPERIMENTAL|siRNA(RO7445482)+ Programmed Death Ligand-1 Locked Nucleic Acid (PD-L1 LNA; RO7191863) + NUC [1]|Participants will receive RO7445482 (Dose 2) during Weeks 1-24 and RO7191863 (Dose 1) will be administered during Weeks 13-24, in addition to their background NUC therapy for the 24-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485153|NCT04225715|EXPERIMENTAL|siRNA (RO7445482) + PD-L1 LNA (RO7191863) + NUC [2]|Participants will receive RO7445482 (Dose 2) during Weeks 1-24 and RO7191863 (Dose 1) will be administered during Weeks 25-36, in addition to their background NUC therapy for the 36-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
62485154|NCT06559371||68Ga-FAPI PET/CT|68Ga-FAPI PET/CT
62485155|NCT05811793|EXPERIMENTAL|Bevacizumab arterial infusion combined with Tislelizumab intrathecal injection|"This is a prospective, interventional, multicenter Phase 2 trial for the treatment of patients with recurrent GBM who will receive Bevacizumab arterial infusion combined with Tislelizumab intrathecal injection. The study consists of two parts: the arterial infusion part in part 1, where each subject will receive 15 mg/Kg of Bevacizumab by cerebral arterial infusion over 15 minutes at a fixed time (d0, d30, d60); the infusion of 20% mannitol 12.5 ml over 120 seconds prior to the infusion of Bevacizumab; and the intrathecal injection part in part 2, where the subject will receive a fixed dose of intrathecal PD1 therapy (Tislelizumab 20 mg, d1, Q3W) intrathecal injection every 3 weeks for 6 cycles."
62326765|NCT04106830||MOGAD|Patients with myelin oligodendrocyte glycoprotein antibody-associated disease
62326766|NCT04106830||Healthy controls (HC)|Healthy people without any neuroinflammation disease
62326767|NCT06679114|EXPERIMENTAL|Behavioral: ACT Therapy|Participants randomized to this group will receive a single-session ACT intervention
62326768|NCT06679114|ACTIVE_COMPARATOR|Attention control|Participants in the control group will receive minimally enhanced usual care to receive treatment as usual enhanced by a health information group session.
62326769|NCT06746610|OTHER|Monogenic Diabetes Genetic Screening and Molecular Diagnosis|
62326770|NCT06715371||Cardiac Surgery Patients|Patients undergoing cardiac surgery (eg., coronary revascularization) at Sunnybrook Health Sciences Centre.
62326771|NCT06708156|ACTIVE_COMPARATOR|Experimental group (0.01% atropine sulfate eye drops)|1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
62485156|NCT06077786|EXPERIMENTAL|Part A: Lu AG06474 + Placebo|Participants will receive a single dose of Lu AG06474 (oral solution) and a single dose of placebo (3 placebo capsules).
62485157|NCT06077786|EXPERIMENTAL|Part B: Ibuprofen + Placebo to Lu AG06474|Participants will receive a single dose of ibuprofen (3 ibuprofen capsules) and a single dose of placebo to Lu AG06474 (oral solution).
62485158|NCT06077786|EXPERIMENTAL|Part C: Pregabalin + Placebo to Lu AG06474|Participants will receive a single dose of pregabalin (1 capsule + 2 placebo capsules) and a single dose of placebo to Lu AG06474 (oral solution).
62485159|NCT06077786|EXPERIMENTAL|Part D: Placebo to Lu AG06474 + Placebo|Participants will receive a single dose of placebo to Lu AG06474 (oral solution) and a single dose of placebo (3 placebo capsules).
62485160|NCT01468623|EXPERIMENTAL|OnDose®|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
62485161|NCT01468623|ACTIVE_COMPARATOR|Body Surface Area (BSA)|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.
62485162|NCT06003933|NO_INTERVENTION|Control group|patients received general anesthesia only.
62133654|NCT03351699|EXPERIMENTAL|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
62326772|NCT06708156|ACTIVE_COMPARATOR|Experimental group (0.02% atropine sulfate eye drops)|1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
62326773|NCT06708156|PLACEBO_COMPARATOR|Control group (placebo eye drops)|1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
62326774|NCT06715436|OTHER|Mediterranean Diet|The MedDiet will be planned according to the Mediterranean diet pyramid. Energy prescriptions will be tailored to each patient's specific needs. The initial calorie prescription will be calculated taking into account usual dietary intake REE and physical activity level (PAL). Changes to calorie prescriptions will be made as needed during the course of follow-up. A minimum of 0.8-1 g of animal protein (e.g. eggs, milk, meat, poultry and fish) per kilogram of body weight per day will be given.
62326775|NCT06715436|EXPERIMENTAL|Ketogenic Diet|Modified Atkins diet with a maximum of 20 g of carbohydrates per day. Fat-rich foods of plant origin will be encouraged in order to reach the prescribed daily caloric intake. Energy prescriptions will be tailored on each patient's specific requirements. The initial calorie prescription will be based on an average between the pre-diet intake, REE and physical activity levels. A minimum of 0.8-1 g of protein from animal sources (e.g. eggs, milk, meat, poultry and fish) per kilogram of body weight per day will be given.
62326776|NCT06715436|OTHER|Control group|The control group will be asked to continue their dietary and lifestyle habits.
62326777|NCT06740305||Healthy Volunteers|Each participant in this group will be exposed to simulated altitude.
62326778|NCT06516965|EXPERIMENTAL|Povorcitinib Dose 1|Povorcitinib at the protocol-defined dose.
62326779|NCT06516965|EXPERIMENTAL|Povorcitinib Dose 2|Povorcitinib at the protocol-defined dose.
62326780|NCT06516965|PLACEBO_COMPARATOR|Placebo|Placebo at the protocol-defined dose.
62326781|NCT06746064|EXPERIMENTAL|CHF10073 active|
62326782|NCT06746064|PLACEBO_COMPARATOR|placebo|
62485163|NCT06003933|EXPERIMENTAL|ISP group|patients received bilateral ultrasound guided inter-semispinal plane (ISP) block at the level of C5 using 10 ml of 0.25% bupivacaine and 10ml xylocaine on each side to reduce the toxicity
62485164|NCT06535932|ACTIVE_COMPARATOR|Amara View Minimal Contact Full Face Mask|Participants will wear the Amara View mask for 15 days
62133655|NCT03351699|EXPERIMENTAL|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
62133656|NCT03351699|EXPERIMENTAL|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
62133657|NCT03351699|EXPERIMENTAL|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
62326783|NCT06746844|EXPERIMENTAL|Cognitive assessment group|All participants will undergo cognitive evaluation using VM Atlas and traditional tests
62326784|NCT06745986|ACTIVE_COMPARATOR|Fascia iliaca group|The ultrasound-guided fascia iliaca compartment block (FICB) group included 42 patients who had a fascia iliaca compartment block by bupivacaine 0.25% in a total volume of 40 ml.
62326785|NCT06745986|ACTIVE_COMPARATOR|spinal anesthesia|spinal anesthesia included 42 patients had spinal anesthesia with 2.5 ml bupivacaine 0.5%.
62326786|NCT06747117||Patients with lower extremity acute limb ischemia|Device: Indigo Aspiration System
62326787|NCT06745999|EXPERIMENTAL|cryotherapy followed by 10% ALA gel Red light PDT|
62326788|NCT06745999|EXPERIMENTAL|10% ALA gel Red Light PDT followed by cryotherapy|
62326789|NCT06747715|EXPERIMENTAL|Clinical Intervention|The therapeutic intervention is a two stage surgical procedure (with a third stage biopsy for research purposes in this trial) in which a primary traumatic or post-surgical craniofacial deformity is treated first with autologous fat grafting using freshly harvested adipose tissue. A second fat grafting procedure is performed at 3.0 months after the first procedure using autologous adipose tissue that had been cryopreserved during the first procedure.
62485165|NCT06535932|ACTIVE_COMPARATOR|F40 Minimal Contact Full Face Mask|Participants will wear the F40 for 15 days
62485166|NCT01053585|ACTIVE_COMPARATOR|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
62485167|NCT01053585|PLACEBO_COMPARATOR|Placebo|Placebo suspension (single dose 90 minutes prior to physiologic measurement)
61933698|NCT03252938|EXPERIMENTAL|Solid tumors + peritoneal carcinomatosis|Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
61933699|NCT03252938|EXPERIMENTAL|Solid tumors + chemotherapy|Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
61933700|NCT03252938|EXPERIMENTAL|Solid tumors + Avelumab/IMP321 therapy|"Avelumab and IMP321 as follows:~* 800 mg avelumab every 2 weeks i.v. (for a maximum of 24 cycles \[48 weeks\])~* 6 mg (cohort 1) or 30 mg (cohort 2) IMP321 every 2 weeks s.c. (for a maximum of 12 cycles \[24 weeks\])"
61933701|NCT03252938|EXPERIMENTAL|Solid tumors + Avelumab/IMP321 combination therapy|"Avelumab and IMP321 as follows:~• 800 mg avelumab every 2 weeks i.v. and 30 mg IMP321 every 2 weeks s.c. for a maximum of 24 cycles \[12 months\]"
61933702|NCT03946488|NO_INTERVENTION|Inactive neuroprosthesis|
61933703|NCT03946488|EXPERIMENTAL|Active neuroprosthesis|
61933704|NCT03712631|ACTIVE_COMPARATOR|bone without a collagen membrane|not covering bone with collagen membrane
62326790|NCT06746311|EXPERIMENTAL|Part A|Single ascending Dose of HT-101 or placebo in Healthy participants subcustaneously.
62326791|NCT06746311|EXPERIMENTAL|Part B|Multiple Ascending Dose of HT-101 or placebo in patients with Chronic hepatitis B virus subcustaneously.
62326792|NCT06747351|EXPERIMENTAL|All Participants (HYQVIA and TAK-881)|"Ramp-up Epoch:~Participants on IGIV or cIGSC will switch to HYQVIA during ramp-up epoch with gradually increasing doses/volumes. For participants switching from IGIV, first HYQVIA dose is given two weeks after their last IGIV infusion. For participants switching from cIGSC, first dose is given one week after a weekly infusion or two weeks after a bi-weekly infusion, using a SC investigational needle set.~Treatment Epoch:~After completing ramp-up, participants will enter HYQVIA dosing epoch 2-3 weeks later, depending on treatment interval. Those already on HYQVIA at screening will skip ramp-up and proceed directly to dosing phase, lasting 18 weeks for a 3-week interval and 20 weeks for 4-week interval. After HYQVIA PK sampling period, participants will switch to TAK-881 with a 1:1 dose conversion. TAK-881 dosing lasts 24 weeks with a SC infusion needle set.~Extension Epoch:~Post-TAK-881, participants will enter the extension epoch, continuing treatment for up to 3 years."
62485168|NCT05981794|EXPERIMENTAL|Heating Pad heated|An electrical heating pad will be applied prior to the cystoscopy or urodynamic procedure
62485169|NCT05981794|PLACEBO_COMPARATOR|Placebo heating pad|An electrical heating pad that is not heated will be applied prior to the cystoscopy or urodynamic procedure
62692765|NCT05644301|ACTIVE_COMPARATOR|High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Celecoxib + Treatment As Usual (TAU)|
62692766|NCT05644301|PLACEBO_COMPARATOR|High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Placebo + Treatment As Usual (TAU)|
61933705|NCT03712631|EXPERIMENTAL|bone with collagen membrane|covering bone with collagen membrane
61933706|NCT02632643|EXPERIMENTAL|lifestyle counseling|
61933707|NCT01087697|EXPERIMENTAL|Implanted with NUC|Patients who have been implanted with the Neo-Urinary Conduit
61933708|NCT06710743|ACTIVE_COMPARATOR|Reference food|Glucodin powder solution
61933709|NCT06710743|EXPERIMENTAL|Food 1|Quaker Whole Oats
61933710|NCT06710743|EXPERIMENTAL|Food 2|Quaker Quick Cooking White Oats
61933711|NCT06710743|EXPERIMENTAL|Food 3|Saffola Oats
61933712|NCT06710743|EXPERIMENTAL|Food 4|Quaker Oats
61933713|NCT06710743|EXPERIMENTAL|Food 5|Quaker Oats Multigrain
61933714|NCT06710743|EXPERIMENTAL|Food 6|Ragi Flakes
61933715|NCT06710743|EXPERIMENTAL|Food 7|Bajra Flakes
61933716|NCT06710743|EXPERIMENTAL|Food 8|Jowar Flakes
62485170|NCT03949296|ACTIVE_COMPARATOR|Mindfulness Intervention|Mindfulness-Based Treatment for Insomnia intervention led by a certified instructor. It is adapted from the Mindfulness-Based Stress Reduction Curriculum developed by the Center for Mindfulness in Medicine, Health Care, and Society at the University of Massachusetts Medical School. It introduces the concept of mindfulness and provides the opportunity to practice it within sessions and during home practice. Participants learn about stress, and explore habitual behavioral, physical, emotional and cognitive patterns, as well as more effective responses to challenges and demands of everyday life. Each class includes mindfulness practice, group discussions, and practices and exercises related to the class topics. Participants receive home assignments with guided meditation and yoga practices.
62485171|NCT03949296|PLACEBO_COMPARATOR|Sleep Hygiene|Control group participants attend a 30-minute group counseling session on sleep hygiene. The session includes a handout from the Centre for Clinical Intervention in Australia that provides 15 sleep hygiene tips.
62485172|NCT06376500|EXPERIMENTAL|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds.
62326793|NCT06681207|EXPERIMENTAL|Explore the effects of brain stimulation on locomotor skill learning in stroke survivors|To explore the trends of locomotor skill learning in three groups: stroke survivors after five sessions of anodal tDCS (a-tDCS, real brain stimulation), stroke survivors after five sessions of sham tDCS (s-tDCS), and stroke survivors with no brain stimulation (control; CON).
62326794|NCT06681207|EXPERIMENTAL|determine the effects of a-tDCS on the cortical excitation before and after locomotor learning|measure changes in cortical neuronal activation before and after five sessions of locomotor skill training in healthy adults and stroke participants.
62326795|NCT06681207|EXPERIMENTAL|To explore improvements in learning capacity between healthy adults and stroke participants.|Compare stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group.
62326796|NCT06681207|EXPERIMENTAL|To explore the trends of functional improvements after five tDCS session in stroke survivors|Compare functional improvements (gait performance, balance, motor and cognitive function) between healthy adults and stroke participants after five sessions of brain stimulation.
62326797|NCT06718244|EXPERIMENTAL|intervention group|Administration with Inaticabtagene autoleucel CD19 CAR-T cells in the MRD positive B-ALL patients in CR1.
62326798|NCT04161755|EXPERIMENTAL|Pancreatic Cancer|Radiologically resectable primary pancreatic tumors
62326799|NCT05102006|EXPERIMENTAL|LBL-007&Toripalimab|LBL-007 Injection; dose A or dose B; Q3W
62326800|NCT04843371||Patient Group|All patients undergoing an echocardiogram at Tulane Medical Center may be asked to participate in the study. Doctors, including PI and co-PI, will identify eligible patients from their clinic using their clinical knowledge and expertise and the patients' medical history and records. They will provide patients with information regarding the study and if interested, patients will be consented prior to their scheduled echocardiogram.
62326801|NCT06051864|ACTIVE_COMPARATOR|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62326802|NCT06051864|PLACEBO_COMPARATOR|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
62326803|NCT05696821|OTHER|Cluster 1|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 3 months unexposed and 18 months exposed outcomes."
62326804|NCT05696821|OTHER|Cluster 2|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 4 months unexposed and 17 months exposed outcomes."
62326805|NCT05696821|OTHER|Cluster 3|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 5 months unexposed and 16 months exposed outcomes."
62326806|NCT05696821|OTHER|Cluster 4|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 6 months unexposed and 15 months exposed outcomes."
62326807|NCT05696821|OTHER|Cluster 5|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 8 months unexposed and 13 months exposed outcomes."
62326808|NCT05696821|OTHER|Cluster 6|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 10 months unexposed and 11 months exposed outcomes."
62485173|NCT06376500|SHAM_COMPARATOR|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued.
61933717|NCT06710743|EXPERIMENTAL|Food 9|Maltabella
61933718|NCT06710743|EXPERIMENTAL|Food 10|FutureLife Smart + White Oats
61933719|NCT01397669|OTHER|HIV infection and non HIV infection|
62485174|NCT04210947|EXPERIMENTAL|Foam-roller I-II-III|Participants will use foam roller in following order of 30RPM(I), 15RPM(II) and self-determined(III)
62692767|NCT05526157||Patients with CKD+T2D in Study period I|In the pre-finerenone approval period (Study period I), 4 new-user cohorts to be identified, based on the first use of any drug in these classes: SGLT2i, GLP-1 RA, sMRA, or nsMRA.
62692768|NCT05526157||Patients with CKD+T2D in Study period II|In the post-finerenone study period (study period II), 3 new-user cohorts will be identified: SGLT2i, GLP-1 RA, and finerenone.
62326809|NCT05696821|OTHER|Cluster 7|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 12 months unexposed and 9 months exposed outcomes."
62326810|NCT05696821|OTHER|Cluster 8|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 13 months unexposed and 8 months exposed outcomes."
62326811|NCT05696821|OTHER|Cluster 9|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 14 months unexposed and 7 months exposed outcomes."
62692769|NCT03462121|EXPERIMENTAL|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
62692770|NCT03462121|PLACEBO_COMPARATOR|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
62326812|NCT05696821|OTHER|Cluster 10|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 15 months unexposed and 6 months exposed outcomes."
62326813|NCT03205527|EXPERIMENTAL|Slip training for chronic stroke|Chronic stroke subjects in this training group will receive bilateral overground, slip perturbation training.
62326814|NCT03205527|NO_INTERVENTION|Control for chronic stroke|Chronic stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
62326815|NCT03205527|EXPERIMENTAL|Slip training for sub-acute stroke|Sub-acute stroke survivors in this training group will receive bilateral overground, slip perturbation training.
62326816|NCT03205527|NO_INTERVENTION|Control for sub-acute stroke|Sub-acute stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
62326817|NCT06747611|EXPERIMENTAL|Alopecia Areata study group|randomized to receive antibiotics and MTT oral capsule
62326818|NCT06747611|PLACEBO_COMPARATOR|Alopecia Areata control group|randomized to receive placebo antibiotics and placebo MTT oral capsule
62326819|NCT06746259||Untrained Operator|"Untrained Operators have no training or hands-on experience in conducting laboratory testing (moderate or high complexity). Should not have previous training or experience with FebriDx but may have limited experience with other waived or home use tests.~Untrained operators will test patients with ARI with the FebriDx test after reviewing and familiarizing themselves with the study articles and the manufacturer's instructions (QRI and IFU)."
62326820|NCT06746259||Trained Operator|"Trained operators are qualified to perform moderate complexity testing and have previous training and/or experience with the FebriDx test.~Trained operators will test patients with ARI with the FebriDx test after completing a training seminar which includes review of the test procedure as described in the IFU/QRI, a competency test, interpretation of mock test results, as well as at least one (1) practice test"
62485175|NCT04210947|EXPERIMENTAL|Foam-roller I-III-II|Participants will use foam roller in following order of 30RPM(I), self-determined(III) and 15RPM(II)
62485176|NCT04210947|EXPERIMENTAL|Foam-roller II-I-III|Participants will use foam roller in following order of 15RPM(II), 30RPM(I) and self-determined(III)
62485177|NCT04210947|EXPERIMENTAL|Foam-roller II-III-I|Participants will use foam roller in following order of 15RPM(II), self-determined(III) and 30RPM(I)
62692771|NCT06637072|EXPERIMENTAL|Efgartigimod PH20 SC|Participants start efgartigimod PH20 SC treatment after discontinuing IVIg
61933720|NCT01083173||Participants with HIV-1 infection|Participants treated with Kaletra (lopinavir/ritonavir 200 mg/50 mg and 100 mg/25 mg) tablet
62485178|NCT04210947|EXPERIMENTAL|Foam-roller III-I-II|Participants will use foam roller in following order of self-determined(III), 30RPM(I) and 15RPM(II)
62485179|NCT04210947|EXPERIMENTAL|Foam-roller III-II-I|Participants will use foam roller in following order of self-determined(III), 15RPM(II) and 30RPM(I)
62485180|NCT03574805|ACTIVE_COMPARATOR|PRS-060|PRS-060 or Placebo
62692772|NCT04416815|NO_INTERVENTION|Usual care|The participants allocated to the control group received no intervention. However, they could, on their own initiative, approach the usual range of community or health services (e.g., home help services, rehabilitation, or medical care).
62326821|NCT06748066|EXPERIMENTAL|Group of experts in the field of ACL reconstruction surgery and follow-up|A group of nine experts in the field of ACL reconstruction, each with a minimum of five years of experience and at least 100 patients managed, will collaborate to select the items to be included in the SMART-ACL ( Simple Measure of Attitudes and Risk-Taking after ACL Reconstruction) Scale.
62326822|NCT06748066|EXPERIMENTAL|ACL - reconstruction group, scale validation|Seventy-five patients who have undergone ACL reconstruction within the past two years and are currently in the 'Return to Sport' process, with follow-up in the sports medicine department, will complete the SMART-ACL Scale as part of the validity and reliability testing process.
62326823|NCT06747104|ACTIVE_COMPARATOR|Assessment of acute effects of manipulation and muscle strength|Performing the manipulation with a preliminary two-second tension of the joint capsule in the shoulder and elbow joints.
62326824|NCT06746584|EXPERIMENTAL|Intervention Group|Since patients diagnosed with psychotic disorder and schizophrenia have delusions and hallucinations, the effect of some instructions in the Benson relaxation technique on these symptoms cannot be known. Therefore, it was planned to exclude psychosis and schizophrenia patients with delusions and hallucinations from the study.
62326825|NCT06746584|NO_INTERVENTION|Control Group|Since patients diagnosed with psychotic disorder and schizophrenia have delusions and hallucinations, the effect of some instructions in the Benson relaxation technique on these symptoms cannot be known. Therefore, it was planned to exclude psychosis and schizophrenia patients with delusions and hallucinations from the study
62326826|NCT06747429|EXPERIMENTAL|High fat diet|Patients receiving a high-fat diet
62326827|NCT06747429|ACTIVE_COMPARATOR|Control|Patients receiving a standard diet
62326828|NCT06746220|EXPERIMENTAL|A+ group (probiotic and physical activity)|Microbiota sample Salivary sample Quality of life questionnaires Nutritional evaluation Assessment of physical health Physical activity Treatment with placebo or probiotic
62326829|NCT06746220|EXPERIMENTAL|A- group (probiotic and non-physical activity)|Microbiota sample Salivary sample Quality of life questionnaires Nutritional evaluation Assessment of physical health Physical activity Treatment with placebo or probiotic
62326830|NCT06746220|EXPERIMENTAL|T+ group (placebo and physical activity)|Microbiota sample Salivary sample Quality of life questionnaires Nutritional evaluation Assessment of physical health Physical activity Treatment with placebo or probiotic
62326831|NCT06746220|EXPERIMENTAL|T- group (placebo and non-physical activity)|Microbiota sample Salivary sample Quality of life questionnaires Nutritional evaluation Assessment of physical health Physical activity Treatment with placebo or probiotic
62326832|NCT06747884||Congenital myotonic dystrophy (CDM)|Children with congenital myotonic dystrophy. No intervention will be administered to either group.
62326833|NCT06747884||Childhood Myotonic Dystrophy|Children with childhood myotonic dystrophy. No intervention will be administered to either group.
62326834|NCT03436485|EXPERIMENTAL|ODM-208 Part 1 Dose escalation|
62326835|NCT03436485|EXPERIMENTAL|ODM-208 Part 2 Dose expansion|
62326836|NCT03436485|EXPERIMENTAL|ODM-208 Part 2 Drug drug interaction|
62326837|NCT04768777|EXPERIMENTAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
62326838|NCT04768777|NO_INTERVENTION|waitlist control condition|Participants will have 16-weeks of no intervention or interaction.
62485181|NCT03574805|PLACEBO_COMPARATOR|Placebo|PRS-060 or Placebo
62485182|NCT03168503|EXPERIMENTAL|LGG+Promitor™|LGG:10\^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
62692773|NCT04416815|EXPERIMENTAL|eHealth|The intervention will be delivered for 6 months on top of usual care.
62326839|NCT05536076|ACTIVE_COMPARATOR|Intervention hypercapnia arm|Intermittent hypercapnia treatment five days per week for two weeks.
62326840|NCT05536076|EXPERIMENTAL|SCD|Intermittent hypercapnia treatment five days per week for two weeks.
62485183|NCT03168503|EXPERIMENTAL|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
62485184|NCT03168503|EXPERIMENTAL|LGG-PB12+Promitor™|LGG-PB12:10\^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
62485185|NCT03168503|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
62485186|NCT01958294|OTHER|MICHI Neuroprotection System|Subjects enrolled into this study will be male or female subjects who are candidates for carotid angioplasty and stenting, who, after meeting all of the eligibility criteria, undergo transcervical Carotid Artery Stenting with carotid flow reversal using the MICHI Neuroprotection System.
62485187|NCT03475251|EXPERIMENTAL|CS1003|
62326841|NCT05536076|EXPERIMENTAL|Able-Bodoed|Intermittent hypercapnia treatment five days per week for two weeks.
62485188|NCT03475251|EXPERIMENTAL|CS1003 + regorafenib|
62692774|NCT05802134|EXPERIMENTAL|Fruit and Vegetable recipient|For 4 weeks, the individuals will receive supplemental, culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) supported by intensive education for chronic disease management.
62692775|NCT05269797|EXPERIMENTAL|Health-coaching Intervention|A nurse-lead health coaching intervention to support heart failure self-care management is employed by the nurses. This is a pre-post single group design - there is only one arm.
62485189|NCT04207528|EXPERIMENTAL|Peer Helping Condition|Participants in the peer helping condition will be asked to write about their experiences in their first-year at UCLA (freshman or first-year after post-transfer), with an emphasis on using the experience to benefit someone who is about to be a first-year student.
62485190|NCT04207528|ACTIVE_COMPARATOR|Facts-only Control|Participants in the facts-only writing condition will be asked to write facts about their experiences in their first-year at UCLA (freshman or first-year post-transfer). Unlike the previous conditions, they will not be instructed to write for the benefit of another individual.
62485191|NCT04383587|OTHER|Serologic Arm|Enrolled participants will have COVID19 IgG antibody testing performed.
62485192|NCT06078748|EXPERIMENTAL|EX + DIET|Participants will engage in 3 sessions per week (2 EX, 1 DIET, totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet).
62485193|NCT06078748|ACTIVE_COMPARATOR|EX + ED|Participants will engage in 3 sessions per week (2 EX, 1 ED, totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet).
62485194|NCT06078748|ACTIVE_COMPARATOR|STRETCH + DIET|Participants will engage in 3 sessions per week (2 STRETCH, 1 DIET, totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet).
62485195|NCT06078748|PLACEBO_COMPARATOR|STRETCH + ED|Participants will engage in 3 sessions per week (2 STRETCH, 1 ED) totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet)
62485196|NCT01739647|EXPERIMENTAL|AZD3293|Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg
62485197|NCT01739647|PLACEBO_COMPARATOR|Placebo|Placebo given (2 subjects in each cohort)
62485198|NCT05509023|EXPERIMENTAL|ADX-914|
62485199|NCT05509023|PLACEBO_COMPARATOR|Placebo|
62485200|NCT01749553|EXPERIMENTAL|sleeper stretch|
62485201|NCT01749553|NO_INTERVENTION|no intervention|
62692776|NCT06637410|EXPERIMENTAL|HILT (HILT Group)|HILT group received HILT 3 sessions per week for 3 weeks in addition to the therapeutic exercise program applied 5 sessions per week for 3 weeks. HILT was performed by a single physiotherapist experienced in using a laser device. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. For the biostimulation effect, the continuous wave method was used in phase II. In the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles area for a total energy of 2500 J for 25 minutes and 57 seconds up to 25 cm.
61933721|NCT00736879|EXPERIMENTAL|Dapagliflozin 1 mg|Dapagliflozin: 1 mg
62485202|NCT05567003|OTHER|Patients with benign biliary strictures|Patients with benign biliary strictures with current or prior biliary obstruction, who would otherwise receive standard treatment with long-term biliary tube drainage.
62485203|NCT04692558|EXPERIMENTAL|HYALURONIC ACID|CAF+CTG+HA
62485204|NCT04692558|ACTIVE_COMPARATOR|WITHOUT HYALURONIC ACID|CAF+CTG
62485205|NCT04375943||diabetic HF-pEF patients|It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (\>45%).
62485206|NCT04375943||diabetic HF-rEF patients|It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).
62485207|NCT01717352|ACTIVE_COMPARATOR|Weight Loss Education|Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
62485208|NCT01717352|ACTIVE_COMPARATOR|Sleep and Eating Routine|Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
61933722|NCT00736879|EXPERIMENTAL|Dapagliflozin 2.5 mg|Dapagliflozin: 2.5 mg
61933723|NCT00736879|EXPERIMENTAL|Dapagliflozin 5 mg|Dapagliflozin: 5 mg
61933724|NCT00736879|PLACEBO_COMPARATOR|Placebo|Placebo: 0 mg
62485209|NCT03420092|EXPERIMENTAL|Treatment A|The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours.
62485210|NCT03420092|EXPERIMENTAL|Treatment B|The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours.
62485211|NCT03420092|EXPERIMENTAL|Treatment C|The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours.
62485212|NCT03420092|EXPERIMENTAL|Treatment D|The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours.
62485213|NCT03420092|EXPERIMENTAL|Treatment E|The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours.
62485214|NCT03420092|EXPERIMENTAL|Treatment F|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
62485215|NCT06561191|OTHER|Single Arm|All patients recieve three month of treatment with hemodialysis, hemodiafiltraten, treatment with high flux dialyzer and treatment with low flux dialyzer
62485216|NCT01257633||The study population|Laryngeal cancer patients requiring surgical tumor resection.
62485217|NCT04254133||Case Ascertainment|Men with prostate cancer
62485218|NCT04254133||Family Recruitment|Male relatives of men with prostate cancer
62485219|NCT06617468|EXPERIMENTAL|computer-aided diagnosis with explainable AI|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with explainable AI
62485220|NCT06617468|ACTIVE_COMPARATOR|computer-aided diagnosis with deep learning|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with deep learning
62485221|NCT01660243|ACTIVE_COMPARATOR|MT-9938 2.5μg|
62485222|NCT01660243|ACTIVE_COMPARATOR|MT-9938 5μg|
62485223|NCT01660243|ACTIVE_COMPARATOR|MT-9938 10μg|
62692777|NCT06637410|ACTIVE_COMPARATOR|Ultrasound therapy (US Group)|Ultrasound therapy was performed by a single physiotherapist experienced in using US device. US group received an ultrasound program 3 days a week in addition to a therapeutic exercise program of 5 sessions per week for 3 weeks. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.
62692778|NCT03766399|EXPERIMENTAL|Part 1a (SAD) Cohort 1|6 participants will receive inhaled dose 1 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
62692779|NCT03766399|EXPERIMENTAL|Part 1a (SAD) Cohort 2|6 participants will receive inhaled dose 2 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
61933725|NCT04104334|ACTIVE_COMPARATOR|"Monitored group M (optimized controlled anesthesia)"|"Patients in the Monitored group M, the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume."
61933726|NCT04104334|ACTIVE_COMPARATOR|"Control group C (standard of care anesthesia)"|"Patients in the Control group C will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100."
61933727|NCT01199107|EXPERIMENTAL|Prolonged Exposure + Exercise|
61933728|NCT01199107|ACTIVE_COMPARATOR|Prolonged Exposure + Wellness Intervention|
61933729|NCT04200859|EXPERIMENTAL|Cold application with ice pack|Before the chest tube was removed, two ice packs with a size of 15.5x9cm were inserted around the chest tube so as to make as much contact as possible
61933730|NCT04200859|EXPERIMENTAL|Cold application with gel pad group|Before the chest tube was removed, a gel pad with a radius of 15 cm was completely inserted around the chest tube
61933731|NCT04200859|NO_INTERVENTION|Control group|Routine analgesic drugs are not administered to patients before removal of the chest tube in thoracic surgery clinic. However, analgesic is performed according to the severity of pain after the procedure.
61933732|NCT06707194|EXPERIMENTAL|BPG with ETN|"Blinded BPG with ETN from Week 0 to Week 12, open-label BPG with ETN from Week 12 to Week 24."
61933733|NCT06707194|PLACEBO_COMPARATOR|Placebo with ETN|"Blinded Placebo with ETN from Week 0 to Week 12, open-label BPG with ETN from Week 12 to Week 24."
61933734|NCT03506061|EXPERIMENTAL|Participants With Evidence of Partial Function (sweat chloride < 80 mEq/L or pancreatic sufficiency)|Participants with CF with evidence of partial function (sweat chloride \< 80 milliequivalents per liter (mEq/L) or pancreatic sufficiency) will receive Trikafta for 28 days.
61933735|NCT03506061|EXPERIMENTAL|Participants who Encode the N1303K Variant|Participants with CF who encode the N1303K variant will receive Trikafta for 28 days.
61933736|NCT03225274|EXPERIMENTAL|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
61933737|NCT03225274|NO_INTERVENTION|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
62485224|NCT01660243|PLACEBO_COMPARATOR|Placebo|
62485225|NCT02222064|EXPERIMENTAL|Mindfulness|8 week self-managed mindfulness based intervention
62692780|NCT03766399|EXPERIMENTAL|Part 1a (SAD) Cohort 3|6 participants will receive inhaled dose 3 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
62692781|NCT03766399|EXPERIMENTAL|Part 1a (SAD) Cohort 4|6 participants will receive inhaled dose 4 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
62692782|NCT03766399|PLACEBO_COMPARATOR|Part 1a (SAD) Cohort 5|6 participants will receive inhaled dose 5 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
62692783|NCT03766399|EXPERIMENTAL|Part 1a (SAD) Cohort 6|6 participants will receive inhaled dose 6 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
61933738|NCT03374631|EXPERIMENTAL|Active anodal tDCS, Then Sham tDCS|Active anodal tDCS followed by behavioral testing; one week later, sham tDCS followed by behavioral testing
61933739|NCT03374631|SHAM_COMPARATOR|Sham tDCS, then Active anodal tDCS|Sham tDCS followed by behavioral testing; one week later, active anodal tDCS followed by behavioral testing.
61933740|NCT04918576|EXPERIMENTAL|Tranexamic Acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
61933741|NCT04918576|PLACEBO_COMPARATOR|Normal Saline|40 mL topical of 0.9% normal saline
62133658|NCT03351699|EXPERIMENTAL|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
62485226|NCT06188663|ACTIVE_COMPARATOR|Salt supplementation|Salt supplementation in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
62485227|NCT06188663|NO_INTERVENTION|Usual salt intake (no change in intake)|Usual salt intake (no change in intake)
62485228|NCT01924247|OTHER|Interventional Arm|Interventional Arm
62485229|NCT01924247|OTHER|Control Arm|Control Arm: Standard treatment by family physician
62485230|NCT02278302|EXPERIMENTAL|Aggrenox®|treatment alone or in combination with Ethanol
62485231|NCT02278302|PLACEBO_COMPARATOR|Placebo|treatment alone or in combination with Ethanol
62692784|NCT03766399|EXPERIMENTAL|Part 1b (IV cohort 1)|All 6 participants will receive single IV dose of AZD0449 solution.
61933742|NCT06279013|ACTIVE_COMPARATOR|Arm I - Interactive Voice Response (IVR) Monitoring|Patients receive IVR symptom monitoring calls once a week for 12 weeks, and a summary symptom report is sent to their provider. Call duration is approximately 15 minutes.
62485232|NCT05212350|ACTIVE_COMPARATOR|Pancreatic anastomosis|"Pancreatic anastomosis (PA) will be carried out according to the techniques adopted by the participating Centre, either pancreaticojejunostomy (PJ) (i.e. dunking PJ, Cattel-Warren duct-to-mucosa PJ, Blumgart PJ) or pancreatico-gastrostomy (PG) will be considered eligible. Any mitigation strategy (i.e. ETS, use of glues/biological matrices to protect the anastomosis, surgical feeding jejunostomy, prophylactic hydrocortisone/somatostatin administration) can be used according to the Center practice. The other two anastomosis, hepaticojejunostomy and duodenojejunostomy (in case of Longmire-Traverso pancreatoduodenectomy) or gastrojejunostomy (in case of Kausch-Whipple pancreatoduodenectomy), will be carried out as usual according to each Institution's operative standards.~At least one surgical drain will be placed in the retroperitoneum in all patients."
62485233|NCT05212350|EXPERIMENTAL|Total pancreatectomy|Total pancreatectomy will be carried out according to each Institution's operative standards. Preservation of the spleen will be considered whenever possible according to Kimura technique. Either ligation or preservation of gastric vessels (right/left gastric artery/vein) will be allowed according to clinical necessity but will be recorded and correlated with postoperative outcomes. The reconstruction phase will be carried out according to each Institution's operative standards. One or more surgical drains can be left in place according to surgeon's preference.
62485234|NCT03476226|EXPERIMENTAL|Group 1|"The research team will provide the intervention to subjects. Intervention: The nursing-driven Cognitive Dysfunction Coping Strategy Teaching Sheet and provide education as to its use.~QOL survey administered"
62485235|NCT03476226|NO_INTERVENTION|Group 2|Provide current standard of education for cognitive dysfunction. QOL survey administered
62326842|NCT06477419|EXPERIMENTAL|Participants with Mesothelioma|Participants will have pathologically confirmed diffuse pleural mesothelioma. Patients will undergo cross-sectional imaging after the first 2 cycles and subsequently after every 3 cycles until disease progression. Biopsies will take place at screening, prior to cycle 3, and an optional biopsy at the end of treatment if consent was obtained and deemed to be safe and feasible.
62326843|NCT06717425|EXPERIMENTAL|PF-07976016 Dose 1|
62326844|NCT06717425|EXPERIMENTAL|PF-07976016 Dose 2|
62326845|NCT06717425|EXPERIMENTAL|PF-07976016 Dose 3|
62326846|NCT06717425|PLACEBO_COMPARATOR|Placebo|
62326847|NCT06747143|EXPERIMENTAL|Intervention group|Healthy subjects
62326848|NCT06746558|EXPERIMENTAL|Potassium Nitrate Gel with Diode Laser Therapy|
62326849|NCT06746558|ACTIVE_COMPARATOR|Potassium Nitrate Gel Alone|
62326850|NCT06747052||Adults residents in Lombardia Region|Adults with age ranging between 18 and 64 years, residents in Lombardia Region and spoken/reader Italian language
62326851|NCT06716879|EXPERIMENTAL|Low Dose of donzakimig in Chinese participants|Chinese participants will be randomized to receive a predefined dosage of donzakimig.
62326852|NCT06716879|EXPERIMENTAL|High Dose of donzakimig in Chinese participants|Chinese participants will be randomized to receive a predefined dosage of donzakimig.
62326853|NCT06716879|PLACEBO_COMPARATOR|Low Dose of placebo in Chinese participants|Chinese participants will be randomized to receive a predefined dosage of placebo.
62485236|NCT05442034|EXPERIMENTAL|recombinant human platelet derived growth factor (rh-PDGF) in combination with bone allograft|recombinant human platelet derived growth factor is a protein that is found in blood serum. It helps to recruit stem cells into the area to aid in cell differentiation and proliferation. When added to mineralized bone allograft, it stimulates the angiogenesis in the area, and this in turn may increase the outcomes of regeneration.
62485237|NCT05442034|ACTIVE_COMPARATOR|Enamel matrix derivatives (EMD) in combination with bone allograft.|Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle. It has been available for decades and has been proved to help in regeneration of intrabony defects when applied into the root surface. When combined with bone allograft, it results in regeneration of intrabony defects.
62485238|NCT01515163|EXPERIMENTAL|Exercise|3-month exercise training program
62692785|NCT03766399|EXPERIMENTAL|Part 2a (MAD) Cohort 1|6 participants will receive inhaled dose 7 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
61933743|NCT06279013|EXPERIMENTAL|Arm II - Automated Telephone Symptom Management (ATSM), TIPC|Patients receive the Symptom Management and Survivorship handbook and receive IVR symptom monitoring calls for 12 weeks, with summary symptom reports sent to their provider. Call duration is approximately 20 minutes. Patients who report anxious, discouraged, or sad mood items on their monitoring calls for two consecutive weeks between weeks 1 and 4 also receive Telephone Interpersonal Counseling (TIPC) calls for up to 8 weeks. TIPC call duration is approximately 30 minutes.
62326854|NCT06716879|PLACEBO_COMPARATOR|High Dose of placebo in Chinese participants|Chinese participants will be randomized to receive a predefined dosage of placebo.
62326855|NCT06716879|EXPERIMENTAL|Low Dose of donzakimig in Japanese participants|Japanese participants will be randomized to receive a predefined dosage of donzakimig.
62326856|NCT06716879|EXPERIMENTAL|High Dose of donzakimig in Japanese participants|Japanese participants will be randomized to receive a predefined dosage of donzakimig.
62326857|NCT06716879|PLACEBO_COMPARATOR|Low Dose of placebo in Japanese participants|Japanese participants will be randomized to receive a predefined dosage of placebo.
62326858|NCT06716879|PLACEBO_COMPARATOR|High Dose of placebo in Japanese participants|Japanese participants will be randomized to receive a predefined dosage of placebo.
62326859|NCT06747195||the MB Group|a subcutaneous injection of 0.1% MB (1% MB 1 ml + 0.1% ropivacaine 4 ml + 0.9% saline 5 ml) will be administered with a skin test needle at the edge of the perianal incision
62326860|NCT06747195||the ketorolac group|Patients in the ketorolac group will receive 30 mg of intravenous ketorolac ( Shandong New Times Pharmaceutical Co., Ltd, 1ml:30mg) at the beginning of the procedure.
62326861|NCT06746545|EXPERIMENTAL|Experimental|
62133659|NCT01243814|ACTIVE_COMPARATOR|supartz|active intervention arm
62326862|NCT06746805|EXPERIMENTAL|CHO+KETONE|Interventional drink with glucose + ketone monoester
62326863|NCT06746805|PLACEBO_COMPARATOR|CHO+PLACEBO|Placebo drink with glucose + placebo
62485239|NCT01515163|NO_INTERVENTION|Control|Control group
62485240|NCT01515163|EXPERIMENTAL|Healthy control|
62485241|NCT04819386|EXPERIMENTAL|Active group|18 half-hour in-office active vision therapy sessions with the NEIVATECH Virtual Reality-based system
62485242|NCT02189811|EXPERIMENTAL|IPV|IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
62485243|NCT02189811|EXPERIMENTAL|bOPV|bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
62485244|NCT02189811|EXPERIMENTAL|bOPV and IPV|bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
62485245|NCT02189811|EXPERIMENTAL|bOPV and IPV and IPV2|bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
62485246|NCT02189811|ACTIVE_COMPARATOR|tOPV|tOPV at birth, 6, 10, 14, 18 and 22 weeks of age
62485247|NCT02013882||1-1-12 wash-in|wash-in using O2:N2O 1:1 L/min with desflurane 12%
62485248|NCT06416241|OTHER|Eylea 2.0mg/0.05ml|
62485249|NCT06056115|EXPERIMENTAL|Tislelizumab Combined With Platinum-containing Drug Chemotherapy|"1. Tislelizumab PD-1 inhibitor~2. Platinum-containing drug chemotherapy"
62485250|NCT00819169|EXPERIMENTAL|Part 1 Cohort 3|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)
62485251|NCT00819169|EXPERIMENTAL|Part 1 Cohort 1|AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)
62485252|NCT00819169|EXPERIMENTAL|Part 1 Cohort 2|AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)
62485253|NCT00819169|EXPERIMENTAL|Part 2|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg Q3W, or the MTD, as determined in Part 1 of the study
62485254|NCT02075333|ACTIVE_COMPARATOR|Sucrose (50g)|A 381g blackcurrant drink (cordial and water) providing 50g of sucrose
62485255|NCT02075333|PLACEBO_COMPARATOR|Sucralose (0.92 g sugars)|A 381g blackcurrant drink (cordial and water) providing 0.92g of natural sugars
62485256|NCT01943877|EXPERIMENTAL|Propolis|
62485257|NCT01943877|SHAM_COMPARATOR|scaling and root planing|
62485258|NCT02435264|EXPERIMENTAL|Healthier Dining Program Intervention|Food centers that receive the Healthier Dining Program (HDP)
62485259|NCT02435264|NO_INTERVENTION|Control centers|Food centers that do not receive the Healthier Dining Program (HDP)
62485260|NCT05772702|EXPERIMENTAL|Closed-loop tACS|Closed-loop individual alpha tACS daily for five consecutive days.
62485261|NCT04963270|EXPERIMENTAL|Satralizumab|Participants will receive Satralizumab at Weeks 0, 2, 4, and Q4W thereafter. Adolescent patients who first enter the study in the OLE period will receive satralizumab SC loading doses at Week 0, 2, and 4 in the OLE, followed by maintenance doses Q4W thereafter and will remain on stable background therapy until Week 24 of the OLE.
62692786|NCT03766399|EXPERIMENTAL|Part 2a (MAD) Cohort 2|6 participants will receive inhaled dose 8 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
62485262|NCT04963270|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo at Weeks 0, 2, 4, and Q4W thereafter
62485263|NCT01146223||Basic science (correlative studies)|Patient mRNA samples from diagnosis are analyzed via quantitative PCR to measure WT1 and VEGF-1 expression.
62485264|NCT03045458|ACTIVE_COMPARATOR|Tissue level dental implant|Tissue level dental implants (Straumann AG, Waldenburg, Switzerland) were inserted in patients group I (n=20).
62692787|NCT03766399|EXPERIMENTAL|Part 2b (MAD/healthy volunteers) Cohort 3|18 healthy volunteers will receive inhaled dose 9 of AZD0449 nebulized suspension and 12 healthy volunteers will receive inhaled placebo.
62692788|NCT03766399|EXPERIMENTAL|Part 3a (DPI/PoM)|18 participants will receive inhaled dose 10 of AZD0449 DPI and 6 participants will receive inhaled placebo.
62485265|NCT03045458|ACTIVE_COMPARATOR|Bone level dental implant|Bone level dental implants (Straumann AG, Waldenburg, Switzerland ) were inserted in patients group II (n=20).
62485266|NCT04764175|EXPERIMENTAL|Telephone All Nations Breath of Life|This is a culturally targeted smoking cessation program developed for American Indian communities. It includes individual telephone counseling, text messaging, and educational materials.
62485267|NCT04764175|ACTIVE_COMPARATOR|Comparison Program|This is a non-culturally targeted smoking cessation program. It includes individual counseling, text messaging, and educational materials.
62485268|NCT06475651||Workpackage 1, group 1|Patients (children) with CHARGE syndrome
62485269|NCT06475651||Workpackage 1, group 2|Healthy negative controls (children) matched for age and sex
62485270|NCT06475651||Workpackage 1, group 3|Fetuses with CHARGE syndrome
62485271|NCT06475651||Workpackage 1, group 4|Fetuses with no genetic pathology
62485272|NCT06475651||Workpackage 2, group 5|Patients (children) with KABUKI syndrome
62692789|NCT03766399|EXPERIMENTAL|Part 1b (IV cohort 2)|6 healthy volunteers will receive single IV dose of AZD0449 solution.
62692790|NCT03766399|EXPERIMENTAL|Part 3b (DPI/healthy volunteers)|Part 3b is optional. 8 healthy volunteers; 6 volunteers will receive AZD0449 DPI and 2 volunteers will recieve placebo.
62692791|NCT03208790|EXPERIMENTAL|Group A|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 10mg for 3 months.
62133660|NCT01243814|PLACEBO_COMPARATOR|saline injection|placebo intervention arm
62485273|NCT06475651||Workpackage 2, group 6|Fetuses with KABUKI syndrome
62485274|NCT06475651||Workpackage 3, group 7|Fetuses with hydrolethalus syndrome
62485275|NCT06475651||Workpackage 3, group 8|Fetuses with Meckel/OFD IV syndrome
62485276|NCT06475651||Workpackage 3, group 9|Fetuses with Fowler syndrome
62485277|NCT00948792|ACTIVE_COMPARATOR|Long transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of two hours.
62485278|NCT00948792|EXPERIMENTAL|Short transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of 30 minutes.
62485279|NCT02412358|ACTIVE_COMPARATOR|Pulsar|Patients use Pulsar toothbrush for plaque removal
62485280|NCT02412358|ACTIVE_COMPARATOR|Crossaction|Patients use Crossaction toothbrush for plaque removal
62485281|NCT02412358|ACTIVE_COMPARATOR|Butler|Patients use Butler toothbrush for plaque removal
62485282|NCT06354023|EXPERIMENTAL|Intra-articular Injection of Recombinant Human Growth Hormone|
61933744|NCT02506946||PCOS subjects|Forty adolescents and young adults between the ages of 14 and 25 years with Polycystic Ovary Syndrome (PCOS) at least two years past menarche.
62692792|NCT03208790|EXPERIMENTAL|Group B|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 5mg for 3 months.
61933745|NCT02506946||Control subjects|Forty unaffected adolescents and young adults between the ages of 14 and 25 years at least two years past menarche.
61933746|NCT00229151|EXPERIMENTAL|Sleep deprivation|Sleep deprivation and sleep phase advancement
62326864|NCT06747507|EXPERIMENTAL|Continue on DTG-based Therapy|Participants in this arm will continue their pre-randomization DTG-based ART regimen
62326865|NCT06747507|ACTIVE_COMPARATOR|Switch to PI-based Therapy|Participants in this arm will be switched to ritonavir-boosted darunavir (DRV/r)-based ART regimen on the day of randomization
62326866|NCT06746506|EXPERIMENTAL|Amigurumi toy, pain and fear|
62326867|NCT06746506|NO_INTERVENTION|control not pain and fear|
62326868|NCT06746896||Healthy Controls|Absence of neurological symptoms or known diagnosis, absence of a known gastrointestinal pathology.
62326869|NCT06746896||Newly diagnosed MS patients|Absence of a known gastrointestinal pathology.
62692793|NCT03208790|PLACEBO_COMPARATOR|Group 3|patients with oral premalignant lesions will receive placebo buccal tablets for 3 months.
62692794|NCT00035984|EXPERIMENTAL|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
62692795|NCT00035984|EXPERIMENTAL|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
62692796|NCT00035984|PLACEBO_COMPARATOR|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
61933747|NCT00229151|ACTIVE_COMPARATOR|usual treatment|
61933748|NCT00739050|EXPERIMENTAL|1|Arm 1: Drug
62133661|NCT03610594|EXPERIMENTAL|kalaripayattu|The experimental groups will treated with kalaripayattu exercises for the period of 12 weeks
62692797|NCT00035984|PLACEBO_COMPARATOR|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
62692798|NCT03312543|EXPERIMENTAL|Active Cell: Active Mask|Cleanser, Moisturizer, Active Mask
62692799|NCT03312543|SHAM_COMPARATOR|Sham Cell: Sham Mask|Cleanser, Moisturizer, Sham Mask
62133662|NCT03610594|NO_INTERVENTION|Wait list control|Control group will not be given any intervention. After the treatment period is over, all the subjects will be given Kalaripayattu training.
62133663|NCT04881175|EXPERIMENTAL|FlexSure Applicator|The TempSure FlexSure applicator will be used on the abdomen or flanks.
62326870|NCT06747091|ACTIVE_COMPARATOR|PVI using PFA energy|Pulmonary vein isolation using PFA energy
62326871|NCT06747091|ACTIVE_COMPARATOR|PVI and posterior wall isolation using PFA energy|Pulmonary vein isolation and posterior wall isolation using PFA energy
62326872|NCT06747091|ACTIVE_COMPARATOR|PVI and posterior wall isolation (PFA) and mitral isthmus ablation using RFA or PFA energy.|Pulmonary vein isolation and posterior wall isolation (PFA) and mitral isthmus ablation using RFA or PFA energy.
62326873|NCT06747780|EXPERIMENTAL|Intervention group|Participants and their eligible family members in the intervention group will receive a digital booklet via MMS and daily text messages related to happy family meals via SMS for two weeks. The content of these messages will be based on five positive psychology themes: joy, gratitude, flow, savoring, and listening, adapted from the Happy Family Kitchen II project. Participants in the intervention group will receive notifications prompting them to join two family-based activities, adapted from the Happy Family Kitchen II project, as boosters at one-month and three-month after they receive the daily SMS, respectively.
62326874|NCT06747780|OTHER|Waitlist control group|Participants in the waitlist control group will not receive the intervention immediately but will be offered the same 14-day SMS intervention and two family-based activities three months post-intervention.
62326875|NCT06742957|EXPERIMENTAL|Test: Tapinarof Cream 1%|Tapinarof Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days.
62692800|NCT06637111|ACTIVE_COMPARATOR|Ultrasound guided office hysteroscopy group|"All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.~Transabdominal ultrasound will be used to guide the access of the hysteroscope to the uterine cavity"
62692801|NCT06637111|ACTIVE_COMPARATOR|Conventional office hysteroscopy group|"All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia."
61933749|NCT00739050|PLACEBO_COMPARATOR|2|Arm 2: Placebo
61933750|NCT06709885|EXPERIMENTAL|Chidamide + Tislelizumab + chemotherapy (CapeOX )|4 cycles of combination therapy (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; tislelizumab, 200mg/m2 iv.gtt; Day1,4,8,11Chidamide 20 mg BIW,PO; Day1-Day14, capecitabine 850-1000mg/m2, BID, PO)
61933751|NCT06709885|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy (CapeOX)|4 cycles Capeex (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ）
62133664|NCT00739908|EXPERIMENTAL|CX157 (TriRima)|
62133665|NCT00739908|PLACEBO_COMPARATOR|Placebo|
62133666|NCT02107261|ACTIVE_COMPARATOR|Placebo Then Botulinum Toxin|Placebo dose first does then boosters at week 2 and week 4 then 4 weeks washout, then Incobotulinumtoxin A first dose, with boosters at 2 week and week 4.
62326876|NCT06742957|ACTIVE_COMPARATOR|VTAMA®|(Tapinarof) Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days.
62326877|NCT06742957|PLACEBO_COMPARATOR|Vehicle Product|Vehicle of the Test Product, Cream, Apply a thin layer once daily to psoriatic affected areas for 84 days.
62326878|NCT05466838|EXPERIMENTAL|PERT plus Standard of Care|Initiation of PERT at time of discharge post pancreaticoduodenectomy with dose escalation upon symptom presentation
62326879|NCT05466838|OTHER|Standard of Care|Standard of care (no PERT) until presentation of PEI symptoms.
62326880|NCT06745336|EXPERIMENTAL|CS-001|CS-001 Topical Treatment
62326881|NCT06745336|PLACEBO_COMPARATOR|Placebo|Placebo Topical Treatment
62326882|NCT06691698|EXPERIMENTAL|CO-OP for adolescents with mild intellectual disability|CO-OP intervention during 10 weeks. Outcomes measures at baseline, directly after and 6 months after intervention
62485283|NCT05419739||Group 1|Children under 18 years of age with traumatic brain injury
61933752|NCT05753527|EXPERIMENTAL|Progressive relaxation exercise group|The students in the intervention group will be given progressive relaxation exercises before the simulation application. Before and after the simulation, vital signs will be taken and scales will be applied.
61933753|NCT05753527|NO_INTERVENTION|The group not applied progressive relaxation exercise|The students in the control group will be taken into the simulation application without applying relaxation exercises. Before and after the simulation application, vital signs will be taken and scales will be applied.
61933754|NCT03148275|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 52 cycles in the absence of disease progression or unacceptable toxicity.
61933755|NCT02637622||Best-Worst Scaling (Case 2)|Preference measured by best-worst scaling (case 2)
61933756|NCT02637622||Discrete Choice Experiment|Preference measured by discrete choice experiment
61933757|NCT03472872|EXPERIMENTAL|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
61933758|NCT03472872|EXPERIMENTAL|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
61933759|NCT06706856||Cohort|This is a single arm study in which all participants undergo the same research procedures.
62133667|NCT02107261|ACTIVE_COMPARATOR|Incobotulinumtoxin A Then Placebo|Incobotulinumtoxin A dose first does then boosters at week 2 and week 4 then 4 weeks washout, then Placebo first dose, with boosters at 2 week and week 4.
62133668|NCT00415402|PLACEBO_COMPARATOR|placebo|non vitamin D containing sugar granules
62133669|NCT00415402|EXPERIMENTAL|Vitamin D3|vitamin D granules
62133670|NCT00133250|EXPERIMENTAL|A|Abciximab
62133671|NCT00133250|PLACEBO_COMPARATOR|B|Heparin Sodium
62326883|NCT06726018|EXPERIMENTAL|High Exposure (HE)|Participants will receive five sessions total: four sessions of the Intervention, CPM and TMS as an outcome in every session and questionnaires and QST as an outcome in the first and fifth sessions.
61933760|NCT00572897|EXPERIMENTAL|Fludarabine, Melphalan +/- ATG|Fludarabine, Melphalan +/- ATG
62133672|NCT04503772|EXPERIMENTAL|Experimental arm (all patients)|"Patients will receive preoperative hypofractionated stereotactic radiosurgery (SRS).~According to the association of french-speaking neuro-oncologists (ANOCEF) recommendations, total dose and fractionation will be 33 Gy in 3 fractions at the isocenter, 23.1 Gy in envelope (70% isodose), i.e. 30 Gy in growth tumor volume (GTV) envelope.) Surgery will take place within 3 days of the preoperative SRS."
62133673|NCT01718600||Neuroimaging Correlates|Carotid revascularization can significantly reduce the risk of stroke in patients with severe carotid stenosis; however, it has been associated with cognitive decline in 25% of the older adults who undergo the procedure. Neuroimaging techniques that characterize white matter integrity and regional hypoperfusion have the potential to provide sensitive brain structure indicators that may be associated with memory decline following revascularization procedures. In this proposal, we hope to determine the risk factors and cognitive effect of microembolization following carotid revascularization procedures.
62133674|NCT02932761|EXPERIMENTAL|VR + GnRHa|CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
62133675|NCT02932761|PLACEBO_COMPARATOR|VR|CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
62133676|NCT03920592|EXPERIMENTAL|Video watching|"All participants will watch 4 videos of potential everyday school situations, adapted for boys and girls.~Videos contain different levels of bullying (presence/absence) and virtual reality (presence/absence).~Every pupil will watch the 4 types of video content randomly."
62133677|NCT05770427|EXPERIMENTAL|Intervention group|
62133678|NCT03432338||idiopathic parkinson|Classical Parkinson´s disease, idiopathic
62133679|NCT03432338||secondary parkinsonism|parkinsonism due to other reasons than idiopathic
62326884|NCT06726018|ACTIVE_COMPARATOR|Low Exposure (LE)|Participants will receive only two sessions in total: one session of the intervention, questionnaires, quantitative sensory testing, CPM and TMS as an outcome at both sessions.
61933761|NCT06553170||before|all patients before the presentation of new protocol about management of diabètes in perioperative urology et visceral surgery
61933762|NCT06553170||after|all patients after the presentation of new protocol about management of diabètes in perioperative urology et visceral surgery
62133680|NCT03432338||controls|persona matched by age and gender, non parkinsonism
62326885|NCT06747663||Cervical Epidural Injection Group|Participants undergoing cervical epidural injections for chronic neck and radicular pain. Needle depth will be measured pre-procedurally using MRI and ultrasound and compared with fluoroscopy-guided needle placement to assess reliability and radiation exposure.
62326886|NCT06747234|EXPERIMENTAL|Oat bran|Daily consumption of oat bran along with standard medical treatment
62326887|NCT06747234|OTHER|Control|Standard medical treatment
62326888|NCT06746857|EXPERIMENTAL|Accelerated iTBS|
62326889|NCT06747559|EXPERIMENTAL|Vitamin D oral supplement|Using vitamin D oral supplement that has been widely used in clinic
61933763|NCT06707311|ACTIVE_COMPARATOR|patients received calcium hydroxide with resin composite|patients received calcium hydroxide lining material then restored with resin composite
61933764|NCT06707311|ACTIVE_COMPARATOR|patients received TheraCal LC with resin composite|patients received TheraCal LC lining material then restored with resin composite
61933765|NCT06707311|ACTIVE_COMPARATOR|patients received universal bonding with resin composite|patients received universal bonding as lining material then restored with resin composite
61933766|NCT06707311|ACTIVE_COMPARATOR|patients received bioactive bonding with resin composite|patients received bioactive bonding as lining material then restored with resin composite
62133681|NCT03399604|EXPERIMENTAL|LIQ861 Inhaled Treprostinil|"LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.~LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg to 150 μg treprostinil QID in individual patients."
62133682|NCT01139944||Group 1|Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
62133683|NCT00078624|EXPERIMENTAL|1|Traditional exercise program supplemented with knee stability training activities
62692802|NCT04681885|EXPERIMENTAL|Tapered bristles A|Test toothbrush with tapered bristle
62692803|NCT04681885|ACTIVE_COMPARATOR|Tapered bristles B|Test toothbrush with tapered bristle
62692804|NCT04681885|ACTIVE_COMPARATOR|End rounded bristles|Conventionla toothbrush with end rounded bristle
62692805|NCT05269082||Cohort 1|Pediatric and adult participants who are on Gammagard S/D prescribed for any approved indication will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
61933767|NCT01854203|EXPERIMENTAL|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
61933768|NCT01854203|EXPERIMENTAL|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
61933769|NCT06704776|EXPERIMENTAL|"The medially pedicled IPFP flap group"|"In the The medially pedicled IPFP flap group, the IPFP was exposed and separated, and the lateral side was left intact and the medial side was tipped to form a complete medially tipped IPFP flap, and the IPFP flap was clipped and draped over the medial side to avoid interference of the IPFP with the operative field. After successful implantation of the prosthesis, the IPFP was fixed with in situ sutures."
61933770|NCT06704776|ACTIVE_COMPARATOR|"Complete IPFP removal group"|"In the Complete IPFP removal group, the entire IPFP was resected from below the patellar tendon prior to femoral preparation."
61933771|NCT06569251|EXPERIMENTAL|Group intervention (shortened dexamethasone regimen)|Dexamethasone 12 mg IM every day for 2 days. Total dose: 24 mg
61933772|NCT06569251|ACTIVE_COMPARATOR|Group control (conventional dexamethasone regimen)|Dexamethasone 6 mg IM every 12 hours for 2 days. Total dose: 24 mg.
61933773|NCT06707779|EXPERIMENTAL|PNF with electrical stimulation|participants in this arm receive PNF with electrical stimulation to reduce pain and functional disability in patients with chronic lumbar radiculopathy
61933774|NCT06707779|EXPERIMENTAL|PNF without electrical stimulation|participants in this arm receive PNF without electrical stimulation to reduce pain and functional disability in patients with chronic lumbar radiculopathy
61933775|NCT06338748|OTHER|Single Arm|All patients will receive the Dexcom G7 continuous glucose monitor (CGM)
61933776|NCT00674973|EXPERIMENTAL|Erlotinib|Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
61933777|NCT00674973|PLACEBO_COMPARATOR|Placebo|Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
61933778|NCT02818231||NON EXPOSED|"Male, \>50 years, unexposed to wood dust, without any nasal pathology, without known tumor~-\> Brushing of the olfactory cleft"
61933779|NCT02818231||EXPOSED|"Male, \>50 years, exposed to wood dust, without any nasal pathology, without known tumor~-\> Brushing of the olfactory cleft"
61933780|NCT02588937|EXPERIMENTAL|EntecaBell ODT.|
61933781|NCT02588937|ACTIVE_COMPARATOR|Baraclude Tab.|
61933782|NCT05262725|EXPERIMENTAL|Values-based Behavioral Activation (BA)|
61933783|NCT06710002|EXPERIMENTAL|Asynchronous Online Telerehabilitation Program|"For this study, a five weeks course called Pelvify: Menopause and dyspareunia treatment will be created. This will be based on a set of explanatory and demonstrative videos focused on self-treatment of pain during sexual intercourse.~Each patient will have an individual access (own user). All groups in the sixth week will have a face-to-face visit to assess their progress. A telephone follow-up will be carried out at six months and twelve months after the end of the treatment."
62133684|NCT00078624|ACTIVE_COMPARATOR|2|Traditional exercise program
62133685|NCT00931710|EXPERIMENTAL|Valsartan/amlodipine/HCTZ|Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.
62133686|NCT00931710|ACTIVE_COMPARATOR|Losartan/HCTZ|Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.
62326890|NCT06747559|NO_INTERVENTION|No vitamin D supplementation|
62326891|NCT06608212||Finerenone group|Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) initiating finerenone. Retrospective analysis using secondary data collection from existing healthcare data from the US. Considered data sources include the HealthVerity Chronic Kidney Disease Masterset
62485284|NCT02553863|EXPERIMENTAL|Intervention group|Acupuncture for 30min \[twice weekly for 8 weeks\]
62692806|NCT05269082||Cohort 2|Pediatric and adult participants who were previously treated with Gammagard S/D prescribed for any approved indication and are on another human immunoglobulin treatment will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
61933784|NCT06710002|ACTIVE_COMPARATOR|Face to Face Physical Therapy Protocol|"This consists of carrying out 5 individual sessions of 45 minutes, 1 day a week at the physiotherapy clinic RAPbarcelona S.L.~Patients will be placed comfortably supine with a pillow under their head, with their legs flexed on two leg warmers, in the lithotomy position, without underwear and covered with a drape.~In each of the treatment sessions, the same structure will always be applied and the established protocol will be followed.~All groups in the sixth week will have a face-to-face visit to assess their progress. A telephone follow-up will be carried out at six months and twelve months after the end of the treatment."
61933785|NCT06710002|ACTIVE_COMPARATOR|Face to Face Protocol Combined With an Asynchronous Telerehabilitation Program|"This group will carry out the same 5 individual sessions of 45 minutes, 1 day a week at the RAPbarcelona S.L physiotherapy clinic following the protocol described for the Face to Face Physical Therapy Protocol group and in addition to the first visit they will be given access and instructions to follow in parallel the asynchronous online telerehabilitation program Pelvify: Menopause and dyspareunia treatment.~All groups in the sixth week will have a face-to-face visit to assess their progress. A telephone follow-up will be carried out at six months and twelve months after the end of the treatment."
61933786|NCT05841901|EXPERIMENTAL|Huang-long Zhi-xiao Granule|Huang-long Zhi-xiao Granule, Honey ephedra 6g, shot dried 10g, earth dragon 10g, Ganoderma lucidum 20g, Qianhu 12g, perilla seed 10g, Zhejiang fritillary 9g, soaphorn thorn 9g, scorched mulberry white peel 20g, fried white nuts 10g, fructus nume 10g, licorice 6g.
61933787|NCT05841901|PLACEBO_COMPARATOR|Huang-long Zhi-xiao Granule placebo|The Huang-long Zhi-xiao Granule placebo is prepared by adding 5% of the drug on the basis of dextrin and bitter agent, and its appearance, weight, color and smell are consistent with Chinese medicine granules.
61933788|NCT03183011|OTHER|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
61933789|NCT00287079|EXPERIMENTAL|Rebif®|
61933790|NCT00287079|OTHER|No Treatment|
61933791|NCT05345054||Phase 1|Study Population and Enrollment. To ensure survey feasibility and acceptability for our target population we will purposively recruit older African American patients at each of the three participating sites. Using conservative estimates of clinical volume as well as US county level census data we estimate enrolling 3 elderly (\>65 years of age) African American participants per site per week with a target enrollment of 12 patients per site.
61933792|NCT05345054||Phase 2|To gain a broad understanding of barriers to surgical access and care in the Deep South, each study site will conduct key informant interviews. Participants will be recruited from five socioecological levels: patient, caregivers/provider, organizational, community, and policy-levels. At each site, two key informant interviews will be performed at each socioecological level (2 patients, 2 caregivers, 2 providers, 2 organizational leaders, 2 community leaders, and 2 policy leaders = 12 per site). We will purposively sample 100% of the participants at the patient and caregiver level (n=12) to be African American and \>65 years old.
61933793|NCT05345054||Phase 3|"Enrollment Process. Eligibility criteria for this phase of study enrollment will be broadened to include all English-speaking patients \>18 years of age undergoing or having recently undergone (\<7 days) an ACS-NSQIP defined surgical procedure. At each site, eligible participants will be approached by a trained research associate pre-operatively in clinic (for elective cases) or post-operatively in the hospital (for emergency cases \<7 days). Because each enrollment site has a unique schedule, site representatives will coordinate the most efficient weekly schedule.~We expect to reach our target enrollment (100 participants total, 33 at each site) in 1 year based on conservative estimates of clinical case volume. We expect to enroll at least 20% elderly participants (\>65 years of age) and between 30-50% African American participants based on county level (Greenville - Butler County, Demopolis - Marengo County, Alexander City - Tallapoosa County) census data."
61933794|NCT06706596||Vulnerable populations residing in the Barcelona metropolitan area with a high risk of developing TB|Individuals from vulnerable populations residing in the Barcelona metropolitan area who are at high risk of developing tuberculosis (i.e. war refugees, migrants, individuals living in socio-deprived neighborhoods)
61933795|NCT01316354|EXPERIMENTAL|Beta-glucan|Bread with purified beta-glucan
61933796|NCT01316354|EXPERIMENTAL|Rye kernels|Rye bread with kernels
61933797|NCT01316354|EXPERIMENTAL|White bread|White bread
61933798|NCT01316354|EXPERIMENTAL|Arabinoxylan|Bread with Purified arabinoxylan
61933799|NCT00799110|EXPERIMENTAL|Group 2|Vaccine, GM-CSF and imiquimod,
61933800|NCT00799110|EXPERIMENTAL|Group 1|Vaccination plus GM-CSF
61933801|NCT06708442|EXPERIMENTAL|Intervention Writing Group A (WA)|First, the guardian of the participant will read the informed consent. After the guardian signs the informed consent, the participant will complete the demographic, emotional and cognitive pre-assessment. The participant will then receive a group cognitive behavioral intervention for 40 minutes each day in the following 3 days. The intervention will take place in school classrooms in a format similar to offline school classes. The therapists are one senior undergraduate and one first-year PhD student from the School of Psychological and Cognitive Sciences who have received sufficient training. The intervention based on the theory of children's cognitive behavioral therapy, with a self-compiled manual. The three sessions are aimed at emotional awareness and management, thoughts recognition, and coping. Each session will be accompanied by the presence of the head teachers.
61933802|NCT06708442|ACTIVE_COMPARATOR|Drawing Group A (DA)|For DA group, the procedures of informed consent, pre assessments, cognitive behavior group intervention, and follow-up assessments will be the same as those for WA. After completing the group intervention, the participants in DA will be required to complete the GNT drawing in accordance with the guidelines at a fixed time each day, under the guidance and supervision of the school teachers, and to complete two short mood tests and the post-painting assessments in the following 3 days. Each drawing session will last for 20-30 minutes.
61933803|NCT01698112|EXPERIMENTAL|Flaxseed High Dose|
61933804|NCT01698112|EXPERIMENTAL|Flaxseed Low Dose|
61933805|NCT01698112|NO_INTERVENTION|Flaxseed control|
62485285|NCT02553863|OTHER|Control group|Standard care
62326892|NCT06608212||Comparator group|Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) not using finerenone. Retrospective analysis using secondary data collection from existing healthcare data from the US. Considered data sources include the HealthVerity Chronic Kidney Disease Masterset
62485286|NCT04463108||Participants with MDD and Active Suicidal Ideation with Intent|Participants with Major Depressive Disorder (MDD) and active suicidal ideation with intent as defined/confirmed by Investigator will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical records of each participant.
62485287|NCT05906251|EXPERIMENTAL|SRP-6004|Participants will receive single IV infusion of SRP-6004 on Day 1.
62485288|NCT02083939||Antibiotic Prophylaxis|This cohort will receive antibiotic prophylaxis prior to the hernia repair
62485289|NCT02083939||No Antibiotic Prophylaxis|This cohort will not receive antibiotic prophylaxis prior to the surgery
62485290|NCT01906372|EXPERIMENTAL|Acthar Gel|Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
62485291|NCT04334863|EXPERIMENTAL|WP1066|There will be 5 groups based on the enrollment timing. The first group of participants will receive the lowest dose level of WP1066. Each subject within a group will receive an assigned dose of the investigational drug. The dose levels are 4, 6, 8 and 16 mg/kg of the investigational drug given twice a day. The first group will receive the lowest dose level, 4mg/kg twice a day, and subsequent groups will escalate to the next higher dose level. All groups will be treated identically, except for the dose of drug administered, with the liquid formulation of the drug.
62485292|NCT03548194|EXPERIMENTAL|BNC210|Administered orally b.i.d. for 5 days.
62485293|NCT03548194|PLACEBO_COMPARATOR|Placebo|Administered orally b.i.d. for 5 days.
62485294|NCT04690985|SHAM_COMPARATOR|Control group|The control group will be asked to continue their own daily routes. One research assistant, who will not be involved in other procedures of the study, will contact with the participants to talk about different issues except the SO related topic. The frequency of face-to-face meetings and telephone calls will be similar to the experimental group. The issues talked in the control group could be as follows but not limited: a) normal social communication topics such as greetings, recent living conditions, news in the past week; b) health consultations asked by the participants; c) avoid to mention dietary or exercise related information. An appointment of post-test will be made in the last time telephone call.
62326893|NCT03350516|EXPERIMENTAL|Daily 500 mg Calcium|
62326894|NCT03350516|ACTIVE_COMPARATOR|Daily1500 mg Calcium (Standard dose)|
62326895|NCT06747156|EXPERIMENTAL|ABO2203|
62326896|NCT06746870|EXPERIMENTAL|Cohort 1a|NSQ-NSCLC
62326897|NCT06746870|EXPERIMENTAL|Cohort 1b|SQ-NSCLC
62326898|NCT06746870|EXPERIMENTAL|Cohort 2|TNBC
62485295|NCT04690985|EXPERIMENTAL|Experimental group|The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive 6 times face-to-face meetings (on week 1, 2, 3, 4, 8 and 12) and weekly telephone call. Each face-to-face meetings will last for around 1 hour, during which the reseacher will help to establish the participants' intention for dietary behavior change, then help transform the intention into detailed plan, and help monitor the execution of the plan continuously.
62485296|NCT05411276||Group 1|HER2 rare mutation advanced/metastatic non-small lung cancer (IV)
62485297|NCT02374112|EXPERIMENTAL|Experimental|Creatine supplementation
62485298|NCT02374112|PLACEBO_COMPARATOR|Control|Placebo supplementation
62485299|NCT01957059|EXPERIMENTAL|Dose escalation phase|In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject). In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week). The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2). The actual doses may be amended or repeated based on emerging data from previous doses.
62692807|NCT05269082||Cohort 3|Pediatric and adult primary immunodeficiency (PID) participants with immunoglobin A (IgA) deficiency who have a serum IgA level of less than (\<) 7 milligrams per deciliter (mg/dL) (0.07 grams/liter \[g/L\]) or below the detectable limit and have received other therapies (prophylactic antibiotics or immunoglobulin treatment other than Gammagard S/D) will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
61933806|NCT00121173|EXPERIMENTAL|Low dose|"3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.~Genetic (recombinant DNA vaccine)"
62326899|NCT06747676|EXPERIMENTAL|Active HD-tDCS|Participants will receive six sessions of 2mA active HD-tDCS cathode center over the contralesional TPJ for 20 minutes, 3 times daily for 2 days with session intervals greater than 3 hours.
62326900|NCT06747676|SHAM_COMPARATOR|Sham HD-tDCS|Participants will receive six sessions of 2mA sham HD-tDCS cathode center over the contralesional TPJ for 20 minutes, 3 times daily for 2 days with session intervals greater than 3 hours.
62326901|NCT06746753|EXPERIMENTAL|Angiotensin II|Continuous infusion of Angiotensin II for up to 48 hours
62326902|NCT06746753|ACTIVE_COMPARATOR|Norepinephrine|Continuous infusion of Norepinephrine for up to 48 hours
62326903|NCT06747533||Coaching on Deep Inspiration Breath Hold|"Participants are expected to be in this research study for the duration of radiation treatment.~Participants will be asked to undergo a lung function test (called a spirometry test) about 1 week before CT simulation and at CT simulation as well as answer a questionnaire about treatment anxiety and satisfaction during these visits and at weekly standard of care visits."
62326904|NCT06746961|EXPERIMENTAL|QL1706 plus Lenvatinib|"QL1706 will be administrated at a dose of 5 mg/kg intravenously (IV), every 3 weeks, until progressive disease or intolerable or other reasons according to the criteria for termination of treatment. QL1706 will be administrated up to 2 year.~Lenvatinib will be administrated at a dose of 8 mg or 12mg orally (PO) once daily (QD)"
62326905|NCT06747390|NO_INTERVENTION|Control Arm - No Injection|No injection at the time of direct laryngoscopy.
62485300|NCT01957059|EXPERIMENTAL|Regimen selection|After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks. 3 more treatment-naïve subjects will be entered into this Group. These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC. At the time of this amendment (4) this part of the study has been completed. Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing). Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
62692808|NCT04265651|EXPERIMENTAL|Infigratinib 0.016 mg/kg|"Dose Escalation:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
62692809|NCT04265651|EXPERIMENTAL|Infigratinib 0.032 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
62692810|NCT04265651|EXPERIMENTAL|Infigratinib 0.064 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
62326906|NCT06747390|EXPERIMENTAL|Lidocaine Injectible product|Intratumoral injection of 1% lidocaine at the time of direct laryngoscopy.
62326907|NCT05253976||Patients who received the NexGen TM Augmentation Patella|
62326908|NCT06746090|EXPERIMENTAL|Reminders for wearing class II elastics through text message|Reminders daily via whatsapp text message.
62326909|NCT06746090|EXPERIMENTAL|Reminders for wearing class II elastics through phone call|Reminders weekly via phone call.
62326910|NCT06746090|NO_INTERVENTION|No reminders for wearing class II elastics|No reminder for wearing elastics.
62326911|NCT06747897||Adult users|Use of product 3 months prior to recruitment
62326912|NCT06747897||Caregivers of children (2-12 years old)|Use of product 3 months prior to recruitment
61933807|NCT00121173|EXPERIMENTAL|Intermediate dose|3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
61933808|NCT00121173|EXPERIMENTAL|High dose|3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
61933809|NCT02808650|EXPERIMENTAL|Treatment (prexasertib)|Patients receive prexasertib IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
61933810|NCT06653036|ACTIVE_COMPARATOR|DPE group|Participants who receive the dural puncture epidural (DPE) for labor analgesia.
62326913|NCT06747897||Caregivers of children (<2 years old)|Use of product 3 months prior to recruitment
62326914|NCT06746194||Patients diagnosis of advanced unresectable hepatocellular carcinoma|
62326915|NCT06687343|ACTIVE_COMPARATOR|EAA + NEAA|Dietary intake of both EAA and NEAA, representing a normal diet
62692811|NCT04265651|EXPERIMENTAL|Infigratinib 0.128 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
61933811|NCT06653036|ACTIVE_COMPARATOR|SET group|Participants who will be receiving standard epidural technique (SET) for labor analgesia.
61933812|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
61933813|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
61933814|NCT04520373|EXPERIMENTAL|Treatment Group 1: AD-MSC Injection|Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
61933815|NCT04520373|ACTIVE_COMPARATOR|Treatment Group 2: Best Medical Management|Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
61933816|NCT03200158|OTHER|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
62133687|NCT01308567|EXPERIMENTAL|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
62326916|NCT06687343|EXPERIMENTAL|EAA + maltodextrin|Dietary intake of EAA, with NEAA replaced by maltodextrin
62326917|NCT06687343|EXPERIMENTAL|EAA|Dietary intake of EAA, with NEAA replaced by additional EAA
62326918|NCT06746597|ACTIVE_COMPARATOR|Three different air-insole presures (80 mmHg, 160 mmHg, and 240 mmHg)|
62326919|NCT06746597|ACTIVE_COMPARATOR|Two different durations (10 and 20 minutes)|
62326920|NCT06218914|EXPERIMENTAL|NT-112|Dose Escalation of NT-112.
62326921|NCT05465941|EXPERIMENTAL|Treatment (pegylated SN-38 conjugate PLX038)|Patients receive PLX038 IV over 1 hour on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, biopsy, as well as blood and stool sample collection during screening and on the trial.
61933817|NCT03701321|EXPERIMENTAL|Phase I (DVd, venetoclax)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, dexamethasone PO on days 1, 8, and 15 of cycles 1-8, and venetoclax PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62133688|NCT01308567|EXPERIMENTAL|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
62326922|NCT06618755|EXPERIMENTAL|Experimental group : PSH (usual care) with motivational interviewing|People randomised to the experimental group will have scheduled appointments to collect study data (monthly assessment). They will take part in an initial motivational interview to lay the foundations for the work that will be carried out throughout the follow-up period. Then, for 4 and a half months, a motivational interview will be scheduled every 14 days.
62326923|NCT06618755|NO_INTERVENTION|Control group : PSH (usual care)|People randomised to the control group will have scheduled appointments for study-related data collection (monthly assessment), in addition to their routine care.
62326924|NCT05473637||Genetic group|Patients who have positive DNA results by NGS screening of the following 5 genes: NOTCH3 (19q13.12), HTRA1 (10q26.13), GLA (Xq22.1), TREX1 (3p1.31) and COL4A1 (13q34).
62326925|NCT05473637||Nongenetic group|Patients who have negative DNA results by NGS screening .
62326926|NCT06661746|ACTIVE_COMPARATOR|Multimodal Group|
62326927|NCT06661746|ACTIVE_COMPARATOR|Epidural Group|
62326928|NCT06685718|EXPERIMENTAL|Phase 1a: Dose Escalation and Safety Expansion|Sequential cohorts of increasing dose levels of BG-60366 will be evaluated as monotherapy.
62326929|NCT06685718|EXPERIMENTAL|Phase 1b: Dose Expansion|Recommended Dose(s) for Expansion (RDFE\[s\]) of BG-60366 as monotherapy determined from Phase 1a will be evaluated.
62326930|NCT05419388|EXPERIMENTAL|Low dose every three weeks (Q3W)|Participants will receive RO7247669 Q3W until loss of clinical benefit, unacceptable toxicity, or a maximum of 24 months.
62326931|NCT05419388|EXPERIMENTAL|High dose Q3W|Participants will receive RO7247669 Q3W until loss of clinical benefit, unacceptable toxicity, or a maximum of 24 months.
62326932|NCT06688435|EXPERIMENTAL|SYS6020 injection: 2*106CAR+ T-cells per kg(dose level 1)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells to manufacture SYS6020 injection, during which no lymphodepleting chemotherapy will be performed. Participants will receive 3 doses treatment of SYS6020 injection, with a dose level of 2\*106CAR+ T-cells per kg. If one DLT occurs in three participants, additional 3 ones may be considered to be enrolled after SMC safety data review and make a determination.
62326933|NCT06688435|EXPERIMENTAL|SYS6020 injection: 6*106CAR+ T-cells per kg(dose level 2)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells to manufacture SYS6020 injection, during which no lymphodepleting chemotherapy will be performed. Participants will receive 3 doses treatment of SYS6020 injection, with a dose level of 6\*106CAR+ T-cells per kg. If one DLT occurs in three participants, additional 3 ones may be considered to be enrolled after SMC safety data review and make a determination.
62326934|NCT06688435|EXPERIMENTAL|SYS6020 injection: 1.8*107CAR+ T-cells per kg(dose level 3)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells to manufacture SYS6020 injection, during which no lymphodepleting chemotherapy will be performed. Participants receive 3 doses of SYS6020 injection, with a dose level of 1.8\*107CAR+ T-cells per kg. If one DLT occurs in three participants, additional 3 ones may be considered to be enrolled after SMC safety data review and make a determination.
62326935|NCT06688435|EXPERIMENTAL|SYS6020 injection: 3.6*107CAR+ T-cells per kg(dose level 4)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells to manufacture SYS6020 injection, during which no lymphodepleting chemotherapy will be performed. Participants receive 3 doses of SYS6020 injection, with a dose level of 3.6\*107CAR+ T-cells per kg. If one DLT occurs in three participants, additional 3 ones may be considered to be enrolled after SMC safety data review and make a determination.
62326936|NCT06688435|EXPERIMENTAL|SYS6020 injection: 5.4*107CAR+ T-cells per kg(dose level 5)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells to manufacture SYS6020 injection, during which no lymphodepleting chemotherapy will be performed. Participants receive 3 doses of SYS6020 injection, with a dose level of 5.4\*107CAR+ T-cells per kg. If one DLT occurs in three participants, additional 3 ones may be considered to be enrolled after SMC safety data review and make a determination.
62326937|NCT06704672|EXPERIMENTAL|Group A: Accu-Chek SmartGuide CGM Solution|
62326938|NCT06704672|OTHER|Group B: Self-Monitoring of Blood Glucose (SMBG)|
62326939|NCT06738472|EXPERIMENTAL|Duloxetin+home based therapy|
62326940|NCT06738472|NO_INTERVENTION|Duloxetin only|
62133689|NCT01308567|ACTIVE_COMPARATOR|Docetaxel 75 mg/m^2|Docetaxel (TXT) 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
62133690|NCT00920972|EXPERIMENTAL|Stratum 1|Recipients with non-malignant disorders, excluding thalassemia. Related or unrelated 8/8 HLA-matched bone marrow
62326941|NCT01719055||Boston Scientific SCS Systems|Subjects permanently implanted with a Boston Scientific neurostimulation systems
62326942|NCT06351592|EXPERIMENTAL|Cohort 1 - Low Dose|Placebo during double-blind treatment period
62326943|NCT06351592|EXPERIMENTAL|Cohort 2 - Mid Dose|Placebo during double-blind treatment period
62326944|NCT06351592|EXPERIMENTAL|Cohort 3 - High Dose|Placebo during double-blind treatment period
62326945|NCT06351592|EXPERIMENTAL|Cohort 4 (Optional) ≤ High Dose|Placebo during double-blind treatment period
62326946|NCT06746350|EXPERIMENTAL|Thermotherapy|This arm receives thermotherapy right after CL diagnosis
62326947|NCT06746350|OTHER|Control group for three months|This arm receives thermotherapy three-month after CL diagnosis.
62692812|NCT04265651|EXPERIMENTAL|Infigratinib 0.25 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.~Dose Expansion:~Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose."
62326948|NCT06746038|EXPERIMENTAL|Experimental Group|Participants who are fit with study Lyric devices and tested on speech intelligibility and effort using two different fitting algorithms
62326949|NCT06742151||Group 1|Patient who received an implant after surgery.
62326950|NCT06742151||Group 2|Patient who didn't receive an implant due to insufficient bone volume or implant primary stability for implant placement.
62326951|NCT06747377||diabetic foot ulcer|Diabetic Patients with DFU, who were diagnosed by a vascular surgeon based on Diabetic Foot Study Group guidelines.
62326952|NCT06748079|EXPERIMENTAL|TQC3721 inhalation powder|TQC3721 inhalation powder is administered as a single dose or continuously for 7 days.
62326953|NCT06748079|PLACEBO_COMPARATOR|Placebo for TQC3721 inhalation powder|Placebo for TQC3721 inhalation powder inhalation is administered as a single dose or continuously for 7 days.
62326954|NCT06746207||Patients and Caregivers|This cohort includes two groups: patients undergoing major elective surgery and their caregivers. The patients are asked to provide feedback on their understanding and satisfaction with the informed consent process. The caregivers, who often provide the informed consent on behalf of the patients, are also surveyed to assess their perspectives on the consent process. There is no intervention in this study; the focus is on evaluating perceptions, satisfaction, and the communication process surrounding informed consent in a surgical setting.
62326955|NCT06747637|EXPERIMENTAL|Group A: Treatment Group Receives the Classes Soon after Randomization|The Spanish-language caregiver classes are called Unidos en el Cuidado and are taught online by Alzheimer's Los Angeles. Sessions are provided at no cost and held weekly for about 2 hours.
62326956|NCT06747637|ACTIVE_COMPARATOR|Group B: Wait List Control Group Receives the Classes after a Waiting Period|This wait list control group receives the same classes but after a 3-4 week waiting period.
62326957|NCT06747975|EXPERIMENTAL|group A|fifty patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
62326958|NCT06747975|PLACEBO_COMPARATOR|group B|fifty patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
62326959|NCT06747949|EXPERIMENTAL|Dazodalibep/Dazodalibep|Participants who completed the 48-week dazodalibep treatment in trials HZNP-DAZ-301 or HZNP-DAZ-303 will continue with their assigned dose (1 or 2) for an additional 144 weeks.
62326960|NCT06747949|EXPERIMENTAL|Placebo/Dazodalibep|Participants who completed the 48-week placebo treatment in trials HZNP-DAZ-301 or HZNP-DAZ-303 will be randomized 1:1 to dazodalibep (dose 1 or 2) for an additional 144 weeks.
62326961|NCT06746519|EXPERIMENTAL|BN104 Combined Intensive Chemotherapy in patients with newly diagnosed AML|
61933818|NCT03701321|EXPERIMENTAL|Phase II Arm D (DVd, venetoclax)|Patients receive venetoclax PO QD on days 1-21, daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61933819|NCT03701321|ACTIVE_COMPARATOR|Phase II Arm E (DVd)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61933820|NCT05095831||Suspicion of solid neoplastic lesion|Patients with high suspicion of solid pancreas neoplasia: carcinoma, intrapapillary mucinous neoplasia (IPMN), neuroendocrine tumor, lymphoma, or intrapancreatic metastasis; based on CT/MR.
62133691|NCT00920972|EXPERIMENTAL|Stratum 2|Recipient with transfusion dependent thalassemia. Related or unrelated. 8/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
62133692|NCT00920972|EXPERIMENTAL|Stratum 3|Recipient with hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
62326962|NCT06746519|EXPERIMENTAL|BN104 Combined Venetoclax/Azacitidine in patients with newly diagnosed AML|
62326963|NCT06746519|EXPERIMENTAL|BN104 Combined Venetoclax/Azacitidine in patients with relapsed/refractory AML|
62326964|NCT06746116|EXPERIMENTAL|Single Arm|Durvalumab + Chemotherapy (chemotherapy phase) plus Durvalumab + Olaparib (maintenence phase)
62326965|NCT06746025||Session 1|Approximately 15-20 participants that have selected Session 1 as their preferred session
62326966|NCT06746792|EXPERIMENTAL|Muscle thickness|Muscular hypertrophy , or muscle growth, refers to an increase in muscle mass. There are two types of muscular hypertrophy: myofibrillar, which is an increase in myofibrils, and sarcoplasmic, which is an increase in muscle glycogen storage.
62326967|NCT06746792|EXPERIMENTAL|Muscle stiffness and strength|Muscle and tendon stiffness is defined as an internal resistance to changes in muscle and tendon shape caused by an external force. Muscle strength production takes place with the help of the elastic behavior of the muscles and tendons
62326968|NCT06746740|EXPERIMENTAL|Exercise|Exercise intervention
62326969|NCT06747455|EXPERIMENTAL|Experimental group|"Common name: BCG for Therapeutic Use Specification: 60mg/bottle. Each bottle contains 60mg of BCG, and the number of viable bacteria per 1mg BCG should not be less than 1.0×10\^6CFU.~Expiration date: 24 months. Production unit: Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd."
62133693|NCT00920972|EXPERIMENTAL|Stratum 4|Recipient with non-malignant disorder, excluding hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
62133694|NCT04949503||study group|Patients of study group were all treated with chemoradiotherapy plus nimotuzumab.
62133695|NCT04949503||control group|Patients of control group were only treated with chemoradiotherapy, and were collected at least 3 times as many patients as the study group.
62133696|NCT01631851|EXPERIMENTAL|Cognitive behavior therapy|
62326970|NCT06747455|ACTIVE_COMPARATOR|Control group|"Common name: BCG for Therapeutic Use ( BI SAI JI ) Specification: 60mg (6.0×10\^7CFU)/bottle. Each bottle contains 60mg of BCG, and the number of viable bacteria per 1mg BCG should not be less than 1.0×10\^6CFU.~Expiration date: 18 months. Production unit: Chengdu Institute of Biological Products Co., Ltd."
62326971|NCT06747208||head and neck cancer patients|patients with head and neck cancer undergoing radiation therapy
62692813|NCT00265122|EXPERIMENTAL|Population 1: Placebo SC followed by ustekinumab SC|Placebo injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
62485301|NCT01957059|EXPERIMENTAL|48-week Treatment Phase|"Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis.~Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level).~After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or \[down-\]titrate)."
62485302|NCT01957059|EXPERIMENTAL|Dosing extension|All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053. Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored. The dose extension phase will provide BMN 053 treatment for 48 weeks.
62485303|NCT01496495|EXPERIMENTAL|ARRY-614|
62485304|NCT02120872|ACTIVE_COMPARATOR|PRF and SMV Group|sites treated with Open Flap Debridement with Platelet Rich Fibrin along with Simvastatin
62485305|NCT02120872|SHAM_COMPARATOR|PRF Group|sites treated with Open Flap Debridement with autologous Platelet Rich Fibrin
61933821|NCT05095831||Suspicion of a solid inflammatory lesion|Patients with high suspicion of solid inflammatory lesions: acute, chronic, or autoimmune pancreatitis; based on CT/MR.
62133697|NCT05778526|EXPERIMENTAL|Social VR Intervention|Social VR intervention is developed to enhance the social interaction skills of children. The participants will wear a head-mounted display for the Social VR intervention. Each session of the Social VR intervention lasts for a maximum of 20 minutes to ensure the participants focus on the intervention and prevent causing any physical effect. The duration will be adjusted depending on the emotion of the participants during the intervention. The Social VR intervention will mainly help the participant to enhance their social interaction skills and executive function. The intervention contains three real-life virtual scenarios, including (1) classroom and playground, (2) MTR station and compartment, and (3) supermarket and restaurant. One scenario will be adopted in each session. The sequences of the scenarios used in each session will be the same for all participants.
62133698|NCT05778526|ACTIVE_COMPARATOR|Traditional social skills training|An experienced SEN teacher will teach the participants social interaction skills through tradidactic instructions and role-play activities. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise. These modules have been applied in many studies (Braswell \& Bloomquist, 1991; Huang et al., 2015). The content of this training will be as similar as possible to the Social VR training. The training lasts 20 minutes which depends on the emotion of the participants.
62326972|NCT04386746|EXPERIMENTAL|Intravesical Gemcitabine/Docetaxel|Gemcitabine/Docetaxel induction is given intravesically in sequential order once a week for six consecutive weeks. One gram of gemcitabine in 50 ml of sterile water is slowly instilled into the bladder via a Foley catheter and the catheter is clamped for 60 minutes. The bladder is then drained and 40 mg of docetaxel in 50 ml of NSS is then slowly instilled via the Foley catheter into the bladder. The catheter is again clamped for 60 minutes before draining. If initial efficacy seen, patients will have monthly maintenance instillations of Gemcitabine/Docetaxel.
62326973|NCT03215706|EXPERIMENTAL|Module A|Chemotherapy/Biologics combined
61933822|NCT05095831||Control group|Patients without a history of any type of solid or hematologic malignancy, hepato-pancreato-biliary disease (including fatty liver and pancreas disease), tobacco/alcohol habits, or morbid obesity with bariatric surgery criteria; who require EUS evaluation (e.g., suspicious of a subepithelial lesion in the context of chronic dyspepsia).
61933823|NCT01410539|EXPERIMENTAL|Stent Thrombosis|Consecutive patients with stent thrombosis with stent strut assessment by OCT
61933824|NCT01410539|ACTIVE_COMPARATOR|Controls|Control subjects without stent thrombosis from the RHR OCT database
61933825|NCT02147912|ACTIVE_COMPARATOR|Aerobic exercise|A six week aerobic exercise intervention in COPD depressed population.
62133699|NCT05778526|NO_INTERVENTION|Waitlist control group|The participants in this group will receive no training and they can participate in the social VR training after the intervention period. To ensure the consistency of the experiment, the participants are not allowed to initiate or change their pharmacological treatment during the 3-week intervention period.
62326974|NCT03215706|ACTIVE_COMPARATOR|Module B|Chemotherapy Combination
62326975|NCT06746441|EXPERIMENTAL|Psilocybin Therapy Group|Participants will receive two oral doses of psilocybin (5-6 grams per dose), administered six weeks apart. Each session will occur in a controlled environment with medical monitoring until the hallucination phase subsides. Participants will continue their routine antidepressant medications during the study.
62326976|NCT06746441|NO_INTERVENTION|Control Group|Participants will continue their routine antidepressant medications (e.g., SSRIs such as citalopram, escitalopram, or sertraline) without any additional intervention.
62485306|NCT02120872|OTHER|OFD Group|sites treated with Open Flap Debridement i.e. conventional flap surgery
62692814|NCT00265122|EXPERIMENTAL|Population 1: Ustekinumab SC followed by Placebo SC:|Ustekinumab 90 mg injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
62692815|NCT00265122|EXPERIMENTAL|Population 1: Placebo IV followed by ustekinumab IV|Placebo given as 1 intravenous (IV) infusion at Week 0 during Intervention Period 1 and ustekinumab 4.5 mg/kg given as one IV infusion at Week 8 during Intervention Period 2.
61933826|NCT02147912|NO_INTERVENTION|Control sample|"Only participants randomized in the arm named Aerobic exercise will receive a six weeks aerobic exercise intervention."
61933827|NCT01231854|ACTIVE_COMPARATOR|Ciclosporingroup|
61933828|NCT01231854|ACTIVE_COMPARATOR|Alitretinoingroup|
62326977|NCT06746441|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT) Group|Participants will undergo 8-10 structured sessions of Cognitive Behavioral Therapy over six weeks. Each session will last approximately 90 minutes, focusing on restructuring negative thought patterns and addressing depression symptoms. Participants will continue their routine antidepressant medications during the study.
62485307|NCT03049748|ACTIVE_COMPARATOR|Control Group|Participants in the control group (20 LVAD patients) will receive usual care over 6 months. Usual care consists of routine clinic visits/follow-up at 1, 3, and 6 months post hospital discharge. A customary LVAD self-management/discharge education and training will be provided to patients and caregiver before hospital discharge and as need throughout the duration of the study. The control group will NOT receive the VAD Care App.
62485308|NCT03049748|EXPERIMENTAL|Intervention Group|Participants in the experimental group (20 LVAD patients) will receive usual care plus VAD Care App. They will implement LVAD self-management as directed by VAD Care App. The app will be used daily by patients and/or caregivers for over 6 months. Their LVAD self-management competencies will be assessed at months 1 and 5 post hospital discharge with a review of LVAD self-management skills provided by the LVAD RN Coordinator.
62485309|NCT06230094|EXPERIMENTAL|Group A ( moderate intensity training)|warm up protocol to reach maxHR 50% than moderate intensity exercise. Group A will be given moderate intensity exercise i.e brisk walk will be performed.(HR will be between 50-60%).
62485310|NCT06230094|EXPERIMENTAL|Group B( high intensity training)|warm up protocol to achieve 70% of maxHR . group Bwill be given highintensity exercise i.e skipping rope ( HR will be between 70-85%).
62485311|NCT01602328|ACTIVE_COMPARATOR|AC607|Treatment with AC607
62692816|NCT00265122|EXPERIMENTAL|Population 1: Ustekinumab IV followed by Placebo IV:|Ustekinumab 4.5 mg/kg given as one intravenous(IV) infusion at Week 0 during Intervention Period 1 followed by placebo given as one IV infusion at Week 8 during Intervention Period 2.
62326978|NCT06746441|ACTIVE_COMPARATOR|Psilocybin-Assisted CBT Group|Participants will receive both psilocybin therapy and Cognitive Behavioral Therapy. Psilocybin will be administered in two oral doses (5-6 grams per dose), six weeks apart, with medical monitoring during sessions. In addition, participants will undergo 8-10 CBT sessions over six weeks. Routine antidepressant medications will be continued.
62326979|NCT06747312|EXPERIMENTAL|Experimental: SOC+Belimumab arm|Belimumab 10mg/kg once a month as an add-on treatment regimen. SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
62326980|NCT06747312|ACTIVE_COMPARATOR|Experimental: SOC arm|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
62326981|NCT06747026||initial iRT for locally advanced NSCLC|For unresectable locally advanced NSCLC: definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT (Sequential iRT) or concurrently with RT (Concurrent iRT).
62485312|NCT01602328|PLACEBO_COMPARATOR|Placebo|Treatment with Placebo
62485313|NCT05661591|EXPERIMENTAL|Treatment group A|SHR2554+ Fluconazole Capsules
62485314|NCT06219031||valid group（CR/PR）|CR/PR
62485315|NCT06219031||invalid group（SD/PD）|SD/PD
62485316|NCT06389448|OTHER|pCLE-gastr|pCLE will be used to acquire the images from the gastric tissue of the participants after preoperative fluorescein sodium allergy test (negative) and pre-ESD assessment，and before ESD resection.
62485317|NCT04957979||Nursing/Medical Model of Care Coordination|Someone with medical/nursing training coordinates involvement of various medical resources and provides patients with education, self-management support, and referrals to community resources.
62485318|NCT04957979||Medical/Social Model of Care Coordination|In addition to the services provided in the Medical/Nursing Model, a social worker by education has dedicated FTE as a member of the care team at the clinic, providing some direct services for care coordination patients and either spending some time on-site or in regular communication with its clinicians in addition to providing social work services.
62485319|NCT04215328|EXPERIMENTAL|Mixed-Meal|Ensure Nutrition Shake
62485320|NCT04215328|PLACEBO_COMPARATOR|Electrolyte Solution|Pedialyte Solution
62326982|NCT06747026||initial iRT for de novo metastatic NSCLC|For de novo metastatic NSCLC: radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT (Sequential iRT) or concurrently with RT (Concurrent iRT).
62326983|NCT06747026||Salvage iRT in post-treatment progressive NSCLC|For post-treatment progressive NSCLC: salvage radiotherapy must have been performed during immunotherapy or within 90 days after the cessation of immunotherapy (RT after discontinuation of ICI) , or concurrently with RT (RT with maintenance of ICI).
62485321|NCT00319696|EXPERIMENTAL|Bosentan|Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter
62485322|NCT03220958|EXPERIMENTAL|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
62485323|NCT03220958|PLACEBO_COMPARATOR|Placebo|Normal saline, administered as an intravenous drip
62485324|NCT00557726||1|Patients with a variety of infections and inflammatory diseases.
62485325|NCT03210038|ACTIVE_COMPARATOR|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
62485326|NCT03210038|ACTIVE_COMPARATOR|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
62485327|NCT03210038|ACTIVE_COMPARATOR|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
62485328|NCT03210038|ACTIVE_COMPARATOR|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
62692817|NCT00265122|EXPERIMENTAL|Population 2: Ustekinumab SC|Ustekinumab 90 mg injected subcutaneously (SC) once a week at Weeks 0-3 during Intervention Period 1. No intervention given during Intervention Period 2.
62692818|NCT00265122|EXPERIMENTAL|Population 2: Ustekinumab IV|Ustekinumab 4.5 mg given as one intravenous (IV) infusion at Week 0 during Intervention Period 1. No intervention given during Intervention Period 2.
61933829|NCT06707857|EXPERIMENTAL|Tendon neuroplastic training|"Group A will be treated with tendon neuroplastic training. The exercise involved isolated abduction external rotation ,internal rotation and flexion paced to an external audio cue on the patients' smartphone The patient was to listen to the sound and track the movement of the metronome with his eyes, as pacing to these types of external cues has been shown to modulate conspiratorial excitability.The pace of the metronome was set to 6 beats per minute such that each beat was ten seconds apart. This allowed a ten second isometric, eccentric and concentric phase, in 30 seconds totally. Three sets of 10 repetitions of slow progressive exercises (eccentric, concentric and isometric respectively) of the wrist rotator cuff muscles at each treatment session were performed, with 1-min rest interval between each set.~The patient followed the supervised exercise programme 3 times a week for 6 weeks"
62485329|NCT02134821||Low pain sensitivity group|total Pain Sensitivity Questionnaire score \<6.5
62485330|NCT02134821||High pain sensitivity group|total pain sensitivity questionnaire score ≥ 6.5
61933830|NCT06707857|ACTIVE_COMPARATOR|Conventional training|Group B will be treated with conventional therapy Participants will perform isometric contraction of the arm at 90° of elevation in the scapular plane. External and internal rotation, respectively) will be performed in the same positions of isometric strength assessment.Individuals will perform three sets, sustained for 32 s, at 70% of maximal voluntary isometric contraction (MVIC), resting for 80 seconds between sets.Resistance load will be determined according to maximal isometric strength of elevation and external and internal rotations measured during the pre-intervention assessment
61933831|NCT05704725|EXPERIMENTAL|ABP 938|Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS.
61933832|NCT05704725|EXPERIMENTAL|Aflibercept|Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS.
61933833|NCT06440629|EXPERIMENTAL|TDM-group|In the TDM-group, the TNFi dose will be adjusted in order to keep the drug level within the therapeutic range
61933834|NCT06440629|NO_INTERVENTION|Standard of Care group|In the Standard of Care group, TNFi will be administered according to standard of care without knowledge of serum drug levels or ADAb
61933835|NCT04606914|EXPERIMENTAL|neoadjuvant chemotherapy regimen|"* IV Carboplatin AUC 5 (Q21 days) 7 cycles (first cycle is Carbo alone, dosing for C1D1 will be provider's choice)~* IV Mirvetuximab 6 mg/kg (adjusted ideal body weight) day 1 (Q21 days) 6 cycles (starting with cycle #2)"
61933836|NCT02712255|EXPERIMENTAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
61933837|NCT02712255|EXPERIMENTAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the patient. The partner is actively participating in forming plans by the patient.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning"
61933838|NCT02712255|EXPERIMENTAL|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (the patient and the partner). Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
61933839|NCT02712255|ACTIVE_COMPARATOR|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
61933840|NCT06433401|EXPERIMENTAL|Transition care group|The transitional care group is a group that will receive a transitional care training consisting of a total of 3 modules in which the content is arranged for individualized needs with expert opinion from 10 faculty members working in the field of Child Health and Diseases Nursing.The education sessions will be conducted every 3 months in sessions of approximately 35-40 minutes face-to-face in the training room allocated to the individual researcher.
61933841|NCT06433401|NO_INTERVENTION|Control group|The control group is the group receiving routine care that continues the normal follow-up of the clinic without any intervention. However, in terms of compliance with ethical principles, the same training will be given to them upon their request after the research is completely completed.
62326984|NCT06746415|ACTIVE_COMPARATOR|Conventional Gait Group|Conventional walking training group will be given 20 minutes of NMES, 20 minutes of weight transfer, stretching, mobilization, bobath exercises and 20 minutes of parallel bar walking exercises.Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks.
62326985|NCT06746415|EXPERIMENTAL|Robotic Gait Group|. The robot-assisted walking group will receive 20 minutes of NMES, 20 minutes of weight transfer, stretching,mobilization, bobath exercises and 20 minutes of robot-assisted walking exercises. Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks.
62326986|NCT06746298||Rectal cancer patients receiving neoadjuvant therapy|
62326987|NCT04483115|EXPERIMENTAL|TPN171H 2.5mg group|TPN171H 2.5mg tablet + Placebo 10mg tablet
62326988|NCT04483115|EXPERIMENTAL|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg tablet
62326989|NCT04483115|EXPERIMENTAL|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet
62485331|NCT04006808|EXPERIMENTAL|PED-HZ/su 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, receiving 2 doses of the investigational vaccine (PED HZ/su)
62485332|NCT04006808|NO_INTERVENTION|Control 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, not receiving the investigational vaccine but being treated according to the local standard of care
61933842|NCT02310932|EXPERIMENTAL|Healthy Living Intervention|The Healthy Living Intervention group will participate in an intervention designed to improve depression, anxiety, diabetes and CVD outcomes. This will be achieved through a 12 month intervention which consists of participation in healthy living groups and integrated collaborative clinic care at their Primary Health Clinic (PHC).
61933843|NCT02310932|PLACEBO_COMPARATOR|Enhanced Standard Care Model|"Patients in control groups will receive an enhanced standard care model, which includes providing referrals for mental health needs."
62326990|NCT04483115|PLACEBO_COMPARATOR|Placebo group|Placebo 5mg tablet+ Placebo 10mg tablet
62326991|NCT04483115|ACTIVE_COMPARATOR|tadalafil 20mg group|tadalafil tablet 20mg
62326992|NCT04483115|ACTIVE_COMPARATOR|tadalafil 40mg group|tadalafil tablets 20mg \*2
62326993|NCT00378742||Participants|Participants with inherited eye diseases or relative of affected participant
62692819|NCT06674798|EXPERIMENTAL|Intervention Group|In the intervention group, students will participate in 6 health promoting video sessions and three sessions will be delivered by trained facilitators per month. The session will be 30 to 40 minutes and the intervention will be provided over two months. The video material will be focused on the leading risk factors associated with NCDs as reported by different studies such as physical inactivity, unhealthy diet and overweight, obesity, harmful alcohol consumption and tobacco use.
62326994|NCT06260878|EXPERIMENTAL|Ringer's lactate 2500 cc IV|
62326995|NCT06260878|EXPERIMENTAL|Ringer's lactate 2000 cc IV|
62326996|NCT06260878|EXPERIMENTAL|Ringer's lactate 1500 cc IV|
62326997|NCT06260878|EXPERIMENTAL|Ringer's lactate 1000 cc IV|
62326998|NCT06260878|ACTIVE_COMPARATOR|Ringer's lactate 500 cc IV|
62326999|NCT06746987|EXPERIMENTAL|Meditation|Study and control groups will be determined. Firstly, randomization of the study and control groups in the research will be done by an independent researcher on the randomizer.org website. Secondly, the Pitsburg Sleep Quality Scale and PERMA test will be applied to the study and control groups as a pre- test. Thirdly, theta healing meditation will be applied to the study group for 4 weeks, 2 days a week, 15- 30 minutes a day. After the 4 week meditation practice is completed with the study group, a final test will be given to the study and control groupsthe Pitsburg Sleep Quality Scale and PERMA test will be applied as the final test.
62327000|NCT06747819|EXPERIMENTAL|Interventional group I|
62327001|NCT06747819|ACTIVE_COMPARATOR|Interventional group II|
62327002|NCT06748040|ACTIVE_COMPARATOR|Immediate Return of Results|Immediate return of pharmacogenetic (PGx) results to substudy (APOL1 negative) participant.
62327003|NCT06748040|ACTIVE_COMPARATOR|Delayed Return of Results|Delayed return of pharmacogenetic (PGx) results to substudy (APOL1 negative) participant until after the completion of the 6 month final study visit.
62327004|NCT06746480|EXPERIMENTAL|Single Arm|1.0 × 10\^8 PFU/day per cycle, intratumoral injection for 3 consecutive days in 28-day cycles.
62327005|NCT06747260|EXPERIMENTAL|Intranasal breast milk|Fresh own mother's breast milk expressed within 4 hours, will be administered 2 times daily, 0.4 ml in each nostril for 28 days.
62327006|NCT06746324||Pre-Deployment Cohort|Patients undergoing standard chest X-rays prior to the introduction of the AI-based Computer Aided Detection (CAD) system. This cohort represents the baseline population used for comparison, with no AI intervention applied during their imaging or reporting process.
62327007|NCT06746324||Post-Deployment Cohort|"Patients undergoing chest X-rays after the AI-based Computer Aided Detection (CAD) tool has been integrated into the clinical workflow. Although not assigned as an intervention group per a traditional trial protocol, these patients receive imaging evaluated by the AI tool, and the impact on diagnostic outcomes will be compared to the pre-deployment cohort."
62327008|NCT06746818|NO_INTERVENTION|Usual care|No care
62327009|NCT06746818|EXPERIMENTAL|Intervention|". The key components of Heart Math interventions include:~1. Heart Rate Variability (HRV) Training: This involves biofeedback techniques to help individuals learn how to control their heart rate and promote emotional balance.~2. Quick Coherence Technique: Participants are guided through a series of steps to shift their emotional state from stress to calmness, facilitating a sense of peace and emotional clarity.~3. Focus on Positive Emotions: Encouraging individuals to cultivate feelings like gratitude and compassion can enhance resilience and overall mental well-being.~4. Mindfulness Practices: Incorporating mindfulness helps individuals become more aware of their thoughts and feelings, allowing them to respond to stressors more effectively."
62327010|NCT05781360|EXPERIMENTAL|Experimental: PART ONE- Dose escalation|The purpose of the Dose Escalation Phase (Part one) is to characterize the safety and tolerability of SIM0237 and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.
62327011|NCT05781360|EXPERIMENTAL|Experimental: PART TWO- Dose expansion|Patients will be administered a recommended dose of SIM0237 established from the Dose Escalation Phase of the study.
62327012|NCT04656340|ACTIVE_COMPARATOR|Standard rehabilitative care (SC)|Twice weekly physical therapy, occupational therapy and pain psychoeducation
61933844|NCT01935102||Chemotherapy|MBC patients treated with a first-line chemotherapy including paclitaxel without bevacizumab
61933845|NCT01935102||bevacizumab+chemotherapy|histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1, 8 and 15, every 4 weeks
61933846|NCT02374515|ACTIVE_COMPARATOR|Endocuff assisted Colonoscopy|Endocuff assisted Colonoscopy
61933847|NCT02374515|ACTIVE_COMPARATOR|Standard Colonoscopy|Standard colonoscopy
61933848|NCT06433570||50 patients with beta thalassemia intermedia|
61933849|NCT06433570||50 patients with beta thalassemia major|
61933850|NCT06708481|EXPERIMENTAL|Self-Assembling Peptide (P11-4)|self-assembling peptide in a brush-on liquid applied after cleaning and chemical preparation.The P11-4 peptide, called Curodont Repair (Credentis; now manufactured by vVARDIS)
62327013|NCT04656340|EXPERIMENTAL|Complementary and Integrative Health (CIH) therapies in addition to Standard rehabilitate care (SC)|Twice weekly chiropractic, acupuncture, yoga and foam roller instruction, in addition to SC
61933851|NCT06708481|EXPERIMENTAL|Self-Assembling Peptide (P11-4) with fluoride varnish|CR Fluoride Plus (CRFP) (Credentis; now manufactured by vVARDIS) also includes 500 ppm sodium fluoride and is registered with the US Food and Drug Administration (NDC 72247-101) as an anticaries drug under the fluoride monograph (21CFR355).
62327014|NCT05208814|EXPERIMENTAL|Renal Insuffiency|Subjects with various degrees of renal insuffiency
62485333|NCT04006808|EXPERIMENTAL|PED-HZ/su 1-11 Group|"Paediatric renal transplant recipients aged 1 to 11 years old, receiving 2 doses of the investigational vaccine (PED HZ/su).~Enrolment into this group will be in a staggered manner. Following enrolment into the PED-HZ/su 12-17 group, a safety evaluation of data collected up to visit month 2 will be performed. Upon favourable outcome of the evaluation, enrolment into this group will begin."
62485334|NCT04006808|NO_INTERVENTION|Control 1-11 Group|Paediatric renal transplant recipients aged 1 to 11 years old, not receiving the investigational vaccine but being treated according to the local standard of care
62485335|NCT04602754|EXPERIMENTAL|BERLIM 25/20|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
62327015|NCT05208814|EXPERIMENTAL|healthy subjects|healthy subjects
62327016|NCT04917809|EXPERIMENTAL|Participants with FGFR3-mutant or -fusion noninvasive bladder tumors|25 participants with FGFR3-mutant or -fusion noninvasive bladder tumors will be accrued.
62485336|NCT04602754|ACTIVE_COMPARATOR|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association placebo, oral;~1 tablet empagliflozin, oral;~1 tablet rosuvastatin calcium, oral."
62485337|NCT03480880|EXPERIMENTAL|Group BIS|Thiopentone dosing during induction of anaesthesia based on guidance of Bispectral Index values.
62485338|NCT03480880|NO_INTERVENTION|Group Clinical|Thiopentone dosing during induction of anaesthesia based on clinical guidance targeted to loss of eyelash reflex or loss of response to noxious stimulus.
62485339|NCT02312154|EXPERIMENTAL|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.~(We performed split face study)"
62485340|NCT02312154|NO_INTERVENTION|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
62485341|NCT03559907|EXPERIMENTAL|Cooking Matters for Parents|Trained instructors with a background in nutrition or culinary arts will lead six weekly, two-hour sessions to groups of 10 parent participants at local Family Support Centers.
62485342|NCT03559907|EXPERIMENTAL|Mealtime PREP|Trained group leaders with experience in pediatric occupational therapy will lead six weekly, two-hour, Mealtime PREP sessions to groups of 10 parent participants at local Family Support Centers.
62327017|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 1a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
62327018|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 1b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
62327019|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 1c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
62327020|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 1d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
62327021|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 1e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
62485343|NCT03559907|EXPERIMENTAL|Cooking Matters + Mealtime PREP|Parents will receive both programs in succession. They will attend Cooking Matters for Parents followed by Mealtime PREP. In total, this will equal 12 weekly, two-hour sessions delivered to groups of 10 parent participants at a local Family Support Center.
62485344|NCT02491099|EXPERIMENTAL|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
62485345|NCT01554410|EXPERIMENTAL|IMRT/Cisplatin/Gemcitabine|All patients get IMRT with concurrent cisplatin \& gemcitabine, with the dose of gemcitabine varying according to cohort
62485346|NCT04784663|EXPERIMENTAL|Message Exposure|Participants exposed to 4 study videos over a one-month period and complete telephone-based assessments at baseline, 1- and 2-month follow up. Study videos are delivered by study's mobile app downloaded to participants' own Smartphone.
62485347|NCT04784663|PLACEBO_COMPARATOR|Wait List Control|While wait-listed, participants will receive one push notification each week thanking them for participation, informing them that they will receive messages in the near future or reminding them of the length of the study. Telephone-based assessments are completed at baseline, 1- and 2-month follow up. Push notifications are delivered by study's mobile app downloaded to participants' own Smartphone.
62485348|NCT00493805|EXPERIMENTAL|Interventional Study arm (with insulin resistance)|"HOMA IR (homeostasis model assessment-estimated insulin resistance) of \> 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment."
61933852|NCT06708481|ACTIVE_COMPARATOR|Resin Infilteration|ICON® contains 15% HCl as an etchant, ethanol as a dehydrating agent, and triethylene glycol dimethacrylate (TEGDMA) resin as an infiltrant
61933853|NCT05255029|EXPERIMENTAL|PODEYE Toric Intra Ocular Lens Implantation experimental|Implantation of PODEYE toric intraocular lenses.
61933854|NCT05067595|EXPERIMENTAL|Arm I (upper FMT)|Patients receive upper FMT capsules PO over 2 days. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
61933855|NCT05067595|EXPERIMENTAL|Arm II (Lower FMT)|Patients undergo lower FMT via colonoscopy on day 0. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
61933856|NCT05067595|EXPERIMENTAL|Arm III (upper FMT, fiber supplementation)|Patients receive upper FMT capsules PO over 2 days. Patients receive fiber supplementation PO while on study. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
61933857|NCT05067595|EXPERIMENTAL|Arm IV (Lower FMT, fiber supplementation)|Patients undergo lower FMT via colonoscopy on day 0. Patients receive fiber supplementation PO while on study. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
61933858|NCT04575844|EXPERIMENTAL|Exercise Alone|24 weeks of treatment
61933859|NCT04575844|EXPERIMENTAL|Liraglutide Alone|24 weeks of treatment
61933860|NCT04575844|EXPERIMENTAL|Exercise + Liraglutide|24 weeks f treatment
61933861|NCT02544074||eSAGE score of 10|Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
61933862|NCT02544074||eSAGE score of 11|Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
61933863|NCT02544074||eSAGE score of 12|Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
62327022|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 1f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
62327023|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 2a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
62327024|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 2b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
62327025|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 2c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
62327026|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 2d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
62327027|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 2e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
62485349|NCT00493805|EXPERIMENTAL|Non interventional study arm (without insulin resistance)|"HOMA IR \<= 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to~European labeling)."
62485350|NCT00755677|OTHER|pulses|Interventional. Participants are registered sequentially to undergo daily consumption of pulses for eight weeks
61933864|NCT02544074||eSAGE score of 13|Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
61933865|NCT02544074||eSAGE score of 14|Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
61933866|NCT02544074||eSAGE score of 15|Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
61933867|NCT02544074||eSAGE score of 16|Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
61933868|NCT02544074||eSAGE score of 17|Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
61933869|NCT02544074||eSAGE score of 18|Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
61933870|NCT02544074||eSAGE score of 19|Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
61933871|NCT02544074||eSAGE score of 20|Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
61933872|NCT02544074||eSAGE score of 21|Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
61933873|NCT02544074||eSAGE score of 22|Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
61933874|NCT02544074||eSAGE score of 9|Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
61933875|NCT02544074||eSAGE score of 8|Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
61933876|NCT02544074||eSAGE score of 6|Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
61933877|NCT02544074||eSAGE score of 7|Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
61933878|NCT02544074||eSAGE score of 5|Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
61933879|NCT02544074||eSAGE score of 4|Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
61933880|NCT02544074||eSAGE score of 3|Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
61933881|NCT02544074||eSAGE score of 2|Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
61933882|NCT02544074||Smartphone eSAGE score of 13|Participants who score a 13 on the smartphone eSAGE. Interventions include neuropsychological testing.
62485351|NCT06338826|NO_INTERVENTION|Arm 1|- Arm 1 (reference arm): Continuation of continuous (7 days/week) triple antiviral therapy including TDF or TAF
62485352|NCT06338826|EXPERIMENTAL|Arm 2 (T4):|- Arm 2 (T4): Relief from previous triple antiviral therapy (containing TDF or TAF) on 4 out of 7 consecutive days
62485353|NCT06338826|EXPERIMENTAL|Arm 3 (B7)|Switch from prior triple antiviral therapy (containing TDF or TAF) to continuous dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
62485354|NCT02718963|EXPERIMENTAL|Control group|"* control group(N=10): who does not have dysphagia symptom~* apply Synchronized Electrical Stimulation Device~  * before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~ * during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
62485355|NCT02718963|EXPERIMENTAL|Experimental group|"* experimental group(N=10): who have dysphagia symptoms~* apply Synchronized Electrical Stimulation Device~  * before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~ * during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
62692820|NCT06674798|NO_INTERVENTION|Control Group|The control group will not receive any intervention, and the end-line assessment will be conducted after two months of the intervention from both the groups. However, to maintain ethical standards, one session regarding NCDs and their associated risk factors will be delivered by trained facilitators to the control group after the end-line assessment.
62692821|NCT06638359|EXPERIMENTAL|exercise|moderate intensity or interval exercise
62692822|NCT06638359|SHAM_COMPARATOR|control|without exercise
62692823|NCT00085839|EXPERIMENTAL|Erlotinib|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
62692824|NCT00085839|ACTIVE_COMPARATOR|Standard Chemotherapy|Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
61933883|NCT02544074||Smartphone eSAGE score of 14|Participants who score a 14 on the smartphone eSAGE. Interventions include neuropsychological testing.
62485356|NCT05247567|OTHER|First year students|Students in their first year of Hairdressing School
62692825|NCT06614933|EXPERIMENTAL|Biphasic followed by monophasic taVNS group|"Participants in the group Biphasic followed by monophasic taVNS will be in this group for up to 6 hours."
62692826|NCT06614933|ACTIVE_COMPARATOR|Monophasic followed by biphasic taVNS group|"Participants in the group monophasic followed by biphasic will be in this group for up to 6 hours."
62692827|NCT04366531|NO_INTERVENTION|Monitoring/Treatment as usual|Veterans will not receive any study related interventions.
62692828|NCT04366531|ACTIVE_COMPARATOR|Reentry Program|Veterans will receive the START-VET reentry program
62692829|NCT06174649|NO_INTERVENTION|Standard of Care|When a blood culture growing GNB is randomized standard of care arm the positive blood cultures will be characterized using standard of care antimicrobial susceptibility testing (AST)
62133700|NCT06027489|NO_INTERVENTION|Control|Nursing students with dysmenorrhea in the control group were informed that drawing and listening to music practices would be performed after the initial, second and third month evaluations of the study. In the meantime, it was stated that he should not make any interventions other than her routine applications. At baseline, second, and third month, participants will measure pain, menstrual symptoms, and perceived stress on the first day of the menstrual cycle using the VAS, MSS, and PSS, respectively.
62327028|NCT04170062|EXPERIMENTAL|Baseline followed by intervention 2f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
62327029|NCT01224691||Asmathics|Asmathics
62327030|NCT01224691||Non-Asmathics|Non-Asmathics
62327031|NCT03759379|EXPERIMENTAL|Vutrisiran + Vutrisiran (HELIOS-A)|Participants will receive vutrisiran 25 mg subcutaneous (SC) injection once every 3 months (q3M) for 18 months during the Treatment Period followed by vutrisiran 50 mg SC injection once every 6 months (q6M) or vutrisiran 25 mg q3M during the Randomized Treatment Extension (RTE) Period. Upon implementation of Amendment 6, participants receiving vutrisiran SC 50 mg q6M will transition to vutrisiran SC 25 mg q3M at their next scheduled dosing.
62485357|NCT05247567|OTHER|Third year students|Students in their third year of Hairdressing School
62327032|NCT03759379|ACTIVE_COMPARATOR|Patisiran + Vutrisiran (HELIOS-A)|Participants will receive patisiran 0.3 mg/kg intravenous (IV) infusion once every 3 weeks (q3w) for 18 months during the Treatment Period followed by vutrisiran 50 mg SC injection once q6M or vutrisiran 25 mg q3M during the RTE Period. Upon implementation of Amendment 6, participants receiving vutrisiran SC 50 mg q6M will transition to vutrisiran SC 25 mg q3M at their next scheduled dosing.
62327033|NCT03687359||Participants with atopic dermatitis (AD)|Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enroll in the study.
62327034|NCT06746246||1. Standard care with remote monitoring|"Liver cirrhosis patients participating in remote monitoring as part of new standard care pathway. They will give digital consent after subscription to the remote monitoring platform. Retrospective and prospective data will be gathered. Follow-up lasts 15 years, or until death.~Patients participating in remote monitoring can be approached to give feedback about remote monitoring in terms of satisfaction, usability, applicability, compliance and feasibility."
62327035|NCT06746246||Standard care without remote monitoring|Liver cirrhosis patients not participating in remote monitoring. They will not be approached for informed consent and give implicit consent for data gathering unless otherwise stated in their individual electronic patient record. Retrospective and prospective data will be gathered. Follow-up lasts 15 years, or until death.
62327036|NCT05142345|EXPERIMENTAL|CONTINUUM Intervention Post-Hospital Discharge|Participants will receive CONTINUUM intervention visit with a nurse practitioner within three business days of hospital discharge and complete questionnaires about their cancer and care.
62692830|NCT06174649|ACTIVE_COMPARATOR|Reveal|When a blood culture growing GNB is randomized to the Reveal arm, the positive blood culture will be characterized using Reveal, a rapid AST, and the standard of care AST.
61933884|NCT02544074||Smartphone eSAGE score of 15|Participants who score a 15 on the smartphone eSAGE. Interventions include neuropsychological testing.
61933885|NCT02544074||Smartphone eSAGE score of 16|Participants who score a 16 on the smartphone eSAGE. Interventions include neuropsychological testing.
62485358|NCT03922490|EXPERIMENTAL|Knee Arthroscopy + Adipose Derived Stem Cells (ADSC)|Experimental Group: will undergo diagnostic knee arthroscopy with injection of adipose derived stem cells. Will also carry out all procedures associated with study (Physical Exam, Magnetic Resonance Imaging (MRIs), X-rays, Questionnaires).
62692831|NCT01760863|EXPERIMENTAL|Oral Antibiotics|Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.
62692832|NCT01760863|NO_INTERVENTION|No oral antibiotics|No oral antibiotics.
62692833|NCT06673654|EXPERIMENTAL|Ruxolitinib Topical Cream 1.5%|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
62692834|NCT06673654|ACTIVE_COMPARATOR|OPZELURA (Ruxolitinib) Cream|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
62692835|NCT06673654|PLACEBO_COMPARATOR|Placebo Control|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
61933886|NCT02544074||Smartphone eSAGE score of 17|Participants who score a 17 on the smartphone eSAGE. Interventions include neuropsychological testing.
61933887|NCT02544074||Smartphone eSAGE score of 18|Participants who score a 18 on the smartphone eSAGE. Interventions include neuropsychological testing.
61933888|NCT02544074||Smartphone eSAGE score of 19|Participants who score a 19 on the smartphone eSAGE. Interventions include neuropsychological testing.
61933889|NCT02544074||Smartphone eSAGE score of 20|Participants who score a 20 on the smartphone eSAGE. Interventions include neuropsychological testing.
61933890|NCT02544074||Smartphone eSAGE score of 21|Participants who score a 21 on the smartphone eSAGE. Interventions include neuropsychological testing.
61933891|NCT02544074||Smartphone eSAGE score of 22|Participants who score a 22 on the smartphone eSAGE. Interventions include neuropsychological testing.
62327037|NCT05142345|ACTIVE_COMPARATOR|Usual Care Post-Hospital Discharge|Participants will receive standard oncology care following hospital discharge with follow-up appointments scheduled per primary team and participant preferences. Participants will complete questionnaires about their cancer and care.
62327038|NCT06746233|EXPERIMENTAL|Drug coated balloon (DCB)|Drug (paclitaxel) coated balloon (DCB) with concentration of 3 μg Paclitaxel per 1 mm2
62692836|NCT06644898|ACTIVE_COMPARATOR|Level walking|It will walk at a 0-degree slope (0) throughout the research.
62692837|NCT06644898|EXPERIMENTAL|Downhill walking|It will walk at a 10-degree downhill slope (-10) throughout the research.
62692838|NCT06644898|EXPERIMENTAL|Uphill walking|It will walk at a 10-degree uphill slope (+10) throughout the research.
62692839|NCT00515229|ACTIVE_COMPARATOR|1|Verum 1: Each individual capsule has a filling volume of 25 mg amitriptyline, given once an day in the evening over 28 days
61933892|NCT02291536|EXPERIMENTAL|tetrahydrocannabinol|oral administration of 10mg of tetrahydrocannabinol, once
61933893|NCT02291536|EXPERIMENTAL|cannabidiol|oral administration of cannabidiol, 600mg, once
61933894|NCT02291536|PLACEBO_COMPARATOR|placebo|oral administration of placebo, once
62692840|NCT00515229|ACTIVE_COMPARATOR|2|Verum 1: Each individual capsule has a filling volume of 50 mg amitriptyline, given once an day in the evening over 28 days
61933895|NCT02232191|ACTIVE_COMPARATOR|Nonoperative|Pneumococcal vaccine (Pneumovax-23) will be administered within 72 hours of injury. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
61933896|NCT02232191|ACTIVE_COMPARATOR|Angioembolization|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after embolization. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
61933897|NCT02232191|ACTIVE_COMPARATOR|Splenectomy|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after splenectomy. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
61933898|NCT02372240|EXPERIMENTAL|VLX1570 and dexamethasone|"VLX1570 IV (0.05, 0.15, 0.3, 0.6, 1.2, 2.0 mg/kg) on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle~Dexamethasone 20 mg PO/IV"
61933899|NCT03552458|EXPERIMENTAL|LR group|Lactobacillus Reuteri Oral Solution \[BioGaia\]
61933900|NCT03552458|PLACEBO_COMPARATOR|Placebo group|Placebos: The control agent will not contain the active agent
61933901|NCT06143553|EXPERIMENTAL|Paclitaxel Polymeric Micelles for Injection|300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
62327039|NCT06746233|ACTIVE_COMPARATOR|Second generation of drug eluting stents (DES)|Drug eluting stent (DES)
62327040|NCT06746649|EXPERIMENTAL|Morning group|The experimental factor will be applied in the morning (8:00-9:00).
62327041|NCT06746649|EXPERIMENTAL|Afternoon group|The experimental factor will be applied in the afternoon (16:00-17:00).
62692841|NCT00515229|ACTIVE_COMPARATOR|3|Verum 3: Each individual capsule has a filling volume of 75 mg amitriptyline, given once an day in the evening over 28 days
62692842|NCT00515229|PLACEBO_COMPARATOR|0|Placebo: Each individual capsule has a filling volume of 25 mg placebo (corn starch), given once an day in the evening over 28 days
62692843|NCT06256016|EXPERIMENTAL|Neck pain massage|Subjects in this group will be treated with a neck muscle massage protocol.
62692844|NCT06256016|EXPERIMENTAL|Neck and thoracic massage|Subjects in this group will be treated with a massage protocol of the neck muscles and the posterior thoracic region.
62692845|NCT06369545|EXPERIMENTAL|GROUP I: TENS|PHYSIOTHERAPY PROGRAM PLUS TENS
62692846|NCT06369545|ACTIVE_COMPARATOR|GROUP II: ESWT|PHYSIOTHERAPY PROGRAM PLUS ESWT
62692847|NCT06644443|EXPERIMENTAL|Experimental：Treatment group|patients treated with BCMA-GPRC5D CAR-T cells
62327042|NCT06746649|NO_INTERVENTION|Control group|None expertimental factor will be aplied
62327043|NCT05377489|EXPERIMENTAL|RTX-GRT7039|Participants will receive injections of RTX-GRT7039 into either the index knee (affected knee or in case of bilateral OA the knee with highest pain intensity), or each of both knees up to Week 52.
62327044|NCT06747858|EXPERIMENTAL|Cohort 1|Dose Level A of ARCT-032, inhaled daily for 28 days
62327045|NCT06747858|EXPERIMENTAL|Cohort 2|Dose Level B of ARCT-032, inhaled daily for 28 days
62485359|NCT03922490|OTHER|Observation Cohort: Knee Arthroscopy|Observational Group: will undergo diagnostic knee arthroscopy (No injection of adipose derived stem cells). Will also carry out all procedures associated with study (Physical Exam, MRIs, X-rays, Questionnaires).
62485360|NCT00374231|EXPERIMENTAL|Immunosuppression|All the patients who enroll in this study will receive the same medications (tacrolimus, mycophenolate mofetil, and a short course of steroids) to prevent rejection of the liver transplant. All participants will be gradually taken off prednisone if they are 90 days or longer post liver transplant and have not had a rejection in the last 30 days.
62485361|NCT05169710|EXPERIMENTAL|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg/day
62485362|NCT05169710|EXPERIMENTAL|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg/day
62485363|NCT05169710|PLACEBO_COMPARATOR|Placebo|Placebo
61933902|NCT06143553|ACTIVE_COMPARATOR|The Doctor chooses the treatment（TPC）|"Control Group：The Doctor chooses the treatment（TPC）：Eribulin Mesilate injection；Capecitabine Tablets；Gemcitabine Hydrochloride for Injection；Vinorelbine Tartrate Injection；Paclitaxel (albumin-bound).~Eribulin Mesilate injection：on days 1 and 8 of the 21-day cycle, 1.4 mg/m2 , intravenous administration; Capecitabine Tablets: On days 1 to 14 of the 21-day cycle, 1000-1250mg/m2，oral administration, twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2); Gemcitabine Hydrochloride for Injection: On days 1, 8 and 15 of the 28-day cycle, 800-1200mg/m2, intravenous administration; Vinorelbine Tartrate Injection: Every first day of the week, 25mg/m2，intravenous administration; Paclitaxel (albumin-bound): On day 1 of the 21-day cycle, 260mg/m2，intravenous administration for more than 30 minutes. Three weeks constituted one course of treatment."
61933903|NCT00949273||cylindrical abdominoperineal resection|patients underwent cylindrical abdominoperineal resection for advanced very low rectal cancer
61933904|NCT00949273||abdominoperineal resection|patients underwent conventional abdominoperineal resection for advanced very low rectal cancer
61933905|NCT00638807|EXPERIMENTAL|A|
61933906|NCT00638807|PLACEBO_COMPARATOR|B|
62327046|NCT06747858|EXPERIMENTAL|Cohort 3|Dose Level C of ARCT-032, inhaled daily for 28 days
61933907|NCT06547021|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|Participants will receive tDCS simultaneously with cognitive exercises for one month every day excluding weekends.
61933908|NCT06547021|EXPERIMENTAL|Gamma Transcranial Alternating Current Stimulation (tACS)|Participants will receive personalized gamma tACS simultaneously with cognitive exercises for one month every day excluding weekends.
62133701|NCT06027489|EXPERIMENTAL|Music Group|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore) \[21\]. Written permission was obtained from Juan Sebastian Martin-Saavedra to use the composed song in the research. The access link of the composed song will be sent to the participants via social media (WhatsApp).
61933909|NCT06547021|EXPERIMENTAL|Theta Transcranial Alternating Current Stimulation (tACS)|Participants will receive personalized theta tACS simultaneously with cognitive exercises for one month every day excluding weekends.
62485364|NCT06563193||overactive bladder group|OAB was diagnosed according to the patient's complaint of urgency with or without urge incontinence as the core symptom according to the criteria defined by the International Continence Society
62327047|NCT06747806||Patients who undergo cardiac surgery and procedures|Patients who undergo cardiac surgery and procedures will have tissue specimens that are removed during surgery and collected blood samples of 5 mL.
62327048|NCT05041309||Axicabtagene Ciloleucel (KTE-C19)|All participants who previously received axicabtagene ciloleucel (KTE-C19) in the parent study will be enrolled in this cohort for long-term follow-up.
62327049|NCT05041309||Brexucabtagene Autoleucel (KTE-X19)|All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this cohort for long-term follow-up.
62485365|NCT06563193||control group|As a control group, patients who were admitted to the outpatient clinic for other reasons and who did not have OAB symptoms and have normal voiding functions were included
62485366|NCT01649921|ACTIVE_COMPARATOR|Interferon-gamma|
62485367|NCT01649921|PLACEBO_COMPARATOR|Saline 0.9%|
62485368|NCT01616823||HIV Positive Women|HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
62485369|NCT03768635||Necrotizing external otitis|description of necrotizing external otitis
62485370|NCT03932045|EXPERIMENTAL|SYB Filler (SF-01)|PCL filler
62485371|NCT03932045|ACTIVE_COMPARATOR|Ellansé M|PCL filler
62485372|NCT06241222|NO_INTERVENTION|control group|pregnancies in control group need no intervention.
62485373|NCT06241222|EXPERIMENTAL|probiotics group|pregnancies in probiotics group need probiotics management
62485374|NCT03272685|EXPERIMENTAL|Very Low Nicotine Content Cigarettes|Very Low Nicotine Content Cigarettes (0.4 mg nicotine/g tobacco; 9 mg of tar): Median nicotine content, averaged across menthol and non-menthol cigarettes:
62485375|NCT03272685|ACTIVE_COMPARATOR|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (15.8 mg nicotine/g tobacco; 9 mg of tar): Median nicotine content, averaged across menthol and non-menthol cigarettes
62485376|NCT05465863|ACTIVE_COMPARATOR|Patients|
62485377|NCT05465863|ACTIVE_COMPARATOR|Healthy controls|
61933910|NCT06547021|EXPERIMENTAL|Sham Stimulation|Participants will receive sham stimulation simultaneously with cognitive exercises for one month every day excluding weekends.
62485378|NCT02584608|EXPERIMENTAL|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
62485379|NCT02889107|NO_INTERVENTION|standard care|Patients received standard listening strategies for 10 weeks
62485380|NCT02889107|EXPERIMENTAL|intervention|Patients received an assistive listening device (personal frequency modulated systems) for 10 weeks
62485381|NCT06371807|ACTIVE_COMPARATOR|Arm 1: (KXCb - PA[E]C)|Pembrolizumab (K) every 3 weeks (Q3W) + paclitaxel (X) + carboplatin (Cb) once weekly (QW) for 4 cycles in the neoadjuvant setting followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) for 4 cycles followed by pembrolizumab every 6 weeks for 5 cycles (total of 1 year of pembrolizumab) in the adjuvant setting.
62485382|NCT06371807|EXPERIMENTAL|(KPA[E]C - KXCb)|Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) for 4 cycles in the neoadjuvant setting followed by pembrolizumab (K) every 3 weeks (Q3W) + paclitaxel (X) + carboplatin (Cb) once weekly (QW) for 4 cycles followed by pembrolizumab every 6 weeks for 5 cycles (total of 1 year of pembrolizumab) in the adjuvant setting
62485383|NCT05327777|NO_INTERVENTION|Control|Normal standard practices
62485384|NCT05327777|EXPERIMENTAL|Opioid Sparing|Providers required to prescribe 10 narcotic pills only
62485385|NCT05327777|EXPERIMENTAL|Zero Opioid|No narcotic prescription is provided to patient at discharge
62485386|NCT02393014|EXPERIMENTAL|Low fall risk|low fall risk patients
62485387|NCT02393014|EXPERIMENTAL|Medium fall risk|medium fall risk patients
62485388|NCT02393014|EXPERIMENTAL|High fall risk|high fall risk patients
62327050|NCT05041309||Anitocabtagene autleucel|All participants who previously received anitocabtagene autleucel in the parent study will be enrolled in this cohort for long-term follow-up.
62327051|NCT05041309||KITE-753|All participants who previously received KITE-753 in the parent study will be enrolled in this cohort for long-term follow-up.
62327052|NCT05041309||KITE-197|All participants who previously received KITE-197 in the parent study will be enrolled in this cohort for long-term follow-up.
62327053|NCT05041309||KITE-363|All participants who previously received KITE-363 in the parent study will be enrolled in this cohort for long-term follow-up.
62485389|NCT03864380||Person running a marathon|"Exams performed before (1 month maximum) and after the marathon (1 hour maximum) :~Color retinography Optical Coherence Tomography - Angiography (OCT-A) Blood pressure measurement"
62485390|NCT03336580|EXPERIMENTAL|PRX004|"Dose escalation in up to 6 dose levels~Expansion of previously studied cohort(s) from Dose Escalation~Extended dosing at RP2D"
62485391|NCT01347749|EXPERIMENTAL|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
62485392|NCT01347749|ACTIVE_COMPARATOR|Present Centered Therapy for PTSD|This is a more standard from of group psychotherapy (talk therapy) which focusses on current symptoms and stressors
62485393|NCT06093919||Liver transplant patients|This cohort will consist of all liver transplant patients followed between 01/01/2023 and 06/30/2024
62485394|NCT02185144|EXPERIMENTAL|PATH for Triples (PFT)|The Nurse Health Navigator (NHN) meets at least weekly with the experimental participants to implement the adherence component of PFT using approaches tailored to the communication and comprehension of the person that includes memory aids, education regarding side effects and other treatment aspects, engagement with participants' social networks and treatment providers, and active community outreach. PFT will be implemented for 6 months and participants will be followed for an additional 3 months to allow examination of potential decay of the intervention after it is withdrawn.
62485395|NCT02185144|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|Participants in the the Treatment as Usual (TAU) group receive usual treatment after inpatient care.
62485396|NCT00834132|EXPERIMENTAL|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
62485397|NCT00834132|ACTIVE_COMPARATOR|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
62327054|NCT05349838|EXPERIMENTAL|DTG/RPV FDC Regimen|One combined Dolutegravir 50mg /Rilpivirine 25mg FDC tablet taken orally once daily
62327055|NCT05349838|ACTIVE_COMPARATOR|Continued ART Regimen|Patients will continue the current boosted PI regimen (or other antiretroviral combination) for 48 weeks. Patients will then be switched to one combined Dolutegravir/Rilpivirine FDC tablet taken orally once daily for 48 weeks.
62485398|NCT03036228|EXPERIMENTAL|Dose escalation|Karonudib is an oral inhibitor of MTH1 supplied as an oral solution and now as tablets. Each cycle is defined as 28 days.
62485399|NCT05952739||Disease group|No interventions
62485400|NCT05952739||Control group|No interventions
62485401|NCT02469363|ACTIVE_COMPARATOR|Macintosh laryngoscope|Endotracheal intubation with classic (Macintosh) laryngoscope
61933911|NCT06708000|EXPERIMENTAL|Clinical Likelihood-Based Diagnostic Strategy|Patients in this arm will be assessed using the Clinical Likelihood (CL) models, including the Risk Factor-Weighted Clinical Likelihood (RF-CL) and Coronary Artery Calcium Score-Weighted Clinical Likelihood (CACS-CL) models.
61933912|NCT06708000|ACTIVE_COMPARATOR|Standard of Care|Patients in this arm will follow the standard diagnostic pathway.
62327056|NCT06747832|EXPERIMENTAL|iNK Cell therapy group|Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.
62485402|NCT02469363|ACTIVE_COMPARATOR|Mc-Coy laryngoscope|Endotracheal intubation with Mc-Coy laryngoscope
62485403|NCT02469363|ACTIVE_COMPARATOR|C-Mac videolaryngoscope|Endotracheal intubation with C-Mac videolaryngoscope
62485404|NCT02469363|ACTIVE_COMPARATOR|McGrath videolaryngoscope|Endotracheal intubation with McGrath videolaryngoscope
62485405|NCT04614155|EXPERIMENTAL|Screening (questionnaire, health education, self-collection)|Participants complete questionnaires, take part in a health education session, and receive HPV self-collection kit.
62485406|NCT03324139|EXPERIMENTAL|Study Group|Treatment with low molecular weight Heparin.
62485407|NCT03324139|PLACEBO_COMPARATOR|Control Group|Treatment with Placebo.
62485408|NCT04879537|NO_INTERVENTION|Control|Participants in this group are routinely treated.
62485409|NCT04879537|ACTIVE_COMPARATOR|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
62485410|NCT01326663|ACTIVE_COMPARATOR|divalproex sodium|
62133702|NCT06027489|EXPERIMENTAL|Drawing Group|In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn. After drawing pictures three days before the menstrual cycle and the first day of menstruation (for a total of four days), pain, menstrual symptoms, and perceived stress on the first day of menstruation will be measured using the VAS, MSS, and PSS, respectively.
62485411|NCT01326663|PLACEBO_COMPARATOR|sugar pill|
62485412|NCT06368154||Less than 32 weeks|The gestational age was less than 32 weeks, there was no history of surgery, blood transfusion, congenital malformation and inherited metabolic diseases. The corrected gestational age of less than 44 weeks。
62485413|NCT06368154||32 to 36+6 weeks|The gestational age was 32-36+6 weeks, there was no history of surgery, blood transfusion, congenital malformation and inherited metabolic diseases. The corrected gestational age of less than 44 weeks。
62692848|NCT06039761|EXPERIMENTAL|local intraperitoneal anesthetics + alveolar recruitment maneuver + abdominal compression maneuver|Overall Procedure : The specific interventions are carried out at the end of the surgical intervention and include the use of intraperitoneal local anesthetics insufflated by the surgeon, the alveolar recruitment maneuver carried out by the anesthetist and that of abdominal compression carried out by the surgeon.
62692849|NCT06039761|ACTIVE_COMPARATOR|Standard Procedure|Standard Procedure : Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia.
62692850|NCT06534723|EXPERIMENTAL|Wujia Yizhi Granules|Participants received Wujia Yizhi Granules 6g ,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 months.
62692851|NCT06534723|PLACEBO_COMPARATOR|Placebo|Participants received Wujia Yizhi granules simulator 6g ,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 months.
62692852|NCT06502418|EXPERIMENTAL|Acupuncture arm|Acupuncture therapy
61933913|NCT02294773|ACTIVE_COMPARATOR|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
62327057|NCT04164472|EXPERIMENTAL|Friend to Friend with Coaching|Program for relationally aggressive girls and their classmates delivered by school personnel who have been coached by study team.
62327058|NCT04164472|NO_INTERVENTION|Control|Referral to school counselor as needed as per standard practice.
62327059|NCT06284408|OTHER|Centralized Screening Unit (CSU)|"The CSU intervention will shift workflow by leveraging EMR data to direct automated messages to LCS-eligible patients, inviting them to connect with the CSU. The CSU incorporates evidence-based strategies for active outreach to inform patients about LCS and to offer support from lay navigators. Patients are identified through meaningful use of medical records data"
62327060|NCT06284408|NO_INTERVENTION|No Intervention Yet Started|"Standard of Care during the no intervention period"
62692853|NCT06502418|NO_INTERVENTION|Control arm|usual care
62692854|NCT04817436|ACTIVE_COMPARATOR|Without adapted physical activity program (APA)|
62692855|NCT04817436|EXPERIMENTAL|With adapted physical activity program (APA)|
62327061|NCT05360329|EXPERIMENTAL|Mild to moderate knee osteoarthritis (Kellgren Lawrence Score 1-3)|Geniculate artery embolization will be performed in all eligible participants.
62327062|NCT05964413|EXPERIMENTAL|vilobelimab|Patients will be treated with vilobelimab IV, Q2W for 26 weeks
62327063|NCT05964413|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo IV in the same schedule as patients in Arm 1
62327064|NCT06276023|EXPERIMENTAL|Mindful and Self-Compassionate Care Program (MASC)|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
62485414|NCT06368154||control group|Term infants with a gestational age of 37+0-41+6 weeks, no blood transfusion, no surgery, no congenital malformation, no inherited metabolic diseases, no history of parenteral nutrition, no intestinal diseases. The corrected gestational age of less than 44 weeks.
62485415|NCT00625560|EXPERIMENTAL|A|entecavir 1.0 mg QD
61933914|NCT02294773|ACTIVE_COMPARATOR|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
61933915|NCT03272230|EXPERIMENTAL|Arm 1|The Arm consists of two separate visits, each occurring on a different day, and includes the following components: the ECOCAPTURE observation phase in ecological conditions, a comprehensive neuropsychological assessment, a series of experimental tasks (some of which are computer-based), an MRI scan (including T1, T2, rs-fMRI, and MS-DWI), and a blood sample collection.
61933916|NCT02218983|EXPERIMENTAL|Limited transthoracic echocardiogram (LTTE)|LTTE (SonoSite Ultrasound), which will be performed every 10 - 30 minutes, after each fluid challenge or transfusion, until two consecutive equivalent measurements are reached without fluid challenge or transfusion
61933917|NCT02218983|ACTIVE_COMPARATOR|Usual care|measurements on :blood pressure, heart rate, urine output, lactate, lactate clearance (after 6 hrs), base deficit, creatinine
61933918|NCT03506932|EXPERIMENTAL|Untreated|Bread containing 20% yellow pea flour.
61933919|NCT03506932|EXPERIMENTAL|Heat treated with 0% moisture|Bread containing 20% yellow pea flour.
62485416|NCT00625560|ACTIVE_COMPARATOR|B|lamivudine 100 mg QD
62485417|NCT05324033||muscle invasive cancer bladder|
62485418|NCT05324033||non-muscle invasive cancer bladder|
61933920|NCT03506932|EXPERIMENTAL|Heat treated with 10% moisture|Bread containing 20% yellow pea flour.
61933921|NCT03506932|ACTIVE_COMPARATOR|Wheat|Bread made with 100% wheat flour
61933922|NCT00862290||sepsis group|Patients who develop sepsis in the ICU
62485419|NCT04692155|EXPERIMENTAL|phase 1b and phase 2|"for phase 1 B portion, Ublitixumab will be given IV at dosage 900mg from Cycle 1 Day1 till cycle 6. If investigator decides to continue the treatment as maintenance, Ublitixumab will be given IV every 8 weeks for 24 months Umbralisib (800mg) will be given orally once a day within 30 minutes of a meal from Cycle 1 Day1 till cycle 6.If investigator decides to continue the treatment as maintenance,• Umbralisib will be given at orally daily for 24 months.~Chemotherapy combination of CHOP-cyclophosphamide IV 750mg/m2 for Age \<70 years, 500 mg/m2 for Age\>70 years doxorubicin IV 50mg/m2for Age \<70 years, 25 mg/m2 for Age\>70 years , and vincristine IV 1mg/m2 (max 2mg)) are administered on Cycle 1 day 1 till Cycle 6. Prednisone 50-100mg will be given orally on days 1 through 5 of every cycle.~For Phase II portion- Once Umbralisib dose is defined in phase Ib, the study will expand to phase II portion after SMC/DSMB (Safety monitoring committee/Data Safety Monitoring Committee) agrees."
62485420|NCT05780463|EXPERIMENTAL|MP0420 plus SOC|"* MP0420 600 mg solution (4 vials of 15 mg/mL); administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62485421|NCT05780463|PLACEBO_COMPARATOR|Placebo plus SOC|"* Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
62485422|NCT06219941|EXPERIMENTAL|Sub Study 1 - AZD0901 MONOTHERAPY|Sub Study 1 will investigate AZD0901 monotherapy in order to evaluate the safety, tolerability, and efficacy of AZD0901.
62485423|NCT06219941|EXPERIMENTAL|Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS|Substudy 2 will investigate the safety and efficacy of AZD0901 as first line systemic treatment used in combination with different chemotherapy agents
61933923|NCT00862290||SIRS group|Patients who develop SIRS after cardiac surgery with cardiopulmonary bypass
61933924|NCT00862290||control group|normal healthy volunteers
61933925|NCT03815617|ACTIVE_COMPARATOR|Probiotic|The study design is a crossover randomized double-blind two-block placebo-controlled single center trial with an allocation ratio of 1:1 conducted between February 2017 and May 2018. Subjects are randomized at baseline visit to receive Block 1 (Zircombi 3 g, containing Bifidobacterium longum BB536 four billion CFU, Lactobacillus rhamnosus HN001 one billion CFU with B6 vitamin 1.4 mg) and Block 2 (placebo: maltodextrins, corn starch, silicon dioxide) depending on the randomization sequence. Subjects received one sachet pack daily containing placebo or probiotic. The active treatment was undistinguishable from placebo by physical and organoleptic characteristics. Participants in the study followed a free diet.
61933926|NCT03815617|PLACEBO_COMPARATOR|Placebo|Same appearance of probiotic.
62327065|NCT06276023|ACTIVE_COMPARATOR|Health Education Program (HEP)|"The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives."
62327066|NCT06746727|EXPERIMENTAL|ACT-SHARE|This is a single-arm intervention with all participants assigned to receive Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE). ACT-SHARE has been adapted for this study from existing interventions using Acceptance and Commitment Therapy (ACT) to address alcohol use, PTSD, social functioning, and IPV use.
62485424|NCT02570958|EXPERIMENTAL|Indocyanine green|
62485425|NCT04921696||RBC transfusion|RBC was transfused to the infants.
62485426|NCT04921696||no-RBC transfusion|RBC was not transfused to the infants.
62692856|NCT05245058|EXPERIMENTAL|SPH5030 tablets|"Subjects will take SPH5030 tablets orally on an empty stomach once or twice a day.~Each subject will receive only one corresponding dose, and there were five dose groups: 50mg/ d, 100mg/ d, 200mg/ d, 300mg/ d and 400mg/ d."
62327067|NCT06746389|EXPERIMENTAL|Vitamin D|3000 IU/Day 12 weeks
62327068|NCT06746389|PLACEBO_COMPARATOR|Placebo|Placebo one/day 12 weeks
62485427|NCT06267625||Elderly Individuals|This group will consist of individuals aged 65 and over
62485428|NCT00700739|OTHER|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
62485429|NCT00700739|ACTIVE_COMPARATOR|Cervical Total Disc Replacement|DISCOVER™ Artificial Cervical Disc
62485430|NCT04292548||study group (passive smoking children)|
62485431|NCT04292548||control group|
62485432|NCT02235922|EXPERIMENTAL|Dual task training|Dual task training
62485433|NCT02235922|EXPERIMENTAL|Conventional training|Conventional training
62485434|NCT02716311|OTHER|Afatinib|Afatinib 40 mg/d until progression
62485435|NCT02716311|EXPERIMENTAL|Afatinib + cetuximab|Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²)
62692857|NCT05547464|EXPERIMENTAL|BNT164a1|Escalating dose levels
62692858|NCT05547464|EXPERIMENTAL|BNT164b1|Escalating dose levels
62692859|NCT05547464|PLACEBO_COMPARATOR|Placebo|Isotonic sodium chloride (NaCl) solution (0.9%)
62692860|NCT01832038|EXPERIMENTAL|Lacosamide|Lacosamide treatment of 100 - 400 mg/day for long-term
62692861|NCT05983705|EXPERIMENTAL|Experiment group|The experiment group will receive written psychoeducation about children with externalizing behaviors, and start their parental program AFFEKT approximately one week from the information meeting (baseline).
61933927|NCT06003569|NO_INTERVENTION|Usual care|School nurses/schools randomized to usual care will continue to receive their usual care from school nurses and then subsequently provide the intervention given their asthma remains poorly controlled at the start of the next school year following enrollment.
61933928|NCT06003569|EXPERIMENTAL|BACK-S|The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly).
61933929|NCT06003569|EXPERIMENTAL|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
62692862|NCT05983705|ACTIVE_COMPARATOR|Control group|The control group will receive written psychoeducation about children with externalizing behaviors, and start their parental program AFFEKT approximately seven weeks from the information meeting (when the experiment group has finished their AFFEKT program).
61933930|NCT01077232||Psoriasis Patients|Patients with moderate to severe plaque psoriasis
61933931|NCT01222858|ACTIVE_COMPARATOR|Internet Education Program|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors.
61933932|NCT01222858|EXPERIMENTAL|Innovative Technology Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback.
61933933|NCT06247800|ACTIVE_COMPARATOR|Patient undergoing chest drain with the use of VR device|Patient undergoing chest drain with the use of VR device on, for those on VR device, they will be shown a video consisting of calming nature scene together with soothing instrumental music.
61933934|NCT06247800|ACTIVE_COMPARATOR|Patient undergoing chest drain without the use of VR device|Patient undergoing chest drain without the use of VR device on, as per standard practise
61933935|NCT01840618||Obese PCOS and sleep apnea|"BMI \>95%ile AND Polysomnography with AHI \>2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
61933936|NCT01840618||Obese PCOS without sleep apnea|BMI \>95%ile AND Polysomnography with AHI \<2.5
61933937|NCT01840618||Normal weight Controls|BMI \<85%ile AND regular menses
61933938|NCT01840618||Lean PCOS and sleep apnea|"BMI \<85%ile AND Polysomnography with AHI \>2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
61933939|NCT01840618||Lean PCOS without sleep apnea|BMI \<85%ile AND Polysomnography with AHI \<2.5
61933940|NCT00311662|EXPERIMENTAL|1|Tonabersat 40mg
61933941|NCT00311662|PLACEBO_COMPARATOR|2|
61933942|NCT01439568|EXPERIMENTAL|LY2510924 + Carboplatin + Etoposide|"LY2510924: 20 milligram (mg) administered once daily as a subcutaneous(SC) injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m\^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
61933943|NCT01439568|ACTIVE_COMPARATOR|Carboplatin + Etoposide|"Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m\^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
61933944|NCT00884533|EXPERIMENTAL|Group 1|Group 1 - placebo on Day -1, rosi XR 8mg from Days 1-20, rosi XR 20mg on Day 21
61933945|NCT00884533|PLACEBO_COMPARATOR|Group 3|Placebo on Day -1, Days 1-20 and Day 21
61933946|NCT00884533|ACTIVE_COMPARATOR|Group 2|Placebo for Day -1, placebo on Days 1-20 and moxifloxacin active comparator 400 mg on Day 21
61933947|NCT04524169|EXPERIMENTAL|Thymosin Alpha 1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
61933948|NCT04524169|NO_INTERVENTION|Standard Care|Participants under the regularly treatment
61933949|NCT06707727||myasthenia gravis|
61933950|NCT06707727||controls|
61933951|NCT06639217|EXPERIMENTAL|a comprehensive nursing care protocol|a comprehensive nursing care protocol provided for nurses who provide direct care for women with pelvic organ prolapse and urinary incontinence on their knowledge and practices as well as its impact on the women quality of life
61933952|NCT04072575|EXPERIMENTAL|Paliperidone Palmitate 6 month(PP6M)|"Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level (moderate or higher) that the participant received during previous study. Participants in the moderate dose level will receive PP6M Dose 1 and higher dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months."
62327069|NCT04789044|EXPERIMENTAL|PEG mediated reconstruction|NTX-001 will be administered topically via isolation chamber medical device. Dose Unit: 2.5 mL NTX-001 is a single use surgical product intended for use as adjunct treatment in the repair of severed peripheral nerves in patients requiring standard suture neurorrhaphy.
62327070|NCT04789044|NO_INTERVENTION|Conventional nerve reconstruction|Conventional nerve reconstruction
61933953|NCT01407744||Correlative studies|Archived tumor tissue samples are analyzed by laboratory biomarker analysis for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix MIP arrays, and FISH. Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
61933954|NCT00857402|ACTIVE_COMPARATOR|Peanuts|
61933955|NCT00857402|ACTIVE_COMPARATOR|Daboqolo|
61933956|NCT02935101|EXPERIMENTAL|Prednisolon|Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
61933957|NCT02935101|PLACEBO_COMPARATOR|Placebo|Identical looking capsules like the IMP containing placebo (without active component) for oral administration.
61933958|NCT05695196|EXPERIMENTAL|direct NMT|swab parent nares then insert swab directly into neonate nares
61933959|NCT05695196|EXPERIMENTAL|indirect NMT|swab parent nares, inoculate swab into saline, instill liquid into neonate nares
61933960|NCT05695196|PLACEBO_COMPARATOR|placebo|instill sterile saline into neonate nares
62133703|NCT01499316|EXPERIMENTAL|High Flow oxygen|10 minute of 10/L min of inhaled oxygen with reservoir bag.
62133704|NCT01499316|EXPERIMENTAL|Room Air|
62133705|NCT05057936||Control|Healthy healthcare workers
62692863|NCT05395312|EXPERIMENTAL|Blended stepped-care group|Participants in the blended stepped-care group can access the online materials at levels based on their psychological distress through login to the platform of the JCTH+ project. They can choose their preferred online courses by using online course taster. Also, they can join offline programs corresponding to their levels of psychological distress.
62692864|NCT05395312|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will receive their usual treatment and follow their usual practice if any. They will be offered the opportunity to receive the services in the blended stepped-care group after the study has ended.
62692865|NCT06094855||Persons with Multiple sclerosis|Persons with a diagnosis of Multiple Sclerosis
62327071|NCT06747585|EXPERIMENTAL|Phase I Dose Escalation- ALE.P02|Patients will receive ALE.P02 as monotherapy via intravenous infusion. The ALE.P02 will be given at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Phase I dose escalation part of the study.
62327072|NCT06747585|EXPERIMENTAL|Phase I Dose Expansion- ALE.P02|Patients will receive ALE.P02 as monotherapy via intravenous infusion. The safe recommended dose of ALE.P02 will be given in Phase I dose expansion part of the study to identify Recommended Phase II Dose (RP2D) for Phase II.
62327073|NCT06747585|EXPERIMENTAL|Phase II- ALE.P02|Patients will receive ALE.P02 as monotherapy via intravenous infusion at the RP2D, or according to the dosing schedule after the dose expansion phase.
62327074|NCT06746883||Acinetobacter baumannii-calcoaceticus complex (ABC)|Hospitalized participants with a proven or strongly suspected ABC infection who have received sulbactam-durlobactam as standard of care.
62327075|NCT06745973|EXPERIMENTAL|EPI-003|
62327076|NCT06747065||PU covered implants|prepectoral IBBR with a PU covered implant followed by radiotherapy
62327077|NCT06747065||non-PU covered implants|prepectoral IBBR with a non-PU covered implant followed by radiotherapy
62327078|NCT06746376|EXPERIMENTAL|Intervention|"Description:~Participants assigned to the intervention group will undergo a 8-week supervised hand exercise program designed to improve pain, manual dexterity, and functionality. Sessions will last 45 minutes and occur once per week under the supervision of a qualified occupational therapist and one self-administrated home exercise session. The program includes three structured phases per session~Warm-Up Phase (10 minutes)~Gentle hand and wrist stretches Main Exercise Phase (25 minutes)~This phase focuses on strengthening, manual dexterity, and functional tasks:~Strengthening Exercises~Manual Dexterity Exercises~Functional Tasks (Simulated Activities of Daily Living - AVDs):~Cool-Down Phase (10 minutes)~8 weeks, with 45-minute sessions twice weekly."
62327079|NCT06746376|NO_INTERVENTION|Control|"Description:~Participants in the control group will not receive any intervention during the study period. They will undergo the same assessments as the intervention group at baseline and after 8 weeks to evaluate changes over time.~Details:~The control group will serve as a comparison to determine the effects of time alone on pain, manual dexterity, and hand functionality in women with hormone therapy-related arthralgia.~Participants will continue their usual daily activities and standard care during the study period.~No specific exercises or additional therapies will be provided as part of the study."
62327080|NCT06747624|EXPERIMENTAL|Geranylgeraniol 300 mg|
62692866|NCT04126785|PLACEBO_COMPARATOR|Control without exercise in heated water-based|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the xiphoid process level for 30 min.
62327081|NCT06747624|PLACEBO_COMPARATOR|Placebo|
62327082|NCT06746831|EXPERIMENTAL|S-Meth, R-Meth, Racemic Isomer|First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine
62327083|NCT06746831|EXPERIMENTAL|R-Meth, Racemic Isomer, S-Meth|First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth
62327084|NCT06746831|EXPERIMENTAL|Racemic Isomer, S-Meth, R-Meth|First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth
62327085|NCT06747494|EXPERIMENTAL|General Anesthesia|Participants in this group will receive general anesthesia for TJA for up to 2 hours.
62327086|NCT06747494|EXPERIMENTAL|Spinal Anesthesia|Participants in this group will receive spinal anesthesia for TJA for up to 2 hours.
62327087|NCT06747845|EXPERIMENTAL|Niraparib + Ipilimumab (Arm A)|niraparib + ipilimumab
62327088|NCT06747845|OTHER|FOLFIRI (Arm B)|standard chemotherapy FOLFIRI
62327089|NCT06747273|EXPERIMENTAL|SRP-9004|Participants will receive a single dose of SRP-9004 on Day 1.
62327090|NCT06747325|EXPERIMENTAL|Test group|The patients in the trial group received routine standard treatments, and oral Fei Re Qing Granules (One bag/time, 3 times/day).
62327091|NCT06747325|PLACEBO_COMPARATOR|Control group|The patients in the control group received routine standard treatments, and Placebo granules
62327092|NCT06747247|EXPERIMENTAL|SAD Study- MT1013|SAD Study: Patients receive a single dose of MT1013 via IV, three times per week after dialysis.
62692867|NCT04126785|EXPERIMENTAL|High Intensity Interval Exercise in Heated Water|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
62692868|NCT04126785|EXPERIMENTAL|Continuous Moderate Exercise in Heated Water|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light) level of RPE.
62692869|NCT00773591|ACTIVE_COMPARATOR|Botulinum Toxin Typ A|
62692870|NCT00773591|PLACEBO_COMPARATOR|Placebo|
62692871|NCT05300607||questionnaire|rotator cuff diseases patients will self report the items of the Arabic version of The Western Ontario Rotator Cuff Index questionnaire
62327093|NCT06747247|PLACEBO_COMPARATOR|SAD Study- Placebo|SAD Study: Patients receive a single dose of placebo via IV, three times per week after dialysis.
62327094|NCT06747247|EXPERIMENTAL|MAD Study- MT1013|MAD Study: Patients receive multiple doses of MT1013 three times a week via IV for a total of 2 weeks or 4 weeks (depending on different dose levels).
62327095|NCT06747247|PLACEBO_COMPARATOR|MAD Study- Placebo|MAD Study: Patients receive multiple doses of placebo three times a week via IV for a total of 2 weeks or 4 weeks (depending on different dose levels).
62327096|NCT06747247|EXPERIMENTAL|Single Arm MT1013 Long Term Treatment|All patients will recieve MT1013 three times a week via IV after dialysis, for a total of 52 weeks.
62327097|NCT06126276|ACTIVE_COMPARATOR|Arm I (neratinib maleate)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
62327098|NCT06126276|EXPERIMENTAL|Arm II (neratinib maleate, palbociclib)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
62692872|NCT06639893|ACTIVE_COMPARATOR|Milled Titanium secondary copings|
61933961|NCT03617354||Trainee Gynaecologists|"1. RANZCOG accredited O\&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;~2. Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).~3. Will be able to attend each of the 10 training days."
61933962|NCT00959712|NO_INTERVENTION|Control|Subjects are given a pedometer and step count log in which to record their daily step counts for 1 year.
62133706|NCT05057936||Chronic kidney disease (CKD)|CKD stage 3-5 (eGFR \< 60 mL/min/1.73m3)
62133707|NCT05057936||Dialysis patients|CKD stage 5 requiring HD
62133708|NCT05057936||kidney transplant patients|patients receiving kidney transplantation for more than 3 months
62133709|NCT05057936||dialysis patients|CKD patients requring continuos ambulatory peritoneal dialysis
62133710|NCT04169256|EXPERIMENTAL|HYR-PB21 & Placebo|
62133711|NCT04169256|ACTIVE_COMPARATOR|Liposome Bupivacaine & Placebo|
62133712|NCT04938752|EXPERIMENTAL|Sequence I|
62133713|NCT04938752|EXPERIMENTAL|Sequence II|
62133714|NCT00494949|EXPERIMENTAL|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
62133715|NCT00494949|ACTIVE_COMPARATOR|Control|Ringer's lactate
62133716|NCT04687293|EXPERIMENTAL|HUBER|"HUBER is an isometric strengthening device. It consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed.~Intervention will consist of 2 sessions of HUBER per week. Each session lasts approximatively 30 minutes. The intervention is 8 weeks long."
62133717|NCT04687293|NO_INTERVENTION|Control|The control group will not received any intervention except usual care.
62133718|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
62133719|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
62133720|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
62133721|NCT03840902|EXPERIMENTAL|cCRT plus M7824 followed by M7824|Participants received cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with M7824 followed by M7824.
62133722|NCT03840902|ACTIVE_COMPARATOR|cCRT plus placebo followed by durvalumab|Participants received cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with placebo matched to M7824 followed by durvalumab.
62133723|NCT02872480|EXPERIMENTAL|ACTIVE Training|Healthy participants will be progressed from 60-80% of their VO2max as determined by the progressive exercise test over the course of 6 30-minute training sessions. Concussed participants will begin 30-minute training sessions at 60% of the VO2 achieved at symptom exacerbation of the exercise test. Intensity will be progressed as tolerated by the participant and training sessions will continue until the participant is asymptomatic for 24 consecutive hours (total number of sessions variable based on clinical recovery).
62327099|NCT06746012|ACTIVE_COMPARATOR|Phase I (design)|Survivor-caregiver dyads and SMEs complete semi-structured interview over 60-90 minutes and surveys over 15 minutes for intervention content, format, and feature design and development on study
62692873|NCT06639893|EXPERIMENTAL|3D printed chrom cobalt copings.|
61933963|NCT00959712|ACTIVE_COMPARATOR|ECA Interaction|"Subjects are given pedometers and step count logs in which to record their daily steps for 1 year. Subjects are also given a tablet computer and instructed to interact with the ECA (Embodied Conversational Agent) Tanya every day for 2 months."
61933964|NCT04196751|EXPERIMENTAL|Clinical Supervision Intervention|All the enrolled participants will be undergoing Clinical Supervision sessions with their selected supervisors for pre-identified objectives for their skill and knowledge development.
62133724|NCT02872480|NO_INTERVENTION|Control|Healthy controls will be asked to follow their normal routine for rest and physical activity. Concussed controls will be asked to follow the guidance for rest and activity as prescribed by the physicians and athletic trainers overseeing their clinical care.
62692874|NCT06639893|EXPERIMENTAL|Milled Poly-ether Ketone Ketones copings.|
62692875|NCT06643260|EXPERIMENTAL|Piclidenoson treatment|
61933965|NCT00130273|EXPERIMENTAL|1|Participants will receive managed problem solving for 12 months
61933966|NCT00130273|ACTIVE_COMPARATOR|2|Participants will receive standard of care for 12 months
62692876|NCT06643260|PLACEBO_COMPARATOR|Placebo|
62133725|NCT05111951|EXPERIMENTAL|Mobile health-delivered physical exercise and physical activity|"* Duration: 6 months~* Supervised online exercise sessions (30-45 min/session) performed as individual or as group sessions. Exercises are tailored to individual needs in physical fitness and target at least moderate exercise intensity to obtain positive effects on cardiovascular health. Targeted dose: 2 sessions/week during months 1-3 and 1 session/week months 4-6.~* Prescription of an individual exercise-regime through the mobile-application (dose is determined based on participants needs).~* Application of behavior change techniques for physical activity. Two person-centered interviews with a physiotherapist seeking to assess motivation, exercise preferences and barriers to physical activity, and to identify 1-2 individual physical activity goals. The goals are followed-up and revised if needed months 1-6. Educational videos regarding physical activity and health are prescribed."
62133726|NCT05111951|ACTIVE_COMPARATOR|Mobile health-delivered behavioural change techniques for physical activity|"* Duration: 6 months~* Remote service and contact with physiotherapists (video and chat) through a mobile application designed for this study.~* Behavioural change techniques for physical activity including general advice about physical activity, goal-setting, information and two follow-ups across the intervention period."
62133727|NCT04476810|EXPERIMENTAL|combined (phaco-kdb)|Prospective, non-comparative, uncontrolled, non-randomized interventional case series. Consecutive patients with medically-treated glaucoma and visually-significant cataract underwent combined surgery. Subgroup analysis of glaucoma subtypes was performed.
62133728|NCT03447496||Closed reduction|The children were treated with closed reduction.
62133729|NCT03447496||Open reduction|The children were treated with open reduction.
61933967|NCT03109054||Low Anxiety Level|The patients had low anxiety levels. Anxiety levels will determine with S-Anxiety TX-1 (State-Trait Anxiety Inventory Test:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
62133730|NCT01746706|EXPERIMENTAL|patients|
62133731|NCT01746706|EXPERIMENTAL|volunteers|
62133732|NCT06175520|EXPERIMENTAL|Preconception care (PCC) intervention|There will be 12 clusters under the PCC intervention arm. Eligible participants (newlywed women) in PCC intervention areas will be followed up prospectively. The investigators will enroll around 2,500 participants residing in the study area and with no intention to relocate in the next 2 years. Under this arm, all the relevant healthcare providers and their line managers will be provided training on preconception care. Healthcare providers will enroll the participants using their couple registrars to provide preconception care.
62133733|NCT06175520|NO_INTERVENTION|Comparison area|There will be 12 clusters under the comparison arm. Eligible participants will receive services through the existing health system.
62133734|NCT05043805|ACTIVE_COMPARATOR|Dextromethorphan|add on therapy
62133735|NCT05043805|PLACEBO_COMPARATOR|placebo|add on therapy
62133736|NCT04842513|EXPERIMENTAL|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
62133737|NCT00308997|EXPERIMENTAL|1|Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
62133738|NCT00308997|SHAM_COMPARATOR|2|sham rTMS to Wernicke's area and a right homologous area
62133739|NCT00990808|EXPERIMENTAL|Panel A|Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859
62133740|NCT00990808|EXPERIMENTAL|Panel B|Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
62133741|NCT05937685|NO_INTERVENTION|Usual Care|Participants receive the usual care received by patients of the medical center
62327100|NCT06746012|ACTIVE_COMPARATOR|Phase II (user-experience testing)|Dyads complete semi-structured interview and participate in think-aloud sessions over 60-90 minutes and complete surveys over 15 minutes to test the Healthy Buckeyes app on study.
61933968|NCT03109054||High Anxiety Level|The patients had high anxiety levels. Anxiety levels will determine with S-Anxiety (State-Trait Anxiety Inventory Test: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
62133742|NCT05937685|EXPERIMENTAL|Intervention|Participants follow the intervention protocol, including receiving educational materials, a home blood pressure monitor, coaching calls from BP REACH coaches and medication management from a pharmacist.
62133743|NCT01851668||Preterm inter-hospital transfers|preterm infants \<31 weeks gestation and \<=day 3 of life
62133744|NCT01851668||Preterm infants inborn|Preterm infants \<31 weeks gestation and \<=3 days old born and remaining at same hospital.
62133745|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
62133746|NCT00703820|ACTIVE_COMPARATOR|ADE|"Cytarabine + Daunorubicin + Etoposide~NK cells for infusion are prepared using the CliniMACS System."
62133747|NCT00703820|ACTIVE_COMPARATOR|Clo/AraC|"Clofarabine + Cytarabine~NK cells for infusion are prepared using the CliniMACS System."
62133748|NCT04480918||Major Depressive Episode|After referral to the University of Iowa's Interventional Psychiatry Clinic, the patient will be clinically evaluated and, if appropriate, commence the procedural-based treatment course.
62133749|NCT06209684|EXPERIMENTAL|Experimental|CarboFix implant for spinal surgery
62133750|NCT06209684|ACTIVE_COMPARATOR|Traditional|Titanium implant for spinal surgery
61933969|NCT02947412||sleeve gastrectomy|laparoscopic sleeve gastrectomy
61933970|NCT06005142|ACTIVE_COMPARATOR|Eriomin/Placebo|Group A will receive Eriomin (250 mg/day) for 12 weeks, followed by a 2-week washout period, and then placebo (250 mg/day) for 12 weeks.
61933971|NCT06005142|PLACEBO_COMPARATOR|Placebo/Eriomin|Group B will receive placebo (250 mg/day) for 12 weeks, followed by a 2-week washout period, and then Eriomin (250 mg/day) for 12 weeks.
61933972|NCT06228131||subjects who provided early pregnancy urine samples|
62485436|NCT04304209|EXPERIMENTAL|Cohort A|After 4 cycles of neoadjuvant sintilimab treatment, the patients and doctors could choose one of the following treatments: (1) surgery, followed by 4 cycles of adjuvant sintilimab with or without Capeox chemotherapy; (2) another 4 cycles of sintilimab, followed by radical surgery or observation (only for patients with clinical complete response).
62485437|NCT04304209|EXPERIMENTAL|Cohort B-arm 1|After four cycles of neoadjuvant Sintilimab, Capeox and radiotherapy, the patients and doctors could choose one of the following treatments: (1) curative surgery and four cycles of adjuvant Capeox chemotherapy;(2)four cycles of Capeox chemotherapy then observation (only for patients with clinical complete response after neoadjuvant therapy)
62485438|NCT04304209|ACTIVE_COMPARATOR|Cohort B-arm 2|After four cycles of neoadjuvant Capeox chemotherapy and radiotherapy, the patients and doctors could choose one of the following treatments: (1) curative surgery and four cycles of adjuvant Capeox chemotherapy;(2)four cycles of Capeox chemotherapy then observation (only for patients with clinical complete response after neoadjuvant therapy)
62485439|NCT02315963|NO_INTERVENTION|No intervention group|Patients in stroke rehabilitation receiving standard therapy
62485440|NCT02315963|ACTIVE_COMPARATOR|Intervention group|Patients in stroke rehabilitation receiving standard therapy plus performance feedback
62485441|NCT03505151|EXPERIMENTAL|BI 409306 tablet + intravenous isotope BI 409306 (C-13/N-15)|"On day 1, subjects were administered the Test treatment (T): a single dose of 50 milligram (mg) of BI 409306 film-coated tablet orally with 240 milliliter (mL) of water, followed 30 minutes (min) later by the Reference treatment (R): 0.1 mg isotope BI 409306 (C-13/N-15) as intravenous (i.v.) infusion over 30 minutes.~Both treatments were given in fasted state."
62485442|NCT05323981|EXPERIMENTAL|HS627(210mg/7ml)|
61933973|NCT05255653|EXPERIMENTAL|p53abn-RED trial: experimental|Adjuvant radiotherapy and chemotherapy followed by olaparib (lynparza), 300 mg twice daily, for one year
62133751|NCT05831969|EXPERIMENTAL|Lenalidomide|lenalidomide be used after Lenvatinib combined with PD-1 inhibitors in the first-line treatment
62133752|NCT03392038|EXPERIMENTAL|Thin ADM|Periodontal root coverage surgery using a coronally positioned tunnel and thin acellular dermal matrix (ADM GBR)
62327101|NCT06746012|EXPERIMENTAL|Phase III (pilot study)|Dyads use the Healthy Buckeyes app to set goals, self-monitor, elicit social support, reinforcement, time management, relapse prevention, and receive exercise videos and recipes tailored to CRC survivors on study. Dyads also watch three 3 minute videos on strategies for improving healthy lifestyle behaviors weekly, wear a Fitbit and use exercise bands, and receive health coaching over 10 weeks on study. Dyads will be prompted through the app to identify specific ways they will support each other (team activity and team huddle) in meeting their goals throughout the week for 10 weeks on study.
62327102|NCT06746454|EXPERIMENTAL|Video Instructed Training Group|Video Instructed Training Group Before the study is conducted, the expert video that will be used for the VI group instructions will be created. The expert video was created with an athlete with a LESS score of less than 4 and an FPPA of less than 10 who performs a DVJ task following the instructions. The video recording was used only for the video group instructions.
62327103|NCT06746454|EXPERIMENTAL|Verbal Combined Focus Instructed Training Group|"Participants will be given combined verbal instruction such as Focus on how hard you push yourself off the ground after the jump and how quickly you straighten your knees during this push, in which internal and external focus directions were given simultaneously."
62327104|NCT01445288||1|Pediatric Patients with Central Nervous System Tumors
62327105|NCT04006613|EXPERIMENTAL|Circuit Training|Structured intervention to improve aerobic capacity, balance and strength
62327106|NCT04006613|ACTIVE_COMPARATOR|Usual Care|Unstructured intervention to improve mobility and balance
62485443|NCT05323981|EXPERIMENTAL|HS627(420mg/14ml)|
62133753|NCT03392038|ACTIVE_COMPARATOR|Thick ADM|Periodontal root coverage surgery using coronally positioned tunnel surgery and thick acellular dermal matrix graft (ADM)
62327107|NCT06226571|EXPERIMENTAL|SNDX-5613|"Dose Escalation:~* Induction: Sequential cohorts of escalating dose levels of SNDX-5613 with chemotherapy regimen.~* Consolidation: Cohorts will receive high-dose cytarabine (HiDAC) chemotherapy followed by SNDX-5613.~* Maintenance Monotherapy: Cohorts will receive SNDX-5613.~Dose Expansion:~* Induction: SNDX-5613 at tolerated dose level with chemotherapy regimen.~* Consolidation: Cohorts will receive SNDX-5613 with chemotherapy regimen and HiDAC.~* Maintenance Monotherapy: Cohorts will receive SNDX-5613."
62327108|NCT06237452|EXPERIMENTAL|VE303|Subjects assigned to the VE303 arm will take 3 capsules containing VE303 per day for 14 days after completing 10 to 21 days of standard of care antibiotic treatment for the qualifying CDI episode.
62133754|NCT00233090|EXPERIMENTAL|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
62133755|NCT00233090|PLACEBO_COMPARATOR|Placebo|
62133756|NCT03644849|EXPERIMENTAL|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
62133757|NCT03644849|SHAM_COMPARATOR|Sham laser intervention group|
62133758|NCT03822234|EXPERIMENTAL|Modified ileal conduit|With our modified ileal conduit technique
62133759|NCT03822234|NO_INTERVENTION|Conventional ileal conduit|Conventional ileal conduit
62133760|NCT00485329|EXPERIMENTAL|Low dose papain|Ratio of drug to placebo treated patients will be 4:1
62133761|NCT00485329|EXPERIMENTAL|Medium dose papain|Ratio of drug to placebo treated patients will be 4:1
62327109|NCT06237452|PLACEBO_COMPARATOR|Placebo|Subjects assigned to the placebo arm will take 3 placebo capsules per day for 14 days after completing 10 to 21 days of standard of care antibiotic treatment for the qualifying CDI episode.
62485444|NCT05323981|ACTIVE_COMPARATOR|PERJETA|
62485445|NCT01321567||Rabeprazole Sodium|
62133762|NCT00485329|EXPERIMENTAL|High dose papain|Ratio of drug to placebo treated patients will be 4:1
62133763|NCT03259516|EXPERIMENTAL|Nivo + FC|Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days
61933974|NCT05255653|ACTIVE_COMPARATOR|p53abn-RED trial: control|Adjuvant radiotherapy and chemotherapy
62133764|NCT03259516|EXPERIMENTAL|Nivo + LDAC + ATRA|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd
61933975|NCT05255653|EXPERIMENTAL|MMRd-GREEN trial: experimental|Adjuvant radiotherapy combined with and followed by durvalumab, 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles)
61933976|NCT05255653|ACTIVE_COMPARATOR|MMRd-GREEN trial: control|Adjuvant pelvic external beam radiotherapy +/- chemotherapy
62133765|NCT03259516|EXPERIMENTAL|Nivo + LDAC + Sildenafil|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid
62133766|NCT03259516|EXPERIMENTAL|Nivo + Melphalan|Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days
62327110|NCT03723551|EXPERIMENTAL|Afabicin|"In Part A, afabicin will be given intravenous (IV) at a dose 160 milligrams (mg) twice daily (BID) for a minimum of 1 day (at least 1 dose) and up to a maximum of 14 days (2 weeks), followed by a switch to oral Afabicin at a dose of 240 mg BID for the remaining treatment duration.~In Part B, participants will be administered with open label afabicin IV at a dose of 55 mg BID for a minimum of 1 day (at least 1 dose) and up to a maximum of 14 days (2 weeks) followed by a switch to oral afabicin at a dose of 80 mg BID for the remaining treatment duration. In certain study conditions a higher dosing regimen of afabicin might be used: afabicin intravenous (IV) at a dose of 80 mg BID for a minimum of 1 day (at least 1 dose) and up to a maximum of 14 days (2 weeks) followed by a switch to oral afabicin at a dose of 120 mg BID for the remaining treatment duration."
62327111|NCT03723551|ACTIVE_COMPARATOR|Standard of Care (SOC) (Parts A and B)|Participants will be administered with SOC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.
62327112|NCT06214819|EXPERIMENTAL|VIVO ISAR DES in the first lesion|
62327113|NCT06214819|ACTIVE_COMPARATOR|XIENCE Skypoint DES in the first lesion|
62327114|NCT06132256|EXPERIMENTAL|Axatilimab|Participants will receive axatilimab every 2 weeks during the 26-week Treatment Period.
62327115|NCT06132256|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo every 2 weeks during the 26-week Treatment Period.
62327116|NCT06746428|EXPERIMENTAL|Immediate Start Group|Participants in this group will start the intervention during the first week of radiation therapy and continue through and post-completion of radiation
62327117|NCT06746428|EXPERIMENTAL|Delayed Start Group|Participants in this group will start 6-8 weeks post - radiation and continue 16-19 weeks post-radiation.
62327118|NCT06746688|EXPERIMENTAL|Cohort C1: 50µg ES2B-C001 adjuvanted with Montanide™|
62327119|NCT06746688|EXPERIMENTAL|Cohort C2: 150µg ES2B-C001 adjuvanted with Montanide™|
62327120|NCT06746688|EXPERIMENTAL|Cohort C3: 450µg ES2B-C001 adjuvanted with Montanide™|
62327121|NCT05374395|NO_INTERVENTION|Usual Services|clinics will continue to deliver their normal outpatient services
62327122|NCT05374395|EXPERIMENTAL|Peer Recovery Support - Delivered Dropout Prevention + Usual Services|clinics will continue to deliver their normal outpatient services plus the peer recovery support-delivered dropout prevention enhancement
62327123|NCT06746181|EXPERIMENTAL|A: FiO2 = 30%|FiO2 of group A = 30%. If SPO2 \< 94%, improve FiO2; if FiO2≥40%, eliminate the patient.
62133767|NCT03259516|EXPERIMENTAL|Nivo + 5-aza|Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days
62133768|NCT05222399|EXPERIMENTAL|LY3871801 (Period 1)|LY3871801 solid dispersion suspension administered orally.
62327124|NCT06746181|EXPERIMENTAL|B: FiO2＝40%|FiO2＝40%
62327125|NCT06746181|EXPERIMENTAL|C: FiO2＝60%|FiO2＝60%
62327126|NCT06746181|EXPERIMENTAL|D: FiO2＝80%|FiO2＝80%
62327127|NCT06747416|EXPERIMENTAL|KN057|
62327128|NCT06747962|ACTIVE_COMPARATOR|Pull out tenolysis group|A1 pulley release and pull out tenolysis for the treatment of trigger fingers and thumb
61933977|NCT05255653|EXPERIMENTAL|NSMP-ORANGE trial: experimental|Adjuvant radiotherapy followed by oral progestagens (medroxyprogesterone acetate or megestrol acetate) for two years
61933978|NCT05255653|ACTIVE_COMPARATOR|NSMP-ORANGE trial: control|Adjuvant radiotherapy and chemotherapy
61933979|NCT05255653|OTHER|POLEmut-BLUE trial: main cohort|"No adjuvant therapy in women with:~* stage IA (not confined to polyp), grade 3, pN0, with or without LVSI~* stage IB, grade 1 or 2, pNx/N0, with or without LVSI~* stage IB, grade 3, pN0, without substantial LVSI~* stage II (microscopic), grade 1 or 2, pN0, without substantial LVSI"
61933980|NCT05255653|OTHER|POLEmut-BLUE trial: exploratory cohort|"No adjuvant therapy or vaginal brachytherapy or pelvic external beam radiotherapy in women with:~* stage IA grade 3 - stage III not included in main cohort of the POLEmut-BLUE trial~* Multiple molecular classifiers Stage IA (not confined to polyp), grade 3 - Stage III"
62133769|NCT05222399|EXPERIMENTAL|LY3871801 (Period 2)|LY3871801 crystalline freebase tablet administered orally.
62327129|NCT06747962|PLACEBO_COMPARATOR|Simple A1 pulley release group|Simple A1 pulley release for the treatment of trigger fingers and thumb
62327130|NCT06746662|EXPERIMENTAL|Counseling based on the philosophy of hypnobreastfeeding|Hypno-breastfeeding is a method that involves a natural effort to use subconscious energy so that the breastfeeding process can proceed comfortably and smoothly and the mother can produce enough breast milk for the baby's growth and development needs (AIMI, 2010; Sofiyanti et al., 2019). With hypno-breastfeeding, the breastfeeding process takes place comfortably and the mother subconsciously registers that breastfeeding is a natural and comfortable process (Sembırıng, 2017; Altıparmak, 2021; Kilçi Erciyas and Sevil, 2021). In the philosophy of hypno-breastfeeding, positive schemas for breastfeeding are created in the subconscious. By focusing on the use of the primitive brain, the stimulation of the neocortex with unnecessary information and stimuli is avoided (Aluş Tokat and Gökçe İsbir, 2023). This technique, which helps to facilitate a holistic look at the mind, body and soul of breastfeeding mothers, allows the mother to be more relaxed, calm and comfortable during breastfeeding
62327131|NCT06746662|NO_INTERVENTION|Control|
62327132|NCT06747013|EXPERIMENTAL|Ablation using study catheter|All patients will undergo a standard ablation protocol using the study catheter (Farapoint)
62327133|NCT06747741|EXPERIMENTAL|PNF Stretching technique Group|The participants will receive PNF stretching technique of contract-Relax with agonist contraction for 3 days per week on alternate days for the symptoms of RLS in elderly population.
62133770|NCT04694014||Emotional Intelligence Skills study among frontline HCW managing Covid19 in Busia Kenya|Researchers from Alupe University College will select study participants as follows 6 Clinical officers, 2 nurses, 1 nutritionist, 1 lab technician, 2 lab technologists, 7 members on the sub county surveillance Matayos, Teso north and Bunyala 2 from UHC office
61933981|NCT02320318|EXPERIMENTAL|Ibodutant 10 mg|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
62133771|NCT01391832|SHAM_COMPARATOR|Sham rTMS|Sham Treatment Intervention: Device: Repetitive Transcranial Magnet Stimulation (sham treatment)
62327134|NCT06747741|ACTIVE_COMPARATOR|Conventional physical therapy Group|The participants will receive Conventional physical therapy including calf stretchinf and strenthening exercises, 3 days per week on alternative days for the symptoms of RLS in elder population.
62327135|NCT06746974|EXPERIMENTAL|Shockwave|
62327136|NCT06746974|ACTIVE_COMPARATOR|Splint|
62327137|NCT06745960|ACTIVE_COMPARATOR|intervention group|study group (interferential current )
62327138|NCT06745960|PLACEBO_COMPARATOR|physical therapy exercises group|control group (exercise group)
62327139|NCT06747442||CEREMONY|Any Native individuals seeking treatment in the integrated perinatal SUD clinical program specifically created for Native mothers may opt to enroll in prospective data collection during their time in the program
62327140|NCT06747442||Contemporary comparison cohort|Utah Population Database will be queried for individuals who could have met criteria for prospective data collection but did not participate in the SUD clinical program. The outcomes of these individuals (administrative data only) will be compared to individuals taking part in the SUD program for Native pregnant people who agree to have their data collected.
62327141|NCT06747572||Part A|Eligible participants will complete a single visit to complete a blood sample collection for PKD1/2 genotyping.
62327142|NCT06747572||Part B|Participants who have completed all assessments in Part A and have a subset of variants in PKD1 will complete 1 year of follow-up.
62327143|NCT05463003|ACTIVE_COMPARATOR|OCT1 and CYP2D6 wildtype genotypes|In this group, the participants are OCT1 and CYP2D6 wildtype genotypes. The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm (cohort) 1 and arm (cohort) 2 and 3, respectively.
62327144|NCT05463003|ACTIVE_COMPARATOR|OCT1 deficient and CYP2D6 wildtype genotypes|In this group, the participants are OCT1 deficient and CYP2D6 wildtype genotype.
62327145|NCT05463003|ACTIVE_COMPARATOR|OCT1 wildtype and CYP2D6 deficient genotypes|In this group, the participants are OCT1 wildtype and CYP2D6 deficient genotype.
61933982|NCT02320318|PLACEBO_COMPARATOR|Placebo|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
61933983|NCT02746068|EXPERIMENTAL|AXS-02|Administered orally in the morning for 6 weeks
62327146|NCT05109234|EXPERIMENTAL|Brivaracetam arm|Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
62327147|NCT06747871|EXPERIMENTAL|Very Low Nicotine Cigarette (VLNC) Group|Participants in this condition will be provided with VLNCs and asked to switch to smoking only study cigarettes for 4 weeks.
62327148|NCT06747871|ACTIVE_COMPARATOR|Normal Nicotine Cigarette (NNC) Group|Participants in this condition will be provided with NNCs and asked to switch to smoking only study cigarettes for 4 weeks.
62327149|NCT06747182|NO_INTERVENTION|the wait-list control group|the wait-list control group
61933984|NCT02746068|PLACEBO_COMPARATOR|Placebo|Administered orally in the morning for 6 weeks
62327150|NCT06747182|EXPERIMENTAL|mobile phone-based intervention group|Participants will receive a 12-week intervention with follow-up at week 26.
62327151|NCT03575013|EXPERIMENTAL|Avelumab and Docetaxel|"Induction phase:~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles~Maintenance phase:~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
62327152|NCT05165485|EXPERIMENTAL|Revefenacin|Revefenacin administered with Tiotropium Placebo
62327153|NCT05165485|ACTIVE_COMPARATOR|Tiotropium|Tiotropium administered with Revefenacin Placebo
62327154|NCT05411484|EXPERIMENTAL|Pilot Arm|Self-controlled 12 healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel
61933985|NCT04856891|EXPERIMENTAL|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) at 3 mg/kg.
61933986|NCT04856891|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive 6 monthly doses of placebo at 3 mg/kg.
61933987|NCT05532475||cases|patient with retinal vein occlusion
61933988|NCT05532475||control|cataract patient undergoing cataract surgery
62133772|NCT01391832|ACTIVE_COMPARATOR|active rTMS|"Active Repetitive Transcranial Magnet Stimulation treatment~Intervention: Device: Active rTMS of dorsolateral pre-frontal cortex"
62327155|NCT06748001|EXPERIMENTAL|Avapritinib|Participants who have participated in a Blueprint Medicines sponsored study (the parent study) and continue to benefit from avapritinib.
62327156|NCT05663034|ACTIVE_COMPARATOR|Cognitive behavioral therapy for insomnia (CBT-I)|CBT-I treatment will involve a standardized 6-session blended intervention that combines cognitive and behavioral techniques. The core components include (1) education about sleep and insomnia, stimulus control (SC) and sleep restriction (SRT) (week 1); (2) sleep hygiene education (week 2); and (3) relaxation training, cognitive restructuring (to counter-arousal and address sleep-interfering cognitions), adherence monitoring, and adjusting the recommended sleep-wake schedule (weeks 3 through 6). The final session will also include a review of treatment content and relapse prevention. Common to all sessions is an initial review of participant diary data, charting progress, setting measurable goals, discussing adherence, and reinforcing learned skills.
62485446|NCT05988840||The hardware group (on-board camera)|A physical device equipped with a camera and embedding the acquisition/monitoring software. Positioned in the living space, it will be possible to capture the facial expressions of the person in ecology, for example when watching a TV program or reading.
61933989|NCT04850313|NO_INTERVENTION|Conventional Treatment|"* Corneal ulcer scraping sent for microbial culture~* Admission to the hospital for initiation of fortified vancomycin 25mg/mL every 1 hour alternating with fortified tobramycin 15mg/mL every 1 hour, preservative free artificial tears every 2 hours, and doxycycline 100mg twice daily.~After 48 hours of conventional treatment, consent will be obtained regarding the use of experimental treatment with ProKera Plus® versus continuing conventional method of treatment"
62133773|NCT01217905|EXPERIMENTAL|1|
62133774|NCT05168085|EXPERIMENTAL|Intervention group|One chicken egg per day
62485447|NCT05988840||The software-only group (running on a PC or tablet and using the available webcam)|Software running on a computer, connected to the computer's camera (webcam). If the person is teleworking on a PC, it is expected that images will be captured during videoconferencing-type interactions.
62485448|NCT03251755|EXPERIMENTAL|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
62485449|NCT03251755|NO_INTERVENTION|Control|Usually clinical practice
62485450|NCT05748561|EXPERIMENTAL|Experimental group|The patients will receive intravenous erythropoietin - 10,000 IU every 24 hours for 5 days.
62485451|NCT05748561|PLACEBO_COMPARATOR|Control group|The patients will receive intravenous methylprednisolone - 1 g every 24 hours for 5 days.
62485452|NCT05280288|NO_INTERVENTION|The control group (Standard care)|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management under follow-up having usual care alone conducted by physicians and therefore not able to use the app Bone@BC in any versions (access denied).
62485453|NCT05280288|EXPERIMENTAL|The intervention group|Intervention: This arm will be assigned to the intervention which will be that the participants will be invited to become active users of the app Bone@BC version 4.0 combined with usual care alone.
62133775|NCT05168085|NO_INTERVENTION|Control group|True control
62133776|NCT04154384|EXPERIMENTAL|Life Care Specialist (LCS) Intervention|In addition to receiving current standard-of-care for pain management in the aftermath of trauma, participants will have the full communication of opioid risk - via the validated Opioid Risk Tool (ORT) and a detailed substance abuse and mental health screening. As part of the daily LCS intervention, the inpatients will engage in behavioral pain management, opioid education and harm-reduction strategies (naloxone education), while also being screened for eligibility for respective referrals for complex needs, such as mental health and substance use disorders. Upon discharge, each participant will be educated by the LCS on future available modes of contact (telephone, email, video-call, follow up- visits at 2-, 6- and 12-weeks).
62327157|NCT05663034|ACTIVE_COMPARATOR|Mindfulness-based treatment for insomnia (MBTI)|MBTI treatment will involve a standardized 6-session intervention which integrates the mindfulness training and exercises from mindfulness-based stress reduction (MBSR) with behavioral strategies based on sleep restriction therapy and stimulus control delivered within the context of mindfulness principles. Mindfulness principles include: 1) increase awareness of the mental and physical states that promote sleep (i.e., sleepiness), 2) shift sleep-related metacognitions to reduce hyperarousal, and 3) promote a mindful stance to respond when symptoms of insomnia arise. An overview of the treatment program, sleep education, and an introduction to the principles of mindfulness meditation is given (week 1). Then a combination of mindfulness meditations, sleep restriction, and stimulus control is conducted (week 2-6).
62327158|NCT05601505|NO_INTERVENTION|Traditional neoadjuvant chemoradiotherapy group|"Eligible patients randomized into arm A will receive traditional neoadjuvant chemoradiotherapy, including long-course radiotherapy with a total number of 45-50.4Gy in 25-28 fractions, and with concurrent 3 times of oral capecitabine, the strategies of capecitabine are:~During radiotherapy: capecitabine 1650mg/m2/d, orally administered twice a day, d1-d14, every 3 weeks as a course; During the non-radiotherapy period: capecitabine 2000mg/m2/d, orally administered twice daily, d1-d14, every 3 weeks as a course"
62327159|NCT05601505|EXPERIMENTAL|ctDNA-guided neoadjuvant treatment group|"After sequencing tumor tissue, those with MSI-H/TMB-H or POLD/POLE2 mutation willed be arranged to receive immune therapy following NCRT，Terelizumab，200mg.~The others are arranged to randomly receive TNT (VAF\>0.4%) or NCRT (VAF\<0.4%) according to VAF value by the level of ctDNA.~TNT： Long course radiotherapy combined with 2 courses of single-agent capecitabine chemotherapy → 6 courses of CapeOX (Capecitabine 2000mg/m2/ day, twice orally, d1-14; Oxaliplatin 100-130mg/m2, intravenous infusion, d1; Every 3 weeks for a course of treatment.) chemotherapy was performed 2 to 3 weeks after the end of chemotherapy."
62327160|NCT01931462|EXPERIMENTAL|Certus 140™|During the operation: use of Certus 140™ microwave device for pre-coagulation of the kidney tissue adjacent to the tumor.
62327161|NCT00206999|EXPERIMENTAL|1|
62327162|NCT03680794|EXPERIMENTAL|Patients with ophthalmic surgery|
62327163|NCT04009174|EXPERIMENTAL|Imaging Panel|Patients who provided written informed consent and found to be eligible for study were asked to complete Positron Emission Tomography (PET) + Dynamic CT imaging, PET/MRI (with endorectal coil) and 3D-Transrectal ultrasound prior to standard of care radical prostatectomy.
62327164|NCT03276936|EXPERIMENTAL|Minocycline Foam 1.5%|FMX-103
62327165|NCT04068558|EXPERIMENTAL|VNI-NAVA/sNIPPV|Ventilation of the child non-invasive ventilation (VNI) NAVA then sNIPPV
62327166|NCT04068558|EXPERIMENTAL|sNIPPV/VNI-NAVA|Ventilation of the child sNIPPV then non-invasive ventilation (VNI) NAVA
62485454|NCT00894855|ACTIVE_COMPARATOR|education only|This comprehensive education program included a health educator visit, on the education van, who gave education about sun safety.
62485455|NCT00894855|EXPERIMENTAL|education plus dermatologist skin exam|"In addition to the education program, participants received free skin exams by board certified dermatologists from Brigham and Women's Hospital. The van was equipped with a private clinical setting conducive to carry out such examinations. Based on the recommendations of the American Academy of Dermatology (AAD), a visual full body exam was provided to participants. At the end of each skin exam the dermatologist provided a presumptive diagnosis to the participant, and made appropriate recommendations and referrals for follow up with the participants' physician/dermatologist (if and when necessary). All participants undergoing the skin exam were required to complete an AAD Skin Cancer Screening Registration and Report form."
62485456|NCT00894855|EXPERIMENTAL|educ, biometric fb, and derm skin exam|Participants received the active components of the other three conditions.
62485457|NCT00894855|EXPERIMENTAL|education plus biometric feedback|In addition to the educational program, participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
62485458|NCT06406725||NIV PPV|We will recruit patients who are currently on noninvasive positive pressure ventilation (NIV PPV) who are scheduled for fiberoptic nasolaryngoscopy (FNL) with the otolaryngology team for evaluation of vocal fold motion impairment (VFMI).
62327167|NCT03499951|OTHER|Wheelchair Skills Trainers|Individuals will receive remotely delivered wheelchair skills training, after which they will be assessed on their ability to teach the Wheelchair Skills Trainees a series of wheelchair skills in a one-on-one environment. The intervention for this group is Wheelchair Skills Training - Remote.
62327168|NCT03499951|OTHER|Wheelchair Skills Trainees|Individuals will receive one-on-one wheelchair skills training from the Wheelchair Skills Trainers. The intervention for this group is Wheelchair Skills Training - In Person.
62327169|NCT03097328|EXPERIMENTAL|TAK-228|"* TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle~* Dosage will be determined by the study team"
62327170|NCT03009331|EXPERIMENTAL|Prone position|Intervention: Lungrecruitment in prone position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s.
62327171|NCT03009331|ACTIVE_COMPARATOR|Supine position|Intervention: Lungrecruitment in supine position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s. Clinical routine.
62327172|NCT03502252|EXPERIMENTAL|Treatment Group|Semillas de Apego is a group-based psychosocial program for victimized caregivers with children 2 to 5 in Colombia, a country devastated by violence. The program's builds upon scientific evidence on (i) the way in which violence hinders early childhood development and erodes mothers' mental health and their capacity to form nurturing relationships with their children, and (ii) the effectiveness of promoting healthy child-parent attachments to mitigate the effects of toxic stress on toddlers (Lieberman and Van Horn, 2011).
62327173|NCT03502252|NO_INTERVENTION|Control Group|Centers and participants assigned to the this group continue to have access to the regular early childhood programs offered through the centers to which children are affiliated.
62327174|NCT03175393||postprandial dyslipidemia|
62327175|NCT03762122|EXPERIMENTAL|Rogaratinib|Rogaratinib is given at a dose of 600 mg twice daily in continuous 28-days cycles, without treatment breaks (except for toxicity management). Trial treatment is continued until evidence of tumor progression, unacceptable toxicity, consent withdrawal or withdrawal by the investigator.
62327176|NCT03934593|EXPERIMENTAL|Faith-Based (FB, BHT DSMS)|The BHT DSMD intervention strategies adapted Stanford DSMP in a spiritual context is used in this group. Participants in the FB group will participate in BHT DSMS, which includes a Health Sermon, a 6-session Health Bible Study with cooking demonstrations, the Stanford DSMP and a Diabetes Resource Seminar delivered by two trained church lay leaders.
62327177|NCT03934593|ACTIVE_COMPARATOR|Faith-Placed (FP, Stanford DSMP)|The traditional Stanford DSMP is conducted in this control group. Participants in the FP group will first attend a 7-session community health and safety curriculum as a partial attention control intervention, followed by the Stanford DSMP and Diabetes Resource Seminar facilitated by the local public health department.
62327178|NCT03702790||Back pain SPECT evaluation|Patients with poorly localized back pain being imaged for clinical decision making
62327179|NCT03971461|EXPERIMENTAL|Lutathera|
62327180|NCT03100942|EXPERIMENTAL|Lanraplenib|Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
62327181|NCT03100942|EXPERIMENTAL|Filgotinib|Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
62327182|NCT03100942|EXPERIMENTAL|Tirabrutinib|Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
62327183|NCT03100942|PLACEBO_COMPARATOR|Placebo, then active treatment|"Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48:~* filgotinib + lanraplenib placebo + tirabrutinib placebo~* lanraplenib + filgotinib placebo + tirabrutinib placebo~* tirabrutinib + filgotinib placebo + lanraplenib placebo"
62327184|NCT03862079|EXPERIMENTAL|Arm I (TGD + FMT)|Patients receive piperacillin-tazobactam PO TID and nystatin QID. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
62327185|NCT03862079|EXPERIMENTAL|Arm II (FMT)|Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
62327186|NCT03862079|ACTIVE_COMPARATOR|Arm III (standard therapy)|Patients receive standard of care.
62327187|NCT05725057|ACTIVE_COMPARATOR|AX-158 - (Arm 1)|AX-158 Dosage:5 mg capsules Form: Capsule Frequency - 2 capsules daily taken orally Duration - 28 consecutive days
62327188|NCT05725057|PLACEBO_COMPARATOR|Placebo - (Arm 2)|Placebo Dosage: NA Form: Capsule Frequency: 2 capsules daily taken orally Duration: 28 consecutive days
62327189|NCT01199263|EXPERIMENTAL|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
62327190|NCT01199263|EXPERIMENTAL|Arm II (paclitaxel and wild-type reovirus)|Patients receive paclitaxel as in arm I and wild-type reovirus IV over 1 hour on days 1-5.
62327191|NCT01051375|EXPERIMENTAL|Waitlist Group|The intervention involves completion of a single workshop, provision of psychoeducational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list, within a month of our receiving the referral.
62327192|NCT01051375|NO_INTERVENTION|Standard of Care|These patients continue to receive the standard of care while awaiting formal assessment.
62327193|NCT03259334|EXPERIMENTAL|Ontamalimab 25 mg|Participants will receive 25 milligrams (mg) of ontamalimab (SHP647) subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
62327194|NCT03259334|EXPERIMENTAL|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
62327195|NCT03259334|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
62327196|NCT03220048|OTHER|Cohort A: Sentinel Group|Sentinel group in which subjects received a challenge virus inoculum volume of 100uL on Day 0.
62327197|NCT03220048|EXPERIMENTAL|Cohort B: PrEP-001|PrEP-001 6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
62327198|NCT03220048|EXPERIMENTAL|Cohort B: Placebo|Nasal dose of placebo Comparator equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
62485459|NCT06559046||High grade|
62485460|NCT06559046||Low grade|
62485461|NCT04134910|EXPERIMENTAL|Physical therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
62692877|NCT04369326|EXPERIMENTAL|Community-Based TPT Initiation|All TB index patients who agree to participate will have a home visit by clinic staff who will perform: (1) contact enumeration (2) TB symptom screening of all children \<15 years (3) Initiation of TPT for all asymptomatic children and (4) Referral of all symptomatic children less than 15 years, including those living with HIV. HIV testing will be offered to all child contacts 12 months of age and older. Those children less than 12 months will be referred to the clinic for HIV testing, if indicated by local guidelines. In South Africa, these home visits will occur by a combination of community health workers and professional nurses. In Ethiopia, home visits will occur by health extension workers supported by nurses.
62133777|NCT04154384|ACTIVE_COMPARATOR|Standard of Care with Clinical Coordination|Participants will receive the current standard-of-care for pain management in the aftermath of trauma, including a standardized prescription protocol, and hospital-system approved discharge instructions which provide written instruction on how to taper opioid use and links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
62133778|NCT04154384|OTHER|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse. Participants will be followed for one-year post-operation. An official pain management protocol will be developed during the pilot portion of this study
62133779|NCT02387645|EXPERIMENTAL|Patients prior to surgery for EC/suspicion|Patient undergoing surgery for strong suspicion of EC
62133780|NCT02926794|EXPERIMENTAL|SA and II|Combined self-affirmation and implementations intention arm
62133781|NCT02926794|EXPERIMENTAL|SA and No II|Self-affirmation and control intentions condition
62133782|NCT02926794|EXPERIMENTAL|No SA and II|Implementation intentions intervention and control writing task
62133783|NCT02926794|EXPERIMENTAL|No SA and No II|Control writing task and control intentions condition
62133784|NCT06038695|EXPERIMENTAL|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|Subjects in this arm will have a xenogeneic volume-stable collagen matrix in combination with recombinant human platelet-derived growth factor-BB at the time of immediate implant placement.
62133785|NCT03074617|EXPERIMENTAL|LTE field|
62327199|NCT02610556|EXPERIMENTAL|TP plus IMRT|Concurrent chemotherapy: TP - Docetaxel 60mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
62327200|NCT02610556|ACTIVE_COMPARATOR|DDP plus IMRT|Concurrent chemotherapy: DDP - Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
62327201|NCT05470036|OTHER|Educational intervention|In-clinic or virtual educational session on germline testing in prostate cancer with a trained educator.
62327202|NCT04426123|ACTIVE_COMPARATOR|Botulinum toxin|Botulinum toxin type A
62327203|NCT04426123|PLACEBO_COMPARATOR|Saline solution|NaCl
62485462|NCT02959879|EXPERIMENTAL|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
62485463|NCT02959879|EXPERIMENTAL|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
62133786|NCT03074617|SHAM_COMPARATOR|sham field|
62133787|NCT06513975|EXPERIMENTAL|Subjects requiring 24-hour ambulatory blood pressure monitoring|Subjects prescribed for ambulatory blood pressure monitor (ABPM) measure 24-hour blood pressure using both the CART BP and sphygmomanometer
62133788|NCT02280148|EXPERIMENTAL|Endoscopy of Intravenous Anesthesia|20-70 year-old volunteers who hold legitimate licenses were recruited to have gastroscopy or colonoscopy under intravenous anesthesia with propofol
62133789|NCT03617315|EXPERIMENTAL|Hyaluronic Acid|One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days
62133790|NCT03617315|EXPERIMENTAL|CrossLinked Hyalurnic Acid|One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days
62133791|NCT02824458|EXPERIMENTAL|Gefitinib + Apatinib|"(Part A) Phase I, Open-label, Dose-escalation Study Escalating doses(500mg, 750mg, or 250mg) of Apatinib in combination with 250mg Gefitinib daily orally. Participants may continue to receive treatment until progress or intolerable.~(Part B)Multicenter, Randomized, Double-Blind Study Apatinib (dose determined from Part A of study) in combination with 250mg Gefitinib."
62133792|NCT02824458|PLACEBO_COMPARATOR|Gefitinib + Placebo|"(Part A) Not Applicable~(Part B) Placebo in combination with 250mg Gefitinib. Participants may continue to receive treatment until progress or intolerable."
62327204|NCT00767156|ACTIVE_COMPARATOR|SBA24 capsule plus Omega7 cream|the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream
62327205|NCT00767156|ACTIVE_COMPARATOR|SBA24 capsule plus base cream|the subjects took SBA24 sea buckthorn oil capsule and apply a base cream
62327206|NCT00767156|ACTIVE_COMPARATOR|Omega7 Cream|The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day
62327207|NCT00767156|PLACEBO_COMPARATOR|Base cream|The subjects use base cream on the face, twice per day
62327208|NCT05636579|EXPERIMENTAL|EO2002 with Ripasudil|EO2002 + topical Ripasudil daily, then reinjection at week 6 + topical Ripasudil daily
62327209|NCT05636579|EXPERIMENTAL|EO2002 without Ripasudil|EO2002 injection at Day 0 and re-injection at Week 6
62327210|NCT01619384|NO_INTERVENTION|Treatment as Usual|Usual VA care
62327211|NCT01619384|EXPERIMENTAL|MBSR|participation in an 8-week stress reduction course (mindfulness-based stress reduction)
62485464|NCT02959879|ACTIVE_COMPARATOR|standard adjuvant chemotherapy|"Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.~12 cycles of standard adjuvant chemotherapy are administrated following the surgery"
62327212|NCT06368739|EXPERIMENTAL|Nurture + regular benefits (exposed group)|"1. Monthly packages sent every four weeks until end of pregnancy with maximum of eight packages. Each package includes:~   US $40 grocery store gift card A healthy eating information sheet selected from Brighter Bites project. (https://brighterbites.org/).~   A set of three recipes. Nutrition-related Frequently Asked Questions (in four of eight packages).~2. Two 30-minute telephonic nutritional consultations. Designed by a Registered Dietitian Nutritionist (RDN) who trained a bilingual nutrition specialist to deliver the consultations. Topics revolved around healthy eating during pregnancy, such as food choices, portion sizes, budget-friendly shopping, food safety, and food preparation. No nutrition therapy advice to manage diseases was provided.~3. Regular benefits Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP."
62485465|NCT01736007|SHAM_COMPARATOR|Liquid light guide tip on laser|Excimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
62327213|NCT06368739|ACTIVE_COMPARATOR|Regular benefits (comparison group)|"Regular benefits~Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP."
62327214|NCT00909142||Group1|
62327215|NCT06693609|EXPERIMENTAL|EMP-01|
62327216|NCT06693609|PLACEBO_COMPARATOR|EMP-01 Placebo|
62327217|NCT02344628|ACTIVE_COMPARATOR|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
62327218|NCT02344628|EXPERIMENTAL|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
62327219|NCT02432001||Image-Guided Biopsies|Image-guided biopsies will be performed at the Dream Team Site enrolling the patient. Lesions will be chosen based upon the strength of the evidence suggesting the presence of metastasis and with the goal of minimizing patient risk. Soft tissue lesions and lesions with documented radiologic progression should be prioritized for biopsy. If the Radiologist in charge of the procedure cannot identify a lesion amenable for biopsy, the patient will be considered a screening failure.
62327220|NCT03484923|EXPERIMENTAL|Arm 1: LAG525 + PDR001 (randomized section)|Participnats randomized to receive LAG525 at a dosage of 600 mg administered intravenously every 4 weeks, in combination with PDR001 at a dosage of 400 mg administered intravenously every 4 weeks
62327221|NCT03484923|EXPERIMENTAL|Arm 2: INC280+PDR001 (randomized section)|Participants randomized to receive INC280 orally at a dosage of 400 mg twice daily, in combination with PDR001 intravenously at a dosage of 400 mg every 4 weeks
62327222|NCT03484923|EXPERIMENTAL|Arm 3: ACZ885 + PDR001 (randomized section)|Participants randomized to receive to receive ACZ885 at a dosage of 300 mg administered subcutaneously every 4 weeks, in combination with PDR001 at a dosage of 400 mg administered intravenously every 4 weeks
62327223|NCT03484923|EXPERIMENTAL|Arm 4: LEE011 + PDR001 (randomized section)|Participants randomized to receive LEE011 orally at a dosage of 600 mg once daily on Days 1-21 of a 28-day cycle, in combination with PDR001 intravenously at a dosage of 400 mg every 4 weeks
62327224|NCT03484923|EXPERIMENTAL|Arm 1A: LAG525 + PDR001 (non-randomized section)|LAG-3 positive participants received LAG525 at a dosage of 600 mg administered intravenously every 4 weeks, in combination with PDR001 at a dosage of 400 mg administered intravenously every 4 weeks
62327225|NCT01996774||Child, peanut/ nut allergy, no treatment|
62327226|NCT01996774||Child, peanut/nut allergy, tolerance|
62327227|NCT01996774||Non allergic child, without atopia|
62327228|NCT02042404|EXPERIMENTAL|Mild to severe hearing impairment|Sound amplification provided via the EarLens System assistive hearing device.
62327229|NCT05742464|EXPERIMENTAL|Treatment|
62327230|NCT01830361|EXPERIMENTAL|midostaurin (PKC412), capsules|midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.
62327231|NCT03293095||Acute musculoskeletal pathology patients|Musculoskeletal pathology patients that they will perform functional tasks measuring with motion sensors and motion capture.
62327232|NCT03293095||Match control|Healthy people of the same age as the acute musculoskeletal pathology subjects. They will perform functional tasks measuring with motion sensors and motion capture.
62485466|NCT01736007|ACTIVE_COMPARATOR|308-nm excimer laser to alopecia patch|Laser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
62327233|NCT04723524|EXPERIMENTAL|Treatment group|150 Cases, treated with Jinhua Qinggan (JHQG) Granules
62327234|NCT04723524|PLACEBO_COMPARATOR|Control group|150 Cases, Placebo treated
62327235|NCT04307147|EXPERIMENTAL|NX (vinorelbine and capecitabine )|Standard therapy plus NX chemotherapy for 4 cycles, (vinorelbine 25 mg/m² d1,8 and capecitabine 1250 mg/m² d1-14, every 3 weeks)
62327236|NCT04307147|NO_INTERVENTION|Control group|Standard therapy
62327237|NCT02151006|ACTIVE_COMPARATOR|DHEA|women will receive DHEA 6 weeks before starting IVF/ICSI
62327238|NCT02151006|NO_INTERVENTION|Control|
62327239|NCT02558153|EXPERIMENTAL|DEB - drug eluting balloon (APERTO)|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon
62327240|NCT02558153|ACTIVE_COMPARATOR|standard PTA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).
62485467|NCT04905082|ACTIVE_COMPARATOR|Arm I (usual care)|Patients receive education pamphlet about WES and have their genomics test results returned by their clinician in a typical manner.
62485468|NCT04905082|EXPERIMENTAL|Arm II (genomics test results, HOPE-Genomics)|Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available.
62485469|NCT04905082|EXPERIMENTAL|Arm III (HOPE-Genomics, genomics test results)|Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool.
61933990|NCT04850313|EXPERIMENTAL|ProKera Plus® Treatment|1. Experimental Treatment Arm , ProKera Plus® will be placed in the eye with the corneal ulcer
62133793|NCT05786352|EXPERIMENTAL|ERAS|"ERAS Protocol~Preoperative:~1. Clear carbohydrate ( pulp free juice) drink 4 hours before cesarean. Water drinking is allowed until 4 hours before cesarean.~2. Prophylactic antibiotics 1 hour before cesarean ( Cephazole 2 g iv)~Intraoperative:~1. Hypothermia prevention (warming devices)~2. Pneuomatic compression stockings~3. Skin preparation with clorhexidine-alcohol~4. Vaginal preparation with povidone-iodine solution~Postoperative:~1. Regular diet within 2 hours after cesarean~2. Sugar-free gum chewing at postoperative 3rd, 5th and 7th hours, for 20 minutes~3. Tight control of capillary blood glucose~4. Mobilization at postoperative 4th hour.~5. Urinary catheter removal at postoperative 4th hour~6. Pneuomatic compression stockings~7. Prevention of nausea and vomiting with routine use of Metoclopramide.~8. Routine analgesia with Diclofenac sodium suppository application and oral Paracetamole."
62327241|NCT02614872|EXPERIMENTAL|GLASSIA®|Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
62327242|NCT02614872|NO_INTERVENTION|Institution standard of care (SOC)|Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
62327243|NCT01665417|EXPERIMENTAL|Experimental Icotinib|Icotinib: 125mg, oral administration, three times per day.
62327244|NCT01665417|ACTIVE_COMPARATOR|Chemotherapy Regimen 1|Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
62327245|NCT01665417|ACTIVE_COMPARATOR|Chemotherapy Regimen 2|Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
62327246|NCT03013777|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|The patient would participate in eight forty-five minute sessions of CBT with a mental health therapist. Cognitive behavioral therapy (CBT), defined as a program of interventions that utilize education to teach relaxation, healthy coping skills, stress management, assertiveness training in order to help the individual identify and correct maladaptive beliefs in combination with education to help practice symptom reduction and improve quality of life and function.
61933991|NCT04973696|EXPERIMENTAL|Toolkit for Optimal Recovery after Orthopedic Injury - Active|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
62133794|NCT05786352|NO_INTERVENTION|SOC (Standard of Care)|"Preoperative:~1. Fasting until 6 hours before cesarean.~2. Prophylactic antibiotics post-delivery during cesarean per institutional protocol ( Cephazole 2 g iv)~Intraoperative:~1. Pneuomatic compression stockings as needed~2. Skin preparation with povidone-iodine solution~Postoperative:~1. Water intake at 4th hour after cesarean, traditional delayed feeding until return of intestinal function (bowel sounds or flatus)~2. Capillary glucose control~3. Mobilization at postoperative 6th hour.~4. Urinary catheter removal at postoperative 6th hour~5. Pneuomatic compression stockings as needed.~6. Analgesia with Diclofenac sodium intramuscular and oral Paracetamole as needed."
62133795|NCT02446145|EXPERIMENTAL|Experimental intervention arm|"Eltrombopag daily from day 12 to 25: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~* concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.~* one cycle lasts 28 days"
62327247|NCT04506827|ACTIVE_COMPARATOR|Control group|patients in the control group received Demineralized Bovine Bone Mineral for the maxillary sinus augmentation
62327248|NCT04506827|EXPERIMENTAL|Test group 1|patients in the test group 1 received TCP with particle size from 250 to 1000 µm
62327249|NCT04506827|EXPERIMENTAL|Test group 2|patients in the test group 2 received TCP as in test group1 plus crosslinked Hyaluronic Acid
61933992|NCT04973696|ACTIVE_COMPARATOR|Minimally Enhanced Usual Care (MEUC) - Control|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
61933993|NCT00833716|EXPERIMENTAL|A|
61933994|NCT06051591|ACTIVE_COMPARATOR|Attention Control|Participants will receive nutrition education and anticipatory guidance to support healthy meal preparation in addition to usual care.
61933995|NCT06051591|EXPERIMENTAL|Food FARMacia intervention|Participants will enroll in the Food FARMacia program and receive groceries twice monthly for 6 months. They will also receive nutrition education and anticipatory guidance to support healthy meal preparation.
61933996|NCT00355654|EXPERIMENTAL|Group 1|Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
61933997|NCT00355654|ACTIVE_COMPARATOR|Group 2|Participants will receive Infanrix hexa with Prevenar at Visit 1
61933998|NCT05884710|EXPERIMENTAL|Exercise Group|Foot core exercises consist of 4 movements; short foot exercise, towel curls, toe spread and squeeze, balance board training
61933999|NCT05884710|ACTIVE_COMPARATOR|Control Group|Conventional Physiotherapy Program
62327250|NCT05536713||Federally Qualified Health Center 1|Patients who received an order for colorectal cancer screening, either using a stool-based test or colonoscopy, but failed to complete the screening after six months will be recruited to participate in the study.
62485470|NCT02393144|OTHER|Spontaneous labor arm|Women with term pregnancies whose labor started spontaneously. Spontaneous labor is determined by either spontaneous rupture of membranes at term and/or powerful, regular uterine contractions that cause cervical change. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Labor augmentation will be performed for women with inadequate uterine contractions, i.e. contractions measuring less than Montevideo units, irregular weak uterine contractions. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
61934000|NCT06325904|ACTIVE_COMPARATOR|1|"* This group included 30 adult patients with stage I/II pleural empyema who operated initially by VATS.~* All patients were subjected to the following:~  1. Full history taking. 2.Full clinical examination. 3-Routine Laboratory investigations and Pleural fluid sample analysis. 4- Radiological investigations: Chest X-ray , CT chest.~* All patients will be managed by general anesthesia using double lumen endoteracheal tube to achieve single lung ventilation.~* All patients were positioned in lateral decubitus position.~* Single port skin incisions was made to pass the port through which the camera head and instruments were introduced into the chest .~* One chest tubes ws inserted as drains."
61934001|NCT06325904|PLACEBO_COMPARATOR|2|"* This group included 30 adult patients with stage I/II pleural empyema who underwent conventional tube thoracotomy.~* All patients were subjected to the following:~  1. Full history taking. 2.Full clinical examination. 3-Routine Laboratory investigations and Pleural fluid sample analysis. 4- Radiological investigations: Chest X-ray , CT chest.~* The patient is placed in a supine position.~* The intercostals pace is opened .~* Chest tube is inserted in proper position regarding the site of fluid collection."
62327251|NCT05536713||Federally Qualified Health Center 2|Patients who received an order for colorectal cancer screening, either using a stool-based test or colonoscopy, but failed to complete the screening after six months will be recruited to participate in the study.
62327252|NCT05536713||Federally Qualified Health Center 3|Patients who received an order for colorectal cancer screening, either using a stool-based test or colonoscopy, but failed to complete the screening after six months will be recruited to participate in the study.
62327253|NCT00149656|PLACEBO_COMPARATOR|1|
62327254|NCT00149656|EXPERIMENTAL|2|Multivitamins
62327255|NCT00149656|EXPERIMENTAL|3|Multivitamins with Selenium
62327256|NCT00149656|EXPERIMENTAL|4|Selenium
62327257|NCT03702582|EXPERIMENTAL|Rivaroxaban|"Rivaroxaban: Direct inhibitor of Factor Xa, an enzyme that stimulates the formation of thrombin from prothrombin (A critical step in both the intrinsic and extrinsic aspects of the coagulation cascade)~Dosage form: Per Os (Oral)~Dosage and Frequency: 20 mg every evening with the evening meal (No titration requirements). For patients with decreased glomerular filtration rate (GFR between 15 ml/min and 50 ml/min), dosing will be decreased to 15 mg every evening with the evening meal.~Duration: 30 days (Possibility of continuation after post-operative cardiology clinic visit)"
62327258|NCT03702582|ACTIVE_COMPARATOR|Warfarin|"Warfarin: Competitive inhibitor of vitamin K epoxide reductase complex 1, an important enzyme in the activation pathway for vitamin K dependent coagulation factors~Dosage form: Per Os (Oral)~Dosage and Frequency: Initial dose of 2 - 5 mg nightly after the evening meal (QHS) with appropriate titration to goal INR 2.0 - 3.0 (Initial dose based on weight, age, gender, co-morbidities and concurrent medications). INR will be checked daily to weekly depending on stability of dosing and medication regimen.~Duration: 30 days (Possibility of continuation after post-operative Cardiology clinic visit)"
62327259|NCT03282201||Transfused|Patients in whom blood transfusion is used
62327260|NCT03282201||Nontransfused|Patients in whom blood transfusion is not used
62327261|NCT01840176|NO_INTERVENTION|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
62327262|NCT01840176|OTHER|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
62327263|NCT00151060|EXPERIMENTAL|Estramustine, Etoposide and Paclitaxel|
62327264|NCT00965705|ACTIVE_COMPARATOR|Guided Self Help|
62327265|NCT00965705|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|
62327266|NCT00965705|ACTIVE_COMPARATOR|Dialectical Behavioral Therapy|
62327267|NCT06451380|EXPERIMENTAL|Patient-controlled propofol sedation|"Patients in the experimental arm will receive self-controlled sedation using a programmable infusion device, which will deliver boluses of propofol at the patient's request.~The initial dose of propofol, the bolus dose and the refractory period will be determined according to a standardized protocol used in current practice.~Patients will be trained in the use of the device prior to the procedure. An anesthetist will be present to monitor the patient and intervene in the event of complications."
62327268|NCT06451380|ACTIVE_COMPARATOR|Anesthesiologist-controlled propofol sedation|"Patients in the control arm will receive sedation administered and monitored by an anesthetist, who will adjust the dose of propofol according to the patient's needs.~A standardized protocol for propofol administration and dose adjustment criteria will be followed until a mild sedation score is achieved.~The anesthetist will continuously monitor the patient and adjust the sedation accordingly."
62327269|NCT00006222|EXPERIMENTAL|Arm I|Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
62327270|NCT03581773|ACTIVE_COMPARATOR|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
62327271|NCT03581773|PLACEBO_COMPARATOR|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
62692878|NCT04369326|NO_INTERVENTION|Facility-Based TPT Initiation|Children less than 15 years living in the home of TB index patients who agree to participate in the study will be referred to clinic for TB symptom screening and initiation of TPT for all asymptomatic child contacts. Symptomatic child contacts will be referred to a physician for evaluation, as is currently the standard of care. Additionally, child contacts identified in any maternal and child health program will be referred to the TB clinic for TB symptom screening. HIV testing will be offered at the clinic for all child contacts and will be performed according to local guideline.
61934002|NCT04741698|ACTIVE_COMPARATOR|Propranolol 2mg IV|"At the time of labor dystocia, patients randomized to the treatment arm of propranolol will receive a one-time administration of IV 2mg propranolol in pre-mixed syringes prepared by the pharmacy.~The propranolol IV administration recommended in clinical practice guidelines is 1 mg IV over 1 minute. Therefore, total administration time will be 2 minutes."
62133796|NCT02446145|PLACEBO_COMPARATOR|Control intervention arm|"Placebo daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~* concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.~* one cycle lasts 28 days"
61934003|NCT04741698|NO_INTERVENTION|No intervention|At the time of labor dystocia, patients randomized to the placebo arm will not receive any intervention
62133797|NCT05031234|ACTIVE_COMPARATOR|Group with morphine|conventional general anaesthesia with morphine
62133798|NCT05031234|EXPERIMENTAL|Group without opiates|general anaesthesia without opiates
62133799|NCT05099549|EXPERIMENTAL|Phase 1, Dose Escalation|"It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants.~SNK01 (fixed dose) will be administered weekly by IV infusion."
62133800|NCT05099549|EXPERIMENTAL|Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
62133801|NCT05099549|EXPERIMENTAL|Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)|SNK01 (fixed dose) will be administered weekly by IV infusion.
62133802|NCT05099549|EXPERIMENTAL|Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
62133803|NCT05871658|EXPERIMENTAL|the electroacupuncture group|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
62133804|NCT05871658|SHAM_COMPARATOR|the sham electroacupuncture group|According to the previous trial,\[19\] sham acupoints were 1cm away from the level of the acupoints used in the EA group, which avoided the area corresponding to any of the 14 meridians of TCM. The insertion of the needle was shallower (less than 0.2cm) and had similar pain to that of normal needle insertion. The stimulation intensity was 0mA. However, the model of electroacupuncture, the frequency, and duration of treatment in the SEA group were identical in the TA group.
62133805|NCT01661569|EXPERIMENTAL|Headspace On-the-go app|Participants were given access to a 45-day mindfulness meditation programme via the Headspace smartphone app
62133806|NCT01661569|NO_INTERVENTION|Waitlist control|Participants will be asked to wait for 8 weeks before starting the intervention
61934004|NCT02793011|EXPERIMENTAL|Dexamethasone|Liquid or capsule dexamethasone - to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
62133807|NCT04978233||MUHC COVID-19 patients|COVID-19 infected patients, newly diagnosed at the RI-MUHC
62133808|NCT05857020|EXPERIMENTAL|Auricular Acupressure (AA) Group|Participants will receive the AA intervention over a 5 day period in addition to their Standard of Care treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), and complete daily study questionnaires
62133809|NCT05465382|EXPERIMENTAL|Intra-articular saline lavage|"Subjects in Group 1 will then undergo saline joint lavage as follows:~Subjects will undergo aspiration of the injured ankle joint via the standard anteromedial arthroscopy portal approach. This will be performed with sterile technique using a 16-gauge needle attached to a 10cc syringe. After synovial fluid aspiration, three 10cc syringes will be filled with 10cc of sterile 0.9% normal saline. Normal saline will be injected into the ankle joint and withdrawn from the joint via the existing anteromedial 16 gauge needle. After three rounds of lavage, 10cc of 1% lidocaine without epinephrine will be injected into the joint via the existing anteromedial 16-gauge needle. Subjects will undergo a period of soft tissue rest to allow for the resolution of soft tissue swelling. At the time of surgical fixation subjects will again undergo intra-articular aspiration of the injured ankle joint."
62133810|NCT05465382|NO_INTERVENTION|No intra-articular saline lavage|"Subjects in group 2 will not undergo normal saline lavage as follows:~Subjects will undergo aspiration of the injured ankle joint via the standard anteromedial arthroscopy portal approach. This will be performed with sterile technique using a 16-gauge needle attached to a 10cc syringe. After synovial fluid aspiration, they will undergo intra-articular injection of 10cc of 1% lidocaine without epinephrine via the existing anteromedial 16-gauge needle. Subjects will undergo a period of soft tissue rest to allow for the resolution of soft tissue swelling. At the time of surgical fixation, subjects will again undergo intra-articular aspiration of the injured ankle joint."
61934005|NCT02793011|PLACEBO_COMPARATOR|Placebo|Placebo liquid or capsule to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
62133811|NCT02220439||Case: non-rotavirus seroconverters|Infants not demonstrating seroconversion to rotavirus vaccination, as measured anti-RV Immunoglobulin A \< 20 U/ml
62133812|NCT02220439||Control: rotavirus seroconverters|Infants demonstrating seroconversion to rotavirus vaccination, as measured by anti-rotavirus Immunoglobulin A \> 20 U/ml
62133813|NCT05460793|EXPERIMENTAL|Surgical treatment|Minimally invasive endoscopy-guided surgery in addition to standard medical management for the treatment of spontaneous supratentorial intracerebral hemorrhage performed within 8 hours of symptom onset.
62133814|NCT05460793|NO_INTERVENTION|Standard medical management|Standard medical treatment for the treatment of spontaneous supratentorial intracerebral hemorrhage (treatment of blood pressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration).
62133815|NCT03700034|EXPERIMENTAL|mHealth integrated model of hypertension, diabetes, anemia, and antenatal care|The mIRA trial intervention will consist of an electronic decision support system (EDSS), provided to healthcare providers at primary-level facilities in India and Nepal to deliver enhanced ANC with improved detection and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM) and anemia.
61934006|NCT05997771|EXPERIMENTAL|Study Intervention Group|"The study intervention group will be undergoing 3 months of Personalized Nutrition Advisor (PNA)-assisted remote nutritional counselling.The PNA data analysis tool will be used by the dietitians during remote nutritional counselling sessions.The service will be delivered to patients undergoing GLP-1 based obesity treatment as part of their usual care. The study intervention group will report treatment-satisfaction and self-efficacy via questionnaires at baseline, 1.5 - and 3 months.~Patients who expressed their interest in participating in a focus group at the time of study inclusion, will be invited for a 60 min online interview session chaired by an experienced moderator. The focus group will consists of a maximum of 10 participants and address the patient's perspective on the utility of the dietitians' advice, discrepancy from expectations, general feedback and suggestions for PNA improvement using a semi structured discussion guide held in an open and spontaneous format"
61934007|NCT06528873|NO_INTERVENTION|usual care|"Standard of Care treatment will be performed according to a provided standard of care manual according to most recent guidelines followed at each corresponding site (EWMA , S3-Leitlinie,...) and will proceed as follows:~* Removal of old dressing~* Application of analgesic if necessary~* Debridement if necessary~* Wound cleansing~* Application of new dressing (according to the wound healing phases, medical prescription)~* Application of compression therapy according to study standardized procedure (details in section 6.1).~In the case the participant is at home, this procedure will be performed by a caregiver."
62133816|NCT03700034|NO_INTERVENTION|Routine antenatal care|In the control clusters, pregnant women will receive the existing standard of care (usual care) from Frontline Health Workers (FHWs). Evidence-based guidelines in the form of posters/pamphlets on current national and state guidelines on screening and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM), anemia, and routine ANC procedures will be provided to all the control health facilities.
62327272|NCT01103817|NO_INTERVENTION|Vitamin D Sufficient|"Sufficient is defined as a 25 OH vitamin D level \>50 nmol/l measured at baseline. No clinical intervention will be assigned to this group.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
62327273|NCT01103817|EXPERIMENTAL|Vitamin D Deficient|"Deficient is defined as a 25 OH vitamin D level ≤ 37.5 nmol/l. This group will receive Vitamin D.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
62327274|NCT01823627|OTHER|Spirometry with reversibility test|Spirometry with reversibility test
62327275|NCT05942339|EXPERIMENTAL|Targeted Epidural Spinal Stimulation|"Single arm study: the participants that have undergone the STIMO study will be proposed to exchange their currently implanted system with selected components from the ARC-IM Lumbar system.~After the surgery, the participants will perform around 20 optimization sessions that may include rehabilitation to configure the neuromodulation system. Then the participants will use the ARC-IM Lumbar system independently during daily life activities until the end of the 36 months post-surgery. Assessments will be planned throughout the course of the study at the end of the optimization phase, after 12 and 24 months post-surgery and at the end of the study, with and/or stimulation."
62327276|NCT04188665|EXPERIMENTAL|MASL treated|Patients treated with lozenge containing MASL
62327277|NCT04188665|PLACEBO_COMPARATOR|Placebo treated|Patients treated with lozenge without MASL
62327278|NCT05348265|ACTIVE_COMPARATOR|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
62327279|NCT05348265|EXPERIMENTAL|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
62327280|NCT03580577||Cirrhotic with venous thromboembolism|"cirrhotic patients with a venous thromboembolic event (including deep venous thrombosis, pulmonary embolism, acute non-malignant portal vein thrombosis, splenic vein, inferior vena cava thrombosis or mesenteric vascular occlusion).~Each patient will subjected to through history taking and careful examination to detect and risk factors also laboratory work to detect thrombocytopenia, disease severity, coagulation status thrombelastography before starting anticoagulants.~* Patients will start treatment with anticoagulants therapy after liaise with the specialized physician.~* Protein C, protein S and antithrombin III level will be assessed 3 months after the acute thrombotic event and 1 month of vitamin K antagonist (VKA) withdrawal."
62485471|NCT02393144|OTHER|Induced labor arm|Women with term pregnancies who are induced for birth before the onset of spontaneous labor. Labor will be induced with either oxytocin infusion for women with high Bishop score, or labor will be induced with dinoprostone pessary for women requiring cervical ripening, i.e. poor. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
62133817|NCT05021341|ACTIVE_COMPARATOR|Berberine|500 mg of Berberine
62485472|NCT04293653|EXPERIMENTAL|Care bundle|Patients above 75 years where emergency surgery is indicated, deemed fit for surgery, will be included in a perioperative care-bundle. While waiting for surgery, patients will be monitored and optimized if their condition deteriorates. Antibiotics will be administered if indicated. Surgery will be delivered within 2h to 72h, depending on the suspected abdominal pathology and the patient's clinical condition.
62485473|NCT03808519|EXPERIMENTAL|n3 PUFA|n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
62485474|NCT03808519|PLACEBO_COMPARATOR|Placebo|Organic Sunflower Oil 5000mg per day
62485475|NCT05351567|EXPERIMENTAL|infertility educatıon group|women wıll educate with model about infertility
62485476|NCT05351567|NO_INTERVENTION|control group (non-education)|Routıne care
62485477|NCT05244876|EXPERIMENTAL|Experimental group|Intervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
62485478|NCT05244876|NO_INTERVENTION|Control group|I declare that I will not change my lifestyle during the study process.
62485479|NCT01538459|ACTIVE_COMPARATOR|Bupivacaine|50 randomized participants in group receive 20cc 0.25% bupivacaine injected perineurally for interscalene nerve block.
62485480|NCT01538459|EXPERIMENTAL|Dexamethasone and Bupivacaine|50 randomized participants in group will 8 mg(2cc of 4mg/cc solution) Dexamethasone added to 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection. Injected perineurally for interscalene nerve block pre-operatively.
62485481|NCT06562998|ACTIVE_COMPARATOR|PTX group|paclitaxel based regimens plus Pentoxifylline 400mg twice daily for 12weeks.
62485482|NCT06562998|PLACEBO_COMPARATOR|Control group|include those assigned for Taxol-based chemotherapy without intervention for 12 weeks
62485483|NCT05815667|EXPERIMENTAL|Intervention group|I-ACE. All participants are offered the I-ACE programme for the duration of 5 weeks.
62485484|NCT05815667|NO_INTERVENTION|Control group|Waiting list.
61934008|NCT06528873|EXPERIMENTAL|COMS Therapy|"COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:~Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)~If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device."
61934009|NCT05869565|ACTIVE_COMPARATOR|Normal saline arm|Sodium chloride (0.9%) referred as 0.9% NaCl for 72 hours post symptom onset (60-72 hourspost randomization);
62133818|NCT05021341|ACTIVE_COMPARATOR|Dihydroberberine 200|200 mg of Dihydroberberine
62133819|NCT05021341|ACTIVE_COMPARATOR|Dihydroberberine 100|100 mg of Dihydroberberine
62133820|NCT05021341|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62133821|NCT00879333|EXPERIMENTAL|Everolimus + BSC|All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
62133822|NCT00879333|PLACEBO_COMPARATOR|Placebo + BSC|All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
62485485|NCT03034096|EXPERIMENTAL|Propofol infusion|Maintenance of general anesthesia with propofol infusion
62133823|NCT00110552|EXPERIMENTAL|1|Sage capsules taken by mouth
61934010|NCT05869565|ACTIVE_COMPARATOR|normal saline sodium acetate 3;1|Sodium chloride (0.9%) and sodium acetate (0.9%) mixture 3:1 ratio for 72 hours post symptom onset (60-72 hours post randomization
61934011|NCT05869565|ACTIVE_COMPARATOR|normal saline sodium acetate 2;1|Sodium chloride (0.9%) and sodium acetate (0.9%) mixture 2:1 ratio for 72 hours post symptom onset (60-72 hours post randomization);
61934012|NCT05869565|ACTIVE_COMPARATOR|normal saline sodium acetate 1;1|Sodium chloride (0.9%) and sodium acetate (0.9%) mixture 1:1 ratio for 72 hours post symptom onset (60-72 hours post randomization).
62133824|NCT00110552|NO_INTERVENTION|2|No intervention, no-pill as control
62133825|NCT02376842|ACTIVE_COMPARATOR|Severe sepsis early warning best practice alert|Patients in this arm will actively generate the alert.
62133826|NCT02376842|PLACEBO_COMPARATOR|Standard care|This arm will be the current standard of care and will not generate the alert.
62133827|NCT01087359|ACTIVE_COMPARATOR|LPS + melatonin night|
62133828|NCT01087359|PLACEBO_COMPARATOR|LPS + placebo night|
62133829|NCT01087359|ACTIVE_COMPARATOR|LPS + melatonin day|
62133830|NCT01087359|PLACEBO_COMPARATOR|LPS + placebo day|
62133831|NCT01087359|EXPERIMENTAL|LPS night|
62133832|NCT01087359|EXPERIMENTAL|LPS day|
62485486|NCT03034096|EXPERIMENTAL|Volatile agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
62485487|NCT06491797|EXPERIMENTAL|Immediate reactivation|Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
62485488|NCT06491797|NO_INTERVENTION|Delayed reactivation|The control intervention will also be PTP as applied usually, in the control group before the application of the booster measure (applied delayed by three months).
62327281|NCT03580577||Cirrhotic without venous thromboembolism|"cirrhotic patients without any thrombotic events Each patient will subjected to through history taking and careful examination to detect and risk factors.~- Protein C, protein S and antithrombin III level will be assessed at baseline."
62327282|NCT03782740|EXPERIMENTAL|Dysmenorrhea Melatonin 10 mg|In the dysmenorrhea group: 2 capsules with 5 mg melatonin will be given in the evening for seven days consecutively during menstruation for two mentrual cycles. Compared with placebo.
62485489|NCT02043522|EXPERIMENTAL|Nuclear Imaging|Planar, conventional SPECT imaging and CZT SPECT imaging will be done. Imaging will begin immediately following radioisotope injection with CZT SPECT imaging for 15 minutes, followed by 1) planar anterior view imaging for 10 minutes, 2) conventional SPECT imaging for 12.5 minutes and 3) CZT SPECT imaging for 12 minutes. A low dose CT transmission scan will be acquired for attenuation correction (GE Infinia Hawkeye) with the initial conventional SPECT imaging and not repeated with subsequent imaging. Participants will undergo repeat imaging at 1, 2, 3 and 4 hours after radiotracer injection with each imaging session to include 1) planar anterior, 2) conventional SPECT and 3) CZT SPECT imaging.
35272012|NCT05549440|EXPERIMENTAL|Orsiro|
35272013|NCT05549440|ACTIVE_COMPARATOR|Resolute Onyx|
62485490|NCT05464836|EXPERIMENTAL|CB-103+Venetoclax|Control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients.
61934013|NCT04829448|EXPERIMENTAL|Protein Intervention Group|Patients who receive the protein nutritional supplement as part of their prescribed exercise-based rehabilitation program.
61934014|NCT04829448|NO_INTERVENTION|Control Group|Patients who receive the prescribed exercise-based rehabilitation program, without protein supplement.
61934015|NCT05456919||BRCA Mutated and no RRS|
61934016|NCT05456919||BRCA Mutated and RRS|
61934017|NCT05456919||BRCA Mutated and oncological diagnosis|
61934018|NCT05456919||BRCA Wildtype without oncological diagnosis|
61934019|NCT04416308|OTHER|Seroprevalence survey|NG Test + short self-questionnaire (except validation survey and detailed survey)
61934020|NCT04416308|OTHER|Validation test of the NG test survey|Blood test + NG test + detailed self-questionnaire
61934021|NCT04416308|OTHER|Detailed Survey|NG test + self-questionnaire complementary to the short questionnaire
61934022|NCT04416308|OTHER|Prevalence monitoring (2 population samples)|"Participants having presented a certain or probable COVID: acts of the validation test survey, + follow-up questionnaire,+ blood test + NG test, on D30 and D90~Others Participants : drawn by lot: acts of the seroprevalence survey, + follow-up questionnaire + NG test, on D90"
61934023|NCT01360281|EXPERIMENTAL|ECR|
61934024|NCT01360281|NO_INTERVENTION|Control|
61934025|NCT01360281|EXPERIMENTAL|NMES|
61934026|NCT05011656|EXPERIMENTAL|1- Seraph-100 plus State of the Art Care|The Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. Seraph 100 is an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. It is intended for use with standard, commercially available bloodlines compatible with the pump system used. Female Luer connectors are required to connect to the Seraph 100 blood ports.
61934027|NCT05011656|ACTIVE_COMPARATOR|2 - State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
61934028|NCT01419639|EXPERIMENTAL|RAD001|RAD001 taken orally continuously until disease progression or unacceptable toxicity, dosed according to age
61934029|NCT02260531|EXPERIMENTAL|Cohort 1 - Cabozantinib, Trastuzumab for HER2+|"HER2-positive~* Cabozantinib- orally administered daily per treatment cycle, 60 mg per day~* Trastuzumab- IV administered once per cycle, 8 mg/kg IV loading dose followed by 6 mg/kg IV Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
61934030|NCT02260531|EXPERIMENTAL|Cohort 2 - Cabozantinib for ER+ and/or PR+|"Hormone receptor-positive (ER+ and/or PR+)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
61934031|NCT02260531|EXPERIMENTAL|Cohort 3 - Cabozantinib for ER-, PR-, HER2-|"Triple negative (ER-, PR-, HER2-)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
61934032|NCT04176575|EXPERIMENTAL|Acupuncture|"Eligible participants:~* have advanced stage cancer and associated pain~* will receive up to 12 acupuncture sessions~* will attend sessions at UPMC's Center for Integrative Medicine~* will complete study assessments at each visit~* will complete a follow-up 4 to 6 weeks after their last acupuncture visit. Total study involvement will range from 16 to 18 weeks."
61934033|NCT06596668|EXPERIMENTAL|Bomedemstat + Carbamazepine|A single dose of bomedemstat will be administered On Day 1 of Period 1. There will be a washout of 7 days between bomedemstat dosing in Period 1 and the first carbamazepine (CBZ) dose in Period 2. In Period 2, CBZ will be administered twice daily (BID) for 17 consecutive days, with a single dose of bomedemstat coadministered with the morning dose on Day 14.
62133833|NCT04770324|EXPERIMENTAL|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
62327283|NCT03782740|EXPERIMENTAL|Endometriosis Melatonin 20 mg|In the endometriosis group: 4 capsules with 5 mg melatonin will be given every evening during eight weeks. Compared with placebo.
62327284|NCT04077970|EXPERIMENTAL|Intrauterine flushing follicular fluid|Women underwent intrauterine flushing with follicular fluid plus granulosa cells
62327285|NCT04077970|NO_INTERVENTION|Without intrauterine flushing with follicular fluid|Women without intrauterine flushing with follicular fluid
62327286|NCT06305104|EXPERIMENTAL|TB subjects in 18-65 years old|140 TB subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
62485491|NCT03461380|EXPERIMENTAL|Menopause Relief EP-40|Fixed combination of black cohosh EP-40 and Rhodiola rosea EPR-7 206.5 mg orally twice daily; daily dose 413 mg of active ingredients
62133834|NCT04353232||DANCAVAS trial|"We performed a population-based, parallel-group, randomized, controlled trial involving men 65 to 74 years of age living in 15 Danish municipalities. The participants were randomly assigned in a 1:2 ratio to undergo screening (the invited group) or not to undergo screening (the control group) for subclinical cardiovascular disease. Randomization was based on computer-generated random numbers and stratified according to municipality.~A total of 46,611 participants underwent randomization. After exclusion of 85 men who had died or emigrated before being invited to undergo screening, there were 16,736 men in the invited group and 29,790 men in the control group; 10,471 of the men in the invited group underwent screening (62.6%). In intention-to-treat analyses, after a median follow-up of 5.6 years, 2106 men (12.6%) in the invited group and 3915 men (13.1%) in the control group had died."
62327287|NCT06305104|EXPERIMENTAL|healthy subjects in 18-65 years old|180 healthy subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
62327288|NCT06305104|EXPERIMENTAL|non-TB subjects with lung disease in 18-65 years old|40 non-TB subjects with lung disease in 18-65 years old,each subject's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
62327289|NCT06305104|EXPERIMENTAL|TB subjects in 3-17 years old and 66-75 years old|Each enrolled subject received a single intradermal injection of 0.1 ml of the test drug (EEC) in one arm; the Mantoux method was used to inject intradermally into the middle and lower 1/3 of the volar side of the forearm.
62327290|NCT06305104|EXPERIMENTAL|non-TB subjects in 3-17 years old and 66-75 years old|Each enrolled subject received a single intradermal injection of 0.1 ml of the test drug (EEC) in one arm; the Mantoux method was used to inject intradermally into the middle and lower 1/3 of the volar side of the forearm.
62327291|NCT02980770||Obstructive Sleep Apnea (OSA)|Patients with OSA
62327292|NCT02980770||Obesity-Hypoventilation Syndrome (OHS)|Patients with OHS
62327293|NCT02980770||Normal Blood Gases|Normal Blood Gases
62327294|NCT02415296||stage 1|French online gamblers.
62327295|NCT02415296||stage 2|Validation of problematic gamblers score on possible problematic gamblers.
62327296|NCT02415296||stage 3|240 problematic gamblers.
62327297|NCT02738437|NO_INTERVENTION|control|Control Group receiving standard treatment
62327298|NCT02738437|ACTIVE_COMPARATOR|intervention group|Intervention Group receiving the standard treatment and the kryptonite-bone cement
62327299|NCT01684501||Amputees|Adults with history of traumatic unilateral transtibial amputation
62327300|NCT06560632|EXPERIMENTAL|Arm 1: RP-3467 monotherapy|Eligible participants will be treated with escalating doses of RP-3467 monotherapy
62327301|NCT06560632|EXPERIMENTAL|Arm2: RP-3467 + Olaparib combination|Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
62327302|NCT00697047|NO_INTERVENTION|1- Usual Care|Usual Care (UC) includes an annual birthday letter with information on overdue screening tests including CRC screening.
62327303|NCT00697047|EXPERIMENTAL|2 - Automated Mailing|Usual care plus automated mailing. Mailing 1 is a pamphlet about screening choices and number to call for colonoscopy. Mailing 2 is a FIT kit if not requesting colonoscopy. Mailing 3 is a Reminder letter.
62327304|NCT00697047|EXPERIMENTAL|3 - Automated Mailing Plus Assisted|Usual care, automated mailing plus, if screening is still not completed, phone assistance by a medical assistant (MA) who asks about patients screening intent, and provides brief assistance to complete this (e.g. sends another fecal test, assists with provider order for a colonoscopy).
62327305|NCT00697047|EXPERIMENTAL|4 - Auto Plus Assisted Plus Navigation|Usual care, automated mailing, phone assistance by a medical assistant, plus navigation by a registered nurse (RN) if still not screened. Navigators are trained to use motivational interviewing techniques. They assess CRC and procedure risk, facilitate screening choice, address barriers, and provide follow-up until screening is completed.
62327306|NCT05994014|OTHER|Main group|All patients undergo both, experimental and standard, tests
62327307|NCT02709434|ACTIVE_COMPARATOR|Intervention group|Patients with quiescent IBD who are randomized to receive the active intervention of the psychoeducational programme
62485492|NCT03461380|ACTIVE_COMPARATOR|High Dose Black Cohosh|Black cohosh 500 mg orally twice daily; daily dose 1000 mg of active ingredient
62485493|NCT03461380|PLACEBO_COMPARATOR|Placebo|Placebo capsule 600 mg excipients orally twice daily
62485494|NCT03461380|ACTIVE_COMPARATOR|Low Dose Black Cohosh|Black cohosh 6.5 mg orally twice daily; daily dose 13 mg of active ingredient
62327308|NCT02709434|PLACEBO_COMPARATOR|Control group|Randomized to standard care
62327309|NCT01328158||Lopinavir/Ritonavir|Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated
62485495|NCT04264221|EXPERIMENTAL|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
62133835|NCT04353232||VIVA trial|In this randomised controlled trial, we randomly allocated (1:1) all men aged 65-74 years living in the Central Denmark Region to screening for abdominal aortic aneurysm, peripheral arterial disease, and hypertension, or to no screening. We based allocation on computer-generated random numbers from 1 to 100 in blocks of 1067 to 4392, stratified by 19 municipalities. Only the non-screening group and the investigator assessing outcomes were masked. We invited participants who were found to have abdominal aortic aneurysm or peripheral arterial disease back for confirmation and eventual initiation of relevant pharmacological therapy. We further offered participants with abdominal aortic aneurysm annual control or surgical repair. We referred participants with suspected hypertension to their general practitioner. The primary outcome was all-cause mortality, assessed 5 years after randomisation. This trial is registered at ClinicalTrials.gov, number NCT00662480.
62327310|NCT04421989|EXPERIMENTAL|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
62327311|NCT04421989|ACTIVE_COMPARATOR|Support Group|Participants randomized to FBT + Support parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The parent support group facilitates parent discussion and support around a variety of topics central to treatment for pediatric AN including: understanding medical co-morbidities, levels of care for treatment, understanding expected body weight, navigating FMLA, and medications. The facilitator introduces each topic weekly and opens up discussion between parents. The facilitator's role is to ensure the group remains on topic and on time.
62133836|NCT03891316||Anaesthesiologists balanced|Anaesthesiologists performing balanced anaesthesia with sevoflurane.
62133837|NCT03891316||Anaesthesiologists TIVA|Anaesthesiologists performing only total intravenous anaesthesia.
62133838|NCT03891316||Surgeons|Surgeons working in the operating room while anaesthesia of the patients is randomly maintained with sevoflurane or propofol.
62133839|NCT03891316||Anaesthesiologists PACU|Anaesthesiologists working in the postoperative care unit.
62133840|NCT03891316||Anaesthesiologists outside the operating room|Anaesthesiologists working outside of the operating room, for example pain service or anaesthesiological walk-in clinic
62133841|NCT03891316||Physicians not exposed|Physicians not having contact with patients on wards/outpatient clinics after exposure with sevoflurane
62133842|NCT03891316||Patients|Patients having undergone sevoflurane anesthesia for elective surgery
62133843|NCT05533658|EXPERIMENTAL|VisionPure Dietary Supplement|One dose (2 softgel capsules) will be consumed once daily for 60 days. A single dose contains: 976mg fish oil (120mg eicosapentaenoic acid, 610 mg docosahexaenoic acid), 20mg lutein, 4mg zeaxanthin isomers, 25mcg vitamin D3.
62133844|NCT05533658|PLACEBO_COMPARATOR|Placebo|One dose (2 softgel capsules) will be consumed once daily for 60 days. A single dose contains: 727mg organic sunflower oil, 15mg organic lemon essential oil, 1.5mg vitamin E T-70, 0.7mg natural fish flavor.
62327312|NCT06142253|EXPERIMENTAL|WATER+CT|This is 8-month long two phase intervention consisting of: 1) 6 months of aquatic exercise followed by 2) 2 months of cognitive training.
62327313|NCT06142253|OTHER|Usual Care|This arm consists of psychoeducation regarding brain health and healthy lifestyles.
62327314|NCT01008254|EXPERIMENTAL|Musical prompt|
62327315|NCT01008254|ACTIVE_COMPARATOR|Delayed musical prompt|
62327316|NCT01008254|NO_INTERVENTION|No musical prompt|
62327317|NCT01623817|NO_INTERVENTION|Vancomcyin, maintain dose|This arm is received only maintain dose of vancomycin (15mg/kg twice a day or 1g twice a day).
62327318|NCT01623817|EXPERIMENTAL|Vancomycin loading|This group is received loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
62133845|NCT00044564|EXPERIMENTAL|Arm 1|
62133846|NCT02747394|EXPERIMENTAL|Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of adaptive Cogmed
62133847|NCT02747394|OTHER|Non-Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of non-adaptive Cogmed
62133848|NCT01671449|ACTIVE_COMPARATOR|S-1 plus Cisplatin|"* S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~  : If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~* Cisplatin: 60 mg/ m2/day, i.v., day 1~* Every 3 weeks"
62133849|NCT01671449|EXPERIMENTAL|S-1 plus Oxaliplatin|"* S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~  : If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~* Oxaliplatin: 130 mg/ m2/day, i.v., day 1~* Every 3 weeks"
62133850|NCT04027439|ACTIVE_COMPARATOR|Part A: RPL554|Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
62133851|NCT04027439|ACTIVE_COMPARATOR|Part B: RPL554|Double-blind, placebo-controlled, complete block cross-over
62133852|NCT00537212|ACTIVE_COMPARATOR|1|"Subjects will receive phototherapy and dietary counselling consistent with The South Beach diet."
62133853|NCT00537212|ACTIVE_COMPARATOR|2|"Subjects will receive phototherapy and dietary counselling consistent with The Ornish Diet."
62133854|NCT00537212|SHAM_COMPARATOR|3|Subjects will receive phototherapy alone, without dietary counselling.
62133855|NCT01646450|EXPERIMENTAL|Icotinib|Icotinib: 125mg, oral administration, three times per day.
62133856|NCT02275611|ACTIVE_COMPARATOR|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
62485496|NCT04264221|NO_INTERVENTION|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
62485497|NCT05204368|EXPERIMENTAL|Imipenem/Cilastatin/XNW4107|Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg ,q6h(0.5h infusion)
62485498|NCT05204368|ACTIVE_COMPARATOR|Meropenem|Meropenem 1g ,q8h (0.5h infusion)
62327319|NCT01355068|ACTIVE_COMPARATOR|Treatment A|Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
62327320|NCT01355068|EXPERIMENTAL|Treatment B|Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)
62327321|NCT06401512|EXPERIMENTAL|Intervention group|
62327322|NCT06401512|NO_INTERVENTION|Control group|Regular follow-up by primary care physician.
62327323|NCT03601416|EXPERIMENTAL|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.
62327324|NCT03601416|ACTIVE_COMPARATOR|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia.
62327325|NCT00713401|EXPERIMENTAL|Cohort A|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion
62327326|NCT00713401|EXPERIMENTAL|Cohort B|Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion
62327327|NCT00713401|EXPERIMENTAL|Cohort C|Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion
62327328|NCT00713401|EXPERIMENTAL|Cohort D|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion
62327329|NCT00713401|EXPERIMENTAL|Cohort E|Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion
62327330|NCT06548022|EXPERIMENTAL|Rare Group PM Plus|"Rare Group PM Plus consists of 5 weekly sessions. Each session lasts 90 minutes.~Session 1: Managing Stress Session 2: Managing Problems Session 3: Get Going, Keep Doing Session 4: Strengthening Social Support Session 5: Staying Well and Looking Forward"
62327331|NCT06215898|NO_INTERVENTION|Control Group|Patients with Parkinson's Disease who were in the control group did not receive any interventional application.
62327332|NCT06215898|EXPERIMENTAL|Exercise Group (LSVT-Big protocol)|Patients with Parkinson's disease who were in the exercise group have completed a four-week supervised aerobic exercise protocol via Tele-rehabilitation.
62327333|NCT02963727|EXPERIMENTAL|Wharton Jelly mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
62485499|NCT05105607|EXPERIMENTAL|Cohort 1: 0.25 mg/kg D-4517.2|Participants will be administered a single dose of 0.25 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the safety review committee (SRC) will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
62485500|NCT05105607|EXPERIMENTAL|Cohort 2: 0.5 mg/kg D-4517.2|Participants will be administered a single dose of 0.5 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
62485501|NCT05105607|EXPERIMENTAL|Cohort 3: 1.0 mg/kg D-4517.2|Participants will be administered a single dose of 1.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
62485502|NCT05105607|EXPERIMENTAL|Cohort 4: 2.0 mg/kg D-4517.2|Participants will be administered a single dose of 2.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort.
62327334|NCT05871125|EXPERIMENTAL|Patients receiving reimbursement|Monthly reimbursement to offset trial-related expenses
62327335|NCT01526018||Novel bottle|
62327336|NCT02423824|ACTIVE_COMPARATOR|Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
62327337|NCT02423824|ACTIVE_COMPARATOR|Non-Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
62327338|NCT06462586|EXPERIMENTAL|Lumateperone 42 mg|Lumateperone 42 mg capsules
62327339|NCT06462586|PLACEBO_COMPARATOR|Placebo|Matching placebo
62327340|NCT00398710|EXPERIMENTAL|Perifosine|Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.
62327341|NCT04951648|EXPERIMENTAL|Almonertinib|
62327342|NCT04951648|ACTIVE_COMPARATOR|Platinum-based doublet chemotherapy|
62327343|NCT06692842|EXPERIMENTAL|CONEMO|CONEMO is a low-intensity psychoeducational program which is made available to users via smartphones compatible with Android or iOS systems. At the same time, the designed healthcare professional use a tablet to monitor user adherence to the intervention. CONEMO comprise seven weekly modules, totally self-guides.
62327344|NCT06350552||Hemodialysis|They will be assessed for postural abnormalities. Also, they will do some physical function tests.
62327345|NCT06350552||Peritoneal Dialysis|They will be assessed for postural abnormalities. Also, they will do some physical function tests.
62327346|NCT01916122|EXPERIMENTAL|(FES) PET/CT for Imaging|"FES PET/CT studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 5 mCi (+/- 10%) of FES PET/CT will be injected intravenously. 60 (+/- 10) minutes following tracer injection, the patient will be positioned on a GE Discovery PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first, 60-80mAs, 120-140kVp, with a 5mm slice thickness while the patient was free breathing. PET will be acquired at 3-5 minutes per bed position using the 3D mode, approximately 6-7 bed positions. FES PET/CT imaging will take less than 60 minutes. Scans will be reconstructed with iterative reconstruction.~If follow-up FES PT/CT scans are performed on a patient, then the same parameters will be used as the initial FES PET/CT scan."
62327347|NCT01064453||Group 1|
61934034|NCT06708923|EXPERIMENTAL|IVF with Acupuncture Group: Patients undergoing IVF cycles with acupuncture performed before and aft|"IVF with Acupuncture Group:~This group includes patients who underwent IVF cycles with acupuncture performed at two key time points:~Before Embryo Transfer: Acupuncture was administered 25 minutes prior to transfer at specific acupoints (e.g., Baihui, Guanyuan, Sanyinjiao) to enhance endometrial receptivity and reduce stress.~After Embryo Transfer: A second acupuncture session was conducted immediately following the transfer at additional acupoints (e.g., Zusanli, Taichong) to support implantation and relaxation.~IVF without Acupuncture Group:~This group includes patients who underwent IVF cycles without any acupuncture treatment. Their IVF procedures followed standard clinical protocols for frozen embryo transfer (FET), including hormonal preparation of the endometrium and embryo transfer, without any complementary therapies.~The study retrospectively compares clinical outcomes, including clinical pregnancy rate (CPR), ongoing pregnancy rate (OPR), and live birth rate (LBR), betwee"
62485503|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
61934035|NCT02547948|EXPERIMENTAL|CAR T cells|In interventional studies, participants are assigned to accept CD19-targeting CAR T Cells infusion so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. Arm refers to each group or subgroup of participants in a clinical trial that receives specfic interventions (or no intervention) according to the study protocol. This is decided before the trial begins.
62133857|NCT02275611|PLACEBO_COMPARATOR|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
62133858|NCT05255835|ACTIVE_COMPARATOR|Semiconductor knee-sleeves|Knee-sleeves containing semiconductor elements within the fabric constitute the intervention arm.
62133859|NCT05255835|PLACEBO_COMPARATOR|Placebo knee-sleeves|Cotton knee-sleeves constitute the placebo arm.
62133860|NCT00418613|EXPERIMENTAL|1|MK0633
62133861|NCT00418613|PLACEBO_COMPARATOR|2|Placebo
62133862|NCT03000101|EXPERIMENTAL|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
62133863|NCT03000101|PLACEBO_COMPARATOR|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
62133864|NCT03694691|EXPERIMENTAL|Biopsy|Biopsies taken at protocol specified time points
62133865|NCT02481466|EXPERIMENTAL|Portfolio diet and structured exercise|Participants will receive advice on a therapeutic diet appropriate for hypercholesterolemia (ie \<7% of energy from saturated fat, \<200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be instructed on a standardized physical activity/exercise component supervised by kinesiologists.
62133866|NCT02481466|ACTIVE_COMPARATOR|DASH-like diet and structured exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a be instructed on the Laval exercise program-a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).
62133867|NCT02481466|EXPERIMENTAL|Portfolio diet and routine exercise|Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie \<7% of energy from saturated fat, \<200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
62133868|NCT02481466|ACTIVE_COMPARATOR|DASH-like diet and routine exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
62133869|NCT03681366|NO_INTERVENTION|Single vision soft contact lens|single vision, spherical soft contact lens
62133870|NCT03681366|EXPERIMENTAL|DISC3.5 Plus lens|A soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
62133871|NCT03124017|EXPERIMENTAL|Alert Group|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
62485504|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
62133872|NCT03124017|NO_INTERVENTION|Control Group|No electronic alert and no Geneva Risk Score calculation tool issued in the electronic patient chart
62133873|NCT00624442|EXPERIMENTAL|Cohort 1|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
62133874|NCT00624442|EXPERIMENTAL|Cohort 2|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
62133875|NCT00624442|EXPERIMENTAL|Cohort 3|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
62133876|NCT00624442|EXPERIMENTAL|Cohort 4|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
62133877|NCT00624442|EXPERIMENTAL|Cohort 5|2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
62133878|NCT03427866|EXPERIMENTAL|Ruxolitinib Eligible pre-HSCT|"* Ruxolitinib will be taken orally at a fixed dose twice every day~* Dosing will be continuous, with a new cycle scheduled to start every 28 days.~* There will be no break in dosing between cycles~* Ruxolitinib can be administered with or without food."
62485505|NCT03751137||Breast Feeding|Infants who, when enrolled, are exclusively breast feeding.
62485506|NCT03751137||Formula Feeding|Infants who, when enrolled, are exclusively formula feeding.
62485507|NCT02402660|EXPERIMENTAL|ALK-001|Daily, oral administration of one capsule. See details below.
62327348|NCT01270581|EXPERIMENTAL|High Flow Nasal Cannula|Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
62327349|NCT01270581|ACTIVE_COMPARATOR|Control Group- Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
62327350|NCT03408496|EXPERIMENTAL|Myofascial release|"Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through traces executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue."
62327351|NCT03408496|EXPERIMENTAL|Muscle Stretching|The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
62327352|NCT03408496|ACTIVE_COMPARATOR|Control|It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
62327353|NCT00003019|EXPERIMENTAL|Chemotherapy Treatment|Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
62327354|NCT04962542|ACTIVE_COMPARATOR|ventilated group|the lungs will be kept inflated by delivery of oxygen : air 3 liter/min with FiO2 50% pressure-controlled mode, RR 20/min, PIP will be adjusted to keep Vt 2- 4 mL/kg as possible
62327355|NCT04962542|ACTIVE_COMPARATOR|CPAP group|lungs will be kept inflated by delivery of oxygen: air 3 liters/min with FiO2 50% and CPAP will be maintained via a circle system with airway pressure maintained at 5 cm H2O by PEEP valve
62327356|NCT04962542|NO_INTERVENTION|controlled group|lungs will be deflated by disconnecting the breathing circuit from the ventilator (passive deflation).
62485508|NCT02402660|PLACEBO_COMPARATOR|Placebo|Daily, oral administration of one capsule. See details below.
62485509|NCT02116595|EXPERIMENTAL|feeding a high acid diet x 24 hrs|2 diets, one low and one high net acid loads
61934036|NCT02547948|NO_INTERVENTION|No Intervention|
61934037|NCT04088656|EXPERIMENTAL|Hypertension Systems Analysis and Improvement|Eight (8) health facilities will receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
61934038|NCT04088656|NO_INTERVENTION|Control|Eight (8) health facilities will not receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
61934039|NCT00570414|ACTIVE_COMPARATOR|1|Laryngeal mask airway (LMA)
61934040|NCT00570414|ACTIVE_COMPARATOR|2|Endotracheal tube (ETT)
61934041|NCT06415318|EXPERIMENTAL|Experimental: Neoadjuvant Therapy TIP (Paclitaxel + Ifosfamide + Cisplatin) & Toripalimab|Drug: Toripalimab 240mg, ivgtt, d1 Drug: Paclitaxel 175 mg/m2, ivgtt, d1 Drug: Cisplatin 25mg/m2·d, ivgtt, d1-3 Drug: Ifosfamide 1.2g/m2·d, ivgtt, d1-3
61934042|NCT06215716|EXPERIMENTAL|EFX 28 mg|
61934043|NCT06215716|EXPERIMENTAL|EFX 50 mg|
62485510|NCT02116595|ACTIVE_COMPARATOR|low acid diet|
62485511|NCT03198923|EXPERIMENTAL|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
62485512|NCT06626165|ACTIVE_COMPARATOR|Mirikizumab|When the patients were endoscopically active and pathologically high neutrophil infiltration in epithelium of the colonic mucosa (Geboes score Grade ≥3.2), using Geboes biopsy histology scores they will be administered by mirikizumab.
61934044|NCT06215716|PLACEBO_COMPARATOR|Placebo|
61934045|NCT06173141|ACTIVE_COMPARATOR|Group A (low- to moderate-continuous intensity cycling exercises:|"Patients performed aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
61934046|NCT06173141|ACTIVE_COMPARATOR|Group B (moderate- to high-interval intensity cycling exercises),|"Patients performed aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
62692879|NCT02402647|EXPERIMENTAL|Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
61934047|NCT06173141|SHAM_COMPARATOR|group (C)|received the hemodialysis sessions only.
61934048|NCT03488927|EXPERIMENTAL|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
61934049|NCT03488927|NO_INTERVENTION|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
61934050|NCT03054454|ACTIVE_COMPARATOR|intervention|This group will receive Podiatry treatment and care from the MDT which is the intervention group.
61934051|NCT03054454|NO_INTERVENTION|comparator|This group will receive usual care
61934052|NCT05513820||Retrospective group|Retrospective group: 700 patients from the databases of the AP-HP, the Lyon University Hospital and the Lille University Hospital for training and validation of the algorithms.
61934053|NCT05513820||Prospective group|Prospective group: 550 patients (test-set) from AP-HP (CHU Pitié, Tenon, Bicêtre, Necker), CHU Lille, CHU Lyon, CHU Bordeaux and CHU Strasbourg to tes the performance of the algorithms.
61934054|NCT04840069|NO_INTERVENTION|MRI-guided radiotherapy|Patients will undergo standard of care MRI-guided radiotherapy.
61934055|NCT04840069|EXPERIMENTAL|MRI + Fluciclovine PET-guided radiotherapy|Patients will undergo MRI + Fluciclovine PET-guided radiotherapy
61934056|NCT03857906||IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease Intra-Aortic Ballon Pump insertion 1-6 hours prior to surgery
61934057|NCT03857906||No-IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease No IABP
61934058|NCT06596577|ACTIVE_COMPARATOR|Palliative care needs information provision|Clinicians will receive an EHR alert providing information about a patient's serious illness diagnosis(-es) and unmet palliative care needs
61934059|NCT06596577|ACTIVE_COMPARATOR|Palliative care needs information provision + default consult order|The palliative care needs information provision intervention will be supplemented with a default palliative care consult order such that clinicians will receive an EHR alert providing information about a patient's serious illness diagnosis(-es) and unmet palliative care needs, and offered the choice to cancel the default consult order.
61934060|NCT06596577|NO_INTERVENTION|Control/Usual Care|During the control phase, patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care. All hospitals will contribute a minimum of 3 months of outcomes data prior to adopting the intervention. The total duration of the control phase will differ for each hospital dependent on their randomly assigned time to adopt Intervention 1 in this stepped-wedge trial design.
61934061|NCT01347307|OTHER|SBRT for Benign Extradural Spine Tumors|Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
61934062|NCT01347307|OTHER|SBRT for Vertebral/Paraspinal Metastases|Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
61934063|NCT06359431|ACTIVE_COMPARATOR|Standard Speculum/Novel Speculum|In this arm, the standard speculum will be administered before the novel speculum
61934064|NCT06359431|ACTIVE_COMPARATOR|Novel Speculum/Standard Speculum|In this arm, the novel speculum will be administered before the standard speculum
61934065|NCT00406094|EXPERIMENTAL|1|montelukast
61934066|NCT00406094|PLACEBO_COMPARATOR|2|placebo
62485513|NCT06626165|ACTIVE_COMPARATOR|Vedolizumab|When the patients are endoscopically active and pathologically low neutrophil infiltration in epithelium of the colonic mucosa (Geboes score Grade 3.1), using Geboes biopsy histology scores, they will be administered by vedolizumab.
61934067|NCT04685031|EXPERIMENTAL|nitroglycerin|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
61934068|NCT04685031|EXPERIMENTAL|clobetasol|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
61934069|NCT04685031|NO_INTERVENTION|routine|routine nursing care
62133879|NCT03427866|EXPERIMENTAL|Ruxolitinib Not Eligible pre-HSCT|"* Ruxolitinib will be taken orally at a fixed dose twice every day after transplant~* Dosing will be continuous, with a new cycle scheduled to start every 28 days.~* There will be no break in dosing between cycles~* Ruxolitinib can be administered with or without food."
62133880|NCT03643055||MTC 18F-fluorocholine PET/CT|Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
62485514|NCT02282722|ACTIVE_COMPARATOR|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
61934070|NCT04545554|EXPERIMENTAL|Romosozumab: 12 - < 18 Years of Age|Participants will receive 1 of 3 dose levels of romosozumab. All participants also received calcium and vitamin D.
61934071|NCT04545554|EXPERIMENTAL|Romosozumab: 5 - < 12 Years of Age|Participants will receive 1 of 3 dose levels of romosozumab. All participants also received calcium and vitamin D.
61934072|NCT01241240|EXPERIMENTAL|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
61934073|NCT01241240|ACTIVE_COMPARATOR|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
61934074|NCT00455767|ACTIVE_COMPARATOR|1|Depelestat
62485515|NCT02282722|EXPERIMENTAL|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
62485516|NCT02063139|EXPERIMENTAL|Flutiform 50/5 ug (2 puffs bid) pMDI|Flutiform 50/5 ug (2 puffs bid) pMDI
62485517|NCT02063139|ACTIVE_COMPARATOR|Fluticasone 50 ug (2puffs bid) pMDI|Fluticasone 50 ug (2puffs bid) pMDI
62485518|NCT02063139|OTHER|Beclometasone Autohaler 50 ug (2 puffs bid)|Active control
62692880|NCT02402647|ACTIVE_COMPARATOR|Exposure Therapy (ET)|The investigators propose to use a robust control condition, exposure therapy (ET), with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
62692881|NCT00670514|ACTIVE_COMPARATOR|1 Nix Individual|High Treatment Intensity
62692882|NCT00670514|PLACEBO_COMPARATOR|2 Fimpa dig fri|Low Treatment Intensity
62692883|NCT03794947|EXPERIMENTAL|Remote Ischaemic Conditioning|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg (arm) and 220 mmHg (leg). RIC will be completed 3 times weekly for 4 weeks.
62327357|NCT03763643|EXPERIMENTAL|Rituximab + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day -1, 0 and +1 prior to or after kidney transplantation in addition to standard plasmapheresis.
62327358|NCT03763643|PLACEBO_COMPARATOR|Placebo + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day -1, 0 and +1 prior to or after kidney transplantation in addition to standard plasmapheresis.
62485519|NCT01075516||Standard Follow Up|ICD patients followed through periodic in-hospital visits
62485520|NCT01075516||Remote Follow Up|ICD patients followed with remote transmitters (Merlin@Home) that periodically communicate correct system functioning
62485521|NCT06157268||Core myopathies|Patients with a genetically confirmed core myopathy
62133881|NCT02229721|ACTIVE_COMPARATOR|Syntocinon Nasalspray 32 IU|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
62133882|NCT02229721|PLACEBO_COMPARATOR|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
62485522|NCT06157268||Nemaline myopathy|Patients with a genetically confirmed nemaline myopathy
62485523|NCT06157268||Centronuclear myopathy|Patients with a genetically confirmed centronuclear myopathy
62485524|NCT05937451|ACTIVE_COMPARATOR|Intervention group|The intervention group receives the prediction results daily until the patient is discharged or up to 7 days after admission.
62485525|NCT05937451|NO_INTERVENTION|Usual care group|The usual-care group does not receive analysis results. The user-care group continues the existing treatment.
62485526|NCT04775004|ACTIVE_COMPARATOR|Bone marrow venting procedure (BMVP)|Subjects randomized in the OR to undergo BMVP surgical augmentation
62485527|NCT04775004|ACTIVE_COMPARATOR|Platelet rich plasma (PRP)|Subjects randomized in the OR to undergo PRP surgical augmentation
62485528|NCT03793803|EXPERIMENTAL|Home Palliative Care|Randomized to Intervention Arm
62485529|NCT03793803|NO_INTERVENTION|Control Arm|Usual Care - Patients will be cared for by the physician who treats their primary illness(es).
62485530|NCT05876819||Iranians|Disabled Middle and Older Adults
62133883|NCT00275392|EXPERIMENTAL|Vestibular Rehabilitation|vestibular exercises plus standard balance and gait exercises
62133884|NCT00275392|PLACEBO_COMPARATOR|Placebo|placebo exercises plus standard balance and gait exercises
62133885|NCT01091649|ACTIVE_COMPARATOR|A|Low dose ABT-450 capsule and ritonavir capsules (reference).
62133886|NCT01091649|ACTIVE_COMPARATOR|B|Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)
62133887|NCT01091649|ACTIVE_COMPARATOR|C|Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).
62133888|NCT01091649|ACTIVE_COMPARATOR|D|High dose ABT-450 capsule and ritonavir capsules (reference).
62133889|NCT01091649|ACTIVE_COMPARATOR|E|High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)
62133890|NCT00609297||Supportive Care|Alive Hospice Patients with Pain
62485531|NCT05876819||Lebanese|Disabled Middle and Older Adults
62485532|NCT01171768||patients with hemoptysis within 2 weeks|
62485533|NCT01171768||patients without hemoptysis within 2 years|
62485534|NCT05533411|EXPERIMENTAL|350 milligram (mg) Donanemab|Single 350 mg Donanemab dose administered intravenously (IV) on Day 1.
62485535|NCT05533411|EXPERIMENTAL|700 mg Donanemab|Single 700 mg Donanemab dose administered IV on Day 1.
62485536|NCT05533411|EXPERIMENTAL|1400 mg Donanemab|Single 1400 mg Donanemab dose administered IV on Day 1.
62485537|NCT05533411|PLACEBO_COMPARATOR|Placebo|Single placebo dose administered IV on Day 1.
62485538|NCT04593160|EXPERIMENTAL|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
62485539|NCT04593160|EXPERIMENTAL|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
62485540|NCT04593160|PLACEBO_COMPARATOR|Placebo|Preoperative single dose of placebo
62485541|NCT04340063|ACTIVE_COMPARATOR|Treadmill group|Participants randomized to the Treadmill group will complete high intensity gait training on a treadmill.
62692884|NCT03794947|SHAM_COMPARATOR|Sham Intervention|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The arm and leg blood pressure cuffs in the sham intervention will inflate to 20mmHg. Sham will be completed 3 times weekly for 4 weeks.
62692885|NCT03843073|EXPERIMENTAL|Connected Catheter Users|
61934075|NCT00455767|PLACEBO_COMPARATOR|2|Placebo
61934076|NCT01646073|EXPERIMENTAL|Adalimumab|Adalimumab 40 mg every other week (eow)
61934077|NCT01646073|PLACEBO_COMPARATOR|Placebo|placebo
61934078|NCT06082830|NO_INTERVENTION|Control|The control arm will not receive any intervention materials.
62327359|NCT05164861|EXPERIMENTAL|Intervention/kombucha-based beverage|"Subjects randomized to this group will receive newly developed food product - non-alcoholic pasteurized beverage based on kombucha enriched with inulin and vitamins, flavoured as Black currant with juniper or Strawberries with lime or 'Mango with passion fruit"
62327360|NCT05164861|NO_INTERVENTION|Control|Subjects of this group will receive standard diet with similar quantity of water as in experimental group
62327361|NCT02927093||Case|neonates with NH reaching exchange transfusion threshold
62327362|NCT02927093||Control|neonates with NH within moderate threshold of the phototherapy charts
62327363|NCT04405804|EXPERIMENTAL|Ivabradine|Eligible patients will be given treatment with ivabradine during a titration period which will last from a minimum of 3 days to a maximum of 15 days. This will be followed by a maintenance period of another 14 days. At the end of maintenance period, primary endpoint will be assessed. After maintenance period, the patient will continue ivabradine at the same dosage during a follow-up period that will last 4 months.
62485542|NCT04340063|EXPERIMENTAL|Movement Amplification group|The locomotor training protocol described for the Treadmill group will be used for the Movement Amplification group with one exception. The Movement Amplification group will perform all gait training within the movement amplification environment.
62485543|NCT01079845|EXPERIMENTAL|Low-glycemic Load Diet|
62485544|NCT01079845|ACTIVE_COMPARATOR|Low-fat Diet|
62692886|NCT06181058|EXPERIMENTAL|escape room game|"The participant list will be uploaded to a program and teams of 6-8 people will be formed with random names. The participant list will be uploaded to a program and teams of 6-8 people will be formed with random names. Each team will play the escape game.~Participants will be informed about the game. He/she will be asked to solve puzzles within the framework of an oncology patient scenario. There will be a debriefing session at the end of the escape game.~Participants will be informed with a scenario containing the story of an oncology patient, and puzzles-riddles related to the case will be given within the game. They will get a letter when they solve each riddle and complete the game by solving the password."
62692887|NCT06637189|EXPERIMENTAL|PPOS - study group|"Patients belonging to this arm will initiate controlled ovarian stimulation by administering FSHr gonadotropin at doses between 225 IU-300 IU/day (according to patient characteristics) + 10mg medroxyprogesterone/day (IMP) from day 2-3 of their menstrual cycle.~Both groups will continue with the usual regimen of administration of all medications related to Ovarian Stimulation"
62692888|NCT06637189|ACTIVE_COMPARATOR|GnRH antagonists - control group|Patients belonging to this arm will initiate controlled ovarian stimulation by administering FSHr gonadotropin at doses between 225 IU-300 IU/day (according to patient characteristics) from day 2-3 of their menstrual cycle, and treatment with the GnRH antagonist at a dose of 0.25 mg/day from the 6th day of stimulation or when a follicle with a size equal to or greater than 14mm is present. Both groups will continue with the usual regimen of administration of all medications related to Ovarian Stimulation
61934079|NCT06082830|EXPERIMENTAL|Intervention|The trial duration will be four weeks. The intervention arm includes five components: personalized goal, meal timing, nutrition skills, home food environment, and engagement strategies. The specific number, design and content of the text messages for each component will be prepared and vetted by the investigators and by adolescents and parents through CHOP's Family Partners Program prior to study launch. The text messages will be sent through the REDCap Twilio integration.
61934080|NCT02207673|ACTIVE_COMPARATOR|Spikes as biomarker|"In arm  spikes the resection of epileptogenic tissue is guided by epileptiform spikes in the aECoG (current standard). (Independent of the randomisation ictiform spike patterns will always be resected.)"
61934081|NCT02207673|EXPERIMENTAL|HFOs as biomarker|"In arm HFOs resection of epileptogenic tissue is guided by HFOs in the aECoG (new). (Independent of the randomisation ictiform spike patterns will always be resected.)"
61934082|NCT03263585|ACTIVE_COMPARATOR|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
61934083|NCT03263585|ACTIVE_COMPARATOR|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
61934084|NCT03263585|NO_INTERVENTION|Control|Women in the control group get no intervention for six months.
61934085|NCT06448182|EXPERIMENTAL|Postbiotic group|1 postbiotic capsule daily in the morning during 12 weeks
61934086|NCT06448182|PLACEBO_COMPARATOR|Placebo group|1 placebo capsule daily in the morning during 12 weeks
61934087|NCT03182062|ACTIVE_COMPARATOR|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs\> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
62327364|NCT02409784|EXPERIMENTAL|Ketogenic diet|"Pre/Post TEP study with a 4 days ketogenic diet (KD).~Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet~Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet"
62327365|NCT06116461|EXPERIMENTAL|Nivolumab|Patients in the experimental arm receive three reduced nivolumab doses of 240 mg Q4W
62485545|NCT01312064|ACTIVE_COMPARATOR|rituximab and everolimus|Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
62485546|NCT01312064|ACTIVE_COMPARATOR|thymoglobulin and tacrolimus|The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.
62485547|NCT03192007||Patients with Stable Renal Function|Patients will be given MRI
62485548|NCT03192007||Patients with Worsening Renal Function due to complications|MRI
62692889|NCT05708508|EXPERIMENTAL|"Immuno-guided strategy arm"|"* Patients in the low risk group will be monitored between D+15 and W+28 according to a strategy preemptive.~* Patients in the high risk group (anti-CMV response \<130 SFC/106 cells) will be treated according to the terms of the universal prophylaxis arm from D+15 and until W+15.~At the W+15 visit:~* If the patient is considered at low risk, the antiviral treatment is stopped and he will continue the follow-up according to the modalities of the universal prophylaxis arm until W+28.~* If the patient is still at high risk antiviral treatment will be continued until W+28."
61934088|NCT03182062|ACTIVE_COMPARATOR|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.~Postoperatively, standard oxygen therapy."
61934089|NCT06379087|EXPERIMENTAL|Single Arm|"Neoadjuvant therapy regimen (2 cycles):~1. Receive 3-day hypofractionated treatment on Day 1, Day 2, and Day 3, with a total dose of 24Gy (8Gy\*3).~2. Within 1 week after radiotherapy, receive neoadjuvant tislelizumab (200 mg, intravenous drip, d1) combined with anlotinib (10 mg, oral, D1-14) . Each 3 weeks is a medication cycle.~Surgical protocol: The surgical approach was determined by the surgeon according to the patient's condition, including but not limited to thoracoscopic/open lobectomy/sleeve lobectomy/combined lobectomy/pneumonectomy. Lymph node dissection requires at least three stations of mediastinal lymph node dissection.~Adjuvant therapy regimen: tislelizumab (200 mg, intravenous drip, d1) combined with Anlotinib (10 mg, oral, D1-14). Each 3 weeks is a medication cycle, for 1 year."
61934090|NCT02173184|PLACEBO_COMPARATOR|Placebo|Placebo vehicle (0.9% NaCl solution)
61934091|NCT02173184|EXPERIMENTAL|Gynevac|Gynevac suspension for injection, a vaccine containing Lactobacillus strains 15, 34, 79, 84, 127 inactivated by formaldehyde in 0.9% NaCl solution
61934092|NCT06134167|EXPERIMENTAL|Transdermal Compress Device|The Transdermal Compress device is a bone-anchored transdermal implant that addresses the shortcomings of a socket prosthesis and provides options to amputees who are not able to utilize a conventional socket prosthesis.
61934093|NCT05635669|EXPERIMENTAL|Sacral acupoints group (Sacral group)|Participants will receive sacral acupoints combination treatment at bilaterally Huiyang(BL35) and Zhongliao(BL33) with prone position during the whole treatment course.
61934094|NCT05635669|EXPERIMENTAL|Abdominal acupoints group (Abdominal group)|Participants will receive abdominal acupoints combination treatment at unilateral Zhongji(RN3), Guanyuan(RN4) and bilaterally Dahe(KI12) with dorsal position during the whole treatment course.
62327366|NCT03169738|EXPERIMENTAL|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
62327367|NCT05824845||ARC Study Cohort|
62327368|NCT02214186|NO_INTERVENTION|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
62327369|NCT02214186|ACTIVE_COMPARATOR|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
62485549|NCT01172158||Forgotten ureteral stents|
62485550|NCT03587545|EXPERIMENTAL|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
62485551|NCT03587545|EXPERIMENTAL|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
62485552|NCT03587545|PLACEBO_COMPARATOR|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.~Placebo nasal spray."
62485553|NCT03587545|EXPERIMENTAL|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
62485554|NCT03587545|EXPERIMENTAL|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
62485555|NCT03587545|PLACEBO_COMPARATOR|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
62485556|NCT04928027||Persons with PD|Adults with PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Self-Assessment
62485557|NCT04928027||Significant Others of those with PD|Adults whose significant other has a diagnosis of PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Observer report
62485558|NCT00625222|EXPERIMENTAL|1|
62485559|NCT01861080||incident hypertensives|"Inclusion Criteria:~* age≧30years~* primary incident hypertension~* signed informed consent"
62485560|NCT05133440|EXPERIMENTAL|Experimental Arm|Participants will receive two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT to the target index lesion(s) should be completed within 30 days after simulation after completion of the 2nd infusion of Radium (Ra-223) dichloride. Specific dose constraints, dosing schedules, and management of SBRT to multiple sites will be at the discretion of the treating Radiation oncologist. The goal is to complete simulation and SBRT within 30 days. Only active or progressive disease is to be treated at the discretion of the treating investigator.
62485561|NCT05133440|ACTIVE_COMPARATOR|Control Arm:|Participants will receive SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. SBRT should begin within 30 days (+/- 7 days) of randomization. Only active or progressive disease is to be treated at the discretion of the treating investigator.
62485562|NCT02471027||Experimental group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is neoadjuvant chemotherapy combined with cervical cancer radical surgery .
62485563|NCT02471027||control group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is cervical cancer radical surgery.
62485564|NCT01275235||Exposure to Type II Diabetes for two siblings|Two sibling pairs with the same parents, between the ages of 20 to 34 in the Baton Rouge Area, having mother with diabetes while pregnant with one.
62485565|NCT03287154|EXPERIMENTAL|Active tDCS stimulations|Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).
62485566|NCT03287154|SHAM_COMPARATOR|Sham tDCS|"Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks).~As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped."
62485567|NCT04670107|EXPERIMENTAL|combination group|
62485568|NCT01487057||Thyroid cancer, lipids, LT4 withdrawal|
62485569|NCT01487057||Thyroid cancer, Lipids, LT4 substitution|
62485570|NCT03156816|EXPERIMENTAL|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
62485571|NCT03156816|PLACEBO_COMPARATOR|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
62485572|NCT01360333|OTHER|Tap water, sodium chloride, carbohydrate rich fluid|
62485573|NCT04922554|EXPERIMENTAL|Omadacycline 300 mg PO|omadacycline 150 mg tablets (x 2) administered orally, once daily, q24h
61934095|NCT05635669|EXPERIMENTAL|Alternating acupoints group (Alternating group)|Participants will receive treatment of sacral acupoints combination and abdominal acupoints combination alternately. (For example, A for the first time, B for the second time, A for the third time, and so on. )
61934096|NCT00426231|EXPERIMENTAL|Patient Navigator intervention|Patient Navigator intervention
62327370|NCT05460871|NO_INTERVENTION|Control|Participants will receive standard peri-operative pain management
62327371|NCT05460871|EXPERIMENTAL|Study (Pregabalin)|Participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days. Then Stop.
62327372|NCT05702684||People living with colorectal cancer|Patients (who are living with colorectal cancer) who have agreed to complete the eHNA intervention (within 31 days of diagnosis) and care planning consultation and clinicians who work in cancer services and provide the eHNA intervention to patients who are living with colorectal cancer
62327373|NCT05702684||People living with treatable-but-not-curable cancer|Patients who have received the ARC Holistic Needs Assessment (HNA) intervention from the ARC clinic and clinicians responsible for developing/delivering the ARC HNA intervention.
62485574|NCT04922554|PLACEBO_COMPARATOR|Placebo PO|Placebo tablets resembling omadacycline (x 2) administered once daily, q24h
62485575|NCT03319394|EXPERIMENTAL|The First Twenty|TF20 group completed a structured exercise program. Once a week a trained firefighter with current CPR and First Aid certifications met with the group to assess progress and answer questions about the workouts or the program. The rest of the time, the participants completed the workouts on their own time. Workouts contained a combination of aerobic (e.g., running, rowing, jumping), body weight (e.g., air squats, pushups, situps), and weight lifting (e.g., presses, back squats, lunges) exercises with workouts designed to use equipment available in an exercise/gym facility (e.g., weight racks, benches). Sixty-minute TF20 sessions included a warm-up, workout and cool down. All sessions were able to be logged online in TF20 program.
61934097|NCT00426231|ACTIVE_COMPARATOR|Information control|Information control
61934098|NCT01068652|ACTIVE_COMPARATOR|Detemir + Met|Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \[under the skin\]) if treatment target of HbA1c below 7.0% was not reached.
62485576|NCT03319394|ACTIVE_COMPARATOR|Comparison|The Comparison Group followed and documented their regular workout routine for 14 weeks. Once a week, a trained firefighter with current CPR and First Aid certifications met with the group to discuss questions. Participants were able to choose when to complete their workouts.
62485577|NCT00391365||Group 1|Subjects undergoing ankle arthrodesis (fusion) for treatment of ankle arthritis
62485578|NCT00391365||Group 2|Subjects undergoing ankle arthroplasty (replacement) for treatment of ankle arthritis
62485579|NCT03073798|ACTIVE_COMPARATOR|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
62485580|NCT03073798|PLACEBO_COMPARATOR|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
62485581|NCT05104710||AIM 1|"Hypothesis: IMC-βγ can help to differentiate between ALS and mimic diseases at initial presentation.~Patients who present to a neuromuscular clinic with symptoms that might be from ALS but for whom a diagnosis is not yet known, will be studied. Measurements of intermuscular coherence will be made using surface electrodes. A standard neurological examination and questionnaire about ALS symptoms will be completed. No interventions will be made. A patient's final diagnosis will be determined using standard-of-care testing. Six months after initial IMC measurement, a determination will be made whether the IMC predicted the diagnosis of ALS."
62485582|NCT05104710||AIM 2|"Hypothesis: Characterization of demographic-specific distributions will improve the specificity of IMC-βγ for ALS.~To optimize cutoff values for abnormal IMC, IMC-βγ will be measured in neurotypical controls across a range of age, race, ethnicity, and sexes."
62485583|NCT05104710||AIM 3|"Hypothesis: IMC-βγ will decrease with disease progression.~Because IMC-βγ measures functional input from motor neurons in the brain, it should decrease as these neurons are lost. IMC will be measured sequentially about every 3 months in patients with ALS, and will be compared to measures of clinical progression."
62485584|NCT03783663|EXPERIMENTAL|Sleep education plus Misfit Shine 2|This arm receives sleep education from the study nurse and also receives a Misfit Shine 2 to wear for 12 weeks to self-monitor sleep.
62692890|NCT05708508|ACTIVE_COMPARATOR|"Universal prophylaxis arm"|Patients will receive from D+15 post-transplant an antiviral treatment with valganciclovir (ROVALCYTE) for the first 3 months following the transplant. Clinico-biological monitoring during the 6 months according to the usual practices of the 2 centers and monitoring of CMV DNAemia.
62692891|NCT00403052|EXPERIMENTAL|1|Low dose of 1018 ISS
61934099|NCT01068652|ACTIVE_COMPARATOR|BIAsp 30 + Met|Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
61934100|NCT01715714|ACTIVE_COMPARATOR|Statin Recapture Therapy|Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin\* on admission. (\*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)
61934101|NCT01715714|PLACEBO_COMPARATOR|Placebo|Placebo given orally 12 hrs and 2 hrs before CABG
61934102|NCT03375827|EXPERIMENTAL|Survey QOL|"* Study participants will be provided with the Individualized Goals of Care Discussion Guide (IGCDG) consisting of a brief pamphlet and the IGCDG questionnaire.~* Participants will be asked to complete the IGCDG questionnaire prior to their next visit.~* Participants will also complete an 8-week follow-up survey after the clinic visit to evaluate the impact on patient satisfaction with care, communication, and care received."
61934103|NCT00857415|EXPERIMENTAL|Autopsy Cohort|End-of-life subjects (life expectancy \< 6 months) consenting to brain donation at autopsy.
62133891|NCT02378649|EXPERIMENTAL|Sildenafil|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
62327374|NCT03641989|ACTIVE_COMPARATOR|Plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
62327375|NCT03641989|PLACEBO_COMPARATOR|Non-plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the over-the-counter, non-plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
62327376|NCT01518582||Radiculopathy Cervical|Radiculopathy, Cervical
62327377|NCT00885235||A|Subjects that are indicated for colonoscopy who are suspected or known to suffer from large bowel diseases.
62327378|NCT01543490|EXPERIMENTAL|ISV-305|0.1% dexamethasone in DuraSite® 2
62327379|NCT01543490|PLACEBO_COMPARATOR|Vehicle|DuraSite® 2 vehicle
62327380|NCT03418402|EXPERIMENTAL|Airseal®|Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.
62327381|NCT03418402|ACTIVE_COMPARATOR|Standard insufflator|laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.
62327382|NCT03575091|NO_INTERVENTION|control group|The infants will receive the standard care at the ward.
62327383|NCT03575091|EXPERIMENTAL|Non-individualized|The parents will be guided manually by the nursing staff and receive written information about how to change body positions of their child regularly throughout the hospital stay.
62327384|NCT03575091|EXPERIMENTAL|Individualized|The infant will receive frequent changes of body positions, stimulation to physical activity, and stimulation to deep breathing while bouncing on a large ball in the arms of an adult. Additional light chest compressions and inhalations may be given. A physiotherapist will perform the intervention at least once daily, and the parents will be manually guided and receive written information about how to change body positions of their child regularly in a similar way throughout the hospital stay.
62327385|NCT01497314|OTHER|Low Lactose Infant Formula|
62327386|NCT04652063|EXPERIMENTAL|OMM|Neonates randomized to receive osteopathic manipulation
62327387|NCT04652063|NO_INTERVENTION|Control|Neonates randomized to receive standard care only
62327388|NCT00395252|EXPERIMENTAL|one arm study|Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months
62485585|NCT03783663|NO_INTERVENTION|sleep education only|This arm receives only sleep education from the study nurse.
62485586|NCT04666636|PLACEBO_COMPARATOR|Placebo|Participants in the group will receive placebo.
62485587|NCT04666636|EXPERIMENTAL|Mirabegron|Participants in this group will receive Mirabegron for 16 weeks.
62485588|NCT06561269|EXPERIMENTAL|Multifidus plane block (MPB) group|Participants will be injected bupivacaine at the fascial plane between the multifidus muscle and the median sacral crests of S2 and S3
62485589|NCT06561269|EXPERIMENTAL|Caudal block (CB) group|Participants will be injected by bupivacaine, between the two sacral cornua
62692892|NCT00403052|EXPERIMENTAL|2|Middle dose of 1018 ISS
62692893|NCT00403052|EXPERIMENTAL|3|High dose of 1018 ISS
62692894|NCT01955356|EXPERIMENTAL|Scratching|induced endometrial injury
62692895|NCT01955356|NO_INTERVENTION|No scratching|None intervention
62692896|NCT03113929||Alcoholic Liver Disease Patients|
62692897|NCT04956016|ACTIVE_COMPARATOR|classic rTMS treatment|Arm A: classic rTMS treatment (use of the 8-shaped coil) and standard therapy
62692898|NCT04956016|ACTIVE_COMPARATOR|treatment with deep rTMS|Arm B: treatment with deep rTMS (use of the H1-shaped coil (helmet)) and standard therapies
62692899|NCT06570889|EXPERIMENTAL|Vitamin D3 (cholecalciferol) 3200 IU/day|Oral intake of 1 capsule daily from week 22-26 of gestation until 1 week after delivery
62692900|NCT06570889|PLACEBO_COMPARATOR|Placebo Pearls with olive oil|Oral intake of 1 capsule daily from week 22-26 of gestation until 1 week after delivery
61934104|NCT00857415|EXPERIMENTAL|Specificity Cohort|Younger healthy controls presumed to be devoid of beta-amyloid plaques.
62327389|NCT02996539||Type 2 diabetes|With Clinical examination and laboratory measurements
62327390|NCT03362645||Fabry cardiomyopathy|
62327391|NCT03362645||Hypertrophic cardiomyopathy|
62327392|NCT06287736|NO_INTERVENTION|Conventional Medical Management (CMM). Group1|
62327393|NCT06287736|ACTIVE_COMPARATOR|Spinal Cord Stimulator (SCS) immediate activation. Group 2|
62327394|NCT06287736|ACTIVE_COMPARATOR|Spinal Cord Stimulator (SCS) Delayed activation. Group 3|
62327395|NCT05034484|EXPERIMENTAL|ALPN-303 Regimen A|
62327396|NCT05034484|PLACEBO_COMPARATOR|Placebo Regimen A|
62327397|NCT05034484|EXPERIMENTAL|ALPN-303 Regimen B|
62327398|NCT05034484|PLACEBO_COMPARATOR|Placebo Regimen B|
62327399|NCT05431413|PLACEBO_COMPARATOR|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
62327400|NCT05431413|EXPERIMENTAL|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
62692901|NCT05803772|OTHER|Active to Placebo Cross|Participants will first receive a single dose of APHD-012 12 g daily, under fasting conditions prior to main daily meals for 6 weeks (day 1-42), followed by washout period of 4 weeks (day 43-70), and subsequent crossover to the other treatment APH-012P for 6 weeks (day 71-112).
62692902|NCT05803772|OTHER|Placebo to Active Cross|Participants will first receive a single dose of APH-012P daily, under fasting conditions prior to main daily meals for 6 weeks (day 1-42), followed by washout period of 4 weeks (day 43-70), and subsequent crossover to the other treatment APHD-012 12 g for 6 weeks (day 71-112).
62692903|NCT05607589|EXPERIMENTAL|DWP213388|"Each cohort, healthy subjects will be administered DWP213388 (6 subjects per each cohort) SAD Cohort 1: DWP213388 x mg QD Cohort 2: DWP213388 x mg QD Cohort 3: DWP213388 x mg QD Cohort 4: DWP213388 x mg QD Cohort 5: DWP213388 x mg QD~MAD Cohort 6: DWP213388 x mg QD Cohort 7: DWP213388 x mg QD Cohort 8: DWP213388 x mg QD Cohort 9: DWP213388 x mg QD"
61934105|NCT02883192|EXPERIMENTAL|ondansetron|ondansetron
61934106|NCT02883192|PLACEBO_COMPARATOR|Placebo|Placebo
61934107|NCT05184075|ACTIVE_COMPARATOR|Reverse hybrid coronary revascularization (HCR)|Patients will undergo reverse hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
61934108|NCT05184075|ACTIVE_COMPARATOR|Standard hybrid coronary revascularization (HCR)|Patients will undergo standard hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
61934109|NCT00013234|OTHER|Arm 1|
62327401|NCT05431413|ACTIVE_COMPARATOR|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection phosphocreatine(1g) in NS BD for two weeks.
61934110|NCT05495685||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a blood sample will be collected.
61934111|NCT05495685||Benign disease arm|Participants with benign pancreatic diseases, from whom a blood sample will be collected.
61934112|NCT06707038|EXPERIMENTAL|AATAP (intervention) Arm|One clinic visit with all transplant providers, racially concordant care team, dedicated social worked. This will incorporate: Cultural congruency, trust, health literacy and psychological support. Questionnaires also to be administered
62327402|NCT04867135||No Sepsis / Sepsis|To compare amikacin PK / PD models of newborns with a confirmed diagnosis of sepsis (clinical or microbiological) and with ruled out sepsis.
62327403|NCT00748540|EXPERIMENTAL|Implanted|Implanted with Vibrant Soundbridge
62327404|NCT04224740|EXPERIMENTAL|Pembrolizumab plus standard of care chemotherapy|"-Pembrolizumab combined with standard of care therapy~* Standard of care therapy: ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles"
62327405|NCT03253406|EXPERIMENTAL|Polar M400 + Facebook Group (PM400+FG)|Will be provided a Polar M400 to track physical activity and energy expenditure while also being included in a Facebook group wherein Social Cognitive Theory-based physical activity and nutritious eating tips will be provided twice weekly for 12 weeks.
62327406|NCT03253406|ACTIVE_COMPARATOR|Facebook Only Group (FG)|Included exclusively in a separate, but content-identical, Facebook group for 12 weeks.
62327407|NCT02425267|EXPERIMENTAL|Telerehabilitation|Telerehabilitation at home from a clinic
62327408|NCT02425267|ACTIVE_COMPARATOR|Face-to-face intervention in a clinic|Conventional physiotherapy
62327409|NCT04146272|ACTIVE_COMPARATOR|Moderate Hearing loss current Mermaid first, then new|Participants were randomized to wear the current Mermaid hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new Mermaid Hearing aid for another 10 days.
62327410|NCT04146272|ACTIVE_COMPARATOR|Moderate Hearing loss new Mermaid first, then current|Participants were randomized to wear the new Mermaid hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current Mermaid Hearing aid for another 10 days.
62327411|NCT04146272|ACTIVE_COMPARATOR|Severe hearing loss current Power first, then new|Participants were randomized to wear the current power hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new power Hearing aid for another 10 days.
62327412|NCT04146272|ACTIVE_COMPARATOR|Severe hearing loss new Power first, then current|Participants were randomized to wear the new power hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current power Hearing aid for another 10 days.
62327413|NCT06376916|EXPERIMENTAL|Experimental Arm One, Magnesium Sulfate 2g|Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl)
62327414|NCT06376916|EXPERIMENTAL|Experimental Arm Two, Magnesium Sulfate 4g|Magnesium Sulfate 4g/50ml 0.9% NaCl
62327415|NCT06376916|PLACEBO_COMPARATOR|Control Arm, normal saline|50ml 0.9% NaCl
62327416|NCT04723108|EXPERIMENTAL|Virtual reality arm|Participants will be asked to use virtual reality during their infusion for a duration of at least 10 minutes.
62327417|NCT02620332|PLACEBO_COMPARATOR|Placebo injection|Water for injection
62327418|NCT02620332|EXPERIMENTAL|MultiPepT1De injection low dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
62327419|NCT02620332|EXPERIMENTAL|MultiPepT1De injection medium dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
62485590|NCT03621995||Obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
61934113|NCT06707038|NO_INTERVENTION|Standard of Care (Control) Arm|Separate visits with nephologist, surgeons and social worker. This arm will follow common standard of care at the site. Questionnaires also to be administered
61934114|NCT03718871|EXPERIMENTAL|Healer HIV testing intervention|We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
61934115|NCT03718871|NO_INTERVENTION|Healer control arm|Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.
61934116|NCT06391385|NO_INTERVENTION|Non-Ileostomy Arm|Participants in this arm do not undergo the intervention of a protective ileostomy. The management for this group involves. The outcomes for this arm will be assessed in comparison to the group that receives the protective ileostomy. This arm serves as the control/comparative group to evaluate the impact of the intervention on the specified outcomes.
61934117|NCT06391385|EXPERIMENTAL|Ileostomy Arm|Ileostomy Arm Description: Participants in this arm undergo the intervention of a protective ileostomy. The surgical procedure involves. This arm serves as the experimental group to evaluate the impact of the protective ileostomy on specified outcomes. The outcomes for this arm will be compared to those in the non-interventional (comparative) arm to assess the effectiveness and potential benefits of the ileostomy intervention.
61934118|NCT01267656|EXPERIMENTAL|Lubricating and Rewetting Drops|Lubricating and Rewetting Drops, after one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week.
61934119|NCT01267656|ACTIVE_COMPARATOR|AMO Blink Contacts Lubricant Eye Drops|AMO Blink Contacts Lubricant Eye Drops, After one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week
61934120|NCT06019507|EXPERIMENTAL|Arm 1|TCD601administered after liver transplant with splenectomy with cyclophosphamide and immunosuppression therapy
62327420|NCT02620332|EXPERIMENTAL|MultiPepT1De injection high dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
62485591|NCT03621995||Non obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
62485592|NCT03621995||Negative group|Malondialdehyde and Catalase level measurement without cryopreservation
61934121|NCT05607771|EXPERIMENTAL|Manual|Oocytes will be prepared for vitrification using the manual protocol
61934122|NCT05607771|EXPERIMENTAL|Automated|Oocytes will be prepared for vitrification using Davitri device
61934123|NCT06275607|EXPERIMENTAL|Cognitive Behavioral Affective Therapy|Group receiving CBAT.
62485593|NCT03097445|EXPERIMENTAL|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
62485594|NCT03097445|NO_INTERVENTION|Control|No intervention control group
62485595|NCT06040658||Vascular 'hot' clinic.|All adults (aged \> 17 years) referred to an urgent-referral, consultant-led, Vascular Surgery outpatient clinic, who have capacity, will be eligible for inclusion in this study.
62485596|NCT04796480|ACTIVE_COMPARATOR|YOGURT|Group 1 children were given home made plain yogurt in treatment of acute diarrhea
62485597|NCT04796480|ACTIVE_COMPARATOR|LACTOSE FREE FORMULA MILK|Group 2 children were given lactose free formula milk in treatment of acute diarrhea
62485598|NCT06126939|EXPERIMENTAL|Denver group|In addition to routine health guidance, one-to-one parent classes were conducted to guide parents to interact with children once a week for 1h each time; A group leader was assigned to supervise the formulation of the intervention plan and ensure the quality of the intervention. The intervention lasted for 3 months
62485599|NCT06126939|NO_INTERVENTION|Control group|Regular autism related knowledge health education
62485600|NCT06362356||Pregnant persons|This prospective longitudinal cohort will enroll pregnant patients in their first trimester of pregnancy (10-14 weeks gestation).
62692904|NCT05607589|PLACEBO_COMPARATOR|Placebo|"Each cohort, healthy subjects will be administered placebo (2 subjects per each cohort) SAD Cohort 1: Placebo QD Cohort 2: Placebo QD Cohort 3: Placebo QD Cohort 4: Placebo QD Cohort 5: Placebo QD~MAD Cohort 6: Placebo QD Cohort 7: Placebo QD Cohort 8: Placebo QD Cohort 9: Placebo QD"
61934124|NCT06275607|PLACEBO_COMPARATOR|Emotional Education|Group receiving general emotion psychoeducation.
61934125|NCT00315159|NO_INTERVENTION|No intervention|Patients with negative SLN will be followed on no intervention arm
61934126|NCT01460316||Conotruncal cardiac defects patients|
61934127|NCT01460316||Mothers of patients|
61934128|NCT02035501|ACTIVE_COMPARATOR|L-Tyrosine|
61934129|NCT02035501|PLACEBO_COMPARATOR|Placebo|
62133892|NCT02378649|PLACEBO_COMPARATOR|Placebo|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
62133893|NCT04788459|EXPERIMENTAL|0.5 mg PB|"0.5 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 1 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
62133894|NCT04788459|EXPERIMENTAL|1 mg PB|"1 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 2 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
62133895|NCT04788459|EXPERIMENTAL|2 mg PB|"2 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 4 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
62133896|NCT04788459|EXPERIMENTAL|2 mg P|"2 mg P (Prime) - Total dose: 2 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1"
62133897|NCT06438094|EXPERIMENTAL|Type A gingival recession defects|Gingival recession defects that present with a visible CEJ. These defects will receive root coverage surgery only.
62133898|NCT06438094|EXPERIMENTAL|Type B gingival recession defects|Gingival recession defects that do not present a visible CEJ. A cervical composite restoration will be done prior to root coverage surgery.
62133899|NCT05308069|OTHER|Single vision contact lens|Subjects will wear a single vision soft contact lens during the study visit
62133900|NCT05308069|OTHER|Multifocal contact lens|Subjects will wear a multifocal soft contact lens during the study visit
62485601|NCT05722496|EXPERIMENTAL|High Intensity Interval Training Group (Group A)|"Each training session consist of three parts of 30 minutes:~* Warm up (5 minutes) free active exercise of the lower extremities,~* Training continued with three exercise intervals lasting 3 min each, at an exercise intensity of 85%-95% of HRpeak equalling 15-17 on the Borg scale. Each interval was separated by 4 min of active breaks at an intensity of 60%-70% of HRpeak.~* Cool down (5 minutes) free exercise of lower extremities. Training program will last for 8 weeks with frequency 3times / week."
61934130|NCT06199050|EXPERIMENTAL|360° Virtual Reality Movies|"assess the amount of fear, anxiety and stress by using specific questionnaires:~* SPecifIc RadIation Treatment related questions (SPIRIT)~* Hospital Anxiety and Depression Scale (HADS)~* Dutch version of the Questionnaire on stress symptoms (QSC-R23)~General questions:~* Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline~Clinical data:~* Age~* Gender~* Cancer type~* WHO status~* TNM"
62133901|NCT01300975|EXPERIMENTAL|Intralesional antimony|3 intralesional injections of antimony at D1, D3 and D7
62327421|NCT04897503|ACTIVE_COMPARATOR|CXL using Riboflavin/Dextran solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 20% dextran
62327422|NCT04897503|ACTIVE_COMPARATOR|CXL usinng Riboflavin/Methylcellulose solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 1.0% hydroxypropylmethylcellulose ( HPMC)
61934131|NCT06199050|EXPERIMENTAL|Group without intervention|"In a measurement over 5 months without any intervention the investigators have assessed the amount of fear, anxiety and stress by using a specific subjective questionnaire on the items below: assess the amount of fear, anxiety and stress by using specific questionnaires:~* SPecifIc RadIation Treatment related questions (SPIRIT)~* Hospital Anxiety and Depression Scale (HADS)~* Dutch version of the Questionnaire on stress symptoms (QSC-R23)~General questions:~* Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline~Clinical data:~* Age~* Gender~* Cancer type~* WHO status~* TNM"
61934132|NCT01444352|EXPERIMENTAL|Vaccine Formulation 1 (Low dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
62327423|NCT05293132|EXPERIMENTAL|Montelukast group|30 patients will receive montelukast sodium 10 mg/day film coated tablets (Singulair®; Merck \& Co Inc) or (Clear air®; Amoun Pharmaceutical Company S.A.E., Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
62327424|NCT05293132|EXPERIMENTAL|Co Enzyme Q10 group|30 patients will receive co enzyme Q10 capsule 210 mg / day (MEPACO Pharmaceutical Company (Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
62327425|NCT05293132|ACTIVE_COMPARATOR|Control group|30 patients will receive the standard treatment of sepsis from the onset of the diagnosis of sepsis till discharge from ICU, or death.
62327426|NCT01719471||Smokers|Nicotine dependent individuals otherwise medically healthy
62327427|NCT01719471||Healthy|Medically healthy individuals who do not smoke
62327428|NCT04583566||COVID-19 Severe Symptoms|Patients with severe symptoms need oxygen and ventilation.
62327429|NCT04583566||COVID-19 Mild Symptoms|Patients with moderate symptoms, like normal flu symptoms. They do not need oxygen or ventilation
62485602|NCT05722496|EXPERIMENTAL|Moderate intensity continous training group (Group B)|"Each training session consist of three parts of 30 minutes:~* Warm up (5 minutes) free active exercise of the lower extremities,~* Training continued with cycling at low-to-moderate exercise intensity of 50%-60% of HRpeak, representing 11-13 on the Borg scale.~* Cool down (5 minutes) free exercise of lower extremities. Training program will last for 8 weeks with frequency 3times / week."
62485603|NCT06620939|EXPERIMENTAL|LNG-IUS group|Participants will receive Mirena placement after hysteroscopic polypectomy
61934133|NCT01444352|EXPERIMENTAL|Vaccine Formulation 2 (Middle dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
61934134|NCT01444352|EXPERIMENTAL|Vaccine Formulation 3 (High dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
61934135|NCT01444352|PLACEBO_COMPARATOR|Placebo Pooled|Participants who receive 2 injections of tris buffered saline
61934136|NCT00719095|EXPERIMENTAL|1-week buprenorphine taper|1-week buprenorphine taper + behavioral therapy + urine toxicology
61934137|NCT00719095|EXPERIMENTAL|2-week buprenorphine taper|2-week buprenorphine taper + behavioral therapy + urine toxicology
62133902|NCT01300975|ACTIVE_COMPARATOR|Cryotherapy|Liquid nitrogen until freezing at DF1 and D14
62133903|NCT01300975|PLACEBO_COMPARATOR|Topical cream|topical treatment 3 times a day during 21 days with an emollient cream
62133904|NCT01574716|EXPERIMENTAL|MORAb-004, gemcitabine, docetaxel|
62327430|NCT04583566||Control Healthy|Healthy group with out any infection or symptoms.
62327431|NCT05303519|EXPERIMENTAL|safusidenib 125mg bid|safusidenib 125mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
62133905|NCT01574716|ACTIVE_COMPARATOR|Placebo, gemcitabine, docetaxel|
62485604|NCT06620939|NO_INTERVENTION|Control group|Participants will receive none additional treatment after hysteroscopic polypectomy.
62485605|NCT02565836||fixed-dose aPCC|Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.
62133906|NCT03278873|EXPERIMENTAL|Biological-Low dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single low dose of either AAV - CNGB3 or AAV - CNGA3
62327432|NCT05303519|EXPERIMENTAL|safusidenib 250mg bid|safusidenib 250mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
62327433|NCT05303519|EXPERIMENTAL|safusidenib 500mg qd|safusidenib 500mg qd administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
62327434|NCT05303519|EXPERIMENTAL|safusidenib 375mg bid|safusidenib 375mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
62327435|NCT05303519|EXPERIMENTAL|safusidenib 500mg bid|safusidenib 500mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
62327436|NCT03493685|EXPERIMENTAL|sparsentan for double-blind and open-label extension|Sparsentan will be administered as a single oral dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
62327437|NCT03493685|ACTIVE_COMPARATOR|Irbesartan|Irbesartan will be administered as a single oral dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
62327438|NCT05226598|EXPERIMENTAL|Pembrolizumab/Vibostolimab + Carboplatin + Cisplatin + Paclitaxel + Nab-paclitaxel + Pemetrexed|Participants receive pembrolizumab/vibostolimab (co-formulation of 200mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous.
62327439|NCT05226598|ACTIVE_COMPARATOR|Pembrolizumab + Carboplatin + Cisplatin + Paclitaxel + Nab-paclitaxel + Pemetrexed|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to \~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous.
62327440|NCT04350658||TAVR|all comers study including all transfemoral or transcarotid TAVR procédures. direct implantation is the default strategy usually used in our enter as in may centers
62327441|NCT00003750|EXPERIMENTAL|DG2 positive relapsed or refractory solid tumors|The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
62327442|NCT01296919||Sinus drainage|Adult patients with chronic rhinosinusitis who failed treatment with antibiotics and topical corticosteroids and underwent endoscopic sinus surgery. Preoperative evaluation included paranasal sinus CT scans. The diagnosis was confirmed by endoscopic examination showing purulent and/or mucopurulent discharge in the middle and/or superior meatus.
62327443|NCT03924024|EXPERIMENTAL|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
62327444|NCT00506051|EXPERIMENTAL|ZD6474 (vandetanib) 100mg|
62327445|NCT00506051|EXPERIMENTAL|ZD6474 (vandetanib) 300mg|
62327446|NCT02102282||Subject study|Patients with breast cancer during pregnancy
62327447|NCT06285474|EXPERIMENTAL|Active Caudate|"Low Intensity Focused Ultrasound Pulsation (LIFUP) will be directed at the caudate head. To minimize the ultrasound energy's exposure to air, a gel pad will be placed between the transducer and the participant's scalp. The sonication protocol will consist of 10 ultrasound sonications in a 30 s ON, 30 s OFF fashion at 650KHz, Ispta≤720 mW/cm2, 50% duty cycle, 5ms pulse width, 1.44W/cm2 ISPPA, and 100Hz pulse repetition frequency. For active sonication, the gel pad will allow the ultrasound energy to pass through. The sham/active gel pads are identical in appearance."
62327448|NCT06285474|SHAM_COMPARATOR|Sham Caudate|"Low Intensity Focused Ultrasound Pulsation (LIFUP) will be directed at the caudate head. To minimize the ultrasound energy's exposure to air, a gel pad will be placed between the transducer and the participant's scalp. The sonication protocol will consist of 10 ultrasound sonications in a 30 s ON, 30 s OFF fashion at 650KHz, Ispta≤720 mW/cm2, 50% duty cycle, 5ms pulse width, 1.44W/cm2 ISPPA, and 100Hz pulse repetition frequency. For sham sonication, the gel pad will block close to all of the ultrasound energy from the transducer from entering the brain. The sham/active gel pads are identical in appearance."
62327449|NCT00903903||1|RA patients with at least one active synovitis
62327450|NCT00903903||2|Non-RA patients with at least one active synovitis
62327451|NCT03011840|NO_INTERVENTION|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
62485606|NCT02565836||variable-dose PCC|Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.
62327452|NCT03011840|EXPERIMENTAL|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
62327453|NCT00944606|ACTIVE_COMPARATOR|Vitamin D|
62327454|NCT00944606|PLACEBO_COMPARATOR|Placebo|
62327455|NCT01349504||Mesalmine|
61934138|NCT00719095|EXPERIMENTAL|4-week buprenorphine taper|4-week buprenorphine taper + behavioral therapy + urine toxicology
62692905|NCT04285567|EXPERIMENTAL|VEN + G|Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
62133907|NCT03278873|EXPERIMENTAL|Biological-medium dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single medium dose of either AAV - CNGB3 or AAV - CNGA3
62327456|NCT04341194|NO_INTERVENTION|Standard care with glucose|Control Group with standard care comprises facilitated tucking done by a nurse or the parent, oral glucose (300 mg/ml) and the opportunity to suck on a pacifier or on a parent's or a nurse's plastic gloved finger. The infant is placed on an examination table for the venipuncture.
62327457|NCT04341194|EXPERIMENTAL|Skin-to-skin contact|Skin-to-skin contact is a method widely used in neonatal care globally. The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
62327458|NCT04341194|EXPERIMENTAL|Skin-to-skin contact/breastfeeding/parental singing|Parent-driven interventions are skin-to-skin care, breastfeeding and multi-sensory stimulation like vocalisation. They are all a combination of multiple sensory inputs comprising auditory, tactile and olfactory recognition. Research has started to investigate breastfeeding in combination with Kangaroo-mother- care for example, which has shown to be an effective mix. A multimodal approach that includes a combination of non-pharmacological approaches is considered more effective during venipuncture than single strategies and provides greater pain relief.
62327459|NCT02294149|PLACEBO_COMPARATOR|Placebo|A ineffective placebo drug with the same taste, route of administration and physical appearance as the study drug (omega 3/Vit D 3) that has received approval by health Canada.
62327460|NCT02294149|EXPERIMENTAL|Omega 3 FA/Vitamin D3 sublingual|patients will be allocated randomly to receive Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.
62327461|NCT01476176|EXPERIMENTAL|Experimental paracetamol formulation|experimental formulation
62327462|NCT01476176|ACTIVE_COMPARATOR|paracetamol marketed formulation|Paracetamol marketed formulation
62327463|NCT02222012|ACTIVE_COMPARATOR|single channel|
62327464|NCT02222012|EXPERIMENTAL|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|
62327465|NCT00712114|EXPERIMENTAL|Cohort 1|10 mg HE3286 (1 x 5 mg HE3286, BID)
62327466|NCT00712114|EXPERIMENTAL|Cohort 2|20 mg HE3286 (2 x 5 mg HE3286 BID)
62485607|NCT06627803|EXPERIMENTAL|Laboratory alcohol administration with longitudinal follow-ups|All participants will be in this single arm, which consists on behavioral testing of alcohol administration in the lab, followed by longitudinal follow-ups using Ecological Momentary Assessment and surveys.
62692906|NCT04285567|ACTIVE_COMPARATOR|FCR/BR|Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
62133908|NCT03278873|EXPERIMENTAL|Biological-high dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single high dose of either AAV - CNGB3 or AAV - CNGA3
62133909|NCT03598946|EXPERIMENTAL|Human Papilloma Virus Test urinary|Urinary Test by a kit which is send to the woman's house
62133910|NCT05558423|EXPERIMENTAL|Self-controlled|n-of-1 design. Participants complete a baseline habitual eating phase following by an intervention TRE phase.
62133911|NCT03612375|EXPERIMENTAL|Intervention group|
62133912|NCT03612375|ACTIVE_COMPARATOR|Control group|
62327467|NCT00712114|EXPERIMENTAL|Cohort 3|40 mg HE3286 (4 x 5 mg HE3286 BID)
62327468|NCT06042699|EXPERIMENTAL|Oral ferrous sulfate|Participants will receive oral ferrous sulfate tablets, 325mg (65mg elemental iron). Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.
62485608|NCT06618339|OTHER|Psychoeducation|8 session Psychoeducation, for anxiety and depression.
62485609|NCT06618339|SHAM_COMPARATOR|Cognitive flexibility and resilence|8 Session cognitive flexibility and resilience trainning.
62485610|NCT04953520|EXPERIMENTAL|Ultrasound-CT fusion imaging guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
62485611|NCT04953520|ACTIVE_COMPARATOR|Pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
62133913|NCT05838677|EXPERIMENTAL|Intervention Group: Pain at Work Toolkit|Intervention participants receive the PAW toolkit plus 3 x optional occupational therapy calls (approximately 30 minutes each) involving orientation to the PAW Toolkit and individually tailored advice and behavioural strategies for managing pain at work. This digital web-based toolkit is designed to support people with chronic pain in self-managing their condition at work. PAW offers evidence-based advice about chronic or persistent pain, disability rights, work capacity, pain self-management strategies and signposting to support.
62327469|NCT06042699|PLACEBO_COMPARATOR|Oral placebo tablets|Participants will receive placebo tablets. Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.
62327470|NCT06042699|NO_INTERVENTION|Observational follow-up|Participants who do not qualify for randomization may be invited to complete study measures through postoperative follow-up as part of an observational study.
62327471|NCT04500171|ACTIVE_COMPARATOR|English Original Assessment Tools|Short-Test of Functional Health Literacy in Adults ColoCARE Instruction Sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
62327472|NCT04500171|ACTIVE_COMPARATOR|Samoan Original Assessment Tools|Samoan Short-Test of Functional Health Literacy in Adults ColoCARE Instruction sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
62485612|NCT05617391||Pediatric Childhood Cancer Survivors|The comparison of two ECGs in terms of predictive risk.
62485613|NCT03134664|EXPERIMENTAL|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
62485614|NCT03134664|EXPERIMENTAL|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
62692907|NCT06501313|ACTIVE_COMPARATOR|Photobiomodulation with active device|
62692908|NCT06501313|SHAM_COMPARATOR|Control with Sham device|
62692909|NCT06116526|EXPERIMENTAL|Dupilumab - discontinuation|Participants will discontinue their dupilumab treatment for atopic dermatitis.
62133914|NCT05838677|ACTIVE_COMPARATOR|Active Control Group: Treatment as Usual|Participants do not receive the PAW Toolkit but instead have treatment as usual (TAU) from their employer. The nature of TAU will be recorded as part of the feasibility study. Depending on the employing organisation, TAU may consist of (but is not limited to) any combination of the following: occupational health, counselling, line manager support, signposting to education about factors that may have positive or negative effects on chronic pain. Participants can access non-specialist telephone calls from a researcher to discuss their participation in the study.
62327473|NCT04500171|EXPERIMENTAL|English Modified Assessment Tools|Short-Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
62327474|NCT04500171|EXPERIMENTAL|Samoan Modified Assessment Tools|Samoan Short Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
62327475|NCT04093739||G7 Freedom Constrained Liners|Patients that have been implanted with a G7 Freedom Constrained liner to repair hip malfunction or disease.
62327476|NCT05844800|EXPERIMENTAL|Pectus Excavatum|Patients included in the study after preoperative examination underwent the Nuss surgery procedure - a minimally-invasive repair technique of Pectus Excavatum (MIRPE)
62327477|NCT05844800|NO_INTERVENTION|Healthy Control|Healthy control group with no posture defects
62327478|NCT05087602|EXPERIMENTAL|Toripalimab plus Anlotinib capsules|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62327479|NCT00333268|EXPERIMENTAL|NGOIS|
62327480|NCT00333268|ACTIVE_COMPARATOR|BSS Plus|
62327481|NCT01595737|EXPERIMENTAL|Levosimendan|
62485615|NCT01885819|EXPERIMENTAL|Treatment|Autologous stromal vascular fraction cells
62485616|NCT02749604|ACTIVE_COMPARATOR|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
62133915|NCT03063866|ACTIVE_COMPARATOR|M group|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg
62133916|NCT03063866|ACTIVE_COMPARATOR|P Group|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v
62327482|NCT01595737|PLACEBO_COMPARATOR|Placebo|
62327483|NCT03649100|EXPERIMENTAL|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
62327484|NCT03649100|ACTIVE_COMPARATOR|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
62327485|NCT01608789|EXPERIMENTAL|Virtue® Male Sling|Patient implanted Virtue® Male Sling
62327486|NCT01253681|EXPERIMENTAL|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
62327487|NCT00856271|EXPERIMENTAL|1|olmesartan medoxomil
62327488|NCT00856271|ACTIVE_COMPARATOR|2|losartan potassium
62327489|NCT00556361|PLACEBO_COMPARATOR|1|
62327490|NCT00556361|EXPERIMENTAL|2|
62327491|NCT00689377||1|Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus
62327492|NCT06486636|EXPERIMENTAL|Left Posterior Pericardiotomy Group|The surgeon will perform a left posterior pericardiotomy during the patient's cardiac surgery.
62327493|NCT06486636|NO_INTERVENTION|No Posterior Pericardiotomy Group|The surgeon will not perform a posterior pericardiotomy during the patient's cardiac surgery.
62327494|NCT03613415|EXPERIMENTAL|Expansion by Densah bur|"* Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~* A mid crestal flap will be reflected.~* For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~* Sequential use of Densah bur under copious irrigation.~* An implant of 3.9\*10 mm will be inserted.~* Smart peg will be placed on implant and Osstell will be used to record ISQ.~* Healing collars will be placed on implants.~* Flap will be prepared for closure and suturing."
62327495|NCT03613415|ACTIVE_COMPARATOR|Expander|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~* A mid crestal flap will be reflected.~* For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~* Sequential use of screw expanders.~* An implant of 3.9\*10 mm will be inserted.~* Smart peg will be placed on implant and Osstell will be used to record ISQ.~* Healing collars will be placed on implants.~* Flap will be prepared for closure and suturing."
62327496|NCT04041388|OTHER|Tooth tipping|
62327497|NCT06127173|ACTIVE_COMPARATOR|(group ZEEP)|children will receive mask ventilation with PEEP level 0 cmH2O.
62327498|NCT06127173|EXPERIMENTAL|(group PEEP 3)|children will receive mask ventilation with PEEP level 3 cmH2O.
62327499|NCT06127173|ACTIVE_COMPARATOR|(group PEEP 5)|children will receive mask ventilation with PEEP level 3 cmH2O.
62327500|NCT04423926|EXPERIMENTAL|Lenalidomide+CHOP|
62327501|NCT06503536||Participants Receiving Upadacitinib|Participants with Atopic Dermatitis (AD) undergo chart review up to180 days after initiating upadacitinib.
62485617|NCT02749604|EXPERIMENTAL|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
62485618|NCT05982860|NO_INTERVENTION|Control (n:18)|Players in this group will not be given any nutritional advice/intervention. They will maintain their usual eating habits.
62692910|NCT06116526|EXPERIMENTAL|Dupilumab - dose reduction|Participants whose standard dupilumab dosing for atopic dermatitis is 200 mg or 300 mg every 2 weeks will decrease drug administration to every 4 weeks, and participants whose standard dupilumab dosing is 200 mg or 300 mg every 4 weeks will decrease administration to every 8 weeks.
62692911|NCT06116526|EXPERIMENTAL|Dupilumab - standard dosing|"Participants will continue to receive standard maintenance dupilumab dosing for atopic dermatitis according to FDA labeling, as indicated below.~Infants ≥6 months and Children \<6 years:~5 to \<15 kg: 200 mg every 4 weeks. 15 to \<30 kg: 300 mg every 4 weeks~Children ≥6 years and Adolescents ≤17 years:~15 to \<30 kg: 300 mg every 4 weeks 30 to \<60 kg: 200 mg every other week~≥60 kg: 300 mg every other week"
62692912|NCT06555601|EXPERIMENTAL|Cohort 1|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 1) or placebo.
61934139|NCT03710876|ACTIVE_COMPARATOR|Treatment Group|rAd-IFN (Study Day 1) + celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 \[i.e., Days 1 and 8 of the first gemcitabine treatment cycle\], gemcitabine will be administered on a 21-day cycle, unless the cycle is modified due to toxicity/delay, and repeated every 3 weeks until disease progression/early termination \[ET\]
61934140|NCT03710876|PLACEBO_COMPARATOR|Control Group|Celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 \[i.e., Days 1 and 8 of the first gemcitabine treatment cycle\], gemcitabine will be administered on a 21-day cycle, unless the cycle is modified due to toxicity/delay, and repeated every 3 weeks until disease progression/ET.
62327502|NCT05819138|EXPERIMENTAL|Semaglutide|"Participants will receive 0.25 mg once weekly semaglutide injection for 4 weeks.~Participants will receive 0.50 mg once weekly semaglutide injection for 4 weeks.~Participants will receive 1.0 mg once weekly semaglutide injection for 6 months."
62692913|NCT06555601|EXPERIMENTAL|Cohort 2|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 2) or placebo.
62692914|NCT06555601|EXPERIMENTAL|Cohort 3|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 3) or placebo.
62692915|NCT06555601|EXPERIMENTAL|Cohort 4|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 4) or placebo.
61934141|NCT05337436||All patients receive conventional dialysis treatment at enrollment|All patients receive conventional dialysis treatment at enrollment
61934142|NCT04178473|ACTIVE_COMPARATOR|total abdominal hysterectomy|Total abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
61934143|NCT04178473|ACTIVE_COMPARATOR|subtotal abdominal hysterectomy|subtotal abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
61934144|NCT03075046|EXPERIMENTAL|blue LED 405 nm in vulvovaginal candidiasis|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session. This part of the study will see if there is fungicidal effect of the blue led 405 nm
61934145|NCT03075046|EXPERIMENTAL|blue LED 405 nm in healthy women|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.This part of the study will see the security and the effects of the blue led 405 nm in healthy vaginal microflora
61934146|NCT03075046|NO_INTERVENTION|Sociodemographic data of women with vulvovaginal candidiasis|The women will answer some questions of the anamnesis as: Age, weight, height, form of intimate hygiene, and others to evaluate possible correlations of these data with the presence of vulvovaginal candidiasis
61934147|NCT00518973|PLACEBO_COMPARATOR|Placebo|The primary outcome was to determine the effect of quetiapine compared with placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorder Inventory-2 (EDI-2).
61934148|NCT00518973|EXPERIMENTAL|Quetiapine|Secondary outcomes were to determine if quetiapine is superior to placebo in reducing anxiety, depression and obsessionality assessed with the State Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM D) and Yale-Brown Obsessive Compulsive Scale, respectively. In addition, another secondary goal was to determine if quetiapine is superior to placebo in terms of weight gain. Adverse events were also determined.
61934149|NCT06699875|EXPERIMENTAL|TRAK software intervention group|The patients will undergo 4 weeks of treatment using the TRAK platform for shoulder mobility-oriented exercises.
61934150|NCT06699875|ACTIVE_COMPARATOR|Paper sheet group|The patients will undergo 4 weeks of treatment using an exercise paper sheet routine to improve shoulder mobility.
62133917|NCT00832169|EXPERIMENTAL|1|
62327503|NCT05819138|PLACEBO_COMPARATOR|Placebo|Participants will receive 0.25 mg once weekly placebo injection for 4 weeks. Participants will receive 0.50 mg once weekly placebo injection for 4 weeks. Participants will receive 1.0 mg once weekly placebo injection for 6 months.
62692916|NCT06555601|EXPERIMENTAL|Cohort 5|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 5) or placebo.
62692917|NCT06555601|EXPERIMENTAL|Cohort 6|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 6) or placebo.
62692918|NCT06555601|EXPERIMENTAL|Cohort 7|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 7) or placebo.
62692919|NCT06555601|EXPERIMENTAL|Cohort 8|Study participants randomized to this arm will receive a single dose of UCB3101 (Dose 8) or placebo.
62692920|NCT00834782||IOP|Measuring IOP
62692921|NCT06450314|EXPERIMENTAL|ctDNA negative cohort at baseline|"Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study~* In case of radiological progression with or without ctDNA positive test, prior treatment will be restarted or new anti-HER2 treatment will be initiated according investigator choice~* In case of ctDNA positive test without radiological progression, prior treatment will be restarted."
61934151|NCT02134197|EXPERIMENTAL|Lupartumab Amadotin (BAY1129980)|Dose escalation with consecutive expansion at MTD (maximum tolerated dose) with BAY1129980.
61934152|NCT03543618|SHAM_COMPARATOR|Control|Installation of conventional design dental implant
61934153|NCT03543618|ACTIVE_COMPARATOR|Sloped|Installation of sloped design dental implant
62327504|NCT06331923|EXPERIMENTAL|CGM group|Participants who receive continuous glucose monitoring (CGM) during the perioperative period. Glucose monitoring should be continued until the 7th day after surgery or discharge.
61934154|NCT05600738|EXPERIMENTAL|Treatment|
62133918|NCT00467272|EXPERIMENTAL|Daptomycin|Daptomycin 6 mg/kg intravenous (IV) every 24 hours for at least 7-14 days, depending on the type of bacteria.
61934155|NCT05804942|EXPERIMENTAL|High glycemic index|The participants will be fed a fixed calorie meal, which is high glycemic index with constant fat and protein.
61934156|NCT05804942|EXPERIMENTAL|Medium glycemic index|The participants will be fed a fixed calorie meal, which is medium glycemic index with constant fat and protein.
61934157|NCT05804942|EXPERIMENTAL|Low glycemic index|The participants will be fed a fixed calorie meal, which is low glycemic index with constant fat and protein.
61934158|NCT06348901||Healthy subjects and Stroke patients|Healthy subjects and Stroke patients
61934159|NCT00969904|ACTIVE_COMPARATOR|1|
61934160|NCT00969904|PLACEBO_COMPARATOR|2|
61934161|NCT06708715|ACTIVE_COMPARATOR|TREATMENT|Subjects will be given a patch that incorporates a vibrotactile haptic technology (VTT) sensory pattern (PEACE Patch)
61934162|NCT06708715|SHAM_COMPARATOR|CONTROL|Subjects will be given a sham patch that does not incorporate vibrotactile haptic technology.
61934163|NCT00895427||1|Male ages 45-54, without diabetes, CAC score from 0 to \>1000
61934164|NCT00895427||2|Male ages 55-64, without diabetes, CAC score from 0 to \>1000
61934165|NCT00895427||3|Male ages 65+, without diabetes, CAC score from 0 to \>1000
61934166|NCT00895427||4|Male ages 45-54, with diabetes and CAC score from 0 to \>1000
61934167|NCT00895427||5|Male ages 55-64, with diabetes, CAC score from 0 to \>1000
61934168|NCT00895427||6|Male ages 65+, with diabetes, CAC score from 0 to \>1000
62485619|NCT05982860|EXPERIMENTAL|MIND diet (n:18)|Players in this group will be asked to include the food groups in the MIND diet in their diet in accordance with their consumption frequency. As a result of the interviews with the coaches and experienced athletes, it was learned that the majority of the athletes did not consume the foods such as wine, berries, and fish included in the MIND diet template. Therefore, these foods, which are the main components of the MIND diet, will be provided by the researcher/project in accordance with the recommended frequencies. However, since wine consumption is not frequently preferred in our country due to religious and socio-cultural reasons, ''hardaliye'', a fermented grape juice (100 mL/day), which is easy to consume and has similar nutritional values to wine (resveratrol and ORAC), will be provided. Berries will be supplied in 2 portions/week, and fish (tons) in 1 portion/week.
62692922|NCT03658304|EXPERIMENTAL|Mitomycin C|
61934169|NCT00895427||7|Female ages 50-59, without diabetes, CAC score from 0 to \>1000
61934170|NCT00895427||8|Females ages 60-69, without diabetes and CAC score from 0 to \>1000
61934171|NCT00895427||9|Females ages 70 +, without diabetes, CAC score from 0 to \>1000
61934172|NCT00895427||10|Female ages 50- 59, with diabetes, CAC score from 0 to \>1000
62133919|NCT05900505|EXPERIMENTAL|Intervention Group|Participants in the intervention group will be referred to a social navigator to address their identified social needs.
62133920|NCT05900505|NO_INTERVENTION|Control Group|Participants in the control group will be referred to a social worker, as per standard care.
62133921|NCT05246943||UTMB's Colorectal Surgical Cohort|Subjects who meet the inclusion criteria that will have colorectal surgery at UTMB
62133922|NCT05055700|EXPERIMENTAL|Intervention group|This arm will review a mobile app to learn information about prenatal genetic testing before their appointment with maternal-fetal medicine specialists.
62133923|NCT05055700|NO_INTERVENTION|Control group|This arm will only receive usual care - visit maternal-fetal medicine specialists.
62133924|NCT05979922|EXPERIMENTAL|Caring Mind mobile app|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
62133925|NCT05979922|ACTIVE_COMPARATOR|Traditional educational program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
62133926|NCT03142672|EXPERIMENTAL|Experimental group|Pulpotomy and tooth filling
62133927|NCT03142672|ACTIVE_COMPARATOR|Control group|Tooth filling
62133928|NCT05054920|EXPERIMENTAL|Concentric exercises group|"patient will do Concentric exercises. Patients will receive 3 sessions per week for 4 weeks. Exercise will be done under the supervision of the same physical therapist. During each session.~Exercise will be in the form of glenohumeral scaption, internal and external rotation exercises.~patient will also do stretching for posterior capsule and pectoralis minor"
61934173|NCT00895427||11|Female ages 60-69, with diabetes, CAC score from 0 to \>1000
61934174|NCT00895427||12|Female age 70+, with diabetes, CAC score from 0 to \>1000
61934175|NCT05521724|EXPERIMENTAL|exercise group|"The exercise protocol includes balance training and resistance training for all major muscle groups. The program will be performed twice a week.~* Squat~* Step up~* Step-up sideways~* Upright row~* Chest presS~* Biceps curl In balance exercises; It will start with static balance exercises and progress to dynamic balance exercises and will be applied 2 days a week for a minimum of 15 minutes.~* Tandem stance~* Semitandem stance~* Standing exercises on one leg will be performed first with eyes open and then with eyes closed.~As dynamic balance exercises;~* Just tip toe walking~* Don't just walk on heels~* Tandem walking is selected."
61934176|NCT05521724|ACTIVE_COMPARATOR|control group|No intervention will be made to the control group during the study.
61934177|NCT02521571|EXPERIMENTAL|Intervention Group|
61934178|NCT02521571|PLACEBO_COMPARATOR|Control Group|
61934179|NCT05040399|OTHER|Locking Compression Plates|Patients in whom we used Locking compression plates for sternal fixation
61934180|NCT05040399|OTHER|Wires|Patients in whom we used Sternal Wires for sternal fixation
61934181|NCT02092272|EXPERIMENTAL|instructional exercise video source|instructional exercise video source
61934182|NCT02092272|NO_INTERVENTION|Standard Therapy|Standard Therapy
61934183|NCT02671773||BTS Step 2 Asthmatic patients|Group of 20 asthmatic patients on British Thoracic Society (BTS) treatment step 2 - regular low dose inhaled corticosteroids (dose of \<400 micrograms/day BDP equivalent)
61934184|NCT02671773||BTS Step 4 Asthmatic patients on treatment with fluticasone|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled fluticasone (dose of \>500 micrograms/day)
61934185|NCT02671773||BTS Step 4 Asthmatic patients on treatment with budesonide|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled budesonide (dose of \>800 micrograms/day)
62327505|NCT06331923|NO_INTERVENTION|Control group|Perioperative blood glucose monitoring was performed according to institutional treatment guidelines.Glucose monitoring should be continued until the 7th day after surgery or discharge.
61934186|NCT00386607|EXPERIMENTAL|Core Treatment|Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
61934187|NCT00386607|EXPERIMENTAL|Extension Treatment|"For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.~The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits."
62327506|NCT00086840|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.
62327507|NCT03542071|EXPERIMENTAL|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
62327508|NCT03542071|EXPERIMENTAL|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
62692923|NCT06571799|OTHER|BENEV Exosome Regenerative Complex+|BENEV Exosome Regenerative Complex+® post SylFirmX® RF microneedling procedure applied to the scalp monthly for 4 sessions.
62692924|NCT06675188|EXPERIMENTAL|PF-07275315|Participants will receive a single dose of PF-07275315 via IV infusion
62692925|NCT06675188|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo via IV infusion
62692926|NCT06346132|EXPERIMENTAL|Experimental Group|In this group, virtual reality will be added to usual care
62692927|NCT06346132|NO_INTERVENTION|Standard Group|In this group, no extra intervention will be added to usual care
62327509|NCT01477697|ACTIVE_COMPARATOR|Omega-3|50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
62692928|NCT04124419|EXPERIMENTAL|Treatment Arm|Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
62692929|NCT04060238||Normal colour vision|Normal trichromopsia
62692930|NCT04060238||Inherited red blindness|Protanopia
61934188|NCT01131767|EXPERIMENTAL|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
61934189|NCT01131767|ACTIVE_COMPARATOR|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
62692931|NCT05021835|EXPERIMENTAL|Ziltivekimab|Participants will receive Ziltivekimab B or Ziltivekimab C subcutaneously once monthly for up to 4 years.
61934190|NCT02688712|EXPERIMENTAL|LY2157299 + Chemoradiation + Surgery|Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
61934191|NCT01057771|EXPERIMENTAL|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
62692932|NCT05021835|PLACEBO_COMPARATOR|Placebo|Participants will receive either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously once monthly for up to 4 years.
62692933|NCT02315950|OTHER|Arm 1|Botulinum toxin and cineMRI-UDS
62692934|NCT05935150|EXPERIMENTAL|OMSLNB|
62692935|NCT06570291|EXPERIMENTAL|Mesenchymal progenitor cells|
62692936|NCT06570291|PLACEBO_COMPARATOR|Sodium hyaluronate|
61934192|NCT01057771|EXPERIMENTAL|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
62327510|NCT01477697|PLACEBO_COMPARATOR|Placebo|50 mg/kg per day of vehicle
62327511|NCT03653702|EXPERIMENTAL|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
62327512|NCT06684626|EXPERIMENTAL|Butirprost and antibiotic|The treatment schedule was based on fluoroquinolone (levofloxacin, 1 tablet 500 mg daily for 4 weeks) plus 1 tablet of Butirprost® daily for 4 weeks
62327513|NCT06684626|ACTIVE_COMPARATOR|Antibiotic|the treatment schedule was based on oral fluoroquinolone only (levofloxacin, 1 tablet 500 mg daily for 4 weeks)
62327514|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
62485620|NCT04161898|EXPERIMENTAL|Arm 1: Upadacitinib|Participants will be administered updadacitinib once daily (QD) along with prednisolone.
62485621|NCT04161898|EXPERIMENTAL|Arm 2: Placebo for Upadacitinib|Participants will be administered placebo once daily (QD) along with prednisolone.
62692937|NCT02971137|EXPERIMENTAL|Smoking Cessation plus CBI (SMK-CBI)|An intervention that includes a proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
62692938|NCT02971137|ACTIVE_COMPARATOR|Smoking Cessation Standard (SMK-STD)|A contact-equivalent control that provides standard smoking cessation telephone counseling
62692939|NCT04416724|EXPERIMENTAL|Phacoemulsification|Main study intervention will be Phacoemulsification
62692940|NCT04416724|EXPERIMENTAL|SLT|Main study intervention will be Selective Laser Trabeculoplasty
62692941|NCT01424137|OTHER|Easyhaler type A|
62692942|NCT01424137|OTHER|Easyhaler type B|
62692943|NCT01424137|OTHER|Diskus inhaler|
62485622|NCT02167659|EXPERIMENTAL|BIS Assessment|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15\*, 18, 21\*, 24, and 36 months post-op. Measures include L-Dex, skin assessment and self-report forms. Patients with \< 6.5 L-Dex units change will continue follow-up for 36 months. Patients with an L-Dex value change ≥ 6.5 will undergo circumference measurement and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~\*At discretion of the site PI or attending physicians."
62692944|NCT05259501|EXPERIMENTAL|Guided video recording with tamper-evident packaging|This method uses automated visual recognition web-based platform and QR tamper-evident labels to enhance the security of the take-home regimen currently used in methadone clinics. Single-use liquid methadone bottles are made tamper-evident through the application of a QR security label.
62692945|NCT01628952|EXPERIMENTAL|TAP|
62692946|NCT01628952|ACTIVE_COMPARATOR|curare|Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
62327515|NCT04755296|EXPERIMENTAL|Low level laser therapy and aerobic exercises group|They received low level laser therapy and aerobic exercises using a treadmill, 3 sessions per week for 12 weeks.In addition to traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
62327516|NCT04755296|ACTIVE_COMPARATOR|Control group (aerobic exercises group)|They received aerobic exercises 3 times weekly for 12 weeks.In addition to the same traditional physical therapy program.
62327517|NCT06412744||Total cohort|No intervention, all participants undergo the same measurements
62327518|NCT05635552||PCS patients|Patients with a COVID-19 infection at least 3 months ago (positive PCR or rapid antibody test) and PCS typical symptoms (e.g. fatigue, breast pain, heart palpitations, cognitive impairment) ongoing for at least 2 months and which cannot be explained by an alternative diagnosis.
62692947|NCT02797548|EXPERIMENTAL|Aspirin only|
62692948|NCT02797548|ACTIVE_COMPARATOR|No antiplatelet therapy|
62692949|NCT06431581|EXPERIMENTAL|Intervention group (educational video, SMS and reminder phone call)|An intervention group will receive standard care along with m-health intervention that includes tailored educational video, SMS and reminder phone call for follow up
61934193|NCT01057771|NO_INTERVENTION|Waiting list control|Waiting list control subjects will be treated exactly like those in active intervention groups, but will not receive interventions.
61934194|NCT04627025|EXPERIMENTAL|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
62327519|NCT05635552||COVID-19 recovered participants|Participants with Sars-CoV-2 infection at least 3 months ago (positive PCR or positive rapid antibody test) which are fully recovered.
62327520|NCT05635552||COVID-19 infection naïve|"No history of COVID-19 infection (exclusion via measurement of specific antibodies).~Consists of an already established, pre-pandemic healthy cohort and a cohort recruited during the pandemic."
62327521|NCT06515652|ACTIVE_COMPARATOR|Allopathic|"1. Tablet.Rosuvastatin 10mg once daily for 3 months~2. Tablet. Telmisartan 40mg once daily for 3 months~3. Tablet. Sitagliptin / Metformin 50/500mg once daily for 3 months"
62327522|NCT06515652|ACTIVE_COMPARATOR|Herbal|"1. Cinammon powder 2 gm once daily for 3 months~2. Garlic powder 1 gm once daily for 3 months~3. Ginger powder 4 gm once daily for 3 months~4. Fenugreek powder 10 gm once daily for 3 months~5. Arjuna 2 gm once daily for 3 months"
62327523|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
62327524|NCT04585945||Group 1 (Cases)|Patients that test positive for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
62327525|NCT04585945||Group 2 (Control)|Historic group of patients delivering prior to the COVID-19 pandemic.
62327526|NCT06693791|EXPERIMENTAL|Romiplostim N01|
62327527|NCT02041546|ACTIVE_COMPARATOR|Bolus surfactant|Bolus surfactant 100 mg/kg proctant alfa
62327528|NCT02041546|ACTIVE_COMPARATOR|Lung lavage with surfactant|Lung lavage with surfactant
62327529|NCT06397729|ACTIVE_COMPARATOR|Patients - Wait-List Control|"* Complete questionnaires at baseline, within 48 hours of their routine clinic visit, and 6-months after the clinic visit. All surveys will be administered electronically or by mail~* A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
62327530|NCT06397729|EXPERIMENTAL|Patients- PREVENT Tool|"* Complete questionnaires at baseline, within 48 hours of their routine clinic visit, and 6-months after the clinic visit. All surveys will be administered electronically or by mail~* At the clinic visit, the provider will use the PREVENT tool to discuss CVH risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. Community Health Workers will follow up with patients monthly to support behavior change."
62327531|NCT06397729|NO_INTERVENTION|Providers|All eligible providers will be sent questionnaires electronically to their email at baseline, following provider training and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline.
62327532|NCT01003028|EXPERIMENTAL|Limited|Limit the maximum plasma concentration target to 9.8 ng/ml
62327533|NCT01003028|ACTIVE_COMPARATOR|Control|Use 20 ng/ml as max plasma concentration
62692950|NCT06431581|NO_INTERVENTION|Control Group (standard care, control video and reminder phone call for follow up)|A control group will receive standard care along with a control video and reminder phone call for follow-up
62692951|NCT06010719|EXPERIMENTAL|Azithromycin|Children enrolled in the trial will be randomized to either the azithromycin, amoxicillin, or placebo arm. Children randomized to the azithromycin arm will receive all standard severe acute malnutrition (SAM) outpatient treatment per Burkinabe national guidelines, except that the standard amoxicillin treatment will be changed to azithromycin. Children will receive a directly observed dose of azithromycin (20 mg/kg, single directly observed dose, oral suspension), followed by a 7-day course of placebo (administered at 80 mg/kg, split into 2 daily doses for 7 days, oral suspension).
61934195|NCT04627025|PLACEBO_COMPARATOR|Placebo|Placebo for apraglutide, SC injection once weekly
61934196|NCT05667194|EXPERIMENTAL|KH617 dose 1|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
62485623|NCT02167659|ACTIVE_COMPARATOR|Tape Measure|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15\*, 18, 21\*, 24, and 36 months post-op. Measures include arm volume (tape measure), skin assessment and self-report forms. Patients with no volume increase will continue follow-up for 36 months. Patients with a volume change of between ≥ 5% and \< 10% in the at-risk limb will undergo L-Dex testing and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~\*At discretion of the site PI or attending physicians."
62485624|NCT01225523|ACTIVE_COMPARATOR|Preoperative chemotherapy followed by surgery|
62485625|NCT01225523|ACTIVE_COMPARATOR|Perioperative chemotherapy with surgery|
62485626|NCT02958176|EXPERIMENTAL|HRV Biofeedback|At home HRV biofeedback using mobile device
62485627|NCT02958176|EXPERIMENTAL|HRV Biofeedback with Autogenic Training|At home HRV biofeedback using mobile device plus autogenic training recording
62485628|NCT02958176|NO_INTERVENTION|Wait List|Wait list control
62485629|NCT06559631|EXPERIMENTAL|Treatment Group|Experimental group will receive the indigenously adapted Community Reinforcement Approach based psychotherapeutic sessions after the completion of drugs related detoxification (after 21 days since hospitalization) for 90-120 days in residential treatment.
62692952|NCT06010719|ACTIVE_COMPARATOR|Amoxicillin|Children enrolled in the trial will be randomized to either the azithromycin, amoxicillin, or placebo arm. Children randomized to the amoxicillin arm will receive all standard severe acute malnutrition (SAM) outpatient treatment per Burkinabe national guidelines, including a 7-day course of amoxicillin (administered at 80 mg/kg, split into 2 daily doses for 7 days, oral suspension).
62692953|NCT06010719|PLACEBO_COMPARATOR|Placebo|Children enrolled in the trial will be randomized to either the azithromycin, amoxicillin, or placebo arm. Children randomized to the placebo arm will receive all standard severe acute malnutrition (SAM) outpatient treatment per Burkinabe national guidelines, except that the the standard amoxicillin treatment will be changed to placebo (administered at 80 mg/kg, split into 2 daily doses for 7 days, oral suspension).
61934197|NCT05667194|EXPERIMENTAL|KH617 dose 2|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
61934198|NCT05667194|EXPERIMENTAL|KH617 dose 3|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
62327534|NCT05682664|ACTIVE_COMPARATOR|Usual care|Usual care for children with preschool wheeze consist of regular visits to the outpatient clinic every three months after starting the study, while in between these visits contact with the healthcare team is by telephone as needed. At inclusion and at every outpatient clinical visits (e.g. 3, 6, 9 and 12 months), parents/caregivers will be asked to update the healthcare team on disease symptoms by completing a digital version of Test for Respiratory and Asthma Control in Kids (TRACK) questionnaire.
62327535|NCT05682664|EXPERIMENTAL|Luchtbrug Junior (intervention)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
62327536|NCT06346028|EXPERIMENTAL|Patients Receiving rTMS|Participants will receive 3 weeks of daily (Monday to Friday) rTMS sessions followed by 3 weeks of weekly rTMS sessions for a total of 6 weeks of treatment. Each session lasts about 25 minutes and is provided by an rTMS technician at the Temerty Center at 1025 Queen Street West, with medical supervision.
62327537|NCT04929262|ACTIVE_COMPARATOR|Researcher-Only|The researcher-facilitated presentation, led by two clinical psychology graduate students, will be the same for all schools.
62327538|NCT04929262|EXPERIMENTAL|Key Opinion Leader|The key opinion leader (KOL) co-facilitated presentations will include the same core principles as the researcher-facilitated presentation but may vary by school in terms of specific examples and content emphasized based on KOL feedback. A caregiver KOL from the local community (selected by the parent teacher association or a similar group) will co-facilitate the presentation with a clinical psychology graduate researcher.
62485630|NCT06559631|NO_INTERVENTION|Control Group: Treatment as usual|This group will receive treatment as usual which includes detoxification of drugs, general counselling for drug addiction prevention, 12 steps program and life skills training. Duration of residential treatment is between 90-120 days.
62692954|NCT01816399||Routine coronary angiography patients|
62692955|NCT02598167||RRMS Population|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
62692956|NCT06300632||older adults|older adults Geriatric Locomotive Function Scale Tampa Kinesiophobia Scale Physical Activity Scale for the Elderly (PASE) Brief Physical Performance Battery Fatigue Severity Scale Montreal Cognitive Assessment Scale (MoCA)
62692957|NCT01271231|PLACEBO_COMPARATOR|Group IP1|
62692958|NCT01271231|EXPERIMENTAL|Group IP2|
62692959|NCT01271231|ACTIVE_COMPARATOR|Group IP3|
62692960|NCT04825600|OTHER|toxo+|
62692961|NCT04825600|OTHER|uninfected|
61934199|NCT05667194|EXPERIMENTAL|KH617 dose 4|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
61934200|NCT05667194|EXPERIMENTAL|KH617 dose 5|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
61934201|NCT03706131|EXPERIMENTAL|experimental group|one session 15 minutes cervical mobilisation and home exercise
61934202|NCT03706131|NO_INTERVENTION|control grup|no intervention
62485631|NCT05458687|EXPERIMENTAL|intervention group|"* Chinese herbal medicine decoction.~* Acupuncture or Laser acupuncture pen treatment.~* Acupoint Tuina massage.~* Acupoint application of traditional Chinese herbal medicinal cake.~* Nursing and health education and guidance.~* Diet and health education."
62485632|NCT05458687|NO_INTERVENTION|control group|"* Nursing and health education and guidance~* Diet and health education"
62485633|NCT02623647|OTHER|A single-arm, nonrandomized|stereotactic body radiotherapy SBRT, 40 Gy for 3 fractions
62485634|NCT03073850|EXPERIMENTAL|Antiplatelet therapy|acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
62485635|NCT03073850|EXPERIMENTAL|Low-dose OAC therapy|Edoxaban of 30mg (Reduced dose of 15mg if body weight \< 60kg, CCr\< 50 ml/min, concomittant use of P-gp)
62692962|NCT04825600|OTHER|mother and child duo|
62692963|NCT04825600|OTHER|toxo+ more than 10 years|
61934203|NCT05704010|EXPERIMENTAL|Lynch Syndrome|Video capsule endoscopy every 2 years
61934204|NCT03802812|NO_INTERVENTION|Conventional arm|"Perform bronchial washing using conventional methods.~* CT-guided thick bronchoscope"
62133929|NCT05054920|EXPERIMENTAL|Eccentric exercises group|"patient will do eccentric exercises. Patients will receive 3 sessions per week for 4 weeks. Exercise will be done under the supervision of the same physical therapist during each session.~Exercise will be in the form of glenohumeral scaption, internal and external rotation exercises.~patient will also do stretching for posterior capsule and pectoralis minor"
62133930|NCT01075152|EXPERIMENTAL|Earlier HIV Therapy|HIV therapy initiated at 7-13 days of cryptococcal meningitis diagnosis. HIV therapy consisting of a nucleoside with lamivudine and efavirenz.
62133931|NCT01075152|ACTIVE_COMPARATOR|Deferred HIV Therapy|"HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week).~HIV therapy consisting of a nucleoside with lamivudine and efavirenz."
62327539|NCT05820100||Normally Sighted|Participants with clinically normal ocular findings and BCVA better than logMAR 0.3 in each eye.
62327540|NCT05820100||Severely Sight Impaired|Participants with BCVA no better than logMAR 1.6 in better seeing eye, and worse than logMAR 1.9 in the worse seeing eye, and a clinical diagnosis of advanced RP
62692964|NCT05752032||ICM-203|Participants who previously received ICM-203 in ICM-203 clinical studies
62692965|NCT05752032||Placebo|Participants who previously received placebo in ICM-203 clinical studies
62692966|NCT05468177|EXPERIMENTAL|neoadjuvant chemotherapy|Cetuximab+ mFOLFOX+ Anti-PD-1+Surgery
62692967|NCT06639295|EXPERIMENTAL|611|611 2ml Q2W, subcutaneous (SC) injection
62692968|NCT06639295|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous (SC) injection.
62692969|NCT03533569||Osteoarthritis|Participants with an established diagnosis of knee osteoarthritis
62133932|NCT04794218|EXPERIMENTAL|Study Group 1|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10\^4 or Placebo
62133933|NCT04794218|EXPERIMENTAL|Study Group 2|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10\^5 or Placebo
62327541|NCT02626819|EXPERIMENTAL|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
62327542|NCT02626819|ACTIVE_COMPARATOR|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
62327543|NCT06397391|EXPERIMENTAL|Medical device|Patients will test medical device on site during 1 hour. EMG (electromyogram) and accelerometry will be performed before and after this hour. As same as clinical scale (Fahn-tolosa-Marin)
62327544|NCT06555367||scleral lenses group|The case group consists of patients with irregular corneas who wear scleral lenses.
62327545|NCT06555367||control group|The control group comprises patients with irregular corneas who have not undergone treatment with scleral lenses.
62327546|NCT01531127||Combined Therapy|ADHD Medication and Learning Strategies Treatment
62327547|NCT01531127||ADHD Medication Treatment|Control group
62692970|NCT03533569||Rheumatoid arthritis|Participants with an established diagnosis of rheumatoid arthritis
62692971|NCT03533569||Spondyloarthritis or psoriatic arthritis|Participants with an established diagnosis of spondyloarthritis or psoriatic arthritis
62692972|NCT03533569||Case controls|Participants with no arthritis or knee pain as controls
62692973|NCT05412979|EXPERIMENTAL|ST-1891|
62692974|NCT05412979|ACTIVE_COMPARATOR|Levothyroxine|
62692975|NCT05403268|SHAM_COMPARATOR|Usual Care|Usual care group. Participants undergo twice daily DeltaScan measurements in addition to usual care. An adapted device is used, that masks the measurement result (it generates a QR-code, that is scanned into the patient data management system). The results will be unblinded one enrollment is complete.
62692976|NCT05403268|EXPERIMENTAL|Usual Care + DeltaScan|Intervention group. Participants undergo twice daily DeltaScan measurements in addition to usual care. The measurement result is used together with routine delirium screening observations to guide management, according to the local delirium protocol.
62692977|NCT04805528|EXPERIMENTAL|Experimental: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS) Therapy|Six (6) small electrodes will be placed on specific points of the body using adhesive pads. These electrodes are connected to the ALTENS device, which will send controlled, low-level electrical impulses through the skin and into the tissue underneath.
61934205|NCT03802812|ACTIVE_COMPARATOR|Investigational arm|"Perform bronchial washing using investigational methods.~* virtual bronchoscopic navigation (VBN)-guided thin bronchoscope (4.0mm of outer diameter)"
61934206|NCT05080127|EXPERIMENTAL|study subjects|"Children with proven IgE-mediated food allergy to one of the allergenic foods described.~Parallel to the skin tests that are done as part of the accepted follow-up:~1. The parents will fill a questionnaire regarding the quality of life (QOL) and another questionnaire regards family and personal relevant medical history.~2. Patch test sticker with the allergenic food will be placed on the forearm for 15 minutes.~3. A week later and 2 months later, the same QOL questionnaire will be sent by e-mail."
61934207|NCT05080127|ACTIVE_COMPARATOR|Control - atopic children|"Children with atopic comorbidities except for food allergy (ie. atopic dermatitis, asthma, allergic rhinitis).~1. The parents will fill a questionnaire regarding family and personal relevant medical history and foods that the child is exposed to regularly.~2. Patch test stickers with two of the food allergen list will be placed on the forearm for 15 minutes."
61934208|NCT05080127|ACTIVE_COMPARATOR|Control - healthy children|"Children without any atopic comorbidity (ie. atopic dermatitis, asthma, allergic rhinitis, and food allergy).~1. The parents will fill a questionnaire regarding family and personal relevant medical history and foods that the child is exposed to regularly.~2. Patch test stickers with two of the food allergen list will be placed on the forearm for 15 minutes."
61934209|NCT01384097||Conventional care|patients treated by conventional haemodynamic care intraoperatively
61934210|NCT01384097||Haemodynamic algorithm|patients treated within a goal-directed haemodynamic algorithm intraoperatively
61934211|NCT04432272|EXPERIMENTAL|Group A|Hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring \>6 L of oxygen to maintain oxygen saturation \>92%. Patient may not require intubation, and may be admitted for no longer than 14 days.
62133934|NCT04794218|EXPERIMENTAL|Study Group 3|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10\^6 or Placebo
62133935|NCT04794218|EXPERIMENTAL|Study Group 4A|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10\^7 or Placebo
62133936|NCT04794218|EXPERIMENTAL|Study Group 5|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10\^5 or Placebo
62133937|NCT04794218|EXPERIMENTAL|Study Group 6|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10\^6 or Placebo
62133938|NCT04794218|EXPERIMENTAL|Study Group 7|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10\^7 or Placebo
62133939|NCT04794218|EXPERIMENTAL|Study Group 4B|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 and Day 42 2 X 10\^7 or Placebo
62133940|NCT00982917|EXPERIMENTAL|teachers taught curriculum|Teachers taught Stamp-in-Safety curriculum
62133941|NCT00982917|EXPERIMENTAL|teachers do not learn curriculum|Teachers are not taught Stamp-in-Safety curriculum
62327548|NCT06692647|EXPERIMENTAL|MK-4318 Plus Diltiazem|Participants will move sequentially through 2 Periods. In Period 1, participants receive MK-4318 orally. In Period 2, participants receive MK-4318 orally plus diltiazem orally.
62327549|NCT03408574|EXPERIMENTAL|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
62692978|NCT05896826||healthy volunteers|
61934212|NCT04432272|EXPERIMENTAL|Group B|Hospitalized COVID-19 patients ages ≥18 years requiring intubation.
62327550|NCT03408574|EXPERIMENTAL|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
62327551|NCT03827473|EXPERIMENTAL|Arm A (ADT, docetaxel)|Participants receive androgen deprivation therapy (ADT) per standard of care and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62485636|NCT03073850|ACTIVE_COMPARATOR|Standard-dose OAC therapy|Edoxaban of 60mg (Reduced dose of 30mg if body weight \< 60kg, CCr\< 50 ml/min, concomittant use of P-gp)
62485637|NCT01875562|EXPERIMENTAL|Qishe Pill|
62692979|NCT05896826||chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination|
61934213|NCT02597868|ACTIVE_COMPARATOR|Capecitabine|Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.
61934214|NCT02597868|EXPERIMENTAL|endocrine therapy|endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.
62133942|NCT05591872|ACTIVE_COMPARATOR|LD+I+TRB|"Patient will get heparin dose according to their weight i.e. (\<60 Kg-2000 IU; 60-80 Kg-2500 IU; \>80 Kg-3000 IU)~And access site will be secured with InnoSEAL patch plus TRB"
62133943|NCT05591872|ACTIVE_COMPARATOR|LD+TRB|"Patient will get heparin dose according to their weight i.e. (\<60 Kg-2000 IU; 60-80 Kg-2500 IU; \>80 Kg-3000 IU)~And access site will be secured with TRB alone"
62133944|NCT05591872|ACTIVE_COMPARATOR|SD+I+TRB|"Patient will get standard heparin dose of 5000 IU.~And access site will be secured with InnoSEAL patch plus TRB"
62133945|NCT05591872|NO_INTERVENTION|SD+TRB|"This is the control arm. Patient will get standard heparin dose of 5000 IU.~And access site will be secured with TRB."
62692980|NCT03924284||NPA positive|NPA specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
62692981|NCT03924284||NPA negative|NPA specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
62692982|NCT03924284||Saliva positive|Saliva specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
62692983|NCT03924284||Saliva negative|Saliva specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
62692984|NCT01555580|EXPERIMENTAL|GM-CSF|
61934215|NCT02427828|ACTIVE_COMPARATOR|Treatment Group|Assessment of Visensia Respiration Rate Estimation Service (product) to provide Respiration Rate from PPG signal, providing 3 vital signs (heart rate, oxygen saturation and respiration rate) to facilitate continuous Safety Index (VSI) calculation by Visensia, alongside standard routine intermittent observations (vital signs every 4 - 6 hours).
61934216|NCT02427828|NO_INTERVENTION|Control Group|Using standard routine intermittent observation (vital signs every 4 - 6 hours) and calculation of NEWS/MEWS scores for early detection of patient deterioration.
61934217|NCT01887340|EXPERIMENTAL|Cohort 1|"* PET-TDM~* carboplatine: Dose (mg) = AUC x (GFR + 25)~  * GFR : glomérulaire filtration (ml/min)~ * AUC : area under curve (mg/ml x min)"
61934218|NCT01887340|EXPERIMENTAL|Cohort 2|"* PET-TDM~* ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)~* carboplatine: Dose (mg) = AUC x (GFR + 25)~  * GFR : glomérulaire filtration (ml/min)~ * AUC : area under curve (mg/ml x min)"
62692985|NCT03043573|EXPERIMENTAL|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
62692986|NCT03043573|ACTIVE_COMPARATOR|Supportive Therapy|Supportive Therapy focuses on: 1. Facilitating expression of affect; 2. Conveying to the patient that he or she is understood; 3. Offering empathy; and 4. Highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
62692987|NCT05507437|EXPERIMENTAL|TIN816|Administered as an intravenous dose
62692988|NCT05507437|PLACEBO_COMPARATOR|Placebo|0.9% sterile sodium chloride solution administered as an intravenous dose
62692989|NCT06129903|EXPERIMENTAL|Early Psychiatric Referral|Participants will be randomized to the Early Psychiatric Referral group
62692990|NCT06129903|NO_INTERVENTION|No Referral|Participants will be randomized to the No Referral group
62692991|NCT05541861|EXPERIMENTAL|BNT162b2 Bivalent 30 µg + BNT162b4 5 µg - participants aged 18-55 years|Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 5 µg. Cohort 1. Two doses (at Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).
62692992|NCT05541861|EXPERIMENTAL|BNT162b2 Bivalent 30 µg + BNT162b4 10 µg - participants aged 18-55 years|Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 10 µg. Cohort 2. Two doses (at Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1)
62692993|NCT05541861|EXPERIMENTAL|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 15 µg - participants aged 18-55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg.~Cohort 3a. Two doses (at Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 15 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg"
62692994|NCT05541861|EXPERIMENTAL|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 15 µg - participants aged >55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg.~Cohort 3b. Two doses (at Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 15 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg"
61934219|NCT05264415|EXPERIMENTAL|Families Over-Coming Under Stress-Early Childhood Program (FOCUS-EC)|"FOCUS-EC is a trauma-informed, family-level, skill building program that provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping (including emotional regulation, problem solving, goal setting, communication, and management of trauma \& loss reminders), which foster parent-child and family cohesion. It is delivered in approximately 8 weekly sessions (including approximately six 60-minute sessions with parent/caregivers only, and two 30-60 minute sessions with children and parent/caregivers together). Each session is structured with a check-in, review of the previous week's home activity, new skills-based activity and discussion, selection of a new home activity, and a closing check-out. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family timeline and 2) enhancing parent-child interactions."
62327552|NCT03827473|EXPERIMENTAL|Arm B (ADT, abiraterone acetate, prednisone)|Participants receive androgen deprivation therapy (ADT) per standard of care, abiraterone acetate PO daily, and prednisone PO twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
62327553|NCT00678275|OTHER|A|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, RECEIVING ATG in conditioning regimen
61934220|NCT05264415|ACTIVE_COMPARATOR|Parenting Education Website|The Parenting Education Website includes information and high-quality parenting resources covering topics such as typical child development, common child reactions to family stress and transitions, play, positive parenting strategies, and the importance of self-care.
61934221|NCT01676727||CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
61934222|NCT03139279|EXPERIMENTAL|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
61934223|NCT03139279|PLACEBO_COMPARATOR|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
62327554|NCT00678275|OTHER|B|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, NOT RECEIVING ATG in conditioning regimen
62327555|NCT00675974|EXPERIMENTAL|1|Pressure garment therapy
62327556|NCT00675974|NO_INTERVENTION|2|No pressure garment therapy
62327557|NCT01883323|EXPERIMENTAL|Cyclophosphamide and Fludarabine followed by TILs and IL-2|Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10\^10 - 1.6x10\^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
62327558|NCT04937478||Hemodialysis patients|Patients who undergo hemodialysis in hospital every two to three days.
61934224|NCT03092271|ACTIVE_COMPARATOR|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
61934225|NCT03092271|EXPERIMENTAL|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
61934226|NCT02910869||Successful weight loss|Patients who have lost =\>5% of their weight after completing MOVE! or TeleMOVE!
61934227|NCT02910869||Unsuccessful weight loss|Patients who have lost \<5% of their weight after completing MOVE! or TeleMOVE!
61934228|NCT04490239|EXPERIMENTAL|Experimental Arm|"Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL.~Acute phase:~On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~Chronic phase:~The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records."
61934229|NCT00723931||Participants with Chronic Hepatitis C|Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with Chronic Hepatitis C are generally treated.
61934230|NCT05455385|ACTIVE_COMPARATOR|Control group|
61934231|NCT05455385|EXPERIMENTAL|Hydrotherapy group|
61934232|NCT05455385|EXPERIMENTAL|Ground exercise group|
62133946|NCT02798367|EXPERIMENTAL|CBT-I plus Melatonin 3 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 3mg. Melatonin 3mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
62133947|NCT02798367|EXPERIMENTAL|CBT-I plus Melatonin 5 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 5mg. Melatonin 5mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
62327559|NCT06473623|EXPERIMENTAL|Treatment Arm|Receiving intervention of the non-invasive neurostimulation device.
62327560|NCT00934557|EXPERIMENTAL|Good prognosis/mismatched donor/BM|
62327561|NCT00934557|EXPERIMENTAL|Good prognosis/mismatched donor/PB|
62327562|NCT00934557|EXPERIMENTAL|Poor prognosis/matched donor/BM|
62327563|NCT00934557|EXPERIMENTAL|Poor prognosis/matched donor/PB|
62327564|NCT00934557|EXPERIMENTAL|Poor prognosis/mismatched donor/BM|
62327565|NCT00934557|EXPERIMENTAL|Poor prognosis/mismatched donor/PB|
62327566|NCT00934557|EXPERIMENTAL|Good prognosis/matched donor/BM|
62327567|NCT00934557|EXPERIMENTAL|Good prognosis/matched donor/PB|
62327568|NCT06470100|PLACEBO_COMPARATOR|Control group|0.2% ropivacaine for erector spinae plane block
62485638|NCT00768963|EXPERIMENTAL|1|Patients will receive one injection of ranibizumab 3 days prior to surgery
62485639|NCT00768963|EXPERIMENTAL|2|Patients will undergo one injection of ranibizumab at the time of surgery
62485640|NCT04268615|EXPERIMENTAL|Patients|Patients suffering from chronic bilateral vestibular hypofunction
62485641|NCT04268615|ACTIVE_COMPARATOR|healthy subject group|
61934233|NCT01986140|EXPERIMENTAL|PAXMAN Orbis Scalp Cooler|Scalp Cooling
61934234|NCT01986140|OTHER|Control No treatment|Control
61934235|NCT05666622|OTHER|Kahramanmaraş Sütçü İmam University|Only routine non-surgical periodontal treatment was applied to the patients.
61934236|NCT04243785|EXPERIMENTAL|Part 1a (Monotherapy Cohort Escalation)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). The BTX-A51 starting dose for Cohort 1 is 1 mg, to be given 5 days per week (maximum weekly dose of 5 mg). Beginning with Cohort 2, doses are intended to be administered 3 days per week. Barring dose-limiting toxicity (DLT), sequential dose escalation of BTX-A51 is planned with up to a total of eight dose levels to a maximum of 21 mg (63 mg/week); on the basis of these an MTD will be identified. The numbers of participants and actual doses administered will be determined using a Bayesian optimal interval (BOIN) design to determine the DLTs and MTD of BTX-A51.
61934237|NCT04243785|EXPERIMENTAL|Part 1b (Monotherapy Cohort Expansion)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). Part 1b will continue at the MTD or the highest dose achieved in Phase 1a.
61934238|NCT04243785|EXPERIMENTAL|Part 1c (Azacitidine Combination Dose Escalation)|After determination of MTD and RP2D from Part 1a, combination dose escalation in Part 1c may begin. Patients with AML will receive BTX-A51 combined with azacitidine in escalating BTX-A51 dose cohorts. Dosing in this stage of the study consists of the first cycle of therapy (i.e., 28 days). The starting dose of BTX-A51 will be RP2D. Part 1c will follow a BOIN design as described for Part 1a. The numbers of patients and actual doses administered will be determined in response to DLTs a. There will be at least 3 patients per cohort.
62327569|NCT06470100|EXPERIMENTAL|Dexamethasone|0.2% ropivacaine + 4mg Dexamethasone for erector spinae plane block
62327570|NCT06470100|EXPERIMENTAL|Dexmedetomidine|0.2% ropivacaine + 50ug Dexmedetomidine for erector spinae plane block
62327571|NCT02680847|EXPERIMENTAL|ALO-02|One arm, open label, active
62327572|NCT02027298|EXPERIMENTAL|Abatacept|Abatacept by SC injection of 125 mg weekly for 6 months
62327573|NCT00860340|EXPERIMENTAL|1|Study patient will take 100mg tablet of Spironolactone
61934239|NCT04951440|EXPERIMENTAL|Intervention group|"Intervention group: 30min intravenous point. Infusion of 1400 mg of tetranitrone was given to bed I with a dose of 100ml, twice a day, with an interval of 12 hours, and continued administration for 7 days, that is, a total of about 14 times.~version"
61934240|NCT04951440|PLACEBO_COMPARATOR|Placebo group|Placebo group: 30 minutes to earn pulse, I, 1, and dripping Yunmi gave 100mL placebo (sodium chloride injection). It is administered twice a day for 1 to 2 hours, and the pattern is transferred to about 7 people, that is, about 14 times in total.
61934241|NCT05159856||Prospective cohort study (observational)|400 children/adolescents, aged 6-18 years, with type 1 diabetes for more than 12 months
61934242|NCT00910988|ACTIVE_COMPARATOR|olanzapine|olanzapine injection in healthy control
61934243|NCT00910988|ACTIVE_COMPARATOR|ziprasidone|ziprasidone injection in healthy control
61934244|NCT00910988|PLACEBO_COMPARATOR|saline|saline injection in healthy control
61934245|NCT03850665|ACTIVE_COMPARATOR|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
61934246|NCT03850665|ACTIVE_COMPARATOR|Anterolateral approach|Anterolateral Approach surgery to replace the hip.
61934247|NCT03850665|ACTIVE_COMPARATOR|Posterolateral approach|Posterolateral Approach surgery to replace the hip.
61934248|NCT00689598|PLACEBO_COMPARATOR|III|Placebo
61934249|NCT00689598|EXPERIMENTAL|Experimental|Drug intervention
61934250|NCT06409351|EXPERIMENTAL|Intervention group|"Study period: 6 months (1st 3 months intervention, last 3 months no intervention) No. of sessions: up to 6 per participant Mode: 3 sessions are conducted face-to-face and 3 sessions via telehealth methods e.g. phone, text message or video conferencing using virtual platforms like zoom.~Where: Face-to-face at the participant's preferred exercise space like home, outdoor fitness zone, parks, gyms etc.~Duration of sessions: each face-to-face session will take 60-90 mins Details of intervention: Physical activity counselling on adaptation of exercises, goal setting, action planning, problem solving around barriers to physical activity and provision of study resources"
61934251|NCT06409351|ACTIVE_COMPARATOR|Control group|Study period: 6 months No. of sessions: 2 sessions (at month 1 and 3) Mode: Face-to-face Where: At the participant's home Duration of session: 20- 30 minutes Details of control: physical activity information without any other support.
62133948|NCT02798367|OTHER|CBT-I plus placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo. The participants shall administer the placebo tablets to enable the double-blind study. Placebo will be dispensed to 65 (first stage) and 56 (second stage) participants of this group and shall administer 01 tablet orally every 24 hours one hour before bedtime for 21(±2) days.~Sleep hygiene is a psychoeducational intervention that teaches patients to prevent external or environmental factors generate adverse effects and harmful to sleep. The stimulus control technique is based on five instructions that encourages the patient to establish a proper sleep-wake rhythm and strengthens the links between the way for a quick and well consolidated sleep. The CBT-I guidelines are standardized in clinical protocol."
62133949|NCT04452318|EXPERIMENTAL|REGN10933 + REGN10987|
61934252|NCT02713204|EXPERIMENTAL|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram \[mg\]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
61934253|NCT02713204|EXPERIMENTAL|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
61934254|NCT02713204|EXPERIMENTAL|Aflibercept (IAI) 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.
61934255|NCT03507062|EXPERIMENTAL|Chloride-rich solution|Patients will receive two boluses of 10 and 20 ml/kg of the 0.9% saline in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
61934256|NCT03507062|EXPERIMENTAL|Low-chloride solution A|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's lactate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
62133950|NCT04452318|PLACEBO_COMPARATOR|Placebo|
62133951|NCT02190149||ADVATE (Factor VIII)|Participants will remain on their current (pre-study) treatment regimen of ADVATE throughout the study period
62133952|NCT02190149||RIXUBIS (Factor IX)|Participants will remain on their current (pre-study) treatment regimen of RIXUBIS throughout the study period
62133953|NCT02461628|EXPERIMENTAL|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
62133954|NCT02461628|NO_INTERVENTION|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
62327574|NCT02633995||preeclampsia|spinal anaesthesia will be given for cesarean section
62327575|NCT02633995||normotensive|spinal anaesthesia will be given for cesarean section
62327576|NCT05578651||SternaLock XP|Median sternotomy with rigid plate fixation (SternaLock XP) as the sole closure method
61934257|NCT03507062|EXPERIMENTAL|Very low-chloride solution|Patients will receive two boluses of 10 and 20 ml/kg of a plasmalyte-like solution (namely soluzione elettrolitica reintegrante \[SER\]) in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
61934258|NCT01297998|EXPERIMENTAL|gemcitabine , cisplatin|
61934259|NCT01725607|NO_INTERVENTION|the control group (Group C)|general anesthesia
61934260|NCT01725607|EXPERIMENTAL|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
61934261|NCT01725607|EXPERIMENTAL|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
61934262|NCT06344741||Latent phase|Participants admitted to the delivery room in the latent phase will be included.
61934263|NCT06344741||Active phase|Participants accepted to the delivery room in the active phase will be included.
61934264|NCT03048461|EXPERIMENTAL|Platelet Rich Plasma|Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart
61934265|NCT03048461|PLACEBO_COMPARATOR|Placebo (sterile saline)|Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart
61934266|NCT03589014|NO_INTERVENTION|Control|Standard Treatments recommended for CCM
61934267|NCT03589014|EXPERIMENTAL|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
61934268|NCT06710938|EXPERIMENTAL|Endovascular therapy used as treatment of TAAA|Traditional methods of treatment of TAAA include open surgery and hybrid surgery. Open surgery requires Thoracoabdominal incision which will result in a huge wound and the reconstruction of the visceral artery is also complicated. endovascular therapy has been developed for many years and has demonstrated significant advantages, such as small wounds, and fewer complications. Now Endovascular therapy is gradually used in the treatment of TAAA as well. Compared with traditional open surgery and hybrid surgery, the risk-benefit ratio of endovascular therapy is much better. When the risk-benefit gap between the investigational device and existing treatments is so wide that a control group is ethically unfeasible. So a single-arm exploratory study is adopted.
61934269|NCT04870281||CRT-DX System|
61934270|NCT01927341|EXPERIMENTAL|Phase Ib: Dose escalation|Phase Ib: Dose escalation.
61934271|NCT01927341|EXPERIMENTAL|Phase II: Patients with mutant RAS mCRC|Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
61934272|NCT01927341|EXPERIMENTAL|Phase II: Patients with acquired mutant RAS mCRC|Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.
61934273|NCT01927341|EXPERIMENTAL|Phase II: Patients with WT RAS mCRC (pretreated)|Patients with WT RAS mCRC who have been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
61934274|NCT01927341|EXPERIMENTAL|Phase II: Patients with WT RAS mCRC (not pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
61934275|NCT00678340|ACTIVE_COMPARATOR|1|WACA and PVI
61934276|NCT00678340|ACTIVE_COMPARATOR|2|PVAC
61934277|NCT02127723|EXPERIMENTAL|Macrolane|All subjects will receive hyaluronic acid injection (Macrolane VRF30)
61934278|NCT05132868|EXPERIMENTAL|pre-educated with educational video|"Participants will receive a message to view educational videos prior to their genetic counseling appointment if they are assigned to a pre-educated arm. The video will be shared with patients via MyHealth in the education tab in advance of the genetic counseling session"
61934279|NCT05132868|EXPERIMENTAL|pre-educated with pamphlet|Participants will receive a message to view a pamphlet prior to their genetic counseling appointment if they are assigned to a pre-educated arm. The pamphlet will be sent to patients who cannot access the video via regular mail in advance of the genetic counseling session
61934280|NCT05132868|OTHER|educated during the session|Participants will receive traditional genetic counseling. . After the genetic counseling session, they will fill out a validated survey called the Multi-dimensional Measure of Informed Choice (MMIC) that assesses attitudes, knowledge, and uptake of genetic testing
61934281|NCT04731961|ACTIVE_COMPARATOR|Controls|Subjects in this arm will be administered the standard injection site protocol (15 sites).
61934282|NCT04731961|EXPERIMENTAL|Experimental|Subjects in this arm will be administered the same amount of Botox in 5 injection sites.
61934283|NCT04789681|EXPERIMENTAL|Prevention (canakinumab)|Patients receive canakinumab SC on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
61934284|NCT06152731|OTHER|HRD tests|To determine HRD status on the tumor, 2 different tests will be used concomitantly
61934285|NCT06205381|EXPERIMENTAL|AV078|"In part A, a single ascending doses of AV078 oral solution will be investigated in separate cohorts. The starting dose will be 0.5 mg and ascending doses will be determined based on data from previous cohorts.~In Part B, multiple ascending doses of AV078 oral solution will be administered once daily for 14 days. Dose levels will be determined based on data from the single ascending dose study and previous cohorts in the multiple ascending dose study.~In Part C the effect of food (fasting or high calorie) on the pharmacokinetics of a single dose of AV078 will be investigated. The dose will be determined from Part A of the study."
61934286|NCT06205381|PLACEBO_COMPARATOR|Placebo|"In Part A, placebo oral solution (containing no active ingredient) will be administered once.~In Part B, placebo oral solution (containing no active ingredient) will be administered once daily for 14 days."
62327577|NCT05557890|EXPERIMENTAL|System Constellation VR-Seminar (exp. group)|By externalising significant elements, systemic constellations render the inner image someone has of a personally important social system in a visible and tangible way to get more clarity about psycho-social conflicts to make goal-oriented changes. In this study, the method System Constellation will be applied in a Virtual Reality (VR) setting during two to three day seminars.
62692995|NCT05541861|EXPERIMENTAL|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 30 µg - participants aged 18-55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg.~Cohort 4a. Two doses (at Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 30 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg"
62327578|NCT05557890|EXPERIMENTAL|System Constellation VR-Seminar (control group)|By externalising significant elements, systemic constellations render the inner image someone has of a personally important social system in a visible and tangible way to get more clarity about psycho-social conflicts to make goal-oriented changes. In this study, the method System Constellation will be applied in a Virtual Reality (VR) setting during two to three day seminars. Study participants randomized to this group receive the intervention (system constellations VR-seminar) 4 months after the experimental group.
62327579|NCT02930655|EXPERIMENTAL|Lucerastat group|Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks in addition to their standard of care treatment (enzyme replace therapy).
62485642|NCT06408168|EXPERIMENTAL|Cohort 1|Cohort 1 will include participants who have never received fulvestrant before. The first 15 participants enrolled in Cohort 1 will receive the study drug combination starting on Day 1 of their first treatment cycle. The next 14 participants enrolled in Cohort 1 will begin with fulvestrant alone for at least 12 days and then start repotrectinib sometime between Days 13 and 20 (depending on when their Cycle 1 biopsy is performed). This is done in order to use the biopsy results to study the effects of fulvestrant alone in these patients.
62485643|NCT06408168|EXPERIMENTAL|Cohort 2|About 6 months after the first 15 participants are enrolled, based on their study data, Cohort 2 will begin enrolling up to 29 participants who have received fulvestrant in earlier treatments. Participants in Cohort 2 will receive repotrectinib alone.
62485644|NCT01932021|EXPERIMENTAL|adipose tissue grafting|
62485645|NCT03332732|EXPERIMENTAL|Part 1A|In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..
62327580|NCT02930655|EXPERIMENTAL|Control group|Four subjects with Fabry Disease under enzyme replace therapy (ERT) as standard of care treatment were included as a control group.
62327581|NCT01596842|ACTIVE_COMPARATOR|Omega-3 fatty acid|
62327582|NCT01596842|PLACEBO_COMPARATOR|Olive oil|
62327583|NCT00678509|EXPERIMENTAL|A|
62692996|NCT05541861|EXPERIMENTAL|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 30 µg - participants aged >55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg.~Cohort 4b. Two doses (at Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 30 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg"
62692997|NCT05541861|ACTIVE_COMPARATOR|BNT612b2 Bivalent 30 µg - participants aged 18-55 years|Intramuscular injection at Day 1. Cohorts 1, 2 and 3a. BNT612b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg.
61934287|NCT06205381|OTHER|Itraconazole|In Part D, 200 mg itraconazole will be administered as an oral capsule once daily for 9 days, to investigate the effect of itraconazole on the pharmacokinetics of AV078.
61934288|NCT06205381|OTHER|Midazolam and fexofenadine|In Part E, 2.5 mg midazolam will be administered as an oromucosal solution and 120 mg fexofenadine will be administered as an oral tablet on day 1 and day 18, to investigate the effect of AV078 on the pharmacokinetics of midazolam and fexofenadine.
62133955|NCT01307085|EXPERIMENTAL|preconditioning|Adult patients undergoing elective pulmonary lobectomy were received a remote ischemic preconditioning group after induction of anaesthesia.
62133956|NCT01307085|NO_INTERVENTION|conventional|Adult patients undergoing pulmonary lobectomy were received no treatment after induction of anaesthesia.
62133957|NCT02515071|EXPERIMENTAL|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
62133958|NCT02515071|PLACEBO_COMPARATOR|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
62327584|NCT06290830|EXPERIMENTAL|Abdominal massage group|Abdominal massage is demonstrated by the researchers to a female student with functional constipation. The student will apply exfoliation (superficial and deep), petrissage, and vibration massage movements for about 15 minutes twice a day in the morning and evening hours and at least 30 minutes after the nutritional meal, 5 days a week, for a total of 12 weeks.
62327585|NCT06290830|EXPERIMENTAL|Kegel Exercises group|In this group students will perform Kegel exercises; 2 times a day in the morning and evening hours, 5 days a week, for a total of 12 weeks.
62327586|NCT06290830|EXPERIMENTAL|Both abdominal massage and kegel exercises to gether|students will perform both abdominal massage and kegel exercises to gether for a total of 12 weeks
62327587|NCT06290830|NO_INTERVENTION|Control group|No intervention
62327588|NCT05670964|EXPERIMENTAL|UPLUG Arm|Patients will have regular central veinous catheter and UPLUG device for their dialysis sessions.
62327589|NCT05670964|OTHER|Standard Of Care Arm|Patients will have regular central veinous catheter (standard of care) for their dialysis.
62327590|NCT02954003|EXPERIMENTAL|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
62327591|NCT05965739|ACTIVE_COMPARATOR|BrainHQ Active Comparator|5 sessions/week at 30 min/session
62485646|NCT03332732|EXPERIMENTAL|Part 1B|In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.
62327592|NCT05965739|EXPERIMENTAL|BrainHQ|5 sessions/week at 30 min/session
62327593|NCT05965739|EXPERIMENTAL|BrainHQ + PASC CoRE|BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session
62485647|NCT03332732|EXPERIMENTAL|Part 2 - 2A|Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022
62485648|NCT03332732|EXPERIMENTAL|Part 2 - 2B|Multiple dose administration of High Dose VNRX-5133 + VNRX-5022
62692998|NCT05541861|ACTIVE_COMPARATOR|BNT612b2 Bivalent 30 µg - participants aged >55 years|Intramuscular injection at Day 1. Cohort 3b. BNT612b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg.
62692999|NCT05541861|EXPERIMENTAL|BNT162b4 30 µg - participants aged 18-55 years|Intramuscular injection. Cohort 5. Two doses (at Day 1 and 2 months post-Dose 1
62693000|NCT06591728|OTHER|Oral PCA|
62693001|NCT04005326|EXPERIMENTAL|QLB Group|this group will receive ultrasound-guided transmuscular quadratus lumborum block; (Anterior QLB or QLB III)
61934289|NCT06560398|EXPERIMENTAL|Catchment Area Priority Zone (CAPZ) Intervention - Community Residents and Moffitt Patients|"Study interventions will be deployed in geographically defined intervention priority zones including Clinical Trial Education sessions and the ACT WONDER²S Phone-line/Email. Community residents in these zones may be exposed to these interventions.~Residents who are also new patients to Moffitt may be exposed to the CHOICES DA website once they are registered at Moffitt."
62693002|NCT04005326|EXPERIMENTAL|FIB Group|this group will receive suprainguinal fascia iliaca block
62693003|NCT04838652|EXPERIMENTAL|Pembrolizumab plus Chemotherapy|All patients will receive 1 dose of 200 mg pembrolizumab IV as single agent upfront, followed by 2 cycles of IV P-ICE (pembrolizumab, ifosfamide, carboplatin, etoposide) and a PET/CT-based restaging. Following a PET-guided treatment strategy, patients will then receive either another 2 cycles of IV P-ICE in case of a negative PET (i.e., Deauville score 1-3), or 2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin) in case of a positive PET (i.e., Deauville score \> 3). After completion of treatment with P-ICE or P-DHAP, respectively, patients will receive a consolidation therapy with pembrolizumab for another 6 cycles. In case of non-CR after at least 4 cycles of combination therapy (4x P-ICE or 2x P-ICE + 2x P-DHAP), physicians may decide to go for HDCT or an alternative standard of care treatment option.
62133959|NCT04987294|EXPERIMENTAL|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. ALLN-346 will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
62133960|NCT04987294|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules for oral administration. Placebo capsules will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
62327594|NCT05965739|EXPERIMENTAL|Brain HQ + tDCS-active|2.0 mA stimulation delivered for 30 min during each BrainHQ session
62327595|NCT05965739|PLACEBO_COMPARATOR|Brain HQ + tDCS-sham|Inactive stimulation delivered for 30 min during each BrainHQ session
62327596|NCT04498533|ACTIVE_COMPARATOR|B (brace) group|The patients in the B group were informed about the application of the forearm strap (counterforce brace). Patients were advised to wear the counterforce brace for three weeks continuously.
62327597|NCT04498533|ACTIVE_COMPARATOR|KT (kinesio tape) group|In the KT group, a standard 2-inch (5 cm) Kinesio®Tex tape (Kinesio Holding Corporation, Albuquerque, New Mexico, USA) was used with techniques of muscle inhibition and fascia correction. Kinesio tape was applied once a week for four weeks.
62327598|NCT06130696|EXPERIMENTAL|Clamshell exercise|Clamshell exercise
62327599|NCT06130696|ACTIVE_COMPARATOR|strengthening exercises with clamshell exercise|Isometric and muscle strengthening exercises with clamshell exercise.
62327600|NCT02531035|PLACEBO_COMPARATOR|Placebo|Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
62327601|NCT02531035|EXPERIMENTAL|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
62327602|NCT05529706|EXPERIMENTAL|Brain Health Program|A multimodal educational and interactive diet, exercise and computerized cognitive exercise public health program.
62327603|NCT02549911|EXPERIMENTAL|HIPEC,Chemotherapy AND surgery|"1. surgical exploration,if PCI\<20,then we perform this study~2. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. chemotherapy(3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~4. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~5. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
62327604|NCT03885726|ACTIVE_COMPARATOR|Treatment as Usual|
62327605|NCT03885726|EXPERIMENTAL|High Velocity Nasal Insufflation|
62693004|NCT06640647|EXPERIMENTAL|HDM1005 injection 0.1mg|HDM1005 injection or placebo 0.1mg once subcutaneous injection
61934290|NCT06560398|ACTIVE_COMPARATOR|Catchment Area Priority Zone (CAPZ) Control - Community Residents and Moffitt Patients|Study interventions will not be deployed in the control priority zones. Community residents in these zones are unlikely to be exposed to any of the study interventions.
61934291|NCT06560398|EXPERIMENTAL|Catchment Area Priority Zone (CAPZ) Intervention - Community Physicians|Study interventions will be deployed in geographically defined intervention priority zones including Continuing Medical Education events, the Trial Connect Portal, and Clinical Trial Newsletters. Community physicians in these zones may be exposed to these interventions.
62327606|NCT04152525|EXPERIMENTAL|experimental group|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
62327607|NCT04152525|NO_INTERVENTION|control group|Routine care
62327608|NCT01864759|EXPERIMENTAL|ICOVIR5|ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.
62485649|NCT03332732|PLACEBO_COMPARATOR|Part 2 - 2C|Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)
62693005|NCT06640647|EXPERIMENTAL|HDM1005 injection 0.25mg|HDM1005 injection or placebo 0.25mg once subcutaneous injection
62693006|NCT06640647|EXPERIMENTAL|HDM1005 injection 0.5mg|HDM1005 injection or placebo 0.5mg once subcutaneous injection
62693007|NCT06640647|EXPERIMENTAL|HDM1005 injection 1.0mg|HDM1005 injection or placebo 1.0mg once subcutaneous injection
62693008|NCT06640647|EXPERIMENTAL|HDM1005 injection 2.5mg|HDM1005 injection or placebo 2.5mg once subcutaneous injection
61934292|NCT06560398|ACTIVE_COMPARATOR|Catchment Area Priority Zone (CAPZ) Control- Community Physicians|Study interventions will not be deployed in the control priority zones. Community physicians in these zones are unlikely to be exposed to any of the study interventions.
61934293|NCT06560398|EXPERIMENTAL|Cancer Center Clinical Research Coordinators (CRCs)|CRCs that work on therapeutic clinical trials at Moffitt will have access to the implicit bias educational module and digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal and Recruitment Dashboard.
62327609|NCT01537770|ACTIVE_COMPARATOR|Vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
62327610|NCT01537770|SHAM_COMPARATOR|lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
62693009|NCT06640647|EXPERIMENTAL|HDM1005 injection 5.0mg|HDM1005 injection or placebo 5.0mg once subcutaneous injection
62327611|NCT02759146|EXPERIMENTAL|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
62327612|NCT02759146|EXPERIMENTAL|Meditative Practice|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
62327613|NCT02759146|NO_INTERVENTION|Control|Control - no intervention
62327614|NCT03488472|EXPERIMENTAL|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
62327615|NCT01593683|EXPERIMENTAL|Psychological education program|Patients receive the psychological education program upon study enrollment.
62327616|NCT01593683|NO_INTERVENTION|Waitlist|Participants are assigned to a 16-week wait-list period upon enrollment. Participants are invited to receive the psychological education program following the waitlist period.
62327617|NCT05522335|ACTIVE_COMPARATOR|BBV154 Lot-1|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
62327618|NCT05522335|ACTIVE_COMPARATOR|BBV154 Lot-2|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
62693010|NCT06640647|EXPERIMENTAL|HDM1005 injection 10.0 mg|HDM1005 injection or placebo 10.0mg once subcutaneous injection
61934294|NCT06560398|EXPERIMENTAL|Cancer Center Physicians|Physicians at Moffitt will have access to the implicit bias educational module and to digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal, Recruitment Dashboard, Portfolio Profiler, and the Eligibility Criteria Calculator.
61934295|NCT06070012|EXPERIMENTAL|Tebentafusp (IMCgp100)|"Dose: 20mcg W1D; 30mcg W2D1; 68mcg W3D1and subsequent doses~Frequency: Weekly on D1 of 12-week cycles"
62133961|NCT00933712|EXPERIMENTAL|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
62327619|NCT05522335|ACTIVE_COMPARATOR|BBV154 Lot-3|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
62327620|NCT05522335|ACTIVE_COMPARATOR|COVAXIN®|Immunogenicity Group :In this group, 160 participants will be recruited, receive Covaxin vaccine (0.5 mL each dose) on day 0 and day 28 via intramuscular route and assess for the Immunogenicity.
62327621|NCT05921006|EXPERIMENTAL|RJ4287 Tablets|single-dose or Multiple-doses, ascending dosing groups (cohorts) will be evaluated
62327622|NCT05921006|PLACEBO_COMPARATOR|Placebo|Single or multiple doses of Placebo
62327623|NCT02072317|EXPERIMENTAL|Paclitaxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
62327624|NCT02072317|ACTIVE_COMPARATOR|taxol|taxol 135 mg/m2, every three weeks for a cycle
62327625|NCT01028651||Portopulmonary hypertension|
62327626|NCT05723549|EXPERIMENTAL|group1|Period1 : HCP1803-3
62327627|NCT05723549|ACTIVE_COMPARATOR|group2|Period1 : RLD2002, HCP1904-1
62693011|NCT04519567|EXPERIMENTAL|CTI-1601|
61934296|NCT01825603|EXPERIMENTAL|Treatment (ADH-1, cisplatin, gemcitabine hydrochloride)|Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride.
62133962|NCT03449173|EXPERIMENTAL|Sunitinib|Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
62133963|NCT06520306|EXPERIMENTAL|Dilute 0.25% ropivacaine + 20 mg methylene blue to 30 ml|
62133964|NCT06520306|EXPERIMENTAL|0.25% ropivacaine + 40 mg methylene blue diluted to 30 ml|
62133965|NCT06520306|NO_INTERVENTION|0.25% ropivacaine 30 ml|
62133966|NCT02596919|OTHER|No arms|No randomisation therefore no arms. All patients will receive the same research treatment.
62327628|NCT01507610|EXPERIMENTAL|Investigational|OPTINOSE SUMATRIPTAN, single dose of 20 mg intranasally (10 mg to each nostril).
62693012|NCT04519567|PLACEBO_COMPARATOR|Placebo|
62693013|NCT06615219|EXPERIMENTAL|Intergroup contact training + Regular course training|In addition to the regular curriculum, the experimental group of nursing students were required to receive the intervention program developed by this study.
62133967|NCT03971851||Low frailty|Frailty risk score less than 5
62485650|NCT04022122||Heart Failure patients|The study does not imply any specific therapeutic intervention, and will not imply any change in the management of the participating patients, who will follow the usual clinical controls and will receive the medical and invasive treatments usually provided to patients with HF in our health area; as well as the different modalities of specific health education for this disease. At the time of hospital discharge, patients will be handled according to the usual protocols of the center established for outpatient follow-up of HF patients.
62133968|NCT03971851||Intermediate Frailty|Frailty risk score 5-15
62133969|NCT03971851||High frailty|Frailty risk score 15 and above
62133970|NCT04929106|EXPERIMENTAL|MHealth intervention|Tailored physical activity program with motivational mobile health support on everyday levels of physical activity
62133971|NCT02448576|EXPERIMENTAL|PCI group|Receiving prophylactic cranial irradiation after response to first line chemotherapy.
62133972|NCT02448576|NO_INTERVENTION|observation group|Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.
62327629|NCT01507610|ACTIVE_COMPARATOR|IMITREX Nasal Spray|IMITREX® (sumatriptan) Nasal Spray, single dose of 20 mg intranasally (20 mg to one nostril).
62327630|NCT01507610|ACTIVE_COMPARATOR|IMITREX Oral Tablet|IMITREX® (sumatriptan) Oral Tablet, single dose of 100 mg, administered orally with 240 mL water.
62693014|NCT06615219|ACTIVE_COMPARATOR|Regular course training only|Nursing undergraduates in the control group received regular course teaching and practical activities, including geriatric nursing, daily courses and community activities.
62327631|NCT01507610|ACTIVE_COMPARATOR|IMITREX Subcutaneous Injection|IMITREX® (sumatriptan) Subcutaneous Injection, single dose of 6 mg injected subcutaneously in the abdomen.
62327632|NCT04933305||RYGB patients|Patients that already received RYGB one year prior commencement of their participation in the study
62327633|NCT01401816|EXPERIMENTAL|Intervention Group|Subjects in this group will receive a prescription for emergency contraception and then text-messages (on Day 1, 3 and 5 after enrollment) to their personal cell phone with a reminder to fill their prescription.
62327634|NCT01401816|NO_INTERVENTION|Control Group|Subjects in this group will receive a only a prescription for emergency contraception and no reminder text messages.
62327635|NCT05920187|ACTIVE_COMPARATOR|Mediterranean diet group|following dietary intervention based on Mediterranean diet
62693015|NCT00959049|EXPERIMENTAL|Afluria Cohort A|Age 6 months to \< 3 years
62327636|NCT05920187|ACTIVE_COMPARATOR|Anti-inflammatory diet group|following dietary intervention based on IBD-Anti-inflammatory diet.
62327637|NCT05920187|NO_INTERVENTION|control group|Patients of the control group will not be instructed to follow a specific dietary intervention.
62327638|NCT05891249|EXPERIMENTAL|Luspatercept|
62327639|NCT02938065|OTHER|2% Milk|16 participants will drink 10 ounces of 2% milk Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
62693016|NCT00959049|EXPERIMENTAL|Afluria Cohort B|Age 3 to \< 9 years
62693017|NCT00959049|EXPERIMENTAL|Afluria Cohort C|Age 9 to \< 18 years
62327640|NCT02938065|OTHER|Apple Juice|16 participants will drink 10 ounces of apple juice Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
62485651|NCT01461785|EXPERIMENTAL|GROUP A: PRP +|Group A (16 subjects) will receive lipofilling enriched with 3 ml of autologous PRP ( Platelet rich plasma) with lipofilling
62693018|NCT00959049|ACTIVE_COMPARATOR|Fluzone Cohort A|Age 6 months to \< 3 years
62693019|NCT00959049|ACTIVE_COMPARATOR|Fluzone Cohort B|Age 3 to \< 9 years
61934297|NCT04268550|EXPERIMENTAL|Treatment (selpercatinib)|Patients receive selpercatinib orally PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61934298|NCT05527405|EXPERIMENTAL|Caregiver Training Program|This condition will involve the implementation of an assistive technology software (named the MapHabit System) with an added Caregiver Training Program into the daily care of individuals with mild to moderate stages of Alzheimer's disease and related dementias. The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.
61934299|NCT05527405|ACTIVE_COMPARATOR|The MapHabit System|This control condition will act as the active comparator to the experimental condition. The same assistive technology, the MapHabit System, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include the caregiver training program.
61934300|NCT04326075|EXPERIMENTAL|Early CPAP treatment|Early treatment with CPAP in addition to current clinical practice
61934301|NCT04326075|NO_INTERVENTION|Control|Current clinical practice, which currently does not involve the use of CPAP.
61934302|NCT06707558||Patients from emergency department undergoing peripheral nerve blockade (PNB)|Patients admitted to the emergency department with ≤2 trauma fractures who undergo peripheral nerve blockade (PNB) will be enrolled
61934303|NCT02138422|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously every 2 weeks
61934304|NCT02138422|ACTIVE_COMPARATOR|Xilonix|Xilonix administered intravenously every 2 weeks
61934305|NCT06123663|EXPERIMENTAL|Tetanus Vaccine, Adsorbed (TTVA)|1 dose of (TTVA) (0.5ml)
62133973|NCT06499766|ACTIVE_COMPARATOR|Nature-based exposure by biodiversity component in lotion.|Biodiversity component is highly diverse microbial extract mimicking Finnish forest soil biodiversity. Component is added to the common moisturizer on the Finnish market.
62133974|NCT06499766|PLACEBO_COMPARATOR|Placebo by coloring component in lotion.|Coloring ingredient is safe, biochemically non-active component which purpose is to make the placebo lotion looking same as the biodiversity lotion in other arm. Component is added to the common moisturizer on the Finnish market (same as in the other arm).
62133975|NCT00995696|EXPERIMENTAL|PhaST|Group receiving PhaST IVR phone calls.
62133976|NCT00995696|NO_INTERVENTION|Usual Care|Group NOT receiving IVR phone calls.
62133977|NCT02088372||Vanguard with E1 PS Bearing|"E1™ Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty.~Vanguard Total Knee System™ The Vanguard™ Knee System was designed to incorporate features from prior designs, including: ACG, Maxim, \& Ascent."
62327641|NCT02938065|OTHER|Ensure Clear|16 participants will drink 10 ounces of ensure clear Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
62327642|NCT02332356|ACTIVE_COMPARATOR|step up|Procedure: MREC patients receive therapeutic step up
62327643|NCT02332356|NO_INTERVENTION|observation step up|
62327644|NCT02332356|ACTIVE_COMPARATOR|step down|Procedure: MREC patients receive therapeutic step down
62327645|NCT02332356|NO_INTERVENTION|observation step down|
62485652|NCT01461785|PLACEBO_COMPARATOR|GROUP B: PRP -|Group B ( 16 subjects) will receive lipofilling without addition PRP. 27 ml blood will be drawn from the patient, but will be discarded, and not turned into PRP.
62485653|NCT05668650|ACTIVE_COMPARATOR|Medical Reference Product|"Keytruda® will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first.~Those subjects with clinical benefit from treatment (CR, PR, and SD) as per the investigator's discretion, will be allowed to continue receiving treatment with MB12/Keytruda® in the Extended Study Period, according to the arm initially assigned, every 3 weeks, for a maximum of 52 weeks from the first infusion or until evidence of disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first."
62693020|NCT00959049|ACTIVE_COMPARATOR|Fluzone Cohort C|Age 9 to \< 18 years
62693021|NCT05657171||PCOS +GINGIVITIS|FEMALE PATIENTS WITH PCOS AND GINGIVITIS ON CPA/EE DRUG REGIMEN
62693022|NCT05634343|EXPERIMENTAL|experimental group 1|The laughter therapy program consists of 16 sessions, twice a week for eight weeks. Each session; It is planned to last 30-45 minutes with a maximum of 25 nurses.
61934306|NCT06123663|ACTIVE_COMPARATOR|Tetanus Vaccine, Adsorbed (TT)|1 dose of (TT) (0.5ml)
61934307|NCT06707259|EXPERIMENTAL|CB IL-10-CD19-CAR NK|All subjects were intravenously administrated with IL-10-CD19-CAR NK
61934308|NCT02237911|EXPERIMENTAL|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
61934309|NCT02237911|ACTIVE_COMPARATOR|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
62133978|NCT02746549|EXPERIMENTAL|1.5 Tesla MRI|Measurement of renal perfusion by 1.5 Tesla MRI with arterial spin labelling
62133979|NCT02746549|EXPERIMENTAL|3.0 Tesla MRI|Measurement of renal perfusion by 3.0 Tesla MRI with arterial spin labelling
62133980|NCT01823536|EXPERIMENTAL|MenACWY-CRM (≥7-≤10 years of age)|Subjects, who had previously received 2 injections of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
62693023|NCT05634343|EXPERIMENTAL|experimental group 2|The mindfulness practice program consists of 16 sessions, twice a week for eight weeks. Each session is planned to last 45-60 minutes with a maximum of 25 nurses.
62693024|NCT05634343|NO_INTERVENTION|Control Group|No intervention was made in the control group.
61934310|NCT02237911|NO_INTERVENTION|Wait-listed usual medical care|Wait-listed usual medical care - no intervention provided by study.
61934311|NCT04169100|EXPERIMENTAL|Prednisone Group|These patients have CTD and QTc over 500 msec. Prednisone is administered as a preventative measure against arrhythmia via QTc shortening.
61934312|NCT03190369|PLACEBO_COMPARATOR|Placebo|Participants received a single IA injection of phosphate buffered saline on Day 1 and were observed for 26 weeks.
61934313|NCT03190369|EXPERIMENTAL|Hylan G-F 20|Participants received a single IA injection of 6 mL Hylan G-F 20 (Synvisc-One) on Day 1 and were observed for 26 weeks.
61934314|NCT06500273|EXPERIMENTAL|cemacabtagene ansegedleucel, ALLO-647|Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine, cyclophosphamide, and ALLO-647.
61934315|NCT06500273|EXPERIMENTAL|cemacabtagene ansegedleucel|Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide.
61934316|NCT06500273|OTHER|Observation|Participants do not receive any study treatments. They are observed as per the current standard of care.
62133981|NCT01823536|EXPERIMENTAL|MenACWY-CRM_1 (≥7-≤10 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
62485654|NCT05668650|EXPERIMENTAL|Investigational Product|"MB12 will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first.~Those subjects with clinical benefit from treatment (CR, PR, and SD) as per the investigator's discretion, will be allowed to continue receiving treatment with MB12/Keytruda® in the Extended Study Period, according to the arm initially assigned, every 3 weeks, for a maximum of 52 weeks from the first infusion or until evidence of disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first."
62693025|NCT03181984|EXPERIMENTAL|Hemoporfin|
62693026|NCT05377723|EXPERIMENTAL|Neodyne Device|After eligible patients have provided informed consent, the side of the abdomen to be treated with the Neodyne Device will be randomly selected by opening a sealed randomization envelope. The selected side will be treated with the Neodyne Device through the full study. The Neodyne Device will be applied to a portion of the abdominal incision by the health care provider at 1 week (4-8 days) after the procedure. The other portion of the abdominal incision (Arm Title: Control) will serve as the control and will be treated per the investigator's standard of care. Subjects will return to the Investigator's office for a total of 8 weeks for application and removal of the Neodyne Dressing.
62693027|NCT05377723|OTHER|Control|See above
62693028|NCT06499376||PATIENTS ADMITTED IN THE HOSPITAL IN 2019|"Inclusion criteria: patients over 18 years of age hospitalised on conventional hospital wards, in medical and surgical departments or awaiting a bed during their stay in the emergency department.~Exclusion criteria: patients with poor vital prognosis and DNR orders."
62693029|NCT06499376||PATIENTS ADMITTED IN THE HOSPITAL IN 2021|"Inclusion criteria: patients over 18 years of age hospitalised on conventional hospital wards, in medical and surgical departments or awaiting a bed during their stay in the emergency department.~Exclusion criteria: patients with poor vital prognosis and DNR orders."
62693030|NCT02407938|EXPERIMENTAL|rice meal|High resolution manometry will be performed. Esophageal function will be tested using liquid swallows, solid swallows and a test meal (200g rice)
61934317|NCT05420727|EXPERIMENTAL|Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1|Positive Ga-68-PSMA-11 PET/CT prior to two cycles of Lu-177-ITG-PSMA-1 i scheduled six weeks apart.
61934318|NCT03095443|EXPERIMENTAL|Personalized Music|Receives personalized playlist twice a day.
61934319|NCT03095443|ACTIVE_COMPARATOR|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
61934320|NCT03095443|ACTIVE_COMPARATOR|Attention Control|Receives audio-book twice a day.
61934321|NCT05760105||Ankylosing Spondylitis Patients|Patients diagnosed with ankylosing spondylitis.
61934322|NCT02889692|EXPERIMENTAL|TCM granules plus EGFR-TKIs|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day，until progression or unacceptable toxicity."
61934323|NCT02889692|PLACEBO_COMPARATOR|Placebo granules plus EGFR-TKIs|Placebo granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day until progression or unacceptable toxicity.
61934324|NCT06656975|OTHER|Enhanced Usual Care control group|"Participants will receive an informational booklet on improving loneliness and may initiate or continue Collaborative Care for other conditions on a not research basis.~Besides the baseline survey participants will also take 2 more surveys, 3-months and 6-months from the first survey. Those surveys will ask similar questions and will take about 45 minutes to complete. These can be done online or over the phone with a researcher that will not know the treatment arm assignment."
61934325|NCT06656975|EXPERIMENTAL|Brief Cognitive Therapy then Social Prescribing|Besides the baseline survey participants will also take 2 more surveys, 3-months and 6-months from the first survey. Those surveys will ask similar questions and will take about 45 minutes to complete. These can be done online or over the phone with a researcher that will not know the treatment arm assignment.
61934326|NCT06656975|EXPERIMENTAL|Social Prescribing then Brief Cognitive Therapy|Besides the baseline survey participants will also take 2 more surveys, 3-months and 6-months from the first survey. Those surveys will ask similar questions and will take about 45 minutes to complete. These can be done online or over the phone with a researcher that will not know the treatment arm assignment.
61934327|NCT02344615|ACTIVE_COMPARATOR|NS-guided infraclavicular block|NS-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
61934328|NCT02344615|EXPERIMENTAL|US-guided infraclavicular block|US-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
61934329|NCT06134375|EXPERIMENTAL|TM and Capecitabine with or without Pembrolizumab|Tetrathiomolybdate (TM) and Capecitabine +/- Pembrolizumab will be administered concurrently for 6 months, TM will continue for 2.5 more years (total duration of TM treatment is 3 years)
61934330|NCT06134375|ACTIVE_COMPARATOR|Capecitabine with or without Pembrolizumab|Capecitabine +/- Pembrolizumab will be administered for 6 months (participants will remain on study for 2.5 more years).
61934331|NCT02499978|EXPERIMENTAL|DRV/COBI, DTG Immediate switch|DARUNAVIR/COBICISTAT (800mg/150MG), DOLUTEGRAVIR 50MG DAILY at randomization and follow through week 48.
61934332|NCT02499978|ACTIVE_COMPARATOR|DRV/COBI, DTG Delayed Switch|DARUNAVIR/COBICISTAT (800MG150MG), DOLUTEGRAVIR 50MG DAILY at week 24 and follow through week 48.
61934333|NCT05599269|OTHER|Examination of dentures with SR Phonares II teeth|
61934334|NCT01654627|EXPERIMENTAL|Regenecure AMCA GBR Dental membrane|16 patients will undergo the guided bone regeneration procedure using the Regenecure AMCA Membrane
61934335|NCT01654627|ACTIVE_COMPARATOR|Collagen membrane|16 patients will undergo the guided bone regeneration procedure using a commercially available collagen membrane
61934336|NCT01606644|EXPERIMENTAL|HBO|30 90-minute hyperbaric oxygen sessions at 2.4 atm.
61934337|NCT01606644|NO_INTERVENTION|No HBO|No intervention. No hyperbaric oxygen is administered. Otherwise, the patient will follow the examination program.
61934338|NCT05041946|EXPERIMENTAL|Methylphenidate|treatment of attention deficit disorder and narcolepsy (sleep disorder)
61934339|NCT05041946|EXPERIMENTAL|Placebo|Sugar pill
61934340|NCT00074438|EXPERIMENTAL|1|
62485655|NCT04309773|EXPERIMENTAL|Bezafibrate in addition to standard UDCA therapy|"Bezafibrate (400mg) in addition to standard 15-20 mg/kg/day UDCA therapy (experimental arm)"
62485656|NCT04309773|PLACEBO_COMPARATOR|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate in addition to standard 15-20 mg/kg/day UDCA therapy
61934341|NCT00074438|EXPERIMENTAL|2|
61934342|NCT00074438|EXPERIMENTAL|3|
61934343|NCT00074438|EXPERIMENTAL|4|
61934344|NCT00074438|EXPERIMENTAL|5|
61934345|NCT00074438|EXPERIMENTAL|6|
61934346|NCT00074438|PLACEBO_COMPARATOR|7|
61934347|NCT00074438|PLACEBO_COMPARATOR|8|
62485657|NCT06618092|EXPERIMENTAL|Intervention|Relisten
62693031|NCT06353841|EXPERIMENTAL|Intervention Group|Therapeutic Touch will be applied to infants for three consecutive days, once a day, ten minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of three times in one week.
62693032|NCT06353841|NO_INTERVENTION|Control group|The therapeutic touch will not be applied to the control group infants.
61934348|NCT00074438|PLACEBO_COMPARATOR|9|
62485658|NCT06618092|NO_INTERVENTION|Control|Usual care
62485659|NCT06415760||Obstetric Patients|Adult pregnant women in their third trimester of prenancy with no prenatal risk factors and an uncomplicated pregnancy.
62485660|NCT03665194|EXPERIMENTAL|Cortexolone 17α-propionate 7.5% solution|
62485661|NCT03665194|PLACEBO_COMPARATOR|Vehicle solution|
62485662|NCT05850676||Idiopathic Hypersomnia|Men and women with a current diagnosis of Idiopathic Hypersomnia
62485663|NCT05850676||Hypersomnia Associated with a Psychiatric Disorder|Men and women with a current diagnosis of Hypersomnia Associated with a Psychiatric Disorder
61934349|NCT05907291|EXPERIMENTAL|Sequential Dose|Sequential, open-label, 12-week fixed-dose cohorts.
61934350|NCT01479504|EXPERIMENTAL|1A(nedaplatin and IMRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)
61934351|NCT01479504|ACTIVE_COMPARATOR|1B(cisplatin and IMRT)|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)
61934352|NCT01479504|EXPERIMENTAL|2A(nedaplatin and CRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)
61934353|NCT01479504|ACTIVE_COMPARATOR|2B((cisplatin and CRT))|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)
61934354|NCT04007211|EXPERIMENTAL|ABT13107|
61934355|NCT04007211|ACTIVE_COMPARATOR|Hyalobarrier|
61934356|NCT05432141|EXPERIMENTAL|Primary immunization group|A total of 2000 infants aged 2-3 months will randomly assigned to two groups according to 1:1 using scratch cards: 1000 infants in the sIPV vaccine group and 1000 infants in the sIPV vaccine group plus DTaP vaccine group
61934357|NCT05432141|EXPERIMENTAL|Booster immunization group of sIPV vaccine|A total of 1200 children aged 18 months will randomly assigned to four groups according to 2:2:1:1 using scratch cards: 400 in the sIPV booster group, 400 in the sIPV booster group plus inactivated hepatitis A vaccine simultaneously, 200 in the sIPV booster group plus MMR simultaneously, and 200 in the sIPV booster group plus attenuated hepatitis A vaccine.
61934358|NCT01093638|EXPERIMENTAL|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with premature infant formula
61934359|NCT01093638|PLACEBO_COMPARATOR|Oral Formulation of Placebo|Oral formulation of placebo fed concomitantly with premature infant formula
61934360|NCT04170842|EXPERIMENTAL|Music intervention|"The music intervention used in the study will be a patient selected list of songs or other music delivered to the participant by passive listening via in-ear or on-ear headphones. They will be given the choice of using their own personal headphones or use a pair provided by the hospital. If choosing to use a hospital device, the earphones provided will be disposable to minimise infection risk from re-use.~Patient preferred music has shown to be more effective than preselected, or prescriptive music. Prescriptive music, if not of the patient's preference, could cause further discomfort, distress or anxiety. Therefore, investigators will use streaming services to provide a bank of music containing a wide range of music and genres to suit the majority of music preferences. Music will also be curated based on feedback from age-appropriate sources to identify common and popular music in the target participant age group."
61934361|NCT04170842|NO_INTERVENTION|Control|Wound dressing procedure conducted according to clinical practice
61934362|NCT01121731|EXPERIMENTAL|Interferon α-5|
61934363|NCT01121731|EXPERIMENTAL|Interferon α-5 plus Interferon α-2b|
61934364|NCT01121731|ACTIVE_COMPARATOR|Interferon α-2b (INTRON® A)|
62327646|NCT03158688|ACTIVE_COMPARATOR|Kd - Carfilzomib and Dexamethasone|"Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles."
62485664|NCT01933282|EXPERIMENTAL|MESA chemotherapy|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
62485665|NCT04352062|EXPERIMENTAL|Treatment Group|Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
62485666|NCT04352062|PLACEBO_COMPARATOR|Placebo|1 tablet twice daily (period 6 months)
62485667|NCT04352062|OTHER|Helicobacter pylori infected group|Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
62485668|NCT02028221|PLACEBO_COMPARATOR|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
62485669|NCT02028221|EXPERIMENTAL|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the remaining duration of he intervention period.
62485670|NCT04515719|EXPERIMENTAL|Belimumab 2mg/kg|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Belimumab 2mg/kg is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
62485671|NCT04515719|PLACEBO_COMPARATOR|Placebo|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Placebo (normal saline) is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
62485672|NCT01398085|ACTIVE_COMPARATOR|Radioactive iodine (RAI) ablation Arm|Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq
62485673|NCT01398085|NO_INTERVENTION|No Radioactive iodine (No-RAI) ablation|Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation
62485674|NCT02180321|ACTIVE_COMPARATOR|Control|
62485675|NCT02180321|EXPERIMENTAL|Tranexamic acid|
62485676|NCT05196347|EXPERIMENTAL|dapagliflozin + integrated CKD care program|"Subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.~In both arms, the integrated CKD care program includes CKD stage 4 and 5 education, diet counseling, bioimpedance and echocardiography measurements to control overhydration at 0-1 liter (by body composition monitor (BCM; Fresenius))"
62485677|NCT05196347|ACTIVE_COMPARATOR|integrated CKD care program|In both arms, the integrated CKD care program includes CKD stage 4 and 5 education, diet counseling, bioimpedance and echocardiography measurements to control overhydration at 0-1 liter (by body composition monitor (BCM; Fresenius))
62485678|NCT02640235|EXPERIMENTAL|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
62485679|NCT02640235|ACTIVE_COMPARATOR|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
62485680|NCT02099227||Ultrasound|those who received point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
62485681|NCT02099227||No Ultrasound|those who did not receive point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
62693033|NCT05036330||Observational (evaluation, examination, questionnaire)|Patients undergo speech and swallow evaluation by speech pathologist or study staff member and examination of TEP and laryngectomy stoma. Patients also complete questionnaires over 30 minutes about use the ProvoxLife HME system, symptoms, ability to communicate, exercise and physical activity levels, and quality of life at baseline and 3 months post-ProvoxLife.
62693034|NCT06001008||General or regional anesthesia|Patients who have undergone inguinal or umbilical hernia surgery
62133982|NCT01823536|EXPERIMENTAL|Vaccine naive (≥7-≤10 years of age)|Vaccine naive subjects, age-matched to the ≥7-≤10 years of age groups, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
62485682|NCT06627621|OTHER|Alveolar bone grafting|Scaffold guided bone regeneration
62693035|NCT04034927|ACTIVE_COMPARATOR|Arm I (olaparib)|Patients receive olaparib PO BID in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
62485683|NCT05705869|NO_INTERVENTION|Routine care arm|Patients in this arm will undergo routine diabetes care. They will be managed and followed up as per routine clinical care. They will be remotely monitored for heart failure events electronically. Quality of life questionnaires (Kansas City Cardiomyopathy Questionnaire-12 and EQ-5D) will be collected.
62693036|NCT04034927|EXPERIMENTAL|Arm II (olaparib, tremelimumab)|Patients receive olaparib as in Arm I. Patients also receive tremelimumab IV over 60 minutes on day 1. Cycles of tremelimumab repeat every 4 weeks for 4 doses and then every 12 weeks for up to 2 years total in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
62693037|NCT02014103|ACTIVE_COMPARATOR|Sequence 1|"Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation Sandoz, Panacea, Accord, Mylan, Dr. Reddy's, Astellas~Patients will be receiving the same tacrolimus dose identified at baseline for each formulation."
62485684|NCT05705869|EXPERIMENTAL|Investigational arm|"Patients in this arm will have a blood sample taken to measure N-terminal prohormone of B-type natriuretic peptide (NT-proBNP).~In addition to this, routine blood samples, an ECG, body measurements, patient reported outcomes and observations will be recorded.~Further blood and urine samples will be collected and stored within Glasgow University storage facilities for future measurement of relevant biomarkers and for use in future ethically approved research.~Patients with an elevated NT-proBNP (≥125 pg/mL) will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Patients will then also undergo a handheld echocardiogram with a CE-marked handheld point of care EchoNous Kosmos echocardiogram device.~Patients who are classified as having heart failure (HFrEF, HFmrEF, or HFpEF) will be managed according to the latest version of European Society of Cardiology guidelines."
62485685|NCT03007563|EXPERIMENTAL|newborn infants checked for jaundice|an experimental way of bilirubin concentration estimation from smartphone pictures is applied and compared with two standard methods: bilirubin concentration measured in standard blood samples, and bilirubin concentration measured by transcutaneous device.
62485686|NCT03431961|PLACEBO_COMPARATOR|Placebo|0.9% normal saline administered twice daily for 14 days
62485687|NCT03431961|EXPERIMENTAL|Intranasal Corticosteroid|Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days
62485688|NCT00549484||1|10 mL/kg platelet transfusion
62485689|NCT00549484||2|15 mL / kg platelet transfusion
62327647|NCT03158688|EXPERIMENTAL|KdD - Carfilzomib, Dexamethasone and Daratumumab|"Carfilzomib was administered intravenously (IV) at 20 mg/m\^2 in Cycle 1: days 1 and 2; at 56 mg/m\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.~Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only."
62485690|NCT05845723|EXPERIMENTAL|Tocilizumab+GCS for VBS|Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
62693038|NCT02014103|ACTIVE_COMPARATOR|Sequence 2|"Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation Accord, Sandoz, Dr. Reddy's, Panacea, Astellas, Mylan~Patients will be receiving the same tacrolimus dose identified at baseline for each formulation."
61934365|NCT06701318||Parkinson's patients group|Parkinson's disease diagnosed patients who meet the eligibility criteria and not complain of other neurological or musculoskeletal diseases that can affect muscle stiffness.
62133983|NCT01823536|EXPERIMENTAL|MenACWY-CRM_1 (≥11-≤15 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 7-10 years of age, were administered 1 injection of the same vaccine at 11-15 years of age.
62133984|NCT01823536|EXPERIMENTAL|Vaccine naive (≥11-≤15 years of age)|Vaccine naive subjects, age-matched to the ≥11-≤15 years of age group, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
62133985|NCT04302142|EXPERIMENTAL|Intervention group|
62133986|NCT04302142|PLACEBO_COMPARATOR|Control Group|
62327648|NCT05083156||Milk Elimination|cohort will be observed for treatment response to elimination of cow's milk
62485691|NCT05845723|EXPERIMENTAL|Tofacitinib+GCS for VBS|Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with oral tofacitinib 5mg twice a day for 24 weeks of treatment.
62485692|NCT05845723|EXPERIMENTAL|Cyclophosphamide+GCS for VBS|Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
62485693|NCT02313558|EXPERIMENTAL|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
62485694|NCT02313558|PLACEBO_COMPARATOR|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
62485695|NCT03849547|EXPERIMENTAL|App training group|Subjects in App training group will receive App Balance training via smartphone application.
62485696|NCT03849547|ACTIVE_COMPARATOR|Home training group|Subjects in Home training group will receive Home Balance training advised by physical therapist.
62485697|NCT03849547|NO_INTERVENTION|Control group|Control group will receive only education of ankle injury prevention related information.
62693039|NCT02014103|ACTIVE_COMPARATOR|Sequence 3|"Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation Dr. Reddys, Accord, Astellas, Sandoz, Mylan, Panacea~Patients will be receiving the same tacrolimus dose identified at baseline for each formulation."
62693040|NCT02014103|ACTIVE_COMPARATOR|Sequence 4|"Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 4: Formulation Astellas, Dr. Reddy's, Mylan, Accord, Panacea, Sandoz~Patients will be receiving the same tacrolimus dose identified at baseline for each formulation."
62693041|NCT02014103|ACTIVE_COMPARATOR|Sequence 5|"Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 5: Formulation Mylan, Astellas, Panacea, Dr. Reddy's, Sandoz, Accord~Patients will be receiving the same tacrolimus dose identified at baseline for each formulation."
61934366|NCT06701318||Healthy non Parkinson's group|Healthy age matched individuals who do not meet the criteria of Parkinson's disease diagnosis and not complain of other neurological or musculoskeletal diseases that can affect muscle stiffness.
61934367|NCT05075382||Pilot group|Group of 40 patients that will act as observationnal group for this study
62133987|NCT06413693|EXPERIMENTAL|Cohort 1|Healthy adult participants will receive a single dose of PF-07293893 or placebo
62133988|NCT06413693|EXPERIMENTAL|Optional Cohort 2|Healthy adult participants will receive a single dose of PF-07293893 or placebo
62485698|NCT00796562|EXPERIMENTAL|Myeloablative haploidentical BMT|"* All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.~* Participants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days."
62485699|NCT02179294|ACTIVE_COMPARATOR|Pethidine|Pethidine is pain relief in labour
62485700|NCT02179294|ACTIVE_COMPARATOR|Remifentanil|Remifentanil intravenous patient controlled analgesia
62485701|NCT02483195|ACTIVE_COMPARATOR|Combination Group|This group will use a mixed combination of 5% Minoxidil and 200mg Spironolactone for 12 months to be used once daily.
62485702|NCT02483195|ACTIVE_COMPARATOR|Single Group|This group will use a mixed combination of 5mg Finasteride with placebo topical preparation for 12 months to be used once daily.
62485703|NCT03034356|EXPERIMENTAL|Levetiracetam, Then Placebo|4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
62485704|NCT03034356|EXPERIMENTAL|Placebo, Then Levetiracetam|4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
62485705|NCT05364177|EXPERIMENTAL|68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT scan|Participants with multiple myeloma will perform 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT within 7-day interval
62485706|NCT04418219|EXPERIMENTAL|Treatment (SV-BR-1GM, pembrolizumab)|Patients receive cyclophosphamide IV over 1-2 hours on day 1, SV-BR-1-GM ID on day 3, pembrolizumab IV over 30 minutes on day 5, and interferon-alpha-2b ID on days 5 and 7. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62485707|NCT01954277|EXPERIMENTAL|Electroacupuncture|All patients will receive 10 electroacupuncture sessions.
62485708|NCT01954277|SHAM_COMPARATOR|Placebo Sham|All patients will receive 10 placebo sham sessions.
62485709|NCT00766389||1|Defined glaucoma patients
62485710|NCT00766389||2|Glaucoma suspects and normal controls
62485711|NCT05915858|EXPERIMENTAL|muscle energy technique|muscle energy technique
62485712|NCT05915858|ACTIVE_COMPARATOR|stretching exercise|stretching exercises along with piriformis stretch
62485713|NCT01165047|EXPERIMENTAL|Nitric Oxide|80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM
62485714|NCT06408519|EXPERIMENTAL|Open-label Placebo|Treatment with open-label placebo pills 3x/day
62133989|NCT00405054|OTHER|1|continuous infusion every 14 days
62485715|NCT06408519|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual defined as Ibuprofen 3x/day
62485716|NCT00363077|EXPERIMENTAL|GSK1247446A Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62485717|NCT00363077|ACTIVE_COMPARATOR|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
62485718|NCT02730650|EXPERIMENTAL|Platelet Rich Therapy|Each subject will receive six injections of Platelet Rich Plasma (PRP) at designated points on each side of their face (twelve total). Injection points are spaced evenly across the inferior border of the cheek and mid-cheek, and are consistent on each patient. Patients will receive a post-injection phone call within 48 hours of the procedure. Photographs will be taken at two time points as part of the research to serve as a point of comparison before and after platelet rich plasma. Patients will receive the Global Aesthetic Improvement Scale amd tje Face-Q Questionnaire 1 month post-op
62485719|NCT05625178|EXPERIMENTAL|tVNS group|This will be a single-arm study where all study participants will receive transcutaneous vagus nerve stimulation (tVNS) at the cymba concha of the left ear for 60 minutes. The tVNS parameters will be a below-discomfort-threshold intensity with 25 Hz and a pulse width of 250 uS.
62485720|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
62485721|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
62485722|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
62485723|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
62485724|NCT00673010|EXPERIMENTAL|1|131 I-iodine (131-I), 124 I-iodine (124-I)
62485725|NCT01215760|ACTIVE_COMPARATOR|MIRROR|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
62485726|NCT01215760|ACTIVE_COMPARATOR|Home program|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
62485727|NCT02127463|EXPERIMENTAL|MC-1101 active|Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
62133990|NCT06648837|EXPERIMENTAL|Warfarin patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
62133991|NCT01260896|EXPERIMENTAL|Investigational Test Product|150 mg Venlafaxine Hydrochloride Extended-Release Capsules
62485728|NCT02127463|PLACEBO_COMPARATOR|MC-1101 Vehicle Control|"Topical Drug:~Ophthalmic Solution Topically, two times per day; morning and bedtime"
62485729|NCT04063631||1/Birth cohort|Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.
62485730|NCT04063631||2/mild wheezers and controls|Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls
62485731|NCT04063631||3/pre-school aged severe wheezers|50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.
61934368|NCT01867112|ACTIVE_COMPARATOR|Individualized Program|Based on personal fitness an individualized physical activity program will be built and followed by each individual in the arm
62485732|NCT04063631||4/school aged severe asthmatics|50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.
62485733|NCT00473954|EXPERIMENTAL|EGEN-001|
61934369|NCT01867112|ACTIVE_COMPARATOR|General Physical Activity Guidelines|The entire group of individuals in this arm will follow a physical activity program according to the General Physical Activity Guidelines
61934370|NCT06709469|EXPERIMENTAL|Arm A|Children and young adults with CD19+/- CD22+ B-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available.
61934371|NCT06709469|EXPERIMENTAL|Arm B|Children and youn adults with T-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available.
61934372|NCT00441454|ACTIVE_COMPARATOR|A|Retropubic Tension-free Vaginal Tape (TVT)
61934373|NCT00441454|ACTIVE_COMPARATOR|B|Transobturator Tension-free Vaginal Tape (TVT-O)
61934374|NCT00486174|ACTIVE_COMPARATOR|1|standard sepsis therapy plus Methylene Blue
61934375|NCT00486174|NO_INTERVENTION|2|standard sepsis therapy
62327649|NCT03615755|NO_INTERVENTION|Standard Therapy|Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)
62327650|NCT03615755|ACTIVE_COMPARATOR|Combination Therapy|Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)
61934376|NCT05357547|EXPERIMENTAL|Buspirone|
61934377|NCT05357547|PLACEBO_COMPARATOR|Control|
61934378|NCT04149873|PLACEBO_COMPARATOR|Control group|Control group' has the treatment with \[Physical chest care \]
62327651|NCT00235339|ACTIVE_COMPARATOR|1|Standard exercise training rehabilitation at the hospital
62485734|NCT05455671||Cohort 1 - Healthy Controls|Persons, male or female, between the ages of 3 and 21 (inclusive) with healthy lungs, defined by no known or suspected chronic or temporary lung disease. A single study visit
62485735|NCT05455671||Cohort 2 - CF Longitudinal|Persons, male or female, with CF, defined by two known disease-causing mutations and/or a sweat chloride value of \>60mmol/L, between the ages of 3 and 21 (inclusive).
61934379|NCT04149873|PLACEBO_COMPARATOR|Experimental group-A|'Experimental group-A' has the treatment with \[Mechanical-Insufflation- Exsufflation\]
61934380|NCT04149873|EXPERIMENTAL|Experimental group-B|'Experimental group-B' has the treatment with \[Mechanical-Insufflation- Exsufflation\] and \[Physical chest care\]
61934381|NCT03654066|ACTIVE_COMPARATOR|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
61934382|NCT03654066|ACTIVE_COMPARATOR|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
62327652|NCT00235339|EXPERIMENTAL|2|Interval exercise training on treadmills, with high intensity
62327653|NCT05566678|ACTIVE_COMPARATOR|Cigarette|Smokers who self-selected to continue smoking cigarettes.
62327654|NCT05566678|ACTIVE_COMPARATOR|Tobacco Heating System|Smokers who self-selected to switch to THS use.
62327655|NCT05566678|ACTIVE_COMPARATOR|Smoking Abstinence|Smokers who self-selected to abstain from smoking.
62327656|NCT03984318|EXPERIMENTAL|patient treated with immune checkpoint targeted monoclonal AB|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
62327657|NCT05913908|EXPERIMENTAL|Treatment|Treatment with the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System)
62485736|NCT05455671||Cohort 3 - CF Exacerbation|Persons, male or female, with CF, defined by two known disease-causing mutations and/or a sweat chloride value of \>60mmol/L, between the ages of 3 and 21 (inclusive), experiencing a pulmonary exacerbation requiring antibiotics.
62485737|NCT01212276|EXPERIMENTAL|Cohort 1|MORAb-028 0.1 mg/kg intravenous
62485738|NCT01212276|EXPERIMENTAL|Cohort 2|MORAb-028 0.2 mg/kg intravenous
62485739|NCT01212276|EXPERIMENTAL|Cohort 3|MORAb-028 0.5 mg/kg intravenous
62485740|NCT01212276|EXPERIMENTAL|Cohort 4|MORAb-028 1.0 mg/kg intravenous
61934383|NCT04865575||controlled asthmatics|moderate-to-severe asthmatic children with good asthma control
61934384|NCT04865575||uncontrolled asthmatics|moderate-to-severe asthmatic children with poor asthma control / recurrent exacerbations
61934385|NCT06508944|EXPERIMENTAL|Group A: Behavioral modifications and vaginal 17beta-estradiol|• 17beta-Estradiol 10 mcg + Behavioral modifications
61934386|NCT06508944|PLACEBO_COMPARATOR|Group B: Behavioral modifications + Placebo|• Placebo + Behavioral modifications
61934387|NCT00645684|EXPERIMENTAL|A|one layer running suture technique
61934388|NCT00645684|EXPERIMENTAL|B|two-layer suture technique
61934389|NCT05685836||Bevacizumab|After determining eligibility, all patients will undergo standard-of-care treatment with the sole addition of a pre-treatment 89Zr-Bevacizumab PET/CT-scan. Patients will first receive 5 mg 89Zr-Bevacizumab 4 days before PET/CT scan. This is followed by standard-of-care intravenous 7.5mg/kg bevacizumab (Avastin) therapy, administered every three weeks for six months
61934390|NCT06157060||Patient with hepatocellular carcinoma|Patient with hepatocellular carcinoma who can undergo radical resection
61934391|NCT06384261|EXPERIMENTAL|Cusatuzumab in combination with venetoclax and azacitidine|Cusatuzumab 20 mg/kg administered intravenously on days 3 and 17 in combination with venetoclax administered orally up to 400 mg once daily and azacitidine 75 mg/m\^2 administered subcutaneously or intravenously once daily for 7 days of a 28 day cycle
62133992|NCT01260896|ACTIVE_COMPARATOR|Reference Listed Drug|150 mg Effexor® XR Extended-Release Capsules
62485741|NCT06439238|EXPERIMENTAL|Menthol cigarettes smokers group 1|Smokers regularly using menthol cigarettes (at least 80% of the time) who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking. Randomized to ventilated non-menthol cigarettes
62485742|NCT06439238|EXPERIMENTAL|Menthol cigarettes smokers group 2|Smokers regularly using menthol cigarettes (at least 80% of the time) who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking. Randomized to minimally ventilated non-menthol cigarettes
62485743|NCT00091377|EXPERIMENTAL|Arm A|Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles
62485744|NCT00091377|EXPERIMENTAL|Arm B|Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles
62485745|NCT03173872|EXPERIMENTAL|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
62485746|NCT01350986|EXPERIMENTAL|Directive|
62485747|NCT01350986|ACTIVE_COMPARATOR|Non-Directive|
62485748|NCT01368380|EXPERIMENTAL|Psychological Intervention|
62485749|NCT01368380|NO_INTERVENTION|Usual care|
62485750|NCT04042415|NO_INTERVENTION|Free diet controls|Patients on free diet
62485751|NCT04042415|EXPERIMENTAL|Caloric restriction|Patients will be treated with a mild caloric restriction (15-20% caloric restriction)
62485752|NCT04042415|EXPERIMENTAL|Caloric restriction without cow's milk and gluten|Patients will be treated with a mild caloric restriction (15-20% caloric restriction) with exclusion of cow's milk, its derivatives and gluten
62485753|NCT00688571|EXPERIMENTAL|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PV conduit.
62485754|NCT04366960|ACTIVE_COMPARATOR|40 mg subcutaneous enoxaparin o.d.|Effects of 40 mg subcutaneous enoxaparin o.d.
62485755|NCT04366960|ACTIVE_COMPARATOR|40 mg subcutaneous enoxaparin b.i.d|Effects of 40 mg subcutaneous enoxaparin b.i.d
62485756|NCT06563141|EXPERIMENTAL|traction with mobilization|it consists of 35 patients and patients will receive traction with mobilization 3 sessions per week for 3 months with a total of 36 sessions. there will be a follow-up for 2 months with home program exercises and postural instructions only followed by the same pre and post-treatment assessment measures
62327658|NCT01998581|EXPERIMENTAL|JUVEDERM VOLBELLA® XC|Lips injected with JUVEDERM VOLBELLA® XC
62327659|NCT01998581|ACTIVE_COMPARATOR|Restylane-L®|Lips injected with Restylane-L®
62327660|NCT02659111|EXPERIMENTAL|High-intensity physical exercise, HIFE|
62327661|NCT02659111|ACTIVE_COMPARATOR|Physical training advice|
62485757|NCT06563141|ACTIVE_COMPARATOR|active exercise therapy)|it consists of 35 patients and patients will active exercises 3 sessions per week for 3 months with a total of 36 sessions. there will be a follow-up for 2 months with home program exercises and postural instructions only followed by the same pre and post-treatment assessment measures
62485758|NCT02680444|EXPERIMENTAL|Reappraisal-Only Intervention|Participants were instructed to independently practice the Self-Administered Reappraisal-Only Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the positive reappraisal instructions available online. This involved thinking about how one could grow, learn or benefit from the negative event in any way possible.
62693042|NCT02014103|ACTIVE_COMPARATOR|Sequence 6|"Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 6: Formulation Panacea, Mylan, Sandoz, Astellas, Accord, Dr. Reddy's~Patients will be receiving the same tacrolimus dose identified at baseline for each formulation."
62133993|NCT01235806|OTHER|MRI|MRI of the scaphoid bone fracture suspicion
62133994|NCT01855516|ACTIVE_COMPARATOR|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
62327662|NCT05511753|EXPERIMENTAL|pure tone audiometry improving|Pure tone audiometry: observe changes in hearing ability Evaluation time: Before acupuncture treatment, 2 weeks, 4 weeks, 6 weeks after treatment, and 2 weeks after acupuncture treatment, pure-tone audiometry was performed. The pure tone audiometry measures the hearing thresholds of 2KHz, 4KHz and 8KHz respectively.
62327663|NCT04626518|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg). Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to \~2 years).
62327664|NCT04626518|EXPERIMENTAL|Coformulation Favezelimab/Pembrolizumab|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg). Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
62327665|NCT04626518|EXPERIMENTAL|Pembrolizumab + MK-4830|Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to \~2 years).
62485759|NCT02680444|EXPERIMENTAL|Mindful-Reappraisal Intervention|Participants were instructed to independently practice the Self-Administered Mindful-Reappraisal Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the Mindful-Reappraisal instructions available online. This involved thinking about the negative event in an objective, non-judgmental way, then following the Reappraisal-Only instructions, and closing off with a brief mindfulness breathing technique.
62485760|NCT02680444|ACTIVE_COMPARATOR|Event Recall Active Control|Participants were instructed to independently practice the Self-Administered Event Recall Exercise in the evening for five days. In this condition, participants were only instructed to recall a negative event from that day with no reappraisal exercise.
62485761|NCT06627088|EXPERIMENTAL|Part A LY4100511 (tablet formulation) and [14C]-LY4100511 capsule|Participants will receive a single oral dose 1 or dose 2 unlabeled LY4100511 (tablet formulation) administered with a dose 1 \[14C\]-LY4100511 capsule containing approximately 100 µCi (3.7 MBq) of radioactivity in the fasted state
62485762|NCT06627088|EXPERIMENTAL|Part B LY4100511 (tablet formulation) and [14C]-LY4100511|Participants will receive a single oral dose 1 or dose 2 unlabeled LY4100511 (tablet formulation) in the fasted state, followed by a single intravenous (IV) dose of of \[14C\]-LY4100511, containing ≤1 μCi (≤37 kBq) of radioactivity, administered as an infusion.
62485763|NCT00774189|EXPERIMENTAL|1|clarithromycin 250 mg tablets of Ranbaxy Laboratories
62485764|NCT00774189|ACTIVE_COMPARATOR|2|Biaxin 250 mg tablets
62485765|NCT05513196||ESPB Group|Erector spinae plane block performed group.
62485766|NCT05513196||Control Group|Control group.
62485767|NCT03196284|EXPERIMENTAL|Concizumab|Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes
62485768|NCT03196284|ACTIVE_COMPARATOR|Eptacog alfa and concizumab|Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase
62485769|NCT02293928||Elective hybrid coronary revascularization|All patients are treated with non-enteric coated aspirin 75 mg once daily prior to study participation. Aspirin treatment is discontinued 8-10 days prior to surgery and resumed 6-9 hours after surgery. Left internal mammary grafting of the left descendent coronary artery is performed off-pump through an inferior J-hemisternotomy (JOPCAB). All patients receive an oral loading dose of aspirin 300 mg 6-9 hours after surgery followed by daily maintenance doses of 75 mg aspirin. An oral loading dose of clopidogrel 300 mg 12 hours prior to PCI is followed by daily maintenance doses of 75 mg for 12 months. Patients are followed for 1 year.
62485770|NCT02462837|EXPERIMENTAL|Treatment Arm|after stent placement, patient will be given Mirabegron 50 mg, PO, once daily, for 2 weeks
62485771|NCT02462837|PLACEBO_COMPARATOR|Placebo Arm|after stent placement, patient will be given placebo PO, once daily, for 2 weeks
62485772|NCT02066038|EXPERIMENTAL|A|Pemetrexed 500mg/m2+Carboplatin area under curve(AUC)=5, every 3 weeks, maximum 4 cycles, Erlotinib 150mg/d every cycle d2-15, and Erlotinib 150mg/d from the last cycle until disease progression
62485773|NCT05411653|EXPERIMENTAL|Virtual reality training with motor imagery|Xbox Kinect VR with MI training Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session
62485774|NCT05411653|ACTIVE_COMPARATOR|Conventional physical therapy|a range of motion exercises, muscle strengthening, functional training, balance training, and gait training. T
62327666|NCT04626518|EXPERIMENTAL|Pembrolizumab + Belzutifan|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~ 2 years). Belzutifan will be administered orally once-daily (QD) until progressive disease or discontinuation.
62485775|NCT03856580|EXPERIMENTAL|Self-injection|Participants will be trained on how to self-inject (intramuscular, gluteal muscle) an inert version of injectable cabotegravir. The inert substance is intended to mimic injectable cabotegravir as closely as possible (e.g., injection equipment, location of injection, volume of injection is identical to injectable cabotegravir). Specifically, participants will self-inject their choice of 300mg vitamin B12 or saline (3ml fluid) every 2 months for a total of 6 months (for a total of 4 injections). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as instructions on how to self-inject, FAQs about self-injection, study contact information, etc..
62485776|NCT03856580|EXPERIMENTAL|"Injection by HCP at drop-in clinics"|"Participants will report to a drop-in clinic, where a healthcare provider will inject them with an inert version of injectable cabotegravir. Visits will take \<10 minutes, and participants will be able to come whenever they want (when their injection is due) during clinic drop-in hours, which will be staggered in 2-hour windows during each week day. The inert substance that will be injected is intended to mimic injectable cabotegravir as closely as possible (described above). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as drop-in clinic hours, directions to the drop-in clinic site, study contact information, etc..."
62693043|NCT05375929|EXPERIMENTAL|Abrocitinib 100 mg|Participants will receive abrocitinib 100 mg by mouth (QD).
62693044|NCT05375929|EXPERIMENTAL|Abrocitinib 200 mg|Participants will receive abrocitinib 200 mg QD.
62327667|NCT04626518|EXPERIMENTAL|Belzutifan + Lenvatinib|Participants will receive Belzutifan 120 mg PLUS lenvatinib 20 mg. Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
62327668|NCT04626518|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
62327669|NCT04703660|ACTIVE_COMPARATOR|group A|This group will receive antero-posterior cervical mobilization at c5-6 grade III oscillation
62485777|NCT03856580|NO_INTERVENTION|Control group|Participants will make an appointment when their injection is due to report to our clinic to complete injections. Visits and the injection protocol will follow similar procedures to HPTN-083/084. Participants will not have access to the mHealth adherence app.
62485778|NCT04332198|EXPERIMENTAL|ALS patients|
62485779|NCT00831103|EXPERIMENTAL|EPB-348 1000 mg|EPB-348 1000 mg dosed once daily for seven days
62485780|NCT00831103|EXPERIMENTAL|EPB-348 2000 mg|EPB-348 2000 mg dosed once daily for seven days
62485781|NCT00831103|EXPERIMENTAL|EPB-348 3000 mg|EPB-348 3000 mg dosed once daily for seven days
62485782|NCT00831103|ACTIVE_COMPARATOR|Valacyclovir|Valacyclovir 1000 mg dosed three times daily for seven days
62485783|NCT00018616|OTHER|1|
62693045|NCT06258564||single cohort of women with cervical excision for CIN2+|single cohort of women with cervical excision for CIN2+; those with HPV vaccination and those without HPV vaccination
62693046|NCT06499181|EXPERIMENTAL|Experimental Group Exparel|The experimental arm will be injected with 133mg (10cc) of liposomal bupivacaine (Exparel) near to the incision site one time only at the completion of the procedure.
62485784|NCT00538031|ACTIVE_COMPARATOR|Arm I|Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62485785|NCT00538031|EXPERIMENTAL|Arm II|Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62485786|NCT04277793|EXPERIMENTAL|Monitored self-guided problem solving intervention|Monitored self-guided problem solving intervention
62327670|NCT04703660|ACTIVE_COMPARATOR|group B|This group will receive lateral glide cervical mobilization at c5-6 grade III oscillation
62327671|NCT04703660|ACTIVE_COMPARATOR|group C|This group will receive postero-anterior cervical mobilization at c5-6 grade III oscillation
62327672|NCT06195384|EXPERIMENTAL|Anti-cancer Neoantigen mRNA Vaccine|Anti-cancer neoantigen mRNA vaccine will be produced to treat advanced solid tumors.
62327673|NCT00392171|EXPERIMENTAL|Temozolomide|Temozolomide will be administered at a dose of 50 mg/m\^2 for cycles of 28 days for 12 months or until progression.
62485787|NCT03447535||classic oppositional defiant disorder|"CODD Group:  classic  oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group CODD ( classic  oppositional defiant disorder): teacher report SDQ total difficulties score (≥ 12), parents report SDQ total difficulties score (≥14)"
62485788|NCT03447535||intrafamilial oppositional defiant disorder|"IODD group: intrafamilial oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group IODD (Intrafamilial Oppositional Defiant Disorder): teacher report SDQ total difficulties score normal (\<12), parents report SDQ total difficulties score abnormal (\>16)"
62485789|NCT03705117|EXPERIMENTAL|V565|V565 orally three times daily for up to 7 days
62485790|NCT04350697||Mini-Sternotomy|Patients underwent aortic surgery by Mini-Sternotomy
62485791|NCT04350697||Mini-Thoracotomy|Patients underwent aortic surgery by Mini-Thoracotomy
62485792|NCT05144451|EXPERIMENTAL|TCD arm|All patients will be evaluated with TCD for prediction of the post-transplant neurological complications
62327674|NCT05471297||Handball players|Professional handball players
62327675|NCT03637842|ACTIVE_COMPARATOR|Lorcaserin XR|Lorcaserin XR 20mg daily
62327676|NCT03637842|PLACEBO_COMPARATOR|Placebo|Placebo Oral Capsule
62327677|NCT06342804|EXPERIMENTAL|AB sequence|Group 1 (sequence AB) will take the drug on an empty stomach in Period I and after a meal in Period II
62327678|NCT06342804|EXPERIMENTAL|BA sequence|Group 2 (BA sequence) will take the drug after a meal in Period I and on an empty stomach in Period II
62327679|NCT03940651|EXPERIMENTAL|Knee Arthroplasty|Surgery to replace the knee joint with prothetic joint
62327680|NCT03940651|EXPERIMENTAL|Hip Arthroplasty|Surgery to replace the hip joint with prothetic joint
62327681|NCT01045772|EXPERIMENTAL|IL-1 trap|
62327682|NCT03965988|EXPERIMENTAL|Docosahexaenoic Acid|Docosahexaenoic acid
62327683|NCT03965988|PLACEBO_COMPARATOR|Placebo drug|Placebo
62327684|NCT02960932|EXPERIMENTAL|hemiplegic cerebral child|Ultrasound scanner used to the SSI technical reproducibility.
62327685|NCT04208867|EXPERIMENTAL|Intervention - Women|Women who receive MH services from a facility participating in the QI collaborative to improve PCC
62327686|NCT04208867|NO_INTERVENTION|Control - Women|Women who receive MH services from a facility not participating in the QI collaborative to improve PCC
62485793|NCT02828449|EXPERIMENTAL|therapeutic education program|therapeutic education program which aims is to improve the adherence to the treatment and management of adverse effects of this treatment in patients taking an oral chemotherapy for active cancer
62327687|NCT04208867|EXPERIMENTAL|Intervention - Provider|Provider working at a facility participating in the QI collaborative to improve PCC
62327688|NCT04208867|NO_INTERVENTION|Control - Provider|Provider working at a facility not participating in the QI collaborative to improve PCC
62327689|NCT04684485|PLACEBO_COMPARATOR|Placebo of SCD-044 product|Placebo tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
62485794|NCT04807426|ACTIVE_COMPARATOR|Multi Sensory stimulation exercises|only Multisensory stimulation Exercises
62693047|NCT06499181|ACTIVE_COMPARATOR|Control Group Bupivacaine|The control arm will be injected with 10cc of 0.5% bupivacaine (50 mg) with 1:50,000 epinephrine near to the incision site one time only at the completion of the procedure per standard procedure.
61934392|NCT06384261|ACTIVE_COMPARATOR|Venetoclax in combination with azacitidine|Venetoclax administered orally up to 400 mg once daily and azacitidine 75 mg/m\^2 administered subcutaneously or intravenously once daily for 7 days of a 28 day cycle
62327690|NCT04684485|ACTIVE_COMPARATOR|SCD-044 Tablets_Dose 1|SCD-044 Tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
62327691|NCT04684485|ACTIVE_COMPARATOR|SCD-044 Tablets_Dose 2|SCD-044 Tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
62327692|NCT04684485|ACTIVE_COMPARATOR|SCD-044 Tablets_Dose 3|SCD-044 Tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
62327693|NCT02711761|EXPERIMENTAL|15 cm|The depth of guide wire will be 15 cm from puncture site of skin prior to tissue dilation during central venous catheterization
62327694|NCT02711761|EXPERIMENTAL|17.5 cm|The depth of guide wire will be 17.5 cm from puncture site of skin prior to tissue dilation during central venous catheterization
62327695|NCT02711761|ACTIVE_COMPARATOR|20 cm|The depth of guide wire will be 20 cm from puncture site of skin prior to tissue dilation during central venous catheterization
62327696|NCT00830661|ACTIVE_COMPARATOR|LIFT|those subjects receiving the Ligation of Intersphincteric Fistula Track procedure
62327697|NCT00830661|ACTIVE_COMPARATOR|Plug|those subjects randomized to the receive the placement of the porcine anal fistula plug
62327698|NCT04702893||Chronic fibrosing interstitial lung disease (ILD) patients with a progressive phenotype|
62327699|NCT05009823||Stabilization phase|"The dietetic treatment is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
62327700|NCT05009823||Transition phase|The child is assigned to one the therapeutic regimen depending on the treatment received during the stabilization phase and the results of the appetite test.
62327701|NCT02003651|EXPERIMENTAL|Quick Defense|250 mg E. purpurea root and 83 mg E.angustifolia root standardized to 10 mg alkylamides, and 210 mg of a proprietary synergistic extract blend containing andrographis paniculata leaf, black elderberry berries, sambucus nigra, ginger root, and zingiber officinale
62327702|NCT02003651|PLACEBO_COMPARATOR|Placebo|Placebo will contain the excipients vegetable glycerin and olive oil. Placebo and echinacea capsules will be colored green and contain the same proportions of inert ingredients.
62327703|NCT04253301|EXPERIMENTAL|Treatment|Subjects will have the InnoVein Valve implanted
62327704|NCT01058369|EXPERIMENTAL|Deferasirox|
62327705|NCT03886727|ACTIVE_COMPARATOR|Rubber Dam|Isolation of single tooth using rubber dam
62327706|NCT03886727|ACTIVE_COMPARATOR|Cotton Roll|Isolation of quadrant using cotton rolls
62327707|NCT04964219|EXPERIMENTAL|S-ketamine group|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
62327708|NCT04964219|PLACEBO_COMPARATOR|Control group|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
62327709|NCT05821257||Early Multiple Sclerosis|Arm swing evaluation and functional tests will be tested in this group.
62327710|NCT05821257||Healthy Controls|Arm swing evaluation will be tested in this group.
62327711|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
62327712|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
62485795|NCT04807426|EXPERIMENTAL|Task Oriented Exercises|Task-oriented exercises without Multisensory stimulation Exercises
62485796|NCT04807426|EXPERIMENTAL|Task oriented exercises and Multisensory stimulation exercises.|Task-oriented exercises with Multisensory stimulation Exercises
62485797|NCT04741776|EXPERIMENTAL|Resilience Enhancement Skills Training|video-based family therapy
61934393|NCT01672736|EXPERIMENTAL|ASP7487, Velcade, Dexamethasone|ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg
62327713|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
62327714|NCT03493529||Obesity Clas III|BMI\> 40 Kg/m2
62693048|NCT02722330|EXPERIMENTAL|Baha 5 SuperPower on Baha Attract System|"The device involves the following parts:~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling."
62693049|NCT06126172|EXPERIMENTAL|Multiparametric magnetic resonance imaging|Detecting and localizing prostate cancers. The radiomics provide comprehensive quantitative information of all tumor data which could be used for risk stratification and prognosis prediction.
62485798|NCT04741776|ACTIVE_COMPARATOR|Standard of care|video-based individual therapy
62485799|NCT02385708|ACTIVE_COMPARATOR|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
62485800|NCT02385708|ACTIVE_COMPARATOR|Treatment Arm|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
62133995|NCT01855516|ACTIVE_COMPARATOR|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
62485801|NCT06435793|EXPERIMENTAL|Healthy subjects|
62485802|NCT05058430|EXPERIMENTAL|Subjects with xerostomia|"The primary objective of this research is to assess the human factors in relabeling the SaliPen from a prescription-based device to an OTC.~Primary performance endpoints:~* The user can select the device properly.~* The user can use the device as instructed in the IFU."
62485803|NCT05058430|ACTIVE_COMPARATOR|Subjects without xerostomia|"The primary objective of this research is to assess the human factors in relabeling the SaliPen from a prescription-based device to an OTC.~Primary performance endpoints:~• The user can select the device properly."
62485804|NCT02280707|EXPERIMENTAL|Intervention|
62327715|NCT01670513|EXPERIMENTAL|IDP-118 Low Strength|IDP-118 Low Strength
62693050|NCT04678544|EXPERIMENTAL|Intervention Group|Before the chemotherapy, patients in intervention group will use cooling cap 30 minutes before chemotherapy. Once chemotherapy drug be ready, patients will receive chemotherapy. After the chemotherapy, patients go to the cooling cap area (room) and wear the cooling cap additional 20 minute for Taxane and 90 minute for other drugs, respectively.
62133996|NCT03380013|EXPERIMENTAL|OMT group|Osteopathic Manipulative Therapy (OMT); two treatments between day 4 and 7 of life
62327716|NCT01670513|EXPERIMENTAL|IDP-118 High Strength|IDP-118 High Strength
62327717|NCT03236350|EXPERIMENTAL|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
62327718|NCT03236350|SHAM_COMPARATOR|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
62485805|NCT02280707|NO_INTERVENTION|Control|
62485806|NCT05471596||NeuWave Microwave Ablation System|Patients who underwent a Microwave Ablation at a participating institution and a NeuWave generator was utilized.
61934394|NCT01941043|EXPERIMENTAL|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
62133997|NCT03039803|ACTIVE_COMPARATOR|single-layer continuous uterotomy suture|Single-layer continuous uterotomy suture
62133998|NCT03039803|ACTIVE_COMPARATOR|double-layer continuous uterotomy suture|double-layer continuous uterotomy suture
61934395|NCT01941043|EXPERIMENTAL|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
61934396|NCT01941043|PLACEBO_COMPARATOR|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
62133999|NCT04063514|EXPERIMENTAL|Focused Ultrasound|The ultrasound treatment will last either 1 hour or 20 minutes total time for the DWL device or Brainsonix Focused Ultrasound Device, respectively.
62485807|NCT05213663||1/parents of the Cerebral Palsy children|parents of the children with cerebral palsy will be evaluated about the awereness of their children's disease, physical and social activities and physiotherapy and rehabilitation.
62134000|NCT00281892|EXPERIMENTAL|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
62327719|NCT05418062|EXPERIMENTAL|Intervention arm|Patients randomised into Group 1 will begin the 8 week group first.
62327720|NCT05418062|OTHER|Control crossover group|Patients randomised into Group 2 will act as the control for the first 8 weeks and then cross over into the intervention arm.
62327721|NCT04623190|EXPERIMENTAL|Providers|-All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline. The providers will be delivering the PREVENT tool.
62327722|NCT04623190|ACTIVE_COMPARATOR|Patients - Wait-List Control|"* Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail~* A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
62485808|NCT01834157||methotrexate|methotrexate with or without low-dose corticosteroids
62485809|NCT01834157||other DMARDs|other DMARDs (leflunomide, azathioprine, mycophenolate mofetil) with or without low-dose corticosteroids
62485810|NCT01834157||low-dose corticosteroids|low-dose corticosteroids without DMARDs
62485811|NCT01834157||No DMARD or corticosteroids|No DMARD or corticosteroid treatment
62485812|NCT01834157||CPH/CSA - Exploratory cohort|cyclophosphamide or cyclosporine-A with or without other DMARDs or low-dose corticosteroids
62485813|NCT01834157||Biologics - Exploratory cohort|Biologic therapy with or without other DMARDs or low-dose corticosteroids
62485814|NCT01834157||Combinations - Exploratory cohort|Combination of two or more DMARDs with or without low-dose corticosteroids
62485815|NCT03328026|EXPERIMENTAL|SV-BR-1-GM, retifanlimab combination original sequence|Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab with cycles every 3 weeks
62693051|NCT04678544|NO_INTERVENTION|Controlled Group|chemotherapy with usual care
62693052|NCT02199912|EXPERIMENTAL|Patients with colorectal surgery|
62693053|NCT05807945|EXPERIMENTAL|Ropivacaine 0.75% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
62485816|NCT03328026|EXPERIMENTAL|SV-BR-1-GM, retifanlimab combination alternative sequence|"Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab as follows:~Cycle 1: SV-BR-1-GM only Cycle 2: resume retifanlimab on Day 2±1 Cycle 3 and beyond: retifanlimab can be administered on Day -2, Day 0, 1, 2, or 3."
62485817|NCT03512483|NO_INTERVENTION|Usual Care|Control group participants will be notified of their assignment and will continue their usual care with the AF clinic receiving onsite care. Participants will be contacted at 3 time points (baseline, 3 months, and 6 months)
62485818|NCT03512483|EXPERIMENTAL|Virtual Atrial Fibrillation Clinic|Participants in the intervention group can expect to receive between 1 and 4 telehealth appointments over a 6 month period, as well as being contacted by the research team at 3 time points for data collection (baseline, 3 months, and 6 months). Telehealth appointments will consist of remote interactions with clinicians. Telehealth appointments will take place in participants' homes, using their personal computer/tablet/smartphone. Participants will also receive an orientation to the website and will be encouraged to visit often and utilize the resources. To promote and encourage website interaction, emails will be sent to participants once semi-monthly for the duration of the intervention with highlights and important messages from the website.
62485819|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
61934397|NCT04368273|EXPERIMENTAL|treatment|PD-1 antibody combined CCRT for patients with local advanced cervical cancer.
61934398|NCT03307304||Family members|Unaffected family members of individuals diagnosed with CLN3-Batten
61934399|NCT03307304||Proband/Affected Individuals|Individuals diagnosed with CLN3-Batten
61934400|NCT00841971|EXPERIMENTAL|anidulafungin|anti-fungal agent
62134001|NCT00281892|ACTIVE_COMPARATOR|fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
62327723|NCT04623190|EXPERIMENTAL|Patients - PREVENT Tool|"* Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail~* At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
62327724|NCT01324583|EXPERIMENTAL|Arm 1|"Patients will receive cabazitaxel as the dose of corresponded level~1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²"
62327725|NCT05645029|EXPERIMENTAL|glass ionomer-chlorhexidine|
62485820|NCT03459339|EXPERIMENTAL|Experimental OFDI capsule imaging|"Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.~Intervention: 'Tethered Capsule Endomicroscopy (TCE) Imaging of Barrett's esophagus using OFDI capsule"
62485821|NCT05400239||Cohort 1|Surgically resectable disease, followed by adjuvant radiotherapy +/- chemotherapy
62134002|NCT02217514|EXPERIMENTAL|Treatment sequence 1 in male subjects|Midazolam alone and 1 h after low dose BI44370BS in male subjects
62485822|NCT05400239||Cohort 2|Primary radiotherapy +/- concurrent chemotherapy
62485823|NCT05400239||Cohort 3|Recurrent or metastatic HNSCC undergoing platinum based chemotherapy +/- cetuximab
62485824|NCT03253354|ACTIVE_COMPARATOR|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
62693054|NCT05807945|ACTIVE_COMPARATOR|Ropivacaine 0.2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
62693055|NCT05913167|ACTIVE_COMPARATOR|Erector spina plan block|Erector spina plan block will be administered to the patients in this group.
62693056|NCT05913167|ACTIVE_COMPARATOR|Transversus abdominis plan block|Transversus abdominis plan block will be administered to the patients in this group.
61934401|NCT00841971|ACTIVE_COMPARATOR|Fluconazole|anti-fungal agent
61934402|NCT05909904|ACTIVE_COMPARATOR|Tislelizumab|Tislelizumab 200 milligrams (mg) administered once every 3 weeks
62134003|NCT02217514|EXPERIMENTAL|Treatment sequence 1 in female subjects|Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects
62693057|NCT03577470||Group 1|Participants will not receive any intervention as a part of this study. This group will include participants in treatment with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), who were always being treated with boosted-darunavir (DRV)-based regimen. The primary data source will be the medical records of each participant participating in this study.
61934403|NCT05909904|EXPERIMENTAL|Tislelizumab + BGB-A425|Tislelizumab 200 mg administered once every 3 weeks with BGB-A425
61934404|NCT05909904|EXPERIMENTAL|Tislelizumab + LBL-007|Tislelizumab 200 mg administered once every 3 weeks with LBL-007
61934405|NCT05909904|EXPERIMENTAL|Tislelizumab + BGB-A425 + LBL-007|Tislelizumab 200 mg administered once every 3 weeks with BGB-A425 and LBL-007
62134004|NCT02217514|EXPERIMENTAL|Treatment sequence 2|Midazolam before and 48 h after high dose BI44370BS
62134005|NCT02217514|EXPERIMENTAL|Treatment sequence 3|Midazolam before and 24 h after high dose BI44370BS
62485825|NCT03253354|ACTIVE_COMPARATOR|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
62485826|NCT03253354|ACTIVE_COMPARATOR|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
62485827|NCT03253354|SHAM_COMPARATOR|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
62485828|NCT02611687|EXPERIMENTAL|pitolisant|tablet, oral, once a day.
62485829|NCT02611687|PLACEBO_COMPARATOR|placebo|tablet, oral, once a day.
62485830|NCT06144996||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
62485831|NCT06144996||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
62485832|NCT05437848|EXPERIMENTAL|Cotadutide|Those subjects who were randomized to cotadutide once daily SC will begin at 50 μg once daily, then up-titrated to 100 μg once daily a week later, after that up-titration will be done at 100 μg increment weekly, till to a maximum of 600 μg once daily.
62485833|NCT05437848|PLACEBO_COMPARATOR|Placebo|Placebo: Placebo subcutaneous injection
62485834|NCT02206893|EXPERIMENTAL|Mobile: Professional and peer support|A mobile app that provides both professional support and peer support
62485835|NCT02206893|EXPERIMENTAL|Mobile: Peer support|A mobile app that provides peer support, but not professional support
62693058|NCT03577470||Group 2|Participants will not receive any intervention as a part of this study. This group will include participants who started their antiretroviral (ARV) treatment with any combination excluding DRV before starting D/C/F/TAF treatments, who were always being treated with ARV treatment with any combination excluding DRV before starting D/C/F/TAF treatments. The primary data source will be the medical records of each participant participating in this study.
62693059|NCT03577470||Group 3|Participants will not receive any intervention as a part of this study. This group will include participants started with D/C/F/TAF as naive. The primary data source will be the medical records of each participant participating in this study.
62693060|NCT04506892|EXPERIMENTAL|Adept Meditators|Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness.
62693061|NCT06639009|SHAM_COMPARATOR|Group A|Photobiomodulation therapy given intraorally on bilateral buccal mucosa and extraorally (sham) with conventional non-invasive management.
62693062|NCT06639009|ACTIVE_COMPARATOR|Group B|Photobiomodulation therapy given intraorally (bilateral buccal mucosa) and extraorally (bilateral masseter muscle) with conventional non-invasive management.
62693063|NCT06639009|SHAM_COMPARATOR|Group C|Sham (Use of laser handpiece with only red guide light and without using the foot pedal which activates the laser)Photobiomodulation therapy(Placebo) (Intraoral and Extraoral) with conventional non-invasive management.
61934406|NCT02158260|EXPERIMENTAL|position changing|During the examination, subjects changed position in the following sequence: left lateral head-down position, supine position, prone head-down position, right lateral head-down position, supine position, left lateral position, prone position, prone hip-high position, right lateral position and sitting position.
61934407|NCT02158260|NO_INTERVENTION|free position|
61934408|NCT03930953|EXPERIMENTAL|Part A: Dose Escalation|
62134006|NCT02217514|EXPERIMENTAL|Treatment sequence 4|Midazolam before and 1 h after high dose BI44370BS
62134007|NCT01784744||ASD Control|Patients aged 5 to 17 diagnosed with ASD.
62134008|NCT01784744||ASD Case|Patients diagnosed with ASD aged 5 to 17 with a history of amelioration of symptoms during febrile episodes.
62134009|NCT06330064|EXPERIMENTAL|Cohort 1: Endometrial Cancer|Participants with recurrent or metastatic endometrial cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62134010|NCT06330064|EXPERIMENTAL|Cohort 2: Head and Neck Squamous Cell Carcinoma|Participants with recurrent or metastatic head and neck squamous carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
61934409|NCT03930953|EXPERIMENTAL|Part B: Dose Expansion|
62327726|NCT05645029|EXPERIMENTAL|glass ionomer -titanium dioxide powder.|
62327727|NCT05645029|ACTIVE_COMPARATOR|glass ionomer|
62327728|NCT03974828|NO_INTERVENTION|Non-Contact|Participants in the non-contact group will be monitored by anesthesia control tower clinicians who will utilize AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes predictions, but who will not contact the postoperative provider unless it is clinically necessary for patient safety purposes.
62327729|NCT03974828|EXPERIMENTAL|Brief contact|PACU and ward providers caring for participants in the brief contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a brief summary of the patient's forecast risk of major adverse events.
62327730|NCT03974828|EXPERIMENTAL|Full contact|PACU and ward providers caring for participants in the full contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.
62327731|NCT02916498|ACTIVE_COMPARATOR|Bipolar then alternative field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with bipolar stimulation for 21 days, then alternative field shape stimulation for 21 days
62327732|NCT02916498|EXPERIMENTAL|Alternative then bipolar field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with alternative field shape stimulation for 21 days, then bipolar stimulation for 21 days
62327733|NCT06175650||Female|Female patients undergoing cardiac surgery
62327734|NCT06175650||Male|Male patients undergoing cardiac surgery
62134011|NCT06330064|EXPERIMENTAL|Cohort 3: Pancreatic Ductal Adenocarcinoma|Participants with recurrent or metastatic pancreatic ductal adenocarcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62485836|NCT02206893|EXPERIMENTAL|Mobile: Professional Support|A mobile app that provides professional support, but no peer support
62485837|NCT02206893|ACTIVE_COMPARATOR|Mobile: No Support|A mobile app that provides neither peer support nor professional support
62485838|NCT02206893|ACTIVE_COMPARATOR|Web: No Support|A web app that provides neither peer support, nor professional support
62485839|NCT00250263|PLACEBO_COMPARATOR|1|Matching placebo- control arm (first year)
62485840|NCT00250263|ACTIVE_COMPARATOR|2|Drug Staloral (active group)
62134012|NCT06330064|EXPERIMENTAL|Cohort 4: Colorectal Cancer|Participants with recurrent or metastatic colorectal cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62485841|NCT02937935|EXPERIMENTAL|Protocol Guided-RRT|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
61934410|NCT02864719|EXPERIMENTAL|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
61934411|NCT06278662|EXPERIMENTAL|Intervention arm|The cohort multiple Randomised Controlled Trial (also known as TwiCs 'trials within cohorts') is a prospective study design in which (eHealth) intervention arms will be established over time. The interventions will be evaluated on the primary outcome measures of the cohort.
61934412|NCT06278662|NO_INTERVENTION|Cohort control group|
62134013|NCT06330064|EXPERIMENTAL|Cohort 5: Hepatocellular Carcinoma|Participants with recurrent or metastatic hepatocellular carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd at the determined dose.
61934413|NCT06708611|EXPERIMENTAL|Extended release torsemide|Drug: Extended release torsemide 24 mg tablet. Subjects will receive oral dose of 24 mg extended release torsemide tablet and a placebo of 20 mg immediate release torsemide.
61934414|NCT06708611|ACTIVE_COMPARATOR|Immediate release torsemide|Drug: Immediate release torsemide 20 mg tablet. Subjects will receive oral dose of 20 mg of immediate release torsemide and a placebo of 24 mg extended release torsemide.
62485842|NCT02937935|ACTIVE_COMPARATOR|On Demand-RRT|In the protocol guided group patients all patients would be considered for dialysis within 6 hours of randomization After randomization patients would receive dialysis as three sessions per week of at least 4 h with a blood flow \>200 mL/min and a dialysate flow \>500 mL/min in intermittent group and as 20-25 mL/kg/h of effluent, by filtration and/or diffusion in continuous form until recovery of renal functions
62485843|NCT03786341|EXPERIMENTAL|with auxiliary illuminator|the walking training was by conventional strategy with lase quad-cane.
62485844|NCT03786341|PLACEBO_COMPARATOR|control group|Ambulation training WITHOUT laser quad-cane.
62485845|NCT02588144|ACTIVE_COMPARATOR|[standard STN]|Device: standard stimulation on subthalamic (STN) contacts
62485846|NCT02588144|EXPERIMENTAL|[STN+SNr]|Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)
62485847|NCT02482922|EXPERIMENTAL|IET and Nutrition|3 times per week of interval exercise training Once daily meal replacement
62485848|NCT03741777|ACTIVE_COMPARATOR|3 ml/kg of clear oral fluid|This group of patient will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
62485849|NCT03741777|ACTIVE_COMPARATOR|5 ml/kg of clear oral fluid|This group of patient will consume 5 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
62485850|NCT03741777|ACTIVE_COMPARATOR|7 ml/kg of clear oral fluid|This group of patient will consume 7 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
62485851|NCT03741777|ACTIVE_COMPARATOR|10 ml/kg of clear oral fluid|This group of patient will consume 10 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
62485852|NCT03172286|ACTIVE_COMPARATOR|Patient treated with fake radiofrequencer|
61934415|NCT02225509|OTHER|Patients with thyroid nodules|Patients with thyroid nodules with an indication for FNA biopsy to detect thyroid cancer. These patients will undergo FNA at the time of first visit and also when considered necessary by the clinician during the course of the study.
61934416|NCT05716399|EXPERIMENTAL|Transcutaneous electric stimulation pretreatment group|30 minutes before the implementation of spinal anesthesia, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points.
62134014|NCT06330064|EXPERIMENTAL|Cohort 6: Adenocarcinoma of esophagus, gastroesophageal junction, and stomach|Participants with recurrent or metastatic adenocarcinoma of esophagus, gastroesophageal junction, and stomach who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62134015|NCT06330064|EXPERIMENTAL|Cohort 7: Urothelial carcinoma|Participants with recurrent or metastatic urothelial carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62134016|NCT06330064|EXPERIMENTAL|Cohort 8: Ovarian cancer|Participants with recurrent or metastatic non-squamous ovarian cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62134017|NCT06330064|EXPERIMENTAL|Cohort 9: Cervical cancer|Participants with recurrent or metastatic cervical cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62134018|NCT06330064|EXPERIMENTAL|Cohort 10: Biliary tract cancer|Participants with recurrent or metastatic biliary tract cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62485853|NCT03172286|EXPERIMENTAL|Patient treated with radiofrequencer|
61934417|NCT05716399|ACTIVE_COMPARATOR|Transcutaneous acupoint electrical stimulation treatment group|Within 30 minutes after the occurrence of hypotension, TEAS (density wave 10/50Hz, one side of Neiguan point and Quchi point connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points.
61934418|NCT05716399|SHAM_COMPARATOR|Transcutaneous acupoint pseudo electric stimulation group|Paste the electrode, turn on the power, but no current output.
61934419|NCT06313593|EXPERIMENTAL|Part 1 Dose Escalation - with MF|INCB160058 will be administered at a protocol defined starting regimen to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) will enroll in this group.
61934420|NCT06313593|EXPERIMENTAL|Part 2 Dose Expansion - with MF|INCB160058 will be administered at the RDE(s) identified during Part 1. Participants with MF will enroll in this group.
61934421|NCT05736224|EXPERIMENTAL|Sunscreen|Portion of skin covered by sunscreen. There are 3 different formulations of sunscreen (Formulation 1, Formulation 2, Formulation 3)
61934422|NCT05736224|OTHER|No treatment control|Portion of skin not covered by sunscreen.
61934423|NCT05998278|EXPERIMENTAL|Experimental group|Experimental group received targeted biopsy plus personalized systematic biopsy
62693064|NCT02475993|EXPERIMENTAL|SMART app|SMART, a mobile phone-based self-monitoring service to enhance outpatient treatment in chronic illness will be tested for its utility to help reduce acute care utilization rates for patients given SMART following acute care visits at the Sickle Cell Day Hospital. SMART will enable symptom monitoring with a particular emphasis on pain measures, co-symptoms, and related interventions aided by provider daily monitoring and support guided by patient report via SMART to provide a Sickle Cell Disease Information interchange (SCDi) service. Instead of using their current routine of triaging phone messages daily, assessing patients' need for intervention, providers will instead monitor patients' entries via SMART daily.
62327735|NCT04240067||Acute Heart Failure|
62327736|NCT04240067||No Acute Heart Failure|
62327737|NCT01229488|NO_INTERVENTION|No Arms|Project was withdrawn before starting
62693065|NCT02475993|NO_INTERVENTION|Standard of care control group|The control group will get standard of care, including a printed plan for medications to be taken, phone number to call for questions or issues, and the return date for visit
62693066|NCT06162728|EXPERIMENTAL|Briquilimab|This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.
62693067|NCT06162728|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62693068|NCT04981145|EXPERIMENTAL|IGU Group|
62693069|NCT04981145|ACTIVE_COMPARATOR|HCQ Group|
62327738|NCT03000309|OTHER|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
62327739|NCT06569147|EXPERIMENTAL|Elranatamab Dose Schedule|"Phase I: Phase I will enroll up to 20 participants. All participants in Phase I will be hospitalized during Cycle 1 dosing. The first 5 participants will be hospitalized for 9 days, and subsequent participants will be hospitalized for 5 days. Elranatamab will be administered subcutaneously at a dose of 12 mg on C1D1, 32 mg on C1D4, and 76 mg on C1D8. Subsequent treatment doses will be 76 mg thereafter. If two or more participants at Level 0 experience DLT, dose will be decreased to Level -1. If 2 or more participants at Level -1 experience DLT, the trial will be discontinued.~Phase II: All participants in Phase 2 will receive the RP2D determined in Phase 1. Phase 2 will enroll an additional 29 participants. If RP2D is determined to be Dose Level 0, the treatment schedule will be the same as described in Dose Level 0. If RP2D is determined to be Dose Level -1, the treatment schedule will be the same as described in Dose Level -1.Treatment duration is 6 cycles of 28 days per cycle."
61934424|NCT05998278|NO_INTERVENTION|Control group|Control group received targeted biopsy plus systematic biopsy
61934425|NCT04660253|EXPERIMENTAL|LTP Plus Dads|Participants in this group will receive 10 sessions of LTP plus dads
61934426|NCT04161066|EXPERIMENTAL|Open-label|Psilocybin with facilitated counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
62485854|NCT00464763|EXPERIMENTAL|Dexmedetomidine|
62485855|NCT00464763|PLACEBO_COMPARATOR|Placebo (PBO)|
61934427|NCT03860142||full-term child born|use of a new scale to rate the severity of food disorders on full-term child born
62485856|NCT03162159||cohort for model computing|patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
62485857|NCT03162159||cohort for model validation|patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
61934428|NCT03860142||premature child born|use of a new scale to rate the severity of food disorders on premature child born
61934429|NCT00073073|EXPERIMENTAL|Exemestane|exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects.
61934430|NCT02962154||Coronary Artery Disease (CAD)|"Patients with known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test, or invasive coronary angiography (ICA) and who are hemodynamically stable~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
61934431|NCT02962154||Major Depressive Disorder|"Patients with a diagnosis of major depressive disorder and/or a diagnosis of bipolar 1 or bipolar 2 disorder~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
61934432|NCT02905656|PLACEBO_COMPARATOR|Brief Advice|Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
62693070|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
61934433|NCT02905656|EXPERIMENTAL|Motivational Interviewing (MI)|Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
61934434|NCT02905656|EXPERIMENTAL|Rate Reduction (RR)|Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
61934435|NCT02905656|EXPERIMENTAL|MI + RR|In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.
61934436|NCT06558006|EXPERIMENTAL|Treatment Group|2 tablets of Predimenol (400 mg Predimenol)
61934437|NCT06558006|EXPERIMENTAL|Treatment + Placebo Group|1 tablet of Predimenol (200 mg Predimenol) + 1 tablet of placebo
61934438|NCT06558006|PLACEBO_COMPARATOR|Control Group|2 tablets of placebo
61934439|NCT01660308||Tumor induced osteomalcia|
62693071|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
61934440|NCT01465061||Online support user|
61934441|NCT02922400|EXPERIMENTAL|Social Cognition Assessment and Training|Assessment and training program to enhance social function
61934442|NCT05324618|ACTIVE_COMPARATOR|Tacrolimus group|100 patients treated by thin layer of 0.03% topical tacrolimus ointment on the affected areas twice daily for 4 months.
61934443|NCT05324618|ACTIVE_COMPARATOR|Hydrocortisone group|100 patients treated by thin layer of 1% hydrocortisone cream on the affected areas twice daily for 4 months.
61934444|NCT05436834|EXPERIMENTAL|mRNA-1273.214 (Part 1)|Participants who have not been previously vaccinated against SARS-CoV-2, will receive 2 intramuscular (IM) injections of mRNA-1273.214 vaccine on Day 1 and Day 29.
61934445|NCT05436834|EXPERIMENTAL|mRNA-1273.214 (Part 2)|Participants who have previously been vaccinated with a mRNA-1273 primary series, will receive a single IM BD of mRNA-1273.214 vaccine at least 4 months after completion of the mRNA-1273 primary series.
61934446|NCT05436834|EXPERIMENTAL|mRNA-1273.815 (Part 3)|Participants who have previously been vaccinated with an authorized/approved COVID-19 vaccine, will receive a single IM BD of mRNA-1273.815 vaccine on BD Day 1, at least 4 months after the last dose of a COVID-19 vaccine.
61934447|NCT05436834|EXPERIMENTAL|mRNA-1273.815 (Part 4)|Participants in Part 4 Cohort A will receive a single IM injection of mRNA-1273.815 vaccine on Day 1. Participants in Part 4 Cohort B will receive IM injections of mRNA-1273.815 vaccine on Day 1 and Day 29.
61934448|NCT02097043|EXPERIMENTAL|[Group 1] DA-7218|200mg, By mouth or orally (PO) \& intravenous(IV) administration
61934449|NCT02097043|PLACEBO_COMPARATOR|[Group 1] Placebo|Placebo, By mouth or orally (PO) \& intravenous(IV) administration
61934450|NCT02097043|EXPERIMENTAL|[Group 2] DA-7218|400mg, By mouth or orally (PO) administration
61934451|NCT02097043|PLACEBO_COMPARATOR|[Group 2] Placebo|Placebo, By mouth or orally (PO) administration
61934452|NCT02097043|EXPERIMENTAL|[Group 3] DA-7218|600mg, By mouth or orally (PO) administration
61934453|NCT02097043|PLACEBO_COMPARATOR|[Group 3] Placebo|Placebo, By mouth or orally (PO) administration
61934454|NCT04422743|EXPERIMENTAL|standard of care + citicoline plus homotaurine (CIT/HOMO)|CIT/HOMO was supplemented for 4 months to the standard of care (SOC, i.e. topical intraocular pressure, IOP, lowering medication)
61934455|NCT04422743|NO_INTERVENTION|standard of care|only standard of care (SOC, i.e. topical IOP lowering medication) for 4 months
61934456|NCT01889524|ACTIVE_COMPARATOR|NIV plus jet|Noninvasive ventilation-NIV plus jet nebulizer
61934457|NCT01889524|EXPERIMENTAL|NIV plus Mesh|Noninvasive ventilation- NIV plus Mesh nebulizer
61934458|NCT02546635|EXPERIMENTAL|Potential food effect|
61934459|NCT02546635|EXPERIMENTAL|Multi-dosing|
61934460|NCT04171284|EXPERIMENTAL|SCT-I10A plus Docetaxel|SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles
61934461|NCT04171284|ACTIVE_COMPARATOR|Placebo puls docetaxel|Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles
61934462|NCT04171284|EXPERIMENTAL|Maintenance therapy of SCT-I10A|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
61934463|NCT04171284|PLACEBO_COMPARATOR|Maintenance therapy of Placebo|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
61934464|NCT04330183|PLACEBO_COMPARATOR|Normal Saline|Patients here will be administered 3cc of normal saline as placebo
62485858|NCT02913924|EXPERIMENTAL|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
62485859|NCT02913924|PLACEBO_COMPARATOR|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
62485860|NCT03025087|EXPERIMENTAL|Phase 1|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery.
62485861|NCT03025087|EXPERIMENTAL|Phase 2|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg daily until the day of MRI imaging on postoperative day 1-5
62485862|NCT03025087|EXPERIMENTAL|Phase 3|6 evaluable cardiac subjects 1000 mg HCQ on the day prior to surgery followed by 400 mg twice daily (800 mg total) until the day of MRI imaging on postoperative day 1-5.
62485863|NCT03025087|EXPERIMENTAL|Phase 4|6 evaluable cardiac subjects: 1000 mg HCQ on the day prior to surgery followed by 500 mg twice daily (1000 mg total) until the day of MRI imaging on postoperative day 1-5.
62485864|NCT03025087|EXPERIMENTAL|Phase 5|6 evaluable cardiac subjects: 1000 mg HCQ 1-2 hours after separation from CPB followed by the highest tolerated dose from the previous 4 phases divided into 2 equal daily doses until the day of MRI imaging on postoperative day 1-5.
62485865|NCT01844843|EXPERIMENTAL|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
62485866|NCT02426918|EXPERIMENTAL|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
62485867|NCT02426918|EXPERIMENTAL|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
62485868|NCT02426918|PLACEBO_COMPARATOR|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
62485869|NCT03986294|EXPERIMENTAL|S1 and liposomal irinotecan|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.
62485870|NCT03986294|EXPERIMENTAL|Liposomal irinotecan, Leucovorin and 5-fluoracil|Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
62485871|NCT03187821|ACTIVE_COMPARATOR|Superior|Laser peripheral iridotomy done at superior part of iris.
62485872|NCT03187821|ACTIVE_COMPARATOR|Nasal/temporal|Laser peripheral iridotomy done at temporal/nasal part of iris.
61934465|NCT04330183|EXPERIMENTAL|Ketamine Interventions|Patients will be administered weight based 0.3mg/kg of ketamine
62134019|NCT06330064|EXPERIMENTAL|Cohort 11: Human epidermal growth factor 2 (HER2)-low breast cancer|Participants with recurrent or metastatic human epidermal growth factor 2 (HER2)-low breast cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62327740|NCT05298033|EXPERIMENTAL|Active NBUVB plus Crisaborole 2% topical ointment|12 participants will receive 6 months of treatment with crisaborole 2% topical along with 6 months of treatment with active NBUVB
62327741|NCT05298033|EXPERIMENTAL|Active NBUVB plus PF-07038124 0.01% topical ointment|12 participants will receive 6 months of treatment with active NBUVB, to be combined with 3 months of treatment with PF-07038124 0.01% topical ointment followed by 3 months of vehicle ointment
62327742|NCT05298033|ACTIVE_COMPARATOR|Active NBUVB plus vehicle ointment|8 participants will receive 6 months of treatment with active NBUVB combined with 6 months of vehicle ointment application
62134020|NCT06330064|EXPERIMENTAL|Cohort 12: HER2 immunohistochemistry (IHC) 0 breast cancer|Participants with recurrent or metastatic HER2 immunohistochemistry (IHC) 0 breast cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62327743|NCT05298033|EXPERIMENTAL|Sham phototherapy plus crisaborole 2% topical ointment|12 participants will receive 6 months of treatment with crisaborole 2% topical ointment combined with 6 months of sham phototherapy
62485873|NCT01403363|EXPERIMENTAL|fentanyl patch|
62327744|NCT05298033|EXPERIMENTAL|Sham phototherapy plus PF-07038124 0.01% topical ointment|12 participants will receive 3 months of treatment with PF-07038124 0.01% topical ointment, followed by 3 months of vehicle ointment, along with 6 months of sham phototherapy
62327745|NCT05298033|PLACEBO_COMPARATOR|Sham phototherapy plus vehicle ointment|8 participants will receive 6 months of sham phototherapy combined with 6 months of vehicle ointment application
62485874|NCT01884701|EXPERIMENTAL|Intervention|Intervention
62485875|NCT03578497|EXPERIMENTAL|IL-1 receptor antagonist Anakinra 100 mg|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
62485876|NCT01741545|EXPERIMENTAL|Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
62485877|NCT01741545|EXPERIMENTAL|Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
62485878|NCT02286466|ACTIVE_COMPARATOR|Health Education Program|The presence and usage of Health Education Program.
62485879|NCT02286466|EXPERIMENTAL|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
62485880|NCT03603990|EXPERIMENTAL|Vitrectomy|"Patient with standard pars plana vitrectomy~During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
62485881|NCT03603990|ACTIVE_COMPARATOR|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
62485882|NCT04773600|EXPERIMENTAL|Roflumilast Cream 0.15%|Participants apply roflumilast cream 0.15% once daily (qd) for 4 weeks.
62485883|NCT04773600|PLACEBO_COMPARATOR|Vehicle Cream|Participants apply vehicle cream qd for 4 weeks.
62485884|NCT06543303|EXPERIMENTAL|BTV100 Low dose|1% Cevimeline Ophthalmic Solution
62485885|NCT06543303|EXPERIMENTAL|BTV100 Mid dose|2% Cevimeline Ophthalmic Solution
62485886|NCT06543303|EXPERIMENTAL|BTV High dose|4% Cevimeline Ophthalmic Solution
61934466|NCT06710041|ACTIVE_COMPARATOR|Kinesiotaping plus tendon and nerve gliding exercises|Kinesiotaping was applied 3 times with 5-day intervals
61934467|NCT06710041|SHAM_COMPARATOR|Sham taping plus tendon and nerve gliding exercises|Sham taping was applied 3 times with 5-day intervals without stretching and without having the proper position.
61934468|NCT06710041|OTHER|tendon and nerve gliding exercises alone|The control group received exercise therapy only
62134021|NCT06330064|EXPERIMENTAL|Cohort 13: Cutaneous melanoma|Participants with recurrent or metastatic cutaneous melanoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
62134022|NCT06371755|OTHER|Execution of additional diagnostic examination|The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
62327746|NCT03737968|EXPERIMENTAL|Durvalumab monotherapy Arm|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
62485887|NCT06543303|PLACEBO_COMPARATOR|Vehicle|Vehicle
62485888|NCT00881569|EXPERIMENTAL|1|CS-7017 tablets twice daily at strength ranging from 0.5 mg to 0.75 mg
62485889|NCT06261294||two group Study arm determination based|"Subjects will be assigned into Test group or Control group based on the criteria:~* Test group: Individual who has been diagnosed with lung nodule(s) or mass by his/ her healthcare provider utilizing LDCT or CT scan and has already scheduled for interventional procedure;~* Control group: Individual is willing to undergo COPD examination and LDCT or CT scan with 3-5 mm spatial z-axis resolution and has no findings from the scan and examination"
62485890|NCT04620057|EXPERIMENTAL|Butyrate + standard care for pediatric obesity|standard care for pediatric obesity + sodium butyrate (20 mg/kg body weight/day)
62485891|NCT04620057|PLACEBO_COMPARATOR|placebo + standard care for pediatric obesity|standard care for pediatric obesity + placebo (cornstarch)
62485892|NCT02241577|EXPERIMENTAL|Surgical treatment|Surgical access for scaling and disinfection of dental implant
62485893|NCT02241577|EXPERIMENTAL|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of dental implant
62485894|NCT05138094|ACTIVE_COMPARATOR|Minimally invasive two-stage resection|Minimally invasive resection of the primary colorectal carcinoma and liver metastases in two stages. The liver metastases or the colorectal carcinoma can be resected during the first surgical procedure.
61934469|NCT05413031|ACTIVE_COMPARATOR|relative motion splint|
61934470|NCT05413031|ACTIVE_COMPARATOR|static splint|
61934471|NCT01570920|EXPERIMENTAL|walking|a cohort of stroke patients trained during 3 month, based on walking
62134023|NCT04172038|EXPERIMENTAL|Phase I: Physical Therapy (PT)|Initial Randomization: The initial PT treatment session will occur within 7 days of enrollment in the study. Precise dosage (i.e, number of PT sessions) will be at the discretion of the physical therapist directing the participant's care, up to a maximum of 2-3 sessions per week over the 6-week Phase I treatment period.
62485895|NCT05138094|EXPERIMENTAL|Minimally invasive simultaneous resection|Minimally invasive resection of both the primary colorectal carcinoma and the liver metastases in one procedure.
62485896|NCT06134453|EXPERIMENTAL|Reiki|According to randomization, patients in the reiki group will be taken to a quiet single room and reiki will be applied for approximately 25-30 minutes. Reiki practice will be applied by a researcher who has been trained at the Reiki Master level.
62485897|NCT06134453|SHAM_COMPARATOR|Sham Reiki|According to randomization, the patients in the sham reiki group were taken to a quiet single room and sham reiki was applied for approximately 25-30 minutes. will be applied. According to random distribution, patients in the sham reiki group will be taken to a quiet single room and sham reiki will be applied for approximately 25-30 minutes. Sham Reiki will be administered by a healthcare professional who has not received Reiki training. Their hands will remain in the same position and for the same duration as if they were actually doing Reiki, but Reiki energy will not be given to the patient.
61934472|NCT02496962|EXPERIMENTAL|Statin group|drug: atorvastatin (Pfizer, U.S.); the frequency: 20mg atorvastatin was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
61934473|NCT02496962|PLACEBO_COMPARATOR|Control group|drug: placebo (Pfizer, U.S.); the frequency: Placebo was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
61934474|NCT01886716|EXPERIMENTAL|Anxiety Attention Training only|Participants will receive Anxiety Attention Training and placebo Alcohol training.
62327747|NCT03737968|ACTIVE_COMPARATOR|Durvalumab + tremelimumab combination therapy Arm|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
62485898|NCT06134453|NO_INTERVENTION|Control Group|The control group will be given routine care in the pre-operative waiting room without any intervention, and the data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
62485899|NCT05865652|EXPERIMENTAL|Patient group|"Participants of this group are subjects with ultra high risk of psychotic transition.~At inclusion visit, subjects will have a psychiatric evaluation and a cerebral MRI examination with phosphorus 31 Magnetic Resonance Spectroscopy in order to investigate membrane phospholipid metabolism and cellular energy metabolism.~One and two years after the inclusion visit, subjects will have a psychiatric evaluation in order to objectivize if a psychotic transition has occured."
62134024|NCT04172038|EXPERIMENTAL|Phase I: Move to Health (M2H)|"Initial Randomization: M2H is a key component of Army Medicine's System for Health, along with the Performance Triad. It is a person-centered, holistic, and experience-centric approach to promoting healthy behaviors (nutrition, physical activity, sleep, instrinsic factors, extrinsic factors). Precise dosage (i.e, number of M2H sessions) will be at the discretion of the health coaches. Sessions may be delivered in-person or utilize technology including text messaging, telephone, e-mail, video chat, app-based self-management etc."
62485900|NCT05865652|ACTIVE_COMPARATOR|Control group|Participants of this group are healthy volunteers. Subjects will have one single visit with a psychiatric evaluation and a cerebral MRI examination with phosphorus 31 Magnetic Resonance Spectroscopy in order to investigate membrane phospholipid metabolism and cellular energy metabolism.
62485901|NCT03018990|ACTIVE_COMPARATOR|Alcoholic liver fibrosis|
62485902|NCT03018990|ACTIVE_COMPARATOR|Non-alcoholic steatohepatitis|
62485903|NCT03018990|ACTIVE_COMPARATOR|Healthy control|
62485904|NCT01032213|PLACEBO_COMPARATOR|group C|control group
62485905|NCT01032213|EXPERIMENTAL|group M|magnesium group
62485906|NCT03026153|OTHER|Control group - Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
62485907|NCT03026153|OTHER|Intervention Group - Oral Survey 2|Oral Survey 2 will be administered as the intervention : patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
62485908|NCT06596889||Not any equipment|Control group
61934475|NCT01886716|EXPERIMENTAL|Alcohol Attention Training only|Participants will receive Alcohol Attention Training and placebo Anxiety training.
62134025|NCT04172038|EXPERIMENTAL|Phase II: Combine PT & M2H|Sequential Randomization: Participants randomized to receive a combination of PT and M2H as a Phase II intervention will continue their Phase I treatment (either M2H or PT). The participant will begin the treatment component that was not part of their Phase I intervention.
62134026|NCT04172038|EXPERIMENTAL|Phase II: MORE Mindfulness|Sequential Randomization: Participants randomized to receive mindfulness as a Phase II intervention will discontinue their Phase I treatment. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment was designed specifically to address symptoms and underlying mechanisms of chronic pain in the military context and is led over 8 individual sessions.
62327748|NCT03698604|ACTIVE_COMPARATOR|Total Laparoscopic Hysterectomy|The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
62327749|NCT03698604|ACTIVE_COMPARATOR|Total Abdominal hysterectomy|The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
62485909|NCT06596889||Other types of equipment|Brand new oral airways
61934476|NCT01886716|EXPERIMENTAL|Anxiety + Alcohol Attention Training|Participants will receive both Anxiety Attention Training and Alcohol Attention Training.
62134027|NCT05129722|EXPERIMENTAL|Patients receiving low dose combination polydiuretic therapy|This patient group will receive a low dose combination polydiuretic therapy treatment consisting of: bumetanide 0.5 mg (loop diuretic), eplerenone 25 mg (mineralocorticoid receptor antagonist) and empagliflozin 10mg (sodium-glucose co-transporter 2 inhibitor) daily on top of their background therapy.
62327750|NCT01031758|OTHER|Group 1|Group 1 is comprised of 6 healthy subjects with HDL-C levels between the 25th and 75th percentile.
62327751|NCT01031758|OTHER|Group 2|Group 2 is comprised of 6 healthy subjects with high HDL-C levels \> 75th percentile.
62327752|NCT01031758|OTHER|Group 3|Group 2 is comprised of 6 healthy subjects with low HDL-C levels \< 25th percentile.
62485910|NCT05451264|EXPERIMENTAL|Hydrocortisone|During the PREMILOC trial, patients received hydrocortisone (0.5mg/kg/12h for 7 days and 0.5mg/kg/24h for 3 days).
61934477|NCT01886716|PLACEBO_COMPARATOR|Control Training|Participants will receive placebo Anxiety Training and placebo Alcohol training.
61934478|NCT03805906||Primary group|Ultrasound-Guided L5 Dorsal ramus block
62485911|NCT05451264|PLACEBO_COMPARATOR|Placebo|During the PREMILOC trial, patients received placebo (0.5mg/kg/12h for 7 days and 0.5mg/kg/24h for 3 days).
61934479|NCT02958501|ACTIVE_COMPARATOR|IU/Day|This is standard dose of the drug (colecalciferol), which is not calculated in relation to patient body weight
62485912|NCT04802655|EXPERIMENTAL|Exergame Group (EG)|In addition to routine NDT training, Structured Exergame Program for upper extremity and trunk control will be applied in this group. Xbox one - Kinect supported video games will be selected for video-game based exergame program. The Video games to be included in the Exergame program will be selected by Analytical Hierarchy Process. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
62485913|NCT04802655|ACTIVE_COMPARATOR|Activity Based Exercise Group (AG)|In addition to routine NDT training, Goal Directed Activity Based Exercises for upper extremity and trunk will be applied to this group. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
62485914|NCT02273492|EXPERIMENTAL|Asasantin ER after a standardized breakfast|
62485915|NCT02273492|ACTIVE_COMPARATOR|Asasantin ER at fasted state|
62134028|NCT05129722|ACTIVE_COMPARATOR|Comparator group receiving monotherapy empagliflozin|This comparator patient group will receive empagliflozin 10mg (sodium-glucose co-transporter 2 inhibitor) daily on top of their background therapy.
62134029|NCT02629679||Males nonathletes|Boys non-involved in organized sport and exercising
62134030|NCT02629679||Females nonathletes|Girls non-involved in organized sport and exercising
62134031|NCT02629679||Males athletes|Athletic boys (involved in sports)
62134032|NCT02629679||Females athletes|Athletic girls (involved in sports)
62134033|NCT03486600|OTHER|fluid resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
62134034|NCT04044651|EXPERIMENTAL|Lenvatinib plus nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w+ lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
62134035|NCT04044651|ACTIVE_COMPARATOR|Lenvatinib|Lenvatinib 12 mg (or 8 mg) Po once daily
62327753|NCT05933577|EXPERIMENTAL|V940 + Pembrolizumab|Participants receive up to 9 doses of V940 via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
62327754|NCT05933577|ACTIVE_COMPARATOR|Placebo + Pembrolizumab|Participants receive up to 9 doses of dose matched placebo to V940 via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
62327755|NCT02834052|EXPERIMENTAL|Phase 1|"This Run In phase is aimed to determine if poly-ICLC can be safely combined with standard dosages of pembrolizumab:~i. Pembrolizumab will be administered 200 mg intravenously (IV) every 3 weeks (q3w)~ii. Poly-ICLC will be administered intramuscularly (IM) twice weekly at one of two dose levels: 1 mg or 2 mg~Each dose level will enroll 3-6 participants, up to 12 participants total, depending on the occurrence of dose limiting toxicities (DLT) at each dosing level.~Participants may receive treatment for 1 year (\~17 cycles)."
62134036|NCT00707772|ACTIVE_COMPARATOR|1|Genotype 2 or 3 in Hemophilic Patients with HCV
62327756|NCT02834052|EXPERIMENTAL|Phase 2|"In Phase 2, all participants will receive the standard pembrolizumab dose (200 mg IV q3w) in addition to the maximum tolerated dose of poly-ICLC (either 1 mg or 2 mg), as determined by the Phase 1 arm.~Up to 30 participants will be treated in Phase 2. Participants may receive treatment for 1 year (\~17 cycles)."
62327757|NCT05442918||General Surgery|All patients undergoing either elective laparoscopic/open cholecystectomy, laparoscopic/open hiatus hernia repair, laparoscopic/open inguinal hernia repair, laparoscopic/open umbilical hernia repair or laparoscopic ventral wall hernia repair.
62327758|NCT05442918||Bariatric Surgery|Participants undergoing elective bariatric surgery (laparoscopic sleeve gastrectomy or roux-en-y gastric bypass). Those in the bariatric arm must have been on a VLCD pre operatively
62485916|NCT02763345|ACTIVE_COMPARATOR|Paper-based CCM (Standard Care)|Children are assessed and treated according to the WHO and UNICEFs paper-based Community Case Management decision aid for Malawi for a minimum of 2 and a maximum of 7-weeks. Clinical assessment is guided by the paper-based 'Sick Child Form' presented in English, and clinical data is recorded by Health Surveillance Assistants manually in the Village Clinic Register.
62134037|NCT00707772|ACTIVE_COMPARATOR|2|Other Genotypes (except 2 or 3) in Hemophilic Patients with HCV
62134038|NCT04710849||Treatment Failure Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. Definition of systemic glucocorticoid treatment failure during hospitalization is (Reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): The following occurs from the 2nd to the 7th day after admission Situation: ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
61934480|NCT02958501|ACTIVE_COMPARATOR|IU/Kg/Day|This is dose of the drug (colecalciferol), which is based or calculated in relation to patient actual body weight
62327759|NCT00589888|ACTIVE_COMPARATOR|Intralipid 20%@ 20cc/hour|Intralipid 20% IV infusion at 20cc/hour
62485917|NCT02763345|EXPERIMENTAL|SL eCCM App + paper CCM|Health Surveillance Assistants use the Supporting LIFE electronic Community Case Management App (SL eCCM App) deployed on a smartphone and replicating paper-based CCM guidelines to assess and treat children in conjunction with standard care, for a minimum of 2-weeks and maximum of 7-weeks. Clinical data is recorded in both the SL eCCM App and Village Clinic Register.
62485918|NCT06006273|EXPERIMENTAL|Arm A: Dose expansion-Ewings sarcoma|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
62485919|NCT06006273|EXPERIMENTAL|Arm B: Dose expansion -Rhabdomyosarcoma|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
62485920|NCT06006273|EXPERIMENTAL|Arm C: Dose expansion- other solid tumor histologies|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
62485921|NCT06006273|EXPERIMENTAL|Arm D: Dose finding levels 0,-1 and -2|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
62485922|NCT04061746|EXPERIMENTAL|Group A Treatment|2.5 x 10\^6 MSC per kg will be infused intravenously on Day 1
62485923|NCT04061746|PLACEBO_COMPARATOR|Group B Placebo|Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1
62693072|NCT04973319|EXPERIMENTAL|test group|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment. The subject who has a second primary malignant tumor in a non-breast area will continue to be followed up until a recurrent disease or death due to primary breast cancer. The subjects who are hormone receptor-positive will be advised to receive endocrinotherapy simultaneously. Within 28 days after the last administration of the test drug, the subjects in the test group must complete the safety follow-up and the end-of-treatment visit and continue to receive the follow-up visit.
62134039|NCT04710849||Treatment Success Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. The treatment success group was defined as not meeting any of the following conditions for failure of systemic hormone therapy during hospitalization (reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
62134040|NCT02078232|EXPERIMENTAL|19G flex needle puncture|puncture of head of pancreas
62134041|NCT02078232|ACTIVE_COMPARATOR|22G needle puncture|puncture of head of pancreas
62134042|NCT06082635|EXPERIMENTAL|TGRX-326|Subjects to be treated with the investigational drug TGRX-326 at 60 mg once day in 28-day cycles.
62134043|NCT06082635|ACTIVE_COMPARATOR|Crizotinib|Subjects to be treated with the active control drug crizotinib at 250 mg twice day in 28-day cycles.
62134044|NCT02379936|ACTIVE_COMPARATOR|The NeoHilda Point of care method|Evaluating baby including lactate dehydrogenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
62134045|NCT02379936|SHAM_COMPARATOR|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
62134046|NCT01296646|ACTIVE_COMPARATOR|Arm 1|Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
62134047|NCT01296646|ACTIVE_COMPARATOR|Arm 2|Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
62134048|NCT01296646|ACTIVE_COMPARATOR|Arm 3|Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
62134049|NCT01296646|ACTIVE_COMPARATOR|Arm 4|Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions
62134050|NCT04164784|EXPERIMENTAL|therapeutic monitoring|"Based on the dietary habits from guidelines, the patients will be instructed to adjust the diet according to the ambulatory glucose profile (AGP) and the recorded log monitored by the continuous glucose monitoring system, thereby implementingtherapeutic monitoring."
61934481|NCT05136807||Observational (quality of life questionnaire)|Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.
61934482|NCT00096083|ACTIVE_COMPARATOR|Melphalan Administration PHP|
62134051|NCT04164784|NO_INTERVENTION|The control group|Patients will be given the basic diet, lifestyle instructions according guidelines.
62134052|NCT01345422|EXPERIMENTAL|Wii Balance Board|Wii Balance Board Training
62134053|NCT05239156|EXPERIMENTAL|Janesse 15|Sixteen patients will be administered Janesse® 15 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
62134054|NCT05239156|EXPERIMENTAL|Janesse 20|Sixteen patients will be administered Janesse® 20 (Cross-linked Hyaluronic Acid) for the treatment of medium-sized facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
62134055|NCT05239156|EXPERIMENTAL|Janesse 25|Sixteen patients will be administered Janesse® 25 (Cross-linked Hyaluronic Acid) for the treatment of major facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
62327760|NCT00589888|ACTIVE_COMPARATOR|Intralipid 20% @ 40cc/hour|Intralipid 20% IV infusion at 40cc/hour
62327761|NCT00589888|PLACEBO_COMPARATOR|Normal Saline infusion @ 40cc/hour|Normal Saline continuous IV infusion at 40cc/hour for 8 hours
62327762|NCT00589888|ACTIVE_COMPARATOR|32-gram oral fat load|32-gram oral fat load once
62134056|NCT03983759|EXPERIMENTAL|treatment group|"phlebotomation 50ml 1-7 days before chemotherapy for culture of R-CIK cells chemotherapeutic regimen EP or EC as follows: VP-16 100mg/m2 D1-3 plus cisplatin 75mg/m2 D1 or VP-16 100mg/m2 D1-3 plus carboplatin AUC=5 D1 R-CIK cells were transfused back to the patients 2-7 days after the end of chemotherapy, and the amount of R-CIK cells returned each time was about 5×109 three weeks each cycle efficacy evaluated every two cycles patients with the efficay is CR, PR or SD after 4-6 cycles enter the sintilimab maintenance therapy for one year or until the progression of disease, or occurrence of intolerable adverse events.~the dose of sintilimab is fixed dose of 200mg every three weeks"
62485924|NCT06026163|EXPERIMENTAL|Caffeine citrate group|Infants receive either caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
62485925|NCT06026163|PLACEBO_COMPARATOR|Control group|Infants received equivalent volume of saline.
62134057|NCT04230200||Healthy cohort|People who received routine physical examination including blood test, and after 3 year follow-up, have not been diagnosed as any kind of malignant tumor.
62693073|NCT04973319|OTHER|control group|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
62485926|NCT05337241|EXPERIMENTAL|Single arm treatment|All subjects meeting inclusion/exclusion criteria and successfully consented will be treated with the study device.
62485927|NCT05017935|EXPERIMENTAL|Renal Denervation|
62485928|NCT03954483|EXPERIMENTAL|Buspirone|Participants will receive buspirone 10 mg prior to experiments.
62485929|NCT03954483|EXPERIMENTAL|Triazolam|Participants will receive triazolam 0.25 mg prior to experiments.
62327763|NCT00589888|ACTIVE_COMPARATOR|64-gram oral fat load|64-gram oral fat load once
62327764|NCT02482363|ACTIVE_COMPARATOR|Active UVA radiation|This arm will receive 20 minutes of UVA to the skin while resting quietly.
62327765|NCT02482363|SHAM_COMPARATOR|Sham control|This arm will receive 20 minutes of quiet rest and heat but with their skin protected from UVA
62327766|NCT02715960|EXPERIMENTAL|single-arm|intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.
62327767|NCT06516796||sublobar resection without lymphadenectomy|Patients received sublobar resection but had no lymphadenectomy
62327768|NCT06516796||sublobar resection with lymphadenectomy|Patients received sublobar resection plus lymphadenectomy
62327769|NCT06516796||lobectomy plus lymphadenectomy|Patients received lobectomy plus lymphadenectomy
62327770|NCT03240211|EXPERIMENTAL|Arm A: Pembrolizumab plus Pralatrexate|Subjects will receive pembrolizumab 200 mg IV day 1 with pralatrexate 30 mg/m2 IV day 1, 8, and 15.
62327771|NCT03240211|EXPERIMENTAL|Arm B: Pembrolizumab plus Pralatrexate plus Decitabine|Subjects will receive pembrolizumab 200 mg IV day 8 with pralatrexate 20 mg/m2 IV day 1, 8, and 15 and decitabine 10 mg/m2 from day 1 to 5 ( or day 1 to 3, depending on dose level).
62327772|NCT03240211|EXPERIMENTAL|Arm C: Pembrolizumab plus Decitabine|Subjects will receive pembrolizumab 200 mg IV and decitabine 20 mg/m2 from day 1 to 5 (or day 1 to 3, depending on dose level).
62327773|NCT01629342||Transient Ischemic Attack Patients|Patients discharged after a Transient Ischemic Attack
62327774|NCT04769960||Participants with breast tissue expanders|Participants with breast tissue expanders that require an MRI for clinical purposes are eligible for this study.
62327775|NCT04645017|EXPERIMENTAL|Intergenerational Music Program|An intergenerational music program will be administered by adolescent musicians for older adults with early-stage cognitive decline.
62327776|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
62327777|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
62693074|NCT06642896||severe head trauma in children with osmotherapy treatment|Admission to the pediatric intensive care or neurosurgical intensive care unit, pupillometry measurement before and after osmotherapy treatment
61934483|NCT05432362|EXPERIMENTAL|Verum Normal Weight|Normal weight participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
61934484|NCT05432362|EXPERIMENTAL|Verum Obesity|Adipose participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
62327778|NCT01150994|NO_INTERVENTION|Treatment as Usual|
62327779|NCT01150994|NO_INTERVENTION|Screening Alone|Enhanced screening among ED patients
62327780|NCT01150994|EXPERIMENTAL|Safety Assessment and Follow-up Telephone Intervention|SAFTI: Safety Assessment in the ED combine with a Follow-up Telephone Intervention.
62327781|NCT01814800|EXPERIMENTAL|RI-002 Treatment|Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks
62327782|NCT04254289|ACTIVE_COMPARATOR|Usual Care|Usual care administered at the Pulmonary Arterial Hypertension (PAH) clinic at the University of Michigan.
62485930|NCT03954483|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo prior to experiments.
62485931|NCT04672044|ACTIVE_COMPARATOR|active rTMS+Exercise|active rTMS
61934485|NCT05432362|EXPERIMENTAL|Verum Depression|Depressive participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
62485932|NCT04672044|SHAM_COMPARATOR|sham rTMS+Exercise|sham rTMS
62485933|NCT04403035||ID NOW vs. Acccula arm|Each patient serves as his or her own control. The ID NOW test is the one that is being currently used (i.e. the control) and the Accula test is the newer test being evaluated.
62485934|NCT00506831|EXPERIMENTAL|Imatinib mesylate|100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated
62485935|NCT03922763|ACTIVE_COMPARATOR|Anatomically-matched cut|
62485936|NCT03922763|ACTIVE_COMPARATOR|Cutting guide|
61934486|NCT05432362|PLACEBO_COMPARATOR|Placebo Normal Weight|"Normal weight participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free."
61934487|NCT05432362|PLACEBO_COMPARATOR|Placebo Obesity|"Obese participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free"
61934488|NCT05432362|PLACEBO_COMPARATOR|Placebo Depression|"Depressive participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free"
61934489|NCT06710470||Cohort 1|Participants exposed to deucravacitinib for the full pregnancy duration
61934490|NCT06710470||Cohort 2|Participants exposed to deucravacitinib for the first trimester
61934491|NCT06710470||Cohort 3|Participants exposed to deucravacitinib for the first 20 weeks of gestation
61934492|NCT06710470||Cohort 4|Participants exposed to other systemic psoriasis medications for the full pregnancy duration
61934493|NCT06710470||Cohort 5|Participants exposed to other systemic psoriasis medications for the first trimester
61934494|NCT06710470||Cohort 6|Participants exposed to other systemic psoriasis medications for the first 20 weeks of gestation
61934495|NCT06710470||Cohort 7|Participants not exposed to any systemic medications for the full pregnancy duration
61934496|NCT06710470||Cohort 8|Participants not exposed to any systemic medications during the first trimester
61934497|NCT06710470||Cohort 9|Participants not exposed to any systemic medications during the first 20 weeks of gestation
61934498|NCT06702930|NO_INTERVENTION|Control|No exercise was performed and ambulatory blood pressure was assessed for 24 hours.
62327783|NCT04254289|EXPERIMENTAL|Home-based exercise program|Home-based individualized exercise program based on heart rate reserve (HRR).
62327784|NCT01967667|EXPERIMENTAL|Liposomal glutathione|dose steps
62327785|NCT01967667|PLACEBO_COMPARATOR|Placebo|dose steps
62327786|NCT05774912||Pregnant women|Healthy women with singleton uncomplicated pregnancy
62327787|NCT04357353|SHAM_COMPARATOR|Placebo|All arms will have phlebotomy (blood drawn). This group will receive saline injection only.
61934499|NCT06702930|EXPERIMENTAL|Morning high-intensity interval exercise|High-intensity interval exercise was performed between 8-10 am and ambulatory blood pressure was assessed for 24 hours after.
62327788|NCT04357353|EXPERIMENTAL|Platelet rich plasma|All arms will have phlebotomy (blood drawn). This group will receive PRP injection only.
62327789|NCT03277950|EXPERIMENTAL|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
62327790|NCT03277950|ACTIVE_COMPARATOR|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
62327791|NCT03277950|OTHER|Healthy|Participants do not play virtual reality game.
62327792|NCT06168721||Expert panel|This group will be composed of experts in primary care physiotherapy.
62327793|NCT01513798|EXPERIMENTAL|Exercise under observation|Modified paleolithic diet and exercise 3 sessions/week under observation
62327794|NCT01513798|EXPERIMENTAL|General advice on exercise|Modified paleolithic diet and general advice on exercise
62327795|NCT03544671|EXPERIMENTAL|400 IU/d vitamin D2|Children received 1mililiter (dosage applicator) containing 400 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
62327796|NCT03544671|EXPERIMENTAL|800 IU7d vitmin D2|Children received 2 mililiter (dosage applicator) containing 800 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
61934500|NCT06702930|EXPERIMENTAL|Evening high-intensity interval exercise|High-intensity interval exercise was performed between 5-7 pm and ambulatory blood pressure was assessed for 24 hours after.
61934501|NCT02586285|ACTIVE_COMPARATOR|S-Adenosyl Methionine Treatment|Patients will be treated with S-Adenosyl Methionine treatment after curative resection.
61934502|NCT02586285|NO_INTERVENTION|Control group|Patients will be treated without S-Adenosyl Methionine treatment after curative resection.
61934503|NCT00950287||cohort|One group of preterm infants
61934504|NCT04265469|EXPERIMENTAL|Patients with diabetics get mobile education|Patients with diabetics get mobile education
61934505|NCT04265469|NO_INTERVENTION|Patients with diabetics|Patients with diabetics
61934506|NCT02107352||Naltrexone|50mg/day
61934507|NCT02107352||Acamprosate|1332mg/day if patient weights less than 60 kg, 1998mg/day if patient weights more than 60 kg
61934508|NCT02107352||Baclofen|30 mg/day
61934509|NCT02107352||Placebo|
61934510|NCT02413177|ACTIVE_COMPARATOR|EEG-RTNF|Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
61934511|NCT02413177|ACTIVE_COMPARATOR|EEG-no RTNF|Group 2 will receive EEG (no RTNF feedback). They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
61934512|NCT05873673|ACTIVE_COMPARATOR|coenzyme group|
61934513|NCT05873673|PLACEBO_COMPARATOR|control group|
61934514|NCT01695512||Immunocompromised Patients|Patients with acute leukemia undergoing induction chemotherapy or undergoing allogeneic stem cell transplantation
61934515|NCT01695512||Control Group|Patients underdoing bronchoscopy and diagnostic BAL without immunosuppression and without signs of infection (Sarcoidosis, Lung Cancer)
62327797|NCT03544671|EXPERIMENTAL|1000 IU vitamina D3|Children received 1drop (dosage applicator) containing 1000 IU of vitamin D3 per day. dosage form (1 drop), frequency (daily) and duration 16 weeks
62327798|NCT03544671|PLACEBO_COMPARATOR|Multiple vitamin|Children received 1 mililiter of a supplement with multiple vitamins (dosage applicator) frequency (daily) and duration 16 weeks
62327799|NCT02621268|EXPERIMENTAL|Indocyanine Green|Dosage calculated by weight of individual, 5mg/kg.
61934516|NCT04741230|EXPERIMENTAL|Gebauer Lenticule|Gebauer Lenticule implant device
61934517|NCT01952600||Chronic Kidney Disease (CKD)|Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
61934518|NCT01952600||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
61934519|NCT01952600||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
61934520|NCT00945555||All participants|Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
61934521|NCT03311620|OTHER|Endobronchial ultrasound transbronchial needle aspirate|
61934522|NCT04251273|EXPERIMENTAL|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
61934523|NCT04251273|OTHER|Assessment only Control|After an initial enrollment message, participants will be contacted periodically to assess e-cigarette use. At the end of the intervention period, they will receive information on how to sign up for This is Quitting if they are interested in the program
61934524|NCT05658536|ACTIVE_COMPARATOR|6-Week Self-Management Group|6-week telemedicine group-based intervention designed to improve symptom management and coping in adults with Post-COVID. The intervention consists of six weekly group sessions that are 1.5 hours long. Group size is 8-10 participants.
61934525|NCT05658536|NO_INTERVENTION|6-Week Waitlist Group|6-week waitlist period during which participants will complete study assessments. After completing the study, waitlist participants will be offered the active intervention.
61934526|NCT03164577|ACTIVE_COMPARATOR|DARTNA|DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
61934527|NCT03164577|PLACEBO_COMPARATOR|Usual care plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
62134058|NCT04230200||Malignancy Cohort|People who were diagnosed as one of the following malignant disease: breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer
62693075|NCT06642896||pupillometry measurement in non-cerebral pediatric patients|feasibility of pupillometry in children for different age groups and obtain baseline values for non-neurologically sedated children in 4 age groups from 0 to 17 years of age
62693076|NCT02073201||High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
62693077|NCT02073201||Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
62693078|NCT02073201||Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
62693079|NCT02805348||Chronic kidney disease|Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.
62693080|NCT06500130|EXPERIMENTAL|Liraglutide Group|All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide intervention.
61934528|NCT05930769||Case group|Patients that have undergone laparoscopy, with surgical indication of myomectomy or adenomyomectomy, with augmented reality (AR).
61934529|NCT05930769||Control group|Patients that have undergone laparoscopy, with surgical indication of myomectomy or adenomyomectomy, without augmented reality (AR).
61934530|NCT06021665|EXPERIMENTAL|Fortetropin Group|The Fortetropin group will receive a 20cc size scoop with their product and will be instructed to mix 2 scoops of product with water or a milk of their choice daily.
61934531|NCT06021665|PLACEBO_COMPARATOR|Control Group|The control group will receive a 50cc size scoop with their product and will be instructed to mix 2 scoops of product with water or a milk of their choice daily. The difference in scoop size is to allow for macronutrient matching of the intervention and control products.
61934532|NCT02862899|EXPERIMENTAL|Heating cable|
61934533|NCT03139318|EXPERIMENTAL|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
62134059|NCT04241952|EXPERIMENTAL|Exercise group|Usual care and bedcycling.
62134060|NCT04241952|NO_INTERVENTION|Control group|Usual care
62134061|NCT02420431|EXPERIMENTAL|metacognitive therapy plus CR|Group psychological treatment focused on reducing worry and rumination and modifying beliefs about thinking in addition to treatment as usual (standard cardiac rehabilitation)
62134062|NCT02420431|ACTIVE_COMPARATOR|CR alone (control)|Usual group-based cardiac rehabilitation (treatment as usual) involving stress management, exercise, education
62134063|NCT00800579|EXPERIMENTAL|1|GS-9411 0.6 mg
62134064|NCT00800579|EXPERIMENTAL|2|GS-9411 1.2 mg
62134065|NCT00800579|EXPERIMENTAL|3|GS-9411 2.4 mg
62485937|NCT03701945|EXPERIMENTAL|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to every patient that accepts the intervention and presents an acute exacerbation
62485938|NCT06485557|EXPERIMENTAL|group A|receive 3 cycles of sintilimab plus platinum-based chemotherapy
62485939|NCT06485557|EXPERIMENTAL|group B|receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
62485940|NCT06485557|EXPERIMENTAL|group C|receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab
62485941|NCT00109512|PLACEBO_COMPARATOR|placebo|
62485942|NCT00109512|EXPERIMENTAL|NBI-56418 75 mg|
62485943|NCT00109512|EXPERIMENTAL|NBI-56418 150 mg|
62485944|NCT04565587|OTHER|Videofluoroscopy|All participants will undergo a Videofluoroscopy when swallowing different viscosity levels of the thickener Tsururinko Quickly (japanese thickener)
62485945|NCT05098743|EXPERIMENTAL|Participants using the medication adherence mobile application.|Participants in this arm will use the Medisafe app to receive medication reminders for thirty days.
62485946|NCT05098743|ACTIVE_COMPARATOR|Participants using a printed copy of their medication list.|Participants in this arm will use a printed out copy of their medication list for thirty days.
62485947|NCT02528279|OTHER|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
62485948|NCT03373643|EXPERIMENTAL|Patient suspected for NAFLD|
62485949|NCT04032418|ACTIVE_COMPARATOR|Arm I (200mg pembrolizumab 3 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
62485950|NCT04032418|EXPERIMENTAL|Arm II (200mg pembrolizumab 12 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
62485951|NCT02331563|EXPERIMENTAL|0.5% bupivacaine|group 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
62485952|NCT02331563|ACTIVE_COMPARATOR|dexmedetomidine added bupivacaine|group II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
62485953|NCT02145273|EXPERIMENTAL|Intervention|Subjects screen positive for depression and are offered a group Therapy intervention for depression: Interpersonal Psychotherapy for Depression Group.
62485954|NCT02145273|NO_INTERVENTION|Control|Subjects screen positive for depression and are offered Treatment as usual: External referral.
62327800|NCT03689283|EXPERIMENTAL|Dry Needling Group|Individuals in the DN arm will receive two treatment sessions of DN to latent trigger points of the gastrocnemius muscle.
62327801|NCT03689283|SHAM_COMPARATOR|Control Group|Individuals in the control group will receive two treatment sessions of sham dry needling.
62485955|NCT02145273|NO_INTERVENTION|comparison|Subjects screen negative for depression: no referral or intervention.
62485956|NCT06032741||mechanical ventilation group|Patients with Guillain-Barré Syndrome require mechanical ventilation during hospitalization
62485957|NCT06032741||no mechanical ventilation group|Patients with Guillain-Barré Syndrome do not require mechanical ventilation during hospitalization
62485958|NCT00705666||PegIntron as monotherapy or in combination with Ribavirin.|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.
62485959|NCT01783535|EXPERIMENTAL|Stratum A|"Participants with early bilateral or unilateral (unifocal or multifocal) retinoblastoma (R-E I-III, IC A-B; R-E IV with IC A or B; or IC C with limited sub-retinal seeding), and participants with bilateral disease in whom the advanced eye has been enucleated upfront (without any high risk histopathology) and the remaining eye has early stage disease (as defined above).~Interventions (see detailed description): vincristine, carboplatin, topotecan, filgrastim or PEG-filgrastim, and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
62485960|NCT01783535|EXPERIMENTAL|Stratum B|"Participants considered candidates for conservative management including those:~1. Participants with bilateral retinoblastoma who have R-E IV-V and IC D in one eye~2. Participants with advanced unilateral (unifocal or multifocal) retinoblastoma (R-E IV-V and IC D-E) who demonstrate foveal sparing by the tumor during EUA. Due to foveal sparing, these patients have potential for vision preservation.~Interventions (see Detailed Description): vincristine, topotecan, carboplatin, etoposide, filgrastim or PEG-filgrastim and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
62485961|NCT01783535|EXPERIMENTAL|Stratum C|"Participants with advanced (R-E IV-V and IC D-E) unilateral retinoblastoma who require upfront enucleation. Participants will be assessed and treated by low, intermediate or high risk.~Interventions (see Detailed Description): vincristine, cyclophosphamide, MESNA, doxorubicin, etoposide, carboplatin, filgrastim or PEG-filgrastim, enucleation"
61934534|NCT01793831|EXPERIMENTAL|Fecal microbiota transplantation|Standard fecal microbiota transplantation, which has been defined as washed microbiota transplantation since 2019.
62327802|NCT05249543|EXPERIMENTAL|Unified protocol|Transdiagnostic cognitive-behavioral therapy focusing on emotional processes central to the development and maintenance of anxiety disorders, particularly neuroticism.
62485962|NCT01783535|EXPERIMENTAL|Stratum D|"Participants with bilateral retinoblastoma who may require upfront enucleation for one eye due to advanced disease (R-E IV-V and IC E).~Interventions (see Detailed Description): vincristine, carboplatin, topotecan, etoposide, enucleation, filgrastim or PEG-filgrastim, focal therapy, including cryotherapy, laser photocoagulation, thermotherapy (and thermo-chemotherapy) and episcleral plaque brachytherapy, and external beam radiation or proton beam radiation in select cases."
61934535|NCT01793831|NO_INTERVENTION|Traditional treatments|Traditional treatments for Crohn's disease and its complications according to the guidelines.
61934536|NCT02854176|EXPERIMENTAL|Somatosensory electrical stimulation|
62693081|NCT05042479|EXPERIMENTAL|Standard treatment then virtual reality then choice between the two|"Efficiency of VR will be evaluated for each patient across 3 potentially painful care-procedures :~For the first treatment, the child will benefit usual distraction and pain prevention techniques.~For the 2nd, the child will use a VR headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age and parental agreement.~For the 3rd treatment, the child will choose his/her favorite technique."
61934537|NCT02854176|SHAM_COMPARATOR|Control|
61934538|NCT04282512|EXPERIMENTAL|Group A : sodium bicarbonate-rich mineral water and tap water|"First 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.~15-days washout period Last 15-days period with daily intake of 1.5l of tap water."
61934539|NCT04282512|EXPERIMENTAL|Group B : tap water and sodium bicarbonate-rich mineral water|First 15-days period with daily intake of 1.5l of tap water. 15-days washout period Last 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
61934540|NCT05173480|EXPERIMENTAL|Experimental group|VRRS rehabilitation exercise therapy through a virtual reality rehabilitation system in addition to conventional rehabilitation.
61934541|NCT05173480|ACTIVE_COMPARATOR|Control group|VRRS rehabilitation exercise therapy through a virtual reality rehabilitation system, with sensors not connected, in addition to conventional rehabilitation.
61934542|NCT02405754||Treatment Group|Patients receiving Age/Sex/Gene Expression Score (ASGES) or Corus CAD test
61934543|NCT03084510|EXPERIMENTAL|Lotus Edge™ Valve System|The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
61934544|NCT04378946|EXPERIMENTAL|Experimental - Error Augmented feedback (Restricted area)|Error augmented feedback. Random targets always INSIDE of workspace area.
61934545|NCT04378946|ACTIVE_COMPARATOR|Control - General feedback (Full area)|General feedback about task success. Random target INSIDE or OUTSIDE of workspace area.
62327803|NCT05249543|ACTIVE_COMPARATOR|Diagnosis-specific cognitive-behavioral therapy|Cognitive-behavioral therapy specifically designed for a particular anxiety disorder as specified in evidence-based treatment protocols, which are commonly based on a specific theory or model of the development and maintenance of an anxiety disorder.
62327804|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
62327805|NCT01563484||low-osmolar contrast media|Patients undergo TACE of low-osmolar contrast media on day 1.
62327806|NCT01563484||iso-osmolar contrast media|Patients undergo TACE of iso-osmolar contrast media on day 1.
62693082|NCT06673498|EXPERIMENTAL|Treatment group|Lusutrombopag combined with recombinant human thrombopoietin
62693083|NCT05910424|EXPERIMENTAL|Adults with Autism Spectrum Disorder|"* Adults with autism spectrum disorder~* Aged between 18 and 60 years old~* Dental cares and follow-up in Nancy hospital"
62693084|NCT03899428|EXPERIMENTAL|Immune Checkpoint Therapy|The subjects will receive durvalumab 1500 mg Q4W
62134066|NCT00800579|PLACEBO_COMPARATOR|4|Inhaled volume-matched sterile saline placebo
62327807|NCT03023982|EXPERIMENTAL|Pectoralic block group|After general anesthesia, 40ml of 0.25% Bupivacaine Hydrochloride will be administered before procedure Thoracotomy. Block will be administrated between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib., in assistance of ultrasound for visualization anesthetic injection point.
62693085|NCT03899428|EXPERIMENTAL|Target Therapy|The subjects will receive tyrosine kinase inhibitors, including sorafenib, lenvatinib, regorafenib, or cabozantinib, daily
61934546|NCT01365065|EXPERIMENTAL|Vorinostat|Vorinostat 400mg ( 4 X 100mg ) orally daily for 14 days
61934547|NCT02554851|PLACEBO_COMPARATOR|placebo|This group will receive the standard medication and the placebo drug
61934548|NCT02554851|EXPERIMENTAL|recombinant human Epidermal Growth Fact|This group will receive the standard medication and the recombinant human Epidermal Growth Factor (HEBERPROT)
61934549|NCT02471976|NO_INTERVENTION|Group A|the centres applies their usual practices
61934550|NCT02471976|OTHER|Group B|strategy promoting early consideration and collegiate vulnerability of patients
61934551|NCT05110443|OTHER|Main arm|Patients will perform a D-WB PET/CT scan as a substitute for their clinical PET.
61934552|NCT06556693|EXPERIMENTAL|Intervention group|
62327808|NCT03023982|ACTIVE_COMPARATOR|Control group|Patients in this group will receive standard pain control with opioids and NSAIDs
62693086|NCT06644313|EXPERIMENTAL|Vebreltinib|
62693087|NCT05064722|EXPERIMENTAL|SNAP-S|Creation of a D-I diversion in participants undergoing primary sleeve gastrectomy (SNAP-S cohort)
62693088|NCT05064722|EXPERIMENTAL|SNAP-PS|Creation of a D-I diversion in participants who have experienced inadequate weight loss following sleeve gastrectomy (SNAP-PS cohort)
62693089|NCT04721106||Vizimpro treatment group|This group is included the patients that Vizimpro are prescribed and administrated according to local label in the routine clinical practice
61934553|NCT05339126|ACTIVE_COMPARATOR|Condition A|high-frequency short bursts (HFSB: 100 Hz, 160 µs pulse width, 200 msec burst)
61934554|NCT05339126|ACTIVE_COMPARATOR|Condition B|low-frequency long bursts (LFLB: 5 Hz, 160 µs pulse width, 5 sec burst)
61934555|NCT03860961|ACTIVE_COMPARATOR|Standard Survivorship Care Plan (SCP)|Practices review a SCP with patients and send it to the PCP during the last week of RT.
61934556|NCT03860961|EXPERIMENTAL|Enhanced Survivorship Care Plan (SCP)|Practices review a treatment plan with patient and send it to the PCP at the beginning of RT. Practices also review a SCP with patients and send it to the PCP during the last week of RT.
61934557|NCT01484054|OTHER|EAPVPDE/EADE|etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
62134067|NCT06058585|EXPERIMENTAL|Finerenone|Finerenone 10mg or 20mg tablets
62134068|NCT06058585|PLACEBO_COMPARATOR|Placebo Finerenone|Finerenone matched placebo tablets
62134069|NCT05220943|OTHER|Video|All participants are invited to complete a pre survey, watch a five minute video, and then complete a post survey.
62693090|NCT06639672|EXPERIMENTAL|Arm 1|8Gy x 3f + Chemotherapy+Immunotherapy
62693091|NCT06639672|EXPERIMENTAL|Arm 2|16Gy x 1f + Chemotherapy+Immunotherapy
62693092|NCT06639672|EXPERIMENTAL|Arm 3|2.76Gy x 15f + Chemotherapy+Immunotherapy
62693093|NCT06639672|EXPERIMENTAL|Arm 4|0.5Gy x 12-18f + Chemotherapy+Immunotherapy
61934558|NCT01484054|OTHER|EADE/EAPVPDE|etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
62134070|NCT01233115||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections
62134071|NCT00971724|PLACEBO_COMPARATOR|Placebo|Treatment with placebo for 15 days
62327809|NCT05239897|EXPERIMENTAL|postoperative delirium|We will use Confusion Assessment Method (CAM) to determine the incidence of postoperative delirium in participants twice per day. We will use the Memorial Delirium Assessment Scale(MDAS)and Mini-mental state examination(MMSE) to examine postoperative delirium severity.
62134072|NCT00971724|EXPERIMENTAL|Prednisolone 7.5 mg daily|Treatment with prednisolone 7.5 mg daily for 15 days
62134073|NCT00971724|EXPERIMENTAL|Prednisolone 15 mg daily|Treatment with prednisolone 15 mg daily for 15 days
62134074|NCT00971724|EXPERIMENTAL|Prednisolone 30 mg daily|Treatment with prednisolone 30 mg daily for 15 days
62134075|NCT00971724|EXPERIMENTAL|Prednisolone 75 mg|Treatment with prednisolone 75 mg for a single day
62134076|NCT00971724|EXPERIMENTAL|Prednisolone 15 mg twice daily|Treatment with prednisolone 15 mg twice daily for a single day
62134077|NCT06366490|EXPERIMENTAL|Innocell an Autologous Cellular Immunotherapy|Autologous Cellular Immunotherapy
62134078|NCT06417892||Fruquintinib + albumin paclitaxel|Fruquintinib combined with albumin paclitaxel
62134079|NCT06417892||Fruquintinib + albumin paclitaxel + PD-1 antibody|Fruquintinib, albumin paclitaxel combined with PD-1 antibody
62134080|NCT01094626|EXPERIMENTAL|Experimental|Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
62485963|NCT03829670||Delirium Group|"1. UBACC: University of California, San Diego Brief Assessment of Capacity to Consent.~2. The participant may decline participation after this UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) assessment and will be removed from the study.~3. The Short IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) is administered to the legally authorized representative or caregiver by Dr. Schmidt. If the potential participant scores 3.3 or lower, the participant will continue in the delirium group. If higher, patient likely with pre-existing dementia. These patients are not eligible for study participation.~4. Delirium Rating Scale 98 will be performed on the ALGH (Advocate Lutheran General Hospital) rehabilitation unit~5. Cytochrome P450 testing~6. Delirium Status: Admission, Hospital Discharge, Outpatient Visit~7. FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
62693094|NCT02709707||Patients with diabetes|
61934559|NCT01702831|EXPERIMENTAL|BuMel + lenalidomide Maintenance|I.V. Busulfan + I.V. Melphalan for conditioning prior ASCT, followed by Lenalidomide maintenance at day 100 after ASCT.
61934560|NCT01880216|ACTIVE_COMPARATOR|Enoxaparin sodium|subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
62693095|NCT04066504||Sonidegib|Patients with laBCC undergoing sonidegib treatment in routine clinical practice
61934561|NCT01880216|EXPERIMENTAL|Bemiprin sodium|Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
62134081|NCT01094626|NO_INTERVENTION|Controls|Fifteen subjects will be selected as controls, undergoing MRI without secretin-enhancement and matched for age, sex, race and tumor-type.
62134082|NCT04255979|EXPERIMENTAL|Cohort 1|Single dose of HY209 0.1 mg/kg or placebo.
62134083|NCT04255979|EXPERIMENTAL|Cohort 2|Single dose of HY209 0.2 mg/kg or placebo.
62134084|NCT04255979|EXPERIMENTAL|Cohort 3|Single dose of HY209 0.4 mg/kg or placebo.
62327810|NCT05599126|EXPERIMENTAL|Mianserin with escitalopram|
62693096|NCT02531451|EXPERIMENTAL|Ibuprofen|Resistance exercise 20 sessions during 8 weeks Daily consumption of 1200 mg ibuprofen (400 mg x 3) during 8 weeks
61934562|NCT06488248|EXPERIMENTAL|Endoscopic third ventriculostomy (ETV) group|The investigational group undergoes endoscopic third ventriculostomy (ETV) for the treatment of idiopathic normal pressure hydrocephalus (iNPH).
62134085|NCT04255979|EXPERIMENTAL|Cohort 4|Single dose of HY209 0.8 mg/kg or placebo.
62134086|NCT04255979|EXPERIMENTAL|Cohort 5|Single dose of HY209 1.6 mg/kg or placebo.
62134087|NCT04255979|EXPERIMENTAL|Cohort 6|Single dose of HY209 3.2 mg/kg or placebo.
62134088|NCT06145802|EXPERIMENTAL|GT316 treatment group|
62134089|NCT02097381|OTHER|naïve for cART that met the criteria to start treatment|"patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy."
62134090|NCT02189434||Cytoreductive surgery|Patients having undergone cytoreductive surgery with or without HIPEC will have serum procalcitonin lab draws
62134091|NCT02436174||study group|patients undergoing cesarean under epidural anesthesia
62134092|NCT01154387|ACTIVE_COMPARATOR|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
62134093|NCT01154387|EXPERIMENTAL|TOL101 (Dose A)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
62134094|NCT01154387|EXPERIMENTAL|TOL101 (Dose B)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
62134095|NCT02731599|EXPERIMENTAL|treadmill training|20-minutes treadmill training per day, 6 times a week, for 4 weeks
62134096|NCT02023346||Malignant Glioma patients|This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
62327811|NCT05599126|ACTIVE_COMPARATOR|Lorazepam with escitalopram|
62693097|NCT02531451|ACTIVE_COMPARATOR|Acetylsalicylic acid|Resistance exercise 20 sessions during 8 weeks Daily consumption of 75 mg acetylsalicylic acid (75 mg x 1) during 8 weeks
62693098|NCT03184025|OTHER|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
61934563|NCT06488248|OTHER|Ventriculoperitoneal shunt (VPS) group|The control group undergoes ventriculoperitoneal shunt (VPS) implantation for the treatment of iNPH.
62327812|NCT06478758|ACTIVE_COMPARATOR|Acetaminophen group|The acetaminophen group (n=35) received 1000 of mg acetaminophen intravenously in 100 mL saline at the end of the cholecystectomy.
62327813|NCT06478758|EXPERIMENTAL|Ibuprofen group|The ibuprofen group (n=36) was administered 800 mg of ibuprofen at the end of the cholecystectomy.
62327814|NCT04089605|EXPERIMENTAL|intravitreal dexamethasone implant|The eyes undergo dexamethasone intravitreal implant 0.7 mg injections at baseline and every 3 or 4 months thereafter. Dexamethasone implants are re-injected in minimal 3-month interval if macular edema persisted or recurred with CFT more than 350 μm or manifestation of apparent submacular fluid and/or intramacular cysts. If DME subside with CFT less than 350 μm without accompanying fluid and cysts, repeated injection is mandatory in maximal 4-month interval.
62327815|NCT04089605|ACTIVE_COMPARATOR|intravitreal ranibizumab|As for intravitreal ranibizumab 0.5 mg (IVR), we use OCT-guided treat-and-extend protocol for DME treatment after modifying the settings of TREX-DME study.4 The regimen include 3 monthly loading doses then extending the treatment injection interval one month more if CFT less than 350 μm without obvious submacular fluid and intramacular cysts. The injection interval shorten one month if CFT more than 350 μm or presence of obvious fluid and/or cysts. The patients are intentionally injected at most every 3 months even DME not existing.
62327816|NCT02379234|NO_INTERVENTION|Control|"All nurses received a 4 hours formation, called conventional formation, given by a professional trainer, that included 2 hours of theorical formation and 2 hours of practical training, based on CVVH generator demonstration. In addition, the trainer was present in the ICU during the first week of CVVH implementation, to answer any questions and to help nurses with their first CVVH sessions"
62327817|NCT02379234|EXPERIMENTAL|Simulated|The 'Simulated formation',used high fidelity mannequin and CVVH generator, is composed of 3 training sessions of 2 hours each one. This formation is associated with the 'conventional formation'.
62327818|NCT03075397|OTHER|HIV-1 infected patients|Blood sample and sperm sample are collected
62327819|NCT00983450|EXPERIMENTAL|study group|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
62327820|NCT00983450|EXPERIMENTAL|CONTROL|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
62327821|NCT03077178|EXPERIMENTAL|Prospective cohort|Geriatric assessment
62327822|NCT02659683|EXPERIMENTAL|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
62327823|NCT02659683|ACTIVE_COMPARATOR|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
62327824|NCT04833985|EXPERIMENTAL|transesophageal echocardiography guidance|
62327825|NCT04833985|EXPERIMENTAL|intracardiac echocardiography guidance|
62327826|NCT04833985|EXPERIMENTAL|fluoroscopy only guidance|
62327827|NCT02915861||EXPa|Scrub typhus patients: Group A
62327828|NCT02915861||EXPb|Scrub typhus patients: Group B
62327829|NCT02915861||EXPc|Scrub typhus patients: Group C
62327830|NCT02915861||EXC|Control group
62327831|NCT03631862|EXPERIMENTAL|Apatinib combined with CHOP regimen|Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
62327832|NCT03631862|EXPERIMENTAL|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
62327833|NCT04691752||COPD patients|"* Adults (men or women) aged more than 40 years old~* Diagnostic code in Andalusian clinical records (Diraya) in accordance with ICD-9 (Diagnostic codes 496, 492.8, 494.0, 491.20, 493.2)~* Current of former smokers of at least 10 pack- years~* Patient with a minimum follow up of 1 year, who have been assisted in a scheduled primary care appointment at inclusion date."
62327834|NCT02929563|EXPERIMENTAL|pantoprazole|pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.
62327835|NCT02929563|PLACEBO_COMPARATOR|placebo (for pantoprazole)|an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.
62327836|NCT00711399||group A|Study group
62693099|NCT06151717||Observational|Patients have their medical records reviewed on study.
62327837|NCT04852588|EXPERIMENTAL|Treatment Arm|Small pieces of suspicious chest lymph nodes will be removed with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA).
62327838|NCT01061515|EXPERIMENTAL|Dose Level 1|"Intraperitoneal oxaliplatin 25 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
62327839|NCT01061515|EXPERIMENTAL|Dose Level 2|"Intraperitoneal oxaliplatin 50 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
62327840|NCT01061515|EXPERIMENTAL|Dose Level 3|"Intraperitoneal oxaliplatin 65 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
62327841|NCT01061515|EXPERIMENTAL|Dose Level 4|"Intraperitoneal oxaliplatin 85 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
61934564|NCT00003254|EXPERIMENTAL|776C85 + 5-FU|776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
61934565|NCT05005754|EXPERIMENTAL|Probiotics|Subjects are instructed to take one capsule of probiotics daily for a total of 3 months
61934566|NCT05005754|PLACEBO_COMPARATOR|Placebo Control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
62485964|NCT03829670||Patients without delirium|"1. Cytochrome P450 testing~2. Delirium Status: Admission, Hospital Discharge, Outpatient Visit~3. FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
62693100|NCT06539728|EXPERIMENTAL|Interaction with Coated Surfaces|"Participants in this arm will interact with the device and surface coated with the polymer-antibody coating. Subjects will be trained with a positive test and negative test prior to device testing. Subjects will then administer the synthetic saliva themselves and asked to determine if there was COVID antigen in the saliva by touching the device to compare the test patch to the positive and negative control patches. Subjects will also rate device usability."
62693101|NCT02065986|EXPERIMENTAL|Arm A: Immediate offer of Truvada-PrEP|Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
62134097|NCT04527094||AI_PRF|Adults patients undergoing general anesthesia
62327842|NCT01061515|EXPERIMENTAL|Dose Level 5|"Intraperitoneal oxaliplatin 100 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
62327843|NCT04018963||Uninostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the single nostril approach.
62327844|NCT04018963||Binostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the bilateral nostril approach.
62327845|NCT06689059||Hip Replacement Cohort|This cohort includes patients undergoing hip replacement surgery. The HoPreM platform is used for multi-task predictive analysis of perioperative complications, including AKI, blood transfusion requirements, postoperative discharge within 48 hours, ICU transfer, and length of hospital stay (LOS).
62327846|NCT01832714||mTBI|Subjects who undergo an mTBI event
62327847|NCT01832714||Control|Subjects who do not undergo an mTBI
62327848|NCT02688842|EXPERIMENTAL|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
62327849|NCT02510235|EXPERIMENTAL|Lubricin|Lubricin 150 µg/ml eye drops solution
62327850|NCT02510235|ACTIVE_COMPARATOR|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
62327851|NCT00921856|NO_INTERVENTION|CAD|Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.
62327852|NCT00921856|EXPERIMENTAL|No-CAD|Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.
62327853|NCT05070273|EXPERIMENTAL|Hypoglossal nerve conduction study.|
62327854|NCT03356158|EXPERIMENTAL|CPGJ 602 low dose|Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
62327855|NCT03356158|EXPERIMENTAL|CPGJ 602 normal dose|Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
62327856|NCT03356158|ACTIVE_COMPARATOR|Cetuximab normal dose|Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.
62327857|NCT03782818|EXPERIMENTAL|Olaparib|After a 4-week pre-treatment phase to ensure that patients are on stable doses of PAH medication, patients will be given progressive doses of olaparib up to 300 mg BID for 24 weeks.
62134098|NCT03190850|EXPERIMENTAL|Intervention|"Intervention: Exercises wih load Device: Powerbreathe"
62134099|NCT03190850|PLACEBO_COMPARATOR|Control|Control: Exercises without load
62134100|NCT01218490|EXPERIMENTAL|lymphadenectomy|after surgery of the ovarian cancer, patient will have Pelvis and aortic-cava lymphadenectomy
62134101|NCT01218490|NO_INTERVENTION|no lymphadectomy|after surgery, the patient will not have pelvic and aortic-cave lymphadenectomy
62134102|NCT01995903|EXPERIMENTAL|Amyotrophic lateral sclerosis|Clinical examination for ALS(amyotrophic lateral sclerosis) and subjects with lower motor neuron signs will be completed. These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to assess neurological conditions.
62327858|NCT06257238|EXPERIMENTAL|Experimental|The study group includes 38 post neck dissection surgeries with shoulder dysfunction patients treated with fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller) for 30 min., each session includes three games exercise (Dance loop, Tennis and Boxing) with 10 min. for each game and 1 min. rest in between; in addition to their physical therapy program (Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
62327859|NCT06257238|ACTIVE_COMPARATOR|Active comparator|The study group includes 38 post neck dissection surgeries with shoulder dysfunction patients treated with traditional physical therapy program (Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
62327860|NCT03417284|EXPERIMENTAL|Group 1 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L."
62327861|NCT03417284|EXPERIMENTAL|Group 2 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L."
62327862|NCT04758273|EXPERIMENTAL|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
62327863|NCT04758273|EXPERIMENTAL|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
62693102|NCT02065986|OTHER|Arm B: Deferred (12m) offer of Truvada-PrEP|Access to Truvada from 12 months after enrolment
62693103|NCT04209543|EXPERIMENTAL|Estetrol 15 mg -Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
62134103|NCT01995903|ACTIVE_COMPARATOR|Healthy controls (MRI)|These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to compare against diseased subjects.
62327864|NCT04758273|PLACEBO_COMPARATOR|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
62485965|NCT06559917|EXPERIMENTAL|Experimental Group|"Upon admission to the cancer-related ward, after explaining the purpose and process of the study, patients who agree to participate in the study will complete the first questionnaire before the intervention with the social media Happiness Ledger. The family members will have one week to organize photos, after which the patients will share the meaning of the photos. The process will be recorded by the researcher and will last approximately 40 to 60 minutes. Afterward, the researcher will create a video of about three minutes using the photos and ask the participating family members to assist in uploading the photos to the family LINE group as feedback to the research subjects. The patients will then complete the second questionnaire."
62693104|NCT04209543|EXPERIMENTAL|Estetrol 20 mg -Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
61934567|NCT01200849|EXPERIMENTAL|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
61934568|NCT01200849|NO_INTERVENTION|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
61934569|NCT03548233|OTHER|bcg vaccinated|children under five year vaccinated by bcg vaccine
61934570|NCT05218239|ACTIVE_COMPARATOR|Routine education group|Routine education, including postpartum lifestyle, Kegel exercise and Knack method.
61934571|NCT05218239|EXPERIMENTAL|Global training group|Global training was added on the basis of routine education.
61934572|NCT00976170|EXPERIMENTAL|1|
61934573|NCT00753779|EXPERIMENTAL|1|colesevelam HCl Tablets and simvastatin tablets
61934574|NCT00753779|PLACEBO_COMPARATOR|2|simvastatin and Welchol placebo
61934575|NCT04594148|EXPERIMENTAL|Weight-shift training|The experimental group will receive a single session of 10x 2.5min of weight-shift training with the VR Wasp Game
61934576|NCT04594148|NO_INTERVENTION|Passive control|The passive control group will not receive any form of training. Instead, they will relax for 25min (i.e. talking with the researcher and/or reading a magazine)
61934577|NCT01910571|EXPERIMENTAL|P7435|"* In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~* In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
61934578|NCT01910571|PLACEBO_COMPARATOR|Placebo|"* In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~* In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
61934579|NCT06706843|EXPERIMENTAL|motivational interview group|This group received motivational interviewing training based on the transtheoretical model.
62327865|NCT04758273|EXPERIMENTAL|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62485966|NCT06559917|NO_INTERVENTION|Control Group|"After explaining the purpose and process of the study to the patients and their family members on the day of admission, and obtaining their consent to participate in the study, they will complete the first questionnaire. One week later, they will complete the second questionnaire. After the entire study is completed, the control group will receive the same social media Happiness Ledger intervention as the experimental group. Data collection will be conducted for both groups before and after the intervention."
62485967|NCT05651243|EXPERIMENTAL|Ketone Ester|Oral ketone ester supplement
62485968|NCT05651243|PLACEBO_COMPARATOR|Placebo|Taste and viscosity matched placebo
62485969|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
62134104|NCT04689178|EXPERIMENTAL|Invitation letter + GP reminder (Arm 1)|
62327866|NCT04758273|EXPERIMENTAL|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62327867|NCT04758273|PLACEBO_COMPARATOR|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
62327868|NCT04758273|EXPERIMENTAL|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62693105|NCT04209543|PLACEBO_COMPARATOR|Placebo - Efficacy Part|Placebo will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
62693106|NCT04209543|EXPERIMENTAL|Estetrol 20 mg + P4 100 mg - Safety Part|Estetrol (E4) 20 mg and Progesterone (P4) 100 mg will be administered once daily for up to 53 weeks
61934580|NCT06706843|EXPERIMENTAL|control group|No intervention was performed. Patients continued their routine treatment.
61934581|NCT00598702|EXPERIMENTAL|IV Acetaminophen|40 to 75 mg/kg/day every 4 to 6 hours
61934582|NCT04916769|EXPERIMENTAL|Bosutinib capsule contents mixed with applesauce|Bosutinib capsule contents mixed with applesauce to healthy participants
61934583|NCT04916769|EXPERIMENTAL|Bosutinib capsule contents mixed with yogurt|Bosutinib capsule contents mixed with yogurt to healthy participants
61934584|NCT04916769|ACTIVE_COMPARATOR|Bosutinib intact capsules|Bosutinib intact capsules to healthy participants
62134105|NCT04689178|ACTIVE_COMPARATOR|Invitation letter (Arm 2)|
62134106|NCT04689178|NO_INTERVENTION|Usual care (Arm 3)|
62134107|NCT01868399||Suspected dengue fever subjects|No any intervention
62134108|NCT01868399||Community Healty Residents|No intervention
62134109|NCT02317783|EXPERIMENTAL|All Participants|All enrolled subjects will complete three imaging sessions on separate days that consist of: 1) \[18F\]Flutemetamol-PET/CT, 2) FDG-PET/CT, and 3) MRI. The order of the performance of these studies will be based upon subject and radioisotope availability, but they will all be completed within 2 months of each other.
62134110|NCT01412736|EXPERIMENTAL|2mg|sterile lyophilized formulation, 2mg
62485970|NCT02624297|NO_INTERVENTION|Control Group|Healthy control group for comparisons with coronary artery disease groups.
62693107|NCT06371378|ACTIVE_COMPARATOR|GROUP I: PEEP 0|Patients will receive 0 cmH20 PEEP
62693108|NCT06371378|ACTIVE_COMPARATOR|GROUP II: PEEP 4|Patients will receive 4 cmH20 PEEP
62693109|NCT06371378|ACTIVE_COMPARATOR|GROUP III: PEEP 8|Patients will receive 8 cmH20 PEEP
62693110|NCT04100993||Patient group|60 participants ≥16 years of age with a confirmed diagnosis of a childhood-onset NMD
61934585|NCT06317441|EXPERIMENTAL|Probiotic (High dose)|A high dosage probiotic per capsule
61934586|NCT06317441|EXPERIMENTAL|Probiotic (Low dose)|A low dosage probiotic per capsule
61934587|NCT06317441|NO_INTERVENTION|Control group (Placebo)|No probiotic dosage
61934588|NCT01047735|EXPERIMENTAL|Roux-en-Y Gastric Bypass Surgery|Roux-en-Y Gastric Bypass Surgery
61934589|NCT01047735|EXPERIMENTAL|Laparoscopic Adjustable Gastric Banding|Laparoscopic Adjustable Gastric Banding
61934590|NCT01047735|EXPERIMENTAL|Lifestyle/Behavioral Weight Loss|Lifestyle Weight Loss Intervention
61934591|NCT05630092|ACTIVE_COMPARATOR|Maximal then Normal Speed Walk Test|Maximal speed walking test (Max_6MWT) followed by normal speed walking test (Nor_6MWT).
61934592|NCT05630092|ACTIVE_COMPARATOR|Normal then Maximal Speed Walk Test|Normal speed walking test (Nor_6MWT) followed by Maximal speed walking test (Max_6MWT)
61934593|NCT00423670|ACTIVE_COMPARATOR|Arm 1. PEG +RBV for 48 Wks (Part I)|"Participants treated with PegIntron (1.5 μg/kg, once weekly \[QW\]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily \[TID\]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks."
61934594|NCT00423670|EXPERIMENTAL|Arm 2. PEG + RBV + BOC for 28 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
61934595|NCT00423670|EXPERIMENTAL|Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
61934596|NCT00423670|EXPERIMENTAL|Arm 4. PEG +RBV + BOC for 48 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
61934597|NCT00423670|EXPERIMENTAL|Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
62134111|NCT01412736|EXPERIMENTAL|20mg|sterile lyophilized formulation, 20mg
62485971|NCT02624297|NO_INTERVENTION|CAD without OSA - Control|Clinical follow-up.
62693111|NCT04100993||Exploratory reference group|20 healthy adults ≥16 years of age
62693112|NCT05531942|ACTIVE_COMPARATOR|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours;combined with Acetylsalicylic acid (Aspirin) given at a dose of 100 mg per day for 90 days.
62693113|NCT05531942|PLACEBO_COMPARATOR|aspirin|Patients in the aspirin group received the same volume saline injection as placebo for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
61934598|NCT00423670|EXPERIMENTAL|Arm 6. PEG + RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
61934599|NCT00423670|EXPERIMENTAL|Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
62134112|NCT01412736|EXPERIMENTAL|100mg|sterile lyophilized formulation, 100mg
62134113|NCT01412736|PLACEBO_COMPARATOR|Placebo|two SC administration on day 1
62134114|NCT02766946|EXPERIMENTAL|Mechanical Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Mechanical Ventilation~Interventions :~* Ultrasound of the right diaphragm~* Ultrasound of the pectoral muscle~* Neuromyopathy score~* Respiratory performances"
62134115|NCT02766946|ACTIVE_COMPARATOR|Non-invasive Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Non-invasive Ventilation~Interventions :~* Ultrasound of the right diaphragm~* Ultrasound of the pectoral muscle~* Neuromyopathy score~* Respiratory performances"
62134116|NCT02766946|ACTIVE_COMPARATOR|Spontaneous Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Spontaneous Ventilation~Interventions :~* Ultrasound of the right diaphragm~* Ultrasound of the pectoral muscle~* Neuromyopathy score~* Respiratory performances"
62134117|NCT06127147|EXPERIMENTAL|Study Group|Patients who will perform inspiratory muscle training (IMT) with %60 of MIP intensity
62485972|NCT02624297|EXPERIMENTAL|CAD without OSA - Intervention|Aerobic exercise training.
62485973|NCT02624297|NO_INTERVENTION|CAD with OSA - Control|Clinical follow-up.
62485974|NCT02624297|EXPERIMENTAL|CAD with OSA - Intervention|Aerobic exercise training.
62485975|NCT02873832||MPS|
62485976|NCT02873832||Control|
62485977|NCT06561451|EXPERIMENTAL|ICSI+AOA group|ICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
62485978|NCT06561451|ACTIVE_COMPARATOR|ICSI group|a single sperm will be injected within 4 hours after the follicular aspiration.
62485979|NCT00940563|EXPERIMENTAL|Imatinib|
62134118|NCT06127147|SHAM_COMPARATOR|Sham Group|Patients who will perform Sham-IMT
62485980|NCT02726360||Oncology physician|Physicians (MD or DO) in the oncology departments of participating hospitals will complete a survey. Non-English language proficiency will be assessed by self-assessment using Interagency Language Roundtable (ILR) scale, which the PI has previously used. The physician survey is collected among treating physicians of patients enrolled to MSK IRB approved protocols 12-099 and 12-223 at some of the participating hospitals. For physicians who already completed this survey as part of participation in protocol 12-099 or 12-223, data will be extracted from the respective study's REDCap database.
62485981|NCT02726360||patients|Audio record the initial visits between patients and their treating physician. Analyze 48 patient-physician dyad recordings using the Roter Interaction Analysis System (RIAS).
62485982|NCT00425308|ACTIVE_COMPARATOR|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|Everolimus dose has been adjusted to reach in Group 2, assessment of everolimus dose/trough level (C0), between 6 and 10 ng/ml plus Enteric-coated Mycophenolate Sodium (EC-MPS) 720 mg/d (360mg the morning and 360 mg the evening) plus steroids
62485983|NCT00425308|ACTIVE_COMPARATOR|Everolimus + Cyclosporine|Everolimus dose has been adjusted to reach in Group 1, assessment of everolimus dose/trough level (C0), between 3 and 8 ng/ml plus Cyclosporine in which Group 1 dose adjusted to reach, assessment of Cyclosporine dosage and blood concentration (C2), between 200 and 450 ng/ml plus steroids
62485984|NCT00989950|EXPERIMENTAL|Daytrana 9 hr wear|
62485985|NCT00989950|EXPERIMENTAL|Daytrana 10 hr wear|
62485986|NCT00989950|EXPERIMENTAL|Daytrana 11 hr wear|
62485987|NCT00989950|EXPERIMENTAL|Daytrana 12 hr wear|
62485988|NCT00087529|EXPERIMENTAL|1|
62485989|NCT00087529|PLACEBO_COMPARATOR|2|
62485990|NCT03821974|EXPERIMENTAL|dry group|The sequence of the technique of the puncture is dry-wet-dry-wet.
62485991|NCT03821974|EXPERIMENTAL|wet group|The sequence of the technique of the puncture is wet-dry-wet-dry.
62693114|NCT05253196|EXPERIMENTAL|Use of Foley Catheter Assistive Device|All participants will use Foley Catheter Assistive Device
61934600|NCT00423670|EXPERIMENTAL|Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I)|"Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks."
61934601|NCT04407611|NO_INTERVENTION|Conventional modality|Control arm. Conventional modality entails telephone disclosure of genetic results by a licensed genetic counselor.
61934602|NCT04407611|EXPERIMENTAL|Online modality|Online self-guided modality entails return of genetic results directly to participants, with optional genetic counselor follow-up via telephone.
61934603|NCT06708091||population description|adult patients with T2DM who initiated add-on SGLT2i treatment to gliclazide MR 60 mg, in routine practice
61934604|NCT03114488|EXPERIMENTAL|Anodal Stimulation|
61934605|NCT03114488|SHAM_COMPARATOR|Sham Stimulation|
62134119|NCT00476463|ACTIVE_COMPARATOR|1|AZT+FTC+EFV
61934606|NCT04963231|EXPERIMENTAL|Stage 1: Setmelanotide (Open-Label)|Participants received once daily SC injection of setmelanotide from Day 1 to Week 16 in an open-label treatment stage (Stage 1). Participants ≥12 years of age started on setmelanotide 2.0 milligrams (mg) once daily for approximately 2 weeks, then increased to 3.0 mg once daily. Participants \<12 years of age started on setmelanotide 1.0 mg once daily for approximately 1 week, then increased to 2.0 mg once daily for approximately 1 week, then increased to 3.0 mg once daily.
62134120|NCT00476463|ACTIVE_COMPARATOR|2|TDF+FTC+EFV
62134121|NCT02380105|EXPERIMENTAL|Counseling Group|Patients allocated to the counseling group (Group I) were informed about possible etiological factors and educated to not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions, as a way of reinforcing the information provided during the initial consultation. In subsequent returns at 7, 15, 30 and 60 days of follow-up, the instructions were given again and patients were asked whether they had detected any habits related to the initiation and maintenance of painful symptoms of TMD, as a way to further highlight the association between the presence of these harmful behaviors and the worsening signs and symptoms of TMD.
62327869|NCT04758273|EXPERIMENTAL|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
62327870|NCT04758273|PLACEBO_COMPARATOR|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
62485992|NCT06039306|EXPERIMENTAL|intervention|Participants will be given 2 servings immunonutrition daily for five (5) days before tentative elective surgery. ERAS protocol will implement and continued 2 servings of immunonutrition for post-operative seven (7) days.
62485993|NCT06039306|NO_INTERVENTION|conventional|Participants will be on usual diet intake before tentative elective surgery. ERAS protocol will implement and will be prescribed 2 servings of polymeric formula daily only if unable to finish 75% of the diet served in ward.
62485994|NCT06154083|EXPERIMENTAL|Follitropin-delta 20 mcg/day from D1|
62485995|NCT06154083|ACTIVE_COMPARATOR|Follitropin-delta 15 mcg/day from D1|
62485996|NCT04876001|EXPERIMENTAL|Face-to-face BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call."
62485997|NCT04876001|EXPERIMENTAL|Web-based BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call. All treatments will be delivered using pre-established web and telephone."
62485998|NCT04876001|NO_INTERVENTION|Waiting-list|The participant in this arm will be asked to filled the online questionnaires at weeks 0 (baseline), 1 (mid-treatment), 2 (post-treatment), 4 and 12 (follow up). After the final follow up, all participants will be allowed to join the web-based BBTI treatment.
62485999|NCT03412058|EXPERIMENTAL|Melanoma|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
62693115|NCT04108156|EXPERIMENTAL|PDS Arm|Participants randomized to the PDS arm will receive intravitreal ranibizumab injection every 4 weeks (loading phase) and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 24-weeks (Q24W) thereafter
62486000|NCT03412058|EXPERIMENTAL|NSCLC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
62486001|NCT03412058|EXPERIMENTAL|HNSCC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
62486002|NCT03553979|EXPERIMENTAL|Stress management program (SM)|The stress management program (SM) is a program which has been tailored to meet the specific needs of low-SES participants. The SM consists of 4-weekly sessions (1.5hours/session) and a follow-up session 8 weeks later. A core element of SM is its group-based format in which psycho-educative topics on stress responses and coping and motivation to stop smoking link up with cognitive and behavioural technique activities.
62693116|NCT04108156|ACTIVE_COMPARATOR|Intravitreal Arm|Participants randomized to the intravitreal arm will receive intravitreal ranibizumab injection every 4 weeks until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.
62693117|NCT04108156|EXPERIMENTAL|Substudy: Cohort 1|Participants will undergo re-implantation with the updated PDS implant (pre-filled with ranibizumab 100 mg/mL) on Day 1 (or enrollment visit) and then will have two refill-exchanges (ranibizumab 100 mg/mL) Q24W up to 48 weeks.
62693118|NCT04108156|EXPERIMENTAL|Substudy: Cohort 2a|Participants who received an updated PDS implant, have \< 24 weeks post-re-implantation follow-up and no refill exchange visit in the main study, will undergo two refill-exchange procedures (ranibizumab 100 mg/mL) Q24W, post main study re-implantation visit.
62134122|NCT02380105|ACTIVE_COMPARATOR|Splint Group|Patients allocated to the splint group (Group II) were treated using interocclusal appliances, according to the following protocol: At baseline, an anterior bite plate (front-plateau) was made from acrylic resin that was placed in the maxillary arch to include the the canine to canine region and promote the disocclusion of the posterior teeth. Patients were instructed to use the device for 24 hours, interspersed with rests of equal length during the first week. After 7 days, the device was removed. A hard splint was then made. At 30 days of follow-up, the splint was fitted and the patients were also asked to use it when they were sleeping.
62327871|NCT03792776|ACTIVE_COMPARATOR|Air|Endotracheal tube cuff inflation with air
62327872|NCT03792776|EXPERIMENTAL|Lidocaine 1%|Endotracheal tube cuff inflation with Lidocaine 1%
62327873|NCT03792776|EXPERIMENTAL|Lidocaine 2%|Endotracheal tube cuff inflation with Lidocaine 2%
62327874|NCT06693830|OTHER|Group 1|"All participants on this study will receive standard immunochemotherapy treatment for the first 4 cycles. Blood samples will be collected for real-time ctDNA sequencing with the PhasED-seq assay.~Participants with undetectable ctDNA from the first day of cycle 4 and in a complete response (CR) on their PET/CT scan will get de-escalated treatment for cycle 5 and cycle 6 (rituximab alone without chemotherapy)"
62327875|NCT06693830|OTHER|Group 2|All participants on this study will receive standard immunochemotherapy treatment for the first 4 cycles. Blood samples will be collected for real-time ctDNA sequencing with the PhasED-seq assay. Participants with detectable ctDNA, not in in a CR on PET/CT, and/or whose ctDNA sequencing was unsuccessful for any reason will continue standard of care for the remainder of treatment (cycle 5 and 6).
62327876|NCT06350227|EXPERIMENTAL|The absorbable hemostat|
62693119|NCT04108156|EXPERIMENTAL|Substudy: Cohort 2b|Participants who received an updated PDS implant, have \< 48 weeks post-re-implantation follow-up and one refill exchange visit in the main study, will undergo one refill-exchange procedure (ranibizumab 100 mg/mL) Q24W, post main study re-implantation visit.
62134123|NCT01859559|EXPERIMENTAL|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
62327877|NCT06350227|ACTIVE_COMPARATOR|Electrocoagulation|
62327878|NCT06350227|PLACEBO_COMPARATOR|Suture alone|
62327879|NCT03160404|EXPERIMENTAL|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
62327880|NCT03160404|ACTIVE_COMPARATOR|ZOLPIDEM|10 mg/night during 6 weeks
62327881|NCT02344069|ACTIVE_COMPARATOR|Fibrinogen|Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician.
62327882|NCT02344069|PLACEBO_COMPARATOR|Placebo|Saline 0.9%
62327883|NCT05361980||Longitudinal Observational Group|Pediatric patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU.
62693120|NCT06570174|EXPERIMENTAL|Protein Supplement group|This group received a daily oral protein supplement providing 18g of protein. The supplement was administered postoperatively and continued throughout the study period to evaluate its impact on nutritional status, quality of life, muscle mass, muscle strength, and gait speed.
62693121|NCT06570174|PLACEBO_COMPARATOR|Placebo group|This group received a placebo that contained carbohydrates instead of protein. The placebo was identical in appearance and taste to the protein supplement, ensuring the double-blind nature of the study. This arm was used to compare the effects of the protein supplement on the same outcomes.
62693122|NCT03574363|EXPERIMENTAL|KBP-5074 0.25 mg tablet|KBP-5074 0.25 mg tablet QD orally, 84 days
62693123|NCT03574363|EXPERIMENTAL|KBP-5074 0.5 mg tablet|KBP-5074 0.5 mg tablet QD orally, 84 days
62327884|NCT05994794|EXPERIMENTAL|Alpha-GPC, Creatine and Ashwagandha (Sensoril®)|"Two servings (12 capsules) of study products will be taken twice per day with meals, one serving in the morning and one serving the afternoon/evening. One serving consists of 6 capsules. The time difference between the two servings must be at least 6 hours.~One serving:~* One capsule of Alpha GPC supplement~* Four capsules of Creatine monohydrate supplement~* One capsule of Sensoril (ashwagandha) supplement"
62327885|NCT05994794|PLACEBO_COMPARATOR|Placebo|Participants will consume one serving (6 capsules), twice per day, with meals at least 6 hours apart.
62327886|NCT01797198|EXPERIMENTAL|gemfibrozil + ASP3652|Multiple doses of gemfibrozil and single dose of ASP3652
62327887|NCT01797198|EXPERIMENTAL|ASP3652 + repaglinide|Multiple doses of ASP3652 and the single dose of repaglinide
61934607|NCT04963231|EXPERIMENTAL|Stage 2: Setmelanotide (Double-Blind)|Participants from Stage 1 who were eligible for Stage 2 received once daily SC injection of setmelanotide 3.0 mg from Week 16 to Week 40 in a double-blind treatment Stage (Stage 2).
61934608|NCT04963231|PLACEBO_COMPARATOR|Stage 2: Placebo (Double-Blind)|Participants from Stage 1 who were eligible for Stage 2 received once daily SC injection of matching placebo 3.0 mg from Week 16 to Week 40 in a double-blind treatment Stage (Stage 2).
61934609|NCT03264313|ACTIVE_COMPARATOR|dTMS active|patients undergoing of dTMS real
61934610|NCT03264313|SHAM_COMPARATOR|dTMS Sham|patients undergoing to placebo dTMS
61934611|NCT02276404|EXPERIMENTAL|relaxation training|Each participant of the experimental group 1 receives 2 one-hour sessions of guided relaxation training prior to surgery.
61934612|NCT02276404|EXPERIMENTAL|acupuncture|Each participant of the experimental group 2 receives 3 acupuncture treatments with a semi-standardized acupoint scheme: once a week over 2 weeks and the day before surgery.
61934613|NCT02276404|EXPERIMENTAL|relaxation training and acupuncture|Each patient of the experimental group 3 receives 3 acupuncture treatments with a semi-standardized acupoint scheme and 2 one-hour sessions of guided relaxation training prior to surgery.
61934614|NCT02276404|NO_INTERVENTION|usual care|Patients receive usual senological treatment
62134124|NCT01859559|EXPERIMENTAL|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
62327888|NCT02254668|EXPERIMENTAL|Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
62327889|NCT02254668|ACTIVE_COMPARATOR|Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
62486003|NCT03553979|EXPERIMENTAL|Stress management + Buddy program (SM-B)|The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
62486004|NCT03553979|NO_INTERVENTION|Control|Participants in the control condition are instructed to continue with their normal daily behaviour. They will be invited to complete the questionnaires and objective measurements at the equivalent times as the intervention groups, thus at baseline, 4 weeks after baseline and 12 weeks after baseline. After the control period, participants in the control condition will be offered the intervention.
62486005|NCT01602575|EXPERIMENTAL|mindfulness treatment|Mindfulness based stress reduction is the intervention in this single arm trial
62486006|NCT03131895|EXPERIMENTAL|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A \[test\]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B \[reference\]), orally, once on Day 1 of Period 2 following a 10-hour fast.
62693124|NCT03574363|PLACEBO_COMPARATOR|Placebo tablet|Placebo tablet QD orally, 84 days
62693125|NCT05468918|EXPERIMENTAL|Participants tested with comparator devices first, then Audeo Lumity devices|All participants who completed speech in noise testing in the lab with the comparator devices first, and then the Audeo Lumity devices.
61934615|NCT02675712||Adults with acute mood disorders|Adults aged over 18 diagnosed with an acute episode of a mood disorder using DSM-V criteria
61934616|NCT05177133|EXPERIMENTAL|Capecitabine, oxaliplatin and retifanlimab|IV and PO Capecitabine 1000 mg/m2, oxaliplatin 130 mg/m2, every three weeks (up to 2 cycles) IV retifanlimab 500mg, every four weeks
62134125|NCT01859559|EXPERIMENTAL|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
62134126|NCT01065506|ACTIVE_COMPARATOR|Standard Care plus Wellness Program|
62134127|NCT01065506|ACTIVE_COMPARATOR|Standard Care plus Exercise Program|
61934617|NCT05752981||tr-FNIRS neuromonitor|During shoulder surgery, the tr-fNIRS (time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)) neuromonitor will be used to gather data on cerebral oxygenation of multiple brain regions for these patients. No intervention will be administered based on the results of the tr-fNIRS.
61934618|NCT06301464||Patients with gastric neoplasms|Patients with gastric neoplasms
61934619|NCT06301464||Normal control|Normal control without gastric neoplasms
61934620|NCT04520893|EXPERIMENTAL|VCV pause|volume controlled ventilation with pause time 30%
61934621|NCT04520893|ACTIVE_COMPARATOR|VCV|volume controlled ventilation (without pause)
61934622|NCT04520893|ACTIVE_COMPARATOR|PCV-VG|pressure controlled ventilation - volume guaranteed
61934623|NCT06710158|EXPERIMENTAL|SC-102 for once weekly|Participants will receive SC-102 as a single agent once weekly on a 4-week cycle at the selected dose.
61934624|NCT06710158|EXPERIMENTAL|SC-102 for once biweekly|Participants will receive SC-102 as a single agent once biweekly on a 4-week cycle at the selected dose.
61934625|NCT06131320||CP child|
61934626|NCT06131320||CP child with a PVSE test and a cerebral MRI performed during his/her follow-up|
62327890|NCT04904653|EXPERIMENTAL|Hemopatch Group:|Hemopatch + suction drainage
62327891|NCT04904653|OTHER|Control group|No sealant (liquid, gel or patch) + suction drain
62327892|NCT00112099|ACTIVE_COMPARATOR|1|Procedure/Surgery: Surgery: Splenectomy
62327893|NCT00112099|EXPERIMENTAL|2|Procedure/Surgery: Surgery: Spleen-preservation
62327894|NCT01574222|EXPERIMENTAL|Arm 1|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling
62486007|NCT03131895|EXPERIMENTAL|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B \[reference\]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A \[test\]), orally, once on Day 1 of Period 2 following a 10-hour fast.
62486008|NCT03131895|EXPERIMENTAL|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C \[test\]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D \[reference\]), orally, once on Day 1 of Period 2 following a 10-hour fast.
62486009|NCT03131895|EXPERIMENTAL|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D \[reference\]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C \[test\]), orally, once on Day 1 of Period 2 following a 10-hour fast.
62486010|NCT06626737|EXPERIMENTAL|Dapagliflozin arm|Participants will take Dapagliflozin10mg every day in -1 to 14 days.
62486011|NCT05025137|EXPERIMENTAL|Flexi-Bar group|Participants in the Flexi-Bar group performed a 60-minute Flexi-Bar exercise every week for 12 consecutive weeks.
62486012|NCT05025137|EXPERIMENTAL|Multi-Component exercise group|Participants in the Multi-Component exercise group performed a 60-minute Multi-Component exercise every week for 12 consecutive weeks.
62486013|NCT05496920|EXPERIMENTAL|Single Arm|Patients will receive both a standard of care PET/CT and a low dose PET/CT
62486014|NCT01685762|EXPERIMENTAL|Metformin|Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12).
62486015|NCT01501448|ACTIVE_COMPARATOR|OCP|
62486016|NCT01501448|ACTIVE_COMPARATOR|Oral estradiol valerate|
62134128|NCT03640403|EXPERIMENTAL|DP|Dihydroartemisinin-piperaquine (DP), antimalarial drug to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
62134129|NCT03640403|ACTIVE_COMPARATOR|ASAQ|Artesunate-amodiaquine (ASAQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
62134130|NCT03640403|NO_INTERVENTION|Control|No intervention drugs will be given, but normal routine standard of care will be provided.
62486017|NCT02654145|EXPERIMENTAL|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
62486018|NCT05255393||Standard lymphadenectomy(LND) with sentinel lymph node mapping (SLN)|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
62486019|NCT05255393||Standard lymphadenectomy(LND) alone|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
62486020|NCT06476093|EXPERIMENTAL|Anlotinib+SRT Group|Anlotinib#12mg#PO#Q3W#d1-14#
62486021|NCT04693533|OTHER|treatment effect|No 2 arms and only 1 intervention
62486022|NCT02404753|EXPERIMENTAL|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
62486023|NCT02404753|ACTIVE_COMPARATOR|Open gastrectomy|Open distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
62486024|NCT01978925|EXPERIMENTAL|Pharmaceutical care|In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.
62486025|NCT01978925|NO_INTERVENTION|Usual care|In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.
62486026|NCT06468254|EXPERIMENTAL|Statin Group|Statins, 40 mg daily for 1 year or with dosage adjusted based on patient tolerance
62486027|NCT06468254|PLACEBO_COMPARATOR|Control Group|Sugar pill daily for 1 year
62486028|NCT03930732|EXPERIMENTAL|Dupilumab|Participants received dupilumab 300 mg administered as SC injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, EOT visit occurred 2 weeks after last administration of treatment i.e., at Week 52).
62134131|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
62134132|NCT01057433|EXPERIMENTAL|Pitavastatin|Healthy adult subjects
62134133|NCT04095884||Urinary Tract Infection|"Inclusion criteria (one from the list below):~1. Positive leukocytes, positive nitrites on dipstick~2. Negative leukocytes, Positive nitrites on dipstick~3. Positive leukocytes, negative nitrites, plus bacteriuria on microscopy~4. Positive leukocytes, negative nitrities plus no bacteriuria, only pyuria on microscopy PLUS clinical features e.g. fever, pain on urination, offensive smelling urine.~Exclusion criteria (one from the list below):~1. No evidence of UTI on dipstick"
62486029|NCT03930732|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to dupilumab 300 mg as subcutaneous (SC) injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, end of treatment \[EOT\] visit occurred 2 weeks after last administration of treatment i.e., at Week 52).
62486030|NCT04443998|EXPERIMENTAL|Bone reduction forceps|
62486031|NCT04178122|EXPERIMENTAL|Immediate Results|Participants in the Immediate Results arm will receive their genetic testing results from a genetic counselor at baseline following randomization.
62486032|NCT04178122|EXPERIMENTAL|Delayed Results|Participants in the Delayed Results arm will receive their genetic testing results from a genetic counselor 6 months after randomization.
62486033|NCT00828321|EXPERIMENTAL|1|
62486034|NCT00828321|ACTIVE_COMPARATOR|2|
62486035|NCT03563833|OTHER|Minimal Flow Anesthesia|"Minimal Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5). In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
62693126|NCT05468918|EXPERIMENTAL|Participants who were tested with Audeo Lumity first, then comparator devices|All participants who completed speech in noise testing in the lab with the Audeo Lumity devices first, and then the comparator devices.
62693127|NCT05581121|OTHER|Arm A|Control arm
62486036|NCT03563833|OTHER|High Flow Anesthesia|"High Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5) In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
62486037|NCT05244213|EXPERIMENTAL|Sintilimab plus chemo|3 cycles of neoadjuvant Sintilimab (200mg every 3 weeks) with nab-paclitaxel and carboplatin (nab-paclitaxel 260 mg/m2, d1 and carboplatin AUC 5, d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including EGFR-TKIs for up to 1 year or till disease progression or unacceptable toxicity.
62486038|NCT04154592|EXPERIMENTAL|Experimental Group|In addition to the conservative treatment of the control group, humeral head depressor muscle co-activation training will be applied for 14 weeks.
61934627|NCT05909735|EXPERIMENTAL|Visually significant partial LSCD|Patient with visually significant partial LSCD, as defined by a best corrected visual acuity of 20/100 or less, and partial LSCD on slit lamp exam with at least 25% of the limbus intact or at least 25% of the corneal surface covered with corneal epithelium will be enrolled in the first arm.
62134134|NCT04095884||Upper respiratory tract infection|"Inclusion criteria (one from the list below)::~1. Evidence of nasal discharge AND/OR~2. Inflammation throat/ tonsils on direct examination AND/OR~3. Inflammation of middle or outer ear on direct examination~4. History of fever AND history of stridor/ barking cough~5. History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e sore throat/ cough~Exclusion criteria (one from the list below)::~1. Foreign body inserted in either nose/ ear~2. Traumatic perforation of ear drum~3. Allergic rhinitis i.e. good contact history~4. Evidence of LRTI"
62134135|NCT04095884||Lower respiratory tract infection|"Inclusion criteria (one from the list below):~1. Focal signs on auscultation of the chest i.e crepitations/ wheeze/ reduced air entry~2. Fever \> 38.5C AND chest recessions AND/OR raised respiratory rate~3. Radiological evidence of LRTI~Exclusion criteria (one from the list below):~1. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever"
62134136|NCT04095884||Diarrhoea/ gastroenteritis|"Inclusion criteria (one from the list below):~1. Abrupt onset of 3 or more loose/liquid stools/ day~2. Ova, cysts, parasites identified on stool microscopy PLUS symptomatic diarrhoea,and/ or fever and/or vomiting~3. Fever AND vomiting WITHOUT other source of fever i.e UTI/LRTI/URTI~Exclusion criteria (one from the list below):~1. Normal breast milk stool~2. Neurological cause of vomiting"
62134137|NCT04303377|EXPERIMENTAL|Evolocumab|Evolocumab administration in the acute phase of ST elevation myocardial infarction
62486039|NCT04154592|ACTIVE_COMPARATOR|Control Group|The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).
62486040|NCT06154408|EXPERIMENTAL|omega-3 fatty acids group|
62486041|NCT06154408|PLACEBO_COMPARATOR|placebo group|
62486042|NCT00873587|OTHER|Inspiration|
62486043|NCT00873587|OTHER|Expiration|
62134138|NCT04303377|NO_INTERVENTION|Standard of care|
62486044|NCT05361252|ACTIVE_COMPARATOR|the low-SVV group|the value of stroke volume variation will be less than or equal to 10 this group
62486045|NCT05361252|ACTIVE_COMPARATOR|the high-SVV group|the value of stroke volume variation will be higher than 10 this group
62486046|NCT01576458|ACTIVE_COMPARATOR|ursodeoxycholic acid|10 pregant women with intrahepatic cholestasis of pregnancy
62486047|NCT01576458|ACTIVE_COMPARATOR|placebo|10 pregnant women with intrahepatic cholestasis of pregnancy
62486048|NCT00834873|EXPERIMENTAL|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
62693128|NCT05581121|EXPERIMENTAL|Arm B|Experimental arm
62693129|NCT06570200|ACTIVE_COMPARATOR|PMPR only|scaling and root planing only will be made for group 1 (control group)
62693130|NCT06570200|EXPERIMENTAL|PMPR + iPRF|scaling and root planing plus locally applied iPRF in the periodontal pocket will be made for test group 1.
62693131|NCT06570200|EXPERIMENTAL|PMPR + iPRF + Vit.D|"scaling and root planing plus locally applied iPRF and vitamin D in the periodontal pocket will be made for test group 2.~vitamin D will be obtained from a commercial product in the Egyptian pharmacies called (Devarol S) in the form of injectable ampoules containing 200000 IU of cholecalciferol (2.5 mg/ml)"
62693132|NCT05775042|EXPERIMENTAL|Group A|CM338 will be injected subcutaneously.
62693133|NCT05775042|EXPERIMENTAL|Group B|CM338 will be injected subcutaneously.
62693134|NCT05775042|EXPERIMENTAL|Group C|CM338 will be injected subcutaneously.
62693135|NCT02684162|EXPERIMENTAL|Treatment (guadecitabine, DLI)|Patients receive guadecitabine SC QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI IV over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.
62486049|NCT00834873|ACTIVE_COMPARATOR|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
62486050|NCT06623227|ACTIVE_COMPARATOR|ASD Placebo|"If the age is up to 4 years old:~• Risperidone (0.02-0.06 mg/KgBW) and Behavior Therapy as maintenance therapy and Capsule Placebo.~If age is above 4 years old:~• Risperidone (0.02-0.06 mg/KgBW) and Behavior Therapy as maintenance therapy and Capsule Placebo."
62486051|NCT06623227|EXPERIMENTAL|ASD Active compound|"If the age is up to 4 years old:~• Risperidone (0.02-0.06 mg/KgBW) and Behavior Therapy as maintenance therapy and Capsul containing Vitamin E 150 IU and Vitamin C 100 mg.~If age is above 4 years old:~• Risperidone (0.02-0.06 mg/KgBW) and Behavior Therapy as maintenance therapy and Capsul containing Vitamin E 200 IU and Vitamin C 200 mg."
62486052|NCT04569773||Participants undergoing surgery for clinical|Participants will be undergoing surgery for clinical stage I endometrioid endometrial cancer
62486053|NCT01698645||PecFent®|
62486054|NCT02736123|EXPERIMENTAL|Arm A consists of 3 phases or steps|"Induction Phase Nivolumab 3 mg/kg IV infusion every 2 weeks for 3 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 3 mg/kg IV infusion every 3 weeks"
62486055|NCT02736123|EXPERIMENTAL|Arm B consists of 3 phases or steps|"Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses; then, Nivolumab 3 mg/kg IV infusion every 3 weeks"
62486056|NCT03396939|EXPERIMENTAL|Orthosis|The intervention will be performed individually and will run for 12 weeks both at the community rehabilitation unit (3 times a week for 3 weeks) and at home (9 weeks). The group will receive an orthotic device for use during the study-specific exercises.
61934628|NCT05909735|EXPERIMENTAL|Total/near-total LSCD with recurrent or persistent epithelial defects (PED)|Patient with visually significant total LSCD, as defined by a best corrected visual acuity of 20/100 or less, and total LSCD on slit lamp exam with over 25% of the limbus intact or less than 25% of the corneal surface covered with corneal epithelium; and a history of a persistent epithelial defect that has persisted over 2 weeks despite maximal medical therapy, or a history of recurrent epithelial erosions that occur more frequently than once a month; will be enrolled in the second arm.
61934629|NCT05555758|ACTIVE_COMPARATOR|experimental group|Four ascending dose levels of Aom0319 (n=24) for intravenous injection for once. Dosage day is Day 1.
61934630|NCT05555758|PLACEBO_COMPARATOR|placebo group|Four ascending dose levels of placebo (n=8) for intravenous injection for once. Dosage day is Day 1.
62486057|NCT03396939|NO_INTERVENTION|Control|The group will receive the same amount of a study-specific training program without the orthotic device.
62486058|NCT00994058|EXPERIMENTAL|Intevention with Inhibitor|
62486059|NCT04404439|EXPERIMENTAL|Nortriptyline + topiramate|Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
62486060|NCT04404439|EXPERIMENTAL|Verapamil + paroxetine|Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
62486061|NCT04404439|PLACEBO_COMPARATOR|Placebo|Placebo pill.
62486062|NCT03359863|EXPERIMENTAL|Treatment Arm|Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).
62486063|NCT03227276|PLACEBO_COMPARATOR|Placebo|
62486064|NCT03227276|EXPERIMENTAL|Litramine|
61934631|NCT00945997|ACTIVE_COMPARATOR|A|
61934632|NCT00945997|ACTIVE_COMPARATOR|B|
61934633|NCT01107418|EXPERIMENTAL|1|
61934634|NCT01107418|EXPERIMENTAL|2|
61934635|NCT01107418|EXPERIMENTAL|3|
61934636|NCT01107418|EXPERIMENTAL|4|
62327895|NCT04065022|EXPERIMENTAL|Head stimulation|Each subject will be stimulated at two different days. One day with the presence of topical anesthetic cream on the scalp above the MC and in the other day with absence of the anesthetic cream. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 4\*1 gel-filled cup-electrodes is placed over each of motor cortex. Each subject follows three sessions of 12 min length each day. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
62327896|NCT04065022|EXPERIMENTAL|Arm stimulation|Each subject will be stimulated on only one day. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 2\*1 gel-filled cup-electrodes is placed over the contralateral arm. Each subject follows three sessions of 12 min length. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
62327897|NCT03590262|EXPERIMENTAL|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
62327898|NCT02899793|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
62327899|NCT00177541|EXPERIMENTAL|Biofeedback|Biofeedback assisted pelvic floor muscle therapy (3 visits)
62486065|NCT04562935||Pediatric intensive care|Children admitted to a pediatric intensive care unit before one year of age and admitted for to days or more and treated with mechanical ventilation and alive at follow
62486066|NCT00835705|EXPERIMENTAL|Amoxicillin Clavulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 400-57 mg Chewable Tablet (reference) dosed in second period
62486067|NCT00835705|ACTIVE_COMPARATOR|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (reference) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in second period
62486068|NCT00852696|PLACEBO_COMPARATOR|Placebo Group|Placebo Orally 9 weeks once daily.
62486069|NCT00852696|EXPERIMENTAL|Solifenacin Group|Solifenacin Orally 9 weeks once daily.
62486070|NCT00669162|EXPERIMENTAL|RT, Docetaxel, Hormonal Therapy|Radiation Therapy (RT) to 66 Gy in 33 treatment fractions at 2.0 Gy/fx Concurrent Docetaxel (with RT) at 20 mg/m2 weekly x 7 Casodex (50 mg po daily)x 6 months Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)
62486071|NCT05718687|EXPERIMENTAL|Treatment|open-label GBT021601
62486072|NCT03489629|EXPERIMENTAL|Treatment|"Subjects are treated with one oral antibiotic, one topical antibiotic, an oral rinse, and instructed to use environmental decontamination techniques.~Trimethoprim Sulfamethoxazole (TMP/SMX) is the primary oral antibiotic to be used. Subjects with allergy or intolerance to TMP_SMX will use minocycline as an alternative antibiotic. Topical antibiotics are nasal Mupirocin, and the oral rinse/gurgle with 0.12% chlorhexidine gluconate."
62486073|NCT06081634|ACTIVE_COMPARATOR|Enhancing cognitive reserve|After the baseline assessment, subjects will be randomly assigned by non-research staff, following the balanced clocks method, to receive a psychological intervention for the improvement of cognitive reserve (N=60) or to the group receiving TAU only (N=60). All assessments will be common to both groups. The experimental group will receive an intervention consisting of 12 weekly sessions of approximately 60 minutes duration. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Patients will also receive pharmacological follow-up in each center. A psychologist blind to the results of the assessment will provide the therapeutic approach for the improvement of cognitive reserve.
62486074|NCT06081634|PLACEBO_COMPARATOR|Placebo group|This group will receive only pharmacological treatment supervised by the Psychiatrists of each Unit.
62327900|NCT03393364|EXPERIMENTAL|Opioid arm|Patients receive opioid medication, oxycodone, after outpatient urologic surgery.
62486075|NCT03856320|NO_INTERVENTION|Usual Care|Patient attends a MOVE! visit (weight management visit).
62486076|NCT03856320|EXPERIMENTAL|Intervention|Patient attends a MOVE! visit (weight management visit) and watches an educational video describing obesity treatment options available in the VA.
62327901|NCT03393364|EXPERIMENTAL|Non-opioid arm|Patients receive a non-opioid medication, ketorolac, after outpatient urologic surgery.
62486077|NCT01916915|EXPERIMENTAL|Tramadol 1|1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
62327902|NCT03041116|EXPERIMENTAL|Fosmetpantotenate|Administered as powder for reconstitution.
62327903|NCT03041116|PLACEBO_COMPARATOR|Placebo|Administered as powder for reconstitution.
62486078|NCT01916915|EXPERIMENTAL|Tramadol 2|2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
62486079|NCT01916915|PLACEBO_COMPARATOR|Levobupivacaine|0.25% levobupivacaine 4ml/h infusion
62486080|NCT04031690||patient-caregiver dyads|
62486081|NCT05800457|EXPERIMENTAL|Total knee replacement with partial synovectomy|Patients in this arm will undergo partial synovectomy during total knee replacement surgery.
62486082|NCT05800457|NO_INTERVENTION|Total knee replacement without partial synovectomy|Patients in this arm will not undergo partial synovectomy during total knee replacement surgery.
62486083|NCT05154890|EXPERIMENTAL|Pegtarviliase Cohort 1|Planned for 4 subjects ≥18 years of age dosing at Dose A weekly for a total of 4 doses
62486084|NCT05154890|EXPERIMENTAL|Pegtarviliase Cohort 2|Planned for 4 subjects ≥12 years of age dosing at Dose B weekly for a total of 4 doses
62486085|NCT05154890|EXPERIMENTAL|Pegtarviliase Cohort 3|Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose C weekly for a total of 4 doses
62486086|NCT05154890|EXPERIMENTAL|Pegtarviliase Cohort 4|Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose D weekly for a total of 4 doses
62486087|NCT05154890|EXPERIMENTAL|Pegtarviliase Cohort 5|Optional cohort for up to 12 subjects ≥12 years of age (≥18 in the US) dosing at Dose E weekly for a total of 13 doses
62486088|NCT04037722|EXPERIMENTAL|Healthy + Whey|Healthy conditions (overnight fast)
62486089|NCT04037722|EXPERIMENTAL|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
62486090|NCT04037722|EXPERIMENTAL|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
62486091|NCT00712959|EXPERIMENTAL|Group 1: Previous Tdap or Tdap-IPV Recipients|Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
62486092|NCT00712959|ACTIVE_COMPARATOR|Group 2: Tdap vaccine-naïve|Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
62486093|NCT00712959|NO_INTERVENTION|Group 3|Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study
62327904|NCT01648608|EXPERIMENTAL|Exemestane|Exemestane for neoadjuvant chemotherapy
62327905|NCT01841658|EXPERIMENTAL|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
62327906|NCT01841658|EXPERIMENTAL|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
62327907|NCT04346628|EXPERIMENTAL|Favipiravir|In addition to SOC, participants will receive favipiravir for 10 days, and be evaluated for health outcomes through day 28.
61934637|NCT04516135|EXPERIMENTAL|Arm A (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with \< 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.
62486094|NCT06235723|NO_INTERVENTION|SOC (A)|SOC = Standard-of-Care
61934638|NCT04516135|ACTIVE_COMPARATOR|Arm B (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
61934639|NCT00950495|ACTIVE_COMPARATOR|Mandibular advancement device (MAD)|an MAD is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
61934640|NCT00950495|ACTIVE_COMPARATOR|nasal CPAP|The device is turned on, and the nasal mask is placed on the nose prior to sleep. After waking up in the morning, the device is turned off and the mask is removed
61934641|NCT00950495|PLACEBO_COMPARATOR|placebo|the placebo appliance is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
61934642|NCT02943460|EXPERIMENTAL|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks
61934643|NCT02943460|EXPERIMENTAL|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks
61934644|NCT02943460|PLACEBO_COMPARATOR|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks
61934645|NCT02943460|EXPERIMENTAL|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.
61934646|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
61934647|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
61934648|NCT02719327|EXPERIMENTAL|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
61934649|NCT02719327|PLACEBO_COMPARATOR|placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
61934650|NCT05979285|EXPERIMENTAL|N1-Headache App|All participants used the N1-HEadache App, a digital migraine diary that allows identification of triggers/protectors for migraine (as well as monitoring of medication use)
61934651|NCT02002611|EXPERIMENTAL|Lobeglitazone|Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.
62327908|NCT04346628|ACTIVE_COMPARATOR|Placebo|In addition to SOC, participants will receive placebo to match favipiravir for 10 days, and be evaluated for health outcomes through day 28.
62327909|NCT01379534|EXPERIMENTAL|TKI258|1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status
62327910|NCT06681077|EXPERIMENTAL|Prevention (I CAN intervention)|Participants attend an I CAN intervention workshop over 2 hours.
62327911|NCT02015598|EXPERIMENTAL|Carbocysteine|Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
62327912|NCT02015598|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
62327913|NCT02839967|EXPERIMENTAL|Photobiomodulation group|For the purposes of photobiomodulation is used a portable cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), and 1 905 nm diode LASER, 4 875 nm LED diodes and 4 670 nm diodes LED, 4 cm2 beam, emitting an energy of 39.27 J.
62327914|NCT02839967|PLACEBO_COMPARATOR|Photobiomodulation placebo group|"To provide the blinding of the participants of the study we will use two identical photobiomodulation equipment supplied by the manufacturer, being an active and another a placebo, but both have identical light and sound device (do not send energy and heat, non-coherent light without biological effect). The devices are named in X and Y for a researcher who does not participate in treatment and assessments."
62327915|NCT05208424||Normal glycemia|100 patients without evidence of dysglycemia.
62486095|NCT06235723|EXPERIMENTAL|VR (B)|VR = Virtual Reality
62486096|NCT00847535|OTHER|1|Transurethral dose escalation
61934652|NCT02002611|EXPERIMENTAL|Warfarin|Subjects received Warfarin 25 mg once at period 1 and 2.
61934653|NCT05388695|EXPERIMENTAL|19+22 CART and 19+20 CART|Eligible patients will be treated with 19+22 CAR-T and 19+20 CAR-T.
61934654|NCT05830084|EXPERIMENTAL|Induction chemotherapy (VDC/IE) and local treatment /consolidation chemotherapy|"Standard ES treatment consists of: induction chemotherapy (VDC/IE) and local treatment (surgery/radiotherapy), followed by consolidation chemotherapy (VC/IE)/ Bu-Mel (according to physician and patient choice).~Regorafenib will be administered during induction chemotherapy (VDC/IE) and during consolidation chemotherapy with conventional chemotherapy (VC/IE) but not Bu-Mel therapy Conventional chemotherapy will be administered at the recommended dose (100%) and only regorafenib will be escalated/de-escalated.~Regorafenib will only be given concomitant to radiotherapy in case the primary tumor is located in the extremities. In case of primary tumors located in the pelvis, abdomen, thorax, spine, brain, head or neck, regorafenib will be stopped at least 1 week before start of radiotherapy."
61934655|NCT05521568||Index test : Abbott ID NOW STREP A 2|
61934656|NCT05521568||Reference standard test : Composite of culture and PCR-based tests based on a throat swab|
61934657|NCT05521568||Comparator test : Rapid antigen detection test (usual care)|
61934658|NCT06562803|EXPERIMENTAL|Double plasma cytokine adsorption system with sequential low-dose plasma exchange|30 patients in this group will receive treatment of double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) and comprehensive internal medical treatment.
61934659|NCT06562803|ACTIVE_COMPARATOR|Plasma exchange|30 patients in this group will receive treatment of plasma exchange(PE) and comprehensive internal medical treatment.
61934660|NCT03957031||Cases|Patients with a pathological confirmation of GC diagnosis
62486097|NCT00847535|OTHER|2|Periurethral dose escalation
62486098|NCT01994980|ACTIVE_COMPARATOR|Default 4 days antibiotic therapy|Default 4 days antibiotic therapy
62486099|NCT01994980|NO_INTERVENTION|Default 8 days antibiotic therapy|Default 8 days antibiotic therapy
62486100|NCT04405479||Patients with multiple sclerosis|MS patients will be chosen by an independent neurologist.
62486101|NCT04405479||Healthy volunteers|Healthy controls will be paired by age and sex with MS patients.
62486102|NCT04574960|EXPERIMENTAL|Neoadjuvant Chemotherapy Arm|Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy).
62486103|NCT04574960|ACTIVE_COMPARATOR|Adjuvant Chemotherapy Arm (Standard of Care)|"Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy.~Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin.~Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles.~Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles."
62486104|NCT05583162|EXPERIMENTAL|Intervention|All pupils attending a Elite Sport Jr High School receive intervention
62486105|NCT02945618|EXPERIMENTAL|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
62486106|NCT02945618|ACTIVE_COMPARATOR|Conventional program with ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
62486107|NCT01688011||Newly diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)|Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
62486108|NCT01688011||Newly diagnosed Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
62486109|NCT01688011||Newly diagnosed Acute Myeloid Leukemia (AML)|Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
62486110|NCT01688011||Treated Myelofibrosis (MF)|Newly treated MF patients receiving treatment for MF or MF-related cytopenias. This cohort also includes patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, excluding juvenile myelomonocytic leukemia (JMML).
62486111|NCT01688011||Newly diagnosed Idiopathic cytopenia of undetermined significance (ICUS)|Newly diagnosed ICUS patients.
62327916|NCT05208424||Prediabetes|100 patients with evidence of pre-diabetes defined as hemoglobin A1C (HbA1c) 5.7-6.4% with or without fasting plasma glucose (FPG) of 100 mg/dL to 125 mg/dL.
62327917|NCT05208424||Diabetes|100 patients without evidence diabetes defined as hemoglobin HbA1c \> 6.4% with or without FPG \>125 mg/dL.
62327918|NCT02918188|EXPERIMENTAL|Hydrogen|Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)
62327919|NCT02293954|EXPERIMENTAL|Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)|Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
62327920|NCT02702908||mPC|Prostate cancer patients with bone metastases (mPC)
62327921|NCT02702908||mCRPC|Patients with castration-resistant prostate cancer with bone metastases (mCRPC)
62327922|NCT00740779|EXPERIMENTAL|Silodosin 4 mg|4 mg daily
62327923|NCT00740779|EXPERIMENTAL|Silodosin 8 mg|Silodosin 8 mg daily
62327924|NCT00740779|PLACEBO_COMPARATOR|Placebo|1 placebo capsule daily
62327925|NCT04290650|OTHER|Modified CBT for insomnia|All patients admitted to one of the psychosis ward will be offered the same customized treatment focusing on sleep in addition to treatment as usual.
62327926|NCT04290650|OTHER|Treatment as usual|All patients admitted to the other two psychosis wards will only receive treatment as usual.
62327927|NCT05994157|EXPERIMENTAL|CD38-SADA:177Lu-DOTA Complex|
62327928|NCT06002282|EXPERIMENTAL|Tailored Messaging|Tailored messages based on parents' HPV vaccine hesitancy and perceived barriers to vaccination.
62327929|NCT06002282|ACTIVE_COMPARATOR|Standard Messaging|Standard (untailored) messages about HPV vaccination reminder/recall.
62327930|NCT01892033|EXPERIMENTAL|Aerobic Exercise|The aerobic exercise intervention is a 12-week program consisting of four 30- to 40-minute exercise sessions of brisk walking per week.
61934661|NCT03957031||Control|Patients with confirmed absent of GC
62327931|NCT02032537|ACTIVE_COMPARATOR|Callmax cream|
62327932|NCT02032537|PLACEBO_COMPARATOR|Placebo|
62327933|NCT05698771|EXPERIMENTAL|NR|A total of 6 individuals comprising 3 males and 3 females will receive NR 1200 mg daily (600 mg x 2) for 8 days, with a total measurement/assessment period of 20 days. These will be the same individuals as in the NMN-arm. The individuals will enter the two arms sequentially and with a washout period of 14 days.
62327934|NCT05698771|EXPERIMENTAL|NMN|A total of 6 individuals comprising 3 males and 3 females will receive NMN 1200 mg daily (600 mg x 2) for 8 days, with a total measurement/assessment period of 20 days. These will be the same individuals as in the NR-arm. The individuals will enter the two arms sequentially and with a washout period of 14 days.
62327935|NCT02472548|EXPERIMENTAL|Group A, DPX-RSV(A) low dose (Step 1)|
62327936|NCT02472548|EXPERIMENTAL|Group B, RSV(A)-Alum low dose (Step 1)|
62327937|NCT02472548|EXPERIMENTAL|Group D, DPX-RSV(A) high dose (Step 2)|
62327938|NCT02472548|EXPERIMENTAL|Group E, RSV(A)-Alum high dose (Step 2)|
62327939|NCT02472548|PLACEBO_COMPARATOR|Group C & F, Placebo control (Step 1 and 2)|
62327940|NCT02969343|EXPERIMENTAL|Intervention|Patients and providers on hospital care units where the PSLL patient safety health information technology tools are implemented, during the interventional phase of a stepped wedge randomized trial design.
62327941|NCT02969343|NO_INTERVENTION|Usual Care|Patients on hospital care units where the PSLL patient safety health information technology tools have been implemented or are to be implemented, but are not during the usual care phase of a stepped wedge randomized trial design.
62486112|NCT01688011||Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS)|Treated LR-MDS patients receiving first active treatment regimen containing at least one non-ESA therapy
61934662|NCT05937373|EXPERIMENTAL|Continuous Glucose Monitor|CGM placed preoperative to monitor blood glucose and insulin correction to achieve perioperative glucose management
61934663|NCT05937373|ACTIVE_COMPARATOR|Standard of Care|no study intervention-conventional glucose management per subjects medical providers as standard of care
61934664|NCT01423149|EXPERIMENTAL|36 mg/m2 Combretastin A-4 Phosphate|
62134139|NCT04777383|EXPERIMENTAL|Vascular effects of iontophoresed vasoactive substances|"Iontophoretically administered vasoactive substances in five concentrations (1%,0.1%,0.01%,0.001%, 0.0001%) dissolved in sterile water. Each concentration of the drug is separately administered using a electrical charge of 12 millicoulomb (mC) (600 seconds x 0.02 milliampere) for 3 repeated pulses (total electrical charge 36 mC). Each iontophoresis pulse is separated by a 30 minute wash-out period.~Vasoactive substances:~* Miochol-E (Acetylcholine),10 mg/ml, Bausch \& Lomb~* Methacholine chloride, 100 mg/ml, APL~* Norepinephrine, 1 mg/ml, Pfizer~* Phenylephrine, 10 mg/ml, Unimedic~* Atropine, 10 mg/ml, Bausch \& Lomb~* Neostigmine, 2.5 mg/ml, Unimedic Pharma~* Sterile water, 100 ml, Braun"
62134140|NCT00858650||Standard of Care|Hypogonadal males treated by standard of care, with or without testosterone replacement therapy
62134141|NCT01020643|EXPERIMENTAL|controlled sedation using propofol|
62134142|NCT02374463|EXPERIMENTAL|Multimodality Balance Intervention (MMBI)|Multimodality Balance Intervention (MMBI)
62134143|NCT02374463|ACTIVE_COMPARATOR|Tai Chi|Tai Chi Intervention
62134144|NCT04072419||enhanced recovery after surgery group|"1. weaning mechanical ventilation after surgery (less than 48h),~2. no post-operative chest tube and urinary catheterization)~3. Establishment of early feeding (D3 post-operative)"
62134145|NCT04072419||control group|"1. the time of mechanical ventilation after surgery is more than 48 hours~2. routine postoperative indwelling chest tube and urinary catheterization)~3. Establishment of feeding after D3 post-operative"
62134146|NCT01939899|EXPERIMENTAL|IXAZOMIB|Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL. After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
62134147|NCT02901522|ACTIVE_COMPARATOR|Control|Spirometry (baseline) Spirometry (20 - 22weeks)
62134148|NCT02901522|EXPERIMENTAL|Telemedicine|Spirometry (baseline) Telemonitoring Teleconsultation Spirometry (20 - 22weeks)
62134149|NCT05948449|EXPERIMENTAL|SOX+Cadonilimab（AK104）|3 cycles of neoadjuvant therapy: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
62134150|NCT01596296|ACTIVE_COMPARATOR|Transcervical foley catheter|
62134151|NCT01596296|ACTIVE_COMPARATOR|Dinoprostone|
62134152|NCT02576275|EXPERIMENTAL|Duvelisib + Rituximab + Bendamustine|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Bendamustine is administered as an intravenous (IV) infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
62134153|NCT02576275|PLACEBO_COMPARATOR|Placebo + Rituximab + Bendamustine|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules of duvelisib.~Bendamustine is administered as an IV infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
62327942|NCT01977053|NO_INTERVENTION|A: Standard medical care|Arm A: standard supervision and medical care during an adjuvant chemotherapy treatment in France
62327943|NCT01977053|EXPERIMENTAL|B: telephonic monitoring|Arm B: telephonic monitoring during inter-treatment intervals + personalized medical care.
62327944|NCT03697967|EXPERIMENTAL|Supine|Infant placed supine for 120 seconds before cord clamping
62327945|NCT03697967|EXPERIMENTAL|Prone|Infant placed prone for 120 seconds before cord clamping
62327946|NCT06625112||Natural history study participants|
62327947|NCT04095286|EXPERIMENTAL|AMB dispersed in water/AMB oral tablet/reference AMB|Eligible participants will receive a single oral dose of 5 milligram (mg) AMB tablet dispersed in water during treatment period 1 followed by a single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive a single oral dose of reference 5 mg AMB tablet. There will be a washout period of 7 days between doses in each treatment period.
62486113|NCT01688011||Luspatercept treated cohort (LTC)|Participants that have initiated luspatercept treatment for a myeloid malignancy.
61934665|NCT01423149|EXPERIMENTAL|45 mg/m2 Combretastatin A-4 Phosphate|
61934666|NCT01423149|EXPERIMENTAL|27 mg/m2 Combretastatin A-4 Phosphate|
61934667|NCT04073368|ACTIVE_COMPARATOR|AXA1957 high dose|AXA1957 20.3g
62486114|NCT06627686||Traumatic brain injury|Air way occlusion pressure and maximum inspiratory pressure
62486115|NCT05169931|EXPERIMENTAL|Study group|Treatment group to receive study drops (RegenerEyes) twice daily for 12 weeks
62486116|NCT04849390|EXPERIMENTAL|ESO-101|Oral use of 1 hard gelatin capsule (800 μg)
62486117|NCT04849390|PLACEBO_COMPARATOR|Placebo|Oral use of 1 hard gelatin capsule
62486118|NCT03881943|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor 60mg BD for 3 months
61934668|NCT04073368|ACTIVE_COMPARATOR|AXA1957 low dose|AXA1957 13.5g
61934669|NCT04073368|ACTIVE_COMPARATOR|AXA1125|AXA1125 24g
61934670|NCT04073368|PLACEBO_COMPARATOR|Placebo|Placebo 24g
61934671|NCT03732677|EXPERIMENTAL|Arm 1|Chemotherapy + Durvalumab
61934672|NCT03732677|ACTIVE_COMPARATOR|Arm 2|Chemotherapy alone
61934673|NCT01590576||lower urinary tract symptoms and pelvic organ prolapse|
61934674|NCT05388396||PIMS-TS patients|Pediatric patients with PIMS-TS admitted to the PICU in selected time period
61934675|NCT05410392|EXPERIMENTAL|Combined physical and cognitive exercise intervention|Participants will receive both the physical exercise intervention and the cognitive exercise intervention for 3 months.
61934676|NCT05410392|EXPERIMENTAL|Physical exercise intervention|Participants will receive the physical exercise intervention for 3 months.
61934677|NCT05410392|EXPERIMENTAL|Cognitive exercise intervention|Participants will receive the cognitive exercise intervention for 3 months.
61934678|NCT05410392|ACTIVE_COMPARATOR|Control group|Participants will receive health education for 3 months.
61934679|NCT06708130||Cohort 1|Patients who are proposed to undergo or have undergone allogeneic hematopoietic stem cell transplantation at the Stem Cell Transplant Center and Post-Transplant Medical Consortium at Regent Hospital
62693136|NCT06502119||Health Provider|The study will include obstetricians and gynecologists practicing in Egypt. These healthcare professionals specialize in the management of pregnancy, childbirth, and women's reproductive health. Participants will be recruited from various healthcare settings, including public and private hospitals, ensuring a diverse representation of clinical experiences and perspectives on operative vaginal birth practices. All participants must actively engage in obstetric care and possess direct experience with operative vaginal births, allowing for an in-depth exploration of their knowledge, attitudes, and practices related to this procedure within the Egyptian healthcare context.
62693137|NCT06307769||Geriatric Group|balance assessment
62693138|NCT06307769||Control Group|balance assessment
62693139|NCT04411069|NO_INTERVENTION|Patients without previous CINV|Patients who didn't have chemotherapy or that didn´t have any nausea and/or vomiting induced by chemotherapy (CINV) before surgery
62693140|NCT04411069|OTHER|Patients with previous CINV|Patients who had previous nausea and vomiting induced by chemoterapy.
62693141|NCT06570668|EXPERIMENTAL|5 g of CDD-2101 and 15 g of placebo;|"CDD-2101 is a botanical drug candidate in granule form, with same formulation as the Chinese herbal medicine MZRW, based on the water extract from six botanical raw materials (in the form of decoction pieces) including Huomarean, Dahuang, Kuxingren, Houpo, Baishao and Zhishi (stir-fried with wheat bran). Dextrin and magnesium stearate are added as excipients.~The placebo is in the form of granules for oral use. The granules are a mixture of color and flavor additives (caramel coloring, riboflavin, citric acid and sucrose octaacetate) with dextrin as an excipient."
62693142|NCT06570668|EXPERIMENTAL|10 g of CDD-2101 and 10 g of placebo;|"CDD-2101 is a botanical drug candidate in granule form, with same formulation as the Chinese herbal medicine MZRW, based on the water extract from six botanical raw materials (in the form of decoction pieces) including Huomarean, Dahuang, Kuxingren, Houpo, Baishao and Zhishi (stir-fried with wheat bran). Dextrin and magnesium stearate are added as excipients.~The placebo is in the form of granules for oral use. The granules are a mixture of color and flavor additives (caramel coloring, riboflavin, citric acid and sucrose octaacetate) with dextrin as an excipient."
61934680|NCT02585622|EXPERIMENTAL|Bone marrow-derived Mesenchymal Stromal Cells|
61934681|NCT02585622|PLACEBO_COMPARATOR|Cryostor CS10|
61934682|NCT06707246|EXPERIMENTAL|Secukinumab treatment group|Participants will take secukinumab 300mg every week in the first month and every four weeks thereafter till 1 year
62134154|NCT04025164|EXPERIMENTAL|Hypofractionated Radiotherapy|"40 Gy/15 fractions irradiation is delivered to the whole breast, 2.67 Gy per fraction, 5 fractions weekly.~Tumor bed is boosted to 48 Gy simultaneously, 3.2 Gy per fraction, 5 fractions weekly."
62327948|NCT04095286|EXPERIMENTAL|AMB oral tablet/reference AMB/AMB dispersed in water|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive single dose of 5 mg AMB tablet dispersed in water. There will be a washout period of 7 days between doses in each treatment period.
62327949|NCT04095286|EXPERIMENTAL|Reference AMB/AMB dispersed in water/AMB oral tablet|Eligible participants will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
62486119|NCT03881943|ACTIVE_COMPARATOR|Aspirin|Aspirin 100mg daily for 3 months
62486120|NCT01991548|OTHER|Diabetic participants with study devices|
61934683|NCT06707246|EXPERIMENTAL|Tofacitinib treatment group|Participants will take tofacitinib 11mg daily for 1 year
61934684|NCT02595970|EXPERIMENTAL|Secukinumab|Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
61934685|NCT06605456|EXPERIMENTAL|Group A: PNF with postural education|PNF neck pattern intervention with a rhythmic initiation technique implemented. This exercise intervention consisted of a two-phase exercise set: stretching the muscles and strengthening them
61934686|NCT06605456|ACTIVE_COMPARATOR|Group B: Active neck muscle stretching and strengthening exercises|Active neck muscle stretching and self-isometric strengthening exercises, targeting all cervical muscle groups.
61934687|NCT02545595|EXPERIMENTAL|Sugammadex 1mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
61934688|NCT02545595|EXPERIMENTAL|Sugammadex 2mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
61934689|NCT02545595|EXPERIMENTAL|Sugammadex 4mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
61934690|NCT02715973|EXPERIMENTAL|Nutritional Supplement|"Diet Counseling (Energy=200 kcal/kg/day, (present weight) protein =3-4 gm/kg/day)~Nutritional supplement (Providing extra 40 kcal/kg/day)"
61934691|NCT02715973|ACTIVE_COMPARATOR|Standard nutritional treatment|"Diet counselling only (Energy=200 kcal/kg/day (present weight) protein =3-4 gm/kg/day).~Standard nutritional treatment"
61934692|NCT00816114||Chronic Myelogenous Leukemia|All CML patients in any phase of the disease that received imatinib treatment outside of MDACC clinical trials and has had at least one MDACC clinic visit.
62486121|NCT01968551|EXPERIMENTAL|Cohort 1|"Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks.~Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks."
62486122|NCT01968551|EXPERIMENTAL|Cohort 2, Treatment Group 1|Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
62486123|NCT01968551|ACTIVE_COMPARATOR|Cohort 2, Treatment Group 2|Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
62486124|NCT05586880|EXPERIMENTAL|EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
62486125|NCT05586880|PLACEBO_COMPARATOR|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
62486126|NCT02495207|NO_INTERVENTION|Conventional Surgery|No intervention in this arm. The patients are going to undergo normal surgical intervention. Conventional surgery will be performed to extract the impacted third molars.
62486127|NCT02495207|EXPERIMENTAL|Piezosurgery|Patients here will undergo a piezosurgery to extract their third molars on both sides.
62486128|NCT06449534|EXPERIMENTAL|The enriched therapeutic environment group (Group 1)|Group 1 will receive treatment in a physiotherapy unit which has following characteristics ; enlightened with sunlight, has a view of green trees and includes other participants exercising. Patients will receive a treatment consisting of patient education, exercise therapy and cold application for a total of 15 sessions, 3 times a week. Each session will last approximately 60 minutes. After the patient education and exercise therapy is completed, the participants will listen to classical music pieces selected by us during 15 minutes of cold application.
62486129|NCT06449534|EXPERIMENTAL|The isolated therapeutic environment group (Group 2).|Group 2 will receive treatment in a quiet single room. The room is illuminated by artificial light, curtains are closed so that patients cannot see outside view. Patients will receive a treatment consisting of patient education, exercise therapy and cold application for a total of 15 sessions, 3 times a week. Each session will last approximately 60 minutes. After the patient education and exercise therapy is completed, the participants will rest silently for 15 minutes of cold application.
62486130|NCT02263703|EXPERIMENTAL|HPV vaccine|Quadrivalent HPV vaccine
62486131|NCT05560087||Coronary artery disease|
62486132|NCT05560087||control|
62486133|NCT03789110|EXPERIMENTAL|Nivolumab+Ipilimumab|"* Ipilimumab is administered intravenously every 6 weeks~* Nivolumab is administered intravenously every 2 weeks"
62486134|NCT01899352|OTHER|Tracheostomy|The investigators will enroll all the critical ill patients undergoing tracheostomy performed in intensive care units
62486135|NCT00842062|EXPERIMENTAL|MyoScience Tissue Remodeling Device|
62486136|NCT06430632|EXPERIMENTAL|Robotic Gait Training|Participants will receive robotic gait training with a physical therapist for 90 minutes each week throughout the course of their inpatient rehabilitation stay.
62327950|NCT04095286|EXPERIMENTAL|AMB dispersed in water/reference AMB/AMB oral tablet|Eligible participants will receive single dose of 5 mg AMB tablet dispersed in water during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
62327951|NCT04095286|EXPERIMENTAL|AMB oral tablet/AMB dispersed in water/reference AMB|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of reference 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
62327952|NCT04095286|EXPERIMENTAL|Reference AMB/AMB oral/AMB dispersed in water|Eligible participants in this arm will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB tablet dispersed in water There will be a washout period of 7 days between doses in each treatment period.
62327953|NCT06517953|EXPERIMENTAL|Icotinib + Befotertinib|orally Icotinib 125mg Tid plus orally Befotertinib 100mg qd until progression disease
62486137|NCT06430632|ACTIVE_COMPARATOR|Usual Care Gait Training|Participants will receive usual care gait training with a physical therapist for 90 minutes each week throughout the course of their inpatient rehabilitation stay.
62486138|NCT04627857|ACTIVE_COMPARATOR|Arm 1: Manual toothbrush|
62486139|NCT04627857|EXPERIMENTAL|Arm 2: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
62486140|NCT04627857|EXPERIMENTAL|Arm 3: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
62486141|NCT04627857|EXPERIMENTAL|Arm 4: Sonic toothbrush (Philips Sonicare ProtectiveClean) and water flosser|
62486142|NCT05877274||Patients with ACNES|Patients with ACNES who fulfill the inclusion criteria.
62486143|NCT00818558|EXPERIMENTAL|1|stade IA \[pT1 N0M0\]
62486144|NCT00818558|EXPERIMENTAL|2|stade IB \[pT2 N0M0\]
62486145|NCT00818558|EXPERIMENTAL|3|stade IIA \[pTI N1M0\]
62486146|NCT00818558|EXPERIMENTAL|4|stade IIB \[pT2 N1 et T3N0M0\]
62486147|NCT00818558|EXPERIMENTAL|5|control groupe \[tabagic subject\]
62486148|NCT00818558|EXPERIMENTAL|6|Control group B \[intervention for a pulmonaire non tumoral pulmonary lesion\]
62486149|NCT04426851|EXPERIMENTAL|Part 2: BI 1358894 (Test 2-Reference 2)|BI 1358894
62486150|NCT04426851|EXPERIMENTAL|Part 2: BI 1358894 (Reference 2-Test 2)|BI 1358894
62486151|NCT04426851|EXPERIMENTAL|Part 1: BI 1358894 (Test 1-Reference 1)|BI 1358894
62486152|NCT01243983|EXPERIMENTAL|LX211|
62486153|NCT01243983|PLACEBO_COMPARATOR|Placebo|
62486154|NCT01134549|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo intravenous injection.
62486155|NCT01134549|EXPERIMENTAL|Etelcalcetide|Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.
62693143|NCT06570668|EXPERIMENTAL|15 g of CDD-2101 and 5 g of placebo;|"CDD-2101 is a botanical drug candidate in granule form, with same formulation as the Chinese herbal medicine MZRW, based on the water extract from six botanical raw materials (in the form of decoction pieces) including Huomarean, Dahuang, Kuxingren, Houpo, Baishao and Zhishi (stir-fried with wheat bran). Dextrin and magnesium stearate are added as excipients.~The placebo is in the form of granules for oral use. The granules are a mixture of color and flavor additives (caramel coloring, riboflavin, citric acid and sucrose octaacetate) with dextrin as an excipient."
62693144|NCT06570668|EXPERIMENTAL|20 g of CDD-2101|CDD-2101 is a botanical drug candidate in granule form, with same formulation as the Chinese herbal medicine MZRW, based on the water extract from six botanical raw materials (in the form of decoction pieces) including Huomarean, Dahuang, Kuxingren, Houpo, Baishao and Zhishi (stir-fried with wheat bran). Dextrin and magnesium stearate are added as excipients.
61934693|NCT06701591|EXPERIMENTAL|Group A (Kinesiotaping group)|"Participants will be seated on a chair, KT will be applied bilaterally at the end of the expiration on the fifth to sixth and ninth to tenth intercostal muscles transversally and on the anterior and posterior axillary line longitudinally with 50% tension. In order to stimulate the muscle and support the function, the stimulation technique is usually applied from the origin to the insertion of the muscle with the recommended stretching of 25 to 50%.~Additionally, traditional physical therapy program will be conducted to participants in the study group."
61934694|NCT06701591|ACTIVE_COMPARATOR|Group B (control group)|They will receive the chest physical therapy program which is consisted of deep breathing exercises, postural drainage, cough, 3 times /week for 4 weeks.
61934695|NCT05648760|OTHER|Usual training|Participants randomized to the control condition received a standard training of how to communicate bad news to patients
62693145|NCT06570668|PLACEBO_COMPARATOR|20 g of placebo|The placebo is in the form of granules for oral use. The granules are a mixture of color and flavor additives (caramel coloring, riboflavin, citric acid and sucrose octaacetate) with dextrin as an excipient.
61934696|NCT05648760|EXPERIMENTAL|Simulation training|Participants randomized to the simulation training group received simulation training based on a standard training of how to communicate bad news to patients
61934697|NCT04904679|ACTIVE_COMPARATOR|Amniotic Membrane group|Patients who will be treated with a amniotic membrane plug
62134155|NCT04025164|ACTIVE_COMPARATOR|Conventional Irradiation|"50 Gy/25 fractions irradiation is delivered to the whole breast, 2 Gy per fraction, 5 fractions weekly.~Additional 10 Gy/5 fractions is boosted to tumor bed sequentially, 2 Gy per fraction, 5 fractions weekly."
62134156|NCT01691079|PLACEBO_COMPARATOR|placebo|placebo 2 puffs prior to exercise challenge
62486156|NCT01534845|NO_INTERVENTION|only Radiotherapy|fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy
62693146|NCT06638749|EXPERIMENTAL|Tranexamic acid|The experimental group will receive 1 gram of intravenous tranexamic acid at skin incisions and 1 gram at skin closure.
62693147|NCT06638749|PLACEBO_COMPARATOR|Normal Saline|The control group will receive 100 ml of normal saline, 50 ml at incision and 50 ml at closure instead of tranexamic acid.
62693148|NCT06673888|EXPERIMENTAL|Alkasite-Based Resin Composite Restorative Material (Bioactive Material)|Alkasite material releases hydroxyl ions, calcium, fluoride, and phosphate ions which explains its caries-prevention mechanisms. Many researches indicate that this alkasite material neutralizes acids and prevents enamel and dentin demineralization when exposed to lactic acid for an extended length of time together with the added advantageous of maximum properties and esthetics of resin composite
61934698|NCT04904679|ACTIVE_COMPARATOR|Internal Limiting Membrane group|patients who will be treated with a internal limiting membrane flap
61934699|NCT06688266|EXPERIMENTAL|Nerve Gilding Exercises|Nerve Gilding Exercises
61934700|NCT06688266|ACTIVE_COMPARATOR|Conventional Grip Strength Exercises|Conventional Grip Strength Exercises
62134157|NCT01691079|ACTIVE_COMPARATOR|ipratropium bromide|ipratropium bromide HFA 2 puffs prior to exercise challenge
62693149|NCT06673888|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer Restorative Material|Resin-modified glass-ionomers have mainly the same clinical applications as conventional glass-ionomers. Their biocompatibility and ability to release fluoride are two of their advantages. In addition, it has advantages over traditional glass ionomer in terms of stronger features, better aesthetics, earlier finishing, and longer working time. They are considered the gold standard in restoring cervical carious lesions of anterior teeth over GI due to their added benefit of higher esthetics.
61934701|NCT02263209|EXPERIMENTAL|Bioguard Group|Randomised study to either Bioguard or control stock
61934702|NCT02263209|ACTIVE_COMPARATOR|Control Group|Randomised study to either Bioguard or control stock
61934703|NCT06383598|EXPERIMENTAL|68Ga-Nb-1|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-Nb-1 PET/CT scans (At the investigator's discretion, a total of no more than 0.5 mg of non-radiolabeled precursor may be considered for injection. To reduce liver and bone marrow uptake). After resting for 40 minutes or 1 hour, participants underwent United Imaging Healthcare total-body PET/CT for whole body scans or a Siemens Biograph m-CT flow PET/CT from the top of the head to the upper third of the thighs.
61934704|NCT05515172|EXPERIMENTAL|Intervention group|Mindfulness-based intervention is composed of micropractices, cohesion groups, affirmations, and journaling. This was administered via a webpage designed for this intervention.
61934705|NCT04723901|EXPERIMENTAL|Treatment group|Dual target CAR-T cell therapy
61934706|NCT06580080|EXPERIMENTAL|Are You Ready?|
61934707|NCT06580080|SHAM_COMPARATOR|Social Media Awareness Shorts|
62134158|NCT06234956|EXPERIMENTAL|BIMERVAX|
62134159|NCT06394206|EXPERIMENTAL|Specialized Unit|This group of participants will be visited in the specialized consultation and will continue to receive the rest of their follow-up visits.
62134160|NCT06394206|ACTIVE_COMPARATOR|Usual Follow-Up|This group of participants will undergo their usual follow-up visits but will not be visited in the specialized consultation.
62134161|NCT00982644|EXPERIMENTAL|IDeg OD|
62134162|NCT00982644|ACTIVE_COMPARATOR|IGlar OD|
62134163|NCT05792293|EXPERIMENTAL|Study Group|Fifty female patients diagnosed with breast cancer receiving Anthracycline based chemotherapy
62134164|NCT05792293|PLACEBO_COMPARATOR|Control Group|Fifty female patients diagnosed with breast cancer receiving Anthracycline based chemotherapy
62486157|NCT01534845|ACTIVE_COMPARATOR|CCRT with Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles).
62486158|NCT06627361|EXPERIMENTAL|PRO-FLEX PIVOT|The patient will be fitted with PRO-FLEX PIVOT® foot for a duration of 28 days, with a variance of ±2 days
62486159|NCT06627361|ACTIVE_COMPARATOR|Class III ESAR foot|The patient will be fitted with his usual class III ESAR foot for a duration of 28 days, with a variance of ±2 days
62486160|NCT01874535|ACTIVE_COMPARATOR|GERD Los Angeles A and B-4 week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 4 week group
62486161|NCT01874535|ACTIVE_COMPARATOR|GERD Los Angeles A and B-8-week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 8 week group
61934708|NCT00589290|EXPERIMENTAL|Belinostat Treatment|1000 mg/m\^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
62327954|NCT04090281|OTHER|Precision medicine implementation|Patients will receive a precision medicine approach, incorporating both CYP2C19 genotyping and platelet reactivity phenotyping, to guide dual antiplatelet therapy selection for patients with ACS, post PCI and followed over a 12 month period.
62327955|NCT01850849|EXPERIMENTAL|LEO 39652 cream|Active drug
62486162|NCT03608228||Parkinson's Disease|
62486163|NCT02512900|EXPERIMENTAL|MEDI9929, 140 mg, Cohort 1 (12 to 14 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.
62486164|NCT02512900|EXPERIMENTAL|MEDI9929, 140 mg, Cohort 2 (15 to 17 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.
62486165|NCT05237635|EXPERIMENTAL|Threshold estimates|Descriptive case-scenarios
61934709|NCT02394548|EXPERIMENTAL|Contralateral Esophagus Sparing Technique (CEST)|IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
62134165|NCT01323686|EXPERIMENTAL|Imaging guided LV lead placement|
62134166|NCT01323686|NO_INTERVENTION|Empiric LV lead placement|LV lead placement using standard clinical routine.
62134167|NCT04971070||Hypoglycemic disturbance group|
62134168|NCT04971070||Hypoglycemia was not a disorder of consciousness group|
62327956|NCT01850849|PLACEBO_COMPARATOR|LEO 39652 cream vehicle|Placebo drug
62327957|NCT04070313|EXPERIMENTAL|S-1|single-arm
62327958|NCT04053179|EXPERIMENTAL|Connected patch validation|
62327959|NCT05480787|EXPERIMENTAL|Remimazolam 0.1mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.1 mg/kg/h.
62327960|NCT05480787|EXPERIMENTAL|Remimazolam 0.3mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.3 mg/kg/h.
62486166|NCT05237635|ACTIVE_COMPARATOR|Alternative threshold estimates|Descriptive case-scenarios
62327961|NCT05480787|EXPERIMENTAL|Remimazolam 0.5mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.5 mg/kg/h.
62486167|NCT02671630|NO_INTERVENTION|Control group|Patients receive only usual hospital care
62693150|NCT06569485|EXPERIMENTAL|Intervention/Treatment|"Experimental: Trilaciclib+R-CHOP~Patients with DLBCL were treated with Trilaciclib (240mg/m2, d1, within 4 hours before each chemotherapy) combined with Rituximab (375 mg/m2，d0), Cyclophosphamide (50 mg/m2，d1), Doxorubicin (50 mg/m2，d1) or Epirubicin（60 mg/m2，d1）, Vincristine (1.4 mg/m2), and Prednisone (100 mg，d1-5).~A total of 6 cycles of treatment were performed every 21 days as a cycle."
62693151|NCT00112385|ACTIVE_COMPARATOR|Etanercept|Subjects randomized to Etanercept will be provided with syringes contain 50 mg and will be injected subcutaneously once a week for 52 weeks.
61934710|NCT04604158|EXPERIMENTAL|Elly Mobile Phone Application|
62327962|NCT06467435|EXPERIMENTAL|Patients with Thyroid Eye Disease (TED)|Participants receive a regimen of 96 mg tablets of K9 twice a day for 4 weeks
62327963|NCT06467435|EXPERIMENTAL|Healthy Volunteers|Participants receive one dose of 96 mg tablets of K9 based on weight
61934711|NCT03238742|EXPERIMENTAL|Intervention Group|100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
61934712|NCT03238742|PLACEBO_COMPARATOR|Placebo group|normal saline 200 mL every 12 hours for 5 days
61934713|NCT05888415||sophrology practitioners|Practice sophrology - no intervention
61934714|NCT05888415||non practitioners|Do not practice sophrology - no intervention
61934715|NCT03400644|ACTIVE_COMPARATOR|With Collar|Subjects are prescribed with custom-made rigid cervical collar which are to be worn for 3 weeks postoperatively
61934716|NCT03400644|NO_INTERVENTION|Without Collar|Subjects do not need to wear any cervical collar postoperatively
62134169|NCT05063045|EXPERIMENTAL|smart-cloth|Participants receive smart-cloth assisted home nursing care
62134170|NCT05063045|NO_INTERVENTION|routine care|This group receive routine care
62134171|NCT05150106||Laryngeal dystonia|Patients with laryngeal dystonia (or spasmodic dysphonia)
62134172|NCT05150106||Voice tremor|Patients with voice tremor (essential or dystonic)
62134173|NCT05150106||Healthy controls|Healthy research volunteers
62134174|NCT06593938|EXPERIMENTAL|HRS-5965 capsule|
62134175|NCT06593938|EXPERIMENTAL|Eculizumab Injection|
62327964|NCT01942213||Subjects receiving Ranibizumab|150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection.
62327965|NCT01942213||Subjects receiving Aflibercept|150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection
62327966|NCT04065880|ACTIVE_COMPARATOR|TachoSil®|TachoSil® is a collagen sponge coated with the human coagulation factors fibrinogen and thrombin.
62327967|NCT04065880|ACTIVE_COMPARATOR|Neoveil®|Neoveil® sheet made of polyglycolic acid (PGA). It is a biodegradable, thermoplastic and non-antigenic polymer.
62486168|NCT02671630|EXPERIMENTAL|Experimental group|Patients receive only usual hospital care and community-based computerized cognitive training program
62486169|NCT04955990|EXPERIMENTAL|Participants with PAH|Participants with pulmonary arterial hypertension (PAH) who newly initiate any PAH therapy(ies) at the index date (date when a participant starts the first new PAH therapy after baseline assessments) in a routine clinical setting, either as first-line therapy, as replacement therapies, as concomitant with other PAH therapies, or have already been receiving macitentan 10 milligrams (mg) for at least 3 months prior to the index date. The primary data source for this study will be the medical records of each participant.
62327968|NCT05332067|EXPERIMENTAL|Omalizumab|Single dose of omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
62486170|NCT04263506|EXPERIMENTAL|Vignette with supervisor's opinion|Participants in this arm will receive vignettes with an additional sentence describing supervisor's opinion (i.e. supervisor does not oppose to detrimental research practice)
62486171|NCT04263506|ACTIVE_COMPARATOR|Vignette without supervisor's opinion|Participants in this arm will receive vignettes without an additional sentence describing supervisor's opinion.
62486172|NCT04698473|ACTIVE_COMPARATOR|NCPAP|"Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of \>%50, capillary blood gas obtained at the 4th hour of therapy showing pH\<7.20 or pCO2\>60 cmH2O."
62486173|NCT04698473|ACTIVE_COMPARATOR|NIPPV|"Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of \>%50, capillary blood gas obtained at the 4th hour of therapy showing pH\<7.20 or pCO2\>60 cmH2O."
62486174|NCT01252953|EXPERIMENTAL|Anacetrapib|
62486175|NCT01252953|PLACEBO_COMPARATOR|Placebo anacetrapib|
62486176|NCT06423014|NO_INTERVENTION|Control|
62486177|NCT06423014|ACTIVE_COMPARATOR|Wearable devices only|
62486178|NCT06423014|EXPERIMENTAL|Wearable devices with the 1st behavior change technique|
62486179|NCT06423014|EXPERIMENTAL|Wearable devices with the 2nd behavior change technique|
62486180|NCT06423014|EXPERIMENTAL|Wearable devices with the 3rd behavior change technique|
62486181|NCT06423014|EXPERIMENTAL|Wearable devices with the 4th behavior change technique|
62486182|NCT06423014|EXPERIMENTAL|Wearable devices with the 5th behavior change technique|
62486183|NCT06423014|EXPERIMENTAL|Wearable devices with all behavior change techniques|
62486184|NCT02730533|ACTIVE_COMPARATOR|Control group|No PPI treatment should given after the initial allocation. Patient will be admitted, and ESD will be performed. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
62486185|NCT02730533|EXPERIMENTAL|Esomeprazole group|Esomeprazole should start as soon as possible after the initial allocation. During the 7 days of p.o. treatment, patient will be admitted, and ESD will be performed as soon as completing the p.o. treatment. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
62486186|NCT04021511|NO_INTERVENTION|Phase A|The first one (Phase A) will occur in the emergency department with the application of OAR only by the physicians (without changing the standard of care) during 4 weeks
62486187|NCT04021511|EXPERIMENTAL|Phase B|The second one (Phase B) will occur after the Phase A. Nurses will apply OAR according to the protocol. This phase will also lasts 4 weeks.
62486188|NCT01277276||Diagnostic tool|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
62486189|NCT00744679|EXPERIMENTAL|Natalizumab 300 mg|Natalizumab infused at 300 mg every 28 days during the screening and assessment periods of the study which continues the therapy of the previous 12 months and maintains steady-state pharmacokinetics.
62486190|NCT04938635|EXPERIMENTAL|VIT-2763 60 mg QD|VIT-2763 60 mg administered once daily
62486191|NCT04938635|EXPERIMENTAL|VIT-2763 60 mg BID|VIT-2763 60 mg administered twice daily
62693152|NCT00112385|PLACEBO_COMPARATOR|Placebo|Subjects will be given syringes containing placebo. Injections will be given subcutaneously, one time per week for 52 weeks.
62327969|NCT05332067|PLACEBO_COMPARATOR|Placebo for omalizumab|Single dose of placebo for omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
62327970|NCT05239286|ACTIVE_COMPARATOR|Group conventional|
62327971|NCT05239286|EXPERIMENTAL|Group PVI|
62327972|NCT00190203|EXPERIMENTAL|A|HEMICRANIECTOMY
62327973|NCT04746612|EXPERIMENTAL|HH30134|HH30134 administered orally on a continuous once daily(QD), start from 100mg QD.
62327974|NCT04615962|EXPERIMENTAL|SNG100|Combination of low potency steroid with hydrating and moisturizing agents
62327975|NCT04615962|ACTIVE_COMPARATOR|Hydrocortisone|This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).
62486192|NCT04938635|EXPERIMENTAL|VIT-2763 120 mg BID|VIT-2763 120 mg administered twice daily
62486193|NCT04938635|PLACEBO_COMPARATOR|Placebo|Placebo capsule administered twice daily
62486194|NCT06443385|EXPERIMENTAL|Legal Mandate Messaging|
62486195|NCT06443385|EXPERIMENTAL|Clinical Benefit Messaging|
62693153|NCT06637774|EXPERIMENTAL|Videofluoroscopic Swallow Study + Aspirometer|Consecutively referred patients for modified barium swallow due to suspicion of dysphagia with aspiration, undergo the modified barium swallow test with Aspirometer sensors taped to the anterior neck. Signals are time-linked to images.
62327976|NCT04615962|ACTIVE_COMPARATOR|Mometasone furoate|This medication is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.
62327977|NCT02252874|PLACEBO_COMPARATOR|Control Group|Receive leisure activities (e.g. reading, web-surfing, playing chess/ Mahjong) Twenty hours (2-3 sessions per week, 1.5 hours per session)
62327978|NCT02252874|ACTIVE_COMPARATOR|Intervention Group 1|Receive slow motion Nintendo Wii video games Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
62486196|NCT06443385|NO_INTERVENTION|Control|
62486197|NCT04422262||Moli-sani Study sub-cohort|A sample of 2,500 men and women from the Moli-sani Study cohort (2005-2010) who were re-examined in 2017-2020. Participants will be contacted by telephone by researchers of the Moli-sani Study recruitment team in order to collect dietary, lifestyle and psychosocial information and assess potential changes possibly occurred during Phase 1 lockdown.
62486198|NCT04422262||Italian general population|The project will retrospectively collect data through a web-based survey using Google form. The questionnaire consists of the same items used for the Moli-sani sub-cohort. The project aims at including as many subjects' records as possible.
62486199|NCT04018404|NO_INTERVENTION|Control|Subjects will be approached for enrollment prior to or following clinic visit with physician. Only children present with a biological mother will be considered for enrollment. Charts of controls will be flagged so that they will not be able to be enrolled in the FRI clinical program if they present to a morning clinic where the program is offered.
62486200|NCT04018404|EXPERIMENTAL|Subject|Mothers and children will be approached by study personnel (separate from Outreach Coordinators who will obtain consent for use of information to evaluate the FRI Clinical Program) for enrollment in the FRI Research Program following completion of all FRI Clinical Program activities for that day. Both mother and child will be enrolled and contribute data and samples to the FRI Research Program.
62693154|NCT06497140|EXPERIMENTAL|Embolization group|Genicular arteries embolization of the target knee will be performed using an ethiodized oil-based emulsion (3:1 mix of ethiodized oil and contrast agent ioversol 300 mgI/ml); 86 patients will be allocated to embolization group (2:1 randomization).
62486201|NCT02772822|EXPERIMENTAL|Experimental|SCT400 plus CHOP, six cycles SCT400: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
62486202|NCT02772822|ACTIVE_COMPARATOR|Active Comparator|Rituximab plus CHOP, six cycles Rituximab: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
62486203|NCT00627744|PLACEBO_COMPARATOR|BE 1|Patients in this arm are randomly assigned to treatment with placebo
62486204|NCT00627744|ACTIVE_COMPARATOR|BE 2|Patients in this arm are randomly assigned to treatment with Sitagliptin
62486205|NCT05869721|EXPERIMENTAL|Yoga group|Participants will receive yoga programme over a period of eight weeks
62693155|NCT06497140|SHAM_COMPARATOR|Sham group|"All the gestures will be mimed using the same equipment as in GAE group. Superficial femoral artery catheterization, selective catheterization of target arteries and emulsion injection will be mimicked by the interventional radiologist (table movements, syringes manipulation) to keep the patient blind from the actual treatment.~44 patients will be allocated to sham group (2:1 randomization)."
62693156|NCT00583531|EXPERIMENTAL|I|Active treatment with AST-120
62693157|NCT05515237|EXPERIMENTAL|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components administered over the specific time frame of 2-3 weeks.
62134176|NCT03200808|EXPERIMENTAL|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
62486206|NCT05869721|NO_INTERVENTION|Control group|The participants in the control group will receive usual care, and complete all assessments on the same timeline as the intervention group. They will be offered yoga programme at the completion of the final measurement.
62486207|NCT01572662|EXPERIMENTAL|Fludarabine + Busulfan|"Fludarabine administered by vein at dose of 40 mg/m2 in 100 ml of normal saline (NS) on Days -6 through -3.~First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies."
62693158|NCT02465112|EXPERIMENTAL|metabolic radiotherapy|In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
62693159|NCT02465112|ACTIVE_COMPARATOR|No metabolic radiotherapy - simple monitoring|No metabolic radiotherapy - simple monitoring without theraoy
62693160|NCT01839409|NO_INTERVENTION|control|Control without vestibular stimulation
62693161|NCT01839409|NO_INTERVENTION|Bilateral areflexia|Patient with vestibular bilateral areflexia
62134177|NCT05681234|EXPERIMENTAL|18F-RD2|
62693162|NCT01839409|NO_INTERVENTION|Areflexia controls|Controls for patients with vestibular bilateral areflexia, matched in sex and age
62134178|NCT01746641|ACTIVE_COMPARATOR|Remifentanil|"Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
62134179|NCT01746641|ACTIVE_COMPARATOR|Propofol|"Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
62693163|NCT01839409|EXPERIMENTAL|vestibular stimulation|Subjects submitted to vestibular stimulation in order to improve circadian rhythms
62693164|NCT06473714|EXPERIMENTAL|tDCS|
62693165|NCT06473714|SHAM_COMPARATOR|SHAM|
62693166|NCT06675760|NO_INTERVENTION|the control groups|The control group received pressure injury assessment training through traditional education methods.
62693167|NCT06675760|EXPERIMENTAL|The mobile augumented reality application intervention group|The intervention group received training through a mobile augmented reality application in the laboratory.
62693168|NCT03119129|EXPERIMENTAL|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
62693169|NCT03119129|EXPERIMENTAL|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
62693170|NCT03119129|EXPERIMENTAL|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
62693171|NCT03119129|EXPERIMENTAL|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
62693172|NCT06561776||Young adults|This group will consist of individuals aged 18 and over
62327979|NCT02252874|ACTIVE_COMPARATOR|Intervention Group 2|Receive fast motion Nintendo Wii video games (e.g. shooting game) Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
62327980|NCT01688752||Sibling Controls|Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.
62327981|NCT01688752||Acute Lymphoblastic Leukemia Survivors|Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.
62327982|NCT02028364|EXPERIMENTAL|Everolimus given in conjunction with exemestane|Everolimus 10mg orally daily given in conjunction with exemestane 25mg orally daily until disease progression or treatment discontinuation for any other reasons.
62327983|NCT02908958|EXPERIMENTAL|PEG-somatropin|Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
62327984|NCT02908958|EXPERIMENTAL|PEG-Somatropin|High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
62327985|NCT02026908|EXPERIMENTAL|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
62327986|NCT06472258|EXPERIMENTAL|IV Artesunate Group|IV Artesunate with weight appropriate dosage on 0, 12, 24 and 48 hours, and continued 12 hourly for a maximum duration of seven days. Each dose diluted in normal saline given as infusion.
62327987|NCT06472258|EXPERIMENTAL|Combination Group|IV Artesunate with weight appropriate dose on 0, 12, 24 and 48 hours, plus IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
62327988|NCT02256865|PLACEBO_COMPARATOR|Placebo and Drug Group 2|Placebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day.
62327989|NCT02256865|ACTIVE_COMPARATOR|Drug and Placebo Group 1|Ketoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day
62327990|NCT03852810||Receiving surgical intervention via XEN Gel Stent (XEN)|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
62327991|NCT03852810||Receiving surgical intervention via trabeculectomy|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
62327992|NCT06692517||Elective cholecystectomy|Elective cholecystectomy. Patients with recurrent gallstone attacks, previous cholecystitis, previous cholangitis, or previous pancreatitis. ERCP may be involved if a gallstone is detected in the common bile duct perioperatively.
62327993|NCT02226042|EXPERIMENTAL|Mindfulness-based Cognitive Therapy|Individuals currently in remission from depression will choose to enter the Mindfulness-based Cognitive Therapy (MBCT) arm and undergo the 8 week MBCT group programme
62486208|NCT06066749|EXPERIMENTAL|NIOSH certified N95 personal face covering (mask)|During the third woodsmoke exposure, half of the subjects will be randomly assigned to wear a NIOSH (National Institute of Occupational Safety \& Health) certified N95 personal face covering (mask) while undergoing an exposure to approximately 500 μg/m\^3 wood smoke for 2 hours while exercising intermittently (15 min exercise followed by 15 min rest) on a stationary bike at a workload sufficient to maintain approximately 12 L/min/m\^2 minute ventilation.
62486209|NCT06066749|EXPERIMENTAL|Surgical Mask|During the third woodsmoke exposure, half of the subjects will be randomly assigned to wear a surgical mask while undergoing an exposure to approximately 500 μg/m\^3 wood smoke for 2 hours while exercising intermittently (15 min exercise followed by 15 min rest) on a stationary bike at a workload sufficient to maintain approximately 12 L/min/m\^2 minute ventilation.
62486210|NCT00673842|EXPERIMENTAL|Implantable Cardioverter Defibrillator + Usual Care|Medtronic ICD
62486211|NCT00673842|ACTIVE_COMPARATOR|Usual Care|Usual post-MI care
62486212|NCT03599193|EXPERIMENTAL|DFD-03 Lotion|DFD-03 Lotion will be applied to the affected areas twice daily for 1 minute and rinsed off. 29 subjects will be enrolled into this arm.
62486213|NCT03599193|ACTIVE_COMPARATOR|Tazorac Cream|Tazorac Cream will be applied to the affected areas once daily and left on for \~12 hours. 29 subjects will be enrolled into this arm.
62486214|NCT03051945|EXPERIMENTAL|Ketamine|Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
62693173|NCT04539405||Memsorb|M for memsorbTM group with the minimal gas flow possible (sevoflurane administration at 0.2L.min-1) with the ventilator Draeger A-500 Perseus,
62486215|NCT03051945|PLACEBO_COMPARATOR|Placebo|Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
62693174|NCT04539405||Dräegersorb|D for DraegersorbTM group with gas flow at 2L.min-1 (classical sevoflurane administration) with the same ventilator Draeger A-500 Perseus.
62327994|NCT02226042|NO_INTERVENTION|Non-MBCT arm|Individuals currently in remission from depression will choose not to undergo the 8 week MBCT group programme
62327995|NCT02226042|NO_INTERVENTION|Healthy volunteers|Individuals who have never experienced major depression
62327996|NCT06099600|EXPERIMENTAL|pre-habilitation stays|Pre-habilitation involves taking part in a half-day information session led by a physiotherapist and a nurse prior to surgery. Patients will benefit from digital monitoring via the Orthense application, as well as scheduled surgery (anterior cruciate ligament reconstruction) and the usual peri-operative medical follow-up.
62327997|NCT06099600|ACTIVE_COMPARATOR|conventional care|During their pre-operative visit with the surgeon, patients will receive a booklet containing information on the peri-operative period, possible complications, how to prevent them and what to do should they occur. Patients will benefit from standard computerized follow-up, as well as the scheduled surgical procedure (anterior cruciate ligament reconstruction) and the usual peri-operative medical follow-up.
62693175|NCT05222945|OTHER|Single arm composed by 34 HIV-1 infected male subjects|
62693176|NCT06569589||Suspected PA|Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines.
62693177|NCT06501963|EXPERIMENTAL|Live Attenuated Influenza Vaccine|Participants receiving a single dose of the live attenuated influenza vaccine (LAIV).
62693178|NCT06636578|ACTIVE_COMPARATOR|Group (DR)|will receive 30 ml of 0.25% ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
62693179|NCT06636578|ACTIVE_COMPARATOR|Group (R)|will receive 30 ml of 0.25% of plain ropivacaine for each side.
62486216|NCT01379313|ACTIVE_COMPARATOR|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
62486217|NCT01379313|EXPERIMENTAL|1:1 group|1:1 I:E ratio group, inspiratory time : expiratory time = 1:1
62486218|NCT01379313|EXPERIMENTAL|2:1 group|inverse ratio group, inspiratory time : expiratory time = 2:1
62486219|NCT01379313|ACTIVE_COMPARATOR|1:2 PEEP group|I:E ratio of 1:2 with external PEEP of 5 cm H2O
62486220|NCT03810937|ACTIVE_COMPARATOR|Group sniffing (S)|intervention: Head position changes : we will start by performing first videolaryngoscopy to find best view in flat position then the anesthesiologist will remove the Glidescope and the patient will be positioned in sniffing position using the pillow and another videolaryngoscopy will be attempted in sniffing position to find best view in this position and the patient will be intubated in this position.
62486221|NCT03810937|ACTIVE_COMPARATOR|Group Flat (F)|intervention: Head position changes same procedure will be done but starting from sniffing position and the patient will be intubated in flat position.
62486222|NCT06560983||Acute stroke with hyperglycemia|Exposed group signifies acute stroke presenting in emergency department with hyperglycemia
62486223|NCT02241551|EXPERIMENTAL|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
62486224|NCT02241551|EXPERIMENTAL|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
62486225|NCT06209749|EXPERIMENTAL|Intervention group|"Sensory-based intervention module will be given for three sessions a week for 12 weeks (30 minutes per session).~Usual school activities will be given four days a week for 12 weeks (6 hours per day)"
62486226|NCT06209749|NO_INTERVENTION|Control group|Usual school activities will be given four days a week for 12 weeks (6 hours per day)
62486227|NCT05031260|NO_INTERVENTION|Control group|The individuals in the control group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum.
62486228|NCT05031260|EXPERIMENTAL|Experimental group|The individuals in this group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum. Instead, they will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
62486229|NCT02992964|EXPERIMENTAL|Nivolumab|"Regimen: Nivolumab will be administered every 14 days until disease progression or treatment discontinuation due to unacceptable toxicities. Treatment may extend up to 2 years in patients who show clinical and radiological benefit.~Dose: 3 mg/kg intravenously as a continuous infusion over 60 min (+/-10 min window)"
62486230|NCT04889898||ALS Patients|All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.
62486231|NCT04889898||Listeners|Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.
62486232|NCT04310345|EXPERIMENTAL|Animal-Assisted Interaction|Children and their caregivers will spend approximately 10-15 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
62486233|NCT04084639|EXPERIMENTAL|Ingestion of 20g Mycoprotein Drink|Milkshake containing 20g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
62486234|NCT04084639|EXPERIMENTAL|Ingestion of 40g Mycoprotein Drink|Milkshake containing 40g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
62486235|NCT04084639|PLACEBO_COMPARATOR|Ingestion of Isocaloric Control Drink|Milkshake containing 250ml full-fat milk, 50g glucose, 19g dried skim milk and 9g full-fat dried milk
62486236|NCT05878080|EXPERIMENTAL|FPl-TMS|Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.
62486237|NCT05878080|EXPERIMENTAL|MFG-TMS|Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.
61934717|NCT06703385|ACTIVE_COMPARATOR|conventional program|Twenty patients will receive conventional physical therapy including Hot pack and exercise therapy program (ROM exercise, stretching exercise, isometric strengthening exercise for cervical muscles
61934718|NCT06703385|EXPERIMENTAL|suboccipital release|Twenty patients will receive suboccipital release plus the Same conventional physical therapy program.
62486238|NCT05878080|ACTIVE_COMPARATOR|S1-TMS|Transcranial magnetic stimulation to the primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.
62693180|NCT06636578|SHAM_COMPARATOR|Group (C)|the control group will not receive any regional anesthesia and only will receive fentanyl 1μg/kg/hr.
61934719|NCT06703385|EXPERIMENTAL|instrumental assisted soft tissue mobilization|Twenty patients will receive instrumental assisted soft tissue mobilization plus the Sam conventional physical therapy program.
61934720|NCT06023225||Postoperative patients|Pediatric female patients undergoing a surgical procedure
61934721|NCT06306053|EXPERIMENTAL|A Group|Only tDCS treatment
61934722|NCT06306053|ACTIVE_COMPARATOR|B Group|Only Motor Training
61934723|NCT06306053|ACTIVE_COMPARATOR|C Group|Both Treatment (tDCS+Motor Training)
62327998|NCT05599685||Participants with metastatic NSCLC initiated on 1L treatment with NIVO/IPI/PBC|
62327999|NCT04686006||Graves disease|
62328000|NCT01724736|PLACEBO_COMPARATOR|Placebo Comparator:|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
62486239|NCT06625021|EXPERIMENTAL|Control group|-The first group is the control group (n=12); Transcutaneous electrical nerve stimulation, ultrasound and appropriate neck exercises are planned to be applied every day for 4 weeks.
62486240|NCT06625021|ACTIVE_COMPARATOR|Chiropractic Group|-The second group is the chiropractic group and will be applied twice a week for 3 weeks by me, a Bahcesehir University Chiropractic Masters graduate (2017), targeting the lower cervicals.
62486241|NCT06625021|ACTIVE_COMPARATOR|Classic Hand-Wrist Exercises Group|-Classic hand-wrist exercises such as range of motion, stretching and strengthening were applied to the third group in all directions of the wrist.
62486242|NCT06625021|ACTIVE_COMPARATOR|Proprioceptive Exercises Group|-In the fourth group, proprioceptive exercises such as joint approximation, traction and mobilization, similar to the classic hand-wrist exercise group, will be performed every day for 4 weeks.
62486243|NCT05479058|EXPERIMENTAL|Filgotinib 200 mg|Participants received filgotinib 200 mg and placebo to match filgotinib 100 mg once daily orally.
62486244|NCT05479058|EXPERIMENTAL|Filgotinib 100 mg|Participants received filgotinib 100 mg and placebo to match filgotinib 200 mg once daily orally.
62486245|NCT04990648|EXPERIMENTAL|Buzzy group|Buzzy ® was placed on the left arm deltoid muscle site and kept there for 30 seconds. After 30 seconds, Buzzy ® was taken 1 cm up and MMR vaccine injection was administered to the left deltoid muscle site. After the vaccine injection, Buzzy ® was taken to the injection site and kept for another 30 seconds.
62486246|NCT04990648|NO_INTERVENTION|Control group|MMR vaccine injection was administered to the left deltoid muscle without any intervention or application to the injection site.
62693181|NCT06569992||Group 1|Spontaneous subarachnoid hemorrhage and spontaneous intracerebral hemorrhage
62328001|NCT01724736|ACTIVE_COMPARATOR|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
62328002|NCT03002389|OTHER|All COPD Subjects|"All subjects will be assessed with hyper polarized xenon-129 MRI, pulmonary function test, quality of life measures (BDI, TDI, SGRQ, CRQ, BODE, GOLD), and blood test.~Intervention: All subjects will received Anoro one puff once a day for 30 days first, then 3 day washout, then Arnuity 250 microgram one puff twice a day for 30 days to complete the study."
62328003|NCT04329611|ACTIVE_COMPARATOR|hydroxychloroquine|hydroxychloroquine 400 mg po bid loading dose for 1 day followed by 200 mg po twice daily for 4 days
62328004|NCT04329611|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62328005|NCT06158854|EXPERIMENTAL|Dose Escalation: ABBV-383 Dose A|Participants will receive ABBV-383 dose A during the approximately 2 year study duration.
62328006|NCT06158854|EXPERIMENTAL|Dose Escalation: ABBV-383 Dose B|Participants will receive ABBV-383 dose B during the approximately 2 year study duration.
62328007|NCT06158854|EXPERIMENTAL|Dose Escalation: ABBV-383 Dose C|Participants will receive ABBV-383 dose C during the approximately 2 year study duration.
62328008|NCT06158854|EXPERIMENTAL|Safety Expansion: ABBV-383 Expansion A|Participants will receive ABBV-383 expansion dose A during the approximately 2 year study duration.
62328009|NCT06158854|EXPERIMENTAL|Safety Expansion: ABBV-383 Expansion B|Participants will receive ABBV-383 expansion dose B during the approximately 2 year study duration.
62328010|NCT01734187|EXPERIMENTAL|Fermented Cinnamon Vine Powder|
62328011|NCT01734187|PLACEBO_COMPARATOR|Placebo|
62486247|NCT03946995|EXPERIMENTAL|Dry needling|Dry needling will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
62486248|NCT03946995|ACTIVE_COMPARATOR|Graston|Graston Technique will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
62486249|NCT01586039|ACTIVE_COMPARATOR|Compact Fluorescent Light 90 lux|90 lux exposure of a commercially available Compact Fluorescent Light (CFL).
62693182|NCT06569992||Group 2|Traumatic intracranial hemorrhage
62693183|NCT06569992||Group 3|Ischemic cerebrovascular events and hypoxic-ischemic brain injury (including cases of cardiac arrest, drowning, carbon monoxide poisoning, etc.)
62693184|NCT05444439|OTHER|One group of naive H.Pylori infection will submitted for upper endoscopy.|"Upper endoscopy will be done under complete septic condition and multiple gastric biopsies from corpus and antrum will be taken for :~1. Histopathological examination.~2. Culture and sensitivity of endoscopic biopsies.~3. detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent Helicobacter Pylori genotypes by polymerase chain reaction amplification(PCR).~4. Then start empirical antibiotics regimens."
62693185|NCT06240754|EXPERIMENTAL|Enasidenib|"Participants will receive enasidenib 100 mg daily for 18 cycles (each cycle is 28 days).~Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator."
62328012|NCT04514237|EXPERIMENTAL|Part 1: Regimens AB(CD)|Participants received 50 milligrams (mg) BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 1, followed by 50 mg BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 \[E1 or E2\]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
62486250|NCT01586039|EXPERIMENTAL|Blue-depleted LED light 90 lux|90 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
62486251|NCT01586039|ACTIVE_COMPARATOR|Compact Fluorescent Light 50 lux|50 lux exposure of a commercially available Compact Fluorescent Light (CFL).
62486252|NCT01586039|EXPERIMENTAL|Blue-depleted LED light 50 lux|50 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
62486253|NCT02667951|NO_INTERVENTION|Control group|Caregivers received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
62486254|NCT02667951|EXPERIMENTAL|Intervention group|Caregivers received solutions for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
62486255|NCT02947945|OTHER|Open-Label|all subjects will receive the study medication- reslizumab.
62486256|NCT03413423|EXPERIMENTAL|BAT-CS|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
62693186|NCT01484756|PLACEBO_COMPARATOR|calcium carbonate 500 mg|Control group received one daily tablet of calcium carbonate 500 mg for 6 months
62486257|NCT03413423|ACTIVE_COMPARATOR|Smoking Cessation and Health & Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
62486258|NCT01793584|ACTIVE_COMPARATOR|Laparoscopic hysterectomy|Total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy
62486259|NCT01793584|ACTIVE_COMPARATOR|Abdominal hysterectomy|Total Abdominal Hysterectomy
62486260|NCT01325909|ACTIVE_COMPARATOR|Exercise|
62486261|NCT01325909|NO_INTERVENTION|No Exercise|
62693187|NCT01484756|EXPERIMENTAL|daily multi micronutrient supplement|Experimental group received one daily multi micro-nutrient supplement tablet for 6 months
62693188|NCT06264596|EXPERIMENTAL|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag (epinephrine concentration 1:3,000,000 for each bag).
62328013|NCT04514237|EXPERIMENTAL|Part 1: Regimens BA(CD)|Participants received 50 milligrams (mg) BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 1, followed by 50 mg BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 \[E1 or E2\]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
62328014|NCT02476981|EXPERIMENTAL|Remifentanil|Remifentanil is commonly used in monitored anesthesia care because of its rapid onset and short duration of action.
62693189|NCT06264596|PLACEBO_COMPARATOR|Normal saline|The control group will have two 3-L normal saline solution bags prepared with no additive
62328015|NCT02476981|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine is a highly selective α 2 adrenergic agonist and has both sedative and analgesic properties, and rarely causes respiratory depression.
62328016|NCT02476981|OTHER|midazolam|Midazolam is commonly used before induction for its anxiolytic effect.
62328017|NCT02476981|OTHER|propofol|Propofol is the most commonly used in sedative analgesia for its rapid onset and recovery time.
62328018|NCT02476981|OTHER|ephedrine|Adrenergic agonist to treat hypotension
62328019|NCT03712163|EXPERIMENTAL|Norketotifen or Placebo (Cohort 1)|
62328020|NCT03712163|EXPERIMENTAL|Norketotifen or Placebo (Cohort 2)|
62328021|NCT03712163|EXPERIMENTAL|Norketotifen or Placebo (Cohort 3)|
62693190|NCT00553969|EXPERIMENTAL|1|Coreg CR + lisinopril
62328022|NCT03712163|EXPERIMENTAL|Norketotifen or Placebo (Multiple Dose)|
62328023|NCT01087528|EXPERIMENTAL|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
62328024|NCT03011372|EXPERIMENTAL|Pemigatinib|
62328025|NCT01815710||Vomiting & Diarrhea|Alberta Health Services Acute Childhood Vomiting \& Diarrhea Pathway
62328026|NCT01815710||Pediatric Asthma Clinical Pathway|Pediatric Asthma Clinical Pathway
62328027|NCT01554956|EXPERIMENTAL|Human Plasminogen|Human Plasminogen Eye Drop treatment
62328028|NCT02520804|ACTIVE_COMPARATOR|normal saline|normal saline for fluid resuscitation and maintenance for 72 hours
62328029|NCT02520804|EXPERIMENTAL|sterofundin|sterofundin for fluid resuscitation and maintenance for 72 hours
62328030|NCT06691906|EXPERIMENTAL|Enlicitide Decanoate Treatment A|Participants will receive a single dose of enlicitide decanoate formulation 1 on Day 1 on an empty stomach.
62328031|NCT06691906|EXPERIMENTAL|Enlicitide Decanoate Treatment B|Participants will receive a single dose of enlicitide decanoate formulation 2 on Day 1 on an empty stomach.
62486262|NCT06122805|EXPERIMENTAL|Orthognathic Surgery Manual Toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention: Manual toothbrush."
62486263|NCT06122805|EXPERIMENTAL|Orthognathic Surgery Sonic toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention:Sonic toothbrush without activation of the dual light feature."
62486264|NCT06122805|EXPERIMENTAL|Orthognathic Surgery Sonic and dual light toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention:Sonic toothbrush with activation of the dual light feature"
62486265|NCT06122805|EXPERIMENTAL|Bone Graft Manual Toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention:Manual toothbrush."
62486266|NCT06122805|EXPERIMENTAL|Bone Graft Sonic Toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention:Sonic toothbrush without activation of the dual light feature."
62693191|NCT00553969|EXPERIMENTAL|2|Coreg CR + placebo
62693192|NCT00553969|EXPERIMENTAL|3|lisinopril + placebo
62693193|NCT00553969|PLACEBO_COMPARATOR|4|placebo + placebo
62693194|NCT00802906|ACTIVE_COMPARATOR|1|1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
62693195|NCT00802906|ACTIVE_COMPARATOR|2|initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
62693196|NCT00802906|NO_INTERVENTION|3|control
62693197|NCT04809064|EXPERIMENTAL|Arthroscopic Bankart repair with remplissage of Hill-Sachs lesion/rehabilitation|Arthroscopic Bankart repair surgery with remplissage of Hill-Sachs lesion and post-operative rehabilitation.
62693198|NCT04809064|EXPERIMENTAL|Open Bankart/rehabilitation|Open Bankart surgery and post-operative rehabilitation.
62693199|NCT04809064|EXPERIMENTAL|Latarjet/rehabilitation|Latarjet surgical procedure and post-operative rehabilitation.
61934724|NCT05278208|EXPERIMENTAL|Phase I-II|"Pediatric patients (4 -12 years, Phase I) and adolescent and young adult patients (\>12years, Phase II) with recurrent/progressive high-grade central nervous system tumors and meningiomas that express SST2A and demonstrate uptake on DOTATATE PET will receive Lutathera once every 8 weeks (1 cycle) for a total of 4 doses over 8 months~Phase I starting dose will be 200 mCi\*(BSA/1.73m2), corresponding to the BSA-adjusted FDA approved adult Lutathera dosing. The first cycle will be used as the DLT period. Once MTD/RP2D is established, an efficacy expansion cohort of up to 10 patients will be opened to determine the preliminary efficacy of MTD/RP2D of Lutathera in this cohort~Phase II patients will receive the adult RP2D of 200 mCi every 8 weeks to determine the anti-tumor activity of Lutathera in this patient population, through evaluation of 6-month PFS as the primary efficacy endpoint. Response will be assessed on imaging (brain/spine MRI and DOTATATE PET) following every cycle."
62134180|NCT01715194|ACTIVE_COMPARATOR|Telemedicine intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if~1. CPAP was used \<4h/ night for 2 consecutive night~2. the median leakage was above 0.4 L/sec on 2 consecutive nights The nurse informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions are discussed according to the ELF facts sheet (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits, appendix 1). The patient is encouraged to use CPAP every night. In the case of regular use and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail (for procedural rules, see appendix 4)."
61934725|NCT04691401|NO_INTERVENTION|Standard WL (white light) colonoscopy|all patients receive standard colonoscopy (with high definition- HD- endoscopes) with white light (WL) in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination.
62134181|NCT01715194|NO_INTERVENTION|Control (without telemedicine)|In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
62134182|NCT00687219|EXPERIMENTAL|Peginterferon alfa-2b + Ribavirin|
62328032|NCT00883558|EXPERIMENTAL|INSULIN-PH20 NP / Insulin Lispro|"All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump."
62328033|NCT01233401||Mothers|
62328034|NCT01233401||Other Infant Caregivers|Includes fathers, grandparents, and other adults who are infant caregivers
62328035|NCT03666117||Study group|children and adolescents with type 1 diabetes
62328036|NCT03382899|EXPERIMENTAL|Pegilodecakin + Pembrolizumab|"Participants received pegilodecakin subcutaneously (SQ) at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Pembrolizumab administered as an intravenous (IV) infusion at 200 mg on Day 1 of a 21-day cycle."
62328037|NCT03382899|ACTIVE_COMPARATOR|Pembrolizumab|Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle.
62328038|NCT05903300||Professional orchestra musicians|The study group consists of adult, professionally active people (women and men) who are professional orchestra musicians. The mother tongue of the respondents must be Polish.
62328039|NCT04158024|NO_INTERVENTION|Volatile Anesthetic Control|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
62328040|NCT04158024|EXPERIMENTAL|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique in addition to the standard of care Volatile Anesthetic Treatment.
62328041|NCT06239909||Urinary incontinence due to prostate surgery|Consecutive adult male patients with urinary incontinence due to prostate surgery.
62328042|NCT01583322|EXPERIMENTAL|vargatef/Nintedanib|
62693200|NCT06570629|EXPERIMENTAL|Oronasal CPAP|CPAP with an oronasal mask for 7 days.
62693201|NCT06570629|EXPERIMENTAL|Chinstrap|CPAP with a nasal mask and a chinstrap for 7 days.
62697546|NCT05286619|EXPERIMENTAL|Pembrolizumab plus Platinum and Gemcitabine|Pembrolizumab 200 mg will be administered as 30-minute IV infusion Day 1 of every 3 weeks. Pembrolizumab will be administered first followed by the platinum and gemcitabine infusions. Cisplatin will be administered on Day 1 and 8 of each 3-weeks treatment cycle with a dose of 35 mg/m2 for 60 minutes. Carboplatin will be administered on Day 1 of each 3-weeks treatment cycle given as a dose of AUC 5 for 60 minutes. Gemcitabine will be administered on Day 1 and 8 of each 3-weeks treatment given as a dose of 1250 mg/m2 for 30 minutes. AEs associated with pembrolizumab exposure, including coadministration with additional compounds, may represent an immunologic aetiology. If one or all of the chemotherapy components is discontinued, subjects can continue with pembrolizumab up to the full 35 cycles.
62328043|NCT01583322|PLACEBO_COMPARATOR|placebo|
62328044|NCT04332029|EXPERIMENTAL|CBT + WGP + CM|The experimental intervention includes three components: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation; 2) Weight Gain Prevention module (WGP) and; 3) Contingency Management (CM) procedure reinforcing tobacco abstinence.
62328045|NCT04332029|ACTIVE_COMPARATOR|CBT + WGP|The active comparator will include only the first two components of the experimental intervention: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation and 2) Weight Gain Prevention module (WGP).
61934726|NCT04691401|EXPERIMENTAL|Standard colonoscopy with assistance of Artificial Intelligence (CAD-EYE (Fujifilm Co, Tokyo, Japan)|all patients receive colonoscopy examinations (with HD endoscopes) equipped with an Ai system (CAD-EYE, Fujifilm Co, Tokyo, Japan) in both insertion and withdrawal phase). This system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.All polyps identified are removed and sent for histopathology examination.
61934727|NCT00428129|EXPERIMENTAL|1|
62328046|NCT01105416|PLACEBO_COMPARATOR|Enhanced Standard Care (ESC)|Standard emergency department care plus informational brochures
62328047|NCT01105416|EXPERIMENTAL|Brief Prevention Intervention (BPI)|Brief Prevention Intervention in the Pediatric ED
62328048|NCT04552535||Second line (2L) afatinib|Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
62328049|NCT04552535||Second line (2L) chemotherapy|Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
62328050|NCT04229550|NO_INTERVENTION|Control subjects|1 week of normal daily life and only by the National Health Board recommendated alcohol consumption.
62693202|NCT04427111||Mild-moderate OSA patients for MAD treatment|Patients are classified as mild Obstructive Sleep Apnea (OSA) if they have between 5-15 Apnea-Hypopnea Index, moderate if they have between 15-30, and severe if they have \>30, as measured by Polysomnography (Epstein LJ, Kristo D, Strollo PJ, et al. 2009). The principal treatment methodology for OSA patients is positive airway pressure. In patients with mild to moderate OSA, oral appliances such as mandibular advancement devices (MAD) is alternately indicated (Ramar K, Dort LC, Katz SG, et al. 2015) The American Academy of Dental Sleep Medicine (Ramar K, Dort LC, Katz SG, et al. 2015) recommended titratable-customized MADs for patient comfort and the ability to permit modifications in the amount of mandibular protrusion for treatment efficacy. However, Aarab et al (Aarab G, Lobbezoo F, Hamburger HL, Naeije M. 2010) demonstrated similar therapeutic efficiency of non-titratable-customized MADs in the treatment of OSA
61934728|NCT06374095||Patients|25 consecutive recipients of a single or dual kidney transplant from ideal or marginal donors who, from 01/04/2023 to 31/12/2023, were induced with one single perioperative RATG infusion (Patients) at the Renal Transplant Center of the Azienda Socio Sanitaria Territoriale (ASST) of the Papa Giovanni XXIII Hospital, in Bergamo (Italy)
62134183|NCT03471585|PLACEBO_COMPARATOR|Placebo oral capsule|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the THC arm.
62134184|NCT03471585|EXPERIMENTAL|THC|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the placebo arm.
62134185|NCT02097394|ACTIVE_COMPARATOR|Combizym-treated group|The patients who received polypectomy of colon polyps take the digestion enzyme (Combizym) regularly.
62134186|NCT02097394|ACTIVE_COMPARATOR|Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take Bifidobacteri regularly
62328051|NCT04229550|EXPERIMENTAL|Festival subjects|1 week's participation in Roskilde Festival 2016
62328052|NCT04044391||Intention to Treat: Cardiac Catheterization|All patients meeting inclusion criteria and scheduled to undergo cardiac catheterization will undergo a CardioFlux magnetocardiogram (MCG) to determine presence of patterns which indicate myocardial ischemia.
62328053|NCT04044391||Post Percutaneous Coronary Intervention|All patients found to have significant coronary artery obstruction seen via angiography +/- fractional flow reserve (FFR) or instant wave-free ratio (iFR) and who receive a catheter based intervention will have a post-procedure CardioFlux MCG scan. Follow up over the next 30 and 180 days will be performed to determine if a persistent pattern suggesting residual ischemia will correlate with an increased incidence of major cardiac adverse events (MACE).
62328054|NCT03705962|EXPERIMENTAL|Antibiotic|Subjects will be injected locally at the wound cavity (i.e. fracture site, surrounding soft tissue which include muscle, and subcutaneous space) with 80mg/40mL of tobramycin after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
62328055|NCT03705962|PLACEBO_COMPARATOR|Normal Saline|Subjects will be injected locally with 40 mL 0.9% NS after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
62328056|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
62328057|NCT00170248|NO_INTERVENTION|1|Physicians in this arm will be using the standard MOXXI electronic health record.
62328058|NCT00170248|EXPERIMENTAL|2|In addition to the standard MOXXI electronic health record, physicians in this arm will be using the computer-based decision support for asthma management
62328059|NCT04140708|EXPERIMENTAL|Exercise--Rock Steady Boxing class|Participants will be going twice a week to a Rock Steady Boxing class for an hour/class. Participants will be going to this class for a total of three months.
61934729|NCT06374095||Reference patients|The most recent 50 consecutive recipients (Reference-Patients) of a single or dual kidney transplant from ideal or marginal donors who before 01/04/2023 were induced with seven perioperative RATG infusions (on top of the same induction and maintenance treatment used for patients receiving one single RATG infusion) at the Renal Transplant Center of the (ASST) of the Papa Giovanni XXIII Hospital, in Bergamo (Italy)
62328060|NCT01244542|EXPERIMENTAL|Patients with schizophrenia|
62328061|NCT01244542|ACTIVE_COMPARATOR|Healthy controls|controls matched with patients on age, sex and education level
62328062|NCT01313104|EXPERIMENTAL|Screening|See Detailed Description
62328063|NCT05516901|EXPERIMENTAL|The erector spinae plane block group|The erector spinae plane block group: Patients will receive general anesthesia plus bilateral ultrasound guided ESP block.
62328064|NCT05516901|PLACEBO_COMPARATOR|Control group|Control group (group І): Patients will receive general anesthesia alone.
62328065|NCT00584220|OTHER|senofilcon A toric / alphafilcon A toric|senofilcon A toric contact lenses worn daily during the first period, then alphafilcon A toric contact lenses worn daily during the second period
62328066|NCT00584220|OTHER|alphafilcon A toric / senofilcon A toric|alphafilcon A toric contact lenses worn daily during the first period, then senofilcon A toric contact lenses worn daily during the second period
62328067|NCT03587675|OTHER|EVH in high-school elite athletes|EVH-test, skin prick test, sputum induction in all subjects Interventional but no drug or device tested
62328068|NCT06175611||Site 1. Laboratorio Central Health Diagnostics Quirónsalud|COVID-19/Flu A/Flu B/RSV Test Kit
62328069|NCT06175611||SIte 2. Hospital General Universitario Dr. Balmis de Alicante|COVID-19/Flu A/Flu B/RSV Test Kit
62328070|NCT06175611||Site 3. Hospital Universitario de Getafe|COVID-19/Flu A/Flu B/RSV Test Kit
62328071|NCT01888705||Control group|Group of nonsmokers individuals without respiratory disease.
62328072|NCT01888705||NE|Smokers wiht normal spirometry.
62328073|NCT01888705||LV|Patients with COPD level I, mild.
62328074|NCT01888705||MOD|Patients with COPD level II, moderate.
62328075|NCT01888705||GV|Patients with COPD level III, severe.
62328076|NCT01888705||MGV|Patients with COPD level IV, very severe.
62328077|NCT01507584|ACTIVE_COMPARATOR|Prostaglandin Analogue|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (PGA + BB)
62328078|NCT01507584|ACTIVE_COMPARATOR|Carbonic Anhydrase Inhibitor|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (CAI+ BB)
62328079|NCT02255851||Treatment Group|TAVR + SENTINEL (Cerebral Protection System)
62328080|NCT01850563|OTHER|HBO feasibility|
61934730|NCT06529757|EXPERIMENTAL|Hot and Dry Environment_no cooling|Subjects will exercise for 60 minutes in a hot and dry environment while being exposed to no cooling.
62134187|NCT02097394|ACTIVE_COMPARATOR|Combizym + Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take drugs (Combizym + Bifidobacteri) regularly
62134188|NCT02097394|NO_INTERVENTION|control|The patients who received polypectomy of colon polyps take no drugs
62134189|NCT05124613||Patients waitlisted for Knee Surgery|Adults identified by a consultant orthopaedic surgeon at the study site as being on a waiting list for surgery on their knee and as experiencing a delay to their knee surgery as a result of the COVID-19 pandemic will be eligible to participate in this survey. The survey will include one validated questionnaire and a series of bespoke questions.
62328081|NCT01689207|EXPERIMENTAL|Drug: A|Avibactam (AVI)
62328082|NCT01689207|EXPERIMENTAL|Drug: B|Aztreonam (ATM)
62328083|NCT01689207|EXPERIMENTAL|Drug: C|combination of Aztreonam-Avibactam (ATM-AVI)
62328084|NCT01689207|PLACEBO_COMPARATOR|Drug: D|Matching Placebo
62328085|NCT00086957|EXPERIMENTAL|ZD1839, Trastuzumab and Docetaxel|
62328086|NCT03653611||Clinician Participants|Two Aim 2 practices are selected by each of their 5 affiliated PBRNs based upon willingness to participate and variability of primary care practice type within the PBRN. Differences in practice size, staffing, ownership, prior quality improvement engagement, geography, patient population socioeconomic status (SES) or languages spoken are among the among the selection criteria the PBRNs will utilize to choose.
62328087|NCT03653611||Patient Participants|200 patients, who are enrolled in Aim 1 (approximately 40 from each PBRN) will be invited to take a CAPTURE opinion survey
62328088|NCT06499545|EXPERIMENTAL|Pressure release|Application of pressure release as a trigger point treatment of the flexor digitorum brevis muscle. Performing 3 pressure cycles until the disappearance of the referred pain for a minimum of 90 seconds.
62328089|NCT06499545|SHAM_COMPARATOR|Non-emision Laser|Application of a non-emitting laser for 5 minutes.
62134190|NCT04295382|EXPERIMENTAL|Software Application|
62328090|NCT05218499|EXPERIMENTAL|Brigimadlin (BI 907828) low dose|Phase II
62328091|NCT05218499|EXPERIMENTAL|Brigimadlin (BI 907828) high dose|Phase II
62328092|NCT05218499|EXPERIMENTAL|Brigimadlin (BI 907828) arm|Phase III
62328093|NCT05218499|ACTIVE_COMPARATOR|Doxorubicin arm|Phase II/III
62328094|NCT04060173|EXPERIMENTAL|Treatment with ABP-671|Three sequential dose escalation cohorts of ABP-671 administered orally for 10 days.
62328095|NCT04060173|PLACEBO_COMPARATOR|Treatment with placebo|Three sequential dose escalation cohorts of ABP-671 matching placebo administered orally for 10 days.
62328096|NCT00878540|EXPERIMENTAL|mirtazapine|
62328097|NCT03532945|EXPERIMENTAL|Bioactive Glass-Ceramic Spacer|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with Novomax, which is the bioactive glass ceramic intervertebral spacer.
62328098|NCT03532945|ACTIVE_COMPARATOR|Titanium cage|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with titanium cage.
62328099|NCT00500786|EXPERIMENTAL|100 mcg CYT006-AngQb Healthy Volunteers|
62328100|NCT00500786|EXPERIMENTAL|100 mcg CYT006-AngQb Hypertensives|
62328101|NCT00500786|EXPERIMENTAL|300 mcg CYT006-AngQb Hypertensives|
62328102|NCT00500786|PLACEBO_COMPARATOR|Placebo Healthy Volunteers|
62328103|NCT00500786|PLACEBO_COMPARATOR|Placebo Hypertensives|
62328104|NCT03311607|OTHER|Cohort treated with AmBisome 15 mg/kg|280 patients, receiving AmBisome
62693203|NCT06230640||cardiac surgery with cardiopulmonary bypass|Any subject undergoing cardiac surgery with cardiopulmonary bypass and at high risk of bleeding and transfusion.
62693204|NCT06175533|EXPERIMENTAL|plantar fasciitis|
62693205|NCT06571929|EXPERIMENTAL|Group INTERACT|The INTERACT group will participate in an intervention with augmented reality games. During the games, participants will perform hand and arm movements, as well as activities such as sitting and standing up from a chair or climbing and descending steps. The augmented reality software to be used, BRAINN_XR, includes games such as puzzles and ping pong. The intervention will be conducted by physiotherapists trained in the use of the software. The sessions will take place three times a week, lasting 1 hour and 20 minutes, over a total period of 4 weeks.
62693206|NCT06571929|NO_INTERVENTION|Control group|
62693207|NCT05781685|EXPERIMENTAL|Testosterone|Sublingual testosterone
62134191|NCT02672891|EXPERIMENTAL|Device|condom balloon catheter which is composed of a latex condom (SURE natural latex condom, Shanghai) and a 16-20 F, 2 ways silicon coated Foley catheter (Egypt). The catheter was introduced inside the condom and tied over tightly several times with a silk suture, to prevent air escape.
62134192|NCT02031185|NO_INTERVENTION|Wait-list control|No intervention
62134193|NCT02031185|EXPERIMENTAL|FitBit only|Participants will use the FitBit device
62134194|NCT02031185|EXPERIMENTAL|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
62328105|NCT04951336|EXPERIMENTAL|Mushrooms|Drug: FoTv The dosage of FoTv is 8 capsules three times a day for 4 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary. Should swallowing capsules be an issue, they can be opened and dispensed into water or juice for easy ingestion.
62328106|NCT04951336|PLACEBO_COMPARATOR|Placebo|Placebo: organic brown rice The dosage of Placebo is 8 capsules three times a day for 4 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary. Should swallowing capsules be an issue, they can be opened and dispensed into water or juice for easy ingestion.
62328107|NCT06255561|EXPERIMENTAL|active rTMS treatment|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target.
62328108|NCT05856799|ACTIVE_COMPARATOR|Leadless Pacemaker|Implantation with a leadless pacemaker
62328109|NCT05856799|ACTIVE_COMPARATOR|Transvenous pacemaker|Implantation with a transvenous pacemaker
62328110|NCT00488033|NO_INTERVENTION|1|Standard of Care
62328111|NCT00488033|OTHER|2|CT Angiography
62328112|NCT00454064|ACTIVE_COMPARATOR|1|cognitive-behavioral treatment
62328113|NCT00454064|ACTIVE_COMPARATOR|2|cognitive-behavioral treatment with biofeedback elements
62328114|NCT00543829|EXPERIMENTAL|1|4 cycles of doxorubicin and docetaxel with tamoxifen
62328115|NCT00543829|ACTIVE_COMPARATOR|2|4 cycles of doxorubicin and docetaxel without tamoxifen
62328116|NCT05356624|EXPERIMENTAL|Mulligan Mobilization|Mobilization with movement (3 sets per 10 repetitions).
62328117|NCT05356624|EXPERIMENTAL|Soft tissue mobilization|Soft tissue mobilization (3 sets per 10 repetitions)
62328118|NCT01833273|EXPERIMENTAL|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
62328119|NCT03839147|EXPERIMENTAL|Education and Counseling|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. This education consisted of the definition and the purpose of hysterosalpingography, when and how it was applied, in what cases it was applied, whether it was a painful procedure, possible side effects and additional benefits of infertility treatment
62328120|NCT03839147|NO_INTERVENTION|Control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography. Within 5 minutes of completing the hysterosalpingography procedure, participants were asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale .
62328121|NCT01003561|EXPERIMENTAL|ultrasonographic exam|
62328122|NCT02674737|EXPERIMENTAL|Dexmedetomidine,tramadol and flurbiprofen|Both sedative and analgesic(dexmedetomidine, tramadol and flurbiprofen) are applied to this group of patients.
62693208|NCT05781685|PLACEBO_COMPARATOR|Placebo|Placebo
62693209|NCT06671301|EXPERIMENTAL|PSAI group|Behavioural counselling
62693210|NCT06671301|OTHER|Control group|No intervention used
62693211|NCT00979407|EXPERIMENTAL|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62693212|NCT00979407|EXPERIMENTAL|GSK2340274A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62693213|NCT06507956||Adults with cystic fibrosis followed at Hôpital Lyon Sud's cystic fibrosis center-single-arm study.|
62693214|NCT06161181|EXPERIMENTAL|Experimental Group|50 MBC patients receive the DSS for three months. Patients are instructed to use the DSS ad libitum.
62693215|NCT06161181|NO_INTERVENTION|Control Group|50 MBC patients not subjected to the intervention receive standard medical advice.
62693216|NCT06608303|EXPERIMENTAL|Topical Human Granulocyte Macrophage Stimulating Factor Gel|The diabetic wounds were treated with Topical Human Granulocyte Macrophage Stimulating Factor Gel for 2 weeks on top of the standard clinical treatment protocol.
62693217|NCT06608303|PLACEBO_COMPARATOR|saline|The diabetic wounds were treated with saline for 2 weeks on top of the standard clinical treatment protocol.
62693218|NCT06643286|EXPERIMENTAL|Intervention group|Participants receive access to the Digizorg Melanoma app, on top of care as usual.
62486267|NCT06122805|EXPERIMENTAL|Bone Graft Sonic and Dual-light Toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention:Sonic toothbrush with activation of the dual light feature"
62693219|NCT06643286|NO_INTERVENTION|Control group|Participants have access to care as usual, but have no access to the Digizorg Melanoma app and its functionalities.
61934731|NCT06529757|EXPERIMENTAL|Hot and Dry Environment_whole body skin wetting|Subjects will exercise for 60 minutes in a hot and dry environment while being exposed to whole body skin wetting.
62134195|NCT05808595|EXPERIMENTAL|AlphaWave® L-Theanine|Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1. If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule. Participants will be advised not to exceed 3 capsules daily.
62328123|NCT02674737|ACTIVE_COMPARATOR|Tramadol and flurbiprofen|Only routine analgesic(tramadol and flurbiprofen) are applied to this group of patients.
62328124|NCT03002116|ACTIVE_COMPARATOR|Group N|Healthy volunteers without peripheral arterial disease according to clinical examination and Duplex ultrasound
62328125|NCT03002116|EXPERIMENTAL|Group DN|Patients suffering from diabetes and diabetic foot without vascular compromise according to clinical assessment continuous-wave Doppler and Duplex ultrasound
62328126|NCT03002116|EXPERIMENTAL|Group DC|Diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
62328127|NCT03002116|EXPERIMENTAL|Group NDC|Non diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
62328128|NCT02493309|EXPERIMENTAL|Prolonged sitting|
62328129|NCT02493309|ACTIVE_COMPARATOR|Light activity breaks|
62328130|NCT00257192|PLACEBO_COMPARATOR|2.0|
62328131|NCT00257192|ACTIVE_COMPARATOR|1.0|
62328132|NCT01989546|EXPERIMENTAL|1/Talazoparib (BMN 673)|Single agent
62328133|NCT01100307|EXPERIMENTAL|pegaptanib sodium|
62328134|NCT01100307|SHAM_COMPARATOR|sham injection|
62693220|NCT04908046|EXPERIMENTAL|HMPL-295S1 open-label treatment arm|"During dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile. Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
62134196|NCT05808595|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1. If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule. Participants will be advised not to exceed 3 capsules daily.
62328135|NCT00386893|OTHER|Treatment as usual|simultaneous EEG/fMRI
62328136|NCT05039580|EXPERIMENTAL|PD-1 monoclonal antibody group|PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age \>=18 years, or age \<18 years but weight \>=40kg. While for patients age \<18 years, the dose of PD-1 monoclonal antibody is 3mg/kg.
62328137|NCT01878851||pulpotomy|
62328138|NCT05894278||Compliance|Prescription properly filled for specific parameters
62328139|NCT05894278||Non Compliance|Prescription is not filled with specific parameters
62328140|NCT05894278||Not available - NA|Prescription does not contain specific data
62328141|NCT06693154||Premature infants diagnosed with stage 2 and stage 3 NEC and a matched control group.|
62328142|NCT01215734|ACTIVE_COMPARATOR|High-Dose Trivalent Inactivated Influenza Vaccine|Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine
62328143|NCT01215734|ACTIVE_COMPARATOR|Standard dose Trivalent Inactivated Flu Vaccine|Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.
62328144|NCT03968861||Standard care with moderate hypothermia|Surviving children allocated to standard care with moderate hypothermia in the TOBY-Xe trial
62328145|NCT03968861||30% Xenon for 24 hours combined with moderate hypothermia|Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial
62328146|NCT04527354|EXPERIMENTAL|Treamid 50 mg|1 tablet of Treamid 50 mg once a day during 4 weeks of treatment period.
62328147|NCT04527354|PLACEBO_COMPARATOR|Placebo|1 tablet of Placebo once a day during 4 weeks of treatment period
62328148|NCT03864263||Children with HBsAg-positive patients|Children from a father or mother who are infected with HBV
62328149|NCT03864263||Children without a family history of HBV|Children without a family history of HBV infection
62328150|NCT06302309|EXPERIMENTAL|Intervention|The intervention group will receive 4 sessions of the 'managing the mental state' intervention immediately after randomization.
62328151|NCT06302309|EXPERIMENTAL|Waitlist|The control group will enter a waiting period of 4 weeks and receive the same 4-week intervention thereafter.
62328152|NCT03165513|EXPERIMENTAL|Experimental arm|mhGAP-IG psychosocial intervention
62486268|NCT06122805|EXPERIMENTAL|No surgery, Manual Toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate 5, Intervention:Manual toothbrush."
62486269|NCT06122805|EXPERIMENTAL|No Surgery, Sonic Toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention:Sonic toothbrush without activation of the dual light feature."
62486270|NCT06122805|EXPERIMENTAL|No Surgery, Sonic and Dual-light Toothbrush|"1. Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~2. Between the ages of 6 and 20 years~3. Physical status of ASA I or II~4. Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~5. Intervention:Sonic toothbrush with activation of the dual light feature"
62486271|NCT00694408|ACTIVE_COMPARATOR|Steroid immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid containing immunosuppression regimen post transplant. This group of patients will receive steroids in conjunction with other prescribed immunosuppressive agents. Intervention is use of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management
62486272|NCT00694408|ACTIVE_COMPARATOR|Steroid free immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid free immunosuppression regimen post transplant. The patients in this arm will receive immunosuppression but not steroids to compare with those treated with steroids to measure differences in rejection and safety of a steroid free immunosuppressive regimen. Intervention is omission of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management. No steroids will be used routinely in this arm
62486273|NCT01923740|EXPERIMENTAL|Absorb BVS System|Absorb BVS System: Subjects receiving Absorb BVS System
62486274|NCT01923740|ACTIVE_COMPARATOR|XIENCE V EECSS|XIENCE V EECSS: Subjects receiving XIENCE V
62486275|NCT02722421|EXPERIMENTAL|Efavirenz group|HIV-infected women receiving efavirenz-based antiretroviral therapy plus increased dose levonorgestrel subdermal implants.
62486276|NCT04081558|EXPERIMENTAL|Electronic follow-up|
62486277|NCT05509309|EXPERIMENTAL|Experimental group|"In the experimental group, in-service training on autism, program quality, and APERS will be provided to participating staff. Furthermore, APERS-rating to assess the program quality for students with ASD/SCC will be conducted. Pertaining feedback on program areas of strength and improvement will be provided by the APERS-raters to the classroom teachers.~Subsequently, assigned coaches (already employed at the school as special educators or equivalent) will based on the APERS-ratings develop an action plan to improve program quality for students with ASD and SCC, in collaboration with classroom teachers. Subsequently, the coach will provide weekly or bi-weekly coaching to promote program quality during the course of two school semesters (approximately 8-9 months)."
62486278|NCT05509309|NO_INTERVENTION|Comparison group|The classrooms in the comparison group will also be rated with the APERS, and feedback will provided to classroom teachers. However, no further support will be provided in transforming APERS-ratings with pertaining feedback into best practice.
62486279|NCT00691782||1|African American females between the ages of 21 and 60
62693221|NCT06643182|EXPERIMENTAL|Back Gupport Group|After the transfemoral angiography procedure, the patient will be taken to bed and monitored. Approximately 2 hours after the procedure, under the control of the doctor and nurse, the sheath in the patient's groin area will be pulled and a 3 kg sandbag will be left. A 36x33x10 cm gel-containing visco pillow will be placed in the patient's lumbar cavity by the research nurse and primary nurse to fill the anatomical space. The patient will be monitored in a supine position with the head elevated (30 degrees) and blood pressure, pulse, respiratory rate, oxygen saturation and comfort and pain level will be recorded at 0, 3 and 6 hours.
62693222|NCT06643182|NO_INTERVENTION|Control Group|The patients in this group will be monitored in the supine position with the head elevated (30 degrees) without pillow support and blood pressure, pulse, respiratory rate, oxygen saturation and comfort and pain level will be recorded at 0, 3 and 6 hours.
62693223|NCT05405608||Group O|Ondansetron applied only, no tourniquet applied
62693224|NCT05405608||Group TO|Ondansetron and tourniquet applied,
62693225|NCT05405608||Group S|No ondansetron and tourniquet applied
62134197|NCT02229812||thrombolytic therapy in stroke|
62134198|NCT01623908|EXPERIMENTAL|Zoledronate|
62328153|NCT04005209|ACTIVE_COMPARATOR|Pain management without ketamine infusion|Pain management without ketamine infusion. No other restrictions on pain management or medications.
62693226|NCT05405608||Group TS|Ondansetron not applied, only tourniquet applied
62328154|NCT04005209|EXPERIMENTAL|Pain management with ketamine infusion|Pain management that includes a ketamine infusion. No other restrictions on pain management or medications.
62328155|NCT02241746||malnutrition|
62328156|NCT01234012|EXPERIMENTAL|Treatment: IMF-001|100 or 200 mcg will be administered to patients subcutaneously every 2 weeks for 6 injections.
62328157|NCT01269957||Mouth breathing|
62328158|NCT01269957||Nasal breathing|
62328159|NCT05862324|EXPERIMENTAL|TAC01-CLDN18.2|Lymphodepletion followed by TAC01-CLDN18.2 as a single IV infusion.
62328160|NCT04357379|EXPERIMENTAL|IQOS group|
62328161|NCT05320458|EXPERIMENTAL|Pulmonary Rehabilitation|Pulmonary rehabilitation program will be applied 3 days a week at 40-60% of submaximal heart rate for a total of 8 weeks. Diaphragmatic breathing, pursed lips and segmental breathing exercises will be applied to the patients in the presence of a physiotherapist. Walking and aerobic exercise training will be given.
62134199|NCT06376552||BrS Patients|The 200 BS patients have been selected and clinically evaluated by Department of Cardiac Electrophysiology and Arrhythmology, San Raffaele Hospital, for the presence of a type I electrocardiogram (ECG), either spontaneous or induced by flecainide or ajmaline. Morphologic and functional characteristics of the heart have been analysed in all patients by trans-thoracic echocardiography and stress test to rule out patients with Arrhythmogenic Right Ventricular Dysplasia and ischemic heart disease. Among clinical characteristics, 12-lead signal averaged ECG parameters and all possible risk factors have been evaluated. Electrophysiological study has been performed in spontaneous BS pattern 1 ECG patients or patients with induced BS pattern 1 ECG and at least one risk factor. In patients with higher susceptibility for the induced Ventricular Tachycardia, ICD has been implanted.
62328162|NCT04352322|EXPERIMENTAL|A+HA(tm)|20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250\~500 ml water under fasting condition in the morning.
62486280|NCT05997797||Single Group|A total of 175 patients with a range of foot or ankle problems were included for the review. Informed consent was taken from the review members in written form. They all finished the Urdu version of FAAM in the test session. With a time, span of 3 days after the primary recording, a total of the 175 patients whose conditions were relied upon to stay stable were approached to complete the forms again in the retest meeting; no treatment was given during this time-frame. The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually. Also, toward the finish of the structure, patients were approached to rate the current degree of function with a 4-point Likert scale. Patients evaluated everything as indicated by the trouble they go over with each undertaking on account of their foot or ankle condition. After assortment, information was saved in a safe spot to keep away from any dispositions.
62486281|NCT00654186|EXPERIMENTAL|1|
62486282|NCT04697173|NO_INTERVENTION|Standard consent|This group will be consented for invasive procedures using standard Hospital policy. Informed consent will be obtained either in person or via telephone with a witness from the patient or his/her legal guardian for any/all procedures medically indicated at that time, at the discretion of the Attending Physician.
62486283|NCT04697173|EXPERIMENTAL|Bundled consent|"Upon admission, this group will received the document titled Common PICU Procedures Explained and encourage to read the document. They will then, within 24 hours of admission be consented using the Bundle Consent Document for the group of invasive procedures listed and explained in that document."
62486284|NCT05289440|EXPERIMENTAL|Low-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
62486285|NCT05289440|EXPERIMENTAL|High-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
62486286|NCT05289440|EXPERIMENTAL|Saline infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
62693227|NCT03436732|EXPERIMENTAL|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
61934732|NCT06096272|EXPERIMENTAL|Augment Therapy app|The app will be implemented with the participant's compatible iPad that will be securely integrated with a network-server for real-time data access and storage. If the participant does not have a compatible device, this will be provided by the research team. Participants will be provided an on-site or virtual CHLA tutorial about using the app and set up of the gaming system. Participants will access their home program on the app at least for 20 minutes, 3 times a week over a 4-week period. A coordinator will check in virtually with the participant during the program. They will complete baseline and final surveys. Exercise data will be collected and stored through the Augment Therapy™ app and self log book.
61934733|NCT05535231|EXPERIMENTAL|Turmeric test product|Turmeric
61934734|NCT05535231|ACTIVE_COMPARATOR|Turmeric comparator|Turmeric
62134200|NCT02426138|EXPERIMENTAL|Med. Tailored Meal Delivery, Usual Care + Choose Myplate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
62134201|NCT02426138|ACTIVE_COMPARATOR|Usual Care + Choose Myplate, Med. Tailored Meal Delivery|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
62328163|NCT04352322|PLACEBO_COMPARATOR|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250\~500 ml water under fasting condition in the morning.
62328164|NCT06692543|EXPERIMENTAL|Physically active|"Participants of this group are physically active subjects~- V1 will take place at the Nice University Hospital, in the morning, on an empty stomach.~After signing the consent form, the participant will have a blood sample taken (24mL), answer questionnaire and have a body assessment by bone densitometry. At the end of the appointment , the participant will wear an accelerometer and fill in his or her food intake for one week.~- V2 (approximatly 2 weeks after V1), will take place at LAMHESS, the participant will perform neuromuscular tests on an ergometer, with high-density electromyography (HDEMG) sensors on the thighs."
62328165|NCT06692543|EXPERIMENTAL|Physically inactive|"Participants of this group are physically inactive subjects~- V1 will take place at the Nice University Hospital, in the morning, on an empty stomach.~After signing the consent form, the participant will have a blood sample taken (24mL), answer questionnaire and have a body assessment by bone densitometry. At the end of the appointment , the participant will wear an accelerometer and fill in his or her food intake for one week.~- V2 (approximatly 2 weeks after V1), will take place at LAMHESS, the participant will perform neuromuscular tests on an ergometer, with high-density electromyography (HDEMG) sensors on the thighs."
62328166|NCT01743586|NO_INTERVENTION|Control|
62693228|NCT03436732|EXPERIMENTAL|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at recommended phase 2 dose (RP2D)
62693229|NCT03221335|EXPERIMENTAL|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
62134202|NCT06248229|ACTIVE_COMPARATOR|Dyanavel XR (Active Agent)|Dyanavel 5, 10, 15 or 20 mg once daily in the morning
62134203|NCT06248229|PLACEBO_COMPARATOR|Placebo|Matching placebo 5, 10, 15 or 20 mg once daily in the morning
62134204|NCT01284920|EXPERIMENTAL|dose-escalation cohort-1|MDV3100 low dose arm
62134205|NCT01284920|EXPERIMENTAL|dose-escalation cohort-2|MDV3100 middle dose arm
62693230|NCT06099405|EXPERIMENTAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga training for 24 consecutive weeks for a total of 72 training sessions.
61934735|NCT05483270|ACTIVE_COMPARATOR|Immediate FET group|Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.
61934736|NCT05483270|EXPERIMENTAL|Postponed FET group|Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval.
62134206|NCT01284920|EXPERIMENTAL|dose-escalation cohort-3|MDV3100 high dose arm
62486287|NCT01674387|EXPERIMENTAL|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral cervical Jiaji (EX-B2),and two trigger points.Bilateral Jianzhongshu (SI15) and Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
62486288|NCT01674387|OTHER|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS(Transcutaneous Electrical Nerve Stimulation) therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
62486289|NCT03711539||Lifelong Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (\> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
61934737|NCT00846404||Case|Patients with Diastolic Dysfunction
62486290|NCT03711539||Late-onset Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (\> 5 pack years) or diabetes, ii) they have a history of smoking (\> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
62486291|NCT03711539||Healthy Non-athletes|Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than \>3 hours / week, ii) have a history of smoking (\> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) \>3 hours /week is allowed.
62486292|NCT02321943||Follow-Up Group|"An earlier investigated cohort with first episode psychosis patients from two Norwegian counties. Being between 18 - 65 years old and being consecutive in- or outpatient referred to first adequate treatment for a DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychosis."
62486293|NCT00829712|EXPERIMENTAL|1|
62486294|NCT00829712|ACTIVE_COMPARATOR|2|Focalin®
62486295|NCT05751447|EXPERIMENTAL|Immune cells|Lymph node puncture and/ or bronchoscopy.
62486296|NCT01942239|ACTIVE_COMPARATOR|CGM-group|CGM-group: the intervention(s) to be administered is Continuous glucose monitoring with real time glycemia each 5 minutes
62486297|NCT01942239|NO_INTERVENTION|IGM-group|IGM-group: the intervention(s) to be administered is intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia
62486298|NCT05853653|EXPERIMENTAL|Using dolls in breastfeeding education|In the breastfeeding training, the researchers will explain the pre-created training content. It will then be demonstrated practically using the baby. A training brochure will be given at the end of the training.
62693231|NCT06099405|ACTIVE_COMPARATOR|Traditional Yoga|Participants will perform standard Hatha yoga with slow controlled speed movements for 24 consecutive weeks for a total of 72 training sessions.
62693232|NCT05770245|EXPERIMENTAL|Mild dermatophytosis and one treatment|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's diseased area until half a bottle (200ml) of water is used.
61934738|NCT00846404||Control|Patients without Diastolic Dysfunction
61934739|NCT03838965|EXPERIMENTAL|biobeat sensor|
62134207|NCT01284920|EXPERIMENTAL|dose-expansion cohort|dose expansion with MDV3100 middle dose
62134208|NCT02011854|EXPERIMENTAL|Acupuncture with rehabilitation|Electric acupuncture,Chinese medicine,Chinese medicine cupping,rehabilitation,To treat five times a week,Total course is eight weeks
62134209|NCT02011854|OTHER|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
62134210|NCT05326971|EXPERIMENTAL|Tenofovir disoproxil TDF|Participants who have used TDF as part of their stable antiretroviral regimen for at least past six months.
62134211|NCT05326971|ACTIVE_COMPARATOR|Tenofovir alafenamide (TAF)|Participants who have used TAF as part of their stable antiretroviral regimen for at least past six months.
62134212|NCT03466242|EXPERIMENTAL|Intranasal Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)
62134213|NCT03466242|ACTIVE_COMPARATOR|IV Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)
62134214|NCT03185052|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
62134215|NCT01330160||cohort of stroke patients|patients, over 40 years old and without dementia, displaying an hemorrhagic or an ischemic stroke, with a sus-tentorial localization, and included 72h before the onset of symptoms
62134216|NCT02254720|EXPERIMENTAL|BEA 2180 BR IV|Rising doses
62134217|NCT02254720|PLACEBO_COMPARATOR|Placebo|
62134218|NCT02254720|EXPERIMENTAL|BEA 2180 BR inhalation|
62328167|NCT01585961||Catheter Ablation|These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
62328168|NCT04378309|EXPERIMENTAL|ePrep|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
62328169|NCT04158908||Oncolo-GIST Arm: Caregivers|Caregiver stakeholders were bereaved family members of a patient who had died from solid tumor cancer in the past year. Stakeholders reviewed an initial version of the Oncolo-GIST manual to provide feedback and refine the manual for Phase 2.
62693233|NCT03708315|ACTIVE_COMPARATOR|Order 1|Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)
62486299|NCT05853653|NO_INTERVENTION|Verbal expression is used in breastfeeding education|In the breastfeeding training, the researchers will verbally explain the pre-created training content. A training brochure will be given at the end of the training.
62486300|NCT01034215|ACTIVE_COMPARATOR|Imagery Practice, live trainer|Patients attend a five week training program, with the instructor in the room with them, and actively practice imagery techniques, both in the classroom, and daily, outside of the classroom. Classes are four hours a week for five weeks. Patients practice what they learn for a full 17 weeks, beginning with the first week of class.
62486301|NCT01034215|ACTIVE_COMPARATOR|"Envision the Rhythms of Life /video"|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD.
62486302|NCT01034215|NO_INTERVENTION|Waitlist Control Group|No treatment delivery during the 17 weeks of testing live delivery (trainer in the room with patients) vs. distance delivery (trainer delivers program via telemedicine/videoconferencing equipment)
62486303|NCT06559644|EXPERIMENTAL|Hema-NeoTIL01 treatment|In this study, we adopted a 3+3 design with dose escalation. Initially, three dose groups were established: 2.0×10\^7, 6.0×10\^7, and 2.0×10\^8 cells/kg. Each dose group received treatment on Days 0, 3, and 6 through i.v. injection, with bone marrow examination performed on Day 7 to assess tumor burden. Upon assessment by the investigators and discussion with the Safety Review Committee (SRC), it will be determined that whether patients may benefit from additional infusions. With SRC approval, the number of administrations could be increased, not exceeding a maximum of six doses. At the end of dose escalation, the SRC may decide to adjust the number of participants in the designated dose group as deemed appropriate.
62486304|NCT00724607||TBI (Case) Group|Members of the TBI group have sustained a TBI in accordance with inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant.
62486305|NCT00724607||Non-TBI (Control) Group|Members of the Non-TBI group have not sustained a TBI and are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize a control group to account for normal aging and other control factors.
62486306|NCT00724607||Non-TBI Non-deployed (Control) Group|Members of the Non-TBI Non-Deployed group have neither sustained a TBI nor have been deployed but are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize this Non-deployed control group to account for deployment-specific factors.
62486307|NCT02901028|EXPERIMENTAL|Collar Device|The Device is a standard hockey neck guard, adapted for the purposes of this study. The Device incorporates two bulges localized over the site of the internal jugular veins bilaterally. Experiments performed with jugular Doppler ultrasound demonstrate that while wearing the Device, flows within the jugular veins are reduced, while flow within the carotid arteries and all portions of the cerebrum are preserved (JA Fisher, unpublished data). Thus, application of the Device to the subject will not cause any untoward health risks. The pressure exerted by the Device on the region of the neck superficial to the internal jugular vein is akin to the pressure felt when a person yawns or wears a snugly fitting necktie.
62486308|NCT02901028|SHAM_COMPARATOR|Arm Device|the subject is wearing a sham arm device, which will be placed on the upper arm and not cause venous engorgement. The subject will undergo the same testing as when wearing the collar device (strength, Vo2, vision, blood, urine, etc)
62486309|NCT01539239|EXPERIMENTAL|Hydrus Aqueous Implant (Treatment)|Cataract surgery plus Hydrus Aqueous Implant
62693234|NCT03708315|PLACEBO_COMPARATOR|Order 2|Subjects will be given a sublingual film of placebo.
62693235|NCT04732468|EXPERIMENTAL|Cohort 1- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 1, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) were administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Suspension for injection) again on day 22 (boost).
62328170|NCT04158908||Oncolo-GIST Arm: Clinicians|Clinician stakeholders were physicians, nurses, nurse practitioners, and social workers with expertise in treating advanced cancer patients. Stakeholders reviewed an initial version of the Oncolo-GIST manual to provide feedback and refine the manual for Phase 2.
62328171|NCT04169334|NO_INTERVENTION|Control group|Group receiving care as usual
62486310|NCT01539239|ACTIVE_COMPARATOR|Cataract Surgery (Control)|Cataract surgery only
62693236|NCT04732468|EXPERIMENTAL|Cohort 2- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 2, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) were administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Oral capsule) on day 22 (boost).
62693237|NCT04732468|EXPERIMENTAL|Cohort 3 - hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 3, hAd5-S-Fusion+N-ETSD (Oral capsule) were administered on days 1 (prime) and on day 22 (boost).
62693238|NCT04732468|EXPERIMENTAL|Cohort 4 - hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 4, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) were administered on day 1 (prime) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on days 15 (boost) and 22 (boost).
62693239|NCT00684684|EXPERIMENTAL|1|
62693240|NCT04269265|EXPERIMENTAL|All Participants|In this single-arm study, all participants will receive the intervention
62693241|NCT05559047|EXPERIMENTAL|In-House Usability Study Group|Human subjects will interact with two different CPAP interfaces including a traditional CPAP mask and the 2nd generation DreamPort-Eclipse. Subjects will be requested to put on each of the different CPAP interface options a total of three times for a total of 6 trials. The order of device tries will be randomized.
62134219|NCT03682250||Patients with type 1 diabetes with a high cardiovascular risk|
62328172|NCT04169334|EXPERIMENTAL|Intervention group|Intervention group receiving a standardized preventive program (5 days at the Obstetric department)
62486311|NCT01559363|EXPERIMENTAL|Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing|Participants received tesevatinib 50 milligrams (mg) tablet orally once daily (QD) for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum duration: up to 36 months).
62486312|NCT01559363|EXPERIMENTAL|Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing|Participants received tesevatinib 100 mg tablet orally QD for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 36 months).
62486313|NCT01559363|EXPERIMENTAL|Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing|Participants received tesevatinib 150 mg tablet orally QD for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 36 months).
62486314|NCT01559363|EXPERIMENTAL|Phase 2a: Cohort 4: Tesevatinib: Bi-weekly Dosing|Participants received tesevatinib 150 mg tablet orally bi-weekly in alternative dosing schedules on Monday and Thursday for initial 25 days. After initial 25 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
62486315|NCT01559363|EXPERIMENTAL|Phase 2a: Cohort 5: Tesevatinib: Tri-weekly Dosing|Participants received tesevatinib 150 mg tablet orally tri-weekly in alternative dosing schedules on Monday, Wednesday and Friday for initial 26 days. After initial 26 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
62486316|NCT01559363|EXPERIMENTAL|Phase 2a: Safety in Larger Kidneys (SILK) Cohort: Tesevatinib 50 mg Once Daily Dosing|Participants with autosomal dominant polycystic kidney disease (and Baseline estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 35 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) and less than or equal to (\<=) 80 mL/min/1.73 m\^2, and height-adjusted total kidney volume (htTKV) \>=1000 mL were enrolled and received tesevatinib 50 mg tablet orally QD for initial 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
62486317|NCT00264108||1|Epoetin alfa 40 000 IU once weekly variable treatment length.
62486318|NCT00264108||2|Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
62486319|NCT06621784|ACTIVE_COMPARATOR|Traditional exercise (control) group|The first group followed a standard home exercise program for three times per week for six weeks
62486320|NCT06621784|ACTIVE_COMPARATOR|core exercise group|The second group followed a standard home exercise program and core stabilization exercises for three times per week for six weeks
62486321|NCT05548465|EXPERIMENTAL|Long-term-opioid-free anesthesia group.|
62486322|NCT05548465|ACTIVE_COMPARATOR|Long-term-opioid anesthesia group.|
62486323|NCT03946462|EXPERIMENTAL|NO Group|
62486324|NCT03946462|PLACEBO_COMPARATOR|Placebo Group|
62486325|NCT06043349|EXPERIMENTAL|Intervention Group|The first group, called the intervention group, will receive a combination therapy of platelet-rich plasma injection (PRP) with topical 5% minoxidil for three months. PRP injection will be given every 4 weeks with a total of three injections. Respondents will be instructed to apply topical minoxidil twice daily for three months.
62486326|NCT06043349|ACTIVE_COMPARATOR|Control Group|The second group (control group) will receive topical 5% minoxidil as standard therapy. Respondents will be instructed to apply topical minoxidil twice daily for three months.
62486327|NCT03173651|EXPERIMENTAL|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
62486328|NCT03173651|EXPERIMENTAL|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
62486329|NCT03173651|EXPERIMENTAL|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
62486330|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
62486331|NCT02975856|EXPERIMENTAL|Table Red Wine|250 ml Table Red Wine (12% ethanol)
62486332|NCT02975856|EXPERIMENTAL|Young Port Red Wine|150 ml Young Port Red Wine (20% ethanol)
62486333|NCT01129986|EXPERIMENTAL|Dermastream|
62486334|NCT05733585||Patients with abdominal aortic pathology|Patients with abdominal aortic pathology (aneurysmal or steno occlusive disease) candidate to open repair with PuraBond haemostatic agent.
62693242|NCT06638216|EXPERIMENTAL|Geriatric Assessment|"Frailty is assessed using the G8 questionnaire.~Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected."
62693243|NCT04841148|EXPERIMENTAL|HCQ|Patients will receive HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
62693244|NCT04841148|EXPERIMENTAL|Avelumab|Patients will receive Avelumab, 10 mg/kg, IV, D1 and D15 of each 28-day cycle.
61934740|NCT04019431|EXPERIMENTAL|Whey protein|VLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
62693245|NCT04841148|EXPERIMENTAL|Palbociclib and Avelumab|Patients will receive Palbociclib 125 mg daily, by mouth on D1-21 concurrently with Avelumab, 10 mg/kg IV on D1 and D15 of each 28-day cycle
62693246|NCT04841148|EXPERIMENTAL|Palbociclib and HCQ|Patients will receive Palbociclib 75 mg daily, by mouth on D1-28 concurrently with HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
62486335|NCT02451358|EXPERIMENTAL|Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months|Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.
62486336|NCT02451358|EXPERIMENTAL|Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years|Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.
62486337|NCT02451358|EXPERIMENTAL|Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years|Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.
62486338|NCT02451358|EXPERIMENTAL|Quadrivalent Influenza Vaccine Group 4: >=18 Years|Participants aged \>=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.
62486339|NCT04566497|EXPERIMENTAL|Experimental|no systematic stress testing during follow-up
62486340|NCT04566497|ACTIVE_COMPARATOR|Active Comparator|systematic annual stress testing during follow-up
62486341|NCT05492032|EXPERIMENTAL|Active cathodal (inhibitory) tDCS vs. Sham-tDCS condition|"Experimental group: active multisession tDCS + active booster tDCS vs Active control group: sham multisession tDCS + sham booster tDCS~To test whether active cathodal \[inhibitory\] tDCS over the left dlPRC will facilitate learning through stimulation and thus improve cognitive function in patients with ASD, the primary outcomes (SRS-2 scores) of the two groups at the start (T0), 1-month (T1), 3-month (T2), 6-month (T3), and at the end of study i.e. 12-months (T4) will be compared."
62486342|NCT05492032|EXPERIMENTAL|Active booster tDCS treatment vs. Sham booster tDCS treatment|"Experimental group: active multisession tDCS + active booster tDCS vs Active control group: active multisession tDCS + sham booster tDCS~To test whether booster treatment cycles of tDCS will prolong the cognitive benefits in individuals with ASD), the primary outcome, the total SRS-2 score, and the secondary outcomes, the E/I ratio and the cognitive composite score at the start (T0), 1-month (T1), 3-month (T2), 6-month (T3), and at the end of study i.e. 12-months (T4), will be compared."
62486343|NCT05492032|EXPERIMENTAL|Change in EEG E/I ratios in the active tDCS vs. sham tDCS groups|"Experimental group: active multisession tDCS + active booster tDCS vs Active control group: sham multisession tDCS + sham booster tDCS~To test whether enhanced neuronal network organization, as indicated by EEG E/I ratios, in patients with ASD will mediate the beneficial effects of tDCS in terms of improvements in cognitive function, measurements taken at baseline, 1-day and 1-month after tDCS treatment will be compared. The change in EEG E/I ratios in patients in the active tDCS and sham tDCS groups will be compared using E/I ratios averaged from channels Fp1, F3, and F7 to increase the signal-to-noise ratio of the EEG data and to represent the left frontal E/I ratio."
62486344|NCT05412485|EXPERIMENTAL|Treatment group|"Lokomat Certified physiotherapists will perform robotic assisted gait trainings. It will be performed 4 times per a week with a duration of 30 minutes on the lokomat with a treatment of 6 weeks phase.~Initially the Physical therapist will adjust the body -weight support at 70 % which will be gradually reduced until obtain flexion of the knees during stance phases. The lokomat certified physiotherapist will monitor the condition of the knees and adjust the body weight support during the training.~The Gait speed will be set at 0.7 km/hour and will gradually increase according to the comfortable speed selected by the child. The gait speed, Body weight support and the guidance force of the Lokomat will be adjusted and modified individually according to the ability of the child.~Virtual reality games will be used to motivate the participants and verbal encouragement will be used to increase their adherence to the intervention."
62486345|NCT05412485|ACTIVE_COMPARATOR|Control group|The same procedures will be given twice a week frequency.
62486346|NCT04580784|EXPERIMENTAL|Hypofractionation|Hypofractionated whole breast radiotherapy using a dose of 28.5 Gy over 5 fractions with once weekly fractions.
62486347|NCT01963663|ACTIVE_COMPARATOR|Metformin|patients receiving fixed dose metformin 1000 mg daily
62486348|NCT01963663|ACTIVE_COMPARATOR|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
62486349|NCT05288972|EXPERIMENTAL|Mattress 1|Mattress 1 group will receive Polyurethane, Bonnel spring, medium-hard mattress
62486350|NCT05288972|ACTIVE_COMPARATOR|Mattress 2|Mattress 2 group will receive Polyurethane, pocket spring, medium mattress
62486351|NCT06452030|EXPERIMENTAL|Specific sensorimotor control training|One low-load treatment session of selective multifidus activation.
62486352|NCT06452030|ACTIVE_COMPARATOR|Aspecific extension training|One low-load treatment session of back muscle activation.
62328173|NCT03064776|EXPERIMENTAL|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to~1. Continuously capture multidimensional behaviour as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.~2. Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision support system (CDSS) and Recommender operation.~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient-initiated (i.e. on-demand) real-time assessments, to the participants and in their own environment."
62328174|NCT03064776|EXPERIMENTAL|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
62328175|NCT06693063||Patient followed by a general practitionner|GP consulted in the last 12 months
62328176|NCT06693063||Patient not followed by a general practitionner|Patient without regular follow-up
62486353|NCT06452030|EXPERIMENTAL|Fascia training|One low-load treatment session of general movement exercises.
62486354|NCT00031707|ACTIVE_COMPARATOR|megestrol + placebo|"Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
62486355|NCT00031707|ACTIVE_COMPARATOR|eicosapentaenoic acid + placebo|"Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
62693247|NCT03958643||1|In a population of adult patients with SCD we will comprehensively evaluate renal function.
62486356|NCT00031707|EXPERIMENTAL|megestrol + eicosapentaenoic acid|"Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
62486357|NCT06063213||Liver Transplant Group|Patients \<1 month post-surgery for liver transplant only.
62486358|NCT06063213||Liver-Kidney Transplant Group|Patients \<1 month post-surgery for simultaneous kidney-liver transplant only.
62486359|NCT00472212|EXPERIMENTAL|Spectacles|Spectacles with hyperopic lenses
62486360|NCT00472212|PLACEBO_COMPARATOR|Control|Spectacles with placebo lenses
61934741|NCT04019431|ACTIVE_COMPARATOR|Vegetable proteins|VLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
62328177|NCT04987983|EXPERIMENTAL|Experimental SLP-R|Infant placed in a SLP-R on the researcher's lap. Infant body positioned on side-lying position on the right side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
62328178|NCT04987983|EXPERIMENTAL|Experimental SLP-L|Infant placed in a SLP-L on the researcher's lap. Infant body positioned on side-lying position on the left side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands).
62328179|NCT06034834|EXPERIMENTAL|Traumatic injuries|"Acute patients treated surgically for:~* Open deglovement (n=20)~* Crush injury (n=20)~* Open fractures (n=20)~The setting is defined acute when there is less than 24 hours between sustaining the injury and surgery.~Elective patients treated surgically for:~* Fracture related infection (FRI) (n=10)~* Non-union of fractures (n=50) Subdivided into 5 groups of 10.~  * Elective osteosynthesis of non-union clavicula fracture N=10~    * Primarily operated on N=5~   * Primarily treated conservatively N=5~ * Elective osteosynthesis of non-union tibia. N=10~ * Elective osteosynthesis of non-union ulna. N=10~    * Primarily operated on N=5~   * Primarily treated conservatively N=5~ * Elective osteosynthesis of non-union humerus. N=10~ * Elective osteosynthesis of non-union of the rib. N=10"
62328180|NCT02844101|OTHER|non-blinded group|The non-blinded subjects will be informed that the accelerometer device (GT3X Actigraph accelerometer) is an accelerometer that assessed physical activity levels and patterns
62486361|NCT04606550|EXPERIMENTAL|Vaginal Laser HR+|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
62486362|NCT04606550|ACTIVE_COMPARATOR|Vaginal Estrogen HR-|The women in the vaginal estrogen group will be prescribed and asked to administer: Conjugated estrogen cream (Premarin®): 0.5 g of cream intravaginally daily (using applicator or fingertip) for two weeks (fourteen days) then 0.5 g twice weekly for 24 ± 2 additional weeks.
62486363|NCT04606550|ACTIVE_COMPARATOR|Vaginal Laser HR-|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
62486364|NCT01558635|EXPERIMENTAL|Cardioblate CryoFlex Surgical Ablation|Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.
61934742|NCT04019431|ACTIVE_COMPARATOR|Animal proteins|VLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days.Patients will be given four meals per day containing natural animal protein (meat, fish, eggs, dairy products without whey protein).
61934743|NCT02999399|EXPERIMENTAL|[D10]phe and Brussels sprouts|All subjects are given 1 microgram \[D10\]phe before and after consuming Brussels sprouts once daily for 7 consecutive days.
61934744|NCT06488313|EXPERIMENTAL|ARCT-810|Participants will receive up to 5 IV infusions of ARCT-810 administered at 14-day intervals.
61934745|NCT04465162|EXPERIMENTAL|Treatment (radiation therapy)|Patients undergo radiation therapy QD 5 times weekly over 3.5-5 weeks.
61934746|NCT02098824|ACTIVE_COMPARATOR|Galantamine|Single administration of capsule containing 16 mg Galantamine
62328181|NCT02844101|OTHER|blinded group|The blinded subjects will be informed that they will test the reliability of a new device for body posture assessment and these youngsters will not receive any information with regards to physical activity.
62328182|NCT05987293||Supine group|Fifty-four patients undergoing elective surgery in general anesthesia for more than 2 hours with endotracheal tube applied in China-Japan Friendship Hospital will be enrolled (See in Sample Size calculation). Patients will be divided into two groups according to the surgery: supine position (Supine group)
61934747|NCT02098824|PLACEBO_COMPARATOR|Placebo|Single oral administration of capsule containing placebo
61934748|NCT02098824|ACTIVE_COMPARATOR|Methylphenidate|Single administration of capsule containing 10 mg Methylphenidate
61934749|NCT03236831|OTHER|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
61934750|NCT00751621|EXPERIMENTAL|IgPro20|Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).
61934751|NCT01094756|ACTIVE_COMPARATOR|Obese group - Group 1|If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
62693248|NCT02603497|EXPERIMENTAL|Control (Subjects with normal renal function)|Oral
62693249|NCT02603497|EXPERIMENTAL|Mild renal impairment|Oral
62328183|NCT05987293||Flexion group|The high-risk positions (Flexion group) which include patients scheduled for surgery under the prone position, cervical traction position, and beach chair position.
62328184|NCT02446054|EXPERIMENTAL|One Arm Study|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
62328185|NCT01473251|ACTIVE_COMPARATOR|Avastin for Diabetic Macular Edema|1.25 mg avastin monthly for 4 months
62328186|NCT01473251|ACTIVE_COMPARATOR|Avastin for Exudative Macular Degeneration|1.25 mg Avastin monthly for 4 months
62328187|NCT01473251|ACTIVE_COMPARATOR|Lucentis for Exudative Macular Degeneration|0.5 mg Lucentis monthly for 4 months
62328188|NCT01574313|EXPERIMENTAL|Stellate ganglion block|treated with SGB
62328189|NCT01574313|ACTIVE_COMPARATOR|Oral medication|treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).
62328190|NCT02142179|EXPERIMENTAL|KARE Intervention|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
62328191|NCT02142179|NO_INTERVENTION|A traditional curriculum education.|The control group will receive a traditional curriculum education.
62328192|NCT04775797|EXPERIMENTAL|Part 1 (Healthy Subjects): Single Ascending Dose (SAD)|Two cohorts (Cohorts A and B) of healthy subjects will receive single doses of AB-836/placebo in an alternating cohort design under fasted conditions. One additional treatment will be administered under fed conditions.
62328193|NCT04775797|EXPERIMENTAL|Part 2a (Healthy Subjects): Multiple Ascending Dose (MAD)|Participants in Cohorts C, D and E will receive a once daily dose of AB-836/placebo for 10 days
62328194|NCT04775797|EXPERIMENTAL|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohorts F-H|Participants in Cohorts F, G, and H will receive multiple doses of AB-836/placebo once daily for 28 days.
62328195|NCT04775797|EXPERIMENTAL|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort I|Participants in Cohort I will receive multiple doses of AB-836/placebo once daily for 28 days in combination with ongoing nucleos(t)ide analog (NA) therapy.
62328196|NCT04775797|EXPERIMENTAL|Part 2b (Healthy Subjects): MAD|Participants in Cohorts J will receive a once daily dose of AB-836/placebo for 35 days
62693250|NCT02603497|EXPERIMENTAL|Moderate renal impairment|Oral
62693251|NCT02603497|EXPERIMENTAL|Severe renal impairment|Oral
62693252|NCT04470037|EXPERIMENTAL|DAAOI-P|DAAOI-P 250-1500mg
62693253|NCT04470037|PLACEBO_COMPARATOR|Starch pill|
61934752|NCT01094756|NO_INTERVENTION|Lean group - Group 2|If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
62328197|NCT01666275||Aspirin desensitization|This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.
62328198|NCT06141213||Normal fetal chromosomes|"This group will consist of participants with confirmed normal fetal chromosomes.~Fetal membrane thickness measurements will be taken at enrollment and may be followed up with subsequent measurements throughout the pregnancy.~The data from this group will serve as the control for comparison with the chromosomal abnormality group."
62328199|NCT06141213||Abnormal fetal chromosomes|"This group will include participants whose fetuses have been diagnosed with chromosomal abnormalities.~These participants will also have their fetal membrane thickness measured at the same gestational age as the control group to ensure consistency.~The comparison of fetal membrane thickness between this group and the control group will be a primary focus of the study."
62328200|NCT03415919||IBD patients|Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
62328201|NCT03415919||CRC patients|Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
62328202|NCT03415919||Control patients|Patients who are scheduled to have a colonoscopy for routine screening to serve as a control population.
62328203|NCT00110656||Kidney Transplant|All patients entered into the study will have received a kidney transplant.
62328204|NCT05916833|EXPERIMENTAL|hypopressive breathing technique|"These exercises involved sucking in the abdomen and opening the ribs by engaging the accessory inspiratory muscles, such as the serratus anterior, external intercostalis, scalenes, and sternocleidomastoid, while maintaining the glottis closed, a process known as diaphragmatic suction."
62328205|NCT05916833|EXPERIMENTAL|noble technique|The Noble technique is (partially sitting up while manually flexing the rectus Abdominis muscles.
62328206|NCT03987620|EXPERIMENTAL|Ibrexafungerp (SCY-078)|300 mg BID for one day
62328207|NCT03987620|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62693254|NCT03789370|ACTIVE_COMPARATOR|Propofol|Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
62693255|NCT03789370|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
62693256|NCT05849844|EXPERIMENTAL|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
62693257|NCT05430321|EXPERIMENTAL|Effect of facilitated tucking after preterm labor|Implementation of facilitated tucking after preterm labor
62693258|NCT05430321|NO_INTERVENTION|Supine position after preterm labor|Implementation of supine position after preterm labor
62486365|NCT03192397|EXPERIMENTAL|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
62486366|NCT06033417|EXPERIMENTAL|Increased lifestyle walking (intervention)|Intentional increase in daily steps: 3,000 extra steps/day, 5-days a week, 8-weeks total.
62486367|NCT06033417|OTHER|Health education only (control)|Health education and no intentional increase in baseline daily steps (but with the option to receive the intervention upon conclusion of the initial 8-weeks).
62693259|NCT06540495|EXPERIMENTAL|Single Arm Study|"Cohort A: Peri-operative (subjects starting neoadjuvant chemotherapy or within 4-8 weeks after curative-intent thoracic surgery which could be segmentectomy, lobectomy of pneumonectomy), irrespective of adjuvant treatment - expected recruitment: 15 subjects~Cohort B: Subjects Subjects starting definitive chemotherapy and radiation for locally advanced lung cancer- expected recruitment: 15 subjects~Cohort C: Subjects with stage IV metastatic non-small cell lung cancer irrespective of type of treatment - expected recruitment: 30 subjects"
62693260|NCT05303857|ACTIVE_COMPARATOR|Treatment|Baseline vascular function parameters will be obtained and the patient will be given semaglutide 1.34 mg/ml (SC, administered by personal injector, once weekly)
62693261|NCT05303857|PLACEBO_COMPARATOR|Placebo|Baseline vascular function parameters will be obtained and the patient will be given placebo (SC, administered by personal injector, once weekly)
62697547|NCT01991873|EXPERIMENTAL|Maintenance Chemotherapy + Panitumumab|"Maintenance therapy:~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
62328208|NCT02269111|EXPERIMENTAL|Diagnostic (hybrid MRI)|Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
62328209|NCT00465153|EXPERIMENTAL|1|Flax oil
62328210|NCT00465153|PLACEBO_COMPARATOR|2|corn oil
62328211|NCT00849979|OTHER|Questionnaire|
62328212|NCT00849979|OTHER|Questionnaire + Interview|
62328213|NCT03212404|EXPERIMENTAL|CK-301 (cosibelimab)|Part 1 - Dose Escalation; Part 2 - Dose Expansion
62328214|NCT03811223|EXPERIMENTAL|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
62328215|NCT03811223|PLACEBO_COMPARATOR|Placebo|Placebo injection once every 2 weeks for 12 weeks
62328216|NCT01920620|EXPERIMENTAL|Intervention Arm|Inpatient weight loss counseling Motivational interviewing and troubleshooting via phone
62486368|NCT03469401||intervention|Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage
62486369|NCT06562374|EXPERIMENTAL|Low Frequency Ultrasound (LFU) Intervention|Subjects will be given ultrasound at a frequency of 33 kHz with a program of 1.6 seconds on and 1.6 seconds off for 30 min at either a power level of 4 or 10 Pascals to determine which power level is optimal for osteoarthritis. Follow up visits after two-three days will be used to continue therapy.
62486370|NCT00656786|EXPERIMENTAL|Group 1|Subjects will be treated if, after starting treatment with an EGFRi, acute signs and symptoms of rash on the face/neck and/or upper chest emerge, that are suspected of being related to the EGFRi treatment.
62486371|NCT00656786|EXPERIMENTAL|Group 2|Subjects will receive pre-emergent rash treatment starting 1 day prior to beginning EGFRi therapy
62328217|NCT01920620|NO_INTERVENTION|Usual Care Arm|Participants in the usual care group were not provided with any specific instructions regarding weight loss, diet or exercise prior to discharge. Follow-up phone calls for usual care subject were used only to obtain weight and assess for changes in medications or health condition.
62328218|NCT03666260|EXPERIMENTAL|Quadratus Lumborum Block arm|
62328219|NCT03666260|ACTIVE_COMPARATOR|Femoral block arm|
62328220|NCT01647594|ACTIVE_COMPARATOR|Young Women's Intervention (YWI)|
62328221|NCT01647594|ACTIVE_COMPARATOR|Physical Activity Intervention (PAI)|
62328222|NCT03398018|EXPERIMENTAL|Treatment|Treated with repository corticotropin injection
62328223|NCT05320770|EXPERIMENTAL|TMD patients with joint hyper mobility|
62328224|NCT04670965||E-PRF/rhBMP-2 (similar ratios)|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
62328225|NCT04670965||E-PRF/ACS/rhBMP-2|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
62328226|NCT04670965||rhBMP-2/E-PRF|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
62328227|NCT04670965||E-PRF only|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
62328228|NCT02159963|EXPERIMENTAL|Supervised training|8 weeks of high intensity training three times a week, once supervised. Followed by 8 weeks home based, unsupervised optional training.
62328229|NCT02159963|EXPERIMENTAL|Unsupervised training|"Participants have 8 weeks of non-intervention Control period, followed by 8 weeks of home based, unsupervised high intensity interval training."
62328230|NCT04076722|EXPERIMENTAL|Stress reactivity weight stigma|This study arm received a stress reactivity paradigm that involved weight stigma content in the form of an evaluated speech task.
62693262|NCT02936323|EXPERIMENTAL|Phase 1: Dose Escalation|"Cohort 1 will consist of two (2) participants who will receive PEN-221 at the starting dose of 1.0 mg. The first participant will be followed for at least 7 days for safety and dose limiting toxicity (DLT). If PEN-221 is tolerated, the second participant will be enrolled into the cohort. The two (2) participants will be followed for safety and DLTs for at least a 4-week observation period. The Safety Review Committee (SRC) will determine the initiation of cohort 2.~Cohort 2 and each subsequent dose escalation cohort will consist of 3 to 6 participants who will be treated at each dose level of PEN-221 as determined by the SRC and will be followed for safety and DLTs for at least a 3-week observation period. Each dose escalation level and cohort initiation will be determined by the SRC.~Dose escalation will continue until the Maximum Tolerated Dose (MTD) of PEN-221 is determined and the Recommended Phase 2a Dose (RP2D) is established by the SRC."
62693263|NCT02936323|EXPERIMENTAL|Phase 2a: Dose Expansion (GI mid-gut NET)|Gastrointestinal mid-gut NET Cohort
62693264|NCT02936323|EXPERIMENTAL|Phase 2a: Dose Expansion (PNET)|Pancreatic NET Cohort
62693265|NCT02936323|EXPERIMENTAL|Phase 2a: Dose Expansion (SCLC)|Small Cell Lung Cancer Cohort
61934753|NCT05663268|EXPERIMENTAL|Patients of Hidradenitis suppurativa resistant to conventional therapy|injection Infliximab-dyyb biosimilar (according to weight, single injection of 120mg if weight \<80kg, 2 injections if weight \> 80kg) will be injected subcutaneously at week 0,1, 2,3,4, and then fortnightly till 24 weeks.
61934754|NCT01298973|EXPERIMENTAL|Saline|One group will receive Saline to irrigate the wound
61934755|NCT01298973|EXPERIMENTAL|Viscoat|One group will receive Viscoat to close the surgical wound
61934756|NCT02413021|EXPERIMENTAL|deferasirox + cytarabine|deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m\^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
61934757|NCT02413021|ACTIVE_COMPARATOR|cytarabine|cytarabine group will receive just cytarabine at 20 mg/m\^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
61934758|NCT06708104|EXPERIMENTAL|Outdoor horse-assisted perturbation training|Outdoor perturbation training during Equine Dynamic Balance
61934759|NCT05044091||ovarian/fallopian tube/primary peritoneal cancer patients|ovarian/fallopian tube/primary peritoneal cancer patients treated with PAPRi for more than four weeks
61934760|NCT06710795|EXPERIMENTAL|MaxTack™ Motorized Fixation Device|Subjects treated with MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair
61934761|NCT05235477|EXPERIMENTAL|Tube technique.|"The excavator is used to do the same on the palatal aspect. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect. To harvest the graft, the incision is made parallel to and 2 mm away from the gingival margin. A thin flap containing the keratinized tissue is separated, then the second incision is made parallel to the gingival margin, but perpendicular to the alveolar bone. With a sharp periosteal elevator, the graft is raised with the periosteum and released at its anterior and posterior ends, and then from its base ."
61934762|NCT05235477|ACTIVE_COMPARATOR|Hyaluronic acid.|The product used in this trial is Restylane Lidocaine (Restylane-Lidocaine cross-linked Hyaluronic Acid Filler, Galderma S.A, Sweden). Restylane was the first FDA-approved HA filler in 2003. Restylane is a non-animal stabilised cross-linked HA filler with an HA concentration of 20 mg/ml. It is a minimally invasive non-surgical injection of hyaluronic acid that observed to overcome the major limiting factor in most surgical techniques regarding the limited blood supply and the small working space. Supported by a recent study conducted by Jinng etal. 2019, who reported significant increase in the height of the gingival papilla and reduction of the area of the black triangle between baseline and 3 or 6 months in a group with thick gingival biotype after injection with hyaluronic acid, that was adding possible maximum effect with minimal postoperative hazards.
61934763|NCT05213000|EXPERIMENTAL|Exercise post-immunization|After the initial mRNA-based COVID-19 vaccine is received, a supervised 90 minute light to moderate exercise session will take place.
61934764|NCT05213000|NO_INTERVENTION|Daily routine as usual (control)|After the initial mRNA-based COVID-19 vaccine is received, participants will be asked to go about their daily routine as usual, but avoid exercise for that day.
61934765|NCT06265051|EXPERIMENTAL|Tirofiban group|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
61934766|NCT06265051|PLACEBO_COMPARATOR|placebo group|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the control group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
62134220|NCT05793541|EXPERIMENTAL|Just-in-time intervention for promoting use of the safety plan or its components|"Completed surveys will be assigned to a risk level (High Risk, Medium/Low Risk, or No Risk) based on self-reported level of suicidal urge and intent. Participants will be micro-randomized to one of the available intervention options based on the survey's risk level. All interventions will include reminders to use the safety plan or its components. At High Risk, participants will be randomized to either receive a phone call from a clinician, text messaging from a clinician, or automated interactive smartphone tool. At Medium/Low risk, participants will be randomized to receive an automated interactive smartphone tool, non-interactive pop-up messages, or no intervention. No randomization will occur (and no intervention given) at No Risk."
62328231|NCT04076722|ACTIVE_COMPARATOR|Stress reactivity non-weight stigma.|This study arm received a stress reactivity paradigm that involved non-weight stigma content in the form of an evaluated speech task.
62134221|NCT01974102|ACTIVE_COMPARATOR|lifestyle|Attentional control group will receive weekly meeting to view relaxing video and facilitate discussion along with counseling on nutrition and physical activity for 8 weeks.
62134222|NCT01974102|EXPERIMENTAL|therapy|Active group will receive weekly mindfulness based parenting stress reduction (PMH) plus nutrition and physical activity counseling for 8 weeks.
62328232|NCT01194557|ACTIVE_COMPARATOR|rapid diagnostic test|Treatment and diagnosis of malaria in drugs hops using rapid diagnostic tests
61934767|NCT06523283|EXPERIMENTAL|Natural Landscape Pictures Accompanied by Music İntervention Group|Natural Landscape Pictures Accompanied by Music video will be applied to interevention group. They will watch the video for 10 sessions.
62134223|NCT04180579|EXPERIMENTAL|Participants with Breast Cancer|Any adult woman with a new diagnosis of breast cancer, Stage I-III
62134224|NCT04755920|EXPERIMENTAL|Patients with colorectal brain metastases|10 mg SGM-101, administration 3 to 5 days prior to surgery.
62328233|NCT01194557|NO_INTERVENTION|Presumptive malaria treatment|Presumptive treatment for malaria in drug shops
62328234|NCT00237796|EXPERIMENTAL|ARM 1|Cognitive Behavioral Social Skills Training (CBSST)
62328235|NCT00237796|ACTIVE_COMPARATOR|ARM 2|Goal Focused Supportive Contact (GFSC)
62328236|NCT05170893|EXPERIMENTAL|Intervention group|Oral Coenzyme Q10 capsules daily for 12 weeks.
62328237|NCT05170893|PLACEBO_COMPARATOR|Control group|Oral capsules similar to the intervention daily for 12 weeks.
62328238|NCT06320665||Class I|Patient with class I occlusion, with at least one impacted third molar
62328239|NCT06320665||Class II|Patients with class II malocclusion, with at least one impacted third molar
62328240|NCT06320665||Class III|Patients with class III malocclusion, with at least one impacted third molar
62328241|NCT06416059|EXPERIMENTAL|Mobile Application|Participants complete a 45 minute intervention at baseline and will have access to intervention material for up to 3-months after the baseline appointment via the mobile health application.
62328242|NCT04941378|EXPERIMENTAL|OTL 38|The study drug in question is an Investigational New Drug (IND), folate analog ligand conjugated with an indole cyanine green-like dye called OTL38. There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, completed at least 1 hour prior to intraoperative imaging
62328243|NCT00977327|OTHER|Intraoperative MR|Use of intraoperative MR during resection of intraaxial tumor, Glioma
62328244|NCT00977327|OTHER|Intraoperative Ultrasound|Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
62328245|NCT01452126|EXPERIMENTAL|Ropivacaine|Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
62328246|NCT01461954|EXPERIMENTAL|FST-100|
62328247|NCT01461954|PLACEBO_COMPARATOR|FST-100 Vehicle|
62328248|NCT05769608|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 12 weeks
62328249|NCT05769608|EXPERIMENTAL|Dose 1|lorundrostat Dose 1 once daily for 12 weeks
62328250|NCT05769608|EXPERIMENTAL|Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks
62328251|NCT02882399|EXPERIMENTAL|Shortystrap|
62693266|NCT01817777|EXPERIMENTAL|Metformin Small Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
62134225|NCT04741113|EXPERIMENTAL|Intervention group -educational module|"The study intervention will include an online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion. The module will be sent to participants via secured link."
62134226|NCT04741113|NO_INTERVENTION|Control group|No intervention
61934768|NCT06523283|NO_INTERVENTION|Control group with no intervention|Control group will not receive any intervention.
61934769|NCT06710262||Healthy donors|Subjects with no evidence of primary hemostasis abnormalities
62134227|NCT01693211|EXPERIMENTAL|Group A|Capsulorhexis and pre-fragmentation of the nucleus are performed by the femtosecond laser.
62328252|NCT05513703|EXPERIMENTAL|Telisotuzumab Vedotin|Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
62328253|NCT01911624|EXPERIMENTAL|direct thrombin inhibition|dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible
62328254|NCT01911624|ACTIVE_COMPARATOR|enoxaparin|enoxaparin 40 mg od, sc
62328255|NCT03977285|SHAM_COMPARATOR|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
62328256|NCT03977285|EXPERIMENTAL|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
62328257|NCT03977285|ACTIVE_COMPARATOR|Air Powder|An Air-Powder treatment will be provided on the implant surface
62328258|NCT01321996|OTHER|68Ga-DOTANOC PET/CT in patients with IPF and NSIP|one arm study: all patients were studied by 68Ga-DOTANOC PET/CT
62328259|NCT04649528|EXPERIMENTAL|Supervised HIIT|Exercise intervention, 20 supervised by healthcare professional
62328260|NCT04649528|EXPERIMENTAL|APP HIIT|Exercise intervention, 20 self-monitored assisted by a mobilephone application
62328261|NCT05679687|EXPERIMENTAL|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
62328262|NCT01543464|EXPERIMENTAL|Vaccine+adjuvants+temozolomide treatment|Experimental arm
62328263|NCT02110810|EXPERIMENTAL|Indomethacin|100 mg of Indomethacin suppository immediately afterwards while still under sedation
62328264|NCT02110810|PLACEBO_COMPARATOR|2.6-g suppository of glycerin|suppository of 2.4 g of glycerin immediately afterwards while still under sedation
62486372|NCT03669250|ACTIVE_COMPARATOR|CVN058, low dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 15mg or 75mg substitution of 15mg.
62486373|NCT03669250|ACTIVE_COMPARATOR|CVN058, high dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
62328265|NCT05896761|EXPERIMENTAL|Participants receiving CAB LA 400 milligrams (mg) and RPV LA 600 mg|Participants will receive an Intramuscular (IM) injection of CAB LA 400 mg on one lateral thigh and RPV LA 600 mg into the opposite lateral thigh on Day 1 in every 4 weeks (Q4W) for a total of 16 weeks during Thigh injection phase. Participants will then return to the clinic 4 weeks later to receive their first IM gluteal injection (at Week 16) of CAB LA 400 mg and RPV LA 600 mg during the Return to Gluteal Injection Phase. The subsequent gluteal injection will occur at Week 20.
62328266|NCT05896761|EXPERIMENTAL|Participants receiving CAB LA 600 mg and RPV LA 900 mg|Participants will receive an IM injection of CAB LA 600 mg on one lateral thigh and RPV LA 900 mg into the opposite lateral thigh on Day 1 in every 8 weeks (Q8W) for a total of 16 weeks during Thigh injection phase. Participants will then return to the clinic 8 weeks later receive their first IM gluteal injection (at Week 16) of CAB LA 600mg and RPV LA 900 mg during the Return to Gluteal Injection phase. The subsequent gluteal injection will occur at Week 24.
62328267|NCT02372292|ACTIVE_COMPARATOR|Group 1|Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
62328268|NCT02372292|ACTIVE_COMPARATOR|Group 2|Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
62328269|NCT05049512|EXPERIMENTAL|Multi-nut OIT|Participants will have a personalised combination of two nuts they are allergic to for their multi-nut OIT (a. peanut, b. almond, c. cashew, d. hazelnut, e. walnut). In the escalation visit, participants will receive 5 increasing doses of personalised multi-nut OIT in clinic at 20-minute intervals: 1 mg, 3 mg, 6 mg, 12 mg, 24 mg total nut protein, 12 mg/nut. The build-up phase will consist of daily home doses of multi-nut OIT and clinic visits every 2 weeks for up-dosing, up to a maintenance dose of 600 mg total protein, 300 mg/nut, over 3-8 months. In the maintenance phase, participants will continue to take their multi-nut OIT dose of 600 mg total protein each day at home for the remainder of the 18 months, with visits to the clinic every 3 months.
62328270|NCT05049512|NO_INTERVENTION|Standard Care|Strict avoidance of the 2 study nuts the participants are allergic to over 18 months - a. peanut, b. almond, c. cashew, d. hazelnut, e. walnut, as per standard care instructions for children with allergies in Australia.
62328271|NCT01727635|EXPERIMENTAL|counseling|body-mind-spirit group therapy
61934770|NCT06710262||Aspirin monotherapy|Subjects taking aspirin monotherapy
61934771|NCT06710262||Dual antiplatelet therapy|Subjects taking dual antiplatelet therapy (aspirin plus either clopidogrel, prasugrel, or ticagrelor)
61934772|NCT06710262||Von Willebrand Disease|Subjects with a prior diagnosis of Von Willebrand Disease
61934773|NCT04298034|EXPERIMENTAL|Treatment|The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol or nifedipine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects.
61934774|NCT04298034|NO_INTERVENTION|No-treatment|
61934775|NCT06281171|EXPERIMENTAL|Video Library Group|This arm will receive the intervention. This intervention is access to the SkillTalk for AYA Microskills video library, about 60 minutes in duration. The library includes a curriculum covering skills such as setting boundaries, resolving conflict, and emotional regulation.
61934776|NCT06281171|ACTIVE_COMPARATOR|Flyer Library Group|During the intervention period, arm 2 will receive flyers with information on relationship skills. This arm will receive the intervention upon completion of follow-up study activities.
61934777|NCT02967718||Control group|the healthy patients
62134228|NCT01693211|ACTIVE_COMPARATOR|Group B|The Capulorhexis and nuclear fragmentation are performed manually.
62486374|NCT03669250|PLACEBO_COMPARATOR|Placebo|Matching placebo.
62486375|NCT06414200|NO_INTERVENTION|Control group/usual care group|The usual care as given at that moment in that hospital. The group to compare the intervention with.
61934778|NCT02967718||Metabolic syndrome group|Include patients who are accordance with diagnostic criteria of metabolic syndrome
61934779|NCT02967718||CHD stable stage group|Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome
61934780|NCT02967718||Acute coronary syndrome group|Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction
61934781|NCT02967718||PCI or CABG group|Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting
61934782|NCT02967718||CHD heart failure group|Include the patients who suffered heart failure cause by CHD
61934783|NCT06525532||Patients|subjects who have undergone surgery for subtalar arthroritis with a reabsorbable endorthotic PLLA implant
62134229|NCT03355534|EXPERIMENTAL|nasal dexmedetomidine|dexmedetomidine is given nasally, saline is given intravenously
62134230|NCT03355534|EXPERIMENTAL|intravenous dexmedetomidine|saline is given nasally, dexmedetomidine is given intravenously
61934784|NCT05237297|ACTIVE_COMPARATOR|ilaprazole & naproxen|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : naproxen 500mg/tab, twice a day, 4 days and naproxen 500mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + naproxen 500mg/tab, twice a day, 5 days"
61934785|NCT05237297|ACTIVE_COMPARATOR|ilaprazole & aceclofenac|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
62134231|NCT03355534|PLACEBO_COMPARATOR|normal saline|saline is given nasally and intravenously
62134232|NCT06522178||Group 1|Group I patients contained those who were between 80 (included) and 89 (included) years of age.
62134233|NCT06522178||Group 2|Those who were 90 years of age and above were included in Group II
62134234|NCT04851743|EXPERIMENTAL|Dry needling Group|Participants will be used as their own controls, with 1 lower extremity randomly receiving intervention. The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
62486376|NCT06414200|ACTIVE_COMPARATOR|Intervention group|The intervention consists of a tailored nutritional follow-up plan, including a parent empowerment program, made by a multidisciplinary support team (primarily responsible clinician, dietician, psychologist and, if indicated, a speech therapist). At discharge and follow-up at 6, 12 and 18 weeks after discharge, food diaries (including growth) and questionnaires\* relating to feeding behaviour and parental stress are filled out by parents/caregivers.
62693267|NCT01817777|EXPERIMENTAL|Metformin Large Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
62693268|NCT05584566|EXPERIMENTAL|OSSIX Breeze|
62134235|NCT04851743|NO_INTERVENTION|Control Group|Participants will be used as their own controls, with 1lower extremity randomly receiving intervention. The control extremity did not receive any intervention, and outcomes were assessed 2 minutes apart.
62134236|NCT03247842|ACTIVE_COMPARATOR|suprascapular nerve RF|Eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups (Figure1); forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (PRF) followed by injection through the radiofrequency needle of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1)
62134237|NCT03247842|ACTIVE_COMPARATOR|suprascapular nerve block|and forty patients received fluoroscopically guided supra-scapular nerve injection of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.
62134238|NCT00790894|ACTIVE_COMPARATOR|1|
62134239|NCT00790894|EXPERIMENTAL|2|
62328272|NCT01571037|OTHER|inhaled nebulized Milrinone|"Drug: Inhaled, nebulized, Milrinone~1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation."
62328273|NCT01655264|ACTIVE_COMPARATOR|Home-based self training exercises|The control group will receive home-based self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
62328274|NCT01655264|EXPERIMENTAL|Tele-rehabilitation exercises|The experimental group will receive tele-rehabilitation treatment of comparable duration and intensity to those in the home-based self training exercise group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
62693269|NCT05584566|ACTIVE_COMPARATOR|Jason membrane|
62693270|NCT03925246|EXPERIMENTAL|Nivolumab|Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 weeks for 8 doses (4 months), followed by a 60 minutes intravenous infusion at dose of 480 mg every 4 weeks for 8 doses (8 months) or until progression, death , unacceptable toxicity or end of the research.
62693271|NCT02810405||1/Patient Samples|Patients treated at NCI with available tissue samples.
62693272|NCT02002858|EXPERIMENTAL|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
62693273|NCT02002858|ACTIVE_COMPARATOR|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
62693274|NCT06643299|ACTIVE_COMPARATOR|Probiotic Arm|Probiotic pill taken once daily
62693275|NCT06643299|PLACEBO_COMPARATOR|Placebo Arm|Identical placebo pill taken once daily
62693276|NCT04951843|EXPERIMENTAL|Black soybean koji product|Oral supplement 2 servings of black soybean koji product per day, for 10 weeks.
62693277|NCT06641206|ACTIVE_COMPARATOR|Group 1|A group of Patients from Tanta University suffering from Chronic painful knee osteoarthritis who didn't receive medical treatment and progressed to have chronic pain with decreased physical function and poorer quality of life.
62134240|NCT04464759|EXPERIMENTAL|Phase 1a: Nivolumab and Hydroxychloroquine (HCQ)|"Dose escalation:~Dose Level 1: HCQ 400 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Dose Level 2: HCQ 600 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
62134241|NCT04464759|EXPERIMENTAL|Phase 2: Nivolumab and Hydroxychloroquine (HCQ)|"HCQ 400-600 mg (maximum tolerated dose from Phase 1a) orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
62134242|NCT04464759|EXPERIMENTAL|Phase 1b: Nivolumab + Ipilimumab +Hydroxychloroquine (HCQ)|"HCQ 400-600 mg orally every 12 hours and nivolumab 3 mg/kg IV plus ipilimumab 1 mg/kg IV every 3 weeks x4 cycles~Then 6 weeks after the last dose of ipilimumab/nivolumab begin maintenance nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
61934786|NCT05237297|ACTIVE_COMPARATOR|ilaprazole & celecoxib|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : celecoxib 200mg/cap, twice a day, 4 days and celecoxib 200mg/cap, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + celecoxib 200mg/cab, twice a day, 5 days"
61934787|NCT02493387|EXPERIMENTAL|Exercise group|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the RPE 6-20 scale
61934788|NCT02493387|ACTIVE_COMPARATOR|PAP group|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
62134243|NCT00824642|EXPERIMENTAL|Group 1|Applied Acu-TENS prior to exercise
62134244|NCT00824642|EXPERIMENTAL|Group 2|Applied Acu-TENS prior to and during exercise
62328275|NCT00483249|EXPERIMENTAL|Interventional|Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).
62328276|NCT05873101|OTHER|Mobilization With Movement (MWM)|
62328277|NCT05873101|EXPERIMENTAL|Kelternborn Treatment Technique|
62328278|NCT00668434|EXPERIMENTAL|Prednisone|Participants will receive a 15-day tapering course of prednisone capsules.
62328279|NCT00668434|PLACEBO_COMPARATOR|Placebo|Participants will receive a 15-day course of placebo capsules.
62328280|NCT01123278|EXPERIMENTAL|Testosterone gel|Testosterone transdermal gel 50 mg/day
62328281|NCT01123278|PLACEBO_COMPARATOR|Placebo gel|Placebo gel
62328282|NCT03088293|EXPERIMENTAL|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
62328283|NCT03088293|EXPERIMENTAL|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
62328284|NCT02433288|OTHER|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
62328285|NCT02433288|OTHER|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
62328286|NCT03557398|EXPERIMENTAL|Hydeal-D vaginal pessaries|Vaginal application of Hydeal-D vaginal pessaries
62328287|NCT00906607||Group I|10-18 years
62328288|NCT00906607||Group II|20-35 years
62328289|NCT00906607||Group III|45-60 years
62328290|NCT00906607||Group IV|65-75 years
62328291|NCT01231633|EXPERIMENTAL|Group 1|Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
62328292|NCT01231633|ACTIVE_COMPARATOR|Group 2|Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
61934789|NCT04765111|EXPERIMENTAL|Treatment (acalabrutinib, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 3-4 hours on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2-12, 14, 18, 20, 22, and 24. Cycles repeats every 28 days for up to 24 months or until complete remission is achieved in the absence of disease progression or unacceptable toxicity.
61934790|NCT06710665||Good responders|Good responders (TRG 0-1). The pathologic report of the patient after neoadjuvant combined surgery
62328293|NCT03914287|EXPERIMENTAL|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
62328294|NCT03914287|NO_INTERVENTION|Control|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
62328295|NCT02634879|NO_INTERVENTION|Control|Control Group
61934791|NCT06710665||Poor responders|Poor responders (TRG 2-3). The pathologic report of the patient after neoadjuvant combined surgery
62134245|NCT00824642|PLACEBO_COMPARATOR|Group 3|Applied placebo TENS prior to exercise
62134246|NCT04124185||Patients with Achromatopsia|
62134247|NCT01777516||healthy volunteers|1 group with no treatment : They provide the blank plasma to be used at in vitro study.
62328296|NCT02634879|ACTIVE_COMPARATOR|Loss Aversion|Each physician in this arm will have access to funds prior to earning them.
62328297|NCT02634879|ACTIVE_COMPARATOR|Group Incentive|Each physician will receive 50% of their potential incentive based on group performance. Physicians will also receive information on the performance of physicians on key CI measures in their group.
62328298|NCT02588274|EXPERIMENTAL|Acupuncture|Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) acupuncture points (Table 1). After patients are in prone position with relax, the investigators will use 75% alcohol pads to sterile the skin around the acupuncture points, and then insert steel needles (Huatuo, Suzhou, China 0.3mm\*40mm/0.3mm\*75mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted into about 50-60mm with 45 degree, for Huiyang (BL 35), the needle will be inserted into 50-60mm. for Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25-30 mm. The treatment sessions are 24 after baseline, 3 times a week, and the each time the patients will accept a 30 minutes treatment.
62693278|NCT06641206|ACTIVE_COMPARATOR|Group 2|A group of Patients from Tanta University suffering from Chronic painful knee osteoarthritis who didn't receive medical treatment and progressed to have chronic pain with decreased physical function and poorer quality of life.
62693279|NCT04802590|EXPERIMENTAL|Arm A|Ibrutinib (+ CD20Ab)
62693280|NCT04802590|EXPERIMENTAL|Arm B|Ibrutinib + Venetoclax (+CD20Ab)
62693281|NCT06636799|EXPERIMENTAL|Microneedling only|In this procedure, only the derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used.
62693282|NCT06636799|ACTIVE_COMPARATOR|Microneedling associated with actives|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles associated with active ingredients were used.
62693283|NCT06636799|NO_INTERVENTION|Control|This group did not receive intervention but participated in pre- and post-protocol assessments.
62693284|NCT04526925|ACTIVE_COMPARATOR|standard CPET|Standard CPET will be performed without in-line filter
62693285|NCT04526925|EXPERIMENTAL|standard CPET with in-line filter|An in-line filter will be placed on the mouthpiece during standard CPET
62693286|NCT02087852||kidney cancer patients receiving care at MSKCC|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
62328299|NCT02588274|PLACEBO_COMPARATOR|placebo needle|The participants in placebo needle group will receive placebo needle at the same acupuncture points to treatment group. Investigators will use a sort of blunt needle that cannot penetrate skin and stimulate deep tissues while the thrusting and twisting manipulation will be used by acupuncturists to mock the treatment procedure and blind the patients. The duration and frequency of sessions are same to the treatment group.
62328300|NCT01992445||Suicidal|
62328301|NCT01992445||Other mental health|
62328302|NCT01992445||Control (non suicidal, non mental health)|
62693287|NCT02087852||relatives of patients with kidney cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
62693288|NCT02087852||healthy controls who are unrelated & do not have hx of cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
62693289|NCT02087852||high risk|Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation
62693290|NCT06641219|EXPERIMENTAL|Prostate cancer|One single intravenous injection of \[177Lu\]Lu-BQ7876
61934792|NCT00608972|EXPERIMENTAL|Doxil, Carboplatin and Bevacizumab|
62134248|NCT05262738|EXPERIMENTAL|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects in this arm will be randomized to the 50 micrograms of vaginal misoprostol (intervention) group, they will be admitted to labor and delivery and undergo placement of 50 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
62134249|NCT05262738|ACTIVE_COMPARATOR|25 Micrograms Vaginal Misoprostol (Control)|Subjects in this arm will be randomized to the 25 micrograms of vaginal misoprostol (control) group, they will be admitted to labor and delivery and undergo placement of 25 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
62134250|NCT02883660||Cases|"patients who had empirically defined increased AEs on one of the specified antidepressants (SSRIs/ SNRIs). This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
62134251|NCT02883660||Controls|"patients who did not have empirically defined increased AEs with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were nonresponders to that antidepressant. This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
62134252|NCT05621278||Children|Grade 4 to 6 students (aged 9-12) in primary school.
62134253|NCT05621278||Adolescent|Grade 7 to 12 students (aged 12-18) in middle school and high school.
62134254|NCT05621278||Students' teachers|School Teachers
62134255|NCT05621278||Students' parents|Parents of students mentioned above.
62134256|NCT01536834|EXPERIMENTAL|Medical Device|The Investigational device is a liquid in a delivery system for the treatment of verrucas
62134257|NCT01615770|NO_INTERVENTION|Open Label CBT and Pharmacotherapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label, this group received general supportive therapy delivered via four telephone calls made to participants over a 12-week period.
62134258|NCT01615770|EXPERIMENTAL|Behavioral: cognitive behavior therapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label treatment, half the participants received an additional 12 weeks of CBT that combined clinic-based skills training sessions, voicemail monitoring and telephone counseling
62134259|NCT05343715|EXPERIMENTAL|Agalsidase Beta from Biosidus|Participants received a single infusion at a dose 1 mg/kg
62328303|NCT04152005||Control|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
62328304|NCT04152005||Periodontitis|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
62134260|NCT05343715|ACTIVE_COMPARATOR|Fabrazyme (Sanofi-Genzyme)|Participants received a single infusion at a dose 1 mg/kg
62328305|NCT04152005||Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
62328306|NCT04152005||Periodontitis+Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
62328307|NCT01641835||Normals|No eye disease.
62693291|NCT05580406|NO_INTERVENTION|Usual Care|Participants assigned to usual care will not receive outreach messages (online or via telephone) by study staff.
62693292|NCT05580406|EXPERIMENTAL|Outreach Messaging|Participants in the outreach messaging arm will receive messages via online secure message system (embedded within the health care record) and/or telephone.
62134261|NCT03103048|ACTIVE_COMPARATOR|Group 1|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages (start); 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage.
62134262|NCT03103048|PLACEBO_COMPARATOR|Group 2|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo (start); 3 - With bandage; 4 - With tensioned bandage.
62134263|NCT03103048|ACTIVE_COMPARATOR|Group 3|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage (start); 4 - With tensioned bandage.
62134264|NCT03103048|ACTIVE_COMPARATOR|Group 4|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage (start).
62134265|NCT05055752|OTHER|PL-ASA capsule, then IR-ASA tablet|One PL-ASA 325 mg capsule, 14 day washout then one IR-ASA 325 mg tablet
62134266|NCT05055752|OTHER|IR-ASA tablet, then PL-ASA capsule|One IR-ASA 325 mg tablet, 14 day washout, then one PL-ASA 325 mg capsule,
62328308|NCT05429723|EXPERIMENTAL|HS-10383|HS-10383 was administered at 8 am on the first day, 4 dose levels
62328309|NCT05429723|PLACEBO_COMPARATOR|HS-10383 Placebo|Matching placebo to HS-10383 was administered at 8 am on the first day, 4 dose levels
62328310|NCT02756715|ACTIVE_COMPARATOR|propofol group|The patient who anesthetized by using propofol.
62328311|NCT02756715|ACTIVE_COMPARATOR|Desflurane group|The patient who anesthetized by using sevoflurane.
62134267|NCT02134106|ACTIVE_COMPARATOR|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000 Units (U)/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 million units (MU) 8 hourly for 5 days will be prescribed.
62134268|NCT02134106|EXPERIMENTAL|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
62134269|NCT03093428|EXPERIMENTAL|Pembrolizumab Plus Radium-223|"* Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose~* Pembrolizumab will be administered intravenously every 3 weeks at a pre-determined dose~Radium-223 will be halted after 3 doses. Once radiographic progressive disease occurs, the last 3 doses of radium will be given."
62134270|NCT03093428|EXPERIMENTAL|Radium-223|- Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
62134271|NCT03516942||Observational (questionnaire)|Patients complete questionnaires over 20-60 minutes at baseline and at 3, 6, 12, and 24 months after cancer diagnosis.
62134272|NCT01343459|EXPERIMENTAL|IOERT followed by hypofractionated WBRT|HIOB: IOERT of 11.1 Gy followed by WBRT with 15 times 2.7 Gy per fraction.
62134273|NCT02627391|EXPERIMENTAL|Early surgery|Surgical aortic valve replacement
62134274|NCT02627391|ACTIVE_COMPARATOR|Delayed surgery according to guidelines|Surgical aortic valve replacement
62134275|NCT00582972|EXPERIMENTAL|Experimental|Subjects will receive omeprazole 40 mg daily for 30 days
62134276|NCT05867927||da Vinci Patients|Consecutive enrollment of patients with indications of interest and having a da Vinci robotic-assisted surgery
62134277|NCT05867927||Epidemiological Data Audit|Extended data collection on patients with indications of interest, eligible for a robotic-assisted surgery, but treatment choice was not a da Vinci surgery
62134278|NCT01701401|EXPERIMENTAL|LDV/SOF 12 weeks|LDV/SOF administered for 12 weeks
62134279|NCT01701401|EXPERIMENTAL|LDV/SOF+RBV 12 weeks|LDV/SOF+RBV administered for 12 weeks.
62134280|NCT01701401|EXPERIMENTAL|LDV/SOF 24 weeks|LDV/SOF administered for 24 weeks
62328312|NCT05874401|EXPERIMENTAL|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m²|"Patients randomized 1:1 to trilaciclib. Patients receive trilaciclib (240 mg/m²) administered once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients receive topotecan (1.5 mg/m²)"
62328313|NCT05874401|PLACEBO_COMPARATOR|Placebo + Topotecan 1.5 mg/m²|"Patients are randomized 1:1 to placebo. Patients receive placebo administered once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of placebo on Days 1 to 5, patients receive topotecan (1.5 mg/m²)."
62328314|NCT03796156|EXPERIMENTAL|Aspirin|75mg of non enteric coated or dispersible aspirin once daily added to usual medications
62328315|NCT03796156|NO_INTERVENTION|Usual care|Usual medications only
62328316|NCT04109625|EXPERIMENTAL|Non-immunized Hepatitis B|subjects non-immunized against hepatitis B (naive)
62328317|NCT04109625|EXPERIMENTAL|Vaccine Hepatitis B|subjects vaccinated against hepatitis B
62328318|NCT04109625|EXPERIMENTAL|Ongoing, Old or cured Hepatitis B|subjects with hepatitis B (old or cured)
62328319|NCT01576016|EXPERIMENTAL|Lead Safety|Patient implanted with an Accent MRI system to evaluate safety of the Tendril MRI lead
62328320|NCT01576016|EXPERIMENTAL|Accent MRI system MRI Scan Group|Patient implanted with an Accent MRI system will receive an MRI scan to evaluate safety and efficacy of the Accent MRI system in an MRI environment
62328321|NCT05515601|EXPERIMENTAL|Mirikizumab (Reference)|200 milligram (mg) of mirikizumab as reference formulation \[100 mg/milliliter (mL)\], 2 × 1-mL autoinjector administered as a subcutaneous (SC) injection into the arm/thigh/abdomen on day 1.
62328322|NCT05515601|EXPERIMENTAL|Mirikizumab (Test)|200 mg of mirikizumab as test formulation (100 mg/mL), 2 × 1-mL autoinjector administered as a SC injection into the arm/thigh/abdomen on day 1.
62328323|NCT05483816|EXPERIMENTAL|Virtual Reality and Transcutaneous Electrical Nerve Stimulation|"for healthy subjects: painful stimulus induction (electrical stimulation) for patients: focus/non focus on pain~Therapy is released in presence of pain"
62328324|NCT05483816|ACTIVE_COMPARATOR|Virtual Reality only|only VR delivers therapy
62134281|NCT01701401|EXPERIMENTAL|LDV/SOF+RBV 24 weeks|LDV/SOF+RBV administered for 24 weeks.
62134282|NCT04852315|EXPERIMENTAL|Caffeine supplementation|Acute caffeine supplementation
62486377|NCT05159921|NO_INTERVENTION|Standard Consent|Standard consent procedure: The rationale, risks, benefits, and alternatives for the intended procedure (diagnostic or screening OGD or colonoscopy) will be discussed in the outpatient clinic by a consultant general surgeon (DOK) or members of the surgical team. Patients will be given the opportunity to ask questions. All patients will receive a written information leaflet, which includes contact details for the endoscopy department should patients wish to ask further questions (supplemental data). Those undergoing colonoscopy will receive further instructions along with prescribed colonoscopy 'prep' medication by post. On the day of the procedure, patients are required to sign a standardised consent form.
62693293|NCT04605146|EXPERIMENTAL|Tele-monitoring group|"In the experimental group, in addition to routine practice, each patient will benefit of a tele-monitoring of one year, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.~50 patients are expected in this arm."
61934793|NCT04645888|ACTIVE_COMPARATOR|Articaine|"All surgeries were performed by the same surgeon and monitored by the same person. 4 % articaine with 1:200.000 epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
62134283|NCT04852315|PLACEBO_COMPARATOR|Placebo supplementation|Acute placebo supplementation
62134284|NCT02788695||Group 1 - aged 20-90 years|25 participants from each decade from 20-90. Those from 50+ will be recruited from the NICOLA study and retinal/lens images assessed to confirm normality.
62328325|NCT01343134||Retinal detachment cohort|
62328326|NCT04409795|OTHER|HLA+ Group|Participants who are high-risk HLA-DR3 and/or DR4 (+); monogenic variant (+) with rare exome variant ensemble learner (REVEL) score\>0.75; and both glutamic acid decarboxylase (GAD65) and islet antigen (IA2) autoantibody (-)
62328327|NCT04409795|OTHER|HLA- Group|Participants who are high-risk HLA-DR3 and DR4 (-); with known or yet unknown monogenic variants with REVEL score\>0.75; and either GAD65 and IA2 autoantibody (-), or autoantibody (+) with titers close to the cutoff
62328328|NCT05158205|EXPERIMENTAL|Yoga postures or slow, deep breathing|
62328329|NCT05158205|SHAM_COMPARATOR|Control|
62328330|NCT01366911||Stem cell & quanitative computed tomography QCT testing|"The association between bone mineral denity adjacent to acetabular implants, as measured by quanitative computed tomography (QCT), at least 2 years post Total Hip Arthoplasty (THA) surgery and mesechymal stem cell assays, obtained at time of surgery, will evaluate if stem cells can predict orthopaedic surgical outcomes.~Detailed Description:~Subjects who have undergone a THA and who previously consented to Stem Cell Quality Assays: Correlation with Aging/Health study which used excess bone marrow and blood samples to complete stem cell assay labs will be invited back at least 2 years post THA to complete bilateral hip x-rays, if not already completed as part of routine medical follow up plus a QCT bone density testing and to complete a questionnaire regarding smoking, alcohol and exercise history along with recording BMIs."
62134285|NCT02788695||Group 2: aged 60 years|Group 2: 250 participants NICOLA participants aged 60 will be invited to participate; only those whose ocular images confirm normality will be included.
62134286|NCT01672060|EXPERIMENTAL|Nurse-Family Partnership (NFP)|
62134287|NCT01672060|ACTIVE_COMPARATOR|Existing services|
62134288|NCT03657693||BPD|Infants born premature requiring oxygen
62134289|NCT03657693||Controls|
62134290|NCT05889299|EXPERIMENTAL|OMS906 study drug|OMS906 study drug repeat-dose 5 mg/kg SC administration at 4-week intervals
62134291|NCT03539952|ACTIVE_COMPARATOR|Penicillamine arm|Patients randomized to penicillamine during the postrandomisation and 1st extension period
62134292|NCT03539952|EXPERIMENTAL|Trientine arm|Patients randomized to TETA 4HCl during the postrandomisation and 1st extension period
62134293|NCT03417479||1:1 Randomization|Patients will be randomized to either a single dose of 15mg/kg up to 600 mg of gabapentin or a placebo equivalent at a 1:1 ratio. The subjects will be enrolled in the study at the orthopedic surgeon's office with randomization occurring on the day of surgery by the hospital pharmacist. The method for the randomization will be the creation of a sequence of sealed envelopes containing assignment information for a dose of 600 mg of gabapentin or placebo.
62134294|NCT01354444|ACTIVE_COMPARATOR|Carvedilol|Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.
62134295|NCT01354444|PLACEBO_COMPARATOR|Placebo|Non active substance
62328331|NCT03156556|EXPERIMENTAL|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.~* Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.~* Lesson 2 presents different strategies to generate helpful cognitions.~* Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~* Lesson 4 describes avoidance and safety behaviors and graded exposure.~* Lesson 5 is about problem solving and relapse prevention.~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
62328332|NCT03165136|EXPERIMENTAL|Hydroxychloroquine|The treatment will be orally administrated, at a daily dose of 400 mg of hydroxychloroquine . The treatment will be started before conception and will be stopped at the end of the tenth week of gestation or before in case of pregnancy loss.
62693294|NCT04605146|NO_INTERVENTION|Control group|"In the control group, patients will have a routine follow-up as per institutional practice, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.~50 patients are expected in this arm."
62134296|NCT03952871||Intensive care patient with hemodynamic instability|The study group is composed of intensive care patients which already need an invasive monitoring of the cardiac output because of a shock state.
62134297|NCT01297894|ACTIVE_COMPARATOR|colistin|Colistimethate sodium 2.5-5mg/kg iv
62134298|NCT01297894|ACTIVE_COMPARATOR|colistin plus fosfomycin|colistimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
62134299|NCT05879705|EXPERIMENTAL|An OT-ParentShip intervention|Each family will participate in a series of 11 individual weekly sessions of 90 minutes each and another session after three months from the end of the intervention.
62486378|NCT05159921|EXPERIMENTAL|Standard consent + access to an automated conversational agent (SurgInfoBot)|Patients in the SurgInfoBot arm will be consented as above, but will also be granted access to the SurgInfoBot, which they will be invited to use between their outpatient appointment and their endoscopy procedure date. Participants will be provided with an access link and Unique Study Identifier in order to pseudonymise participant data. Participants will be able to access the SurgInfoBot as many times as they wish, and can ask any questions they see fit.
62486379|NCT02226250|EXPERIMENTAL|3 Placebo Beverages|Sugar beverage 2 hr before meal and with meal and 2 hr after meal
62486380|NCT05600699||left bundle branch potential group|the left bundle branch potential was recorded at implantation
62486381|NCT05600699||Purkinje potential group|the purkinje potential was recorded at implantation
62486382|NCT05600699||no-potential group|no potential was recorded at implantation
62486383|NCT03659565|EXPERIMENTAL|Enhanced Pre-Visit Consultation|Patients and caregivers will participate in an enhanced pre-visit consultation using Zoom for remote video and audio conferencing with screen sharing capabilities.
62486384|NCT03659565|ACTIVE_COMPARATOR|Usual Care Control|Patients continue to receive usual care from their cardiologist.
62486385|NCT05490563|EXPERIMENTAL|SLS-005 0.75 g/kg Dose|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week.~For 52 weeks"
62486386|NCT05490563|EXPERIMENTAL|SLS-005 0.50 g/kg Dose|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.50 g/kg by IV infusion once a week.~For 52 weeks"
62486387|NCT05490563|PLACEBO_COMPARATOR|Placebo volume equivalent to a SLS-005 0.75 g/kg dose calculation|"Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.75 g/kg dose.~For 52 weeks"
62486388|NCT05490563|PLACEBO_COMPARATOR|Placebo volume equivalent to a SLS-005 0.50 g/kg dose calculation|"Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.50 g/kg dose.~For 52 weeks"
61934794|NCT04645888|ACTIVE_COMPARATOR|Bupivacaine|"All surgeries were performed by the same surgeon and monitored by the same person. % 0.5 bupivacaine without epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
62486389|NCT00200785|ACTIVE_COMPARATOR|Garlic powder in ambient water|high allicin
62486390|NCT00200785|EXPERIMENTAL|garlic powder in boiling water|no allicin
62486391|NCT05968638|PLACEBO_COMPARATOR|Regular Diet|
62486392|NCT05968638|ACTIVE_COMPARATOR|Ketogenic Diet|
62328333|NCT03165136|PLACEBO_COMPARATOR|Placebo|A similar placebo will be orally administrated every day.
62328334|NCT02801097|EXPERIMENTAL|RRx-001 + Irinotecan|Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.
62328335|NCT02151123||Diagnosed colon cancer patients|Patients undergoing colectomy for colonic adenocarcinoma.
62328336|NCT01955343||Lung cancer|Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
62486393|NCT04125407|EXPERIMENTAL|Interventional|"Experimental group will receive one customized pair of sensorimotor foot orthoses (insoles).~Intervention: Other: Sensorimotor foot orthoses with any other supplementary treatment."
62486394|NCT04125407|NO_INTERVENTION|Control|Control group will receive neither orthotic nor other supplementary intervention.
62486395|NCT05238428|NO_INTERVENTION|Control sender + control content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486396|NCT05238428|EXPERIMENTAL|Control sender + Low trust boost content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486397|NCT05238428|EXPERIMENTAL|Control sender + Medium trust boost content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62328337|NCT01955343||Control|Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
62328338|NCT05236673||Patients who have started at first time on Jardiance®|
62328339|NCT04446936||Propeller flaps|Patients who undergone propeller flap surgery
62328340|NCT04446936||Random flaps|Patients who undergone random flap surgery
62328341|NCT04420455|EXPERIMENTAL|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
62328342|NCT00431847||Group 1|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
62328343|NCT00431847||Group 2|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.
62328344|NCT03523832|ACTIVE_COMPARATOR|Group 1|celecoxib 400mg and pregabaline 150mg 1 hour before operation
62328345|NCT03523832|ACTIVE_COMPARATOR|Group 2|celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation
62328346|NCT03523832|PLACEBO_COMPARATOR|Group 3|No treatment given
62693295|NCT03709472|EXPERIMENTAL|Computer Assisted CIFFTA|CA CIFFTA (Computer Assisted Culturally Informed and Flexible Family Based Treatment for Adolescents) consists of a hybrid intervention utilizing office-based CIFFTA and technology-delivered material. Over 16 weeks CIFFTA participants receive 45 minutes of face-to-face sessions plus approximately 45 minutes of web-based intervention per week. During the continuing care phase participants access website resources and receive targeted messages (e.g., handling family conflicts). CA CIFFTA will: 1) deliver psycho-educational modules (e.g., depression, emotion regulation), 2) collect diary-card information, and 3) provide additional resources. During videos parents and adolescents can report symptoms and information that is automatically transmitted to therapists and used in the next session
61934795|NCT02185846|ACTIVE_COMPARATOR|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
61934796|NCT02185846|EXPERIMENTAL|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.Ve Tic. A. Ş., Turkey, one tablet, once
61934797|NCT02378675||Healthy (1)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
61934798|NCT02378675||GDM (2)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
61934799|NCT04535765|EXPERIMENTAL|experimental group|The experimental group began to perform warm water sitz bath 6 hours after the operation (the day of the operation).Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
62328347|NCT02177851|EXPERIMENTAL|Single oral iron supplement per day (120 mg)|Single oral iron dose of 120 mg per day for 3 consecutive days
61934800|NCT04535765|OTHER|control group|The control group began to perform warm water sitz bath at 8:00 in the morning on the first day after the operation as usual.Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
61934801|NCT04335838||Polytrauma Patients|Patients with an ISS \>16 points, an AIS \>3 in one body region and at least 2 different body regions affected were included.
61934802|NCT00526604|ACTIVE_COMPARATOR|2|The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.
61934803|NCT02857582|ACTIVE_COMPARATOR|Vancomycin|Secondary treatment for relapse of Clostridium difficile infection.
61934804|NCT02857582|EXPERIMENTAL|Cultured human intestinal microbiota1|Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.
61934805|NCT02857582|EXPERIMENTAL|Cultured human intestinal microbiota2|Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.
61934806|NCT05825755|NO_INTERVENTION|Usual care (UC)|"The follow-up of the patients in the UC arm will be carried out in accordance with the usual clinical practice of each recruitment center. All recruiting centers have active and mature HF programs in place and therefore each center will decide how to follow up the patient. However, medical professionals will be required to register each patient on the platform, enter their baseline data (sociodemographics and risk factors) and enter all possible clinical events (death, non-fatal HF event, hospitalization or emergency room visit). that the patient could suffer during the entire follow-up period.~The number of pre-planned contacts will be defined according to the particular clinical practice of each recruitment center."
61934807|NCT05825755|EXPERIMENTAL|Telemonitoring (TM)|Patients in the TM arm will be followed up with the vitalera platform and app. Physiological parameters (measured periodically), socio-demographic data, risk factors, medication tracking, symptomatology questionnaire for patients, NYHA-class, clinical interventions, health questionnaire answers, classified alarms with their respective timestamp and annotation by the MD, and measurement ranges for each personalized alarm and their changes.
61934808|NCT06707168|OTHER|Surgeon #1|One by digital palpation over the limbal area; and the other using a short wooden cotton-tipped applicator (CTA) over the limbal area.
61934809|NCT06707168|OTHER|Surgeon #2|One by digital palpation over the limbal area; and the other using a short wooden cotton-tipped applicator (CTA) over the limbal area.
62134300|NCT05879705|OTHER|A psycho-educational intervention group.|Each family will receive a general, psycho-educational, video-based intervention. The program includes 6 videos with an average length of 20 minutes each.The participants are asked to watch the video according to the order once every two weeks.
62134301|NCT03830567||Pharmacist prescription|
62134302|NCT03830567||Clinician prescription|
62134303|NCT00862706|EXPERIMENTAL|A|
62134304|NCT00979121|ACTIVE_COMPARATOR|Rosuvastatin|"Half of the subjects were randomized to the active drug (Rosuvastatin).~Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.~Duration: drug was administered daily until:~1. 28 days after randomization or 3 days after ICU discharge (whichever comes first),~2. Discharge from study hospital,~3. Death"
62328348|NCT02177851|ACTIVE_COMPARATOR|B.i.d. oral iron supplement (2x 60 mg)|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
62328349|NCT02267863|EXPERIMENTAL|Dose Escalation and Expansion|APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.
62328350|NCT00870948|EXPERIMENTAL|Regimen A|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
62328351|NCT00870948|EXPERIMENTAL|Regimen B|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein
62134305|NCT00979121|PLACEBO_COMPARATOR|Placebo|"Half of the subjects were randomized to placebo.~10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug."
62134306|NCT03208881||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
62486398|NCT05238428|EXPERIMENTAL|Control sender+ high trust boost content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486399|NCT05238428|EXPERIMENTAL|Low trust boost Sender + control content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62328352|NCT00870948|EXPERIMENTAL|Regimen C|One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
62486400|NCT05238428|EXPERIMENTAL|Low trust boost Sender + low trust boost content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486401|NCT05238428|EXPERIMENTAL|Low trust boost Sender + medium trust boost content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486402|NCT05238428|EXPERIMENTAL|Low trust boost sender + high trust boost content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486403|NCT05238428|EXPERIMENTAL|Medium trust boost Sender + control content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486404|NCT05238428|EXPERIMENTAL|Medium trust boost sender + low trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62693296|NCT03709472|ACTIVE_COMPARATOR|Behavioral: Traditional face-to-face treatment-no technology|Participants randomized to Treatment-As-Usual (TAU) work over a 16-week period with their community agency. They may receive individual or family treatment. The team coordinates with the TAU agencies to minimize the overlap of data collected. The team will refer out to service locations that are most convenient for the participant. A great deal of thought has gone into the selection of the Treatment as Usual condition. The investigators wanted to compare CA CIFFTA's ability to retain and bring about change in participants with what is typically done in the community. Although running an in-house comparison condition gives more control of the delivery of services and tracking of clients, it is difficult to know how that compared to the services that are typically provided in the community
62693297|NCT04775108|EXPERIMENTAL|Implanted patients|Implantation of Epygon mitral valve prosthesis
62693298|NCT06439706|ACTIVE_COMPARATOR|Mailed Kit Only Control|Participants receive an HPV self-sampling kit in the mail with instructions on how to self-collect a sample and return it to the lab for testing.
61934810|NCT06350773|ACTIVE_COMPARATOR|tadalafil-receiving arm|Patients will take tadalafil for the 12 week period of follow up, in addition to the standard evidence-based therapy for the left heart disease.
61934811|NCT06350773|NO_INTERVENTION|Tadalafil non-receiving arm|Patients will not take tadalafil for the 12 weeks follow up, only standard evidence-based therapy for the left heart disease.
62328353|NCT00870948|EXPERIMENTAL|Regimen D|One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
62328354|NCT00870948|EXPERIMENTAL|Regimen E|700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein
61934812|NCT04637113||All patients admitted to the PICU meeting eligible criteria|This is a non-interventional study.
61934813|NCT03589781|EXPERIMENTAL|Mikei Red Reishi Essence EX|There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).
62328355|NCT01434472|EXPERIMENTAL|Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)|Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).
62486405|NCT05238428|EXPERIMENTAL|Medium trust boost sender + Medium trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62486406|NCT05238428|EXPERIMENTAL|Medium trust boost Sender+ high trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
62693299|NCT06439706|EXPERIMENTAL|Education Plus Mailed Kit|Participants receive information about cervical cancer risks and screening guidelines in a small-group format with a bilingual health educator. Participants also receive an HPV self-sampling kit in the mail with instructions on how to self-collect a sample and return it to the lab for testing.
61934814|NCT03589781|PLACEBO_COMPARATOR|Placebo|Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.
61934815|NCT06604520|EXPERIMENTAL|Patient Treatment Arm (Vortioxetine)|Individuals with bvFTD and mood symptoms receiving the study drug, vortioxetine.
62328356|NCT02223221|EXPERIMENTAL|With PGS|"IVF/ICSI cycles with PGS. Select embryos by SNP-array based PGS for the number of all chromosomes on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
62328357|NCT02223221|ACTIVE_COMPARATOR|Without PGS|"IVF/ICSI cycles without PGS. Selection of embryos are based on blastocyst morphology criteria on day 5.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
62328358|NCT02920684|ACTIVE_COMPARATOR|Passive legs mobilisation|A physiotherapist performs passive legs movement
62328359|NCT02920684|ACTIVE_COMPARATOR|Passive cycloergometer|A motorized cycloergometer performs passive legs cycling
62328360|NCT02920684|ACTIVE_COMPARATOR|Muscular electrical stimulation|Quadriceps neuromuscular electrical stimulation
62328361|NCT02920684|ACTIVE_COMPARATOR|FES cycling|A motorised cycloergometer performs a quadriceps neuromuscular electrical stimulation during passive
62328362|NCT00746031|ACTIVE_COMPARATOR|1|GnRH analogue-Zoladex
62328363|NCT00746031|ACTIVE_COMPARATOR|2|GnRH antagonist plus GnRH analogue
62693300|NCT06267768||Stroke participants|People diagnosed with stroke and meeting all inclusion criteria will be included in this study.
62693301|NCT06267768||Healthy participants|Healthy adults meeting all inclusion criteria will be included in this study.
62693302|NCT02788292|EXPERIMENTAL|Acetylcysteine (NAC)|NAC added to tumescent solution for liposuction and eventual fat grafting.
61934816|NCT05360368|EXPERIMENTAL|HLX07|"This study uses the 3+3 design to investigate the safety and determine the MTD of HLX07. Four dose levels of 800 mg, 1200 mg, 1500 mg and 1800 mg are planned for dose finding. Enrollment will continue until a maximum of 24 patients are enrolled."
62134307|NCT04678375||Retinal diseases diagnosed by artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
62134308|NCT04977700|EXPERIMENTAL|Intervention Group|Participants will be enrolled on a rolling basis and participate in SS for 4 weeks in the intervention condition. After pretesting, participants will receive sun protection messages from SS through emails/comments based on results from their activity data. All participants will complete posttest survey 4 weeks from randomization.
62134309|NCT04977700|NO_INTERVENTION|Control Group|A small control group will be included to see if a no-treatment control condition is acceptable to users and estimate follow-up rates for planning a randomized trial. Participants will be enrolled on a rolling basis and will complete a pretest at randomization. All participants will complete a posttest survey 4 weeks from randomization.
61934817|NCT01172210||Bulimia Nervosa|
62328364|NCT00746031|NO_INTERVENTION|3|
62328365|NCT03851276|OTHER|Patients with 3-vessels diseased referred to CABG surgery|Patients with 3-vessel disease (with or without left main involvement) for which the regular and conventional Heart Team has made already the decision to refer the patient for CABG treatment.
62328366|NCT00088634|EXPERIMENTAL|Lurasidone|80 mg AM dosing once daily
62328367|NCT00088634|PLACEBO_COMPARATOR|Placebo|
62328368|NCT05368285|EXPERIMENTAL|barzolvolimab 75 mg then 150 mg|barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks
62328369|NCT05368285|EXPERIMENTAL|barzolvolimab 75 mg then 300 mg|barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks
62328370|NCT05368285|EXPERIMENTAL|barzolvolimab 150 mg|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks
62328371|NCT05368285|EXPERIMENTAL|barzolvolimab 300 mg|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks
62328372|NCT05368285|EXPERIMENTAL|Placebo then barzolvolimab 150 mg|Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks
62328373|NCT05368285|EXPERIMENTAL|Placebo then barzolvolimab 300 mg|Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks
61934818|NCT01172210||Bulimia Nervosa w/ Alcohol Use Disorder|
61934819|NCT01172210||Healthy Controls|
61934820|NCT00716131||ALS|Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
62134310|NCT01962090|EXPERIMENTAL|Thoracic Spine Thrust in Seated Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in a seated position.
62693303|NCT02788292|NO_INTERVENTION|Control|Just tumescent solution for liposuction and fat grafting.
62134311|NCT01962090|EXPERIMENTAL|Thoracic Spine Thrust in Supine Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in the supine position.
62134312|NCT03707236|EXPERIMENTAL|Treatment arm|Patients in the treatment arm will have monthly office visits for weeks 0-4 and then have monthly teledermatology visits during weeks 8-20 with a final office visit at week 24. Standardized baseline photographs including 3 facial images (front, left, and right) as well as 2 truncal images of the chest and back (if affected) will be taken in the office at treatment week 0 and 24 for all patients. All patients will be required to take photos in front of a white wall to facilitate blinding.
62134313|NCT03707236|NO_INTERVENTION|Control arm|Patients in the control arm will have the same series of photographs taken at each monthly visit. These patients will also be required to fill out a monthly survey assessing acne severity, quality of life, cost of attending appointment, time missed from school/work, satisfaction with treatment (only to be reviewed by study staff) and will be screened for adverse events by their provider. Every patient will be counseled about isotretinoin and contraception (if applicable) by their provider in order to adhere with iPledge requirements. All photographs will be uploaded into the patient's medical record. The physician will be required to document a progress note in the electronic medical record after each visit as per standard hospital protocol.
62134314|NCT02530190|NO_INTERVENTION|Control|20 minutes of supine rest
62134315|NCT02530190|ACTIVE_COMPARATOR|Intermittent pneumatic compression|20 minutes of intermittent pneumatic compression
62134316|NCT02530190|ACTIVE_COMPARATOR|Massage|20 minutes of massage therapy
62693304|NCT06502028|EXPERIMENTAL|Video LMA|The airway is secured with a video laryngeal mask airway (VLMA).
62693305|NCT06502028|ACTIVE_COMPARATOR|Control|The participant is intubated with an endotracheal tube via direct laryngoscopy.
62693306|NCT06377748|EXPERIMENTAL|Facilitated tucking position|Newborns in this group will take the facilitated tucking position during routine Hepatitis B vaccine administration.
62134317|NCT05538494|EXPERIMENTAL|BFR group|Training is applied to this group using low-load exercises with restriction of blood flow.
62134318|NCT05538494|ACTIVE_COMPARATOR|High load group|A program will be applied to this group of exercise with high loads as a method of treatment
62134319|NCT06463977||1A 2B 3C|1. Intermediate; 1.A. Reference dependent; 2. Poor; 2.B. Absolute prognosis; 3. Good; 3.C. Both
62693307|NCT06377748|EXPERIMENTAL|ShotBlocker|ShotBlocker will be used during routine Hepatitis B vaccine administration of newborns in this group.
62693308|NCT06377748|EXPERIMENTAL|Combined facilitated tucking position and ShotBlocker|Neonates in this group will take facilitated tucking position during routine Hepatitis B vaccine administration and ShotBlocker will be used during the procedure.
62693309|NCT06377748|NO_INTERVENTION|Control|The control group will receive routine Hepatitis B vaccination.
62693310|NCT03633201|ACTIVE_COMPARATOR|Cruciate Retaining|
62693311|NCT03633201|ACTIVE_COMPARATOR|Medial Congruent|
62134320|NCT06463977||1A 2C 3B|1. Intermediate; 1.A. Reference dependent; 2. Poor; 2.C. Both; 3. Good; 3.B. Absolute prognosis
62134321|NCT06463977||1B 2A 3C|1. Intermediate; 1.B. Absolute; 2. Poor; 2.A. Reference dependent; 3. Good; 3.C. Both
61934821|NCT00716131||Neuro|Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
61934822|NCT00716131||Healthy|Normal Controls
61934823|NCT00716131||Autopsy|
61934824|NCT04508335|EXPERIMENTAL|Reia Vaginal Pessary|
62134322|NCT06463977||1B 2C 3A|1. Intermediate; 1.B. Absolute; 2. Poor; 2.C. Both; 3. Good; 3.A. Reference dependent
62134323|NCT06463977||1C 2A 3B|1. Intermediate; 1.C. Both; 2. Poor; 2.A. Reference dependent; 3. Good; 3.B. Absolute
62134324|NCT06463977||1C 2B 3A|1. Intermediate; 1.C. Both; 2. Poor; 2.B. Absolute; 3. Good; 3.A. Reference dependent
62134325|NCT01485406|EXPERIMENTAL|Pn Group|Toddlers 12-23 months of age receiving GSK2830930A vaccine.
62134326|NCT01485406|ACTIVE_COMPARATOR|Control Group|Toddlers 12-23 months of age receiving Synflorix.
62134327|NCT00409838|EXPERIMENTAL|Abatacept and Methotrexate|
62134328|NCT00409838|PLACEBO_COMPARATOR|Placebo and Methotrexate|(standard of care)
62134329|NCT00409838|EXPERIMENTAL|Abatacept - Open Label|Open-label extension phase
62328374|NCT02065947|ACTIVE_COMPARATOR|general anesthesia|fentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
62328375|NCT02065947|EXPERIMENTAL|paravertebral block|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
62134330|NCT02874534|EXPERIMENTAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
62328376|NCT05869851|EXPERIMENTAL|Brace Treatment|Patients randomized to the brace treatment group will be treated with a Pavlik harness for a minimum of six weeks.
62693312|NCT03633201|NO_INTERVENTION|Healthy Controls|
62693313|NCT06571617|ACTIVE_COMPARATOR|Mini PCNL (mini percutaneous nephrolithotomy)|Under general anesthesia, a 5/ 6 Fr ureteric catheter will be placed in the pelvicalyceal system. then the patient is turned to the prone position. A puncture will be done using an 18 G needle under fluoroscopy guidance. The tract will be dilated up to 15 F and then a sheath will be placed. A 12 F nephoscope (MIP-M, Karl Storz Endoscopy, Tuttlingen, Germany) will be used. Stone fragmentation will be performed using holmium YAG Laser energy. Then, Fragments will be evacuated using vacuum cleaner effect, tipless basket, or 5 FR stone forceps for stone analysis. A nephrostomy tube 12 Fr will be fixed at the end of the procedure.
62486407|NCT05238428|EXPERIMENTAL|High trust boost sender + control content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
62697548|NCT01991873|EXPERIMENTAL|Maintenance Chemotherapy w/o Panitumumab|"Maintenance therapy:~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
62134331|NCT02874534|ACTIVE_COMPARATOR|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
62134332|NCT04056702||Prescribed triple combination|A group of 60 people with CF who are clinically prescribed elexacaftor-tezacaftor-ivacaftor and have chronic sinusitis
62134333|NCT04056702||Not eligible for modulators|A group of 10 patients with two class I/II mutations who are ineligible for elexacaftor-tezacaftor-ivacaftor based on their genotype and have chronic sinusitis.
62328377|NCT05869851|NO_INTERVENTION|Active Monitoring|Patients randomized to the control group will undergo observation only.
62328378|NCT01073696|ACTIVE_COMPARATOR|granisetron IV|
62328379|NCT01073696|EXPERIMENTAL|granisetron patch|
62328380|NCT02013024|ACTIVE_COMPARATOR|cryopreservation technique|slow freezing cryopreservation technique
62328381|NCT02013024|ACTIVE_COMPARATOR|vitrification cryopreservation technique|vitrification cryopreservation technique
62328382|NCT06338553|PLACEBO_COMPARATOR|Participants receiving placebo|Participants receive a placebo orally once before the pre-TZIELD® MMTT. Participants also receive a placebo orally once before one of the post-TZIELD® MMTTs.
62328383|NCT06338553|EXPERIMENTAL|Participants receiving a semaglutide (Rybelsus®)|Participants receive 7mg of semaglutide (Rybelsus®) orally once before one of the post-TZIELD® MMTTs. Rybelsus is only given one time.
62328384|NCT02592603|ACTIVE_COMPARATOR|Endocuff-assisted Colonoscopy|Endocuff-assisted Colonoscopy with the ARC Endocuff-vision® attached at the distal tip of the scope.
62328385|NCT02592603|NO_INTERVENTION|Standard Colonoscopy|Standard Colonoscopy without any additional device
62328386|NCT01967420|EXPERIMENTAL|Cognitive remediation plus social cognition training|A combined intervention of 60 minutes of computerised cognitive remediation and 30 minutes of computerised social cognition training.
62328387|NCT01967420|ACTIVE_COMPARATOR|Cognitive remediation alone|An active control condition consisting of 60 minutes of computerised cognitive remediation and 30 minutes of free computer time.
62328388|NCT04182659|ACTIVE_COMPARATOR|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
62328389|NCT04182659|SHAM_COMPARATOR|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
62328390|NCT01319591||CNS lymphoma patients|
62328391|NCT06693687||Metastatic Cancer|"Participants will have 24/7 access to the ApricityCare service. Participants can check in and report any symptoms or side effects through the ApricityCare app, or by phone, at any time.~Participants will be asked to report your status at least weekly, even if participants are not experiencing any side effects. ApricityCare nurses will review each participants report and provide appropriate education and/or virtual management or escalate, as needed, to the study doctor or emergency service, based on guidelines. Each encounter with an ApricityCare nurse will be sent to the electronic health record (EHR) in real time for review/inclusion into your medical record.~For any in-person visits participants attend, the study doctor will review the ApricityCare symptom summary with participants. For all these visits, please bring your smartphone, which carries the ApricityCare application, for this review."
62328392|NCT02597023|EXPERIMENTAL|MitoQ|MitoQ, 20 mg per day for six weeks
62328393|NCT02597023|PLACEBO_COMPARATOR|Placebo|Placebo, inert excipient, one time per day for six weeks
62328394|NCT03744676|EXPERIMENTAL|Lisocabtagene maraleucel|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
62328395|NCT04065230||TAF antiviral therapy group|
62328396|NCT05549063|EXPERIMENTAL|Mobility and Stability Exercise|The patients were divided into two groups. Exercises were applied to both groups for 4 weeks.
62328397|NCT05549063|ACTIVE_COMPARATOR|Stretching Exercise|The patients were divided into two groups. Exercises were applied to both groups for 4 weeks.
62328398|NCT02041715|EXPERIMENTAL|TKM-100802 for Injection|
62328399|NCT02041715|PLACEBO_COMPARATOR|Placebo|
62328400|NCT00595699|PLACEBO_COMPARATOR|2|Double-blind
62328401|NCT00595699|EXPERIMENTAL|1|escitalopram group
62328402|NCT06269341||high-risk|Smoker and Drinker with Esophageal Squamous Cell Carcinoma after Esophagectomy
62328403|NCT06269341||low-risk|Non-Smoker and Non-Drinker with Esophageal Squamous Cell Carcinoma after Esophagectomy
62328404|NCT01597622|EXPERIMENTAL|Open-label Belimumab|Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
62134334|NCT00220740|EXPERIMENTAL|Group 1|IGIV-C
62486408|NCT05238428|EXPERIMENTAL|High trust boost sender + low trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
62486409|NCT05238428|EXPERIMENTAL|High trust boost Sender + medium trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
62693314|NCT06571617|ACTIVE_COMPARATOR|RIRS (retrograde intrarenal surgery/ flexible URS)|Under general anesthesia, the children will be placed in the lithotomy position . Cystoscopy or rigid ureteroscopy will be performed to place a hydrophilic guidewire to the renal pelvis under fluoroscopic guidance. After passing a 0.035/0.038-inch safety guidewire into the renal pelvis, a ureteral access sheath will be placed (9.5/11.5 Fr, 35 cm) will be used according to the surgeon preference. . RIRS will be performed using a single use digital Flexible ureteroscopy . A manual irrigation pump system will be used to hydro dilate the ureter during ureteroscopy. The stones will be fragmented with a holmium:YAG laser until they will be deemed small enough to pass spontaneously. Some residual fragments will be removed by tipless nitinol basket for stone analysis. A double-J stent OR URETERIC CATHETER will be placed at the end of the procedure based on surgeon's decision. .
62134335|NCT00220740|PLACEBO_COMPARATOR|Group 2|
62134336|NCT01989455|EXPERIMENTAL|Cohort 1|"Single dose of 500mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
62134337|NCT01989455|EXPERIMENTAL|Cohort 2|"Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.~Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.~Subjects enrolled to cohort 2 will receive an oral dose of deferiprone."
62134338|NCT01989455|EXPERIMENTAL|Cohort 3|"Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.~Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
62134339|NCT01989455|EXPERIMENTAL|Cohort 4|"Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
62134340|NCT00505934|EXPERIMENTAL|Levetiracetam|
62328405|NCT05863689||SLE Patients|"Patients fulfilling the 1997 revised American College of Rheumatology (ACR) criteria for the diagnosis of SLE (21) and aged between 18 and 80 years old.~Ophthalmological inclusion criteria: (1) best-corrected visual acuity ≤ 0.3 LogMAR, (2) intra-ocular pressure \<21 mm Hg on diurnal testing with measurements using Goldmann applanation tonometry, (3) spherical equivalent refractive error between -6.0 and +4.0 diopters, and (4) open anterior chamber angle on slit lamp examination."
62328406|NCT05863689||Healthy Controls|Healthy controls matched for sex and age with SLE Patients. Ophthalmological inclusion criteria: (1) best-corrected visual acuity ≤ 0.3 LogMAR, (2) intra-ocular pressure \<21 mm Hg on diurnal testing with measurements using Goldmann applanation tonometry, (3) spherical equivalent refractive error between -6.0 and +4.0 diopters, and (4) open anterior chamber angle on slit lamp examination.
62328407|NCT00549237|ACTIVE_COMPARATOR|Nutrition|Pre-operative Glucose load and post-operative immediate enteral nutrition
62328408|NCT00549237|NO_INTERVENTION|Control|No pre-operative glucose load. No early post-operative nutrition
62328409|NCT02551133|ACTIVE_COMPARATOR|0.1 mg/kg dexamethasone|0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.
62328410|NCT02551133|ACTIVE_COMPARATOR|0.2 mg/kg dexamethasone|0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.
62328411|NCT03445013|EXPERIMENTAL|SB414 6%|SB414 6% topically twice daily
62328412|NCT03445013|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Cream topically twice daily
62328413|NCT06130657|ACTIVE_COMPARATOR|Group 1: Lateral Maxillary Sinus Floor Elevation using surgical guide|
62328414|NCT06130657|ACTIVE_COMPARATOR|Group 2: Lateral Maxillary Sinus Floor Elevation without surgical guide|
62328415|NCT04039685|EXPERIMENTAL|Aerobic exercise group|
62328416|NCT04039685|EXPERIMENTAL|Resistance exercise group|
62328417|NCT04039685|EXPERIMENTAL|Combined (aerobic+resistance) exercise group|
62328418|NCT04039685|NO_INTERVENTION|Non-exercise group|
62328419|NCT01958606|EXPERIMENTAL|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
62328420|NCT01958606|ACTIVE_COMPARATOR|Traditional aerobic training|Moderate intensity continuous aerobic exercise on a treadmill
62328421|NCT03218293|EXPERIMENTAL|RIPC|Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
62328422|NCT03218293|NO_INTERVENTION|Blank control group(BC)|Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
62328423|NCT02772354|EXPERIMENTAL|Ablation|Standard radiosurgery ablation of premature ventricular complexes using navigation system.
62328424|NCT02772354|ACTIVE_COMPARATOR|Control|Antiarrhythmic therapy of premature ventricular complexes according to the guidlines
62486410|NCT05238428|EXPERIMENTAL|High trust boost sender + high trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
62486411|NCT04858126|EXPERIMENTAL|Single Group Assignment|ECOM endotracheal cardiac output monitor in patients undergoing cardiac and liver surgery.
62486412|NCT03644550|EXPERIMENTAL|1/LMB- 100+pembrolizumab|"LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles.~LMB-100 140mcg/kg Intravenous infusion (IVI), Days 1, 3, 5 in cycles 1, 2. Pembrolizumab 200mg IVI, every (Q) subsequent cycle on Day 1."
62486413|NCT04371224|EXPERIMENTAL|NaliCap|nal-IRI/Capecitabine
62486414|NCT04371224|ACTIVE_COMPARATOR|NAPOLI|nal-IRI/5-FU/LV
62486415|NCT01929486|EXPERIMENTAL|<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg|\<Phase Ia\> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.
62486416|NCT01929486|EXPERIMENTAL|<Phase Ib> Mogamulizumab of the tolerated dose|\<Phase Ib\> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.
62486417|NCT01929486|EXPERIMENTAL|<Phase Ib> Mogamulizumab 0.1mg/kg|\<Phase Ib\> Mogamulizumab 0.1mg/kg will be administered 8 times every week.
62693315|NCT05724771|EXPERIMENTAL|Combination of Botox + CGRPmAb|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL = 50
62693316|NCT01589640||Blink Tears|Blink Tears is an over the counter artificial tear
62693317|NCT01589640||Blink Gel Tears|Blink Gel Tears is an over the counter artifical tear product
61934825|NCT06525571|EXPERIMENTAL|Blue light Cystoscopy|Patients with bladder tumors will undergo BLC TURBT
61934826|NCT06525571|ACTIVE_COMPARATOR|White light Cystoscopy|Patients with bladder tumors will undergo WLC TURBT
61934827|NCT02355496|EXPERIMENTAL|Displaying medicare fee data|The active arm is the intervention group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will have medicare fee data displayed in the computerized provider order entry system.
61934828|NCT02355496|NO_INTERVENTION|Control Arm|The control arm is the group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will not have medicare fee data displayed.
61934829|NCT03170856|EXPERIMENTAL|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
61934830|NCT03170856|NO_INTERVENTION|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
61934831|NCT04150939|EXPERIMENTAL|Treatment (cryoablation)|Beginning 1 week prior to the next scheduled standard of care immunotherapy infusion, patients undergo core biopsy of the lesion to be ablated and a non-ablated lesion and also undergo cryoablation. Patients undergo a mandatory second core biopsy of the non-ablated lesion at 4 weeks after cryoablation.
61934832|NCT06710327|PLACEBO_COMPARATOR|Placebo|Participants will receive an intravenous (IV) administration of a placebo prior to their Aquablation procedure. This placebo is a saline solution that looks identical to the tranexamic acid (TXA) used in the Intervention Group but contains no active medication. The placebo is given to mimic the administration of TXA to ensure that the study conditions are the same for both groups, except for the active treatment. All other aspects of the surgical procedure and postoperative care remaining standardized across both study arms.
62328425|NCT03830008|NO_INTERVENTION|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over the list with the general practitioners (GP) in the neighborhood of the participant and the written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by this physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
62328426|NCT03830008|EXPERIMENTAL|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
62328427|NCT01066078||CRT recipients|
62328428|NCT04993586|EXPERIMENTAL|Group A|
62328429|NCT04993586|EXPERIMENTAL|Group B|
62328430|NCT04993586|EXPERIMENTAL|Group C|
61934833|NCT06710327|EXPERIMENTAL|TXA Administration|Participants receive tranexamic acid (TXA) preoperatively via intravenous (IV) administration. The dose consists of 1g of TXA delivered in a single IV push immediately prior to the Aquablation therapy. TXA acts as an antifibrinolytic agent, preventing excessive blood loss by stabilizing the formation of blood clots during surgery. This intervention aims to assess TXA's efficacy in reducing perioperative blood loss compared to placebo, with all other aspects of the surgical procedure and postoperative care remaining standardized across both study arms.
61934834|NCT06529042||Pregnancies of Individuals with Sickle Cell Disease|
62328431|NCT04993586|EXPERIMENTAL|Group D|
62328432|NCT04993586|EXPERIMENTAL|Group E|
62328433|NCT04463329|ACTIVE_COMPARATOR|Group C|conventional two-operator axillary brachial plexus blockage
62328434|NCT04463329|ACTIVE_COMPARATOR|Group J|axillary brachial plexus block with single operator using Jedi grip
62693318|NCT01589640||Systane Balance|Systane Balance is an over the counter artificial Tear product
62693319|NCT00593619|ACTIVE_COMPARATOR|Iron Dextran|
62693320|NCT00593619|ACTIVE_COMPARATOR|Iron Sucrose|
62486418|NCT06627114|ACTIVE_COMPARATOR|Nutrition education Program|"patients randomized to the intervention group, will participate in a nutritional education. the nutrition education sessions will be based on theory of planned behavior, which will include three 45-60-minute sessions about understanding NAFLD and nutrition basics, the role of social influences and support systems in managing NAFLD and overcoming barriers and building confidence.~Several educational methods will be using such as lectures, slides, group discussion, question and answers, instructional images, poster, booklet and Use case studies or scenarios. Participants will encourage to increase the intake of fruits, vegetables, complex carbohydrate, low fat dairy, healthy fats, white meat and fish, and also avoid the intake of unhealthy fats and refined carbohydrates. Furthermore, in each session, will be reviewing the patients' dietary practice and provided recommendations. Adherence to dietary intervention will assess by weekly phone calls and dietary records."
62328435|NCT05344079|ACTIVE_COMPARATOR|Epidural|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space.
62486419|NCT06627114|ACTIVE_COMPARATOR|Omega-3 supplementation|Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules (containing DHA 220 mg and EPA 330 mg) in two dose per day, to be taken orally with meal. Planned duration of the treatment is 12 weeks.
62486420|NCT06627114|ACTIVE_COMPARATOR|control|Patients randomized to the control group, who receive routine care at the outpatient clinic in Rizgari teaching hospital. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
62486421|NCT03873805|EXPERIMENTAL|Treatment (PSCA CAR T cells)|Patients may receive lymphodepleting regimen (either standard or modified) including fludarabine IV on days -5 to -3 and cyclophosphamide IV on days -5 to -3 or on days -4 and/or -3. The study PI and the protocol team will choose a chemotherapy regimen, for lymphodepletion prior to the PSCA-CAR T cell infusion (with the exception of cohorts 1 and -1 which will not receive lymphodepletion), based on the research participant's disease type and prior therapies. Patients then receive autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes IV over 10-15 minutes at day 0.
62486422|NCT02325180|EXPERIMENTAL|DHA-PQ|One tablet of dihydroartemisinin-piperaquine consists of 40 mg of dihydroartemisinin and 320 mg of piperaquine. DHA-PQ is administered once daily for 3 days (at enrolment, hour 24 and you 48). Dosing should be given based on body weight. Daily dose for dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 mg/kg (total 54 mg/kg).
62486423|NCT02325180|ACTIVE_COMPARATOR|AL|Half a tablet of artemether-lumefantrine consists of 20 mg of artemether and 120 mg of lumefantrine is given per 5 kg body weight. AL is administered as 6-dose regimens given twice daily for 3 days (at enrolment, hour 8, hour 24, hour 36, hour 48 and hour 60).
62486424|NCT03503435|OTHER|Art therapy intervention|Participants will then take part in six-weeks of group art therapy with a goal of increasing self-awareness and expression. During the intervention sessions, participants will have access to a wide range of materials conventionally used in art therapy excluding materials that may be abrasive or powdery and unsuitable around people wearing a stoma.
62486425|NCT06274762|EXPERIMENTAL|Experimental group|A pre-test will be conducted to determine socio-demographic data and to assess breast cancer awareness (champion health belief model scale). Experimental and control groups will be formed. The 45 people in the experimental group will be divided into 5 groups of 8 people. Each group will receive 45 minutes of theoretical training and 60 minutes of BSE application and will be explained and applications will be provided on the model. Question - Answer - 20 minutes will be allocated for feedback. 5 groups will be allocated one day each.4 weeks after the training, the experimental group will be called again in 5 groups and the champion health belief model scale will be repeated, they will be asked to perform the BSE application on the model and evaluation will be made according to the BSE evaluation form prepared by the researcher. 6 months after the study, the whatsapp group will be questioned about whether individuals have BSE.
62693321|NCT05783466|OTHER|Low-fat dairy products within a dietary handling for weight loss|3 servings/day of low-fat dairy products: 1 serving of low-fat cheese, 1 serving of low-fat yogurt and 1 serving of (semi-)skimmed milk.
62693322|NCT05783466|EXPERIMENTAL|Whole-fat dairy products within a dietary handling for weight loss|3 servings/day of whole-fat dairy products: 1 serving of whole cheese, 1 serving of whole yogurt and 1 serving of whole milk.
62328436|NCT05344079|ACTIVE_COMPARATOR|local infiltrative analgesia|At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line.
62328437|NCT03785717|ACTIVE_COMPARATOR|ROG only|cancellous (1-2 mm) \& cortical (250-1000 mm) bone allograft and pericardium membrane without extracorporeal shockwave therapy
62328438|NCT03785717|ACTIVE_COMPARATOR|ROG & ESWT|cancellous 1-2mm \& cortical 250-1000mm Bonegrafts and membrane with extracorporeal shockwave therapy
62328439|NCT00461955|EXPERIMENTAL|1|autologous peripheral blood stem cell transplantation
62328440|NCT04446234|EXPERIMENTAL|Risperidone|Risperidone tablet
62328441|NCT04446234|EXPERIMENTAL|Aripiprazole|Aripiprazole tablet
62328442|NCT04446234|EXPERIMENTAL|Ziprasidone|Ziprasidone tablet
62328443|NCT04446234|EXPERIMENTAL|Amisulpride|Amisulpride tablet
62328444|NCT04446234|EXPERIMENTAL|Quetiapine|Quetiapine tablet
62328445|NCT06242236|ACTIVE_COMPARATOR|Intervention group: respiratory effort guide sedative dosage adjustment.|Following the enrollment of participants (acute respiratory failure requiring mechanical ventilation which sedation needed), the investigators proceeded to randomize participants into two groups: this intervention group, which employed the optimal respiratory effort parameters to guide the adjustment of sedative levels.
62328446|NCT06242236|NO_INTERVENTION|Control group: usual care guide sedative dosage adjustment.|Following the enrollment of participants (acute respiratory failure requiring mechanical ventilation which sedation needed), the investigators proceeded to randomize participants into two groups: this control group, which employed usual care to guide the adjustment of sedative levels.
62328447|NCT04747548|ACTIVE_COMPARATOR|Kurbo Only|Participants will receive 1-month access to the Kurbo digital program.
62328448|NCT04747548|EXPERIMENTAL|Kurbo + PolyRules!|Participants will receive 1-month access to the Kurbo digital program and the PolyRules! app.
62486426|NCT06274762|ACTIVE_COMPARATOR|Control Group|A pre-test will be conducted to determine socio-demographic data and to assess breast cancer awareness (champion health belief model scale). Experimental and control groups will be formed.The control group will not be intervened until the study is over.
62486427|NCT00635648|EXPERIMENTAL|Caspofungin 50 mg Intravenous (IV)|
62328449|NCT01125176|EXPERIMENTAL|All subjects|In Cycle -1, even numbered patients will receive oral lenalidomide daily on days 1-14 and then no treatment on days 15-28. In Cycle -1, odd numbered patients will receive oral thalidomide daily days 1-14 followed by no treatment on days 15-28. Starting with cycle 1, all patients will alternate daily thalidomide (every odd day) with daily lenalidomide (every even day) for days 1-28. Rituximab will be given on days 1, 8, 15, and 22 starting with Cycle 1, and then again every 6th cycle thereafter (cycles 7, 13, 19, etc.)
62328450|NCT04429503|ACTIVE_COMPARATOR|aflibercept Q8|Administered every 8 weeks after a loading phase
62486428|NCT06507176|EXPERIMENTAL|flexible ureteroscopic lithotripsy|
62486429|NCT06507176|ACTIVE_COMPARATOR|percutaneous nephrolithotomy|
62693323|NCT05783466|EXPERIMENTAL|Whole-fat dairy products enriched with milk polar lipids within a dietary handling for weight loss|3 servings/day of whole-fat dairy products (1 milk, 1 yogurt, 1 cheese) among which 1 serving/day is enriched with milk polar lipids via butterier.
62693324|NCT06522997|PLACEBO_COMPARATOR|Arm 1|Placebo OD and sham titration after 14 days and after 28 days
62693325|NCT06522997|EXPERIMENTAL|Arm 2|BAY3283142 (dose 1) OD and sham titration after 14 days and after 28 days
62693326|NCT06522997|EXPERIMENTAL|Arm 3|BAY3283142 (dose 2) OD and sham titration after 14 days and after 28 days
62693327|NCT06522997|EXPERIMENTAL|Arm 4|BAY3283142 (dose 2) OD and uptitration to dose 3 OD after 14 days and sham titration after 28 days
61934835|NCT06710379|EXPERIMENTAL|Phase 1a Dose Escalation|Increasing doses of ADRX-0405 will be administered to identify the maximum tolerated dose (MTD) and the recommended dose to be used in the Phase 1b part.
62328451|NCT04429503|EXPERIMENTAL|High-Dose aflibercept Q12|Administered every 12 weeks after a loading phase
62328452|NCT04429503|EXPERIMENTAL|High-Dose aflibercept Q16|Administered every 16 weeks after a loading phase
62328453|NCT06296628|ACTIVE_COMPARATOR|Conventional Therapy Group|Participants in this group with train using Mirror Therapy (MT), the current standard of care.
62328454|NCT06296628|EXPERIMENTAL|Miraπ Group|Participants in this group will train with the Miraπ device.
62328455|NCT03569293|PLACEBO_COMPARATOR|Placebo / Upadacitinib|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
62328456|NCT03569293|EXPERIMENTAL|Upadacitinib 15 mg QD|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
62328457|NCT03569293|EXPERIMENTAL|Upadacitinib 30 mg QD|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
62328458|NCT05497778|EXPERIMENTAL|Dose Escalation Phase followed by a Dose Expansion Phase|In the Dose Escalation Phase of the study, we will identify the RPD2 of IM156. Subsequently, we will evaluate IM156 at the RP2D (established in the Dose Expansion Phase) and gemcitabine + nab-paclitaxel in the Dose Expansion Phase.
62328459|NCT05399238||Healthy subjects|The objective is to measure the temperature of the lingual dorsum
62486430|NCT05972590|OTHER|50-75 years old volunteers cohort|Biological samples collection Blood drawing + faeces collection
62328460|NCT05399238||Burning mouth syndrome|The objective is to measure the temperature of the lingual dorsum
62486431|NCT01062490|EXPERIMENTAL|Treosulfan|Patients with myelodysplastic syndrome, (MDS) according to WHO classification (\< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation
62693328|NCT06522997|EXPERIMENTAL|Arm 5|BAY3283142 (dose 2) OD and uptitration to dose 3 OD after 14 days and to dose 4 OD after 28 days
62693329|NCT06522997|EXPERIMENTAL|Arm 6|BAY3283142 (dose 3) OD and uptitration to dose 5 OD after 14 days and sham titration after 28 days
61934836|NCT06710379|EXPERIMENTAL|Phase 1b Dose Expansion|ADRX-0405 will be initially administered at the dose recommended from the Phase 1a part in subjects with previously treated mCRPC.
62328461|NCT06262555|EXPERIMENTAL|Arm 1|Photophrin 2mg/kg 48 hours before treatment. Navigational bronchoscope guide the catheter into the tumor and adjacent to the tumor and give lipiodol for light diffusion and give light 200J/cm from different angle
62486432|NCT05643638|EXPERIMENTAL|CYP-001 plus corticosteroids|
62693330|NCT02392442|EXPERIMENTAL|1 - Endotoxin|6 hour lavage post endotoxin
62693331|NCT02392442|EXPERIMENTAL|2 - Endotoxin|24 hour lavage post endotoxin
62693332|NCT02392442|EXPERIMENTAL|3 - Endotoxin|48 hour lavage post endotoxin
62693333|NCT02392442|PLACEBO_COMPARATOR|4 Placebo comparator|6 hour control lavage
62134341|NCT04579198|EXPERIMENTAL|Families receiving intervention|
62134342|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
62134343|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
62486433|NCT05643638|PLACEBO_COMPARATOR|Placebo plus corticosteroids|
62486434|NCT01266902|EXPERIMENTAL|Rilpivirine|Rilpivirine 25 mg once daily
62486435|NCT04976179|EXPERIMENTAL|FCM - Intravenous Ferric carboxymaltose|Intravenous Ferric Carboxymatlose administered in a single dose of 20mg/Kg to a maximum of 1000mg in 200mls of infusion given over minimum of 15 - 20 minutes at enrollment.
62486436|NCT04976179|ACTIVE_COMPARATOR|FS -Oral Ferrous sulphate|Oral Ferrous Sulphate (containing 65mg of elemental iron) to be taken as one 200mg tablet 3 times a day until delivery.
62486437|NCT04002024|ACTIVE_COMPARATOR|Placebo and Treatment Arm A|The patients in treatment arm A group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the right side of their face and placebo which is moisturizer without those active ingredients on the left side of their face.
62486438|NCT04002024|ACTIVE_COMPARATOR|Treatment and Placebo Arm B|The patients in treatment arm B group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the left side of their face and placebo which is moisturizer without those active ingredients on the right side of their face.
62486439|NCT04184947||SGLT2i|Patients who received new prescription of a SGLT-2 inhibitor
61934837|NCT04215588|ACTIVE_COMPARATOR|Individualized heparin and protamine titration|The device Hemostasis Management System Plus (Medtronic, Minneapolis, MN) will be used to determine the patients' sensitivity to heparin and its concentration in whole blood. Then, it will automatically calculate the necessary dose for anticoagulation during bypass. The protamine dose to eliminate heparin effect will be calculated from the remaining heparin concentration (0.75mg/100 International Units circulating heparin).
62134344|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
62134345|NCT01721291|EXPERIMENTAL|COPD 1|COPD patients
62328462|NCT02053272|ACTIVE_COMPARATOR|2 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 2 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
62328463|NCT02053272|ACTIVE_COMPARATOR|5 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 5 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
62328464|NCT02053272|ACTIVE_COMPARATOR|15 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 15 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
62328465|NCT02053272|PLACEBO_COMPARATOR|Placebo|Licaps® size double zero (Size 00) hard gelatin capsules containing excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
62328466|NCT01712386|EXPERIMENTAL|COPD|
62328467|NCT01831934|EXPERIMENTAL|MELAS group:13-60 years of age.|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
62328468|NCT01831934|EXPERIMENTAL|Control Group: 18-65 years of age|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
62328469|NCT04030052|EXPERIMENTAL|Untreated/minimally treated moderate HA no inhibitors|Previously untreated patients (PUPs) and minimally treated patients (MTPs) \<3 years of age with moderately severe (≤2% FVIII) HA and no inhibitors.
62328470|NCT04030052|EXPERIMENTAL|Treated any moderate HA with existing inhibitors|Children \<21 years of age with moderately severe (≤2% FVIII) HA and with already existing inhibitors (LTI or HTI).
62328471|NCT05609747|EXPERIMENTAL|TYPE 2 DIABETIC PATIENTS|NON SURGICAL ROOT CANAL TREATMENT
62328472|NCT05609747|EXPERIMENTAL|HEALTHY CONTROL GROUP PATIENTS|NON SURGICAL ROOT CANAL TREATMENT
62328473|NCT06554314|EXPERIMENTAL|Probiotics|Probiotic capsules, 300 mg each, one daily for a total of 300 mg for 4 weeks
62328474|NCT06554314|PLACEBO_COMPARATOR|Placebo|The placebo capsules had the same composition as the experimental capsules, except that they did not contain probiotics, and should be used for 4 weeks.
62328475|NCT03463694|EXPERIMENTAL|Hypertonic Saline ~2.6% NaCl|3 drops each nostril of Hypertonic Saline (HS) at least 4 times a day until asymptomatic or maximum of 28 days
62328476|NCT03463694|NO_INTERVENTION|Standard Care|Control arm of standard symptomatic care only
62328477|NCT02857907||ATG group|Patients who received T cell depleting ATG therapy (blood sample one year after transplantation)
62486440|NCT04184947||GLP-1RA|Patients who received new prescription of a GLP-1 receptor agonist
62486441|NCT05664243|EXPERIMENTAL|1) Autologous: Phase 2 Arm A|Arm A subjects with newly diagnosed disease will receive autologously derived, genetically modified gamma-delta T cells administered with maintenance temozolomide.
62486442|NCT05664243|EXPERIMENTAL|2) Allogeneic: Phase 1b|Phase 1b subjects with relapsed disease will have allogeneic derived, genetically modified gamma-delta T cells administered with temozolomide
62486443|NCT05664243|EXPERIMENTAL|3) Allogeneic: Phase 2 Arm B|Arm B subjects with relapsed disease will have allogeneic derived, genetically modified gamma-delta T cells administered with temozolomide
62486444|NCT05664243|EXPERIMENTAL|4) Allogeneic: Phase 2 Arm C|Arm C subjects with newly diagnosed disease will receive allogeneic derived, genetically modified gamma-delta T cells administered with maintenance temozolomide.
62693334|NCT04642976||Atrial fibrillation ablation|All patients undergoing ablation with undergo pre-procedural CT as well as HFS mapping and ablation of GPs.
62134346|NCT01721291|EXPERIMENTAL|Healthy|Healthy participants
62134347|NCT01721291|EXPERIMENTAL|COPD 2|Second group of COPD patients
62134348|NCT01721291|ACTIVE_COMPARATOR|Asthmatics|Asthmatics patients
62134349|NCT03562338|EXPERIMENTAL|Manual Therapy and Exercise|
62134350|NCT03562338|ACTIVE_COMPARATOR|Usual Care|
62134351|NCT05896774|EXPERIMENTAL|Maplirpacept (PF-07901801)|single arm study
62134352|NCT00448669|ACTIVE_COMPARATOR|TDF-FTC,condoms,adh/risk counseling|Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
62328478|NCT02857907||anti-CD25 group|Patients who received nondepleting anti-CD25 (blood sample one year after transplantation)
62328479|NCT00843310|EXPERIMENTAL|ReMeDex|"Treatment phase (28 days/cycle x 6 cycles):~Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.~Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):~lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles."
62328480|NCT01096446|EXPERIMENTAL|Higher Infusion|Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
62328481|NCT01096446|OTHER|Standard Infusion|Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
62328482|NCT00683358|EXPERIMENTAL|1|
62328483|NCT03535701|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients receive standard of care therapy with paclitaxel.
61934838|NCT04215588|ACTIVE_COMPARATOR|Activated Clotting Time guided heparin and protamine dose|Heparin initial dose will be determined according to the patients' weight to achieve a required Activated Clotting Time (ACT) to initiate cardiopulmonary bypass. Subsequent doses of heparin will be administered according to ACT and protamine dose will be calculated from total heparin dose (0.75mg protamine/100 International Units heparin)
61934839|NCT03029429|EXPERIMENTAL|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
62328484|NCT03535701|EXPERIMENTAL|Arm II (standard of care, ketogenic diet)|Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.
62328485|NCT00120445|ACTIVE_COMPARATOR|2|air vs perfluoropropane gas in pneumatic retinopexy
62328486|NCT02618850|OTHER|Advanced CRC patients undergoing first-line chemotherapy|single cohort
62328487|NCT06342726|PLACEBO_COMPARATOR|Passive rewarming|Wrapping of participants using a 3-layered model with a vapor barrier, insulating materials and an outer shell.
62328488|NCT06342726|ACTIVE_COMPARATOR|Active rewarming|"Same as Passive rewarming but with an added external heat source"
62328489|NCT05794516|EXPERIMENTAL|ZB004|
62328490|NCT05794516|PLACEBO_COMPARATOR|Placebo|
62328491|NCT03403504|EXPERIMENTAL|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 10 mg
62328492|NCT03403504|ACTIVE_COMPARATOR|OXYCONTIN®|OXYCONTIN® Tablet 10 mg
62328493|NCT05091190|OTHER|cancer patients|MADMAS will include 30 patients with metastatic NSCLC and 30 patients with metastatic head and neck cancers; patients will NSCLC will receive an immunotherapy-based treatment in first line metastatic setting; patients with head and neck cancers are included if they are planned to receive an immunotherapy-based treatment, whatever the line.
62328494|NCT03901612|PLACEBO_COMPARATOR|Saline solution|Post operative analgesia throw the thoracic Erector spinae catheter with saline solution and opioid rescue
62328495|NCT03901612|EXPERIMENTAL|Ropivacaine|Post operative analgesia throw the thoracic Erector spinae catheter with Ropivacaine 0.2% solution and opioid rescue
62328496|NCT00107770|OTHER|1|ALS patient
62328497|NCT05940844|EXPERIMENTAL|open label OB-002 monotherapy 0.25 mg/kg|Dose Level 1
61934840|NCT03029429|PLACEBO_COMPARATOR|Placebos|Theophylline capsule by mouth once daily or Theophylline elixir by mouth q6h
61934841|NCT04461288|EXPERIMENTAL|Pride Posts|This six month intervention will be conducted on the Facebook platform. Participants will receive regular social media posts tailored to the sexual and gender minority communities (LGBTQ+). Weekly live sessions with a tobacco expert will be available. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
62328498|NCT05940844|EXPERIMENTAL|open label OB-002 monotherapy 0.5 mg/kg|Dose Level 2
62328499|NCT05940844|EXPERIMENTAL|open label OB-002 monotherapy 1.0 mg/kg|Dose Level 3
61934842|NCT04461288|EXPERIMENTAL|Pride Posts Plus|This six month intervention will include all elements of the Pride Posts arm. In addition, the intervention will include gamification, gaming elements designed to encourage participation in the program and behavior change. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
62328500|NCT05940844|EXPERIMENTAL|open label OB-002 monotherapy 1.5 mg/kg|Dose Level 4
62328501|NCT05940844|EXPERIMENTAL|open label OB-002 monotherapy expansion cohort|Dose Expansion
62328502|NCT02329522||Stable COPD patients|Patients will be assessed using USCOM and spirometry. For those with FEV1 to FVC ratio smaller than 70%, they will be classified as COPD.
62328503|NCT02329522||AECOPD patients|Patients will be assessed using USCOM and spirometry. Spirometry will be assessed after 2 to 4 weeks post-hospital discharge.
62328504|NCT02329522||Patient Controls|Patients will be assessed using USCOM and spirometry. For those with COPD symptoms but FEV1 to FVC ratio greater than 70%, they will be classified as non-COPD.
62328505|NCT02329522||Healthy Controls|Healthy subjects, with no history of COPD or other significant chronic illness will be recruited as healthy controls. Subjects will be matched for age and gender with the patient groups. They will be assessed using USCOM.
62328506|NCT01242020|OTHER|Lean Healthy Subjects|"Lean defined as (BMI ≥18 and ≤25)"
62328507|NCT01242020|OTHER|Obese Healthy Subjects|Obese grade I-II defined as (BMI\>30 and ≤35)
62328508|NCT05118958|EXPERIMENTAL|Part 1 - Period 1 - Prototype 1 600 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fasted state as a single dose
62328509|NCT05118958|EXPERIMENTAL|Part 1 - Period 3 - Prototype 2 600 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 prototype 2 modified-release tablet dosed orally in fasted state as a single dose
62328510|NCT05118958|EXPERIMENTAL|Part 1 - Period 4 - Prototype 1 900 mg (single dose fasted)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fasted state as a single dose
62328511|NCT05118958|EXPERIMENTAL|Part 1 - Period 5 - Prototype 1 600 mg and Prototype 3 300 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet plus 300 mg (1 x 300 mg) Prototype 3 dosed orally in fasted state as a single dose
62328512|NCT05118958|EXPERIMENTAL|Part 1 - Period 6 - Prototype 1 900 mg (single dose fed)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fed state as a single dose
62328513|NCT05118958|EXPERIMENTAL|Part 3 - KVD824 Prototype 1 600 mg (multiple dose fed)|600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
62328514|NCT05118958|PLACEBO_COMPARATOR|Part 3 - Placebo to KVD824 Prototype 1 600 mg (multiple dose fed)|Placebo to 600 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
62328515|NCT05118958|EXPERIMENTAL|Part 3 - KVD824 Prototype 1 900 mg (multiple dose fed)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
62486445|NCT02786433|ACTIVE_COMPARATOR|GROUP CONTROL|"Participants in the control group only underwent conventional physiotherapy. Conventional therapy includes stretching and strengthening exercises with cane aid, leggings , elastic band and overball for upper and lower limbs , in addition to gait and balance training.~The intervention for the control group was applied for five weeks with sessions of 60 minutes twice a week"
62486446|NCT02786433|EXPERIMENTAL|EXPERIMENTAL GROUP|The subjects in the experimental group underwent conventional physiotherapy (The same applied in the control group) associated with virtual reality , performed with the console X -Box Kinect® of Microsoft. Durante the achievement of the virtual reality practice, Kinect and Kinect games Adventures® Dance® demanded the anterior movements players -posterior and lateral , as well as jumps and squats to get rid of the game obstacles. They Kinect Dance® game were all required movements of the previous game more dance . The intervention lasted five weeks , with two weekly sessions lasting 30 minutes to conventional therapy and 30 minutes to virtual reality.
62486447|NCT01909024|EXPERIMENTAL|embolisation of pelvic veins & treatment of leg varicose veins|transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
62486448|NCT01909024|ACTIVE_COMPARATOR|endovenous treatment of leg recurrent varicose veins alone|endovenous treatment of leg recurrent varicose veins alone
62486449|NCT01430533|EXPERIMENTAL|Verum|Topical application of verum (azelaic acid pre foam formulation) on the skin
62486450|NCT01430533|PLACEBO_COMPARATOR|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
62486451|NCT01430533|PLACEBO_COMPARATOR|Negative control|Topical application of distilled water (negative control) on the skin
62486452|NCT01572051|EXPERIMENTAL|Group 1A (3month plus phone)|This group will attend to two courses with a 3 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
62486453|NCT01572051|EXPERIMENTAL|Group 1B (3month no phone)|This group will attend to two courses with a 3 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
62486454|NCT01572051|EXPERIMENTAL|Group 2A (2month plus phone)|This group will attend to two courses with a 2 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
62693335|NCT06641921|EXPERIMENTAL|Seerlinq intervention arm|Participants in the intervention arm will be haemodynamically-guided based on the results from the Seerlinq telemedical monitoring system.
62693336|NCT06641921|NO_INTERVENTION|Seerlinq control group|Participants in the control group will continue to receive standard of care management according to patients' clinical signs and symptoms.
61934843|NCT04461288|ACTIVE_COMPARATOR|Usual Care Condition|Participants in this arm will be provided with a referral to smokefree.gov, a federally-funded website which provides support and digital-based interventions to assist in smoking cessation activities. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
61934844|NCT05254223|EXPERIMENTAL|Control Diet (NDA)|No dietary advice (NDA)
61934845|NCT05254223|EXPERIMENTAL|Anti-inflammatory Diet (AIDA)|Anti-inflammatory Dietary advice (AIDA)
61934846|NCT04753476|EXPERIMENTAL|Secretome-MSCs (n=24)|This group will be given Covid-19 standard therapy with intramuscular Hypoxic S-MSC secretome
62134353|NCT00448669|PLACEBO_COMPARATOR|Placebo,condoms,adh/risk counseling|Eligible participants were randomized to the placebo arm and received placebo oral tablets that were visually identical to the TDF-FTC tablet and taken once daily. The placebo tablets contained no active ingredients. The ratio of randomization was 1:1. Participants randomized to the placebo arm received male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
62328516|NCT05118958|PLACEBO_COMPARATOR|Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fed)|Placebo to 900 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
62328517|NCT05118958|EXPERIMENTAL|Part 3 - KVD824 Prototype 1 900 mg (multiple dose fasted)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fasted state for 13 days with a single dose on day 14.
61934847|NCT04753476|OTHER|Control (n=24)|This group will receive standard Covid-19 therapy with the best supportive care
61934848|NCT02584699|EXPERIMENTAL|SABR|SABR group includes patients receiving pre-identified fractionated Stereotactic Ablative Radiotherapy (SABR)
62134354|NCT03239301|ACTIVE_COMPARATOR|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
62134355|NCT03239301|ACTIVE_COMPARATOR|Robotic Rehabilitation + Conventional Rehab|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. A
62328518|NCT05118958|PLACEBO_COMPARATOR|Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fasted)|Placebo to 900 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fasted state for 13 days with a single dose on day 14.
62486455|NCT01572051|EXPERIMENTAL|Group 2B (2month no phone)|This group will attend to two courses with a 2 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
62486456|NCT01572051|EXPERIMENTAL|Group 3A (1month plus phone)|This group will attend to two courses with a 1 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
61934849|NCT02266914|EXPERIMENTAL|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
61934850|NCT05637671|ACTIVE_COMPARATOR|oxybutynin|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks
61934851|NCT05637671|ACTIVE_COMPARATOR|paroxetine|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks
62134356|NCT04267458|OTHER|HCV infected patients with non-elevated sCr than basal levels|a group of egyption patients with HCV infection with non-elevated sCr than basal levels and treated with sofuspovir as an direct acting antiviral drug
62328519|NCT05118958|ACTIVE_COMPARATOR|Part 1 - Period 2 - KVD824 IR Capsule 600 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 immediate release Capsule dosed orally in fasted state as a single dose
62328520|NCT04702555||Vitalis Pharmaceuticals (VTS)-Aspirin and Ketamine|An oral combination drug of VTS-Aspirin and ketamine (VTS-K) would facilitate the shift from IV opioids to a non-IV therapy for patients presenting to the ED with acute MSK pain. This formulation has a potential to provide effective analgesia in the ED with reduced side effects. VTS-K's proprietary oral formulation of established, safe, and well-understood APIs, makes it uniquely appropriate for use in the ED. VTS-K is administered orally, which is suitable for resource-poor environments in which the healthcare setting may be inadequate as well as suitable to improve the throughput of ED Patients by reducing their length of stay. This is especially pertinent given the alternative of IV opioids for pain management of acute MSK pain, which requires both clinical monitoring and equipment, whereas VTS-K promotes weaning off opioids, alleviating the resource consumption.
62328521|NCT05663996|EXPERIMENTAL|St. John's Wort oil|Experimental group participants were treated with St. John's Wort oil.
62328522|NCT05663996|PLACEBO_COMPARATOR|Olive Oil|Control group participants were treated with olive oil.
62328523|NCT03132792|EXPERIMENTAL|Autologous genetically modified AFPᶜ³³²T cells|
62328524|NCT04374825|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Weekly video conference groups led by a trained facilitator introducing key concepts of ACT
62328525|NCT04374825|ACTIVE_COMPARATOR|Cognitive Behavioral Stress Management (CBSM)|Weekly video conference groups led by a trained facilitator introducing key concepts of CBSM
62328526|NCT04374825|NO_INTERVENTION|Usual care|Patients' usual health care as received over the duration of the pilot trial
62328527|NCT00041717|ACTIVE_COMPARATOR|fampridine-SR 50mg/day|
62328528|NCT00041717|PLACEBO_COMPARATOR|Placebo|
62328529|NCT06463769|EXPERIMENTAL|Patients with prodromal PD on New Nordic LPF-diet (intervention)|Patients with prodromal PD will take part in an 8-week patient-centered intervention program on a predominantly plant-based New Nordic LPF-Diet.
62328530|NCT06463769|EXPERIMENTAL|Patients with clinical PD on New Nordic LPF-diet (intervention)|Patients with clinical PD will take part in an 8-week patient-centered intervention program on a predominantly plant-based New Nordic LPF-Diet. Patients with clinical PD will be randomized to intervention or control group.
62328531|NCT06463769|NO_INTERVENTION|Patients with clinical PD receiving standard of care (control)|Patients with clinical PD will receive standard of care information on a healthy diet and serve as control. Patients with clinical PD will be randomized to intervention or control group.
62328532|NCT00757562|EXPERIMENTAL|DL|Desloratadine syrup once daily
62328533|NCT00757562|PLACEBO_COMPARATOR|Placebo|placebo syrup once daily
61934852|NCT06709183|SHAM_COMPARATOR|Standard oral care (Control - intervention)|The nurses in the control-intervention group will perform standard oral care in the first oral care and oral care using the oral care retractor in the second oral care.
62134357|NCT00940524|EXPERIMENTAL|Chemotherapy|A phase I study designed to determine the dose of dasatinib that can be safely administered with cytarabine and high-dose mitoxantrone in Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia patients.
62328534|NCT04856436||Pregnant women with exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and were filled at least one benzodiazepine prescription during the first trimester (first 90 days of pregnancy).
62328535|NCT04856436||Pregnant women without exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and did not fill a benzodiazepine prescription during the 3 months before the pregnancy onset through the end of the first trimester
61934853|NCT06709183|ACTIVE_COMPARATOR|Oral care retractor (Intervention - Control)|The nurses in the intervention-control group will perform the first oral care with an oral care retractor, and in the second oral care, they will perform standard oral care without using an oral care retractor.
61934854|NCT03169309|EXPERIMENTAL|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
62134358|NCT03976557|EXPERIMENTAL|BIP CVC|Polyurethane CVC with noble metal coating
62134359|NCT03976557|ACTIVE_COMPARATOR|Standard CVC|Standard CVC made of polyurethane
62328536|NCT06561685|EXPERIMENTAL|LY4050784 (Phase 1a - Dose Escalation)|Escalating doses of LY4050784 administered orally.
61934855|NCT06150755|PLACEBO_COMPARATOR|mplant supported overdenture by ball attachment|immediate loaded implant supported overdenture by ball attachment
62328537|NCT06561685|EXPERIMENTAL|LY4050784 (Phase 1b - Dose Optimization/Part A)|Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally.
62328538|NCT06561685|EXPERIMENTAL|LY4050784 (Phase 1b - Dose Expansion/Part B)|LY4050784 administered orally.
62328539|NCT03754283|EXPERIMENTAL|Silicone|Indirect bonding performed with the silicone trays
61934856|NCT06150755|ACTIVE_COMPARATOR|implant supported overdenture by bar|immediate loaded implant supported overdenture by intraoral welding titanium bar splinted two implant
62328540|NCT03754283|ACTIVE_COMPARATOR|Vacuum formed|Indirect bonding performed with the vacuum formed trays
62328541|NCT02330627|EXPERIMENTAL|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
62328542|NCT02330627|NO_INTERVENTION|Delayed Treatment (Waitlist)|
62328543|NCT00251407|EXPERIMENTAL|taxotere, cisplatin, irinotecan|
62328544|NCT00571363|ACTIVE_COMPARATOR|standard surgery|basal cell carcinomas were excised with 4 mm margins
62328545|NCT00571363|ACTIVE_COMPARATOR|Mohs|Basal cell carcinoma were removed via Mohs Micrographic surgery
62328546|NCT06692803||First Treatment Cohort|Patients newly diagnosed with CML who received first treatment with imatinib, dasatinib, nilotinib, or bosutinib.
62328547|NCT06692803||Second Treatment Cohort|Patients from first treatment cohort with a subsequent line of therapy (i.e., second treatment) with imatinib, dasatinib, nilotinib, bosutinib, or ponatinib.
61934857|NCT04151329|EXPERIMENTAL|2.4mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box, 2.4mg/kg IV infusions
62486457|NCT01572051|EXPERIMENTAL|Group 3B (1month no phone)|This group will attend to two courses with a 1 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
62486458|NCT01572051|EXPERIMENTAL|Group 4A (no course plus phone)|This group will NOT attend to any courses This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
62486459|NCT01572051|EXPERIMENTAL|Group 4B (no course no phone)|This group will NOT attend to any courses This group will NOT receive phone calls This group will only receive printed material This group will be reassessed in 6 months
62486460|NCT06425757|OTHER|Severe Hypoproteinemia|Blood albumin concentration≤30g/L
62486461|NCT06425757|OTHER|Moderate Hypoproteinemia|Blood albumin concentration 30g/L-40g/L
62486462|NCT06425757|OTHER|Normal plasma albumin|Blood albumin concentration \>40g/L
62486463|NCT05890547||Study group|comprises 30 patients with Covid-19 infection representing the study group COVID-19 diagnosis will be based on a positive SARS-CoV-2 nasopharyngeal swab on real-time reverse transcription-polymerase chain reaction (RT-PCR) in the presence of clinical and/or radiological signs.
61934858|NCT04151329|EXPERIMENTAL|3.6mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box,3.6mg/kg IV infusions
62134360|NCT03349970||TEE vs PAC|we will compare the SV measurements obtained by PAC thermodilution technique to those obtained by different TEE methods in 60 patients undergoing coronary artery bypass grafting (CABG) and/or aortic valve (AV) or aortic surgery with cardiopulmonary bypass (CPB) in 2 different cardiac centres. The LV cardiac deformation, expressed as global longitudinal strain (GLS) will be calculated off-line from the acquired images. We will also determine the intra and inter-observer reproducibility of each TEE method.
62328548|NCT04066816|EXPERIMENTAL|Walnut Consumption|After screening, participants will avoid foods high in ellagic acid. These foods include pomegranates, hazelnuts, pistachios, strawberries, raspberries, blackberries, oak-aged wines, spirits, and walnuts (besides the ones given by researchers); a complete list will be provided to the subjects. Participants will then return to research facility and provide urine and stool samples, as well as a set of 3-day dietary records. Then, they will start to consume 2 ounces of walnuts per day for 21 days with their usual diet. At the end, they will collect another urine and stool sample as well as another set of dietary records, and then come in for the scheduled colonoscopy where they will be asked to provide biopsy specimens. That completes the intervention and participation in the study.
62486464|NCT05890547||Control group|comprises 30 patients without a history of Covid-19 infection as a control group.
62486465|NCT03106545|EXPERIMENTAL|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves
62486466|NCT03106545|ACTIVE_COMPARATOR|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves
62486467|NCT03106545|SHAM_COMPARATOR|General anesthesia|General anesthesia
61934859|NCT06039488|EXPERIMENTAL|Exercise|2 days/week of resistance and cardiovascular exercise for 8-weeks
61934860|NCT05437159|EXPERIMENTAL|Sub-syllabic learning and fMRI|60 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations during 6 training sessions over 2 days. Following training, subjects will participate in a functional magnetic resonance imaging (fMRI) session on a third day to measure brain activity associated with producing the words learned during training and with a set of unfamiliar words also formed by non-native phoneme combinations.
61934861|NCT05437159|EXPERIMENTAL|Sub-syllabic learning and anodal tDCS of inferior frontal sulcus|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations. During the training, anodal transcranial direct current stimulation (tDCS) will be applied to the the subject's left inferior frontal sulcus.
62328549|NCT04481425|OTHER|intervention group|Text messages will be sent to the subjects through the investigator, including giving popularization of psychiatric knowledge, coping skills, emotional regulation strategies, and brief care. Two or three times a week for two months.
62328550|NCT04481425|NO_INTERVENTION|control group|Subjects both collected in the outpatient department and the ward were randomly divided into the control group and regularly followed up.
62328551|NCT02411227|EXPERIMENTAL|1|Immediate Intervention
62328552|NCT02411227|NO_INTERVENTION|2|Wait list
62486468|NCT04237415|EXPERIMENTAL|EMG biofeedback group|
62486469|NCT04237415|NO_INTERVENTION|control group|
62486470|NCT06556043|EXPERIMENTAL|cM1 stimulation group|cM1= primary motor cortex (M1) contralateral to the moving leg
62486471|NCT06556043|EXPERIMENTAL|cPPC stimulation group|cPPC= posterior parietal cortex (PPC) contralateral to the moving leg
62486472|NCT06556043|EXPERIMENTAL|iCBM stimulation group|iCBM= cerebellar cortex ipsilateral to the moving leg
62486473|NCT06556043|SHAM_COMPARATOR|Sham group|
62486474|NCT03545880|EXPERIMENTAL|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
62486475|NCT03545880|PLACEBO_COMPARATOR|Placebo|Individuals will not perform any action after the application of trigger point dry needling
62486476|NCT05966922|EXPERIMENTAL|Electrical Stimulation|Electrical Stimulation and Sham will be delivered transcutaneously in random consecutive sessions
62486477|NCT02436200|EXPERIMENTAL|Intervention|Patients receiving neuromuscular electrical stimulation.
62486478|NCT02108535|EXPERIMENTAL|Nanocrystalline silver|Flexible polyester low-grip coated nanocrystalline silver dressing. The dressing was applied to the lesion after being soaked in sterile distilled water. About this compresses to bandage movements will have been added and comes to avoid tourniquet bandage on-site maintenance, temperature of the affected area, cushioning and absorption of wound exudate when present. Is finished with the application of crepe bandages in the form of flakes containment curative and maintenance of pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, avoiding tourniquet. The exchanges were performed every three days.
62486479|NCT02108535|ACTIVE_COMPARATOR|Silver sulfadiazine|Ranges for rayon containing cream 1% silver sulfadiazine were used. Involving this layer, bandages for dressings were added in movements back and forth to avoid the tourniquet, providing maintenance of the temperature of the affected area, cushioning and absorption of wound exudate when present. This application was completed with crepe bandages to contain the dressing and maintain pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, scales, avoiding the tourniquet. Dressing changes were performed daily.
62486480|NCT04020458|ACTIVE_COMPARATOR|Periodontitis, no kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
62486481|NCT04020458|ACTIVE_COMPARATOR|Experimental- chronic kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
62486482|NCT04020458|NO_INTERVENTION|Control- no Periodontitis or kidney disease.|Only regular dental cleaning
62486483|NCT00807495|EXPERIMENTAL|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
62486484|NCT01152645|EXPERIMENTAL|ARQ 197|
62486485|NCT05062564|EXPERIMENTAL|LipiFlow group|Single preoperative treatment with the thermal pulsation system LipiFlow within two months before cataract surgery
62486486|NCT05062564|ACTIVE_COMPARATOR|Control group|Eyelid warm compresses plus eyelid massage twice a day for the preoperative month
61934862|NCT05437159|EXPERIMENTAL|Sub-syllabic learning and anodal tDCS of cerebellum|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable words formed by non-native phoneme combinations. During the training, continuous anodal transcranial direct current stimulation (tDCS) will be applied to the the subject's right cerebellum.
61934863|NCT05437159|SHAM_COMPARATOR|Sub-syllabic learning and sham tDCS|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable words formed by non-native phoneme combinations. During training, Sham transcranial direct current stimulation stimulation (tDCS) will be delivered to the subject's brain.
62134361|NCT02478177||Stroke|Patients who had an acute ischemic stroke while taking one of the novel oral anticoagulants or patients who had an intracerebral hemorrhage while taking warfarin or one of the novel oral anticoagulants
62134362|NCT01838343|NO_INTERVENTION|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
62134363|NCT01838343|EXPERIMENTAL|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
62328553|NCT02734602|NO_INTERVENTION|Single PET scan|Subjects will participate in 1 PET scan (up to 2 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan.
62328554|NCT02734602|ACTIVE_COMPARATOR|PET scans and ketamine administration|"Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.~Bipolar subjects will not participate in any ketamine arms."
62328555|NCT02734602|NO_INTERVENTION|PET scans for subjects undergoing ketamine treatment|"For subjects currently undergoing treatment with ketamine. Subjects will participate in 1-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. Baseline scan will occur prior to initiation of ketamine treatment. Subsequent scans will occur after several treatments with ketamine and after completion of treatment.~Bipolar subjects will not participate in any ketamine arms."
62328556|NCT02544971|EXPERIMENTAL|NF-N group|Neurofeedback in a neutral context
62328557|NCT02544971|ACTIVE_COMPARATOR|NF-T group|Neurofeedback in a trauma-related context
62134364|NCT01485887|EXPERIMENTAL|Venlafaxine ER|
62328558|NCT02544971|ACTIVE_COMPARATOR|Control group|Treatment as usual
62328559|NCT04776356||QuickFix Small Staple|The QuickFix Small Staple will be used for an Akin osteotomy to correct hallux valgus interphalangeus.
62328560|NCT00102453|EXPERIMENTAL|Solution|All enrolled participants were give pentoxifylline in this pilot protocol.
62328561|NCT02526927|EXPERIMENTAL|Patients 20 - 30 years-old|HR-pQCT and DEXA for measure bone quality and quantity
62486487|NCT06140082||Gene mutation-type group|According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected, genetic testing was performed, GSTP1 mutant (AG/GG) was classified into this group, and the time and degree of myelosuppression in this group were recorded.
62486488|NCT06140082||Gene wild-type group|According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected for genetic testing, GSTP1 wild type (AA) was classified into this group, and the time and degree of myelosuppression in this group were recorded.
62486489|NCT06139133|PLACEBO_COMPARATOR|Placebo supplementation Group|Pregnant women with 07-11 weeks of gestation having normal response to 75g OGTT but with low levels of Vitamin D3 (\<30ng/ml) will be included. The study subjects will be randomly assigned to receive placebo until delivery.
62486490|NCT06139133|EXPERIMENTAL|Vitamin D supplementation group|pregnant women with 07-11 weeks of gestation having normal response to 75g OGTT but with low levels of Vitamin D3 (\<30ng/ml) will be included for Vitamin D3 supplementation (2 00,000 IU/Week) for 04 -06 week. The study subjects will be randomly assigned to receive vitamin D3 supplementation (2 00,000 IU/Week) for 04 -06 weeks.
62134365|NCT01998958|EXPERIMENTAL|Esketamine 14 mg|Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
62134366|NCT01998958|EXPERIMENTAL|Esketamine 28 mg|Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
62328562|NCT02526927|EXPERIMENTAL|Patients 10 - 20 years-old|Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
62328563|NCT02462005||ALL COMERS|Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.
62328564|NCT06388590|EXPERIMENTAL|Patient Cohort: Control|Patient sample will be both control and treatment groups. Individuals will not be divided into distinct groups. Patients will serve as their own controls. Control patients will be participating in standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention. The same patients will then crossover and be re-evaluated and will be offered Acupuncture with Dragon technique (see attachment Protocol for Needle Insertion) as a means of pain control once per week for 4 weeks.
62486491|NCT03720444||MDT (mechanical diagnosis and therapy) method|
62134367|NCT01998958|EXPERIMENTAL|Esketamine 56 mg|Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
62134368|NCT01998958|EXPERIMENTAL|Esketamine 84 mg|Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
62134369|NCT01998958|PLACEBO_COMPARATOR|Placebo|Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
62486492|NCT01174849|ACTIVE_COMPARATOR|Synflorix|
62486493|NCT01174849|ACTIVE_COMPARATOR|Prevenar13|
62486494|NCT01174849|EXPERIMENTAL|COMBO|COMBINATION SCHEDULE of comparator vaccine 1 and comparator vaccine 2 Synflorix at 1,2,4 months then Prevenar13 at 6 months.
62486495|NCT06393530|SHAM_COMPARATOR|Sham group|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
62486496|NCT06393530|ACTIVE_COMPARATOR|ESPB group|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0.2% Ropivacaine
62486497|NCT05442086|EXPERIMENTAL|Music and Theta Auditory Beat Stimulation|Behavioural: Listening to calm music and auditory beat stimulation Participants will listen to calm music with theta auditory beat stimulation for 24 minutes
62486498|NCT05442086|SHAM_COMPARATOR|Pink Noise (control)|Behavioural: Listening to pink noise Participants listened to pink noise for 24 minutes
62486499|NCT03904095|ACTIVE_COMPARATOR|Psoas compartment block group (PCB)|Single- shot ultrasound (Esaote Mylab30) guided PCB with 15 ml 0.25% bupivacain ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the PCB group (Group I).
62486500|NCT03904095|ACTIVE_COMPARATOR|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the ESP group (Group II).
62486501|NCT03904095|PLACEBO_COMPARATOR|The Control group|The Control group receive no intervention ( Group III).
62486502|NCT04571294|EXPERIMENTAL|group A|PALN removal
62486503|NCT04571294|NO_INTERVENTION|group B|No PALN removal
62486504|NCT04273971|EXPERIMENTAL|Plyometric exercise|
62486505|NCT03375957|EXPERIMENTAL|ATx201 2% Gel|
62486506|NCT03375957|EXPERIMENTAL|ATx201 4% Gel|
62486507|NCT03375957|PLACEBO_COMPARATOR|ATx201 Gel Placebo|
62486508|NCT03005366|ACTIVE_COMPARATOR|Flecainide|Conventional cardioversion group using intravenous flecainide.
61934864|NCT05437159|EXPERIMENTAL|Multisyllabic learning and fMRI in adults|30 adults persistent developmental stuttering (AWS) and 30 adults with neurotypical speech development (ANS) will participate in this arm. Subjects will learn nonsense words formed by novel combinations of 3 syllables that are legal in American English during 6 training sessions over 2 days. Following training, subjects will participate in a functional magnetic resonance imaging (fMRI) session on a third day to measure brain activity associated with producing the words formed by pairing 2 learned 3-syllable strings learned during training and those formed by pairing 2 unfamiliar 3-syllable strings. Behavioral measures extracted from the data will be used to compare performance before and after training and across the AWS and ANS participants.
62134370|NCT02911441|EXPERIMENTAL|Treatment Group|Receives 8-12 weeks of one-on-one Cognitive Behavioral Therapy sessions
62328565|NCT06388590|EXPERIMENTAL|Patient Cohort: Intervention|Patient sample will be both control and treatment groups. Individuals will not be divided into distinct groups. Patients will serve as their own controls. Control patients will be participating in standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention. The same patients will then crossover and be re-evaluated and will be offered Acupuncture with Dragon technique (see attachment Protocol for Needle Insertion) as a means of pain control once per week for 4 weeks.
62328566|NCT05826197||Axillary lymph node metastasis|
62328567|NCT05826197||No axillary lymph node metastasis|
62328568|NCT02021058|EXPERIMENTAL|Experimental Formula|Experimental Formula
62328569|NCT02021058|OTHER|Standard Formula|Standard Control formula
62328570|NCT02600026|EXPERIMENTAL|Video Camera: Intervention|DriveCam video event recorder with feedback
62328571|NCT02600026|PLACEBO_COMPARATOR|Video Camera: Monitoring|DriveCam video event recorder with no feedback
62328572|NCT06257706|OTHER|Group 1: Corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission|Group 1 will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH.
62328573|NCT06257706|OTHER|Group 2: Corticosteroid-free clinical remission + biomarker remission.|Group 2 will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission.
62328574|NCT01822470||Study group|a. Study Subjects will be recruited from patients who are already undergoing upper enteroscopy and aspiration for diagnosis of SIBO.
62328575|NCT01822470||Control group|b. Control Subjects will be recruited from patients who are already undergoing a double balloon enteroscopy or upper enteroscopy for another medical reason
62486509|NCT03005366|ACTIVE_COMPARATOR|Vernakalant|Atria-preferential and atrial-specific blockade group using intravenous vernakalant.
62697549|NCT05841667||CES1 without or without single nucleotide polymorphism (SNP)|We will determine the CES1 genotype of participants through a laboratory test. Several different types of SNPs can be identified, and analyses can be further stratified by CES1 SNP type.
62134371|NCT02911441|NO_INTERVENTION|Control Group|Receives no intervention during data-collection phase. Participants in this group will receive the intervention post-data collection.
62134372|NCT04111471|PLACEBO_COMPARATOR|Placebo Arm|20 patients will receive 5.6 g of placebo product (maltodextrin) daily for a total of 21 days (7 days before and until 2 weeks after transplant)
62134373|NCT04111471|EXPERIMENTAL|Prebiotic (Inulin) Arm|20 patients will receive 10 g of inulin product daily for a total of 21 days (7 days before and until 2 weeks after transplant)
62486510|NCT06270745||Indocyanine Green|Indocyanine green infusion during digestive system surgery
62486511|NCT06270745||non-Indocyanine Green|No indocyanine green infusion during digestive system surgery
62697550|NCT05726968|ACTIVE_COMPARATOR|● Group P1 (N 15)|Patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
62486512|NCT04085861|EXPERIMENTAL|Dancers|Recruited group of professional dancers from the Norwegian University of dance
62486513|NCT04085861|NO_INTERVENTION|Control|Recruited group of professional art students from the Oslo Academy of the Arts (Norway)
62134374|NCT01780675|ACTIVE_COMPARATOR|Prophylactic Cranial Irradiation|Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)
62134375|NCT01780675|EXPERIMENTAL|Hippocampal Avoidance PCI|Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).
62328576|NCT05952856|EXPERIMENTAL|Enlicitide Decanoate|Participants will receive 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks.
62328577|NCT05952856|PLACEBO_COMPARATOR|Placebo|Participants will receive enlicitide decanoate-matching placebo orally QD for up to 52 weeks.
62328578|NCT01062451|PLACEBO_COMPARATOR|Placebo|
62328579|NCT01062451|ACTIVE_COMPARATOR|Perindopril|
62328580|NCT01062451|ACTIVE_COMPARATOR|Candesartan|
62486514|NCT04085861|EXPERIMENTAL|Dance teachers|Recruited group of dance teachers from the Norwegian University of dance
62486515|NCT05448209|EXPERIMENTAL|Experimental|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
62486516|NCT05448209|NO_INTERVENTION|control group|control group will receive standard practice
62486517|NCT04637139|EXPERIMENTAL|Group 1|VBR 300 mg solution containing 2 µCi \[14C\]VBR
62486518|NCT06022107|EXPERIMENTAL|LDART|Participants will be asked to log onto the LDART website each night for a month.
62486519|NCT04210557|ACTIVE_COMPARATOR|TMS to insula|"This study will recruit 30 clinical voice hearers (P+H+). They will complete two parallel forms of the conditioned hallucinations task (with different visual and auditory stimuli) on two occasions, separated by a week.~TMS and sham will be delivered in a randomized counterbalanced order. Hypothesis: Inhibiting the insula will decrease prior over-weighting. If this computational perturbation is responsible for conditioned hallucinations, then ameliorating it with TMS that increases insula engagement will decrease conditioned hallucination responses. Furthermore, the prior weighting parameter will be reduced following active TMS compared with sham."
62134376|NCT04783025|EXPERIMENTAL|Intervention Group (IG)|The participants in the IG will receive BGCTS, a blended training programme
62328581|NCT04792853|EXPERIMENTAL|Tab-G (tablet-based group CBT education)|Tab-G participants will receive 4 weekly CBT(cognitive behavioral therapy)-based group learning sessions to encourage a simple walking activity through videoconferencing meetings in a group of 5 members. The educational materials emphasize shared goal setting and mutual reinforcement.
62328582|NCT04792853|NO_INTERVENTION|Usual care group|A usual care group will receive general arthritis management education. Participant are instructed to maintain usual activity during the study period.
62328583|NCT02179515|EXPERIMENTAL|modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine|Three cohorts will receive modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
62328584|NCT06227390|EXPERIMENTAL|MTA and stainless-steel crown|
62328585|NCT06227390|EXPERIMENTAL|Biodentine® and stainless-steel crown|
62328586|NCT06227390|EXPERIMENTAL|TheraCal PT® and stainless-steel crown|
62328587|NCT06227390|EXPERIMENTAL|MTA and glass ionomer restoration|
62328588|NCT06227390|EXPERIMENTAL|Biodentine® and glass ionomer restoration|
62328589|NCT06227390|EXPERIMENTAL|TheraCal PT® and glass ionomer|
62328590|NCT02647762|EXPERIMENTAL|CF101 1mg|CF101 1mg, orally q12 hours
62328591|NCT02647762|EXPERIMENTAL|CF101 2mg|CF101 2mg, orally q12 hours
62328592|NCT02647762|ACTIVE_COMPARATOR|MTX once weekly|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.
62328593|NCT02647762|PLACEBO_COMPARATOR|Placebo|Placebo control , orally q12 hours
62693337|NCT05833542|EXPERIMENTAL|Health education materials only|"Participants will receive informational materials on their HIV treatment options and related support-service options. These will include a brief Frequently Asked Questions document with answers and a video comparing long-acting injectable with daily oral antiretroviral therapy, and explaining considerations for patients who may be interested in long-acting injectable treatment options. Both components are designed for patient self-guided use, but can also be presented or discussed in a session with medical case management program staff."
62693338|NCT05833542|EXPERIMENTAL|Health education materials and shared patient-provider decision tool|Prior to or during a medical case management visit, participants will receive informational materials (described above) on their HIV treatment options and related support-service options. During their medical case management visit, the participant and their medical case management provider will review a shared decision tool to facilitate patient-provider agreement on an HIV treatment plan.
62134377|NCT04783025|ACTIVE_COMPARATOR|Control Group (CG)|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staff.
62134378|NCT02292004|EXPERIMENTAL|ACL repair with MIACH scaffold|Patients will undergo ACL repair surgery using the newly developed MIACH scaffold
62134379|NCT02292004|ACTIVE_COMPARATOR|Standard ACL reconstruction|Patients will undergo a standard ACL reconstruction surgery
62328594|NCT05437224|EXPERIMENTAL|ambrisentan|Open Label
62328595|NCT03455478|EXPERIMENTAL|corrected refractive error|
62328596|NCT03455478|NO_INTERVENTION|uncorrected refractive error|
62134380|NCT00402246|EXPERIMENTAL|Remote Arm|Remote Management
62134381|NCT00402246|ACTIVE_COMPARATOR|In-office Arm|In-Office Care
62328597|NCT02075762|ACTIVE_COMPARATOR|Transbronchial biopsy|S-TBBx will be performed using standard biopsy forceps (Boston Scientific, Natick, MA) - 2.0mm diameter.
62328598|NCT02075762|ACTIVE_COMPARATOR|Cryoprobe biopsy|C-TBBx will be performed using the cryoprobe (ERBE, Tubingen, Germany) -1.9 mm diameter, 78cm in length. This cryoprobe is routinely used in the bronchoscopy suite for carcinoma-TBBX; therefore it is a technique already employed by the interventional pulmonologists who are familiar with its use.
62328599|NCT02075762|ACTIVE_COMPARATOR|VATS biopsy|Once the biopsies are obtained by the interventional pulmonologist, the thoracic surgeon will perform VATS biopsy. Following their procedure, subjects will be monitored in the post-anesthesia care unit as per standard of care. As part of their ongoing follow-up care, all subjects will be monitored for any adverse events that may have resulted from either the surgical or bronchoscopic procedure, specifically bleeding or pneumothorax.
62328600|NCT05520996|EXPERIMENTAL|one arm study|Memory test performed before and after cyberball task
62328601|NCT01757639|EXPERIMENTAL|Treatment (ipilimumab)|"INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 12 weeks after last dose of induction ipilimumab, patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62328602|NCT03709810|EXPERIMENTAL|Test Denture Adhesive|Test denture adhesive will be applied directly from the tubes using a continuous strip pattern to the upper and lower denture which will then be placed in mouth of the participants.
62328603|NCT03709810|OTHER|Control|Participants will not apply any denture adhesive in this treatment arm.
62328604|NCT04729088|EXPERIMENTAL|Test Drug|Isosorbide 0.5% gel
62328605|NCT02973464||Valganciclovir 900mg a day|Valganciclovir 900mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
62486520|NCT04210557|ACTIVE_COMPARATOR|TMS to cerebellum|This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.
62486521|NCT01342939||MODY2|Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.
62486522|NCT01342939||MODY3|Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.
62486523|NCT01342939||Healthy control subjects|
62486524|NCT01140438|ACTIVE_COMPARATOR|Metformin + NPH Insulin|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization insulin treatment will be added in the form of injections of NPH insulin in the evenings.
62486525|NCT01140438|ACTIVE_COMPARATOR|Metformin + sitagliptin +/-repaglinid|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is \> 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
62486526|NCT01261949|EXPERIMENTAL|Combined frontal and temporal rTMS|Combined low frequency frontal and temporal transcranial magnetic stimulation of auditory cortex and right DLPFC
62486527|NCT01261949|EXPERIMENTAL|Temporal low frequency rTMS|temporal low frequency rTMS of auditory cortex
62486528|NCT00735176|EXPERIMENTAL|Artificial Cervical Disc|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
62486529|NCT00735176|ACTIVE_COMPARATOR|ACDF|Anterior cervical discectomy and fusion (ACDF)
62486530|NCT03499873|EXPERIMENTAL|Nepafenac 0.3% Opthalmic Suspension|Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.
62486531|NCT03499873|ACTIVE_COMPARATOR|Ilevro 0.3% Opthalmic Suspension|Reference product manufactured by Alcon Laboratories Inc.
62486532|NCT03499873|PLACEBO_COMPARATOR|Placebo (vehicle) Opthalmic Suspension|Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.
62486533|NCT00860886||1|Mongolian Women
62486534|NCT00860886||2|Women in other parts of the world other than Mongolia.
62486535|NCT01624272|NO_INTERVENTION|Control|Usual care
62328606|NCT02973464||Valganciclovir 450mg a day|Valgancigclovir 450 mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
62328607|NCT02973464||Ganciclovir|Ganciclovir 5mg/kg fluids by intravenous after renal transplant，once a day for the first 14 days；and than sequential Ganciclovir 1g tablet by mouth，third a day till to Day 100 posttransplant.
62328608|NCT04371172||Patients with TAVI|cognitive research battery, MRI, laboratory values
62328609|NCT03568149||Group A: endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
62486536|NCT01624272|EXPERIMENTAL|Threshold Inspiratory Muscle Training|Inspiratory muscle training regime
61934865|NCT05437159|EXPERIMENTAL|Multisyllabic learning in children|45 children with persistent developmental stuttering (CWS) and 45 children with neurotypical speech development (CNS) will participate in this arm. Subjects will learn nonsense words formed by novel combinations of 2 syllables that are legal in American English during 6 training sessions over 2 days. Behavioral measures extracted from the data will be used to compare performance before and after training and across the CWS and CNS participants.
62134382|NCT04425863||Mild cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
62328610|NCT03568149||Group B: no endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
62328611|NCT05740436||Frail elderly subjects|Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
62486537|NCT01624272|EXPERIMENTAL|Controlled breathing exercises|Yoga Pranayama breathing exercises
62486538|NCT02974907|EXPERIMENTAL|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
62486539|NCT02974907|PLACEBO_COMPARATOR|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
62486540|NCT06070480|ACTIVE_COMPARATOR|Spinal Anesthesia Group|Intraocular pressure values of the patients operated with spinal anaesthesia were measured
62486541|NCT06070480|ACTIVE_COMPARATOR|Desflurane Group|Intraocular pressure values were measured in patients operated under general anaesthesia with desflurane.
62486542|NCT06070480|ACTIVE_COMPARATOR|Propofol Group|Intraocular pressure values were measured in patients operated under general anaesthesia with desflurane.
62486543|NCT03223779|EXPERIMENTAL|TAS-102|"* Photon treatments will be performed on a linear accelerator~* Photon SBRT will be given during TAS-102 dosing~* TAS-102 dosing occurs on days 1 through 5 and 8 through 12~* TAS-102 tablets should be taken twice a day orally"
62328612|NCT05740436||Pre-Frail elderly subjects|Pre-Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
62328613|NCT05740436||Non-frail elderly Frail subjects|Non-frail Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
62328614|NCT05437172|EXPERIMENTAL|injectable platelet rich fibrin with deminerlized dentin graft|injectable platelet rich fibrin with deminerlized dentin graft for ridge preservation after teeth extraction
62328615|NCT05437172|ACTIVE_COMPARATOR|deminerlized dentin graft|deminerlized dentin graft for ridge preservation after teeth extraction
62328616|NCT04081649||Cardiac surgery|Patients undergoing non-emergent cardiac surgery for coronary bypass graft and/or valvular replacement
62328617|NCT03341897|EXPERIMENTAL|Surgical varicocelectomy|
62486544|NCT06457308|EXPERIMENTAL|Agility exercise training.|Participants attend training class focused on agility training. Rope ladders and cones are used to perform multiple tasks of direction changes, acceleration and deceleration of footsteps, hand and foot coordination and spatial orientation training.
62697551|NCT05726968|ACTIVE_COMPARATOR|● Group P2 (N 15)|Patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).
62134383|NCT04425863||Moderate cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR\> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
62328618|NCT02026622|OTHER|3 groups of subjects|"3 groups: depressive subjects, subjects remitted from depression and control subjects, with the same interventions.~psychometric tests, MRI, transcranial doppler and TPI, explicitative interview"
62134384|NCT04425863||Severe cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia
62134385|NCT03680638|SHAM_COMPARATOR|Control (Lactated Ringer's)|This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
62134386|NCT03680638|EXPERIMENTAL|Tempol|This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
62134387|NCT03680638|EXPERIMENTAL|Apocynin|This site will only be infused with apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone; 100µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
62134388|NCT03680638|EXPERIMENTAL|Allopurinol|This site will only be infused with tempol (1H-pyrazolo\[3,4-d\]pyrimidin-4(2H)-one; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
62134389|NCT06459193|ACTIVE_COMPARATOR|Intervention|Trimetazidine Tablet 35 mg once daily for the treatment period
62134390|NCT06459193|PLACEBO_COMPARATOR|Control|Placebo once daily for the treatment period
62134391|NCT05629793|EXPERIMENTAL|Persistent COVID group|Patients with persistent COVID will be recruited by the physicians of the Post COVID-19 Multidisciplinary Clinic of the Complexo Hospitalario Universitario de Ourense.
62134392|NCT05629793|EXPERIMENTAL|Recovered COVID group|The controls will be recruited in a matched manner with the clinical sample in age, sex, epidemic wave and vaccination status, from among previously COVID-positive patients cured without sequelae and attended in Primary Care in the Health Centers of A Cuña, Valle Inclán and Novoa Santos in Ourense.
62134393|NCT00275288||Healthy Normal|
62134394|NCT00275288||Active Disease|
62134395|NCT06035536|EXPERIMENTAL|Symphony™ treatment|Arm receives an application of Symphony™ treatment and appropriate Off-loading.
62134396|NCT06035536|ACTIVE_COMPARATOR|Standard of Care (SOC) treatment|Arm receives an application of SOC comprising of calcium alginate Fibracol dressing and appropriate Off-loading.
62328619|NCT03166436|EXPERIMENTAL|RFA plus stenting|Endoluminal radiofrequency ablation followed by biliary stenting
62328620|NCT03166436|ACTIVE_COMPARATOR|Stenting alone|Biliary stenting alone
62134397|NCT03755752|EXPERIMENTAL|Phacoemulsification with Trypan Blue|Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy
62134398|NCT03755752|EXPERIMENTAL|Phacoemulsification without Trypan Blue|Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with
62134399|NCT05379075|EXPERIMENTAL|Female students of Chen Taichi training based on Relaxation guidelines|"Relaxation theory is different from coordination. It only focuses on relaxing the body and mind to an extreme level. Previously, masters of Taichi described or taught it as relax or let nature take its course. This explanation may lead to ignoring it since it is against intuition. Pavel explained the relaxation method as mastering muscle tension. The critical point of Pavel's book is the viewpoint of canceling the stretch reflection. The present study applied this viewpoint to judge the extent and rotation degree when practicing taichi. In other words, students will be taught this skill to relax their bodies when the tension comes out from low posture movements. The relaxation skills also include dropping the control of the body, exhale when stretching, moving like a string puppet without muscle power, steps like cats, and three-line relaxation method. Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
62328621|NCT04761094||Insulin pump|All patient treated with insulin pump.
62328622|NCT06295081||Walkers|Amateur athletes who perform a walking exercise with a minimum distance of 20 km
62328623|NCT06295081||Runners|Amateur athletes who perform a running exercise with a minimum distance of 15 km
62328624|NCT06295081||Cyclists|Amateur athletes who perform a cycling exercise with a minimum distance of 100 km
62328625|NCT02260167|EXPERIMENTAL|Treatment with MIND|
62328626|NCT05508776|EXPERIMENTAL|LEO 152020 Dose A|A single oral dose of LEO 152020 Dose A according to the randomization schedule.
62328627|NCT05508776|EXPERIMENTAL|LEO 152020 Dose B|A single dose of LEO 152020 Dose B according to the randomization schedule.
62328628|NCT05508776|ACTIVE_COMPARATOR|Moxifloxacin|A single oral dose of moxifloxacin 400 mg according to the randomization schedule.
62328629|NCT05508776|PLACEBO_COMPARATOR|Placebo|A single dose of placebo according to the randomization schedule.
62486545|NCT06457308|ACTIVE_COMPARATOR|Resistance exercise training.|Participants attend training class focused on resistance training. Resistance training for upper and lower limb muscles and core muscles, including squats, use of elastic bands, and simple bars.
62486546|NCT06457308|NO_INTERVENTION|Control|Participants only receive osteoporosis education usual care.
62486547|NCT06255145|EXPERIMENTAL|Experimental group|In all participants, body composition evaluation was carried out with the Beurer BF 1000 Super Precision device using the Bioelectrical Impedance Analysis principle, fatigue evaluation was carried out with the Fatigue Severity Scale, mobility evaluation was carried out with the Rivermead Mobility Index, and functional status evaluation was carried out with the Functional Independence Scale.
62486548|NCT06255145|ACTIVE_COMPARATOR|Control Group|In all participants, body composition evaluation was carried out with the Beurer BF 1000 Super Precision device using the Bioelectrical Impedance Analysis principle, fatigue evaluation was carried out with the Fatigue Severity Scale, mobility evaluation was carried out with the Rivermead Mobility Index, and functional status evaluation was carried out with the Functional Independence Scale.
62486549|NCT06462027|EXPERIMENTAL|Packed Red Blood Cells (1 unit)|500 mL of packed red blood cells
62486550|NCT06462027|EXPERIMENTAL|Packed Red Blood Cells (2 units)|1000 mL of packed red blood cells
62486551|NCT06462027|PLACEBO_COMPARATOR|Saline solution|Treatment of 500 mL of normal saline.
62328630|NCT03003143|EXPERIMENTAL|Vigabatrin treatment group|
62328631|NCT05655390|NO_INTERVENTION|Treatment As Usual|(TAU)
62328632|NCT05655390|EXPERIMENTAL|Intervention Group|Treatment As Usual + Safety Intervention Planning.
62328633|NCT01848964|EXPERIMENTAL|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
62328634|NCT05122663||ED Physical Therapy|Patients in the ED physical therapy group will have been evaluated by an emergency department physical therapist for dizziness/vertigo during their index ED visit.
62328635|NCT05122663||Usual Care|Patients in the usual care group will NOT have received an evaluation by an ED physical therapist for dizziness/vertigo symptoms during their index ED visit.
62486552|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & HGB|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and the Hipogastric component (HGB)
62693339|NCT05810467||Control Arm|"Men diagnosed with low-grade PrCa undergoing Active Surveillance and are not known to have an increased genetic risk for PrCa e.g. Men without high-risk mutations or high polygenic risk score (PRS).~Men diagnosed with PrCa suitable for Active Surveillance who wish to continue follow up at The Royal Marsden Hospital (RMH) will be offered enrolment in collection and monitoring of various biological samples. These men will act as a control group, as they do not have a known higher genetic risk of PrCa. The control group will have genetic analysis carried out on provided saliva samples. Their family history will be captured. They will be genotyped using the latest technology and at a minimum have PRS testing done.~Men may be moved out of the control arm and into the high-risk arm, if identified at a higher genetic risk or as having a strong family history of PrCa for the purposes of the analysis. Any clinically significant genetic results will be discussed with the participants."
62134400|NCT05379075|EXPERIMENTAL|Male students of Chen Taichi training based on Relaxation guidelines|"Relaxation theory is different from coordination. It only focuses on relaxing the body and mind to an extreme level. Previously, masters of Taichi described or taught it as relax or let nature take its course. This explanation may lead to ignoring it since it is against intuition. Pavel explained the relaxation method as mastering muscle tension. The critical point of Pavel's book is the viewpoint of canceling the stretch reflection. The present study applied this viewpoint to judge the extent and rotation degree when practicing taichi. In other words, students will be taught this skill to relax their bodies when the tension comes out from low posture movements. The relaxation skills also include dropping the control of the body, exhale when stretching, moving like a string puppet without muscle power, steps like cats, and three-line relaxation method. Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
62328636|NCT02891031|ACTIVE_COMPARATOR|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
62328637|NCT02891031|PLACEBO_COMPARATOR|Placebo|500 mg twice daily after meal for 6 weeks
62486553|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & VBx|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and Viabahn Balloon Expandable ( VBx)
62486554|NCT04067739||Readmission group|Readmission is defined as ICU readmission within ≤ 3 months of initial ICU discharge
62486555|NCT04067739||Non readmitted group|Non readmission is defined as no need for ICU readmission within ≤ 3 months of initial ICU discharge
62486556|NCT05802563||Heart Failure|Study participants with systolic heart failure (Left ventricular ejection fraction \< 35%) without documented atrial fibrillation
62486557|NCT05802563||Atrial Fibrillation|Study participants with documented atrial fibrillation without heart failure
62486558|NCT05802563||Reference|Individuals without cardiovascular disease
62328638|NCT01540188|NO_INTERVENTION|Starndard care arm|Participants of the standard care arm are control groups of IDUs and family members. They do not attend intervention sessions.
62328639|NCT01540188|EXPERIMENTAL|Intervention arm|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
62328640|NCT00659919|PLACEBO_COMPARATOR|Placebo|The patients in this arm received placebo
62328641|NCT00659919|ACTIVE_COMPARATOR|Trazodone|The patients on this arm received Trazodone for 3 consecutive days
62328642|NCT02739594|EXPERIMENTAL|Ibandronate|Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
62486559|NCT05444803|OTHER|Femoral nerve block group|Thirty minutes before the placement of spinal block, patients will be receive a femoral nerve block with Bupivacaine.
62486560|NCT05444803|OTHER|Peri-capsular nerve group block group|Thirty minutes before the placement of spinal block, patients will be receive a peri-capsular nerve group block with Bupivacaine.
61934866|NCT05437159|EXPERIMENTAL|Sub-syllabic learning in PPA|30 adults with primary progressive aphasia (PPA) will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations during 8 training sessions over 2 days. Following training, subjects will complete a behavioral test to compare their performance on the words learned during training with a set of unfamiliar words also formed by non-native phoneme combinations.
62328643|NCT02739594|ACTIVE_COMPARATOR|Zoledronate|Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
62328644|NCT03415477|EXPERIMENTAL|denosumab (Xgeva) treatment|Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
61934867|NCT06243224|ACTIVE_COMPARATOR|High intensity interval training (HIIT)|Patients will receive high intensity interval training (HIIT).
62328645|NCT03026543|EXPERIMENTAL|Pulmonary recruitment maneuver|One minute of ventilator-piloted PRM at the end of laparoscopic cholecystectomy, intending to remove residual carbon dioxide (CO2) from the abdomen.
62328646|NCT03026543|ACTIVE_COMPARATOR|Control group|Ordinary ventilation at the end of laparoscopic cholecystectomy.
62328647|NCT05828238|EXPERIMENTAL|[18F]SF-DEVD-2|
62328648|NCT01532323|EXPERIMENTAL|Oral disorder children|Oral disorder children aged 2 to 15 years
62328649|NCT01532323|ACTIVE_COMPARATOR|Control group|No oral disorder children aged 2 to 15 years
62328650|NCT05880368|EXPERIMENTAL|Patient partnership tool|Study participants as patients visiting primary care providers in the clinics using the study patient engagement tools aimed to reduce preventable adverse drug events.
62328651|NCT05880368|NO_INTERVENTION|Control|Study participants as patients visiting primary care providers in the clinics without the study patient engagement tools.
62328652|NCT03288272|ACTIVE_COMPARATOR|Arm 1 - WBRT 10 x 2 Gy|Arm 1 - WBRT 10 x 2 Gy Whole brain radiotherapy with a total dose of 20 Gy in single fractions of 2 Gy
62328653|NCT03288272|ACTIVE_COMPARATOR|Arm 2 - WBRT 15 x 2 Gy|Arm 2 - WBRT 15 x 2 Gy Whole brain radiotherapy with a total dose of 30 Gy in single fractions of 2 Gy
62328654|NCT03288272|ACTIVE_COMPARATOR|Arm 3 - Best Supportive Care|Symptomatic treatment includes steroids, pain medication, nutritional support etc.
62328655|NCT02288767|ACTIVE_COMPARATOR|Control group|For the traditional method group, crystalloid and colloid (maximum 50 ml/kg) are provided through the traditional method of assessing the blood pressure, heart rate and urine volume.
62328656|NCT02288767|EXPERIMENTAL|SVV group|The method of fluid administration to be employed (traditional or SVV via a FloTrac/ EV1000™ monitor) is determined based on the group. Fluid administration is performed in accordance with the group; in general, about 10 ml/kg/h is administered although it may vary for each patient depending on the preoperative fasting, fluid loss during surgery (evaporation, emanation, urination, surgical area, etc.), and blood loss. Crystalloid is administered in the SVV-monitored group with a target below SVV 12%, and a 200-300 ml of colloid (maximum 50 ml/kg) is loaded when SVV is above 12%. If the patient shows hypertension even when SVV is below 12%, a vasoconstrictor should be administered intermittently or consistently.
62328657|NCT06691945|EXPERIMENTAL|Prophylactic amnioinfusion|
62328658|NCT06691945|NO_INTERVENTION|Routine Care|
62328659|NCT02929095|EXPERIMENTAL|Patients in the dexmedetomidine group|Patients in the dexmedetomidine group are given 1 μg/kg/h of dexmedetomidine for 10 minutes on initiation of the procedure and then 0.2-0.7 μg/kg/h until end of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
62328660|NCT02929095|ACTIVE_COMPARATOR|Patients in the midazolam group|Patients in the midazolam group are given midazolam 0.02-0.05mg/kg bolus on initiation of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
62328661|NCT00817986|EXPERIMENTAL|Arbaclofen placarbil 20 mg|Arbaclofen placarbil 20 mg, BID, for 14 days including the taper period.
62328662|NCT00817986|PLACEBO_COMPARATOR|Placebo for Arbaclofen placarbil|Placebo for 14 days
61934868|NCT06243224|ACTIVE_COMPARATOR|Moderate intensity (MICT)|Patients will receive moderate intensity continuous training (MICT).
61934869|NCT06709833||Meningioma resection|patients undergoing resection for meningioma
61934870|NCT06709833||Glioma resection|Patients undergoing glioma resection as a control cohort for meningioma patients
61934871|NCT06709833||Healthy controls|Healthy controls without tumor and surgical resection
62328663|NCT00817986|EXPERIMENTAL|Arbaclofen placarbil 30 mg|Arbaclofen placarbil 30 mg, BID, for 14 days including the taper period.
62328664|NCT00817986|EXPERIMENTAL|Arbaclofen placarbil 40 mg|Arbaclofen placarbil 40 mg, BID, for 14 days including the taper period.
62328665|NCT03108755|EXPERIMENTAL|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
62328666|NCT03108755|PLACEBO_COMPARATOR|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
62328667|NCT03108755|EXPERIMENTAL|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
62486561|NCT00604162|EXPERIMENTAL|PillCam COLON and Colonoscopy|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases, had capsule endoscopy with PillCam COLON after bowel preparation and before standard colonoscopy.
62486562|NCT05059262|EXPERIMENTAL|Part 1/Part 2 - vimseltinib/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) vimseltinib for 24 weeks in Part 1 and continue on 30 mg biw vimseltinib in Part 2
62486563|NCT05059262|PLACEBO_COMPARATOR|Part 1/Part 2 - placebo/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) matching placebo for 24 weeks in Part 1 and have option to receive 30 mg biw vimseltinib in Part 2
62486564|NCT04005690|EXPERIMENTAL|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
62486565|NCT04005690|EXPERIMENTAL|Arm II (cobimetinib)|Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
62486566|NCT04005690|EXPERIMENTAL|Arm IV (onvansertib)|Patients receive onvansertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
62693340|NCT05810467||High-risk Arm|"Men who have been diagnosed with low grade PrCa and are undergoing active surveillance who are at genetically higher risk of PrCa defined as:~1. Men of European ancestry with a family history defined as at least one first degree (or second degree if through the female line) relative with PrCa diagnosed at \<70 years (diagnosis verified).~2. Men of Black African or Caribbean ancestry irrespective of family history~3. Men of any ethnicity known to carry a mutation in a high-risk gene (Appendix A).~4. Men with a high genetic risk (common and/or rare variants) defined as those with a RR of ≥2."
62693341|NCT04857281|EXPERIMENTAL|nVNS device|Candidates who, after the screening period are eligible to receive the nVNS device.
62693342|NCT06642948|EXPERIMENTAL|Exercise group|Patients in the intervention group will engage in a home-based exercise program in addition to standard rehabilitation guidance.
62328668|NCT03108755|PLACEBO_COMPARATOR|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
62328669|NCT03108755|EXPERIMENTAL|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
62328670|NCT03108755|PLACEBO_COMPARATOR|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
62328671|NCT00972244|EXPERIMENTAL|1|1mg dapagliflozin
62328672|NCT00972244|EXPERIMENTAL|2|2.5mg dapagliflozin
62328673|NCT00972244|EXPERIMENTAL|3|5mg dapagliflozin
62328674|NCT00972244|EXPERIMENTAL|4|10mg dapagliflozin
62328675|NCT00972244|PLACEBO_COMPARATOR|5|Placebo
62328676|NCT01668563|ACTIVE_COMPARATOR|Endovascular management|Endovascular treatment will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
62328677|NCT01668563|ACTIVE_COMPARATOR|Surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
62328678|NCT00050349|EXPERIMENTAL|EPO906|
62328679|NCT03985072|EXPERIMENTAL|Andes-1537|There will be 5 different cohorts each representing a different type of solid cancer (gallbladder and biliary tract cancer, cervical cancer, gastric cancer, pancreatic cancer, and colorectal cancer). All patients will receive a dose of 400 mg of Andes-1537 five days per week for continuous cycles of 4 weeks that will be repeated until the patients presents drug toxicity requiring treatment discontinuation or disease progression without any noted clinical benefit as assessed by the investigator.
62328680|NCT02805868|EXPERIMENTAL|Treatment (siltuximab)|Patients receive siltuximab IV over 60 minutes on day 1. Patients also undergo bone marrow biopsy and aspiration at baseline and at the end of treatment (within 30 days of last siltuximab dose) or as clinically indicated. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are responding after 6 courses may receive additional siltuximab treatment for up to 1 year at the discretion of the study doctor.
62328681|NCT06692569|ACTIVE_COMPARATOR|Control|Conventional Physical Therapy
62328682|NCT06692569|EXPERIMENTAL|Experimental|Conventional Physical Therapy and modified constraint induced movement therapy
62328683|NCT04285346|OTHER|Open-label|ganaxolone suspension (50 mg/ml) TID for 12 weeks with 24 week extension
62328684|NCT03329937|EXPERIMENTAL|Participants with HER2-negative and BRCAmut breast cancer|Participants with HER2-negative and BRCAmut localized breast cancer (primary tumor \>=1 cm) will receive niraparib (200 mg PO).
62328685|NCT04898829|EXPERIMENTAL|PKU Explore|PKU Explore will be prescribed by the study dietitian based on the patient's individual requirement.
62486567|NCT04005690|EXPERIMENTAL|Arm V (azenosertib)|Patients receive azenosertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
62486568|NCT04005690|EXPERIMENTAL|Arm VI (AZD5305)|Patients receive AZD5305 PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
62486569|NCT04005690|EXPERIMENTAL|Arm VII (tremelimumab)|Patients receive tremelimumab IV over 60 minutes one-time. Within 12-24 hours of cycle completion, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
62486570|NCT01515605||Patients after kidney transplantation|Patients after kidney transplantation
62486571|NCT03129685|EXPERIMENTAL|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
62486572|NCT04143516|EXPERIMENTAL|Patients with Liver Metastases|The standard of care tumor ablation procedure, post-ablation biopsies and pre- and post-ablation PET scans. If the PET scan is positive (shows areas of cancer in the treated metastases), study participants will undergo additional needle biopsies of the positive areas on the scan. If the biopsies show areas of cancer cells that are still alive, the participants will be immediately retreated with a second ablation procedure.
62486573|NCT01237444|EXPERIMENTAL|lopinavir/ritonavir plus lamivudine|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
62486574|NCT01237444|ACTIVE_COMPARATOR|lopinavir/ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype"
62693343|NCT06642948|NO_INTERVENTION|Control group|Patients will receive guidance on breast cancer endocrine therapy-related knowledge, including exercise rehabilitation for bone and joint symptoms (including the freedom to choose the form, type, and intensity of exercise), psychological counseling, and health education.
62328686|NCT02191423|EXPERIMENTAL|postpartum depression|"Women suffering from postpartum depression, assessed by fMRI and then treated by dyadic psychotherapy~1. All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~2. All women in this group participate in 8-weeks of dyadic psychotherapy (DP) at the outpatient Psychiatric Department, Tel-Aviv Medical Center.~3. A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS \& STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
62328687|NCT02191423|OTHER|normal controls|"Normal control women not suffering from postpartum depression assessed by fMRI~1. All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~2. A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS \& STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
62328688|NCT02126904||IVR group|
62328689|NCT03091062|EXPERIMENTAL|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
62328690|NCT06512818|EXPERIMENTAL|INTERVENTION WITH PSIDIUM GUAVA EXTRACT|The volunteers in this group will undergo an intervention with a dose of 300 mg of psiguavin derived from Psidium guava extracts, three times a day, with each main meal.
62328691|NCT06512818|PLACEBO_COMPARATOR|PLACEBO CONTROLLED INTERVENTION|The volunteers in this group will undergo a placebo (microcellulose) with similar aspect than intervention, three times a day, with each main meal.
62328692|NCT04458727||Patients who used supportive measures during home training|
62328693|NCT04458727||patients who did not use supp. measures during home training|
62328694|NCT03442335||Recurrent miscarriage: 2+ miscarriages|Women who suffered 2 or more unexplained recurrent miscarriages.
62486575|NCT05517304|EXPERIMENTAL|tcVNS|Stimulation twice daily with transcutaneous Vagal Nerve Stimulation (tcVNS)
62486576|NCT05517304|ACTIVE_COMPARATOR|sham|stimulation with sham
62486577|NCT04212845|ACTIVE_COMPARATOR|Group ESP|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine and 8 mg dexamethasone
61934872|NCT04710420||WIfI stage 1|Very low risk of amputation was determined according to the SVS WIfI classification system.
61934873|NCT04710420||WIfI stage 2|Low risk of amputation was determined according to the SVS WIfI classification system.
62328695|NCT03442335||Extreme recurrent miscarriage: 5+ miscarriages|Women who suffered 5 or more unexplained recurrent miscarriages.
62328696|NCT02795351|EXPERIMENTAL|Active|Sildenafil 100 mg single dose
62328697|NCT02795351|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62486578|NCT04212845|ACTIVE_COMPARATOR|Group TF|Fluoroscopy-guided transforaminal injection with 4 ml of 0.25% bupivacaine and 8 mg dexamethasone
62486579|NCT05570539|ACTIVE_COMPARATOR|Immediate Release formulation|IR Formulation
62486580|NCT05570539|EXPERIMENTAL|Extended Release formulation|ER formulation
62486581|NCT03283982|ACTIVE_COMPARATOR|Robotic IPOM|Robotic Ventral Hernia Repair with IPOM: The da Vinci® Surgical System robotic platform (Intuitive Surgical, Inc.) will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
62486582|NCT03283982|ACTIVE_COMPARATOR|Laparoscopic IPOM|Laparoscopic Ventral Hernia Repair with IPOM: The standard laparoscopic platform will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
62693344|NCT04049214|OTHER|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
62697552|NCT05726968|ACTIVE_COMPARATOR|● Group P3 (N 15)|patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)
62697553|NCT02678533|EXPERIMENTAL|Fanconi anemia|G-CSF and Plerixafor
61934874|NCT04710420||WIfI stage 3|Moderate risk of amputation was determined according to the SVS WIfI classification system.
61934875|NCT04710420||WIfI stage 4|High risk of amputation was determined according to the SVS WIfI classification system.
61934876|NCT05523297|EXPERIMENTAL|Octaplex|Each participant to receive up to 2 Octaplex infusion intravenously within first 24 hours. Exceeding 24 hours frozen plasma will be administered
62328698|NCT06498739|OTHER|Erector Spinae Plane block (high concentration-low volume)|Patients will preoperatively receive high concentration-low volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patient).
62328699|NCT06498739|OTHER|Erector Spinae Plane block (low concentration-high volume)|Patients will preoperatively receive low concentration-high volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
62328700|NCT03890887|EXPERIMENTAL|All subjects: Reference followed by Test treatments|Reference - BI 1291583 alone. Test - BI 1291583 + Itraconazole
61934877|NCT05523297|ACTIVE_COMPARATOR|Frozen plasma|Each participant will be administered FP according to the local standard
61934878|NCT05476536|EXPERIMENTAL|experimental arm|self-management skills and healthy technology APP
62328701|NCT05275153|EXPERIMENTAL|Home based cognitive rehabilitation program|The intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
62328702|NCT05275153|NO_INTERVENTION|No intervention|In the control group, natural cognitive changes with the passage of time were observed.
62328703|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
61934879|NCT05476536|NO_INTERVENTION|control group|Health education leaflet
61934880|NCT00771316|EXPERIMENTAL|Group 1|MK0826 (ertapenem)
62328704|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
62328705|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
62328706|NCT05205434|EXPERIMENTAL|Synchronous telerehabilitation program (Video conference)|Participants will exercise program at home for an average of 30 minutes a day, 3 days a week, under the supervision of a physiotherapist via synchronized video conference. The program will continue for 8 weeks. The exercise program will consist of physical exercises (aerobic and strength exercises) along with breathing exercises and an educational program. Physical exercises will be adjusted in 3 different difficulty levels: sitting, standing with or without support.
62328707|NCT05205434|EXPERIMENTAL|Asynchronous telerehabilitation programme (Mobil app.)|The same exercises as in the synchronous telerehabilitation program will be done at the same frequency. Participants will watch the videos sent by the investigator via the mobile application and then do the exercises at home. The participants will meet with the investigator once a week to an update exercise program.
62693345|NCT02248233|EXPERIMENTAL|Saline + citicoline|The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days. Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment.
62697554|NCT01448642|ACTIVE_COMPARATOR|Atorvastatin|
62697555|NCT01448642|PLACEBO_COMPARATOR|Placebo|
62697556|NCT01161966|EXPERIMENTAL|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
61934881|NCT00771316|ACTIVE_COMPARATOR|Group 2|meropenem
61934882|NCT06324708|EXPERIMENTAL|Hip arthroplasty group|This single group is composed by patients undergoing hip arthroplasty
61934883|NCT01556737|EXPERIMENTAL|Supplement|
62328708|NCT05205434|NO_INTERVENTION|Control|Participants in this group will only receive an educational program
62328709|NCT05473624|EXPERIMENTAL|HRS-1167|
62328710|NCT05769842|EXPERIMENTAL|propofol group|Children aged 3 to 8 years who had had their tonsil adenoidectomy were collected. Propofol 3mg/kg, remifentanil 3-5ug /kg and atropine 0.01mg/kg were used for intravenous induction intubation. Sevoflurane was used for intraoperative anesthesia, propartamol 30mg/kg and hydromorphone 5-10ug /kg were used for postoperative analgesia.When sevoflurane was shut down at the end of the operation, oxygen flow was increased to more than 7L/min, and extubation was prepared for spontaneous respiration recovery, propofol was given a small amount of 1\~2mg/kg multiple times without inhibition of spontaneous respiration.
62328711|NCT05769842|SHAM_COMPARATOR|control group|Anesthesia induction is the same as before.At the end of the operation, sevoflurane was shut down and oxygen flow was increased to more than 7L/min. No other treatment was performed during extubation.
62328712|NCT05681741|SHAM_COMPARATOR|current pump flow (between 2 and 2.4 l/min/m²)|the pump flow will be constant during this randomized phase
62328713|NCT05681741|ACTIVE_COMPARATOR|high pump flow (between 2.6 and 3 l/min/m²)|the pump flow will be constant during this randomized phase
62328714|NCT04188340|PLACEBO_COMPARATOR|control group|using bergamot massage oil apply to GV20, GV24 SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
62328715|NCT04188340|EXPERIMENTAL|test group|using Su-Man formula massage oil ap-ply to GV20, GV24, SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
62697557|NCT01161966|ACTIVE_COMPARATOR|Zonegran|Zonegran Capsules 100 mg of EISAI INC
62697558|NCT00784017|ACTIVE_COMPARATOR|asparaginase medac|
62697559|NCT00784017|EXPERIMENTAL|recombinant asparaginase|
62697560|NCT03753516|ACTIVE_COMPARATOR|Laparoscopic - Vaginal Cuff Closure|
61934884|NCT01556737|PLACEBO_COMPARATOR|Placebo|
61934885|NCT01904565|EXPERIMENTAL|Thermoradiotherapy|Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
61934886|NCT04903522|EXPERIMENTAL|Depressive patients|Patients suffering from major depressive disorder with anxiety symptoms
61934887|NCT02643329|EXPERIMENTAL|BF-Gliclazide Tablet 80mg|During the study session, healthy male subjects will be administered a single oral dose of BF-Gliclazide Tablet 80 mg after an overnight fast of approximately 10 hours.
61934888|NCT02643329|ACTIVE_COMPARATOR|Diamicron 80mg Tablet|During the study session, healthy male subjects will be administered a single oral dose of Diamicron 80 mg Tablet after an overnight fast of approximately 10 hours.
61934889|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for cutaneous squamous cell carcinoma (CSCC) (A1)|Participants who have not received prior systemic therapy for metastatic or locally and/or regionally advanced unresectable CSCC and who are not eligible for curative radiation will receive vidutolimod intratumoral(ly) (IT) and cemiplimab intravenous (IV) according to the treatment schedule until a reason for treatment discontinuation is reached.
62134401|NCT05379075|ACTIVE_COMPARATOR|Female students of Chen Taichi training based on Coordination guidelines|"Coordination theory is also called three in one. It mainly guides exercisers to practice Taichi by integrating the mind, movements, and breathing in a unity state. Students in this group will be taught how to integrate the three requests according to the principles. The principles are Waist axis, Movements softy and slowly, Inspiratory contraction and Expiratory stretch. The training will be conducted on the warming-up time by practicing a single movement and the club time by practicing a learned routine.~Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
62328716|NCT04492956|EXPERIMENTAL|Ecopipam HCl ~2mg/kg/day|Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks
62328717|NCT04492956|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo tablets for daily, oral administration for 12 weeks
62328718|NCT01248624|ACTIVE_COMPARATOR|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
62328719|NCT01248624|PLACEBO_COMPARATOR|Conventional Cancer Care|This control arm receives standard cancer care.
62328720|NCT04368806|EXPERIMENTAL|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)
62328721|NCT04368806|PLACEBO_COMPARATOR|Placebo|Normal Saline with Autologous Serum
62328722|NCT00619411|EXPERIMENTAL|I|
62328723|NCT06556056|EXPERIMENTAL|SesZen-Bio Serum|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: liquid Frequency: Daily Night application. Rout of administration: Topical"
62328724|NCT06556056|ACTIVE_COMPARATOR|Minoxidil Hair Serum (1%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Rout of administration: Topical"
62328725|NCT06556056|PLACEBO_COMPARATOR|Placebo|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Rout of administration: Topical"
62328726|NCT03803904|EXPERIMENTAL|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
62328727|NCT03803904|ACTIVE_COMPARATOR|Control|Participants in the control group will be equalized (frequency and duration) to the Spin group for contact and monitoring. As such they will report to the same facility and interact with the same experienced interventionist; however instead of progressive Spin exercise they will participate in sessions focused on balance and stretching. Similar to the aerobic intervention, these exercises will take place in a group setting and heart rate will be consistently monitored during each session to verify heart rate does not reach 50% HRR.
62328728|NCT06242665|EXPERIMENTAL|Meal Delivery|"Dietary change (low ultra-processed meal delivery) and nutrition guidance to follow a low UPF diet.~All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following 2 weeks comprise the dietary intervention period. Meal delivery and nutritional guidance is provided by the study team for 14 days in accordance with a low UPF diet.~Visit 3 comprises post-intervention assessment All participants will complete remote assessments at 1 month and 6 month follow-ups."
62328729|NCT06242665|EXPERIMENTAL|Nutritional Guidance|"Dietary change (nutritional guidance)~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Nutritional guidance is provided by the study team for 14 days in accordance with a low UPF diet. Participants are delivered a box of snacks consistent with a low UPF diet.~Visit 3 comprises post-intervention assessment. All participants will complete remote assessments at 1 month and 6 month follow ups."
62693346|NCT02248233|EXPERIMENTAL|Nimodipine|"The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period.~Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment."
62693347|NCT02236897|EXPERIMENTAL|PET Scanning|Imaging of mGluR5 using PET scanning
62328730|NCT03167580|EXPERIMENTAL|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
62693348|NCT06122909|EXPERIMENTAL|Group VTI|Group VTI (n=45): will receive resuscitation guided by LVOT-VTI variation after PLR test.
62486583|NCT04821232|EXPERIMENTAL|interventional|"Students in the intervention group will be given a total of 120 minutes out of 40 minutes, and 24 sessions of yoga for 8 weeks, 3 days a week. The researcher who will make yoga with each student will be sent videos on the online platform, including a yoga introduction and a full yoga session with the students after a yoga session. The students were asked to do yoga 3 times a week in accordance with the video and the researcher will be called twice a week to get information about the process. Content of education;~1. Breath Awareness Training (10 minutes)~2. Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
62693349|NCT06122909|ACTIVE_COMPARATOR|Group IVC|Group IVC (n=45): will receive resuscitation guided by IVC diameter variation after PLR test.
62134402|NCT05379075|ACTIVE_COMPARATOR|Male students of Chen Taichi training based on Coordination guidelines|"Coordination theory is also called three in one. It mainly guides exercisers to practice Taichi by integrating the mind, movements, and breathing in a unity state. Students in this group will be taught how to integrate the three requests according to the principles. The principles are Waist axis, Movements softy and slowly, Inspiratory contraction and Expiratory stretch. The training will be conducted on the warming-up time by practicing a single movement and the club time by practicing a learned routine.~Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
61934890|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for CSCC (A2)|Participants who have progressed while receiving a programmed cell death protein 1 (PD-1)-blocking antibody or within 12 weeks of discontinuation of PD-1 blocking antibody for metastatic or locally and/or regionally advanced unresectable CSCC, will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
62328731|NCT03167580|ACTIVE_COMPARATOR|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 cm H2O) after intubation and during all mechanical ventilation.
62328732|NCT01793051|EXPERIMENTAL|Minocycline|"Minocycline 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance chemotherapy for MM.~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
62693350|NCT06347978|EXPERIMENTAL|ON-OFF (Stimulation-Sham)|Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period.
62693351|NCT06347978|EXPERIMENTAL|OFF-ON (Sham-Stimulation)|Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.
61934891|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for Merkel cell carcinoma (MCC) (B1)|Participants who have not received prior systemic therapy for metastatic or locally and/or regionally advanced unresectable MCC will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
61934892|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for MCC (B2)|Participants who have progressed while receiving a PD-1-blocking antibody or within 12 weeks of discontinuation of the PD-1 blocking antibody, will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
61934893|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for triple negative breast cancer (TNBC) (C1)|Participants who have not received prior therapy with immune checkpoint inhibitors (iCPIs) and who must have previously received treatment with sacituzumab govitecan (all advanced or metastatic TNBC participants), with trastuzumab deruxtecan \[human epidermal growth factor receptor 2 (HER2)-low participants\] and with adenosine diphosphate ribose polymerase (PARP) inhibitor \[for BReast CAncer gene (BRCA)\] for TNBC will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
61934894|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for TNBC (C2)|Participants who have previously received treatment with sacituzumab govitecan (all advanced or metastatic TNBC participants), with trastuzumab deruxtecan (HER2-low participants) and with PARP inhibitor (for BRCA) and who have progressed while receiving a PD-1-blocking antibody or within 12 weeks of discontinuation of a PD-1 blocking antibody for advanced or metastatic TNBC, will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
61934895|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for basal cell carcinoma (BCC) (D)|Participants who have not received prior hedgehog pathway inhibitor therapy, or prior anti-PD-1/programmed cell death ligand 1 (PD-L1) therapy and who do not wish to receive or who are not candidates for a hedgehog inhibitor, for metastatic or locally and/or regionally advanced unresectable BCC and will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
62134403|NCT06449859|EXPERIMENTAL|TQC2938 Injection (52.5mg/0.35ml)|TQC2938 Injection is administered as a single dose of subcutaneous (SC) injection.
62328733|NCT01793051|PLACEBO_COMPARATOR|Placebo|"Placebo 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
62328734|NCT05647811|EXPERIMENTAL|Cohort 1|6 subjects will receive NM8074 at 5 mg/kg weekly.
62328735|NCT05647811|EXPERIMENTAL|Cohort 2|6 subjects will receive NM8074 at 10 mg/kg every 2 weeks.
62328736|NCT05647811|EXPERIMENTAL|Cohort 3|6 subjects will receive NM8074 at 20 mg/kg every 2 weeks.
62328737|NCT06275971|EXPERIMENTAL|CGM arm|Glycemic control was monitored using CGM data for seven days following cardiac surgery
62328738|NCT06275971|ACTIVE_COMPARATOR|SMBG or venous/arterial glucose arm|Glycemic control was monitored using SMBG or venous/arterial glucose data for seven days following cardiac surgery
62693352|NCT00721110|ACTIVE_COMPARATOR|Lidocaine|Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
62693353|NCT00721110|PLACEBO_COMPARATOR|Placebo|A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
62328739|NCT05687994|EXPERIMENTAL|Audiovisual Speech Entrainment Practice|Audiovisual Speech Entrainment includes repeated practice of speaking synchronously with a recorded model, which provides contextual, temporal, and audiovisual cues for speaking.
62486584|NCT04821232|OTHER|Control groups|No intervention will be applied to students in the control group.
62486585|NCT05426395|ACTIVE_COMPARATOR|Dose 1 (2.6 µg)|Adding Vitamin B12 at a dose of 2.6 µg
62486586|NCT05426395|ACTIVE_COMPARATOR|Dose 2 (10 µg)|Adding Vitamin B12 at a dose of 10 µg
62486587|NCT05426395|ACTIVE_COMPARATOR|Dose 3 (50 µg)|Adding Vitamin B12 at a dose of 50 µg
62486588|NCT05471947|EXPERIMENTAL|Treatment|Treatment of hand lentigines with 15% trichloroacetic acid + 3% glycolic acid
62486589|NCT05020444|EXPERIMENTAL|TriPRIL CAR T Cells-Dose Escalation|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:~* Leukapheresis: On day -8 white blood cells will be collected.~* Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~TriPRIL CAR T Cells will be administered intravenously on day 0 using a 3+3 dose escalation design"
62486590|NCT05020444|EXPERIMENTAL|TriPRIL CAR T Cells-Dose Expansion|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:~* Leukapheresis: On day -8 white blood cells will be collected.~* Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~TriPRIL CAR T Cells will be administered intravenously on day 0 using the respective dose (at or below the Maximum Tolerated Dose-MTD), as determined during the dose escalation part."
62486591|NCT04877145|EXPERIMENTAL|single drill|one drill to place the implants 3.25mm diameter stainless steel drill was used.
62486592|NCT04877145|ACTIVE_COMPARATOR|sequential drills|For the control group, four drills (2.2mm, 2.75mm, 3.25mm and 4mm diameter),
62328740|NCT05687994|EXPERIMENTAL|Auditory Speech Entrainment Practice|Auditory Speech Entrainment includes repeated practice of speaking synchronously with a recorded model, which provides contextual, temporal, and auditory cues for speaking.
62328741|NCT05260931||Gestational diabetes group|This group will be formed by women with gestational diabetes (GD). The diagnosis of GD was made when one or more of the venous plasma glucose measurements met or exceeded the following thresholds after a 75 g Oral Glucose Tolerance Test (75 g OGTT): fasting blood glucose ≥ 92 mg/dL, 1 h plasma glucose level ≥ 180 mg/dL or 2 h plasma glucose level ≥ 153 mg/dL, as recommended by the International Association of the Diabetes and Pregnancy Study Groups.
62486593|NCT05723250|EXPERIMENTAL|Upfront Educational Intervention|Participants will receive a video-based intervention after completing baseline survey instruments and prior to retesting after 4-6 months.
62486594|NCT05723250|EXPERIMENTAL|Delayed Educational Intervention|Participants will complete baseline survey instruments and again complete surveys after 4-6 months. They will then receive the video-based educational tablet.
62486595|NCT06556329|NO_INTERVENTION|Standard of Care (Control)|This arm will include topical anesthetic as well as a combination of parental support, child life services and/or healthcare provider support, at the discretion of the treating team and family.
62486596|NCT06556329|EXPERIMENTAL|Robot (Intervention)|This arm will include the addition of robot distraction to current departmental standard of care. Distraction will include interaction with a socially intelligent, autonomous humanoid robot, the development of which will be informed by the other work packages.
62486597|NCT03915600|EXPERIMENTAL|Quinoa|Personalized diet added with quinoa
62486598|NCT03915600|EXPERIMENTAL|Flaxseed|Personalized diet added with Flaxseed
62486599|NCT03915600|EXPERIMENTAL|Quinoa and Flaxseed|Personalized diet added with quinoa and flaxseed
62486600|NCT03915600|NO_INTERVENTION|Normal diet|Personalized diet without dietary supplement
62486601|NCT06026215||Group 1|Heart failure patients requiring ventricular assist device implantation will be included into group 1.
62486602|NCT06026215||Group 2|Heart transplant recipients requiring early extracorporeal membrane oxygenation will be recruited into group 2.
62486603|NCT06026215||Group 3|Heart transplant recipients who have not previously received a VAD will be recruited into group 3.
62328742|NCT05260931||Control group|This group will be formed by women with normal 75 g OGTT findings.
62328743|NCT01728584|EXPERIMENTAL|Standard NMB and Standard Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted Train of Four \[TOF\] ratio of 10%)/Standard insufflation pressure (starting pressure of 12 mmHg).
62486604|NCT05822375|EXPERIMENTAL|Intervention|Will be offered the BT coaching intervention over 4-months (Sept 1st 2023- Dec 31st 2023).
62486605|NCT05822375|NO_INTERVENTION|Waitlist control|Will be offered the coaching intervention following 4-month waitlist control (Feb 1st 2024 - May 31st 2024).
62486606|NCT03784534|EXPERIMENTAL|Healthy volunteers|"Subjects will be asked to perform:~* high= density (64 sensors) EEG~* clinical and behavioral data will be also collected from each subject to evaluate their motor skills: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer~* anatomical MRI (T1 and tensor imaging) scan)"
62486607|NCT03784534|EXPERIMENTAL|Patients|"Patients will be asked to perform:~* high= density (64 sensors) EEG~* clinical and behavioral data will be also collected from each patient to assess their motor recovery progress: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, Fugl Meyer, test of Ashworth~* anatomical MRI (T1 and tensor imaging) scan)"
62486608|NCT03090880|NO_INTERVENTION|Control|usual care,
62486609|NCT03090880|EXPERIMENTAL|Experimental|tinzaparin sodium
62486610|NCT01641302||Patients undergoing robot-assisted laparoscopic prostatectomy|Patients undergoing robot-assisted laparoscopic prostatectomy under general anesthesia
62486611|NCT06488157|EXPERIMENTAL|Intervention (I-HoME)|Participants receive video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs.
62486612|NCT03641001|EXPERIMENTAL|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
62486613|NCT03641001|NO_INTERVENTION|Control|Control will receive usual health messages from government and NGO
62486614|NCT05608239|EXPERIMENTAL|Sculptra® Aesthetic|
62486615|NCT06562920|EXPERIMENTAL|neoadjuvant anti-PDL-1 Immunotherapy combined chemotherapy and SBRT|Three cycles of neoadjuvant PDL-1 combined chemotherapy and SBRT followed by surgery for limited-stage small cell lung cancer
62486616|NCT02287480|EXPERIMENTAL|VSV-ZEBOV lower dose|"One intramuscular (deltoid) injection of a lower dose (10\^7 plaque-forming units) of VSV-ZEBOV.~Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10\^5 plaque-forming units) of VSV-ZEBOV"
62486617|NCT02287480|EXPERIMENTAL|VSV-ZEBOV higher dose|"One intramuscular (deltoid) injection of a higher dose (5 x 10\^7 pfu) of VSV-ZEBOV.~Study amendment (01.2015) : interrupted"
62486618|NCT02287480|PLACEBO_COMPARATOR|Placebo|One intramuscular (deltoid) injection of normal saline (0.5 ml)
62486619|NCT04948476|EXPERIMENTAL|Standardized Dialysis and Structured Discontinuation (S2D2)|Prescription to minimize dialysis-induced ischemia and standardize dialysis discontinuation
62486620|NCT04948476|ACTIVE_COMPARATOR|Usual Care|Dialysis prescription ordered by their primary nephrologist/intensivist.
62486621|NCT05270499||Single Arm|Non randomized
62486622|NCT03931616|EXPERIMENTAL|STEMO deployment|STEMOs are specialized stroke ambulances providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
62486623|NCT03931616|ACTIVE_COMPARATOR|Regular care|Regular prehospital care consists of normal ambulance care. In suspected life-threatening cases, an emergency physician is sent to the emergency scene in parallel.
62486624|NCT05578443|EXPERIMENTAL|10g Astragalus membranaceus|
62328744|NCT01728584|EXPERIMENTAL|Standard NMB and Low Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted TOF ratio of 10%)/Low insufflation pressure (starting pressure of 8 mmHg).
62328745|NCT01728584|EXPERIMENTAL|Deep NMB and Standard Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Standard insufflation pressure (starting pressure of 12 mmHg).
62328746|NCT01728584|EXPERIMENTAL|Deep NMB and Low Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Low insufflation pressure (starting pressure of 8 mmHg).
62328747|NCT02323672||oral premalignant patients|15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia.
62486625|NCT05578443|EXPERIMENTAL|Routine treatment|
62486626|NCT05578443|EXPERIMENTAL|20g Astragalus membranaceus|
62486627|NCT04823091|EXPERIMENTAL|Fludarabine + Cyclophosphamide + anti-CD7 CAR-T Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (250 mg/kg) on day -5, -4, and -3, followed by the infusion of CAR7-T cells with the dose of 1×10\^6/kg and 2×10\^6/kg (with an allowance of ±20%). If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
62486628|NCT04260373|EXPERIMENTAL|[14C]SHR4640|Patients will receive single dose of \[14C\]SHR4640 (Suspension, 10mg/80μCi).
62486629|NCT02319655|ACTIVE_COMPARATOR|Air tamponade|Air is injected after vitrectomy/membrane peeling
62486630|NCT02319655|ACTIVE_COMPARATOR|Balanced salt solution filling|Balances salt solution is injected after vitrectomy/membrane peeling
62486631|NCT06356636|ACTIVE_COMPARATOR|Treatment group|The intervention arm involves communities within Homa Bay County in Kenya and Kamwenge District in Uganda, where the FINISH Mondial initiative is implemented. This intervention aims to improve sanitation and health through a public-private partnership model, engaging communities, governments, entrepreneurs, and financiers to enhance sanitation services and supply chains.
62486632|NCT06356636|NO_INTERVENTION|Control group|The control arm includes communities in Siaya County in Kenya and Bushenyi in Uganda, where the FINISH intervention is not implemented, serving as a comparison to evaluate the effectiveness of the intervention.
62486633|NCT01710722|EXPERIMENTAL|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
62693354|NCT00721110|ACTIVE_COMPARATOR|Ketamine|Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
62328748|NCT02323672||oral malignant patients|15 patients suffering from oral malignant lesions
62328749|NCT02323672||control subjects|15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease.
62486634|NCT01710722|EXPERIMENTAL|leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
62486635|NCT01710722|EXPERIMENTAL|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
62486636|NCT01524874|ACTIVE_COMPARATOR|Powder D3 Capsule - 2,000 IU per Cap|Vital Nutrients
62486637|NCT01524874|ACTIVE_COMPARATOR|Chewable D3 Tablet - 2,000 IU per Tab|Integrative Therapeutics Inc.
62486638|NCT01524874|ACTIVE_COMPARATOR|Liquid D3 Drop - 2,000 IU per Drop|Biotics Research
62486639|NCT01662960|EXPERIMENTAL|Mirror therapy|4 weeks of home-based mirror therapy. Participants practiced making movements with mirrored visual feedback of the low-functioning arm.
62486640|NCT01662960|ACTIVE_COMPARATOR|Divider therapy|4 weeks of home-based divider therapy (control therapy to mirror therapy; mirror replaced by a divider). Participants practiced making movements with no visual feedback of the low-functioning arm.
62486641|NCT00767481|EXPERIMENTAL|Travoprost/Brinzolamide PM, Vehicle AM|Travoprost/Brinzolamide PM, Vehicle AM
62693355|NCT00721110|ACTIVE_COMPARATOR|ketamine + Lidocaine|both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.
62693356|NCT04458194|ACTIVE_COMPARATOR|Standard Care|Cancer survivors receive their standard care
62328750|NCT04932525|EXPERIMENTAL|solid tumor or hematological malignancy|
62328751|NCT01035606|EXPERIMENTAL|Goal-oriented Attention Regulation Training|training in goal-directed attention regulation
62328752|NCT01035606|ACTIVE_COMPARATOR|Education|brain health education
62328753|NCT01035606|EXPERIMENTAL|Technology-assisted Goal-directed Self-Regulation Training|computer-assisted training in goal-directed attention regulation
62328754|NCT04297670||Unvaccinated against HPV boys|Sexually active unvaccinated against HPV 16-20 years old boys.
62328755|NCT05858736|EXPERIMENTAL|Level 1|AI-061, 200 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.
62486642|NCT00767481|EXPERIMENTAL|Travoprost/Brinzolamide AM, Vehicle PM|Travoprost/Brinzolamide AM, Vehicle PM
62486643|NCT00767481|ACTIVE_COMPARATOR|Cosopt|Cosopt BID
62486644|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
62486645|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
62486646|NCT02818790|NO_INTERVENTION|Group 1. Control|
62486647|NCT02818790|EXPERIMENTAL|Group 2. Intervention 1|
61934896|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for non-small cell lung cancer (NSCLC) (E)|"Participants with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression \[tumor proportion score (TPS) ≥50%\] based on a prior PD-L1 result as determined by College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) (or equivalently licensed) lab, with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or ros oncogene 1 (ROS1) aberrations, and who have not received prior anti-PD-1/PD-L1 therapy and are amenable to IT therapy and do not wish to receive chemotherapy.~Note: this cohort is not conducted in Europe"
61934897|NCT04916002|EXPERIMENTAL|Vidutolimod and cemiplimab for recurrent/metastatic Oropharynx Squamous Cell Carcinoma (OPSCC) (F)|Participants with PD-L1 combined positive score (CPS) ≥ 1, based on a prior PD-L1 result and human papillomavirus (HPV)-positive disease based on a prior result, who have not received prior systemic therapy for recurrent/metastatic disease. Participants will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
61934898|NCT04367883||Hospital admissions among COVID cases in the assigned population of the Terrassa Health Consortium|"Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.~No intervention is performed."
61934899|NCT04367883||Evolution of COVID cases in patients receiving antihistamines|"COVID cases, hospital admissions and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with antihistamines.~No intervention is performed."
61934900|NCT04367883||Evolution of COVID cases in patients receiving amantadine.|"COVID cases, hospital admissions and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with amantadine.~No intervention is performed."
61934901|NCT00992927|EXPERIMENTAL|CPIHD|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
62328756|NCT05858736|EXPERIMENTAL|Level 2|AI-061, 400 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.
62328757|NCT05858736|EXPERIMENTAL|Level 3|AI-061, 600 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.
62328758|NCT01615224|NO_INTERVENTION|single dose|Patients receive the standard treatment with 800mcg of vaginal misoprostol
62328759|NCT01615224|EXPERIMENTAL|repeated doses|patients receive 800mcg of vaginal misoprostol. In addition to this they receive repeated doses of 400mcg oral misoprostol after 3 and 5 hours. Women of more than 9 weeks pregnancy according to last menstrual period will be given a choice of vacuum aspiration or further medical treatment with 2 additional doses of misoprostol given after 7 and 9 hours after the initial vaginal treatment.
62328760|NCT00694876||1|Adequate Health Literacy (as determined by TOFHLA)
62328761|NCT00694876||2|Inadequate Health Literacy (as determined by TOFHLA)
62328762|NCT05951738|OTHER|Depressed|
62328763|NCT05951738|OTHER|At high risk|
62328764|NCT05951738|OTHER|Control|
62328765|NCT01675531|EXPERIMENTAL|Targin|Targin
62328766|NCT06499506|ACTIVE_COMPARATOR|Skew Flap|skew Flap technique for below knee amputation
62328767|NCT06499506|ACTIVE_COMPARATOR|Long Posterior Flap|Long Posterior Flap for Below knee amputation
62486648|NCT02818790|EXPERIMENTAL|Group 2. Intervention 2|
62486649|NCT00712816|EXPERIMENTAL|A|
62486650|NCT00712816|ACTIVE_COMPARATOR|B|
62486651|NCT05653986||Ubrogepant + Atogepant|Participants will receive ubrogepant in combination with atogepant as prescribed by their physician in routine clinical practice.
62486652|NCT00945490|EXPERIMENTAL|NX-1207|
62693357|NCT04458194|EXPERIMENTAL|YOCAS|Cancer survivors receive 8 virtual yoga sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
62328768|NCT02951611|SHAM_COMPARATOR|Sham stimulation|Put the electrodes on SI3, SJ6, PC6 and LI4 without stimulation.
62328769|NCT02951611|EXPERIMENTAL|Treatment: Acupuncture stimulation|Stimulate the SI3, SJ6, PC6 and LI4 since 30 minutes before anesthesia induction until the end of operation. Stimulate again at above acupoints at 6 and 24h after operation, for 30 minutes each time. The stimulation frequency is 2/100Hz. The stimulation current is two to three times of the lowest current that the patient can feel.
62328770|NCT00745485|EXPERIMENTAL|Zoldronic|
62328771|NCT04352634||Healthcare workers|Workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)
62328772|NCT05111496||Patient requiring intervention (complex coronary dilation or coronary recanalization)|Patient requiring intervention with a predicted risk of exceeding the radiological threshold (Air Kerma\> 3Gy): complex coronary dilation, coronary recanalization
62486653|NCT00945490|PLACEBO_COMPARATOR|Placebo|
62486654|NCT03125408||chronic HCV Infected patients|chronic HCV patients who will undergo standard of care FDA approved antiviral therapy to treat genotype 1,2, or 3 infections and will have blood drawn at various time points and tested using the DxN HCV Assay. Study is observational and results will not be used to manage patient care.
62693358|NCT04508530|EXPERIMENTAL|Panzyga|Panzyga 10% IVIG
62693359|NCT04508530|PLACEBO_COMPARATOR|Placebo|Placebo
62693360|NCT06638931|EXPERIMENTAL|Single-Arm Efficacy Study|Treatment will be administered with intravenous nivolumab at a dose of 480 mg every 4 weeks. Treatment will continue until limiting toxicity, disease progression, or for a maximum of 12 months as maintenance if the individual achieves stable disease, partial response, or complete response.
62697561|NCT03753516|ACTIVE_COMPARATOR|Vaginal - Vaginal Cuff Closure|
62486655|NCT02586350|EXPERIMENTAL|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
62486656|NCT02586350|PLACEBO_COMPARATOR|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
62486657|NCT06311929|EXPERIMENTAL|Combined adjuvant therapy group|Patients in the combined adjuvant therapy group received PD-1 monoclonal antibody with Lenvatinb adjuvant therapy after liver resection.
62134404|NCT06449859|EXPERIMENTAL|TQC2938 Injection (210mg/1.4ml)-subcutaneous injection|TQC2938 Injection is administered as a single dose of subcutaneous injection.
62328773|NCT02773719|EXPERIMENTAL|True biofield therapist|Subject will have a 40 minutes therapy with a real biofield therapist to treat the wart
62328774|NCT02773719|PLACEBO_COMPARATOR|Fake biofield therapist|Subject will have a 40 minutes therapy with a fake biofield therapist to treat the wart
62328775|NCT05420272||Pes planus|Evaluation group- Trunk performance and endurance lower extremity biomechanics
62328776|NCT05420272||Control group healthy|Trunk performance and endurance lower extremity biomechanics
62328777|NCT03190720|EXPERIMENTAL|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
62328778|NCT03190720|EXPERIMENTAL|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
62134405|NCT06449859|EXPERIMENTAL|TQC2938 Injection (210mg/1.4ml)-intravenous injection|TQC2938 Injection is administered as a single dose of intravenous (IV) injection .
62134406|NCT06449859|EXPERIMENTAL|TQC2938 Injection (420mg/2.8ml)|TQC2938 Injection is administered as a single dose of subcutaneous injection.
62328779|NCT03179306||Samples|de-identified images and clinical data from NCI studies.
62328780|NCT04160468|EXPERIMENTAL|Exebacase|
62328781|NCT04160468|PLACEBO_COMPARATOR|Placebo|
62328782|NCT04436822|EXPERIMENTAL|Subjects with diabetes wearing DS5|Subjects wearing DS5 over 7 days and participating in FSTs.
62328783|NCT01107977|EXPERIMENTAL|Iyengar yoga|
62486658|NCT06311929|ACTIVE_COMPARATOR|Monotherapy group|Patients in the monotherapy group received PD-1 monotherapy after liver resection.
62486659|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
62134407|NCT06449859|EXPERIMENTAL|TQC2938 Injection (840mg/5.6ml)-subcutaneous injection|TQC2938 Injection is administered as a single dose of subcutaneous injection.
62134408|NCT06449859|EXPERIMENTAL|TQC2938 Injection (1260mg/8.4ml)|TQC2938 Injection is administered as a single dose of subcutaneous injection.
62328784|NCT01107977|NO_INTERVENTION|Waitlist control|
62134409|NCT06449859|EXPERIMENTAL|TQC2938 Injection (210mg/1.4ml)-subcutaneous injection-multiple doses|TQC2938 Injection is administered as a multiple doses of subcutaneous injection, once every 28 days, three times in total.
62134410|NCT06449859|EXPERIMENTAL|TQC2938 Injection (840mg/5.6ml)-subcutaneous injection-multiple doses|TQC2938 Injection is administered as a multiple doses of subcutaneous injection, once every 28 days, three times in total.
62134411|NCT06449859|EXPERIMENTAL|TQC2938 Injection (630mg/4.2ml)|TQC2938 Injection is administered as a multiple doses of subcutaneous injection, once every 28 days, three times in total.
62134412|NCT06449859|PLACEBO_COMPARATOR|TQC2938 Placebo|TQC2938 Placebo is administered as a single dose or multiple doses, once every 28 days, three times in total.
62134413|NCT01448681||SICU patients with ICP|Surgical intensive care unit patients with elevated intracranial pressure
62328785|NCT06235463|EXPERIMENTAL|Osteopathic Pedal Pump|Participant lays supine on the table and the operator stands at foot of table. Operator places hands on the feet, contacting the balls of the feet, and carefully plantar flexing to a slight degree. Operator dorsiflexes the feet to cause the whole body to move cephalad. The body is allowed to rebound back caudad towards foot of the table. The operator times the next dosiflexion motion to occur towards the end of the caudad motion wave. Technique time is 5 minutes.
62328786|NCT06235463|SHAM_COMPARATOR|Light Touch Treatment|Participant lays supine on the table and the operator stands at foot of table. Operator places hands on the feet and touches participant body on the balls of the feet, but operator does not palpate feet or lower limbs.
62328787|NCT04165083|EXPERIMENTAL|Pembrolizumab + MK-4830|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years)
62328788|NCT04165083|EXPERIMENTAL|Pembrolizumab + MK-0482|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-0482 IV for a maximum of 35 cycles (approximately 2 years)
62328789|NCT01370278|ACTIVE_COMPARATOR|Normal Saline|Normal saline sprayed into stent/airway tubes then suctioned out through bronchoscope.
62328790|NCT01370278|ACTIVE_COMPARATOR|Sodium Bicarbonate|Sodium bicarbonate sprayed into stent/airway tubes then suctioned out through bronchoscope.
62328791|NCT04356144||Critical infection|Patients with signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2 admitted to the ICU
62328792|NCT02196194||tiotropium|
62328793|NCT02918487|EXPERIMENTAL|Active|\[Formoterol + Fluticasone\] Single maintenance and reliever therapy(SMART) and Active polyherbal capsule
62486660|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
62486661|NCT03638063||Control|healthy controls
62486662|NCT06113991||Patients without professional exposure to beryllium|Patients without professional exposure to beryllium
62486663|NCT06113991||Patients with chronic pulmonary berylliosis|Patients with chronic pulmonary berylliosis
62486664|NCT00583999||A|bariatric surgery
62486665|NCT01283503|EXPERIMENTAL|BKM120|
62134414|NCT05530317|EXPERIMENTAL|Cardiac Rehabilitation|Participants will undergo 12 weeks of standard of care cardiac rehabilitation.
62134415|NCT05142046||Pediatric cardiac surgery|The group consists of all the children who undergo cardiac surgery in our institution from 2008 to 2018. The age limit was from birth to 16 years old.
62134416|NCT00829634|OTHER|l-methamphetamine|
62486666|NCT04830540|NO_INTERVENTION|Control|Participants assigned to the control group will be asked to continue wearing their typical shoes and to complete every two weeks the footwear and injury log provided
62134417|NCT01965665|EXPERIMENTAL|Medihoney HCS dressing|weekly Medihoney pin site care until frame removal. Standard size dressings and application technique will be used at each pin site with prefabricated materials.
62134418|NCT04540588|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62134419|NCT05371275|EXPERIMENTAL|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
62693361|NCT02543385|ACTIVE_COMPARATOR|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
62693362|NCT02543385|PLACEBO_COMPARATOR|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
62134420|NCT04190108||Case patients|All consecutive, new patients older than 18 years with PsA (CASPAR criteria) at onset observed over 3-year period, who had any abdominal symptoms.
62134421|NCT04190108||Controls|All consecutive new patients meeting the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) at onset.
62134422|NCT01083316|EXPERIMENTAL|Single Arm - Investigational|"Induction:~Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
62134423|NCT04308083|ACTIVE_COMPARATOR|convergent neck|Group A Sweden \& Martina Prama (P). Transgingival tapering machined collar, 2.8 mm in height.
62134424|NCT04308083|SHAM_COMPARATOR|divergent neck|Group B Straumann Tissue Level (TL). Transgingival widening polished collar, 1.8 mm in height.
62134425|NCT00409799|EXPERIMENTAL|1|Experimental - high dose
62134426|NCT00409799|EXPERIMENTAL|2|Experimental - low dose
62328794|NCT02918487|PLACEBO_COMPARATOR|Placebo|\[Formoterol + Fluticasone\] conventional along with inert similar looking placebo capsules
62328795|NCT05465603|EXPERIMENTAL|20-22 hours of daily TERT intervention|Patients that have suffered an injury to the finger causing flexion contracture of the Proximal interphalangeal joint will be treated using an elastic tension neoprene orthosis for a period of 3 weeks.
62328796|NCT05465603|ACTIVE_COMPARATOR|11-13 hours daily TERT intervention|Patients that have suffered an injury to the finger causing flexion contracture of the Proximal interphalangeal joint will be treated using an elastic tension neoprene orthosis for a period of 3 weeks.
62328797|NCT02191202||Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
62486667|NCT04830540|EXPERIMENTAL|Intervention|Individuals assigned to the intervention group will be provided with 2 styles of the OOFOS recovery shoes, and will be asked to wear the OOFOS slide, sandal and/or closed toe shoes as their primary footwear outside training and competition for the 6 weeks between study visits. Intervention participants will also be asked to complete a daily shoe wear log and a shoe comfort assessment survey every other week.
62486668|NCT06560034||Cross-Sectional Group|Blood pressure reading of one group of participants
62134427|NCT00409799|ACTIVE_COMPARATOR|3|Autograft
62134428|NCT05741489|EXPERIMENTAL|ESKD with Burnt-out Diabetes|Participants with ESKD and burnt-out diabetes wearing a CGM for 10 days.
62134429|NCT05741489|EXPERIMENTAL|ESKD without Diabetes|Non-diabetic participants with ESKD wearing a CGM for 10 days.
62134430|NCT06330298|EXPERIMENTAL|Experimental condition: Receives T-ScEmo Treatment|Experimental group. Receives T-ScEmo Treatment during the study between T0 and T1
62134431|NCT06330298|NO_INTERVENTION|Waiting list group: Will be on waiting list instead of treatment|Waiting list group: Will be on waiting list for instead of the treatment for the duration of the treatment between T0 and T1.
62134432|NCT00185276|EXPERIMENTAL|Arm 1|
62134433|NCT00185276|EXPERIMENTAL|Arm 2|
62134434|NCT02424201|EXPERIMENTAL|study|Intramuscular oxytocin 10 units, 400 micrograms of misoprostol
62486669|NCT05256992|EXPERIMENTAL|Treatment-Enhanced Services (Standard + Ray of Hope)|Treatment group participants receive standard and enhanced services. Standard services are delivered as primary services to participants in both study groups under a shared condition, and they are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Finally, only the treatment group receives 10 hours of the Ray of Hope curriculum as an enhanced service. Optional services are available to both study groups by selecting 1-3 hours of coursework from a menu of courses in the Mini-Clinic that address a variety of needs.
61934902|NCT00992927|ACTIVE_COMPARATOR|CRIHD|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
61934903|NCT04214873|EXPERIMENTAL|POH|Treatment of POH Using PiQo4 Laser System
61934904|NCT03135626|EXPERIMENTAL|Biodentine|Biodentine pulpotomy agent
62134435|NCT02424201|OTHER|control|Intramuscular oxytocin 10 units, 2 tablets of placebo which will be vitamin c
62328798|NCT01333982|EXPERIMENTAL|Referral compliance|Health workers will receive a basic maternal, newborn and child health training under the MNCS programme. Newborn sepsis management training will be organised for the study. The Bangladesh Perinatal Society (BPS) will take the lead in developing and implementing the training programme with support from Saving Newborn Lives (SNL) and other partners.Referral slips will be used in the intervention unions for all the sick newborns identified so that they seek care on a timely fashion.
62328799|NCT01333982|EXPERIMENTAL|Neonatal sepsis|Existing health delivery systems in the community level in managing neonatal sepsis.
62328800|NCT01798134|OTHER|DEB-TACE|"Transarterial Chemoembolization with TANDEM™ - DOX Microspheres (DEB-TACE)~Treatment: Lobes; Dosing: TANDEM™/Doxorubicin; Second Treatment:TANDEM™/Doxorubicin"
62328801|NCT00000271|EXPERIMENTAL|Desipramine|Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
62328802|NCT00000271|PLACEBO_COMPARATOR|Placebo|Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.
62328803|NCT04313335|EXPERIMENTAL|Duloxetine|Apart from the standard treatment, participants in the Duloxetine Arm will be administered with oral duloxetine (up to 60 mg per day) in the acute herpes zoster period.
62328804|NCT04313335|NO_INTERVENTION|Control|Participants will be given the standard treatment during the acute herpes zoster period.
61934905|NCT03135626|EXPERIMENTAL|ProRoot MTA|ProRoot MTA pulpotomy agent
62328805|NCT03062904|EXPERIMENTAL|drug|
62328806|NCT03233490|EXPERIMENTAL|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
62328807|NCT03233490|EXPERIMENTAL|CPR training intervention|CPR training without web course
62328808|NCT05029596|ACTIVE_COMPARATOR|Heparin Group|"Participants will receive the UTSW standard of of care for PICC line maintenance.~All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws."
62328809|NCT05029596|EXPERIMENTAL|Normal Saline Group|Participants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.
62328810|NCT03161678|ACTIVE_COMPARATOR|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
62328811|NCT03161678|EXPERIMENTAL|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
62328812|NCT03161678|EXPERIMENTAL|Carriers of CES1 rs7498748 Mutation|Research subjects who carry a CES1 rs7498748 minor allele will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
62328813|NCT01267097|EXPERIMENTAL|Cognitive Behavioural Therapy (CBT)|Group-based lifestyle counseling for parents
62328814|NCT01267097|EXPERIMENTAL|Psycho-Education Program (PEP)|Group-based lifestyle counseling for parents
62328815|NCT03807739|EXPERIMENTAL|Part I: GDC-0134 F16 vs F09 Capsule Formulation|In Part 1 participants will receive single doses of either GDC-0134 F16 capsules (prototype) or GDC-0134 F09 capsules (reference) after having consumed a standard meal.
61934906|NCT03135626|EXPERIMENTAL|MTA Plus|MTA Plus pulpotomy agent
62328816|NCT03807739|EXPERIMENTAL|Part II: GDC-0134 F15 vs F09 Capsule Formulation|In Part 2, participants will receive a single dose of either GDC-0134 F15 capsules (prototype) or GDC-0134 F09 capsules (reference) after an overnight fast.
62328817|NCT03389126|EXPERIMENTAL|Avelumab|Avelumab 10 mg/kg every 2 wks until disease progression or unacceptable toxicity
62328818|NCT06095245||35 patients with advanced PD treated with subthalamic deep brain stimulation|35 patients with advanced PD treated with subthalamic deep brain stimulation. The decision of DBS treatment had been performed on the clinical decision by the treating neurologist and the patients. Patients are between 18 and 80 years old.
62328819|NCT04820452|EXPERIMENTAL|cohort 1 IBI302 treated with high dose level of IBI302|Drug: IBI302 4mg/eye;Intraocular injection
61934907|NCT03135626|ACTIVE_COMPARATOR|Ferric Sulfate 20% Dental Gel|Ferric Sulfate %20 Dental Gel pulpotomy agent
62134436|NCT01510236|EXPERIMENTAL|Early self-help program|The early self-help program starts directly after randomization i.e. 4 weeks after diagnosis.
62134437|NCT01510236|EXPERIMENTAL|Later self-help program|The later self-help program starts sixty-two weeks after diagnosis.
62328820|NCT04820452|ACTIVE_COMPARATOR|Aflibercept|Drug: Aflibercept 2mg/eye;Intraocular injection
62328821|NCT04820452|EXPERIMENTAL|cohort 1 IBI302 treated with low dose level of IBI302|Drug: IBI302 2mg/eye;Intraocular injection
62328822|NCT02363036||Active labor|Women in active labor normal pregnancy at term.
61934908|NCT02204280||Type 2 Diabetic|Patiens with type 2 diabetic which conform to the WHO in 1999 diabetes diagnostic criteria.
61934909|NCT02204280||Diabetic With macro-or Microalbuminuria|Patients with diabetic with macro-or microalbuminuria.
61934910|NCT02204280||proteinuria,nondiabetic renal disease|Patients with proteinuria due to nondiabetic renal disease,such as IgA nephropathy,FSGS,Hypertensive renal damage and MN.
62328823|NCT02363036||Planned Cesarian Section|Women, normal pregnancy at term who came for elective Cesarean Section without signs of labor (pain/contractions, etc).
62328824|NCT05145504||20 obese patients, with BMI ≥ 30|
62328825|NCT05145504||20 normal weight patients with BMI between 18.5 - 24.9 inclusive|
62693363|NCT02960893|EXPERIMENTAL|Troriluzole|"Troriluzole - Randomization Phase: Participants received Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.~Troriluzole/Troriluzole - Extension Phase: Participants received Troriluzole 140 mg capsules orally QD for 48 weeks."
62328826|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI\<13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
62486670|NCT05256992|EXPERIMENTAL|Control-Standard Services|Only standard services are delivered to participants in the control group under a shared condition with the treatment group, and they are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services are available to both study groups by selecting 1-3 hours of coursework from a menu of courses that address a variety of needs.
62486671|NCT05319054|NO_INTERVENTION|Cohort|Patients who have undergone colonic resection for colorectal cancer in the last 10 years. Patient reported outcome measures collected at 3-monthly intervals.
62693364|NCT02960893|PLACEBO_COMPARATOR|Placebo|"Placebo - Randomization Phase: Participants received matching placebo capsules orally QD for 8 weeks.~Placebo/Troriluzole - Extension Phase: Participants who received placebo during randomization phase, received Troriluzole 140 mg capsules orally QD for 48 weeks."
62693365|NCT03439072|OTHER|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
61934911|NCT02204280||healthy controls|Healthy person.
61934912|NCT05152563|EXPERIMENTAL|SC 150 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 150 mg of lirentelimab (AK002) administered subcutaneously.
61934913|NCT05152563|EXPERIMENTAL|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 300 mg of lirentelimab (AK002) administered subcutaneously.
61934914|NCT05152563|EXPERIMENTAL|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 450 mg of lirentelimab (AK002) administered subcutaneously.
61934915|NCT05152563|OTHER|Placebo|Placebo
61934916|NCT06551688||group D|vitamin D-deficient group (\<30nmol/L)
61934917|NCT06551688||group S|vitamin D-sufficient group (≥30nmol/L)
61934918|NCT02325661|OTHER|cognitive interviewing|individual cognitive interviewing, 30 minutes per patient
61934919|NCT01443273||Infants with thrombotic events|All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
61934920|NCT05935514|EXPERIMENTAL|WW Intervention|Participants in the intervention arm will receive a voucher code that provides 12 months of access to the WW program and instructions for redeeming the code by study staff. The program will include access to weekly Virtual Workshops and the WW App. WW is a widely available, commercial behavioral weight management program that encourages healthy habits in the areas of food, activity, mindset, and sleep, with topics tailored specific to T2D. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System to wear for the duration of the trial.
61934921|NCT05935514|ACTIVE_COMPARATOR|Usual Care|Patients in the Usual Care group will continue to receive routine medical care by their healthcare provider. In addition, within 4 weeks of the baseline visit, participants in the Usual Care group will receive one 50-minute virtual on-line session of nutrition counseling with a registered dietitian with additional materials at the time of their 6- and 12-month follow-up assessments, based on current recommendations of the American Diabetes Association.
61934922|NCT01649609|ACTIVE_COMPARATOR|Reduction of standard immunosuppression|Low dose Tacrolimus with low dose Mycophenolate acid
61934923|NCT01649609|ACTIVE_COMPARATOR|mTOR Arm|Low dose Sirolimus with low dose Mycophenolate acid (mTOR Substitution)
61934924|NCT05093348|ACTIVE_COMPARATOR|Click2Print digital Artificial Eye|Supply and fit a digitally designed and manufactured ocular prosthesis for four months in comparison to the current hand-made ocular prosthesis in a cross over trial
61934925|NCT05093348|ACTIVE_COMPARATOR|Current hand made artificial eye|Wear the hand-made artificial eye for four months and compare to the digitally design ed and manufactured artificial eye
62328827|NCT02667990|EXPERIMENTAL|orthopaedic stilettoe|orthopaedic stilettoe will be compared to standard stilettoe and comfy trainer
62328828|NCT02811458|EXPERIMENTAL|Transdiagnostic CBT|Group psychotherapy according to the Transdiagnostic Cognitive-Behavioral Therapy treatment protocol (Norton, 2012)
62328829|NCT02811458|NO_INTERVENTION|Treatment-as-usual|Treatment-as-usual and a differed intervention (if desired by participants) after the 8-month follow up.
62328830|NCT00694512|PLACEBO_COMPARATOR|1|low fat diet for two weeks.
62328831|NCT00694512|ACTIVE_COMPARATOR|2|High fat diet for two weeks followed by blood sampling.
62328832|NCT00694512|ACTIVE_COMPARATOR|3|Medium Chain Triglyceride diet
61934926|NCT03364530|OTHER|Gemcitabine-Oxaliplatin Regimen|
61934927|NCT05043558|EXPERIMENTAL|beprostaglandin sodium|
61934928|NCT05043558|NO_INTERVENTION|control group|
61934929|NCT01484132|EXPERIMENTAL|Composite|
61934930|NCT02534220|ACTIVE_COMPARATOR|Manual Toothbrush|Patients were instructed in the Roll Brushing Technique, twice daily for 2 min.
61934931|NCT02534220|EXPERIMENTAL|Oscillating-rotating toothbrush|Patients received manufacturer's instructions for use, including brushing twice daily for 2 min.
62328833|NCT00809172|ACTIVE_COMPARATOR|1|Ciclosporin
62328834|NCT00809172|EXPERIMENTAL|2|Methotrexate
62693366|NCT03439072|OTHER|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
62693367|NCT06640556|NO_INTERVENTION|non-intervention group|the group will not be trained
62693368|NCT06640556|EXPERIMENTAL|Mothers who have had a caesarean section or normal birth|"The animation A Green Future with the Hands of a Midwife will be downloaded to mothers' phones and played in a quiet and non-stimulating environment before discharge. In addition, the animation will be played again after the data collection tools are applied on the 7th, 21st and 30th day."
62486672|NCT05319054|ACTIVE_COMPARATOR|Optimised Conservative Management|Cohort participants who are identified as having 'major LARS' at any point are treated with Optimised Conservative Managements, consisting of medication, dietary advice, lifestyle advice and physiotherapy.
62486673|NCT05319054|ACTIVE_COMPARATOR|Trans-Anal Irrigation|Cohort participants who are identified as having 'major LARS' at any point are treated with Trans-anal irrigation, in additional to receiving optimised conservative management. Transanal irrigation system will be decided upon with the participant and procured locally.
62328835|NCT06222372|EXPERIMENTAL|Single dose rifampin (SDR)|To household contacts of newly diagnosed leprosy patients SDR is provided as follows: 600 mg rifampicin for adults weighing 35 kg and over, 450 mg for adults weighing less than 35 kg and for children older than 9 years, and 300 mg for children aged 5 to 9 years.
62328836|NCT06222372|EXPERIMENTAL|Single double dose rifampin (SDDR)|To household contacts of newly diagnosed leprosy patients SDDR is provided as follows: 1200 mg rifampicin for adults weighing 35 kg and over, 900 mg for adults weighing less than 35 kg and for children older than 9 years, and 600 mg for children aged 5 to 9 years.
62134438|NCT02209246|EXPERIMENTAL|Intervention|The intervention group will be comprised of patients who will complete the PROMIS- CAT for pain interference, pain behavior and physical function prior to the encounter with the physician and then will complete the MISS-21 after the encounter.
62134439|NCT02209246|EXPERIMENTAL|Control|The control group will complete the PROMIS- CAT for pain interference, pain behavior and physical function after the encounter and after completing a satisfaction questionnaire (MISS-21).
62486674|NCT05319054|ACTIVE_COMPARATOR|Sacral NeuroModulation|Cohort participants who are identified as having 'major LARS' at any point are treated with Sacral Neuromodulation system, in addition to receiving optimised conservative management. Medtronic Interstim system will be used.
62486675|NCT00576654|EXPERIMENTAL|Dose escalation (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days -1 to 14 (days 3-14 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61934932|NCT04449887|EXPERIMENTAL|The treatment group|The subjects in this group were treated with Xiangsha Liujunzi granule for 4 weeks
61934933|NCT05120661|EXPERIMENTAL|Carbohydrate-rich food product (to be determined)|This is a nutritional product, such as bread or cake, containing 50 gram carbohydrates.
62134440|NCT03450460|EXPERIMENTAL|1/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program once per week.
61934934|NCT05120661|EXPERIMENTAL|Another carbohydrate-rich food product (to be determined)|This is a nutritional product, such as bread or cake, containing 50 gram carbohydrates.
62134441|NCT03450460|NO_INTERVENTION|wait list control group|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support once the trial period is complete.
62328837|NCT05339438|EXPERIMENTAL|Epileptic patients|Epileptic patients with anterior temporal lobe epilepsy
62328838|NCT05339438|EXPERIMENTAL|Healthy volunteers|Healthy volunteers
62486676|NCT00576654|EXPERIMENTAL|Expansion portion (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days 1-15 (days 2-15 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62486677|NCT00576654|EXPERIMENTAL|Intermittent dose escalation (irinotecan, ABT-888)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 3 and 10 and veliparib PO BID on days 1 to 4 and 8-11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62486678|NCT01167335|EXPERIMENTAL|BGG492|
62328839|NCT02322320|ACTIVE_COMPARATOR|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
62328840|NCT02322320|ACTIVE_COMPARATOR|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
62328841|NCT02322320|ACTIVE_COMPARATOR|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
62486679|NCT01167335|PLACEBO_COMPARATOR|Placebo|
62486680|NCT04143880|EXPERIMENTAL|experimental group|Progesterone
62328842|NCT02519751|EXPERIMENTAL|D3 Creatine followed by creatine supplementation|Every participant will be orally administered with 60mg of D3 Creatine in a fasted state in a non-gelatin capsule. Creatine supplemented throughout the study will be administered in the following doses-0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
62328843|NCT06691100|EXPERIMENTAL|Intervention|30-minute exercise bout in a cycle ergometer at 60 to 70% of the Heart Rate Reserve (HRR) and corresponding power (watts).
62328844|NCT05673005|EXPERIMENTAL|MED3000 topical gel treatment|All qualified enrolled patients will receive treatment with MED3000 topical gel on demand through the 12-week follow-up visits.
62328845|NCT00435032|ACTIVE_COMPARATOR|1|Early appendectomy
61934935|NCT00679978||A|A: etidronate
61934936|NCT04589325|EXPERIMENTAL|Ixekizumab|
61934937|NCT04589325|PLACEBO_COMPARATOR|Placebo|
61934938|NCT05274165|ACTIVE_COMPARATOR|Group A|Participants will be fit with commercially available Lyric devices, which range from size XXS to XXL.
61934939|NCT05274165|EXPERIMENTAL|Group B|Participants will be fit either with the commercially available Lyric devices OR devices which are designed with a new fitting characteristic. This increases the pool of sizes from which the hearing care professional can choose to fit participant.
61934940|NCT04326959|EXPERIMENTAL|UC-MSCs + CM|A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
62134442|NCT05769413||Patients with human immunodeficiency virus infection|Patients with human immunodeficiency virus infection
62134443|NCT03188341||vascular surgery patients|"* clinically concealed repolarization disturbances during vascular surgery procedure~* clinically disclosed cardiac complications during and after vascular surgery procedure"
62328846|NCT00435032|ACTIVE_COMPARATOR|2|Interval appendectomy
62328847|NCT00928616|EXPERIMENTAL|plant sterol esters|Participants consume plant sterol ester supplemented margarine (3 g/day)
62486681|NCT04143880|PLACEBO_COMPARATOR|control grou|saline
62486682|NCT06628297||48 patients with type 2 diabetes and increased risk of microvascular disease|"Baseline measurements of:~* \[15O\]H2O PET of heart and brain~* Blood sampling~* Echocardiography~* Brain MRI~* Cognitive tests~* Cardiorespiratory fitness test~* Muscular function test"
62486683|NCT06628297||24 healthy age-matched participants|"Baseline measurements of:~* \[15O\]H2O PET of heart and brain~* Blood sampling~* Echocardiography~* Brain MRI~* Cognitive tests~* Cardiorespiratory fitness test~* Muscular function test"
62486684|NCT01539096|SHAM_COMPARATOR|Sham tDCS plus CIMT|Subjects in this group will be trained on Constraint induced movement therapy (CIMT) for the hand while concurrently receiving placebo noninvasive brain stimulation (tDCS). They will be receiving Sham tDCS: placebo noninvasive brain stimulation. They will be provided treatment for 3 days a week for 5 weeks for 1 hr each day at the Cleveland Clinic. They would be asked to use affected hand in daily activities for 5 hrs everyday at home while wearing a mitt on their unaffected hand.
62486685|NCT01539096|EXPERIMENTAL|tDCS plus CIMT|Patients with stroke affecting the hand will receive Constraint-induced movement therapy (CIMT) concurrent with tDCS: noninvasive brain stimulation. TDCS will be applied to areas of the brain responsible for movement of the affected hand. This combination of tDCS and CIMT will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
61934941|NCT04326959|EXPERIMENTAL|CM + CM|A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
61934942|NCT04326959|EXPERIMENTAL|Triamcinolon acetonide|A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.
62328848|NCT00928616|PLACEBO_COMPARATOR|Placebo|Placebo is a non-sterol ester supplemented margarine
62328849|NCT02274324|ACTIVE_COMPARATOR|PD patients- Diet B first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet B and then crossover to diet C.
62486686|NCT00663234|EXPERIMENTAL|Age 10 to 14|Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
62486687|NCT00663234|EXPERIMENTAL|Age 15 to 23|Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
62486688|NCT03586219|NO_INTERVENTION|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
62486689|NCT03586219|EXPERIMENTAL|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
62486690|NCT04341883|EXPERIMENTAL|anti-PD-1|PD-1+albumin-bound paclitaxel
62486691|NCT01540422||CABG w/saphenous vein grafts harvested using endoscopy|Those who have CABG surgery with saphenous vein grafts harvested using endoscopic techniques
62486692|NCT00975494|ACTIVE_COMPARATOR|sildenafil|sildenafil 50 mg three times/day
61934943|NCT03306810|ACTIVE_COMPARATOR|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
61934944|NCT03306810|NO_INTERVENTION|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
62328850|NCT02274324|ACTIVE_COMPARATOR|PD patients- Diet C first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet C and then crossover to diet B.
62693369|NCT03863574|EXPERIMENTAL|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
61934945|NCT06680193|EXPERIMENTAL|Processing of Positive Memories Technique|PPMT was administered as a 4-session protocol in this arm.
62328851|NCT05160077|OTHER|Fasting|All examinations are in a fasting state.
62328852|NCT05160077|OTHER|Standardised Breakfast|"Preprandial examination is in fasting state, all postprandial examinations will be conducted with standardized dietary.~30 minutes after the beginning of the preprandial examination participants receive an standardized breakfast. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal."
62328853|NCT05160077|OTHER|Standardised Breakfast and ICG|"Preprandial examination are in a fasting state, all postprandial examinations will be conducted with standardized dietary including indocyanine green (ICG) dye.~30 minutes after the beginning of the preprandial examination participants receive an standardised breakfast containing ICG. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal without ICG."
62328854|NCT06552585|EXPERIMENTAL|Weight program group|
62328855|NCT06552585|EXPERIMENTAL|Elastic band program group|
62328856|NCT06552585|SHAM_COMPARATOR|Control|
62328857|NCT04111276|EXPERIMENTAL|Subjects diagnosed with osteoarthritis of the knee|Subjects must be diagnosed with marked unicompartimental degenerative joint space narrowing.
62486693|NCT00975494|PLACEBO_COMPARATOR|Placebo|Placebo
62486694|NCT04423380|EXPERIMENTAL|SH3051 capsules treatment|Oral Twice Daily Administration of SH3051
62486695|NCT05624788||Specialist Referral: Neurology|
62486696|NCT05624788||Specialist Referral: Ophthalmology|
62486697|NCT05624788||Specialist Referral: Oncology|
62693370|NCT03863574|EXPERIMENTAL|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
61934946|NCT04547790|EXPERIMENTAL|Psyllium group|Subjects will take psyllium once daily for the first three days, then twice daily starting Day 4 until the end of the study.
61934947|NCT04547790|EXPERIMENTAL|Wheat Dextrin group|Subjects will take wheat dextrin once daily for the first three days, then twice daily starting Day 4 until the end of the study.
61934948|NCT01641510|EXPERIMENTAL|Prasugrel|Loading and maintenance dose of prasugrel
61934949|NCT01641510|ACTIVE_COMPARATOR|Clopidogrel|Loading and maintenance dose of clopidogrel
62486698|NCT05579548||Pregnant Women with PKU|This study will enroll pregnant women diagnosed with PKU who have been treated with pegvaliase from 2 weeks prior to LMP or at any time during pregnancy.
62486699|NCT00774540|EXPERIMENTAL|1|Ketorolac
62486700|NCT00774540|PLACEBO_COMPARATOR|2|saline
62486701|NCT06622330|EXPERIMENTAL|Group given position|Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
61934950|NCT02462174|ACTIVE_COMPARATOR|Topical ketamine and topical bupivacaine|0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered directly around the spermatic cord in the wound after end of surgery and before closure of the wound.
62486702|NCT06622330|NO_INTERVENTION|Control group|No intervention was made to the control group.
62486703|NCT05129176|EXPERIMENTAL|levofloxacin-tetracycline-containing quadruple group|patients in levofloxacin-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d
62486704|NCT05129176|ACTIVE_COMPARATOR|metronidazole-tetracycline-containing quadruple group|patients in metronidazole-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and metronidazole 400mg po qid for 14d
62486705|NCT00052221|EXPERIMENTAL|Arm I: Epoetin Alfa|Epoetin alfa subcutaneously (SC) once weekly for 6 weeks
62486706|NCT00052221|PLACEBO_COMPARATOR|Arm II: Placebo|Placebo subcutaneously (SC) once weekly for 6 weeks
62486707|NCT05325268||Monteggia Cohort|Including all Patients. Patients who had suffered a Monteggia fracture and were treated with osteosynthesis
62486708|NCT02114788||group 1|No intervention
62486709|NCT02114788||Group 2|Intervention with interactive website
62328858|NCT06693271|ACTIVE_COMPARATOR|intervention of protein, blueberries, and exercise|"treatment groups will receive the STRONG intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day. They will also participate in three 60-minute multimodal exercise sessions per week. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.~The intervention lasts for 12 months."
62328859|NCT06693271|NO_INTERVENTION|Control group|Participants receive usual standard of care.
62134444|NCT00643188|EXPERIMENTAL|1|"Radiofrequency ablation of atrial fibrillation:~Subjects assigned to the catheter AF ablation strategy will undergo ablation within 48 hours after baseline evaluation. The aim of the procedure is to achieve isolation of all Pulmonary Veins (PVs) and to restore sinus rhythm. Only radiofrequency catheter based AF ablation is permitted; other methods, like cryoablation, ultrasound and laser, are not permitted in this study.~Before ablation, a transesophageal echocardiogram must be performed in order to rule out presence of atrial thrombi.~Anticoagulation should be initiated, or continued, for at least six months post ablation. Six months after successful ablation and in absence of any recurrence of AF, antiarrhythmic drugs should be discontinued."
62328860|NCT06302933|OTHER|Children enrolled in Pediacam III ANRS12225 cohort|
62328861|NCT03833674|EXPERIMENTAL|Adults with incomplete SCI|Adults with chronic, incomplete SCI who have \>20% impairment in respiratory function, who will complete a battery of clinical assessments and 4 randomly ordered intervention and testing blocks (Daily AIH Block, Sham dAIH Block, Respiratory Strength Training Block and AIH + Strength Training Block).
62486710|NCT01787695|NO_INTERVENTION|No treatment (covered)|
62486711|NCT01787695|ACTIVE_COMPARATOR|UVA1|
62486712|NCT01002287|EXPERIMENTAL|SprayShield Adhesion Barrier|SprayShield Adhesion Barrier
62486713|NCT01002287|SHAM_COMPARATOR|Control|Good Surgical Technique Alone
62486714|NCT05213052|EXPERIMENTAL|Topical cream, 1 - 2 times daily|Application of a pea-sized amount of cream applied to skin over the area with chronic pain
61934951|NCT02462174|ACTIVE_COMPARATOR|Caudal ketamine and caudal bupivacaine|0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered by caudal epidural route after anesthesia and before the start of surgery.
61934952|NCT04370431|EXPERIMENTAL|PartA: TTYP01 single ascending doses|In Part A: a single-ascending-dose (SAD) escalation study with four consecutive cohorts, single ascending doses of TTYP01 (60, 120, 180 and 240 mg) will be orally administrated.
62486715|NCT02007863|EXPERIMENTAL|Umbilical Cord Blood + Chemotherapy|Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)
62486716|NCT05834751|EXPERIMENTAL|experimental group|PEG-rhG-CSF
62486717|NCT05834751|ACTIVE_COMPARATOR|control group|rhG-CSF
62486718|NCT02637141|EXPERIMENTAL|AMG 714 150 mg|Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
62486719|NCT02637141|EXPERIMENTAL|AMG 714 300 mg|Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
62486720|NCT02637141|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
62693371|NCT03863574|PLACEBO_COMPARATOR|Placebo|Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
62693372|NCT01652157||Cystic fibrosis (CF) patients in the CF Patient Registry|Patients diagnosed with cystic fibrosis at participating sites who are providing data to the Cystic Fibrosis Patient Registry
62693373|NCT06563687|EXPERIMENTAL|Experimental: Unblinded CGM|"CGM data will be unblinded, with alarms on for hypo and hyperglycemia. CGM data will be used to support clinical management including blood glucose measurements and decision making. Changes in glucose and insulin infusion will be based primarily on the real-time CGM data but blood glucose concentrations will be checked in case of rapid changes in CGM data or before any treatment."
62693374|NCT06563687|OTHER|Blinded CGM|CGM data will be blinded. Alarms for Hypo and hyperglycemia will be off. Glucose control will be monitored and managed according to standard clinical practice using intermittently sampled blood glucose concentrations.
62693375|NCT06638047|EXPERIMENTAL|RA TKA|Robotic-assisted TKA
62486721|NCT03928405|EXPERIMENTAL|Virtual reality group|The subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT). The virtual reality group was trained with games selected from different categories such as balance and aerobic exercises with Nintendo Wii virtual reality device for 6 weeks, 1 session 30 min, 2 times a week. In the control group, no treatment was performed during this period and routine medical treatments were continued. In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control.
62486722|NCT03928405|NO_INTERVENTION|Control Group|The sociodemographic characteristics of the subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT).the control group was reevaluated at the end of the 6th week after the initial evaluation. After the study was completed, training was given to the volunteers from the control group.
62486723|NCT03342339|OTHER|patients with Parkinson's disease|"1. cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~2. viewing of video : scale of differential emotions and Positive and Negative Affect Scale~3. Test of Iowa Gambling Task"
62486724|NCT03342339|OTHER|witnesses|"1. cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~2. viewing of video : scale of differential emotions and Positive and Negative Affect Scale~3. Test of Iowa Gambling Task"
62486725|NCT02244190|EXPERIMENTAL|new Tipranavir + Ritonavir|
62486726|NCT02244190|ACTIVE_COMPARATOR|current Tipranavir + Ritonavir|
62486727|NCT01196390|EXPERIMENTAL|Arm I (radiotherapy, chemotherapy, trastuzumab)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, 22, 29, 36, and 57 and paclitaxel intravenously IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Beginning 21-56 days after surgery, patients receive trastuzumab IV over 30-90 minutes. Treatment repeats every 21 days for 13 courses in the absence of disease progression or unacceptable toxicity.
62486728|NCT01196390|EXPERIMENTAL|Arm II (radiotherapy and chemotherapy)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive paclitaxel IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
62486729|NCT05941390|NO_INTERVENTION|control|patients undergoing one of the procedures without using VR device
62486730|NCT05941390|ACTIVE_COMPARATOR|VR without sound|patients undergoing one of the procedures using VR device without sound
62486731|NCT05941390|ACTIVE_COMPARATOR|VR with sound|patients undergoing one of the procedures using VR device with sound
62486732|NCT05104996|EXPERIMENTAL|Intervention Group|In the first interview, the patients were met and their consent for participation in the study was obtained. Afterwards, The Patient Descriptive Characteristics Form, ESCA and CAPS forms were filled. After this, patients were given discharge training and patient counseling service was provided by telephone for two months after discharge. At the end of two months, the ESCA and CAPS forms were filled again.
62486733|NCT05104996|NO_INTERVENTION|Control Group|In the first interview, the patients were interviewed and their consent was obtained to participate in the study. Then, the Patient Descriptive Characteristics Form, ESCA and CAPS forms were filled. After this, the patients did not undergo any intervention for two months. At the end of two months, the ESCA and CAPS forms were filled again and a copy of the guideline was submitted.
62486734|NCT03827395|EXPERIMENTAL|HEV-239|0.5 mL of HEV-239 administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=20
62486735|NCT03827395|PLACEBO_COMPARATOR|Placebo|0.5 mL of HEV-239 placebo administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=5
62486736|NCT00680498|ACTIVE_COMPARATOR|1|
62486737|NCT00680498|ACTIVE_COMPARATOR|2|
62693376|NCT06638047|ACTIVE_COMPARATOR|CI TKA|TKA with conventional instruments
62693377|NCT03794635|EXPERIMENTAL|Patients|Latino/a advanced cancer patients
62486738|NCT03921801|ACTIVE_COMPARATOR|Gait retraining|8-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback.
62486739|NCT03921801|EXPERIMENTAL|Gait retraining + strength training|8-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback and home-based strength training session for plantarflexor muscles three times per week.
62486740|NCT02316054||diabetes and MPHI|myocardial perfusion heterogeneity imaging
62486741|NCT00887419|EXPERIMENTAL|Coping Skills Training|Coping Skills Training in pain management
62486742|NCT00887419|ACTIVE_COMPARATOR|Education|Chronic Pain Education
62486743|NCT00887419|NO_INTERVENTION|Usual Care|Patients receive no study intervention, continue with usual medical care.
62693378|NCT03794635|EXPERIMENTAL|Caregivers|Caregivers of Latino/a advanced cancer patients
62693379|NCT02415114|ACTIVE_COMPARATOR|Healthy Population|Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
62693380|NCT02415114|ACTIVE_COMPARATOR|Population taking Statins|Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
62693381|NCT06475300|EXPERIMENTAL|BL-B01D1+PD-1 Monoclonal Antibody|Participants receive BL-B01D1+PD-1 Monoclonal Antibody as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62697562|NCT03056469|ACTIVE_COMPARATOR|Care providers do have access to PROs|Participants complete patient-reported outcome (PRO) questionnaires. Care providers do have access to the PROs and use them in clinical decision making.
62697563|NCT03056469|ACTIVE_COMPARATOR|Care providers do not have access to PROs|The participants complete patient-reported outcome (PRO) questionnaires. Care providers do not have access to the PROs.
62697564|NCT03056469|NO_INTERVENTION|Control group|Standard follow-up. The participants do not complete PRO questionnaires.
62486744|NCT05029427|EXPERIMENTAL|Study period 1: β-glucan Oat ; Study period 2: Wheat|For the first period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan. For the second period, the participant will receive food products made from wheat.
62486745|NCT05029427|EXPERIMENTAL|Study period 1: Wheat ; Study period 2: β-glucan Oat|For the first period, the participant will receive food products made from wheat. For the second period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan.
61934953|NCT04370431|PLACEBO_COMPARATOR|Part A: Placebo|Placebo control for Part A of the study
61934954|NCT04370431|EXPERIMENTAL|Part B: TTYP01 (oral edaravone) first then IV edaravone|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 60 mg oral edaravone tablet (TTYP01); Period 2: 30 mg IV edaravone (Radicut® ampoule), Period 3: 120 mg oral edaravone tablet (TTYP01); Period 4: 60 mg IV edaravone (Radicut® bag). Each dose will be spearated by a minimum of 7 days washout period.
62328862|NCT03636776|EXPERIMENTAL|quality of life in metastatic BC|"Patients benefit from a longitudinal follow-up determined according to the treatments.~Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment.~The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre.~The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II)."
62134445|NCT00643188|ACTIVE_COMPARATOR|2|"Conventional treatment:~Subjects assigned to the conventional treatment strategy will be treated according to current guidelines for the management of patients with chronic heart failure and/or atrial fibrillation. Efforts to maintain sinus rhythm in this study arm are recommended.~Anticoagulation will be initiated, if not already started, and maintained throughout the study according to current guidelines."
62134446|NCT01125254|EXPERIMENTAL|Amlodipine|amlodipine 5mg qd
62134447|NCT01125254|PLACEBO_COMPARATOR|Controls|placebo
62134448|NCT06699264|EXPERIMENTAL|Experimental Group|Group 1 (experimental group) will be trained with the intervention method (low-load strength training) using the Tourniquet Touch (VBM Medizintechnik GmbH Einsteinstrasse 1, 72172 Sulz a.N., Germany)
62134449|NCT06699264|ACTIVE_COMPARATOR|Control Group|Group 2 (controll group) receives the same strength training only without simultaneous restriction blood flow.
62134450|NCT04579250|EXPERIMENTAL|Group 1: H10ssF-6473 (20 mcg), ages 18-50 years|H10ssF-6473 (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0)
62134451|NCT04579250|EXPERIMENTAL|Group 2A: H10ssF-6473 (60 mcg), ages 18-50 years|H10ssF-6473 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
62134452|NCT04579250|EXPERIMENTAL|Group 2B: H10ssF-6473 (60 mcg), ages 55-70 years|H10ssF-6473 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
62134453|NCT05180591|EXPERIMENTAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
62134454|NCT05180591|PLACEBO_COMPARATOR|Saline Injection|2 placebo injections spaced 4 weeks apart at the beginning of the trial
62134455|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
62134456|NCT03214185|EXPERIMENTAL|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
62328863|NCT03986346|EXPERIMENTAL|Laser group|Participants in this group receive pulsed dye laser to treat the scar.
62486746|NCT00918684|EXPERIMENTAL|Escitalopram|12-week open label with 2 week placebo period (14 weeks total)
62486747|NCT06040723||Experimental: Intervention arm|All patients within the study are included in the intervention arm: The Hill classification is determined by the physician and the AI method.
62486748|NCT04068818||Eyes with normal anterior segment|
62486749|NCT04068818||Eyes with anterior segment abnormalities|
62486750|NCT04317417|EXPERIMENTAL|Condition 1|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
62486751|NCT04317417|EXPERIMENTAL|Condition 2|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
62486752|NCT04317417|EXPERIMENTAL|Condition 3|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
62134457|NCT03214185|ACTIVE_COMPARATOR|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
62134458|NCT01777009|EXPERIMENTAL|Patellar Eversion|Patients randomized to the Patellar Eversion arm of the study were surgically exposed by everting the patella during their Primary Total Knee Replacement Surgery.
62134459|NCT01777009|ACTIVE_COMPARATOR|Patellar Lateral Retraction|Patients randomized to the Patellar Lateral Retraction arm of the study were surgically exposed by laterally retracting the patella during their Primary Total Knee Replacement Surgery.
62134460|NCT02854241|EXPERIMENTAL|LC group|LC group under surveillance of biannual ultrasonography and annual noncontrast liver MRI. Six month after the last MRI, contrast enhanced liver CT is performed to investigate presence of HCC.
62134461|NCT01898585|EXPERIMENTAL|Zelboraf Arm|
62134462|NCT00580593|ACTIVE_COMPARATOR|1|
62134463|NCT00580593|SHAM_COMPARATOR|2|
62328864|NCT03986346|ACTIVE_COMPARATOR|Control group|Participants in this group receive standardized care.
62328865|NCT02069223|ACTIVE_COMPARATOR|Gastrectomy|Subjects in this group will undergo a gastrectomy as their first surgery with a BPD-DS 1-year later.
62486753|NCT04317417|EXPERIMENTAL|Condition 4|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62134464|NCT01888744|ACTIVE_COMPARATOR|Group 1 (GnRH agonist group)|The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels \< 80 pg/ml, FSH ≤ 10 IU/l and progesterone \< 1,5ng/ml)
62486754|NCT04317417|EXPERIMENTAL|Condition 5|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
62486755|NCT04317417|EXPERIMENTAL|Condition 6|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
62486756|NCT04317417|EXPERIMENTAL|Condition 7|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
62486757|NCT04317417|EXPERIMENTAL|Condition 8|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62697565|NCT01651208|EXPERIMENTAL|Motivational interviewing (MINT)|The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
62328866|NCT02069223|ACTIVE_COMPARATOR|BPD-DS|Subjects in this group will undergo a BPD-DS as their first surgery with a gastrectomy 1-year later.
62328867|NCT02069223|ACTIVE_COMPARATOR|Gastrectomy+BPD-DS|Subjects in this group will undergo a gastrectomy AND a BPD-DS concomitantly. They will then be closely monitored for the remainder of the study.
62328868|NCT03516292||OAB-POP group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
62328869|NCT03516292||POP only group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
62328870|NCT02973529|EXPERIMENTAL|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
62328871|NCT02973529|EXPERIMENTAL|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
62328872|NCT05553756|NO_INTERVENTION|preoperative clear liquid|Patients will drink 200 ml of clear liquid two hours before Cesarean section
62328873|NCT05553756|ACTIVE_COMPARATOR|preoperative maltodextrin|Patients will drink 200 ml of maltodexin two hours before Cesarean section
62328874|NCT06258577||candidates|In the first phase, patients with hepatosplenomegaly of unknown etiology will be initially screened using an electronic medical record database, and in the second phase, laboratory analysis of biomarkers, including Dry blood spot (DBS) for GBA1 enzyme activity, plasma Lyso-GB1 levels and GBA1 gene sequencing, will be performed.
62328875|NCT06258577||control|Compare the blood test with the candidates group.
62328876|NCT03988829|ACTIVE_COMPARATOR|Low-C|In an experimenter-designed simulation game, participants will be trained on predictable low attentional control shifts during working memory.
62328877|NCT03988829|EXPERIMENTAL|High-C|In an experimenter-designed simulation game, participants will be trained on unpredictable high attentional control shifts during working memory.
62328878|NCT03988829|EXPERIMENTAL|High-C+|In this commercially-available video game, in addition to unpredictable shifts of attentional control in working memory, task switching and resource planning will be trained.
62328879|NCT02778516|ACTIVE_COMPARATOR|Sodium Restriction 1500mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
62328880|NCT02778516|ACTIVE_COMPARATOR|Sodium Restriction 2400mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
62486758|NCT04317417|EXPERIMENTAL|Condition 9|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
62486759|NCT04317417|EXPERIMENTAL|Condition 10|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
62486760|NCT04317417|EXPERIMENTAL|Condition 11|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
62486761|NCT04317417|EXPERIMENTAL|Condition 12|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62486762|NCT04317417|EXPERIMENTAL|Condition 13|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
62486763|NCT04317417|EXPERIMENTAL|Condition 14|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
62486764|NCT04317417|EXPERIMENTAL|Condition 15|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
62486765|NCT04317417|EXPERIMENTAL|Condition 16|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62486766|NCT04317417|EXPERIMENTAL|Condition 17|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
61934955|NCT04370431|EXPERIMENTAL|Part B: IV edaravone first then TTYP01 (oral edaravone)|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 30 mg IV edaravone (Radicut® ampoule); Period 2: 60 mg oral edaravone tablet (TTYP01); Period 3: 60 mg IV edaravone (Radicut® bag); Period 4: 120 mg oral edaravone tablet (TTYP01). Each dose will be spearated by a minimum of 7 days washout period.
61934956|NCT04370431|EXPERIMENTAL|Part C: TTYP01: fasted dosing first then fed dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fasted condition; Period 2: under fed condition. Each dose will be spearated by a minimum of 7 days washout period.
61934957|NCT04370431|EXPERIMENTAL|Part C: TTYP01: fed dosing first then fasted dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fed condition; Period 2: under fasted condition. Each dose will be spearated by a minimum of 7 days washout period.
61934958|NCT03171051|OTHER|Lipolysis treatment|"The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.~The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes."
61934959|NCT01011738||Cohort|
62134465|NCT01888744|ACTIVE_COMPARATOR|Group 2 (GnRH antagonist group)|Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
62134466|NCT01921075||Volunteers|young (age\<30), healthy, lean (BMI\<25) volunteers
62134467|NCT04148482|ACTIVE_COMPARATOR|Genotype of interest group|Individuals with desired genetic susceptibility will receive a standardized and an election meal in a full-day clinic visit.
62328881|NCT02778516|NO_INTERVENTION|Control Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
62328882|NCT06689839|EXPERIMENTAL|F2 Filter and Delivery System|The F2 Cerebral Embolic Protection System will be used during your Transcatheter Aortic Valve Replacement procedure
62328883|NCT06689839|ACTIVE_COMPARATOR|Either the Sentinel Cerebral Protection System or no embolic protection device|Either the Sentinel Cerebral Protection System or no embolic protection device will be used during your Transcatheter Aortic Valve Replacement procedure depending on the Standard of Care at the treating institution
61934960|NCT02525042||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
61934961|NCT02525042||Comparator 1|family controls
62134468|NCT04148482|PLACEBO_COMPARATOR|Control|Individuals without genotype of interest (i.e., carrying the opposite genotype) will receive a standardized and an election meal in a full-day clinic visit.
62328884|NCT04026438|EXPERIMENTAL|Intervention Arm - potassium phosphate injection|
62328885|NCT04026438|NO_INTERVENTION|Control Arm|
62328886|NCT02261870|EXPERIMENTAL|ALL_patients|MRI T2 quantification : heart transplant patients will have 4-6 MRI exams for T2 quantification during their first year after transplantation.
62328887|NCT03384290|PLACEBO_COMPARATOR|Placebo|
61934962|NCT02525042||Comparator 2|population controls
62134469|NCT06150924|EXPERIMENTAL|Cohort 1|
62134470|NCT06150924|EXPERIMENTAL|Cohort 2|
62134471|NCT06700317|EXPERIMENTAL|HSS1|Surgery performed using HSS1
62134472|NCT02669771||Enzalutamide group|oral
62134473|NCT05038618|EXPERIMENTAL|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62134474|NCT03908060|EXPERIMENTAL|Intravenous single-dose methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
62134475|NCT03908060|ACTIVE_COMPARATOR|Intravenous single-dose morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
62134476|NCT05486598|EXPERIMENTAL|AL8326(Fasting）|After screening, the subjects were randomly assigned to two sequence groups A and B. after fasting at least 10 hours overnight, they took al8326 tablets according to the requirements of two sequence groups A and B.
62134477|NCT05486598|EXPERIMENTAL|AL8326（Postprandial）|After screening, the subjects were randomly assigned to two sequence groups A and B. after fasting at least 10 hours overnight, they took al8326 tablets according to the requirements of two sequence groups A and B.
62328888|NCT03384290|EXPERIMENTAL|PRS-060|
62328889|NCT04593940|ACTIVE_COMPARATOR|Standard of Care + infliximab or matching placebo|infliximab (single dose IV 5mg/kg given on day 1) or matching placebo
62328890|NCT04593940|ACTIVE_COMPARATOR|Standard of Care + abatacept or matching placebo|abatacept (single dose IV 10 mg/kg up to 1,000 mg given on day 1) or matching placebo
62486767|NCT04317417|EXPERIMENTAL|Condition 18|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
62486768|NCT04317417|EXPERIMENTAL|Condition 19|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
62486769|NCT04317417|EXPERIMENTAL|Condition 20|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62486770|NCT04317417|EXPERIMENTAL|Condition 21|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
62134478|NCT02065193||Beijing group|
62134479|NCT02065193||Guangdong group|
62134480|NCT02065193||Shenzhen group|
62134481|NCT02065193||Shanxi group|
62134482|NCT02065193||Liaoning group|
62134483|NCT02065193||Jilin group|
62328891|NCT04593940|ACTIVE_COMPARATOR|Standard of Care + cenicriviroc or matching placebo (closed to enrollment as of 3-Sep-2021)|cenicriviroc \[tablet, Day 1/Loading Dose: 450 mg (300mg morning and 150mg evening) Day 2 - 29/Maintenance Dose: 300 mg (150 mg BID) through Day 29\]. or matching placebo
62328892|NCT01463826||Children with bruxism|14 children with bruxism
62328893|NCT01463826||children without bruxism|19 children without bruxism
62328894|NCT03665350|NO_INTERVENTION|non insulin|standard care + antidiabetic therapy non insulin
62328895|NCT03665350|EXPERIMENTAL|Insulin|standard care including insulin
62328896|NCT05387382||Patients pending bariatric surgery|A continuous cohort of patients pending bariatric surgery
62486771|NCT04317417|EXPERIMENTAL|Condition 22|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
62328897|NCT03431675|NO_INTERVENTION|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
62328898|NCT03431675|ACTIVE_COMPARATOR|Household prophylaxis arm|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension)
62486772|NCT04317417|EXPERIMENTAL|Condition 23|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
62328899|NCT03431675|ACTIVE_COMPARATOR|Community prophylaxis arm|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension)
62328900|NCT03123354|EXPERIMENTAL|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
62328901|NCT05399706||Men|Male participants
62328902|NCT05399706||Women|Female Participants
62328903|NCT01975766|EXPERIMENTAL|Ketogenic diet|Ketogenic diet designed to sustain ketone levels through treatment.
62328904|NCT06330272|EXPERIMENTAL|CPP-ACPF treatment|"To apply the dental mousse, prophylaxis will first be carried out on teeth affected by pumice. The application of Tooth Mousse Plus to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush, the amount of mousse will be a pea grain. The cream will remain on the surface for 1 minute. The application will be carried out once a week, for four consecutive weeks."
62328905|NCT04045613|EXPERIMENTAL|Substudy 1: Derazantinib 300 mg once daily|Patients with urothelial cancer were treated with derazantinib 300 mg once daily
62328906|NCT04045613|EXPERIMENTAL|Substudy 2 (Dose-Level 1): Derazantinib 200 mg once daily + atezolizumab 1200 mg|Patients with any solid tumors were treated with derazantinib 200 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as intravenous (IV) infusion
62328907|NCT04045613|EXPERIMENTAL|Substudy 2 (Dose-Level 2): Derazantinib 300 mg once daily + atezolizumab 1200 mg|Patients with any solid tumors were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion
62328908|NCT04045613|EXPERIMENTAL|Substudy 3: Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Patients with urothelial cancer were treated with derazantinib 200 mg twice daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion
62328909|NCT04045613|EXPERIMENTAL|Substudy 4 (Cohort 4a):Derazantinib 300 mg once daily|Patients with FGFR inhibitor resistant urothelial cancer were treated with derazantinib 300 mg once daily
62486773|NCT04317417|EXPERIMENTAL|Condition 24|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62486774|NCT04317417|EXPERIMENTAL|Condition 25|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62486775|NCT04317417|EXPERIMENTAL|Condition 26|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
62486776|NCT04317417|EXPERIMENTAL|Condition 27|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
62486777|NCT04317417|EXPERIMENTAL|Condition 28|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/Achievable Goals and 5) Acts of Kindness
62134484|NCT02065193||Heilongjiang group|
62328910|NCT04045613|EXPERIMENTAL|Substudy 4 (Cohort 4b):Derazantinib 300 mg once daily + atezolizumab 1200 mg|Patients with urothelial cancer were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion
62328911|NCT04045613|EXPERIMENTAL|Substudy 5: Derazantinib 200 mg twice daily|Patients with urothelial cancer were treated with derazantinib 200 mg twice daily
62328912|NCT04575857||Statin arm|To receive pill packet with atorvastatin (40mg/day) which will be taken nightly.
62328913|NCT04575857||Placebo arm|To receive pill packet with placebo which will be taken nightly
62328914|NCT03065504|ACTIVE_COMPARATOR|Turmeric group|"2,000 mg turmeric per day - supplied by Banyan® Botanicals )~o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg."
62328915|NCT03065504|ACTIVE_COMPARATOR|Turmeric-containing combination tablets|"• 2,000 mg Healthy Skin™ Tablets, contains:~* Turmeric (Curcuma longa) - 50 mg/tablet~* Hemidesmus Indicus root (Anantamul)~* Indian Madder root~* Neem leaf~* Gotu Kola leaf~* Indian TInospora stem~* Amla fruit~* Licorice root~* Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets."
62486778|NCT04317417|EXPERIMENTAL|Condition 29|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
62486779|NCT04317417|EXPERIMENTAL|Condition 30|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
62486780|NCT04317417|EXPERIMENTAL|Condition 31|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
62486781|NCT04317417|EXPERIMENTAL|Condition 32|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
62328916|NCT03065504|PLACEBO_COMPARATOR|Placebo tablets group|"* Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals~* Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder~* Dose: subjects in this group will take 2 tablets twice per day"
62328917|NCT06093022||BCLM-surg|BCLM underwent liver resection
62328918|NCT06093022||BCLM-med|BCLM underwent medical treatment alone
62486782|NCT00868660|EXPERIMENTAL|ZP1848|Healthy Subjects or Crohn's Disease patients
62486783|NCT00868660|PLACEBO_COMPARATOR|Placebo|Healthy subjects or Crohn's Disease patients
62486784|NCT01867658|EXPERIMENTAL|Progel® Pleural Air Leak Sealant|
62486785|NCT02610647|OTHER|Control group|"Subjects randomized to this group will have a tapping test with no sensory blocking.~Intervention: Tapping test"
62486786|NCT02610647|EXPERIMENTAL|Wrist anesthesia|"Subjects randomized to this group will have an axillary block / regional anesthesia followed by a tapping test.~Intervention: Wrist anesthesia~Intervention: Tapping test"
62486787|NCT02610647|EXPERIMENTAL|Wrist anesthesia, masked|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Tapping test"
62486788|NCT02610647|EXPERIMENTAL|Wrist anesthesia, helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Anti-noise helmet~Intervention: Tapping test"
62486789|NCT02610647|EXPERIMENTAL|Wrist anesthesia, masked & helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Anti-noise helmet~Intervention: Tapping test"
61934963|NCT02047149|EXPERIMENTAL|Zileuton/Dasatinib|zileuton/dasatinib: This is a traditional phase I design. Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
61934964|NCT02986971|EXPERIMENTAL|New IMD|Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
61934965|NCT06087406|EXPERIMENTAL|Imvotamab (Dose Escalation)|Imvotatmab administered intravenously
62328919|NCT01204840|ACTIVE_COMPARATOR|Group A - Control group|"Group A (n=10; control group) will receive the patch protocol consisting of the 100ug estrogen patch (Estradot), a Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), and gonadotropin stimulation with 412 IU of recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris)."
61934966|NCT06087406|PLACEBO_COMPARATOR|PBO IV|Placebo administered intravenously
61934967|NCT06087146|EXPERIMENTAL|Athletes supplemented with sauerkraut|10 professional athletes (9 male) who will during 10 days consume approximately 250 g of sauerkraut (Brassica oleracea v. capitata) daily.
62486790|NCT01393951|EXPERIMENTAL|sc dose 1|subcutaneous (sc) vaccination of ASP7374 dose-1
62486791|NCT01393951|EXPERIMENTAL|sc dose 2|subcutaneous vaccination of ASP7374 dose-2
62486792|NCT01393951|EXPERIMENTAL|im dose 3|intramuscular (im) vaccination of ASP7374 dose-3
61934968|NCT05443360|EXPERIMENTAL|amorphous calcium carbonate (ACC group)|oral use, 2 ACC tablets (1000 mg / tablet, 200 mg calcium element / tablet) twice daily given after breakfast and dinner.
61934969|NCT05443360|ACTIVE_COMPARATOR|crystalized calcium carbonate (CCC group)|oral use, 2 CCC tablets (1000 mg / tablet, 200 mg calcium element / tablet) twice daily given after breakfast and dinner.
62486793|NCT05614453|EXPERIMENTAL|Treatment|Tislelizumab 200mg (IV) every 21 days for up to 35 cycles Sitravatinib 100mg (oral) given daily until disease progression or unacceptable toxicity
61934970|NCT06161272|EXPERIMENTAL|Arm1：Fluzoparib|Fluzoparib capsule: oral administration, 3 capsules/dose (150 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 4 weeks is a treatment cycle.
61934971|NCT06161272|EXPERIMENTAL|Arm2：Fluzoparib + apatinib|"Fluzoparib capsule: oral administration, 2 capsules/dose (100 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 4 weeks is a treatment cycle.~Apatinib: oral administration, 1 tablet/dose (375 mg/tablet), once a day, it is recommended to take orally within 0.5h after breakfast, continuous administration. Every 4 weeks is a treatment cycle."
61934972|NCT06685068|EXPERIMENTAL|GEN1286|
62486794|NCT02555137||outcome cohort study|'prediction score' and 'rule-out criteria'
62486795|NCT00736658|EXPERIMENTAL|AZD1386|4 groups receiving a specified volume of the active component AZD1386 at different points of time.
62486796|NCT00736658|PLACEBO_COMPARATOR|Placebo|Included in each dose group
62486797|NCT05891522|EXPERIMENTAL|portable scanner|
61934973|NCT02921360|EXPERIMENTAL|12 hours|Non-contrast CT and CT-angiography are performed in 11 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 12 hours after thrombolysis
62134485|NCT02065193||Jiangsu group|
62134486|NCT02065193||Zhejiang group|
62486798|NCT05891522|ACTIVE_COMPARATOR|fixed scanner|
62486799|NCT04107064|EXPERIMENTAL|Neurodiversity at Work (NaW) Group|Individuals in this group will receive a 6-week Autism at Work pre-employment training. Upon onboarding, each individual will be supported by a team manager, a team buddy, a peer mentor, a job/life skills coach, a vocational rehabilitation counselor, and a personal counselor. Ongoing support for members of support circles will be provided during the 12 weeks immediately after onboarding.
62486800|NCT04107064|EXPERIMENTAL|Neurodiversity at Work - Delayed Start (NaW-DS)|Participants in this group will receive typical orientation for neurotypical employees after onboarding. The support of peer mentor, job/life skills coach, vocational rehabilitation counselor, and a personal counselor will start 6 months after onboarding. Managers, co-workers, team buddies and mentors for all recruited and hired employees in both groups will receive the same specialized training to enhance their abilities to work with individuals with ASD.
62486801|NCT00789516||1|Normal control
62134487|NCT02065193||Fujian group|
62486802|NCT00789516||2|B thalassemia regular transfusion
62486803|NCT00789516||3|B thalassemia post transplantation
62328920|NCT01204840|EXPERIMENTAL|Group B - treatment group|"Group B will consist of 30 subjects. In addition to the same hormone stimulation patch protocol as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection."
62486804|NCT02986555|PLACEBO_COMPARATOR|Stress relief with existing biofeedback|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with existing biofeedback approach to relieve stress.
62486805|NCT02986555|ACTIVE_COMPARATOR|Stress relief with biofeedback and VR|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with biofeedback combined to virtual reality relaxation.
62328921|NCT01996735|ACTIVE_COMPARATOR|Ticagrelor 180 mg single dose|Ticagrelor 180 mg single dose
62486806|NCT01274143|ACTIVE_COMPARATOR|Telephone-delivered risk intervention|Participants in this arm receive a personalized telephone-risk assessment intervention provided by a trained cancer risk counselor.
62486807|NCT01274143|ACTIVE_COMPARATOR|Mailed pamphlet intervention group|Participants in this group receive a mailed pamphlet containing information about familial colorectal cancer risk and screening.
62486808|NCT05790863|EXPERIMENTAL|High-intensity interval training group|Each ergometer cycling training session consists of a warm-up phase lasting two minutes, five interval bouts of one minute each at 76% to 90% of one's HRmax, separated by one minute of passive or low-intensity recovery, and a three-minute cool-down phase. After 4 weeks of the intervention, the minimal intensity that had to be met will be progressively raised (weeks 1-4: 76-85%, weeks 5-7: 85-90%HRmax, respectively). For individuals who are unable to reach 76% HRmax, scores of 15 to 17 (hard to very hard) on the Borg scale will be followed.
62486809|NCT05790863|ACTIVE_COMPARATOR|Moderate-intensity continuous training group|During the first four weeks, participants will be advised to modify the pedal cadence and/or resistance of the ergometer to obtain an HR equivalent to 65-70% HRmax, rising to 70-75% HRmax during the final 3 weeks. Each session lasts less than 30 minutes of moderate-intensity continuous ergometer cycling, which starts with a two-minute warm-up and ends up with a three-minute cool-down.
62486810|NCT05759715||2-0 darkbown-green (2-0 bg)|Those with distinctively dark brown in the central area, slightly green in the peripheral area,
62486811|NCT05759715||1-0 lightbrown-green (1-0 bg).|Those with slightly dark brown in the central area and green in the peripheral area,
62328922|NCT01996735|PLACEBO_COMPARATOR|Placebo|Placebo single dose
62486812|NCT05759715||dark brown (1-1 db)|Eyes with the same color structure in the central iris and the peripheral iris.
62486813|NCT05759715||light brown (1-1 lb)|Eyes with the same color structure in the central iris and the peripheral iris.
62486814|NCT05759715||dark brown (2-0 b)|Those with distinctively dark brown in the central iris area compared to the periphery .
62486815|NCT05759715||slightly dark brown (1-0 b)|Those with slightly dark brown (1-0 b) in the central iris area compared to the periphery .
62486816|NCT02955901|ACTIVE_COMPARATOR|3-day low residue diet|Group A - 3 day low residue diet prior to the colonoscopy
62486817|NCT02955901|PLACEBO_COMPARATOR|1-day low residue diet|Group B - 1 day low residue diet prior to the colonoscopy
62486818|NCT00052286|EXPERIMENTAL|drug dosage 1|- Arm I: Patients receive oral high-dose modafinil twice daily.
62486819|NCT00052286|EXPERIMENTAL|drug dosage 2|- Arm II: Patients receive oral low-dose modafinil twice daily.
62486820|NCT06623084||NAFL GROUP|The investigators plan to recruit n=33 subjects with NAFLD
62486821|NCT06623084||NASH GROUP|The investigators plan to recruit n=33 subjects with histologically proven NASH
62486822|NCT06623084||Cirrhotic patients|The investigators plan to recruit n=33 subjects with metabolic non-viral cirrhosis
62486823|NCT06623084||Controls group|The investigators plan to recruit n=33 sex- and age-matched metabolically healthy volunteers (without NAFLD)
62486824|NCT00840203|EXPERIMENTAL|Mesalamine|Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
62486825|NCT00840203|ACTIVE_COMPARATOR|Rowasa®|Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
61934974|NCT02921360|NO_INTERVENTION|24 hours|Non-contrast CT and CT-angiography are performed in 23 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 24 hours after thrombolysis
61934975|NCT02503007|PLACEBO_COMPARATOR|Placebo|A placebo similar in composition and appearance to the experimental treatment.
62486826|NCT04589286|EXPERIMENTAL|Pack Health's Digital Life Coaching (DLC)|Participants will receive 16 weeks of access to a trained human life coach employed by Pack Health. Coaches will communicate via phone calls, text messages, emails, and links to web-based Pack Health resources plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
61934976|NCT02503007|EXPERIMENTAL|HMB-FA|Active treatment consisting of 3 g of HMB-FA per day.
61934977|NCT02634281|EXPERIMENTAL|group A|Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
62328923|NCT05201859|EXPERIMENTAL|Adjuvant Sintilimab Plus Capecitabine|Lead-in Phase: Sintilimab (200mg, D1, D14 for 2 cycles); Adjuvant Phase: Sintilimab ( 200mg D1, every three weeks, a total of 24 weeks, 8 cycles) + Capecitabine ( 1000 mg/m2, BID, D1-14 every three weeks, a total of 24 weeks, 8 cycles).
62486827|NCT04589286|ACTIVE_COMPARATOR|Quasi-usual care control arm|Participants will receive usual supportive care for stem cell transplantation plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
62486828|NCT06370104|EXPERIMENTAL|Remote Brief Cognitive Behavioral Therapy for Suicide Prevention|Participants in the experimental condition will be treated with online CBT-SP, a personalized intervention of approximately 12 sessions via chat or phone, in which therapist and client create a safety plan, try to restrict the access to lethal means and use a narrative assessment of a recent suicidal crisis to create a case formulation. This case formulation is then used to choose from several treatment modules, such as dealing with unhelpful thoughts and reducing sleep problems.
62697566|NCT01651208|ACTIVE_COMPARATOR|Mailed DVD|A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.
62697567|NCT00928772|ACTIVE_COMPARATOR|Alpha-Stim intervention|One hour Alpha-Stim intervention with sham midazolam
62697568|NCT00928772|SHAM_COMPARATOR|Sham Alpha-Stim with midazolam|Sham Alpha-Stim intervention with real midazolam administration
61934978|NCT02634281|ACTIVE_COMPARATOR|group B|group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
61934979|NCT00445978|EXPERIMENTAL|Sapropterin dihydrochloride|2.5, 5, 10, 20 mg/kg/day of sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks, with an optional extension phase at the highest tolerated dose for up to a total of 2 years.
61934980|NCT06707870|EXPERIMENTAL|Cervical retraction exercise|Cervical retraction exercise
61934981|NCT06707870|EXPERIMENTAL|Facet oscillatory mobilization|Facet oscillatory mobilization
61934982|NCT04564495|EXPERIMENTAL|Live zoom exercise classes|Participants will engage in a live zoom exercise session. Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
61934983|NCT04564495|ACTIVE_COMPARATOR|Recorded zoom exercise classes|Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks, using a pre-recorded class that they can do according to their own schedule. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
61934984|NCT03670927||Cases|Cases (incident patients with a diagnosis of primary sarcoma and histologically confirmed by an expert pathologist of the RRePS or ResOs networks in the 15 districts of France participating to this study) Environmental, occupational and lifestyle-related exposures
61934985|NCT03670927||Controls|"Subjects never diagnosed with a primary sarcoma and individually-matched by sex, age (5-years group), and districts of residence and randomly selected from electoral list.~Environmental, occupational and lifestyle-related exposures"
61934986|NCT01555983|ACTIVE_COMPARATOR|Vaporization of Cannabis 6.7% THC|Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
62328924|NCT05201859|ACTIVE_COMPARATOR|Adjuvant Capecitabine|Capecitabine 1000 mg/m2, BID, D1-14, every three weeks, a total of 24 weeks, 8 cycles.
61934987|NCT01555983|ACTIVE_COMPARATOR|Vaporization of Cannabis 2.9% THC|Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
61934988|NCT01555983|PLACEBO_COMPARATOR|Vaporization of Cannabis Placebo THC|Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
61934989|NCT04280146|ACTIVE_COMPARATOR|Degree of food processing|unprocessed vs ultra-processed foods according to NOVA table.
61934990|NCT04280146|ACTIVE_COMPARATOR|eating rate|slow vs fast eating rate (kcal/min), manipulated by food form
62134488|NCT02065193||Henan group|
62134489|NCT02065193||Hubei group|
62134490|NCT02065193||Hunan group|
62134491|NCT02065193||'Shanxi group|
62328925|NCT02256332|ACTIVE_COMPARATOR|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
62328926|NCT02256332|ACTIVE_COMPARATOR|High dose plant based ingredient|Reference food with high dose of plant based ingredient
62328927|NCT02256332|PLACEBO_COMPARATOR|Reference food format|Reference food without plant-based ingredient
62697569|NCT00928772|PLACEBO_COMPARATOR|Placebo|No Alpha-Stim and only topical anesthetics
61934991|NCT05129423|EXPERIMENTAL|Part 1: MTPS9579A Dose A|In Part 1, participants will receive MTPS9579A dose A every 4 weeks from randomization to Week 12.
61934992|NCT05129423|PLACEBO_COMPARATOR|Part 1: Placebo|In Part 1, participants will receive placebo matched with MTPS9579A, every 4 weeks from randomization through Week 12.
61934993|NCT05129423|EXPERIMENTAL|Part 2: MTPS9579A Dose A|In Part 2, participants will receive MTPS9579A dose A, every 4 weeks from randomization to Week 12.
61934994|NCT05129423|EXPERIMENTAL|Part 2: MTPS9579A Dose B|In Part 2, participants will receive MTPS9579A dose B, every 4 weeks from randomization to Week 12.
61934995|NCT05129423|EXPERIMENTAL|Part 2: MTPS9579A Dose C|In Part 2, participants will receive MTPS9579A dose C, every 4 weeks from randomization to Week 12.
61934996|NCT05129423|EXPERIMENTAL|Part 2: MTPS9579A Dose D|In Part 2, participants will receive MTPS9579A dose D, every 4 weeks from randomization to Week 12.
61934997|NCT05129423|PLACEBO_COMPARATOR|Part 2: Placebo Dose A|In Part 2, participants will receive placebo matched with MTPS9579A dose A and B, every 4 weeks from randomization through Week 12.
61934998|NCT05129423|PLACEBO_COMPARATOR|Part 2: Placebo Dose B|In Part 2, participants will receive placebo matched with MTPS9579A dose C and D, every 4 weeks from randomization through Week 12.
61934999|NCT01282203||Adults requiring anesthesia for surgery|This post-marketing observational study will be conducted in a prospective, multi-centre format. It is a non-interventional, observational study in which Sevorane is prescribed for adult patients undergoing general surgery for induction and maintenance of anesthesia in the usual manner in accordance with the terms of the local marketing authorization. Sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist. No additional procedures (other than standard of care) shall be applied to the patients. Each patient will be observed from the start of anesthesia through anesthesia end. Markers of myocardial ischemia will be detected up to the first 24 hours after anesthesia (if available). Additionally the correlation between the experience and training background of anesthesiologists and patient related outcomes of general anesthesia with Sevorane as a single anesthetic will be assessed.
61935000|NCT04780581|ACTIVE_COMPARATOR|RECOVERY|intermediate-dose dexamethasone (6mg/24h - 10 days)
61935001|NCT04780581|EXPERIMENTAL|BOLUS|high-dose methylprednisolone bolus (250mg/4h - 3 days)
61935002|NCT01056731|EXPERIMENTAL|Aliskiren and Aliskiren_HCTZ|aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
61935003|NCT03345069||Infants born very preterm|This is a single group prospective longitudinal, multisite cohort study of very preterm infants born at or below 32 weeks gestational age at birth
61935004|NCT05019794|EXPERIMENTAL|Gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) with FGFR2 amplification|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
61935005|NCT05019794|EXPERIMENTAL|Advanced Solid tumors[Exclude GC/GEJ Arm and CHOL,UC]with FGFR1-3 fusions/rearrangements/mutations|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
61935006|NCT06678724||Recurrent/Metastatic squamous cell carcinoma of the head and neck|"Patient inclusion criteria, must fulfill with all the items below~1. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2.\>=20 years old.~3. had pathologically confirmed squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx that was recurrent or metastatic and not curable by local therapy.~4. had at least one tumor lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 5. Medical records during treatment are available."
61935007|NCT03049254||Proband|Proband - the person who is the first to present with a diagnosis of AVC
61935008|NCT03049254||Family members (consultands)|First-degree relatives of probands with AVC (who may be living or deceased) In some circumstances where multiple family members are or may be affected, they may be eligible.
61935009|NCT01272102||Glaucoma|subjects with glaucoma
61935010|NCT05126498||Cohort 2018|All surgically treated patients in the surgical audits for lung cancer surgery (DLCA-S), Upper gastrointestinal cancer surgery (DUCA), pancreatic cancer surgery (DPCA), hepatobiliary surgery (DHBA), colorectal cancer surgery (DCRA), hip fracture surgery (DHFA), aortic aneurysm surgery (DSAA), and bariatric surgery (DATO), from the participating hospitals in 2018
61935011|NCT05126498||Cohort 2019|All surgically treated patients in the surgical audits for lung cancer surgery (DLCA-S), Upper gastrointestinal cancer surgery (DUCA), pancreatic cancer surgery (DPCA), hepatobiliary surgery (DHBA), colorectal cancer surgery (DCRA), hip fracture surgery (DHFA), aortic aneurysm surgery (DSAA), and bariatric surgery (DATO), from the participating hospitals in 2019
61935012|NCT05126498||Cohort 2020|All surgically treated patients in the surgical audits for lung cancer surgery (DLCA-S), Upper gastrointestinal cancer surgery (DUCA), pancreatic cancer surgery (DPCA), hepatobiliary surgery (DHBA), colorectal cancer surgery (DCRA), hip fracture surgery (DHFA), aortic aneurysm surgery (DSAA), and bariatric surgery (DATO), from the participating hospitals in 2020
61935013|NCT04407052|EXPERIMENTAL|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
61935014|NCT04407052|ACTIVE_COMPARATOR|HCG|HCG is used to trigger ovulation
61935015|NCT00850707||1|220 hemodialysis patients with Arterovenous fistula (AVF group)
62328928|NCT00174616|EXPERIMENTAL|Single arm|
61935016|NCT00850707||2|58 hemodialysis patients with Arterovenous graft (AVG group)
61935017|NCT00850707||3|180 hemodialysis patients with Tunneled cuffed catheters (TCC group)
61935018|NCT00850707||4|60 healthy subjects as controls
61935019|NCT02672280|EXPERIMENTAL|Medical Collagen Membrane with MSC|Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).
61935020|NCT02672280|ACTIVE_COMPARATOR|Medical Collagen Membrane|Application of medical collagen membrane only.
61935021|NCT05120609|EXPERIMENTAL|Parkinson's Application|Subjects will complete at-home allied health therapy exercises delivered through a smartphone application. Subjects will use the application daily for 4 weeks, each daily session takes up to 30 minutes to complete.
61935022|NCT05120609|PLACEBO_COMPARATOR|Digital Placebo|Subjects will have access to a digital placebo application and continue usual care.
62328929|NCT03919253|EXPERIMENTAL|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously; nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
61935023|NCT06081400|EXPERIMENTAL|Cryoablation|One single cryoablation of the desmoid tumor at Day 0
61935024|NCT06081400|ACTIVE_COMPARATOR|Medical therapy|"Chemotherapy: at the investigator's discretion: either~* methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or~* vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
61935025|NCT04252365|EXPERIMENTAL|arm 1|"Patients with PD-L1 high expression (TPS≥50%) receive Sintilimab injection 200mg i.v. on day 1 every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.~Patients with PD-L1 low or negative expression (TPS\<50%) receive Sintilimab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Sintilimab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
61935026|NCT04252365|ACTIVE_COMPARATOR|arm 2|"Patients with PD-L1 high expression (TPS≥50%) receive Pembrolizumab injection 200mg i.v. on day 1once every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.~Patients with PD-L1 low or negative expression (TPS\<50%) receive Pembrolizumab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Pembrolizumab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
62134492|NCT02126982||Clopidogrel hydrogen sulfate (CHS)|Clopidogrel hydrogen sulfate, 75 mg / day
62134493|NCT02126982||Clopidogrel Besylate (CB)|Clopidogrel Besylate , 75 mg / day
62134494|NCT06455488||MANAGE-VT Patients|Patients will be assessed on the status of their ventricular tachycardia as well as other criteria such as: EKG,
62134495|NCT01658241|EXPERIMENTAL|Single Arm Main population|
62134496|NCT01618500||INPH-patients|"Inclusion criteria~Older than 60 years of age Probable INPH according to the NIH guidelines Planned shunt surgery based on a diagnosis of INPH.~Exclusion criteria~Known cause for hydrocephalus (i.e., secondary NPH). Medical condition preventing cognitive testing (e.g. deafness, blindness).~Patients not considered for shunt operation."
62134497|NCT00645359||Diffusion MRI|Patients will undergo a Diffusion MRI (dMRI) at baseline and 7 days.
62134498|NCT04531059|ACTIVE_COMPARATOR|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 600mg bid Tetracycline 500mg qid Metronidazole 400mg qid
62134499|NCT04531059|EXPERIMENTAL|Minocycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 600mg bid Minocycline 100mg bid Metronidazole 400mg qid
62134500|NCT06499441|EXPERIMENTAL|Myofascial induction in the gastrocnemius muscle|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
62328930|NCT05238467||A|Group A will consist of 50 participants with a diagnosis of one of the following cancers: breast, colorectal, or prostate cancers who received myelosuppressive cytotoxic chemotherapy at the time of COVID vaccination, or who received chemotherapy within 30 days prior to the initial or booster vaccination, or who started on chemotherapy within 30 days after the initial or booster COVID vaccination. Cytotoxic chemotherapy can be given either in the neoadjuvant/adjuvant setting or metastatic setting.
62328931|NCT05238467||B|Group B will consist of 25 participants with a diagnosis of breast, colorectal, or prostate cancers who are on non-myelosuppressive treatment including endocrine therapy, tyrosine kinase inhibitor or anti-HER 2 therapy.
62328932|NCT05238467||C|Group C will consist of 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent, without evidence of disease recurrence, and \>12 months from completion of chemotherapy or radiation.
61935027|NCT04033510||AF/NR|Single cohort with a known or new diagnosis of atrial fibrillation, and intention attain/maintain normal rhythm. Subjects with be their own controls: Tablet-based cognitive testing to be performed while in atrial fibrillation (AF), and while they are in normal rhythm (NR). Results of both sets of cognitive testing will be compared.
61935028|NCT02091973|EXPERIMENTAL|Everolimus|everolimus dosing to tough level 6-10 ng/ml
62134501|NCT06499441|ACTIVE_COMPARATOR|Preassure release in gastrocnemius muscle|Also called ischaemic pressure. Three cycles of pressure are applied to the trigger point of the gastrocnemius muscle until the pain disappears on pressure.
62134502|NCT05521672|EXPERIMENTAL|Single Dose|"This is an uncontrolled trial, phase IIa, proof of concept. Group control has not been included.~All patients will receive one single dose of 120 million cells"
62134503|NCT02285114|EXPERIMENTAL|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to \< 18 years of age and ≥ 35 kg in body weight will switch their current 2-NRTI containing regimen to F/TAF (200/25 mg for unboosted 3rd agent and 200/10 mg for boosted 3rd agent) while continuing on their 3rd ARV agent for 48 weeks.
62134504|NCT02285114|EXPERIMENTAL|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to \< 12 years of age and ≥ 25 kg in body weight must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF 200/25 mg while continuing on their boosted PI for 48 weeks.
62328933|NCT01552928|EXPERIMENTAL|Anagrelide Therapeutic (0.5 mg)|
62134505|NCT02285114|EXPERIMENTAL|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to \< 12 years of age and between 17 kg to \< 25 kg in body weight must be on a boosted protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF 120/15 mg while continuing their 3rd ARV agent for 48 weeks.
62134506|NCT02285114|EXPERIMENTAL|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to \< 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
62134507|NCT02285114|EXPERIMENTAL|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to \< 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
62134508|NCT02285114|EXPERIMENTAL|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
62134509|NCT02285114|EXPERIMENTAL|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
62486829|NCT06370104|ACTIVE_COMPARATOR|Remote Semi-guided self-help course|Participants in the control group will be treated with a self-help course, in which they are given psychoeducation on suicidal thoughts, create a safety plan and are thought several techniques from cognitive therapy, such as cognitive restructuring and worry times. The course consists of 6 sessions, on which subjects receive feedback from a therapist. In this study, feedback will be given in a live conversation with the therapist via chat or phone, instead of via e-mail, to increase safety and reduce the difference in attention between the groups.
62693382|NCT06321029|EXPERIMENTAL|Single-arm waitlist control|"The initial assessment will take place at the time of study enrollment (T1). Participants will be offered a choice of assignment to either the eDTU (online Diabetes Tune-Up Group intervention participation) or iDTU (in-person Diabetes Tune-Up Group intervention participation) series. After a 3-month waiting period, participants will complete baseline assessment (T2). The group intervention will then take place over the next 6 to 8 weeks. Immediately following completion of the intervention, participants will complete surveys (T3). A final assessment will be completed 3 months after baseline, approximately 4 to 6 weeks following the completion of the intervention (T4).~The participant will participate in one series of the DTU intervention either, in person or online, at the participant's choosing. The intervention will take place over the course of 6 to 8 weeks. Participants will wear their continuous glucose monitor throughout the course of the intervention."
62693383|NCT04598087|EXPERIMENTAL|Prehabilitation|- Tailored exercise prescription involving aerobic and resistance training, supported by a clinical exercise physiologist.
62693384|NCT03026777|EXPERIMENTAL|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
62134510|NCT02285114|EXPERIMENTAL|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
62693385|NCT03026777|NO_INTERVENTION|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
62693386|NCT00778401|EXPERIMENTAL|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
62693387|NCT00778401|ACTIVE_COMPARATOR|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd.
62693388|NCT06454188|EXPERIMENTAL|Upadacitinib|Participants randomized to this arm will receive Upadacitinib 15 mg tablets, once per day, for 12 weeks.
62134511|NCT02285114|EXPERIMENTAL|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
62328934|NCT01552928|EXPERIMENTAL|Anagrelide Supratherapeutic (2.5 mg)|
62328935|NCT01552928|ACTIVE_COMPARATOR|Moxifloxacin|
62328936|NCT01552928|PLACEBO_COMPARATOR|Placebo|
62328937|NCT05024123|PLACEBO_COMPARATOR|Placebo|
62328938|NCT05024123|EXPERIMENTAL|Experimental|
62328939|NCT06434103|EXPERIMENTAL|SHR-A1921 combined with Adebrelimab and SHR-8068 with or without carboplatin|
62328940|NCT00166010|EXPERIMENTAL|Nesiritide|
62328941|NCT03008746|EXPERIMENTAL|not Pseudomonas aeruginosa colonized|
62328942|NCT03008746|EXPERIMENTAL|Pseudomonas aeruginosa colonized|
62328943|NCT03008746|EXPERIMENTAL|Pseudomonas aeruginosa OprD mutant colonized|
62693389|NCT06454188|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive matching placebo tablets with no active ingredients, once per day, for 12 weeks.
62328944|NCT03972592|EXPERIMENTAL|Topical sirolimus|The experimental group will consist in one area of the CMLM (almost half of it) that will receive 0.1% sirolimus preparation. This product will be applied 1/day on the randomly allocated area, by a nurse at home, during 12 weeks.
62328945|NCT03972592|PLACEBO_COMPARATOR|Vehicle|The control group will consist in the other half area of the CMLM, that will receive the same vehicle than the one used in the topical 0.1% sirolimus preparation. It will be applied 1/day in the corresponding area by a nurse, at home, during 12 weeks.
62693390|NCT05002309|EXPERIMENTAL|Psychotherapy|Cognitive-behavioural therapy
62693391|NCT05002309|EXPERIMENTAL|Pharmacotherapy|Antidepressant medication
62328946|NCT06331065|EXPERIMENTAL|Mindfulness meditation practice group|Group informed about mindfulness meditation and experimenting with an adapted program based on mindfulness meditation (intervention group).
62328947|NCT06331065|ACTIVE_COMPARATOR|Group without mindfulness meditation practice|Group informed about mindfulness meditation and without experimentation of mindfulness meditation practice (control group).
62328948|NCT02469831|ACTIVE_COMPARATOR|group D|deep neuromuscular block by rocuronium defined :post tetanic (PTC) \>1 but no response to a train of four (TOF) stimulation.
62328949|NCT02469831|ACTIVE_COMPARATOR|group I|intermediate neuromuscular block by rocuronium defined as TOF count of 1-3.
62328950|NCT03681652||Azathioprine or 6MP|Patients treated with thiopurines for post-operative prophylaxis.
62328951|NCT03681652||Anti-TNF drug|Patients treated with anti-TNF alpha monotherapy for post-operative prophylaxis.
62328952|NCT05784948|EXPERIMENTAL|Virtual Reality Mindfulness Treatment|Experience virtual reality mindfulness treatment with a screen from a head-mounted display for 30 minutes in a comfortable sitting position.
62328953|NCT05784948|SHAM_COMPARATOR|Relaxing scenery and music experience|Experience relaxing scenery and music with a screen from a head-mounted display for 30 minutes in a comfortable sitting position.
62328954|NCT01542411||recurrent pregnancy loss|
62328955|NCT01542411||thrombophilia, aspirin|
62328956|NCT01542411||heparin|
62486830|NCT04182126|PLACEBO_COMPARATOR|Regular long-lasting insecticidal nets|All participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
61935029|NCT02091973|EXPERIMENTAL|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
61935030|NCT05273307|EXPERIMENTAL|Miracle Fruit|Participants will receive 1 Miracle Fruit Farm miracle fruit cube by mouth three times a day before meals
61935031|NCT05273307|PLACEBO_COMPARATOR|Miracle Fruit Placebo|Participants will receive 1 placebo cube by mouth three times a day before meals
61935032|NCT04490161|EXPERIMENTAL|Interventional|Subjects will receive reinstallation of CSF intravenously.
61935033|NCT04490161|NO_INTERVENTION|Observational|Subjects will not receive study intervention; CSF will be sampled and analyzed in comparison to the Interventional arm,
61935034|NCT06557109|EXPERIMENTAL|Intervention|Intervention All students who agreed to participate in the study received theoretical training on Basic Life Support based on the AHA 2015 guidelines from an Emergency Medicine faculty member who holds an AHA First Aid Instructor Certificate for 2 class hours. After the training, the control group students practiced standard CPR, while the intervention group listened to music that would be used during CPR and then performed CPR with music accompaniment.
61935035|NCT06557109|NO_INTERVENTION|Control|Control All students who agreed to participate in the study received theoretical training on Basic Life Support based on the AHA 2015 guidelines from an Emergency Medicine faculty member who holds an AHA First Aid Instructor Certificate for 2 class hours. After the theoretical training, the students were divided into intervention and control groups. After the training, the control group students practiced standard CPR, while the intervention group listened to music that would be used during CPR and then performed CPR with music accompaniment.
61935036|NCT02073110||≥ 18 years, solid enhancing renal mass suspected for RCC|
61935037|NCT06365541|EXPERIMENTAL|Self Control|Compare the heart function of dialysis patients before treatment and during the third and sixth months of treatment.
61935038|NCT03148418|EXPERIMENTAL|Atezolizumab Monotherapy|Participants will continue to receive atezolizumab monotherapy in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
61935039|NCT03148418|EXPERIMENTAL|Combined Agents with Atezolizumab|Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
61935040|NCT03148418|ACTIVE_COMPARATOR|Comparator Treatment|Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
62134512|NCT02285114|EXPERIMENTAL|FTC/TAF +3rd ARV agent (Extension Phase)|After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) the participant turns 18 and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or, b) F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or, c) Gilead Sciences elects to terminate development of F/TAF in the applicable country.
62134513|NCT01800487|ACTIVE_COMPARATOR|silymarin|Silymarin 140 mg three times a day for 4 weeks
62134514|NCT01800487|PLACEBO_COMPARATOR|placebo|"Placeo~1 tab three times a day for 4 weeks"
62134515|NCT00111683|EXPERIMENTAL|MK-0457|Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration
62134516|NCT05953363||All participants|Participants who require a BD NRFit™ Spinal Needles, NRFit™ Spinal Introducer Needles, and NRFit™ Syringes as part of their routine medical care.
62134517|NCT04970511|EXPERIMENTAL|The group I: BBAT Face-to-Face Training group|"Exercises consist of supine, sitting, standing position awareness exercises and walking exercises.~Considering eight weeks, the training is designed to progress gradually each week."
62134518|NCT04970511|EXPERIMENTAL|The group II: Online BBAT training group|"Patients in the Internet-based BFT group will conduct their training with a physiotherapist to be connected via an online video conference system.~This group will be given the same training as the face-to-face BFT group."
62328957|NCT03777579|EXPERIMENTAL|JS001 Plus Nab-Paclitaxel|Participants assigned to JS001 plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
62328958|NCT03777579|PLACEBO_COMPARATOR|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
62328959|NCT03900559|EXPERIMENTAL|"NO-FEAR Airlines program with still images"|"Intervention group that uses NO-FEAR Airlines program with still images to carry out the exposure."
61935041|NCT01913223|EXPERIMENTAL|submucosal dissection by dissector water jet|
61935042|NCT05113290|EXPERIMENTAL|H101+Sorafenib|H101 combined with Sorafenib
61935043|NCT05113290|ACTIVE_COMPARATOR|Sorafenib|Patients take Sorafenib only
61935044|NCT02034032|ACTIVE_COMPARATOR|Regenexx SD|Regenexx-SD (Same Day) is a bone marrow based injection procedure.
61935045|NCT02034032|ACTIVE_COMPARATOR|Exercise Therapy|Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
61935046|NCT05243641|EXPERIMENTAL|Part 1b (dose escalation)|This portion of the study will enroll a maximum of 27 patients in the dose-finding trial including the possibility of adding up to 6 additional ER+ patients in a safety assessment of aromatic inhibitor treatment
61935047|NCT05243641|EXPERIMENTAL|Part 2 (dose expansion)|This portion of the study will enroll a maximum of 29 patients
61935048|NCT04041375|EXPERIMENTAL|iNSPiRED|Peer coaching intervention
61935049|NCT04041375|ACTIVE_COMPARATOR|Usual Care|Directory of resources and encouragement to follow-up with Primary Care Physician
62134519|NCT04970511|NO_INTERVENTION|The group III: Control group|No training will be applied to the control group patients.
62134520|NCT01238042|EXPERIMENTAL|Light Dose Escalation|Light Dose escalated from 150 joules/cm to 200 joules/cm
62693392|NCT06340360|EXPERIMENTAL|Low Dose|Rezpegaldesleukin Low Dose Every 2 weeks
61935050|NCT01140373|EXPERIMENTAL|autologous T cells & cyclophosphamide.|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells targeted to Prostate-Specific Membrane Antigen (PSMA) administered one day after pretreatment with cyclophosphamide.
61935051|NCT02197793|EXPERIMENTAL|Community Mobilization Program|Intervention activities will map onto six mobilization domains identified as key components for communities to mobilize for change around testing, linkage and retention in care (Treatment as Prevention (TasP)).
61935052|NCT02197793|NO_INTERVENTION|Control Arm|The control arm does not receive the Community Mobilization Intervention.
61935053|NCT04798495|EXPERIMENTAL|HAPPY|Single arm longitudinal design.
61935054|NCT00625794|EXPERIMENTAL|1|8 weeks or counseling plus 6 weeks of nicotine nasal spray
62134521|NCT02409667|ACTIVE_COMPARATOR|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
62134522|NCT02409667|EXPERIMENTAL|Secukinumab 300mg in PASI 90 responders (longer intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.
62328960|NCT03900559|EXPERIMENTAL|"NO-FEAR Airlines program with still and navigable images"|"Intervention group that uses NO-FEAR Airlines program with still and navigable images to carry out the exposure."
62486831|NCT04182126|EXPERIMENTAL|Piperonyl butoxide-treated LLIN|"All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1 and Stage 2 interventions provided that PBO-LLINs are effective at Stage 1 interventions. Each household will be provided on PBO-LLIN per two people with appropriate eduction.~PBO-LLIN: Olyset Plus, containing 2% permethrin and 1% PBO."
62693393|NCT06340360|EXPERIMENTAL|High Dose|Rezpegaldesleukin High Dose Every 2 weeks
61935055|NCT00625794|ACTIVE_COMPARATOR|2|8 weeks or counseling only.
62134523|NCT02409667|EXPERIMENTAL|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to \<90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
62134524|NCT02409667|ACTIVE_COMPARATOR|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to \<90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.
62134525|NCT01581372|EXPERIMENTAL|Pharmacist care|
62328961|NCT03900559|NO_INTERVENTION|Waiting list control group|"Participants of this group are able to access NO-FEAR Airlines program after 6 weeks of waiting period.~After that period, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (only still images or still + navigable images)."
62328962|NCT02909673|EXPERIMENTAL|Fourth R|Fourth R: 27 lesson curriculum addressing youth risk and health promoting behaviors
62486832|NCT04182126|EXPERIMENTAL|PBO-LLIN plus larval source management|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1. However, if Stage 1 intervention is not effective, half of them will randomized to receive PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including chemical methods by larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. The investigators will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
61935056|NCT06668649||Patients|Both sexes, aged 18 or older. The group will include 80 patients with multiple sclerosis, 80 patients with amyotrophic lateral sclerosis and 50 survivors of ischemic stroke
61935057|NCT06668649||Control|Both sexes, aged 18 or older. The group will include 100 healthy controls.
61935058|NCT01567735|EXPERIMENTAL|TMC435|
61935059|NCT04187677|ACTIVE_COMPARATOR|Hand Therapy Group|
61935060|NCT04187677|EXPERIMENTAL|Sensory Training Group|
61935061|NCT06704347|EXPERIMENTAL|Cohort 1: 1.5 mg XT-150|Participants will be administered 1.5 mg of XT-150 once by intrathecal injection on Day 1. An intrathecal injection is an injection using a thin needle inserted into the spinal canal at the base of your spinal cord performed by your study doctor.
61935062|NCT06704347|EXPERIMENTAL|Cohort 2: 4.5 mg XT-150|Participants will be administered 1.5 mg of XT-150 once by intrathecal injection on Day 1. An intrathecal injection is an injection using a thin needle inserted into the spinal canal at the base of your spinal cord performed by your study doctor.
61935063|NCT02682407|EXPERIMENTAL|OMS721 (narsoplimab)|Administration of OMS721 (narsoplimab)
61935064|NCT01632046|ACTIVE_COMPARATOR|BicaVera, dialysis|Two Parallel arms. If patient randomised to the BicaVera arm he will be dialysed with bicarbonate based PD fluid (BicaVera) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
62134526|NCT01581372|NO_INTERVENTION|Usual care|
62134527|NCT02829931|EXPERIMENTAL|Combination Therapy|"Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab.~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab"
62134528|NCT04351386||Atrial Fibrillation (AF)|Patients diagnosed with AF during reference ECG
62134529|NCT04351386||Normal Sinus Rhythm (NSR)|Patients with NSR during reference ECG
62134530|NCT04351386||Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
62693394|NCT06340360|PLACEBO_COMPARATOR|Placebo|Placebo Every 2 weeks
62697570|NCT01437189|EXPERIMENTAL|Parkinson's disease patients with depression|It is a self-controlled study only contains one arm, aims to investigate the effects of Sertraline on depression in Parkinson's disease
61935065|NCT01632046|ACTIVE_COMPARATOR|Balance, dialysis|If patient is randomised to the Balance arm, he will be dialysed with lactate based PD fluid (Balance) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
61935066|NCT05653258|OTHER|Younger Lean Group|Participants will be aged 18-30 years and have a BMI of 18.5 - 24.9 kg/m2
62134531|NCT03150446|EXPERIMENTAL|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
62134532|NCT02757898|EXPERIMENTAL|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
62134533|NCT03333109|EXPERIMENTAL|AMG334 70 mg|AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
62134534|NCT03333109|EXPERIMENTAL|AMG334 140 mg|AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
62134535|NCT03333109|PLACEBO_COMPARATOR|Placebo|Two pre-filled syringes containing placebo identical in appearance to erenumab
62134536|NCT02796586|PLACEBO_COMPARATOR|Individual Contraceptive Counseling|Performed by a medical provider and planned to simulate a typical clinic visit addressing contraception.
62134537|NCT02796586|EXPERIMENTAL|Group Contraceptive Counseling|Performed by a bicultural study staff member who speaks the primary languages of participants and had been formally trained in contraception counseling.
62134538|NCT05804994|EXPERIMENTAL|Medical device group|Group applying the tested medical device
62134539|NCT05804994|NO_INTERVENTION|Control group|Group not applying the tested medical device
62134540|NCT01735500||CAG without PCI|
62134541|NCT01735500||CAG with PCI|
62134542|NCT03494959|EXPERIMENTAL|Treatment with Pentaglobin|Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days.
62134543|NCT01989117||Osteopathy|
61935067|NCT05653258|OTHER|Older Lean Group|Participants will be over 65 years of age with a BMI of 18.5 to 24.9 kg/m2
61935068|NCT05653258|EXPERIMENTAL|Older Obese Group|Participants will be over 65 years of age with a BMI of 30-39.9 kg/m2.
61935069|NCT00683085|EXPERIMENTAL|Peptide vaccination|VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.
61935070|NCT05358015|EXPERIMENTAL|scaphoid nonunion|pedicled and free ABG for treatment of scaphoid nonunion
61935071|NCT02058472|EXPERIMENTAL|G3041|Amlodipine orotate 10mg/Olmesartan medoxomil 40mg
61935072|NCT02058472|ACTIVE_COMPARATOR|SEVIKAR®|Amlodipine besylate 10mg/Olmesartan medoxomil 40mg
62134544|NCT01989117||No osteopathy|
62134545|NCT06151301||control group|20 subjects of apparently healthy persons for estimating the standard levels of the tested biomarkers.
62134546|NCT06151301||case group|60 patients divided into mild, moderate and severe toxicity according to the poisoning severity score.
62134547|NCT01521052|EXPERIMENTAL|elderly depressed patients|Twenty seven (27) patients aged 68 years or above, currently suffering from a major depressive episode, who did not respond to treatment with at least one antidepressant medications in the recommended dosage and duration, or could not tolerate at least two antidepressants.
62134548|NCT00587275|EXPERIMENTAL|1|AST-120, 2 gram sachets
62134549|NCT00587275|PLACEBO_COMPARATOR|2|Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.
62134550|NCT00124735|EXPERIMENTAL|Rocuronium bolus maintenance|Rocuronium bolus maintenance
62134551|NCT00124735|EXPERIMENTAL|Rocuronium continuous infusion maintenance|Rocuronium continuous infusion maintenance
62134552|NCT02387866|EXPERIMENTAL|50 mg AG-221 tablet|50 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
62134553|NCT02387866|EXPERIMENTAL|100 mg AG-221 tablet|100 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
62134554|NCT02387866|EXPERIMENTAL|300 mg AG-221 tablet|300 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
62134555|NCT04405921|EXPERIMENTAL|Hydroxychloroquine associated to azithromycin|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. Azithromycin: 500 mg at day 1 then 250 mg/day for 4 days. with standard of care in association to treatments.
62134556|NCT04405921|ACTIVE_COMPARATOR|Hydroxychloroquine with placebo|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. with standard of care in association to treatments.
62134557|NCT02675244|ACTIVE_COMPARATOR|MVS Alone|Participants will undergo mitral valve surgery alone.
62134558|NCT02675244|ACTIVE_COMPARATOR|MVS + TV Annuloplasty|Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.
62134559|NCT05622110|EXPERIMENTAL|One abdominal side|Arm randomized for adhesive glue closure
62134560|NCT05622110|EXPERIMENTAL|Second abdominal side|Arm randomized for subcuticular suture closure
62134561|NCT01768689|NO_INTERVENTION|Run-in period|First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
62134562|NCT01768689|EXPERIMENTAL|Adherence-encouraging period|"Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions:~1. adherence-encouraging interventions - Group meetings~2. adherence-encouraging interventions - Individual meetings~3. adherence-encouraging interventions - Monthly phone calls~Patient will receive routine treatment for CML according to the physician discretion."
62134563|NCT04994795||Pembrolizumab monotherapy|
62134564|NCT04994795||Chemotherapy and pembrolizumab combination therapy|
62134565|NCT04994795||Chemotherapy doublet|
62134566|NCT06461286|EXPERIMENTAL|Single arm dose escalation study of PYC-001|"Drug: PYC-001~Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in participants with Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy"
62328963|NCT02909673|NO_INTERVENTION|Control|Control: Treatment as usual (standard health class curriculum)
62328964|NCT04802252||62 patients with benign prostatic hyperplasia in the experimental group|The pulse sound waves of three parts and five layers of each of the two hands of 62 patients with benign prostatic hyperplasia were collected by acoustic pulse detection system.
62328965|NCT04802252||62 relatively healthy men without benign prostatic hyperplasia in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 62 relatively healthy men without benign prostatic hyperplasia were collected by acoustic pulse detection system.
62328966|NCT06092242|EXPERIMENTAL|TAS-102 combined with bevacizumab|
62328967|NCT03440216|EXPERIMENTAL|Sampling if GFR = or > 30 mL/min|"Note: GFR = Glomerular Filtration Rate~Patients with a normal of moderately decreased renal function~* Temocillin: 6 g in continuous infusion over 24 h;~* Ceftriaxone: bolus 2 g (in 30 min) every 12h~* Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content when possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration when possible"
62328968|NCT03440216|EXPERIMENTAL|Sampling if GFR < 30 mL/min|"Patients with severe renal insufficiency or hemodialysis:~* Temocillin: 6 g in continuous infusion over 24 h;~* Ceftriaxone: bolus 2 g (in 30 min) every 12h~* Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content if possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration if possible"
62328969|NCT05475262|EXPERIMENTAL|Night A active white noise|Patients receiving active level of white noise on night A
62328970|NCT05475262|SHAM_COMPARATOR|Night B inactive white noise|"Patients will receive a lower Level of white noise on night B. Termed inactive, because do not expect the level to have a noticeable change in sound level changes, and thus sleep."
62328971|NCT06018584|SHAM_COMPARATOR|Control Group|No application was made after the tooth extraction procedure in the control group.
62328972|NCT06018584|EXPERIMENTAL|Low- Level Laser Group (Doctor Smile Wiser)|In the Laser group, the diode laser device Doctor Smile Wiser (Wiser, Doctor Smile, Milan, Italy) (Figue 1) with a wavelength of 980 nm and a power of 0.5 W was used for LLLT. During the procedure, the patient, physician, and assistant staff wore protective glasses (Wiser, Doctor Smile, Milan, Italy). With 300 mW of energy, a 400 m tip held 1 cm away from the extraction socket was applied to the extraction socket for 60 seconds from three points determined from the vestibule, lingual/palatal, and occlusal surfaces.
62134567|NCT03927820|ACTIVE_COMPARATOR|Pharmacist Intervention|Patients randomized to the intervention arm received usual care plus inhaler review by study pharmacist who made recommendations for inhaler changes based on clinical guideline and insurance formulary compliance. Recommendations were sent to the patient's team for final approval prior to discharge.
62328973|NCT04286412|EXPERIMENTAL|Treatment Arm|At least twenty five eligible male subjects will be enrolled in the treatment arm to receive Nonacog alfa until 16 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
62328974|NCT03856086|ACTIVE_COMPARATOR|Enhanced usual care (EUC)|"ICs randomized to EUC following baseline questionnaire completion will be given instructions (Appendix I) on how to access or create an account to access the myMSK online portal IC Resources page (https://my.mskcc.org/login). If the caregiver does not wish to enroll in MyMSK, the research study staff will send them an email with sample referral material ( Appendix D. The IC Resources page includes links to extant MSK educational materials for ICs (e.g., A Guide for Caregivers \[47\]), contact information for psychosocial services (e.g., Caregivers Clinic in the MSK Counseling Center), and external resources (e.g., educational materials and services through the CSC, American Cancer Society, and others) (Appendix D,)."
62134568|NCT03927820|NO_INTERVENTION|Usual Care|Patients randomized to the usual care arm received care by the primary team which includes an inpatient pharmacist who does not have access to benefits investigation technology. The study pharmacist was not involved to review inhalers for optimization prior to discharge.
62134569|NCT00459524||Questionnaire|AML and MDS Patients
62134570|NCT03176888|EXPERIMENTAL|Exercise|Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints. Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy. The duration of the intervention will be the weeks between enrolling in the study and surgery (\~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
62134571|NCT03176888|NO_INTERVENTION|Standard care|Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study. They will however undergo the same testing sessions as patients in the Exercise group.
62328975|NCT03856086|EXPERIMENTAL|CancerSupportSource-CG screening plus consultation (S+C)|"ICs randomized to S+C will complete the web-based CSS-CG (Appendix C) using a tablet immediately following baseline study measures. In case of technical issues, ICs may complete Appendix C with the guidance of a member of the research study team. The CSS-CG asks ICs to rate their level of concern for 33 different possible problems: if a need is rated as low (i.e., A little or less concern), after each problem is rated ICs will be prompted to request pertinent educational materials if they are interested. If a need is endorsed (i.e., Moderate or greater concern), ICs are asked through the web-based electronic platform (https://mskcc.mycarereport.com) whether they would like educational materials and/or to speak with someone about that need (i.e., receive a referral)."
62134572|NCT02426229|EXPERIMENTAL|dabigatran 75mg|dabigatran etexilate 75mg orally twice daily for 6 months
62134573|NCT01865474|EXPERIMENTAL|Treatment I|DLBS1033 bioactive fraction tablet 490 mg thrice daily
62134574|NCT01865474|EXPERIMENTAL|Treatment II|Placebo tablet of DLBS1033, thrice daily
62134575|NCT01111513|ACTIVE_COMPARATOR|Continuous femoral block|Patients receive a continuous femoral block for 48 hours and they have patient controlled analgesics.
62134576|NCT01111513|ACTIVE_COMPARATOR|Single dose femoral block|Patients receive a single dose femoral block and have patient controlled analgesics.
62134577|NCT01111513|ACTIVE_COMPARATOR|Patient controlled analgesics|Patients do not receive a femoral block. They only have patient controlled analgesics.
62134578|NCT01145729|ACTIVE_COMPARATOR|Biomarker feedback|Biomarkers of tobacco exposure (laboratory values) delivered to health care provider
62134579|NCT01145729|PLACEBO_COMPARATOR|Usual care (general counseling)|Brochure about pesticides, lead, SHS
62134580|NCT05898191|EXPERIMENTAL|laser|laser treatment (Laser CO² MIXTO PRO, LASERING SRL, Modena, Italy; three sessions, one per month)
62134581|NCT05898191|NO_INTERVENTION|control|no intervention
62134582|NCT03000595|EXPERIMENTAL|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
62134583|NCT03000595|PLACEBO_COMPARATOR|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
62134584|NCT01811394|EXPERIMENTAL|protons|16x4GyE protons
62134585|NCT01811394|EXPERIMENTAL|Carbon ions|16x4GyE carbon ions
62134586|NCT00404742|PLACEBO_COMPARATOR|Placebo|
62134587|NCT00404742|ACTIVE_COMPARATOR|LX211, 0.2 mg/kg|
62134588|NCT00404742|ACTIVE_COMPARATOR|LX211, 0.4 mg/kg|
62134589|NCT00404742|ACTIVE_COMPARATOR|LX211, 0.6 mg/kg|
62134590|NCT04105712|EXPERIMENTAL|Pre and Post Dietary Change (within subjects)|Participants do an initial call for baseline data. Then the active assessment period (pre / post dietary change) begins. Pre - dietary change procedure is 5 days of standard high HP diet while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Post - dietary change is 5 days of lower HP diet (food provided for 3 of 5 days) while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Daily assessments of affect, craving, and withdrawal are all virtual. On day 4-5 of post assessment, participants complete a food journal to report foods they ate to ensure compliance to low HP food diet. The pre / post-dietary change phone appointments include 1) psychosocial stress task, 2) cue reactivity task, 3) questionnaires 4) self-reported weight. Participants may also complete a follow up period of questionnaires every other day and self-report weight at the end of follow up.
62134591|NCT01737021|EXPERIMENTAL|Psycho-educational intervention|Psycho-education
62134592|NCT01737021|NO_INTERVENTION|Treatment as usual|
62134593|NCT01997346||Key Informant Interviews|We will conduct interviews with 4 clinic personnel (16 across the 4 sites) to learn about practices and provider perspectives in the HIV clinic or ancillary clinics such as VCT. The 4 clinic personnel in each site will include: the physician-in-charge, a nurse, one peer educator, and a nurse or community counselor from the VCT clinic. A semi-structured interview guide will be used to query respondents about: procedures for enrolling new clients, conducting active testing, identifying and initiating patients on ART, CD4 monitoring, tracking clients who have missed appointments, support programs, and peer education. We will also aim to understand how each respondent views her/his role, how s/he counsels patients on pre-ART care, and the challenges faced from each one's perspective.
62693395|NCT05479981|EXPERIMENTAL|AOC 1001|AOC 1001 will initially be administered quarterly. On Day 43 patients will receive an additional dose. Treatment assignment will be based on treatment received in AOC 1001-CS1. If participant did not receive AOC 1001 on Day 43 in AOC 1001-CS1, participant will receive AOC 1001 treatment on Day 43 in AOC 1001-CS2. Beginning in September 2024, AOC 1001 will be administered every 8 weeks.
62134594|NCT04674995||Stent|Patients with tracheal stenosis treated with stent placement via rigid bronchoscopy.
62134595|NCT04674995||Balloon dilatation|Patients with tracheal stenosis treated with balloon dilatation via laryngoscope.
62134596|NCT06464692|EXPERIMENTAL|Safety Run-In Cohort 1: ABBV-400 Dose A|Participants with unresectable locally advanced/metastatic colorectal cancer (CRC) will receive ABBV-400 dose A during the approximately 2.5 year study duration.
62134597|NCT06464692|EXPERIMENTAL|Safety Run-In Cohort 2: ABBV-400 Dose B|Participants with unresectable locally advanced/metastatic CRC will receive ABBV-400 dose B during the approximately 2.5 year study duration.
62134598|NCT06464692|EXPERIMENTAL|Dose Expansion Part 1: ABBV-400 Optimal Dose|Participants with unresectable locally advanced/metastatic CRC will receive ABBV-400 at the optimal dose during the approximately 2.5 year study duration.
62134599|NCT06464692|EXPERIMENTAL|Dose Expansion Part 2: ABBV-400 Dose B|If further analysis is warranted, participants with unresectable locally advanced/metastatic CRC will receive ABBV-400 dose B during the approximately 2.5 year study duration.
62134600|NCT04175899|EXPERIMENTAL|POCCP (Pharmacist-led Oral Chemo Care Program)|"Intervention Group :~Subjects undergo structured intensified pharmaceutical care program (POCCP) led by oncology experienced pharmacist (run alongside oncologist patient review at the clinic or daycare) in addition to Current Standard Best Care (SBC)"
62134601|NCT04175899|NO_INTERVENTION|SBC (Current Standard Best Care)|"Control Group :~Subjects undergo usual procedure which is Current Standard Best Care (SBC) for oral chemotherapy treatment which includes pre-chemotherapy review by doctor and prescribing of chemotherapy and supportive medications according to patient's chemotherapy protocol at each visit. Subsequently the patients will collect their prescribed oral medications at the ambulatory pharmacy counter according to the standard procedure of medication dispensing which includes prescription screening, medication filling, double checking, dispensing and counselling at the pharmacy counter as per usual practice of pharmaceutical care of patients."
62134602|NCT03322124|EXPERIMENTAL|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
62134603|NCT03322124|PLACEBO_COMPARATOR|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
62134604|NCT01032668|EXPERIMENTAL|high dose clopidogrel|
62134605|NCT01154192|EXPERIMENTAL|PCOS group|Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
62486833|NCT04182126|EXPERIMENTAL|PBO-LLIN plus enhanced methods|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2, i.e., annual IRS using Kenya Government recommended insecticides.
62486834|NCT04182126|EXPERIMENTAL|LLIN plus indoor residual spraying|All participants will received regular LLINs plus indoor residual spraying (IRS) (LLIN+IRS) at Stage 1 and Stage 2 interventions provided that LLIN+IRS is effective at Stage 1 interventions. For LLIN+IRS clusters, each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl (Actellic 300CS) at the recommended dosage of 1g/m² and at the government-recommended frequency. If Kenya government switch the IRS insecticide, the investigators will use the same insecticide as the government recommended.
62486835|NCT04182126|EXPERIMENTAL|LLIN+IRS twice a year|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. IRS will be increased to twice a year.
62486836|NCT04182126|EXPERIMENTAL|LLIN+IRS plus enhanced method|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. Enhanced method will be added on these clusters at Stage 2 interventions.The enhanced intervention is the regular IRS plus IRS treating animal sheds and other outdoor structures.
62486837|NCT03078608|EXPERIMENTAL|Intervention arm|Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
62486838|NCT03078608|ACTIVE_COMPARATOR|Active control arm|Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
62486839|NCT03078608|OTHER|Wait list control arm|Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
62486840|NCT03492138|EXPERIMENTAL|Participants with relapsed/refractory multiple myeloma|ONC201, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Run-in phase of ONC201 and dexamethasone weekly until progression at 4 weeks, lack of response at 8 weeks, or progression followed by the addition of weekly ixazomib.
62486841|NCT05492162|OTHER|paramedic students|para-experimental arm
62486842|NCT03413202|EXPERIMENTAL|butylphthalide(NBP)|Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
62486843|NCT03413202|PLACEBO_COMPARATOR|placebo|Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
62486844|NCT00799162||Women with a scheduled cesarean section|
62486845|NCT02888756|EXPERIMENTAL|iHIVARNA-01|Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
62486846|NCT02888756|ACTIVE_COMPARATOR|TriMix|Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
62486847|NCT02888756|PLACEBO_COMPARATOR|Placebo|Water for injection 3 vaccinations, two weeks interval
62134606|NCT01154192|EXPERIMENTAL|Normal group|Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
62328976|NCT04585399|EXPERIMENTAL|Contingency Management|Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.
62328977|NCT04585399|NO_INTERVENTION|Standard Care|Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.
62328978|NCT03887559|EXPERIMENTAL|Intervention group|Group-based stabilization and skill-training combined with individual treatment.
62486848|NCT03276559|EXPERIMENTAL|Randomized controlled trial EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
62697571|NCT02888340|EXPERIMENTAL|Acupuncture|One session of acupuncture prior to receiving pain medications after arriving to the emergency department with pain as a symptom.
62134607|NCT01154192|EXPERIMENTAL|Oligomenorrhea group|Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
62134608|NCT01291810|EXPERIMENTAL|TNF Kinoid|
62134609|NCT01291810|PLACEBO_COMPARATOR|Placebo|
62134610|NCT01470300|EXPERIMENTAL|Standard ED|100% energy density
62134611|NCT01470300|EXPERIMENTAL|Reduced ED - F/V|80% energy density by adding fruit and vegetables
62134612|NCT01470300|EXPERIMENTAL|Reduced ED - Fat|80% energy density by decreasing fat
62134613|NCT01470300|EXPERIMENTAL|Reduced ED - Plain water|80% energy density by adding plain water
62134614|NCT03762772|EXPERIMENTAL|TAF/EVG vaginal insert|Post-dose sampling at 4 and 48 hours or at 24 and 72 hours, per randomization
62134615|NCT02754596|EXPERIMENTAL|Travoprost Intraocular Implant, high elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
62134616|NCT02754596|EXPERIMENTAL|Travoprost Intraocular Implant, low elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
62134617|NCT02754596|ACTIVE_COMPARATOR|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol, a beta blocker, will be dosed twice daily
62134618|NCT05398055|EXPERIMENTAL|A|Azithromycine group
62134619|NCT05398055|PLACEBO_COMPARATOR|B|Placebo group
62134620|NCT03148600|ACTIVE_COMPARATOR|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
62134621|NCT03148600|PLACEBO_COMPARATOR|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
62134622|NCT02766517|EXPERIMENTAL|Capsaicin|Single topical dose of capsaicin
62486849|NCT03276559|PLACEBO_COMPARATOR|Randomized controlled trial Enhanced usual care arm|"The usual care arm indicates regular ICU support for informal caregivers (i.e. social work, chaplaincy) as recorded in the patient's medical record, a general information packet for informal caregivers, and a site-specific resource list.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone."
62486850|NCT03276559|EXPERIMENTAL|Open trial COVID-19 phase arm|The COVID-19 open trial phase arm did not include randomization or control arm. All participants received the EMPOWER intervention. Assessments will occur pre-intervention, immediately post-intervention, and then 1-month and 3-months from post-intervention assessment.
62486851|NCT04051307|EXPERIMENTAL|intervention|"Vaccination with:~PD-L1 peptide:~PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL Dose: 100 µg PD-L1 long1 dissolved in DMSO/water - Total volume: 0,5 ml.~Arginase1 peptide:~ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL Dose: 200 µg ARGLong2 dissolved in DMSO/water - Total volume: 0,5 ml.~Both vaccines are given at a treatment. Adjuvant Montanide ISA 51 0,5ml is mixed with the peptides before treatment To be administered every second week - a total of twelve times, with a possibility of additional six treatments."
62486852|NCT05365698||Cohort I|randomly assigned 12 health facilities (treatment/intervention group) that will have access to CHN program components
62486853|NCT05365698||Cohort II|randomly assigned 12 health facilities that will serve as a control for the first year of the program implementation and then transition into the intervention/treatment group
62486854|NCT01470430||ROP infants treated with intravitreal anti-VEGF agents|
62486855|NCT01470430||ROP infants treated with retinal laser photocoagulation|
62486856|NCT04436198|EXPERIMENTAL|Treatment group: toric IOL plus capsular tension ring|
62486857|NCT04436198|ACTIVE_COMPARATOR|Control group: toric IOL only|
62486858|NCT04169815||ED Setting|An acute HF population enrolled at the emergency department. Testing of clinical samples will be performed with the Access natriuretic peptide assay.
62486859|NCT06559995|ACTIVE_COMPARATOR|Ketone Supplement|"Ketone supplement D-beta-hydroxybutryric acid and R-1,3 butanediol (Kenetik: Ketone Drink, VitaNav Inc., Washington D.C.) 12g of ketones, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit."
62486860|NCT06559995|PLACEBO_COMPARATOR|Placebo Beverage|Placebo beverage, visually matched, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit.
62486861|NCT06301386|EXPERIMENTAL|Everolimus in combination with PD-1|Patients will be treated with Everolimus and PD-1
62486862|NCT01600963|EXPERIMENTAL|Arm A|
62486863|NCT01600963|PLACEBO_COMPARATOR|Arm B|
62486864|NCT03389113|EXPERIMENTAL|Whole body vibration group|Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
62486865|NCT03389113|ACTIVE_COMPARATOR|Exercise only group|The control group performed the same session without vibration.
61935073|NCT06187337|EXPERIMENTAL|Early maxillary expansion|"The subjects in the experimental group will be treated with a maxillary expansion appliance with bands on the second deciduous molars and arms to the deciduous canines. The screw gives a expansion of 0,20 millimeter per activation. The arms are bonded to the deciduous canines with light curing composite and the bands are cemented with glassionomer cement.~The subject are instructed to activate the appliance once a day (1/4 turn) for 2 weeks and thereafter every second day until adequate space for the lateral incisors is obtained.During the expansion the subjects will be asked to complete a questionnaire on pain and discomfort.~The subjects will be recalled for follow-up visits after 24 months (T1), 36 months (T2), 48 months (T3) and when all permanent premolars are erupted (T4).~At T4 the subjects are asked to fill out the Psychosocial Impact of Dental Aesthetics Questionnaire (PIDAQ).~The subjects need for further treatment will be evaluated and initiated at T4."
61935074|NCT06187337|NO_INTERVENTION|Control group|"The control group is not going to receive any treatment under the observation period.~The subjects will be recalled for follow-up visits with photographs (4 extraoral photos and 5 intraoral photos) and study models (digital or cast) after 24 months (T1), 36 months (T2), 48 months (T3) and when all permanent premolars are erupted (T4).~At T4 the subjects are asked to fill out the Psychosocial Impact of Dental Aesthetics Questionnaire (PIDAQ) to evaluate their oral health related quality of life.~The subjects need for further treatment will be evaluated and initiated at T4."
61935075|NCT02857361|EXPERIMENTAL|Treatment A: Simultaneous Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.
62328979|NCT03887559|ACTIVE_COMPARATOR|controls|Individual treatment as usual only.
62328980|NCT00771407|ACTIVE_COMPARATOR|Strattice fascial inlay|Strattice will be placed as a fascial inlay to support the ostomy site
62486866|NCT03797248||Cohort 1|adjuvant chemotherapy combined with Chinese herbal medicine
62486867|NCT03797248||Cohort 2|adjuvant chemotherapy only
62693396|NCT05479981|EXPERIMENTAL|AOC 1001 (with Placebo at Day 43)|AOC 1001 will initially be administered quarterly. On Day 43 patients will receive an additional dose. Treatment assignment will be based on treatment received in AOC 1001-CS1. If participant received AOC 1001 on Day 43 in AOC 1001-CS1, participant will receive blinded placebo treatment on Day 43 in AOC 1001-CS2. Beginning in September 2024, AOC 1001 will be administered every 8 weeks.
61935076|NCT02857361|EXPERIMENTAL|Treatment B: Sequential Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.
61935077|NCT02831374|EXPERIMENTAL|Use of platelet rich plasma (Group A)'|Local anesthesia, surgical extraction of impacted third molar, Preparation of PRP gel, Placing platelet Rich plasma and suturing, Postoperative medication
62328981|NCT00771407|OTHER|Standard ostomy construction|Ostomy will be created in the standard fashion
62328982|NCT06099509|EXPERIMENTAL|Self-administered diabetes screen|"Self-administered 75-gram oral glucose tolerance test with 4-week virtual follow-up visit.~Drug: GlucoCrush"
62486868|NCT03875547||Patients with haemophilia B|Both patients who have not previously been exposed to Refixia® and patients previously exposed to Refixia® in one of the clinical trials can be included.
62697572|NCT02888340|NO_INTERVENTION|Usual Care|Usual care for pain, without intervention, after arriving to the emergency department with pain as a symptom.
62328983|NCT06099509|NO_INTERVENTION|Routine postpartum care|"Office based oral glucose tolerance test at 6 weeks postpartum, per normal protocol.~Drug: GlucoCrush"
62328984|NCT05822895||Computer-aided polyp detection|patients undergoing colonoscopy with CADe enabled programme
62328985|NCT05822895||without CADe|patients undergoing colonoscopy without CADe enabled programme
62328986|NCT02764632|ACTIVE_COMPARATOR|Didgital group|After induction of anesthesia, and after ensuring muscle relaxation, NGT will be inserted through the selected nostril and advanced for 12 cm then the NGT was advanced according to study group advancing. In control group; NGT was inserted with patient head flexed. In D group, after feeling the NGT in pharynx, with the head in neutral position,the index finger was used to support the NGT with slight direction towards the left side. This will prevent tube kinking at this point in front of the resistance offered by the inflated tube cuff or arytenoids cartilage. Also, this digital support reinforces the tube at the area weakened by its openings
62328987|NCT02764632|NO_INTERVENTION|Control group|
62328988|NCT00993603|EXPERIMENTAL|Lifestyle programme.|8 month lifestyle programme.
62328989|NCT00828087|EXPERIMENTAL|Everolimus Arm|Everolimus Eluting Coronary Stent System
62328990|NCT00828087|ACTIVE_COMPARATOR|non drug eluting stent Arm|cobalt chromium balloon expandable stent
62328991|NCT02334332|ACTIVE_COMPARATOR|Cohort I (standard care)|Participants receive standard post-operative care.
62328992|NCT02334332|EXPERIMENTAL|Cohort II (educational brochure)|Participants receive a 2-page educational brochure after surgery and prior to discharge home.
62328993|NCT02819648|EXPERIMENTAL|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France); administered 30 minutes before endodontic treatment
62328994|NCT02819648|PLACEBO_COMPARATOR|Control|Milk tablet administered 30 minutes before endodontic treatment
62328995|NCT01701583|EXPERIMENTAL|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
62328996|NCT02631135|PLACEBO_COMPARATOR|Group 1 (TIVA)|Only propofol (started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1) and rocuronium for intubation
62328997|NCT02631135|ACTIVE_COMPARATOR|Group 2 (TIVA+D)|Propofol started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1),and also dexmedetomidine infusion (started as 0.5 μg.kg-1 without making the loading dose and the dose change was not made during the operation) and rocuronium for intubation
62328998|NCT04653909|EXPERIMENTAL|Case|A patient who was diagnosed with the calfan syndrome
62328999|NCT00943293|EXPERIMENTAL|Vaccine|
62329000|NCT06692478|EXPERIMENTAL|Exercise|This structured exercise program will incorporate a specially designed, low intensity, resistance based exercise regime created by our physical therapist. In addition to standard of care, it consists of strengthening, endurance, stretching and relaxation exercises tailored according to age and their ability to perform activities throughout their hospitalization. This exercise program will be done three times a week for 30-45 mins supervised by the same physiotherapist throughout hospitalization and will be self-administered every weekend. A home exercise program printout with the appropriate resistance exercises will be provided to the family upon discharge, with instructions on how often to complete throughout the week. Discharged children will attend one supervised exercise session per week with the physiotherapist for six weeks. The family and patient will also be provided a weekly sheet to check off the days they completed strengthening and endurance exercises.
62693397|NCT01208766|ACTIVE_COMPARATOR|R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)|All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
61935078|NCT02831374|PLACEBO_COMPARATOR|surgical extraction (Group B)|Local anesthesia, surgical extraction of impacted third molar, Suturing, Postoperative medication
62134623|NCT04514718|ACTIVE_COMPARATOR|low energy holmium laser|30 watts
62134624|NCT04514718|ACTIVE_COMPARATOR|high energy holmium laser|80-100 watts
62134625|NCT01920191|EXPERIMENTAL|IMA 950 and Poly ICLC|
62134626|NCT02828618|ACTIVE_COMPARATOR|Arm I PDS and chemotherapy|PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
62134627|NCT02828618|EXPERIMENTAL|Arm II Timing of surgery after 3 cycles of SOC CTX|3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
62134628|NCT01310348|PLACEBO_COMPARATOR|Very low magnitude vibration|Very low magnitude vibration
62134629|NCT01310348|EXPERIMENTAL|Training|The whole-body vibration (WBV) training
62134630|NCT03838978|EXPERIMENTAL|Calypso Knee System|Calypso Knee System
62134631|NCT00692809||1|HIV+ve+LTBI (n=100)
62134632|NCT00692809||2|HIV+ve+clinical TB (n=50)
62134633|NCT00692809||3|HIV-ve+clinical TB (n=15)
62134634|NCT00692809||4|Normal control (n=15)
62134635|NCT02930200|ACTIVE_COMPARATOR|Treatment as Usual|Behavioral: Treatment as Usual (TAU) is the Tobacco Treatment Research Program (TTRP) which offers all components of an intensive tobacco treatment intervention including: 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians, 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation.
62134636|NCT02930200|ACTIVE_COMPARATOR|NCI QuitGuide|Behavioral: The National Cancer Institute's (NCI's) QuitGuide app is a free smartphone app that is available through the Smokefree.gov website. Participants can track cravings, smoking triggers, and motivations for quitting. Participants who are randomly assigned to the QuitGuide app group will receive a smartphone that is preloaded with the QuitGuide app and a quit date scheduled for 1 week after the baseline visit.
62134637|NCT02930200|EXPERIMENTAL|Smart-T|"Behavioral: The Smart-Treatment (Smart-T) phone based smoking cessation intervention has multiple components (e.g., an on-demand Quit Tips function, an on-demand Medications function/button that offers information about nicotine replacement therapy (NRT), button available 24/7 that offers general smoking cessation advice, daily treatment messages, and an algorithm that uses participant's EMA responses to assess risk of lapse and automatically push relevant messages to help them avoid smoking)."
62486869|NCT05302128|EXPERIMENTAL|Cold vapor group|Cold vapor will be applied to the experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtime-un600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
62329001|NCT06692478|NO_INTERVENTION|Standard of Care|The second arm of the study involves patients following standard of care during the HSCT period in the hospital with PT evaluation and management prescribed as needed by their transplant medical team including any additional PT interventions as a result of clinical indications. No additional intervention is incorporated in this group
62486870|NCT05302128|NO_INTERVENTION|Control group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of nausea and vomiting when they come to the recovery room and at the 2nd, 6th,12th, and 24th hours after the surgery in the postoperative service.
62486871|NCT06627634|EXPERIMENTAL|Treatment arm|Patients with oligometastatic spread form gastric og GEJ-cancer are offered standart curative treatment along with metastatectomia in the liver.
62486872|NCT00728351|EXPERIMENTAL|vildagliptin + metformin|
62486873|NCT00728351|ACTIVE_COMPARATOR|metformin|
62486874|NCT02827682|EXPERIMENTAL|study group|Using Angel-6000D Multiparameter Anesthesia Monitor to maintain the Hemodynamic stability during surgery. Keep IoC1 40 to 60 while IoC2 30-50.Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when IoC1\<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when IoC2\>50 but was decreased by 1 ng/ml per adjustment when IoC2\<30, with the maintenance value between 30 and 50.
62486875|NCT02827682|PLACEBO_COMPARATOR|control group|Using BIS VISTA Monitor to maintain the Hemodynamic stability during surgery. Keep BIS 40 to 60.The doses of propofol and remifentanil were adjusted by the anesthetists according to BIS. Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when BIS\<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when BIS\>60 but was decreased by 1 ng/ml per adjustment when BIS\<40, with the maintenance value between 40 and 60.
62486876|NCT03227939|EXPERIMENTAL|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
61935079|NCT01931332|ACTIVE_COMPARATOR|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) was performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hertz (Hz) with pulse width 0.1ms. Once a quadriceps muscle twitch was identified at a stimulated current between 0.2 and 0.5milliamperes (mA), 20mls of 0.375% levobupivacaine (75mg) was injected in fractionated amounts after negative aspiration
61935080|NCT01931332|ACTIVE_COMPARATOR|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
62486877|NCT03227939|ACTIVE_COMPARATOR|LSG Group|LSG only
62486878|NCT01670890|ACTIVE_COMPARATOR|TMZ group|patients were treated with TMZ alone
62486879|NCT01670890|EXPERIMENTAL|TMZ plus CDDP group|patients were treated with TMZ plus CDDP
62486880|NCT03098901|OTHER|no other arm|
61935081|NCT06680336|OTHER|Post-stroke Delirium|Assessment of cognitive functioning using a multi-component neuropsychological assessment and tasked-based functional MRI (introducing a modified working memory task) at three time points S1, S2, S3.
61935082|NCT06680336|OTHER|Non-post-stroke Delirium|Assessment of cognitive functioning using a multi-component neuropsychological assessment and tasked-based functional MRI (introducing a modified working memory task) at three time points S1, S2, S3.
61935083|NCT03894046|EXPERIMENTAL|Part A - Group 1|"Part A was the pivotal, assessor-blind, randomized, comparative portion of the study in patients with documented ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), ventilated pneumonia (VP), or bacteremia.~Part A - Group 1 (experimental): 1.0 g sulbactam/1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h"
61935084|NCT03894046|ACTIVE_COMPARATOR|Part A - Group 2|Part A - Group 2 (control group): 2.5 mg/kg colistin IV infused over 30 minutes every 12 hours (after an initial loading dose of colistin 2.5 to 5 mg/kg) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h.
62134638|NCT06463249|EXPERIMENTAL|Intensive Helpline|Participants receive 2 scheduled coaching calls/month and individualized coach-scripted feedback via emails twice/month for 6 months.
62134639|NCT06463249|ACTIVE_COMPARATOR|Enhanced Helpline|Participants receive 1 participant-initiated call/month. Additionally, the participants receive individualized coach-scripted feedback via emails twice/month for 6 months
62486881|NCT02988258|EXPERIMENTAL|Cohort 1 - 10^4 transduced cells/kg|The first 3 patients will receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10\^4 T cells/kg recipient weight
62486882|NCT02988258|EXPERIMENTAL|Cohort 2 - 10^5 transduced cells/kg|If no cases grade III-IV GVHD in Cohort 1 the remaining patients (N=7) each receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10\^5 T cells/kg recipient weight
62486883|NCT02988258|EXPERIMENTAL|Cohort 1a - 10^3 transduced cells/kg|If 1 case grade III-IV GVHD in Cohort 1, next three patients to be treated with a single infusion of bulk CMV-TCR transduced donor-derived T cells of 1 x 10\^3 T cells/kg recipient weight
62486884|NCT01373515|EXPERIMENTAL|Cohort 1; 1x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
62486885|NCT01373515|EXPERIMENTAL|Cohort 2; 2.5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
62697573|NCT02489279|EXPERIMENTAL|Active - SAC|Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
62693398|NCT01208766|EXPERIMENTAL|R1: 1 (2) cycle(s) HDM|All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
61935085|NCT03894046|EXPERIMENTAL|Part B - Group 3|"Part B (Group 3) was the open-label, supportive portion of the study that included patients known to have HABP, VABP, VP, and/or bacteremia infections associated with ABC organisms resistant to colistin or polymyxin B, who failed a colistin or polymyxin B regimen prior to study entry or were on acute renal replacement therapy, and patients with infections due to colistin- or polymyxin B-resistant ABC with sources of infection other than HABP, VABP, VP, and/or bacteremia.~Part B - Group 3: 1.0 g ETX2514/1.0 g sulbactam IV infused over 3 hours q6h plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h."
61935086|NCT01050127|EXPERIMENTAL|Low dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
61935087|NCT01050127|EXPERIMENTAL|Mid Dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
61935088|NCT01050127|EXPERIMENTAL|High Dose ABT-436|ABT-436 or placebo administered once daily for 14 days.
61935089|NCT00975637|EXPERIMENTAL|140 mg SC|140 mg SC
61935090|NCT00975637|EXPERIMENTAL|70 mg SC|70 mg SC
61935091|NCT00975637|EXPERIMENTAL|280 mg SC|280 mg SC
61935092|NCT00975637|PLACEBO_COMPARATOR|210 mg SC|210 mg SC
61935093|NCT00975637|EXPERIMENTAL|Placebo|Placebo
61935094|NCT03711201|ACTIVE_COMPARATOR|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
61935095|NCT03711201|NO_INTERVENTION|Group NoIORE|The patient's hemodynamic data will be measured in the evening service before surgery. The patient will be brought to the operating room by the anesthesiologist on the day of surgery and hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured in the preop unit. The hemodynamic data and the ST-STAI scale will measure the anxiety level in the operating room.
61935096|NCT02556203|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.
61935097|NCT02556203|ACTIVE_COMPARATOR|Antiplatelet|Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.
61935098|NCT04234451|ACTIVE_COMPARATOR|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
61935099|NCT04234451|SHAM_COMPARATOR|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
61935100|NCT03779958||Study Group|All patients will be given information about a mobile app to use during the recovery period to assist with hand therapy activities
62134640|NCT06463249|OTHER|Extended Helpline|Participants who achieved 2% weight loss at 2-month, will continue to Extended Helpline, where the participants can continue receiving 1-on-1 coaching through 1 participant-initiated calls per month for 6 months.
62134641|NCT06463249|OTHER|CORE Helpline|All participants will receive the CORE Helpline program for 2 months
62329002|NCT05474508|EXPERIMENTAL|Diaphragmatic breathing along with aerobic exercises|Experimental Group (Group A) will receive both aerobic exercises and diaphragmatic breathing exercise. Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks. Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks
62329003|NCT05474508|ACTIVE_COMPARATOR|Diaphragmatic breathing only without aerobic exercises|Active comparator (Group B) will receive only diaphragmatic breathing exercises. Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
62329004|NCT05785117|EXPERIMENTAL|Vagus nerve stimulation group|Vagus nerve stimulation group
61935101|NCT06253104||Study Cohort|All enrolled participants with no randomization group allocations
61935102|NCT05318339|EXPERIMENTAL|Trastuzumab + Pyrotinib|"Patients receive a loading dose of trastuzumab IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes every three weeks.~Meanwhile, patients also receive pyrotinib 400mg PO daily. Treatment may continue till unacceptable toxicity or disease progression occurs."
61935103|NCT06557317|EXPERIMENTAL|Intervention Adolescent/Caregiver Dyads|Adolescent/Caregiver dyads receive 12-week in-person lifestyle program consisting of a Wellness session, Dance Classes, and an at-home Cooking Experience.
62134642|NCT06274879|ACTIVE_COMPARATOR|Control arm|Standard of care consisting of chemotherapy + durvalumab + endoscopic stenting
62693399|NCT01208766|NO_INTERVENTION|R2: none|No consolidation, patients will continue to Lenalidomide maintenance.
62693400|NCT01208766|EXPERIMENTAL|R2: 2 cycles of VRD|In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
62693401|NCT03502200|EXPERIMENTAL|E-cigarette|5% nicotine JUUL e-cigarette (Tobacco or Menthol flavor). Will also receive counseling.
62134643|NCT06274879|EXPERIMENTAL|Biliary radiofrequency ablation|Standard of care consisting of chemotherapy + durvalumab + endoscopic stenting plus intraductal radiofrequency ablation (bRFA)
62134644|NCT06294223|EXPERIMENTAL|Measurement of Upper Extremity Muscle Oxygenation|Measuring muscle oxygenation with fatigue protocol.
62134645|NCT05835934|EXPERIMENTAL|Arms|2 μg/0.212 μCi/kg \[14C\]HSK21542
62693402|NCT03502200|ACTIVE_COMPARATOR|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard assessments. Will also receive counseling.
62486886|NCT01373515|EXPERIMENTAL|Cohort 3; 5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
62486887|NCT01373515|EXPERIMENTAL|Cohort 4; 5x10E7 DCP-001|n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001. Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
62486888|NCT05521360|EXPERIMENTAL|Experimental|Participants randomized to the experimental group will complete baseline assessments, the 6 week AMT treatment online and then complete the follow up assessment (8 weeks total)
62486889|NCT05521360|NO_INTERVENTION|Control|Participants randomized to the control group will be matched to the experimental group on demographic and outcome measures. Control participants will take the baseline assessments, will wait 7 weeks and take the follow-up assessment (8 weeks total). Control group participants are able to enrol in the AMT intervention at the end of their wait-list control period.
62486890|NCT06058845|ACTIVE_COMPARATOR|10% Tamarindus indica fruit pulp juice|Participants will follow a daily consumption of 600ml of Tamarindus indica fruit juice containing 10% Tamarindus indica fruit pulp for 30 days
62486891|NCT06058845|EXPERIMENTAL|30% Tamarindus indica fruit pulp juice|Participants will follow a daily consumption of 600ml of Tamarindus indica fruit juice containing 30% Tamarindus indica fruit pulp for 30 days
62486892|NCT02916862|EXPERIMENTAL|Soluble Corn Fiber (SCF) + Calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
62486893|NCT02916862|ACTIVE_COMPARATOR|Soluble Corn Fiber (SCF) without calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
62486894|NCT02916862|PLACEBO_COMPARATOR|Placebo|This group will receive a similar supplement without SCF or calcium, administered twice a day
62486895|NCT02916862|PLACEBO_COMPARATOR|Placebo + calcium|This group will receive a similar supplement without SCF + 600 mg/d of elemental calcium carbonate, administered twice a day
62486896|NCT05744492|EXPERIMENTAL|Supervised Vivifrail (S-ViF)|A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Once-per-week, subjects assigned to this group will attend the primary care center to execute one of the three exercise sessions per week under the supervision of the physical therapist.
62486897|NCT05744492|EXPERIMENTAL|Non-supervised Vivifrail Group (NS-ViF)|A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Subjects assigned to this group will follow a domiciliary-based program and they will not attend the primary care center to execute the exercises.
62486898|NCT05744492|NO_INTERVENTION|Control group (UCG)|Subjects will receive usual care following prevention protocols of Primary Care Services in Madrid. Concisely, the benefits of physical activity are individually explained and subjects are advised to walk as much as possible with the aim of reaching at least 30 minutes a day, 5 days a week, following the recommendations of the World Health Organization. No structured exercise-based interventions are programmed in this group.
62486899|NCT05448235|EXPERIMENTAL|conventional treatment|the patient will receive conventional treatment daily for up to one week
62486900|NCT05448235|EXPERIMENTAL|thoracic cage mobilization|the patient will receive thoracic cage mobilization added to conventional treatment daily for up to one week
62486901|NCT04658225|ACTIVE_COMPARATOR|Solution 1|0.12% chlorhexidine
62486902|NCT04658225|PLACEBO_COMPARATOR|Solution 2|Saline solution
62486903|NCT06449690|EXPERIMENTAL|Dog-assisted therapy|"Patients in the dog-assisted therapy arm will participate in two group sessions (groups of 3 to 7 participants) of canine-assisted therapy, supervised by a healthcare professional certified in animal-assisted therapy alongside a psychiatric caregiver, for 30 minutes each week over 6 weeks."
62486904|NCT06449690|ACTIVE_COMPARATOR|Occupational activities|"Patients in the occupational activities arm will participate in two group sessions (groups of 3 to 7 participants) of occupational activities, supervised by a healthcare professional experienced in group occupational activities alongside a psychiatric caregiver, for 30 minutes each week over 6 weeks."
62486905|NCT06382896||Patients undergoing ambulatory arthroscopic knee surgery|
62486906|NCT02282124|EXPERIMENTAL|Intervention|"The intensity of the intervention follows a defined algorithm during the first eight months after renal transplantation. Behaviours are classified in three groups:~* Group 1: Patients with optimal behaviour in all three behaviours.~* Group 2: Patients with slight deviation (defined) from optimal behaviour in one or more behaviours.~* Group 3: Patients with larger deviation (defined) from optimal behaviour in one or more behaviours.~All patients (group 1-3) will receive an assessment, education and a monthly reassessment.~Patients from group 2 und 3 will receive additionally behavioral education and peer involvement. Patients from group 3 will receive additionally a consilium of specialized healthcare professionals such as a nutritionist, physiotherapist, or psychologist."
62486907|NCT02282124|OTHER|Control|
62486908|NCT03911635|EXPERIMENTAL|Hypospadias in children|Distal shaft hypospadias at age of 12 years or less
61935104|NCT05850312|EXPERIMENTAL|Round 1|Initially the aim is to recruit 5 clinicians to play the existing MoM game in a controlled environment. The goal is to congregate their collective feedback about the existing game as well as additional features that needs to be implemented to comprise Exposure Therapy to treat OCD with cleanliness. In addition, a feasibility analysis will be conducted to the proposed gameplay described in section 3.1.1. With these assessments, implementation process will be initiated.
62134646|NCT01943994|EXPERIMENTAL|Psilocybin-assisted treatment|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a high dose of psilocybin (30mg / 70kg) to be administered on the Target Quit Date in week 5.
62329005|NCT05785117|EXPERIMENTAL|Circuit weight training group Group|Circuit weight training group Group
62486909|NCT05542056||Patients with newly prescribed thiazide or thiazide-like diuretic|As the study population of this observational study shall be as representative as possible all patients with a new thiazide or thiazide-like diuretic regardless of the indication, co-morbidities and co-medication can be included.
62486910|NCT05597631|NO_INTERVENTION|Control|Control
62486911|NCT05597631|EXPERIMENTAL|G-IVF PLUS|G-IVF PLUS
62486912|NCT03520972|EXPERIMENTAL|PB-119 75ug|PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
62486913|NCT03520972|EXPERIMENTAL|PB-119 150ug|PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
62486914|NCT03520972|EXPERIMENTAL|PB-119 200ug|PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
62486915|NCT03520972|PLACEBO_COMPARATOR|placebo|placebo injection subcutaneously injected once-weekly for 12 weeks
62329006|NCT03564171|NO_INTERVENTION|Standard of Care|Patients will receive standard treatment without added intervention.
62329007|NCT03564171|EXPERIMENTAL|Intervention|"These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :~exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy."
62329008|NCT00722553|OTHER|Dietary Supplement Vitamin B12 & Folic Acid (Vitamin B9)|"Vitamin B12 : 1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.~Folic Acid: 1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
62329009|NCT02338076|EXPERIMENTAL|Interventional arm|petrolatum application under occlusion
62329010|NCT00293774||Standard|Standard hip replacement subjects (polyethylene)
62329011|NCT00293774||Alternative Bearing|Subjects with ceramic on ceramic total hip replacement or metal on metal hip resurfacing.
62329012|NCT03555903||Endometriosis cohort|The aim of the study is to advance the scientific knowledge of deep infiltrating endometriosis (DIE) and to evaluate the impact of surgery on the quality of life and the fertility of affected women.
62329013|NCT05092971|EXPERIMENTAL|Anxiety patient|Participants with anxiety completed computer tasks. They were given different choices and had to make choice(s). The objective was to find the optimal choice by sampling through the choices. They received an unpleasant or pleasant stimulus based on their choice(s). They repeated these tasks many times.
62329014|NCT05092971|EXPERIMENTAL|Healthy volunteer|Healthy volunteers completed computer tasks. They were given different choices and had to make choice(s). The objective was to find the optimal choice by sampling through the choices. They received an unpleasant or pleasant stimulus based on their choice(s). They repeated these tasks many times.
62329015|NCT01785433|EXPERIMENTAL|Treatment ABCD|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day"
62329016|NCT01785433|EXPERIMENTAL|Treatment BDAC|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day"
62329017|NCT01785433|EXPERIMENTAL|Treatment CADB|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day"
62329018|NCT01785433|EXPERIMENTAL|Treatment DCBA|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day"
62486916|NCT06433258|EXPERIMENTAL|Enhanced TSSC curriculum|
62486917|NCT06433258|ACTIVE_COMPARATOR|Original TSSC curriculum|
62486918|NCT01669460|EXPERIMENTAL|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days
62486919|NCT01888276|OTHER|healthy volunteers|evaluation of word generation and of motivation
62486920|NCT01888276|OTHER|compulsive gamblers|evaluation of word generation and of motivation
62486921|NCT03914664||Tourette Syndrome|Adults (\>18 years of age) with diagnosis of Tourette syndrome
62486922|NCT03914664||Healthy Control|Adults who are generally healthy with no known neurologic or psychiatric diagnoses
62486923|NCT04980105|EXPERIMENTAL|Platelet-rich plasma arm|
62486924|NCT04980105|ACTIVE_COMPARATOR|Hyaluronic acid arm|
62329019|NCT02512003|EXPERIMENTAL|Fantom Treatment group|
62329020|NCT05589116|EXPERIMENTAL|Intervention group|Participants given immediate access to two-week, online compassionate imagery course.
62329021|NCT05589116|NO_INTERVENTION|Wait-list control group|Participants will not access intervention during 10-week study period (access will be given to online compassionate imagery course after all outcome measures have been completed).
62329022|NCT01102153||Coolgard|invasive cooling
62329023|NCT01102153||ArcticSun|non-invasive (surface) cooling
62486925|NCT04980105|ACTIVE_COMPARATOR|Methylprednisolone acetate arm|
62486926|NCT02187796||Normal Cognition|HIV+ individuals with no detectable neurocognitive impairment
62486927|NCT02187796||ANI (asymptomatic neurocognitive impairment)|"HIV+ individuals where impairment involves at least two cognitive domains, and results in neuropsychological testing performance at least 1 Standard Deviation (SD) below the appropriate mean age/education norm for:~* Information processing speed~* Sensory/motor skills~* Short-term and long-term memory~* Ability to learn new skills and solve problems~* Attention, concentration, and distractibility~* Logical and abstract reasoning functions~* Ability to understand and express language~* Visual-spatial organization Visual-motor coordination~* Planning, synthesizing and organizing abilities"
62486928|NCT02187796||MCD (Mild Cognitive Disorder)|HIV+ individuals with cognitive impairment same as ANI but patient or caregivers report that cognitive deficit interferes with mental acuity, work efficiency, home making or social activity
62693403|NCT04692597|EXPERIMENTAL|Group 1 (LLLT)|"Group 1: Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes affected per hand.~The protocol for each group will involve one minute of LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
62693404|NCT04692597|SHAM_COMPARATOR|Group 2 (LLLT Sham)|"Group 2: Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes affected per hand.~The protocol for each group will involve one minute of sham LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
62693405|NCT04818229|EXPERIMENTAL|Investigational Group 1|Therapeutic and supratherapeutic multiple oral doses of CBP-307.
62693406|NCT04818229|PLACEBO_COMPARATOR|Investigational Group 2A|Moxifloxacin (positive control for method validation) and Placebo oral administration.
62329024|NCT01975272|ACTIVE_COMPARATOR|Ferinject|Once an infusion of Ferinject 1000 mg, 1 day after surgery
62329025|NCT01975272|ACTIVE_COMPARATOR|Ferrous fumarate|2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery
62693407|NCT04818229|PLACEBO_COMPARATOR|Investigational Group 2B|Moxifloxacin (positive control for method validation) and Placebo oral administration.
62693408|NCT05855746|EXPERIMENTAL|Colchicine|Participant receive in addition to standard of care therapy, six months of Colchicine
62134647|NCT01943994|ACTIVE_COMPARATOR|Nicotine Replacement Therapy (NRT)|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a standard 8 to 10-week regimen of NRT to be administered beginning on the Target Quit Date in week 5. NRT for this study will be a transdermal nicotine patch administered according to recommended label usage (For individuals who smoke more than 10 cigarettes per day: 21mg daily weeks 1-6, 14mg daily weeks 7-8, 7mg daily weeks 9-10. For individuals who smoke 10 or less cigarettes per day: 14mg daily for weeks 1-6, 7mg daily for weeks 7-8).
62134648|NCT02339519|ACTIVE_COMPARATOR|group LMA supreme|Patients who received Laryngeal Mask Airway; LMA supreme
62134649|NCT02339519|ACTIVE_COMPARATOR|group LMA classic|Patients who received Laryngeal Mask Airway; LMA classic
62134650|NCT02339519|ACTIVE_COMPARATOR|group Fastrach|Patients who received Laryngeal Mask Airway; LMA fastrach
62134651|NCT03257410|EXPERIMENTAL|Theranova 400|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
62134652|NCT03257410|ACTIVE_COMPARATOR|Elisio-17H|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
62134653|NCT00538759|EXPERIMENTAL|EBRT|External beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
62134654|NCT00538759|SHAM_COMPARATOR|Control|Sham external beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
62134655|NCT02492412|EXPERIMENTAL|HE10|Drug: HE10 1\~2 drops b.i.d at 12 hour interval for 12 weeks
62134656|NCT02492412|ACTIVE_COMPARATOR|Restasis|Drug: Restasis(Cyclosporine 0.05%) 1\~2 drops b.i.d at 12 hour interval for 12 weeks
62134657|NCT05470231|ACTIVE_COMPARATOR|Beetroot juice|The swimmers ingested a shot of Beet-It 70 ml beetroot juice (BJ)) 3 hours before undergoing a 6x100m crawl intermittent maximal speed performance test.
62134658|NCT05470231|PLACEBO_COMPARATOR|Placebo|The swimmers ingested a shot of Beet-It (70 ml placebo (PL)) 3 hours before undergoing a 6x100m crawl intermittent maximal speed performance test.
62134659|NCT05565508|EXPERIMENTAL|new laparoscopic access technique|in which we used our new laparoscopic access
62134660|NCT05565508|EXPERIMENTAL|Hasson's technique|in which we used the well-known Hasson's technique for primary laparoscopic access
62134661|NCT02691169|EXPERIMENTAL|18F-DCFPyL Injection|The subjects will receive the 18F-DCFPyL Injection (less than or equal to 9 mCi (333 MBq)) at visits 2 and 3.
62134662|NCT06120049|EXPERIMENTAL|Healthy controls (part 2)|"25 healthy subjects (5 young 20-40y and 20 between 50-85y) will be enrolled for the head-to-head comparison with \[18F\]-MFBG, \[123I\]-MIBG and \[18F\]-FE-PE2I (Part 2).~In 5 healthy controls, arterial sampling will be carried out for kinetic modelling."
62134663|NCT06120049|EXPERIMENTAL|PD vs MSA cohort (part 3a)|"In total, 40 PD patients will be included. In order to determine relationships with disease progression, two subgroups will be included with disease duration up to 5 years and 5 years or more respectively. In total, 15 MSA-P patients will be enrolled. For both groups, abnormal previous \[18F\]-FE-PE2I or \[123I\]-FP-CIT SPECT scan is required.~Head-to-head comparison with \[18F\]-MFBG, \[123I\]-MIBG and \[18F\]-FE-PE2I (Part 3)."
62134664|NCT06120049|EXPERIMENTAL|AD vs DLB cohort (part 3b)|"In total 15 patients with probable DLB (including biomarker selection through abnormal previous \[18F\]-FE-PE2I or \[123I\]-FP-CIT SPECT scan) and 15 patients with probable AD (including biomarker proven amyloid-beta positivity either by cerebrospinal fluid biomarker analysis or by \[18F\]-NAV4694 imaging as standard of care).~Head-to-head comparison with \[18F\]-MFBG, \[123I\]-MIBG and \[18F\]-FE-PE2I (Part 3)."
62134665|NCT06120049|EXPERIMENTAL|Dosimetry in healthy controls (Part 1)|For dosimetry of \[18F\]-MFBG only, 3 subjects (18-80 y) will be enrolled (Part 1).
62134666|NCT03631290||Patients who were approached to undergo deprescribing|If the patient's nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing.
62134667|NCT03631290||Providers|Nephrologists and Advanced Practice Providers who see patients at a Duke affiliated DaVita hemodialysis (HD) clinic where Duke nephrologists serve as medical directors and rounding physicians
62329026|NCT01975272|PLACEBO_COMPARATOR|Placebo infusion and tablets|Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery
62329027|NCT01987986|EXPERIMENTAL|AA4500 0.06 mg (low dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
62329028|NCT01987986|EXPERIMENTAL|AA4500 0.48 mg (mid-dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
62693409|NCT05855746|PLACEBO_COMPARATOR|Placebo|Participant receive in addition to standard of care therapy, six months of placebo
61935105|NCT05850312|EXPERIMENTAL|Round 2|A second round of data collection will be conducted with a sample size of 10 subjects (5 clinicians and 5 non-clinician adults). In this second round it is intended to recruit both clinicians and non-clinicians as participants of the study. In the first phase of this study, the clinicians will play the game MoMG to carefully review the revised version of the game. In the second phase the non-clinicians will play the game in presence of clinicians with a goal to ensure that this game does not harm and the gameplay is enjoyable to the participants. While recruiting the non clinicians, it will be ensured via screening that none of the the participants have OCD or other germaphobia.
61935106|NCT01869725|EXPERIMENTAL|Diagnostic (gallium Ga 68-edotreotide PET/CT)|Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.
61935107|NCT01012167|ACTIVE_COMPARATOR|1: galantamine/placebo-oxytocin|Subjects randomized to galantamine will receive galantamine and placebo-oxytocin
61935108|NCT01012167|ACTIVE_COMPARATOR|2: oxytocin/placebo-galantamine|Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine
61935109|NCT01012167|PLACEBO_COMPARATOR|3: placebo-galantamine /placebo-oxytocin|Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin
61935110|NCT06212427|OTHER|HMO supplement|
61935111|NCT06671873|EXPERIMENTAL|100 µCi [14C] HMPL-306|After an overnight fasting of at least 10 hours, subjects will receive \[14C\] HMPL-306 containing 250 mg HMPL-306 (approximately 100 μCi radioactivity) 30 minutes after start of breakfast (must be completed within 30 minutes) and ensure that all of the drug is taken within 10 minutes.
61935112|NCT00756015|ACTIVE_COMPARATOR|Early Motion|Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
61935113|NCT00756015|OTHER|Immobilization|Immobilization following rotator cuff repair.
61935114|NCT01675427|EXPERIMENTAL|Chronic hepatitis C patients|
61935115|NCT01262209|EXPERIMENTAL|Low Vision Aids|"All patients will receive:~1. A low vision examination:~   1. Low vision refraction~  2. Distance best corrected visual acuity~  3. Near best corrected visual acuity~  4. Contrast Sensitivity~  5. Quality of life questionnaire~2. Low vision therapy: to teach strategies for more effective use of remaining vision and use of low-vision devices~3. Prescribed low vision devices including binocular telescope (2.1x or 3.5x), monocular telescope, 6x telemicroscopes, microscopes, magnifiers, portable CCTV and absorptive filters."
61935116|NCT02072902||diabetes free|No intervention
61935117|NCT02072902||Diabetes prevalent|The exposure is diabetes morbidity present at study entery
61935118|NCT02072902||Diabetes incidence|The exposure is diabetes incidence during study follow up
61935119|NCT04376879||Step 1: creation of the score|Cohort for the creation of clinical-biological score to predict the risk of intubation in COVID-19
61935120|NCT04376879||Step 2: validation of the score|Cohort for the validation of clinical-biological score to predict the risk of intubation in COVID-19
61935121|NCT02071927|EXPERIMENTAL|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
61935122|NCT02071927|EXPERIMENTAL|CB-Aza|CB-839 administered as oral capsules twice daily (BID) in combination with azacitidine in 28-day cycles until disease progression or unacceptable toxicity
61935123|NCT01222884|ACTIVE_COMPARATOR|Iron isomaltoside 1000|Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
61935124|NCT01222884|ACTIVE_COMPARATOR|Iron sucrose|Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
62329029|NCT01987986|EXPERIMENTAL|AA4500 0.84 mg (high dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
62693410|NCT05988229|EXPERIMENTAL|Discharge equity tools|Participants randomized into this arn will receive the toolkit of linguistically appropriate discharge teaching aids at hospital discharge.
61935125|NCT01291433|EXPERIMENTAL|PENTOCLO|Association pentoxifylline, tocopherol and clodronate
61935126|NCT01291433|PLACEBO_COMPARATOR|Placebo|Triple placebo
61935127|NCT04676854|EXPERIMENTAL|PRIMA Bionic Vision System|
61935128|NCT01135290|OTHER|B|
61935129|NCT01135290|ACTIVE_COMPARATOR|A|
61935130|NCT02761434|ACTIVE_COMPARATOR|Dehydration|Infusion of 3% sodium chloride for osmotic stimulation of vasopressin
61935131|NCT02761434|PLACEBO_COMPARATOR|Euhydration|Infusion of 0.9% sodium chloride that will induce similar expansion of plasma volume without any significant change in osmolality and vasopressin
62329030|NCT01987986|PLACEBO_COMPARATOR|Placebo|"Placebo~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
62329031|NCT05703802||Sepsis|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
62329032|NCT05703802||SIRS|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
61935132|NCT06065423|EXPERIMENTAL|Telerehabilitation Group|patients received exercises and massages through TR three times a week, conducted by a physiotherapist and a clinician. They were encouraged to perform their exercises and wear compression garments on the remaining days. Prior to the program, patients or their relatives received training from physiotherapists regarding exercises and Manual Lymphatic Drainage (MLD). Patients or their relatives were informed about the Zoom program and were instructed to acquire the application online. Two physiotherapists and groups of five patients each were organized based on rehabilitation days and hours, and access to the Zoom link was provided.
62329033|NCT05703802||Adiposity|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
62486929|NCT02187796||HAD (HIV-associated dementia)|"HIV+ individuals where impairment involves at least two cognitive domains and results in neuropsychological testing at least 2 SD below the appropriate mean age/education norm for:~* Information processing speed~* Short-term and long-term memory~* Ability to learn new skills and solve problems~* Attention, concentration, and distractibility~* Logical and abstract reasoning functions~* Ability to understand and express language~* Visual-spatial organization Visual-motor coordination~* Planning, synthesizing and organizing abilities Cognitive impairment significantly interferes with work, home life, social activities or ADL's."
62486930|NCT02187796||Healthy Controls (HIV-)|Our P300 COGNISION apparatus has been used only in subjects over the age of 60, whereas our participants in the HAND study will all be younger than 60. So, we cannot use COGNISION normative data base for comparison. We will add 10 HIV- healthy controls to our planned 40 HIV+ subjects. These HIV- participants will be age- and gender-matched to the HIV- Asymptomatic Neurocognitive Impairment (ANI) patients, and will undergo all the same assessments
62486931|NCT06626789|EXPERIMENTAL|Intervention group|Real-time functional Magnetic Resonance Imaging (fMRI) neurofeedback from the Blood Oxygenation Level Dependent (BOLD) signal of the amygdala
62486932|NCT06626789|EXPERIMENTAL|Control group|Feedback that is less correlated with amygdala BOLD signal
61935133|NCT06065423|ACTIVE_COMPARATOR|Home- Exercise Group|patients were provided with a brochure explaining the massages and exercises they needed to perform. Additionally, they were contacted three times a week by a physiotherapist and a clinician to remind them of the treatments, assess the continuity and accuracy of the treatments, encourage them to perform the treatments correctly and consistently, and promote the wearing of compression garments.
62329034|NCT05703802||Granulomatosis with polyangiitis / microscopic polyangiitis|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
62329035|NCT05703802||Pre-eclampsia|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
62329036|NCT05703802||Healthy controls|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
62329037|NCT03659747|EXPERIMENTAL|Probiotic|"* 6 g sachet containing probiotic powder (1.8 x 10\^12 colony forming units (CFU) Probiotic) in sachet~* One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
62329038|NCT03659747|ACTIVE_COMPARATOR|Lactrase|"* 6 g sachet containing 4500 FCC units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier~* One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
62329039|NCT03659747|PLACEBO_COMPARATOR|Placebo|"* 6 g sachet containing placebo powder (maltodextrin) in sachet~* One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
62329040|NCT03828006|EXPERIMENTAL|Active Group|One tablet per day through oral administration of a dietary supplement containing red rice yeast as the main active ingredient
62329041|NCT03828006|PLACEBO_COMPARATOR|Placebo Group|One tablet per day of placebo.
62329042|NCT06031480|EXPERIMENTAL|anlotinib+TQB2450|
62329043|NCT01984541|EXPERIMENTAL|1|Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
62329044|NCT01053546|EXPERIMENTAL|Arm I (Early exercise group)|Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
62329045|NCT01053546|EXPERIMENTAL|Arm II (Late exercise group)|Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
62329046|NCT01598727|EXPERIMENTAL|Fluobeam(TM) Imaging System (Fluoptics)|Single arm observational pilot study
62329047|NCT00610935|PLACEBO_COMPARATOR|Placebo|Placebo intramuscular injection
62329048|NCT00610935|EXPERIMENTAL|Peramivir|Single intramuscular injection of 300mg peramivir
62329049|NCT04151537|ACTIVE_COMPARATOR|Intervention|The intervention group is provided with a PA tracker that enables self-monitoring of PA and are instructed to obtain a personalized PA goal on a weekly basis.
62486933|NCT06563037||Weightlifters and Judo Athletes|At least 3 years of experience in their respective sports. Athletes without acute injuries that could affect performance tests were included.
62486934|NCT02649335|ACTIVE_COMPARATOR|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study.
62486935|NCT02649335|ACTIVE_COMPARATOR|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy (SMT) .
62486936|NCT05243251|ACTIVE_COMPARATOR|Olanzapine|82 patients will receive olanzapine 5 mg daily at night for 4 weeks
62486937|NCT05243251|PLACEBO_COMPARATOR|Placebo|82 patients will receive placebo for 4 weeks
61935134|NCT04058418||Familial breast cancer risk assessment services in England|All familial breast cancer risk assessment services in England
62329050|NCT04151537|ACTIVE_COMPARATOR|Control|The control group is recommended to follow national PA guidelines, which can be considered as the 'intervention' offered to the public.
62329051|NCT06317272|ACTIVE_COMPARATOR|ABC DIBH|Active Breathing Controlled (ABC) technique for deep breath inspiration hold (DIBH)
62329052|NCT06317272|EXPERIMENTAL|VC DIBH|Voluntary Coached (VC) technique for deep breath inspiration hold (DIBH)
62329053|NCT05676528|EXPERIMENTAL|Intervention|Exercise intervention
61935135|NCT01490164||scoliosis|young adults requiring surgical correction
61935136|NCT00509392|ACTIVE_COMPARATOR|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation \& ClosureFAST catheter
62329054|NCT03184909|EXPERIMENTAL|Tulsi active|
62329055|NCT03184909|PLACEBO_COMPARATOR|Tulsi placebo|
62329056|NCT04137276|EXPERIMENTAL|vitamin C and thiamine|patients who received intravenous vitamin C and thiamine
62486938|NCT04934098|EXPERIMENTAL|Adjustable compression wrap|Daily use of the Adjustable Compression Wrap on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
62329057|NCT04137276|ACTIVE_COMPARATOR|thiamine|patients who received thiamine
62329058|NCT02648035||Subcutaneous Tocilizumab|Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.
62329059|NCT02522962|EXPERIMENTAL|GroupCoreSIT|Before the group training starts, the physiotherapist in charge of the group does a clinical assessment of each participant in order to individualise the training. Each training group will consist of three participants. The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm.
62329060|NCT02522962|ACTIVE_COMPARATOR|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
62329061|NCT02883582|EXPERIMENTAL|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA)with or without ICS)+ hydrogen/ oxygen inhaled
62329062|NCT02883582|EXPERIMENTAL|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
62329063|NCT06554392||Ankylosing Spondylitis patients|Identification of Glutathione Peroxidase 4 in blood.
62329064|NCT06554392||Axial Psoriatic Arthritis Patients|Identification of Glutathione Peroxidase 4 in blood.
62329065|NCT06554392||healthy controls|Identification of Glutathione Peroxidase 4 in blood.
62329066|NCT06340152||Low-risk pregnancy|Pregnant subjects with none of the following: chronic hypertension, pregestational diabetes, renal disease, autoimmune disease, history of preterm preeclampsia in a prior pregnancy
62329067|NCT06340152||High-risk pregnancy|Pregnant subjects with one or more of the following: chronic hypertension, pregestational diabetes, renal disease, autoimmune disease, history of preterm preeclampsia in a prior pregnancy
62329068|NCT02689219|EXPERIMENTAL|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
62329069|NCT02689219|EXPERIMENTAL|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
62329070|NCT03783650|EXPERIMENTAL|Cohort 1|0-6 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist, Registry \& BP measurement 7-12 months: QIC with Subspecialist to improve communication and standardize, 13-18 months: Hub and Spoke co-management QIC with Primary care and Subspecialist 19-24 months: Sustainability of changes
62329071|NCT03783650|ACTIVE_COMPARATOR|Cohort 2|0-6 months: Control condition Usual Care and Registry \& BP measurement, 7-12 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist 13-18 months: QIC with Subspecialist to improve communication and standardize 19-24 months: Hub and Spoke co-management QIC with Primary care and Subspecialist
62329072|NCT01399801|EXPERIMENTAL|hemodynamicaly guided LV lead placement|optimized left ventricular lead placement
62329073|NCT01399801|ACTIVE_COMPARATOR|Standard lead placement|Standard LV lead placement with no measurements to guide LV lead placement
62329074|NCT03879148|ACTIVE_COMPARATOR|Erector spinae plane block (Group I)|The ultrasound (US) guided ESPB was performed under aseptic conditions at the level of T5 vertebrae using the GE Vivid Q® US device. A high frequency 12 MHz linear US probe was covered with a sterile sheath and placed longitudinally 2-3 cm lateral to the T5 transvers process. After visualizing trapezius, rhomboid major, erector spinae muscles superficial to the hyperechoic transverse process shadow respectively, a 22-gauge 50 mm block needle (Braun Stimuplex Ultra 360, Germany) was inserted in a cephalad to caudad direction. Once the needle tip had been placed within the interfacial plane below the erector spinae muscle, 2 mL of saline were injected to confirm the proper injection site, and then a 20 mL dose of 0.25% bupivacaine was injected. Patients received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit
62329075|NCT03879148|NO_INTERVENTION|Control group (Group II)|Patients in control group only received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit.
62329076|NCT02856581|EXPERIMENTAL|Intervention group (varenicline and behavioral intervention)|Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
62329077|NCT02856581|PLACEBO_COMPARATOR|Control group (placebo and behavioral intervention)|Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
62329078|NCT04991506|EXPERIMENTAL|Part 1 ES102 Escalation in combination with JS001|ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.
62329079|NCT04991506|EXPERIMENTAL|Part 2 ES102 Expansion in combination with JS001|Subjects will be treated with ES102 at the RP2D in combination with JS001.
62329080|NCT03400696|EXPERIMENTAL|Randomized- Lower carbohydrate diet|
62486939|NCT04934098|ACTIVE_COMPARATOR|Compression Bandage|Daily use of compression bandage on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
62486940|NCT03911115||Bariatric surgery|Individuals that have undergone a gastric bypass (RYGB) or a sleeve gastrectomy (SG)
62329081|NCT03400696|EXPERIMENTAL|Randomized- Higher fiber diet|
62329082|NCT03400696|EXPERIMENTAL|Randomized- Exercise focused|
62329083|NCT03400696|EXPERIMENTAL|Participant chooses- Lower carbohydrate diet|
62329084|NCT03400696|EXPERIMENTAL|Participant chooses- Higher fiber diet|
62329085|NCT03400696|EXPERIMENTAL|Participant chooses- Exercise focused|
62329086|NCT06177054|OTHER|Rotation of sites|Each participants is first included with no instruction of rotation and then after 2 weeks instructed to avoid areas with hyperechogenicity
61935137|NCT00509392|ACTIVE_COMPARATOR|Endovenous Laser|Treatment invention of venous disease with an Endovenous Laser.
62486941|NCT01975116|EXPERIMENTAL|Treatment: p28|Pts receive azurin-derived cell-penetrating peptide p28 IV over 15 min 3x/week for 4 wks. Tx repeats every 6 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
62486942|NCT03448094|EXPERIMENTAL|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
62486943|NCT03448094|PLACEBO_COMPARATOR|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
62486944|NCT01943045|EXPERIMENTAL|NGM282 Dose 1|NGM Dose 1
62486945|NCT01943045|EXPERIMENTAL|NGM282 Dose 2|NGM Dose 2
62486946|NCT01943045|EXPERIMENTAL|NGM282 Dose 3|NGM Dose 3
62693411|NCT05988229|NO_INTERVENTION|Standard of hospital discharge care|Participants randomized into this arm will receive the standard of care at hospital discharge.
62693412|NCT02446457|EXPERIMENTAL|Cohort I (rituximab, pembrolizumab)|Patients receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 16 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
61935138|NCT04943718|EXPERIMENTAL|personalized vaccine|patients with recurrent malignant gliomas enrolled into this arm will receive the personalized vaccine through sub-cutaneous.
61935139|NCT04950166|EXPERIMENTAL|Fluorescence imaging with pegsitacianine|1 mg/kg of pegsitacianine administered IV 24-72 hours prior to surgery.
62329087|NCT05517525|EXPERIMENTAL|Cohort 1: Brensocatib|Healthy participants with normal hepatic function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with hepatic impairment.
62329088|NCT05517525|EXPERIMENTAL|Cohort 2: Brensocatib|Participants with mild hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
62329089|NCT05517525|EXPERIMENTAL|Cohort 3: Brensocatib|Participants with moderate hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
62329090|NCT05517525|EXPERIMENTAL|Cohort 4: Brensocatib|Participants with severe hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
62329091|NCT02487849|EXPERIMENTAL|HIPEC|If patient is eligible - secondary cytoreductive operation will be followed by HIPEC with 800 mg/m² body surface (KOF) Carboplatin with closed technique.
62329092|NCT01855542|EXPERIMENTAL|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
62329093|NCT01855542|ACTIVE_COMPARATOR|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
62329094|NCT04759638||Rectal Cancer|Rectal Cancer
62329095|NCT04443127|EXPERIMENTAL|Game-Based Rehabilitation|
62329096|NCT04443127|PLACEBO_COMPARATOR|Conventional Rehabilitation|
62329097|NCT02361203|NO_INTERVENTION|No Exercise|
62329098|NCT02361203|EXPERIMENTAL|Exercise Pre|30 minutes of aerobic exercise before exposure therapy
62329099|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (\>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
62329100|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
62329101|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
62329102|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
62486947|NCT01943045|PLACEBO_COMPARATOR|Placebo|Placebo
62486948|NCT01983735|EXPERIMENTAL|TELMINUVO Tab. (80/2.5mg, 80/5mg)|
62486949|NCT01983735|ACTIVE_COMPARATOR|S-Amlodipine 2.5, 5mg|
62486950|NCT01885897|EXPERIMENTAL|Study treatment|Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.
62486951|NCT04778501|EXPERIMENTAL|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
62486952|NCT02719665|EXPERIMENTAL|Phase 1a (OMEGA-SPM-DOSE)|PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.
62486953|NCT02719665|ACTIVE_COMPARATOR|SPM - Phase 1b (OMEGA-SPM-DOSE)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
62486954|NCT02719665|PLACEBO_COMPARATOR|Placebo - Phase 1b (OMEGA-SPM-PLACEBO)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
62486955|NCT02451163|ACTIVE_COMPARATOR|polysaccharides from wheat|12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).
62486956|NCT02451163|PLACEBO_COMPARATOR|control product|12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).
62693413|NCT02446457|EXPERIMENTAL|Cohort II (rituximab, pembrolizumab, lenalidomide)|Patients receive rituximab IV over 4-8 hours on days 1, 8 and 15 of cycle 1, and day 1 of cycle 2. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 2 years, and lenalidomide PO on days 1-14 every 3 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62693414|NCT04585035|EXPERIMENTAL|Dose escalation of D-1553 monotherapy|Phase 1a will evaluate up to 7 sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
62693415|NCT04585035|EXPERIMENTAL|Dose combination of D-1553 with other therapies|Phase 1b will determine the MTD of D-1553 in combination treatment in subjects with advanced or metastatic NSCLC, CRC and other solid tumors. There are multiple groups in Phase 1b for different tumor types and treatment combinations to evaluate safety, MTD and RP2D.
62486957|NCT03671954|EXPERIMENTAL|TKA Intervention Group|The TKA intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy.
62134668|NCT04807790|EXPERIMENTAL|Telerehabilitation based structured home program group|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
62486958|NCT03671954|ACTIVE_COMPARATOR|TKA Control Group|The TKA control group will receive standard physical therapy alone.
62486959|NCT03671954|ACTIVE_COMPARATOR|Healthy Control Group|The Healthy Control Group, aged 49-85 years without any signs of degenerative joint, disease will undergo the preoperative assessments only.
62486960|NCT05049291|EXPERIMENTAL|Intervention|One time receipt and review of an information sheet
62486961|NCT05049291|NO_INTERVENTION|Non-Intervention|Usual care will be delivered per standards of care.
62486962|NCT01073735||Cancer Survivors|Examine the construct validity, short-term stability, internal consistency and item-response performance of a health-related needs assessment self-report instrument for adult childhood cancer survivors.
62134669|NCT04807790|NO_INTERVENTION|Routine physiotherapy and rehabilitation group|Routine physiotherapy and rehabilitation practices, consist of activities organized by physiotherapists as one or two sessions per week according to the functional levels of children with CP. Routine physiotherapy and rehabilitation applications include increasing postural control, gaining motor development steps, strengthening training, balance training, long-term stretching training, manual therapy, hydrotherapy, hippotherapy and neurodevelopmental therapy approaches.
62134670|NCT05869617|ACTIVE_COMPARATOR|Land-based exercise|Traditional active exercise in an land-based setting (i.e., gym) has been shown to be effective in improving chronic pain management.
62134671|NCT05869617|EXPERIMENTAL|Aquatic exercise|Exercise completed in a therapy pool with warm water that is matched to the active comparator.
62329103|NCT02500199|EXPERIMENTAL|Pyrotinib|A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
62329104|NCT01675804|EXPERIMENTAL|Computerized cognitive rehabilitation|-Computer-assisted cognitive rehabilitation (CACR): 20 Ninety-minute sessions of CACR.
62329105|NCT01675804|PLACEBO_COMPARATOR|Placebo CACR [PCACR]|-PCACR group simultaneously received 20 Ninety-minute sessions of Placebo CACR.
62329106|NCT01675804|EXPERIMENTAL|Ritalin|-2 to 3 doses of 10 mg Ritalin tablets per day during two months.
62486963|NCT01079858|EXPERIMENTAL|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
62486964|NCT05001698|EXPERIMENTAL|Anifrolumab|All eligible participants will receive anifrolumab via intravenous (IV) infusion pump.
62486965|NCT00529191|EXPERIMENTAL|Atorvastatin|Two out of every three patients will receive atorvastatin.
62486966|NCT00529191|PLACEBO_COMPARATOR|Placebo|One out of three subjects will receive a placebo.
62486967|NCT02143258|EXPERIMENTAL|Neurointerventional|Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.
61935140|NCT06679790||Comprehensive Behavioral Intervention for Tics (CBIT)|behavior therapy for tics
62329107|NCT05962996||Amines|Sedated and intubated patients requiring a deep venous catheter, unable to communicate their level of pain, and treated with aminergic drugs (no curare) Assessment of pain levels by pupillometry during the placement of the deep venous catheter
62329108|NCT05962996||Curares|Sedated and intubated patients requiring a deep venous catheter, unable to communicate their level of pain, and treated with curares (no aminergic drug) Assessment of pain levels by pupillometry during the placement of the deep venous catheter
62329109|NCT05962996||Sedation alone|Sedated and intubated patients requiring a deep venous catheter, unable to communicate their level of pain, without any aminergic drug nor curare Assessment of pain levels by pupillometry during the placement of the deep venous catheter
62486968|NCT00835146|EXPERIMENTAL|1|
62486969|NCT00835146|ACTIVE_COMPARATOR|2|
62486970|NCT05936645|EXPERIMENTAL|Tourniquet Group|A temporary sub-placental uterine tourniquet will be temporarily applied before fetal extraction.
62486971|NCT05936645|EXPERIMENTAL|Non-Tourniquet Group|No tourniquet will be used in this arm.
62486972|NCT04358237|EXPERIMENTAL|Experimental: lurbinectedin (PM01183) + pembrolizumab|"During the phase I stage, patients will start receiving pembrolizumab at a fixed dose of 200 mg as a 30-min intravenous (IV) infusion followed by lurbinectedin at a starting dose of 2.4 mg/m2 as a 1-h IV infusion on Day 1, both every 3 weeks (Q3W). Lurbinectedin dose will be escalated from the starting dose in successive cohorts of patients, with a pre-established fixed dose increase (in mg/m2) of approximately 30%.~During the phase II stage, patients will receive pembrolizumab at a fixed dose of 200 mg as a 30-min IV infusion followed by lurbinectedin as a 1-h IV infusion on Day 1 Q3W at the redommended dose (RD) determined during the phase I stage. A cycle is defined as an interval of 3 weeks. No dose escalation will be allowed during the phase II stage."
62486973|NCT03372876|EXPERIMENTAL|Protein-carbohydrate (PC) (protein intake after exercise)|ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon. The resistance exercise was performed equally by both groups.
62486974|NCT03372876|PLACEBO_COMPARATOR|Carbohydrate-protein (CP) (protein intake far to exercise)|ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. The resistance exercise was performed equally by both groups.
62693416|NCT04585035|EXPERIMENTAL|Phase 2 of D-1553 monotherapy and combination therapies|The Phase 2 portion is a multi-arm, parallel, open label study to evaluate the efficacy of D- 1553 single agent and combination treatments in subjects with advanced or metastatic solid tumors with KRas G12C mutation. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose.
62697574|NCT02489279|ACTIVE_COMPARATOR|Control - Scrabble|"Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions."
62486975|NCT01566435|EXPERIMENTAL|Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy|"ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)~1. nab-Paclitaxel 100 mg/m\^2 on Days 1, 8, and 15~2. Cisplatin 75 mg/m\^2 on Day 1~3. 5-FU 750 mg/m\^2 on Days 1-3~If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.~Definitive Therapy~1. Cisplatin 100 mg/m\^2 IV on Days 1, 22, and 43~2. Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.~3. If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m\^2 IV week for 8 weeks"
62486976|NCT00873990|ACTIVE_COMPARATOR|1|application of total etch bonding agent ( 5th generation) for placement of resing based pit and fissure sealants.
62486977|NCT00873990|EXPERIMENTAL|2|Self etch bonding agent (7th generation) application for placement of resin based pit and fissure sealant
62693417|NCT06206837|EXPERIMENTAL|vepdegestrant in combination with PF-07220060|vepdegestrant administered orally once daily (QD) continuously and PF-07220060 administered orally twice daily (BID) continuously on 28-day cycles
62134672|NCT03387189||Quality Improvement Project (Pre-Period)|Quality Improvement Project: Pre-Period (7/1/2016 to 12/31/2017) Patients received care at the intervention hospital in the 18 months before providers participated in the department-wide, simulation-based educational training.
62329110|NCT04355091|EXPERIMENTAL|Intervention Group|"The pregnant women in this group will be informed about the application of EFT with a written material.~The pregnant women who have undergone EFT will be interviewed a week or two after the application, and how they feel and whether the problem still disturbs him. If a new issue is reported, similar actions will be repeated for this new issue. The number of EFT sessions was decided based on the condition of the pregnant woman. After all EFT sessions are completed, a re-evaluation (post-test) of Edinburgh Postpartum Depression Scale, Stress Coping Scale and State-Trait Anxiety Inventory will be done.~The same participants will be asked to apply the other inventories and the postpartum interview form if she had birth three months and six months after the last application (follow-up). In the follow-up study performed three months after the last application, EFT will be applied to the pregnant women in need."
62486978|NCT01637480|EXPERIMENTAL|Patellofemoral Pain Syndrome|Participants with Patellofemoral Pain Syndrome
62134673|NCT03387189||No Quality Improvement Project (Pre-Period)|No Quality Improvement Project: Pre-Period (7/1/2016 to 12/31/2017) Patients received care at the comparison hospital where no quality improvement educational training had occurred.
62134674|NCT03387189||Quality Improvement Project (Post-Period)|Quality Improvement Project: Post-Period (1/1/2018 to 6/30/2019) Patients received care at the intervention hospital in the 18 months after providers participated in the department-wide, simulation-based educational training.
62486979|NCT01637480|ACTIVE_COMPARATOR|Healthy control|Age- and gender-matched participants without Patellofemoral Pain Syndrome
61935141|NCT02869438|EXPERIMENTAL|Benralizumab arm|Benralizumab administered subcutaneously
61935142|NCT02869438|PLACEBO_COMPARATOR|Placebo arm|Placebo administered subcutaneously
62134675|NCT03387189||No Quality Improvement Project (Post-Period)|No Quality Improvement Project: Post-Period (1/1/2018 to 6/30/2019) Patients received care at the comparison hospital where no quality improvement educational training had occurred.
62134676|NCT06389890||All patients undergoing pancreatic surgery|All patients with at least one pancreatic surgery procedure code
62134677|NCT06389890||Subgroup: Total pancreatectomy|All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55250', '55251', '55252', '5525x', '5525y'
62134678|NCT06389890||Subgroup: Pancreaticoduodenectomy|All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55241', '55242', '55243'
62134679|NCT06389890||Subgroup: Segmental resection|All patients with at least one of the following pancreatic procedure code (OPS-codes): '55244'
62134680|NCT06389890||Subgroup: Distal pancreatectomy|All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55240', '552400', '552401', '552402'
62134681|NCT06389890||Subgroup: Other partial resections|All patients with at least one of the following pancreatic procedure codes (OPS-codes): '5524x', '5524y'
62486980|NCT06143202||Pediatric patients with hyperglycemia|Any pediatric patient admitted to the hospital and requiring an endocrine consult for frequent glucose monitoring and hyperglycemia management
62486981|NCT06143202||Nursing staff|Nursing staff providing medical care for pediatric patients enrolled in the study.
62693418|NCT02075684|OTHER|In-office, Percutaneous Renal Biopsy|
62693419|NCT04797481|EXPERIMENTAL|Novel Intervention|Novel Intervention Exercise group.
62693420|NCT04797481|ACTIVE_COMPARATOR|Control|Self-managed Exercise group.
62134682|NCT02020694|EXPERIMENTAL|Vitamin D and Diet|"Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.~Hypocaloric diet"
62134683|NCT02020694|PLACEBO_COMPARATOR|Placebo & Diet|"Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.~Hypocaloric diet"
62134684|NCT06373835|EXPERIMENTAL|Emodepside 5 mg|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62134685|NCT06373835|EXPERIMENTAL|Emodepside 10 mg|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62134686|NCT06373835|EXPERIMENTAL|Emodepside 15 mg|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62134687|NCT06373835|EXPERIMENTAL|Emodepside 20 mg|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62134688|NCT06373835|EXPERIMENTAL|Emodepside 25 mg|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62134689|NCT06373835|EXPERIMENTAL|Emodepside 30 mg|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62134690|NCT06373835|PLACEBO_COMPARATOR|Placebo|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62486982|NCT00731939|OTHER|Titan® OTR IPP|Subjects implanted with Titan® One Touch Release (OTR) Inflatable Penile Prosthesis (IPP)
61935143|NCT04732169|ACTIVE_COMPARATOR|Epidiolex (cannabidiol) (CBD)|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
62134691|NCT06373835|ACTIVE_COMPARATOR|Ivermectin 3 mg|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or ivermectin (200 μg/kg) or placebo.
62329111|NCT04355091|NO_INTERVENTION|control group|"The participants in this group will be talked about the problems they should have in routine midwifery care, the problems they encounter during pregnancy or postpartum period and the subjects they want to receive information.~If necessary, suggestions will be made for problems related to pregnancy, postpartum period or newborn care. Again, with these participants, after the depression risk determination (pre-test), after the interviews ended (post-test), three months and six months after the last application, Edinburgh Postpar All Depression Scale, Stressful Life Events List, Stress Coping Scale. If the pregnant woman has given birth, State-Trait Anxiety Inventory and postnatal interview form will be performed."
61935144|NCT04732169|PLACEBO_COMPARATOR|Placebo|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
61935145|NCT02928120||CRC group (exploratory)|"Blood samples from approximately 210 patients diagnosed with colorectal carcinoma collected prospectively and consecutively at the Department of Surgical Gastroenterology, Aalborg University Hospital during the time period 2003-2006 will be used. The blood samples were collected at the time of diagnosis, before and after treatment (surgery and radio-chemo-therapy) and at regular intervals for a time period of two years after treatment. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
61935146|NCT02928120||Control group (exploratory)|"Blood samples (8ml) from patients (n=142) who underwent work-up for lower gastrointestinal malignancy during the time period 2003-2006. Colonoscopy was performed, and no malignancy or premalignant lesions found. Blood samples were collected before/after colonoscopy. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
61935147|NCT02928120||CRC group (validation)|Blood samples from 143 patients were collected prospectively and consecutively for a previous study on the effect of omega 3 fatty acids an postoperative complications after colorectal surgery. All study participants have provided written informed consent (N-VN-20050035).
61935148|NCT02928120||Control group (validation)|There will be recruited approximately 100 control subjects with a positive occult faecal blood but with a normal colonoscopy for blood sampling (28 ml).
62134692|NCT05125874|EXPERIMENTAL|V-01 COVID-19 Vaccine|One dose administrated by intramuscular injection
62134693|NCT04437641||Experimental|A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.
62134694|NCT04826094|EXPERIMENTAL|Group 1: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
62134695|NCT04826094|EXPERIMENTAL|Group 2: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
62329112|NCT01532700|EXPERIMENTAL|Ofatumumab with GSK2110183|
62329113|NCT03901287|EXPERIMENTAL|dual energy CT|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
62329114|NCT06100471||case|Patients with endometriotic adnexal pathology
62329115|NCT06100471||control|Patients with non endometriotic adnexal pathology
62329116|NCT06100471||analytical control|Patients with no gynecological pathology, not undergoing surgery
62329117|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
62329118|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
62329119|NCT05438680|ACTIVE_COMPARATOR|Group I: bovine colostrum group|
62329120|NCT05438680|PLACEBO_COMPARATOR|group II : control group|
62329121|NCT03108014||Breast milk fed|Fed primarily breast fed as an infant
62486983|NCT00408616|EXPERIMENTAL|1|Grazax treatment
62486984|NCT00408616|PLACEBO_COMPARATOR|2|Grazax Placebo
62486985|NCT04518072||Biopsy prostatic group|positive biopsy (100) negative biopsy (100)
62486986|NCT04518072||Control group|No prostate cancer (50)
62486987|NCT00837564|EXPERIMENTAL|CBASP|CBASP psychotherapy
62486988|NCT00837564|EXPERIMENTAL|Escitalopram|Escitalopram pharmacotherapy and clinical management
62486989|NCT01490190|EXPERIMENTAL|NuvaRing|
62486990|NCT04468880|OTHER|Milk A1A2|Group (A1 → A2) receiving control milk A1A2 in period 1 then the milk evaluated A2A2 in period 2
62486991|NCT04468880|OTHER|Milk A2A2|Group (A2 → A1) receiving the milk evaluated A2A2 in period 1 then the control milk A1A2 in period 2
61935149|NCT02928120||IBD group (validation)|In collaboration with The Department of Medical Gastroenterology, Aalborg University Hospital, there will be recruited approximately 120 patients with ulcerous colitis for blood sampling (28 ml).
61935150|NCT03015545|ACTIVE_COMPARATOR|Control|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval, but no vibration will be given.
61935151|NCT03015545|ACTIVE_COMPARATOR|High intensity whole body vibration|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval. The whole body vibration platform will be set with frequency at 30Hz and amplitude at 1.5mm.
61935152|NCT05661357|EXPERIMENTAL|Disitamab Vedotin combined with Fruquintinib|Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has received at least two standard treatment failures
62134696|NCT04826094|EXPERIMENTAL|Group 3: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
62134697|NCT04826094|EXPERIMENTAL|Group 4: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
62134698|NCT04826094|EXPERIMENTAL|Group 5: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
62134699|NCT04826094|EXPERIMENTAL|Group 6: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
62134700|NCT04826094|EXPERIMENTAL|Group 7: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
62134701|NCT01814839|ACTIVE_COMPARATOR|ALN-TTRSC (revusiran)|
62134702|NCT01814839|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62134703|NCT01206972|EXPERIMENTAL|Arm 1|
62134704|NCT01206972|EXPERIMENTAL|Arm 2|
62134705|NCT01206972|EXPERIMENTAL|Arm 3|
62134706|NCT01206972|ACTIVE_COMPARATOR|Arm 4|
62134707|NCT05307835|EXPERIMENTAL|Personalized neoantigen vaccines|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
62329122|NCT03108014||Milk based formula fed|Fed primarily milk based formula as an infant
62329123|NCT03108014||Soy based formula fed|Fed primarily soy based formula as an infant
61935153|NCT01904539|EXPERIMENTAL|Healthy Volunteer|Healthy volunteers receiving a single dose of obeticholic acid 10 mg.
61935154|NCT01904539|EXPERIMENTAL|Mild Hepatic Impairment|Subjects with mild hepatic impairment defined as Child-Pugh class A receiving a single dose of obeticholic acid 10mg.
61935155|NCT01904539|EXPERIMENTAL|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment defined as Child-Pugh class B receiving obeticholic acid 10mg.
61935156|NCT01904539|EXPERIMENTAL|Severe Hepatic Impairment|Subjects with severe hepatic impairment defined as Child-Pugh class C receiving obeticholic acid 10 mg.
61935157|NCT06703697|EXPERIMENTAL|Intervention group: eDrugSafe|Participants will use the eDrugSafe mobile web platform to manage their medication history and access electronic medicinal product information (ePI). QR codes are provided with each prescription to connect users directly to ePI content.
61935158|NCT06703697|NO_INTERVENTION|Control group: Usual care|Participants will use traditional methods, like paper, for managing and accessing medication information. Use of any digital platforms is not permitted in this group.
61935159|NCT04879069||Intermediate-high risk PE|Confirmed PE causing right ventricle dysfunction confirmed by computed tomography pulmonary angiography or transthoracic echocardiography and elevated troponin level
61935160|NCT04879069||High-risk PE|"Confirmed PE causing hemodynamic instability:~1. Cardiac arrest (need for cardiopulmonary resuscitation) or,~2. Obstructive shock (systolic blood pressure \< 90 mmHg or vasopressors required to achieve a systolic blood pressure ≥90 mmHg despite adequate filling status and end-organ hypoperfusion), or~3. Persistent hypotension (systolic blood pressure \< 90 mmHg for at least 15 minutes)"
61935161|NCT00560274|EXPERIMENTAL|1|
61935162|NCT02765685|EXPERIMENTAL|ODRA|
61935163|NCT02765685|ACTIVE_COMPARATOR|usual care|
62134708|NCT05307835|NO_INTERVENTION|control group|observe
61935164|NCT06418750|OTHER|group preventive|
61935165|NCT06418750|OTHER|group curative|
62134709|NCT06614270|EXPERIMENTAL|Participant Group|anti-CD19 CAR-NK cells
62134710|NCT05551286|EXPERIMENTAL|Young Adults Taking Action|The programme is person-centered, goal-oriented, and peer-based and is structured around a 5-day residential stay, an online follow-up after five weeks and a 2-day residential follow-up stay after ten weeks.
62134711|NCT06165146|EXPERIMENTAL|Repaglinide - Period 1|Single dose of repaglinide administered orally.
62134712|NCT06165146|EXPERIMENTAL|Pirtobrutinib - Period 2|Multiple doses of pirtobrutinib administered orally.
62134713|NCT06165146|EXPERIMENTAL|Pirtobrutinib + Repaglinide - Period 2|"Pirtobrutinib administered in combination with repaglinide orally.~There will be a washout period of 11 days between the dose of repaglinide from Period 1 to 2."
62134714|NCT06521619||Patient receiving Sciatic and Femoral nerve blocks|Patient receiving Sciatic and Femoral nerve blocks
62134715|NCT06521619||Patient receiving Adductor canal block and infiltration of posterior capsule of knee|Patient receiving Adductor canal block and infiltration of posterior capsule of knee
62134716|NCT04859296|PLACEBO_COMPARATOR|Placebo|0 mg CBG, 0 mg THC
62134717|NCT04859296|ACTIVE_COMPARATOR|Low strength CBG|5 mg CBG, 0 mg THC
62134718|NCT04859296|ACTIVE_COMPARATOR|High strength CBG|15 mg CBG, 0 mg THC
62134719|NCT04859296|ACTIVE_COMPARATOR|Low strength THC|0 mg CBG, 5 mg THC
62329124|NCT02099916|ACTIVE_COMPARATOR|gonadotropins plus DHEA|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Prior to the stimulation will be treated with DHEA 25 mg PO tid for 12 weeks.
62329125|NCT02099916|ACTIVE_COMPARATOR|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
62329126|NCT04200105|ACTIVE_COMPARATOR|EBUS TBNA|Patients will undergo a standard EBUS examination, with sampling using a standard 22G EBUS needle.
62329127|NCT04200105|EXPERIMENTAL|Acquire TBNB|Patients will undergo a standard EBUS examination, with sampling using an Acquire TBNB needle.
61935166|NCT05635071|EXPERIMENTAL|Nintedanib 100mg|Traditional hormone replacement (HRT) cycle medication (Tegretol 2mg bid for 20 days, followed by Darvon 10mg bid for the last 10 days) + Nintedanib 100mg bid \*15 days orally.
62329128|NCT06093763|ACTIVE_COMPARATOR|Patients with symptomatic malunion of distal radius receiving bone grafting|Open wedge corrective osteotomy and plate fixation with harvesting and using bone from the iliac crest.
62329129|NCT06093763|ACTIVE_COMPARATOR|Patients with symptomatic malunion of distal radius receiving none bone grafts|Open wedge corrective osteotomy and plate fixation without harvesting and using bone from the iliac crest.
62329130|NCT03047993|EXPERIMENTAL|Treatment (glutaminase inhibitor CB-839, azacitidine)|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.
61935167|NCT05635071|EXPERIMENTAL|Nintedanib 150mg|Traditional hormone replacement (HRT) cycle medication (Tegretol 2mg bid for 20 days, followed by Darvon 10mg bid for the last 10 days) + Nintedanib 150mg bid \*15 days orally.
62486992|NCT01949805|ACTIVE_COMPARATOR|Hydroxyurea|Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
62486993|NCT01949805|EXPERIMENTAL|Peg-P-IFN-alpha-2b (AOP2014)|Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
62486994|NCT05232825|ACTIVE_COMPARATOR|Ocrelizumab: Intravenous (IV) formulation|Participants will receive the first dose of ocrelizumab IV as two IV infusions given 14 days apart. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between SC doses. Participants will undergo 96 weeks of study treatment.
61935168|NCT03115073|EXPERIMENTAL|0,2% Candiplus|Candiplus® 0.2%
62486995|NCT05232825|EXPERIMENTAL|Ocrelizumab: Subcutaneous (SC) formulation|Participants will receive the first dose of ocrelizumab SC as one SC injection at a dose which is expected to result in non-inferior exposure to ocrelizumab IV. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between the first and second SC doses, and between subsequent SC doses. Participants will undergo 96 weeks of study treatment.
62486996|NCT03882762|EXPERIMENTAL|Group I - Cebranopadol 200 μg tablet|"Mild Renal Impairment:~PK evaluable non-dialyzed patients with mildly impaired renal function (eGFR = 60-89 mL/min/1.73 m2)"
61935169|NCT03115073|EXPERIMENTAL|0,3% Candiplus|Candiplus® 0.3%
61935170|NCT03115073|EXPERIMENTAL|0,4% Candiplus|Candiplus® 0.4%
61935171|NCT03115073|ACTIVE_COMPARATOR|Clotri mono|Clotrimazole mono
61935172|NCT03242538|EXPERIMENTAL|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
61935173|NCT01304160|EXPERIMENTAL|strereotactic radiotherapy, gemcitabine|stereotactic radiotherapy (30Gray in 5 fractions) followed by gemcitabine
62134720|NCT04859296|ACTIVE_COMPARATOR|High strength THC|0 mg CBG, 30 mg THC
62134721|NCT04859296|ACTIVE_COMPARATOR|Low strength CBG + Low strength THC|5 mg CBG + 5 mg THC
62134722|NCT04859296|ACTIVE_COMPARATOR|Low strength CBG + High strength THC|5 mg CBG + 15 mg THC
62134723|NCT04859296|ACTIVE_COMPARATOR|High strength CBG + Low strength THC|15 mg CBG + 5 mg THC
62134724|NCT04859296|ACTIVE_COMPARATOR|High strength CBG + High strength THC|15 mg CBG + 15 mg THC
62134725|NCT04508010|EXPERIMENTAL|IVR survey|Participants will receive an IVR survey
62134726|NCT04508010|EXPERIMENTAL|CATI survey|Participants will receive a CATI survey
62134727|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
62134728|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
62134729|NCT02438137|ACTIVE_COMPARATOR|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
62134730|NCT02438137|PLACEBO_COMPARATOR|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
62134731|NCT01119313|EXPERIMENTAL|LAS 41002|
62134732|NCT01119313|ACTIVE_COMPARATOR|Active|
62134733|NCT05406765|ACTIVE_COMPARATOR|Spinal|Spinal anesthesia
62134734|NCT05406765|PLACEBO_COMPARATOR|Placebo|Placebo spinal
62134735|NCT04307550|EXPERIMENTAL|Isopropyl Alcohol|10 inhalations of an isopropyl alcohol pad held within 2cm from the nares
62134736|NCT04307550|PLACEBO_COMPARATOR|Sterile Saline|10 inhalations of a sterile saline pad held within 2cm from the nares
62134737|NCT02500758|EXPERIMENTAL|Parachlorometaxylenol|Reducing bacterial load after preoperative surgical scrubbing using 3% PCMX. Both hands have been prepared by preparatory handwash.
62329131|NCT02353637|ACTIVE_COMPARATOR|Male High Protein, Restricted Carbo, Partial Meal Replacement|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
62329132|NCT02353637|ACTIVE_COMPARATOR|Female High Protein, Restricted Carbo, Partial Meal Replaceme|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
62329133|NCT01420705||Low birth-weight cohort|Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area
62329134|NCT00601523|ACTIVE_COMPARATOR|Pramipexole|Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily
62329135|NCT00601523|PLACEBO_COMPARATOR|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
62329136|NCT04511637|EXPERIMENTAL|Test C: 15 mg ODT with water, then 15 mg film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
62486997|NCT03882762|EXPERIMENTAL|Group II - Cebranopadol 200 μg tablet|"Moderate Renal Impairment:~PK evaluable non-dialyzed patients with moderately impaired renal function (eGFR = 30-59 mL/min/1.73 m2)"
62486998|NCT03882762|EXPERIMENTAL|Group III - Cebranopadol 200 μg tablet|"Severe Renal Impairment:~PK evaluable non-dialyzed patients with severely impaired renal function (eGFR = 15-29 mL/min/1.73 m2)"
62486999|NCT03882762|EXPERIMENTAL|Group IV - Cebranopadol 200 μg tablet|"Normal Renal Function:~PK evaluable participants with normal renal function (eGFR greater than or equal to 90 mL/min/1.73 m2)"
62487000|NCT00736827||Patients with non-septic shock|Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
62487001|NCT00736827||Patients with septic shock|Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
62487002|NCT04179058||IPAF patients|IPAF definition according to 2015 ERS/ATS criteria
62487003|NCT04179058||non-IPAF patients|
62487004|NCT05139563|SHAM_COMPARATOR|Placebo injection|This group will first receive 3 mL intramuscular injections of a 20% fat emulsion (Intralipid 20%) every 2 months for 6 months.
62487005|NCT05139563|EXPERIMENTAL|Placebo implant|This group will first receive a single-use subdermal implant in the inner side of the upper arm for a duration of 6 months before removal.
62487006|NCT02849951|EXPERIMENTAL|LT-02|1.6 g PC in LT-02 BID
62487007|NCT02849951|PLACEBO_COMPARATOR|LT-02 Placebo|0 g PC in LT-02 Placebo BID
62487008|NCT03462342|EXPERIMENTAL|A. Olaparib Pill + AZD6738.|"Cohort A: Recurrent platinum-sensitive ovarian cancer (progression greater than 6 months from last receipt of platinum-based chemotherapy), approximately 37 patients could be treated with an interim analysis after 17 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
62487009|NCT03462342|EXPERIMENTAL|B. Olaparib Pill + AZD6738.|"Cohort B: Recurrent platinum-resistant ovarian cancer (progression less than or equal to 6 months of the last receipt), approximately 37 patients could be treated with an interim analysis after 12 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
61935174|NCT04574323|EXPERIMENTAL|Paleolithic lifestyle group|The Paleolithic lifestyle (PL) intervention during radiotherapy consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed. Patients were supposed to start the PL intervention at least two days prior to the first irradiation and to protocol their food consumption on two days during the first week on the diet. They were also asked about their compliance to the PL intervention at each weekly measurement appointment.
62329137|NCT04511637|EXPERIMENTAL|Test C: 15 mg film-coated tablet, then 15 mg ODT with water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
62329138|NCT04511637|EXPERIMENTAL|Test D: 15 mg ODT without water, then 15 film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
62329139|NCT04511637|EXPERIMENTAL|Test D: 15 mg film-coated tablet, then 15 mg ODT without water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
62329140|NCT04072146|EXPERIMENTAL|Varenicline oral tablet 1mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|OC-01 0.12 mg was administered intranasally 50 ul into each nostril in a fasted state
62487010|NCT03462342|EXPERIMENTAL|C. Olaparib Pill + AZD6738.|"Cohort C: PARP inhibitor (PARPi) resistant (subjects who have progressed on a PARPi), patients must be platinum-sensitive, and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 subjects could be treated.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
61935175|NCT04574323|OTHER|Standard diet group|This group is on a standard diet while receiving radiotherapy.
61935176|NCT05771792|EXPERIMENTAL|eccentric exercise group|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP The modified exercise group will perform 6 exercises
62329141|NCT04072146|ACTIVE_COMPARATOR|OC-01 (varenicline solution) nasal spray 0.12 mg, then Varenicline oral tablet 1 mg|Varenicline oral tablet 1mg was administered orally in a fasted stated with 200 ml water
62329142|NCT02782663|EXPERIMENTAL|Upadacitinib (ABT-494) Dose A|Open label dose A once daily (QD)
62697575|NCT01702298|EXPERIMENTAL|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin \>=1000 mg per day.
62697576|NCT05845749|OTHER|Vosoritide|This is a single arm open label study of daily SQ dose of vosoritide
62697577|NCT01462747|EXPERIMENTAL|KULIST|Medical Device, Activated carbon
62693421|NCT05249660|EXPERIMENTAL|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
62487011|NCT03462342|EXPERIMENTAL|D-1. Olaparib Pill + AZD6738.|"Cohort D Part I: Patients will be platinum sensitive/platinum resistant ovarian cancer. Patient may or may not have received prior PARPi and will be enrolled irrespective of their BRCA status. The number of subjects treated will depend on the number of dose levels explored with a minimum of 12 subjects up to 30 subjects.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
62487012|NCT03462342|EXPERIMENTAL|D-2 Olaparib Pill + AZD6738.|"Cohort D Part II: Patients with ovarian cancer who are PARP inhibitor (PARPi) resistant (patients who have progressed on a PARPi). Patients must be platinum-sensitive and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 patients will be treated.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
62487013|NCT05920447||ETT|"the patients in group T were intubated with Endotracheal tube (ETT) (flexicare) size 7 for female and 8 for male~The patients were ventilated with a volume-controlled mode at a Tidal Volume (TV) 7ml/kg, Respiratory Rate 12 /min, I: E 1:2. The patient was then positioned in the lithotomy position.~Ventilatory parameters including expired TV, peak airway pressure, inspired- expired TV and the end-tidal carbon dioxide were all monitored and recorded every 5 min.~In case of leaking from the LMA that interfere with the ventilation before the patients were being positioned in the lithotomy position, the patients were excluded and replaced by another.~The incidence of aspiration as revealed clinically( witnessed vomiting followed by decreased oxygen saturation, increased airway pressure, tachycardia, etc..) and confirmed radiologically, Failure of insertion or intubation, sore throat and air leak were reported as a complications."
62693422|NCT05249660|ACTIVE_COMPARATOR|Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
62693423|NCT01653314|EXPERIMENTAL|Megavec|
62693424|NCT01653314|ACTIVE_COMPARATOR|Glivec|
62693425|NCT05335057|ACTIVE_COMPARATOR|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62693426|NCT05335057|ACTIVE_COMPARATOR|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62693427|NCT05335057|ACTIVE_COMPARATOR|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62329143|NCT02782663|EXPERIMENTAL|Upadacitinib (ABT-494) Dose B|Open label dose B QD
62329144|NCT05553431|EXPERIMENTAL|No EP system Group|Patients were performed left bundle branch pacing without EP system.
62693428|NCT05335057|EXPERIMENTAL|Time 4|Participant will be randomly assigned to the remainingintervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
62693429|NCT06549335|EXPERIMENTAL|Experimental: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)|
62693430|NCT01160718|ACTIVE_COMPARATOR|Arm A: Fulvestrant / AZD6244|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid
62693431|NCT01160718|PLACEBO_COMPARATOR|Arm B: Fulvestrant / Placebo|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)
62329145|NCT00367640|EXPERIMENTAL|100 IR|100 IR grass pollen allergen extract tablet
62329146|NCT00367640|EXPERIMENTAL|300 IR|300 IR grass pollen allergen extract tablet
62329147|NCT00367640|EXPERIMENTAL|500 IR|500 IR grass pollen allergen extract tablet
62329148|NCT00367640|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62329149|NCT00738504||1|
62329150|NCT00738504||2|
62329151|NCT00738504||Group 1|Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
62329152|NCT00738504||Group 2|Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
61935177|NCT05771792|ACTIVE_COMPARATOR|control group|CONVENTIONAL EXERCISES PROGRAM GROUP The conventional exercises program will perform conventional exercises.
62329153|NCT06683209|ACTIVE_COMPARATOR|Group A|One eye examined with the Schocket scleral depressor, the other eye with the Josephberg-Besser scleral depressor
62329154|NCT06683209|ACTIVE_COMPARATOR|Group B|One eye examined with the Schocket scleral depressor, the other eye with the cotton tip applicator
62329155|NCT06683209|ACTIVE_COMPARATOR|Group C|One eye examined with the cotton tip applicator, the other eye with the Josephberg-Besser scleral depressor
61935178|NCT02193698|EXPERIMENTAL|Lenalidomide+Dexamethasone|Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
61935179|NCT04945876|NO_INTERVENTION|Control group|"Participants is encouraged to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. No further follow up except for testing at 12 weeks and six months.~After the completion of the study the control group will be offered a session of individual exercise and diet guidance as well as a period of digital follow-up as needed."
62693432|NCT05015049||Neonatal population - hypertensive disorder of pregnancy|All babies born to a woman with a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
62693433|NCT05015049||Neonatal population - no hypertensive disorder of pregnancy|All babies born to a woman without a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
62693434|NCT04023058|NO_INTERVENTION|CABG/increasing MR|non-massive IMR with increasing IMR during exercise - CABG only
62693435|NCT04023058|EXPERIMENTAL|CABG+mitral surgery (MS)/increasing MR|non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
62693436|NCT04023058|NO_INTERVENTION|CABG/non-increasing MR|non-massive IMR non-increasing IMR during exercise - CABG only
62329156|NCT04559152|EXPERIMENTAL|Zinc Supplementation Group|Zinc capsule (20mg) was taken in the morning after meals once daily for 12 weeks. All subjects in this arm were also given iron and folic acid tablets in accordance with the Indonesian government program.
62329157|NCT04559152|PLACEBO_COMPARATOR|Placebo Group|Placebo (sugar tablet) was taken in the morning after meals once daily for 12 weeks. All subjects were also given iron and folic acid tablets in accordance with the Indonesian government program. Each placebo tablet was inserted into a capsule of the same shape and color with zinc capsule
62329158|NCT00875017|EXPERIMENTAL|Meal + Lanthanum|
62329159|NCT00875017|ACTIVE_COMPARATOR|Meal + Sevelamer|
62329160|NCT00875017|NO_INTERVENTION|Meal Only|
62329161|NCT00875017|NO_INTERVENTION|Fasting|
62329162|NCT03229759|EXPERIMENTAL|Investigational Product|Polyester cloth impregnated with investigational product
62329163|NCT03229759|PLACEBO_COMPARATOR|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
62329164|NCT03229759|PLACEBO_COMPARATOR|Saline Control (SC)|Saline applied wtih polyester cloth
62329165|NCT02100748|EXPERIMENTAL|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
62329166|NCT02100748|EXPERIMENTAL|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
62329167|NCT02100748|EXPERIMENTAL|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
62329168|NCT02100748|EXPERIMENTAL|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
62329169|NCT02100748|ACTIVE_COMPARATOR|Morphine|Morphine 4 mg IV Q4H x 48 h
62329170|NCT02100748|PLACEBO_COMPARATOR|Placebo|Placebo (D5W) IV Q4H x 48 h
62693437|NCT04023058|EXPERIMENTAL|CABG+MS/non-increasing MR|non-massive IMR non-increasing IMR - CABG+ mitral surgery
62693438|NCT04023058|OTHER|Control 1|massive IMR at rest without increasing during exercise - CABG+ mitral surgery
62693439|NCT04023058|OTHER|Control 2|massive IMR at rest with increasing during exercise - CABG+ mitral surgery
62693440|NCT02825563|EXPERIMENTAL|Anlotinib(In the fasting state)|In the fasting state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
62487014|NCT05920447||LMA|"The patients in group L were intubated with an I gel Laryngeal mask airway (LMA) , the size was selected based on the body weight according to the manufacturer's instructions,~The patients were then ventilated with a volume-controlled mode of ventilation at a Tidal Volume (TV) 7ml/kg, Respiratory Rate 12 /min, I: E 1:2. The patient was then positioned in the lithotomy position and secured~Ventilatory parameters including expired TV, peak airway pressure, TV inspired- TV expired and the end-tidal CO2 were all monitored and recorded every 5 min.~In case of leaking from the LMA that interfere with the ventilation before the patients were being positioned in the lithotomy position.~The incidence of aspiration as revealed clinically( witnessed vomiting followed by decreased oxygen saturation, increased airway pressure, tachycardia, etc..) and confirmed radiologically, Failure of insertion or intubation, sore throat and air leak were reported as a complications."
62487015|NCT01046084|EXPERIMENTAL|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
62487016|NCT01046084|ACTIVE_COMPARATOR|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
62487017|NCT04494607|EXPERIMENTAL|Test arm|Determination of Glycemic and Insulinemic curves under different alimentary intake
62487018|NCT04299087|EXPERIMENTAL|Dystonia and/or tremor|Adults with a diagnosis of dystonia and/or tremor
62487019|NCT04299087|EXPERIMENTAL|Control|Healthy adults without a history of any neurological disorder, with a similar age distribution and sex ratio as the dystonia and/or tremor group
62487020|NCT03575351|ACTIVE_COMPARATOR|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
62487021|NCT03575351|EXPERIMENTAL|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
62487022|NCT05860777|NO_INTERVENTION|Control|This is the control group who receive standard of care
62487023|NCT05860777|EXPERIMENTAL|Intervention|This is the group in units who are identified via AI model and in which interpreter services are actively reaching out to clinicians
62487024|NCT04842435|EXPERIMENTAL|Stage 1. Group 1|Group 1 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 1 mL/kg in addition to standard therapy
62487025|NCT04842435|EXPERIMENTAL|Stage 1. Group 2|Group 2 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 2 mL/kg in addition to standard therapy
62487026|NCT04842435|EXPERIMENTAL|Stage 1. Group 3|Group 3 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 4 mL/kg in addition to standard therapy
62329171|NCT01032512|EXPERIMENTAL|IMMUNE-ENHANCING|"40 patients will be instructed to consume 600 ml of the special immune-enhancing formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density)."
62329172|NCT01032512|SHAM_COMPARATOR|CONTROL|40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.
62134738|NCT02500758|ACTIVE_COMPARATOR|Clorhexidine digluconate|Reducing bacterial load after preoperative surgical scrubbing using 4% CHG. Both hands have been prepared by preparatory handwash.
62134739|NCT05297136|EXPERIMENTAL|Pre-op Stenting|Pre-operative pancreatic stent inserted by Endoscopic Retrograde Cholangiography, followed by distal pancreatectomy
62329173|NCT04032496|EXPERIMENTAL|Mindfulness Intervention|Participants in this arm will participate in the Contemplative-Based Intervention for People Living with SLE intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
62329174|NCT04032496|ACTIVE_COMPARATOR|HEP Intervention|Participants in this arm will participate in the Health Enhancement Program (HEP) intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
62329175|NCT01425190|EXPERIMENTAL|Cohort 1: Children 17 to ≥13 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
62693441|NCT02825563|EXPERIMENTAL|Anlotinib(In the high fat diet state)|In the high fat diet state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
62693442|NCT05638217||Patients of 4 to 12 years old eligible to received dental cavity treatment|"Patients of 4 to 12 years old that are eligible to received dental cavity treatment. The goal of this observational study is to identify the efficacy of silver diamine fluoride 38% followed by sodium fluoride varnish 5%, using CaviGuard® as delivery method, in a population with untreated dental caries age range 4 to 12 years old."
62134740|NCT05297136|ACTIVE_COMPARATOR|Surgery alone|Distal pancreatectomy alone
62134741|NCT01520259||cases|Women from the cohort with gallbladder cancer
62134742|NCT01520259||cohort|Women from Chile screened for gallbladder cancer with and without gallstones
62329176|NCT01425190|EXPERIMENTAL|Cohort 2: Children <13 to ≥7 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
62487027|NCT04842435|PLACEBO_COMPARATOR|Stage 1. Group 4|Group 4 - 39 subjects who will receive a single intravenous infusion of placebo at a dose of 1 mL/kg in addition to standard therapy
62487028|NCT04842435|ACTIVE_COMPARATOR|Stage 2. Group 1|Group 1 - 110 subjects who will receive a single intravenous infusion of COVID-globulin at a dose defined at Stage 1 in addition to standard therapy
62693443|NCT00467493|EXPERIMENTAL|Anastrozole - A|Treatment for 26 consecutive days
62693444|NCT00467493|EXPERIMENTAL|Anastrozole -B|Treatment for 7 consecutive days early in menstrual cycle
62693445|NCT00467493|EXPERIMENTAL|Anastrozoe - C|Treatment for 7 consecutive days mid follicular phase
62693446|NCT00467493|EXPERIMENTAL|Anastrozole - D|Treatment for 7 consecutive days - mid cycle
62693447|NCT00467493|EXPERIMENTAL|Anastrozole - E|Treatment for 7 consecutive days - luteal
62693448|NCT00467493|PLACEBO_COMPARATOR|Anastrozole - F|Treatment with placebo for 26 consecutive days
62329177|NCT01425190|EXPERIMENTAL|Cohort 3: Children <7 to ≥3 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
62693449|NCT06555081|EXPERIMENTAL|Period 1: Dose Treatment A|Ruxolitinib IR will be administered at protocol defined dose.
62693450|NCT06555081|EXPERIMENTAL|Period 1: Dose Treatment B|Ruxolitinib XR will be administered at protocol defined dose.
62693451|NCT06555081|EXPERIMENTAL|Period 2: Dose Treatment A|Ruxolitinib IR will be administered at protocol defined dose.
61935180|NCT04945876|EXPERIMENTAL|Intervention group|Participants will receive a session of individual exercise and diet guidance with focus on goals and motivation for diet and exercise and help to overcome any barriers for self-efficacy. They will also receive an activity tracker and an introduction on how to use it. Further they will receive a monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise. The participants can also send sms if they have questions during the follow-up period. They will be encouraged to continue to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. If needed they can get help to find suitable exercise groups in their own municipality. The Garmin wristband will be used to facilitate daily activity and continuing exercise at recommended intensity level at home. Participants who are malnourished, or at risk of malnutrition, will receive specific guidance session on nutrition.
62329178|NCT02276157|EXPERIMENTAL|MB group|Direct POC performed with third-generation prototype multibending ultra-slim endoscope (CHF-Y0010; Olympus Medical Systems, Co., Ltd., Tokyo, Japan)
62329179|NCT02276157|ACTIVE_COMPARATOR|Conventional group|Direct POC performed with conventional ultra-slim endoscope (GIF-XP290N; Olympus Medical Systems, Co., Ltd., Tokyo, Japan)
62329180|NCT02318914|EXPERIMENTAL|gevokizumab|Solution for subcutaneous injection
62329181|NCT04009096|EXPERIMENTAL|Group 1|3 volunteers receiving 5 x 10\^10 vp ChAd63 PvDBP and 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later.
62329182|NCT04009096|EXPERIMENTAL|Group 2|Up to 10 volunteers receiving one dose of 5 x 10\^10 vp ChAd63 PvDBP, 12-18 months later receiving a second dose of 5 x 10\^10 vp ChAd63 PvDBP and 8 weeks later 2 x 10\^8 pfu MVA PvDBP, followed by blood-stage CHMI 2-4 weeks later.
62329183|NCT04009096|EXPERIMENTAL|Group 3|"If fewer than 6 volunteers complete the study in Group 2, then new volunteers will be recruited into Group 3, to make up a total of 6 volunteers between Groups 2 and 3 who complete all vaccinations and CHMI.~Volunteers in Group 3 will receive 5 x 10\^10 vp ChAd63 PvDBP and 2 x10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later."
62329184|NCT01840020||Gastric bypass|patients recruited from Central Norway
62329185|NCT01840020||Gastric sleeve|patients recruited from Central Norway
62329186|NCT00932139|EXPERIMENTAL|Electro-acupuncture control|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the Electro-acupuncture control treatment."
62329187|NCT00932139|EXPERIMENTAL|Electro-acupuncture test|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the active Electro-acupuncture treatment."
62329188|NCT04709991||Procedures with EndoNaut|
61935181|NCT05416151|OTHER|Arm 1, Test: freeze-dried B. lactis|
61935182|NCT05416151|OTHER|Arm 2, Control: freeze-dried maltodextrin|
62329189|NCT04709991||Procedures without Endonaut|
62329190|NCT03285217|EXPERIMENTAL|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
62329191|NCT03285217|ACTIVE_COMPARATOR|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
62329192|NCT04082364|EXPERIMENTAL|Chemotherapy-free arm|margetuximab plus retifanlimab
62329193|NCT04082364|EXPERIMENTAL|Margetuximab, retifanlimab, and chemotherapy arm|"margetuximab plus retifanlimab plus investigator choice of chemotherapy options.~Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)"
61935183|NCT01021579|ACTIVE_COMPARATOR|Metformin plus Simvastatin|PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)
62329194|NCT04082364|EXPERIMENTAL|Margetuximab, tebotelimab and chemotherapy arm|margetuximab plus tebotelimab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
62329195|NCT04082364|EXPERIMENTAL|Margetuximab and chemotherapy arm|margetuximab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
62329196|NCT04082364|ACTIVE_COMPARATOR|Trastuzumab and chemotherapy arm|Trastuzumab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
62329197|NCT05913427|EXPERIMENTAL|EDP-M plus MEGESTROL ACETATE 160 mg|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Concomitant mitotane therapy will be administered continuously. Megestrole 160 mg 2 tablets will be administered once daily (in the morning) and will be stopped 21 days after the last administration of the EDP.
62693452|NCT06555081|EXPERIMENTAL|Period 2: Dose Treatment B|Ruxolitinib XR will be administered at protocol defined dose.
62693453|NCT03242031|EXPERIMENTAL|1 session|
62693454|NCT03242031|ACTIVE_COMPARATOR|4 sessions|
62693455|NCT04016610|EXPERIMENTAL|ASR Treatment|Single and/or multi-treatment ASR device applied to the keloid scar for a period of 2 minutes for each 3 cm.
62693456|NCT04709393|EXPERIMENTAL|Pre-screening|Receiving FRAX+SARC-F questionnaire pre-screening results on estimated fracture risk
62487029|NCT04842435|PLACEBO_COMPARATOR|Stage 2. Group 2|Group 2 - 110 subjects who will receive a single intravenous infusion of placebo at a dose equal to the COVID-globulin dose in addition to standard therapy
62487030|NCT02216981|EXPERIMENTAL|Intensive Cognitive Behavioural Therapy|Intensive CBT (an average of 12-18 hours of CBT offered in an intensive format, delivered on 2-3 days per week over a period of 3 weeks)
62487031|NCT02216981|ACTIVE_COMPARATOR|Weekly Cognitive Behavioural Therapy|Weekly CBT (an average of 12-18 hours of CBT delivered in 60-90 minute sessions on a weekly basis)
62487032|NCT02216981|NO_INTERVENTION|Wait list|Wait list (3 months). Participants randomized to wait list will commence treatment after 3 months, in the treatment condition to which they are re-randomized (either Intensive or Weekly CBT).
62693457|NCT04709393|NO_INTERVENTION|Control|Not receiving FRAX+SARC-F questionnaire pre-screening preliminary results on estimated fracture risk
62693458|NCT06640283|OTHER|Active laboratory monitoring|Phase I Monitoring through collection of laboratory tests
62329198|NCT05913427|PLACEBO_COMPARATOR|EDP-M plus PLACEBO|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Concomitant mitotane therapy will be administered continuously. Placebo 2 tablets will be administered once daily (in the morning) and will be stopped 21 days after the last administration of the EDP.
62329199|NCT03736746|EXPERIMENTAL|Motivational Interviewing|"* Will entail two-to-four Motivational Interviewing sessions per participant~* Will include a battery of questionnaires~* Investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs).~* The investigator will elicit questions and goals that participants will be encouraged to discuss with their palliative care providers"
62693459|NCT06640283|EXPERIMENTAL|Intervention with Immunotherapy|"Phase II for participants who are ctDNA positive after standard treatment.~Intervention will be with Pembrolizumab"
62693460|NCT05500521||Patients with severe-to-profound hearing loss|Patients with severe-to-profound hearing loss will undergo investigation with caloric irrigation, video head impulse test and vestibular evoked myogenic potential. Patients will complete the Dizziness Handicap Inventory-questionnaire.
62693461|NCT05500521||Controls|Controls will undergo investigation with caloric irrigation, video head impuls test and vestibular evoked myogenic potential. Controls will complete the Dizziness Handicap Inventory-questionnaire.
62693462|NCT02781558|EXPERIMENTAL|SOF/VEL|SOF/VEL FDC for 12 weeks
61935184|NCT01021579|PLACEBO_COMPARATOR|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
62329200|NCT03648476|EXPERIMENTAL|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
62329201|NCT03648476|OTHER|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
62329202|NCT04397393||non-camel milk consumption|non-camel milk consumption over life time
62487033|NCT03007524|EXPERIMENTAL|High dose rosuvastatin|20mg/d quaque nocte(qN), at least 6 months
62487034|NCT03007524|ACTIVE_COMPARATOR|Low dose rosuvastatin|10mg/d quaque nocte（qN）, at least 6 months
62487035|NCT04854460|EXPERIMENTAL|T test|Test drug (Revemact) 1 tablet contains 6 mg Ivermectin
62329203|NCT04397393||camel milk consumption|camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).
62693463|NCT02781558|EXPERIMENTAL|SOF/VEL + RBV|SOF/VEL FDC + RBV for 12 weeks
62693464|NCT05552573|EXPERIMENTAL|Low-dose vaccine(18-59 years)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
62487036|NCT04854460|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
62487037|NCT04854460|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
62487038|NCT03862573|EXPERIMENTAL|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during the dental procedure
62487039|NCT03862573|NO_INTERVENTION|Control (Standard of Care)|Participants are distracted with Standard-of-Care by dentists and/or parents.
62693465|NCT05552573|EXPERIMENTAL|Low-dose vaccine(60 years old and above)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
61935185|NCT06680245|EXPERIMENTAL|Mitomycin-C Treatment|The intervention aims to assess the efficacy of Mitomycin-C in preventing postoperative hypertensive phases by inhibiting fibroblast proliferation around the surgical site. Patients in this arm will receive a 0.2 mg/mL Mitomycin-C injection into the sclera during Ahmed Glaucoma Valve implantation surgery. The total volume of the injection will be 1 mL, administered once intraoperatively.
62693466|NCT05552573|EXPERIMENTAL|High-dose vaccine(18-59 years)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
62693467|NCT05552573|EXPERIMENTAL|High-dose vaccine(60 years old and above)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
62693468|NCT04627103|EXPERIMENTAL|Device Placement|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion. Following the diversion creation, a sleeve gastrectomy will also be performed.
62693469|NCT04478890||Observational Group|Characterize right ventricular function while undergoing LVAD implantation
62693470|NCT05832541||Test group (peri-implantitis)|peri-implant tissue specimen will be taken after identification of diseased interproximal implant sites. Following local anesthesia specimen will be taken either by supracrestal incision to remove all diseased soft tissue surrounding the implant or by making 2 parallel incisions, 4 mm apart, with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of implant. The biopsies, including the entire supracrestal soft tissue portion of the diseased site, will be carefully retrieved and prepared for histopathological and immunohistochemical analysis
61935186|NCT06680245|NO_INTERVENTION|Control|Patients in this arm will undergo the Ahmed Glaucoma Valve implantation surgery without the addition of Mitomycin-C. This group serves as a control to evaluate the effects of the Ahmed Valve alone in managing intraocular pressure in patients with refractory glaucoma. Postoperative care remains consistent with the experimental group, involving the same regimen of topical antibiotics and steroids.
62134743|NCT01520259||controls|Women from the cohort with gallstones
62134744|NCT05562089|EXPERIMENTAL|Prevail|
62329204|NCT01295112|SHAM_COMPARATOR|Group 1|Active bevacizumab (Avastin®) and Sham Ozurdex®
62329205|NCT01295112|ACTIVE_COMPARATOR|Group 2|Active bevacizumab (Avastin®) and Active Ozurdex®
61935187|NCT00614328|ACTIVE_COMPARATOR|1|Naltrexone (50 mg once a day) + placebo baclofen + behavioral therapy (n=10)
62134745|NCT01773746|ACTIVE_COMPARATOR|Room Air|Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
62134746|NCT01773746|ACTIVE_COMPARATOR|60% Group|Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
62134747|NCT05216770|OTHER|Spatial and temporal CNS pathophysiology of laryngeal dystonia and voice tremor|Simultaneous fMRI with EEG and MEG imaging will be used to examine neural dynamics during phonation.
62134748|NCT05216770|ACTIVE_COMPARATOR|Sensorimotor modulations of laryngeal dystonia and voice tremor with bupivacaine|Topical laryngeal block (1 ml of 0.75% bupivacaine solution) will be used to modulate somatosensory feedback from the laryngeal mucosa during speech production and examine associated changes in brain activity.
62134749|NCT05216770|OTHER|Motor learning and CNS pathophysiology of laryngeal dystonia and voice tremor|"Implicit learning of the production of motor sequences will be examined during simultaneous fMRI/EEG and MEG imaging.~Sensorimotor adaptation of speech production during MEG imaging will be examined during perturbing pitch or formants of auditory feedback consistently during speech production and examining the behavioral and neural correlates of the resulting across-trial adaptation responses."
62134750|NCT05216770|PLACEBO_COMPARATOR|Placebo effects in laryngeal dystonia and voice tremor|1 ml of saline placebo matching to 1 ml of 0.75% bupivacaine solution will be used for a comparison with the topical laryngeal block to modulate somatosensory feedback from the laryngeal mucosa during speech production and examine associated changes in brain activity.
62134751|NCT05216770|OTHER|Auditory feedback processing in laryngeal dystonia and voice tremor|The role of auditory feedback processing on task-induced speech sensorimotor activity will be examined using MEG imaging during perturbing pitch or formants of auditory feedback, unpredictably during speech production, and examining the behavioral and neural correlates of the resulting within-trial compensation responses.
62134752|NCT02641912|EXPERIMENTAL|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
62134753|NCT02641912|OTHER|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
62134754|NCT04541303|EXPERIMENTAL|Intervention|Topical application of tranexamic acid to granulating wound defect status post Mohs micrographic surgery.
62134755|NCT04541303|PLACEBO_COMPARATOR|Placebo|Topical application of normal saline to granulating wound defect status post Mohs micrographic surgery.
62134756|NCT04900467|ACTIVE_COMPARATOR|Pfizer-Pfizer|Pfizer-Pfizer Length of use : 1 day
62134757|NCT04900467|EXPERIMENTAL|Pfizer-Moderna|Pfizer-Moderna Length of use : 1 day
62134758|NCT04900467|ACTIVE_COMPARATOR|Moderna- Moderna|Moderna- Moderna Length of use : 1 day
62134759|NCT04900467|EXPERIMENTAL|Moderna - Pfizer|Moderna - Pfizer Length of use : 1 day
62329206|NCT00444886|ACTIVE_COMPARATOR|1|To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
62329207|NCT00444886|ACTIVE_COMPARATOR|2|To assess the effect of BOTOX injection on numbness and tingling and quality of life.
61935188|NCT00614328|ACTIVE_COMPARATOR|2|Placebo naltrexone + baclofen (10 mg t.i.d) + behavior therapy (n=10)
61935189|NCT00614328|ACTIVE_COMPARATOR|3|Baclofen (10 mg t.i.d) + naltrexone (50 mg once per day) + behavior therapy (n=10)
61935190|NCT00614328|PLACEBO_COMPARATOR|4|Placebo baclofen + placebo naltrexone + behavior therapy
61935191|NCT05245253||Trauma patients|Trauma patients 20-60 years of age
61935192|NCT02484287|ACTIVE_COMPARATOR|Integra External Drainage Catheter|The Integra External Drainage Catheter non antibiotic-impregnated EVD catheter
61935193|NCT02484287|ACTIVE_COMPARATOR|Ventriclear EVD Antibiotic Catheter|The Ventriclear EVD Antibiotic Catheter antibiotic-impregnated EVD catheter
61935194|NCT02484287|ACTIVE_COMPARATOR|Codman Bactiseal EVD Catheter Set|The Codman Bactiseal EVD Catheter Set antibiotic-impregnated EVD catheter
62134760|NCT06454682|EXPERIMENTAL|RJK002 Intrathecal injection|
62134761|NCT06699654|PLACEBO_COMPARATOR|Group I (control group)|Participants in this arm will receive oral hygiene instruction and full mouth SRP of all teeth plus placebo gel instillation in the pocket.
62134762|NCT06699654|ACTIVE_COMPARATOR|Group II (experimental I)|Participants in this arm will receive oral hygiene instruction and full mouth SRP of all teeth followed by insertion of the spirulina gel instillation in the deepest selected periodontal pocket after drying the area around it.
62134763|NCT06699654|EXPERIMENTAL|Group III (experimental II)|Participants in this arm will receive oral hygiene instruction and full mouth SRP of all teeth followed by insertion of the spirulina nanogel instillation in the deepest selected periodontal pocket after drying the area around it.
62134764|NCT01432106|ACTIVE_COMPARATOR|Aliskiren/Valsartan (Valturna)|Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
62134765|NCT01432106|ACTIVE_COMPARATOR|Ramipril|Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
62134766|NCT00733811|EXPERIMENTAL|1|Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
62134767|NCT00733811|ACTIVE_COMPARATOR|2|Deferiprone alone at 75 mg/kg divided into three oral daily doses
62134768|NCT01205048|EXPERIMENTAL|Emervel Classic Lidocaine|NLFs (Nasolabial Folds) were injected with Emervel Classic Lidocaine (20 mg/mL with 0.3% lidocaine).
62134769|NCT01205048|ACTIVE_COMPARATOR|Juvederm® Ultra|NLFs were injected with Juvéderm Ultra (24 mg/mL).
62134770|NCT04119063|EXPERIMENTAL|Gait Training with Exoskeleton Assistance|Gait training with ankle exoskeleton assistance. All participants received high frequency gait training followed by a washout period then low frequency gait training.
62134771|NCT00455650|ACTIVE_COMPARATOR|Schizophrenia, Mecamylamine|
62134772|NCT00455650|ACTIVE_COMPARATOR|Schizophrenia, Varenicline|
62134773|NCT00455650|PLACEBO_COMPARATOR|Schizophrenia, Placebo|
62134774|NCT00455650|ACTIVE_COMPARATOR|Control, Mecamylamine|
62134775|NCT00455650|ACTIVE_COMPARATOR|Control, Varenicline|
62134776|NCT00455650|PLACEBO_COMPARATOR|Control, placebo|
62134777|NCT06355063|EXPERIMENTAL|CellFX nsPFA Treatment Arm|Adult subjects who are clinically indicated for a concomitant cardiac surgical procedure will undergo left pulmonary vein, roof and floor ablations to form a left atrial posterior box using the CellFX® nsPFA™ Cardiac Surgery System.
62134778|NCT04225507|OTHER|Lifestyle Intervention|Diet and exercise.
62134779|NCT04225507|EXPERIMENTAL|Lifestyle Plus CPAP Intervention|CPAP treatment, diet and exercise.
62134780|NCT04564443|EXPERIMENTAL|(Medaxis Debritom+™) micro fluid jet wound therapy|Medaxis Debritom+™ is a high-quality, micro fluid jet therapy device designed to remove fibrin, necrotic tissue, and biofilm from wound surfaces by mechanical cleaning and stimulation of the diabetic foot wound
62134781|NCT04564443|ACTIVE_COMPARATOR|Sharp Surgical Debridement|Use of a surgical scalpel or curette to remove fibrin, necrotic tissue and biofilm from wound surfaces by mechanically cleaning the wound
62134782|NCT00804648|ACTIVE_COMPARATOR|hemihydrate/maleate/maleate gel|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
62134783|NCT00804648|ACTIVE_COMPARATOR|maleate/maleate gel/hemihydrate|Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
62134784|NCT00804648|ACTIVE_COMPARATOR|maleate gel/hemihydrate/maleate|Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
62134785|NCT00804648|ACTIVE_COMPARATOR|hemihydrate/maleate gel/maleate|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
62134786|NCT00804648|ACTIVE_COMPARATOR|maleate/hemihydrate/maleate gel|Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
62134787|NCT00804648|ACTIVE_COMPARATOR|maleate gel, maleate, hemihydrate|Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
62134788|NCT01036724||Carto 3|Those subjects whose cases use the CARTO 3 EP Navigation System.
62134789|NCT01036724||NAVX|Those subjects whose cases use the NAVX(TM) EP Navigational System.
61935195|NCT02637336|EXPERIMENTAL|Acupuncture|acupuncture session were inserted, and maintained for 20 minutes in paragraph 6 of the channel the pericardium (Neiguan).
61935196|NCT02637336|EXPERIMENTAL|Aerobic Exercise|The aerobic exercise session was conducted through 20 minutes.
62134790|NCT03954275||Critically ill patients with a CrCl24h|Patients admitted to any intensive care unit (surgical, medical or cardiac) and having at least one 24h creatinine clearance measurement available.
62329208|NCT04322630||Pediatric Cardiac Bypass Patients|Blood samples obtained from patients ages from birth-19 years-old as well as cyanotic and acyanotic cardiac lesions who underwent cardiac bypass.
62329209|NCT05270538|ACTIVE_COMPARATOR|comparison of clinical and gasometric parameters between the study group and the control group|"To carry out the study, we defined a control group and a study group distributing them between the two groups. The control group will perform the exercise, without using a mask, while the study group will perform the exercise using Masks Zero Mask Sewing Virus Bac-Off Lupo® for the duration of the exercise.~The exercise consisted of 15 minutes of treadmill without inclination interspersing every 2 minutes at speeds 10 Km/h and 12 Km/h, being by definition of a dynamic aerobic exercise of intensity 4 of 5 in the Borg scale- classification of the intensity of physical exercise. Physical activity was performed in water deprivation and fasting at least 30 minutes before the start of activated."
62329210|NCT06381648||Intrahepatic Cholangiocarcinoma, With Lymph node metastasis (Training)|Patients with ICC who had lymph node metastases at the time of primary tumor treatment with D2 dissection, in the first cohort.
62329211|NCT06381648||Intrahepatic Cholangiocarcinoma, Without Lymph node metastasis (Training)|Patients with ICC who did not have lymph node metastases at the time of primary tumor treatment with D2 dissection, in the first cohort.
62329212|NCT06381648||Intrahepatic Cholangiocarcinoma, With Lymph node metastasis (Validation)|Patients with ICC who had lymph node metastases at the time of primary tumor treatment with D2 dissection, in the second cohort.
62329213|NCT06381648||Intrahepatic Cholangiocarcinoma, Without Lymph node metastasis (Validation)|Patients with ICC who did not have lymph node metastases at the time of primary tumor treatment with D2 dissection, in the second cohort.
62329214|NCT01397071|ACTIVE_COMPARATOR|Ground Beef Patty with Avocado|Test burgers with fresh avocado added just prior to consumption
62329215|NCT01397071|ACTIVE_COMPARATOR|Ground Beef Patty without Avocado|Test burgers
62329216|NCT00559052|NO_INTERVENTION|1|Baseline measurement. No drug with the liquid meal during perfusion procedure to establish baseline secretion.
62329217|NCT00559052|EXPERIMENTAL|2|The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.
62329218|NCT00532883|PLACEBO_COMPARATOR|Placebo Pills and Placebo Liquid|
62329219|NCT00532883|ACTIVE_COMPARATOR|Hydroxyurea Pills and Placebo Liquid|
62329220|NCT00532883|ACTIVE_COMPARATOR|Placebo Pills and Magnesium Pidolate Liquid|
62329221|NCT00532883|ACTIVE_COMPARATOR|Hydroxyurea Pills and Magnesium Pidolate Liquid|
62329222|NCT04398017|ACTIVE_COMPARATOR|Standard support|
62329223|NCT04398017|EXPERIMENTAL|Hypnosis|
62487040|NCT06555939|EXPERIMENTAL|CoCM+PRISM|Collaborative Care Model (CoCM) includes a care manager, a defined population of patents/registry for tracking inclusion and progress, validated patient-reported outcome measures, and weekly inter-professional team meetings. This arm includes the use of an inter professional team to triage, plan and deliver care. the PRISM intervention, a brief, skills-based program targeting 4 resilience resources, will be delivered 1:1 as part of this treatment arm.
61935197|NCT02637336|EXPERIMENTAL|Aromatherapy|Eucalyptus essential oil was inhaled by volunteers for 20 minutes
62134791|NCT00071799|EXPERIMENTAL|Azacitidine|Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
62134792|NCT00071799|ACTIVE_COMPARATOR|Conventional Care|Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
62134793|NCT01946386|EXPERIMENTAL|LEO 90100|
62329224|NCT01958671|EXPERIMENTAL|Ertugliflozin 5 mg/Ertugliflozin 5 mg|Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
62329225|NCT01958671|EXPERIMENTAL|Ertugliflozin 15 mg/Ertugliflozin 15 mg|Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
62329226|NCT01958671|OTHER|Placebo/Metformin|Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
62329227|NCT01469013|PLACEBO_COMPARATOR|Placebo|"2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
62487041|NCT01418573|EXPERIMENTAL|Palaeolithic-type meal 1|
62487042|NCT01418573|EXPERIMENTAL|Palaeolithic-type meal 2|
62487043|NCT01418573|PLACEBO_COMPARATOR|The reference meal|
61935198|NCT02637336|NO_INTERVENTION|Control|In the control session the volunteers remained seated at rest for 20 minutes without performing therapy.
61935199|NCT01526122|EXPERIMENTAL|G0041(75/100mg)|
61935200|NCT01526122|ACTIVE_COMPARATOR|Clopidogrel & Aspirin|
61935201|NCT03925064||Diabetic pregnancies|Pregnant women with pregestational or gestational diabetes mellitus
62693471|NCT05832541||Control group (clinically healthy)|"tissue sample for control group will be collected from patients undergoing implant surgery. After local anesthesia, a crystal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants of 4.5-5.0 mm in diameter will be placed. A narrow diameter healing abutment will be screwed in with an insertion torque \> 20 NM., and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment.~Sample harvesting will be done after 2 months of healing using circular punch of 4.5-5.0 mm diameter or performing a circular incision by surgical blade by which a 1.5 mm thick collar of peri-implant soft tissue will be harvested and prepared for histopathological and immunohistochemical analysis. A new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly after the biopsy sampling."
62693472|NCT03517358|ACTIVE_COMPARATOR|Pharmacy|service of care: pharmacy
62693473|NCT03517358|ACTIVE_COMPARATOR|Case management|service of care: case management
62693474|NCT05677347|EXPERIMENTAL|GSK3923868 500 mcg SD/Placebo SD/GSK3923868 1500 mcg RD|Eligible participants will receive a single dose (SD) of GSK3923868 500 microgram (mcg) in Treatment Period 1 followed by a single dose of placebo matching GSK3923868 in Treatment Period 2. Participants will also receive a repeat dose (RD) of GSK3923868 1500 mcg in Treatment Period 3. There will be a washout period between each treatment period. Participants will have a follow-up of 14 days after the last dose of GSK3923868.
62693475|NCT05677347|EXPERIMENTAL|GSK3923868 500 mcg SD/GSK3923868 1000 mcg SD/Placebo RD|Eligible participants will receive a single dose of GSK3923868 500 mcg in Treatment Period 1 followed by a single dose of GSK3923868 1000 mcg in Treatment Period 2. Participants will also receive a repeat dose of placebo matching GSK3923868 in Treatment Period 3. There will be a washout period between each treatment period. Participants will have a follow-up of 14 days after the last dose of GSK3923868.
62693476|NCT05677347|EXPERIMENTAL|GSK3923868 500 mcg SD/GSK3923868 1000 mcg SD/GSK3923868 1500 mcg RD|Eligible participants will receive a single dose of GSK3923868 500 mcg in Treatment Period 1 followed by a single dose of GSK3923868 1000 mcg in Treatment Period 2. Participants will also receive repeat dose of GSK3923868 1500 mcg in Treatment Period 3. There will be a washout period between each treatment period. Participants will have a follow-up of 14 days after the last dose of GSK3923868.
62693477|NCT05677347|EXPERIMENTAL|Placebo SD/GSK3923868 1000 mcg SD/GSK3923868 1500 mcg RD|Eligible participants will receive a single dose of placebo matching GSK3923868 in Treatment Period 1 followed by a single dose of GSK3923868 1000 mcg in Treatment Period 2. Participants will also receive a repeat dose of GSK3923868 1500 mcg in Treatment Period 3. There will be a washout period between each treatment period. Participants will have a follow-up of 14 days after the last dose of GSK3923868.
62329228|NCT01469013|EXPERIMENTAL|1-mg Baricitinib (LY3009104)|"1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
62329229|NCT01469013|EXPERIMENTAL|2-mg Baricitinib (LY3009104)|"2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
62329230|NCT01469013|EXPERIMENTAL|4-mg Baricitinib (LY3009104)|1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
62329231|NCT01469013|EXPERIMENTAL|8-mg Baricitinib (LY3009104)|2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
62329232|NCT02555644|EXPERIMENTAL|Prexasertib + Cisplatin + Radiation Therapy (Part A)|"Prexasertib administered intravenously (IV) every 14 days over an approximately 49-day treatment period.~Cisplatin administered IV every 7 days over an approximately 49-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 49-day treatment period.~Participants may remain on treatment until completion of the treatment period."
62134794|NCT05912088|EXPERIMENTAL|Intervention Group|The strength and balance activities of the sLiFE program will be carried out. Participants will be invited to participate in groups of about 14 people in Primary Care Heath Centers.
62134795|NCT05912088|PLACEBO_COMPARATOR|Control Group|Participants will receive the usual health advice.
62134796|NCT02917512|EXPERIMENTAL|HU00701|"HU00701(Cyclosporine 0.01% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
62134797|NCT02917512|EXPERIMENTAL|HU007|"HU007(Cyclosporine 0.02% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
62134798|NCT02917512|ACTIVE_COMPARATOR|Restasis|"Restasis(Cyclosporine 0.05%)~1 drop b.i.d at 12 hour interval for 12 weeks"
62134799|NCT02917512|PLACEBO_COMPARATOR|Placebo(without main component)|"Placebo~1 drop b.i.d at 12 hour interval for 12 weeks"
62134800|NCT02247375|EXPERIMENTAL|Low dose of BIIL 284 BS|
62134801|NCT02247375|EXPERIMENTAL|High dose of BIIL 284 BS|
62134802|NCT02247375|PLACEBO_COMPARATOR|Placebo|
62134803|NCT06000800|EXPERIMENTAL|Group (clamping at 30 seconds)|Umbilical cord clamping at 30 seconds
62134804|NCT06000800|EXPERIMENTAL|Group clamping at 60 seconds|Umbilical cord clamping at 60 seconds
62693478|NCT06067139|EXPERIMENTAL|Digital cognitive behavioral therapy (dCBT-I)|CBT-I is designed to change sleep habits and scheduling factors that affect sleep, and to address misconceptions about sleep and insomnia that perpetuate sleep difficulties. The investigators will employ SHUTi, which is an extensively studied dCBT-I program. SHUTi is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia - CBT-I) in adults with chronic insomnia. It is a six-core internet-delivered CBT-I web-based app that is run through a browser. It is accessible via iPhone/iPad, Android phone/tablet, computer or laptop (any device with a browser). SHUTi follows evidence-based CBT-I principles.
62134805|NCT06000800|EXPERIMENTAL|Group clamping at 90 seconds|Umbilical cord clamping at 90 seconds
62134806|NCT06000800|ACTIVE_COMPARATOR|Group clamping immediately|Umbilical cord clamping immediately after birth (5 second)
62693479|NCT06067139|ACTIVE_COMPARATOR|Patient Education (PE)|Participants will be given access to a patient education website. It will provide nontailored material about insomnia symptoms; the impact, prevalence, and causes of insomnia; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
62134807|NCT05594511|EXPERIMENTAL|Experimental Group (muscle-energy technique)|Mandibular muscle energy technique: In the supine position, the patient will open the mouth and perform isometric contractions for closure controlled by the physiotherapist. Passively, the physiotherapist will increase the range of mandibular opening. The technique consists of performing 3 sets, with 3 isometric contractions in each set of 3 seconds each. At the end of each set, the physiotherapist will passively try to gain mouth opening in order to continue the rest of the sets. At the end of all sets, gently return to the resting position.
62329233|NCT02555644|EXPERIMENTAL|Prexasertib + Cetuximab + Radiation Therapy (Part B)|"Prexasertib administered IV every 14 days over an approximately 56-day treatment period.~Cetuximab administered IV every 7 days over an approximately 56-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 56-day treatment period (starting at Week 2).~Participants may remain on treatment until completion of the treatment period."
62329234|NCT00807846|EXPERIMENTAL|Celecoxib|
62329235|NCT00807846|EXPERIMENTAL|Naproxen|
62329236|NCT00633438|PLACEBO_COMPARATOR|B|
62329237|NCT00633438|EXPERIMENTAL|A|
62329238|NCT04719169|EXPERIMENTAL|Post-low pelvic colorectal anastomosis|Single armed study
62329239|NCT01786616||Formoterol|12 mcg BID for four weeks
62329240|NCT00252486|PLACEBO_COMPARATOR|Flax oil, placebo oil|
62329241|NCT04015947|EXPERIMENTAL|Active treatment|This is an open label, single-institution pilot study to evaluate local response to split-thickness skin grafts from a matched bone marrow donor to chronic GVHD-affected skin in a hematopoietic stem cell transplant patient.
62329242|NCT02275689|ACTIVE_COMPARATOR|Arthrocopic acromioplasty|Surgical intervention with arthroscopic acromioplasty, bursectomy and subacromial decompression
62693480|NCT06569472|EXPERIMENTAL|CD19-targeted CAR-T|The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).
62693481|NCT06469242|OTHER|LID233309, then Oasys MF|Serafilcon A multifocal contact lenses worn in Period 1, followed by senofilcon A multifocal contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during waking hours for at least 10 hours per day, each wear period \[14 days (-0/+2)\]. Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE.
62329243|NCT02275689|ACTIVE_COMPARATOR|Radiofrequency microtenotomy|Surgical intervention With arthroscopic radiofrequency microtenotomy
61935202|NCT03925064||non-diabetic pregnancies|Pregnant women without pregestational or gestational diabetes mellitus
61935203|NCT06631755|OTHER|Coronary Artery Disease (CAD)|
61935204|NCT00173433||Culture-confirmed relapse of TB|Patients who have a recurrent episode of culture-confirmed TB after completion of treatment for the first episode of culture-confirmed TB
62134808|NCT05594511|SHAM_COMPARATOR|Control Group (sham technique)|Sham technique: In the supine position, the physiotherapist will place his hands under the patient's skull with the fingertips in contact with the suboccipital musculature for 5 minutes, without applying pressure or therapeutic intent. The objective is to provide a stimulus as similar as possible to the original Suboccipital Inhibition Technique, but without force of movement. The patient will keep the eyes closed for the duration of the technique.
62134809|NCT05049421||Patients following CABG|Recruitment amongst patients enrolled in SWEDEGRAFT RCT at Aarhus University Hospital scheduled for follow-up
62329244|NCT02275689|NO_INTERVENTION|Physical therapy|Muscle strength training, home trainings programme
62329245|NCT01428063|EXPERIMENTAL|Daclatasvir + Asunaprevir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule or 200-mg tablet, by mouth twice daily + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (\<75 kg=1000 mg once daily; \>=75 kg=1200 mg once daily) for 24 weeks
62329246|NCT01428063|EXPERIMENTAL|Daclatasvir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, (two 30-mg tablets or one 60-mg tablet, by mouth once daily) + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (\<75 kg=1000 mg once daily; \>=75 kg=1200 mg once daily) for 24 weeks
62329247|NCT01428063|EXPERIMENTAL|Daclatasvir + Asunaprevir|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule, by mouth twice daily for 24 weeks
62329248|NCT00255684|EXPERIMENTAL|Conditioning therapy followed by TBI|Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
62329249|NCT01884454||Total sleep deprivation|Healthy volunteers will be submitted to total sleep deprivation (TSD) for 48 hours.
62329250|NCT01884454||moderate to severe OSA|Patients diagnosed with moderate to severe obstructive sleep apnea syndrome (OSA) with normal or overweight body mass index (BMI), will be recruited.
62329251|NCT01884454||REM sleep deprivation|Healthy volunteers will be submitted to selective REM sleep deprivation (REMSD) for 48 hours.
62329252|NCT01884454||Control|The control group will be subjects with an apnea hypopnea index \<5/h.
62329253|NCT04801537||normal body temperature and warm extremities|standard set of environmental temperature is done, and the infant's body temperature is normal and extremities are warm
62329254|NCT04801537||normal body temperature and cold extremities|standard set of environmental temperature is done, and infant's body temperature is normal and extremities are cold
62329255|NCT01259752|EXPERIMENTAL|compression stockings|
62693482|NCT06469242|OTHER|Oasys MF, then LID233309|Senofilcon A multifocal contact lenses worn in Period 1, followed by serafilcon A multifocal contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during waking hours for at least 10 hours per day, each wear period \[14 days (-0/+2)\]. Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE.
62693483|NCT06641752||Study population|"The study population must correspond to the research inclusion criteria:~Adult patient admitted to the emergency department, presenting with one or more clinical signs (asthenia, headache, nausea, vomiting, loss of consciousness, etc.) and a history compatible with CO intoxication (collective symptoms, notion of smoke, activation of a detector, etc.)"
62693484|NCT01212692|EXPERIMENTAL|Mentally stimulating activities|
61935205|NCT00138177|EXPERIMENTAL|Treatment (vorinostat, mFOLFOX)|"Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD."
61935206|NCT04102956|EXPERIMENTAL|Kallikrein+Standard treatment group|The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
62693485|NCT01212692|ACTIVE_COMPARATOR|Mentally stimulating activities- other|
61935207|NCT04102956|NO_INTERVENTION|Standard treatment group|The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
61935208|NCT06260098|EXPERIMENTAL|Yoga with High Breath work & meditation; Low movement/postures|
61935209|NCT06260098|EXPERIMENTAL|Yoga with Low Breath work & meditation; High movement/postures|
61935210|NCT06392971|EXPERIMENTAL|Preventive use of deep-sea fish oil|
61935211|NCT06392971|PLACEBO_COMPARATOR|Preventive use of placebo|
61935212|NCT01404975|EXPERIMENTAL|Paravertebral Block|Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
61935213|NCT01404975|ACTIVE_COMPARATOR|Standard intravenous opioid analgesia|"Patient Controlled Analgesia (PCA) :~PCA: the patients who are randomized to PCA group will receive standard of care for this modality."
61935214|NCT04259554|EXPERIMENTAL|OFC rTMS|repetitive transcranial magnetic stimulation
61935215|NCT01067976|EXPERIMENTAL|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw \[0.1 ml/kg bw\] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
61935216|NCT06312722|OTHER|Study Arm|Optilume BPH Catheter System
61935217|NCT02517216|OTHER|parabolic flight and MRI scans|
61935218|NCT04802070|EXPERIMENTAL|CIK|
62329256|NCT01259752|PLACEBO_COMPARATOR|standard non compressive stockings|
62329257|NCT01374815|EXPERIMENTAL|The Online Advocate|
62329258|NCT05161351|EXPERIMENTAL|Baclofen|Participants will receive a single dose of either 10mg, 30mg, 60mg or 90mg of Baclofen administered as oral tablets.
62329259|NCT05161351|PLACEBO_COMPARATOR|Vitamin D3|Participants will receive a single dose of either 20μg, 60μg or 120μg of Vitamin D3 administered as oral tablets.
62329260|NCT04755543|EXPERIMENTAL|I-A|LP002 dose escalation (3+3 design): 6-12 patients with malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment will receive LP002 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W), for up to 2 year.
62329261|NCT04755543|EXPERIMENTAL|I-B|If the safety profile in Arm A is acceptable, 9-12 patients with malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments will receive LP002 600mg or 900 mg IV on Day 1, Q2W, for up to 2 year.
62329262|NCT04755543|EXPERIMENTAL|I-C|If the safety profile in Arm A is acceptable, 15-20 patients with metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W,for up to 2 year.
62329263|NCT04755543|EXPERIMENTAL|I-D|Perioperative treatment: If the safety profile in Arm A is acceptable, 15-20 patients with gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W, for 3 cycles, 4-6 weeks before operation of the tumor and receive additional 6 cycles of the same therapy 4 weeks after the operation.
62329264|NCT04755543|EXPERIMENTAL|I-E|Dose escalation (3+3 design) of OH2 (an oncolytic virus) + LP002 900mg：If the safety profile in Arm A is acceptable, 15-30 patients with advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments will receive LP002 900mg IV on Day 1, Q2W, and OH2 10\^6 or 10\^7 or 10\^8 CCID50/mL by intra-tumoral injection, Q2W, for up to 2 year.
62329265|NCT01145027|NO_INTERVENTION|Control group|
62693486|NCT06641375|ACTIVE_COMPARATOR|Anti reflux endoscopic theraphy using Argon plasma coagulation in GERD|"To the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated."
62693487|NCT06641375|PLACEBO_COMPARATOR|Endoscopy|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
62693488|NCT04556006|NO_INTERVENTION|Control|The patients in the control group received only the standard care provided by the clinicians. After the collection of post-test data, the content of the training was also explained to these patients and the study was completed by giving them the training guide.
61935219|NCT05288413||Goldstandard DVT diagnostic through specialist sonographer|Patients with DVT symptomatic of lower limb which present at the DVT Clinic the Bays at St. Mary's Hospital will receive Goldstandard Scan through specialist.
61935220|NCT05288413||DVT diagnostic with Ultrasound probe with AutoDVT Software|Above patients will receive a second Ultrasound scan by a non-specialist with AutoDVT device.
61935221|NCT05288413||Retrospective data evaluation|result of AutoDVT is equivalent to diagnosis of specialist sonographer. Results specifically highlighted in patients with adipositas or malignant disease.
61935222|NCT04622982|EXPERIMENTAL|All participants|Obese subjects with BMI \>= 30 and with one or more of metabolic comorbidities (type 2 diabetes mellitus, dyslipidemia, high blood pressure, hyperuricemia, and others).
62134810|NCT04664998|ACTIVE_COMPARATOR|Male participants|200 male participants whose partners are enrolled in the parent study (Kampala Women's Bone study). All male participants will undergo the same study procedures at each visit, such as HIV and STI testing, and urine tenofovir testing if on PrEP.
62329266|NCT01145027|EXPERIMENTAL|Sensorial Stimulus|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste, in order to trigger the cephalic phase of insulin secretion
61935223|NCT01013298|EXPERIMENTAL|Video-guided PCT|Patients that will be extubated and re-intubated with the ETT-TVT, and monitored throughout intubation and PCT
62329267|NCT04680286|PLACEBO_COMPARATOR|Placebo|A 5 ml syringe with saline will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
62329268|NCT04680286|EXPERIMENTAL|Methadone|A 5 ml syringe with 1 mg/ml of methadone will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
62329269|NCT03443726|EXPERIMENTAL|Infiltrative technique|Patients in this arm will have buccal and lingual infiltrative anesthesia with 4% articaine 1:100.000 epinephrine for third molar extraction.
62329270|NCT03443726|ACTIVE_COMPARATOR|Nerve block technique|Patients in this arm will have inferior alveolar nerve and buccal nerve block with 4% articaine 1:100.000 epinephrine for third molar extraction.
62329271|NCT05952869|EXPERIMENTAL|Enlicitide Decanoate|Participants will receive 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks.
62329272|NCT05952869|PLACEBO_COMPARATOR|Placebo|Participants will receive enlicitide decanoate-matching placebo orally QD for up to 52 weeks.
61935224|NCT05354505|EXPERIMENTAL|Treatment|GOLDBAL2 balloon will be placed for Fetus diagnosed with Congenital diaphragmatic hernia (CDH) at Gestational age of 27w0d - 29w6d and retrieved at Gestational age of 34w0d to 34w 6 days
61935225|NCT03215979|EXPERIMENTAL|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
62329273|NCT00527111|EXPERIMENTAL|Chemoradiotherapy plus Cetuximab|Pelvic irradiation plus 5-fluorouracil plus cetuximab
62329274|NCT00527111|ACTIVE_COMPARATOR|Chemoradiotherapy alone|Pelvic irradiation plus 5-fluorouracil
61935226|NCT03215979|PLACEBO_COMPARATOR|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
61935227|NCT04704284|EXPERIMENTAL|ZTE MRI Imaging|Pediatric patients that have gotten a clinically indicated CT within a 6 week time period will receive a Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)
62134811|NCT04664998|ACTIVE_COMPARATOR|Female participants|300 female participants from the parent study (Kampala Women's Bone study) will be enrolled to recruit their male sexual partner(s). All female participants will receive HIV testing, STI testing, and urine tenofovir testing (if on PrEP) at quarterly visits.
62134812|NCT00288288||1|Epicardial left ventricular lead placement during a clinically indicated open chest surgery
62134813|NCT00288288||2|Transvenous left ventricular lead implant during a clinically indicated CRT system implant
62134814|NCT04986475|EXPERIMENTAL|Music Therapy|Music therapy was applied during the non-stress test.
62134815|NCT04986475|NO_INTERVENTION|Control|A routine non-stress test was performed.
62329275|NCT05813327|EXPERIMENTAL|Phase I: ADI-PEG 20 + ifosfamide + radiotherapy|Patients will receive ADI-PEG 20 on Day -7 of Cycle 1 and Days 1, 8, and 15 of each of three 21-day cycles, and ifosfamide per dose escalation/de-escalation schedule on days 1 through 5 of each cycle. Mesna will be given on days 1 through 5 with ifosfamide as supportive care. Patients will also receive radiotherapy (XRT) starting on Week 4.
62487044|NCT04882241|EXPERIMENTAL|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
62487045|NCT04882241|PLACEBO_COMPARATOR|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
62487046|NCT04882241|EXPERIMENTAL|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\^2 via IV infusion, oxaliplatin 85 mg/m\^2 via IV infusion, 5FU 2600 mg/m\^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m\^2, oxaliplatin 85 mg/m\^2, 5FU 2600 mg/m\^2, and leucovorin 200 mg/m\^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
62487047|NCT04882241|PLACEBO_COMPARATOR|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\^2 via IV infusion, oxaliplatin 85 mg/m\^2 via IV infusion, 5FU 2600 mg/m\^2 via IV infusion, and leucovorin 200 mg/m\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\^2 via IV infusion, oxaliplatin 85 mg/m\^2 via IV infusion, 5FU 2600 mg/m\^2 via IV infusion, and leucovorin 200 mg/m\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
62487048|NCT01341951|EXPERIMENTAL|G-CSF therapy in acute liver failure and alcoholic hepatitis|G-CSF therapy given in cases with acute liver failure and alcoholic hepatitis
62693489|NCT04556006|ACTIVE_COMPARATOR|Intervention|The training program was applied by the researcher who also work as an academic nurse. The contact information of the patients was obtained and the contact information of the researcher was also given to the patients. In order to consolidate the information given, the training guide was given to the patients in the intervention group. After the training, the patients in the intervention group were contacted again in the 2nd week by using face-to-face interview and in the 4th-8th and 12th weeks by phone calls. During these interviews, the questions of the patients, if any, were answered and the problems they faced regarding the disease management were tried to be solved. In the last interview, an appointment day was determined to meet face-to-face at home, workplaces or hospital according to the preferences of the patients.
62693490|NCT04132427|EXPERIMENTAL|Group A: Treatment|Vancomycin, magnesium citrate, microbiota
62693491|NCT04132427|PLACEBO_COMPARATOR|Group B: Placebo|placebo vancomycin, real magnesium citrate (because it obviously empties the bowels) and placebo microbiota
62693492|NCT00404911|EXPERIMENTAL|MFG therapy|Participants will receive multi-family group therapy
62693493|NCT00404911|ACTIVE_COMPARATOR|Standard of Care|Participants will receive standard care
62693494|NCT06082843|EXPERIMENTAL|Placebo|
62693495|NCT06082843|EXPERIMENTAL|Avenciguat (BI 685509)|This trial contemplates a dose-titration period, depending on dose tolerability.
62693496|NCT05200338|OTHER|Cohort 1a|SCD patients that are vaccinated against hepatitis B virus before matched sibling donor allogeneic SCT.
62693497|NCT05200338|OTHER|Cohort 1b|SCD patients that are vaccinated against hepatitis B virus before haploidentical donor allogeneic SCT.
62693498|NCT05200338|OTHER|Cohort 2|SCD patients that are vaccinated against hepatitis B virus without undergoing allogeneic SCT (control group).
62693499|NCT05200338|OTHER|Cohort 3a|SCD patients undergoing matched sibling donor allogeneic SCT whose donor is vaccinated against hepatitis B virus before stem cell collection.
62693500|NCT05200338|OTHER|Cohort 3b|SCD patients undergoing haploidentical donor allogeneic SCT whose donor is vaccinated against hepatitis B virus before stem cell collection.
61935228|NCT02455882||Neoadjuvant|Patients initiating standard of care treatment with primary systemic therapy for breast cancer
62329276|NCT05813327|EXPERIMENTAL|Phase II: ADI-PEG 20 + ifosfamide + radiotherapy|Patients will receive ADI-PEG 20 on Day -7 of Cycle 1 and Days 1, 8, and 15 of each of three 21-day cycles, and ifosfamide per the RP2D determined in Phase I of the study on days 1 through 5 of each cycle. Mesna will be given on days 1 through 5 with ifosfamide as supportive care. Patients will also receive radiotherapy (XRT) starting on Week 4.
62329277|NCT02036593|EXPERIMENTAL|Walk Your Heart to Health intervention|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
62134816|NCT06014697||Non-invasive lesion|Lesion with histological confirmation of a actinic keratosis or Bowens disease (non-invasive lesions).
62487049|NCT06336993|EXPERIMENTAL|herbal compound|
62487050|NCT06336993|ACTIVE_COMPARATOR|celecoxib|
62487051|NCT06449703|EXPERIMENTAL|Insulin Degludec/Liraglutide|
62487052|NCT06449703|ACTIVE_COMPARATOR|Xultophy®|
62487053|NCT01802112|PLACEBO_COMPARATOR|Maltodextrins|15 grams of maltodextrins per day dissolved in water during 21 days
62487054|NCT01802112|EXPERIMENTAL|Resistant maltodextrins|15 grams of resistant maltodextrins per day, dissolved in water during 21 days
62487055|NCT03508596|EXPERIMENTAL|Intervention|"Intervention group (IG)~An educational intervention for the supervisors"
62487056|NCT03508596|NO_INTERVENTION|Control|control group (CG)
62487057|NCT03508596|NO_INTERVENTION|Non-Intervention|group without intervention (GWI)
62487058|NCT03332082|EXPERIMENTAL|Tooth positioner treatment group|The participants that meet the inclusion criteria will be treated with tooth positioner.
62487059|NCT03921918|OTHER|Evaluation of Fluid Expression Technology|This study aims to provide important insights with respect to the safety, performance, and real-life usability of pumping technology
62693501|NCT06075277|EXPERIMENTAL|BI 1810631 (iCF) fed state (Reference, R) then fasting state (Test, T)|
62693502|NCT06075277|EXPERIMENTAL|BI 1810631 (iCF) fasting state (Test, T) then fed state (Reference, R)|
62134817|NCT06014697||Invasive lesion|Lesion with histological confirmation of a squamous cell carcinoma (invasive lesions).
62329278|NCT02036593|OTHER|Walk Your Heart to Health lagged|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
62329279|NCT00845923|OTHER|Civamide Patch 0.015%|All subjects in study will receive the Civamide Patch 0.015%
62329280|NCT01350037|ACTIVE_COMPARATOR|remifentanil|sedative mixture for PCS consisting of propofol 10mg/ml 20 ml and remifentanil 50 mkg/ml 5 ml
62329281|NCT01350037|ACTIVE_COMPARATOR|alfentanil 0.04 mg/ml|sedative mixture for PCS consisting of propofol10 mg/ml 20 ml,alfentanil 0.5 mg/ml 2 ml, NaCL 9 mg/ml 3 ml
62329282|NCT01350037|ACTIVE_COMPARATOR|alfentanil 0.08 mg/ml|sedative mixture for PCS consisting of propofol 10 mg/ml 20 ml, alfentanil 0.5 mg/ml 4 ml,NaCl 9mg/ml 1ml
62329283|NCT04556084|EXPERIMENTAL|Blinatumomab|Up to 2 cycles of continuous infusion blinatumomab will be given based on the end of Cycle 1 disease response. Cycle 2 of blinatumomab can be given to subjects who have achieved remission (\< 5% marrow blasts) after Cycle 1 but have persistent disease identified by multi-parameter flow cytometry (minimal residual disease (MRD) positive ≥ 0.01%) after Cycle 1.
62329284|NCT05464758|EXPERIMENTAL|Cold habituation|8-day cold habituation
62329285|NCT00541892|EXPERIMENTAL|1|Medium with no human serum albumine added
62329286|NCT00541892|ACTIVE_COMPARATOR|2|Conventional medium
62329287|NCT02580487||retrospective group|Patients whose pain evaluation, analgesics used and details of surgery were collected from patient files
62329288|NCT02580487||Prospective group|Patients who were interviewed before and after surgery when they were at the hospital
62329289|NCT01879618|EXPERIMENTAL|Fragmin|Fragmin given according to the flexible dosing regimen outlined in the protocol
62329290|NCT04413435||Confirmed COVID-19 cases|Patients with PCR test positive were considered as the confirmed COVID-19 cases.
62329291|NCT04413435||Suspected COVID-19 cases|The suspected COVID-19 cases were defined as follows: those who were interpreted in favor of the suspected covid-19 on c-CT by radiologists in addition to the typical symptoms of the novel coronavirus disease such as cough, high fever (\>38,5 °C), or dyspnea, and those with a history of contact with another confirmed COVID-19 patient in addition to typical symptoms.
62329292|NCT03816306||Single group study|
62329293|NCT03342469|EXPERIMENTAL|ADHD- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
62329294|NCT03342469|EXPERIMENTAL|ADHD - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
62329295|NCT03342469|EXPERIMENTAL|Controls- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
62487060|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
62487061|NCT02702895||Phase 1|Former ASPIRE participants
62487062|NCT02702895||Phase 2 HOPE participants|Former HOPE participants
62487063|NCT02702895||Phase 2 Male Partners|Male partners of HOPE participants
62487064|NCT05025163|NO_INTERVENTION|control group|no intervention in the control group
62487065|NCT05025163|EXPERIMENTAL|fluoride foam group|intervention; fluoride foam application (with 1.23% fluoride foam application on teeth )
62487066|NCT05025163|EXPERIMENTAL|fluoride varnish group|intervention; fluoride varnish application (with 2.26% fluoride varnish application on teeth)
62487067|NCT00898508||Normal benign breast disease or ductal carcinoma in situ|
62487068|NCT00898508||Invasive breast cancer|
62487069|NCT06560450|OTHER|Real-time audio feedback|Physiotherapist-defined real-time audio feedback
62487070|NCT01125072||entire cohort|patients presenting to the emergency department with chest pain and being admitted to rule out acute coronary syndrome
62487071|NCT03605641|EXPERIMENTAL|JUUL electronic cigarette|JUUL electronic cigarette. Virginia Tobacco 5% tobacco-derived nicotine.
62487072|NCT03605641|ACTIVE_COMPARATOR|VUSE Solo electronic cigarette|Reynolds American International VUSE Solo electronic cigarette. Original flavor 4.8% tobacco-derived nicotine.
62693503|NCT06644872|EXPERIMENTAL|Cardiac magnetic resonance measurements|Healthy participants will undergo a three and half-hour experimental day including repeated measurements of cardiac magnetic resonance and blood sampling.
62693504|NCT04037644|EXPERIMENTAL|Albumin|fluid loading with 200 mL of 4% albumin over a 10' interval
61935229|NCT02455882||Adjuvant|Patients initiating standard of care treatment with surgery followed by adjuvant chemotherapy for breast cancer
61935230|NCT02455882||Recurrence|Patients with a history of breast cancer who are diagnosed with disease recurrence
61935231|NCT05276947|EXPERIMENTAL|Peanut ball intervention|The experimental group. In the active phase of the labor (cervical dilatation = 5 cm), the peanut ball, which has a cover provided by the researcher and changed in each patient, will be placed between the knees of the participant for at least 30 minutes every hour, and a position change will be provided with the peanut ball in each time. The positions to be given with the peanut ball, semi sitting lunge, side lying, tucked, leaning forward, pushing and sitting position.
61935232|NCT05276947|NO_INTERVENTION|Control group|Standard care will be given to the control group without positioning with a peanut ball.
62329296|NCT03342469|EXPERIMENTAL|Controls - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
62329297|NCT04591912|EXPERIMENTAL|mind. body. voice.|The 10-week mind. body. voice. program.
62329298|NCT04591912|NO_INTERVENTION|Control|Assessment-only control
62487073|NCT03605641|ACTIVE_COMPARATOR|Conventional cigarette|Canadian purchased, store bought (not hand-rolled) conventional full-flavored cigarettes of subjects' preference.
62487074|NCT03769428|ACTIVE_COMPARATOR|group B:ESP block|"Patients in the experimental arm will receive an erector spinae plane block prior to induction of general anesthetic :- 150 mg of Ropivacaine : 40cc of Ropivacaine (3.75mg/cc)~* An intravenous patient controlled analgesia device will be given to the patients postoperatively"
61935233|NCT03764085|EXPERIMENTAL|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
61935234|NCT03764085|ACTIVE_COMPARATOR|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
61935235|NCT03029130|EXPERIMENTAL|Catheter Extension|Patients in this arm will have a foley catheter re-passed, to remain in situ for an additional 14 days, after which time the catheter will be removed and the patient discharged to return for follow up exam at 3 months postop.
61935236|NCT03029130|NO_INTERVENTION|Discharge|Patients in this arm will be discharged, to return for follow up exam at 3 months postop.
62134818|NCT04664426||Kidney transplant recipients|Kidney transplant recipients will undergo examination according to the E-PSS, amTCNS, QST (thermal threshold testing), and NCS (amplitude, velocity and distal latency of measurements at the sural sensory nerve, ulnar sensory nerve, peroneal motor nerve, tibial motor nerve and ulnar motor nerve, soleus H reflex will be measured).
62134819|NCT03230006|ACTIVE_COMPARATOR|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
62329299|NCT00766259||1|Hemodialysis
62329300|NCT00766259||2|Intensive care
62329301|NCT00766259||3|vascular patients with open wounds
61935237|NCT06410404|ACTIVE_COMPARATOR|Levobupivacaine group|"* Patients in this group shall receive levobupivacaine alone.~* Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of levobupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle."
62329302|NCT00766259||4|nursing home
62693505|NCT04037644|ACTIVE_COMPARATOR|Ringer Lactate|fluid loading with 5 mL/kg actual body weight of Ringer Lactate over a 10' interval
62329303|NCT00766259||5|skin infections
62329304|NCT00766259||6|control- ambulatory care clinic patients with no infections
62329305|NCT01528800|PLACEBO_COMPARATOR|Placebo|Microcrystalline Methylcellulose
62329306|NCT01528800|ACTIVE_COMPARATOR|Vitamin K1|Vitamin K1
62329307|NCT02840058|EXPERIMENTAL|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting anti PD1/PDL1 treatment), and then 1 month, 3 months and 12 months after initiation of anti-PD1/PDL1 treatment.~Peripheral blood mononuclear cells (PBMC) and plasma will be collected.~Available tumor tissues will be collected."
62487075|NCT03769428|PLACEBO_COMPARATOR|group P: Sham ESP block|"Patients allocated to the placebo-control arm will receive a sham erector spinae plane block .they will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block:- 40 cc of normal saline will be injected~-An intravenous patient controlled analgesia device will be given to the patients postoperatively"
62487076|NCT04322513||Covid-19 positive patients|all drugs used for standard treatment
62487077|NCT04322513||Covid-19 negative patients|
62487078|NCT03016806|OTHER|Full Intensity, TBI-based Conditioning|Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses \[to be completed 24 hours after final Cyclophosphamide dose\] followed by Cord Blood Infusion Other names: TBI/Cy
62693506|NCT05402332|EXPERIMENTAL|AVTX-801, then Placebo|Participants receive AVTX-801 1.5g/kg/day (in applesauce) during Treatment Period 1 and then placebo (in applesauce) during Treatment Period 2.
62487079|NCT03016806|OTHER|Full Intensity, Chemo-based Conditioning|Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients \<5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients \>/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses \[to be completed 24 hours after final Cyclophosphamide dose\] followed by Cord Blood Infusion Other names: Bu/Cy
62487080|NCT03016806|OTHER|Reduced Intensity Chemotherapy|Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
62487081|NCT03016806|OTHER|Non-Myeloablative Conditioning|Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose \[to be completed 24 hours after Cyclophosphamide dose\] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
62487082|NCT00284518|EXPERIMENTAL|botulinum toxin Type A 300 U|Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.
62487083|NCT00284518|EXPERIMENTAL|botulinum toxin Type A 200 U|Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.
62487084|NCT00284518|EXPERIMENTAL|botulinum toxin Type A 100 U|Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.
62487085|NCT00284518|PLACEBO_COMPARATOR|Placebo (Normal Saline)|Placebo (Normal Saline) transperineal or transrectal injection on Day 1.
62487086|NCT01791062|EXPERIMENTAL|HYTOP®|
62487087|NCT04516460|EXPERIMENTAL|PuraStat|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection
62487088|NCT00961376|ACTIVE_COMPARATOR|Cohort A|PBMC re-infusion
62487089|NCT00961376|EXPERIMENTAL|Cohort B|CD25 depletion
62487090|NCT00364559|EXPERIMENTAL|B|A, Active B, Historical Register
62487091|NCT01174186|ACTIVE_COMPARATOR|Spondyloarthritis and calprotectin elevated|Spondylitis patients with elevated levels of fecal calprotectin. Patients are treated with adalimumab
62487092|NCT01174186|ACTIVE_COMPARATOR|Spondyloarthritis and calprotectin normal|Spondylitis patients with normal levels of fecal calprotectin. Patients are treated with adalimumab.
62487093|NCT01582464||Older Adults in a Senior Community|Residents of a Continuing Care Retirement Community (CCRC) that is a part of The Be Group (previously known as Southern California Presbyterian Homes), with no exclusion other than being able to communicate in English and provide consent to participate.
62487094|NCT03921762|EXPERIMENTAL|Artis Active IOL|Artis Active IOLs (Artis Active Mid, Artis Active Plus) will be implanted in patients eyes during cataract surgery
62487095|NCT03921762|EXPERIMENTAL|AT Lara IOL|AT Lara IOLs will be implanted in patients eyes during cataract surgery
62487096|NCT06485284|EXPERIMENTAL|El Camino|Adolescents receiving the intervention/treatment - El Camino.
62487097|NCT06485284|OTHER|Control|Adolescents receiving the control - alternative life skills program.
62487098|NCT05750849||OPTIMAL SERUM P4 LEVEL|Serum progesterone levels on β-hCG day over the threshold point calculated
62487099|NCT05750849||SUB-OPTIMAL SERUM P4 LEVEL|Serum progesterone levels on β-hCG day below the threshold point calculated
62487100|NCT02265679|EXPERIMENTAL|BIIL 284 BS, low dose in pediatric patients|
62487101|NCT02265679|EXPERIMENTAL|BIIL 284 BS, medium dose in pediatric patients|
62487102|NCT02265679|EXPERIMENTAL|BIIL 284 BS, high dose in pediatric patients|
62693507|NCT05402332|EXPERIMENTAL|Placebo, then AVTX-801|Participants receive placebo (in applesauce) during Treatment Period 1 and then AVTX-801 1.5g/kg/day (in applesauce) during Treatment Period 2.
62693508|NCT06640231|ACTIVE_COMPARATOR|Bioceramic sealer activation with XP Endo Finisher.|
62693509|NCT06640231|ACTIVE_COMPARATOR|Bioceramic sealer without activation.|
62693510|NCT03856918|EXPERIMENTAL|PEEP 3 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 3 cm of water during thoracic surgery.
62487103|NCT02265679|EXPERIMENTAL|BIIL 284 BS, low dose in adult patients|
62487104|NCT02265679|EXPERIMENTAL|BIIL 284 BS, medium dose in adult patients|
62487105|NCT02265679|EXPERIMENTAL|BIIL 284 BS, high dose in adult patients|
62487106|NCT02265679|PLACEBO_COMPARATOR|Placebo|
62487107|NCT04003363||Participants with Myotonic Dystrophy|
62487108|NCT02550535|EXPERIMENTAL|Gene-modified WT1 TCR-transduced T cells|A single dose of bulk WT1 TCR-transduced T cells (≤ 2 x 107/kg) will be intravenously (i.v.) administered following protocol-specified lymphodepletive conditioning regimen. Additionally, daily IL-2 subcutaneous injections (1x106 units/m2 subcutaneously (s.c.)) will be administered for 5 days concomitantly to each subject, following infusion of the ATIMP.
62487109|NCT02827045||Depressive phase|Vestibular test
62487110|NCT02827045||Maniac phase|Vestibular test
62487111|NCT02827045||Euthimic phase|Vestibular test
62487112|NCT02827045||Healthy subject|Vestibular test
62487113|NCT02781883|EXPERIMENTAL|Untreated AML|BP1001 in combination with Ventoclax plus decitabine
62487114|NCT02781883|EXPERIMENTAL|Refractory/Relapsed AML|BP1001 in combination with Ventoclax plus decitabine
62487115|NCT02781883|EXPERIMENTAL|Refractory/Relapsed AML (ventoclax-intolerant or resistant)|BP1001 + decitabine combination in patients who are resistant or intolerant of venetoclax-based treatment, or considered not optimal candidates for a venetoclax-based therapy.
62487116|NCT05170087||Breast malignancies|Those diagnosed with breast malignancies
62487117|NCT05170087||Head and Neck malignancies|Those diagnosed with head and neck malignancies
62487118|NCT05170087||Brain malignancies|Those diagnosed with brain malignancies
62487119|NCT05170087||Gynecological malignancies|Those diagnosed with gynecological malignancies
62487120|NCT02323256|EXPERIMENTAL|newly cochlear implanted adult patients|longitudinal group
62487121|NCT02323256|EXPERIMENTAL|newly cochlear implanted children|longitudinal group
62487122|NCT02323256|ACTIVE_COMPARATOR|cochlear implanted adult patients (CI>1 year)|transversal group
62487123|NCT02323256|ACTIVE_COMPARATOR|normal hearing adult subjects|transversal group
62487124|NCT04544618|EXPERIMENTAL|Intervention group|Participants will be exposed to a virtual reality simulation of the operating room environment for a minimum of ten minutes.
62487125|NCT04544618|NO_INTERVENTION|Treatment as usual group|Participants will receive standard of care with no additional intervention aside from information received at their surgical oncology appointment and optional preoperative education classes (available to all patients).
62487126|NCT05399446|EXPERIMENTAL|Diabetes Body Project|
62487127|NCT05399446|ACTIVE_COMPARATOR|Educational Group|
62487128|NCT02853019|SHAM_COMPARATOR|Healthy volunteers|Healthy volunteers
62487129|NCT02853019|EXPERIMENTAL|Patients with schizophrenia|Patients with schizophrenia
62487130|NCT03209505|OTHER|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
62487131|NCT03209505|OTHER|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night \& Day Aqua
62487132|NCT05762705|EXPERIMENTAL|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Viral Combat on their mobile phones, and, for 24 weeks, game-related text messages guided by self-reported medication adherence.
62487133|NCT05762705|ACTIVE_COMPARATOR|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game.
62487134|NCT01386853|EXPERIMENTAL|Pitavastatin|
62487135|NCT01386853|ACTIVE_COMPARATOR|Atorvastatin|
62487136|NCT02722187|EXPERIMENTAL|microsurgery|40 patients will undergo subinguinal microscopic varicocelectomy
62487137|NCT02722187|ACTIVE_COMPARATOR|laparoscopy|20 patients will undergo laparoscopic varicocelectomy
62487138|NCT01083693||Rheumatoid, Psoriatic Arthritis, Ankylosing Spondylitis|Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, patients with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.
62487139|NCT01261663||NOS intake either at end of meals or as snackings.|
62487140|NCT03850522|EXPERIMENTAL|Vaccination|Vaccination with PD-L1 peptide
61935238|NCT06410404|ACTIVE_COMPARATOR|Combined levobupivacaine, and dexmeditomedine group|"* Patients in this group shall receive levobupivaciane in addition to dexmeditomedine as an adjuvant.~* Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of levobupivacaine 0.25%, together with dexmeditomedine in a dose of 1 ug/kg will be injected between the transversus thoracic muscle and the internal intercosatal muscle."
62487141|NCT05645120|EXPERIMENTAL|Health Professionals|Education intervention for health professionals
62487142|NCT05645120|EXPERIMENTAL|Non-health Professionals|Education intervention for non-health professionals
62693511|NCT03856918|EXPERIMENTAL|PEEP 6 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 6 cm of water during thoracic surgery.
61935239|NCT01563211||Patients receiving endocrine treatment for breast cancer|Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer.
62693512|NCT03856918|EXPERIMENTAL|PEEP 9 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 9 cm of water during thoracic surgery.
61935240|NCT01563211||Patients receiving chemotherapy for breast cancer|Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel).
61935241|NCT02103218|EXPERIMENTAL|Risky sex prevention|education, activities, empowerment, racial pride building
61935242|NCT02103218|ACTIVE_COMPARATOR|Healthy behaviors|General health education, activities
61935243|NCT04160481|ACTIVE_COMPARATOR|Tomato extract|
61935244|NCT04160481|PLACEBO_COMPARATOR|Placebo|
61935245|NCT05610514|NO_INTERVENTION|Combustible Cigarette|Participants in this arm will smoke their usual brand of combustible cigarettes for two weeks.
62487143|NCT04652622|EXPERIMENTAL|Intervention arm|Participants will receive 4 hours of exposure to the Mindful Garden digital therapeutic platform in addition to standard care
62487144|NCT04652622|NO_INTERVENTION|Control Arm|Participants will be monitored over a 4 hour period of standard care interventions
62487145|NCT06146959|EXPERIMENTAL|Group A|Group A: will receive corrective kinesiotaping (50-75% stretch) for 4 weeks, 2 times per week, with 1 day rest
62487146|NCT06146959|ACTIVE_COMPARATOR|Group B|Group B: will receive a placebo non-corrective kinesio taping (without tension) with no mechanical correction of calcaneus
62487147|NCT06146959|PLACEBO_COMPARATOR|Group C|Group C: will receive a home program of intrinsic foot strengthening and stretching exercises.
62487148|NCT02956096|ACTIVE_COMPARATOR|tDCS device and Treatmill|The stimulation is accomplished with a direct current-tDCS Stimulator Plus device, via two surface electrodes sponge (non-metallic) 5-7 cm2 in saline moistened with a 2mA current during 20 minutes after hemodinamic analysis is performed for 15 minutes and then made only training treadmill for 20 minutes. Placebo tDCS will follow the same procedures, but the tDCS device will only be switched on for 20 seconds. The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve (MACKO , 2005).
62487149|NCT02956096|SHAM_COMPARATOR|1- tDCS|1. Who received stimulation transcranial direct current active will receive Sham stimulation and who received the placebo stimulation receive active stimulation and then the two groups will do the workout on the treadmill
62487150|NCT05168163|EXPERIMENTAL|Arm A (atezolizumab, cabozantinib or lenvatinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62487151|NCT05168163|ACTIVE_COMPARATOR|Arm B (cabozantinib or lenvatinib)|Patients receive cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62487152|NCT01181635|EXPERIMENTAL|Psychotherapy|Short-term pychotherapy and/or psychoeduchative courses.
62487153|NCT04008563|EXPERIMENTAL|Bariatric Surgery and Progestin Intrauterine Device|This group will receive a progestin intrauterine device and be offered to undergo bariatric surgery.
62134820|NCT03230006|PLACEBO_COMPARATOR|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
62329308|NCT05187806|EXPERIMENTAL|Experimental group|"After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions of 30-60 (mean 45 min) min each. The sessions were structured according to the Behavior Change Stage Identification Form developed by the researcher by making use of the trans-theoretical model and adapting it to diabetic patients. The subject of the first session was Opening, Structuring the Discussion, and Establishing the Agenda; the subject of the second session was Improving Motivation for Change; the subject of the third session was Summarizing, Support, and Talking about the Change; and the subject of the fourth session was Evaluation . The discussions were completed in four weeks, with one discussion held every week. The final test and the Diabetes Self-Management Instrument were applied again to the members of the intervention group in the third month after completion of the MI method sessions."
62329309|NCT05187806|NO_INTERVENTION|Control group|The control group received routine treatment. The final test and the Diabetes Self-Management Instrument were applied again to the members of the control group in the third month.
62329310|NCT02467803|ACTIVE_COMPARATOR|Intervention|We applied scapula mobilization with shoulder ROM exercises
62329311|NCT02467803|OTHER|Control|We applied only shoulder ROM exercises
62329312|NCT04993950|EXPERIMENTAL|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
62329313|NCT04993950|ACTIVE_COMPARATOR|SNAGS with thoracic postural correction techniques|active as well as therapist-facilitated stretches.thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
62329314|NCT00664092|NO_INTERVENTION|1|Usual Aftercare Condition
62329315|NCT00664092|EXPERIMENTAL|2|Oxford House Condition
62487154|NCT04008563|NO_INTERVENTION|Progestin Intrauterine Device Alone|This group will receive a progestin intrauterine device alone.
62487155|NCT02569138|EXPERIMENTAL|Insole (Experimental)|specially designed insole, featuring hard and thin design, modified insole
62487156|NCT02569138|EXPERIMENTAL|Insole (Control)|usual insole found in footwear, non-modified insole
62134821|NCT02169869|EXPERIMENTAL|Immediate postplacental IUD insertion|Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
62134822|NCT02169869|ACTIVE_COMPARATOR|6 weeks postpartum IUD insertion|Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.
62134823|NCT05902845|EXPERIMENTAL|RD13-02 cell infusion|drugs use generic name : RD13-02 CAR-T cell injection; dosage form : Cell injection dosage : 2×10\^8 CAR+ T cells frequency : Once
62134824|NCT04164940||Age 21-30|Patients aged 21-30 when admitted to hospital and receiving brief alcohol intervention
62134825|NCT04164940||Age 31-40|Patients aged 31-40 when admitted to hospital and receiving brief alcohol intervention
62134826|NCT04164940||Age 41-50|Patients aged 41-50 when admitted to hospital and receiving brief alcohol intervention
62329316|NCT00664092|EXPERIMENTAL|3|Therapeutic Community Condition
62329317|NCT04145830|EXPERIMENTAL|Ultrasound Cyclo Plasty (UCP)|Ultrasound Cyclo Plasty (UCP) using focused ultrasound
62329318|NCT01351077|EXPERIMENTAL|CHICA DevScreen Module|This arm will get the CHICA Developmental Screening Module
62329319|NCT01351077|NO_INTERVENTION|CHICA DevScreen Control|This arm will get CHICA without the developmental screening module
62329320|NCT02713230|ACTIVE_COMPARATOR|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
62329321|NCT02713230|ACTIVE_COMPARATOR|EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
62329322|NCT02713230|PLACEBO_COMPARATOR|Placebo|20 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
62487157|NCT01442376|EXPERIMENTAL|Palonosetron 10 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
62487158|NCT01442376|EXPERIMENTAL|Palonosetron 20 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
62487159|NCT01442376|ACTIVE_COMPARATOR|Ondansetron|"Ondansetron and placebo to Palonosetron~Drug:~Comparator: Ondansetron"
62487160|NCT05277402|EXPERIMENTAL|Dose escalation|ADG116 combination treatment with pembrolizumab (KEYTRUDA®), both drugs will be administered in each cohort.
62487161|NCT01562613||Hypertensive patients|All eligible hypertensive patients treated with eprosartan
62487162|NCT05347459||New Antidiabetic|Type 2 diabetic patients receiving SGLT2 inhibitors and/or DPP-4 inhibitors with metformin
62487163|NCT05347459||Traditional Antidiabetic|Type 2 diabetic patients treated with metformin
62487164|NCT05347459||Control|Healthy non-diabetic patients
62134827|NCT04164940||Age 51-60|Patients aged 51-60 when admitted to hospital and receiving brief alcohol intervention
62487165|NCT00318188|EXPERIMENTAL|Intervention group|The patients in this group will do a personalized standardized rehabilitation program on the quality of life.
62487166|NCT00318188|NO_INTERVENTION|Control group|Habitual care
62487167|NCT04270383||2019-nCoV infection group|Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019-nCoV infection group.
62693513|NCT05081609|EXPERIMENTAL|Part 1 Monotherapy Dose Escalation: TransCon IL-2 β/γ|TransCon IL-2 β/γ in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D
62134828|NCT04164940||Age 61-70|Patients aged 61-70 when admitted to hospital and receiving brief alcohol intervention
62487168|NCT04270383||Control group|Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019-nCoV infection group are classified as the control group.
62487169|NCT00754455|EXPERIMENTAL|Low dose|
62487170|NCT00754455|EXPERIMENTAL|Mid dose|
62487171|NCT00754455|EXPERIMENTAL|High dose|
62487172|NCT00754455|PLACEBO_COMPARATOR|Placebo|
62487173|NCT04808362|EXPERIMENTAL|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
62487174|NCT00746850|EXPERIMENTAL|H|early LC within 72 hours after the diagnosis with H (Harmonic)
62487175|NCT00746850|ACTIVE_COMPARATOR|MD|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
62487176|NCT00045786|EXPERIMENTAL|400 mg CC-1088|
62487177|NCT00045786|EXPERIMENTAL|800 mg CC-1088|
62487178|NCT00045786|EXPERIMENTAL|1200 mg CC-1088|
62487179|NCT00045786|EXPERIMENTAL|1500 mg CC-1088|
61935246|NCT05610514|EXPERIMENTAL|E-Cigarette|Participants in this arm will smoke electronic cigarettes for two weeks. E-cigarettes (either JUUL or Vuse Alto) and pods (JUUL: Virginia tobacco flavor at 3% or 5% nicotine concentration; Vuse Alto: golden tobacco flavor at 1.8%, 2.4%, or 5% nicotine concentration) will be provided.
61935247|NCT00662220|ACTIVE_COMPARATOR|Standard dose|Standard-dose ribavirin (12-15 mg/kg/day) in combination with peginterferon 180µg QW
61935248|NCT00662220|EXPERIMENTAL|High dose|High-dose ribavirin (25-29 mg/kg/day) in combination with peginterferon 180µg QW
61935249|NCT04385732|EXPERIMENTAL|Standard of Care plus Melanoma Surveillance Photography|Clinical surveillance standard of care with addition of 2D or 3D Melanoma Surveillance Photography and digital dermoscopy.
61935250|NCT04385732|NO_INTERVENTION|Standard of Care|Clinical surveillance standard of care without Melanoma Surveillance Photography.
61935251|NCT05116358|ACTIVE_COMPARATOR|Active|An active phototherapy device
61935252|NCT05116358|SHAM_COMPARATOR|Sham (Placebo)|An inactive device
61935253|NCT00122278|EXPERIMENTAL|Dexamethasone|Dexamethasone 10 mg
61935254|NCT00122278|PLACEBO_COMPARATOR|Placebo|Placebo Dexamethasone, 10 mg
62134829|NCT04164940||Age 71-80|Patients aged 71-80 when admitted to hospital and receiving brief alcohol intervention
62134830|NCT04164940||Age 81 and older|Patients aged 81 and older when admitted to hospital and receiving brief alcohol intervention
62134831|NCT05948813|EXPERIMENTAL|TY-9591 Tablets|TY-9591 (160mg orally, once daily), in accordance with the randomization schedule.
62329323|NCT02776696|EXPERIMENTAL|Advanced HybridClosed Loop System (AHCL)|Advanced Hybrid Closed Loop System (AHCL) - all subjects wearing the study system during 36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3 or 5 days in a camp setting and 21 days at home during segment 4.
62329324|NCT02776696|EXPERIMENTAL|Hybrid Closed Loop System (HCL)|"Hybrid Closed Loop System (HCL) - all subjects wearing the study system during:~36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3"
62329325|NCT02050633||Severe cranial trauma|This is a cohort of adult patients who have suffered a severe TBI between 1 July 2005 and 1 May 2007.
62329326|NCT01240122|ACTIVE_COMPARATOR|Biotrue MPS|
62329327|NCT01240122|EXPERIMENTAL|Investigational MPS|
62329328|NCT05239949|EXPERIMENTAL|Hypopressive exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of hypopressive exercises (HE). A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform HE in an upright position. For this maneuver, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage. Four sets of 10 repetitions with a 3-minute interval between each set will be performed."
62487180|NCT04950426|EXPERIMENTAL|Treatment with reconsolidation therapy|Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet
62487181|NCT06095180|ACTIVE_COMPARATOR|corticosteroid group|In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
62487182|NCT06095180|ACTIVE_COMPARATOR|dry needling group|In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
62487183|NCT06095180|OTHER|control group|The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
62487184|NCT00070291|EXPERIMENTAL|Cyclosporine|High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.
62487185|NCT04987216|EXPERIMENTAL|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
62487186|NCT06271005|ACTIVE_COMPARATOR|Treatment with NeuroTears|
62487187|NCT06271005|PLACEBO_COMPARATOR|Placebo|
62693514|NCT05081609|EXPERIMENTAL|Part 2 Combination Dose Escalation: TransCon IL-2 β/γ with Pembrolizumab|TransCon IL-2 β/γ with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D
62487188|NCT05633186|EXPERIMENTAL|Condition 1|Moodbuster Life + Mobile Application + Guidance by a coach + Motivational Content
62487189|NCT05633186|EXPERIMENTAL|Condition 2|Moodbuster Life + Mobile Application + Guidance by a coach
62487190|NCT05633186|EXPERIMENTAL|Condition 3|Moodbuster Life + Mobile Application + Motivational Content
62487191|NCT05633186|EXPERIMENTAL|Condition 4|Moodbuster Life + Mobile Application
62487192|NCT05633186|EXPERIMENTAL|Condition 5|Moodbuster Life + Guidance by a coach + Motivational Content
62487193|NCT05633186|EXPERIMENTAL|Condition 6|Moodbuster Life + Guidance by a coach
62487194|NCT05633186|EXPERIMENTAL|Condition 7|Moodbuster Life + Motivational Content
62487195|NCT05633186|EXPERIMENTAL|Condition 8|Moodbuster Life
62487196|NCT01678339||1|
62487197|NCT02463981|EXPERIMENTAL|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
62487198|NCT02463981|SHAM_COMPARATOR|sham control|Sham control group receives sham neurofeedback from a large control brain region.
62487199|NCT05166109|EXPERIMENTAL|Vamorolone 500mg/day [250mg if <50kg body weight]|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
62487200|NCT05166109|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
62487201|NCT05480943||Hospitalized non-alcoholic veterans|Any veteran with full admission to the VA Sierra Nevada Healthcare System Hospital.
62487202|NCT01597791|PLACEBO_COMPARATOR|Foley catheter|Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
62134832|NCT05948813|ACTIVE_COMPARATOR|Osimertinib|Osimertinib (80mg orally, once daily), in accordance with the randomization schedule.
62134833|NCT05113810|EXPERIMENTAL|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
62487203|NCT01597791|EXPERIMENTAL|No Foley Catheter|Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
62134834|NCT05113810|ACTIVE_COMPARATOR|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
62134835|NCT03693066|EXPERIMENTAL|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
62134836|NCT03693066|ACTIVE_COMPARATOR|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
62487204|NCT01616329||Cases and Controls|Cases: alloantibody formers Controls: non-alloantibody formers
62693515|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with SOC Chemo|TransCon IL-2 β/γ using the RP2D with SOC Chemotherapy to evaluate safety/tolerability and anti-tumor activity of the combination
62693516|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with TransCon TLR7/8 Agonist|TransCon IL-2 β/γ with TransCon TLR7/8 Agonist using the RP2D to evaluate safety/tolerability and anti-tumor activity of the combination
62487205|NCT02121028||Intracranial Atherosclerotic Disease, Stroke/TIA|Stroke/TIA due to high grade IAD ≤21 days from symptom onset.
62487206|NCT00834444|EXPERIMENTAL|1|
62487207|NCT00834444|ACTIVE_COMPARATOR|2|
62693517|NCT05081609|EXPERIMENTAL|Part 3 Monotherapy Dose Expansion: TransCon IL-2 β/γ followed by surgery|(Optional Arm): TransCon IL-2 β/γ using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
61935255|NCT04832087||Cohort A|Participants with SBS who started Teduglutide after FDA approval (May 2019)
62487208|NCT02294305|EXPERIMENTAL|Vortioxetine|Vortioxetine 10 to 20 mg PO QD for 12 weeks.
62487209|NCT02294305|PLACEBO_COMPARATOR|Placebo|Placebo PO QD for 12 weeks.
62487210|NCT03363555|EXPERIMENTAL|SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
62487211|NCT02705573|EXPERIMENTAL|Mannitol 20%|Mannitol 1g/ kg BW
62487212|NCT02705573|PLACEBO_COMPARATOR|Nacl 0.9%|NaCl 0.9% 5ml/ kg BW
62487213|NCT06627387|EXPERIMENTAL|Balance training|The intervention will be carried out in two phases. The first phase will take place at Vall d'Hebron Hospital, where patients will undergo balance training under the supervision of a physiotherapist. The scheduled dose will be 60 minutes a day, 3 days a week for 4 weeks. If the patients meet the inclusion criteria, the intervention will be extended for two more weeks at home.
62487214|NCT01751087|OTHER|Osmotic dilators + placebo (vit c) + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
62487215|NCT01751087|ACTIVE_COMPARATOR|Osmotic dilators + placebo (vit c) + misoprostol|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
62487216|NCT01751087|ACTIVE_COMPARATOR|Osmotic dilators + mifepristone + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
62487217|NCT01188863|EXPERIMENTAL|Solid Oral Dose - 150 mg tablets|
62487218|NCT01188863|EXPERIMENTAL|Solid Oral Dose - 50 mg tablets|
62487219|NCT01188863|EXPERIMENTAL|Liquid Oral Dose|
62487220|NCT06321653||Hypofractionated radiotherapy|Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
62487221|NCT05803135|ACTIVE_COMPARATOR|Double-Blind Iguratimod|Iguratimod (25mg twice daily) combined with Tofacitinib (5mg twice daily) for 24 weeks (6 months)
62487222|NCT05803135|PLACEBO_COMPARATOR|Double-Blind Placebo|Placebo (25mg twice daily) combined with Tofacitinib (5mg twice daily) for 24 weeks (6 months)
62487223|NCT01927744|EXPERIMENTAL|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
62487224|NCT01927744|EXPERIMENTAL|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
62487225|NCT02438735||Endometrioma|Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.
62487226|NCT02438735||Healthy Controls|"Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.~Controls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months."
62487227|NCT02438735||Historical controls who underwent surgical excision|20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).
62487228|NCT00506376||Surgical Treatment Preferences|Assessment of patient's feelings toward risks associated with surgical treatment of cervical cancer.
62487229|NCT03965429||Donor|In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor.
62487230|NCT03965429||Receiver|Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used
62487231|NCT04335162||Patients with cardiovascular complications|Patients presenting with cardiomyopathies or venous thromboembolism
62487232|NCT04335162||Patients without cardiovascular complications|Patients without cardiomyopathies or venous thromboembolism
62487233|NCT04335162||Intensive Care Unit patients|Patients admitted in intensive care unit
62487234|NCT04335162||Hospital Ward patients|Patients admitted in hospital ward
62487235|NCT00728754|EXPERIMENTAL|Dental implant Osseotite Prevail|Dental implant with lateralized design
62487236|NCT00728754|ACTIVE_COMPARATOR|Dental implant Osseotite|Dental implant without the lateralized design
62487237|NCT03611335||Site 1 H+H|Lincoln Medical and Mental Health Center
62487238|NCT03611335||Site 2 H+H|Bellevue Hospital
61935256|NCT04832087||Cohort B|Subjects who participated in any of the teduglutide pediatric clinical trial studies (TED-C13-003, TED-C14-006, SHP633-303, or SHP633-304) and subsequently started therapy with teduglutide
62487239|NCT03611335||Site 3 H+H|Metropolitan Hospital
62134837|NCT03693066|ACTIVE_COMPARATOR|Control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
62134838|NCT00068458|ACTIVE_COMPARATOR|Arm 1: calcium diet|Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
62487240|NCT03611335||Site 4 H+H|Elmhurst Hospital Center
62487241|NCT03611335||Site 5 H+H|Coney Island Hospital
62487242|NCT03611335||Site 6 H+H|Woodhull Medical and Mental Health Center
62487243|NCT03510208|EXPERIMENTAL|Cohort 1 -50mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 50mg (Cohort 1) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
62487244|NCT03510208|EXPERIMENTAL|Cohort 2 -100mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 100mg (Cohort 2) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
61935257|NCT05816096|ACTIVE_COMPARATOR|A (Hall Technique)|"31 child will be treated by one performed metal crown using Hall technique on one of HSPM affected tooth.~The correct size of SSC for tooth will be selected. Use the separating rubber if necessary. Dried the tooth and cemented the SSC by glass ionomer luting cement and used finger pressure to seat the crown and instructed the child to bite down on the SSC.~Half of the total number of children will received performed metal crown at the first by divided them randomly to the two groups using the randomization table."
62487245|NCT03510208|EXPERIMENTAL|Cohort 3 -100mg panitumumab-IRDye800|Cohort 3 dose will be determined based on Cohort 1 and Cohort 2, with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery
62487246|NCT01573663|EXPERIMENTAL|Ambroxol and Levodropropizine|
62487247|NCT01573663|ACTIVE_COMPARATOR|Ambroxol|
62487248|NCT01573663|ACTIVE_COMPARATOR|Levodropropizine|
62487249|NCT03544216|EXPERIMENTAL|Single Vision First|Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.Therefore, this group will receive both study interventions.
62487250|NCT03544216|EXPERIMENTAL|Multifocal first|Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks. Therefore, this group will receive both study interventions.
62487251|NCT04231643|EXPERIMENTAL|Bipolar Disorder|adults with bipolar disorder
62487252|NCT04231643|ACTIVE_COMPARATOR|Healthy Volunteers|adults with no psychiatric disease
62487253|NCT04604938|EXPERIMENTAL|Losartan group|Drug: Losartan
62487254|NCT04604938|PLACEBO_COMPARATOR|Placebo group|Drug: Placebo Oral Tablet
62487255|NCT00013390|ACTIVE_COMPARATOR|1|Tinnitus Masking
62487256|NCT00013390|OTHER|2|Tinnitus Retraining Therapy
62487257|NCT02277093|EXPERIMENTAL|Pacritinib|"* Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID)~* Pacritinib should be take at approximately the same times every day with a glass of water, with or without food"
62487258|NCT06595342||Patients with cervical/intracranial arteries stenosis|Investigators plan to enroll 60000 patients with cervical/intracranial arteries stenosis including mild stenosis, moderate stenosis, severe stenosis or occlusion.
62487259|NCT05920486|EXPERIMENTAL|High-Intensity Laser Therapy (HILT) Group|Participants in the HILT group will receive an 8-week course of High-Intensity Laser Therapy (HILT) for the treatment of sacroiliitis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. Participants will receive no other specific interventions during the study period.
62487260|NCT05920486|SHAM_COMPARATOR|Sham-Control Group|Participants in the sham-control group will receive a sham HILT treatment for the treatment of sacroiliitis. The sham treatment will be delivered using a device that looks like the HILT device, but does not emit laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. Participants will receive no other specific interventions during the study period.
62487261|NCT02729987|EXPERIMENTAL|Minimum Support Group (MSG)|Intervention group with 8 week access to the online stress management programme with minimal support from a coach (WorkGuru).
62487262|NCT02729987|EXPERIMENTAL|Discussion Group|Intervention group with 8 week access to the online stress management programme with minimal support from a coach, plus access to an online facilitated messaging board (WorkGuru).
62487263|NCT02729987|NO_INTERVENTION|Waiting List Control (WLC)|Control group with access to the intervention after 16 weeks
62487264|NCT02878148|EXPERIMENTAL|Patients with suspected acute uncomplicated renal colic|Diagnostic imaging
62693518|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with Pembrolizumab followed by surgery|TransCon IL-2 β/γ using the RP2D with Pembrolizumab followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
62134839|NCT00068458|ACTIVE_COMPARATOR|Arm 2: Exercise + Calcium-Rich Diet|Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
62134840|NCT00068458|ACTIVE_COMPARATOR|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|Dietary counseling + materials promoting strength training and aerobic activity + a diet that has \< 20% of energy coming from fat and intakes of fruits and vegetables of \> 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
62329329|NCT05239949|EXPERIMENTAL|Pelvic floor muscle exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of pelvic floor muscle exercises. A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform pelvic floor muscle exercises in a sitting position. The patient is instructed to hold each contraction for 6 seconds, with three to four contractions added on the top. Four sets of 10 repetitions with a 2-minute interval between each set will be performed."
62329330|NCT02460926|EXPERIMENTAL|Scaling & Root Planing - Quadrant|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. Q-SRP patients received four quadrants sessions of PT with an interval of 1 week between sessions
62329331|NCT02460926|EXPERIMENTAL|Scaling & Root Planing - Full Mouth|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. FM-SRP patients received treatment within 24 hrs in two separate sessions, one side of the mouth for each session: two quadrants were instrumented in an afternoon session, whereas the other two were instrumented the following morning
62329332|NCT01926041|EXPERIMENTAL|Intervention|A 16-week FIT2 program that combines smoking cessation therapy with individualized behavior coaching in diet and physical activity for PCWG restriction.
62329333|NCT01926041|NO_INTERVENTION|Control|Usual care
62329334|NCT03930680|EXPERIMENTAL|Dexrazoxane 100mg/m2|one dose of 100mg/m2 dexrazoxane
62329335|NCT03930680|EXPERIMENTAL|Dexrazoxane 200mg/m2|one dose of 200mg/m2 dexrazoxane
62329336|NCT03930680|EXPERIMENTAL|Dexrazoxane 300mg/m2|one dose of 300mg/m2 dexrazoxane
61935258|NCT05816096|EXPERIMENTAL|B (ART)|"31 child will be treated by Bulk fill glass hybrid restorative system (Equia Forte HT®) using Atraumatic restoration treatment on one of HSPM affected tooth.~Isolate the tooth by cotton rolls, remove the carious soft tissue using hand instrument excavators then condition the cavity with a polyacrylic acid solution 11.5% for 10 seconds. After washed and dried the cavity insert the GIC and protect it by Equia forte coat.~Half of the total number of children will received ART at the first by divided them randomly to the two groups using the randomization table."
62134841|NCT05145205||LSG|
62134842|NCT05145205||RYGB|
62134843|NCT03769870|OTHER|Teneligliptin|
62329337|NCT03930680|EXPERIMENTAL|Dexrazoxane 400mg/m2|one dose of 400mg/m2 dexrazoxane
62329338|NCT03930680|EXPERIMENTAL|Dexrazoxane 500mg/m2|one dose of 500 mg/m2
62329339|NCT00658372|EXPERIMENTAL|PD 0332334 225 mg BID|
62329340|NCT00658372|EXPERIMENTAL|PD 0332334 300 mg BID|
62329341|NCT00658372|ACTIVE_COMPARATOR|Paroxetine 20 mg QD|
62134844|NCT03769870|OTHER|Atorvastatin|
62134845|NCT03769870|OTHER|Teneligliptin + Atorvastatin|
62134846|NCT04544982|ACTIVE_COMPARATOR|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
62487265|NCT00795821|EXPERIMENTAL|LY2216684|"10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.~1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
61935259|NCT02119169|EXPERIMENTAL|pigtail catheter|Pigtail catheter for pleural drainage of recurrent hepatic hydrothorax
61935260|NCT01061983|EXPERIMENTAL|Deep Brain Stimulation|Participants will receive deep brain stimulation.
61935261|NCT02171572|EXPERIMENTAL|Dabigatran etexilate low|
61935262|NCT02171572|EXPERIMENTAL|Dabigatran etexilate high|
61935263|NCT05727462|EXPERIMENTAL|Manual Therapy with TECAR|Participants allocated to this group received 15 sessions of a manual therapy protocol applied by two resistive TECAR bracelet electrodes (one in each hand).
62134847|NCT04544982|PLACEBO_COMPARATOR|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
62134848|NCT00084396|EXPERIMENTAL|Letrozole/Surgery|
62329342|NCT00658372|PLACEBO_COMPARATOR|Placebo BID|
62329343|NCT01839188|EXPERIMENTAL|PR5I (V1); Pediacel® (V2); PR5I (V3)|\[Vaccination 1\]: Single doses of PR5I (V419) + NeisVac-C® + Prevenar 13® by intramuscular (IM) injection + oral RotaTeq®, given at 2 months of age. \[Vaccination 2\]: Single doses of Pediacel® + NeisVac-C® + Prevenar 13® by IM injection + oral RotaTeq®, given at 4 months of age. \[Vaccination 3\]: Single dose of PR5I (V419) by IM injection + oral RotaTeq®, given at 6 months of age.
62329344|NCT03342391|OTHER|Treatment Phase|Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
62329345|NCT00390000|EXPERIMENTAL|Arm I|See Detailed Description
62329346|NCT06103695|OTHER|Vtama|open label Vtama
62329347|NCT02588248|EXPERIMENTAL|Peppermint Oil|"Solution A) Peppermint oil solution (1.6% peppermint oil, which is 0.8% L-menthol)~Ingredients:~1. 16mL of peppermint oil (provided by the NowFoods® company)~2. 0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~3. 1L prepackage sterile water~4. 2.6mL of undyed simethicone"
62329348|NCT02588248|PLACEBO_COMPARATOR|Placebo|"Solution B) Placebo solution~Ingredients:~1. 0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~2. 1L prepackage sterile water~3. 2.6mL of undyed simethicone~   Instructions to prepare:~4. Add tween and simethicone to sterile water. Then, shake vigorously.~5. Once solution has settled, and patient has been randomized, draw 20mL of solution into a plastic syringe"
62329349|NCT04645459|EXPERIMENTAL|low phosphorus meal group (LP group)|The proteins of the low phosphorus meal had been removed by an average 20 -30% of the phosphorus through boiling the meats before cooking process.
62329350|NCT04645459|PLACEBO_COMPARATOR|control group|The boiling method did not process for the control meals.
62329351|NCT01893190|ACTIVE_COMPARATOR|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
62329352|NCT01893190|EXPERIMENTAL|Nimodipine Microparticles|Single intraventricular injection
62329353|NCT03766750|EXPERIMENTAL|LIMA|
62329354|NCT03766750|ACTIVE_COMPARATOR|Tradjenta®|
62329355|NCT03766750|ACTIVE_COMPARATOR|Forxiga®|
62329356|NCT01060735|EXPERIMENTAL|Larger doses of vitamin D supplementation|The subjects enrolled in this arm will be supplemented during the third trimester of pregnancy with 2000IU vitamin D per day
62329357|NCT01060735|NO_INTERVENTION|Conventional vitamin D supplementation|Regular supplementation during pregnancy with 400IU vitamin D
62487266|NCT00795821|PLACEBO_COMPARATOR|Placebo|"10-week Acute Treatment Phase: 3 tablets QD for 10 weeks~1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
61935264|NCT05727462|ACTIVE_COMPARATOR|Manual Therapy without TECAR bracelet electrodes|Participants allocated to this group received the same Manual Therapy protocol without the resistive TECAR bracelet electrodes
61935265|NCT05162859||Former Exercise Training|Patients that were randomized to high-intensity-interval training, moderate continuous training (OptimEx-Clin) or moderate continuous training + resistance training (Ex-DHF)
61935266|NCT05162859||Former Control|Patients that were randomized to guideline control (OptimEx-Clin) or usual care (Ex-DHF)
62329358|NCT05946135|ACTIVE_COMPARATOR|Control|lansoprazole + placebo for Fexuprazan Hydrochloride
62329359|NCT05946135|EXPERIMENTAL|Intervention|placebo for lansoprazole + Fexuprazan Hydrochloride
62487267|NCT06432751||Cohort|Adults patients with pre-operative simplified predictive risk index for renal replacement therapy after cardiac surgery ≥2, with cardiac surgery performed in Louis Pradel Hospital between 08/2022 and 02/2024.
62487268|NCT01007994|ACTIVE_COMPARATOR|New Medication|A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.
62487269|NCT01007994|NO_INTERVENTION|Control|Subjects in the control group will continue to take their medications as usual.
61935267|NCT05036369|EXPERIMENTAL|Active capsule|The Vibrant non-biodegradable capsule administrated twice a week
61935268|NCT05036369|PLACEBO_COMPARATOR|Placebo|The placebo capsule is a softgel biodegradable capsule which is visually similar to the Vibrant active capsule and administrated twice a week
62134849|NCT05598359|EXPERIMENTAL|TA-65|TA-65 (250 U) taken once per day
62134850|NCT05598359|PLACEBO_COMPARATOR|Placebo|Placebo taken once per day
62134851|NCT04804566||ERT User- Did Not Switch to Galafold|ERT users with mutation amenable to Galafold who did not switch
62134852|NCT04804566||ERT User- Switched and Stayed on Galafold|ERT users with the mutation amenable to Galafold who switched and stayed on Galafold
62134853|NCT04804566||No Previous Therapy- Started Galafold and Stayed On|Those naïve to therapy with the mutation amenable to Galafold who went on and stayed on Galafold
62693519|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion:TransCon IL-2 β/γ with TransCon TLR7/8 Agonist followed by surgery|TransCon IL-2 β/γ with TransCon TLR7/8 Agonist using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
62693520|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion:TransCon IL-2 β/γ + Pembrolizumab + SOC Chemo followed by surgery|TransCon IL-2 β/γ using the RP2D with Pembrolizumab and SOC Chemotherapy followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
62693521|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion|TransCon IL-2 β/γ + Pembrolizumab TransCon IL-2 β/γ using the RP2D with Pembrolizumab
61935269|NCT00474838|ACTIVE_COMPARATOR|Oral AntiDiabetic Drug|glimepiride and metformin and/or once daily glargine
61935270|NCT00474838|EXPERIMENTAL|intensive insulin group|insulin glargine insulin glulisine
62329360|NCT06624085|EXPERIMENTAL|Gemcitabine + Glofitamab + Oxaliplatin|Participants will receive a single dose of intravenous (IV) obinutuzumab pretreatment 7 days prior to the first dose of glofitamab, followed by up to 8 cycles of glofitamab + gemcitabine + oxaliplatin. This will be followed by up to 4 cycles of glofitamab monotherapy, for a total of up to 12 cycles of glofitamab (cycle length = 21 days).
62329361|NCT01532271||Concussed|Patients with recent concussion
62329362|NCT01532271||Matched controls|Athletes with no recent concussion
62329363|NCT04156750|EXPERIMENTAL|LY3556050 (Part A)|LY3556050 administered orally.
62329364|NCT04156750|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally.
62329365|NCT04156750|OTHER|Iohexol (Part B)|Iohexol given intravenously (IV). (Part B is optional.)
62329366|NCT04156750|OTHER|Metformin (Part B)|Metformin given orally. (Part B is optional.)
62329367|NCT04156750|EXPERIMENTAL|LY3556050+ Iohexol (Part B)|Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)
62487270|NCT02152046||Spring loaded retractor|The Alfonso Eyelid Speculum, newborn size
61935271|NCT06130917|EXPERIMENTAL|Experimental Group|Experimental group will receive education on diabetes and conventional treatment exercises. The interventional multisystem exercises program will consist of four components, with each exercise lasting for a duration of 10 minutes per session. These components encompass proprioception training, balance exercises, strengthening routines, and reaction time training. This total multisystem exercises session will be performed for 30 minute, 3 times a week for 8 weeks in total.
61935272|NCT06130917|OTHER|Control group|Control group will receive health education on diabetes. Conventional treatment will include Stretching, Range of motion (ROM) exercise , balance and strengthening for 10 minutes each exercise in one session. Each stretch holds for 15-20 sec. This exercise session will be performed for 30 minute, 3 times a week for 8 weeks in total.
61935273|NCT02026960|EXPERIMENTAL|Renal Cell Carcinoma Tumor Tissue|
62134854|NCT04804566||No Previous Therapy- No Current Therapy|Those who were naïve to therapy with the mutation amenable to Galafold and have never been on any therapy.
62134855|NCT04804566||ERT Users- Switched and Discontinued Galafold|Participants who are ERT users with an amenable mutation who switched to and later discontinued Galafold
62134856|NCT04804566||No Previous Therapy- Started Galafold and Discontinued|Participants who are naïve to therapy with an amenable mutation, went on Galafold, and discontinued
62329368|NCT04156750|EXPERIMENTAL|LY3556050 + Metformin (Part B)|Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)
62329369|NCT05701969|EXPERIMENTAL|Melatonin group|These subjects will receive melatonin
62329370|NCT05701969|PLACEBO_COMPARATOR|Placebo group|These subjects will receive placebo
62329371|NCT06459531|EXPERIMENTAL|Virtual Reality (VR) Therapy|
62329372|NCT06459531|OTHER|Conservative Treatment|
62329373|NCT03196505|ACTIVE_COMPARATOR|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
62329374|NCT03196505|ACTIVE_COMPARATOR|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
62329375|NCT05526170||Patients with previously diagnosed paroxysmal or persistent atrial fibrillation|Patients with previously diagnosed paroxysmal or persistent atrial fibrillation who are in sinus rhythm at inclusion time. During trial period subjects will be monitored for different atrial arrhythmias and divided into the following subgroups: atrial fibrillation, atrial flutter, atrial tachycardia, premature atrial contractions (bigeminy, trigeminy, couplets), multiple atrial arrhythmias and no arrhythmia detected.
62329376|NCT00718419|EXPERIMENTAL|A: Enzastaurin|
62487271|NCT02152046||Screw retractor|Cook Eyelid Speculum, infant size
62487272|NCT01412281|EXPERIMENTAL|Group A - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
62487273|NCT01412281|ACTIVE_COMPARATOR|Group B - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
62329377|NCT00342342||Beaver Dam Eye Study|Individuals over 45 years of age enrolled in Beaver Dam Wisconsin
62487274|NCT01412281|EXPERIMENTAL|Group C - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
62693522|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ monotherapy|TransCon IL-2 β/γ monotherapy
62693523|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ + trastuzumab|TransCon IL-2 β/γ + trastuzumab
62693524|NCT05081609|EXPERIMENTAL|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ + trastuzumab emtansine (T-DM1)|TransCon IL-2 β/γ + trastuzumab emtansine (T-DM1)
62693525|NCT05081609|EXPERIMENTAL|Part 4 Combination Dose Optimization|TransCon IL-2 β/γ + Pembrolizumab TransCon IL-2 β/γ using the RP2D in titrating doses and/or different dose frequencies with Pembrolizumab
62693526|NCT06643910|EXPERIMENTAL|BST08|Intravenous infusion
62697578|NCT02287779|EXPERIMENTAL|SHP626|9/12 subjects -1x daily dose of 20mg for 12 days 9/12 subjects-1x daily dose of 40mg for 12 days 9/12 subjects-1x daily dose of 80mg for 12 days 9/12 subjects-1x daily dose of 120mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-1x daily dose of 160mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD) for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD; lower or higher than cohort 6) for 12 days 9/12 subjects-1x or 2x daily dose of SHP626 in an escalating titration (doses TBD). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days 9/12 subjects will take a 1x or 2x daily dose of SHP626 in escalating titration (doses TBD; lower or higher dose than cohort 8). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days
62134857|NCT03833440|EXPERIMENTAL|Durvalumab + Monalizumab|
62329378|NCT00342342||Framingham Eye Study|Subset of individuals from the Framingham Heart Study who received eye examinations
62329379|NCT01135953|EXPERIMENTAL|ARM 1 - CONTROL|Subject given tDCS every day of the week (5 sessions) at 2 mA.
62329380|NCT01135953|EXPERIMENTAL|Arm 2 - INCREASING|Subjects given increasing intensity during tDCS across the week (Monday 1mA, Tuesday 1.5mA, Wednesday 1.5 mA, Thursday 2 mA, Friday 2mA).
62329381|NCT01135953|EXPERIMENTAL|ARM 3 - CYCLOSERINE|D-cycloserine (100 mg) given on the Monday and Thursday sessions, administering tDCS at 2 mA.
62329382|NCT04006899||subj 1|Three commercially available BIA devices vs SBIS device
62329383|NCT03657680||ATQ Group|Convenience sample of patients from Porto Alegre (RS, Brazil) who were experiencing unilateral hip osteoarthritis and were submitted to THA in referral hospitals at least five months previously to data collection. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
62329384|NCT03657680||Control Group|The control group was composed of asymptomatic individuals from the community. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
62329385|NCT03347331|EXPERIMENTAL|Input function group|Each subject underwent a 90 min acquisition PET scan with concomitant arterial blood sampling
62329386|NCT03347331|EXPERIMENTAL|Test-retest group|Each subject underwent 2 PET scans distant from 1 to 3 weeks
62329387|NCT03781882|ACTIVE_COMPARATOR|Intervention group|All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds
62329388|NCT03781882|ACTIVE_COMPARATOR|Control group|All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma
62329389|NCT01544777|EXPERIMENTAL|Both Eyes|Model 751 IOL implanted in both eyes.
62329390|NCT01544777|EXPERIMENTAL|Single eye|Model 751 IOL in one eye
62329391|NCT01544777|ACTIVE_COMPARATOR|Control|Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
62329392|NCT06552520|EXPERIMENTAL|TQH2722 injection|TQH2722 injection, 14 days for a treatment cycle
62329393|NCT06552520|PLACEBO_COMPARATOR|Placebo of TQH2722 injection|Placebo of TQH2722 injection, 14 days for a treatment cycle
62329394|NCT04022174|EXPERIMENTAL|Moderate dosage training|
62329395|NCT04022174|EXPERIMENTAL|Intensive dosage training|
62329396|NCT02150369||Patient, care partner, primary nurse case|In Phase I of this pilot, a case is comprised of the metastatic RCC patient receiving IL-2, their care partner, and their primary nurse. In Phase II, the IL-2 patient can either have MM or metastatic RCC. The care partner for this study will be the family member or friend staying with the IL-2 patient throughout treatment.
62329397|NCT04875039|ACTIVE_COMPARATOR|Perineural dexamethasone|Addition of dexamethasone 2mg to local anesthetics in infraclavicular brachial plexus block
62329398|NCT04875039|EXPERIMENTAL|Perineural dexamethasone plus dexmedetomidine|Addition of dexamethasone plus dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
62329399|NCT04165343||Non-Alcoholic Fatty Liver Disease (NAFLD)|"Cohort: Patients with known Non-Alcoholic Fatty Liver Disease (NAFLD)~All patients will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood test"
62329400|NCT04165343||Healthy Control Subjects|"Cohort: Healthy controls~All healthy subjects will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood tests"
62329401|NCT04142047||HIV|Participants (ages 60 and above) with HIV
62329402|NCT04142047||Control|Participants (ages 60 and above) without HIV
62329403|NCT05117229|EXPERIMENTAL|MetaWear Sensor on radiograph|subjects being considered for surgical orthopedic surgery will have a MetaWear sensor added to their standard of care lateral sit to stand radiograph
62329404|NCT00035425|EXPERIMENTAL|A.|Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
62329405|NCT00035425|EXPERIMENTAL|B.|
62329406|NCT03286088|OTHER|Group A|TransEsophageal Echocardiography + TransThoracic Echocardiography
62329407|NCT03286088|OTHER|Group B|TransEsophageal Echocardiography + TransThoracic Echocardiography + cardiac Magnetic Resonance
62329408|NCT03286088|OTHER|Group C|TransEsophageal Echocardiography + TransThoracic Echocardiography + MitraClip
62329409|NCT04708392|EXPERIMENTAL|Tonic spinal cord stimulation|Patients are programmed with tonic (continuous) spinal cord stimulation for a period of four weeks.
62329410|NCT04708392|EXPERIMENTAL|Burst spinal cord stimulation|Patients are programmed with burst (intermittent) spinal cord stimulation for a period of four weeks.
62134858|NCT03833440|EXPERIMENTAL|Durvalumab + MEDI9447|
62329411|NCT05663359|ACTIVE_COMPARATOR|1940 nm|Endovenous laser at 1940 nm
62329412|NCT05663359|ACTIVE_COMPARATOR|1470 nm|Endovenous laser at 1470 nm
62134859|NCT03833440|EXPERIMENTAL|Durvalumab + AZD6738|
62134860|NCT03833440|ACTIVE_COMPARATOR|Docetaxel|
62134861|NCT03833440|EXPERIMENTAL|durvalumab+savolitinib|
62329413|NCT05556239|NO_INTERVENTION|The usual care group|The usual care group receives standard care in accordance to current clinical practice at Rigshospitalet
62487275|NCT01412281|ACTIVE_COMPARATOR|Group D - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
62329414|NCT05556239|EXPERIMENTAL|Resistance Exercise Training|Patients included in the intervention group will receive usual care plus the exercise training intervention.
62329415|NCT01137331|EXPERIMENTAL|K301|K301 applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
62329416|NCT01137331|PLACEBO_COMPARATOR|Placebo|Placebo applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
62329417|NCT00787696|EXPERIMENTAL|Skills Training|intervention group received information, motivation and skills training: condom application, assertive communication \& problem solving
62329418|NCT00787696|ACTIVE_COMPARATOR|Health Education|Comparsion group received information and motivation
62329419|NCT01247220|EXPERIMENTAL|Peripheral Laser + Ranibizumab|Angiography-directed peripheral laser + ranibizumab
62329420|NCT01247220|ACTIVE_COMPARATOR|Ranibizumab|Ranibizumab
62329421|NCT03649958|ACTIVE_COMPARATOR|HIRREM-SOP or Cereset|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time. This group will have 10 sessions.
62329422|NCT03649958|ACTIVE_COMPARATOR|Cereset 2x|Participants randomized to the Cereset 2x group will be seated in a comfortable zero-gravity chair identical to those in the HIRREM-SOP arm. They will listen to a pattern of musical notes linked to their brain activity patterns, but also receive intermittent very low level electrical stimulation of the scalp linked to brain activity. This group will only have 5 sessions,
62329423|NCT04594239|EXPERIMENTAL|Treatment, needle|
62693527|NCT06570330|EXPERIMENTAL|Intervention - SuperHMO|"The investigation product is commercially available and is marketed as SuperHMO Prebiotic Mix with 5 HMOs. This product is a dietary supplement which contains five major types of human milk oligosaccharides includes 2'-Fucosyllactose (2'-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 6'-Sialyllactose (6'SL), and 3'-Sialyllactose (3'SL). SuperHMO is designed to boost the number and variety of beneficial bacteria in the gut by feeding them with five different kinds of human milk oligosaccharide prebiotics. This product does not contain any flavoring, colorants, preservatives or fillers. Each bottle contains 118 grams of the mix, 28 servings, with 4.2 grams per serving (2 scoops).~Study participants will be instructed to take 1 scoop (2.1 g) per day for the first five days and increase to 2 scoops (4.2g) per day for days 6-30, the formulation can be dissolved in their beverage of choice and taken at any time of the day, with or without food."
62697579|NCT02287779|PLACEBO_COMPARATOR|Placebo|Three subjects per cohort will take a matched placebo
62697580|NCT05715021|EXPERIMENTAL|Bankart repair + Remplissage (randomized cohort)|Arthroscopic repair of anterior capsulo-labral structures
62697581|NCT05715021|NO_INTERVENTION|Conservative treatment (randomized cohort)|Non surgical intervention
61935274|NCT02026960|EXPERIMENTAL|Genitourinary tumor tissue (Expansion cohort)|Bladder, prostate or testicular cancer
62134862|NCT05618951|EXPERIMENTAL|Group A: Lower Trapezius Strengthening Exercises|"Hot pack at neck area, upper trapezius stretching neck isometrics transverse mobilization glide and~Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra and Standardized Physical Therapy treatment will be given as Hot pack at neck area, upper trapezius stretching, neck isometrics and transverse mobilization glide."
62134863|NCT05618951|NO_INTERVENTION|Group B: Standardized Physical Therapy|"Hot pack at neck area, upper trapezius stretching neck isometrics transverse mobilization glide~Group B given Standardized Physical therapy management"
62134864|NCT01248260|EXPERIMENTAL|Higher-strength folic acid|Higher-strength folic acid (4mg).
62134865|NCT01248260|NO_INTERVENTION|Low-strength folic acid|Low-strength (0.8mg) folic acid (standard of care)
62134866|NCT00006017|ACTIVE_COMPARATOR|Rebeccamycin 1 day|Patients receive rebeccamycin analogue IV over 1 hour on day 1.
62134867|NCT00006017|ACTIVE_COMPARATOR|Rebeccamycin 5 day|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.
62134868|NCT01298076|ACTIVE_COMPARATOR|AVASTIN|intravitreal bevacizumab
62134869|NCT01298076|ACTIVE_COMPARATOR|OZURDEX|intravitreal dexamethasone
62134870|NCT00504322|PLACEBO_COMPARATOR|placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
62134871|NCT00504322|ACTIVE_COMPARATOR|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
62134872|NCT01532388|EXPERIMENTAL|eScreen|Web based self-monitoring of problematic alcohol and drug use.
62134873|NCT01532388|NO_INTERVENTION|Control group|Untreated control group
62329424|NCT04594239|EXPERIMENTAL|Treatment, cannula|
62329425|NCT04594239|OTHER|Untreated-control / delayed-treatment, needle|
62329426|NCT04594239|OTHER|Untreated-control / delayed-treatment, cannula|
62329427|NCT01386580|EXPERIMENTAL|2B3-101 Single Agent Dose Escalation|Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
62487276|NCT04800718|EXPERIMENTAL|Door-to-door screening|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
61935275|NCT04268589|NO_INTERVENTION|control group|routine study
61935276|NCT04268589|EXPERIMENTAL|virtual reality group|Three days a week, 2 times a day, 15 minutes in the morning and in the evening for 9 days in total
61935277|NCT05910177|EXPERIMENTAL|Karelizumab combined with etoposide and cisplatin group|The cycle dose should be strictly controlled according to the experimental design. The order of administration is as follows: Karelizumab → Cisplatin → Etoposide (with an interval of at least 30 minutes)
61935278|NCT01906593||Tiantan biologial's vaccine|Tiantan Biological's vaccine group is the population injected with this vaccine.
61935279|NCT01906593||other group|Other vaccine group is the population injected with other manufacturers' vaccine except Tiantan Biological CO, Ltd.
61935280|NCT00287651|ACTIVE_COMPARATOR|2|Patients with diagnosed Diabetic Retinopathy are enrolled as treated with pulsatile intravenous insulin or as a control patient with weekly treatment sessions. Baseline and quarterly fundus photography is performed to measure and monitor progress.
61935281|NCT00287651|NO_INTERVENTION|1|Patients diagnosed with Diabetic Retinopathy are enrolled as control patients that do not receive the pulsatile intravenous insulin therapy. Control patients come into the center receive baseline fundus photography and quarterly fundus photography to measure progress and outcomes of diabetic retinopathy and are compared to the patients who receive pulsatile intravenous insulin therapy.
61935282|NCT00210132|EXPERIMENTAL|Ropivacaine|
61935283|NCT02164773|ACTIVE_COMPARATOR|magnesium sulfate|magnesium sulfate 50mg caudal 1ml(5%) prepared after addition of 9ml of 0.9%normal saline to 1ml of 500mg(50%)of magnesium sulfate to be added to 1ml/kg of 0.25%of bupivacaine in caudal block in children undergoing lower abdominal surgery under sevoflurane anesthesia to prevent emergence agitation.
61935284|NCT02164773|PLACEBO_COMPARATOR|o.9%normal saline|0.9% of normal saline added to the conventional 0.25% bupivacaine in caudal block.
61935285|NCT01155505|EXPERIMENTAL|CC-5013 in combination with Paclitaxel|"Cohorts of 3 evaluable patients will initially be entered within each dose level, sequentially. In each dose level the second and third patient will enter 2 weeks after the first one. The second and third patient may be treated simultaneously, except if a DLT is reported in the first patient, in which case the second and third patient should be treated sequentially, at least one week apart.~Dose escalation will be done when all the patients included in each DL will finish the first treatment cycle. Three additional patients will be sequentially entered (separated by one week each other) if one DLT is observed in cycle 1 among the first 3 patients entered within a dose level. If a DLT is observed in a second patient at this dose level, no further dose escalation will be allowed and the dose level will be considered the MTD.~Once the RD (one level below the MTD) has been defined, additional patients (up to 12) will be treated in order to confirm the safety profile of the combination."
61935286|NCT06008028|EXPERIMENTAL|BR1015|
61935287|NCT06008028|ACTIVE_COMPARATOR|BR1015-1 + BR1015-2|
62134874|NCT02210442|EXPERIMENTAL|Educaguia intervention|Implementation of practice clinical guidelines with educational games
62329428|NCT01386580|EXPERIMENTAL|2B3-101 in combination with trastuzumab|HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
62487277|NCT04800718|NO_INTERVENTION|Routine awareness activities,Control Arm|The control arm VC will continue its routine awareness activities \& health talk sessions in the community.
62487278|NCT03028545|OTHER|schizophrenia|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in schizophrenia
62487279|NCT03028545|OTHER|bipolar disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in bipolar disorders
62487280|NCT03028545|OTHER|eating disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in eating disorders
62693528|NCT06570330|PLACEBO_COMPARATOR|Control|Control participants will receive a commercially available maltodextrin, NOW Sports Nutrition, Non-GMO corn Maltodextrin, Rapid Absorption. The composition and absorption properties are similar to the investigational product and will be given in the same dosage (2.1g/day for days 1-5 and increasing to 4.2 g/day for days 6-30) and route of administration as the investigational product. The use of maltodextrin as a comparator in prebiotic supplementation in human trials is well-documented.
62134875|NCT02210442|ACTIVE_COMPARATOR|Control group|Implementation of clinical practice guidelines with standard practice care
62134876|NCT05356676|EXPERIMENTAL|Isometrics|They will be treated with progressive isometric exercises added to 60 min of combined therapy (excluding scapular stabilizing exercises) treatment session at alternative 3 days/week for 8weeks
62134877|NCT05356676|EXPERIMENTAL|Combination Therapy|They will be treated with both isometric and scapular stabilizing exercises.and will get 60minutes of treatment sessions at alternative 3 days/week for 8weeks
62134878|NCT00130546|ACTIVE_COMPARATOR|1|Cypher Stent
62134879|NCT00130546|ACTIVE_COMPARATOR|2|Taxus Stent
62134880|NCT02966613|ACTIVE_COMPARATOR|CI|TKA using conventional instrumentation (CI)
62329429|NCT01386580|EXPERIMENTAL|2B3-101 solid tumor expansion|Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
62487281|NCT03028545|OTHER|personality disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in personality disorders
62487282|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
62487283|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
62487284|NCT02775994|EXPERIMENTAL|Treatment Arm|Single dose of Canakinumab 4mg/kg
62134881|NCT02966613|EXPERIMENTAL|PSCG|TKA performed using Patient specific cutting guides (PSCG)
62134882|NCT02966613|EXPERIMENTAL|PSCG-D|TKA performed using fully disposable Patient specific cutting guides (PSCG-D)
62134883|NCT01602640|EXPERIMENTAL|Morphine|
62134884|NCT01602640|ACTIVE_COMPARATOR|Fentanyl and Midazolam|Control
62487285|NCT02799992|ACTIVE_COMPARATOR|Half Dose Photodynamic Therapy|Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
62329430|NCT01386580|EXPERIMENTAL|2B3-101 glioma expansion|Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
62329431|NCT01441440|EXPERIMENTAL|venlafaxine ER 75 mg/day (fixed dose)|
61935288|NCT05986760|EXPERIMENTAL|SPARK|The SPARK is an evidence based plan designed to improve health-related well-being and to maintain the positive socialization and enjoyment of physical activities or academic achievements.(4) The SPARK discipline is in line with NASPE (National Association of Sport and PE) guidelines. A standard SPARK lesson will be delivered in two parts: a health fitness activity and a skill-fitness activity. In the health fitness activity part, there will be 13 activities that include aerobic dance, running games and jump ropes. In this part, the main focus will be on developing cardiovascular endurance and promotion by modifying the intensity, duration and complexity of the activities. The activities will be mostly aimed to develop abdominal and upper body strength.
62693529|NCT04670484|OTHER|Healthy subjects wearing masks|Subjects wearing masks to prevent coronavirus infection spread in COVID19 pandemic
62693530|NCT01500135|EXPERIMENTAL|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
61935289|NCT05986760|EXPERIMENTAL|Fundamental Motor training|In terms of motor development, fundamental motor skills (FMS, e.g., locomotor and object manipulation)-such as running, jumping, throwing, and kicking-are considered the essential building blocks for further, more complex gross motor movement. (24) There will be 13 FMS activities including; running, jumping, Gallop, hopping, side gliding, skipping, leaping, catching, stationary dribbles, kicking, striking a stationary ball, overarm throw and underarm throw. FMS group will receive 30 sessions for 10 weeks (3 sessions per week, 60 min per session including CPT).
61935290|NCT05341934|ACTIVE_COMPARATOR|Conditionning|
62329432|NCT01441440|EXPERIMENTAL|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|
62693531|NCT01500135|ACTIVE_COMPARATOR|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
62693532|NCT06106568||EOB-MRI|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI
62693533|NCT06106568||non-EOB-MRI|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MBI
62693534|NCT06106568||EOB-MRI with surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI and surgery
62693535|NCT06106568||non-EOB-MRI with surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MRI but with a record of surgery
62693536|NCT06106568||EOB-MRI without surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI but without a record of surgery
62329433|NCT01441440|PLACEBO_COMPARATOR|Placebo|
62693537|NCT06106568||non-EOB-MRI without surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MRI or surgery
62693538|NCT06106568||EOB-MRI with an open-close laparotomy|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI and an open-close laparotomy
62693539|NCT06106568||non-EOB-MRI with an open-close laparotomy|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MRI but with a record of an open-close laparotomy
62693540|NCT04357470|ACTIVE_COMPARATOR|USF Group|DRF with ulnar styloid fracture
61935291|NCT05341934|PLACEBO_COMPARATOR|Placebo|
61935292|NCT01782911|EXPERIMENTAL|Resveratrol|Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.
62329434|NCT00830037|EXPERIMENTAL|IV Iron|
62329435|NCT00830037|ACTIVE_COMPARATOR|Oral Iron|
62329436|NCT05992519||People suspected with asthma|"Patients will receive an in invitation letter at the time of BPT scheduling. In the week proceeding the test, the clinical inhalation therapist will discuss the project and schedule the study visit on the day of the BPT. The study visit will be done prior to BPT whenever possible.~Baseline visit:~* Medical history~* 5-item Asthma Control Questionnaire (ACQ-5)~* FeNO measurement (NIOX VERO device)~* Nasosorption for nasal epithelial lining fluid (NELF) biobanking~* blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO),~* urine sample (biobank)"
62693541|NCT04357470|ACTIVE_COMPARATOR|NON-USF Group|DRF without ulnar styloid fracture
62693542|NCT02133872|OTHER|Minocycline Dose Escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
62693543|NCT06643585|EXPERIMENTAL|Arm A|Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
62693544|NCT06643585|ACTIVE_COMPARATOR|Arm B|Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)
62329437|NCT03572270|EXPERIMENTAL|case|PLWH
62329438|NCT03572270|OTHER|control|HIV negative women, going to medically assisted procreation consultation for male infertility
62329439|NCT05058664|NO_INTERVENTION|Control (standard care)|
62487286|NCT02799992|EXPERIMENTAL|689 nm Laser Treatment|A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
62487287|NCT03780608|EXPERIMENTAL|GC|Patients with refractory gastric cancer who have failed secondary chemotherapy treatments for advanced disease will be enrolled. Patients must have imaging confirmed progression on previous chemotherapy for gastric cancer treatment with at least one measurable lesion per modified RECIST 1.1. GC patients must not have received previous therapy with immune checkpoint inhibitors. Prior exposure to AZD6738 is not allowed.
62487288|NCT03780608|EXPERIMENTAL|Melanoma|Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.
62329440|NCT05058664|EXPERIMENTAL|A-F texting component|The A-F texting component will include content consistent with best-practice recommendations for parents to buffer youth against suicide risk.
62329441|NCT05058664|EXPERIMENTAL|A-F texting plus P-F texting component|A-F texting plus P-F texting component arm includes the A-F component, as above, and P-F component. The P-F component includes an embedded micro-randomized trial (MRT) involving two daily randomizations to P-F message vs. no message conditions for the duration of the 6-week intervention. Participants who are randomized to this arm will be randomized twice each day (morning and evening) to either receive or not receive the P-F message at each randomization.
62329442|NCT02742077|OTHER|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
62329443|NCT03063775|ACTIVE_COMPARATOR|1. Mucograft® Seal + Bio-Oss®|
62329444|NCT03063775|ACTIVE_COMPARATOR|2. FGG + Bio-Oss®|
62487289|NCT05645081||Healthy Control|A group of participants with no previous symptoms or diagnosis of TIA or stroke.
62487290|NCT05645081||Non-TIA Control|A group of participants who were referred to TIA clinic with symptoms of a TIA, however, were subsequently confirmed as not suffering with a TIA.
62487291|NCT05645081||TIA, non-stroke|A group of participants who were confirmed as suffering a TIA by a stroke clinician following admission to hospital, admission to Accident and Emergency or after being referred to TIA clinic. These participants did not suffer a stroke within 12 months of TIA diagnosis.
62697582|NCT05715021|EXPERIMENTAL|Bankart repair + Remplissage (non-randomized cohort)|Arthroscopic repair of anterior capsulo-labral structures
62697583|NCT05715021|NO_INTERVENTION|Conservative treatment (non-randomized cohort)|Non surgical intervention
61935293|NCT01782911|PLACEBO_COMPARATOR|Control|Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.
62134885|NCT03822520|EXPERIMENTAL|Celecoxib, Moxifloxacin, Water in order|"1. Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~   Wash-out period (3\~6 days)~2. Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~   Wash-out period (3\~6 days)~3. Intervention Pure water: Water 150ml by mouth without any drug, once for one day"
62134886|NCT03822520|EXPERIMENTAL|Celecoxib, Water, Moxifloxacin in order|"1. Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~   Wash-out period (3\~6 days)~2. Intervention Pure water: Water 150ml by mouth without any drug, once for one day~   Wash-out period (3\~6 days)~3. Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day"
62134887|NCT03822520|EXPERIMENTAL|Moxifloxacin, Water, Celecoxib in order|"1. Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~   Wash-out period (3\~6 days)~2. Intervention Pure water: Water 150ml by mouth without any drug, once for one day~   Wash-out period (3\~6 days)~3. Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
62134888|NCT03822520|EXPERIMENTAL|Water, Moxifloxacin, Celecoxib in order|"1. Intervention Pure water: Water 150ml by mouth without any drug, once for one day~   Wash-out period (3\~6 days)~2. Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~   Wash-out period (3\~6 days)~3. Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
62134889|NCT01594957|EXPERIMENTAL|LCQ908 (mild hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with mild hepatic impairment and will receive a single dose of LCQ908.
62134890|NCT01594957|EXPERIMENTAL|LCQ908 (moderate hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with moderate hepatic impairment and will receive a single dose of LCQ908.
62134891|NCT01594957|EXPERIMENTAL|LCQ908 (severe hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with severe hepatic impairment and will receive a single dose of LCQ908.
62134892|NCT00910338|EXPERIMENTAL|PFMT with Extracorporeal Biobeedback|
62134893|NCT06450301||Thin endometrial lining|"Patients following long-term use of oral contraceptives with known thin endometrial lining (less than 7mm, confirmed in at least two cycles and unresponsive to estrogen-induced growth).~We will ask each woman to undergo an endometrial biopsy as part of the study during their luteal phase."
62134894|NCT06450301||Asherman's syndrome|Patients with Asherman's syndrome following Dilation and curettage (D\&C). We will ask each woman to undergo an endometrial biopsy as part of the study during their luteal phase.
62329445|NCT03063775|ACTIVE_COMPARATOR|3. FGG + Gelatine sponge (Spongostan®)|
62329446|NCT03063775|ACTIVE_COMPARATOR|4. Spongostan®+ Mucograft® Seal|
62329447|NCT03063775|NO_INTERVENTION|5. Spongostan®|
62329448|NCT02564159|EXPERIMENTAL|High-risk patient for malnutrition acquired in ICU|Patients admitted in ICU and treated with mechanical ventilation with expected duration of 48 hours or more
62329449|NCT02564159|OTHER|Controls patients: Elective surgery|"Controls patients: Elective surgery (neurosurgery, thoracic surgery, vascular surgery)~- Patients admitted in a post-operative care unit of the university hospital of Nantes after elective surgery with expected duration ICU length of stay \< 48 hours"
61935294|NCT03500471||Experimental: Robotic surgery|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy
61935295|NCT03500471||Compared: Laparoscopic surgery|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy
62487292|NCT05645081||TIA, stroke|A group of participants who were confirmed as suffering a TIA by a stroke clinician following admission to hospital, admission to Accident and Emergency or after being referred to TIA clinic. These participants went on to suffer a stroke within 12 months of TIA diagnosis.
62693545|NCT06357377|EXPERIMENTAL|Phase 1b safety, dose finding, brain-tumor delivery, and pharmacokinetics of IN NEO100|"Patients will receive IN NEO100 that will follow a dose titration design, followed by a standard dose escalation design to establish safety. Brain tumor delivery of NEO100 will be confirmed in each disease sub-type by surgical resection/needle biopsy only if clinically indicated and scheduled for clinical purposes and testing with residual tissue for NEO100 and the major metabolite of NEO100 (Perillic Acid).~The study will use a modified Fibonacci dose titration design, followed by a standard dose escalation design.~* Cohort 1: 192 mg NEO100, QID on a 28-day cycle~* Cohort 2: 288 mg NEO100, QID on a 28-day cycle~* Cohort 3: 384 mg NEO100, TID on a 28-day cycle;~* Cohort 4 (ceiling dose): 576 mg NEO100, BID on a 28-day cycle.~Patients undergoing surgical or needle biopsy (only when clinically indicated) will receive a minimum of four days IN NEO100 treatment prior to the procedure."
62693546|NCT05199844||Group A|cardiac patients with regular heart rate
62693547|NCT05199844||Group B|cardiac patients with irregular heart rate
61935296|NCT05770869|EXPERIMENTAL|ALIBIRD mHealth platform|Participants are followed-up using the ALIBIRD mHealth platform. The ALIBIRD platform is made up of a mobile application for patients and a web application for the healthcare team. Through the ALIBIRD mobile application, patients regularly register Patients Reported Outcomes (PROs) and Patients Reported Outcome Measures (PROMs) regarding lifestyle (diet, physical activity, sleep, mood), and get access to individualized recommendations in order to assume more responsibility for achieving the best outcomes from their care. Moreover, the patient application includes features for tracking the appearance of symptoms, with alerts sent to the healthcare team in response to these parameters. In addition, the application contains articles and educational information.
61935297|NCT06680154|ACTIVE_COMPARATOR|Transcranial alternating current stimulation|During tACS, an alternating electrical current with a 1 milliamp peak-to-peak amplitude will be delivered, featuring a 15-second ramp-up at the start and a 15-second ramp-down at the end. The stimulation duration is 20 minutes and four channels are used for delivering sinusoidal alternating currents to the head. The alternating current was delivered to the prefrontal cortex bilaterally with the electrodes at F3 and F4 and the return electrodes were placed at the ipsilateral mastoids at TP9 and TP10 (international 10-20 EEG electrode placement system).
61935298|NCT06680154|ACTIVE_COMPARATOR|intermittent theta burst stimulation|The intermittent theta burst stimulation (iTBS) is regarded as safe for high-frequency neuromodulation. The pulse bursts are applied for two seconds in 5Hz intervals followed by an eight-second break before the next bursts are applied. This pattern is repeated for 190 seconds resulting in 600 pulses per protocol. 80% of the individual subjects' active motor threshold (AMT) are used for stimulation intensity and will be applied four times within a 20-minute time frame starting at 0 minutes, 5 minutes, 10 minutes, and 15 minutes from the beginning of the intervention resulting in 2400 delivered pulses for the whole intervention
61935299|NCT06680154|ACTIVE_COMPARATOR|combited iTBS- tACS peak|To combine tACS and the iTBS protocol, a customized circuit is developed in-house to phase-lock the TMS pulses to the waveform generated by tACS. TMS pulses were delivered using two figure-of-eight shaped coils (double 70 mm, PMD coil type; Mag and More GmbH, Munich, Germany). For the stimulation, the center of the TMS coils are placed over the two prefrontal tACS electrodes (F3 and F4 electrode positions) with an orientation of 45 degrees to the midline and the handles pointing backward. Using the customized circuit, TMS pulses will be delivered at the peak of the tACS wave.
61935300|NCT06680154|ACTIVE_COMPARATOR|Combined iTBS-tACS trough|To combine tACS and the iTBS protocol, a customized circuit is developed in-house to phase-lock the TMS pulses to the waveform generated by tACS. TMS pulses were delivered using two figure-of-eight shaped coils (double 70 mm, PMD coil type; Mag and More GmbH, Munich, Germany). For the stimulation, the center of the TMS coils are placed over the two prefrontal tACS electrodes (F3 and F4 electrode positions) with an orientation of 45 degrees to the midline and the handles pointing backward. Using the customized circuit, TMS pulses will be delivered at the trough of the tACS wave.
61935301|NCT06680154|SHAM_COMPARATOR|sham|80% of the individual subjects' active motor threshold (AMT) four times within a 20-minute time frame starting at 0 minutes, 5 minutes, 10 minutes, and 15 minutes from the beginning of the intervention resulting in 2400 delivered pulses for the whole intervention
61935302|NCT06708416|EXPERIMENTAL|ONO-1110|ONO-1110 tablets once a day
61935303|NCT06708416|PLACEBO_COMPARATOR|Placebo|Placebo tablets once daily
61935304|NCT02273531|EXPERIMENTAL|Asasantin ER, new formulation|
61935305|NCT02273531|ACTIVE_COMPARATOR|Asasantin ER, present commercial formulation|
61935306|NCT05391542|EXPERIMENTAL|Coaxial tubular superelastic nickel-titanium Group (TuNT)|0.016-inch coaxial tubular superelastic nickel-titanium archwire (TuNT) (Speed tubular supercable, Speed System™ Orthodontics, Ontario, Canada) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks
61935307|NCT05391542|EXPERIMENTAL|Copper-nickel-titanium Group (CuNT)|0.014-inch Copper-nickel-titanium archwire (CuNT) (Damon Optimal-Force Copper Ni-Ti®, Ormco, Glendora, Calif) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks.
61935308|NCT05231681|EXPERIMENTAL|Eye Concealer|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer
61935309|NCT04185870|EXPERIMENTAL|3D scan and standard photography arm|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum. In addition, all participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
62134895|NCT06450301||Control|"Patients already scheduled to undergo an endometrial biopsy for infertility management.~We will ask each woman to undergo an endometrial biopsy as part of the study during their luteal phase. In some cases, we may be able to access archived endometrial samples from women in the control group who agree to participate and who have already had an endometrial biopsy."
62134896|NCT00604955|EXPERIMENTAL|A|Paromomycin IM Injection (approved product in India)
62487293|NCT00851305|EXPERIMENTAL|1 confocal laser endomicroscopy|Targeted biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by confocal laser endomicroscopy.
62693548|NCT01282398|EXPERIMENTAL|simvastatin|The experimental group will take simvastatin 40mg for at least two years.
62329450|NCT04032639||Prader-Willi Syndrome|24 children and adolescents (7-16 years) with diagnosed Prader-Willi Syndrome will be recruited
62329451|NCT04032639||Controls|24 children and adolescents (7-16 years) without diagnosed Prader-Willi Syndrome will be matched for age, sex, and BMI-percentile to the Prader-Willi group
62693549|NCT01282398|PLACEBO_COMPARATOR|placebo|the control group wiil take placebo pills for at least two years.
62693550|NCT03891446|EXPERIMENTAL|Lead-in study 192024-091 or -092 or -095|"Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.~Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
62693551|NCT03891446|EXPERIMENTAL|Lead-in study 192024-093 Stage 1|"Participants who received 1, 2 or 3 administrations and participants in Stage 2 who received 1 Bimatoprost SR administration due to safety concern or received 2 administrations.~Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.~Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
62693552|NCT03891446|EXPERIMENTAL|Lead-in study 192024-093 Stage 2|"Participants who received 1 Bimatoprost administration due to sustained efficacy:~Study eye (Eye that received Bimatoprost SR in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
62693553|NCT03891446|EXPERIMENTAL|Lead-in study ARGOS|"Study eye (Eye that received Bimatoprost SR first in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration.~Treated Fellow eye (Eye that received Bimatoprost SR second in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration.~Untreated Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Untreated fellow eye will receive only standard of care, based on the investigator's judgment."
62693554|NCT06569940|OTHER|Sleepiz One+ vs. gold standard|Each enrolled participant will undergo a simultaneous recording with the Sleepiz One+, Capnography device and cardiorespiratory polygraphy to measure respiration rate at and heart rate at rest, while sitting and lying down on a bed.
62693555|NCT03223987|EXPERIMENTAL|1|The study is one armed
62693556|NCT06641024|EXPERIMENTAL|MC-1-50|Patients will be be treated with CD19 CAR- T cells
61935310|NCT00093782|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR or PR receive 2 additional courses beyond CR or PR.
61935311|NCT04634838|OTHER|MedCu Antibacterial Wound Dressings with Copper Oxide|Wound dressings impregnated with copper oxide microparticles will be applied in wounds treated with antibacterial wound dressings with silver that their sizes were not reduced by at least 50% during three weeks of treatment.
61935312|NCT02494362|EXPERIMENTAL|Experimental Group|Computer gaming hand exercise regimen.
61935313|NCT00353639||IBD subjects|Subjects with Inflammatory Bowell Disease
61935314|NCT01033461|EXPERIMENTAL|calcium and probiotic|intervention
61935315|NCT01033461|EXPERIMENTAL|probiotic|intervention
61935316|NCT01033461|PLACEBO_COMPARATOR|placebo|placebo, no intervention
62134897|NCT04957849|ACTIVE_COMPARATOR|Trans-frontal keyhole approach|After general anesthesia, the patient was placed in supine position with head frame fixed. A straight or arc incision was made in the hairline of the affected side. The incision was 3cm beside the midline. The length of the incision was about 4cm and the diameter of the bone window was about 2.5cm. According to the preoperative thin-layer CT scan, the dura mater and part of the cerebral cortex were cut, and the endoport and other hard channels were inserted. The incision reached 2 / 3 of the length of the hematoma along the direction parallel to the long axis of the hematoma, During the operation, mini aneurysms were clipped to close the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity. The external drainage tube led out the skin through the subcutaneous tunnel, and the dura was sutured.
62329452|NCT02917187|EXPERIMENTAL|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
62329453|NCT02917187|EXPERIMENTAL|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
62329454|NCT02801630|SHAM_COMPARATOR|Sham Crossover|"After the enrollment and lead in period, subjects will be given a sham device to sleep with every night for a month. They will be asked to fill out their pain and analgesic use logs, and undergo the bi weekly assessments. After a month they will be crossed over to an active Painshield SAW patch device and will continue to complete their pain and analgesic use logs as well as undergo biweekly assessments for months two and 3."
62487294|NCT00851305|ACTIVE_COMPARATOR|2 Conventional endoscopy|Routine biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by conventional endoscopy.
61935317|NCT05330455|EXPERIMENTAL|Part 1 Cohort 1: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 1) + Placebo; in period 2: GSK3965193 (Dose 2) + Placebo; in period 3: GSK3965193 (Dose 3) + Placebo and in period 4: GSK3965193 (Dose 4) + Placebo. There will be a minimum of 7 days washout between dosing in each treatment period.
61935318|NCT05330455|EXPERIMENTAL|Part 1 Cohort 2: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 5) + Placebo; in period 2: GSK3965193 (Dose 6) + Placebo; in period 3: GSK3965193 (Dose 7) + Placebo and in period 4: GSK3965193 (Dose 8) + Placebo. There will be a minimum of 7 days washout between dosing in each period.
61935319|NCT05330455|EXPERIMENTAL|Part 2A Cohort 3: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses of either GSK3965193 (Dose X) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
61935320|NCT05330455|EXPERIMENTAL|Part 2A Cohort 4: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses of either GSK3965193 (Dose X) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
61935321|NCT05330455|EXPERIMENTAL|Part 2A Cohort 5: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses of either GSK3965193 (Dose X) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
61935322|NCT05330455|EXPERIMENTAL|Part 2B Cohort 6: GSK3965193|Healthy Participants will be randomized 1:1 to receive single doses of GSK3965193 (Dose A) under fasted and fed conditions in treatment period 1. In period 2, the participants who received GSK3965193 (Dose A) under fasted conditions in treatment period 1 will receive the same dose under fed conditions, and vice versa. In the third period, all participants will receive a single dose of GSK3965193 (Dose B) different strength under fasted conditions. The dose level for the third period will be selected based on the results of the first two periods. There will be a minimum of 7 days washout between dosing in each treatment period.
61935323|NCT05330455|EXPERIMENTAL|Part 3 Cohort 7: GSK3965193 or placebo|PLWCHB on stable nucleos(t)ide analog (NA) therapy will be randomized 3:1 to receive repeat dose of either GSK3965193 (Dose E) or placebo. This part will commence after completion of both Part 1 and Part 2.
61935324|NCT05330455|EXPERIMENTAL|Part 3 Sub-Cohort 7: Open label bepirovirsen|PLWCHB participants on stable NA therapy who have completed GSK3965193/placebo monotherapy (Part 3, Cohort 7) will be given the option to receive subsequent treatment of optional open label bepirovirsen only for 24 weeks.
62693557|NCT06571916|EXPERIMENTAL|Brief-SfSL (B-TAU)|Participants will receive the Brief-SfSL treatment within 1 week of their screening.
61935325|NCT05330455|EXPERIMENTAL|Part 4 Cohort 8: GSK3965193 and bepirovirsen or placebo and bepirovirsen|PLWCHB participants on stable NA therapy who have not participated in Part 3 of the study will be randomized 3:1 to receive repeat dose either GSK3965193 or placebo. In addition, all participants in this cohort will also receive bepirovirsen. This part will commence after completion of Part 3, contingent on the clinical safety and efficacy data from Part 3.
61935326|NCT05633654|EXPERIMENTAL|Sacituzumab govitecan-hziy (SG) + Pembrolizumab|"Participants will receive SG 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles for 8 cycles.~Treatment will be administered until a maximum of 8 cycles, local or distant disease recurrence, unacceptable toxicity, physician decision, consent withdrawal, or death."
61935327|NCT05633654|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC): Pembrolizumab or Pembrolizumab + Capecitabine|"Participants will receive one of the following TPC regimens determined prior to randomization:~* Pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles for 8 cycles OR~* Pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles and capecitabine 1000 mg/m\^2 orally twice daily on Days 1 through 14 of 21-day cycles for 8 cycles.~Treatment will be administered until a maximum of 8 cycles, local or distant disease recurrence, unacceptable toxicity, physician decision, consent withdrawal, or death."
61935328|NCT04663061|EXPERIMENTAL|High intensity medical weight loss (HIWL)|Participants randomized to the HIWL treatment group will be placed on a meal replacement-based weight loss protocol. Participants will consume a minimum of 80 grams of protein daily in 4-5 servings of meal replacement. Participants will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-24, caloric prescriptions will be between 1100 to 1600 calories a day, using a combination of meal replacements and food, for continued weight loss. Beyond week 25, caloric intake will be individually tailored to achieve continued gradual weight loss or maintenance of body weight based on individual weight loss goals. We will recommend continued use of at least 1 serving of meal replacement per day for maintenance of weight loss.
61935329|NCT04663061|ACTIVE_COMPARATOR|Diabetes self-management education (DSME)|"The DSME intervention will be administered and delivered at the Wake Forest Baptist Health Diabetes Center, located next to the Weight Management Center, by a team of certified diabetes educators, nurses, and nutritionists in group and individual settings.~The diabetes education program is accredited by the American Diabetes Association in recognition of meeting national standards for diabetes self-management education. The goal of the program is to provide participants with information to make informed decisions about how to best integrate diabetes management strategies into their daily lives. Assessment, planning, implementation, and evaluation are the basic components of the diabetes education process."
61935330|NCT04663061|EXPERIMENTAL|High intensity medical weight loss (HIWL) plus continuous glucose monitoring (CGM)|Participants randomized to the HIWL + CGM treatment group will be placed on a meal replacement-based weight loss protocol as described in the HIWL arm. In addition, the participants in this arm will receive a supply of continuous glucose monitors to use throughout the trial. The CGM we provide will give the patient instant feedback on blood glucose levels and be readable using a mobile phone device or an associated CGM reader. The data from the CGM will be integrated into the Carium app and used to help guide the patient's actions based on defined care pathways.
62693558|NCT06571916|NO_INTERVENTION|Wait List (WL-TAU)|Participants will be put on a wait list and receive the Brief-SfSL treatment 3 months after their screening.
61935331|NCT01425788|ACTIVE_COMPARATOR|Osiris Phleum pratense - Group A|"Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.~Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day"
62329455|NCT02801630|ACTIVE_COMPARATOR|Active Device|After the enrollent and lead in period, subjects will be given an active PainSHield SAW Patch device to sleep with every night. They will be asked to fill out their pain and analgesic use logs, and undergo bi weekly assessments. They will continue to use the device while completing their logs and undergoing assessments for 3 months.
62693559|NCT04155632|EXPERIMENTAL|N-acetylcysteine + Theta Burst Stimulation|
62693560|NCT04155632|SHAM_COMPARATOR|N-acetylcysteine + Sham Theta Burst Stimulation|
62693561|NCT04155632|EXPERIMENTAL|Placebo + Theta Burst Stimulation|
62693562|NCT04155632|NO_INTERVENTION|Placebo + Sham Theta Burst Stimulation|
62693563|NCT04573881|EXPERIMENTAL|HistoSonics System|
62693564|NCT05960201|EXPERIMENTAL|invasive lobular breast cancer|images for 90 minutes after F-18 FES injection
62693565|NCT00834197|EXPERIMENTAL|1|
62693566|NCT00834197|ACTIVE_COMPARATOR|2|
62329456|NCT03536312|NO_INTERVENTION|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
62134898|NCT04957849|ACTIVE_COMPARATOR|Trans-occipital keyhole approach|After general anesthesia, the patient was placed in prone position with head frame fixed. According to the preoperative thin-layer CT scan, the long axis of hematoma was perpendicular to the ground, and the occipital puncture point was found along the extension line of the long axis of hematoma. Taking the puncture point as the center, a straight or arc incision parallel to the sagittal sinus was taken. The length of the incision was about 4cm, and the diameter of the bone window was about 2.5cm, Endoport and other hard channels were inserted to reach 2 / 3 of the long diameter of the hematoma along the direction parallel to the long axis of the hematoma. Under the neuroendoscope, the hematoma was aspirated or resected in blocks. During the operation, mini aneurysm clamp was used to clamp the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity.
62134899|NCT01905462||Exposed cohort|Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.
62134900|NCT01905462||Non-exposed cohort|Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).
61935332|NCT01425788|ACTIVE_COMPARATOR|Osiris Phleum pratense - Group B|"Group B Up-dosing schedule:~Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day"
61935333|NCT01425788|ACTIVE_COMPARATOR|Osiris Phleum pratense - Group C|"Group C up-dosing schedule:~Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day"
61935334|NCT02562833|EXPERIMENTAL|Self-Management and exercise|
62134901|NCT02837211|EXPERIMENTAL|Tapered Diet|
62134902|NCT02837211|ACTIVE_COMPARATOR|Traditional Low Calorie Diet|
62134903|NCT00324350|ACTIVE_COMPARATOR|1|intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
62134904|NCT00324350|ACTIVE_COMPARATOR|2|standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
62134905|NCT04116372|EXPERIMENTAL|Empty Nest Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
62134906|NCT04116372|EXPERIMENTAL|Retirement Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
62134907|NCT04116372|NO_INTERVENTION|Empty Nest Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
62134908|NCT04116372|NO_INTERVENTION|Retirement Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
62134909|NCT05878470|EXPERIMENTAL|Brief video intervention|Brief (119 seconds) social contact-based video
62134910|NCT05878470|NO_INTERVENTION|Non-intervention control|Non-intervention control
62329457|NCT03536312|OTHER|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
62329458|NCT05126368|EXPERIMENTAL|Eyhance toric II|The Eyhance toric II intraocular lens will be implanted in one of the patients eyes during cataract surgery
62134911|NCT01910896|EXPERIMENTAL|Overnight Intensive Patch|Overnight intensive patch (OIP), on polyolefin foam basis containing acrylate, extractum cepae and allantoin is a class I, CE (Conformité Européenne) marked medical device. Subjects will have their two scars randomized for Overnight Intensive Patch application versus no treatment.
62329459|NCT06234735|ACTIVE_COMPARATOR|Control Group|The control group will follow the conventional protocol established by the Catalan Institute of Oncology (ICO) for the treatment of lung cancer. In addition, physical activity guidelines will be recommended with the aim of encouraging patients to lead a more active life that helps them improve their physical capabilities. The research team will meet individually with participants in the control group and inform them about the importance of physical activity, motivating them to practice regularly.
62329460|NCT06234735|EXPERIMENTAL|Experimental Group|Motivational interviews will be used to help identify individual motivations, barriers, and preferences towards physical activity (PA). Objectives and personalized exercise regimens (e.g. walking, cycling, nordic walking) with a person-centered approach. Patients will engage in a minimum of 3 PA sessions/week (45min each) for 6 months, reporting via a phone app. Weekly patient-reported outcome measures (PROMs) will track progress. The first 3 months involve group sessions for instruction and correction; the last 3 months include one monthly in-person session combining resistance and aerobic training, with a duration of 1.5 hours. To drive behavior change, personalized weekly challenges will be presented.
62329461|NCT04247022|EXPERIMENTAL|female subjects, 18-59 y, healthy|74 female subjects, 18 to 59 years of age, healthy with complaints of vaginal dryness that will receive the heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days.
61935335|NCT02562833|ACTIVE_COMPARATOR|Educational|
61935336|NCT02434367|EXPERIMENTAL|Arm A|Women randomized to the WWE program will receive a workbook, and a daily walking log, the latter to be completed during the study.
61935337|NCT02434367|NO_INTERVENTION|Arm B|Patients randomized to the usual care arm will receive a document with information on exercise to improve fatigue during radiotherapy
62487295|NCT03601403|NO_INTERVENTION|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
61935338|NCT06681675|NO_INTERVENTION|Placebo group|No intervention was made to the primiparous pregnant women in the control group other than routine intrapartum care applied in the hospital. After being admitted to the hospital for delivery, the pregnant women in the control group were informed about the study. Written consent was obtained. A personal information form was applied at the first clinic admission. When the cervical dilatation was 5 cm, VAS, Fear of Childbirth and Childbirth Comfort scales were applied. When the cervical dilatation was 9 cm, the labor monitoring form, VAS, Fear of Childbirth and Childbirth Comfort scales were applied. The routine practices and care of the maternity ward affiliated to the hospital were performed (anamnesis was taken, file was filled, intravenous access was established, routine blood tests were taken, vital signs were taken, enema was performed, vaginal examination every two hours and cervical changes were recorded on the partograph, continuous EFM (Electronic Fetal Monitoring) was applied
61935339|NCT06681675|EXPERIMENTAL|The group that applied the Intrapartum Care Model|In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission. •The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations. Data were collected using the Personal Information Form, Labor and Postpartum Follow-up Form, Visual Analog Scale (VAS), Labor Comfort Scale (CSC), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Labor Scale. VAS, CSC, and Fear of Labor Scale were applied to women when cervical dilation was 5 cm and 9 cm. After delivery, the Women's Perception of Supportive Care Given During Labor Scale was applied.
61935340|NCT05932784||OHCA patients receiving TEE|Out-of-hospital cardiac arrest (OHCA) patients undergo transesophageal echocardiography (TEE) during resuscitation to determine if their aortic valve is being compressed.
61935341|NCT03004222|EXPERIMENTAL|Local anesthetic (Bupivicaine)|The experimental arm intervention is 75 subjects will receive the study agent (20 mL of 0.5% bupivacaine) to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
61935342|NCT03004222|PLACEBO_COMPARATOR|Placebo 20 ml|75 subjects will be treated with normal saline/placebo to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
61935343|NCT05635851|EXPERIMENTAL|Glyceryl trinitrate sublingual spray|Glyceryl trinitrate (GTN) sublingual spray will be administered up to three times every fifteen minutes, each dose being 0.4mg.
61935344|NCT05635851|PLACEBO_COMPARATOR|Placebo sublingual spray|An approximate flavour-matched placebo sublingual spray will be administered up to three times every fifteen minutes.
61935345|NCT03956381||THR with OPS system-TriFit TS/Trinity combination|Hip prosthesis combination: TriFit TS stem/ Trinity cup implanted by Surgeon 1 via a posterolateral approach according to their standard of practice.
62134912|NCT01910896|NO_INTERVENTION|No treatment|Subjects serve as their own control. Eligible subjects have two comparable scars in same body regions, one scar will be treated with Overnight Intensive Patch, the second scar will not be treated.
62134913|NCT02974322|EXPERIMENTAL|GED-0301 1 x 160 mg once daily|GED-0301 1 x 160 mg tablet once daily (QD)
62134914|NCT02974322|EXPERIMENTAL|GED-0301 - 4 x 40 mg once daily|GED-0301 4 x 40 mg tablets once daily (QD)
62487296|NCT03601403|EXPERIMENTAL|Inhaler technique|The intervention group received the standard medical and pharmacological care provided by the hospital. In addition, a tablet-assisted training on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program.
62487297|NCT02485951|ACTIVE_COMPARATOR|Central air injection|The needle was moved radially inside the trephination site and advanced to the central or paracentral cornea.
62134915|NCT02974322|PLACEBO_COMPARATOR|Placebo once daily|Placebo once daily (QD)
62134916|NCT03819166|EXPERIMENTAL|experimental group|The participants recruited in the group will receive the input of deep touch pressure during their procedures of dental treatment.
62134917|NCT03819166|SHAM_COMPARATOR|control group|The participants recruited in the group will not receive the input of deep touch pressure during their procedures of dental treatment.
62134918|NCT03942445|EXPERIMENTAL|Control patients|
62487298|NCT02485951|ACTIVE_COMPARATOR|Peripheral air injection|The needle was inserted into the deep stroma from the trephination site and advanced into the peripheral cornea to approximately 1.5 mm anterior to the limbus.
62487299|NCT03001596|EXPERIMENTAL|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by minimally invasive esophagectomy in enrolled patients.
62134919|NCT03942445|EXPERIMENTAL|Chronic ischemia|
62134920|NCT03942445|EXPERIMENTAL|Acute ischemia|
62134921|NCT03865056|EXPERIMENTAL|High-Flow Nasal Cannula|
62134922|NCT03865056|EXPERIMENTAL|Noninvasive ventilation|
62134923|NCT03480776|ACTIVE_COMPARATOR|Acetylsalicylic Acid (ASA)|
62487300|NCT03001596|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (NCT) is performed followed by minimally invasive esophagectomy in enrolled patients.
62134924|NCT03480776|SHAM_COMPARATOR|Placebo|
62134925|NCT06433713|EXPERIMENTAL|Lidocaine Group|Intravenous lidocaine infusion, 2 mg/kg/hour
62134926|NCT06433713|PLACEBO_COMPARATOR|Control Group|Normal saline infusion
62134927|NCT03167736|EXPERIMENTAL|Electric dry needling, manipulation|
62134928|NCT03167736|ACTIVE_COMPARATOR|conventional physical therapy|
62134929|NCT02957799|EXPERIMENTAL|Accountable Condition- 8 clinics|In the Accountable Condition, the intervention includes mothers who will receive home visits from government-funded CHW who will be trained once under Philani and receive ongoing monitoring and supervision.
62134930|NCT02957799|EXPERIMENTAL|Control Condition- 8 clinics|The Control Condition will include mothers who receive home visits from government-funded CHW who will be trained once under Philani and receive supervision and monitoring consistent with local government practices.
62134931|NCT04565028|EXPERIMENTAL|Contingency Management (CM)|Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users. CM is an intensive behavioral therapy in which participants are paid to reduce substance use.
62487301|NCT02330939|ACTIVE_COMPARATOR|Low fat- Low glycemic index|Participants consumed a meal with low glycemic index and poor in fat
62134932|NCT04820049|PLACEBO_COMPARATOR|Placebo group|
62134933|NCT04820049|EXPERIMENTAL|F573 group|
62487302|NCT02330939|EXPERIMENTAL|MUFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in MUFA
62487303|NCT02330939|EXPERIMENTAL|SAFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in SAFA
62487304|NCT02330939|ACTIVE_COMPARATOR|Low fat- High glycemic index|Participants consumed a meal with high glycemic index and low in fat
62487305|NCT02330939|EXPERIMENTAL|MUFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in MUFA
62487306|NCT02330939|EXPERIMENTAL|SAFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in SAFA
62487307|NCT02940444|EXPERIMENTAL|case group|start heparin sodium (5000IU, BID) upon admission, and continue until discharge
62487308|NCT02940444|ACTIVE_COMPARATOR|control group|start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
62487309|NCT05215197|EXPERIMENTAL|intracochlear prf administration group|intracochlear prf administration group
62134934|NCT03895515||Fiasp®|Participants with type 1 diabetes who have switched to a basal-bolus insulin regimen with Fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin.
62134935|NCT04672967||Autism Spectrum Disorder|Children diagnosed with ASD between the ages of 18-60 months
62134936|NCT04672967||Non-ASD (developmental delay or typically developing)|Children diagnosed with non-ASD between the ages of 18-60 months
62329462|NCT01081223|EXPERIMENTAL|TVI-Brain-1|Cancer vaccine plus immune adjuvant Biological/vaccine Other
62329463|NCT06324747|OTHER|Control group|Control group will have a full thickness flap, followed by an immediate implant placement using a surgical guide. Then a guided bone regeneration will be achieved by bone graft (autogenous bone chips and xenograft particles and a membrane barrier 1 mm thickness will be applied. The membrane shield then will be stabilized to the apical bone using 2 membrane tacks, customized healing abutment will be connected , then, the elevated flap will be sutured to its original position.
62487310|NCT03835767|EXPERIMENTAL|Milk DBPCFC|There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: - All participants who eat baked milk less than once per month. - Participants who never eat baked milk or straight milk. On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
62487311|NCT03835767|EXPERIMENTAL|One-Step Open Feeding|Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
62487312|NCT03835767|EXPERIMENTAL|Peanut DBPCFC|The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: - All participants who eat peanut less than once per month - Participants who never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
62487313|NCT03835767|EXPERIMENTAL|Two-Step Open Feeding|Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
62487314|NCT06013163|ACTIVE_COMPARATOR|Xenical - EMP22 part 1 crossover blinded|After a 5-day diet run-in period, orlistat in its conventional form (Xenical®, 120 mg orlistat) will be taken 3 times daily (ter in die \[TID\]) together with the 3 main daily meals for a 9-day treatment period. After a 4-to-14-day wash-out period; EMP22 (120 mg modified release orlistat) will be taken TID together with the 3 main daily meals for a 9-day treatment period.
62487315|NCT06013163|ACTIVE_COMPARATOR|EMP22 - Xenical part 1 crossover blinded|After a 5-day diet run-in period, EMP22 (120 mg modified release orlistat) will be taken 3 times daily (ter in die \[TID\]) together with the 3 main daily meals for a 9-day treatment period. After a 4-to-14-day wash-out period; orlistat in its conventional form (Xenical®, 120 mg orlistat) will be taken TID together with the 3 main daily meals for a 9-day treatment period.
62487316|NCT06013163|ACTIVE_COMPARATOR|EMP16 - Xenical part 2 sequential open label|Single dose of EMP16 (120 mg orlistat/40 mg acarbose) will be taken together with breakfast during one PK study day. After a 4-to-14-day wash-out period, Xenical® (120 mg orlistat) will be taken together with breakfast during one PK study day.
62487317|NCT01285713|EXPERIMENTAL|5% Dextrose (D5) in Normal Saline (NS)|10cc/kg D5NS, followed by 30cc/kg NS
62487318|NCT01285713|ACTIVE_COMPARATOR|Normal Saline (NS)|10cc/kg NS, followed by 30cc/kg NS
62693567|NCT05533437|EXPERIMENTAL|Dry needling|During dry needling, a practitioner inserts several filiform needles into your skin. Filiform needles are fine, short, stainless steel needles that don't inject fluid into the body.
61935346|NCT03956381||THR with OPS system-MetaFix/Trinity combination|Hip prosthesis combination: MetaFix stem/ Trinity cup implanted by Surgeon 2 via a direct anterior approach according to their standard of practice.
62134937|NCT03640195|EXPERIMENTAL|Experimental group|Transcutaneous nerve electrical stimulation and Auricular acupressure.
62134938|NCT03640195|NO_INTERVENTION|Control group|without intervention
62134939|NCT02548806|EXPERIMENTAL|Clonidine MBT 50µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
62134940|NCT02548806|EXPERIMENTAL|Clonidine MBT 100µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
62134941|NCT02548806|ACTIVE_COMPARATOR|Catapres 100μg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
62134942|NCT06207565|EXPERIMENTAL|Vestibular Flap Group|Vestibular Flap with immediate implant placement, bone graft and customized healing abutment.
62134943|NCT06207565|ACTIVE_COMPARATOR|Single Flap Approach group|Single Flap approach with immediate implant placement, bone graft and customized healing abutment.
62134944|NCT00681213|EXPERIMENTAL|A|Tacrolimus/Sirolimus
61935347|NCT05805930|ACTIVE_COMPARATOR|Arm 1: Steroids|"Treatment with prednisone will be initiated at a dosage of 1 mg/kg/day (maximum 50 mg/day) in twice daily administration for 14 days. In case of complete response to treatment, prednisone will be reduced from day 14, otherwise it will be continued at 1 mg/kg/day until day 28 (week 4). Patients with complete response at day 28 will continue the study entering part 2, in which therapy will be progressively tapered.~In part 2, prednisone will be tapered progressively by 0.1-0.15 mg/kg/day of prednisone (or 5 mg in patients on the maximum dose of 50 mg/day) from current treatment every week until the break. If there is no relapse, treatment will be discontinued over a 10-week period. Patients will then be evaluated every 4 weeks until the end of the study (week 24)."
61935348|NCT05805930|EXPERIMENTAL|Arm 2: Anakinra|"Treatment with anakinra will be initiated at a dose of 2 mg/kg/day (maximum dose 100 mg/day) as a single daily dose and maintained until day 28 (week 4).~Patients who achieve a complete treatment response at week 4 (day 28) will continue the study into Part 2. Patients without a complete treatment response will drop out of the study.~In Part 2 patients will continue daily anakinra treatment through week 12. The treatment will then be progressively reduced through the reduction of one weekly administration of the drug. The reductions will be made every 2 weeks until the interruption. Therefore, if no relapse occurs, treatment will be discontinued at week 24."
61935349|NCT05399303|EXPERIMENTAL|bioceramic sealer obturation|
61935350|NCT05399303|EXPERIMENTAL|resin sealer|
61935351|NCT06681181|EXPERIMENTAL|Cohort 1: Dose 1|Participants will be administered Dose 1 of GSK4528287.
62134945|NCT00681213|EXPERIMENTAL|B|Tacrolimus/MMF
62134946|NCT00681213|EXPERIMENTAL|C|Neoral/Sirolimus
62134947|NCT03865199|EXPERIMENTAL|Intervention Group|The intervention arm will view a digital story on a tablet created by the research team, then respond to a writing prompt. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
62134948|NCT03865199|NO_INTERVENTION|Control Group|The control group will receive care as usual at the abortion clinic. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
62134949|NCT06190717|EXPERIMENTAL|Diagnostic Arm|All subjects will have the EchoMark implanted. Subjects will be assessed every 2 weeks (+/- 1 week) (but no more frequently than weekly) with the EchoSure system until fistula maturation occurs and/or permanent access use is achieved.
62134950|NCT06190717|ACTIVE_COMPARATOR|Standard of Care|Subjects will be evaluated per KDOQI guidelines (with physical examination at approximately 2 weeks (+/- 1 week) and between 4 and 6 weeks (+/- 1 week)). If evaluation yields abnormal findings, subjects will receive a Duplex ultrasound assessment (DUS). All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
62134951|NCT06449677|ACTIVE_COMPARATOR|UC Group|Participants randomized to the Usual Care (UC) group will use their existing insulin delivery method in conjunction with a study CGM during the first 13-week of the study (RCT phase). The UC group will then initiate use of the BP System for the remaining 13 weeks of the study (Extension Phase).
62134952|NCT06449677|EXPERIMENTAL|BP Group|Participants randomized to the intervention group will use the BP group using the iLet Bionic Pancreas System (BP) and continuous glucose monitoring (CGM) during the first 13-week of the study (RCT phase). After the RCT phase, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system.
62134953|NCT02638337|EXPERIMENTAL|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
62487319|NCT04298086|EXPERIMENTAL|Exercise Treatment and Plant-Based Diet|Will consist of structured exercise treatment plus a calorie-restricted plant-based diet. Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service. Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention. If a patient is temporarily unable to complete supervised sessions as a result of unforeseen circumstances, patients may be assigned low intensity unsupervised training sessions per EP/PI discretion
61935352|NCT06681181|EXPERIMENTAL|Cohort 2: Dose 2|Participants will be administered Dose 2 of GSK4528287.
62134954|NCT02638337|PLACEBO_COMPARATOR|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
62134955|NCT02978716|EXPERIMENTAL|Group 1: Gemcitabine/Carboplatin (Days 1 and 8)|Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square \[mg/m\^2\] and carboplatin area under the curve \[AUC\] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).
62134956|NCT02978716|EXPERIMENTAL|Group 2: Trilaciclib + Gemcitabine/ Carboplatin (Days 1 and 8)|Participants received IV infusion of trilaciclib 240 mg/m\^2 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.
62134957|NCT02978716|EXPERIMENTAL|Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)|Participants received IV infusion of trilaciclib 240 mg/m\^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.
62134958|NCT04010435|ACTIVE_COMPARATOR|Group A (r TMS group)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.
62134959|NCT04010435|ACTIVE_COMPARATOR|Group B (Galvanic stimulation)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo galvanic vestibular stimulation; in addition to designed vestibular rehabilitation exercises.
62134960|NCT04010435|NO_INTERVENTION|Control (Group C)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo designed vestibular rehabilitation exercises.
61935353|NCT06681181|EXPERIMENTAL|Cohort 3: Dose 3|Participants will be administered Dose 3 of GSK4528287.
61935354|NCT06681181|EXPERIMENTAL|Cohort 4: Dose 4|Participants will be administered Dose 4 of GSK4528287.
61935355|NCT06681181|EXPERIMENTAL|Cohort 5: Dose 5|Participants will be administered Dose 5 of GSK4528287.
62487320|NCT04298086|ACTIVE_COMPARATOR|Physical activity and nutrition counseling|Patients will receive a home-based, general physical activity program and nutrition counseling. Specifically, all patients assigned to the counseling arm will receive a study kit which includes an activity tracker, heart rate monitor, scale, and tablet. Treadmills may also be provided to patients in the counseling arm if they do not already have access to one.
62487321|NCT01647828|EXPERIMENTAL|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel
62487322|NCT01647828|EXPERIMENTAL|Gemcitabine and Nab-Paclitaxel plus Placebo|Gemcitabine and Nab-Paclitaxel plus Placebo
62487323|NCT02275962|EXPERIMENTAL|K-877|K-877
62329464|NCT06324747|ACTIVE_COMPARATOR|Test group|Elaskary Vestibular socket therapy instruments will be used for the intervention, A 1 cm long vestibular access incision at the allocated hopeless tooth will be made at the base of the hopeless tooth to the adjacent teeth. The vestibular pouch will then be dissected in an incisal direction exposing the total socket area and allowing direct access to the socket environment. An immediate implant will be installed using a surgical guide. A membrane shield 1 mm thick will be, trimmed, and tucked through the vestibular access incision starting at 1 mm beyond the socket orifice and reaching to the apical area of the socket. The gap and/ or the defect between the implant body and the shield will then be filled with the same grafting components so the control group. Finally, the vestibular incision will be secured with sutures. The socket will be sealed with a customized healing abutment.
62329465|NCT04162886|EXPERIMENTAL|Exercise Group|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
62329466|NCT04162886|NO_INTERVENTION|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
62329467|NCT04687202||Patients developing CA|Including patients developing intraoperative cardiac arrest during transcatheter aortic valve implantation from January 2014 to May 2019
62329468|NCT04664920||Intervention|Exergame intervention arm.
62329469|NCT05910294|ACTIVE_COMPARATOR|standard of care|Standard of care arm will receive treatment at the time symptoms develop. Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
62329470|NCT05910294|EXPERIMENTAL|intervention|Patients who are randomized to the upfront arm will receive sexual health counseling and be initiated on non-hormonal moisturizers 3-5 times per week (based on data regarding need in our patient population) at the time ovarian suppression. The upfront intervention group will also be educated about dilators and have a consultation with a pelvic floor physical therapist. Some potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules.
62487324|NCT02275962|EXPERIMENTAL|K-877 with Rifampin|K-877 with Rifampin
62487325|NCT04762576||Cardiac Surgical Patients|All consenting adults undergoing cardiac surgery at Toronto General Hospital.
62487326|NCT02256943|ACTIVE_COMPARATOR|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
62693568|NCT05533437|ACTIVE_COMPARATOR|kinesio taping|The Kinesio Taping Method is a therapeutic taping technique which alleviates pain and facilitates lymphatic drainage by microscopically lifting the skin. This lifting affect forms convolutions in the skin increasing interstitial space and allowing for decreased inflammation in affected areas. Based upon research and years of clinical use, The Kinesio Taping Method specifically applies Kinesio tape based on evaluation and assessment to dictate a specific application.
62134961|NCT03884296|OTHER|Study Phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
62134962|NCT04000516|NO_INTERVENTION|Control|The control group was asked to continue their usual eating schedule and pattern.
62134963|NCT04000516|EXPERIMENTAL|Evening Fasters (EF)|Evening fasters were asked to not consume food after 3 pm until the next morning.
62329471|NCT03436446||Orthopedic Patients|Orthopedic patients will undergo an interview with the research team regarding the framing of various social incentives to promote increased response rates for patient reported outcome measures post-operatively.
62487327|NCT02256943|ACTIVE_COMPARATOR|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
62487328|NCT02559843|EXPERIMENTAL|pomegranate juice|200 ml pomegranate juice + lifestyle modification
62487329|NCT02559843|ACTIVE_COMPARATOR|control|lifestyle modification including dietary recommendations
62487330|NCT00673660||Statins|Patients with dyslipidemia who are taking or planning to take a statin treatment (Atorvastatin, Fluvastatin, Prevastatin, Rosuvastatin, Simvastatin or generics).
62697584|NCT06554821|EXPERIMENTAL|Rosuvastatin (Dose 1) + Ticagrelor|Participants will receive rosuvastatin (dose 1) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2. During Period 2, participants will also receive ticagrelor 90 mg BID (twice a day) on Day 6 through Day 10.
61935356|NCT06681181|EXPERIMENTAL|Cohort 6: Dose 6|Participants will be administered Dose 6 of GSK4528287.
61935357|NCT06681181|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo.
62329472|NCT05118386|EXPERIMENTAL|RSM01|Participants were randomized to receive different dose levels of RSM01. Participants were randomized in a ratio of 6:1 where for every 6 participants received active drug (RSM01), 1 participant received Placebo.
62329473|NCT05118386|PLACEBO_COMPARATOR|Placebo|Participants received Placebo matched to RSM01.
62329474|NCT05058131|ACTIVE_COMPARATOR|Dietary fibre|Butyrate-promoting dietary fibre
62329475|NCT05058131|PLACEBO_COMPARATOR|Placebo compound|Placebo compound
62487331|NCT03586622|EXPERIMENTAL|Low FODMAP diet|Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
62697585|NCT06554821|EXPERIMENTAL|Rosuvastatin (Dose 2) + Ticagrelor|Participants will receive rosuvastatin (dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2. During Period 2, participants will also receive ticagrelor 90 mg BID on Day 6 through Day 10.
61935358|NCT01634763|EXPERIMENTAL|Dose-escalation|Open-label dose escalation study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)
61935359|NCT01634763|EXPERIMENTAL|Dose-expansion|Open-label study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in ALK to see further safety, anti-tumor activity, and PK data in patients who has progressed since prior therapy with alectinib
62487332|NCT03586622|EXPERIMENTAL|VSL#3®|Each IBS patient randomized to the probiotic VSL#3 arm (n=52) will at randomization be given VSL#3 for 4 weeks (56 sachets) together with a leaflet on VSL#3 - holding information on the product from the manufacture regarding storage, nutritional information etc. If the patients have any questions regarding the treatment, they can ask the project investigator handing out the VSL#3 to them. They will be instructed in taking their VSL#3 (2 sachets a day) as described by the manufacturer
61935360|NCT00986479|EXPERIMENTAL|AZD6765 (150 mg) / Placebo|Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period.
61935361|NCT00986479|PLACEBO_COMPARATOR|Placebo / AZD6765 (150 mg)|Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period.
61935362|NCT04008238|EXPERIMENTAL|Biomarker analysis|This study is a single arm study with biomarker analysis
62134964|NCT04000516|EXPERIMENTAL|Morning Fasters (MF)|Morning fasters were asked to not consume food from the time they woke until 11 am.
62134965|NCT01042275||TOT|transobturator sling, outside-in (TOT)
62134966|NCT01042275||TVT-O|Tension-free transobturator tape, inside-out (TVT-O)
62329476|NCT06224894|EXPERIMENTAL|music therapy|"The child in the music therapy group will receive a standard antiemetic treatment procedure 15 minutes before the cisplatin infusion. Music therapy will be applied with the start of cisplatin infusion. The song The Happiest Child, developed by creating rhythms and developed by Fulya Merve KOS, a researcher with a RhythmotherapistTM certificate issued by the Ministry of National Education, will be used in music therapy. The sound will be adjusted to 45 db. The speaker will be placed at the end of the foot, approximately 30 cm from the child's ear, five minutes before the procedure and will be played to the child during the procedure. After the infusion, music therapy will be terminated and the level of nausea, irritability and anxiety will be evaluated with data collection forms."
62329477|NCT06224894|EXPERIMENTAL|antiemetic treatment|Standard approach; Granisetron IV 40mcg/kg/24, Aprepitant PO 125 mg/24 hour and Dexamethasone 6 mg/m2 IV/PO are administered to children receiving cisplatin treatment.
61935363|NCT04322981|EXPERIMENTAL|Community Pharmacist-Led|Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.
62329478|NCT05818293|EXPERIMENTAL|study group -control group|Group (A) (study group) will receive radiofrequency, medical standard care for insulin resistance and regular diet habits.
62329479|NCT05818293|NO_INTERVENTION|control group|Group (B) (control group) will receive regular diet habits only.
62329480|NCT02689336|EXPERIMENTAL|Erlotinib and Temozolomide|"* Erlotinib is an oral drug that will be administered on an outpatient basis at a dose of 85 mg/m\^2/dose once a day continuously (every day of a 28-day cycle)~* Temozolomide is an oral drug that will be administered on an outpatient basis at a dose of 180mg/m2/dose once a day on Days 1-5 of a 28-day cycle."
62329481|NCT04031378|ACTIVE_COMPARATOR|A|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation using PET/CT imaging studies every 6 months
62487333|NCT04196062|EXPERIMENTAL|Robotic ESD|Treatment of early colorectal neoplasia / lateral spreading tumors by ESD using EndoMASTER EASE robotic system
62487334|NCT06120153|ACTIVE_COMPARATOR|POC PCR-test device|In the seven-week intervention, the Point-of-Care PCR-testing device will be made available for approximate 50 clinics. Besides the general instructions on how to include patients, clinics in the intervention arm will be instructed that it is entirely up to the GP whether or not to use the PCR-testing device on each individual patient. In addition, no specific instructions on medical treatments or follow up procedures are made.
62329482|NCT04031378|EXPERIMENTAL|B|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months stratified by whether disease is castrate-sensitive (mCS-PCa) or castrate-resistant (mCR-PCa)
62329483|NCT02195791|ACTIVE_COMPARATOR|Pioglitazone|
61935364|NCT04322981|ACTIVE_COMPARATOR|Academic hepatology|Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.
61935365|NCT02979717|EXPERIMENTAL|high protein, high fiber|Participants receive a high protein, high fiber dietary supplement pre-load
61935366|NCT02979717|PLACEBO_COMPARATOR|Low protein, low fiber|Participants receive a low protein, low fiber isocaloric pre-load
61935367|NCT04766073|EXPERIMENTAL|New Closure Technique|This group will have the uterus closed after delivery of the fetus during cesarean section with a new technique.
62134967|NCT01042275||IVS|retropubic Intravaginal Sling (IVS)
62134968|NCT01042275||TVT|retropubic tension-free vaginal tape (TVT)
62134969|NCT01042275||REMEEX|Re-adjustable mechanical external sling (REMEEX)
62134970|NCT00201149|EXPERIMENTAL|1|In one team of clinicians we will implement only the patient-centered counseling program.
62134971|NCT00201149|NO_INTERVENTION|3|The control group will provide usual care
62134972|NCT00201149|EXPERIMENTAL|2|In a subset of those clinicians receiving the patient-centered counseling program intervention, we will augment it with cultural competency training.
62134973|NCT03877198|EXPERIMENTAL|CLiO2|Automated oxygen control by the CLiO2 algorithm
62134974|NCT03877198|EXPERIMENTAL|Oxygenie|Automated oxygen control by the Oxygenie algorithm
62134975|NCT04286269|EXPERIMENTAL|Intervention|Participants in this group will be randomized to receive the intervention.
62134976|NCT04286269|SHAM_COMPARATOR|Placebo|Participants in this group will be randomized to receive a sham treatment.
62134977|NCT05046613||Pregnant women with migraine exposed to Rimegepant|Pregnant women with a diagnosis of migraine who are exposed to rimegepant at any time during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
62487335|NCT06120153|NO_INTERVENTION|Standard testing|In the seven-week control period, the Point-of-Care PCR-testing device will not be available in approximately 50 clinics. Patients attended by the GP during control periods will receive treatment as usual. Like GPs in the intervention arm, GPs in the control arm are not actively encouraged to change their prescription patterns, but they must record data from patients with respiratory tract infections parallel to the intervention group.
61935368|NCT04766073|NO_INTERVENTION|Regular closure technique|The usual method of closing the surgical incision is to suture the entire wall of the uterus with a stratafix suture without locking the suture.
62134978|NCT05046613||Pregnant women with migraine not exposed to Rimegepant|Pregnant women with a diagnosis of migraine who are not exposed to rimegepant (up to 5 product half-lives prior to conception) but who may be exposed to other products for the treatment/prevention of migraine at any time during pregnancy or just prior to pregnancy
62134979|NCT04995627|ACTIVE_COMPARATOR|Salt (NaCl)|"12 grams (12 capsules) of NaCl per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
62134980|NCT04995627|PLACEBO_COMPARATOR|Placebo|"12 capsules of placebo per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
62134981|NCT02059538|OTHER|Group 1|Metabolic syndrome
62329484|NCT02195791|PLACEBO_COMPARATOR|Placebo|
62134982|NCT02059538|OTHER|Group 2|Severly obese patients
62329485|NCT03375112|EXPERIMENTAL|Fascia Iliaca Compartment Block|A Fascia Iliaca Compartment Block will be administered in the block room.
62329486|NCT03375112|PLACEBO_COMPARATOR|Control|The patients will be brought back to the block room, prepped, and a blunt needle will be touched to the skin. A band aid will be applied over the site.
62329487|NCT04045249|NO_INTERVENTION|1st Group|Children were treated as per standard CMAM protocols; provided RUTF until MUAC reaches 11.5 cm
62329488|NCT04045249|EXPERIMENTAL|2nd Group (1st Intervention group)|Children were initially provided RUTF until MUAC reach 11 cm then 50 % calories were provided from RUTF and 50% calories from home based food
62329489|NCT04045249|EXPERIMENTAL|3rd Group (2nd Intervention)|Children were initially provided RUTF until MUAC reach 11 cm then 100 % calories provided from home based food
62329490|NCT03930212|EXPERIMENTAL|Progesterone|received rectal progesterone suppositories 400 mg once daily
62329491|NCT03930212|PLACEBO_COMPARATOR|Control group|received placebo suppositories rectally once daily.
62329492|NCT02666092||Fish allergy|"51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited.~Interventions will include:~* A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations~* A detection of anti-Anisakis and anti-fish antibodies"
62329493|NCT02666092||Control|"51 subjects presenting no allergic manifestations after contact with fish.~Interventions will include:~* A questionnaire on domestic exposure to fish~* A detection of anti-Anisakis and anti-fish antibodies"
62329494|NCT01597557|ACTIVE_COMPARATOR|Magnesium Sulfate|Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure
62487336|NCT03811145|EXPERIMENTAL|Tendoncel|Topically applied experimental gel - Tendoncel. 80ul applied once a day for 21 consecutive days.
62487337|NCT03811145|PLACEBO_COMPARATOR|Placebo control gel|Placebo control gel. Similar to Tendoncel but without platelet derived small molecules and growth factors. 80ul applied once a day for 21 consecutive days.
62487338|NCT01456962||Raltegravir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with raltegravir (RAL)
62487339|NCT01456962||Atazanavir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with ritonavir (RIT)-boosted atazanavir (ATZ)
62487340|NCT06068491|EXPERIMENTAL|Arm 1: Vet-CALD Intervention|Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
62487341|NCT06068491|NO_INTERVENTION|Arm 2: Usual Care|Usual Care Participants will receive the standard of care from their usual VA healthcare provider. The care counselor will not contact the usual care condition participants.
61935369|NCT06709820|EXPERIMENTAL|LY4060874 (Part A Subcutaneous)|Single ascending dose of LY4060874 administered subcutaneously (SC).
62134983|NCT02059538|OTHER|Group 3|Type-2 diabetics patients
61935370|NCT06709820|EXPERIMENTAL|LY4060874 (Part A Intravenous)|Single ascending dose of LY4060874 administered intravenously (IV).
62134984|NCT02059538|OTHER|Group 4|Patients with first recent (\< 2 weeks) acute coronary syndrome (ACS)
62329495|NCT01597557|PLACEBO_COMPARATOR|Placebo|Patients in this arm receive normal saline drip intravenously before the cardioversion procedure
62329496|NCT06424873|EXPERIMENTAL|One arm study|Additionnal images during PET/CT
62329497|NCT06387888|EXPERIMENTAL|Intervention group-30|During the care, from the beginning to the end, mother's voice was played to the newborns. It took about 20 minutes. The mini Bluetooth speaker and the decibel meter were disinfected with the rapid surface disinfectant used in the clinic. The speaker was placed 30 cm away from the infant's ear and the sound level in the incubator was adjusted to be 50-60 dB by using a decibel meter. Mother's voice was played from the beginning of the provision of care and continued for 15 minutes after the end of the provision of care. During the provision of care, COMFORTneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.
62329498|NCT06387888|NO_INTERVENTION|Control group-30|Standard nursing care lasting 20 minutes was performed in the routine sound environment of the neonatal intensive care unit. COMFORTneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.
62329499|NCT02955654|EXPERIMENTAL|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
61935371|NCT06709820|EXPERIMENTAL|LY4060874 (Part B)|Multiple ascending doses of LY4060874 administered SC.
61935372|NCT06709820|EXPERIMENTAL|LY4060874 (Part B Chinese)|Multiple ascending doses of LY4060874 administered SC in Chinese participants.
61935373|NCT06709820|EXPERIMENTAL|LY4060874 (Part C Japanese)|Multiple ascending doses of LY4060874 administered SC in Japanese participants.
61935374|NCT06709820|PLACEBO_COMPARATOR|Placebo (SC)|Placebo administered SC in Part A, B, and C.
61935375|NCT06709820|PLACEBO_COMPARATOR|Placebo (IV)|Placebo administered IV in Part A.
61935376|NCT06058078|EXPERIMENTAL|RY_SW01 group 1 does 1 RY_SW01 cell injection|Receive the best basic treatment and one million cells per kilogram of body weight
61935377|NCT06058078|EXPERIMENTAL|RY_SW01 group 2 does 2 RY_SW01 cell injection|Receive the best basic treatment and two million cells per kilogram of body weight
61935378|NCT06058078|OTHER|control group|Receive the best basic treatment
61935379|NCT01863238||Ivacaftor Treated|
61935380|NCT01884623|EXPERIMENTAL|Cetuximab|Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
61935381|NCT01884623|ACTIVE_COMPARATOR|Methotrexate|Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
61935382|NCT05617443|ACTIVE_COMPARATOR|selective laser melting (SLM) CO-Cr metal surgical-guides|
61935383|NCT05617443|EXPERIMENTAL|digital light processing (DLP) resin surgical-guides|
62487342|NCT04603703|EXPERIMENTAL|HVLAT Manipulation|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics, HVLAT
62487343|NCT04603703|ACTIVE_COMPARATOR|Conventional physical therapy|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics
62487344|NCT02280863|EXPERIMENTAL|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
62693569|NCT04175184|EXPERIMENTAL|Experimental group|"1. Exercise programme: 2-3 sets of 10-15 repetitions of shoulder girdle and glenohumeral strengthening exercises performed in different positions in addition to three stretching exercises.~2. Mobilisation with movement (MWM): the participant and physiotherapist will decide one movement more functionally relevant to the patient. Afterwards, attempts of MWM will be applied to different joints in order to identify one particular MWM that improves significantly the movement previously selected. Then, one set of six to ten repetitions will be applied. This process of pragmatically using MWM will be conducted in every session, but from the second session onwards, two to three sets of ten repetitions will be applied, with an interval of sixty seconds between sets. In case of failure to identify an MWM that improves the movement significantly, the patient decides which one seemed to be best and one set of six repetitions will be applied to the onset of discomfort."
61935384|NCT01962831|EXPERIMENTAL|dinoprostone|Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours
61935385|NCT01962831|EXPERIMENTAL|Single balloon foley catheter|Group of women that will have a single balloon foley catheter inserted for induction of labour
62134985|NCT02059538|OTHER|Group 5|Patients with stable chronic coronary artery disease without heart failure
62487345|NCT02280863|EXPERIMENTAL|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
62487346|NCT05862805|ACTIVE_COMPARATOR|Heavy Menstrual Bleeding|Participants with heavy menstrual bleeding will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
62487347|NCT05862805|ACTIVE_COMPARATOR|Regular Mensural Bleeding|Participants with normal menstrual bleeding will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
61935386|NCT06680323||Classic melanoma|Classic malignant melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
61935387|NCT06680323||Spitzoid melanoma|Spitzoid melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
61935388|NCT06680323||Other melanoma|Other melanoma as melanoma on congenital nevi under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
61935389|NCT02069132||Warfarin in elderly with comorbidity|Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement
62487348|NCT04511208|EXPERIMENTAL|Cooling vest, then without cooling vest, then without cooling vest, then cooling vest (ABBA)|Surgeons first performed one surgery with the cooling vest. On another day, they then performed one surgery without the cooling vest. Then on another day, they performed another surgery without the cooling vest. Then they finally performed one surgery with the cooling vest.
61935390|NCT05327959|EXPERIMENTAL|Treatment Group|The population target is all subjects suffering clavicle fracture suitable for open reduction and internal fixation by the A.L.P.S. Clavicle Plating System in accordance with the IFU.
61935391|NCT01199731|EXPERIMENTAL|GSK2248761 100mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
61935392|NCT01199731|EXPERIMENTAL|GSK2248761 200mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
61935393|NCT01199731|ACTIVE_COMPARATOR|Etravirine|In combination with darunavir/ritonavir BID and raltegravir BID
61935394|NCT01015053|EXPERIMENTAL|Regional block|"An ultrasound-guided rectus sheath block will be performed by the regional block anesthesiologist in the regional block arm."
62134986|NCT02059538|OTHER|Group 6|Patients with ischemic systolic heart failure (CHF)
62134987|NCT02059538|OTHER|Group 7|Patients with non-ischemic chronic heart failure
62134988|NCT02059538|OTHER|Group 8|Healthy volunteers
62134989|NCT03304834|EXPERIMENTAL|ECHOPULSE|Arm of patient treated by HIFU
62134990|NCT04623567|EXPERIMENTAL|Jiangtang Tiaozhi Recipe Group|Jiangtang Tiaozhi formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.
62134991|NCT04623567|ACTIVE_COMPARATOR|Metformin Group|500mg metformin tablet per time, 3 times a day, take it with meals.
61935395|NCT01015053|ACTIVE_COMPARATOR|Wound infiltration|"Local wound infiltration will be performed by the surgeon in the wound infiltration arm."
61935396|NCT00806338|EXPERIMENTAL|Trodusquemine (MSI-1436) 3mg/m2|
61935397|NCT00806338|EXPERIMENTAL|Trodusquemine (MSI-1436) 6mg/m2|
61935398|NCT00806338|EXPERIMENTAL|Trodusquemine (MSI-1436) 10mg/m2|
61935399|NCT00806338|PLACEBO_COMPARATOR|Placebo|
61935400|NCT02372370|ACTIVE_COMPARATOR|Interventions|All participants receive all interventions.
61935401|NCT01176331||vitrectomy|
61935402|NCT06681337|EXPERIMENTAL|BCMA CART + CD19 CART|BCMA CART + CD19 CART
61935403|NCT05589272|EXPERIMENTAL|Cognitive training + active-tDCS|Cognitive training + active-tDCS 4 times per week (20 minutes per session, each (\~25cm²; current density = 0.08 mA/cm²); anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for four weeks.
62487349|NCT04511208|EXPERIMENTAL|Without cooling vest, then cooling vest, then cooling vest, then without cooling vest (BAAB)|Surgeons first performed one surgery without the cooling vest. On another day, they then performed one surgery with the cooling vest. Then on another day, they performed another surgery with the cooling vest. Then they finally performed one surgery without the cooling vest.
62693570|NCT04175184|SHAM_COMPARATOR|Placebo group|"1. The exercise programme is exactly the same as the experimental group.~2. Sham MWM: the participant and physiotherapist will decide together one movement that is more functionally relevant to the patient. Afterwards, a sham MWM (Delgado-Gil et al 2015) will be applied and the movement previously selected will be repeated six times in the first consultation. The participant will be informed that he/she should move to the onset of symptoms, if they occur.This process will be conducted in every session, but from the second session onwards, two to three sets of 10 repetitions will be applied, with an interval of sixty seconds between sets. In case the sham MWM failed to improve the movement significantly, one set of six repetitions will be applied only."
61935404|NCT05589272|SHAM_COMPARATOR|Cognitive training + sham-tDCS|Cognitive training + sham-tDCS 4 times per week (20 minutes per session, each \~25cm²; current density = 0.08 mA/cm²); anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for four weeks.
61935405|NCT02832388||Primary aldosteronism patients for cardiac MRI|A subgroup of primary aldosteronism (PA) patients perform a cardiac MRI, including stress-testing with adenosine, and are compared to a sex- and age-matched group of healthy controls who perform the same MRI procedure
61935406|NCT02832388||Healthy controls|Healthy controls that are age-and sex-matched to the subgroup of PA patients performing cardiac MRI, perform MRI including adenosine as stress-test.
61935407|NCT02832388||Primary aldosteronism patients diagnosed from 2013 onwards|"All PA patients diagnosed or subtyped at Haukeland University from 2013 onwards are asked for inclusion in the main observational PA-study.~From 2025 onwards, PA patients diagnosed or subtyped at Oslo University hospital will also be included."
61935408|NCT06707714||Gastric cancer patients combine with hypertension|Gastric cancer patients diagnosed with hypertension
61935409|NCT06707714||Gastric cancer patients combine with diabetes|Gastric cancer patients diagnosed with diabetes
61935410|NCT06707714||Gastric cancer patients combine with fatty liver|Gastric cancer patients diagnosed with fatty liver
61935411|NCT02646254|ACTIVE_COMPARATOR|blood cardioplegia|these patients received blood cardioplegia
61935412|NCT02646254|ACTIVE_COMPARATOR|del nido cardioplegia|these patients received del nido cardioplegia
61935413|NCT02611037|EXPERIMENTAL|Chemoperfusion + Questionnaire|"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m\^2), methotrexate (100 mg/m\^2) and gemcitabine (1000 mg/m\^2).~Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.~Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire."
61935414|NCT04521777|EXPERIMENTAL|Supportive care (exercise intervention)|Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week.
61935415|NCT03950791|EXPERIMENTAL|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials.
61935416|NCT03950791|PLACEBO_COMPARATOR|Health Education|A 2-hour in-person informational session about general health education. Participants receive a list of resources in the community.
61935417|NCT04946461||group 1; lisdex - dex|subjects are assigned to group 1 based on the type of medication prescribed by the practitioner. Subjects which started with lisdexamphetamine are assigned to group 1.
61935418|NCT04946461||group 2; dex - lisdex|subjects are assigned to group 2 based on the type of medication prescribed by the practitioner. Subjects which started with dexamphetamine are assigned to group 1.
61935419|NCT03439943|EXPERIMENTAL|Lixisenatide|Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
61935420|NCT03439943|PLACEBO_COMPARATOR|Placebo|Placebo: once daily subcutaneous injection
61935421|NCT05220917||SGLT-2i (Comparison 1)|For SGLT-2i vs. DPP4i SGLT-2i - exposure group DPP4i - referent group
61935422|NCT05220917||DPP-4i (Comparison 1)|For SGLT-2i vs. DPP4i SGLT-2i - exposure group DPP-4i - referent group
61935423|NCT05220917||SGLT-2i (Comparison 2)|For SGLT-2i vs GLP-1 RA SGLT-2i - exposure group GLP-1 RA - referent group
61935424|NCT05220917||GLP-1 RA (Comparison 2)|For SGLT-2i vs GLP-1 RA SGLT-2i - exposure group GLP-1 RA - referent group
61935425|NCT05220917||GLP-1 RA (Comparison 3)|For GLP-1 RA vs DPP-4i GLP-1 RA - exposure group DPP-4i - referent group
61935426|NCT05220917||DPP-4i (Comparison 3)|For GLP-1 RA vs DPP-4i GLP-1 RA - exposure group DPP-4i - referent group
62487350|NCT04511208|EXPERIMENTAL|Cooling vest, then cooling vest, then without cooling vest, then without cooling vest (AABB)|Surgeons first performed one surgery with the cooling vest. On another day, they then performed another surgery with the cooling vest. Then on another day, they performed one surgery without the cooling vest. Then they finally performed another surgery without the cooling vest.
62693571|NCT00974272|EXPERIMENTAL|Exenatide|
62693572|NCT00974272|PLACEBO_COMPARATOR|Placebo|
62487351|NCT04511208|EXPERIMENTAL|Without cooling vest, then without cooling vest, then cooling vest, then cooling vest (BBAA)|Surgeons first performed one surgery without the cooling vest. On another day, they then performed another surgery without the cooling vest. Then on another day, they performed one surgery with the cooling vest. Then they finally performed another surgery with the cooling vest.
62487352|NCT04998526|EXPERIMENTAL|Experimental group|After routine drug treatment is given to hypertension patients, the cold gel pack will be applied to the nape for 3 minutes.
62487353|NCT04998526|PLACEBO_COMPARATOR|Placebo group|After routine drug therapy is given to hypertension patients, the gel pack kept at room temperature will be applied to the nape for 3 minutes.
62487354|NCT04998526|NO_INTERVENTION|Control group|Routine drug treatment will be given to hypertension patients and no application will be made.
62134992|NCT03169413||cases|Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
62329500|NCT02955654|ACTIVE_COMPARATOR|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
62329501|NCT02955654|OTHER|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
62329502|NCT01252797|ACTIVE_COMPARATOR|Stereotactic Radiosurgery (15 Gy)|Group A: If the tumor which will be surgically removed is at least 2 cm and up to 4 cm in maximum diameter, then this group will receive Dose Level II (15 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
62329503|NCT01252797|EXPERIMENTAL|Stereotactic Radiosurgery (12Gy)|Group B: If the tumor which will be surgically removed is larger than 4 cm and up to 6 cm in diameter, then this group will receive Dose Level I (12 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
62329504|NCT01048190|EXPERIMENTAL|Infants I-1|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains). Group I-1: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
62329505|NCT01048190|EXPERIMENTAL|Infants I-2|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
62329506|NCT01048190|EXPERIMENTAL|Infant I-3|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
62329507|NCT01951014|EXPERIMENTAL|Teen Social Media Education|See description under intervention description
62329508|NCT01951014|NO_INTERVENTION|Healthcare Provider Insights|Healthcare providers providing care to pregnant adolescents will serve as key informants to provide an additional perspective for adolescent health beliefs and behaviors.
62329509|NCT03367130|EXPERIMENTAL|Intervention|HIV-positive individuals will receive the standard HIV care following the national ART guidelines. In addition, the intervention group will receive mobile phone calls. A mobile phone reminder will be made two days prior to their scheduled appointment for pills pick up. Trained research assistants will remind them of their scheduled clinic appointment of pills pick up. If the first call is missed, the second call will be made within the same day, if the second call is also missed, the final call will be made next day. The intervention will be delivered over the period of six months. Outcome assessors will not be involved in the phone calls.
62487355|NCT06403033|EXPERIMENTAL|Mini-implant-supported Twin-Block|Treatment will be done using the Mini-implant-supported Twin-block appliance until the correction is achieved.
62134993|NCT03169413||control one|Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
62134994|NCT03169413||control two|Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
62487356|NCT06403033|ACTIVE_COMPARATOR|Conventional Twin-Block group|Treatment will be done using the Twin-block appliance until the correction is achieved.
62134995|NCT04400136|NO_INTERVENTION|GROUP A - no PPI|no PPI treatment (control group)
62329510|NCT03367130|PLACEBO_COMPARATOR|Control|Control group will also receive the standard HIV care following the national ART guidelines and phone calls educating them on healthy living. Phone calls will be made once a month.
62329511|NCT02898025|ACTIVE_COMPARATOR|G1 (Active IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.
62329512|NCT02898025|ACTIVE_COMPARATOR|G2 (Active IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.
62487357|NCT04981262|EXPERIMENTAL|Stimulance|4 weeks intervention with Stimulance for all participants
62487358|NCT04981262|EXPERIMENTAL|Stimulance 6 months|6 months intervention
62487359|NCT04981262|NO_INTERVENTION|No intervention|6 months control group
62487360|NCT00773149|EXPERIMENTAL|1|all included patients
62487361|NCT02985060|EXPERIMENTAL|Therapeutic hypothermia group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Stroke care based on international guidelines except therapeutic hypothermia using surface cooling device (Arctic Sun)
62487362|NCT02985060|OTHER|Control group|Stroke care based on international guidelines
62487363|NCT01323491||routine smokers|would-be non-smokers, no actual nicotine replacement therapy
62487364|NCT03356691|NO_INTERVENTION|Control group|No intervention.
61935427|NCT05220917||SGLT-2i (Comparison 4)|For SGLT-2i vs SU SGLT-2i - exposure group SU - referent group
61935428|NCT05220917||SU (Comparison 4)|For SGLT-2i vs SU SGLT-2i - exposure group SU - referent group
61935429|NCT05220917||GLP-1 RA (Comparison 5)|For GLP-1 RA vs SU GLP-1 RA - exposure group SU - referent group
61935430|NCT05220917||SU (Comparison 5)|For GLP-1 RA vs SU GLP-1 RA - exposure group SU - referent group
61935431|NCT05220917||DPP-4i (Comparison 6)|For DPP-4i vs SU DPP-4i - exposure group SU - referent group
61935432|NCT05220917||SU (Comparison 6)|For DPP-4i vs SU DPP-4i - exposure group SU - referent group
61935433|NCT05220917||SGLT2i (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
61935434|NCT05220917||GLP-1 RA (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
61935435|NCT05220917||DPP-4i (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
61935436|NCT05220917||SU (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
61935437|NCT05220917||SGLT2i (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
61935438|NCT05220917||GLP-1 RA (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
61935439|NCT05220917||DPP-4i (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
61935440|NCT04450836|EXPERIMENTAL|Arm A (R-TT)|Regorafenib followed by trifluridine-tipiracil.
61935441|NCT04450836|EXPERIMENTAL|Arm B (TT-R)|Trifluridine-tipiracil followed by Regorafenib.
61935442|NCT01681017|OTHER|Facilities|Have appropriate staff trained in HBB and have HBB equipment provided
61935443|NCT01681017|OTHER|Master Trainers|Receive appropriate HBB training
61935444|NCT01681017|OTHER|Facilitators|Receive appropriate HBB training
61935445|NCT01681017|OTHER|Learners|Receive appropriate HBB training
62134996|NCT04400136|EXPERIMENTAL|GROUP B PPI 1/day for 6 months|(standard dose-long term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months
62329513|NCT02898025|ACTIVE_COMPARATOR|G3 (Placebo IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.
62487365|NCT03356691|EXPERIMENTAL|Complementary Spiritist Therapy|"Prayer, Spirit education, Spiritist passe and magnetized water"
62487366|NCT03356691|OTHER|Prayer|Prayer during 1-2 minutes
61935446|NCT03246620|EXPERIMENTAL|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
61935447|NCT03246620|ACTIVE_COMPARATOR|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
61935448|NCT03246620|ACTIVE_COMPARATOR|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
61935449|NCT01570868|EXPERIMENTAL|Ponatinib 45 mg|Ponatinib at a dose of 45 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
62134997|NCT04400136|EXPERIMENTAL|GROUP C PPI 1/day for 3 months|(standard dose-short term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months
62134998|NCT03749785|ACTIVE_COMPARATOR|Regular carbohydrate feeding|Ingestion of 75 g sucrose, given in regular doses for the first 75 minutes of exercise during a time to exhaustion run
62134999|NCT03749785|ACTIVE_COMPARATOR|Single carbohydrate bolus|Ingestion of 75 g sucrose, given in a single bolus after 75 minutes of exercise, during a time to exhaustion run
62135000|NCT06119711||Short stay|Patients admitted to the ICU with a need for mechanical ventilation of less than 48 hours
62135001|NCT06119711||Long stay|Patients admitted to the ICU with a need for mechanical ventilation of 48 hours or more
62487367|NCT03356691|OTHER|"Spiritist passe"|"Spiritist passe during 5-10 minutes."
62487368|NCT03356691|PLACEBO_COMPARATOR|Laying on of hands with intent to heal|laying on of hands with intent to heal during 5-10 minutes.
62487369|NCT03356691|OTHER|Fluid water or magnetized water|Spiritist healers laying on of hands hands on the glass of water and desire health, restoration of balance and health for the patient.
61935450|NCT01570868|EXPERIMENTAL|Ponatinib 30 mg|Ponatinib at a dose of 30 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
61935451|NCT06707571|EXPERIMENTAL|Landmark Group|patients will receive spinal anesthesia using the surface landmark-guided
61935452|NCT06707571|EXPERIMENTAL|Ultrasonography Group|patients will receive spinal anesthesia after us-assisted technique
61935453|NCT00063323|ACTIVE_COMPARATOR|Bupropion|Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
61935454|NCT00063323|ACTIVE_COMPARATOR|Nicotine gum|Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
61935455|NCT00063323|ACTIVE_COMPARATOR|Bupropion+Nicotine Gum|Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
61935456|NCT00063323|PLACEBO_COMPARATOR|Double placebo|Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.
61935457|NCT05844397|ACTIVE_COMPARATOR|LASIK using Contoura with Phorcides|LASIK using Contoura with Phorcides in one eye.
61935458|NCT05844397|ACTIVE_COMPARATOR|SMILE|small incision lenticule extraction (SMILE) refractive surgery on the contralateral eye.
61935459|NCT00200161|ACTIVE_COMPARATOR|Metronomic Therapy Cohort|Concurrent temozolomide and radiotherapy plus lose dose of temozolomide
61935460|NCT00200161|EXPERIMENTAL|Dose-Dense Therapy Cohort|Concurrent temozolomide and radiotherapy plus high dose of temozolomide
61935461|NCT01607671|EXPERIMENTAL|Timolol|This group will receive ophthalmic Timolol maleate 0.5%, 1 drop to the effected eye twice daily for 4 weeks.
61935462|NCT01607671|NO_INTERVENTION|Standard Care|This group will be treated with current standard care. This does not include Timolol or other medications to reduce intraocular pressure.
61935463|NCT06668181|EXPERIMENTAL|Bimekizumab|Study participants will receive a bimekizumab dose which is dependent on their weight.
61935464|NCT00751010||1|In a mailed survey (Part 1 of this study), 127 women with a documented diagnosis of IC agreed to be contacted for an in-office examination.
61935465|NCT03436836|EXPERIMENTAL|Group N|"group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline.~Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study"
61935466|NCT03436836|ACTIVE_COMPARATOR|Group C|Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
61935467|NCT05280210|EXPERIMENTAL|Neoadjuvant therapy based on PTC drug screening|Patients will receive neoadjuvant therapy based on PTC drug screening. The regimen is complied with NCCN and CSCO guidelines. PD-1 inhibitor will be used if effective in drug screening.
61935468|NCT05280210|NO_INTERVENTION|Neoadjuvant therapy based on clinical experience|Patients will receive neoadjuvant therapy based on clinical experience. The regimen is complied with NCCN and CSCO guidelines.
61935469|NCT00883987||Back Pain|"Patients with chronic mechanical low back pain (Chronic low back pain is defined as having pain between the lower ribs and gluteal folds, with minimal radiation to the thigh and never below the knee, present for a minimum of seven weeks)"
62329514|NCT02898025|PLACEBO_COMPARATOR|G4 (Placebo IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.
62329515|NCT04867655|EXPERIMENTAL|Orange juice only|Experimental test for 24 hours after consumption of orange juice only (Tropicana 'with bits').
62329516|NCT04867655|EXPERIMENTAL|Orange Juice mixed with either 6g or 3 g of β-Glucan|Experimental test for 24 hours after consumption of orange juice (Tropicana 'with bits') with either 6g or 3 g of β-Glucan.
62329517|NCT03883022|EXPERIMENTAL|Vancomycin (V Group)|
62329518|NCT03883022|ACTIVE_COMPARATOR|Without Vancomycin (NV Group)|
62329519|NCT04802876|EXPERIMENTAL|Spartalizumab (PDR001) (Cohort-1 PD1-high)|400mg/intravenous every 28 days
62329520|NCT04802876|EXPERIMENTAL|Spartalizumab (PDR001) (Cohort-2 PD1-low)|400mg/intravenous every 28 days
62487370|NCT03356691|OTHER|Non-fluidic water|individuals receive water without fluidification (no laying on of hands hands on the glass of water).
62487371|NCT02465125|ACTIVE_COMPARATOR|Low transfusion trigger|Intervention group. Low or restrictive transfusion trigger: hemoglobin \< 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.
61935470|NCT00950911|EXPERIMENTAL|1|
62329521|NCT04802876|EXPERIMENTAL|Tislelizumab (Cohort-3 PD1-high)|300mg/intravenous every 28 days
61935471|NCT03707054|EXPERIMENTAL|Study Arm|Measurements of optic nerve diameter, Urine and plasma osmolality, Serum vasopressin.
61935472|NCT03555435|EXPERIMENTAL|On Your Own|Participants in this group will use the online program on their own for 6 weeks.
61935473|NCT03555435|EXPERIMENTAL|Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
61935474|NCT03555435|PLACEBO_COMPARATOR|Wait|Participants in this group will wait 6 weeks.
61935475|NCT06169852|EXPERIMENTAL|Arm 1 (0-4 months)|In this arm we will stimulate from either STN alone, GPi alone, or a combination of both STN and GPi.
61935476|NCT06169852|EXPERIMENTAL|Arm 2 (4-8 months)|In this arm we will stimulate from either STN alone, GPi alone, or a combination of both STN and GPi, whichever was not used in Arm 1.
61935477|NCT06169852|EXPERIMENTAL|Arm 3 (8-12 months)|In this arm we will stimulate from either STN alone, GPi alone, or a combination of both STN and GPi, whichever was not used in Arms 1 and 2.
62135002|NCT06698848|EXPERIMENTAL|Intravenous Ketamine|Intravenous ketamine will be given at a dose of 0.5 mg/kg over 40 minutes with a maximum dose of 60 mg.
62135003|NCT04194710|ACTIVE_COMPARATOR|Arthroscopic Resection|43 patients will be assigned to this arm. This is the standard technique to treat lateral epicondylitis. After randomization, patients will be informed and the surgery will be scheduled.
62329522|NCT03127215|EXPERIMENTAL|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
62329523|NCT03127215|OTHER|Arm C: Physician's choice|Physician's choice
62329524|NCT03546725|EXPERIMENTAL|Leg with compression stocking|Leg wearing compression stocking during the flight
62329525|NCT03546725|NO_INTERVENTION|Leg without compression stocking|Leg not wearing compression stocking during the flight
62329526|NCT01703286|EXPERIMENTAL|Linagliptin 5mg|given once daily over 28 days
62329527|NCT01703286|ACTIVE_COMPARATOR|Glimepiride|given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
62329528|NCT01703286|PLACEBO_COMPARATOR|Placebo|given once daily over 28 days
62329529|NCT01474330|EXPERIMENTAL|0.5-mg Pomalidomide or placebo (Cohort A)|A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions
62329530|NCT01474330|EXPERIMENTAL|1-mg Pomalidomide or placebo (Cohort B)|This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
62329531|NCT01474330|EXPERIMENTAL|2-mg Pomalidomide or placebo (Cohort C)|This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
62487372|NCT02465125|ACTIVE_COMPARATOR|High transfusion trigger|Control group. High or liberal transfusion trigger: hemoglobin \< 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery
62693573|NCT05497206|EXPERIMENTAL|Robotic-Assisted THA|Consecutive participants will receive THA via the ROSA Hip System.
61935478|NCT04763174|EXPERIMENTAL|mHealth Coping Skills Training for Symptom Management (mCOPE)|mHealth Coping Skills Training for Symptom Management (mCOPE) protocol tests the efficacy of a theory-based symptom management intervention designed to target multiple interrelated symptoms (pain, fatigue, psychological distress) with content uniquely relevant for young and middle-aged colorectal cancer patients. Addressing the co-morbid consequences of cancer while providing support in the context of age-related challenges (e.g., caring for children and parents, career) has the potential to significantly improve overall quality of life in young and middle-aged patients with cancer.
61935479|NCT04763174|NO_INTERVENTION|Standard Care|Standard Care group will complete assessment questionnaires at the same time points as mCOPE, but will not receive mCOPE protocol.
61935480|NCT00538564|EXPERIMENTAL|Tadalafil|Participants assigned to this arm were given oral 10 mg tadalafil tablets to take 3 times a week for 16 weeks.
61935481|NCT00538564|PLACEBO_COMPARATOR|Placebo|Participants assigned to this arm were given a placebo pill 3 times a week for the first 8 weeks, and then Tadalafil 10 mg 3 times a week for weeks 9-16.
62487373|NCT04007796|EXPERIMENTAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
62487374|NCT04007796|ACTIVE_COMPARATOR|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
62487375|NCT06627075|EXPERIMENTAL|Surface Guided RadioTherapy without face mask|"Radiotherapy sessions will be carried out using the surface camera system, replacing the restraint mask.~Self-assessment questionnaires will also be completed by healthcare professionals concerning the level of difficulty encountered during each SGRT session without mask.~Skin side effects are recorded by the radiotherapist during weekly follow-up consultations.~At the end of treatment, patients complete a patient experience questionnaire."
62487376|NCT05208892|EXPERIMENTAL|SZMN Treatment Group|Patients randomized into the SZMN treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic per side.
61935482|NCT00753428||Baseline evaluation|Prior to the implementation of the pilot project of giving routine HAART as a method of PMTCT, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households for the first round.
61935483|NCT00753428||Following implementation|Two years after full implementation of the pilot project of giving routine HAART for PMTCT across all sites, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households. \[Note: At time of implementation, we used the same sampling frame for each community. Because of the population increased observed in parts of Kafue, the final number of households significantly exceeded the minimum threshold.\]
61935484|NCT06210581|EXPERIMENTAL|Group I|The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
61935485|NCT06210581|OTHER|Group II|Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises.
61935486|NCT06002490|EXPERIMENTAL|P1101|Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
61935487|NCT02764697|OTHER|H.P. Acthar Subcutaneous Gel Injection|For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
61935488|NCT00690222|NO_INTERVENTION|TM|Topical mydriasis without pseudoexfoliation
61935489|NCT00690222|EXPERIMENTAL|ICM|Intracameral mydriasis without pseudoexfoliation
61935490|NCT00690222|NO_INTERVENTION|TM - PXF|Topical mydriasis with pseudoexfoliation
61935491|NCT00690222|EXPERIMENTAL|ICM - PXF|Intracameral Mydriasis with pseudoexfoliation
61935492|NCT01598675|ACTIVE_COMPARATOR|Control|Symmetric Gait. Dual-belted treadmill belts moving at the same belt speeds during training
61935493|NCT01598675|EXPERIMENTAL|Gait Asymmetry|Error Augmentation. Belts of a dual-belted treadmill may move at different belt speeds to amplify spatiotemporal gait asymmetry during training
61935494|NCT01598675|EXPERIMENTAL|Gait Symmetry|Error Minimization. Belts of a dual-belted treadmill may move at different belt speeds to encourage spatiotemporal gait symmetry during training
62135004|NCT04194710|EXPERIMENTAL|Cytokine rich serum injection|43 patients will be assigned to this arm. After randomization, patients will be informed and the first injection of serum rich cytokines will be scheduled. After 15 days, they will be injected again with serum rich cytokines.
62135005|NCT01171976|EXPERIMENTAL|TE Ranibizumab 0.5 mg and Laser|On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
62329532|NCT01600183|ACTIVE_COMPARATOR|casting|subjects with MTA will be treated with cast for 20 weeks. casting is replaced during every study visit.
62329533|NCT01600183|EXPERIMENTAL|UNFO-s|subjects with MTA will be treated with the UNFO-s device for 12 weeks - will be worn day and night during first 6 weeks and only at night during next 6 weeks
62329534|NCT01124058|EXPERIMENTAL|Loading|1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose
62329535|NCT01124058|ACTIVE_COMPARATOR|Maintenance|Re-start same dose as previously stable on
62693574|NCT02260232|EXPERIMENTAL|exercise intervention|Components of the program included supervised moderate to high intensity cardiorespiratory exercise, resistance training, and flexibility.
62693575|NCT02260232|NO_INTERVENTION|control|
62487377|NCT05208892|EXPERIMENTAL|SZMN+Dexmedetomidine Treatment Group|Patients randomized into the SZMN+Dexmedetomidine treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic along with 0.25 mcg/kg (max 10 mcg) Dexmedetomidine on each side (total of 0.5 mcg/kg, total max 20 mcg).
62487378|NCT05208892|NO_INTERVENTION|No Intervention: Control Group|Patients in this group will receive the standard of care for T\&A procedures within the pediatric population.
62487379|NCT02367872|ACTIVE_COMPARATOR|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
62487380|NCT02367872|EXPERIMENTAL|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
62693576|NCT02268656|OTHER|concentration of propofol in male|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in male
62693577|NCT02268656|OTHER|concentration of propofol in female|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in female
62693578|NCT06641960|EXPERIMENTAL|Probiotics group|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
62487381|NCT02367872|EXPERIMENTAL|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
62693579|NCT06641960|ACTIVE_COMPARATOR|The control group without Probiotics|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction without probiotic lozenges.
62693580|NCT06640153||Experimental: Gastroesophageal junction or upper gastric adenocarcinoma|Patients with biopsy verified gastroesophageal junction or upper gastric adenocarcinoma undergo mpMRI in addition to conventional CT imaging
62693581|NCT04700800|EXPERIMENTAL|Exercise, Infusion of Amino Acids|Exercise followed by infusion of amino acids, or infusion of amino acids alone.
62693582|NCT04700800|ACTIVE_COMPARATOR|Exercise|Exercise with no infusion of amino acids
62135006|NCT01171976|EXPERIMENTAL|TE Ranibizumab 0.5 mg alone|Patients received ranibizumab intravitreal injection therapy only.
62135007|NCT01171976|ACTIVE_COMPARATOR|PRN Ranibizumab 0.5 mg|Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.
62135008|NCT04959669|NO_INTERVENTION|Control group|Usual care
62487382|NCT02367872|EXPERIMENTAL|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
62487383|NCT02367872|EXPERIMENTAL|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
62487384|NCT02367872|ACTIVE_COMPARATOR|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
62693583|NCT01342120||Quetiapine|Quetipine users
62693584|NCT01342120||All other atypical antipsychotics|All other atypical antipsychotics users
62693585|NCT01342120||Risperidone|Risperidone users
62487385|NCT02367872|EXPERIMENTAL|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
62487386|NCT02367872|EXPERIMENTAL|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
62135009|NCT04959669|EXPERIMENTAL|Intervention group|DeSSBack (Decision Support System for Low Back Pain)
62135010|NCT02847715|NO_INTERVENTION|Audit phase|In the audit-phase, a group of 59 patients will be recruited and followed over a 12 month period. Data will be collected on clinical and patient outcomes in an audit in order to be able to compare to the intervention (after-phase) group.
62135011|NCT02847715|EXPERIMENTAL|Intervention (pilot-phase)|In the pilot-phase, a group of 59 patients will be recruited and followed over a 6-12 month period. Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely. All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
62135012|NCT06697301|ACTIVE_COMPARATOR|Arm 1|Participants in this arm will receive Placebo and Standard of Care (Pembrolizumab).
62135013|NCT06697301|EXPERIMENTAL|Arm 2|Participants in this arm will receive EIK1001 (selected dose 1) + Standard of Care (Pembrolizumab).
62135014|NCT06697301|EXPERIMENTAL|Arm 3|Participants in this arm will receive EIK1001 (selected dose 2) + Standard of Care (Pembrolizumab).
62329536|NCT02245568|EXPERIMENTAL|LMTM|
62693586|NCT01342120||Olanzapine|Olanzapine users
62693587|NCT05720351|ACTIVE_COMPARATOR|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
62693588|NCT05720351|ACTIVE_COMPARATOR|Staircase maneuver|Patients undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
62693589|NCT02957019|EXPERIMENTAL|L19-IL2 + RTX|"Phase I (Dose definition):~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.~Phase II (Activity Evaluation):~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
62693590|NCT05299671|EXPERIMENTAL|Video consultation group|Patients starting a new oral anti-cancer drug (OACD) will receive help to identify and manage potential drug-drug interactions alongside patient's oncologist through a one-time video consultation.
62693591|NCT06638476|EXPERIMENTAL|Perturbation induced step training|Participants will receive 18 sessions over 6 weeks.
62693592|NCT06638476|ACTIVE_COMPARATOR|Voluntary Step training|Participants will receive 18 sessions over 6 weeks.
62693593|NCT06015438|EXPERIMENTAL|Home Exercise EP Group|Participants in this group will follow an at home personalized EP for up to 12 weeks.
62693594|NCT06015438|ACTIVE_COMPARATOR|Short EP Group|Participants in this group will be enrolled in the short EP program.
61935495|NCT04056351|OTHER|Cohort of 50 enrolled patients|The following visits will be performed: direct post-OP, 3 weeks, 6 weeks, 3 months and 6 months after surgery. Surgical details will be assessed from the surgical notes. Medical images will be collected according to the standard of care. A post-OP CT scan will also be acquired when the treating surgeon requests it as per standard of care, or additionally, as a study specific imaging procedure for the rest of the participants. Patient activity will be estimated based on various factors, including questionnaires on demographics, activity level, comorbidity score and contralateral grip strength. The actual post-OP shoulder activity will be measured by motion tracking by means of sensors attached to upper arm of the treated side and on the chest for 6 weeks and by grip strength assessed at the treated arm at week 6. Fixation failure status will be determined 6 months post-OP. Imaging and details regarding the fixation failure event will be sent to ARI.
61935496|NCT00749515|EXPERIMENTAL|Single Arm|All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring and HIDA scan. Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well).
61935497|NCT06676995|EXPERIMENTAL|TPS|
61935498|NCT01805778||Acute Cohort|Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
61935499|NCT01805778||Survivor Cohort|Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
62329537|NCT04611711|OTHER|decitabine＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine (10mg ivgttqd, d1-5) combined with TQB2450 injection (1200mg ivgtt, d5)
62693595|NCT04205812|EXPERIMENTAL|INCMGA00012 + chemotherapy (nonsquamous NSCLC)|INCMGA00012 with pemetrexed + cisplatin OR carboplatin followed by INCMGA00012 plus pemetrexed until progression.
62693596|NCT04205812|ACTIVE_COMPARATOR|Placebo + chemotherapy (nonsquamous NSCLC)|Placebo with pemetrexed + cisplatin OR carboplatin followed by placebo plus pemetrexed until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
62693597|NCT04205812|EXPERIMENTAL|INCMGA00012 + chemotherapy (squamous NSCLC)|INCMGA00012 with carboplatin + paclitaxel OR nab-paclitaxel followed by INCMGA00012 until progression.
61935500|NCT04771884||Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)|The use of antimicrobial agents depends on the clinical practice.
61935501|NCT06709755|EXPERIMENTAL|STePS in Person. This is the STePS intervention provided in an inperson modality|The participants will receive the 9-session STePS intervention in person
61935502|NCT06709755|EXPERIMENTAL|STePS Virtual. This is the STePS intervention provided in a virtual format|The participants will receive the 9-session STePS intervention virtually
61935503|NCT06709755|ACTIVE_COMPARATOR|Diabetes Education Group|The Participants will receive diabete education directed toward adolescents matching time, group experience and homework assignments, delivered virtually
61935504|NCT05558644|EXPERIMENTAL|single arm for all patients|"single arm for all patients tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
61935505|NCT00476359|OTHER|double-boosted PI|double-boosted protease inhibitor combination
61935506|NCT05661214|NO_INTERVENTION|Control Group 1|This group is the control group 1 (one) that will be taught using structured standard teaching content. Before teaching, participants will be applied pre tests. After teaching, they will be applied post tests.
61935507|NCT05661214|EXPERIMENTAL|Intervention Group 1|This group is the intervention group 1 (one) that will be taught using model-based structured teaching content. In this teaching content, researchers will teach pressure injury risk factors; after teaching, participants will plan nursing interventions with Clinical Decision Support System (CDSS) integrated software. Before teaching, participants will be applied pre tests. After teaching, they will be applied post tests.
62135015|NCT04670887|ACTIVE_COMPARATOR|Immediate surgery|Patients undergo excision of a renal mass by partial or radical nephrectomy and will be followed by UISS risk classification.
62135016|NCT04670887|ACTIVE_COMPARATOR|Active surveillance|Patients enter active surveillance protocol. Delayed surgery on active surveillance will be recommended if progression from Bosniak 3 to 4 or a solid mass is noted on imaging by radiologist
62329538|NCT04611711|OTHER|decitabine + anlotinib ＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine and Anlotinib (decitabine 10mg ivgtt qd, d1-5; Anlotinib 8mg po.qd, d5-18) combined with TQB2450 injection (1200mg ivgtt, d5), using the traditional 3+3 experimental design (First enroll 3 subjects. If 1 case of DLT is observed, 3 more subjects need to be added to the same dose group to further evaluate the toxicity) to observe DLT to evaluate MTD. The trial starts from the 8mg dose of Anlotinib Start.
62329539|NCT02131051||Azelastine group|Azelastine nasal spray Azelastine eye drops
62693598|NCT04205812|ACTIVE_COMPARATOR|Placebo + chemotherapy (squamous NSCLC)|Placebo with carboplatin + paclitaxel OR nab-paclitaxel followed by placebo until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
62329540|NCT02131051||Ectoin group|Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
62329541|NCT01139385||clipless|laparoscopic cholecystectomy performed by harmonic scalpel with closure and division of the cystic duct only by the device
62693599|NCT06642064|EXPERIMENTAL|Intervention group and Control group (2 groups)|This study held a group meeting before the formal experiment to guide all participants in advance and explain the entire experimental process to them in detail. Students with questions were given a unified and detailed explanation. Each participant received a health education manual and a physical activity record book. During the experimental stage, the researchers reminded the participants to attend the health education lectures and physical activity experiments on time. Participants were required to participate in the experiment according to the experimental content.
62693600|NCT06642064|NO_INTERVENTION|control group|Control group: Participants only received a logbook to record their physical activity every week and participated in regular physical exercise activities at school
62329542|NCT01139385||traditional|laparoscopic cholecystectomy performed by harmonic scalpel with closure of the cystic duct only by titanium clip
62329543|NCT05999474|EXPERIMENTAL|Fractional CO2 laser combined with topical tioconazole|"Fractional CO2 laser (10,600 nm) will be done. The sessions will be done every 2 weeks.~Topical tioconazole 28% nail solution will be applied in between the sessions twice daily"
62329544|NCT05999474|ACTIVE_COMPARATOR|Q switched ND-Yag|Laser protocol with a specific parameters will be applied on the affected nails. In one session two passes across each nail plate will be performed with two minutes pauses between each pass. Sessions will be done every 2 weeks
62693601|NCT06380270|EXPERIMENTAL|Probiotic supplement group|Participants in this arm will receive a daily single sachet of oral probiotic Streptococcus salivarius eK12 (Bactoblis® EVOL: containing ca. 10 billion CFU of S. salivarius eK12) for 28-days. Participants will be followed for a further 2-months to assess for probiotic treatment safety and tolerance.
62693602|NCT06380270|NO_INTERVENTION|Control group|Participants in this arm will not receive probiotic supplementation. They will be followed in a similar way as the participants in the probiotic eK12 group.
62693603|NCT06640270|EXPERIMENTAL|Main Arm for PREF-Lucie|Interventional, quasi-experimental, multicentre, comparative clinical research study
62693604|NCT05453539|EXPERIMENTAL|Healthy volunteers dose level 1|0.53 mL ADx-001 / kg
62693605|NCT05453539|EXPERIMENTAL|Patients dose level 1|0.53 mL ADx-001 / kg
62693606|NCT05453539|EXPERIMENTAL|Patients dose level 2|1 mL ADx-001 / kg
62693607|NCT05453539|EXPERIMENTAL|Patients dose level 3|2 mL ADx-001 / kg
62693608|NCT05453539|EXPERIMENTAL|Patients dose level 4|4 mL ADx-001 / kg
62693609|NCT05410314||cHL (85%) and DLBCL (15%)|Patients enrolled in this study are cHL (85%) and DLBCL (15%) long-term survivors, treated mainly with ABVD+ radiotherapy (not under diaphragmatic and pelvic irradiation), without relapse (during quinquennial follow-up) who are followed at the clinic dedicated to fertility in oncology of our Department, which is a regional referral center for this purpose. Therefore, the investigators conducted a prospective observational controlled study on two groups: the first one (A group) underwent oral supplementation with MIC for 12 months; the second group (B group) underwent follow-up without any nutritional supplement for 12 months
62135017|NCT03582592|EXPERIMENTAL|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
62135018|NCT03582592|NO_INTERVENTION|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
62329545|NCT01470573|EXPERIMENTAL|Progenitor Autologous Cells|Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
62693610|NCT06639867|EXPERIMENTAL|VR-based home physiotherapy|Home-based non-immersive virtual reality using sensors strapped to the users limbs and body. They take part in a variety of games associated with movements of physiotherapy exercises.
62693611|NCT06639867|ACTIVE_COMPARATOR|Standard physiotherapy care|Standard care as prescribed by the treating physiotherapist.
62135019|NCT03592732||A|Patients with atrial fibrillation
62135020|NCT03592732||B|Patients without atrial fibrillation
62329546|NCT01301742|ACTIVE_COMPARATOR|BI 10773|Subject to receive one single dose BI 10773
62329547|NCT01301742|EXPERIMENTAL|BI 10773 plus gemfibrozil|Subject to receive one single dose BI 10773 plus 600 mg gemfibrozil bid for 5 days
62329548|NCT02532595|ACTIVE_COMPARATOR|Group 1 manual therapy and exercise|manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
62693612|NCT06344247|EXPERIMENTAL|Basic treatment|RAS inhibitors（Losartan®️/Valsartan®️） : maintain the maximum dose/maximum tolerated dose.
62693613|NCT06344247|EXPERIMENTAL|Basic treatment+SGLT2i|On the basis of RAS inhibitors treatment, combined with dapagliflozin and titrated to the target dose (10 mg qd).
62693614|NCT06344247|EXPERIMENTAL|Basic treatment+GLP-1RA|On the basis of RAS inhibitors treatment, combined with semaglutide titrated to the target dose (1 mg qw).
62693615|NCT06344247|EXPERIMENTAL|Basic treatment+SGLT2i+GLP-1RA|On the basis of RAS inhibitors treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw).
62693616|NCT04639726|ACTIVE_COMPARATOR|Whey Protein|
62693617|NCT04639726|PLACEBO_COMPARATOR|Placebo|
62693618|NCT02126891|EXPERIMENTAL|Canoeists|13 canoeists from a training center of the French canoeing team
62693619|NCT02126891|EXPERIMENTAL|Military|10 young recruits in military school of officers in ground forces of the French army
62693620|NCT04653376||Chronic tonsillitis|Patients with tonsil sizes grade 1 and 2, and tonsillectomy indications included frequently recurrent tonsillary infection, sore throat, and malodorous mouth problems were accepted as the chronic tonsillitis group.
62693621|NCT04653376||Tonsillar hypertrophy|Patients with tonsil size grades 3 and 4 and tonsillectomy indications included obstructive symptoms such as snoring, open mouth breathing, difficulty in breathing, and swallowing problems were accepted as the tonsillar hypertrophy group.
61935508|NCT05661214|NO_INTERVENTION|Control Group 2|This group is the control group 2 (two) that will be taught using structured standard teaching content. After teaching, they will be applied post tests. This group has no pre-test and will be created to increase internal validity, only.
62697586|NCT06427980|EXPERIMENTAL|HXLS group|The HXLS granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonurus heterophyllus, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthamus tinctorius L, 6.0g).
62697587|NCT06427980|PLACEBO_COMPARATOR|placebo group|The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. It included Hu Jing (28.0g)
62487387|NCT04124315||PAD Patients Completing SET|This single-group study includes patients with peripheral artery disease (PAD) who are completing a physician-prescribed supervised exercise training (SET) program.
62487388|NCT02129140||Hernia graft/mesh|Hernia repair patients implanted with biologic hernia graft during surgery
62487389|NCT02153645|EXPERIMENTAL|240mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 240mg daily for 12 weeks post two week titration phase.
62693622|NCT03862417|EXPERIMENTAL|Schroth exercise group|Will attend 5 1-hr long individual sessions to learn Schroth exercises and the home program. A 30-min. daily home program of 3 to 4 exercises will be progressed by the certified Schroth therapist using an algorithm. Patients will attend weekly 1-hr long group therapist-led exercise classes for 3 months. At each group class, adequate exercise performance will be assessed using the checklist. An algorithm guides the prescription of exercises intensity and progression from static to dynamic depending on the participant's ability. Prescription begins with Sitting on a Ball. If performed adequately, a more challenging exercise is attempted. The 3 most challenging exercises performed adequately as per the checklist will be prescribed with a detailed handout.
62693623|NCT03862417|NO_INTERVENTION|Control group|Observation without treatment or with previously prescribed pain medication is the current standard for adults with degenerative scoliosis not planning surgery.
62693624|NCT06643819|EXPERIMENTAL|Test Group1|
62693625|NCT06643819|EXPERIMENTAL|Test Group2|
62693626|NCT06643819|ACTIVE_COMPARATOR|CONTROL|
62693627|NCT03982810||Surgical Site Infections|Patients equal or greater than 18 years of age undergoing non-emergent non-cardiac surgical procedures involving a skin incision will be included in the study.
61935509|NCT05661214|EXPERIMENTAL|Intervention Group 2|This group is the intervention group 2 (two) that will be taught using model-based structured teaching content. In this teaching content, researchers will teach pressure injury risk factors; after teaching, participants will plan nursing interventions with Clinical Decision Support System (CDSS) integrated software. After teaching, they will be applied post tests. This group has no pre-test and will be created to increase internal validity, only.
61935510|NCT05806723|EXPERIMENTAL|type 2 diabetic patients at high cardio vascular risk|atorvastatin 40 mg a day for six months
61935511|NCT04644991|EXPERIMENTAL|Kinesiotape|Experimental group consisting of transfemoral amputees who kinesiology tape will be applied
61935512|NCT04644991|SHAM_COMPARATOR|ShamKinesiotape|The placebo group of transfemoral amputees who shame kinesiology tape will be applied
61935513|NCT06223035|EXPERIMENTAL|Secretome characterization and signaling to the adipose tissue|To identify possible exercise stimulated secreted proteins which signal to the adipose tissue, subcutaneous adipose and blood will be collected both before and at multiple timepoints following a VO2max test. Adipose will be collected from the abdominal subcutaneous region and blood will be collected from the arm. Blood will be analyzed for change in protein abundance and adipose will be analyzed for change in gene expression.
61935514|NCT03839082|ACTIVE_COMPARATOR|Usual Care then FitBit|This is the waitlist control arm.
61935515|NCT03839082|EXPERIMENTAL|FitBit then Usual Care|Intervention includes education, physical activity, and a nutrition assessment.
61935516|NCT04761822|EXPERIMENTAL|Moderna COVID-19 Vaccine|The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.
61935517|NCT04761822|EXPERIMENTAL|Pfizer-BioNTech COVID-19 Vaccine|The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.
61935518|NCT04761822|EXPERIMENTAL|Placebo +Moderna COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.5 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Moderna COVID-19 Vaccine, with the first dose administered 1 month later. The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart."
62329549|NCT02532595|EXPERIMENTAL|Group 2 TDN, manual therapy and exercise|trigger point dry needling (TDN) to trigger points in the gastrocnemius, soleus and tibialis posterior; manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
62329550|NCT01463072|EXPERIMENTAL|Treatment (nab-paclitaxel)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62329551|NCT01577160|EXPERIMENTAL|Paliperidone Extended Release (ER)|
62329552|NCT02253706|ACTIVE_COMPARATOR|Low flow nasal oxygen supplementation|Low flow nasal oxygen supplementation as per routine standard of care(control arm)
62487390|NCT02153645|EXPERIMENTAL|320mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 320mg daily for 12 weeks post a two week dose titration phase.
62487391|NCT02153645|PLACEBO_COMPARATOR|Placebo tablets|Placebo Tablets matching Amantadine HCl ER Tablets taken daily for 16 weeks.
62487392|NCT03453554|EXPERIMENTAL|DMN/Smart Home Partnership|Participants will learn how to use a digital memory notebook partnered with smart environment prompting technology to support everyday activities of daily living and reduce problems associated with memory deficits.
62487393|NCT03453554|ACTIVE_COMPARATOR|Digital Memory Notebook app|Participants will learn how to use a Digital Memory Notebook app to support everyday activities of daily living and reduce problems associated with memory deficits.
62487394|NCT02089282||Clavicle fractures|
62693628|NCT04730960||Study Group|Healthy patients between the ages of 18 and 30 without neck problems will be included in the study.
62693629|NCT05520307||HF|Patients with heart failure.
62693630|NCT05520307||IHD|Patients with ischemic heart disease.
62693631|NCT06641661||Experimental group|Hybutimibe 10mg QD was added to the conventional treatment
62693632|NCT06639282|EXPERIMENTAL|Drug Arm|Randomly assigned subjects who will receive an escalating dose of Siponimod (0.25-1 mg/day) for 12 months.
62693633|NCT06639282|PLACEBO_COMPARATOR|Placebo Arm|Randomly assigned subjects who will receive a placebo daily for 12 months.
62693634|NCT00967252||atorvastatin 10 mg or equivalent dose|Patients already taking atorvastatin 10 mg or equivalent dose in another statin who is undergoing high risk surgery
62487395|NCT04556045|EXPERIMENTAL|Radiation Therapy + Exercise Therapy|This group will receive exercise intervention in addition to their standard of care radiation treatment. At the baseline visit, they will meet with the certified exercise trainer (CET) and will be provided with a personalized exercise prescription and log to record what they do in between daily radiation treatment visits. The participant will also undergo an in-person exercise session prior to radiation therapy, which will take place either on the same day that the physical function tests are preformed or on a separate day. Participants will exercise between 1 and 7 times/week depending on the patient's tolerance to the exercise prescription. The CET will meet with the participant at every radiation treatment visit for an exercise counseling check-in. After five radiation treatments, the CET will follow-up with the participants via phone call once per week for 4 weeks during the follow-up period.
62487396|NCT04556045|NO_INTERVENTION|Radiation Therapy|The observational group will continue with their usual standard of care of radiation therapy. The study team will provide patients with an educational pamphlet at the end of their baseline visit. They will also be provided with a self-directed exercise program framework. Additionally, the participant's medical record will be reviewed for serious adverse events during their time on study. Baseline and final measurements will be obtained.
61935519|NCT04761822|EXPERIMENTAL|Placebo+Pfizer-BioNTech COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.3 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Pfizer-BioNTech COVID-19 Vaccine, with the first dose administered 1 month later. The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart."
62487397|NCT01773408|EXPERIMENTAL|Part 1: RO5503781|Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
62487398|NCT01773408|EXPERIMENTAL|Part 2: RO5503781 + Cytarabine|Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
61935520|NCT01654861|EXPERIMENTAL|HDIVC|Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
62487399|NCT01773408|EXPERIMENTAL|Part3:RO5503781+Cytarabine+Anthracycline|Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
62487400|NCT01773408|EXPERIMENTAL|Part 4: Optimized RO5503781 + Cytarabine|Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
62693635|NCT00967252||atorvastatin 20 mg or equivalent dose|Patients already taking atorvastatin 20 mg or equivalent dose in another statin who is undergoing high risk surgery
62693636|NCT00967252||atorvastatin 40 mg or equivalent dose|Patients already taking atorvastatin 40 mg or equivalent dose in another statin who is undergoing high risk surgery
61935521|NCT06434818|EXPERIMENTAL|Enhanced Digital-Chemosensory-Based Olfactory Training (EDITOR)|"The EDITOR device is designed to stimulate intensive neural activity in OFC over long periods of time. It consists of 40 daily cycles of intervention with a combination of olfactory stimulation and training tasks, lasting \~45 minutes, delivered once daily over three months. The device also includes 60% beta-caryophyllene chemosensory stimulation to target AUD and stimulant use disorder and 10 digital enhancements for the purpose of remote treatment, remote acquisition of behavioral and physiological data, and seamless data transmission to providers, through a HIPAA-compliant clinic end portal.~Participants assigned to this arm will receive their treatment-as-usual (TAU) alongside daily EDITOR therapy for three months. TAU will depend on the drug abused \[Buprenorphine with a median dose of 24 mg (range 16 - 32 mg) for Opioid use disorder and naltrexone (50-100 mg daily for Alcohol use disorder (AUD)."
61935522|NCT06434818|ACTIVE_COMPARATOR|Chemosensory-Based Olfactory Training (CBOT)|"CBOT with olfactory stimulants \& orbitofrontal (OFC) tasks~TAU same as above + CBOT (Chemosensory-Based Olfactory Training) therapy (40 cycles of olfactory stimulation and OFC training tasks, lasting \~45 minutes, once daily over three months) + use of their smartphone to communicate with their clinic provider/staff"
61935523|NCT06434818|SHAM_COMPARATOR|Chemosensory-Based Olfactory Training (CBOT) Sham|"Control Device (Sham) is CBOT device without olfactory stimulants and orbitofrontal tasks.~TAU same as above + CBOT sham + use of their smartphone to communicate with their clinic provider/staff. This CBOT device uses compressed room air scented with phenylethylamine (rose scent) instead of olfactory stimulants and has shape pattern matching tasks instead of cognitive tasks in order to blind users to their treatment assignment. Similar to the active arm, sham COT will be used daily for 45 minutes."
61935524|NCT03327597|ACTIVE_COMPARATOR|Abnormal Non-MGUS|Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.
61935525|NCT03327597|EXPERIMENTAL|MGUS group arm 1|Participants diagnosed with MGUS, randomized to group 1.
61935526|NCT03327597|EXPERIMENTAL|MGUS group arm 2|Participants diagnosed with MGUS, randomized to group 2.
61935527|NCT03327597|EXPERIMENTAL|MGUS group arm 3|Participants diagnosed with MGUS, randomized to group 3.
61935528|NCT03327597|ACTIVE_COMPARATOR|Normal group|Participants without MGUS.
62487401|NCT06300216||Octreotide microspheres standard dose monotherapy|
62487402|NCT06300216||Octreotide microspheres standard dose combination therapy|
62693637|NCT00967252||atorvastatin 80 mg or equivalent dose|Patients already taking atorvastatin 80 mg or equivalent dose in another statin who is undergoing high risk surgery
62693638|NCT00967252||non-statin group|Patients who are not taking or cannot take a statin drug who is undergoing high risk surgery
62697588|NCT05432609||Healthy|Weight bearing CT in fully extended and flexed (20 degrees) position, loaded and unloaded, respectively.
62697589|NCT05432609||Trochlear dysplasia|Weight bearing CT in fully extended and flexed (20 degrees) position, loaded and unloaded, respectively.
62697590|NCT04104789|EXPERIMENTAL|Kovanaze Nasal Spray (General Practice)|Adults who require restorations in the maxillary teeth that would need local anesthesia
62487403|NCT06300216||Octreotide microspheres incremental or increased frequency therapy|
62487404|NCT06300216||Octreotide microspheres maintenance therapy after targeted or chemotherapy|
62697591|NCT04104789|ACTIVE_COMPARATOR|Articaine Injections (General Practice|Adults who require restorations in the maxillary teeth that would need local anesthesia
62487405|NCT04185363|EXPERIMENTAL|Maralixibat|All subjects will receive Maralixibat oral solution
62697592|NCT06225349|EXPERIMENTAL|Microencapsulated Magnesium|This group will be provided with a the product Microencapsulated Magnesium.
61935529|NCT03327597|ACTIVE_COMPARATOR|Controls|Participants without MGUS, matched to MGUS participants by age and gender.
61935530|NCT02423772|EXPERIMENTAL|Intervention|Treatment as usual, plus 12 weeks of group based intervention to improve functioning and decrease problematic effects of opioid use.
61935531|NCT02423772|NO_INTERVENTION|Treatment as Usual|
61935532|NCT06664827|EXPERIMENTAL|BFR Training on the UCL|
61935533|NCT02089854|EXPERIMENTAL|endocrine therapy|toremifene 60mg PO. per day for premenopausal and perimenopausal patients; anastrozole 1mg PO. per day for postmenopausal patients
61935534|NCT02089854|NO_INTERVENTION|observation|
61935535|NCT00251355|EXPERIMENTAL|5-FU/gemcitabine/RT|
61935536|NCT00202176|EXPERIMENTAL|1|Ipratropium Bromide
61935537|NCT00202176|PLACEBO_COMPARATOR|2|Saline Solution (0.9% NaCl)
61935538|NCT06710587|NO_INTERVENTION|Control - Standard Pathway|Standard GLP/GIP-1RA pathway as offered by Voy as part of participants usual care for weight loss
61935539|NCT06710587|EXPERIMENTAL|Intervention - Standard Pathway + Voy Program|Standard GLP/GIP-1RA pathway as offered by Voy as part of participants usual care for weight loss + Voy Program - coaching and access to the Voy app to support behavioural changes
61935540|NCT04550169||Intensive Care Coordination|Intensive Care Coordination along with Standard of Care
61935541|NCT04550169||Control|Standard of Care alone
61935542|NCT04204122|EXPERIMENTAL|Arm 1: Eye treated with Vigamox|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
61935543|NCT04204122|PLACEBO_COMPARATOR|Arm 2: Eye treated with placebo|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
61935544|NCT01008150|ACTIVE_COMPARATOR|Arm 1: paclitaxel + trastuzumab then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
61935545|NCT01008150|EXPERIMENTAL|Arm 2: paclitaxel + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
61935546|NCT01008150|EXPERIMENTAL|Arm 3: paclitaxel + trastuzumab + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
61935547|NCT01008150|EXPERIMENTAL|Arm 3 NR: paclitaxel+trastuzumab+neratinib|Non-randomized: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
61935548|NCT04343300|OTHER|Control group|Control group without Pilates exercise during 12 weeks Participants were advised to keep their routine Falls diary calendar
62135021|NCT02056236|EXPERIMENTAL|Anti-epileptic drugs|"Step 1: Phenytoin (loading dose 15-20 mg/kg iv, maintenance doses 150 mg iv twice per day) PLUS one of the following benzodiazepines (bolus + continuous infusion): lorazepam or midazolam. Benzodiazepine dosing regimes should be based on national and local protocols for status epilepticus treatment~Step 2: Propofol infusion (with a maximum rate of 8 mg/kg/hour) PLUS a second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.~Step 3: Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages, treatment should be guided by the EEG pattern."
62487406|NCT05463601|EXPERIMENTAL|Mecapegfilgrastim +dalpiciclib + endocrine therapy|Mecapegfilgrastim / dalpiciclib / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
62487407|NCT05463601|ACTIVE_COMPARATOR|dalpiciclib + endocrine therapy|dalpiciclib / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
62487408|NCT06422286|EXPERIMENTAL|children allocated to low-level laser|"The laser device with wavelength 940 nm, energy 4J, and 3-4 mm away from the tissue is applied on PC6 acupoint without causing pain to the patient for 1 minute.~Immediately after the laser acupuncture, an alginate impression is going to be taken."
62487409|NCT06422286|EXPERIMENTAL|children allocated to microcurrent electrical stimulation|"A meridian acupuncture pen with AA battery will be applied on PC6 for one minute.~Immediately after using the meridian pen, an alginate impression is going to be taken."
62487410|NCT06422286|PLACEBO_COMPARATOR|placebo control group|A meridian acupuncture pen will be deactivated by the operator. Then an alginate impression is going to be taken.
62487411|NCT06560671|OTHER|Conventional|
62487412|NCT06560671|EXPERIMENTAL|Novel|
62697593|NCT06225349|EXPERIMENTAL|Magnesium Oxide|This group will be provided with a the product Magnesium Oxide.
62697594|NCT06225349|EXPERIMENTAL|Magnesium Citrate|This group will be provided with a the product Magnesium Citrate.
62697595|NCT06225349|EXPERIMENTAL|Magnesium Bisglycinate|This group will be provided with a the product Magnesium Bisglycinate.
61935549|NCT04343300|EXPERIMENTAL|Pilates group|Pilates classes were held twice weekly for one hour. The classes were divided into a warm-up, mat Pilates with accessories and a cool-down. Participants used small items of equipment such as bands, circles or rings, blocks, spyke balls and foam rollers. The intervention lasted 12 weeks; the classes were supervised twice a week. The supervised exercises were evaluated every four weeks (frequency and intensity) focused on the lower limb (muscles related to gait), core and trunk (muscles related to posture). The participants were asked to perform supplementary at-home workouts three times a week using a booklet and video that was provided to the participants. The video and booklet to introduce the six principles of Pilates, warm-up exercises, exercises on the chair, mat Pilates exercises and cool-down exercises. Participants were advised to perform these exercises three times a week for 30 minutes at home.
61935550|NCT00443027|EXPERIMENTAL|Vaginal Heat Wash-Out Device|
61935551|NCT05724225||First group with atrial fibrillation disease|10 Atrial fibrillation(AF), predominant right atrial dilatation with at least moderate IT
62487413|NCT05887427|EXPERIMENTAL|Neural Mobilisation Group (NMG)|The neural mobilisation group received one session of conservative physiotherapy and neural mobilization at the end of the session. The content of the conservative program was the same in both groups. Before the neural mobilization application, a nerve stretching test was performed to provide a specific stretching position for each nerve and the patient was asked if he/she had any complaints. After adjusting the intensity of the neural mobilization tension, all participants were asked if they felt numbness, tension or tingling sensation in the nerve. When the symptoms were at a level that did not bother the patient, the nerve was held in that position for 10 seconds and then the nerve was left in the relaxation position. Each neural mobilization was performed in 10 repetitions.
61935552|NCT05724225||Second group with atrial fibrillation disease and tricuspid insufficiency|10 AF, predominantly right atrial dilatation without TI (or TI no more than mild)
61935553|NCT05724225||Third group with AF and mitral insufficiency|10 AF, predominantly left atrial dilatation with at least moderate MI
61935554|NCT05724225||Fourth group with atrial fibrillation and IM|10 AF, predominantly left atrial dilatation without MI (or no more than mild MI)
61935555|NCT05724225||Fifth group with tricuspid insufficiency|10 IT at least moderate to right ventricular remodeling in patients with pulmonary hypertension
61935556|NCT05724225||Sixth group with mitral insufficiency|10 MI at least average from left ventricular remodeling from left ventricular dysfunction
62329553|NCT02253706|EXPERIMENTAL|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35
62487414|NCT05887427|ACTIVE_COMPARATOR|Control Group (CG)|Control group patients received one session of conservative physiotherapy program. The conservative program consisted of 20 minutes of heat application to the cervical region, 20 minutes of Transcutaneous Electrical Stimulation (TENS) application and 5 minutes of ultrasound application.
62487415|NCT04801654||Ion released group|First 30 patients will be assessed for metalic ion released by blood sample. the patients will be monitored until 10 years follow-up for long term performance of the device
62487416|NCT04801654||Other group|The remaining 125 patients will be not assessed for metalic ion released; they will be monitored until 10 years follow-up for long term performance of the device
62487417|NCT04026243|ACTIVE_COMPARATOR|QL group (n = 25)|After general anesthesia (GA), patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then moved dorsally until the QL muscle is identified with its attachment to lateral edge of the transverse process of the L4 vertebral body with identification of shamrock sign. The needle is inserted in-plane to transducer (lateral edge) and tip of needle is advanced through the QL muscle. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the QL and psoas major.
61935557|NCT05821426|EXPERIMENTAL|eTrieve PE Kit|
61935558|NCT02518412|EXPERIMENTAL|Active tDCS|Participants receive active tDCS stimulation. Half of the participants receive active tDCS stimulation, i.e 30 minutes active stimulation of the temporal cortex.
61935559|NCT02518412|PLACEBO_COMPARATOR|Placebo tDCS|Participants receive placebo tDCS stimulation. Half of the participants receive placebo tDCS stimulation, i.e 30 minutes inactive stimulation of the temporal cortex.
61935560|NCT01667692|EXPERIMENTAL|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
61935561|NCT01667692|EXPERIMENTAL|clarithromycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
61935562|NCT01331733||hMG-HP|Patients with a condition
61935563|NCT01331733||hMG-HP + GnRH antagonist|Patients with a condition
61935564|NCT05263596|OTHER|No Sarcopenia (Control Group)|healthy participants
61935565|NCT05263596|OTHER|Sarcopenia is probable|"Low muscle strength (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
61935566|NCT05263596|OTHER|Sarcopenia is confirmed|"Low muscle strength + low muscle quantity (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
62329554|NCT00905879||Group 1|
62329555|NCT04348487|OTHER|Standard procedure|For the conventional TIVAPS with cephalic vein approach, incision was made either in the midline of infraclivular or supraclavicular. Cathether was introduced to the central and then connected to the laterally implanted port in the deltopectoral region. The experience in the local center experienced several pitfalls with this method such as pneumothorax, pinch-off syndrome, compression of the catheter by the clavicle, kinking of the catheter, and loss of patencty.
62697596|NCT04983030|EXPERIMENTAL|Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus PGT121, PGDM1400, and VRC07-523LS bNAbs|Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
62697597|NCT04983030|ACTIVE_COMPARATOR|Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus Placebo|Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. Placebo will be administered at week 24, and at week 28.
61935567|NCT02787460|EXPERIMENTAL|Behavioral Text Messages|Couples assigned to a treatment group will receive weekly behavioral theory-based messages encouraging them to attend the sessions.
62329556|NCT01054677|EXPERIMENTAL|Educational intervention on antibiotic prescribing|The participants in this group received an educational intervention.
61935568|NCT02787460|NO_INTERVENTION|Simple Reminder Text Messages|"Couples in the control group will receive simple reminder text messages that include the date, time, and location of their next group session"
61935569|NCT04996641|EXPERIMENTAL|Intervention|Root canal treatment and crown restoration
62329557|NCT01054677|NO_INTERVENTION|No educational intervention|The participants in this group did not receive the educational intervention
62329558|NCT05868993|EXPERIMENTAL|Brachial Plexus Block Group 1|Interscalene
62329559|NCT05868993|EXPERIMENTAL|Brachial Plexus Group 2|Supraclavicular
62329560|NCT05868993|EXPERIMENTAL|Brachial Plexus Group 3|Suprascapular
62329561|NCT06555692||Test Group|Among patients scheduled for total mastectomy due to the breast cancer, Female patients aged 20 to 69 who are willing to undergo immediate breast reconstruction using implants will be enrolled. The test group will be prospectively selected in 60 patients who undergo the breast reconstruction surgery applying with SC Derm(Inverstigational ADM processed by the supercritical technology).
62329562|NCT06555692||Control Group|"The control group will be retrospectively collected in 60 patients who underwent the breast reconstruction surgery applying with other ADM from the current medical records for one year of 2022.~Among patients who underwent implant-based immediate breast reconstruction after total mastectomy, those who had the procedure between January 1, 2022, and December 31, 2022, and who completed at least 6 months of follow-up by June 2023 were included in the study.~For this retrospective study, medical records of patients who met the inclusion and exclusion criteria were extracted. Data collection was carried out in the same manner as it would be for a prospective study."
62329563|NCT01225640|EXPERIMENTAL|PNU-100480 600 mg BID|
62329564|NCT01225640|EXPERIMENTAL|PNU-100480 1200 mg QD|
62329565|NCT01225640|ACTIVE_COMPARATOR|RHZE|conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally
62329566|NCT01168713|ACTIVE_COMPARATOR|Levofloxacin|
62329567|NCT01168713|EXPERIMENTAL|CEM-101|
62329568|NCT03651193||AOSD|Patients fulfill Japan's Yamaguch AOSD classification
62329569|NCT03651193||Control|Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
62329570|NCT06554938|ACTIVE_COMPARATOR|water pik|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
62329571|NCT06554938|ACTIVE_COMPARATOR|Super floss|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
62329572|NCT01778387|ACTIVE_COMPARATOR|Laparoscopic ventral hernia repair|Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
62329573|NCT01778387|PLACEBO_COMPARATOR|Open ventral hernia repair|Open repair: Incision was made over hernia defect, reducing herniary contents by opening sac if it is necessary. We made 4 cm soft tissue flaps around edge of defect depending on available healthy fascial tissue. Chevrel technique with fascial closure using anterior rectus sheath with continuous and absorbable suture and placement of polypropylene mesh (Parietene standart polypropylene mesh, Covidien, Norwalk, CT) in an onlay position fixed with polypropylene suture.
62329574|NCT05029544|ACTIVE_COMPARATOR|intervention group 1|dynamic taping and standard rehabilitation program
62329575|NCT05029544|ACTIVE_COMPARATOR|intervention group 2|Kinesio taping and standard rehabilitation program
62329576|NCT05029544|OTHER|Control group|No taping on shoulder, only standard rehabilitation program
62329577|NCT03257072|EXPERIMENTAL|A: 50 Necator americanus L3 larvae|Mock infections with water at week 0 and 2, infection with 50 Necator americanus L3 larvae at week 4
62329578|NCT03257072|EXPERIMENTAL|B: 100 Necator americanus L3 larvae|Mock infections with water at week 0, infection with 50 Necator americanus L3 larvae at week 2 and 4
62329579|NCT03257072|EXPERIMENTAL|C: 150 Necator americanus L3 larvae|Infection with 50 Necator americanus L3 larvae at week 0, 2 and 4
62329580|NCT04181567|EXPERIMENTAL|electroconvulsive therapy + agomelatine|electroconvulsive therapy 2 times weekly + agomelatine 50 mg daily
62329581|NCT04181567|ACTIVE_COMPARATOR|electroconvulsive therapy + placebo|electroconvulsive therapy 2 times weekly + placebo
62329582|NCT01420588||gastric cancer|
62329583|NCT01420588||gastritis|
62329584|NCT01420588||gastric ulcer|
62329585|NCT01420588||normal|
62329586|NCT01029288|ACTIVE_COMPARATOR|Statin Choice Decision Aid|Subjects will receive an intervention of Statin Choice Decision Aid and usual care for antihyperglycemic medication discussion with their clinician.
62329587|NCT01029288|ACTIVE_COMPARATOR|Diabetes Medication Choice Decision Aid|Subjects will receive an intervention of Diabetes Medication Choice Decision Aid and usual care for lipid therapy medication discussion with their clinician.
62487418|NCT04026243|ACTIVE_COMPARATOR|TF group (n = 25)|After GA, patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in midaxillary line just cephalad to the iliac crest. Scanning anteriorly will identify the three muscles of the anterior abdominal wall. The transversus abdominis typically tapers to form a hyper echoic aponeurosis that passes posterior to quadratus lumborum. Scan will be continued posteriorly to visualize solid organs or viscera deep to the transversus abdominis. The needle will be positioned such that it enters the skin anterior to the ultrasound probe and passes in-plane posterolateral through the three lateral abdominal muscles. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the transversus abdominis muscle and the transversalis fascia anterolateral to quadratus lumborum.
62487419|NCT00387530|OTHER|Single Arm Study of Biopsy|
62487420|NCT00603967|OTHER|Aromatase inhibitor|
62693639|NCT06308211|EXPERIMENTAL|GROUP A (MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY)|"Group A will receive treatment session of 60 minutes including motor imagery for 20 minutes and mirror therapy for 20 minutes along with routine physical therapy of 20 minutes for 5 days per week for 12 weeks.In motor imagery subjects will watch the video and will be asked to close the eyes to focus and imagine how they are doing task they had previously observed 10 times and instructed to carry out the task in verbal commands given whenever necessary.~In mirror therapy,The unaffected limb will be placed in front of the mirror and patient will try to make the identical motions with the paretic limb while moving the non-paretic limb during the session and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions)."
62329588|NCT06413173|EXPERIMENTAL|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation. Stimulation will be applied for 20 minutes at the beginning of each session. Current will be ramped from 0 mA to 2 mA over 30 seconds, and then ramped down from 2 mA to 0 mA at the end of 20 minutes. Current will be applied via two electrodes consisting of a pre-inserted carbon rubber snap electrode that is pre-saturated with saline and connects directly to designated electrode sites located on the tDCS headband. The anodal stimulating electrode will be at location F3 (based on the 10-20 EEG location system) and the cathodal electrode at location F4.
62697598|NCT04983030|ACTIVE_COMPARATOR|Placebo Plus PGT121, PGDM1400, and VRC07-523LS bNAbs|Participants will receive Placebo at week 0 and 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
62329589|NCT06413173|SHAM_COMPARATOR|Sham tDCS|Electrodes will be placed at the same positions as for active stimulation (F3 and F4), but current will be ramped down immediately after the initial 30s ramp up period and then at 20 minutes ramped up and down as done at the beginning. Thus, participants feel the initial tingling sensation associated with tDCS, but will receive no active current for the rest of the stimulation period
62329590|NCT06055881||Observational|Patients undergo blood sample collection and complete questionnaires on study.
62329591|NCT03332108|EXPERIMENTAL|Intervention|Those allocated to the intervention arm will be enrolled in the mHealth intervention (EpxBreastfeeding) for six months, and will also be asked about breastfeeding status at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
62329592|NCT03332108|OTHER|Control|Those in the control arm will be asked about breastfeeding status (exclusive, supplementing, or formula only) at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
62329593|NCT02150824|EXPERIMENTAL|BI 187004 low dose mono QD|patient to receive one tablet containing low dose of BI 187004 or matching placebo
62329594|NCT02150824|EXPERIMENTAL|BI 187004 medium dose mono QD|patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo
62329595|NCT02150824|EXPERIMENTAL|BI 187004 high dose mono QD|patient to receive one tablet containing high dose of BI 187004 or matching placebo
62487421|NCT01251068|EXPERIMENTAL|gest age, cerebral ,somatic oxygenation measurement|
62487422|NCT03762954||Research Subjects|All adults aged 60 years or older scheduled to undergo outpatient ERCP and/or EUS at Vanderbilt University Medical Center (VUMC) will be invited to participate in the study. Invited patients who consent to participate as study subjects will undergo neurocognitive and functional assessment pre-procedure and at 90 days post-procedure.
62697599|NCT03303729|EXPERIMENTAL|Meat hydrolysate & Cluster Dextrin|Meat hydrolysate containing 25g of protein given together with 75 grams of Cluster Dextrin.
62135022|NCT02056236|ACTIVE_COMPARATOR|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
62329596|NCT02150824|EXPERIMENTAL|BI 187004 high dose QD add on|patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose
62329597|NCT01166412|ACTIVE_COMPARATOR|Dose level AG1000-6.5|
62329598|NCT01166412|ACTIVE_COMPARATOR|Dose level AG1000-12.5|
62329599|NCT02342561|EXPERIMENTAL|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
62329600|NCT02342561|NO_INTERVENTION|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
62329601|NCT03714113|EXPERIMENTAL|Kidney transplant recipients.|Patients who undergo kidney transplant in 2018 or 2019.
62329602|NCT06504173||diced cartilage (DC)|After removing a part of the rip cartilage and microsurgery, the exposed internal mammary vessels in autologous free flap breast reconstruction was restored with diced cartilage (DC) out of the removed rip cartialge.
62135023|NCT05171985|EXPERIMENTAL|Dexmedetomidine sedation group|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
62135024|NCT05171985|OTHER|control group|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics
62693640|NCT06308211|EXPERIMENTAL|GROUP B (MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY)|"GROUP B will receive treatment session of 60 minutes including motor relearning program of 40 minutes duration along with routine physical therapy of 20 minutes as explained in group A protocol. Treatment session will be given 5 days per week for 12 weeks.~Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training."
62693641|NCT04629196|EXPERIMENTAL|IV Weight-Based Induction Dose|
62693642|NCT04629196|ACTIVE_COMPARATOR|Standard Subcutaenous Dose|
62329603|NCT06504173||control|After removing a part of the rip cartilage and microsurgery, the exposed internal mammary vessels in autologous free flap breast reconstruction was NOT restored.
61935570|NCT06356090|EXPERIMENTAL|SPACE treatment with random baselines|Participants are randomly allocated to one of three baseline periods (4 weeks, 6 weeks or 8 weeks). Only the parents of the participating families receive the SPACE treatment (12 sessions across 12 weeks). After the SPACE treatment, there is a follow-up period of 6 month after baseline.
61935571|NCT00567593|OTHER|Rosiglitazone|Rosiglitazone; 8mg tablet once a day for 14 days
61935572|NCT06143800|EXPERIMENTAL|retrieval + self-focused cognitive reappraisal|Participants in this arm will first accept a memory reactivation to open the reconsolidation window, then accept the self-focused cognitive reappraisal intervention.
62135025|NCT03074656|EXPERIMENTAL|Therapeutic drug monitoring|Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies
62135026|NCT03074656|ACTIVE_COMPARATOR|Standard care|Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies
62329604|NCT01081873||Advanced prostate cancer participants|Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
62329605|NCT03648840|OTHER|Higher lifetime alcohol drinking|Half of the participants will have a history of higher lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
62329606|NCT03648840|OTHER|Lower lifetime alcohol drinking|Half of the participants will have a history of lower lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
62329607|NCT03648840|OTHER|Resting state connectivity|Some participants will also complete a functional magnetic resonance imaging (fMRI) session to determine resting state connectivity. All participants in this Arm will have completed both of the iv alcohol self-administration sessions (Aversive cue, Neutral cue).
62329608|NCT01860053|EXPERIMENTAL|behavioral intervention|
62329609|NCT01860053|NO_INTERVENTION|no treatment control|
62693643|NCT05613946|OTHER|Microbubble contrast agent Lumason|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
62329610|NCT01052168|ACTIVE_COMPARATOR|Speed Group|The Speed Group, (n=20) will train in laparoscopic suturing on the validated FLS suturing model until the expert level of speed (i.e. task duration \< 70 seconds) has been achieved on two consecutive attempts.
62329611|NCT01052168|EXPERIMENTAL|Motion Group|The Motion Group, (n=20) will train in laparoscopic suturing until expert levels of motion (pathlength 6700 and smoothness 560) have been achieved.
62693644|NCT05613946|OTHER|Microbubble contrast agent Optison|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
62693645|NCT05613946|OTHER|Microbubble contrast agent Definity|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
62693646|NCT01251055|PLACEBO_COMPARATOR|Placebo|
62693647|NCT01251055|EXPERIMENTAL|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1 4000 mg/day
62697600|NCT03303729|ACTIVE_COMPARATOR|Meat hydrolysate & placebo|Meat hydrolysate containing 25g of protein given together with 75 grams of Glucose.
61935573|NCT06143800|EXPERIMENTAL|retrieval + context-focused cognitive reappraisal|Participants in this arm will first accept a memory reactivation to open the reconsolidation window, then accept the context-focused cognitive reappraisal.
61935574|NCT06143800|ACTIVE_COMPARATOR|non-retrieval + self-focused cognitive reappraisal|Participants in this arm will directly accept the self-focused cognitive reappraisal intervention without memory reactivation.
61935575|NCT06143800|ACTIVE_COMPARATOR|non-retrieval + context-focused cognitive reappraisal|Participants in this arm will directly accept the context-focused cognitive reappraisal intervention without memory reactivation.
61935576|NCT06665906|EXPERIMENTAL|PainTrainer Followed by Social Intervention|At study entry participants will receive web-based cognitive behavior therapy (PainTrainer) which is a self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises. At Week 12, social intervention will begin. Social intervention includes at least six phone call visits, plus or minus 4, with patient navigator to coordinate care.
62135027|NCT05482945|EXPERIMENTAL|Intervention|Patients will be ventilated with a mixture of Ar 70%/O2 30% for 4 hours
62135028|NCT05482945|NO_INTERVENTION|Control-standard|Ventilation with a FiO2 of 30% in room air is continued for 4 hours.
62135029|NCT06540443|EXPERIMENTAL|Dose cohort 1|pre- and post-enhanced MRI
62135030|NCT06540443|EXPERIMENTAL|Dose cohort 2|pre- and post-enhanced MRI
62135031|NCT06540443|EXPERIMENTAL|Dose cohort 3|pre- and post-enhanced MRI
62135032|NCT06540443|EXPERIMENTAL|Dose cohort 4|pre- and post-enhanced MRI
62135033|NCT05652075|EXPERIMENTAL|PENG and LFCN|
62135034|NCT05652075|EXPERIMENTAL|lumbar plexus|
62135035|NCT00715884|EXPERIMENTAL|1|CYPHER® ELITE™ Sirolimus-Eluting Stent System.
62135036|NCT00715884|ACTIVE_COMPARATOR|2|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
62135037|NCT03532165|OTHER|Positive lower extremity ultrasound|This group found to to have a deep venous thrombosis on lower extremity ultrasound will not have a CT of the chest ordered from the emergency department, and will be treated for the DVT and presumed PE.
62329612|NCT01052168|EXPERIMENTAL|Speed and Motion Group|The Speed and Motion Group (n=20) will train in laparoscopic suturing until expert levels of speed AND motion have been achieved.
62487423|NCT06206148|EXPERIMENTAL|Hand-written pain journal|Post-operative orthopedic surgery patient will be given a pen and journal with chart inside and instructed to fill out the chart with time/date and pain intensity level as frequently as they want.
62487424|NCT06206148|EXPERIMENTAL|Smartphone app|Post-operative orthopedic surgery patient will be given a research smartphone and an app to record their pain and will be instructed to fill out the pain survey as frequently as they want.
62487425|NCT06206148|EXPERIMENTAL|Novel electronic pain recording device|Post-operative orthopedic surgery patient will be given a pain recording device and will be instructed to input their pain using the buttons on the device as frequently as they want.
62487426|NCT03939364|EXPERIMENTAL|0.1% SBS-101|
62487427|NCT03939364|EXPERIMENTAL|0.3% SBS-101|
62487428|NCT03939364|EXPERIMENTAL|0.2% SBS-101|
62487429|NCT03939364|PLACEBO_COMPARATOR|Placebo|
62487430|NCT01894802|EXPERIMENTAL|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
62487431|NCT00592579|EXPERIMENTAL|1|Open label, oral administration of 2ME2
62487432|NCT01949324|EXPERIMENTAL|NT-501 Implant procedure|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
62487433|NCT01949324|SHAM_COMPARATOR|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
62487434|NCT02895802|OTHER|Verbal instructions with picture diagram|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a picture diagram of handwashing.
62487435|NCT02895802|OTHER|Verbal instructions with video of ADSC|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a video of the adult down syndrome center
62487436|NCT02895802|OTHER|verbal instructions w. video of w/o DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and viewing an educational video depicting a person without down syndrome washing their hands.
62487437|NCT02895802|OTHER|verbal instructions w.video w/DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and watching an educational video depicting a person with down syndrome washing their hands.
62487438|NCT01608646|NO_INTERVENTION|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
62693648|NCT05937243|EXPERIMENTAL|Base self-help CBT program plus Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
62697601|NCT01661543|EXPERIMENTAL|Bean consumption to lower cholesterol|"This arm will consume 120 grams of cooked beans per day in a food item such as a soup or stew for 5 out of 7 days for 6 weeks.~The bases (i.e. vegetables, broth, seasonings, etc) for all food items are the same in all groups."
61935577|NCT06665906|EXPERIMENTAL|Social Intervention Followed by PainTrainer|Participants will have social intervention at study entry. Social intervention includes at least six phone call visits, plus or minus 4, with patient navigator to coordinate care. At week 12, web-based cognitive behavior therapy (PainTrainer) will begin. PainTrainer is a self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.
62135038|NCT03532165|OTHER|Negative lower extremity ultrasound|This group that does not have a deep venous thrombosis on lower extremity ultrasound will proceed to get the CT of the chest .
62135039|NCT00746655|OTHER|SBRT / TACE|
62135040|NCT02137616|ACTIVE_COMPARATOR|risperidone|low dosage of antipsychotic drug
62135041|NCT02137616|ACTIVE_COMPARATOR|olanzapine|low doseage of antipsychotic
62135042|NCT02137616|ACTIVE_COMPARATOR|quetiapine|low doseage of antipsychotic
62135043|NCT02137616|ACTIVE_COMPARATOR|aripiprazole|low doseage of antipsychotic
62135044|NCT03933800|EXPERIMENTAL|High flow nasal cannula (HFNC)|High flow nasal cannula therapy
62135045|NCT03933800|ACTIVE_COMPARATOR|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure therapy
62135046|NCT01954836|EXPERIMENTAL|Initial fasting|Fasting during chemotherapy of the first half of chemotherapy cycles (1 and 2 of four or 1 to 3 of six cycles)
62487439|NCT05535868|EXPERIMENTAL|SPN3.|Inoculation with SPN3 at D0 visit. 0.1ml of pneumococcus is given
62487440|NCT05535868|EXPERIMENTAL|SPN3 booster|inoculation booster at day 14 This visit will only occur for participants who have tested negative for SPN3 at days 2 and 7. 0.1ml of pneumococcus is given
62487441|NCT00615667|EXPERIMENTAL|tacrolimus(fk506) treatment|tacrolimus(fk506) treatment
62487442|NCT02729090|EXPERIMENTAL|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks
62487443|NCT02729090|ACTIVE_COMPARATOR|Device: treadmill Train_Comb_aerobic|strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series.
62487444|NCT04816396|EXPERIMENTAL|experimental|For 8 weeks, Reminiscence Therapy based on Roy Adaptation Model will be applied
61935578|NCT06665906|EXPERIMENTAL|PainTrainer Only|At study entry participants will receive web-based cognitive behavior therapy (PainTrainer) which is a self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.
61935579|NCT01907100|PLACEBO_COMPARATOR|Placebo + pemetrexed/cisplatin|Placebo controlled arm
62329613|NCT03306615|EXPERIMENTAL|Treatment Arm|Hyaluronidase plus saline
62329614|NCT03306615|PLACEBO_COMPARATOR|Control Arm|Normal Saline
61935580|NCT01907100|EXPERIMENTAL|Nintedanib 200mg + pemetrexed/cisplatin|Experimental arm
61935581|NCT06589661||Unexpected cesarean delivery under general anesthesia|Patients who have an unexpected cesarean delivery under general anesthesia.
61935582|NCT04483167|EXPERIMENTAL|99mTccAbVCAM1-5|"Healthy volunteers and asymptomatic patients~1. Pré-screening of the volunteers by the CIC or the Vascular Surgeon and sending or handing over the newsletter~2. Visit 0 Selection: Validation of IC / NIC + Consent collection + additional exams~3. Visit 1 Inclusion: J0 Scintigraphic imaging following injection 99mTc-cAbVCAM1-5 (370 MBq - 550 MBq - 750 MBq depend of the SAE or AE )~4. Visit 2: Follow-up visit (Day 14 +/- 7 days post injection)~5. Visit 3: End of the study, follow-up visit (70 days +/- 10 days post injection)"
61935583|NCT05291026|NO_INTERVENTION|control group|Type 2 diabetes patients, 18 years old and above, enrolled in the out-patient, diabetes clinic of the tertiary health facility, receiving only standard of care, and who gave their informed consent
62329615|NCT01245426|EXPERIMENTAL|GW870086 2mg|GW870086 2mg once daily in the morning for 27 ± 2 days
62329616|NCT01245426|EXPERIMENTAL|GW870086 4mg|GW870086 4mg once daily in the morning for 27 ± 2 days
62329617|NCT01245426|PLACEBO_COMPARATOR|Placebo|Placebo once daily in the morning for 27 ± 2 days
62329618|NCT01245426|EXPERIMENTAL|GW870086 1mg|GW870086 1mg once daily in the morning for 27 ± 2 days
62329619|NCT01245426|EXPERIMENTAL|GW870086 3mg|GW870086 3mg once daily in the morning for 27 ± 2 days
62329620|NCT03633227|EXPERIMENTAL|Obeticholic Acid (OCA)|Participants will initiate treatment with OCA 5 milligrams (mg) tablets orally once weekly. At Week 12, if there are no safety concerns, the dose will be up-titrated to OCA 5 mg twice weekly. Every 6 weeks thereafter, based on tolerability assessments, further up-titration of dose will be considered. At each titration visit, the participants will start the higher dose regimen no earlier than 2 days after the prior dose. The maximum dose titration will be OCA 10 mg twice weekly at least 3 days apart. The minimum treatment duration will be 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).
62329621|NCT03633227|PLACEBO_COMPARATOR|Placebo|Participants will receive OCA matching placebo orally once weekly or twice weekly for the duration of at least 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).
62329622|NCT02855346|EXPERIMENTAL|200 mg of DPV|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
61935584|NCT05291026|EXPERIMENTAL|intervention group|type 2 diabetes patients, 18 years old and above, enrolled in the out-patient diabetes clinic of the tertiary health facility, receiving standard of care in addition to a mobile phone - based health education and follow-up messaging on a frequency of once a day corresponding to how often they are expected to take their medications (that is every day), and who gave their informed consent.
61935585|NCT05985005|EXPERIMENTAL|online simulation of high alert medication safety training|
61935586|NCT05985005|NO_INTERVENTION|classroom teaching regarding high alert medication|
61935587|NCT03585348||Study cohort|The estimated cohort consists of 317.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (205.000) as well as Massachusetts General Hospital (112.000) and received treatment by anesthesia and surgical providers who have completed at least 50 anesthesias and surgeries at their respective institution, respectively.
62329623|NCT02855346|EXPERIMENTAL|200 mg of DPV + 320 mg LNG|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
62329624|NCT02411201|EXPERIMENTAL|DOTAREM|
62329625|NCT01120093|EXPERIMENTAL|Aclidinium bromide 100 μg bid|Aclidininum bromide 100 μg twice daily by inhalation
62329626|NCT01120093|EXPERIMENTAL|Aclidininum bromide 200 μg bid|Aclidininum bromide 200 μg twice daily by inhalation
62329627|NCT01120093|EXPERIMENTAL|Aclidininum bromide 400 μg bid|Aclidininum bromide 400 μg twice daily by inhalation
62329628|NCT01120093|PLACEBO_COMPARATOR|Placebo|Placebo twice-daily by inhalation
62329629|NCT01120093|ACTIVE_COMPARATOR|Formoterol 12 μg bid|Formoterol 12 μg twice daily by inhalation
62329630|NCT01403740||Acquired haemophilia patients|
62329631|NCT00337467|EXPERIMENTAL|A1|
62329632|NCT02205827|NO_INTERVENTION|Single-arm|healthy volunteers
62329633|NCT00541086|EXPERIMENTAL|A - anastrozole|Up-front adjuvant anastrozole for 5 years
62329634|NCT00541086|EXPERIMENTAL|B - exemestane|Up-front adjuvant exemestane for 5 years
62329635|NCT00541086|EXPERIMENTAL|C - letrozole|Up-front adjuvant letrozole for 5 years
62329636|NCT00541086|ACTIVE_COMPARATOR|D - tamoxifen followed by anastrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by anastrozole for 3 years
62329637|NCT00541086|ACTIVE_COMPARATOR|E - tamoxifen followed by exemestane|Switch adjuvant treatment with tamoxifen for 2 years followed by exemestane for 3 years
62329638|NCT00541086|ACTIVE_COMPARATOR|F - tamoxifen followed by letrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by letrozolefor 3 years
62329639|NCT00850460|PLACEBO_COMPARATOR|Placebo|Lactose placebo pill
62329640|NCT00850460|ACTIVE_COMPARATOR|Statins|Statin medications
61935588|NCT06412575|EXPERIMENTAL|JNT group|In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
62135047|NCT01954836|ACTIVE_COMPARATOR|Secondary fasting|Fasting during the second half of chemotherapy cycles (3 and 4 of four cycles or 4 to 6 of six cycles)
62135048|NCT06405841||Patients with rib fractures|Patients with rib fractures that correspond to inclusion and exclusion criteria
62329641|NCT00038701|EXPERIMENTAL|Gemzar Chemoradiation + TNP-470|
62135049|NCT06451016|EXPERIMENTAL|Vitamin D group|
62135050|NCT06451016|PLACEBO_COMPARATOR|Control Group|
62135051|NCT02572700||Patients with psoriatic arthritis|PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.
62135052|NCT02572700||Patients with skin psoriasis without arthrits|20 patients with skin psoriasis without arthrits will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
62135053|NCT02572700||Healthy controls|20 healthy controls will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
62135054|NCT06465485|EXPERIMENTAL|Benralizumab|Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be all treated by study Drug.
62135055|NCT04587505|ACTIVE_COMPARATOR|Epidural anesthesia and analgesia|Epidural catheter insertion: Th 12- L 1 or Th 11 - Th 12 using the midline approach. Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml). Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml).
62329642|NCT02194400|PLACEBO_COMPARATOR|Placebo|Saline infusion
62135056|NCT04587505|ACTIVE_COMPARATOR|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
62487445|NCT04816396|NO_INTERVENTION|No İntervention|No intervention will be applied to this group.
62693649|NCT05937243|EXPERIMENTAL|Base self-help CBT program plus Just-in-time, adaptive interventions (JITAIs)|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
62693650|NCT05937243|EXPERIMENTAL|Base self-help CBT program plus JITAIs plus Advanced Digital Data Sharing with Coaches|When Advanced DDS with Coaches and JITAIs are both ON, participants will receive machine learning-informed interventions. In addition, participants will also receive weekly emails from coaches to provide additional support to improve treatment adherence and skills utilization.
62693651|NCT05937243|ACTIVE_COMPARATOR|Base self-help cognitive behavior therapy (CBT) program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participants to set personalized goals each week. Modules will be completed in succession over the course of 12 weeks and a new module will be made open each week. At the end of each weekly module, participants will complete an end-of-the-week survey and report on the frequency of skills use in the past week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
62693652|NCT04904549|EXPERIMENTAL|Stage 1: SARS-CoV-2 vaccine|2 injections of monovalent SARS-CoV-2 vaccine at Day 1 and Day 22
62693653|NCT04904549|PLACEBO_COMPARATOR|Stage 1: Placebo|2 injections of placebo at Day 1 and Day 22
61935589|NCT06412575|ACTIVE_COMPARATOR|TNT group|In the TNT group, the traditional decompression nasogastric tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
61935590|NCT00792077|EXPERIMENTAL|Sleep time|"Assessment of patients with chronic lymphocytic leukemia (CLL) experience severe cancer related fatigue (CRF):~Lenalidomide + Actigraph + Questionnaire + Sleep Test"
62135057|NCT00644514|EXPERIMENTAL|LPS endotoxin inh f/u bronchoscopy|Participants receive inhalation of LPS endotoxin, followed by bronchoscopy in this study.
61935591|NCT05067673|PLACEBO_COMPARATOR|Control group|Placebo dry needling
61935592|NCT05067673|EXPERIMENTAL|Experimental group|Dry needling
62135058|NCT05971875|ACTIVE_COMPARATOR|vNOTES vs Vaginal Hysterectomy|Group A: If VH is concidered safe and feasable; the patient is randomized between VH and vNOTES
62135059|NCT05971875|ACTIVE_COMPARATOR|vNOTES vs Laparoscopic Hysterectomy|If VH is not concidered safe and feasable; The patient is randomized between LH and vNOTES
62135060|NCT01289314|ACTIVE_COMPARATOR|Total laparoscopic hysterectomy|
62135061|NCT01289314|ACTIVE_COMPARATOR|Laparoscopic supracervical hysterectomy|
62329643|NCT02194400|EXPERIMENTAL|RSLV-132|0.3 - 10 mg/kg experimental drug
62329644|NCT03212131|EXPERIMENTAL|Normal hepatic function|Subjects with normal hepatic function
62329645|NCT03212131|EXPERIMENTAL|Mild hepatic impairment|Subjects with mild hepatic impairment
62329646|NCT03212131|EXPERIMENTAL|Moderate hepatic impairment|Subjects with moderate hepatic impairment
62487446|NCT01011413|ACTIVE_COMPARATOR|600 milligram (mg) Efavirenz|Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
62487447|NCT01011413|EXPERIMENTAL|400mg Efavirenz|Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
62487448|NCT01427062|EXPERIMENTAL|anticipatory and compensatory postural control training|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
62487449|NCT01427062|ACTIVE_COMPARATOR|strength-focused training|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
62487450|NCT01488448|EXPERIMENTAL|Nebulized Hypertonic Saline|4mL nebulized 3% sodium chloride every 4 hours until discharge
62487451|NCT01488448|PLACEBO_COMPARATOR|Nebulized Normal Saline|4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
62487452|NCT04862806|EXPERIMENTAL|Israel CLL study group|BNT162b2 mRNA vaccine
62487453|NCT01028586|ACTIVE_COMPARATOR|Arm 1|Number of Cycles: until progression or unacceptable toxicity develops.
62487454|NCT01028586|ACTIVE_COMPARATOR|Arm 2|Number of Cycles: until progression or unacceptable toxicity develops.
62487455|NCT01028586|PLACEBO_COMPARATOR|Arm 3|Placebo
62487456|NCT04084795|ACTIVE_COMPARATOR|EMDR plus MtCS|MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
62487457|NCT04084795|PLACEBO_COMPARATOR|EMDR plus sham-MtCS|Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
62487458|NCT04084795|NO_INTERVENTION|Treatment as Usual|Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry. The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.
62487459|NCT06263842|EXPERIMENTAL|Immediate Implant Placement Using Socket Shield Technique alone|after insertion of immediate implant Using Socket Shield Technique, the bone defect between the socket shield and the implant fixture will be left ungrafted
62487460|NCT06263842|EXPERIMENTAL|Immediate Implant Placement Using Socket Shield Technique with xenograft|the shield/fixture jumping gap will be grafted with xenograft
62693654|NCT04904549|EXPERIMENTAL|Stage 2: SARS-CoV-2 vaccine|2 injections of bivalent SARS-CoV-2 vaccine at Day 1 and Day 22
62693655|NCT04904549|PLACEBO_COMPARATOR|Stage 2: Placebo|2 injections of placebo at Day 1 and Day 22
62693656|NCT05418426|EXPERIMENTAL|IVR: estradiol 80 ug/day + progesterone 4mg/day|28-day IVR 80/4
62693657|NCT05418426|EXPERIMENTAL|IVR: estradiol 160 ug/day + progesterone 8mg /day|28-day IVR 160/8
62693658|NCT05418426|ACTIVE_COMPARATOR|Oracle Estrace(R)/Prometrium(R)|29 days (estradiol 1mg/progesterone 100 mg oral capsule)
62693659|NCT06196034||Asthma|Subjects with asthma
62693660|NCT06196034||Control|Subjects with no asthma
61935593|NCT04449861|EXPERIMENTAL|Durvalumab plus 4-6 cycles chemotherapy|Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.
62693661|NCT06643221|EXPERIMENTAL|Exercise Cohort|After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)
62693662|NCT06643221|PLACEBO_COMPARATOR|Exercise + Beta Blocker Cohort|Healthy participants will complete a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake under the following conditions: (1) Placebo; (2) 10mg bisoprolol ingestion; (3) 80ng nadolol ingestion; (4) 50ng carvedilol ingestion; (5) 10mg bisoprolol + 100mcg roflumilast ingestion. All drugs and placebo will be ingested 2-3h prior to exercise. Trial conditions will be double-blind and cross over with each participant serving as their own cntrol
61935594|NCT00503516|EXPERIMENTAL|1|Megestrol acetate 160 mg b.i.d. during 24 weeks
61935595|NCT00503516|PLACEBO_COMPARATOR|2|1 sachet of powder of placebo b.i.d. during 24 weeks
62487461|NCT06263842|EXPERIMENTAL|Modified Elamrousy Approach for Immediate Implant Placement Using Socket Shield Technique|Immediate Implant Placement Using Socket Shield Technique with autogenous whole tooth graft after immediate implantation using Socket Shield Technique, the palatal root portion and the decoronated crown will be converted to autogenous whole tooth graft and used for grafting the defect between the socket shield and the implant fixture
62487462|NCT03068780|EXPERIMENTAL|Oleogel-S10|
62487463|NCT03068780|PLACEBO_COMPARATOR|Control Gel|
62487464|NCT00634205|EXPERIMENTAL|A|Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin
62487465|NCT06561425|EXPERIMENTAL|Phase 1 (Dose escalation phase): Dose level 1|Participants will receive a single dose of GLPG5101 intravenous (IV) cell suspension for infusion at dose level 1 on Day 0.
62487466|NCT06561425|EXPERIMENTAL|Phase 1 (Dose escalation phase): Dose level 2|Participants will receive a single dose of GLPG5101 IV cell suspension for infusion at dose level 2 on Day 0.
62487467|NCT06561425|EXPERIMENTAL|Phase 1 (Dose escalation phase): Dose level 3|Participants will receive a single dose of GLPG5101 IV cell suspension for infusion at dose level 3 on Day 0.
62487468|NCT06561425|EXPERIMENTAL|Phase 2 (Dose expansion phase): DLBCL|Participants with DLBCL will receive a single dose of GLPG5101 IV cell suspension for infusion at RP2D level on Day 0.
62487469|NCT06561425|EXPERIMENTAL|Phase 2 (Dose expansion phase): High-risk DLBCL|Participants with High-risk DLBCL will receive a single dose of GLPG5101 IV cell suspension for infusion at RP2D level on Day 0.
62487470|NCT06561425|EXPERIMENTAL|Phase 2 (Dose expansion phase): Indolent B-cell NHL|Participants with indolent B-cell NHL (FL and MZ) will receive a single dose of GLPG5101 IV cell suspension for infusion at RP2D level on Day 0.
62487471|NCT06561425|EXPERIMENTAL|Phase 2 (Dose expansion phase): MCL|Participants with MCL will receive a single dose of GLPG5101 IV cell suspension for infusion at RP2D level on Day 0.
62487472|NCT06561425|EXPERIMENTAL|Phase 2 (Dose expansion phase): BL|Participants with BL will receive a single dose of GLPG5101 IV cell suspension for infusion at RP2D level on Day 0.
62487473|NCT06561425|EXPERIMENTAL|Phase 2 (Dose expansion phase): PCNSL|Participants with PCNSL will receive a single dose of GLPG5101 IV cell suspension for infusion at RP2D level on Day 0.
62487474|NCT05559736|EXPERIMENTAL|Artemis Proximal Femoral Nail (PFN) implant|All participants will receive the Artemis Proximal Femoral Nail (PFN) implant.
62135062|NCT03028389|EXPERIMENTAL|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
62329647|NCT05264571||critically ill adult patients with intra-abdominal infection|"The ICCA study is an ancillary study of a non-interventional prospective cohort study (the pBDG2 study, NCT03997929) The pBDG 2 study has enrolled ICU patients with intra-abdominal infection requiring abdominal surgery. During the surgery, peritoneal fluid has been collected to identify the pathogens involved and guide anti-infective therapies. After the routine analyses, the remained peritoneal fluid was stored to create a biological collection.~This biological collection, in which the content of bacterias and yeasts is known, will be analysed with the calscreener."
62329648|NCT04111887|EXPERIMENTAL|Change Ahead|Each of the 6 weekly 1-hour sessions begins with a voluntary commitment to actively participate and to try something new in the upcoming week; includes a section devoted to selecting and publicly committing to one change focused on reducing negative/increasing positive cognitions and one change focused on increasing pleasant activities; and ends with home practice assignments. Additional exercises designed to increase dissonance induction include (a) group discussions for changing conditions, (b) roleplays to generate quick comebacks to written negative thoughts provided by other group members, (c) in-session writing exercises on the benefits of doing fun activities, (d) discussion of methods for creating internal and external accountability for positive change, (e) home practice assignment of engaging in actions to help someone else' mood, (f) writing a letter to my future self about positive intentions, and (g) providing positive feedback to other group members at the last session.
62329649|NCT04111887|ACTIVE_COMPARATOR|Blues Program|The 6 weekly 1-hour sessions begin with a review of concepts and (after Session 1) review of past home practice assignments; all sessions conclude with home practice assignments. Each session has a portion devoted to thought identification/recording and cognitive restructuring and a portion devoted to increased involvement in pleasant activities. We use motivational enhancement exercises to maximize willingness to use the new skills, behavioral techniques to reinforce use of the new skills, and group activities to foster feelings of group cohesion.
62329650|NCT04111887|PLACEBO_COMPARATOR|Brochure control|"NIMH brochure that describes major depression and recommends treatment for depressed youth (Let's Talk About Depression NIH Pub. 01-4162), as well as information about local treatment options."
62329651|NCT02763904|EXPERIMENTAL|Intensive nutritional counseling|Dietary counseling + energy dense oral nutritional supplements
62329652|NCT02763904|ACTIVE_COMPARATOR|Dietary counseling|Dietary counseling
62329653|NCT02422953|EXPERIMENTAL|Intervention|Wheat Soya Blend, Wawa Mum, Micronutrient Powders, Behavior change and preventive health massages
62329654|NCT02422953|NO_INTERVENTION|Control|Control group will receive routine public and private health services available in the area.
62329655|NCT01542476||IDet users|
62329656|NCT05490628|ACTIVE_COMPARATOR|Control Group|"Traditional exercises:~stretching exercises, strengthening exercises, balance exercises, walking exercises and fine motor skill exercises."
62329657|NCT05490628|EXPERIMENTAL|Cognitive Rehabilitation Group|Cognitive rehabilitation; memory, executive function, attention, concentration and calculation exercises.
62329658|NCT02353260|EXPERIMENTAL|Ultrasound Hyperthermia+Chemotherapy|"Chemotherapy:~1. Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)~2. The treatments will be administrated in accord with the guideline for other types of cancer.~Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles"
62329659|NCT02353260|ACTIVE_COMPARATOR|Chemotherapy|"Chemotherapy:~1. Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)~2. The treatments will be administrated in accord with the guideline for other types of cancer."
62329660|NCT02404155|EXPERIMENTAL|Clozapine|
62135063|NCT03028389|NO_INTERVENTION|Convention|Elderly patients undergoing non-cardiac surgery received no treatment after induction of anaesthesia
62135064|NCT04418973|EXPERIMENTAL|A - load/apnea|Threshold inspiratory load then apnea
62135065|NCT04418973|EXPERIMENTAL|B- apnea/load|apnea than threshold inspiratory load
62135066|NCT00504023|EXPERIMENTAL|imiquimod|This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).
62135067|NCT01149759|EXPERIMENTAL|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks.
62135068|NCT00731341|EXPERIMENTAL|Hysteroscopic cryoablation|Women undergoing hysteroscopic ultrasound guided cryoablation for the treatment of uterine fibroids.
62135069|NCT06287944|EXPERIMENTAL|Treatment ( Actinium Ac 225-DOTA-Daratumumab)|Patients receive daratumumab IV over 45 minutes followed by indium In 111-DOTA-daratumumab IV over 15 minutes and actinium Ac 225-DOTA-daratumumab IV over \~20-40 minutes on day -15. Patients receive TMLI BID on days -8 to -5, fludarabine IV on days -4 to -2 and melphalan IV on day -2, followed by HCT on day 0. Patients receive GVHD prophylaxis with sirolimus and tacrolimus starting on day -1. Patients also undergo CT during screening, nuclear scan and SPECT scans on study, bone marrow biopsy and aspiration, echocardiography, or MUGA, and blood sample collection during screening and throughout study.
62135070|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"* 2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.~* 300 participants with an isolated cognitive complaint and an age of 60 years or more."
62135071|NCT05412316|EXPERIMENTAL|Healthy Volunteers|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
62135072|NCT05166070|EXPERIMENTAL|Administration of RD133|"Three dose groups of 1.0×10\^6 CAR-T/kg, 3.0×10\^6 CAR-T/kg, and 6.0×10\^6 CAR-T/kg RD133 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.~RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of RD133 will be infused in a single infusion within 30 minutes on day 0."
62135073|NCT05672095|EXPERIMENTAL|Treatment (selenium, niraparib)|Patients receive selenium IV and niraparib PO on study. Patients also undergo CT, MRI, biopsy, and collection of blood samples throughout the trial.
62487475|NCT04309968|EXPERIMENTAL|solid tumors|Experimental: Solid tumors Part 1 - Dose-escalation of SYHA1801 in patients with advanced solid tumors.Daily dosing of SYHA1801 on Days 1 and 4-31 of 28-day cycle. Escalating dose cohorts.
62487476|NCT04309968|EXPERIMENTAL|advanced cancers|Part 2 - Dose-expansion of SYHA1801 in patients with advanced cancers potentially sensitive to BRD4 inhibitor.The dose level and schedule of SYHA1801 of 28-day cycle at the MTD determined in Part 1.
62693663|NCT06643221|EXPERIMENTAL|Isoproterenol Infusion Cohort|To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)
62487477|NCT02046863|EXPERIMENTAL|Automated Programming|Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting.
62693664|NCT06550128|EXPERIMENTAL|AHB-137|AHB-137 300 mg will be injected subcutaneously once a week with a loading dose during each of the first two weeks.
62693665|NCT06550128|PLACEBO_COMPARATOR|Placebo|Placebo will be injected subcutaneously once a week for the first 8 weeks, with a loading dose during each of the first two weeks. Afterwards, AHB-137 will be injected subcutaneously once a week, until the 24th week.
62693666|NCT02447406|EXPERIMENTAL|AZD6094 (Volitinib) in combination with docetaxel|"Phase Ib:Volitinib should be administered at least 200mg orally once a day in 21 days for achieving appropriate antitumor activity.~Phase II: Subjects will receive Volitinib once daily ( at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
62329661|NCT04211610||Group 1 - Healthy subjects without any evidence of cardiac o|"Inclusion criteria:~1. Normal serum troponin (below the 99th percentile)~2. GFR 60ml/min~3. Proteinuria \<1gr/gr creatinine~Blood and urine samples will be collected for troponin and other measures."
62693667|NCT00928720|ACTIVE_COMPARATOR|CES device|Participants will use the device for 60 minutes each day for 8 weeks.
62693668|NCT00928720|SHAM_COMPARATOR|Sham device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
62693669|NCT00928720|NO_INTERVENTION|Usual care alone|No intervention; participants will receive usual medical care
62693670|NCT04855435|EXPERIMENTAL|MBS8(1V270)|Treatment arm (single arm study)
61935596|NCT06182280|NO_INTERVENTION|Condition A: Standard of Care (SOC)|SOC will include linkage to the CDC's HIV Prevention Services Locator, a US directory of HIV testing and PrEP services. A Digital Library of HIV prevention, sexual health, and anti-stigma materials (written and video media) will be provided. This content is curated from CDC, Gate Trans Men \& HIV Project, UCSF Center for Excellence in Trans Health, and National LGBTQIA+ Health Education Center, among other sources.
61935597|NCT06182280|EXPERIMENTAL|Condition B: Online one-on-one peer navigation (SOC + PrEP4T)|PrEP4T is an individualized TMSM-specific intervention consisting of online one-on-one sessions between a peer and a participant. PrEP4T has 9 hours of content: 6 1.5-hour sessions conducted weekly for 6 weeks. Participants will also receive access to the SOC materials.
62135074|NCT01435252|EXPERIMENTAL|Arm A|Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.
62135075|NCT01435252|EXPERIMENTAL|Arm B|Patients will be treated with chemoradiation in combination with concurrent cetuximab.
62329662|NCT04211610||Group 2 - Subjects with acute myocardial infarction and norm|"Inclusion criteria:~1. At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~2. GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
62487478|NCT04442503|PLACEBO_COMPARATOR|Placebo|Participants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days.
62487479|NCT04442503|EXPERIMENTAL|SAGE-217 50 mg|Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days.
62487480|NCT02174926|ACTIVE_COMPARATOR|Conservative treatment|Written lifestyle guidance and fiber supplements
62487481|NCT02174926|EXPERIMENTAL|Elective laparoscopic sigmoid resection|
62487482|NCT03721718|EXPERIMENTAL|GLS-5300 with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
62487483|NCT03721718|EXPERIMENTAL|GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
62487484|NCT03721718|EXPERIMENTAL|GLS-5300 at 0.6mg DNA/dose (3 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
62487485|NCT03721718|EXPERIMENTAL|GLS-5300 at 0.6mg DNA/dose (2 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
62693671|NCT06442891|EXPERIMENTAL|ARM I (relaxing acupressure)|Patients receive access to acupressure mobile application and an AcuWand on study and self-administer relaxing acupressure to 9 acupoints over 27 minutes QD for 6 weeks.
62693672|NCT06442891|PLACEBO_COMPARATOR|ARM II (sham acupressure)|Patients receive access to acupressure mobile application and an AcuWand and self-administer sham acupressure to non-acupressure point locations over 27 minutes QD for 6 weeks.
62693673|NCT06571240||Anterior Cruciate Ligament Injury Patients|Patients who will undergo anterior cruciate ligament reconstruction because of anterior cruciate ligament rupture
62693674|NCT01339091|EXPERIMENTAL|Dalbavancin|
62693675|NCT01339091|ACTIVE_COMPARATOR|Vancomycin with possible switch to oral linezolid|
62487486|NCT04170335||Bariatric surgery group|Women older than age 40 and younger than age 74 undergoing primary bariatric surgery and having a BMI of ≥35 will be enrolled in this study. Pre operative and postoperative mammograms, inflammatory markers and breast cancer risk scores will be compared.
62487487|NCT04745234|EXPERIMENTAL|Mogamulizumab|
62487488|NCT04534621||Brazilian chiropractors|A cross-sectional survey will be performed with this population (Brazilian chiropractors) to assess outcomes regarding what is the current impact and what measures they have implemented while facing the COVID-19 pandemic.
62487489|NCT04388358|OTHER|mixed Chinese herb formula|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
62487490|NCT02878018||TCM intervention|Participants with HSPN of the Heat-Toxin type will take the Qi-Ji Shen-Kang formula. HSPN patients of the Wet-Heat type will take the Zhu-Bai formula. Those of Qi-Deficiency with Blood-Stasis type will take the Yu-Shen formula.
62329663|NCT04211610||Group 3 - Subjects with acute myocardial infarction and decr|"Inclusion criteria - Group 3a:~1. At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~2. 30 GFR \<60ml/min/1.73m2~   Inclusion criteria - Group 3b:~3. At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~4. GFR \<30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
62487491|NCT02878018||WM conventional intervention|The WM conventional intervention, recommended by the Chinese Medical Association's (CMA) Scientific Statement, includes angiotensin-converting enzyme (ACE) inhibitor, adrenergic receptor binder (ARB), adrenal cortical hormone, Tripterygium wilfordii polyglycosidium and an immunosuppressant.
62487492|NCT05971056|EXPERIMENTAL|Care transition|-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.
62487493|NCT05971056|ACTIVE_COMPARATOR|No care transition|-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.
62487494|NCT04386577|ACTIVE_COMPARATOR|Vitamin D + fish oil|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Each capsule contains 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA).
61935598|NCT06182280|EXPERIMENTAL|Condition C: Online peer-delivered small group-based behavioral intervention (SOC + LS4TM)|LS4TM is a theory-based peer-delivered small group-based behavioral intervention. The LS4TM manualized intervention is comprised of 9 hours of content: 6 2-hour small-group sessions with up to 12 participants per group delivered weekly for 6 weeks. Participants will also receive access to the SOC materials.
61935599|NCT06182280|EXPERIMENTAL|Condition D: Peer-delivered and group-based intervention (SOC + PrEP4T + LS4TM)|Both PrEP4T and LS4TM will be delivered to participants. Group D will receive 21 hours of content: 6 2-hour LS4TM sessions and 6 1.5-hour PrEP4T sessions. Group D participants may not receive both interventions simultaneously within 6 weeks.
62135076|NCT03992274|NO_INTERVENTION|Standard implementation|During Standard Implementation, sites will use standard Yunnan Center for Disease Control and Prevention strategies to introduce HIV prevention innovations.
62135077|NCT03992274|EXPERIMENTAL|Enhanced implementation|During Enhanced Implementation, sites will transition to receive enhanced Implementation Support to plan and implement PrEP.
62135078|NCT01956032||Participants with Parkinson's disease|"Participants diagnosed with Parkinson's disease and have continued disabling motor complications despite optimized per-oral or other treatment regimens suitable for Duodopa treatment in accordance with the Swedish Summary of Products Characteristics.~Other name for Duodopa is Levodopa Carbidopa Intestinal Gel (LCIG)."
62135079|NCT06514417|ACTIVE_COMPARATOR|external oblique intercostal block|receive US-guided external oblique intercostal block after induction
62135080|NCT06514417|NO_INTERVENTION|No block|receive postoperative morphine on patient request
62135081|NCT02639936||Immunocompetent controls|Control persons without immunodeficiency with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
62135082|NCT02639936||Solid organ transplant recipients|Patients after solid organ transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
62135083|NCT02639936||Stem cell transplant recipients|Patients after stem cell transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
62135084|NCT02639936||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
62135085|NCT02639936||Patients with chronic renal failure|Patients with chronic renal failure with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
62135086|NCT02639936||Individuals with HIV infection|Individuals with HIV infection with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
62135087|NCT05089266|EXPERIMENTAL|CAR T cells|
62135088|NCT06109454||Huaier Granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.
62135089|NCT06109454||Control|The subjects received standard platinum dual-drug chemotherapy.
62135090|NCT00662519|EXPERIMENTAL|Neulasta|Subjects will receive Neulasta subcutaneously every 2 weeks for 12 weeks (6 doses). In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
62135091|NCT00662519|PLACEBO_COMPARATOR|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
62135092|NCT04436289|NO_INTERVENTION|PLWH care-as-usual (CAU) study arm|Participants living with HIV will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
62135093|NCT04436289|EXPERIMENTAL|PLWH Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take \<30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
62135094|NCT04436289|NO_INTERVENTION|PLWOH care-as-usual (CAU) study arm|Participants living without HIV will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
62487495|NCT04386577|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary supplement: Fish oil placebo
62487496|NCT04386577|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Dietary supplement: Vitamin D3 placebo
62487497|NCT04386577|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|Dietary supplement: Vitamin D3 placebo Dietary supplement: Fish oil placebo
62487498|NCT05893563||Direct Anterior|Patients who underwent the Direct Anterior (DA) surgical approach
62487499|NCT05893563||Direct Lateral|Patients who underwent the Direct Lateral (DL) surgical approach
62487500|NCT02750878|NO_INTERVENTION|Control group|Participants will receive only the standard verbal TOT surgical consent counseling.
62487501|NCT02750878|OTHER|Intervention group|Participants will receive the standard verbal TOT surgical consent counseling plus a handout describing their surgical intervention
62487502|NCT01987128|EXPERIMENTAL|Intraneural injection|All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
62329664|NCT04211610||Group 4 - Subjects with decreased GFR but without any eviden|"Inclusion criteria - Group 4a:~1. Normal serum troponin (below the 99th percentile)~2. No known past medical history of any cardiac disease and/or procedure.~3. 30 GFR \<60ml/min/1.73m2~   Inclusion criteria - Group 4b:~4. Normal serum troponin (below the 99th percentile)~5. No known past medical history of any cardiac disease and/or procedure.~6. GFR \<30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
62329665|NCT04211610||Group 5 - Subjects with chronic myocardial injury and normal|"Inclusion criteria:~1. At least one measurements of serum troponin above the 99th percentile, with neither a rise nor fall in cardiac troponin levels.~2. GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
61935600|NCT03246984|EXPERIMENTAL|VasQ device implantation|
61935601|NCT01057823||Inpatient Elders Age 50 and up|The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
62329666|NCT04211610||Group 6 - patients on RRT|"Inclusion criteria:~a. Patients who are dependent on renal replacement therapy, including hemodialysis, peritoneal or hemodiafiltration.~Blood and urine samples will be collected for troponin and other measures."
62329667|NCT00756587|ACTIVE_COMPARATOR|I|Group one received feeding by bottle as the standard method of feeding in the NICU
62329668|NCT00756587|EXPERIMENTAL|II|Group 2 received all feeding by cup
62487503|NCT01987128|ACTIVE_COMPARATOR|extraneural injection|All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
62487504|NCT03224143|EXPERIMENTAL|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:~1. A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~2. The nurse presents the object (doll or cube) to the patient.~3. The nurse leaves the patient alone with the object.~4. Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~5. The nurse returns into the room and takes back the object."
62487505|NCT03224143|ACTIVE_COMPARATOR|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:~1. A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~2. The nurse presents the cube to the patient.~3. The nurse leaves the patient alone with the cube.~4. Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~5. The nurse returns into the room and takes back the cube."
62329669|NCT01133210|EXPERIMENTAL|Maraviroc|Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).
62329670|NCT01133210|PLACEBO_COMPARATOR|Placebo|Subjects will receive 12 weeks of treatment with placebo
62329671|NCT05646303|EXPERIMENTAL|Psilocybin|2 oral doses of 25mg psilocybin capsules
62329672|NCT05646303|PLACEBO_COMPARATOR|Placebo|2 oral doses of placebo (microcrystalline cellulose) capsules
62487506|NCT01390415||Losartan 50 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 50 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
62487507|NCT01390415||Losartan 100 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 100 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
62487508|NCT05436028|EXPERIMENTAL|LuX-Valve Plus transvenous tricuspid valve and delivery system（LuX-Valve Plus System）|The LuX-Valve Plus System is intended for the treatment of patients with at least severe TR who are determined by a Heart Team to be at high risk of traditional open-heart surgery.
62487509|NCT00849797|EXPERIMENTAL|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
62329673|NCT05901714|EXPERIMENTAL|Part 1: Afimetoran followed by phenytoin + afimetoran|
62329674|NCT05901714|EXPERIMENTAL|Part 2: Midazolam followed by afimetoran + midazolam|
62693676|NCT06645093|EXPERIMENTAL|Fasting group|This group will fast 24 hours before and 24 hours after chemotherapy for all treatment cycles (4-6 cycles).
62693677|NCT06645093|NO_INTERVENTION|Control group|This group will receive standard treatment, which include no fasting.
61935602|NCT01442038|EXPERIMENTAL|Ranolazine|
61935603|NCT01442038|PLACEBO_COMPARATOR|Placebo|
62329675|NCT05956249|EXPERIMENTAL|Intervention Group: Online group therapy|"Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.~All meetings will be weekly, in groups and will last an average of 1 hour. After the end of the intervention, a scientific initiation fellow will contact the study participants, from both groups, to reapply the scales."
62487510|NCT00849797|ACTIVE_COMPARATOR|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
62487511|NCT05269238|OTHER|control group patient|performing lumbar punctures by students with standard training
62487512|NCT05269238|EXPERIMENTAL|experimental group patient|performing lumbar punctures by students with standard training and an augmented reality simulator
62329676|NCT05956249|ACTIVE_COMPARATOR|Control Group: Without online group therapy|The control group will only receive the intervention after the reassessment of the scales by the scholarship holder, who is blind to the groups.
62487513|NCT01746550|EXPERIMENTAL|MD-12-001 Stent Arm|This study includes a single arm, the MD-12-001 Stent Arm.
61935604|NCT06359990|EXPERIMENTAL|BrotherlyACT Intervention Group|Three components make up BrotherlyACT: 1) Brief psychoeducational modules adapted from an evidence-based violence prevention program; 2) A Safety Planning Toolkit offering tools for risk assessment, mood tracking, goal setting, and mindfulness-based stress reduction; 3) A Service Engagement Chatbot that uses NLP to provide zip-code based navigational support and talk therapy.
61935605|NCT06359990|OTHER|Waitlist Control Group (WCG)|Waitlist Control Group (WCG)
62329677|NCT01977209|EXPERIMENTAL|Arm A|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.
62329678|NCT01977209|PLACEBO_COMPARATOR|Arm B|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.
62329679|NCT04439630|SHAM_COMPARATOR|reference|Test product without the active components
62329680|NCT04439630|EXPERIMENTAL|Nopal fraction 1|Fraction one out of two possible
62329681|NCT04439630|EXPERIMENTAL|Nopal fraction 2|Fraction two out of two possible
62329682|NCT03847155|EXPERIMENTAL|Nicotine|The patients randomized into this study arm will receive a medical intervention - nicotine patch for the period of a maximum of 7 days.
62329683|NCT03847155|PLACEBO_COMPARATOR|Placebo|The patients randomized into this study arm will receive a placebo patch for the period of a maximum of 7 days.
62329684|NCT03154723|EXPERIMENTAL|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
61935606|NCT04996797|EXPERIMENTAL|Cohort 1 Tulisokibart|Participants who are CDx+ and CDx- will receive tulisokibart administered by intravenous (IV) infusion at 1000 mg on Day 1, Week 0, and 500 mg on the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
62329685|NCT05362851|EXPERIMENTAL|YYC301-1, YYC301-2, YYC301-3 & Celecoxib placebo|"* YYC301-1 is a capsule. It is composed of Celecoxib 200mg and Tramadol 37.5mg complex.~* YYC301-2 is a capsule. It is composed of Celecoxib 200mg and Tramadol 75mg complex.~* YYC301-3 is a capsule. It is composed of Celecoxib 200mg and Tramadol 150mg complex."
62329686|NCT05362851|ACTIVE_COMPARATOR|YYC301-1 placebo, YYC301-2 placebo, YYC301-3 placebo & Celecoxib|"Concomitant Drugs with Celecoxib 200mg and YYC301-1 placebo one capsule.~Concomitant Drugs with Celecoxib 200mg and YYC301-2 placebo one capsule.~Concomitant Drugs with Celecoxib 200mg and YYC301-3 placebo one capsule."
62487514|NCT01585844||Women with sleep apnea|
62697602|NCT01661543|PLACEBO_COMPARATOR|Control (rice) consumed to show results|"The control group will consume 110 grams (\~3/4 c) of rice per day in a food item such as a soup or study for 5 out of 7 days for 6 weeks. This amount of rice is similar in volume to 120g of beans or peas.~The bases (i.e. vegetables, broth, seasonings, etc) for all food items are the same in all groups."
62329687|NCT03182205|EXPERIMENTAL|Inspiratory muscle exercise (IME)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure.
62329688|NCT03182205|SHAM_COMPARATOR|Sham IME|Participants will be submitted to inspiratory muscle exercise with the same equipment as the intervention group, but without a load generating resistance.
62329689|NCT05436613|EXPERIMENTAL|Device: transcranial direct current stimulation|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
62329690|NCT04388280|OTHER|Imaging|Echocardiography combined with coronary flow reserve (CFR) and strain imaging, or computed tomography (CT) angiography with direct visualization of coronary arteries.
62329691|NCT04388280|NO_INTERVENTION|Observation|No imaging for the estimation of coronary artery disease
62329692|NCT00907881||All participants|Participants with type 2 diabetes mellitus (T2DM) who had sulfonylurea treatment added to an on-going regime of oral hypoglycemic agent(s).
62329693|NCT02607969|EXPERIMENTAL|seen once every six weeks|Parents will be educated about home program and they will be asked to control once every six weeks.
62329694|NCT02607969|EXPERIMENTAL|seen once a week.|Parents will be educated about home program and they will be asked to control once a week.
62329695|NCT01798784|NO_INTERVENTION|Control Arm|Arm 1 will be the Control arm, in which participants receive an electronic pill container and are provided with daily reminders to take their medication but are not enrolled in the sweepstakes.
62329696|NCT01798784|EXPERIMENTAL|Sweepstakes Incentive 1|Arm 2 will be a sweepstakes incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
62487515|NCT01585844||Women without sleep apnea|
62487516|NCT04884022|EXPERIMENTAL|Miniplates in mandibular symphysis & infrazygomatic|
62487517|NCT04884022|ACTIVE_COMPARATOR|Miniplates in external oblique ridge & anterior maxillary region|
62487518|NCT04884022|NO_INTERVENTION|Growing skeletal Class II subjects|
62487519|NCT02128308|EXPERIMENTAL|Levofloxacin and Streptomycin added|Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
62487520|NCT02128308|EXPERIMENTAL|Moxifloxacin and Kanamycin added|Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
62487521|NCT06342830|EXPERIMENTAL|Nanocurcumin gel .|"Preparation Method: Olive oil (5%), surfactant (Tween 80 (8%)) and co-surfactant (PEG 400 (2%)) were used as excipients and their selection was based on the solubility of curcumin. A high-energy ultrasonication techniquewas used to prepare the Cur-NE. Curcumin (0.3%) was dissolved in oil /surfactant/ co-surfactant mixture and stirred till obtaining clear solution. The mixture was microtitrated with distilled water (85 %) to achieve a coarse emulsion. A 20 kHz ultrasonic processor was used for the production of the desired nano-emulsion.~Gel Preparation:~0.4gm of Carboxymethyl cellulose (Loba CHIME, india) was sprinkled gently and gradually over the solution of Cur NE 0.3% under mild temperature with vigorous stirring to get homogenous gel"
61935607|NCT04996797|PLACEBO_COMPARATOR|Cohort 1 Placebo|Participants who are CDx+ and CDx- will receive placebo administered by intravenous (IV) infusion on Day 1, Week 0 and the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
62329697|NCT01798784|EXPERIMENTAL|Sweepstake Incentive 2|Arm 3 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which monetary prizes may be awarded if participants take their medication prior to receiving a reminder.
62329698|NCT01798784|EXPERIMENTAL|Sweepstake Incentive 3|Arm 4 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which each participant maintains an account that will accumulate money based on their medication adherence throughout the study.
62329699|NCT01519245|EXPERIMENTAL|Trial Drug|Solution containing 2 grams tranexamic acid + normal saline
62329700|NCT01519245|PLACEBO_COMPARATOR|Placebo|Normal saline
62329701|NCT00631488|EXPERIMENTAL|MK-0893 + Sitagliptin|
62329702|NCT00631488|EXPERIMENTAL|MK-0893 + Metformin|
62487522|NCT06342830|EXPERIMENTAL|Curcumin gel|curcumin 250 mg powder + carboxymethyl cellulose 300mg+distilled water to 10ml
62487523|NCT06342830|EXPERIMENTAL|Ciprofloxacin 500 mg +Ibuprofen 400 mg|Ciprofloxacin 500 mg +ibuprofen 400mg powder +carboxymethyl cellulose 300 mg +distilled water to 10 ml
62487524|NCT06342830|ACTIVE_COMPARATOR|calcium hydroxide|Metapaste
62487525|NCT02786576||Participants receiving adalimumab|Hidradenitis Suppurativa (HS) participants receiving adalimumab
62487526|NCT06556602|EXPERIMENTAL|MPACT Intervention|Enrolled clinic staff will be exposed to the MPACT intervention components over the trial period. This includes accredited training, clinic self assessment, reflective supervision for counseling/peer/case management staff, and wellness education with navigation to trauma symptoms assessment and resources including trauma treatment. Periodic surveys of staff and patients will be conducted to assess outcome measures (primary and secondary) and patient chart reviews will verify patient outcomes.
62487527|NCT06556602|NO_INTERVENTION|Control for MPACT|Enrolled clinic staff will not receive any portion of the intervention. Periodic surveys of staff and patients will be conducted to assess outcome measures (primary and secondary) and patient chart reviews will verify patient outcomes.
62487528|NCT06559930|ACTIVE_COMPARATOR|Traditional Neurological Rehabilitation|In-bed lower and upper extremity passive-active assisted-active ROM exercises Lower and upper extremity strengthening exercises with Theraband Electrotherapy will be applied to increase muscle strength in the tibialis anterior, quadriceps femoris, forearm extensors and elbow extensors.
62487529|NCT06559930|EXPERIMENTAL|Traditional Neurological Rehabilitation + Dual Task Focused Training|"In our Traditional Neurological Rehabilitation + Dual Task Focused Training group; Dual-task exercises were added in addition to the conventional treatment program.~For dual task training:~During in-bed exercises, the person will be asked to perform simple addition operations and rhythmic counting by 4 from 1 to 100.~During balance and walking exercises, the person will be asked to count rhythmically by 2 from 1 to 40."
62487530|NCT04632641|EXPERIMENTAL|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|Perclose ProGlide Suture-Mediated Closure System (SMC) will be used as closure strategy for venous access sites using sheath sizes greater than 13F.
62487531|NCT04632641|ACTIVE_COMPARATOR|Figure 8 Suture - LARGE-BORE PROCEDURES|Figure 8 suture will be used as a closure technique for venous access sites using sheath sizes greater than 13F.
62487532|NCT06563232|EXPERIMENTAL|FNA group|FNA needles adopted to acquire lesion tissues
62487533|NCT06563232|EXPERIMENTAL|Adapt FNB group|Adapt FNB needles adopted to acquire lesion tissues
62487534|NCT04114890|EXPERIMENTAL|Pregnant woman with second trimester and third trimester|
62487535|NCT01592240|EXPERIMENTAL|Q28d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
62329703|NCT00631488|ACTIVE_COMPARATOR|Sitagliptin + Metformin|
62487536|NCT01592240|EXPERIMENTAL|Q14d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.
62487537|NCT03029364||Male and Female Adults|Completion of Study Protocol
62487538|NCT02871076|EXPERIMENTAL|Verum Acupuncture|Patients will receive verum acupuncture twice weekly for twelve weeks.
61935608|NCT04996797|EXPERIMENTAL|Cohort 2 Tulisokibart|Participants who are CDx+ will receive tulisokibart administered by intravenous (IV) infusion at 1000 mg on Day 1, Week 0 and 500 mg on the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
61935609|NCT04996797|PLACEBO_COMPARATOR|Cohort 2 Placebo|Participants who are CDx+ will receive placebo administered by intravenous (IV) infusion on Day 1, Week 0 and the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
62487539|NCT02871076|PLACEBO_COMPARATOR|Sham Placebo Acupuncture|Patients will receive sham placebo acupuncture twice weekly for twelve weeks.
61935610|NCT04407260||Intervention|Patients on oxygen hoods who have fail conventional high-flow oxygen delivery systems.
62329704|NCT01766830|EXPERIMENTAL|Phase 3 Diagnostic|A total of 10 RDTs will be assessed in the patients cohort for the respective target condition
62487540|NCT00168558|ACTIVE_COMPARATOR|1|Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
62329705|NCT05267353|NO_INTERVENTION|Usual care|All patients received care as usual. Patients receive wound care and pain management post-surgery. Before RT, generally advising to do neck stretch and mouth opening exercises. Telephone follow-up was not provided to usual care group. Furthermore, patients in usual care group went to receive physical therapy were free to do. During the follow-up period, well-trained research nurses (assessors) recorded their physical therapy sections.
62329706|NCT05267353|EXPERIMENTAL|Exercise intervention programs|Based on our previous literature review, we will have two major parts of exercises in our intervention: (1) Upper Body Exercise (stretching in shoulder and neck, and mouth-opening); and (2) General Physical Function Training.
62329707|NCT05811494|EXPERIMENTAL|End-Effector walking training|Participants in the End-effector group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of Lexo training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
62329708|NCT05811494|EXPERIMENTAL|Fixed Exoskeleton walking training|Participants in the fixed-exoskeleton group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of Lokomat training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
62329709|NCT05811494|EXPERIMENTAL|Body-Weight Support treadmill training with augmented reality|Participants in the Body-Weight Support treadmill training with augmented reality group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of C-Mill training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
62329710|NCT05811494|ACTIVE_COMPARATOR|Body-Weight Support treadmill training|Participants in the Body-Weight Support treadmill training group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of body-weight support treadmill training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
62329711|NCT03793816|ACTIVE_COMPARATOR|BiZact™ device|"BiZact™ device will be used appropriately to its purpose to remove one tonsil by:~* Incision of the anterior palatal arch~* Locating of the cranial pole of the tonsil~* Dissection of the tonsil capsule~* Localized coagulation of bleeding vessels~* Detaching of the inferior pole from the pharynx tissue"
62329712|NCT03793816|ACTIVE_COMPARATOR|Cold steel dissection (CD)|Cold steel dissection (CD) with localized cauterization for hemostasis serves as the comparative procedure within each patient (cross-over).
62329713|NCT06317857|EXPERIMENTAL|Centio Forte (Ivoclar).|"A new class of bioactive alkasite restorative materials has been released in the market. They're composed of three main filler types: salinized inert barium aluminium silicate glass, calcium barium aluminium fluorosilicate glass similar to glass-ionomers, and calcium fluorosilicate glass or alkasite glass. Cention N (Ivoclar Vivadent) was the first available material in the material in the form of powder/liquid, later on, Cention forte was released which is the modified capsulated form with a special adhesive system Marovic et al. (2022).~Cention has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release Par et al. (2020)."
62487541|NCT00168558|ACTIVE_COMPARATOR|2|Standard titre Schwarz measles vaccine at 9 months of age
62487542|NCT00168558|ACTIVE_COMPARATOR|3|Standard titre Edmonston-Zagreb measles vaccine at 9 months of age
62487543|NCT00857779|ACTIVE_COMPARATOR|subcutaneous immunotherapy|subcutaneous immunotherapy using a slow updosing schedule
62487544|NCT00857779|ACTIVE_COMPARATOR|subcutaneous injections|subcutaneous immunotherapy using a fast updosing schedule
62487545|NCT04511845|EXPERIMENTAL|Dose escalation cohort of SPYK04|Patients will receive SPYK04 at escalated dose.
62487546|NCT04511845|EXPERIMENTAL|Expansion part in NSCLC, ovarian cancer and other solid tumors|Patients will receive SPYK04 at the recommended dose.
62487547|NCT03497130|EXPERIMENTAL|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
62487548|NCT03497130|NO_INTERVENTION|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
62487549|NCT00598780||1|Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
62135095|NCT04436289|EXPERIMENTAL|PLWOH Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take \<30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
62697603|NCT01661543|EXPERIMENTAL|Peas consumed to lower cholesterol|"This arm will consume 120 g of cooked peas per day per day in a food item such as a soup or stew for 5 days out of 7 days for 6 weeks.~The bases (i.e. vegetables, broth, seasonings, etc) for all food items are the same in all groups."
61935611|NCT04407260||Control|Patients maintained on conventional high-flow oxygen delivery systems (such as non-rebreather masks, high-flow nasal cannula, BiPAP, CPAP) or who have failed on these conventional symptoms and were subsequently mechanically ventilated.
62135096|NCT01219790|EXPERIMENTAL|irradiation + zometa|
62135097|NCT05381532|EXPERIMENTAL|Chronic variable sleep deficiency - follicular phase|This will be the first of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a chronic variable sleep deficiency schedule during the follicular phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
62329714|NCT06317857|ACTIVE_COMPARATOR|Highly viscous glass ionomer|"Glass-ionomer restorations (GI) are widely used in restorative dentistry. One of their advantages is their chemical adhesion to tooth structure. They also possess a fluoride-releasing property and biocompatibility. Although GIs are commonly used, they have some disadvantages. The most intractable problem with the conventional GIs is probably their lack of strength and toughness. In order to improve the mechanical properties of conventional GICs, reinforced GIs were developed. These reinforced GIs or now commonly known as highly viscous GIs provide improved mechanical properties and wear resistance, easier application allowing their use in posterior stress bearing cavity preparations Bakhadher et al.~(2019)."
62329715|NCT00002663|EXPERIMENTAL|EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)|Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) following hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel (tab-cel) at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329716|NCT00002663|EXPERIMENTAL|EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)|Patients with EBV+ PTLD following solid organ transplant (SOT) who were R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329717|NCT00002663|EXPERIMENTAL|EBV+ AID-LPD (Tab-cel Only)|Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329718|NCT00002663|EXPERIMENTAL|EBV+ LMS (Tab-cel Only)|Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329719|NCT00002663|EXPERIMENTAL|EBV+ NPC (Tab-cel Only)|Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329720|NCT00002663|EXPERIMENTAL|EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)|Patients with EBV+ following PTLD HCT who were R/R to rituximab or rituximab naive will receive IV infusion of transplant donor-derived EBV-cytotoxic T lymphocytes (CTLs) at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329721|NCT00002663|EXPERIMENTAL|EBV+ PTLD-SOT R/R Rituximab + Chemo (EBV-CTLs Only)|Patients with EBV+ PTLD following SOT who were R/R to rituximab and chemotherapy will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329722|NCT00002663|EXPERIMENTAL|EBV+ Viremia (EBV-CTLs Only)|Patients with EBV+ viremia will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329723|NCT00002663|EXPERIMENTAL|EBV+ PID-LPD (Tab-cel or EBV-CTLs)|Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel or transplant donor-derived EBV- CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
61935612|NCT04866329||In Vitro Fertilisation protocol|Women followed in the department for an in vitro fertilisation protocol
61935613|NCT02024282|OTHER|usual care|
61935614|NCT02024282|ACTIVE_COMPARATOR|Use of C-reactive protein point of care (CRP POC) test|"CRP analysis will be performed during the consultation in accordance with the manufacturer's instructions.~The CRP point of care test will be performed in case of a positive decision tree (irrespective of the intervention group) and also in case of a negative decision tree by clinicians of intervention group 1 and 2. Because no reliable cut-off points for CRP are known currently (as this is the aim of this study) for acute infections in children in primary care (nor for referral, nor for prescription of antibiotics), clinicians will not be given guidance on the interpretation of the CRP results.~We will not impose restrictions on the clinicians about treatment, other technical investigations nor referrals.~The device distributor will provide technical assistance. All clinicians will be trained in the use of the CRP device prior to the start of the study."
61935615|NCT02024282|ACTIVE_COMPARATOR|Brief intervention and parent leaflet|
61935616|NCT02024282|ACTIVE_COMPARATOR|CRP POC test and brief intervention & parent leaflet|Combination of CRP POC test and the brief intervention \& parent information leaflet intervention groups (factorial design)
61935617|NCT04648709||asymptomatic patients|asymptomatic patients with PCR-positive PCR
61935618|NCT04648709||mild symptoms patients|patients with mild symptoms and PCR positive
62329724|NCT00002663|EXPERIMENTAL|EBV+ Lymphoma (Tab-cel or EBV-CTLs)|Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel or transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
62329725|NCT02401750|EXPERIMENTAL|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
62329726|NCT02401750|EXPERIMENTAL|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
62135098|NCT05381532|EXPERIMENTAL|Chronic variable sleep deficiency - luteal phase|This will be the second of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a chronic variable sleep deficiency schedule during the luteal phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
62329727|NCT02401750|PLACEBO_COMPARATOR|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
62487550|NCT03613038|OTHER|Phonetic complexity effects|Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity. Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
62487551|NCT05644106|ACTIVE_COMPARATOR|Unaided|
62487552|NCT05644106|ACTIVE_COMPARATOR|Aided|
62487553|NCT00840840|EXPERIMENTAL|1|
62487554|NCT00840840|ACTIVE_COMPARATOR|2|
62487555|NCT00269386|ACTIVE_COMPARATOR|1 (i)|Clarithromycin S/R 1g od From April 2004, clarithromycin S/R (Klaricid XL) ceased to be available and subsequent patients will receive either standard clarithromycin 500mg bd or placebo tables of identical size, colour and taste
62487556|NCT00269386|PLACEBO_COMPARATOR|2 (ii)|placebo tablets of identical size, colour and taste
62487557|NCT00473772|ACTIVE_COMPARATOR|Cypher Stent|
62693678|NCT06569810||Non-responders to Conventional Treatments|This observational, real-world, web-based registry study will collect treatment data from multiple clinics of children aged 8-16 years old who have insufficient control of progression under myopia treatments for at least six months, and are receiving or intend to receive RLRL therapy. Insufficient control is defined as meeting either of the following criteria: AL elongation of less than 0.3mm per year or SER progression of 0.5 diopter (D) or greater per year. These subjects will then be defined as non-responders to conventional treatments for myopia, and offered RLRL therapy.
62329728|NCT05379426||Screening tests and semi-structured interview|Battery of screening tests with semi-structured interview First, the Mini-Mental State Examination will be administered to participants to assess whether they meet the inclusion criteria and an identification code will be assigned to eligible participants. Posteriorly, a clinical psychologist will administer the Frontal Assessment Battery, Center for Epidemiologic Studies Depression Scale, Geriatric Anxiety Inventory, Loneliness Scale 3 Portuguese version, Quality of Life - Alzheimer's Disease, and will conduct a semi-structured interview about the difficulties experienced by the older adult during the pandemic period.
62329729|NCT05881551|EXPERIMENTAL|eEgg-Arm|Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
62329730|NCT05881551|OTHER|NRS-Arm|Patients are asked to document their current pain at hourly intervals for 24 hours (starting from the end of the intervention) according to the usual clinical routine. The first measurement is taken before the intervention.
62329731|NCT02073981||Parkinson Disease|
62487558|NCT00473772|EXPERIMENTAL|DEBlue Stent|
62487559|NCT04560725|EXPERIMENTAL|[68Ga] P137|Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo \[68Ga\]P137 PET/CT scans.
62487560|NCT04277507|EXPERIMENTAL|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
62487561|NCT05870215||Exacerbation patients|Age ≥12 years old with physician-diagnosed asthma since \>6 months experiencing an asthma attack with a patient and/or physician decision to initiate a burst of systemic corticosteroids (but not yet started), assessed within 24 hours on weekdays after a screening telephone call.
62487562|NCT05870215||Healty controls|Age ≥12 years, non-atopic, non-smoking, with normal spirometry and no history of lung disease.
62487563|NCT05096286|EXPERIMENTAL|Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy|"* A diagnostic MRI-only, simulation-free plan will be generated from diagnostic brain MRI imaging, using a semi-automated, AI-assisted plan template within the Ethos Therapy system.~* The radiation prescription dose twill be 3.0 Gy daily over approximately 2 weeks for a total of 30.0 Gy (10 fractions)."
62487564|NCT02651987|EXPERIMENTAL|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
62487565|NCT01195233|OTHER|bioxtra spray and mouth rinse|Drug: BioXtra spray or mouth rinse Patients had been xerostomia due to radiation of head and neck were selected for the study. Gender, age, medical history, VAS, dichotomous questionnaire of xerostomia , and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received BioXtra spray and second group used BioXtra mouth rinse for 2 weeks and then 1 weeks wash -out period and for other 2 weeks drugs is switched . Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and 35 days after first visit.
62487566|NCT00258687|EXPERIMENTAL|Treatment Arm A|GVAX for Sarcoma / Renal Cell Patients
62487567|NCT00258687|EXPERIMENTAL|Treatment Arm B|GVAX for Pediatric Melanoma Patients
61935619|NCT04648709||seriously symptomatic patients|seriously symptomatic patients with PCR positive
62487568|NCT03515707|EXPERIMENTAL|Treatment (busulfan, etoposide, ASCT)|Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
62693679|NCT03849144|EXPERIMENTAL|Therapy dog activity|Interact with visiting therapy dogs for 15 minutes on two Fridays
61935620|NCT04648709||patients in resuscitation|patients in resuscitation with positive PCR
62135099|NCT05381532|EXPERIMENTAL|Control sleep - follicular phase|This will be the third of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a control sleep schedule during the follicular phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
62487569|NCT05008380|EXPERIMENTAL|Standard of care + prone positioning|Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.
62487570|NCT05008380|NO_INTERVENTION|Standard of care|Standard of care
62487571|NCT00820885|OTHER|cohort A|20 mg dose 20 mg/ML concentration and placebo
62487572|NCT00820885|OTHER|Cohort AR|20 mg in 50 mg/ml concentration and placebo
62329732|NCT01524445||bortezomib retreatment|bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
62487573|NCT00820885|OTHER|Cohort C|25 mg in 50mg/ml concentration and placebo
62487574|NCT00820885|OTHER|Cohort D|15 mg in 50mg/ml concentration and placebo
62693680|NCT03849144|ACTIVE_COMPARATOR|Low impact physical activity|Participate in 15-minute low impact physical activity on two Fridays
61935621|NCT04648709||heathly volunteer|heathly volunteer as control
61935622|NCT01052844|PLACEBO_COMPARATOR|Control group|"Placebo:~* Five and four days before chemotherapy (day -5 and day -4): 1x daily~* Three and two days before chemotherapy (day -3 and day -2): 2x daily~* One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
61935623|NCT01052844|EXPERIMENTAL|Gabapentin|"Gabapentin 300mg:~* Five and four days before chemotherapy (day -5 and day -4): 1x daily~* Three and two days before chemotherapy (day -3 and day -2): 2x daily~* One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
62329733|NCT03606252|OTHER|pneumocystosis with favourable evolution|patients with a favourable pneumocystosis outcome
62329734|NCT03606252|OTHER|pneumocystosis with unfavourable outcome|patients with unfavourable pneumocystosis outcome
62329735|NCT03606252|OTHER|Pneumocystis colonization|subject colonized by Pneumocystis jirovecii
62329736|NCT02148458|OTHER|Control group|Western diet for 8 weeks, followed by 8 weeks of Western diet with intermittent fasting.
62329737|NCT02148458|EXPERIMENTAL|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting.
62329738|NCT02575079|EXPERIMENTAL|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
62329739|NCT02575079|NO_INTERVENTION|Historical Cohort|Pediatric patients receiving hematopoietic cell transplantation in the 16 months preceding the study intervention. Data were obtained retrospectively through medical records for the purpose of comparing CLABSI rates among recipients of parafilm to a control group.
62487575|NCT00820885|OTHER|Cohort E|10 mg in 50mg/ml concentration and placebo
62487576|NCT00820885|OTHER|Cohort F|30mg in 50mg/ml concentration and placebo
62487577|NCT00820885|OTHER|Cohort H|50mg in 50mg/ml concentration and placebo
62487578|NCT00820885|OTHER|cohort I|80mg in 50mg/ml concentration and placebo
62487579|NCT03633721|ACTIVE_COMPARATOR|HIV positive; cannabis|HIV positive women will be given cannabis and tested
62487580|NCT03633721|ACTIVE_COMPARATOR|HIV positive; placebo|HIV positive women will be given placebo and tested
62487581|NCT03633721|ACTIVE_COMPARATOR|HIV negative; cannabis|HIV negative women will be given cannabis and tested
62487582|NCT03633721|ACTIVE_COMPARATOR|HIV negative; placebo|HIV negative women will be given placebo and tested
62487583|NCT06561542|EXPERIMENTAL|LX22001 for Injecton|
62487584|NCT06561542|ACTIVE_COMPARATOR|Tegoprazan tablet|
62487585|NCT06561542|ACTIVE_COMPARATOR|Esomeprazole sodium for injection|
62487586|NCT01287351||IPDI: Qvar|ICS initiation as Qvar
62487587|NCT01287351||IPDI FP|ICS initiation as fluticasone
62487588|NCT01287351||IPDA Qvar|ICS step-up as Qvar
62487589|NCT01287351||IPDA FP|ICS step-up as fluticasone
62487590|NCT03807440||Subjects with Diabetes Mellitus, Type 2|
62487591|NCT06430294||Participants|Chiropractors will perform spinal mobilizations on three different pediatric-sized manikins while a sensor will measure the force and time parameters used.
62693681|NCT02274675|EXPERIMENTAL|Robot group|Receive 0.5 hour of robot-assisted therapy for wrist and forearm and 1.5 hours of daily standard rehabilitation therapy
62693682|NCT06518655||Pulmonary Nodules|Pre-surgery adult patients with pulmonary nodule found by CT scan.
62693683|NCT05852340|ACTIVE_COMPARATOR|Treatment A|ritlecitinib 1 x 30 milligram (mg) intact blend-in-capsule (BiC) in fasted state
62693684|NCT05852340|ACTIVE_COMPARATOR|Treatment B|contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on strawberry jam in fasted state
62693685|NCT05852340|ACTIVE_COMPARATOR|Treatment C|contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on yoghurt in fasted state
62693686|NCT05852340|ACTIVE_COMPARATOR|Treatment D|contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on applesauce in fasted state
62693687|NCT05852340|ACTIVE_COMPARATOR|Treatment E|ritlecitinib 1 x 30 mg intact BiC given with high fat meal
62487592|NCT06491342|PLACEBO_COMPARATOR|Placebo|Maltodextrin in bovine gelatin capsule look same as probiotic (250 mg/capsule ) 2 capsule twice daily after breakfast and dinner
62487593|NCT06491342|ACTIVE_COMPARATOR|probiotic|Lactobacillus Zeae and Lactobacillus reuteri probiotic mixed with Maltodextrin in ratio 15:85 in bovine gelatin capsule (250 mg/capsule ) 2 capsule twice daily after breakfast and dinner (1,000 mg =1x109 CFU/g)
62487594|NCT00003223|EXPERIMENTAL|treatment|Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.
62487595|NCT01297504||Palivizumab|Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
62487596|NCT05250323||Case|Patients with genetic confirmation of Huntington's disease, symptomatic (motor manifestations with a score greater than 4 on the Unified HD scale), who can walk with minimal support, without sensory deficits or other systemic diseases an Investigator judgment that may interfere with the execution of the study, coming from the Enroll study.
62487597|NCT05250323||Control|Age, gender-matched non-gene carriers family relatives
62487598|NCT05943522||Asciminib|Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice
62487599|NCT03711253|OTHER|Biktarvy|All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study
62487600|NCT04540094|EXPERIMENTAL|5% Human Albumin Solution|Participants allocated to the treatment arm will receive intravenous 5% Human Albumin Solution (HAS) administered as the sole intravenous fluid during the initial 6-hour resuscitation period. The clinician can deliver up to 10ml/kg in the first 3 hours using 250ml boluses of HAS based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). After 3 hours further HAS boluses up to 6 hours post-randomisation will be at clinical discretion and will be documented in the CRF. Patients in the albumin arm should not receive balanced crystalloid as a resuscitation fluid in the first 6 hours.
62693688|NCT06638554|EXPERIMENTAL|Active Choice (Stage 1) + Low Touch (Stage 2)|Participants in this arm will be offered the option via outreach letter to complete an SDM visit via telehealth or in-person (Stage 1) and if individuals do not schedule an SDM visit within 30 days (non-responders), they will receive asynchronous text messages alone (Stage 2)
61935624|NCT06680284||Staff anesthesiologists or anesthesia fellows|Participating study subjects will go through a staff education program to encourage proper waste disposal.
61935625|NCT05010408|PLACEBO_COMPARATOR|Control beverage for Habitual full-calorie CSD cohort|Full sweetness (sugar) for 6 months
62329740|NCT01742468|EXPERIMENTAL|Dietary supplement: n-3 LC-PUFA|Name: microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany; rich in docosahexaenoic acid (DHA); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
61935626|NCT05010408|PLACEBO_COMPARATOR|Control beverage for Habitual low-calorie CSD cohort|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
61935627|NCT05010408|ACTIVE_COMPARATOR|Test beverage 1 for Habitual full-calorie CSD cohort|Reduced sweetness (moderate sugar level) for 6 months
61935628|NCT05010408|ACTIVE_COMPARATOR|Test beverage 1 for Habitual low-calorie CSD cohort|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
61935629|NCT05010408|ACTIVE_COMPARATOR|Test beverage 2 for Habitual full-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
61935630|NCT05010408|ACTIVE_COMPARATOR|Test beverage 2 for Habitual low-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
61935631|NCT05868473|OTHER|Mobilization With Movement|Mobilization With Movement for Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
62329741|NCT01742468|PLACEBO_COMPARATOR|Dietary supplement: sunflower oil|Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
61935632|NCT05868473|EXPERIMENTAL|Kinesotaping|Kinesotaping for Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
62329742|NCT02187094|PLACEBO_COMPARATOR|Placebo|One capsule of placebo administered as a single dose.
62329743|NCT02187094|EXPERIMENTAL|2 mg TC-6499|One capsule of 2 mg TC-6499 administered as a single dose.
62329744|NCT02187094|EXPERIMENTAL|5 mg TC-6499|One capsule of 5 mg TC-6499 administered as a single dose.
62329745|NCT02187094|EXPERIMENTAL|10 mg TC-6499|One capsule of 10 mg TC-6499 administered as a single dose.
61935633|NCT00497276|EXPERIMENTAL|I|Ultrasound guided placement of popliteal catheter
61935634|NCT00497276|EXPERIMENTAL|II|Nerve stimulation guided placement of popliteal catheter
61935635|NCT06709586||Therma ablation|
61935636|NCT06709586||Parathyroidectomy|
62693689|NCT06638554|EXPERIMENTAL|Active Choice (Stage 1) + High Touch (Stage 2)|Participants in this arm will be offered the option via outreach letter to complete an SDM visit via telehealth or in-person (Stage 1) and if individuals do not schedule an SDM visit within 30 days (non-responders), they will receive asynchronous text messages in combination with synchronous digital care coordination (Stage 2).
61935637|NCT04281641|EXPERIMENTAL|TCHP|"Neoadjuvant Therapy (Cycles 1-7):~Cycle 1: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) Cycle 2-7: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) + followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~Adjuvant Therapy:patients would complete 1 year of PH-based regimen in the adjuvant setting.~Patients are assessed by \[18F\]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 68Ga-Affibody HER-2 Imaging PET. Besides, the changes of biomarkers would be examined by gene sequencing and organoid drug sensitivity test."
61935638|NCT02908867||Therapeutic strategies group|To know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions, mainly medicinal plants.
61935639|NCT03793868|EXPERIMENTAL|Low dose|Perampanel 4mg PO x1
62329746|NCT04960345||The traditional group|The traditional group underwent prosthesis placement using traditional intramedullary positioning method.
62697604|NCT03508583||Participation|"Parents will complete the The Measure of Processes of Care 56- 20 (MPOC 56-20) questionary~Service providers will complete The Measure of Processes of Care for Service Providers (MPOC-SP)"
62329747|NCT04960345||The navigation group|The navigation group performed surgery using the Brainlab Knee 3 navigation system.Informed consent was signed after grouping.
62329748|NCT06473155|NO_INTERVENTION|Wait List Control (WLC)|Wait List Control
62329749|NCT06473155|EXPERIMENTAL|Humanistic Integrative Psychotherapy and Identity Exploration (HIP+EYME)|Humanistic Integrative Psychotherapy and Identity Exploration with Virtual Reality using Explore Your Meanings (EYME)
62329750|NCT06473155|EXPERIMENTAL|Humanistic Integrative Psychotherapy, Identity, and Geniotype Exploration (HIP+EYME+GENIOTYPE)|Humanistic Integrative Psychotherapy, Identity Exploration with Virtual Reality using Explore Your Meanings, and Geniotype characterization
62329751|NCT03514303||Ragweed|Subjects will test positive or negative to the allergen Ragweed.
62487601|NCT04540094|ACTIVE_COMPARATOR|Intravenous balanced crystalloid|Participant allocated to the usual care arm will receive intravenous balanced crystalloid administered as the sole intravenous fluid during the initial 6 hour resuscitation period. The clinician can deliver up to 30ml/kg in the first 3 hours using 250ml boluses of balanced crystalloid based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). Thereafter, further crystalloid boluses up to 6 hours will be at the discretion of the clinical team and will be documented in the CRF. Patients in the balanced crystalloid arm should not receive albumin as a resuscitation fluid in the first 6 hours.
62487602|NCT01756807|EXPERIMENTAL|The Combo Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
62487603|NCT01487720|EXPERIMENTAL|GEMOX|GEMOX treatment
62487604|NCT01852799|EXPERIMENTAL|PAD Followed by ASCT|"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
62487605|NCT04815239|ACTIVE_COMPARATOR|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) for at-risk offspring includes 8 sessions over 6 months delivered via secure telemedicine platform. The basis of the intervention is the treatment manual iteratively developed and tested in close consultation with content experts during our open pilot study and R34.The intervention focuses on education about BP risk, stabilizing sleep and daily routines and interpersonal relationships.
62693690|NCT06638554|EXPERIMENTAL|Telehealth Only (Stage 1) + Low Touch (Stage 2)|Participants in this arm will be offered the option via outreach letter to complete an SDM visit via telehealth only (Stage 1) and if individuals do not schedule an SDM visit within 30 days (non-responders), they will receive asynchronous text messages alone (Stage 2).
62693691|NCT06638554|EXPERIMENTAL|Telehealth Only (Stage 1) + High Touch (Stage 2)|Participants in this arm will be offered the option via outreach letter to complete an SDM visit via telehealth only (Stage 1) and if individuals do not schedule an SDM visit within 30 days (non-responders), they will receive asynchronous text messages in combination with synchronous digital care coordination (Stage 2).
62693692|NCT01458457|ACTIVE_COMPARATOR|Usual care|
62693693|NCT01458457|ACTIVE_COMPARATOR|Usual Care + Complementary Medicine|
62693694|NCT00280488|ACTIVE_COMPARATOR|1) MI with SO|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with inclusion of a significant other (SO) in prolonged, intensive alcohol treatment.
61935640|NCT03793868|PLACEBO_COMPARATOR|Placebo|Receiving placebo
62329752|NCT03514303||Timothy Grass|Subjects will test positive or negative to the allergen Timothy Grass.
62329753|NCT03514303||Johnson Grass|Subjects will test positive or negative to the allergen Johnson Grass.
61935641|NCT03793868|EXPERIMENTAL|High dose|Perampanel 8 mg PO x1
61935642|NCT05232981|EXPERIMENTAL|Study group|Conservative management of PAS with Ligation of the bilateral internal iliac arteries
62329754|NCT03514303||Bermuda Grass|Subjects will test positive or negative to the allergen Bermuda Grass.
62329755|NCT03514303||Cladosporium|Subjects will test positive or negative to the allergen Cladosporium.
62329756|NCT03514303||Cat Dander|Subjects will test positive or negative to the allergen Cat Dander.
62329757|NCT03514303||Cockroach|Subjects will test positive or negative to the allergen Cockroach.
62329758|NCT03514303||Dust Mite|Subjects will test positive or negative to the allergen Dust Mite.
62329759|NCT03514303||Oak|Subjects will test positive or negative to the allergen Oak.
62329760|NCT03514303||Dog Dander|Subjects will test positive or negative to the allergen Dog Dander.
62329761|NCT03016442|EXPERIMENTAL|Cook double balloon catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination İt is placed for 12 hours
62487606|NCT04815239|ACTIVE_COMPARATOR|Healthy Lifestyle Intervention (HL)|HL is based on the treatment manual developed in a prior trial for adults and adolescents with BP. HL includes psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health. In HL, patients are taught to develop and maintain an individualized lifestyle plan and provided support and encouragement for making progress toward their goals. HL clinicians will deliver 8 sessions over 6 months via secure telehealth platform.
62487607|NCT02643407|EXPERIMENTAL|Docetaxel plus Nedaplatin|docetaxel 60mg/m2 and nedaplatin 80mg/m2, d1 every 3 weeks
62487608|NCT02643407|ACTIVE_COMPARATOR|Docetaxel plus Cisplatin|docetaxel 60mg/m2 and cisplatin 75mg/m2, d1 every 3 weeks
62487609|NCT04432558||Preoperative anxiety level|
62487610|NCT04432558||Postoperative pain and analgesic consumption|
62487611|NCT06559527|EXPERIMENTAL|Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate \[eGFR\] - 60 - 89 milliliter per min \[mL/min\]) will administer a single dose of NNC0487-0111 on Day 1.
61935643|NCT05232981|ACTIVE_COMPARATOR|Control group|Conservative treatment with Shehata's technique and no internal iliac ligation
61935644|NCT00993161|EXPERIMENTAL|patients|Patients with neuromuscular disorder and controls
61935645|NCT00993161|EXPERIMENTAL|Controls|healthy controls
61935646|NCT01841307|EXPERIMENTAL|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
62329762|NCT03016442|ACTIVE_COMPARATOR|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
62487612|NCT06559527|EXPERIMENTAL|Moderate Renal Impairment|Participants with moderate renal impairment (eGFR - 30 - 59 mL/min) will administer a single dose of NNC0487-0111 on Day 1.
62487613|NCT06559527|EXPERIMENTAL|Severe Renal Impairment|Participants with severe renal impairment (eGFR - less than 30 mL/min not requiring dialysis) will administer a single dose of NNC0487-0111 on Day 1.
62487614|NCT06559527|EXPERIMENTAL|End-Stage Renal Disease (ESRD)|Participants with ESRD (requiring dialysis treatment) will administer a single dose of NNC0487-0111 on Day 1.
62487615|NCT06559527|EXPERIMENTAL|Normal Renal Function|Participants with normal renal function (eGFR - greater than or equals 90) will administer a single dose of NNC0487-0111 on Day 1.
61935647|NCT05774275|EXPERIMENTAL|Treatment Arm|"There will be 52 patients with high-risk localized extremity and trunk soft tissue sarcoma recruited.~In safety lead-in phase (phase Ib): using 3+3 design, patients will receive 4 cycles of Doxil or doxorubicin hydrochloride, sintilimab and radiotherapy.~In phase II: Doxil in RP2D, sintilimab and radiotherapy will be applied as before."
62487616|NCT03739502|EXPERIMENTAL|HBO arm|
62487617|NCT03739502|NO_INTERVENTION|non-HBO arm|
61935648|NCT04960800|EXPERIMENTAL|Intervention group|The participants in the intervention group will participate in a 12- week specific exercise programme led by an experienced women's health physiotherapist. These groups will take place at a private physiotherapy clinic twice a week. In addition, the participants will carry out a self-managed exercise program twice weekly for the same 12-week period. They will be provided with an exercise diary so that adherence to the intervention can be registered and monitored. This exercise diary will be sent to the participants once a week as an electronic questionnaire; this will ensure that the information recorded is standardized and that the research assistant can aid the participants to register their activity and encourage the participants to adhere to the intervention.
62329763|NCT01696734|EXPERIMENTAL|Treatment (domperidone)|Patients receive domperidone PO TID or QID. Treatment continues in the absence of disease progression or unacceptable toxicity.
62329764|NCT00006708|ACTIVE_COMPARATOR|ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
62329765|NCT00006708|EXPERIMENTAL|Rituximab-ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3
62329766|NCT05841134|EXPERIMENTAL|Tislelizumab combined with CAPOX|Successfully screened subjects will receive 4 cycles of neoadjuvant therapy with tislelizumab combined with chemotherapy (CAPOX) before surgery； undergo radical surgery 4-6 weeks after the end of the last medication; tislelizumab will be given after surgery Monoclonal antibody ± chemotherapy adjuvant therapy (the investigator judges whether to add chemotherapy based on the patient's comprehensive condition), until disease progression or unacceptable toxicity, the longest treatment is 12 months.
62329767|NCT03611933|NO_INTERVENTION|Control group (CG)|Patients in the CG were provided with routine nursing care, as practiced in the clinic, including restricted bed rest. For this purpose, patients were given supine position in which the HOB was elevated 15° for 6-10 h; the patient's leg on the of the side of intervention was kept straight.
62329768|NCT03611933|EXPERIMENTAL|Experimental group (EG)|Patients in the EG were applied position changes between the first minute and sixth hour. During the initial six hours a supportive, thin pillow, 4 x 40 x 100 cm in size, was placed between the patient's shoulders and gluteals; this reduced the pressure on local tissues and muscle groups.
62329769|NCT03758378|EXPERIMENTAL|Dietary intervention|
62329770|NCT00968253|EXPERIMENTAL|Phase I: RAD001 + Combination Chemo|"Optimal dose finding of Everolimus (RAD001) beginning dose 5 mg + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, \& 7 and Methotrexate \& Cytarabine (Ara-C) during Cycles 2, 4, 6, \& 8.~First chemotherapy combination Hyper-CVAD = Cyclophosphamide, Vincristine, Adriamycin (doxorubicin), and Dexamethasone; Second chemotherapy combination Methotrexate and Ara-C."
62487618|NCT01695239|EXPERIMENTAL|Ixekizumab Q2W|Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
62487619|NCT01695239|EXPERIMENTAL|Ixekizumab Q4W|Administered by 80 mg SC injection every 4 weeks (Q4W).
62487620|NCT01695239|PLACEBO_COMPARATOR|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
62487621|NCT01695239|ACTIVE_COMPARATOR|Adalimumab Q2W|Administered by 40 mg SC injection Q2W.
62487622|NCT01724463||Electronically Screened Sepsis Patients|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
62487623|NCT00276536|EXPERIMENTAL|Treatment|IFN weekly
62487624|NCT05652257|EXPERIMENTAL|[14C]-brensocatib|Healthy participants will receive single oral dose of \[14C\]-brensocatib on Day 1 under fasted conditions.
62487625|NCT00645853|EXPERIMENTAL|1|
62487626|NCT00645853|ACTIVE_COMPARATOR|2|
62487627|NCT06123195|EXPERIMENTAL|Constipation treatment|A 4-week intervention of constipation treatment with lactulose
62487628|NCT06123195|NO_INTERVENTION|Control|No constipation treatment except bisacodyl rescue therapy
62487629|NCT05929781||Young healthy adults|1. 20-39 years old
62487630|NCT05929781||Middle to older healthy adults|"1. 40-80 years old~2. age-matched with People with Parkinson's disease group"
62487631|NCT05929781||People with Parkinson's disease|"1. 40-80 years old~2. Diagnosis of idiopathic Parkinson's disease~3. Hoehn and Yahr stage 1-2"
62693695|NCT00280488|ACTIVE_COMPARATOR|2) MI with patient only|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with the individual patient
62693696|NCT00280488|ACTIVE_COMPARATOR|3) Assessment only|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
62693697|NCT01613885||Twins|Twins that are ages 0 to 80 years, with or without allergy disease.
62693698|NCT03716973|EXPERIMENTAL|High density programming|High density programming of spinal cord stimulator for paraesthesia-free therapy.
62697605|NCT01192074||Ultrasound of the spine|Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery
62487632|NCT03585556|EXPERIMENTAL|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
62487633|NCT01126463|EXPERIMENTAL|Rhenium Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
62487634|NCT01448096|EXPERIMENTAL|primary breast DLBCL|isolated breast involvement with or without nodal disease
62487635|NCT04756921||Patients cohort|Patients with HER2 positive MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included.
62487636|NCT05625490|EXPERIMENTAL|Asymptomatic Subjects (Normal Controls)|Normal control subjects are asymptomatic, without history of cardiovascular disease or significant cardiovascular risk factors. These participants will receive two \[68Ga\]Galmydar intravenous administrations, 2 mCi during rest and 4 mCi during stress for the \[68Ga\]Galmydar PET MPI performed on Imaging Day-1. On Imaging Day-2, asymptomatic subjects will receive two single intravenous administrations each of 10 mCi of \[13N\]Ammonia during the rest and stress PET MPI. \[68Ga\]Galmydar and \[13N\]Ammonia imaging visits will be separated by a minimum of 3 days.
62487637|NCT05625490|EXPERIMENTAL|Symptomatic Patients with Normal SPECT|Patients in this group have had a SPECT MPI examination that is normal and do not have an invasive coronary angiography (ICA) referral. Participants will receive one \[68Ga\]Galmydar intravenous administration, 2 mCi during rest for the \[68Ga\]Galmydar PET MPI.
61935649|NCT04960800|NO_INTERVENTION|Control group|The control group will not participate in any exercise intervention. The participants in the control group will be explained the importance of a control group in RCTs and will be recommended to continue with their normal activity levels. They will however, be recommended to follow national guidelines for general exercise during pregnancy and will receive information about these guidelines (15).
62487638|NCT05625490|EXPERIMENTAL|Symptomatic Patients with Abnormal SPECT|Patients in this group have had a SPECT MPI examination that is positive for ischemia in two myocardial segments and have been referred for invasive coronary angiography (ICA) as part of their routine standard-of-care. Subjects will undergo \[68Ga\]Galmydar PET/CT prior to any intervention. Participants will receive one \[68Ga\]Galmydar intravenous administration, 2 mCi during rest.
61935650|NCT05921747|ACTIVE_COMPARATOR|Core stability exercise by Physiotherapist|Postpartum women in this group will receive standard core stability exercise program (Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting) under the supervision of physiotherapist.
61935651|NCT05921747|EXPERIMENTAL|Core stability exercise by Virtual Reality|Postpartum patients with lumbopelvic pain will receive two sessions per week for a period of 4 weeks of a novel digital therapeutic that combines virtual embodiment with graded motor imagery to deliver functional rehabilitation exercises using an off-the-shelf virtual reality system. The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
61935652|NCT00760214|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD|
61935653|NCT00760214|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD|
62487639|NCT00239005|ACTIVE_COMPARATOR|Mycophenolate Mofetil (MMF)|250 mg capsules or 500 mg tablets of mycophenolate mofetil. Daily dose decided by physician, was taken morning and evening.
62487640|NCT00239005|EXPERIMENTAL|Enteric-Coated Mycophenolate Sodium (EC-MPS )|Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium. Daily dose decided by the physician, was taken morning and evening.
62487641|NCT05269069||Patients with rheumatoid arthritis|patients with rheumatoid arthritis
62693699|NCT00970710|EXPERIMENTAL|Lifestyle counseling|VACOPP (Vaasa Childhood Obesity Primary Prevention Study): Intensified lifestyle counseling including physical activity and nutritional information beginning during maternity health care and continuing during child health care clinic visits.
62693700|NCT06429072|EXPERIMENTAL|I-MASS Program plus Enhanced Education|
61935654|NCT00760214|ACTIVE_COMPARATOR|Ramipril 10 mg QD|
61935655|NCT03720834||Patients|Questionnaire on risk perception
61935656|NCT03720834||Clinicians|Questionnaire on risk perception
61935657|NCT05936281|EXPERIMENTAL|Genakumab group|Genakumab 100mg single injection,Genakumab 200mg single injection
61935658|NCT05936281|ACTIVE_COMPARATOR|Colchicine group|Colchicine 0.5mg qd po.for 12 weeks
61935659|NCT03964116|OTHER|AYA|Questionnaires set all 3 months and psychological interviews if needed
61935660|NCT05266716|EXPERIMENTAL|Primary Arm|The study will involve a total of approximately 48 individuals enrolled during a six-week period as participants in the field test of the Affect digital therapeutic platform
61935661|NCT00068783|EXPERIMENTAL|Treatment|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
61935662|NCT00446342|EXPERIMENTAL|Dose-escalation of SNS-032 injection|Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group.
61935663|NCT06681415|EXPERIMENTAL|Albumin group|The standard CPB priming volume of 1050 ml, comprising isochloremic solution Deltajonin® and 250 ml of 15% Mannitol, was used. The study group replaced 100 ml of Deltajonin® solution with 100 ml of 20% human albumin.
61935664|NCT06681415|NO_INTERVENTION|No-albumin group|The standard CPB priming volume of 1050 ml, comprising isochloremic solution Deltajonin® and 250 ml of 15% Mannitol
61935665|NCT03346044|ACTIVE_COMPARATOR|Carpentier-Edwards SAV bioprostheses|
61935666|NCT03346044|ACTIVE_COMPARATOR|Medtronic Mosaic bioprostheses|
61935667|NCT04317976|ACTIVE_COMPARATOR|Centrally located oesophagus post GA|Oesophagus remained central after general anaesthesia, cricoid pressure applied by fingertips under ultrasound guidance
62329771|NCT00968253|EXPERIMENTAL|Phase II: MTD RAD001 + Combination Chemo|MTD dose of Everolimus + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, \& 7 and Methotrexate \& Ara-C during Cycles 2, 4, 6, \& 8.
62487642|NCT05269069||Control group|healthy volunteers without rheumatoid arthritis matched for age, sex, BMI and menopausal status
62693701|NCT06429072|ACTIVE_COMPARATOR|Enhanced Education Intervention Only|
62487643|NCT05846282|EXPERIMENTAL|STRIVE|Based on the Learning to BREATHE (L2B) curriculum (Broderick, 2013), the STRIVE intervention is a mindfulness-based program designed to facilitate the development of emotion regulation for middle to high school students. Goals of the program include helping students understand their thoughts and feelings, learning how to use mindfulness-based skills to manage emotions, and providing opportunities for guided group mindfulness meditation practice. Delivered in twelve 60-minute group sessions, the intervention will be include the core components of the L2B program (i.e. body awareness; understanding and working with thoughts; understanding and working with feelings; integrating awareness of thoughts, feelings, and bodily sensations; reducing harmful self-judgments, and integrating mindful awareness into daily life) with content framed around the needs of high achieving, college-bound BIPOC students with the goal of offsetting the costs of resilience.
62487644|NCT05846282|PLACEBO_COMPARATOR|Study Skills|The attention control condition will incorporate face-valid content to support college readiness and achievement in twelve 60- minute group sessions. Twelve sessions will cover the SOAR study skills curriculum (Kruger, 2017), including goal-setting, organization and time-management, and study skills for reading comprehension, writing papers, note-taking, and test-taking.
62487645|NCT05303649|EXPERIMENTAL|Intermittent TBS (iTBS) of the left hemisphere plus behavioral aphasia therapy|15 sessions of 200-second of iTBS over the pars triangularis of Broca's area in the left hemisphere (BA 45), preceding 45-minutes of behavioral aphasia therapy.
62487646|NCT05303649|EXPERIMENTAL|Continuous TBS (cTBS) of the right hemisphere plus behavioral aphasia therapy|15 sessions of 40 seconds of cTBS over the pars triangularis of the right inferior frontal gyrus (BA 45 homologue), preceding 45-minutes of behavioral aphasia therapy.
62487647|NCT05303649|SHAM_COMPARATOR|Sham TBS (sTBS) of the left hemisphere plus behavioral aphasia therapy|15 sessions of sham TBS over the pars triangularis of Broca's area in the left hemisphere (BA 45), preceding 45-minutes of behavioral aphasia therapy.
62487648|NCT03997799|EXPERIMENTAL|uniportal transcervical approache|Uniportal lobectomy with complete lymphadenectomy - transcervical approach with elevation of the sternum
62487649|NCT03997799|EXPERIMENTAL|uniportal intercostal approache|Uniportal lobectomy with complete lymphadenectomy - intercostal approache
62487650|NCT01091480||Patients with HCM|Patients ≥ 15 years with HCM(sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
62487651|NCT03610542|EXPERIMENTAL|Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting.
62487652|NCT03610542|EXPERIMENTAL|Cognitive Behaviour Therapy with 2 Booster Sessions|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting. 2 booster sessions (forty-five minutes each) will be provided at three and nine months. Each session will recap the content of the initial 6 sessions.
62329772|NCT05169645||CSUA patients|CSUA patients
62487653|NCT03610542|NO_INTERVENTION|Control|This is a no intervention control arm
62487654|NCT04411680|EXPERIMENTAL|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
62693702|NCT04849273|EXPERIMENTAL|TPX-0131|The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.
62693703|NCT05974787||Cancer patients|All adult patients with solid or hematological malignancies and receiving systemic therapy or having received systemic therapy within the last 3 months admitted to the emergency department of the Erasmus Medical Center for the oncology, hematology, lung- and neuro-oncology medical unit are eligible for inclusion.
62693704|NCT05864469|EXPERIMENTAL|12-week psychosocial dyadic intervention|The 12-week psychosocial dyadic intervention will comprise six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
62693705|NCT05864469|NO_INTERVENTION|Usual care|Participants in the control group will receive the usual care provided by the clinical team in the hospital
62329773|NCT02928406|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62329774|NCT02572830|EXPERIMENTAL|Delayed Bilateral Eye Movements|Delayed Bilateral Eye Movements after reactivation of fear-memory.
62487655|NCT04411680|ACTIVE_COMPARATOR|Control Arm|Standard of care for COVID-19
62693706|NCT05317936|EXPERIMENTAL|Pirtobrutinib+venetoclax|Pirtobrutinib by mouth at the same time each day Venetoclax by mouth at the same time each day.
62693707|NCT05529602|EXPERIMENTAL|post isometric relaxation exercises and core stability|for pain and disability secondary to SIJ dysfunction in postpartum females
62693708|NCT05529602|OTHER|conventional physical therapy|for management of lower back pain
62693709|NCT06434350|EXPERIMENTAL|Enfortumab Vedotin with Radiation|"Particpants will receive enfortumab vedotin by vein over about 1-2 hours on Days 1 and 8 of every 28-day cycle. Two dose levels of enfortumab vedotin will be tested. The dose of enfortumab vedotin participants receive will depend on when the participant join the study.~Participants will also receive radiation therapy 5 times a week (Monday through Friday) for about 4-5 weeks."
62697606|NCT05961527|EXPERIMENTAL|MDMA-assisted group therapy|Four Preparatory Sessions, two MDMA Sessions, and four Integrative Sessions following each MDMA Session.
62697607|NCT03770286|ACTIVE_COMPARATOR|Fluoride Varnish alone|5% sodium fluoride varnish will be applied to all teeth the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
62329775|NCT02572830|ACTIVE_COMPARATOR|Undelayed Bilateral Eye Movements|Undelayed Bilateral Eye Movements after reactivation of fear-memory.
62329776|NCT01912768|EXPERIMENTAL|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days
62329777|NCT01912768|ACTIVE_COMPARATOR|renu fresh|Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days
62329778|NCT01680094|EXPERIMENTAL|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
62487656|NCT05636254||Chronic Meningitis|"* Chronic meningitis : Case definition~  * Headache with or without fever, nuchal stiffness and systemic symptoms AND~ * CSF suggestive of meningitis Pleocytosis (\>20 cells per μL) with lymphocyte predominance (\>50%) OR Protein concentration greater than age-specific normal value; especially \>1•0 g/L OR Glucose concentration less than 60% of concentration in blood OR MRI suggestive of meningeal enhancement on contrast enhanced T1 sequences AND~ * Deemed by the treating physician that the syndrome is consistent with chronic meningitis~* Patients who are positive for antibodies to HIV and pregnant females will also be included."
62487657|NCT05098223|NO_INTERVENTION|Promotions|Participants in this group will see a version of the website which will reproduce the types and frequency of promotions that can be found in any online supermarket, for example multi-buy offers and temporary price reductions will be applied to a pre-determined percentage of food products within the target categories \[confectionery; biscuits and crackers; crisps, nuts and snacking fruit; cakes and tarts\]. Promotions will be applied to match the current levels and types of promotions on the website of the largest UK retailer present in a specific week, shortly before the study launch.
62329779|NCT04720508||Group A (patient group)|"included 25 patients with BC admitted to department of medical Oncology, South Egypt Cancer Institute, Assiut University.~blood samples will be obtained after getting informed consent."
62329780|NCT04720508||Group B (control group)|included 25 controls age-matched , sex-matched and apparently healthy. blood samples will be obtained after getting informed consent .
62329781|NCT00918476|EXPERIMENTAL|1. filibuvir + Oral Contraceptives|
62329782|NCT03132805|NO_INTERVENTION|Control|Schools which receive no intervention
62329783|NCT03132805|EXPERIMENTAL|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
62329784|NCT03132805|EXPERIMENTAL|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
62329785|NCT04676750|EXPERIMENTAL|MBSR|receives 8-week MBSR course
62329786|NCT04676750|NO_INTERVENTION|control|receives intervention after experiment finishes
62329787|NCT05300100|EXPERIMENTAL|Activities|"The duration of the experience will last 1 hour per participant in a single session.~The proposed actions were chosen from a very large sensorimotor repertoire of activities in everyday life for a child aged 5 to 8.~The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests."
62329788|NCT06517615|EXPERIMENTAL|trial|Home Visit Supported Nursing Training Program
62329789|NCT06517615|NO_INTERVENTION|control|standart care
62329790|NCT01966562|EXPERIMENTAL|WBV TRAINING|WHOLE-BODY VIBRATION TRAINING
62329791|NCT01966562|ACTIVE_COMPARATOR|MC TRAINING|MULTICOMPONENT TRAINING
62329792|NCT01966562|NO_INTERVENTION|CG|Control group
62329793|NCT02566330||EndoBarrier|Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
62487658|NCT05098223|EXPERIMENTAL|No promotions|All price promotions will be removed so no promotions will be present on any of the products within the target food categories \[confectionery; biscuits and crackers; crisps, nuts and snacking fruit; cakes and tarts\] offered to participants when searching for products.
62487659|NCT02113722|ACTIVE_COMPARATOR|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation
62697608|NCT03770286|EXPERIMENTAL|SDF with Super Floss|SDF will be applied to target interproximal lesions with the use of Super Floss for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
62697609|NCT03770286|EXPERIMENTAL|SDF without Super Floss|SDF will be applied to around the (buccal, lingual, and occlusal) embrasures of the target interproximal lesions with the use of a microbrush for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
62329794|NCT04125797|ACTIVE_COMPARATOR|Adhesive 1|This arm investigates one type of silicone adhesive (3M2475P) on adult female skin.
62329795|NCT04125797|ACTIVE_COMPARATOR|Adhesive 2|This arm investigates one type of silicone adhesive (RX1449P) on adult female skin.
62329796|NCT04125797|ACTIVE_COMPARATOR|Adhesive 3|This arm investigates one type of silicone adhesive (PS-1243) on adult female skin.
62329797|NCT00313807|ACTIVE_COMPARATOR|1|Intravenous saline infusion plus amino acid infusion
62329798|NCT00313807|PLACEBO_COMPARATOR|2|Intravenous saline infusion plus placebo infusion
62329799|NCT03977727|EXPERIMENTAL|Fiasp/Novolog|7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
62329800|NCT03977727|EXPERIMENTAL|Novolog/Fiasp|7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
62329801|NCT03121872|EXPERIMENTAL|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
62329802|NCT03121872|ACTIVE_COMPARATOR|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
62329803|NCT04806932|ACTIVE_COMPARATOR|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
61935668|NCT04317976|EXPERIMENTAL|Eccentric located oesophagus post GA|Oesophagus eccentric located after general anaesthesia, paralaryngeal pressure and cricoid pressure applied by fingertips under ultrasound guidance
61935669|NCT05563844|EXPERIMENTAL|PM 8.4 mg/m2|15 case，Take the medicine once on D1 ，D 1 through 21.
62329804|NCT04806932|PLACEBO_COMPARATOR|The conventional approach|The first three attempts via the conventional approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
62329805|NCT00941616|EXPERIMENTAL|PK|Includes subjects participating in the pharmacokinetic component of the study.
62329806|NCT00941616|EXPERIMENTAL|Prophylaxis|Includes subjects receiving 12 months of prophylactic therapy.
62329807|NCT00941616|EXPERIMENTAL|On-demand|Includes subjects receiving 12 months of on-demand treatment.
62329808|NCT00941616|EXPERIMENTAL|Cross-over to prophylaxis|"Includes subjects completing 12 months of on-demand treatment (the On-demand arm) who cross-over to prophylactic therapy for an additional 12-month period."
62329809|NCT03492463|ACTIVE_COMPARATOR|Nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
62329810|NCT03492463|ACTIVE_COMPARATOR|Non-nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes not containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
62329811|NCT03492463|ACTIVE_COMPARATOR|Nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
62487660|NCT02113722|PLACEBO_COMPARATOR|Standard of care|Continuing medical therapy
62487661|NCT05084963|EXPERIMENTAL|Arm 1: IRL201104 Dose A|IRL201104 IV on Days 0, 7, and 14
62329812|NCT03492463|PLACEBO_COMPARATOR|Non-nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes not containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
62329813|NCT04831216|EXPERIMENTAL|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
62487662|NCT05084963|EXPERIMENTAL|Arm 2: IRL201104 Dose B|IRL201104 IV on Days 0, 7, and 14
62487663|NCT05084963|PLACEBO_COMPARATOR|Arm 3: Placebo|Placebo IV on Days 0, 7, and 14
62487664|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
62487665|NCT05597228|EXPERIMENTAL|Behavioral: Cognitive-Behavioral Stress Management and Health Education|Weekly video conference groups led by a trained facilitator
62487666|NCT06154096||Healthy volunteer|Subject without MASLD or metabolic-associated disease
61935670|NCT05563844|EXPERIMENTAL|PM 11.2 mg/m2|15 case，Take the medicine once on D1 ，D 1 through 21.
61935671|NCT05830903|EXPERIMENTAL|Mild ED/NS|10 patients with mild or none executive function impairment and mild or none negative symptoms.
61935672|NCT05830903|EXPERIMENTAL|Mild ED/Severe NS|10 patients with mild or none executive function impairment and severe or moderate negative symptoms.
61935673|NCT05830903|EXPERIMENTAL|Severe ED/Mild NS|10 patients with severe or moderate executive function impairment and mild or none negative symptoms.
61935674|NCT05830903|EXPERIMENTAL|Severe ED/NS|10 patients with severe or moderate executive function impairment and severe or moderate negative symptoms.
61935675|NCT00116428|EXPERIMENTAL|NAVISTAR® THERMOCOOL® Catheter|
61935676|NCT00116428|ACTIVE_COMPARATOR|Antiarrhythmic drug|
62329814|NCT02934412|EXPERIMENTAL|SHR-1314 20mg|20mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
62329815|NCT02934412|EXPERIMENTAL|SHR-1314 40mg|40mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
62329816|NCT02934412|EXPERIMENTAL|SHR-1314 80mg|80mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
62329817|NCT02934412|EXPERIMENTAL|SHR-1314 160mg|160mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
62329818|NCT02934412|EXPERIMENTAL|SHR-1314 240mg|240mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
62329819|NCT01924910|PLACEBO_COMPARATOR|Placebo Pill|Received identical pills that do not contain vitamin D. Blood levels of 25(OH)D determined at 10 days, 3 months, and 1 year following placebo dose.
61935677|NCT03511118||Tranexamic acid (TXA)|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62329820|NCT01924910|ACTIVE_COMPARATOR|Vitamin D|250,000 IU cholecalciferol as single, oral dose. Blood levels 25(OH)D measured at 10 days, 3 months, and 1 year following dose.
62487667|NCT06154096||MASLD|Subject with MASLD
62487668|NCT01731977|EXPERIMENTAL|Strengths-based family psychoeducation|Family psychoeducation in addition to treatment as usual
62487669|NCT01731977|NO_INTERVENTION|Waiting list|Treatment as usual
62487670|NCT05878015|EXPERIMENTAL|IV Acetaminophen Group|Subjects presented to emergency department (ED) and diagnosed with small bowel obstruction which receive IV acetaminophen
62487671|NCT05878015|NO_INTERVENTION|Usual Care Group|Subjects presented to emergency department (ED) and diagnosed with small bowel obstruction will receive intravenous opioids per their provider's choice as standard of care.
62487672|NCT00985439|EXPERIMENTAL|Diclofenac Test (lower dose)|One 18-mg Diclofenac Test Capsule and 1 placebo capsule
62487673|NCT00985439|EXPERIMENTAL|Diclofenac Test (upper dose)|One 35-mg Diclofenac Test Capsule and 1 placebo capsule
62487674|NCT00985439|ACTIVE_COMPARATOR|Celecoxib 400 mg|
62487675|NCT00985439|PLACEBO_COMPARATOR|Placebo|
62487676|NCT05250960|EXPERIMENTAL|Intervention - SCD arm|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
62487677|NCT05250960|NO_INTERVENTION|Control - no SCD arm|Patient will receive 1L of LR during and after epidural placement with no use of SCDs
62487678|NCT05037318|EXPERIMENTAL|Stress arousal reappraisal|
62487679|NCT05037318|EXPERIMENTAL|Worked examples|
62487680|NCT05037318|EXPERIMENTAL|Stress arousal reappraisal + Worked examples|
62487681|NCT05037318|NO_INTERVENTION|Control|
62487682|NCT02965898|ACTIVE_COMPARATOR|Vitamin D 100ug|The highest safest dose. Expected to lower risk of chronic pancreatitis after acute pancreatitis.
62487683|NCT02965898|PLACEBO_COMPARATOR|Vitamin D 10ug|Placebo dose. Minimal recommended dose
62487684|NCT03221049||chronic hepatitis B patients|ultrasound and radiomics
61935678|NCT03511118||labetalol|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62487685|NCT03221049||patients with liver space occupying lesions|ultrasound and radiomics
62487686|NCT03221049||patients undergo ablation|ablation, ultrasound and radiomics
62487687|NCT06345235||with ATTR cardiomyopthy|blood sample
62487688|NCT06345235||TTR variant carier and no ATTR cardiomyopthy|blood sample
61935679|NCT03511118||metformin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935680|NCT03511118||nifedipine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935681|NCT03511118||clindamycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935682|NCT03511118||oxycodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62135100|NCT05381532|EXPERIMENTAL|Control sleep - luteal phase|This will be the fourth of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a control sleep schedule during the luteal phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
62487689|NCT06345235||controls|blood sample
61935683|NCT03511118||azithromycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935684|NCT03511118||escitalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62329821|NCT02029404|ACTIVE_COMPARATOR|Tibial nerve group|In the TN (tibial nerve ) group probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Identified the tibial nerve we will proceed , previous local anaesthesia, to insert a catheter medially to tibial branch of the sciatic nerve according to in plane approach.
62487690|NCT03684330|ACTIVE_COMPARATOR|Vitamin D supplementation|
62487691|NCT03684330|PLACEBO_COMPARATOR|Vitamin D placebo|
62487692|NCT01305109|EXPERIMENTAL|Oral Rotavirus Vaccine 116E (ORV 116E)|Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5 mL at 4 week intervals
62487693|NCT01305109|PLACEBO_COMPARATOR|Placebo|3 doses of 0.5 mL at 4 week intervals
62487694|NCT01440179|EXPERIMENTAL|SAR3419|Administered for one to two induction cycles, followed by maintenance cycles up to 6 cycles.
62487695|NCT04025021|NO_INTERVENTION|Control group (standard fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. As feedings are advanced to goal of 150 ml/kg/day, the TPN and SMOF lipids (Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil) will be decreased per standard management and NICU guidelines."
62487696|NCT04025021|EXPERIMENTAL|Intervention group (targeted fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. During this time, as the volume decreases, the TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day. Breast milk analysis will occur on a weekly basis immediately after birth for all infants enrolled in the study."
62487697|NCT05428826|EXPERIMENTAL|Prednisone|Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
62487698|NCT05106803||Wound infection|Patients with surgical site infection as diagnosed by the attending physician
62487699|NCT06619704||Group I|Postmenopausal female patients who initiated ribociclib combinations per local label.
62487700|NCT06619704||Group II|Postmenopausal female patients who were eligible for cyclin-dependent kinase inhibitors (CDKis) according to local label but started chemotherapy.
62487701|NCT02182713|EXPERIMENTAL|Arm 1 - CombiventTM followed by Salbutamol|
62487702|NCT02182713|ACTIVE_COMPARATOR|Arm 2 - Salbutamol followed by CombiventTM|
62487703|NCT03090321|ACTIVE_COMPARATOR|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
62487704|NCT03090321|ACTIVE_COMPARATOR|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
62487705|NCT03090321|ACTIVE_COMPARATOR|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
61935685|NCT03511118||sertraline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62135101|NCT00520221||2|"Minocycline group: 300 mg of minocycline hydrochloride was instilled into the pleural space through the catheter.~Control group consisted of 33 patients who had successful simple aspiration alone between January 2004 and December 2005."
62135102|NCT04430634|EXPERIMENTAL|ABDC|Subjects use MybluTM e-cigarette product variant A (2.4 % nicotine) ad libitum for 2 days, then switch to use variant B (3.6% nicotine) for 2 days, then D (4.0% nicotine) for 2 days and then C (2.5% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
62329822|NCT02029404|ACTIVE_COMPARATOR|Tibial peroneal nerve group|"In the TPN (tibial -peroneal nerve) group the probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Afterwards, proceeding cranially with the probe according to in plane approach, we will identify the confluence of tibial with peroneal branch and in this point, previous local anaesthesia, we will position the catheter within the confluence of peroneal and tibial nerve."
62329823|NCT06692829|ACTIVE_COMPARATOR|Conventional Therapy|It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.
61935686|NCT03511118||ondansetron|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935687|NCT03511118||Ciprofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935688|NCT03511118||Doxycycline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935689|NCT03511118||Levofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935690|NCT03511118||Methylphenidate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935691|NCT03511118||Sumatriptan|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935692|NCT03511118||Citalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935693|NCT03511118||Cyclobenzaprine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935694|NCT03511118||Furosemide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935695|NCT03511118||Gabapentin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935696|NCT03511118||Hydrochlorothiazide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62135103|NCT04430634|EXPERIMENTAL|BCAD|Same as previous arm, but in a different randomization order.
62329824|NCT06692829|EXPERIMENTAL|Robot Assisted Therapy|In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.
62329825|NCT02963714|EXPERIMENTAL|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62487706|NCT03090321|PLACEBO_COMPARATOR|Read AHA website|Daily reminder to read the American Heart Association (AHA) website.
62487707|NCT03090321|NO_INTERVENTION|Baseline monitoring|No feedback is provided to the users. This is the control arm.
62487708|NCT00597454|EXPERIMENTAL|1|
62487709|NCT03997890|EXPERIMENTAL|Symfony group|The subjects who underwent cataract surgery with binocular implantation of either Symfony or Symfony toric IOLs
62487710|NCT03736577|EXPERIMENTAL|NorGeP-NH|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend.~Intervention: Drug reviews with NorGeP-NH Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH) and they will do a structured drug review on the participants' drug charts."
62329826|NCT02963714|EXPERIMENTAL|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
62487711|NCT03736577|NO_INTERVENTION|Control nursing home|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend. Physicians will not attend any lecture about drug reviews and they will keep treating participants as usual."
62487712|NCT00182260|ACTIVE_COMPARATOR|Proton Pump Inhibitor|Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
62487713|NCT00182260|ACTIVE_COMPARATOR|Laparoscopic Nissen Fundoplication|Surgical patients underwent LNF using previously published technique.
62487714|NCT04552665||Adults|Patients who have cardiac arrhythmia
62487715|NCT02266407|ACTIVE_COMPARATOR|ASEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for aseptic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with ASEPTIC failed primary TKA and revised without use of the Aquamantys® System.
62487716|NCT02266407|ACTIVE_COMPARATOR|SEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for septic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with SEPTIC failed primary TKA revised without use of the Aquamantys® System.
62487717|NCT04444063|EXPERIMENTAL|NIPSA technique with Allograft plus PRF|Non-incised papilla preservation technique to treat intraosseous bony defects with the addition of Allograft plus PRF
62693710|NCT03894462|ACTIVE_COMPARATOR|Zero Suicide Usual Care|"In Onondaga County, New York State (NYS) aims to implement a countywide Zero Suicide Safety Net of providers who share enhanced protocols for clinical care, staff training, and data collection (improved coding of suicidal behavior). Participating behavioral health systems have agreed to common protocols for clinical care, training, and data collection. Participating providers receive robust training in suicide prevention best practices. Because of the wide participation of mental health facilities in the NYS Office of Mental Health (OMH) Zero Suicide project, most subjects who engage in outpatient treatment will receive that treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged."
61935697|NCT03511118||Hydroxyurea|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935698|NCT03511118||Rosuvastatin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935699|NCT03511118||Topiramate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62135104|NCT04430634|EXPERIMENTAL|CDBA|Same as previous arm, but in a different randomization order.
62329827|NCT02327286|EXPERIMENTAL|Intervention|Promote and support healthy behaviors
62329828|NCT02327286|NO_INTERVENTION|Control|Conventional care for women with prior GDM.
62487718|NCT04444063|ACTIVE_COMPARATOR|NIPSA technique|Non-incised papilla preservation technique to treat intraosseous bony defects without the addition of Allograft plus PRF
62487719|NCT03721653|ACTIVE_COMPARATOR|FOLFOXIRI + Bevacizumab|"(to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
62329829|NCT05833893|EXPERIMENTAL|Treatment group|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
62329830|NCT00421343|OTHER|Treatment for osteoporosis and falls|calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention
62329831|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
62329832|NCT00894413|PLACEBO_COMPARATOR|Placebo|
62329833|NCT00894413|EXPERIMENTAL|Tadalafil|Tadalafil 20 mg once per day
62329834|NCT02076555|EXPERIMENTAL|Education - Diabetes and Social Issues|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Social Issues"
62329835|NCT02076555|NO_INTERVENTION|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
61935700|NCT03511118||Trazodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62329836|NCT06018467|EXPERIMENTAL|Dasatinib plus Quercetin (DQ)|Study participants will receive a combination of 100 mg/d dasatinib (oral) for two consecutive days and 1.250 mg/d quercetin (oral) for three consecutive days followed by 25 days without treatment, with treatment being repeated every 4 weeks for a total of 20 weeks (i.e., 5 times)
62329837|NCT06018467|EXPERIMENTAL|Nicotinamide Riboside (NR)|The participants will receive treatment with 1g Nicotinamide Riboside (oral) daily for 20 weeks
62329838|NCT06018467|NO_INTERVENTION|Control|The participants in the Control group, will not receive any treatment for 20 weeks.
62329839|NCT04308512|EXPERIMENTAL|Intervention Group (IG): Care coordination with Care4AD system|All participants will receive Care4AD device.All reminders will be activated in the intervention group (IG). Essential activity daily living (ADL) tasks will be pre-programmed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
62329840|NCT04308512|NO_INTERVENTION|Control Group (CG): Standard of care|Participants in control group (CG) will also receive Care4AD device. However, all reminders and programming of activity daily living (ADL) tasks will be de-activated in the CG.
62329841|NCT01196169|EXPERIMENTAL|Daptomycin|Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
62329842|NCT01196169|ACTIVE_COMPARATOR|Vancomycin|Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
62329843|NCT02358330||EHR Enhanced Clinic Referral|"A set of standard EHR modifications will be implemented in 18 clinics as part of the MBD (multiple baseline design) experiment.The key new EHR functions that will be implemented and tested are: 1) a modified screen for smoking sta-tus to enhance the identification and documentation of all smokers visiting targeted primary care clinics; 2) a Smoker Registry to track smokers, document their receipt of treatment services, and organize direct-to-consumer communications; 3) a 1-click referral system to evidence-based smoking treat-ment with UW-CTRI case managers; 4) a closed-loop feedback feature to communicate to the clinician the fate of a referral, documenting receipt of the referral and treatment engagement; and 5) EHR-based communication options to inform smokers of treatment resources"
62329844|NCT02358330||Standard care (control) clinics|10 control clinics will also be inducted into the study. These clinics will use existing EHR resources to identify smokers (e.g., the expanded vital signs) and to document their smoking status, and then use the standard paper fax-to-quit methods to refer patients to the Wisconsin Tobacco Quit Line
62329845|NCT04284982|EXPERIMENTAL|Heavy resistance training program|
62329846|NCT04360187|EXPERIMENTAL|Crisaborole ointment|Crisaborole ointment application twice daily for 28 days
62329847|NCT04360187|PLACEBO_COMPARATOR|Crisaborole Placebo Vehicle|Vehicle Ointment application twice daily for 28 days
62329848|NCT01186211||Patients presenting for elective TKA|Patients will be advised preoperatively about an accelerated path while in hospital that will share many attributes of the standard TOH care map but with several additions, chosen to help reduce pain and hemarthrosis, both felt to be the major impediments to faster recuperation.
62329849|NCT05596968||sorafenib group|FLT3-ITD+ AML patients who receive sorafenib maintenance therapy after allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
62329850|NCT06241599|EXPERIMENTAL|AK104|AK104: 6mg/kg intravenous infusion for more than 60 minutes
62329851|NCT06241599|PLACEBO_COMPARATOR|Placebo|placebo: 6mg/kg intravenous infusion for more than 60 minutes
62329852|NCT03950245|OTHER|Gastric bypass operated patients|Four test days in a randomized, patient-blinded, cross-over design
61935701|NCT03511118||Valganciclovir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935702|NCT03511118||Venlafaxine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62329853|NCT03950245|OTHER|Sleeve gastrectomy operated patients|Four test days in a randomized, patient-blinded cross-over, design
62329854|NCT03950245|OTHER|Un-operated controls|Four test days in a randomized, patient-blinded cross-over, design
61935703|NCT03511118||Verapamil|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62135105|NCT04430634|EXPERIMENTAL|DACB|Same as previous arm, but in a different randomization order.
62329855|NCT05282264||Patient with hybrid closed-loop systems|
62329856|NCT05282264||Patient without hybrid closed-loop systems|
62329857|NCT05066997|EXPERIMENTAL|OCS-01|dexamethasone ophthalmic suspension,1.5% \[15 mg/ mL\]
62329858|NCT05066997|PLACEBO_COMPARATOR|Vehicle placebo arm|Vehicle ophthalmic suspension
62329859|NCT03537820||before nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, before nurses formation and installation of a noise warning device
62329860|NCT03537820||after nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, after nurses formation and installation of a noise warning device
62329861|NCT01529476|EXPERIMENTAL|Nemonoxacin 500 mg|
62487720|NCT03721653|EXPERIMENTAL|FOLFOXIRI + Bevacizumab + Atezolizumab|"Atezolizumab 840 mg iv over 30 minutes(60 minutes at the first infusion) day 1 followed by Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev and atezolizumab until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
62487721|NCT03600753|EXPERIMENTAL|symptomatic patients|symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
62329862|NCT01529476|ACTIVE_COMPARATOR|Levofloxacin 500 mg|
62487722|NCT03600753|ACTIVE_COMPARATOR|asymptomatic patients|"symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus.~A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed"
62487723|NCT03600753|OTHER|healthy subjects|Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
62487724|NCT05716490|ACTIVE_COMPARATOR|Standard|Control group which will cover surgical wound with conventional wound dressing
61935704|NCT03511118||Remdesivir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935705|NCT03511118||Anakinra|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935706|NCT03511118||Tocilizumab|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935707|NCT03511118||Fluvoxamine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62329863|NCT04339075||Venablock|Patients that have undergone Venablock treatment
62329864|NCT06363045|EXPERIMENTAL|Adults 18 years old or older|NIDEK TONOREFIII
62329865|NCT05523713|OTHER|Patients with major elective digestive surgery|"The size of the cohort is 240 patients~Population: Patients with major elective digestive surgery (eg, colon or colorectal resection, partial or total gastrectomy, pancreaticoduodenectomy, hepatectomy)."
61935708|NCT03511118||Amoxicillin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935709|NCT03511118||Bupropion|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935710|NCT03511118||Buprenorphine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62329866|NCT03013322|ACTIVE_COMPARATOR|Treatment Group|The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).
62329867|NCT03013322|PLACEBO_COMPARATOR|Placebo Group|The placebo group is treated with 0.9% sodium chloride.
62329868|NCT01580592|EXPERIMENTAL|Omalizumab 150mg|
62329869|NCT01580592|EXPERIMENTAL|Omalizumab 300mg|
62329870|NCT01580592|PLACEBO_COMPARATOR|Placebo|
62329871|NCT05012319|EXPERIMENTAL|treatment arm|"Nitric Oxide Nasal Spray Enovid"
62487725|NCT05716490|EXPERIMENTAL|PICO|Group that will use Pico® device for wound dressing
62329872|NCT05012319|PLACEBO_COMPARATOR|Placebo|Placebo
62329873|NCT03727321|PLACEBO_COMPARATOR|Placebo|Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
62329874|NCT03727321|EXPERIMENTAL|Fecal Microbial Transplant and cellulose|"1. Fecal Microbial Transplant - Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.~2. Cellulose x 6weeks"
62329875|NCT03727321|EXPERIMENTAL|Fiber|Soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
62329876|NCT03727321|EXPERIMENTAL|Fecal Microbial Transplant and Fiber|"1. Fecal Microbial Transplant~2. Soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS)."
62329877|NCT01889199|PLACEBO_COMPARATOR|Sugar pill|Placebo intervention
62329878|NCT01889199|EXPERIMENTAL|Flutamide|Flutamide 125 mg orally daily for six 28-day cycles.
62329879|NCT00553059|EXPERIMENTAL|Arm I: Palonosetron, Dexamethasone + Dronabinol|Palonosetron hydrochloride intravenous (IV) and dexamethasone IV 30 minutes before chemotherapy administration on day 1, and oral dronabinol 3 times a day for 5 days beginning 30 minutes before chemotherapy administration on day 1.
62135106|NCT04430634|EXPERIMENTAL|EFHG|Subjects use MybluTM e-cigarette product variant E (3.6 % nicotine) ad libitum for 2 days, then switch to use variant F (2.4% nicotine) for 2 days, then H (3.6% nicotine) for 2 days and then G (4.0% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
62329880|NCT00553059|ACTIVE_COMPARATOR|Arm II: Palonosetron + Dexamethasone|Palonosetron hydrochloride and dexamethasone as in arm I, and oral placebo 3 times a day for 5 days beginning 30 minutes before chemotherapy on day 1.
62487726|NCT05716490|EXPERIMENTAL|PREVENA|Group that will use Prevena® device for wound dressing
62487727|NCT03419247|EXPERIMENTAL|Tumor tissue and blood sample collection|
61935711|NCT03511118||Hydrocodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62135107|NCT04430634|EXPERIMENTAL|FGEH|Same as previous arm, but in a different randomization order.
62135108|NCT04430634|EXPERIMENTAL|GHFE|Same as previous arm, but in a different randomization order.
62135109|NCT04430634|EXPERIMENTAL|HEGF|Same as previous arm, but in a different randomization order.
62135110|NCT02315456|OTHER|Capsule centration|Capsulorhexis made with capsule centration
62135111|NCT02315456|OTHER|Pupil centration|Capsulorhexis made with pupil centration
62135112|NCT05811936|NO_INTERVENTION|Usual Care|Caregiver- Survivor Dyads in this group will receive routine follow-up care in the HNC clinic. Current standard of care is an Advanced Practice Provider (Physician Assistant or Nurse Practitioner)-delivered survivorship visit after treatment. This visit will take place according to UC in the clinic. UC dyads will also receive printed caregiving and survivorship materials.
62135113|NCT05811936|EXPERIMENTAL|SNAP|Caregiver- Survivor Dyads in this group will receive a two-session intervention spanning 3 months, with a caregiver module within 1-2 weeks of the end of RT and a dyadic module at 3 months. Each session will include a needs- assessment, a tailored care plan with a goal setting discussion, and referrals for unmet needs. Each session follows with a supportive mobile app for 6 weeks.
62135114|NCT00909324|EXPERIMENTAL|Pre-LASIK 0.3% hypromellose|
62135115|NCT00909324|ACTIVE_COMPARATOR|Post-LASIK 0.3% hypromellose|
62135116|NCT02136641|ACTIVE_COMPARATOR|Midazolam|1. Sedation with Midazolam 0.03 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
62135117|NCT02136641|EXPERIMENTAL|Midazolam+Fentanyl Combination|2. Sedation with Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
62135118|NCT02136641|EXPERIMENTAL|Midazolam+Ketamine Combination|3. Sedation with Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
62135119|NCT03589625|EXPERIMENTAL|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
62135120|NCT03589625|EXPERIMENTAL|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
62135121|NCT01183598|EXPERIMENTAL|Single Arm|
62135122|NCT05395234|EXPERIMENTAL|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura \& McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction \& flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
61935712|NCT03511118||Levetiracetam|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
62135123|NCT02259049|ACTIVE_COMPARATOR|L-Tyrosine|We will administer 1,000 mg of L-tyrosine BID for 24 hours and record BP and HR.
62135124|NCT02259049|PLACEBO_COMPARATOR|Sugar Pill|We will administer a sugar pill BID for 24 hours and record BP and HR.
62135125|NCT04207424|EXPERIMENTAL|Embolization|Patients undergoing embolization of the gastro-epiploic arcade
62135126|NCT04257487|ACTIVE_COMPARATOR|Treatment A|Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
62135127|NCT04257487|ACTIVE_COMPARATOR|Treatment B|Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
62135128|NCT04257487|PLACEBO_COMPARATOR|Treatment C|2 indistinguishable placebo capsules BID, for 12 months
62135129|NCT02438059|EXPERIMENTAL|Intervention|Access to the SoSu-liv website and app for 38 weeks.
62135130|NCT02438059|NO_INTERVENTION|Control|No treatment for 38 weeks.
62135131|NCT05018910|OTHER|Heart Rate Variability|All infants enrolled in the study had their heart rate variability measured before, during, and after skin-to-skin sessions. This was the only arm of the study.
62135132|NCT05078255|PLACEBO_COMPARATOR|placebo injections + placebo infusion|
62487728|NCT04401137|PLACEBO_COMPARATOR|Placebo|
62487729|NCT04401137|EXPERIMENTAL|QDX 25|
62487730|NCT04401137|EXPERIMENTAL|QDX 50|
62487731|NCT04401137|EXPERIMENTAL|QDX 100|
62487732|NCT04401137|EXPERIMENTAL|QDX 200|
62487733|NCT03713866|EXPERIMENTAL|EP Imaging and Testing|MRI images,120 lead body surface mapping and NIPS testing will be completed to correlate areas of VT scar.
62135133|NCT05078255|EXPERIMENTAL|Semaglutide 1.34 mg/ml injections + GIP infusion|
62135134|NCT05078255|EXPERIMENTAL|placebo injections + GIP infusion|
62329881|NCT05112458|EXPERIMENTAL|Cope 360 application|Participants are given access to the application and will use it to care for their child with cancer for a period of 6 months.
62329882|NCT05112458|ACTIVE_COMPARATOR|Usual Care|Participants are given usual care and not given access to the application. They will be surveyed along with the experimental group for a period of 6 months.
62329883|NCT03121183||Patients who have undergone an extraction of implantable pace|
62329884|NCT02869750||Obese PCOS|PCOS patients with BMI more than 25 kg/m2
62329885|NCT02869750||Lean PCOS|PCOS patients with BMI less than 25 kg/m2
62329886|NCT02869750||PCOS with normal HOMA2-1R|PCOS without Insuline resistance
62329887|NCT02869750||PCOS with elevated HOMA2-IR|PCOS with Insuline resistance
62329888|NCT02639793|ACTIVE_COMPARATOR|manual radiofrequency ablation|Radiofrequency catheter ablation using manual catheter manipulation will be used as an ablation technique.
62329889|NCT02639793|ACTIVE_COMPARATOR|magnet navigation ablation|Radiofrequency catheter ablation using remote magnet navigation will be used as an ablation technique.
62487734|NCT01769898|PLACEBO_COMPARATOR|Placebo+formoterol-budesonide|"Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.~Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
61935713|NCT03511118||Paroxetine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935714|NCT03511118||Duloxetine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
61935715|NCT03432312|EXPERIMENTAL|Nicotine 4 mg mint lozenges|
61935716|NCT03432312|ACTIVE_COMPARATOR|NiQuitin 4 mg mint lozenges|
61935717|NCT00674076||sleep apnea|a patient has been diagnosed as having obstructive sleep apnea
62135135|NCT05078255|EXPERIMENTAL|Semaglutide 1.34 mg/ml injections + placebo infusion|
62329890|NCT02639793|ACTIVE_COMPARATOR|cryoablation|Catheter ablation using cryoablation technique will be used as an ablation technique of atrial fibrillation.
62329891|NCT05121727|ACTIVE_COMPARATOR|Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
62329892|NCT05121727|ACTIVE_COMPARATOR|Deep and Superficial Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 10 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anteror area to superficial serratus anteror area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 10 ml of 0.25% bupivacaine will be injected for superficial serratus anetrior block into the interfacial area.
62329893|NCT06457984|EXPERIMENTAL|Low dose selenium supplementation group+lifestyle intervention|Low dose selenium supplementation:50μg/d +lifestyle intervention
62487735|NCT01769898|EXPERIMENTAL|Theophylline+formoterol-budesonide|"Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.~Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
61935718|NCT00674076||control|a case who has a negative polysomography or noraml score of Pittsburg sleep questionaire
61935719|NCT02614651|EXPERIMENTAL|The study population|"The study population consists of subjects with a concentric constriction of the visual field (retinitis pigmentosa, glaucoma) whose motor capacity allows the use of a computer keyboard with one hand. Subjects are recruited on a voluntary basis, from information disseminated to professionals in the rehabilitation of functional low vision and patient associations, in the Ophthalmology Service of the University Hospital of Nimes and within the ARAMAV Institute.~Intervention: Find visual comfort threshold related to light intensity~Intervention: Find the size of the visual field~Intervention: Effectiveness of brightness control~Intervention: Performance of color correction~Intervention: Vuzix Wrap 1200DX virtural reality glasses"
62135136|NCT04467671|EXPERIMENTAL|Tissue Engineered Vascular Grafts|
62135137|NCT03095872|EXPERIMENTAL|Bepanthen/Vaseline|One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
62329894|NCT06457984|EXPERIMENTAL|High dose selenium supplementation group+lifestyle intervention|High dose selenium supplementation :300μg/d+lifestyle intervention
62329895|NCT06457984|PLACEBO_COMPARATOR|Placebo control group+lifestyle intervention|Placebo control group: sugar free chunk gum 1piles/d+lifestyle intervention
62329896|NCT03451864||Deficient Vit D|Mothers with serum 25(OH) D levels less than 20 ng/dl
62135138|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
62135139|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
62135140|NCT04531800|EXPERIMENTAL|Study Group|The necrotic bone was removed with rotating burs, curettage was performed, and the surface of the bone was smoothened. CGF was then applied to the surgical area in the study group (n=14), and the area was primarily closed after additional releasing incisions were made to the periosteum to assure tension-free soft tissue closure.
62329897|NCT03451864||Normal vit D|Mothers with serum 25(OH) D levels more than 20 ng/dl
62329898|NCT05796453|EXPERIMENTAL|Clareon Vivity IOL - Non Toric|Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon Vivity IOL.
62329899|NCT05796453|EXPERIMENTAL|Clareon Vivity IOL - Toric|Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon Vivity IOL.
62487736|NCT06272617|EXPERIMENTAL|treatment group|verum acupuncture
62329900|NCT05796453|EXPERIMENTAL|Clareon PanOptix IOL - Non Toric|Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon PanOptix IOL.
62329901|NCT05796453|EXPERIMENTAL|Clareon PanOptix IOL - Toric|Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon PanOptix IOL.
62329902|NCT05217680|EXPERIMENTAL|PRO-169|Bevacizumab 1.25 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
62329903|NCT05217680|ACTIVE_COMPARATOR|Lucentis ®|Ranibizumab 0.5 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
62329904|NCT04641364|PLACEBO_COMPARATOR|Control: placebo|Subjects received 0.9% sodium chloride injection.
62329905|NCT04641364|ACTIVE_COMPARATOR|Control: Human Serum Albumin(HSA)|Subjects received Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
62329906|NCT04641364|EXPERIMENTAL|Experimental:recombinant human albumin|Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study. For the multiple dose study, subjects received recombinant Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
62329907|NCT04980846|EXPERIMENTAL|Intervention group|Intervention: Other: Driving under the influence of alcohol with a driving simulator
62329908|NCT02671890|EXPERIMENTAL|Cohort I (gemcitabine hydrochloride and disulfiram)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO on days 1-28 or days 1-35.
62329909|NCT02671890|EXPERIMENTAL|Cohort II (chemotherapy and disulfiram)|Patients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.
62329910|NCT05789264|ACTIVE_COMPARATOR|Standard of Care|Participants assigned to the standard of care arm will be guided through clearing out clots in the nose (if using oxymetazoline), correct head positioning and how to appropriately hold nasal pressure and +/- oxymetazoline applied by a trained medical provider. No packing material will be inserted into the nares and only external pressure will be applied.
62329911|NCT05789264|EXPERIMENTAL|Nasal Compression Device|Participants assigned to the nasal compression device arm will be provided with the device package which will include the compression device, nasal sponges, and +/- oxymetazoline nasal spray to apply to the sponges as well as written/graphical assembly and application instructions. Participants will then assemble and apply the device themselves under the supervision of a trained medical provider.
62329912|NCT06693414|EXPERIMENTAL|Intervention group: Health promotion education|A 14-week health promotion program will be implemented for the intervention group. The training will use lecture, question-and-answer, individual work, and group work techniques. Additionally, activities targeting health-promoting behaviors will be conducted.
62329913|NCT06693414|ACTIVE_COMPARATOR|Control group: routine nursing education group|Participants in the control group will not receive additional health promotion training apart from vocational training.
62329914|NCT06512441|EXPERIMENTAL|Experimental：VitaminB6 group|Based on the standard treatment，VitaminB6 （10mg/tablet）is given orally once a day,one tablet each time,for 3 weeks.
62329915|NCT06512441|PLACEBO_COMPARATOR|Placebo Comparator:Control group|Based on the standard treatment，the same type of placebo tablets are given orally once a day,one tablet each time,for 3 weeks.
62329916|NCT02731508|EXPERIMENTAL|True stimulation|True repetitive bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, daily 20 minutes for 20 sessions
62329917|NCT02731508|SHAM_COMPARATOR|Sham stimulation|Repetitive bihemispheric transcranial direct current stimulation, as the experimental stimulation condition but only for 120 seconds
62329918|NCT00174707|ACTIVE_COMPARATOR|A|Sequential Epidoxorubicin followed by CMF: ciclophosphamide/Methotrexate/fluorouracile (±TAM: tamoxifen)
62329919|NCT00174707|EXPERIMENTAL|B|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
62693711|NCT03894462|EXPERIMENTAL|Zero Suicide Usual Care + ASSIP|"Patients in this treatment arm will receive ASSIP brief therapy in addition to being able to access any usual care as recommended by their provider.~ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan."
61935720|NCT04332380|EXPERIMENTAL|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol.
62329920|NCT00174707|EXPERIMENTAL|C|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
62329921|NCT00363805|EXPERIMENTAL|Green Tea|Patients receive green tea beverage and placebo capsules for 6 months.
62329922|NCT00363805|EXPERIMENTAL|Polyphenon E|Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.
62329923|NCT00363805|PLACEBO_COMPARATOR|Placebo|Patients receive placebo beverage and placebo capsules daily for 6 months.
62487737|NCT06272617|SHAM_COMPARATOR|control group|sham acupuncture
62693712|NCT06493084|ACTIVE_COMPARATOR|treatment arm|LAE102 injection
62693713|NCT06493084|PLACEBO_COMPARATOR|comparator arm|saline
61935721|NCT02939079|EXPERIMENTAL|Fingolimod and Fish Oil|Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year.
61935722|NCT02939079|ACTIVE_COMPARATOR|Fingolimod and Placebo|Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year.
61935723|NCT02639156|EXPERIMENTAL|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day will be changed onto an equivalent prescription of AYMES LONDON for a period of 9 days.
62487738|NCT04306601|EXPERIMENTAL|Low-Intensity focused ultrasound brain stimulation|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
62487739|NCT01851772|EXPERIMENTAL|Treatment|"Subjects enrolled will undergo brachytherapy treatment in combination with EBRT. The maximum length of treatment will be 56 days. The treating physician will determine the appropriate course of treatment based on the physician's current practice or experience using Iridium-192 or Cesium HDR after-loaders to administer cervical brachytherapy treatments.~Subjects enrolled will be treated with approximately 80-90 Gy total treatment dose over 4-6 fractions. Examples of commonly used dose regimens in the US are listed in section 7.6.7. This study will include data collection from the initiation of EBRT through administration of the final Xoft Axxent treatment fraction, and at one (1) month and three (3) months."
62487740|NCT02768701|EXPERIMENTAL|Experimental: Single Arm|Subjects will receive a single dose (300 mg/m2) of cyclophosphamide given the day before cycle 1 of pembrolizumab (200 mg), which will be administered every 3 weeks.
62487741|NCT06012006|EXPERIMENTAL|pulmonary rehabilitation|COPD patients will be admitted for pulmonary rehabilitation, the duration and modalities of which vary from center to center.
62487742|NCT04388722|NO_INTERVENTION|Control Arm|
62487743|NCT04388722|EXPERIMENTAL|Investigational Arm|
62487744|NCT04242823|OTHER|Baseline screening cohort|This group undergoes HPV testing using self-collected swabs. Triage evaluation occurs in all women who test HPV positive which includes visual inspection with acetic acid, colposcopy and image capture for automated visual evaluation. The WLHIV in the cohort who test HPV positive at baseline but who have concurrent benign histopathology results will be invited back for re-screening at a 2-year interval, and undergo similar HPV testing and triage procedures. The WLHIV in the cohort who test HPV negative at baseline will be invited back for re-screening at a 3-year interval and undergo similar HPV testing and triage procedures.
62487745|NCT04955158|EXPERIMENTAL|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack
62487746|NCT04955158|EXPERIMENTAL|Ketamine|50 mg ketamine soaked pharyngeal pack
62487747|NCT04955158|EXPERIMENTAL|Saline placebo|20 ml 0.9% saline soaked pharyngeal pack
62487748|NCT00857038|EXPERIMENTAL|1|Doxycycline 100mg daily
62487749|NCT00857038|PLACEBO_COMPARATOR|2|Placebo
62487750|NCT00966160|ACTIVE_COMPARATOR|PI|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
62487751|NCT00966160|ACTIVE_COMPARATOR|NNRTI|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
62487752|NCT02539628|EXPERIMENTAL|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
62487753|NCT02539628|ACTIVE_COMPARATOR|Continuous infusion|ropivacaine 0.2%, 7ml/h
62487754|NCT04157335|EXPERIMENTAL|Benralizumab|Benralizumab administered subcutaneously
62487755|NCT04157335|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62487756|NCT00608322|EXPERIMENTAL|1|Subjects receive inhaled nitric oxide (40 parts per million) for six hours.
61935724|NCT05646940||PI-OMM|25 PI fed with OMM and their mothers
61935725|NCT05646940||PI-DHM|25 PI fed with DHM and their mothers
62487757|NCT00608322|SHAM_COMPARATOR|2|Subjects receive sham inhaled nitric oxide for six hours.
62487758|NCT01047150||Tetrofosmin Rest patients|Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin
62487759|NCT01047150||Sestamibi stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi
62487760|NCT01047150||Tetrofosmin stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin
62487761|NCT01047150||Sestamibi rest patients|Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi
62487762|NCT06542237|EXPERIMENTAL|YCT-529|Open label, ascending dose, 2 part study (Part 1b and Part 2a)
62487763|NCT06425562|EXPERIMENTAL|Adult asthma patients|Lung function tests (full lung function, multiple breath nitrogen washout, impulse oscillometry) and questionaires (asthma control test, asthma control questionnaire, asthma quality of life questionnaire) will be conducted, once at baseline and once 3 - 6 months later during follow-up.
62487764|NCT05221554|EXPERIMENTAL|Prospective Computer-Navigated Cohort|Patients in this arm will receive standard patient of care implants but navigation software will be used to plan optimal acetabular cup placement.
61935726|NCT05646940||TI-OMM|25 TI fed with OMM and their mothers as control group
62135141|NCT04531800|EXPERIMENTAL|Control Group|The surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy, in the control group (n=14).
62487765|NCT05221554|ACTIVE_COMPARATOR|Cross-sectional Standard of Care Cohort|Patients in this arm will receive standard of care implants and undergo standard of care procedure for total hip arthroplasty.
62487766|NCT01719770|ACTIVE_COMPARATOR|Rocuronium|Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
62487767|NCT01719770|PLACEBO_COMPARATOR|Placebo|Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
62487768|NCT06627556|EXPERIMENTAL|SAD Cohort 1: H021 6.25 milligrams (mg)|Participants will receive H021, 6.25 mg oral tablet, as single-dose on Day 1 under fasting or fed conditions.
62487769|NCT06627556|EXPERIMENTAL|SAD Cohort 2: H021 12.5 mg|Participants will receive H021, 12.5 mg oral tablet, as single-dose on Day 1 under fasting conditions.
62487770|NCT06627556|EXPERIMENTAL|SAD Cohort 3: H021 25 mg|Participants will receive H021, 25 mg oral tablet, as single-dose on Day 1 under fasting conditions.
62487771|NCT06627556|EXPERIMENTAL|SAD Cohort 4: H021 50 mg|Participants will receive H021, 50 mg oral tablet, as single-dose on Day 1 under fasting conditions.
62487772|NCT06627556|EXPERIMENTAL|SAD Cohort 5: H021 100 mg|Participants will receive H021, 100 mg oral tablet, as single-dose on Day 1 under fasting conditions.
62135142|NCT01695954|EXPERIMENTAL|Arm A|Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.
62135143|NCT01695954|EXPERIMENTAL|Arm B|Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.
62487773|NCT06627556|EXPERIMENTAL|MAD Cohort 6: H021 12.5 mg|Participants will receive H021, 12.5 mg oral tablet once daily from Day 1 to Day 7 under fasting conditions.
62487774|NCT06627556|EXPERIMENTAL|MAD Cohort 7: H021 25 mg|Participants will receive H021, 25 mg oral tablet once daily from Day 1 to Day 7 under fasting conditions.
62693714|NCT01145183|EXPERIMENTAL|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
62135144|NCT06210659|ACTIVE_COMPARATOR|Intervention group|Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles.
62135145|NCT06210659|NO_INTERVENTION|Control group|Students will be required to record their daily step count using a pedometer. Students will be monitored for 3 menstrual cycles. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated.
62135146|NCT01421667|EXPERIMENTAL|Brentuximab vedotin+rituximab|
62693715|NCT01145183|PLACEBO_COMPARATOR|Placebo|Matched placebo daily dosing.
62693716|NCT03469960|ACTIVE_COMPARATOR|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
62693717|NCT03469960|EXPERIMENTAL|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
62135147|NCT01421667|EXPERIMENTAL|Brentuximab vedotin|
62135148|NCT01894074|PLACEBO_COMPARATOR|Placebo|Lifestyle counseling:standard dietary education and counseling with a goal of reducing calories to 1500-1800 kcal/day
62135149|NCT01894074|ACTIVE_COMPARATOR|Intensive Dietary Intervention|Intensive Dietary Intervention employing very low energy diet (800 kcal/day) x 12 weeks followed by transition to regular foodstuffs over 4-6 weeks.
62329924|NCT03963245|EXPERIMENTAL|Intervention group|MA\&R - an eight months rehabilitation intervention in addition to standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
62329925|NCT03963245|ACTIVE_COMPARATOR|Control group|Standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
62329926|NCT01448291|EXPERIMENTAL|Nuvaring|This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.
62329927|NCT02868216|EXPERIMENTAL|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
62329928|NCT02868216|NO_INTERVENTION|Without management training|No anger management training
62329929|NCT01227538||Stimulated urinary C peptide|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
62329930|NCT02686697|EXPERIMENTAL|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
62329931|NCT02686697|PLACEBO_COMPARATOR|Placebo|matching placebo
62329932|NCT05803837||intervention group|one group
62329933|NCT01121159||Preoperatively preformed orbital plates|Reconstruction with MatrixMIDFACE Preformed Orbital Plate (Synthes) or Custom-made orbital implant
62329934|NCT01121159||Non-preformed orbital plates|Reconstruction with Orbital Floor Mesh Plate or SynPOR Titanium Reinforced Fan Sheet (both Synthes)
62329935|NCT04355312|EXPERIMENTAL|Kysindo|Group of 45 patients with short-term desire for pregnancy who will undergo laparoscopic ovarian cystectomy with use of indocyanine green. Evaluation of the ovarian reserve preoperatively and longitudinal cohort follow-up after surgery at 6 months and 12 months. Analysis by a new imaging technique.
62329936|NCT05935904||MetS_risk|Pregnant women in their first trimester who have one or more of the following risk factors: abdominal obesity defined as waist circumference ≥ 2 standard deviations (SD) for gestational age in the first half of pregnancy or presentational BMI \>30 kg/m2; triglycerides concentration \>150 mg/dl; HDL cholesterol concentrations \<50 mg/dL; fasting glucose \> 105 mg/dL; and blood pressure \> 130/85 mm Hg.
62329937|NCT05935904||MetS_Free|Pregnant women in their first trimester who are free of any MetS component.
62329938|NCT03650348|EXPERIMENTAL|PRS-343 in Combination with Atezolizumab|
62487775|NCT06627556|EXPERIMENTAL|MAD Cohort 8: H021 50 mg|Participants will receive H021, 50 mg oral tablet once daily from Day 1 to Day 7 under fasting conditions.
62487776|NCT06627556|PLACEBO_COMPARATOR|SAD-H021 Placebo|Participants will receive H021, placebo oral tablet, as single-dose on Day 1 under fasting or fed conditions.
62487777|NCT06627556|PLACEBO_COMPARATOR|MAD-H021 Placebo|Participants will receive H021, placebo oral tablet once daily from Day 1 to Day 7 under fasting conditions.
62487778|NCT04789434|EXPERIMENTAL|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose：200mg frequency：1 time for 2 months duration：2 years
62487779|NCT04789434|NO_INTERVENTION|No intervention|No intervention
62487780|NCT03694197|EXPERIMENTAL|Open label|
62693718|NCT02719509||Observational Cohort|All emergency department patients who had a cardiac ultrasound performed as part of their diagnostic workup
62693719|NCT04785820|EXPERIMENTAL|Lomvastomig|
62693720|NCT04785820|EXPERIMENTAL|Tobemstomig|
62693721|NCT04785820|ACTIVE_COMPARATOR|Nivolumab|
62693722|NCT03290677|EXPERIMENTAL|CT-guided Percutaneous Cryoablation of Lung Tumor|"* Image-guided core needle biopsy to confirm cancer will be perform~* Patients will undergo cryoablation as a standard procedure~* cryoablation will be performed with a three-cycle freeze-thaw phase protocol~* Non-contrast CT images will be obtained in 3 to 5 minutes intervals to visualize the evolving ablation zone"
62693723|NCT06191445|ACTIVE_COMPARATOR|Conventional Landmark Group|The investigator will perform spinal anesthesia using the conventional landmark technique.
62487781|NCT03999645|ACTIVE_COMPARATOR|Group E: Early LC (n=60)|Early laparoscopic cholecystectomy (within 72h from symptom onset)
62487782|NCT03999645|ACTIVE_COMPARATOR|Group L: Late LC (n=60)|Late laparoscopic cholecystectomy (after 72h up to seven days from symptom onset)
62487783|NCT01170741|NO_INTERVENTION|Delayed Control Condition|Participants assigned to the delayed treatment control condition will be offered biological testing and the tailored cue-card intervention upon completion of their 3- month follow-up interview. Use of a delayed treatment control group design will permit us to separate intervention effects on HIV risk behaviors from the general effects of participating in the study and completing a detailed HIV risk assessment.
62487784|NCT06322264||Pediatric patients|Pediatric patients between the ages of 4 and 12 undergoing conventional X-ray examinations.
62487785|NCT06322264||Parents|Parents of the included pediatric patients between the ages of 4 and 12 undergoing conventional X-ray examinations.
62487786|NCT06322264||Radiographers|Radiographers who examine the included pediatric patients between the ages of 4 and 12 undergoing conventional X-ray examinations.
62693724|NCT06191445|ACTIVE_COMPARATOR|USAS Group|The investigator will perform spinal anesthesia using ultrasound-assisted technique.
62693725|NCT06191445|ACTIVE_COMPARATOR|US-RTG Group|The investigator will perform spinal anesthesia using real-time ultrasound-guided technique.
62135150|NCT04549831||SARS-CoV-2 PCR positive individuals|Adult (\> o equal to 18 years) SARS-CoV-2 PCR positive individuals with different clinical outcome: from asymptomatic to severely affected COVID-19 patients.
62329939|NCT02255812|PLACEBO_COMPARATOR|200 mL tap water|Single intragastric instillation of 200 mL tap water via nasogastric tube
62329940|NCT02255812|ACTIVE_COMPARATOR|2 g citric acid|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
62329941|NCT02255812|ACTIVE_COMPARATOR|2 g salt|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
62329942|NCT02255812|ACTIVE_COMPARATOR|0.017 g quinine|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
62329943|NCT02255812|ACTIVE_COMPARATOR|1 g monosodium glutamate|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
62329944|NCT02255812|ACTIVE_COMPARATOR|25 g glucose|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
62329945|NCT02656992|EXPERIMENTAL|High-IMT group|Intervention group receive supervised training sessions three times per week for 8 weeks. Each sessions lasted 21 minutes and comprised seven cycles of 2 minutes of breathing on an inspiratory threshold device followed by 1 minute of rest. High-IMT was performed at the maximal load tolerable for each 2-minute work interval and was progressively increased over the training period.
62329946|NCT02656992|SHAM_COMPARATOR|Control group|Control group was prescribed at 10% of baseline maximal inspiratory pressure, and remained at this level during all training sessions for 8 weeks.
62329947|NCT05883592||Fabulous Thoracic Aortic Stent System|
62329948|NCT01109004|ACTIVE_COMPARATOR|Tandem auto transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
62329949|NCT01109004|ACTIVE_COMPARATOR|RVD consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
62329950|NCT01109004|ACTIVE_COMPARATOR|Lenalidomide maintenance|Initial autologous transplant followed by lenalidomide maintenance
62329951|NCT03472378|EXPERIMENTAL|Active Treatment Group|DFN-15
62329952|NCT03472378|PLACEBO_COMPARATOR|Placebo Group|
62487787|NCT03750448|ACTIVE_COMPARATOR|Telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
62487788|NCT03750448|ACTIVE_COMPARATOR|No intervention|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
62693726|NCT06636695|EXPERIMENTAL|PRP and HA|Cellular-Matrix
62693727|NCT06636695|ACTIVE_COMPARATOR|HA|Orthovisc
62693728|NCT01003327|OTHER|I-gel inserted first|The I-gel airway is insewrted first, then the LMA-Unique
62693729|NCT01003327|OTHER|LMA-Unique inserted first|LMA-Unique airway is inserted first, then the I-gel
62693730|NCT06635122||Experimental group: TIPS for PSVD|This group of PSVD patients received TIPS treatment.TIPS is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein.
62693731|NCT06635122||Control group: Endoscopic therapy for PSVD|This group of PSVD patients received endoscopic treatment.Endoscopic treatment includes endoscopic variceal ligation, endoscopic injection sclerotherapy and endoscopic variceal histoacryl injection therapy
62693732|NCT06635122||Control Group: TIPS for Cirrhosis Due to Hepatitis B|This group of Cirrhosis Due to Hepatitis B patients received TIPS treatment.
62693733|NCT04659343||Cohort 1|Patients treated for metastatic renal cell carcinoma in Denmark over a 6-year period.
62693734|NCT06642597|EXPERIMENTAL|Incremental PD|Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.
62693735|NCT06642597|ACTIVE_COMPARATOR|Full dose PD|Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
62693736|NCT05600751|EXPERIMENTAL|Radiosurgery of Ganglion Stellatum|Patients will undergo radiosurgery of the ganglion stellatum (left one or both)
62135151|NCT00946413|EXPERIMENTAL|CBT plus parent education|
62135152|NCT00946413|EXPERIMENTAL|CBT alone|
62487789|NCT03750448|ACTIVE_COMPARATOR|Unsupervised rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
62487790|NCT02734511|EXPERIMENTAL|Drug: sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
62329953|NCT05906641|EXPERIMENTAL|High-protein diet|Participants will receive an isocaloric diet with a distribution of 50% carbohydrates, 30% fat and 20% protein for the two-week intervention. Additionally, they will receive a dietary supplement for the second week that will contribute another 10% of protein, obtaining 30% of protein consumption in the second week.
62329954|NCT06085352|EXPERIMENTAL|Receive Investigational TetraLens BCL|At random, one eye will receive the contact lens that contains the tetracaine HCL
62487791|NCT06249113|PLACEBO_COMPARATOR|NaCl 0.9% continous intravenous on tumor craniotomy surgery|NaCl 0.9% continous intravenous on general anesthesia during tumor craniotomy surgery
62487792|NCT06249113|ACTIVE_COMPARATOR|Adjuvant lidocaine continous intravenous on tumor craniotomy surgery|Adjuvant lidocaine continous intravenous on general anesthesia during tumor craniotomy surgery
62487793|NCT04532879|EXPERIMENTAL|All patients enrolled|"Bowel habits before and after the HygiRelief procedure will be assessed.~Samples will be sent for microbiome evaluation."
62487794|NCT04382963|OTHER|High Risk- intense coaching|"age ≥ 55 with MORE than three of the following risk factors:~* History of TIA/Stroke~* History of Coronary Artery disease~* History of Hypertension and/or current elevated blood pressure~* History of Diabetes~* Current smoker~* BMI ≥30"
62487795|NCT04382963|OTHER|High Risk - standard care|"age ≥ 55 with MORE than three of the following risk factors:~* History of TIA/Stroke~* History of Coronary Artery disease~* History of Hypertension and/or current elevated blood pressure~* History of Diabetes~* Current smoker~* BMI ≥30"
62487796|NCT04382963|OTHER|Low risk - control|"age ≥ 55 with LESS than three of the following risk factors:~* History of TIA/Stroke~* History of Coronary Artery disease~* History of Hypertension and/or current elevated blood pressure~* History of Diabetes~* Current smoker~* BMI ≥30"
62487797|NCT04122950|EXPERIMENTAL|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
62487798|NCT04122950|NO_INTERVENTION|Control|Continue with normal daily routine.
61935727|NCT05650242|EXPERIMENTAL|BA1106|"Part A (Dose-Escalation): Mixed solid tumors participants will receive ascending doses of BA1106. BA1106 will be administered by intravenous (IV) infusion. The observation period of Dose Limiting toxicity (DLT) is 28 days, then the participants will receive BA1106 every three weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years.~Part B (Dose-Expansion): Participants of selected tumors will receive a fixed dose of BA1106 that selected according to the results of Part A once every 3 weeks (Q3W) or once every 2 weeks (Q2W), until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years."
61935728|NCT02269046|EXPERIMENTAL|Acupuncture and moxibustion|"* therapeutic lifestyle change~* Group I:Juque (RN14), Tianshu (ST25, bilateral), Fenglong (ST40, bilateral), Zusanli (ST 36, bilateral), Sanyinjiao (SP6, bilateral)~* Group II: Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)~* Group I and II will change alternatively every other week .~* Once per day five days per week."
61935729|NCT02269046|ACTIVE_COMPARATOR|Simvastatin|"* therapeutic lifestyle change~* simvastatin~* oral administration with 10mg per day~* seven days per week for 12 weeks."
61935730|NCT02269046|OTHER|waiting list|- therapeutic lifestyle change
62135153|NCT02282709|EXPERIMENTAL|Daclatasvir and asunaprevir|daclatasvir 60 mg once daily asunaprevir 100 mg BID
62135154|NCT01884805|OTHER|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|
62135155|NCT01650896|NO_INTERVENTION|General Medicine|
62487799|NCT01449188|ACTIVE_COMPARATOR|ondansetron, 8 mg IV over 15 minutes|the lower ondansetron IV dose will be used in one of the four treatment periods
62135156|NCT01650896|ACTIVE_COMPARATOR|Geriatric Medicine|Daily medical review, adjust medications, treat infection, occupational therapy
62135157|NCT01250769|ACTIVE_COMPARATOR|Manual Toothbrush 1|Manual Toothbrush used for 1 minute twice a day
62135158|NCT01250769|ACTIVE_COMPARATOR|Manual Toothbrush 2|Manual Toothbrush used for 2 minutes twice a day
62135159|NCT01250769|EXPERIMENTAL|Manual Toothbrush + Interproximal Cleaning 1|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used once a day
62329955|NCT06085352|SHAM_COMPARATOR|Receive standard bandage contact lens|At random, one eye will receive the standard of care bandage contact lens
62329956|NCT02779192|ACTIVE_COMPARATOR|SPI-1005 200 mg|200 mg SPI-1005, capsule, bid, po, x7d
62329957|NCT02779192|ACTIVE_COMPARATOR|SPI-1005 400 mg|400 mg SPI-1005, capsule, bid, po, x7d
62329958|NCT02779192|PLACEBO_COMPARATOR|Placebo|0 mg SPI-1005, capsule, bid, po, x7d
62329959|NCT05445622|EXPERIMENTAL|Experimental|Subjects were able to practice spinal manipulation using the Activ5 device (Activbody, San Diego, CA, USA) for real-time objective visual feedback during in class lecture and lab. Activ5 device has a built-in force sensor that can provide realtime objective visual feedback via a Bluetooth connected mobile device.
62487800|NCT01449188|ACTIVE_COMPARATOR|ondansetron, 32 mg IV over 15 minutes|the higher ondansetron IV dose will be used in one of the four treatment periods
62487801|NCT01449188|PLACEBO_COMPARATOR|placebo for ondansetron, IV over 15 minutes|placebo for ondansetron IV dose will be used in one of the four treatment periods
62487802|NCT01449188|ACTIVE_COMPARATOR|moxifloxacin, 400mg tablet (oral)|moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods
62135160|NCT01250769|EXPERIMENTAL|Manual Toothbrush + Interproximal Cleaning 2|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used twice a day
62329960|NCT05445622|ACTIVE_COMPARATOR|Control|Subjects were taught spinal mobilization using the traditional approach.
62329961|NCT06377800|EXPERIMENTAL|navicular mobilization along with conventional therapy.|"In the prone position, when the foot is stabilized by a towel underneath, navicular mobilization is administered. The therapist's fixing hand wraps the calcaneus, grasps the talus bone, and fixes it.~By placing the thumb on the plantar surface of the foot and pushing with the thumb of the other hand in a dorsal direction, navicular mobilization is provided.~This dorsal glide will be given with 2 sets of 5 minutes. Each session will be of 30 minutes."
62329962|NCT06377800|OTHER|conventional therapy|ultrasound therapy at 1.5 w/cm2 for 7 minutes in continuous mode at a 3MHz frequency. Stretching targets the medial arch and surrounding muscles like calf and tibialis posterior with exercises such as arch lift, heel raise, towel pickup, and toe lift. Additionally, strengthening exercises for intrinsic foot muscles like standing toe curls and towel toe curls are included. Ice pack application for 10 minutes follows
62329963|NCT03308084|ACTIVE_COMPARATOR|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
62329964|NCT03308084|PLACEBO_COMPARATOR|IV dexamethasone|Standard systemic (IV) dexamethasone only
62329965|NCT03392155|EXPERIMENTAL|Training & Nutrition|Participants receive performance training twice a week for 12 weeks and group and individual nutritional counseling during the 12 weeks.
62329966|NCT01146067|EXPERIMENTAL|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
62329967|NCT01146067|ACTIVE_COMPARATOR|Exelon|Exelon 1.5 mg capsules of Novartis
62329968|NCT04669678|EXPERIMENTAL|Group 1 DOR + ETG|100mg DOR-containing ART \[oral tablet taken daily\] + 68mg ETG implant (follow up for 30 weeks)
62329969|NCT04669678|EXPERIMENTAL|Group 2 DOR + IM DMPA|100mg DOR-containing ART \[oral tablet taken daily\] + 150mg IM DMPA (follow up for 18 weeks)
62329970|NCT04669678|EXPERIMENTAL|Group 3 DOR + SC MPA|100mg DOR-containing ART \[oral tablet taken daily\] + 104mg SC MPA (follow up for 18 weeks)
62329971|NCT04669678|EXPERIMENTAL|Group 4 DOR + IUD|100mg DOR-containing ART \[oral tablet taken daily\] + 1 non-hormonal IUD device (follow up for 30 weeks)
62329972|NCT04669678|ACTIVE_COMPARATOR|Group 5 DTG + DMPA|50mg DTG-containing ART \[oral tablet taken daily\] + 150mg IM DMPA DMPA administered at enrolment (follow up for 18 weeks)
62487803|NCT03812913||Turner Syndrome|"* 35 girls with Turner syndrome (except patients with part of a Y chromosome in their karyotype and r(X) cases).~* age : 7 years -16 years and 11 months.~* Psychological evaluation of cognition, social cognition and affective cognition"
62487804|NCT03812913||isolated GHD|"* 35 girls with isolated Growth Hormone Deficiency (GHD).~* age : 7 years -16 years and 11 months.~* Psychological evaluation of cognition, social cognition and affective cognition"
62135161|NCT04008316|EXPERIMENTAL|colchicine 1mg/day|Colchicine per os: 1 tablet (1mg) / day during 6 months
62135162|NCT04008316|PLACEBO_COMPARATOR|placebo|placebo 1 tablet / day during 6 months
62135163|NCT01070940|PLACEBO_COMPARATOR|Isotonic saline infusion|
62329973|NCT05238948|EXPERIMENTAL|Midazolam with/without CKD-506|Single arm and 1-sequence crossover
62329974|NCT03840668|EXPERIMENTAL|Dry eye|Participants who will be using the USB-powered eye mask.
62329975|NCT02661607|OTHER|Point of care echocardiography after central venous catheter|Point of care echocardiography plus chest radiography
62329976|NCT01589068|ACTIVE_COMPARATOR|Male Smokers|
62329977|NCT01589068|ACTIVE_COMPARATOR|Female Smokers (Follicular Phase)|
62329978|NCT01589068|ACTIVE_COMPARATOR|Female Smokers (Luteal Phase)|
62329979|NCT02388516|PLACEBO_COMPARATOR|Group A|Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.
62329980|NCT02388516|EXPERIMENTAL|Group B|Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
62329981|NCT02388516|EXPERIMENTAL|Group C|Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
62329982|NCT02388516|EXPERIMENTAL|Group D|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
62329983|NCT02388516|EXPERIMENTAL|Group E|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
62329984|NCT00375882|OTHER|cochlear implantation with mild hypothermia|
62329985|NCT04719338|EXPERIMENTAL|participants|"Immediately after confirmation of 24 weeks SVR after the end of treatment, we will collect samples of peripheral blood from each patient into EDTA tube and test for HCV RNA in peripheral blood mononuclear cells (PBMCs) .~All patients included in this study will be subjected to full history taking and thorough clinical examination. The initial pre treatment data of the patients will be revised including body mass index (BMI), pre treatment status (naïve,experienced), pretreatment viral load by sensitive real-time HCV PCR technique, liver function tests, complete blood count, prothrombin time, international normalized ratio , Child-Pugh score, MELD score and FIB-4 score ."
62487805|NCT03304223|EXPERIMENTAL|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
62487806|NCT03098485|EXPERIMENTAL|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
62135164|NCT01070940|ACTIVE_COMPARATOR|Intravenous L-NMMA dose 2|
62329986|NCT04857073|ACTIVE_COMPARATOR|Control group - glucose check every day|Patients will be instructed to check their glucose 4 times a day, every day. This is currently the standard of care.
62135165|NCT01070940|ACTIVE_COMPARATOR|Intravenous L-NMMA dose 3|
62135166|NCT01070940|ACTIVE_COMPARATOR|Intravenous L-NMMA dose 1|
62135167|NCT06597058|EXPERIMENTAL|MAR COMBO|MAR Active 0.6 g, Tablet, once-daily, 180 days
62135168|NCT06597058|PLACEBO_COMPARATOR|MAR PLACEBO|MAR Placebo 0.6 g, Tablet, once-daily, 180 days
62135169|NCT06151314|ACTIVE_COMPARATOR|"digital milled implant supported removable partial overdenture"|patients received digital milled implant supported removable partial overdenture.
62135170|NCT06151314|ACTIVE_COMPARATOR|"implant supported fixed bridge"|patients received an implant supported fixed bridge
62135171|NCT05138133|EXPERIMENTAL|Anifrolumab|Solution for intravenous infusion
62135172|NCT05138133|PLACEBO_COMPARATOR|Placebo|Solution for intravenous infusion
62329987|NCT04857073|EXPERIMENTAL|Experimental group - glucose check every other day|Patients will be instructed to check their glucose every other day, 4 times glucose monitoring
62135173|NCT04518813|EXPERIMENTAL|RSP-24|Subjects will perform calibrations on the IMD (Prototype 0.5) for 41 days over a 60 day period.
62135174|NCT02555475|NO_INTERVENTION|Group 1, tertiary hospital based care|Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for hepatitis C care, transient elastography and DAA treatment (traditional / standard model of care).
62135175|NCT02555475|EXPERIMENTAL|Group 2, community based care|Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
62135176|NCT02920710|EXPERIMENTAL|Experimental: H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
62135177|NCT01700296|NO_INTERVENTION|Standard Care|"Standard Care: finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP. In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic. The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the Best care group"
62135178|NCT01700296|EXPERIMENTAL|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
62135179|NCT05512962|EXPERIMENTAL|Suprachoroidal Triamcinolone acetonide 2.4mg|The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 2.4mg/60µl Triesence® will be applied.
62135180|NCT05512962|EXPERIMENTAL|Suprachoroidal Triamcinolone acetonide 4.0mg|The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 4.0mg/100µl Triesence® will be applied.
62135181|NCT03102034|EXPERIMENTAL|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants received a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
62135182|NCT03102034|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo at study entry (Day 0).
62135183|NCT00056966|EXPERIMENTAL|1|recipients of HLA matched sibling transplants
62135184|NCT00056966|EXPERIMENTAL|2|recipients of unrelated or mismatched family donor transplants
62135185|NCT05374525|EXPERIMENTAL|Routine Implementation (RI)|PSPs will receive APRETUDE injection and optional Cabotegravir tablets as oral lead in (OLI) . PSPs and SSPs will have access to standard toolkits for APRETUDE to use as needed.
62135186|NCT05374525|EXPERIMENTAL|Dynamic Implementation (DI)|PSPs will receive APRETUDE injection and optional Cabotegravir tablets as oral lead in (OLI). PSPs and SSPs will have access to enhanced toolkits, a digital health implementation strategy and implementation facilitation for APRETUDE to use.
62135187|NCT04251442|EXPERIMENTAL|Study Group|The study group will have soft tissue balance performed with the use of IOS.
62135188|NCT04251442|NO_INTERVENTION|Control Group|Control group patients will have soft tissue balance performed manually, with final soft tissue balance values measured using IOS, while the surgeon will remain blinded to those values.
62135189|NCT00468052|ACTIVE_COMPARATOR|fentanyl|fentanyl bolus 1ug.kg-1
62135190|NCT00468052|EXPERIMENTAL|dexmedetomidine|dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1
62135191|NCT04840433|EXPERIMENTAL|MACE|Patients will receive MACE for IDA.
62135192|NCT05750966|EXPERIMENTAL|Very short-course antibiotics|The antibiotic regimens will be according to the local hospital's antibiotic guideline for cholangitis (e.g. dosage form, dosage, frequency)and/or the national SWAB guideline in the Netherlands. In the experimental group, duration of ABT after adequate drainage will be 1 day. The duration will be 4 days and can be extended to 7 days in case of gram-negative bacteraemia, according to the national SWAB guideline regarding gram-negative sepsis.
62135193|NCT05750966|ACTIVE_COMPARATOR|Standard course antibiotics|"The antibiotic regimens will be according to the local hospital's antibiotic guideline for cholangitis, which are based on the previously mentioned national SWAB guideline. This means that the type of ABT, dosage and frequency will be comparable to the experimental group.~In the comparator group treatment duration with ABT after ERCP will be according to the international well known and widely used TG18. The duration will be 4 days and can be extended to 7 days in case of gram-negative bacteraemia, according to the national SWAB guideline regarding gram-negative sepsis."
62135194|NCT03484416|ACTIVE_COMPARATOR|Routine calcium|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium (by calcium carbonate) and 1,000 IU/day cholecalciferol for 2 weeks, beginning on the first postoperative day
62135195|NCT03484416|NO_INTERVENTION|control|Patients in the control group did not receive calcium or cholecalciferol for 2 weeks
62135196|NCT01662154|EXPERIMENTAL|Nerve stimulator|Patients in this group will have their nerve blocks assessed with a common nerve stimulator (Stimuplex HNS 12, B.Braun, Germany).
62135197|NCT01662154|ACTIVE_COMPARATOR|Neurometer|Patients in this group will have their nerve block assessed using the Neurometer.
62329988|NCT02053389|EXPERIMENTAL|DVD Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) AND the DVD decision aid (Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer), which provides instruction and recommendations on how to participate in shared decision making with one's physician."
62329989|NCT02053389|ACTIVE_COMPARATOR|Written Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) alone."
62487807|NCT03098485|EXPERIMENTAL|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
62135198|NCT02941484|EXPERIMENTAL|1 early oral intake|early oral intake since postoperative day 1.
62487808|NCT03098485|EXPERIMENTAL|Cefpodoxime|200mg tab by mouth twice per day for 5 days
62487809|NCT03098485|EXPERIMENTAL|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
61935731|NCT06705218|EXPERIMENTAL|MINDSET|2.5-hour mHealth intervention consisting of three modules containing brief films and corresponding interactive reflection activities aimed to improves whole patient health (physical, social, emotional, and functional quality of life as measured by the FACT-G) in patients undergoing systemic treatment for cancer with curative intent. Films feature interviews with people living with cancer describing their experience with diagnosis, treatment, and recovery, and the importance of their mindsets during their experience. The films also feature Stanford faculty with expertise in oncology, psychiatry, and psychology who offer a scientific framework for the importance of mindsets during cancer treatment and provide examples from their clinical practices. The reflection exercises that follow the films are designed to help patients craft a personalized strategy (a) for changing maladaptive mindsets and maintaining adaptive ones and (b) for translating ideas from the film into actionable behavio
61935732|NCT06705218|ACTIVE_COMPARATOR|Digital Information Series for Cancer|This behavioral intervention provides educational information on coping strategies for individuals undergoing cancer treatment through a hybrid of videos and corresponding questions.
61935733|NCT00121264|EXPERIMENTAL|Treatment (sorafenib tosylate, tanespimycin)|Patients receive oral sorafenib twice daily on days -14 to 28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive 17-AAG IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61935734|NCT02476422|EXPERIMENTAL|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
61935735|NCT02476422|ACTIVE_COMPARATOR|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
62329990|NCT05610462|ACTIVE_COMPARATOR|Usual Care Control|Participants who are randomized to usual care will attend routine clinic visits but will not receive any teaching or supervision and will not participate in any in-person or virtual exercise sessions. Instead, they will receive standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
62329991|NCT05610462|EXPERIMENTAL|Guided Exercise Training Program|Participants who are randomized to the guided exercise group will undergo initial training that consists of: one video demonstration, one exercise training session or group session, one follow up home visit, and virtual check-ins.
62329992|NCT05465733|EXPERIMENTAL|Envafolimab|
62329993|NCT00344149|EXPERIMENTAL|Rituximab|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
62329994|NCT00344149|PLACEBO_COMPARATOR|Placebo|I.V infusion of NaCl 0.9%
62329995|NCT03570281|EXPERIMENTAL|Edoxaban group|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
62329996|NCT03570281|ACTIVE_COMPARATOR|Enoxaparin group|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
61935736|NCT04578678||Apathy Group|Patients diagnosed with apathy
61935737|NCT04578678||Dysarthria Group|Patients diagnosed with dysarthria
61935738|NCT04578678||No Apathy and Dysarthria Group|Patients diagnosed with neither apathy nor dysarthria
61935739|NCT04578678||Apathy and Dysarthria Group|Patients diagnosed with apathy as well as dysarthria
61935740|NCT06588218|EXPERIMENTAL|Watermelon Condition|This group will maintain a normal diet supplemented with 2.5 cups (\~375 grams, 115 kcals, 0.5g fat, 1.5g fiber, 17,225mcg lycopene, 30.75mg vitamin C) of fresh watermelon daily for six weeks
61935741|NCT06588218|ACTIVE_COMPARATOR|Control Condition|This group will maintain a normal diet supplemented with an isocaloric control snack (Belvita breakfast sandwich; 115 kcals, 1.5g fiber, 4.5g fat, 0mg lycopene, 0mg vitamin C) as well as 12 ounces of water
61935742|NCT03491306|ACTIVE_COMPARATOR|Group 1|patients will receive partial denture constructed from breflex material
62329997|NCT00861484|EXPERIMENTAL|GSK958108 3 mg|Experimental
62487810|NCT03711448|ACTIVE_COMPARATOR|Control group|
62487811|NCT03711448|EXPERIMENTAL|Experimental group|
62487812|NCT05291234|EXPERIMENTAL|Stage A: ABBV-916|Participants will receive ABBV-916 for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
62329998|NCT00861484|PLACEBO_COMPARATOR|Placebo of GSK958108|Placebo
62329999|NCT06247059|EXPERIMENTAL|Box Fan|Classrooms receive box fans equipped with a filter.
62330000|NCT06247059|EXPERIMENTAL|UV Germicidal Irradiation Lamp Unit|Classrooms receive UV germicidal irradiation lamp unit(s).
62330001|NCT06247059|EXPERIMENTAL|Combined: Box Fan and UV Germicidal Irradiation Lamp Units|Classrooms receive box fans equipped with a filter and UV germicidal irradiation lamp unit(s).
62330002|NCT06247059|NO_INTERVENTION|Non-Interventional Control|Classrooms receive no intervention to their standard classroom setup.
62330003|NCT01379638||cardiac output|Adult patients undergoing cardiac surgery with normothermic cardiopulmonary bypass
62330004|NCT03174717|EXPERIMENTAL|Music intervention|LTC residents will participate in an individualized music performance with a musician
62330005|NCT02058927||HIV-1 infected children|HIV-1-infected children initiating ART
62330006|NCT02058927||HIV-1 uninfected children|control group of HIV-1 uninfected children matched by age
62330007|NCT02058927||HIV-1 infected children revaccinated|nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers
62487813|NCT05291234|PLACEBO_COMPARATOR|Stage A: Placebo for ABBV-916|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
62693737|NCT06644508|NO_INTERVENTION|Observation of current local practices|Current local practices regarding fluid management will be observed. Population: Critically ill children receiving mechanical ventilation due to respiratory insufficiency. Patients will be treated according to local protocols at the discretion of the attending physicians.
61935743|NCT03491306|EXPERIMENTAL|Group 2|patients will receive partial denture constructed from PEEK material
61935744|NCT06680947|EXPERIMENTAL|Group A|Subjects will receive 610 for 36 weeks.
61935745|NCT06680947|EXPERIMENTAL|Group B|Subjects will receive 610 for 36 weeks.
61935746|NCT06680947|PLACEBO_COMPARATOR|Placebo group|Subjects will receive placebo for 36 weeks.
61935747|NCT02241993||Type 1 diabetic|
61935748|NCT00090051|ACTIVE_COMPARATOR|Fludarabine+Cyclophosphamide (FC)|
62330008|NCT03235544|EXPERIMENTAL|Cohort 1: Treatment A (Exposed to Ibrutinib)|"Participants received parsaclisib 20 mg tablets, orally, once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to 52 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group."
62330009|NCT03235544|EXPERIMENTAL|Cohort 1: Treatment B (Exposed to Ibrutinib)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to 116 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group."
62330010|NCT03235544|EXPERIMENTAL|Cohort 2: Treatment A (Bruton's Tyrosine Kinase Inhibitor Naïve)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 20 mg QW for up to approximately 145 weeks.~Participants who had not received a BTK inhibitor previously were included in this group."
62330011|NCT03235544|EXPERIMENTAL|Cohort 2: Treatment B (Bruton's Tyrosine Kinase Inhibitor Naïve)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to approximately 136 weeks.~Participants who had not received a BTK inhibitor previously were included in this group."
62330012|NCT01380106|ACTIVE_COMPARATOR|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
62330013|NCT01380106|ACTIVE_COMPARATOR|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle
62330014|NCT04289129|EXPERIMENTAL|men|
62330015|NCT04289129|EXPERIMENTAL|women|
62330016|NCT01153763|OTHER|All patients|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
62330017|NCT00488618|EXPERIMENTAL|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
62330018|NCT00488618|PLACEBO_COMPARATOR|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
62330019|NCT05787834|ACTIVE_COMPARATOR|Group I (low resistance RMT Group)|Patients receive usual care for 12 weeks on study and a Respiratory Muscle training Device with small breathing resistance
62330020|NCT05787834|EXPERIMENTAL|Group II (Moderate to highter resistance RMT)|Patients undergo RMT using a respiratory muscle training device with moderate to higher breathing resistance for 12 weeks on study.
62330021|NCT02193269|PLACEBO_COMPARATOR|sugar pill|0.0mg
62330022|NCT02193269|ACTIVE_COMPARATOR|Minocycline|200mg
62330023|NCT02687594||single group|sucroferric oxyhydroxide
62330024|NCT03084575|ACTIVE_COMPARATOR|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
62330025|NCT03084575|ACTIVE_COMPARATOR|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
61935749|NCT00090051|EXPERIMENTAL|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
61935750|NCT02824965|EXPERIMENTAL|Pembrolizumab+1x10^9 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months. Should dose limiting toxicities be observed participants may be transferred a lower dosage of CVA21.
61935751|NCT03796832|EXPERIMENTAL|Flat Flexible Shoes+Exercise Therapy|This arm will wear Flat Flexible Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
62330026|NCT03794141|EXPERIMENTAL|Tervas|Follow up group from an earlier study. Information on risk gene status. All test persons were given information on healthy diet and life style.
62330027|NCT03794141|EXPERIMENTAL|Informed|Information on risk gene status was given before intervention. All test persons were given information on healthy diet and life style.
62330028|NCT03794141|ACTIVE_COMPARATOR|non informed|Information on risk gene status was not given before intervention. All test persons were given information on healthy diet and life style.
62330029|NCT00365716|EXPERIMENTAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
62330030|NCT00365716|EXPERIMENTAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
62487814|NCT05291234|EXPERIMENTAL|Stage B: ABBV-916 Dose A|Participants will receive ABBV-916 Dose A for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
62135199|NCT02941484|EXPERIMENTAL|2 jejunostomy tube feeding (JTF)|jejunostomy tube feeding (JTF) was carried out after PD
62330031|NCT00365716|EXPERIMENTAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
62330032|NCT00365716|EXPERIMENTAL|Placebo (mcg) (Aluminum Adjuvant) 225|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
62487815|NCT05291234|PLACEBO_COMPARATOR|Stage B: Placebo for ABBV-916|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
61935752|NCT03796832|ACTIVE_COMPARATOR|Stable Supportive Shoes+Exercise Therapy|This arm will wear Stable Supportive Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
62693738|NCT06644508|ACTIVE_COMPARATOR|Strict adherence to european guidelines|In this intervention attending physicians will be encouraged to strictly adhere the European (ESPNIC) guidelines regarding fluid management.
61935753|NCT04627337|EXPERIMENTAL|Saccharomyces boulardii (1 capsule of 250 ug BID) + Dietary advice|Patients received 1 capsule of Saccharomyces boulardii 250 ug BID plus dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
61935754|NCT04627337|ACTIVE_COMPARATOR|Dietary advice without medication|Patients received dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
61935755|NCT04680156||EN3835|Previously treated with EN3835 in EN3835-210 or the pivotal phase 3 studies
61935756|NCT04680156||Placebo|Previously treated Placebo in EN3835-210 or the pivotal phase 3 studies
61935757|NCT04349085|EXPERIMENTAL|Effective PBMT/sMF before WOD and Placebo PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
61935758|NCT04349085|EXPERIMENTAL|Placebo PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
62330033|NCT00365716|EXPERIMENTAL|Placebo (mcg) (Aluminum Adjuvant) 450|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
62330034|NCT02704728|EXPERIMENTAL|Thetanix|In Part A, 8 subjects will receive a single dose and in Part B, 8 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules
62330035|NCT02704728|PLACEBO_COMPARATOR|Placebo|In Part A, 2 subjects will receive a single dose and in Part B, 2 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules.
62330036|NCT04374305|EXPERIMENTAL|Sub-study A (brigatinib) - CLOSED TO ENROLLMENT|Subjects treated in this arm will receive brigatinib 90 mg by mouth daily for 7 days and then increased to 180 mg by mouth daily if the drug is tolerated.
62330037|NCT04374305|EXPERIMENTAL|Sub-study B (neratinib)|The first three participants treated in this arm will receive neratinib 200 mg mg by mouth daily. If these participants tolerate the medication well, subsequent participants will receive neratinib 240 mg by mouth daily.
62693739|NCT01904279|EXPERIMENTAL|TCZ SC 162 mg Q3W|Participants with body weight less than (\<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
62693740|NCT01904279|EXPERIMENTAL|TCZ SC 162 mg Q2W|Participants with body weight greater than or equal to (\>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
62330038|NCT03072719|EXPERIMENTAL|Dentifrice containing stannous fluoride|Toothpaste
62330039|NCT03072719|ACTIVE_COMPARATOR|Dentifrice containing Sodium Monofluorophosphate|Toothpaste
62330040|NCT02654704||Healthy Young Adults|Healthy young adults aged 18-25. Vaccination in all cohorts/groups.
62330041|NCT02654704||Asthma Young Adults|Young adults aged 18-25 with asthma. Vaccination in all cohorts/groups.
62487816|NCT05291234|EXPERIMENTAL|Stage B: ABBV-916 Dose B|Participants will receive ABBV-916 Dose B for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
62487817|NCT01616550||Patients undergoing thoracic surgery|Assessment of postoperative pain management in patients undergoing elective thoracoscopy or thoracotomy in a teaching hospital
62487818|NCT02802852|EXPERIMENTAL|Calf Compression, Filgrastim injection|All patients enrolled in the study will undergo pneumatic calf compression though use of the Art Assist device as well as stem cell mobilization through administration of Filgrastim 10 mcg/kg subcutaneously, every 3rd day for 30 days.
62693741|NCT02180542||Ischemic stroke patients|Patients admitted with ischemic stroke from march 2012 to april 2014
62693742|NCT06645301|EXPERIMENTAL|BGT007|Intravenous infusion
62697610|NCT02921256|ACTIVE_COMPARATOR|Arm I (mFOLFOX6, RT, capecitabine)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity. Participants assigned to Arm I concurrently with Arm II or with Arm III.
61935759|NCT04349085|EXPERIMENTAL|Effective PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
61935760|NCT04349085|PLACEBO_COMPARATOR|Placebo PBMT/sMF before WOD and Placebo PBMT/sMF after WOD.|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
61935761|NCT03110731|EXPERIMENTAL|Intervention group|Physical training (2x / week) was performed for 12 weeks
61935762|NCT03110731|NO_INTERVENTION|Control Group|no intervention
61935763|NCT04644536||Granules in long bone & extremities|Filling of post-traumatic or surgically created bone defects
61935764|NCT04644536||Wedges in long bone & extremities|Osteotomies with fixation
62330042|NCT02654704||Immunocompromised Young Adults|"Young adults aged 18-25 that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
62330043|NCT02654704||Healthy Older Adults|Healthy older adults aged 55+ Vaccination in all cohorts/groups.
62330044|NCT02654704||Asthma Older Adults|Older adults 55+ with asthma. Vaccination in all cohorts/groups.
62487819|NCT03966911|OTHER|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.
62693743|NCT06253767|EXPERIMENTAL|Treatment Group (TG)|They are composed of 29 participants. After endodontic treatment, they will receive PBM for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall
62330045|NCT02654704||Immunocompromised Older Adults|"Older adults aged 55+ that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
62330046|NCT03277170|EXPERIMENTAL|High-dose Montelukast Oral Granules|30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
62330047|NCT03277170|PLACEBO_COMPARATOR|Placebo|Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
62330048|NCT01734941|ACTIVE_COMPARATOR|TSO 2500|2500 TSO every other week
62330049|NCT01734941|ACTIVE_COMPARATOR|7500 TSO|7500 TSO every other week
62330050|NCT01734941|PLACEBO_COMPARATOR|Placebo|placebo every other week.
62330051|NCT05740449|EXPERIMENTAL|sub-study A - Epigenetic approach|"Decitabine / Venetoclax and Navitoclax.~Each cycle lasts 28 days.~Cycle 1: Decitabine is given 10 mg/m2 intravenous, once a day on 5 consecutive days (Day 1 - 5), venetoclax 400 mg adult equivalent dose, once a day, Day 1 - Day 28 orally, with a ramp-up dose on day 1 and navitoclax once a day, Day 3 - 28 orally depending on the weight of the patient (dose level 1).~Cycle 2: Decitabine is given 10 mg/m2 intravenous, once a day on 5 consecutive days (Day 1 - 5), venetoclax 400 mg adult equivalent dose, once a day, Day 1 - Day 28 orally and navitoclax once a day, Day 1 - 28 orally depending on the weight of the patient (dose level 1).~Patients in dose level 2: will receive decitabine 20 mg/m2 intravenous once a day on 5 consecutive days (Day 1 - 5).~Patients in dose level -1: will receive venetoclax 200 mg adult equivalent dose, once a day, Day 1 - Day 28 orally.~All patients receive age adapted intrathecal chemnotherapy."
62330052|NCT04183842|EXPERIMENTAL|LACIME Anti-hangover|Combination of plant extracts under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
62330053|NCT04183842|PLACEBO_COMPARATOR|Placebo|Carrot juice under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
62330054|NCT01803763|ACTIVE_COMPARATOR|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
62330055|NCT01803763|PLACEBO_COMPARATOR|Placebo|Fixed dose of Placebo is subcutaneously administered in total 4 monthly doses
62330056|NCT01881035|EXPERIMENTAL|Renal nerve denervation|Renal nerve denervation
62330057|NCT02434627|EXPERIMENTAL|Sodium Nitrate (Beetroot Juice)|Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.
62330058|NCT01395095|EXPERIMENTAL|OPTICARE-A|Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
62330059|NCT01395095|ACTIVE_COMPARATOR|OPTICARE-B|Standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions)
62330060|NCT01395095|EXPERIMENTAL|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
62330061|NCT02241395|EXPERIMENTAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
62330062|NCT01868178||BIS Spectral Entropy Group|intraoperative monitoring with BIS and Spectral Entropy
62330063|NCT05414708|EXPERIMENTAL|Art Therapy Arm|8 weeks of individual art therapy
62330064|NCT05556733|EXPERIMENTAL|Faecal Microbiota Transplantation|Subjects will receive Faecal Microbiota Transplantation
62330065|NCT05556733|NO_INTERVENTION|Control|The control subjects will not receive FMT
62330066|NCT06199440|ACTIVE_COMPARATOR|Group I|Chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
62330067|NCT06199440|EXPERIMENTAL|Group II|Received azithromycin dosage is 250 mg/day for 5 days, after an initial dose of 500 mg one hour before NSPT
62487820|NCT01923545|EXPERIMENTAL|DA-3031 3.6mg|PEG-G-CSF
62487821|NCT01923545|EXPERIMENTAL|DA-3031 6mg|PEG-G-CSF
62487822|NCT01923545|ACTIVE_COMPARATOR|Leucostim®|G-CSF
62487823|NCT00107263|EXPERIMENTAL|Arm I: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
62693744|NCT06253767|SHAM_COMPARATOR|Control Group (CG)|They are composed of 29 participants. After endodontic treatment, they will receive a simulation of the PBM session with all individual preparation involved, such as individual protection with goggles, and the sounds of the equipment (Laser Duo®, MMOptics, São Carlos, SP) will be recorded and played at the time of the session, but the equipment will not be activated.
62135200|NCT01721343|EXPERIMENTAL|Arm I (enhanced usual care)|Patients undergo enhanced usual care comprising telephonic monitoring with monthly status reports provided to their oncology care teams for 6 months.
62135201|NCT01721343|EXPERIMENTAL|Arm II (enhanced usual care, RCM)|Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered telephonically by the Fitness Care Manager (FCM) and adapted, as required, by a local physical therapist for 6 months.
62487824|NCT00107263|EXPERIMENTAL|Arm II: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
62135202|NCT01721343|EXPERIMENTAL|Arm III (enhanced usual, RCM, PCM)|Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the FCM as in Arm II, and receive optimized pain management through a nurse Pain Care Manager (PCM) for 6 months.
62330068|NCT06199440|EXPERIMENTAL|Group III|Consisted of 5 type 2 Diabetes Mellitus patients with periodontitis who were received doxycycline 20mg twice/day.
62487825|NCT06054633|ACTIVE_COMPARATOR|Oral L-arginine|Participants in the intervention arm will receive oral L- arginine tablets, 2 g three times daily
62487826|NCT06054633|PLACEBO_COMPARATOR|Placebo|The control group will receive an identical inert placebo tablet, three times daily
62487827|NCT05959187|EXPERIMENTAL|Pharmacogenomic testing group|In the pharmacogenomic testing group, patients underwent collection of oral mucosal epithelial cells for common psychiatric drug gene testing, the clinical doctors were required to combine the patients' symptom characteristics with their own clinical experience and refer to the results of pharmacogenomic testing to guide drug treatment.
62487828|NCT05959187|NO_INTERVENTION|Control|In the control group, patients did not undergo pharmacogenomic testing, and the clinical doctors were required to provide drug treatment based on their own diagnostic and therapeutic experience and the patients' symptom characteristics.
62487829|NCT05605652|NO_INTERVENTION|Control group|leveling and alignment will be commenced without micro- osteoperforations
62487830|NCT05605652|EXPERIMENTAL|Experimental group|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
62693745|NCT06639321|EXPERIMENTAL|percutaneous left ventricular assist system|Subjects with coronary artery disease receiving high-risk PCI will be supported by Percutaneous Ventricular Assist System during the procedure.
62693746|NCT06639321|ACTIVE_COMPARATOR|extracorporeal membrane oxygenation (ECMO)|Subjects with coronary artery disease receiving high-risk PCI will be supported by ECMO during the procedure.
62693747|NCT05363930|ACTIVE_COMPARATOR|Single balloon enteroscopy|Patients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy
62693748|NCT05363930|ACTIVE_COMPARATOR|Novel Motorized Spiral Enteroscopy|Patients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy
62693749|NCT01675440||Severe (≥3-4+) Mitral Valve Regurgitation|Mitral valve regurgitation ≥3-4+
62135203|NCT02752230|ACTIVE_COMPARATOR|Exparel (Bupivicaine Liposome)|Patient will have Exparel (Bupivicaine Liposome) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
62135204|NCT02752230|ACTIVE_COMPARATOR|Marcaine (Bupivicaine)|Patient will have Marcaine (Bupivicaine) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
62330069|NCT03192982|EXPERIMENTAL|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
62330070|NCT03192982|ACTIVE_COMPARATOR|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
62330071|NCT05304182|EXPERIMENTAL|Pre-Op|The experimental intervention is non-invasive optical imaging, in particular digital photography and optical coherence tomography, conducted with the investigational and comparator device, for the purpose of measuring dimensions of the eye.
62330072|NCT05304182|ACTIVE_COMPARATOR|Post-Op|The experimental intervention is non-invasive optical imaging, in particular digital photography and optical coherence tomography, conducted with the investigational and comparator device, for the purpose of measuring dimensions of the eye.
62330073|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
62487831|NCT00615823|ACTIVE_COMPARATOR|1|Atorvastatin group: receive atorvastatin 10 mg daily in addition to supportive care
62487832|NCT00615823|PLACEBO_COMPARATOR|2|Placebo group: receive matching placebo in addition to supportive care.
62487833|NCT06298877|EXPERIMENTAL|Frailty|Single arm study evaluating frailty by assessment of questionnaires and three different frailty tools
62487834|NCT02147379|EXPERIMENTAL|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
62487835|NCT02147379|NO_INTERVENTION|Treatment as usual|Patients randomized to this arm will continue their usual treatment.
62487836|NCT02496104||Preterm infants|Preterm infants born between 25 weeks and 32 weeks + 6 days of gestation
62487837|NCT02496104||Term newborns|Infant born at term
62487838|NCT06626919|EXPERIMENTAL|anito-cel|Single dose of anito-cel cells infused intravenously
62487839|NCT02627963|EXPERIMENTAL|Tivozanib hydrochloride|Participants randomized to this arm will receive the study drug, tivozanib hydrochloride.
62487840|NCT02627963|ACTIVE_COMPARATOR|Sorafenib|Participants randomized to this arm will receive the comparator drug, sorafenib.
62487841|NCT02097160|ACTIVE_COMPARATOR|Control Group 1|regular fortified milk + regular cheese/yogurt
62487842|NCT02097160|EXPERIMENTAL|Intervention Group 2|Vitamin D fortified yogurt and cheese; vitamin D dose increment of 252 IU vs grp 1
62487843|NCT02097160|EXPERIMENTAL|Intervention Group 3|Vitamin D fortified yogurt and cheese, vitamin D dose increment of 420 IU vs grp 1
62135205|NCT03640299|EXPERIMENTAL|ERAS procedure|"In this arm, ERAS perioperative cares patients planned to undergoing laparoscopic surgery, following the ERAS protocols.~Extensive preoperative counselling and education by surgeon and anesthetists.~No Bowel preparation.~6 h fast for solid food and carbohydrate loading with clear fuilds 2h before surgery.~Oral nonselective NSAIDs premedication.~Total Intravenous Anesthesia via TCI, wound infiltration and the transversus abdominis plane (TAP).~Minimally invasive surgery.~Maintenance of normothermia.~Avoidance of surgical drains and nasogastric tubes.~Nonselective NSAIDs postoperative medication.~Postoperative nausea and vomiting active control.~Early oral feeding and ambulation.~VTE prophylaxis postoperative."
62135206|NCT03640299|NO_INTERVENTION|Traditional treatment procedure|"In this arm, control patients planned to undergoing laparoscopic surgery, following the traditional treatment protocols.~Conventional preoperative visits and education.~Mechanical bowel preparation.~Fasting overnight, and no fluids before surgery.~No oral nonselective NSAIDs premedication.~Continuous epidural anesthesia is administered before surgery. Sevoflurane and sufentanil maintain the depth of anesthesia.~Minimally invasive surgery.~No maintenance of normothermia.~Drainage tube insertion if needed.~Postoperative patient-controlled intravenous analgesia.~Postoperative Nausea Control if needed.~Conventional oral feeding and mobilization.~No bowel routine.~VTE prophylaxis postoperative."
62135207|NCT03177044|EXPERIMENTAL|Behavioural treatment|2 to 6 sessions of bowel behavioural training with a pelvic floor physiotherapist
62135208|NCT03912831|EXPERIMENTAL|Phase 1A: 1 x 10^6 KITE-439 (Cohort 1)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, intravenous (IV) infusion, once on Days -7 and -6 and fludarabine, 25 mg/m\^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10\^6 E7 T-cell receptor (TCR) T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, subcutaneous (SC) injection, once on Days 0 to 6.
62135209|NCT03912831|EXPERIMENTAL|Phase 1A: 3 x 10^6 KITE-439 (Cohort 2)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m\^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 3 × 10\^6 E7 TCR T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
62330074|NCT00551824|EXPERIMENTAL|1|"First dilation session with topical mitomycin applied over esophageal mucosa after dilation.~Second dilation session (after 14 days): standard dilation without topical mitomycin."
62330075|NCT00551824|EXPERIMENTAL|2|"First dilation session: standard dilation without topical mitomycin.~Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation."
62330076|NCT04548089|EXPERIMENTAL|Immediate Intervention Group|Participants assigned to the immediate intervention group will engage in a 4-week 2.5-hour Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) with intervention elements of brief psycho-education, weekly mindfulness meditation, facilitated creative art making, reflective writing, group sharing and discussion.
62330077|NCT04548089|EXPERIMENTAL|Waitlist Control Group|Participants assigned to the wait-list control group will not receive Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) until one month after baseline assessment.
62330078|NCT01333267|EXPERIMENTAL|PTHrP group|Subjects receive PTHrP(1-36) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTHrP doses.
62693750|NCT01675440||Severe (≥3-4+) Tricuspid Valve Regurgitation|Tricuspid valve regurgitation ≥3-4+
62693751|NCT01675440||End Stage Renal Disease (ESRD)|End stage renal disease requiring renal replacement therapy or a creatinine clearance (CRCL) \<20 cc/min, but not on dialysis
61935765|NCT04644536||HA paste in long bone & extremities|Filling of post-traumatic or surgically created bone defects
62330079|NCT01333267|EXPERIMENTAL|PTH dosing group|Subjects receive PTH(1-34) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTH doses.
62330080|NCT05022771|EXPERIMENTAL|Single Ascending Doses Cohort 1a|Subjects will receive either Dose level 1 of PMG1015 or Placebo
62330081|NCT05022771|EXPERIMENTAL|Single Ascending Doses Cohort 1b|Subjects will receive either Dose level 2 of PMG1015 or Placebo
62330082|NCT05022771|EXPERIMENTAL|Single Ascending Doses Cohort 1c|Subjects will receive either Dose level 3 of PMG1015 or Placebo
62135210|NCT03912831|EXPERIMENTAL|Phase 1A: 1 x 10^7 KITE-439 (Cohort 3)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m\^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10\^7 E7 TCR T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
62330083|NCT05022771|EXPERIMENTAL|Single Ascending Doses Cohort 1d|Subjects will receive either Dose level 4 of PMG1015 or Placebo
62330084|NCT05022771|EXPERIMENTAL|Single Ascending Doses Cohort 1e|Subjects will receive either Dose level 5 of PMG1015 or Placebo
62330085|NCT05022771|EXPERIMENTAL|Single Ascending Doses Cohort 1f|Subjects will receive either Dose level 6 of PMG1015 or Placebo
62330086|NCT05022771|EXPERIMENTAL|Single Ascending Doses Cohort 1g|Subjects will receive either Dose level 7 of PMG1015 or Placebo
62487844|NCT03351296|EXPERIMENTAL|LV5FU2 + streptozotocin|
62487845|NCT03351296|EXPERIMENTAL|Capecitabine + temozolomide|
62487846|NCT03351296|EXPERIMENTAL|LV5FU2 + streptozotocin + Bevacizumab|
62487847|NCT03351296|EXPERIMENTAL|Capecitabine + temozolomide + Bevacizumab|
62487848|NCT01512628|ACTIVE_COMPARATOR|PENTA group|Pentaspan is administered as a colloid.
62487849|NCT01512628|ACTIVE_COMPARATOR|voluVEN group|Voluven is administered as a colloid.
62487850|NCT01512628|ACTIVE_COMPARATOR|voluLYTE group|Volulyte is administered as a colloid.
62693752|NCT01675440||Low Gradient Low Output Aortic Stenosis|Low gradient low output aortic stenosis
62693753|NCT01675440||Failed Bioprosthetic Surgical Aortic Valve|Stenosed, insufficient or combined bioprosthetic surgical aortic valve failure
62693754|NCT01675440||2 or More Conditions|2 or more of the listed conditions
62487851|NCT03259165|EXPERIMENTAL|Nitrate Intense Strategy|Patients randomized to the Nitrate intense strategy will be treated according to protocol with nitrates in combination with IV loop diuretics. This protocol only involves therapies used in everyday AHF clinical practice.
62487852|NCT03259165|EXPERIMENTAL|Diuretic Intense Strategy|Patients randomized to the Diuretic intense strategy will be treated according to protocol with IV loop diuretics in combination with nitrates. This protocol only involves therapies used in everyday AHF clinical practice.
62487853|NCT04225364|EXPERIMENTAL|camrelizumab plus concurrent chemotherapy|Neoadjuvant immunotherapy, PD-1, plus concurrent chemotherapy（albumin-bound paclitaxel + Cisplatin） will be applied to patients with operable esophageal squamous cell carcinoma before surgery.
62487854|NCT06382662|ACTIVE_COMPARATOR|metaxalone m640 mg|metaxalone micronized 640 mg tablet, single dose at Visit 2 or Visit 3
62487855|NCT06382662|ACTIVE_COMPARATOR|tizanidine 8 mg|tizanidine 8 mg tablet, single dose at Visit 2 or Visit 3
62693755|NCT05006040|EXPERIMENTAL|Hybrid Closed-Loop Insulin System During Chemo with Steroid and Asparaginase|Subjects will receive insulin via hybrid closed-loop insulin delivery system during the chemotherapy phases that contains steroid and asparaginase. This treatment will be initiated within 4 days of starting induction chemotherapy treatment.
62693756|NCT04441138|EXPERIMENTAL|Concurrent, Split Course Chemoradiation Followed by Durvalumab|Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
62693757|NCT03829501|EXPERIMENTAL|KY1044 monotherapy phase 1|KY1044 monotherapy dose escalation
62693758|NCT03829501|EXPERIMENTAL|KY1044 and atezolizumab phase 1|KY1044 and atezolizumab combination dose escalation
61935766|NCT04644536||Granules in Spine|Spinal cage filling
61935767|NCT04644536||HA paste in Spine|Spinal cage filling
61935768|NCT05956873||RTAAA patients treated with REVAR|Included population were consecutive patients presented with evidence of active bleeding (frank ruptures), or without active bleeding but with periaortic structures infiltration/hematoma (contained rupture); undergoing urgent/emergent endovascular RTAAA (Crawford's extend I-IV + suprarenal AAA) repair within the first 24 hours, requiring a proximal landing zone above the celiac trunk with off-the-shelf, F/B-EVAR, PMEG and PG.
61935769|NCT04398862||Children with Down syndrome and aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
61935770|NCT04398862||Children with Down syndrome without aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
61935771|NCT03929627||Group 1 - Medical personnell|Group 1 consists of 70 participants belonging to medical staff of the Medical University of Vienna/University Hospital of Vienna and is divided into subgroups consisting of medical technical assistants, nurses, assistant physicians and physicians.
62330087|NCT03359005|EXPERIMENTAL|5d VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 50mg/m2/d IV over 60 minutes on days 1-5.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
62330088|NCT03359005|ACTIVE_COMPARATOR|5d x 2 VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 20mg/m2/d IV over 60 minutes on days 1-5 and 8-12.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
62330089|NCT03352414|EXPERIMENTAL|Alvimopan|alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
62330090|NCT03352414|PLACEBO_COMPARATOR|Placebo|Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
62330091|NCT04341597|EXPERIMENTAL|transperineal sonographic cervix assessment|
62330092|NCT04341597|ACTIVE_COMPARATOR|endovaginal sonographic cervix assessment|
62330093|NCT06428643|EXPERIMENTAL|Chlamydia, gonorrhea, syphilis, and HIV screening|Community screening of individuals for chlamydia and gonorrhea is not normally done. We are testing to see if this intervention will impact the rates of chlamydia among women.
62330094|NCT03834129|EXPERIMENTAL|(Dex group) intravenous infusion of dexmedetomidine|Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%
62330095|NCT03834129|PLACEBO_COMPARATOR|(Control group) intravenous infusion of physiological serum|Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%
62330096|NCT04118686|EXPERIMENTAL|Experimental group|The group receives CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)
62330097|NCT04118686|SHAM_COMPARATOR|Control group|The group receives CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)
61935772|NCT03929627||Group 2 - Control|Group 2 consists of 70 participants and is recruited from the General non-medical staff of the Austrian Federal Ministry of Defence and Sports, Austrian Armed Forces.
62330098|NCT02488551|EXPERIMENTAL|CALM Tools for Living - computer|This intervention includes the delivery of CALM via computer
62330099|NCT02488551|ACTIVE_COMPARATOR|CALM Tools for Living - manual|This intervention includes the delivery of CALM delivered manual
62330100|NCT05927727|ACTIVE_COMPARATOR|Malign Group|The group includes patients who have malignant axillary lymph nodes which are proven by biopsy
62487856|NCT04919005|EXPERIMENTAL|Healthy elderly people|Twelve healthy elderly people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
62693759|NCT03829501|EXPERIMENTAL|KY1044 monotherapy phase 2|KY1044 monotherapy
62693760|NCT03829501|EXPERIMENTAL|KY1044 and atezolizumab phase 2|KY1044 and atezolizumab combination
62693761|NCT01881958|EXPERIMENTAL|DiaPep277®|
62330101|NCT05927727|ACTIVE_COMPARATOR|Benign Group|The group includes patients who have benign axillary lymph nodes which are proven either by biopsy or follow-up
62330102|NCT03779425|EXPERIMENTAL|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
62330103|NCT01921257|EXPERIMENTAL|Treatment|Cat-PAD and Placebo
62330104|NCT02362308||Adrenalectomy|Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism
62330105|NCT02362308||Medical Therapy|Subjects will undergo assessment before and after medical treatment of primary aldosteronism
62330106|NCT03027804||Ross Operation|Patients undergone Ross Operation. Patients requiring reoperation
62330107|NCT03797040|EXPERIMENTAL|4 million PLX-R18 cells/kg-up to a maximal dose of 400 million|
62487857|NCT04919005|EXPERIMENTAL|Elderly people with Alzheimer's in the initial phase|Seven elderly people with Alzheimer's in the initial phase. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
62487858|NCT04919005|EXPERIMENTAL|Healthy young people|Fifteen healthy young people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
62487859|NCT04218435||Observational|"Sacubitril/valsartan is a combination of a neprilysin inhibitor, sacubitril and an angiotensin II receptor blocker, valsartan.~The recommended starting dose is one 49/51 mg (sacubitril/valsartan) tablet twice-daily. Double the dose of Sacubitril/valsartan after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.~Reduce the starting dose to 24/26 mg (sacubitril/valsartan) twice-daily for:~* Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.~* Patients with severe renal impairment (CrCl less than 30 ml/min)~* Patients with moderate hepatic impairment. (Child Pugh B) Double the dose of Sacubitril/valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient"
62487860|NCT02364531||Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
62487861|NCT03708133|EXPERIMENTAL|Test Treatment + Reference Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~1. Test treatment~2. Reference treatment"
62487862|NCT03708133|EXPERIMENTAL|Reference Treatment + Test Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~1. Reference treatment~2. Test treatment"
62487863|NCT01747174|EXPERIMENTAL|Std PCI + Intra-coronary (IC) Adenosine|IC Adenosine in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
62487864|NCT01747174|EXPERIMENTAL|Std PCI + IC Sodium Nitroprusside (SNP)|IC SNP in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
62487865|NCT01747174|ACTIVE_COMPARATOR|Std PCI|Standard PCI only
62487866|NCT04133311|EXPERIMENTAL|DE-130A|Instillation of one drop, once daily in the evening (9 pm ±1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
62487867|NCT04133311|ACTIVE_COMPARATOR|Xalatan®|Instillation of one drop, once daily in the evening (9 pm ± 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
62487868|NCT04133311|OTHER|DE-130A/DE-130A|After 12 weeks, continue to use DE-130A once daily for an additional 12 months.
62487869|NCT04133311|OTHER|Xalatan®/DE-130A|After 12 weeks, use DE-130A instead of Xalatan® once daily for an additional 12 months.
62487870|NCT03071562|EXPERIMENTAL|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
62693762|NCT06478693|EXPERIMENTAL|MT-303|Participants will receive MT-303 through intravenous infusion.
62693763|NCT01321580|EXPERIMENTAL|Group A|
62135211|NCT03912831|EXPERIMENTAL|Phase 1A: 3 x 10^7 KITE-439 (Cohort 4)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m\^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 3 × 10\^7 E7 TCR T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
62135212|NCT03912831|EXPERIMENTAL|Phase 1A: 1 x 10^8 KITE-439 (Cohort 5)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m\^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10\^8 E7 TCR T cells/kg on Day 0 (maximum allowable dose is 5 × 10\^9 E7 TCR T cells) along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
62135213|NCT03912831|EXPERIMENTAL|Phase 1A: 1 x 10^8 KITE-439 (Cohort 6)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m\^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10\^8 E7 TCR T cells/kg on Day 0 (maximum allowable dose is 1 × 10\^10 E7 TCR T cells) along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
62487871|NCT03071562|NO_INTERVENTION|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
62487872|NCT02542254|ACTIVE_COMPARATOR|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
62487873|NCT02542254|EXPERIMENTAL|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
62487874|NCT02542254|ACTIVE_COMPARATOR|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
62487875|NCT02542254|EXPERIMENTAL|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
62487876|NCT02542254|EXPERIMENTAL|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
62487877|NCT02542254|PLACEBO_COMPARATOR|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
62693764|NCT05498870|ACTIVE_COMPARATOR|Adductor Canal Block (ACB) Only|Participants randomized to the ACB only group will receive an adductor canal block alone.
62693765|NCT05498870|ACTIVE_COMPARATOR|ACB + iPACK|Participants randomized to the ACB + iPACK group will receive both the ACB and iPACK block.
62693766|NCT05153317|EXPERIMENTAL|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
62693767|NCT01048853|EXPERIMENTAL|Treatment (conservative surgery)|Patients undergo a complete lymphatic mapping with sentinel lymph node biopsy and/or pelvic lymph node dissection. If future fertility is no longer desired, patients also undergo hysterectomy with or without bilateral salpingo-oophorectomy.
62487878|NCT03669861|EXPERIMENTAL|Abatacept|To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD
62487879|NCT04784923||Instrumentation patients|Instrumentation patients
62487880|NCT06314633|OTHER|study procedures|Hair cut for DNA damage and chemical exposome variation analysis and Socio-economic characteristics
61935773|NCT04522531|EXPERIMENTAL|Exercise performed on stabil ground|Open cinetic chain shoulder exercise will performed on stabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
61935774|NCT06586190|OTHER|Observational Arm|Patients with lower extremity traumatic injuries that are medically clear for physically ready for therapy and will receive a floor pedal bike with guided exercises at home.
61935775|NCT01104701|ACTIVE_COMPARATOR|Group A|2 mg exenatide once weekly subcutaneous (SC). This arm is used as a reference arm in the study.
61935776|NCT01104701|EXPERIMENTAL|Group B|Low dose 5 mg exenatide once monthly suspension SC.
61935777|NCT01104701|EXPERIMENTAL|Group C|Medium dose 8 mg exenatide once monthly suspension SC.
62330108|NCT00536978|EXPERIMENTAL|NK Cell/T-Cell Infusion|Possible Cell Adback - infusion NK cells or T-cells from donor given after blood stem cell transplantation for either Reduced intensity chemotherapy of campath, modified BEAM regimen of Campath-IH 15 mg intravenous (IV) Daily for 3 Days + BEAM Daily for 4 days (BCNU 300 mg/m\^2 IV, Etoposide 100 mg/m\^2 IV, Ara-C 100 mg/m\^2 IV Daily for 4 days and Melphalan 100 mg/m\^2 IV Over 30 Minutes for 1 Day) + Rituximab 375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks\]; or Non-myeloablative Preparative Regimen \[Fludarabine 30 mg/m\^2 IV Daily Over 1 Hour for 3 Days; Cyclophosphamide 1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days; Rituximab 375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks; Campath-IH 15 mg IV Daily Over 30 Minutes for 3 Days; plus Total Body radiation (TBI)\].
62330109|NCT04972032|EXPERIMENTAL|Estrogen Intrauterine Stent System|An Intrauterine Stent System with estrogen will be introduced into the uterine cavity after TCRA(transcervical resection of adheison).
62330110|NCT04972032|OTHER|Foley balloon combined with self-cross-link sodium hyaluronate gel|Subjects will be given Foley balloon (manufacturer: Zhanjiang Star Enterprise Co., Ltd.) combined with self-cross-linked sodium hyaluronate gel (manufacturer: BioRegen Biomedical (Changzhou) Co., Ltd.) after TCRA surgery.
62330111|NCT04129684|EXPERIMENTAL|Test group|SRP+BioGaia Prodentis oil drops and lozenges
62330112|NCT04129684|PLACEBO_COMPARATOR|Control group|SRP+subgingival delivery of placebo and placebo lozenges
62330113|NCT01536977|EXPERIMENTAL|Supportive care (BBT-I)|"Patients complete the BBT-I, comprising the following modules: 1) What to expect in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) A review of the Spielman Model of insomnia; 3) A discussion (based on the Spielman Model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) An introduction to the concept and practice of Stimulus Control Therapy; 5) An introduction to Sleep Scheduling Specifically modified for cancer patients; 6) Sleep Compression; and 7) Concomitant Medications and Substance Use."
62330114|NCT00580177|ACTIVE_COMPARATOR|L|The Lichtenstein procedure for repair of inguinal hernia (Single On-lay patch)
62487881|NCT04771195||Class of 2023|Stanford undergraduate students who are expected to graduate in Spring of 2023
62487882|NCT04771195||Class of 2024|Stanford undergraduate students who are expected to graduate in Spring of 2024
62487883|NCT04391270|EXPERIMENTAL|web-based intervention group|"Except Library, the participants in this group will also have access to the Intervention sub-section of the website. It will consist of six sessions delivered every two weeks following the same time schedule as the essay delivery in Library."
62487884|NCT04391270|EXPERIMENTAL|blended intervention group|"Except visiting Library and Intervention of the website, the participants in this group will also receive three face-to-face workshops (40 min per session) held at their workplaces."
62487885|NCT04391270|NO_INTERVENTION|Control group|"The participants in the control group will have access to the Library sub-section of the website. General information of MVPA, health and work productivity will be provided with 18 short essays, which can be downloaded and printed out. The information will be factual and non-personally tailored."
61935778|NCT01104701|EXPERIMENTAL|Group D|High dose 11 mg exenatide once monthly suspension SC.
61935779|NCT05755737|ACTIVE_COMPARATOR|Ondansetron|2 doses of Ondansetron 8mg PO (evening before and morning of study)
61935780|NCT05755737|ACTIVE_COMPARATOR|Placebo|2 doses of matching placebo 8 mg PO (evening before and morning of study)
62330115|NCT00580177|ACTIVE_COMPARATOR|P|The well-konown PerFixPlug technique for inguinal hernia repair.
62330116|NCT00580177|ACTIVE_COMPARATOR|PHS|The well-known Prolene Hernia System method for inguinal hernia repair.
62330117|NCT00540436|EXPERIMENTAL|GSK1325760A|Single arm safety and efficacy
62487886|NCT02708251|EXPERIMENTAL|glyceryl trinitrate cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL glyceryl trinitrate cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
62487887|NCT02708251|EXPERIMENTAL|lidocaine cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
62487888|NCT02708251|PLACEBO_COMPARATOR|placebo cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine.1 mL placebo cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
62487889|NCT00796328|EXPERIMENTAL|1|
62487890|NCT05496868|EXPERIMENTAL|Reparixin + Standard of care|Reparixin tablets 1200 mg TID (2 tablets x 600 mg TID) as add-on to the standard of care (SoC).
61935781|NCT06271486|ACTIVE_COMPARATOR|Group A (pregabalin group)|Received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
62693768|NCT05383898|EXPERIMENTAL|Phase 1a Dose escalation of D-1553|Phase 1a will evaluate up to sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation
62330118|NCT02708043|OTHER|F-LMA group|LMA were placed to 814 patients for adenoidectomy surgery. Researchers evaluated flexible laryngeal mask airway use during pediatric adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction levels.
62330119|NCT02088684|EXPERIMENTAL|LEE011 + BKM120 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BKM120 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
62330120|NCT02088684|EXPERIMENTAL|LEE011 + BYL719 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BYL719 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
62330121|NCT02088684|EXPERIMENTAL|LEE011 + fulvestrant|LEE011 - 28 day cycles (3 weeks on, 1 week off) or (continuous daily dosing - dose escalating) fulvestrant - 500 mg i.m. given on Day 1 and Day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
62330122|NCT01936285|PLACEBO_COMPARATOR|Control group|Patients taking placebo
62330123|NCT01936285|EXPERIMENTAL|Colchicine|Active treatment group
62330124|NCT01599754|EXPERIMENTAL|Axitinib|
62330125|NCT01599754|PLACEBO_COMPARATOR|Placebo|
62330126|NCT02683915||Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
62330127|NCT02683915||Non-cooled group|Infants in the non-cooled group received the current standard of care and will be placed under radiant heaters or in incubators, which are servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0± 0.2°C.
62330128|NCT01550718|ACTIVE_COMPARATOR|ESML-Exercise (Physical Activity Program)|ESML-Exercise consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic. Classes are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the class gets individual attention and that all exercises are done safely using proper form.
62330129|NCT01550718|ACTIVE_COMPARATOR|ESML-SOCIAL (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session. Seminars are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the seminar gets individual attention and that everyone has a chance to bring up any concerns."
62330130|NCT01550718|NO_INTERVENTION|No Intervention|This arm will receive no intervention during the active treatment period. After the 4 month assessment participants can choose to attend a support group.
62330131|NCT01876732|EXPERIMENTAL|Vitamin B12|Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
61935782|NCT06271486|ACTIVE_COMPARATOR|Group B (EBP group)|Received active therapy in the form of an EBP and Group C (control group) received conservative treatment.
61935783|NCT06271486|ACTIVE_COMPARATOR|Group C (the control group)|received conservative treatment.
62693769|NCT05383898|EXPERIMENTAL|Phase 1b Dose expansion of D-1553|Phase 1b will evaluate more subjects with up to 2 different doses of D-1553 to confirm the recommended phase 2 dose.
62330132|NCT06086639|EXPERIMENTAL|Research group; mothers receiving online occupational therapy group training|"Participants in this group received online occupational therapy group training for 1 hour per week for 4 weeks.~Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs"
62330133|NCT06086639|NO_INTERVENTION|Control group; Participants in this group did not receive any occupational therapy intervention duri|Participants in this group did not receive any occupational therapy intervention during the 4-week period.
62330134|NCT03591679|EXPERIMENTAL|study group|patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
62330135|NCT03591679|ACTIVE_COMPARATOR|control group|patients at risk of uterine atony undergoing cesarean section received oxytocin only.
62487891|NCT05496868|PLACEBO_COMPARATOR|Placebo + Standard of care|Placebo tablets with the same schedule of reparixin, as add-on to the standard of care (SoC)
62487892|NCT05404789|OTHER|Diabetic Subjects|Individuals with history of diabetes mellitus
62487893|NCT05404789|OTHER|Subjects with history of arrhythmia|Individuals with history of cardiac arrhythmia
62487894|NCT05404789|OTHER|Control Subjects|Individuals without history of either Diabetes or cardiac arrhythmia
62487895|NCT00675779|EXPERIMENTAL|2|oral contraceptive + atorvastatin
61935784|NCT06380179|ACTIVE_COMPARATOR|Photobiomodulation Treatment (PBMT)|PBMT will be delivered at 32-40 watts (W) (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.
61935785|NCT06380179|SHAM_COMPARATOR|Sham PBMT|The inclusion of sham PBMT will ensure all participant treatment procedures remain the same, with the exception of emission of photons (active treatment), thus, allowing for contribution of any differences between groups to be credited to the use of PBMT.
62487896|NCT00675779|ACTIVE_COMPARATOR|1|oral contraceptive
62693770|NCT05383898|EXPERIMENTAL|Phase 2 of D-1553 monotherapy|Phase 1b will evaluate more subjects at the recommended phase 2 dose of D-1553 to evaluate the efficacy.
62693771|NCT06641050||Patients with dizziness|Individuals aged 18 years and over who present to the emergency department with dizziness will be assessed using the TriAGE+ score.
62487897|NCT03368443|ACTIVE_COMPARATOR|Single-room group|The participants assigned to the Single-room group will receive treadmill training and overground gait training in one room (Room A) throughout the training sessions.
62487898|NCT03368443|EXPERIMENTAL|Two-room group|The participants in the Two-room group will receive treadmill training and overground gait training in 2 rooms (Room A and B) in an alternating order.
61935786|NCT04223232|EXPERIMENTAL|MD1003|radiolabeled 14C MD1003 (High Dose Biotin) 100mg
61935787|NCT02162472||Adalimumab|Subjects will receive adalimumab as standard of care for psoriasis
61935788|NCT02162472||Methotrexate|Subjects will receive methotrexate as standard of care for psoriasis
61935789|NCT00972088|OTHER|capsule endoscopy|patients eligible according to inclusion criteria who underwent a capsule endoscopy
61935790|NCT04119310|EXPERIMENTAL|Lumbar thrust-mobilization|The investigator will perform a lumbar thrust-mobilization with the subject in right and then left sidelying position
61935791|NCT04119310|SHAM_COMPARATOR|Sham-mobilization|No lumbar-thrust mobilization will be performed. Subject will receive simple passive inter-vertebral range of motion.
61935792|NCT02667327|ACTIVE_COMPARATOR|Granexin gel plus Standard of Care|Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
61935793|NCT02667327|PLACEBO_COMPARATOR|Vehicle gel plus Standard of Care|Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
61935794|NCT02667327|NO_INTERVENTION|Standard of Care|Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.
61935795|NCT03512899|ACTIVE_COMPARATOR|Internal jugular vein access|Internal jugular vein access preferably right, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
61935796|NCT03512899|ACTIVE_COMPARATOR|Axillary vein access|Axillary vein access with single incision, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
61935797|NCT02106910|EXPERIMENTAL|Participants with Barrett's and No History of Ablation|Participants with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE.
61935798|NCT02106910|EXPERIMENTAL|Participants with Barrett's and a History of Ablation|Participants with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
61935799|NCT05005078|PLACEBO_COMPARATOR|Placebo|WST-057 Matching placebo
62135214|NCT03912831|EXPERIMENTAL|Phase 1B: KITE-439|Participants will receive cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m\^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, at a dose selected based on Phase 1A along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
62135215|NCT01905826||Patient Relatives|Blood relatives of enrolled patients.
62487899|NCT02761525|EXPERIMENTAL|gel silver nanoparticles|topic gel silver nanoparticles 12 ppm
62487900|NCT02761525|PLACEBO_COMPARATOR|placebo|topic innocuous gel
62487901|NCT06626633|EXPERIMENTAL|STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia|Drug Product: CRD3874 solution for injection (CRD3874-SI) Type of drug: Synthetic small molecule Formulation: Sterile solution of CRD3874 for injection Route of Administration: IV infusion over one hour Strength: 6 mg/mL Schedule: Cycle: once weekly infusion x 4 (Days 1, 8, 15 and 22) over 28-day for Cycles 1 and 2. For Cycle 3 and onward, weekly infusion x 3 (Days 1, 8 and 15), until they develop unacceptable toxicities or disease progression, or do not achieve at least a morphologic leukemia-free state response after 6 cycles.
62487902|NCT02471807|EXPERIMENTAL|Edwards FORMA Tricuspid Transcatheter Repair System|Edwards FORMA Tricuspid Transcatheter Repair System
62487903|NCT00143273|EXPERIMENTAL|Lasofoxifene Dose 1|0.05 mg
62487904|NCT00143273|EXPERIMENTAL|Lasofoxifene Dose 2|0.25 mg
62487905|NCT00143273|EXPERIMENTAL|Lasofoxifene Dose 3|0.5 mg
62693772|NCT00581919|EXPERIMENTAL|Bort, Dex, and Dox with ALCAR|
61935800|NCT05005078|EXPERIMENTAL|WST-057|WST-057 topical solution
61935801|NCT00801918|OTHER|DD Alone|Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
61935802|NCT00801918|EXPERIMENTAL|DD with ICE Chemotherapy|For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
61935803|NCT03432156|EXPERIMENTAL|Experimental group|subjects who are treated with autologous Tcm cells immunotherapy
61935804|NCT03432156|NO_INTERVENTION|No intervention group|subjects who are treated without autologous Tcm cells immunotherapy
62693773|NCT05988281|EXPERIMENTAL|Type I dental implant placement.|Type I dental implant placement (immediately after extraction)
61935805|NCT00006363|EXPERIMENTAL|Induction Arm I|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1-3. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of cytarabine IV continuously on days 1-5 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1 and 2.
61935806|NCT00006363|EXPERIMENTAL|Induction Arm II|Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
62135216|NCT01905826||Patients|Patients with known mutations in GATA2 or those with clinical and laboratory characteristics strongly consistent with GATA2 deficiency.
62135217|NCT01136694||RA patients who are new bDMARD users|
62135218|NCT01136694||RA patients who are existing DMARD users|
62135219|NCT00246805|EXPERIMENTAL|1. VRS ON|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.~This arm (1) is randomized to Function Ventricular Rate Stabilization ON."
62487906|NCT00143273|PLACEBO_COMPARATOR|Placebo|0 mg
62693774|NCT05988281|EXPERIMENTAL|Type II dental implant placement.|Type II dental implant placement (6-8 weeks after extraction)
62693775|NCT05988281|EXPERIMENTAL|Type III/IV placement.|Type III/IV placement in socket preserved sites after 3-6 months.
62487907|NCT02741687|EXPERIMENTAL|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels \>180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels \>180 mg/dl, or with average daily blood glucose levels \>180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
62487908|NCT02741687|PLACEBO_COMPARATOR|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels \>180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels \>180 mg/dl, or with average daily blood glucose levels \>180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
62487909|NCT00354419|EXPERIMENTAL|Arm I|See Detailed Description
62693776|NCT06644859||WHS|A large existing and anonymized dataset of older women enrolled in the Women's Health Study From 2011 to 2015, 17,466 women wore a triaxial accelerometer during waking hours for a week
62693777|NCT04105283|EXPERIMENTAL|Tc99m-MAA|"* Tc99m-MAA will be administered by selective or supra-selective arterial injection via the bronchial artery or branches thereof.~* Administration will occur over a period of 30-240 seconds"
62330136|NCT02280967|EXPERIMENTAL|Education about HPV by school nurse|The educational intervention consists of education about HPV and a special designed leaflet and self-reported questionnaires. The educational intervention is included in the regular health interview with the school nurse (scheduled for about one hour) and includes information about HPV; facts about the virus, transmission, what it can cause and prevention (i.e. safe sex with condom use and HPV vaccination), facts about HPV vaccine and the importance of attending future cervical cancer screening controls. Students complete questionnaires before the health interview at baseline and after three months. A follow-up with parts of the boys will be performed with qualitative interviews. Participants (n=40)
62330137|NCT02280967|NO_INTERVENTION|Control group 1|Students allocated to control group 1 receives standard treatment, the regular health interview with the school nurse. Students complete questionnaires before the health interview at baseline and after three months (n=400).
62330138|NCT04574284|EXPERIMENTAL|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62330139|NCT04574284|EXPERIMENTAL|TQB2450|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
62330140|NCT04574284|EXPERIMENTAL|Anlotinib|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62330141|NCT02910180||Repository Group|The Repository Group consists of patients which have donated tissue to the repository.
62330142|NCT03929588|EXPERIMENTAL|Refraction with a Hand-held Device Supported by Mobile App.|BCVA with handheld device with app.
62330143|NCT03929588|ACTIVE_COMPARATOR|Manual Refraction|BCVA with phoropter
62330144|NCT03929588|ACTIVE_COMPARATOR|Automated Refraction|BCVA with autorefractoer
62330145|NCT06182072|EXPERIMENTAL|Dose Escalation|"ProAgio Dose Levels (DL) 1,2,3,4~ProAgio combined with gemcitabine and nab paclitaxel is administered to study participants by intravenous injections on days 1, 8, 15, 22 every 4-week Cycle.~Other Names:~ACT50, G-nP: Gemcitabine and nab-Paclitaxel"
62330146|NCT06182072|EXPERIMENTAL|Standard Arm|"Participants will receive ProAgio at the RP2D combined with gemcitabine and nab paclitaxel is administered to study participants by intravenous injections on days 1, 8, 15, 22 every 4-week Cycle.~Other Names:~ACT50, G-nP: Gemcitabine and nab-Paclitaxel"
62330147|NCT02026843||Diabetic retinopathy,humor,angiogenic|Samples of aqueous humor was taken before injection and before surgery. The injection include bevacizumab or triamcinolone.
62330148|NCT02026843||Nondiabetic,angiogenic,humor|Aqueous humor was taken before surgery. Surgery include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
62330149|NCT04332640|EXPERIMENTAL|Next Generation Phaco System|VERITAS Vision System
62330150|NCT03566693|EXPERIMENTAL|Continous Glucose Monitor|
62330151|NCT03566693|ACTIVE_COMPARATOR|Self Monitoring Blood Glucose|
62693778|NCT06468826|EXPERIMENTAL|Group 1: Normal Renal Function|Participants in Group 1 will receive a single dose of avacopan on Day 1.
62693779|NCT06468826|EXPERIMENTAL|Group 2: ESRD Requiring HD|Participants in Group 2 will receive a single dose of avacopan on Day 1 in each of 2 treatment periods (Period 1/on HD and Period 2/off HD).
62693780|NCT03748472|EXPERIMENTAL|Bolus feeding|
62330152|NCT02266901||Cases (endoscopic drainage)|Septic patients presenting post-bariatric collections related to leaks not adequately drained by percutaneous drain, for whom endoscopic drainage of the collections was performed by transluminal or percutaneous route.
62693781|NCT03748472|EXPERIMENTAL|continuous gavage feeding|
62693782|NCT06640907|EXPERIMENTAL|Intervention group|
62693783|NCT06640907|ACTIVE_COMPARATOR|Control group|
62330153|NCT04632095|ACTIVE_COMPARATOR|Sternotomy AVR|Aortic valve replacement due to sternotomy
62330154|NCT04632095|ACTIVE_COMPARATOR|Mini AVR|Aortic valve replacement due to parasternal right anterior mini-thoracotomy
62330155|NCT04095988|EXPERIMENTAL|Verum-AMR|Patients receiving Verum-Allogeneic Microbiota Reconstitution via gastroscopy
62693784|NCT06124404|EXPERIMENTAL|Small dose|
62330156|NCT04095988|PLACEBO_COMPARATOR|Placebo-AMR|Patients receiving Placebo(Saline)-Infusion via gastroscopy
62330157|NCT03165591|EXPERIMENTAL|Experimental|Daily tablet of V3-P given orally for 2 months
62693785|NCT06124404|EXPERIMENTAL|Medium dose|
62693786|NCT06124404|EXPERIMENTAL|Large dose|
62693787|NCT06211517||Adolescents|Adolescents suffering from anorexia nervosa 12 to 25 years
62693788|NCT06211517||Parents|Parents whose adolescents suffer from anorexia nervosa
62330158|NCT05276713||Tucidinostat-based therapy|30 mg tucidinostat was given orally(as six 5 mg tablets per day) twice a week (either, Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday) for 4 consecutive weeks in a 4-week cycle.The endocrine drugs combined with tucidinostat were given based on previous treatment.Patients received tucidinostat-based treatment until disease progression or intolerable adverse events.
62330159|NCT00748059|EXPERIMENTAL|A|Patients with Orthostatic Hypotension
62330160|NCT00369668|EXPERIMENTAL|High Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; four 90-minute sessions/week for 2 weeks.
62330161|NCT00369668|ACTIVE_COMPARATOR|Low Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; two 90-minute sessions/week for 2 weeks.
62330162|NCT00369668|ACTIVE_COMPARATOR|Control|Bilateral training moving both arms coupled with sham neuromuscular electrical stimulation
62330163|NCT02618928||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
62330164|NCT01614769|EXPERIMENTAL|Placebo → Glimepiride 2 mg → Glimepiride 4 mg|Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
62330165|NCT01614769|EXPERIMENTAL|Glimepiride 2 mg → Glimepiride 4 mg → Placebo|Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
62330166|NCT01614769|EXPERIMENTAL|Glimepiride 4 mg → Placebo → Glimepiride 2 mg|Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
62330167|NCT01614769|EXPERIMENTAL|Placebo → Glimepiride 4 mg → Glimepiride 2 mg|Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
62330168|NCT01614769|EXPERIMENTAL|Glimepiride 2 mg → Placebo → Glimepiride 4 mg|Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
62330169|NCT01614769|EXPERIMENTAL|Glimepiride 4 mg → Glimepiride 2 mg → Placebo|Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
62330170|NCT02567344|EXPERIMENTAL|Active rTMS|Active rTMS will be delivered to the Left DLPFC at 10Hz. A total of 4000 pulses will be delivered.
62330171|NCT02567344|SHAM_COMPARATOR|Sham rTMS|Sham rTMS will be delivered to the Left DLPFC at 10 Hz using an electronic sham system used in multiple other investigations. A total of 4000 pulses of sham rTMS will be delivered.
62330172|NCT01912729|EXPERIMENTAL|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a trained peer coach.
62330173|NCT01912729|EXPERIMENTAL|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a clinician coach.
62330174|NCT01912729|NO_INTERVENTION|Wait List Control|Participants may be asked to wait for up to 8 weeks until minimum group size is met. After 4 weeks from baseline, if a group has not yet started, we will conduct another assessment. These participants will serve as the Wait List Control group.
62330175|NCT01721408|EXPERIMENTAL|Group A|
62330176|NCT01721408|ACTIVE_COMPARATOR|Group B|
62330177|NCT03121222|PLACEBO_COMPARATOR|Lactose|The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
62330178|NCT03121222|EXPERIMENTAL|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
62330179|NCT05397886|EXPERIMENTAL|Remimazolam with flumazenil|Patients allocated to remimazolam with flumazenil group receives remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
61935807|NCT00006363|EXPERIMENTAL|Intensification Favorable|Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
62330180|NCT05397886|ACTIVE_COMPARATOR|Propofol total intravenous anesthesia|Patients allocated to propofol total intravenous anesthesia group receives propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
62330181|NCT02311855|OTHER|Influenza vaccination|all patients are vaccinated per protocol
62330182|NCT06110793|EXPERIMENTAL|Lenvatinib, Pembrolizumab, and Fulvestrant|This is an open-label phase Ib/II trial of lenvatinib (20mg orally PO daily) plus pembrolizumab (400mg IV Q6W) plus fulvestrant (500mg IM Q4W) in patients with unresectable, locally advanced/metastatic ER+/HER2- breast cancer.
62330183|NCT01742624|EXPERIMENTAL|Advagraf group|
62330184|NCT01742624|ACTIVE_COMPARATOR|Prograf group|
62330185|NCT05747131|EXPERIMENTAL|Emotion Detectives In-Out|Emotion Detectives In-Out consists of 15 weekly sessions with the children (9 face-to-face group sessions, 4 online sessions and 2 videoconference sessions).
62330186|NCT05747131|ACTIVE_COMPARATOR|Coping Cat|Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents.
61935808|NCT00006363|EXPERIMENTAL|Intensification Unfavorable PBSCT Group|Patients receive etoposide IV continuously and HiDAC IV over 2 hours every 12 hours on days 1-4. Patients also receive G-CSF SC daily beginning on day 14 and continuing until PBSC collection is completed. Patients who are not able to undergo PBSCT after HiDAC/etoposide continue treatment in the non-PBSCT group. At least 4 weeks after HiDAC/etoposide recovery, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3 prior to PBSCT. Patients receive autologous PBSC infusion on day 0. Patients also receive G-CSF SC beginning on day 0 and continuing until hematopoietic recovery.
61935809|NCT00006363|EXPERIMENTAL|Intensification Unfavorable Non-PBSCT Group|Patients receive etoposide, HiDAC, and G-CSF as in the PBSCT group. After hematopoietic recovery, patients then receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more course.
61935810|NCT00006363|EXPERIMENTAL|Immunotherapy Arm I|Patients begin therapy no later than 120 days after the first day of the last course of HiDAC treatment OR day 0 of PBSCT. Patients receive low-dose IL-2 SC on days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90. In addition, patients receive high-dose IL-2 SC on days 15-17, 29-31, 43-45, 57-59, and 71-73.
61935811|NCT00006363|ACTIVE_COMPARATOR|Immunotherapy Arm II|Patients are observed and receive no further therapy.
61935812|NCT01288027|EXPERIMENTAL|Alglucosidase Alfa|
61935813|NCT05671471||Allergic Children|Patients followed in the Pediatric Allergy and Pulmonology Unit, CHU Lille, aged 0-18 years with peanut and/or tree nut allergy
61935814|NCT02593201|EXPERIMENTAL|Treatment|One extra week of antibiotic therapy
61935815|NCT02593201|SHAM_COMPARATOR|Control|No extra antibiotics
61935816|NCT00642720|OTHER|pegvisomant-placebo|patients in this arm received(as addition)for the first 8 weeks Pegvisomant and the later for 8 weeks Placebo. This was divided by a 4 weeks wash-out period.
61935817|NCT00642720|OTHER|placebo-pegvisomant|Patient received for the first 8 weeks Pegvisomant and after a wash out period of 4 weeks the received 8 of placebo treatment
61935818|NCT05032248|EXPERIMENTAL|tacrolimus|group I (Colchicine and topically applied Tacrolimus),
62330187|NCT03152916|EXPERIMENTAL|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
62330188|NCT02165657|EXPERIMENTAL|Excimer laser|Excimer laser treatment
62330189|NCT03071224|EXPERIMENTAL|[18F]MNI-946|To evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.
62330190|NCT04261387|EXPERIMENTAL|LUT014 Gel|LUT014 Gel topical application to the dermatitis area qd for 28 days
62330191|NCT04261387|PLACEBO_COMPARATOR|Placebo for LUT014 Gel|
62330192|NCT04659226|EXPERIMENTAL|Episodic or chronic migraine|Women starting treatment with erenumab according to clinical indication
62330193|NCT04148924||Patients|Anyone who is hospitalized in the palliative care service of the Lyon Sud Hospital Center.
62330194|NCT04148924||Doctors|Doctors taking care of patients in the study will be solicited by the research nurse or a study investigator.
61935819|NCT05032248|PLACEBO_COMPARATOR|placebo|group II (Colchicine and topically applied Placebo),
62330195|NCT04148924||Nurses|Nurses taking care of patients in the study will be solicited by the research nurse or a study investigator.
62330196|NCT04148924||Caregivers|Caregivers taking care of patients in the study will be solicited by the research nurse or a study investigator.
62330197|NCT05158595|EXPERIMENTAL|low intensity group|Will receive wobble board based Exergame balance training, game intensity will be low for this group (Size of goal will be kept large)
61935820|NCT00467610|EXPERIMENTAL|Panhematin|
62330198|NCT05158595|EXPERIMENTAL|moderate intensity group|Will receive wobble board based Exergame balance training, game intensity will be low for this group (Size of goal will be kept large)
62330199|NCT05158595|EXPERIMENTAL|high intensity group|Will receive wobble board-based Exergame balance training, game intensity will be high for this group (Size of goal will be kept small).
62330200|NCT05158595|ACTIVE_COMPARATOR|control group|Will receive Exer-game balance training with Wii Fit balance games
62330201|NCT01662297|ACTIVE_COMPARATOR|Quetiapine|Veterans remaining on quetiapine for insomnia.
61935821|NCT02674373||Localized gastric cancer|resectable tumor receiving a curative intent treatment.
61935822|NCT02674373||advanced gastric cancer|unresectable tumor treated with palliative chemotherapy
61935823|NCT01241084|PLACEBO_COMPARATOR|Placebo|Antileukotrienes+Placebo
61935824|NCT01241084|ACTIVE_COMPARATOR|Lactobacillus reuteri|Antileukotrienes+Lactobacillus reuteri
61935825|NCT01634490||infants receiving extensively hydrolysed casein formula|infants receiving extensively hydrolysed casein formula as substitutive formula
61935826|NCT01634490||extensively hydrolysed casein formula with Lactobacillus GG|infants receiving extensively hydrolysed casein with LGG as substitutive formula
61935827|NCT01634490||infants receiving rice hydrolyzed formula|infants receiving rice hydrolyzed formula as substitutive formula
62330202|NCT01662297|ACTIVE_COMPARATOR|Trazodone|Veterans switching from quetiapine to trazodone for the treatment of insomnia.
62330203|NCT05128253||NASH GROUP|Recruited (n=22) patients with non-alcoholic steatohepatitis.
62330204|NCT05128253||NAFL GROUP|Recruited (n=22) patients with non-alcoholic fatty liver.
62330205|NCT04051021|OTHER|Usual Care|
62330206|NCT04051021|EXPERIMENTAL|Comfort Coach|
62330207|NCT05127096||Cohort A|Cohort A will include subjects with a recent diagnosis of colorectal cancer and/or advanced adenoma requiring additional endoscopic or surgical resection (surgery).
62330208|NCT05127096||Cohort B|Cohort B will include subjects undergoing routine screening colonoscopies will be enrolled in the screening cohort.
62330209|NCT01009801|ACTIVE_COMPARATOR|Arm I|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
62330210|NCT01009801|EXPERIMENTAL|Arm II|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
62330211|NCT03899194|ACTIVE_COMPARATOR|escitalopram|Patients will only be treated with escitalopram from the minimum dosage.
62330212|NCT03899194|EXPERIMENTAL|escitalopram+ fish oil capsules|Patients will be treated with escitalopram from the minimum dosage and fish oil capsules according to direction for use.
62330213|NCT02477085||all women with an induced labor|prospective population-based cohort of all women who have an induced labor during one month in seven perinatal networks
62330214|NCT02577250|EXPERIMENTAL|Six ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.
62330215|NCT04629989|ACTIVE_COMPARATOR|Low-flow nasal cannula|The standard oxygen delivery system (low-flow nasal cannula) is worn by the patient, without the DTM or the SM
62330216|NCT04629989|EXPERIMENTAL|Double-Trunk Mask|The Double-Trunk Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
62330217|NCT04629989|EXPERIMENTAL|Surgical Mask|The Surgical Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
62330218|NCT03213626|EXPERIMENTAL|Cabozantinib + erlotinib|
62330219|NCT03566524|EXPERIMENTAL|Citrulline|In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 20 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
62330220|NCT03566524|PLACEBO_COMPARATOR|alanine|In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 20 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
62330221|NCT06515327||Steroid Group|Patients using corticosteroids for any reason before cardiac arrest
62330222|NCT06515327||Non-Steroid Group|Patients not using corticosteroids and having cardiac arrest
62487910|NCT06082505|EXPERIMENTAL|In-Person Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker deliver behavioral education and referrals to low-cost services. Deliver in person to participants in community and clinic settings. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
62487911|NCT06082505|EXPERIMENTAL|Telephone Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker deliver behavioral education and referrals to low-cost services. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
62693789|NCT06211517||Healthcare professionals|Healthcare professionals in charge of adolescents suffering from anorexia nervosa
61935828|NCT01634490||infants receiving soy-based formula|infants receiving soy-based formula as substitutive formula
62135220|NCT00246805|NO_INTERVENTION|2. VRS OFF|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.~This arm (2) is randomized to Function Ventricular Rate Stabilization OFF."
62330223|NCT05195333|EXPERIMENTAL|First group|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient. You will be asked to do these exercises as home exercise with 10 repetitions 3 days a week, until the 34th week of pregnancy.
62330224|NCT05195333|EXPERIMENTAL|Second group|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy
62693790|NCT05051228||GEAR cohort|This is a noninvasive study that screens healthy and non-healthy volunteers for cardiovascular disease.
61935829|NCT01634490||infants receiving amino-acid based formula|infants receiving amino-acid based formula as substitutive formula
61935830|NCT04645420|EXPERIMENTAL|Apremilast|"15 PsA patients with active disease and naïve to conventional synthetic and biologic disease modifying anti-rheumatic drugs.~Treatment with apremilast orally in the whole group (n = 15). Escalating dose the first Week (10 mg once day1, 10 mg bid day2, 10 mg-20 mg day3, 20 mg bid day4, 20 mg-30 mg day5, 30 mg bid on day6), and 30 mg bid from day7 until week24."
62135221|NCT02797184|EXPERIMENTAL|10mmol KNO3|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
62330225|NCT05195333|NO_INTERVENTION|Third group|The participants will not be given any exercise program, they will be asked to continue their routine care.
62693791|NCT01381679||All participants|Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.
62693792|NCT00666042|EXPERIMENTAL|A|Vigamox delivered as spray
62693793|NCT00666042|ACTIVE_COMPARATOR|B|Patients will receive the commercially available Vigamox drops
62693794|NCT04472468|EXPERIMENTAL|Treatment (pericardiotomy)|"* Patient in this arm will receive balloon pericardiotomy before insertion of pericardiocentesis.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is used to dilate the pericardium.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.~* Standard pericardiocentesis with prolonged drainage is performed afterwards.~* Pericardial drain is removed when output is less than 100cc/day"
62693795|NCT04472468|NO_INTERVENTION|Control (standard pericardiocentesis)|"* Standard pericardiocentesis procedure is performed using standard pigtail pericardial drain. - Pericardial fluid is then tapped until dry on table.~* Pericardial drain is removed when output is less than 100cc/day"
62693796|NCT02371187|EXPERIMENTAL|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
62135222|NCT02797184|EXPERIMENTAL|20mmol KNO3|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
62330226|NCT06355557|ACTIVE_COMPARATOR|22 medical students (AI)|medical students randomised to this arm
62330227|NCT06355557|ACTIVE_COMPARATOR|22 medical students (Simulator)|medical students randomised to this arm
62330228|NCT06355557|ACTIVE_COMPARATOR|22 medical students (control)|medical students randomised to this arm
62330229|NCT00819624|OTHER|Interactive Voice Response System|
62330230|NCT00819624|OTHER|Personal Digital Assisstant|
62330231|NCT06363448|ACTIVE_COMPARATOR|Yamani technique|Yamani technique for aphakia
62330232|NCT06363448|ACTIVE_COMPARATOR|Proline mesh for aphakia|Proline mesh for aphakia
62330233|NCT01835496|NO_INTERVENTION|Ferriprox|single 1500 mg dose of Ferriprox
62330234|NCT06693752|EXPERIMENTAL|Brain contrast-enhanced ultrasound|The study duration per subject will be up to 30 minutes including the time to prepare the contrast agent, perform the pre-contrast imaging and the contrast-enhanced ultrasound (CEUS), as well as the 60-minute monitoring period after the administration of the contrast agent. A second CEUS exam may be performed within 1-2 weeks from the first scan for up to two CEUS exams of 1 hour and 30-minute duration each. Study participation will be complete when the 60-minute monitoring period of the last CEUS performed is complete.
62330235|NCT01180413|EXPERIMENTAL|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment
62330236|NCT00940342|EXPERIMENTAL|Treated and Relapsed - Group 1|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
62330237|NCT00940342|EXPERIMENTAL|Treated and High-Risk for Progression - Group 2|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
62330238|NCT00940342|EXPERIMENTAL|70 Years of Age and Refused Chemo - Group 3|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
62330239|NCT02858609|EXPERIMENTAL|Patients with Diarrhoea|Patients admitted in emergency room with Diarrhoea
62330240|NCT04137133|EXPERIMENTAL|collection of expectoration, stools and blood|
62330241|NCT04341675|ACTIVE_COMPARATOR|Sirolimus|Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.
62330242|NCT04341675|PLACEBO_COMPARATOR|Placebo|Matching placebo
62330243|NCT00506077|EXPERIMENTAL|MK0249|
62330244|NCT00506077|PLACEBO_COMPARATOR|Placebo|
62330245|NCT01815333|EXPERIMENTAL|Feraheme|Magnetic resonance imaging (MRI) acquired prior to the injection of Feraheme® and repeated at approximately 48 hours and 72 hours from the time of injection (scan time). The scan time will be adjusted, as needed. The MRI scan prior to the Feraheme injection is the routine scan. The scans at 48 and 72 hours are investigational.
61935831|NCT03053583|ACTIVE_COMPARATOR|Miller Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Miller blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
61935832|NCT03053583|ACTIVE_COMPARATOR|Wis-Hipple Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Wis- Hipple blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
61935833|NCT03053583|ACTIVE_COMPARATOR|C-Mac Laryngoscope blade|An image of the best glottic view will be saved on C-MAC monitor's SD card during laryngoscopy using C-MAC straight blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
62330246|NCT01661400|NO_INTERVENTION|Control|No intervention
61935834|NCT02004392|EXPERIMENTAL|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
61935835|NCT02004392|EXPERIMENTAL|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
61935836|NCT05345873|EXPERIMENTAL|SCTV01E Group|one dose of SCTV01E, intramuscular
62330247|NCT01661400|EXPERIMENTAL|Metronomic Cyclophosphamide|Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children \< 40kg or 100 mg daily for children \> 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
62330248|NCT01661400|EXPERIMENTAL|Thalidomide|Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
62330249|NCT01957826|PLACEBO_COMPARATOR|placebo comparator|transendocardial injection of placebo solution
62330250|NCT01957826|EXPERIMENTAL|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
62693797|NCT02371187|PLACEBO_COMPARATOR|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
62693798|NCT03612531|EXPERIMENTAL|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
61935837|NCT05345873|ACTIVE_COMPARATOR|mRNA-1273|one dose of mRNA-1273, intramuscular
61935838|NCT04210583|EXPERIMENTAL|Vulvovaginal Treatment|"At visit 1 -(6 months post treatment in the CS0716 study):~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional),~At Visit 2 (6 months post treatment in the CS0716 study):~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional), Administer study treatment (optional: internal, mons pubis and/or labia treatment).~Discomfort/pain 10 cm VAS, immediate response assessment (applicable only if treatment provided)~Final AE follow-up 30 days post Visit 2 Treatment (if applicable): AE assessment (applicable only if treatment provided at Visit 2 in the FE1019 study)."
61935839|NCT04857970||Electronic HRQoL questionnaires with feedback to physicians|40 patients allocated in this arm will answer HRQOL questionnaires using an electronic form in CHES Software. The HRQoL scores, presented as graphics, will be transmitted to physicians.
62330251|NCT03575520|EXPERIMENTAL|Peg group|
62330252|NCT04023513|EXPERIMENTAL|Strength Training and Protein high|6 weeks of high protein intake (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
62330253|NCT04023513|EXPERIMENTAL|Strength Training and Protein low|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
62330254|NCT04023513|OTHER|Control|No Intervention.
62487912|NCT04211935|EXPERIMENTAL|Patient Controlled Analgesia|This technique involves connecting a patient controlled analgesia pump to the intravenous line. The patient has the ability to push a button to obtain a predetermined dose of an intravenous opioid with a set lockout time period to minimize the potential for over sedation. PCA pumps will be connected to the intravenous line of the patient at the end of the MIRPE operation. anesthesiologists with experience in regional anesthesia.
62487913|NCT04211935|EXPERIMENTAL|Erector Spinae Block|This method consists of the anesthesiologist placing two catheters on each side of the vertebrae which then delivers pain medicine continuously via pumps for 2-3 days post-surgery.
62487914|NCT04211935|EXPERIMENTAL|Intercostal Nerve Cryoablation|The INC technique relies on multilevel freezing of the intercostal neurovascular bundle intraoperatively to block sensation and pain for approximately 2 months postoperatively. Trained pediatric surgeons will perform the INC at the time of a MIRPE procedure.
62487915|NCT05644392|EXPERIMENTAL|Cadonilimab Injection in combination with Regorafenib|Cadonilimab Injection in combination with Regorafenib
62487916|NCT00758797|EXPERIMENTAL|1|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
61935840|NCT04857970||Paper-pencil HRQoL questionnaires w.o. feedback to physician|"40 patients allocated in this arm will answer HRQOL questionnaires using pencil-paper, without transmission of the HRQoL scores to physicians."
61935841|NCT00447317|EXPERIMENTAL|A|Intervention
62330255|NCT02426658|EXPERIMENTAL|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.
62330256|NCT02516800||Aortic valve calcification|Patients with calcific aortic valve disease, age = 65 years or below
62330257|NCT02516800||Control group|Matched control group
62330258|NCT01515982|EXPERIMENTAL|Aerobic exercise|The training exercise intensity is established at 60% of VO2máx. Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
62487917|NCT01093833|EXPERIMENTAL|Continuous Glucose Monitoring|Each subject will participate in one experimental intervention. Blood glucose will be measured with the BD continuous glucose monitor (BD CGM), with the Medtronic Guardian CGM and the YSI Glucose Analyzer as controls for 12-14 hours.
61935842|NCT00447317|OTHER|B|Attention control, standard dietary education
61935843|NCT00369122|EXPERIMENTAL|Treatment (radiation therapy, bevacizumab, cisplatin)|"Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45 Gy.~Some patients also undergo low-dose rate brachytherapy twice, 1-3 weeks apart, beginning \>= 4 weeks after initiating EBRT or high-dose rate brachytherapy 5 times, \>= 48 hours apart, beginning \>= 2 weeks after initiating EBRT. EBRT and chemotherapy are halted on the day of high-dose rate brachytherapy. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 35."
61935844|NCT04537455|EXPERIMENTAL|Abnormal cardiac conduction|patients with abnormal cardiac conduction will undergo an ultra-high frequency electrocardiogram
61935845|NCT02443519|EXPERIMENTAL|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day \& Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
61935846|NCT02443519|NO_INTERVENTION|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
61935847|NCT06597916|EXPERIMENTAL|Group 1-3 (2 times verum)|Group 1-3 receive 2 doses of the RSV vaccine at visit 1 and visit 3, 1-2 months apart.
61935848|NCT06597916|PLACEBO_COMPARATOR|Group 4 (1 time verum, 1 time placebo, randomised)|Group 4 receives 1 doses of the RSV vaccine or placebo at visit 1 and visit 3.
61935849|NCT03985384|ACTIVE_COMPARATOR|Semaglutide|Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
61935850|NCT03985384|PLACEBO_COMPARATOR|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
62330259|NCT01515982|NO_INTERVENTION|Control group|All participants were asked not to commence any new exercise regimen.
62487918|NCT04695041|EXPERIMENTAL|Cohort A: 1200 mg PBI-4050|
61935851|NCT05746962|ACTIVE_COMPARATOR|Group that does not use the scopeguide screen|The control group should remove the looping of colonoscope by looking at the general colonoscopy screen The control group cannot use scopeguide screen Scopeguide screen is blinded by an opaque wrapping paper
62487919|NCT04695041|EXPERIMENTAL|Cohort B: 1600 mg PBI-4050|
62487920|NCT04695041|EXPERIMENTAL|Cohort C: 2000 mg PBI-4050|
62487921|NCT04695041|EXPERIMENTAL|Cohort D: 2400 mg PBI-4050|
62487922|NCT04695041|EXPERIMENTAL|Cohort E: 2400 mg PBI-4050|
62487923|NCT04695041|EXPERIMENTAL|Cohort F (Supplemental): 1600 mg PBI-4050|
62487924|NCT02575651|EXPERIMENTAL|Fluzoparib|Each subject will receive a single dose of fluzoparib on day 1, and then subject will receive fluzoparib twice daily for 28 days during cycle 1.
62487925|NCT02805764|EXPERIMENTAL|Homeoblock functional dental appliance|Removable functional dental appliance to be used at during sleep for one year.
62487926|NCT05957146||Chronic hemodialysis patients|Adult patients treated with routine hemodialysis 3x/week during at least 3 months
62487927|NCT02197195|EXPERIMENTAL|Chocolate Milk Beverage|Chocolate milk beverage and sitting quietly
62487928|NCT02197195|EXPERIMENTAL|Chocolate Milk Beverage and Exercise|Chocolate milk beverage and exercising
62487929|NCT02197195|EXPERIMENTAL|Fruit Drink Beverage|Fruit drink beverage and sitting quietly
62487930|NCT02197195|EXPERIMENTAL|Fruit Drink Beverage and Exercise|Fruit drink beverage and exercising
62487931|NCT06428539||patients with active lupus nephritis|patients with active lupus nephritis as active urinary sediment, or rising renal chemistry
62487932|NCT06428539||patients with lupus nephritis in remission|Patients who were previously active, but now in remission
62487933|NCT06428539||normal individuals|normal healthy participants
62693799|NCT02621944|EXPERIMENTAL|Participants 1-10|"This group will receive a 0.5 mg/kg enteral dose of Melatonin. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
61935852|NCT05746962|EXPERIMENTAL|Group using the scopeguide screen|The experimental group uses a general endoscopic image during colonoscopic insertion The experimental group should remove the looping of colonoscope by looking at the scopeguide screen
61935853|NCT00794781|EXPERIMENTAL|1|
61935854|NCT03773367|EXPERIMENTAL|Treatment with chemotherapy pre- and postoperative.|
62330260|NCT05322863|ACTIVE_COMPARATOR|active HD-tDCS|The participants will be instructed to relax during the first 5 minutes of the session while the equipment is set up. A mild stimulation (with a level of only 2 milliamps stimulation) will be delivered for 20 minutes, with the current gradually increased and decreased over 30 seconds. The patients will be instructed to relax and remain motionless during the intervention. The administrator will closely monitor the impedance throughout each session and record any side effects experienced by the participants. The participants will be allowed 5 minutes of rest after the intervention and will be actively asked about any discomfort. Each session will last around 30 minutes, with a total of 10 sessions (two consecutive weeks of treatment for 5 days per week).
62330261|NCT05322863|SHAM_COMPARATOR|sham-HD-tDCS|The procedure for sham stimulation will be identical, except that the current will be gradually ramped down to zero after the first 30 s, thus giving the same initial sensation of HD-tDCS. The stimulator will be programmed to switch the current on and off, so no intervention by the operator will be required. The computer will be placed behind the subjects' heads so they cannot see the readout.
62330262|NCT00988559|EXPERIMENTAL|PMED Delivery - groups 1 and 2|Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
62330263|NCT00988559|EXPERIMENTAL|IM injections - groups 5 and 6|Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
62330264|NCT00988559|EXPERIMENTAL|Intralesional delivery - group 3 and 4|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
62330265|NCT00988559|EXPERIMENTAL|Intralesional delivery + imiquimod - group 7|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
62330266|NCT01252043||cohort|cholestatic children without esophageal variceal bleeding
62330267|NCT01252043||study|cholestatic children with esophageal variceal bleeding
62330268|NCT01252043||cholestatic children without EV|cholestatic children without esophageal variceal bleeding
62330269|NCT04798885|NO_INTERVENTION|Enhanced usual care|Participants will be informed about typical Post Concussion Symptoms and the process of typical recovery as well as given reassurance concerning the prognosis. Advice concerning the use of pain relief medication will also be provided.
62330270|NCT04798885|EXPERIMENTAL|GAIN 2.0 intervention|An eight-week, interdisciplinary intervention program based on principles from cognitive behavioural therapy (CBT) and gradual return to activities.
62330271|NCT01655823|PLACEBO_COMPARATOR|Placebo (twice daily)|Placebo for injection (1 ml volume), twice a day for four consecutive days.
62330272|NCT01655823|EXPERIMENTAL|Low dose Tetrodotoxin (twice daily)|Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
62330273|NCT01655823|EXPERIMENTAL|Mid-range dose of Tetrodotoxin (twice daily)|Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
61935855|NCT00595842||Group one|Subjects are drawn from a search of all patients treated with MTA between ages 5-40
61935856|NCT01516229||Somatropin|
61935857|NCT04282278|EXPERIMENTAL|Group A|
61935858|NCT04282278|EXPERIMENTAL|Group B|
61935859|NCT04282278|EXPERIMENTAL|Group C|
61935860|NCT02407418|ACTIVE_COMPARATOR|Spinal Manipulation|In a repeated measures, crossover design, all subjects received spinal manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
62330274|NCT01655823|EXPERIMENTAL|Max dose Tetrodotoxin (once daily)|Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
62330275|NCT01655823|EXPERIMENTAL|Max dose Tetrodotoxin (twice daily)|Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
62330276|NCT01402284|EXPERIMENTAL|Carfilzomib, Lenalidomide, Dexamethasone|Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year
62330277|NCT02932475|ACTIVE_COMPARATOR|Treatment|Metformin 1000 mg twice a day
62487934|NCT06451653|EXPERIMENTAL|Men in Maternity Health (MiM) Intervention|The men in maternity health (MiM) education program provided male partners of pregnant women with comprehensive education on maternal health, covering topics such as pregnancy complications, obstetric danger signs, maternal health care (including antenatal, delivery, and postnatal care), the benefits of birth preparedness and complication readiness (BPCR), and safe delivery practices. Invitation letters were sent to male partners by public health supervisors every first and third week to encourage participation in the MiM program's activities, while maternal health education sessions were conducted every second and fourth week.
62487935|NCT06451653|NO_INTERVENTION|Control|Male partners in the control group can only receive routine maternal health education if they accompany their female partners to antenatal care services at health facilities.
62135223|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
62135224|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
62330278|NCT02932475|SHAM_COMPARATOR|Placebo|Placebo, identical to Metformin
62330279|NCT03302793|EXPERIMENTAL|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
62330280|NCT03302793|EXPERIMENTAL|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
62330281|NCT03541512|ACTIVE_COMPARATOR|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
62330282|NCT03541512|ACTIVE_COMPARATOR|Education only|Educational materials only
62330283|NCT03215264|EXPERIMENTAL|Dose level 1|Regorafenib 160mg daily 1-21 of 28-day cycle , Entinostat 3mg weekly, HCQ 600mg daily.
62330284|NCT03215264|EXPERIMENTAL|Dose level 2|Regorafenib 160mg daily 1-21 of 28-day cycle Entinostat 5mg weekly, HCQ 600mg daily
62330285|NCT03215264|EXPERIMENTAL|Dose level 3|Regorafenib 160mg daily 1-21 of 28-day cycle, Entinostat 5mg weekly, HCQ 600mg BID (1200mg daily).
62330286|NCT00186745|EXPERIMENTAL|1|All patients in this cohort receive treatment with weight-adjusted, standard-dose tinzaparin for treatment of venous thromboembolism. Trough anti-Xa level measurements done on any 2 of days 3, 5 or 7 of treatment. Patients with a trough anti-Xa level \> 0.5 IU/mL receive dose adjustment of the tinzaparin.
62330287|NCT02848690|EXPERIMENTAL|Educational Intervention Group|Participants assigned to the educational intervention group will have dietitian consultation to receive a dietary planning based on diet rich of fruits, vegetables, low fat, low processed foods and high nonfat dairy. During six months they will have monthly dietitian appointments including educational sessions to stimulate sodium restriction and enhance to follow the dietary planning. Each 15 days they will be contacted by phone to reinforce adherence to sodium restriction diet.
62330288|NCT02848690|SHAM_COMPARATOR|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI\> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
62330289|NCT04153006||Chest pain patients|"Patients who are admitted to the cardiac ED because of chest pain for ruling out acute coronary syndrome by troponin analysis are eligible for participation.~Troponin analysis will be performed according to standard protocol (0-1h protocol). From every included patient capillary blood samples and an extra venous blood sample will be drawn to evaluate HS cTnI levels obtained with the POC instrument and central laboratory (CL)."
62330290|NCT00719576|EXPERIMENTAL|MACI|autologous cultured chondrocytes on porcine collagen membrane
62330291|NCT00719576|ACTIVE_COMPARATOR|Microfracture|Microfracture
62330292|NCT00606762|ACTIVE_COMPARATOR|LPLC, HPLC|LPLC: Low pressure pneumoperitoneum is defined as intraabdominal pressure kept at8 mm Hg after initial trocar insertion at 12 mm Hg HPLC: High pressure pneumoperitoneum is defined as intra abdominal pressure kept at 12 mm Hg throughout the procedure
62330293|NCT05337813|EXPERIMENTAL|A. Overactive bladder|Overactive bladder (LiESWT therapy once a week, duration 8 weeks)
62330294|NCT05337813|EXPERIMENTAL|B. Stress incontinence|Stress incontinence (LiESWT therapy once a week, duration 8 weeks + PRP therapy once a month, duration 3 months)
62330295|NCT05337813|EXPERIMENTAL|C. Interstitial cystitis|Interstitial cystitis (LiESWT therapy once a week, duration 8 weeks + PRP therapy once a month, duration 3 months)
62330296|NCT05337813|EXPERIMENTAL|D. Female sexual dysfunction|Female sexual dysfunction (LiESWT therapy once a week, duration 8 weeks)
62330297|NCT01986569|EXPERIMENTAL|[18F]fluoroestradiol (FES)|The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. \[18F\]FES PET/CT for imaging.
62330298|NCT05839431|EXPERIMENTAL|Virtual Reality Therapy for Youth Phobias|Participants will undergo up to 10 weeks of virtual reality-assisted exposure therapy.
62487936|NCT03354338|EXPERIMENTAL|Experimental Group|Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
62330299|NCT03229915|ACTIVE_COMPARATOR|PTSD|Will receive Cognitive Processing Therapy
62330300|NCT03229915|ACTIVE_COMPARATOR|Trauma-exponsed control|Will receive Cognitive Processing Therapy
62330301|NCT03229915|NO_INTERVENTION|no trauma healthy control|Scanned twice (13 weeks apart) without any intervention
62330302|NCT06693583|NO_INTERVENTION|Control Arm : Standard colposcopy care|Women in the control arm will be offered all aspects of standard colposcopy care for their pain relief. This includes : nursing support, local anaesthetic and gas and air as required.
62330303|NCT06693583|EXPERIMENTAL|Virtual reality headsets as a distraction method|The patient will attend for colposcopy at which the consultation will begin as normal. When the time comes for examination +/- biopsy +/- treatment, the patient will be offered the virtual reality headset as a form of immersive therapy to distract them during the procedure. This will be continued until cessation of examination. All other standard forms of pain relief will also be provided for the patient.
62487937|NCT03354338|PLACEBO_COMPARATOR|PLACEBO|Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
62487938|NCT04738968|EXPERIMENTAL|Cochlear implant for single-sided deafness|Children with single-sided deafness, cochlear implant in the deaf ear
62487939|NCT04738968|NO_INTERVENTION|Control single-sided deafness|Children with single-sided deafness, no intervention
62487940|NCT04738968|NO_INTERVENTION|Control normal hearing|Children with normal hearing, no intervention
62487941|NCT03965572||Postpartum women who requested cabergoline|A cohort of postpartum women, after a live birth, who request cabergoline for lactation suppression.
62487942|NCT03965572||Control group|An age-matched cohort of women after a live birth who have not requested cabergoline for lactation suppression.
62487943|NCT05768334|ACTIVE_COMPARATOR|lubiprostone|50 patients
62487944|NCT05768334|PLACEBO_COMPARATOR|Control arm|50 patients
61935861|NCT02407418|SHAM_COMPARATOR|Sham Manipulation|In a repeated measures, crossover design, all subjects received the sham manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
62330304|NCT01769690|EXPERIMENTAL|DBS stimulator setting alteration|
62330305|NCT05387915|EXPERIMENTAL|Treatment (reduced dose radiation therapy)|Patients who are ctHPVDNA negative after surgery undergo reduced dose radiation therapy for 3 weeks (15 treatments). Patients who are ctHPVDNA positive after surgery undergo standard of care radiation therapy.
62330306|NCT05502263||moderate/high risk|FEV and/or DLCO \<80% And VO2peak \<20ml/kg.min or \<75% predicted value
62330307|NCT05502263||Control|FEV and DLCO \>80% and VO2peak \> 20ml/kg.min or \>75% predicted value
62330308|NCT00243230|EXPERIMENTAL|Double-Blind - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized antiretroviral therapy (ART) regimen containing a ritonavir-boosted protease inhibitor (PI/r) for 48 weeks.
62330309|NCT00243230|EXPERIMENTAL|Double-Blind - Vicriviroc 20 mg|Vicriviroc 20 mg QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
62330310|NCT00243230|PLACEBO_COMPARATOR|Double-Blind - Placebo|Placebo QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
62330311|NCT00243230|EXPERIMENTAL|Open-label - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized ART regimen containing a ritonavir-boosted protease inhibitor (PI/r) for up to 45 months.
62330312|NCT05853562|NO_INTERVENTION|T0-T1 period|It was a control period. Participants were asked to continue their routine activities for 4 weeks.
61935862|NCT03619343|EXPERIMENTAL|No ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography.
62330313|NCT05853562|EXPERIMENTAL|T1-T2 period (structured vestibular rehabilitation program)|A structured vestibular rehabilitation program was applied in 50-minute sessions under the supervision of a physiotherapist once a week and as a home exercise program 3 days a week over 4 weeks.
62330314|NCT05853562|ACTIVE_COMPARATOR|T2-T3 period|A structured vestibular rehabilitation program was applied in 50-minute sessions under the supervision of a physiotherapist once a week and as a home exercise program 3 days a week over 4 weeks. Afterwards, participants participated in the home program with telerehabilitation for 8 weeks.
62330315|NCT01516164|ACTIVE_COMPARATOR|MacIntosh|
62487945|NCT01328652|EXPERIMENTAL|Proton Pump Inhibitor|Treatment with dexlansoprazole 60 mg once daily for 3 months
62487946|NCT01995162|EXPERIMENTAL|Free-living conditions|
62487947|NCT01847495|EXPERIMENTAL|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
62487948|NCT00913627|EXPERIMENTAL|1|1 x 600 mg ibuprofen IR/ER-roller compaction caplet
61935863|NCT03619343|ACTIVE_COMPARATOR|ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
61935864|NCT04014309|EXPERIMENTAL|Supportive and survivorship care program|Routine distress screening will be conducted using the Distress Thermometer (DT) and an accompanying problem list. Participants will complete the screening tool before their consults with oncologists and the results will be stored in their medical records. During the consult, oncologists will review the DT scores and problem list with each participant to provide the corresponding educational materials, advice or referrals. Highly distressed participants may be referred by oncologists to the supportive care nurses (SCN) for further triage and review.
61935865|NCT04014309|PLACEBO_COMPARATOR|Usual care|No routine distress screening will be performed.
61935866|NCT05596942|EXPERIMENTAL|Albumin Chana Striata Extract|
61935867|NCT05596942|ACTIVE_COMPARATOR|Human Albumin|
61935868|NCT06330454||Painfull TKA|Pulsed electromagnetic field therapy
62330316|NCT01516164|ACTIVE_COMPARATOR|McGrath MAC direct|
62330317|NCT01516164|ACTIVE_COMPARATOR|McGrath MAC indirect|
62330318|NCT05391984|EXPERIMENTAL|Activity oriented|Activity-oriented therapy will be given to 15 patients which will train the structures around the shoulder in different activities of daily life.
62330319|NCT05391984|EXPERIMENTAL|Structural oriented|Structural-oriented therapy will be given to 15 patients including a fixed sequence of physiotherapy techniques.
62330320|NCT03510832||STEMI patients undergoing Emergent PCI|
62330321|NCT02619019|ACTIVE_COMPARATOR|Dexamethasone group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
62330322|NCT02619019|ACTIVE_COMPARATOR|Pethidine group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
62330323|NCT02619019|PLACEBO_COMPARATOR|Control group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
62487949|NCT00913627|EXPERIMENTAL|2|1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
62487950|NCT00913627|ACTIVE_COMPARATOR|3|1x 220 mg naproxen sodium (Aleve caplet)
62487951|NCT00913627|PLACEBO_COMPARATOR|4|1 x placebo caplet
62487952|NCT03500094|EXPERIMENTAL|migalastat HCl 150 mg|"One migalastat 123 milligrams (mg) capsule equivalent to 150 mg migalastat hydrochloride (HCl) (herein referred to as migalastat) was administered every other day for 12 months."
62487953|NCT01247103|PLACEBO_COMPARATOR|Part A: single ascending dose|AZD4316: single oral dose, with 1 group with/without food
62487954|NCT01247103|PLACEBO_COMPARATOR|Part B: multiple ascending dose|AZD4316: multiple oral doses
62487955|NCT01537718|EXPERIMENTAL|REPLY 200 implanted patients|REPLY 200 implanted patients
62487956|NCT01912807|EXPERIMENTAL|Dextrose (D5NS)|The participants received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis and Dextrose 5% in 0.9 % Normal Saline (D5NS) was used as a second antiemetic, at an intravenous rate calculated based on their weight and determined for the purpose of the study.
62487957|NCT01912807|ACTIVE_COMPARATOR|Ondansetron (Control)|The control group received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis. Ondansetron (dose 0,05 mg/Kg) was used as a second prophylactic antiemetic.
62487958|NCT02431949||Controls|Participants without a psychosis disorder diagnosis.
62487959|NCT02431949||Patients|Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
62487960|NCT03084263|EXPERIMENTAL|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
62487961|NCT03084263|ACTIVE_COMPARATOR|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
62487962|NCT05781737||Ulcerative colitis|
62487963|NCT05781737||Crohn disease|
62487964|NCT05781737||Control group|
62487965|NCT04318808|EXPERIMENTAL|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), LI11 (Quchi, B2), PC6 (Neiguan, B3), ST36 (Zusanli, B2), ST37 (Shangjuxu, B2), ST39 (Xiajuxu, B2), SP4 (Gongsun, B3) , SP9 (Yinlingquan, B2).
62487966|NCT04318808|SHAM_COMPARATOR|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
62487967|NCT06366555|EXPERIMENTAL|Manual acupuncture twirling|"In the intervention group, acupuncture needles were inserted using a tube with manipulation parameters, puncture is carried out using a sized needle 0.14 x 25 mm penetrates the plaster and skin with using the help of a 30 mm long tube to achieve a puncture depth of 20 mm and a twirling manipulation is carried out. For kinematic parameters of rotational movement in the same direction clockwise (to the right) by 180 degrees, 3 rad/s for 30 seconds at points PC2 and LU5.~The time parameters were retained for 20 minutes and twirling was manipulated 0 minutes and 10 minutes. After the retention is over, control the bleeding with Press on the needle insertion point for 10 seconds or until the bleeding stops"
62487968|NCT06366555|SHAM_COMPARATOR|Manual acupuncture sham|in the sham group acupuncture needles were inserted using a tube without any manipulation parameters and not penetrating the skin. The needles then left for 20 minutes.
62487969|NCT00827164|EXPERIMENTAL|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
62487970|NCT00827164|OTHER|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
62487971|NCT03006835|EXPERIMENTAL|Domestic Clopidogrel 300mg|Domestic Clopidogrel 300mg
61935869|NCT02922933|ACTIVE_COMPARATOR|Omeprazole|"Treatment A: 5mg entinostat on Day 1~Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1"
61935870|NCT02922933|ACTIVE_COMPARATOR|Famotidine|"Treatment C: 5mg entinostat on Day 1~Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1"
62330324|NCT05336526|EXPERIMENTAL|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Participants who meet the requirements for bilateral breast augmentation in primary intention and have been implanted with ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants
62487972|NCT03006835|EXPERIMENTAL|Domestic Clopidogrel 600mg|Domestic Clopidogrel 600mg
62487973|NCT03006835|EXPERIMENTAL|Imported Clopidogrel 300mg|Imported Clopidogrel 300mg
62487974|NCT03006835|ACTIVE_COMPARATOR|Imported Clopidogrel 600mg|Imported Clopidogrel 600mg
62487975|NCT06627348|ACTIVE_COMPARATOR|Hilotherapy|Cooling of hands and feet during Taxan-based chemotherapy
61935871|NCT02922933|ACTIVE_COMPARATOR|Acidic Beverage|"Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water~Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage"
61935872|NCT03143881|EXPERIMENTAL|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
62330325|NCT03699852|EXPERIMENTAL|LED group|The study had two groups of participants: the LED group (GL) and the control group (GC), both with Membracel®, a porous membrane that regenerates crystalline cellulose, as the primary cover in the donor area of the skin graft (no secondary cover was used) ). In one of the groups (GL), a light-emitting diode (LED) plate was applied, which was covered with sterile waterproof and transparent film to prevent contamination. The participant was positioned so that the skin graft donor area was accessible. The LED plate covered the entire skin donor area and was irradiated with a radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED plate was applied in contact with the skin graft donor area in the immediate postoperative period and on Membracel® on the 1st, 3rd, 5th and 7th postoperative days. The primary coverage remained until spontaneous removal.
62487976|NCT06627348|NO_INTERVENTION|No Cooling|No cooling of hands and feet during Taxan-based chemotherapy
62487977|NCT02964039|EXPERIMENTAL|Error reduction|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error reduction mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
61935873|NCT03143881|NO_INTERVENTION|Control|Control patients will receive ED standard of care.
61935874|NCT06084013||Observational|Patients receive indocyanine green IV during surgery, undergo imaging and have their medical records reviewed on study.
62330326|NCT03699852|OTHER|Control group|The participants remained and were evaluated under the same conditions. The only difference between the groups is that no LED photobiomodulation session was applied to the control group.
62693800|NCT02621944|EXPERIMENTAL|Participants 11-20|"This group will the Melatonin dose of 3 mg/kg enteral, only if the group Participants 1-10 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
62487978|NCT02964039|EXPERIMENTAL|Error augmentation|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error augmentation mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
62693801|NCT02621944|EXPERIMENTAL|Participants 21-30|"This group will receive Melatonin dose of 5 mg/kg enterally, only if the group Participants 11-20 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
62487979|NCT02964039|SHAM_COMPARATOR|Activity matched control|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in transparent mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
62487980|NCT04615741|EXPERIMENTAL|Trauma Informed Yoga|Participants will receive 8 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
62487981|NCT04615741|EXPERIMENTAL|Trauma Informed Psychotherapy|Participants will receive 8 x 90 min group-based psychotherapy sessions, delivered synchronously over Zoom.
62487982|NCT04615741|NO_INTERVENTION|Control|These participants will not receive an intervention.
62487983|NCT01067950|EXPERIMENTAL|Isolated Pancreas Transplant|
62330327|NCT00634244|EXPERIMENTAL|Arm A (carboplatin and topotecan hydrochloride)|Patients receive carboplatin and topotecan hydrochloride IV continuously over 24 hours on days 1-5.
62330328|NCT00634244|EXPERIMENTAL|Arm B (alvocidib, mitoxantrone, cytarabine)|Patients receive alvocidib IV over 4.5 hours QD on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9.
62330329|NCT00634244|EXPERIMENTAL|Arm C (sirolimus, mitoxantrone, etoposide, cytarabine)|Patients receive sirolimus PO QD on days 2-9, mitoxantrone hydrochloride IV over 15 minutes QD, etoposide IV over 1 hour QD, and cytarabine IV over 3 hours QD on days 4-8 or 5-9. (Closed to accrual)
62487984|NCT01067950|ACTIVE_COMPARATOR|Intensive Insulin Therapy|
62487985|NCT01920334|EXPERIMENTAL|Zolpidem CR 12.5mg|Patients receive zolpidem CR 12.5mg at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
62487986|NCT01920334|PLACEBO_COMPARATOR|Placebo|Patients receive placebo at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
62487987|NCT04738864|EXPERIMENTAL|behcet's disease patient|patient who presented with manifestation of behcet disease
62693802|NCT05013138|ACTIVE_COMPARATOR|Standard of Care Arm|During the study period, standard of care providers will continue to provide standard of care treatment(s); however, families receiving care from the standard of care providers will complete all study surveys. Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination. However, standard of care providers will still be able to provide resources to the families as part of standard of care.
62330330|NCT01661361||vancomycin cohort|
62487988|NCT04738864|EXPERIMENTAL|Healthy people|healthy control people
62487989|NCT02893735|ACTIVE_COMPARATOR|Charisma-Diamond|Charisma Diamond was randomly applied for diastema closure.
62487990|NCT02893735|ACTIVE_COMPARATOR|Filtek-Z550|Filtek-Z550 was randomly applied for diastema closure.
62693803|NCT05013138|EXPERIMENTAL|Intervention Arm|Intervention providers will undergo training for ACEs screening and discussion. Eligible families will be enrolled into the study at the intake of their child's 4-month, 6-month, 9-month, 15-month, or 18-month well child check. Caregivers will complete the intake surveys including demographics, caregiver ACEs, resilience, warmth, PTSD, and depression. The providers will lead a discussion regarding the impact of caregiver ACEs. Patients will be contacted 1-week, 6-months, and 18-months following their enrollment to obtain repeat measures of the survey instruments. At the 18-month time point, the electronic medical record (EMR) will be queried to obtain outcome measures.
62693804|NCT00756509|EXPERIMENTAL|nilotinib|nilotinib
62487991|NCT05444205|EXPERIMENTAL|Higher resources/lower challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they did not posses any measured risk factors. Participants are provided with a choice of the following preventive interventions: Text4Baby/Bright by Text (depending on child age), Nurture Program, and/or Family Centers.
62487992|NCT05444205|EXPERIMENTAL|Lower Resources/Lower Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they were low-income, a teen parent, their newborn had health challenges (more than five weeks premature or a neonatal intensive care unit stay of longer than 4 weeks, or they reported mild parenting challenges. They did not endorse any more serious measured risk factors. Participants are provided with a choice of the following preventive interventions: Nurture Program and/or Video Interaction Project.
62487993|NCT05444205|EXPERIMENTAL|Moderate Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they had a history of mental health problems, low social support, or moderate parenting challenges. They did not endorse any more serious measured risk factors. Participants are provided with a choice of the following preventive interventions: Nurture Program and/or Video Interaction Project.
62487994|NCT05444205|EXPERIMENTAL|Serious Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they had a histories of involvement with child welfare, incarceration, opioid use disorder, recent homelessness, or that their child is displaying serious behavior problems. Participants are provided with a choice of the following preventive interventions: Smart Beginnings, Family Check-Up or if the child was less than two weeks old, Healthy Families America.
62487995|NCT04149691|EXPERIMENTAL|CPL304110|CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.
62487996|NCT04487184|ACTIVE_COMPARATOR|Facilitation|From origin to insertion
62487997|NCT04487184|EXPERIMENTAL|Relaxation|From insertion to origin
62487998|NCT04487184|PLACEBO_COMPARATOR|Cross|Cross the muscle fiber
61935875|NCT01810211|EXPERIMENTAL|Horizontal Adduction Stretch and Pendulums|"Horizontal Adduction Stretch- Individual standing with their operative scapula against a wall and rotating toward the side to be stretched to stabilize scapula and the operative arm is relaxed. The opposite hand is placed under the elbow of the involved extremity and assists the operative shoulder into horizontal adduction attempting to bring the hand to the opposite shoulder.~Pendulum -Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
61935876|NCT01810211|EXPERIMENTAL|Modified Sleeper Stretch and Pendulum|"Modified Sleeper Stretch: Individual in supine with operative shoulder abducted to approximately 45 degrees and elbow at 90 degrees of flexion with neutral rotation of the glenohumeral joint. The individual then places other hand on the wrist of the involved extremity and passively moves the glenohumeral joint into internal rotation.~Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
61935877|NCT01810211|NO_INTERVENTION|Pendulum Exercise|Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction.
61935878|NCT06668194|ACTIVE_COMPARATOR|Light force (150g Niti Coil Spring)|One of the maxillary canines to be retracted will be assigned to the light force group randomly. Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (150g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms.
61935879|NCT06668194|EXPERIMENTAL|Heavy force (400g NiTi Coil Spring)|One side of the maxillary canines to be retracted will have a heavy force assigned randomly. Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (400g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms.
61935880|NCT00629174|EXPERIMENTAL|1|Exercise
62135225|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
62135226|NCT04899024|EXPERIMENTAL|PARTI and CM (Contingency Management)|The PARTI intervention will be delivered in five individual sessions during a 12-week contingency management protocol for PrEP adherence
62135227|NCT04899024|ACTIVE_COMPARATOR|Attention-Control and CM (Contingency Management)|The attention-control condition will consist of five individual sessions where participants complete self-report measures and neutral writing exercises during a 12-week contingency management protocol for PrEP adherence
62487999|NCT04487184|SHAM_COMPARATOR|Control|No tape
62488000|NCT01296607|OTHER|Urocortin 2|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 2 in the presence and absence of a saline washout between incremental doses.
62488001|NCT01296607|OTHER|Urocortin 3|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 3 in the presence and absence of a saline washout between incremental doses.
62488002|NCT04748991|EXPERIMENTAL|Intravenous Vernakalant|Patients randomized to Vernakalant will receive a bolus of 3mg/kg over 10 minutes and an observation period of 15 minutes, if the patient is still in AF, they will receive an additional 2.0mg/kg bolus of Vernakalant.
62488003|NCT04748991|ACTIVE_COMPARATOR|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive 150mg IV bolus and an amiodarone infusion of 1mg/hr x 6 hours followed by 0.5mg/hr x 12 hours.
62488004|NCT00484679|EXPERIMENTAL|1|Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
62488005|NCT06014424|EXPERIMENTAL|CBD|Participants randomized to the CBD arm will be titrated up to a maximum dose of 800 mg/day
62330331|NCT02145299|EXPERIMENTAL|TruePath CTO Device|"The TruePath™ CTO Device (Boston Scientific Corporation, Natick, MA) is a new solution for intraluminal treatment of chronic total occlusions (CTO). It is the longest available crossing device (165 cm), and has a diamond-coated distal tip that can rotate at 13,000 rpm. Its profile is similar to a 0.018 guidewire, and includes a shapeable distal tip allowing 1:1 torque response. In addition, it provides audio and visual navigation during CTO crossing."
62330332|NCT02145299|ACTIVE_COMPARATOR|CROSSER CTO Device|"The CrosserTM CTO Recanalization Catheter (Crosser system) (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing."
62330333|NCT05392127|EXPERIMENTAL|single arm|SHR0302 Tablets + probe drugs (Midazolam Maleate Tablets + Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Repaglinide Tablets) + Vitamin K1 Tablets
62330334|NCT00466999|ACTIVE_COMPARATOR|surgery|standard surgical treatment (either dilation and curettage or manual vacuum aspiration)
62488006|NCT06014424|EXPERIMENTAL|Placebo|Participants randomized to the placebo will be titrated up to a maximum dose of 800 mg/day
62488007|NCT01828203|EXPERIMENTAL|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
61935881|NCT00629174|EXPERIMENTAL|2|Mental training (computer lessons)
61935882|NCT00629174|NO_INTERVENTION|3|
61935883|NCT01427322|EXPERIMENTAL|lapatinib + radiation therapy|lapatinib given orally 2-4 hours prior to first fraction of radiation
61935884|NCT01427322|ACTIVE_COMPARATOR|No therapy prior to radiation|Radiation therapy alone
61935885|NCT04824365|EXPERIMENTAL|Treatment of COVID-19 infected patients with a sodium pyruvate nasal spray|In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVID-19 infection.
61935886|NCT04824365|PLACEBO_COMPARATOR|Placebo control treatment of COVID-19 infected patients|In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVID-19 infection.
61935887|NCT05997758||Patients|"Patients who suffer from potentially surgically remediable drug-resistant focal epilepsy and who require evaluation with intracranial stereo-EEG electrodes and have them implanted in the anterior insula.~N = 10"
61935888|NCT05997758||Subclinical|"Healthy individuals who match the clinical population in age and level of education.~N = 40"
61935889|NCT01231347|PLACEBO_COMPARATOR|Placebo + gemcitabine|Arm 1: AMG 479-placebo IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
62330335|NCT00466999|ACTIVE_COMPARATOR|misoprostol|400 mcg misoprostol
62330336|NCT03152136|EXPERIMENTAL|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
62488008|NCT01828203|PLACEBO_COMPARATOR|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
62488009|NCT02784236|OTHER|pre-post evaluation|All patients undergo the condition of telemedicine.
62488010|NCT01149057|EXPERIMENTAL|Single Arm|
62488011|NCT00926835|EXPERIMENTAL|Paroxetine|Paroxetine monotherapy
61935890|NCT01231347|EXPERIMENTAL|AMG 479 12 mg/kg dose + gemcitabine|Arm 2: AMG 479 12 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
61935891|NCT01231347|EXPERIMENTAL|AMG 479 20 mg/kg + gemcitabine|Arm 3: AMG 479 20 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
61935892|NCT05237271|NO_INTERVENTION|Control Group|Control group treats their simulated patients using standard practice and have no introduction to the new SomaLogic test.
61935893|NCT05237271|EXPERIMENTAL|Intervention Group 1|Intervention group 1 will receive educational materials on the single cardiovascular disease in type 2 diabetes risk score. They will then be forced to used the risk score for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
61935894|NCT05237271|EXPERIMENTAL|Intervention Group 2|Intervention group 2 will receive educational materials on the cardiovascular disease in type 2 diabetes (CVD-T2D) risk score as well as the panel of metabolic scores. They will then be forced to used the CVD-T2D score and the metabolic panel scores for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
61935895|NCT01933217|EXPERIMENTAL|Methylphenidate|The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
61935896|NCT01933217|PLACEBO_COMPARATOR|Placebo|The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
62330337|NCT03152136|SHAM_COMPARATOR|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
62488012|NCT00926835|ACTIVE_COMPARATOR|Escitalopram|Escitalopram monotherapy
62488013|NCT00926835|ACTIVE_COMPARATOR|Venlafaxine|Venlafaxine monotherapy
62488014|NCT00926835|ACTIVE_COMPARATOR|Paroxetine+Bupropion|
62488015|NCT00926835|ACTIVE_COMPARATOR|Paroxetine+Lamotrigine|
62488016|NCT00926835|ACTIVE_COMPARATOR|Paroxetine+Lithium|
62488017|NCT00926835|ACTIVE_COMPARATOR|escitalopram+mirtazapine|
62488018|NCT00926835|ACTIVE_COMPARATOR|Escitalopram+Aripiprazole|
62488019|NCT00926835|ACTIVE_COMPARATOR|Paroxetine + Venlafaxine|
62488020|NCT02827097|EXPERIMENTAL|Rectus sheath block group|"1. administration of denogan~2. rectus sheath block with 0.375% ropivacaine"
62488021|NCT02827097|PLACEBO_COMPARATOR|Control group|just administration of denogan
62488022|NCT05377164||Vegetarian group|
62488023|NCT05377164||Omnivorous group|
62330338|NCT03152136|NO_INTERVENTION|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
62488024|NCT05377164||Low carbohydrate group|
62488025|NCT02000388|OTHER|Ketorolac tromethamine (SPRIX)|A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
62488026|NCT02000388|OTHER|Standard of care|The intervention used will be standard of care
62488027|NCT04558450|OTHER|Group 1|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in intensive care unit
61935897|NCT05082831|ACTIVE_COMPARATOR|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery.
61935898|NCT05082831|NO_INTERVENTION|microfracture surgery only|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the microfracture surgery (standard of care).
61935899|NCT02496065|EXPERIMENTAL|BLZ-100|
61935900|NCT05921604|EXPERIMENTAL|Group 1 (baclofen)|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
61935901|NCT05921604|EXPERIMENTAL|Group 2 (gabapentin)|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
61935902|NCT01270542|EXPERIMENTAL|Avastin Injection Group (AIG)|Subjects in this group will get single 0.05 mL intravitreal injection of bevacizumab 1.25 mg 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
61935903|NCT01270542|SHAM_COMPARATOR|Sham Injection Group (SIG)|Subjects in this group will get a sham injection 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
61935904|NCT02693392|ACTIVE_COMPARATOR|Control|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up without add-on fenugreek extract.
61935905|NCT02693392|EXPERIMENTAL|Fenugreek|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up with add-on fenugreek extract.
61935906|NCT05847283|ACTIVE_COMPARATOR|DPOS protocol|Women will receive oral Dydrogesterone 10mg (Duphaston 10mg) t.i.d daily from the first day of ovarian stimulation till the day of final oocyte maturation.
62330339|NCT03707652|EXPERIMENTAL|Cohort A (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
62330340|NCT03707652|EXPERIMENTAL|Cohort A (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
62330341|NCT03707652|EXPERIMENTAL|Cohort A (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
62330342|NCT03707652|EXPERIMENTAL|Cohort A (oral supplement A)-1 or 4 capsules|Oral supplement A (1 or 4 capsules) administered daily for 3 days
62330343|NCT03707652|EXPERIMENTAL|Cohort A (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
61935907|NCT05847283|PLACEBO_COMPARATOR|GnRH antagonist protocol|Women will receive GnRH antagonist (Ganirelix 0.25mg) once subcutaneously daily from day 5 of ovarian stimulation till the day of final oocyte maturation
62488028|NCT04558450|OTHER|Group 2|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in a medicine unit
61935908|NCT04012125|EXPERIMENTAL|Prospective, single-arm trial|
61935909|NCT02612129|EXPERIMENTAL|Arimoclomol Single PK Dose|Participants less than 12 years received a single oral dose of arimoclomol capsule, based on participant's body weight, on Day 1.
62488029|NCT04558450|OTHER|Group 3|Patients with confirmed infection by SARS-Cov-2, not requiring hospitalization
62488030|NCT04558450|OTHER|Group 4|4) individuals having performed a test for SARS-Cov-2 infection, but resulted to be negative
61935910|NCT02612129|EXPERIMENTAL|Arimoclomol (12-month Double-blind Phase)|Participants received arimoclomol capsules orally three times a day (TID) for 12 months. The dose was 31-124 mg arimoclomol base TID (equivalent to 50-200 mg arimoclomol citrate TID), based on participant's body weight.
61935911|NCT02612129|PLACEBO_COMPARATOR|Placebo (12-month Double-blind Phase)|Participants received matching placebo capsules (with regard to weight, appearance, smell, flavor etc.) orally TID for 12 months.
61935912|NCT01851915|ACTIVE_COMPARATOR|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
61935913|NCT01851915|EXPERIMENTAL|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
61935914|NCT00632307||1|COPD
62330344|NCT03707652|EXPERIMENTAL|Cohort A (oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
62330345|NCT03707652|EXPERIMENTAL|Cohort B (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
62330346|NCT03707652|EXPERIMENTAL|Cohort B (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
62330347|NCT03707652|EXPERIMENTAL|Cohort B (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
62330348|NCT03707652|EXPERIMENTAL|Cohort B (oral supplement C)- 1 or 4 capsules|Oral supplement C (1 or 4 capsules) administered daily for 3 days
62330349|NCT03707652|EXPERIMENTAL|Cohort B (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
62330350|NCT03707652|EXPERIMENTAL|Cohort B(oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
62488031|NCT00779519|PLACEBO_COMPARATOR|Placebo|
62488032|NCT00779519|EXPERIMENTAL|TTP435|
62488033|NCT03198663|EXPERIMENTAL|POSSE Intervention|
62488034|NCT03198663|OTHER|Control|Delayed intervention
62330351|NCT03965663|EXPERIMENTAL|Trans-tibial Amputees|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living
62330352|NCT03965663|EXPERIMENTAL|Trans-tibial Amputees with TSR|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living. The subjects underwent a functional nerv-transfer surgery prior to participation, where the proximal part of the sural nerv was to the distal part of the saphenous nerv.
62330353|NCT05079282|EXPERIMENTAL|ONO-4685 monotherapy|Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy
62330354|NCT04516018|EXPERIMENTAL|Cold acclimation arm|An oral glucose tolerance test will be performed on day 1 of the study. The next day (day 2), subjects will be exposed to shivering thermogenesis for at least 1 hour. The day after, an oral glucose tolerance test will be performed (day 3). The following 9 days, subjects will be exposed daily to shivering thermogenesis for at least 1 hour (day 4-12). On the last day (day 13), an oral glucose tolerance test will be performed.
62330355|NCT02432287|EXPERIMENTAL|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
62330356|NCT02432287|EXPERIMENTAL|Placebo|Placebo
62330357|NCT03073655|EXPERIMENTAL|Group 1|it has been limited evidence of KT is effective
62330358|NCT03073655|EXPERIMENTAL|Group 2|it has been not known that KT is effective or not
62330359|NCT03073655|EXPERIMENTAL|Group 3|it has been known that KT has excellent result
62330360|NCT04258111|EXPERIMENTAL|IBI310 + Sintilimab|
62330361|NCT05131451|NO_INTERVENTION|Usual care with educational reinforcement|Standard of care referral to Eye Care Provider (ECP) for the diabetic eye exam with educational reinforcement
62330362|NCT05131451|EXPERIMENTAL|Diabetic Retinopathy Exam|Point of care (POC) Diabetic Retinopathy Exam using Autonomous AI on non-mydriatic fundus camera
61935915|NCT00632307||2|lung cancer
61935916|NCT00632307||3|airway infection
62330363|NCT04150874|EXPERIMENTAL|Lumason Microbubbles|Participants will receive an IV administrative of Lumason® microbubbles, prior to radioembolization. 2 doses of 2.5mL will be administered
62488035|NCT00789776|EXPERIMENTAL|Treatment (non-myeloablative transplant)|"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.~DONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.~POST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 to 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 to 84, followed by a taper until day 180 in the absence of GVHD.~NK CELL INFUSION: Patients undergo donor lymphocyte infusion of NK cells on day 7."
61935917|NCT00632307||4|interstitial lung disease
61935918|NCT00632307||5|sleep apnea
61935919|NCT00632307||6|pulmonary disorders with pleural infusions
61935920|NCT00632307||7|sarcoidosis
61935921|NCT00632307||8|healthy persons
62330364|NCT03144141|OTHER|Patients with the diagnosis of threat of uterine delivery|
62330365|NCT01825590||Subjects undergoing sodium alignment|Dialysate and serum sodium concentration aligned
62330366|NCT01825590||Subjects not undergoing sodium alignment|Dialysate and serum sodium concentration not aligned
62330367|NCT05302739|EXPERIMENTAL|Facial cooling|Between each simulated fencing match participants will spend the first 30 s of rest having a facial water mist sprayed onto the face with accompanying fanning from 50 cm away from the face.
62330368|NCT05302739|NO_INTERVENTION|Placebo|
62330369|NCT02077075|ACTIVE_COMPARATOR|Web-based weight loss program|Subjects will have access to a web-based weight loss program for an 8-week period.
62330370|NCT02077075|EXPERIMENTAL|On-line health coaching in addition to web-based program|Subjects will have access to the web-based wellness program and will also receive weekly personalized health coaching emails.
62330371|NCT05569304|EXPERIMENTAL|Endoscopic Sleeve Gastroplasty Arm|Prospective cohort of patients with classes 1 and 2 obesity that had consented to undergo endoscopic sleeve gastroplasty.
62330372|NCT05569304|NO_INTERVENTION|Retrospective cohort|Retrospective cohort of patients with classes 1 and 2 obesity who did not undergo endoscopic sleeve gastroplasty and had been put on GLP-1 analogues
62330373|NCT03200457|EXPERIMENTAL|Patients with hepatic iron overload or steatosis|Each patient (80) will have two MRI exams on the same day: one performed in common practice on a 1.5 Tesla device and the other on a 3 Tesla device.
62330374|NCT04398719|ACTIVE_COMPARATOR|CBD|
62330375|NCT04398719|PLACEBO_COMPARATOR|Placebo|
62330376|NCT02462304|EXPERIMENTAL|Combination Anti-VEGF and EPM laser|Subjects will receive both anti-VEGF injections and EPM laser.
61935922|NCT01885871|EXPERIMENTAL|Picosecond QS Nd:YAG Laser|Laser Treatment with Investigational Device
61935923|NCT06708234||single layer|patients who underwent caesarean section with hysteroraffia performed in single layer
61935924|NCT06708234||double layer|patients who underwent caesarean section with double-layer hysteroraffia
61935925|NCT01998815||Obese patients|Laparoscopic Roux-en-Y gastric bypass
61935926|NCT03265678||Arm|Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
61935927|NCT02080637|ACTIVE_COMPARATOR|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
61935928|NCT02080637|PLACEBO_COMPARATOR|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
61935929|NCT06676709|EXPERIMENTAL|I-CRP group|IMMUNEPOTENT-CRP (I-CRP) was supplied in a 5 Unit (U) per vial presentation. One U is defined as the lyophilized product obtained from the dialysis of 1×10\^8 bovine spleen cells. The dosing schedule extended over 14 days. On the first day (Day 0), outpatients ingested seven doses at two-hour intervals each one. From days one through four, four doses were taken one every four hours, and from days five to thirteen, three doses were consumed one every eight hours.
62135228|NCT00934817|EXPERIMENTAL|TR sequential group|Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
62135229|NCT00934817|ACTIVE_COMPARATOR|RT sequential group|Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
62488036|NCT04936529|EXPERIMENTAL|Group 1|Group 1 participants receive oral β-glucan (40 mg/kg/day x 14 days) starting week 1. This schedule includes annual booster vaccinations, with β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 \& #4-10). Participants will not receive GM-CSF.
62488037|NCT04936529|EXPERIMENTAL|Group 2|Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1. Participants also receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#9; and x5 days with vaccination #10. The treatment includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 \& #4-10)
62488038|NCT04936529|EXPERIMENTAL|Group 3|Group 3 will include participants who cannot be randomized (e.g., due to allergy to GMCSF). It will also include participants previously treated with this vaccine and oral β-glucan on the predecessor MSK protocol IRB# 05-075 or on this protocol (participants can therefore be enrolled more than one time on this protocol). These participants will be treated as in Group 1. Participants who are registered to Group 3 and have been previously treated with vaccine (in this protocol or MSK predecessor 05-075) will not receive vaccines 4 and 6. These patients will receive a total of 8 injections. The analyses in this group will be exploratory.
62488039|NCT03574051|EXPERIMENTAL|Probiotic|Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days
62488040|NCT06322485|EXPERIMENTAL|Internet-based self-management intervention|At the beginning of the treatment, a face-to-face introductory meeting is scheduled between the participant and a psychologist, where treatment goals will be set. Afterwards, a tailored self-management intervention, based on cognitive-behavioral methods, will be offered via an internet-based program. The psychologists offering the treatment have been trained in the tailored cognitive-behavioral protocol. One month and 2,5 months after finishing the online program, patients will be contacted by their treating psychologist for two booster sessions via telephone. Patients' goals will be evaluated and strategies to strengthen the achieved results will be discussed.
62488041|NCT06322485|NO_INTERVENTION|Waitlist|Patients in the control condition will be assigned to a waiting list and will receive the internet-based self-management intervention after the active treatment group (after 6 months).
62488042|NCT01760551||Patients assessed with AMA guide fifth edition|
62488043|NCT01760551||Patients assessed with AMA guide sixth edition|
62488044|NCT05203835|EXPERIMENTAL|Placebo and acebilustat|Participants will take acebilustat and placebo over a period of 9 months.
62488045|NCT01253564|EXPERIMENTAL|Single Arm|
62488046|NCT03797196|ACTIVE_COMPARATOR|group 1|standard tacrolimus with mycophenolate mofetil
62488047|NCT03797196|EXPERIMENTAL|group 2|low dose tacrolimus with everolimus
62488048|NCT03714373|EXPERIMENTAL|OLE DCCR|75 - 525 mg DCCR
62488049|NCT03714373|EXPERIMENTAL|RW DCCR|75 - 525 mg DCCR
62488050|NCT03714373|PLACEBO_COMPARATOR|RW Placebo|75 - 525 mg Placebo for DCCR
62488051|NCT05958433|ACTIVE_COMPARATOR|standard postoperative education.|These patients will receive stoma care and stoma education beginning on postoperative day1.
62488052|NCT05958433|EXPERIMENTAL|preoperative rehabilitation group|The rehabilitation group will receive preoperative stoma education in addition
61935930|NCT06676709|PLACEBO_COMPARATOR|Placebo control|The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP). The dosing schedule extended over 14 days. On the first day (Day 0), outpatients ingested seven doses at two-hour intervals each one. From days one through four, four doses were taken one every four hours, and from days five to thirteen, three doses were consumed one every eight hours.
61935931|NCT05077878||normal|Patients with non-orthodontic treatment and have no root resorption
61935932|NCT05077878||mild to moderate|Patients with orthodontic treatment and have mild to moderate root resorption
61935933|NCT05077878||severe|Child patients with non-orthodontic treatment and have severe root resorption
61935934|NCT04482712|PLACEBO_COMPARATOR|Placebo|Administration of placebo daily during hospitalization
61935935|NCT04482712|ACTIVE_COMPARATOR|Rapamycin|Administration of rapamycin (sirolimus) 1mg daily during hospitalization
61935936|NCT01781533|EXPERIMENTAL|algorithm|
61935937|NCT02516254|EXPERIMENTAL|fortified bread|daily intake of fortified bread (1000IU vitamin D per 50 g) plus placebo
62488053|NCT06227741|EXPERIMENTAL|concept mapping|utility of concept mapping as a learning tool for problem solving. As well, examine the effect of using concept mapping as a tool for problem based learning on students' Metacognitive Awareness, problem solving skills, , and self -directed learning at Zagazig Faculty of Nursing
61935938|NCT02516254|EXPERIMENTAL|supplement|daily intake of plain bread (50 g) plus supplement (1000 IU per tablet)
61935939|NCT02516254|PLACEBO_COMPARATOR|placebo|daily intake of plain bread plus placebo
61935940|NCT04926077|EXPERIMENTAL|Validation Arm|Participants will wear the DreamKit device (test device) while instrumented with an esophageal manometry catheter (reference standard) to record respiratory effort.
61935941|NCT02794012||At-Risk Rheumatoid Arthritis subjects|
61935942|NCT02794012||Early Rheumatoid Arthritis subjects|
61935943|NCT02794012||Healthy Controls|
61935944|NCT02794012||Non-Rheumatoid Arthritis Autoimmune Controls|
61935945|NCT05665023|EXPERIMENTAL|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
61935946|NCT01087242|PLACEBO_COMPARATOR|controlled group|Tang-min Lin analogue 6g,tid,po
61935947|NCT01087242|EXPERIMENTAL|Tang-min Lin pill|Tang-min Lin pills 6g,tid,po
61935948|NCT05809622|EXPERIMENTAL|Shoulder and scapular strengthening group|
61935949|NCT05809622|ACTIVE_COMPARATOR|Control group|
61935950|NCT02968511|EXPERIMENTAL|fecal microbiota transplant|250 mL of fecal transplant material by enema as treatment
62135230|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
62135231|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
62135232|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
61935951|NCT00877110|EXPERIMENTAL|chemotherapy, allogeneic NK cells, 3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.
62330377|NCT02462304|ACTIVE_COMPARATOR|Anti-VEGF monotherapy|Subjects will receive anti-VEGF injections monotherapy.
61935952|NCT02810340|EXPERIMENTAL|MCV-5 with adjuvant|Received a single intramuscular injection of Adjuvanted MCV-5.
61935953|NCT02810340|EXPERIMENTAL|MCV-5 without adjuvant|Received a single intramuscular injection of Non-Adjuvanted MCV-5.
61935954|NCT02810340|ACTIVE_COMPARATOR|Menactra®|Received a single intramuscular injection of Menactra.
61935955|NCT02490410|EXPERIMENTAL|whey protein|2 x 10g whey protein per day orally for 6 months
61935956|NCT02490410|OTHER|whey protein+soy protein|10g whey protein + 10g soy protein per day orally for 6 months
61935957|NCT02490410|OTHER|soy protein|2 x 10g soy protein per day orally for 6 months
61935958|NCT03361033||Medulloblastoma|Participants who are survivors of pediatric medulloblastoma and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
62135233|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
62135234|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
62135235|NCT02135679||Cohort 6|Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy
62135236|NCT02135679||Cohort 7|Patients with locally advanced NSCLC undergoing stereotactic radiotherapy followed by concurrent mediastinal chemoradiotherapy
62135237|NCT02129283|EXPERIMENTAL|Simulation training|End-of-life simulation training of critical care physicians and nurses using standardized patients to improve communication and interpersonal skills.
62135238|NCT02129283|NO_INTERVENTION|Control|No simulation training
62135239|NCT05128968|EXPERIMENTAL|Simple extension|After induction of anesthesia, endotracheal intubation was performed in simple extension without a pillow using a McGrath MAC videolaryngoscope.
62135240|NCT05128968|EXPERIMENTAL|Head elevated position|After induction of anesthesia, endotracheal intubation was performed in a head elevated position with a pillow using a McGrath MAC videolaryngoscope.
62135241|NCT05128968|EXPERIMENTAL|Sniffing position|After induction of anesthesia, endotracheal intubation was performed in a sniffing position using a McGrath MAC videolaryngoscope.
62135242|NCT01066767|EXPERIMENTAL|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited
62135243|NCT01066767|ACTIVE_COMPARATOR|Allegra|Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,
62135244|NCT02293733||Patients NSCLC EGFR mutated|This is an observational study, there is no intervention.
62135245|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
62135246|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
62135247|NCT01426412|EXPERIMENTAL|LY3015014 intravenously (IV)|A single dose of LY3015014 up to 10.0 milligrams per kilogram (mg/kg) administered IV
62135248|NCT01426412|EXPERIMENTAL|LY3015014 IV Japanese|Single dose of LY3015014 10.0 mg/kg administered IV to Japanese participants. Added per protocol amendment effective October, 2012.
62135249|NCT01426412|PLACEBO_COMPARATOR|Placebo IV|Administered IV once only
62135250|NCT01426412|EXPERIMENTAL|LY3015014 subcutaneously (SC)|A single dose of LY3015014 up to 3.0 mg/kg administered SC
62135251|NCT01426412|EXPERIMENTAL|LY3015014 SC + Statin|A single dose of LY3015014 up to 3 mg/kg administered SC in addition to participant's dose of statin
62330378|NCT05433389|ACTIVE_COMPARATOR|Breath Counting|
62330379|NCT05433389|EXPERIMENTAL|Body Scan|
62330380|NCT05433389|EXPERIMENTAL|Mindful Breathing|
62135252|NCT01426412|PLACEBO_COMPARATOR|Placebo SC|Administered SC once only
62135253|NCT02959229|EXPERIMENTAL|Early Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 1 of life and continued for 4-6 weeks.
62135254|NCT02959229|EXPERIMENTAL|Late Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 3 of life and continued for 4-6 weeks.
62135255|NCT02959229|ACTIVE_COMPARATOR|Placebo Group|placebo in form of distilled water once starting on day 1 of life and continued for 4-6 weeks.
62135256|NCT05318066|ACTIVE_COMPARATOR|Arm Fluids (FL)|500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.
62135257|NCT05318066|ACTIVE_COMPARATOR|Arm Vasopressor (VP)|Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.
62330381|NCT05433389|EXPERIMENTAL|Mindfulness of Pain|
62330382|NCT05433389|EXPERIMENTAL|Mindful Savoring|
62330383|NCT04655495|EXPERIMENTAL|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
62330384|NCT04655495|ACTIVE_COMPARATOR|Balanced gluten free diet|Balanced gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients.
62330385|NCT00736710|EXPERIMENTAL|1|
62330386|NCT00736710|SHAM_COMPARATOR|2|
62330387|NCT00926055|NO_INTERVENTION|Control|
62330388|NCT00926055|ACTIVE_COMPARATOR|Ezetimibe|
62488054|NCT06227741|NO_INTERVENTION|traditional learning experience|utility of traditional learning experience as a learning tool
62488055|NCT04934007|EXPERIMENTAL|Active stimulation|Active rTMS stimulation , 2 session per day during 10 days.
62488056|NCT04934007|SHAM_COMPARATOR|Sham Stimulation|Sham rTMS stimulation , 2 session per day during 10 days.
62488057|NCT03640741||Laparoscopy|The group consists of patients who undergoes laparoscopy procedure during which changes in cerebral oxygenation are estimated.
62488058|NCT04092387|EXPERIMENTAL|RC 1 only|Research cigarettes #1
62488059|NCT04092387|EXPERIMENTAL|RC 2 only|Research Cigarettes #2
62488060|NCT04092387|EXPERIMENTAL|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
62488061|NCT04092387|EXPERIMENTAL|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
62488062|NCT05882630|EXPERIMENTAL|Surufatinib Combined With Serplulimab and EC Chemotherapy|
62488063|NCT01949922|EXPERIMENTAL|Injection of autologous muscle fibers in the anal sphincter|All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
62488064|NCT03633214|ACTIVE_COMPARATOR|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
62488065|NCT03633214|NO_INTERVENTION|No training module (Control)|
62488066|NCT03406845|EXPERIMENTAL|Chair-side mindfulness intervention|Consists of individually conducted meditative practices, lasting 20 minutes/session, 3 times per week for 8 weeks. The interventions will be conducted during their dialysis sessions. The mindfulness meditation sessions include well-described meditations such as the body scan (being aware of bodily sensation), gentle arm movements, guided and silent breath meditations.
62488067|NCT03406845|ACTIVE_COMPARATOR|Health Enhancement Plan (HEP)|Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
62488068|NCT01177657||Gastroenteritis cohort|Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis
62488069|NCT01177657||Hospital control cohort|Children hospitalized for non gastroenteritis causes
62488070|NCT01177657||Neighbourhood control cohort|Children without any symptoms of gastroenteritis or severe gastroenteritis
62488071|NCT03616379|PLACEBO_COMPARATOR|Psychoeducational Control|
62488072|NCT03616379|EXPERIMENTAL|Affect Regulation Condition|
62488073|NCT03616379|EXPERIMENTAL|Affect Labelling Condition|
62488074|NCT01679158|EXPERIMENTAL|Continuous Horizontal row|Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum
62488075|NCT01679158|EXPERIMENTAL|"Reduction in ring opening"|"Use the IOP system from USGI to install suture anchors to reduce the ring opening to the antrum"
62135258|NCT01323166||Excision of the levator muscle|The abdominal part of the operation is performed as an TME and the perineal part of the operation is performed with the intent to get a cylindrical specimen thus removing part of or the entire levator muscle with the specimen
62488076|NCT01679158|EXPERIMENTAL|Control Arm|Use the IOP system from USGI to install suture anchors in the Current V shape in distal body
62135259|NCT01323166||Traditional perineal operation|The abdominal part of the operation performed as a TME. The perineal operation performed with the intent of removing the tumour with CRM free of tumour and the levator left in place
62135260|NCT04291638|EXPERIMENTAL|Remote Caregiver Training|The Remote Caregiver Training arm consists of participation in a 5-hour, videoconferencing-based caregiver training program.
62135261|NCT04291638|EXPERIMENTAL|Remote Caregiver Training + Intensive Treatment|The Remote Caregiver Training + Intensive Treatment arm consists of participation in a 5-hour, videoconferencing-based caregiving training program, followed by participation in the videoconferencing-based intensive group behavioral treatment program.
62488077|NCT05782439|EXPERIMENTAL|Healthy adults|Manual and instrumental evaluation to identify if there is an equal or different stiffness between the right and left ileotibial band.
62488078|NCT01604239|EXPERIMENTAL|Shinbaro|
62488079|NCT00470691|EXPERIMENTAL|complete plaster cast|reduction and a complete plaster cast,
62488080|NCT00470691|ACTIVE_COMPARATOR|dorsal plaster splint|reduction and a dorsal plaster splint.
62488081|NCT04273386|EXPERIMENTAL|Evaluation|Cases will be evaluated for oral health and data will be recorded.
62488082|NCT00765635|EXPERIMENTAL|2|Taponoto ® (potassium carbonate 20 mg/1 ml, ethyl alcohol, glycerol 480, thymol 0.4; Teofarma Iberica S.A., Barcelona, Spain),
62488083|NCT00765635|PLACEBO_COMPARATOR|3|sterile saline solution (NaCl 0.9%, Braun Medical SA, Barcelona, Spain).
62488084|NCT00765635|EXPERIMENTAL|1: Chlorobutanol|ceruminolytic product, Otocerum® (Chlorobutanol 50 mg/1 ml, phenol 10 mg/1 ml, turpentine essence 0.15 ml/1 ml, ethyl alcohol; Reig Jofre laboratories, Barcelona, Spain),
62488085|NCT04492930|ACTIVE_COMPARATOR|Comparator|Time restricted eating
62488086|NCT04492930|EXPERIMENTAL|Intervention|Time restricted eating
62488087|NCT00171145|EXPERIMENTAL|1|Darifenacin
62488088|NCT00171145|PLACEBO_COMPARATOR|2|Placebo
62488089|NCT05385835||1Nurses|"The research is a pre-post-test observation study without a control group, aiming to determine the effect of the training given to nurses on the knowledge and practices of brachial artery blood pressure measurement.~The research is carried out with a group of 60 nurses."
62488090|NCT02665780|EXPERIMENTAL|Treatment|Periodontal debridement, tongue cleaning, mouth rinsing with 20ml Cetylpyridium Chloride daily for 24 weeks
62693805|NCT03503331|EXPERIMENTAL|[C-11]PiB-PET/MRI|All participants in this study will undergo an amyloid-PET imaging using the tracer \[C-11\]PiB with a simultaneous PET/MRI system. The \[C-11\]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
62693806|NCT00130390|EXPERIMENTAL|1|One nitazoxanide 500 mg tablet twice daily for 28 days
62330389|NCT00926055|EXPERIMENTAL|Ezetimibe/Simvastatin|
62330390|NCT01743339|ACTIVE_COMPARATOR|Control|Control (brief check-in calls) and Cognitive Processing Therapy (12 individual weekly sessions)
62330391|NCT01743339|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (4 individual therapy sessions over 5 weeks) and Cognitive Processing Therapy (12 individual weekly sessions)
62330392|NCT05129813||Buprenorphine MOUD in FQHC|Participants receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center. Recovery Guide counseling is provided weekly.
62330393|NCT05129813||Telemedicine Provision of Buprenorphine MOUD in a community site|Participants receiving buprenorphine treatment provided by telemedicine from a hub clinic and Recovery Guide counseling in a church or faith-based community organization. Recovery Guide counseling is provided weekly.
62488091|NCT04807777|EXPERIMENTAL|Ruxolitinib|"In a safety lead-in of 6 patients, subjects will receive 15mg of ruxolitinib twice daily (BID). After 4 weeks, if dose-limiting toxicities (DLT) are observed in 1 or fewer patients, the study will enter stage 1 of the Simon two-stage design where all subsequent patients will receive a starting dose of ruxolitinib 15mg BID.~Subjects will have regularly scheduled study visits at the clinical site on Day 1 and Day 15 (± 3 days) of the first 2 cycles, then on Day 1 (± 3 days) of every subsequent cycle (starting cycle 3), where safety assessments, including laboratory assessments, vital signs, and physical examinations will be performed."
62693807|NCT00130390|PLACEBO_COMPARATOR|2|One placebo tablet twice daily for 28 days
61935959|NCT03361033||Other Brain Tumors|Participants who are survivors of other pediatric brain tumors (excluding medulloblastoma and craniopharyngioma), who have not been treated with craniospinal irradiation (CSI), and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
61935960|NCT06316115|NO_INTERVENTION|Wound debridement of patients with diabetic foot ulcers|No Intervention: The patient's pain and anxiety will be evaluated by a nurse independent of the research before and during the debridement procedure, without any intervention to the patients
61935961|NCT06316115|EXPERIMENTAL|Patients with diabetic foot ulcers using stress balls during wound debridement|Intervention Group: Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
61935962|NCT05467176||Participants with Prostate Cancer|Patients with prostate cancer who are initiating treatment or have initiated treatment with ORGOVYX (per label instructions) within 1 month prior to enrollment and who remain on treatment at the time of enrollment.
61935963|NCT04319731|EXPERIMENTAL|Treatment|"Treatment groups:~1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)"
61935964|NCT04708600|EXPERIMENTAL|Group 1|Sham therapy Intervention 1: PET Intervention 2: ART
61935965|NCT04708600|EXPERIMENTAL|Group 2|Sham therapy Intervention 1: ART Intervention 2: PET
61935966|NCT02031211|PLACEBO_COMPARATOR|Placebo|0.4 ml/kg of normal saline will be administered subcutaneously.
62330394|NCT04019093|EXPERIMENTAL|Jaw pain patients|Individuals seeking care for jaw pain, including temporomandibular joint and muscle disorder (TMD).
62330395|NCT04019093|EXPERIMENTAL|Healthy controls|Healthy social drinkers without jaw pain recruited as a comparison group.
62330396|NCT00837512|EXPERIMENTAL|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
61935967|NCT02031211|EXPERIMENTAL|Etanercept|Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.
61935968|NCT03637179|EXPERIMENTAL|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
61935969|NCT03637179|EXPERIMENTAL|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
61935970|NCT00739999|OTHER|1|6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.
61935971|NCT00739999|OTHER|2|10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.
62135262|NCT02095717|EXPERIMENTAL|Curcumin|curcumine capsule
61935972|NCT04104529|EXPERIMENTAL|Biological collection|"Biological collection~For all the patients include in the study :~samples of blood samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database~Ancillary study :~For metastatic thyroïd cancer and neuroendocrine tumor : anapath blocks of the initial diagnosis will be archived and dosimetric data will be collected for the cycle 1 For neuroendocrine tumor : blood sample additionnal will be realized at the cycle 1 (pre and post treatment)"
62135263|NCT02095717|PLACEBO_COMPARATOR|Placebo|placebo capsule
62330397|NCT00837512|ACTIVE_COMPARATOR|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
62330398|NCT05047640|EXPERIMENTAL|BNT162b2 vaccine Group|Participants in this arm will receive one booster dose of the BNT162b2.
62330399|NCT05047640|EXPERIMENTAL|JNJ-78436735 vaccine Group|Participants in this arm will receive one booster dose of the JNJ-78436735
62330400|NCT02774226|EXPERIMENTAL|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
62488092|NCT04985149|OTHER|Grup 1; participants with fibromyalgia|Participants with fibromyalgia
62488093|NCT04985149|OTHER|Grup 2: patients without fibromyalgia|Patients without fibromyalgia
62488094|NCT00736190|EXPERIMENTAL|TDF|300-mg tablet (marketed formulation) taken orally once daily
62488095|NCT04069936|EXPERIMENTAL|MILs™ - NSCLC plus nivolumab with or without tadalafil|Locally advanced and unresectable and metastatic NSCLC subjects previously treated with anti-programmed cell death-1 (PD-1) will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil.
62488096|NCT06144034|EXPERIMENTAL|Epilepsy patients|1 and 3 quadrants got the same treatment and 2 and 4 got the same treatment. Air polishing with erythritol powder was used to remove biofilm and EMS ultrasonic scaler to remove calculus if present. also rubber cup and prophylaxis paste spearmint (Kemdent Works, Purton. Swindon, Wiltshire. SN5 4HT, UK). and EMS ultrasonic scaler to remove calculus if present.
62488097|NCT06144034|EXPERIMENTAL|Non-epileptic pateints|1 and 3 quadrants got the same treatment and 2 and 4 got the same treatment. Air polishing with erythritol powder was used to remove biofilm and EMS ultrasonic scaler to remove calculus if present. also rubber cup and prophylaxis paste spearmint (Kemdent Works, Purton. Swindon, Wiltshire. SN5 4HT, UK). and EMS ultrasonic scaler to remove calculus if present.
62488098|NCT04185857||Patients with primary aldosteronism (PA)|"After two biochemical and clinical evaluations under baseline conditions PA patients will be treated with canrenone 50-100 mg orally once a day.~After one month of such therapy they will undergo the a clinical and biochemical evaluation (FW1). After, they will continue with a combination therapy with canrenone, plus olmesartan starting with 10 mg a day for oral administration, a dose that can be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2)."
62488099|NCT01675115|ACTIVE_COMPARATOR|BNG-1 plus Aspirin|BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks
62488100|NCT01675115|SHAM_COMPARATOR|Aspirin|Aspirin 100mg QD for 4 weeks
62330401|NCT02774226|EXPERIMENTAL|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
61935973|NCT06327659|ACTIVE_COMPARATOR|Group I|
61935974|NCT06327659|EXPERIMENTAL|Group II|
61935975|NCT00398827|EXPERIMENTAL|Dexmedetomidine 0.5 mcg/kg load|
62330402|NCT02351245||lip hemangiomas|
62330403|NCT03387904|EXPERIMENTAL|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62488101|NCT01374451|EXPERIMENTAL|Paseriotide LAR + Everolimus|everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
62488102|NCT01374451|EXPERIMENTAL|Everolimus|everolimus 10 mg once daily po alone
62488103|NCT05308186|EXPERIMENTAL|Auditory stimulation|Exposing the patient to an audio-based stimulus.
61935976|NCT00398827|EXPERIMENTAL|Dexmedetomidine 1 mcg/kg load|
61935977|NCT00398827|PLACEBO_COMPARATOR|Placebo|
61935978|NCT02809326|EXPERIMENTAL|17 week Trauma Management Therapy (TMT)|TMTconsists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions (14 sessions) are followed by Social and Emotional Regulation (SER) sessions conducted in small groups. Individual exposure therapy includes virtual reality to assist in augmenting exposure therapy. Group therapy includes anger management, social skills training, problem solving and behavioral activation for depression. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
62135264|NCT02378922|EXPERIMENTAL|Treatment (gene-modified stem cells)|"CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.~STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.~Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells."
62135265|NCT04355221|ACTIVE_COMPARATOR|Group A|using the standard settings of pulsed radiofrequency technique (PRFT). two cycles, each one for 2 minutes at 45 Volts (V) with a pulse width of 10 milliseconds (ms) and a pulse frequency of 4 Hertz (Hz). The cut-off needle tip temperature is set at 420 Celsius (C).
62135266|NCT04355221|EXPERIMENTAL|Group B|using prolonged duration of PRFT. four cycles, each one for 2 minutes at 45V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
62135267|NCT04355221|EXPERIMENTAL|Group C|using higher voltage PRFT.. two cycles, each one for 2 minutes at 60V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
62135268|NCT02162225|EXPERIMENTAL|Beet Juice|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
62135269|NCT06244771|EXPERIMENTAL|FMC-376|Dose Escalation, Dose Expansion, and Cohort Expansion; Administered for 21-day cycle
62135270|NCT01929759|OTHER|Drug switching|Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
62135271|NCT04453332|ACTIVE_COMPARATOR|Oral hormone therapy|Estradiol 1mg and micronized natural progesterone 200mg 14 days a month (oral)
62135272|NCT04453332|ACTIVE_COMPARATOR|Non-oral hormone therapy|Percutaneous estradiol gel 1.5mg and micronized progesterone 200mg vaginal 14 days a month (non-oral)
62135273|NCT00569387|EXPERIMENTAL|Vaccine group|
62135274|NCT02273999|NO_INTERVENTION|Control Group (no device)|No devices were delivered after third molar tooth extraction
62330404|NCT03387904|ACTIVE_COMPARATOR|Irinotecan|Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62488104|NCT05308186|EXPERIMENTAL|Auditory and tactile stimulations|Combination of tactual and audio-based stimuli.
62488105|NCT02764853|EXPERIMENTAL|STEP-AD (10 sessions)|"Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled Striving Towards EmPowerment and Medication Adherence."
62488106|NCT02764853|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive 1 session of Lifesteps and appropriate services and referrals as needed, followed by bi-weekly check-ins with a study research assistant.
61935979|NCT02809326|EXPERIMENTAL|3 week Trauma Management Therapy (TMT)|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
61935980|NCT02809326|ACTIVE_COMPARATOR|17 week Exposure Therapy Control Arm|The Control Arm of the study contains 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
62330405|NCT06471465|EXPERIMENTAL|Experimental arm|"Experimental: bevacizumab + prednisolone~The patient will receive bevacizumab 7.5 mg/kg IV given on Q3W for4 cycles or until progression of radionecrosis or unacceptable adverse event.~Once the patient has started the study treatment, the dose of prednisolone will be tapered every 7 days beginning at C2D1 (at least 10 mg prednisolone or equivalent), depending on tolerance.~If the patient weighs more than 100 kg, the tapering can be increased by 10 to 20 mg per week for the first 3 months.~Interventions:~Drug: bevacizumab Drug : prednisolone"
62330406|NCT06471465|PLACEBO_COMPARATOR|Placebo arm|"Placebo arm: placebo + prednisolone~The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on on Q3W for4 cycles or until progression of radionecrosis or unacceptable adverse event.~Once the patient has started the study treatment, the dose of prednisolone will be tapered every 7 days beginning at C2D1 (at least 10 mg prednisolone or equivalent), depending on tolerance.~If the patient weighs more than 100 kg, the tapering can be increased by 10 to 20 mg per week for the first 3 months.~Interventions:~Drug: placebo Drug : prednisolone"
62330407|NCT01741272|ACTIVE_COMPARATOR|Group A (Usual Care)|Will be immobilized in a sling for 6 weeks. Intervention: Procedure: Sling
62330408|NCT01741272|EXPERIMENTAL|Group B (Early ROM)|Will use the sling for comfort only. Intervention: Procedure: No sling
62330409|NCT02636348|EXPERIMENTAL|Calcium/Vitamin D Bar|Dietary supplement consumed as 2 calcium and vitamin D fortified snack bars per day
62488107|NCT01530048|EXPERIMENTAL|U200|
62488108|NCT01530048|ACTIVE_COMPARATOR|U100|
62488109|NCT01151280|EXPERIMENTAL|WallFlex Biliary Fully Covered Stent|All eligible patients entered into the study will be treated with a WallFlex Biliary Fully Covered Stent
61935981|NCT01736020|PLACEBO_COMPARATOR|Placebo|Placebo
61935982|NCT01736020|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine intravenous infusion during scan.
61935983|NCT01736020|EXPERIMENTAL|Propofol|Propofol intravenous infusion during scan.
61935984|NCT01736020|EXPERIMENTAL|Ketamine|Ketamine intravenous infusion during scan.
61935985|NCT01736020|EXPERIMENTAL|Nitrous Oxide|Nitrous Oxide inhalation during scan.
61935986|NCT01323946|EXPERIMENTAL|GSK1562902A 6 to 12 M Group|Subjects between 6 and 12 months of age (6 to 12 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
61935987|NCT01323946|EXPERIMENTAL|GSK1562902A 12 to 24 M Group|Subjects between 12 and 24 months of age (12 to 24 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
62135275|NCT02273999|PLACEBO_COMPARATOR|Placebo group (Inactivated device)|Inactivated devices were delivered after third molar tooth extraction
62135276|NCT02273999|EXPERIMENTAL|Test (activated device)|Activated devices were delivered after third molar tooth extraction
62330410|NCT02636348|EXPERIMENTAL|Calcium/Vitamin D Pill|Dietary supplement consumed as several capsules per day
62330411|NCT02636348|PLACEBO_COMPARATOR|Placebo Bar|Placebo consumed as 2 isocaloric, unfortified snack bars per day
62330412|NCT02636348|PLACEBO_COMPARATOR|Placebo Pill|Placebo consumed as several capsules per day
62330413|NCT04035135|EXPERIMENTAL|Open Label Treatment Arm|One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.
62330414|NCT00300300|NO_INTERVENTION|1|applying a patellar graft using conventional surgical technique.
62330415|NCT00300300|NO_INTERVENTION|2|applying a hamstring graft using conventional surgical technique.
62330416|NCT00300300|EXPERIMENTAL|3|applying a patellar graft using a computer-assisted surgy technique.
62330417|NCT00300300|EXPERIMENTAL|4|hamstring graft CAOS
62330418|NCT04883580|EXPERIMENTAL|experimental group|
62330419|NCT04883580|ACTIVE_COMPARATOR|control group|
62488110|NCT04143607|EXPERIMENTAL|ASK120067+ placebo Gefitinib|ASK120067 (80 mg orally, twice daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
62488111|NCT04143607|ACTIVE_COMPARATOR|Gefitinib + placebo ASK120067|Gefitinib (250 mg orally, once daily) plus placebo ASK120067 (80 mg orally, twice daily), in accordance with the randomization schedule.
62488112|NCT04785963|EXPERIMENTAL|Music with Suggestion|Active condition where participants will be provided with recordings of pre-determined music in addition to recorded suggestions instructing the participant on how to listen to the music.
62488113|NCT04785963|ACTIVE_COMPARATOR|Music|Control group where participants will be provided recordings of pre-determined music
62488114|NCT04785963|ACTIVE_COMPARATOR|Pain Information|Non-arts group receiving structured attention and standard care
62488115|NCT01439620|EXPERIMENTAL|OFDI imaging|Subject will swallow an OFDI capsule and images will be obtained using MGH Optical Frequency Domain Imaging (OFDI) imaging system.
62693808|NCT03539614|EXPERIMENTAL|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
62330420|NCT01327040|EXPERIMENTAL|sensitization duration 1.375h|This group will experience a 1.375h sensitization duration prior to the 12h light exposure
62488116|NCT01528735|EXPERIMENTAL|BI 207127 NA, BI 201335 NA(high dose), R|Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
62488117|NCT01528735|EXPERIMENTAL|BI 207127 NA,BI 201335 NA(low dose),RBV|Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
61935988|NCT01323946|EXPERIMENTAL|GSK1562902A 24 to 36 M Group|Subjects between 24 and 36 months of age (24 to 36 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
61935989|NCT05201742|ACTIVE_COMPARATOR|Inspiratory muscle trainer|Inspiratory muscle trainer group - Inspiratory muscle training was performed.
61935990|NCT05201742|ACTIVE_COMPARATOR|Incentive spirometer|Incentive spirometer group - Incentive spirometry was performed.
62135277|NCT05933213|EXPERIMENTAL|Mescaline sodium enteric-coated tablets group|"Treating with glucocorticoids + mescaline sodium enteric-coated tablets~(1) Induction period: Prednisone tablets: orally, recommended dose 0.4-0.8 mg/kg/d, with gradual dose reduction (10% per month) at the end of 3-6 months; mescaline sodium enteric-coated tablets: orally, twice a day, at 720-1440 mg/d, for 3-6 months; (2) Maintenance period: Prednisone tablets 5-7.5 mg/d, mescaline sodium enteric-coated tablets 360-540mg/d, maintenance treatment for 1 year"
62135278|NCT05933213|ACTIVE_COMPARATOR|Morte-mescaline group|"Treating with glucocorticoids + morte-mescaline~1. Induction period: Prednisone tablets: oral, recommended dose 0.4-0.8 mg/kg/d, with gradual dose reduction (10% per month) at the end of 3-6 months; mortifamate: oral, twice a day, dose 1-2 g/d, 3-6 months;~2. Maintenance period: Prednisone tablets 5-7.5 mg/d, mortifamate 0.5-0.75 g/d, with maintenance treatment for 1 year."
62135279|NCT02860741|EXPERIMENTAL|Intervention|Churches in the REJOICE intervention arm will provide the REJOICE intervention over an 8 week period
62135280|NCT02860741|OTHER|Control|Churches in the control arm will receive an educational materials about both identifying depressive symptoms and managing depressive symptoms. This is consistent with self-management interventions commonly utilized for individuals experiencing subclinical levels of depressive symptoms.
62135281|NCT06225310|OTHER|Experimental: Selinexor/Ruxolitinib/Steroids|The regimen will follow a 3+3 dose escalation schedule starting at dose level 0. Subjects enrolled at dose level 0 will receive 1) selinexor (once weekly) starting at 40 mg, 2) ruxolitinib (twice a day (BID) on days 1-28) starting at 10 mg, and 3) oral methylprednisolone (every other day (QOD)) a set dose at 40 mg. Subjects at dose level 1 will receive 1) selinexor (once weekly) 60 mg, 2) ruxolitinib (BID) on days 1-28 10 mg, and 3) methylprednisolone (QOD) 40 mg. Subjects at dose level 2 will receive 1) selinexor (once weekly) 60 mg, 2) ruxolitinib (BID) on days 1-28 15 mg, and 3) oral methylprednisolone (QOD) 40 mg.
62135282|NCT04294862|EXPERIMENTAL|TNP-2092 300mg IV|TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose
62330421|NCT01327040|EXPERIMENTAL|sensitization duration 5.5h|This group will experience a 5.5h sensitization duration prior to the 12h light exposure
62488118|NCT03625973|EXPERIMENTAL|16 Weeks of 3D-RT|Participants will receive 16 weeks of Reminiscence Therapy using 3D printed objects as stimuli.
62488119|NCT03625973|EXPERIMENTAL|8 Weeks of 3D-RT|Participants will receive 8weeks of Reminiscence Therapy using 3D printed objects as stimuli and 8 weeks of RT using verbal stimuli.
62488120|NCT03625973|ACTIVE_COMPARATOR|16 Weeks of RT using Verbal Stimuli|Participants will receive 16 weeks of RT using verbal stimuli to reminiscence.
61935991|NCT01589328|EXPERIMENTAL|Early Palliative care|"The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
62135283|NCT01259557|EXPERIMENTAL|Botulinum toxin type A(Meditoxin®)|
62135284|NCT06699004||İn our study there is only one group, and no intervention was made.|İn our study there is only one group, and no intervention was made.
62135285|NCT05316766|EXPERIMENTAL|Intervention|Will receive intervention through the multi-user touch surface
62135286|NCT05316766|ACTIVE_COMPARATOR|Treatment as usual|This will receive conventional therapy
62135287|NCT03866967|EXPERIMENTAL|AK105|Subjects receive AK105 200 mg intravenously (IV) once every 2 weeks (Q2W) until progression.
62330422|NCT01327040|EXPERIMENTAL|sensitization duration 22h|This group will experience a 22h sensitization duration prior to the 12h light exposure
62330423|NCT01327040|EXPERIMENTAL|sensitization duration 0.33h|This group will experience a 0.33h sensitization duration prior to the 12h light exposure
62330424|NCT01918098|EXPERIMENTAL|Oxycodone/naloxone prolonged release tablets|Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
62330425|NCT01918098|ACTIVE_COMPARATOR|Oxycodone prolonged release tablets|Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
62330426|NCT01406210||Prospective Group|Those patients that will be consented and data collected prospectively
62330427|NCT01406210||Retrospective Group|Those charts that will be utilized to collect retrospective data, waiver of consent will be granted by the IRBs.
62330428|NCT05745896|ACTIVE_COMPARATOR|Usual Care|Pregnants at usual care attending appointments in-person.
62330429|NCT05745896|EXPERIMENTAL|Telemedicine Prenatal Care|Pregnants under telemedicine based group attending at least 6 in-person outpatient clinic appointments and the remaining ones (i.e., 3) online.
62488121|NCT01094457|ACTIVE_COMPARATOR|standard group|patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
61935992|NCT01589328|NO_INTERVENTION|Contol: usual oncologic care|Patients randomly assigned to usual oncologic care were not scheduled to meet with the palliative care service unless a meeting was requested by the patient, the family, or the oncologist; those who were referred to the service did not cross over to the early palliative care group or follow the specified palliative care protocol.
61935993|NCT06517563|EXPERIMENTAL|UFH Cohort|Subjects will be administered 2 single doses of 5000 IU UFH i.v. on Day 1 and Day 5, oral doses of the DOAC Rivaroxaban QD from Day 2 until the morning of Day 5, and one single dose of 170 mg VMX-C001 i.v. on Day 5.
61935994|NCT06517563|EXPERIMENTAL|LMWH Cohort|Subjects will be administered 2 single doses of 40 mg Enoxaparin s.c. on Day 1 and Day 4, and one single dose of 170 mg VMX-C001 i.v. on Day 4.
62330430|NCT04115033|EXPERIMENTAL|True CES|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to cranial electrical stimulation (CES), which involves transfer of current from the alpha-stim device using earclip electrodes. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The treatments can be self administered by the participants. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
62488122|NCT01094457|EXPERIMENTAL|intensive group|patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
62693809|NCT03539614|EXPERIMENTAL|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
61935995|NCT01632137|PLACEBO_COMPARATOR|Placebo (vehicle)|
61935996|NCT01632137|EXPERIMENTAL|Rebamipide 2% ophthalmic suspension|
61935997|NCT06709729|EXPERIMENTAL|Control-IQ or Smartguard system|Patients with use of the Control-IQ system or Smartguard system (closed-loop hybrid system) and previous users of AndroidAPS (closed-loop hybrid system)
61935998|NCT02963831|EXPERIMENTAL|Cohort A: ONCOS-102 Dose Escalation|"ONCOS-102, 1 x 10\^11 viral particles (VPs) monotherapy for 6 weeks, followed by durvalumab 1500 mg starting on Day 71.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered intravenously (IV) 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused intraperitoneally (IP) in a total volume of 500 mL saline (0.9 mg/mL sodium chloride \[NaCl\] in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose every 4 weeks (Q4W) for 10 cycles, starting on Day 71.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
61935999|NCT02963831|EXPERIMENTAL|Cohort B: ONCOS-102 Dose Escalation|"ONCOS-102, 1 x 10\^11 VPs + durvalumab 1500 mg starting on Day 15.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused IP in a total volume of 500 mL saline (0.9 mg/mL NaCl in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose Q4W for 12 cycles, starting on Day 15.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
62135288|NCT03972046|EXPERIMENTAL|T-Vec + BRAF/MEK|"Participants will begin taking the following 3 medications:~BRAF Inhibitor dabrafenib 150 mg by mouth twice a day; MEK inhibitor trametinib 2 mg by mouth once a day; Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection (Dose #1: 10\^6 PFU/mL; Dose #2: 10\^8 PFU/mL 21 (+3) days after first dose; Subsequent doses: 10\^8 PFU/mL every 14 (+/-3) days).~Dosing to continue for at least 3 months, or up to 6 months if no plateau in response.~May stop earlier than 3 months at physician discretion depending on side effects and response.~Ultrasound of tumor nodal basin(s) monthly.~Labs every 4 weeks: CBC with differential, CMP, LDH CT of chest/abdomen/pelvis every 3 months.~PET CT or brain MRI as needed at discretion of the investigator.~Manual tumor measurement in office prior to each injection."
62330431|NCT04115033|SHAM_COMPARATOR|Sham CES|Veterans with fibromyalgia who meet study criteria and are randomized to the sham comparator group will receive standard therapy in addition to a CES device that does not deliver active electrical stimulation. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
62330432|NCT02532361||Cohort 1 / Hysteroscopic device placement|Patients that had undergone sterilization through hysteroscopic device placement
62330433|NCT02532361||Cohort 2 / Tubal ligation|Patients that had undergone sterilization through tubal ligation
62330434|NCT00441558|EXPERIMENTAL|flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
62488123|NCT03407209|SHAM_COMPARATOR|PEIB - Use of local levobupivacaine anesthetics: 0.625 mg / ml|"* automatic hourly bolus: 8ml (5mg) on 3 min~* patient controlled bolus: 8ml (5mg) on 3 min~* refractory period: 8min~* continuous infusion: 0~* maximum dose: 65mg/4h"
62330435|NCT05678413|ACTIVE_COMPARATOR|DVIU with paclitaxel|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
62693810|NCT01751425|EXPERIMENTAL|Treatment (TKIs, ruxolitinib)|Participants receive commercially available TKIs (imatinib mesylate, nilotinib, or dasatinib) as they had been receiving during the last 6 months and ruxolitinib PO BID. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62693811|NCT05835323|EXPERIMENTAL|Robotic-assisted mini-Percutaneous Nephrolithotomy (PCNL)|Participants with kidney stones will be enrolled for robotic-assisted mini-percutaneous nephrolithotomy procedure using the MONARCH Platform, Urology for removal of kidney stones. The MONARCH Platform, Urology enables electro-mechanical articulation and precise control of a flexible ureteroscope and/or a flexible mini-PCNL suction catheter for visualization and access to the urinary tract for diagnostic and therapeutic procedures.
62693812|NCT06592001|EXPERIMENTAL|AtaCor EV-ICD Lead System|Subjects implanted with the Atala™ lead
62693813|NCT06505395|EXPERIMENTAL|SYHX2008 injection|
61936000|NCT02963831|EXPERIMENTAL|Cohort 1: Epithelial Ovarian Cancer|"ONCOS-102, 3 x 10\^11 VPs + durvalumab 1500 mg starting on Day 15.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused IP in a total volume of 500 mL saline (0.9 mg/mL NaCl in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose Q4W for 12 cycles, starting on Day 15.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
62135289|NCT00701701|EXPERIMENTAL|Regimen A: Alglucosidase alfa and Cyclophosphamide|Participants exhibiting clinical decline since starting alglucosidase alfa (Myozyme®) therapy and having inhibitory antibodies and/or a sustained high recombinant human acid alpha-glucosidase (rhGAA) antibody titer (defined as at least 2 titers greater than or equal to \[\>=\] 25,600 obtained at least 1 month apart), regardless of their CRIM status, were assigned to Regimen A. In Regimen A, participants received alglucosidase alfa (Myozyme®) Intravenous (IV) infusion of 20 milligram per kilogram (mg/kg) every other week (qow) for a minimum of 18 months or, until the participant reached the age of 2 years (if the participant was less than \[\<6\] months of age at the time of enrollment). In addition, cyclophosphamide 250 milligram per square meter (mg/m\^2) IV infusion was administered every 4 weeks (q4w) after Myozyme® infusion for 6 months.
62330436|NCT05678413|ACTIVE_COMPARATOR|DVIU|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue.
62330437|NCT04126967|OTHER|allo-PBSCT patients with no NGS text|
62330438|NCT01300611|EXPERIMENTAL|TXA127 300 mcg/kg/day|Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
62330439|NCT01300611|EXPERIMENTAL|TXA127 1000 mcg/kg/day|Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
62330440|NCT05918874||obese|"The demographic characteristics of the children, type of asthma, dietary habits, socioeconomic income level and number of meals were asked to the child; the use of vitamin D in childhood and for how long, whether the child was breastfed or not, how many months the child was breastfed if breastfed, whether the mother had a smoking habit, and whether the mother had urinary tract infection during pregnancy were asked to the mother.~Asthma control level was recorded according to the asthma control test. Body mass index was calculated according to the Center of Disease Control and Prevention. The leisure-time activity scale and the International Physical Activity Questionnaire for Children-C (IPAQ-C) were used to assess physical activity level."
62330441|NCT05918874||non-obese|"The demographic characteristics of the children, type of asthma, dietary habits, socioeconomic income level and number of meals were asked to the child; the use of vitamin D in childhood and for how long, whether the child was breastfed or not, how many months the child was breastfed if breastfed, whether the mother had a smoking habit, and whether the mother had urinary tract infection during pregnancy were asked to the mother.~Asthma control level was recorded according to the asthma control test. Body mass index was calculated according to the Center of Disease Control and Prevention. The leisure-time activity scale and the International Physical Activity Questionnaire for Children-C (IPAQ-C) were used to assess physical activity level."
62330442|NCT03771508||PillCam SB3 procedure|Subjects with normal/abnormal PillCam SB3 procedure
62330443|NCT04523844|ACTIVE_COMPARATOR|Brinzolamide-brimonidine fixed combination|One drop of the brinzolamide-brimonidine fixed combination is instilled in the eyes of patients two hours before the intravitreal injection
62330444|NCT04523844|NO_INTERVENTION|No topical IOP-lowering medication|No IOP-lowering drops are instilled before the intravitreal injections
62693814|NCT06505395|ACTIVE_COMPARATOR|Octreotide Microspheres cohort (Sandostatin LAR@)|
62693815|NCT03085290|EXPERIMENTAL|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
62693816|NCT03085290|EXPERIMENTAL|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
62693817|NCT05078437|EXPERIMENTAL|Treatment optimization|Participants will undergo an evaluation of all the medications taken and changes will be proposed for treatment optimization.
62693818|NCT05250934|EXPERIMENTAL|Robotic group|In the robotic group, each patient undergoes 20 upper limb robotic telerehabilitation sessions, each session lasting 1 hour. The frequency is 5 sessions/week. Each session is performed at the patient's home, with direct supervision of a caregiver and remote supervision of a physical therapist, using three webcams able to show (a) the frontal and (b) the sagittal plane of the patient, as well as (c) the monitor of the robot.
62693819|NCT05101551|EXPERIMENTAL|Talazoparib with topotecan and gemcitabine|Talazoparib will be administered orally on Days 1 to 5 concurrently with topotecan and a single dose of gemcitabine on Day 1 of 28 day cycle for 1 or 2 cycles. Subjects on dose level 5 will receive an additional 5 day treatment course of talazoparib on days 15-19.
62693820|NCT01174966||Survivor Nonsurvivor|
62330445|NCT04263337|OTHER|Low Cognitive Functioning/Low Concussion History|Former NFL players with low cognitive function and low concussion history will be included in this group.
62693821|NCT06637683|PLACEBO_COMPARATOR|Control group|"The Control group receives routine treatment according to the hospital's standard internal medicine protocol, which includes:~* Anti-inflammatory drugs: sulfasalazine (Azulfidine®), corticosteroids (Prednisone)~* Immunosuppressants: azathioprine (Imuran®) and mercaptopurine (Purinethol®)~* Antibiotics: metronidazole (Metrogyl®)~* Other medications: anti-diarrheal drugs, laxatives, and other pain relievers (as prescribed by a doctor).~All concurrent medications will be documented accordingly."
61936001|NCT02963831|EXPERIMENTAL|Cohort 2: Metastatic Colorectal Cancer|"ONCOS-102, 3 x 10\^11 VPs + durvalumab 1500 mg starting on Day 15.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused IP in a total volume of 500 mL saline (0.9 mg/mL NaCl in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose Q4W for 12 cycles, starting on Day 15.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
61936002|NCT00960739|EXPERIMENTAL|Topotecan / 131-iodine MIBG association|"* The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). \*~* Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. \*~* A dosimetry is performed during hospitalization.~* A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. \*~* Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG.~  * If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled."
61936003|NCT00200096|ACTIVE_COMPARATOR|1|Acupuncture and questionnaires
61936004|NCT00200096|SHAM_COMPARATOR|2|placebo acupuncture and questionnaires
61936005|NCT05774548|EXPERIMENTAL|(PHASE I) Attributes identification|To identify attributes of importance for our research question and assign possible levels to these attributes, a combination of literature review and qualitative approaches will be conducted
61936006|NCT04439175|EXPERIMENTAL|Treatment (taselisib)|Patients receive taselisib 4 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61936007|NCT01822496|EXPERIMENTAL|EGFR: Erlotinib|Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
61936008|NCT01822496|ACTIVE_COMPARATOR|EGFR: No Erlotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
61936009|NCT01822496|EXPERIMENTAL|ALK: Crizotinib|Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
61936010|NCT01822496|ACTIVE_COMPARATOR|ALK: No Crizotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
61936011|NCT02616419|EXPERIMENTAL|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
61936012|NCT02616419|ACTIVE_COMPARATOR|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
61936013|NCT06672146|ACTIVE_COMPARATOR|Arm 1 (ASTX727 + venetoclax)|Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
61936014|NCT06672146|EXPERIMENTAL|Arm 2 (ASTX727 + venetoclax + enasidenib)|Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
61936015|NCT05401240|EXPERIMENTAL|CEPT informed|the patient is informed and asked to returned to the outpatient department (OPD) in order to received cardiac rehabilitation, as well as to take an important examination (cardiopulmonary exercise testing) for his/her cardiorespiratory fitness.
61936016|NCT05401240|NO_INTERVENTION|CPET not informed|the patient is asked to returned to the outpatient department (OPD) in order to received cardiac rehabilitation, but not informed about the cardiopulmonary exercise testing.
62330446|NCT04263337|OTHER|High Cognitive Functioning/ High Concussion History|Former NFL players with high cognitive function and high concussion history will be included in this group.
62330447|NCT04263337|OTHER|Low Cognitive Functioning/High Concussion History|Former NFL players with low cognitive function and high concussion history will be included in this group.
62330448|NCT04263337|OTHER|High Cognitive Functioning/Low Concussion History|Former NFL players with high cognitive function and low concussion history will be included in this group.
62330449|NCT04263337|OTHER|Healthy Male Controls|Healthy male demographically matched controls will be included in this group.
62330450|NCT04263337|OTHER|Low Cognitive Functioning/Medium Concussion History|Former NFL players with low cognitive function and medium concussion history will be included in this group.
62330451|NCT04263337|OTHER|Medium Cognitive Functioning/Low Concussion History|Former NFL Players with medium cognitive functioning and low concussion history with be included in this group.
62330452|NCT04263337|OTHER|Medium Cognitive Functioning/Medium Concussion History|Former NFL Players with medium cognitive functioning and medium concussion history with be included in this group.
61936017|NCT02192073|ACTIVE_COMPARATOR|Suprapectoral Biceps Tenodesis|Suprapectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the superior border of the pectoralis major insertion
61936018|NCT02192073|ACTIVE_COMPARATOR|Subpectoral Biceps Tenodesis|Subpectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the inferior border of the pectoralis major insertion
62330453|NCT04263337|OTHER|Medium Cognitive Functioning/High Concussion History|Former NFL Players with medium cognitive functioning and high concussion history with be included in this group.
62330454|NCT04263337|OTHER|High Cognitive Functioning/Medium Concussion History|Former NFL Players with high cognitive functioning and high concussion history with be included in this group.
62330455|NCT02380430||ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
62488124|NCT03407209|EXPERIMENTAL|FREE programming - levobupivacaine anesthetics: 0.625 mg / ml|"Epidural analgesia totally controlled by the patient~* automatic hourly bolus: 0~* patient controlled bolus: 8ml (5mg) on 3 min~* refractory period: 8min~* continuous infusion: 0~* maximum dose: 65mg/4h"
61936019|NCT06517212|EXPERIMENTAL|tirzepatide|Patients will be treated with tirzepatide 15mg subcutaneously (SC) weekly (starting with 2.5mg SC weekly and increasing by 2.5mg monthly over 6 months) and will be monitored closely for tolerability, safety, and weight loss. Patients may be treated with tirzepatide for up to 2 years on trial if they remain without evidence of metastatic disease recurrence and provided there's demonstrated safety of tirzepatide with associated weight loss.
61936020|NCT00390598|ACTIVE_COMPARATOR|senna 36 mG + PEG 2L|Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
61936021|NCT00390598|ACTIVE_COMPARATOR|4 L PEG|Bowel preparation with 4 L PEG prior to colonoscopy.
61936022|NCT03161132|EXPERIMENTAL|Olaparib 300mg|Olaparib bid orally at 300 mg (tablet formulation) continuously, combined with chemotherapy with Pegylated Liposomal Doxorubicin (up to 6 cycles), then, as monotherapy at the same dose and frequency (300mg bid orally) until progression of disease or unaccepted toxicity.
61936023|NCT03161132|OTHER|Pegylated Liposomal Doxorubicin (PLD)|PLD 40mg/m2 every 28 days intravenous for up to 6 cycles. This treatment will be combined with Olaparib (as described earlier).
61936024|NCT05961878|EXPERIMENTAL|Sarcopenic|subjects with sarcopenia diagnosis
61936025|NCT05961878|PLACEBO_COMPARATOR|Non sarcopenic|subjects without sarcopenia diagnosis
61936026|NCT04834674|EXPERIMENTAL|DEB-TACE combined with apatinib and PD-1 antibody|The participants will receive the combined treatment of local therapy (DEB-TACE, oxaliplatin and gemcitabine), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
61936027|NCT03211338|ACTIVE_COMPARATOR|Preterm labor placentas and progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
61936028|NCT03211338|ACTIVE_COMPARATOR|Term labor placentas and progesterone|IMC cells taken from term labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
61936029|NCT03211338|ACTIVE_COMPARATOR|Preterm labor placentas without progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
61936030|NCT03211338|ACTIVE_COMPARATOR|Term labor placentas without progesterone|IMC cells taken from term labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
61936031|NCT03211338|ACTIVE_COMPARATOR|Term placentas from progesterone treated pregnancies|IMC cells taken from term labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
62330456|NCT04486443|EXPERIMENTAL|Intervention Group|Patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour. All forms were applied to the group before the music therapy, respectively. Prior to musical therapy, the patient's preferred classical music (Rast or Hejaz modes) was asked by the specialist and 10 minutes of music therapy was performed according to patient's choice. Clinical data and pain scores were obtained 5, 30 and 60 minutes after music therapy. 6 sessions of music therapy were applied on different days. Patient Follow-up Form was recorded before and after each therapy. The forms were evaluated 3 times, before the application, after the 3rd and 6th application.
62488125|NCT05077449|EXPERIMENTAL|XZP-3287+Fulvestrant|
62488126|NCT05077449|PLACEBO_COMPARATOR|Placebo + Fulvestrant|
61936032|NCT03211338|ACTIVE_COMPARATOR|Preterm placentas from progesterone treated pregnancies|IMC cells taken from preterm labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
62330457|NCT04486443|NO_INTERVENTION|control group|The control group consisted of patients who only received analgesic treatment and underwent routine nursing care, and didn't have any interventions. All forms were assessed 3 times, before application, after the 3rd application and after the 6th application. The Patient Information Form and K-MASF were applied only once.
62330458|NCT04736706|EXPERIMENTAL|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 18 administrations (up to \~2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
62488127|NCT02779400|EXPERIMENTAL|Evaluation of the device perfomance|
62488128|NCT03899935||Group A: obese patients|Obese patients undergoing laparoscopic surgery for endometriosis
61936033|NCT03211338|ACTIVE_COMPARATOR|Term placentas not treated with progesterone in pregnancy|IMC cells taken from term placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
61936034|NCT03211338|ACTIVE_COMPARATOR|Preterm placentas not treated with progesterone in pregnancy|IMC cells taken from preterm placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
61936035|NCT03211338|ACTIVE_COMPARATOR|Term postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
62693822|NCT06637683|EXPERIMENTAL|Test group|"The Experimental group receives the routine treatment and uses distilled water plus B. subtilis and B. clausii at 3 billion CFU/5 mL (LiveSpo COLON)~The standard internal medicine treatment protocol of the hospital includes:~* Anti-inflammatory drugs: sulfasalazine (Azulfidine®), corticosteroids (Prednisone)~* Immunosuppressants: azathioprine (Imuran®) and mercaptopurine (Purinethol®)~* Antibiotics: metronidazole (Metrogyl®)~* Other medications: anti-diarrheal drugs, laxatives, and other pain relievers (as prescribed by a doctor).~All concurrent medications will be documented accordingly."
62693823|NCT05528939|EXPERIMENTAL|EndeavorRx|Children will be asked to begin digital attentional control training at home within 6 weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).
61936036|NCT03211338|ACTIVE_COMPARATOR|Preterm postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
62488129|NCT03899935||Group B: non-obese patients|Non-obese patients undergoing laparoscopy for endometriosis
62488130|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
62488131|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
61936037|NCT03211338|ACTIVE_COMPARATOR|Term postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
61936038|NCT03211338|ACTIVE_COMPARATOR|Preterm postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
62330459|NCT04736706|EXPERIMENTAL|Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (co-formulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered IV Q6W for up to 18 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
62330460|NCT04736706|ACTIVE_COMPARATOR|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 18 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
62330461|NCT02306187|EXPERIMENTAL|Non-Alfacaocidol|Ahead of Eldecalcitol treatment, this group has not taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
62330462|NCT02306187|EXPERIMENTAL|Alfacalcidol|Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
62330463|NCT02580916|EXPERIMENTAL|Group 1 (Postal)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team and deemed 'low risk'; SCQOLIT questionnaires will be administered by post.
61936039|NCT05732220|EXPERIMENTAL|EMA+ group|EMA assessment + EMA-based cessation counselling
61936040|NCT05732220|ACTIVE_COMPARATOR|EMA group|EMA assessment only + Usual peer counselling
61936041|NCT05732220|ACTIVE_COMPARATOR|Control|Usual peer counselling
62330464|NCT02580916|EXPERIMENTAL|Group 2 (Clinic-based)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team, for whom all aspects of the study will be conducted in the Dermatology clinic. SCQOLIT questionnaires will be administered according to the protocol.
62330465|NCT02580916|NO_INTERVENTION|Group 3 (Interviews)|A Qualitative Researcher (Co-Investigator) will undertake structured interviews with approximately 20 patients from both Group 1 and 2. Potential participants will be invited to volunteer their contact details at the time of consent to the Questionnaire study. This is optional; they may refuse to do so and still take part in the main questionnaire study. The patient will then be contacted by the Qualitative Researcher (Co-Investigator) at a later date and subsequently consented for the interview.
62330466|NCT02580916|NO_INTERVENTION|Group 4 (Clinician focus group)|We aim to discuss the project at the end of the study period in the same setting, to establish staff perspectives on the study, to establish usefulness of the SCQOLIT tool and to identify any barriers to implementation.
62330467|NCT01766336|EXPERIMENTAL|Group 1 ELND005/ELND005|Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
62488132|NCT06060834|EXPERIMENTAL|Application of product|Apply intervention to wet hair on scalp and massage in for 30 seconds after shampooing (if applicable), daily.
62488133|NCT02911701|EXPERIMENTAL|Acetaminophen|Study participants randomized to the acetaminophen group will receive 650mg of acetaminophen orally every 6 hours during their postpartum hospital stay.
62488134|NCT02911701|ACTIVE_COMPARATOR|Ibuprofen|Study participants randomized to the ibuprofen group will receive 600mg of ibuprofen orally every 6 hours during their postpartum hospital stay.
62488135|NCT00978458|ACTIVE_COMPARATOR|Arm I|Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
61936042|NCT06418893|ACTIVE_COMPARATOR|Isoflurane|Drug- Isoflurane Dosage form- Inhalational, 1-2% Frequency- Continuously Duration- Throughout Intraoperative period
61936043|NCT06418893|EXPERIMENTAL|Propofol|Drug- Propofol Dosage form- Intravenously, 2.5 mcg/ml target plasma concentration Frequency- Continuously Duration- Throughout Intraoperative period
61936044|NCT04704973|EXPERIMENTAL|Transdiagnostic short-term psychotherapy|
61936045|NCT06576843|EXPERIMENTAL|Cohort 1|SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 600 mg on Day 8, Day 92, and Day 176)
61936046|NCT06576843|EXPERIMENTAL|Cohort 2|SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 600 mg on Day 8, Day 64, Day 120, and Day 176)
61936047|NCT06576843|EXPERIMENTAL|Cohort 3|SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, 600 mg Day 8, followed by 250 mg on Day 15, Day 43, Day 71, and Day 99)
61936048|NCT06576843|EXPERIMENTAL|Cohort 4|SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 100 mg on Day 8, Day 36, Day 64, and Day 92)
62135290|NCT00701701|EXPERIMENTAL|Regimen B: Alglucosidase alfa, Rituximab and Methotrexate|CRIM-negative participants were assigned to Regimen B if they either(1)exhibited clinical decline since starting alglucosidase alfa (Myozyme®)therapy and did not have inhibitory antibodies and/or a sustained rhGAA antibody titer(defined as at least 2 titers \>=25,600 obtained at least 1 month apart),or(2) did not exhibit clinical decline since starting alglucosidase alfa(Myozyme®) therapy, regardless of their anti-rhGAA or inhibitory antibody status. Regimen B participants with CRIM-negative status received alglucosidase alfa(Myozyme®) IV infusion of 20 mg/kg qow for a minimum of 18 months or,until participant reached the age of 2 years (if participant was \<6 months of age at time of enrollment). In addition,rituximab 375 mg/m\^2 IV was administered weekly beginning the day after Myozyme® infusion for 4 weeks(an optional 2nd cycle could be administered at the discretion of the investigator) and biweekly methotrexate 15 mg/m\^2 subcutaneous on the day after Myozyme® infusion for 6 months.
62135291|NCT05780619||Patients with abnormal vasoreactivity|
62488136|NCT00978458|EXPERIMENTAL|Arm II|Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
61936049|NCT06576843|EXPERIMENTAL|Cohort 5|SUBLOCADE 100 mg, followed by INDV-6001 (600 mg on Day 29 and Day 113)
61936050|NCT06576843|EXPERIMENTAL|Cohort 6|SUBLOCADE 300 mg, followed by INDV-6001 (600 mg on Day 29, Day 85 and Day 141)
61936051|NCT01456507|EXPERIMENTAL|A|1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.
61936052|NCT01456507|EXPERIMENTAL|B|1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).
61936053|NCT01456507|EXPERIMENTAL|C|1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.
61936054|NCT02147028|EXPERIMENTAL|Hippocampal sparing whole brain RT|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
62135292|NCT05780619||Patients with normal vasoreactivity|
62330468|NCT01766336|EXPERIMENTAL|Group 2 PLACEBO/ELND005|Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.
62330469|NCT00340626||Control|healthy individuals with no history of oral cleftsto serve as controls
62330470|NCT00340626||Oral Cleft Family Members|individuals with unilateral or bilateral cleft lip with or without cleft palate and their unaffected relatives
62330471|NCT04356755|EXPERIMENTAL|AdMSC|Subcutaneous injections of cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma
62330472|NCT04356755|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma
62330473|NCT01754922||Exposed|Veterans deployed to OEF/OIF/OND and environmentally exposed to high levels of particulate matter
62330474|NCT01754922||Control|OEF/OIF/OND Veterans deployed to regions other than Southwest Asia
62330475|NCT05307822|EXPERIMENTAL|Cohort 1: Menthol with HTP device (20020064)|Subjects will self-assign to one of three menthol flavor variants of non-combusted cigarette products based on their self-reported flavor usage history.
62488137|NCT05274763|EXPERIMENTAL|Supportive Care|Patients undergo 4 to 8 sessions (2-4 per week) of Compassion Centered Spiritual Health (CCSH) over 30 minutes with a chaplain while impatient.
62488138|NCT04895553||Cohort Apixaban|"patients who have switched from low molecular weight heparin (LMWH) to apixaban at the recommended dose of the treating physician.~FDA approved dose 10 mg twice daily (BID) for 7 days followed by 5 mg PO BID OR physician prescribed dose"
62488139|NCT02013635||Cerebral Venous Thrombosis|patients over 16 years old with acute cerebral venous thrombosis
62488140|NCT03119077|EXPERIMENTAL|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
62488141|NCT03119077|PLACEBO_COMPARATOR|Placebo|Placebo Dose 1 to 6 of BAY 1161116
62488142|NCT00687206|EXPERIMENTAL|1|
62488143|NCT04444141|EXPERIMENTAL|AK104|AK104 450mg IV every 2 weeks (Q2W)
62488144|NCT00544492|EXPERIMENTAL|A1|Buttonhole cannulation technique
61936055|NCT02147028|ACTIVE_COMPARATOR|Control: Conventional whole brain RT|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
61936056|NCT01672762|EXPERIMENTAL|ASP1941 group|oral
61936057|NCT05268055|EXPERIMENTAL|"Sign Here training intervention"|"Participants randomized to the experimental condition will view the new Sign Here training film for healthcare providers."
61936058|NCT05268055|OTHER|Intervention as usual|"Participants randomized to intervention as usual will review Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)"
61936059|NCT06599697|EXPERIMENTAL|Intravenously Administered Pooled Human Immunoglobulin (IVIG)|Participants will receive intravenously administered pooled human immunoglobulin (IVIG) 2g/kg every 4 weeks for 24 weeks.
61936060|NCT06599697|NO_INTERVENTION|Placebo|Participants will receive an infusion of 0.9% sodium chloride solution every 4 weeks for 24 weeks at equivalent volume to corresponding IVIG weight-based dose.
62135293|NCT03609359|EXPERIMENTAL|Lenvatinib + Pembrolizumab|Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
62135294|NCT02261649||Cerebellar Tumor Surgically Removed|"Quantitative Sensory Testing and Neuroimaging~* Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~* Cold water bath~* MRI scanner~* Questionnaires"
62135295|NCT02261649||Healthy Volunteer|"Quantitative Sensory Testing and Neuroimaging~* Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~* Cold water bath~* MRI scanner~* Questionnaires"
61936061|NCT04110587|PLACEBO_COMPARATOR|arthroscopy|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.
61936062|NCT04110587|ACTIVE_COMPARATOR|arthroscopy plus hyaluronic Acid|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative. An hyaluronic acid injection of 1 mL (Durolane®, 20 mg / mL, Zambon, Barcelona, Spain) at the end of arthroscopy that was only performed in this arm.
62488145|NCT00544492|ACTIVE_COMPARATOR|A2|Rope ladder cannulation technique
62488146|NCT00544492|EXPERIMENTAL|B1|Catheter with bevel point
62488147|NCT00544492|ACTIVE_COMPARATOR|B2|Catheter with cylindrical point
62488148|NCT01090505|EXPERIMENTAL|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2|Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy
62488149|NCT01090505|NO_INTERVENTION|surgery|Procedure/Surgery: Gastrectomy with D2 dissection
62488150|NCT00137735|ACTIVE_COMPARATOR|1|Gabapentin
62488151|NCT00137735|PLACEBO_COMPARATOR|2|Placebo
62693824|NCT05528939|ACTIVE_COMPARATOR|Control|An active control program designed to replicate aspects of the intervention (e.g., regular use of digital device to access fun educational activities) while engaging cognitive skills not particularly involving attention.
61936063|NCT03110744|EXPERIMENTAL|Palbociclib|application on 21 consecutive days of a 28 days cycle
61936064|NCT04562493|ACTIVE_COMPARATOR|Magnesium sulphate group|Effect of transforaminal Magnesium sulphate on oxidative stress markers and radicular pain
61936065|NCT04562493|EXPERIMENTAL|Ozone Group|Effect of transforaminal Ozone on oxidative stress markers and radicular pain
61936066|NCT04562493|OTHER|Steroid group|Effect of transforaminal steroids on oxidative stress markers and radicular pain
61936067|NCT04302818|EXPERIMENTAL|Social skills group training SKOLKONTAKT|Manualised social skills group training.
61936068|NCT04302818|ACTIVE_COMPARATOR|Active control comparison group|Social activities in a group setting.
62330476|NCT05307822|EXPERIMENTAL|Cohort 2: Non-Menthol with HTP device (20020064)|Subjects will self-assign to a non-menthol flavor variant of a non-combusted cigarette product based on their self-reported flavor usage history.
62330477|NCT02307344|ACTIVE_COMPARATOR|Nigella Sativa Supplement|Fifty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest capsules containing 2 grams of Nigella Sativa divided into 1 grams twice a day.
62330478|NCT02307344|ACTIVE_COMPARATOR|Patients receiving a placebo tablet|Twenty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest placebo capsules twice a day, that look like the capsules of those receiving the Nigella Sativa.
62330479|NCT04645472||CT-Ultrasound group|
62135296|NCT05674669|EXPERIMENTAL|Group 1 N=3|Single dose, follow-up visits at one day, one week, and one month after dose.
62135297|NCT05674669|EXPERIMENTAL|Group 2 N=7|Single dose, follow-up visits at one day, one week, and one month after dose.
62135298|NCT05674669|EXPERIMENTAL|Group 3 N=3|Single dose, follow-up visits at one day, one week, and one month after dose.
62135299|NCT05674669|EXPERIMENTAL|Group 4 N=10|Randomized treatment with placebo followed by single dose, separated by 7 days. Follow-up visits at one day, one week, and one month after last dose.
62330480|NCT04056364||Asthma|Asthma patients will be diagnosed according to a clinical history of wheezing, cough, chest tightness or shortness of breath, as well as the presence of BHR (cumulative dose caus¬ing a 20% decrease in FEV1), based on the GINA guidelines. None of them had a history of COPD, or previous doctor-diagnosed ACO. All subjects had not used any oral or/and inhaled corticosteroid (ICS) in the previous 12 weeks. The included patients with asthma had initial diagnosis and were under uncontrolled stage.
62488152|NCT05325515|ACTIVE_COMPARATOR|Fosamax (conventional alendronate)|Conventional alendronate 70mg weekly for 16 weeks
62488153|NCT05325515|EXPERIMENTAL|Binosto (effervescent and buffered alendronate)|Effervescent and buffered alendronate70mg weekly for 16 weeks
62488154|NCT04906070|EXPERIMENTAL|HB-001 DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62488155|NCT03835468|EXPERIMENTAL|Galacto-oligosaccharides (GOS) Group|Participants in this group will receive the daily dosage of galacto-oligosaccharides (GOS) prebiotic for 4 weeks
62488156|NCT03835468|PLACEBO_COMPARATOR|Maltodextrin Group|Participants in this group will receive the daily dosage of Maltodextrin placebo for 4 weeks
62488157|NCT00452348|ACTIVE_COMPARATOR|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
62488158|NCT00452348|ACTIVE_COMPARATOR|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
62488159|NCT01723683|EXPERIMENTAL|MISTCPAP group|MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP.
62488160|NCT01723683|ACTIVE_COMPARATOR|INSURE group|INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP.
62693825|NCT03077061|ACTIVE_COMPARATOR|Control - Open flap debridement|The surgical procedure includes flap elevation, debridement of the peri-implant defect and decontamination of the implant surfaces using saline for irrigation. Flaps are replaced in their original position and carefully sutured. Patients are provided with post-surgical information and thereafter called in for regular follow-up visits.
62330481|NCT04056364||COPD|COPD patients were diagnosed according to the GOLD criterion, which included a post-bronchodilator spirometry to confirm airflow obstruction (FEV1 to forced vital capacity ratio \[FEV1/FVC\] ,70%), in a clinical context (dyspnea, chronic cough or sputum production, and a history of expo¬sure to risk factors for the disease). They had received a COPD diagnosis at least 1 year before the study. None of them had a history of asthma. All subjects had not used any oral or/and ICS in the previous 4 weeks. The included COPD patients had exacerbations. The GOLD stage of COPD was defined according to the 2019 recommendations of GOLD.
62330482|NCT04056364||ACO|ACO will be diagnosed by two steps: the first step is the identification of a history of chronic airway disease, i.e., chronic or recurrent cough, sputum production, wheezing, or repeated acute lower respiratory tract infections. In the second step, the features of asthma and those of COPD that best describe the patients
62330483|NCT00586924|EXPERIMENTAL|5 mcg/kg|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
62488161|NCT00396162|PLACEBO_COMPARATOR|Placebo pill|Placebo pills on same schedule as active intervention.
62488162|NCT00396162|ACTIVE_COMPARATOR|Probiotic|L. rhamnosus R0011 strain
62488163|NCT01306838|EXPERIMENTAL|Treatment|The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
62488164|NCT01306838|ACTIVE_COMPARATOR|Control Group|Routine care
62488165|NCT05574036|ACTIVE_COMPARATOR|Group 1 Febuxostat group|35 non alcoholic steatohepatitis hyperuricemic patients receiving Febuxostat 80 mg once daily for 6 months duration
62488166|NCT05574036|ACTIVE_COMPARATOR|Group 2 vitamin E group|35 non alcoholic steatohepatitis Hyperuricemic patients receiving vitamin E 400 mg twice daily for 6 months duration
61936069|NCT01243671|EXPERIMENTAL|Adalimumab|Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.
61936070|NCT01039844|EXPERIMENTAL|Weekly LOC-paclitaxel Injection|LOC-paclitaxel IV by a 1 hour infusion on Day 1, 8, 15, 22 and 29; repeated every 42 days (6 weeks) per cycle.
61936071|NCT05324332|EXPERIMENTAL|68Ga-P16-093 and 68Ga-PSMA-11 PET/ CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days, each patient underwent whole-body PET/CT scan after intravenous administration of 68Ga-P16-093 and 68Ga-PSMA-11, respectively.
61936072|NCT06709794|NO_INTERVENTION|Control group|A control group that receives a standard eligibility notice informing them of their eligibility for marketplace coverage.
61936073|NCT06709794|EXPERIMENTAL|Enhanced Outreach|A treatment group that receives a standard eligibility notice informing them of their eligibility for marketplace coverage and an informational flyer describing what Covered California is, the availability of financial assistance, and information on benefit design and private insurance terminology, such as deductibles and copays.
61936074|NCT06709794|EXPERIMENTAL|Pre-Selected Plan|A treatment group that receives a modified eligibility notice that includes information on the pre-selected lowest-cost silver health insurance plan with a personalized quote for their net premium amount, as well as the informational flyer.
61936075|NCT04338984|ACTIVE_COMPARATOR|General anesthesia alone (AG)|"Opioid based analgesia:~Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
61936076|NCT04338984|EXPERIMENTAL|Erector Spinae Plane Block and General Anaesthesia (ESPAG)|"Bilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision.~Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
61936077|NCT01241773|EXPERIMENTAL|001|TMC435 Two 75 mg capsules once daily for 14 days
62330484|NCT00586924|EXPERIMENTAL|10 mcg/kg|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
62488167|NCT05591729|EXPERIMENTAL|Pilates exercise|pilates exercise will be received twice a week for four weeks
62488168|NCT05591729|ACTIVE_COMPARATOR|postural correction exercise|postural correction exercises will be received twice a week for four weeks
62488169|NCT06562465|EXPERIMENTAL|Experimental group|The overweight and obese children aged 3-6 years old,receive dietary and exercise management, combined reward support mechanisms.
62488170|NCT06562465|ACTIVE_COMPARATOR|Control group|The overweight and obese children aged 3-6 years old only receive basic health guidance,do not receive dietary and exercise management nor combined reward support mechanisms like experimental group.
62488171|NCT04567303|EXPERIMENTAL|Part 1: Intravitreal Injections|Zifibancimig administered in ascending dose levels through IVT injections.
62488172|NCT04567303|EXPERIMENTAL|Part 2: Port Delivery with High Dose|Zifibancimig administered at a high dose through the PD implant.
62488173|NCT04567303|EXPERIMENTAL|Part 2: Port Delivery with Low Dose|Zifibancimig administered at a low dose through the PD implant.
62488174|NCT04567303|EXPERIMENTAL|Part 3: Port Delivery with High Dose|Zifibancimig administered at a high dose through the PD implant.
62488175|NCT04567303|EXPERIMENTAL|Part 3: Port Delivery with Low Dose|Zifibancimig administered at a low dose through the PD implant.
62488176|NCT04567303|ACTIVE_COMPARATOR|Part 3: Port Delivery with Ranibizumab|100 milligrams/milliliter (mg/mL) of ranibizumab administered through the PD implant.
62488177|NCT06532513|EXPERIMENTAL|Experimental Group: Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application|Participants in this group will receive routine physiotherapy and rehabilitation for 10 weeks, along with an additional 1-hour training for family centered goal-oriented physiotherapy and rehabilitation practices. Families will be instructed to perform these practices at home for 1 h every day.
62693826|NCT03077061|EXPERIMENTAL|Test - Bone replacement graft|The surgical procedure is identical to the control procedure with the exception of the application of the bone replacement graft. Following decontamination, Bio-Oss Collagen® is placed into the peri-implant bony defect. Flaps are carefully sutured and patients are provided with the same information and follow-up as patients in the control group.
62693827|NCT06675292||Individuals with tension type headache|
61936078|NCT01241773|EXPERIMENTAL|002|efavirenz One 600 mg tablet once daily for 14 days
62330485|NCT00586924|EXPERIMENTAL|20 mcg/kg|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
61936079|NCT01241773|EXPERIMENTAL|003|TMC435 + efavirenz Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet once daily for 14 days
61936080|NCT01241773|EXPERIMENTAL|004|TMC435 Two 75 mg capsules once daily for 7 days
61936081|NCT01241773|EXPERIMENTAL|005|raltegravir One 400 mg tablet twice daily for 7 days
61936082|NCT01241773|EXPERIMENTAL|006|TMC435 + raltegravir Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
62330486|NCT00586924|EXPERIMENTAL|30 mcg/kg|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
62330487|NCT00586924|EXPERIMENTAL|40 mcg/kg|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
62330488|NCT00586924|EXPERIMENTAL|50 mcg/kg|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
62330489|NCT03065712|EXPERIMENTAL|FES PET/CT|"This is a single arm study that involves FES PET/CT.~Procedure: Computed Tomography~* Drug: \[F-18\] fluoroestradiol: \[F-18\]FES~* Other: Laboratory Biomarker Analysis~* Procedure: Positron Emission Tomography"
62330490|NCT03960138|EXPERIMENTAL|Intermittent Theta-burst stimulation (iTBS)|Cross-over design - participants will receive both experimental treatments.
62330491|NCT03960138|EXPERIMENTAL|Continuous Theta-burst stimulation (cTBS)|Cross-over design - participants will receive both experimental treatments.
62330492|NCT06052735|OTHER|Correlation arm|
62330493|NCT00362063|EXPERIMENTAL|growth hormone|children with proven growth hormone deficiency
62330494|NCT00362063|NO_INTERVENTION|healthy controls|No growth hormone is given
61936083|NCT01842815|EXPERIMENTAL|755nm Alexandrite Laser Single Pass (Right Side).|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The right side will be treated once within the same visit.
61936084|NCT01842815|EXPERIMENTAL|755nm Alexandrite Laser Double Pass (Left Side)|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The left side of the tattoo will be treated twice within the same visit 20 minutes apart.
62330495|NCT06336031|EXPERIMENTAL|Image and video data set shown with BII stimuli.|Participants will undergo this test on two separate days. On each day, participants will be asked to watch a series of videos and images. For this arm of the study, participants will view the BII phobia-related stimuli.
62330496|NCT06336031|PLACEBO_COMPARATOR|Image and video data set shown with neutral stimuli.|Participants will undergo this test on two separate days. On each day, participants will be asked to watch a series of videos and images. For this arm of the study, participants will view the neutral stimuli.
62330497|NCT04460378|EXPERIMENTAL|Cognitive Behavioral Therapy|Manualized Cognitive Behavioral Therapy starting at the patients' home.
62330498|NCT03201198|EXPERIMENTAL|Active Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
62330499|NCT03201198|SHAM_COMPARATOR|Chair exercises|The Chair exercise intervention includes chair exercises, behavioral relaxation and health education.
62330500|NCT04053543|EXPERIMENTAL|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
62330501|NCT05517603|ACTIVE_COMPARATOR|Experimental: AJ201|Subjects taking active drug AJ201 600mg/day for 12 weeks.
62330502|NCT05517603|PLACEBO_COMPARATOR|Placebo Comparator|Subjects taking placebo for 12 weeks.
62330503|NCT02417870|EXPERIMENTAL|aldesleukin|
62330504|NCT00909766|ACTIVE_COMPARATOR|Panel A|
62330505|NCT00909766|ACTIVE_COMPARATOR|Panel B|
62330506|NCT00909766|ACTIVE_COMPARATOR|Panel C|
62330507|NCT00909766|ACTIVE_COMPARATOR|Panel D|
62330508|NCT00909766|ACTIVE_COMPARATOR|Panel E|
62330509|NCT00909766|ACTIVE_COMPARATOR|Panel F|Low Dose
62330510|NCT00909766|ACTIVE_COMPARATOR|Panel G|High Dose
62330511|NCT00909766|PLACEBO_COMPARATOR|Panel H|
62330512|NCT01762540|PLACEBO_COMPARATOR|Calcium supplement|Capsule with tablet of calclium supplement
62330513|NCT01762540|ACTIVE_COMPARATOR|Glucocorticoids|Capsule with tablet of Prednisolone 37,5mg
62693828|NCT06284304|EXPERIMENTAL|Experimental radiotherapy treatment|SBRT 5x30Gy of whole prostate and isotoxic 45 Gy GTV plus intra-prostatic margin
62693829|NCT04886856|EXPERIMENTAL|Mindful Moms|"Weekly Mindful Moms sessions"
61936085|NCT05773703|EXPERIMENTAL|Trillium Compound Alone|Single dose of PSMA-Targeted \[In-111\]-Labeled Trillium Compound
62330514|NCT05142332|EXPERIMENTAL|Intervention Arm: PROCOVAXED|Covid vaccine educational intervention consisting of vaccine messaging platforms (flyers, videos, scripted face-to-face messaging)
62693830|NCT04886856|ACTIVE_COMPARATOR|Prenatal Education|Weekly prenatal education sessions
62693831|NCT06183541|ACTIVE_COMPARATOR|PENG Block group|PENG block group; USG probe is placed on the transverse plane medial to the anterior inferior iliac spine (AIIS), the medial end of the probe is placed on the superior pubic It is rotated approximately 45° counterclockwise to align it with the ramus. For the PENG block, an 80 mm block needle is placed in the fascial plane between the psoas tendon and pubic ramus and 20 ml of 0.5% bupivacaine is administered after spinal anesthesia,
62488178|NCT06532513|NO_INTERVENTION|Control Group: Routine Physiotherapy and Rehabilitation Program|Participants in this group will undergo routine physiotherapy and rehabilitation for 10 weeks.
62488179|NCT05546060|EXPERIMENTAL|Venetoclax Combined With Dexamethasone and Etoposide|Patients who met the inclusion criteria will receive venetoclax combined with dexamethasone and etoposide for 8 weeks.
62693832|NCT06183541|OTHER|Control group|Control group; 10 ml 0.5% bupivacaine + 10 ml 2% lidocaine is infiltrated into the surgical area by the surgical team at the end of surgery
62135300|NCT05674669|EXPERIMENTAL|Group 5 N=9|Randomized treatment with single dose followed by second dose, separated by 7 days. Follow-up visits at one day, one week, and one month after last dose.
62330515|NCT05142332|NO_INTERVENTION|Non-interventional Arm: PROCOVAXED|Usual care
62330516|NCT01739777|EXPERIMENTAL|ucMSC|Umbilical cord derived mesenchymal are injected intravenously to Patients.
62330517|NCT01739777|PLACEBO_COMPARATOR|Controls|Intravenous placebo solution are administrated to Patients.
62330518|NCT00218036|EXPERIMENTAL|1|Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
62330519|NCT00218036|EXPERIMENTAL|2|Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
62330520|NCT00218036|EXPERIMENTAL|3|Citalopram 20/ Methadone Maintenance 1.2mg/kg
62330521|NCT00218036|EXPERIMENTAL|4|Citalopram 40/ Methadone Maintenance 1.2 mg/kg
62330522|NCT00218036|PLACEBO_COMPARATOR|5|Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
62330523|NCT05228444|EXPERIMENTAL|Circadiancare|limits the circadian impact of hospitalisation by enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
62330524|NCT05228444|NO_INTERVENTION|Control|
62330525|NCT00524316|EXPERIMENTAL|Sunitinib|oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
62330526|NCT03904446|EXPERIMENTAL|Methylergonovine 0.2 mg|Standard Oxytocin Infusion at the time of Cesarean Section plus 0.2 mg of Intramuscular Methergine
62488180|NCT00606658|OTHER|Oil dripping therapy|Single Arm
62488181|NCT03165669|EXPERIMENTAL|Cervical pillow|"The cervical pillow is known as the Viscospring PostuRite - medium model, made by SOFF-ART S.r.l. - Via Maestri del Lavoro 49 - 05100 Terni, Italy. The Viscospring PostuRite pillow is externally made of viscoelastic polyurethane and internally 60 independent, individually coated harmonic phosphate-coated steel springs, are thought to promote correct posture of the cervical spine, due to the adaptation of the pillow to the shape and movements of the head.~Each intervention will be supported by a 30-minutes informative session delivered by a physical therapist, and will be completed by the delivery of an informative brochure."
62693833|NCT06642285|NO_INTERVENTION|Control Group|: it will include thirty premature neonates who will receive the usual hospital care in accordance with hospital protocols, without any extra procedures or therapies.
62693834|NCT06642285|EXPERIMENTAL|Bundle group|: it will include thirty premature neonates who will receive evidence-based guidelines on the prevention of nasal pressure injuries in form of a care bundle from the first day of providing NIRS till weaning.
62693835|NCT06464640|EXPERIMENTAL|podcast intervention|The podcast will be used for intervention in the experimental group.
62693836|NCT06464640|SHAM_COMPARATOR|Ebook intervention|Participants in the active control group will use E-book.
62693837|NCT06324461|EXPERIMENTAL|Dulaglutide group|Subject randomized into this group will receive single subcutaneous dose of Dulaglutide 0.75mg 7 to 14 days prior to surgery, on top of routine peri-operative care
62693838|NCT06324461|NO_INTERVENTION|Control group|Subject randomized into this group will receive routine peri-operative care
62693839|NCT06396325|EXPERIMENTAL|Exergaming Intervention for 8 Weeks|Extension Phase: Participants randomized ot the intervention arm will play Tales from the Magic Keep at home for the 8 week open-label extension phase
62693840|NCT06396325|ACTIVE_COMPARATOR|Usual Care for 8 weeks.|Extension Phase: Participants randomized to waitlist usual care will play Tales from the Magic Keep at home for the 8 week open-label extension phase
62693841|NCT02431871||Treated for DDH in childhood|Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
62693842|NCT02431871||Control|Age an sex matched controls of DDH patients
62693843|NCT03409770|NO_INTERVENTION|Usual care|Usual care (normothermia) arm
62135301|NCT05443464|EXPERIMENTAL|2M cells/kg|Dose level 1. 3 subjects will receive OSSM-001 at 2M cells/kg and followed for 28 days post dose to observe for DLT.
62330527|NCT03904446|PLACEBO_COMPARATOR|Placebo (Normal Saline)|Standard Oxytocin Infusion at the time of Cesarean Section plus 1 milliliter (mL)of normal saline given intramuscular
62330528|NCT06156111|OTHER|Transepithelial abutment|The patients randomized to the transepithelial abutment group will receive a fixed screw implant-supported zirconia prosthesis which will be attached to the implants through an implant-abutment connection.
62330529|NCT06156111|EXPERIMENTAL|Direct to implant|The patients randomized to the direct to implant group will receive a fixed screw implant-supported zirconia prosthesis which will be attached direct to the implants connection.
62330530|NCT04808154|EXPERIMENTAL|test drug|Powder for oral solution of SNP-630.
62330531|NCT04921345|EXPERIMENTAL|Cohort 1: Participants aged 7-11 years|Participants aged 7-11 years will receive nemolizumab for 52 weeks.
62330532|NCT04921345|EXPERIMENTAL|Cohort 1.1: Participants aged 7-11 years|Participants aged 7-11 years will receive nemolizumab for 52 weeks.
62330533|NCT04921345|EXPERIMENTAL|Cohort 2: Participants aged 2-6 years|Participants aged 2-6 years will receive nemolizumab for 52 weeks.
62330534|NCT03899129|EXPERIMENTAL|simultaneous working length control|• Using simultaneous working length control during root canal preparation using E-CONNECT S endomotor with integrated apex locator.
62330535|NCT03899129|ACTIVE_COMPARATOR|Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
62330536|NCT05021536|PLACEBO_COMPARATOR|Placebo|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
62330537|NCT05021536|EXPERIMENTAL|AMX0035|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
62488182|NCT03165669|ACTIVE_COMPARATOR|Education|The educational intervention will be conducted by a physical therapist and will consist of a advice on positions, movements and activities recommended or not recommended for people with chronic neck pain, both in the workplace and in leisure time, including nighttime postures. Each educational intervention will be carried out individually, will last half an hour and will be supported by the delivery of an informative brochure.
62488183|NCT05978791||Hospitalized patients with suspected coronary artery disease|Take aspirin and ticagrelor maintenance dose ≥3 days, or loading dose of aspirin (300mg) and ticagrelor (180mg) ≥12 hours
62488184|NCT05978791||healthy volunteers|Age 18-75 years old, body weight ≥45kg, regardless of gender;
62488185|NCT01370811|PLACEBO_COMPARATOR|oxybutynin and clonidine oral solution treatment D|Placebo
62488186|NCT01370811|EXPERIMENTAL|oxybutynin and clonidine oral solution treatment C|High dose oxybutynin and clonidine
62488187|NCT01370811|EXPERIMENTAL|oxybutynin and clonidine oral solution treatment A|Low dose oxybutynin and clonidine
62488188|NCT01370811|EXPERIMENTAL|oxybutynin and clonidine oral solution treatment B|Intermediate dose oxybutynin and clonidine
62488189|NCT05779358|ACTIVE_COMPARATOR|E+ G+|Participants with the expectation of receiving gluten-containing bread and actually receiving gluten-containing oat bread during the test day.
62330538|NCT05687695|EXPERIMENTAL|backward walking training group|six weeks of backward walking training program 3 times per week
62488190|NCT05779358|ACTIVE_COMPARATOR|E+ G-|Participants with the expectation of receiving gluten-containing bread, but actually receiving gluten-free oat bread during the test day.
62488191|NCT05779358|ACTIVE_COMPARATOR|E- G+|Participants with the expectation of receiving gluten-free bread but actually receiving gluten-containing oat bread during the test day.
62488192|NCT05779358|PLACEBO_COMPARATOR|E- G-|Participants with the expectation of receiving gluten-free bread and actually receiving gluten-free oat bread during the test day.
62488193|NCT04272437|EXPERIMENTAL|TRA group|"Tokoro Combination and Rehmannia and Akebia Formula (TRA) in each one batch number were manufactured by Chuang Song Zong Pharmaceutical Co., Ltd., a famous manufacturer of concentrated herbal extract granules in agreement with the standards of good manufacturing practices (GMP) in Kaohsiung City, Taiwan.~TRA contains Tokoro Combination and Rehmannia and Akebia Formula Tokoro Combination and Rehmannia and Akebia Formula consists of Dioscorea Hypoglaucae Rhizoma, Acori Graminei Rhizoma, Linderae Radix, Alpiniae Oxyphyllae Fructus, Poria, Rehmanniae Radix, Akebiae Caulis, Lophatheri Hebra, and Glycyrrhizae Radix at a 2:2:2:2:1:1.3:1.3:1.3:2.5 ratio."
62488194|NCT04272437|PLACEBO_COMPARATOR|placebo group|The placebo was also prepared as granules by Chung Song Zong Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of TRA.
62488195|NCT05699538|EXPERIMENTAL|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
62488196|NCT05699538|NO_INTERVENTION|Standard of Care|Subjects will be asked to follow standard of care recommendations as prescribed by the physician.
62693844|NCT03409770|EXPERIMENTAL|Therapeutic hypothermia - 48 h|Whole body cooling (33 to 34 C) for 48 hours
62693845|NCT03409770|EXPERIMENTAL|Therapeutic hypothermia - 72 h|Whole body cooling (33 to 34 C) for 72 hours
62693846|NCT05749094||GCA group|Ascertainment of GCA will occur 6 months after study inclusion and will require all the following features: 1) initial symptoms and clinical evolution consistent with GCA; 2) at least one positive diagnostic test for GCA, including ultrasound of temporal arteries, temporal artery biopsy, cranial MRI or cranial PET; and 3) satisfies the 2022 ACR-EULAR classification criteria for GCA.
61936086|NCT05773703|EXPERIMENTAL|Trillium Compound + Single Dose PTI-122|Single dose of PSMA-Targeted \[In-111\]-Labeled Trillium Compound plus single dose of PTI-122 at 5, 10 or 15 mg
61936087|NCT05773703|EXPERIMENTAL|Trillium Compound + Multiple Dose PTI-122|Single dose of PSMA-Targeted \[In-111\]-Labeled Trillium Compound plus two doses of PTI-122 at the preferred dose level
61936088|NCT05426798|EXPERIMENTAL|TQB2618 injection|TQB2618 injection combined with demethylation drugs, 28 days as a treatment cycle until the disease progresses or the investigator judges that it is not suitable for subject to continue to take medicine.
61936089|NCT06288126||High Risk Group|This group include women at high risk for gestational diabetes (GDM) according to most of the European guidelines. They have one or more of the following criteria: age ≥35 years, overweight or obesity, family history of diabetes, high-risk ethnicities, history of previous GDM or previous macrosomia, and high levels of fasting glycemia during the first trimester screening.
61936090|NCT06288126||Low Risk Group|This group will include women at low risk for GDM according to most of the European guidelines. They have none of the following criteria: age ≥35 years, overweight or obesity, family history of diabetes, high-risk ethnicities, history of previous GDM or previous macrosomia, and high levels of fasting glycemia during the first trimester screening.
62488197|NCT04323527|ACTIVE_COMPARATOR|Low Dose Chloroquine Diphosphate (5 days) (Study stage 1) - Clorocovid 1|Low dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
62488198|NCT04323527|ACTIVE_COMPARATOR|High Dose Chloroquine Diphosphate (10 days) (Study stage 1) - Clorocovid 1|High dose chloroquine group consists of 600 mg bid (4 tablets of 150 mg, every 12 hours) for 10 days. Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
62693847|NCT05749094||Non-GCA group|Participants who do not meet the composite clinical test validation for GCA (above).
62135302|NCT05443464|EXPERIMENTAL|6M cells/kg|Dose level 2. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 6M cells/kg and followed for 28 days post dose to observe for DLT.
62330539|NCT05687695|ACTIVE_COMPARATOR|core training group|six weeks of core training 3 times per week
62330540|NCT05687695|NO_INTERVENTION|control group|patients will not receive any intervention for six weeks
62330541|NCT03087825|SHAM_COMPARATOR|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
62488199|NCT04323527|PLACEBO_COMPARATOR|Placebo (5 days) (Study stage 2) - Clorocovid 3|Placebo group consists of 3 placebo tablets bid (day 1), and 3 placebo tablets once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
62488200|NCT04323527|ACTIVE_COMPARATOR|Low Dose Chloroquine Diphosphate (5 days) (Study stage 2) - Clorocovid 3|Low dose chloroquine group consisted of 450 mg bid (3 tablets of 150 mg) on D1, and 3x150mg tablet once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
62135303|NCT05443464|EXPERIMENTAL|12M cells/kg|Dose level 3. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 12M cells/kg and followed for 28 days post dose to observe for DLT.
62330542|NCT03087825|ACTIVE_COMPARATOR|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
62330543|NCT05323968|OTHER|Acute diverticulitis|Patients with clinical suspicion of acute diverticulitis
62330544|NCT00303108|EXPERIMENTAL|Arm 1|Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.
62330545|NCT01601054|ACTIVE_COMPARATOR|Anterior lumbar interbody fusion|Anterior lumbar interbody fusion using a tantalum cage. Cage will be inserted through a left sided retroperitoneal approach.
62330546|NCT01601054|ACTIVE_COMPARATOR|Posterior instrumentation alone|Posterior pedicle screw instrumentation
62330547|NCT05108909||mild to moderate traumatic brain injury|patients diagnosed with mild to moderate traumatic brain injury within 1 week after onset of TBI.
62330548|NCT05108909||isolated orthopaedic trauma patients|Patients with isolated orthopaedic trauma were identified and enrolled using the same process as that for patients with TBI.
62330549|NCT05108909||healthy non-injury control|Healthy non-injured controls were recruited either via a relationship with a TRACK-TBI participant or through public advertisement within TRACK-TBI institutions, and were able to provide informed consent.
62330550|NCT05115500|EXPERIMENTAL|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|
62330551|NCT06462417|EXPERIMENTAL|Arbidol|Arbidol Hydrochloride Tablets
62330552|NCT03757481|OTHER|no intervention|patients with history of PE (pulmonary embolism) with acute DVT (deep veinous thrombosis) treated with heparin plus edoxaban or heparin plus warfarin
62330553|NCT02002442|ACTIVE_COMPARATOR|0.12% Chlorhexidine|Alcohol-free Chlorhexidine Gluconate Oral Rinse USP, 0.12% from GUM®
62488201|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
62488202|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
62488203|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
62488204|NCT03759704||Hyperpolarized 13CPyruvate and gadolinium|Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
62693848|NCT03809351|EXPERIMENTAL|[F-18]AV-1451-PET/MRI|All participants in this study will undergo a tau-PET imaging using the tracer \[F-18\]AV-1451 with a simultaneous PET/MRI system. The \[F-18\]AV-1451 dosage is 740MBq (10 mCi) given intravenously, and the PET/MRI imaging will occur 75-105 min after tracer injection.
62693849|NCT06332352|EXPERIMENTAL|Intra-Articular hip injection of PRP|Single Group Assignment Recruitment will occur at the University of Utah Orthopedic Center by physician and study staff members medical chart review before patient visits. 45 mL of blood will be collected from eligible participants and processed. A single processed neutrophil-poor PRP injection will be given once to a single hip.
62330554|NCT02002442|ACTIVE_COMPARATOR|Essential oil|LISTERINE® ZERO™ Mouthwash
62488205|NCT05545436|EXPERIMENTAL|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX / XELOX
62488206|NCT05416424|EXPERIMENTAL|Study group|Healthy patients aged 18-50 who have a uterus, identify as female and have come to the outpatient Center for Women's Health (CWH) for management of bleeding, pelvic pain and fibroids. They will be offered enrollment post-surgery or procedure and will be followed longitudinally for 12 months.
62488207|NCT04779827|EXPERIMENTAL|Egalitarian Networks of Homogeneous Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
62488208|NCT04779827|EXPERIMENTAL|Egalitarian Networks of Diverse Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
62330555|NCT02002442|ACTIVE_COMPARATOR|0.07% Cetylpyridinium Chloride|Crest Pro-Health Multi-Protection Rinse - Refreshing Clean Mint (Procter and Gamble)
62330556|NCT02002442|PLACEBO_COMPARATOR|Saline|
62330557|NCT03866863||HFME births.|All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2017.
62330558|NCT04917835|EXPERIMENTAL|treatment with argon- and nitrogen-NTAPP|PLADUO (argon- and nitrogen- non-thermal, atmospheric-pressure plasma) treatment
62330559|NCT02184143|EXPERIMENTAL|CBPT intervention|CBPT program consisting of weekly phone calls.
62330560|NCT02184143|ACTIVE_COMPARATOR|Education intervention|Education program consisting of weekly phone calls.
62330561|NCT04950582||UTI-high risk patients|patients who are at high risk for developing a urinary tract infection (UTI).
62330562|NCT05390450|EXPERIMENTAL|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block.
62330563|NCT05390450|EXPERIMENTAL|Ultrasound-Guided Fascia Iliaca block|Patients in this group will receive Fascia Iliaca block.
62330564|NCT02692339||Lenalidomide/Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma
61936091|NCT03708848|EXPERIMENTAL|Tailored Therapy|Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.
62135304|NCT05443464|EXPERIMENTAL|24M cells/kg|Dose level 4. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 24M cells/kg and followed for 28 days post dose to observe for DLT.
62693850|NCT06625931|EXPERIMENTAL|NTCB01-1|
61936092|NCT05394714|EXPERIMENTAL|Magicell-NK|Magicell-NK Cohort 1: 2 x 10\^8 cells x 6 infusions Cohort 2: 6 x 10\^8 cells x 6 infusions Cohort 3: 12\~18 x 10\^8 cells x 6 infusions
61936093|NCT03969511|EXPERIMENTAL|Direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and pre stroke mRS, and performing the blood sample, patient undergoes rotational CBCT in order to exclude intracerebral hemorrhage and cerebral angiography to confirm proximal arterial occlusion. Mechanical thrombectomy is then performed as well as intravenous thrombolysis in the absence of contraindications.
61936094|NCT03969511|ACTIVE_COMPARATOR|Standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy, mechanical thrombectomy or intravenous thrombolysis alone when indicated.
61936095|NCT01674283|EXPERIMENTAL|Glucagon|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.~The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer."
62135305|NCT05838469|EXPERIMENTAL|Strip Crown|This is a single-arm study. High viscosity glass ionomer strip crowns will be performed to all patients.
62135306|NCT03621735|OTHER|Sham then Active|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
62135307|NCT03621735|OTHER|Active then Sham|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both an active treatment and a sham treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
62135308|NCT04680845|EXPERIMENTAL|Self-affirmation|"Participants will be asked to complete a standard questionnaire including:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will... ...think about the things I value about myself~* remember things that I have succeeded in~* think about what I stand for~* think about things that are important to me~If...______________________________________________________________________"
62135309|NCT04680845|NO_INTERVENTION|Control|Participants will be asked to complete a standard questionnaire.
62135310|NCT02972788|EXPERIMENTAL|Experimental Group|Group will receive enamel matrix protein derivative treatment along with scaling and root planing.
62135311|NCT02972788|SHAM_COMPARATOR|Control Group|Group will receive placebo (saline) treatment along with scaling and root planing.
62135312|NCT04224792|EXPERIMENTAL|Center-based exercise group|Subjects will be enrolled into a center-based exercise program.
62135313|NCT04224792|EXPERIMENTAL|Home-based exercise group|Subjects will be enrolled into a home-based exercise program.
62135314|NCT01784328|OTHER|Use of a bowel irrigation system|Open label. No placebo use in this study. All volunteers will trial the bowel irrigation system. Eligible volunteers will be those patients who have failed conventional supportive bowel care.
62135315|NCT06154876|EXPERIMENTAL|Cough assist device and designed chest physical therapy|Cough assist device involved 3-5 cycles with insufflation/exsufflation pressure beginning with +15 cm H2O to -15 cm H2O and maximum pressure of +40 cm H2O to -40 cm H2O for 4-5 sets for pediatric patients .and percussion, vibration, end expiratory pressure and bed mobility exercise.
62135316|NCT06154876|ACTIVE_COMPARATOR|Designed chest physical therapy|Percussion, vibration, end expiratory pressure and bed mobility exercise.
62135317|NCT05142189|EXPERIMENTAL|Cohort 1A - BNT116 monotherapy|
62135318|NCT05142189|EXPERIMENTAL|Cohort 1B - BNT116 monotherapy|
62135319|NCT05142189|EXPERIMENTAL|Cohort 2 - BNT116 + cemiplimab (PD-1/PD-L1 inhibitor refractory/relapsed patients)|
62135320|NCT05142189|EXPERIMENTAL|Cohort 3 - BNT116 + docetaxel|
62135321|NCT05142189|EXPERIMENTAL|Cohort 4 - BNT116 + cemiplimab (frail patients)|
62135322|NCT05142189|EXPERIMENTAL|Cohort 5 - BNT116 + cemiplimab (after concurrent chemoradiotherapy [CRT])|
62135323|NCT05142189|EXPERIMENTAL|Cohort 6 - BNT116 + cemiplimab + carboplatin + paclitaxel|BNT116 + cemiplimab + carboplatin + paclitaxel as neo-adjuvant treatment followed by surgery, thereafter adjuvant treatment with BNT116 + cemiplimab
62135324|NCT05142189|EXPERIMENTAL|Cohort 7 - BNT116 + CTLA4 antibody|Dose finding for the combination of BNT116 with CTLA4 antibody with dose escalation of the CTLA4 antibody
62135325|NCT03075254||Healthy Control|normal volunteers (HC) Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
62693851|NCT06625931|ACTIVE_COMPARATOR|NTCB-P|
62693852|NCT06562946|EXPERIMENTAL|The mild (Child-Pugh score 5 to 6) hepatic impairment.|Subjects will enter the study site on Day -1 and will remain there until after the collection of the 48 h PK samples on Day 3. On Day 1 all participants will receive a single 25 mg oral dose of pimicotinib under fasting conditions, followed by extensive blood collection and urine sample collection for measurement of pimicotinib and its metabolites.
62488209|NCT04779827|EXPERIMENTAL|Centralized Networks of Homogeneous Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices."
62488210|NCT04779827|EXPERIMENTAL|Centralized Networks of Diverse Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices."
62693853|NCT06562946|EXPERIMENTAL|The moderate (Child-Pugh score 7 to 9) hepatic impairment.|Subjects will enter the study site on Day -1 and will remain there until after the collection of the 48 h PK samples on Day 3. On Day 1 all participants will receive a single 25 mg oral dose of pimicotinib under fasting conditions, followed by extensive blood collection and urine sample collection for measurement of pimicotinib and its metabolites.
62693854|NCT06562946|EXPERIMENTAL|The healthy subjects.|Subjects will enter the study site on Day -1 and will remain there until after the collection of the 48 h PK samples on Day 3. On Day 1 all participants will receive a single 25 mg oral dose of pimicotinib under fasting conditions, followed by extensive blood collection and urine sample collection for measurement of pimicotinib and its metabolites.
62693855|NCT05272280|ACTIVE_COMPARATOR|External oblique intercostal (EOI) block|
62693856|NCT05272280|ACTIVE_COMPARATOR|Erector spinae plane block (ESPB)|
62330565|NCT02123160|EXPERIMENTAL|Child Parent Psychotherapy (CPP)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads will be randomly assigned to either Child Parent Psychotherapy (CPP) treatment or control (usual treatment) group. CPP treatment will be conducted by a CPP study clinician over approximately six months (24 weekly sessions). CPP includes developmental guidance and fostering affect regulation , continuity in daily living, reciprocity between mother and child, and helping the mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma.
62330566|NCT02123160|ACTIVE_COMPARATOR|Usual Treatment|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred for usual treatment via referral to therapists in the community and at Columbia University Medical Center, for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Additionally, control patient dyads will be monitored through regular contact with the study research assistant. If the research assistant detects worsening of depressive symptoms or the presentation of new symptoms, a licensed study clinician will follow up to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
62330567|NCT01395589|ACTIVE_COMPARATOR|Injectable + oral vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL.
62330568|NCT01395589|ACTIVE_COMPARATOR|Oral-only Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL.
62330569|NCT04604236|EXPERIMENTAL|Mapping Enhanced Counseling (MEC)|MEC will target attitudes and norms. Attitudes include motivation for change, such as problem recognition and a belief that treatment will help. Subjective norms include normative beliefs about SU in adolescence (e.g., belief that it is ok to allow SU with parental supervision; experimentation is normal) and expectations about treatment.
62330570|NCT04604236|EXPERIMENTAL|Active Linkage (AL)|AL will target perceived control. Perceived control includes perceived logistical barriers and the degree to which individuals feel they can overcome them.
62339965|NCT01021852|EXPERIMENTAL|Placebo/MK-6096 5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
62488211|NCT04779827|EXPERIMENTAL|Independent Control of Homogeneous Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
62693857|NCT03066180|EXPERIMENTAL|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
62693858|NCT03066180|EXPERIMENTAL|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
62693859|NCT05826626|EXPERIMENTAL|Experimental Group|The group will undergo 10 sessions (2 weeks) of a treatment combining prismatic adaptation (PA) and serious games (SG) for cognitive training, using the Mindlenses Professional device. In each session, the PA procedure will be performed, followed by approximately 30 minutes of SG. SG will be focused on attention, executive functions and language.
62693860|NCT05826626|ACTIVE_COMPARATOR|Control Group -1|The group will undergo 10 sessions (2 weeks) of a treatment using the serious games (SG) for cognitive training provided by the Mindlenses Professional device. SG will be focused on attention, executive functions and language.
62693861|NCT05826626|ACTIVE_COMPARATOR|Control Group -2|The group will perform 2 weeks of the standard cognitive training offered by IRCCS San Camillo Hospital.
62693862|NCT05971173|EXPERIMENTAL|Nutritional Supplements|Juven and Centrum Silver 50+ will be administered to this group
62693863|NCT05971173|NO_INTERVENTION|Control|Standard of care procedures
62693864|NCT04304300||Study group|Glioma, IDH mutated, grade 2 and 3
62135326|NCT03075254||Fibromyalgia Only|The diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
62330571|NCT05493865|EXPERIMENTAL|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|The PC-SMILE integrates the growth mindsets of intelligence, failure, and negative emotions and introduces these growth mindsets to students and parents, which consist of five components: (a) an introduction to brain functions regarding the potential of neuroplasticity and the possibility of changes in intelligence and emotions; (b) stories and testimonials from high-school-aged youths who describe their beliefs-in-change; (c) short videos with stories of improving intelligence and emotions and of failure-is-enhancing; (d) common questions and misconceptions about growth mindset; and (e) self-persuasion writing exercises in which the participants write notes to young students/others about the growth mindsets. The interventions for parents and students are different in terms of narrative and content. A total of 10 weekly booster messages with core intervention content will be sent between the two-week post-test and the three-month follow-up survey.
62330572|NCT05493865|EXPERIMENTAL|The Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (C-SMILE)|The C-SMILE only provides intervention to children, which has the same components as PC-SMILE.
62330573|NCT05493865|NO_INTERVENTION|Waitlist control group|The waitlist control group will continue with normal education activities and do the pre- and post-intervention surveys at the same timeframe as the intervention groups. Participants in the waitlist group and C-SMILE group will be invited to complete the PC-SMILE after the three-month post-intervention survey.
62330574|NCT06484530|EXPERIMENTAL|NAT2 gene testing group|Tuberculosis patients will undergo NAT2 gene testing before starting anti-tuberculosis medication. If the NAT2 gene phenotype is identified as slow acetylator, the patient will receive NAC medication at a dose of 600 mg twice daily for 8 weeks in addition to anti-tuberculosis medication. If the NAT2 gene phenotype is identified as rapid or intermediate acetylator, the patient will receive only anti-tuberculosis medication.
62330575|NCT06484530|NO_INTERVENTION|Non NAT2 gene testing|Tuberculosis patients will receive standard anti-tuberculosis medication without NAT2 gene testing.
62330576|NCT04462718|ACTIVE_COMPARATOR|CONTROL GROUP:|You will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks.
62330577|NCT04462718|EXPERIMENTAL|EXPERIMENTAL GROUP|"After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.~The treatment is administered with a pulsatile short-wave equipment and inductive electrodes of 100 W peak power, with a frequency of application of twice daily with a dose submitis (grade I), for 10 min, with a frequency of repetition of the impulses of 46 Hz and a pulse duration of 0.2 ms."
62330578|NCT03539458|EXPERIMENTAL|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
62488212|NCT04779827|EXPERIMENTAL|Independent Control of Diverse Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
62488213|NCT01402050|ACTIVE_COMPARATOR|FOLEY BALLOON|Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
62693865|NCT04304248|EXPERIMENTAL|Neoadjuvant chemo-immunotherapy|"Neoadjuvant treatment (Albumin-bound paclitaxel + carboplatin + toripalimab) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment."
62488214|NCT01402050|ACTIVE_COMPARATOR|CERVIDIL|
62693866|NCT06354049|EXPERIMENTAL|Reiki therapy|This is a feasibility single arm trial of Reiki for oncology participants.
62693867|NCT06089317|ACTIVE_COMPARATOR|Compound Decoction (CD) group|
62693868|NCT06089317|ACTIVE_COMPARATOR|Dendrobii Caulis (DC) group|
62693869|NCT06089317|ACTIVE_COMPARATOR|Houttuynia Cordata (HC) group|
61936096|NCT01674283|PLACEBO_COMPARATOR|Sodium chloride 0.9%|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.~The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer."
61936097|NCT04399837|EXPERIMENTAL|Spesolimab SC low dose|
61936098|NCT04399837|EXPERIMENTAL|Spesolimab SC medium dose|
62693870|NCT06089317|PLACEBO_COMPARATOR|Placebo Atomization (PA) group|
61936099|NCT04399837|EXPERIMENTAL|Spesolimab SC high dose|
61936100|NCT04399837|PLACEBO_COMPARATOR|Placebo|
61936101|NCT04795622|EXPERIMENTAL|Treatment Ulthera System|
62693871|NCT06089317|OTHER|Artificial Tears (AT) group|
62693872|NCT06337305||Bladder cancer patients undergoing radical cystectomy.|This is a prospective cross-sectional survey of bladder cancer patients undergoing radical cystectomy.
62693873|NCT05056818||Observational (medical records)|Patients' medical records and past imaging examinations are reviewed.
61936102|NCT04795622|OTHER|Delayed-treatment Ulthera System|
61936103|NCT05678582||HBV with hepatic steatosis|HBV with hepatic steatosis on liver biopsy
61936104|NCT05678582||HBV without hepatic steatosis|HBV without hepatic steatosis on liver biopsy
61936105|NCT04622462||Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia|"No evidence of dysplasia~Mild dysplasia~Moderate dysplasia~Severe dysplasia"
61936106|NCT03469570|EXPERIMENTAL|Assisted Fluid Management|Subjects enrolled in the validation study will have their fluid management decisions guided by the Acumen™ Assisted Fluid Management Feature. The Principal Investigator will accept or decline fluid recommendations.
61936107|NCT05059587|EXPERIMENTAL|MBA-P01|MBA-P01 will be injected into the GL: initial double-blind treatment on Day 1.
61936108|NCT05059587|ACTIVE_COMPARATOR|BOTOX®|BOTOX® will be injected into the GL: initial double-blind treatment on Day 1.
62693874|NCT01141764|EXPERIMENTAL|Study Group|"In our study, patients will be scanned with their DBS electrodes turned on and off.~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.~Procedures performed in this study are not part of the standard management of epilepsy."
62330579|NCT06252311|EXPERIMENTAL|Mindfulness-Based Breastfeeding Programme group|"Participants in the experimental group will receive the Mindfulness-Based Breastfeeding Programme, which consists of six 30-minute sessions within 0-72 hours. They will also be asked to complete a personal information form. In addition to the hospital sessions, educational materials, including home applications and audio recordings, will be sent via WhatsApp after discharge. During the first week after discharge, counselling will be provided by phone or WhatsApp on the continuation of mindfulness-based practices, continuation of breastfeeding and problems related to breastfeeding, and referral to the health facility in case of problems, Iowa Infant Feeding Attitude Scale and Mindful Breastfeeding Scale will be administered by phone call in the 2nd month and finally the Infant Feeding Follow-up Form prepared by the researcher based on the literature will be used to assess the continuity of breastfeeding in the 1st week, 2nd month, 4th month and 6th month."
62330580|NCT06252311|NO_INTERVENTION|Control group|After the women in the control group have been informed about the study and have given their consent, they will complete a personal information form and then receive general information about correct breastfeeding technique, duration and breast care. They will also receive routine breastfeeding support and standard hospital care. The control group will be administered the Iowa Infant Feeding Attitude Scale and the Mindful Breastfeeding Scale by telephone interview at month 2 and the Infant Feeding Follow-up Form at week 1, month 2, month 4 and month 6.
61936109|NCT01147172|EXPERIMENTAL|Elevess|Gel implant (dermal filler) composed of hyaluronan produced by Streptococcus equi (bacterial fermentation) that is cross-linked and suspended in phosphate buffered saline with 0.3% lidocaine HCl and 0.1% sodium metabisulfite
61936110|NCT05135247|EXPERIMENTAL|continuous aerobic training (CA)|The CA group was trained with 70% of maximum heart rate (MHR) for 30 minutes.
62330581|NCT01640587|EXPERIMENTAL|DP|2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
62330582|NCT01640587|ACTIVE_COMPARATOR|MAS3|4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2
62330583|NCT00952289|EXPERIMENTAL|Ruxolitinib|Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count \> 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
62330584|NCT00952289|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.
62330585|NCT05794932|EXPERIMENTAL|Stress test|All patients will undergo a stress test before and after venous recanalization.
62330586|NCT05889520||Lactacting women who are breastfeeding full-term infants|Caucasian women aged between 18 and 35 who are breastfeeding full-term infants observed at Pediatrics Section of Department of Translational Medical Sciences (University of Naples Federico II)
62330587|NCT05073458|EXPERIMENTAL|Group A: Parsaclisib|Participants will receive parsaclisib for 24 weeks (double-blind period). Participant who completed the double-blind period and tolerating the study treatment upon investigator's opinion will continue into open-label period for an additional 24 weeks. Participants may then continue to receive parsaclisib in a long-term extension period.
62330588|NCT05073458|PLACEBO_COMPARATOR|Group B: Placebo followed by Parsaclisib|Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive parsaclisib in the 24 week open-label period. Participants may then continue to receive parsaclisib in a long-term extension period.
62330589|NCT01264250|EXPERIMENTAL|1|
62330590|NCT01264250|PLACEBO_COMPARATOR|2|
62330591|NCT06210191|EXPERIMENTAL|union of fracture|Intramedullary headless screw fixation for metacarpal and phalangeal fractures
62693875|NCT06041139||Alcon PanOptix|Patients will have had bilateral implantation of PanOptix IOLs with the toric and/or non-toric models at the time of uncomplicated cataract surgery.
61936111|NCT05135247|EXPERIMENTAL|resistance training (R)|The R sessions consisted of a set of each proposed exercise: sitting bench press, legpress, back row, leg extension, shoulders high pull, seated leg curl, biceps curls, standing calf, triceps in the pulley, and abdominal crunches, with 8 - 10 repetitions with 75% 1MR.
62135327|NCT03075254||Chronic fatigue and Fibromyalgia Syndrome|Diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
62135328|NCT04209712|EXPERIMENTAL|haploid allogeneic NK cell therapy|haploid allogeneic NK cell therapy with chemotherapy
62330592|NCT02742922|EXPERIMENTAL|Culturally adapted therapy (C-MAP)|Culturally adapted manual assisted (C-MAP) brief problem solving therapy
62693876|NCT06041139||Johnson & Johnson Synergy|Patients will have had bilateral implantation of Synergy IOLs with the toric and/or non-toric models at the time of uncomplicated cataract surgery.
62693877|NCT03163667|ACTIVE_COMPARATOR|CB-839 + Everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
62693878|NCT03163667|PLACEBO_COMPARATOR|Placebo + Everolimus|Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles.
61936112|NCT05135247|EXPERIMENTAL|interval aerobic training (IA)|The IA group was submitted to exercise intensities of 60% for 2 minutes and 80% for 2 minutes, alternately, with a total of 30 minutes.
61936113|NCT05135247|NO_INTERVENTION|control (C)|Individuals in the control group maintained their usual activities.
61936114|NCT01945112|EXPERIMENTAL|Paper Tape|Paper tape will be applied to study participants' blister prone areas or a randomly selected spot (if no blister history on that foot) - with untaped areas of the same foot as control.
61936115|NCT05588271||Group with PIs|stage 1pressure injury: non-blanchable erythema of intact skin; stage 2 pressure injury: partial-thickness skin loss with exposed dermis; stage 3 pressure injury: full-thickness skin loss; stage 4 pressure injury: full-thickness skin and tissue loss; unstageable pressure injury: obscured full-thickness skin and tissue loss; deep tissue pressure injury: persistent non-blanchable deep red, maroon or purple discoloration
61936116|NCT05588271||Group without PIs|Skin in good condition
62135329|NCT02109601|ACTIVE_COMPARATOR|Control|Control patients receive iPad tablets during their hospital stay with only LIMITED bedside training from a research assistant on how to access and effectively use their patient portal.
62330593|NCT02742922|NO_INTERVENTION|Treatment as usual|This arm will receive no intervention only TAٓU.
62330594|NCT00786838|EXPERIMENTAL|Trabectedin|3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).
62330595|NCT00443378|EXPERIMENTAL|1|"Arm 1, CARE+ arm is the study arm that receives the CARE+ computer intervention."
62330596|NCT00443378|NO_INTERVENTION|2|Arm 2, the control arm, is the study arm that receives computerized risk assessment only.
62330597|NCT01560546|ACTIVE_COMPARATOR|Testim|
62330598|NCT01560546|PLACEBO_COMPARATOR|Placebo|Placebo for 24 weeks
62330599|NCT05959772|EXPERIMENTAL|Photobiomodulation ON|Photobiomodulation therapy Group PBM Application of Photobiomodulation exposure time between 4 and 9 minutes, application of PBM with treatment time of 5 weeks
62330600|NCT05959772|PLACEBO_COMPARATOR|Photobiomodulation Off|Photobiomodulation Placebo Group Appication of Photobiomodulatio off, time between 4 and 9 minutes, to 5 weeks
62330601|NCT01429987|EXPERIMENTAL|plecanatide 0.3 mg|Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
62330602|NCT01429987|EXPERIMENTAL|plecanatide 1.0 mg|Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
62330603|NCT01429987|EXPERIMENTAL|plecanatide 3.0 mg|Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
61936117|NCT04053634|EXPERIMENTAL|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
61936118|NCT04053634|PLACEBO_COMPARATOR|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
61936119|NCT01509508|EXPERIMENTAL|Immediate ARV treatment initiation|Initiation of ARV treatment regardless of participants's immunological and clinical staging
61936120|NCT01509508|OTHER|South African recommendation guided ARV initiation|HIV-infected individuals will be assessed clinically and immunologically and when eligible for treatment as per South African guidelines will be offered ART
61936121|NCT01079507||adult acute lymphoblastic leukemia|Patients were diagnosed as adult acute lymphoblastic leukemia.
61936122|NCT02783677||DM with PAD before angioplasty|Diabetic patients diagnosed with peripheral artery disease via vascular Duplex.
61936123|NCT02783677||DM without PAD|Diabetic patients diagnosed without peripheral artery disease via vascular Duplex.
61936124|NCT02783677||Healthy volunteers|Healthy volunteers
62135330|NCT02109601|EXPERIMENTAL|Intervention|Intervention patient receive iPad tablets during their hospital stay with EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
62135331|NCT02240420|ACTIVE_COMPARATOR|Life Style counseling (Star-Mama)|Star-Mama intervention group will receive during 6 months weekly phone calls with queries and narratives about health habits. The participant's answers will be sent to a health coach who will follow up with the participant, and develop a plan with the participant to address her needs.
62135332|NCT02240420|NO_INTERVENTION|Educational Resource Support|Participants in the control group of the study will receive a set of educational materials with information about their health and the health of their babies.
61936125|NCT02783677||DM with PAD after angioplasty|Diabetic patients diagnosed with PAD underwent balloon-angioplasty
61936126|NCT00920101|ACTIVE_COMPARATOR|Atorvastatin|
61936127|NCT00920101|PLACEBO_COMPARATOR|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
61936128|NCT00943124|EXPERIMENTAL|MK0524B then Simvastatin + MK0524A|"Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).~Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets."
61936129|NCT00943124|EXPERIMENTAL|Simvastatin + MK0524A then MK0524B|"Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.~Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg)."
61936130|NCT03796533|OTHER|Posaconazole pharmacokinetics|Patients with AML over the age of 18 years treated with intensive chemotherapy in induction and consolidation whose was under antifungal prophylaxis by PCZ formulation tablets.
62135333|NCT01260870|EXPERIMENTAL|Cotavance|
62135334|NCT01260870|ACTIVE_COMPARATOR|Standard balloon angioplasty|POBA
62135335|NCT03476798|EXPERIMENTAL|Bevacizumab + Rucaparib|
62330604|NCT01429987|PLACEBO_COMPARATOR|Placebo|Subjects receive placebo for 12 consecutive weeks
62330605|NCT01071746||Acute decompensation of cirrhosis|acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
62330606|NCT02336594|EXPERIMENTAL|Sequence ABCD|2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.
62330607|NCT02336594|EXPERIMENTAL|Sequence BACD|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat
62330608|NCT02336594|EXPERIMENTAL|Sequence ABDC|2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
62330609|NCT02336594|EXPERIMENTAL|Sequence BADC|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
62330610|NCT01488825|NO_INTERVENTION|Wait-list control group|The wait-list control group received no intervention, or instruction and they were observed with their usual care for 12-weeks intervention period. Upon completion of the study, this group received 12 weeks of yoga intervention.
62330611|NCT01488825|EXPERIMENTAL|Yoga Intervention Group|The yoga sessions developed specifically for study participant consisted of 12 weekly 60-minute designed to benefit in episodic tension type headache.
62330612|NCT04517617||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
62330613|NCT01193348|EXPERIMENTAL|Eculizumab|
62693879|NCT02088086|EXPERIMENTAL|BMI screening and reporting (Group 1)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will send BMI reports home to parents.
62135336|NCT05477316|EXPERIMENTAL|Treatment|Intensity-modulated Radiation Therapy (IMRT)/VMAT with integrated boost to the cerebellum and metastases and Stereotactic Radiosurgery (SRS) to the cerebral metastases as a novel treatment combination for brain metastases
62135337|NCT04229368|ACTIVE_COMPARATOR|Low Vitamin D3 Supplementation|Subjects enrolled into Group 1 (low-dose Vitamin D3 supplementation) will receive 800 IU of oral Vitamin D3 (Cholecalciferol) daily for 4 weeks prior to surgery, followed by 800 IU of oral Vitamin D3 daily for 3 months after surgery. Vitamin D3 supplementation will be given for a total of 4 months. Supplementing Vitamin D-deficient patients with a minimum of 800 IU of Vitamin D3 daily is supported by the IOM.
62330614|NCT06187987||FlowTriever|Acute PE patients treated with the FlowTriever device
62330615|NCT06187987||Intravenous Thrombolysis|Acute PE patients treated with intravenous thrombolysis
62330616|NCT01831973|EXPERIMENTAL|Lipotecan, injection for chemotherapy|Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
62330617|NCT02566525|EXPERIMENTAL|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
62330618|NCT02566525|NO_INTERVENTION|Control|Standard of care
62330619|NCT05275738|ACTIVE_COMPARATOR|Nicotinamide|Participants will receive 750mg nicotinamide tablets 1+1 per day (1.5g) for 6 weeks and after that 2+2 per day (3.0g).
62330620|NCT05275738|PLACEBO_COMPARATOR|Placebo|Participants will receive 750mg placebo tablets 1+1 per day for 6 weeks and after that 2+2 per day.
62330621|NCT05878808||Cases with ocd|
62330622|NCT05878808||Cases without ocd|
62330623|NCT02734589|ACTIVE_COMPARATOR|Fecal microbiota transplantation (FMT) without Diet|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 from the same donor without dietary conditioning.
62330624|NCT02734589|EXPERIMENTAL|FMT with Diet for the donor and for the recipient|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 with dietary pre-conditioning of the donor for 14 days and dietary treatment of the recipient immediately after transplantation and for the following 12 weeks.
62693880|NCT02088086|ACTIVE_COMPARATOR|BMI screening only (Group 2)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will NOT send BMI reports home to parents.
62693881|NCT02088086|NO_INTERVENTION|No BMI screening or reporting (Group 3)|For two school years, 3rd-8th grade students will NOT have their heights and weights measured at school.
62693882|NCT06638437|EXPERIMENTAL|CBT group|The treatment arm will carry out the CBT preventive program before surgery
62693883|NCT06638437|NO_INTERVENTION|Control group|The control arm will not do any preventive program (traditional monitoring)
62135338|NCT04229368|ACTIVE_COMPARATOR|High Vitamin D3 Supplementation|Subjects enrolled into Group 2 (high-dose Vitamin D3 supplementation) will receive 50,000 IU of oral Vitamin D3 (Cholecalciferol) twice per week for 1 weeks followed by 50,000 IU once per week for 3 weeks prior to surgery. After surgery they will receive 50,000 IU of oral Vitamin D3 once per week for 4 weeks followed by 800 IU daily for 8 weeks. Vitamin D3 supplementation will be given for a total of 4 months.
62330625|NCT02734589|ACTIVE_COMPARATOR|Dietary therapy only|The patient will receive detailed instructions regarding the UC diet to be used over 12 weeks without FMT.
62330626|NCT05872971|EXPERIMENTAL|Dry Needling|The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN.
62330627|NCT05872971|ACTIVE_COMPARATOR|Lasertherapy|The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics.
62330628|NCT02020096|EXPERIMENTAL|U+N group|Ultrasound and nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic block
62330629|NCT02020096|ACTIVE_COMPARATOR|N group|Nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic nerve block
62330630|NCT00649467|EXPERIMENTAL|1|Topiramate Sprinkle Capsules 25 mg
62330631|NCT00649467|ACTIVE_COMPARATOR|2|Topamax® Sprinkle Capsules 25 mg
62330632|NCT05954832||Echocardiography|Patients participating in this study will undergo routine anesthetic and perioperative care with the addition of an echocardiography and Clearsight BP measurement.
62330633|NCT01249872|ACTIVE_COMPARATOR|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
62330634|NCT01249872|ACTIVE_COMPARATOR|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
62330635|NCT01249872|ACTIVE_COMPARATOR|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
62693884|NCT06640946|PLACEBO_COMPARATOR|Placebo|Sham cream placed and then removed prior to laser follicle ablation.
62693885|NCT06640946|ACTIVE_COMPARATOR|Active agent|Topical lidocaine cream placed and then removed prior to laser follicle ablation.
62693886|NCT04375826|ACTIVE_COMPARATOR|Epidural analgesia|Only Epidural analgesia is used for this group
62693887|NCT04375826|ACTIVE_COMPARATOR|Preperitoneal analgesia and IV-PCA|This group is given with both preperitoneal analgesia and Intravenous Patient Controlled Analgesia (IV-PCA)
62488215|NCT02382224|EXPERIMENTAL|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
62488216|NCT02382224|PLACEBO_COMPARATOR|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
62488217|NCT02311894|EXPERIMENTAL|Somatropin|Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
62488218|NCT01378962|EXPERIMENTAL|Single Arm|
62488219|NCT06095596|EXPERIMENTAL|Combination treatment group|A combination treatment of vedolizumab and upadacitinib for 8 weeks in the induction therapy, then followed by a single treatment of vedolizumab in the maintenance therapy
62488220|NCT06095596|PLACEBO_COMPARATOR|Single treatment group|single treatment of vedolizumab both in the induction and maintenance therapy
62488221|NCT06173050|OTHER|PAP System A (with Amalfi) then PAP System B (with CLA11)|Participants will be asked to take home the investigational PAP system (Amalfi) to use at night while they sleep in place of their own PAP system. The participant's therapy and comfort settings will not be altered. Participants will be randomized as to the order they will trial PAP System A and PAP System B. This arm will first use the Amalfi for 7 days and then use the CLA 11 for 7 days.
62488222|NCT06173050|ACTIVE_COMPARATOR|PAP System B (with CLA11) then PAP System A (with Amalfi)|Participants will be asked to take home the comparator PAP system B (CLA 11) to use at night while they sleep in place of their own PAP system. The participant's therapy and comfort settings will not be altered. Participants will be randomized as to the order they will trial PAP System B and PAP System A. This arm will first use the CLA 11 for 7 days and then use the Amalfi for 7 days.
62488223|NCT05604014|EXPERIMENTAL|My Health Coach|Participants receive the My Health Coach app and try it on their personal smartphones for 6 weeks.
62488224|NCT05206851|EXPERIMENTAL|Manual Lymphatic Drainage and Hot pack|
62693888|NCT06672809|EXPERIMENTAL|Core Stability Training Group|This group receives core stability training aimed at strengthening deep stabilizing muscles, including the transversus abdominis, to improve lumbar support and control. Participants perform a 50-minute session three times per week over eight weeks, focusing on exercises using unstable surfaces like the Pilates reformer to enhance proprioception and core engagement.
62693889|NCT06672809|ACTIVE_COMPARATOR|Control Group|This group participates in aerobic exercise sessions as a comparative intervention. Participants engage in a 50-minute session three times per week over eight weeks. The exercise includes warm-up, a main session (walking at a controlled intensity), and cool-down, with intensity levels adjusted over time to match cardiovascular improvements.
62693890|NCT03578172|EXPERIMENTAL|Experimental-HMG stimulation group|Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer
61936131|NCT06064604|EXPERIMENTAL|Stroke Survivors|"This study will be divided into 2 sessions that will occur on 2 separate days: 1) Hip Exoskeleton session and 2) Ankle Exoskeleton session. In each session, subjects will undergo two conditions in which they complete the outcomes measures 1) while wearing the exoskeleton and 2) in a baseline condition without the exoskeleton. Order of condition and session will be randomized.~Prior to the exoskeleton condition, subjects will be allowed time to acclimate to the device during a walking session on the treadmill. Subjects will complete several timed walking tests both indoors and outdoors. Measurements of energy expenditure may also be recorded along with patient reported outcomes data to assess participant perception of their performance with and without the devices."
61936132|NCT03998878|EXPERIMENTAL|Low-Carbohydrate Diet|Participants will be instructed to consume less than 30 grams of carbohydrates per day.
61936133|NCT03998878|EXPERIMENTAL|Intermittent Energy Restriction|Participants choose 2 non-consecutive days per week in which they will consume 500-650 calories.
61936134|NCT03998878|EXPERIMENTAL|Hunger Training|Participants monitor their hunger symptoms and blood glucose, and eat only when blood glucose is below a certain threshold level.
61936135|NCT01295229|ACTIVE_COMPARATOR|Lifestyle Intervention|
61936136|NCT01295229|ACTIVE_COMPARATOR|Surgery|
61936137|NCT01225887|EXPERIMENTAL|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61936138|NCT05016219|ACTIVE_COMPARATOR|Active Intervention plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
61936139|NCT05016219|ACTIVE_COMPARATOR|Active Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
61936140|NCT05016219|ACTIVE_COMPARATOR|Placebo Light plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
62488225|NCT05206851|ACTIVE_COMPARATOR|Hot Pack|
62488226|NCT05207072||Mobile Cardiac Rehabilitation (mCR) group|The mCR programme involves a home-based programme for 12 months in which patients are supplied with a smartphone/application with a data subscription from LIVA. Through this application patients are able to measure and register physical activity, heart frequency and intensity (BORG scale) and can monitor progress. A healthcare professional (coach) also has access to a portal to monitor progress of different patients, advice on rehabilitation approach and stimulate compliance. Together with their coaches every patient makes their own rehabilitation programme. Patients will be coached for 12 months starting intensively with decreasing amounts of contacts over time.
62693891|NCT03578172|ACTIVE_COMPARATOR|Control-HRT group|Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer
61936141|NCT05016219|PLACEBO_COMPARATOR|Placebo Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
61936142|NCT03024814|EXPERIMENTAL|acetaminophen group|Babies who took acetaminophen
61936143|NCT03024814|EXPERIMENTAL|Placebo group (Dextrose 5)|Babies who took placebo
61936144|NCT01086423|EXPERIMENTAL|INFANRIX-IPV+HIB 1 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.
61936145|NCT01086423|EXPERIMENTAL|INFANRIX-IPV+HIB 2 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.
61936146|NCT01086423|ACTIVE_COMPARATOR|INFANRIX-HIB+POLIORIX GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.
61936147|NCT03819426|EXPERIMENTAL|High Intensity Interval Training|Participants will be shown the appropriate techniques and intensity (high intensity; i.e., 70-90% of maximum heart rate (220-age) with a verified online youtube video. Participants will be provided with this video and other options that can be followed to complete 15 minute HIIT interventions at home. Interventionist will observe participant engaging in HIIT for 15 minutes. HIIT intervention (for 15 minutes) will also be observed during Session 4 and 8.
61936148|NCT03819426|EXPERIMENTAL|Walking|This intervention will be demonstrated during Session 1. Participants will be shown the appropriate walking intensity (low intensity; i.e., approximately 50% of maximum heart rate (220-age) or lower) by interventionist. Interventionist will observe participant engaging in walking at appropriate intensity level for 15 minutes. Walking intervention (for 15 minutes) will also be observed during Session 4 and 8.
61936149|NCT06680115|EXPERIMENTAL|Sintilimab|
61936150|NCT06680115|NO_INTERVENTION|Control|
62488227|NCT05207072||Traditional Cardiac Rehabilitation (CR) group|The traditional CR programme involves standard a standard CR programme over a 6-8 weeks period. Subjects receive no advice or coaching after the end of the traditional CR program.
62488228|NCT00170677|ACTIVE_COMPARATOR|A|
62693892|NCT02209675|OTHER|patients with elevated liver enzymes|Patients with elevated liver enzymes and/or hyperbilirubinemia post transplantation for hepatitis C virus related disease will have liver biopsy
62693893|NCT05020769|EXPERIMENTAL|SI-B001 combined with osimertinib_A|Patients with locally advanced/metastatic NSCLC progressed on 3rd generation EGFR-TKI treatment.
62693894|NCT05020769|EXPERIMENTAL|SI-B001 combined with osimertinib_B|Patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment and with T790M negative mutation.
61936151|NCT00837928|EXPERIMENTAL|Bendamustine and Fractionated stereotactic radiotherapy|Bendamustine 40 mg/m2 and will be administered IV on days 1,2,and 3 prior to surgery on each day of SRT (Sterotactic radiation therapy). Laboratory biomarker analysis will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. Pharmacokinetic samples will not be collected from patients who begin SRT on day 1). Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine) Stereotactic fractionated radiation therapy starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri). Concurrent Bendamustine is administered on Days of Stereotactic Radiotherapy (Arm 1: 40 mg/m2/ Day; Arm 2: 50 mg/m2/day).
61936152|NCT04579848|ACTIVE_COMPARATOR|Methotrexate|"Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.~Additional Folic acid 1mg prescribed daily."
62488229|NCT00170677|EXPERIMENTAL|B|
62488230|NCT02373462|EXPERIMENTAL|olmesartan group|olmesartan (20mg qd then 40mg qd for titrating BP \<140/90 mmHg)
62488231|NCT02373462|ACTIVE_COMPARATOR|other group|other anti-hypertensive drug (titrating BP \<140/90 mmHg)
62488232|NCT04980170|EXPERIMENTAL|clindamycin group|Patients who take Clindamycin after Dental implants
62488233|NCT04980170|EXPERIMENTAL|Amoxicillin With Clavulanic Acid group|Patients who take Amoxicillin With Clavulanic Acid after Dental implants
62488234|NCT03167606|EXPERIMENTAL|Immediate Intervention|Study participants randomized to the immediate intervention arm will have access to the MyPEEPS Mobile from the baseline visit to 3-month follow-up visit. They will continue with follow-up visits at 6 months and 9 months, but will no longer have access to the MyPEEPS Mobile past the 3-month follow-up visit.
62693895|NCT05020769|EXPERIMENTAL|SI-B001 combined with osimertinib_C|Patients with locally advanced/metastatic NSCLC and with EGFR exon20ins mutation.
62693896|NCT01198691|PLACEBO_COMPARATOR|Control Group|This group will receive the standard metallic staples to close their incision.
62693897|NCT01198691|EXPERIMENTAL|Case Group|This group will receive the Insorb absorbable staples to close their incision.
62693898|NCT06572020|EXPERIMENTAL|Physiotherapy students|Physiotherapy students
62693899|NCT06545903|ACTIVE_COMPARATOR|LMA Supreme Group|Paramedics using the LMA Supreme airway device
62693900|NCT06545903|EXPERIMENTAL|Other Supraglottic Airway Group|Paramedics using other supraglottic devices
62693901|NCT05916937|ACTIVE_COMPARATOR|omalizumab 300 mg every six weeks|20 subjects are randomized to receive omalizumab 300 mg every six weeks from week 12 to week 36.
62693902|NCT05916937|ACTIVE_COMPARATOR|omalizumab 300 mg every four weeks|20 subjects are randomized to receive omalizumab 300 mg every four weeks from week 12 to week 36.
62697611|NCT02921256|EXPERIMENTAL|Arm II (mFOLFOX6, RT, capecitabine, veliparib)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
62330636|NCT01249872|ACTIVE_COMPARATOR|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
62330637|NCT01249872|ACTIVE_COMPARATOR|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
62330638|NCT01249872|ACTIVE_COMPARATOR|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
62488235|NCT03167606|EXPERIMENTAL|Delayed Intervention|Study participants randomized to the delayed intervention arm will complete visits at baseline, 3 months, 6 months, 9 months, and 12 months. They will have access to the MyPEEPS Mobile from the 9-month follow-up visit until the 12-month follow-up visit.
62488236|NCT01411462||VIBE-DEB|
62488237|NCT04175158|EXPERIMENTAL|GB222|1mg/kg
62488238|NCT04175158|ACTIVE_COMPARATOR|Bevacizumab|1mg/kg
62488239|NCT04207229||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
62488240|NCT05731687|OTHER|Hybrid DEB|Patients randomized to hybrid DEB group will receive application of DEB in the side branch.
62488241|NCT05731687|OTHER|Two-stent strategy|Patients randomized to two-stent strategy will receive implantation of a second DES in the side branch, using Culotte or TAP/T technique.
61936153|NCT04579848|PLACEBO_COMPARATOR|Placebo|"3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.~Additional Folic acid 1mg prescribed daily."
62330639|NCT01880255|ACTIVE_COMPARATOR|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 stimulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left then right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
62330640|NCT01880255|SHAM_COMPARATOR|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
62330641|NCT01556516||Women with Pompe Disease|
62330642|NCT05616767|EXPERIMENTAL|Training on self-screening and HPV vaccination administration|teaching SMM in Tanzania to conduct self-exams for oropharyngeal hrHPV-associated cancers using cellphone-mediated oral selfies, and administering the HPV vaccination series (with 2 and 6-8 month follow-up) to those who request it
62488242|NCT02225457|EXPERIMENTAL|Hypercaloric diet and polyphenols|"polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.~Hypercaloric diet will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
62488243|NCT02225457|ACTIVE_COMPARATOR|Hypercaloric diet and placebo|"Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.~Overfeeding will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
62488244|NCT03415867|EXPERIMENTAL|Dose escalation sequential cohorts|Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 24 cycles. Those patients enrolled in the trial that obtain objective clinical benefit under treatment with glasdegib (defined as the achievement of at least a partial response at one or more target organs), will be allowed to proceed to a slow dose withdrawal phase over a period of 6 months after the end of Cycle 24. The dose reduction scheme is fully detailed in the protocol.
62488245|NCT03580915|EXPERIMENTAL|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
62488246|NCT03580915|ACTIVE_COMPARATOR|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
62488247|NCT05388071||Intervention: Treatment with the aid of telemedicine|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
62488248|NCT05388071||No intervention: Usual treatment|Treatment will be performed as usual without the usage of telemedicine.
62488249|NCT00976443|PLACEBO_COMPARATOR|Placebo (normal saline)|Gastric injections of normal saline
62488250|NCT00976443|ACTIVE_COMPARATOR|BTA 100 U|Gastric injections of botulinum toxin A, 100 Units
62488251|NCT00976443|ACTIVE_COMPARATOR|BTA 300 U|BTA 300 U, gastric injections under EUS guidance
62488252|NCT04026048|EXPERIMENTAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
62488253|NCT04026048|EXPERIMENTAL|Waitlist Control Group|Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
61936154|NCT01104155|ACTIVE_COMPARATOR|eribulin mesylate, 21 day cycle|
61936155|NCT01104155|ACTIVE_COMPARATOR|eribulin mesylate, 28 day cycle|
61936156|NCT03885440||Young adult, without OSAS|20\<=Age\<40 years old, apnea-hypopnea index(AHI)\<5
61936157|NCT03885440||Young adult, with OSAS|20\<=Age\<40 years old, AHI\>=5
61936158|NCT03885440||older adult, without OSAS|Age\>=40 years old, AHI\<5
61936159|NCT03885440||older adult, with OSAS|Age\>=40 years old, AHI\>=5
62135339|NCT04229368|NO_INTERVENTION|No supplementation|Subjects with serum 25(OH)D level ≥30ng/mL will not receive any Vitamin D supplementation both pre- and postoperatively, as these are considered sufficient. These control patients will be asked to take any supplements containing Vitamin D for the duration of their participation in the trial. All patients in group 3 will have their serum 25(OH)D checked at 3 months after the surgery.
62693903|NCT06011655||General intensive care and emergency servise nurses|"The research was planned as a descriptive study to be carried out in the general intensive care and emergency departments of the Sanatorium Hospital. After obtaining permission from the institution where the study will be conducted, the Personal Information Form, Attitude Towards Suicide Attempts and Stigma towards Suicide scale will be sent to the nurses working in the general intensive care and emergency services of the hospital by the researcher online via Google Forms. Nurses, 5-10 min to answer. They will fill in the scales, which will continue, on their duty leave or on holidays."
62693904|NCT06284122|EXPERIMENTAL|Mosun-Len|Mosunetuzumab + lenalidomide
62693905|NCT06284122|ACTIVE_COMPARATOR|R-CHOP|Rituximab-CHOP
61936160|NCT00603785|PLACEBO_COMPARATOR|A|Subjects to receive placebo treatment for 6 months
61936161|NCT00603785|EXPERIMENTAL|B|Subjects to receive Xolair treatment for 6 months
61936162|NCT02041988||0,2 mg/kg oral morphine|Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored
61936163|NCT02041988||0,4 mg/ kg oral morphine|morphine and analgesic consumption throughout surgery will be monitored
61936164|NCT05658003|EXPERIMENTAL|[177Lu]Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% \[177Lu\]Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used.
61936165|NCT05658003|ACTIVE_COMPARATOR|Androgen receptor-directed therapy (ARDT)|For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used.
61936166|NCT05715333|EXPERIMENTAL|Group 1|CM326 220 mg/2 mL or matched placebo, subcutaneous at low dose
61936167|NCT05715333|EXPERIMENTAL|Group 2|CM326 220mg/2 mL or matched placebo, subcutaneous at medium dose
61936168|NCT05715333|EXPERIMENTAL|Group 3|CM326 220mg/2mL or matched placebo, subcutaneous at high dose
61936169|NCT05715333|EXPERIMENTAL|Group 4|CM326 220mg/2mL or matched placebo, subcutaneous at medium dose
61936170|NCT00979069|EXPERIMENTAL|Aerobic Group|12 weeks of aerobic exercise 3 times a week
61936171|NCT00979069|NO_INTERVENTION|Control Group|No contact control
61936172|NCT00244517|ACTIVE_COMPARATOR|I|Isoflurane (only in part I)
61936173|NCT00244517|ACTIVE_COMPARATOR|II|Sevoflurane
61936174|NCT00244517|ACTIVE_COMPARATOR|III|Desflurane
61936175|NCT06519825|EXPERIMENTAL|Forward head posture-Study|participants with a forward head posture who will undergo an exercise program
61936176|NCT06519825|NO_INTERVENTION|Forward head posture-Control|participants with forward head posture who will not perform an exercise program
61936177|NCT06519825|NO_INTERVENTION|Control group|control group without forward head posture
61936178|NCT02640469|ACTIVE_COMPARATOR|Chlorhexidine with water rinse|This is a traditional method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
62693906|NCT06284122|ACTIVE_COMPARATOR|G-CHOP|Obinutuzumab-CHOP
62693907|NCT06284122|ACTIVE_COMPARATOR|R-Benda|Rituximab-Bendamustin
62693908|NCT06284122|ACTIVE_COMPARATOR|G-Benda|Obinutuzumab-Bendamustin
61936179|NCT02640469|EXPERIMENTAL|Chlorhexidine without water rinse|This is an experimental method of disinfection. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
61936180|NCT02640469|ACTIVE_COMPARATOR|Chlorhexidine + sterillium hand rub|This is a standard method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
61936181|NCT04034082|EXPERIMENTAL|IHT group|Intermittent hypoxia therapy on top of the conventional phase 2 in-hospital rehabilitation program
62135340|NCT03243006|PLACEBO_COMPARATOR|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
62693909|NCT05255666|EXPERIMENTAL|Pembrolizumab + Liposomal Irinotecan|"* 400 mg of pembrolizumab intravenously on Day 1 of each Cycle (Cycle is 42 days)~* 50 mg/m\^2 of liposomal irinotecan (Nal-IRI) intravenously every 2 weeks of each Cycle (Cycle is 42 days)"
62693910|NCT04733495|EXPERIMENTAL|Supportive care (resistance exercise, counseling)|Patients undergo personalized resistance exercises over 1 hour daily. Patients receive dietary counseling over 60 minutes at week 1 and then over 15-30 minutes weekly for up to 6 weeks. Patients also receive group-based behavioral counseling BIW in weeks 1-8, QW in weeks 9-12, and then twice a month in weeks 13-24.
61936182|NCT04034082|ACTIVE_COMPARATOR|Conventional group|Conventional phase 2 in-hospital rehabilitation program
61936183|NCT00869427|ACTIVE_COMPARATOR|1 vitamin C|Vitamin C 1g bid
61936184|NCT00869427|NO_INTERVENTION|2|Usual Care
61936185|NCT03773380|EXPERIMENTAL|Feasibility|50 patients will be recruited to take part in this feasibility study. They will all undergo this Breathe Anew Program post-surgery. Breathe Anew consists of radiological surveillance, physical rehabilitation using a Fitbit, mindfulness therapy, and referral for symptom management specialists when needed.
61936186|NCT06237647|EXPERIMENTAL|PRP+HA|5mL of PRP+HA
61936187|NCT06237647|NO_INTERVENTION|PRP injection|4mL of PRP added 1 mL of lidocaine
61936188|NCT06237647|NO_INTERVENTION|Steroid|1 mL of rinderon added 4 mL of lidocaine
61936189|NCT06237647|EXPERIMENTAL|PROLOTHERAPHY|4 mL of 20% dextrose added1 mL lidocaine
61936190|NCT06482749|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation Group|"Repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
62135341|NCT03243006|ACTIVE_COMPARATOR|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
62693911|NCT04528186||1|Low eating index scores(50-70)
62135342|NCT03243006|ACTIVE_COMPARATOR|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
62330643|NCT01603316|ACTIVE_COMPARATOR|Food Voucher Program (Voucher)|Food Voucher arm, each participant will receive a debit card specifically created for this program. Each month for the duration of study participation (6 months), the debit card will be credited with $128 \& given to the patient in person or via mail. Patients will be instructed to use these cards only for food purchases. If patients are not able to use the debit card at their local grocery stores, patients will be provided with a money order of the same dollar value instead of the debit card. They will be counseled on using their vouchers only for healthful foods, in a way that stretches their food dollars. Purchases will be tracked by having patients bring their receipts in for review each month when they come in to pick-up their next monthly vouche, or by providing electronic copies of receipts. Patients will be provided with a receipt holder to assist in storing receipts for review. For voucher cards sent via mail, patients will receive a mailing letter accompanying each card.
62330644|NCT01603316|EXPERIMENTAL|Home Grocery Delivery (Delivery)|"In the Home Grocery Delivery arm, each participant will receive home grocery delivery from PeaPod grocery delivery service or from FreshDirect (depending on the participants zip code), worth $128 per month, for the duration of study participation (6 months). Patients in the Delivery arm will review a list of food categories and a subset of items in each category with a COA."
62330645|NCT01603316|EXPERIMENTAL|Medically-Tailored Hospital-Based Food Pantry (Pantry)|Patients in this arm will have access to the pantry for the duration of their study participation (6 months). Those accessing the medically-tailored food pantry will pick-up a pantry bag weekly or bi-weekly (per patient preference) at the hospital, either during one of their medical appointments or at another preferred time. Each patient's food prefereces will be assessed once during baseline and they will be given food bags, tailored when possible and when available to these preferences and to their medical needs and cultural preferences.
62330646|NCT04345991|EXPERIMENTAL|COVID-19 convalescent plasma|A plasma unit provided by a COVID-19 convalescent pathogen-reduced plasma will be used for the treatment of the patients.
62330647|NCT04345991|NO_INTERVENTION|Control patients|Control patients will receive the best standard of care
62330648|NCT06492785|EXPERIMENTAL|Hyaluronic Acid(EmbryoGlue®)|High HA concentrations (0.5 mg/ml)
62330649|NCT06492785|ACTIVE_COMPARATOR|Hyaluronic Acid (G2 medium)|Low HA concentrations (0.125 mg/ml)
62330650|NCT04511234|EXPERIMENTAL|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
62330651|NCT04511234|ACTIVE_COMPARATOR|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
62330652|NCT01079962|EXPERIMENTAL|Bisoprolol|
62330653|NCT01079962|ACTIVE_COMPARATOR|Atenolol|
62330654|NCT06185218|ACTIVE_COMPARATOR|MAP 1 (Posterior wall only)|Type 1 map injection will be used to bladder in one session. In this arm, Botulinum toxin type A injection will be apply to non-trigonal only posterior wall of bladder. The application will be done with cystoscopy and, 20 different point will be aimed. Totally 100 IU Botulinum toxin type A will be applied.
62330655|NCT06185218|ACTIVE_COMPARATOR|MAP 2 (Posterior wall + bilateral side walls)|Type 2 map injection will be used to bladder in one session. In this arm, Botulinum toxin type A injection will be apply to non-trigonal posterior wall + bilateral side walls of bladder. The application will be done with cystoscopy and, 20 different point will be aimed. Totally 100 IU Botulinum toxin type A will be applied.
62330656|NCT06185218|ACTIVE_COMPARATOR|MAP 3 (Non-trigonal all walls)|Type 3 map injection will be used to bladder in one session In this arm, Botulinum toxin type A injection will be apply to non-trigonal all walls of bladder. The application will be done with cystoscopy and, 20 different point will be aimed. Totally 100 IU Botulinum toxin type A will be applied.
62330657|NCT03272854||Renal Transplant Recipients|A cohort or renal transplant recipients, all more than 1 year after transplantation at inclusion
62330658|NCT00981383|EXPERIMENTAL|Treatment|Omega-3 Fatty Acid Supplement, 1.9 g ω-3 FAs daily
62330659|NCT00981383|PLACEBO_COMPARATOR|Placebo|Matching placebo, less than 0.12 g ω-3 FAs daily
62330660|NCT01368341|ACTIVE_COMPARATOR|Doxycycline|Doxycycline, 100 mg, tablets, b.i.d., 14 days
62330661|NCT01368341|ACTIVE_COMPARATOR|Penicillin|Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
62488254|NCT02701101|OTHER|Daily Skin Assessments (SoC and SEM Scanner Readings)|"The SEM Scanner 200 measures sub-epidermal moisture (SEM), which has been studied as an indicator of localized edema characteristic of pressure-induced tissue damage. Daily assessments were performed at the sacrum and both heels unless the anatomical location(s) were not assessable. Daily assessments included:~1. Risk Assessment (standard of care; Braden, Waterlow, or Norton)~2. Skin Assessment (standard of care visual skin assessments utilizing tactile and visual cues)~3. SEM Scanner readings (test variable in this study). Standard of care evaluations were conducted by individuals meeting the definition of Specialist specified in the study protocol whereas separate individuals meeting the definition of Generalist performed SEM Scanner 200 measurements. Specialists were blinded to the assessment by the Generalists, and vice versa."
62488255|NCT01277835|EXPERIMENTAL|Lidocaine Infusion|
62135343|NCT03409055||Group 0|patients without pleural effusion
62330662|NCT01368341|ACTIVE_COMPARATOR|Amoxicillin|Amoxicillin 500 mg capsula, t.i.d., 14 days
62330663|NCT01850784|ACTIVE_COMPARATOR|High energy formula|High energy formula (Similac)
62330664|NCT01850784|ACTIVE_COMPARATOR|Standard formula|Standard formula
62330665|NCT00868959|EXPERIMENTAL|lurasidone|
62330666|NCT01119274|ACTIVE_COMPARATOR|Non-genotype-guided dosing algorithm|
62330667|NCT01119274|EXPERIMENTAL|Genotype-guided dosing algorithm|
62330668|NCT01836575|EXPERIMENTAL|Arm B|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\] + Antiemetic therapy at investigator's discretion.
62135344|NCT03409055||Group 1|patients with pleural effusion
62135345|NCT03409055||Group 2|patients with pleural Effusion and need of drainage
62135346|NCT01571466|EXPERIMENTAL|Vaccine group|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
62135347|NCT01571466|PLACEBO_COMPARATOR|Placebo|
62135348|NCT02799875|ACTIVE_COMPARATOR|Higher permissive hypercapnia|Extubation criteria: partial pressure carbon dioxide (pCO2) ≥ 60mmHg with an upper limit ≤ 75mmHg; pH ≥ 7.20; oxygen saturation (SpO2) ≥ 88% with fraction of inspired oxygen (FiO2) ≤ 0.50; mean airway pressure (MAP) \< 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude \< 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 \> 75mmHg; pH \< 7.20; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (\> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
62330669|NCT01836575|ACTIVE_COMPARATOR|Arm A:|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.
62330670|NCT04302610|EXPERIMENTAL|HME MASK|During the Exercise, participants wore either an HME mask (MASK) (ColdAvenger® expedition balaclava, USA, www.coldavenger.com)
61936191|NCT06482749|SHAM_COMPARATOR|Sham Stimulation Group|"Sham repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped sham coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
61936192|NCT04308603|EXPERIMENTAL|pregnant patient whose fetuses have an antenatal NIH|All pregnant patients whose fetuses have an antenatal revelation of NIH from the first trimester ultrasound scan will be included in this study.
62330671|NCT04302610|SHAM_COMPARATOR|SHAM mask|a sham mask (SHAM) which was the same HME mask with holes cut across the entire ventilator cup and the ventilator removed
62330672|NCT04302610|NO_INTERVENTION|Control|No mask (CONT) wearing only the balaclava to which the HME and SHAM mask were attached. Mouth and face not covered.
62330673|NCT06430047|EXPERIMENTAL|Experimental Group|
62330674|NCT04801342|EXPERIMENTAL|Unilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with unilateral hippocampal avoidance and Concurrent use of Memantine HCL
62330675|NCT04801342|ACTIVE_COMPARATOR|Bilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with bilateral hippocampal avoidance and Concurrent use of Memantine HCL
62330676|NCT01186146|ACTIVE_COMPARATOR|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
62330677|NCT01186146|EXPERIMENTAL|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
62330678|NCT03323229|NO_INTERVENTION|Usual care (control group)|Patient receives care as usual.
62330679|NCT03323229|EXPERIMENTAL|Enhanced communications & ultrasound|The paramedic will record a brief video summary of the patient's condition, then remotely supported point of care ultrasound scans will be performed, and both file types sent to the hospital for review and feedback from the consultant.
62330680|NCT02028429|EXPERIMENTAL|Intervention 'Sildenafil'.|MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
62330681|NCT02028429|NO_INTERVENTION|'No sildenafil'|Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.
62488256|NCT01277835|PLACEBO_COMPARATOR|Placebo|Saline Infusion
62693912|NCT04528186||2|High eating index scores(Above 70)
61936193|NCT00932737|ACTIVE_COMPARATOR|Hyoscine butylbromide (HBB) 20mg 1-5 tablets per episode|Patient to receive 1-5 tablets containing 20mg HBB per Abdominal pain associated with cramping (APC) episode
61936194|NCT00932737|PLACEBO_COMPARATOR|Placebo|patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode
62330682|NCT03270696|EXPERIMENTAL|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
61936195|NCT04022434|PLACEBO_COMPARATOR|Placebo|"Psyllium powder is used as the placebo. A member of the research staff will package and dispense L-alanine and placebo in similar containers. A standard measuring spoon will be provided to the subject for preparing the placebo solution. Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.~Meal Placebo Breakfast \* 1-2 scoops Snack \* .5 - 1 scoop Lunch \* 1-2 scoops Snack \* .5 - 1 scoop Dinner \* 1-2 scoops"
62330683|NCT03270696|EXPERIMENTAL|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
62330684|NCT02857855|EXPERIMENTAL|80% fraction of inspired oxygen|80% fraction of inspired oxygen delivered either by a nonrebreathing facemask with a reservoir with oxygen flow of 14 l/min and air flow of 2 l/min or by a respirator for first 6 postoperative hours
62330685|NCT02857855|ACTIVE_COMPARATOR|28% fraction of inspired oxygen|28% fraction of inspired oxygen delivered either by a Venturi facemask or by a respirator for first 6 postoperative hours
62330686|NCT00882726|EXPERIMENTAL|CNTO 3649 IV (Healthy participants)|
62330687|NCT00882726|EXPERIMENTAL|CNTO 3649 SC (Healthy participants)|
62330688|NCT00882726|EXPERIMENTAL|CNTO 3649 SC (Diabetic patients)|
62330689|NCT04437017|EXPERIMENTAL|Olanzapine+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists(a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
62488257|NCT01696305|EXPERIMENTAL|Hyalobarrier|ACP200 (Auto-crosslinked polysaccharide:inner ester of hyaluronic acid) 30mg/ml\*10ml/syringe and 5cm-cannula
62693913|NCT00530257|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill);Subjects will be equally randomized and will receive one week of treatment with placebo and compared to subjects who were randomized to receive one week of OROS-methylphenidate.
62488258|NCT01696305|ACTIVE_COMPARATOR|Guardix-SG|Poloxamer/sodium alginate mixture 6g/syringe
61936196|NCT04022434|EXPERIMENTAL|Experimental Alanine|"L-alanine, USP (Spectrum® Chemicals and Laboratory Products, Gardena, CA) will be packaged and dispensed by one member of the research staff who will have no other role in the study. A one-month supply will be dispensed to the subjects.~Meal L-Alanine Breakfast \* 1-2 scoops Snack \* .5 - 1 scoop Lunch \* 1-2 scoops Snack \* .5 - 1 scoop Dinner \* 1-2 scoops"
62330690|NCT04437017|ACTIVE_COMPARATOR|Dexamethasone+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists (a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administered, and on day 2-4, the given dose of dexamethasone is 8 mg.
62135349|NCT02799875|ACTIVE_COMPARATOR|Lower permissive hypercapnia|Extubation criteria: pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg; pH ≥ 7.25; SpO2 ≥ 88% with FiO2 ≤ 0.50; mean airway pressure (MAP) \< 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude \< 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 \> 55mmHg; pH \< 7.25; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (\> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
62135350|NCT03217669|EXPERIMENTAL|Sirolimus/Epacadostat Dose Escalation|"Traditional 3 + 3 dose escalation design.~Starting doses: sirolimus 3milligrams (mg) loading/1mg maintenance and epacadostat 300mg twice daily (BID). If 0 in 3 subjects develops dose limiting toxicity (DLT), next 3 subjects will be treated at dose level 2 (DL2): sirolimus 6mg loading/2mg maintenance and epacadostat 300mg BID. If 1 subject in dose level 1 (DL1) develops DLT, 3 additional subjects will be enrolled in DL1. If 2 or more subjects in a total of 6 subjects, or 2 or more subjects in the initial 3 subjects develop DLT, the next 3 subjects will be treated at dose level -1 (DL-1): 3mg loading/1mg sirolimus + epacadostat 100mg BID. If only 1 subject in a total of 6 develops DLT, dose escalation to DL2 will be made for the next 3 subjects. Same algorithm will apply to DL2 except no further dose escalation/de-escalation will be made.~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
62330691|NCT05868876|EXPERIMENTAL|The dose escalation stage, dose expansion stage of AK127 combination with AK104|The dose escalation stage： 5 dose groups were set up, which were 0.3mg/kg、1 mg/kg, 3 mg/kg, 7.5 mg/kg, 15 mg/kg Q3W in dose escalation stage; The dose expansion stage： 8 cohorts with different indications were included in each group with 10-20 subjects in dose expansion stage.
62330692|NCT04115046||Treatment Arm|Consecutive, eligible patients reporting for an ultrasound and liver biopsy for evaluation of fibrosis will be enrolled. Each subject will undergo both procedures (FibroScan and EUS with SW Elastography).
62330693|NCT03003416||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.
62330694|NCT00704743|ACTIVE_COMPARATOR|1|Cylindrical cast
62330695|NCT00704743|ACTIVE_COMPARATOR|2|Modified sugar tong cast
61936197|NCT02163980|PLACEBO_COMPARATOR|Caudal ropivacaine + normal saline|1.5ml kg-1 ropivacaine 0.15% with normal saline (Control group, n=40).
61936198|NCT02163980|EXPERIMENTAL|Caudal ropivacaine + dexmedetomidine|1.5ml kg-1 ropivacaine 0.15% with dexmedetomidine 1 μg kg-1 (DEX group, n=40)
61936199|NCT02887573|EXPERIMENTAL|Free-residue nutrients+PEG|"Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm.~Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy."
61936200|NCT02887573|EXPERIMENTAL|Low fiber diet+PEG|"Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given.~Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test.~Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy."
61936201|NCT03799211|EXPERIMENTAL|Motivational Interviewing|
61936202|NCT03799211|ACTIVE_COMPARATOR|Usual Care|
61936203|NCT01923714||Glaucoma|Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC.
62330696|NCT00704743|ACTIVE_COMPARATOR|3|Volar dorsal splint
62488259|NCT01046097||Synflorix Group|Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
61936204|NCT04769856|EXPERIMENTAL|Non-fasting group|
62330697|NCT01613287|EXPERIMENTAL|Immunoadsorption|Patients are treated with the TheraSorb® Ig flex adsorber used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy (5 treatments) performed over 5 to 8 consecutive days
62488260|NCT05323149|PLACEBO_COMPARATOR|Group C|Group C, will be received saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
61936205|NCT04769856|EXPERIMENTAL|Fasting group|
61936206|NCT00731016|OTHER|1|Zoledronic acid, pravastatin
61936207|NCT01670604|EXPERIMENTAL|VOL group|patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
61936208|NCT01670604|EXPERIMENTAL|TET group|patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L
61936209|NCT02640716|ACTIVE_COMPARATOR|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
62135351|NCT03217669|EXPERIMENTAL|Sirolimus/Epacadostat Dose Expansion|"Once recommended phase 2 dose (RP2D) is defined, a total of 10 non-small cell lung cancer (NSCLC) patients who meet eligibility will be enrolled in the dose expansion cohort. Treatment will be sirolimus RP2D once daily and epacadostat RP2D twice daily (BID).~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
62330698|NCT03803540|EXPERIMENTAL|Fecal Microbiota Transplantation|Lean healthy donor frozen fecal microbiota will be administered via duodenal infusion in an upper gastrointestinal endoscopy
62330699|NCT04829383|EXPERIMENTAL|Study Treatment|Atezolizumab 1,200 mg IV and bevacizumab 15 mg/kg IV every 3 weeks (on day 1 of each 21-day cycle). Treatment will continue until disease progression or development of unacceptable toxicity.
62330700|NCT00603980|OTHER|Treatment sequence 1|Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330701|NCT00603980|OTHER|Treatment sequence 2|Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330702|NCT00603980|OTHER|Treatment sequence 3|Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330703|NCT00603980|OTHER|Treatment sequence 4|Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330704|NCT00603980|OTHER|Treatment sequence 5|Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330705|NCT00603980|OTHER|Treatment sequence 6|Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330706|NCT00603980|OTHER|Treatment sequence 7|Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330707|NCT00603980|OTHER|Treatment sequence 8|Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330708|NCT00603980|OTHER|Treatment sequence 9|Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330709|NCT00603980|OTHER|Treatment sequence 10|Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330710|NCT00603980|OTHER|Treatment sequence 11|Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330711|NCT00603980|OTHER|Treatment sequence 12|Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330712|NCT00603980|OTHER|Treatment sequence 13|Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330713|NCT00603980|OTHER|Treatment sequence 14|Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
62330714|NCT01869829||Pediatric Invasive Candidiasis|Pediatric patients (age \> 120 days and \< 18 years) with documented proven or probable invasive candidiasis
62330715|NCT04186000|EXPERIMENTAL|group 1|Booster vaccine with AD26.ZEBOV after 1 year
62330716|NCT04186000|EXPERIMENTAL|group 2|Booster vaccine with AD26.ZEBOV after 2 years
62693914|NCT00530257|ACTIVE_COMPARATOR|OROS-methylphenidate|Subjects will be equally randomized and will receive one week of treatment with the optimal dose of OROS methylphenidate compared with subjects randomized to receive one week of placebo.
61936210|NCT02640716|PLACEBO_COMPARATOR|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
62330717|NCT06553339|EXPERIMENTAL|Phase Ia dose escalation arm|Participants will be assigned to pre-specified dose level to identify the MTD/MAD of HS-10516.
62330718|NCT06553339|EXPERIMENTAL|Phase Ib dose expansion arm 1|Participants with VHL Syndrome associated RCC, whose lesions diameter ≤ 3 cm.
62488261|NCT05323149|EXPERIMENTAL|Group T|Group T, will be received TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
62488262|NCT00154258|EXPERIMENTAL|1|
62693915|NCT05317481|EXPERIMENTAL|BE-SMART-DR|Participation will include research clinical/behavioral interviews and symptom self-ratings, magnetic resonance imaging (MRI) scanning, actigraphy wearables, and use of smart phones for ecological momentary assessment (EMA). Subjects will participate in 12 weekly sessions and 6-month in person follow-up.
62693916|NCT05317481|ACTIVE_COMPARATOR|control comparator condition|Matched for experimental, participation will include research clinical/behavioral interviews and symptom self-ratings, magnetic resonance imaging (MRI) scanning, actigraphy wearables, and use of smart phones for ecological momentary assessment (EMA). Subjects will participate in 12 weekly sessions and 6-month in person follow-up.
62330719|NCT06553339|EXPERIMENTAL|Phase Ib dose expansion arm 2|Participants with VHL Syndrome associated RCC, who could not be included in arm 1.
62330720|NCT06553339|EXPERIMENTAL|Phase Ib dose expansion arm 3|Participants with VHL Syndrome associated non-RCC tumors.
62330721|NCT02586636|OTHER|OCT1 -/-|Cohort of patients with two loss of function alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort.
62330722|NCT02586636|OTHER|OCT wt/wt|"Cohort of patients with two normal or wild type alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort."
62330723|NCT01762293|EXPERIMENTAL|Famitinib|Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
62330724|NCT01762293|PLACEBO_COMPARATOR|Placebo|Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
62330725|NCT02242994|EXPERIMENTAL|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
62330726|NCT02217319|ACTIVE_COMPARATOR|Sevoflurane|Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
62330727|NCT02217319|PLACEBO_COMPARATOR|TIVA|Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
62330728|NCT00660036|EXPERIMENTAL|Gemtuzumab ozogamicin/Mitoxantrone/Etoposide|
62330729|NCT01290081|ACTIVE_COMPARATOR|Active referral|Case management intervention group - study personnel scheduled the TB doctor appointment for the participant, reminded to keep it, and transportation to the clinic was organized when needed.
62330730|NCT01290081|NO_INTERVENTION|Passive referral|Participants were instructed to schedule an appointment with TB services themselves.
62330731|NCT00958308|PLACEBO_COMPARATOR|Placebo|Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
62330732|NCT00958308|ACTIVE_COMPARATOR|BIO-K+ CL-1285|Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
62330733|NCT00958308|OTHER|BIO-K+ CL-1285® & placebo|One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
62330734|NCT02381106||Women with preeclampsia|Women delivered by cesarian section and with preeclampsia
62330735|NCT02381106||Women with dysfunctional labor|Women delivered with cesarian section due to dtsfunctional labor
62330736|NCT02381106||Women with cesarian section due to maternal request|Women with cesarian section due to maternal request
62330737|NCT02381106||Women with preamture labor|Women with pemature labor undergoing cesarian section
62488263|NCT03715751|ACTIVE_COMPARATOR|ASV|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2\>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted to target the same minute ventilation achieved prior to any change in Vt. Patients will then be switched to ASV mode. The percentage minute volume (%minVol) will be adjusted to target the same minute ventilation as was achieved before the change. Settings will be maintained for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
62488264|NCT03715751|ACTIVE_COMPARATOR|Lung Protective Ventilation|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2\>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted (while leaving the Vt at 6cc/kg) to achieve the same minute ventilation. Patients will then be maintained on their current lung protective ventilation settings for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
62693917|NCT06571331|EXPERIMENTAL|De-Stress & Snooze Gummies-U001|
62330738|NCT05132816|EXPERIMENTAL|Main arm|
62330739|NCT03894527|ACTIVE_COMPARATOR|Control|"Subjects with simple obesity will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
62693918|NCT06571331|EXPERIMENTAL|De-Stress & Snooze Gummies-I001|
62693919|NCT06571331|PLACEBO_COMPARATOR|Placebo Gummies 002|
62488265|NCT05663255||Exposed group|Patients treated with CFTR modulator with at least the discontinuation of one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics) during the year of initiation (A0) of CFTR modulator.
62135352|NCT03801148|EXPERIMENTAL|Part 1:Dexlansoprazole 30mg (TOB) + Dexlansoprazole 30mg (TPC)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A \[test\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B \[reference\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
62135353|NCT03801148|EXPERIMENTAL|Part 1:Dexlansoprazole 30mg (TPC) + Dexlansoprazole 30mg (TOB)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B \[reference\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A \[test\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
62488266|NCT05663255||Control group|Patients treated with CFTR modulator without any discontinuation of respiratory co-therapy (azithromycin, RhDNase, inhaled antibiotics) during the year of initiation (A0) of CFTR modulator.
62693920|NCT06638138|ACTIVE_COMPARATOR|FLEXBAND|This group will undergo a lateral ankle ligament repair using the modified Broström technique with Artelon FLEXBAND augmentation of the ATFL.
62693921|NCT06638138|NO_INTERVENTION|Control|This group will undergo a lateral ankle ligament repair using the modified Broström technique. This technique utilizes anchors to repair the ATFL, in some cases the CFL, lateral ankle capsule and extensor retinaculum. This will be done without Artelon FLEXBAND augmentation.
62693922|NCT03551119|EXPERIMENTAL|Exercise|"Personnel experienced in training people with chronic conditions (exercise specialist) will supervise the exercise training. At each in-center session in phase 1, the patient's exercise will be monitored to assess whether they are achieving target levels. Training intensities will be prescribed based on the most recent exercise test.~Phase 1: an eight-week program of once weekly-supervised facility-based exercise sessions and twice weekly home-based sessions.~Phase 2: a 16-week home-based exercise program overseen by an exercise specialist. During this phase, participants will be progressed through their home-based exercise program from Phase 1 on an individual basis.~i. Frequency. A minimum of three exercise sessions per week. ii. Intensity. A moderate intensity (40-60% heart rate reserve) based on exercise testing.~iii. Time. 150 minutes of exercise per week. iv. Type. We will prescribe aerobic exercise supplemented with isometric resistance exercises."
62693923|NCT03551119|OTHER|Enhanced usual care|Participants in the control group will perform accelerometry. This is enhanced usual care because physical activity measurement is not routinely performed in CKD clinics. Control arm participants will only receive their accelerometry data after they have completed the study.
62693924|NCT06637085|EXPERIMENTAL|LLLT group|The LLLT group consist of (20) patients, who will receive the vagus nerve stimulation through LLLT from the first day postoperative until the seventh day, in addition to routine physiotherapy program
62693925|NCT06637085|EXPERIMENTAL|ACU tens group|The acu tense group consist of (20) patients, who will receive the acu tens on (pc6) point from the first day postoperative until the seventh day, in addition to routine physiotherapy program
62693926|NCT06637085|ACTIVE_COMPARATOR|control group|The control group consist of (20) patients, who will receive only routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)
62135354|NCT03801148|EXPERIMENTAL|Part 2:Dexlansoprazole 60mg (TOB) + Dexlansoprazole 60mg (TPC)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C \[test\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D \[reference\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
62135355|NCT03801148|EXPERIMENTAL|Part 2:Dexlansoprazole 60mg (TPC) + Dexlansoprazole 60mg (TOB)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D \[reference\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C \[test\]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
62488267|NCT02663921|EXPERIMENTAL|Healthy volunteers|Healthy volunteers without cutaneous disorders associated with pigmentary changes
62488268|NCT06065839|NO_INTERVENTION|Control group|non-nutritive sucking was not given before feeding
62330740|NCT03894527|ACTIVE_COMPARATOR|Metabolic Syndrome|"Subjects with metabolic syndrome will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
62488269|NCT06065839|ACTIVE_COMPARATOR|Experimental group A|Give pacifier non-nutritive sucking for 5 minutes before feeding
62488270|NCT06065839|PLACEBO_COMPARATOR|Experimental group B|Give pacifier non-nutritive sucking for 15 minutes before feeding
62488271|NCT02177617|ACTIVE_COMPARATOR|Botox only|Participants randomized to receive Botox injections alone.
62488272|NCT02177617|ACTIVE_COMPARATOR|Botox plus Physical Therapy|Participants randomized to receive Botox injection combined with Physical Therapy
62488273|NCT00433745|EXPERIMENTAL|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
62488274|NCT05137093||Healthy subjects|Healthy subjects
62488275|NCT05137093||Atopic dermatitis|Atopic dermatitis
62488276|NCT06626672|EXPERIMENTAL|Digital Health Intervention|"Children and their guardians are given access to a 12-week digital platform with content to improve their lifestyle.~Physical activity is monitored with a Garmin Vivofit Jr. 2."
62488277|NCT06626672|NO_INTERVENTION|Control|During 12-week control period participants receive no access the digital platform. Physical activity is monitored with a Garmin Vivofit Jr. 2.
62488278|NCT02792790||Patients with carpal tunnel syndrome.|Patients undergoing carpal tunnel release surgery.
62488279|NCT05837832|EXPERIMENTAL|Experimental group|Participants will consume the dietary supplement every morning for 4 weeks.
61936211|NCT02291744|EXPERIMENTAL|XELOX plus surgery|Eight cycles of XELOX chemotherapy plus surgery:Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle. After 4 cycles, the patients are randomized to surgery group. Then the rest four cycles are administrated.
61936212|NCT02291744|ACTIVE_COMPARATOR|XELOX|Eight cycles of XELOX chemotherapy: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
62135356|NCT05510310|EXPERIMENTAL|Breast stimulation|Breast pump for breast stimulation: The suction cup will be placed on the breast, held by the patient or a strap, alternated between nipples every 15 minutes, with a pause of 15 minutes after each 30 minutes. Suction intensity will be adjusted to the maximum tolerated by the patient while avoiding causing pain or discomfort. Treatment will be continued for a maximum of 12 hours.
62135357|NCT05510310|ACTIVE_COMPARATOR|Low-dose oxytocin|Low-dose oxytocin will be administered intravenously, starting at a dose of 0.5-2 milliunits\\minute, and increasing incrementally by 1-2 milliunites\\minute every 15-40 minutes. Treatment will be continued for a maximum of 12 hours.
62135358|NCT04124120|EXPERIMENTAL|Single Arterial Graft (SAG) group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
62135359|NCT04124120|EXPERIMENTAL|Multiple Arterial Graft (MAG) group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
62135360|NCT00753493|EXPERIMENTAL|1|This is a one arm pharmacokinetic and safety study.
62330741|NCT01952834|EXPERIMENTAL|GoodBelly Probiotic and Vancomycin|Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
62488280|NCT02294981|ACTIVE_COMPARATOR|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
61936213|NCT01549470|EXPERIMENTAL|Study vaccine|Participants in this arm will receive a total of three doses of study vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection (dose strength 4 mg/mL) and will be administered by IM injection in the deltoid muscle.
62135361|NCT02670109|EXPERIMENTAL|Unique|"Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2 or Busulfan 16 mg/kg (according to availability), Cyclophosphamide 80mg/kg, and Carboplatin 1400/m2.~Then they will undergo an Autologous Hematopoietic Stem Cell Transplantation."
62135362|NCT01807481|EXPERIMENTAL|Mircera Arm|Once Monthly Mircera
62135363|NCT04017793|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction Program|
62135364|NCT04017793|ACTIVE_COMPARATOR|Relaxation Group|
62135365|NCT06699459|EXPERIMENTAL|Irinotecan liposome|* Irinotecan liposomes: 70mg/m2, intravenous infusion, Q2W, d1; ②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
62135366|NCT06699459|OTHER|Capecitabine|Capecitabine, 1250mg/m2 oral, bid, Q3W, d1-14;
62135367|NCT03741049||Consultants|
62135368|NCT03741049||Trainee anaesthetists|
62135369|NCT03741049||Paramedics|
62135370|NCT03741049||Students|
62135371|NCT05662124|EXPERIMENTAL|Remote Monitoring|"Patients in this arm will be asked to record their spirometry and oximetry three times weekly. This will be performed using a spirometer and oximeter which upload the results via bluetooth to the patientMpower app on their smartphones/tablets. These results are immediately available for review by their clinical teams who will be asked to review them at least once a fortnight.~All patients will be asked to complete surveys at baseline, 3, 6, and 12 months and for clinical outcome data during the observation period to be collected."
62135372|NCT05662124|NO_INTERVENTION|Usual Care|Patients in this arm will undergo usual clinical care as planned by their medical team. They will be asked to complete surveys at baseline, 3,6 and 12 months and for clinical outcome data during the observation period to be collected.
62135373|NCT03883152||Head and neck cancer|Eating difficulty is one of the most common problems for head and neck cancer (HNC), in particular, who are in advanced disease stage and receive surgery, radiation (RT) or concurrent radio-chemotherapy (CCRT) (Vissink, Burlage, Spijkervet, Jansma, \& Coppes, 2003; Lazarus et al., 2014). The consequences of multi-treatment bring structural and functional changes in oral, pharynx, or larynx and influence the normal eating process (Logemann et al., 2006; Lazarus et al., 2013; Patterson, McColl, Wilson, Carding, Rapley, 2015; McLaughlin, 2014).
62330742|NCT05629533||Phase 1|"Subjects to undergo right heart catheterization SimpleSense data collected from the first set of subjects and associate the data from SimpleSense to the right heart catheterization values.~Undergoing right heart catheterization for a clinical indication including but not limited to :~* Prognosis of advanced heart failure~* During endomyocardial biopsy~* Candidacy for heart transplant~* Management of cardiogenic shock"
62330743|NCT05629533||Phase 2|Subjects to undergo right heart catheterization SimpleSense data collected from the second set of subjects and evaluate the algorithms developed to estimate cardiac output from SimpleSense data. The second set of subjects are from within the sample population that are sequestered from the first set used for association of data from SimpleSense to the data from the right heart catheterization.
62488281|NCT02294981|EXPERIMENTAL|Plaque based dosing|Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
61936214|NCT01549470|PLACEBO_COMPARATOR|Placebo vaccine|Participants in this arm will receive a total of three doses of a placebo vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection and will be administered by IM injection in the deltoid muscle.
61936215|NCT00537784|ACTIVE_COMPARATOR|1|Injection of autologous platelet concentrate into repair site
61936216|NCT00537784|PLACEBO_COMPARATOR|2|No injection
61936217|NCT03092024|EXPERIMENTAL|SPIN-HAND program|
62330744|NCT03253991|EXPERIMENTAL|MRgFUS treatment|MRgFUS device treatment, thalamotomy
62488282|NCT00756171|EXPERIMENTAL|1|Verum; colesevelam
62488283|NCT00756171|PLACEBO_COMPARATOR|2|placebo
62488284|NCT05714293|EXPERIMENTAL|Surgical Aortic Valve Replacement|Patients undergoing surgical aortic valve replacement with a bioprosthesis will be asked to perform a thorax CT scan before surgery and one more at least 90 days after surgery.
62488285|NCT03086876|EXPERIMENTAL|Stepping Stones Triple P|Trained practitioners will deliver Level 4 SSTP to parents in 6 weekly group sessions and will also provide 3 telephone of face to face contacts to each participant but they will not be involved in routine care for participants in either arm. Each therapist responsible for delivering SSTP will be trained in the Group Stepping Stones Training and Accreditation programme which includes three training days and a further half day accreditation workshop after 6 weeks. The group sessions not only educate but actively train the parents in skills and the individual consultations aim to facilitate independent problem solving. The learning objectives focus on maintaining behavioural change, using skills within a group learning environment, learning from peers in the group and sharing difficulties or achievements, providing support, considering if more intensive work is required, referring further if needed, talking about risk and protective factors operating within families.
62488286|NCT03086876|NO_INTERVENTION|Treatment as usual (TAU)|"TAU will be available to participants in both arms of the trial. It may include a range of services such as:~1. Health visitor services; 2. Primary care engagement and advice; 3. Potentially some version of early intervention maybe provided by either community paediatric services or Child and Adolescent Mental Health Services, although our understanding is that very little is available for children of this age. 4. Parenting advice and support sessions by carers groups or other third sector organisations.~Parents allocated to TAU will receive a list of national and local resources and the Contact a Family guide to challenging behavior with tips and advice on social and health care supports."
62488287|NCT06118697|EXPERIMENTAL|Infants with Complex Feeding Difficulties|Weekly manometric esophageal stimulation as well as consistent nutritive oral feeding therapy
62693927|NCT05596812|EXPERIMENTAL|Intervention (Risk Stratification Pathway)|"Those randomized to Intervention (Risk Stratification Pathway) will have their demographic and clinical data entered into the risk stratification screening calculator, and will be assigned to either Low Risk (Novel (Low Impact) Care Pathway) or High Risk (Routine Care Pathway) groups.~Women in the Routine Care Pathway group will be followed in the DIP clinic according to routine care protocols and will provide bi-weekly glucometer data.~Women in the Novel (Low Impact) Care Pathway group will be followed in the New Care Pathway, which will include continuation of lifestyle and dietary modification, continuation of capillary self blood glucose monitoring, and routine prenatal care."
62693928|NCT05596812|NO_INTERVENTION|Control (Routine Care)|Those randomized to Control (Routine Care) will continue in-person and virtual visits as per routine care protocols. This group will also provide bi-weekly glucometer data.
62693929|NCT06640660|EXPERIMENTAL|MindLenses Group|The group will undergo 10 sessions (2 weeks) of a treatment combining prismatic adaptation (PA) and serious games (SG) for cognitive training, using the Mindlenses Professional device. In each session, the PA procedure will be performed, followed by approximately 30 minutes of SG. SG will be focused on attention, executive functions and language.
61936218|NCT03092024|NO_INTERVENTION|Not Offered the SPIN-HAND program|Treatment as usual
62135374|NCT05435794||Patient treated with CPAP|
62330745|NCT05179031|OTHER|Arm 1|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62330746|NCT05179031|OTHER|Arm 2|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62330747|NCT05179031|OTHER|Arm 3|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62330748|NCT05179031|OTHER|Arm 4|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62488288|NCT00597922||1|2,000 women between the ages of 18 and 55 years who are hospitalized with a heart attack
62488289|NCT00597922||2|1,000 men between the ages of 18 and 55 years who are hospitalized with a heart attack
62488290|NCT01654419|ACTIVE_COMPARATOR|Class II elastics alone|Use of class II elastics alone to correct class II dental malocclusions
62488291|NCT01654419|EXPERIMENTAL|Class II elastics with Sliding Jig|Class II elastics with Sliding Jig for correction of dental class II malocclusion
62488292|NCT01085981|ACTIVE_COMPARATOR|GRAS ingredients cream|"The study will be placebo controlled double blind study which will require two office visits after informed consent and sensitivity testing done with the study cream on the day of recruitment.~On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit Then placebo or active cream will be applied and the pt restudied. the same process is repeated another day with the second arm cream."
62488293|NCT01085981|PLACEBO_COMPARATOR|placebo cream then doppler study|
62488294|NCT03224663|EXPERIMENTAL|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
62488295|NCT03224663|EXPERIMENTAL|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
61936219|NCT03130491|OTHER|TAVR + Embolic protection|subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
61936220|NCT03642665|EXPERIMENTAL|Natural cycle|no medication
62135375|NCT05435794||Patient treated with MAD|
62135376|NCT05344573||Non-pulsatile cardiopulmonary bypass|Subjects who undergo cardiac surgery with non-pulsatile cardiopulmonary bypass
62135377|NCT05344573||Pulsatile cardiopulmonary bypass|Subjects who undergo cardiac surgery with pulsatile cardiopulmonary bypass
62135378|NCT04703283|EXPERIMENTAL|Lifestyle Medicine Group|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
62135379|NCT04703283|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
62135380|NCT02089763|EXPERIMENTAL|PEG-BCT-100|pegylated recombinant human arginase 1
62488296|NCT02881541|EXPERIMENTAL|Patients having Enhanced Support|"* A preoperative consultation with a nurse. This time will be dedicated to the preparation of returning home: explanation of the clinical pathway, realization of postoperative wound care, information on pain management and answer any questions the patient.~* A nurse call on D + 1, the day after the operation to ensure the smooth running of returning home, assess postoperative pain, the correct performance of local care, answer questions from the patient, and provide advice to to limit pain .. A reminder to J2 / J3 will be produced at the request of the patient or on FDI initiative if particular difficulties are reported"
61936221|NCT03642665|ACTIVE_COMPARATOR|Artificial cycle|"Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.~Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy."
62330749|NCT05179031|OTHER|Arm 5|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62488297|NCT02881541|EXPERIMENTAL|Patients having usual care|no intervention will be made for this group. Patients will receive usual care respecting intern procedure
62488298|NCT01003938|EXPERIMENTAL|topotecan and erlotinib|Topotecan 0.4 mg/m\^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
62488299|NCT04296123|EXPERIMENTAL|Intervention|
62488300|NCT04296123|NO_INTERVENTION|Control|
62488301|NCT06432985|OTHER|Focus Group|The investigators will iteratively develop an acceptable mobile CM protocol using qualitative feedback from Veterans in VA patients in LCS or in cancer care and LCS and oncology staff.
62488302|NCT06432985|EXPERIMENTAL|Contingency Management|Veterans in VA LCS or cancer care will receive mobile CM plus behavioral counseling and cessation medication over 5 weeks.
62488303|NCT06432985|ACTIVE_COMPARATOR|TUD Treatment as Usual|Participants assigned to TAU will receive time-matched Medication Management plus usual care (referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline).
62488304|NCT01150422|NO_INTERVENTION|Standard of care for post medical abortion follow-up|Standard of care includes a routine hospital visit two weeks after mifepristone administration. At the hospital visit, the woman will undergo a bimanual and vaginal ultrasound examination. In the event the woman fails to return for the follow-up visit, each hospital will follow their standard procedure for contacting women who fail to attend their follow-up visit, i.e. three efforts to contact the woman. Form 2a will document the results of any clinical examinations, any additional medical abortion-related care given and the abortion outcome. At the follow-up visit, women will also be asked about the acceptability of current medical abortion follow-up procedures and their future preferences.
62488305|NCT01150422|ACTIVE_COMPARATOR|Alternative follow-up|"At their first clinic visit, women will be asked to provide their phone number for contact purposes. Women will also be asked to complete a semi-quantitative pregnancy test in the clinic and the results of the test will be noted on a study form. After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist.~Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned date two weeks after mifepristone administration. The checklist will indicate that if the woman answers yes to any of the questions, then she should return to the clinic for a follow-up visit. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests."
62488306|NCT04046705|EXPERIMENTAL|HLA matched haematopoietic stem cell transplantation|Peripheral blood stem cell from matched HLA related donor.
62488307|NCT04046705|OTHER|Control arm|Best standard care : Patients will receive the best standard care according to their situation and their previous treatment: initiation of Hydroxyurea, continuation or optimization of the dose of Hydroxyurea, initiation or continuation of TP, initiation of a new drug proved to improve SCD and having authorization to use in France.
62488308|NCT03012451|EXPERIMENTAL|Advancing Adolescents|Received structured eight-week psychosocial sessions
62488309|NCT03012451|NO_INTERVENTION|Control|Controls wait-listed for the intervention, matched for age and urban residence
62488310|NCT01024855|EXPERIMENTAL|RevitaLens OcuTec Multipurpose Solution (Investigational MPS)|
62330750|NCT05179031|OTHER|Arm 6|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62330751|NCT05179031|OTHER|Arm 7|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62488311|NCT01024855|ACTIVE_COMPARATOR|Opti-Free RepleniSH Multipurpose Solution (MPS, Control)|
62488312|NCT02600247|EXPERIMENTAL|Duloxetine group|"Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon"
62488313|NCT02600247|ACTIVE_COMPARATOR|routine pain control group|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
62330752|NCT05179031|OTHER|Arm 8|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62330753|NCT05179031|OTHER|Arm 9|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
62693930|NCT06640660|ACTIVE_COMPARATOR|Control Group|The group will perform 2 weeks of the standard cognitive training offered by IRCCS San Camillo Hospital.
62693931|NCT04743232|NO_INTERVENTION|Standard practice|Standard practice concerning advanced care directives; care as usual
62693932|NCT04743232|EXPERIMENTAL|Decision aid implementation|Stepped-wedge implementation of the intervention
62488314|NCT06016582|OTHER|Patients benefiting from the virtual reality hypnosis headset during frozen embryo transfer|"The study will involve women, aged between 18 and 45, receiving care within the Reproductive Medicine Department at the Mother-Child-Woman Hospital in Lyon, as part of an assisted reproduction journey, and for whom a frozen embryo transfer is planned. The patients should have previously undergone an embryo transfer to be familiar with the medical procedure to be performed. Their partner must have planned to be present during the FET, in order to comply to identity vigilance regulations.~The study will be proposed to them during the consultation scheduled for the dispensing of their prescriptions in preparation for the transfer. If the patient agrees to participate, she will then use a virtual reality hypnosis headset during her frozen embryo transfer."
62488315|NCT05387109|EXPERIMENTAL|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
62488316|NCT01165632|EXPERIMENTAL|Arm I|Beginning at no more than 1 week before biopsy or resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.
62488317|NCT06196047|ACTIVE_COMPARATOR|ticagrelor arm|the ticagrelor arm will receive (180 mg loading dose during the first 12 hours of stroke onset followed by 90 mg b.i.d from the 2nd to the 90th day) and aspirin at a loading dose of 75 to 300 mg, followed by 75 mg daily for 21 days.
62488318|NCT06196047|ACTIVE_COMPARATOR|cilostazol arm|The cilostazol arm will receive (a 200mg loading dose during the first 12 hours of stroke onset, followed by 100mg twice daily from the 2nd day to the 90th day) and aspirin at a loading dose of 75 to 300 mg, followed by 75 mg daily for 21 days.
62488319|NCT00614861||001|
62488320|NCT00218322|PLACEBO_COMPARATOR|1|Treatment with placebo or atomoxetine for 12 weeks.
62488321|NCT00218322|EXPERIMENTAL|2|
62488322|NCT02095613|ACTIVE_COMPARATOR|Corn-soy-blend plus|food A type of ground meal called corn-soy-blend plus
61936222|NCT03414671||historical control|All infants born \< 30 weeks gestation admitted to the Swedish Hospital NICU from 11/30/2015-11/30/2017 (historical control, pre-standardized defined CSCPE
61936223|NCT03414671||Standardized|All infants born \< 30 weeks gestation admitted to the Swedish Hospital NICU from 6/1/2018 - 12/31/20 (the group following implementation of the standardized defined CSCPE)
61936224|NCT06160076||Radiofrequency|Patient with atrial fibrillation ablated per radiofrequency
61936225|NCT06160076||Pulsed electric field|Patient with atrial fibrillation ablated per pulsed electric field
61936226|NCT03449368||Cohort 1|Includes age group 5-10 with a cap at 50 subjects. This is a retrospective, observational study.
61936227|NCT03449368||Cohort 2|Includes age group 11-15 with a cap of 50 subjects. This is a retrospective, observational study.
61936228|NCT03449368||Cohort 3|Includes age group 16-20 with a cap of 40 subjects. This is a retrospective, observational study.
61936229|NCT03449368||Cohort 4|Includes age group 21-30 with a cap of 40 subjects. This is a retrospective, observational study.
61936230|NCT03449368||Cohort 5|Includes age group 31-40 with a cap at 40 subjects. This is a retrospective, observational study.
61936231|NCT03449368||Cohort 6|Includes age group 41-50 with a cap at 40 subjects. This is a retrospective, observational study.
62488323|NCT02095613|ACTIVE_COMPARATOR|Ready-to-use-supplementary food|food A nutrient dense food comprised of peanuts, oil, multivitamins.
62488324|NCT03067987|ACTIVE_COMPARATOR|720 shockwave therapy|5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
62488325|NCT03067987|ACTIVE_COMPARATOR|600 shockwave therapy|"Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration."
62693933|NCT06559007|EXPERIMENTAL|Experimental: HRS-5041 dose level 1|Sing dose level 1
61936232|NCT03449368||Cohort 7|Includes age group 51-70 with a cap at 40 subjects. This is a retrospective, observational study.
61936233|NCT01742936|EXPERIMENTAL|Spinal fusion|Patients undergoing a posterior spinal fusion and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
61936234|NCT01742936|EXPERIMENTAL|Cardiac bypass|Patients undergoing surgery requiring cardiopulmonary bypass and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
62488326|NCT01665404|EXPERIMENTAL|Dosing Period 1|
62693934|NCT06559007|EXPERIMENTAL|Experimental: HRS-5041 dose level 2|Sing dose level 2
61936235|NCT05126953|EXPERIMENTAL|samfilcon A Lenses with EPG01 Packaging Solution|
61936236|NCT05126953|ACTIVE_COMPARATOR|B+L Ultra Lenses|
61936237|NCT00101712|EXPERIMENTAL|Vildagliptin|
61936238|NCT00101712|PLACEBO_COMPARATOR|Placebo|
61936239|NCT03004443|EXPERIMENTAL|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
61936240|NCT03004443|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
61936241|NCT06415942|EXPERIMENTAL|MOMS intervention|Participants in this condition will receive the MOMS symptom monitoring and decision support intervention. This is a single arm trial.
61936242|NCT03891836||medical students|All students from the chosen classes in each study year will be invited to complete self-administered questionnaire
61936243|NCT03875235|EXPERIMENTAL|Treatment Arm|Durvalumab + Gemcitabine + Cisplatin
61936244|NCT03875235|PLACEBO_COMPARATOR|Placebo Arm|Placebo + Gemcitabine + Cisplatin
62488327|NCT01665404|EXPERIMENTAL|Dosing Period 2|
62488328|NCT02697682|EXPERIMENTAL|Intervention|All patients are recieving the treatment.
62693935|NCT05893732|EXPERIMENTAL|High-Intensity Laser Therapy (HILT) Group|Participants in this group will receive High-Intensity Laser Therapy (HILT) treatment for Meralgia Paresthetica (MP).
62488329|NCT06229912|EXPERIMENTAL|Arm 1|Participants found to be eligible to take part in this study, will take revumenib 2 times a day (each dose about 12 hours apart), every day of each 28-day study cycle.
62488330|NCT04171115|EXPERIMENTAL|10mg of G03-52-01|8 subjects randomized to 10 mg of G03-52-01 and 2 subjects randomized to placebo
62488331|NCT04171115|EXPERIMENTAL|25mg of G03-52-01|8 subjects randomized to 25 mg of G03-52-01 and 2 subjects randomized to placebo
62488332|NCT04171115|EXPERIMENTAL|50 mg of G03-52-01|8 subjects randomized to 50 mg of G03-52-01 and 2 subjects randomized to placebo
62488333|NCT04171115|EXPERIMENTAL|100 mg of G03-52-01|8 subjects randomized to 100 mg of G03-52-01 and 2 subjects randomized to placebo
62488334|NCT06266741||Patients with infective endocarditis|Patients between the ages of 18-65 diagnosed with infective endocarditis according to the Duke criteria
62488335|NCT06266741||Patients without infective endocarditis|Patients between the ages of 18-65 without diagnosed with infective endocarditis according to the Duke criteria
62488336|NCT02625298|EXPERIMENTAL|ProRoot MTA|Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
62693936|NCT05893732|SHAM_COMPARATOR|Sham High-Intensity Laser Therapy (Sham HILT) Group|Participants in this group will receive sham High-Intensity Laser Therapy (sham HILT) treatment for Meralgia Paresthetica (MP).
62693937|NCT06015516|EXPERIMENTAL|Treatment Test: Oral minoxidil 1 mg tablets|Participants will be administered one tablet of oral minoxidil 1mg once a day, orally, after fasting for at least 10 hours, with 240 mL or 8 Oz. of water, and fasting for a further 5 hours.
62693938|NCT06015516|ACTIVE_COMPARATOR|Treatment Reference: Regaxidil 20 mg/ml (2%) topical solution|Participants will be administered topically on the scalp after fasting for at least 10 hours pre-dose and 5 hours post-dose. After the administration subject should not wash her head for at least 5 hours. Each one mL dose of 2% topical minoxidil will be carefully measured to provide 20 mg of minoxidil using the syringe provided with each bottle.
61936245|NCT01199328|ACTIVE_COMPARATOR|1|Aspirin 81 mg
62135381|NCT02362139|EXPERIMENTAL|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
62330754|NCT04834882||Healthcare workers|Medical and paramedical staff in Reims University Hospital and EPSM Marne working in COVID-19 units and non COVID-19 units
62330755|NCT06505057|EXPERIMENTAL|ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
62330756|NCT02427477|EXPERIMENTAL|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
62330757|NCT02427477|ACTIVE_COMPARATOR|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
62330758|NCT02724774|EXPERIMENTAL|Promoting First Relationships® (PFR)|10 week home visiting program
62330759|NCT02724774|NO_INTERVENTION|Parent Information Packet|A packet is mailed to the families, including handouts related to child development, health, and local resources.
62488337|NCT02625298|EXPERIMENTAL|MTA+ Cercamed|Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment
62488338|NCT01139762|EXPERIMENTAL|Tadalafil|
62330760|NCT04382859|ACTIVE_COMPARATOR|TAP block with liposomal bupivacaine|Active comparator
62330761|NCT04382859|OTHER|TAP block with 0.25% bupivacaine|Standard comparator
62330762|NCT00137852|EXPERIMENTAL|Cisplatin/CPT-11/Celecoxib/XRT/Surgery|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
62330763|NCT04276220|OTHER|Tenosynovial Biopsy|
62330764|NCT01806077|EXPERIMENTAL|PZ-128|
62488339|NCT01139762|PLACEBO_COMPARATOR|Placebo|
62488340|NCT02588781|EXPERIMENTAL|Pemetrexed|Pemetrexed 500 mg/m2 IV Q 3 weeks
62488341|NCT06278090||Patients treated with Ursodeoxycholic acid|Patients that recieved prescription for Ursodeoxycholic acid, 10-15 mg/kg for at least 6 months.
62488342|NCT06278090||Patients not treated with Ursodeoxycholic acid|Patients without prescription of Ursodeoxycholic acid
62488343|NCT04015024|EXPERIMENTAL|SKLB1028 150mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs.
61936246|NCT01199328|ACTIVE_COMPARATOR|2|Esomeprazole 20mg/aspirin 81mg
62135382|NCT02362139|NO_INTERVENTION|The control group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
62330765|NCT01596959|ACTIVE_COMPARATOR|ECI CONTACT-ACTIVE|Irrigated Radiofrequency ablation performed using the ECI contact data
62488344|NCT04015024|EXPERIMENTAL|SKLB1028 200mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
62488345|NCT04015024|EXPERIMENTAL|SKLB1028 300mg qd|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
62488346|NCT01101386||Voriconazole|Pharmacokinetic Monitoring
62488347|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
62488348|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
62488349|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
62488350|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
62693939|NCT06636110|EXPERIMENTAL|Pregnant without Criminal Justice Oversight|Pregnant women who are without criminal justice oversight
62693940|NCT06636110|EXPERIMENTAL|Pregnant with Criminal Justice Oversight|Pregnant women who are under Community Supervision (CS), on probation or parole with criminal justice oversight
62330766|NCT01596959|PLACEBO_COMPARATOR|ECI CONTACT-INACTIVE|irrigated RF ablation performed to the right atrium without the use of ECI contact data
62330767|NCT04175704|OTHER|Cohort 1|0.2 mg/kg UB-221 or placebo
62330768|NCT04175704|OTHER|Cohort2|0.6 mg/kg UB-221 or placebo
62330769|NCT04175704|OTHER|Cohort 3|2 mg/kg UB-221 or placebo
62330770|NCT04175704|OTHER|Cohort 4|6 mg/kg UB-221 or placebo
62330771|NCT05233696|EXPERIMENTAL|RT followed by nab-paclitaxel/paclitaxel plus pembrolizumab|Nab-paclitaxel/paclitaxel plus pembrolizumab will be started within 7 days of completion of RT.
62330772|NCT04292405||Heart Failure Patients|Simultaneous recordings of cardiac acoustic biomarkers (CABs) by the Wearable Cardioverter Defibrillator and the AUDICOR AM
62330773|NCT03903393||preeclamptic women|systolic blood pressure(BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg; hypertension diagnosed after 20 weeks gestation; new-onset hypertension with new-onset proteinuria or other signs/symptoms of preeclampsia after 20 weeks or chronic proteinuria with newonset hypertension.
62330774|NCT03903393||controls|Normal pregnant women
62330775|NCT04436627|EXPERIMENTAL|Mild severity:|Brunnstrom stage of distal part: 5-6
62330776|NCT04436627|EXPERIMENTAL|Moderate severity:|Brunnstrom stage of distal part: 4
62330777|NCT04436627|EXPERIMENTAL|severe severity:|Brunnstrom stage of distal part: 2-3
62488351|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
62488352|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
62488353|NCT02452619||Brain trauma|Patients with chronic brain injury that have been treated with Hyperbaric oxygen therapy and underwent MRI imaging and cognitive tests before and after the treatment
62330778|NCT02434341||septic patients|wake septic patients on mechanical ventilation
62330779|NCT02434341||COPD patients|wake COPD patients on mechanical ventilation
62330780|NCT04316689|EXPERIMENTAL|S-588210 (S-488210 + S-488211)|Participants will receive subcutaneous injections once a week for 4 weeks and then a biweekly extension treatment for 8 weeks. Each treatment will consist of 1 subcutaneous injection of 1 mL of S- 488210 and 1 subcutaneous injection of 1 mL of S-488211 containing 1 mg each of the 5 peptides.
62330781|NCT03417180|EXPERIMENTAL|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI\>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
62330782|NCT03417180|EXPERIMENTAL|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI\>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
62330783|NCT03417180|EXPERIMENTAL|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI\>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
62488354|NCT02099318|ACTIVE_COMPARATOR|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
62330784|NCT01258348|EXPERIMENTAL|LY573636 +sunitinib|
62488355|NCT02099318|PLACEBO_COMPARATOR|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
62488356|NCT04381871|EXPERIMENTAL|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
62488357|NCT04381871|PLACEBO_COMPARATOR|Control group|This group will be provided with pectin powder provided as one-gram-dose
62330785|NCT02079883||ocriplasmin|
62330786|NCT00685620|NO_INTERVENTION|Group 1|Standard care following detoxification
62330787|NCT00685620|ACTIVE_COMPARATOR|Group 2|Recovery housing following detoxification
62330788|NCT00685620|EXPERIMENTAL|Group 3|Recovery housing plus counseling
62330789|NCT01073345||Major hepatic resection|Patients undergoing resection of \> 2 liver segments
62330790|NCT01073345||Minor hepatic resection|Patients undergoing resection of \</= 2 liver segments
62330791|NCT01073345||Control group|Patients undergoing exploratory laparotomy for hepatobiliary disease without resection (e.g. due to inoperable disease)
62330792|NCT03435991||OAB patients|
62330793|NCT03435991||Healthy volunteers|
62330794|NCT03928834|EXPERIMENTAL|Adapted Nzira Itsva Intervention|Participants will be attending clinics that provide an enhanced adherence package to the adolescents consisting of viral load (VL) testing using DBS, including the Nzira Itsva(NI) intervention and low-cost genotyping and drug resistance monitoring
62330795|NCT03928834|NO_INTERVENTION|Standard of Care( SOC)|Participants will be attending clinics that provide the standard of care (SOC) VL testing and management to adolescents
62330796|NCT04427787|EXPERIMENTAL|Cabozantinib+lanreotide|Cabozantinib will be administered orally at a dose of 60 mg/day continuously in combination with Lanreotide 120 mg injection every 28 days. Both treatments will start the same day
62488358|NCT01408654|EXPERIMENTAL|Peer Companionship|Behavioral intervention: Receipt of peer companionship provided by trained, supervised volunteer companions.
62488359|NCT01408654|NO_INTERVENTION|Care-as-Usual|Care-as-Usual in Primary Care
62488360|NCT01758601|EXPERIMENTAL|Fish - no fish|The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Then switched to previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood.
62488361|NCT01758601|ACTIVE_COMPARATOR|No fish - fish|Patients were on previous diet except for the avoidance of fish and any other seafood for 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
62488362|NCT02132910|EXPERIMENTAL|RESTORE Intervention|"1. First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.~2. For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.~3. For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.~4. At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~5. At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
62135383|NCT02405559|EXPERIMENTAL|Lymphatic occlusion pressure lower limb|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the leg to visualize at which pressure lymph flow is interrupted.
62135384|NCT05766462||PLR group|The pacemaker lower rate of PLR group will be set as 75 bpm and might be adjusted according to physician diagnosis based on patients situation.
62488363|NCT02132910|NO_INTERVENTION|Control Group 2|"1. First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.~2. You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.~3. At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~4. At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
62693941|NCT06644339|EXPERIMENTAL|Heart Failure|"Patients with chronic heart failure who was hospitalized due to decompensation of their condition. Their condition should be stabilized before discharge.~Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure."
61936247|NCT03563287|EXPERIMENTAL|Phenotyping cocktail of 9 CYP probe drugs before surgery|
61936248|NCT03563287|EXPERIMENTAL|Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery|
61936249|NCT04768725|ACTIVE_COMPARATOR|Dietary intervention|Participants will consume a self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day).
61936250|NCT04768725|ACTIVE_COMPARATOR|Physical-cognitive intervention|Participants will perform home-based physical-cognitive training for 60 minutes per session, 3 session a week.
61936251|NCT04768725|EXPERIMENTAL|Physical-cognitive with dietary intervention|Participants will receive both dietary intervention and physical-cognitive training same as those in the dietary and physical-cognitive intervention groups.
61936252|NCT04768725|NO_INTERVENTION|Control|Participants in the control group will be encouraged to continue their activities and calorie intakes as they usually would.
61936253|NCT05860335|EXPERIMENTAL|Toripalimab +AP-induced chemotherapy|Study drug: toripalimab JS001 dosage：240mg Drug administration plan and mode：Intravenous infusion of 30min (not less than 20min and not more than 60min), followed by observation of 60min (only the first 2 cycles), once every 3 weeks (Q3W).
61936254|NCT06709664||Women with Spinal Cord Injury|Women with Spinal Cord Injury who are currently going through or have gone through the Perimenopause/Menopause
62135385|NCT05766462||control group|The pacemaker lower rate of control group will be set as 60 bpm.
61936255|NCT05726734|ACTIVE_COMPARATOR|Vonoprazan-containing Triple Therapy|Vonoprazan 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
61936256|NCT05726734|EXPERIMENTAL|Empiric Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
61936257|NCT01848704|ACTIVE_COMPARATOR|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
61936258|NCT01848704|EXPERIMENTAL|abstract without spin|The abstracts with spin were systematically rewritten without spin
61936259|NCT05964205||PT-PENCIL cohort|patients discharged from the hospital while the PT-PENCIL was active
61936260|NCT05964205||Control cohort|patients discharged from the hospital while the PT-PENCIL was not active
61936261|NCT01631812|EXPERIMENTAL|SPM 962|
61936262|NCT01291654|EXPERIMENTAL|Paracetamol|Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
61936263|NCT01291654|EXPERIMENTAL|NSAID|Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
62135386|NCT06498414|ACTIVE_COMPARATOR|4 months standard dose rifampin (4R10)|120 doses daily self-administered rifampin at 10 mg/kg/day (max. 600 mg/day)
62135387|NCT06498414|EXPERIMENTAL|2 months high dose rifampin (2R20)|60 doses daily self-administered rifampin at 20 mg/kg/day (max.1200 mg/day)
62135388|NCT06498414|EXPERIMENTAL|1 month levofloxacin and rifapentine (1LP)|30 doses daily self-administered levofloxacin (15 mg/kg/day, max. 750 mg/day and rifapentine (10mg/kg/day, max. 600mg)
62135389|NCT01767350||children with organ transplant|Subjects who received an solid organ transplant at our institution at the age of 0-19 yrs and who were subject to pharmacokinetic evaluation during their follow up. Additional blood withdrawal for DNA will be performed
62135390|NCT02345720|EXPERIMENTAL|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
62135391|NCT02475343|EXPERIMENTAL|Control|People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.
62330797|NCT02083510|EXPERIMENTAL|Colchicine|Patients will be enrolled with either gout/pericarditis or hypertriglyceridemia, have VAP and Apolipoprotein CIII levels at baseline, administer Colchicine for 6 weeks with reassessment of Apolipoprotein CIII and VAP.
62488364|NCT02424435|EXPERIMENTAL|Methylprednisolone|This is an open-label study of methylprednisolone in patients with FRDA. Subjects will begin oral administration of 48 mg methylprednisolone at day 1 and will decrease their administered dose by 8 mg per day. After 6 days, subjects will spend 22 days off medication before repeating the same treatment cycle. Last dosing cycle of methylprednisolone will be administered at 24 weeks after baseline. Visits will occur at weeks 2, 6, 14, 26, and 30 following baseline.
62488365|NCT01160549||Cases|Women living in rural environments
62488366|NCT01160549||Controls|Women living in more urban environments
62488367|NCT03090022|ACTIVE_COMPARATOR|Mesh implantation|Prior to closure of the abdominal wall a mesh will be implanted in a standardized fashion
62488368|NCT03090022|ACTIVE_COMPARATOR|Single running suture of abdominal fascia|The closure of the abdominal wall a Standard technique will be applied using a running suture
62488369|NCT04755335|OTHER|Early detection of PAD, assessment of the disease progression and treatment response|"The objective of this arm of the study is to evaluate the potentials of Ultrasound Perfusion imaging technique for early detection of peripheral arterial disease in patients and assess the disease progression and monitor the treatment response.~The investigators anticipate that our new cost-effective and non-invasive ultrasound perfusion technique offers a quantitative perfusion estimation of calf muscle that would separate PAD from non-PAD and help early detection of PAD and would help monitoring the disease progression and treatment response."
62488370|NCT04007835|EXPERIMENTAL|Anlotinib Hydrochloride combined with EGFR-TKI|Patients receive anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of following EGFR-TKIs: Gefitinib is administered 250 mg once per day. Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
62488371|NCT03994952||Uninjured Physically Active Young Adults|"This is a group of physically active, and currently uninjured young adults. They will complete a single balance assessment, the modified balance error scoring system protocol, as outlined by the Sway Balance application.~There is no comparison group for this investigation."
61936264|NCT01327456|EXPERIMENTAL|Self-Management Intervention|participants who receive the one-on-one self-management intervention
61936265|NCT01327456|NO_INTERVENTION|Usual Care|group receives no additional education or intervention then they would as usual care of their COPD
61936266|NCT04152044||Liver biopsy, Visceral and subcutaneous obesity|Those with histology and LFT's and quantificaiton of obesity
62135392|NCT02475343|EXPERIMENTAL|Keratoconic patients|Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.
62330798|NCT05580172|EXPERIMENTAL|Dose Level 1|RH324
62330799|NCT05580172|EXPERIMENTAL|Dose Level 2|RH324
62488372|NCT05846139|EXPERIMENTAL|PerioTabs® brushing solution|At baseline, patients were given instructions for the home use of PerioTabs® for daily gum and toothbrushing for 10 consecutive days, according to the product's directions for use. The procedure consisted of brushing the teeth and gums for 2 minutes in the evening during a 10-day period. After one week, one-stage full-mouth disinfection was performed with the use of ultrasonic devices on each quadrant. In addition, two cycles of 90 seconds ozone-therapy were carried out.
62693942|NCT06644339|EXPERIMENTAL|Diabetes mellitus|"Patients with diabetes mellitus who was hospitalized with unstable glucose level. Their condition should be stabilized before discharge.~Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight, glucose) related to diabetes mellitus."
61936267|NCT03298776|ACTIVE_COMPARATOR|standard white light endoscopy|Patients will undergo the standard of care which is standard white light endoscopy
62330800|NCT05580172|EXPERIMENTAL|Dose Level 3|RH324
62330801|NCT03825601|OTHER|Patients with multiple sclerosis|The multiple sclerosis group (n=30) will be subdivided in two subgroups: 15 patients with a relapsing remmitting MS (RRMS), and 15 patients with a primary progressive MS (PPMS).
61936268|NCT03298776|EXPERIMENTAL|Endoscopy and I-Scan|Patients will undergo standard of care endoscopy plus the I-Scan
61936269|NCT04499976|EXPERIMENTAL|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily dose, 900 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
61936270|NCT04499976|PLACEBO_COMPARATOR|Placebo Comparator|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
62330802|NCT03825601|OTHER|healthy subjects|15 healthy subjects will be included. Among them 7 to 8 subjects will be matched for age and gender with the RRMS subgroup, and 7 to 8 will be matched for age and gender with the PPMS subgroup.
62330803|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
62330804|NCT04898907|EXPERIMENTAL|ANG-3777 (Therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
61936271|NCT02520661|NO_INTERVENTION|Usual Care|Older adults discharged from an ED to home who receive the usual processes and services.
62488373|NCT05846139|ACTIVE_COMPARATOR|Chlorhexidine 0.2% mouth rinse|At baseline, patients were given instructions for the home use of toothbrush with chlorhexidine 0.12 % toothpaste for 15 days toothbrushing twice daily (morning and evening). Also, a chlorhexidine 0.2% mouth rinse had to be used every evening for the course of the 15 days. After two weeks, the one-stage full-mouth disinfection was performed in the same way as in Group 1.
62488374|NCT00899951||Cohort 1|receiving fentaly citrate
62488375|NCT04470739|ACTIVE_COMPARATOR|Infants born to COVID-19 positive mothers|Infants, born to COVID-19 positive mothers, will be evaluated for cardiothymic index in their first chest X-ray.
62488376|NCT04470739|NO_INTERVENTION|Infants born to COVID-19 negative mothers|Infants, born to COVID-19 negative mothers, will be evaluated for cardiothymic index in their first chest X-ray.
62488377|NCT03340545|OTHER|Healthy Individuals|Healthy individuals will be imaged for comparison purposes
62488378|NCT03340545|OTHER|Disc Herniation|Subjects diagnosed with Intervertebral Disc Herniation will be imaged to evaluate sensitivity of the proposed method.
62488379|NCT06212076|EXPERIMENTAL|Cohort 1 (200 mg BID)|Starting at 200mg BID cohort, 3 subjects will be enrolled. After 3 subjects completed DLT evaluation, the Safety Monitoring Committee (SMC) will review all available safety and PK/PD data from all treated subjects (DLT evaluable and non-DLT evaluable subjects), taking into consideration the dose-assignment recommendation based on 3+3 decision rule , to make the recommendation on the conduct of the study including the dose level and dose schedule for subsequent subjects.
62488380|NCT06212076|EXPERIMENTAL|Cohort 2 (250 mg BID)|Starting at 250 mg BID cohort, 3 subjects will be enrolled. After 3 subjects completed DLT evaluation, the Safety Monitoring Committee (SMC) will review all available safety and PK/PD data from all treated subjects (DLT evaluable and non-DLT evaluable subjects), taking into consideration the dose-assignment recommendation based on 3+3 decision rule , to make the recommendation on the conduct of the study including the dose level and dose schedule for subsequent subjects.
62488381|NCT06212076|EXPERIMENTAL|Cohort 3 (NSCLC)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with non small cell lung cancer (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
62488382|NCT06212076|EXPERIMENTAL|Cohort 4 (TNBC)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with triple-negative breast cancer (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
62488383|NCT06212076|EXPERIMENTAL|Cohort 5 (head and neck cancer)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with head and neck cancer (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
61936272|NCT02520661|ACTIVE_COMPARATOR|Care Transitions Intervention|Older adults discharged from an ED to home who receive the Care Transitions Intervention.
61936273|NCT05542186|EXPERIMENTAL|Kinesiotaping|
62330805|NCT04898907|PLACEBO_COMPARATOR|Normal Saline|The placebo will be administered as a single dose on separate occasions intravenously as 30-minute infusions on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
62330806|NCT04898907|ACTIVE_COMPARATOR|Moxifloxacin Hydrochloride|The comparator will be administered as a single dose oral Moxifloxacin Hydrochloride tablet (open-label), with a total of 240 mL of water. There will be a minimum washout of 3 days between each study drug administration.
61936274|NCT03250871|PLACEBO_COMPARATOR|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
61936275|NCT03250871|EXPERIMENTAL|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.~It is divided into three phases:~* induction: attention of the patient fixed on an object or a part of the body,~* the dissociation where the patient cuts off auditory, visual and tactile perceptions,~* and finally the opening towards a hypnotic experience thanks to the imaginary."
61936276|NCT06665672|EXPERIMENTAL|Apollo device applied followed by no device applied|Participants will be randomized to first wear the Apollo Neuro device immediately before, during, and immediately after sleep opportunities during the study protocol. Next, the participant will complete the protocol without the device.
61936277|NCT06665672|EXPERIMENTAL|No device applied followed by the Apollo device applied|Participants will be randomized to first complete the protocol without the Apollo Neuro device applied then complete a condition with the Apollo Neuro device applied immediately before, during, and immediately after sleep opportunities during the study protocol.
62330807|NCT04898907|EXPERIMENTAL|ANG-3777 (Supra-therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
61936278|NCT04048551|NO_INTERVENTION|No S&D Reduction Training; PrEP and SRH only|Arm 1 does not receive stigma and discrimination (S\&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
61936279|NCT04048551|EXPERIMENTAL|No S&D Reduction Training; PrEP and SRH + YWHC|Arm 2 does not receive stigma and discrimination (S\&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
62135393|NCT02475343|EXPERIMENTAL|Patients received keratoplasty|Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..
62488384|NCT06212076|EXPERIMENTAL|Cohort 6 (brain glioma)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with brain glioma (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
62135394|NCT04036955|EXPERIMENTAL|intervention group|"The INFOSA-DEM programme consists of five, 90-minute informational/training sessions delivered consecutively over one week. Morning or afternoon groups are offered depending on the caregiver's availability. Programme content was developed for use in small groups of 6-8 caregivers. Topics covered in the sessions include basic concepts in dementia and specific issues such as nutrition, rest, medication, physical and cognitive changes, management of behavioural symptoms, affective problems in the patient and informal caregiver, verbal and non-verbal communication techniques, caregiver self-care and information on available resources and community services.~The sessions are conducted using audio-visual material to facilitate understanding of the content and to encourage active participation among caregivers when talking about their experiences."
62330808|NCT04434053|EXPERIMENTAL|MIETHKE M.blue®|
62330809|NCT04434053|ACTIVE_COMPARATOR|MIETHKE proGAV 2.0® (with SA 2.0®)|
62330810|NCT02166021|EXPERIMENTAL|IT- Treated|Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.
62330811|NCT02166021|EXPERIMENTAL|IV - Treated|Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.
62330812|NCT02166021|PLACEBO_COMPARATOR|Placebo|Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV.
62330813|NCT05754190||Healthy Controls|\[general study + sub study\] No history of chronic pain
62330814|NCT05754190||Acute pain|\[general study\] Pain duration \< 3 months
62330815|NCT05754190||Chronic pain|"\[general study\] Pain duration \> 6 months~\[sub-study\] diagnosis of chronic low back pain, failed back surgery syndrome, or fibromyalgia"
62330816|NCT02446730|ACTIVE_COMPARATOR|BES with Prasugel 5mg|Biolimus-eluting stent with Prasugrel 5mg once daily MD
62330817|NCT02446730|ACTIVE_COMPARATOR|BES with Clopidogrel 75mg|Biolimus-eluting stent with Clopidogrel 75mg once daily MD
62330818|NCT02738827|OTHER|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.
62330819|NCT02417233|NO_INTERVENTION|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
62330820|NCT02417233|ACTIVE_COMPARATOR|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
62330821|NCT02417233|ACTIVE_COMPARATOR|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
62330822|NCT02541838|EXPERIMENTAL|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
62330823|NCT01519622||Sick elderly in community|
62330824|NCT01834144|ACTIVE_COMPARATOR|Moderate intensity exercise|150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
62330825|NCT01834144|ACTIVE_COMPARATOR|Moderate + Vigorous Intensity Exercise|150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
62330826|NCT02000570|EXPERIMENTAL|sitting position|
62330827|NCT01158833||spastic diplegia due to Cerebral Palsy|
62330828|NCT02840487|EXPERIMENTAL|Group 1|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.
62330829|NCT02840487|EXPERIMENTAL|Group 2|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.
62330830|NCT02840487|EXPERIMENTAL|Group 3|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.
62330831|NCT02840487|EXPERIMENTAL|Group 4|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.
62330832|NCT01433458|EXPERIMENTAL|RLX030: Group 1 mild hepatic impairment|Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
62330833|NCT01433458|EXPERIMENTAL|RLX030: Group 2 moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
62330834|NCT01433458|EXPERIMENTAL|RLX030: Group 3 severe hepatic impairment|Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
62330835|NCT01433458|ACTIVE_COMPARATOR|RLX030: Group 4 - healthy volunteers|Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.
62330836|NCT03823417|PLACEBO_COMPARATOR|Normal saline placebo|the participant will get saline 0.9% intravenous infusion for the duration of the surgery
61936280|NCT04048551|ACTIVE_COMPARATOR|S&D Reduction Training; PrEP and SRH only|Arm 3 receives stigma and discrimination (S\&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
61936281|NCT04048551|EXPERIMENTAL|S&D Reduction Training; PrEP, SRH + YWHC|Arm 4 receives stigma and discrimination (S\&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
62488385|NCT05710354||The Study Group|Patients in the study group (N=57), in addition to the usual diet, received nutritional support with the Oral Nutrition Supplement (ONS) Nutridrink Compact Protein in the amount of 2 bottles per day for 14 days prior to surgery and 14 days following surgery. During the hospital stay, additional nutritional support was added to the patient's standard hospital diet. On an outpatient basis, the patient received the required amount of ONS at his/her disposal and took it as a supplement to his/her usual and habitual diet. The ONS was recommended to be taken between main meals
62488386|NCT05710354||The Control Group|Patients in the control group (N=57) followed the standard hospital diet, and at outpatient basis - their usual habitual diet
62488387|NCT02623218|EXPERIMENTAL|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
62693943|NCT06644339|EXPERIMENTAL|Arterial hypertension|"Patients with arterial hypertension who was hospitalized with unstable arterial pressure. Their condition should be stabilized before discharge.~Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, hypotension sings, signs of damage to target organs)."
62693944|NCT06644339|EXPERIMENTAL|Lymphoproliferative diseases|"Patients with any lymphoproliferative disease who is undergoing chemotherapy. Their condition should be stabilized before discharge.~Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate) related to chemotherapy complications."
61936282|NCT02602899|EXPERIMENTAL|PINS Deep Brain Stimulator|Deep Brain Stimulator is on,continuous stimulation to the brain,
61936283|NCT06221917|ACTIVE_COMPARATOR|Face-to-face|Face-to-face teaching method
61936284|NCT06221917|EXPERIMENTAL|Live-streaming|Live-streaming teaching method
62330837|NCT03823417|EXPERIMENTAL|Intravenous Tranexamic acid|Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
62330838|NCT05618457|OTHER|Aminoglycoside dose adjustment|Eligible patients will be assessed for attainment of PK/PD target under standard dosing, dose adjustment to attain target will be proposed where appropriate
61936285|NCT05352399|EXPERIMENTAL|Intervention (NeuViCare AI)|An anticipated 55 participants will be part of the Intervention arm participants and will engage with NeuViCare AI, including all variations of its 5 components described further below.
61936286|NCT01902433|EXPERIMENTAL|Astym|A form of soft tissue mobilization using instruments
61936287|NCT01902433|ACTIVE_COMPARATOR|Eccentric Exercise|Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.
61936288|NCT05400915|EXPERIMENTAL|Variltinib, Paclitaxel|
61936289|NCT04107779|EXPERIMENTAL|JUUL 5% Virginia Tobacco ENDS|JUUL 5% Virginia Tobacco flavored ENDS product \[6 days\] in confinement.
61936290|NCT04107779|EXPERIMENTAL|JUUL 3% Virginia Tobacco ENDS|JUUL 3% Virginia Tobacco flavored ENDS product \[6 days\] in confinement.
61936291|NCT04107779|EXPERIMENTAL|JUUL 5% Mint ENDS|JUUL 5% Mint flavored ENDS product \[6 days\] in confinement.
61936292|NCT04107779|EXPERIMENTAL|JUUL 3% Mint ENDS|JUUL 3% Mint flavored ENDS product \[6 days\] in confinement.
61936293|NCT04107779|EXPERIMENTAL|JUUL 5% Menthol ENDS|JUUL 5% Menthol flavored ENDS product \[6 days\] in confinement.
61936294|NCT04107779|EXPERIMENTAL|JUUL 3% Menthol ENDS|JUUL 3% Menthol flavored ENDS product \[6 days\] in confinement.
61936295|NCT04107779|EXPERIMENTAL|JUUL 5% Mango ENDS|JUUL 5% Mango flavored ENDS product \[6 days\] in confinement.
62330839|NCT00916123|EXPERIMENTAL|Dose Level 1|177Lu-J591 at 20 mCi/dose
62330840|NCT00916123|EXPERIMENTAL|Dose Level 2|177Lu-J591 at 25 mCi/dose
61936296|NCT04107779|EXPERIMENTAL|JUUL 3% Mango ENDS|JUUL 3% Mango flavored ENDS product \[6 days\] in confinement.
61936297|NCT04107779|EXPERIMENTAL|Dual-use of JUUL 5% and UB of Combustible Cigarette|JUUL 5% Virginia Tobacco, Mint, Menthol, or Mango flavored ENDS product and usual brand of combustible cigarette \[6 days\] in confinement.
61936298|NCT04107779|ACTIVE_COMPARATOR|UB of Combustible Cigarette|Usual brand combustible cigarette \[6 days\] in confinement.
62135395|NCT04036955|NO_INTERVENTION|usual care|Caregivers in the Group control received usual care in the centres where the follow-up was carried out. This consisted of annual or quarterly consultations with a health professional (GP, geriatrician or neurologist) and, depending on the health centre, a nurse and social worker.Currently, there is no homogenous protocol for all care centres for the patient with high levels of cognitive impairment and dependency.
62330841|NCT00916123|EXPERIMENTAL|Dose Level 3|177Lu-J591 at 30 mCi/dose
62330842|NCT00916123|EXPERIMENTAL|Dose Level 4|177Lu-J591 at 35 mCi/dose
62488388|NCT02623218|SHAM_COMPARATOR|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
62488389|NCT02623218|ACTIVE_COMPARATOR|C-ACUP|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
62488390|NCT02623218|SHAM_COMPARATOR|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
61936299|NCT04107779|OTHER|Tobacco/Nicotine Abstention|Smoking abstention (no smoking) \[6 days\] in confinement.
62330843|NCT00916123|EXPERIMENTAL|Dose Level 5|177Lu-J591 at 40 mCi/dose
62488391|NCT02623218|ACTIVE_COMPARATOR|C-EX|This group of participants without TBI will receive one acupuncture treatment following 30-60 minutes of aerobic exercise, and serve as a healthy control group.
62330844|NCT06217458|EXPERIMENTAL|Interventional Group|Patients with mammographically newly detected ductal in situ carcinoma who undergo surgery at CHC Rijeka in 2024, 2025, and 2026 (consecutively), who agree to have a CEM performed prior to surgery as part of the diagnostic work-up in addition to standard mammography, and who agree to participate in the examination. Group number: 50 patients.
62330845|NCT06217458|NO_INTERVENTION|Historical Control|Patients diagnosed with ductal in situ carcinoma who underwent surgery at CHC Rijeka in the period from 2019 to 2024 and whose clinical data are available in the prospectively managed clinical registry for breast diseases at CHC Rijeka and in the Hospital Information System (IBIS). Group number: 50 patients.
62488392|NCT00794794|EXPERIMENTAL|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
62488393|NCT01847235|EXPERIMENTAL|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
62488394|NCT05783089|EXPERIMENTAL|Anti-mesothelin CAR-T cells Injection|Anti-mesothelin CAR-T cells Injection will be infused at a dose ranging from 0.1×10\^6/Kg ～ 2.0×10\^6/Kg after receiving lymphodepleting chemotherapy.
62693945|NCT06644339|EXPERIMENTAL|Total knee replacement|"Patients who underwent total knee replacement. Their condition should be stabilized before discharge.~Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (pain, fever) related to replacement complications."
62693946|NCT02940119|ACTIVE_COMPARATOR|Active PBMT|The volunteers received active phototherapy in each session.
61936300|NCT03882788|ACTIVE_COMPARATOR|Volatile Anesthesia|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane.~Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
61936301|NCT03882788|ACTIVE_COMPARATOR|Narcotic based anesthesia|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose)."
61936302|NCT02370277||Group A (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (before surgery), at 1 week before initiation of adjuvant chemotherapy (after surgery), and at 1 and 4 months after completion of adjuvant chemotherapy.
61936303|NCT02370277||Group B (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (after surgery), at 1 week before initiation of adjuvant chemotherapy, and at 1 and 4 months after completion of adjuvant chemotherapy.
61936304|NCT02370277||Group C (stool collection after neoadjuvant chemotherapy)|Patients undergo collection of stool samples at baseline, 1 month after completion of neoadjuvant chemotherapy (before surgery), and at 1 and 4 months after surgery
61936305|NCT03566511|EXPERIMENTAL|Healthy (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
61936306|NCT03566511|PLACEBO_COMPARATOR|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
61936307|NCT03566511|EXPERIMENTAL|T2D (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
62135396|NCT03149302|EXPERIMENTAL|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
62135397|NCT03149302|EXPERIMENTAL|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
62135398|NCT03149302|EXPERIMENTAL|LNT plus balance exercises|Local neck treatment plus balance training program.
62135399|NCT03149302|EXPERIMENTAL|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
62135400|NCT03955575|ACTIVE_COMPARATOR|Liraglutide/placebo-colesevelam|Liraglutide as active and colesevelam as placebo
62135401|NCT03955575|ACTIVE_COMPARATOR|Placebo-Liraglutide/colesevelam|Liraglutide as placebo and colesevelam as placebo
62330846|NCT00555828|EXPERIMENTAL|A1|5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
62330847|NCT00555828|OTHER|A2|5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
62330848|NCT00555828|EXPERIMENTAL|B1|5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
62330849|NCT00555828|OTHER|B2|3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
62330850|NCT00555828|EXPERIMENTAL|C1|5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
62693947|NCT02940119|PLACEBO_COMPARATOR|Placebo PBMT|The volunteers received placebo phototherapy in each session.
62693948|NCT04031677|OTHER|Standard arm|Surgery alone
61936308|NCT03566511|PLACEBO_COMPARATOR|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
61936309|NCT04953299|EXPERIMENTAL|Functional Imagery training|The FIT sessions will occur weekly for four weeks and last an hour per session. The sessions will be conducted over Zoom. Sessions will be facilitated by the PI who is trained in FIT, and attended by 4 participants.
61936310|NCT04953299|ACTIVE_COMPARATOR|Control|The control condition will ask participants to complete the 12 week NHS weight loss plan.
61936311|NCT06016192|ACTIVE_COMPARATOR|Continuous aerobic training|Moderate continous endurance training, ergometer
61936312|NCT06016192|EXPERIMENTAL|Interval aerobic training|Moderate intensity interval training, ergometer
62330851|NCT00555828|OTHER|C2|2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
62488395|NCT06020430|EXPERIMENTAL|CTV-omitted|CTV was omitted for the radical radiotherapy for locally advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.
62488396|NCT06020430|ACTIVE_COMPARATOR|CTV-delineated|CTV was delineated for the radical radiotherapy for locally advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.
62488397|NCT00503867|EXPERIMENTAL|SIR-Spheres microspheres|SIR-Spheres microspheres
62693949|NCT04031677|EXPERIMENTAL|Experimental arm|Preoperative chemotherapy and surgery
62488398|NCT02664415|EXPERIMENTAL|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
62488399|NCT02664415|PLACEBO_COMPARATOR|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
62488400|NCT05031858|EXPERIMENTAL|Vojta Therapy|Reflex turn first phase: Patient positioned supine with legs flexed 30º-45º. The pectoral area is stimulated for five minutes on each side x 2 consecutive times. Total 20 minutes per session.
62488401|NCT05031858|ACTIVE_COMPARATOR|Control Group|.Inspiratory techniques, mucociliary clearance techniques (expiratory). Use of inspiratory and expiratory incentives. Employment of mechanical assistants
62488402|NCT04432753|EXPERIMENTAL|Decision aid with incidental findings information|Participants in this arm will view a video decision aid that include information on incidental findings in lung cancer screening.
62488403|NCT04432753|ACTIVE_COMPARATOR|Decision aid without incidental findings information|Participants in this arm will view a video decision aid that does not include information on incidental findings in lung cancer screening.
61936313|NCT03857035|EXPERIMENTAL|Piezosurgery group|"One side of the patients will be randomly selected and labeled as experimental group. In experimental group, impacted third molar will be extracted using piezosurgery."
62330852|NCT06092138|EXPERIMENTAL|Wearable Device Group|The Wearable Device Group uses wearable devices to perform rehabilitation exercises using the provided strategies. It includes the application of IoT technology to build a cloud platform combining software and hardware, using the spine sensors described in this project to collect behavioral data (it is recommended that they be worn during working hours every day for no less than 7 hours/week), and using end-to-end AI algorithms for health monitoring; the visualized data is synchronized to the spine health platform for real-time viewing and analysis by both doctors and patients. Through cell phone software and internet platform, spine health files are established to realize convenient and efficient communication between patients and professional doctors.
62330853|NCT06092138|NO_INTERVENTION|Traditional group|The Traditional intervention group used traditional interventions, i.e., routine patient education, guidance on rehabilitation exercises, and tips on proper lifestyle habits.
62330854|NCT03599141|ACTIVE_COMPARATOR|Depression Management|8 weekly group sessions
62330855|NCT03599141|EXPERIMENTAL|Trust-building Self-management Together|8 weekly group sessions
62330856|NCT03860311|EXPERIMENTAL|Bladder Ultrasound|The bladder ultrasound group will undergo point-of-care ultrasound upon enrollment, and bladder ultrasound will be repeated every 30 minutes, unless the patient's bladder is full at time of initial scan.
62330857|NCT03860311|ACTIVE_COMPARATOR|Standard of Care|Bladder (Urethral) Catheter group. The standard of care group will undergo placement of a urethral bladder catheter to allow retrograde filling of the bladder.
62330858|NCT02427594|EXPERIMENTAL|Controlled diet first|In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is \<70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
62330859|NCT02427594|EXPERIMENTAL|Sodium bicarbonate first|In this arm participants will first consume a controlled diet plus sodium bicarbonate for one week. They will then consume an identical controlled diet plus added table salt (sodium chloride) for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is \<70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
62488404|NCT01316536|EXPERIMENTAL|With Music|This randomized group will receive music
62488405|NCT01316536|PLACEBO_COMPARATOR|Control Arm|Will not receive music but will receive audio loop of recorded ICU sounds
62488406|NCT01438060|EXPERIMENTAL|Aripiprazole (BMS-337039)|Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140)
62330860|NCT02439281|ACTIVE_COMPARATOR|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
62488407|NCT01438060|PLACEBO_COMPARATOR|Placebo|Double blind Acute Phase (Week 1 to Week 10)
62488408|NCT03981731|EXPERIMENTAL|Cardiac coherence|
62488409|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
62488410|NCT01717313|EXPERIMENTAL|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
62488411|NCT01717313|PLACEBO_COMPARATOR|Placebo to Omarigliptin|Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
62488412|NCT02452463|EXPERIMENTAL|Arm I (nintedanib)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62488413|NCT02452463|PLACEBO_COMPARATOR|Arm II (placebo)|Beginning 4-8 weeks after completion of radiation therapy, patients receive placebo capsules PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62693950|NCT02346279||Persons in physical therapy treatment|Questionnaires (MSQPT, HAQUAMS, Transition Questionnaire for Patient and treating physiotherapist), physical tests (9HPT, 6MTWT, BBS, 6MWT), EDSS
62693951|NCT00844220|EXPERIMENTAL|CT/MR|CT/MRI-directed clinical management strategy
61936314|NCT03857035|PLACEBO_COMPARATOR|Rotary Instruments Group|"The other side will be accepted as control group. In the control group, impacted third molar will be extracted using conventional rotary instruments."
61936315|NCT01279473|EXPERIMENTAL|Nilotinib|
61936316|NCT00985816|ACTIVE_COMPARATOR|L reuteri DSM 17938|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties (Connolly, 2005). The placebo consists of an identical formulation except that the L. reuteri is not present. This dose of the oil formulation with L. reuteri has been shown to induce significant colonisation in infants and is well-tolerated (Abrahamsson et al., 2007; Savino et al., 2007; Indrio et al., 2008).
61936317|NCT00985816|PLACEBO_COMPARATOR|Placebo|
62330861|NCT02439281|EXPERIMENTAL|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
62330862|NCT02396823|EXPERIMENTAL|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
62330863|NCT02396823|NO_INTERVENTION|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
62330864|NCT05768620|EXPERIMENTAL|CAVE|10 immersive virtual reality sessions to train spatial memory
62330865|NCT05768620|ACTIVE_COMPARATOR|TAU|10 paper and pencil sessions to train spatial memory
62330866|NCT01101568|EXPERIMENTAL|Single Sequence|Simvastatin will be administered on Day 1 and Day 10. Rosuvastatin will be administered on Day 3 and Day 12. GSK1292263 will be administered on Days 6 to 14.
61936318|NCT00126607|EXPERIMENTAL|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62330867|NCT01350349|EXPERIMENTAL|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
62330868|NCT01350349|ACTIVE_COMPARATOR|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
62330869|NCT01449357|EXPERIMENTAL|zalutumumab|
62330870|NCT04054778|EXPERIMENTAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
62330871|NCT04054778|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
62330872|NCT05373706|EXPERIMENTAL|Cue Reactivity Personalized Feedback Intervention (PFI)|Participants randomized to the Cue Reactivity PFI condition will receive personalized feedback at the end of completing 17 days of ecological momentary assessments (EMAs) four times a day. The personalized feedback will be delivered online and contains information summarizing participants' desire to drink as it varied as a function of several real-world factors across the 17-day EMA period.
62330873|NCT05373706|NO_INTERVENTION|Assessment-only control|Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.
62330874|NCT01468909|PLACEBO_COMPARATOR|Arm I (paclitaxel and placebo)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62330875|NCT01468909|EXPERIMENTAL|Arm II (paclitaxel and pazopanib hydrochloride)|Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62330876|NCT01187901|ACTIVE_COMPARATOR|Erlotinib and Sulindac|Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
62488414|NCT02452463|EXPERIMENTAL|Arm III (nintedanib, durvalumab)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28 and standard of care durvalumab IV over 60 minutes on days 1 and 15. Treatment with nintedanib repeats every 28 days for up to 6 cycles and treatment with durvalumab repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
62488415|NCT05947266|EXPERIMENTAL|Haitian immigrant iENGAGE (H-iENGAGE) intervention|"1. Enrollment;~2. Baseline assessment;~3. Upon baseline completion, scheduling of H-iENGAGE sessions 1 through 4~4. Following Session 4, conduct Process evaluation;~5. Post-intervention assessment;~6. Six-month follow up assessment\*~   \*Six participants will complete AIM 3: Identify multi-level implementation factors contributing to intervention outcomes, using photovoice in mixed methods.~7. End of study participation"
62693952|NCT00844220|ACTIVE_COMPARATOR|Catheterization|Standard clinical management
61936319|NCT01933711|EXPERIMENTAL|Rituximab maintenance|maintenance therapy with rituximab (375 mg/m2) administered every 3 months for 2 years.
62693953|NCT00949039|EXPERIMENTAL|Chemotherapy|Isolated pelvis perfusion
62693954|NCT00949039|ACTIVE_COMPARATOR|Control|Standard treatment
62693955|NCT03939065|EXPERIMENTAL|Insulin Pump and CGM|
61936320|NCT01933711|NO_INTERVENTION|Observation|observational arm, no intervention
61936321|NCT04790396||Patient presenting at emergent department with cardiac arrest|
61936322|NCT06161571|EXPERIMENTAL|EFX 50 mg|
61936323|NCT06161571|PLACEBO_COMPARATOR|Placebo|
62330877|NCT01187901|PLACEBO_COMPARATOR|Placebo A and Placebo B|Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months
62330878|NCT01236612|EXPERIMENTAL|Immunization + bloodstage challenge|
62330879|NCT01236612|ACTIVE_COMPARATOR|Immunization + mosquito challenge|
62693956|NCT03939065|OTHER|Standard of Care and CGM|
61936324|NCT06161571|EXPERIMENTAL|EFX 50 mg (Open-Label Rollover)|
61936325|NCT01776047|ACTIVE_COMPARATOR|Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)|Exforge® 10/160
61936326|NCT01776047|EXPERIMENTAL|G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)|G-0081
61936327|NCT05912660||Aortic valve replacement with surgically implanted bioprostheses|
61936328|NCT05912660||Aortic valve replacement with TAVI|
61936329|NCT02836353|NO_INTERVENTION|Observational only|Oral glucose tolerance test, neurocognitive questionnaire tasks only.
61936330|NCT02836353|EXPERIMENTAL|Somatostatin|Oral glucose tolerance test after 100mcg Somatostatin
61936331|NCT02836353|EXPERIMENTAL|Antibiotics|Oral glucose tolerance test after treatment of small intestinal bacterial overgrowth
61936332|NCT05544370|EXPERIMENTAL|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
61936333|NCT05544370|EXPERIMENTAL|Extensive high-intensity intervallic training group|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
61936334|NCT05544370|NO_INTERVENTION|Control group|The control group will carry out their usual physical education classes which consist of games, jumping, moving, balance and different sports.
61936335|NCT00488280||Kids Step Study: Locomotor Training|All children who participate will be in the experimental cohort, KSS-#, and receive 60 sessions of daily locomotor training. This experimental cohort will also undergo clinical and neurophysiological testing pre, during, and post 60 sessions of locomotor training.
61936336|NCT04701788|EXPERIMENTAL|Study group|The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.
61936337|NCT04701788|PLACEBO_COMPARATOR|Control group|The control group had never been vaccinated with any pneumococcal vaccine.
61936338|NCT03508375|EXPERIMENTAL|SSc without ILD|
61936339|NCT03508375|EXPERIMENTAL|SSc with ILD|
62135402|NCT04421365|ACTIVE_COMPARATOR|Active neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using active EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected to be effective for symptom improvement.
62135403|NCT04421365|SHAM_COMPARATOR|Sham neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using sham EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected not to be effective for symptom improvement.
62330880|NCT01236612|PLACEBO_COMPARATOR|Control - Bloodstage challenge|
62330881|NCT01236612|PLACEBO_COMPARATOR|Control - Mosquito challenge|
62330882|NCT05560841|EXPERIMENTAL|Nailner 2 in 1|"Nailner Brush 2-in-1 (5ml)~Liquid solution in glass bottle with a brush applicator Topical application twice a day during 4 weeks then once a day until 6 months"
62330883|NCT02941107|EXPERIMENTAL|Rotarix|Rotarix (RV1) vaccine, 1mL liquid suspension administered orally.
62330884|NCT02941107|PLACEBO_COMPARATOR|Placebo|Placebo liquid suspension manufactured to mimic Rotarix (RV1) vaccine, 1ml administered orally
61936340|NCT03508375|ACTIVE_COMPARATOR|patients with idiopathic pulmonary fibrosis|
61936341|NCT06710249|EXPERIMENTAL|Salovum/SPC flakes|
61936342|NCT04099342|EXPERIMENTAL|A: FEAST|Focally Electrically-administered Seizure Therapy (FEAST) is a form of Electroconvulsive therapy (ECT) that combines unidirectional stimulation, control of polarity, and an asymmetrical electrode configuration.
61936343|NCT04099342|EXPERIMENTAL|B: RP FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Polarity (RP) utilizes the same electrode placement as FEAST but a reversed directionality of current flow.
61936344|NCT06087458|EXPERIMENTAL|Experimental: Low|Single intravitreal injection of VOY-101
61936345|NCT06087458|EXPERIMENTAL|Experimental: Medium|Single intravitreal injection of VOY-101
61936346|NCT06087458|EXPERIMENTAL|Experimental: High|Single intravitreal injection of VOY-101
61936347|NCT06087458|EXPERIMENTAL|Experimental: Higher|Single intravitreal injection of VOY-101
61936348|NCT03727425|EXPERIMENTAL|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
61936349|NCT03939156||Group 1 - before starting ET|women candidate to receive ET and interviewed before starting treatment
61936350|NCT03939156||Group 2 - within 1 year of ET|women interviewed within 1 years from beginning of ET
61936351|NCT03939156||Group 3 - between 4 and 6 years of ET|women interviewed after more than 4 years but no more than 6 years of ET
62693957|NCT05197387||Cases|Women with intrahepatic cholestasis of pregnancy
61936352|NCT02752204|OTHER|Stage 1|AZD 2014 oral tablets will be given to patients
61936353|NCT02752204|OTHER|Stage 2|AZD 2014 oral tablets and rituximab infusion will be given to patients
62693958|NCT05197387||Controls|Women without intrahepatic cholestasis of pregnancy
61936354|NCT06244017|EXPERIMENTAL|EEG Spectrogram-guided|The general anesthesia administration is guided by using the EEG spectrogram in this group. Other perioperative care protocols are the same between the two study group.
62488416|NCT03095248|EXPERIMENTAL|Stratum 1 - NF2 related vestibular schwannomas- NOW CLOSED|Stratum 1 included patients with NF2 with vestibular schwannomas who exhibit hearing loss. Participants received continuous twice daily dosing of selumetinib. Dosing was based on BSA calculated at the beginning of each course. One course is equivalent to 28 days. Therapy continued for up to two years (26 courses) in the absence of disease progression or unacceptable toxicity. Stratum 1 arm was closed in November, 2022.
61936355|NCT06244017|ACTIVE_COMPARATOR|Bispectral index-guided|The general anesthesia administration is guided by using the processed EEG index, namely the bispectral index (BIS) in this group. Other perioperative care protocols are the same between the two study group.
61936356|NCT01209728|EXPERIMENTAL|Primary insomnia patients and healthy subjects|Elderly participants, including primary insomnia patients and healthy subjects
61936357|NCT04462510|EXPERIMENTAL|Illioinguinal/Illiohypogastric Block|A single shot 20ml of 0.25% Ropivacaine was used to block illioinguinal/illiohypogastric nerves using ultrasound right before incision was given
61936358|NCT04462510|EXPERIMENTAL|Wound infiltration|Surgeon infiltrated the wound using 20ml of 0.25% Ropivacaine right after the skin was closed.
61936359|NCT03819673|EXPERIMENTAL|Intervention Group (IG)|Care based on the computerised decision-support tool
62330885|NCT04757779|EXPERIMENTAL|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach. Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle). On Day1 and Day8, subjects are required to inject irinotecan(65mg/m2) or docetaxel(60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
61936360|NCT03819673|NO_INTERVENTION|Control Group (CG)|Usual care advice by primary care provider or dietitian of participating hospital
61936361|NCT03964805|ACTIVE_COMPARATOR|group A|Embryo culture at 20% O2
61936362|NCT03964805|ACTIVE_COMPARATOR|group B|Embryo culture at 5% O2
61936363|NCT03964805|ACTIVE_COMPARATOR|group C|Embryo culture at 5% O2 and at 20% O2
61936364|NCT02366858|ACTIVE_COMPARATOR|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle.
62330886|NCT02739022|EXPERIMENTAL|Early Psychological Support for the Critically Ill (EPSCI)|patients will receive EPSCI in parallel with medical treatment
62330887|NCT04610034|EXPERIMENTAL|"Resilient Caregivers"|Intervention program
62330888|NCT04610034|OTHER|Control group|Care as usual
62330889|NCT00780897||1|POF patients; 18 years \<Age\> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
62330890|NCT00780897||2|Control Group No POF patients; Benign ovarian pathology; 18 years \<Age\> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
62330891|NCT01165021|EXPERIMENTAL|Pemetrexed + Cisplatin|
62330892|NCT00332514|OTHER|Patients offered follow-up phone call|Patients offered follow-up telephone call
61936365|NCT02366858|ACTIVE_COMPARATOR|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle.
61936366|NCT02521766|EXPERIMENTAL|All HMIOL Cohort|HMIOL implantation with or without optic exchange
61936367|NCT02521766|EXPERIMENTAL|Cohort 1|HMIOL implantation with no optic exchange
61936368|NCT02521766|EXPERIMENTAL|Cohort 2|HMIOL implantation with optic exchange
61936369|NCT02521766|OTHER|Fellow Eye|IOL implantation per standard of care
61936370|NCT02414451|EXPERIMENTAL|Propranolol arm|"Propranolol will be administered via oral capsule(s) daily for a period of 10 weeks, involving gradual titration up from 40mg to 100mg and subsequent tapering off of the drug. The titration/tapering schedule will be as follows:~Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning \& night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, \& 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning \& 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules"
61936371|NCT02414451|PLACEBO_COMPARATOR|Placebo arm|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules"
61936372|NCT04121988||Denoising MRI group|Patients suspected of Cushing disease undergoing deep learning based denoising MRI
61936373|NCT05559866|ACTIVE_COMPARATOR|Control Group: ESG|Subjects will undergo ESG utilizing approved device alone
61936374|NCT05559866|EXPERIMENTAL|Treatment Group: ESG + HAPC|Subjects will undergo ESG as approved and on-label while also utilizing Hybrid APC approved and on-label.
61936375|NCT01279031|EXPERIMENTAL|Abbott WHITESTAR Signature System|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
61936376|NCT01279031|EXPERIMENTAL|Alcon Infiniti|Alcon Infiniti with the OZIL Torsional Handpiece
61936377|NCT04293731|ACTIVE_COMPARATOR|Symbiter-Smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
61936378|NCT04293731|PLACEBO_COMPARATOR|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
61936379|NCT01343927|ACTIVE_COMPARATOR|Yoga|12 weeks of weekly yoga classes plus 40 weeks of either drop-in classes or home practice.
61936380|NCT01343927|ACTIVE_COMPARATOR|Physical Therapy|15 individual physical therapy treatment sessions over 12 weeks plus 40 weeks with either 5 booster sessions or home practice.
62330893|NCT01094717|EXPERIMENTAL|acitretin and active excimer laser|patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions.
62488417|NCT03095248|EXPERIMENTAL|Stratum 2: other NF2 related tumors (meningiomas and ependymoma)|Stratum 2 will include patients who have progressive lesions other than VS (including non-vestibular schwannomas, meningiomas, and spinal cord lesions). Participants will receive continuous twice daily dosing of selumentinib. Dosing is based on BSA calculated at the beginning of each course. One course is equivalent to 28 days. Therapy may continue for up to two years (26 courses) in the absence of disease progression or unacceptable toxicity.
62488418|NCT00399555||One|Patients with HLHS that have had surgical palliation with the Norwood procedure (Stage I palliation) at Children's Healthcare of Atlanta after January 1, 2001. These patients must be between the ages of 2.5 years and 6 years of age.
62488419|NCT00503919|EXPERIMENTAL|MDC|Multi-spectral Digital Colposcopy for Fluorescence Spectroscopy
62488420|NCT05245500|EXPERIMENTAL|Phase 1/1B|Dose Escalation/Evaluation
62488421|NCT05245500|EXPERIMENTAL|Phase 2|MRTX1719 RP2D administered to separate cohorts of patients with selected solid tumor malignancies with MTAP homozygous deletion to include the following: Mesothelioma, Pancreatic Adenocarcinoma, NSCLC, Malignant Peripheral Nerve Sheath Tumor, Other Solid Tumors
62135404|NCT03514836|EXPERIMENTAL|DCVac and ONCOS-102|ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses
62330894|NCT01094717|EXPERIMENTAL|acitretin and sham excimer laser|Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of body psoriasis lesions.
62330895|NCT01094717|EXPERIMENTAL|tazarotene and active excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and excimer (active) laser to randomly assigned left or right side of body psoriasis lesions.
62330896|NCT01094717|EXPERIMENTAL|tazarotene and sham excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and sham excimer laser to randomly assigned left or right side of body psoriasis lesions.
62330897|NCT02142192|EXPERIMENTAL|natalizumab|natalizumab 300mg SC every 4 weeks for up to 12 treatment administrations (i.e. Day 1 through Week 44)
62488422|NCT05245500|EXPERIMENTAL|Phase 1b Sub-Study|MRTX1719 in combination with standard of care therapy in selected solid tumor malignancies with MTAP homozygous deletion
61936381|NCT01343927|ACTIVE_COMPARATOR|Education|"The Back Pain Helpbook which gives exercises and tips for self-care pain management."
62330898|NCT02523326||Group A|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days
62330899|NCT02523326||Group B|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days
62330900|NCT02523326||Group C|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days
62330901|NCT03393052|ACTIVE_COMPARATOR|Left Radial access|Left Radial approach for coronary angiography in patients with prior history of CABG surgery
62330902|NCT03393052|ACTIVE_COMPARATOR|Femoral access|Femoral approach for coronary angiography in patients with prior history of CABG surgery
62330903|NCT04004624|ACTIVE_COMPARATOR|Study Arm|The left ventricle is mapped during atrial and right or left ventricular pacing (site close to the infarct) at a similar cycle length of 600ms. Radio-frequency ablation is performed selectively in areas of activation slowing (defined as ≤40ms per 5mm while voltage abnormalities and late potentials were not specifically targeted.
62330904|NCT04004624|NO_INTERVENTION|Control|Patient who underwent ablation using similar technology and irrigated catheters guided by standard substrate mapping techniques.
62330905|NCT02557971||BOTOX®|Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.
62330906|NCT05491057||Neratinib extended ajuvant treatmeng for 1 year|
62330907|NCT05281601|EXPERIMENTAL|AZD7442|All participants will receive a single dose of AZD7442 on Day 1, either IM (AZD8895 followed by AZD1061) or IV (AZD8895 + AZD1061 concurrently).
62488423|NCT01936662|EXPERIMENTAL|Largyngeal Mask Airway for EGD procedure|Patients randomized to LMA to maintain airway through EGD procedure
62488424|NCT01936662|ACTIVE_COMPARATOR|Endotracheal Tube for EGD procedure|Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
62488425|NCT02674711|EXPERIMENTAL|Educational Video|Evidence-based video: Best Advice for People Taking Opioid Medication
62488426|NCT02674711|NO_INTERVENTION|Usual Care|Usual care education provided at time of pre-operative appointment.
61936382|NCT00886912|ACTIVE_COMPARATOR|Hypoxia|training in simulated altitude
61936383|NCT00886912|PLACEBO_COMPARATOR|Normoxia|training under normoxic conditions
61936384|NCT06142903|PLACEBO_COMPARATOR|7 medically-tailored meals per week|Patients will be randomized to medically tailored dinner meals delivered to their homes for four weeks.
62488427|NCT00864396|EXPERIMENTAL|Prevacid|
62488428|NCT05490095|EXPERIMENTAL|Group I|"13 subjects will receive~1. First Dose: Afinitor 5mg, single dose~2. Wash out period : more than 10 days~3. Second Dose: SVG101 5mg, single dose"
62488429|NCT05490095|EXPERIMENTAL|Group II|"13 subjects will receive~1. First Dose: SVG101 5mg, single dose~2. Wash out period : more than 10 days~3. Second Dose: Afinitor 5mg, single dose"
62488430|NCT02267707|EXPERIMENTAL|Cohort 1 - Bilirubin level > 1.5 x ULN to 3 x ULN|4 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
62488431|NCT02267707|EXPERIMENTAL|Cohort 2 - Bilirubin level > 3 x ULN to 5 x ULN|6 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2 nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
62488432|NCT03574545|ACTIVE_COMPARATOR|Reference VAY736 Drug Product|Powder for solution for injection / infusion
62488433|NCT03574545|EXPERIMENTAL|Test VAY736 Drug Product|Solution for injection
62488434|NCT03487939|EXPERIMENTAL|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
62488435|NCT04472039||Studygroup|Retrospective analysis of OCT, IOP and distance corrected visual acuity from the patients history.
62488436|NCT02994147|PLACEBO_COMPARATOR|Placebo|"1. Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~2. At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
62330908|NCT02519244|EXPERIMENTAL|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
62330909|NCT01323257|EXPERIMENTAL|001|TMC435 150 mg capsule once daily for 7 days (Trt A C D)
62693959|NCT06568172|ACTIVE_COMPARATOR|Arm 1 (surgery, radiation)|Patients undergo surgery per standard of care within 6 weeks of randomization. Starting within 84 days of surgery, patients may undergo IGRT with IMRT for 5 fractions per week for 6 weeks as clinically indicated. Patients also undergo CT, MRI, and/or PET/CT on study, and CT and/or MRI during follow up. Patients may also undergo optional collection of tissue, whole blood, and plasma on study.
62693960|NCT06568172|EXPERIMENTAL|Arm 2 (cemiplimab, surgery, radiation)|Patients receive cemiplimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo response-adaptive surgery 21 days after last dose of cemiplimab. Starting within 84 days of surgery, patients may undergo IGRT with IMRT for 5 fractions per week for 6 weeks as clinically indicated. Starting within 6 weeks of completion of surgery or radiation therapy (if indicated), patients without pCR receive cemiplimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or PET/CT on study, and CT and/or MRI during follow up. Patients may also undergo optional collection of tissue, whole blood, and plasma on study.
62330910|NCT01323257|EXPERIMENTAL|002|erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
62330911|NCT01323257|EXPERIMENTAL|003|erythromycin 500 mg tablets three times a day for 7 days (Trt C)
62330912|NCT01323257|EXPERIMENTAL|004|TMC435 50 mg capsule once daily for 7 days (Trt F)
62330913|NCT01323257|EXPERIMENTAL|005|Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
62330914|NCT01323257|EXPERIMENTAL|006|Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
61936385|NCT06142903|ACTIVE_COMPARATOR|21 medically-tailored meals per week|Patients will be randomized to three medically tailored dinner meals each day delivered to their homes for four weeks.
61936386|NCT05612698|EXPERIMENTAL|Aerobic training|Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax.
61936387|NCT05612698|EXPERIMENTAL|Aerobic training + resistance training|Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action.
62330915|NCT00187837|EXPERIMENTAL|SW intervention|Stepwise Excavation
62330916|NCT00187837|OTHER|DCE intervention|Control intervention Direct complete excavation. The updated terminology for completed excavation is non-selective excavation to hard dentin
62330917|NCT01364571|EXPERIMENTAL|1|SA4Ag vaccine low dose
62330918|NCT01364571|EXPERIMENTAL|2|SA4Ag vaccine mid dose
62330919|NCT01364571|EXPERIMENTAL|3|SA4Ag vaccine high dose
62330920|NCT01364571|PLACEBO_COMPARATOR|4|Placebo
62330921|NCT02714673||ADELC|Cohort of patients on long term anticoagulation and undergoing a primary hip or knee replacement.
62330922|NCT02714673||CONTROL|Cohort of patients not on long term anticoagulation and undergoing a primary hip or knee replacement.
62488437|NCT02994147|EXPERIMENTAL|AC-201CR 72mg|"1. Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~2. At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
62488438|NCT04888767|NO_INTERVENTION|Control group|Patients benefiting from the usual re-training sessions
62330923|NCT04276311|EXPERIMENTAL|symptomatic patients with complex de novo FP arterial lesions|in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo FP arterial lesions (TASC C).
62330924|NCT03766087|EXPERIMENTAL|surgery group|Decompressive craniectomy associated with optimal medical management of intracranial pressure.
62330925|NCT03766087|NO_INTERVENTION|conservative group|Optimal medical management of intracranial pressure only.
62330926|NCT00430521|EXPERIMENTAL|GSK1562902A V/I/6 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
62330927|NCT00430521|EXPERIMENTAL|GSK1562902A V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
62330928|NCT00430521|EXPERIMENTAL|GSK1562902A 2V/I/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.
62488439|NCT04888767|EXPERIMENTAL|ITHI Group|Patients benefiting from ITHI re-training sessions
62488440|NCT05937126||Standard culture and antimicrobial susceptibility testing (AST)|Lower respiratory tract sputum samples (expectorated sputum, induced sputum, tracheal secretions, or bronchoalveolar lavage) collected in the inpatient setting per standard of care from adults with lower respiratory tract infections will receive standard culture and antimicrobial susceptibility testing (AST).
62488441|NCT05937126||Standard culture and AST PLUS rapid identification and AST|Lower respiratory tract sputum samples (expectorated sputum, induced sputum, tracheal secretions, or bronchoalveolar lavage) collected in the inpatient setting per standard of care from adults with lower respiratory tract infections will receive standard culture and AST PLUS rapid identification and AST using the FDA-approved/cleared FilmArray Pneumonia Panel
62693961|NCT03906084|ACTIVE_COMPARATOR|Corticotomy facilitated orthodontics.|Corticotomy is carried out under local anesthesia in right side.
62693962|NCT03906084|EXPERIMENTAL|Corticotomy and low level laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
62693963|NCT05715827|EXPERIMENTAL|Robotic Assisted Surgery (RAS)|Robotic Assisted radical prostatectomy and cholecystectomy
62693964|NCT06640218|ACTIVE_COMPARATOR|bio-ceramic sealer activation with Eddy sonic before obturation|cleaning and shaping the root canals and Well Root bio ceramic sealer activation using Eddy sonic before obturation
62693965|NCT06640218|ACTIVE_COMPARATOR|bio-ceramic sealer activation with AF max before obturation|cleaning and shaping the root canals and Well Root bio ceramic sealer activation using AF max before obturation
62693966|NCT06640218|ACTIVE_COMPARATOR|bio-ceramic sealer obturation without any activation (negative control)|obturation of root canals with bio ceramic sealer directly without any activation
62693967|NCT04904913|EXPERIMENTAL|IBI362 high dose|high dose IBI362 administered subcutaneously (SC) once a week.
62693968|NCT04904913|EXPERIMENTAL|IBI362 low dose|Low dose IBI362 administered subcutaneously (SC) once a week.
61936388|NCT05612698|EXPERIMENTAL|High Intensive Interval Training intervention|High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO.
62135405|NCT02612142|EXPERIMENTAL|aerobic exercise (AE)|Intervention type: Behavioral. Intervention name: Aerobic exercise Intervention description: 10 days of daily aerobic exercise (brisk walking, jogging); duration: 30 minutes per session; intensity: 65%-75% of age-predicted maximal heart rate. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
62330929|NCT00430521|EXPERIMENTAL|GSK1562902A 2V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
62330930|NCT00430521|EXPERIMENTAL|GSK1562902A V/I/12 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
62330931|NCT00430521|EXPERIMENTAL|GSK1562902A V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
62330932|NCT00430521|EXPERIMENTAL|GSK1562902A 2V/I/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
62330933|NCT00430521|EXPERIMENTAL|GSK1562902A 2V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
62693969|NCT04904913|PLACEBO_COMPARATOR|placebo|placebo administered subcutaneously (SC) once a week.
61936389|NCT05612698|NO_INTERVENTION|Control|Participants in the control group will receive written standard PA recommendations in this phase.
62135406|NCT02612142|SHAM_COMPARATOR|stretching exercise (ST)|Intervention type: Behavioral. Intervention name: Stretching exercise Intervention description: 10 days of daily stretching exercise; duration: 30 minutes per session. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
62330934|NCT03661268|EXPERIMENTAL|Septic shock|Patients (at least 18 years of age, no more than 75 years old) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of pulmonary artery catheter. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
62330935|NCT06316791|EXPERIMENTAL|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before the investigational treatment, CNCT19.
62693970|NCT04904913|EXPERIMENTAL|IBI362 moderate dose|moderate dose IBI362 administered subcutaneously (SC) once a week.
62693971|NCT04904913|EXPERIMENTAL|IBI362 extra high dose|extra high dose IBI362 administered subcutaneously (SC) once a week.
62693972|NCT06183528|ACTIVE_COMPARATOR|PENG group|PENG block was placed in the fascial plane between the pseudotendon and pubic ramus with USG in-plane technique, 20 ml of 0.5% bupivacaine was administered after spinal anaesthesia.
61936390|NCT01330706|EXPERIMENTAL|Sterile Saline solution|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
62135407|NCT02612142|NO_INTERVENTION|no intervention (NI)|No behavioral intervention. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
62330936|NCT02426372|EXPERIMENTAL|QBECO SSI 0.02 mL|0.02 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
62330937|NCT02426372|EXPERIMENTAL|QBECO SSI 0.05 mL|0.05 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
62488442|NCT00754858|EXPERIMENTAL|belotecan and Cisplatin|belotecan 0.5 mg/m2 and Cisplatin 60mg/m2
62488443|NCT03850158|EXPERIMENTAL|Interventional Arm, ICG and NIR imaging|NIR fluorescence imaging is performed after white light laparoscopy. 0.3mg/kg bodyweight of ICG is administered i.v. All suspected lesions are removed and labeled whether they are seen in WL or NIR imaging or both. Evaluation is performed after the histological analysis of the lesions.
62693973|NCT06183528|PLACEBO_COMPARATOR|non-PENG group|group non-PENG, surgery was started without PENG block after spinal anaesthesia.
62693974|NCT06445127|EXPERIMENTAL|MRI|A participant will undergo a MRI (1-4).
62693975|NCT03107182|EXPERIMENTAL|Induction Chemotherapy|"All enrolled patients will receive three 21-day cycles of chemotherapy consisting of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total), carboplatin (AUC 5 on day 1; 3 doses total), and nivolumab (360 mg on days 1; 3 doses total). Growth factor support will be provided using G-CSF administered on days 16-18.~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy."
61936391|NCT03948607||Adult ADHD|Adult ADHD patients without current comorbidity and treatment.
61936392|NCT03948607||Healthy controls|Healthy controls without ADH, paired in age and gender.
61936393|NCT04860427|ACTIVE_COMPARATOR|Trapezoidal condylar plate|Trapezoidal condylar plate open reduction and internal fixation of subcondylar fractures
61936394|NCT04860427|ACTIVE_COMPARATOR|two miniplates|two miniplates open reduction and internal fixation of subcondylar fractures
61936395|NCT01690026|OTHER|Brief intervention|Motivational intervention based brief intervention
62135408|NCT05326789|EXPERIMENTAL|interventional|20 patients with inclusion criteria and without exclusion criteria will be entered in the interventional arm attempting to use REBOA during non-traumatic cardiac arrest.
62135409|NCT01936051||OCD patients|OCD patients being treated with any dose of escitalopram
62135410|NCT04769596|EXPERIMENTAL|Treatment|Subject in this arm will undergo treatment with the NEUROMARK device.
62330938|NCT02426372|EXPERIMENTAL|QBECO SSI 0.1 mL|0.1 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
62330939|NCT04042610|EXPERIMENTAL|Intervention: electronic prompt to interrupt sitting time|The intervention will consist of two components: education and an electronic prompt via the iOS application Stand Up and notification through the Amzafit BIP device. The Stand-Up application will generate a prompt every hour during the workday to interrupt sitting time and encourage 2 minutes of physical activity. The intervention group participants will be given verbal and written educational materials on the health benefits of incorporating physical activity throughout their workday as well as the health risks of a sedentary lifestyle. Suggestions and demonstrations of physical activity will be given including but not limited to: use a restroom further away from their workstation, take a brief walk around the office, walk-in place, stretch. In addition, they will record their steps via the Amazfit BIP device and submit their daily step counts for weeks: 1,2,4, 6 and 8.
62330940|NCT04042610|NO_INTERVENTION|Control Group|The control group will be given an Amazfit BIP device to record their steps. They will submit their daily steps counts for weeks: 1,2,4, 6 and 8.
62330941|NCT00862966|EXPERIMENTAL|citrate|
62330942|NCT00862966|ACTIVE_COMPARATOR|heparin|
62330943|NCT06121557|EXPERIMENTAL|LNL treatment + Camrelizumab + another anti-tumor drug|Participants receive LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive camrelizumab PLUS another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor at investigator's discretion.
62693976|NCT03107182|EXPERIMENTAL|Single Modality De-escalation Arm (SDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. De-intensified adjuvant RT will be given for adverse pathologic features. Patients may refuse TORS treatment.~Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 G."
62135411|NCT04769596|SHAM_COMPARATOR|Sham|Subjects in this arm will undergo the procedure with a Sham device. At 3 months post treatment these subjects will cross over to Arm 1.
61936396|NCT01690026|OTHER|Standard intervention|Standard intervention condition
61936397|NCT03310710|EXPERIMENTAL|treatment with Viabahn BX stent|Treatment with Viabahn BX stent as branch device in fenestrated EVAR
61936398|NCT02700022|EXPERIMENTAL|Alisertib combined with R-EPOCH|Dose escalation will take place within cohorts. Subjects will receive alisertib tablets twice daily in combination with R-EPOCH chemotherapy on days 1 through 5 of each 21-day cycle. The treatment will be given in 6 cycles. The first 3 patients to be enrolled will receive a 20 milligram (mg) dose of alisertib. The dose of alisertib will be increased or decreased as more subjects enter the study. Each dose level will be evaluated for safety and tolerability before the next higher dose is given. The dose levels will be modified until the maximum tolerated dose (MTD) is reached. Once the MTD has been established, enrollment into that cohort will continue with up to a maximum of 24 patients total enrolled into the study.
61936399|NCT05778851|NO_INTERVENTION|A1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm A2 but without an EsoGuard result and in a different order.
61936400|NCT05778851|ACTIVE_COMPARATOR|A2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm A1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
61936401|NCT05778851|NO_INTERVENTION|B1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm B2 but without an EsoGuard result and in a different order.
61936402|NCT05778851|ACTIVE_COMPARATOR|B2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm B1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
62330944|NCT06358417|EXPERIMENTAL|Nutrition-enhanced CHW intervention|This intervention integrates a nutrition component into the Basic CHW hypertension intervention to address gaps in patients' knowledge, skills, and resources for consuming and sustaining a healthful diet. CHWs will administer a 4-part nutrition curriculum that is tailored to the needs and preferences of a food-insecure population with limited resources. The nutrition education materials provided to participants will include a booklet of nutrition information that will serve as the primary educational resource for CHW use with participants.
62693977|NCT03107182|EXPERIMENTAL|Intermediate De-escalation Arm (IDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients who have low risk disease with \<50% but ≥30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 45 Gy (3 cycles).~Patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles)."
61936403|NCT05778851|NO_INTERVENTION|C1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm C2 but without an EsoGuard result and in a different order.
61936404|NCT05778851|ACTIVE_COMPARATOR|C2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm C1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
61936405|NCT00641303|SHAM_COMPARATOR|Arm I (control)|Patients receive 8 weekly sessions of sham acupuncture treatment comprising 20 minutes of a non-penetrating device consisting of a retractable needle and an adhesive tube on the skin using the Park Sham Device (PSD) in 14 non-acupuncture points. Patients may receive 4 free acupuncture sessions (not sham) after the 12 or 24-week follow-up visit.
61936406|NCT00641303|EXPERIMENTAL|Arm II (treatment)|Patients receive 8 weekly sessions of acupuncture treatment comprising 20 minutes of needle insertion in 15 acupuncture points including CV 4, CV 6, CV12 and bilateral LI 4, MH 6, GB 34, ST 36, KI 3, BL 65.
61936407|NCT00270712||Retrospective Cohort|537 transplant recipient records used retrospectively
61936408|NCT00270712||Prospective Cohort|3137 transplant recipients enrolled prospectively
61936409|NCT05050929|ACTIVE_COMPARATOR|20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain Metastases|Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
61936410|NCT05050929|EXPERIMENTAL|8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain Metastases|A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
62330945|NCT06358417|ACTIVE_COMPARATOR|Basic CHW intervention|The CHW provides basic hypertension education, coaching about adherence to medications and primary care visits, and home BP cuffs and promotion of BP self-monitoring. All participants are provided home BP cuffs and remote monitoring free of charge.
61936411|NCT03539354|ACTIVE_COMPARATOR|CABG + b-blockers|Standart coronary artery bypass grafting is performed with b-blockers treatment. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
61936412|NCT03539354|EXPERIMENTAL|CABG + b-blockers + temporary SCS|Before coronary artery bypass grafting in the experimental group, 3 days of temporary spinal cord stimulation is performed than device turned off and coronary artery bypass grafting procedure is made. The device for spinal cord is turned on in intensive care unit for 7 days. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
61936413|NCT00591344|ACTIVE_COMPARATOR|Progressive resistance training|Subjects will perform between 60 and 90 minutes of progressive resistance training two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
61936414|NCT00591344|ACTIVE_COMPARATOR|Modified Fitness Counts|Subjects will perform between 60 and 90 minutes of modified Fitness Counts two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
61936415|NCT05629546|EXPERIMENTAL|Arm 1: Autologous: Memory-like natural killer cells + nivolumab + relatilimab|"* Subjects enrolled into arm 1 will receive autologous ML NK cells on Day 0.~* Relatlimab and nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier."
61936416|NCT05629546|EXPERIMENTAL|Arm 2: Allogeneic: Memory-like natural killer cells + nivolumab + relatilimab|"* Subjects with a haploidentical donor will enroll into Arm 2~* Subjects will receive the IV infusion of ML NK cells on Day 0.~* Relatlimab and nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier."
61936417|NCT05629546|NO_INTERVENTION|Allogeneic Donors|
61936418|NCT06195683|EXPERIMENTAL|anti-PDL-1 Immunotherapy followed by Surgical Resection|Participants will receive four preoperative doses of PDL-1 inhibitor Serplulimab in adults with untreated, surgically resectable early (stage IB, II, or IIIA) NSCLC. Serplulimab (at a dose of 4.5mg per kilogram of body weight) was administered intravenously every 3 weeks, with surgery planned approximately 4 weeks after the last dose.
61936419|NCT02595996|EXPERIMENTAL|Treatment|Patients will be given propranolol in escalating doses
61936420|NCT00600535|EXPERIMENTAL|Abiraterone acetate (non-fasting)|
61936421|NCT00600535|EXPERIMENTAL|Abiraterone acetate (fasting)|
61936422|NCT02796742||Group MSSA|
61936423|NCT02796742||Group MRSA|
62693978|NCT03107182|EXPERIMENTAL|Regular Dose Arm (RDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients who have low risk disease and \<30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 75 Gy (5 cycles).~Patients who have high risk disease and \<50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).~Any patient who has progressive disease will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
62488444|NCT01567553||Control group|Only unenhanced MR scanning will be performed in a control group of normal, age-matched subjects and after acceptance of the protocol by an independent ethical committee for the implication of a normal population in such an MRI research project.
61936424|NCT02796742||Group PVL-negative strains|
62135412|NCT05398224|EXPERIMENTAL|Experimental arm: Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|Zanubrutinib in combination with rituximab and methotrexate, followed by zanubrutinib maintenance in patients with secondary central nervous system lymphoma (SCNSL)
62330946|NCT02261168|OTHER|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
62330947|NCT05554159|EXPERIMENTAL|Actigraph|A device worn on the waist that measures physical activity (such as the number of steps participants walk each day, how long participants spend standing, and how long partticipants spend laying down). Participants should wear the ActiGraph at least 10 hours a day for 7 days.
62330948|NCT04547738||Tuberculosis (TB) index patients|- Patients (older than 5 years) diagnosed with TB before initiation of TB treatment
62330949|NCT04547738||TB contacts|- Children (5-17 years old), who had contact with TB index patients
62330950|NCT03116399|EXPERIMENTAL|PRISM 2.0 Condition|Exposing participants to the PRISM 2.0 interface.
62330951|NCT03116399|PLACEBO_COMPARATOR|Tablet Condition|Exposing participants to the regular computer/tablet
62330952|NCT05076851|PLACEBO_COMPARATOR|placebo group|placebo+ADT
62330953|NCT05076851|EXPERIMENTAL|Proxalutamide|Proxalutamide +ADT
62330954|NCT03657914|EXPERIMENTAL|Inflatable mediastinal mirror|Patients with especially esophageal squamous cell carcinoma ( ESCC ) who meet the inclusion criteria and do not meet the exclusion criteria will undergo radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, and will be followed up until 3 years after discharging from the hospital.
62330955|NCT01327287||Trauma patients eligible to receive thoracic epidural|Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
62330956|NCT01327287||Control Arm|Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain
62330957|NCT01680419|EXPERIMENTAL|Mission Reconnect only|Autonomous use of the Mission Reconnect multimedia instructional program at home.
62330958|NCT01680419|ACTIVE_COMPARATOR|PREP only|Participation in a standard PREP for Strong Bonds weekend retreat program.
62330959|NCT01680419|ACTIVE_COMPARATOR|PREP plus Mission Reconnect|Participation in a standard PREP for Strong Bonds weekend retreat followed by autonomous use of the Mission Reconnect multimedia instructional program at home.
62330960|NCT01680419|NO_INTERVENTION|Wait-list control|No intervention, followed by delivery of the Mission Reconnect multimedia program materials for home use after the end of the study period.
62488445|NCT01567553||Experimental group|CIS at presentation (clinically isolated syndromes) will be recruited with MRI evidence of at least two asymptomatic brain MRI lesions. The group will compromise 50 CIS patients. These CIS patients will be included within three months after first clinical presentation.
62330961|NCT01457118|EXPERIMENTAL|NKTR-102|
62330962|NCT03645408|EXPERIMENTAL|Exenatide then Placebo|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a 5 mcg dose of immediate release exenatide on the day of the first alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Subjects in this arm then received a sham injection on the day of the second alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
62330963|NCT03645408|EXPERIMENTAL|Placebo then Exenatide|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a sham injection on the day of the first alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Subjects in this arm then received a 5 mcg dose of immediate release exenatide on the day of the second alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
62330964|NCT04293042|EXPERIMENTAL|BK cystitis and/or nephropathy|All patients with symptoms that are consistent with BK cystitis and/or nephropathy (frequency, dysuria, hematuria, elevated creatinine) will have serum quantitative DNA PCR for BK virus level measured in log copies per mL (results also expressed in copies per milliliter), performed in the Children's Hospital of Philadelphia Infectious Disease Diagnostics Laboratory
62330965|NCT00159744|ACTIVE_COMPARATOR|Arm 1|Asenapine
62330966|NCT00159744|ACTIVE_COMPARATOR|Arm 2|Olanzapine
62330967|NCT00159744|PLACEBO_COMPARATOR|Arm 3|Placebo
61936425|NCT02796742||Group PVL-positive strains|
62135413|NCT04073953|EXPERIMENTAL|RPQ (-) enantiomer|Cohort 1 will receive 15mg of RPQ every day for 5 days. Cohort 2 will receive 22.5 mg of RPQ every day for five days.
62135414|NCT04073953|EXPERIMENTAL|SPQ (+) enantiomer|Cohort 1 will receive 15mg of SPQ every day for 5 days. Cohort 2 will receive 22.5 mg of SPQ every day for five days.
62693979|NCT03183947|EXPERIMENTAL|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
62693980|NCT03183947|EXPERIMENTAL|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
61936426|NCT06341764|EXPERIMENTAL|Single arm|Patient will receive four cycles of cisplatin (CDDP) 25 mg/mq i.v. and gemcitabine (GEM) 1000 mg/mq i.v. days 1 and 8 every 21 days, plus durvalumab 1120 mg day 1, followed (one week after the last dose of CDDP/GEM) by two administrations of durvalumab i.v. at 1500 mg once every 4 weeks and one administration of tremelimumab i.v. at 300 mg single dose. Premedication with antihistamines at standard doses can be applied.
61936427|NCT00071578|EXPERIMENTAL|1|Group therapy Negative Emotion Focus
61936428|NCT00071578|PLACEBO_COMPARATOR|2|Group Psychotherapy- Self Esteem Focus
61936429|NCT00900601|EXPERIMENTAL|Sacroilliac fusion|Pastient are treated with sacroiliac joint arthrodesis to the sacroiliac joint and symphysis
61936430|NCT00145704|ACTIVE_COMPARATOR|Growth Hormone only|No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
62330968|NCT00915005|EXPERIMENTAL|Group 1|"Group 1: Photon Therapy - 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
62330969|NCT00915005|EXPERIMENTAL|Group 2|"Group 2: Proton Therapy - 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
62330970|NCT00915005|EXPERIMENTAL|Group 3|"Group 3: Receives either photon or proton therapy, whichever participant's doctor decides is better, for for 6-7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
62330971|NCT00915005|EXPERIMENTAL|Group 4|"Photon Therapy - Highest practical dose (74 CGE, 66 CGE) radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
62330972|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by \> 10% increase in FVC (or at least \> 200-ml change) or \> 15% increase in single-breath DLCO (or at least \> 3 ml/min/mm Hg)
62330973|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with \> 10% decrease in FVC ( or \> 200ml change) or \> 15% decrease in DLCO (or at least \> 3ml/min/mm Hg change).
62330974|NCT03101397||stable group|not included in improved group or deteriorated group
62330975|NCT01470885||glucose value|glucose value
62330976|NCT05888428|EXPERIMENTAL|Experimental|Participants will be provided with the take-home MyoTrain system, which includes the MyoTrain armband, iPad, and MyoTrain software. Participants will progress through the training modules of the MyoTrain software, starting with eliciting paired single DoF antagonistic movements and ending with the proportional control of complex, 2-DoF hand and wrist movements.
62330977|NCT05888428|ACTIVE_COMPARATOR|Control|Participants will be provided motor imagery exercises that involve brief attempts to move the missing limb in a similar manner to how they would control their pattern recognition system to strengthen their muscles. These exercises do not involve any real-time control feedback.
62330978|NCT03260205|PLACEBO_COMPARATOR|Placebo|Participant will receive placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
62330979|NCT03260205|EXPERIMENTAL|SPD489 (Lisdexamfetamine dimesylate)|Participants will be randomized to receive SPD489 capsule in a 5:5:5:5:6 ratio to SPD489 5, 10, 20, 30 milligram (mg) orally once daily for 6 weeks. Dosing will begin with the lowest strength of SPD489 (5 mg), and will be titrated until the randomly assigned fixed-dose is reached.
62330980|NCT04954222||COVID19 long haulers|Individuals that have been diagnosed with COVID19 and continue to have lingering symptoms associated with COVID19
61936431|NCT00145704|EXPERIMENTAL|Growth Hormone & Bisphosphonate Therapy|Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
61936432|NCT06707350|EXPERIMENTAL|RIPC Group|6 cycles of 5-minute inflation and 5-minute deflation on 2 upper and lower libms with a blood pressure cuff at 72, 36, 24 hours before surgery
62330981|NCT04954222||COVID19 no residual symptoms|Individuals that have been diagnosed with COVID19 and do not have lingering symptoms that are associated with COVID19
62330982|NCT04288804||Control (healthy, non-PD participants)|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
62693981|NCT05280860|EXPERIMENTAL|Group R: bilateral RSB under ultrasound guidance after general anesthesia|Group R was subjected to a bilateral RSB under ultrasound guidance after general anesthesia.
62693982|NCT05280860|NO_INTERVENTION|Group G: simple general anesthesia|Group G received simple general anesthesia.
62693983|NCT02732444||COPD and APD patients in LTOT|• COPD and APD patients in LTOT
61936433|NCT06707350|SHAM_COMPARATOR|Control group|8 cycles of 5-minute inflation to a pressure of 20 mm Hg followed by 5-minute cuff deflation on 2 upper and lower libms with a blood pressure cuff at 72, 36, 24 hours before surgery
61936434|NCT06710314||Diagnostic Test：Hypertension|Hypertension
61936435|NCT06710314||Diagnostic Test：Diabetes|Diabetes
61936436|NCT06710314||Diagnostic Test：fatty liver|fatty liver
62693984|NCT02732444||Healthy Control|• Patients without significant cardiorespiratory disease, matched for age and body mass index with the other group.
62693985|NCT04557124|EXPERIMENTAL|USS|social cognitive training
62693986|NCT04557124|ACTIVE_COMPARATOR|MovingForward|problem solving training
62693987|NCT02007460|EXPERIMENTAL|Exercise leg|
62693988|NCT02007460|NO_INTERVENTION|Control leg|
62693989|NCT04441515|EXPERIMENTAL|Music|music supplied by ipod
62693990|NCT04441515|ACTIVE_COMPARATOR|oral books|Listening to books on ipod
62488446|NCT06009796|ACTIVE_COMPARATOR|Full Coverage Rapid Palatal Expansion (FCRPE) group:|Impressions were taken from the maxilla using alginate to obtain study models. In the obtained study model, a 10 mm hyrax expansion screw (Dentarum®, Germany) was placed at the midline as close to the palate as possible and parallel to the occlusal plane. The vestibular, occlusal, and palatal surfaces of all maxillary teeth are covered in acrylic, and this acrylic support extends toward the median palatal suture in the palatal region. Under pressure, the acrylic appliance was polymerized.
62488447|NCT06009796|ACTIVE_COMPARATOR|Modified McNamara Rapid Palatal Expansion (MMRPE) Group:|Impressions were taken from the maxilla using alginate to obtain study models. In the obtained study model, a 10 mm hyrax expansion screw (Dentarum®, Germany) was placed at the midline as close to the palate as possible and parallel to the occlusal plane. The vestibular, occlusal, and palatal surfaces of the posterior maxillary teeth are covered in acrylic, and this acrylic support extends toward the median palatal suture in the palatal region. Under pressure, the acrylic appliance was polymerized.
62488448|NCT06009796|ACTIVE_COMPARATOR|Miniimplant Assisted Rapid Palatal Expansion (MARPE) Group|The MARPE appliance was composed of a central expansion jackscrew (Dentarum), 4 tubes, 2 bands on the upper first molars to facilitate placement of the appliance, and 1.5-mm diameter stainless steel arms extending to the premolar teeth. Soldered stainless steel tubes (internal diameter: 2.0 mm; external diameter: 3.0 mm; length: 2.0 mm) served as guides for miniscrew placement. The size of the screws (PSM) was chosen as 1.8 mm in diameter and 11 mm in length, considering the 2 mm height of the tubes, 1 to 2 mm gap between the appliance and the palate surface, 1 to 2 mm gingiva thickness, and 5 to 6 mm length required for the bicortical placement of the screw in the bone.
62488449|NCT06009796|NO_INTERVENTION|Control Group|A control group in the same age, without maxillary constriction was also added to our study.Polygraphy for respiratory evaluation, rhinomanometry for nasal airway resistance were used. Polygraphy and rhinomanometry measurements were obtained at the beginning of the follow-up and at the end of the 4-month follow-up period.
62488450|NCT01087502|EXPERIMENTAL|Linagliptin|52 weeks treatment
62488451|NCT01087502|PLACEBO_COMPARATOR|Placebo|First 12 weeks of treatment
62488452|NCT01087502|ACTIVE_COMPARATOR|Glimepiride|Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)
62488453|NCT05191862|OTHER|Sequence 1|Treatment RTRT
62488454|NCT05191862|OTHER|Sequence 2|Treatment TRTR
62488455|NCT00829894|EXPERIMENTAL|1|Risperidone 1 mg Tablet
62488456|NCT00829894|ACTIVE_COMPARATOR|2|Risperdal® 1 mg Tablet
62693991|NCT04441515|PLACEBO_COMPARATOR|usual care|Usual care
62693992|NCT05247398|EXPERIMENTAL|Dynamic Stability Exercise Program|Involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults. The intervention focuses on enhancing mobility and strength of the thumb for use during daily activities.
62693993|NCT03376282|OTHER|HBOT treatment|HBOT treatment: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
62693994|NCT03376282|NO_INTERVENTION|Standard treatment|follow up with the standard recommended treatment
62693995|NCT06092346||Family Member of a subject with known or suspected DPPM|1. At least one month of age;2. Relationship either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected DPPM;3. Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possiblecondition; and4. Ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document.5. If during the consenting/assenting procedure, clinical suspicion arises that a family member has symptoms of the diagnosed DPPMs, additional review and/or studies may be requested to clarify the clinical status before enrolling a family member as an unaffected participant.
62693996|NCT06092346||Healthy Volunteers|1. No personal or family history of DPPMs;2. At least one month old;3. No symptoms of DPPMs;4. Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of the DPPM under study; 5. And ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document.
61936437|NCT00537238|ACTIVE_COMPARATOR|B|
62330983|NCT04288804||PD|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
61936438|NCT00537238|ACTIVE_COMPARATOR|A|
61936439|NCT01240876|EXPERIMENTAL|CEP-37247|
61936440|NCT01240876|PLACEBO_COMPARATOR|Matching placebo|
61936441|NCT06706271|EXPERIMENTAL|GFR more than 90 mL/min/1,73 m2|Children with GFR more than 90 mL/min/1,73 m2, and will be given 2000 IU of Vitamin D for 6 weeks
61936442|NCT06706271|EXPERIMENTAL|GFR less than 90 mL/min/1,73 m2|Children with GFR less than 90 mL/min/1,73 m2, and will be given 2000 IU of Vitamin D for 6 weeks
62135415|NCT04073953|PLACEBO_COMPARATOR|Placebo|Cohort 1 will receive placebo capsules every day for 5 days. Cohort 2 will receive placebo capsules every day for five days.
62330984|NCT02624401|EXPERIMENTAL|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion.
62330985|NCT02624401|EXPERIMENTAL|Propofol|Intravenous propofol using target controlled infusion.
62330986|NCT02624401|EXPERIMENTAL|S-ketamine|Intravenous S-ketamine using target controlled infusion.
62330987|NCT02624401|EXPERIMENTAL|Sevoflurane|Inhalational sevoflurane using target controlled inhalation.
62330988|NCT02624401|PLACEBO_COMPARATOR|Placebo|Intravenous saline.
62330989|NCT03161769||Percutaneous neurovascular treatment|Procedure: Percutaneous neurovascular treatment of intracranial aneurysms
62330990|NCT01280890|EXPERIMENTAL|Staff training using VIPS framework|The staff will be trained to give person-centred care using the VIPS framework
62330991|NCT01280890|EXPERIMENTAL|Staff training using DCM|Staff will be supervised in how to give person-centred care using Dementia Care Mapping
62330992|NCT01280890|PLACEBO_COMPARATOR|Control group|Traditional lectures using films will be given to care staff
62330993|NCT00118482|EXPERIMENTAL|fludrocortisone acetate|
62330994|NCT00118482|PLACEBO_COMPARATOR|Placebo|
62330995|NCT01856595|EXPERIMENTAL|PF-06291874|
62330996|NCT01856595|PLACEBO_COMPARATOR|Placebo|
62488457|NCT05132426|EXPERIMENTAL|OMT Intervention Arm|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
62693997|NCT06092346||Subjects with known or suspected or uncharacterized DPPMs|1. Regardless of gender, at least one month of age;2. A medical history that, in the expert opinion of the study team, is consistent with the DPPM; 3. Have a primary metabolic or genetic physician, or primary care provider; and 4. Ability of the subject, parent/s (in the case of children), or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
62693998|NCT06587230|EXPERIMENTAL|Tealeaf|Teachers in the Tealeaf arm receive in-depth training and regular supervision and coaching from the study team.
62693999|NCT06587230|ACTIVE_COMPARATOR|RE-SEED|Teachers in the RE-SEED arm receive much less in-depth training. The study team does not provide supervision allowing only the school counselor to provide supervision.
61936443|NCT02897765|EXPERIMENTAL|Drug: NEO-PV-01 + Nivolumab + Adjuvant|Nivolumab at a dose of 240 mg administered by intravenous (IV) infusion over 30 minutes every two weeks. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with nivolumab.
61936444|NCT04526509|EXPERIMENTAL|Substudy 1: Cohort 1 - GSK3901961 in previously treated metastatic NSCLC|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as intravenous (IV) infusion after completing lymphodepleting chemotherapy.
61936445|NCT04526509|EXPERIMENTAL|Substudy 1: Cohort 2 - GSK3901961 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as IV infusion after completing lymphodepleting chemotherapy.
61936446|NCT04526509|EXPERIMENTAL|Substudy 2: GSK3845097 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as IV infusion after completing lymphodepleting chemotherapy.
61936447|NCT04526509|EXPERIMENTAL|Substudy 3: GSK4427296 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK4427296, as IV infusion after completing lymphodepleting chemotherapy.
61936448|NCT04373174|ACTIVE_COMPARATOR|Group E|Thoracic Epidural block + Regional oximetry probe will be placed in the frontal area of the head
61936449|NCT04373174|SHAM_COMPARATOR|Group P|Regional oximetry probe will be placed in the frontal area of the head
61936450|NCT04137432|EXPERIMENTAL|Oxytocin (24 IU)|Intranasal administration of 24 international units (IU) of oxytocin (OT) 30 minutes before the start of four intervention sessions
61936451|NCT04137432|PLACEBO_COMPARATOR|Placebo|Intranasal administration of a placebo spray 30 minutes before the start of four intervention sessions
61936452|NCT01727843|EXPERIMENTAL|tranexamic acid|3000mg/mL tranexamic acid in saline applied directly to the wound at the end of the surgical procedure.
62330997|NCT04182997|PLACEBO_COMPARATOR|Placebo Group|Patients in this group will be given the placebo (sterile saline).
62694000|NCT05085756|ACTIVE_COMPARATOR|Guided treatment|8-week transdiagnostic CBT with written guidance from M.Sc-level students under supervision.
62694001|NCT05085756|ACTIVE_COMPARATOR|Unguided treatment|8-week transdiagnostic CBT without guidance.
62694002|NCT05085756|OTHER|Waitlist|8-week transdiagnostic CBT without guidance, made available 6 months after recruitment.
62694003|NCT04476147||Participates|This is an observational study
62694004|NCT06207435|EXPERIMENTAL|West Philadelphia Residents|For eligible residents of West Philadelphia, patients are contacted by Community Support Program Representative and offered free Lyft transportation to and from appointment. If patient has other questions about their upcoming appointment (location, time, etc.), Patient Navigator assists in answering questions
62694005|NCT06207435|NO_INTERVENTION|Non West Philadelphia Residents|For patients outside West Philadelphia, no contact is made and no free transportation is provided. Research coordinator logs their appointment attendance after the appointment date in question.
62694006|NCT04543786|EXPERIMENTAL|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation on lower back for 30-60 minutes for 5 consecutive days.
61936453|NCT01727843|PLACEBO_COMPARATOR|saline|3000mg/mL saline applied directly to the wound at the end of the surgical procedure
61936454|NCT02645721|EXPERIMENTAL|Extended self-help program with guidance|The program is a comprehensive CBT program lasting 12 weeks, with as many modules. The modules are quite extensive. A guide with basic education in psychotherapy assists and counsels participants online.
62330998|NCT04182997|ACTIVE_COMPARATOR|Dexamethasone Group|Patients in this group will be given the study drug (dexamethasone).
62694007|NCT06643143|EXPERIMENTAL|Placebo Control|Placebo
61936455|NCT02645721|ACTIVE_COMPARATOR|Briefer Self-help program, no guidance|This self-help program also lasts 12 weeks but contains only 9 modules; a pause occurs during the final weeks of the program for self-testing of acquired skills. The modules are quite brief. Participants receive no guidance.
61936456|NCT02645721|OTHER|WL: Extended self-help program, choice of guidance intensity|Participants will be put on a waiting list. After 12 weeks on the waiting list, participants will receive access the the extended self-help program used in the experimental arm. However, participants will be offered a choice between three guidance options of varying intensity: proactive guidance, reactive guidance (only at participant request) or no guidance.
61936457|NCT00831350|EXPERIMENTAL|ranibizumab|
61936458|NCT02874287|OTHER|Hydroxychloroquine|Subjects are treated with hydroxychloroquine sulfate tablets.All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
62488458|NCT05132426|SHAM_COMPARATOR|OMT Sham Arm|"MFR of the thoracic inlet Sham: Operator's hands would encircle the thoracic inlet and would feel for somatic dysfunction in the area but would refrain from treating this area.~Pectoral traction Sham: The doctor would contact the armpit area and diagnose the somatic dysfunction, but unlike the treatment group they would not do any treatment.~Diaphragm release with MFR Sham: The doctor's hands are placed just below the ribcage and will feel for the direct restrictive barriers but will not augment the release.~Fascial release of the breast Sham: The doctor would encircle the breast with their hands but would not induce motion or engage any direct barriers. The operator will find the barrier in the tissue but will refrain from treating it.~Thoracic pump Sham: The doctor will hold their hands in place over the chest wall but will not try to affect the breathing motion and will not resist the upward motion of the rib cage during inhalation."
62694008|NCT06643143|EXPERIMENTAL|300mg|300mg
62488459|NCT06272877|EXPERIMENTAL|Experimental Group|Fluidotherapy will be applied to the group in addition to the conservative rehabilitation program received by the control group. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
62488460|NCT06272877|ACTIVE_COMPARATOR|Control group|Only the conventional rehabilitation program will be applied by a physiotherapist for 6 weeks.
62488461|NCT04435782|EXPERIMENTAL|JNJ-67896049|Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
62488462|NCT02840669|OTHER|Friedreich's Ataxia|
62488463|NCT02840669|OTHER|Healthy Volunteers (Controls)|
62694009|NCT06643143|EXPERIMENTAL|500mg|500mg
62135416|NCT03638674|ACTIVE_COMPARATOR|2nd lumbar spine acquisition in same position|spine and hip STRATOS DR + 2nd lumbar spine acquisition in same position (with template)
62135417|NCT03638674|ACTIVE_COMPARATOR|2nd lumbar spine acquisition|spine and hip STRATOS DR + 2nd lumbar spine acquisition (no template)
62488464|NCT02228486|ACTIVE_COMPARATOR|Cue Exposure Therapy and verum tDCS|During alcohol cue exposure, an active tDCS with a duration of 15 minutes and 2 mA is applied to the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2).
62488465|NCT02228486|PLACEBO_COMPARATOR|Cue Exposure Therapy and sham tDCS|During alcohol cue exposure, a placebo tDCS is used with electrodes placed over the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2). There is a 20 second ramp going up until 2 mA and back to 0 again at the beginning and the end of the placebo stimulation with no active stimulation during the cue exposure.
62488466|NCT02228486|NO_INTERVENTION|Waiting list control group|The Cue-Reactivity of patients assigned to this arm will be measured twice with an interval of 5 weeks. Afterwards, patients will take part in the cue exposure therapy like subjects assigned to the active arms of the study
62488467|NCT03583398||TAVI TAo|
62488468|NCT03583398||TAVI TF|
62694010|NCT02679274|PLACEBO_COMPARATOR|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
62694011|NCT02679274|EXPERIMENTAL|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
62694012|NCT05245175|EXPERIMENTAL|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
62694013|NCT05245175|EXPERIMENTAL|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
61936459|NCT02874287|OTHER|placebo|Subjects are treated with placebo tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
62135418|NCT03638674|ACTIVE_COMPARATOR|2nd hip acquisition in same position|spine and hip STRATOS DR + 2nd hip acquisition in same position (with template)
62135419|NCT03638674|ACTIVE_COMPARATOR|2nd hip acquisition|spine and hip STRATOS DR + 2nd hip acquisition (without template)
62330999|NCT06131346||Patients with anti-IgLON5 antibodies|Adults patients who tested positive for anti-IgLON5 antibodies in the French Reference centre of Autoimmune Encephalitis
62331000|NCT00001458||Cardiovascular|subjects with cardiovascular symptoms or known disease.
62331001|NCT05932511|EXPERIMENTAL|30% Ascorbic Acid in DMSO|Topical application twice daily of 300ul 30% (w/v) solution of ascorbic acid in DMSO
62331002|NCT02916030||Group 1 (hemorrhagic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
62488469|NCT03583398||AVR|
62488470|NCT00471510|EXPERIMENTAL|1|NEOSH101 2%
62488471|NCT00471510|EXPERIMENTAL|2|NEOSH101 1%
62488472|NCT00471510|EXPERIMENTAL|3|NEOSH101 0.5%
62488473|NCT00471510|PLACEBO_COMPARATOR|4|
62488474|NCT06513052|PLACEBO_COMPARATOR|Control|\<100 mg cocoa flavanols/day for 12 weeks
62488475|NCT06513052|EXPERIMENTAL|Intervention|500 mg cocoa flavanols/day for 12 weeks
62694014|NCT05245175|PLACEBO_COMPARATOR|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
62694015|NCT05245175|EXPERIMENTAL|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
62694016|NCT05245175|EXPERIMENTAL|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
62694017|NCT00855335|EXPERIMENTAL|Group 1: Darunavir 600 /Ritonavir 100|TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
62694018|NCT00855335|EXPERIMENTAL|Group 2: Darunavir 800/Ritonavir 100|TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
62694019|NCT00855335|EXPERIMENTAL|Group 3: Etravirine|TMC125 (etravirine) 200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
62694020|NCT00855335|EXPERIMENTAL|Group 4: Rilpivirine|TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
62488476|NCT04164706|EXPERIMENTAL|HumiGard (plus standard care)|HumiGard device will be used to provide warmed humidified CO2 for insufflation during laparoscopic surgery. The device will be used alongside standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.
62488477|NCT04164706|SHAM_COMPARATOR|Standard Care (with sham HumiGard device).|"Patients will receive standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.~A sham HumiGard device will be used in the standard care arm. This will be the same HumiGard device as is in the intervention arm. However, the sham device will be turned off so that the gas delivered to the peritoneal cavity for insufflation is not heated or humidified. The sham device will deliver CO2 (as is the case for current standard practice in the hospital) through the HumiGard tubing. The sham device will look and sound the same as the active intervention arm where the HumiGard device is switched on and is delivering warm, humidified CO2 to the peritoneal cavity."
62488478|NCT02970188|NO_INTERVENTION|Normal Feeding|Subjects will be instructed to eat within their normal feeding window.
62488479|NCT02970188|EXPERIMENTAL|Time Restricted Feeding|Subjects will be instructed to eat with an 8 hour feeding window, starting between 10:30-11:30 AM and stopping between 5:30-6:30 PM.
62488480|NCT06031844|EXPERIMENTAL|Treatment Sequence 1|Participants will be administered Placebo and different doses of DFV890
62488481|NCT06031844|EXPERIMENTAL|Treatment sequence 2|Participants will be administered Placebo and different doses of DFV890
62488482|NCT06031844|EXPERIMENTAL|Treatment sequence 3|Participants will be administered different doses of DFV890
62488483|NCT06031844|PLACEBO_COMPARATOR|Treatment sequence 4|Participants will be administered Placebo
62488484|NCT06276153||Gallbladder cancer|"Diagnostic criteria:~Patients with gallbladder cancer diagnosed by pathology, and combined with clinical manifestations and imaging results, the first diagnosis and discharge were diagnosed as patients with gallbladder cancer."
62488485|NCT04307680|ACTIVE_COMPARATOR|Kegel exercise|Using high-intensity Kegel exercise regimen for 8 weeks (5 times a week; 3 times a day involved; 3 sets of 10-12 contractions)
62488486|NCT04307680|ACTIVE_COMPARATOR|Magnetic stimulation|Using 16 extracorporeal magnetic innervation treatments during 8 weeks (2 times a week).
62488487|NCT06555640|EXPERIMENTAL|Cohort 1: DR10624 injection|DR10624 injection administered weekly (QW)
62488488|NCT06555640|PLACEBO_COMPARATOR|Cohort 1: Placebo|Placebo administered weekly (QW)
62488489|NCT06555640|EXPERIMENTAL|Cohort 2: DR10624 injection|DR10624 injection administered weekly (QW)
62488490|NCT06555640|PLACEBO_COMPARATOR|Cohort 2: Placebo|Placebo administered weekly (QW)
62488491|NCT06555640|EXPERIMENTAL|Cohort 3: DR10624 injection|DR10624 injection administered weekly (QW)
62488492|NCT06555640|PLACEBO_COMPARATOR|Cohort 3: Placebo|Placebo administered weekly (QW)
62488493|NCT02236858|SHAM_COMPARATOR|Sham HEPA Air Cleaner|Sham HEPA Air Cleaner and Delayed Intervention. Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
62694021|NCT00855335|EXPERIMENTAL|Group 5: Darunavir 800/Cobicistat 150|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
62488494|NCT02236858|ACTIVE_COMPARATOR|HEPA Air Cleaner|HEPA Air Cleaner also containing carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time. These air cleaners are suitably sized to provide clean air delivery rates for the rooms in which they will be placed. Participants will be instructed to run the air cleaners continually during the course of the study and the units will be modified to prevent them from being turned off by the participants.
62694022|NCT01987999|EXPERIMENTAL|Acetogenins|Acetogenins twice (BID) per day for 12 months
62694023|NCT04953026||Normal control group-Grade 0|Arthroscopic examination of the labrum was normal, and the labrum was intact without injury or tear.
62694024|NCT04953026||Ligament injury -Grade 1|Arthroscopic examination of the shoulder showed labrum degeneration or injury, but no local or complete tear.
62488495|NCT05532631|EXPERIMENTAL|Angioplasty|percutaneous coronary angioplasty with drug eluting stent implantation.
62488496|NCT05532631|ACTIVE_COMPARATOR|Coronary artery bypass grafting|Coronary artery bypass grafting has been chosen as the comparator because it is currently the reference strategy for revascularization in patients with multi-vessel disease and heart failure (ESC guidelines). Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines.
62488497|NCT04257838||Piperacillin-Tazobactam or Meropenem Cohort|Patients hospitalized for sepsis or septic shock that are treated with Piperacillin-Tazobactam or Meropenem and meet all the inclusion criteria and none of the exclusion criteria.
62488498|NCT03331458|EXPERIMENTAL|subjects with prostate cancer|
62488499|NCT03101358|EXPERIMENTAL|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
62488500|NCT03101358|EXPERIMENTAL|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
62488501|NCT03101358|EXPERIMENTAL|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days or up to 56 days
62488502|NCT04608448|ACTIVE_COMPARATOR|Topical Rapamycin|Ointment is applied to a color coded area on the subject forearm daily.
62694025|NCT04953026||Ligament tear-Grade 2|Arthroscopy of the shoulder revealed partial or complete loss of labrum.
62694026|NCT05211466||Depressive disorder, major|Patients with major depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
62694027|NCT05211466||Depressive disorder, bipolar|Patients with bipolar depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
62488503|NCT04608448|PLACEBO_COMPARATOR|Placebo|Placebo ointment is applied to a color coded area on the subject forearm daily.
62488504|NCT05543720|NO_INTERVENTION|Control|Control groups will be compared to 350 patients who received standard of care via propensity-matched controls from the ICES provincial database.
61936460|NCT05689944|NO_INTERVENTION|Control group|Patients in the control group will not participate in any art-therapy or yoga interventions. They will be asked to complete pain and sleep diaries, questionnaires and pain, fatigue and mood scales at the same times and for the same duration as the other groups.
61936461|NCT05689944|EXPERIMENTAL|Dance-therapy group|Patients in the dance-therapy group will attend a weekly session of dance-therapy between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
61936462|NCT05689944|EXPERIMENTAL|Art-therapy group|Patients in the art-therapy group will attend a weekly session of art-therapy (drawings, collages...) between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
61936463|NCT05689944|EXPERIMENTAL|Yoga group|Patients in the yoga group will attend a weekly session of Vinyasa yoga between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
61936464|NCT01724411|EXPERIMENTAL|Resistant Starch 3|Resistant Starch Type 3:dose of 26g/day males and 22g/day female during 11 days of the maintenance period. (C ActiStar 11700, Tapioca Maltodextrin, Cargill, Belgium)
61936465|NCT01724411|NO_INTERVENTION|Control Non- RS3|Non-Resistant Starch type 3 food items during 11 days of the maintenance period.
62488505|NCT05543720|EXPERIMENTAL|Telemonitoring (Medly MCC)|Medly is a smartphone application allows patients with heart failure, diabetes, depression, hypertension, and/or COPD to measure and record their daily self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
62488506|NCT02741895||Postoperative patients|The target populations for the study are patients undergoing robotic cystectomy, open colectomy, abdominal hysterectomy, esophagectomy, lung lobectomy, gastric bypass, and hip replacement at Cedars-Sinai Medical Center.
62488507|NCT04533620|ACTIVE_COMPARATOR|Standardized CIRT|Patients will receive standardized CIRT with a dose of 63 GyE/21 fx.
62488508|NCT04533620|EXPERIMENTAL|Individualized CIRT|A previously predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
62488509|NCT03453840|ACTIVE_COMPARATOR|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
62488510|NCT03453840|EXPERIMENTAL|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
62488511|NCT03453840|ACTIVE_COMPARATOR|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
62488512|NCT03453840|EXPERIMENTAL|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
62488513|NCT03612154|EXPERIMENTAL|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
62488514|NCT05913245|NO_INTERVENTION|Fasting arm|Patients included in the fasting arm will not drink or eat anything after the dinner of the night before the surgery.
62488515|NCT05913245|ACTIVE_COMPARATOR|Water arm|Patients included in the water intake arm will drink the same amount of mililiters than the carbohydrate loading drink.
62488516|NCT05913245|EXPERIMENTAL|Carbohydrate loading arm|"Patients included in the intake arm of carbohydrate loading treatment should take 400ml the night before the intervention and 200ml the two hours before the intervention.~The hydrocarbonate drink provided will be Sugarmix (Maltodextrin 12.5%)."
62488517|NCT00981838|EXPERIMENTAL|1|Rituximab (375 mg/m2).
61936466|NCT06010732|OTHER|Treatment Period 1|0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
62488518|NCT05579405||Acute Ischemic Stroke|Ischemic stroke within 24 hours of onset and modified Rankin Scale 0 to 2
62488519|NCT05579405||Transient ischemic attack|Transient ischemic attack without MRI positivity within 7 days of onset
62488520|NCT05579405||Patient Control|Contemporary patients with neurological symptoms required for differentiation from ischemic stroke or transient ischemic attack
62488521|NCT04682327||Responder group|"After the 4 cycles of anti-PD-1/PD-L1 mAbs treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Responders are defined as complete remission, partial remission, or stable disease."
62488522|NCT04682327||Nonresponder group|"After the 4 cycles of anti-PD-1/PD-L1 treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Nonresponders are defined as disease progression."
62488523|NCT04833205|EXPERIMENTAL|Leptomeningeal metastases received EGFR-TKI and Nimotuzumab|The patients received Nimotuzumab 200 mg,which was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping.And the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks.One the other hand,the patient received the third generation of EGFR-TKI
61936467|NCT06010732|OTHER|Treatment Period 2|0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
62488524|NCT03864094|ACTIVE_COMPARATOR|Ephedrine Propofol Remifentanil|Prophylactic Ephedrine
62488525|NCT03864094|ACTIVE_COMPARATOR|Phenylephrine Propofol Remifentanil|Prophylactic Phenylephrine
62135420|NCT05368350|EXPERIMENTAL|Active Pre-SMA tDCS treatment|This open-label treatment will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS), by utilizing 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to pre-supplementary motor area for 20 minutes over 10 sessions. There will be baseline testing, and follow up testing immediately after and 8 weeks after completion of treatment.
62488526|NCT03864094|ACTIVE_COMPARATOR|Norepinephrine Propofol Remifentanil|Prophylactic Norepinephrine
62488527|NCT03864094|SHAM_COMPARATOR|Sodium chloride Propofol Remifentanil|NaCl Placebo
62488528|NCT02940457|EXPERIMENTAL|Verum tDCS|prefrontal anodal stimulation
62488529|NCT02940457|EXPERIMENTAL|Sham tDCS|sham stimulation, same electrode positions
62488530|NCT03895879|EXPERIMENTAL|Intervention|Tocilizumab administered every 2 weeks
62694028|NCT05211466||Depressive disorder, recurring|Patients with recurring depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
62694029|NCT05211466||Digital care staff|Staff working most of their time (20% or more) with the digital healthcare platform.
62694030|NCT05211466||Traditional care staff|Staff working traditionally, using the digital healthcare platform to a very little extent.
62694031|NCT06642220|EXPERIMENTAL|Y-90 radioembolization treatment arm|Patients with non-metastatic renal cell carcinoma (RCC) that is \> 4 cm without local invasion (i.e. T1b or T2) who are poor candidates for surgery will have their tumors treated with transarterial radioembolization with Y-90 glass spheres.
62135421|NCT05368350|EXPERIMENTAL|Active LIFG tDCS treatment|This open-label treatment will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS), by utilizing 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to left inferior frontal gyrus for 20 minutes over 10 sessions. There will be baseline testing, and follow up testing immediately after and 8 weeks after completion of treatment.
62331003|NCT02916030||Group 2 (Ischemic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
62331004|NCT01726920|EXPERIMENTAL|naratriptan + naproxen|Fixed-dose combination of naratriptan + naproxen
62331005|NCT01726920|ACTIVE_COMPARATOR|naratriptan|
62694032|NCT06643988|NO_INTERVENTION|Healthy controls|Participants who meet criteria as healthy volunteers, will receive no MemFlex training but will undergo assessments as well as fNIRS computerized tasks.
61936468|NCT06010732|OTHER|Treatment Period 3|0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
61936469|NCT05554575|EXPERIMENTAL|BT-007 CD7 CAR-T cells in R/R T-LBL|Subjects will receive BT-007 CD7 CAR-T cells infusion on Day 0 : 100% of total dose.
62331006|NCT01726920|ACTIVE_COMPARATOR|naproxen|
62331007|NCT02496637|EXPERIMENTAL|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
62331008|NCT02496637|ACTIVE_COMPARATOR|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
62331009|NCT02496637|NO_INTERVENTION|No Treatment Control|No intervention, assessment only
62331010|NCT06391073|NO_INTERVENTION|Usual Care Group|The usual care group is standard of care. They will receive the standard ED discharge materials available as recommended by their ED physician. These materials recommend lifestyle changes, dietary changes, medication as directed, and follow-up with a PCP as directed.
62488531|NCT03895879|ACTIVE_COMPARATOR|Control|Tocilizumab administered every week
62488532|NCT03895879|ACTIVE_COMPARATOR|Standard dose (screening < 15 mg/L)|Tocilizumab administered every week
62488533|NCT01124786|EXPERIMENTAL|CO-1.01|
62488534|NCT01124786|ACTIVE_COMPARATOR|gemcitabine|
62488535|NCT05496192|EXPERIMENTAL|Nivolumab IV followed by Nivolumab SC|
62488536|NCT05748626|EXPERIMENTAL|Group #1: Anti-snoring appliance|Group #1: Anti-snoring appliance (Zyppah) that will be utilized during their procedure.
62488537|NCT05748626|ACTIVE_COMPARATOR|Group #2: Control group, that will not utilize anti-snoring appliance|Group #2: Control group, that will not utilize (Zyppah) anti-snoring appliance during their procedure.
62488538|NCT06288217|EXPERIMENTAL|Paired nTVNS Stimulation|"Non-invasive electrical stimulation of the trigeminal and vagus nerves will be delivered by the NeuraStasis Stimulator System. The non-invasive Stimulation Electrode is positioned on the head (forehead and in the ear). The operator controls the stimulation delivery through the accompanying Controller.~Rehabilitation sessions begin with a stimulation tolerability assessment where the dose of therapy is selected. A 15-minute priming stimulation is delivered next, followed by the standard of care rehabilitation over the remaining session. During this rehabilitation paired nTVNS is delivered with repetitive motions."
62488539|NCT06288217|SHAM_COMPARATOR|Sham Stimulation|"For the active shame comparator group, the non-invasive Stimulation Electrode is positioned on the head (forehead and in the ear) as in the experimental group. The operator controls the stimulation delivery through the accompanying Controller.~Rehabilitation sessions begin with a stimulation tolerability assessment where the dose of therapy is selected. A sham stimulation dosage will follow for the remaining procedure, including the priming stimulation, period and the standard of care rehabilitation"
62488540|NCT04509154|EXPERIMENTAL|Multimodal pain therapy|"The treatment will last 6 weeks maximum 8 weeks. The three questionnaires will be completed by all study subjects in a maximum time of 10 minutes. Immediately after receiving the two face-to-face sessions; 6 weeks after (8 weeks maximum after treatment) and three months just after having completed treatment.~The pain management application includes automatic monitoring, skills training, social support, education, goal setting and achievement of 4 components: exercises, psychological well-being, pharmacological and health assets interventions. Every week participants have a look at digital presentations about every component, doing then 3 activities related to each of them.This program will be."
62135422|NCT04646733|EXPERIMENTAL|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet.
62488541|NCT04509154|EXPERIMENTAL|Standardized treatment.|Both groups (control and intervention) received two face-to-face health education sessions led by nurses and physicians, and had access to a non-interactive web page with material for pain management from a self-help approach.
62135423|NCT04646733|ACTIVE_COMPARATOR|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water.
62135424|NCT01290341|EXPERIMENTAL|NAFT-600 ( naftin 2 % gel)|Topical; applied once daily for two weeks
62135425|NCT01290341|PLACEBO_COMPARATOR|Placebo|Topical; applied once daily for two weeks.
62135426|NCT06655480|EXPERIMENTAL|[ARNI + SGLTi + AMR]|Patients will receive combination therapy with ARNI, gliflozin and AMR
62135427|NCT06655480|ACTIVE_COMPARATOR|[SGLTi + previously taken RAAS blocker]|Patients will receive combination therapy with gliflozin and previously taken RAAS blocker
62135428|NCT00698113|ACTIVE_COMPARATOR|1|This group receives the massage intervention for a period of six weeks. Children and parents are asked to journal weekly for the six week period.
62135429|NCT00698113|NO_INTERVENTION|2|The control group does not receive any massage intervention during the initial six weeks of the study. The children are asked to journal during this six week period.
62135430|NCT02132455|EXPERIMENTAL|3 minutes in the right side colon|Colonoscopy, at least 3 minutes in the right side colon from the total withdrawal time
62135431|NCT02132455|EXPERIMENTAL|4 minutes in the right side colon|Colonoscopy, at least 4 minutes in the right side colon from the total withdrawal time
62135432|NCT02132455|NO_INTERVENTION|6 minutes whole withdrawal time|Colonoscopy, at least 6 minutes whole withdrawal time regardless of time spent in any segment
62135433|NCT02132455|EXPERIMENTAL|8 minutes whole withdrawal time|Colonoscopy, at least 8 minutes whole withdrawal time regardless of time spent in any segment
62135434|NCT04160936|ACTIVE_COMPARATOR|study group :infiltration with 0.25% bupivacaine post-op|At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin
62135435|NCT04160936|NO_INTERVENTION|control group , no anesthesia infiltration post-op|control group: no anesthesia infiltration had been given post opertatively
62135436|NCT05705856||intravenous maintenance at early stage|Participants who have evidence of high activity clinically, biochemically or endoscopically : HBI ≥8, inflammatory markers significantly increased (CRP \> 5mg/L, fecal calprotectin\> 200mg/g), SES-CD≥ 7, will get multiple intravenous injections of Ustekinumab maintenance after induction.
62135437|NCT05705856||intravenous escalation when poor response|Participants who experience a loss of response or poor response to 90 mg Ustekinumab standard therapy will receive Ustekinumab intravenously at regular interval or at shorten interval.
62694033|NCT06643988|EXPERIMENTAL|OUD|Participants who meet criteria for OUD and are on a stable dose of medication assisted therapy for OUD will be trained in memory flexibility training (MemFlex) - cognitive training exercises.
62135438|NCT06464224||low respiratory effort|patients under low respiratory effort
62135439|NCT06464224||high respiratory effort|patients under high respiratory effort
62135440|NCT01863485|EXPERIMENTAL|CM082|CM082 tablet
62135441|NCT00873782|EXPERIMENTAL|1|Participants will undergo retrograde high pressure transvenous limb perfusion with normal saline.
62135442|NCT02190708|EXPERIMENTAL|PQ912 & Midazolam & Omeprazole|day2 - day6 800mg PQ912 twice per day po day1 / day6 2.5 mg Midazolam once per day day1 / day6 20 mg Omeprazole once per day
62135443|NCT04238858|ACTIVE_COMPARATOR|Before application|Forty-nine eyes belonging to 37 patients before injection aPRP.
62135444|NCT04238858|NO_INTERVENTION|After application|Forty-nine eyes belonging to 37 patients after injection aPRP.
62135445|NCT04238858|SHAM_COMPARATOR|Sham application|11 patients before - after aPPP injection
62135446|NCT04886505|EXPERIMENTAL|Treatment|Single arm study - treatment with Electrolytic eCLIPs Bifurcation System
62135447|NCT02789020|EXPERIMENTAL|Rasagiline|This group will receive a 1 mg rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
62135448|NCT02789020|PLACEBO_COMPARATOR|Placebo|This group will receive a placebo tablet in the same forum as the rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
62135449|NCT00874536|EXPERIMENTAL|ALA|This group will receive the ALA supplement
62135450|NCT00874536|PLACEBO_COMPARATOR|Placebo|This group will receive the placebo supplement
62135451|NCT01138254|NO_INTERVENTION|control group|ESRD patients will not receive FIR therapy in this study.
62135452|NCT01138254|EXPERIMENTAL|Far infrared therapy|Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
62135453|NCT05733507||Intravenous thrombolysis (IVT)|group of patients treated with IVT alone
62135454|NCT05733507||Tirofiban + IVT|groups of patients treated with simultaneous infusion of tirofiban and IVT
62488542|NCT00660660|EXPERIMENTAL|Nexium 20mg|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
62488543|NCT00660660|PLACEBO_COMPARATOR|Placebo|
62488544|NCT03591276|EXPERIMENTAL|Pembrolizumab and PLD|"Cohort S1: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 every 3 weeks.~Reduced Dose Cohort (R1)\*: IV pembrolizumab 200 mg flat dose with IV PLD 24 mg/m2 every 3 weeks.~\*Subjects will be recruited into the R1 cohort only if DLT is reported in 2 or more subjects during the first 2 cycles of treatment in the first 6 patients of the S1 cohort."
62488545|NCT00748722||1|Female patients, age 18-60 years, suitable for breast reconstruction using the lower abdominal tissue.
62331011|NCT06391073|EXPERIMENTAL|REACH OUT|"REACH OUT messaging is based on BP control. Control is defined as SMBP \<135/85. Every 4 weeks SMBP measurements will be assessed and mHealth components will be escalated, de-escalated, or remain the same.~If BP is controlled, SMBP prompts will be sent once a week and there will be no facilitated appointments.~If BP is uncontrolled, SMBP prompts will be sent three times per week and facilitated provider scheduling and transportation will occur.~Participants will have the option include a partner, friend, or family member with text-messaging capability who could support them on their BP journey. The partner will receive Reach Out materials and text messages to remind the participant to engage in SMBP and of their upcoming appointments (if uncontrolled)."
62694034|NCT02070211|EXPERIMENTAL|omega-3 PUFAs in add on to standard care|omega-3 PUFA supplementation as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
62694035|NCT02070211|PLACEBO_COMPARATOR|Placebo in add on to standard care|Placebo made by paraffin oil (not absorbed by the gastrointestinal tract) as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
61936470|NCT00982124|EXPERIMENTAL|Treatment Arm (only)|Zoledronic acid infusion
61936471|NCT04908657|EXPERIMENTAL|Treatment group|treatment group will administrate oral sildenafil 20 mg three times per day for 3 years
61936472|NCT04908657|NO_INTERVENTION|Control group|the control group will not receive any specific therapy for decreasing the pulmonary vascular resistance
61936473|NCT03014492|EXPERIMENTAL|Collar Group|Soccer girls that wore the collar device
62331012|NCT01300468|EXPERIMENTAL|Dose-escalation|
62331013|NCT04265586|NO_INTERVENTION|No insomnia|This group contains participants who report only mild symptoms of insomnia (Insomnia Severity Index, ISI\<15).
62331014|NCT04265586|EXPERIMENTAL|Digital Cognitive Behavioural Therapy (iCBT)|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI \>14). Intervention is iCBT for participants with insomnia (7-16 weeks).
62331015|NCT04265586|EXPERIMENTAL|Sleep hygiene education|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI \>14). Sleep hygiene education (approximately 1 hour)
62331016|NCT04212338|EXPERIMENTAL|study group 1|Before intravitreal injection music intervention: These patients received the standard treatment and listened to music for a period of 15 minutes 30 minutes before the injection.
62331017|NCT04212338|EXPERIMENTAL|study group 2|During-intravitreal injection music intervention:These patients received the standard treatment and listened to music during the injection (approximately 5 minutes).
62331018|NCT04212338|NO_INTERVENTION|control group|The music intervention was not conducted with the patients in the control group. These patients received the standard treatment.
62331019|NCT03264508|EXPERIMENTAL|Heat therapy|Hot water immersion 3-4x per week for 8-10 weeks
62331020|NCT03264508|SHAM_COMPARATOR|Thermoneutral water immersion|Thermoneutral water immersion 3-4x per week for 8-10 weeks
62331021|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
62331022|NCT05990660|EXPERIMENTAL|Treatment|
62331023|NCT02196038|OTHER|Attention Control|Usual care group with bi-weekly contact from study staff
62331024|NCT02196038|ACTIVE_COMPARATOR|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
61936474|NCT03014492|NO_INTERVENTION|No Collar Group|soccer girls that did not wear the collar
61936475|NCT00905216|EXPERIMENTAL|Test|Heparin sodium - Bergamo
61936476|NCT00905216|ACTIVE_COMPARATOR|Comparator|Heparin APP
61936477|NCT04497207||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values \>47.0D, inferior- superior(I-S) asymmetry measured to be \> 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
62135455|NCT01277250|OTHER|Usual Care|Standard smoking cessation information provided to all hospitalized patients as part of discharge packet.
62331025|NCT05681195|EXPERIMENTAL|Induction Therapy + SOC Treatment|"Participants will receive the induction therapy (oral zanubrutinib + IV pemetrexed) and be placed into one of the cohorts according to standard of care (SOC) treatment:~Cohort 1: Induction Therapy + Autologous Stem Cell Transplant (ASCT) After completion of the induction therapy, ASCT candidates will undergo transplant as per SOC. If the transplant is delayed and 8 induction cycles have been completed, oral zanubrutinib maintenance will proceed until transplant, but will not occur after transplant.~Cohort 2: Induction Therapy + Whole Brain Radiation Therapy (WBRT) After completion of the induction therapy, WBRT candidates will undergo WBRT as per SOC. Oral zanubrutinib maintenance will start 7-10 days after the completion of WBRT. 28-d maintenance cycles will continue until disease progression.~Cohort 3: Induction Therapy Alone After completion of the induction therapy, 28-day oral zanubrutinib maintenance cycles will begin and continue until disease progression"
62694036|NCT03886636|EXPERIMENTAL|Neuroscience pain education group|in Group 1, participants received Neuroscience pain education, manual therapy and a home exercise program.
62694037|NCT03886636|EXPERIMENTAL|Manual therapy group|in Group 2, participants received manual therapy and a home exercise program.
62694038|NCT03886636|ACTIVE_COMPARATOR|Control group|in Group 3, participants received home exercise program only.
62694039|NCT06018519|OTHER|CTD male patients|Case group 24 male CTD patients having a confirmed mutation in the SLC6A8 gene, aged \> 5 to \< 35 years.
62694040|NCT06018519|OTHER|Sex and chronological age matched male controls|Control group 24 male, sex and chronological age matched controls, aged \> 5 to \< 35 years
62135456|NCT01277250|EXPERIMENTAL|Smoking Cessation Program|"Web-based program tailored to patients who smoke and are hospitalized. Program is tailored to participant's specific hospital experience and other characteristics. E-messages, social support and a transition coach are provided to each participant in this condition."
62135457|NCT02765100|EXPERIMENTAL|Low CRP|Subjects have CRP \> 3
62135458|NCT02765100|EXPERIMENTAL|High CRP|Subjects have CRP =/\> 3
62135459|NCT03377205|ACTIVE_COMPARATOR|Plate|Compression screws and neutralization plate.
62331026|NCT02046031|EXPERIMENTAL|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 \~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
62135460|NCT03377205|EXPERIMENTAL|Intramedullary nail|Acumed Fibular Rod System
62135461|NCT05585346|EXPERIMENTAL|Laser acupuncture Group|"LA group used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy). MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.~In LA group, based on clinical experience, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 7 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST25 (Tian Shu), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong). The acupoints in the limbs and trunk area, were applied bilaterally. Power of laser device is 50%.~Oral vitamin B1."
62331027|NCT01652248|PLACEBO_COMPARATOR|Standard generator replacement|Standard generator replacement
62331028|NCT01652248|ACTIVE_COMPARATOR|Upgrade to cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
62331029|NCT02037802|ACTIVE_COMPARATOR|caudal epidural catheterization group|30 patients received continuous intra and post-operative caudal epidural infusion of bupivacaine 0.125% with fentanyl (2 microgram/ml) over 24 hours
62331030|NCT02037802|SHAM_COMPARATOR|control group|30 patients didn't receive caudal epidural analgesia
62331031|NCT00819208|ACTIVE_COMPARATOR|Physical Activity Program + General Health Education Materials|Intervention Arm
62331032|NCT00819208|ACTIVE_COMPARATOR|General Health Education Materials|Control Arm
62331033|NCT03255291|EXPERIMENTAL|Risk Display Format:Risk Ladder:Imagery Behavior:Exercise|"* With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic \& health questions. It then provides personalized risk estimates for participants' current activity level \& how it would change with regular exercise.~* Participants take Baseline Survey 1.~* Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal \& are asked to practice the mental imagery twice a day for 3 weeks.~* Participants take Baseline Survey 2.~* Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~* Participants take surveys via text at the end of each week for 4 weeks.~* 90 days post-baseline, participants complete a survey sent through the mail.~* Participants may be contacted for another survey 1 year later."
62331034|NCT03255291|EXPERIMENTAL|Risk Display Format:Risk Ladder:Imagery Behavior:Sleep|"* With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic \& health questions. It then provides personalized risk estimates for participants' current activity level \& how it would change with regular exercise.~* Participants take Baseline Survey 1.~* Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal \& are asked to practice the mental imagery twice a day for 3 weeks.~* Participants take Baseline Survey 2.~* Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~* Participants take surveys via text at the end of each week for 4 weeks.~* 90 days post-baseline, participants complete a survey sent through the mail.~* Participants may be contacted for another survey 1 year later."
62331035|NCT03255291|EXPERIMENTAL|Risk Display Format:Table:Imagery Behavior:Exercise|"* With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic \& health questions. It then provides personalized risk estimates for participants' current activity level \& how it would change with regular exercise.~* Participants take Baseline Survey 1.~* Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal \& are asked to practice the mental imagery twice a day for 3 weeks.~* Participants take Baseline Survey 2.~* Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~* Participants take surveys via text at the end of each week for 4 weeks.~* 90 days post-baseline, participants complete a survey sent through the mail.~* Participants may be contacted for another survey 1 year later."
62694041|NCT06018519|OTHER|Sex and mental age matched male controls|Control group 24 male, sex and mental age matched controls, aged \> 2 to \< 8 years
62694042|NCT06018519|OTHER|Typically developed children|"Control group 80 typically developed children aged \> 2 to \< 8 years, which corresponds to the mental age of CTD patients.~40 children aged \> 2 to \< 5 years, and 40 children aged \> 6 to \< 8 years will perform the newly developed outcome measures."
62694043|NCT06018519|OTHER|CTD female patients|15 female CTD patients having a confirmed mutation in the SLC6A8 gene, aged \>5 to \< 60 years
62694044|NCT06018519|OTHER|Sex and mental age matched female controls|Control group 15 female, sex and mental age matched controls, aged \> 2 to \< 8 years
62694045|NCT06018519|OTHER|Sex and chronological age matched female controls|Control group 15 female, sex and chronological age matched controls, aged \> 5 to \< 60 years
62694046|NCT05399212|EXPERIMENTAL|FPT-20|FPT-20 should be used regularly (\>6 to 12 months) until the therapeutic purpose is achieved.
62694047|NCT04096677||hysteroscopy repair|patients with post cesarean scar defect
62694048|NCT04096677||transvaginal repair|patients with post cesarean scar defect
61936478|NCT04497207||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
62488546|NCT03371186|EXPERIMENTAL|Bundled RMNCH Intervention|Stepped wedge, cluster-controlled implementation science trial of 5 bundled intervention components (1. Community Health Worker, 2, Continuous Surveillance, 3. CB-Integrated Management of Newborn and Childhood Illness, 4. Group Antenatal and Postnatal Care, and 5. Balanced Post-Partum Contraceptive Counseling) implemented across 40 village clusters in Achham District, Nepal and 40 village clusters in Dolakha District, Nepal (covering a total population of approximately 300,000) in coordination with district authorities and study staff. The investigators anticipate the experimental arm will enroll approximately 12,000 women and their children over the 18mo enrollment period.
62488547|NCT05267444|EXPERIMENTAL|Intervention group|Individualized motion-based interactive game program
62488548|NCT05267444|NO_INTERVENTION|Control group|The control group participants will receive usual care, that is, service that provided by community elderly center
62488549|NCT03285438|EXPERIMENTAL|Reduced dose of DOAC|A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 36 months (12 to 65 months)
62488550|NCT03285438|ACTIVE_COMPARATOR|Full dose of DOAC|A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 36 months (12 to 65 months).
62488551|NCT00533507|EXPERIMENTAL|Synflorix group|Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
62488552|NCT04352205|EXPERIMENTAL|Treatment (daratumumab-based treatment)|Patients receive daratumumab IV weekly of cycles 1-3 and on day 1 only of cycle 4, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV or PO on days 1-4 of cycle 1 and on day 1 of cycles 2-4 and PO on days 8 and 15 of all cycles. Beginning cycle 2, patients may also receive lenalidomide PO daily on days 1-14 or thalidomide PO QD on days 1-21. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62488553|NCT06094764|EXPERIMENTAL|Personal monitoring device and a cooling vest , Then personal monitoring device only|
62488554|NCT06094764|EXPERIMENTAL|Personal monitoring device only, Then personal monitoring device and a cooling vest|
62488555|NCT05397444||Full robust|no low HGS without HGS asymmetry
62135462|NCT05585346|ACTIVE_COMPARATOR|Control Group|"LA group used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy). MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.~In LA group, based on clinical experience, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 7 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST25 (Tian Shu), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong). The acupoints in the limbs and trunk area, were applied bilaterally. Power of laser device is 25%.~Oral vitamin B1."
62488556|NCT05397444||low HGS alone|low HGS without HGS asymmetry
62694049|NCT01405664|NO_INTERVENTION|Non-Weight Bearing x 6 weeks|
61936479|NCT04497207||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
62135463|NCT02984332|EXPERIMENTAL|Lower limb immobilisation|All participants will undergo 7 days of unilateral leg immobilization. Participants will wear a leg brace (Donjoy X-ACT, DJO Global, USA) on one of their legs which will fix the leg at 40 degrees of flexion for the 7 days. Participants will not be allowed to remove the brace at any stage and are prohibited from bearing weight on the immobilized leg, and will ambulate on crutches throughout the week of immobilization.
62135464|NCT01738438|EXPERIMENTAL|Cabozantinib|Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.
62135465|NCT03210896|NO_INTERVENTION|Main Group|100 subjects (70 T2D and 30 Controls) consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers.
62135466|NCT03210896|EXPERIMENTAL|Sub Group I|20 subjects from the main group (10 T2D and 10 Controls) to remain after providing the above samples. These patients will stay for an additional 3 hours and provide 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers at the following time intervals: 5, 30, 60, 120 \& 180 minutes.
62488557|NCT05397444||HGS asymmetry alone|no low HGS with HGS asymmetry
62488558|NCT05397444||low HGS with HGS asymmetry|non
62488559|NCT04007939||Employee population|Subject comprised of employees of Metagenics but later will be expanded to those recruited from practitioner practices
62488560|NCT04865120|ACTIVE_COMPARATOR|merocyanine|
62488561|NCT04865120|PLACEBO_COMPARATOR|placebo|
62488562|NCT05293106|ACTIVE_COMPARATOR|Pathogen-reduced (PR) platelet transfusions|FDA approved and already used in this patient population
62488563|NCT05293106|ACTIVE_COMPARATOR|Large volume delayed sampling - LVDS|FDA approved and already used in this patient population
62488564|NCT05293106|NO_INTERVENTION|No platelet transfusion|Subject will not receive a platelet transfusion
62488565|NCT05886803||Spontaneous Breathing Test|The first group will be composed only by patients admitted in intensive care/critical care for ventilation support, and who successed the spontaneous breathing test.
62488566|NCT05886803||Non Spontaneous Breathing Test|The second group will be composed only by patients admitted in intensive care/critical care for ventilation support, and who failed the spontaneous breathing test.
62488567|NCT04303208|OTHER|study group|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum .Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
62694050|NCT01405664|EXPERIMENTAL|Immediate Weight-Bearing as Tolerated|
62694051|NCT05525520|EXPERIMENTAL|EP547 100 mg|
62694052|NCT05525520|PLACEBO_COMPARATOR|Placebo|
62694053|NCT04966169|EXPERIMENTAL|Sonendo GentleWave|Every participant will receive the same experimental treatment, which is root canal therapy using the Sonendo GentleWave System.
62135467|NCT03210896|NO_INTERVENTION|Sub Group II|5 control subjects consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers. This will be followed by 1 capillary blood sample and 3 breath samples every hour for a total of 5 hours.
62694054|NCT06637657||'Current practice' group|The 'current practice' treated patients' group will provide data on current practices in the preventive treatment after hospitalization for acute coronary syndrome or coronary revascularization. (i.e. incremental, individual titration at treating physician's discretion)
62694055|NCT06637657||'First-time-right' (FTR) group|In line with the 2021 ESC Prevention guidelines, the FTR group will be treated according to the 'first-time-right' strategy(1). While no specific therapeutic protocols are mandated by our observational study, participating centers will be required to apply the 'first-time- right' strategy: i.e. the direct, in-hospital initiation or planned initiation of all guideline-recommended preventive pharmacotherapeutic treatments.
62694056|NCT06563869|EXPERIMENTAL|Neoadjuvant patients|All subjects who meet the inclusion criteria will receive sintilimab combined with platinum-containing chemotherapy for 2 cycles (21 days for one cycle) as neoadjuvant therapy according to the research plan. Polyethylene glycolylated recombinant human granulocyte stimulating factor will be given 24 hours after the end of chemotherapy. Radical surgical treatment will be received within 3 to 6 weeks after the completion of the last neoadjuvant treatment.
62694057|NCT04705233|EXPERIMENTAL|Sputum chart|Use of the 5 point sputum colour chart, adapted from Bronkotest® a self-management (SM) plan and rescue pack (RP) containing 5 days supply of antibiotic and steroid treatment
62694058|NCT04705233|NO_INTERVENTION|Control|Use of the plan and rescue pack alone (best usual care)
62694059|NCT06487936||Implanted TransLoc 3D SIJ Fusion Patients|Patients who were diagnosed with sacroiliitis and were treated with the TransLoc 3D System ≥ 1 year ≤ 18 months at the time of consent.
61936480|NCT03851471|EXPERIMENTAL|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
61936481|NCT04554173||surgical resection neurogenic tumors|
61936482|NCT04033198||fourth decade|appendectomy done , appendix send for histopathological examination
61936483|NCT04033198||fifth decade|appendectomy done , appendix send for histopathological examination
61936484|NCT04033198||sixth decade|appendectomy done , appendix send for histopathological examination
62694060|NCT06643572|EXPERIMENTAL|VR simulation|In this group, the practitioner will perform lumbar transforaminal epidural steroid injections after undergoing training using a 3D virtual simulator based on the patient's CT images.
62694061|NCT06643572|NO_INTERVENTION|Conventional|In this group, the patients will undergo lumbar transforaminal epidural steroid injections without the practitioner receiving any additional training.
62694062|NCT06643923|EXPERIMENTAL|Treatment|Both groups of participants will receive the same urotherapy education from the same therapist (Demet Öztürk). Following the education, both groups will be instructed to implement the lifestyle changes taught during the urotherapy education for a period of eight weeks. In addition to the education, the treatment group will receive online, supervised exercise sessions based on lumbopelvic stabilization exercises, administered by the physiotherapist. The exercise program has been designed according to the FITTEA principle, which is one of the key principles in exercise prescription.
62694063|NCT06643923|ACTIVE_COMPARATOR|Active Control|Approximately 1.5 hours of urotherapy training will be given and the patient will be asked to apply the lifestyle changes learned in this training for 8 weeks.
62694064|NCT05939544|EXPERIMENTAL|Milk Fat Globule Membrane-enriched Powdered Ingredient|Participants will be provided with pre-weighed, foil sachets containing a ready-to-mix flavoured powdered supplement that is rich in milk fat globule membrane (and associated complex milk lipids). They will be asked to consume two sachets daily (mixed with water) during the 4-week study period. Sachets will be coded to maintain study blinding.
61936485|NCT04033198||older than 60 years|appendectomy done , appendix send for histopathological examination
61936486|NCT02583373|ACTIVE_COMPARATOR|CAL02 Low-dose|Liposomal formulation
61936487|NCT02583373|ACTIVE_COMPARATOR|CAL02 High-dose|Liposomal formulation
61936488|NCT02583373|PLACEBO_COMPARATOR|Placebo|Saline
61936489|NCT02963935|EXPERIMENTAL|Liraglutide|
61936490|NCT02963935|PLACEBO_COMPARATOR|Placebo|
61936491|NCT04256096|EXPERIMENTAL|thrombectomy|mechanical thrombectomy with stent-retriever and/or thromboaspiration
62331036|NCT03255291|EXPERIMENTAL|Risk Display Format:Table: Imagery Behavior:Sleep|"* With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic \& health questions. It then provides personalized risk estimates for participants' current activity level \& how it would change with regular exercise.~* Participants take Baseline Survey 1.~* Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal \& are asked to practice the mental imagery twice a day for 3 weeks.~* Participants take Baseline Survey 2.~* Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~* Participants take surveys via text at the end of each week for 4 weeks.~* 90 days post-baseline, participants complete a survey sent through the mail.~* Participants may be contacted for another survey 1 year later."
61936492|NCT04256096|ACTIVE_COMPARATOR|Clinical treatment|Best Medical treatment
61936493|NCT01813110|PLACEBO_COMPARATOR|Placebo|Identical olive oil capsules
61936494|NCT01813110|EXPERIMENTAL|Omega-3|4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)
61936495|NCT05843162|EXPERIMENTAL|Telmisartan|Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg
61936496|NCT05843162|ACTIVE_COMPARATOR|Losartan|Cozaar Tab.(Losartan) 50mg(100mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg
61936497|NCT03686514|EXPERIMENTAL|H3N2 birth cohort|The H3N2 cohort consists of participants born between 1968-1977.
61936498|NCT03686514|EXPERIMENTAL|H1N1 birth cohort|The H1N1 cohort consists of participants born between 1948-1957.
61936499|NCT06710184|EXPERIMENTAL|Aspirin alone|Treatment with aspirin alone. The intervention is removal of treatment with fondaparinux
61936500|NCT06710184|ACTIVE_COMPARATOR|Standard Treatment - Aspirin and Fondaparinux|Standard treatment regime with Aspirin in combination with Fondaparinux.
62488568|NCT04303208|OTHER|control group|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum .Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
62135468|NCT06409897|OTHER|Sequential head-of-bed elevation|Patients will be positioned at 0 degrees of head-of-bed elevation, and after stabilization of the plethysmogram, data from electrical impedance tomography, hemodynamics, and arterial blood gas will be collected (arterial blood will be drawn by a nurse or physician). Sequentially and in the same manner, the bed will be adjusted to 10, 20, 30, and 40 degrees (the same data will be collected, except for the arterial blood sample, which will only be collected at the 40-degree elevation). Then, an alveolar recruitment maneuver will be performed, followed by a PEEP titration with 10-degree of head-of-bed elevation, and the data will be collected just as in the 0° and 40° steps.
62331037|NCT03255291|EXPERIMENTAL|Risk Display Format:Text:Imagery Behavior:Exercise|"* With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic \& health questions. It then provides personalized risk estimates for participants' current activity level \& how it would change with regular exercise.~* Participants take Baseline Survey 1.~* Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal \& are asked to practice the mental imagery twice a day for 3 weeks.~* Participants take Baseline Survey 2.~* Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~* Participants take surveys via text at the end of each week for 4 weeks.~* 90 days post-baseline, participants complete a survey sent through the mail.~* Participants may be contacted for another survey 1 year later."
62331038|NCT03255291|EXPERIMENTAL|Risk Display Format:Text:Imagery Behavior:Sleep|"* With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic \& health questions. It then provides personalized risk estimates for participants' current activity level \& how it would change with regular exercise.~* Participants take Baseline Survey 1.~* Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal \& are asked to practice the mental imagery twice a day for 3 weeks.~* Participants take Baseline Survey 2.~* Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~* Participants take surveys via text at the end of each week for 4 weeks.~* 90 days post-baseline, participants complete a survey sent through the mail.~* Participants may be contacted for another survey 1 year later."
62488569|NCT04899934|EXPERIMENTAL|Mobile and technology assisted aftercare|participants randomized to this condition will receive up to 26 sessions with a community support specialist aftercare provider and 6 months of access to behavioral health mobile applications.
62488570|NCT04899934|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants randomized to this condition receive standard treatment services available to persons discharging from a CSU.
62135469|NCT02704416|NO_INTERVENTION|Control arm|Control arm - continued implanted cardioverter defibrillator therapy
62135470|NCT02704416|ACTIVE_COMPARATOR|Intervention Arm|ablation of areas of fragmented signal in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy
62135471|NCT02704416|OTHER|Single Cross Over Arm|these patients were initially assigned to the control arm of the study. When these patients met the primary outcome of the study it is allowed for these patients to be included in the intervention arm and/or to start quinidine
62135472|NCT00391898|EXPERIMENTAL|Levodopa/carbidopa/entacapone|
62135473|NCT00391898|ACTIVE_COMPARATOR|Levodopa/carbidopa|
62135474|NCT04144335|ACTIVE_COMPARATOR|Group 1: N-803 and bNAbs Only|Group 1 will receive only N-803 and the bNAbs; they will not receive the haNK™ cells
62135475|NCT04144335|EXPERIMENTAL|Group 2: N-803 and bNAbs with haNK™ Cells|The protocol for Group 2 will be identical to the one followed by Group 1, except that they will receive haNK™ cells on the same day as each dose of N-803.
62135476|NCT03658616|EXPERIMENTAL|WO3970|Formulation containing WO3979 for topical application
62135477|NCT03658616|PLACEBO_COMPARATOR|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
62488571|NCT02589366|EXPERIMENTAL|Lymphoseek plus Vital Blue Dye|Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
62488572|NCT02616380||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
62488573|NCT06119685|EXPERIMENTAL|Phase 1: Single Agent IDP-023 - Single Dose|NHL or MM patient treated with a single dose of IDP-023 monotherapy
62488574|NCT06119685|EXPERIMENTAL|Phase 1: Single Agent IDP-023 - Multiple Doses|NHL and MM patients treated with multiple doses of IDP-023 monotherapy
62488575|NCT06119685|EXPERIMENTAL|Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2|NHL and MM patients treated with multiple doses of IDP-023 monotherapy
62135478|NCT05297851||Cytoflavin|Patients who underwent reperfusion for acute stroke (intravenous thrombolysis and/or mechanical thrombectomy) and receive intravenous Cytoflavin® at a discretion of the physician, starting this treatment within the first 24 hours from the onset of stroke
62135479|NCT05297851||Control|Patients who underwent reperfusion for acute stroke (intravenous thrombolysis and/or mechanical thrombectomy) and do not receive Cytoflavin as part of their routine clinical practice, but may receive any other neuroprotective medications.
62135480|NCT03290859||Training intervention|Train anesthesia providers who deliver propofol sedation for GI endoscopy procedures to follow a uniform propofol monotherapy administration guideline to titrate propofol monotherapy infusion to effect according to a standardized protocol.
62135481|NCT03290859||Effectiveness of training intervention|Compare the effectiveness of training intervention and standardized titration to effect through aggregate data for metrics of recovery times.
62135482|NCT04738201|ACTIVE_COMPARATOR|Control group|Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle.
62488576|NCT06119685|EXPERIMENTAL|Phase 2: Combination IDP-023 plus rituximab|NHL patients treated with multiple doses of IDP-023 in combination with rituximab
62488577|NCT06119685|EXPERIMENTAL|Phase 2: Combination IDP-023 plus daratumumab|MM patients treated with multiple doses of IDP-023 in combination with daratumumab
62488578|NCT04646603|EXPERIMENTAL|MRG-001|Multiple SC dose of 0.0066 mL/kg MRG-001 (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
62488579|NCT04646603|PLACEBO_COMPARATOR|Placebo|Single SC dose of 0.0066 mL/kg Sterile Injectable Saline (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
62488580|NCT03555695|EXPERIMENTAL|Karate Class Participants|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD. Subjects will also complete an in-person pre-intervention focus group and post-intervention focus group, as well as a 6 month post-intervention follow up phone call.
62488581|NCT06468839|EXPERIMENTAL|Experimental|"• Experimental group will receive the addiction management model. The addiction management model consists of a combination of standard education on addiction and emotional freedom techniques.~They will receive 6 sessions of training:~Weeks 1-4: Education on adolescence, addiction, and psychological resilience Weeks 5-6: Application of emotional freedom techniques."
62488582|NCT06468839|NO_INTERVENTION|control|The control group receives only the standard education provided at the school.
62488583|NCT01632215|EXPERIMENTAL|preoperative gabapentine,|Gabapentine
62488584|NCT01632215|PLACEBO_COMPARATOR|sugar pill|Placebo group
62488585|NCT03908736|OTHER|Single-arm cohort|Baseline experimental measurements will be collected for each individual participant twice prior to zinc supplementation (0 month and 3 month time points). After zinc supplementation, experimental measurements will be collected for each individual participant at the 6 month and 9 month time points. The zinc intervention is zinc picolinate 15 mg once per day for 6 months.
62488586|NCT02970123|EXPERIMENTAL|SLIMM Intervention|Sit Less, Interact, Move More (SLIMM): instruction and monitoring feedback to promote decrease in sedentary activity duration, increase in casual walking duration, and increase in sedentary breaks
62488587|NCT02970123|NO_INTERVENTION|Standard of Care|Subjects will receive standard of care treatment for chronic kidney disease, with no instruction or feedback to alter sedentary or casual walking durations
62331039|NCT03662503||nutrition not aggressive group|"Children will be grouped according to their calorie and protein during the first week of life. The tertile 1 will represent the group of children with the lowest nutritional intake (called the nutrition not aggressive )"
62331040|NCT03662503||aggressive nutrition group|"Children will be grouped according to their calorie and protein during the first week of life. the tertile 3 will define the group of children presenting the contributions highest nutritional levels (called the aggressive nutrition group)"
62331041|NCT02912000|EXPERIMENTAL|Intervention|The intervention group will receive the TEACH intervention - an electronic tablet screening in waiting room for the modifiable risk factors
62331042|NCT02912000|NO_INTERVENTION|Control|Care as usual: No electronic tablet in waiting room
62331043|NCT00313599|EXPERIMENTAL|Lapatinib and Paclitaxel|Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.
62331044|NCT06491953||Patients receiving invasive treatment|Patients receiving PCI or CAG were enrolled to evaluate the impact of SGLT-2 inhibitors use or not use and duration of SGLT-2 inhibitors administration
62331045|NCT02668120||Cases|Patients with chronic histiocytic intervillositis during pregnancy followed at University Hospital of Lille. Alkaline phosphatase assay was performed during pregnancy and is documented in the medical record. The cases are included retrospectively.
62331046|NCT02668120||Low-risk pregnancy|Patients with a low risk pregnancy followed at University Hospital of Lille and recruited prospectively in prenatal consultation. These patients have no pathological obstetric history.
62331047|NCT02668120||High-risk pregnancy|Patients with severe pregnancy complication (IUGR, Preeclampsia or Death in Utero), but without chronic intervillositis, and hospitalized in the maternal-fetal pathology department of the University Hospital of Lille. They are recruited prospectively.
62331048|NCT00184106|ACTIVE_COMPARATOR|Cognitive Therapy|Cognitive Therapy
62331049|NCT00184106|ACTIVE_COMPARATOR|Seroxat and SE|SSRI with Self exposure
62331050|NCT00184106|ACTIVE_COMPARATOR|Seroxat and Cognitive Therapy|Combination of Seroxat and Cognitive Therapy
62331051|NCT00184106|PLACEBO_COMPARATOR|Pill-Placebo|Pill Placebo
62331052|NCT05866835|EXPERIMENTAL|Athlete|healthy, adult or minor (16 years or older), high-level sportsmen and women, volunteers
62331053|NCT03153215|ACTIVE_COMPARATOR|Intervention group|women with severe IUGR
62331054|NCT03153215|ACTIVE_COMPARATOR|Control group|women with severe IUGR
62331055|NCT04296500||Decision tree algorithm training/testing|The investigators divided data of 67 patients into 5 groups to do 5 fold cross validation. Four groups were used to train decision tree algorithm and one group was used to test it.
62331056|NCT05075096||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
62488588|NCT03102385|EXPERIMENTAL|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
62488589|NCT03102385|PLACEBO_COMPARATOR|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
62488590|NCT05691153|EXPERIMENTAL|Dose Level 1|ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）
62488591|NCT05691153|EXPERIMENTAL|Dose Level 2|ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）
62488592|NCT00757419|EXPERIMENTAL|1|
62488593|NCT00757419|PLACEBO_COMPARATOR|2|
62488594|NCT03151954|EXPERIMENTAL|nasal polyps|"1. Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.~2. Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.~3. Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;~4. Explore the regulation of hippo-YAP pathway in NESCs."
62488595|NCT03151954|PLACEBO_COMPARATOR|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
62488596|NCT01709903|EXPERIMENTAL|QVA149|QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
62488597|NCT01709903|ACTIVE_COMPARATOR|fluticasone/salmeterol|Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device
62331057|NCT05075096||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
62331058|NCT05075096||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
62331059|NCT04406246|EXPERIMENTAL|Nitazoxanide early treatment|Health workers with symptoms of COVID-19 not requiring hospitalization will receive an early treatment with nitazoxanide.
62331060|NCT03233100|EXPERIMENTAL|FMT group|
62331061|NCT01952197|EXPERIMENTAL|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
62331062|NCT01073527|ACTIVE_COMPARATOR|Hypertonic saline-salbutamol combination|NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
62331063|NCT01073527|PLACEBO_COMPARATOR|normal saline-salbutamol combination|Standard treatment normal saline 4cc with salbutamol 0.5cc
62331064|NCT01876914||DME patients|Patients suspected to have a problem with at least one eye called diabetic macular edema or DME
62331065|NCT04855123|OTHER|patient|
62488598|NCT04044573|EXPERIMENTAL|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
62488599|NCT06363617|EXPERIMENTAL|FLI test implementation|A training session will be conducted for healthcare professionals on the risks of hepatic steatosis in patients with a body mass index (BMI) equal to or greater than 25. Additionally, professionals will be instructed in the use of the Fatty Liver Index (FLI) tool, validated for assessing the risk of steatosis. This tool will be implemented in the center's computer system, making it accessible via a link for the professionals receiving the intervention.
62488600|NCT06363617|NO_INTERVENTION|control|This group of healthcare professionals will continue with their usual clinical practice.
62488601|NCT05345249|EXPERIMENTAL|ESPB with ropivacaine|Patients in the experimental group will receive locoregional analgesia via ESPB with injectate consisting of ropivacaine 0.375 mg/mL with no additives, two times 30mL bilaterally at the transverse processs of the T12-vertebra (total dose of 225 mg).
62488602|NCT05345249|PLACEBO_COMPARATOR|ESPB with placebo|Patients in the placebo group will receive an injection performed as the procedure of ESPB with injectate consisting of sodiumchloride 0.9% with no additives, two times 30mL bilaterally at the transverse processs of the T12-vertebra.
61936501|NCT03438318|EXPERIMENTAL|Part A (CMP-001, Atezolizumab and Optional Radiation Therapy)|Participants will receive CMP-001 5 milligrams (mg) SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by every 3 weeks thereafter until discontinuation of treatment in combination with atezolizumab SC every 3 weeks starting at Week 2. Route of administration (IT/SC) for CMP-001 beyond Week 5 will be determined by Investigator. Participants enrolled in Part A who progressed per RECIST v1.1 on combination of CMP-001 and atezolizumab have opportunity to enroll in Part A optional radiation therapy add-on after documented disease progression per CT/MRI or PET scan. After CMP-001 washout period of 10 days, participants will be treated with radiation consisting of 20 grays in 5 fractions for 5 days then resume CMP-001 treatment.
62331066|NCT03462446||Treatment group with Rivaroxaban|Patients treated with Rivaroxaban
62331067|NCT03462446||Control group with VKAs|Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
62331068|NCT02202031|EXPERIMENTAL|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
62331069|NCT02202031|EXPERIMENTAL|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
62331070|NCT02005848|EXPERIMENTAL|Alpha1 Antitrypsin (Glassia)|60 mg/kg body weight
62331071|NCT02005848|EXPERIMENTAL|Alpha-1 Antitrypsin (Glassia)|120 mg/kg body weight
62331072|NCT02005848|PLACEBO_COMPARATOR|Placebo|Placebo
62331073|NCT05807724|NO_INTERVENTION|Current care|Current care at the ED
62488603|NCT05541198|NO_INTERVENTION|Control Group|"Routine clinical care continued to be provided to the patients in the control group.~Routine maintenance applications include the following parameters;~1. Risk assessment using Braden Risk Scale~2. Positioning~3. Elevate the heels."
61936502|NCT03438318|EXPERIMENTAL|Part B (Radiation Therapy, CMP-001 and Atezolizumab)|Participants will be treated with radiation therapy consisting of 20 grays in 5 fractions for 5 days, then participants will receive CMP-001 5 mg SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by dosing every 3 weeks thereafter until discontinuation of treatment. The route of administration (that is, IT or SC) for CMP-001 beyond Week 5 will be determined by the Investigator. First dose of CMP-001 will be administered within 2 days of radiation therapy. Atezolizumab will be administered SC in combination with CMP-001 every 3 weeks starting at Week 2.
61936503|NCT06274307|ACTIVE_COMPARATOR|Active Comparator: Transversus abdominis plane (TAP) block performed in operating room|The treatment group will have a transversus abdominis plane (TAP) block performed prior to closing surgical port sites post-operatively in an insufflated abdomen in the operating room (OR). The local anesthetic used for the TAP block will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% divided equally bilaterally. Each study participant will receive standard post-operative pain medication orders of morphine 2mg q5mins times 4 doses followed by hydromorphone. 0.5mg q10mins times 4 doses.
62694065|NCT05939544|PLACEBO_COMPARATOR|Control (Placebo) Powdered Ingredient|Participants will be provided with pre-weighed, foil sachets containing an energy- and macronutrient-matched ready-to-mix powdered placebo supplement that is devoid of milk fat globule membrane (and associated complex milk lipids). They will be asked to consume two sachets daily (mixed with water) during the 4-week study period. Sachets will be coded to maintain study blinding.
62488604|NCT05541198|EXPERIMENTAL|Intervention Group|"A pressure injury care bundle was developed in line with the relevant literature. After the development of the bundle, a 30-minute training program was applied to the nurses on general information about pressure injuries, the pressure injury care bundle, and how to use the bundle. The training program was carried out in four separate sessions arranged according to the working schedules of 40 nurses providing services in ICU.~Care Bundle include this parameters;~1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management"
62694066|NCT06610903|EXPERIMENTAL|Healthy subject group 1|15mg/tablet，one tablet each time. Participants will receive a single dose of Hemay005 tablet in Day1and Day8
61936504|NCT06274307|ACTIVE_COMPARATOR|Transversus abdominis plane (TAP) block performed in PACU|The treatment group will have a transversus abdominis plane (TAP) block performed post-operatively after the patient has been transferred from the Operating Room to the Post Anesthesia Care Unit (PACU). The local anesthetic used for the TAP block will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% divided equally bilaterally. Each study participant will receive standard post-operative pain medication orders of morphine 2mg q5mins times 4 doses followed by hydromorphone. 0.5mg q10mins times 4 doses
61936505|NCT01914731|EXPERIMENTAL|Capsule|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule"
61936506|NCT02378727|ACTIVE_COMPARATOR|A Standard Care Group (SCG)|Standard Care Conventional Group (SCG): 158 subjects to receive lumbar epidural procedure with the loss of resistance syringe used to identify the epidural space
61936507|NCT02378727|EXPERIMENTAL|Experimental Procedure Group (EPG).|158 of subjects to receive lumbar epidural procedure with the CompuFlo® Epidural System used to identify the epidural space
61936508|NCT04177927|EXPERIMENTAL|endtidalcarbondioxide monitoring group|The patients performed gastrointestinal endoscopy will be monitored with Capnostream 20p / Coviden for etCO2 (End tidal CO2), RR (Respitarory rate), SpO2 and PR (heart rate).
61936509|NCT04177927|ACTIVE_COMPARATOR|Control Group|Rutine monitorization will be performed to control group of patients.
61936510|NCT06704386||Patients with amputations|Patients with amputation who are over 18 years of age, have sufficient Turkish reading and comprehension skills, and have experienced at least one year since the amputation, excluding those with congenital amputations or chronic pain.
61936511|NCT06704386||Patients with Chronic Pain|Patients with chronic pain who are over 18 years of age, have experienced pain for more than 3 months, and possess sufficient Turkish reading and comprehension skills.
61936512|NCT06039410|EXPERIMENTAL|Treatment|ISO-101 Device
61936513|NCT03828409|ACTIVE_COMPARATOR|Short stitch|short stitch used as one arm
61936514|NCT03828409|ACTIVE_COMPARATOR|Long stitch|Long stitch as conventional mass-closure technique
61936515|NCT04801173|EXPERIMENTAL|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
61936516|NCT04801173|ACTIVE_COMPARATOR|Low calorie diet|Control treatment with a low calorie standard diet
62135483|NCT04738201|EXPERIMENTAL|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
62694067|NCT06610903|EXPERIMENTAL|Healthy subject group 2|15mg/tablet，one tablet each time. Participants will receive a single dose of Hemay005 tablet in Day1and Day8
62694068|NCT04962113|EXPERIMENTAL|Tunnel group Tube bath during the phototherapy|
62694069|NCT04962113|NO_INTERVENTION|Tunnel group rutin care|
62694070|NCT04962113|EXPERIMENTAL|LED group Tube bath during the phototherapy|
61936517|NCT02160782|EXPERIMENTAL|LUM001 (Maralixibat)|"LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid \[sBA\] level and ItchRO\[Obs\] score) and safety assessment.~Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat."
61936518|NCT02160782|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
61936519|NCT04192370|EXPERIMENTAL|Cannabidiol|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.
62135484|NCT06404723||Healthy Control Group|: this group contains 50 healthy individual
62135485|NCT06404723||Lupus Simplex (mild to moderate disease) activity Group|this group contains 50 patients with a systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score less than 15.
62694071|NCT04962113|NO_INTERVENTION|LED group rutine care|
62694072|NCT02095457|ACTIVE_COMPARATOR|Frequent Monitoring and Feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
62488605|NCT02589093|EXPERIMENTAL|Stimulation|Subjects will receive progressive electrical stimulations with an external nerve stimulator over the ulnar nerve, from 0 mA to 30 mA in increments of 5 (2 Hz single twitch mode), for 3 minutes at each intensity. They will be asked to score their pain level (NRS 0-10) every minute. ANI will be recorded constantly.
62331074|NCT05807724|EXPERIMENTAL|Phone-based fall-prevention strategy|"The phone-based fall-prevention strategy is based on the CDC's Stopping Elderly Accidents Deaths \& Injuries (STEADI) program (https://www.cdc.gov/steadi/index.html). The STEADI Algorithm will be the template for both fall-prevention strategies utilized in this study. In addition, the CDC Check For Safety-A Home Prevention Checklist for Older Adults pamphlet will be used.~At the time of study enrollment, the STEADI program written material will be provided and components of it will be discussed with the study subjects and caregivers, if present.~The phone-based strategy will provide the patient and caregiver easy to read materials before ED discharge and a structured phone call around 14 days post ED discharge."
62488606|NCT01370863|EXPERIMENTAL|SPD557|
62488607|NCT01370863|PLACEBO_COMPARATOR|Placebo|
62694073|NCT02095457|SHAM_COMPARATOR|Infrequent monitoring without feedback|In the control arm, patients will infrequently fill short monitoring questionnaires, the results of which are not fed back to their therapists and staff. The frequency of monitoring is between about once a year
62694074|NCT02386072||1. patients diagnosed with OAB taking mirabegron|patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
61936520|NCT05392517|EXPERIMENTAL|Group A|self-mobilization technique
61936521|NCT05392517|OTHER|Group B|: conventional treatment
61936522|NCT03057379|NO_INTERVENTION|Control arm|Usual source of care
61936523|NCT03057379|EXPERIMENTAL|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
61936524|NCT03057379|EXPERIMENTAL|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
61936525|NCT03057379|EXPERIMENTAL|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
61936526|NCT00351988||African American caregivers|African American caregivers for patients with advanced non-small cell lung cancer or breast cancer.
61936527|NCT00351988||Latino caregivers|Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
61936528|NCT00351988||White non-Latino caregivers|White non-Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
61936529|NCT04112888|EXPERIMENTAL|Collagen group|"Patients will receive 3 to 5 infiltrations of collagen on the scar once a week.~Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes."
61936530|NCT04112888|ACTIVE_COMPARATOR|Control group|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes.
61936531|NCT02620007|EXPERIMENTAL|Experimental arm|oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks
61936532|NCT02620007|PLACEBO_COMPARATOR|Control arm|a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks
61936533|NCT06191523|PLACEBO_COMPARATOR|Control Group|The control group will receive standard therapy and placebo.
61936534|NCT06191523|EXPERIMENTAL|Treatment Group|The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
62488608|NCT01539564|EXPERIMENTAL|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
62488609|NCT01539564|NO_INTERVENTION|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
62694075|NCT02386072||2. patients diagnosed with OAB taking an antimuscarinic|patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
62694076|NCT05442879|EXPERIMENTAL|Knowledge Translation Intervention|The group participating in the KT intervention program will participate in focus groups, individual meetings, and receive videos, informational handouts and on-field training from the researchers. The researchers and participants will work together to determine barriers and facilitators towards implementation of an ACL-IPP, and create an ACL-IPP that follows established clinical practice guidelines and is individualized to the local contextual needs.
62694077|NCT05442879|ACTIVE_COMPARATOR|Educational Handout|The coaches will receive an educational handout describing an ACL-IPP.
62694078|NCT04701710|EXPERIMENTAL|Experimental Group|"The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.~Standard biosecurity care"
62694079|NCT04701710|NO_INTERVENTION|Control Group|Standard biosecurity care
61936535|NCT02385370|ACTIVE_COMPARATOR|using standard method of applying MMC|applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes
61936536|NCT02385370|ACTIVE_COMPARATOR|intratendon injection of MMC|intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure
61936537|NCT00572923||1|"Inclusion criteria~* Histological or cytological proven SCLC~* UICC stage I-III, limited disease~* Performance status 0-2~* FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~* Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)~* stage IV~* performance status 3 or more~* FeV 1 or DLCO\< 30% of the age-predicted value"
61936538|NCT06557252||not received PDCA training|no intervention
61936539|NCT06557252||PDCA training|The group of endoscopists underwent PDCA training to observe whether it ultimately improved the diagnosis rate of autoimmune gastritis.
61936540|NCT06384690|EXPERIMENTAL|Micro-vegetable blend|
61936541|NCT06384690|PLACEBO_COMPARATOR|Placebo|
61936542|NCT00521612|EXPERIMENTAL|A|Sevoflurane group, experimental group
61936543|NCT00521612|ACTIVE_COMPARATOR|B|Isoflurane group, control group
61936544|NCT06313827|ACTIVE_COMPARATOR|Control exercise group (CG-1)|Participants will receive their usual physiotherapy treatment.
62488610|NCT04193150||Reassessment Cohort|"150 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.~Intervention includes:~1. Extensive pulmonary and allergy assessments. Questionnaires, FeNO-measurement, Skin prick-test, Spirometry, Blood sampling, Body Plethysmography and Diffusion capacity measurement, Bronchial challenge test, Induced sputum.~2. Treatment optimization As per GINA and Nordic Severe Asthma Network guidelines. Treatment can either be stepped up (e.g. added biological treatment), stepped down or held constant.~Treatment is then monitored with regard to symptoms and socioeconomical parameteres such as sick leave over a 12 month period using questionnaires and official databases."
62488611|NCT04193150||Control Cohort|"400 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.~The control cohort is followed for 12 months using questionnaires and official databases with regard to disease control and socioeconomic parameteres such as sick leave."
62488612|NCT06628037|EXPERIMENTAL|1st cohort|Testing 0.10% SN514-066b gel
62488613|NCT06628037|EXPERIMENTAL|2nd cohort|Testing 0.20% gel
62488614|NCT06628037|EXPERIMENTAL|3rd cohort|Testing 0.40% gel
62488615|NCT06628037|EXPERIMENTAL|4th cohort|Testing 0.80% gel
62488616|NCT03330990|OTHER|Entrectinib / Midazolam|
62488617|NCT03987295|EXPERIMENTAL|Granulin|IV administration of AL001; 60 mg/kg, every 4 weeks \[q4w\]
62488618|NCT03987295|EXPERIMENTAL|C9orf72|IV administration of AL001; 60 mg/kg, every 4 weeks \[q4w\]
62488619|NCT04130464|EXPERIMENTAL|Ropivacaine|Subjects will receive a continuous intraperitoneal infusion of ropivacaine
62488620|NCT04130464|EXPERIMENTAL|Ropivacaine + Ketorolac|Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac
62488621|NCT04130464|PLACEBO_COMPARATOR|Normal Saline|Subjects will receive a continuous intraperitoneal infusion of normal saline
62488622|NCT01394094|EXPERIMENTAL|Gum Chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
62488623|NCT01394094|NO_INTERVENTION|Conventional|Conventional postoperative feeding schedule
62488624|NCT02557464|EXPERIMENTAL|Alzheimer's disease group|24 patients with an Alzheimer's disease or related disorders
62694080|NCT03314584|EXPERIMENTAL|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
61936545|NCT06313827|EXPERIMENTAL|Exercise plus monitoring group (TG-2)|Participants will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment.
61936546|NCT06313827|EXPERIMENTAL|Exercise plus monitoring and follow-up group (TGF-3)|Participants will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment, plus telematic control (via 1:1 real-time videoconferencing) of exacerbations with feedback from the physiotherapist.
61936547|NCT06680986||Hypertensive patients|Patients having undergone a blood pressure assessment during hospitalization in the Fédération de Cardiologie at Hôpital de la Croix Rousse and Hôpital Lyon Sud from January 2018 to December 2021
61936548|NCT05621551|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg
62331075|NCT05807724|EXPERIMENTAL|Home-visit fall prevention strategy|The specific components of the home-visit fall prevention strategy are similar to the Phone-Based Fall-Prevention Strategy. The essential difference is the in-person visit by the research associate to discuss and reinforce the fall-prevention strategy.
62331076|NCT01429103||Early Perimenopause|Early perimenopause is defined as the presence of irregular periods (cycle length differs by 7 days from usual).
62331077|NCT01429103||Late Perimenopause|Late perimenopause is defined as at least 2 skipped periods over the past 12 months (cycle double usual length) and one period of amenorrhea (over 60 days without a period), with at least one menstrual cycle over the past 12 months.
62488625|NCT02557464|ACTIVE_COMPARATOR|control group|24 age matched controls participants
62488626|NCT05480423|EXPERIMENTAL|Online mindfulness-based intervention|The online programme lasts for 28 days. Parents will receive the links of daily mini-lectures that introduced basic principles in mindfulness and mindful parenting, audio files of guided mindfulness practice, and exercises that facilitates parents to integrate mindfulness in their daily lives. The total time spent in each session will be around 15 to 20 minutes. Weekly meeting will be arranged with mindfulness instructor and participants.
62488627|NCT05480423|NO_INTERVENTION|Waitlist controlled group|Participants will be offered same intervention three months later
62488628|NCT04124354|EXPERIMENTAL|Immediate Experimental Group|Participants will immediately begin an experimental supervised moderate-intensity treadmill walking intervention program.
62488629|NCT04124354|NO_INTERVENTION|Delayed Intervention Control Group|Participants will be asked to maintain their usual physical activity during the initial 8-week intervention period but will undergo all data collection procedures. Following the initial intervention period, these participants will be given the option to complete the 8-week intervention, with identical data collection procedures employed.
62488630|NCT03562182||Women Receiving Antenatal Steroids|Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.
62488631|NCT03562182||Normal Pregnancy Controls|1) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.
62488632|NCT00845637|ACTIVE_COMPARATOR|Eggplant extract|
62488633|NCT00845637|PLACEBO_COMPARATOR|Placebo|
62488634|NCT02997176|EXPERIMENTAL|Group A (control, normal hepatic function)|
62488635|NCT02997176|EXPERIMENTAL|Group B (mild hepatic dysfunction)|
62488636|NCT02997176|EXPERIMENTAL|Group C (moderate hepatic dysfunction)|
62488637|NCT02997176|EXPERIMENTAL|Group D (severe hepatic dysfunction)|
62488638|NCT01131260|EXPERIMENTAL|Open Group|• Fetal STAN monitor electrode inserted and data available to caregivers
61936549|NCT05621551|NO_INTERVENTION|Standard of care|Standard care treatment of diabetes patients during perioperative cardiac surgery in our center
61936550|NCT00857428|EXPERIMENTAL|1|Oxymorphone ER 40 mg tablets Sandoz
61936551|NCT00857428|ACTIVE_COMPARATOR|2|Opana ER 40 mg tablets Eon Pharmaceuticals
62488639|NCT01131260|OTHER|Masked Group|•Fetal STAN monitor electrode inserted, but data masked to the caregivers
62488640|NCT04431518|EXPERIMENTAL|Hemodialysis Group|Receipt of JULUCA one pill per day up to 14 days
62488641|NCT04431518|ACTIVE_COMPARATOR|Normal Renal Function Group|Receipt of JULUCA one pill per day up to 14 days
61936552|NCT04504279|EXPERIMENTAL|FB-401|FB-401 applied topically for 16 weeks.
61936553|NCT04504279|PLACEBO_COMPARATOR|Placebo|Placebo applied topically for 16 weeks.
61936554|NCT02386306|EXPERIMENTAL|Treatment Cohort 1|Each study participant will be administered with one 1mg dose capsule per day of GC021109 for 28 days.
61936555|NCT02386306|PLACEBO_COMPARATOR|Placebo Cohort 1|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
62488642|NCT01239303|ACTIVE_COMPARATOR|citrulline|
61936556|NCT02386306|EXPERIMENTAL|Treatment Cohort 2|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 1 safety data through day 14
61936557|NCT02386306|PLACEBO_COMPARATOR|Placebo Cohort 2|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
61936558|NCT02386306|EXPERIMENTAL|Treatment Cohort 3|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 2 safety data through day 14
61936559|NCT02386306|PLACEBO_COMPARATOR|Placebo Cohort 3|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
61936560|NCT02589379||Pancreatic Resection|All consecutive patients undergoing pancreatic resection for benign or malignant disease and meet inclusion criteria.
61936561|NCT05441761|EXPERIMENTAL|liposomal mitoxantrone hydrochloride|Patients with recurrent and refractory peripheral T-cell lymphoma will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with gemcitabine, dexamethasone, and cisplatin for 6 cycles (planned) (21 days per cycle).
61936562|NCT00498524||1|Sib who has received an ICD
62488643|NCT01239303|PLACEBO_COMPARATOR|alanine|
62488644|NCT03522532|EXPERIMENTAL|Amalgam (Amg)|Amalgam was sealed in 8-K2 patients and 6-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
62488645|NCT03522532|EXPERIMENTAL|Tetric EvoCeram (TEC)|Tetric EvoCeram was sealed in 12-K2 patients and 5-K5 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
62488646|NCT03522532|EXPERIMENTAL|Beautifil (BF)|Beautifil was sealed in 15-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
62488647|NCT03522532|EXPERIMENTAL|Zinc phosphate cement (ZPhC)|"Zinc phosphate cement was sealed in 7-K2 patients, 4-K3 patients, 1-K4 patients and 2-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
62694081|NCT03314584|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex.
61936563|NCT00498524||2|Sib who has not received an ICD
61936564|NCT01356927||DMPA|DMPA given at the time of mifepristone for medical abortion
61936565|NCT01356927||Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone for medical abortion
62488648|NCT03522532|EXPERIMENTAL|Zinc polycarboxylate cement (ZPoC)|"Zinc polycarboxylate cement was sealed in 5-K2 patients, 4-K3 patients and 5-K4 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
62488649|NCT03522532|EXPERIMENTAL|Glass ionomer cement (GIC)|"Glass ionomer cement was sealed in 11-K2 patients, 2-K3 patients and 1-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
62488650|NCT01354470|EXPERIMENTAL|Modafinil|
62488651|NCT01354470|PLACEBO_COMPARATOR|placebo (cornstarch)|
61936566|NCT04877743||Prospective Cohort|This prospective cohort study will include participants who receive the AZD1222 vaccine. Enrolment is permitted within 28 days of the first dose of AZD1222 and can be completed at the vaccination site or remotely.
61936567|NCT01859143|EXPERIMENTAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
61936568|NCT01859143|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
62135486|NCT06404723||Severe disease activity Group|this group contains 50 patients with a systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score ≥ 15.
62135487|NCT01951170|EXPERIMENTAL|Tocilizumab|Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.
62488652|NCT03482180|EXPERIMENTAL|Investigational Group- KI1106|KI1106 tablet - daily administration
62488653|NCT03482180|ACTIVE_COMPARATOR|Control Group - Atorvastatin|Atorvastatin Calcium 20mg - daily administration
62488654|NCT06013150|EXPERIMENTAL|Epinephrine|"Dosage Level:~Part 1 of the study: Participants across cohort 1 to 3 will receive a single dose of either 1mg or 1.3mg or 1.5mg respectively of epinephrine or placebo via DMC-IHI device.~Dosage form: Single-use capsule based dry powder inhaler~Route of administration: Inhalation"
62488655|NCT06013150|PLACEBO_COMPARATOR|Placebo|"Drug: Placebo~Participants will receive matching placebo across the study."
62488656|NCT06339658||ICG|ICG tracer
62488657|NCT06339658||Blue patent|Blue patent tracer
62488658|NCT05836311||Patients treated with one Perclose Proglide|Patients undergoing transfemoral TAVI implantation treated with one Perclose Proglide Suture
62488659|NCT05836311||Patients treated with two Perclose Proglide Suture|Patients undergoing transfemoral TAVI implantation treated with two Perclose Proglide Suture
62488660|NCT01370122||Subjects exposed to radiation|
62488661|NCT01370122||Subjects not exposed to radiation|
62488662|NCT02509143|EXPERIMENTAL|High-dose acupuncture with intravenous infusion of ramosetron|Three sessions of acupuncture on the points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4), Pericardium 6 (PC6), Heart 8 (HT8), and Gall Bladder 41 (GB41) within 48 hours after surgery
62488663|NCT02509143|ACTIVE_COMPARATOR|P6 stimulation with intravenous infusion of ramosetron|P6 stimulation by wearing a study wristband within 48 hours after surgery
62488664|NCT02509143|ACTIVE_COMPARATOR|Intravenous infusion of ramosetron|A mixture of standard antiemetic medication (5-Hydroxytryptophan receptor antagonist; ramosetron hydrochloride 0.3 mg) and analgesics, including anon-steroidal anti-inflammatory drug (NSAID) (ketorolac tromethamine 120 mg), and a semi-synthesized opioid (oxycodone 20 mg), will be infused by intravenous patient-controlled analgesia (1ml bolus/20 min lockout, 1ml/hr continuous infusion).
62488665|NCT01798628|EXPERIMENTAL|Sequence ABC|
62488666|NCT01798628|EXPERIMENTAL|Sequence ACB|
62488667|NCT01798628|EXPERIMENTAL|Sequence BAC|
62488668|NCT01798628|EXPERIMENTAL|Sequence BCA|
62135488|NCT03167944|EXPERIMENTAL|Conventional electrocautery|
62488669|NCT01798628|EXPERIMENTAL|Sequence CAB|
62488670|NCT01798628|EXPERIMENTAL|Sequence CBA|
62488671|NCT02638428|EXPERIMENTAL|Refractory/relapsed solid tumor or AML|Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™
62488672|NCT03993145|EXPERIMENTAL|Web-based lifestyle intervention|participants will be provided access to web-based lifestyle intervention program with personalized coaching from a clinical dietician
62488673|NCT02093728|EXPERIMENTAL|selumetinib; itraconazole; selumetinib + itraconazole|Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule
62488674|NCT02093728|EXPERIMENTAL|selumetinib; fluconazole; selumetinib + fluconazole|Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg.
62488675|NCT00841022|EXPERIMENTAL|1|Information of children with comic leaflet
62488676|NCT00841022|NO_INTERVENTION|2|
62488677|NCT01871714||XLHED affected Males|All males ages 4 and up affected by XLHED
62488678|NCT01871714||Females affected by XLHED|Adult females (ages 18-45) affected by XLHED
62488679|NCT01871714||Unaffected females|Unaffected adult female controls (ages 18-45)
62488680|NCT05561088|EXPERIMENTAL|experimental group|Mechanical thrombectomy was followed by acupuncture and guideline-based conventional treatment
62488681|NCT05561088|EXPERIMENTAL|control group|Conventional treatment based on guidelines was administered after mechanical thrombectomy
62488682|NCT04615117||Study Group|Patients treated with Superior Capsular Reconstruction with Allomend
62488683|NCT01513239|EXPERIMENTAL|MK-6072 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI
62135489|NCT03167944|EXPERIMENTAL|Low thermal electrosurgery system|
62488684|NCT01513239|EXPERIMENTAL|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI
62488685|NCT01513239|PLACEBO_COMPARATOR|Placebo + SOC|Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI
62488686|NCT01640041|EXPERIMENTAL|Implanted|All participants.
62488687|NCT01406080|ACTIVE_COMPARATOR|Adapalene|Differin® gel 0.3% (adapalene Gel 0,3%)
62488688|NCT01406080|ACTIVE_COMPARATOR|Tretinoin|Tretinoin 0,05% emollient cream
62135490|NCT03966898|EXPERIMENTAL|SHR6390, Letrozole or Anastrozole|SHR6390, Letrozole or Anastrozole
62135491|NCT03966898|PLACEBO_COMPARATOR|Placebo, Letrozole or Anastrozole|Placebo, Letrozole or Anastrozole
62135492|NCT01627561|EXPERIMENTAL|Cervarix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received two doses of Cervarix vaccine at Day 0 and Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
62135493|NCT01627561|ACTIVE_COMPARATOR|Priorix + Infanrix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received one dose of Priorix vaccine at Day 0 and one dose of Infanrix vaccine at Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
62135494|NCT01429324||Cardiac disease|Aortic arch surgery
62135495|NCT05729997|EXPERIMENTAL|Intervention group|The intervention group listened for 4 weeks to live classical music during HD sessions lasting 30 to 40 minutes each.
62488689|NCT05114512|EXPERIMENTAL|RAPTOR Physical Therapy Intervention|RAPTOR intervention: hybrid in-person + telehealth physical therapy care for rural-dwelling individuals with knee osteoarthritis
62488690|NCT03422380||Weight Loss Maintainers (WLM)|Individuals maintaining ≥13.6 kg (30 lb) weight loss for ≥1 year
62488691|NCT03422380||Normal Weight Controls (NC)|Individuals with normal weight whose BMI was matched to the current BMI of the WLM. NC had to be weight stable and not maintaining a weight loss of ≥13.6kg
62135496|NCT05729997|NO_INTERVENTION|Control group|the control group carried out the usual treatment
62488692|NCT03422380||Controls with Overweight/Obesity (OC)|Individuals with overweight/obesity whose BMI was matched to the pre-weight loss maximum BMI of WLM. OC had to be weight stable and not maintaining a weight loss of ≥13.6kg
62488693|NCT05372250|EXPERIMENTAL|Order of body positions for ultrasound measurements : supine position, 45°, sitting, standing|
62488694|NCT05372250|EXPERIMENTAL|Order of body positions for ultrasound measurements : 45°, sitting, standing, supine position.|
62488695|NCT05372250|EXPERIMENTAL|Order of body positions for ultrasound measurements : sitting, standing, supine, 45°.|
62488696|NCT05372250|EXPERIMENTAL|Order of body positions for ultrasound measurements : standing, supine, 45°, seated.|
62488697|NCT04911218|EXPERIMENTAL|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for diagnostic angiography through the distal radial artery (anatomical snuffbox).
62488698|NCT04911218|ACTIVE_COMPARATOR|Conventional 5Fr arterial sheath|Placement of Conventional 5Fr arterial sheath arterial sheath for diagnostic angiography through the distal radial artery (anatomical snuffbox).
61936569|NCT02022631|EXPERIMENTAL|Alternative SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
61936570|NCT02022631|ACTIVE_COMPARATOR|Current SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
61936571|NCT04571008|PLACEBO_COMPARATOR|Placebo|At least 16 weeks of placebo.
61936572|NCT04571008|EXPERIMENTAL|NMN supplementation|At least 16 weeks of NMN.
61936573|NCT00003800|NO_INTERVENTION|Laboratory/CT evaluation|Observation following orchiectomy
61936574|NCT03225599|EXPERIMENTAL|Procedure|
61936575|NCT05454306|EXPERIMENTAL|Anser Clavicle Pin|Patients treated with Anser Clavicle Pin in the setting of a displaced midshaft clavicle fracture
61936576|NCT03347188|EXPERIMENTAL|Fremanezumab|Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters \[mL\] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
62488699|NCT06287216|EXPERIMENTAL|Mental Hygiene Group|This is the group participating in the mental hygiene challenge that is willing to give informed consent and conduct pre-post as well as daily well-being surveys.
62694082|NCT05289544|EXPERIMENTAL|Phone-Based Walk With Ease Program|Telephone-based Walk With Ease Program adapted from the Arthritis Foundations program
62694083|NCT05289544|OTHER|Delayed Phone-Based Walk With Ease Program|Telephone-Based Walk With Ease Program starting after the 1 year assessment
62694084|NCT00745355||1|new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion
62694085|NCT06645405|NO_INTERVENTION|Control|No AI reconstruction
62694086|NCT06645405|EXPERIMENTAL|AI software|An AI approach will be used for automated segmentation and reconstruction of CTA for intracranial LVO. Physicians begin to receive reconstructions and have the authority to view AI-activated images. Diagnosis and treatment decisions will be based on the clinical evaluation and review of the images by the treating physician, as per routine standard of care.
62694087|NCT02998320|EXPERIMENTAL|Genvoya|Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days
62694088|NCT03368144|EXPERIMENTAL|ClearLumen II Peripheral Thrombectomy System|Patients treated with the ClearLumen II Peripheral Thrombectomy System
62694089|NCT05208437|EXPERIMENTAL|Complete oral feeding intervention group|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale. Feeding of premature infants using different interventions based on the results of the Feeding Preparation Scale.
62694090|NCT05208437|ACTIVE_COMPARATOR|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding. Routine nursing care is identical to the control group.
61936577|NCT03347188|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
61936578|NCT02219347|OTHER|DMARD cessation|All patients recruited to the study who have a Disease Activity in 28 Joints C-Reactive Protein (DAS28-CRP) score of \< 2.4 and who do not have power Doppler synovitis on a 7-joint musculoskeletal ultrasound scan will stop their DMARD therapy. These patients will then be followed-up for a period of 6 months or until flare of their arthritis activity, whichever is sooner.
61936579|NCT05739630|EXPERIMENTAL|M+PTCy group|For the M-PTCy group, Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
62488700|NCT06287216|ACTIVE_COMPARATOR|Self-Care Group|Similar to the above, instead of recommending mental hygiene, we will be recommending daily self-care, and offer standard government issued resources, as well as resources from other reputable organizations.
62488701|NCT05282693|EXPERIMENTAL|ReMag|Liquid Lemon flavor drink containing 300 mg magnesium chloride (Regmag) consumed twice daily for 9 days
62694091|NCT04280783|EXPERIMENTAL|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
62694092|NCT04280783|OTHER|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
62694093|NCT05313373|EXPERIMENTAL|Virtual Reality Group|
62694094|NCT05313373|NO_INTERVENTION|Control Group|
62694095|NCT06352073|OTHER|Open Label dupilumab|Open label dupilumab 300mg injection given subcutaneously weekly, for 52 weeks.
62694096|NCT06639269|NO_INTERVENTION|control group|"All those who remain will be asked to fill out the Introductory Information Form, Fertility Health Information Scale and Healthy Life Awareness Scale during the pre-test phase.~6 weeks after the pre-test, the authorized person in the control groups will be contacted and expected to complete the Fertility Health Information Scale and Healthy Life Awareness Scale.~The control group will not receive training."
62694097|NCT06639269|EXPERIMENTAL|educational program intervention group|"The Fertility Health Education Program, which will be created in line with literature information, will be applied to the intervention group. Participants selected for the intervention group will be divided into groups of 10-15 people. Participants in each group will be informed about the date, time and location of the education program through methods suitable for the student; e-mail, phone or message. The education program will consist of 3 sessions. Education sessions will be planned on days and times when the researcher, classrooms and students are available. For students who cannot attend group education, make-up education will be provided within a week. In this study, the interval between sessions will be planned as 1 week. Group education will be planned according to the times when the students are available. PowerPoint presentation, models, booklets and brochures will be used in the education sessions."
62694098|NCT06258382||Male with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
61936580|NCT05739630|ACTIVE_COMPARATOR|BuCy group|For the BUCY group, the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
61936581|NCT02161029|ACTIVE_COMPARATOR|New drill biopsy instrument|To take biopsies from gastric submucosal tumors with a new drill biopsy instrument used with flexible endoscopes.
61936582|NCT02161029|ACTIVE_COMPARATOR|Conventional biopsy instrument|To take biopsies from gastric submucosal tumors with conventional biopsy forceps used with flexible endoscopes
61936583|NCT05064904|ACTIVE_COMPARATOR|never received RAAS blockers or multidiscipline consultation before AKI.|The enrollees assigned to the control group should not receive RAAS blockers or AKD consultation at least in 180 days after index discharge. In addition, these multidiscipline consultation and administration of RAAS blockers are continuing, and results regarding them remain masked. All patients provided written informed consent.
61936584|NCT05064904|ACTIVE_COMPARATOR|had received RAAS blockers and multidiscipline consultation before AKI.|"All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.~Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D)."
61936585|NCT01998139||Test Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.
62694099|NCT06258382||Female with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
62694100|NCT06258382||Partner to male with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
61936586|NCT01998139||Validation Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .
62135497|NCT00176800|EXPERIMENTAL|1|Paclitaxel is administered intravenously over 1 hour on Days 1, 8, 15, and 22. Cisplatin will then be administered intravenously over 1 hour on Days 1 and 22. Radiation treatments will be given twice/day, on Days 1-5, 8-12 and 15-19. The subject's esophagus will be surgically removed on approximately Day #50. Approximately 4-6 weeks after surgery, the subject will start taking Tetrathiomolybdate, for 2 years or until treatment is no longer working to control your cancer. The subject will have blood drawn weekly while he/she is receiving chemotherapy and radiation prior to their surgery. 4-6 weeks after their surgery (when the subject starts taking Tetrathiomolybdate), a blood test will be performed every other week for 2 times, and monthly thereafter. When the level of copper has been lowered sufficiently an additional blood test and a baseline chest x-ray will be obtained. Additional blood will be drawn and tested every 6 months for the first 2 years.
62135498|NCT06275477|EXPERIMENTAL|Ga68-FAPI46 TEP scan|In addition to the usual routine care, the study adds the performance of a \[68Ga\] Ga-FAPI PET/CT scan
62135499|NCT03784170|EXPERIMENTAL|Treatment|FemPulse System at one device setting
62331078|NCT06271200|EXPERIMENTAL|Intensive lifestyle intervention|"Participants assigned to the Intensive lifestyle intervention (ILI) group will be instructed intensive lifestyle intervention, including: (1) reduce calories intake and eat as 168 pattern, namely, eating foods for 8 hours while fast for 16 hours at daily basis, and plus (2) walking more than 10,000 steps per day. While participants in the ULI group will be instructed to keep habitual meal timing. Those participants of ILI will be instructed to follow a diet restriction of reduction of 500 kcal per day (40-55% of energy as carbohydrate, 15-20% as protein, 20-30% as fat) Those participants of ILI will be instructed to follow a diet restriction of reduction of 500 kcal per day (40-55% of energy as carbohydrate, 15-20% as protein, 20-30% as fat)."
62331079|NCT06271200|NO_INTERVENTION|Usual lifestyle intervention|Usual lifestyle
62488702|NCT05282693|PLACEBO_COMPARATOR|ReMag Placebo|Liquid Lemon flavor drink placebo comparator consumed twice daily for 9 days.
62488703|NCT06557603|EXPERIMENTAL|Ivermectin cream|Ivermectin 1% cream
62488704|NCT06557603|ACTIVE_COMPARATOR|Soolantra (Ivermectin) cream|Soolantra (Ivermectin) 10 mg/g cream
62694101|NCT06258382||Partner to female with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
62488705|NCT00870129|EXPERIMENTAL|MRI|The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
62488706|NCT01032590|EXPERIMENTAL|Arm I|Arm I (12-week Internet-based weight-loss intervention): After a baseline evaluation, subjects will start a 12 week Internet-based weight-loss intervention.
62488707|NCT01032590|ACTIVE_COMPARATOR|Arm II|Arm II (wait-list control): Patients are instructed to continue their usual dietary and physical activity routines during a 12-week wait period. After the waiting period, patients receive the Internet-based weight-loss intervention for 12 weeks as in arm I.
62488708|NCT03699930|ACTIVE_COMPARATOR|tDCS + speech therapy|Participants will receive 20 minutes of anodal tDCS paired with speech and language therapy over five consecutive days.
62488709|NCT03699930|SHAM_COMPARATOR|sham + speech therapy|Participants will receive 20 minutes of sham tDCS paired with speech and language therapy over five consecutive days.
62488710|NCT04651036|EXPERIMENTAL|Pegfilgrastim biosimilar product|QL0605 subcutaneously at a dose of 6 mg/0.6 mL.
62488711|NCT04651036|ACTIVE_COMPARATOR|US Neulasta|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
62488712|NCT05778630|OTHER|Group A. Focus group|Individuals will participate in one or several, semi-structured focus group meetings.
62488713|NCT05778630|OTHER|Group B. Individual|Individuals will participate in a semi-structured qualitative interview.
62488714|NCT06520904|EXPERIMENTAL|PCSK9 inhibitor group|PCSK9 Inhibitors Combined with Moderate-Intensity Statin Therapy
62694102|NCT06258382||Male control group|Different data will be collected along with several questionnaires concerning reproductive health . Approximate 100 individuals will be included
61936587|NCT05091671|ACTIVE_COMPARATOR|Free From Pain Exercise Programme Variation 1|"Participants will have the initial online consultation and will be provided with the exercise booklet and the 12 information/metaphor leaflets. The ongoing 12 Zoom online sessions are not included in this option. Instead, participants will be asked to independently engage in the exercises within the exercise booklet. They will be advised to either do all 3 sets of exercises 3 times a week or to do the neck and low back exercises twice a week and the Otago exercises 3 times a week. The exercises should take around an hour to complete each day. The ideal plan would be as follows:~Monday - Otago exercises. Tuesday - Neck and Back exercises. Wednesday - Otago exercises. Thursday - Rest day. Friday - Neck and Back exercises. Saturday - Otago exercises. Sunday - Rest day."
62488715|NCT06520904|OTHER|Intensive statin group|Intensive statin therapy
62488716|NCT03905967|EXPERIMENTAL|Lenvatinib + TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib.
62488717|NCT03905967|ACTIVE_COMPARATOR|Lenvatinib|Lenvatinib alone
61936588|NCT05091671|EXPERIMENTAL|Free From Pain Exercise Programme Variation 2|Participants will have the initial online consultation and will be provided with the exercise booklet and12 information/metaphor leaflets. This variation also includes the online zoom sessions. The online zoom session will involve a short presentation and a group discussion for 15 minutes followed by a 45-minute exercise class which will be delivered by a suitably trained individual. The exercise class will include the exercises from the Otago Exercise programme + the Motor Control Exercises for low back pain + Isometric and strengthening exercise for the neck. Participants assigned to this intervention will also be asked to independently engage in the exercises within the exercise booklet. They will be advised to use the same weekly structure described previously.
61936589|NCT04209348|EXPERIMENTAL|Physical Activity Intervention|The behavioral physical activity (PA) intervention focuses on walking, or stepping in place when it is not possible to walk (e.g., stormy weather). The primary goal of the PA intervention is to achieve at least 30 minutes per day of walking/stepping in place. The secondary goal is to use a PA tracker (e.g., the Fitbit Charge 3 provided by the intervention) to log and review walking/stepping, and to accumulate at least 3,000 steps during their 30 minutes of walking/stepping each day.
61936590|NCT04209348|ACTIVE_COMPARATOR|Wellness Education|The Wellness Education intervention will deliver information on mom and baby wellness that is unrelated to physical activity, diet, metabolism, or weight (e.g., immunizations during pregnancy and encouragement to immunize the baby on schedule, postpartum contraceptive options and developing a contraceptive plan, infant car seats \& safety checks).
62488718|NCT03678363|EXPERIMENTAL|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
62488719|NCT03678363|PLACEBO_COMPARATOR|Control group B|2 tai chi session per week during 2 month (M2 to M4)
62488720|NCT06627036|EXPERIMENTAL|Intervention - Dermoscopy|Those allocated to this arm will have their suspicious skin lesion marked using a dermatoscope - a commercially available CE marked medical device used to magnify skin lesions and examine them with polarised light, in order to better characterise their borders and features
62488721|NCT06627036|NO_INTERVENTION|Control - Loupe magnification|Those allocated to this arm will have their suspicious skin lesion marked using the conventional method of surgical loupe magnification (2.5x - 3.5x) and theatre lights
62694103|NCT06258382||Female control group|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included
62694104|NCT05670756||Medication allergy|Patients who have a medication allergy listed in their electronic medical record.
62694105|NCT03272334|EXPERIMENTAL|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
62135500|NCT03784170|SHAM_COMPARATOR|Control|FemPulse System at a different device setting
62488722|NCT04166162|EXPERIMENTAL|Focus Group|The Focus Group consists of the participating parents who are BTC employees with child/children in the range of 8 to 16 years old. The Focus Group will receive a total of 6 weekly sessions of the TBD Intervention.
62488723|NCT04166162|EXPERIMENTAL|Social Development Strategy (SDS) Group|All participating BTC workers will be receiving SDS intervention for a minimum of 1 session.
62694106|NCT03272334|EXPERIMENTAL|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
62135501|NCT04944563|EXPERIMENTAL|Segmentectomy|Patients receive segmentectomy
62331080|NCT05800444|EXPERIMENTAL|BAY3283142 (low dose)|Participants will receive BAY3283142 as single low dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.
61936591|NCT06708637|EXPERIMENTAL|FYB203 2 mg (0.05 mL of 40 mg/mL)|FYB203 provided in a pre-filled syringe (PFS), containing 2 mg of 40 mg/mL aflibercept in 0.05 mL for intravitreal (IVT) administration
61936592|NCT06477133|EXPERIMENTAL|Magnesium|Patients in the first group will receive 2 grams magnesium sulfate at the end of surgery as a bolus over approximately 10 minutes intravenously.
62488724|NCT04166162|EXPERIMENTAL|Brief Intervention Motivational Interviewing (BIMI) Group|Participating 11 to 16 year old children of BTC employees will be receiving the BIMI intervention.
62488725|NCT04166162|EXPERIMENTAL|Business that Care (BTC) Coalition Group|Participating BTC employees who are selected by the respective directors of the participating companies to be part of the BTC Coalition will receive a total of 8 BTC training sessions in the space of 6 months.
62488726|NCT04659096|EXPERIMENTAL|ION537|Multiple ascending doses of ION537 will be administered by intravenous (IV) injection on Days 1, 4, 8, 11, 15, and 22 in Cycle 1 and weekly dosing in each subsequent cycle until disease progression.
62488727|NCT02328677||ColoCare FHCC|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2023: n=741
62488728|NCT02328677||ColoCare Moffitt (affiliated cohort)|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2023: n=1,043
62488729|NCT02328677||University Hospital Heidelberg|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2023: n=773
62488730|NCT02328677||ColoCare Huntsman Cancer Institute|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2023: n=514
62488731|NCT02328677||Cedars-Sinai Medical Center|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2023: n=291
62488732|NCT02328677||Washington University School of Medicine in St. Louis|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2023: n=278
62488733|NCT02328677||University of Tennessee|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2023: n=253
62488734|NCT03858933|EXPERIMENTAL|Limbic Modulation Index Neurofeedback|"This arm of the study will undergo a novel neurofeedback treatment, targeting downregulation of deep limbic structures, specifically the amygdalae.~Participants in this arm will complete 15 neurofeedback sessions."
62488735|NCT03858933|ACTIVE_COMPARATOR|Alpha/Theta Neurofeedback|"This arm of the study will undergo a proven PTSD neurofeedback treatment, alpha/theta regulation, during which participants will try various mental strategies to increase the presence of theta waves.~Participants in this arm will complete 15 neurofeedback sessions."
62488736|NCT04828538|ACTIVE_COMPARATOR|1 - Vitamin D, Omega 3, Vitamins B, C, Zinc|"Vitamin D of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3~\[60 days\]"
62488737|NCT04828538|ACTIVE_COMPARATOR|2 - Vitamin D, Omega 3|"Vitamin D of F1 Omega 3 of F2 Placebo of F3~\[60 days\]"
62488738|NCT04828538|ACTIVE_COMPARATOR|3 - Vitamin D, Vitamins B, C, Zinc|"Vitamin D of F1 Placebo of F2 Vitamins B, C, Zinc of F3~\[60 days\]"
62488739|NCT04828538|ACTIVE_COMPARATOR|4 - Vitamin D|"Vitamin D of F1 Placebo of F2 Placebo of F3~\[60 days\]"
61936593|NCT06477133|NO_INTERVENTION|No magnesium|Patients in the second group will receive no magnesium.
61936594|NCT06146881|EXPERIMENTAL|Diquafosol sodium 3% group|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
61936595|NCT06146881|ACTIVE_COMPARATOR|Sodium hyaluronate 0.1% group|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
62135502|NCT04944563|ACTIVE_COMPARATOR|Lobectomy|Patients receive lobectomy
62135503|NCT05888805|OTHER|DIMS lens group|Participants will be prescribed with a pair of DIMS spectacle lenses for 24 months.
62135504|NCT05225376|EXPERIMENTAL|Establishment of physical activity sessions for pregnant women|All the women will receive the studied intervention
62135505|NCT03480451|OTHER|Single Arm|"This project is being withdrawn. No revisions to ARM is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
62331081|NCT05800444|EXPERIMENTAL|BAY3283142 (medium dose)|Participants will receive BAY3283142 as single medium dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9 (optional arm).
62488740|NCT04828538|ACTIVE_COMPARATOR|5 - Omega 3, Vitamins B, C, Zinc,|"Placebo of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3~\[60 days\]"
62488741|NCT04828538|ACTIVE_COMPARATOR|6 - Omega 3|"Placebo of F1 Omega 3 of F2 Placebo of F3~\[60 days\]"
62488742|NCT04828538|ACTIVE_COMPARATOR|7 - Vitamins B, C, Zinc|"Placebo of F1 Placebo of F2 Vitamins B, C, Zinc of F3~\[60 days\]"
62488743|NCT04828538|PLACEBO_COMPARATOR|8 - No Interventions|"Placebo of F1 Placebo of F2 Placebo of F3~\[60 days\]"
62488744|NCT05203692|EXPERIMENTAL|DS-7011a|"Stage 1: Healthy participants who will be randomized to receive a single intravenous (IV) ascending dose of DS-7011a (starting dose 0.1 mg/kg).~Stage 2: Healthy participants who will be randomized to receive a single subcutaneous (SC) ascending dose of DS-7011a (starting dose will be centered around estimated therapeutic dose confirmed in Stage 1).~Stage 3: Healthy Japanese participants who will be randomized to receive an IV dose of DS-7011a (based on estimated therapeutic dose confirmed in Stage 1)."
62488745|NCT05203692|PLACEBO_COMPARATOR|Placebo|Healthy participants who will be randomized to receive a single dose of placebo.
62488746|NCT00308906||1|Hospitalized, untreated infants and children
62488747|NCT00308906||2|Aminoglycoside treated infants and children without renal injury
61936596|NCT06304038||Vaccinated subjects|Healthcare workers that received quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra in a single administration
61936597|NCT06304038||Unvaccinated subjects|Healthcare workers that did not received flu vaccine
61936598|NCT06680596|EXPERIMENTAL|T-DXd|T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
61936599|NCT02427971||Perseus|Use of Perseus® A 500 with VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min)
61936600|NCT02427971||Aysis|Use of Aysis® Cs2 ventilator with automated control of end-tidal inhalation anesthetic concentration, EtControl® mode.
61936601|NCT00240227|OTHER|Placebo|Placebo no active medication
61936602|NCT00240227|ACTIVE_COMPARATOR|prazosin|Prazosin flexible dose titration up to 12 mg per day.
61936603|NCT02040285|ACTIVE_COMPARATOR|Free laxative CTC|
61936604|NCT02040285|EXPERIMENTAL|Low-dose laxative bowel preparation for CTC|
61936605|NCT02787551|EXPERIMENTAL|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|"Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.~Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted."
61936606|NCT02787551|ACTIVE_COMPARATOR|GLP-1 Receptor Agonist|Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily \[BID\], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
61936607|NCT05962749||Children With Cerebral Palsy|
61936608|NCT03173027|EXPERIMENTAL|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
62135506|NCT05661708|NO_INTERVENTION|Control|LEEP was performed in an outpatient setting by a single resident physician (KG). A full blood count was taken (hematocrit 1). The procedure was designed according to colposcopic findings such as the type of transformation zone and position of the lesion. After positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) was applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix. LEEP was performed as described in a previous trial. After the hemostasis that obtained using the ball electrode at a 40-W coagulation setting, the remaining cervical tissue was washed with 20 ccs of sterile saline to ensure no active bleeding from the cervical wound. An empty spray pump was used because we cannot find any identical powder for the placebo
62135507|NCT05661708|EXPERIMENTAL|Chitosan|LEEP was performed in an outpatient setting by a single resident physician (KG). A full blood count was taken (hematocrit 1). The procedure was designed according to colposcopic findings such as the type of transformation zone and position of the lesion. After positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) was applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix. LEEP was performed as described in a previous trial. After the hemostasis that obtained using the ball electrode at a 40-W coagulation setting, the remaining cervical tissue was washed with 20 ccs of sterile saline to ensure no active bleeding from the cervical wound. The application of 3 or 4 pumps of chitosan powder was carried out into the wound bed by spray pump which was prepared by a nurse.
62135508|NCT05979038|EXPERIMENTAL|Metformin arm|In this arm patients will administrate metformin 500 mg three times a day together with the standard care of sepsis.
61936609|NCT03173027|PLACEBO_COMPARATOR|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
61936610|NCT02628717||SOF/SMV|SOF/SMV 400mg/150mg QD 12-24 weeks
61936611|NCT02628717||SOF/DCV|SOF/DCV 400mg/60mg QD 12-24 weeks
61936612|NCT02628717||SOF/LDV|SOF/LDV 400mg/90mg QD 12-24 weeks
61936613|NCT02628717||treatment duration|12 - 24 weeks
61936614|NCT05074043||covid19|covid 19 proven by clinical, PCR. not associated with mucor
61936615|NCT05074043||covid19 associated with mucor|covid19 associated with mucor proven by clinical, histopathological
61936616|NCT03606629||Endoprosthesis implantation|Device implantation
61936617|NCT02271373|EXPERIMENTAL|intervention group|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
61936618|NCT02271373|NO_INTERVENTION|control group|The control school did not have any interventions.
61936619|NCT06033612|EXPERIMENTAL|Part A Single Ascending Dose (SAD) - RV299/Placebo|Participants will receive RV299 or placebo as a single dose on Day 1. Sentinel dosing will be used (one on RV299 and one on placebo) before the rest of the cohort are dosed together.
61936620|NCT06033612|EXPERIMENTAL|Part B Multiple Ascending Dose (MAD) - RV299/Placebo|"Participants will receive RV299 or placebo twice daily on Day 1-4 and a single dose on Day 5. Participants in each cohort will receive ascending doses of RV299, depending on emerging safety and PK data.~Part B, Cohort 3 will investigate interaction between midazolam and RV299. Participants will receive a single dose of midazolam on Day 1 and Day 7, and receive RV299 twice daily on Days 2 - 6"
61936621|NCT06033612|EXPERIMENTAL|Part C Food Effect (FE)- RV299|Participants will receive RV299 as a single dose on Day 1 and Day 5; treatment will be administered in the first treatment period fasted and the second treatment period fed (or vice versa).
61936622|NCT00761579|EXPERIMENTAL|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
61936623|NCT04436211||TKA (mechanical alignment)|
61936624|NCT04436211||TKA (kinematic alignment)|
62135509|NCT05979038|NO_INTERVENTION|Control Arm|In this arm patients will receive the standard care of sepsis only
62488748|NCT00308906||3|Aminoglycoside treated infants with renal injury
62488749|NCT04501848||Study|parents of obstructive sleep disordered breathing (OSDB) children before and after surgical treatment
62488750|NCT04501848||Control|A group of parents to healthy children comprised the control group.
62488751|NCT02042547||Patients about to undergo heart surgery|
62488752|NCT04935580|EXPERIMENTAL|GC012F treatment|GC012F will be infused at a dose of1- 3 x 10\^5 CAR+ T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
62488753|NCT00177164|ACTIVE_COMPARATOR|1|Oral Risperidone followed by Long acting Risperidone injections (Consta)
62488754|NCT00177164|ACTIVE_COMPARATOR|2|Oral second generation antipsychotic agents other than clozapine or risperidone (olanzapine, quetiapine, ziprasidone, aripiprazole)
62488755|NCT06406088|EXPERIMENTAL|EarGenie MVP|Infants who have a test completed with EarGenie MVP in a single test session
62488756|NCT01993186|EXPERIMENTAL|UX007|"Participants randomized to receive UX007 enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
62488757|NCT01993186|PLACEBO_COMPARATOR|Placebo|"Participants randomized to receive placebo enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, placebo participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
62488758|NCT01232660|ACTIVE_COMPARATOR|Delayed|Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
62488759|NCT01232660|EXPERIMENTAL|Immediate|Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
62488760|NCT05301218|ACTIVE_COMPARATOR|angiography-guided group|the treatment (including lesion preparation, stent sizing and post implantation optimization) will be performed by angiography. Once the result is considered optimal by the operator, a control OCT run will be acquired.
62488761|NCT05301218|EXPERIMENTAL|OCT-guided group|a preliminary OCT run will be recorded. An initial predilation with 1.5 to 2.0 mm balloon could be accepted in order to facilitate OCT catheter delivery through the target lesion. The PCI strategy will be guided by a pre-defined algorithm based on initial OCT findings. Post PCI result will be assessed by control OCT and potential optimization steps could be applied according to the results. The MLD-MAX optimization approach will be applied. Final OCT run will be performed at the end of the procedure.
62488762|NCT04342936|EXPERIMENTAL|Camrelizumab for Injection|Participants receive Camrelizumab 200mg intravenously (IV) on Day 1 of each 2-week cycle
62488763|NCT04342936|ACTIVE_COMPARATOR|Chemotherapy|Participants receive investigator's choice of chemotherapy (Gemox, IGEV or DHAP) for up to 6 cycles.
62488764|NCT01135784|ACTIVE_COMPARATOR|MIGRA-ZEN RELIEF PLUS|Active treatment
62488765|NCT01135784|PLACEBO_COMPARATOR|Placebo for Migra zen plus|Placebo
62488766|NCT00989716|ACTIVE_COMPARATOR|Glyceryl trinitrate transdermal patch|
62488767|NCT00989716|EXPERIMENTAL|Continue or stop pre-stroke antihypertensives|
62488768|NCT03467360|EXPERIMENTAL|One experimental arm|non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer
62488769|NCT01187823|ACTIVE_COMPARATOR|Nocturnal oxygen therapy|
62488770|NCT01187823|ACTIVE_COMPARATOR|Adaptive servo ventilation|Bipap® auto SV Advanced
62488771|NCT01664650|PLACEBO_COMPARATOR|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
62488772|NCT01664650|EXPERIMENTAL|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
62488773|NCT00078923|EXPERIMENTAL|Placebo|Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.
62135510|NCT05370287|EXPERIMENTAL|Glaucoma with oxygen|Primary open angle glaucoma subjects as well as pre-perimetric glaucoma suspects will be classified by clinical exam by an experienced glaucoma specialist according to the American Academy of Ophthalmology Practice Patterns. Glaucoma subjects and suspects will undergo adaptive optics (AO) imaging of several macular locations. A subset of subjects will undergo oxygen challenge intervention, which involves breathing 100% oxygen through a mask during AO imaging at pre-determined retinal vessel locations.
62135511|NCT05370287|EXPERIMENTAL|Healthy control with oxygen|Age-matched healthy control cohort will undergo the same AO imaging procedures as glaucoma cohort. A subset of subjects will undergo the same oxygen challenge intervention as the glaucoma cohort.
62135512|NCT05370287|EXPERIMENTAL|Healthy control with stimulation|Healthy control subjects will undergo AO imaging at several macular locations while flashes of visible light stimulus are delivered.
62488774|NCT00078923|EXPERIMENTAL|Soy isoflavones and placebo|Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.
62135513|NCT05370287|EXPERIMENTAL|Glaucoma|Glaucoma subjects and suspects will undergo AO imaging at several macular locations without intervention.
62135514|NCT05370287|EXPERIMENTAL|Healthy control|Healthy control subjects will undergo AO imaging at several macular locations without intervention
62331082|NCT05800444|EXPERIMENTAL|BAY3283142 (high dose)|Participants will receive BAY3283142 as single high dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.
62488775|NCT00078923|EXPERIMENTAL|Soy Isoflavones/Placebo|Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.
62488776|NCT00078923|EXPERIMENTAL|Soy Isoflavones|Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.
62488777|NCT04969562|EXPERIMENTAL|experiment|Individuals with multiple sclerosis in the experimental group will be included in six sessions of EFT at seven-day intervals, in which one session lasts 30-45 minutes. SUDS will be applied before and after each EFT session. At the same time, resting heart rate and blood pressure will be measured in the EFT group before and after each session.
62488778|NCT04969562|NO_INTERVENTION|control|They will continue their routine treatment.
62488779|NCT03417076|EXPERIMENTAL|Bexagliflozin|Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of \< 30 ug 14C-bexagliflozin in 0.9% saline solution).
62488780|NCT04212390||FISiM MDS patients|Patients receiving a diagnosis of MDS and prospectively enrolled in the FISiM registry.
62488781|NCT03821675|ACTIVE_COMPARATOR|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
62488782|NCT03821675|SHAM_COMPARATOR|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
62488783|NCT01200186||Group 1|
62488784|NCT01200186||Group 2|
62488785|NCT02270697||Regular Diagnosis|Difficult in regular diagnosis specimens, assistance with array.
62488786|NCT01158118|EXPERIMENTAL|Arm 1 - Donor|"Days 1-5: Mobilization with 5 mcg/kg/day GM-CSF (first 4 donors were mobilized with 10 mcg/kg GM-CSF then changed to 5 mcg/kg for remaining donors)~Day 5: Mobilization with 320 mcg/kg plerixafor IV~Day 5: Leukopheresis~If PBSC collected are not adequate, then donor will be mobilized with GM-CSF and plerixafor IV on day 6 and have leukopheresis collection on day 6."
62488787|NCT01158118|NO_INTERVENTION|Arm 2 - Recipient|"Conditioning Regimens~* fludarabine and busulfan +/- thymoglobulin~* fractionated total body irradiation and cyclophosphamide~* busulfan and cyclophosphamide~* single dose total body irradiation and cyclophosphamide~Day -2 = GvHD prophylaxis~Day 0 or +1 = PBSC transplant~Day +7 until neutrophil engraftment = G-CSF 5 ug/kg/day"
62488788|NCT05715463|OTHER|Arm 1|Arm 1 is the control arm which will receive the standard of care resource sheets.
62135515|NCT06510790||Patients undergoing DJ stent|All patients coming to TUTH OPD and ER for urological surgery were assessed for the placement of a DJS (polyurethane). Patients fulfilling inclusion criteria were admitted and underwent DJS placement after their respective procedures
62135516|NCT03434496|EXPERIMENTAL|Experimental group|The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
62135517|NCT03434496|ACTIVE_COMPARATOR|Control Group|The control group will perform only conventional gait treadmill training, besides physical exercises to improve muscle force and tone. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
62135518|NCT00960024|EXPERIMENTAL|Individual Placement and Support-vocational rehabilitation|
62135519|NCT00960024|ACTIVE_COMPARATOR|Vocational rehabilitation available at study site|
62331083|NCT05800444|PLACEBO_COMPARATOR|Matching placebo|Participants will receive a BAY3283142 matching placebo as single dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.
62488789|NCT05715463|EXPERIMENTAL|Arm 2|Arm 2 will receive the assistance of a community resource specialist (CRS)- an individual without formal medical training with community-based expertise.
62488790|NCT05715463|EXPERIMENTAL|Arm 3|Arm 3 will receive the assistance of a bilingual (English and Spanish) nurse patient navigator with nursing training and additional rheumatology-specific training.
62488791|NCT00809705|EXPERIMENTAL|1|
62488792|NCT00809705|EXPERIMENTAL|2|
62488793|NCT00809705|PLACEBO_COMPARATOR|3|
62488794|NCT04752605|EXPERIMENTAL|Intervention|play sessions included as a part of normal early childhood education; parents' evening for all parents; parents' group for the parents of children that have difficulties in self-regulation and that are offered more individualized small group activity
62488795|NCT04752605|NO_INTERVENTION|Control|normal early childhood education
62488796|NCT02350036||preeclmapsia|women developed preeclampsia. ultrasound monitoring and uterine artery Doppler
62488797|NCT02350036||control|women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler
62488798|NCT01780051|EXPERIMENTAL|Sequence A|
62488799|NCT01780051|EXPERIMENTAL|Sequence B|
62488800|NCT04790643||Stage 1 - Development of the new cardiac risk stratification protocol|This will be a prospective cohort study, in which individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables that will be used to guide the elaboration of the cardiac risk stratification protocol. After this initial evaluation, the volunteers will be followed for 2 months during their habitual cardiac rehabilitation routine for the evaluation and registry of the occurrence of minor adverse events, defined as signs and symptoms (arrhythmias, blood pressure alterations, tachypnea, pallor, chest pain, cramps, muscle pain, fatigue, and nausea). The cardiac rehabilitation program in which the volunteers will be recruited is based on moderate-intensity aerobic exercise.
62488801|NCT04790643||Stage 2 - Reproducibility and efficiency of the new protocol|"This will be a prospective cohort study, in which a new sample of individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables and stratified in one of the three following risk classes: low risk, moderate risk, and high risk accordingly to the new risk stratification protocol. After that, the sample will be followed for 2 months of rehabilitation to the evaluation of the occurrence of signs and symptoms. The cardiac rehabilitation program from where the volunteers will be recruited is based on moderate-intensity aerobic exercise and resistance training. With these data, the reproducibility and efficiency of the protocol will be evaluated."
62488802|NCT04790643||Stage 3 - Protocols´ agreement between evaluators|This will be a cross-sectional observational study in which a new sample of participants will be evaluated by two independent physiotherapists for clinical and physical variables, and based on these data will be stratified by the new protocol by the same evaluators independently. After these procedures, the protocol´s agreement between evaluators will be analyzed.
62488803|NCT00681486|ACTIVE_COMPARATOR|A, 1|Ghrelin
62488804|NCT00681486|ACTIVE_COMPARATOR|A, 2|Ghrelin.
62488805|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
62135520|NCT03122236|ACTIVE_COMPARATOR|Standard walking with Sham tDCS|Neurorehabilitation of Standard Walking and Sham Transcranial Direct Current Stimulation (Sham tDCS)
62135521|NCT03122236|ACTIVE_COMPARATOR|Complex walking with Sham tDCS|Neurorehabilitation of Complex Walking and Sham Transcranial Direct Current Stimulation (Sham tDCS)
62135522|NCT03122236|ACTIVE_COMPARATOR|Complex walking with Active tDCS|Neurorehabilitation of Complex Walking and Active Transcranial Direct Current Stimulation (Active tDCS)
62135523|NCT04324099||Conduct disorder|children and adolescents with CD
62135524|NCT04324099||Autism-Spectrum disorder|children and adolescents with ASD
62135525|NCT04324099||typically developing adolescents|typically developing adolescents
62135526|NCT02019459|ACTIVE_COMPARATOR|0.8 mg nicotine with 10.5 mg tar|SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine yield with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)
62135527|NCT02019459|EXPERIMENTAL|0.03 mg nicotine with 9 mg tar|SPECTRUM Cigarette: 0.03 mg (± 0.02) nicotine yield with 9 mg (± 1.5) tar
62331084|NCT06293625|EXPERIMENTAL|NeoAdjuvant Chemotherapy arm|
62135528|NCT03428620|EXPERIMENTAL|Mobilization|High Velocity Low Amplitude mobilization group. The three joints that will be manipulated include proximal tibiofibular, the distal tibiofibular, and talocrural joints and will be mobilized the first three sessions prior to the participants performing the exercise protocol.
62135529|NCT03428620|ACTIVE_COMPARATOR|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
62135530|NCT06314932|EXPERIMENTAL|High UPF|Group starting with the Mediterranean diet (MD) high in ultra-processed foods (UPF)
62135531|NCT06314932|ACTIVE_COMPARATOR|Low UPF|Group starting with the Mediterranean diet (MD) low in ultra-processed foods (UPF)
62331085|NCT06293625|ACTIVE_COMPARATOR|Current standard of care|
62331086|NCT03025737||athletes|Healthy highly trained elite athletes, recreational athletes, young and master athletes free of known structural myocardial disease
62331087|NCT03025737||controls|Healthy volunteers without a history of competitive physical exercise
62331088|NCT04640324|NO_INTERVENTION|NAFLD wild type control group|Consisted of not treated NAFLD wild type patients
62331089|NCT04640324|ACTIVE_COMPARATOR|NAFLD wild type treated group|Consisted of NAFLD wild type patients treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
62331090|NCT04640324|EXPERIMENTAL|NAFLD mutated treated group|Consisted of NAFLD patients carrying at least one mutation among PNPLA3, TM6SF2, MBOAT7 genes, treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
62331091|NCT02081339||Macular diseases|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
62331092|NCT02849990|EXPERIMENTAL|Treatment (neoadjuvant chemotherapy)|Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
62331093|NCT02496728|EXPERIMENTAL|Cardiovascular Health|Participants will be given the results of their health assessment and feedback regarding their health behaviors and overall health. Recommendations for change will be given if warranted. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor health behaviors that are not already at ideal levels using the study application (environmental cues). Participants will be asked to join a secret Facebook group where informational materials will be posted, participants can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
62331094|NCT02496728|ACTIVE_COMPARATOR|Whole Health|Participants will be given the results of their health assessment. They will then receive educational materials about sunscreen use, safe sex, hydration and vehicular safety. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor how much water they drink using the study application. Participants will be asked to join a secret Facebook group where informational materials will be posted, they can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
62331095|NCT06555003|EXPERIMENTAL|DEBIRI+ Chemotherapy +/- Targeted therapy|Patients will receive systemic chemotherapy on day 0 and 14 and DEBIRI on day 7 and 21.
62331096|NCT06555003|ACTIVE_COMPARATOR|Chemotherapy +/- Targeted therapy|Patients will receive 4 cycles of systemic chemotherapy.
62331097|NCT05794152|OTHER|Standardized breakfast|Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g)
62331098|NCT05794152|OTHER|Standardized snack|Tomato (50g) and skim milk (200g)
62331099|NCT05794152|OTHER|Standardized lunch|Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g)
62331100|NCT00069576|ACTIVE_COMPARATOR|Nutritional counseling & self blood glucose monitoring|Within one week of enrollment, women in the treatment group receive formal nutritional counseling and will be instructed on the technique of self blood glucose monitoring using a memory-based reflectance meter.
62331101|NCT00069576|NO_INTERVENTION|No treatment|This group will not receive any specific dietary therapy except for written information concerning general nutritional recommendations for normal pregnancy.
62135532|NCT02224105|EXPERIMENTAL|BI 653048 BS|escalating doses
62331102|NCT05630404|ACTIVE_COMPARATOR|Group IE= Surgical Injection ESPB|Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
62488806|NCT03390790|EXPERIMENTAL|Lidocaine gel|If assigned to this arm, participants have lidocaine gel 2% applied to their external urethra and vagina one time prior to the urodynamics procedure.
62488807|NCT03390790|PLACEBO_COMPARATOR|Lubricant gel|If assigned to this arm, participants will have a standard lubricant gel applied to their external urethra and vagina prior to the urodynamics procedure.
62488808|NCT02809196|ACTIVE_COMPARATOR|1: Tailored, friend and mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F\&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend and mother are invited to participate."
62488809|NCT02809196|ACTIVE_COMPARATOR|2: Standardized, friend and mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend and mother are invited to participate."
62488810|NCT02809196|ACTIVE_COMPARATOR|3:Tailored, friend and not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F\&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend is invited to participate but not mother."
62488811|NCT02809196|ACTIVE_COMPARATOR|4: Standardized, friend and not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend is invited to participate but not mother."
62488812|NCT02809196|ACTIVE_COMPARATOR|5:Tailored, mother and not friend|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F\&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Mother is invited to participate but not friend."
62488813|NCT02809196|ACTIVE_COMPARATOR|6: Standardized, mother and not friend|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Mother is invited to participate but not friend."
62488814|NCT02809196|ACTIVE_COMPARATOR|7:Tailored, not friend, not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F\&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Neither friend nor mother is invited to participate."
62488815|NCT02809196|ACTIVE_COMPARATOR|8: Standardized, not friend, not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Neither friend nor mother is invited to participate."
62488816|NCT02809196|OTHER|9: No SMS program|Control Group; no SMS-based educational program
62488817|NCT00185757|EXPERIMENTAL|Cytokine-induced Killer Cells|The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
62488818|NCT02044731|EXPERIMENTAL|Family group sessions|Active and Healthy Families
62488819|NCT01215721|EXPERIMENTAL|Vesicare|Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
62488820|NCT06307288|EXPERIMENTAL|minocycline treatment group|The patient was treated with oral minocycline capsules, 50mg each time, once a day, for 12 weeks.
62694107|NCT03272334|EXPERIMENTAL|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
62694108|NCT06642246|EXPERIMENTAL|Arm 1|Sleep goal, Sleep guidance messaging, Loss-framed incentive, Supportive feedback.
62694109|NCT05983809|EXPERIMENTAL|Experimental Group (HO, Hunova-Observation)|Patients in the HO group will undergo a specific rehabilitation treatment for balance disorders using the robotic platform Hunova® Movendo Technology srl, Genova, IT), for 4 weeks, 3 times a week for 45 minutes each. In particular, the technological rehabilitation carried out with the platform will have as main objective the improvement of balance, both in sitting and standing position, and static and dynamic exercises, dual-task exercises and exercises to improve trunk control will be proposed. Afterwards, patients will undergo 4 weeks of observation without rehabilitation treatment.
62694110|NCT05983809|ACTIVE_COMPARATOR|Control Group (OH, Observation-Hunova)|Patients in the OH group will undergo 4 weeks of observation without rehabilitation treatment, followed by specific rehabilitation treatment for balance disorders using the robotic platform Hunova® Movendo Technology srl, Genova, IT), for 4 weeks, 3 times a week for 45 minutes each. In particular, the technological rehabilitation carried out with the platform will have as main objective the improvement of balance, both in sitting and standing position, and static and dynamic exercises, dual-task exercises and exercises to improve trunk control will be proposed.
62694111|NCT01228032|EXPERIMENTAL|Intervention|
62488821|NCT06307288|EXPERIMENTAL|tranilast treatment group|The patient was treated with oral tranilast capsules, 0.1g each time, three times a day, for 12 weeks.
62135533|NCT02224105|ACTIVE_COMPARATOR|Prednisolone low|
62135534|NCT02224105|ACTIVE_COMPARATOR|Prednisolone high|
62135535|NCT02224105|PLACEBO_COMPARATOR|Placebo|
62135536|NCT03058445|EXPERIMENTAL|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
62135537|NCT05820594|EXPERIMENTAL|Intradermal injection with BCG SSI|Intradermal injection with BCG (bacillus calmette-guerin) vaccine at day 0.
62135538|NCT03279224|ACTIVE_COMPARATOR|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
62135539|NCT03279224|PLACEBO_COMPARATOR|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
61936625|NCT05735353|EXPERIMENTAL|High-Speed Circuit Resistance Training Group|Participants in this group will receive high-speed circuit resistance training for 12 consecutive weeks.
62135540|NCT01948661|EXPERIMENTAL|Anthocyanins+Phospholipidic Curcumin|Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days
62488822|NCT06307288|EXPERIMENTAL|tranilast combined with minocycline treatment group|The patient was treated with oral tranilast capsules, 0.1g each time, three times a day; oral minocycline capsules, 50mg each time, once a day, for 12 weeks.
62488823|NCT00510848|EXPERIMENTAL|1|Reconstruction with an autograft tendon (hamstrings)
62488824|NCT00510848|EXPERIMENTAL|2|Reconstruction with an allograft tendon (tibialis posterior)
62488825|NCT02761122|EXPERIMENTAL|Patients with lichen|"Patients with non-erosive lichen planus, erosive lichen planus or lichen sclerosus.~Human biological samples :~* Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy"
62488826|NCT02854826||UCLA Ronald Reagan Medical Center|"Site 1 (UCLA Regan Medical Center): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
62488827|NCT02854826||Huntington Hospital|"Site 2 (Huntington Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research Council/ Evidence Based Practice will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
62488828|NCT02854826||Torrance Memorial Hospital|"Site 3 (Torrance Memorial Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/ Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
62488829|NCT00749658|ACTIVE_COMPARATOR|Bupropion + Placebo Varenicline|Bupropion + Placebo Varenicline \\Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \\Bupropion + Placebo Varenicline
62331103|NCT05630404|ACTIVE_COMPARATOR|Group UE= US guided ESPB|Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
62488830|NCT00749658|ACTIVE_COMPARATOR|upropion + Varenicline|Bupropion + Varenicline \\Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \\Bupropion + Varenicline
61936626|NCT05735353|EXPERIMENTAL|High-Speed Multidirectional Yoga Group|Participants in this group will receive high-speed multidirectional yoga for 12 consecutive weeks.
61936627|NCT06516822|EXPERIMENTAL|CPVI-MLA|Patients randomized to the CPVI-MLA group first undergo ethanol infusion in the vein of Marshall (EI-VOM) followed by CPVI, left atrial posterior wall isolation (PWI), linear ablation of mitral isthmus (MI), left atrial intima adjoining CS (LAI-CS) and cavo-tricuspid isthmus (CTI), and superior vena cava isolation (SVCI).
61936628|NCT06516822|ACTIVE_COMPARATOR|CPVI only|Patients randomized to the CPVI group undergo right PV ablation, followed by the left PV ablation. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia in a wide-area circumferential pattern. Complete CPVI is achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished.
61936629|NCT02185755|ACTIVE_COMPARATOR|Internet-Based Glucose Monitoring System|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
61936630|NCT02185755|OTHER|Normal Medication Positive Control|The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
61936631|NCT04879277|OTHER|Healthy subject|"The intervention, specific to the study, is to take blood samples on patients healthy volunteers.~Healthy subject will be paired to patient with phenylketonuria according to body mass index and sex."
61936632|NCT04879277|OTHER|Patient with phenylketonuria|The intervention, specific to the study, is to take blood samples on patients with phenylketonuria
61936633|NCT01384006||Control|standard pancreas allograft recipients
61936634|NCT01384006||Study|recipients of extended donor criteria pancreas allografts
62135541|NCT01948661|PLACEBO_COMPARATOR|placeboA + placeboB|placeboA + placeboB per day for four weeks
62135542|NCT05829525|OTHER|Healthy young adults group|Face-to-face assessment study
62135543|NCT00692185|EXPERIMENTAL|1|Participants will take olanzapine.
62135544|NCT00692185|PLACEBO_COMPARATOR|2|Participants will take matched placebo.
62135545|NCT01198366|PLACEBO_COMPARATOR|Dose Finding Gr 1 placebo x 2|Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.
62135546|NCT01198366|EXPERIMENTAL|Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2|Subjects received two doses (x2) of AERAS-402 (1.5 x 10\^10 vp) on study days 0 and 28.
62488831|NCT06550661|EXPERIMENTAL|Ba duan jin training|twice a week
62488832|NCT06550661|NO_INTERVENTION|usual care|once a week with video
62488833|NCT00301886|EXPERIMENTAL|zoledronate|zoledronate
62331104|NCT05630404|NO_INTERVENTION|Group C = Control group|"Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.~Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit."
62488834|NCT00301886|EXPERIMENTAL|ibandronate|ibandronate
62488835|NCT00685464|ACTIVE_COMPARATOR|2|Intravenous bolus Abciximab.
62488836|NCT00685464|ACTIVE_COMPARATOR|Abciximab|Intracoronary bolus abciximab.
62488837|NCT06205264|EXPERIMENTAL|Fast Group|"Effect of strength training on executive functions in children.~Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 8 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The multi joint exercises will be controlled movements and not harmful, but at maximum speed during the concentric phase of the exercise."
62488838|NCT06205264|EXPERIMENTAL|Conventional Group|"Effect of strength training on executive functions in children.~Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 8 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. This group will perform each phase of the planned exercises at a constant speed."
62488839|NCT03692455|EXPERIMENTAL|BPG Group|Patients will be submitted to Roux-en-Y Bypass Gastric Surgery.
62488840|NCT03692455|EXPERIMENTAL|Sleeve Group|Patients will be submitted to Vertical Sleeve Gastrectomy Surgery.
62488841|NCT03909633||A: anesthesia group|Patients accepting endoscopy check under anesthesia will be included in this group as group A,will doing a series of tests
62488842|NCT03909633||B:Non-anesthesia group|patients undergoing endoscopy check without anesthesia will be included in this group as controls voluntarily,namely group B,will doing a series of tests
62135547|NCT01198366|EXPERIMENTAL|Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2|Subjects received two doses (x2) of AERAS-402 (3.0 x 10\^10 vp) on study days 0 and 28.
62135548|NCT01198366|EXPERIMENTAL|Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2|Subjects received two doses (x2) of AERAS-402 (1.0 x 10\^11 vp) on study days 0 and 28.
62331105|NCT02801162|ACTIVE_COMPARATOR|Conventional ABG analyser|
62331106|NCT02801162|EXPERIMENTAL|Proxima 3® arterial blood gas|
62331107|NCT01276665|EXPERIMENTAL|Restrictive regimen group|treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.
62488843|NCT04777305|EXPERIMENTAL|Aerobic exercise training|"The aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on the Borg scale.~Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training."
62694112|NCT01228032|NO_INTERVENTION|Control|referral only
62694113|NCT01711099|EXPERIMENTAL|ESMR treated|
62135549|NCT01198366|EXPERIMENTAL|Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3|Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10\^11 vp) on days 0, 28 and 280.
62135550|NCT01198366|PLACEBO_COMPARATOR|Expanded Safety Phase Gr 5 Placebo x3|Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.
62135551|NCT04160741|EXPERIMENTAL|Hot environment with radiation|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
62135552|NCT04160741|EXPERIMENTAL|Hot environment without radiation|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
62135553|NCT04160741|EXPERIMENTAL|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
62135554|NCT04160741|ACTIVE_COMPARATOR|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
62135555|NCT00476905||Spectral-Diagnosis|Method for noninvasive detection of cutaneous malignancies
62135556|NCT05099341|EXPERIMENTAL|Patients with recurrent depression with a number of depressive episodes ≥ 3|
62135557|NCT05099341|EXPERIMENTAL|Patients with a first depressive episode|
62135558|NCT05099341|ACTIVE_COMPARATOR|Healthy, non-depressed subjects|
62135559|NCT06326125|EXPERIMENTAL|TICK-B|active distraction technique as non-pharmacology in treating children's pain and fear during venipuncture procedure.
62331108|NCT01276665|ACTIVE_COMPARATOR|Control group|treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)
62135560|NCT06326125|EXPERIMENTAL|TkTx-Cream|as Pharmacological approach will be use in managing children's pain and fear during venipuncture procedure.
62135561|NCT06326125|EXPERIMENTAL|TICK-B and TkTx-C|Pharmacological approache and non-Pharmacological will be use in managing children's pain and fear during venipuncture procedure.
62135562|NCT06326125|NO_INTERVENTION|Control Group|No intervention will applied in this group
62135563|NCT02763449|EXPERIMENTAL|Sedentary|Individuals will reduce their physical activity level for 14-days
62135564|NCT02763449|EXPERIMENTAL|Active|Individuals will increase their physical activity level for 14-days
62135565|NCT00052364|EXPERIMENTAL|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62488844|NCT04777305|EXPERIMENTAL|Resistance exercise training|Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and body weight exercises.
62694114|NCT06565182|EXPERIMENTAL|Continuous aerobic exercise|The continuous aerobic intervention was performed on a bicycle in a seated position at a moderate exercise intensity. Heart rate and RPE was implemented to ensure moderate intensity level. The participants were allowed to warm up for 5 minutes before starting to cycle at the predetermined HR ranges for 25 minutes. The total duration of exercise was 30 minutes.
62694115|NCT06565182|EXPERIMENTAL|Resistance exercise|The acute resistance intervention consisted of four exercises performed using Technogym equipment at a moderate intensity. Every exercise consisted of 3 sets of 20 repetitions, with 1 minute rest in between sets, equaling 30 minutes of exercise in total. The four exercises were performed using the following Technogym devices: vertical traction, chest press, low row, leg press. Prior to the start of each exercise, a short maximal resistance test provided by the Technogym equipment was executed to determine moderate intensity.
62694116|NCT03653819|OTHER|HIIT + compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session with compression garments/second without.
62135566|NCT04682288|EXPERIMENTAL|Levofloxacin Ocular Implant|Biphasic levofloxacin antibiotic implant
62135567|NCT01804387|ACTIVE_COMPARATOR|Telbivudine plus adefovir|study drugs
62135568|NCT01804387|ACTIVE_COMPARATOR|Lamivudine plus adefovir|standard drugs
62135569|NCT03786211|ACTIVE_COMPARATOR|IANB without panoramic|They will get Ianb without using panoramic
62135570|NCT03786211|EXPERIMENTAL|IANB with panoramic|They will get IANB by the guide of panoramic
62135571|NCT02282657|EXPERIMENTAL|One single arm|Procedure: Baseline ventilator settings will be established per the EXPRESS protocol: VT = 6 mL/kg (ideal body weight); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3, PEEP set so that the plateau pressure (Pplat), measured during the end-inspiratory pause of 0.2 to 0.5 s, will be within the following limits: 28 cm H2O ≤ Pplat ≤ 30 cm H2O; Set RR to 20-35 to maintain approximately the same minute ventilation as before study initiation. Baseline ventilator settings will be maintained for a 2-hour run-in time (time to setup ECCO2R devices). Use heated humidifiers for gas humidification and minimize instrumental dead space. ECCO2R will be initiated during the 2-hour run-in time. Neuromuscular blocking agents (NMBA) will be used. EtCO2 will be monitored. RR will be kept what it was at Baseline. Sweep gas flow will be adapted. Ventilation will be adapted. Respiratory rate will be adapted.
62135572|NCT03862963|ACTIVE_COMPARATOR|Standard of Diabetes Care|Standard of diabetes care in the Marshall Islands
61936635|NCT03564028|EXPERIMENTAL|energy conservation technique|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
62694117|NCT03653819|OTHER|HIIT - compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session without compression garments/second with
62135573|NCT03862963|EXPERIMENTAL|Lifestyle Intervention|Plant-based, whole foods diet with moderate exercise
62135574|NCT05692817|EXPERIMENTAL|one- weeks group|
62694118|NCT05614869|EXPERIMENTAL|Treatment Group|Subjects undergoing 1 of 4 types of surgery will be enrolled and treated with the PREVENA Plus Incision Management System
62697612|NCT02921256|EXPERIMENTAL|Arm III (mFOLFOX6, RT, capecitabine, pembrolizumab)|ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62135575|NCT05692817|EXPERIMENTAL|three-weeks group|
62135576|NCT05509855||Patients treated with WU-CART-007|Patients who received previous treatment with WU-CART-007
62135577|NCT04347824||low risk|"This group has a normal urine status on admission to hospital. Abnormal urine status is defined anuric OR as 2\* or more of the following findings:~1. urine osmolarity below normal values~2. leukozyturia~3. hematuria~4. albuminuria/ proteinuria \* if urine is positive for nitrite or bacteria, abnormal urine status is defined as 3 or more of the findings."
62135578|NCT04347824||intermediate risk|This group has an abnormal urine status on admission to hospital WITHOUT serum-albumin below 2.0 g/dl AND WITHOUT antithrombin III level below 70%.
62135579|NCT04347824||high risk|This group has an abnormal urine status on admission to hospital PLUS serum-albumin below 2.0 g/dl OR antithrombin III level below 70%.
61936636|NCT03564028|OTHER|Control session|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
62135580|NCT04567979||Patients with solid tumors|Patients with solid tumors under chemotherapy and / or radiotherapy treatment at our center.
62135581|NCT04567979||Healthcare workers|Healthcare workers at the chemotherapy and radiotherapy unit in our center.
62135582|NCT06154694||Shoulder osteoarthritis patients|Patients with glenohumeral osteoarthritis
62135583|NCT06154694||Healthy control|Healthy adult volunteers with no history of shoulder pain or trauma
62135584|NCT05494294|ACTIVE_COMPARATOR|Intraoral|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
61936637|NCT02322021|EXPERIMENTAL|MCI/Prodromal Cohort: Low Dose|A low dose of E2609 will be assessed.
62488845|NCT04777305|EXPERIMENTAL|Combination exercise training|"The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterwards the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale.~The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale."
62488846|NCT04777305|NO_INTERVENTION|The control group|The control group will receive routine health care without exercise supervision (clinical and nutritional follow up).
62488847|NCT04434716|OTHER|Feasibility of Wearing a Readiband|"Participants will wear the Fatigue Science Readiband for 42 consecutive day. On day one, every seventh day and at the end of the study each participant will complete the Dyspnea-Characteristic scale, BRICS NINR PROMIS Fatigue Short Form6a scale , Modified Pulmonary Functional Status, Dyspnea Questionnaire and the BRICS NINR PROMIS SF v1.0-Sleep Disturbance 6a scale.The Minnesota Living with Heart Failure Questionnaire and Self-Care of Heart Failure Index will be completed on day one and day 60. The purpose of this intervention is to assess the Feasibility of Wearing a Readiband.~Semi-structured Interview will be conducted at the end of 42 days to assess patient comfort and challenges with wearing the Readiband."
62488848|NCT06561308|EXPERIMENTAL|Neoadjuvant chemotherapy combined with PD-1 inhibitor in FIGO III/IV Endometrial carcinoma|Patients with advanced endometrial cancer were enrolled for 2-3 cycles of neoadjuvant chemotherapy in combination with putlizumab, with imaging to assess efficacy; intermittent subtractive surgery (transabdominal hysterectomy + bilateral adnexectomies + pelvic lymph node dissection + pelvic and abdominal tumors resections +/- para-abdominal aortic lymph node dissection) was performed in patients with complete remissions (CR)/partial remissions (PR), and continued with 3-4 cycles of neoadjuvant chemotherapy in combination with putlizumab.
62488849|NCT04879381||Cystic Fibrosis patients|Sputum samples
62694119|NCT06600971|EXPERIMENTAL|acupressure|The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week. The first application was performed in a room in the polyclinic by a researcher with an acupressure application certificate. Immediately after the preparation phase, the researcher applied acupressure with the thumb in a certain order (Ht7-Ht7 and St36-St36) on each point to be pressed, in accordance with the acupressure application protocol, for a duration of 2 minutes. Verbal communication was maintained during the procedure to ensure the patient's relaxation. After the first application, the application was taught to the patient. In addition, the researcher established a WhatsApp group for regular follow-up of the patients in the experimental group, and the video recording of the acupressure was sent to the patients and they were asked to watch it.
62694120|NCT06600971|NO_INTERVENTION|Control|During the study, it was explained to the control group that their fatigue and sleep quality levels would be monitored for four weeks without any intervention (other than routine treatment given by the physician). Patients in this group were asked to fill out the Fatigue Severity Scale and the Richard-Campbell Sleep Scale at the beginning and again in the 4th week.
62694121|NCT02082379|ACTIVE_COMPARATOR|Term newborns 1-6 week old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B\&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
62694122|NCT02082379|ACTIVE_COMPARATOR|Infants 6-8 month old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B\&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
62694123|NCT02321514|EXPERIMENTAL|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement
62694124|NCT06642883|ACTIVE_COMPARATOR|Prolife 10 Forte|Treatment: 1 dose/die (contains 10 ml with: in particular, 7 strains of Lactobacillus (L. casei R215, L. plantarum Lp-115, L. helveticus R0052, L. acidophilus La-14, L. gasseri Lg-36, L. brevis Lbr-35, L. rhamnosus HN001), 2 strains of Bifidobacteria (B. lactis Bl-04 and HN019) and Bacillus coagulans BC4. In addition, it contains 10 mg of glucoligosaccharide and a pool of Vitamin B (B1, B2, B6, B12).
62135585|NCT05494294|ACTIVE_COMPARATOR|Extraoral|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
62135586|NCT06387381|EXPERIMENTAL|68Ga-PSFA|Patients will receive a single administration of 68Ga-PSFA.
62135587|NCT06322446|EXPERIMENTAL|Intervention|"Telematic Exercise:~A remotely supervised resistance exercise program will be carried out for 16 weeks, with two weekly sessions lasting approximately 60 minutes each. Training will be performed in groups of four patients, according to their lung function/physical fitness.~The first training session will be on site (University) for familiarization, planning and adjustment of the exercises, and the following sessions will be performed online. Each session is divided into: (i) Warm-up and joint mobility; (ii) main part: strength exercises for different muscle groups; and (iii) cool down: stretching and breathing exercises."
62135588|NCT06322446|NO_INTERVENTION|Control|Control group will follow routine recommendations from the multidisciplinary CF team based on WHO´s guidelines
62135589|NCT03756571|EXPERIMENTAL|Ankle Foot Orthoses-Footwear Combination|The intervention is a Ankle Foot Orthoses Footwear Combination (AFO-FC). This is some form of solid ankle AFO combined with modified footwear individually designed per algorithm.
62135590|NCT03756571|ACTIVE_COMPARATOR|Traditional Solid Ankle AFO (TSAFO)|"The intervention is a solid AFO (SAFO) aligned with the ankle at 90 degrees and worn with regular footwear. We'll refer to this as the traditional SAFO (TSAFO)..."
62135591|NCT05104866|EXPERIMENTAL|Dato-DXd|Arm 1: Dato-DXd
62135592|NCT05104866|ACTIVE_COMPARATOR|Investigators Choice of Chemotherapy (ICC)|"Arm 2: ICC~Capecitabine~Gemcitabine~Eribulin mesylate~Vinorelbine"
62135593|NCT04363866|EXPERIMENTAL|Hydroxychloroquine|400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
61936638|NCT02322021|EXPERIMENTAL|MCI/Prodromal Cohort: Middle Dose|A middle dose of E2609 will be assessed.
62694125|NCT06642883|PLACEBO_COMPARATOR|Placebo|Treatment 1dose/die ( All additional components except probiotics and vitamins)
62694126|NCT01752179|EXPERIMENTAL|kinesio tape|kinesio Tape : Width 5cm ,Length 35cm Y shape
62694127|NCT01752179|NO_INTERVENTION|Control group|without using Kinesio tape
62694128|NCT03988205|EXPERIMENTAL|Intervention|The study intervention is the application of a prescribed outpatient care model including a nurse teacher educational program and quality of life surveys for both subjects and caregivers. Induction therapy and medical follow up are performed without prophylactic admission to an inpatient facility. Subjects will also receive CPX-351 according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
62694129|NCT05213221|EXPERIMENTAL|Treatment group|Envafolimab, Lenvatinib and TACE
61936639|NCT02322021|EXPERIMENTAL|MCI/Prodromal Cohort: High Dose|A high dose of E2609 will be assessed.
61936640|NCT02322021|PLACEBO_COMPARATOR|MCI/Prodromal Cohort: Placebo|
61936641|NCT02322021|EXPERIMENTAL|Mild to Moderate AD Cohort: Low Dose|A low dose of E2609 will be assessed.
61936642|NCT02322021|EXPERIMENTAL|Mild to Moderate AD Cohort: High Dose|A high dose of E2609 will be assessed.
61936643|NCT02322021|PLACEBO_COMPARATOR|Mild to Moderate AD Cohort: Placebo|
61936644|NCT02322021|EXPERIMENTAL|Mild to Moderate AD cohort: Middle Dose|A middle dose of E2609 will be assessed.
61936645|NCT05140850||PRES group|PE or E with PRES
61936646|NCT05140850||non-PRES group|PE or E without PRES
62135594|NCT04363866|PLACEBO_COMPARATOR|Placebo|Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
61936647|NCT00277797|ACTIVE_COMPARATOR|Biowave first|First Treatment: Biowave; Second Treatment: TENS
61936648|NCT00277797|ACTIVE_COMPARATOR|TENS first|First Treatment: TENS; Second Treatment: Biowave
62135595|NCT05606484|EXPERIMENTAL|Intervention Group (IG)|They will perform an intradialysis physical exercise program with non-immersive virtual reality during the first two hours of hemodialysis treatment (n = 40).
62331109|NCT01160055||Cohort A|Subjects with a new episode of Acute Otitis Media (\<3 days of onset) who have not yet received antibiotic therapy for the episode.
62331110|NCT01160055||Cohort B|Subjects who have had a diagnosis of Acute Otitis Media within 2-3 days prior to study enrolment and received antibiotic therapy, but remain symptomatic.
62694130|NCT04794504|EXPERIMENTAL|Botox Injection Group|Two weeks pre-operatively, patients in the Botox injection group will receive intramuscular injections of Botox totaling 100U bilaterally (50U/side). 10 U will be injected into the temporalis (over 5 sites) and 40 U will be injected into the masseter muscle (over 4 sites). Botox will be reconstituted from a powdered form in 2cc of 0.9% sterile saline, and appropriate volumes will be administered.
62694131|NCT04794504|PLACEBO_COMPARATOR|Saline Injection Group|Two weeks pre-operatively, patients in the saline injection group will receive intramuscular injections of Botox totaling the same volumes administered for Botox patients above, across the same number of sites in the temporalis and masseter muscles bilaterally.
62694132|NCT04806399|NO_INTERVENTION|Usual Care Control Group|
62694133|NCT04806399|ACTIVE_COMPARATOR|Outreach Contact with Decision Counseling Group|
62694134|NCT05611775|OTHER|Activity Monitor Assessment|Subjects will be assessed in the Motion Analysis Laboratory at Mayo Clinic Rochester and have activity monitored in the free-living environment.
62694135|NCT03376386|OTHER|HNSCC receiving (chemo)radiotherapy|Imaging
62694136|NCT06519994|EXPERIMENTAL|Artesunate vaginal inserts|Participants will self-administer the study drug nightly for 5 days, take a week off, and repeat 2 times (study drug application on weeks 1, 3, 5).
62694137|NCT06519994|PLACEBO_COMPARATOR|Placebo vaginal inserts|Participants will self-administer the study placebo nightly for 5 days, take a week off, and repeat 2 times (study drug application on weeks 1, 3, 5).
62694138|NCT04877041|EXPERIMENTAL|Exercise (Intradialytic Cycling)|Participants will receive a standardized baseline exercise counseling session as per control and then participate in a supervised intradialytic cycling program for 12-weeks
62694139|NCT04877041|NO_INTERVENTION|Usual Care|Participants will receive a standardized baseline exercise counseling session. Participants in the control group will not undergo formal exercise intervention, but will not be prohibited from participating in exercise outside of hemodialysis. They will be asked to not to participate in intradialytic cycling during the study (16 weeks total).
61936649|NCT06511050|EXPERIMENTAL|Long Covid|Boluoke® brand lumbrokinase capsules, 300,000 functional units (FUs) twice per day, daily for 6 weeks.
61936650|NCT06511050|EXPERIMENTAL|Post-treatment Lyme Disease Syndrome|Boluoke® brand lumbrokinase capsules, 300,000 functional units (FUs) twice per day, daily for 6 weeks.
61936651|NCT06511050|EXPERIMENTAL|ME/CFS|Boluoke® brand lumbrokinase capsules, 300,000 functional units (FUs) twice per day, daily for 6 weeks.
62135596|NCT05606484|ACTIVE_COMPARATOR|Control Group (CG)|They will exercise with a static pedal during the first two hour of hemodialysis treatment (n = 40).
62135597|NCT05983185|ACTIVE_COMPARATOR|Prism adaptation Therapy|People with spatial neglect will receive this effective treatment to reduce symptoms, which the investigators' previous work indicated may be particularly effective for Aiming SN symptoms.
61936652|NCT01572259|EXPERIMENTAL|interruption of the growth hormone treatment.|
61936653|NCT01572259|EXPERIMENTAL|Patients traited by grouth hormone|
61936654|NCT05314478|EXPERIMENTAL|Participants|Participants will be required to attend a single consultation and screening appointment to discuss the investigation procedure, and this will occur at least a week before the Continuous Laryngoscopy during Exercise (CLE) test. Participants will then attend one appointment for the CLE test. There will be no follow up assessments using the headgear.
61936655|NCT04552925|ACTIVE_COMPARATOR|Exercise Group|Exercise group will receive ROM exercises, stretching and anterior deltoid re-education exercises described by Levy et al. Subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
62135598|NCT05983185|NO_INTERVENTION|No spatial neglect|People without spatial neglect symptoms will not receive an intervention for spatial neglect.
62135599|NCT05374642|EXPERIMENTAL|cognitive training|
62331111|NCT01452958|EXPERIMENTAL|TNF-α|Beromun, Boehringer-Ingelheim, Germany
62331112|NCT01452958|EXPERIMENTAL|Endotoxin|
61936656|NCT04552925|EXPERIMENTAL|EMG-BF Group|EMG-BF group will receive the same exercises as with the other group, but deltoid re-education exercises were performed under the guidance of EMG-BF device. All subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
61936657|NCT04117139|OTHER|Study Group|In addition to other standard imaging modalities in the fast track cancer program, included patients will have a PET/MRI done.
62694140|NCT01782274|EXPERIMENTAL|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
61936658|NCT06061731|ACTIVE_COMPARATOR|Low frequency group treatment|Low frequency group treatment: The treatment frequency is selected as 50Hz, pulse width 0.3ms, waveform is intermittent waveform, stimulation intensity is tolerated by the patient, the instrument program is set to stimulate the first group of acupoints → second group → first group → third group, forming a set of programmed movements, cyclic operation, appearing alternate movements of flexor and extensor muscles, namely: wrist dorsal extension, five-finger extension → five-finger flexion → wrist dorsal extension, five-finger extension → thumb-index finger pair pinching, simulating fine movements Grasp of the hand, thumb-index finger pair pinch. The treatment course was the same as that of the electroacupuncture group.
61936659|NCT06061731|NO_INTERVENTION|Electroacupuncture group treatment|Electroacupuncture group treatment: After the above acupuncture to deqi, choose KWD-808 Ⅰ type Indy brand pulse acupuncture treatment instrument, the waveform is continuous wave, the stimulation frequency is 2Hz, the intensity to be tolerated by the patient. There should be muscle contraction at the acupuncture site during electroacupuncture treatment. The treatment time should be 30 minutes each time, once a day, 6 days a week with 1 day off, for a total of 3 weeks.
61936660|NCT01702571|EXPERIMENTAL|Trastuzumab Emtansine (All Participants)|This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
61936661|NCT01702571|EXPERIMENTAL|Trastuzumab Emtansine (Asian Participants)|This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
61936662|NCT05426096|NO_INTERVENTION|Control|
61936663|NCT05426096|EXPERIMENTAL|BPA Intervention|"The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines. When a patient meets the study criteria, the BPA will provide an automated notification through the electronic health record system. These automated notifications will pop up intraoperatively after the glucose check reminder in cases where the patient meets the study criteria. The provider is not forced to follow the recommendations of the insulin dosing calculator, rather it just serves as a reminder of best practices as defined by our department.~The intervention will be assessed using a sequential and repeated cross-over design at the institutional level with periods of time for wash in, wash out, control and study intervention."
61936664|NCT02767505|EXPERIMENTAL|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
61936665|NCT02767505|ACTIVE_COMPARATOR|Gastric bypass|Laparoscopic Roux-en-Y gastric bypass
61936666|NCT03360747|EXPERIMENTAL|AKCEA-ANGPTL3-LRx 20 mg|Participants received a subcutaneous (SC) injection of AKCEA-ANGPTL3-LRx, 20 milligrams (mg), weekly (QW) for 13-weeks of treatment period. Participants were followed up to Week 26.
61936667|NCT03981952|EXPERIMENTAL|Cohort A (Step 1)|Individuals receive one dose of either 6.25 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
61936668|NCT03981952|EXPERIMENTAL|Cohort B (Step 2)|Individuals receive one dose of either 12.5 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
62135600|NCT05374642|ACTIVE_COMPARATOR|active control|
61936669|NCT03981952|EXPERIMENTAL|Cohort C (Step 3)|Individuals receive one dose of either 25 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
61936670|NCT03981952|EXPERIMENTAL|Cohort D|Individuals receive one or two doses of the highest, well-tolerate dose among Cohorts A-C of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
61936671|NCT02938039|ACTIVE_COMPARATOR|Ambu LMA|Ambu Laryngeal Mask Airway device of different sizes for age
61936672|NCT02938039|ACTIVE_COMPARATOR|I-Gel LMA|I-Gel Laryngeal Mask Airway device of different sizes for age
61936673|NCT01050049||Before guidelines implemented|
61936674|NCT01050049||After guidelines implemented|
61936675|NCT00632073|EXPERIMENTAL|VCV + Failing HAART|Vicriviroc plus failing highly-active antiretroviral therapy
61936676|NCT03852004|EXPERIMENTAL|Osteopatic treatment|An osteopatic treatment will be realised by osteopath
62135601|NCT01472510|ACTIVE_COMPARATOR|Arm 1:The PRN Group|You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
62135602|NCT01472510|ACTIVE_COMPARATOR|arm 2:The Monthly Group:|You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
62331113|NCT02833649|EXPERIMENTAL|Toric Implantable contact Lens|The Visian implantable collamer lens (Staar Surgical AG, Nidau, Switzerland), is a monoblock single-piece plate haptic lens made of collamer (an extremely hydrophilic and highly biocompatible flexible collagen copolymer with a refractive index of 1.452 that is permeable to oxygen and nutrients
62331114|NCT01165723|EXPERIMENTAL|IV Dose 1: experimental|
62331115|NCT01165723|EXPERIMENTAL|IV Dose 2: experimental|
62331116|NCT03122028|EXPERIMENTAL|LAmbre closure system|
62488850|NCT06562010|EXPERIMENTAL|Intervention group|The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
62135603|NCT06527703||preoperative liquid fasting duration in adult patients undergoing elective surgery|"Adult patients scheduled for elective procedures and either requiring general anaesthetic, regional anaesthesia or sedation will be eligible to participate. The necessary institutional approvals will be obtained.~Data will be collected on the same day among the participating centres. After obtaining consent and screening for eligibility, the patients will answer a short questionnaire regarding their last liquid intake.~The type of procedure, type of anaesthesia and time of arrival in the holding bay / operating room as well as the date and time at which clear fluids were last consumed will be recorded"
62331117|NCT00947570|EXPERIMENTAL|Cognitive behavioral therapy|Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
62488851|NCT06562010|NO_INTERVENTION|Control|The control arm will receive no intervention except usual care.
62488852|NCT02184715|ACTIVE_COMPARATOR|Virtual reality video game|Participants received rehabilitation treatment and additional virtual reality system (30 minutes of interactive virtual reality system play, two times per week, in eight sessions over a 4-week span) for 1 month, followed by rehabilitation treatment for 1 month
62488853|NCT02184715|PLACEBO_COMPARATOR|Virtual reality system|received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system (30 minutes of interactive video game play, two times per week, in eight sessions over a 4-week span) during the one month of intervention period.
62488854|NCT06623695|EXPERIMENTAL|Stable Ground Group (SGG)|Stable Ground Group (SGG) participants performed exercises on a stable floor surface
62488855|NCT06623695|EXPERIMENTAL|Unstable Ground Group (USGG)|Unstable Ground Group (USGG) participants completed the exercise program on a bosuball.
62488856|NCT06623695|NO_INTERVENTION|Control Group (CG)|Control Group (CG) did not participate in any exercise program. CG continued their daily routine activities and maintained their current physical activity levels.
62488857|NCT04563481|EXPERIMENTAL|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
62488858|NCT04563481|EXPERIMENTAL|Rehabilitation by Physiotherapist in the Clinic|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist in the clinic for 3 sessions per week.
62488859|NCT03193021|EXPERIMENTAL|Cardiva Mid-Bore VVCS|Cardiva Mid-Bore VVCS will be used to close all femoral venous access sites at the end of the case.
62488860|NCT03193021|ACTIVE_COMPARATOR|Manual Compression|Direct manual compression to the access sites will be used to close all femoral venous access sites at the end of the case.
62488861|NCT02275403|EXPERIMENTAL|Arm A: Standard care plus acupuncture|Medication taken to manage the symptom burden of CIPN plus acupuncture
62488862|NCT02275403|ACTIVE_COMPARATOR|Arm B: Standard care alone|Medication taken to manage the symptom burden of CIPN
62331118|NCT04870112|EXPERIMENTAL|Patients with NSCLC|Patients with Non-Small Cell Lung Cancer
62331119|NCT04870112|EXPERIMENTAL|Patients with SCLC|Patients with Small Cell Lung Cancer
62331120|NCT04875975|EXPERIMENTAL|Rozanolixizumab|Participants will be randomized to receive a predefined dose of rozanolixizumab.
62488863|NCT02638922||no treatment|girls who never received estradiol treatment
62488864|NCT02638922||Estradiol treatment|girls who received estradiol treatment
62488865|NCT01756716|EXPERIMENTAL|MT-3995 Low group|
62488866|NCT01756716|EXPERIMENTAL|MT-3995 High group|
62488867|NCT01756716|PLACEBO_COMPARATOR|Placebo group|
62488868|NCT00474058|EXPERIMENTAL|Rotigotine|Rotigotine transdermal patch
62488869|NCT00474058|PLACEBO_COMPARATOR|Placebo|Placebo transdermal patch
62331121|NCT04875975|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive a dose of placebo.
62331122|NCT06373913||Nephrotic syndrome|"Patients with nephrotic syndrome (n=32). Blood samples and 24 hour urine samples will be obtained an all participants. Kidney biopsy will be used from 11 test persons, whos been subjected to kidney biopsy unrelated to the research project.~3"
62331123|NCT06373913||Kidney healthy controls|Patient with normal kidney function and no proteinuria (n=32). Blood samples and 24 hour urine samples will be obtained an all participants.
62488870|NCT06102148|EXPERIMENTAL|PNF Group|
62488871|NCT06102148|SHAM_COMPARATOR|Control Group|
62488872|NCT00209690|EXPERIMENTAL|1|
62488873|NCT00934323|EXPERIMENTAL|TR sequential group|Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
62488874|NCT00934323|ACTIVE_COMPARATOR|RT sequential group|Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
62488875|NCT02672267|EXPERIMENTAL|Stem Cells|Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells
62488876|NCT02672267|PLACEBO_COMPARATOR|Placebo|Lactated Ringer's Solution
62488877|NCT05570955|OTHER|Intervention|50% of subjects will be randomized to a reporting tool designed to promote better adherence to treatment by having subjects report their progress on a weekly basis (the goal is not to test this tool but to help assure there is a broad range of adherence behavior including some positive adherence outliers)
62488878|NCT05570955|NO_INTERVENTION|No Intervention|50% of subjects will not receive additional outreach to improve adherence
62488879|NCT06627790|EXPERIMENTAL|Potassium nitrate containing herbal mouthwash|Group A: Participants will be adviced to use mouthwash twice daily in 10ml volume for 60 seconds, 30 minutes after brushing and not to eat anything for 45 minutes
62488880|NCT06627790|ACTIVE_COMPARATOR|Potassium oxalate mouthwash|Group B: Participants will be adviced to use mouthwash twice daily in 10ml volume for 60 seconds, 30 minutes after brushing and not to eat anything for 45 minutes.
62488881|NCT02031250|ACTIVE_COMPARATOR|Control Arm|Standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
62694141|NCT01782274|ACTIVE_COMPARATOR|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
62694142|NCT02843425|EXPERIMENTAL|Regular Diet + Beans, Then Regular Diet - Beans|
61936677|NCT03852004|PLACEBO_COMPARATOR|simulated osteopathic treatment|A simulated ostepathic treatment will be realised by osteopath
61936678|NCT02144129|EXPERIMENTAL|active WB-EMS|2 sessions/week with 20 min of active WB-EMS application
61936679|NCT02144129|EXPERIMENTAL|Passive WB-EMS|2 sessions/week with 20 min of passive WB-EMS application in a resting supine position
61936680|NCT02144129|NO_INTERVENTION|Inactive Control Group|sedentary non-training control group
61936681|NCT02586051|EXPERIMENTAL|Cohort 1: Single Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Day 1 followed by high dose intravenous immunoglobulin (IVIG) on Days 22 and 43 of treatment period.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation \[within the first 48 hours of the transplantation\] and second at Week 24 post-transplantation)."
61936682|NCT02586051|EXPERIMENTAL|Cohort 2: Repeated Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Days 1 and 15 followed by high dose IVIG on Days 22 and 43. An additional dose of obinutuzumab may be administered on Day 169 at investigator's discretion.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation \[within the first 48 hours of the transplantation\] and second at Week 24 post-transplantation)."
61936683|NCT03995836||Obstructive Sleep Apnea|
61936684|NCT03995836||Non Obstructive Sleep Apnea|
61936685|NCT03987776|EXPERIMENTAL|Anti-inflammatory diet|energy-reduced diet with the use of low glycemic foods, wholegrain products, legumes, colorful vegetables and fruit, nuts, seeds, marine fish, olive oil, green/black tea, and multiple spices and herbs
61936686|NCT03987776|EXPERIMENTAL|Control energy-resticted diet|isocaloric to anti-inflammatory diet, energy restricted diet (55-60% carbohydrates, 25% fat, 15-20% protein) used in a standard obesity management
61936687|NCT00953381|EXPERIMENTAL|5 mg ilaprazole|
61936688|NCT00953381|EXPERIMENTAL|10 mg ilaprazole|
61936689|NCT00953381|EXPERIMENTAL|20 mg ilaprazole|
61936690|NCT00953381|ACTIVE_COMPARATOR|20 mg omeprazole|
61936691|NCT00512967||sarcoidosis|21 onset patients, non-treated
61936692|NCT00512967||IPF|15 IPF patients, partially treated
62135604|NCT06527703||preoperative liquid fasting time|"Adult patients scheduled for elective procedures and either requiring general anaesthetic, regional anaesthesia or sedation will be eligible to participate. The necessary institutional approvals will be obtained.~Data will be collected on the same day among the participating centres. After obtaining consent and screening for eligibility, the patients will answer a short questionnaire regarding their last liquid intake.~The type of procedure, type of anaesthesia and time of arrival in the holding bay / operating room as well as the date and time at which clear fluids were last consumed will be recorded"
62135605|NCT06296992|EXPERIMENTAL|12-week TEAM peer mentor program|A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
62488882|NCT02031250|EXPERIMENTAL|Boost Arm|Boost radiation to hypoperfused/low-diffusion volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
62694143|NCT02843425|ACTIVE_COMPARATOR|Regular Diet - Beans, Then Regular Diet + Beans|
62694144|NCT06643754|EXPERIMENTAL|SHR-3276 for Injection will be administrated per dose level in which the patients are assigned.|
62694145|NCT05621837||Metastatic melanoma patients|MDSC quantification in Metastatic melanoma patients undergoing first/second-line treatment with BRAF and MEK inhibitors (BRAFi+MEKi) or immune checkpoint inhibitors (antagonists of PD-1 or CTL4, or both) (n=100);
61936693|NCT00512967||COPD|15 COPD patients within 24 hours after their last exacerbation
62694146|NCT05621837||hormone receptor positive/Human Epidermal growth factor Receptor-2 negative cancer patients|MDSC quantification in Metastatic HR+(hormone receptor positive)/ HER2-(Human Epidermal growth factor Receptor-2 negative) breast cancer patients already treated with a combination of an hormonal agent and a CDK(Cyclin-dependent kinase)4/6 inhibitor and receiving chemotherapy (n=100);
61936694|NCT00512967||controls|25 healthy controls, matched for age and gender
61936695|NCT04940208||post COVID-19 ICU survivors|Patients hospitalized to the ICU in the context of severe COVID-19 and discharged alive during the first French COVID-19 pandemic wave
61936696|NCT04295473|EXPERIMENTAL|Reduced port laparoscopic gastrectomy|The definition of reduced port laparoscopic gastrectomy was 1-3 ports used in laparoscopic gastrectomy for gastric cancer.
61936697|NCT04295473|NO_INTERVENTION|Standard laparoscopic gastrectomy|5 ports were used in standard laparoscopic gastrectomy
61936698|NCT06374771|ACTIVE_COMPARATOR|Melatonin (M group)|Two hours before surgery, patients will receive 10 mg of melatonin (Melatonin 10 mg - Puritan's Pride premium company) orally which will be continued once daily for 3 days postoperative at the same time as the first administration.
61936699|NCT06374771|ACTIVE_COMPARATOR|Vitamin C (V group)|Two hours before surgery, patients will receive 1gm of vitamin C (Sanso C 1000 mg - AUG pharma company) orally which will be continued once daily for 3 days postoperative at the same time as the first administration.
62488883|NCT06626646||Peripheral Artery Disease|20 patients with clinically significant/symptomatic Peripheral Artery Disease defined as symptomatic claudication and an ABI of \<0.85
62488884|NCT06626646||Control Group|20 patients who do not have Peripheral Artery Disease
62488885|NCT01878864|EXPERIMENTAL|Bupivacaine lozenge|Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
62488886|NCT01878864|ACTIVE_COMPARATOR|Lidocaine-adrenalin injection|Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.
62488887|NCT03051776|EXPERIMENTAL|Kinesio Taping|It was done a four week phase with Kinesio Taping in the arm affected with lymphedema.
62488888|NCT03051776|ACTIVE_COMPARATOR|Compression garment|It was done a four week phase with Compression garment in the arm affected with lymphedema.
62488889|NCT02798458|EXPERIMENTAL|SmartPill Test|All subjects will be asked to complete a SmartPill test. The SmartPill capsule is pill-shaped and about an inch long and ½ inch wide, or about the size of a vitamin pill. The receiver unit is about the size of a paperback book. The receiver gets signals from the capsule and stores the signals on a computer chip. The capsule detects the level of acidity, temperature, and pressures in your stomach and intestines and sends the information by radio wave signals to the receiver.
62488890|NCT02798458|EXPERIMENTAL|Endoscopic Mucosal Resection|An additional small group of subjects will also be asked to complete a Sigmoidoscopy (an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed. In the Endoscopy Mucosal Resection (EMR) procedure we will use an instrument called an endoscope (a lighted, flexible tube) to take a tissue sample from the rectum. This is the same type of instrument used in a routine colonoscopy
62488891|NCT04777552||Fixed-schedule|Untill mid 2013 patients with individually determined fixed-schedule dosage of benzodiazepines in the case of alcoholdependence.
62488892|NCT04777552||CIWA-Ar|Halfway through the year 2013 the department of psychiatry changed the protocol in alcohol withdrawal treatment and changed it to a symptom-triggered therapy with the use of CIWA-Ar to assess the severity of the alcohol withdrawal syndrome.
62488893|NCT01756885|ACTIVE_COMPARATOR|Standard Varenicline Treatment|"12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Days 85-168: Placebo - 1.0mg twice daily orally"
62488894|NCT01756885|EXPERIMENTAL|Extended Varenicline Treatment|"24 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally"
62488895|NCT01121419||Neuroblastoma|
62694147|NCT05621837||Advanced RCC(renal cell carcinoma) patients|MDSC quantification Advanced RCC patients receiving immune checkpoint inhibitors (antagonists of PD-1, PD-L1 or CTL4, or combinations) or anti-angiogenics alone or combined with immune checkpoint inhibitors; locally advanced/metastatic UC(Urothelial Carcinoma) patients receiving first-line chemotherapy, immune checkpoint inhibitors or combinations (n=100);
62694148|NCT05621837||SCCHN or SCC(Small Cell Carcinoma) patients|MDSC quantification in SCCHN or SCC(Small Cell Carcinoma) patients treated with first-line chemotherapy, cetuximab,immune checkpoint inhibitors or combinations (n=100).
62488896|NCT00393276|EXPERIMENTAL|A|HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.
62488897|NCT00393276|EXPERIMENTAL|B|HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.
62488898|NCT00393276|EXPERIMENTAL|C|HCV/HIV-coinfected as defined above in Arms A and B.
62488899|NCT01806272|EXPERIMENTAL|Arm A|"Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.~Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
62488900|NCT01806272|ACTIVE_COMPARATOR|Arm B|"Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
62488901|NCT05266287|EXPERIMENTAL|Investigational supplement|Participants in this arm will take a supplement containing 2'-fucosyllactose (2'-FL)
62488902|NCT05266287|PLACEBO_COMPARATOR|Placebo supplement|Participants in this arm will take a placebo supplement
62488903|NCT02057562||Routine colonoscopy|Patients receiving routine colonoscopy (for a multitude of indications) at the study centers are eligible for participation
62488904|NCT02042560||Patients with ITP|
62488905|NCT02042560||Controls|
62488906|NCT05281354|NO_INTERVENTION|standard care|Follow-up according to standard practice
62694149|NCT05621837||NSCLC patients|MDSC quantification in NSCLC patients undergoing radical surgery for stage III cancer (n=100);patients with unresectable/metastatic NSCLC receiving first line treatment with chemotherapy, immune checkpoint inhibitors (antagonists of PD-1, PD-L1 or CTL4) or combinations (n=100).
62488907|NCT05281354|EXPERIMENTAL|multimodal intervention|Addition of a treatment to normalise resting energy expenditure according to the observed abnormalities
62488908|NCT01855880|EXPERIMENTAL|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
62488909|NCT01855880|EXPERIMENTAL|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
62694150|NCT05621837||Age and gender-matched healthy donors|Age and gender-matched healthy donors (n=400) will be enrolled in the study, to allow us investigating the same immunological parameters under physiological conditions and define normal values for the myeloid-related biomarkers here assessed.
62694151|NCT03573089|ACTIVE_COMPARATOR|Liberal phosphate target|Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
62694152|NCT03573089|EXPERIMENTAL|Intensive phosphate target|Intensive serum phosphate target of ≤1.50 mmol/L.
62488910|NCT01855880|PLACEBO_COMPARATOR|Placebo AbGn-168H|Subject to receive placebo
62488911|NCT04739735|EXPERIMENTAL|Computer Controlled -Intraligamentary Anaesthesia (CC-ILA)|"CC-ILA will be administered using the Wand-STA system according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted mandibular teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle."
62488912|NCT04739735|ACTIVE_COMPARATOR|Conventional Injection of Inferior Alveolar Nerve Block|"* In the control group, a standard technique for the Inferior Alveolar Nerve Block (IANB) will be used supplemented with long buccal infiltration for the buccal gingiva.~* A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed between the two primary molars on the opposite side of the arch, entering the tissues at the level of the occlusal plane or slightly lower until bony resistance is met.~Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. Two-thirds the needle length should be inserted. The needle is withdrawn, then 0.5 ml as a long buccal infiltration distal to the second primary molar is administered."
62488913|NCT05321030||Smartphone addict|
62488914|NCT05321030||Smartphone non addict|
62488915|NCT03245658|EXPERIMENTAL|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
61936700|NCT06374771|ACTIVE_COMPARATOR|Melatonin and Vitamin C (VM group)|Two hours before surgery, patients will receive 10mg of melatonin and 1gm of vitamin C orally which will be continued once daily for 3 days postoperative at the same time as the first administration.
61936701|NCT01299987|EXPERIMENTAL|Intraoperative radiotherapy|single arm with intraoperative radiotherapy
61936702|NCT02175784|EXPERIMENTAL|ipragliflozin group|oral
62331124|NCT06373913||Kidney biopsy control|Patients without proteinuria who is subjected to kidney biopsy regardless of the research project.
62331125|NCT01412645|PLACEBO_COMPARATOR|Placebo|
62331126|NCT01412645|EXPERIMENTAL|High-dose Resveratrol|
62331127|NCT01412645|EXPERIMENTAL|Low-dose Resveratrol|
62331128|NCT02405052||Patients|Emergency department patients with unexplained chest pain
62331129|NCT05495074|EXPERIMENTAL|Dietary Intervention|Participants will be assigned a diet for two months following the indications of the National Cholesterol Education Program Adult Treatment Panel III program.
62331130|NCT00316303|EXPERIMENTAL|1|Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
62331131|NCT00316303|PLACEBO_COMPARATOR|2|Participants will receive enhanced treatment as usual.
62331132|NCT01881594|ACTIVE_COMPARATOR|No stimulation|unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb.
62331133|NCT01881594|EXPERIMENTAL|Stimulation|stimulation of the efferent limb of the ileostomy prior to ileostomy closure.
62331134|NCT05087628|EXPERIMENTAL|PRV-3279|Sterile solution for intravenous administration, every 4 weeks
62331135|NCT05087628|EXPERIMENTAL|Placebo|Sterile solution for intravenous administration, every 4 weeks
62331136|NCT04119726|OTHER|Control Group|The control group will receive a simplified tool including only the education message. The methodology will ensure that potential confounders by differences in nonspecific support and attention could be adjusted. Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behavior. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
62331137|NCT04119726|EXPERIMENTAL|Intervention Group|The intervention group will receive a complete social medial tool (web-based application ) installed on mobile phones including general education about coronary disease、personalized reminders and internet-based counseling. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
62331138|NCT04421196|NO_INTERVENTION|Standard multimodal analgesic pathway with opioids|"This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.~The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) \& Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr"
62331139|NCT04421196|EXPERIMENTAL|Modified multimodal analgesic pathway without opioids|"This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.~The modified multimodal analgesic regimen utilizes the following medications:~includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr"
62331140|NCT01758393|EXPERIMENTAL|Medium Dose|Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
62331141|NCT01758393|EXPERIMENTAL|High Dose|Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
62488916|NCT03245658|NO_INTERVENTION|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
62488917|NCT03497858|EXPERIMENTAL|coconut water|participants will complete the simulated basketball game with coconut water supplementation
62488918|NCT03497858|PLACEBO_COMPARATOR|Placebo - water|participants will complete the simulated basketball game with water supplementation
61936703|NCT02175784|EXPERIMENTAL|placebo group|oral
61936704|NCT03174249|EXPERIMENTAL|Exposure therapy|Graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.
62488919|NCT03497858|EXPERIMENTAL|Sports drink|participants will complete the simulated basketball game with sports drink supplementation
62331142|NCT04626024|EXPERIMENTAL|All Subjects Enrolled (stop taking TKI)|Patients with a diagnosis of Philadelphia chromosome- or BCR-ABL1-positive CML (as determined by cytogenetics, FISH, or PCR), prior evidence of a quantifiable BCR-ABL1 transcript by RT-PCR, and whom have been taking TKI for \> 36 months with a current status of complete molecular remission (CMR). TKI cessation begins within 7 days of study registration. Patients undergo BCR-ABL1 test every month in 24 months.
62331143|NCT01290484|EXPERIMENTAL|Open Label|Sildenafil oral tablet three times daily
62488920|NCT05239169|EXPERIMENTAL|A: Cape+Durva+Treme|Capecitabine + Durvalumab + Tremelimumab
62488921|NCT05239169|ACTIVE_COMPARATOR|B: Durva+Treme|Durvalumab + Tremelimumab
62488922|NCT04699084|EXPERIMENTAL|Music Group|Patients received music intervention and usual postoperative care.
62135606|NCT06296992|NO_INTERVENTION|12-week waitlist control|A 12-week waitlist control group that receives usual care, including standard educational resources developed by the Canadian Society of Exercise Physiology and the American Heart Association for adopting and sustaining daily PA. Adolescents randomized to the control arm will receive the 12 week intervention following the 24 week follow-up time point.
62488923|NCT04699084|NO_INTERVENTION|Control Group|Patients received only postoperative usual care.
62488924|NCT03401281|ACTIVE_COMPARATOR|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
62488925|NCT03401281|ACTIVE_COMPARATOR|Butter|50g Butter to be consumed daily for four weeks
62488926|NCT03401281|ACTIVE_COMPARATOR|Olive oil|50g extra virgin olive oil to be consumed daily for four weeks
62694153|NCT01380080|EXPERIMENTAL|Arm A: Empiric|Study treatment for Arm A participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral treatment as soon as possible following randomization and within no more than 3 days following randomization plus a 4-drug anti-tuberculosis treatment (ATT) regimen (defined as rifampin/isoniazid/ethambutol/pyrazinamide) as soon as possible following randomization and within no more than 7 days following initiation of antiretroviral therapy. After 2 months (or 8 weeks), the 4-drug ATT will be followed with 4 months (or 16 weeks) of 2-drug ATT (defined as rifampin/isoniazid). All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only
62135607|NCT06324786|EXPERIMENTAL|IBMT|An evidence-based preventive intervention - integrative body-mind training (IBMT) has shown positive effects in reducing stress and improving self-control and brain plasticity. It has bodifulness and mindfulness components.
62135608|NCT06324786|EXPERIMENTAL|NF|An evidence-based intervention - NF can not only provide real-time feedback for practice but also target the self-control networks, suggesting the possibility of augmenting IBMT effects via NF.
62331144|NCT05990764|EXPERIMENTAL|Probiotic, Prebiotic, Polyphenol-rich Extracts|18 patients with IBS
62331145|NCT05990764|EXPERIMENTAL|Probiotic, Prebiotic|18 patients with IBS
62135609|NCT06324786|EXPERIMENTAL|IBMT + NF|The combined IBMT and NF also show positive effects in reducing substance use.
62488927|NCT02033902||Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
62488928|NCT06175364|OTHER|Health Professionals in the Field of Orthotics Prosthetics|Health professionals in the field of orthotics and prosthetics generally include orthotic and prosthetic specialists, physiotherapists, rehabilitation specialists, orthopedic surgeons, biomechanics experts, physiologists, and engineers. These professionals specialize in the design, production, application, and rehabilitation of orthoses and prostheses.
62488929|NCT03095781|EXPERIMENTAL|Treatment (pembrolizumab, XL888)|Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62488930|NCT03273751|EXPERIMENTAL|Remote Ischemic Preconditioning (RIPC)|Four cycles of upper arm ischemia/reperfusion
62488931|NCT03273751|SHAM_COMPARATOR|Sham control|Placement of a blood pressure cuff around upper arm without inflation.
62135610|NCT06324786|SHAM_COMPARATOR|Sham NF|Sham NF has the same settings as the active NF but does not have correct parameters of stimulation.
62331146|NCT05990764|PLACEBO_COMPARATOR|Placebo|18 patients with IBS
62331147|NCT01029002|EXPERIMENTAL|Vitamin D 50000 IU|Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
62331148|NCT01029002|PLACEBO_COMPARATOR|Placebo|Patients randomized to this arm will receive a placebo pill once weekly.
62331149|NCT02756390|EXPERIMENTAL|Arm A (Sleep Hygiene & CBTI-CS)|Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions
62331150|NCT02756390|OTHER|Arm B (Telehealth Pilot of CBTI-CS)|Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.
62488932|NCT00627328||1|pacemaker patients with previously diagnosed AT.
62488933|NCT00627328||2|pacemaker patients without previously diagnosed AT.
62488934|NCT01601353|EXPERIMENTAL|Treatment|Injection of adipose derived cells into penis
62488935|NCT01601353|NO_INTERVENTION|Control|No intervention through 9 months
62488936|NCT02068651|EXPERIMENTAL|Advance care planning programme|Participants in the experimental group will receive a structured advance care planning programme, namely Let Me Talk, delivered by a trained nurse facilitator. The programme will be conducted on individual basis through three one-hour home visits, once weekly. Family carers of the participants will be invited to all sessions.
62488937|NCT02068651|NO_INTERVENTION|Usual care|Participants in the control group will receive three weekly home visits with basic health assessment and education provided by the trained nurse facilitator. If they request advance care planning information or assistance, an advance directive form, which is available on the Internet for public access, will be provided to them for their information.
62488938|NCT01918813|EXPERIMENTAL|Preoperative MRSA nasal colonization|Interventions in arm of preoperative MRSA nasal colonization consisted of antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA with application of 2% mupirocin ointment twice daily to nares for 5 days
62135611|NCT02910713|EXPERIMENTAL|Intranasal Application|Intranasal Tear Neurostimulator applied intranasally device (active), intranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
62488939|NCT06559800|EXPERIMENTAL|Cognitive behavior therapy for children and youth with role-plays in virtual reality|Child/youth cognitive-behavioral program with up to 10 individual, face-to-face, weekly sessions
62488940|NCT02073890||traumatic subarachnoid haemorrhage|
62488941|NCT01820091|EXPERIMENTAL|Cohort 1 - Fusilev - 20 doses|"5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle~Days 2 and 16: 4 doses/day~Days 3 and 17: 4 doses/day~Days 4 and 18: 2 doses/day~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
62488942|NCT01820091|EXPERIMENTAL|Cohort 2 - Fusilev - 12 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
62135612|NCT02910713|SHAM_COMPARATOR|Extranasal Application|Intranasal Tear Neurostimulator device applied extranasally (control) for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
62135613|NCT06398600|ACTIVE_COMPARATOR|Caudal block group|This group of patient receiving caudal block in prone position before the operation.
62331151|NCT06128005|EXPERIMENTAL|knowledge translation in nursing for pressure injury care|Using guideline and evidence based practice for pressure injury. The experimental group has received knowledge translation in nursing for pressure injury care with precaution teaching plan by using self-designed teaching materials, manuals, videoes, multimedia tools (power point, LINE official account, LINE one-on-one lesson, virtual lesson), in-person assistance and assessment in 12weeks.
62331152|NCT06128005|PLACEBO_COMPARATOR|Regular care|The controlled group maintained the regular nursing intervention.
62331153|NCT06555926|EXPERIMENTAL|Acupressure group|The pregnant women will receive acupressure and advice for 12 weeks
62135614|NCT06398600|ACTIVE_COMPARATOR|Quadratus lumborum plane block|This group of patient receiving quadratus lumborum plane block in prone position before the operation.
62135615|NCT06398600|NO_INTERVENTION|controlled group|this group of patient will not receive any blocks, only undergoing operation under general anesthesia and receive only 1 g paracetamol 30 min before end of operation
62135616|NCT01101711||Patients with subarachnoid hemorrhage|
62135617|NCT05100784||Sperm with normal spermogramm and more than 10 millions spermatozoids|Normal spermogramm : concentration ≥15 million / ml or total count\> 39 million, progressive mobility ≥32% or total mobility ≥40%
62135618|NCT06266936||Cohort with health students|
62135619|NCT03468634|EXPERIMENTAL|Adenocarcinoma|patients diagnosed with adenocarcinoma
62135620|NCT03468634|EXPERIMENTAL|Squamous cell cancer|patients diagnosed with squamous cell cancer
62331154|NCT06555926|ACTIVE_COMPARATOR|Advice group|The pregnant women will receive advice only for 12 weeks
62331155|NCT05729217||Group 1 aged 7-12 years|Group 1 will mainly be primary school students from grade 1 to 6.
62331156|NCT05729217||Group 2 aged 13-15 years|Group 2 will mainly be middle school students from grade 13 to 15.
62331157|NCT05729217||Group 2 aged 16-18 years|Group 3 will mainly be high school students from grade 16 to 18.
62331158|NCT03572439|ACTIVE_COMPARATOR|Cephalad to caudal|Sensory block level check using ice, moving from cephalad to caudal
62331159|NCT03572439|ACTIVE_COMPARATOR|Caudal to cephalad|Sensory block level check using ice, moving from caudal to cephalad
62331160|NCT04068467|EXPERIMENTAL|Active|Instructed to download the app and use the app daily for 30 days.
62331161|NCT04068467|ACTIVE_COMPARATOR|Waitlist Control|Waitlist control.
62488943|NCT01820091|EXPERIMENTAL|Cohort 3 - Fusilev - 8 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
62488944|NCT01820091|EXPERIMENTAL|Cohort 4 - Fusilev - 4 doses|"5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
62488945|NCT01820091|EXPERIMENTAL|Cohort 5 - Fusilev - 2 doses|"5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
62488946|NCT05299463|OTHER|Exercise|
62488947|NCT03225664|EXPERIMENTAL|Treatment (trametinib, pembrolizumab)|Patients receive trametinib PO QD 14 days prior to cycle 1 and days 1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62488948|NCT01942135|EXPERIMENTAL|Arm A|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
62135621|NCT03468634|EXPERIMENTAL|Other|patients diagnosed with another condition
62135622|NCT03468634|EXPERIMENTAL|Barrett's oesophagus|patients diagnosed with Barrett's oesophagus
62135623|NCT03468634|EXPERIMENTAL|Low-grade dysplasia|patients diagnosed with low-grade dysplasia
62135624|NCT03468634|EXPERIMENTAL|High-grade dysplasia|patients diagnosed with high-grade dysplasia
62135625|NCT03468634|EXPERIMENTAL|Indefinite for dysplasia|patients where the diagnosis is unclear
62135626|NCT03468634|EXPERIMENTAL|no dysplasia|patients not diagnosed with any cancer
62135627|NCT05222646|ACTIVE_COMPARATOR|Metoclopramide group|They will be receiving10mg of Metoclopramide intramuscularly
62135628|NCT05222646|ACTIVE_COMPARATOR|Hyoscine bromide group|They will be receiving 20 mg of Hyoscine bromide
62135629|NCT03562325|OTHER|ACT|Acceptance \& Commitment Therapy (ACT)
62135630|NCT00477893|PLACEBO_COMPARATOR|Placebo|
62135631|NCT00477893|ACTIVE_COMPARATOR|Adalimumab|
62135632|NCT06241560|EXPERIMENTAL|BI 1015550, then Pirfenidone + BI 1015550|
62331162|NCT05197595|EXPERIMENTAL|Compassion condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
62331163|NCT05197595|ACTIVE_COMPARATOR|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extracurricular activity.
62488949|NCT01942135|ACTIVE_COMPARATOR|Arm B|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
62488950|NCT02959619|EXPERIMENTAL|Ensartinib|Escalating dose of ensartinib was orally given once er day
62488951|NCT05441592|EXPERIMENTAL|Irrigation that contains tranexamic acid (TXA)|
62488952|NCT05441592|OTHER|No additional irrigation usual care|
62488953|NCT01185158|EXPERIMENTAL|ZD1839 (IRESSA) 250mg|ZD1839(IRESSA) 250mg orally (po) daily
62488954|NCT00354159|EXPERIMENTAL|Treatment Arm|Physicians have access to device-based hemodynamic monitor information to guide patient management
62488955|NCT00354159|PLACEBO_COMPARATOR|Control Arm|Physicians do not have access to device-based hemodynamic monitor information to guide patient management
61936705|NCT00976677|ACTIVE_COMPARATOR|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes (with or without bevacizumab IV over 30-90 minutes) on day 1. Patients also receive placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive placebo (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
62135633|NCT02847013|PLACEBO_COMPARATOR|Placebo- Tap block w normal saline|After completion of surgery with closer of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, 20cc of Normal saline will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
62135634|NCT02847013|EXPERIMENTAL|Intervention-Tap block w Liposomal bupivacaine|After completion of surgery w closure of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
62135635|NCT03158805|ACTIVE_COMPARATOR|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
62135636|NCT03158805|PLACEBO_COMPARATOR|Placebo|Placebo (no active drug)
62135637|NCT06263881|EXPERIMENTAL|Raphamin|"Oral administration, without food. The tablet should be held in the mouth until complete dissolution.~On the first day 8 tablets are administered using the following scheme: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), followed by three more tablets at regular intervals during the rest of the day. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 7 days."
62135638|NCT06263881|PLACEBO_COMPARATOR|Placebo|"Oral administration, without food. The tablet should be held in the mouth until complete dissolution.~Placebo is administered according to the Raphamin regimen for 7 days."
62331164|NCT04104100||Women with nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for \<65 year-old women.
62331165|NCT04104100||Women without nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for \<65 year-old women.
62331166|NCT03326219|OTHER|Aethoxysklerol clarivein during leg amp|Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
62331167|NCT03173820|PLACEBO_COMPARATOR|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
62331168|NCT03173820|ACTIVE_COMPARATOR|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
62488956|NCT01959828|EXPERIMENTAL|inhaled nitric oxide|"Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to \~ 24 hrs).~Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to \~24 hrs).~Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
62488957|NCT05644184|EXPERIMENTAL|Group 1: Young Children, nOPV1 10^5.5 CCID50|48 young children aged 1 to \<5 years will receive 2 doses of nOPV1 at a dose level of 10\^5.5 CCID50 on Day 1 and Day 29
62135639|NCT03794024||Dorsal Column Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
62135640|NCT03794024||Dorsal Root Ganglion Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Axium Neurostimulator System
62135641|NCT03789734|EXPERIMENTAL|BLS-M22 or Placebo 500mg group|Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
62135642|NCT03789734|EXPERIMENTAL|BLS-M22 or Placebo 1,000mg group|Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
62488958|NCT05644184|EXPERIMENTAL|Group 3: Young Children, nOPV1 10^6.0 CCID50|48 young children aged 1 to \<5 years will receive 2 doses of nOPV1 at a dose level of 10\^6.0 CCID50 on Day 1 and Day 29
62488959|NCT05644184|EXPERIMENTAL|Group 5: Young Children, nOPV1 10^6.5 CCID50|48 young children aged 1 to \<5 years will receive 2 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 1 and Day 29
62488960|NCT05644184|ACTIVE_COMPARATOR|Groups 2, 4 and 6: Young Children, mOPV1|48 young children aged 1 to \<5 years will receive 2 doses of mOPV1 at a dose level of ≥ 10\^6.0 CCID50 on Day 1 and Day 29
62488961|NCT05644184|EXPERIMENTAL|Group 7: Infants, nOPV1 10^5.5 CCID50|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10\^5.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
62488962|NCT05644184|EXPERIMENTAL|Group 9: Infants, nOPV1 10^6.0 CCID50|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10\^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
62488963|NCT05644184|EXPERIMENTAL|Group 11: Infants, nOPV1 10^6.5 CCID50|48 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
62135643|NCT03789734|EXPERIMENTAL|BLS-M22 or Placebo 2,000mg group|Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
62488964|NCT05644184|EXPERIMENTAL|Group 11b: Infants, nOPV1 10^6.5 CCID50|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 3 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 29, Day 57 and Day 85, and a challenge dose of mOPV on Day 141.
62135644|NCT03789734|EXPERIMENTAL|Multiple Ascending Dose group|Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration
62488965|NCT05644184|EXPERIMENTAL|Group 13: Infants, nOPV1 10^7.0 CCID50|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 3 doses of nOPV1 at a dose level of 10\^7.0 CCID50 on Day 29, Day 57 and Day 85, and a challenge dose of mOPV on Day 141.
62488966|NCT05644184|EXPERIMENTAL|Group 15: Infants, nOPV1 10^7.5 CCID50|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 3 doses of nOPV1 at a dose level of 10\^7.5 CCID50 on Day 29, Day 57 and Day 85, and a challenge dose of mOPV on Day 141.
62694154|NCT01380080|EXPERIMENTAL|Arm B: IPT|Study treatment for Arm B participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral therapy as soon as possible following randomization and within no more than 3 days following randomization and of initiating anti-TB treatment (ATT) only when indicated according to local standard practice and at the discretion of the site investigator. All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only. Pyridoxine is provided by the sites to all participants while they are receiving isoniazid (INH).
62694155|NCT05399511||Practising GPs|GPs working in primary care setting.
62694156|NCT04767048|EXPERIMENTAL|Experimental Arm|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
62694157|NCT04767048|ACTIVE_COMPARATOR|Control Arm|Tonsillectomy alone (unilateral or bilateral at the choice of the investigator)
61936706|NCT00976677|EXPERIMENTAL|Arm II|Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm I. Patients also receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
61936707|NCT06464471|EXPERIMENTAL|Older adults completing the CHAMP tool before treatment decision is made|Eligible participants who consent to the study will be asked to complete questionnaires about socio-demographic characteristics, literacy, and technology comfort. Subsequently, participants will be asked to complete the CHAMP tool at home or in the clinic before the participants' medical appointment with the clinician. Next, participants will see the clinician for the consultation. Approximately one week after the consultation, participants will be asked to complete 3 questionnaires about the participants' experience and satisfaction with the CHAMP tool.
61936708|NCT05076396|EXPERIMENTAL|PM14|Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
61936709|NCT02208895||iSTAT Study Group|Measure glucose of pleural fluid via glucometer, in the laboratory, and using the iSTAT device to see if the three methods give a similar reading or not.
62135645|NCT06264531|EXPERIMENTAL|bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
62135646|NCT06264531|PLACEBO_COMPARATOR|placebo|NaCl 0.9% as a slow infusion over 90 minutes every 14 days for a total of 6 injections
62135647|NCT00750620|EXPERIMENTAL|1. Severe renal impairment|severe renal impairment
62135648|NCT00750620|EXPERIMENTAL|2. Moderate renal impairment|moderate renal impairment
62135649|NCT00750620|EXPERIMENTAL|3. Mild renal impairment|mild renal impairment
62135650|NCT00750620|EXPERIMENTAL|4. Normal renal function|normal renal function
62135651|NCT06229730||Healthy children without hearing or balance problems|Healthy children in the age of 6 months to 10 years, without any known hearing or balance problems and with normal gross motor development are recruited in local nurseries, kinder gardens, and schools.
62135652|NCT05106270||Combined procedure|The whole cohort underwent combining procedure of catheter ablation and left atrial appendage closure, atrial pressure was measured before and after pulmonary vein isolation, and after left atrial appendage closure.
62135653|NCT03695757|EXPERIMENTAL|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
62135654|NCT03695757|EXPERIMENTAL|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
62488967|NCT05644184|ACTIVE_COMPARATOR|Groups 8, 10, 12, 12b, 14, 16: Infants mOPV1|192 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1 then 2 to 3 doses of mOPV1 at a dose level of ≥10\^6.0 CCID50 on Day 29, Day 57, Day 85 (groups 12b, 14 \& 16 only) and a challenge dose of mOPV on Day 113 (groups 8, 10 \& 12) on Day 141 (groups 12b, 14 \& 16)
62694158|NCT01489137|EXPERIMENTAL|neurosurgery with fixation|
62694159|NCT00572819|ACTIVE_COMPARATOR|Misoprostol|
62135655|NCT01340859|EXPERIMENTAL|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
62135656|NCT01340859|NO_INTERVENTION|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
62694160|NCT00572819|PLACEBO_COMPARATOR|Placebo|
62694161|NCT03847519|EXPERIMENTAL|Safety Phase Part A|"Enroll subjects with metastatic squamous or non-squamous NSCLC who have become refractory or intolerant to standard therapy. ADXS-503 monotherapy will be evaluated at 2 planned escalating dose levels:~* Dose level 1: 1e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~* Dose level 2: 5e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
62694162|NCT03847519|EXPERIMENTAL|Safety Phase Part B|"Enroll subjects with metastatic squamous or non-squamous NSCLC. ADXS-503 will be evaluated at 2 planned escalating dose levels in combination with a fixed dose of pembrolizumab:~* Dose level 1: 1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~* Dose level 2: 5e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met. (recruitment is on hold for this arm)"
62135657|NCT02376790|ACTIVE_COMPARATOR|Methotrexate Monotherapy|Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
62135658|NCT02376790|EXPERIMENTAL|Etanercept Monotherapy|Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
62694163|NCT03847519|EXPERIMENTAL|Efficacy Phase Part C|"Enroll subjects with metastatic squamous or non-squamous NSCLC.~1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
62135659|NCT02376790|EXPERIMENTAL|Methotrexate + Etanercept|Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.
62331169|NCT02034357|OTHER|Neurocognitive function|Neurocognitive function assessment (verbal learning and memory) as measured by CVLT and sleep evaluations in Parkinson's disease patients at baseline, and after 4 months and 1 year of CPAP treatment
62331170|NCT02361762|EXPERIMENTAL|Training|Computerized executive control training
62331171|NCT02361762|NO_INTERVENTION|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
62331172|NCT02391506|EXPERIMENTAL|Cartiva|Synthetic Cartilage Implant
62331173|NCT05954377|EXPERIMENTAL|Standard multidisciplinary follow-up reinforced with telemedicine|Standard annual multidisciplinary follow-up, reinforced with telemedicine (remote quarterly motivational interviews)
62331174|NCT05954377|NO_INTERVENTION|Standard multidisciplinary follow up|Standard annual multidisciplinary follow-up without telemedicine follow up
62331175|NCT01419665|EXPERIMENTAL|GP2013|Type: Biological/Vaccine
62331176|NCT01419665|ACTIVE_COMPARATOR|rituximab|Type: Biological/Vaccine
62331177|NCT05902507||Breast Cancer Participants|Participants will receive both MRI and CT simulation scans.
62331178|NCT04721236|EXPERIMENTAL|Single|hyperimmune plasma with titre 1:80 or more
62331179|NCT02778750||Stable Group|
62135660|NCT05613088|EXPERIMENTAL|MORAb-202|
62135661|NCT05613088|EXPERIMENTAL|Investigator's Choice Chemotherapy|
62135662|NCT01717651||CPM device|a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.
62135663|NCT02867072|ACTIVE_COMPARATOR|Open appendectomy|Subjects that underwent open surgery for appendicitis
62135664|NCT02867072|ACTIVE_COMPARATOR|Laparoscopic appendectomy|Subjects that underwent laparoscopic surgery for appendicitis
62135665|NCT05459701|PLACEBO_COMPARATOR|group (A) for controlled (placebo).|25 patients will recieve placebo for 6 months.
62135666|NCT05459701|ACTIVE_COMPARATOR|group (D) for Dapagliflozin.|25 patients will recieve 10 mg Dapagliflozin daily for 6 months.
62135667|NCT03631407|EXPERIMENTAL|Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg)|Participants receive vicriviroc 150 mg tablets per os (PO) every day (QD) of each 21-day cycle up to 35 cycles and pembrolizumab 200 mg as a 30-minute intravenous (IV) infusion on Day 1 of each 21 day cycle up to 35 cycles (cycle length: 21 days).
62331180|NCT02778750||Rapid Decliner Group|
62331181|NCT03640806|EXPERIMENTAL|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
62331182|NCT03640806|NO_INTERVENTION|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
62331183|NCT04898426|NO_INTERVENTION|Standard Bowel Preparation Instruction|Patients receive the standard-of-care bowel preparation instruction.
62135668|NCT03631407|EXPERIMENTAL|Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg)|Participants receive vicriviroc 250 mg tablets PO QD of each 21-day cycle up to 35 cycles and pembrolizumab 200 mg as a 30-minute IV infusion on Day 1 of each 21 day cycle up to 35 cycles (cycle length: 21 days).
62694164|NCT05903989||LAMA|
62135669|NCT04072328|EXPERIMENTAL|Propofol alone|Participants who receive propofol alone during sedative endoscopy.
62135670|NCT04072328|ACTIVE_COMPARATOR|Midazolam with propofol|Participants who receive midazolam + propofol during sedative endoscopy.
62135671|NCT05246124|EXPERIMENTAL|Intervention group|This study used Zumba dance exercise done 3 times a week during 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
62331184|NCT04898426|EXPERIMENTAL|Enhanced Bowel Preparation Instruction|Patients receive enhanced instructions (SMS, phone call, info website) in addition to the standard-of-care bowel preparation instruction.
62694165|NCT05903989||LAMA plus LABA|
62331185|NCT00638326|NO_INTERVENTION|1|Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
62331186|NCT00638326|EXPERIMENTAL|2|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
62331187|NCT00638326|ACTIVE_COMPARATOR|3|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel
62331188|NCT05505968|EXPERIMENTAL|virtual reality - Day1|Use of the virtual reality headset during the first epidural infiltration (Day 1). The second infiltration (Day 3) will be performed without the virtual reality headset.
62331189|NCT05505968|EXPERIMENTAL|virtual reality - Day3|First epidural infiltration without the virtual reality headset (day 1). The second infiltration will be performed with the virtual reality headset (Day 3).
62694166|NCT05903989||ICS plus LABA|
62694167|NCT05473715|EXPERIMENTAL|Customized treatment interval|After the initial study injection at baseline, participants will receive their next study injection at Week 16. Participants in this study arm will also be issued a home monitoring device, which will allow for regular OCT monitoring (at least 5 times a week) at home.
62694168|NCT05473715|ACTIVE_COMPARATOR|Treat and extend (T&E) 2 week adjustment|Participants will receive treatment in intervals maintained (8 weeks) or adjusted in 2 weeks increments each time (up to a maximum of 16 weeks and minimum of 4 weeks), as long as all extension/shortening criteria are met.
62694169|NCT01734122||Essential Tremor|Patients with severe, medication-refractory Essential Tremor
62694170|NCT01734122||Parkinsonian Tremor|Patients with severe, medication-refractory, tremor-dominant Parkinsons
61936710|NCT02497612|EXPERIMENTAL|Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the body weight (BW), participants received orally a single dose of ferroquine (FQ) capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of artefenomel (OZ439) (maximum dose up to 800 milligrams \[mg\]) oral suspension as follows: BW greater than or equal to (\>=) 35 kilograms (kg): FQ 400 mg + OZ439 800 mg; BW \>=24 kg to less than (\<) 35 kg: FQ 300 mg + OZ439 600 mg; BW \>=15 kg to \<24 kg: FQ 200 mg + OZ439 400 mg; BW \>=10 kg to \<15 kg: FQ 150 mg + OZ439 300 mg; BW \>=7 kg to \<10 kg: FQ 100 mg + OZ439 200 mg; \>=5 kg to \<7kg: FQ 75 mg + OZ439 150 mg.
61936711|NCT02497612|EXPERIMENTAL|Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW \>= 35 kg: FQ 600 mg + OZ439 800 mg; BW \>=24 kg to \<35 kg: FQ 450 mg + OZ439 600 mg; BW \>=15 kg to \<24 kg: FQ 300 mg + OZ439 400 mg; BW \>=10 kg to \<15 kg: FQ 225 mg + OZ439 300 mg; BW \>=7 kg to \<10 kg: FQ 150 mg + OZ439 200 mg; \>=5 kg to \<7kg: FQ 115 mg + OZ439 150 mg.
62135672|NCT05246124|NO_INTERVENTION|Control group|No intervention during 2-week self-isolation period
62135673|NCT04725136|EXPERIMENTAL|High-dose repeat administration group|FURESTEM-AD Inj 1.0 x 10\^8 cells /body 3 repeated subcutaneous injection at 4 week intervals
62135674|NCT04725136|EXPERIMENTAL|High-dose single administration group|FURESTEM-AD Inj 1.0 x 10\^8 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
62135675|NCT04725136|EXPERIMENTAL|Low-dose repeat administration group|FURESTEM-AD Inj 5.0 x 10\^7 cells /body 3 repeated subcutaneous injection at 4 week intervals
62135676|NCT04725136|EXPERIMENTAL|Low-dose single administration group|FURESTEM-AD Inj 5.0 x 10\^7 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
62135677|NCT04725136|PLACEBO_COMPARATOR|Placebo|Normal saline(0.9% NaCl) 3 repeated subcutaneous injection at 4 week intervals
62135678|NCT02761616||eBC treated participants|Participants with metastatic disease after previously being treated for eBC were observed for 24 months.
62135679|NCT04280289|EXPERIMENTAL|Cannabidiol extract|"10 healthy subjects (5 female, 5 male), will be enrolled into the study. Each subject will receive a single CBDE dose delivering 2.5 mg/kg CBD, after consumption of a standardized meal.~Nine (9mL) of blood for PK analysis, at each of the following timepoints: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the study drug administration.~Urine will be collected at the following timepoints: Predose, 0-4 hrs, 4-8 hrs, 8-12 hrs, 12-24 hrs, 24-36 hrs, 36-48 hrs, and 48-72 hrs for PK analysis"
62135680|NCT00439270|ACTIVE_COMPARATOR|Dasatinib, 50 mg + Docetaxel, 60 mg/m^2|Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m\^2.
62135681|NCT00439270|ACTIVE_COMPARATOR|Dasatinib, 50 mg + Doxetaxel, 75 mg/m^2|Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.
62135682|NCT00439270|ACTIVE_COMPARATOR|Dasatinib, 70 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.
62135683|NCT00439270|ACTIVE_COMPARATOR|Dasatinib, 100 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.
62135684|NCT00439270|ACTIVE_COMPARATOR|Dasatinib, 120 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.
62135685|NCT00645034|ACTIVE_COMPARATOR|Arm 1|
62135686|NCT00645034|PLACEBO_COMPARATOR|Arm 2|
62135687|NCT03814369|EXPERIMENTAL|AmplifEYE colonoscopy|Colonoscopy performed with AmplifEYE equipped
62135688|NCT03814369|NO_INTERVENTION|Standard colonoscopy|Standard colonoscopy performed
62135689|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
62331190|NCT03765801|EXPERIMENTAL|GRTA9906 60 mg PR tablet (fed)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.
62488968|NCT05644184|EXPERIMENTAL|Group 17: Neonates, nOPV1 10^6.5 CCID50|330 neonates (day of birth +3 days) will receive 3 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 1, Day 29 \& Day 57
62488969|NCT05644184|EXPERIMENTAL|Group 19: Neonates, nOPV1 10^7.0 CCID50|330 neonates (day of birth +3 days) will receive 3 doses of nOPV1 at a dose level of 10\^7.0 CCID50 on Day 1, Day 29 \& Day 57
62488970|NCT05644184|EXPERIMENTAL|Group 21: Neonates, nOPV1 10^7.5 CCID50|330 neonates (day of birth +3 days) will receive 3 doses of nOPV1 at a dose level of 10\^7.5 CCID50 on Day 1, Day 29 \& Day 57
62488971|NCT05644184|ACTIVE_COMPARATOR|Groups 18, 20 & 22: Neonates, mOPV1|330 neonates (day of birth +3 days) will receive 3 doses of mOPV1 at a dose level of ≥ 10\^6.0 CCID50 on Day 1, Day 29 \& Day 57
62694171|NCT00605189|ACTIVE_COMPARATOR|VAC NPWT|
62694172|NCT00605189|ACTIVE_COMPARATOR|Gauze-Based NPWT|
62694173|NCT00605189|ACTIVE_COMPARATOR|Moist Wound Therapy|
62694174|NCT06300528|EXPERIMENTAL|Treatment: All Patients|The study will investigate the effectiveness of pemigatinib.
62694175|NCT06048042|EXPERIMENTAL|Autogenous Demineralized Dentin Graft|An Autogenous Demineralized Dentin Graft will be prepared from the participant's freshly extracted teeth and placed in the intrabony defect following the modified minimally invasive surgical technique.
61936712|NCT02497612|EXPERIMENTAL|Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW \>= 35 kg: FQ 900 mg + OZ439 800 mg; BW \>=24 kg to \<35 kg: FQ 675 mg + OZ439 600 mg; BW \>=15 kg to \<24 kg: FQ 450 mg + OZ439 400 mg; BW \>=10 kg to \<15 kg: FQ 335 mg + OZ439 300 mg; BW \>=7 kg to \<10 kg: FQ 225 mg + OZ439 200 mg; \>=5 kg to \<7kg: FQ 170 mg + OZ439 150 mg.
61936713|NCT02497612|EXPERIMENTAL|Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW \>= 35 kg: FQ 1200 mg + OZ439 800 mg; BW \>=24 kg to \<35 kg: FQ 900 mg + OZ439 600 mg; BW \>=15 kg to \<24 kg: FQ 600 mg + OZ439 400 mg; BW \>=10 kg to \<15 kg: FQ 450 mg + OZ439 300 mg; BW \>=7 kg to \<10 kg: FQ 300 mg + OZ439 200 mg; \>=5 kg to \<7kg: FQ 225 mg + OZ439 150 mg.
61936714|NCT02188225|EXPERIMENTAL|Acupuncture|12 sessions of acupuncture / 3 sessions weekly/ 20 minutes each session
61936715|NCT02188225|ACTIVE_COMPARATOR|fluoxetine|10 mg daily
61936716|NCT01072669|ACTIVE_COMPARATOR|ambrisentan|"drug arm~use of ambrisentan in limited scleroderma patients with raynaud's to evaluate digital microvascular flow"
61936717|NCT01072669|PLACEBO_COMPARATOR|sugar pill|those getting sugar pill to evaluate if the active drug improves digital microvascular flow in limited scleroderma patients
61936718|NCT02024529|EXPERIMENTAL|AMPION™ 4 mL dose|4 mL injection of Ampion
62135690|NCT06349577|ACTIVE_COMPARATOR|Non-pulsatile blood flow|Non-pulsatile blood flow during cardiopulmonary bypass
62135691|NCT06349577|ACTIVE_COMPARATOR|Pulsatile blood flow|Pulsatile blood flow during cardiopulmonary bypass
61936719|NCT02024529|PLACEBO_COMPARATOR|Placebo 4 mL dose|4 mL injection of placebo
62331191|NCT03765801|EXPERIMENTAL|GRTA9906 60 mg PR tablet (fasting)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
61936720|NCT02209831|EXPERIMENTAL|BIBR 796 BS + pantoprazole|
62331192|NCT03765801|EXPERIMENTAL|GRTA9906 60 mg IR capsule (fed)|Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.
62331193|NCT03765801|EXPERIMENTAL|GRTA9906 60 mg IR capsule (fasting)|Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
62331194|NCT01487668|NO_INTERVENTION|Arm 1 - Usual Care|Usual care will include standard mental health and medical care available in the VA clinics but with no active management by the LGCC health specialist.
62331195|NCT01487668|EXPERIMENTAL|Arm 2 - Life Goals Collaborative Care|
62694176|NCT06048042|ACTIVE_COMPARATOR|Autogenous bone Graft|An Autogenous Bone Graft will be harvested from the retromolar area and placed in the intrabony defect following the modified minimally invasive surgical technique.
61936721|NCT02209831|ACTIVE_COMPARATOR|BIBR 796 BS without pantoprazole|
61936722|NCT02758171|EXPERIMENTAL|Empagliflozin+Linagliptin FDC|One tablet fix dose combination (FDC)
61936723|NCT02758171|ACTIVE_COMPARATOR|Empagliflozin+Linagliptin single tablets|
61936724|NCT04537039|OTHER|All the participants.|This study only includes 1 arm.
61936725|NCT05766501|EXPERIMENTAL|DOR/ISL|Participants will receive fixed dose combination (FDC) tablet of DOR/ISL (100 mg/0.25 mg) taken once daily (QD) orally from Day 1 to Week 96. After Week 96, eligible participants may continue on DOR/ISL until week 240 or until DOR/ISL becomes commercially accessible, whichever comes first.
61936726|NCT06680505|EXPERIMENTAL|YZJ-1139 10mg|
61936727|NCT06680505|EXPERIMENTAL|YZJ-1139 20mg|
61936728|NCT06680505|EXPERIMENTAL|YZJ-1139 40mg|
61936729|NCT06680505|EXPERIMENTAL|YZJ-1139 60mg|
62331196|NCT03634358|ACTIVE_COMPARATOR|Bipolar scissors group|Group of male infants undergoing circumcision using bipolar scissors to separate the foreskin
62331197|NCT03634358|ACTIVE_COMPARATOR|Classic scalpel group|Group of male infants undergoing circumcision using classic scalpel to separate the foreskin, and sutures to control bleeding
62331198|NCT02814357|PLACEBO_COMPARATOR|Control (market standard)|100 g wheat flour (atta)
62331199|NCT02814357|ACTIVE_COMPARATOR|High fibre 1|81% wheat flour (atta) + 15% chickpea + 4% guar gum
62694177|NCT05583721|EXPERIMENTAL|Stratum A|Sickle Cell patients with diastolic dysfunction
62694178|NCT05583721|EXPERIMENTAL|Stratum B|Sickle cell patients without diastolic dysfunction
62694179|NCT05583721|EXPERIMENTAL|Stratum C|Healthy controls
61936730|NCT06680505|PLACEBO_COMPARATOR|Placebo|
61936731|NCT06340061||Treatment group|
61936732|NCT06340061||Control group|
61936733|NCT03805607|PLACEBO_COMPARATOR|Placebo|1 ml of normal saline
61936734|NCT03805607|EXPERIMENTAL|Ketorolac|30 mg of ketorolac in 1 ml
61936735|NCT00132639|EXPERIMENTAL|1|Preoperative docetaxel-cisplatin combination chemotherapy
61936736|NCT00132639|ACTIVE_COMPARATOR|2|Preoperative docetaxel monotherapy
61936737|NCT01038193||aSAH patients|Cognitive assessment
61936738|NCT02321631|EXPERIMENTAL|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
62135692|NCT05673746|ACTIVE_COMPARATOR|Arm A|"Treatment for peripheral neuropathy (including neuropathic pain), according to the standard of care (e.g. Cetirizine, Gabapentin). Patient will be followed-up as per protocol for a total of 9 weeks ."
62135693|NCT05673746|EXPERIMENTAL|Arm B|"In addition to the treatment for peripheral neuropathy and neuropathic pain, according to the standard of care (e.g. Cetirizine, Gabapentin), patient will receive acupuncture administration twice a week and for a 6-week treatment period. Patient will also be followed-up for 3 weeks after the end of treatment."
62135694|NCT01824056|EXPERIMENTAL|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP . Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
62488972|NCT06562959|ACTIVE_COMPARATOR|Control Group|The fluid restriction program included (a) General small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions.
62488973|NCT06562959|EXPERIMENTAL|Study Group|The intervention bundle, the fluid restriction program, and auricular acupressure were received at four appointments: Shenmen, Kidney Concha, Point Zero, and Upper Tragus.
62694180|NCT06317909|OTHER|single arm|It is an exploratory study. All participants will undergo allergen challenge.
62694181|NCT04482920||Transgender males|Transgender males who are clinically ready to start testosterone
62331200|NCT02814357|ACTIVE_COMPARATOR|High fibre 2|80% wheat flour (atta) + 15% chickpea + 2% guar gum + 3% barley
62488974|NCT05789173|EXPERIMENTAL|Baseline (control)|Each CYP2B6 normal metabolizer (NM) (\*1/\*1), intermediate metabolizer (IM) (\*1/\*6), and poor metabolizer (PM) (\*6/\*6, \*6/\*18, or \*18/\*18) group will receive a single dose of methadone (10 mg) and a single dose of tizanidine (4 mg) orally simultaneously at baseline (control).
62488975|NCT05789173|EXPERIMENTAL|Efavirenz (treatment)|Each CYP2B6 normal metabolizer (NM) (\*1/\*1), intermediate metabolizer (IM) (\*1/\*6), and poor metabolizer (PM) (\*6/\*6, \*6/\*18, or \*18/\*18) group will be administered a single dose of methadone (10 mg) and a single dose of tizanidine (4 mg) orally simultaneously after 16-day oral treatment with 600 mg/day efavirenz
62488976|NCT03849846||Adults with low socio-economic status|Four focus groups will be conducted with adults with low socioeconomic status recruited through community centres in the Québec City area.
62488977|NCT04125394|EXPERIMENTAL|NaCl 5%|Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days.
62488978|NCT01584882|NO_INTERVENTION|Control (Usual care)|Return patients seen within the data collection window in HealthPartners Dental Clinics (new patient exams were excluded) who were documented as using tobacco, specifically cigarettes, at their last dental encounter. Randomization was at the clinic level.
62488979|NCT01584882|EXPERIMENTAL|Tobacco Cessation Tool (CATI Tool)|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a 'CATI'\[Computer Assisted Tobacco Intervention\] tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
62488980|NCT04491422|ACTIVE_COMPARATOR|Integrated Next Steps Counseling using poi|At quarterly visits, intervention arm participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine TFV levels \<1000 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing.
62488981|NCT04491422|NO_INTERVENTION|Standard adherence counseling|Control arm participants will receive standard adherence counseling.
62488982|NCT00075608|EXPERIMENTAL|2nd Stem Cell Transplant|Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion
62488983|NCT06185244|EXPERIMENTAL|Therapist-supported internet delivered trauma-focused CBT|Therapist-supported internet delivered trauma-focused CBT. The protocol mirrors the exact content of first-line treatment for children with PTSD but is delivered through a digital platform and will comprise of text-based material as well as audio files and video illustrations in an age-appropriate manner that the participant gains access to sequentially. iTF-CBT will be therapist-assisted, and each participant will have a designated therapist to guide them through treatment. Treatment will span over 12 weeks and integrates cognitive, behavioral, interpersonal, and family therapy principles as well as trauma interventions. Parallel to the child's treatment, the caregivers are provided the same components and parenting practices, and joint child-parent activities are included. Participants will have access to a therapist that will guide them through treatment in a text based format.
62694182|NCT04482920||Transgender females|Transgender females who are clinically ready to start estradiol
62694183|NCT02730169|EXPERIMENTAL|BGS649 0.1 mg|BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
62694184|NCT02730169|EXPERIMENTAL|BGS649 0.3 mg|BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
62694185|NCT02730169|EXPERIMENTAL|BGS649 1.0 mg|BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
62694186|NCT02730169|PLACEBO_COMPARATOR|Placebo|Placebo weekly (3 indistinguishable placebo capsules)
62694187|NCT02959463|EXPERIMENTAL|Cohort 1 (hemithoracic radiation therapy, pembrolizumab)|Patients undergo hemithoracic radiation therapy. After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62694188|NCT02959463|EXPERIMENTAL|Cohort 2 (palliative radiation therapy, pembrolizumab)|Patients undergo palliative radiation therapy over 1-3 weeks to only the region of palliation (a region that does not include the entire side of the chest or thorax). After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62694189|NCT04862403|EXPERIMENTAL|Intervention group I|In intervention group I - clamped at a distance of 2 cm - umbilical cord was measured 2 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 2 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group I.
62331201|NCT02814357|ACTIVE_COMPARATOR|High fibre 3|77% wheat flour (atta) + 15% chickpea + 3% guar gum + 5% barley
62331202|NCT04661930|EXPERIMENTAL|Fenofibrate + Usual Care|Participants in this arm will receive the study drug, Fenofibrate, in combination with usual care.
62694190|NCT04862403|EXPERIMENTAL|Intervention group II|In intervention group II - clamped at a distance of 3 cm - umbilical cord was measured 3 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 3 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group II.
61936739|NCT02321631|PLACEBO_COMPARATOR|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
62694191|NCT04862403|NO_INTERVENTION|Control group|Control group - clamped without measuring - no intervention was made in defining the distance at which the umbilical cord of the newborn would be clamped. Another healthcare workers measured the distance at which the umbilical cord had been clamped. The same researcher used a standard measuring tape to measure the distance between the umbilical cord to the clamping point.
61936740|NCT04708119|OTHER|histopathological evaluation|angulation of impacted lower mandibular third molar and histopathological evaluation
61936741|NCT02127593|EXPERIMENTAL|First NGM/EE (Wet Process), then NGM/EE (Dry Process)|Participants will receive 1 tablet (formulated by wet process) containing norgestimate 250 microgram (mcg) and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
61936742|NCT02127593|EXPERIMENTAL|First NGM/EE (Dry Process), then NGM/EE (Wet Process)|Participants will receive 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by wet process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
61936743|NCT00940030|EXPERIMENTAL|MBP+enema|mechanical bowel preparation and enema
61936744|NCT00940030|ACTIVE_COMPARATOR|enema|
61936745|NCT04965766|EXPERIMENTAL|U3-1402|All participants enrolled in the study will receive U3-1402 at a dose of 5.6 mg/kg every 3 weeks until progression or until unacceptable toxicity
61936746|NCT05281952|EXPERIMENTAL|endoscopic ligation|
61936747|NCT05281952|ACTIVE_COMPARATOR|Supra-selective embolization|
61936748|NCT01130103|EXPERIMENTAL|Paroxetine|Paroxetine and Prolonged Exposure Therapy
61936749|NCT01130103|PLACEBO_COMPARATOR|Placebo pill|Placebo pill plus Prolonged Exposure Therapy
61936750|NCT05424523||Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
61936751|NCT03031535|EXPERIMENTAL|Study Part 1 - Arm 1|Day 1 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 7 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms.
61936752|NCT03031535|EXPERIMENTAL|Study Part 1 - Arm 2|Day 1 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 5 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 2000 micrograms.
61936753|NCT03031535|EXPERIMENTAL|Study Part 1 - Arm 3|Day 1 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 3 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 1200 micrograms.
61936754|NCT03031535|EXPERIMENTAL|Study Part 1 - Arm 4|Day 1 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 400 micrograms.
61936755|NCT03031535|EXPERIMENTAL|Study Part 2 - Arm 1|Day 1 - 1 microgram/kilogram of growth hormone-releasing hormone (GHRH) + 30 grams arginine hydrochloride; Day 3 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
61936756|NCT03031535|EXPERIMENTAL|Study Part 2 - Arm 2|Day 1 - 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 3 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
62135695|NCT02332512|EXPERIMENTAL|Apatinib|Apatinib tablet administered orally, 750 mg,once daily until progression
62135696|NCT02332512|PLACEBO_COMPARATOR|Placebo|Placebo tablet administered orally, once a day until progression
62135697|NCT05299346||Post ICU covid survivors|Patients having survived and discharged from ICU care as a result of Covid 19
62694192|NCT02446509|EXPERIMENTAL|Experimental Group|The experimental group will receive a 7-week group psychoeducation intervention. Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
62135698|NCT04921488|EXPERIMENTAL|Patients with indication for colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
62331203|NCT04661930|PLACEBO_COMPARATOR|Placebo + Usual Care|Participants in this arm will receive placebo treatment, in combination with usual care.
62331204|NCT04661930|NO_INTERVENTION|Usual Care (Observetional)|Participants in this arm will receive the usual care and be compared by their medical records and laboratory results
62331205|NCT02853734|EXPERIMENTAL|SEVERE PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
62331206|NCT02853734|OTHER|NO PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
62694193|NCT02446509|ACTIVE_COMPARATOR|Wait List Control Group|Subjects in the wait list control group will receive the same 7 psychoeducation sessions after the experimental group receives these sessions.
62694194|NCT05334940||Atopic disorders|Patients with at least 2 atopic disorders who are eligible for systemic therapy with biologics
62694195|NCT04692779||Intubated ARDS patients undergoing prone positioning|All intubated ARDS patients undergoing prone positioning will be assessed with LUS before and after prone positioning and before and after placing back in the supine position.
62694196|NCT02457546|EXPERIMENTAL|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
62331207|NCT05369117|EXPERIMENTAL|indocyanine green labeled fluorescent laparoscopy|The experimental group was marked with indocyanine green, while the control group was not marked with indocyanine green
62331208|NCT05369117|EXPERIMENTAL|The pathological staging|They were grouped by different pathological stages
62331209|NCT05055115|EXPERIMENTAL|Balloon Eustachian Tuboplasty|Patients with long-lasting symptoms of ETD, who benefits from tympanostomy tube insertion, will be offered Balloon Eustachian Tuboplasty (BET) of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
61936757|NCT06391346|EXPERIMENTAL|Patient|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus gluteus of the affected leg in PAD patients in Fontaine stage II (intermittent claudication)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / treadmill test / stepper exercise 2 minutes"
61936758|NCT03918889|EXPERIMENTAL|dexmedetomidine|patients receive dexmedetomidine infusion
61936759|NCT03918889|EXPERIMENTAL|midazolam|patients receive midazolam infusion
61936760|NCT04045795|EXPERIMENTAL|Dose regimen 1|Isatuximab SC administration dose level 1 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
61936761|NCT04045795|EXPERIMENTAL|Dose regimen 2|Isatuximab SC administration dose level 2 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
61936762|NCT04045795|EXPERIMENTAL|Dose regimen 3|Isatuximab SC administration dose level 3 using the investigational injector device once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
61936763|NCT04045795|EXPERIMENTAL|Dose regimen 4|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
61936764|NCT04045795|EXPERIMENTAL|Dose regimen 5|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
61936765|NCT03003156|EXPERIMENTAL|25 Hz magnetic seizure therapy|10 treatment sessions of 25 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
61936766|NCT03003156|EXPERIMENTAL|50 Hz magnetic seizure therapy|10 treatment sessions of 50 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
61936767|NCT06070441|EXPERIMENTAL|Experimental|Home exercise assisted with a chatbot
61936768|NCT06070441|ACTIVE_COMPARATOR|Control|Home exercise, usual care
61936769|NCT02642029|EXPERIMENTAL|Intermittent TBS (iTBS)|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
61936770|NCT02642029|ACTIVE_COMPARATOR|Continuous TBS (cTBS)|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
61936771|NCT02642029|SHAM_COMPARATOR|Sham TBS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
61936772|NCT01017471|EXPERIMENTAL|control|carpal tunnel release using standard incision
61936773|NCT04329442|EXPERIMENTAL|PrEP Received|Participants will be provided with a free 30-day supply of PrEP.
61936774|NCT00775216|NO_INTERVENTION|Standard care|Standard behavioral counseling
62331210|NCT03633786|OTHER|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
62694197|NCT02457546|ACTIVE_COMPARATOR|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
62694198|NCT03408262|ACTIVE_COMPARATOR|Group A|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
62694199|NCT03408262|EXPERIMENTAL|Group B|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
61936775|NCT00775216|EXPERIMENTAL|Intervention|"Behavioral counseling intervention augmented with an interactive health promotion telephone helpline"
61936776|NCT04804540|EXPERIMENTAL|Vedolizumab 300 mg|Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2 and 6 during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.
61936777|NCT02297243|EXPERIMENTAL|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
61936778|NCT06403215|EXPERIMENTAL|Chewing gum group|Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation. As a result of their meta-analysis study, a study reported that chewing gum for 15 minutes every two hours until oral intake started bowel sounds in a shorter time. Therefore, in the current study, women chewed gum for 15 minutes every two hours, following two hours after the cesarean operation. The bowel sounds of the women were listened to and their flatulation times were recorded before and after gum chewing for 15 minutes every two hours. When women were allowed oral intake, gum-chewing activity was terminated completely. Data for the first time of flatulation and the bowel sounds were collected by verbally asking women, and these data were recorded in the follow-up form.
61936779|NCT06403215|EXPERIMENTAL|Fennel tea group|Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea). Fennel seeds (2 grams) were put into 150 ml water, boiled at a temperature of 100 °C, and left for 20 minutes. Women were then instructed to drink the tea. Bowel sounds were recorded every 2 hours, before and after drinking the fennel tea. The time of the first flatulation and the first bowel sounds were determined by asking the women themselves and this information was then recorded using the study form.
62694200|NCT03408262|EXPERIMENTAL|Group C|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
62694201|NCT03408262|EXPERIMENTAL|Group D|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
62694202|NCT03408262|ACTIVE_COMPARATOR|Group E|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
62694203|NCT03408262|EXPERIMENTAL|Group F|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
62694204|NCT03408262|EXPERIMENTAL|Group G|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
62694205|NCT03408262|EXPERIMENTAL|Group H|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
62694206|NCT05143411|EXPERIMENTAL|Use of mobile application|Single arm: At the first time, the researcher will collect all glycemic levels before using the mobile application. Then, all the participants will receive the mobile application to select their main meals, breakfast, lunch, and dinner. Then, the application must calculate the insulin bolus according to their initial profile and the food before being eaten.
62694207|NCT05200481|OTHER|Brigatinib monotherapy Arm A|Brigatinib 180mg QD (1 x 180mg tablet) until progression
62694208|NCT05200481|EXPERIMENTAL|Brigatinib Carboplatin-Pemetrexed combination therapy Arm B|Brigatinib 180mg QD (1 x 180mg tablet) until progression + Carboplatin AUC of 5 mg/mL/min IV infusion every 3 weeks for 4 infusions + pemetrexed 500 mg/m² IV infusion every 3 weeks for 4 infusions
62694209|NCT03126630|ACTIVE_COMPARATOR|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
62694210|NCT03126630|EXPERIMENTAL|Group II (anetumab ravtansine, pembrolizumab)|Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.
62694211|NCT04600973|ACTIVE_COMPARATOR|Surveillance with Technical Assistance|Surveillance will be offered to 3 teams with Technical Assistance (TA) in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported.
62694212|NCT04600973|ACTIVE_COMPARATOR|Surveillance with EBIP Coaching|Surveillance will be offered to 3 teams with Evidence-Based Infection Prevention Bundle (EBIP) coaching in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention.
62694213|NCT04600973|ACTIVE_COMPARATOR|Technical Assistance No Surveillance|TA will be offered to 3 teams. TA will have monthly scheduled TA calls (60 minutes each) with each team individually to review and discuss the protocol interventions (as is done in the EBIP group) and allow for a consultation with experts on the peri-operative interventions. Surveillance toolkit will only be used for transmission data collection.
62694214|NCT04600973|ACTIVE_COMPARATOR|EBIP Coaching No Surveillance|EBIP will be offered to 3 teams. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Surveillance toolkit will only be used for transmission data collection.
62135699|NCT02993094|EXPERIMENTAL|Ixazomib/Carboplatin|"Accelerated dose-escalation phase with a single-patient cohort per dose level until defined DLT is observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.~Intervention (experimental): Ixazomib; po; 3mg escalated to 4mg; day 1, 8, 15 Intervention (backbone): AUC 1.5 escalated to AUC 2.5; day 1, 8, 15"
62331211|NCT03633786|OTHER|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
62135700|NCT06026800|EXPERIMENTAL|Personalized mRNA Vaccine iNeo-Vac-R01 with standard first-line treatment|Subjects will receive at least 4 cycles of standard first-line treatment according to Chinese Society of Clinical Oncology (CSCO) clinical guidelines. Then subjects will receive iNeo-Vac-R01 via IH injection on Day 1 of each 21-day cycle for up to 9 cycles at an applicable dose, identified during the dose escalation phase of the study.
62135701|NCT05456334|EXPERIMENTAL|Pulsed dye laser-mediated photodynamic therapy|After curretage light-sensitizer (methyl aminolaevulinate cream) was applied on the lesions and covered with an occlusive plastic foil for 2-3-h incubation. Then a local lidocaine anaesthetic spray was applied. The lesions were illuminated with 30% overlapping pulsed laser double-stacked pulses (, energy 7 J/cm2, spot size 7 mm, pulse duration 10 ms, wavelength 595 nm and dynamic cooling 2/3).
62331212|NCT06071494|EXPERIMENTAL|Tropical Fruits|patient will be consuming the chosen fruits, according to the size of the serving following Malaysian Dietary Guideline 2020
62331213|NCT06071494|NO_INTERVENTION|Normal diet|patient will consume normal diet as usual
62331214|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
62694215|NCT06440577|EXPERIMENTAL|Consumer Items Willingness-to-Pay Task|Men and women with OUD receiving medications for OUD treatment will complete a decision-making task during functional magnetic resonance imaging (fMRI) in which they indicate their willingness-to-pay for everyday consumer items that have associations with drug use or not. Interleaved with blocks of the task, participants will briefly observe stimuli that can produce a change in their psychological state and drug craving, via two psychological/behavioral interventions: Audio-visual stimuli (Neutral-Relaxing) and Audio-visual stimuli (Drug).
62488984|NCT06185244|ACTIVE_COMPARATOR|Therapist-supported psychoeducation and stress management|Therapist-supported CBT internet-delivered treatment comprising psychoeducation about PTSD, relaxation/stress management techniques and relapse prevention. The treatment will be delivered in a digital platform for twelve weeks. Participants will have access to a therapist that will guide them through treatment in a text-based material as well as audio files and video illustrations in an age-appropriate manner that the participant gains access to sequentially.
62488985|NCT00337493|EXPERIMENTAL|1|
62488986|NCT00337493|EXPERIMENTAL|2|
62488987|NCT00337493|EXPERIMENTAL|3|
62135702|NCT05456334|ACTIVE_COMPARATOR|Conventional photodynamic therapy|After curretage a light-sensitizer (methyl aminolaevulinate cream) was applied on the lesions and covered with an occlusive plastic foil for 2-3-h incubation. Then a local lidocaine anaesthetic spray was applied. The lesions were illuminated with a red LED light for 7-8 min (exposure 75 J/cm2, wavelength 630 nm).
62135703|NCT05456334|EXPERIMENTAL|Ablative fractional laser- mediated daylight photodynamic therapy|After curretage lidocaine anaesthetic spray was applied on the whole treatment area. Lesions were treated with an ablative fractional CO2-laser (19 W, Dot mode, spacing 1000 µm, stack 3, scanning dwell time 1800 µs, repeat 0.5 s). A thin layer of light sensitizer (methyl aminolaevulinate cream) was applied on the treatment area. The patients were asked to move outdoors (temperature \>10C, no rain, June-August) or to our adPDT-room (IndoorLux®, wavelength 350-750 nm, 15-25 000 lux) within 30 minutes, for the 2h-illumination.
62135704|NCT05456334|ACTIVE_COMPARATOR|Daylight photodynamic therapy|After curretage lidocaine anaesthetic spray was applied on the whole treatment area. A thin layer of light sensitizer (methyl aminolaevulinate cream) was applied on the treatment area. The patients were asked to move outdoors (temperature \>10C, no rain, June-August) or to our adPDT-room (IndoorLux®, wavelength 350-750 nm, 15-25 000 lux) within 30 minutes, for the 2h-illumination.
62488988|NCT03307551|ACTIVE_COMPARATOR|CLADS group|Anaesthesia will be induced and maintained with Propofol administered by CLADS. Its administration rate will be controlled by a feedback loop facilitated by BIS monitoring. A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
62488989|NCT03307551|ACTIVE_COMPARATOR|Manual group|Anaesthesia will be induced and maintained with propofol administration by an intravenous infusion pump. Its administration rate will be controlled manually to maintain a target BIS of 50 during induction and maintenance of anaesthesia.
62488990|NCT05150223|ACTIVE_COMPARATOR|Traditional strength training group|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
62488991|NCT05150223|EXPERIMENTAL|Power Training group|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
62488992|NCT05150223|NO_INTERVENTION|Control group|no intervention Typically developing children
62488993|NCT03564587|EXPERIMENTAL|AWAKE|The AWAKE intervention is an 8 week program including a mobile app and phone-based coaching, focused on improving hope in order to increase quality of life and health-promoting behaviors in young adult cancer survivors.
62488994|NCT03564587|NO_INTERVENTION|No treatment|Control participants will receive the surveys to complete only; however, they may opt to receive the intervention after the 4-month assessment.
62488995|NCT05373576|EXPERIMENTAL|TACHIDINO|
62331215|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
62331216|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
62331217|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
62488996|NCT05373576|NO_INTERVENTION|WAITING LIST|
62488997|NCT00295490|EXPERIMENTAL|240mg Devil claw|Sub clinical dose if the 3 doses employed
62488998|NCT00295490|EXPERIMENTAL|960mg Devil Claw|Active dose
62488999|NCT00295490|EXPERIMENTAL|1920 mg Devil claw|Active dose
62331218|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
62331219|NCT04422665|EXPERIMENTAL|Single Exercise|Subjects allocated to this group will perform a single bout of one-legged resistance exercise. This bout will take place 1 day prior to the start of the bed rest. The resistance exercise will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
62331220|NCT04422665|EXPERIMENTAL|Multi Exercise|Subjects allocated to this group will perform 4 bouts of one-legged resistance exercise. These bouts will take place on alternate days the week leading up to the bed rest. Each resistance exercise bout will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
62135705|NCT02183506|ACTIVE_COMPARATOR|Metformin|
62489000|NCT00295490|PLACEBO_COMPARATOR|Placebo|Comparator for all active intervention arms
62489001|NCT04554290||positive temporal artery biopsy|all adult patients with significant inflammation shown on temporal artery biopsy
62489002|NCT04848090|OTHER|Neonate WGS Testing|Neonate subjects who are eligible and whose parents consent to study will undergo blood sampling which will be sent for whole genome sequencing and bioinformatics analysis, filtering first a targeted panel of 1722 genes most likely to cause genetic disorders in the first year of life, and then with a whole exome filter if no obvious diagnosis is determined using the 1722 gene panel filter.
62489003|NCT04123587|EXPERIMENTAL|Sulfonylurea-dependent|Sulfonylurea is replaced by alternative oral hypoglycemic agent.
62489004|NCT00252161|ACTIVE_COMPARATOR|1|Procedure/Surgery: Gastrectomy with more than D2 dissection
62489005|NCT00252161|EXPERIMENTAL|2|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
62489006|NCT05311072||PEA cohort|patients with CTEPH receiving PEA
61936780|NCT06403215|EXPERIMENTAL|Chewing gum+Fennel tea group|Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation. As a result of their meta-analysis study, a study reported that chewing gum for 15 minutes every two hours until oral intake started bowel sounds in a shorter time.Women were then instructed to drink the tea. Bowel sounds were recorded every 2 hours, before and after drinking the fennel tea. The time of the first flatulation and the first bowel sounds were determined by asking the women themselves and this information was then recorded using the study form.
61936781|NCT06403215|EXPERIMENTAL|Control group|Researcher sounded in bowel movement as hospital protocols.
61936782|NCT02611960|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg Q3W for up to 17 cycles (up to approximately 1 additional year).
62135706|NCT02183506|EXPERIMENTAL|BI 1356 BS and metformin|Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)
62135707|NCT04633941||Post Bariatric Surgery|Post Bariatric Surgery more than 6 month. Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
62135708|NCT04633941||Medical Weight Management|Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
62135709|NCT03689920|ACTIVE_COMPARATOR|WaveWriter Settings|WaveWriter Programming
62135710|NCT03689920|ACTIVE_COMPARATOR|Conventional Settings|Conventional Programming
62489007|NCT05311072||BPA cohort|patients with CTEPH receiving BPA
62489008|NCT05311072||Pulmonary arterial hypertension (PAH)-specific medication|CTEPH patients without PEA or BPA, treatment with any PAH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
62489009|NCT06063460||Ginigival health|The VAS scale will be filled about halitosis, smell and taste perception by patients diagnosed with gingival health during the exam.Patients will be called for a follow-up check in the 1st and 3rd months. Periodontal examinations will be repeated. The VAS scale will be filled in again with halitosis, smell and taste perception.
61936783|NCT02611960|ACTIVE_COMPARATOR|Standard Treatment|Participants receive capecitabine 1000 mg/m\^2 orally (PO) twice each day (BID) on Days 1-14 of each 3-week cycle, or gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle, or docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle until PD or unacceptable toxicity.
61936784|NCT03848338|OTHER|Pilot Group|Intra and Post-operative Electrocochleography
62489010|NCT06063460||Gingivitis|Patients diagnosed with gingivitis during will have the VAS scale filled in with halitosis, smell and taste perception. Phase 1 treatment will be applied. Patients will be called for a follow-up check in the 1st and 3rd months. Periodontal examinations will be repeated. The VAS scale will be filled in again with halitosis, smell and taste perception.
62489011|NCT06063460||Periodontitis|Patients diagnosed with periodontitis d will have the VAS scale filled in with halitosis, smell and taste perception. Phase 1 treatment will be applied. Patients will be called for a follow-up check in the 1st and 3rd months. Periodontal examinations will be repeated. The VAS scale will be filled in again with halitosis, smell and taste perception.
62489012|NCT02213705|EXPERIMENTAL|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide
62489013|NCT02255149|EXPERIMENTAL|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
62489014|NCT00816413|EXPERIMENTAL|Donor Stem Cell Transplant, Pentostatin & Total-Body Irradiation for Hematological Cancer|This phase I/II trial is studying the side effects of giving a donor stem cell transplant after pentostatin and total-body irradiation and to see how well it works in treating patients with hematological cancer.
62135711|NCT03792932|ACTIVE_COMPARATOR|Laparoscopic distal pancreatectomy|
62489015|NCT03955276||Matched Therapy|Targeted therapy matched to each patient's genomic/immunophenotypic tumor profile (whereby oncogenic alterations are matched with targeted agents)
62489016|NCT03955276||Unmatched Therapy|General, unmatched therapy (standard of care)
62135712|NCT03792932|ACTIVE_COMPARATOR|Open distal pancreatectomy|
62331221|NCT00875784|EXPERIMENTAL|TREXIMA tablet followed by IMITREX injection (4mg)|TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®
62489017|NCT02024048||Pregnant|OCT
62489018|NCT02024048||Control|OCT
62489019|NCT04921631|EXPERIMENTAL|Intervention|The intervention arm will receive early specialty palliative care integrated with standard critical care.
61936785|NCT02761928||Epidural|Positive response (\>50% pain relief) to any epidural (e.g. interlaminar/paramedian, transforaminal, caudal)
61936786|NCT02761928||Selective nerve root block|Positive response (\>50% pain relief) to selective nerve root block
61936787|NCT02761928||Facet injection|Positive response (\>50% pain relief) to intra-articular facet injection
61936788|NCT02761928||Medial branch block|Positive response (\>50% pain relief) to median branch nerve block
62489020|NCT04921631|NO_INTERVENTION|No intervention|Usual ICU care; each study ICU has a policy for family meetings within 72 hours of admission and at least weekly thereafter.
61936789|NCT02761928||Medial branch RFA|Positive response (\>50% pain relief) to median branch nerve radiofrequency ablation
62135713|NCT02958800|EXPERIMENTAL|Intervention|The intervention consists of assigning each participant to their own single patient open label trial consisting of a 1:1 randomized sequence of two pre-determined dose reductions of atypical antipsychotics for each participant in order to determine any behavioural issues that arise from atypical antipsychotic dose alteration.
62331222|NCT00875784|EXPERIMENTAL|TREXIMA tablet followed by IMITREX injection (6mg)|TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®
62331223|NCT00875784|ACTIVE_COMPARATOR|IMITREX tablet (100mg)|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
62135714|NCT00670046|OTHER|Arm I (standard of care)|Patients undergo observation according to the standard of care. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
62331224|NCT06555055||trochlear thickness change|Radiological Assessment of trochlear thickness of PFJ in primary TKR by preoperative and postoperative CT scan. and observing Effects of Ct Different measures changes in trochlear thickness on short term TKR outcomes
62331225|NCT00788515|EXPERIMENTAL|1|
62331226|NCT00788515|ACTIVE_COMPARATOR|2|
62331227|NCT00003648||Group 1|Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
62331228|NCT04234815|EXPERIMENTAL|CETA Short Session (CSS)|A single-session, 1.5-2 hour group workshop that includes psychoeducation, self-assessment, safety screening, and training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance. On this phone call they will also be asked about their use of the cognitive coping skill over the last week, and provided feedback if using it incorrectly.
62331229|NCT04234815|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (eTAU)|A single-session, approximately 1-hour group workshop that includes the same psychoeducation, self-assessment, and safety screening as the experimental condition, but no training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance.
61936790|NCT02761928||SIJ injection|Positive response (\>50% pain relief) to sacroiliac joint injection
62135715|NCT00670046|EXPERIMENTAL|Arm II (valproic acid)|Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
62135716|NCT02167958|EXPERIMENTAL|Treatment|"Day -6, -5 Fludarabine 30 mg/M2 IV over 30-60 minutes Cyclophosphamide 14.5 mg/kg IV over 1-2 hours\*, Mesna 14.5 mg/kg IV in 4 divided doses~Day -4 through -2 Fludarabine 30 mg/M2 IV over 30-60 minutes~Day -1 Total Body Irradiation 200 cGy, donor apheresis~Day 0 T cell replete PBSC~Days 3, 4 Cyclophosphamide 50 mg/kg IV Mesna 50 mg/kg IV in 4 divided doses~Day 5 Begin tacrolimus ,mycophenolate, and G-CSF"
62135717|NCT06515457|EXPERIMENTAL|Eye Empower Supplement Arm|Participants in this arm will take three capsules of BioNatureHealth's Eye Empower supplement daily for three weeks.
62135718|NCT05744596||Incisura biopsy +|this arm has the incisura biopsy scored and added in the OLGA final stage
62135719|NCT05744596||Incisura biopsy -|this arm only has corpus and antrum biopsies scored for OLGA staging
62135720|NCT03829436|EXPERIMENTAL|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
62135721|NCT03829436|EXPERIMENTAL|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression.
62135722|NCT03829436|EXPERIMENTAL|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
62135723|NCT03829436|EXPERIMENTAL|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
62135724|NCT01816672|ACTIVE_COMPARATOR|AutoloGel|AutoloGel treatment
62331230|NCT02422927|PLACEBO_COMPARATOR|Standard of Care + Placebo|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo
62489021|NCT05485064|EXPERIMENTAL|electroacupuncture(transcutaneous electrical acupuncture point stimulation )and remimazolam|The investigator 1 combine electroacupuncture(transcutaneous acupoint electrical stimulation ) with remimazolam to sedate patients moderately to finish gastroscopy and colonoscopy.
62489022|NCT05485064|EXPERIMENTAL|placebo needle and remimazolam|The investigator 1 combine placebo needle with remimazolam to sedate patients moderately to finish gastroscopy and colonoscopy.
62489023|NCT05485064|EXPERIMENTAL|fentanyl and remimazolam|The investigator 1 combine fentanyl with remimazolam to sedate patients moderately to finish gastroscopy and colonoscopy.
62135725|NCT01816672|OTHER|Usual and Customary Care|Standard of care
62135726|NCT05076110|ACTIVE_COMPARATOR|Standard of Care Group|Subjects will receive standard of care pain medication Oxycodone for pain control following hip arthroscopy procedure
61936791|NCT02761928||Lateral branch block|Positive response (\>50% pain relief) to lateral branch nerve block for SIJ
61936792|NCT02761928||Greater trochanter injection|Positive response (\>50% pain relief) to greater trochanteric bursa injection
61936793|NCT02761928||Piriformis injection|Positive response (\>50% pain relief) to piriformis injection
61936794|NCT02761928||Trigger point injection|Positive response (\>50% pain relief) to trigger point injection
61936795|NCT05806983|EXPERIMENTAL|Experimental group|-The experimental group that applied the technology-based psychosocial program
61936796|NCT05806983|NO_INTERVENTION|Control group|Control group receiving standard care
62694216|NCT06440577|EXPERIMENTAL|Snack Foods Willingness-to-Pay Task|Men and women with OUD receiving medications for OUD treatment and control participants from the community will complete a decision-making task during functional magnetic resonance imaging (fMRI) in which they indicate their willingness-to-pay for snack food items that vary in their features (savory, sweet, etc.). Interleaved with blocks of the task, participants will briefly observe stimuli that can produce a change in their psychological state and food craving, via two psychological/behavioral interventions: Audio-visual stimuli (Non-Food) and Audio-visual stimuli (Food).
62694217|NCT06373068||Full code|Patients without any restrictions on the types of treatments available, such as cardiopulmonary resuscitation, intubation, various life support measures, surgery, etc., if indicated.
62694218|NCT06373068||Simple Do-Not-Attempt-Resuscitation|The only treatment limitation in patient care is cardiopulmonary resuscitation in case of a cardiac arrest. All other indicated devices or treatments may still be utilized.
62694219|NCT06373068||Do not attempt resuscitation with limited scope|The treatment limitation in patient care includes not performing cardiopulmonary resuscitation and also involve additional limitations, typically including various life support measures.
62694220|NCT04293432||Group/Cohort|Torsade de Pointes induced by drugs reported to the FAERS database from inception till first quarter of 2019 (1990-2019)
62694221|NCT05824728|EXPERIMENTAL|AGB101 first, then placebo|AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) once daily for 6 weeks, washout (4 weeks), then placebo capsule once daily for 6 weeks.
62694222|NCT05824728|EXPERIMENTAL|placebo first, then AGB101|Placebo capsule once daily for 6 weeks, washout (4 weeks), then AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) once daily for 6 weeks.
62694223|NCT06120842|EXPERIMENTAL|Bimatoprost Implant System (High Dose) / IOL Combination|
62694224|NCT06120842|EXPERIMENTAL|Bimatoprost Implant System (Low Dose) / IOL Combination|
62694225|NCT06120842|ACTIVE_COMPARATOR|Timolol Maleate Ophthalmic Solution 0.5%|
62694226|NCT03526666||AML, MDS, and CMML patients|Patients with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
62694227|NCT06639126|PLACEBO_COMPARATOR|Placebo|Placebo treated with 600 mg/capsule/day of microcrystalline cellulose
62694228|NCT06639126|EXPERIMENTAL|Active|Group with wild thyme extract
62694229|NCT05745246|EXPERIMENTAL|Intervention Group|"This arm will receive the online e-health intervention for six months.~The intervention consists of three sections:~1. a novel health information strategy, 90SecondFire Cancer health letters~2. a brief on-line course~3. a problem-solving asynchronous bulletin board to mobilize existing knowledge"
62694230|NCT05745246|NO_INTERVENTION|waitlist control group|This group will be placed on a waitlist and will receive the online treatment program after six months.
62694231|NCT06094803|EXPERIMENTAL|Receiving Mindfulness-based Zentangle Interventions|"Participants in the intervention group will receive two 2-hour weekly sessions, focusing on two main themes, which are Self-awareness and self-kindness as well as Acceptance and non-judgmental attitude. Each session with one hour duration and have five different contents separately."
62694232|NCT06094803|NO_INTERVENTION|Waitlist Control Group|The waitlist control group will not receive any training before all the assessments have been done by both groups. Yet, they will receive the same mindfulness-based Zenatngle training after the assessment period (3 months after baseline). They will be notified that their level of depressive and/or anxiety symptoms when the baseline assessment has been finished. Respondents with Patient Health Questionnaire (PHQ-9) or General Anxiety Disorder (GAD-7) score higher than 14 will be advised to consult a doctor, same as the intervention group.
62694233|NCT03427619|EXPERIMENTAL|OK432 (Picibanil)|There is no control in this study. All participants will receive the actual drug -OK432. With each injection they may receive 0.01 to 0.05mg/mL 6-12 weeks apart up to 4 injections total.
62694234|NCT06639724|EXPERIMENTAL|Fostamatinib in combination with gemcitabine/nab-paclitaxel|Fostamatinib 100 mg will be taken by the study participants orally twice a day for 7 days prior to, and then during chemotherapy with gemcitabine/nab-paclitaxel. These 2 agents will be administered intravenously on days 1, 8, and 15 of each 28-day cycle.
62694235|NCT02937571|EXPERIMENTAL|Carfilzomib, Lenalidomide, and Dexamethasone|"* Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.~* Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16~* Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days~* Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23~* Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23"
62694236|NCT03395093|EXPERIMENTAL|FB with fentanyl|In the Bispectral Index monitoring,our study will use midazolam, propofol and fentanyl in the conscious sedation of FB
61936797|NCT03267303|EXPERIMENTAL|TS-091 5mg|
62331231|NCT02422927|ACTIVE_COMPARATOR|Nutraceutical combination|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination
62694237|NCT03395093|ACTIVE_COMPARATOR|FB without fentanyl|In the Bispectral Index monitoring, our study will use midazolam, propofol in the conscious sedation of FB
62694238|NCT02157545||pyridostigmine|administration of rocuronium to determine its potency.
62694239|NCT02157545||control arm (no pyridostigmine)|determination of potency of rocuronium in patients not taking pyridostigmine
61936798|NCT03267303|EXPERIMENTAL|TS-091 10mg|
61936799|NCT03267303|PLACEBO_COMPARATOR|Placebo|
61936800|NCT06069648|PLACEBO_COMPARATOR|control|factsheet about healthy living
61936801|NCT06069648|EXPERIMENTAL|printed decision aid|receive printed decision aid
61936802|NCT06069648|EXPERIMENTAL|mobile decision aid|receive mobile decision aid
62331232|NCT01592890|EXPERIMENTAL|[14C]-labeled RO4917523|
62331233|NCT03571620|PLACEBO_COMPARATOR|Vehicle|
62331234|NCT03571620|EXPERIMENTAL|1.0% Q301 Cream|
62331235|NCT03571620|EXPERIMENTAL|1.4% Q301 Cream|
62331236|NCT00943319|EXPERIMENTAL|Busulfan and fludarabine|Intravenous busulfan (Busulfan®) in combination with fludarabine
62331237|NCT04956822||ALS|Amyotrophic lateral sclerosis group
62331238|NCT04956822||CMT|peroneal muscular dystrophy group
62331239|NCT04956822||KD|Kennedy's disease group
62331240|NCT04956822||Control|Healthy control group
62331241|NCT03696758|EXPERIMENTAL|Sildenafil followed by Metoprolol|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
62489024|NCT03317067|EXPERIMENTAL|dexmedetomidine|Patients in the Dexmedetomidine (interventional) group will be treated with a continuous infusion of dexmedetomidine in case of agitated delirium.
62489025|NCT03317067|PLACEBO_COMPARATOR|Normal Saline (NaCl 0.9%)|Patients in the Normal Saline (control) group will be treated with a continuous infusion of normal saline in case of agitated delirium.
62489026|NCT04904094|EXPERIMENTAL|Intervention group|This group will receive casting of the lower limb for approximately 2 weeks combined with a passive stretching program of the knee flexors, followed by a homebased stretching exercise program for the plantar flexors and hamstrings for 4 weeks after casting.
62489027|NCT04904094|NO_INTERVENTION|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic devices.
62489028|NCT03081897|EXPERIMENTAL|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
62694240|NCT05472870|EXPERIMENTAL|rTMS Group|Participants will receive cTBS over the left primary motor cortext (M1) for 5 consecutive days. The detailed parameters as follows: 80% of RMT, 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).
62694241|NCT06021613|EXPERIMENTAL|Case-crossover|"Participants will be randomized in two-day blocks to consume then avoid cannabis (Start: On Cannabis) or avoid then consume cannabis (Start: Off Cannabis). Using an case-crossover strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, or the Mosio text messaging software for clinical research, participants will receive instructions and answer questions to help researchers and physicians understand the relationship between inhaled cannabis and heart rhythm."
62694242|NCT03721289||Cohort 1|All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
62694243|NCT03721289||Cohort 2|All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
62489029|NCT03081897|ACTIVE_COMPARATOR|SPRANC Control group|General anaesthesia
62489030|NCT03296956|ACTIVE_COMPARATOR|Day-5 postpartum - Active dietary supplement|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
62489031|NCT03296956|PLACEBO_COMPARATOR|Day-5 postpartum - Placebo|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Placebo"
62489032|NCT04125862|OTHER|Fibrous Dysplasia/McCune-Albright Syndrome|20, Fibrous Dysplasia/McCune-Albright Syndrome Patients with or without pain
62489033|NCT04125862|OTHER|Healthy Controls|20, matched healthy controls
62489034|NCT05697679|EXPERIMENTAL|Usual management group|The intervention group is intervened with the TG
62489035|NCT05697679|ACTIVE_COMPARATOR|Goal-attainment-theory-based self-management group|The group is intervened with the CG
62489036|NCT05795959|EXPERIMENTAL|Intervention|Participants randomized to this arm of the study will receive usual care with supplemental education and support provided by a lay VA volunteer trained on evidence-based lung cancer care.
62489037|NCT05795959|NO_INTERVENTION|Control|Participants randomized to this arm of the study will receive usual clinical care.
62489038|NCT03164460|EXPERIMENTAL|Group I (SBRT)|Patients undergo SBRT every other day for a total of 5 treatments.
62489039|NCT03164460|EXPERIMENTAL|Group II (IMRT/IMPT)|Patients undergo IMRT/IMPT once daily (Monday-Friday) for up to 30-35 treatments.
62489040|NCT03774537|EXPERIMENTAL|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.
62489041|NCT03774537|OTHER|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
62694244|NCT05319197||SLD Group|
62694245|NCT05319197||Healthy Control Group|
62694246|NCT00656695|EXPERIMENTAL|1|taking Iminoral
62694247|NCT00656695|ACTIVE_COMPARATOR|2|taking Neoral
62694248|NCT05972772|ACTIVE_COMPARATOR|Doxycycline|Doxycycline (Vibramycin, 100-mg film-coated tablets; Pfizer)) 200-mg loading dose, followed by 100 mg every 12 hours for 3 days.
62489042|NCT00147134|ACTIVE_COMPARATOR|1|Procedure/Surgery: open colectomy
62489043|NCT00147134|EXPERIMENTAL|2|Procedure/Surgery: laparoscopic colectomy
62489044|NCT03595462|EXPERIMENTAL|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to \~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
62489045|NCT03595462|PLACEBO_COMPARATOR|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
62135727|NCT05076110|EXPERIMENTAL|Non-Opiate Pain Control Group|Subjects will receive a non-opiate pain control regime using Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol for pain control following hip arthroscopy procedure.
62135728|NCT02767765|EXPERIMENTAL|r-HuEPO|Anemic cancer participants will receive r-HuEPO for 4 weeks.
62135729|NCT05126342|EXPERIMENTAL|Cohort A|Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse after more than 6 months of PARPi maintenance therapy.
62135730|NCT05126342|EXPERIMENTAL|Cohort B|Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse within 6 months of PARPi maintenance therapy.
62135731|NCT00786513|ACTIVE_COMPARATOR|Control Arm|
62135732|NCT00786513|EXPERIMENTAL|Intervention Arm|
62489046|NCT03725345|ACTIVE_COMPARATOR|Alcohol Group|Participants who have recently consumed alcohol.
62489047|NCT03725345|SHAM_COMPARATOR|No Alcohol Group|Participants who have not recently consumed alcohol.
61936803|NCT05917210|EXPERIMENTAL|Peer navigation strategy for TB Education and Counseling (TB-EC)|peer-navigation strategy for TB-EC in adults and adolescents with and without HIV starting TB treatment at clinics in Uganda
61936804|NCT05917210|ACTIVE_COMPARATOR|Standard TB-EC|standard TB-EC in adults and adolescents with and without HIV starting TB treatment at clinics in Uganda
62489048|NCT02075645|OTHER|team training|"Intervention: team training course. A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
62489049|NCT06200480|ACTIVE_COMPARATOR|Telephone by nurse|The headache patients will be contacted by nurse by phone after approximately 2 week and 6 week after start of preventive medical treatment. The patient will have a follow-up visit by neurologist after 3 months.
62489050|NCT06200480|NO_INTERVENTION|Patient-initiated follow-up|The headache patient contact their general practitioner (GP) and/or the neurologist by a study-specific email if they have questions regarding the preventive medical treatment
62489051|NCT02408653|ACTIVE_COMPARATOR|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
62489052|NCT02408653|ACTIVE_COMPARATOR|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
62489053|NCT02408653|EXPERIMENTAL|EEG-registration with dry electrodes|EEG-registration with dry electrodes
61936805|NCT04845373|EXPERIMENTAL|Mediterrenean diet|Mediterranean diet:Target macronutrient energy contributions were 40% from carbohydrate, 35%-40% from fat (with \<10% of energy as saturated fat), and 20% of energy as protein.Participant in this group were trained to consume fish, legumes at least 2-3 times a week, walnuts and olive oil every day in accordance with the Mediterranean diet model.
61936806|NCT04845373|ACTIVE_COMPARATOR|Low fat diet|Low fat diet:Target macronutrient energy contributions for the low fat diet diet were 50-60% from carbohydrate, \<30% from fat (with \<10% of energy as saturated fat), and 20% from protein.Participants in this group were especially recommended to consume low-fat foods.
61936807|NCT03012724|ACTIVE_COMPARATOR|H1-Coil|Device: Brainsway H1-Coil Deep TMS System. An FDA cleared deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the lateral prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
61936808|NCT03012724|EXPERIMENTAL|H7-Coil|Device: Brainsway H7-Coil Deep TMS System. A deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the medial prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
61936809|NCT04637490|EXPERIMENTAL|patellar resurfacing|patellar resurfacing in TKA
62135733|NCT06324981|ACTIVE_COMPARATOR|Generic text messages|The information content for these messages will be derived from trusted sources of medical information and contain links to websites such as American Heart Association. An example of such a message would be: Remember to take your blood pressure today! You can find more information from the American Heart Association by clicking here. Patients will be able to return texts with questions which will be addressed by the study team, including a clinical pharmacist if needed.
61936810|NCT04637490|NO_INTERVENTION|non-resurfacing|non-resurfacing TKA
61936811|NCT05907980|EXPERIMENTAL|Part A: Dose-escalation part of Phase Ia|Patients will receive ROSE12 as a IV infusion at escalated doses.
62135734|NCT06324981|ACTIVE_COMPARATOR|Interactive AI chatbot text messaging|This AI system will utilize NLP and ML to facilitate bi-directional system-patient dialogue with messages that incorporate content utilizing tailoring, behavioral nudges and persuasive messaging as described above. An example message would be: Make a promise to yourself to check your blood pressure today! Your goal is to have the top number at 120 or lower and the bottom number at 80 or lower. Each message will end with a question for the participant that will encourage engagement with the AI conversational chatbot that allows greater opportunity to use theoretical content to engage patient autonomy, competence and relatedness, the mechanisms through which we will impact behaviors.
62489054|NCT02684786|EXPERIMENTAL|Prior right heart catheterization|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status.
62489055|NCT02684786|EXPERIMENTAL|Scheduled for right heart catheterization|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
62489056|NCT01315782||Multi-organ failure|Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
62489057|NCT01846091|EXPERIMENTAL|Treatment (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IT on day 1.
62694249|NCT05972772|ACTIVE_COMPARATOR|Azithromycin|Azithromycin (Zithromax, 250-mg capsules; Pfizer) with a 500-mg loading dose, followed by 250 mg every 24 hours for 2 days. This will be followed by three days of doxycycline at the dose in A.
61936812|NCT05907980|EXPERIMENTAL|Part B: Biopsy part of Phase Ia|Serial biopsy will be conducted with patients who will receive ROSE12 as a IV infusion at escalated doses.
61936813|NCT05907980|EXPERIMENTAL|Part C: Dose-escalation part of Phase Ib|Patients will receive ROSE12 and atezolizumab as a IV infusion at escalated doses.
61936814|NCT05907980|EXPERIMENTAL|Part D: Biopsy part of Phase Ib|Serial biopsy will be conducted with patients who will receive ROSE12 and atezolizumab as a IV infusion at escalated doses.
61936815|NCT05907980|EXPERIMENTAL|Part E: Expansion part of Phase Ib in patients with selected solid tumors|Patients will receive ROSE12 and atezolizumab as a IV infusion at the recommended dose.
61936816|NCT00706810|EXPERIMENTAL|All participants|
61936817|NCT04095832||Parturients with preeclampsia|Parturients who were diagnosed with preeclampsia
62694250|NCT06569524|EXPERIMENTAL|TQA2225/AP025 or TQA2225/AP025 Placebo 25mg|TQA2225/AP025 or TQA2225/AP025 Placebo administered 25mg by subcutaneous (SC) injection weekly for 48 weeks
62489058|NCT02427919|EXPERIMENTAL|Early G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will be started post chemotherapy D+7\~D+10 when blasts disappear from peripheral blood smear.~When blasts reappear on peripheral blood smear, G-CSF will be discontinued.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-\> Comparison of the effect of G-CSF (Filgrastim) use"
62489059|NCT02427919|ACTIVE_COMPARATOR|No or delayed G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will not be applied at least post chemotherapy D+25\~D+28. If patient suffers from severe infectious complication and when no blasts are detected on peripheral blood smear, G-CSF can be started then.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-\> Comparison of the effect of G-CSF (Filgrastim) use"
62489060|NCT03366792|EXPERIMENTAL|MRI Targeted Biopsy|
62489061|NCT02760433|EXPERIMENTAL|Arm 1: Olokizumab q4w|"Olokizumab 64mg subcutaneous q4w + placebo + Methotrexate~Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)"
62489062|NCT02760433|EXPERIMENTAL|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
62489063|NCT02760433|PLACEBO_COMPARATOR|Arm 3: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)~Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group."
62489064|NCT01911429|EXPERIMENTAL|Lurasidone 40 mg|Lurasidone 40 mg once daily
62489065|NCT01911429|EXPERIMENTAL|Lurasidone 80 mg|Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
62694251|NCT06569524|EXPERIMENTAL|TQA2225/AP025 or TQA2225/AP025 Placebo 50mg|TQA2225/AP025 or TQA2225/AP025 Placebo administered 50mg by subcutaneous (SC) injection weekly for 48 weeks
62694252|NCT05553236|EXPERIMENTAL|Sequencing Intervention in addition to standard of care|Batched targeted deep sequencing in addition to the locally accepted standard of care drug susceptibility determination of multidrug/extensively drug-resistant tuberculosis (M/XDR-TB)
62694253|NCT05553236|NO_INTERVENTION|Standard of Care|Locally accepted standard of care which is consistent with the WHO recommendations for the drug susceptibility determination of M/XDR-TB
62694254|NCT04353492|EXPERIMENTAL|Ofatumumab|Ofatumumab 20 mg subcutaneous injections every 4 weeks, following loading of 3 doses in the first 14 days
62694255|NCT02758730|EXPERIMENTAL|AFFITOPE® PD01A + Adjuvant|3 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
62694256|NCT02758730|PLACEBO_COMPARATOR|Adjuvant without active component|3 injections of Placebo once every 4 weeks
62694257|NCT04952571|EXPERIMENTAL|GBM at first relapse|
62694258|NCT04952571|EXPERIMENTAL|GBM at second relapse|
62694259|NCT06638190|ACTIVE_COMPARATOR|100% Orange juice|In this arm, the participants will drink a total of 250 mL of a commercial 100% orange juice with known total sugar content (25 g) and matrix composition.
62694260|NCT06638190|EXPERIMENTAL|50% Orange juice|In this arm, the participants will drink 250 mL of a beverage containing 50% of the same commercial orange juice (active comparator) with added sugars to match the content of sugars the 100% juice. The content of matrix will be 50% of the active comparator.
62135735|NCT06324981|ACTIVE_COMPARATOR|Interactive AI chatbot text messaging + proactive pharmacist management|The AI chatbot will be the same as arm 2 (Interactive AI chatbot text messaging alone). In this arm, however, pharmacists will review patient's baseline LE8 risk factors and proactively contact patients via telephone and/or the EHR patient portal to address any risk factor that is in poor/intermediate health categories. The investigators are proposing proactive pharmacist involvement as a population-based approach to address patients with uncontrolled CV risk factors.
62489066|NCT01911429|PLACEBO_COMPARATOR|Placebo|Placebo 40 or 80 mg once daily
62489067|NCT06241976|OTHER|White Caucasian group|Participants from white Caucasian origin
62694261|NCT06638190|EXPERIMENTAL|0% Orange juice|In this arm, the participants will drink 250 mL of 100% water with added sugars to match the content of sugars of the commercial 100% orange juice (active comparator). This drink will not contain the food matrix components.
62694262|NCT06638190|ACTIVE_COMPARATOR|Glucose solution|In this arm, the participants will drink 250 mL of a glucose solution with a total 25 g of glucose (to match the total concentration of sugars in the test beverages). This arm will allow for the measurement of the glycemic indexes of the test drinks. In addition, it will allow for a characterization of the participant (basal glucose level at the start of the intervention and type of responder, e.g. biphasic, monophasic).
61936818|NCT04095832||Healthy parturients|Healthy full-term parturients
62489068|NCT06241976|OTHER|South Asian group|Participants from South Asian origin
62489069|NCT06241976|OTHER|Black African-Caribbean|Participants from Black African-Caribbean origin
62489070|NCT01904513|EXPERIMENTAL|Probiotic|Daily consumption of yogurt supplemented with L. rhamnosus GR-1 at \~10\^10 CFU/day
62489071|NCT01904513|OTHER|Milk|Daily consumption of pasteurized whole milk
62694263|NCT06638190|ACTIVE_COMPARATOR|100% Orange juice Rep|This arm will be a repetition of the 100% Orange juice arm
61936819|NCT04676217|ACTIVE_COMPARATOR|FDP|Face down positioning
62694264|NCT06638190|EXPERIMENTAL|0% Orage juice Rep|Thia arm will be a repetition of the 0% Prange juice arm
62694265|NCT06126900|EXPERIMENTAL|Intervention Group|Reminder + text messaging
62694266|NCT06126900|NO_INTERVENTION|Control Group|No reminder + no text messaging
62694267|NCT01044719|ACTIVE_COMPARATOR|10 days|
62694268|NCT01044719|ACTIVE_COMPARATOR|14 days|
62694269|NCT01044719|ACTIVE_COMPARATOR|21 days|
62489072|NCT05919199||AML patients, de novo or refractory/relapsed|The investigators will collect bone marrow cells under standard clinical work-up after 18F-FDG PET/CT scan and correlate the FDG signal with extramedullary infiltration, histopathological, genomics features of the patients to explore the prognostic value of FDG signal in AML.
62489073|NCT00180401||QRS 120-150 ms|Subjects with a QRS width between 120-150 ms
62489074|NCT00180401||QRS >150 ms|Subjects with a QRS width \>150 ms
62489075|NCT04635020|EXPERIMENTAL|Stable glaucoma iStent|Cataract surgery combined with iStent inject
62489076|NCT04635020|EXPERIMENTAL|Stable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
62489077|NCT04635020|ACTIVE_COMPARATOR|Stable glaucoma|Cataract surgery
62489078|NCT04635020|EXPERIMENTAL|Unstable glaucoma iStent|Cataract surgery combined with iStent inject
62489079|NCT04635020|EXPERIMENTAL|Unstable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
62489080|NCT03056144|EXPERIMENTAL|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
62489081|NCT03416673|ACTIVE_COMPARATOR|CTG+CAF|The surgical procedure will include a connective tissue graft harvested from the palate and used under a coronally advanced flap
62694270|NCT03164993|PLACEBO_COMPARATOR|Arm Chemotherapy + Placebo|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + placebo
62694271|NCT03164993|ACTIVE_COMPARATOR|Arm Chemotherapy + Atezolizumab|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + Atezolizumab
62694272|NCT05277532|ACTIVE_COMPARATOR|Type 1 diabetes with overweight|High intensity interval training (HIIT), a single bout, randomly performed either in the morning or in the afternoon in a cross-over design.
62694273|NCT05277532|ACTIVE_COMPARATOR|Overweight but otherwise healthy control subjects|High intensity interval training (HIIT), a single bout, randomly performed either in the morning or in the afternoon in a cross-over design.
61936820|NCT04676217|EXPERIMENTAL|NSP|"No positioning named non-supine positioning. Participants are to avoid recumbent positioning."
61936821|NCT02515643||Endothelial dysfunction in Cohort 1|Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.
62694274|NCT03951480|EXPERIMENTAL|Manual medicine|
62694275|NCT03951480|ACTIVE_COMPARATOR|Corticosteroids infiltration|
61936822|NCT02515643||Endothelial dysfunction in Cohort 2|Assessment of endothelial dysfunction in renal transplant recipients from cohort 1
61936823|NCT03452228|EXPERIMENTAL|evinacumab|
61936824|NCT03452228|EXPERIMENTAL|Placebo|
61936825|NCT00635791|EXPERIMENTAL|Sorafenib tosylate and vorinostat|Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61936826|NCT01225770|EXPERIMENTAL|Green tea|Gargling with green tea
61936827|NCT01225770|ACTIVE_COMPARATOR|water|Gargling with water
61936828|NCT02623478|EXPERIMENTAL|Insulin Lispro - Test Formulation|Novel formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
61936829|NCT02623478|ACTIVE_COMPARATOR|Insulin Lispro - Reference Formulation|Marketed formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
61936830|NCT05235243|EXPERIMENTAL|The Full Intervention (FI) group|The full intervention (FI) group received a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules, and self-monitoring modules.
62135736|NCT02930954|ACTIVE_COMPARATOR|Gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received Gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
62489082|NCT03416673|EXPERIMENTAL|peCTG+CAF|A papillary extended connective tissue graft reshaped after harvested from the palate will be used under a coronally advanced flap
62489083|NCT05729048||Hemodynamic Monitoring|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor during CRRT treatment.
62489084|NCT04999280|EXPERIMENTAL|Fiber Croissant (FIBCRO) Group|Daily consumption at breakfast for 2 weeks of a fiber-enriched croissant
62489085|NCT04999280|ACTIVE_COMPARATOR|Control Croissant (CONCRO) Group|Daily consumption at breakfast for 2 weeks of a control croissant
62489086|NCT04599751|EXPERIMENTAL|Hair removal treatment|Trio laser module (Alma Lasers)
62489087|NCT05212116|EXPERIMENTAL|SDI-118 low dose|SDI-118 (low dose) orally once daily (QD) for 17±1 day.
62489088|NCT05212116|EXPERIMENTAL|SDI-118 high dose|SDI-118 (high dose) orally once daily (QD) for 17±1 day.
62489089|NCT05212116|PLACEBO_COMPARATOR|Placebo|Placebo orally once daily (QD) for 17±1 day.
62489090|NCT05226390|EXPERIMENTAL|1 x 107 IU/dose MVA-SARS-2-ST|All Participants will receive a single booster dose of 1 x 107 IU MVA-SARS-2-ST in 0.5 mL as inhalation (total inhaled volume 0.5 mL)
62489091|NCT06596148|EXPERIMENTAL|Early dashboard access|The early dashboard access arm will receive access to the Shingrix dashboard as soon as the study begins.
62489092|NCT06596148|OTHER|Wait list control arm|The wait list control arm will receive no intervention for 6-9 months; after this period, this arm will also receive access to the Shingrix dashboard.
62489093|NCT03040895|EXPERIMENTAL|ICDP-intervention for caregivers|Group-based ICDP-intervention for caregivers through a sequence of eight meetings. The groups are led by facilitators trained in the ICDP.
62489094|NCT03040895|OTHER|Treatment as usual|Participants may use other health services (GP, other interventions) as usual through the data Collection period (6 months). Afther this period, they will have the opportunity to join an ICDP-Group if they still want.
62489095|NCT06433232|EXPERIMENTAL|Rhuematoid arhtritis patients|Rhuematoid arhtritis patients: Change in PAI, hsCRP, ESR, SDAI and quality of life using OHIP-14 will be assessed post root canal treatment
62694276|NCT01287208|ACTIVE_COMPARATOR|Unblinded activity monitor|Subjects wear the activity device and can see the data on the device and on a website where the data is uploaded.
62694277|NCT01287208|PLACEBO_COMPARATOR|Blinded activity monitor|Subjects wear a blinded activity device and cannot see the activity on the device and cannot log on to the website where the data gets uploaded.
62489096|NCT06433232|ACTIVE_COMPARATOR|Systemically healthy patients|Systemically healthy patients: Change in PAI, hsCRP, ESR, and quality of life using OHIP-14 will be assessed post root canal treatment
62489097|NCT04001062|ACTIVE_COMPARATOR|Non-operatively|"1. Adults 18 and older~2. Native English-speaker~3. Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
62694278|NCT06644079|EXPERIMENTAL|Topical tranexamic acid|
61936831|NCT05235243|ACTIVE_COMPARATOR|The partial intervention (PI) group|The partial intervention (PI) group received an intervention identical to the FI group (a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules) with the exclusion of the self-monitoring modules.
61936832|NCT05235243|NO_INTERVENTION|Waiting List (WL) group|Waiting List (WL) group did not undergo any intervention during the study period. However, WL participants were told that the program will commence in three months. During their waiting time participants were instructed to reduce their daydreaming activity to the best of their ability. Since all participants were recruited for this study from an online support forum (that is not part of this research design), the investigators labeled WL as the Internet Support as Usual (ISAU) group.
61936833|NCT00912678|ACTIVE_COMPARATOR|MMF and Steroid Group|Group of Patients randomized to MMF and Steroid maintenance immunosuppression after 3 months (Tacrolimus withdrawal)
62331242|NCT03696758|EXPERIMENTAL|Metoprolol followed by Sildenafil|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
62331243|NCT00436969|ACTIVE_COMPARATOR|Control|Subjects randomized to the control arm injection of prescribed anesthetic and corticosteroid, shall receive an equivalent volume (8 mL's).
62331244|NCT00436969|EXPERIMENTAL|Investigational|Subjects randomized to the active treatment in this study will receive a one-time dose of 8 mL's of Orthovisc derived from non-animal source bacterial fermentation, S. Equi.
62331245|NCT05784415||Observational|Clinical information on participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021 will be captured
62331246|NCT02046265|EXPERIMENTAL|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
62331247|NCT02046265|EXPERIMENTAL|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
62331248|NCT02046265|EXPERIMENTAL|Step up to Prevention|Participant receives both the knowledge session and the tailored belief sessions and the participant is offered the HPV vaccine only by their nurse practitioner in clinic. This combined intervention is call Step Up to Prevention.
62331249|NCT02046265|ACTIVE_COMPARATOR|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
62331250|NCT01687738|EXPERIMENTAL|Communication Intervention|Specially trained communicator addresses factual understanding and elicits other barriers to care
62331251|NCT01687738|EXPERIMENTAL|Real Time Registry and data feedback only|Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
62331252|NCT06198049|EXPERIMENTAL|Pilates Training|Group A 17 participants will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week.
62331253|NCT06198049|EXPERIMENTAL|Balance Proprioception Exercises|Group B 17 participants will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. The program will be included four prescribed exercises: (a) exercise without any material, (b) exercise with a ball only, (c) exercise with a balance board only, and (d) exercise with a ball and a balance board. Also for gait and dynamic balance activity training use of Cobblestones walking mat that affects postural control. Walking task on the Cobblestone walking mat included: walking backward, walking sideways, and walking under dim light conditions. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
62331254|NCT04906889|EXPERIMENTAL|dexmedetomidine-lidocaine|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
62489098|NCT04001062|ACTIVE_COMPARATOR|Surgical|"1. Adults 18 and older~2. Native English-speaker~3. Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
62489099|NCT04404907||Males who never deliberately tan|Males responded to an anonymous online survey that they never deliberately tan
62489100|NCT04404907||Males who ever deliberately tan|Males responded to an anonymous online survey that they had ever deliberately tan
62694279|NCT06575868|EXPERIMENTAL|Myo-inositol|
62694280|NCT06575868|PLACEBO_COMPARATOR|Placebo myo-inositol|
62694281|NCT04726527||Florbetapir F 18 Recipients|Participants in this arm of the study will receive a 10 mCi (370 MBq) bolus injection of florbetapir F 18 and then be scanned in a PET scanner for brain imaging.
62694282|NCT02759809||Children previously assigned to donor milk in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive donor milk when mother's own breastmilk was unavailable. Donor milk was from a milk bank part of the Human Milk Banking Association of North America (HMBANA).
62694283|NCT02759809||Children previously assigned to formula in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive preterm formula when mother's own breastmilk was unavailable. Preterm formula was either Similac Special Care or Enfamil Premature depending on hospital contract with formula companies.
62135737|NCT02930954|EXPERIMENTAL|Gefitinib combined with chemotherapy|Gefitinib 250mg Qd combined with pemetrexed or gemcitabine plus carboplatin: Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days, Gemcitabine (1000 mg/m² days 1,d8, intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days
62694284|NCT02926846|EXPERIMENTAL|Lavage arm|Intravenous vancomycin \& gentamicin with adjunctive lavage
62694285|NCT02926846|ACTIVE_COMPARATOR|Standard treatment arm|Intraperitoneal vancomycin \& gentamicin
62694286|NCT05767086|EXPERIMENTAL|Gonadotropin-releasing hormone (GnRH) antagonist|Cetrotide® (0.25 mg, MerckSerono Pharmaceuticals, Darmstadt, Germany)
62694287|NCT05767086|EXPERIMENTAL|Medroxyprogesterone acetate|Tarlusal® (5 mg, Deva Pharma, Istanbul, Turkey)
62135738|NCT02930954|EXPERIMENTAL|Gefitinib combined with antiangiogenesis|Gefetinib 250mg Qd combined with bevacizumab 7.5mg/kg per 21 days
62135739|NCT06699810|EXPERIMENTAL|Continuous Glucose Monitoring with Adjusted Insulin Doses|Patients with ketosis-prone diabetes will wear a continuous glucose monitor (CGM) from the time of hospital discharge until insulin discontinuation. Insulin doses will be adjusted based on CGM glucose readings.
62135740|NCT04278755|EXPERIMENTAL|Continuous OC|Continuous daily oral drospirenone + ethinyl estradiol for 84 days (i.e., 12-weeks).
62135741|NCT03656211||Patients with UAVM|"All patients who have been diagnosed with UAVM (symptomatic or non-symptomatic) between January 1, 2000 and March 30, 2017, and confirmed by an imaging examination.~Telephone interview"
62135742|NCT02962284|EXPERIMENTAL|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
62135743|NCT02187536|EXPERIMENTAL|Telmisartan combined with Simvastatin|Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6)
62135744|NCT02187536|ACTIVE_COMPARATOR|Simvastatin and telmisartan placebo|Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6)
62135745|NCT01461759|EXPERIMENTAL|Chemotherapy|Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
62135746|NCT03106922|EXPERIMENTAL|PMF104|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2\<=Age\<6~* 500 ml in 1-1.5 hours \<= to 18 kg~* 625 ml in 1-1.5 hours \>18 kg 6\<=Age\<12:~* 750 ml in 1-2 hours \<=25 kg~* 1000 ml in 1-2 hours 25-35 kg~* 1250 ml in 1-2 hours \>35 kg 12\>=Age\<18 :~* 1500 ml in 2-3 hours \<= 45 kg~* 1750 ml in 2-3 hours\>45 kg.~Rescue dose (if no clear watery stools 3 hours after the entire solution):~* 250 ml 2 Age \<=6;~* 500 ml 6 \<=Age\<12; up to a cumulative maximum volume of 2000 ml 12\<=Age\<18."
62331255|NCT04906889|ACTIVE_COMPARATOR|remifentanil|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy
62331256|NCT03517683|EXPERIMENTAL|Low speed|Patients will receive intrathecal injection of the anesthetic mixture in a slow speed (1ml in 15 seconds)
62331257|NCT03517683|ACTIVE_COMPARATOR|High speed|Patients will receive intrathecal injection of the anesthetic mixture in a high speed (1ml in 5 seconds)
62331258|NCT04369430|EXPERIMENTAL|AKST4290|Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.
62331259|NCT04369430|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo, twice daily, for 12 weeks.
62694288|NCT05767086|EXPERIMENTAL|Dydrogesterone|Duphaston® (10mg, Abbott Laboratories, Chicago, Illinois, ABD)
61936834|NCT00912678|ACTIVE_COMPARATOR|Low-Dose Tacrolimus Group|Patients randomized to withdrawal of MMF after 3 months and maintenance immunosuppression with low-dose tacrolimus and Steroids
61936835|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
61936836|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
61936837|NCT04993560||Homologous booster|Two doses of BBIBP-CorV, followed by BBIBP-CorV
62694289|NCT01822379|EXPERIMENTAL|Cell transplantation|All patients will undergo transplantation of two distinct vitiligo lesions. One lesion will receive cells prepared with trypsin. The other lesion will receive cells prepared with dispase.
61936838|NCT04993560||Heterologous booster|Two doses of BBIBP-CorV, followed by BNT162b2
61936839|NCT01336192|NO_INTERVENTION|Best supportive care|Best supportive care
61936840|NCT01336192|EXPERIMENTAL|Maintenance gemcitabine|Maintenance therapy of gemcitabine alone
61936841|NCT02976233||Acute Respiratory Failure in NIV|
62331260|NCT01241851|ACTIVE_COMPARATOR|Aerobic exercise|
62331261|NCT01241851|ACTIVE_COMPARATOR|Resistance exercise|
62331262|NCT01241851|NO_INTERVENTION|Control|
62694290|NCT05917145|EXPERIMENTAL|Group A (Dose Escalation)|WSD0628 treatment should be started the day before radiation therapy starts (Day 1). Radiation therapy is given for 10 consecutive business days (Day 2-15, not including weekends and holidays), and WSD0628 will only be given on those 10 consecutive business days ≥30 minutes but ≤2 hours before radiation.
61936842|NCT02027038|EXPERIMENTAL|Patients with sacroiliac joint pain|Patients suffering from sacroiliac joint pain
61936843|NCT02027038|ACTIVE_COMPARATOR|Controls|healthy controls
61936844|NCT01200862|EXPERIMENTAL|BGS649 (Part 1)|BGS649 1mg and 0.1mg in hard gelatin capsules. In part 1 there was individualised dosing to titrate the subject's testosterone into the normal range. If the dose was lower than 0.1mg then specific instructions for dilution of an oral solution of BGS649 were provided.
61936845|NCT01200862|PLACEBO_COMPARATOR|Placebo to BGS649 (Part 2)|Matching placebo to BGS649 (0.3 and 0.1mg). 0.3mg placebo capsule given on Day 1 and 0.1mg placebo capsule on other treatment visits (week 1 to 11).
61936846|NCT01200862|EXPERIMENTAL|BGS649 (Part 2)|0.3 or 0.1mg hard gelatin capsules of BGS649 given orally. 0.3mg on Day 1 and 0.1 on all other treatment visits (week 1 to 11).
61936847|NCT04208568|ACTIVE_COMPARATOR|Gallbladder retrieval from umbilical port|Gallbladder retrieved from 10 mm umbilical port.
61936848|NCT04208568|ACTIVE_COMPARATOR|Gallbladder retrieval from epigastric port|Gallbladder retrieved from 10 mm epigastric port.
62694291|NCT05917145|EXPERIMENTAL|Group B (Dose Expansion)|"WSD0628 treatment should be started the day before radiation therapy starts (Day 1). Radiation therapy is given for 10 consecutive business days (Day 2-15, not including weekends and holidays), and WSD0628 will only be given on those 10 consecutive business days ≥30 minutes but ≤2 hours before radiation.~The Group B (Dose Expansion) portion of the study will be opened after the Group A (Dose Escalation) is complete."
62331263|NCT00045682|EXPERIMENTAL|Treatment (polyglutamate paclitaxel)|Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62694292|NCT05917145|EXPERIMENTAL|Group C (Tumor Penetrance Treatments)|"One treatment of WSD0628 will be given prior to radiation and surgical resection will be performed on the same day. The two doses given will be determined by Group A and Group B. Patients will be randomized in a 1:1 fashion.~* Dose level 1: minimally radiosensitizing concentration of WSD0628 will be achieved.~* Dose level 2: selected based on a prediction that a maximally radiosensitizing concentration of WSD0628 will be achieved.~This portion of the study will open after Group A (Dose Escalation) is complete. This portion of the study will open to patients with recurrent high-grade glioma to further evaluate the efficacy, safety, tolerability, pharmacokinetics and biological activity of WSD0628 when combined with radiation therapy in specific patient subgroups"
61936849|NCT01385631|PLACEBO_COMPARATOR|Atorvastatin plus Placebo|50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
61936850|NCT01385631|EXPERIMENTAL|Atorvastatin plus Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
61936851|NCT03007407|EXPERIMENTAL|durvalumab and tremelimumab|
61936852|NCT02801305|PLACEBO_COMPARATOR|Vaseline|About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.
61936853|NCT02801305|EXPERIMENTAL|Diltiazem Gel 2%|About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.
61936854|NCT02801305|EXPERIMENTAL|Nitroglycerin Ointment 2%|About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.
61936855|NCT01905410|EXPERIMENTAL|single treatment - VVZ-149 Injection|"single ascending dose escalation~* 0.25, 0.5, 1, 2, 4, 6, and 8 mg/kg Cohorts~* 4 hours IV infusion"
61936856|NCT01905410|PLACEBO_COMPARATOR|single treatment - placebo|"* The matching volume of placebo (water for injection) to each experimental cohort~* 4 hours IV infusion"
61936857|NCT01905410|EXPERIMENTAL|multiple treatment - VVZ-149 Injection|"Based on the results of SAD trials, low and high dosage are determined for MAD trials.~* high and low dosage~* 4 hours IV infusion x 2 times/day x 3 days"
61936858|NCT01905410|PLACEBO_COMPARATOR|multiple treatment - placebo|"* The matching volume of placebo (water for injection) to each experimental cohort~* 4 hours IV infusion x 2 times/day x 3 days"
61936859|NCT02133040||T3 > 4 nmol/l|Acute hyperthyroidism with a T3 \> 4 nmol/l
61936860|NCT03438383|SHAM_COMPARATOR|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O)."
61936861|NCT03438383|ACTIVE_COMPARATOR|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
61936862|NCT04934475|EXPERIMENTAL|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A|"Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12; 28-day cycle; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone):~* Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12)~* Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12)~* Lenalidomide: 25 mg per day orally from days 1 to 21~* Dexamethasone: 40 mg orally on day 1, 8, 15, 22"
61936863|NCT04934475|EXPERIMENTAL|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B|"Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2)~* Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~* Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8)~* Lenalidomide: 25 mg per day orally from days 1 to 21~* Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycles 7 to 8)"
61936864|NCT04934475|EXPERIMENTAL|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C|"Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation.~* Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~* Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8)~* Lenalidomide: 25 mg per day orally from day 1 to day 21~* Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycle 7 to 8)"
61936865|NCT04934475|EXPERIMENTAL|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D|Tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.
61936866|NCT04036734|ACTIVE_COMPARATOR|Transverse Ultrasound Orientation|Transverse placement of ultrasound to long axis of target lower limb vein
62331264|NCT02676076|EXPERIMENTAL|CHF 5993 100/6/12.5 µg|"Treatment A:~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB"
62331265|NCT02676076|ACTIVE_COMPARATOR|CHF 1535 100/6 µg|"Treatment B :~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF"
62694293|NCT03713450|EXPERIMENTAL|Control with imaging guidance|
61936867|NCT04036734|EXPERIMENTAL|Longitudinal Ultrasound Orientation|Longitudinal placement of ultrasound to long axis of target lower limb vein
62331266|NCT02232672|EXPERIMENTAL|MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
62331267|NCT00880672|ACTIVE_COMPARATOR|dutasteride|oral, 5mg, once per day, 2 weeks
62331268|NCT00880672|PLACEBO_COMPARATOR|placebo|oral, 5mg, once per day, 2 weeks
62331269|NCT00285298|EXPERIMENTAL|Pentoxifylline|
62331270|NCT00285298|PLACEBO_COMPARATOR|Placebo|
62331271|NCT00511407|EXPERIMENTAL|I|RAD Treatment
62489101|NCT03032536|EXPERIMENTAL|Treatments A, B, C|"Part 1: Cross-Over~* Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.~* Treatment B: AL-3778 2 x 300-mg tablets (fasted) once~* Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once."
62489102|NCT03032536|EXPERIMENTAL|Treatments D, E, F|"Part 2 (optional): Cross-Over~* Treatment D: AL-3778 2×300-mg tablets (fasted) once.~* Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:~* 1000mg: 2 x 500-mg OR~* 800mg: 1 x 300-mg + 1 x 500-mg OR~* 700mg: 1 x 200-mg + 1 x 500-mg~* Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:~* 1000mg: 2 x 500-mg OR~* 800mg: 1 x 300-mg + 1 x 500-mg OR~* 700mg: 1 x 200-mg + 1 x 500-mg"
62489103|NCT03032536|EXPERIMENTAL|Treatment G|"Part 3: AL-3778 twice daily administered under fasted conditions for 14 days.~Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~* 600mg: 2 x 300-mg OR~* 1000mg: 2 x 500-mg OR~* 800mg: 1 x 300-mg + 1 x 500-mg OR~* 700mg: 1 x 200-mg + 1 x 500-mg"
62489104|NCT03032536|ACTIVE_COMPARATOR|Treatment H|Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days
62489105|NCT03032536|EXPERIMENTAL|Treatment I|"Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~* 600mg: 2 x 300-mg OR~* 1000mg: 2 x 500-mg OR~* 800mg: 1 x 300-mg + 1 x 500-mg OR~* 700mg: 1 x 200-mg + 1 x 500-mg"
62489106|NCT03032536|ACTIVE_COMPARATOR|Treatment J|Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days
62489107|NCT03032536|EXPERIMENTAL|Treatment K|"Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~* 600mg: 2 x 300-mg OR~* 1000mg: 2 x 500-mg OR~* 800mg: 1 x 300-mg + 1 x 500-mg OR~* 700mg: 1 x 200-mg + 1 x 500-mg"
62135747|NCT03106922|ACTIVE_COMPARATOR|Klean- prep|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~* 2\<=Age\<6:~  * 90 ml/kg in 1-1.5 hours 2\<=Age\<6~ * 80 ml/kg in 1-1.5 hours 5\<=Age\<6~* 2\<=Age\<6:~  * 80 ml/kg in 1-2 hours 6\<=Age\<10~ * 70 ml/kg in 1-2 hours 10\<=Age\<12~* 12\<=Age\<18:~  * 70 ml/kg in 2-3 hours. Rescue dose (if no clear watery stools 3 hours after the entire Klean-Prep solution): 50% of the initial dose."
62135748|NCT01072838|OTHER|Dose Escalation|
62489108|NCT06628089||1|A questionnaire about H. Pylori infection, mode of transmission, Symptoms, treatment will be carried to primary health care physicians and will be asked to answer it
62489109|NCT06628089||2|
62489110|NCT05406518|EXPERIMENTAL|Intervention|Arm of intervention
62489111|NCT05971394|EXPERIMENTAL|IBS Titan|Subjects treated with IBS Titan™.Participants will be included in this arm.
62135749|NCT02311452||Acute Osteomyelitis|
62135750|NCT02311452||Complicated Pneumonia|
62135751|NCT02311452||Complicated Appendicitis|
62489112|NCT03270254|NO_INTERVENTION|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
62489113|NCT03270254|ACTIVE_COMPARATOR|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
62489114|NCT04807595||Retrospective cohort|Patients with confirmed diagnosis of HER2-neg, unresectable and/or mBC regardless of hormone status dating back from 31 December 2017 - but no older than 01 January 2015 - who progressed on any systematic anti-cancer therapy will be involved in this study.
62489115|NCT06391372|EXPERIMENTAL|local estriol|Patients will receive 1 g of intravaginal estriol via an applicator twice a week before going to bed for 4 weeks preoperatively.
62489116|NCT06391372|NO_INTERVENTION|control|Patients who met the same criteria as the study group and were not treated with local estriol
62489117|NCT00265226|EXPERIMENTAL|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category II ATT according to RNTCP guidelines
62489118|NCT00265226|PLACEBO_COMPARATOR|2|In this Arm patient will receive Placebo along with Category II ATT drugs according to RNTCP guidelines
62489119|NCT02804724||Newly diagnosed individuals with HIV|Individuals newly diagnosed with HIV in Grampian between January 2009 and December 2014
62489120|NCT01441349|ACTIVE_COMPARATOR|Control arm|IP chemotherapy arm
62489121|NCT01441349|EXPERIMENTAL|Treatment arm|IP chemotherapy plus simvastatin arm
62489122|NCT05946239|EXPERIMENTAL|Manage My Pain App Intervention|Participants will have access to the MMP App and standard care for 60 days.
62489123|NCT05946239|NO_INTERVENTION|Control Group|Participants will engage in standard care for 60 days.
62489124|NCT01714622||metabolic syndrome|gastric cancer patients with metabolic syndrome
62489125|NCT01714622||metabolic disease|gastric cancer patients with metabolic disease
62489126|NCT01714622||normal|gastric cancer patients without metabolic syndrome or metabolic disease
62135752|NCT05690152|EXPERIMENTAL|Single Arm|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
62135753|NCT02227134|OTHER|Difficult Airway|Children with a history of difficult airway intubation.
62489127|NCT03289260|EXPERIMENTAL|Interventional Arm|Imiquimod 5% cream therapy Fulguration
62489128|NCT03289260|PLACEBO_COMPARATOR|Placebo Arm|Placebo cream therapy Fulguration
62489129|NCT06563063|EXPERIMENTAL|Flumazenil|
62135754|NCT02227134|OTHER|Obstructive Sleep Apnea|Children with a history of obstructive sleep apnea.
62135755|NCT01144559|ACTIVE_COMPARATOR|Continuous Infusion|Each subject will have one lower extremity (Right or Left) randomized to receive a perineural catheter with a continuous infusion of local anesthetic and then the outcomes will be measured.
62135756|NCT01144559|ACTIVE_COMPARATOR|Bolus Administration|The opposite lower extremity (right or left) will be randomized to receive a perineural catheter with the local anesthetic being delivered via a bolus as opposed to continuous as is the case with their other extremity. The outcome measures will then be assessed as described.
62331272|NCT00511407|NO_INTERVENTION|II|Conventional CVVHD
62331273|NCT03333057|EXPERIMENTAL|NOV03 4 times daily (QID)|Perfluorohexyloctance solution 4 times daily (QID)
62331274|NCT03333057|EXPERIMENTAL|NOV03 2 times daily (BID)|Perfluorohexyloctance solution 2 times daily (BID)
62331275|NCT03333057|PLACEBO_COMPARATOR|Placebo 4 times daily (QID)|Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
62331276|NCT03333057|PLACEBO_COMPARATOR|Placebo 2 times daily (BID)|Saline solution (0.9% sodium chloride solution) 2 times daily (BID)
61936868|NCT06387511|ACTIVE_COMPARATOR|Standard Expanded program on immunization|The standard Expanded Program on Immunization (EPI) in children aged 6-23 months delivered according to the Ministry of Health's routine plans in the community and at health centres and health posts.
61936869|NCT06387511|EXPERIMENTAL|NutriVax|The NutriVax strategy combines the EPI in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres and health posts associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres for children 6-23 months of age.
62135757|NCT05565534|EXPERIMENTAL|Nurse-practitioner led intervention group|A nurse practitioner (NP) who is trained in diabetes on the oncology team will help manage diabetes for breast cancer patients undergoing cancer treatments
62135758|NCT05565534|NO_INTERVENTION|Non-intervention (control) group|Patient will not have access to the nurse practitioner led intervention.
62135759|NCT03791996|NO_INTERVENTION|"Late cranioplasty"|Subjects undergoing cranioplasty within 3 months after craniectomy.
62135760|NCT03791996|EXPERIMENTAL|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
62331277|NCT02167568||Corpus callosum agenesis/dysgenesis|patients with Corpus callosum agenesis/dysgenesis
62331278|NCT02167568||parents|parents of patients with corpus callosum agenesis/dysgenesis
62331279|NCT01474746|PLACEBO_COMPARATOR|Placebo|This arm will undergo identical treatment and assessments as the experimental group, with the exception of the active agent, sertraline. This group will be placed on a placebo.
62331280|NCT01474746|EXPERIMENTAL|Active|This arm will undergo identical treatment and assessments as the placebo group. This group will receive the active agent, sertraline.
62331281|NCT00913978|ACTIVE_COMPARATOR|Group 1: VitaHeat|Patients in group one will be warmed perioperatively with the VitaHeat mattress and IV fluid warmers once they are in the operating room.
62331282|NCT00913978|ACTIVE_COMPARATOR|Group 2: Bair Hugger|Patients in group two will be warmed perioperatively with the upper body bair hugger and IV fluid warmers once they are in the operating room.
62489130|NCT03234127|OTHER|Atherosclerosis- resistance|FH Patient without atherosclerosis
62694294|NCT03713450|ACTIVE_COMPARATOR|Control without imaging guidance|
62694295|NCT03599713|EXPERIMENTAL|Retifanlimab: Chemotherapy: Naïve|
61936870|NCT02044835|PLACEBO_COMPARATOR|OMT controll|placebo 20 ml every time, three times a day, combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
62135761|NCT02566902|ACTIVE_COMPARATOR|T-piece Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
62331283|NCT05504148|EXPERIMENTAL|Crocin group|The chemotherapy/radiotherapy protocols are made by oncologists adopted for patients depending on specific conditions , take saffron total glucosides tablets(provided by Reyoung Pharmaceutical Co., Ltd.) for 8 days during each chemotherapy (started on the 1st day before chemotherapy), 4 tablets/time, 3 times a day.
62331284|NCT05504148|PLACEBO_COMPARATOR|placebo group|Undergoing chemotherapy/radiotherapy protocols as planned, take placebo piece during(the same appearance of crocin tablets, production unit:Reyoung Pharmaceutical Co., Ltd.) for 8 days during each chemotherapy (started on the 1st day before chemotherapy), 4 tablets/time, 3 times a day
62331285|NCT02678741|ACTIVE_COMPARATOR|No clinical response|No clinical response (PD de novo) after a minimum of 3 months on CPI monotherapy
62694296|NCT03599713|EXPERIMENTAL|Retifanlimab: Chemotherapy: Refractory|
62694297|NCT03058887|EXPERIMENTAL|Arm cranking|exercising for 3 months twice per week.
61936871|NCT02044835|EXPERIMENTAL|herbal treatment|Fu-zheng-qu-zhuo oral liquid ( herbal medicine) 20 ml every time, three times a day,combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
61936872|NCT03686761|EXPERIMENTAL|Study|A Involvement with the osteotomy site of the surgery, osteotomy was performed then GCF were collected from teeth neighboring the
61936873|NCT03686761|ACTIVE_COMPARATOR|Control|Involvement with the osteotomy site of the surgery, surgical osteotomy was performed then GCF were collected from teeth away from the osteotomy site
62135762|NCT02566902|EXPERIMENTAL|Breath-Enhanced Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
62135763|NCT05425953||Klinefelter syndrome|Patients with 47, XXY n=60
62331286|NCT02678741|ACTIVE_COMPARATOR|Develop PD|Develop PD after initial clinical response to CPI monotherapy
62331287|NCT02678741|ACTIVE_COMPARATOR|Stable Disease|Stable disease for at least 6 months on CPI monotherapy
62331288|NCT00372190|EXPERIMENTAL|Mesh surgery|Trocar guided tension free vaginal mesh insertion by Prolift mesh kit
62331289|NCT00372190|ACTIVE_COMPARATOR|Conventional vaginal surgery|Classical vaginal prolapse surgery (fascia plication)
62489131|NCT03234127|OTHER|Control|FH patient with atheroclerosis
62489132|NCT03234127|OTHER|the related population without familial hypercholesterolemia|No FH patient
62694298|NCT03058887|EXPERIMENTAL|Cycling|exercising for 3 months twice per week.
62694299|NCT03058887|NO_INTERVENTION|Control group|No exercise intervention.
61936874|NCT03111173|OTHER|Holter device|Holter device to be attached to a Singleton or twin pregnant women at 32 weeks gestation to full term
61936875|NCT02025673||Healthy Controls|Healthy subjects as control group.
61936876|NCT02025673||Type 2 diabetes|Patients with type 2 diabetes.
62489133|NCT05474651||Questionnaires assessed expectant fathers who quit smoking|"Participants who met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).~1. Males ≥18 years old;~2. The wife has given birth, the newborn is live, and the number of days of birth is less than or equal to 28 days;~3. Self-reported smoking at least 1 cigarette per day on average for at least 1 month in the past 1 year;~4. Self-reported that they had quit smoking during their wife's pregnancy on purpose, and maintained it for at least 24 hours;"
62489134|NCT06190977|EXPERIMENTAL|Otago Exercise Program|"Warm-up activities for 5 min head movement, neck movement, back stretching, trunk movement, and ankle movement.~strength and balance training for 30 mins Strengthening training include sitting knee extension, standing hip abduction, standing knee flexion, tiptoe and heel tiptoe Balance training include standing on one foot, walking in the shape of the number eight, walking sideways, walking backward, standing to sit position training, knee bending, toe to heel standing, heel walking, toe to heel walking, toe to heel walking, toe to heel walking, toe to heel walking backward, and climbing stairs Walking training for 10 min"
61936877|NCT02025673||Gestational diabetes mellitus|Patients with gestational diabetes mellitus.
62331290|NCT02143362|EXPERIMENTAL|Dexmedetomidine group|"1. Infusion of dexmedetomidine(0.8μg/kg) at10 minutes before anesthesia induction.~2. Infusion of dexmedetomidine at 0.4 μg•kg-1•h-1during anesthesia maintenance.~3. The infusion rate of dexmedetomidine was reduced to 0.1 μg•kg-1•h-1 for awaken test."
61936878|NCT04075110|PLACEBO_COMPARATOR|Control group|50 patients will receive metformin up to 2000mg/daily (Control group)
62489135|NCT06190977|OTHER|General TKR ptotocol|Ankle pumps Straight leg raises Heel slides Seated knee extensions Standing knee flexion Calf raises Quadriceps contraction Stationary bike
62489136|NCT01112722|ACTIVE_COMPARATOR|Apitox, purified honeybee toxin, injections|active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'
62489137|NCT01112722|PLACEBO_COMPARATOR|histamine injection|the histamine injection produces a similar local effect of pain and erythema as the active drug
62489138|NCT00582205|EXPERIMENTAL|Paclitaxel, Cisplatin IP|There is only one arm for this study and it represents the participants receiving the intraperitoneal chemotherapy
61936879|NCT04075110|EXPERIMENTAL|Montelukast group|50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).
61936880|NCT01316471|EXPERIMENTAL|Online Behavioral Intervention|In addition to standard medical care, children and parents in the online behavioral intervention will receive access to the full web-based program including education about chronic pain, training in behavioral and cognitive coping skills, instruction in increasing activity participation, and education about pain behaviors and parental operant strategies using an engaging, interactive format on the Internet.
62135764|NCT05425953||Turner syndrom|Patients with 45, X n=60
61936881|NCT01316471|ACTIVE_COMPARATOR|Online Patient Education|The Online Patient Education group will serve as an attention control condition. In addition to standard medical care, children and parents will be provided with access to a modified version of the study website that will provide information from publicly available educational websites about pediatric chronic pain management.
61936882|NCT02908243||Prophylaxis|Severe hemophilia A patients who receive factor VIII with dose of 15-25 IU/Kg, 2-3 times/week Severe hemophilia B patients who receive factor IX with dose of 30-50 IU/Kg, 1-2 times/week
62135765|NCT05425953||47, XXX|Patients with 47, XXX n=20
62135766|NCT05425953||47, XYY|Patients with 47, XYY n=20
62135767|NCT05425953||Male controls|Male controls n=80
62135768|NCT05425953||Female controls|Female controls n=80
62135769|NCT01771484|EXPERIMENTAL|Low Sodium Diet|participants will consume a diet (10 milliequivalent Na+/day)for 4-5 days prior to study day.
62135770|NCT01771484|EXPERIMENTAL|High sodium diet|Participants will consume a diet high in sodium (300 milliequivalent Na+/day) for 4-5 days prior to study intervention.
62135771|NCT02955719|EXPERIMENTAL|Enrolled Cases|"Integrated Care Pathway with different treatment interventions~Interventions include:~Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources"
62135772|NCT02955719|NO_INTERVENTION|Enrolled Controls|No intervention: Treatment as usual (TAU) will be provided by the primary care practice staff
62135773|NCT02714075|EXPERIMENTAL|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
62135774|NCT03689946|EXPERIMENTAL|Evolocumab, F18-NaF PET, CCTA|Evolocumab self-administration for 18 months. Baseline (pre-treatment) and follow-up 18F-NaF PET and CCTA (possible beta-blocker and nitroglycerin, if medically safe).
62135775|NCT02907905|OTHER|Population homeless or living in slum|Population homeless or living in slum realizing realizing a capillary sampling
62135776|NCT01764516||Zinc level (micro gram per deciliter)|In all cases
62135777|NCT01764516||Selenium level (micro gram per deciliter)|In all cases
62135778|NCT01764516||Zinc level in male (micro gram per deciliter)|
62135779|NCT01764516||Selenium level in male (micro gram per deciliter)|
62135780|NCT01764516||Zinc level in Female (micro gram per decilitre)|
62135781|NCT01764516||Selenium level in Female (micro gram per decilitre)|
62135782|NCT05682950|EXPERIMENTAL|Online Adaptive Radiotherapy|Patients receive online adaptive radiotherapy. The CTV contours of the following areas: vaginal cuff, obturator nodal chain, internal iliac nodal chain, external iliac nodal chain, presacral nodal chain and common iliac nodal chain. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with online adaptive radiotherapy.
62135783|NCT02840929|EXPERIMENTAL|Second-look OGD group|"Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.~OGD will be offered if signs of rebleeding present)"
62135784|NCT02840929|ACTIVE_COMPARATOR|Standard care group|Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present
62135785|NCT04958317|PLACEBO_COMPARATOR|Early exercise|Participants will exercise for 30 minutes prior to an evening meal
62135786|NCT04958317|EXPERIMENTAL|Late exercise|Participants will exercise for 30 minutes after an evening meal
62489139|NCT04173611|EXPERIMENTAL|EXPAREL®|For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).
62489140|NCT04173611|ACTIVE_COMPARATOR|Bupivacaine|In each cohort, subjects randomized to the bupivacaine arm will receive 15mg of plain bupivacaine HCL (the equivalent of 13.3mg bupivacaine base) providing a 1:1 reference to the starting dose level chosen for EXPAREL®.
62489141|NCT04173611|ACTIVE_COMPARATOR|Placebo|Subjects in the placebo arm will receive normal saline intrathecal injection
62489142|NCT01939080|ACTIVE_COMPARATOR|Medical supervision|Exercise training with supervised sessions Classics training
62489143|NCT01939080|ACTIVE_COMPARATOR|No medical supervision|Exercise training without supervised sessions Classics training
62489144|NCT01896713|OTHER|Diagnostic: Single Arm|Imaging (MS3TMRI)
62331291|NCT02143362|PLACEBO_COMPARATOR|Control group|"1. Infusion normal saline(0.8μg/kg) at 10 minutes before anesthesia induction.~2. Infusion normal saline at 0.4 μg•kg-1•h-1 during anesthesia maintenance.~3. The infusion rate of normal saline was reduced to 0.1 μg•kg-1•h-1 for awaken test."
62331292|NCT06520176|EXPERIMENTAL|EAP regimen group|66 subjects will be enrolled into the EAP regimen group. EAP regimen is the combination of etoposide, cytarabine and PEG-rhG-CSF.
62331293|NCT06520176|ACTIVE_COMPARATOR|CG regimen group|33 subjects will be enrolled into the CG regimen group. CG regimen is the combination of cyclophosphamide and G-CSF.
62331294|NCT01735747|EXPERIMENTAL|Temozolomide, Nedaplatin, Vincristine, Radiotherapy|The newly diagnosed PCNSL patients will be given concurrent temozolomide (75mg/m2, orally) daily during WBRT. Then, the TNV regimen will be given after four weeks. TNV regimen consisted of temozolomide (200mg/m2 orally, days 1-5), nedaplatin (80mg/m2 i.v., day 1), vincristine (1.4mg/m2 i.v., day 1). Each cycle was 4 weeks and a maximum of six cycles were applied.
62489145|NCT00901719|EXPERIMENTAL|Sodium depletion|Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing \>2000 kcal of energy, \>60 g of protein, \<12 mmol of sodium and \<70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
62489146|NCT00901719|PLACEBO_COMPARATOR|Normal diet|Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
62694300|NCT06564363||Urothelial carcinoma Patients|Patients with urothelial carcinoma, which can be primary or recurrent, should be eligible for surgery including transurethral resection of bladder tumours (TURbt), partial cystectomy, radical nephroureterectomy, and kidney-sparing surgery. Urine samples were collected before and after surgery. The follow-up period was 24 months, and the patients underwent routine tests during the follow-up period. The gold standard for recurrence of urothelial carcinoma is surgical/biopsy pathology.
61936883|NCT02908243||On-demand|Severe hemophilia A patients who receive factor VIII injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH); Severe hemophilia B patients who receive factor IX injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH)
61936884|NCT02908243||Collection of baseline data in all hemophilia A and B patients|All severe, moderate and mild types of hemophilia A and B patients
61936885|NCT04319991|PLACEBO_COMPARATOR|Placebo|
61936886|NCT04319991|EXPERIMENTAL|Probiotics product|
61936887|NCT00691067|EXPERIMENTAL|Mifepristone|600mg of Mifepristone
62135787|NCT06699303|EXPERIMENTAL|Uncomplicated Diaper Dermatitis Severity Assessment Scale in Babies|"In the study, a data collection form consisting of 13 questions regarding the sociodemographic characteristics of 0-12 month old babies and the Uncomplicated Diaper Dermatitis Severity Assessment Scale in Babies, developed by Buckley et al. in 2016 and whose Turkish validity and reliability studies were conducted by Keskin, will be used."
62489147|NCT01401062|EXPERIMENTAL|Arm 1 (Fresolimumab 1 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 \& 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
62489148|NCT01401062|EXPERIMENTAL|Arm 2 (Fresolimumab 10 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 \& 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
62135788|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
62331295|NCT02421328|ACTIVE_COMPARATOR|CPAP first|Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
62489149|NCT00111696|EXPERIMENTAL|MEDI-522|Drug
62489150|NCT05347953||Single arm|Patients with self-reported symptoms of positional dependent palpitations
62489151|NCT05897619|EXPERIMENTAL|Maya Perinatal Cognitive Behavioral Skills App|Participants receive the Maya Perinatal Cognitive Behavioral Skills App for 6 weeks.
62489152|NCT02770690|EXPERIMENTAL|spray|apply the ethyl chloride spray before propofol injection
62489153|NCT02770690|ACTIVE_COMPARATOR|lidocaine|apply the lidocaine 0.5 mg/kg under the touniquette state before propofol injection
62489154|NCT02770690|PLACEBO_COMPARATOR|placebo|apply the saline before propofol injection
62489155|NCT00480038|OTHER|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
62694301|NCT06641531||Normal group|normal pap smear
61936888|NCT00691067|PLACEBO_COMPARATOR|Placebos|Placebo
61936889|NCT00808678|EXPERIMENTAL|1|ABT-143 capsules 20/135 mg
61936890|NCT00808678|ACTIVE_COMPARATOR|2|ABT-335 135 mg and rosuvastatin 20 mg
62694302|NCT06641531||Abnormal group|Abnormal routine Pap smears will be classified according to latest Bethesda system into the following categories : Atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells cannot exclude high grade squamous intraepithelial lesion (ASC-H), low grade squamous intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), squamous cell carcinoma (SCC), atypical glandular cells of undetermined significance (AGUS), and adenocarcinoma (ADC).
62694303|NCT03599076||Manifest HD|
62694304|NCT03599076||Premanifest HD|
62331296|NCT02421328|ACTIVE_COMPARATOR|HHHFNC first|Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
62331297|NCT02998554|EXPERIMENTAL|SHP640|Participants instructed to instill 1 drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
62331298|NCT02998554|PLACEBO_COMPARATOR|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
62331299|NCT03090620|EXPERIMENTAL|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
62331300|NCT03090620|EXPERIMENTAL|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
62331301|NCT04969640||infective keratitis|50 cases with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.
62331302|NCT01662700|EXPERIMENTAL|AS2|"Artesunate 2 mg/kg/day for 5 days Combine with~* Primaquine 15 mg is given daily for 14 days.~* Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
62331303|NCT01662700|ACTIVE_COMPARATOR|Chloroquine|"CH25: Chloroquine 25 mg/kg: 15 mg base/kg on the first days (D0), followed by 5 mg base/kg daily on the second and third day (day1-2) (total 25 mg base/ kg).~Combine with~* Primaquine 15 mg is given daily for 14 days.~* Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
62331304|NCT02728128||Low cardiac output syndrome|Patients who experience low cardiac output syndrome
62331305|NCT02728128||No low cardiac output syndrome|Group that does not experience low cardiac output syndrome.
62331306|NCT02467387|EXPERIMENTAL|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
62331307|NCT02467387|PLACEBO_COMPARATOR|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
62331308|NCT05478044|EXPERIMENTAL|Ascorbic acid|Ascorbic acid IV ampoules 20% as a final flush irrigation 3ml after cleaning and shaping.
62331309|NCT05478044|PLACEBO_COMPARATOR|Saline|A mixture of sodium chloride and water (0.9%) as a final flush irrigation 3 ml after cleaning and shaping.
62331310|NCT01930799|OTHER|All Enrolled Patients|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
62331311|NCT02772965|EXPERIMENTAL|Methotrexate|"Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.~Folic Acid (1 mg) daily"
62331312|NCT02772965|PLACEBO_COMPARATOR|Sugar pill (placebo)|"Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.~Folic Acid (1 mg) daily"
62331313|NCT04353960||anticholinergic|Patients who receive anticholinergic medication before strabismus surgery
62331314|NCT04353960||non-anticholinergic|Patients who do not received anticholinergic medication before strabismus surgery
62694305|NCT03599076||Control|
62694306|NCT00839930|EXPERIMENTAL|Cilostazol (test)|Cilostazol 50 mg Tablet (test) dosed in first period followed by Pletal® 50 mg Tablet (reference) dosed in second period
62331315|NCT06131554|EXPERIMENTAL|batch 1 of MCV4|1 dose of Menhycia on Day 0
62331316|NCT06131554|EXPERIMENTAL|batch 2 of MCV4|1 dose of Menhycia on Day 0
62489156|NCT02818751|EXPERIMENTAL|Escitalopram|Patients being randomized to receive escitalopram, at an initial dose of 5 mg (oral) daily for 2 days. On day 3, escitalopram will be increased to 10 mg daily and continued for 7 days. Then, on day 10, escitalopram will be increased to 15 mg. At the week 4 visit, the dose of escitalopram may be increased to 20 mg, based on the investigator's clinical judgment and if significant anxiety symptoms are still present.
62489157|NCT02818751|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo (sugar pill) at an initial dose of 5 mg daily for 2 days. On day 3, placebo will be increased to 10 mg daily and continued for 7 days to match the experimental group.
62331317|NCT06131554|EXPERIMENTAL|batch 3 of MCV4|1 dose of Menhycia on Day 0
62331318|NCT06131554|ACTIVE_COMPARATOR|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra on Day 0
62694307|NCT00839930|ACTIVE_COMPARATOR|Pletal® (reference)|Pletal® 50 mg Tablet (reference) dosed in first period followed by Cilostazol 50 mg Tablet (test) dosed in second period.
62694308|NCT02324244||immunocompetent patients underwent heart surgery|
62694309|NCT03913130|EXPERIMENTAL|Drug QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
61936891|NCT06681597|EXPERIMENTAL|Human administrated with raspberry ketone|
62331319|NCT05458063||Patients admitted in Surgical intensive care unit and trauma intensive care unit|all surgical patients who planned to admit in surgical and trauma intensive care unit in emergency room
62331320|NCT04279561|EXPERIMENTAL|Diagnostic (68GA-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
62489158|NCT02818751|NO_INTERVENTION|Healthy Controls|Healthy adolescents will receive fMRI scans at the same time points, which will provide assessments of the stability of neurophysiologic measures and will be used to adjust and interpret comparisons within the patients (i.e., whether patient values are changing toward or away from those of healthy adolescents).
61936892|NCT06681597|EXPERIMENTAL|Human administrated with placebo|
62135789|NCT03961841|ACTIVE_COMPARATOR|Chemoradiation|weekly 5-Fu and oxaliplatin
62489159|NCT02351700|ACTIVE_COMPARATOR|IV Caldolor (ibuprofen)|Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
62489160|NCT02351700|PLACEBO_COMPARATOR|standard treatment group|IV placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
62489161|NCT05601596||Control Participant|Having No symptoms of Endo. Provide Menstrual samples.
62489162|NCT05601596||Symptomatic participant|Having symptoms of Endo and heading to diagnostic surgery as part of their standard of care (referred).
62489163|NCT02182596|EXPERIMENTAL|DAUNORUBICINE - ARACYTINE - MYLOTARG -|"Adaptive Bayesian method for dose-finding in phase I/II clinical trials based on treatment efficacy and toxicity (Thall, Russel, 1998), with successive patients cohorts and three combined dose levels:~DNR 45 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 200 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~Two consolidation courses for CR patients:~Amsacrine: 90 mg/m2 IV Day 1 Cytarabine: 1g/m2 twice a day IV Days 1 to 4 Mylotarg: 3 mg/m2 IV Day 1."
62489164|NCT01175330|PLACEBO_COMPARATOR|CABG and intralipid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
62489165|NCT01175330|ACTIVE_COMPARATOR|CABG and omega-3 fatty acid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
62489166|NCT05538338|ACTIVE_COMPARATOR|Intervention Group|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group
62489167|NCT05538338|PLACEBO_COMPARATOR|Control Group|an intrauterine infusion of normal saline will be administered to this group
62694310|NCT06476548|EXPERIMENTAL|Usability Testing|Participants will receive brief counseling, nicotine replacement therapy, and intervention content delivered via the app.
62694311|NCT03687671|EXPERIMENTAL|Animal-assisted therapy|The intervention is animal-assisted occupational therapy, animal-assisted physiotherapy or animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
62694312|NCT03687671|ACTIVE_COMPARATOR|Treatment as usual (activation program)|As control intervention patients receive treatment as usual (TAU) in speech therapy, occupational therapy or physiotherapy. The control intervention is named activation program.
61936893|NCT02791399|NO_INTERVENTION|Control|Treatment as usual
62135790|NCT03961841|EXPERIMENTAL|FLOT|Eight perioperative chemotherapy cycles
62135791|NCT03961841|EXPERIMENTAL|FOLFOX|Twelve perioperative chemotherapy cycles
62694313|NCT01926509|EXPERIMENTAL|MK-8892 Panel A|Participants will be administered MK-8892 once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28).
62694314|NCT01926509|EXPERIMENTAL|MK-8892 Panel B|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28).
61936894|NCT02791399|EXPERIMENTAL|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
61936895|NCT03141073|EXPERIMENTAL|HMS5552|75mg BID
61936896|NCT03141073|PLACEBO_COMPARATOR|Placebo|BID
62135792|NCT04572906|EXPERIMENTAL|NTX-001|NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy.
62135793|NCT04572906|NO_INTERVENTION|Standard of Care|standard suture neurorrhaphy
62135794|NCT06445244|EXPERIMENTAL|α-KG group|AKG Double Wood® + lifestyle modification
62135795|NCT06445244|OTHER|Control group|Lifestyle modification only
62135796|NCT02990481|EXPERIMENTAL|Arm 1 - TRK-950|"* Solid tumor~* TRK-950 (Three dose levels will be explored during Arm 1)"
62135797|NCT02990481|EXPERIMENTAL|Arm 2 - TRK-950|"* Colon cancer~* TRK-950 (Low dose and High dose)"
62135798|NCT02990481|EXPERIMENTAL|Arm 3 -TRK-950|"* Cholangiocarcinomas~* TRK-950 (Low dose)"
62135799|NCT03481751||Patients with Crohn Disease|Patients with Crohn's disease scheduled for ileocolonoscopy
62135800|NCT06694155|EXPERIMENTAL|Whey Protein Supplementation|Crossover study
62331321|NCT02114333|ACTIVE_COMPARATOR|A - Live zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
62331322|NCT02114333|ACTIVE_COMPARATOR|B - recombinant zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
62331323|NCT02114333|ACTIVE_COMPARATOR|C - Live zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
62331324|NCT02114333|ACTIVE_COMPARATOR|D - recombinant zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
61936897|NCT06562751||Survey 1 (National Health Service Inflammatory Bowel Disease services)|A survey designed by the investigators to ascertain current Inflammatory Bowel Disease service provision for sexual healthcare. A representative from each service will complete one online survey that should take approximately 15 minutes to complete.
61936898|NCT06562751||Survey 2 (Inflammatory Bowel Disease nurses survey)|A survey designed by the investigators to ascertain current nursing practice for sexual healthcare within Inflammatory Bowel Disease (IBD) services. Registered nurses working with people with IBD will complete one online survey that should take approximately 15 minutes to complete.
61936899|NCT06562751||Survey 3 (men with IBD)|A survey designed by the investigators to ascertain the needs of men with Inflammatory Bowel Disease (IBD). Men with a diagnosis of IBD will complete one online survey that should take approximately 15 minutes to complete.
61936900|NCT06562751||Interviews|Men with a diagnosis of Inflammatory Bowel Disease (IBD) and the partners of men with IBD will undertake online, semi-structured interviews that will last no longer than 60 minutes. Participants can be interviewed with their partner or individually. Participants without a partner or whose partner does not wish to be interviewed will be interviewed individually.
62331325|NCT01467908|EXPERIMENTAL|Vegetative state|Patients with the diagnosis of the vegetative state
62331326|NCT01228071|EXPERIMENTAL|40 mg daily dose of testosterone gel 2%|testosterone gel 2%
62489168|NCT03602339|EXPERIMENTAL|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
62489169|NCT03602339|EXPERIMENTAL|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
61936901|NCT06562751||Focus Groups|Healthcare professionals and appropriate stakeholders (for example charitable organisations) will participate in focus groups. Each focus group will contain 6-8 members. There will be three groups in total.
61936902|NCT06562751||Co-production workshops|A group of 8-12 inclusive of men with IBD, the partners of men with IBD and healthcare professionals and appropriate stakeholders will participate in three co-production workshops to develop a prototype intervention and logic model to patient benefit.
62135801|NCT06694155|PLACEBO_COMPARATOR|Placebo Supplementation|Crossover study
62135802|NCT02923206|EXPERIMENTAL|Phase 0 - healthy volunteers|Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
62135803|NCT02923206|EXPERIMENTAL|Phase A - preeclampsia patients|Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
62331327|NCT04697472|EXPERIMENTAL|Functional task practice (FTP) followed by FTP + ARC Therapy|Clinic-based functional task practice (FTP) for two months followed by FTP + ARC Therapy for an additional 2 months.
62489170|NCT00863330|EXPERIMENTAL|Determine toxicity of treatment regimen.|
62331328|NCT00584337||1|
62331329|NCT00584337||2|
62331330|NCT04894786|EXPERIMENTAL|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization \& Sleeper Stretch
62331331|NCT04894786|ACTIVE_COMPARATOR|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique and Sleeper Stretch
62331332|NCT02343536|EXPERIMENTAL|Oral Azacitidine (CC-486) and R-CHOP|Will examine four escalating dose-levels of CC- 486 (100 mg, 150 mg, 200 mg and 300 mg).
62331333|NCT02343536|ACTIVE_COMPARATOR|R-CHOP|R-CHOP, (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) \* rituximab, cyclophosphamide, doxorubicin, and vincristine are administered on Day 1; while prednisone is administered Days 1-5
62331334|NCT03516019|EXPERIMENTAL|Weekday am personalized notices|Participants in this arm receive personalized weekday am notices on Wednesday at 7am.
62331335|NCT03516019|EXPERIMENTAL|Weekday pm personalized notices|Participants in this arm receive a personalized weekday pm notices on Wednesday at 7pm.
62331336|NCT03516019|EXPERIMENTAL|Weekend am personalized notices|Participants in this arm receive a personalized weekend am notices on Saturday at 7am.
62331337|NCT03516019|EXPERIMENTAL|Weekend pm personalized notices|Participants in this arm receive personalized pm notices on Saturday at 7pm.
62331338|NCT03516019|EXPERIMENTAL|Weekday am standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7am.
62331339|NCT03516019|EXPERIMENTAL|Weekday pm standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7pm
62331340|NCT03516019|EXPERIMENTAL|Weekend am standard notices|Participants in this arm receive standard weekend notices on Saturday at 7am
62331341|NCT03516019|EXPERIMENTAL|Weekend pm standard notices|Participants in this arm receive standard weekend notices on Saturday at 7pm
62331342|NCT03560193|EXPERIMENTAL|Chlorhexidine Group|
62331343|NCT03560193|ACTIVE_COMPARATOR|Povidone Iodine Group|
62331344|NCT05736588|NO_INTERVENTION|Usual care|
62331345|NCT05736588|EXPERIMENTAL|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
62331346|NCT04182620|EXPERIMENTAL|Catheter ablation + renal denervation|Catheter ablation + renal denervation
62331347|NCT04182620|ACTIVE_COMPARATOR|Catheter ablation only|Catheter ablation
62331348|NCT03099369|EXPERIMENTAL|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.~* Week 1: walk at least 3,000 steps every day.~* Week 2: walk at least 3,500 steps every day.~* Week 3: walk at least 4,000 steps every day.~* Week 4: walk at least 4,500 steps every day.~* Weeks 5-12: walk at least 5,000 steps every day."
61936903|NCT03057509|EXPERIMENTAL|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.~* Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.~* Standard LAR Octreotide will be administered.~* Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.~* Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
61936904|NCT02770170|EXPERIMENTAL|BI 655064 dose 1|
62489171|NCT05327894|OTHER|Medium Risk (MR)|Subject is defined as MR if \> 6months of age at diagnosis, OR \< 6 months of age with White Blood cell Count (WBC) \< 300 at diagnosis and good prednisone response. Subject gets 1st cycle of blinatumomab. If MRD is \>0.01%, after 1st cycle of blinatumomab, subject will be allocated to HR treatment from that phase, and will be eligible for HSCT. If MRD is undetectable or \< 0.01% after the 1st cycle of blinatumomab (TP2) patient will be eligible for replacement of MARMA by 2nd cycle of blinatumomab after receipt of lymphoid style consolidation (Protocol IB) or of myeloid style consolidation (ADE/MAE).
62489172|NCT05327894|OTHER|High risk (HR)|"Subject is defined as HR if \< 6 months of age with WBC \> 300 at diagnosis OR poor prednisone response. Also MR patients with end of induction MRD ≥ 1%, or MRD \> 0.01% after the 1st cycle of blinatumomab, will be allocated to HR treatment. Subject gets 1 cycle of blinatumomab.~Thereafter patient is eligible for hematopoietic stem cell transplantation (HSCT) with or without experimental therapy in an investigational window."
62489173|NCT05544123||Cohort 1 HER2+ EBC|newly diagnosed or completed definitive breast surgery
62489174|NCT05544123||Cohort 2 HR+ HER2- EBC|newly diagnosed or completed definitive breast surgery
62489175|NCT05544123||Cohort 3 HER2+ ABC|De novo or relapsed from adjuvant therapy
61936905|NCT02770170|EXPERIMENTAL|BI 655064 dose 2|
61936906|NCT02770170|EXPERIMENTAL|BI 655064 dose 3|
61936907|NCT02770170|PLACEBO_COMPARATOR|Placebo|
61936908|NCT03036605|ACTIVE_COMPARATOR|Group Bupivacaine|4 ml %0.5 bupivacaine and 1 ml %0.9 NaCl infiltration into nasal packing to both sides
61936909|NCT03036605|ACTIVE_COMPARATOR|Group Bupivacaine+Dexamethasone|4 ml %0.5 bupivacaine and 4mg(1 ml) dexamethasone infiltration into nasal packing to both sides
61936910|NCT04896879||Patients|Patients with major LARS
61936911|NCT04896879||Informal caregivers|Informal caregivers of patients with major LARS
61936912|NCT04896879||Healthcare professionals|Healthcare professionals taking care for patients with LARS
61936913|NCT02883166|OTHER|group 1|1000mg abiraterone fasted followed by 500 mg with breakfast
61936914|NCT02883166|OTHER|group 2|500 mg abiraterone with breakfast followed by 1000mg fasted
62331349|NCT03099369|ACTIVE_COMPARATOR|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).~* Walk on a flat surface at a constant speed until there is mild to moderate pain~* Rest until the pain has completely ceased~* Resume walking at the same speed~* Increase the speed when you can walk 8 minutes without stopping for leg symptoms~* Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
62331350|NCT01213433|EXPERIMENTAL|Amodiaquine+Artesunate|
62331351|NCT04989192|OTHER|CT scanner 1|Patients will undergo imaging on scanner 1.
62331352|NCT04989192|OTHER|CT scanner 2|Patients will undergo imaging on scanner 2.
62489176|NCT05544123||Cohort 4 HR+ HER2- ABC|De novo or relapsed from adjuvant therapy
62489177|NCT05438433|SHAM_COMPARATOR|Group A|50 patients with isolated rheumatic mitral valve disease (group A)
62489178|NCT05438433|OTHER|Group B|50 patients with mitral disease and myocardial ischemia (group B)
62489179|NCT05064917||Children with suspected cow's milk allergy|
62489180|NCT06626854|EXPERIMENTAL|Treatment|Recipient of Hypersound Therapy
62489181|NCT04852133||Burn subjects|exposure to burn injury
62489182|NCT04852133||Non-burned control|no exposure to burn injury
62694315|NCT01926509|EXPERIMENTAL|MK-8892 Panel C|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), up to 8 mg (Days 22-28).
61936915|NCT05708586|ACTIVE_COMPARATOR|Control|Standard comfort given
61936916|NCT05708586|EXPERIMENTAL|Virtual Reality (VR)|
62694316|NCT01926509|PLACEBO_COMPARATOR|Placebo (Panels A and B)|Participants will be administered placebo to MK-8892 once daily for 28 days.
61936917|NCT00797602||Proton Radiation|
61936918|NCT05160090|ACTIVE_COMPARATOR|Test- BUPROPION HCl MR TABLETS 300mg|Single dose of Test- BUPROPION HCl MR TABLETS 300mg
61936919|NCT05160090|ACTIVE_COMPARATOR|Reference-Elontril 300 mg|Elontril 300 mg (Bupropion HCl MR tablets 300mg)
61936920|NCT05377203|EXPERIMENTAL|Group A|Quadruple combination of half doses therapy for 4 weeks→Wash out for 2 weeks →Dual combination of standard dose therapy for 4 weeks.
61936921|NCT05377203|EXPERIMENTAL|Group B|Dual combination of standard dose therapy for 4 weeks→Wash out for 2 weeks →Quadruple combination of half doses therapy for 4 weeks.
61936922|NCT00261300|EXPERIMENTAL|1|Pantoprazole 40 mg
61936923|NCT05588778|EXPERIMENTAL|BAILAMOS™ @home/en casa|The BAILAMOS™ @home/en casa dance program is provided twice weekly for 24 weeks. Each month a new dance style is introduced by a professional dance instructor.
61936924|NCT05588778|EXPERIMENTAL|¡En Forma y Fuerte! @home/en casa|¡En Forma y Fuerte! @home/en casa is an exercise and health education program designed to improve arthritis-related outcomes. The classes will meet two times per week for 90 min each for 12 weeks. Each class session consists of 60 min of exercise (flexibility, aerobics and strength training) and 30 minutes of health education using group problem solving based on SCT.
61936925|NCT01945359||Relapsing Remitting MS (RRMS)|
61936926|NCT05002283|EXPERIMENTAL|Study group|the patients undergo free gingival graft harvest from the palate using a patient specific guide
62489183|NCT04604262|EXPERIMENTAL|Treatment Group|Waterpik® in addition to the manual toothbrush
62489184|NCT04604262|NO_INTERVENTION|Control|Manual toothbrush
62489185|NCT02331108|ACTIVE_COMPARATOR|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
62489186|NCT02331108|ACTIVE_COMPARATOR|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
62489187|NCT02331108|ACTIVE_COMPARATOR|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
62489188|NCT02331108|ACTIVE_COMPARATOR|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
62489189|NCT02331108|ACTIVE_COMPARATOR|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age \>55.
62489190|NCT02331108|ACTIVE_COMPARATOR|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age \>55.
62489191|NCT03006757|EXPERIMENTAL|Column titanium dioxide|patient take titanium dioxide denture participants will receive titanium dioxide denture ( made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial.
62489192|NCT03006757|EXPERIMENTAL|column placebo|patient will take denture with conventional acrylic ( 20 minutes cure ) for 1 month in the initial phase
62694317|NCT06642116|EXPERIMENTAL|OCEAN|Application of OCEAN after nasal/sinus surgery
62331353|NCT04989192|OTHER|CT scanner 3|Patients will undergo imaging on scanner 3.
62331354|NCT00587821||1|The first 250 samples will be used as a training set and results of these breast biopsies (benign or malignant) will be used to determine the peptide profile characteristic of a diagnosis of breast cancer on biopsy.
62331355|NCT00587821||2|The predictive capacity of this profile will then be prospectively assessed using the next 250 samples, which will serve as a validation set. Subjects who are candidates for enrollment on cohort B of this study (metastatic disease)
62331356|NCT03218254|OTHER|Methylphenidate - Placebo|Methylphenidate before placebo
62331357|NCT03218254|OTHER|Placebo - Methylphenidate|Methylphenidate after placebo
62489193|NCT05422469|EXPERIMENTAL|Medtronic Percept RC neurostimulator|
62694318|NCT03868280|ACTIVE_COMPARATOR|Supine Positioning, Fracture Table|During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
62331358|NCT03269292||warm autoimmune hemolytic anemia|corticosteroid either oral form or intravenous followed by oral
62331359|NCT00851734|EXPERIMENTAL|LX214 0.02%|LX214 ophthalmic solution 0.02%
62331360|NCT00851734|EXPERIMENTAL|LX214 0.2%|
62489194|NCT02341690|ACTIVE_COMPARATOR|Control|Standard rehabilitation with exercise
62489195|NCT02341690|EXPERIMENTAL|Intervention (Interval Walking Training)|"Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into~1. a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.~2. a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.~3. After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).~IWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre."
62489196|NCT00301964|EXPERIMENTAL|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
62489197|NCT05336097|EXPERIMENTAL|Intervention group|"Participants will receive support from participation coaches trained in Pathways to Empowerment (PTE).~These participation coaches received a four-day training program with two weeks in between each training day, allowing them to immediately implement their acquired set of knowledge and skills. At the end of the training program, participation coaches had to successfully pass an end assignment to become PTE-certified.~In order to ensure the implementation of PTE, the training will be supplemented with a learning cycle. This cycle consists of two workshops on poverty and stress, and of on-the-job coaching. The coaching is tailored to the wishes and needs of the team."
62489198|NCT03210363|EXPERIMENTAL|Guiana population|"Human Biological samples from Guiana population :~Two serum tubes of blood will be collected"
62489199|NCT03801707|EXPERIMENTAL|Intervention group|kidney transplant recipients who receive kidney allograft from hepatitis C viremic donors followed by treatment with direct acting antiviral therapies.
62489200|NCT03968328||Observational (interview, survey)|Patients respond to a survey and participate in an interview with study staff about their fever and when they started feeling unwell.
62331361|NCT00851734|PLACEBO_COMPARATOR|placebo|placebo
62331362|NCT00813280||hyperglycemia|hospitalized patients with BG \>300 ml/dL
62489201|NCT04917991|EXPERIMENTAL|Extra Virgin Olive Oil Group|Subjects will consume 100 grams of Extra Virgin Olive Oil-enriched chocolate spread for 14 days.
62489202|NCT04917991|ACTIVE_COMPARATOR|Palm oil Group|Subjects will consume 100 grams of palm oil enriched chocolate spread for 14 days.
61936927|NCT04540575|ACTIVE_COMPARATOR|Mother Provides MOM|Receive Rush NICU standard of care lactation support
62331363|NCT02843334||Population of adult patients undergoing chronic renal dialysis|Population of adult patients undergoing chronic renal dialysis for end stage kidney disease in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard)
62489203|NCT02828631|ACTIVE_COMPARATOR|Macintosh laryngoscope|Nasotracheal intubation by Macintosh laryngoscope
62489204|NCT02828631|EXPERIMENTAL|McGrath videolaryngoscope|Nasotracheal intubation by McGrath videolaryngoscope
61936928|NCT04540575|EXPERIMENTAL|NICU Acquires MOM|Receive economic interventions in addition to Rush NICU standard of care lactation support
61936929|NCT01753102|EXPERIMENTAL|Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
61936930|NCT01753102|ACTIVE_COMPARATOR|Reference: Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
61936931|NCT01753102|PLACEBO_COMPARATOR|Placebo|Intravaginal self-administration of study medication once daily for 14 days.
62694319|NCT03868280|ACTIVE_COMPARATOR|Lateral Positioning, Free drape|During the lateral positioning phase, patients will be placed in lateral position after anaesthetic has been provided. A beanbag will be placed below the patient, and the patient will be safely turned to a lateral position. The beanbag will be inflated, the leg will be prepped, and a free drape will be applied. No traction will be used. Alternatively, some participating sites may use stulberg positioners rather than an inflatable beanbag, based on hospital preference. This positioning mirrors the positioning utilized for the direct lateral, posterior or posterolateral approach to a total hip arthroplasty or hemiarthroplasty
62694320|NCT01277185|ACTIVE_COMPARATOR|Low Calcium Diet (600-1200 mg/d)|
61936932|NCT02284360|EXPERIMENTAL|Group A: Low dose|"Each volunteer in group A will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 12.5\*10\^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
61936933|NCT02284360|EXPERIMENTAL|Group B: High dose|"Each volunteer in group B will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 25\*10\^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
61936934|NCT05770583|ACTIVE_COMPARATOR|Control group|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
62331364|NCT02238028|EXPERIMENTAL|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
62331365|NCT02238028|NO_INTERVENTION|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
62489205|NCT02828631|EXPERIMENTAL|Pentax videolaryngoscope|Nasotracheal intubation by Pentax videolaryngoscope
62489206|NCT03444883|ACTIVE_COMPARATOR|Treatment Group|10mg Ilaprazole x 2 tablets
62489207|NCT03444883|PLACEBO_COMPARATOR|Control Group|10mg placebo of Ilaprazole x 2 tablets
62489208|NCT03153605|EXPERIMENTAL|SATISI_7|
62489209|NCT03732144|EXPERIMENTAL|Connect Staff-based PA intervention|Sites receiving the Connect physical activity intervention will involve three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum.
62489210|NCT03732144|OTHER|Connect Health Curriculum Control|Sites receiving the general health curriculum control will also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff.
62489211|NCT05621252|EXPERIMENTAL|PLN-74809|160 mg PLN-74809
62694321|NCT01277185|ACTIVE_COMPARATOR|High Calcium Diet (1100-2300mg/d)|
62694322|NCT03708510|EXPERIMENTAL|Filtek Silorane-Er,Cr:YSGG Laser|
62694323|NCT03708510|EXPERIMENTAL|Filtek Silorane- Diamond Bur|
62694324|NCT03708510|EXPERIMENTAL|Kalore- Er,Cr:YSGG Laser|
61936935|NCT05770583|EXPERIMENTAL|ORi+SpO2 (oxygen saturation) group|"* FiO2 will be titrated by reducing 10% if Ori\>0.01 andSpO2 ≥ 98% until Ori is 0.00.~* FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98~* FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
61936936|NCT03898843|EXPERIMENTAL|Animal assisted therapy group|Patients included in this arm will have animal assisted therapy session in a specific room outside of the ICU. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires
61936937|NCT03898843|ACTIVE_COMPARATOR|Control Group|"Patients included in this arm will have a sham session : they will leave their hospital bedroom, to go in the AAT session room. There, no specific activity is planned. After 20 minutes, the patient will go back to his room. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires"
61936938|NCT01338571||Healthly children|Children will be given yogurt twice a day for four weeks. The dose for an adult is 8 ounces of yogurt twice a day. The dose will be scaled to the children based upon surface area dosing charts, but will not exceed a resistant starch load of 1 gram per year of age plus 10 grams10.
61936939|NCT00160173|EXPERIMENTAL|EstroGel® Gel 0.9 grams 0.03%|0.9 g of EstroGel® 0.03% applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.
62694325|NCT03708510|EXPERIMENTAL|Kalore- Diamond Bur|
62694326|NCT03872115|EXPERIMENTAL|Setting 1|PDVibe2 set to high frequency and low amplitude
62331366|NCT03764215|EXPERIMENTAL|Group 1|Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If Nilotinib 150 mg per mouth daily dose is tolerated by the 1st group of 10 participants for 3 months, another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
62489212|NCT05621252|PLACEBO_COMPARATOR|Placebo|Placebo
61936940|NCT00160173|EXPERIMENTAL|EstroGel® Gel 1.25 grams 0.03%|1.25 g of EstroGel® 0.03% applied to one arm and 0.9 g of placebo gel applied on the other arm once daily for 12 weeks.
62331367|NCT05651139|EXPERIMENTAL|Receiving vibration stimulation post-injection|Using a vibration device post-injection on the affected area.
62489213|NCT04966403|EXPERIMENTAL|standard physical therapy|Participants in the standard physical therapy received the standard physical therapy (sPT) program, which was conducted according to the needs of each participant and was generally concerned with building strength, enhancing developmental skills, boosting balance, coordination, and postural control, improving physical fitness, and minimizing the development of the compensatory movement patterns that children with DS are likely to develop.
62489214|NCT04966403|EXPERIMENTAL|trampoline-based stretch-shortening cycle exercises|In addition to the sPT, the SSC group received 15-minute SSC exercise sessions, twice weekly, with a total of 24 sessions over 12 successive weeks.
62489215|NCT00743535|EXPERIMENTAL|1|Transobturatory correction of anterior defect plus TOT
62489216|NCT00743535|ACTIVE_COMPARATOR|2|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
62489217|NCT05049239|EXPERIMENTAL|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.
62489218|NCT05049239|ACTIVE_COMPARATOR|Physical training combined with cognitive support|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.~The cognitive support consists of person centred individual occupational therapy."
62489219|NCT05049239|NO_INTERVENTION|Control group|The control group receive no intervention.
62489220|NCT05526313|EXPERIMENTAL|1.2mg/m2|
62331368|NCT05651139|NO_INTERVENTION|control group|No intervention will be conducted
62489221|NCT05526313|EXPERIMENTAL|2.4mg/m2|
62694327|NCT03872115|EXPERIMENTAL|Setting 2|PDVibe2 set to high frequency and medium amplitude
62489222|NCT05526313|EXPERIMENTAL|4.0mg/m2|
62489223|NCT05526313|EXPERIMENTAL|6.0mg/m2|
62489224|NCT05526313|EXPERIMENTAL|8.4mg/m2|
62489225|NCT05526313|EXPERIMENTAL|11.2mg/m2|
62489226|NCT05526313|EXPERIMENTAL|15mg/m2|
62489227|NCT01181284||Lisinopril|Participants will be randomized 2 to 1 to receive drug versus placebo.
62489228|NCT05431491|EXPERIMENTAL|Ultrafiltration cohort|These patients will be recruited into the study to assess the feasibility of slow continuous ultrafiltration through either a standard central venous catheter, or peripheral intravenous cannula.
62489229|NCT01375309|ACTIVE_COMPARATOR|Active|Bifidobacterium bifidum
62489230|NCT01375309|PLACEBO_COMPARATOR|Placebo|Dextrin without Bifidobacterium bifidum
62489231|NCT03582423|EXPERIMENTAL|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
62489232|NCT03582423|PLACEBO_COMPARATOR|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
62489233|NCT04724707||Myocarditis|Proven or suspected myocarditis
62694328|NCT03872115|EXPERIMENTAL|Setting 3|PDVibe2 set to high frequency and high amplitude
62694329|NCT03872115|EXPERIMENTAL|Setting 4|PDVibe2 set to medium frequency and low amplitude
61936941|NCT00160173|PLACEBO_COMPARATOR|Placebo Gel|0.9 g of placebo gel applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.
61936942|NCT05508997|EXPERIMENTAL|Positive End Expiatory Pressure + Reverse Trendelenburg Position|Group A received the procedures of the physiotherapy part by applying proper positioning for better oxygenation and ventilation (Reverse Trendelenburg Position), which is the patient laid supine with the head up 30 degrees higher than the feet \& received the recruitment maneuver (RM) by Positive End Expiratory Pressure (PEEP) titration
62331369|NCT04905381|ACTIVE_COMPARATOR|Usual care|Behavioral: This arm receives usual care (control group). This group will attend their usual Alief group sessions.
62331370|NCT04905381|EXPERIMENTAL|LENA Star program|Behavioral:LENA Star program. Participants who are selected via the lottery to participate in the LENA Star program will complete ten weekly, 1-hour sessions.
62331371|NCT05863494|EXPERIMENTAL|Treatment|For visits 1-5 (tDCS treatment visits), the investigators will start with 0.5mA ramping up to 0.75mA for 5 minutes. Followed by a brief (8 sec) EEG recording. Then, the investigators will apply .75mA to 1mA for 5 minutes. This will also be followed by 8 second EEG recording. The final application of current will be 1mA to 1.75mA for 10 minutes followed again by 8 second EEG recording.
62489234|NCT04724707||Heart failure|Heart failure (NYHA functional class II-IV) before or during hospitalization with COVID-19
62489235|NCT04724707||ACS|Combination of COVID-19 with ACS or development of ACS during hospitalization with COVID-19 or performed percutaneous coronary intervention
62489236|NCT04724707||Pulmonary embolism|Proven pulmonary embolism
62694330|NCT03872115|EXPERIMENTAL|Setting 5|PDVibe2 set to medium frequency and medium amplitude
62694331|NCT03872115|EXPERIMENTAL|Setting 6|PDVibe2 set to medium frequency and high amplitude
62694332|NCT03872115|EXPERIMENTAL|Setting 7|PDVibe2 set to low frequency and low amplitude
62694333|NCT03872115|EXPERIMENTAL|Setting 8|PDVibe2 set to low frequency and medium amplitude
62694334|NCT03872115|EXPERIMENTAL|Setting 9|PDVibe2 set to low frequency and high amplitude
62331372|NCT05863494|SHAM_COMPARATOR|Sham|"For visits 1-5 (tDCS treatment visits),The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. They will still proceed with the full 20 minutes as does the treatment group but no current will be further applied as indicated in the treatment group. They will still receive EEG readings at the indicated 8 seconds after current is applied but will not receive the current. This is to maintain a blind trial. 0.5mA is negligible current but mimics treatment with an initial small tingle."
62331373|NCT04331873|EXPERIMENTAL|Ultrasound|An ultrasound will be obtained to evaluate placement of the gastrostomy tube prior to obtaining the standard contrast injection
62135804|NCT02923206|EXPERIMENTAL|Phase B - preeclampsia patients|Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
62331374|NCT03994926|EXPERIMENTAL|Experimental|Directed smoking of about 3.6% THC cannabis cigarette
62331375|NCT00207103|EXPERIMENTAL|1|
62331376|NCT00207103|EXPERIMENTAL|2|
62331377|NCT00207103|EXPERIMENTAL|3|
62331378|NCT00207103|EXPERIMENTAL|4|
62331379|NCT00207103|EXPERIMENTAL|5|
62331380|NCT00207103|EXPERIMENTAL|6|
62331381|NCT02632708|EXPERIMENTAL|AG-120 with cytarabine and daunorubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in complete response (CR) or complete remission with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery \[CRp\]) may continue on maintenance therapy and receive daily treatment with AG-120.
62331382|NCT02632708|EXPERIMENTAL|AG-120 with cytarabine and idarubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
62331383|NCT02632708|EXPERIMENTAL|AG-221 with cytarabine and daunorubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
62331384|NCT02632708|EXPERIMENTAL|AG-221 with cytarabine and idarubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
62331385|NCT02632708|EXPERIMENTAL|AG-221 (starting on Day 8) with cytarabine and daunorubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
62489237|NCT04724707||Arrhythmias|Hemodynamically significant arrhythmias (atrial fibrillation, high-grade ventricular premature beats, paroxysmal ventricular arrhythmias), including those associated with the QT interval prolongation
62489238|NCT05348616||pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2013-2020 winter epidemic"
62489239|NCT05348616||Per-Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, 2023-2024 and 2024-2025 epidemics. The need for continuation of the study will be reassessed after each season."
62489240|NCT01740934|ACTIVE_COMPARATOR|Anatabloc Cream|Twice daily use of active facial cream
62135805|NCT03006367|EXPERIMENTAL|NFC-1 100 mg|Single Dose of NFC-1 100 mg
62135806|NCT03006367|EXPERIMENTAL|NFC-1 200 mg|Single Dose of NFC-1 200 mg
62135807|NCT03006367|EXPERIMENTAL|NFC-1 400 mg|Single Dose of NFC-1 400 mg
62135808|NCT03006367|EXPERIMENTAL|NFC-1 800 mg|Single Dose of NFC-1 800 mg
62135809|NCT01155206|EXPERIMENTAL|high glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a dose that has been shown to achieve high physiological plasma levels. The IV glucagon will be administered at a rate of 3ng/kg/min.
62489241|NCT01740934|PLACEBO_COMPARATOR|Placebo Cream|Twice daily use of placebo facial cream
62489242|NCT04677517|EXPERIMENTAL|Implanted patients|All the participants are patients with post-lingual deafness and fitted with cochlear implants
62489243|NCT01937182|ACTIVE_COMPARATOR|Selective Serotonin Reuptake Inhibitors|Intervention Drug: Citalopram
62489244|NCT01937182|PLACEBO_COMPARATOR|Placebo|Intervention Drug: Placebo
62489245|NCT02271035|ACTIVE_COMPARATOR|Deflux|In each patient, Deflux will be injected into one of the ureteral orifices using the the HIT technique.
62489246|NCT02271035|ACTIVE_COMPARATOR|Vantris|Vantris will be injected into the other ureteral orifice using the same technique and the same amount of implant.
62331386|NCT02632708|EXPERIMENTAL|AG-221 (starting on Day 8) with cytarabine and idarubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
61936943|NCT05508997|ACTIVE_COMPARATOR|Reverse Trendelenburg Position|"Group B received only the procedures of the physiotherapy part at the 3rd phase of operation by applying proper positioning for better oxygenation and ventilation (Reverse Trendelenburg Position), in which the patient laid supine with the head at 15-30 degrees higher than the feet to unload the weight of intra-abdominal contents from the diaphragm, this position:~1. Increase pulmonary compliance, functional residual capacity (FRC), and oxygenation.~2. Allows easier ventilation.~3. This position called safe apnea time allows time to secure the airway before desaturation for a 20-minute positioning time."
61936944|NCT03388515|EXPERIMENTAL|SSS11, 1.5mg|SSS11, 1.5mg, iv, single dose at Day 1;
61936945|NCT03388515|EXPERIMENTAL|SSS11, 3.0mg|SSS11, 3.0mg, iv, single dose at Day 1;
61936946|NCT03388515|EXPERIMENTAL|SSS11, 6.0mg|SSS11, 6.0mg, iv, single dose at Day 1;
62331387|NCT04387058|OTHER|patients with cirrhosis and and portal hypertension|All major patients under 70 years of age with cirrhosis and portal hypertension justifying a treatment with TIPS. These patients must be affiliated to a social security and able to sign a free, informed and written consent.
62489247|NCT02349672||Healthy Control|The healthy control group will have 500-800uL (less than 1 mL) of blood collected. This sample will be obtained at the same time that the neonate is already having a standard blood screenings drawn at 24 and 48 hours of life.
62489248|NCT02349672||Clinical Control|The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
62489249|NCT02570828|EXPERIMENTAL|Thermal imaging|All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone.
62489250|NCT00353457|EXPERIMENTAL|Arm 1|Capecitabine, Oxaliplatin and Cetuximab
62489251|NCT04724616|NO_INTERVENTION|Control Group|Participants received no specific educational program
62489252|NCT04724616|EXPERIMENTAL|Intervention Group|Participants received our educational program for five days, with one teaching session per day. Every teaching session will be conducted for 60 minutes in a group of up to 6 children by a trained member of our staff.
62694335|NCT02507934|EXPERIMENTAL|Lubricin|"Lubricin 150 μg/ml eye drops solution~Test investigational device was instilled b.i.d. (two times a day), one drop into each eye, from day 1 to day 7±1 and, then, from 2 to 6 times a day as needed (i.e. prn), one drop into each eye, from day 7±1 to day 14±1.~After the end of the treatment period, all the subjects used Vismed® 0.18% b.i.d. every 8±1 h, one drop into each eye, from day 14±1 to day 21±1.~Before the start of the treatment (from day -6/-4 to day -1), the subjects were allowed to use only Nebul®, NaCl 0.9% ocular solution q.i.d. every 4±1 h, one drop into each eye."
61936947|NCT03388515|EXPERIMENTAL|SSS11, 12.0mg|SSS11, 12.0mg, iv, single dose at Day 1;
61936948|NCT03388515|EXPERIMENTAL|SSS11, 24.0mg|SSS11, 24.0mg, iv, single dose at Day 1;
62135810|NCT01155206|EXPERIMENTAL|low glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a low rate that is designed to mimic basal plasma glucagon concentration. The IV glucagon will be administered at a rate of 0.65ng/kg/min.
62135811|NCT01532648|EXPERIMENTAL|Budesonide MMX|Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
62135812|NCT01532648|PLACEBO_COMPARATOR|Placebo|Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
62331388|NCT05549141|EXPERIMENTAL|Group A 1|Treadmill gait training using an electrical stimulator, as first intervention.
62331389|NCT05549141|ACTIVE_COMPARATOR|Group B1|Treadmill gait training without the use of an electrical stimulator, as second intervention.
62489253|NCT04741477|EXPERIMENTAL|Topical CBD Product with low level of THC|Participants will topically apply a high CBD-product that also contains low levels of THC.
62135813|NCT04699058||Health care workers|questionnaire and COVID antibody test
62489254|NCT04741477|PLACEBO_COMPARATOR|Placebo topical product|Participants will topically apply a placebo product that does not contain cannabinoids.
62489255|NCT04806763|EXPERIMENTAL|Menicon Z Night|The experimental group is allocated to wear Menicon Z Night orthokeratology contact lenses for two years
62489256|NCT04806763|ACTIVE_COMPARATOR|Glasses|The active comparator includes a group that was allocated to wear distance, single-vision glasses for two years
62135814|NCT04699058||Household members|questionnaire and COVID antibody test
62135815|NCT04439500|EXPERIMENTAL|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
62331390|NCT05549141|ACTIVE_COMPARATOR|Group A2|Treadmill gait training without the use of an electrical stimulator, as first intervention.
62331391|NCT05549141|EXPERIMENTAL|Group B2|Treadmill gait training using an electrical stimulator, as second intervention.
62489257|NCT03677960|EXPERIMENTAL|Dose 1 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
62489258|NCT03677960|EXPERIMENTAL|Dose 2 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
62489259|NCT03677960|EXPERIMENTAL|Dose 3 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
62489260|NCT01640743|EXPERIMENTAL|Evertwist 1|Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).
62135816|NCT04439500|ACTIVE_COMPARATOR|Psychosocial Education|Group sessions including education on brain health.
62135817|NCT04560946|EXPERIMENTAL|PACT|Personalized Augmented Cognitive Training (PACT)
62331392|NCT05996731|ACTIVE_COMPARATOR|Healthy subjects|Five healthy donors will be asked to participate in the study to set up the condition for isolation and culture of skin-derived fibroblasts and to establish the RNA-Seq conditions and profile.
62331393|NCT05996731|EXPERIMENTAL|Validation cohort|To develop a diagnostic pipeline for isolation and sequencing of mRNA from cultured skin fibroblasts, 10 adult patients with known genetic defects affecting RNA levels and/or splicing will be enrolled, as positive controls.
62331394|NCT05996731|EXPERIMENTAL|Discovery cohort|"The second group, the discovery cohort, will be composed of 30 undiagnosed symptomatic patients with clinical suspicion of a genetic disease (both children and adults with onset in infancy or early adulthood) referred to the Clinical Research Center for Rare Diseases Aldo e Cele Daccò, and for which WES analyses did not reveal any causative genetic alteration. To this end, the investigators plan to recruit around 60 patients, their available parents and/or their available informative relatives who will undergo WES, if not previously done. On the basis of literature and their experience, the investigators expect that WES will be resolutive in 40-50% of cases. Consequently, investigators hypothesize to identify 30 patients with a negative WES who will enter the discovery RNA-Seq cohort."
62331395|NCT01635751|EXPERIMENTAL|GLA5PR GLARS tablet 150mg(fasted)|
62331396|NCT01635751|EXPERIMENTAL|GLA5PR GLARS tablet 150mg(after high fat meal)|
62331397|NCT01635751|ACTIVE_COMPARATOR|Lyrica Capsule 75mg(fasted)|
62135818|NCT04560946|ACTIVE_COMPARATOR|ETAU|Enhanced Treatment As Usual (ETAU)
62135819|NCT05679479|EXPERIMENTAL|Meplzaumb|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
62331398|NCT06534424|EXPERIMENTAL|Arm I (enhanced risk assessment)|Patients undergo collection of blood or mouthwash samples. Patients undergo genotyping with enhanced risk assessment on study. 4 to 8 weeks later, patients receive a follow-up phone call for return of enhanced risk assessment results and tailored counseling.
62489261|NCT01640743|EXPERIMENTAL|Evertwist 2|Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).
62489262|NCT01826760||acute-on-chronic hepatitis B liver failure, training group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
62489263|NCT01826760||acute-on-chronic hepatitis B liver failure, testing group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
62489264|NCT00866580|EXPERIMENTAL|Group A|
62489265|NCT00866580|EXPERIMENTAL|Group B|
62331399|NCT06534424|ACTIVE_COMPARATOR|Arm II (standard)|Patients undergo collection of blood or mouthwash samples. 4-8 weeks later, patients receive a standard follow-up phone call.
62331400|NCT00901537|EXPERIMENTAL|Azacitidine and Cisplatin|Every 4 weeks, azacitidine is given daily as subcutaneous injection for 5 days from day 1 to day 5, and cisplatin is given as intravenous injection on day 8. The dose of azacitidine will be dose escalated among each group of 3-6 patients, and the dose of cisplatin is fixed.
62331401|NCT03657368|EXPERIMENTAL|Low tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 6 ml/ kg predicted body weight, and PEEP = 5 cm water (H2O).
62489266|NCT04121533|PLACEBO_COMPARATOR|Placebo|Matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
62489267|NCT04121533|EXPERIMENTAL|Vitamin D|Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
62489268|NCT04121533|EXPERIMENTAL|Vitamin D, glucosamine sulfate, and omega-3 fatty acids|Vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids). Supplements taken daily for 84 days (12 weeks).
62135820|NCT05679479|PLACEBO_COMPARATOR|Placebo|First dose: control - Day 1; second dose: control - Day 8
62135821|NCT03572803|ACTIVE_COMPARATOR|Group of Dry Needling|"They will receive a treatment of dry needling, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized using Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds"
62135822|NCT03572803|ACTIVE_COMPARATOR|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized simulating Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds and 3mA each one."
62135823|NCT03572803|SHAM_COMPARATOR|Control Group|They will receive a treatment of punction sham, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
62135824|NCT01733862||Group Japan|Children less than five years of age, hospitalized for RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE, between November 2007 and October 2016 (i.e., before and after the introduction of RV vaccination in Japan) in any of the selected hospitals.
62135825|NCT03574103|ACTIVE_COMPARATOR|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction as dietary weight loss strategy.
62694336|NCT02507934|ACTIVE_COMPARATOR|Sodium Hyaluronate|"Vismed®, 0.18% sodium hyaluronate eye drops~Comparator was instilled b.i.d. (two times a day), one drop into each eye, from day 1 to day 7±1 and, then, from 2 to 6 times a day as needed (i.e. prn), one drop into each eye, from day 7±1 to day 14±1.~After the end of the treatment period, all the subjects used Vismed® 0.18% b.i.d. every 8±1 h, one drop into each eye, from day 14±1 to day 21±1.~Before the start of the treatment (from day -6/-4 to day -1), the subjects were allowed to use only Nebul®, NaCl 0.9% ocular solution q.i.d. every 4±1 h, one drop into each eye."
62694337|NCT05998564||Patients aged 1 to 4 years of age|Patients will be connected to the NOL monitor and the SCA monitor during surgery with general anaesthesia.
62135826|NCT03574103|EXPERIMENTAL|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
62489269|NCT03883126|ACTIVE_COMPARATOR|Group A|Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
62694338|NCT05998564||Patients aged 5 to 12 years of age|Patients will be connected to the NOL monitor and the SCA monitor during surgery with general anaesthesia.
62489270|NCT03883126|ACTIVE_COMPARATOR|Group B|Group B will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention.For the remaining 9 weeks they will not be required to submit breathalyzer samples.
62489271|NCT03883126|SHAM_COMPARATOR|Group C|Group C will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting on time samples regardless of alcohol content.
62489272|NCT03883126|SHAM_COMPARATOR|Group D|Group D will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will not be required to submit breathalyzer samples.
62489273|NCT03883126|NO_INTERVENTION|Group E|Group E will have no intervention, they will only complete assessment sessions.
62489274|NCT03045198|EXPERIMENTAL|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
62489275|NCT00940433|ACTIVE_COMPARATOR|open properitoneal|patients undergoing open properitoneal hernia repair
62489276|NCT00940433|ACTIVE_COMPARATOR|Lechtenstien repair|Patients undergoing Lechtestien hernia repair
62694339|NCT04381806|EXPERIMENTAL|5-ALA|orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)
62694340|NCT06541119|EXPERIMENTAL|Selective peroneus longus strengthening exercise|Group A will receive a weight bearing peroneus longus exercise with conventional physical therapy Programme
62694341|NCT06541119|ACTIVE_COMPARATOR|Conventional physical therapy programme|Group B will receive a program consisting of 3 commonly used exercises in Hallux valgus
62694342|NCT05012124|EXPERIMENTAL|Arm I (t-CoCM)|Patients use the t-CoCM digital app platform and clinic care managers use the t-CoCM web-based registry platform to support delivery of collaborative care. Patient's complete surveys at baseline, 3, 6 and 9 months. Some patients also participate in an interview or focus group about their user experience with the t-CoCM digital platform. Care managers also participate in interviews regarding their experience with CoCM and the newly developed web-based platform.
62694343|NCT05012124|ACTIVE_COMPARATOR|Arm II (u-CoCM)|Patients receive usual care and clinic care managers deliver usual CoCM. Patients complete surveys at baseline, 3, 6 and 9 months.
62694344|NCT05157698|EXPERIMENTAL|BWL + NB medication|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
62135827|NCT03574103|EXPERIMENTAL|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
62135828|NCT02036112|EXPERIMENTAL|Individual ELAPE|Patients will receive Individual ELAPE technique
62135829|NCT02036112|EXPERIMENTAL|Conventional ELAPE|Patients with advanced lower rectal cancer will receive conventional EALPE technique
62694345|NCT05157698|EXPERIMENTAL|BWL + Placebo|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
62694346|NCT05157698|EXPERIMENTAL|NB medication|Participants randomly assigned to this arm will receive 6 months of NB medication taken daily in pill form.
62694347|NCT05157698|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to this arm will receive 6 months of placebo. Placebo will be inactive and taken daily in pill form.
62135830|NCT03177590|EXPERIMENTAL|Recordings of facial and vocal emotional|Recordings of facial and vocal emotional productions during Children are performing three tasks
62135831|NCT03002259|NO_INTERVENTION|Control|No placebo required
62135832|NCT03002259|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
62135833|NCT06135922|EXPERIMENTAL|Experimental: EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose
62135834|NCT01596972|EXPERIMENTAL|Serum quantitative urine pregnancy test|uterine evacuation follow-up consisting of an at-home, self-administered SQ-UPT and standardized pregnancy symptom questionnaire in 1 week
62331402|NCT03657368|EXPERIMENTAL|Low tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 6 ml/kg predicted body weight, and PEEP = 8 cm H2O.
62694348|NCT05453968|EXPERIMENTAL|Berotralstat|Berotralstat administered once daily in 4 dose cohorts determined by participant weight. Cohorts 1 and 2 will enroll in parallel. After 4 participants from Cohort 1 and 2, with ≥ 2 subjects from Cohort 2, have reached Week 2, Cohort 3 will open for enrollment. Cohort 4 will open for enrollment, after ≥ 4 subjects in Cohort 3 have reached Week 2. Prior to dosing Cohort 3 and 4, available PK and safety data will be reviewed to confirm it is safe to proceed and the appropriate weight bands for each. BioCryst will notify sites when Cohorts 3 and 4 are open for enrollment.
62694349|NCT06114472|ACTIVE_COMPARATOR|Group A aromatherapy|three drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
62694350|NCT06114472|NO_INTERVENTION|Group B Control|No intervention
62694351|NCT05190666|EXPERIMENTAL|PACE Weight Loss Program|Participants randomized to this arm will receive personalized diet, activity, and weight loss goals as well as tools to self-monitor behaviors and weight. To facilitate changes, participants will receive coaching calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
62135835|NCT01596972|NO_INTERVENTION|serum hCG|follow-up consisting of a 1 week return visit and serum hCG plus standardized pregnancy symptom questionnaire
62135836|NCT01331044|EXPERIMENTAL|RUTF|Ready to use Therapeutic Food (RUTF) Plumpy nut.
62135837|NCT01331044|ACTIVE_COMPARATOR|Khichuri - Halwa|Cereal Legume
62135838|NCT06110468|EXPERIMENTAL|Intervention, CoreDISTParticpation|"Week 1-2: a)Videos for PwMS and employers on MS, possible work adaptations, physical activity (PA) and function. b)A meeting between PwMS and a work-consultant (WC). They will decide if the PwMS should discuss the work situation with their employer or if the WC and/or other professionals are needed. c)A clinical assessment with a trained MS-OP-PT to explore possibilities for optimalisation of movement.~Week 3-8: a)A clinical assessment with the mPT building on previous assessment. Goal-setting for function and PA. b)CoreDIST-training in groups, 6 weeks, 1/week. indoors and 1/week outdoors. Independent training 1/week, CoreDISTvideos. c)A follow up meeting regarding work, evaluation of goals with mPT. New goal setting for week 10-15 Week 10-15, Self-administered, digitally supported home training: a)CoreDIST-videos 3x10 min/week b)Training of own choice including elements of high intensity and balance 2x30 minutes per week. c)Week 15: Evaluation of goals regarding work and PA"
62135839|NCT06110468|NO_INTERVENTION|Control, usual care|Usual care (control group): These participants will continue with their regular routines and will be encouraged to obtain the national and MS-specific recommendation of 150-300 minutes of moderate physical activity or 75 minutes of high intensity physical activity per week or a combination of these, stay employed, continue medical treatment and seek any health care required, including physiotherapy.
62135840|NCT00491894|OTHER|Patients with Chronic Drooling|Arm receiving study drug
62135841|NCT00724399||Observations|Women attending screening mammography and gynecology visit
62135842|NCT00724399||A|Women attending their annual screening mammography and gynecology clinic visits.
62135843|NCT06500559|EXPERIMENTAL|group I: PRP injection|Accelerated maxillary canine retraction will be done after PRP injection in one random side of the maxillary arch while the other side serve as control
62135844|NCT06500559|EXPERIMENTAL|group II: Combined decortication and PRP injection|Accelerated maxillary canine retraction will be done after combined decortication and PRP injection in one random side of the maxillary arch while the other side serve as control
62135845|NCT02770326|EXPERIMENTAL|Fecal Microbiota Transplantation (FMT)|Patients with recurrent or refractory CDI who meet study eligibility criteria, will consent to undergo either colonoscopy or upper endoscopy with infusion of stool admixture. Safety will be assessed by monitoring infections that occurred within 2 weeks of the FMT procedures. Additionally, 24-hours, 1 week, 2 weeks, 4 weeks, and 6 months post-FMT, a stool sample will be collected. The time window for each time point listed is +/- 48 hours, with the exception of the first, 24 hour, time point. The time window for the 24 hour time point is +48 hours post FMT.
62135846|NCT03851367|EXPERIMENTAL|Sling suspension therapy|3-week duration of exercises using red cord and consisting of 15 sessions for 30 minutes each.
62331403|NCT03657368|EXPERIMENTAL|High tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 5cm H2O.
62331404|NCT03657368|EXPERIMENTAL|High tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 8cm H2O.
62331405|NCT04815590||Sublocade|The only group consists of participants with moderate to severe OUD who will be starting treatment with extended-release injectable buprenorphine as part of standard of care. While individual treatment regimens may vary, these will often consist of 2 once-monthly 300 mg subcutaneous injections followed by 4 once-monthly 100 mg subcutaneous injections. However, participants may receive once-monthly 300 mg subcutaneous injections in place of 100 mg subcutaneous injections for as many months as is deemed necessary by their prescribing physician.
62135847|NCT03851367|ACTIVE_COMPARATOR|Swiss ball therapy|3-week duration exercise for trunk muscles strengthening and posture improvement consisting of 15 sessions for 30 minutes each.
62135848|NCT03513692|ACTIVE_COMPARATOR|Fill-Up composite resin|"In this arm of the study, participants will have the dental restoration completed with FillUp from Coltene, a composite resin a CE marked and licensed restorative material."
62135849|NCT03513692|ACTIVE_COMPARATOR|Conventional; composite|In this arm of the study, participants will have the dental restoration completed with a conventional composite resin using a CE marked and licensed restorative material.
62135850|NCT06699446|NO_INTERVENTION|"Standard of care"|Previous postal call-in without additional communication or special follow-up
62135851|NCT06699446|OTHER|Intensified patient education|via classical communication channels as well as provision of information material for outpatient, preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and telephone postoperative communication (postoperative for Patient-Reported Experience Measures (PREMs) and Patient-Reported Outcome Measures (PROM) analysis) with the surgical center
62135852|NCT06699446|OTHER|Intensified education on new media (mobile app)|with outpatient preoperative rehabilitation (respiratory training, exercise therapy). Creation of an individualized rehabilitation plan and postoperative, two-way communication via mobileapp.
62135853|NCT01048476|ACTIVE_COMPARATOR|Group L20|Dietary Supplement: 20mg Lutein; daily supplementation one year
61936949|NCT06529965|EXPERIMENTAL|Intervention/Treatment|"Experimental: covivio + TAU~Participants allocated to the intervention group will receive access to covivio in addition to treatment as usual (TAU).~covivio is a digital health application designed for individuals with type 2 diabetes mellitus who suffer from elevated levels of diabetes-specific emotional distress, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by covivio are disease literacy, physical activity and exercise, nutrition, stress management, sleep management, mood problems, and social resources.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
62489277|NCT00940433|ACTIVE_COMPARATOR|Laparoscopic transperitoneal repair|Patients undergoing TAPP repair
62489278|NCT00940433|ACTIVE_COMPARATOR|Lap totally extraperitoneal approach|Patients undergoing TEP approach
62489279|NCT05954663||Patients who underwent venous recanalization by angioplasty-stenting|Patients who underwent venous recanalization by angioplasty-stenting for post-thrombotic iliofemoral syndromes from June 2014 to June 2021.
62489280|NCT00935805||Treatment|124 patients attending the primary care unit included after formal consent.
62489281|NCT03431493|EXPERIMENTAL|Behavioral Activation - Rehabilitation|Behavioral Activation - Rehabilitation
62489282|NCT03431493|NO_INTERVENTION|Usual Care Control|Usual Care Control
62135854|NCT01048476|ACTIVE_COMPARATOR|Group L10|Dietary Supplement: 10mg Lutein; daily supplementation one year
62135855|NCT01048476|PLACEBO_COMPARATOR|Group Placebo|Dietary Supplement: Placebo, 0 mg Lutein
62135856|NCT01048476|ACTIVE_COMPARATOR|Active Comparator: Group LZ|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
62135857|NCT06698471|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual from Health System in Senegal
62135858|NCT06698471|EXPERIMENTAL|Relief from Stress via Social Protection in Senegal|Training community workers in Self Help Plus intervention
62489283|NCT00858780|ACTIVE_COMPARATOR|1|50mg once weekly + methotrexate
62489284|NCT00858780|ACTIVE_COMPARATOR|2|25mg once weekly + methotrexate
62135859|NCT05949567|EXPERIMENTAL|Lying position first - then sitting position|
62135860|NCT05949567|EXPERIMENTAL|Sitting position first - then lying position|
62331406|NCT04749979|ACTIVE_COMPARATOR|giving agonist ( eg. decapeptyl )|Giving women agonist
62489285|NCT00858780|PLACEBO_COMPARATOR|3|once weekly + methotrexate
62489286|NCT05210647||conventional laparoscopy surgery|Conventional laparoscopy surgery for colon and rectal disease.
62489287|NCT05210647||robot assisted surgery|robotic assisted surgery for colon and rectal disease.
62489288|NCT04388787|EXPERIMENTAL|stochastic resonance (SR) vibration|SR applied sub threshold at 90% of participant's detection threshold
62489289|NCT04388787|SHAM_COMPARATOR|Sham treatment|SR devices worn but not turned on (0% of participant's detection threshold).
62694352|NCT05190666|SHAM_COMPARATOR|Chronic Disease Self-Management Program|Participants randomized to this arm will receive a chronic disease self-management program including a self-management book. Participants will receive regular calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
61936950|NCT06529965|NO_INTERVENTION|Control|"No Intervention: TAU~Participants allocated to the control group will receive access to treatment as usual (TAU)."
61936951|NCT05839483|EXPERIMENTAL|CXCR4|scanned by 68Ga-PentixaFor PET imaging
62135861|NCT01268436||Injectable pain medication|Patients who receive an injectable form of pain medication.
62489290|NCT04388787|EXPERIMENTAL|Unblinded treatment|SR is applied above participant's detection threshold at a participant selected intensity.
62489291|NCT04750239|EXPERIMENTAL|Nivatrotamab|Subcutaneous administration of nivatrotamab up to 13 cycles
62489292|NCT04002648||MT-Right|
62135862|NCT01268436||Oral pain medication|Patients who receive oral pain medication only
62135863|NCT00826995|EXPERIMENTAL|Video-based education arm:|Subjects receiving the video-based educational material
62135864|NCT00826995|ACTIVE_COMPARATOR|Written education arm:|Subjects receiving the written educational material
62135865|NCT06192433|EXPERIMENTAL|High-frequency repetitive transcranial magnetic stimulation group (40Hz)|High-Frequency Group (40Hz): Participants in this arm receive high-frequency transcranial magnetic stimulation (rTMS) at 40Hz for a specified duration and intensity on the bilateral dorsolateral prefrontal cortex (DLPFC). The stimulation parameters and rest periods are outlined in the study description.
62135866|NCT06192433|ACTIVE_COMPARATOR|Moderately high-frequency repetitive transcranial magnetic stimulation group (10Hz)|Moderately High-Frequency Group (10Hz): Participants in this arm receive moderately high-frequency transcranial magnetic stimulation (TMS) at 10Hz for a specified duration and intensity on the bilateral dorsolateral prefrontal cortex (DLPFC). The stimulation parameters and rest periods are outlined in the study description.
62135867|NCT04243941|EXPERIMENTAL|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
62331407|NCT04749979|ACTIVE_COMPARATOR|Giving HCG (eg. choriomon )|Giving women HCG
62489293|NCT04002648||Sternotomy|
62489294|NCT00595153|ACTIVE_COMPARATOR|B|Asthmatics not on inhaled corticosteroids who will be put on an inhaled steroid during the study
62489295|NCT00595153|NO_INTERVENTION|A|Healthy, non-asthmatics who will not be put on any intervention
62489296|NCT00595153|ACTIVE_COMPARATOR|C|Asthmatics, who are already on inhaled corticosteroids who will be put on standardized dose of inhaled corticosteroids
62489297|NCT05276986|EXPERIMENTAL|DOMS protocol group|DOMS was induced for the trunk muscles with a load equals to 80% of the maximum repetitive voluntary contraction. Pulmonary function parameters, respiratory muscle strength and endurance, exercise capacity, pain, fatigue, and dyspnea perception severity were recorded before DOMS and at the 24th and 48th hours after DOMS.
62489298|NCT00924638|ACTIVE_COMPARATOR|Continuous Monitoring|Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
62489299|NCT00924638|NO_INTERVENTION|Control Arm|Follow-up at the same frequency, but with no Insertable Cardiac Monitor
62489300|NCT02011945|EXPERIMENTAL|dasatinib Only|dasatinib 100 mg QD(CP) or 140 mg QD (AP)
62489301|NCT02011945|EXPERIMENTAL|Dose Level 1|Nivolumab 1 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
62489302|NCT02011945|EXPERIMENTAL|Dose Level 2|Nivolumab 3 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
62489303|NCT01827696|EXPERIMENTAL|Treatment|American Ginseng ingestion
61936952|NCT02863757||CHB Group|Patients with chronic hepatitis B
61936953|NCT02863757||CHB/NAFLD Group|Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease
62135868|NCT06444984|EXPERIMENTAL|Fasting Meal Trial|During the fasting meal trial, participants will report fasted and consume a movie theater style meal.
62331408|NCT03248622||Anti-HBc positive|Anti-HBc positive
62331409|NCT03248622||HCV positive Cohort|HCV positive Cohort
62331410|NCT02435277|EXPERIMENTAL|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
62331411|NCT02435277|EXPERIMENTAL|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
62331412|NCT02435277|EXPERIMENTAL|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
62331413|NCT02435277|ACTIVE_COMPARATOR|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
62331414|NCT02560688|EXPERIMENTAL|Period 1 - DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
62331415|NCT02560688|OTHER|Period 2 - Clopidogrel|Clopidogrel (Plavix) administered orally over 5 days (300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5)
62331416|NCT02560688|EXPERIMENTAL|Period 2 - DS-1040b and Clopidogrel|Concomitant administration of DS-1040b (20 mg single 12-hour intravenous infusion) and clopidogrel (single 75 mg oral dose)
62331417|NCT06144528||Children with autism spectrum condition|Thirty Autism Spectrum Disorder (ASD) children with medium-high functioning, aged 4 to 13 years, IQ \> 75, in the absence of motor deficits due to another clinical condition.
62331418|NCT03487380|EXPERIMENTAL|Alzheimer with rapid DCR|
62331419|NCT03487380|EXPERIMENTAL|Alzheimer without rapid DCR|
62331420|NCT03487380|SHAM_COMPARATOR|Control|
62331421|NCT04603196||Patients with Multiple Sclerosis with obstructive sleep apnea|Patients with Multiple Sclerosis with obstructive sleep apnea
62331422|NCT04603196||Patients with MS without obstructive sleep apnea|Patients with MS without obstructive sleep apnea
62331423|NCT00654511|ACTIVE_COMPARATOR|Fentanyl 1|Fentanyl 1 micrograms (mcg)/kilogram (kg)
62331424|NCT00654511|ACTIVE_COMPARATOR|Fentanyl 2|Fentanyl 2 micrograms (mcg)/kilogram (kg)
62331425|NCT00654511|EXPERIMENTAL|Dex 3|Dexmedetomidine 2 micrograms (mcg)/kilogram (kg)
62331426|NCT00654511|EXPERIMENTAL|Dex 4|Dexmedetomidine 4 micrograms (mcg)/kilogram (kg)
62331427|NCT01815892|ACTIVE_COMPARATOR|Withdrawal of Furosemide|The patient's Furosemide will be withdrawn
62331428|NCT01815892|EXPERIMENTAL|Administration of furosemide|The patient will receive furosemide 120 mgms daily
62331429|NCT05185752|ACTIVE_COMPARATOR|Erector Spinae Plane Block (ESP block)|"The patient is positioned in the prone position, the probe is used to locate in cross-section the T4 spinous process. Next, using a lateral scan, approximately 3 cm away, the costotransverse joint is located, and then change to sagittal ultrasound vision. By locating the intertransverse line with the probe, the following anatomical structures can be identified: three longitudinal muscles (trapezius, rhomboid, erector spinae).~The needle enters in a single punction at an angle of 45º, in the cranio-caudal direction, until it touches the apex of the costotransverse image. Subsequently, 30 cc of 0.25% bupivacaine are administered in the depth of the erector spinae, which will remain elevated."
62331430|NCT05185752|ACTIVE_COMPARATOR|Pectoral Nerve type II Block (PECS II block)|"The patient is positioned supine, with the ipsilateral upper limb extended. The clavicular external third line is drawn. In parallel, the lower costal line and the infraclavicular space are highlighted. The probe obtains an image that allows the identification of the pectoralis major and pectoralis minor.~If colour Doppler is added, the acromiothoracic artery is identified and must be avoided.~The needle enters at an angle of 45º from medial to lateral, and 20 cc of 0.25% bupivacaine are administered. Next, needle advances in the interfascial space between the pectoral minor and serratus anterior and 10 cc of 0.25% bupivacaine are administered."
62331431|NCT05185752|ACTIVE_COMPARATOR|Serratus-Intercostal Fascial Plane Block (SIFP block)|"The patient is positioned supine, with the ipsilateral upper extremity at a 90º angle. The fourth, fifth, and sixth intercostal spaces are identified in the mid-axillary line. In coronal section, it is possible to appreciate the subcutaneous cellular tissue, the serratus anterior, and the intercostal muscles.~The needle is introduced at an angle of 30º. From caudal to cranial and resting the needle on the fourth rib, 30 cc of 0.25% bupivacaine are administered between the serratus anterior and lateral intercostal muscles."
62331432|NCT04762108||Sjögren's syndrome|Sjögren's syndrome with childhood-onset
61936954|NCT02863757||NAFLD Group|Patients with nonalcoholic fatty liver disease
61936955|NCT01223638||Congenital hypothyroidism|Patient which were diagnosed with congenital hypothyroidism
61936956|NCT01223638||Controls|Patients without any endocrine or hearing problems
62135869|NCT06444984|EXPERIMENTAL|Fed Meal Trial|During the fed meal trial, participants will report fasted and first consume a high-fat breakfast. Participants will then be asked to consume a movie theater style meal three hours later.
62331433|NCT04762108||Healthy control|Age matched healthy control
62489304|NCT01827696|PLACEBO_COMPARATOR|Placeobo|non-active ingredient
62489305|NCT02667769|OTHER|Fasting day without any food|Complete fasting: On a fast day under this Protocol no solid food may be eaten unless it is solid, medically prescribed part of a bedtime snack just before falling asleep (which must sometimes be to prevent nocturnal hypoglycaemia with injection of basal insulin before going to sleep) , Otherwise, the patient have ad libitum access to mineral water and unsweetened tea (possibly a fluid intake restriction should be considered for other diseases).
61936957|NCT04931212|EXPERIMENTAL|Intervention|
61936958|NCT03297814|ACTIVE_COMPARATOR|Platelet lysate|A total of 5 ml platelet lysate will be intramuscularly injected in 4 doses with 2 week interval
61936959|NCT03297814|PLACEBO_COMPARATOR|placebo|A total of 5 ml of Normal Saline will be intramuscularly injected in 4 doses with 2 week interval
62135870|NCT02379260|OTHER|Interview|Patients and urologists will be interview by a sociologist.
62135871|NCT02379260|OTHER|Focus Groups|Focus groups contain 5-7 patients. Groups will be stratified according to socio-economic levels and according to treatment (radical prostatectomy with conservation or without preservation of the neuro vascular strips).
62489306|NCT02667769|OTHER|Fasting day with calorie- & carbohydrate-free food|During a fasting day for this protocol, patients may calories in unlimited quantity and (with calorie-free dressing) Take carb food like tomatoes, cucumbers, lettuce to be, both during meal periods and in between, if desired.
62489307|NCT03774329|EXPERIMENTAL|physical activity program|Child with an adapted physical activity program
62694353|NCT05497687|EXPERIMENTAL|12-week strength-building intervention|Participants in the intervention group will participate in a 12-week strength-building intervention comprising of face-to-face/remote sessions with telephone follow-ups.
62694354|NCT05497687|NO_INTERVENTION|Routine care that they currently receiving provided by their primary healthcare providers|The control group will receive routine care that they currently receiving provided by their primary healthcare providers, which include unstructured patient education on lifestyle modification. The usual care does not include structured exercise training.
62694355|NCT01356940|ACTIVE_COMPARATOR|dalfampridine ER 10mg bid-placebo|4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control
62694356|NCT01356940|PLACEBO_COMPARATOR|placebo-dalfampridine ER 10mg bid|placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid
62694357|NCT06640179|ACTIVE_COMPARATOR|Standard Medical Care|Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive brief conducts (\<10 minutes) from the research staff at weeks 6, 12, and 18.
62135872|NCT06492135|EXPERIMENTAL|Arm 1: Participants with a body mass index (BMI) ranging from ≥27.0 kg/m² to ≤40.0 kg/m²|
62331434|NCT06417931|NO_INTERVENTION|Control|
62331435|NCT06417931|EXPERIMENTAL|Intervention|Patients in the intervention group received education and counselling tips about their disease condition and medications
62331436|NCT06536153|EXPERIMENTAL|Amaranth arm|"The pregnant women in the experimental group will be referred as the amaranth arm. Pregnant women in the intervention arm (N = 153) will receive 200 g of flat-bread on a daily basis, comprising 30% chickpea and 70% amaranth grain in mass, for six months."
62331437|NCT06536153|ACTIVE_COMPARATOR|Maize arm|"The pregnant women in the control group will be referred as the maize arm. Pregnant women in the control arm (N = 153) will receive 200 g of bread on a daily basis, comprising 100% maize, for six months."
62331438|NCT05304871|PLACEBO_COMPARATOR|placebo|patients receive saline infusion prior to port placement
62331439|NCT05304871|EXPERIMENTAL|antibiotic|patients receive antibiotic (Cefazolin 2 g) infusion prior to port placement
62331440|NCT03869957|EXPERIMENTAL|Intervention group|We will use \~0.8-0.9 g/kg/day of Clinoleic® (80% olive oil/20 soybean oil) + 0.2-0.1 g/kg/day \[Omegaven® \](100% fish oil), to cover the proposed amount of n-3 PUFAs for 7 days. The infusion rate should not exceed 0.5 ml Omegaven® / kg body weight / hour = 0.05 g fish oil / kg body weight / hour. The intervention group will return to PN without n-3 PUFA after 7 days.
62331441|NCT03869957|NO_INTERVENTION|Control group|Will be administering \~1.0 g/kg/d the lipid emulsion Clinoleic® (80% olive oil/20 soybean oil) without n-3 PUFAs.
62331442|NCT02491437|EXPERIMENTAL|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
62331443|NCT02491437|EXPERIMENTAL|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
62694358|NCT06640179|EXPERIMENTAL|Standard Medical Care plus Lifestyle Intervention|Standard Medical Care plus Lifestyle Intervention will continue to receive their regular standard clinical care and a behavioral intervention focused on dietary modification and physical activity for body weight regulation.
62694359|NCT06650566|EXPERIMENTAL|LM-299 Dose Escalation at different dose levels|Drug:LM-299 LM-299 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
62135873|NCT06492135|EXPERIMENTAL|Arm 2: Participants with a body mass index (BMI) ranging from ≥24.0 kg/m² to <27.0 kg/m²|
62135874|NCT02251652|ACTIVE_COMPARATOR|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
62135875|NCT02251652|ACTIVE_COMPARATOR|Cryotherapy Alone|Cryotherapy only
62331444|NCT01729013||subjects previously given placebo|
62331445|NCT01729013||subjects previously given vitamin D|
62331446|NCT03278080|OTHER|driving test|
62331447|NCT01433627|EXPERIMENTAL|trans-radial and short-term Bivalirudin|Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
62331448|NCT01433627|EXPERIMENTAL|trans-radial and long-term bivalirudin|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
62331449|NCT01433627|EXPERIMENTAL|trans-radial and standard of care pharmacology|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor"
62694360|NCT06650566|EXPERIMENTAL|LM-299 Dose Expansion LM-299 Dose Expansion|Drug:LM-299 LM-299 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
62694361|NCT06650566|EXPERIMENTAL|LM-299 (RP2D) Dose Expansion|Drug: LM-299 LM-299 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
62694362|NCT06650566|EXPERIMENTAL|LM299 (RP2D) combination expansion|Drug: LM299 Administered intravenously Drug: Paclitaxel Administered intravenously Drug: Carboplatin Administered intravenously
62694363|NCT06397040|EXPERIMENTAL|remote monitoring without provider feedback|remote monitoring with FitBit device and daily patient-reported outcome assessment, without real-time provider feedback
62489308|NCT03774329|OTHER|Usual care|
61936960|NCT04542304|ACTIVE_COMPARATOR|Metolazone then placebo|Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.
61936961|NCT04542304|PLACEBO_COMPARATOR|Placebo then Metolazone|Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.
62135876|NCT00732966|EXPERIMENTAL|1|Hypertensive patients will be treated with losartan for one months
62331450|NCT01433627|EXPERIMENTAL|trans-femoral and short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
62489309|NCT02704091|ACTIVE_COMPARATOR|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
62489310|NCT02704091|PLACEBO_COMPARATOR|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
62489311|NCT02578277|EXPERIMENTAL|Single sequence, 3-period DDI (drug-drug interaction)|Single sequence
62489312|NCT03531827|EXPERIMENTAL|1/Lead-In Safety: CRLX101 with Enzalutamide|Combination treatment of increasing dose of CRLX101 (formerly IT-101) with enzalutamide
62489313|NCT03531827|EXPERIMENTAL|2/Efficacy: CRLX101 with Enzalutamide|Tolerable dose of CRLX101 (formerly IT-101) in combination with enzalutamide (8 participants, expandable to 21 total participants)
62489314|NCT05039541|EXPERIMENTAL|ESRD Patients|ESDR Patients will wear the Alio Device over their vascular access for either I) the duration of their dialysis session in clinic or II) for a 90 day period.
62694364|NCT06397040|EXPERIMENTAL|remote monitoring with provider feedback|remote monitoring with FitBit device and daily patient-reported outcome assessment, as well as real-time provider feedback in response to remote data
61936962|NCT05885542|EXPERIMENTAL|cannabidiol 800 mg|Cannabidiol 800 mg will be administered orally once in the laboratory prior to a stress induction paradigm.
61936963|NCT05885542|PLACEBO_COMPARATOR|placebo|Placebo (formulated to appear identical to active condition) administered orally once in the laboratory prior to a stress induction paradigm.
61936964|NCT05577403|EXPERIMENTAL|Experimental Group|Mulligan's mobilization with movement added isometric strength training will be given 3 days a week for six weeks.
62135877|NCT00732966|EXPERIMENTAL|2|Hypertensive patients will be treated with valsartan
61936965|NCT05577403|ACTIVE_COMPARATOR|Control Group|Mobilization-added isometric strength training will be given 3 days a week for six weeks.
62135878|NCT05861570|EXPERIMENTAL|hydrodilatation with steroid|patient received ultrasound-guided 3cc NS + 40mg triamcinolone + 4cc xylocaine
62135879|NCT05861570|ACTIVE_COMPARATOR|hydrodilatation with hyaluronic acid and steroid|patient received ultrasound-guided 3cc hyaluronic acid + 40mg triamcinolone + 4cc xylocaine
62135880|NCT00913289|OTHER|adipose tissue derived stromal cells|
62135881|NCT01637402|EXPERIMENTAL|Standard Dose|1000 milligrams (mg) abiraterone acetate in combination with prednisone taken once a day until progression defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
62135882|NCT01637402|EXPERIMENTAL|Escalated Dose|Participants who progressed on the standard dose will be assigned 1000 milligrams (mg) abiraterone acetate in combination with prednisone taken twice a day for at least 12 weeks until progression as defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
62135883|NCT03203525|EXPERIMENTAL|Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])|Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62135884|NCT03203525|EXPERIMENTAL|Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])|Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62135885|NCT06497010|EXPERIMENTAL|Dose Escalation|"Part A (PD-1 Run-in):~Participants will receive PD-1 via IV infusion on Day 1 of each 21-day cycle for up to 2 cycles.~Part B( InnoPCV in Combination with PD-1)：~Participants will receive InnoPCV via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and PD-1 via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 34 cycles (approximately 2 years of treatment), whichever is sooner."
62135886|NCT06299670|EXPERIMENTAL|Thalidomide|Patient getting Thalidomide
62135887|NCT06299670|EXPERIMENTAL|Hydroxyurea|Hydroxyurea
62135888|NCT06299670|EXPERIMENTAL|Combination|combination of Thalidomide \& Hydroxyurea
62135889|NCT03624335|EXPERIMENTAL|Group 1: ECC|"In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.~Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping"
62135890|NCT03624335|EXPERIMENTAL|Group 2: DCC|In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping
62135891|NCT06698822|EXPERIMENTAL|Tofacitinib 2%|Participants will apply a thin layer of tofacitinib 2% cream 2 times a day on up to 5 treatment-eligible skin lesions.
62135892|NCT01553942|EXPERIMENTAL|Afatinib|Afatinib
62135893|NCT04090151||Austrian HIV Cohort Study (AHIVCOS)|
62135894|NCT04090151||The Australian HIV Observational Database (AHOD)|
62135895|NCT04090151||CHU Saint-Pierre|
62135896|NCT04090151||University Hospital Cologne|
62135897|NCT04090151||The EuroSIDA cohort|
62135898|NCT04090151||Frankfurt HIV Cohort Study|
62135899|NCT04090151||Georgian National AIDS Health Information System (AIDS HIS)|
62135900|NCT04090151||Modena HIV Cohort|
62135901|NCT04090151||San Raffaele Scientific Institute|
62135902|NCT04090151||Swiss HIV Cohort Study (SHCS)|
62135903|NCT04090151||Royal Free HIV Cohort Study|
62331451|NCT01433627|EXPERIMENTAL|Trans-femoral and long-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
61936966|NCT04539873|ACTIVE_COMPARATOR|COLHICINE PLUS STANDARD TREATMENT|Patients treated in the exposed group will consist of a decreasing dose of colchicine: a dose of 1.5 mg orally on the first day (initial 1 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
61936967|NCT04539873|PLACEBO_COMPARATOR|STANDARD TREATMENT|In this case, the centers where the patients will be included adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases), and to standard treatment
61936968|NCT03111966||Spanish cohort with HCV treated with DAA|
62331452|NCT01433627|ACTIVE_COMPARATOR|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
62331453|NCT05078333|NO_INTERVENTION|exercise|All patients in all three groups will perform 15 sessions (for 3 weeks, weekdays), cervical area isometric strengthening exercises, active ROM exercises and stretching exercises for 15 minutes a day with the same physiotherapist.
62331454|NCT05078333|ACTIVE_COMPARATOR|exercise+HILT|In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
62331455|NCT05078333|ACTIVE_COMPARATOR|exercise+dry needling|In addition to the exercise program, dry needling (on 3 trigger points on the bilateral trapezius muscle) will be applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
62331456|NCT04358094|EXPERIMENTAL|Conversational hypnosis script|Patient who received conversational hypnosis script during peripherical veinous access set up
62331457|NCT04358094|OTHER|Standard script|Patient who received standard script during peripherical veinous access set up
62331458|NCT01477190|EXPERIMENTAL|Spinal group|Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
62489315|NCT00042835|EXPERIMENTAL|Group I (cisplatin, etoposide, erlotinib, and docetaxel)|Patients receive cisplatin IV over 2 hours on days 1, 8, 29, and 36; etoposide IV over 1 hour on days 1-5 and 29-33; and oral erlotinib once daily on days 1-49. Patients undergo concurrent radiotherapy 5 days a week for 7 weeks beginning on day 1. Patients receive consolidation therapy comprising docetaxel IV over 1 hour on days 50, 71, and 92. Some patients may also receive oral erlotinib once daily on days 50-112.
62694365|NCT03858244||IS with SDB|Idiopathic scoliosis with untreated and treated sleep-disordered breathing
61936969|NCT05741658|OTHER|Dapagliflozin|4-week, Daily Oral Use of Dapagliflozin 10mg Tablet in Adults with Fontan Circulation
61936970|NCT02395783|ACTIVE_COMPARATOR|Melatonin dose1|Melatonin 10 µg
61936971|NCT02395783|ACTIVE_COMPARATOR|Melatonin dose2|Melatonin 20 µg
62135904|NCT04090151||The ATHENA national observational HIV cohort|ATHENA: AIDS Therapy Evaluation in the Netherlands
62135905|NCT04090151||Nice HIV Cohort|
62135906|NCT04090151||Italian Cohort Naive Antiretrovirals (ICONA)|
62135907|NCT04090151||PISCIS Cohort Study|
62135908|NCT04090151||Swedish InfCare HIV Cohort|
62135909|NCT04090151||Bonn University Hospital|
62135910|NCT05514275|EXPERIMENTAL|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin and Capecitabine
62135911|NCT05824559|EXPERIMENTAL|ME-344 and Bevacizumab|"ME-344 (IV) Cohort 1: Days 1, 8, and 15 of each 28-day cycle. Cohort 2: Days 1 and 15 of each 28-day cycle.~Bevacizumab (IV) Cohorts 1 and 2: Days 1 and 15 of each 28-day cycle."
62331459|NCT01477190|ACTIVE_COMPARATOR|PCA group|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
62694366|NCT03858244||IS without SDB, controls|Idiopathic scoliosis without sleep-disordered breathing, control group
61936972|NCT02395783|PLACEBO_COMPARATOR|Placebo|Placebo
62135912|NCT04974567||Women recently diagnosed with breast cancer who have not undergone any treatment.|Tear sample collection
62135913|NCT06489353|EXPERIMENTAL|Video-watching group|Participants will watch age-appropriate and engaging videos during the venipuncture procedure to distract them from pain and fear.
62135914|NCT06489353|EXPERIMENTAL|Blowing Pinwheels|Participants will blow pinwheels during the venipuncture procedure, using breathing control and distraction to reduce pain and fear.
62135915|NCT06489353|NO_INTERVENTION|routine care group|Participants will receive standard routine care during the venipuncture procedure without additional interventions, serving as the control group.
62135916|NCT06309134|EXPERIMENTAL|Healthy Families Bright Futures Program|This arm will complete the intervention. Assessments will occur at pre-intervention, post-intervention, and three month follow up.
62135917|NCT06309134|NO_INTERVENTION|Waitlist|Waitlist control. This arm will complete assessments on the same schedule as the experimental condition.
62135918|NCT06164704|EXPERIMENTAL|Verekitug (UPB-101)|Participants will be administered 0.5 milliliter (mL) of verekitug (UPB-101) formulated solution (containing 100 milligrams \[mg\] of verekitug \[UPB-101\]) subcutaneously, every 12 weeks for 24 weeks.
62489316|NCT00042835|EXPERIMENTAL|Group II (paclitaxel, carboplatin, and erlotinib|Patients receive induction chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1 and 21. Patients receive consolidation therapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 43, 50, 57, 64, 71, 78, and 85 and oral erlotinib once daily on days 43-91. Patients undergo radiotherapy concurrently with consolidation therapy 5 days a week for 7 weeks beginning on day 43.
62489317|NCT01906190|EXPERIMENTAL|vaccinated group|Vaccinated group means that subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine.
62489318|NCT02173964|EXPERIMENTAL|pinaverium bromide|pinaverium bromide 50 mg tablet per oral administration one time
62489319|NCT02173964|PLACEBO_COMPARATOR|water|water \~100mL
62489320|NCT00989053|ACTIVE_COMPARATOR|escitalopram|
62489321|NCT00989053|PLACEBO_COMPARATOR|placebo|
62489322|NCT05710458|EXPERIMENTAL|25 gauge 20,000 cpm Hypervit Dual Blade|New vitrectomy blade with higher cutting rate
61936973|NCT02521493|EXPERIMENTAL|Arm A (standard risk)|"INDUCTION II: Patients receive cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV over 1-15 minutes, and thioguanine PO BID on days 1-4. Induction II continues for a minimum of 28 days.~INDUCTION III: Patients receive cytarabine, daunorubicin hydrochloride, and thioguanine as in Induction II. Induction III continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 60-120 minutes on days 1-3. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive cytarabine and etoposide as in Intensification I. Intensification II continues for a minimum of 28 days.~(This arm is closed to accrual and treatment with amendment #4A 01/07/2019)"
61936974|NCT02521493|EXPERIMENTAL|Arm B (high risk)|"INDUCTION II: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours on days 1-4 and mitoxantrone hydrochloride IV over 15-30 minutes on days 3-6. Induction II continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours and etoposide IV over 90-120 minutes on days 1-5. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive high dose cytarabine IV over 3 hours Q12 hours on days 1, 2, 8, and 9. Patients also receive asparaginase or asparaginase Erwinia chrysanthemi IM or IV over 30 minutes on days 2 and 9. Intensification II continues for a minimum of 28 days."
61936975|NCT03698331|EXPERIMENTAL|Valbenazine|Valbenazine or placebo oral capsules administered once daily for 7 weeks.
62135919|NCT06164704|PLACEBO_COMPARATOR|Matching placebo|Participants will be administered verekitug (UPB-101) matching placebo solution, subcutaneously, every 12 weeks for 24 weeks.
62135920|NCT06698965|EXPERIMENTAL|Trilaciclib+Envafolimab+Chemotherapy Group（TEC Group）|TEC Group received received treatment with Envafolimab in combination with Etoposide and Carboplatin for 6 cycles. Prior to each chemotherapy cycle, they were given Trilaciclib before each chemotherapy session. After 6 cycles, they were treated with Trilaciclib in combination with Envafolimab as maintenance therapy until disease progression, intolerable adverse reactions, or withdrawal of informed consent by the patient occurred, with a maximum duration not exceeding 2 years.
62135921|NCT06698965|ACTIVE_COMPARATOR|Envafolimab+Chemotherapy Group（EC Group）|EC Group received received treatment with Envafolimab in combination with Etoposide and Carboplatin for 6 cycles. After 6 cycles, they were treated with Envafolimab as maintenance therapy until disease progression, intolerable adverse reactions, or withdrawal of informed consent by the patient occurred, with a maximum duration not exceeding 2 years.
62135922|NCT00995631|NO_INTERVENTION|Premenopausal, Control|Premenopausal women randomized to Control (delayed liposuction surgery)
62331460|NCT04683198|EXPERIMENTAL|Experimental: camrelizumab +apatinib+ Carboplatin + Etoposide|Induced stage：camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1 ; maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
62331461|NCT03154632|ACTIVE_COMPARATOR|US Group|Ultrasound Therapy
62331462|NCT03154632|ACTIVE_COMPARATOR|DCD Group|Digital Capacitive Diathermy Therapy
62331463|NCT06441812|EXPERIMENTAL|SHR-1703 Injection|
62331464|NCT05722236|EXPERIMENTAL|IBD Strong Peer2Peer intervention|
62331465|NCT05722236|OTHER|Waitlist -controls|
62331466|NCT05888467|OTHER|Control group|non-supervised exercise group
62331467|NCT05888467|ACTIVE_COMPARATOR|Intervention: supervised non-infrared exercise group|supervised non-infrared exercise group
62331468|NCT05888467|ACTIVE_COMPARATOR|Intervention: supervised infrared exercise group|supervised infrared exercise group
62331469|NCT05956886|EXPERIMENTAL|sleep chatbot intervention|Using CBT-I principles, participants will receive a four-week intervention delivered through a chatbot. The self-administered intervention is comprised of personalized behavioral prescriptions based on stimulus control principles and sleep schedule modification goals using sleep efficiency (SE) criteria. Participants are allowed to self-adjust expectations and make realistic decisions on sleep schedules. Other CBT-I components will be used as on-demand content. The chatbot will facilitate sleep goal setting with the participant, communicate weekly behavioral prescription and CBT-I educational modules, collect sleep diary and provide adaptive feedback and reactive services (e.g. Q\&A conversations) 24/7.
62331470|NCT05295368|EXPERIMENTAL|multicomponent intervention|1) 1. Training Nurses/service coordinators as Health Coaches and Hybrid Follow-up Approach of in-person, Telephone and Secure Video Sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
62331471|NCT05295368|NO_INTERVENTION|Usual care|treated by physicians and nurses who are not trained in SKOPE treatment algorithms.
62331472|NCT01124084||Health Care Providers|
62331473|NCT04989829|EXPERIMENTAL|Treatment group|
62489323|NCT05710458|ACTIVE_COMPARATOR|25 gauge 10,000 Ultravit vitrectomy cutter|Existing vitrectomy blade with cutting rate 10,000 cut/min
62489324|NCT00348517|EXPERIMENTAL|Systane|
62331474|NCT04691063|EXPERIMENTAL|Treatment group A|
62489325|NCT00348517|ACTIVE_COMPARATOR|Refresh|
62694367|NCT05754996|EXPERIMENTAL|lactulose plus Rifaximin plus nifuroxazide|"Nifuroxazide dosing : 800 mg daily in 4 divided doses for 7 days Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day.~Rifaximin: 550 mg twice daily"
62694368|NCT05754996|ACTIVE_COMPARATOR|Lactulose plus Rifaximin|"Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day.~Rifaximin: 550 mg twice daily"
62331475|NCT04691063|PLACEBO_COMPARATOR|Treatment group B|
62331476|NCT01201096||peptide radioreceptor therapy and liver transplantation|
62694369|NCT06564038|EXPERIMENTAL|Substudy 1 (RR CLL/SLL): Cohort 1A (AZD0486 Monotherapy)|Participants will receive AZD0486 monotherapy as subcutaneous (SC) injection.
62694370|NCT06564038|EXPERIMENTAL|Substudy 1 (RR CLL/SLL): Cohort 1B (AZD0486 + Acalabrutinib)|Participants will receive AZD0486 as SC injection. Participants will receive acalabrutinib tablet orally twice daily.
62331477|NCT06165484|EXPERIMENTAL|patient with failed ivf cycle|
62331478|NCT05149937|EXPERIMENTAL|Interventional group|Implementation of interprof Home measures to improve cooperation between nursing services, general practitioners and members of the therapeutic professions in the care of people living at home with care needs.
62694371|NCT06564038|EXPERIMENTAL|Substudy 2 (RR MCL): Cohort 2A (AZD0486 Monotherapy)|Participants will receive AZD0486 monotherapy as SC injection.
62694372|NCT06564038|EXPERIMENTAL|Substudy 2 (RR MCL): Cohort 2B (AZD0486 + Acalabrutinib)|Participants will receive AZD0486 monotherapy as SC injection. Participants will receive acalabrutinib tablet orally twice daily.
62135923|NCT00995631|ACTIVE_COMPARATOR|Premenopausal, Surgery|Premenopausal women randomized to surgery (femoral lipectomy)
62135924|NCT00995631|NO_INTERVENTION|Postmenopausal, Control|Postmenopausal women randomized to Control (delayed liposuction surgery)
62135925|NCT00995631|ACTIVE_COMPARATOR|Postmenopausal, Surgery|Postmenopausal women randomized to surgery (femoral lipectomy)
62135926|NCT01629589|EXPERIMENTAL|Adacel® Vaccine Group|Participants randomized to receive a single dose of Adacel® vaccine
62135927|NCT01629589|ACTIVE_COMPARATOR|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine
62135928|NCT06288854|EXPERIMENTAL|Olanzapine|Olanzapine 5 mg oral OD
62135929|NCT06288854|PLACEBO_COMPARATOR|Placebo|Placebo
62135930|NCT05577936|EXPERIMENTAL|Xperience no rinse antimicrobial solution group|XPERIENCE Advanced Surgical Irrigation will be utilized as the final wash after the TKA or THA procedure prior to closure
62331479|NCT00089843|ACTIVE_COMPARATOR|2|Placebo Actonel (risedronate) and active testosterone patch
62694373|NCT06564038|EXPERIMENTAL|Substudy 3 (LBCL): AZD0486 + R-CHOP|Participants will receive AZD0486 as intravenous (IV) infusion in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy as per standard of care. For participants achieving CR or PR, AZD0486 will be administered every 3 weeks.
62694374|NCT05570162|EXPERIMENTAL|Low Flash adherence|Adult (\>18 yrs old) type 1 diabetes patients with 4 or less daily Flash scans
62135931|NCT05577936|ACTIVE_COMPARATOR|Normal saline solution group|Standard of care irrigation will be utilized as the final wash after the TKA or THA procedure prior to closure.
62135932|NCT04754022|ACTIVE_COMPARATOR|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.
62135933|NCT04754022|ACTIVE_COMPARATOR|Liberal Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
62135934|NCT05364697|EXPERIMENTAL|IoNIR Ridaforolimus-Eluting Coronary Stent|IoNIR Ridaforolimus-Eluting Coronary Stent System
62135935|NCT04816955|EXPERIMENTAL|Nutrient-based recommendations|Participants in this group will be given nutrient-based recommendations to reduce free sugar intakes.
62135936|NCT04816955|EXPERIMENTAL|Nutrient- and food-based recommendations|Participants in this group will be given nutrient- and food-based recommendations to reduce free sugar intakes.
62135937|NCT04816955|EXPERIMENTAL|Nutrient- and food-based recommendations with food swaps|Participants in this group will be given nutrient- and food-based recommendations and advice on food swaps to reduce free sugar intakes.
62135938|NCT04816955|PLACEBO_COMPARATOR|Control|Participants in this group will not be given any recommendations to reduce free sugar intakes.
62135939|NCT05773092|EXPERIMENTAL|Intervention|Oral S-1 + Oral Osimertinib
62135940|NCT03997994|EXPERIMENTAL|Experimental: DCB Treatment|Stricture patients treated by DCB
62135941|NCT02852824|EXPERIMENTAL|BI 655130 (spesolimab)|
62135942|NCT02852824|PLACEBO_COMPARATOR|Placebo|
62331480|NCT00089843|ACTIVE_COMPARATOR|3|Active Actonel (risedronate) and active testosterone patch
62331481|NCT00089843|ACTIVE_COMPARATOR|4|Active Actonel (risedronate) and placebo testosterone
62331482|NCT00089843|PLACEBO_COMPARATOR|1|Placebo testosterone patch and placebo Actonel (risedronate)
62331483|NCT06255470|NO_INTERVENTION|Periodontally Healthy|Periodontally healthy patients received no intervention.
62331484|NCT06255470|ACTIVE_COMPARATOR|Periodontitis Stage III Grade B|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62331485|NCT06255470|ACTIVE_COMPARATOR|Periodontitis Stage III Grade C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62331486|NCT01880268|EXPERIMENTAL|BCI-then-Standard Rehab Group (Group A)|Participants will take 8 weeks of BCI rehabilitation first (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session. After finishing 8 weeks of BCI rehabilitation, participants will take 3 standard rehabilitation therapy sessions (for 2 hours) each week for 8 weeks (a total of 24 sessions)
62489326|NCT01063244|ACTIVE_COMPARATOR|FoleyBalloon|foley balloon placed in the cervix
62489327|NCT01063244|ACTIVE_COMPARATOR|foley balloon with weight|foley balloon with weight attached
62489328|NCT01732562|NO_INTERVENTION|Control|Patient receives the standard of care.
62489329|NCT01732562|EXPERIMENTAL|Patient e-Learning educational tool|Patient receives the standard of care and access to patient e-Learning educational tool.
62489330|NCT03966651|EXPERIMENTAL|PRRT with 177Lu-DOTATATE|
62489331|NCT00091195|EXPERIMENTAL|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62489332|NCT01394419|EXPERIMENTAL|NAC group|N-acetylcysteine
62489333|NCT01394419|PLACEBO_COMPARATOR|Placebo group|Saline
62489334|NCT01448876||chlamydia care as usual|
62694375|NCT06367101|NO_INTERVENTION|Stage 1:Healthy people|To establish baseline and reliability.
62694376|NCT06367101|NO_INTERVENTION|Stage 2: PD people|To establish stage 3 training protocol.
62694377|NCT06367101|EXPERIMENTAL|Stage 3: PD AR training group|AR training with gait and HRV feedback
62694378|NCT06367101|NO_INTERVENTION|Stage 3: PD Control group|PD Control
62694379|NCT03274466|EXPERIMENTAL|Closed Incision Negative Pressure Therapy (ciNPT)|Prevena Peel \& Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit
62694380|NCT03274466|ACTIVE_COMPARATOR|Standard of Care Dressing|Silver impregnated dressing
61936976|NCT03698331|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules administered once daily for 7 weeks.
62135943|NCT05940298|EXPERIMENTAL|Prostate cancer|At least five (5) evaluable subjects with prostate cancer
62331487|NCT01880268|EXPERIMENTAL|Standard-then-BCI Rehab Group (Group B)|Participants will take 8 weeks of standard rehabilitation therapy first (3 sessions per week, 2 hours for each session, a total of 24 sessions). After that, participants will take 8 weeks of BCI rehabilitation (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session.
62331488|NCT02610400|EXPERIMENTAL|RACD without RAVC|In this arm, subjects will receive RACD without the addition of RAVC.
62331489|NCT02610400|EXPERIMENTAL|RACD+RAVC|"In this arm, subjects will receive both:~(i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)"
62331490|NCT02610400|EXPERIMENTAL|rfMDA without RAVC|In this arm, subjects will receive reactive focal mass drug administration (rfMDA) without the addition of RAVC.
62331491|NCT02610400|EXPERIMENTAL|rfMDA+RAVC|"In this arm, subjects will receive both:~(i) reactive focal mass drug administration (rfMDA) and (ii) RAVC."
62489335|NCT01057368|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction|
62489336|NCT01057368|ACTIVE_COMPARATOR|Health Enhancement Program|
62489337|NCT01057368|NO_INTERVENTION|Wait List Controls|
62489338|NCT01057368|ACTIVE_COMPARATOR|Long Term Meditators|
62489339|NCT05370768|EXPERIMENTAL|Parenting Mindfully (PM) Intervention|PM is an group based 8 week mindfulness intervention for parents.
62489340|NCT05370768|ACTIVE_COMPARATOR|Parent Education (PE) Intervention|PE is a group based 8 week educational intervention for parents that teaches parents about adolescent development.
62489341|NCT04737330|ACTIVE_COMPARATOR|Investigational Arm|Investigational Arm - Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
62694381|NCT05937802|EXPERIMENTAL|Osmotin|Administration of a nutraceutical supplement provided in capsules, that consists of lyophilised and pulverised kiwi leaves from bioengineered kiwi (Actinidia Deliciosa) plants overexpressing the tobacco protein Osmotin.
62694382|NCT01557244|EXPERIMENTAL|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
62694383|NCT01557244|EXPERIMENTAL|Fesoterodine PR 8 mg|Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
62489342|NCT04737330|PLACEBO_COMPARATOR|Control Arm - placebo|Control arm - placebo s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
62489343|NCT03056547|EXPERIMENTAL|Induced dyspnea|
62489344|NCT03354780||endometriosis|Survey on first pregnancy after endometriosis diagnosis
62489345|NCT03354780||non endometriosis|Survey on first pregnancy
62489346|NCT02694653|ACTIVE_COMPARATOR|Drug Arm|Acetaminophen 1000 mg in 100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
62489347|NCT02694653|PLACEBO_COMPARATOR|Placebo Arm|100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
62694384|NCT01557244|ACTIVE_COMPARATOR|Oxybutynin|Oxybutynin
61936977|NCT02248415|EXPERIMENTAL|No pump group|Blood cardioplegia administration without roller pump
61936978|NCT02248415|OTHER|Pump group|Blood cardioplegia administration with roller pump
61936979|NCT02129829||Observational Group|Patients whose viral load, ALT value and fibrosis status does not meet EASL criteria for treatment and are observed 6 monthly
61936980|NCT02129829||Treatment Group (Tenofovir disoproxil)|Patients who meet EASL treatment criteria who receive Tenofovir disoproxil
61936981|NCT00732797|NO_INTERVENTION|Routine Care|Participants will receive routine care.
62135944|NCT05940298|EXPERIMENTAL|Breast cancer|At least five (5) evaluable subjects with breast cancer
62135945|NCT06062875|ACTIVE_COMPARATOR|adalimumab|adalimumab 40 mg every 2 weeks
62331492|NCT04964063|OTHER|Sensodyne Fresh Mint Toothpaste|"Participants will be asked to follow commercial tube instructions as recommended for sensitivity relief: Apply at least a 1-inch strip of the product onto a soft bristle toothbrush. Brush teeth thoroughly for at least 1 minute twice a day (morning and evening), and not more than 3 times a day, or as recommended by a dentist or doctor. Make sure to brush all sensitive areas of the teeth. Minimize swallowing, Spit out after brushing."
62331493|NCT03001037||Group A - Low Back Pain|"Group A:~* Subject provides written authorization and/or consent per institution and geographical requirements~* Subjects in Group A with a predominant complaint of Low back pain, with a minimum daily average VAS ≥ 30/100~* Subjects in Group A are intended to be assessed with ViMove based on standard of care~* Subject is willing to participate in follow-ups at 3, 6, 12 months post initial assessment~Observational study, no intervention"
62489348|NCT03262051||Patient with acute inflammation (surgery)|patients undergoing hip surgery
62489349|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
62489350|NCT03262051||Patient with acute inflammation (SARS-CoV-2 infection)|patients with SARS-CoV-2 infection
62489351|NCT03833050||Heart Transplant Recipients|"Heart Transplant Recipients meeting the criteria for enrollment and consented will be followed post transplant for 1 year after enrollment into the study.~Blood samples will be obtained at their 1, 3, 6, 12 months and any for cause heart biopsy's obtained. There will be no active intervention for recipients that are enrolled. Results from the samples will not be obtained in real time."
62489352|NCT01690780|ACTIVE_COMPARATOR|Ibuprofen|
62489353|NCT01690780|EXPERIMENTAL|Oral morphine|
62489354|NCT05949853||Patients|Patients hospitalized at the Center for Sleep and Respiratory Diseases, between 09/2022 and 11/2022 for suspected OSA All these patients underwent a full night polysomnography
62489355|NCT00012818|OTHER|Arm 1|
62489356|NCT03392051|EXPERIMENTAL|Clopidogrel Dosing|Multiple doses of Clopidogrel to obtain pharmacokinetic information.
62489357|NCT03392051|EXPERIMENTAL|Clopidogrel in combination with ISIS 681257|Multiple doses of clopidogrel administered with 2 doses of ISIS 681257 at 2 individual timepoints to obtain pharmacokinetic information.
62694385|NCT01557244|EXPERIMENTAL|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
62694386|NCT01557244|EXPERIMENTAL|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
62694387|NCT02800785|ACTIVE_COMPARATOR|Antibiotics Therapy Arm|Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days.
62694388|NCT02800785|ACTIVE_COMPARATOR|Appendectomy Arm|Patients in the appendectomy arm will have an appendectomy performed by an open or laparoscopic approach, depending on patient and surgeon preference. Prior to their operation, patients in this arm will receive one dose of antibiotics per currently accepted standards when appendicitis diagnosis is confirmed. Patients may also receive preoperative antibiotics per hospital standards for surgical infection prevention bundle.
62694389|NCT03543423|EXPERIMENTAL|Oral glucose tolerance test|Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.
62135946|NCT06062875|NO_INTERVENTION|Placebo|placebo injection (saline) every 2 weeks.
62135947|NCT05854446||Healthcare Experts|Experts with diverse backgrounds in healthcare and pain management.
62135948|NCT01802827||VAT patients|Patients developing Ventilator Associated Tracheobronchitis
62135949|NCT01802827||VAP|Patients presenting ventilator associated pneumonia
62331494|NCT03001037||Group B - Without Low Back Pain|"* Subject is without current low back pain~* Subject does not have a history of low back pain lasting longer than 3 months in the past 12 months~* Subject is willing to follow up 3 months post initial assessment~Observational study, no intervention"
62331495|NCT01570712|EXPERIMENTAL|Housing First Program|
62135950|NCT01802827||No ventilator associated infection|patients who do not present ventilator associated infection during their stay in ICU
62135951|NCT00802126|EXPERIMENTAL|Bevacizumab and verteporfin|
62135952|NCT06334107|EXPERIMENTAL|Aerobic Exercise Training|Participants will be asked to complete a 16-week aerobic exercise training program.
62135953|NCT06334107|NO_INTERVENTION|Mitochondrial DNA Sequencing|Participants will be asked to provide a blood or saliva sample for mitochondrial DNA sequencing analysis to assess for variants unique to individuals born prematurely.
62135954|NCT05009862|PLACEBO_COMPARATOR|Control|Participants will receive 81mg daily of aspirin + placebo for 30 days.
62135955|NCT05009862|EXPERIMENTAL|Intervention|Participants will receive 81mg of aspirin + rivaroxaban 2.5mg twice daily for 30 days.
62135956|NCT05268302|EXPERIMENTAL|Low Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10\^2 Plaque Forming Units
62135957|NCT05268302|EXPERIMENTAL|Medium Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10\^3 Plaque Forming Units
62135958|NCT05268302|EXPERIMENTAL|High Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10\^4 Plaque Forming Units
62135959|NCT06527755|EXPERIMENTAL|Eplontersen|Single arm
62135960|NCT06549296|EXPERIMENTAL|Intervention|RD06-04
62135961|NCT04926597|EXPERIMENTAL|Intervention group: individualized nutritional support|Intervention group patients will receive individualized nutritional support to reach energy and protein goals with the support of an experienced, unblinded dietician and with use of oral nutritional supplements (ONS) as needed
62331496|NCT01570712|ACTIVE_COMPARATOR|traditional French services|
62331497|NCT00853333|ACTIVE_COMPARATOR|Propofol|Administration via an IV
62331498|NCT00853333|ACTIVE_COMPARATOR|Midazolam|Administration via an IV
62489358|NCT01426360|EXPERIMENTAL|strontium chloride/potassium nitrate dentifrice|
62489359|NCT01426360|PLACEBO_COMPARATOR|control dentifrice|
62489360|NCT04837456|EXPERIMENTAL|Calorie restricted diet and excecise intervention|a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement \[36\]. Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\].Each session was approximately 150 minutes one week for six months and consisted of aerobic exercises, resistance training, and exercises to improve flexibility and balance.
62489361|NCT04837456|EXPERIMENTAL|libitum diet and waiting list control group|participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
62489362|NCT04837456|EXPERIMENTAL|Early APM group|Early APM group participants received APM with syndrome within 3 to 6 months
62489363|NCT04837456|EXPERIMENTAL|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
62489364|NCT00965757|EXPERIMENTAL|1|
62489365|NCT00965757|PLACEBO_COMPARATOR|2|
62135962|NCT04926597|OTHER|Control group: general information on healthy food habits|Control group patients will receive nutritional counselling (general information on healthy food habits) at discharge, but no nutritional support strategy will be used during follow-up
62135963|NCT06605391|EXPERIMENTAL|Caregiving While Black-LIVE|Black dementia caregivers participating in the psychoeducation course, Caregiving while Black-LIVE, over an 8 week time period.
62694390|NCT03543423|EXPERIMENTAL|Liquid mixed meal test|Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min
62694391|NCT01586715|EXPERIMENTAL|Autologous Stem Cells|
62694392|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
62694393|NCT04289493|EXPERIMENTAL|Group 1: first to receive therapy|27 patients that will receive study specific speech therapy in the first 3 months since study inclusion. From months 3-6 they will be group 2 controls.
62135964|NCT01705886||Knee Arthroplasty|"Patients undergoing knee replacement surgery. This may be a Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty.~The MAKO® Robot Assisted surgeries use the RESTORIS Multicompartmental Knee System.~The total knee arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System."
62331499|NCT00853333|ACTIVE_COMPARATOR|Dexmedetomidine|Administration via an IV
62331500|NCT05158309|EXPERIMENTAL|Capsaicin|Capsaicin condition: in this condition participants received pain using a (5x10 cm) 8% topical capsaicin patch on the volar part of the dominant right forearm.
62331501|NCT05158309|PLACEBO_COMPARATOR|Placebo|Placebo condition: participants received no pain.
62331502|NCT04192448|EXPERIMENTAL|AlcoholxAnger|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
62694394|NCT04289493|EXPERIMENTAL|Group 2: second to receive therapy|27 patients that will receive study specific speech therapy during months 3-6 since study inclusion. During the first 3 months of the study period, they will be group 1 controls.
62694395|NCT05612945|EXPERIMENTAL|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. This protocol will elicits moderate-to-severe claudication pain during exertion. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test."
62135965|NCT01463176|NO_INTERVENTION|Standard Care|Children in the Standard Care Control group will receive standard care and will be videotaped by the music therapist but will not receive music therapy during their immunization
62135966|NCT01463176|EXPERIMENTAL|Music Therapy|Children in this group will receive live music therapy during their immunization.
62694396|NCT05612945|EXPERIMENTAL|Low-to-moderate intensity training group (LowMod group)|Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.
62694397|NCT00781898|ACTIVE_COMPARATOR|Depot Naltrexone|
62694398|NCT00781898|PLACEBO_COMPARATOR|Placebo|
62135967|NCT04756440|EXPERIMENTAL|Experimental: Intervention Group|Firstly, Pre-tests were applied to the women in the experimental group. The 4-week training program created by taking into account the cultural characteristics of the Roma; It includes the Anatomy of Female Reproductive Organs, Anatomy of the Cervix, Cancer, Cervical Cancer, Early diagnosis and its importance, Pap smear test, HPV-DNA test, Cancer Early Diagnosis, Screening and Education Center. Afterwards, music therapy will be applied to the women in the experimental group with the song written and composed by the researchers who emphasized the importance of early diagnosis. At the end of the program, a focus group discussion will be held with the participants in the experimental group regarding their educational experiences, learning experiences for cervical cancer and screening, and program outcomes. Final tests will be made 3 months after the training ends.
62331503|NCT04192448|EXPERIMENTAL|AlcoholxControl|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
62331504|NCT04192448|EXPERIMENTAL|SoberxAnger|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
62331505|NCT04192448|SHAM_COMPARATOR|SoberxControl|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
62331506|NCT01883440|PLACEBO_COMPARATOR|Saline+glucose|A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
62694399|NCT01893086|ACTIVE_COMPARATOR|LH alone|LH, laparoscopic hysterectomy
62694400|NCT01893086|EXPERIMENTAL|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
62331507|NCT01883440|ACTIVE_COMPARATOR|Glucose oxidase + glucose|A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.
62331508|NCT02800564|EXPERIMENTAL|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months plus interactive voice response systems (IVRS) and monthly open community meetings.
62331509|NCT02800564|EXPERIMENTAL|Passive mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months
62489366|NCT06372119|ACTIVE_COMPARATOR|Letrozole-stimulated cycle strategy (LETS)|"to fourth day of the menstrual cycle.~Post-letrozole, ultrasound checks follicle growth. If ≥18mm, Ovitrelle® 250 mcg (Merck, Kenilworth, New Jersey, USA) induces ovulation.~Luteal phase support with vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day starting two days post-hCG.~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: no follicle development on day 21 from the day of starting letrozole, spontaneous ovulation, letrozole intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
62697613|NCT06456892|EXPERIMENTAL|Pucotenlimab Combined with Standard Chemotherapy Regimen|"In phase I, it focuses on safety, tolerability, and pharmacokinetics using a 3+3 dose escalation design with three dose groups: 1 mg/kg, 3 mg/kg, and 6 mg/kg. The drug will be administered in combination with the standard regimen for intermediate/high-risk rhabdomyosarcoma once every three weeks (Q3W).~In phase II, after establishing the recommended Phase II dose (RP2D), ll subjects will receive Pucotenlimab combined with the standard regimen for intermediate/high-risk rhabdomyosarcoma for 2-4 cycles of neoadjuvant therapy every 3 weeks (Q3W), followed by surgery.~The standard regimen for intermidiate/high-risk rhabdomyosarcoma refer to the SYSUCC-RMS-2017 in China."
62135968|NCT04756440|NO_INTERVENTION|No Intervention: Control Group|First, pre-tests will be applied to the women in the control group. Women in this group will not be intervened and post-tests will be made 3 months after the pre-test.
62135969|NCT04217330|EXPERIMENTAL|Intervention|Pulmonary rehabilitation programs assigned to the intervention group will offer eligible participants the choice of participating in an 8-week program of either home-based pulmonary rehabilitation or traditional centre-based pulmonary rehabilitation.
62331510|NCT05204199||Group A|Patients without a urological or gastrointestinal malignancy undergoing non-oncological bladder surgery or transurethral resection of the prostate (TUR-P)
62331511|NCT05204199||Group B|Low Risk NMIBC (primary, solitary, Ta / low grad \< 3cm, no carcinoma in situ (CIS))
62331512|NCT05204199||Group C|NMIBC patients, BCG candidates, assessed as intermediate (between the category of low- and high risk) or high risk (T1 or high grade or CIS or multiple, recurrent and large (\> 3 cm) Ta/ low grade tumours).
62489367|NCT06372119|ACTIVE_COMPARATOR|Artificial cycle strategy (AC)|"Oral estradiol valerate (Progynova® 2 milligrams, Bayer Pharma AG, Germany or Valiera® 2 milligrams, Laboratories Recalcine, Chile) 6 milligrams/day for 10 days, starting on the second to fourth day of the menstrual cycle.~Post-estradiol, ultrasound checks endometrial thickness. If ≥7mm, start vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day. If \<7mm, increase the dose of oral estradiol valerate to 8 milligrams/day (5-6 days) and 12 milligrams/day (5-6 days).~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: endometrial thickness \<7mm on day 21 of using estradiol, spontaneous ovulation, oral estradiol valerate intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
62489368|NCT03255733|EXPERIMENTAL|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
62489369|NCT00112437|PLACEBO_COMPARATOR|Placebo|
62489370|NCT00112437|EXPERIMENTAL|Odanacatib 3 mg|
62489371|NCT00112437|EXPERIMENTAL|Odanacatib 10 mg|
62489372|NCT00112437|EXPERIMENTAL|Odanacatib 25 mg|
62489373|NCT00112437|EXPERIMENTAL|Odanacatib 50 mg|
62489374|NCT05333107|EXPERIMENTAL|Sequence 1|Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2).
62135970|NCT04217330|ACTIVE_COMPARATOR|Control|Pulmonary rehabilitation programs assigned to the control group will offer eligible participants the opportunity to participate in an 8-week centre-based pulmonary rehabilitation program, as per current practice.
62135971|NCT06080282||Sepsis|No intervention
62331513|NCT03974347||Acute kidney injury, no acute kidney injury|Acute kidney injury after cardiac surgery will be defined by KDIGO criteria, Creatinine rise from baseline and or urine production.
62331514|NCT03974347||No Acute Kidney Injury|No Acute kidney Injury after Cardiac surgery, according to KDIGO AKI definition
62331515|NCT05425238|EXPERIMENTAL|Blood flow restriction|Resistance training protocol but with Blood flow restriction technique Standard BFR Application: a standard pressure (used for all patients) for e.g. 180 mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.
62489375|NCT05333107|EXPERIMENTAL|Sequence 2|Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2).
62489376|NCT05333107|EXPERIMENTAL|Sequence 3|Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2).
62489377|NCT05333107|EXPERIMENTAL|Sequence 4|Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2).
62135972|NCT03791736|EXPERIMENTAL|Sandostatine|Injection of Sandostatine
62135973|NCT06221137|ACTIVE_COMPARATOR|conventional circumferential supracrestal fiberotomy|"* The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)"
62331516|NCT05425238|ACTIVE_COMPARATOR|Conventional physical therapy|Resistance training to stimulate skeletal muscle hypertrophy and strength adaptations in Duration of 6 weeks
62331517|NCT04397406|ACTIVE_COMPARATOR|Group C (Control group)|pidural analgesia with levobupivacaine alone
62331518|NCT04397406|EXPERIMENTAL|Group D (Dexmedetomidine group)|Epidural analgesia with levobupivacaine and dexmedetomidine
62489378|NCT05333107|EXPERIMENTAL|Sequence 5|Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2).
62489379|NCT05333107|EXPERIMENTAL|Sequence 6|Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2).
62489380|NCT05173298||analytic group|advanced HCC Patients
62489381|NCT02659462||patients post Fontan palliation for single ventricular hear|Cardio Pulmonary Exercise Testing
62489382|NCT02659462||Subjects post surgical correction of congenital heart disease|Cardio Pulmonary Exercise Testing
62489383|NCT02659462||Healthy patients|Cardio Pulmonary Exercise Testing
62489384|NCT01870258|PLACEBO_COMPARATOR|those without MI in 2 weeks|patient without MI in 2 weeks
62489385|NCT01870258|ACTIVE_COMPARATOR|patient with MI|group with MI in 2 weeks
62489386|NCT03541252|EXPERIMENTAL|Basal Cell Carcinoma Patients|Patients (\>18 years) with histologically-verified superficial or nodular basal cell carcinoma (\<20 mm on the face/scalp, \<50mm on the trunk/extremities)
62489387|NCT00983996|EXPERIMENTAL|1|Alendronate Sodium Tablets, 10 mg
62489388|NCT00983996|ACTIVE_COMPARATOR|2|Fosamax Tablets, 10 mg
62489389|NCT06558812|OTHER|conventional space maintainer|Conventional band and loops have been widely used with a high rate of success as the most practical way of space maintenance, as reported in numerous articles . Band and loop space maintainer is used to maintain space for successors of early lost primary molars. This is due to the ease and practicality of fabrication, adjustments and repairs of this space maintainer, as well as its ability to continue to function until the eruption of the permanent successor without interfering with their eruption The need for at least two visits to delivery, therefore cannot be planned in patients under general anesthesia. Fabrication of conventional and loop requires an alginate impression and laboratory work.
62694401|NCT06258512|EXPERIMENTAL|Intervention with narrative approach + standard care|"Intervention with a narrative approach. The objectives will be:~1. Know significant moments in the personal history of the participant and her family according to her life cycle. as well as structural elements.~2. Know information regarding symptoms of non-organic origin, pain crises, personal and family resources for their management.~3. Implement a narrative technique as an alternative for the management of symptoms of non-organic origin, including the following strategies: the participant will be able to tell and retell their story, recognize situations or moments that exacerbate the pain, feel the pain and name it, externalization of the pain. problem, the problem is the problem, absolving oneself from traumatic life experiences, constructing meaning to one\&#39;s dominant stories through the organization of the experience, to obtain a new meaning of what was experienced through the story, construction of alternative stories."
62694402|NCT06258512|NO_INTERVENTION|control with standard care|Participants randomly assigned to the control group will receive usual care from their primary care professionals.
62694403|NCT04025320|EXPERIMENTAL|Group 1|"Intraneural facilitation treatment for 50-60 minutes. 50 minutes if ultrasound received.~9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
62135974|NCT06221137|ACTIVE_COMPARATOR|laser circumferential supracrestal fiberotomy|"* The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed."
62135975|NCT00879840||Females|With endometrial cancer, ovarian cancer, and women undergoing hysterectomy for benign reasons.
62135976|NCT05438992|ACTIVE_COMPARATOR|group A|The patients in this group will be administered 15 ml bupivacaine 0.250 % between the popliteal artery and the capsule of the posterior knee.
62331519|NCT04397406|EXPERIMENTAL|Group F (Fentanyl group)|Epidural analgesia with levobupivacaine and fentanyl
62331520|NCT06105879||Serum|Total Serum bilirubin
62331521|NCT06105879||covered skin|Covered Skin Transcutaneous Bilirubin
62331522|NCT06105879||exposed skin|Exposed skin Transcutaneous Bilirubin
62331523|NCT05311280|EXPERIMENTAL|high intensity interval training plus myotherapy|"Subjects were instructed to perform tongue slide, tongue force, tongue press, tongue reach, swallowing exercise, smiling exercise, jaw press exercise, chewing exercise, breathing exercise and buccinator exercise.These myofunctional exercise were performed 10 repetitions for a set, 2 sets in a treatment session depends on patient's condition. Between each session, subjects were allowed to rest at least 1 minutes.~Exercise training would be implemented in the form of high-intensity interval training and resistance exercise. High-intensity interval training intensity of the target heart rate (THR) was calculated as follows: THR = (HRmax - HRrest) × 80-90%Intensity + HRrest\[26\]. The HIIT program included four 3-min bouts at high-intensity (80-90%HRR), separated by 3-min of active recovery and total for 4 cycles of 24-min HIIT intervention. The HIIT exercise options were running on a treadmill."
62489390|NCT06558812|OTHER|prefabricated space maintainer|Prefabricated band and loop devices have been introduced to dentistry in recent times. They can possibly overcome most of the previously mentioned limitations of conventional space maintainers. The prefabricated band and loop space maintainer is adjusted and applied in one visit and therefore can be planned in patients under general anesthesia. Other advantages include less time, more patient and parent satisfaction, and no laboratory work
62489391|NCT04710823|EXPERIMENTAL|Thoracic paravertebral block|Patients will receive ultrasound-guided continuous thoracic paravertebral blockusing bupivacaine 0.25% for 4 days.
62489392|NCT04710823|EXPERIMENTAL|Serratus anterior plane block|Patients will receive ultrasound-guided continuous SAP block using bupivacaine 0.25% for 4 days.
62489393|NCT06563219||Survivors|Survivors were defined as patients who were still alive after 28 days of admission to the emergency department.
62489394|NCT06563219||Non-survivors|Non-survivors had passed away within 28 days of admission to the emergency department.
62489395|NCT01442051|EXPERIMENTAL|Acute Normovolemic Hemodilution|A pilot study will be performed. Intraoperative data including vital signs, procedures performed, and transfusions of allogenic blood will be collected prospectively. Postoperative outcomes, including transfusions of allogenic blood, perioperative complications, and 30-day mortality will be collected prospectively. These outcomes will be compared to historical controls to assess for the safety and efficacy of ANH in ovarian cancer cytoreductive surgery.
62489396|NCT01360073||Cases|Cases with nonfatal MI or coronary death
62489397|NCT01360073||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
62489398|NCT04031235|EXPERIMENTAL|Safe Sleep Education|Mothers in the intervention group will receive education on American Academy of Pediatrics safe sleep recommendations using a specially-designed children's book (Sleep Baby, Safe and Snug). In addition, they will receive information on the importance of reading with their infant using a brochure created by the AAP.
62489399|NCT04031235|ACTIVE_COMPARATOR|Infant Reading Education|Mothers in the control group will receive education on American Academy of Pediatrics recommendations on reading and talking to infants using a specially-designed children's book (Read Baby, Every Day). In addition, they will receive information on safe sleep using a brochure created by the AAP.
62694404|NCT04025320|SHAM_COMPARATOR|Group 2|"SHAM treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
62694405|NCT03725592|ACTIVE_COMPARATOR|Standard Treatment|Receives arsenic removal device and written instructions and phone calls on how to use the device (Arsenic Removal Device)
62694406|NCT03725592|EXPERIMENTAL|Intensive Education|Receives the Standard Treatment plus in-person visits and phone calls for follow-up (Community Participatory Arsenic Mitigation)
61936982|NCT00732797|ACTIVE_COMPARATOR|Booklet|Participants will receive self-treatment booklets, but no expert telephone support.
61936983|NCT00732797|ACTIVE_COMPARATOR|Booklet &Therapist Support|Participants will receive self-treatment booklets, and up to an hour's expert telephone support.
61936984|NCT01565174||High activity COMT|Carriers of high activity COMT158Val allele who are expected to show higher THC-induced meso-limbic DA release
62135977|NCT05438992|ACTIVE_COMPARATOR|Group B|The patients in this group will be administered 20 ml bupivacaine 0.250 % between the popliteal artery and the capsule of the posterior knee.
62694407|NCT06323083|EXPERIMENTAL|Intervention group|"Emotional Freedom Technique (EFT) application was applied to those in the intervention group.~The study was carried out in three stages with three EFT applications, applied for approximately 20-30 minutes, at 7-day intervals. In the first stage, students who met the inclusion criteria were identified by interviewing students who thought they had a fear of childbirth."
61936985|NCT01565174||Low activity COMT|Carriers of low activity COMT 158Met homozygotes are expected to release low amount of dopamine after smoking a cigarette with THC
61936986|NCT03392077||Group A: cervical dilatation|patients who will have cervical dilatation during Caesarean section
61936987|NCT03392077||Group A: non cervical dilatation|patients who will have not cervical dilatation during Caesarean section
62135978|NCT05438992|ACTIVE_COMPARATOR|Group C|The patients in this group will be administered 25 ml bupivacaine 0.250 % between the popliteal artery and the capsule of the posterior knee.
62135979|NCT06397118|EXPERIMENTAL|Standard Care plus Maternal Nutrition Education|"Mothers whose infants are assigned to this group will be provided individually by a community health worker during weeks 0, 8, and 16. In addition to receiving nutrition counseling, maternal nutrition education will emphasize utilizing locally available foods to enhance the nutritional well-being of young children and families, all while respecting local cultural and religious customs. To reinforce these educational messages, visual aids will be incorporated. The following educational messages will be addressed:~1. appropriate feeding frequency~2. dietary diversity using local foods~3. Complementary food preparation~4. adequate portions~5. individualized, tailored economic education regarding the cost of purchasing foods that can fill nutrient gaps (self-efficacy)"
62489400|NCT02589067|EXPERIMENTAL|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
61936988|NCT02613949|ACTIVE_COMPARATOR|12-week RINCE mode 1|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 1
61936989|NCT02613949|ACTIVE_COMPARATOR|12-week RINCE mode 2|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 2
61936990|NCT02613949|SHAM_COMPARATOR|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
61936991|NCT05936125|EXPERIMENTAL|Patients with tricuspid valve regurgitation undergoing open heart surgery|Patients undergoing open heart surgery (for any reason) with concomitant tricuspid valve regurgitation
61936992|NCT06377306||Regular cycle|Regular cycle length between 21-35 days.
61936993|NCT06377306||Irregular/contraceptives|Irregular cycles (under 21 days or more than 35 days). Contraceptives use of any type (Hormonal intervention).
61936994|NCT06174259|EXPERIMENTAL|Intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day) around standard neoadjuvant chemotherapy.
61936995|NCT06174259|NO_INTERVENTION|regular diet|Regular diet around standard neoadjuvant chemotherapy
62489401|NCT02589067|PLACEBO_COMPARATOR|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
62489402|NCT03973671||UC patients|"Patients diagnosed with primary or recurrent non-muscle-invasive bladder (NMIBC) cancer.~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.~The clinical (demographic, operative and follow-up) and pathological data of the patients will be collected in a complete anonymous way."
62489403|NCT01250730|EXPERIMENTAL|1.0|This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
62694408|NCT06323083|NO_INTERVENTION|Control group|The control group was also tested at the first interview and again 3 weeks later.
62694409|NCT04573738|EXPERIMENTAL|Robotic transanal surgery|Robotic assisted transanal total mesorectal excision for rectal cancer patients
62694410|NCT04573738|ACTIVE_COMPARATOR|Laparoscopic transanal surgery|Laparoscopic transanal total mesorectal excision for rectal cancer patients
62489404|NCT02333123|EXPERIMENTAL|Aspirin|Aspirin 300mg capsule by mouth once a day for 24 weeks.
62489405|NCT02333123|PLACEBO_COMPARATOR|Placebo|Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
62489406|NCT04544800|EXPERIMENTAL|Use of Splint for UADT Visualization|Use of device to view UADT
62694411|NCT00339287||Healthy volunteers|Healthy adult volunteers at least 18 years of age.
62694412|NCT04832698||Observational (survey administration)|Participants complete a survey over 10 minutes before and after completing training and using the Mentice endovascular simulator device.
62694413|NCT06642129||Oberservation Group|Patient requiring surgical treatment with lumboperitoneal shunt for communicating hydrocephalus
62331524|NCT05311280|ACTIVE_COMPARATOR|home exercise training plus myotherapy|"Subjects were instructed to perform tongue slide, tongue force, tongue press, tongue reach, swallowing exercise, smiling exercise, jaw press exercise, chewing exercise, breathing exercise and buccinator exercise.These myofunctional exercise were performed 10 repetitions for a set, 2 sets in a treatment session depends on patient's condition.~Home exercise is composed of ambulation training outside or inside. Three phase including warm up, training phase, and cool down. The intensity of training phase is decided by rating of perceived exertion (RPE) range from 11\~15. 2\~5 training times a week will involved according to patients' preference."
62331525|NCT02763878|EXPERIMENTAL|uncut Roux-en-Y anastomosis|After distal gastrectomy, duodenal stump closure, side to side anastomosis was underwent on the remnant stomach and jejunum,which was 25cm from Treitz ligament. Then underwent side to side anastomosis between jejunum about 35cm distance from gastrojejunostomy and jejunum about 5cm from Triez ligament . close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis by using uncut Closure devices
62694414|NCT03900650|EXPERIMENTAL|Alcoholic beverage, High Provocation Manipulation|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%. Participants then receive an experimental manipulation designed to evoke negative emotions such as frustration.
62135980|NCT06397118|ACTIVE_COMPARATOR|Standard Care Only|Mothers whose infants are assigned to the control group will receive standard nutrition education from the provider at the SCD clinic during weeks 0, 8, and 16.
62331526|NCT02763878|SHAM_COMPARATOR|Billroth II anastomosis|After distal gastrectomy, duodenal stump closure, the investigators first underwent remnant stomach and upper jejunum side anastomosis. Then choose the jejunum about 25cm from Treitz ligament, premenstrual colon using a disposable cutting closure (or tubular stapling) in the rear wall of the stomach and jejunum anastomosis, common opening was closed with the (barbed wire) hand-stitched. After that, steps were same with the group A.
62331527|NCT01673464||High School Athletes|
62331528|NCT02787434|EXPERIMENTAL|PCSPrep decision aid|All participants recruited to the trial will receive the decision aid. This a one-group study with a quasi-experiemental pre/post evaluation design.
62331529|NCT04544709|OTHER|Discogenic Low Back Pain|Patient with Refractory Discogenic Low back pain who will be scheduled for platelet rich plasma injection as standard of care.
61936996|NCT03409068|EXPERIMENTAL|C2-C4 compartment block|Experimental: the C2-C4 compartment anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenous muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
62135981|NCT00124254|EXPERIMENTAL|1|Surgical group undergoing SMPA
62135982|NCT00124254|ACTIVE_COMPARATOR|2|Nosurgical group
62135983|NCT01358669|ACTIVE_COMPARATOR|Denosumab|In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant
62331530|NCT00374153|EXPERIMENTAL|1|Online personal feedback report.
62331531|NCT00374153|EXPERIMENTAL|2|In-person Motivational Interview with personal feedback report
62331532|NCT00374153|EXPERIMENTAL|3|In-person Motivational Interview only (without a personal feedback report)
62331533|NCT00374153|NO_INTERVENTION|4|Assessment only
62331534|NCT00374153|NO_INTERVENTION|5|Delayed Assessment
62331535|NCT02936219||Early complementary breast feeding|The EARLY complementary feeding group is defined as the introduction of complementary food \<17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
62331536|NCT02936219||Early complementary combined feeding|The EARLY complementary feeding group is defined as the introduction of complementary food \<17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
62331537|NCT02936219||Early complementary formula feeding|The EARLY complementary feeding group is defined as the introduction of complementary food \<17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
62489407|NCT05701163|EXPERIMENTAL|Healthy Volunteers|Healthy males with no significant comorbidities, aged 20-45 years who are able to produce a semen sample by masturbation.
62489408|NCT01269268||active tuberculosis|active TB patients : diagnosed with TB through microbiologic examination
62489409|NCT01269268||healthy control|healthy control : no evidence of respiratory disease, no respiratory symptoms, and no history of close contact of active pulmonary TB patients
62694415|NCT03900650|EXPERIMENTAL|Non-alcoholic beverage, High Provocation Manipulation|Participants will receive a beverage that does not contain alcohol (fruit juice only). Participants then receive an experimental manipulation designed to evoke negative emotions such as frustration.
62694416|NCT03900650|EXPERIMENTAL|Alcoholic beverage, Low provocation manipulation|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%. Participants receive an experimental manipulation designed to evoke positive emotions.
62694417|NCT03900650|EXPERIMENTAL|Non-alcoholic beverage, Low provocation manipulation|Participants will receive a beverage that does not contain alcohol (fruit juice only). Participants then receive an experimental manipulation designed to evoke positive emotions.
62135984|NCT01358669|PLACEBO_COMPARATOR|Placebo|Placebo
62489410|NCT01679327|EXPERIMENTAL|Bevacizumab plus chemotherapy（XELOX or FOLFOX）|Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days)
62489411|NCT06060353|EXPERIMENTAL|Regulation Focused Psychotherapy (RFP-C)|
62489412|NCT06060353|ACTIVE_COMPARATOR|Parental Awareness and Child Social Skills Group|
62489413|NCT01229150|ACTIVE_COMPARATOR|KRAS Mut 2|KRAS Mutant patients randomized to combination therapy arm
61936997|NCT03409068|ACTIVE_COMPARATOR|Costagliola block|Active Comparator: the Costagliola anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL injected in the posterior margin of the sternocleidomastoid muscle and along the anterior border of the same muscle.
62135985|NCT03570970|EXPERIMENTAL|Banapenem C1 group|250mg Once daily for 7
62331538|NCT02936219||Late complementary breast feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
62331539|NCT02936219||Late complementary combined feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
62331540|NCT02936219||Late complementary formula feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
62331541|NCT02531373|EXPERIMENTAL|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
62331542|NCT02531373|EXPERIMENTAL|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
62331543|NCT02531373|EXPERIMENTAL|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
62331544|NCT02531373|EXPERIMENTAL|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
62331545|NCT02531373|EXPERIMENTAL|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
62489414|NCT01229150|ACTIVE_COMPARATOR|KRAS Mut 1|KRAS Mutant patients randomized to monotherapy arm
62489415|NCT01229150|ACTIVE_COMPARATOR|WT KRAS 1|Wild-Type KRAS patients randomized to monotherapy arm
62694418|NCT06557811|OTHER|Semaglutide|2 groups: This group will receive semaglutide
62694419|NCT06557811|OTHER|Placebo|2 groups: This group will receive placebo (control population).
62694420|NCT04704648|OTHER|Surgical Excision|Treatment involves EXCISION ONLY (surgery) for the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP). Standard of care topical antibiotics are given for infection prevention following surgery. No drugs or device treatments are administered for treatment of OSSN in this protocol.
61936998|NCT06680258|EXPERIMENTAL|Active Arm|TPST-1120 600 mg by mouth (PO) twice daily (BID) with atezolizumab 1200 mg intravenously (IV) every 3 weeks (Q3W) and bevacizumab 15 mg/kg IV Q3W
61936999|NCT06680258|ACTIVE_COMPARATOR|Control Arm|Placebo tablets PO BID with atezolizumab 1200 mg IV Q3W and bevacizumab 15 mg/kg IV Q3W
61937000|NCT01367431||20 mg|Single dose 20 mg Xanthohumol
61937001|NCT01367431||60 mg|Single dose 60 mg Xanthohumol
62135986|NCT03570970|EXPERIMENTAL|Banapenem C2group|500mg Once daily for 7
62135987|NCT03570970|EXPERIMENTAL|Banapenem C3group|1000mg Once daily for 7
62135988|NCT01507935|ACTIVE_COMPARATOR|Intervention Group I|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I
62135989|NCT01507935|ACTIVE_COMPARATOR|Intervention Group II|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II
62331546|NCT02531373|EXPERIMENTAL|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
62331547|NCT02531373|EXPERIMENTAL|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
62331548|NCT02531373|EXPERIMENTAL|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
62331549|NCT02531373|ACTIVE_COMPARATOR|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
62331550|NCT03738566|ACTIVE_COMPARATOR|Standard Clinical Care Endoscopic Dilation Group|Following standard clinical care consisting of serial endoscopic dilation to achieve an esophageal diameter of at least 10 mm, subjects will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses which is the current standard of care. A relapse will be considered if a patient developed solid food dysphagia at least once a week.
62331551|NCT03738566|ACTIVE_COMPARATOR|Esophageal Self-Dilation Therapy (ESDT) Group|Following standard clinical care consisting of serial endoscopic dilation to achieve an esophageal diameter of at least 10 mm, subjects are instructed to perform esophageal self-dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months.
62331552|NCT03738566|OTHER|Observational Study Group|Subjects undergo either esophageal self-dilation therapy or continued standard of clinical care base on shared decision making with their esophageal provider.
62489416|NCT01229150|ACTIVE_COMPARATOR|WT KRAS 2|Wild-Type KRAS patients randomized to combination therapy arm
62489417|NCT03146143|EXPERIMENTAL|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
62489418|NCT03146143|NO_INTERVENTION|non ultrafiltration control group|no ultrafiltration will be applied in this group
62489419|NCT01202435|EXPERIMENTAL|Pregabalin controlled release, 82.5 mg|
62489420|NCT01202435|OTHER|Pregabalin immediate release, 25 mg|Reference Treatment
62489421|NCT00833534|EXPERIMENTAL|Group I (consolidation phase)|Patients receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62489422|NCT00833534|EXPERIMENTAL|Group II (consolidation phase)|Patients receive lenalidomide as in group I. Patients also receive rituximab IV once on the day before the start of lenalidomide and then once between days 25-30, 50-55, and 75-80 for a total of 4 doses in the absence of disease progression or unacceptable toxicity.
62489423|NCT01731457|EXPERIMENTAL|Etanercept|
62489424|NCT01731457|NO_INTERVENTION|Control|
62489425|NCT01216865|EXPERIMENTAL|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
62489426|NCT01216865|ACTIVE_COMPARATOR|Standard Therapy|Any therapy for diabetic foot which is routinely practiced and accepted in China
62489427|NCT03946436|EXPERIMENTAL|I-AVI|The I-AVI group were involved in a regular tennis training process, two times a week for one hour. Additionally right after the tennis lessons they played a Virtua Tennis 4 active video game for 20 minutes per participant. They use the playstation kinect console. The intervention lasted 6 months.
62489428|NCT03946436|ACTIVE_COMPARATOR|NO-AVI|The NO_AVI group were involved in a regular tennis training process, two times a week for one hour. The training process lasted 6 months.
62489429|NCT02663349|EXPERIMENTAL|Supported SCIT|Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One 2-hour group session will be offered once a week for 12 weeks. In addition, 30 minutes of individual training will be provided weekly by an instructor.
62135990|NCT01507935|PLACEBO_COMPARATOR|Control Group|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
62489430|NCT02666807|EXPERIMENTAL|Ginger|Ginger (Zingiber officinale Roscoe) 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
62489431|NCT02666807|PLACEBO_COMPARATOR|Placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks Placebo twice daily
62489432|NCT05702905|ACTIVE_COMPARATOR|metformin|About 25 subjects will be allocated to this group to receive metformin only, as the active comparator of semaglutide groups. Metformin used in this trial is Glucophage ( 500mg per tablet）produced by Bristol-Myers Squibb.The initial dose of metformin will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
62135991|NCT01507935|NO_INTERVENTION|Reference group|Exclusively breast-fed infants
62135992|NCT05369130||Develop Persistent Postsurgical Pain|Pain present 3 months post-op related to the surgical operation
62135993|NCT05369130||Absence of Persistent Postsurgical Pain|Resolution of post-operative pain within the first three months of the operation
62331553|NCT03738566|EXPERIMENTAL|Standard Clinical Care Endoscopic Dilation, Then ESDT|Subjects that received standard of clinical care endoscopic dilation who required two endoscopic dilations within 3 months of randomization were considered to have failed standard care and offered cross-over to the self-dilation therapy.
62331554|NCT05602259|EXPERIMENTAL|Eosinophil detection|Eosinophils will be measured in blood, sputum, bronchoalveolar lavage if available and biopsies.
62331555|NCT03563703|EXPERIMENTAL|Ultrasound imaging|Ultrasonography offers visual information about the size and depth of blood vessels, potentially facilitating intravenous placement of the needle in real time.
62331556|NCT03563703|EXPERIMENTAL|Near-infrared imaging|Near-infrared imaging devices project near-infrared light onto the skin, which is absorbed by deoxygenated hemoglobin. The invisible image of the underlying vascular pattern is captured by the device, processed and projected, in real time, back onto the patient's skin using visible green light. This technology allows hands-free visualization of a vascular map to guide catheter placement.
62489433|NCT05702905|EXPERIMENTAL|semaglutide|About 25 subjects will be allocated to this group to receive semaglutide only, as one of the experimental groups. Semaglutide used in this trial is WEGOVY (semaglutide) injection produced by Novo Nordisk. Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 1.0 mg is reached, and then maintained 1.0 mg until the end of treatment in total 12 weeks..
62489434|NCT05702905|EXPERIMENTAL|semaglutide and metformin|About 25 subjects will be allocated to this group to receive both semaglutide and metformin, as another of the experimental groups. Metformin used in this trial is Glucophage ( 500mg per tablet）produced by Bristol-Myers Squibb.The initial dose of metformin will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks. Semaglutide used in this trial is WEGOVY (semaglutide) injection produced by Novo Nordisk. Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 1.0 mg is reached, and then maintained 1.0 mg until the end of treatment in total 12 weeks.
62489435|NCT03317080||patients with lung cancer|patients with stages I-III lung cancer eligible for surgery
62135994|NCT04813133|EXPERIMENTAL|Synchronized Lifestyle Modification Program|Synchronized Lifestyle Modification Program
62135995|NCT04813133|EXPERIMENTAL|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronized Lifestyle Modification Program and Physiotherapy
62135996|NCT04813133|EXPERIMENTAL|Physiotherapy|Physiotherapy included Aerobics, Resistance exercise, Flexibility exercise, and Balance exercise.
62135997|NCT04813133|NO_INTERVENTION|Control Group|No intervention will be given to this Group
62135998|NCT03325218||Questionnaire Set A|
62135999|NCT03325218||Questionnaire Set B|
62136000|NCT02629224|EXPERIMENTAL|Renal impairment|
62136001|NCT02629224|EXPERIMENTAL|Haemodialysis|
62136002|NCT03676413|EXPERIMENTAL|Test (T)|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals
62136003|NCT03676413|ACTIVE_COMPARATOR|Reference (R)|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
62136004|NCT03676413|PLACEBO_COMPARATOR|Placebo|
62136005|NCT04876495|ACTIVE_COMPARATOR|Whey protein|Whey protein isolate (45.5g total protein content)
62136006|NCT04876495|ACTIVE_COMPARATOR|Potato protein|Potato protein isolate (45.3g total protein content)
62489436|NCT02054819|OTHER|Single arm study|"Induction chemotherapy and concurrent radiation to primary tumor Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions~Consolidation Radiation: therapy to metastatic sites At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites."
62489437|NCT04224584|ACTIVE_COMPARATOR|Duloxetine|Duloxetine is a serotonin-norepinephrine reuptake inhibitor. Duloxetine will be administrated as follows: 20 mg/daily duloxetinefor 1 week, 40 mg/daily duloxetine for 1 week, 60 mg/daily duloxetine for 10 weeks, 40 mg/daily duloxetine for 1 week, 20 mg/daily duloxetine for 1 week.
62489438|NCT04224584|PLACEBO_COMPARATOR|Placebo|Placebo will be administrated for 14 weeks.
62694421|NCT06645119|EXPERIMENTAL|Whey Protein Beverage|Chocolate flavoured whey protein supplement as a post-exercise recovery beverage. One beverage post-exercise. Dose based on participant body weight.
62694422|NCT06645119|SHAM_COMPARATOR|Control Beverage|Water beverage with calorie-free chocolate syrup as a post-exercise recovery beverage. Isovolumetric.
62694423|NCT05819801|ACTIVE_COMPARATOR|Fasting|Patients in the fasting group will be told to avoid any food past midnight the day before their surgery and any liquids 4 hours before their scheduled surgery.
62694424|NCT05819801|EXPERIMENTAL|Not Fasting|The eating group will be told specifically to eat a light meal (equivalent to two slices of toasted bread with butter and jam and one cup of coffee or juice) the morning of their surgery, within two hours of their procedure start time.
62694425|NCT05555329|EXPERIMENTAL|Group A; Pomalidomide 4 mg every other day in cycle 2|Group A (6 patients): Cycle 1: Pomalidomide 4 mg every day on day 1-21; Cycle 2: 4 mg every other day on day 1-21; Cycle 3: 2 mg every day on day 1-28. In Cycles of 28 days.
61937002|NCT01367431||180 mg|Single dose 180 mg Xanthohumol
61937003|NCT05428293|EXPERIMENTAL|Group A: Ibuprofen/ Acetaminophen oral suspension in fixed dose|Pharmaceutical Form: Oral Suspension Formula: Ibuprofen 100 mg/ Acetaminophen 125 mg/ 5 mL Dosage: 5 mL Administration way: oral
61937004|NCT05428293|ACTIVE_COMPARATOR|Group B: Ibuprofen oral suspension|Pharmaceutical Form: Oral Suspension Formula: Ibuprofen 2 g/100 mL Dosage: 5 mL (100 mg of ibuprofen) Administration way: oral
62331557|NCT05804305|ACTIVE_COMPARATOR|Misoprostol|600 mcg of Misoprostol per day in three divided doses was given to the patients in the treatment group for a period of two months
62331558|NCT05804305|PLACEBO_COMPARATOR|Placebo|Placebo was given to the patients three times daily for a duration of two months
62331559|NCT01253421|ACTIVE_COMPARATOR|MDD-amisulpride|Subjects experiencing a current episode of major depression who are randomized to receive amisulpride
62331560|NCT01253421|PLACEBO_COMPARATOR|MDD-placebo|Subjects experiencing a current episode of major depression who are randomized to receive placebo
62331561|NCT01253421|ACTIVE_COMPARATOR|HC-amisulpride|Subjects having no history of mental disorder (healthy controls, HC) who are randomized to receive amisulpride
62331562|NCT01253421|PLACEBO_COMPARATOR|HC-placebo|Subjects having no history of mental disorder who are randomized to receive placebo
62489439|NCT03595800|EXPERIMENTAL|haploidentical related donors|
62489440|NCT03595800|ACTIVE_COMPARATOR|Matched unrelated donor|
62489441|NCT00803816|OTHER|Addition of everolimus to standard care|refractive to cyclosporine A (CsA) received additional everolimus.
62694426|NCT05555329|EXPERIMENTAL|Group B; Pomalidomide 4 mg every other day in cycle 3|Group B (6 patients): Cycle 1: Pomalidomide 4 mg every day on day 1-21; Cycle 2: 2 mg every day on day 1-28; Cycle 3: 4 mg every other day on day 1-21. In Cycles of 28 days.
62694427|NCT05989269|NO_INTERVENTION|Control Period|Laboratory reporting of respiratory cultures will continue per regular or routine laboratory protocols (standard reporting).
62694428|NCT05989269|OTHER|Intervention|The lab will publish a modified report for respiratory cultures which do not meet clinical criteria for pneumonia and have growth of organisms (other than normal respiratory flora). The modified report will include the likelihood of colonization instead of reporting bacterial identification.
62694429|NCT04456673|EXPERIMENTAL|Dupilumab|Dupilumab administered every 2 weeks
62694430|NCT04456673|PLACEBO_COMPARATOR|Placebo|Placebo dose administered every 2 weeks
62697614|NCT03940248|EXPERIMENTAL|Early Stage Breast Cancer|Patients to be treated with Accelerated Partial Breast Irradiation utilizing pencil beam scanning proton therapy. Treatment will be delivered twice a day, at least 6 hours apart, over 5 treatment days.
61937005|NCT05428293|ACTIVE_COMPARATOR|Group C: Acetaminophen oral suspension|Pharmaceutical Form: Oral Suspension Formula: Acetaminophen 3.2 g/100 mL Dosage: 3.9 mL (125 mg of acetaminophen) Administration way: oral
62136007|NCT04876495|ACTIVE_COMPARATOR|Rice protein|Rice protein isolate (45.5g total protein content)
62136008|NCT05831865||DLBCL patients achieving CR or CMR during interim evaluation|During the interim evaluation, patients achieving complete response (CR) as determined by computed tomography (CT), or complete metabolic response (CMR) as determined by positron emission tomography-computed tomography (PET-CT), will be followed up for up to two years after completing the R-CHOP regimen followed by ASCT.
62489442|NCT05320237|EXPERIMENTAL|Virtual Reality Intervention|Eight weeks of two 30 minute sessions using virtual reality with the upper limb exercise games.
62489443|NCT05320237|NO_INTERVENTION|Control Group|Participants will be asked to continue with their usual care independent of this study.
62489444|NCT00874276|EXPERIMENTAL|No EGT Allele, slow metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
62697615|NCT06643403|EXPERIMENTAL|Arm 1|SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria Dose: min. 95.5%, breathing for max. 45 minutes
61937006|NCT05464173|EXPERIMENTAL|SAF|endocrinotherapy（doctor's choice） According to the drug insert abemaciclib 150mg or 100mg bid, Chidamide 10-30mg biw.
61937007|NCT01922674|NO_INTERVENTION|Watchful Waiting|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that do not have surgery
62694431|NCT01957384|EXPERIMENTAL|Treatment 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 1 are randomised to secondly test either:~1. Coloplast Test product 2 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~2. Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 2"
62694432|NCT01957384|EXPERIMENTAL|Treatment 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 2 are randomised to secondly test either:~1. Coloplast Test product 1 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~2. Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 1"
61937008|NCT01922674|ACTIVE_COMPARATOR|Standard open tension-free inguinal hernia repair with mesh|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that undergo a standard open tension-free repair with mesh.
62136009|NCT05831865||DLBCL patients achieving PR or PMR during interim evaluation|During the interim evaluation, patients achieving partial response (PR) as determined by CT, or partial metabolic response (PMR) as determined by PET-CT, and who are willing to receive Pola-R-CHP as the following treatment regimen followed by ASCT with Pola-BEAM as conditioning regimen, will also be followed up for up to two years.
62136010|NCT03803475|EXPERIMENTAL|Ga-68 labeled PSMA-11 PET PSMA|The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 millicurie (mCi) +/- 10% of 68Ga-PSMA-11.
62136011|NCT00328692|EXPERIMENTAL|2|
62136012|NCT00328692|PLACEBO_COMPARATOR|1|
62136013|NCT02499159|EXPERIMENTAL|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
62136014|NCT02499159|ACTIVE_COMPARATOR|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
62136015|NCT03509909|EXPERIMENTAL|Hatha yoga|12- week group-based yoga class
62489445|NCT00874276|EXPERIMENTAL|1+ EGT Allele, fast metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
62489446|NCT02260063|EXPERIMENTAL|Epinastine syrup|
62136016|NCT03509909|ACTIVE_COMPARATOR|Supportive exercise|12-week group-based stretching and strengthening class
62136017|NCT03001440||ZYBAN/WELLBUTRIN users|Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
62136018|NCT06101927|EXPERIMENTAL|Experimental: Prostate cancer 50 mkg|At least five (5) evaluable subjects with prostate cancer with \[99mTc\]Tc-BQ0413 (50 mkg)
62136019|NCT06101927|EXPERIMENTAL|Experimental: Prostate cancer 100 mkg|At leaAt least five (5) evaluable subjects with prostate cancer with \[99mTc\]Tc-BQ0413 (100 mkg)
62136020|NCT06086054|ACTIVE_COMPARATOR|Intervention|The intervention is comprised of two components to link randomized patients to our health system childcare facility: 1) navigation by the research assistant to the childcare facility and 2) placement of the facility EMR referral. Navigation will occur an eligible patient is randomized to the intervention group. Navigation will consist of the research assistant educating the patient about the childcare facility and providing information about how to access the childcare facility during the telephone contact and via mailed written materials.
62136021|NCT06086054|NO_INTERVENTION|Standard Care|Patients randomized to the control group will undergo current standard of care with regards to childcare, which currently consists of passive sources of information about our childcare facility (Parkland website, signage in the hospital, or via word of mouth). Currently, there is no formalized mechanism for patients referred to gynecology from primary care to receive information about childcare aside from the above passive sources of information.
62136022|NCT00810849|PLACEBO_COMPARATOR|Prednisolone|Six-week tapering course of prednisolone and those assigned to the prednisolone control arm will receive the same number of identically-coated placebo tablets.
62136023|NCT00810849|PLACEBO_COMPARATOR|Mycobacterium w|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months).
62136024|NCT01492049|EXPERIMENTAL|Patient Decision Aid (PtDA)|Participants view Patient decision aid (PtDA) video.
62136025|NCT01492049|ACTIVE_COMPARATOR|Control|Participants view a video on Essential Hypertension.
61937009|NCT02174354||Psoriasis|Patients with psoriasis taking methotrexate
61937010|NCT02643290|OTHER|Patients|Adult patients with low back pain secondary to an high degree scolisis are treated by fiting with a brace 2-4 hours a day and tracked for 6 months.
61937011|NCT06090591||Acute coronary syndrome - ACS|patients who were diagnosed with acute coronary syndrome: STEMI, non-STE ACS - NSTEMI and unstable angina, who underwent coronary angiography and were prescribed with optimal medicament therapy
62136026|NCT05737121|EXPERIMENTAL|VNX001|VNX001 (lidocaine HCl \[200 mg\] and heparin sodium \[50,000 USPU\] in alkalinized buffer), administered as a single dose via intravesical instillation; n=45 (anticipated)
62136027|NCT05737121|PLACEBO_COMPARATOR|Placebo|Alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
62489447|NCT02260063|ACTIVE_COMPARATOR|Epinastine tablets|
62489448|NCT02725580|EXPERIMENTAL|Open Label|Participants with diagnosis of vLINCL6 Batten disease will receive a single intrathecal injection of AT-GTX-501 into the lumbar spinal cord region.
61937012|NCT06090591||Transcatheter aortic valve implantation - TAVI|patients with aortic stenosis who underwent transcatheter percotaneous implantation of the arteficial aortic valve
62489449|NCT00630253|EXPERIMENTAL|Marrow Isolex|bone marrow processed using Isolex 300i (for patients enrolled through April 2010)
62489450|NCT00630253|EXPERIMENTAL|UCB|No processing Notes: sibling donor UCB is used as the stem cell source and co-enroll for unlicensed UCB registry
62489451|NCT00630253|EXPERIMENTAL|Marrow Clinimax|bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)
62489452|NCT06272643||Patients with Left Main Coronary Artery lesion (25-60%)|
62489453|NCT06628024|EXPERIMENTAL|Yoghurt|Yoghurt test product (Commercially available)
62489454|NCT06628024|OTHER|Milk|Commercially available product
62489455|NCT00637533|PLACEBO_COMPARATOR|Placebo|Saline injection
62489456|NCT00637533|EXPERIMENTAL|Botulinum Toxin Type A|Sympathetic Blockade containing Botulinum Toxin Type A
62489457|NCT02105220||Obese|"We will enroll patients with BMI≥40 kg/m2 to describe the impact of obesity on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
62694433|NCT01957384|EXPERIMENTAL|Treatment 3,First Standard care (see below)|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active) are randomised to secondly test either:~1. Coloplast Test product 1 and thereafter Coloplast Test product 2~2. Coloplast Test product 2 and thereafter Coloplast Test product 1"
62694434|NCT02249949|EXPERIMENTAL|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62694435|NCT06598761||Observation cohort|Patients in the observation group were T3-4 or N+ UTUC patients who were intolerant to chemotherapy or refused chemotherapy after radical surgery. No postoperative treatment was performed, and the patients were regularly rechecked.
62489458|NCT02105220||Intraabdominal Hypertension|"We will enroll patients with IAP≥12 mmHg to describe the impact of intraabdominal hypertension on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
62489459|NCT00925223||irritable bowel syndrome|patients with diarrhea-predominant IBS will be enrolled in this group.
62489460|NCT00925223||control group|patients with colon cancer or colon polyp will be enrolled as control group.
62136028|NCT05737121|EXPERIMENTAL|Lidocaine|Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation; n=45 (anticipated)
62136029|NCT05737121|EXPERIMENTAL|Heparin|Heparin sodium (50,000 USPU) in alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
62136030|NCT05768282|EXPERIMENTAL|Administration of oral prednisolone|Oral prednisolone start at a dose of 30 mg/day on the third day after RFA, and continue for 4 weeks.
62331563|NCT06250530|EXPERIMENTAL|BodyCAD|For participants randomized to BodyCAD Fine osteotomy, the HKA radiographs and CT scans will be sent to the manufacturer via a secure weblink as per SoC. The films will be used to calculate the desired correction and the instruments and implants manufactured accordingly. The mechanical medial proximal tibial angle (mMPTA) will be recorded for both pre- and planned post-operative situations and used to determine the accuracy of correction (primary outcome).
62489461|NCT04009447|OTHER|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) 6 sessions of Cognitive Behavioral Training for Insomnia (1 hour each).
62489462|NCT06042231|EXPERIMENTAL|Exercise Intervention|
62489463|NCT06042231|NO_INTERVENTION|Standard Care|
62489464|NCT04483596||M|will receive 5 mg melatonin orally at 9 p.m. the night before surgery and another 5 mg melatonin with 15 ml of plain water 30 min before operation and 5 mg melatonin at 9 p.m. in the day of operation and for the first three postoperative days
62489465|NCT04483596||C|received a placebo in the form of one tablet of 500 mg paracetamol that packaged the same way as melatonin at the same times
62489466|NCT06065280|EXPERIMENTAL|Diabetic/HFrEF Group|40 patients with diabetes mellitus patients will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin.
62489467|NCT06065280|EXPERIMENTAL|Nondiabetic/HFrEF Group|40 patients non-diabetes mellitus group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin.
62489468|NCT05915351|EXPERIMENTAL|Treatment|Enfortumab vedotin, 1.25 mg/kg IV on D 1,8,15 every 28 days
62489469|NCT04244760|ACTIVE_COMPARATOR|Verbal Patients|
62489470|NCT04244760|ACTIVE_COMPARATOR|Non-verbal Patients|
62489471|NCT03837327||Adnexal Mass|Women with an adnexal mass (pelvic mass) as confirmed by imaging
62489472|NCT04516915|EXPERIMENTAL|IMU-838 + Oseltamivir|Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days
62489473|NCT04516915|ACTIVE_COMPARATOR|Oseltamivir|Oseltamivir (75mg BID) for 14 days
62489474|NCT01007058||Response Markers|Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon
62489475|NCT06150196|EXPERIMENTAL|Mindfulness-based Stress Reduction class|Mindfulness-based Stress Reduction (MBSR) is a 9-week class that meets 2.5 hours/week and involves training in mindfulness (being present in the moment), meditation, and yoga. The MBSR course is taught by a certified MBSR instructor.
62694436|NCT06598761||Postoperative immunotherapy+radiotherapy|"Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used."
62694437|NCT04076709|NO_INTERVENTION|Standard Care|
62694438|NCT04076709|EXPERIMENTAL|Goal directed anesthesia|Deep neuromuscular blockade (post tetanic count 1-2 twitches) and nociception guided anaesthesia
62694439|NCT06571812||TSX dental implant system|treatment of tooth loss with TSX dental implants
62694440|NCT06517966||Retrospective branch|All patients diagnosed with recurrent pericarditis within the previous 10 years (of any genesis) were included.
62489476|NCT06150196|ACTIVE_COMPARATOR|Brain Health Education Class|the Brain Health Education Class is a 9-week class that meets 2.5 hours/week and involves lectures/discussion about how the brain works, how the brain ages, neuroplasticity, and other topics on the brain.
62489477|NCT02722395||Single arm cohort study|
62694441|NCT06517966||Prospective branch|"All patients with one of the following conditions were included:~* a specialist-confirmed diagnosis of recurrent pericarditis without an established etiology at the time of inclusion in the study (suspected idiopathic recurrent pericarditis);~* a specialist-confirmed diagnosis of idiopathic recurrent pericarditis."
62694442|NCT06211374|EXPERIMENTAL|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
62694443|NCT03890094||Sufentanil and Midazolam|Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study.
62694444|NCT02003703|EXPERIMENTAL|Recombinant Hepatitis B Virus Vaccine (High Dose)|Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
62694445|NCT02003703|ACTIVE_COMPARATOR|Recombinant Hepatitis B Virus Vaccine (Standard Dose)|Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
62694446|NCT04756232|EXPERIMENTAL|Anticholinergic Challenge|All participants will receive oral mecamylamine or IV scopolamine for 1 day
62694447|NCT04756232|PLACEBO_COMPARATOR|Placebo Challenge|All participants will receive oral placebo for 1 day
62694448|NCT02383823|ACTIVE_COMPARATOR|Estrogens in menopausal women|Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
62694449|NCT02383823|NO_INTERVENTION|Menopausal men|comparative to menopausal women, age span 45-55
61937013|NCT06090591||Venous thromboembolism - VTE|patients with pulmonary embolism and deep vein thrombosis, with a focus on those who underwent thromboaspiration due to high or medium-high risk pulmonary embolism
62331564|NCT06250530|ACTIVE_COMPARATOR|TOMOFIX|For participants randomized to the TOMOFIX system, preoperative planning will use the HKA radiograph. DICOM images will be transported to MEDICAD software program in which alignment angles and alignment correction will be calculated. The mMPTA will again be utilised to determine the accuracy of correction (primary outcome). The preop CT scan will also be used as per the BodyCAD system and the same indices calculated so as to minimise measurement bias between two different imaging modalities. However, the results of the preoperative 3D CT planning will not be made available to the operating surgeon, again to minimise bias between groups.
62331565|NCT05790811|EXPERIMENTAL|patient-oriented video|A patient-oriented video with the goal of instructing patients about the maneuvers needed to make specific diagnoses of the hand and wrist. Wording was changed so that it was more patient friendly and text was added to the screen.
62331566|NCT05790811|ACTIVE_COMPARATOR|physician-oriented training video|A physician-oriented video with the goal of instructing physicians on the maneuvers needed to make specific diagnoses of the hand and wrist.
62331567|NCT05831670|EXPERIMENTAL|KSP-0243|Under double-blinding, KSP 0243 tablets will be orally administered.
62331568|NCT05831670|PLACEBO_COMPARATOR|Placebo|Under double-blinding, placebo tablets will be orally administered.
62331569|NCT01241669|EXPERIMENTAL|Arm 1|
62331570|NCT01241669|EXPERIMENTAL|Arm 2|
62331571|NCT02813798|EXPERIMENTAL|Mild Renal Impairment|A single dose of IV Rivipansel over 20 minutes
62331572|NCT02813798|EXPERIMENTAL|Moderate Renal Impairment|A single dose of IV Rivipansel over 20 minutes
62331573|NCT02813798|EXPERIMENTAL|Severe Renal Impairment|A single dose of IV Rivipansel over 20 minutes
62331574|NCT02813798|EXPERIMENTAL|Normal Renal Functions|A single dose of IV Rivipansel over 20 minutes
62331575|NCT06084390|EXPERIMENTAL|Interdisciplinary rehabilitation + booster-session (intervention)|Standard care by the interdisciplinary rehabilitation teams in primary healthcare + extended access to the team and a booster visit after 3 months.
62331576|NCT06084390|ACTIVE_COMPARATOR|Interdisciplinary rehabilitation (control)|Standard care by the interdisciplinary rehabilitation teams in primary healthcare.
62331577|NCT00626912|ACTIVE_COMPARATOR|1|platinum coils
62331578|NCT00626912|ACTIVE_COMPARATOR|2|hydrogel coils
62331579|NCT01620385|EXPERIMENTAL|ciPDA|
62331580|NCT01636024|EXPERIMENTAL|1|Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
62489478|NCT01633281|EXPERIMENTAL|acupuncture treatment|
62489479|NCT05206838|EXPERIMENTAL|Surgical reconstruction|22 patients undergo surgical reconstruction of gluteus medius with allograft consisting of Achilles tendon with calcaneus block. The calcaneus block is fixed into the greater trochanter and the Achilles tendon i passed through the gluteus medius muscle, tensioned and sutured into the muscle. Postoperatively, partial weight bearing for 2 months followed by physiotherapy for 10 months.
62489480|NCT05206838|NO_INTERVENTION|Physiotherapy|22 patients receive non-operative treatment for their limp with physiotherapy alone during a 12-month period.
61937014|NCT06090591||Heart failure with SGLT2 inhibitor therapy included - HF-SGLT2|patients with heart failure with reduced, mid-reduced and preserved systolic function who were prescribed with a SGLT-2 inhibitor therapy, and other optimal medicament therapy for HF
61937015|NCT06090591||Cardiac implantable electronic device - CIED|patients who were implanted with a cardiac implantable electronic device: pacemaker, conduction system pacing device, cardioverter-defibrilator or cardiac resynchronization therapy with or without defibrilator option
62331581|NCT01636024|PLACEBO_COMPARATOR|2|Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
62489481|NCT04967170|EXPERIMENTAL|Platelet Rich Plasma Group|Subject diagnosed with vulvar lichen sclerosus will receive Autologous Platelet-Rich Plasma (PRP)
62489482|NCT04967170|SHAM_COMPARATOR|Sham Procedure Group|Subject diagnosed with vulvar lichen sclerosus will receive sham procedure of intralesional needle insertion without any injectate administered.
62489483|NCT00672373|EXPERIMENTAL|A|Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
62489484|NCT00672373|PLACEBO_COMPARATOR|B|Matching placebo treatment
62694450|NCT02383823|NO_INTERVENTION|Elderly women|comparative to menopausal women, age span 65-80
62489485|NCT03157115|EXPERIMENTAL|Impaired left ventricular ejection fraction|Patients with reduced left ventricular ejection fraction (\< 50 %)
62489486|NCT03157115|ACTIVE_COMPARATOR|Control|Patients with a normal left ventricular ejection fraction (≥ 50 %), without heart failure. The patients from the reduced left ventricular ejection fraction group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
62489487|NCT02025660|EXPERIMENTAL|Mw|
62489488|NCT02025660|PLACEBO_COMPARATOR|Saline; 0.3 ml x three days sc|
62489489|NCT01186835|EXPERIMENTAL|Combination Botulinum Toxin A and Hyaluronic Acid|One side of face treated with the combination of Botulinum Toxin A and Hyaluronic Acid injections.
62489490|NCT01186835|ACTIVE_COMPARATOR|Botulinum Toxin A alone|Other side of face treated with =Botulinum Toxin A injection alone.
62489491|NCT04413799|ACTIVE_COMPARATOR|lidocaine/ ketamine infusion|Lidocaine/ ketamine infusion will be monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
62489492|NCT04413799|ACTIVE_COMPARATOR|paravertebral block with ropivacaine|Paravertebral block catheter will be placed by Anesthesiology led Acute Pain Service. Once the catheter is inserted, a ropivacaine bolus and infused with ropivacaine, monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
62489493|NCT05121194|ACTIVE_COMPARATOR|ZOOM Video Conference Participants|Participants will be offered the opportunity to join one of two weekly meeting times. Participants will be sent a link to join a Zoom videoconference session at the outset of each week, allowing them to log in at their chosen timeslot. These meeting times will be arranged based on discussions with the PAC around optimal timeslots for their shift workers. Sessions will be 90 minutes in length and will be facilitated by a minimum of 2 trained clinician facilitators and 1 research assistant. The session will include a PowerPoint presentation of the CBTm material in a lecture format. Participants will be invited and encouraged to discuss, comment and ask questions of the facilitators about the material throughout the presentation. Homework will be assigned each session relating to the material that was covered. Participants will have 1 week to work through and practice the skills learned, and this homework will be discussed at the next session.
62694451|NCT02383823|NO_INTERVENTION|Elderly men|comparative to menopausal women, age span 65-80
62694452|NCT02383823|PLACEBO_COMPARATOR|Placebo in menopausal women|Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
62694453|NCT06674850||Diseased group|36 patients with acute lymphoblastic leukemia will be included
62694454|NCT06674850||Control group|36 healthy people will be included
62694455|NCT06642428|EXPERIMENTAL|Neoadjuvant therapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
62694456|NCT06642428|OTHER|Neoadjuvant therapy|Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
62694457|NCT06641791|ACTIVE_COMPARATOR|Standard Radiotherapy (SRT)|
62694458|NCT06641791|EXPERIMENTAL|Stereotactic Body Radioterapy (SBRT)|
62694459|NCT05176665|EXPERIMENTAL|Phase Ib and Phase II|The study will consist of Phase Ib and Phase II. The study is planning to recruit approximately 152 patients in total for advanced/metastatic GI cancers, which include 24 patients in Phase Ib and up to approximately 128 patients in Phase II. For GC, HCC, and BTC groups, up to approximately 24 patients may be enrolled in Phase Ib and Phase II. For CRC group, up to approximately 80 patients may be enrolled in Phase Ib and Phase II with up to 40 patients in each subgroup.
62694460|NCT00989495|EXPERIMENTAL|Brace - Randomized|Participants were randomized to be braced
62694461|NCT00989495|NO_INTERVENTION|Observation - Randomized|Participants were randomized to be observed only
62694462|NCT00989495|EXPERIMENTAL|Brace - preference based|Participants chose to be braced
62331582|NCT01240811|NO_INTERVENTION|Control-No IUD|Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.
62331583|NCT01240811|EXPERIMENTAL|Levonorgestrel IUS|Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
62331584|NCT01240811|EXPERIMENTAL|Copper T380A IUD|Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
62331585|NCT00414310|EXPERIMENTAL|Decitabine|Decitabine 20 mg/m\^2 intravenous (IV) over 1 hour daily for 5 days.
62331586|NCT00414310|EXPERIMENTAL|Decitabine + Valproic Acid|Decitabine 20 mg/m\^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.
62331587|NCT04716192|EXPERIMENTAL|Positional release technique|Positional release technique, Mayofascial release technique and ultrasound
62331588|NCT04716192|ACTIVE_COMPARATOR|Mayofascial release technique and ultrasound|Mayofascial release technique and ultrasound
62331589|NCT06553417|EXPERIMENTAL|Aqua posae + microresyl|• Participants in this arm will receive the moisturizer formulation containing aqua posae and microresyl.
62331590|NCT06553417|ACTIVE_COMPARATOR|10% Urea|• Participants in this arm will receive the moisturizer formulation containing 10% urea.
62331591|NCT00103194|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62331592|NCT02020031|EXPERIMENTAL|Vancomycin 500mg intraosseous|Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
62694463|NCT00989495|NO_INTERVENTION|Observation - preference-based|Participants chose to be observed only
62694464|NCT06264154|EXPERIMENTAL|Fruit-flavored E-cigarettes|Participants randomized to fruit-flavored e-cigarettes will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study provided e-cigarette device and fruit-flavored nicotine pods. Participants will be able to choose between blueberry or watermelon-flavored pods. They will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
62694465|NCT06264154|ACTIVE_COMPARATOR|Tobacco-flavored E-cigarettes|Participants randomized to tobacco-flavored e-cigarettes will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study provided e-cigarette device and tobacco nicotine pods. Participants will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
62694466|NCT06264154|ACTIVE_COMPARATOR|Menthol-flavored E-cigarettes|Participants randomized to menthol-flavored e-cigarettes will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study provided e-cigarette device and menthol nicotine pods. Participants will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
62694467|NCT02184286|EXPERIMENTAL|Nevirapine + Saquinavir-sgc|
62694468|NCT05660187|EXPERIMENTAL|Telehealth care|Telehealth visits will be performed using institutionally-approved, secure, web-based teleconferencing. The standard neurology visits will occur every 6 months with their established neurology clinician via telehealth. The comprehensive care will be offered via telehealth or within the patient's local community. The comprehensive care visits will be adapted for the individual participants' needs and symptoms, consistent with standard clinical care.
62136031|NCT04110743|OTHER|delayed imaging acquisition|10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
62136032|NCT04110743|OTHER|low FDG dose imaging|0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
62331593|NCT02020031|ACTIVE_COMPARATOR|Vancomycin 1g IV|Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
62331594|NCT02118610|EXPERIMENTAL|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
62694469|NCT05660187|ACTIVE_COMPARATOR|In-Clinic care|Standard neurology visits will be conducted in-clinic visits every 6 months with their established neurology clinician. The comprehensive MS care visits will be conducted in-clinic. The comprehensive care visits will be adapted for the individual participants' needs and symptoms, consistent with standard clinical care.
62694470|NCT06200441||Developing GVHD|Group of patients who developed GVHD during follow-up in patients who underwent allogeneic hematopoteic stem cell transplantation for AML
62694471|NCT06200441||non-GVHD|Group of patients who did not develop GVHD during follow-up in patients who received allogeneic hematopoteic stem cell transplantation for AML
61937016|NCT06090591||Arrhythmias|patients who underwent electrophysiology study, including PVI for atrial fibrillation, as well as SVT ablations, and ventricular arrhythmia ablation (both premature ventriclar beats and ventricular tachycardia ablation in ischsmic and non-ischemic cardiomyopathy).
61937017|NCT03126370|EXPERIMENTAL|TAF with a boosted PI and LDV/SOF|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for the next 12 weeks.~After taking TAF/FTC for 12 weeks, participants will then start taking ledipasvir 90mg/sofosbuvir 400mg (LDV/SOV, Harvoni) in combination with TAF/FTC and a boosted protease inhibitor for 4 weeks.~Participants will then return to taking TAF/FTC with a boosted protease inhibitor for the final 12 weeks of the study."
62697616|NCT06028464|EXPERIMENTAL|BI 1810631 (reference) and BI 1810631 + carbamazepine (test)|
61937018|NCT01090973|EXPERIMENTAL|Oral drug treatment|LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 \& 5, then 8, 10 \&12, then 15, 17 \& 19, then 22, 24 \& 26.
61937019|NCT02556736|EXPERIMENTAL|Group 1|Single intravitreal injection of RST-001
61937020|NCT04350606|EXPERIMENTAL|PF-006462700 group|All enrolled participants will be administrated PF-006462700.
62331595|NCT02118610|PLACEBO_COMPARATOR|Sugar Pill|
62331596|NCT05892133|EXPERIMENTAL|Maximal strength training|eight weeks of leg press strength training prior to knee surgery
61937021|NCT04925271|EXPERIMENTAL|X-Tack|The gastrointestinal tract mucosal or submucosal defect is closed using the X-Tack device.
62331597|NCT05892133|NO_INTERVENTION|Control|treatment as usual prior to knee surgery
62331598|NCT04973033|EXPERIMENTAL|Tofactitinib|Tofacitinib 5mg twice a day
62331599|NCT03957109|OTHER|general anesthesia|general anesthesia
62331600|NCT03957109|OTHER|spinal anesthesia|spinal anesthesia
62331601|NCT05718154||Assault-Induced Trauma Patients in Suez Canal University Hospital-Trauma Unit|"Total coverage of all patients fulfilled the inclusion criteria~* From April 2023 to September 2023 in Suez Canal University Hospital, Emergency Department."
62331602|NCT05718154||Assault-Induced Trauma Patients in Assiut University Hospital-Trauma Unit|"Total coverage of all patients fulfilled the inclusion criteria~* From October 2023 to March 2024 in Assiut University Hospital, Trauma Unit."
62694472|NCT06297902|EXPERIMENTAL|Dose painting|Radiation dose will be escalated to the hypermetabolic part of the tumor (maximum point dose 83.3 Gy), shown in pre-treatment FDG-PET images. Dose escalation will be applied to these regions during the first half of the fractionated treatment (17 of 34 fractions).
62694473|NCT06297902|NO_INTERVENTION|Standard radiotherapy|Homogeneous dose to the tumor.
62694474|NCT00661180|EXPERIMENTAL|Arm 1|
62694475|NCT04665245||COVID-19 Positive Patients|The study only includes one cohort: COVID-19 positive patients. Enrollees will not receive any therapeutic intervention; participants will simply report their temperature and any symptoms experienced twice per day for 10 days.
62136033|NCT04110743|OTHER|comparison PET images reconstructed using CT-based attenuation|10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
62694476|NCT02416544|EXPERIMENTAL|Full participation|Participants in this group receive lunch which is calorie-restricted and low-salt during 12 weeks, the total duration of this study.
62694477|NCT02416544|EXPERIMENTAL|Two thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 4 weeks from the beginning of the study and maintain the diet during 8 weeks.
62694478|NCT02416544|EXPERIMENTAL|One thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 8 weeks from the beginning of the study and maintain the diet during 4 weeks.
62694479|NCT03673982|EXPERIMENTAL|iCASK Group|Materials and support to aid transitions.
62694480|NCT05961735||Patients with PECS II Block|PECS 2 block will be applied to patients in this group.
62694481|NCT05961735||Patients with Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block will be applied to patients in this group.
62694482|NCT06154525|PLACEBO_COMPARATOR|Control Group (CC)|The control group receives RO water with a dosage of 1 ampoule per time, 2 times per day for 28 days.
61937022|NCT04925271|ACTIVE_COMPARATOR|Overstitch|The gastrointestinal tract mucosal or submucosal defect is closed using the Overstitch device.
62136034|NCT02494336|ACTIVE_COMPARATOR|Trans-incisional rectus sheath block|rectus sheath block under direct visualization through the umbilical incision by the attending surgeon
62136035|NCT02494336|ACTIVE_COMPARATOR|Laparoscopic guided rectus sheath block|rectus sheath block under direct laparoscopic visualization by the attending surgeon
62136036|NCT06359548|EXPERIMENTAL|Reposition Group|Peeled ILM Reposition
62136037|NCT06359548|ACTIVE_COMPARATOR|Peeling Group|ILM Peeling
62136038|NCT02299349|EXPERIMENTAL|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
62331603|NCT02437097|EXPERIMENTAL|Aerobic Exercise|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 - their age. The aerobic exercise will utilize a Monarch 818E Monarch Lower Body Ergometer (Monark Exercise, Stockholm, Sweden). Participant's heart rate will be monitored using Polar heart rate monitor.
62331604|NCT02437097|EXPERIMENTAL|Video Gaming|Participants will play Brain Age: Train Your Brain in Minutes a Day! on Nintendo 3DS for 30 minutes in a seated resting position.
62694483|NCT06154525|EXPERIMENTAL|Preg-Mom Group (AA)|The Preg-Mom group receives RO water plus B. subtilis, B. clausii, and B. coagulans at 3 billion CFU/5 mL (LiveSpo® Preg-Mom) with a dosage of 1 ampoule per time, 2 times per day for 28 days.
62694484|NCT06154525|EXPERIMENTAL|KIDS Group (BB)|The KIDS group receives RO water plus B. subtilis and B. clausii at 3 billion CFU/5 mL (LiveSpo® KIDS) with a dosage of 1 ampoule per time, 2 times per day for 28 days.
62694485|NCT05059665||HCC Subjects|"All subjects will be recently diagnosed with hepatocellular carcinoma as defined by at least one of the following criteria:~* Subject has a ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance by MRI and/or CT.~* Subject has a lesion of any size indicated to be HCC due to capsule appearance by 4 phase CT scan and/or multiphase contrast enhanced MRI.~* Subjects with a suspicious lesion of less than 2 cm must have HCC confirmed by both MRI and CT.~* Subject has a biopsy that is positive for HCC.~* Diagnostic imaging by multiphasic MRI or CT indicates a suspicious lesion on the liver, which is subsequently confirmed to be HCC by another method (biopsy, or surgical pathology)."
62694486|NCT05059665||Surveillance Subjects|At-risk subjects with chronic liver disease undergoing routine imaging surveillance for HCC.
62694487|NCT06064617|EXPERIMENTAL|Center Distance Multifocal Contact Lens|All participants will wear a Biofinity center distance multifocal contact lens with a +2.50 add and measurements will be obtained.
62697617|NCT03078868|EXPERIMENTAL|Single-point intervention|magnetic resonance scanner
61937023|NCT05137990|EXPERIMENTAL|HIIT Exercise Intervention|At home (N=12): Participants will complete an exercise session 3 times a week for 14 weeks. Each participant will receive a pre-assembled stationary bicycle to use to complete each session, an iPad to receive the intervention virtually from exercise trainers through Zoom, and a Fitbit to assess real-time heart rate.
62136039|NCT02299349|ACTIVE_COMPARATOR|concentrated multi drug injection|concentrated multi drug periarticular injection
62136040|NCT01099566|EXPERIMENTAL|Prasugrel|
62136041|NCT01099566|PLACEBO_COMPARATOR|pills consisting of lactose-starch|
62136042|NCT04541797|PLACEBO_COMPARATOR|Control|Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
62331605|NCT02437097|EXPERIMENTAL|Aerobic Exercise and Video Gaming|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 minus their age on a Monarch ergometer while playing Brain Age: Train Your Brain in Minutes a Day! on a Nintendo 3DS. Participant's heart rate will be monitored using Polar heart rate.
62331606|NCT02437097|PLACEBO_COMPARATOR|Control|Participants will sit quietly for 30 minutes
62331607|NCT04505696|OTHER|Speech-Language Pathology Introduction and scope|Demographic Information Section on Knowledge \& Awareness Section on Practices
62694488|NCT06064617|EXPERIMENTAL|Center Near Multifocal Contact Lens|All participants will wear a Biofinity center near multifocal contact lens with a +2.50 add and measurements will be obtained.
62136043|NCT04541797|EXPERIMENTAL|Intervention|Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
62136044|NCT02586272|EXPERIMENTAL|Daifert|• Interventional Group: The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
62136045|NCT02586272|OTHER|Control Group|Control Group: The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
62136046|NCT00781469||Naive patients|12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
62136047|NCT00781469||Patients in remission|6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
62331608|NCT01094002|EXPERIMENTAL|Occupational therapy intervention (OTI)|198 subjects. The OTI schedule consisted of a daily 45-minute session, Monday through Friday, for the duration of hospitalisation. Activities were carried out in a structured manner and varied according to need and day of admission. On the first day, the patient's needs were analysed, including the need for iatrogenic prevention, retraining in basic and instrumental activities of daily living, technical aids, instruct the primary caregiver in patient mobilisation techniques, and social and occupational motivation. All OTI participants received an average of 5 sessions during hospitalisation.
62331609|NCT01094002|NO_INTERVENTION|Conventional treatment model group|202 subjects. All subjects received medical treatment, nursing care, physical therapy, and social assistance in accordance with the usual practice of the geriatrics unit.
62331610|NCT02572518||2 doses of yellow fever vaccine|30 days,1-5 years and 6 years or more after last dose
62331611|NCT02028546|EXPERIMENTAL|Water|The patients in water group were soaking an arm for 10 minutes with tap water before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.)
62331612|NCT02028546|EXPERIMENTAL|mild cleanser|The patients in mild cleanser group were soaking an arm for 10 minutes with mild cleanser before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.) Non soap base cleanser contained Sodium Cocoyl Isethionate was used in this mild cleanser arm.
62331613|NCT02074579|EXPERIMENTAL|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
62331614|NCT02074579|PLACEBO_COMPARATOR|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
62331615|NCT05796427|EXPERIMENTAL|START Intervention|Participants in the experimental group will be part of a 6-module weekly intervention where they will learn more about ADHD and its treatment.
62331616|NCT05796427|NO_INTERVENTION|Educational Brochure|Participants in the control group will receive an educational brochure by Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD).
62694489|NCT05406401|EXPERIMENTAL|Zilovertamab Vedotin + R-CHP: Dose Escalation/Confirmation|Participants in the dose escalation/confirmation phase receive a dose level of zilovertamab vedotin (from 1.5 mg/Kg up to 2.5 mg/Kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar (truxima) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 8 cycles (up to approximately 5.5 months). Participants also receive 100 mg prednisone or prednisolone per day during Days 1-5 of each 21-day cycle for up to 8 cycles (up to approximately 5.5 months).
62136048|NCT00781469||Patients still have active disease|12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2
62136049|NCT01805219||healthy subjects|
62136050|NCT03956628|EXPERIMENTAL|experimental group|participants in experimental group receive intervention and experimental group consists of two sub groups, teachers and students.
62136051|NCT03956628|NO_INTERVENTION|control group|participants in control group does not receive intervention and control group consists of two sub groups, teachers and students.
62136052|NCT04612868|EXPERIMENTAL|AEYE Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
62136053|NCT00879710|OTHER|Subjects with type 1 diabetes mellitus, option 1|"Half the subjects will start with arm (i.e. every other subject in order)~* Simvastatin 40 mg tablet by month daily for 6 weeks,~* 4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~* Ezetimibe 10 mg by month for 6 weeks~* 4 weeks washout period~* Simvastatin 40 mg tablet by month daily for 6 weeks"
62136054|NCT00879710|OTHER|Subjects with type 2 diabetes mellitus option 1|"Half the subjects will start with arm (i.e. every other subject in order)~* Simvastatin 40 mg tablet by month daily for 6 weeks,~* 4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~* Ezetimibe 10 mg by month for 6 weeks~* 4 weeks washout period~* Simvastatin 40 mg tablet by month daily for 6 weeks"
62136055|NCT00879710|OTHER|Subjects with type 1 diabetes mellitus, option 2|"Half the subjects will start with arm (i.e. every other subject in order)~* Ezetimibe 10 mg by month for 6 weeks,~* 4 weeks washout period"
62136056|NCT00879710|OTHER|Subjects with type 2 diabetes mellitus option 2|"Half the subjects will start with arm (i.e. every other subject in order) Ezetimibe 10 mg by month for 6 weeks,~•4 weeks washout period"
62136057|NCT04218383|ACTIVE_COMPARATOR|Experimental: Active Left OFC Group|2mA will be applied for 20 minutes with the tDCS anode applied to the left OFC and Cathode applied to the right primary motor cortex.
62697618|NCT05470166|EXPERIMENTAL|infusion of intraoperative lidocaine to patients undergoing whipple surgery|lidocaine 1.5mg/kg infused as bolus, then 2mg/kg/hr through the operation
62697619|NCT05470166|EXPERIMENTAL|saline infusion of same volume of lidocaine|same amount of normal saline infused as bolus and infusion
62136058|NCT04218383|SHAM_COMPARATOR|Sham Comparator: Sham left OFC Group|Current will be ramped up for 30s followed by a 30s ramp down to mimic the physical sensation of stimulation and habituation. The anode placed over the left OFC and cathode placed over the right primary motor cortex.
62489494|NCT05121194|ACTIVE_COMPARATOR|WEB Online CBTm Course Participants|Participants will receive access to the online self-guided CBTm course. The material is identical to the material taught in the facilitator-led group. Participants will receive access to the Class 1 upon joining the study at which point they can move through the material. The material is presented in a slide show format with pre-recorded audio to accompany each slide, in accordance with the material covered for in person classes. Material may be completed in a single sitting or they can choose to pause and return to it at a later time. Homework will be assigned as in Arm 1, through online forms at the end of each class. If a participant has questions, they can use a 'contact us' button, allowing questions to be sent to our research team. One week after completion of Class 1, participants will receive access to Class 2. The one-week timeframe prior to accessing the next class is used to mirror the timeline in the facilitator-led groups (Arm 1)
62489495|NCT05121194|NO_INTERVENTION|WAIT participants|(WAIT) participants will be assigned to a waitlist control. These individuals will not receive any type of active intervention but will continue to receive mental health questionnaires to complete in line with the ZOOM and WEB participants at weekly intervals. These individuals will be offered a choice of videoconference CBTm or online CBTm at completion of their waitlist period (6 months).
62489496|NCT02805166|EXPERIMENTAL|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
62694490|NCT05406401|EXPERIMENTAL|Zilovertamab Vedotin + R-CHP: Efficacy Expansion|Participants in the efficacy expansion phase receive the RP2D of zilovertamab vedotin plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar (truxima) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 8 cycles (up to approximately 5.5 months). Participants also receive 100 mg prednisone or prednisolone per day during Days 1-5 of each 21-day cycle for up to 8 cycles (up to approximately 5.5 months).
62331617|NCT04106427|EXPERIMENTAL|cTBS plus SCRT|10 daily sessions of continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
62331618|NCT04106427|PLACEBO_COMPARATOR|Placebo plus SCRT|10 daily sessions of placebo continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
62331619|NCT04106427|SHAM_COMPARATOR|Sham SCRT|16 sessions of sham social cognitive remediation therapy (SCRT) twice per week over an eight week period. Participants will engage in non-effective group activities
62331620|NCT01540461|EXPERIMENTAL|Arm: Brivanib|
62331621|NCT02164513|EXPERIMENTAL|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
62331622|NCT02164513|EXPERIMENTAL|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
62331623|NCT02164513|EXPERIMENTAL|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
62331624|NCT04177056|EXPERIMENTAL|Stereotactic Body Radiotherapy|High dose SBRT to lesion(s) of interest.
62331625|NCT01935687|EXPERIMENTAL|Using of instrumented wheel and ergometer roller|The same patient will receive two types of tests: instrumented wheel and ergometer roller.
62694491|NCT06531018|EXPERIMENTAL|Eltrombopag Arm|Eltrombopag + Prednsolone
62694492|NCT06531018|PLACEBO_COMPARATOR|Prednisolone alone arm|Placebo + Prednisolone
62694493|NCT06640686|EXPERIMENTAL|Inspiratory Muscle Training Group|Inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device.
62694494|NCT06640686|ACTIVE_COMPARATOR|Traditional Physiotherapy Group|The control group will receive the traditional physical therapy program.
62694495|NCT05634811|EXPERIMENTAL|VLA15|Participants will receive 6-valent OspA-based Lyme disease vaccine (VLA15).
62694496|NCT05634811|PLACEBO_COMPARATOR|Normal Saline (Placebo)|Participants will receive 0.9% sodium chloride solution for injection
62694497|NCT06631391|EXPERIMENTAL|Treatment with umbilical cord blood NK cells|All subjects will receive Ex vivo Expanded and activated umbilical cord blood NK cells infusion.
62694498|NCT04548219|EXPERIMENTAL|Mirikizumab (Reference)|200 milligram (mg) of mirikizumab as reference formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a subcutaneous (SC) injection into the arm/thigh/abdomen on day 1.
62694499|NCT04548219|EXPERIMENTAL|Mirikizumab (Test)|200 mg of mirikizumab as test formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a SC injection into the arm/thigh/abdomen on day 1.
62694500|NCT05883709||Cohort 1|Tafa combination therapy group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitors, Tafa combined with Lenalidomide plus chemotherapy (including ADC)
62694501|NCT05883709||Cohort 2|Tafa combination therapy group followed by sequential CAR T or transplantation
62697620|NCT00835549|EXPERIMENTAL|1|
62697621|NCT00835549|ACTIVE_COMPARATOR|2|
62331626|NCT01996137|EXPERIMENTAL|VASST II|Stroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24
62331627|NCT03201172||Univation® X|
62331628|NCT03201172||iUni®|
62331629|NCT01746732|EXPERIMENTAL|Ortho-Cyclen|Ortho-Cyclen (35 microgram (mcg) ethinyl estradiol and 250 mcg norgestimate) administered orally, once daily (QD), for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) in one of two treatment periods. Treatment A
62331630|NCT01746732|EXPERIMENTAL|Ortho-Cyclen + Evacetrapib|Ortho-Cyclen administered orally, QD, for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) and 130 mg evacetrapib orally, QD, for 21 days (Days 1 to 21) in one of two treatment periods. Treatment B
62331631|NCT05126524||Loco-regional Anaesthesia in Video or Robot-assisted Thoracic Pulmonary Surgery|Patients with loco-regional Anaesthesia in Video or Robot-assisted Thoracic Pulmonary Surgery are eligible for this study
62331632|NCT02249234|EXPERIMENTAL|Botox|Botox 200 units reconstituted in 10ml of normal saline for a one-time injection
62331633|NCT02249234|PLACEBO_COMPARATOR|Saline|Saline 10ml of normal saline for a one-time injection
62489497|NCT04609280|EXPERIMENTAL|Reduced C/L elective nodal volume|All patients will receive the reduced C/L elective nodal volume as described. Treatment will be delivered via IMRT/VMAT or PBPT.
62489498|NCT01669980|EXPERIMENTAL|Ceftaroline fosamil|
62489499|NCT01669980|ACTIVE_COMPARATOR|IV Ceftriaxone and Vancomycin|
62489500|NCT04762069|EXPERIMENTAL|Berubicin|"Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base as a 2 hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days)~Each treatment cycle is 21 days. Subjects will be allowed to continue on treatment at the discretion of the Investigator if there is no evidence of disease progression and the subject is not experiencing unacceptable toxicity as well as if both the subject and Investigator agree that further therapy is in the subject's best interest."
62489501|NCT04762069|ACTIVE_COMPARATOR|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules will be administered at the institutionally-approved dose and regimen or per the full prescribing information/summary of product characteristics.
62331634|NCT03314519|EXPERIMENTAL|Ultrasonography|Patients in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering pleural cavity.
62331635|NCT03314519|ACTIVE_COMPARATOR|Fiberoptic bronchoscopy|Patients in this group receive fiberoptic bronchoscope to detect lung collapse after inserting a double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering the pleural cavity.
62489502|NCT01059058|ACTIVE_COMPARATOR|Test Group A: MI Paste Plus Group|
62489503|NCT01059058|ACTIVE_COMPARATOR|Test Group B: Fluoride Varnish Group|
62489504|NCT01059058|PLACEBO_COMPARATOR|Control Group|
62489505|NCT06064435||Tetral Coil Group|Intracranial Aneurysm patients who treated with Target Tetra® coils (70% or more of packing density)
62489506|NCT03986463||Cohort 1|"1. Stage III NSCLC as per the American Joint Committee on Cancer 8th edition (AJCC 8th ed.)~2. Appropriate to undergo concurrent chemotherapy and radiation~3. Planned radiation dose must be between 54 and 66 Gy~4. Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~5. Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~6. No prior system chemotherapy (induction) for their stage III NSCLC, any adjuvant chemotherapy given for resected disease must have been at least 100 days prior to enrollment"
62489507|NCT03986463||Cohort 2|"1. Stage IV NSCLC or stage III NSCLC, as per the AJCC 8th ed.~2. Planning to start systemic cytotoxic chemotherapy, without concurrent radiation~3. Previous treatment with tyrosine kinase inhibitors or immunotherapy (PD-1, PD-L1, CTLA4 directed antibodies) is allowed as long as no cytotoxic chemotherapy was given concurrently~4. Previous palliative radiation is permitted, but must have been completed at least at least 21 days prior to the initiation of treatment~5. Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~6. Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~7. If cytotoxic chemotherapy was previously given for adjuvant or stage III NSCLC it must have been at least 100 days prior to enrollment"
62694502|NCT04447222||Observational (survey)|Participants complete a survey online over 35-45 minutes about their experiences regarding the COVID-19 pandemic.
62694503|NCT03811119|ACTIVE_COMPARATOR|MANTA vascular closure device|Arteriotomy closure with a collagen-based vascular closure device (MANTA™)
62694504|NCT03811119|ACTIVE_COMPARATOR|Suture based vascular closure device|Arteriotomy closure with 2 or more suture-based vascular closure devices (ProGlide)
62694505|NCT05551117|EXPERIMENTAL|Part 1: MGC018 2.0 mg (Arm A)|MGC018 2.0 mg/kg every 4 weeks
62331636|NCT01341431|EXPERIMENTAL|bee venom|
62694506|NCT05551117|EXPERIMENTAL|Part 1: MGC018 2.7 mg (Arm B)|MGC018 2.7 mg/kg every 4 weeks
62694507|NCT05551117|EXPERIMENTAL|Part 2: Anal cancer cohort|MGC018 2.7 mg/kg every 4 weeks
62694508|NCT05551117|EXPERIMENTAL|Part 2: HNSCC cohort|MGC018 2.7 mg/kg every 4 weeks
62136059|NCT03484741|EXPERIMENTAL|MSC and PRP|15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.
62694509|NCT05551117|EXPERIMENTAL|Part 2: Melanoma cohort|MGC018 2.7 mg/kg every 4 weeks
62694510|NCT05551117|EXPERIMENTAL|Part 2: Squamous NSCLC cohort|MGC018 2.7 mg/kg every 4 weeks
62694511|NCT05551117|EXPERIMENTAL|Part 2: SCLC cohort|MGC018 2.7 mg/kg every 4 weeks
62694512|NCT05551117|ACTIVE_COMPARATOR|Part 1: Control Arm|Patients are administered abiraterone or enzalutamide
62136060|NCT06151275||Colonoscopy|18-95 years old patients apply our endoscopy unit for colonoscopy will be included in our study. Patients that have colonic resection history will be excluded from study.
62136061|NCT04876417|ACTIVE_COMPARATOR|tDCS and fatigue|This group will receive the active form of tDCS.
62136062|NCT04876417|SHAM_COMPARATOR|Sham and fatigue|This group will receive the sham form of tDCS.
62136063|NCT04876417|ACTIVE_COMPARATOR|tDCS and non-fatigue|This group will receive the active form of tDCS.
62331637|NCT01341431|PLACEBO_COMPARATOR|saline|
62331638|NCT05020652|EXPERIMENTAL|TQ05105 tablets + Hydroxyurea blank tablets|Take TQ05105 Tablets + Hydroxyurea blank tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration
62331639|NCT05020652|ACTIVE_COMPARATOR|TQ05105 blank tablets + Hydroxyurea tablets|Take TQ05105 blank tablets + Hydroxyurea tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration
62331640|NCT01685632|ACTIVE_COMPARATOR|Surgery with IPCH|Patients having an IPCH (Intra Peritoneal Chemo Hyperthermia) during the surgery time
62331641|NCT01685632|SHAM_COMPARATOR|patients without IPCH|Patients recused for the surgery due to intraoperative contraindication
62694513|NCT06643494|ACTIVE_COMPARATOR|N-111|Nutraceutical N-111 in conjunction with ADT + EBR will be given in this arm, once per day with breakfast.
62694514|NCT06643494|PLACEBO_COMPARATOR|Placebo|A placebo that is inert but appears to look the same as the active comparator in conjunction with ADT + EBR, given once per day with breakfast.
62136064|NCT04876417|SHAM_COMPARATOR|Sham and non-fatigue|This group will receive the sham form of tDCS.
62694515|NCT06643494|NO_INTERVENTION|Control|The control group will proceed with the ADT + EBR treatment without taking the active compactor or the placebo.
62694516|NCT04777916||Standard intensive 3+7 YOUNG OR ELDERLY|Standard intensive 3+7 (anthracycline + cytarabine) chemotherapy ± an approved FLT3 inhibitor (midostaurine, Rydapt®), according to different dose schedules in older versus younger patients
62694517|NCT04777916||GO, Mylotarg®) with 3+7|Combination of sequential gemtuzumab ozogamicin (GO, Mylotarg®) with 3+7
62694518|NCT04777916||CPX-351, Vyxeos®)|Liposomal formulation of daunorubicin + cytarabine (CPX-351, Vyxeos®)
62694519|NCT04777916||Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC)|Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC) in patients considered as not eligible for the more intensive options above
62694520|NCT04777916||Refractory or relapsed AML|"Secondly, no specific salvage regimen has emerged as a standard in patients with primary refractory or relapsed AML (R/R AML). R/R AML is thus an important field for investigational new drugs (INDs) and precision medicine development. To date, the only IND approved to treat R/R AML is gilteritinib for FLT3-mutated AML patients. The French agency ANSM also allow to use GO for treating R/R AML patients in the frame of a RTU (Recommendation Temporaire d'Utilisation).~In the real life, because of the multiplicity of treatments used in these patients, some of them being now quite efficient, it has become difficult to accurately describe the general outcome of R/R AML patients."
62136065|NCT03168750||Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup|All patients enrolled will receive the Medacta Masterloc Stem and MPACT cup with Highcross PE liner.
62136066|NCT05906550|EXPERIMENTAL|Intervention group|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy.
62694521|NCT06638320||Patients with chronic hepatitis B virus infection|
62694522|NCT04054180|EXPERIMENTAL|CPAP S.Box associated with its 3 connected devices|S.BOXTM CPAP associated with its 3 connected devices Each patient will be monitored by a CPAP S.Box, with a Sefam Access application installed on their Smartphone to collect data from 3 connected measuring devices: PROMs, an activity monitor and a blood pressure monitor.
62694523|NCT04813120|EXPERIMENTAL|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
61937024|NCT05137990|PLACEBO_COMPARATOR|Stretching Intervention|At home (N=12): Participants will complete a stretching protocol 3 times a week for 14 weeks. Participants will be asked to complete weekly records of flexibility compliance.
62136067|NCT05906550|ACTIVE_COMPARATOR|Control group|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min, or when clinical signs of flow dysfunction are present.
62136068|NCT03440346|EXPERIMENTAL|Few-foods diet intervention|
62136069|NCT04393389||non-CLI group|Rutherford Clinical Category (RCC) 2-3
62136070|NCT04393389||CLI group|critical limb ischemia，Rutherford Clinical Category (RCC) 4-6
62331642|NCT06203730|NO_INTERVENTION|Routine care|The Blood purification Center provides routine care for MHD patients
62331643|NCT06203730|EXPERIMENTAL|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
62331644|NCT02669797|EXPERIMENTAL|EMI|EMI (Arm 1): (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; and (2) a 8-week maintenance phase with EMI tips delivered on high stress days.
62331645|NCT02669797|EXPERIMENTAL|EMI + HV + Video feedback, Virtual|"EMI + HV + Video Feedback (Arm 2) education visits will all be delivered virtually, and the arm includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
62331646|NCT02669797|EXPERIMENTAL|EMI + HV + Video feedback, Hybrid|"EMI + HV + Video Feedback (Arm 3) education visits will be delivered virtually and in-home, and the arm includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
62331647|NCT03554005|EXPERIMENTAL|PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)|Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
62331648|NCT03554005|EXPERIMENTAL|PEG Interferon Alfa-2b 1.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
62331649|NCT03554005|EXPERIMENTAL|PEG Interferon Alfa-2b 3 mcg/kg OW|Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
62489508|NCT03986463||Cohort 3|"1. Patients with advanced NSCLC set to undergo palliative radiation to the primary or regional or distant metastatic lesion(s), including intracranial lesions~2. Radiation dose scheduling must be 2.5 to 4.0 Gy on days 1 through 3 for extracranial treatment, ideally 40 Gy in 15 fractions, 20 Gy in 5 fractions, or 30 Gy in 10 fractions.~3. Radiation dose for brain lesions must be 6 to 9 Gy per dose, ideally 30 to 35 Gy in 5 daily fractions or 27 Gy in 3 fractions on alternating days~4. No plans for concurrent chemotherapy to be given~5. Five patients in cohort 3 will receive radiation to the primary tumor and five patients will receive radiation to brain lesions"
62136071|NCT05481905|EXPERIMENTAL|ENX-101 15mg daily|
62489509|NCT02821676|EXPERIMENTAL|PEC1/SPB Block|
62489510|NCT02821676|ACTIVE_COMPARATOR|Intercostal Block|
62136072|NCT05481905|EXPERIMENTAL|ENX-101 30mg daily|
62136073|NCT05481905|PLACEBO_COMPARATOR|Placebo daily|
62136074|NCT00918203|ACTIVE_COMPARATOR|Paclitaxel + Carboplatin|"(Initial 4-6 cycles) Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle (Initial 4-6 cycles) Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants who experience progressive disease may cross over to olaratumab monotherapy."
62136075|NCT00918203|EXPERIMENTAL|Olaratumab + Paclitaxel + Carboplatin|"(Initial 4-6 cycles)~Olaratumab 15 milligrams/kilogram (mg/kg) over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit."
62136076|NCT02124668|EXPERIMENTAL|Enzalutamide|Enzalutamide
62136077|NCT04946682|EXPERIMENTAL|Group of mNGS|
62136078|NCT04946682|EXPERIMENTAL|Group of PCR|
62136079|NCT03611075|EXPERIMENTAL|Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
62136080|NCT03611075|EXPERIMENTAL|High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
62136081|NCT03611075|EXPERIMENTAL|Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
62136082|NCT03611075|EXPERIMENTAL|High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
62136083|NCT03611075|EXPERIMENTAL|Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
62136084|NCT03611075|EXPERIMENTAL|High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
62136085|NCT03611075|NO_INTERVENTION|Typically Developing (TD) Healthy Participant Children|Participants will be 5-12 years old
62136086|NCT03611075|NO_INTERVENTION|TD Healthy Participant Adolescents|Participants will be 13-17 years old
62136087|NCT03611075|NO_INTERVENTION|TD Healthy Participant Adults|Participants will be 18-45 years old
62136088|NCT04679662|EXPERIMENTAL|Single-arm study of PLAR Implant and Delivery System to treat severe mitral regurgitation|All enrolled patients will receive the study device
62136089|NCT02348632|OTHER|75 mg - 300 mg of JZP-110|Once Daily Dosing
62136090|NCT06367023|EXPERIMENTAL|Rajyoga Meditation Practice|"Rajyoga Meditation Intervention: 3 months, For 6 days one hour per day Rajyoga meditation basic course will be provided, followed by 1 hour daily spiritual lesson, Positive thinking and motivation classes will be provided to the intervention group where 1. Initiation - In this stage, thoughts in the mind, come in randomly, 2. Concentration - He now, converts all negative thoughts with positive thoughts of peace, happiness, love, bliss, purity, knowledge, and power 3. Realization - This final stage involves feeling the emotions of these positive thoughts and in the control group standard treatment will be given.~Follow-up: Follow up will be done after 1 month of discharge from the rehabilitation centers."
62489511|NCT00642993|EXPERIMENTAL|SCH 497079|SCH 497079, administered orally, once daily
62489512|NCT00642993|PLACEBO_COMPARATOR|Placebo|Placebo capsules, administered orally, once daily
62136091|NCT06367023|NO_INTERVENTION|Standard of care|The usual therapy of the rehabilitation center will be given for 3 months. Baseline, 3 month and follow up after 1 month will be taken
62489513|NCT03053856|EXPERIMENTAL|Pembrolizumab arm|Adjuvant Pembrolizumab
62489514|NCT05757830|EXPERIMENTAL|Exoskeleton-assisted arm|Each subject will perform 3 experimental conditions with and without the exoskeleton to assess the impact of exoskeleton assisted walking on metabolic consumption and cardiorespiratory effort compared to conventional overground walking training without an exoskeleton
62136092|NCT00972049|EXPERIMENTAL|1|Capsule administered once orally
62136093|NCT00972049|PLACEBO_COMPARATOR|2|Capsule administered once orally
62136094|NCT06285253|EXPERIMENTAL|miroliverELAP treatment|48 hour treatment with miroliverELAP
62136095|NCT05708365|ACTIVE_COMPARATOR|Standard-Lung Protective Ventilation|
62489515|NCT02224144|EXPERIMENTAL|Vitamin D3 plus Calcitriol|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months~1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months"
62489516|NCT02224144|PLACEBO_COMPARATOR|Vitamin D3 plus Placebo|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months~1 pill of placebo (sugar pill) per day for 12 months"
62489517|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
62136096|NCT05708365|ACTIVE_COMPARATOR|Ultra-Lung Protective Ventilation|
62136097|NCT03311360||drug-coated balloon|patients with vertebral artery origin stenosis treated with drug-coated balloons
62136098|NCT03311360||bare metal stent|patients with vertebral artery origin stenosis treated with bare metal stent
62136099|NCT03466931|EXPERIMENTAL|Dietary intervention|Meals containing Milk and Milk
62136100|NCT03466931|NO_INTERVENTION|Historical cohort|Standard care
62136101|NCT00785200|EXPERIMENTAL|Chlorhexidine|Approximately 500 detainees housed in approximately 23 detention tanks will be enrolled and receive 2% chlorhexidine-soaked disposable wash cloths (Sage Products, Inc.) to clean their skin on Mondays, Wednesdays, and Fridays for 6 months. Newly arrived detainees in the tanks will be offered enrollment in the study on a biweekly schedule.
62489518|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
62489519|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
62489520|NCT03867071|EXPERIMENTAL|erythropoietin (EPO) group|
62489521|NCT03867071|PLACEBO_COMPARATOR|Placebo (PLA) group|
62489522|NCT02399462|EXPERIMENTAL|Study Drug Arm|Acthar SC injections
62489523|NCT04261374||Measurement of sublingual microcirculation|
62489524|NCT05869136|EXPERIMENTAL|Test group|Microneedling along with hyaluronic acid in thin gingival phenotype
62489525|NCT05869136|ACTIVE_COMPARATOR|Control group|Microneedling in thin gingival phenotype
62331650|NCT03554005|EXPERIMENTAL|PEG Interferon Alfa-2b 4.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
62331651|NCT03554005|EXPERIMENTAL|PEG Interferon Alfa-2b 6 mcg/kg OW|Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
62331652|NCT03554005|EXPERIMENTAL|PEG Interferon Alfa-2b 7.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
62331653|NCT06198959|EXPERIMENTAL|ABCDE|A. Volunteers will be covered with the Adult Blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. B. After a 40 minutes washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. C. After a 40-minute washout period, the volunteers will be covered with the Blanket full body, 30000 connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. D. After a 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. E. Finally and after a last 40-minute washout period, the volunteers will be covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes.
62331654|NCT06198959|EXPERIMENTAL|BDECA|B. Volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. D. After a 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. E. After a 40-minute washout period, the volunteers will be covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. C. After a 40-minute washout period, the volunteer will be covered with the Blanket full body, 30000 connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. A. Finally and after a last 40-minute washout period, the volunteers will be covered with the Adult Blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes.
62489526|NCT04857138|EXPERIMENTAL|Part 1: Dose Escalation (RO7300490 Monotherapy)|Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
62489527|NCT04857138|EXPERIMENTAL|Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)|Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
62489528|NCT04857138|EXPERIMENTAL|Part 3: Dose Expansion (Disease-specific Expansion(s))|Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
62489529|NCT05894148|EXPERIMENTAL|Genakumab injection|Group 1: 120mg，group 2: 200mg
62489530|NCT05894148|PLACEBO_COMPARATOR|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
62489531|NCT01360086|EXPERIMENTAL|Perioperative CT with 5FU-Cisplatine-Cetuximab|6 cycles of intravenous Cetuximab (500mg/m²), Cisplatine (50mg/m²) and LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks. Surgery was planned 3-4 weeks after the end of neaodjuvant CT and postoperative CT, with the same regimen, planned for 6-8 weeks after surgery.
62489532|NCT01460628|EXPERIMENTAL|Armodafinil|Armodafinil is the drug being tested.
62489533|NCT06563284||Study Group|HIV-infected patients in virological suppression who have been treated with a stable antiretroviral regimen for at least six months
62489534|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes \<37 weeks
62489535|NCT02888964|EXPERIMENTAL|ACTOS treatment|Imatinib mesylate at the same daily dose and pioglitazone as add-on therapy at 30 mg/d during 2 months and then 45 mg/d in the absence of serious adverse events
62489536|NCT03385135|ACTIVE_COMPARATOR|Allopurinol group|Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
62489537|NCT03385135|NO_INTERVENTION|No Allopurinol group|Optimal medical therapy alone
62489538|NCT06007729|EXPERIMENTAL|HS-20093 (phase 2a and Phase 2b)|Participants in all subjects will receive HS-20093 at 10mg/kg
62489539|NCT04606056||Patients who underwent contrast enhanced CT scans|
62489540|NCT03513185||Patients with SSD|Patients are diagnosed with SSD by physician according to DSM-5,and will be treated with Deanxit, SSRI or SRNI on the basis of severity assessment by physician.
62489541|NCT03513185||Patients with non-SSD|No SSD is diagnosed by physician according to DSM-5
62489542|NCT03046550|EXPERIMENTAL|Cohort A|Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
62489543|NCT03046550|EXPERIMENTAL|Cohort B|Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
62489544|NCT03046550|EXPERIMENTAL|Cohort C|Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
62697622|NCT04716725|EXPERIMENTAL|Experimental (68Ga-PSMA-11 PET)|Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.
62489545|NCT05623592|EXPERIMENTAL|Methotrexate|The patient will be treated for 12 months weekly with methotrexate. Methotrexate will be provided at a dose of 17.5mg as a pre-filled syringe for self-injection. A dose reduction to 15 mg/week in case of intolerance, elevated liver enzymes \>3x upper limit of normal or to 10 mg/week if glomerular filtration rate \<50/min will be possible. If glomerular filtration rate \<30/min, termination of treatment.
62489546|NCT05623592|PLACEBO_COMPARATOR|Placebo|Patients receive sodium chloride as a placebo subcutaneously. It will be administered in the form of a pre-filled syringe for self-injection once a week for 12 months.
62136102|NCT00785200|PLACEBO_COMPARATOR|Water|Approximately 500 detainees in approximately 23 detention tanks will receive water-soaked wash cloths to clean their skin each Monday, Wednesday, and Friday for a 6-month period. If detainees newly arrive to these study tanks, they will be offered enrollment on a biweekly schedule.
62136103|NCT00785200|NO_INTERVENTION|Usual care|Approximately 500 detainees in approximately 23 detention tanks will be enrolled. These detainees will not receive any intervention. They will be followed for 6 months, and newly arrived detainees will be offered enrollment on a biweekly schedule.
62136104|NCT00756405|ACTIVE_COMPARATOR|Diet Group|Increased antioxidant diet and placebo pill.
62136105|NCT00756405|ACTIVE_COMPARATOR|Supplement Group|Usual diet and antioxidant supplement.
62136106|NCT00756405|PLACEBO_COMPARATOR|Placebo|Usual diet and placebo pill.
62331655|NCT06198959|EXPERIMENTAL|CEBAD|C. Volunteers will be covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. E. After a 40-minute washout period, the volunteers will be covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. B. After a 40-minute washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. A. After a 40-minute washout period, the volunteers will be covered with the adult blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. D. Finally and after a last 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes.
62331656|NCT06198959|EXPERIMENTAL|DCAEB|D. Volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. C. After a 40-minute washout period, the volunteers will be covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. A. After a 40-minute washout period, the volunteers will be covered with the adult blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. E. After a 40-minute washout period, the volunteers will be covered with the blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. B. Finally and after a last 40-minute washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes.
62331657|NCT06198959|EXPERIMENTAL|EADBC|E. Volunteers will be covered with the blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. A. After a 40-minute washout period, the volunteers will be covered with the adult blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. D. After a 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. B. Finally and after a last 40-minute washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. C. Finally and after a last 40-minute washout period, the volunteers will be covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 for 30 minutes.
62331658|NCT02427256||Non-Pathologic Adults age 18-28 yrs|
62331659|NCT02427256||Non-Pathologic Adults age 29-80 yrs|
62331660|NCT02427256||Pathologic Adults age 29-80 yrs|
62331661|NCT05130333||Non-cardiac surgery patients under general anesthesia|\> 18y/o patients undergoing noncardiac surgery with BIS monitoring under general anesthesia.
62331662|NCT01446198||AHPV positive and negative subjects|
62331663|NCT00292474|EXPERIMENTAL|TAXUS Express|
62331664|NCT00292474|PLACEBO_COMPARATOR|Express Bare|
62331665|NCT06291103|EXPERIMENTAL|Experimental|- Experimental arm: conversion to Belatacept CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
62331666|NCT06291103|ACTIVE_COMPARATOR|Control|- Control arm: Standard of care treatment (SOC regimen) with Tacrolimus Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
62331667|NCT05478343|EXPERIMENTAL|IM21 CAR-T cells|
62331668|NCT01449591|EXPERIMENTAL|BFH772|
62331669|NCT01449591|PLACEBO_COMPARATOR|Vehicle|
62331670|NCT01449591|ACTIVE_COMPARATOR|Metronidazole|
62331671|NCT04386044||Hospital in-patients|Cross-sectional study of hospital in-patients admitted with COVID-19 n=200
62331672|NCT04386044||Controls (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
62331673|NCT04386044||Cases (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
62331674|NCT01934192|EXPERIMENTAL|Initial randomization: GSK962040 Arm|Subjects in the GSK962040 Arm will receive 50 mg once daily enteral dose administered through NG tube up to 7 days.
62331675|NCT01934192|PLACEBO_COMPARATOR|Initial randomization: Placebo Arm|Subjects in the placebo arm will receive once daily dose enteral dose administered through NG tube up to 7 days.
62331676|NCT01934192|EXPERIMENTAL|Treatment change due to intolerance: GSK962040 Arm|Subjects that develop intolerance and that originally received Placebo will receive 50 mg once daily enteral dose administered through NG tube + placebo IV
62331677|NCT01934192|ACTIVE_COMPARATOR|Treatment change due to intolerance: Metoclopramide Arm|Subjects that develop intolerance and that originally received GSK962040 will receive metoclopramide 10 mg IV every 6 h + placebo NG
62331678|NCT03445897|EXPERIMENTAL|Intervention|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
62331679|NCT03505567|OTHER|Random Sequenced Interventions|Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.
62694524|NCT04813120|EXPERIMENTAL|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
62136107|NCT05571384|EXPERIMENTAL|high intensity body-weight circuit (HIBC)|HIBC Exercise Protocol- circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10), and modified push-ups (5). The exercise sessions will involve repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Three sessions per week will be completed at home. After three weeks of training, participants will be asked to add a fourth session each week. Initially, the HIBC sessions will be five minutes long, and the duration of the sessions will increase by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session (warm up not included in this timing) as early as the eighth week of training. Session duration will be capped at 10-minutes.
62331680|NCT03979105||Ketamine infusion|Ketamine infusion treatment for acute pain in adult population in all type of surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 48 hours.
62331681|NCT01795222|ACTIVE_COMPARATOR|Oral Midazolam|Midazolam oral syrup 1mg/Kg twenty minutes before starting the procedure
62331682|NCT01795222|PLACEBO_COMPARATOR|placebo|placebo oral syrup twenty minutes before starting the procedure
62331683|NCT05179460||Clean Cohort|Clean cohort refers to cohort of participants who had their first documented exposure to pentosan polysulfate sodium (PPS; Elmiron) on or after 22 May 2018 and who are assumed to have had shorter exposure (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
61937025|NCT06317376|EXPERIMENTAL|experimental group (MICT)|MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
61937026|NCT06317376|OTHER|control group (standard protocol)|Perform standard hospital protocol 2-3 session per week
61937027|NCT01771380||Subjects with impaired glucose tolerance|
61937028|NCT04094623|EXPERIMENTAL|NSSI-DBT|Dialectical behavior therapy, 2 hours every week for 13 weeks.
61937029|NCT04094623|ACTIVE_COMPARATOR|NSSI-SSGT|Social support group therapy, 2 hours every week for 13 weeks.
61937030|NCT02239224|EXPERIMENTAL|Cohort 1: ATYR1940 0.3 mg/kg|Participants will receive ATYR1940 0.3 milligrams/kilograms (mg/kg) intravenous (IV) infusion once weekly for 4 weeks.
61937031|NCT02239224|EXPERIMENTAL|Cohort 2: ATYR1940 1.0 mg/kg|Participants will receive ATYR1940 1.0 mg/kg IV infusion once weekly for 4 weeks.
62331684|NCT05179460||Overall Cohort|Overall cohort refers to cohort of participants who had their first documented exposure to PPS (Elmiron) any time beginning 01 January 2015 and who are assumed to have relatively longer exposure (the earliest available data based on the linked database between the intelligent research in sight (IRIS) registry and Komodo database in this study).
62331685|NCT05179460||Interstitial Cystitis (IC) Cohort|IC cohort refers to cohort of participants who had at least one IC diagnosis beginning 01 January 2015 and had no documented exposure to PPS based on the records from the Komodo database (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
62489547|NCT05366582|ACTIVE_COMPARATOR|Group Macintosh Laryngoscope (ML)|Macintosh laryngoscope is used for intubation after anesthesia induction
61937032|NCT02239224|EXPERIMENTAL|Cohort 3: ATYR1940 3.0 mg/kg|Participants will receive ATYR1940 3.0 mg/kg IV infusion once weekly for 12 weeks.
61937033|NCT02239224|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to ATYR1940 IV infusion once weekly for 4 weeks in Cohorts 1 and 2 and for 12 weeks in Cohort 3.
61937034|NCT04623307||Brain damage patients|Brain damage patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
61937035|NCT04623307||Brain edema patients|Brain edema patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
61937036|NCT04623307||Healthy subjects|Healthy subjects were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
61937037|NCT04872400|NO_INTERVENTION|Control|Subjects randomized to the Control Arm will receive standard of care open fracture wound care (no powder) by the clinical team.
61937038|NCT04872400|EXPERIMENTAL|Vancomycin|Subjects randomized to the Intervention arm will receive standard of care plus 1 gram of vancomycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
61937039|NCT04872400|EXPERIMENTAL|Tobramycin|Subjects randomized to the Intervention arm will receive standard of care plus 1.2 grams of tobramycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
61937040|NCT01230710|EXPERIMENTAL|Erlotinib|Participants received erlotinib 150 mg orally once a day for 48 weeks.
61937041|NCT03302195|ACTIVE_COMPARATOR|Control group|"Heparin dose and cardiopulmonary bypass pump flow rate are calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
61937042|NCT03302195|EXPERIMENTAL|Intervention group A|"Heparin dose is adjusted for lean body weight and cardiopulmonary bypass pump flow rate is calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
62136108|NCT06009393|EXPERIMENTAL|SHR-1918|
62489548|NCT05366582|ACTIVE_COMPARATOR|Group Video Laryngoscope (VL)|Video laryngoscope is used for intubation after anesthesia induction
62489549|NCT02344550|EXPERIMENTAL|Everolimus arm|Everolimus 10mg p.o. daily Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
62694525|NCT04813120|EXPERIMENTAL|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
62697623|NCT03282916|ACTIVE_COMPARATOR|Valacyclovir|The oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day.
62136109|NCT01153113|EXPERIMENTAL|Treatment Arm A|• 5x106 cells per infusion administered ID
62136110|NCT01153113|EXPERIMENTAL|Treatment Arm B|• 1x107 cells per infusion administered ID (Treatment arm B).
62136111|NCT06433050|PLACEBO_COMPARATOR|Placebo first phase, Sotagliflozin second phase|Matching placebo once daily will be administered in the first phase, Sotagliflozin 400 mg once daily will be administered in the second phase
62136112|NCT06433050|ACTIVE_COMPARATOR|Sotagliflozin first phase, Placebo second phase|Sotagliflozin 400 mg once daily will be administered in the first phase, matching placebo once daily will be administered in the second phase
62331686|NCT04905537||Sick Neonates or Stillbirth|Infants and their parents enrolled through Neonatal Intensive Care Unit or stillbirths through Obstetrics Department of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/ physical exam, and the results of the genomic sequencing report.
62331687|NCT00417976|EXPERIMENTAL|Bevacizumab|
62331688|NCT05807334|EXPERIMENTAL|DASH eating plan with eggs|Participants will receive dietary guidance to follow the DASH eating plan with the addition of 2 whole eggs daily during this 8-week treatment period.
62331689|NCT05807334|ACTIVE_COMPARATOR|DASH eating plan without eggs|Participants will receive dietary guidance to follow the DASH eating plan while excluding eggs from their eating plan during this 8-week treatment period.
62489550|NCT02344550|ACTIVE_COMPARATOR|Control arm|Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
62489551|NCT01963260|EXPERIMENTAL|Part 1: MK-8723 1 mg/kg in Healthy Participants|MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.
62489552|NCT01963260|EXPERIMENTAL|Part 1: MK-8723 3 mg/kg in Healthy Participants|MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.
62489553|NCT01963260|EXPERIMENTAL|Part 1: MK-8723 10 mg/kg in Healthy Participants|MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.
61937043|NCT03302195|EXPERIMENTAL|Intervention group B|"Heparin dose is calculated using total body weight and cardiopulmonary bypass pump flow rate is adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
62136113|NCT03516032|EXPERIMENTAL|walking exercises|walking in the hospital corridor
62136114|NCT03516032|EXPERIMENTAL|balance exercises|heel rise exercises
62136115|NCT05335928|EXPERIMENTAL|Abatacept plus standard of care|Abatacept (10 mg/kg) will be administered IV after randomization, again at 24 hours after first study drug treatment, at 14 days after first study drug treatment and an optional 4th dose at 28 days.
62136116|NCT05335928|PLACEBO_COMPARATOR|Placebo plus standard of care|Placebo will be administered at the same intervals.
62136117|NCT04217694|EXPERIMENTAL|Prevention (memantine, CogState)|Patients receive memantine PO BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT.
62136118|NCT06101875|EXPERIMENTAL|Health Coaching|Patients will be assigned a health coach and be eligible to 8 sessions over a 12 week period.
62136119|NCT06101875|ACTIVE_COMPARATOR|Control|Patients will be enrolled onto the digital toolkit.
62136120|NCT00163046|EXPERIMENTAL|Gabapentin|
62136121|NCT00163046|PLACEBO_COMPARATOR|Placebo|
62136122|NCT05911451|ACTIVE_COMPARATOR|Arteriovenous fistula|Patients allocated to usual care will be treated according to current guidelines on vascular access creation. These guidelines recommend placing autologous arteriovenous fistulas at the most distal site with adequate blood vessels, preferably in the non-dominant arm. Patients who have already been on hemodialysis treatment using a central venous catheter must be operated within 6 months of dialysis initiation. Because the study aims to compare the different surgical strategies for vascular access creation in a real-life situation, the study will not interfere with clinical practice at the study sites.
62136123|NCT05911451|EXPERIMENTAL|Arteriovenous graft|Patients who are allocated to the arteriovenous graft strategy will have a commercially available prosthetic tube graft implanted for hemodialysis access. Patients who have already been on hemodialysis treatment using a central venous catheter must be operated within 6 months of dialysis initiation. Because the study aims to compare the different surgical strategies for vascular access creation in a real-life situation, the study will not interfere with clinical practice at the study sites.
62331690|NCT05296850|EXPERIMENTAL|Manual release group|Manual release will perform with plantar fascia and flexor hallucis longus stretching and tissue mobilization. Stretching/mobilization will applied for approximately 3 minutes.
62331691|NCT05296850|EXPERIMENTAL|Kinesio taping group|Two techniques will be used in kinesio taping application; first technique is the gastrocnemius muscle inhibition technique and the plantar fascia ligament correction technique and other technique is the transverse arch ligament correction technique.
62331692|NCT02794051|EXPERIMENTAL|Unified Protocol for Children|Child participants with behavior problems between the ages of 8-12 and their caregivers will participate in a transdiagnostic group therapy protocol.
62331693|NCT01044381|EXPERIMENTAL|Luliconazole Solution, 10%|
62331694|NCT03233412|OTHER|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
62489554|NCT01963260|EXPERIMENTAL|Part 1: MK-8723 30 mg/kg in Healthy Participants|MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.
62489555|NCT01963260|EXPERIMENTAL|Part 1: MK-8723 100 mg/kg in Healthy Participants|MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.
62489556|NCT01963260|PLACEBO_COMPARATOR|Part 1: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.
62489557|NCT01963260|EXPERIMENTAL|Part 2: MK-8723 10 mg/kg in ITP Participants|MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
62489558|NCT01963260|EXPERIMENTAL|Part 2: MK-8723 30 mg/kg in ITP Participants|MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
62136124|NCT05911451|EXPERIMENTAL|Central venous catheter|Patients who are allocated to the central venous catheter strategy will have a dialysis catheter inserted. Because the study aims to compare the different surgical strategies for vascular access creation in a real-life situation, the study will not interfere with clinical practice at the study sites.
62136125|NCT03347851||On-X AAP|Patients with prior AVR surgery with the CryoLife On-X Ascending Aortic Prosthesis (AAP).
62331695|NCT03233412|EXPERIMENTAL|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
62331696|NCT05605379||Responders (with CCR at 1 year)|
62331697|NCT05605379||No responders (without CCR at 1 year)|
62331698|NCT01218412|EXPERIMENTAL|Web-based, Mi=Based Intervention|4 session web-based, MI-based intervention.
62331699|NCT06376474|EXPERIMENTAL|Mild liver damage group|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
62331700|NCT06376474|EXPERIMENTAL|Moderate liver damage group|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
62331701|NCT06376474|EXPERIMENTAL|Healthy subjects|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
62331702|NCT03716232|ACTIVE_COMPARATOR|Multiple plastic stents|"* All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~* Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
62331703|NCT03716232|EXPERIMENTAL|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
62331704|NCT00807833||CBF measurement|"It is a proof of concept study, aimed to evaluate whether the optimal CPP, defined by the best PRx, corresponds to the acceptable CBF values.~Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be monitored on clinical ground will be also monitored with a TD probe and routinely tested for cerebral autoregulation, thus obtaining the CBF corresponding at a given the best CPP and autoregulation status."
62331705|NCT04393636|NO_INTERVENTION|Control arm|Participants will receive at the different time intervals through our custom-made Digital Cardiac Counselling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes.Additional to known risk factors a Covid-19 module will be used as well.
62331706|NCT04393636|ACTIVE_COMPARATOR|Intervention arm|All participants will receive at the different time intervals through our custom-made Digital Cardiac Counseling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes. Additional to above participants in the intervention group will receive through the Digital Cardiac Counseling platform different modules with E-counseling for risk factors evaluated in the questionnaires. Additional to known risk factors a Covid-19 module will be used as well.
62331707|NCT02533518|EXPERIMENTAL|patients with lung cancer|
62331708|NCT03661827|EXPERIMENTAL|Patients with heart failure|Patients with heart failure
62331709|NCT01770873|EXPERIMENTAL|Take Charge 2|Receipt of BBBS mentoring plus youth and parent violence prevention curriculum
62331710|NCT01770873|NO_INTERVENTION|Control|Standard emergency room protocol followed
62331711|NCT03252704|EXPERIMENTAL|High fiber - low fiber|Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top)
62136126|NCT03347851||SJM Masters or Carbomedics Carbo-seal|Patients with St. Jude Medical Masters HP Valved Graft with Gelweave Valsalva™ Technology or Carbomedics Carbo-seal (including Carbo-seal Valsalva) mechanical aortic valve prostheses patients
62331712|NCT03252704|EXPERIMENTAL|low fiber - high fiber|Treatment order described in arm title, conventional flour (low fiber muffin top)- resistant starch (high fiber muffin top)
62331713|NCT05328921||Antihypertensive drugs group|Changes in IOP among patients on antihypertensive drugs
62331714|NCT05328921||Antihistaminic drugs group|Changes in IOP among patients on antihistaminic drugs
62331715|NCT05328921||Antihypertensive and antihistaminic drugs group|Changes in IOP among patients on both antihypertensive and antihistaminic drugs
62489559|NCT01963260|PLACEBO_COMPARATOR|Part 2: MK-8723 100 mg/kg in ITP Participants|MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
62136127|NCT02854033||Cognitively Normal (CN)|"135-500 newly enrolled participants with no apparent memory problems, and 295-300 cognitively normal participants followed from the ADNI2 study.~Currently recruiting non-Caucasian participants only for the normal cognition group."
62331716|NCT02884817|EXPERIMENTAL|Listerine prof.gum.ther|"The test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson \& Johnson,USA).~Intervention; Rinsing 30 sec with test solution twice daily for 21 days"
62331717|NCT02884817|PLACEBO_COMPARATOR|21.6% hydroalcoholic|"a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%.~Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days"
62331718|NCT02884817|SHAM_COMPARATOR|Plain sterile water|"Plain sterile water.~Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days"
62331719|NCT05740852||Infection|Patients who developed pulmonary infection after radical resection of tumor
62331720|NCT05740852||Without infection|Patients without pulmonary infection after radical resection of tumor
62331721|NCT02504476|ACTIVE_COMPARATOR|AMG 581 - Dose 1|
62489560|NCT01963260|PLACEBO_COMPARATOR|Part 2: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
62489561|NCT01466894|EXPERIMENTAL|IMM 124-E high dose|IMM 124-E 3600 mg per day
62489562|NCT01466894|EXPERIMENTAL|IMM 124-E low dose|IMM 124-E 1800 mg per day
62489563|NCT01466894|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62489564|NCT01049581|EXPERIMENTAL|pediatric aquatic therapy|The children of the PAT group participated in a 1 hour/time, twice-per-week, 12-week, PAT program in addition to conventional rehabilitation programs
62489565|NCT01049581|NO_INTERVENTION|conventional therapy|The children included in the control group continued with their original rehabilitation programs
62489566|NCT01677338|EXPERIMENTAL|13C-uracil and 99mTc sulfur colloid|Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.
62489567|NCT01677338|EXPERIMENTAL|99mTc sulfur colloid|Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.
62489568|NCT02754089|EXPERIMENTAL|Rhus|500 mg twice daily after meal for 6 weeks
62489569|NCT02754089|PLACEBO_COMPARATOR|Placebo|500 mg twice daily after meal for 6 weeks
62489570|NCT06627881|EXPERIMENTAL|Continuous aerobic kayak training program|"* Frequency: 5 days a week.~* Intensity: moderate 40.59% RHR or Borg 12-13. Progressing 3rd week 60-70% FCR, Borg 14-17.~* Time: 8 weeks~* Volume:~  5 min warm up upper body and center of the upper body 30 minutes of training Progression after 3 weeks: 35 min Total of 40 sessions."
62694526|NCT04813120|ACTIVE_COMPARATOR|Traditional MT using a mirror box|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
62694527|NCT01435356|ACTIVE_COMPARATOR|recMage-A3 + AS15 ASCI|MAGE-A3 positive patients treated with recMAGE-A3 + AS15 ASCI
62694528|NCT01435356|PLACEBO_COMPARATOR|Placebo|MAGE-A3 positive patients treated with placebo
62694529|NCT06637124|EXPERIMENTAL|50% Blood Flow Restriction Group|"The Blood Flow Restriction device will be set to restrict blood flow at level of 50% of arterial occlusion pressure at rest.~Blood Flow Restriction sessions will be 5 sets of 5 mins of occlusion and 3 mins of free flow , 2 sessions per week for eight weeks exercises to assess its effects on knee osteoarthritis-related outcomes."
62694530|NCT06637124|EXPERIMENTAL|70% Blood Flow Restriction Group|"The Blood Flow Restriction device will be set to restrict blood flow at level of 70% of arterial occlusion pressure at rest.~Blood Flow Restriction sessions will be 5 sets of 5 mins of occlusion and 3 mins of free flow , 2 sessions per week for eight weeks exercises to assess its effects on knee osteoarthritis-related outcomes."
62694531|NCT06637124|ACTIVE_COMPARATOR|Moderate Intensity Exercise training Group|"Patients assigned to this group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) for a total of 16 treatment sessions according to exercise guidelines for seniors with OA.~MIRT protocols consists of 3 sets for every exercise, 12 repetitions per set, rest period between sets 2 mins, 2 session per week for 8 weeks.~Resistance exercises will be performed using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine."
62694532|NCT01950494|EXPERIMENTAL|fiteBac Hand Sanitizer|Blinded fitBac Hand sanitizer
62694533|NCT01950494|PLACEBO_COMPARATOR|Blinded emollient therapy|Blinded emollient therapy
62331722|NCT02504476|ACTIVE_COMPARATOR|AMG 581 - Dose 2|
62331723|NCT02504476|ACTIVE_COMPARATOR|AMG 581 - Dose 3|
62694534|NCT03369808|EXPERIMENTAL|7.5μg H7N9 Vaccine|Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
62694535|NCT03369808|EXPERIMENTAL|15μg H7N9 Vaccine|Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
62694536|NCT03369808|EXPERIMENTAL|30μg H7N9 vaccine|Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
62694537|NCT03369808|PLACEBO_COMPARATOR|Aluminum hydroxide adjuvant|Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.
62331724|NCT02504476|ACTIVE_COMPARATOR|AMG 581 - Dose 4|
62331725|NCT02504476|PLACEBO_COMPARATOR|Placebo - Dose 1|
62331726|NCT02504476|PLACEBO_COMPARATOR|Placebo - Dose 2|
62489571|NCT06627881|ACTIVE_COMPARATOR|Aerobic Endurance Circuit Program|"* Frequency: 5 days a week.~* Intensity: Very light \<30% of 1 RM, Borg \<9 Progression in week 3: light 30-40% of 1 RM, Borg 9-11~* Time: 8 weeks~* Volume: 30 min 5 min upper body and center warm-up 2 aerobic resistance circuits with 8 upper body and core exercises, 18-22 repetitions Week 3 progression: 3 circuits Week 4 progression: 4 circuits Recovery period between circuits: 3 min Total of 40 sessions."
62489572|NCT06627881|ACTIVE_COMPARATOR|High intensity interval program with rope|"* Frequency: 5 days a week.~* Intensity: Vigorous \<30% of RHR, Borg 14-17 with recovery interval intensity of 30-39% of RHR Borg 9-11~* Time: 8 weeks~* Volume: 30 min 5 min upper body and center warm-up Start: 1:3 ratio, intensive intervals lasting 1 min and recovery interval of 3 min, performing 7 intervals with a total duration of 28 min Progression week 3: Interval ratio will be modified 1:2, performing 10 intervals.~Total of 40 sessions."
62489573|NCT06052839|EXPERIMENTAL|Pembrolizumab + Carboplatin with Paclitaxel|"Pembrolizumab: Administer 200 mg intravenously (IV) every 3 weeks (q3w); maintenance will be continued at 400 mg IV q6w for 12 cycles for a total of 2 years of therapy~Carboplatin: Started with cycle 2 (C2) of pembrolizumab and continued thereafter every 3rd cycle of pembrolizumab for a total of 4 cycles with paclitaxel; carboplatin will be given at C2, C5, C8, and C11 of pembrolizumab.~Paclitaxel: Started with cycle 2 (C2) of pembrolizumab and continued thereafter every 3rd cycle of pembrolizumab for a total of 4 cycles with carboplatin."
62331727|NCT02504476|PLACEBO_COMPARATOR|Placebo - Dose 3|
62331728|NCT02504476|PLACEBO_COMPARATOR|Placebo - Dose 4|
62331729|NCT02504476|OTHER|AMG 581/Midazolam - Drug Interaction|
62331730|NCT04753203|EXPERIMENTAL|A single arm study with Alpelisib plus Capecitabine|A phase lb/ll, open label, single arm study with Alpelisib plus Capecitabine in patients with PIK3CA mutant metastatic colorectal cancer
62489574|NCT04333264|ACTIVE_COMPARATOR|suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
62489575|NCT04333264|ACTIVE_COMPARATOR|no suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
62489576|NCT01685255|ACTIVE_COMPARATOR|Epacadostat|Subjects randomized to Arm A (epacadostat) will take epacadostat tablets at a dose of 600 mg BID, beginning on Day 1.
62489577|NCT01685255|ACTIVE_COMPARATOR|Tamoxifen|Subjects randomized to Arm B (tamoxifen) will take tamoxifen tablets at a dose of 20 mg BID, beginning on Day 1.
62489578|NCT04345640||Covid-19 with liver disease|Covid-19 with liver disease
62489579|NCT04345640||Covid-19 without liver disease|Covid-19 without liver disease
62136128|NCT02854033||Mild Cognitive Impairment (MCI)|150 - 515 newly enrolled participants with mild cognitive impairment (MCI), and 275-320 MCI participants followed from the ADNI2 study.
62694538|NCT03369808|PLACEBO_COMPARATOR|Phosphate buffer solution|Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.
61937044|NCT03302195|EXPERIMENTAL|Intervention group C|"Heparin dose and cardiopulmonary bypass pump flow rate are adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
62136129|NCT02854033||Mild Alzheimer's Disease (AD) dementia|85 - 185 newly enrolled participants with mild Alzheimer's disease (AD) dementia, and 130 - 150 mild AD participants followed from the ADNI2 study.
62331731|NCT04561635|EXPERIMENTAL|Intervention group|The intervention group was supplemented with three sachets of MMS each week for every other day for a period of 12 months. Each sachet containing 1 g consisting of ten vitamins and five minerals. It was to be sprinkled over a cooked meal or dissolved in a drink for the child. Written instruction for using and storing the MMS in simple language with visuals was given prior to the supplementation. The intervention group also received health and nutrition advice at 3, 6 and 9 months after supplementation begins.
62331732|NCT04561635|NO_INTERVENTION|Control group|The control group received health and nutrition advice that were similar to intervention group and delivered by the investigator at 3, 6 and 9 months after the study began.
62331733|NCT03104335|EXPERIMENTAL|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
62331734|NCT03593967|EXPERIMENTAL|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
62331735|NCT03593967|EXPERIMENTAL|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
62136130|NCT04383184||TRACHEAL FORMING GROUP|Left pulmonary artery transplantation and slide tracheoplasty
62331736|NCT05851508|ACTIVE_COMPARATOR|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
62331737|NCT05851508|PLACEBO_COMPARATOR|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
62331738|NCT03559244|EXPERIMENTAL|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
62331739|NCT03559244|EXPERIMENTAL|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
62331740|NCT03559244|ACTIVE_COMPARATOR|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
62489580|NCT01717950|EXPERIMENTAL|30 µg Na-APR-1 (M74)/Alhydrogel®|
62489581|NCT01717950|EXPERIMENTAL|30 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
62694539|NCT06638502|EXPERIMENTAL|Active treatment minor hepatic resection|5 participants will receive HRX215 250 mg twice daily orally within 1-3 days after minor (\<=31%) liver resection for colorectal liver metastases for 28 days.
62694540|NCT06638502|ACTIVE_COMPARATOR|Active treatment arm major hepatic resection|10 participants will receive HRX215 250 mg twice daily orally within 1-3 days after major (50-72%) liver resection for colorectal liver metastases for 28 days.
62694541|NCT06638502|PLACEBO_COMPARATOR|placebo arm major hepatic resection|10 participants will receive placebo capsules with matching appearance to HRX215 twice daily orally within 1-3 days after major (50-72%) liver resection for colorectal liver metastases for 28 days
62694542|NCT03383874|PLACEBO_COMPARATOR|Placebo|Participants will receive capsules containing placebo for 24-weeks.
61937045|NCT03266523||Control|The CONTROL (neutral) environment corresponds to the standard environment of the imaging waiting rooms
61937046|NCT03266523||Zen|The ZEN environment will represent a clean, minimalist nature
61937047|NCT03266523||Green|The GREEN environment will represent rural landscapes, undergrowth
61937048|NCT03266523||Sea|The SEA environment will represent lakes, ponds, seaside
61937049|NCT02289001|EXPERIMENTAL|Education on SBAR worksheet|Training in the use of the SBAR worksheet created to structure information exchange between healthcare professionals
62136131|NCT04383184||NON-TRACHEAL FORMING GROUP|only Left pulmonary artery transplantation
62136132|NCT01515501|OTHER|Endoscopic mucosal resection|At time of rectal section biopsy all subjects will under go the additional intervention of an endoscopic muscosal resection.
62331741|NCT01172587|EXPERIMENTAL|Lifestyle Counseling|Couples receive behavioral couples therapy for parental drug use.
62331742|NCT06245018|EXPERIMENTAL|iNK Injection|Cohort1:Low dose iNK injection; Cohort2:Mid dose iNK injection; Cohort3:High dose iNK injection;
62331743|NCT03312777|EXPERIMENTAL|Omnitram|Oral Omnitram 20 mg (overencapsulated 10 mg tablets) administered every 6 hours for nine doses, coadministered with paroxetine.
62489582|NCT01717950|EXPERIMENTAL|30 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
62489583|NCT01717950|EXPERIMENTAL|100 µg Na-APR-1 (M74)/Alhydrogel®|
62489584|NCT01717950|EXPERIMENTAL|100 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
62489585|NCT01717950|EXPERIMENTAL|100 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
62489586|NCT04699396|EXPERIMENTAL|Mobilisation with Movement 1 (MWM1)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at fibula and talus. Three sets of 10 repetitions of each techniques, were administrated.
62489587|NCT04699396|EXPERIMENTAL|Mobilisation with Movement 2 (MWM2)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at talus and fibula (order of application inverted). Three sets of 10 repetitions of each techniques, were administrated.
62489588|NCT04699396|PLACEBO_COMPARATOR|Placebo|The Placebo group participants performed the same number of sets and repetitions of lean/lunge forward into dorsiflexion, without any glide application, in the same position
62136133|NCT03166085|EXPERIMENTAL|PU-H71 With Nab-paclitaxel (Abraxane)|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.
62136134|NCT00093496|EXPERIMENTAL|Treatment (chemotherapy)|Patients are stratified according to gemcitabine hydrochloride therapy (gemcitabine hydrochloride-naive/no prior exposure to gemcitabine hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure to gemcitabine hydrochloride as a single agent with disease progression while on treatment). Patients receive tanespimycin IV over 2 hours on days 1 and 8 during course 1 and days 2 and 9 during subsequent courses and gemcitabine hydrochloride IV over 30 minutes on day 7 during course 1 and days 1 and 8 during subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
62331744|NCT03312777|ACTIVE_COMPARATOR|Tramadol|Oral tramadol 50 mg (overencapsulated 50 mg tablet) administered every 6 hours for nine doses, coadministered with paroxetine.
62331745|NCT03312777|PLACEBO_COMPARATOR|Placebo|Oral placebo (overencapsulated microcrystalline) administered every 6 hours for nine doses, coadministered with paroxetine.
62331746|NCT00339183|EXPERIMENTAL|Panitumumab Plus FOLFIRI|Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
62331747|NCT00339183|ACTIVE_COMPARATOR|FOLFIRI Alone|Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
62331748|NCT05818124|EXPERIMENTAL|Panel A: Molnupiravir Post-Exposure Prophylaxis (Part 2)|Molnupiravir 800 mg every 12 hours Day 0 PM through Day 5 AM, placebo molnupiravir every 12 hours Day 5 PM through Day 6 PM
62331749|NCT05818124|EXPERIMENTAL|Panel B: Molnupiravir Treatment (Part 2)|Placebo molnupiravir every 12 hours Day 0 PM through Day 1 PM, molnupiravir 800 mg every 12 hours Day 2 AM through Day 6 PM
62331750|NCT05818124|ACTIVE_COMPARATOR|Panel C: Oseltamivir Treatment (Part 2)|Placebo oseltamivir Day 0 PM through Day 1 PM, oseltamivir 75 mg plus placebo so the total number of capsules is always 4 per dose every 12 hours Day 2 AM through Day 6 PM
62331751|NCT05818124|PLACEBO_COMPARATOR|Panel D: Molnupiravir Placebo (Part 2)|Placebo molnupiravir every 12 hours Day 0 PM through Day 6 PM
62331752|NCT05818124|EXPERIMENTAL|Virus Inoculation (Part 1 & 2)|Influenza A challenge virus given once by intranasal administration
62331753|NCT02146079|EXPERIMENTAL|Semaglutide 0.5 mg|Dose-escalation trial
62331754|NCT02146079|PLACEBO_COMPARATOR|Semaglutide placebo 0.5 mg|
62331755|NCT02146079|EXPERIMENTAL|Semaglutide 1.0 mg|Dose-escalation trial
62331756|NCT02146079|PLACEBO_COMPARATOR|Semaglutide placebo 1.0 mg|
62489589|NCT04699396|EXPERIMENTAL|Intervention|The experimental groups (MWM1 and MWM2), were later merged into a single Intervention group.
62489590|NCT05326880|EXPERIMENTAL|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
62489591|NCT05326880|ACTIVE_COMPARATOR|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
62489592|NCT05069480|ACTIVE_COMPARATOR|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was one hour and few minutes rest in between. The first part included: reflex inhibiting patterns, strengthening activities, stretching exercises, and postural reactions exercises. The second part included: arm-reaching tasks, arm-hand tasks, hand manipulative tasks for the more affected upper limb through performing functional tasks of daily living activities.~The traditional intervention was carried out three sessions per week for twelve successive weeks."
62694543|NCT03383874|EXPERIMENTAL|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
62331757|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
62331758|NCT04598581|ACTIVE_COMPARATOR|Low Dose Radiation Therapy (LD-RT)|
62331759|NCT04598581|SHAM_COMPARATOR|Sham irradiation|
62331760|NCT05256277|EXPERIMENTAL|CT101a|1 dose infusion
62331761|NCT04355156|EXPERIMENTAL|Axitinib|small molecule multi-kinase inhibitor
62331762|NCT04355156|PLACEBO_COMPARATOR|Placebo|
62331763|NCT06448312|EXPERIMENTAL|SKB264+Pembrolizumab|Participants will receive SKB264 on Day 1、Day 15 and Day 29 of each 6-week cycle,Pembrolizumab on Day1 of each 6-week cycle.
62331764|NCT06448312|ACTIVE_COMPARATOR|Pembrolizumab|Participants will receive Pembrolizumab on Day 1 of each 6-week cycle.
62331765|NCT02248935||Repair with Alyte or Restorelle Y-Mesh|Women who underwent their index robotic-assisted laparoscopic sacrocolpopexy at Morristown Medical Center or Overlook Medical Center using either the Alyte Y-mesh or Restorelle Y-smartmesh between 1/2007 and 8/2011.
62331766|NCT03873467|EXPERIMENTAL|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
62331767|NCT03873467|OTHER|Wait-List Control|The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
62331768|NCT00604058|EXPERIMENTAL|Group A|
62331769|NCT00604058|ACTIVE_COMPARATOR|Group B|
62489593|NCT05069480|EXPERIMENTAL|Experimental Group|"Participants of the experimental group have received two hours treatment program that included three parts, the first and the second parts were similar to that applied for participants in the control group for one hour followed by few minutes rest, then the third part was applied for one hour. The third part included a virtual reality intervention program by using virtual reality equipment to simulate a range of upper limb tasks related to arm-hand activities and hand manipulative tasks through using different games and soft-wares.~The treatment program for the experimental group was carried out three sessions per week for twelve successive weeks."
62489594|NCT06628349|EXPERIMENTAL|Healthy male older adults|Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water
62489595|NCT06628349|EXPERIMENTAL|Healthy female older adults|Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water
62489596|NCT06628349|EXPERIMENTAL|Healthy male old older adults|Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water
62489597|NCT06628349|EXPERIMENTAL|Healthy female old older adults|Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water
61937050|NCT02289001|NO_INTERVENTION|No education on SBAR worksheet|The control group will participate in the simulation without any prior training in teamwork skills beyond those included in the undergraduate nursing degree curriculum, which the intervention group also received.
61937051|NCT04449510|OTHER|E-liquid pH 5, 7, or 9|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned e-liquid pH.
61937052|NCT04449510|OTHER|1 of the other 2 remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 assigned e-liquid pH.
61937053|NCT04449510|OTHER|Remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining assigned e-liquid pH.
61937054|NCT04521673||infectious uveitis|Patients suffering from suspected infectious uveitis, who have vitrectomy performed for diagnostic purpose or anterior chamber tap
62331770|NCT01240044|NO_INTERVENTION|Control Group|In this group the newborns remained at rest 20 minutes and receive no intervention of respiratory therapy.
62331771|NCT01240044|EXPERIMENTAL|Physical Therapy|In this group the newborns are submitted to the mechanical vibrator.
62331772|NCT01240044|EXPERIMENTAL|Thoracoabdominal rebalancing|In this group the newborns receive the thoracoabdominal rebalancing.
62331773|NCT02630082|OTHER|Intervention|Circumcision and flexible sigmoidoscopy
62331774|NCT03637192|EXPERIMENTAL|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
62331775|NCT03637192|EXPERIMENTAL|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
62331776|NCT00411788|EXPERIMENTAL|sirolimus and trastuzumab|Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
62331777|NCT04043338|EXPERIMENTAL|XC130-A10H|XC130-A10H (single dose)
62331778|NCT04043338|PLACEBO_COMPARATOR|Placebo|placebo (single dose)
62331779|NCT02939144|EXPERIMENTAL|Liquorice|Participants of the single-arm study will ingest liquorice candy and their blood, saliva and urine samples will be collected. They will be regularly monitored for any potential side effects.
62331780|NCT05607290|OTHER|Treatment|Empirical supported psychotherapy for alcohol use disorder (Cognitive-Behavioral Therapy, Motivational Interviewing).
62331781|NCT04811313|ACTIVE_COMPARATOR|T group|each participant will receive 15 mg/kg of tranexamic acid diluted in a 10 mL syringe slowly over 10-15 minutes, 15 minutes before skin incision.
61937055|NCT04521673||Control group|Patients suffering from either cataract surgery or vitrectomy who has been ruled out for infectious ocular diseases
61937056|NCT05154201|EXPERIMENTAL|Dose escalation of ORIN1001 as a single agent|"Single-agent dose escalation in Chinese patients with advanced solid tumors. Nine dose groups: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 650 mg, 900 mg, 1200 mg, and 1500 mg orally in 21-day cycles.~A total of 27-54 evaluable patients are expected to be enrolled. However, the dose in the escalation phase is not limited to these dose groups, and the number of enrolled patients is not limited to 27-54."
62331782|NCT04811313|ACTIVE_COMPARATOR|TC group|each participant will receive 10 mg/kg of tranexamic acid diluted in a 5 mL syringe slowly over 5 minutes, 15 minutes before skin incision, and A caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
62331783|NCT04811313|ACTIVE_COMPARATOR|C group|each participant will receive a caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
62331784|NCT04811313|PLACEBO_COMPARATOR|P group|participants will receive the regular standard care without adding tranexamic acid or caudal epidural block
62489598|NCT06628349|EXPERIMENTAL|Sarcopenic male old older adults|Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water
62489599|NCT06628349|EXPERIMENTAL|Sarcopenic female old older adults|Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water
62489600|NCT04614857|EXPERIMENTAL|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
62331785|NCT01808118|EXPERIMENTAL|Double-Blind Adalimumab|40 mg every other week (eow), Weeks 28-68. Blinded adalimumab was discontinued in participants who met the criteria for flare.
62331786|NCT01808118|EXPERIMENTAL|Open-label (OL) Adalimumab|40 mg every other week (eow), Weeks 0-28. If participants flared during the double-blind period, they had an opportunity to receive at least 12 weeks of open-label adalimumab 40 mg eow.
62331787|NCT01808118|PLACEBO_COMPARATOR|Placebo|Placebo every other week (eow), Weeks 28-68. Placebo was discontinued in participants who met the criteria for flare.
62331788|NCT06231199|EXPERIMENTAL|gastrocnemius release|the patients will receive gastrocnemius release manually and by foam roller three times a week for four weeks plus conventional treatment
62331789|NCT06231199|ACTIVE_COMPARATOR|conventional treatment|the patients will receive conventional treatment three times a week for four weeks
62331790|NCT01481636||No treatment, OSA (AHI >15)|Patients with OSA recruited prior to receiving NHS treatment.
62331791|NCT05342129|EXPERIMENTAL|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
62331792|NCT05342129|NO_INTERVENTION|regular rehabilitation exercises|walking exercise
62331793|NCT01763905|ACTIVE_COMPARATOR|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
62331794|NCT01763905|ACTIVE_COMPARATOR|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
62331795|NCT01763905|EXPERIMENTAL|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
62331796|NCT01763905|EXPERIMENTAL|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
62331797|NCT03945045|EXPERIMENTAL|SCV|TIVAD implanted through subclavian vein under real-time ultrasound guidance
62331798|NCT03945045|EXPERIMENTAL|IJV|TIVAD implanted through internal jugular vein under real-time ultrasound guidance
62331799|NCT02626104|EXPERIMENTAL|A - Lactoferrin|Bovine lactoferrin orally - 100 mg twice a day, for whole antibiotic treatment period.
62331800|NCT02626104|PLACEBO_COMPARATOR|B - Maltodextrin|Maltodextrin orally - 100 mg twice a day, for whole antibiotic treatment period.
62331801|NCT01863849|EXPERIMENTAL|Age group 1: adults (18-59 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
62331802|NCT01863849|EXPERIMENTAL|Age group 2: elderly (> 60 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
62489601|NCT05990127|EXPERIMENTAL|AK104 arm|
62489602|NCT05990127|ACTIVE_COMPARATOR|Tislelizumab arm|
62694544|NCT04987775|ACTIVE_COMPARATOR|N-Acetyl Cysteine (NAC)|Participants who are randomized to the intervention arm will receive N-Acetyl-L-Cysteine (Free-Form/NAC) 900mg two times a day for 8 weeks after the initiation of the first dose of study drug.
62331803|NCT00076219|EXPERIMENTAL|Intensive renal replacement therapy|In the intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 6 times per week, and continuous venovenous hemodiafiltration was provided at 35 mL/kg/hour.
62331804|NCT00076219|ACTIVE_COMPARATOR|Less-intensive renal replacement therapy|In the less-intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 3 times per week, and continuous venovenous hemodiafiltration was provided at 20 mL/kg/hour.
62331805|NCT01387295|EXPERIMENTAL|chemotherapy|
62331806|NCT03445052|EXPERIMENTAL|2018 XPAND Intervention Arm|This group will receive the personalised adherence intervention in 2018 in addition to routine clinical care.
62331807|NCT03445052|NO_INTERVENTION|2018 XPAND Control Arm|This group will receive routine clinical care and act as the control group for the primary objective: To compare the mean daily dose of UVR (SEDs) reaching the face between the intervention group and control group over a 3 week period in June to July (follow-up 1). This group will receive the intervention in 2019, to allow within group change to be assessed.
62331808|NCT01933191|EXPERIMENTAL|physical acticity|Experimental: Aerobic treadmill exercise (30 minutes, 70% VO2max)
62331809|NCT01933191|PLACEBO_COMPARATOR|placebo exercise|Aerobic treadmill exercise (30 minutes, 20% VO2max)
62489603|NCT04285268|EXPERIMENTAL|Treatment (rituximab, venetoclax, bortezomib)|Patients receive rituximab IV on day -1 of cycle 1, then on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-14 and bortezomib IV or SC on day -1 of cycle 1, then on days 1, 8, and 15 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles for rituximab and up to 26 cycles for venetoclax and bortezomib in the absence of disease progression or unacceptable toxicity.
62489604|NCT01426854|ACTIVE_COMPARATOR|Nepafenac|Nepafenac Ophthalmic Suspension, 0.1%, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
62489605|NCT01426854|PLACEBO_COMPARATOR|Placebo|Nepafenac Vehicle, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
62694545|NCT04987775|PLACEBO_COMPARATOR|Placebo|Participants who are randomized to the placebo arm will take matching placebo two times a day for 8 weeks after the initiation of the first dose of study drug.
62694546|NCT04232553|EXPERIMENTAL|Mirikizumab SC|Mirikizumab given subcutaneously (SC).
62694547|NCT04232553|EXPERIMENTAL|Mirikizumab IV and SC|Mirikizumab given intravenously (IV) and SC.
62489606|NCT04345107|EXPERIMENTAL|SY-009-1mg/d-1|0.5mg BID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-1mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
62489607|NCT04345107|EXPERIMENTAL|SY-009-1mg/d-2|1mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8.Start at the same time as the SY-009-1mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
62489608|NCT04345107|EXPERIMENTAL|SY-009-2mg/d-1|1mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
62489609|NCT04345107|EXPERIMENTAL|SY-009-2mg/d-2|2mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
62489610|NCT04345107|EXPERIMENTAL|SY-009-4mg/d|2mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. If the test and safety assessment of 4mg daily dose group (2mg bid) are completed and the dose termination standard is not met, the test will be terminated; if the safety assessment during or after the test reaches the dose termination standard, the study of 3mg daily dose group (1.5mg bid) will be carried out, and then the test will be terminated.
62489611|NCT04345107|EXPERIMENTAL|SY-009-3mg/d|1.5mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
62489612|NCT04345107|PLACEBO_COMPARATOR|SY-009 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
62489613|NCT06174558||Patients referred to Sleep Health Center for diagnostic PSG|Prospective obstructive sleep apnea patients referred for diagnostic overnight polysomnogram test
62489614|NCT06251349||Intervention group with prophylactic irradiation|Patients with total hip arthroplasty and irradiation (preoperative on the day before the operation (\>24h preoperative)) Quantity: 128 Period: 01.01.2013 - 31.12.2023
62489615|NCT06251349||Control group with prophylactic NSAID-treatment|Patients with total hip arthroplasty and diclofenac treatment Quantity: 384 Period: 01.01.2013 - 31.12.2023
62489616|NCT01325740|ACTIVE_COMPARATOR|STX107 10 mg|
62489617|NCT01325740|PLACEBO_COMPARATOR|Placebo|
62489618|NCT01325740|ACTIVE_COMPARATOR|STX107 30 mg|
62489619|NCT02921516|EXPERIMENTAL|N'ap Grandi|Both Adolescent and Caregiver participate in assessment and intervention groups. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
62489620|NCT02921516|ACTIVE_COMPARATOR|N'ap Grandi - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
62489621|NCT02921516|PLACEBO_COMPARATOR|Health Promotion - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
62331810|NCT02349334|SHAM_COMPARATOR|Sham electrical stimulation|Sham electrical stimulation to forefoot by TENS
62331811|NCT02349334|ACTIVE_COMPARATOR|Percutaneous tibial nerve stimulation|Active PTNS via Urgent PC Neuromodulation device, Uroplasty
62331812|NCT02996695|EXPERIMENTAL|204,800 PfSPZ of PfSPZ Challenge|204,800 PfSPZ of PfSPZ Challenge every 4 weeks x 3 doses by DVI, n=31
62331813|NCT02996695|PLACEBO_COMPARATOR|NaCl placebo|NaCl placebo every 4 weeks x 3 doses by DVI, n=31
62694548|NCT05393427|EXPERIMENTAL|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62694549|NCT05811949||RRMS patients with de novo DMF treatment|RRMS patients with de novo treatment who start DMF.
62694550|NCT05811949||RRMS patients switching to DMF.|RRMS patients who switch from first-line DMT treatment (interferon, glatiramer acetate, teriflunomide) to treatment with DMF.
62331814|NCT03747835|ACTIVE_COMPARATOR|Exposure and Response Prevention|Inpatients will be provided three 90-minute sessions of Exposure and Response Prevention therapy each week.
62331815|NCT03747835|ACTIVE_COMPARATOR|Motivational Interviewing|Inpatients will be provided two 60-minute sessions of Motivational Interviewing each week.
62331816|NCT06162260||observation group|(1) Liver transplantation was performed between January 1, 2019 and December 31, 2019; (2) Age \< 18 years; (3) The patient was admitted to ICU for the first time due to postoperative monitoring after liver transplantation; (4) Survival on first transfer from ICU.
62331817|NCT06162260||matched group|(1) Liver transplantation was performed between January 1, 2019 and December 31, 2019; (2) Age \< 18 years; (3) The patient was admitted to ICU for the first time due to postoperative monitoring after liver transplantation; (4) survive the first transfer from ICU; (5) No ICU re-entry occurred in the same hospitalization period after liver transplantation.
62331818|NCT00142519|ACTIVE_COMPARATOR|1|methadone
62331819|NCT00142519|EXPERIMENTAL|2|methadone and morphine
62331820|NCT04209296||Major Depressive Disorder (MDD)|DSM-5 Diagnosis of MDD
62331821|NCT04209296||Bipolar Disorder|DSM-5 Diagnosis of Bipolar Disorder
62331822|NCT04209296||Obsessive Compulsive Disorder (OCD)|DSM-5 Diagnosis of OCD
62331823|NCT04209296||Post-traumatic Stress Disorder (PTSD)|DSM-5 Diagnosis of PTSD
62489622|NCT06428149|EXPERIMENTAL|Midline interproximal soft-tissue incision|Marginal approach by midline interproximal soft tissue incision and a limited papilla elevation to the buccal aspect will be made for treating isolated periodontal defect. Enamel matrix derivates will be applied on the debrided root surfaces.
62489623|NCT06428149|ACTIVE_COMPARATOR|Marginal approach by palatal incision|A small incision in the palatal aspect and a limited papilla elevation to the buccal aspect will be made for treating isolated periodontal defect. Enamel matrix derivates will be applied on the debrided root surfaces.
62489624|NCT06428149|ACTIVE_COMPARATOR|Minimally invasive surgical technique|The incision of the defect-associated papilla will be performed according to the principles of the papilla preservation techniques. Enamel matrix derivates will be applied on the debrided root surfaces. Stable primary closure of the flaps will be obtained with internal modified mattress sutures.
61937057|NCT05154201|EXPERIMENTAL|Dose escalation of ORIN1001 in combination with Standard of Care|ORIN1001 will be administered daily as a tablet in combination with standard of care. This arm of the study will be carried out in 8 different cancer indications, including advanced triple-negative breast cancer received ≥ 3 lines of treatment, postmenopausal ER+/HER2-advanced breast cancer received the 1 line of treatment, advanced hepatocellular carcinoma received 1/2 line of treatment, chemotherapy-naive castrate-resistant prostatic cancer, advanced pancreatic cancer received 1/2 line of treatment, platinum-resistant/refractory advanced ovarian cancer received ≥ 2 lines of treatment, non-small cell lung cancer received ≥ 2 lines of treatment, and esophageal cancer received ≥ 2 lines of treatment.
61937058|NCT05154201|EXPERIMENTAL|Dose expansion of ORIN1001 as a single agent or in combination with Standard of Care|"After the recommended phase 2 dose of single-agent ORIN1001 is determined, a single-agent efficacy expansion study for advanced esophageal cancer, as well as a single-agent efficacy expansion study for advanced solid tumors with failure of standard treatments or no effective standard treatment.~After the recommended phase 2 dose of the combination treatment is determined, the efficacy expansion study of the combination treatment will be conducted in the corresponding 8 different indications."
61937059|NCT01284582|EXPERIMENTAL|ATH03 Group A|ATH03, 10 µg, 0.2% Alum
62489625|NCT00627796|EXPERIMENTAL|A|Newly diagnosed patients with acromegaly
62331824|NCT02473133|EXPERIMENTAL|Personalized dose redistribution|Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive). An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
62331825|NCT02473133|SHAM_COMPARATOR|No dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
62489626|NCT04469751|EXPERIMENTAL|patients undergoing neurosurgery|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
61937060|NCT01284582|EXPERIMENTAL|ATH03 Group B|ATH03, 30 µg, 0.2% Alum
61937061|NCT01284582|EXPERIMENTAL|ATH03 Group C|ATH03, 100 µg, 0.2% Alum
61937062|NCT00955123||Active inflammatory bowel disease|Patients with moderate to severe active inflammatory bowel disease (ulcerative colitis and Crohn's disease)
61937063|NCT04515446|OTHER|TROD + PCR diagnosis|For each patient positive for flu with a rapid diagnostic test, sequential nasopharyngeal (NP) samples will be collected for quantitative PCR every day from D1 to D8 or until discharge (if before D8). Sequential quantitative PCR will quantify influenza virus load in the upper airways.
61937064|NCT04920682|ACTIVE_COMPARATOR|Group M (reversion with moderate neuromuscular blockade)|Administration of neostigmine 60 mcg/kg and atropine 30 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4.
61937065|NCT04920682|ACTIVE_COMPARATOR|Group S (reversion with superficial moderate neuromuscular blockade)|Administration of 0.9% saline solution (SF) when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)\> 0.4.
62331826|NCT02380352|EXPERIMENTAL|Short-course|5 days amoxicillin 90 mg/kg/day divided TID followed by 5 days placebo TID
62331827|NCT02380352|ACTIVE_COMPARATOR|Standard|5 days amoxicillin 90 mg/kg/day divided TID followed by alternate formulation 5 days amoxicillin 90 mg/kg/day divided TID
62331828|NCT06440369|EXPERIMENTAL|Training group|Patients will begin the individualized physical activity program during the inclusion visit and will continue it for 6 weeks, with 3 sessions per week (for a total of 18 sessions). At the end, patients will be able to resume their usual activities and will be evaluated again 6 weeks after stopping the program. The training program will be supervised by a physical activity instructor adapted and carried out at the CHRU, in the Nephrology or Rheumatology Department depending on the patient's pathology.
61937066|NCT04920682|ACTIVE_COMPARATOR|Group N (two-step reversal of neuromuscular blockade)|Administration of neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)\> 0.4 .
62331829|NCT06440369|ACTIVE_COMPARATOR|Physical activity orientation group|Patients will be encouraged to engage in physical activity and will receive phone calls for instructions regarding this practice. They will be contacted by telephone each week, for a total of 6 calls, each lasting approximately 10 minutes.
62489627|NCT01574027|PLACEBO_COMPARATOR|Placebo|Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
62489628|NCT01574027|EXPERIMENTAL|Vitamin D3 (cholecalciferol)|Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.
62489629|NCT02030535|EXPERIMENTAL|Tiotropium/Olodaterol FDC|patient will receive tiotropium and olodaterol in a fixed dose combination
62489630|NCT02030535|EXPERIMENTAL|Tiotropium and Olodaterol FC|patient will receive tiotropium and olodaterol in a free combination
62489631|NCT02030535|PLACEBO_COMPARATOR|Placebo|patient will receive placebo
62489632|NCT01945580|ACTIVE_COMPARATOR|Xenform|Prolapse Repair with Xenform Soft Tissue Repair Matrix
62489633|NCT01945580|ACTIVE_COMPARATOR|Control|Prolapse Repair with Native Tissue Only
62489634|NCT00577655|EXPERIMENTAL|Albuterol|Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
62489635|NCT00577655|PLACEBO_COMPARATOR|Placebo|"A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)"
62489636|NCT02736019|ACTIVE_COMPARATOR|Celecoxib|Women will receive oral celecoxib 200mg 2 hours before the procedure
62489637|NCT02736019|ACTIVE_COMPARATOR|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
61937067|NCT04920682|PLACEBO_COMPARATOR|Group P (placebo)|Administration of 0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4.
61937068|NCT05068024|EXPERIMENTAL|Treatment of NSCLC patients with EGFR or HER2 genetic alterations|
61937069|NCT01527318|EXPERIMENTAL|Fibrate Treatment|Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
61937070|NCT05139082|OTHER|CDK4/6 inhibitor (TQB3616) + PD-L1 monoclonal antibody (TQB2450)|TQB3616 capsules (120/150/180mg p.o. qd, d1-d21) combined with TQB2450 injection (1200mg ivgtt, d1)
61937071|NCT01340547|OTHER|Single Arm|Single Arm, non-blinded, non-randomized
61937072|NCT00917111|EXPERIMENTAL|CO2 Gas|
61937073|NCT00917111|PLACEBO_COMPARATOR|Inactive Placebo Gas|
61937074|NCT00750386|EXPERIMENTAL|1|Paclitaxel/Carboplatin
61937075|NCT00619138|ACTIVE_COMPARATOR|1|
61937076|NCT00619138|ACTIVE_COMPARATOR|2|
61937077|NCT00389727|EXPERIMENTAL|Group 1 Patients|Radiotherapy Patients
61937078|NCT00389727|NO_INTERVENTION|Group 2|
61937079|NCT05044000|EXPERIMENTAL|Heavy blanket|Patients will start with heavy blanket during 15 days
61937080|NCT05044000|PLACEBO_COMPARATOR|Non-heavy blanket|Patients will start with non-heavy blanket during 15 days
62331830|NCT06440369|NO_INTERVENTION|Control group|
62331831|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
61937081|NCT03401593|ACTIVE_COMPARATOR|ablation|Patients in this group are treated with radio-frequency catheter ablation.
61937082|NCT03401593|NO_INTERVENTION|non-ablation|Patients in this group are treated with rate control medications (e.g., beta blocker, calcium channel blocker, and digitalis) and anti-arrhythmic drugs. They also can be treated with DC cardio-version.
61937083|NCT06045104|ACTIVE_COMPARATOR|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
61937084|NCT06045104|EXPERIMENTAL|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
61937085|NCT06681792|EXPERIMENTAL|Intervention Group|The experimental group will take part in seven weekly workshops based on Protection Motivation Theory .
62331832|NCT06186882|EXPERIMENTAL|ENVIRONMENTAL STIMULATION|
61937086|NCT06681792|NO_INTERVENTION|Control Group|The control group will not receive any intervention. It was planned to apply the data collection instruments to the control group under the supervision of the researcher and in parallel with the intervention group during the same period.
61937087|NCT01310881|EXPERIMENTAL|Dose 1|
61937088|NCT01310881|EXPERIMENTAL|Dose 2|
61937089|NCT01310881|EXPERIMENTAL|Dose 3|
61937090|NCT01310881|EXPERIMENTAL|Dose 4|
61937091|NCT01310881|EXPERIMENTAL|Dose 5|
61937092|NCT01310881|EXPERIMENTAL|Dose 6|
61937093|NCT01310881|EXPERIMENTAL|Dose 7|
61937094|NCT04160962||lappg|
61937095|NCT04160962||ladgbi|
61937096|NCT02475031|PLACEBO_COMPARATOR|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
61937097|NCT02475031|ACTIVE_COMPARATOR|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
61937098|NCT01498601|EXPERIMENTAL|Oral care treatment group|All subjects in the prospective intervention group will receive the same enhanced oral care protocol
62331833|NCT02892461|EXPERIMENTAL|Umbilical cord milking|The cord will be cut at 25 cm from the umbilical stump within 30 seconds after the infant is taken out from the uterus and its blood will be milked to the infant gently and thoroughly in 30 seconds during resuscitation on the radiant warmer, and then the cord will be cut at 2 to 3 cm from the umbilical stump.
62331834|NCT02892461|NO_INTERVENTION|Routine clinical treatment and care|The cord will be dealt with routine clinical method, which means it will be cut twice within 1minute after the infant is taken out from the uterus, the first cut is on the operating table, while the second cut is on the radiant warmer.
62331835|NCT03184298|OTHER|Group|Participants receive three interventions: Surveys, Interviews, and Group Workshops
62331836|NCT02672319|EXPERIMENTAL|EUS-guided glue injection|Gastroesophageal varices \> 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
62331837|NCT02672319|NO_INTERVENTION|Historical control|A historical control group of HCC patients with gastroesophageal variceal bleeding who underwent conventional cyanoacrylate injection by OGD for index variceal bleeding based on de-identified data from an existing prospective GI bleed database from 2009-2013 would also be included to allow a more meaningful interpretation of the rebleeding rate from gastroesophageal varices from this study.
62331838|NCT02162485|EXPERIMENTAL|Salmeterol/fluticasone Easyhaler|Single dose of Salmeterol/fluticasone Easyhaler
62331839|NCT02162485|EXPERIMENTAL|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)
62331840|NCT02162485|ACTIVE_COMPARATOR|Seretide Diskus|Single dose of Seretide Diskus
62331841|NCT02162485|ACTIVE_COMPARATOR|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)
62331842|NCT02819310|EXPERIMENTAL|BLI400 Laxative|BLI400 Laxative
62331843|NCT04379934|OTHER|Heart failure|Ejection fraction \< 45%
62489638|NCT02736019|PLACEBO_COMPARATOR|Placebo|Women will receive a placebo similar to celecoxib and a placebo similar to Tramadol
62489639|NCT04327401|EXPERIMENTAL|Intervention group|Dexamethasone. After randomization, dexamethasone \[20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days\] + standard treatment (according to the treatment protocol for 2019-nCoV infection).
62489640|NCT04327401|NO_INTERVENTION|Control|Standard treatment (according to the treatment protocol for 2019-nCoV infection).
62489641|NCT03947658|EXPERIMENTAL|Six weeks group|Prosthetic restoration started 6 weeks after surgical crown lengthening
62694551|NCT06639256|EXPERIMENTAL|Test product HY07121 for Dose Escalation|PART ONE- Dose escalation: HY07121 should be administered intravenously at recommended dose. The purpose of the Dose Escalation Phase (Part one) is to characterize the safety and tolerability of the test product HY07121 and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) based on the frequency of the occurrence of Dose-Limiting Toxicity (DLT) in each cohort during the DLT evaluation period.
62694552|NCT06639256|EXPERIMENTAL|Test product HY07121 for Dose Expansion|PART TWO- Dose expansion: HY07121 should be administered intravenously at recommended dose. Patients will be administered a recommended dose of HY07121 established from the Dose Escalation Phase of the study.
62694553|NCT04089111|EXPERIMENTAL|1.1. ASV, MV target 100%|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
62331844|NCT04379934|OTHER|Non-heart failure|Ejection fraction \> 45%
62331845|NCT01834924|ACTIVE_COMPARATOR|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
62694554|NCT04089111|ACTIVE_COMPARATOR|1.2. Volume control, MV target %100|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3 Ventilation frequency will be adjusted to reach the same volume target calculated in arm1.
62694555|NCT04089111|EXPERIMENTAL|2.1. ASV, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
62694556|NCT04089111|ACTIVE_COMPARATOR|2.2. Volume control, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3. Ventilation frequency will be adjusted to reach the target PaCO2 level
62694557|NCT06638515|EXPERIMENTAL|Walking apnea at Low Lung Volume|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes performing series of intermitent apneas
62694558|NCT06638515|ACTIVE_COMPARATOR|Walking normal breathing|Participants walk with normal breathing at 6 km/h (10% slope) on treadmill for 6 minutes.
62331846|NCT01834924|NO_INTERVENTION|Control|Standard provider medication counseling
61937099|NCT01498601|NO_INTERVENTION|Retrospective study group|For comparison purposes, a retrospective chart review of matched in-patient population will reveal pneumonia rates in the same population who did not receive the enhanced oral care protocol.
61937100|NCT06393036||Patients diagnosed with both OSA and IgAN|Patients diagnosed with both OSA and IgAN, and treated with CPAP in addition to nephrological drug therapy or not.
61937101|NCT03848104||bone and joint infection treated with cefoxitin|patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
61937102|NCT01542658||uterine myoma|
61937103|NCT01043146|ACTIVE_COMPARATOR|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
61937104|NCT01043146|PLACEBO_COMPARATOR|placebo|intravenous 0.9 % NaCl
62331847|NCT06263426|EXPERIMENTAL|HIV D+/R+|People living with HIV who receive kidneys from deceased donors with HIV
62331848|NCT06263426|EXPERIMENTAL|HIV D-/R+|People living with HIV who receive kidneys from deceased donors without HIV
62331849|NCT02128620|NO_INTERVENTION|Control Group|Users randomized to the www.sjekkdeg.no A version, consisting en the educative web app, not including the Game-Based Appointment System
61937105|NCT03283111|EXPERIMENTAL|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
62331850|NCT02128620|EXPERIMENTAL|Intervention Group|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
62331851|NCT03181165|EXPERIMENTAL|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
62489642|NCT03947658|EXPERIMENTAL|Fourteen weeks group|Prosthetic restoration started 14 weeks after surgical crown lengthening
62489643|NCT01693809|EXPERIMENTAL|Caffeine|Caffeine 420mg, one time
62489644|NCT02527213|EXPERIMENTAL|Sodium Thiosulfate|Sodium Thiosulfate at 25g in 100 ml normal sterile saline (NSS)
62489645|NCT02527213|PLACEBO_COMPARATOR|Placebo|similarly-formulated placebo in 100 ml NSS
62489646|NCT06248294||TAVI patients with native BAV|Patients undergoing TAVI for severe aortic stenosis and native bicuspid aortic valve
61937106|NCT02578771|EXPERIMENTAL|ZuraPrep with 70% Isopropyl alcohol|Test Article ZuraPrep with 70% isopropyl alcohol (IPA) will be compared with reference positive control Chloraprep
61937107|NCT02578771|EXPERIMENTAL|ZuraPrep without 70% IPA|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline
61937108|NCT02578771|ACTIVE_COMPARATOR|ChloraPrep Teal Tint|Test Article ZuraPrep with 70% isopropyl alcohol will be compared with reference positive control ChloraPrep \[Chlorhexidine gluconate(CHG)/IPA\] Teal Tint
62331852|NCT03181165|NO_INTERVENTION|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
62331853|NCT03381924|EXPERIMENTAL|Intervention group|Neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
62331854|NCT03381924|PLACEBO_COMPARATOR|Control group|Routine clinical practice
62489647|NCT04034277|EXPERIMENTAL|Lee Silverman Voice Therapy|LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.
62489648|NCT04034277|ACTIVE_COMPARATOR|Conventional Treatment|The content and dose of standard SLT is poorly defined within the published literature. For this reason, the standard therapy intervention will encompass all SLT techniques that are not LSVT®. Treatment will be individualized and may include any of the following: exercises targeting respiration, phonation, articulation, behavioral strategies to reduce prosodic abnormality
62489649|NCT04922957|PLACEBO_COMPARATOR|Placebo|Ringer's lactate solution
62489650|NCT04922957|EXPERIMENTAL|ALLOCETRA-OTS|Single IV dose of Allocetra-OTS containing 10x10\^9 cells
62489651|NCT06405815||high-risk surgical margin|High-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up.
62694559|NCT06641700||the gastric cancer group|Pre-operative gastric cancer diagnosed by pathological biopsy in our clinic.
62694560|NCT06641700||the contol group|Adults with no history of malignancy and willing to participate in this study.
61937109|NCT02578771|PLACEBO_COMPARATOR|Normal Saline 0.85%|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline 0.85%
61937110|NCT04659239|EXPERIMENTAL|Investigational Vaccine|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) according to the immunization schedule of D0, D14.
61937111|NCT04659239|PLACEBO_COMPARATOR|Placebo|Participants will receive 2 doses of the placebo according to the immunization schedule of D0, D14.
61937112|NCT05272449|EXPERIMENTAL|Evaluation of a disposable sound sensor for recording respiration during sleep|PneaVoX sensor, CIDELEC
61937113|NCT01008397|EXPERIMENTAL|AHIST for seasonal allergic rhinitis|AHIST for SAR: each green tablet contains 12mg chlorpheniramine tannate.
61937114|NCT01757262|EXPERIMENTAL|Ticagrelor|90 mg Ticagrelor
61937115|NCT01757262|ACTIVE_COMPARATOR|Clopidogrel|75mg Clopidogrel
62331855|NCT04439838|EXPERIMENTAL|1 mg BI 1595043|1 mg BI 1595043
62331856|NCT04439838|EXPERIMENTAL|3 mg BI 1595043|3 mg BI 1595043
62331857|NCT04439838|EXPERIMENTAL|6 mg BI 1595043|6 mg BI 1595043
62331858|NCT04439838|EXPERIMENTAL|12 mg BI 1595043|12 mg BI 1595043
62331859|NCT04439838|EXPERIMENTAL|25 mg BI 1595043|25 mg BI 1595043
62331860|NCT04439838|EXPERIMENTAL|50 mg BI 1595043|50 mg BI 1595043
62331861|NCT04439838|EXPERIMENTAL|90 mg BI 1595043|90 mg BI 1595043
62331862|NCT04439838|EXPERIMENTAL|160 mg BI 1595043|160 mg BI 1595043
62331863|NCT04439838|PLACEBO_COMPARATOR|Matching Placebo|Matching Placebo
62331864|NCT05528497|EXPERIMENTAL|VR+|For patients in the experimental group, using the virtual reality headset, the caregiver will place the headset on the patient as she is laid on the surgical table. The caregiver will ensure that the patient can see and hear the sequence that is being performed. The caregiver can then proceed to the different stages of ovocyte retrieval. Once the procedure is finished, the caregiver tells the patient that she can remove the headset
62331865|NCT05528497|NO_INTERVENTION|Control|For patients in the control group, without a headset, the oocyte retrieval procedure will not be modified.
62331866|NCT04491786|EXPERIMENTAL|GAPA|Participants will treated with preoperative 600 mg of gabapentin plus nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
62331867|NCT04491786|NO_INTERVENTION|Non-GAPA|Participants will treated with nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
62489652|NCT06405815||Low-risk surgical margin|Low-risk margins were defined as R0 surgical margin meanwhile arising distant metastasis during follow-up.
62489653|NCT06466213|EXPERIMENTAL|single session one leg exercise intervantion in COPD|"first session: single session leg Continuous exercise intervantion will be applied to COPD. Unilaterally single leg continuous exercise will be performed as only one session~second session : single session leg high intensity interval exercise intervantion will be applied to COPD. Unilaterally single leg hııt exercise will be performed as only one session~third sessionsingle session leg resistance exercise intervantion will be applied to COPD. Respirocally leg strength (knee extantion ) exercise will be performed"
62489654|NCT04403620|ACTIVE_COMPARATOR|Conventionally fractionated radiotherapy|60 Gy in 30 fractions, 5 fractions/week
62489655|NCT04403620|EXPERIMENTAL|Hypofractionated radiotherapy|"Dose and fractionation determined by Phase I:~Level 1: 44.4 Gy in 12 fractions, 4 fractions/week~Level 0: 46.5 Gy in 15 fractions, 5 fractions/week~Level -1: 52 Gy in 20 fractions, 5 fractions/week~Level -2: 50 Gy in 20 fractions, 5 fractions/week"
61937116|NCT01179893|ACTIVE_COMPARATOR|IVIG|Intravenous Immunoglobulin, 2G/Kg, infused over 2 days in the Medical Day Unit of the University Health Network
62331868|NCT00696865|EXPERIMENTAL|1|
62331869|NCT00696865|PLACEBO_COMPARATOR|2|
62331870|NCT02116660|EXPERIMENTAL|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
62331871|NCT02116660|ACTIVE_COMPARATOR|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
62331872|NCT05224401|EXPERIMENTAL|PAC treatment|
62331873|NCT05224401|ACTIVE_COMPARATOR|Standard treatment|
62331874|NCT05137509||Patients Infected by severe acute respiratory syndrome coronavirus 2 (SARS-cov-2)|Patients Infected by COVID -19 diagnosed by Reverse transcriptase polymerase chain reaction and computerized tomography
62694561|NCT04874194|EXPERIMENTAL|Treatment (omacetaxine, venetoclax)|Patients receive omacetaxine SC BID on days 2-3 or 2-4, and venetoclax PO on days 1-7, 1-10 or 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62694562|NCT06637046|EXPERIMENTAL|Lidocaine group|Patients randomized to this arm received less than a .5cc infiltration of plain lidocaine
62694563|NCT06637046|EXPERIMENTAL|Papavarine|Patients randomized to this arm received less than a .5cc infiltration of 10mg/ml papaverine
62694564|NCT04600089|PLACEBO_COMPARATOR|Standard of Care|Participants in this group will receive standard of care as well as a saline infusion during the study period.
62697624|NCT03282916|PLACEBO_COMPARATOR|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day.
61937117|NCT01179893|EXPERIMENTAL|PLEX|Patients received one plasma volume plasma exchanges with 5% albumin replacement fluid. Five plasma exchange procedures occurred every second day with breaks over the weekend allowed. Patients treated in the apheresis units at the University Health Network.
61937118|NCT01502007|EXPERIMENTAL|Accelerometer feedback and lifestyle counseling|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling.
61937119|NCT01502007|EXPERIMENTAL|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The control group will continue to wear the fitbit for the next 24 weeks without any feedback or activity counseling. Following the 26th week of the study, the subjects in the control group will complete the same program given to the experimental group in weeks 2 through 26.
61937120|NCT01924624|EXPERIMENTAL|Thalidomide|Thalidomide 100mg per day after the radical resection HCC
61937121|NCT01924624|ACTIVE_COMPARATOR|Control|No adjuvant Thalidomide treatment after curative hepatic resection
61937122|NCT05695300|ACTIVE_COMPARATOR|BLM ORGANIC GOLD+|BLM ORGANIC GOLD+ infant formula,800g/can
61937123|NCT05695300|PLACEBO_COMPARATOR|BLM ORGANIC|BLM ORGANIC infant formula,800g/can
62136135|NCT05839067|EXPERIMENTAL|CARE-HF|The problem-solving intervention will be led by a registered nurse. Participants will receive a program manual containing examples of common HF-related problems experienced by heart failure patients and suggested management strategies, with some strategies tailored to the rural sociocultural context. The nurse will lead participants in a card sorting task intended to help participants prioritize current HF-related problems and will guide participants in developing management strategies for the highest priority problem(s). Participants will utilize these strategies until the next session at which time the nurse will guide participants in evaluating the effectiveness of chosen strategies. The iterative process then begins again. Participants will receive 7 follow-up telephone sessions with the nurse. In the intervention, the nurse will focus on problems related to self-care, disease management, mental health, and quality of life, including those specific to the rural population.
62136136|NCT01862016|ACTIVE_COMPARATOR|VAC mode, Controlled ventilation|From randomization, patients are put under controlled ventilation with specific settings
62136137|NCT01862016|EXPERIMENTAL|APRV mode, Spontaneous breathing|During 1 to 3 hours after randomization, patients are put under controlled ventilation with specific settings for baseline data. After that, they are placed under APRV mode with specific settings
62136138|NCT04930406||Historical control group|
62136139|NCT04930406||Intervention group|
62136140|NCT05286788|EXPERIMENTAL|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
62136141|NCT04688060||fallers|stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure Patients who have fallen 1 or more times since stroke
62136142|NCT04688060||non-fallers|"stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure.~Patients who have not fallen 1 or more times since stroke"
62136143|NCT02967861|ACTIVE_COMPARATOR|SRP & pranayama (lifestyle modification)|30 chronic periodontitis subjects treated with SRP \& pranayama for 3 months
62136144|NCT02967861|PLACEBO_COMPARATOR|Scaling and root planing|30 chronic periodontitis subjects treated with scaling and root planing only
62136145|NCT04428710||patients admitted to cancer genetic counseling test|Participants were recruited from all consecutive patients referred to the Cancer Genetic Program at the Hospital Universitari i Politècnic la Fe.
62136146|NCT00811941|PLACEBO_COMPARATOR|Placebo|
62136147|NCT00811941|EXPERIMENTAL|Nalmefene|
62136148|NCT02130557|EXPERIMENTAL|Bosutinib|Bosutinib, 400 mg, oral administration once a day
62136149|NCT02130557|ACTIVE_COMPARATOR|Imatinib|Imatinib, 400 mg, oral administration once a day
62136150|NCT05683990|EXPERIMENTAL|Arm 1|2 injections of Diamyd®
62136151|NCT05683990|EXPERIMENTAL|Arm 2|3 injections of Diamyd®
62136152|NCT02103361||Stelara (ustekinumab) exposed|Stelara (ustekinumab)-exposed pregnant women (this group is now closed to recruitment)
62136153|NCT02103361||Tremfya (guselkumab) exposed|Tremfya (guselkumab-exposed pregnant women
62331875|NCT05137509||patients suffering from chronic lung disease|Diagnosed by clinical manifestation and Computerized tomogarphy
62489656|NCT02761915|OTHER|Dose Level 1|Patients in Dose Level 1 will receive 1x10\^7 1RG-CART/m\^2 intravenously (IV) on Day 0.
61937124|NCT05695300|OTHER|Breast milk|Mother's breast milk
62136154|NCT04576975|EXPERIMENTAL|Ketamine|This group will receive a bolus dose of Ketamine \[Ketamine HCL - Sterop, Belgium\] (0.3 mg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which Ketamine infusion (500 mg vial diluted over 50 cc infusion syringe, concentration 10 mg/ml) will start with rate of 0.3 mg/kg/hr till 10 Minutes before the end of the surgery
62331876|NCT05137509||Healthy Individuals|They must be without prior history of chronic inflammation in the lung
62489657|NCT02761915|OTHER|Dose Level 2|Patients in Dose Level 2 will receive 300 mg/m\^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10\^7 1RG-CART/m\^2 IV on Day 0.
62697625|NCT04742023|EXPERIMENTAL|Intervention Arm|
62697626|NCT04742023|PLACEBO_COMPARATOR|Control Arm|
62489658|NCT02761915|OTHER|Dose Level 3|Patients in Dose Level 3 will receive 300 mg/m\^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m\^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10\^7 1RG-CART/m\^2 IV on Day 0.
62489659|NCT02761915|OTHER|Dose Level 4|Patients in Dose Level 4 will receive 300 mg/m\^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m\^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10\^8 1RG-CART/m\^2 IV on Day 0.
62331877|NCT03204721|ACTIVE_COMPARATOR|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
62331878|NCT03204721|NO_INTERVENTION|Controll|No procedure
62331879|NCT03428412|EXPERIMENTAL|TCM plus conventional drug|The experimental group will receive three type of TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
62331880|NCT03428412|PLACEBO_COMPARATOR|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
62489660|NCT02761915|OTHER|Dose Level 5|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300 mg/m\^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m\^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10\^8 1RG-CART/m\^2 IV which could be be split over two days (Day 0 and Day 1).
62489661|NCT02761915|OTHER|Patients who underwent leukapheresis but did not proceed to receive any IMP|Patients who were enrolled and underwent leukapheresis but who did not receive any IMP.
62489662|NCT00323258|EXPERIMENTAL|Intervention|Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
62489663|NCT00323258|ACTIVE_COMPARATOR|Usual Care|The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
62489664|NCT03573544|EXPERIMENTAL|OBI-888 Escalation Phase|Part A: Three cohorts of escalating dose levels of OBI-888 5, 10, and 20 mg/kg liquid form for intravenous infusion to establish maximum tolerated dose (MTD).
62489665|NCT03573544|EXPERIMENTAL|OBI-888 Expansion Phase|Part B: Five cohorts at dose level 20 mg/kg of liquid form OBI-888 for intravenous infusion.
62489666|NCT01260805|ACTIVE_COMPARATOR|Reference Drug|
62489667|NCT01260805|ACTIVE_COMPARATOR|Test Drug|
62489668|NCT05936554|ACTIVE_COMPARATOR|whole body vibration|will receive whole body Vibration training that elicits a warm up effect to improves muscle power and balance in addition to designed physical program.
62489669|NCT05936554|ACTIVE_COMPARATOR|Functional strength training|will receive Functional strength training that focuses on the movement pattern quality and treats functional movement and provides postural stability while promoting balance independence with confidence
62489670|NCT04228822|EXPERIMENTAL|Low carb diet intervention group|Low carbohydrate diet defined as 25-35% of total energy intake
62489671|NCT04228822|NO_INTERVENTION|Control|Standard diet defined as 45-65% total energy intake
62489672|NCT02379533|NO_INTERVENTION|sedentary control|
62489673|NCT02379533|EXPERIMENTAL|Home-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.
62694565|NCT04600089|EXPERIMENTAL|Sub-Dissociative Ketamine|Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.
62694566|NCT06174220|ACTIVE_COMPARATOR|Tideglusib|Randomization to Tideglusib 1g po daily or matching placebo
62694567|NCT06174220|PLACEBO_COMPARATOR|Placebo|Randomization to matching placebo 1g po daily
62694568|NCT05927298||Cohort 1|Upfront resectable PDAC
62694569|NCT05927298||Cohort 2|Advanced (unresectable PDAC or metastatic)
62331881|NCT05177952|EXPERIMENTAL|Blood Flow Restriction|The BFR group will complete 1 set of 30 (1 x 30) at 30% of their 1 repetition maximum for leg press, leg extension, leg curl, chest press, seated row, and shoulder press completed on exercise machines with 2 minutes between exercises.
62331882|NCT05177952|ACTIVE_COMPARATOR|Standard of Care|The standard of care group will complete 1 set of 8-12 repetitions at 60-80% of their 1 repetition maximum for leg press, leg extension, leg curl, chest press, seated row, and shoulder press completed on exercise machines with 2 minutes between exercises.
62331883|NCT04355975||Medical Therapy / Anticoagulation|
62331884|NCT04355975||Systemic Lysis|
62331885|NCT04355975||Interventional Therapy for PE|
62694570|NCT05022654|EXPERIMENTAL|SI-B001 combined with irinotecan|Patients with recurrent metastatic esophageal squamous cell carcinoma who had failed first-line therapy with PD-1(L1) monoclonal antibody plus platinum-based chemotherapy were enrolled.
62694571|NCT06277219|EXPERIMENTAL|Phase 1 LAT010 Dose Escalation|LAT010 monotherapy with ascending doses in patients with locally advanced or metastatic solid tumors. LAT010 will be administered in planned 7 dose cohorts to determine safety and RP2D. PD profile of LAT010 will also be characterized.
62136155|NCT04576975|EXPERIMENTAL|Dexmedetomidine|This group will receive a bolus dose of Dexmedetomidine \[Precedex® -Hospira, USA\] (0.5 µcg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which, the Dexmedetomidine infusion (200 µcg vial diluted over 50 cc infusion syringe, concentration 4 µcg/ml) will start with rate of 0.5 µcg/kg/hr till 10 Minutes before the end of the surgery
62136156|NCT04576975|PLACEBO_COMPARATOR|Normal Saline 0.9%|This group will receive a bolus dose of NS 0.9% over 10 minutes by 20 ml syringe infused before induction. After which, NS 0.9% (50 ml over 50 cc syringe) will be infused.
62136157|NCT06648395|ACTIVE_COMPARATOR|CBT text messages|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about a CBT skill, day 2 will be a remainder to use the skill that is framed toward preventing future losses from trauma exposure, and day 3 will have a reminder that aims to instill a growth mindset about using the skill. They will also be asked to complete weekly self-reports on PTSD and HD every Monday for four consecutive weeks.
62331886|NCT04355975||Surgical Embolectomy|
62489674|NCT02379533|ACTIVE_COMPARATOR|Center-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher.
62694572|NCT06277219|EXPERIMENTAL|Phase 2 LAT010 Dose Expansion|LAT010 monotherapy at the RP2D and in combination with a PD-1 inhibitor in patients with selected tumor types. LAT010 will be administered at multiple dose levels based on the results of Phase 1. Antitumor activity and safety will be further evaluated.
62694573|NCT03334955|EXPERIMENTAL|polycystic ovary syndrome patients|patients with polycystic ovary syndrome performed laparoscopic ovarian drilling to induce ovulation
62694574|NCT06493526|EXPERIMENTAL|Withdrawal of calcineurin-inhibitors in zero-HLA DQ-mismatched kidney transplant recipients|calcineurin-inhibitor withdrawal, continue on a concentration controlled mycophenolate dose (AUC12 target 60 h.mg/L)
62694575|NCT03235804|NO_INTERVENTION|Control Group|Those assigned to the Control group will be asked to maintain their usual dietary intake over 12 weeks. Participants' usual dietary intake is expected to reflect the North American dietary pattern (i.e. \~15% of total energy intake coming from protein, \~50% from carbohydrate and \~35% from fat).
61937125|NCT00931736|ACTIVE_COMPARATOR|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
61937126|NCT00931736|ACTIVE_COMPARATOR|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
61937127|NCT01110304|ACTIVE_COMPARATOR|Conservative treatment|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed.
61937128|NCT01110304|ACTIVE_COMPARATOR|Surgical treatment|Patients will undergo surgery to treat their AC joint dislocation.
61937129|NCT00694707|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once a day for 6 weeks.
61937130|NCT00694707|EXPERIMENTAL|Cariprazine 1.5 mg|Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
61937131|NCT00694707|EXPERIMENTAL|Cariprazine 3.0 mg|Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
61937132|NCT00694707|EXPERIMENTAL|Cariprazine 4.5 mg|Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
61937133|NCT00694707|ACTIVE_COMPARATOR|Risperidone 4.0 mg|Participants received risperidone 4.0 mg orally once a day for 6 weeks.
62136158|NCT06648395|ACTIVE_COMPARATOR|Supportive Text Messages|Participants will be sent three short supportive messages each week that include messages of support, validation, and hope. They will also be asked to complete the weekly self-reports on PTSD and HD every Monday for four consecutive weeks.
62331887|NCT06373614|EXPERIMENTAL|foot massage|Foot massage will be applied for a total of 30 minutes, 15 on the right foot and 15 on the left foot. In order to move comfortably during the foot massage, non-allergenic baby oil will be used. This intervention will continue in the evenings for 4 days.
62489675|NCT02355730|EXPERIMENTAL|Warfarin Patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
62697627|NCT05337189||Bladder cancer group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting urine specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) test, eligible subjects also need to undergo the examination of standard method.
61937134|NCT00828854|EXPERIMENTAL|Entinostat 5 mg + AI|Entinostat 5 mg tablet orally every week on Days 1, 8. 15 and 22 of each 28-day treatment cycle in combination with continued treatment with AI therapy at labeled dose and schedule until disease progression or unacceptable toxicity.
61937135|NCT02002390|EXPERIMENTAL|Fingolimod (FTY720) group|Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
61937136|NCT02002390|PLACEBO_COMPARATOR|Control group|Patients will receive usual care and drug use in hospital.
61937137|NCT05707936|EXPERIMENTAL|Normal saline 20 ml|
61937138|NCT05707936|EXPERIMENTAL|Normal saline 10 ml|
61937139|NCT05707936|ACTIVE_COMPARATOR|usual care (heparin)|
61937140|NCT03527030||General Population|Adults living in a registered household in the Greater London area.
61937141|NCT03527030||IQOS users|Adult current IQOS users (at the time of survey) living in the Greater London area who are registered in the UK IQOS User Database and agree to be contacted for research purposes at the time of registration.
62489676|NCT02375750|EXPERIMENTAL|GBO and GBG|0.2 g-0,5 g GBO and 1 GBG once after decontamination of implant surface
62694576|NCT03235804|EXPERIMENTAL|Powdered Meal Replacement Group|Those assigned to the Powdered Meal Replacement group will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
62694577|NCT04876456|EXPERIMENTAL|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
62136159|NCT04373512|EXPERIMENTAL|Low Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermitent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
61937142|NCT06680557|EXPERIMENTAL|Children and adolescents aged 10-18 years, diagnosed with T1DM for at least 1 year|Each participant will be assigned to perform either the aerobic or the resistance exercise sessions following the lunch meal in a random sequence by the withdrawal of a sealed envelope containing a paper with a written random sequence of the two exercise sessions. The envelope will be withdrawn randomly and opened immediately before the first exercise session. The other type of exercise session will be performed after 48 hours.
61937143|NCT04072562|EXPERIMENTAL|AZD7594 0.7 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 0.7 mg, delivered dose 1 inhalation
61937144|NCT04072562|EXPERIMENTAL|AZD7594 1.6 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 1.6 mg, delivered dose 1 inhalation
61937145|NCT04072562|ACTIVE_COMPARATOR|AZD7594 720 μg|The study subjects will receive AZD7594 via DPI: 0.72 mg, delivered dose (792 µg nominal dose) 1 inhalation
61937146|NCT05034432|EXPERIMENTAL|Intra-Op Prophylactic VT ablation|Subjects will get ablation procedure as needed if they were determined to be refractory to medical antiarrhythmic control should undergo catheter-based electrophysiology study and ablation on LVAD support
61937147|NCT05034432|ACTIVE_COMPARATOR|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
61937148|NCT01413412|EXPERIMENTAL|Hernia repair using full-thickness skin graft|25 patients
61937149|NCT01413412|EXPERIMENTAL|Hernia repair using Mesh|25 patients
61937150|NCT04839146|EXPERIMENTAL|Group 1: 6 microgram ABNCoV2 with/without MF59 adjuvant|In Group 1 (n=6), subjects will receive 6 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
61937151|NCT04839146|EXPERIMENTAL|Group 2: 12 microgram ABNCoV2 with/without MF59 adjuvant|In Group 2 (n=6), subjects will receive 12 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
62136160|NCT04373512|EXPERIMENTAL|High Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
62331888|NCT06373614|EXPERIMENTAL|bed bath|Bed bath will be applied for a total of 30 minutes with cotton and warm water. This intervention will continue in the evenings for 4 days.
62331889|NCT06373614|NO_INTERVENTION|control|no intervention
62331890|NCT02874690|PLACEBO_COMPARATOR|Placebo|Placebo pill received
62489677|NCT02375750|ACTIVE_COMPARATOR|Standard treatment|Decontamination of surface of implant
61937152|NCT04839146|EXPERIMENTAL|Group 3: 25 microgram ABNCoV2 with/without MF59 adjuvant|In Group 3 (n=6), subjects will receive 25 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
62331891|NCT02874690|EXPERIMENTAL|Methylphenidate|
62331892|NCT04319562|EXPERIMENTAL|needle-embedding therapy|The participants in this group will be treated with intradermal thumbtack needle.
62489678|NCT02235870|ACTIVE_COMPARATOR|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
62489679|NCT02235870|SHAM_COMPARATOR|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
62489680|NCT05947409|EXPERIMENTAL|SMARTO ONE|
62489681|NCT03013530||Patients with chronic disease|
62489682|NCT05612958|EXPERIMENTAL|DKM-410|Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline
62694578|NCT06460662|EXPERIMENTAL|Agility and perturbation training group|"Group A will receive agility and perturbation training techniques in addition to the same routine physical therapy as Group B.~The Agility training exercises include:~* Side Stepping~* Braiding Activities~* Front and Back Crossover Steps During Forward Ambulation~* Multiple Changes in Direction During Walking on Therapist Command~The perturbation training exercises include:~* Double-Leg Foam Balance Activity~* Tilt board Balance Training~* Rollerboard and Platform Perturbations"
61937153|NCT04839146|EXPERIMENTAL|Group 4: 50 microgram ABNCoV2 with/without MF59 adjuvant|In Group 4 (n=6), subjects will receive 50 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
61937154|NCT04839146|EXPERIMENTAL|Group 5: 70 microgram ABNCoV2 with/without MF59 adjuvant|In Group 5 (n=6), subjects will receive 70 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
61937155|NCT04839146|EXPERIMENTAL|Group 6: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 6 (n=6) will receive the next lower dosage of the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
61937156|NCT04839146|EXPERIMENTAL|Group 7: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 7 (n=6) will receive the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
61937157|NCT02362178|EXPERIMENTAL|Thromboelastography (TEG)|Patients in the TEG group received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, only if INR was higher than 1.8 and r time longer than 40 minutes. They received platelets at the amount of 1 apheresis Unit, only if platelets count was lower than 50000/μl and MA was shorter than 30 millimeter.
61937158|NCT02362178|ACTIVE_COMPARATOR|Standard of Care (SOC)|In the SOC group patients received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, when INR was higher than 1.8. They received platelets at the amount of 1 apheresis Unit, when platelets count was lower than 50000/μl.
61937159|NCT04469075|EXPERIMENTAL|topical clindamycin and triamcinolone|Patients who are scheduled to receive TTFields therapy for newly diagnosed GBM will be treated with: topical clindamycin (or approved equivalent) 1% and triamcinolone 0.1%. Participating sites may use an alternative equivalent form of clindamycin, such as a gel, with MSK PI approval
61937160|NCT06218602|EXPERIMENTAL|Arm A|Will receive FMT therapy (both as a colonoscopy / FMT procedure and as capsules taken by mouth) plus the scheduled chemotherapy and CAR-T cell therapy.
61937161|NCT06218602|EXPERIMENTAL|Arm B|Will receive no FMT therapy and only receive their scheduled chemotherapy and CAR-T cell therapy.
61937162|NCT04738734|EXPERIMENTAL|CellFX Procedure|CellFX device using pre-defined energy protocols
61937163|NCT04738734|ACTIVE_COMPARATOR|Cryosurgical Procedure|Cryosurgery will be standardized across all investigational sites. Investigators will perform the Cryosurgical procedure using the Brymill Cry-Ac B700 Liquid Nitrogen Sprayer.
61937164|NCT05927701||Non-Surgical Group|Patients treated non-surgically during adolescence (\<18 years of age) with a baseline Cobb \>40º and minimum 20 years of follow-up.
61937165|NCT05927701||Surgical Group|Patients treated surgically during adolescence (\<18 years of age) with a baseline Cobb \>40º, and minimum 20 years of follow-up
62136161|NCT05421832||PD Cohort 1|PD patients assessed via the Hoehn \& Yahr (H\&Y) Scale to be in Stages 1-2 of PD (inclusive)
61937166|NCT02720237|EXPERIMENTAL|Brief Intervention|Brief Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the ART clinic
61937167|NCT02720237|EXPERIMENTAL|MET+CBT Intervention|MET+CBT Intervention (6 in-person sessions and 3 optional group sessions), study assessment visits, and standard of care from providers at the ART clinic
61937168|NCT02720237|NO_INTERVENTION|Assessment-Only Control|Study assessment visits and standard of care from providers at the ART clinic
61937169|NCT03736694|EXPERIMENTAL|CBTI Workshop|The first intervention group (Group 1) will attend one half-day CBTI workshop in the community setting. The workshop is subdivided into 4 sessions, covering topics regarding regulation of stimuli, limit of sleeping duration, relaxation, sleep hygiene and alteration of cognitive beliefs (Arnedt, Cuddihy, \& Swanson, et al, 2014; Morin, Savard, Ouellet, \& Daley, 2003). One workshop has the capacity of 30 participants.
61937170|NCT03736694|EXPERIMENTAL|Self-Help CBTI|The second intervention group (Group 2) will receive self-help CBTI. A CBTI webpage will be set up and the subjects are asked to review all the materials in it. The content is the same as that in Group 1.
61937171|NCT03736694|ACTIVE_COMPARATOR|SHE Workshop|The control group (Group 3) will receive SHE. To ensure uniformity of the therapy model, the participants will also need to attend one half-day face-to-face session, covering topics related to sleep hygiene only. The capacity is also 30 participants.
61937172|NCT01823354|OTHER|Patients|Polysomnography, Assessment of executive functions, Clinical scales, Medical consultation
61937173|NCT01823354|OTHER|Controls|Polysomnography, Assessment of executive functions, Clinical scales Medical consultation
62136162|NCT05421832||PD Cohort 2|PD patients assessed via the H\&Y Scale to be in Stages 3-4 of PD (inclusive)
62136163|NCT05421832||Prodromal PD|Patients who meet PI-defined criteria for prodromal PD, i.e., the latent phase of disease progression during which clinical PD symptoms have yet to manifest
62136164|NCT05421832||Age and Sex-matched Healthy Control|Age \& sex matched healthy control subjects who have not been diagnosed with PD
62136165|NCT03049319|EXPERIMENTAL|Laser|All six interventions will be applied to patient's back.
62136166|NCT04270045||Single|Non-invasive forced airway oscillometry. Normative data will be established form term neonates without pulmonary disease
62136167|NCT06699381||Stroke|Descriptive research
62136168|NCT01791140||Cohort|
62136169|NCT06447389|OTHER|Evaluation of the Effectiveness of Retraction Cord|For each case, two tooth-supported restorations will be produced: one with and one without the application of a retraction cord. The accuracy of the marginal fit of the produced restorations will be determined through digital analysis of the data.
62136170|NCT05729503|EXPERIMENTAL|2% Lidocaine|1 cotton tip applicator, pre-soaked in 2% lidocaine, inserted into each nare, and left for 10 minutes
62136171|NCT05729503|PLACEBO_COMPARATOR|Placebo|1 cotton tip applicator, pre-soaked in saline, inserted into each nare, and left for 10 minutes
62136172|NCT02381470|EXPERIMENTAL|Faropenem|Faropenem 600mg (with amoxicillin/clavulanic acid, 500mg/125mg) given three times daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
62136173|NCT02381470|EXPERIMENTAL|Cefadroxil|Cefadroxil 1g (with amoxicillin/clavulanic acid, 500mg/125mg) given twice daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
62489683|NCT05612958|ACTIVE_COMPARATOR|Juvederm ULTRA PLUS XC 1.0ml|Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline
62489684|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
61937174|NCT01847001|EXPERIMENTAL|Propranolol + Neoadjuvant Chemotherapy|"Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.~* Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and~* Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).~* If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.~After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.~DOT imaging will be done at 4 additional time points, including beo."
61937175|NCT00560469||1|Men and Women over age 40 who are obese (BMI\>30) and insulin-resistant.
61937176|NCT00560469||2|Men and women over age 40 who are obese (BMI\>30) and insulin-sensitive.
61937177|NCT05789381|ACTIVE_COMPARATOR|24 hours postpartum magnesium sulfate|
61937178|NCT05789381|EXPERIMENTAL|12 hours postpartum magnesium sulfate|
61937179|NCT01933958||Group 1|Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
61937180|NCT05533723||Percutaneous epidural neuroplasty (PEN) group|Patients over 20 years of age with radiating pain in the lower back and legs who received PEN in patients who did not respond to medication and epidural nerve block treatment.
61937181|NCT05533723||Endoscopic epidural neuroplasty (EEN) group|Patients over 20 years of age with radiating pain in the lower back and legs who received EEN in patients who did not respond to medication and epidural nerve block treatment.
61937182|NCT04256954|EXPERIMENTAL|Peer navigation|Those who are assigned to the intervention arm will receive peer navigation service by a trained peer navigator who will link them with mental health, medical and substance use services in the community.
61937183|NCT04256954|NO_INTERVENTION|Standard of Care|SOC consists of TAU + monitoring and emergency referral, as is required to fulfil ethical obligations to trial participants. To determine the naturalistic effects and costs of adding peer navigation intervention, participants in both conditions can receive any other treatment available to them and we will not exclude participants receiving other treatment. We will carefully characterize TAU for each condition as part of our service utilization assessment.
61937184|NCT01658852|ACTIVE_COMPARATOR|Metronidazole|active drug: metronidazole 500mg three time per day for 10 days
62136174|NCT02381470|ACTIVE_COMPARATOR|Control|Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
62489685|NCT01670643||Video camera magnifier|
62489686|NCT03517319|PLACEBO_COMPARATOR|Placebo|Normal Saline 0.9% 1.2 ml will be injected to finger flexor muscles
61937185|NCT01658852|PLACEBO_COMPARATOR|Placebo|Placebo three times per day for 10days
61937186|NCT05573828|EXPERIMENTAL|Angiography group|Patients undergoing initially ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then, post-thyroidectomy ICG angiography to predict immediate parathyroid function.
61937187|NCT05573828|NO_INTERVENTION|Control group|Patients who underwent post-thyroidectomy ICG angiography to predict immediate parathyroid gland function by scoring the degree of fluorescence of the parathyroid glands
61937188|NCT02608203|EXPERIMENTAL|patients with gastroenteropancreatic neuroendocrine tumors|
61937189|NCT03132012|EXPERIMENTAL|Indoor tanning intervention|Web-based intervention modules to discourage tanning.
62489687|NCT03517319|EXPERIMENTAL|Treatment dose 15|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U will be injected to finger flexor muscles
62489688|NCT03517319|EXPERIMENTAL|Treatment dose 30|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U will be injected to finger flexor muscles
61937190|NCT03132012|ACTIVE_COMPARATOR|standard of care control|General information regarding UV protection measures through an online Qualtrics interface. Content will mirror information provided in brochures typically available in a dermatology office or through skin cancer prevention websites.
61937191|NCT00464269|PLACEBO_COMPARATOR|Placebo|Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
61937192|NCT00464269|EXPERIMENTAL|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
62489689|NCT03517319|EXPERIMENTAL|Treatment dose 50|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U will be injected to finger flexor muscles
62489690|NCT03517319|EXPERIMENTAL|Treatment dose 70|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U will be injected to finger flexor muscles
62489691|NCT02363764||Expectorating CF patients|"(=able to expectorate sputum spontaneously)~1. Nasal swab~2. Cough swab~3. Spontaneous expectorated sputum~4. Questionnaire"
61937193|NCT00464269|EXPERIMENTAL|BRV 20mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
61937194|NCT00464269|EXPERIMENTAL|BRV 50mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.
62694579|NCT06460662|ACTIVE_COMPARATOR|Routine physical therapy|"Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques"
62694580|NCT03732794|EXPERIMENTAL|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
61937195|NCT04817735|OTHER|Cohort|
61937196|NCT00316771|EXPERIMENTAL|P38 Inhibitor (4) 150mg|
61937197|NCT00316771|EXPERIMENTAL|P38 Inhibitor (4) 25mg|
61937198|NCT00316771|EXPERIMENTAL|P38 Inhibitor (4) 300mg|
61937199|NCT00316771|EXPERIMENTAL|P38 Inhibitor (4) 50mg|
62136175|NCT06654323|EXPERIMENTAL|26-hour intensive behavioral lifestyle intervention|Participants will receive 4 visits, (1 hour total) with their child's pediatric primary care provider, on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total), and personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional: 16 sessions (60 minutes per session).
62136176|NCT06654323|ACTIVE_COMPARATOR|22-hour intensive behavioral lifestyle intervention|Participants will receive 4 visits, (1 hour total) with their child's pediatric primary care provider, on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total), and personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional for 12 sessions (60 minutes per session).
62136177|NCT06654323|ACTIVE_COMPARATOR|19-hour intensive behavioral lifestyle intervention|Participants will receive 4 visits, (1 hour total) with their child's pediatric primary care provider, on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total), and personalized nutrition counseling delivered by a registered dietitian or similar healthcare professiona for 9 sessions (60 minutes per session).
62136178|NCT06654323|ACTIVE_COMPARATOR|16-hour intensive behavioral lifestyle intervention|Participants will receive 4 visits, (1 hour total) with their child's pediatric primary care provider, on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total), and personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional for 8 sessions (45 minutes per session).
62489692|NCT02363764||Non-expectorating CF patients|"(=unable to expectorate sputum spontaneously)~1. Nasal swab~2. Cough swab~3. Induced sputum after inhalation of hypertonic saline (NaCl 6%)~4. Questionnaire"
62489693|NCT02363764||Bronchoscopy CF patients|"(=undergoing clinically indicated bronchoscopy)~1. Nasal swab~2. Cough swab~3. Induced sputum after inhalation of hypertonic saline (NaCl 6%)~4. Bronchoalveolar lavage (BAL)"
61937200|NCT00316771|EXPERIMENTAL|P38 Inhibitor (4) 75mg|
61937201|NCT00316771|PLACEBO_COMPARATOR|Placebo|
61937202|NCT06247423|EXPERIMENTAL|10kHz|Alternating current stimulation with a 10kHz frequency with a transcutaneous approach, 20 minutes for each intervention.
61937203|NCT06247423|SHAM_COMPARATOR|Sham stimulation|Sham stimulation via transcutaneous approach will be delivered only for the first 30 seconds, following the same procedures as the 10kHz group.
61937204|NCT00835159|EXPERIMENTAL|Rivastigmine Patch|Group receiving Rivastigmine Patch
62331893|NCT04319562|SHAM_COMPARATOR|shame needle-embedding therapy|The participants in this group will be treated with shame intradermal thumbtack needle.
62489694|NCT03335241|EXPERIMENTAL|Arm 1: Fludarabine and Pegylated liposomal doxorubicin|
62489695|NCT03335241|ACTIVE_COMPARATOR|Arm 2: Pegylated liposomal doxorubicin|
62694581|NCT02913846||Hospital revalidation units|The study will take place within the CHU Brugmann hospital (Brussels) who has 4 revalidation units (104 beds). All patients coming within these units during the study duration will be included.
62694582|NCT03140969|EXPERIMENTAL|QR-110|Administered every 3 months
62694583|NCT06642038||Experimental Group|
62694584|NCT03701074|EXPERIMENTAL|ibuprofen and acetaminophen arm (intervention arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants \> 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
61937205|NCT00835159|PLACEBO_COMPARATOR|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
62489696|NCT03929016|EXPERIMENTAL|Active DNDI-0690 male 10mg fasting|Single dose 10mg male fasting
62489697|NCT03929016|PLACEBO_COMPARATOR|Placebo male fasting|Single dose placebo male fasting
62489698|NCT03929016|EXPERIMENTAL|Active DNDI-0690 male 30mg fasting|Single dose 30mg male fasting
61937206|NCT03992729||Tildrakizumab-Exposed Cohort|Exposure to tildrakizumab for the treatment of an approved indication
61937207|NCT03992729||Disease-Matched Comparison Cohort|No exposure to tildrakizumab at any time in the current pregnancy
61937208|NCT02714907|EXPERIMENTAL|AF assessed from Cortrium C3 data|Atrial fibrillation assessed from Cortrium C3 device data
61937209|NCT02714907|EXPERIMENTAL|AF assessed from Holter data|Atrial fibrillation assessed from Holter data
61937210|NCT04743349|EXPERIMENTAL|Experimental arm|Steam inhalations
61937211|NCT04743349|NO_INTERVENTION|Control arm|No intervention
61937212|NCT03781544|EXPERIMENTAL|Diclofenac|Diclofenac (Diclofenacum natricum) A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
62489699|NCT03929016|EXPERIMENTAL|Active DNDI-0690 male 150mg fasting|Single dose 150mg male fasting
62489700|NCT03929016|EXPERIMENTAL|Active DNDI-0690 male 400mg fasting|Single dose 400mg male fasting
62697628|NCT05337189||The normal group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting urine specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) test, eligible subjects also need to undergo the examination of standard method.
62136179|NCT06654323|ACTIVE_COMPARATOR|13-hour intensive behavioral lifestyle intervention|Participants will receive 4 visits, (1 hour total) with their child's pediatric primary care provider, on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total), and personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional for 6 sessions (30 minutes per session).
62136180|NCT00930306|EXPERIMENTAL|1|12 AZD2066 Capsule, 2 mg \& 8 mg 2 Caffeine Tablet, 2 x 50 mg 2 Tolbutamide Tablet, half of 500 mg 2 Omeprazole Tablet, 20 mg 2 Midazolam Tablet, 7.5 mg 2 Metoprolol Tablet, 100 mg 2 Bupropion Tablet, 150 mg
62136181|NCT05394636||cerebral amyloid angiopathy (CAA)|Clinical and 1.5T MRI T2\*-weighted imaging characteristics analyses from sporadic probable CAA patients (according to the modified Boston criteria) presenting with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS,
62136182|NCT06396975||laparoscopic surgery|
62136183|NCT06396975||robotic surgery|
62136184|NCT02278666||upper mini-sternotomy|aortic valve replacement surgery via upper J or T sternotomy (ministernotomy)
62331894|NCT01762657|EXPERIMENTAL|Oral CyclosporineA and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day in two divided dosages given with Lansoprazole dosed at 30 mg per day in two divided dosages for subjects aged 8-15 year and 60 mg per day for those aged 16-60.
62331895|NCT01762657|PLACEBO_COMPARATOR|Placebos|
62331896|NCT01345123|EXPERIMENTAL|Decision Aid with Health Coaching|
62331897|NCT01345123|EXPERIMENTAL|Decision Aid only|
62331898|NCT01345123|NO_INTERVENTION|No condition specific support|
62331899|NCT03583762|EXPERIMENTAL|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
62331900|NCT03583762|EXPERIMENTAL|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
62331901|NCT02367170|EXPERIMENTAL|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
62331902|NCT02367170|SHAM_COMPARATOR|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
62331903|NCT04802850|EXPERIMENTAL|Real MWM|Real mobilization with movement
62331904|NCT04802850|SHAM_COMPARATOR|Sham MWM|sham or placebo mobilization with movement
62331905|NCT02145156|EXPERIMENTAL|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
62489701|NCT03929016|EXPERIMENTAL|Active DNDI-0690 male 1200mg fasting|Single dose 1200mg male fasting
62489702|NCT03929016|EXPERIMENTAL|Active DNDI-0690 male 3600mg fasting|Single dose 3600mg male fasting
62489703|NCT03929016|PLACEBO_COMPARATOR|Placebo male fed|Placebo male fed
61937213|NCT03781544|ACTIVE_COMPARATOR|Paracetamol|"Paracetamol (Paracetamol Sintetica):~A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm)."
61937214|NCT03781544|EXPERIMENTAL|Tramadol|"Tramadol (Tramadol-Mepha):~A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm)."
61937215|NCT04564274||1|patients with rare and common diseases
62489704|NCT03929016|EXPERIMENTAL|Active DNDI-0690 400mg male fed|Single dose 400mg male fed
62489705|NCT03929016|PLACEBO_COMPARATOR|Placebo female fasting|Placebo female fasting
62136185|NCT02278666||right mini thoracotomy|aortic valve replacement/repair surgery via right mini thoracotomy
62136186|NCT02278666||conventional sternotomy|aortic valve replacement surgery via conventional full sternotomy
62136187|NCT04570072|EXPERIMENTAL|Probiotic|Formula probiotic contains freeze-dried Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum, each at a dosage of 3.0 × 10\^10 colony forming unit per 2g sachet.
62136188|NCT04570072|PLACEBO_COMPARATOR|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
62136189|NCT01815242|EXPERIMENTAL|Arm A|nab-Paclitaxel + gemcitabine
62136190|NCT01815242|EXPERIMENTAL|Arm B|nab-Paclitaxel + carboplatin
62136191|NCT00982436|EXPERIMENTAL|Neoadjuvant/Concomitant Chemoradiation|Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin
62136192|NCT01503970|EXPERIMENTAL|Chondrocyte implantation|
62489706|NCT03929016|EXPERIMENTAL|Active DNDI-0690 1200mg female fasting|Single dose 1200mg female fasting
62489707|NCT06062615|ACTIVE_COMPARATOR|Total knee replacement (TKR) without Omnibot system|The participant will undergo TKR utilizing conventional techniques.
62489708|NCT06062615|ACTIVE_COMPARATOR|Total knee replacement (TKR) with Omnibot|The participant will undergo a robotic assisted TKR utilizing the Omnibot Knee System
62489709|NCT03056287|EXPERIMENTAL|Aerobic Exercise|Treadmill aerobic exercise
62489710|NCT03056287|EXPERIMENTAL|rTMS|repetitive transcranial magnetic stimulation
62489711|NCT03056287|EXPERIMENTAL|AET+rTMS|Combined aerobic exercise and rTMS
62489712|NCT03056287|SHAM_COMPARATOR|Sham|Sham rTMS
61937216|NCT04579029|EXPERIMENTAL|Surgical Cohort|"Patients randomised to the surgical group will undergo near infrared spectroscopy imaging to assess suitability and plan the surgical procedure.~Limb measurements with perometry and bio-impedance spectroscopy will be performed at baseline. Under general anaesthetic multiple LVA bypass procedures will be performed on the affected arm. Near infrared spectroscopy imaging will be used throughout. One week after discharge the patient will return for the bandages to be removed and the wounds inspected for any evidence of infection before renewing the bandage. Again, two weeks after surgery, the patient will return for inspection of wound and removal of sutures. It is at this point that the surgical patients will be returned into a standard lymphoedema compression garment, fitted by the research nurse. Thereafter, standard follow up (Bilateral) measurements and checks will be done at 1 month, 3 months, 6 months and 1 year."
61937217|NCT04579029|NO_INTERVENTION|Non-surgical cohort|"The main intervention for the non-surgical group largely encompasses limb measurements with perometry and bio-impedance spectroscopy at baseline before a compression garment is applied. The compression garments will be measured and fitted by a trained lymphoedema specialist and will be given the standard advice as is best practice for such patients currently. This cohort will likewise be followed up at 1 month, 3 months, 6 months and 1 year and undergo perometry readings and measurements with comparable collection of data.~For patients in both surgical and non-surgical groups, the compression garments will be measured and fitted by a trained lymphoedema specialist and they will be given the standard advice as is best practice for such patients currently. For each patient key details of the surgical technique, garment specification, imaging results and perometry/BIS measurements will be recorded on a study specific form for subsequent entry onto the database."
61937218|NCT04284852|EXPERIMENTAL|Experimental arm|Niraparib 200 or 300mg daily orally for 18 cycles unless disease progression or intolerable side effects (whichever occurs first)
61937219|NCT06609668||Isolated PPR|"* Inclusion criteria~* ACR/EULAR 2022 score \< 6~ACR/EULAR 2022 score:~* Shoulder/cervical spine pain/stiffness (+2)~* Sudden loss of vision (+3)~* Jaw claudication (+2)~* Temporal headache (recent) (+2)~* Scalp hyperesthesia (+2)~* Temporal artery abnormality on clinical examination (+2)~* SV \> 50 mm/h or CRP \> 10 mg/L (+3)~* Positive BAT or halo sign (ultrasound) (+5)~* Axillary artery involvement (+2)~* Aortitis (hypermetabolism of the aorta) on FDG-PET (+2)"
61937220|NCT06609668||PPR associated with an ACG|"* Inclusion criteria~* ACR/EULAR 2022 score ≥ 6~ACR/EULAR 2022 score:~* Shoulder/cervical spine pain/stiffness (+2)~* Sudden loss of vision (+3)~* Jaw claudication (+2)~* Temporal headache (recent) (+2)~* Scalp hyperesthesia (+2)~* Temporal artery abnormality on clinical examination (+2)~* SV \> 50 mm/h or CRP \> 10 mg/L (+3)~* Positive BAT or halo sign (ultrasound) (+5)~* Axillary artery involvement (+2)~* Aortitis (hypermetabolism of the aorta) on FDG-PET (+2)"
61937221|NCT06273293|OTHER|Percutaneous coronary intervention (PCI) and guide wire post PCI in multivessel patients|
61937222|NCT02526901||No treatment|
61937223|NCT00674427|EXPERIMENTAL|CR|Subjects who are in CR ater 6-12 weeks after aDLI
61937224|NCT00674427|EXPERIMENTAL|Not in CR|Subjects not in CR after 6-12 weeks after aDLI
61937225|NCT04620395|NO_INTERVENTION|Joint tap|Joint tap and aspiration of synovial fluid
61937226|NCT04620395|EXPERIMENTAL|Punch biopsy|Punch biopsy of a prosthetic joint and extraction of 5-7 biopsies from the synovial membrane
61937227|NCT02974582|EXPERIMENTAL|1/Part 1|60 Participants of high and low SES
61937228|NCT02974582|EXPERIMENTAL|2/Part 2 - Discount Coupons|Randomized to view direct mail marketing
61937229|NCT02974582|EXPERIMENTAL|3/Part 2 - No Discount Coupons|Randomized to view direct mail marketing
61937230|NCT02974582|EXPERIMENTAL|4/Part 2 - Control|Randomized to view direct mail marketing
61937231|NCT02562768|EXPERIMENTAL|LY3154207|LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
61937232|NCT02562768|PLACEBO_COMPARATOR|Placebo|Placebo matching LY3154207 administered once daily for 14 days.
61937233|NCT04079010|PLACEBO_COMPARATOR|Control|Participants will adhere to resistance training protocol.
61937234|NCT04079010|ACTIVE_COMPARATOR|BFR (blood flow restriction)|Participants will adhere to resistance training protocol, while also applying a blood flow restriction cuff during resistance training.
61937235|NCT04079010|ACTIVE_COMPARATOR|BFR (blood flow restriction), plus Arginine|Participants will adhere to resistance training protocol, apply a blood flow restriction cuff during resistance training, and will take the clinically safe dose of arginine prior to training sessions.
61937236|NCT01960673|EXPERIMENTAL|LMA proseal|"The investigator will use proseal LMA in this study. The cuff of the proseal LMA could be inflation. It is thought to fix the larynx shape.~The investigator wants to test the efficacy during 30,45,60 degree of head and neck position."
61937237|NCT01960673|EXPERIMENTAL|igel LMA|"igel LMA did not have cuff. The shape, softness and contours accurately mirror the perilaryngeal anatomy.~The investigator want to test the efficacy of the igel at 30,45,60 degree of head and neck position."
62331906|NCT02145156|OTHER|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
61937238|NCT01960673|EXPERIMENTAL|air Q LMA|"The air-Q LMA should be used routinely as a classic passive airway. It is user-friendly, placement in patients is easy and air movement is outstanding. It has the added benefit of allowing for intubation using standard ET Tubes.~It also has the cuff and the contour of the mask is thought to mimic the the shape of the perilaryngeal region.~The investigator want to test the efficacy of the air Q LMA at 30,45,60 degree of the head and neck position."
61937239|NCT01960673|EXPERIMENTAL|ambu LMA|ambu LMA is also an cuff device LMA. The investigator wanted to test the efficacy about the leak pressure and the view at 30,45,60 degree of head and neck position.
61937240|NCT06681662|ACTIVE_COMPARATOR|Ephedrine group|Ephedrine 0.15 mg/kg. Dose of ephedrine is based on ideal body weight, calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower.
61937241|NCT06681662|PLACEBO_COMPARATOR|Saline group|Saline 1 ml.
61937242|NCT01359007|EXPERIMENTAL|FOLFIRINOX|Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
62489713|NCT03306758|EXPERIMENTAL|Experimental: sodium bicarbonate|
62694585|NCT03701074|ACTIVE_COMPARATOR|ibuprofen and placebo arm (control arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants \> 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.
61937243|NCT01770652|EXPERIMENTAL|Normal renal function|Healthy volunteers, defined as having an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73m\^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
61937244|NCT01770652|EXPERIMENTAL|Mild Renal Impairment|Mild impairment, defined as having an eGFR 60-89 mL/min/1.73m\^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
61937245|NCT01770652|EXPERIMENTAL|Moderate Renal Impairment|Mild impairment, defined as having an eGFR 30-59 mL/min/1.73m\^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
61937246|NCT01770652|EXPERIMENTAL|Severe Renal Impairment|Severe impairment, defined as having an eGFR 15-19 mL/min/1.73m\^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
61937247|NCT00849537|EXPERIMENTAL|Triamcinolone|Injection of intravitreal Triamcinolone
61937248|NCT05800873|EXPERIMENTAL|EVER001|EVER001 for 36 weeks.
61937249|NCT03439657|EXPERIMENTAL|Co-Ad Group|Adults aged ≥50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
61937250|NCT03439657|ACTIVE_COMPARATOR|Control Group|Adults aged ≥50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
61937251|NCT04792515|EXPERIMENTAL|treatment group|Patients were treated with camrelizumab combined with SOX/ or apatinib
61937252|NCT02577497|EXPERIMENTAL|Beclomethasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
61937253|NCT02577497|EXPERIMENTAL|fluticasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
61937254|NCT01465854||LCINS|Never smokers with newly diagnosed lung cancer
61937255|NCT04064177||Babies (24-42 weeks)|All babies born between 24 and 42 weeks
61937256|NCT04064177||Preterm infants|Preterm infants with fetal growth restriction
61937257|NCT03589469|EXPERIMENTAL|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
61937258|NCT04625816|EXPERIMENTAL|Arthroscopic shoulder surgery patients|
61937259|NCT02748473|OTHER|pelvic floor muscle strength|evaluated pelvic floor muscle strength before and after Pilates exercises program on sedentary nulliparous women
61937260|NCT02748473|OTHER|Device: 3D perineal ultrasound|evaluated the pubovisceral muscle thickness and the levator hiatus area before and after Pilates exercises program on sedentary nulliparous women
61937261|NCT05961059|EXPERIMENTAL|A1 - Low dose vaccine (Netherlands)|10 Dutch participants who receive three 2.5 μg doses of the vaccine without adjuvant at a 28-day interval in Cohort A.
62136193|NCT06639074|EXPERIMENTAL|Arm I (FRalphaDCs)|Patients may receive Td or Tdap IM prior to undergoing leukapheresis. Patients receive FRalphaDCs ID on day 1 of each cycle. Cycles repeat every 21 days for cycles 1-5 and then repeat every 91 days for cycles 6-12 in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo biopsy prior to apheresis and optionally at end of treatment, and blood sample collection, CT and/or MRI throughout the study.
62489714|NCT03306758|NO_INTERVENTION|No Intervention|
61937262|NCT05961059|EXPERIMENTAL|A2 - Low dose vaccine + adjuvant (Netherlands)|10 Dutch participants who receive three 2.5 μg dose of the vaccine with 0.1 μg of adjuvant at a 28-day interval in Cohort A.
61937263|NCT05961059|EXPERIMENTAL|B1/C1 - High dose vaccine (Netherlands & Zambia)|10 Dutch participants who receive three 10 μg vaccine doses without adjuvant at a 28-day interval in Cohort B and 15 Zambian participants who receive three 10 μg vaccine doses without adjuvant at a 28-day interval in Cohort C.
61937264|NCT05961059|EXPERIMENTAL|B2/C2 - High dose vaccine + adjuvant (Netherlands & Zambia)|10 Dutch participants that receive three 10 μg vaccine doses with 0.1 μg of adjuvant at a 28-day interval in Cohort B and 15 Zambian participants that receive three 10 μg vaccine doses with 0.1 μg of adjuvant at a 28-day interval in Cohort C.
61937265|NCT05961059|PLACEBO_COMPARATOR|A3/B3/C3 - Placebo (Netherlands & Zambia)|5 Dutch participants who receive three placebo vaccinations at a 28-day interval in Cohort A, another 5 Dutch participants who receive three placebo vaccinations at a 28-day interval in Cohort B and 5 Zambian participants who receive three placebo vaccinations at a 28-day interval in Cohort C.
61937266|NCT00973271|EXPERIMENTAL|290 mg DCCR|
61937267|NCT00973271|EXPERIMENTAL|435 mg DCCR|
61937268|NCT00973271|ACTIVE_COMPARATOR|135 mg fenobric acid|
61937269|NCT00973271|PLACEBO_COMPARATOR|Placebo|
61937270|NCT05048082|EXPERIMENTAL|Fluorescence imaging with pegsitacianine|Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
61937271|NCT00604305|ACTIVE_COMPARATOR|Acrysof|Routine monofocal IOL
61937272|NCT00604305|ACTIVE_COMPARATOR|Acuity's AIOL|Accomodaing IOL
62489715|NCT03315533|EXPERIMENTAL|Duloxetine 30 milligrams (mg)|
62489716|NCT03315533|PLACEBO_COMPARATOR|Placebo|
62489717|NCT03315533|EXPERIMENTAL|Duloxetine 60 milligrams (mg)|
62697629|NCT05258292||Women with type 1 diabetes|
62331907|NCT02145156|OTHER|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
62331908|NCT03546413||LEAP Participants: Peanut Avoidance|Participants of the LEAP study who enrolled in the LEAP Trio study and were originally randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
62489718|NCT05934695||Mild lymphedema (stage 1)|International Society of Lymphology lymphedema severity stage 1, characterized by swelling with pitting, normal skin and tissue turgor. Participants assigned to this group will have mild swelling and tightness of the arm.
62489719|NCT05934695||Moderate lymphedema (stage 2)|International Society of Lymphology lymphedema severity stage 2, characterized by swelling with pitting as well as skin and tissue changes such as dermal thickening. Participants assigned to this group will have moderate swelling and tightness of the arm as well as skin changes without distortional warty-overgrowth or elephantiasis folds.
62489720|NCT05934695||Severe lymphedema (stage 3)|International Society of Lymphology lymphedema severity stage 3, characterized by swelling with non-pitting, and warty-overgrowth or elephantiasis folds of skin. Participants assigned to this group will have severe swelling and tightness of the arm with warty overgrowth of skin.
62489721|NCT06018116|EXPERIMENTAL|Bicalutamide|standard of care (SOC) avelumab with 150mg daily oral bicalutamide
62331909|NCT03546413||LEAP Participants: Peanut Consumption|Participants of the LEAP study who enrolled in the LEAP Trio study and were originally randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
62331910|NCT03546413||Younger Siblings: Peanut Avoidance|Participants enrolled in the LEAP Trio study who are younger siblings of a LEAP Participant who was randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
62331911|NCT03546413||Younger Siblings: Peanut Consumption|Participants enrolled in the LEAP Trio study who are younger siblings of a LEAP Participant who was randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
62331912|NCT03546413||Older Siblings: Peanut Avoidance|Participants enrolled in the LEAP Trio study who are older siblings of a LEAP Participant who was randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
62331913|NCT03546413||Older Siblings: Peanut Consumption|Participants enrolled in the LEAP Trio study who are older siblings of a LEAP Participant who was randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
62489722|NCT06018116|PLACEBO_COMPARATOR|Placebo|standard of care (SOC) avelumab with daily oral placebo
62489723|NCT03010657|EXPERIMENTAL|Intervention|Subjects will add certain foods to what they normally eat.
62489724|NCT03010657|NO_INTERVENTION|Non-experimental intervention|Subjects will continue eating normally.
62489725|NCT03506594|ACTIVE_COMPARATOR|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with the CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41°C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
62489726|NCT03506594|PLACEBO_COMPARATOR|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
62489727|NCT03885934|EXPERIMENTAL|V114, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL intramuscular (IM) injection for 7 to 11 months of age (Pneumococcal conjugate vaccine \[PCV\]-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
62489728|NCT03885934|ACTIVE_COMPARATOR|Prevnar 13®, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL IM injection for 7 to 11 months of age (PCV-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
62489729|NCT03885934|EXPERIMENTAL|V114, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
62489730|NCT03885934|ACTIVE_COMPARATOR|Prevnar 13®, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
62489731|NCT03885934|EXPERIMENTAL|V114, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced) (1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
62694586|NCT05719246|EXPERIMENTAL|IBS Patients Doing Yoga|"All patients will fall under the arm of IBS Patients Doing Yoga and will follow the yoga videos that are assigned to them during the study. The participants are their own controls and their symptom changes will be recorded pre- and post-video watching and participation."
62694587|NCT01166646|EXPERIMENTAL|Halobetasol Proprionate Lotion 0.05%|Subjects randomized to receive lotion
62694588|NCT01166646|ACTIVE_COMPARATOR|Halobetasol Proprionate Cream 0.05%|Subjects randomized to receive cream
62331914|NCT03546413||Parents: Peanut Avoidance|Participants enrolled in the LEAP Trio study who are parents of a LEAP Participant who was randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
62331915|NCT03546413||Parents: Peanut Consumption|Participants enrolled in the LEAP Trio study who are parents of a LEAP Participant who was randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
62331916|NCT00825955|EXPERIMENTAL|Brivanib|
62331917|NCT00825955|PLACEBO_COMPARATOR|Placebo|
62694589|NCT05208762|EXPERIMENTAL|PF-08046054 Monotherapy|PF-08046054 monotherapy
62694590|NCT05208762|EXPERIMENTAL|PF-08046054 Combination Therapy|PF-08046054 + pembrolizumab
62694591|NCT00336063|EXPERIMENTAL|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
61937273|NCT04052282||Mobile Health App - Healthy Individuals|"Mobile health App - Test~Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants.~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
62694592|NCT06643520|ACTIVE_COMPARATOR|19-gauge FNB needle|Biopsy samples obtained by a 19-gauge FNB needles for EUS-LB
61937274|NCT05642078|EXPERIMENTAL|Investigational Vaccine(Low dose group)|Quadrivalent influenza vaccine(Split Virion),Inactivated，Produced by Anhui Zhifei Longcom Biopharmceutical Co., Ltd.；0.25mL/branch, each contains 7.5 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
61937275|NCT05642078|EXPERIMENTAL|Investigational Vaccine(High dose group)|Quadrivalent influenza vaccine(Split Virion),Inactivated，Produced by Anhui Zhifei Longcom Biopharmceutical Co., Ltd.；0.5mL/branch, each contains 15 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
61937276|NCT05642078|ACTIVE_COMPARATOR|Active compared Vaccine|Influenza Vaccine(Split Virion),Inactivated Quadrivalent,Produced by Hualan Biological Vaccine Co., Ltd.;0.25mL/branch,each contains 7.5 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
61937277|NCT06154538|EXPERIMENTAL|Cadonilimab+FOLFOX group|Patients in this group will receive cetuximab combined with FOLFOX regimen, specifically: Cetuximab 6 mg/kg, intravenous infusion, D1; Oxaliplatin (85mg/m2), intravenous infusion, D1; Calcium folinate (400mg/m2), intravenous infusion, D1; 5-FU (400mg/m2), intravenous infusion, D1, then continuous intravenous infusion of 1200mg/(m2·d)×2d (total amount of 2400mg/m2, infusion for 46-48h) every two weeks; in the control group, qualified subjects will receive Oxaliplatin (85mg/m2), intravenous infusion, D1; Calcium folinate (400mg/m2), intravenous infusion, D1; 5-FU (400mg/m2), intravenous infusion, D1, then continuous intravenous infusion of 1200mg/(m2·d)×2d (total amount of 2400mg/m2, infusion for 46-48h) every two weeks. Imaging evaluation will be performed after 3 cycles of preoperative treatment. If the disease is resectable, surgery will be performed. If R0 resection is achieved, the preoperative regimen will continue for up to 9 cycles.
61937278|NCT06154538|ACTIVE_COMPARATOR|FOLFOX group|Patients in this group will undergo FOLFOX chemotherapy regimen, specifically: Oxaliplatin 85 mg/m2 dissolved in 500 ml of 5% glucose solution, intravenous drip, on Day 1, in combination with calcium folinate (400mg/m2), intravenous infusion, on Day 1, and 5-FU (400mg/m2), intravenous infusion, on Day 1, followed by continuous intravenous infusion of 1200mg/(m2·d) for 2 days (total dose of 2400mg/m2, infusion for 46-48 hours), once every 2 weeks. After 3 cycles of preoperative treatment, imaging evaluation will be performed. If the disease is resectable, surgery will be performed. If R0 resection is achieved, the preoperative treatment regimen will be continued after surgery, for a maximum of 9 cycles.
61937279|NCT01498835|EXPERIMENTAL|Combined Sunitinib and irradiation|Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
61937280|NCT02647840|OTHER|Voice therapy|All participants will receive voice therapy based on the Estill model. This is very similar to our usual intervention.
61937281|NCT00372203|EXPERIMENTAL|Endobronchial ultrasound|
61937282|NCT05462470||repeat liver surgery|repeat liver surgery for liver relapse lesions
61937283|NCT05462470||non-repeat liver surgery|non-repeat liver surgery, just only systemic palliative chemotherapy
61937284|NCT05631665|EXPERIMENTAL|postmenopausal women|women with postmenopausal sexual function problems will be the study arm
61937285|NCT06030310|EXPERIMENTAL|INPP Movement Program Group|The INPP Movement Program Group will consist on a group of children aged between 7 and 9 years old enrolled in the second grade class of a catalan school that will participate in the school motor program provided by the Institute of Neuro-Physiology Psychology (INPP). This program consists of exercises that replicate the developmental movements of babies. Each day, a set of specific exercises will be performed, it will be practiced for 6 weeks and replaced by another set of exercises. They will be conducted for 15 minutes daily throughout the entire academic year.
61937286|NCT06030310|NO_INTERVENTION|Non Intervention Group|Children aged between 7 and 9 years old enrolled in the second grade at a catalan school. Students in the Non Intervention Group will continue with their regular academic school year without any additional intervention. If any student from the INPP Movement Program Group chooses not to participate in the study, they will join the class of the Non Intervention Group during the time when their peers are engaged in the school motor program.
62331918|NCT03660813|EXPERIMENTAL|HCG triggering|Ovitrelle ( hCG 250 mcg)
62331919|NCT03660813|EXPERIMENTAL|Dual triggering|Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg\*2 )
62331920|NCT01631279|EXPERIMENTAL|PR610|
62331921|NCT03051334||BiAV|Bicuspid aortic valve
62331922|NCT03051334||TAV|Tricuspid aortic valve
62489732|NCT03885934|ACTIVE_COMPARATOR|Prevnar 13®, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced)(1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
62694593|NCT06643520|EXPERIMENTAL|22-gauge FNB needle|Biopsy samples obtained by a 22-gauge FNB needles for EUS-LB
62694594|NCT05359562|ACTIVE_COMPARATOR|Active Comparator|Male participants will receive a brief EX/RP protocol within a 10-day window.
62694595|NCT05359562|EXPERIMENTAL|Experimental 1|Half of female participants will be randomized to receive a brief EX/RP protocol within the first 10 days after the start of menstruation (early follicular phase).
62694596|NCT05359562|EXPERIMENTAL|Experimental 2|Half of female participants will be randomized to receive a brief EX/RP protocol in days 12-22 of the menstrual cycle (late follicular, early luteal phase).
62694597|NCT04978467|EXPERIMENTAL|single arm|All participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
62331923|NCT04020484|EXPERIMENTAL|Intervention Group|Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.
62489733|NCT00487435|EXPERIMENTAL|001|Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks
62489734|NCT06022588|PLACEBO_COMPARATOR|13C -butyrate control group|5 healthy volunteers performed the breath test without any psychical exercise
62489735|NCT06022588|EXPERIMENTAL|13C -butyrate intervention group|5 healthy volunteers performed the breath test with psychical exercise - bicycle test
62489736|NCT06022588|PLACEBO_COMPARATOR|13C -glucose control group|5 healthy volunteers performed the breath test without any psychical exercise
62489737|NCT06022588|EXPERIMENTAL|13C -glucose intervention group|5 healthy volunteers performed the breath test with psychical exercise - bicycle test
62489738|NCT03103711|EXPERIMENTAL|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
62489739|NCT03103711|NO_INTERVENTION|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
62489740|NCT03643783||Bariatric Obese Patients|Obese patients, including men and women, White (Caucasians), Africa American, and Hispanic or Latino racial categories, and ages 18-70 years, who are enrolled and planning to undertake bariatric surgery in the Outpatient Bariatric Surgery Clinic at Tulane University, HSC (Christopher G. Ducoin, MD, MPH; Chair of Bariatric Surgery Clinic and Surgeon, and Shauna Levy, MD, Bariatric Surgeon Specialist).
62489741|NCT03643783||Lean Control Patients|Plasma samples from lean control patients that have already been collected and are available as part of the Tulane Obesity-Endocannabinoids Study (Tina Thethi, M.D, Collaborator).
62489742|NCT03147053|EXPERIMENTAL|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
62489743|NCT03147053|PLACEBO_COMPARATOR|Placebo|Patients in this group were administered the placebo .
62489744|NCT00516295|EXPERIMENTAL|Arm I (Feasibility assessment of VTCB)|Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 \[course 5\], 17, 18 \[course 6\], 26, 27 \[course 9\], 29, and 30 \[course 10\] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62489745|NCT00516295|EXPERIMENTAL|Arm II (VTCB)|Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in Arm I.
62489746|NCT00516295|ACTIVE_COMPARATOR|Arm III (CTC)|Patients receive vincristine, topotecan hydrochloride, and cyclophosphamide as in arm I.
62489747|NCT06466135|EXPERIMENTAL|WAL0921|Intravenous infusion of investigational drug WAL0921
61937287|NCT03516617|EXPERIMENTAL|Arm A (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
61937288|NCT03516617|EXPERIMENTAL|Arm B (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1 and days 1 of subsequent cycles. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
61937289|NCT03516617|ACTIVE_COMPARATOR|Arm C (observation)|Patients will be observed every 6 months for up to 2 years.
61937290|NCT02404467||Patients receiving transfermoral TAVI|TF TAVI
62489748|NCT06466135|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of normal saline
62489749|NCT05435534|EXPERIMENTAL|Multicomponent intervention|Participants randomly assigned to the Multicomponent intervention group will received a multifactorial intervention.
62489750|NCT05435534|ACTIVE_COMPARATOR|Usual care group|Participants randomly assigned to the usual care group will received normal outpatient care, including physical rehabilitation when needed.
62694598|NCT02768246|ACTIVE_COMPARATOR|Begin with BVGA|The volunteers will be asked to breathe 5 minutes of room air through the BVGA, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the BVGA. Then the same volunteers will be asked to repeat the protocol with the face mask.
62694599|NCT02768246|ACTIVE_COMPARATOR|Begin with Face-mask|The volunteers will be asked to breathe 5 minutes of room air through the face mask, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the face mask. Then the same volunteers will be asked to repeat the protocol with the BVGA.
62694600|NCT01275300|PLACEBO_COMPARATOR|Placebo phase I|Subjects were given 5 days of placebo. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of placebo. Urine was collected sequentially for analysis. The same subjects came back for cross-over study and were assigned to Aspirin group. There was a 2-week washout period between each treatment.
62694601|NCT01275300|ACTIVE_COMPARATOR|Aspirin phase I|Subjects were given 5 days of 81 mg aspirin. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of aspirin or placebo. Urine was collected sequentially for analysis.
62489751|NCT04762251|EXPERIMENTAL|Time-restricted eating (TRE)|The TRE group will be instructed to follow TRE (9 h/day) every day for 12 months with no other dietary instructions or advice provided. The TRE group will attend the same consult schedule as the CP group, but consultations will focus on timing of dietary intake and strategies to promote adherence. No dietary guidance regarding quantity or quality will be provided. Participants will be able to self-select the precise 9-h schedule that will best suit their lifestyles, with the caveat that the latest time of eating will be set at 7:00 pm. Outside of the elected eating window, participants will be allowed to consume water and black coffee and/or tea.
62489752|NCT04762251|ACTIVE_COMPARATOR|Current Best Practice (CP)|This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. No specific advice will be provided regarding time of day to start and finish eating and/or drinking (since this information is not outlined in current practice guidelines).
62694602|NCT01275300|ACTIVE_COMPARATOR|Aspirin phase II|In phase II study, subjects were given 5 days of 81 mg aspirin. On day 6, they were given a single dose of niacin (600 mg) administered 24 hours after the last dose of aspirin. Urine was collected sequentially for analysis
62694603|NCT06565091|EXPERIMENTAL|Multifonction Ophtalmic Measuring Device|Parameters and images of the anterior and posterior chambers of the human eye
62489753|NCT05779943|EXPERIMENTAL|Treatment (furosemide, F-18 rhPSMA-7.3, PET-CT)|Patients receive F-18 rhPSMA 7.3 tracer IV and then undergo PET-CT scans with and without furosemide IV on study.
62489754|NCT04302961|EXPERIMENTAL|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving auditory feedback.
62694604|NCT06275958|ACTIVE_COMPARATOR|Doublet therapy, full dose (low toxicity risk based on G8)|Low risk of toxicity: G8-score of 15 or higher
62694605|NCT06275958|EXPERIMENTAL|Doublet therapy, dose-reduced (low toxicity risk based on G8)|Low risk of toxicity: G8-score of 15 or higher
62694606|NCT06275958|ACTIVE_COMPARATOR|Fluoropyrimidine monotherapy, full dose (high toxicity risk based on G8)|"High risk of toxicity: G8-score of 14 or lower or judged as high toxicity risk by their treating oncologist"
62694607|NCT06275958|EXPERIMENTAL|Fluoropyrimidine monotherapy, dose-reduced (high toxicity risk based on G8)|"High risk of toxicity: G8-score of 14 or lower or judged as high toxicity risk by their treating oncologist"
62697630|NCT04740567|EXPERIMENTAL|Cognitive Intervention|During hospitalization, enrolled patients assigned to the intervention arm will undergo two 20-minute cognitive training sessions daily, 7 days a week. After the patient is discharged from the hospital, cognitive rehabilitation will be administered once a week for 12-weeks at their place of residence. Goal Management Training will be the foundation for cognitive rehabilitation.
62136194|NCT06639074|PLACEBO_COMPARATOR|Arm II (placebo)|Patients may receive Td or Tdap IM prior to undergoing leukapheresis. Patients receive placebo ID on day 1 of each cycle. Cycles repeat every 21 days for cycles 1-5 and then repeat every 91 days for cycles 6-12 in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo biopsy prior to apheresis and optionally at end of treatment, and blood sample collection, CT and/or MRI throughout the study.
62697631|NCT04740567|NO_INTERVENTION|Usual Care|Enrolled patients will undergo usual care during hospitalization and post-hospital discharge.
62489755|NCT04302961|ACTIVE_COMPARATOR|No Feedback|Participants will complete 8 sessions over a 2-week period of walking on a treadmill without receiving feedback.
61937291|NCT04670055|EXPERIMENTAL|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
61937292|NCT06070311|ACTIVE_COMPARATOR|Thymoquinone (0.5%) and Olive oil ointment|thymoquinone (0.5%) and olive oil ointment will be applied to fill the ethmoidal and different sinuses cavities of one randomly chosen side of the nose.
61937293|NCT06070311|NO_INTERVENTION|No intervention|no intervention
61937294|NCT04949464|EXPERIMENTAL|Prevention (smoking cessation, nicotine replacement, LDCT)|Patients use the smartphone application, Positively Smoke Free - Mobile, for 42 days. Patients also receive nicotine replacement therapy for 12 weeks. Within 60 days of study registration, patients undergo LDCT.
62136195|NCT05580003|EXPERIMENTAL|PF-07817883 Dose 1 in PART-1|
62136196|NCT05580003|EXPERIMENTAL|PF-07817883 Dose 2 in PART-1|
62136197|NCT05580003|EXPERIMENTAL|PF-07817883 Dose 3 in PART-1|
62136198|NCT05580003|EXPERIMENTAL|PF-07817883 Dose 4 in PART-1|
62136199|NCT05580003|EXPERIMENTAL|PF-07817883 Dose 5 in PART-1|Optional dose levels
62136200|NCT05580003|EXPERIMENTAL|PF-07817883 Dose 6 in PART-1|Optional dose levels
62136201|NCT05580003|PLACEBO_COMPARATOR|Placebo in PART-1|A single dose of placebo
62136202|NCT05580003|EXPERIMENTAL|PF-07817883 DR1 in PART-2|DR=Dosing regimen; twice a day
62136203|NCT05580003|EXPERIMENTAL|PF-07817883 DR2 in PART-2|
62136204|NCT05580003|EXPERIMENTAL|PF-07817883 DR3 in PART-2|Optional dosing regimen
62136205|NCT05580003|EXPERIMENTAL|PF-07817883 DR4 in PART-2|Optional dosing regimen
62136206|NCT05580003|EXPERIMENTAL|PF-07817883 in Japanese in PART-2|Optional dosing regimen to be studied in Japanese population
62136207|NCT05580003|EXPERIMENTAL|PF-07817883 in Chinese in PART-2|Optional dosing regimen to be studied in Chinese population
62136208|NCT05580003|PLACEBO_COMPARATOR|Placebo in PART-2|
62136209|NCT05580003|EXPERIMENTAL|PF-07817883 Suspension Fasted in PART-3|PART-3 is optional
62136210|NCT05580003|EXPERIMENTAL|PF-07817883 FORM-1 Fasted in PART-3|First solid oral formulation (FORM1)
62136211|NCT05580003|EXPERIMENTAL|PF-07817883 FORM-2 Fasted in PART-3|Second solid oral formulations (FORM-2) is optional
62136212|NCT05580003|EXPERIMENTAL|PF-07817883 FORM-1 Fed in PART-3|
62136213|NCT05580003|EXPERIMENTAL|PF-07817883 FORM-2 Fed in PART-3|
62136214|NCT05580003|EXPERIMENTAL|PF-07817883 in PART-4|PART-4 is optional
62136215|NCT05580003|EXPERIMENTAL|Midazolam 5 mg in PART-5|Single dose of 5 mg alone
62136216|NCT05580003|EXPERIMENTAL|Midazolam 5 mg with PF-07817883 in PART-5|Single dose of 5 mg on Day 10 with multiple doses (twice a day) of PF-07817883
62136217|NCT05580003|EXPERIMENTAL|PF-07817883 in PART-6|A single dose at supratherapeutic exposure administered as divided doses (1h apart)
61937295|NCT02760576|EXPERIMENTAL|BAY 987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61937296|NCT01353261||Elective Cases|Patients with stable CAD undergoing PCI
61937297|NCT01353261||AMI Cases treated with clopidogrel|Patient with AMI undergoing PCI
61937298|NCT01353261||AMI Cases treated with prasugrel|Patients with AMI undergoing PCI
62331924|NCT04020484|OTHER|Waitlist Control|Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete the Baseline and Immediate Follow-up questionnaire at comparable times to families in the intervention arm; they will not complete the Extended Follow-up questionnaire. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session.
62331925|NCT03072017|EXPERIMENTAL|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
62331926|NCT02592629|ACTIVE_COMPARATOR|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
62331927|NCT02592629|ACTIVE_COMPARATOR|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
62331928|NCT02592629|ACTIVE_COMPARATOR|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
62331929|NCT05903196|EXPERIMENTAL|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
62331930|NCT01801137|EXPERIMENTAL|Afinitor|Treatment by Afinitor 10 mg per day
62331931|NCT00818324|EXPERIMENTAL|OPC-12759 Ophthalmic suspension|Instillation, 4times/day
62331932|NCT02934776|EXPERIMENTAL|DTI acquisition|Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images
62331933|NCT02538588|EXPERIMENTAL|Nebulizer 1|Nebulization with akita nebulizer
62331934|NCT02538588|ACTIVE_COMPARATOR|Nebulizer 2|Nebulization with eFlow nebulizer
62331935|NCT01041690|EXPERIMENTAL|Bevacizumab|
62331936|NCT04586894||Patients|
62331937|NCT04935060|ACTIVE_COMPARATOR|Usual Care Dementia assessment|Clinicians will conduct the assessment and outcome process as per their usual practice.
62331938|NCT04935060|EXPERIMENTAL|Guide informed dementia assessment|The guide will be used by both clinicians, patients and their companions to inform the approach to the dementia assessment process.
62331939|NCT05924906|EXPERIMENTAL|NB002 dose level 1|NB002 is a recombinant humanized IgG1 monoclonal antibody
62331940|NCT05924906|EXPERIMENTAL|NB002 dose level 2|NB002 is a recombinant humanized IgG1 monoclonal antibody
62331941|NCT05924906|EXPERIMENTAL|NB002 dose level 3|NB002 is a recombinant humanized IgG1 monoclonal antibody
62331942|NCT05924906|EXPERIMENTAL|NB002 dose level 4|NB002 is a recombinant humanized IgG1 monoclonal antibody
61937299|NCT06218212|ACTIVE_COMPARATOR|Arm 1 patients with AKI and acute on top of CKD who will be treated by electrolytes binders.|they will start calcium carbonate (phosphorus binder) with dosage 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
61937300|NCT06218212|EXPERIMENTAL|Arm 2 patients with AKI and acute on top of CKD who will be treated by Renastart formula.|"* Renastart formula will be used with breast milk, standard infant formula or with diet.~* Preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be started to represent ¼ recommended daily allowance of daily caloric intake and the dose will be adjusted according to serum electrolyte levels."
61937301|NCT02722486|ACTIVE_COMPARATOR|Standard Vestibular Rehabilitation|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions of an hour each). During these sessions, standard balance training exercises will be done at the discretion of the physical therapists.
62331943|NCT05924906|EXPERIMENTAL|NB002 dose level 5|NB002 is a recombinant humanized IgG1 monoclonal antibody
62331944|NCT05924906|EXPERIMENTAL|NB002 dose level 6|NB002 is a recombinant humanized IgG1 monoclonal antibody
62331945|NCT03036332|EXPERIMENTAL|intervention|Aerobic interval training
62331946|NCT03036332|NO_INTERVENTION|Control group|The participants performed only initial evaluation and at the end of the study
62331947|NCT05923489|EXPERIMENTAL|Routine Angiography Follow-up (RAF) group|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
62331948|NCT05923489|ACTIVE_COMPARATOR|Routine Clinical Follow-up (RCF) group|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
62331949|NCT03476785|EXPERIMENTAL|High Intensity Exercise|Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
61937302|NCT02722486|EXPERIMENTAL|Vestibular Rehabilitation/Balance Belt|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions). They will undergo standard balance training exercises with the physical therapists like the control group, but will also undergo an additional 15 minutes of Balance Belt exercises during each session.
61937303|NCT05995119|OTHER|Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fed conditions|
61937304|NCT05995119|OTHER|Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fast conditions|
62331950|NCT03476785|PLACEBO_COMPARATOR|Yoga|Subjects randomized to yoga will receive instructions on strength and flexibility exercises.
62489756|NCT06626542|EXPERIMENTAL|sequence of aerobic cardiovascular training (CVT) then resistance training (RT) exercises|
62694608|NCT06609096|EXPERIMENTAL|PLISSIT Group|Women assigned to the sexual counseling group based on the PLISSIT model will receive four sessions in total, once a week. Each session consisted of an average of 30 min. Sessions will be conducted online as individual counselling sessions. The Plissit model was used based on a four-stage approach. These stages are (P-Permission): Permission, (Ll- Limited Information), providing limited information (SS-Specific Suggestions): Giving specific suggestions, (IT- Intensive Therapy): Intensive Therapy. In this study, the first three stages of the model will be applied. After the first three stages of the model are implemented, women with ongoing sexual problems are referred to specialized sexual therapists for intensive treatment/therapy.
62694609|NCT06609096|EXPERIMENTAL|BETTER Group|Women assigned to the sexual counseling group based on the BETTER model will receive four sessions in total, once a week. Each session will consist of 30 minutes on average. Better model consists of Bring up the topic, Explain, Telling, Timing, Education and Recording steps. The sessions will be conducted online as individual counselling sessions.
62694610|NCT06609096|NO_INTERVENTION|Control Group|Women in the control group will not receive any intervention.
62331951|NCT02216253|ACTIVE_COMPARATOR|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|The combination of L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract will be administered in tablet twice a day 7 days before and after surgery
62331952|NCT02216253|PLACEBO_COMPARATOR|Placebo|Placebo tablet twice a day 7 days before and after surgery
62331953|NCT05754619||patients with HA|20 parents with hemophilic children. The sample will consist of 10 mothers and 10 fathers.
62331954|NCT04673526|EXPERIMENTAL|Intersphincteric resection|After a laparoscopic TME (total mesorectal excision) is carried out down to the elevator ani plane and the anorectal junction, the intersphincteric plane is dissected, opening the space between puborectalis muscle and interior sphincter. Margin of resection is at least 1 cm below the lower margin of the tumor. Rectal excision is completed with transanal circumferential dissection and after specimen extraction through the anus, a colo-anal hand sewn anastomosis is fashioned.
62331955|NCT04673526|ACTIVE_COMPARATOR|Abdomen-perineal procedures|After identification of the elevator ani plane, the descendent colon is transected with a linear stapler and a terminal stoma is fashioned. Then, a circumferential incision is made around anal orifice and perineal dissection is performed circumferentially to the pelvic cavity. Perineal defect is repaired performing mono-lateral or bilateral inferior gluteal flap.
62331956|NCT03219749|EXPERIMENTAL|Exercise Intervention|Exercise training will take place three times per week for six weeks and involve both aerobic and resistance exercise.
62331957|NCT00752609|EXPERIMENTAL|Peginesatide|
62331958|NCT03524833|OTHER|Intraluminal Metronidazole eradication|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
62331959|NCT03524833|OTHER|oral antibiotic triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
62331960|NCT03463616||CT abdomen|Patients who had a CT abdomen as primary work-up before treatment planning for rectal cancer.
62331961|NCT03463616||MRI Abdomen|Patients who had a MRI abdomen as primary work-up before treatment planning for rectal cancer.
62331962|NCT03750032|EXPERIMENTAL|Stapler appendectomy|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using a stapler.
62331963|NCT03750032|EXPERIMENTAL|Endoloop|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using endoloop.
62331964|NCT03750032|EXPERIMENTAL|Hem-O-Lock|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using Hem-O-Lock.
61937305|NCT00715923|EXPERIMENTAL|1|Modified consent form
61937306|NCT00715923|ACTIVE_COMPARATOR|2|Standard consent form
62331965|NCT02260908|ACTIVE_COMPARATOR|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
62331966|NCT02260908|PLACEBO_COMPARATOR|Late initiation of thromboprophylaxis|Initiation of placebo (normal saline) 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
62331967|NCT04208763|EXPERIMENTAL|Imipenem+Tigecycline+GM-CSF|
62331968|NCT04208763|ACTIVE_COMPARATOR|Imipenem+Tigecycline|
62331969|NCT00347555|EXPERIMENTAL|Group D|18 subjects 160 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
62331970|NCT00347555|EXPERIMENTAL|Group A|18 subjects 5 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
62331971|NCT00347555|EXPERIMENTAL|Group B|18 subjects 20 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
62331972|NCT00347555|EXPERIMENTAL|Group C|18 subjects 80 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
62331973|NCT04008433|EXPERIMENTAL|Lidocaine pre-intravenous injection|The initial dose of lidocaine for pre-injection was set at 0.5mg /kg according to previous literature and preliminary test results. The dose of lidocaine was according to the patients' pain level. If there is no pain (negative reaction), the dose of lidocaine in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of lidocaine will be increased in the next patient until the patient is painless.
61937307|NCT03235843|ACTIVE_COMPARATOR|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
61937308|NCT03235843|PLACEBO_COMPARATOR|Rate Adaptive Pacing OFF|DDI-pacing
62331974|NCT03033849|EXPERIMENTAL|Blood glucose measurement|Every study subject shall test three out of the five devices. The testing order of the BGMS will be changed on each subject to minimize any order effects on measurement results.
62331975|NCT03696264|EXPERIMENTAL|Resistance-trained, adult males|Subjects receive varying levels of amino acid intakes ranging from 0.2-3.0g/kg/d
62331976|NCT04017533|EXPERIMENTAL|GMK Sphere|Patients receive a cementless GMK Sphere Total Knee Replacement
62331977|NCT03892785|EXPERIMENTAL|Tocilizumab group|
62331978|NCT03892785|ACTIVE_COMPARATOR|Methotrexate group|
62331979|NCT04738500|ACTIVE_COMPARATOR|PENG Block|PENG Block combinate with PCA
62331980|NCT04738500|SHAM_COMPARATOR|CONTROL|PCA
62331981|NCT01031524|EXPERIMENTAL|vaccine|30 µg of PfCS102 formulated in Montanide ISA 720
62489757|NCT06626542|EXPERIMENTAL|sequence of resistance training (RT) then aerobic cardiovascular training (CVT) exercises|
62489758|NCT06626542|OTHER|control group routine treatment programme only|
62489759|NCT04484740|EXPERIMENTAL|Gepotidacin|
62489760|NCT04268797|EXPERIMENTAL|HR rTMS H7-coil intervention group|
62489761|NCT04268797|SHAM_COMPARATOR|sham control group|
62489762|NCT01956318|EXPERIMENTAL|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Patients are also delivered a booklet with advice on lifestyle.
62136218|NCT05580003|PLACEBO_COMPARATOR|Placebo in PART-6|A single dose of placebo administered as divided doses (1h apart)
62136219|NCT05580003|ACTIVE_COMPARATOR|Moxifloxacin 400 mg in PART-6 (open label)|Moxifloxacin 400 mg at 0h followed by placebo at 1h
62136220|NCT01584752||Fistula patients|Gore-BioA Fistula Plug
62331982|NCT01031524|PLACEBO_COMPARATOR|adjuvant|Montanide ISA 720
62331983|NCT04576637|EXPERIMENTAL|Neurophysiological monitoring during induction|
62331984|NCT02831075|EXPERIMENTAL|Adipose-derived stem cell|Mesenchymal stem cells derived from adipocyte transplantation
62331985|NCT02831075|PLACEBO_COMPARATOR|saline|saline injections
62331986|NCT02244723||Patients with suspected VAP|"Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.~For each patient a lung ultrasound examination will be performed."
62331987|NCT05745402|EXPERIMENTAL|Mobility Checkup Intervention|45-minute Mobility checkup that includes 5 physical performance measures and education based on outcomes compared to age and gender normative values.
62331988|NCT04950881|SHAM_COMPARATOR|Control group|Conventional monitor and treatment The surgery is performed after patient is under general anesthesia. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate.
62331989|NCT04950881|EXPERIMENTAL|Nerve block group|After the patient is under general anesthesia, an attending physicians perform the ultrasound-guided cervical vagus nerve block (using a 50mm Braun nerve stimulation needle, and the patients were injected with 10ml of lidocaine or ropivacaine ). Then the operation starts. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate. After endotracheal tube is removed, the patient will be followed up for next 24 hours.
62331990|NCT03082495|EXPERIMENTAL|Exercise|Aerobic exercise
62331991|NCT03082495|NO_INTERVENTION|Usual Care|Standard medical care
62331992|NCT03350152||LAM group|Have a diagnosis of AML according to World Health Organization (WHO) classification Are at least 70 years of age
62331993|NCT04346069|OTHER|Regular speech therapy|Regular speech therapy will be provided to the controlled group
62331994|NCT04346069|OTHER|Parent-child interaction therapy|Parent child interaction therapy will be provided to the experimental group
62136221|NCT00042731|ACTIVE_COMPARATOR|Oral isoflavones with multivitamin|Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
62136222|NCT00042731|ACTIVE_COMPARATOR|Oral lycopene with multivitamin|Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
62136223|NCT00042731|ACTIVE_COMPARATOR|Multiple vitamin alone|Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
62136224|NCT04747561|EXPERIMENTAL|18F-PEG3-FPN PET|A positron probe for the targeted melanin
62136225|NCT00482742|OTHER|Lifestyle counseling|
62136226|NCT00482742|OTHER|Metformin|
62331995|NCT00924976|EXPERIMENTAL|1|Subjects will be offered the Steps for Achieving Financial Empowerment (SAFE) which helps facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
62331996|NCT00924976|NO_INTERVENTION|2|Representative payeeship as usual
62331997|NCT04408859||NACS|The patients with advanced gastric cancer who received neoadjuvant chemotherapy followed by surgery（NACS）.
62489763|NCT01956318|NO_INTERVENTION|control group|patients are allowed to continue their usual drugs, compression therapy and are delivered a booklet with advice on lifestyle.
62489764|NCT06398522|ACTIVE_COMPARATOR|Food for special medical purposes|Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3
62489765|NCT06398522|PLACEBO_COMPARATOR|Placebo|
62489766|NCT01261767|EXPERIMENTAL|Anti-IL-20|
62489767|NCT01261767|PLACEBO_COMPARATOR|Placebo|
62489768|NCT00874822||Berlin|Patients diagnosed with obstructive sleep apnea by polysomnography after being screened with the Berlin questionnaire.
62489769|NCT01456949|OTHER|Single Arm|Cryoablation
62489770|NCT05510141|EXPERIMENTAL|Virtual Reality Gaming|
62489771|NCT05510141|ACTIVE_COMPARATOR|Nitrous Oxide|Standard procedure
62489772|NCT00111787|EXPERIMENTAL|Overall study|A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
62489773|NCT00529763|EXPERIMENTAL|1|
62489774|NCT05409651|EXPERIMENTAL|Time restricted eating|Everyone in this arm will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
62489775|NCT01698736|ACTIVE_COMPARATOR|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
62489776|NCT01698736|EXPERIMENTAL|Semiselective IA + membrane filtration|Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration
62489777|NCT01591720|EXPERIMENTAL|Tailored Internet-delivered CBT|The intervention is delivered within a primary care clinic.
62489778|NCT02127216|NO_INTERVENTION|Standard of Care Group - A|The control group
62489779|NCT02127216|ACTIVE_COMPARATOR|MOSES - Group B|Individual patients using application and pedometer without healthcare provider support
62489780|NCT02127216|ACTIVE_COMPARATOR|MOSES - Group C|Individual patients using application and pedometer with healthcare provider support
62489781|NCT02127216|ACTIVE_COMPARATOR|MOSES - Group D|Peer patient teams using application and pedometer without healthcare provider support
62489782|NCT02127216|ACTIVE_COMPARATOR|MOSES - Group E|Peer patient teams using application and pedometer with healthcare provider support
62489783|NCT01632423||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
62489784|NCT05069974|EXPERIMENTAL|Linezolid (LZD) 1200|Patients will take film coated tables of LZD 600 mg every 12 hours during 10 days
62489785|NCT05069974|ACTIVE_COMPARATOR|Benzathine Penicillin G (BPG)|Administration of intramuscular BPG 2.4 MIU single dose during day 1
62489786|NCT05069974|EXPERIMENTAL|Linezolid (LZD) 600|Patients will take film coated tables of LZD 600 mg every 24 hours during 5 days
62489787|NCT02225015|ACTIVE_COMPARATOR|FTGC at 1 month|Individuals randomized to the intervention group will receive a tailored cancer risk assessment via a follow-up telephone genetic counselling (FTGC) session within one month of study enrollment.
62489788|NCT02225015|NO_INTERVENTION|Standard Care + FTGC in 12 months|Individuals randomized to the intervention group will receive a tailored cancer risk assessment at 12 months following study enrollment
62489789|NCT02824510|ACTIVE_COMPARATOR|Patients under insulin pump therapy.|Patients under insulin pump therapy. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart).
62489790|NCT02824510|ACTIVE_COMPARATOR|Patients under MDI.|Patients under multiple daily injection regimen. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart and glargine or detemir).
62489791|NCT03204851|ACTIVE_COMPARATOR|Venous Stasis Ulcer|Venous Stasis Ulcer
62331998|NCT04408859||SA|The patients with advanced gastric cancer who received surgery alone.
62489792|NCT03204851|ACTIVE_COMPARATOR|Pressure Ulcers|Pressure Ulcers
62331999|NCT05509205||Patients with stroke|In this study 130 patients with stroke who are treating with stroke rehabilitation programs, will be included.
62489793|NCT03204851|ACTIVE_COMPARATOR|Diabetic Foot Ulcers|Diabetic Foot Ulcers
62489794|NCT03204851|ACTIVE_COMPARATOR|Wounds from a variety of etiologies|Wounds from a variety of etiologies
62489795|NCT00512239||EUPA cohort|Consecutive adult patients presenting to receive rheumatological care at the Sherbrooke University Hospital Centre (CHUS) with an immune-mediated inflammatory arthritis affecting at least 3 joints for a duration of more than 4 and less than 52 weeks.
62489796|NCT01816230|EXPERIMENTAL|NiCord®|NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
62489797|NCT01932853||Hemodialysis patients|Patients \> 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
62489798|NCT00691470|EXPERIMENTAL|1. ATI-5923|Dose adjusted ATI-5923
62489799|NCT00691470|ACTIVE_COMPARATOR|2. Coumadin|Dose adjusted Coumadin (warfarin)
62489800|NCT03108235|EXPERIMENTAL|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
62694611|NCT01756742|EXPERIMENTAL|Respiratory physiotherapy|54 people according to the inclusion criteria were recruited to have a respiratory physiotherapy treatment added to their medical intervention.
61937309|NCT04718961|EXPERIMENTAL|Part 1 Arm 1 - Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
62332000|NCT01999413|EXPERIMENTAL|OMEGAVEN - Daunorubicin - Cytarabine|"If WBC ≥ 30 G/L, chemotherapy the induction cycle :~* Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~* Cytarabine 200 mg/m²/day D1 to D7~* OMEGAVEN® 2 ml/kg D1 to D9,~If WBC ≤ 30 G/L, OMEGAVEN during 48 hours~Induction cycle :~OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~- Cytarabine 200 mg/m²/day IV D1 to D7~bone marrow aspirate at D15: If BM blasts are \> 5% or if second induction course :~* Daunorubicin 35 mg/m²/day IV D17 and D18~* OMEGAVEN® 2 ml/kg~* Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19~For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN \> 1 G/L or \> 0.5 G/L during 3 days).~Consolidation will be administered at investigator's discretion"
62489801|NCT03108235|EXPERIMENTAL|Intervention group B|HOM-HEMP with the smartphone app.
62489802|NCT03108235|ACTIVE_COMPARATOR|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
62694612|NCT01756742|PLACEBO_COMPARATOR|Conservative treatment|49 people were recruited in this group. These participants received conservative medical treatment intervention
62694613|NCT06569316|EXPERIMENTAL|Screening (blood, saliva, tissue collection, genetic testing)|Patients undergo collection of blood or saliva samples on study for genetic testing. Patients also undergo collection of leftover tissue obtained from SOC surgical procedure or biopsy, or stored tissue samples for genetic testing on study. Patients receive the results of their genetic testing and are given resources for counseling and further care.
61937310|NCT04718961|EXPERIMENTAL|Part 1 Arm 2 - Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
61937311|NCT04718961|EXPERIMENTAL|Part 2 Arm 1 - Volixibat Selected Dose mg|Participants randomized to this arm will receive volixibat selected dose (mg) twice daily.
62489803|NCT01316237|OTHER|Cohort 1|(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2) 50 mg GS-6620 or placebo QD in the morning with food \[total daily dose (TDD) = 50 mg\] for 5 days
62489804|NCT01316237|OTHER|Cohort 2|"(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS-6620 or placebo QD in the morning with food (TDD = 100 mg) for 5 days"
62489805|NCT01316237|OTHER|Cohort 3|"Cohort 3 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning with food (TDD = 300 mg) for 5 days"
62489806|NCT01316237|OTHER|Cohort 4|"Cohort 4 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS 6620 or placebo QD in the morning without food (TDD = 100 mg) for 5 days"
62489807|NCT01316237|OTHER|Cohort 5|"Cohort 5 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning without food (TDD = 300 mg) for 5 days"
62332001|NCT04202861|EXPERIMENTAL|in vitro antibiotic combination testing (iACT)|For the intervention arm, CRGNB isolates from the index culture should be transported to the Pharmacy Research Lab in Singapore General Hospital as soon as possible to begin iACT. For external sites, a licensed medical courier will be engaged. Once testing is complete, the iACT results will be sent to the physicians and the ID specialist managing the patient. Several antibiotic combinations can usually be used to treat the infection; a subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and/or the consulting infectious disease doctor may exercise their discretion in continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement, according to the clinical conditions and reactions of the patient to the treatment
62332002|NCT04202861|NO_INTERVENTION|Control|The standard arm will receive standard therapy of either antibiotic monotherapy or unguided combination therapy, a choice based on treating physicians' best clinical judgment. iACT will only be performed on CRGNB isolates from the standard arm at least 30 days after enrolment for collection of microbiological, proteomic and molecular data. Antibiotic combinations found from delayed iACT will be made known to the Infectious Diseases physician caring for the participant.
62332003|NCT05512130|EXPERIMENTAL|Empagliflozin / Placebo|Participants randomized to this arm will receive 25 mg of empagliflozin daily for 2 weeks followed placebo daily for 2 weeks
62332004|NCT05512130|EXPERIMENTAL|Placebo / Empagliflozin|Participants randomized to this arm will receive placebo daily for 2 weeks followed by 25 mg of empagliflozin daily for 2 weeks
62332005|NCT00905021|EXPERIMENTAL|Exemestane plus Sutent|"All patients enrolled on the study will receive treatment as follows:~1. Exemestane 25 mg by mouth every day.~2. Sunitinib 37.5 mg by mouth every day."
62332006|NCT02304783|ACTIVE_COMPARATOR|Oral Piroxicam|Piroxicam : 20 mg per pill; one pill per day for five days associated with placebo (1pill) (taken separately)
62332007|NCT02304783|PLACEBO_COMPARATOR|Placebo|Placebo: two pills per day for five days (taken separately)
62332008|NCT02304783|ACTIVE_COMPARATOR|paracetamol|paracetamol: 2000mg per day for five days two pills taken separately)
62332009|NCT03517748|EXPERIMENTAL|the investigational device: DM05|DM05 eye drops, multidose sterile emulsion, will be administered in the DM05 Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
62332010|NCT03517748|ACTIVE_COMPARATOR|The comparative device : Optive™|Optive™ eye drops, multidose sterile solution, will be administered in the Optive Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
62332011|NCT05345834|NO_INTERVENTION|Usual Care|Participants will participate in usual prenatal care throughout the duration of study.
62332012|NCT05345834|EXPERIMENTAL|Patient Navigation and treatment|"In the patient navigation arm, women who do not meet diagnostic criteria (Group 2a) can participate in: (1) group-based CBT preventative intervention; (2) peer support group (virtual); or (3) both. Women in the threshold risk group, meeting diagnostic criteria for depression/anxiety (Group 2b) at baseline can participate in: (1) individual CBT treatment (2) peer support group (virtual) (3) both~Prevention group includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Individual treatment includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations."
62332013|NCT03584854|ACTIVE_COMPARATOR|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
62332014|NCT03584854|ACTIVE_COMPARATOR|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
62332015|NCT04698590|ACTIVE_COMPARATOR|WFG Scleral Lenses|Scleral lenses with customized wavefront guided optics
62332016|NCT04698590|PLACEBO_COMPARATOR|Traditional Scleral Lenses|Scleral lenses with traditional optics
62332017|NCT02159391|NO_INTERVENTION|Usual Intervention|A standard intervention will be performed by nursing staff during hospital admission. Written information about the consequences of driving under the influence of alcohol and/or drugs will be provided. No psychological intervention.
62332018|NCT02159391|EXPERIMENTAL|Brief Motivational Interview|A Brief Motivational Interviewing will be performed during hospital admission by a psychologist experienced with this intervention.
62332019|NCT03992768|EXPERIMENTAL|NanoZoomer Whole Slide Imaging|Whole slide imaging using the Hamamatsu NanoZoomer S360MD Digital Slide Scanner System
62332020|NCT01771718||Human skin|Multiphoton microscopy imaging to collect information about changes in skin cells and fibrilar structure.
62332021|NCT02287012||Pre-Plerixafor era|The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
62136227|NCT02597751|EXPERIMENTAL|Treatment Arm|Participants are randomized to treatment group. After the first MRI scan, participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a second MRI scan. Twelve weeks later, participants have a third, follow-up scan.
62332022|NCT02287012||Plerixafor era|The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
62489808|NCT01316237|OTHER|Cohort 6|"Cohort 6 (N = 10, genotype 2 or genotype 3): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo QD in the morning without food (TDD = 900 mg) for 5 days"
62332023|NCT02787993|ACTIVE_COMPARATOR|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
62332024|NCT02787993|NO_INTERVENTION|Treatment as usual|Treatment as usual
62332025|NCT05722899|EXPERIMENTAL|Football training|10-week football training program with small-sided games, 2x/week, 45min-1h
62332026|NCT05722899|NO_INTERVENTION|Control|No intervention, no changes in lifestyle and diet
62332027|NCT02020993||Respiratory distress group|Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.
62332028|NCT02020993||Control Group|Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.
62332029|NCT06312267|NO_INTERVENTION|Control Arm|Study participants will undergo surgery using current ERAS protocol standard of care skin cleaning preparation.
62489809|NCT01316237|OTHER|Cohort 7|"Cohort 7 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~450 mg GS 6620 or placebo, administered BID with food (TDD = 900 mg) for 5 days"
62489810|NCT01316237|OTHER|Cohort 9|"Cohort 9 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo BID in the with food (TDD = 1800 mg) for 5 days"
62489811|NCT01316237|OTHER|Cohort 11|"Cohort 11 (N = 10, genotype 1 : (Active drug: 8, Matching Placebo: 2)~Up to 450 mg GS-6620 or placebo as an oral solution, BID, 12 hours apart in the fasted state, 2 hours after a meal (up to TDD = up to 900 mg) for 5 days."
62332030|NCT06312267|EXPERIMENTAL|Experimental Arm|Study participants will use Bioelectrical dressing preoperatively and post-operative.
62332031|NCT06187844|EXPERIMENTAL|Children with impalpable tests|For children with impalpable tests before and under anesthesia and by laparoscopy, cord structures could be seen entering the inguinal canal, inguinal exploration will be done.
62332032|NCT02486510|NO_INTERVENTION|Group 1 (Control)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)"
62332033|NCT02486510|EXPERIMENTAL|Group 2 (Treatment)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc."
62332034|NCT04604106||Patient group|Infant aged 12 months (± four weeks) with a history of general anesthesia exposure
62332035|NCT04604106||Healthy subject group|Infant aged 12 months (± four weeks) without a history of general anesthesia
62332036|NCT03439748|EXPERIMENTAL|Positive Affect Treatment|15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
62332037|NCT03439748|ACTIVE_COMPARATOR|Negative Affect Treatment|15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.
62332038|NCT04304755|EXPERIMENTAL|Investigational Medical Product : Zoledronic acid|Zoledronic acid 5 mg IV at baseline and after 26 weeks.
62136228|NCT02597751|NO_INTERVENTION|Waitlist control|"Participants are randomized to the waitlist control group. After the first MRI scan, participants wait for 12 weeks and then have a 2nd MRI scan. Participants then have 10 treatment sessions with an occupational therapist and are assessed by an independent occupational therapist before and after treatment. Participants then have a third MRI scan to examine brain changes associated with intervention."
62136229|NCT01595282|EXPERIMENTAL|Ketorolac|Intramuscular injection of ketorolac 60 mg in 2cc -plus- placebo tablet (calcium carbonate 600 mg tablet). For subjects who are 50 kg or less, intramuscular injection of ketorolac 30 mg in 1cc -plus- placebo tablet (calcium carbonate 600 mg tablet)
62136230|NCT01595282|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 800 mg tablet -plus- intramuscular injection of 2cc saline placebo. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet -plus- intramuscular injection of 2cc saline placebo
62136231|NCT03582085|EXPERIMENTAL|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
62136232|NCT03582085|PLACEBO_COMPARATOR|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
62136233|NCT04353089||Basic Life Support Participants|All persons attending certified Basic Life Support Courses in Denmark from 2016 to 2019
62136234|NCT04353089||OHCA|Out-of-hospital cardiac arrest victims in Denmark from mid 2016 til mid 2019
62136235|NCT01577524|ACTIVE_COMPARATOR|Diluted Povidone Iodine Solution|
62136236|NCT01577524|PLACEBO_COMPARATOR|Normal Saline Wash|
62332039|NCT04304755|PLACEBO_COMPARATOR|Placebo: NaCl 0,9%|100 ml 0.9% NaCl IV at baseline and after 26 weeks.
62332040|NCT02684019|ACTIVE_COMPARATOR|Dexmedetomidine|1microgram/kilogram loading dose followed by 0.5 microgram/kilogram/hour IV
62332041|NCT02684019|ACTIVE_COMPARATOR|Magnesium sulphate|40milligram/kilogram loading dose followed by 10milligram/kilogram/hour IV
62332042|NCT02259036|OTHER|SmartCAT Enhanced Treatment|Cognitive Behavioral Therapy enhanced with an ecological momentary treatment enhancement smartphone app called SmartCAT.
62332043|NCT01667575|EXPERIMENTAL|10 day Quadruple Therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
62332044|NCT01667575|ACTIVE_COMPARATOR|10 day Triple therapy|Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
62332045|NCT01667575|ACTIVE_COMPARATOR|14 day quadruple therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
62332046|NCT04985799|ACTIVE_COMPARATOR|Gynecare TVT Exact sling|Participants who are planning surgery for SUI are randomized to have placement of Gynecare TVT Exact sling and followed postoperatively for 1 year.
62332047|NCT04985799|ACTIVE_COMPARATOR|Neomedic KIM sling|Participants who are planning surgery for SUI are randomized to have placement of retropubic Neomedic KIM sling and followed postoperatively for 1 year.
62489812|NCT04951778|EXPERIMENTAL|Participants with R/R AML and R/R HR-MDS - Part A|Part A (Dose Escalation) of the study will enroll R/R AML (Relapsed or Refractory Acute Myeloid Leukemia) and R/R HR-MDS (Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes) participants and will evaluate the safety and tolerability of escalating doses of CC-91633, administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 doses (RP2D) and schedule.
62489813|NCT04951778|EXPERIMENTAL|Participants with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML participants.
62136237|NCT03911531||Fetuses|DNA obtained from amniotic fluid samples
62136238|NCT03911531||Neonates|DNA obtained from neonatal blood samples
62136239|NCT06609187|EXPERIMENTAL|GNC-077|Participants receive GNC-077 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62332048|NCT03293277|EXPERIMENTAL|A1|20µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
62332049|NCT03293277|EXPERIMENTAL|A2|20µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intranasally on Day 8
62489814|NCT04951778|EXPERIMENTAL|Participants with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R HR-MDS participants.
62489815|NCT03266224||Wryneck|those with a condition
62489816|NCT06492109|OTHER|Healthy participants|Overall good health, with a BMI between 18 and 25; aged between 18 and 80 years; no complaints of cognitive impairment, normal neurological examination; signed informed consent form.
62136240|NCT00321152|EXPERIMENTAL|1|Deplin/Deplin = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
62136241|NCT00321152|EXPERIMENTAL|2|placebo/Deplin = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
62332050|NCT03293277|EXPERIMENTAL|B1|40µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
62332051|NCT03293277|EXPERIMENTAL|B2|40µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intranasally on Day 8
62332052|NCT03293277|EXPERIMENTAL|C|80µg Dexmedetomidine or Placebo is administered intranasally on Day 1
62332053|NCT03859986|EXPERIMENTAL|ALX-101 Gel 5%|ALX-101 Gel 5% applied topically twice daily for 56 days
62332054|NCT03859986|PLACEBO_COMPARATOR|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle applied topically twice daily for 56 days
62332055|NCT02876055|ACTIVE_COMPARATOR|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
62332056|NCT02876055|ACTIVE_COMPARATOR|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the post-anesthesia care unit (PACU) with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
62694614|NCT03941184||SCAD cases|SCAD cases will be identified based on presence of at least one diagnosis code for SCAD followed by manual verification by a trained individual, OR, inclusion in the previously validated SCAD cohort (Tweet 2012).
62694615|NCT03941184||Controls without SCAD|Potential controls will be identified based on absence of any SCAD diagnosis codes.
62694616|NCT06644911||Normal weight pregnant women|Normal weight (body mass index 18.5-24.9 kg/m2)
62694617|NCT06644911||Obese pregnant women|women (body mass index ≥ 30 kg/m2)
62136242|NCT00321152|PLACEBO_COMPARATOR|3|placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
62136243|NCT00402428|ACTIVE_COMPARATOR|1|180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
62136244|NCT00402428|EXPERIMENTAL|2|900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
62136245|NCT00402428|EXPERIMENTAL|3|1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
62136246|NCT01612312|ACTIVE_COMPARATOR|Thrombectomy|
62136247|NCT01612312|OTHER|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
62136248|NCT01690416|ACTIVE_COMPARATOR|Ultrasound DNTP|the catheter will be placed using ultrasound and DNTT and Lidocaine as local anesthesia, by the same fellow as the one who performs the puncture with the traditional method
62136249|NCT01690416|ACTIVE_COMPARATOR|Traditional palpation technique|arteria cannulation by traditional palpation technique, using preprocedural lidocaine for anesthetic and palpation method by a fellow
62136250|NCT06255860||children with MIS-C|hospitalized children with MIS-C
62136251|NCT06255860||SARS-CoV-2 infection|non hospitalized children infected with SARS-CoV-2 treated by outpatient care
62136252|NCT01988935|EXPERIMENTAL|Prolonged Exposure + Smoking Cessation|Prolonged Exposure therapy plus smoking cessation intervention
62136253|NCT01988935|ACTIVE_COMPARATOR|Smoking Cessation|Smoking cessation intervention
62136254|NCT00280228|EXPERIMENTAL|1|Home Based Treatment
62136255|NCT00280228|ACTIVE_COMPARATOR|2|Treatment as Usual
62136256|NCT02417376|ACTIVE_COMPARATOR|Experimental|"Periodontal intervention in the form of scaling and root planing by:~1. ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and~2. gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
62136257|NCT02417376|NO_INTERVENTION|Control|No periodontal intervention in any form.
62136258|NCT03360513||general group|Comprised 70 caucasian Brazilian individuals with normal occlusion and at least four of Andrew's six keys.
62136259|NCT02633215|EXPERIMENTAL|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
62136260|NCT02633215|ACTIVE_COMPARATOR|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
62136261|NCT02866942|EXPERIMENTAL|Asthma|LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2+
62136262|NCT00998413|EXPERIMENTAL|Multifaceted intervention|Multifaceted intervention:physical exercise, nutrition, and behavioural intervention.
62136263|NCT00998413|NO_INTERVENTION|Control|standard usual care
62694618|NCT06639230|ACTIVE_COMPARATOR|Group 1: Laser-treated group|10 patients will be treated by laser surgery to remove oral granuloma
62489817|NCT06492109|NO_INTERVENTION|Patients with mild cognitive impairment (MCI)|Meets Petersen et al.'s diagnostic criteria for MCI: presence of subjective memory complaints; objective episodic memory impairment (scores on clinical memory tests falling 1-1.5 standard deviations below age- and education-adjusted norms); overall cognitive function is essentially normal, with a score of MMSE ≥ 24 indicating normal cognitive function according to the dementia screening standards specified by the Beijing Collaborative Group; CDR-global score = 0.5; daily living abilities are largely intact (capable of using public transportation, shopping, and managing finances). Does not meet the criteria for dementia according to the International Classification of Diseases, 10th edition (research version), or the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable Alzheimer's disease. Signed informed consent form.
62489818|NCT06492109|NO_INTERVENTION|Patients with Alzheimer's disease (AD)|Meets the NINCDS-ADRDA criteria for probable Alzheimer's disease; CDR-global score = 1; overall cognitive decline: MMSE score of 20-24; impaired daily living abilities: Activities of Daily Living (ADL) scale score \> 26. Signed informed consent form.
61937312|NCT04718961|PLACEBO_COMPARATOR|Part 2 Arm 2 - Placebo (Placebo Comparator)|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
62489819|NCT05128396|ACTIVE_COMPARATOR|Cognitive Training using Cogmed|Subjects will complete computerized cognitive training with varying degrees of difficulty over 5 weeks.
62489820|NCT05128396|ACTIVE_COMPARATOR|Awareness (mindfulness) training|Subject participate in mindfulness training. The meditation and tasks will become increasingly more self-directed over the 5 weeks; the degree of guidance will decrease to keep the subjective effort approximately constant and moderately challenging through the 5 weeks.
61937313|NCT03157960|EXPERIMENTAL|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
61937314|NCT03157960|EXPERIMENTAL|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
61937315|NCT03157960|EXPERIMENTAL|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
61937316|NCT03157960|EXPERIMENTAL|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
61937317|NCT03157960|EXPERIMENTAL|Fructose|Participant will receive a drink containing 35 g of fructose
62489821|NCT05128396|ACTIVE_COMPARATOR|Physical Exercise Training Using an Interactive Video Platform|Subjects will participate in a structured physical exercise training program that aims to progressively increase their level of activity over the 5 week training period.
61937318|NCT03157960|EXPERIMENTAL|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
61937319|NCT04208464|EXPERIMENTAL|Immediate-start arm|Participants will receive 4mg baracitinib daily for 24 weeks from the baseline visit in week 0. After treatment participants will be followed up for 12 weeks.
61937320|NCT04208464|EXPERIMENTAL|Delayed-start arm|After the baseline visit in week 0, participants will wait for a 12 week treatment delay and will then receive 4mg baracitinib daily from week 12-week 36 (i.e. for 24 weeks). After treatment participants will be followed up for 4 weeks for safety.
62332057|NCT02876055|EXPERIMENTAL|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
61937321|NCT03469050|EXPERIMENTAL|Rifaximin delayed released 800 mg b.i.d.|(i.e. 2 x 400 mg tablet twice a day; total daily dose: 1600 mg) for 10 consecutive days a month, for 12 months
62332058|NCT00789477|EXPERIMENTAL|Intravitreal Aflibercept Injection .5Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks
62332059|NCT00789477|EXPERIMENTAL|Intravitreal Aflibercept Injection 2Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks
61937322|NCT03469050|EXPERIMENTAL|Rifaximin delayed released 400 mg b.i.d|(i.e. 1x400 mg tablet plus 1 placebo tablet twice a day; total daily dose: 800 mg) for 10 consecutive days a month, for 12 months
62332060|NCT00789477|EXPERIMENTAL|Intravitreal Aflibercept Injection 2Q8|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks
62694619|NCT06639230|ACTIVE_COMPARATOR|Sclerotherapy-treated group (group 2)|This group was made up of ten patients who were treated with injections of sclerosing agent to remove pyogenic granuloma
61937323|NCT03469050|PLACEBO_COMPARATOR|Placebo b.i.d.|(i.e. 2 x placebo tablets twice a day) for 10 consecutive days a month, for 12 months.
61937324|NCT03696173||Participants taking abatacept|
61937325|NCT03696173||Participants taking abatacept with methotrexate|
61937326|NCT03755388|EXPERIMENTAL|Episealer group|Subjects with a focal cartilage lesion of the distal femur in which biological surgical methods have failed or are not eligible
61937327|NCT02076633|EXPERIMENTAL|L19IL2 + L19TNF|One arm, intratumoral injections of 10 Mio IU of L19IL2 and 312 μg L19TNF. Weekly administration for all combined leasions
61937328|NCT02027376|EXPERIMENTAL|LDE225 (sonidegib) plus docetaxel|Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
61937329|NCT05995808|EXPERIMENTAL|diagnostic group|
61937330|NCT03263000||Healthy|24 healthy volunteers (HVs)
61937331|NCT03263000||Patients|24 patients with blepharospasm
61937332|NCT03263000||Patients 2|24 patients with increased blinking alone.
61937333|NCT04964843|EXPERIMENTAL|N-acetylcysteine|25 participants randomly selected to receive 1500 milligrams of oral n-acetylcysteine twice daily for 7 weeks.
62332061|NCT00789477|EXPERIMENTAL|Intravitreal Aflibercept Injection 2PRN|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria
62489822|NCT05128396|PLACEBO_COMPARATOR|Low Level of Cognitive Training Using the Cogmed Program|Subjects will complete the same computerized training as the active cognitive arm over the course of 5 weeks, but the main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time.
62489823|NCT03784274||Stakeholders|Key stakeholders involved program and policy making
61937334|NCT04964843|PLACEBO_COMPARATOR|Placebo|25 participants randomly selected to receive placebo twice daily for 7 weeks.
62332062|NCT00789477|ACTIVE_COMPARATOR|Laser Photocoagulation|Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.
62332063|NCT03571334|EXPERIMENTAL|IncobotulinumtoxinA|"IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units.~Study participants in this arm will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)~Hands: INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).~Feet: INA will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
62332064|NCT03571334|PLACEBO_COMPARATOR|saline control|"Study participants in this arm will 2.5mL normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)~Hands: saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).~Feet: Saline will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
62332065|NCT06208982||Colorectal ulcers|Colonoscopy images and videos of colorectal ulcers.
62332066|NCT04279912|EXPERIMENTAL|Patients with Multiple Sclerosis and Tremor|Participants will undergo MRgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
62332067|NCT02745158||FOP Patients|
62332068|NCT01014637|ACTIVE_COMPARATOR|Amorolfine 5%|
62332069|NCT01014637|EXPERIMENTAL|RV4104A-cylcopiroxolamine-ciclopirox|
62332070|NCT01002534|NO_INTERVENTION|baseline|visit 1
62332071|NCT01002534|ACTIVE_COMPARATOR|Vardenafil|nasal instillation of Vardenafil ( visit 2 or 3)
62332072|NCT01002534|PLACEBO_COMPARATOR|Placebo|Nasal instillation of placebo (visit 3 or 2)
62332073|NCT01716533|OTHER|Recurrence group|Male or female subjects aged 18 years or older at the time of enrollment, who experienced recurrence of Clostridium difficile infection (CDI) after clinical response to antibiotic treatment to treat the initial CDI episode.
62332074|NCT01716533|OTHER|Sustained response group|Male or female subjects aged 18 years or older at the time of enrollment, who did not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
62332075|NCT01716533|OTHER|Failure to antibiotic Group|Male or female subjects aged 18 years or older at the time of enrollment, withdrawn due to failure of antibiotic treatment to treat the initial CDI episode.
62489824|NCT01129258|EXPERIMENTAL|PF-04991532|
61937335|NCT02884531|EXPERIMENTAL|Patient Education and BBAT|Patients will participate in Patient Education and Basic Body Awareness Therapy
61937336|NCT02884531|ACTIVE_COMPARATOR|Patient Education|Patients will only participate in Patient Education
62332076|NCT01716533|OTHER|Unclassified Group|Male or female subjects aged 18 years or older at the time of enrollment, who couldn't be classified as sustained response, recurrence, or failure to antibiotic due to missing data.
62332077|NCT06150690||Type 2 diabetes|Patients with type 2 diabetes undergoing (partial) pancreatectomy
62332078|NCT06150690||Type 3 diabetes|Patients with type 3 diabetes undergoing (partial) pancreatectomy
62332079|NCT06150690||Non-diabetic controls|Patients with normal glucose metabolism undergoing (partial) pancreatectomy
62332080|NCT05434247|OTHER|Reverse-bevel ProCore™|Historical comparator group of biopsies taken using Echo Tip® HD ProCore™ (Wilson-Cook Medical Inc., Winston-Salem, NC, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
62332081|NCT05434247|EXPERIMENTAL|Fork-tip SharkCore™|Experimental group of biopsies using SharkCore™ (Medtronic Inc., Sunnyvale, CA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
62332082|NCT05434247|EXPERIMENTAL|Franseen Acquire™|Experimental group of biopsies using Acquire™ (Boston Scientific, Marlborough, MA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
62332083|NCT00321984|EXPERIMENTAL|Dexlansoprazole MR 30 mg QD|
62332084|NCT00321984|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62332085|NCT00321984|PLACEBO_COMPARATOR|Placebo|
62332086|NCT03209544|EXPERIMENTAL|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
62332087|NCT03209544|NO_INTERVENTION|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
62332088|NCT05241015|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive standard physiotherapy program used for PD will be applied, 3 times a week for 8 weeks.
62332089|NCT05241015|EXPERIMENTAL|Exercises Group|In addition to standard physiotherapy programme, patients in this group will also receive sensorimotor training.
62489825|NCT01129258|PLACEBO_COMPARATOR|Placebo|
62489826|NCT01246687|EXPERIMENTAL|e-Intervention group|Receive stage-specific dietary intervention via the website \& standard care at the outpatient clinic.
62489827|NCT01246687|NO_INTERVENTION|Control group|Continue with the standard diabetes care at the outpatient clinic without getting access to the web-based intervention.
62489828|NCT03825562|EXPERIMENTAL|research group|Research group is attending the ACT intervention first and from before and afte measurement are compared to the control group
61937337|NCT03652376|EXPERIMENTAL|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
61937338|NCT01604473||Chronic Kidney Disease|Individuals with Chronic Kidney Disease stages IV or V anticipating the need for hemodialysis access through an arterio-venous fistula.
62489829|NCT03825562|ACTIVE_COMPARATOR|control group|Control group is offered to attend the intervention afterwards
62332090|NCT01482741||Pts undergoing chemotherapy for Stage IV colorectal carcinoma|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
62489830|NCT01120028|EXPERIMENTAL|Alemtuzumab/Sirolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
62489831|NCT01120028|EXPERIMENTAL|Alemtuzumab/Tacrolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
62489832|NCT01120028|ACTIVE_COMPARATOR|Basiliximab/Tacrolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
62489833|NCT01120028|ACTIVE_COMPARATOR|Basiliximab/Sirolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
62489834|NCT04162899|ACTIVE_COMPARATOR|Active Comparator: SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
62489835|NCT04162899|ACTIVE_COMPARATOR|Active Comparator: SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
62489836|NCT04162899|ACTIVE_COMPARATOR|Placebo Comparator: Placebo|Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.
62489837|NCT02466490|EXPERIMENTAL|Fimasartan 60 mg Tablets|FMS 60 mg tablets once a day during the initial 8 treatment weeks of the study
62489838|NCT02466490|ACTIVE_COMPARATOR|Fimasartan 120 mg Tablets|FMS 120 mg tablets once a day during 4 weeks (treatment weeks 8 to 12)
62332091|NCT01482741||Parents of pediatric patients stage 1-3 neuroblastoma|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
62332092|NCT01482741||Women who have undergone tx for early stage breast cancer|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
62489839|NCT02466490|ACTIVE_COMPARATOR|Fimasartan; Hydrochlorothiazide 60/12.5|FMS 60 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 4 weeks (treatment weeks 8 to 12)
62489840|NCT02466490|EXPERIMENTAL|Fimasartan; Hydrochlorothiazide 120/12.5|FMS 120 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 12 weeks (treatment weeks 12 to 24)
62489841|NCT04440150|OTHER|Complicated Acute Appendicitis|The patients were assigned to the complicated acute appendicitis group (Group C) based on the preoperative imaging findings (periappendiceal abscess formation or significant periappendiceal fat tissue contamination in ultrasonography and computed tomography), intraoperative exploration findings (presence of gangrenous appendicitis, perforation or abscess formation), and pathological examination findings (acute phlegmonous appendicitis, acute gangrenous appendicitis or acute perforated appendicitis).
62136264|NCT06228573|EXPERIMENTAL|Active tDCS|"Active tDCS Arm:~In Week 1, participants in the Active tDCS arm will undergo five in-person visits for the administration of active transcranial Direct Current Stimulation (tDCS). Subsequently, from Weeks 2 to 9, participants will receive weekly active tDCS sessions preceding the scheduled yoga sessions.~For the active tDCS sessions, a constant current stimulator will be employed to deliver direct current through a pair of surface sponge electrodes (5×7 cm) soaked in saline. Participants will undergo anodal stimulation targeting the primary motor cortex (M1) contralateral to the most painful site (C3 or C4 based on the electroencephalogram 10/20 system). The cathodal electrode will be positioned on the supraorbital area contralateral to the anode. During active tDCS, a constant anodal current of 2 mA will be administered for 20 minutes, a duration known to enhance cortical excitability and alleviate pain. T"
62136265|NCT06228573|SHAM_COMPARATOR|Sham tDCS|"Sham tDCS Arm:~tDCS: In Week 1, participants in the Sham tDCS arm will attend five in-person visits for the administration of sham transcranial Direct Current Stimulation (tDCS). From Weeks 2 to 9, participants will receive weekly sham tDCS sessions before the scheduled yoga sessions.~Constant current stimulator will be used to deliver direct current through a pair of surface sponge electrodes (5×7 cm) soaked in saline. Participants will undergo sham stimulation targeting the primary motor cortex (M1) contralateral to the most painful site (C3 or C4 based on the electroencephalogram 10/20 system).~During sham tDCS, the electrodes will be placed in the same montage as the active tDCS; however, current will only be applied for the initial and final 30 seconds of the 20-minute session. Consequently, participants will experience the sensation of current ramping up and down but will receive no current for the remaining stimulation period."
62489842|NCT04440150|OTHER|Uncomplicated Acute Appendicitis|The patients were assigned to the uncomplicated acute appendicitis group (Group UC) based on the increased diameter and wall thickness of the appendix and detection of minimal contamination in the surrounding fat tissue in the imaging tests; the presence of edema and the absence of gangrene, perforation or abscess in the the exploratory surgery of appendix, and confirmation of the diagnosis of acute appendicitis by the pathological examination findings
62489843|NCT04410653|EXPERIMENTAL|Arm 1 (KRASwt PDAC)|
62489844|NCT04410653|EXPERIMENTAL|Arm 2 (IMA)|
62489845|NCT04410653|EXPERIMENTAL|Arm 3 (other)|
62489846|NCT00857558|EXPERIMENTAL|1|OPC-262 1mg
62489847|NCT00857558|EXPERIMENTAL|2|OPC-262 2.5mg
62489848|NCT00857558|EXPERIMENTAL|3|OPC-262 5mg
62489849|NCT00857558|PLACEBO_COMPARATOR|4|
62489850|NCT04898998|EXPERIMENTAL|TENS to alleviate the effect of thirsty after surgery|Transcutaneous electrical nerve stimulation (TENS) on experimental group 20 mins to treatment postoperative thirsty.
62694620|NCT03914833||Patients|Patients aged 13 to 25 years old with a concussion in sports practice less than 72 hours previously
62694621|NCT03914833||Control - High-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
62694622|NCT03914833||Control - Non-high-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
62694623|NCT02185768|EXPERIMENTAL|DC-BEADS + Idarubicin|Chemoembolization with DC BEAD loaded with idarubicin
62694624|NCT05031897|EXPERIMENTAL|Radiation-Based Cohort (fludarabine, TBI, infusion)|Patients receive fludarabine IV on days -11, -10, -9, and -8, undergo TBI BID on days -10 and -9, undergo DLI on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.
61937339|NCT00352443|EXPERIMENTAL|everolimus/lapatinib|Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28\*\* Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28\*\* Subsequent Cycles, Days 1-28
61937340|NCT04498312|EXPERIMENTAL|Shock wave group|Received Extracorporeal shock wave therapy twice/week for 4 weeks
61937341|NCT04498312|EXPERIMENTAL|Manual lympharic group|Received manual lymphatic drainage twice a week for four weeks
61937342|NCT05560035|EXPERIMENTAL|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
61937343|NCT05560035|PLACEBO_COMPARATOR|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
61937344|NCT01128751|ACTIVE_COMPARATOR|Embol-X|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
61937345|NCT01128751|ACTIVE_COMPARATOR|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
61937346|NCT01128751|NO_INTERVENTION|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
61937347|NCT02942927|EXPERIMENTAL|TAPER|"The intervention is medication reduction. This arm is comprised of:~1. Medication reconciliation~2. Identification of patient priorities for care~3. Identification of medications that are potentially appropriate for discontinuation/dose reduction~4. Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~5. Identification of medications for trial of discontinuation/dose reduction (shared decision making)~6. Pause of medication and clinical monitoring"
61937348|NCT02942927|NO_INTERVENTION|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
61937349|NCT02952729|EXPERIMENTAL|Dose Escalation and Confirmation|XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
61937350|NCT04060862|EXPERIMENTAL|Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant|
61937351|NCT04060862|PLACEBO_COMPARATOR|Phase 3: Placebo + Palbociclib + Fulvestrant|
61937352|NCT01385371|EXPERIMENTAL|SCH 697243|
61937353|NCT01385371|PLACEBO_COMPARATOR|Placebo|
61937354|NCT03327454||Benepali|Treatment of participants with the Benepali pre-filled pen takes place in accordance with the prescribing information and standard medical practice.
61937355|NCT05782231|EXPERIMENTAL|Experimental: GetActive+|A mind-body program focused on increasing physical and emotional function in older adults with chronic musculoskeletal pain
61937356|NCT04264689|ACTIVE_COMPARATOR|thoracic epidural|thoracic epidural will be done before induction of general anesthesia
61937357|NCT04264689|EXPERIMENTAL|serratus anterior block|ultrasound guided serratus anterior block will be done after induction of general anesthesia
61937358|NCT04264689|EXPERIMENTAL|erector spinae block|ultrasound guided erector spinae block will be done after induction of general anesthesia
61937359|NCT01545258|EXPERIMENTAL|Exercise|Exercise training supervised by trained physiotherapists lasting 60 minutes performed 3 times/week.
62136266|NCT06352632|EXPERIMENTAL|IV thrombolysis domain|This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design to optimize the use of intravenous Tenecteplase in participants with Acute Ischemic Stroke.
62136267|NCT06352632|EXPERIMENTAL|Blood Pressure domain|"Third Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED3/MT) as a domain of ACT-GLOBAL to compare three BP lowering management strategies, that of conservative, moderate and intensive BP lowering in patients with Acute Ischaemic Stroke admitted to participating hospitals who has an elevated SBP after reperfusion therapy via Endovascular Thrombectomy, and reliably determine, which approach leads to improved functional outcome.~Locally available and approved i.v. BP lowering agents can be used in this domain."
62694625|NCT05031897|EXPERIMENTAL|Chemotherapy-Based Cohort (fludarabine, melphalan, TBI)|Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo hematopoietic stem cell transplant on day 0. Patients undergo bone marrow biopsy/aspiration, imaging and blood sample collection throughout the study.
61937360|NCT01545258|NO_INTERVENTION|Control|
61937361|NCT00452478|EXPERIMENTAL|1|
61937362|NCT00835822|EXPERIMENTAL|A|Arm treated with Investigational product.
61937363|NCT00835822|PLACEBO_COMPARATOR|B|Arm treated with placebo.
61937364|NCT06525597|EXPERIMENTAL|Stapokibart Group|Stapokibart, subcutaneous, once every two weeks
61937365|NCT06525597|PLACEBO_COMPARATOR|Placebo Group|Placebo, subcutaneous, once every two weeks
61937366|NCT06206265|EXPERIMENTAL|Open Label Oral Psilocybin|
61937367|NCT06206265|OTHER|Waitlist Control|
61937368|NCT02644031|EXPERIMENTAL|Mtwo rotary system|( continuous rotation system)
61937369|NCT02644031|EXPERIMENTAL|safe-sider rotary system|(reciprocating system)
61937370|NCT02644031|EXPERIMENTAL|hand files|k-files
61937371|NCT02563990|EXPERIMENTAL|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
61937372|NCT02563990|ACTIVE_COMPARATOR|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
61937373|NCT04447417|NO_INTERVENTION|Healthy Volunteer|Healthy volunteers with age, gender, location of targeted skin lesion area and study site matched to a selected atopic dermatitis (AD) participants, received no treatment, but were monitored in similar way as like enrolled AD participants.
62489851|NCT04898998|PLACEBO_COMPARATOR|Routine care to alleviate the effect of xerostomia (dry mouth) after surgery|routine care
62489852|NCT04627844|PLACEBO_COMPARATOR|Delayed Feeds|"Patients will receive tube feeds beginning at 6 hours after PEG tube placement. This is our institutions current practice~Intervention Type: Dietary"
62489853|NCT04627844|EXPERIMENTAL|Immediate Feeds|"Patients will receive tube feeds beginning immediately after PEG tube placement.~Intervention Type: Dietary"
62489854|NCT05391594|EXPERIMENTAL|Single Subject Design|The investigators will use a longitudinal design with baseline, immediate and post-intervention data collections. The intervention will include customized posture support in seated, standing or walking devices that will be used in the child's educational setting or home (for early intervention) to facilitate specific educational activities.
62694626|NCT05023018|EXPERIMENTAL|Patients with high-grade meningioma|30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma
61937374|NCT04447417|EXPERIMENTAL|Atopic Dermatitis Patients|"Participants with moderate to severe AD and aged 18 years and older received dupilumab 600 milligrams (mg) (loading dose) subcutaneous (SC) injection on Day 1, followed by dupilumab 300 mg SC injection every 2 weeks (Q2W) through Week 14 (i.e., at Day 15, 29, 43, 57 and 85).~Participants aged greater than or equal to (\>=) 12 to less than (\<) 18 years received treatment based on their body weight: \<60 kilograms (kg) and \>=60 kg - received dupilumab 400 mg and 600 mg (loading dose) SC injection on Day 1, respectively, followed by dupilumab 200 mg and 300 mg SC injection Q2W through Week 14 (i.e., at Day 15, 29, 43, 57 and 85)."
61937375|NCT06207838|NO_INTERVENTION|Actual therapy|The patient continues Multiple Daily Injection/Insulin Pump Therapy with or without CGM use as per routine procedures
61937376|NCT06207838|EXPERIMENTAL|Advanced Hybrid Cloosed Loop System|The patients will be switched to MiniMed 780G advanced hybrid cloosed loop system/ AHCL system
61937377|NCT05515198|EXPERIMENTAL|Arm 1|Patient Education
61937378|NCT05515198|EXPERIMENTAL|Arm 2|Patient Education + Nurse Navigation
61937379|NCT05515198|EXPERIMENTAL|Arm 3|Patient Education + Nurse Navigation + ChatBot
61937380|NCT00071396|EXPERIMENTAL|Campath-1H + Rituximab|"Campath 15 mg/day continuous intravenous (IV) infusion x 6 days, then twice a week for 3 weeks as 30 mg injection under skin to complete 4 week treatment course.~Rituximab 375 mg/m\^2 IV infusion day 1, then 500 mg/m\^2 on days 8, 15 + 22."
61937381|NCT05318482|EXPERIMENTAL|Motivational group|The patients of this group will be equipped with an electronic wristwatch and will be monitored every day by the physiotherapist (PT) through an application on their mobiles. The PT will follow these patients with a daily motivational session (15 minutes, modality 1 patient: 1 PT) and with an educational program about the definition, importance and benefits of physical activity.
61937382|NCT05318482|SHAM_COMPARATOR|Control|The patients of this group will have an electronic wristwatch and will be advised by the PT only with generic recommendations of daily exercise during the hospitalization, besides the usual activities of the rehabilitation program.
61937383|NCT06090357|EXPERIMENTAL|Post-surgical foot and ankle patients|
61937384|NCT03451942|EXPERIMENTAL|surgery group after FLOT regimen chemotherapy|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
61937385|NCT03451942|PLACEBO_COMPARATOR|FLOT regimen chemotherapy|Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.
61937386|NCT06556719|EXPERIMENTAL|Hoosier Sport Re-Social Participants|Arm will receive 6-weeks of intervention, including enhanced PE and health class curriculum
61937387|NCT06556719|NO_INTERVENTION|Regular Health and PE Participants|Arm will receive regular PE and health class curriculum
61937388|NCT05111808|EXPERIMENTAL|Methyl Blue|This group will receive intraoperative IV methyl blue
61937389|NCT02649114|ACTIVE_COMPARATOR|Cognitive-Behavioural Therapy|This version of CBT is based on techniques employed in evidence-based approaches to a transdiagnostic sample. The programme includes; individualized formulation, taking into account different maintaining factors across cases (e.g., nutritional and/or emotional drivers for binging); agenda setting; homework; change in diet (particularly to improve carbohydrate intake); diary-keeping; exposure; behavioral experiments; cognitive restructuring; and surveys. The behavioral change is maintained as a focus, along with changes in mood and cognitions.
62694627|NCT05422482|EXPERIMENTAL|GC1123 30mg|30 mg of IP will be administered every 28 days for all enrolled patients
61937390|NCT02649114|EXPERIMENTAL|Compassion-Focused Therapy|There are four main treatment elements to the program. Two of these are linked to the experience of being a therapy group. This involves patients providing compassionate support to other group members.The third treatment element involves compassionate mind training which mainly focuses on activating the soothing system via imagery and related practical exercises.The final element of the program aims to help patients improve their ability to use their wider social network to access support.
62136268|NCT06352632|EXPERIMENTAL|ACT-42 domain|This domain has a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive design and aim to determine the efficacy and safety of NoNO-42 in participants with Acute Ischaemic Stroke selected for thrombolysis with or without Endovascular Thrombectomy.
62489855|NCT00057941|EXPERIMENTAL|Arm I (anastrozole, gefitinib)|Patients receive oral anastrozole and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62489856|NCT00057941|EXPERIMENTAL|Arm II (fulvestrant, gefitinib)|Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61937391|NCT01011712||1|patients without known or not fully characterized immunodeficiency, who have severe, persistent, or treatment-refractory viral infections
61937392|NCT03355781||Schizophrenic patients|Patients will have clinical psychiatric evaluation, brain imaging and blood sample
61937393|NCT03355781||Related volunteers (first degree relative of patient)|Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
61937394|NCT03355781||Healthy volunteers|Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
62489857|NCT03717701|EXPERIMENTAL|metformin and esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day plus single dose of metformin 1000mg orally single dose once a day
62489858|NCT03717701|PLACEBO_COMPARATOR|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
62489859|NCT02840149|OTHER|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan performed on Neuro-endocrine tumor patients
62489860|NCT01519830|EXPERIMENTAL|Verum|Iron Carboxymaltose (Ferinject)
62489861|NCT01519830|PLACEBO_COMPARATOR|Placebo|0.9% NaCl solution
62489862|NCT02011828|EXPERIMENTAL|Ergocalciferol, then Placebo|Participants first receive Ergocalciferol 50,000 international units (IU)/week for the first 12 weeks. After a 4 week wash-out period, they then receive matching placebo treatment for 12 weeks.
61937395|NCT00957112|EXPERIMENTAL|Arm I|Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
62489863|NCT02011828|EXPERIMENTAL|Placebo, then Ergocalciferol|Participants first receive placebo treatment (matching ergocalciferol 50,000 IU/week) for the first 12 weeks. After a 4 week wash-out period, they then receive ergocalciferol 50,000 IU/week treatment for 12 weeks.
62489864|NCT02573779||Infants fed mother's own milk|Infants fed \>50% mother's own milk with enteral feeding.
62489865|NCT02573779||Donor milk fed infants|Infants fed \<50% mother's own milk (and thus \>50% donor human milk) with enteral feeding.
62489866|NCT02840162|ACTIVE_COMPARATOR|Celecoxib|Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
62489867|NCT02840162|PLACEBO_COMPARATOR|Placebo|Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth
62694628|NCT04625660|EXPERIMENTAL|Single Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
61937396|NCT00957112|NO_INTERVENTION|Arm II|Patients receive standard care. They also receive written information about fatigue as in arm I.
61937397|NCT00957112|EXPERIMENTAL|Arm A|Patients receive treatment as in arm I for 4 more weeks.
62489868|NCT04750590|EXPERIMENTAL|en bloc resection group|Patients scheduled for laser en bloc tumor resection with subsequent morcellation of exophytic part of the tumor
62489869|NCT04750590|EXPERIMENTAL|piecemeal resection group|Patients scheduled for piecemeal bladder tumor TUR with subsequent removing of tissue using the instrument loop or Janet's syringe.
62694629|NCT04593745|OTHER|ALL AIEOP-BFM induction|Intraocular pressure messured in children treated with steroids
62694630|NCT02208167|OTHER|Chronic HIV infection|HXTC infusion
61937398|NCT00957112|NO_INTERVENTION|Arm B|Patients receive standard care as in arm II for 4 more weeks.
62332093|NCT01482741||Men undergoing surveillance imaging after tx for testicular ca|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
62489870|NCT01943435|ACTIVE_COMPARATOR|Medical Care|"Non-steroidal anti-inflammatory drugs (NSAIDs); adjunctive analgesics; adjunctive anti-depressants. Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient.~* NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol~* Adjunctive analgesics: acetaminophen, tramadol, or gabapentin~* Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine~Lumbar epidural injection: these will be prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications."
62489871|NCT01943435|ACTIVE_COMPARATOR|Group Exercise|Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.
62694631|NCT02208167|OTHER|Acute HIV infection|HXTC infusion
62694632|NCT06639828|EXPERIMENTAL|Sonazoid|Participants will receive a single iv dose of Sonazoid™, dosed according to body weight (0.12 μL microbubbles/kg)
61937399|NCT00957112|EXPERIMENTAL|Arm C|Patients learn to self-acupuncture and do so weekly for 4 more weeks.
61937400|NCT05906173|EXPERIMENTAL|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
61937401|NCT02477969|EXPERIMENTAL|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
61937402|NCT02477969|EXPERIMENTAL|PEX168(200µg)|PEX168,200µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
61937403|NCT02477969|PLACEBO_COMPARATOR|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
62694633|NCT01879826|SHAM_COMPARATOR|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
62694634|NCT01879826|EXPERIMENTAL|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
62694635|NCT05845580|EXPERIMENTAL|Patient centered care|Patients concern of refusing statin therapy will initially be addressed.
62694636|NCT05845580|ACTIVE_COMPARATOR|Guideline-centered care|patients will be prescribed the standard of care regardless of their concerns toward statin therapy.
62694637|NCT03941561|EXPERIMENTAL|S-1 for 9 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 9 months after D2 resection
62694638|NCT03941561|ACTIVE_COMPARATOR|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
62694639|NCT03757715|EXPERIMENTAL|Treatment Group|20 mL of 1.3% bupivacaine with 2 mg dexamethasone injected locally in the location for sensory nerves of the sinus cavities and face during the functional endoscopic sinus surgery (FESS) procedure
62489872|NCT01943435|ACTIVE_COMPARATOR|Manual therapy and exercise|"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used in the physical therapy and chiropractic professions. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments will be provided by licensed physical therapists and chiropractors using a combination of Joint Mobilizations (spine, sacroiliac, hip), muscle stretching and strengthening exercises.~Individualized exercises: clinical setting. These exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor."
62332094|NCT01482741||Men & women enrolled in the MSKCC lung ca screening program|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
62489873|NCT01728636|EXPERIMENTAL|Tranexamic Acid|Tranexamic acid 10mg/kg loading dose given pre-incision and 1mg/kg/hr infusion throughout intraoperative period
62489874|NCT01728636|PLACEBO_COMPARATOR|Placebo|Normal saline placebo loading dose 0.5ml/kg and infusion at 0.5ml/kg/hr throughout operative course
62332095|NCT01482741||Men and women enrolled in the thoracic survivorship|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
62332096|NCT05346601|OTHER|Chiauranib(In the fasting state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet
62332097|NCT05346601|OTHER|Chiauranib(In the high fat diet state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state
62332098|NCT02632110|EXPERIMENTAL|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
62332099|NCT02632110|EXPERIMENTAL|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
62332100|NCT02632110|EXPERIMENTAL|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
62332101|NCT02632110|EXPERIMENTAL|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
62332102|NCT02632110|EXPERIMENTAL|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
62332103|NCT02632110|EXPERIMENTAL|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
62332104|NCT02632110|EXPERIMENTAL|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
62489875|NCT03130335|EXPERIMENTAL|Bone Marrow Aspirate (BMA) Injection|
62694640|NCT03757715|NO_INTERVENTION|Control Group|No regional anesthetic of any kind during the functional endoscopic sinus surgery (FESS) procedure
62694641|NCT04893811|EXPERIMENTAL|Single Arm|Bivalent recombinant lipoprotein 2086 vaccine
62694642|NCT03186820|EXPERIMENTAL|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
62136269|NCT06352632|EXPERIMENTAL|INTERACT5 Domain|"This is a domain within the Intracerebral Haemorrhage State of the ACT-GLOBAL adaptive platform trial for stroke.~The objective of this domain is to determine the efficacy of intravenous deferoxamine and low-dose oral colchicine, both individually and in combination, compared to standard of care alone, on improving functional outcome in patients with acute spontaneous supratentorial ICH."
62136270|NCT03986840|EXPERIMENTAL|Exercise program|The exercise program was applied for 6 weeks. A total of 18 sessions were distributed in 3 weekly sessions. The participants performed a resistance exercises: leg press at an intensity of 40%-60% with 10 repetitions, 12 repetitions of steps with their bodyweight and a plantar flexion followed by a cardiovascular HIIT exercise walking on a treadmill.
62136271|NCT03986840|ACTIVE_COMPARATOR|Daily activities|The patients who belongs to this group will continue to perform their daily routines.
62136272|NCT06300879|EXPERIMENTAL|Experimental group|Performing totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique
62136273|NCT00795184|OTHER|Imaging Procedures HDWLE first NBI second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
62136274|NCT00795184|OTHER|Imaging Procedures NBI first HDWLE second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
62332105|NCT02632110|EXPERIMENTAL|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
62332106|NCT02632110|PLACEBO_COMPARATOR|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
62332107|NCT02632110|PLACEBO_COMPARATOR|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
62332108|NCT03161639|NO_INTERVENTION|Operator 1|Perform the pulpectomies except the working length measurement
62332109|NCT03161639|NO_INTERVENTION|Operator 2|Perform the electronic length measurement of the pulpectomies
62332110|NCT03161639|ACTIVE_COMPARATOR|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
62332111|NCT05909566|EXPERIMENTAL|HHFNC + Clinical decision Support|Standardized HHFNC weaning coupled with clinical decision support consisting of electronic record embedded reminders to the clinical team to wean HHFNC
62694643|NCT05374603|EXPERIMENTAL|Savolitinib combine with Durvalumab|single-arm
62694644|NCT06024538||Prospective part of the study|
62694645|NCT05935085|EXPERIMENTAL|ANB032 SC Dose 1|This arm will receive treatment SC
62694646|NCT05935085|EXPERIMENTAL|ANB032 SC Dose 2|This arm will receive treatment SC
62489876|NCT03008005|PLACEBO_COMPARATOR|Placebo Oral Capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
62489877|NCT03008005|EXPERIMENTAL|Dronabinol Cap 5 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
61937404|NCT03699683|EXPERIMENTAL|Physical Combined Activity Program|Before and after a 6-months supervised and individualized program that combined aerobic and resistance training were performed in post bariatric patients. Body composition, physical fitness and cardiovascular risk factors were measured before, after the physical activity program and 6 months later (13 months sinde the program started)
61937405|NCT03126903|EXPERIMENTAL|Single-Arm|KeraKlear Non-Penetrating Keratoprosthesis
61937406|NCT03344354|ACTIVE_COMPARATOR|Brand 1|sterile surgical gloves Two arms of Brand 1 were combined to allow comparison of the total of all comparator gloves.
62489878|NCT03008005|EXPERIMENTAL|Dronabinol Cap 10 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
62694647|NCT05935085|EXPERIMENTAL|ANB032 SC Dose 3|This arm will receive treatment SC
62694648|NCT05935085|PLACEBO_COMPARATOR|Placebo|This arm will receive Placebo SC
62694649|NCT06303453|EXPERIMENTAL|GROUP A (BALANCE EXERCISES)|Group A will receive a session of balance exercises for 45 minutes.Treatment session will be given for 3 days per week for 8 weeks.This balance exercise program consist of three phases.Warm-up phase(5 minutes,after warm-up phase 35 minutes balance exercises then cooling phase (5 minutes).
61937407|NCT03344354|ACTIVE_COMPARATOR|Brand 2|sterile surgical gloves
61937408|NCT03344354|ACTIVE_COMPARATOR|Brand 3|sterile surgical gloves
61937409|NCT03344354|ACTIVE_COMPARATOR|Brand 4|sterile sergical gloves
61937410|NCT05318937|EXPERIMENTAL|SAGE-718|Participants will receive SAGE-718 capsules, orally, once daily in the morning for 42 days.
61937411|NCT05318937|PLACEBO_COMPARATOR|Placebo|Participants will receive SAGE-718-matching placebo capsules, orally, once daily in the morning for 42 days.
61937412|NCT00785018|ACTIVE_COMPARATOR|C1-esterase inhibitor|Endotoxin 2ng/kg followed by C1- esterase inhibitor 100 U/kg infusion
61937413|NCT00785018|PLACEBO_COMPARATOR|Placebo|Endotoxin 2ng/kg followed by saline 0.9%(placebo) infusion
62332112|NCT05909566|ACTIVE_COMPARATOR|HHFNC Weaning|Team does not receive clinical decision support reminders to wean the HHFNC
61937414|NCT05405933|EXPERIMENTAL|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
61937415|NCT05405933|EXPERIMENTAL|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
62332113|NCT00861367|ACTIVE_COMPARATOR|1|aspirin 100mg
62332114|NCT00861367|PLACEBO_COMPARATOR|2|empty capsule
62332115|NCT02596711|EXPERIMENTAL|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
62332116|NCT02596711|EXPERIMENTAL|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
62332117|NCT02596711|EXPERIMENTAL|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
62332118|NCT02593747|EXPERIMENTAL|Loratadine oral solution/syrup then Claritin peach syrup|Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
62332119|NCT02593747|EXPERIMENTAL|Claritin peach syrup then Loratadine oral solution/syrup|Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
61937416|NCT02572609|EXPERIMENTAL|Mucosolvan ® adult syrup|
61937417|NCT02572609|EXPERIMENTAL|Ambroxol hydrochloride soft pastille|
61937418|NCT00886184|EXPERIMENTAL|1|Induction of pre hospital early hypothermia in patients having a cardiac .
61937419|NCT00886184|ACTIVE_COMPARATOR|2|Induction of hypothermia only at hospital arrival.
61937420|NCT01860781|EXPERIMENTAL|paliperidone palmitate|paliperidone palmitate
62332120|NCT01251172|EXPERIMENTAL|Treatment (RO4929097 after autologous stem cell transplant)|"STEM CELL TRANSPLANTATION AND CHEMOTHERAPY: Patients undergo standard mobilization and collection of autologous peripheral stem cells (\>= 4.0 x 10\^6 CD34+ cells/kg). Patients then receive high-dose melphalan IV on days -3 and -2 and undergo autologous stem cell transfusion on day 0. Patients with progressive disease, stable disease, partial response, stringent complete response, or complete response are taken off study; patients with residual/persistent disease (VGPR) continue to therapeutic treatment.~THERAPEUTIC TREATMENT: Beginning 100-110 days after transplantation, patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62332121|NCT05277155|EXPERIMENTAL|Intervention Group (BEJO Red Ginger Extract)|84 patients, dosage: BEJO Red Ginger Extract orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)
62694650|NCT06303453|EXPERIMENTAL|GROUP B (RESISTED EXERCISES)|Group B will receive a session of resisted exercises for 45 minutes.Treatment session will be given for 3 days per week for 8 weeks.This resisted exercises program consist of three phases.Warm-up phase(5 minutes,after warm-up phase 35 minutes balance exercises then cooling phase (5 minutes).
62694651|NCT05082909|ACTIVE_COMPARATOR|Penicillin alone|Penicillin orally at dose of either 250mg, 500mg, 750mg QDS for 36 hours.
62694652|NCT05082909|EXPERIMENTAL|Penicillin plus probenecid|"Penicillin orally at dose of either 250mg, 500mg, 750mg QDS for 36 hours.~PLUS~Probenecid 500mg QDS for 36 hours."
62694653|NCT05744063|EXPERIMENTAL|emapalumab|emapalumab solution for infusion twice weekly at a starting dose of 1 mg/kg
61937421|NCT04727931||Newly diagnosed epileptic patients|Newly diagnosed epileptic patients who have never be treated by antiepileptic drugs and who have no psychiatric (mental illness) and/or evolutive neurological history and for minor patients the non-opposition of the parental authority holders.
61937422|NCT04727931||Normal controls|Matched (on age, gender, socio-educationnal level and manual laterality) healthy controls who have no psychiatric (depression, mental illness) and/or neurological (stroke, traumatic brain injury, etc.) history and for minor patients the non-opposition of the parental authority holders.
62136275|NCT04626037|EXPERIMENTAL|All Participants in Group Zoom Sessions|During each session, the mother-child dyads will meet with Nurture Science program staff virtually. The entire procedure will be done on Zoom or in person depending on school opening. All mother-child pairs will then be asked to interact, with the child sitting on the mother's lap face-to-face. The rest of the session may continue with: (1) Reading Cuddle and Calm Book (2) Mutual Mother and Child Emotional Exchange Prompts (3) Mothers Support Circle to identify and engage members of the mother's family in helping the dyad with emotional connection (4) Mommy Baby Book (5) Bottle of Emotions (6) Plans for continuing the work in the family. Returning mothers will be asked how they have progressed using the Cuddle and Calm and mutual narrative over the week and what their experience with their child after the session has been.
62332122|NCT05277155|PLACEBO_COMPARATOR|Control Group (Placebo)|84 patients, dosage: Placebo orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)
62332123|NCT06482554|ACTIVE_COMPARATOR|Lumateperone|42mg capsule, once a day for 8 weeks
62332124|NCT06482554|ACTIVE_COMPARATOR|Existing medication|Existing medication reformulated in capsule, once or twice daily (as currently prescribed) for 8 weeks
62332125|NCT05048823|EXPERIMENTAL|Intervention Protocol|Visceral techniques for the gastrointestinal system
62332126|NCT05048823|SHAM_COMPARATOR|Placebo Protocol|simulated visceral techniques in the region of the gastrointestinal system, without therapeutic intent
62332127|NCT02028104|EXPERIMENTAL|stem cells|autologous bone marrow mononuclear cell transplantation
62332128|NCT06553144|EXPERIMENTAL|Curcumin|patient with single root and canal, along with apical radiolucent lesions
62332129|NCT06553144|EXPERIMENTAL|Erythrosine B|patient with single root and canal, along with apical radiolucent lesions
62694654|NCT05983133|EXPERIMENTAL|SGN-EGFRd2|SGN-EGFRd2 monotherapy
62694655|NCT03079999|EXPERIMENTAL|Aspirin|Patients on the experimental arm will receive blinded aspirin. Pediatric subjects who weigh less than 110 lbs will take 81mg aspirin twice a day. All other subjects will take 325mg aspirin twice a day.
62694656|NCT03079999|PLACEBO_COMPARATOR|Placebo|Patients on the placebo arm will receive blinded placebo and take it twice a day.
62136276|NCT02823028|ACTIVE_COMPARATOR|NRT + Web Guide|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges)
62136277|NCT02823028|EXPERIMENTAL|NRT + Web Guide + Tweet2Quit-Coed|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a coed Tweet2Quit group
62136278|NCT02823028|EXPERIMENTAL|NRT + Web Guide + Tweet2Quit-Women|Experimental: NRT + Web Guide + Tweet2Quit-Women NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a women-only Tweet2Quit group
62332130|NCT06553144|ACTIVE_COMPARATOR|Control|patient with single root and canal, along with apical radiolucent lesions
62332131|NCT06553144|EXPERIMENTAL|Methylene Blue|patient with single root and canal, along with apical radiolucent lesions
62332132|NCT05682820||Patients with ACL tear|Patients with ACL tear- MRIs will be assessed
62332133|NCT05682820||Patients without ACL tear|Patients without ACL tear - MRIs will be assessed
61937423|NCT06680362||Concentrated group|If the distance between the bifurcation of the splenic artery and the splenic hilum was less than 2 cm, the patient was assigned to the concentrated group
61937424|NCT06680362||distributed group|If the distance between the splenic artery bifurcation and the splenic portal is greater than or equal to 2cm, it is classified as distributed group
61937425|NCT01485393|EXPERIMENTAL|Healthy Control Subjects: Zolpidem, Then Dexmedetomidine|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Zolpidem induced-sleep and then a night of Dexmedetomidine induced-sleep.
62332134|NCT06316622|EXPERIMENTAL|volunteer person|meausered by ultrasound
62694657|NCT06643806|EXPERIMENTAL|Experimental|Twenty marital dyads from the site randomly assigned as the intervention site(s) will receive the 12- week peer leader-facilitated dyadic intervention. Topics over the 12 week intervention will address stress management, family history and genetic risk, dietary habits, physical activity and social support/community engagement.
62489879|NCT02902601|EXPERIMENTAL|Group A: JNJ-54175446|Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.
61937426|NCT01485393|EXPERIMENTAL|Healthy Control Subjects: Dexmedetomidine, Then Zolpidem|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Dexmedetomidine induced-sleep and then a night of Zolpidem induced-sleep.
61937427|NCT05718804||Sepsis-associated kidney injury|Sepsis patients and acute kidney injury No intervention
61937428|NCT05718804||Sepsis but no renal impairment|Sepsis patients without acute kidney injury
61937429|NCT03648827|EXPERIMENTAL|Ataluren|Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.
62332135|NCT03433287|EXPERIMENTAL|18F-NaF-PET/MRI|Eligible patients who give informed consent will be offered a NaF -PET/MRI scan
62489880|NCT02902601|EXPERIMENTAL|Group B: Placebo + JNJ-54175446|Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.
61937430|NCT06681246|EXPERIMENTAL|Antibiotic treatment|intervention arm
61937431|NCT06681246|PLACEBO_COMPARATOR|Placebo|placebo capsules administration
61937432|NCT06135402|EXPERIMENTAL|Laser group|3 monthly fractional laser treatment according to the user manual (correct applicator, vulvar and vaginal preset). In between daily local skin care with a drug free product of patients' choice.
61937433|NCT06135402|ACTIVE_COMPARATOR|Clobetasol group|Maintenance treatment with vulvar TCS (clobetasol) application 2x/week. Instruction given at trial start and monthly check up for treatment control Daily local skin care with a drug free product of patients' choice.
61937434|NCT04533685|ACTIVE_COMPARATOR|Direct scheduling + Pre-commitment + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
61937435|NCT04533685|ACTIVE_COMPARATOR|Direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) a pre-commitment prompt
61937436|NCT04533685|ACTIVE_COMPARATOR|Direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
61937437|NCT04533685|ACTIVE_COMPARATOR|Direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling
61937438|NCT04533685|ACTIVE_COMPARATOR|No direct scheduling + Pre-commitment + Pre-Appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
61937439|NCT04533685|ACTIVE_COMPARATOR|No direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) a pre-commitment prompt
61937440|NCT04533685|ACTIVE_COMPARATOR|No direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
61937441|NCT04533685|ACTIVE_COMPARATOR|No direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling for a flu vaccine appointment
61937442|NCT04533685|NO_INTERVENTION|Control Arm|Participants will not receive any reminder/recall messages regarding influenza vaccination via the patient portal or other intervention components
61937443|NCT02556827||H, Rosacea patients|"Rosacea patients who were between the ages of 18-70, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
62332136|NCT05128435||Positive Children|Children under 15 years old tested positive for SARS-CoV-2 by PCR on nasopharyngeal swab
62332137|NCT02325635|EXPERIMENTAL|Training of Endoscopist|A series of 1 hour classes with ongoing monitoring and feedback to endoscopist only.
62332138|NCT02325635|NO_INTERVENTION|Deferred Training of Endoscopist|No intervention during the data collection period. Training will be deferred to end of study.
62332139|NCT01833767|EXPERIMENTAL|Cyclophosphamide and Interleukin-2|Cytoxan IV on day 1, IL2 IV on days 1-5
62332140|NCT06342050||WLS non-completers|Participants who did not have WLS as part of the main study
62332141|NCT06342050||WLS completers|Participants who had WLS as part of the main study
62489881|NCT02902601|PLACEBO_COMPARATOR|Group C: Placebo|Participants will receive placebo from Day 1 until Day 10.
62489882|NCT00178711|ACTIVE_COMPARATOR|hypothermia|Induction and maintenance of moderate hypothermia to 33 degrees celsius achieved within 2.5 hours of injury and maintained for 48 hours.
62489883|NCT00178711|NO_INTERVENTION|control|treated at normothermia
62489884|NCT05920603||School-aged children (6-12 years old) and women of reproductive age (15-49 years old)|300 healthy school-aged children (6-12 years old), and 300 healthy reproductive-aged women, aged (15-49 years old)
62489885|NCT02658214|EXPERIMENTAL|Cohort 1|ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)
62489886|NCT02658214|EXPERIMENTAL|Cohort 2|Small-cell lung cancer (SCLC)
62489887|NCT02658214|EXPERIMENTAL|Cohort 3|Triple-negative breast cancer (TNBC)
62489888|NCT02658214|EXPERIMENTAL|Cohort 4|Triple-negative breast cancer (TNBC)
62489889|NCT02658214|EXPERIMENTAL|Cohort 5|Gastric/gastro-esophageal junction (GEJ)
62489890|NCT02658214|EXPERIMENTAL|Cohort 6|Pancreatic ductal adenocarcinoma (PDAC)
62489891|NCT02658214|EXPERIMENTAL|Cohort 7|Esophageal squamous cell carcinoma (ESCC)
62489892|NCT06306391|EXPERIMENTAL|Intravenous naloxone|
62489893|NCT06306391|EXPERIMENTAL|Intranasal naloxone|
62332142|NCT04906655|EXPERIMENTAL|Cohort A glycopyrronium 30 minutes cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time in cotton gloves~1. Complete daily diary.~2. Remove all jewelry.~3. Tear open the top of the pouch at the notch.~4. Wash hands thoroughly with warm water, and dry them.~5. Remove the wipe from the pouch and unfold the wipe.~6. Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~7. Return the wipe to the pouch and put it back in the box.~8. Carefully put cotton gloves on both hands.~9. Set timer for 30 minutes.~10. After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
62489894|NCT04870333|ACTIVE_COMPARATOR|Niclosamide|"INN: Niclosamide Ethanolamine Chemical name (IUPAC): 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide.2 aminoethanol CAS registry number: 1420-04-8 Lab code: UNI911~The IMPs niclosamide Nasal Spray 1% and matching Nasal Spray Placebo will be provided in 20 mL amber glass vials with nasal spray pumps, containing 8.5 mL of the respective solution, delivering 140 μL per spray shot. It is an isotonic and euhydric aqueous solution with red colour."
62694658|NCT06643806|ACTIVE_COMPARATOR|Control|"Twenty dyads from the site randomly assigned as the usual care control group site will receive a basic cardiovascular lifestyle modification program. This program will be similar to a classic cardiac rehabilitation program and will consist of diet, physical activity and medical management."
62694659|NCT06641986||Elderly patients|elderly patients undergoing major non-cardiac surgery (aged ≥ 65 years)
61937444|NCT02556827||K, Healthy volunteers|"Healthy volunteers who were compatible in terms of age, sex and skin phenotype, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
61937445|NCT05285644|EXPERIMENTAL|AR 15512 Ophthalmic Solution (0.003%)|0.003% AR 15512 to be administered BID for 90 days. Both eyes will be treated.
61937446|NCT05285644|PLACEBO_COMPARATOR|Vehicle|AR-15512 vehicle to be administered BID for 90 days. Both eyes will be treated.
62332143|NCT04906655|EXPERIMENTAL|Cohort B glycopyrronium 30 minutes under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time under occlusion~1. Complete daily diary.~2. Remove all jewelry.~3. Tear open the top of the pouch at the notch.~4. Wash hands thoroughly with warm water, and dry them.~5. Remove the wipe from the pouch and unfold the wipe.~6. Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~7. Return the wipe to the pouch and put it back in the box.~8. Carefully put gloves on both hands.~9. Set timer for 30 minutes.~10. After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
62332144|NCT04906655|EXPERIMENTAL|Cohort C glycopyrronium overnight in cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight in cotton gloves~1. Complete daily diary~2. Remove all jewelry.~3. Tear open the top of the pouch at the notch.~4. Wash hands thoroughly with warm water, and dry them.~5. Remove the wipe from the pouch and unfold the wipe.~6. Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~7. Return the wipe to the pouch and put it back in the box.~8. Carefully put on the cotton gloves on both hands and go to bed.~9. In the morning, after at least 4 hours of wearing the gloves , remove the cotton gloves and throw them away.~10. Immediately wash hands thoroughly with warm water and soap, and dry them."
62332145|NCT04906655|EXPERIMENTAL|Cohort D glycopyrronium overnight under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight under occlusion~1. Complete daily diary~2. Remove all jewelry.~3. Tear open the top of the pouch at the notch.~4. Wash hands thoroughly with warm water, and dry them.~5. Remove the wipe from the pouch and unfold the wipe.~6. Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~7. Return the wipe to the pouch and put it back in the box.~8. Carefully put on the occlusive gloves and go to bed.~9. In the morning, after at least 4 hours of wearing the gloves, remove the occlusive gloves and throw them away.~10. Immediately wash hands thoroughly with warm water and soap, and dry them."
62332146|NCT02403193|EXPERIMENTAL|PBF-509_80 mg|
62332147|NCT02403193|EXPERIMENTAL|PBF-509_160 mg|
62332148|NCT02403193|EXPERIMENTAL|PBF-509_320 mg|
62332149|NCT02403193|EXPERIMENTAL|PBF-509_640 mg|
62332150|NCT02403193|EXPERIMENTAL|PBF509_160 mg +PDR001|
62332151|NCT02403193|EXPERIMENTAL|PBF509_320 mg+PDR001|
62332152|NCT02403193|EXPERIMENTAL|PBF509_640 mg +PDR001|
62489895|NCT04870333|PLACEBO_COMPARATOR|Placebo niclosamide|Placebo to match niclosamide will be supplied, stored, labelled, dispensed and dosed as for the active formulation. The placebo product is formulated to have the same appearance as the active solution.
62489896|NCT04870333|ACTIVE_COMPARATOR|Ciclesonide|"Chemical name (IUPAC): 2-\[(1S,2S,4R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacycloicosa-14, 17-dien-8-yl\]- 2-oxoethyl 2-methylpropanoate CAS registry number: 141845-82-1~It is a pressurised solution, intended for inhalation use and commercialised under the brand Alvesco. The recommended dose of ciclesonide is 160μg once daily, which leads to asthma control in the majority of patients. However, this may be increased if necessary to 320μg twice daily, in severe asthma."
62489897|NCT04870333|PLACEBO_COMPARATOR|Placebo ciclesonide|Matched placebo contains the same solvent and propellant as the active product but no drug substance.
62694660|NCT03044054|EXPERIMENTAL|ECHOPULSE|ECHOPULSE HIFU
62694661|NCT04070040|EXPERIMENTAL|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
62694662|NCT03312114|EXPERIMENTAL|Single arm|Avelumab and SABR
62332153|NCT02403193|EXPERIMENTAL|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
62332154|NCT02403193|EXPERIMENTAL|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
62489898|NCT04870333|EXPERIMENTAL|Sotrovimab|Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion Colourless or yellow to brown, liquid solution 20 mM histidine, 7% sucrose (w/v), 0.04% PS80 (w/v), 5 mM L-methionine at pH 6.0
62489899|NCT04870333|PLACEBO_COMPARATOR|Placebo sotrovimab|This will be in the form of 0.9% sodium chloride 100mL for infusion and will be sourced from commercially available stock by the site. It may be procured and stored as per sites usual procedures and only requires handling as an IMP upon dispensing and labelling.
62489900|NCT05214716|ACTIVE_COMPARATOR|Intervention|Respiratory specimens from the subjects are tested by the FilmArray Pneumonia panel and the results are reported via an electronic health record system. Treating physicians may adjust empirical antibiotic regimens with assistance from the guidelines formulated by the study investigators. Other microbiologic tests, including cultures, are performed as per routine practice.
62489901|NCT05214716|NO_INTERVENTION|Control|Microbiologic tests, including cultures, are performed as per routine practice. No intervention is made on the antimicrobial treatment in the control arm.
62489902|NCT04733456||IBD Patients (UC and CD)|"Participants will complete a Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, \*EQ5D-5L, \*GAD-774, \*PHQ-975, \*PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, \*Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy (\*questionnaires available through the CIHR IMAGINE grant).~Stool will be collected at baseline and after 16 weeks for assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome (through the International Microbiome Center \[IMC\], U of C). Blood will be drawn and urine collected at baseline and after 16 weeks for inflammatory markers and metabolomic \[IMC\] analysis"
62332155|NCT02529761|EXPERIMENTAL|Sorafenib combined with TACE|220 subjects in this study group will receive the treatment of sorafenib combined with conventional TACE.
62332156|NCT02529761|ACTIVE_COMPARATOR|TACE monotherapy|110 subjects in this study group will receive the treatment of conventional TACE monotherapy.
62489903|NCT00958724|EXPERIMENTAL|Neratinib and Vinorelbine|Neratinib: 240 mg administered daily by mouth continuously, Vinorelbine: 25 mg/m\^2 administered IV on Day 1 and 8 of 21 day cycle
62489904|NCT03960801|EXPERIMENTAL|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
62489905|NCT03960801|ACTIVE_COMPARATOR|Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
62489906|NCT05527639|OTHER|intervention group during study|all participants completed a 12 week strength training program consisting of warm up exercises, dead-lifts and squats. They had all completed a program of Kegel exercise prior.
62489907|NCT05527639|OTHER|control group during study|all participants completed a 12 week strength training program consisting of warm up exercises, dead-lifts and squats
62489908|NCT04221347||Group A - Hepatocellular carcinoma|"Patients with with proved hepatocellular carcinoma in cirrhosis.~N=100"
62489909|NCT04221347||Group B - Cirrhosis|"Cirrhotics of multiple aethiology will be sampled for spectroscopy in order to detect possible differences among cirrhotics with and without subsequent hepatocellular carcinoma.~N=100"
62489910|NCT04221347||Group C - Healthy controls|Healthy controls - healthy military personnel. N=50
62489911|NCT05290896|OTHER|Lens star biometry|Biometry done prior to phacoemulsification
62489912|NCT03277963|ACTIVE_COMPARATOR|Absence of sleep apnea syndrome|Pain perception tests
62489913|NCT03277963|EXPERIMENTAL|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
62489914|NCT05754788||Favorable-prognosis pancreatic adenocarcinoma|Patients experiencing favorable prognosis (defined as RFS≥60 months) following resection for pancreatic adenocarcinoma
62489915|NCT05754788||Unfavorable-prognosis pancreatic adenocarcinoma|Patients experiencing unfavorable prognosis (defined as RFS\<12 months) following resection for pancreatic adenocarcinoma
62697632|NCT06563986|EXPERIMENTAL|Intervention: Systemic treatment (FTD-TPI + bevacizumab) and radioembolization|"* Individualized dose 166Ho radioembolization, combined with systemic treatment:~* 35 mg/m2 FTD-TPI on day 1-5 and 8-12 every 4 weeks~* 5 mg/kg bevacizumab iv. on day 1 and 15 every 4 weeks"
61937447|NCT06392607|EXPERIMENTAL|Euclid orthokeartology (standard coating)|Euclid Orthokeratology Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.
61937448|NCT06392607|EXPERIMENTAL|Euclid orthokeartology (enhanced coating)|Euclid Orthokeratology Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.
61937449|NCT00700570|EXPERIMENTAL|1|
61937450|NCT06677866|EXPERIMENTAL|ASD-CGT- Treatment group (ASD-CGT)|Group of adolescents with ASD that perform the intervention at the beginning of the study (ASD-CGT)
61937451|NCT06677866|OTHER|FXS- Waiting List group (FXS-WL)|Group of adolescents with FXS that perform the intervention once that the sections with the first group are ended (FXS-WL)
61937452|NCT06677866|EXPERIMENTAL|FXS- CGT- Treatment group (FXS-CGT)|Group of adolescents with FXS that perform the intervention at the beginning of the study (FXS-CGT)
62332157|NCT00408421|EXPERIMENTAL|A|duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
62489916|NCT01004510|EXPERIMENTAL|Zoledronic Acid|Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.
62489917|NCT06123754|EXPERIMENTAL|Envalfolimab plus platinum-based doublet chemotherapy|Envalfolimab plus platinum-based doublet chemotherapy for a total of 3-4 cycles of neoadjuvant therapy (determined by the investigator), Envafolimab will be administered after surgery at 600 mg every 3 weeks(Q3W) for 16 cycles at most.
62489918|NCT06123754|ACTIVE_COMPARATOR|Placebo plus platinum-based doublet chemotherapy|Placebo plus platinum-based doublet chemotherapy for a total of 3-4 cycles of neoadjuvant therapy (determined by the investigator), placebo will be administered after surgery every 3 weeks(Q3W) for 16 cycles at most.
62489919|NCT03983135|EXPERIMENTAL|Study group|Patients who undergo revisional bariatric surgery
62489920|NCT02582307|EXPERIMENTAL|Hyoscine butylbromide|Hyoscine butylbromide 10mg oral single dose
62489921|NCT02582307|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen 15mg/kg oral single dose (maximum 1000mg)
62332158|NCT00408421|PLACEBO_COMPARATOR|B|placebo daily (QD), by mouth (PO) for 13 weeks
62332159|NCT05505578|EXPERIMENTAL|GamerFit Condition|Includes use of a Fitbit and exergaming devices, the GamerFit app, and weekly telehealth coaching sessions.
62332160|NCT05505578|ACTIVE_COMPARATOR|Comparator Condition|Youth assigned to the comparator condition (n=30-35) will receive a Fitbit device (same as the intervention condition) and the Fitbit account activated on their device (e.g. phone/tablet/computer). They will receive instructions on using the PA and sleep tracking features, as well as a booklet of healthy habit tips. They will receive reminders to charge, sync and review their Fitbit data for the duration of the intervention.
62332161|NCT06463158|NO_INTERVENTION|Control Group- No Intervention|During the first 8 months of recruitment, participants will be enrolled into the control group which consists of routine care and informational practices of the ICU team.
62332162|NCT06463158|EXPERIMENTAL|Intervention Group- Family Room Application|During the last 10 months of recruitment, participants will be enrolled into the experimental group where they will receive the Family Room application on their personal devices.
62332163|NCT05943327|EXPERIMENTAL|Part A: Multiple Doses of Lu AG06474 or Placebo|Participants will receive multiple oral doses of Lu AG06474 or placebo.
62332164|NCT05943327|EXPERIMENTAL|Part B: Single Doses of Lu AG06474|Participants will receive single oral doses of Lu AG06474.
62332165|NCT06290895||In-vitro fertilization (IVF) cycle using artificial oocyte activation (AOA)|
62332166|NCT06290895||In-vitro fertilization (IVF) cycle without artificial oocyte activation (AOA)|
62332167|NCT02697461|EXPERIMENTAL|Intrinsic Foot Arm|In arm 1, a randomized control trial will be used in the investigation of validity and reliability comparing multisegmented foot motion, clinical joint physiological and accessory motion, and morphologic foot measurements, and the effect of intrinsic foot strengthening on multisegmented foot function.
62332168|NCT02697461|EXPERIMENTAL|Joint Mobilization Arm|In arm 2, the investigation of group differences in clinical and laboratory measures of multisegmented foot motion and kinetics will use a case control design. A randomized controlled trial will be conducted in the study investigating joint mobilization, with the researcher performing the assessments and the provider performing the treatments blinded to group allocation
62332169|NCT02066025||group_0|Women with negative mammography (BIRADS 1-2), as negative controls.
62332170|NCT02066025||group_1|Women with positive biopsy for (ID, IL, DCIS) as patients.
62489922|NCT03718039|EXPERIMENTAL|Treatment Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
62489923|NCT03718039|EXPERIMENTAL|Treatment Group 2: HTX-011 + Aprepitant|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation; Aprepitant, three single doses of aprepitant will be administered orally.
62489924|NCT03718039|EXPERIMENTAL|Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation and a scheduled multimodal analgesic (MMA) regimen.
62489925|NCT01754935|EXPERIMENTAL|VX-509 100 mg qd Arm|
62489926|NCT01754935|EXPERIMENTAL|VX-509 200 mg qd Arm|
62332171|NCT02066025||group_2|Women with positive mammography (BIRADS 3-4-5-6), and a negative biopsy diagnosis for breast cancer (ID, IL, DCIS) will be enrolled as benign (ADH, ALH, LCIS, fibroadenoma, fibrocystic changes (including sclerosing adenosis), Benign papillaoma, normal breast) as benigns.
62332172|NCT02210637||Retrospective Cohort|Retrospective Cohort of scheduled outpatient appointment
62332173|NCT00312884|ACTIVE_COMPARATOR|Usual Care|Recieved usual hospital and community care
62332174|NCT00312884|EXPERIMENTAL|Intervention Arm|Recieved telemonitoring
62332175|NCT02322892|PLACEBO_COMPARATOR|Control Arm|50 mL normal saline solution
62332176|NCT02322892|EXPERIMENTAL|Thiamine|200 mg thiamine in 50 mL normal saline solution
62332177|NCT05676320|EXPERIMENTAL|V-Flex|Bone cement including Inossia Cement Softener
62332178|NCT05676320|ACTIVE_COMPARATOR|V-Steady|Bone Cement alone
62332179|NCT05159596|EXPERIMENTAL|In-Home Technology System|"The full system \[(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors\] will be self-installed by Spanish-speaking caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
62489927|NCT01754935|EXPERIMENTAL|VX-509 300 mg qd Arm|
62489928|NCT01754935|PLACEBO_COMPARATOR|Placebo Arm|
62489929|NCT02028039|EXPERIMENTAL|IPI-145|IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
62694663|NCT05651490|EXPERIMENTAL|Intervention Group (PST-D)|Participants in the intervention group will receive usual care comprising of routine follow-up checks from their hospitals on top of the intervention (PST-D). The intervention consists of one introductory session, up to eight weekly treatment sessions, and three monthly maintenance sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
62489930|NCT02042599|EXPERIMENTAL|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury
62489931|NCT05467163|ACTIVE_COMPARATOR|Biventricular pacing + AV node ablation|Implantation of biventricular pacemaker with or without defibrillator lead placement followed by AV node ablation. Optimal guidelines-based heart failure treatment.
62332180|NCT05159596|SHAM_COMPARATOR|Limited In-Home Technology System|"The full system \[(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors\] will be self-installed by Spanish-speaking caregivers (N=60) in their homes. Only monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm."
62332181|NCT00138151|EXPERIMENTAL|Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b|"* Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~* Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~* Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days"
62332182|NCT05841602||study group|8-13 age group (N=128).
62332183|NCT02634918||Ultrasound|3 groups of hemophilia patients - Those with \> 20 bleeds into a joint, those with \< 2 bleeds into a joint and those with no bleeds into a joint will be enrolled into the study
62332184|NCT02634918||those with < 2 bleeds into a joint and|3 groups of hemophilia patients Group I - Those with \> 20 bleeds into a joint, Group II - those with \< 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
62332185|NCT02634918||those with no bleeds into a joint will be enrolled into the st|3 groups of hemophilia patients Group I - Those with \> 20 bleeds into a joint, Group II - those with \< 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
62332186|NCT02292303|EXPERIMENTAL|zinc-enriched yeast|zinc-enriched yeast capsules
62332187|NCT02292303|ACTIVE_COMPARATOR|zinc oxide|zinc oxide capsules
62332188|NCT02292303|ACTIVE_COMPARATOR|zinc gluconate|zinc gluconate capsules
62332189|NCT04022811|EXPERIMENTAL|Artificial tears|0.1% bromfenac VS Artificial tears
62332190|NCT00789100||1|Group provided with home-based monitor
62332191|NCT00789100||2|Group receives no home-based monitor
62332192|NCT00587418|EXPERIMENTAL|Arginine|
62332193|NCT00587418|PLACEBO_COMPARATOR|Placebo|
62489932|NCT05467163|EXPERIMENTAL|Conduction system pacing + AV node ablation|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement followed by AV node ablation. Optimal guidelines-based heart failure treatment.
62489933|NCT05497986|EXPERIMENTAL|High Flow Nasal Cannula|
61937453|NCT06677866|OTHER|ASD- Waiting List group (ASD-WL)|Group of adolescents with ASD that perform the intervention once that the sections with the first group are ended (ASD-WL)
62332194|NCT03411213|EXPERIMENTAL|Vascular function|Diffuse optical tomography detection of differences in vascular function between healthy volunteers and patients with proven heart disease or diabetes.
62332195|NCT03411213|EXPERIMENTAL|Coronary artery disease|Diffuse optical tomography prediction of presence or severity of coronary artery disease on angiography.
62332196|NCT01115569|EXPERIMENTAL|Hydrocodone Bitartrate|Open-label, all patients fulfilling the protocol Inclusion/Exclusion criteria will receive HC-CR in a flexible dosing regimen.
62332197|NCT04573452||Normal pregnancy group|
62332198|NCT04573452||Placenta accreta at 24-32 weeks group|
62332199|NCT04336397|ACTIVE_COMPARATOR|High Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
62332200|NCT04336397|ACTIVE_COMPARATOR|Medium Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
62332201|NCT04336397|NO_INTERVENTION|Usual Care|usual care (i.e., opportunistic screening recommendation at a clinic visit)
62332202|NCT00920608|EXPERIMENTAL|A|AZD9056 400 mg and Methotrexate
62332203|NCT04478682|EXPERIMENTAL|WhatsApp Messaging Application|Continuous breastfeeding support will be provided for the first 6 months through WhatsApp messaging application. Mothers will be contacted once a week through WhatsApp and feedback will be received on the breastfeeding process. The questions of the mother regarding breastfeeding will be answered by text / voice message or video call.
62489934|NCT05497986|ACTIVE_COMPARATOR|Conventional Oxygenation with low flow cannula|
62489935|NCT04920695|PLACEBO_COMPARATOR|Placebo Control|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquid Healthcare, Montreal, Quebec, Canada).
62694664|NCT05651490|ACTIVE_COMPARATOR|Attention control group|The participants in the control group will receive usual care comprising of routine follow-up checks from their hospitals. They will also receive one introductory session and up to eight weekly treatment sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
61937454|NCT06185127|EXPERIMENTAL|DK group|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion). After the first 15 minutes, a bolus dose of 50 mg ketamine dissolved in 10 ml saline was given.
62332204|NCT04478682|NO_INTERVENTION|Standard breastfeeding support|She will receive standard breastfeeding support after delivery. Breastfeeding will not receive continuous breastfeeding support for the first 6 months after discharge.
62332205|NCT01956409|EXPERIMENTAL|diagnostic accuracy of PET and MR spectroscopy|To investigate the diagnostic accuracy of 18F-Fluorocholine PET and proton MR spectroscopy of breast lesions, using pathology as gold standard.
62332206|NCT05263102|EXPERIMENTAL|Treatment Arm|Treatment duration: 8 weeks Twice treatments per week
62489936|NCT04920695|ACTIVE_COMPARATOR|Inhaled Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX™ gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; Control # 198879, DIN 02451328).
62489937|NCT01873391|ACTIVE_COMPARATOR|Normal saline|Normal saline is a distension media of uterine cavity in diagnostic hysteroscopy.
62489938|NCT01873391|ACTIVE_COMPARATOR|Carbon dioxide|Carbon dioxide is a distension media of uterine cavity in diagnostic hysteroscopy.
62136279|NCT02823028|OTHER|Initial Pilot Group (NRT + Web Guide + Tweet2Quit-Coed)|The initial pilot group was run to check technology functionality and user acceptance; it was not included in outcome assessments. These participants received NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a coed Tweet2Quit group.
62136280|NCT06069700|EXPERIMENTAL|Individualized care program|"Participants in the individualized care stream, will be provided reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms consistent with usual care. Additionally, they will be afforded up to 12 treatments over the course of 6-weeks. Treatments will be standardized; however, given the heterogeneity of symptoms, components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. Regardless of subgroup classification, as part of individualized care, all patients will receive reassurance and psychoeducation about the bio-psycho-social understanding of persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour."
62332207|NCT04699604|ACTIVE_COMPARATOR|Levocetirizine (LTZ)|Participants will take Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children \>11 years per recommended doses) in addition to their current asthma regimen.
62332208|NCT04699604|PLACEBO_COMPARATOR|Placebo|Participants will take a placebo solution previously developed by the Children's Mercy Investigational Pharmacy to match the color, flavor, and consistency of the active drug in addition to their current asthma regimen.
62332209|NCT02773069|EXPERIMENTAL|Weight loss program|Participants will attend a 12 session weight loss program accompanied by maintenance support delivered by a church. Program will include peer education, telenutrition counseling and mobile health feedback.
62332210|NCT05056467|EXPERIMENTAL|IOL|Preeclampsia High-risk Women schedule labor induction at 39 weeks of gestation
62332211|NCT05056467|NO_INTERVENTION|Expectant Management|Preeclampsia High-risk Women under expectant management
62332212|NCT02693483|ACTIVE_COMPARATOR|povidone iodine|153 cases undergoing cesarean sections will have preoperative vaginal cleansing with 10% povidone iodine
62332213|NCT02693483|NO_INTERVENTION|no vaginal cleansing|153 cases undergoing cesarean sections
62332214|NCT03587558|EXPERIMENTAL|Carvedilol group|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
62332215|NCT03587558|ACTIVE_COMPARATOR|Flecainide group|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
62332216|NCT02027116|EXPERIMENTAL|Experimental: 1mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
62332217|NCT02027116|EXPERIMENTAL|Experimental: 3mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
62332218|NCT02027116|EXPERIMENTAL|Experimental: 6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
62332219|NCT04644289|OTHER|cohort A - olaparib monotherapy|Olaparib tablets 2 × 300 mg per day for 3 weeks prior to surgery until one day prior to surgery or withdrawal of informed consent and as long as the patient has received all possible licensed treatment regimens according to national guideline or for whom further licensed treatment options are contraindicated, offered as investigational maintenance therapy for 24 months after completion of primary therapy (chemotherapy).
62332220|NCT04644289|OTHER|cohort B - olaparib + durvalumab combination|Olaparib tablets 2 × 300mg per day for 4 weeks plus durvalumab 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle).
62332221|NCT05834803|ACTIVE_COMPARATOR|Renal artery stenting|Percutaneous transluminal renal angioplasty with stent placement.
62332222|NCT05834803|SHAM_COMPARATOR|Sham treatment|Sham treatment.
62332223|NCT02548104|ACTIVE_COMPARATOR|Adductor canal block (ACB)|Group I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
62332224|NCT02548104|EXPERIMENTAL|Adductor canal ACB + genicular (IPACK)|Group II Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
62489939|NCT01715922|OTHER|oral treatment|"Drug: Fluconazole and flucytosine~Induction treatment for 2 weeks:~Fluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
62489940|NCT04076007|ACTIVE_COMPARATOR|Active|Nitrate rich beetroot juice (7.5 mmol nitrate in 250mls beetroot juice) once daily.
62489941|NCT04076007|PLACEBO_COMPARATOR|Placebo|Nitrate depleted beetroot juice (0.002 mmol nitrate in 250 ml beetroot juice) once daily.
62489942|NCT02203539|EXPERIMENTAL|bright light|Intervention: exposure to bright light
62489943|NCT02203539|EXPERIMENTAL|blue-enriched light|Intervention: exposure to blue-enriched light
62489944|NCT02203539|EXPERIMENTAL|normal light|Intervention: exposure to normal light
62332225|NCT03355287|PLACEBO_COMPARATOR|Traditionally Threshed Teff (TTT)|The control group will consume injera based on teff threshed under the hooves of cattle. We plan to have a certain number of teff flour suppliers, where the teff is traditionally threshed and contains at least 50 mg Fe per 100 g flour.
62489945|NCT02845154|ACTIVE_COMPARATOR|Control (bolus purge)|The portal vein clamp will be totally released after end of portal vein anastomosis and all graft and portal blood contents are allowed free and complete access to the systemic circulation via the inferior vena cave
62694665|NCT02881216|OTHER|Common DES|Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
61937455|NCT06185127|ACTIVE_COMPARATOR|MF group|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) and fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam and 150 μg of fentanyl were administered.
62332226|NCT03355287|EXPERIMENTAL|Lab Threshed Teff (LTT)|The intervention group will consume injera based on teff flour that has been lab threshed using a modern teff threshing machine.
62489946|NCT02845154|EXPERIMENTAL|Intermittent Purge|The portal clamp will be released in situ for 5 seconds to allow purge of the graft and portal contents into the systemic circulation, followed by 30 seconds of portal clamping again. This will be followed by another two cycles of 5 seconds declamping and 30 seconds clamping , then, the portal clamp will be completely released.
62489947|NCT04882254|EXPERIMENTAL|Normothermic machine perfusion|Additional 2 hours of normothermic machine perfusion of donor kidney with a red cell based perfusate.
62489948|NCT04882254|NO_INTERVENTION|Standard-of-care|Standard-of-care, which is hypothermic kidney machine perfusion in the Netherlands.
62489949|NCT00469898|EXPERIMENTAL|Therapeutic Intervention|Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
62489950|NCT02372006|EXPERIMENTAL|afatinib|dose escalation
62489951|NCT05882526|ACTIVE_COMPARATOR|Evaluation of elastomeric power chain for orthodontic maxillary canine retraction|20 Orthodontic patient treated by for elastomeric power chain canine retraction split mouth.
62332227|NCT03355287|ACTIVE_COMPARATOR|Fortified Lab Threshed Teff (FTT)|This arm will be the positive control group consuming Ferrous Sulphate drops ( with injera that consist of lab-threshed teff. The Fe drops have to be consumed with the meal and will provide an additional 6 mg of Ferrous sulfate to the diet of the children.
62332228|NCT00528346|ACTIVE_COMPARATOR|1|Participants will see their own brain activation.
62332229|NCT00528346|PLACEBO_COMPARATOR|2|Participants will see simulated data that does not come from their own brains.
62332230|NCT02536170|EXPERIMENTAL|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
62332231|NCT02536170|EXPERIMENTAL|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
62332232|NCT02536170|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
62332233|NCT02773238|EXPERIMENTAL|Treatment|Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or \> 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.
62332234|NCT00115349|EXPERIMENTAL|L1/DFO|Deferoxamine (DFO) and deferiprone (L1) combination therapy
62332235|NCT00115349|ACTIVE_COMPARATOR|DFO|Deferoxamine (DFO) monotherapy
62332236|NCT02258009|EXPERIMENTAL|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab
62332237|NCT02258009|EXPERIMENTAL|Group 2|Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
62332238|NCT02399813|EXPERIMENTAL|Axalimogene filolisbac|Participants received intravenous (IV) infusion of axalimogene filolisbac administered over 60 minutes every 3 weeks at a dose of 1 x 10\^9 colony forming units (cfu) for up to 2 years or until a discontinuation criterion was met (documented progression, unacceptable adverse events, withdrawn due to investigator's discretion, participant withdraws consent, pregnancy or noncompliance with study procedures or treatments). A treatment cycle was defined as 9 weeks in duration.
62489952|NCT05882526|ACTIVE_COMPARATOR|Evaluation of T loop for orthodontic maxillary canine retraction|20 Orthodontic patient treated by T loop for canine retraction split mouth
62489953|NCT05088551|NO_INTERVENTION|Control group|When the patients were admitted to the clinic,and the face-to-face interview method and the Patient Information Form,Turkey Health Literacy Scale-32,Patient Learning Needs Scale,Functional Assessment Form and Quality of Life Scale Form were filled.The second interview was conducted on the second or third day after the surgery, just before the patients were discharged.The Functional Assessment Form,Discharge Data Collection Form, and Quality of Life Questionnaire were applied.The third interview was performed 15 days after the surgery when the patients came for control or by phone.The 15th Day Recovery Process Data Collection Form were applied.The last interview was carried out six weeks after the surgery,either face-to-face or by phone,and the Functional Assessment Form,6th Week Post-Discharge Recovery Process Data Collection Form,and Quality of Life Questionnaire were applied again.Except for the routine practices of the service,no intervention was made to the control group patients.
62694666|NCT02881216|OTHER|Synergy Stent|Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
62694667|NCT06637514|EXPERIMENTAL|JNT-517 - 75 mg BID|Drug: JNT-517 Tablet
61937456|NCT00105677||Group 1|
62332239|NCT05169307||CPX-351|Adult patients with newly diagnosed, therapy related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who were treated in routine practice with Vyxeos liposomal in the UK.
62332240|NCT05308225|EXPERIMENTAL|STI-6129|Seven dosing cohorts will be evaluated: 0.67 mg/kg, 0.88 mg/kg, 1.18 mg/kg, 1.56 mg/kg, 2.08 mg/kg, 2.77 mg/kg, 3.68 mg/kg where STI-6129 will be intravenously administered once as part of a 4-week treatment cycle.
61937457|NCT03004196|ACTIVE_COMPARATOR|Control Group|They were not given probiotic toothpaste or chlorhexidine mouthwash
62489954|NCT05088551|EXPERIMENTAL|Intervention group|Unlike the control group, the intervention group was given the education plan prepared by the researcher after filling out the forms when the patients were first encountered, and the education was carried out using various training methods such as lecture, question-answer, demonstration, and practice.Patients whose check-up time after discharge was nearing (15 days after the operation) were called a few days before and their visit time was learned. The forms were filled in by interviewing the patients face-to-face by the researcher on the 15th day and the 6th week after the operation or making a phone call on the same day with the patients who could not be reached.
62136281|NCT06069700|ACTIVE_COMPARATOR|Usual care|"Active control - All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
62489955|NCT05725499|EXPERIMENTAL|Participants with a chronic SCI (≥ 6 months after injury)|Participants will complete three days of baseline assessments (including a baseline orthostatic test and a day of neurophysiological mapping), five days of stimulation mapping to locate the optimal spinal sites for a blood pressure response, a day of testing with stimulation applied during an orthostatic provocation and a two-week (total of six days) training period with repeated exposure to stimulation, followed by two days of additional orthostatic tests (with and without stimulation)
62489956|NCT03271125|EXPERIMENTAL|Treadmill group|Participants in the experimental group received supervised treadmill training
62489957|NCT03271125|ACTIVE_COMPARATOR|Resistance group|Participants in the control group were treated with Resistance exercises.
62489958|NCT01891357|EXPERIMENTAL|Paclitaxel + Lapatinib + Trastuzumab|Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
62489959|NCT04967950|EXPERIMENTAL|Secukinumab 300mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
62489960|NCT04967950|EXPERIMENTAL|Secukinumab 150mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
62489961|NCT04967950|ACTIVE_COMPARATOR|methotrexate|methotrexate
62489962|NCT02171988|ACTIVE_COMPARATOR|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
62489963|NCT02171988|ACTIVE_COMPARATOR|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
62489964|NCT02171988|ACTIVE_COMPARATOR|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
62489965|NCT02171988|ACTIVE_COMPARATOR|Bisoprolol+pyridostgmine|start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
62489966|NCT04046380||normal lungs|
62489967|NCT04046380||Acute respiratory distress syndrome (ARDS) group|
62489968|NCT02940613|EXPERIMENTAL|Visual feedback of symptom frequency|Participants in this arm receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
62489969|NCT02940613|NO_INTERVENTION|No visual feedback of symptom frequency|Participants in this arm complete the symptom checklist as is typically done during treatment, but receive no visual feedback of their self-reported symptom frequency over the first 4 weeks of active treatment.
62136282|NCT05566249||ArtiSential group|Patients undergoing laparoscopic surgery using ArtiSential
62489970|NCT01653405|EXPERIMENTAL|Intervention Group|VA patients treated at anticoagulation clinics at 8 sites in VISN 1. The intervention included a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
62489971|NCT01653405|NO_INTERVENTION|Control Group|VA patients treated at anticoagulation clinics at 116 sites outside of VISN 1.
62489972|NCT02075905||Barrett's Esophagus-Low Grade Dysplasia|Subjects enrolled who have Barrett's Esophagus with low grade dysplasia. No research intervention is administered.
61937458|NCT03004196|EXPERIMENTAL|Probiotic Group|"Patients were asked to brush twice daily with given G.D Probiotic Toothpaste and were asked not to eat or drink anything for half-an-hour."
62489973|NCT02075905||Barrett's Esophagus-no dysplasia|Subjects enrolled with Barrett's Esophagus and no dysplasia. No research intervention is administered.
62489974|NCT04968925|EXPERIMENTAL|O1D/P1|Eligible subjects that are habitual wearers of daily disposable soft contact lenses will randomly be assigned sequence (O1D/P1)
62489975|NCT04968925|EXPERIMENTAL|P1/O1D|Eligible subjects that are habitual wearers of daily disposable soft contact lenses will randomly be assigned sequence (P1/O1D)
62489976|NCT06024980|ACTIVE_COMPARATOR|Supraglottic and glottic T2 laryngeal carcinoma|The open partial horizontal laryngectomy was underwent in patients with supraglottic or glottic laryngeal carcinoma in T2
62489977|NCT06024980|ACTIVE_COMPARATOR|Supraglottic and glottic T1 laryngeal carcinoma|The transoral endoscopic laser cordectomy was underwent in patients with supraglottic or glottic laryngeal carcinoma in T1
62136283|NCT05566249||Robot group|Patients undergoing robotic surgery
62136284|NCT05560659|NO_INTERVENTION|Stereotactic ablative body radiotherapy (SABR) alone|1-3 fractions of SABR to all sites of disease
62136285|NCT05560659|EXPERIMENTAL|SABR plus 2 cycles of 177Lu-PSMA|cycles of 177Lu-PSMA with 1-3 fractions of SABR to all sites of disease between cycle 1 and 2
62136286|NCT02969759|OTHER|Patients|ALS defined by El Escorial Criteria.
62489978|NCT02342873|ACTIVE_COMPARATOR|NS-guided interscalene block|NS-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
62489979|NCT02342873|EXPERIMENTAL|US-guided interscalene block|US-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
62489980|NCT05341180|ACTIVE_COMPARATOR|Study group 1(Polyethylene Glycol)|Polyethylene glycol syrup will be used at a dose of 15-30 ml per day for 2 weeks maximum.
62489981|NCT05341180|ACTIVE_COMPARATOR|Study group 2 (Isabgol and Lactulose)|Isabgol 2 teaspoons in 200ml of warm water to consume immediately after soaking before bedtime and syrup Lactulose 30 ml at bedtime for 2 weeks.
62489982|NCT05583409|EXPERIMENTAL|Osimertinib plus SBRT|SBRT with photon and dose is 40Gy/5F after three months after Osimertinib treatment
62489983|NCT05583409|ACTIVE_COMPARATOR|Osimertinib|Osimertinib 80mg, po, Qd
62489984|NCT01534754|ACTIVE_COMPARATOR|Mesalazine|Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
62489985|NCT01534754|ACTIVE_COMPARATOR|Lactobacillus casei|Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
62489986|NCT01534754|ACTIVE_COMPARATOR|Mesalazine plus Lactobacillus casei|Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
62136287|NCT02969759|OTHER|Controls|Asymptomatic subjects with normal examination.
62136288|NCT01367236|ACTIVE_COMPARATOR|standard care|"treatment with:~* atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\* \* as the fixed dose combination Truvada™"
62136289|NCT01367236|ACTIVE_COMPARATOR|Novel therapeutic approach|"* darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\*~* abacavir 600 mg daily\*\*~* maraviroc 150 mg once daily \*\* as the fixed dose combination Kivexa ™"
62136290|NCT05770440||Group 1|Patient with COPD and at least 1 SARS-Cov2 Infection
62136291|NCT05770440||Group 2|Patient with COPD and no SARS-COV2 Infection
62332241|NCT03732391|EXPERIMENTAL|single arm|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will come continued with the same schedule until unacceptable toxicity or disease progression
62332242|NCT00856076||VTE case group 1/2|Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.
62332243|NCT00856076||VTE control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
62332244|NCT00856076||VTE control group 2|Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.
62332245|NCT00856076||VTE case group 3|Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
62332246|NCT00856076||VTE control group 3|Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
62332247|NCT00856076||IUFD group 1|Women who have experienced IUFD - data verified from medical records.
62332248|NCT00856076||IUFD group 2|Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
62332249|NCT00856076||IUFD control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
62332250|NCT00856076||IUFD control group 2|Subjects from VTE control group 1/2 with validated data from medical records.
62332251|NCT00856076||IUFD control group 3|Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.
62332252|NCT00093080|EXPERIMENTAL|Ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
62332253|NCT05280431|EXPERIMENTAL|Experimental Group (AGREE)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the AGREE exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
62332254|NCT05280431|EXPERIMENTAL|Experimental Group (FEXO)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the FEXO exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
62332255|NCT05280431|OTHER|Control Group (Conventional therapy)|15 sessions, 3 sessions per week. Each session consists of 45 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke.
62332256|NCT05135130||ON101 Cream|Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to ON101 Cream arm
62489987|NCT01534754|PLACEBO_COMPARATOR|Placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
62489988|NCT04996953||165 patients with insomnia|
62489989|NCT00406393|ACTIVE_COMPARATOR|Tacrolimus/Methotrexate|Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.
62489990|NCT00406393|EXPERIMENTAL|Tacrolimus/Sirolimus|Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.
62489991|NCT01189747|EXPERIMENTAL|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1.
62332257|NCT05135130||Aquacel® Hydrofiber® dressing|Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to Aquacel® Hydrofiber® dressing arm
62332258|NCT03399175|OTHER|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
62332259|NCT05728671|EXPERIMENTAL|IP2015_PO release form 1|Test formulation 1
62332260|NCT05728671|EXPERIMENTAL|IP2015_PO release form 2|Test formulation 2
62332261|NCT05728671|EXPERIMENTAL|IP2015_PO release form 3|Test formulation 3
62332262|NCT05745324|EXPERIMENTAL|Smoker vs Nonsmokers|SRP would be performed for Smokers (ENDS and conventional cigarette) and Nonsmokers and their inflammatory biomarkers would be assessed.
62332263|NCT05745324|EXPERIMENTAL|ENDS users and Nonsmokers|SRP would be performed for ENDS users and Nonsmokers and their inflammatory biomarkers would be assessed.
62332264|NCT05745324|EXPERIMENTAL|Smokers with periodontitis and Nonsmokers|SRP would be performed for Smokers with periodontitis and health nonsmokers and their inflammatory biomarkers would be assessed.
62332265|NCT05745324|EXPERIMENTAL|Smokers with periodontitis and Nonsmokers with periodontitis|SRP would be performed for Smokers and Nonsmokers with periodontitis and their inflammatory biomarkers would be assessed.
62332266|NCT03638947|NO_INTERVENTION|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
62332267|NCT03638947|ACTIVE_COMPARATOR|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
62332268|NCT01008995|EXPERIMENTAL|001|placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
62489992|NCT01189747|PLACEBO_COMPARATOR|placebo (normal saline)|normal saline injected into bilateral Crow's Feet Line areas on Day 1.
62489993|NCT06054984|EXPERIMENTAL|TCR-T Cells Injection（GB3010 Cells Injection）|This study was designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of TCRT cell injection (GB3010) in patients with advanced pancreatic cancer by intravenous injection. The target population is patients with advanced pancreatic cancer who lack effective treatment methods, so that the benefits of patients participating in clinical trials will outweigh the risks.
62694668|NCT06637514|PLACEBO_COMPARATOR|Placebo - BID|Drug: Placebo Tablet
61937459|NCT03004196|EXPERIMENTAL|Chlorhexidine Mouthwash Group|"Patients were asked to rinse daily with Dr. Reddy's Clohex chlorhexidine mouthwash of 10ml without dilution for three times a day after meals (Breakfast, Lunch Dinner) for 3-4 minutes and were asked not to eat or drink anything for half-an-hour."
61937460|NCT04064788|EXPERIMENTAL|Consecutive mCIMT group|6 hours / day, 10 consecutive days, 60 hours mKZHT + 2 days 45 minutes / day traditional physiotherapy
61937461|NCT04064788|EXPERIMENTAL|Intermittent mCIMT group|6 hours / day 2 days a week 5 weeks, a total of 60 hours mKZHT + 2 days 45 min / day traditional physiotherapy
61937462|NCT04064788|ACTIVE_COMPARATOR|Traditional physiotherapy control group|45 min / day, 2 days a week traditional physiotherapy
61937463|NCT04598464|EXPERIMENTAL|Exercise group|The home-based training program
61937464|NCT04598464|NO_INTERVENTION|control group|All patients participated in a one-session educational program conducted by the investigators at each clinic.
62332269|NCT01008995|EXPERIMENTAL|002|placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16
62332270|NCT01388582|ACTIVE_COMPARATOR|Combined oral contraceptive|10 women will receive COC during breastfeeding
62332271|NCT01388582|ACTIVE_COMPARATOR|Levonorgestrel intrauterine system|10 women will receive a LNG-IUS during breastfeeding
62332272|NCT01388582|ACTIVE_COMPARATOR|Implanon|10 women will receive Implanon during breastfeeding
62332273|NCT01388582|ACTIVE_COMPARATOR|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding
62332274|NCT04752579|EXPERIMENTAL|Pilates exercise program|Participants allocated to this group will receive a 10-week Pilates exercise program with each session having a duration of 45'.
62332275|NCT04752579|PLACEBO_COMPARATOR|Control|Participants allocated to this group received general consulting instructions and a home-based general exercise sheet
62332276|NCT05909254|EXPERIMENTAL|Palatally impacted canine exposure using a surgical template|
62332277|NCT05909254|EXPERIMENTAL|Palatally impacted canine exposure using the conventional free-hand method|
62332278|NCT03644940|EXPERIMENTAL|Subpopulation-specific Algorithm|
62332279|NCT03644940|NO_INTERVENTION|Control Algorithm|
62332280|NCT01106196||MI plus respiratory illness|Patients with an incident myocardial infarction who also have a record of a visit to primary care with a respiratory tract infection
62332281|NCT03419767|ACTIVE_COMPARATOR|surgery with melatonin|Patients under carotid revascularization surgery with melatonin taken during perioperative period.
61937465|NCT03153956|EXPERIMENTAL|Active Treatment Arm|Personally calibrated bio-mechanical device
61937466|NCT03153956|PLACEBO_COMPARATOR|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
62332282|NCT03419767|SHAM_COMPARATOR|surgery with blank control|Patients under carotid revascularization surgery with nothing unnecessary taken during perioperative period
62332283|NCT00120120|EXPERIMENTAL|1|
61937467|NCT06279520|OTHER|Adult drivers|Individuals over the age of 19 who are currently driving
62332284|NCT00120120|EXPERIMENTAL|2|
62332285|NCT02814968|EXPERIMENTAL|Single arm|Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
62332286|NCT01514188|ACTIVE_COMPARATOR|Doxorubicin|
62332287|NCT01514188|EXPERIMENTAL|INNO-206|
62332288|NCT00782665|ACTIVE_COMPARATOR|Group 1|Patients who have labored and subsequently delivered by cesarean section
62332289|NCT00782665|PLACEBO_COMPARATOR|2|Patients who electively select cesarean section
62332290|NCT05016947|EXPERIMENTAL|Venetoclax + Inotuzumab Ozogamicin with Dexamethasone|"Phased 28 day treatment cycles with lead in:~Lead In Cycle: Dose escalated venetoclax 1x daily for days 1-3 with and Dexamethasone daily for days 1-3 lead in, 7 days total.~Induction Cycle 1: Dose escalated venetoclax 1x daily for days 1-21, Dexamethasone daily for days 1-4, Inotuzumab ozogamicin on days 1, 8, and 15~Induction Cycle 2: Dose escalated venetoclax 1x daily for days and Inotuzumab ozogamicin on days 1, 8, and 15~Consolidation Cycles: Up to 5 cycles of dose escalated Venetoclax 1x daily for days and Inotuzumab ozogamicin on days 1, 8, and 15"
62332291|NCT00926796|EXPERIMENTAL|Regimen B: gemifloxacin plus azithromycin|Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
62332292|NCT00926796|EXPERIMENTAL|Regimen A: gentamicin plus azithromycin|Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.
62489994|NCT04301258||Articular Cartilage Defect of the Knee|Patients, who undergo an articular cartilage repair of the knee using ProChondrix CR.
62489995|NCT04301258||Articular Cartilage Defect of the Ankle|Patients, who undergo an articular cartilage repair of the ankle using ProChondrix CR.
62489996|NCT04301258||Articular Cartilage Defect of the Foot|Patients, who undergo an articular cartilage repair of the foot using ProChondrix CR.
62489997|NCT04301258||Articular Cartilage Defect of the Hip|Patients, who undergo an articular cartilage repair of the hip using ProChondrix CR.
62489998|NCT04200833||group 1|All JIA patients that were switched from adalimumab to golimumab because of Treatment failure of their JIA associated uveitis at the Medical University of Graz Austria from 2010 to 2019
62694669|NCT06637514|EXPERIMENTAL|JNT-517 - 150 mg BID|Drug: JNT-517 Tablet - 150 mg BID is a potential dose that may be used in the study. After safety, efficacy and pharmacokinetic data (PK) data have been reviewed for the first 5 participants assigned in the study, a decision will be made to increase dosage for additional participants.
62694670|NCT06642909|EXPERIMENTAL|Zuberitamab 600mg|
62694671|NCT06642909|EXPERIMENTAL|Zuberitamab 1000mg|
62694672|NCT06642909|ACTIVE_COMPARATOR|cyclosporine|
62489999|NCT03216239||Colectomy Group|Mean age 52.3 years (range:20-85), 82% females, and a mean duration of symptoms of 79.9 months in the colectomy group. The indication for colectomy was constipation (36%), diverticular disease (8%), bowel obstruction (8%), colorectal carcinoma (8%), colon polyps (6%), and other (34%).
62490000|NCT03216239||Control Group|Mean age of 49.9 years (range 18-88), 76% females, and mean duration of symptoms 77.6 months,
62490001|NCT06165419|EXPERIMENTAL|SBRT to the spine|
62490002|NCT00405262|ACTIVE_COMPARATOR|1|
62490003|NCT00405262|EXPERIMENTAL|2|
62490004|NCT00405262|EXPERIMENTAL|3|
61937468|NCT01310504|ACTIVE_COMPARATOR|Non peritoneal dialysis patient|
61937469|NCT01310504|ACTIVE_COMPARATOR|Peritoneal dialysis patient|
61937470|NCT01433731|PLACEBO_COMPARATOR|placebo for SHAPE (SHP-141)|placebo for SHAPE (SHHP-141) topical gelled solution
61937471|NCT01433731|EXPERIMENTAL|SHAPE (SHP-141) 0.1%BID|SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
61937472|NCT01433731|EXPERIMENTAL|SHAPE (SHP-141) 0.5% BID|SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
61937473|NCT01433731|EXPERIMENTAL|SHAPE (SHP-141) 1.0% BID|SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
61937474|NCT05008614|EXPERIMENTAL|Erector spinae plane block group (ESP group)|"Patients receiving continuous unilateral ESP block.~Interventions:~Procedure: Ultrasound-guided unilateral ESP block via catheter placement for continuous infusion Drug: Ropivacaine 0.75% Injectable Solution Device: 21-gauge 85 mm perineural catheter, 18-gauge 100 mm stimulator needle (Silverstim, Vygon, Ecouen, France)"
61937475|NCT05008614|ACTIVE_COMPARATOR|Thoracic epidural analgesia group (TEA group)|"Patients receiving thoracic epidural analgesia.~Interventions:~Procedure: Fluoroscopy-guided thoracic epidural analgesia Drug: Ropivacaine 0.75% Injectable Solution Device: 17-gauge Tuohy needle (FlexTip Plus®, Teleflex Medical, USA)"
61937476|NCT04796571|EXPERIMENTAL|Care Coordination Arm|Patients were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care.
61937477|NCT04796571|NO_INTERVENTION|Usual Care|Participants in the usual care arm underwent symptom monitoring through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. Results of the monthly PRO instrument were available to their treating IBD doctor with interventions at their discretion.
61937478|NCT04796571|NO_INTERVENTION|passive control arn|To explore whether our usual care arm was influenced by the monthly PRO measurements required for examination of our primary outcome, we compared IBD charges, total charges, ED visits, hospitalizations, and medication utilization at 12 months in the usual care arm to a passive control arm consisting of patients who met eligibility criteria, but were not enrolled in the intervention or usual care arms.
62332293|NCT01986634|OTHER|Laser Treatment|Patients enrolled will have split face laser treatment. Patients will serve as their own control.
62332294|NCT03108144|NO_INTERVENTION|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
62332295|NCT03108144|EXPERIMENTAL|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
62332296|NCT02934048|EXPERIMENTAL|7-day triple regimen|Patients in this group received a 7-day triple regimen to eradicate H. pylori. The triple therapy contains proton pump inhibitor (PPI)-clarithromycin plus a susceptible antibiotics will be involved in the study.
62332297|NCT02934048|EXPERIMENTAL|10-day triple regimen|Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
62332298|NCT02934048|EXPERIMENTAL|14-day triple regimen|Patients in this group received a 14-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
62332299|NCT03126539|EXPERIMENTAL|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
62490005|NCT04544033||mild group|"Amendment to MOH COVID-19 Protocol:~* Patient with mild clinical symptoms \& clinically table.~* CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line."
62490006|NCT04544033||moderate group|"Amendment to MOH COVID-19 Protocol:~* Patient with non-specific and specific respiratory infection (pneumonia).~* CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening)."
62490007|NCT04544033||severe group|"Amendment to MOH COVID-19 Protocol:~* Patients with respiratory distress (RR \> 30/min, Sa02 \< 92 at room air).~* Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours.~* CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening)."
62490008|NCT00418106||1|Mothers who are pumping breast milk and who are willing to kangaroo hold their infant.
62332300|NCT03126539|EXPERIMENTAL|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
62332301|NCT00300469|ACTIVE_COMPARATOR|A|ABT-335 + 20 mg atorvastatin
62332302|NCT00300469|ACTIVE_COMPARATOR|B|ABT-335 + 40 mg atorvastatin
62490009|NCT01325935|EXPERIMENTAL|Short-term DAPT group|1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
62490010|NCT01325935|NO_INTERVENTION|Long-term DAPT group|1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
62490011|NCT03587129|EXPERIMENTAL|apatinib|1 times a day, atapinib, 500 mg, is taken orally
61937479|NCT02054377|EXPERIMENTAL|Group A (face to face tai chi)|"1. 8 x 1 hour taught individual classes of Tai Chi over 3 months provided by a Tai Chi instructor at the participant's home/convenient location. These focus on 8 core postures. This is in addition to participant's usual routine care. A DVD and booklet to aid home practise will be provided.~2. Daily home Tai Chi practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~3. At the end of the 9 months, local Tai Chi classes can be recommended if requested."
61937480|NCT02054377|ACTIVE_COMPARATOR|Group 2 (online tai chi)|"1. 3 months usual routine care.~2. 8 x 1 hour taught individual classes of Tai Chi over 3 months provided over the internet by a Tai Chi instructor. A DVD and booklet to aid home practise will be provided.~3. Daily Tai Chi home practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~4. At the end of the 9 months, local Tai Chi classes can be recommended if requested."
61937481|NCT05426239||Cohort 1|Participants initiating first-line systemic therapy to treat advanced melanoma.
61937482|NCT00892658|EXPERIMENTAL|Sorafenib + RT|
61937483|NCT05860933|EXPERIMENTAL|LY3537982 + Itraconazole (Part 1)|LY3537982 administered orally alone followed by LY3537982 administered in combination with itraconazole orally.
61937484|NCT05860933|EXPERIMENTAL|LY3537982 + Carbamazepine (Part 2)|LY3537982 administered orally alone followed by LY3537982 administered in combination with carbamazepine orally.
61937485|NCT03753269|EXPERIMENTAL|Fasudil Hydrochloride|Fasudil Hydrochoride will be delivered into culprit vessel right after the first wire passage
61937486|NCT03753269|PLACEBO_COMPARATOR|Placebo saline|Same volume of 0.9% saline will be delivered into culprit vessel right after the first wire passage
62332303|NCT00300469|PLACEBO_COMPARATOR|C|ABT-335 monotherapy
62332304|NCT00300469|PLACEBO_COMPARATOR|D|20 mg atorvastatin monotherapy
62332305|NCT00300469|PLACEBO_COMPARATOR|E|40 mg atorvastatin monotherapy
62332306|NCT00300469|PLACEBO_COMPARATOR|F|80 mg atorvastatin monotherapy
62332307|NCT00562757||A|Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups
62332308|NCT04829955|NO_INTERVENTION|Observation phase|After screening and randomization for either the eccentric orientated intervention group or the concentric orientated intervention group, all measurements will be made for the first time by investigators at point A1. An observational phase for six weeks will follow to achieve an intern acceptance sampling for the measurements which will be used.
62332309|NCT04829955|ACTIVE_COMPARATOR|Eccentric training group|"Subjects in the eccentric training group (GEC) will attend six weeks of eccentric orientated training. The eccentric orientated training will use the cadence 3-0-1 for eccentric - break - concentric.~* 3 sessions/week~* 60 minutes per session including a warming up and cool down phase~* 6 exercises~* total of 18 sessions"
62332310|NCT04829955|ACTIVE_COMPARATOR|Concentric training group|"The concentric training group (GCO) will attend six weeks of concentric orientated training. Each group will perform a manual resistance/bodyweight resistance training accentuating the concentric phase of the movement. The concentric orientated training will use the cadence 1-0-3 for eccentric - break - concentric.~* 3 sessions/week~* 60 minutes per session including a warming up and cool down phase~* 6 exercises~* total of 18 sessions"
62490012|NCT03643731|EXPERIMENTAL|HeatTens|"After baseline measurements and during 4 weeks of follow up~Composition and dosing of the device:~HeatTens (HV-F311-E) 2 - 108 Hz (modulation), 100 microsec (pulse duration) for 30 minutes."
62490013|NCT03643731|NO_INTERVENTION|Control group|No intervention
62490014|NCT03342196|EXPERIMENTAL|Thiotepa + Fludarabine + Melphalan|Melphalan 100 mg/m2 on day -8 Thiotepa 10 mg/kg on day -7 Fludarabine 160 mg/m2 in divided doses given on days -6, -5, -4 and -3.
61937487|NCT04183062|EXPERIMENTAL|Chemotherapy plus BIO-11006|Patients will receive BIO-11006 in addition to GemTax chemotherapy. The BIO-11006 inhalation solution will be given by mouth inhalation twice daily. BIO-11006 will be given during the first three cycles of GemTax and then will be stopped. Subjects will continue with GemTax treatment for three additional cycles. If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment.
62332311|NCT02128763|EXPERIMENTAL|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
62490015|NCT05232773||Experimental group|"Enrolled patients will undergo supervised rehabilitation treatment for rotator cuff repair according to a standardized protocol (5 days/week) and will undergo clinical, kinematic and shoulder muscle strength assessments to collect data useful to define objective criteria for progression between rehabilitation phases. Assessment will be performed at four different times.~The clinical evaluation of the shoulder is carried out through the Constant-Murley Score (CMS).~Pain will be assessed through the visual analogical scale (VAS). Kinematic assessment (shoulder ROM, scapula-humeral rhythm, movement smoothness, movement speed) will be assessed through magneto-inertial measurements units (M-IMU).~The maximal voluntary isometric contraction (MVIC) of shoulder flexor, abductor and rotator cuff muscles of the affected limb will be measured by the Chronojump Boscosystem® Force Sensor Kit"
62490016|NCT05232773||Healthy subjects|Healthy subjects will undergo evaluations with the same timing as patients in the Experimental group.
62490017|NCT03224624|EXPERIMENTAL|self-management|Participants will be taught to monitor blood pressure and make limited adjustments to their medications
62490018|NCT03224624|NO_INTERVENTION|usual care|Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.
61937488|NCT05726916|EXPERIMENTAL|Experimental group|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
62332312|NCT02128763|PLACEBO_COMPARATOR|Placebo|Olive oil-5 gelcaps per day
62332313|NCT05365620|ACTIVE_COMPARATOR|Catheter Suction|Patients in this arm were managed for 8 hours with Catheter Suction whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's
62332314|NCT05365620|EXPERIMENTAL|Mechanical Inexsufflation|Patients in this are were managed for 8 hours with automatic inexsufflation treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with Catheter Suction performed only if signs of airway secretion accumulation manifested
61937489|NCT05726916|ACTIVE_COMPARATOR|Control group|Blood pressure control with renin angiotensin system blockers
61937490|NCT04664959|EXPERIMENTAL|SB16 (Proposed Denosumab Biosimilar)|Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.
61937491|NCT04664959|ACTIVE_COMPARATOR|Prolia® (Denosumab)|"Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects in Prolia® treatment group will be re-randomised in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. After re-randomisation, subjects transited to SB16 group will receive SB16, and subjects remaining in Prolia® group will continue to receive Prolia® at Month 12."
61937492|NCT03303014|EXPERIMENTAL|5-0 Prolene|Half of the wound will be treated with 5-0 prolene
61937493|NCT03303014|EXPERIMENTAL|5-0 Fast Absorbing Gut|Half of the wound will be treated with 5-0 fast absorbing gut
61937494|NCT04095273|EXPERIMENTAL|Dose escalation of Elimusertib|2 dose levels of Elimusertib are planned
61937495|NCT04095273|EXPERIMENTAL|Dose expansion cohort 1a of Elimusertib|Participants with advanced hormone-receptor-positive, Human epidermal growth factor receptor 2 negative breast cancer (HER2-negative BC), known to be positive for Ataxia-telangiectasia mutated (ATM) loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known microsatellite instability-high (MSI-H) cannot be included
61937496|NCT04095273|EXPERIMENTAL|Dose expansion cohort 1b of Elimusertib|Participants with advanced hormone-receptor-positive, HER2-negative BC, known to be DDR deficiency biomarker-positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
61937497|NCT04095273|EXPERIMENTAL|Dose expansion cohort 2a of Elimusertib|Participants with advanced Colorectal cancer (CRC) known to be positive for ATM loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
61937498|NCT04095273|EXPERIMENTAL|Dose expansion cohort 2b of Elimusertib|Participants with advanced CRC, known to be DDR deficiency biomarker -positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
61937499|NCT04095273|EXPERIMENTAL|Dose expansion cohort 3 of Elimusertib|Participants with advanced Gastric/gastroesophageal junction cancer (GC/GEJ) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
61937500|NCT04095273|EXPERIMENTAL|Dose expansion cohort 3a of Elimusertib|Participants with advanced GC/GEJ cancer and without DDR deficiency alterations as described above. Variants of unknown significance (VUS) of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
61937501|NCT04095273|EXPERIMENTAL|Dose expansion cohort 4 of Elimusertib|Participants with advanced Non-small cell lung cancer (NSCLC) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
61937502|NCT04095273|EXPERIMENTAL|Dose expansion cohort 4a of Elimusertib|Participants with advanced NSCLC and without DDR deficiency alterations as described above. VUS of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
61937503|NCT04095273|EXPERIMENTAL|Dose expansion cohort 5 of Elimusertib|Participants with advanced pancreatic cancer, known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
61937504|NCT04095273|EXPERIMENTAL|Dose expansion cohort 5a of Elimusertib|Participants with advanced pancreatic cancer and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
61937505|NCT04095273|EXPERIMENTAL|Dose expansion cohort 6 of Elimusertib|Participants with advanced Metastatic castration-resistant prostate cancer (mCRPC), known to be DDR deficiency biomarker positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
61937506|NCT04095273|EXPERIMENTAL|Dose expansion cohort 6a of Elimusertib|Participants with advanced mCRPC and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
61937507|NCT05601037|EXPERIMENTAL|Axilla dissection + Lymphevenous Anastomosis|Surgical bypass between lymphatic vessel and vein
61937508|NCT05601037|NO_INTERVENTION|Standard surgery|Standard surgery
61937509|NCT05189379|EXPERIMENTAL|Olfaction First|Participants assigned to this arm will undergo the experiment in the following order: Odour based Cue Reactivity Task, Monetary Incentive Delay Task, Image based Cue Reactivity Task
61937510|NCT05189379|EXPERIMENTAL|Image First|Participants assigned to this arm will undergo the experiment in the following order: Image based Cue Reactivity Task, Monetary Incentive Delay Task, Odour based Cue Reactivity Task
61937511|NCT04945031||cannabis-induced psychosis|
61937512|NCT03068598|EXPERIMENTAL|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
61937513|NCT05191654||with Congenital heart diseases|
61937514|NCT05191654||without Congenital heart diseases|
61937515|NCT03965767|PLACEBO_COMPARATOR|control|
61937516|NCT03965767|ACTIVE_COMPARATOR|local group|
61937517|NCT03965767|ACTIVE_COMPARATOR|systemic group|
61937518|NCT03965767|ACTIVE_COMPARATOR|combined local and systemic|
61937519|NCT06680297|ACTIVE_COMPARATOR|Carbohydrates loading|Participants will be given 10mls/kg of Nestle Resource carbohydrates drink a night before operation and 5mls/kg of Nestle Resource carbohydrates drink 2 hrs before operation
61937520|NCT06680297|PLACEBO_COMPARATOR|Control group|Participants will undergo standard 6 hrs fasting with 2hr clear water before operation
62490019|NCT02022306|PLACEBO_COMPARATOR|SAD TD-6450|Single ascending dose (Part A)
62490020|NCT02022306|PLACEBO_COMPARATOR|MAD TD-6450|Multiple ascending dose (Part B)
62490021|NCT02022306|ACTIVE_COMPARATOR|Food effect of TD-6450|Food effect will be assessed in Part A (SAD) of this study.
62490022|NCT00999687|EXPERIMENTAL|Indigo naturalis extract in oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
62490023|NCT00999687|PLACEBO_COMPARATOR|Olive oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
62694673|NCT01955551|EXPERIMENTAL|Motiv. Interviewing|In the MI (motivational interviewing) study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
62694674|NCT01955551|ACTIVE_COMPARATOR|Anticipatory Guidance|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
62694675|NCT06024226||Patients with lung carcinoma surgically treated by surgery only|
61937521|NCT01925274|EXPERIMENTAL|Arm A|PF-05212384 plus Irinotecan
61937522|NCT01925274|ACTIVE_COMPARATOR|Arm B|Cetuximab plus Irinotecan
61937523|NCT00754988|PLACEBO_COMPARATOR|Placebo|Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
62136292|NCT01255514|EXPERIMENTAL|VAD|VAD : high dose dexamethasone -\> response(CR, PR)-\> VAD chemotherapy(vincristine + doxorubicin + dexamethasone)-\> PBSC -\> aSCT
62332315|NCT01656681|EXPERIMENTAL|THIAA|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
61937524|NCT00754988|ACTIVE_COMPARATOR|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
61937525|NCT00754988|EXPERIMENTAL|Taspoglutide 10 mg|Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
61937526|NCT00754988|EXPERIMENTAL|Taspoglutide up-titrated to 20 mg|Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
62136293|NCT01255514|EXPERIMENTAL|PAD|PAD : high dose dexamethasone -\> response(MR,NC,PD)-\> PAD chemotherapy(bortezomib + doxorubicin + dexamethasone)-\> PBSC -\> aSCT
62332316|NCT01656681|ACTIVE_COMPARATOR|Placebo|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
62332317|NCT03934892||lactate during CPB|check lactate levels routinely during cardiac operations with cardiopulmonary bypass, choose the peak lactate data
62332318|NCT04360616||MG+|the lesion could detected by mammography
62332319|NCT04360616||US+|the lesion could detected by breast ulrtasound
62332320|NCT06224985||Malformation|
62332321|NCT06224985||Tumors|
62332322|NCT06224985||Controls|
62332323|NCT00632463|EXPERIMENTAL|1|Dose regimen 1
62332324|NCT00632463|EXPERIMENTAL|2|Dose regimen 2
62332325|NCT00632463|PLACEBO_COMPARATOR|3|Placebo
62490024|NCT01600313|EXPERIMENTAL|treatment, control|
62490025|NCT06627972||periodontal health group|Periodontal parameters were recorded at first visit and the fluid samples were collected from participants.
62490026|NCT06627972||Gingivitis group|Periodontal parameters were recorded at first visit and the fluid samples were collected from participants.
62490027|NCT06627972||periodontitis group|Periodontal parameters were recorded at first visit and the fluid samples were collected from participants.
62490028|NCT02920476|EXPERIMENTAL|Treatment arm|TAS-102
62490029|NCT03334734|EXPERIMENTAL|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
62490030|NCT03334734|EXPERIMENTAL|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
62697633|NCT06496477|ACTIVE_COMPARATOR|Group 1-A bright blue-spectrum white light (BL|Participants will receive therapy with bright blue-spectrum white light (BL) for up to thirty minutes each day for 28 days during their HSCT related hospital admission
62697634|NCT06496477|ACTIVE_COMPARATOR|Group 2- A dim blue-spectrum white light control (DL|Participants will receive therapy with dim blue-spectrum white light control (DL) for up to thirty minutes each day for 28 days during their HSCT related hospital admission
62136294|NCT02588313|ACTIVE_COMPARATOR|Mango fruit powder 100mg|Mango fruit powder 100mg
62136295|NCT02588313|ACTIVE_COMPARATOR|Mango fruit powder 300mg|Mango fruit powder 300mg
62136296|NCT02588313|PLACEBO_COMPARATOR|Placebo formulation|Placebo formulation
62136297|NCT05171777|EXPERIMENTAL|Treatment A|Participants will receive atezolizumab SC followed by atezolizumab IV.
62136298|NCT05171777|EXPERIMENTAL|Treatment B|Participants will receive atezolizumab IV followed by atezolizumab SC.
62332326|NCT03855137|PLACEBO_COMPARATOR|Placebo|Participants received atogepant-matching placebo tablets, orally, twice daily (BID) for 12 weeks in a double-blind (DB) treatment period.
61937527|NCT04189575|EXPERIMENTAL|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
62332327|NCT03855137|ACTIVE_COMPARATOR|Atogepant 30 mg BID|Participants received atogepant 30 mg tablet, orally, BID and atogepant-matching placebo tablets orally, BID for up to 12 weeks in a DB treatment period.
62332328|NCT03855137|ACTIVE_COMPARATOR|Atogepant 60 mg QD|Participants received atogepant 60 mg, orally, once daily (QD) along with atogepant-matching placebo 30 mg as morning dose followed by atogepant-matching placebo 30 mg and 60 mg as evening doses for up to 12 weeks in a DB treatment period.
62332329|NCT06365814||ERAS group|
61937528|NCT01655680|EXPERIMENTAL|ABT-126 Low Dose|ABT-126 Low Dose
62332330|NCT06365814||Conventional group|
62332331|NCT02786732|EXPERIMENTAL|210mg Brodalumab|Administered by subcutaneous injection until Week 12
62332332|NCT02786732|EXPERIMENTAL|140mg Brodalumab|Administered subcutaneous injection until Week 12
62332333|NCT02786732|ACTIVE_COMPARATOR|Ustekinumab|Administered subcutaneous injection until Week 52
62332334|NCT02786732|PLACEBO_COMPARATOR|Placebo|Administered subcutaneous injection until Week 12
62332335|NCT02642887|EXPERIMENTAL|The test group|This group included 30 recession defects treated with mTA + SCTG
62332336|NCT02642887|NO_INTERVENTION|The control group|This group included 30 recession defects treated with cTT + SCTG
62332337|NCT01134692|PLACEBO_COMPARATOR|Propranolol + Placebo|
62490031|NCT03334734|EXPERIMENTAL|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
62490032|NCT03334734|ACTIVE_COMPARATOR|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
62694676|NCT06113289|EXPERIMENTAL|Part 1B|"During cycle 1: Participants will take: ASTX029 tablets daily by mouth on days 1-42. ASTX727 tablets by mouth 1 time every day on Days 15-19. You should take ASTX727 and ASTX029 fasting (about 2 hours before a meal, and 2 hours after a meal).~Cycles 2 and beyond: Participants will take ASTX029 tablets by mouth every day (days 1-28) fasting, (2 hours before and 2 hours after a meal). You will also take ASTX727 tablets by mouth 1 time every day on days 1-5 of each cycle, fasting (2 hours before and 2 hours after a meal)."
61937529|NCT01655680|EXPERIMENTAL|ABT-126 Middle Dose|ABT-126 Middle Dose
61937530|NCT01655680|EXPERIMENTAL|ABT-126 High Dose|ABT-126 High Dose
61937531|NCT01655680|PLACEBO_COMPARATOR|Placebo|Placebo
62332338|NCT01134692|ACTIVE_COMPARATOR|Propranolol + Norfloxacin|drug
62332339|NCT01134692|EXPERIMENTAL|Propranolol + Probiotic|VSL#3
62332340|NCT05836818|EXPERIMENTAL|Question (Q)|Subjects receive no vaccine messaging, but are asked a question about whether they would accept a vaccine
62332341|NCT05836818|EXPERIMENTAL|Messaging (M)|Subjects receive vaccine messaging and are asked a question about whether they would accept a vaccine
62332342|NCT05836818|NO_INTERVENTION|Non intervention|Usual care
62332343|NCT06101394|EXPERIMENTAL|cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab IRDye800 over 30 minutes to 1 hour.
62332344|NCT02097095||Vaccine group|TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018
62332345|NCT02097095||Placebo Comparator|Placebo administered on study TB-018
62332346|NCT00562796||1|Participants with abdominal obesity without growth hormone deficiency
62490033|NCT00759707|EXPERIMENTAL|1|ultrasound imaging of saphenous vein bypass graft following an ischemic stimulus, administration of sublingual nitroglycerin and intravenous administration of L-NMMA.
62490034|NCT04752527|EXPERIMENTAL|Treatment regime|combination of venetoclax plus azacitidine, and Sorafenib for patients with high FLT3-ITD allelic ratio
62490035|NCT05118607|OTHER|Intervention (IG1)|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency
62490036|NCT06406010|EXPERIMENTAL|Ropivacaine group|Ropivacaine 5 mg/ml 20ml
61937532|NCT00807131|EXPERIMENTAL|1|Patient follow-up
61937533|NCT00807131|EXPERIMENTAL|2|Counseling
61937534|NCT00807131|EXPERIMENTAL|3|Drug dispensing
61937535|NCT00807131|ACTIVE_COMPARATOR|4|pharmacy usual care
62332347|NCT00562796||2|Participants with abdominal obesity with growth hormone deficiency
62332348|NCT00562796||3|Participants who are lean controls
62332349|NCT05949099|EXPERIMENTAL|Nirogacestat 150 mg|Patients will receive 3-cycle lead-in with systemic therapy with nirogacestat 150 mg po BID, given continuously.
62332350|NCT04997889|EXPERIMENTAL|artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
62332351|NCT04997889|ACTIVE_COMPARATOR|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
62332352|NCT03266484|ACTIVE_COMPARATOR|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.~The probiotics sachets will be taken twice a day for 12 weeks."
62332353|NCT03266484|PLACEBO_COMPARATOR|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo~The identical placebo sachets will be taken twice a day for 12 weeks."
62490037|NCT06406010|PLACEBO_COMPARATOR|Saline group|NaCl 0.9%
62694677|NCT06113289|EXPERIMENTAL|Part 2|"During cycle 1: Participants will take: ASTX029 tablets daily by mouth on days 1-42. ASTX727 tablets by mouth 1 time every day on Days 15-19. You should take ASTX727 and ASTX029 fasting (about 2 hours before a meal, and 2 hours after a meal).~Cycles 2 and beyond: Participants will take ASTX029 tablets by mouth every day (days 1-28) fasting, (2 hours before and 2 hours after a meal). You will also take ASTX727 tablets by mouth 1 time every day on days 1-5 of each cycle, fasting (2 hours before and 2 hours after a meal)."
62694678|NCT04632862|EXPERIMENTAL|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
62490038|NCT05191030|EXPERIMENTAL|Experimental (High-Stress) Arm|"Participants undergoing the experimental (high-stress) arm are exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993). Participants are given five minutes to prepare for a five-minute speech task followed by a five-minute mental arithmetic task in front of two panelists wearing white lab coats (i.e., a male and female research assistant). The speech task posits the participant in a mock interview, with the two panelists listening to the speech in an unresponsive, neutral manner and asking standardized probing questions. Participants undergoing the mental arithmetic task are instructed to subtract odd numbers (i.e., 7 and 13) from a large number (i.e., 2935) as quickly as possible. If the participant makes a mistake, the panelist interrupts them and instructs them to start the task again from the beginning. The panelists also constantly remind the participant to go faster if they start to slow down with the task."
62694679|NCT04632862|PLACEBO_COMPARATOR|DWP16001 Amg Placebo|DWP16001 Amg Placebo, Tablets, Orally, Once daily
62694680|NCT03743519|PLACEBO_COMPARATOR|Placebo|
62490039|NCT05191030|NO_INTERVENTION|Control Arm|Participants undergoing the control arm are presented with low-stress equivalents to the speech and mental arithmetic tasks from the experimental (high-stress) arm. For the speech task, participants are instructed to talk out loud to themselves for five minutes about a movie or book of their choice. Their speech is recorded using a small audio recorder device the research assistant prepares. For the mental arithmetic task, participants are instructed to count by increments of 15 starting from zero to the largest number they can reach. Participants are left in the room alone for the task for five minutes, after which the participant self-reports to the research assistant the number they reached.
62332354|NCT04684550|PLACEBO_COMPARATOR|Placebo|Health personnel who work in places of greater risk (hospitals and primary level consultation) with conventional protection elements added to the application of 2 nasal puff every 8 hours of a nasal spray containing 0.9% SSN (placebo) and gargles (SSN 0.9%).
62490040|NCT04507698|EXPERIMENTAL|Supervised Exercise Arm|If participants are placed in the Supervised Exercise Group, they will attend supervised group exercise sessions, which are individually tailored to the participants physical condition, at least once a week, every week for the first year of the study. They will be asked to exercise 3 times a week.
62490041|NCT04507698|NO_INTERVENTION|Self-Directed Exercise Arm|If Participants are placed in the Self-directed Exercise Group, they will receive usual medical care (standard of care) and be asked to follow their usual exercise and lifestyle routine. They will receive supportive care in the form of newsletters, covering a variety of topics including pain management, bone health, goal setting, taking control of life, and more.
62694681|NCT03743519|EXPERIMENTAL|Cherry juice|
62694682|NCT06438731|ACTIVE_COMPARATOR|Breast Milk Group|Preterm newborns in this group will be administered their own mother's milk with a sterile syringe as 1 ml single dose 2 minutes before orogastric tube insertion. During administration, the baby will not be allowed to suck the tip of the syringe and breast milk will be dripped onto the tongue. Nothing oral will be given 30 minutes before the procedure.
61937536|NCT04197752||Obese patients|Body mass index \> 30 kg/m2
61937537|NCT04197752||Non-obese patients|Body mass index \< 30 kg/m2
61937538|NCT00661973|EXPERIMENTAL|overall|
61937539|NCT00881101|EXPERIMENTAL|1|Liposomal paclitaxel
61937540|NCT05627648|ACTIVE_COMPARATOR|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
61937541|NCT05627648|PLACEBO_COMPARATOR|Placebo|Intracordal injection, once per week, 3 weeks
61937542|NCT00673946|ACTIVE_COMPARATOR|1|In this arm, patients are monitored with oximeters displaying true saturation values
61937543|NCT00673946|EXPERIMENTAL|2|In this arm, patients are monitored with oximeters with displayed saturations 3 percentage points above true values
61937544|NCT03775291||Low pre-test likelihood for sleep apnea|Subjects at low risk for having sleep apnea due to lack of known risk factors and no complaints of symptoms related to sleep apnea (e.g., excessive daytime sleepiness)
61937545|NCT03775291||High pre-test likelihood for sleep apnea|Suspected sleep apnea patients who are undergoing sleep tests as part of normal medical care or are also known to be non-compliant with therapy.
61937546|NCT00805948|EXPERIMENTAL|DeNovo|Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
62332355|NCT04684550|EXPERIMENTAL|Experimental|Health personnel who work in higher risk places (hospitals and primary level consultation) with conventional protection elements added to the application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
62490042|NCT03086434|EXPERIMENTAL|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
62694683|NCT06438731|ACTIVE_COMPARATOR|Knitted Octopus Group|The knitted octopus method will be applied to preterm newborns in this group before orogastric tube insertion. The arms of the knitted octopus will wrap around the baby's arms and legs, and its head will be on the baby's body.
62694684|NCT06438731|NO_INTERVENTION|Control Group|For preterm newborns in this group, no method will be applied before orogastric tube insertion and routine procedures will be performed.
61937547|NCT00805948|NO_INTERVENTION|Valor|Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study
61937548|NCT03600298|OTHER|Pediatric intensive care unit-nurses|"Phase I: During the month leading up to the simulation two trained observers / raters will observe the rate of Closed-Loop Communication in the pediatric intensive care unit (PICU) among study participants.~Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.~Phase II + III: During the follow up phase, trained raters will again observe the study-participating PICU staff relative to their communication behaviour in the month following simulation training (Phase II) and again three months later (Phase III)."
62332356|NCT04688346|PLACEBO_COMPARATOR|Control|Saline Pellet
62332357|NCT04688346|EXPERIMENTAL|Intervention|Racemic Epinephrine Pellet
62332358|NCT03677687|EXPERIMENTAL|Mindfulness for Physical Activity|A 6-week mindfulness programme (2 hours per week) aimed at increasing physical activity in underactive participants.
62490043|NCT03086434|ACTIVE_COMPARATOR|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
62490044|NCT01768260|ACTIVE_COMPARATOR|Enhanced External conterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
62490045|NCT01768260|ACTIVE_COMPARATOR|aspirin|The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
62490046|NCT03369496||MoNNET-HA Panel|Adults 25 years and older residing in the Montreal Metropolitan Area
62490047|NCT03306277|EXPERIMENTAL|Onasemnogene Abeparvovec-xioi|One-time Intravenous administration of onasemnogene abeparvovec-xioi at the therapeutic dose.
62490048|NCT00735319|NO_INTERVENTION|A|In the 7 control Capital Health community health centers, babies will be followed up according to the current policy. Bilirubin determinations will be performed at the discretion of the visiting nurse if the infant is inappropriately jaundiced or at the request of the physician if risk factors are present. Transcutaneous Bilirubinometers will not be available in each of these 7 centers for all the duration of the study.
62694685|NCT03076151|EXPERIMENTAL|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
62697635|NCT02609594|ACTIVE_COMPARATOR|Standard of Care|Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
62697636|NCT02609594|EXPERIMENTAL|Weekly application of Amnioband|Weekly application of Amnioband plus standard of care.
61937549|NCT06008158|EXPERIMENTAL|Supportive care (APBI)|Patients undergo APBI QD on consecutive business days for 5 treatments.
61937550|NCT05833334|ACTIVE_COMPARATOR|Public health infographic (AIM 3)|Participants will view a standard public health infographic about home air radon testing and will receive information about requesting a free home air radon test kit from their state radon program.
62332359|NCT02150187|EXPERIMENTAL|HCap Formula|Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing.
62332360|NCT02150187|PLACEBO_COMPARATOR|Placebo|Same as treatment with placebo pills
62332361|NCT02385825|EXPERIMENTAL|Group 1: 10 μg RVEc|10 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
62332362|NCT02385825|EXPERIMENTAL|Group 2: 50 μg RVEc|50 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
62332363|NCT02385825|EXPERIMENTAL|Group 3: 75 μg RVEc|75 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
62332364|NCT02993224|EXPERIMENTAL|Deferasirox DT followed by deferasirox FCT|Participants were treated with deferasirox DT followed by deferasirox FCT (core phase). Those who entered the extension phase were treated with deferasirox FCT
62332365|NCT02329873|EXPERIMENTAL|Experimental group|Respiratory rehabilitation exercise training 2 times/day, 10-30 minutes per session for 4 days.
62332366|NCT02329873|NO_INTERVENTION|Control group|Control group received usual care and health education.
62332367|NCT01046448||4C|Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.
62332368|NCT00702052|EXPERIMENTAL|Everolimus|Participants received everolimus tablets, 10 mg, orally, once daily during each 28 day cycle until determination of objective tumor progression or unacceptable toxicity, or death, or consent withdrawal, or discontinuation from the study for any other reason.
62332369|NCT01784406|EXPERIMENTAL|Autonomy-supportive counselling|"2-4 autonomy-supportive conversations with an experienced nurse, educated both theoretically and practically in the method Guided Self-Determination that includes specific reflection sheets and use of advanced communication; in addition to standard care."
62332370|NCT01784406|NO_INTERVENTION|Control|Standard of care.
62332371|NCT04953949|EXPERIMENTAL|NU-MAX®|Topical Hemostat
62332372|NCT04283994|EXPERIMENTAL|Survey-based Patient/Clinician Jumpstart|The Survey-based Patient/Clinician Jumpstart Guide will be developed with two types of data: 1) EHR data; and 2) Survey data. Using automated methods and NLP/ML algorithms, the presence/absence of POLST, advance directives and DPOA documentation will be identified from both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. The survey data will be completed by patients or their surrogate/family at enrollment and will provide assessments of the following: a) preferences for discussions about goals of care; b) most important barrier and facilitator for having such discussions; and c) current goals of care. These elements are contained within the Jumpstart guides and the information is tailored to each recipient (i.e., patient, surrogate/family, or clinician).
62332373|NCT04283994|ACTIVE_COMPARATOR|EHR-based Clinician Jumpstart|The EHR-based Clinician Jumpstart Guide will be developed by using automated methods and NLP/ML algorithms to both inpatient and outpatient EHR notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation. It will not include survey-based information.
62332374|NCT04283994|NO_INTERVENTION|Usual care|Patients in this arm receive usual care; neither subjects nor providers will receive either version of the Jumpstart Guide.
62332375|NCT02426411|EXPERIMENTAL|EMA401 200 mg|2 X 50 mg capsules BID
62332376|NCT02426411|EXPERIMENTAL|EMA401 600 mg|2 X 150 mg capsules BID
62332377|NCT02426411|PLACEBO_COMPARATOR|Placebo|Placebo to match 2 capsules BID
62332378|NCT05223621||Turner|patients with Turner syndrome
62332379|NCT05223621||POI|patients with primary ovarian failure
62332380|NCT03531437|ACTIVE_COMPARATOR|Zoely|Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
62490049|NCT00735319|EXPERIMENTAL|B|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained.Depending on the level of bilirubin obtained and whether risk factors (gestational age \< 38 weeks, blood group incompatibility with DAT positive) are present or not, a different management plan will apply. The algorithm is based on curves established by Bhutani et al to predict the risk of significant hyperbilirubinemia based on predischarge bilirubin measurements.
62490050|NCT00510393|EXPERIMENTAL|1|drug eluting stent
62490051|NCT00510393|PLACEBO_COMPARATOR|2|Bare Metal Stent
62332381|NCT03531437|ACTIVE_COMPARATOR|Minidoz|Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
62490052|NCT01531816|EXPERIMENTAL|Single Arm: Study Intervention|Cycle ergometry and/or Interactive video-game
62490053|NCT04238195|EXPERIMENTAL|Treatment A|600 mg TBPM-PI-HBr (2 x 300 mg tablets) and TBPM-PI-HBr-matching placebo (2 x matching placebo tablets) administered at Hour 0 on Day 1.
61937551|NCT05833334|EXPERIMENTAL|Online health promotion intervention tailored by smoking status (AIM 3)|Participants will view an online health promotion intervention about home air radon testing, with messaging tailored based on whether the participant smokes or does not smoke. Participants will also receive information about requesting a free home air radon test kit from their state radon program.
62490054|NCT04238195|EXPERIMENTAL|Treatment B|1200 mg TBPM-PI-HBr (4 x 300 mg tablets) administered at Hour 0 on Day 1.
62490055|NCT04238195|PLACEBO_COMPARATOR|Treatment C|TBPM-PI-HBr-matching placebo (4 x matching placebo tablets) administered at Hour 0 on Day 1.
62490056|NCT04238195|OTHER|Treatment D|Positive Control - unblinded: 400 mg moxifloxacin (1 x 400 mg tablet) administered at Hour 0 on Day 1.
62490057|NCT04693611|EXPERIMENTAL|Intervention Group|"Participants who meet the inclusion criteria will be randomised to the CS intervention group or to the control group that will maintain their usual treatment.~Participants in the intervention group will participate in two CS sessions per 12 weeks besides their treatment as usual."
62490058|NCT04693611|NO_INTERVENTION|Control Group|Participants in the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed dementia-specific medication.
62490059|NCT02483507|ACTIVE_COMPARATOR|Group T: transversal|Implementation of the vascular catheter with transversal approach under ultrasound guidance
62490060|NCT02483507|ACTIVE_COMPARATOR|Group L: longitudinal|Implementation of the vascular catheter with longitudinal approach under ultrasound guidance
62490061|NCT02483507|ACTIVE_COMPARATOR|Group O: oblique|Implementation of the vascular catheter with oblique approach under ultrasound guidance
61937552|NCT05833334|EXPERIMENTAL|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Participants will view an online health promotion intervention about home air radon testing, with messaging tailored based on whether the participant smokes or does not smoke. Participants will also receive information about requesting a free home air radon test kit from their state radon program, as well as reminder messages about radon testing for about two months after initially viewing the online intervention component.
61937553|NCT05833334|EXPERIMENTAL|Focus group with educational overview (AIM 1)|Participants will participate in a focus group discussion about radon testing and will receive a brief educational overview about radon testing.
61937554|NCT04483323|ACTIVE_COMPARATOR|Group I: Intraarticular group ( IA )|Patients will receive 20 ml of 0.25% bupivacaine intra-articularly through the surgical port
61937555|NCT04483323|EXPERIMENTAL|Group II: Erector Spinae Plane Block group ( ES )|Patients will receive an ultrasound guided erector spinae plane block using 20 ml of 0.25% bupivacaine at the level of T2 transverse process
61937556|NCT00596297|EXPERIMENTAL|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
61937557|NCT00596297|ACTIVE_COMPARATOR|B|Pars plana vitrectomy only
61937558|NCT03508739|EXPERIMENTAL|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
62332382|NCT02876939|EXPERIMENTAL|HSAN III|
62332383|NCT02876939|ACTIVE_COMPARATOR|Control Subjects|
62332384|NCT01810198|ACTIVE_COMPARATOR|Cardiac CT|Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)
62332385|NCT01810198|ACTIVE_COMPARATOR|Invasive Coronary Angiography|Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography
62332386|NCT05006898|EXPERIMENTAL|PBO Investigational drug|Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
62490062|NCT02588911|ACTIVE_COMPARATOR|Conventional Surgery|Limb with GSV insufficiency in the same patient, randomised to conventional surgery
62490063|NCT02588911|ACTIVE_COMPARATOR|Radiofrequency Ablation|Limb with GSV insufficiency in the same patient, randomised to radiofrequency ablation
62490064|NCT04516187||Emergency care|Consecutive enrolment of acutely ill older adults in emergency care
62490065|NCT04516187||General practice|Consecutive enrolment of acutely ill older adults in general practice
62332387|NCT05006898|ACTIVE_COMPARATOR|Pilocarpine|Pilocarpine was instilled in the other oye.
62332388|NCT05006898|ACTIVE_COMPARATOR|Brimonidine|Brimonidine was instilled in the other eye.
62490066|NCT02253329|ACTIVE_COMPARATOR|Treatment during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
62490067|NCT02253329|ACTIVE_COMPARATOR|Treatment prior to sleep|Protein ingestion directly after one-legged NMES, directly prior to sleep
62490068|NCT00680940|ACTIVE_COMPARATOR|Chemotherapy|Paclitaxel + Cisplatin
62490069|NCT00680940|EXPERIMENTAL|Chemoimmunotherapy|Paclitaxel + Cisplatin + Mycobacterium w
62490070|NCT04157205|EXPERIMENTAL|Test arm|All patients. Single arm study
62332389|NCT03430687|EXPERIMENTAL|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec intravesically (10ml of 10\^6 PFU/mL) on days 1, 8, 15, 22, 29, and 36 or days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
62490071|NCT01883960||healthy adults|Inclusion criteria for healthy adults were as follows: 40-70 y/o; good cognition and cooperation; and healthy adults.
62490072|NCT01883960||stroke subjects|Inclusion criteria for subjects with brain damage by stroke were as follows: a diagnosis of first-time-onset stroke and aged 40-70 years old.
62490073|NCT01883960||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 16-18 years old.
62490074|NCT01883960||healthy children|Inclusion criteria for healthy children were as follows: ages of 6-18 y/o ; good cognition and cooperation; and healthy children.
62136299|NCT02307396|EXPERIMENTAL|Intervention|"Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study (gradual discontinuation, Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life."
62332390|NCT03917719|EXPERIMENTAL|Dose 1|Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.
62332391|NCT01273688|ACTIVE_COMPARATOR|Eccentric training only|Eccentric training only active control group (Flex-Bar)
62332392|NCT01273688|EXPERIMENTAL|Eccentric training and elbow brace|Combined eccentric training (Flex-Bar) and elbow brace (Epi-Hit)
62332393|NCT04005820|EXPERIMENTAL|children and young adults supported in one of SFCE's centers|
62332394|NCT00597935|EXPERIMENTAL|SSLF and PMT|Sacrospinous Ligament Fixation (SSLF) and Pelvic Muscle Training \& Exercises (PMT)
62332395|NCT00597935|EXPERIMENTAL|ULS and PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) and Pelvic Muscle Training \& Exercises (PMT)
62332396|NCT00597935|EXPERIMENTAL|SSLF without PMT|Sacrospinous Ligament Fixation (SSLF) without Pelvic Muscle Training \& Exercises (PMT)
62332397|NCT00597935|EXPERIMENTAL|ULS without PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) without Pelvic Muscle Training \& Exercises (PMT)
62490075|NCT01376882|EXPERIMENTAL|Acute withdrawal|Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
62490076|NCT01376882|EXPERIMENTAL|Acute caffeine-independent of withdrawal|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
62490077|NCT01376882|EXPERIMENTAL|Chronic abstinence|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
62490078|NCT01376882|EXPERIMENTAL|Acute caffeine-in state of withdrawal|Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
62490079|NCT01817595|ACTIVE_COMPARATOR|BG Star (Conventional Meter)|25 patients will use the (conventional) BG star meter in which patients will upload their readings onto a computer and send in their readings via email.
62490080|NCT01817595|ACTIVE_COMPARATOR|IBG Star Group (iPhone)|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
62490081|NCT00748566|EXPERIMENTAL|Active treatment (switch to oral Ziprasidone)|
62490082|NCT00623077|EXPERIMENTAL|Total Marrow Irradiation (MTI) with Tomotherapy|TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age), Melphalan 100 mg/m\^2, Thiotepa 500 mg/m\^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
62332398|NCT05288634|EXPERIMENTAL|Experimental|Routine maintenance and Progressive relaxation exercise practice
62332399|NCT05288634|NO_INTERVENTION|Control|Routine maintenance
62332400|NCT00678106|EXPERIMENTAL|1|
62490083|NCT00558402|EXPERIMENTAL|1|Meditation class, 90min/week for 8 weeks, with home assignments, adapted from MBCT program
62332401|NCT00121303|ACTIVE_COMPARATOR|Arm A low dose Dauno|Induction 45 mg Dauno
62332402|NCT00121303|EXPERIMENTAL|ARM B high dose Dauno|Induction 90 mg Dauno
62490084|NCT00558402|ACTIVE_COMPARATOR|2|Education
62332403|NCT00121303|NO_INTERVENTION|Arm 1 no further treatment|
62332404|NCT00121303|EXPERIMENTAL|Arm 2 Mylotarg|Post induction treatment with Mylotarg
62332405|NCT02290535||Patients|Children and Teenager of 5-18 years with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive bronchitis, obstructive pneumonia).
62332406|NCT02290535||Probands|Children and Teenager of 5-18 years without known obstructive pulmonary diseases
62332407|NCT04472364|EXPERIMENTAL|HemoPill|All participants will receive the blood detection capsule HemoPill Acute ®.
62332408|NCT05428072|EXPERIMENTAL|sugar test|Participants will undergo 3 sugar tests followed by
62332409|NCT02274584|EXPERIMENTAL|CAR T cells|Autologous 4th generation anti-CD30 CAR T cells
62490085|NCT00558402|ACTIVE_COMPARATOR|3|Respite care only, 90 mins per week for 8 weeks
62490086|NCT02928744|EXPERIMENTAL|COPD|
62490087|NCT02508233||Control|Healthy subjects (without ankle osteoarthritis) for validation of translation
62490088|NCT02508233||ankle OA|Ankle osteoarthritis patients to ensure validity of translated scale
62490089|NCT04417348|ACTIVE_COMPARATOR|Retinoic Acid|patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter
62490090|NCT04417348|PLACEBO_COMPARATOR|Sunscreen|patients with melasma treated with UV-Visible light filter alone
62490091|NCT05650307||Healthy controls|
62490092|NCT05650307||Bariatric Surgery patients|
62490093|NCT05650307||Cardiac rehabilitation patients|
62490094|NCT01137864|EXPERIMENTAL|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
62136300|NCT02307396|ACTIVE_COMPARATOR|Control|The participants receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
62136301|NCT06601218|PLACEBO_COMPARATOR|Arm 1: Placebo Cannabis|This arm will administer a placebo dose of oral cannabis (no active drug)
62136302|NCT06601218|ACTIVE_COMPARATOR|Arm 2: Active Cannabis Low|This arm will administer an active low dose of cannabis
62136303|NCT06601218|ACTIVE_COMPARATOR|Arm 3: Active Cannabis High|This arm will administer an active high dose of cannabis
62136304|NCT06601218|ACTIVE_COMPARATOR|Arm 4: Active Cannabis (THC+CBD)|This arm will administer an active dose of cannabis (THC+CBD)
62136305|NCT04876846|EXPERIMENTAL|Interventional/Observational|The Gen 3 device will be positioned on the maternal abdomen to measure light scattering and absorption for a period of about 10-20 minutes. A second measurement may be obtained for a total of up to 40 minutes. Subject's end their participation in the study after that time period.
62136306|NCT02540824|EXPERIMENTAL|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
62136307|NCT03868579|EXPERIMENTAL|Observational (pleuroscopy, medical chart review)|Patients undergo biopsy of the lining of the lung using pleuroscopy. Medical chart of patients is also reviewed.
62332410|NCT05257720||Remission|Patient with schizophrenia in remission
62332411|NCT05257720||treatment resistant|patient with treatment resistant schizophrenia
62332412|NCT05257720||controls|healthy controls
62332413|NCT05686473|EXPERIMENTAL|Patient group|Single arm study. The family with child with FASD will act as its own control in the period before intervention starts.
62332414|NCT05427071|EXPERIMENTAL|Study arm|Magnetic seed guided lumpectomy and targeted axillary dissection
62332415|NCT05329181|OTHER|Integrated cognitive behavioral therapy adapted for homeless individuals|Four homeless individuals enrolled in the Treatment First program (a social services program where treatment is offered in conjunction with temporary transitional housing), who had access to stable and sober housing milieus, received the integrated cognitive behavioral treatment.
62332416|NCT05008913|EXPERIMENTAL|[14C]Adavosertib|Patients will receive a single administration of \[14C\]adavosertib as an oral solution on Day 1.
62332417|NCT06553274|EXPERIMENTAL|Individualized nutrition intervention|Full-time clinical nutrition pharmacists evaluate the nutritional status of enrolled patients and design individualized nutrition management programs
62332418|NCT06046495|EXPERIMENTAL|PLB1004|PLB1004 given as a mono-therapy in dose escalation and dose expansion phase.
62332419|NCT05120622|EXPERIMENTAL|Tremelimumab|Patients who will receive local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab
62332420|NCT01720615|NO_INTERVENTION|Propofol or Sevoflurane|General anesthesia
62332421|NCT03778983||Pediatric Live Transplantation Group|Children who underwent pediatric Ltx at RenJi Hospital before 12 month, and now age between 2 and 7 years;
62332422|NCT04087343|EXPERIMENTAL|Meals plus exercise|
62332423|NCT04087343|ACTIVE_COMPARATOR|Meals only|
62332424|NCT02024893||National womens water- polo team|Observational study-members of the national womens waterpolo team participating in formal team training and tournaments for the 2014-2015 season.
62136308|NCT05213312|EXPERIMENTAL|NIT+NCT Group (Arm A)|"1. Neoadjuvant immunotherapy : Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;~2. Neoadjuvant chemotherapy (investigator's choice) : Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.~3. MIE : Esophagectomy plus two/three field lymphadenectomy, 4-6 weeks after neoadjuvant therapy.~4. Adjuvant immunotherapy : 4-6 weeks after operation, (for subjects with non-pCR) Nivolumab injection, 240mg intravenous infusion, Q2W for 16 weeks, followed by 480mg intravenous infusion, Q4W. The maximum duration of adjuvant Nivolumab therapy is one year."
62136309|NCT05213312|PLACEBO_COMPARATOR|NCT Group (Arm B)|"1. Placebo: NS ivgtt (dose, frequency and duration same as the Nivolumab);~2. Neoadjuvant chemotherapy (investigator's choice) : Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.~3. MIE : Esophagectomy plus two/three field lymphadenectomy, 4-6 weeks after neoadjuvant therapy.~4. Adjuvant immunotherapy : 4-6 weeks after operation, (for subjects with non-pCR) Nivolumab injection, 240mg intravenous infusion, Q2W for 16 weeks, followed by 480mg intravenous infusion, Q4W. The maximum duration of adjuvant Nivolumab therapy is one year."
62136310|NCT03878979|EXPERIMENTAL|Newly diagnosed SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN.
62136311|NCT03878979|EXPERIMENTAL|Recurrence of SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred.
62136312|NCT04540003|EXPERIMENTAL|Access to School Based Health Centre|Of the eight school in the intervention arm, four schools will be linked to a school based health center (SBHC) at Sprucecourt or Nelson Mandela Park Public Schools (established in partnership with the department of Pediatrics at St. Michael's hospital) and four schools will be linked to a SBHC at Parkdale Public School (established in partnership with St. Joseph's Health Centre). SBHC pediatricians will attend School Support Team (SST) meetings at all intervention schools and students with developmental concerns identified at the SST meetings will be referred to the SBHC.
62332425|NCT02024893||National mens handball team|Observational study-Twenty men , members of the national , over 18 years old handball team preparing for the european championships for summer 2014
62332426|NCT02024893||National womens volleyball team|20 players who are part of the women's national olympic volleyball team
62332427|NCT00337376|EXPERIMENTAL|1|
62332428|NCT04221906|EXPERIMENTAL|BOS-475 0.5%|Daily application of BOS-475 0.5%
62332429|NCT04221906|EXPERIMENTAL|BOS-475 1%|Daily application of BOS-475 1%
62332430|NCT04221906|EXPERIMENTAL|BOS-475 2%|Daily application of BOS-475 2%
62490095|NCT01137864|NO_INTERVENTION|Control|Patients not receiving infectious disease specialist advice
62697637|NCT02609594|EXPERIMENTAL|Biweekly application of Amnioband|Biweekly application of Amnioband plus standard of care.
62697638|NCT06194838|NO_INTERVENTION|Comparator Baseline|The subject will wear the Ossur OFM-2, a passive mechanical knee which is the most commonly used knee for K2 users, for 3 months, as well as in the lab to complete outcome measures.
62490096|NCT02803879|EXPERIMENTAL|Cardiogoniometry (CGM)|All patients attending clinic for follow up appointments following the implantation of a CRT device will be eligible for inclusion in the study. If they consent for enrolment in the study each patient will undergo a series of 4 CGM recordings whilst in their follow up appointment. They will undergo each of these during different pacemaker settings. These are: 1) No pacing, 2) Paced from the right ventricular lead; 3) Paced from the left ventricular lead and 4) Paced from both ventricular leads. After this has been done the participants involvement in the study will have finished.
62490097|NCT05262322||All Participants (Group 1; Retrospective)|All participants' data will be collected retrospectively from medical records 12 months prior to the date of diagnosis of a first ischaemic stroke attributable to nonvalvular AF
62490098|NCT05262322||Subset of All Participants (Group 2; Prospective)|A subset of participants from Group 1 who were initiated on apixaban, edoxaban or rivaroxaban for secondary prophylaxis of stroke will take part in this prospective component of the study, whereby data on their management pathway (treatments and follow-up appointments) and patient-reported outcomes will be collected for 6 months from the date of first dose of DOAC treatment.
62332431|NCT04221906|PLACEBO_COMPARATOR|Active ingredient-free vehicle cream|Daily application of vehicle cream
62332432|NCT04221906|ACTIVE_COMPARATOR|Daivonex cream|Daily application of Daivonex cream (calcipotriol 0.005%)
62332433|NCT04221906|ACTIVE_COMPARATOR|Betnesol-V cream (betamethasone 0.1%)|Daily application of Betnesol-V cream (betamethasone 0.1%)
62332434|NCT04258332|OTHER|High Salt Diet then Low Salt Diet|"The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure.~The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg)."
62332435|NCT04258332|OTHER|Low Salt Diet then High Salt Diet|"The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg).~The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure."
62332436|NCT03422406||HH group|Group (participants) with pre-gestational history of undergoing hysterosalpingography (HSG) using an oil-soluble iodinated contrast medium
62332437|NCT03422406||Non-HH group|Group (participants) without pre-gestational history of undergoing hysterosalpingography (HSG)
62490099|NCT01924286|EXPERIMENTAL|Prednisone|Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
62490100|NCT01924286|PLACEBO_COMPARATOR|Placebo|Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
62490101|NCT03406598||Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
62694686|NCT06645483|EXPERIMENTAL|ChatGPT Group|"In this group, students will receive ChatGPT-assisted education for the first two weeks of the Emergency and Disaster Management course. ChatGPT will be integrated into the course to answer student questions, explain topics, and provide customized content aligned with the learning objectives. For the following two weeks, students will be taught using traditional instructional methods (lecture-based teaching)."
62136313|NCT04540003|NO_INTERVENTION|Control Arm: Standard of care|Of the eight schools assigned to the control condition, four will be in the South East area of the city closer to Nelson Mandela Park PS and four will be in the South West area of the city closer to St. Josephs Health Center. The eight schools will be subject to standard of care which is: when a child is identified by the SST (no pediatrician present), students identified with developmental concerns are advised to access a pediatric/developmental assessment in the community.
62136314|NCT05793996|ACTIVE_COMPARATOR|Experimental: 1|Drug: Ferinject ® (Ferric carboxymaltose)
62136315|NCT05793996|OTHER|Comparison Group: 2|Diet therapy, without drug therapy
62332438|NCT05255055|EXPERIMENTAL|Manual Therapy Group|Manipulation of the high dorsal region in extension. Cervical mobilizations. Massage therapy. Suboccipital inhibition. Once a week.
62332439|NCT05255055|EXPERIMENTAL|Therapeutic Exercise Group|Recruitment and strengthening of the cervical flexors. Isometric cervical exercises with self-resistance. Shoulder girdle strengthening exercise. Alternating days.
62332440|NCT02040194|EXPERIMENTAL|AM-101 injection|AM-101
62332441|NCT02040194|PLACEBO_COMPARATOR|Placebo injection|Placebo
62332442|NCT03766334|EXPERIMENTAL|Diabetes Diet+Highland Barley Diet|Diabetes Diet+Highland Barley Diet(20g, thrice-daily)
62332443|NCT03766334|NO_INTERVENTION|Diabetes Diet|only Diabetes Diet
62332444|NCT05565300|EXPERIMENTAL|Cycling combined with cognitive tasks|
62332445|NCT05565300|ACTIVE_COMPARATOR|Cycling|
62136316|NCT05793996|NO_INTERVENTION|Control Group: 3|Without therapy
62136317|NCT04776096|EXPERIMENTAL|Bepotastine besilate 1,5% preservative free|Bepotastine besilate 1,5% in preservative-free bottle, administered once a day during the morning.
62136318|NCT04776096|ACTIVE_COMPARATOR|Olopatadine hydrochloride 0,2% with BAK|Olopatadine hydrochloride 0,2% with BAK as preservative, administered once a day during the morning.
62332446|NCT05808348||COVID-19 Group|Demographic and clinical information, Numerical Pain Rating Scale, Falls Efficacy Scale International, Baecke Physical Activity Questionnaire
62697639|NCT06194838|EXPERIMENTAL|Ossur Power Knee|The subject will wear the Ossur Power Knee for 3 months, as well as in the lab to complete outcome measures.
62136319|NCT06120218|EXPERIMENTAL|Emergent Stenting in Anterior circulation|Emergent Carotid Stenting in acute ischemic stroke caused by tandem occlusions
62490102|NCT02272335|EXPERIMENTAL|CB Stress Management|The Cognitive-Behavioral Stress Management (CBSM) intervention arm is a closed, structured group intervention that offers 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the Cancer Wellness and Education (CW) condition as well. i.e. Group Sessions
62490103|NCT02272335|ACTIVE_COMPARATOR|Cancer Wellness (CW)|Enhanced Breast Cancer Wellness and Education (CW). The CW condition consists of 10 weekly sessions that are roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain (e.g., National Cancer Institute, Susan G. Komen Foundation, American Cancer Society).i.e. Group Sessions
62490104|NCT03673267|EXPERIMENTAL|Nutricity|
62490105|NCT03866265|ACTIVE_COMPARATOR|Supplement Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a food supplement capsule (containing 0.125 g of FGE-Salmon-PLs) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the food supplement will now be administered the placebo capsules for 28 days (a placebo capsule per day)"
62490106|NCT03866265|PLACEBO_COMPARATOR|Placebo Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a placebo capsule (containing 0.125 g of glycerin) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the placebo capsules will now be administered the food supplement capsules for 28 days (a food supplement capsule per day)"
62490107|NCT04385485|EXPERIMENTAL|Active mobilisation|The patient see an occupational therapist 1-3 days after surgery. A splint is made to immobilise the wrist and work as a extension block for the MCP-joints. This splint has to be worn day and night for 4 weeks. Another splint that immobilise the distal interphalangeal (DIP) joint and the proximal interphalangeal (PIP) joints are worn whenever the patient is not exercising. During active exercise the patient follows a strict protocol with both active and passive training and increasing number of repetitions. The rehabilitation is proceeding for 3 months.
62490108|NCT04385485|ACTIVE_COMPARATOR|Passive mobilisation with place and hold|1-3 days after surgery the patient gets a new plaster that immobilise the wrist and work as an extension block for the MCP-joints. The occupational therapist attach rubberbands to the nails of all the fingers and the training is done passively with active hold according to a strict protocol. The training with rubberbands is done during 4 weeks. After that the rehabilitation is active. The rehabilitation is proceeding for 3 months.
62490109|NCT06089395|EXPERIMENTAL|Jiajian Guishen granules group|Jiajian Guishen granules + coenzyme Q10 simulant
62490110|NCT06089395|ACTIVE_COMPARATOR|coenzyme Q10 group|Jiajian Guishen granules simulant+ coenzyme Q10
62136320|NCT06120218|EXPERIMENTAL|Emergent Stenting in Posterior circulation|Emergent Extracranial Vertebral Stenting in acute ischemic stroke caused by tandem occlusions
62332447|NCT05808348||Healthy Group|Demographic and clinical information, Numerical Pain Rating Scale, Falls Efficacy Scale International, Baecke Physical Activity Questionnaire
62332448|NCT00816907|EXPERIMENTAL|Metformin|Encapsulated metformin 1000-2000 mg/day
62332449|NCT00816907|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules 2-4 daily
62332450|NCT03670641|EXPERIMENTAL|Insulin and CGM Intervention|10 individuals with newly diagnosed type 2 diabetes will be started on basal (glargine) bolus (lispro) insulin therapy for up to 4 weeks with titrations guided by continuous glucose monitor (Dexcom G6) to achieve euglycemia and then insulin stopped after 4 weeks with hopes of diabetes remission.
62490111|NCT00469885|OTHER|1|Usual care
62136321|NCT06097091|ACTIVE_COMPARATOR|Self-Management Education|Participants in the control group will receive an SME via weekly video calls over 6 weeks.
62136322|NCT06097091|EXPERIMENTAL|Pain Neuroscience Education|Participants in the experimental group will receive a 6-week PNE program.
62136323|NCT02663219|EXPERIMENTAL|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
62136324|NCT02663219|NO_INTERVENTION|Control|Standard of care
62136325|NCT02806674|EXPERIMENTAL|Successful treatment|
62136326|NCT02806674|EXPERIMENTAL|Refractory infection of H.pylori|
62136327|NCT05613985|ACTIVE_COMPARATOR|Arm A: Usual Care alone|
62136328|NCT05613985|EXPERIMENTAL|Arm B: system VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|
62332451|NCT03011034|EXPERIMENTAL|Talacotuzumab|Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
62332452|NCT03011034|EXPERIMENTAL|Daratumumab|Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
62332453|NCT03679663|NO_INTERVENTION|Palpation|Anesthesia performed without ultrasound
62332454|NCT03679663|EXPERIMENTAL|Ultrasound|Anesthesia performed after ultrasound
62332455|NCT00564954|EXPERIMENTAL|Dex-methylphenidate hydrochloride (Focalin XR)|20 mg capsule orally once a day for 7 days
62490112|NCT00469885|OTHER|2|Reduction
62490113|NCT04275349||Exposure group(continuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)
62490114|NCT04275349||Exposure group(uncontinuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )
62332456|NCT00564954|PLACEBO_COMPARATOR|Placebo|orally once a day for 7 days
62332457|NCT01716468|OTHER|Advanced or metastatic cancer|Patients chosen must be diagnosed with advanced or metastatic cancer of the following tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma, sarcoma, non-small cell /small cell lung, genitourinary cancers).All participants will be assigned to a ketogenic diet. There are no randomization to other separate arms since this is a safety and feasibility study.
62332458|NCT00896987|EXPERIMENTAL|1|lamotrigine
62332459|NCT00896987|ACTIVE_COMPARATOR|2|carbamazepine
62332460|NCT03135587|EXPERIMENTAL|Weight 0|The participants will not carry any loading to walk on treadmill.
62332461|NCT03135587|EXPERIMENTAL|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
62332462|NCT03135587|EXPERIMENTAL|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
62332463|NCT03135587|EXPERIMENTAL|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
62332464|NCT03135587|EXPERIMENTAL|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
62332465|NCT03135587|EXPERIMENTAL|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
62332466|NCT05550948|EXPERIMENTAL|alpha tPBM + cognitive training|three days per week for a 2-month intervention period (5 ALL and 5 HL)
62332467|NCT05550948|EXPERIMENTAL|gamma tPBM + cognitive training|three days per week for a 2-month intervention period (5 ALL and 5 HL)
62332468|NCT05550948|EXPERIMENTAL|sham tPBM + cognitive training|Sham stimulations will act as the control for this study three days per week for a 2-month intervention period (5 ALL and 5 HL)
62490115|NCT04275349||Completely unexposed group|xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)
62490116|NCT04275349||Incompletely unexposed group|xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital
62490117|NCT04112199|EXPERIMENTAL|BIV201 plus Standard of Care|BIV201 continuous infusion - treatment for two 28 day cycles.
62136329|NCT04163042|EXPERIMENTAL|Group A: Videoconferencing intervention|Participants allocated to group A will receive a behavioural support intervention via real-time videoconferencing.
62136330|NCT04163042|NO_INTERVENTION|Group B: Usual care|Participants allocated to group B will receive usual care and will be advised to continue with their regular activities of daily living.
62136331|NCT05273944|ACTIVE_COMPARATOR|Reference product-R|Caelyx® (Janssen-Cilag International NV); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Reference Product (Caelyx®) in Cycle 1, will receive the Test Product (Lipodox®) in Cycle 2. Cycle is defined as 28-42 days (RT).
62332469|NCT00547599|ACTIVE_COMPARATOR|1|20 mg tadalafil tablet
62332470|NCT01477151|ACTIVE_COMPARATOR|sevoflurane|These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
62332471|NCT01477151|EXPERIMENTAL|isoflurane|These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
62490118|NCT04112199|NO_INTERVENTION|Standard of care|Per AASLD guidelines: diuretics and therapeutic paracentesis
62490119|NCT02207764|EXPERIMENTAL|Reiki Intervention|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
62490120|NCT02207764|NO_INTERVENTION|nursing presence control|Each patient in the control group will receive usual care including the study nurse presence for the 15-minute period.
62490121|NCT00448825|EXPERIMENTAL|Topiramate|Topiramate + Cognitive Behavioral Therapy
62490122|NCT00448825|PLACEBO_COMPARATOR|Placebo|Placebo + Cognitive Behavioral Therapy
62490123|NCT04706637|EXPERIMENTAL|evogliptin|evogliptin 5 mg + metformin, oral administration once a day for 48 weeks
62136332|NCT05273944|EXPERIMENTAL|Test Product-T|Lipodox® (Sun Pharmaceutical Industries Ltd.); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Test Product (Lipodox®) in Cycle 1, will receive the Reference Product (Caelyx®) in Cycle 2. Cycle is defined as 28-42 days (TR).
62332472|NCT03169829|EXPERIMENTAL|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
62332473|NCT06555315|OTHER|Control Group|After the infant achieves full enteral feeds, the infant is started on 6 mg/kg of oral iron daily supplementation. The dose of 6 mg/kg of enteral iron was chosen based on the aforementioned recommendations with evidence of its safety, while minimizing the need to increase the enteral iron dosage if an infant were to be started on ESAs where a dose of 6 mg/kg of enteral iron supplementation is the standard practice. Phlebotomy to obtain a complete blood count, reticulocyte count, and reticulocyte hemoglobin count is pursued the Monday after starting iron supplementation and every 2 weeks thereafter to weeks to monitor hematocrit or hemoglobin levels and iron status.
62332474|NCT06555315|EXPERIMENTAL|Intervention Group|After the infant achieves full enteral feeds, the infant is started on 6mg/kg of oral iron supplementation administered every other day. The dose of 6 mg/kg of enteral iron was chosen based on the aforementioned recommendations with evidence of its safety, while minimizing the need to increase the enteral iron dosage if an infant were to be started on ESAs where a dose of 6 mg/kg of enteral iron supplementation is the standard practice. Phlebotomy to obtain a complete blood count, reticulocyte count, and reticulocyte hemoglobin count is pursued the Monday after starting iron supplementation and every 2 weeks thereafter to weeks to monitor hematocrit or hemoglobin levels and iron status.
62332475|NCT01996202|OTHER|Resected Melanoma|Subjects with resected melanoma.
62332476|NCT01996202|OTHER|Unresected Melanoma|Subjects with unresected melanoma.
62490124|NCT04706637|ACTIVE_COMPARATOR|dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
62694687|NCT06645483|ACTIVE_COMPARATOR|Traditional Teaching Group|In this group, students will receive traditional lecture-based instruction for the first two weeks of the course. For the following two weeks, they will switch to ChatGPT-assisted education.
62490125|NCT03820063|EXPERIMENTAL|PTC-Pz|"* Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1."
62490126|NCT00664053|EXPERIMENTAL|1|DHEA and Yoga
62490127|NCT00664053|ACTIVE_COMPARATOR|2|DHEA and exercise
62490128|NCT00664053|ACTIVE_COMPARATOR|3|Placebo and Yoga
62490129|NCT00664053|PLACEBO_COMPARATOR|4|Placebo and exercise
62332477|NCT02657668|EXPERIMENTAL|Treatment Group|Emotion focused therapy: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
62332478|NCT02657668|NO_INTERVENTION|Control Group|Control group: For control group interactions to be effective in therapeutic outcomes, the psycho-educational group was assigned as control group. The Psycho-educational group was conducted in four sessions (without pretest and posttest sessions). They became familiar with etiology and role of psychological factors in IBS, without any psychotherapy. Eight members were removed (because of being absent more than three sessions).
62332479|NCT04631120|ACTIVE_COMPARATOR|Standard of Care|The proposed arm will involve an initial assessment using the Clinical Dementia Rating (CDR) Scale and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score for patients and Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard educational material from the AA and Association for the Advancement of Retired Persons (AARP). Two phone sessions with a study nurse will occur post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment; a summary of these and professional education on national evidence-based guidelines will be mailed to the patient's PCP of record. Education provided in this arm will be both patient- and caregiver-centered.
62332480|NCT04631120|EXPERIMENTAL|Integrated Dementia Practice Unit Arm|"The integrated practice unit design is a coordinated, team-based, comprehensive, technology enabled, family focused care delivery design comprised of:~* Dementia Central: Nurses, physicians, psychologists, social workers, and other relevant healthcare providers that will meet monthly to review participants progress and issues. Telehealth visits would facilitate home care.~* Dementia Mobile: A nurse and lay health educator team will perform monthly visits, conduct assessments of subjects and provide education/coaching.~* Dementia Link: Technologies that facilitate communication between Dementia Central and Dementia Mobile and foster proactive collaboration/coaching for study subjects include an mHealth software that allows for real time intervention/communication between professional teams and dyads, combined with management of dyads for multiple parameters like health metrics, behavioral measures and stress management and a portal tailored to specific clinical needs."
62332481|NCT02340819|EXPERIMENTAL|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
62332482|NCT05080179|EXPERIMENTAL|Self-Benefit/Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
62332483|NCT05080179|EXPERIMENTAL|Self-Benefit/No Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. They did not read any information about the number of Pennsylvanians who downloaded the app."
62332484|NCT05080179|EXPERIMENTAL|Other Benefit/Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
62490130|NCT06448390|ACTIVE_COMPARATOR|Five plus training|"During five plus training the participants are standing in front of a wall, which is used for support of the balance. The body is lifted with the calf musculature to the maximal height that the subject can achieve. This is repeated until pain is felt in the calf musculature. Following the initiation of pain the subject performs five extra repetitions. The five extra calf raises are included to secure induction of ischemia followed by reperfusion to secure maximal training effect."
62490131|NCT06448390|ACTIVE_COMPARATOR|walking|Walking at least 30 minutes three times per week.
62490132|NCT04495543|EXPERIMENTAL|Brief-Skills for Safer Living (Brief-SfSL)|Participants with current suicidal ideation (Beck Suicide Scale \>10) will undergo Brief-SfSLtherapy
62490133|NCT05152745|PLACEBO_COMPARATOR|Placebo (OGTT)|The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
62490134|NCT05152745|EXPERIMENTAL|Intervention (OGTT plus Ginger extract)|The intervention group ingested glucose solution followed by 100 ml of ginger aqueous extract (0.2g ginger, each dose).
62490135|NCT01905605|EXPERIMENTAL|phosphatidylcholine supplementation|Phosphatidylcholine supplementation to be administered BID for 8 weeks
62490136|NCT01905605|PLACEBO_COMPARATOR|placebo supplementation|Placebo to be administered BID for 8 weeks
62490137|NCT05877326|ACTIVE_COMPARATOR|Perioperative anesthesia with a BIS target of 35|Anesthesia with a BIS target of 35
62332485|NCT05080179|EXPERIMENTAL|Other Benefit/No Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They did not read any information about the number of Pennsylvanians who downloaded the app."
62332486|NCT02668107|ACTIVE_COMPARATOR|Intervention Group (Hammock positioning)|Babies in the intervention group (IG), will be positioned supine in a hammock in the incubator, with the appropriate postural adjustments.
62332487|NCT02668107|NO_INTERVENTION|Control Group|Those selected for the control group (CG) will be placed in the incubator following the service routine.
62490138|NCT05877326|ACTIVE_COMPARATOR|Perioperative anesthesia with a BIS target of 55|Anesthesia with a BIS target of 55
62490139|NCT02811003|EXPERIMENTAL|Treatment|Treatment with Rotation Medical Bioinductive Implant
62490140|NCT01572857||first phase|"This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.~20 patients hospitalized."
62332488|NCT01633905||alcohol-dependent patients|22 recently detoxified participants diagnosed as alcohol-dependant on the basis of DSM-IV criteria who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
62490141|NCT01572857||Second phase|"Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.~30 patients hospitalized."
62490142|NCT02923336|OTHER|Smart pill|Single group, before and after, the same group is going to be its own control
62490143|NCT03637127|EXPERIMENTAL|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
62490144|NCT03637127|EXPERIMENTAL|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62490145|NCT05395416|EXPERIMENTAL|HEC74647PA+HEC110114 100 mg/200 mg|Phase II: HCV GT 1-6 participants were medicated with HEC74647PA Capsules 100 mg or200 mg once daily and HEC110114 tablets 600 mg once daily
62490146|NCT05395416|EXPERIMENTAL|HEC74647PA+HEC110114|Phase III: HCV GT 1-6 participants were medicated with HEC74647PA Capsules 100 mg /200 mg once daily and HEC110114 tablets 600 mg once daily
62490147|NCT05395416|PLACEBO_COMPARATOR|Placebo|Phase III: HCV GT 1-6 participants were medicated with HEC74647PA Placebo Capsules once daily and HEC110114 Placebo tablets once daily
62490148|NCT01282086||Adults requiring anesthesia for surgery|Adult patients requiring general anesthesia for surgery
62490149|NCT05471687|EXPERIMENTAL|Patients with CAC ≥ 300 three years ago|Patients with CAC ≥ 300 three years ago with the need for repeat screening. Adult asymptomatic diabetic patients whose risk of ischemic complications is considered major in primary prevention due to a calcium score \>300 AU and requiring iterative screening for IMS recommended every 3 at 5 years.
62490150|NCT05471687|EXPERIMENTAL|Patients with CAC between 200-299 three years ago|"Patients with CAC between 200 and 299 three years ago, with the need for a reassessment of their cardiovascular risk.~Adult asymptomatic diabetic patients whose risk of ischemic complications is considered major in primary prevention due to a calcium score that has become pathological \> 300 AU during the reassessment of their cardiovascular risk."
62490151|NCT05471687|EXPERIMENTAL|Patients with a recent positive scintigraphy (< three months)|Patients with a recent positive scintigraphy (\< three months) requiring coronary angiography Stable symptomatic diabetic adult patients, suspected of coronary insufficiency in whom the assessment included a positive scintigraphy with indication of coronary angiography in the perspective of revascularization.
62136333|NCT04359784|EXPERIMENTAL|Prevention (anakinra, lisocabtagene maraleucel)|Patients receive anakinra IV (previously SC) over 10-30 minutes daily on days 0-13 and lisocabtagene maraleucel via infusion on day 0. Patients should also undergo at screening an x-ray, PET/CT or CT, BMA and biopsy (as clinically indicated), and lumbar puncture (as clinically indicated), and at follow-up as clinically indicated. Patients also undergo blood sample collection on study.
62332489|NCT01633905||control group|22 healthy controls without any psychiatric or neurological diagnosis who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
62332490|NCT03480282|EXPERIMENTAL|Prognosis Information and Provider Scripts|Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
62332491|NCT03514758|EXPERIMENTAL|normal hearing participants|normal hearing participants with and without hearing aids
62332492|NCT02389816|PLACEBO_COMPARATOR|Placebo|Placebo tablets, orally, once daily for up to Week 8
62332493|NCT02389816|EXPERIMENTAL|Vortioxetine 10 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 8
62136334|NCT06700018||Stent thrombosis group|40 patients who have suffered cardiovascular events attributed to stent thrombosis within one year of post-stent implementation will be recruited.
62332494|NCT02389816|EXPERIMENTAL|Vortioxetine 20 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8
62332495|NCT02108600|NO_INTERVENTION|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
62490152|NCT01662050|EXPERIMENTAL|One arm for all patients.|Rituximab, Bendamustine, Cytarabine
62332496|NCT02108600|EXPERIMENTAL|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
62332497|NCT05535127|ACTIVE_COMPARATOR|"Palpation with  laryngeal handshake technique "|"With the non-dominant hand, the larynx is stabilized, the hyoid bone is identified with the thumb and index finger by palpation of the greater horns with a horizontal movement from side to side, move thumb and fingers inferiorly to locate thyroid cartilage,Once identified, its location is maintained with the middle finger and thumb, and the index finger travels towards the midline.~The index finger, already in the midline, makes a longitudinal movement downwards to determine the small depression between the cricoid and thyroid cartilage that corresponds to the cricothyroid membrane."
62490153|NCT03914105|ACTIVE_COMPARATOR|Without music|Test without music
62490154|NCT03914105|EXPERIMENTAL|With music|
62490155|NCT03379636|NO_INTERVENTION|no tape|tests are realised without any shoulder tape
62490156|NCT03379636|EXPERIMENTAL|kinesiotape|tests are realised with a kinesiotape applied according to Dr Kase model, over the deltoid muscle and over the acromioclavicular joint
62490157|NCT03379636|SHAM_COMPARATOR|sham tape|tests are realised with a sham tape, applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area
62490158|NCT06002386|EXPERIMENTAL|Vsling device|Vsling device implantation
62694688|NCT05142293||Sites selected for the same-day organisation|Patients will be admitted to the hospital and leave it on the same-day of the procedure.
62136335|NCT06700018||Control group|80 patients not having suffered stent thrombosis but will have uneventful follow-up. An effort will be made so that these patients have similar clinical presentation, baseline demographics and angiographic results post PCI and receive treatment with a similar antiplatelet regime compared to those who suffered stent thrombosis.
62136336|NCT04039906|NO_INTERVENTION|Removal of needle with existing method|Participants will remove needles from syringes with the existing method like they are already doing. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
62490159|NCT06223724||Cochlear implant electrode insertion depth estimation|Electrode insertion depth estimation using impedance telemetry data measured during cochlear implantation and at three regular follow-up visits
62490160|NCT01092455||Citrasate and heparin reduction|Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.
62490161|NCT01986647|EXPERIMENTAL|On the Move Exercise - exercise leader|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by exercise leader
61937559|NCT03508739|EXPERIMENTAL|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
62694689|NCT05142293||Sites with standard overnight hospitalization|Standard organisation with a minimum of one night's stay
61937560|NCT05936268|EXPERIMENTAL|Genacumab group|Genakumab 200mg single injection
61937561|NCT05936268|ACTIVE_COMPARATOR|cholchicine group|Colchicine 0.5mg qd po.for 12 weeks
61937562|NCT00437320|EXPERIMENTAL|Metvix Cream 160 mg/g +Metvix Vehicle Cream (1 Hour Group)|Participants were topically treated with 160 milligrams per gram (mg/g) Metvix cream on one half-face or Metvix vehicle cream on the other half-face for 1 hour at Baseline, Weeks 4 and 8. The target area was then exposed to red light \[using a large-field light emitting diode (LED) light source: Aktilite 128 lamp\] during 7 to 10 minutes to deliver a total dose of 37 Joules per centimeter square J/cm\^2. The total study duration was 20 weeks.
61937563|NCT00437320|EXPERIMENTAL|Metvix Cream 160 mg/g +Metvix Vehicle Cream (2 Hour Group)|Participants were topically treated with 160 mg/g Metvix cream on one half-face or Metvix vehicle cream on the other half-face for 2 hours at Baseline, Weeks 4 and 8. The target area was then exposed to red light (using a large-field LED light source: Aktilite 128 lamp) during 7 to 10 minutes to deliver a total dose of 37 J/cm\^2. The total study duration was 20 weeks.
61937564|NCT00437320|EXPERIMENTAL|Metvix Cream 160 mg/g +Metvix Vehicle Cream (3 Hour Group)|Participants were topically treated with 160 mg/g Metvix cream on one half-face or Metvix vehicle cream on the other half-face for 3 hours at Baseline, Weeks 4 and 8. The target area was then exposed to red light (using a large-field LED light source: Aktilite 128 lamp) during 7 to 10 minutes to deliver a total dose of 37 J/cm\^2. The total study duration was 20 weeks.
61937565|NCT03376100|ACTIVE_COMPARATOR|Control Group|Patients with distal forearm fractures randomized to Hematoma Block.
61937566|NCT03376100|ACTIVE_COMPARATOR|Intervention Group|Patients with distal forearm fractures randomized to Ultrasound guided nerve block
61937567|NCT00482261|EXPERIMENTAL|len-dex|Drug: Lenalidomide 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards; Drug: dexamethasone 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
61937568|NCT00715000|EXPERIMENTAL|1|SRO
61937569|NCT00715000|ACTIVE_COMPARATOR|2|classical hydration via intravenous infusion
61937570|NCT03150160|EXPERIMENTAL|Simbrinza + Travatan|Brinzolamide 1%/brimonidine 0.2% fixed combination + travoprost 0.004% ophthalmic solution
61937571|NCT03150160|PLACEBO_COMPARATOR|Placebo + Travatan|Placebo + travoprost 0.004% ophthalmic solution
62136337|NCT04039906|EXPERIMENTAL|Removal of needle with using ANDYs|Participants will remove needles from syringes with Andy. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
62136338|NCT01900249|ACTIVE_COMPARATOR|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%
62136339|NCT01900249|ACTIVE_COMPARATOR|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%
61937572|NCT06038981|NO_INTERVENTION|Control Group (CG).|no tranexamic acid administration.
61937573|NCT06038981|EXPERIMENTAL|TXA group.|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced.
62136340|NCT01900249|PLACEBO_COMPARATOR|Placebo|Placebo Ophthalmic Solution, 1 drop per eye twice a day for 12 weeks.
62136341|NCT06700083|EXPERIMENTAL|SAD dose 1|
62136342|NCT06700083|EXPERIMENTAL|SAD dose 2|
62136343|NCT06700083|EXPERIMENTAL|SAD dose 3|
62136344|NCT06700083|EXPERIMENTAL|SAD dose 4|
62136345|NCT06700083|EXPERIMENTAL|SAD dose 5|
62136346|NCT06700083|EXPERIMENTAL|SAD dose 6|
62136347|NCT06700083|EXPERIMENTAL|MAD dose 1|
62136348|NCT06700083|EXPERIMENTAL|MAD dose 2|
62136349|NCT06700083|EXPERIMENTAL|MAD dose 3|
62136350|NCT06700083|EXPERIMENTAL|MAD dose 4|
62136351|NCT05470088||Subjects with Autism Spectrum Disorders|
62136352|NCT05470088||Relatives of subjects with Autism Spectrum Disorders|
62136353|NCT05470088||Typically developing subjects|
62136354|NCT06145932|EXPERIMENTAL|rTMS treatment group|treated with real rTMS 1800 pulses / day,for 10 days
62136355|NCT06145932|SHAM_COMPARATOR|Sham rTMS treatment group|treated with sham rTMS 1800 pulses / day,for 10 days
62136356|NCT06052436|EXPERIMENTAL|Phase A: 5.000.000 thyTreg /kg|Allogeneic thyTreg 5.000.000
62136357|NCT06052436|NO_INTERVENTION|Phase A: standard of care|Standard of care
62136358|NCT06052436|EXPERIMENTAL|Phase B: 10.000.000 thyTreg /kg|Allogeneic thyTreg 10.000.000
61937574|NCT04410536|OTHER|Symptomatic drugs - bridge theray - mindfu|"1. abrupt withdrawal of overuse symptomatic drugs, with possibility to use indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide i.m. injection in case of vomiting;~2. oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day);~3. mindfulness practice daily with standard sessions by smartphone 6 minutes per day."
61937575|NCT02563951|EXPERIMENTAL|GNS Spray 0.5mg|One spray of GNS 0.5mg/spray into right nostril.
61937576|NCT02563951|EXPERIMENTAL|GNS Spray 1.0mg|One spray of GNS 0.5mg/spray into both left and right nostril.
61937577|NCT02563951|EXPERIMENTAL|GNS Spray 2.0mg|One spray of GNS 1.0mg/spray into both left and right nostril.
61937578|NCT02563951|ACTIVE_COMPARATOR|Kytril 1mg (IV injection)|A dose of 1mg of Granisetron IV injection (kytril 1mL, 3mg/mL/vial) will be administered as a slow IV injection (over 30 seconds)
61937579|NCT02563951|ACTIVE_COMPARATOR|Kytril 1mg (Tablet)|a single dose (kytril 1mg, one tablet) orally administered with 240mL of water
61937580|NCT03815708||wheelchair rugby players|well-trained spinal cord injured wheelchair rugby players
61937581|NCT03815708||wheelchair basketball players|well-trained spinal cord injured wheelchair basketball players
61937582|NCT04396665|EXPERIMENTAL|Precam Group (Intervention Group)|150 Women without breast cancer, aged from 25 to 50 years old
61937583|NCT04396665|NO_INTERVENTION|Control Group|150 Women without breast cancer, aged from 25 to 50 years old
61937584|NCT05261282|EXPERIMENTAL|Mindful Hand Hygiene Intervention|"Participants in the Mindful Hand Hygiene Intervention will complete the same surveys as participants in the Control Arm at baseline, post-intervention, and 6-months post-intervention. Data will also be collected on baseline hand-hygiene rates during the habituation period, intervention period, and 3-12 months post-intervention. In addition, intervention participants will be asked to complete 3 mindfulness online educational modules and attend group-facilitated discussions on mindfulness. They will be offered the option of using a mobile application program Mindfulness Coach to enhance their mindfulness practices. A key message of the intervention is using hand hygiene as a prompt to practice mindfulness."
61937585|NCT05261282|NO_INTERVENTION|Control Arm|Participants that are assigned to the control arm will be observed for hand hygiene adherence and duration during the habituation period, intervention period, and 3-12 months post-intervention. They will also be asked to complete study surveys at baseline, post-intervention and 6-months post intervention. They will not receive any of the intervention components.
61937586|NCT02517866|EXPERIMENTAL|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \<140/85 mmHg at Week 6.
61937587|NCT06679998|EXPERIMENTAL|Single administration of-AAPB-10mg group|10mg of AAPB for injection was administered as a single intravenous drip
61937588|NCT06679998|PLACEBO_COMPARATOR|Single dose - placebo -10mg group|10mg of placebo was administered as a single intravenous infusion
61937589|NCT06679998|EXPERIMENTAL|Single administration of -AAPB-25mg group|25mg AAPB for injection.The drug was administered as a single intravenous drip
61937590|NCT06679998|PLACEBO_COMPARATOR|Single dose - placebo -25mg group|25mg of placebo was administered as a single intravenous infusion
61937591|NCT06679998|EXPERIMENTAL|Single administration of -AAPB-50mg group|50mg AAPB for injection.The drug was administered as a single intravenous drip
61937592|NCT06679998|PLACEBO_COMPARATOR|Single dose - placebo -50mg group|50mg of placebo was administered as a single intravenous infusion
61937593|NCT06679998|EXPERIMENTAL|Single administration of -AAPB-75mg group|75mg AAPB for injection.The drug was administered as a single intravenous drip
61937594|NCT06679998|PLACEBO_COMPARATOR|Single dose - placebo -75mg group|75mg of placebo was administered as a single intravenous infusion
61937595|NCT06679998|EXPERIMENTAL|Single administration of-AAPB-100mg group|100mg AAPB for injection.The drug was administered as a single intravenous drip
61937596|NCT06679998|PLACEBO_COMPARATOR|Single dose - placebo -100mg group|100mg of placebo was administered as a single intravenous infusion
61937597|NCT06679998|EXPERIMENTAL|Multiple administration-AAPB-A group for injection|AAPB-A group dose for injection An intravenous drip. Once a day for 7 days
61937598|NCT06679998|PLACEBO_COMPARATOR|Multiple dosing -Placebo-A group|Placebo, Group A dose, Intravenous infusion, Once a day for 7 days
61937599|NCT06679998|EXPERIMENTAL|Multiple administration-AAPB-B group for injection|AAPB-B group dose for injection An intravenous drip. Once a day for 7 days
62136359|NCT06052436|NO_INTERVENTION|Phase B: standard of care|Standard of care
61937600|NCT06679998|PLACEBO_COMPARATOR|Multiple dosing -Placebo-B group|Placebo, Group B dose, Intravenous infusion, Once a day for 7 days
61937601|NCT02616848|EXPERIMENTAL|Everolimus, Eribulin|
62136360|NCT04872478|EXPERIMENTAL|Dose Escalation - Level 1|MRX-2843 capsules, QD - 28 day cycles
62136361|NCT04872478|EXPERIMENTAL|Dose Escalation - Level 2|MRX-2843 capsules, QD - 28 day cycles
62136362|NCT04872478|EXPERIMENTAL|Dose Escalation - Level 3|MRX-2843 capsules, QD - 28 day cycles
62136363|NCT04872478|EXPERIMENTAL|Dose Escalation - Level 4|MRX-2843 capsules, QD - 28 day cycles
62136364|NCT04872478|EXPERIMENTAL|Dose Escalation - Level 5|MRX-2843 capsules, QD - 28 day cycles
62136365|NCT04872478|EXPERIMENTAL|Expansion Arm at RP2D|MRX-2843 capsules, QD - 28 day cycles
62697640|NCT06194838|EXPERIMENTAL|Reboocon Intuy Knee|The subject will wear the Reboocon Intuy Knee for 3 months, as well as in the lab to complete outcome measures.
62136366|NCT01902914|EXPERIMENTAL|Hearing Aids, Model P02|A body-worn, local made, digital hearing aids Hearing Aids evaluation
62136367|NCT01902914|ACTIVE_COMPARATOR|Other hearing aids|Other Hearing Aids, Hearing Aids Evaluation
62136368|NCT05800236|OTHER|Gastric adenocarcinoma|patients who undergo gastrectomy
62136369|NCT06180070|EXPERIMENTAL|Ibuprofen/ Paracetamol tablets|Ibuprofen/ Paracetamol tablets (200mg Ibuprofen/ 500mg Paracetamol)
62136370|NCT06180070|ACTIVE_COMPARATOR|Nuromol® tablets|Nuromol® tablets (200mg Ibuprofen/ 500mg Paracetamol)
62136371|NCT02189174|EXPERIMENTAL|CLR457|
62136372|NCT02437422|EXPERIMENTAL|SANGUINATE|Single infusion of SANGUINATE
62332498|NCT05535127|EXPERIMENTAL|Palpation strategy plus sequential ultrasound|Palpation is performed with the previously described laryngeal handshake technique If the participant is unable to identify the location of the cricothyroid membrane with certainty, the mixed ultrasound protocol is continued. as decribed in Identification of the cricothyroid membrane with ultrasound
61937602|NCT04064385|EXPERIMENTAL|Intervention|FES cycle training will be performed on the RT300 FES cycle ideally 3 times per week for 6 weeks, each session lasting up to 90 minutes. Electrical stimulation will be delivered through up to 12 independent channels each delivering up to 140 mA current on the following muscles (both on the right and left leg): quadriceps, femoral biceps and gluteus, gastrocnemius and tibialis anterior. Abdominal and back extensor muscles may also be stimulated if the participant presents with neurological trunk weakness (SCI above T6). The FES unit will stimulate the muscles that extend the hip (gluteals), flex the knee (hamstrings) and extend the knee (quadriceps) in the correct order to bring about a cycling motion. The feet and lower legs of the participants will be strapped into the pedals and the wheelchair will be coupled in a rigid manner with the training device.
61937603|NCT04064385|NO_INTERVENTION|Control|Participants in the control group will receive usual care, consistent with standard NHS care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting approximately 90 minutes. Physiotherapists provide one to one function-oriented physiotherapy session to improve balance, muscle strength and transfer skills.
61937604|NCT03630367|EXPERIMENTAL|study group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
61937605|NCT03630367|ACTIVE_COMPARATOR|control group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous
61937606|NCT01397201|EXPERIMENTAL|BI 54903 - low dose|Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoralkane (HFA) metered dose inhaler (MDI)
61937607|NCT01397201|EXPERIMENTAL|BI 54903 - medium dose|Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI
61937608|NCT01397201|EXPERIMENTAL|BI 54903 - high dose|Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI
61937609|NCT01397201|ACTIVE_COMPARATOR|Fluticasone propionate|Fluticasone HFA MDI containing ICS plus placebo matching Respimat inhaler
61937610|NCT01397201|PLACEBO_COMPARATOR|Placebo|Placebo matching Respimat inhaler plus placebo matching HFA MDI
61937611|NCT00810693|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
61937612|NCT00810693|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
61937613|NCT00810693|PLACEBO_COMPARATOR|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks
61937614|NCT03118973|EXPERIMENTAL|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
61937615|NCT03118973|EXPERIMENTAL|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
61937616|NCT03862716|EXPERIMENTAL|Intervention|Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
61937617|NCT03862716|NO_INTERVENTION|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
61937618|NCT03221907|EXPERIMENTAL|GLA5PR GLARS-NF1 & Pregabalin placebo|GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
61937619|NCT03221907|ACTIVE_COMPARATOR|GLA5PR GLARS-NF1 placebo & Pregabalin|GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
61937620|NCT04348110|PLACEBO_COMPARATOR|Placebo tablets|
61937621|NCT04348110|EXPERIMENTAL|Blueberry Chewable Tablets|
61937622|NCT00185991|ACTIVE_COMPARATOR|Once daily Gentamicin|
62136373|NCT04200287|EXPERIMENTAL|Young adult female (YA-F) cancer survivors|YA-F cancer survivors will complete a baseline survey (T1) of sociodemographic and patient reported outcomes (PRO) and then will be sent a link to access the decision aid tool (website) with instructions to review the website before their upcoming visit. A follow-up survey (T2) will be emailed 4-weeks post-baseline, prior to their clinic visit, to evaluate website access and PROs. A post-visit survey (T3) will be emailed 6- weeks post-baseline (after their survivorship care visit) to assess PROs.
62136374|NCT03836222|EXPERIMENTAL|PCS499 MR Tablet Prototype 2|600 mg single dose
62136375|NCT03836222|ACTIVE_COMPARATOR|Trental MR tablet 400mg|single dose
62136376|NCT03836222|EXPERIMENTAL|PCS499 MR Tablet Prototype 4|600mg single dose
62136377|NCT03836222|EXPERIMENTAL|PCS499 MR Tablet Prototype 1|600mg single dose
62136378|NCT03836222|ACTIVE_COMPARATOR|Trental MR Tablet|400 mg multiple dose
62136379|NCT03836222|EXPERIMENTAL|PCS499 MR Tablet 900mg|multiple dose
62136380|NCT03836222|EXPERIMENTAL|PCS499 MR Tablet 600mg|multiple dose
62136381|NCT06381739|EXPERIMENTAL|ChAd-triCoV/Mac|ChAd-triCoV/Mac
62136382|NCT06381739|PLACEBO_COMPARATOR|Control|Placebo
62490162|NCT01986647|ACTIVE_COMPARATOR|Standard program - exercise leader|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by exercise leader
61937623|NCT00185991|ACTIVE_COMPARATOR|Every eight hour Gentamicin|
61937624|NCT01141387||Patients at the intervention sites|The intervention sites will receive the results of the patient-reported depression severity collected during the phone interviews on a monthly basis. The patients in the intervention arm will be interviewed by phone once per month for 6 months.
62136383|NCT00732849|NO_INTERVENTION|1|Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
62136384|NCT00732849|NO_INTERVENTION|2|Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
62136385|NCT00732849|EXPERIMENTAL|3|Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
62332499|NCT05535127|ACTIVE_COMPARATOR|Identification of the cricothyroid membrane with routine ultrasound|"With the patient on a supine stretcher position, neck extended, with a linear transducer and ultrasound gel, a cross-sectional evaluation of the airway is performed, identifying the cartilaginous referents of the airway. In this case, the midline referent will be the union of the laminae of the thyroid cartilage. The midpoint of the hyperechoic image is located between both referents (MCT).~Next, tracheal rings are identified, the transducer is moved laterally and a 90° turn is performed for axial evaluation of the MCT. The aim is to preserve the same anatomical landmarks already identified in the transverse plane, the cephalocaudal distance between the thyroid cartilage and the cricoid is evaluated, locating the midpoint with the help of the acoustic shadow generated by a yelco without a needle. Based on these 2 measurements, the topographical location of the MCT will be marked with a visible ink marker under UV light, which will serve as a benchmark for comparison."
62332500|NCT05054673|EXPERIMENTAL|intervention|PALFIQUE universal adhesive (Tokuyama self-cure universal adhesive)
62332501|NCT05054673|ACTIVE_COMPARATOR|control|3M™ ESPE™ single bond Universal Adhesive
62332502|NCT06354270|EXPERIMENTAL|Test toothpaste|Participants will dose the toothbrush with a ribbon of toothpaste, across the full brush head and will brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening), for approximately 56 days making sure to brush the sensitive areas of the two 'test teeth' carefully first. Participants who wish to rinse after brushing will be instructed to rinse with 10 milliliter (ml) water using graduated rinsing cup provided.
62332503|NCT06354270|ACTIVE_COMPARATOR|Reference toothpaste (Negative control)|Participants will dose the toothbrush with a ribbon of toothpaste, across the full brush head and will brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening) for approximately 56 days. Participants who wish to rinse after brushing will be instructed to rinse with 10 ml water using graduated rinsing cup provided.
62332504|NCT00198445|EXPERIMENTAL|Bromfenac|Topical bromfenac ophthalmic solution 0.1%
62332505|NCT00198445|PLACEBO_COMPARATOR|Placebo|Vehicle of bromfenac
62332506|NCT04967508|EXPERIMENTAL|SB17 (Proposed Ustekinumab Biosimilar)|
62332507|NCT04967508|ACTIVE_COMPARATOR|Stelara® (Ustekinumab)|
62332508|NCT00986258|EXPERIMENTAL|Tapentadol Prolonged Release|"Other Names:~* Nucynta~* Palexia"
62332509|NCT00657631|EXPERIMENTAL|A|Acceptance and Commitment Therapy will be administered to all subjects.
62136386|NCT00732849|EXPERIMENTAL|4|Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
62136387|NCT06116929|OTHER|Patients with Hodgkin's disease|
62332510|NCT05913960|SHAM_COMPARATOR|Placebo stimulation|The sham group of MDD will receive sham rTMS stimulation.
62332511|NCT05913960|ACTIVE_COMPARATOR|accelerated intermittent theta burst stimulation|Stimulation site: According to the localization of neural orientation navigation system, magnetic resonance data was read in Brainsight software, and three-dimensional brain reconstruction was carried out. The stimulation target was located in the coordinates of Montreal Neurological Institute (MNI), which was located in the left dorsolateral prefrontal cortex BA46(-44, 40, 29).The treatment intensity was 100% exercise threshold, and a TBS stimulus series was stimulated for 2 seconds, including 10 times of 3 intra plexus stimuli of 50Hz and 5Hz intraplexus stimuli, 10s of interval, repeated 60 times, that is, a total of 1800 pulses per treatment, 10 times a day, 50 minutes interval, a total of 18000 pulses per day, continuous for 5 days.
62332512|NCT05913960|ACTIVE_COMPARATOR|high frequency stimulation|Stimulation site: According to the localization of neural orientation navigation system, magnetic resonance data was read in Brainsight software, and three-dimensional brain reconstruction was carried out. The stimulation target was located in the coordinates of Montreal Neurological Institute (MNI), which was located in the left dorsolateral prefrontal cortex BA46(-44, 40, 29).Treatment intensity was 100% exercise threshold, continuous 10Hz stimulation, repeated 75 times, that is, 3000 pulses per treatment, 6 times a day, 50 minutes interval, a total of 18000 pulses per day, continuous stimulation for 5 days.
62332513|NCT05897346|EXPERIMENTAL|Intervention group|Secondary school students will be required to join a 3-phase 'Learning while serving' program.
62332514|NCT05897346|OTHER|Control group|Secondary school students will be only required to attend a 3-hour training workshops.
62332515|NCT02539082|PLACEBO_COMPARATOR|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
62490163|NCT01986647|ACTIVE_COMPARATOR|On the Move - staff activity personnel|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by activity personnel.
62136388|NCT06116929|OTHER|Controls without Hodgkin's disease|
62332516|NCT02539082|EXPERIMENTAL|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
62332517|NCT01218932|EXPERIMENTAL|A|Primaquine only, followed by chloroquine/primaquine, followed by chloroquine only
62332518|NCT01218932|ACTIVE_COMPARATOR|B|Primaquine alone, followed by chloroquine, followed by chloroquine/primaquine
62332519|NCT00462098|EXPERIMENTAL|HBO|Subject receives 40 HBO sessions at 2 atmospheres of pressure over 4 weeks
62332520|NCT00462098|ACTIVE_COMPARATOR|Control|non-HBO comparison group
62332521|NCT06346288|EXPERIMENTAL|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of commercial risankizumab at pre-dose and 1 hour after dosing on Day 1, on Days 4 (± 1), 8 (± 2), 15 (± 3), 29 (± 3), and pre-dose on Day 57 (± 3).~Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study."
62490164|NCT01986647|ACTIVE_COMPARATOR|Standard - staff activity personnel|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by staff activity personnel
62490165|NCT04391829|EXPERIMENTAL|SARS-CoV-2 positive men|Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.
62490166|NCT04197154|EXPERIMENTAL|1. Control nocebo group|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
62332522|NCT01239186||Oligozoospermia|infertile patients presenting a reduced sperm count (less than 20 Millions of spermatozoa/ml)
62332523|NCT02249286|EXPERIMENTAL|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production.
61937625|NCT01141387||Patients at the usual care sites|The usual care sites will receive the results of the patient-reported depression severity at the end of the study. Patients in the usual care arm will be interviewed at 3 months and 6 months post study enrollment.
61937626|NCT02103010||HNC patients|head and neck cancer patients
61937627|NCT04840173|EXPERIMENTAL|Music at home|Caregivers will use Singing, music listening, or moving with music twice a week for 30 minutes with their care recipient.
61937628|NCT03784417|EXPERIMENTAL|EUS-guided laser ablation|Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.
61937629|NCT02869503||Patients with colorectal cancer diagnosis|
61937630|NCT05030246|EXPERIMENTAL|Surufatinib 250mg/Toripalimab 240mg|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody（Toripalimab） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
61937631|NCT04398251|EXPERIMENTAL|Uric acid drug control group|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week
61937632|NCT04398251|ACTIVE_COMPARATOR|Non-drug control group|They are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.
61937633|NCT03161093|EXPERIMENTAL|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
61937634|NCT03161093|EXPERIMENTAL|Fasinumab dosing regimen 2|Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral
61937635|NCT03161093|EXPERIMENTAL|Fasinumab-matching placebo and naproxen|
61937636|NCT03161093|EXPERIMENTAL|Fasinumab-matching placebo and naproxen-matching placebo|
61937637|NCT00942955||CLT|The patients whose blood are analyzed by conventional central laboratory.
61937638|NCT00942955||POCT|the patients group whose lab analyze by POCT device.
61937639|NCT05179850||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
61937640|NCT05179850||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
61937641|NCT01453660||Cisplatin-Based Chemotherapy Group|GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.
61937642|NCT01453660||Surgery-Only Group|GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.
61937643|NCT03844607|EXPERIMENTAL|Active tDCS|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
61937644|NCT03844607|SHAM_COMPARATOR|Sham tDCS|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
62136389|NCT04826822|EXPERIMENTAL|Treatment|"After randomisation (Day 1): Spironolactone \[100 mg 1x/day\] + dexamethasone \[2 mg 2x/day, 12/12h\] Days 2-12\*: Spironolactone \[50 mg 2x/day, 12/12h\] + dexamethasone \[2 mg 2x/day, 12/12h\] Days 13-20: Spironolactone \[25 mg 2x/day, 12/12h\] Days 21-28: Spironolactone \[25 mg 1x/day\] Standard treatment is according to the treatment protocol for 2019-nCoV infection.~\*In case of cortisol levels above 100 nmol/L on days 3 and 4, the dexamethasone dose should be increased to 3 mg in the morning and in the evening (total 6 mg per day)."
61937645|NCT06063772|EXPERIMENTAL|Clevidipine|"Once consented, patients will be randomized into one of two groups using a block randomization table. The treatment arm will receive clevidipine. Clevidipine comes from the manufacturer in a ready to use formulation. It requires no preparation by pharmacy, nursing or physician staff. All patients randomized to receive clevidipine will be in the experimental cohort."
61937646|NCT06063772|PLACEBO_COMPARATOR|Placebo (Lactated Ringers)|The Control arm will receive Lactate Ringers as placebo. All patients randomized to receive lactated ringers will be in the control cohort. Lactated Ringers is stored at room temperature (25°C)
62136390|NCT04826822|ACTIVE_COMPARATOR|Control|Patients receiving standard-of-care treatment for SARS-CoV-2 infection as regulated by the relevant guidelines of the Ministry of Healthcare of the Russian Federation
62136391|NCT03209700|EXPERIMENTAL|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
62490167|NCT04197154|EXPERIMENTAL|2. High-pain nocebo group|Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
62490168|NCT04197154|EXPERIMENTAL|3. High-threat nocebo|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
61937647|NCT05142722|PLACEBO_COMPARATOR|Placebo|one placebo tablet once daily
61937648|NCT05142722|EXPERIMENTAL|obicetrapib 10mg|one 10mg obicetrapib tablet once daily
62136392|NCT04911166|EXPERIMENTAL|Atezolizumab and Interleukin-12 Gene Therapy|
62332524|NCT02249286|NO_INTERVENTION|No intervention|
62332525|NCT03916250|EXPERIMENTAL|PF-06700841 cream 0%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
62332526|NCT03916250|EXPERIMENTAL|PF-06700841 cream 0.1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
62694690|NCT06405412||Mild malnutrition|Patients will be divided into 3 groups according to the MUST malnutrition score in the preoperative period (BMI, weight loss, acute illness/oral feeding difficulty). (mild, moderate, severe malnutrition)
61937649|NCT03550885|EXPERIMENTAL|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
62136393|NCT05172271|SHAM_COMPARATOR|Sham TEST|Anesthesia alone
62136394|NCT05172271|EXPERIMENTAL|Transcranial Electric Stimulation Therapy (TEST)|TEST involves bifrontal electrical brain stimulation at a dose below the seizure threshold, applied in the same manner as standard electroconvulsive therapy (ECT), with scalp electrodes, under anesthesia, using a standard ECT device (modified or unmodified) that can deliver a range of doses below seizure threshold.
62136395|NCT02755805|EXPERIMENTAL|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
62332527|NCT03916250|EXPERIMENTAL|PF-06700841 cream 0.3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
62490169|NCT02786784|OTHER|healthy control|patients with patellofemoral pain
62490170|NCT04205539|EXPERIMENTAL|Dexmedetomidine|All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.
62490171|NCT04224753|EXPERIMENTAL|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
62490172|NCT00642811|EXPERIMENTAL|1|Aspirin + Ticagrelor
62694691|NCT06405412||Moderate malnutrition|Patients will be divided into 3 groups according to the MUST malnutrition score in the preoperative period (BMI, weight loss, acute illness/oral feeding difficulty). (mild, moderate, severe malnutrition)
62694692|NCT06405412||Severe malnutrition|Patients will be divided into 3 groups according to the MUST malnutrition score in the preoperative period (BMI, weight loss, acute illness/oral feeding difficulty). (mild, moderate, severe malnutrition)
62136396|NCT02755805|PLACEBO_COMPARATOR|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
62136397|NCT01990508|EXPERIMENTAL|Targeted beverage education and financial incentives|Study subjects receive monthly letters with beverage education and financial incentives for not purchasing sugar-sweetened beverages
62136398|NCT01990508|SHAM_COMPARATOR|Control|Monthly letters with generic nutrition information only
62490173|NCT00642811|ACTIVE_COMPARATOR|2|Aspirin + Clopidogrel
62694693|NCT06572397|EXPERIMENTAL|H-1337 1.0% Ophthalmic Solution b.i.d.|One drop H-1337 twice daily in the both eyes for 7 days
62490174|NCT02832960|EXPERIMENTAL|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
62490175|NCT02832960|PLACEBO_COMPARATOR|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
62694694|NCT03938740|EXPERIMENTAL|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
61937650|NCT03550885|EXPERIMENTAL|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
61937651|NCT00535366|EXPERIMENTAL|Tiotropium+salmeterol+fluticasone|
61937652|NCT00535366|EXPERIMENTAL|Tiotropium+salmeterol+ciclesonide low|
61937653|NCT00535366|EXPERIMENTAL|Tiotropium+salmeterol+ciclesonide high|
61937654|NCT00535366|PLACEBO_COMPARATOR|Placebo|
62136399|NCT03344094||MS-ocrelizumab treated|ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start
62136400|NCT03344094||MS untreated|age- and sex-matched untreated MS controls
62136401|NCT03344094||Healthy control|age- and sex-matched untreated healthy controls
62136402|NCT03344094||MS interferon-treated|MS with ongoing interferon-beta therapy
62136403|NCT06030700||Laboratory|Simulated kitchen setting including purchase, prep, eating and cleanout
62136404|NCT03932513|EXPERIMENTAL|Treatment A: inarigivir soproxil|Inarigivir 400 mg once per day for 6 weeks (2800mg/week).
62332528|NCT03916250|EXPERIMENTAL|PF-06700841 cream 1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
62332529|NCT03916250|EXPERIMENTAL|PF-06700841 cream 3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
62490176|NCT05341154|ACTIVE_COMPARATOR|Ketamine group|"An anesthesiologist who is not involved in the study will prepare the intervention, ketamine1 mg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~1. Induction with propofol (1-2 mg/kg body weight).~2. Esmeron (1 mg/kg body weight).~3. Isoflurane is a volatile anesthetic agent in 50% O2 and air.~4. Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~5. All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
61937655|NCT05748470|EXPERIMENTAL|Test group|
61937656|NCT05748470|ACTIVE_COMPARATOR|Control group|
61937657|NCT06310200|EXPERIMENTAL|Intervention Arm|Subjects will receive 1 mL of 4% lidocaine (0.5mL in each nostril) administered by intranasal atomization or 0.9% normal saline administered by intranasal atomization.
61937658|NCT06310200|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive normal saline placebo mixed with an edible bittering agent added to blind the participant from recognizing the taste of the lidocaine containing solution.
61937659|NCT03802227|EXPERIMENTAL|Group 1|NKTR-181 400 mg and oxycodone IR placebo
61937660|NCT03802227|EXPERIMENTAL|Group 2|Oxycodone IR 40 mg and NKTR-181 placebo
61937661|NCT00237185|EXPERIMENTAL|imatinib mesylate 400 mg|400 mg once daily
61937662|NCT00237185|EXPERIMENTAL|imatinib mesylate 600 mg|600 mg once daily
61937663|NCT00055224|EXPERIMENTAL|Healthy Participants|Substudy 1/ Neutral, Predictable, and Unpredictable Responses (NPU): physiological responses to different threat of shock conditions - no shock, unpredictable shock, and predictable-cued shock. Substudy 2/ Working Memory Task: Subjects performed a working memory task under threat of shock and in safety. Substudy 5 /Face Stroop Task: Stimuli were pictures of faces exhibiting anger, disgust, fear, happiness, sadness, and surprise intermixed with pleasant, unpleasant, and neutral pictures. Substudy 7/ Active Avoidance Signal Task (AAST) and Sustained Attention Response Task (SART): In AAST, participants performed paradigms which tested whether threats impact the initiation and the inhibition of behavioral responses. In SART, participants were presented with stimuli and either initiated a go or nogo response. Pilot Tasks: Participants completed one/more tasks: nerve stimulation, short speech, air burst, saliva samples, squeezer task, virtual reality task, or computer-based task.
61937664|NCT00055224|EXPERIMENTAL|Anxiety subjects|Substudy 1/ Neutral, Predictable, and Unpredictable Responses (NPU): physiological responses to different threat of shock conditions - no shock, unpredictable shock, and predictable-cued shock. Substudy 2/ Working Memory Task: Subjects performed a working memory task under threat of shock and in safety. Substudy 5 /Face Stroop Task: Stimuli were pictures of faces exhibiting anger, disgust, fear, happiness, sadness, and surprise intermixed with pleasant, unpleasant, and neutral pictures. Substudy 7/ Active Avoidance Signal Task (AAST) and Sustained Attention Response Task (SART): In AAST, participants performed paradigms which tested whether threats impact the initiation and the inhibition of behavioral responses. In SART, participants were presented with stimuli and either initiated a go or nogo response. Pilot Tasks: Participants completed one/more tasks: nerve stimulation, short speech, air burst, saliva samples, squeezer task, virtual reality task, or computer-based task.
61937665|NCT04728165||control group|Age (+/-5 yrs) and BMI (+/- 5 kg/m2) matched control male subjects for inclusion in the control group
61937666|NCT04728165||psoriasis group|Males between the ages of 18 and 70 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group
61937667|NCT05025254||PD patients|This is an observational study. The PD patient group will consist of participants who self-report that they have a diagnosis of Parkinson's disease
61937668|NCT05025254||Healthy controls|This is an observational study. The healthy control group will consist of participants who self-report that they do not have a diagnosis of Parkinson's disease
61937669|NCT05393674|EXPERIMENTAL|Experimental|"Fedratinib (Cycle 1: Run-in-Phase with 400 mg QD for 4 weeks, Cycle 2-12: 400 mg QD, Dose modifications will be allowed based on observed toxicity to a 300 mg or a 200 mg daily dose) + Nivolumab (Cycle 2-12: 240 mg, i.v., q2w)~Patients will receive study treatment until loss of response, death or study discontinuation for other reasons."
61937670|NCT04951804|ACTIVE_COMPARATOR|EUS-CPN with bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL preceded by injection of 10 ml of bupivacaine 0.5%.
62136405|NCT03932513|EXPERIMENTAL|Treatment B: inarigivir soproxil|Inarigivir 400 mg three times per week for 6 weeks (1200mg/week).
62136406|NCT03624972|ACTIVE_COMPARATOR|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
62490177|NCT05341154|ACTIVE_COMPARATOR|Dexmedetomidine group|"An anesthesiologist who is not involved in the study will prepare the intervention, Dexmedetomidine 1 μg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~1. Induction with propofol (1-2 mg/kg body weight).~2. Esmeron (1 mg/kg body weight).~3. Isoflurane is a volatile anesthetic agent in 50% O2 and air.~4. Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~5. All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
62694695|NCT03938740|EXPERIMENTAL|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
61937671|NCT04951804|EXPERIMENTAL|EUS-CPN without bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL only.
61937672|NCT05934942|EXPERIMENTAL|Yasmin® (Reference treatment (R)) followed by BI 1358894 and Yasmin® (Test treatment (T))|
61937673|NCT06681389|EXPERIMENTAL|NP-201 Acetate Injection- Part A|24 healthy participants across 3 cohorts will receive NP-201 acetate injection
61937674|NCT06681389|PLACEBO_COMPARATOR|Placebo|Matching placebo
62136407|NCT03624972|EXPERIMENTAL|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
62694696|NCT05737680|ACTIVE_COMPARATOR|Hydroxychloroquine arm|Hydroxychloroquine 400mg daily
62694697|NCT05737680|ACTIVE_COMPARATOR|Colchicine arm|Colchicine continued
62694698|NCT06201611|EXPERIMENTAL|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
62694699|NCT06201611|ACTIVE_COMPARATOR|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
62694700|NCT06201611|ACTIVE_COMPARATOR|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
61937675|NCT05895864|EXPERIMENTAL|Utidelone|Utidelone Injection: 35 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with recurrent or metastatic urothelial carcinoma Number of Cycles: until progression or unacceptable toxicity develops or up to 8 cycles.
61937676|NCT03853343|PLACEBO_COMPARATOR|Placebo|3 capsules per day (1 before each meal) of cellulose
61937677|NCT03853343|ACTIVE_COMPARATOR|Seaweed extract|3 capsules per day (1 before each meal) of seaweed extract
61937678|NCT06363357|EXPERIMENTAL|Duchenne muscular dystrophy participants|This study compares variables before and after wearing the shoulder orthosis in patients with Duchenne muscular dystrophy.
61937679|NCT06302127|NO_INTERVENTION|Control|During the study, control participant will be provided with existing essential public health service including quarterly follow-ups and annual physical examination, and be advised to see their usual provider for care, as appropriate.
61937680|NCT06302127|EXPERIMENTAL|Intervention|Intervention group will receive the risk-stratified integrated CVD management (RISIMA) model consisting of 5 core elements provided as a package: (1) Team-based care; (2) Risk-stratified care pathway; (3) Strengthened health education; (4) Financial incentives for integration of care; (5) Supporting health information system.
61937681|NCT05863273||Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
61937682|NCT01070758|EXPERIMENTAL|Intervention|Single arm open label study
61937683|NCT00036296|EXPERIMENTAL|1|75mg per day (in 3 doses) Talampanel for 22 days
61937684|NCT00036296|PLACEBO_COMPARATOR|2|3 doses a day for 22 days
61937685|NCT00612027||1|patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.
61937686|NCT06235307|EXPERIMENTAL|motivational interviewing|
61937687|NCT06235307|ACTIVE_COMPARATOR|Control|
61937688|NCT06142630|NO_INTERVENTION|Supine group|Patients remained supine
61937689|NCT06142630|EXPERIMENTAL|Prone group|Patient remained prone
61937690|NCT06142630|EXPERIMENTAL|Lateral position group|Patient remained in a lateral position
62136408|NCT03624972|NO_INTERVENTION|Clinician Arm|Clinicians were consented in order to have their clinic visits audio recorded. No outcomes data were collected from clinician participants.
62694701|NCT02918942|EXPERIMENTAL|Tympanoseal|All subjects will receive the Tympanoseal device.
61937691|NCT02186431|EXPERIMENTAL|history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers with a history of corneal infiltrative events
61937692|NCT02186431|ACTIVE_COMPARATOR|without a history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers without a history of corneal infiltrative events.
61937693|NCT06681454||Lichtenstein Repair Cohort|This group consists of adult male patients who underwent bilateral inguinal hernia repair using the Lichtenstein technique. The Lichtenstein method involves the use of a synthetic mesh to provide support to the weakened abdominal wall, minimizing the risk of recurrence and promoting quicker recovery.
61937694|NCT06681454||Darn Repair Cohort|This group comprises adult male patients who underwent bilateral inguinal hernia repair using the Darn technique. The Darn method is a tension-free repair technique that utilizes the patient's own tissue without the use of mesh, aimed at reducing postoperative pain and complication rates.
61937695|NCT01193842|EXPERIMENTAL|Arm A (VR-DA-EPOCH)|Patients receive vorinostat PO QD on days 1-5; rituximab IV on day 1; etoposide IV over 24 hours, doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on days 1-4; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
61937696|NCT01193842|EXPERIMENTAL|ARM B (DA-R-EPOCH)|Patients receive rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
61937697|NCT03113916|EXPERIMENTAL|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
61937698|NCT03113916|NO_INTERVENTION|Enhanced usual care|Printed materials
61937699|NCT04670172||Chronic rhinosinusitis patients|Adult chronic rhinosinusitis patients capable of using a mobile application.
61937700|NCT06015971|ACTIVE_COMPARATOR|standard hypercaloric, hyperproteic oral supplement|
61937701|NCT06015971|EXPERIMENTAL|omega-3 enriched oral supplement|
61937702|NCT03843827|ACTIVE_COMPARATOR|Group A (LMA Group)|Active Comparator: Group A (LMA Group) LMA-Classic™ laryngeal mask airway (Classic™LMA) by Dr. Archie Brain into clinical practice in 1988 brought about a revolution in anesthesia. In the literature, there are over 2,500 studies supporting Classic™ LMA usage. Following the success and popularity of Classic™ LMA, many different variants of this device have been designed and marketed,trying to offer a simple and effective alternative to the endotracheal intubation.
61937703|NCT03843827|ACTIVE_COMPARATOR|Group B (I gel Group)|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature,thus minimising air leakage
62136409|NCT06016400|EXPERIMENTAL|intervention group|Alfacalcidol Drops,1ug a day,40day
62694702|NCT03982173|EXPERIMENTAL|previously treated patients with solid tumors|previously treated patients with solid tumors harboring a high mutational load.
62490178|NCT05341154|PLACEBO_COMPARATOR|Placebo group|"An anesthesiologist who is not involved in the study will prepare the intervention, normal saline 0.9% in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~1. Induction with propofol (1-2 mg/kg body weight).~2. Esmeron (1 mg/kg body weight).~3. Isoflurane is a volatile anesthetic agent in 50% O2 and air.~4. Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~5. All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
62490179|NCT04174053|EXPERIMENTAL|Temperature measurement|"enteric capsule will be ingested every 24 hours during aplasia. Temperature measurement will be made continuously during aplasia.~In parallel, auricular temperature will be measure every 4 hours during aplasia."
62490180|NCT02368262||CP- incontinent|Children with CP and daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
62490181|NCT02368262||CP- continent|Children with CP without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
62490182|NCT02368262||NoDev - incontinent|Children with normal development with daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
62490183|NCT02368262||NoDev - continent|Children with normal development without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
62490184|NCT05284539|EXPERIMENTAL|Arm A: EGFR mutant Group|EGFR mutant Group.
62490185|NCT05284539|EXPERIMENTAL|Arm B: ALK fusion Group|ALK fusion Group.
62490186|NCT05284539|EXPERIMENTAL|Cohort C: ROS1 fusion Group.|ROS1 fusion Group.
62332530|NCT03916250|EXPERIMENTAL|White petrolatum|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
62332531|NCT05252884|EXPERIMENTAL|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy.
62332532|NCT05252884|ACTIVE_COMPARATOR|routine postoperative calcium and calcitriol|The patient will receive Calcium carbonate + calcitriol
62332533|NCT05556824|ACTIVE_COMPARATOR|Drug Product|Panosyl-isomaltooligosaccharide (PIMO) liquid 1 g (1.5 ml) per day for 8 weeks
62332534|NCT05556824|PLACEBO_COMPARATOR|Placebo|Placebo liquid (1.5 ml) per day for 8 weeks
62332535|NCT00516269|EXPERIMENTAL|Methylphenidate then Placebo|Methylphenidate 18 mg oral daily for 2 weeks then Placebo oral daily for 2 weeks
62332536|NCT00516269|EXPERIMENTAL|Placebo then Methylphenidate|Placebo oral daily for 2 weeks then Methylphenidate 18 mg oral daily for 2 weeks
62332537|NCT01914705|ACTIVE_COMPARATOR|Landmark Procedure|Using Landmarks to guide SCVC placement
62332538|NCT01914705|ACTIVE_COMPARATOR|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
62332539|NCT06197945|EXPERIMENTAL|Mulligan bent leg raise|The Mulligan Bent Leg Raise technique will be performed with 3 repetition, 3-4 times with 20 sec hold and one minute rest between each repetition.
62332540|NCT06197945|EXPERIMENTAL|Mulligan bent leg raise with Bowen therapy|The Mulligan Bent Leg Raise technique will be performed with 3 repetition, 3-4 times with 20 sec hold and one minute rest between each repetition. After that Bowen therapy will be applied on hamstring bilateral.
62490187|NCT02665962|OTHER|Calorie Restricted (CR) program|The intervention will provide individualized CR program, meal replacement products and nutritional counseling sessions.
62490188|NCT01545349|EXPERIMENTAL|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10\^10 LGG per capsule will be given to subjects with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
62490189|NCT01545349|PLACEBO_COMPARATOR|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
62332541|NCT02242825||Patients with hypertension and diabetes mellitus|
62332542|NCT02568033|EXPERIMENTAL|A|"Chemotherapy:~for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle~for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle~Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions~Schedule is:~2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy."
62332543|NCT02419183||Sequence A|Participants will receive a computer administered Word List Recall (WLR) \[SAMSTAR\] on Test Day 1 and an examiner addminstered WLR \[RAVLT\] on Test Day 2 of the study.
62332544|NCT02419183||Sequence B|Participants will receive an examiner-administered WLR \[RAVLT\] on Test Day 1 and a computer adminstered WLR \[SAMSTAR\] on Test Day 2 of the study.
62332545|NCT00735124|ACTIVE_COMPARATOR|Single pre-op dose of Gabapentine|Active treatment with the study drug
62332546|NCT00735124|PLACEBO_COMPARATOR|Placebo|Placebo arm for blinding the medication
62490190|NCT02911909|ACTIVE_COMPARATOR|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
62490191|NCT02911909|EXPERIMENTAL|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
62490192|NCT06138561||Cisplatin-Ineligible Metastatic Bladder Cancer|"Participants receiving standard of care non-cisplatin based therapy (carboplatin-based chemotherapy, enfortumab vedotin plus pembrolizumab or immunotherapy) and will complete study procedures as outlined below:~* Baseline visit with questionnaires.~* Complete surveys every 3 weeks by telephone or by in-office visit for 8 months.~* Optional follow-up phone calls every 6 months for up to 3 years."
62136410|NCT06016400|PLACEBO_COMPARATOR|control group|Placebo
62332547|NCT03744780|EXPERIMENTAL|ACT Workshop for Emotional Eating|All participants will be assigned to a one-day intervention using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
62136411|NCT01981031|EXPERIMENTAL|A|Drug: BioChaperone® Combo
62136412|NCT01981031|ACTIVE_COMPARATOR|B|Drug: Humalog® Mix25
62136413|NCT04733833|EXPERIMENTAL|Arm 1|VB-201 + standard of care
62490193|NCT02632253|ACTIVE_COMPARATOR|Moderate intensity continuous exercise|"Patients perform two weekly supervised MICE session on a cycling ergometer per week plus one self monitored 30-60 min MICE training of choice at home.~MICE is performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down)."
62490194|NCT02632253|EXPERIMENTAL|High intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min.~Additionally patients perform one self monitored 30-60 min MICE training of choice per week at home."
62490195|NCT01355835|ACTIVE_COMPARATOR|[STNmono]|Conventional stimulation on subthalamic contacts
62490196|NCT01355835|EXPERIMENTAL|[STN+SNr]|Combined subthalamic and nigral stimulation
62490197|NCT03170739|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery.
62490198|NCT03170739|EXPERIMENTAL|Dopamine|Dopamine 3ug/kg/min ivpump at the beginning of surgery.
62694703|NCT06020079|EXPERIMENTAL|laughter yoga group|Laughter yoga was administered to the intervention group twice a week, on Tuesdays and Fridays, for 5 weeks, in a total of 10 sessions (the duration of each session was 50 minutes). Apart from the first and last sessions, eight sessions of the laughter yoga intervention were held via an Internet program with on-line meeting option due to the COVID-19 pandemic that started in March 2019. For the feasibility of online sessions, opinions were obtained from experts who provide laughter yoga leadership training.
62694704|NCT06020079|NO_INTERVENTION|Control group|no intervation
62694705|NCT06327165||pregnant women|Women undergoing cesarean section under spinal anesthesia with ANI monitor applied
62694706|NCT06639802|EXPERIMENTAL|Experimental group|"HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) T0he customized functional goals that were previously discussed with the parents (e.g., drinking on one's own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.).~The whole environment is arranged in such a way that children perceive the therapy as fun.~Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest."
62694707|NCT06340269|EXPERIMENTAL|MEX-CD1 Slow Low volume CVVHD|Patients enrolled in the treatment arm will receive 3 sessions of MEX-CD1 treatment in addition to standard of care
61937704|NCT04962048|EXPERIMENTAL|pulse-synchronized negative pressure (PSNP) device|One leg will be treated with the pulse-synchronized negative pressure (PSNP). The other leg serves as non-treated control.
61937705|NCT00359918|EXPERIMENTAL|Prehospital facilitated PCI|
62136414|NCT04733833|ACTIVE_COMPARATOR|Arm 2|Standard of care
61937706|NCT00359918|ACTIVE_COMPARATOR|Primary PCI|
62136415|NCT06699420|EXPERIMENTAL|Qishenyiqi Dripping Pill|
62136416|NCT06699420|PLACEBO_COMPARATOR|Placebo|
62136417|NCT04798261||Patients with acute pulmonary embolism|
62136418|NCT04354389|EXPERIMENTAL|DAS181 b.i.d.+ standard local care for COVID-19|4.5 mg DAS181 b.i.d nebulized inhalation for 10 consecutive days + standard local care for COVID-19
62136419|NCT04354389|PLACEBO_COMPARATOR|Placebo+ standard local care for COVID-19|nebulized inhalation for 10 consecutive days + standard local care for COVID-19
62136420|NCT04354389|EXPERIMENTAL|DAS181 q.d.+ standard local care for COVID-19|4.5 mg placebo q.d. nebulized inhalation for 10 consecutive days + standard local care for COVID-19
62136421|NCT05611346|NO_INTERVENTION|Therapeutic education program|
62136422|NCT05611346|EXPERIMENTAL|Therapeutic education program and Hypnosis|
62136423|NCT04203394|EXPERIMENTAL|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
62136424|NCT04203394|EXPERIMENTAL|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
62136425|NCT02574806||Healthy newborn|Healthy newborn at term of healthy mother.
62490199|NCT03170739|EXPERIMENTAL|Dexmedetomidine+dopamine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery.
62490200|NCT03170739|NO_INTERVENTION|Control group|No intervention
61937707|NCT04180774|EXPERIMENTAL|Melanoma Adjuvant|Patients with completely resected stage III or IV melanoma receiving GMV in the adjuvant setting
61937708|NCT04180774|EXPERIMENTAL|Melanoma Therapeutic|Patients with incompletely resected stage III or IV melanoma receiving GMV in the therapeutic setting
61937709|NCT04180774|EXPERIMENTAL|Renal Cell Adjuvant|Patients with completely resected stage III or IV kidney cancer receiving GMV in the adjuvant setting
61937710|NCT04180774|EXPERIMENTAL|Renal Cell Therapeutic|Patients with incompletely resected stage III or IV kidney cancer receiving GMV in the therapeutic setting
62136426|NCT02574806||Preeclamptic newborn|Newborn at term of mother with pre-eclampsia with severity features.
62136427|NCT02368626|EXPERIMENTAL|RF ablation treatment|'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction
62136428|NCT05819242||Healthy Adults|
62136429|NCT05819242||Rheumatoid Arthritis|
62136430|NCT05819242||Carpal Tunnel Syndrome|
62332548|NCT05818527|EXPERIMENTAL|vibrating device arm|the patients will use vibrating device 20 mins per day
62332549|NCT05818527|NO_INTERVENTION|control group|control group using no devices
62490201|NCT04949737||Helicobacter Pylori detection|Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).
62490202|NCT00621660|EXPERIMENTAL|Acupuncture|
62490203|NCT00621660|PLACEBO_COMPARATOR|Sham|
62490204|NCT01216020|EXPERIMENTAL|cetuximab plus radiotherapy|Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
62332550|NCT05464446||Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy (DMD) between the ages of 5 and 18 who were diagnosed with DMD by a specialist physician as a result of gene analysis and/or muscle biopsy and their families were included in the study.
61937711|NCT01737502|EXPERIMENTAL|Treatment (auranofin and sirolimus)|Patients receive auranofin PO on days 1-28 and sirolimus PO on days 1-28 (days 8-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62490205|NCT01216020|ACTIVE_COMPARATOR|cisplatin plus radiotherapy|CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)
62490206|NCT01232244||Healthy young males|
62490207|NCT02202057||Parkinson's disease|Men and women with Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation and Fluoroscopic swallowing evaluation.
62490208|NCT02202057||Healthy adults|Men and women without Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation.
62490209|NCT03694535|EXPERIMENTAL|Bladder wall thermochemotherapy|Mitomycin-C application with bladder wall thermochemotherapy system after TUR bladder tumor in intermediate and high risk non muscle invasive bladder cancer
62490210|NCT00854126|EXPERIMENTAL|1|
62490211|NCT00646984|ACTIVE_COMPARATOR|1|Standard continuous antiretroviral therapy
62490212|NCT00646984|EXPERIMENTAL|2|CD-4 guided interruption arm
62490213|NCT00646984|EXPERIMENTAL|3|Viral load driven treatment interruption
62694708|NCT05345158|EXPERIMENTAL|Robotic Retroperitoneal Lymph Node Dissection|Robotic retroperitoneal lymph node dissection performed using the DaVinci robotic surgical system.
62694709|NCT05309226||Pregnant Cannabis User|"Pregnant individuals who disclose cannabis use in pregnancy~We will examine patterns of cannabis use including the type of cannabis used, amount and frequency of cannabis use during the perinatal and postpartum periods. If participant decides to stop using cannabis in pregnancy, they will not be excluded from the study."
62694710|NCT05309226||Pregnant Cannabis Non-User|Pregnant individuals who report not using cannabis in pregnancy and who have not used cannabis products for at least 3-months prior to pregnancy.
62694711|NCT05309226||Offspring of Pregnant Cannabis User|Infants born to pregnant participants who disclose cannabis use in pregnancy
61937712|NCT04020328|EXPERIMENTAL|leflunomide + low dose glucocorticoids therapy group|the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment
61937713|NCT04020328|NO_INTERVENTION|Basic conservative treatment group|the basic conservative treatment group is the delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, RAS inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy
61937714|NCT02138435||VSD-patients|Patients who had VSD closure between 1990 and 1995. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
62136431|NCT06292689|EXPERIMENTAL|Treatment|"1.Not systematically treated: 20 patients with recurrent or metastatic vulvar and vaginal cancers enrolled without systemic treatment (platinum-based doublet chemotherapy) will be treated with cardunolizumab + platinum-based doublet chemotherapy ± bevacizumab.~2.Previous systematic treatment: Twenty patients with recurrent or metastatic vulvar and vaginal cancers previously treated with systemic therapy (platinum-based doublet chemotherapy) will be enrolled as subjects receiving cardunolizumab ± investigator\&amp;#39;s choice of chemotherapy ± bevacizumab."
62136432|NCT00570700|EXPERIMENTAL|Dasatinib|Patients receive oral dasatinib once daily in the absence of disease progression or unacceptable toxicity.
62136433|NCT06132529||Post-Traumatic Headache Group|Subjects diagnosed with having post-traumatic headache complete an MRI, speech sample, and electronic daily headache diary.
62332551|NCT05281783|EXPERIMENTAL|Percutaneous Radiofrequency Ablation|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
62332552|NCT04939077|EXPERIMENTAL|CABG with hUC-MSC treatment group|In the CABG with hUC-MSC treatment group, 1×10\^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.
61937715|NCT02138435||Control|A group of healthy control subjects. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
62136434|NCT06132529||Healthy Control Group|Subjects identified as health and not having any headaches will complete an MRI and speech sample.
62136435|NCT02161146|EXPERIMENTAL|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
62136436|NCT02161146|PLACEBO_COMPARATOR|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
62136437|NCT02161146|ACTIVE_COMPARATOR|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
62136438|NCT02161146|OTHER|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
62332553|NCT04939077|NO_INTERVENTION|CABG group|CABG was performed under general anesthesia.
62332554|NCT01426425|EXPERIMENTAL|Cryoablation|Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.
62490214|NCT03543735|EXPERIMENTAL|Wisepill+SMS|
62490215|NCT03543735|ACTIVE_COMPARATOR|Wisepill-only|
62490216|NCT03543735|NO_INTERVENTION|Disulfiram-only|
62490217|NCT02670551|PLACEBO_COMPARATOR|Placebo|Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
62490218|NCT02670551|EXPERIMENTAL|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
62490219|NCT02670551|EXPERIMENTAL|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
62490220|NCT05591105||Group A:|At the end of surgery, on the recovery room, this group will receive lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minutes
62490221|NCT05591105||Group B:|At the end of surgery, on the recovery room, this group will receive placebo (normal salin solution) for 90 minutes
62490222|NCT04637360|EXPERIMENTAL|Cinacalcet treatment|hyperparathyroid dialysis patients using cinacalcet and active vitamin D for 6 months
62490223|NCT04637360|EXPERIMENTAL|traditional therapy active vitamin D|hyperparathyroid dialysis patients using traditional therapy active vitamin D without use cinacalcet for 6 months.
62490224|NCT04633863|EXPERIMENTAL|MDI - 101|Artificial tear containing arabinogalactan, trehalose and hyaluronic acid
62490225|NCT06627023|ACTIVE_COMPARATOR|19 Patients Received Implants with Conical Connections|Thirty eight patients were enrolled and randomly assigned to receive implants with conical connection. For the first arm 19 patients received implants with conical connections. A standard healing abutment was placed after 6 months for two weeks. The definitive screw-retained crowns were manufactured digitally and delivered afterwards. The soft tissue changes were traced till 12 months post-op
62490226|NCT06627023|ACTIVE_COMPARATOR|19 Patients Received Implants with Butt-Joint Connections|Thirty eight patients were enrolled and randomly assigned to receive implants with butt-joint connection. For the first arm 19 patients received implants with conical connections. A standard healing abutment was placed after 6 months for two weeks. The definitive screw-retained crowns were manufactured digitally and delivered afterwards. The soft tissue changes were traced till 12 months post-op
62136439|NCT02161146|OTHER|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
62490227|NCT00465218||1|High dose aspirin (325 mg)
62332555|NCT02241044|ACTIVE_COMPARATOR|the Combined group|The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
62332556|NCT02241044|PLACEBO_COMPARATOR|the Injection group|Injection group patients underwent distilled water alone at index endoscopy. Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
62490228|NCT00465218||2|Low dose aspirin (81 mgs) plus warfarin
62490229|NCT04132063||Generic levetiracetam|
62136440|NCT01747707|EXPERIMENTAL|docetaxel, cisplatin and S-1 (DCS)|All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2.
62136441|NCT06071702|EXPERIMENTAL|IoNIR Ridaforolimus-Eluting Coronary Stent|IoNIR Ridaforolimus-Eluting Coronary Stent System
62136442|NCT01089335||Papillary thyroid cancer|Patients with preoperatively diagnosed highly differentiated papillary thyroid cancer
62332557|NCT03459131|OTHER|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
62332558|NCT03459131|OTHER|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
62332559|NCT03306134||BETA-BLOCKERS|Patients taking beta-blockers with or without dysphagia
62332560|NCT03306134||NO BETA-BLOCKERS|Patients not taking beta-blockers with or without dysphagia
62332561|NCT03350750|ACTIVE_COMPARATOR|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
62332562|NCT03350750|SHAM_COMPARATOR|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(\>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) four months after the procedure.
62332563|NCT03374514|EXPERIMENTAL|DEX|Topical dexamethasone will be placed at a concentration of 20mg / ml in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy in the cochlear implant surgery, paying special attention to the round window membrane completely submerged in the liquid, to the insertion of the electrode assembly
62490230|NCT05016427|EXPERIMENTAL|VT301(low dose)|VT301 low dose: 8.5x10\^4 cells/kg
62490231|NCT05016427|EXPERIMENTAL|VT301(high dose)|VT301 high dose: 1.7x10\^5 cells/kg
62332564|NCT03374514|PLACEBO_COMPARATOR|SF|Sterile isotonic saline solution will be placed in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy during cochlear implant surgery, paying special attention to the fact that the round window membrane is completely submerged in the liquid, prior to insertion of the electrode array
62332565|NCT00773760||dosing|
62490232|NCT02768974|EXPERIMENTAL|OPRX-106 2 mg|Open label, 1:1 randomization ration (up to 10 subjects)
62490233|NCT02768974|EXPERIMENTAL|OPRX-106 8 mg|Open label, 1:1 randomization ration (up to 10 subjects)
62490234|NCT04406545||healthy volunteers|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
61937716|NCT02653534|EXPERIMENTAL|Intervention Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
61937717|NCT02653534|NO_INTERVENTION|Control|Routine visits by government health workers
61937718|NCT00892918|ACTIVE_COMPARATOR|Moxifloxacin|About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
62136443|NCT01089335||Tumour of uncertain malignant potential|Thyroid tumours with preoperative cytology indicating follicular neoplasia, or on cytology suspected but not proven malignancy
62136444|NCT06246253||Virtual implant placement following safe angle concept|
62136445|NCT06246253||actual implant placement following safe angle concept|
62490235|NCT04406545||cardiovascular disease and COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
62490236|NCT04406545||cardiovascular disease without COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
62694712|NCT05309226||Offspring of Pregnant Cannabis Non-User|Infants born to pregnant participants who report no cannabis use in pregnancy
62490237|NCT05726825|EXPERIMENTAL|Therapeutic Plasma Exchange (TPE)|"1 x TPE with donor Fresh Frozen Plasma (FFPs) (1.2 x individual plasma volume) within the first 6 hrs after randomization.~A second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min within 24 hours after the first intervention."
62490238|NCT05726825|NO_INTERVENTION|Standard of Care (SOC)|Non-interventional standard of care
62490239|NCT05056519|EXPERIMENTAL|Experimental group|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine
61937719|NCT00892918|ACTIVE_COMPARATOR|Gatifloxacin|About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
61937720|NCT04068610|EXPERIMENTAL|Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab|Participants in Part 1 safety run-in arm (S1) will receive intravenous (IV) infusions of FOLFOX (5-fluorouracil \[5-FU\]: 2400 mg/m\^2 over 46-48 hours \[Day 1 and 2 of every 14-day Cycle\], oxaliplatin: 85 mg/m\^2, folinic acid: 400 mg/m\^2) and bevacizumab 5 mg/kg on Day 1 of every Cycle (14-day cycle) in combination with IV durvalumab 1500 mg every 4 weeks (Q4W) and IV oleclumab 3000 mg every 2 weeks (Q2W) till 4 doses (Cycle 4) then Q4W starting on Cycle 5 Day 1 until disease progression, unacceptable toxicity, withdrawal of participant consent, or another discontinuation criterion will be met.
61937721|NCT04068610|EXPERIMENTAL|Part 2 (C1): FOLFOX + Bevacizumab|Participants in Part 2 control 1 arm (C1) will receive IV infusions of FOLFOX (5-FU: 2400 mg/m\^2 over 46-48 hours \[Day 1 and 2 of every 14-day Cycle\], oxaliplatin: 85 mg/m\^2, folinic acid: 400 mg/m\^2) in combination with IV bevacizumab 5 mg/kg on Day 1 of every Cycle (14-day cycle) until disease progression, unacceptable toxicity, withdrawal of participant consent, or another discontinuation criterion will be met.
62136446|NCT00754065|EXPERIMENTAL|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one capsule BAY86-5027 \[estradiol valerate (EV) / dienogest (DNG)\] for 26 days, followed by one capsule placebo for 2 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
62136447|NCT00754065|ACTIVE_COMPARATOR|Ortho Tri-Cyclen Lo|Daily oral administration of one capsule Ortho Tri-Cyclen Lo \[Ethinylestradiol (EE)/ Norgestimate (NGM)\] for 21 days, followed by one capsule placebo for 7 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
62332566|NCT05673863|EXPERIMENTAL|Psychological resilience training program|Children in the intervention group participated in a psychological resilience program organized as a group activity.
62136448|NCT04255706|OTHER|Biometric measurement repeatability|Biometric measurements will be performed in all patients
62136449|NCT06521424|PLACEBO_COMPARATOR|Placebo|Maltodextrin + Flavoring
62136450|NCT06521424|EXPERIMENTAL|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
62136451|NCT00989196|EXPERIMENTAL|Human-cl rhFVIII|
62490240|NCT05056519|PLACEBO_COMPARATOR|Placebo group|Healthy people in placebo group will receive a dose of placebo
62490241|NCT04672538|EXPERIMENTAL|Low transition to High Vt protocol|This arm of the study will begin with lower tidal volumes at higher respiratory rates for initial hemodynamic measurements. They will then be transitioned to the higher tidal volume at lower respiratory rate condition for repeat hemodynamic measurement.
62490242|NCT04672538|EXPERIMENTAL|High transition to Low Vt protocol|This arm of the study will begin with higher tidal volumes at lower respiratory rates for initial hemodynamic measurements. They will then be transitioned to the lower tidal volume at higher respiratory rate condition for repeat hemodynamic measurement.
62490243|NCT01529554|ACTIVE_COMPARATOR|Everolimus|Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)
62136452|NCT00989196|ACTIVE_COMPARATOR|Kogenate FS|
62136453|NCT06338540|EXPERIMENTAL|Group 1|Black caries color
61937722|NCT04068610|EXPERIMENTAL|Part 2 (E1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab|Participants in Part 2 experimental 1 arm (E1) will receive IV infusions of FOLFOX (5-FU: 2400 mg/m\^2 over 46-48 hours \[Day 1 and 2 of every 14-day Cycle\], oxaliplatin: 85 mg/m\^2, folinic acid: 400 mg/m\^2) and bevacizumab 5 mg/kg on Day 1 of every Cycle (14-day cycle) in combination with IV durvalumab 1500 mg Q4W and IV oleclumab 3000 mg Q2W till 4 doses (Cycle 4) then Q4W starting on Cycle 5 Day 1 until disease progression, unacceptable toxicity, withdrawal of participant consent, or another discontinuation criterion will be met.
62136454|NCT06338540|EXPERIMENTAL|Group 2|Dark brown caries color
62136455|NCT06338540|EXPERIMENTAL|Group 3|Light brown caries color
62136456|NCT06338540|EXPERIMENTAL|Group 4|Yellow caries color
62136457|NCT05915715|EXPERIMENTAL|McGill stabilization exercise|The patients performed the corresponding exercises 3 days a week and 10 repetitions of each exercise for a period of 6 weeks and a rest interval of 2 minutes between exercises
62136458|NCT05915715|EXPERIMENTAL|Proprioceptive neuromuscular facilitation technique|The total duration of RS will be of approximately 33 minutes
62332567|NCT05673863|NO_INTERVENTION|control group|Children in the control group did not receive any intervention. There was also no intervention for the family members accompanying the children.
62332568|NCT03637699|OTHER|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
62332569|NCT03637699|OTHER|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
62490244|NCT01529554|PLACEBO_COMPARATOR|Placebo|Placebo comparator with identical composition of tablets except everolimus
62490245|NCT01368354|ACTIVE_COMPARATOR|CLTS Arm|To induce behavioural changes by confronting the community with their open defecation behaviour. This will lead to voluntary construction and use of latrines and improved hygiene behaviour. CLTS involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination.
62490246|NCT01368354|NO_INTERVENTION|Control arm|
62490247|NCT03947905|EXPERIMENTAL|Type of visit|Single arm, non-randomized crossover design. All patients will receive both types of visits virtual and physical, and after assessments are made, participants will be classified by physicians into low, moderate or high risk for intervention.
62490248|NCT03685409|ACTIVE_COMPARATOR|Metformin-Group|Metformin hydrochloride tablets 500 mg taken orally once daily for 3 months
62490249|NCT03685409|PLACEBO_COMPARATOR|Placebo-Group|Starch placebo tablets taken orally once daily for 3 months
62490250|NCT06561581|OTHER|Acuity-Basic|
62490251|NCT06561581|EXPERIMENTAL|Acuity-Enhanced|
62490252|NCT01685008|EXPERIMENTAL|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
62490253|NCT03149900||Secukinumab|"Patients will be recruited in the Comprehensive Center for Inflammation Medicine. The study population will consist of 40 subjects (both male and female), aged 18 years and older, in whom treatment with Secukinumab is clinically indicated and according to the licensed product specifications. The study drug will be prescribed by a doctor who is independent of this study. Visit 1 will be carried out prior to the first injection of Secukinumab.~All patients will receive a number and the data will be recorded in a pseudo-anonymised form. No blinding is necessary for investigators or patients (open study), as all patients receive the same treatment (marketed product)."
62490254|NCT04190160|EXPERIMENTAL|6 months treatment|replacement of whatever pre-existing hypoglicaemic therapeutic scheme, with or without insulin, with a single daily and flexible administration of IDegLira in a pilot little group of very old diabetic patients
62694713|NCT05309226||Partners|Partners of pregnant participants enrolled in this study.
62490255|NCT02448160|EXPERIMENTAL|alfapump with albumin treatment|patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment
62490256|NCT03879187|EXPERIMENTAL|High-fat diet|Participants underwent a 7 day high-fat, high-energy diet intervention with metabolic measurements before and after
62490257|NCT00949819||no treatment|Men with previously untreated, early stage prostate cancer.
61937723|NCT01251744|EXPERIMENTAL|CMV Mothers' Group|Pregnant subjects with confirmed primary CMV infection.
62136459|NCT06698705||1-3 years|The child should wear EEG consumables accompanied by their family and be properly secured in the operating room. Induction and maintenance of Remimazolam, collection of EEG information . EEG collection covers the entire perioperative period, including preoperative awake period (or preoperative sedation period), surgical anesthesia period, and anesthesia awake period.
62332570|NCT06033339|OTHER|Blood Sampling|"Collection of 10 ml of blood on EDTA tube during:~* Standard check-up visit as a part of the standard monitoring of the disorder for homozygous and symptomatic heterozygous patients~* Specific study visit for asymptomatic heterozygous patients~* Presurgery blood test for control subjects"
62332571|NCT02197052||Computer Based Survey Arm|Participants randomized to the computer based self-completed survey arm were issued a tablet computer to answer survey questions. All participants were encouraged to ask for technical assistance if needed at any point, and like in the face-to-face interviews, electronic survey could be re-initiated at the point of discontinuation after any interruption. Those in the tablet survey arm also could complete the survey in their preferred language and all were additionally given headsets so they could use audio assist with identical, pre-recorded questions in the selected language.
62332572|NCT02197052||Face-to-face interview arm|Participants randomized to this condition were interviewed in-person by a fully bilingual (English-Spanish), bi-cultural research assistant trained in cultural humility, standard research protocols and interviewing practices. Interviews were conducted in clinical rooms in respondent's preferred language, were easily interrupted for medical care, and the survey could be re-initiated at the point of discontinuation after any interruption. Participant responses during face-to-face interviews were recorded by the research assistant on paper and later recorded electronically.
62332573|NCT00704509|EXPERIMENTAL|Bifeprunox|
62332574|NCT00704509|PLACEBO_COMPARATOR|Placebo|
62332575|NCT00704509|ACTIVE_COMPARATOR|Quetiapine|
62332576|NCT02469181||FD(Fabry disease) group|28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
62332577|NCT03691610|EXPERIMENTAL|Group 1|MenACYW conjugate vaccine + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
62332578|NCT03691610|ACTIVE_COMPARATOR|Group 2|MENVEO® + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
62332579|NCT03691610|EXPERIMENTAL|Group 3|MenACYW conjugate vaccine at 17 to 19 months of age and 20 to 23 months of age
61937724|NCT01251744|EXPERIMENTAL|CMV Newborns' Group|Offsprings of the CMV Mothers' Group, also tested for CMV infection, comprising infants that were live born.
62332580|NCT03691610|ACTIVE_COMPARATOR|Group 4|Menactra® at 17 to 19 months of age and 20 to 23 months of age
62332581|NCT03817255|EXPERIMENTAL|Substance use|In this screening intervention, participants complete a substance use questionnaire (=intervention).
62332582|NCT03817255|ACTIVE_COMPARATOR|Physical activity|In this screening control condition, participants complete a physical activity questionnaire (=control).
62332583|NCT03477526|EXPERIMENTAL|COPD patients (GOLD stage III-IV)|
62332584|NCT03477526|ACTIVE_COMPARATOR|IPF patients|
62332585|NCT00997048|EXPERIMENTAL|Laying open|
62490258|NCT06159647|EXPERIMENTAL|Alcohol Messages|Participants view 12 messages: 10 messages related to health topics (2 messages for each of 5 randomly selected health topics from among all health topics) and 2 control messages.
62490259|NCT06550869|EXPERIMENTAL|QLB-LSAL|The patient received Anterior Quadratus Lumborum Block at the lateral supra-arcuate ligament under laparoscopic direct vision.
62490260|NCT06550869|ACTIVE_COMPARATOR|LA|The patient received local infiltration anesthesia.
62490261|NCT05432115|EXPERIMENTAL|Tid group|Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
62490262|NCT05432115|ACTIVE_COMPARATOR|Qid group|Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid
62490263|NCT00452218|EXPERIMENTAL|Open|
62694714|NCT06636955||passive immunization|Patients having received a passive immunization
62694715|NCT06636955||no passive immunization|Patients not having received a passive immunization
62694716|NCT05603780|OTHER|group 1|one cohort
62490264|NCT01859637|EXPERIMENTAL|Zarzio®/Filgrastim HEXAL®|Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
61937725|NCT00597974||Patients having angioplasty (case)|Patients undergoing carotid artery angioplasty and/or stent-supported angioplasty for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
62332586|NCT00997048|ACTIVE_COMPARATOR|Sinus excision|
62332587|NCT04065477|EXPERIMENTAL|Experimental|The experimental group will receive treatment program designed to train strategic cognitive functions. Sessions will last 50 minutes and take place twice per week for 16 weeks.
62332588|NCT04065477|NO_INTERVENTION|Control group|"The control group will receive no active treatment and will be treated as a no-contact control group."
62332589|NCT06554925||Female|Female sex undergoing cardiac surgery
62332590|NCT06554925||Male|Male sex undergoing cardiac surgery
62490265|NCT00213590|NO_INTERVENTION|1|the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L
62490266|NCT00213590|EXPERIMENTAL|2|the low-exposure group the cyclosporine AUC0-12h target was 50% usual target or 2.2 (2.0 to 2.6, range) mg•h/L
61937726|NCT00597974||Patients having angiography (control)|Patients undergoing coronary angiography for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
62332591|NCT05520814|EXPERIMENTAL|metastatic nasopharyngeal carcinoma|
62490267|NCT04145635|EXPERIMENTAL|Aortix Device|Aortix Pump, Aortix Delivery System, Introducer Set, Aortix Control System, Aortix Retrieval System
62694717|NCT05919498||Patients in the FASTRACS-RCT intervention arm|"The individuals in this group are patients in the intervention arm of the FASTRACS-RCT study.~Once their follow-up for the FASTRACS-RCT study is completed, they will be contacted to participate in the RECOVA-FASTRACS survey. They will be asked to conduct an individual semi-directive interview.~Patients may agree to provide contact information for people who have accompanied them on their return-to-work journey."
62332592|NCT05686616|ACTIVE_COMPARATOR|SGLT2 inhibitor group|Participants will take dapagliflozin propanediol hydrate 12.3 mg once a day for a total of 48 weeks.
62332593|NCT05686616|NO_INTERVENTION|Conventional treatment group|Participants will continue the existing medications for severe TR.
62332594|NCT04243135|ACTIVE_COMPARATOR|ESWT group|All patients in both groups were applied with a hot pack for 40-minutes, transcutaneous electrical nerve stimulation for 30-minutes (100 Hz frequency and 60 milliseconds pulse duration), and a home-based exercise program around the knee for 30-minutes per day for three weeks. Also, each patient in group 1 received shockwaves of continuous frequency and intensity (2000 shocks, 10 Hz, 2.0 to 3.0 bar), while the second group of patients received sham-ESWT. In group 1, for a total of 3 weeks, r-ESWT was undertaken with 2000 pulse each time at a week interval totaling 6000 pulse by using a radial shock wave therapy system (vibrolith ortho tip ESWT (ELMED Turkey)).
62332595|NCT04243135|SHAM_COMPARATOR|Sham-ESWT group|The other group received sham-ESWT at 0.1 bar in the same area. The patients were placed supine with the affected knee at 90 degrees flexion at each treatment session. The shock wave probe was held stationary on painful points around the knee or at the patellofemoral and tibiofemoral borders of the target knee.
62332596|NCT02260102|ACTIVE_COMPARATOR|urinary tract infections|Children requiring antibiotic treatment for urinary tract infections. Intervention: blood sampling for assay of temocillin
62332597|NCT02260102|ACTIVE_COMPARATOR|cholangitis|"Cirrhotic children requiring antibiotic treatment due to suspicion of cholangitis.~Intervention: blood sampling for assay of temocillin"
62332598|NCT02260102|ACTIVE_COMPARATOR|hepatic transplant|Children requiring antibiotic prophylaxis following a hepatic transplant. Intervention: blood sampling for assay of temocillin
62332599|NCT03898336|EXPERIMENTAL|broad-spectrum micronutrients|broad-spectrum micronutrients description: capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
62332600|NCT03898336|PLACEBO_COMPARATOR|placebo|capsules containing placebo
62332601|NCT00672529|ACTIVE_COMPARATOR|Intervention Group|
62332602|NCT00672529|PLACEBO_COMPARATOR|Placebo Group|
62332603|NCT01839292|ACTIVE_COMPARATOR|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
62332604|NCT01839292|ACTIVE_COMPARATOR|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
62332605|NCT04041076||Elective Surgical Patients in Tuen Mun Hospital|Patients who received elective surgical operation in Tuen Mun Hospital from 1July 2012 to 30June 2018
62490268|NCT02144805|ACTIVE_COMPARATOR|Suturing in a single layer|The technique used for single layer to close the uterine incision following cesarean sectio
61937727|NCT04650776|EXPERIMENTAL|High heat strain|participants exercised at 75% of their heart rate maximum (HR max) and wore light athletic clothing (t-shirt and shorts)
61937728|NCT04650776|EXPERIMENTAL|Low heat strain|participants exercised at 50% HR max, wearing protective firefighter clothing (jacket and trousers)
61937729|NCT01689168|EXPERIMENTAL|Counseling plus chiropractic adjustments|
61937730|NCT01689168|ACTIVE_COMPARATOR|Counseling alone|
61937731|NCT02169284|EXPERIMENTAL|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
62490269|NCT02144805|ACTIVE_COMPARATOR|Suturing in two layer|The technique used for two layer technie to close the uterine incision following cesarean sectio
62490270|NCT04210544|EXPERIMENTAL|Dietary protein|Postprandial effects after consuming 20 g of a experimental dietary protein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
61937732|NCT02169284|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
62332606|NCT02755844|EXPERIMENTAL|Olaparib, metformin and metronomic cyclophosphamide|"Phase 1: Dose escalation scheme: a continual reassessment method (CRM) will be used to guide inclusion of patients in drug dose levels pre-specified based on observations of dose-limiting toxicity.~Phase 2 (expansion of cohort): once RP2D will be determined, additional patients will be enrolled, in order to obtain preliminary data about efficacy in a 2 stage Simon's design."
61937733|NCT03565913|EXPERIMENTAL|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
61937734|NCT03565913|ACTIVE_COMPARATOR|CaAcS|Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
62490271|NCT04210544|ACTIVE_COMPARATOR|Casein|Postprandial effects after consuming 20 g of casein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
62490272|NCT04210544|PLACEBO_COMPARATOR|Water|Postprandial effects after consuming 20 g of water mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
62490273|NCT04269122||Part 1|30 eligible subjects will be asked to participate in 3 inpatient visits, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of \[1-13C\]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
62490274|NCT04269122||Part 2|90 eligible subjects will be asked to participate in 1 inpatient visit, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of \[1-13C\]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
62490275|NCT00903292|ACTIVE_COMPARATOR|A, erlotinib|If EGFR mutation found then assigned to thyrosine kinase inhibitor (erlotinib)
62332607|NCT01093924|NO_INTERVENTION|self-guided weight loss maintenance|15-month self-guided weight loss maintenance group will receive monthly reminders to maintain their weight loss and newsletters that contain health information.
62332608|NCT01093924|EXPERIMENTAL|DVD group|15-month weight loss maintenance intervention deliver via DVD.
62332609|NCT01093924|EXPERIMENTAL|face-to-face group|15-month weight loss/weight loss maintenance intervention delivered in a group setting
62332610|NCT06060223|EXPERIMENTAL|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
62332611|NCT06060223|NO_INTERVENTION|Control|Patients in the control group will participate in standard educational practices implemented in the clinic.Patients will be contacted by phone 3 months after discharge. Data collection forms will be applied as a final test.
62332612|NCT04486924|EXPERIMENTAL|Globe Mapping and Ablation System|
62332613|NCT03665376|EXPERIMENTAL|ERAS arm|Preoperative: Counseling and education about the ERAS program; Oral intake until 6 hours before the surgery; Carbohydrate drinks load; No mechanical bowel preparation; Antithrombotic prophylaxis (Tinzaparin 3500 IU) Intraoperative: Spinal anaesthesia (15 mg hyperbaric Bupivacaine + 200mcg intrathecal Morphine); Intravenous Ceftriaxone 2g, Metronidazole 500mg / Gentamycin 160mg, Ondansetron 8mg and Dexamethasone 8mg; Crystalloid fluid 10 to 20ml/Kg; Adrenaline 200mcg in each 500 ml of intravenous fluid; Avoidance of abdominal drains; Postoperative: Early oral intake; Nasogastric tube and urinary catheter removed immediately after the surgery; Early enteral nutrition; Chewing gum for 2 to 4 hours after surgery; Oral sips 8 hours postoperatively; Intravenous fluids discontinued at four hours after transfer to the ward.
62490276|NCT00903292|ACTIVE_COMPARATOR|B, pemetrexed|If EGFR wild type found then assigned to chemotherapy (pemetrexed)
62490277|NCT00826241|EXPERIMENTAL|Temozolomide + Lapatinib|Temozolomide starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
62490278|NCT05726058|OTHER|Control|All control participants will be first be imaged pre-intervention.
61937735|NCT03854188|EXPERIMENTAL|Acupuncture treatment|Patients diagnosed with chronic pelvic pain will be offered acupuncture treatment as an adjuvant therapy to standard of care treatment.
62490279|NCT05726058|OTHER|Glaucoma|All participants with glaucoma will be first be imaged pre-intervention.
62490280|NCT05726058|OTHER|Pre-perimetric Glaucoma|All participants with pre-perimetric glaucoma will be first be imaged pre-intervention.
62490281|NCT03552328|EXPERIMENTAL|Intervention|Seniors receiving daily meals from Meals on Wheels. Intervention: Lunch with Medical Student.
62490282|NCT03552328|PLACEBO_COMPARATOR|Control|Seniors receiving daily meals from Meals on Wheels
62490283|NCT06628271|OTHER|Typical spells|Patients with typical spells should be investigated according to our guidelines
61937736|NCT02200783|ACTIVE_COMPARATOR|Radial|Cardiac catheterization and coronary angioplasty performed via standard radial artery technique.
61937737|NCT02200783|ACTIVE_COMPARATOR|Femoral|Cardiac catheterization and coronary angioplasty performed via standard femoral artery technique.
61937738|NCT02200783|EXPERIMENTAL|TripTable|Cardiac catheterization and coronary angioplasty performed with standard transradial technique plus using the TRIPTable device.
61937739|NCT01978171||breast cancer patients|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.
61937740|NCT05346250||Non exercise program|Subjects receive 12 month lifestyle education alone.
61937741|NCT05346250||Moderate intensity exercise program|Subjects receive 12 month moderate exercise.
61937742|NCT05346250||Vigorous intensity exercise program|Subjects receive 6 month vigorous exercise and subsequent 6 month moderate exercise
61937743|NCT02215031|EXPERIMENTAL|BI 44370|
61937744|NCT02215031|PLACEBO_COMPARATOR|Placebo|
61937745|NCT05058352|EXPERIMENTAL|HS269|Multiple doses of HS269 tablets
61937746|NCT02687373|EXPERIMENTAL|Part 1: Grp 1A - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination."
62332614|NCT03665376|NO_INTERVENTION|Control arm|Preoperative: No carbohydrate drink loads, no antithrombotic prophylaxis; Mechanical bowel preparation as needed; Spinal anaesthesia, fluid therapy and antibiotherapy done according to standard hospital practice. The urinary catheter and drains were removed at the discretion of the surgeon. Postoperative: Enteral feeding delayed by the auscultation of bowel sounds. The standard hospital practices involve keeping active the nasogastric tube, fasting patients postoperative, strict bed rest... Pain control was managed with medication of choice by surgeon and anesthesiologist.
62490284|NCT06628271|NO_INTERVENTION|Non-typical spells|Patients with non-typical spells will be investigated individually, as it is done today
62490285|NCT03510260|PLACEBO_COMPARATOR|Control Group|Subject will undergo regular consenting only. At our unit consent for an elective cesarean delivery occurs in the same day of surgery, few hours before the procedure in a private room in labor and delivery while awaiting surgery. The COMRADE questionnaire (our primary outcome) will be obtained after the completion of the paper consent form.
62490286|NCT03510260|EXPERIMENTAL|Study Group I|Subject will receive an electronic invitation to complete the consent process electronically and will proceed through the Confirmed Consent system prior to arrival to labor and delivery on day of surgery, which is the routine patient flow at this time. The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group) before the completion of the paper consent form, in order to assess satisfaction and understanding of the e-confirmed consenting process completed before the procedure. After completion of the survey, the subject will sign the regular paper consent for the procedure as standard in our institution.
61937747|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 1A - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination."
62136460|NCT06698705||4-6 years|The child should wear EEG consumables accompanied by their family and be properly secured in the operating room. Induction and maintenance of Remimazolam, collection of EEG information . EEG collection covers the entire perioperative period, including preoperative awake period (or preoperative sedation period), surgical anesthesia period, and anesthesia awake period.
62136461|NCT06698705||7-12 years|The child should wear EEG consumables accompanied by their family and be properly secured in the operating room. Induction and maintenance of Remimazolam, collection of EEG information . EEG collection covers the entire perioperative period, including preoperative awake period (or preoperative sedation period), surgical anesthesia period, and anesthesia awake period.
62332615|NCT03885739|OTHER|Patients with hip fracture|15 consecutive HF patients who were admitted to a single level 3 center and who report severe pain despite a standardized analgesia protocol. Patients were assessed by the Pain Service as part of a multidisciplinary care pathway and a Continuous Pericapsular Nerve Group blocks was offered as a component of a multimodal analgesic regimen.
62332616|NCT04176055|EXPERIMENTAL|HALO|
62490287|NCT03510260|EXPERIMENTAL|Study Group II|Subject will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent is obtained in order to assess whether both methods combined together improve the subjects' satisfaction of the consenting methods and better understanding of the surgical procedure.
62136462|NCT05674929|EXPERIMENTAL|BPL-003 arm|
62136463|NCT02071043|EXPERIMENTAL|XELOX|"XELOX: Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
62490288|NCT05014438|PLACEBO_COMPARATOR|Placebo|
62136464|NCT02808403||Evolocumab exposed|Patients for whom evolocumab is prescribed. Dosage, period (start/end date), frequency of injection (Every 2 weeks (Q2W), Every 4 weeks (Q4W)), drug withdrawal (Yes or No, date, reason) and injection site (upper arm, abdomen, thigh) of evolocumab will be collected.
62490289|NCT05014438|EXPERIMENTAL|Treatment BMS-986166 Dose 1|
61937748|NCT02687373|EXPERIMENTAL|Part 1: Grp 1B - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10\^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62332617|NCT05256056|EXPERIMENTAL|Group A|patients will be injected with 20 cc of 0.25% Bupivacaine
62332618|NCT05256056|EXPERIMENTAL|Group B|patients will be injected with 30 cc of 0.25% Bupivacaine.
62490290|NCT05014438|EXPERIMENTAL|Treatment BMS-986166 Dose 2|
62490291|NCT05014438|EXPERIMENTAL|Treatment BMS-986166 Dose 3|
62490292|NCT05014438|EXPERIMENTAL|Treatment Branebrutinib|
61937749|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 1B - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62136465|NCT06698692||Observation group|Trilaciclib combined with chemoradiotherapy
62136466|NCT06698692||Control group|chemoradiotherapy
62136467|NCT01756924|EXPERIMENTAL|CEM-102 plus Rifampin|
62136468|NCT01756924|ACTIVE_COMPARATOR|Standard of Care|
62136469|NCT03343184|ACTIVE_COMPARATOR|SEE and incremental restoration|50 teeth will receive restorations using SEE Strategy and Incremental Restoration
62136470|NCT03343184|EXPERIMENTAL|SEE and bulk restoration|50 teeth will receive restorations using SEE Strategy and Bulk Fill Restoration
62136471|NCT03343184|EXPERIMENTAL|SET and incremental restoration|50 teeth will receive restorations using SET Strategy and Incremental Restoration
62136472|NCT03343184|EXPERIMENTAL|SET and bulk restoration|50 teeth will receive restorations using SET Strategy and Bulk Fill Restoration
62136473|NCT06652750|EXPERIMENTAL|5G cloud follow-up & Routine follow-up|CIED patients undergo both 5G cloud follow-up and routine in-office follow-up during each visit.
62332619|NCT04971395|EXPERIMENTAL|Single IV infusion of 2 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
62332620|NCT04971395|EXPERIMENTAL|Single IV infusion of 4 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
62490293|NCT03135080|EXPERIMENTAL|Long-term HEAD START Training|Fifteen surgeons will participate in long-term HEAD START practice once live surgical training is complete. Each week the participant will complete 2 surgeries on the HEAD START device and mark the surgery number on the cartridge. Monthly, the participant will send the accumulated cartridges to Addis for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his/her impression of the surgeries with the participant during a regular monthly call. He/she will also note the findings on a standardized form. Practice will continue for approximately 4-6 months, depending on the length of the rainy season and time of enrollment.
62490294|NCT03135080|ACTIVE_COMPARATOR|Standard of Care|Once live surgical training is complete, fifteen surgeons will commence live surgery without supervision until the rainy season begins. Then they will break for the rainy season, per the typical practice. The trainer will assess their skill levels on live surgery at the end of training and again at the start of the surgical season in the fall.
62490295|NCT04057105|ACTIVE_COMPARATOR|MusicGlove and Active HD-tDCS|During Active HD-tDCS, current up to 2mA will be delivered transiently for only 30 seconds and it will be turned ON for the remainder of 20 minutes.
62490296|NCT04057105|SHAM_COMPARATOR|MusicGlove and Sham HD-tDCS|During Sham HD-tDCS, current up to 2mA will be delivered transiently for only 30 seconds to simulate the real-tDCS based skin sensation.
62490297|NCT02167594|EXPERIMENTAL|PSP Subjects|Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
62490298|NCT02167594|EXPERIMENTAL|CBD subjects|Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
62490299|NCT02167594|EXPERIMENTAL|Healthy volunteers|Healthy volunteers receiving a flortaucipir PET scan at baseline.
62490300|NCT00310115||Smoking Prevention Usual Care|Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
62490301|NCT00310115||MRP|Arm II (motivational relapse prevention \[MRP\]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 \& 36 weeks gestation then at 2, 4, 7, \& 16 weeks postpartum.
62490302|NCT00310115||Enhanced MRP +|Arm III (enhanced MRP \[MRP+\]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation \& 8 weeks postpartum.
61937750|NCT02687373|EXPERIMENTAL|Part 1: Grp 1C - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10\^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
61937751|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 1C - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62136474|NCT06364852|EXPERIMENTAL|LY007|The CAR T cell preparation to be evaluated in this study is LY007, developed and produced by Shanghai Longyao Biotechnology Co., LTD Cell injection. LY007 cell injection is a chimeric antigen receptor targeting CD20 genetically modified using lentiviral vectors (CAR) Autologous T cells are CD20 CAR-T independently developed by Shanghai Longyao Biotechnology Co., LTD., in the CAR facility The independent co-stimulatory signal receptor OX40 was introduced to increase the proliferation and killing function of CAR-T cells. Table of CAR gene The frame comprises the following elements: (1) MSCVEF1α fusion promoter; (2) Single-chain antibody CD20 scFv targeting CD20; (3) CD8 junction and transmembrane region; (4) Intracellular region of 4-1BB; (5) CD3ζ intracellular region; (6) P2A self-shearing peptide; (7) Co-stimulated receptor OX40
62136475|NCT06435169||38 patients with lumbar disc bulging|Lasegue's test, FAIR (Flexion Adduction Internal Rotation) test and, Freiberg's test will be performed in a single check-up for patients diagnosed with L4-L5 and/or L5-S1 Lumbar Disc Herniation (bulging) by lumbar Magnetic Resonance Imaging (MRI). The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests.
62136476|NCT06435169||38 patients with lumbar disc protrusion|Lasegue's, FAIR (Flexion Adduction Internal Rotation) and, Freiberg's test will be performed in a single check-up for patients diagnosed with L4-L5 and/or L5-S1 Lumbar Disc Herniation (protrusion) by lumbar Magnetic Resonance Imaging (MRI). The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests.
62136477|NCT02871206|EXPERIMENTAL|Adjuvanted Influenza Vaccine|Fluad. A 0.25 ml intramuscular dose of the vaccine will be administered to children aged from 6 months to less than 36 months and a 0.5ml dose will be administered to children aged from 36 months to 6 years. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.25 ml dose of the vaccine four weeks following the first vaccine as per influenza immunization recommendations if they are aged between 6 months and less than 36 months or a second dose of 0.5ml if they are aged from 36 months to 6 years.
62136478|NCT02871206|ACTIVE_COMPARATOR|Quadrivalent Influenza Vaccine|Fluzone. A 0.5 ml dose of the vaccine will be administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose of the influenza vaccine four weeks following the first vaccine as per influenza immunization recommendations.
62332621|NCT01688167|EXPERIMENTAL|Intervention|Experimental condition clinics offer the MC and sexual risk reduction intervention: four group counseling sessions focused on male circumcision and sexual risk reduction.
62490303|NCT06026267|ACTIVE_COMPARATOR|High Dose Arm+Standard Medical therapy|Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg body weight (Maximum 100g)on day 3 along with standard medical therapy.
62490304|NCT06026267|EXPERIMENTAL|Reduced Dose Albumin+Standard Medical therapy|Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.
62490305|NCT00535912|NO_INTERVENTION|A|¨Chemotherapy by 12 courses of CHOP
62136479|NCT04838860|ACTIVE_COMPARATOR|Parallel Arm of iMCD Patients|Enrolling in Stage 1a of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
62136480|NCT04838860|ACTIVE_COMPARATOR|Parallel Arm of TAFRO-iMCD Patients|Enrolling in Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
62136481|NCT03559413|EXPERIMENTAL|Intervention group|
62136482|NCT05911243|EXPERIMENTAL|Arm I (acupressure therapy)|Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.
62332622|NCT01688167|NO_INTERVENTION|Standard of Care|"Male participants in the standard of care control condition CHCs will receive counseling per the VCT protocol guidelines. Participants will attend four video-based time-equivalent attention-control group sessions on endemic disease prevention strategies (e.g., TB, malaria, cholera, waterborne diseases). Female partners will be invited to participate in a similar four session program devoted to endemic disease risk reduction."
62490306|NCT00535912|ACTIVE_COMPARATOR|B|¨Chemotherapy by 3 courses of CHOP, intensification and autograft
61937752|NCT02687373|EXPERIMENTAL|Part 1: Grp 2A - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
61937753|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 2A - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
61937754|NCT02687373|EXPERIMENTAL|Part 1: Grp 2B - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
61937755|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 2B - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
62136483|NCT05911243|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual care on study. Patients also undergo collection of blood samples on study.
62136484|NCT00359606|EXPERIMENTAL|Treatment (5-fluoro-2-deoxycytidine, tetrahydrouridine)|Patients receive tetrahydrouridine PO on day 1; 5-fluoro-2-deoxycytidine PO on days 1 and 8; tetrahydrouridine IV over 3 hours on days 2-5, 8, and 9-12; and 5-fluoro-2-deoxycytidine IV over 3 hours on days 2-5 and 9-12 of course 1. For all subsequent courses, patients receive tetrahydrouridine IV over 3 hours and 5-fluoro-2-deoxycytidine IV over 3 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62136485|NCT04910776|EXPERIMENTAL|Avalglucosidase alfa|Administered intravenously every 2 weeks
62136486|NCT00156208|EXPERIMENTAL|1|
62332623|NCT01688167|NO_INTERVENTION|Observational|"3 CHC sites will be randomly assigned as observation only; only aggregated clinic VCT and circumcision data will be collected."
62332624|NCT04770987||hyperlaxity|30 individuals with systemic hyperlaxity as defined by a score of 5 or greater on the Beighton Hypermobility Scale
62332625|NCT04770987||control|30 healthy, age and gender matched individuals without hyperlaxity
62332626|NCT05366699|EXPERIMENTAL|Group A|Group A will under axillary lymphadenectomy alone
62332627|NCT05366699|ACTIVE_COMPARATOR|Group B|Group B will undergo axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) using reverse mapping using the SPY System.
62332628|NCT03294681||Cochlear Implant Recipients|
62332629|NCT00127062|EXPERIMENTAL|Asthma|Asthma patients ranging from mild to severe
62332630|NCT00127062|OTHER|Healthy Non-Smokers|
62332631|NCT04392102|EXPERIMENTAL|ZL-2306(Niraparib)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
62332632|NCT02856269|ACTIVE_COMPARATOR|45 mg daily|Participants in this arm will take a daily 45 mg dose of zinc gluconate.
62490307|NCT04579653|EXPERIMENTAL|Group A: Experimental|Within-subjects design with a randomization of the order of tVNS administered parameters
62136487|NCT00156208|EXPERIMENTAL|2|
62136488|NCT00003222|EXPERIMENTAL|Peptides pulsed on dendritic cells|4 melanoma peptides pulsed on monocyte-derived dendritic cells
62490308|NCT04579653|ACTIVE_COMPARATOR|Group B: Active Comparator|Within-subjects design with a randomization of the order of tVNS administered parameters
62136489|NCT00003222|EXPERIMENTAL|Peptides in GMCSF-in-adjuvant|4 melanoma peptides administered as an emulsion with GM-CSF and Montanide ISA-51 adjuvant.
62136490|NCT04394897||TIVA|TIVA either with remifentanil and propofol infusions separately
62136491|NCT04394897||MIXTIVA 2/1000|MIXTIVA infusion that had remifentanil/propofol proportion 2/1000
62490309|NCT03369535|PLACEBO_COMPARATOR|Baseline|Baseline corresponds to typical American diet
62490310|NCT03369535|ACTIVE_COMPARATOR|PROT rich diet|Protein rich diet for 6 weeks
62490311|NCT03369535|ACTIVE_COMPARATOR|MUFA rich diet|MUFA rich diet for 6 weeks
62136492|NCT04394897||MIXTIVA 3/1000|MIXTIVA infusion that had remifentanil/propofol proportion 3/1000
62136493|NCT01421836|ACTIVE_COMPARATOR|ERCP guided stent insertion|
62136494|NCT01421836|ACTIVE_COMPARATOR|EUS guided stent insertion|
62332633|NCT02856269|ACTIVE_COMPARATOR|90 mg daily|Participants in this arm will take a daily 90 mg dose of zinc gluconate.
62332634|NCT00961337|EXPERIMENTAL|Vaccination township|Shinwu township was randomly designated as intervention township which freely vaccinated on grade 1-4 and 5-9 students.
62332635|NCT00961337|NO_INTERVENTION|Control townships|Guanyin township was designated as control township which only provide free vaccination on grade 1-4 students.
62332636|NCT00003117|EXPERIMENTAL|Paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of each course. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
62332637|NCT00003117|EXPERIMENTAL|Paclitaxel + Carboplatin|Patients receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
62332638|NCT03747224|EXPERIMENTAL|ARO-ANG3|
62332639|NCT03747224|PLACEBO_COMPARATOR|Placebo|
62490312|NCT03369535|ACTIVE_COMPARATOR|CARB rich diet|CARB rich diet for 6 weeks
62490313|NCT01198938|ACTIVE_COMPARATOR|Melatonin|
62490314|NCT02795858|EXPERIMENTAL|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with ramucirumab starting at a dose of 8 mg/kg intravenously every 14 days of a 28-day treatment cycle. Patients already receiving a somatostatin analog continued somatostatin analog therapy at their current dose. Patients not already receiving a somatostatin analog initiated treatment at an approved dose, according to institutional guidelines.~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
62490315|NCT04353986|EXPERIMENTAL|Beta thalassemia|HCV infected Beta thalassemia major adolescents
62490316|NCT04353986|ACTIVE_COMPARATOR|Control|HCV infected, otherwise healthy, sex and age matched to the thalassemia group serving as control group
62490317|NCT00836862||Arteriovenous Fistula|A tissue bank will be created to collect serum, whole blood, and vein specimens obtained from participants undergoing Arteriovenous Fistula (AVF) placement and revision. The planned specimen harvests will allow for both pre- and post-AVF placement specimens from both maturing and failing AVF.
62332640|NCT02231255||Idiopathic Parkinson's disease patients|
62332641|NCT02437448||Idiopathic lung fibrosis|20 IPF patients
62136495|NCT01678079|EXPERIMENTAL|Micronutrient Powder, Enteric-coated Calcium (500 mg/day)|Encapsulated Calcium
62136496|NCT01678079|EXPERIMENTAL|Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)|Encapsulated Calcium
62332642|NCT02437448||Controls|20 subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
62490318|NCT02143596|ACTIVE_COMPARATOR|Bun/Cr based hydration|receive intravenous normal saline infusion and adjust infusion rate by Bun/Cr followed in the first 72 hours
62490319|NCT02143596|NO_INTERVENTION|control|receive intravenous normal saline infusion as clinician's adjustment
62136497|NCT01678079|EXPERIMENTAL|Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)|Encapsulated Calcium
62136498|NCT01678079|ACTIVE_COMPARATOR|Micronutrient Powder, Uncoated Calcium (500 mg/day)|Non-capsulated Calcium
62136499|NCT01678079|ACTIVE_COMPARATOR|Micronutrient Powder, Uncoated Calcium (1000 mg/day)|Non-capsulated Calcium
62332643|NCT04026152|EXPERIMENTAL|Resistance training + Unified Protocol|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will also receive four weekly hour-long sessions with a therapist to learn cognitive-behavioural strategies to assist them with managing their anxiety when exercising. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (\~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (\~20 minutes each time) follow-up after they have completed the supervised portion of this study.
62490320|NCT01772407||1|laparoscopic surgery in right colon cancer operations
62490321|NCT01772407||2|open surgery in right colon cancer operations
62490322|NCT03347019|EXPERIMENTAL|accelerated rehabilitation after surgery|patients were included progressive rehabilitation programme first week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
62136500|NCT01678079|ACTIVE_COMPARATOR|Micronutrient Powder, Uncoated Calcium (1500 mg/day)|Non-capsulated Calcium
62136501|NCT01321164|ACTIVE_COMPARATOR|Fumaric acid esters|Fumaric acid esters monotherapy
62136502|NCT01321164|EXPERIMENTAL|fumaric acid esters plus narrow band UVB|Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
62136503|NCT04866641|EXPERIMENTAL|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit will be administered via intravenous infusion once every 4 weeks. T-1201 Injection 100 mg Kit is required to be reconstituted with its specific Injection Diluent supplied in the kit, then further diluted with 5% Dextrose solution prior to the intravenous infusion in patients.
62136504|NCT02746926|EXPERIMENTAL|4x20 mg tafamidis meglumine soft gel capsule|
62136505|NCT02746926|EXPERIMENTAL|48.8 mgA tafamidis free acid capsule|
62490323|NCT03347019|EXPERIMENTAL|delayed rehabilitation after surgery|Patients were not allowed to start passive shoulder exercises first three weeks after surgery. Patients were included progressive rehabilitation programme third week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
62490324|NCT00876265|EXPERIMENTAL|Belotero|
62490325|NCT00876265|ACTIVE_COMPARATOR|Zyplast|
61937756|NCT02687373|EXPERIMENTAL|Part 1: Grp 2C - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
62136506|NCT02746926|EXPERIMENTAL|61 mgA tafamidis free acid capsule|
62136507|NCT04248322||Subjects who used TTNS|Subjects will have Neurogenic Lower Urinary Tract Dysfunction and will have participated in a study with TTNS. n=20
62136508|NCT02433782|EXPERIMENTAL|Experimental group|Treatment through myofascial therapy for the treatment of pain and restricted mobility in patients with hemophilic arthropathy of the knee and ankle
62136509|NCT02433782|NO_INTERVENTION|Control group|No myofascial intervention. Patients continue their treatment with FVIII or FIX concentrates, normally
62136510|NCT01728974|EXPERIMENTAL|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
62136511|NCT04810975|OTHER|The effect of exercise A on musculoskeletal health|
62136512|NCT04810975|OTHER|The effect of exercise B on musculoskeletal health|
62136513|NCT02128113|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|A single drop of Vehicle Ophthalmic solution was instilled into the study eye twice daily (approximately 12 hours apart) for a maximum of 28 days, beginning 3 to 7 days prior to cataract surgery and continuing on the day of surgery and for 3 weeks after surgery
62136514|NCT02128113|EXPERIMENTAL|Omaveloxolone Opthalmic Suspension 0.5%|A single drop of Omaveloxolone Ophthalmic suspension 0.5% was instilled into the study eye twice daily (approximately 12 hours apart) for a maximum of 28 days, beginning 3 to 7 days prior to cataract surgery and continuing on the day of surgery and for 3 weeks after surgery
62136515|NCT02128113|EXPERIMENTAL|Omaveloxolone Opthalmic Suspension 1%|A single drop of Omaveloxolone Ophthalmic suspension 1.0% was instilled into the study eye twice daily (approximately 12 hours apart) for a maximum of 28 days, beginning 3 to 7 days prior to cataract surgery and continuing on the day of surgery and for 3 weeks after surgery
62332644|NCT04026152|ACTIVE_COMPARATOR|Resistance training|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (\~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (\~20 minutes each time) follow-up after they have completed the supervised portion of this study.
62332645|NCT04026152|NO_INTERVENTION|Waitlist|Participants randomly assigned to this condition will maintain their usual physical activity and exercise routine and not engage in any additional exercise than they were prior to the study. These participants will fill out questionnaires (\~20 minutes each time) following randomization into this condition, once per week for four weeks, and at 1-week, 1-month, and 3-months (\~20 minutes each time) follow-up. After completing the last follow-up, participants in the waitlist condition will be re-randomized into either the resistance training only or resistance training + Unified Protocol conditions.
62332646|NCT05590663||Patients with knee osteoarthritis|Individuals who are medically diagnosed with knee osteoarthritis and eligible for physiotherapy care in SingHealth Polyclinics will be recruited. Inclusion criteria include: individuals above the age of 45, proficient in colloquial/conversational English, and diagnosed with knee osteoarthritis. Exclusion criteria include additional underlying medical or trauma conditions of the knees (e.g., trauma, fracture, infection, inflammatory disease, tumour), history of knee surgery within the last three months, or clinically recognizable cognitive impairment that inhibits the completion of the questionnaires.
62332647|NCT03765541|EXPERIMENTAL|Standard salvage therapy + dexamethasone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness in combination with dexamethasone
62332648|NCT03765541|ACTIVE_COMPARATOR|Standard salvage therapy alone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness
62332649|NCT04837534|EXPERIMENTAL|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
62490326|NCT03229057|ACTIVE_COMPARATOR|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
61937757|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 2C - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
62136516|NCT02488148|EXPERIMENTAL|Hot yoga|3 hot yoga classes per week to be completed at local studios in Austin, TX.
62136517|NCT02488148|EXPERIMENTAL|Non-heated yoga|3 yoga classes to be completed at local studios in Austin, TX.
62136518|NCT02488148|NO_INTERVENTION|Control|Maintain usual activities for the 12-week duration of the study.
62136519|NCT01876966|EXPERIMENTAL|ETR, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with etravirine for 22 days and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
62136520|NCT01876966|EXPERIMENTAL|DRV/rtv, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with darunavir/ritonavir and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
62490327|NCT03229057|ACTIVE_COMPARATOR|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
62490328|NCT03229057|EXPERIMENTAL|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
62694718|NCT05919498||Trajectory persons|"Trajectory persons are defined by FASTRACS-RCT patients. These persons have accompanied patients on their return-to-work journey. They may be someone close to you (family, friends, etc.), the general practitioner, a person from the company (colleagues, manager, occupational physician), or other health professionals (nurse, psychologist, etc.).~As a first step, all trajectory persons will complete an individual semi-directive interview. Then, some will be offered to participate in focus groups"
61937758|NCT02687373|EXPERIMENTAL|Part 1: Grp 2D - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10\^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62136521|NCT05421117||transumbilical (TU) routes|For the TU group, a surgical glove was created bag during the operation as follows: a sterile, surgical latex glove (size 8.5) was double tied at the level of the wrist, the fingers were removed, and a 75-cm purse-string suture was made using a symmetrical knot to form a bag. The glove bag took an average of 10 min to make. It was lubricated with normal saline to remove the talcum powder and then introduced through the 10-mm umbilical port (optic port). The fingers of the glove were removed to facilitate its insertion with the 10-mm trocar and for ease of movement in the abdominal cavity.
62136522|NCT05421117||transvaginal (TV) routes|A curette was placed into the uterine cavity and stabilized with a tenaculum for manipulation of the uterus. After separation of the adnexal mass ligaments, the manipulator was removed to perform TV retrieval. A vaginal retractor was inserted into the vagina to view the cervix and allow removal of the mass via the TV route. The posterior lip of the cervix was grasped with an Allis forceps and then pulled superiorly to expose the posterior vaginal dome. The sampler was inserted into the vagina and pushed gently against the vaginal wall to define the posterior fornix between the uterosacral ligaments. A 1-2-cm transverse TV posterior colpotomy was performed under laparoscopic control using a 3-mm monopolar hook. The sample was pulled into the vagina by holding the bag mouth from the colpotomy with ring forceps. The bag mouth was opened in the vaginal canal and the sample was transferred from the vagina.
62332650|NCT04837534|EXPERIMENTAL|SMS and phone call reminder group:|In this group after the children have been examined, treatment plan and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol
62332651|NCT04837534|NO_INTERVENTION|Routine standard care group|In this group, the children will undergo ocular examination, and treatment plan. They will be discharged from the department and advised accordingly including a routine follow-up schedule as per hospital protocol.
62332652|NCT00914836|ACTIVE_COMPARATOR|1 cc - Betamethasone Sodium Phosphate|1 cc - Betamethasone Sodium Phosphate
62332653|NCT00914836|ACTIVE_COMPARATOR|2 cc - Betamethasone Sodium Phosphate|2 cc - Betamethasone Sodium Phosphate
62332654|NCT01188382||Healthy elderly|Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease
62332655|NCT03179514|EXPERIMENTAL|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction \& Danshen Decoction at the base of conventional western medicine.
62332656|NCT03179514|OTHER|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
62332657|NCT01524172|ACTIVE_COMPARATOR|Standard Mental Health Treatment|Trauma-informed evidence supported mental health treatment
62332658|NCT01524172|EXPERIMENTAL|Yoga Based Psychotherapy Group|Yoga Based Psychotherapy will be used as an adjunct mental health interventions
62332659|NCT06007482|EXPERIMENTAL|Dose Escalation Cohort|ES009 monotherapy dose level will be escalated in participants with advanced solid tumors.
62332660|NCT02426554|ACTIVE_COMPARATOR|Group 1|
62332661|NCT02426554|PLACEBO_COMPARATOR|Group 2|
62490329|NCT01037231|EXPERIMENTAL|Oxabact (tm)|
62490330|NCT01037231|PLACEBO_COMPARATOR|Placebo|
62694719|NCT05919498||Professionals/Focus group|"This group is composed of some of the trajectory persons and professionals who participated in the delivery of the FASTRACS-RCT study intervention tools.~These individuals will participate in the focus groups."
61937759|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 2D - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62332662|NCT01963299|ACTIVE_COMPARATOR|Ropivacaine alone group|
62332663|NCT01963299|EXPERIMENTAL|Ropivacaine/Clonidine group|
62332664|NCT03836976|EXPERIMENTAL|All participants|All participants receive auditory gamma sensory stimulation.
62332665|NCT05624684||ICU patients with severe pneumonia|Critically ill patients with severe pneumonia under mechanical ventilation including ventilator-associated pneumonia, community-acquired or hospital-acquired pneumonia.
62694720|NCT04661358|EXPERIMENTAL|Fenofibrate 160-mg|
62694721|NCT04661358|PLACEBO_COMPARATOR|Placebo|
62694722|NCT03327129||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
62490331|NCT02957331|EXPERIMENTAL|Propranolol arm|One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic \<100) or bradycardia (heart rate \<60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.
62490332|NCT02957331|NO_INTERVENTION|Non propranolol arm|Non beta blockade arm will receive standard of care treatment and will not receive beta blockade. If a subject randomized to no Inderal develops hypertension and increased heart rate, he/she will be treated according to standard of care by the trauma team caring for the patient.
62490333|NCT01598896|EXPERIMENTAL|Dronabinol + Clonidine|Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
62490334|NCT01598896|PLACEBO_COMPARATOR|Placebo|Placebo
62490335|NCT05659576|ACTIVE_COMPARATOR|One Stage Consent|Patient will sign one consent form.
62490336|NCT05659576|EXPERIMENTAL|Two Stage Consent|Patient will sign two consent forms.
62490337|NCT05659576|EXPERIMENTAL|Sucralfate|During their RT course, patients randomized to the PS arm will receive a prescription for either: 1) sucralfate, 1 gram/10 mL oral suspension or 2) sucralfate 1 gram tablets.
62490338|NCT05659576|ACTIVE_COMPARATOR|Usual Care|Standard supportive care by using opioids.
62490339|NCT06368076|EXPERIMENTAL|Exercise|
62490340|NCT01166529|EXPERIMENTAL|EUS-CPN|
62490341|NCT01694563|OTHER|Atrial Fibrillation|Patients with non-paroxysmal atrial fibrillation (persistent or longstanding persistent)who are scheduled to undergo elective concomitant open, on-pump cardiac surgical procedure and the Maze IV ablation procedure. This single arm registry is designed to monitor the AtriCure Synergy Ablation System for continued safety and efficacy during the peri-procedural and long term phase during commercial use.
62490342|NCT01590563|EXPERIMENTAL|SCu300A IUB|Insertion of a spherical IUD (intrauterine device) with one year follow-up
62490343|NCT02109458|EXPERIMENTAL|Assessing peripheral pulmonary nodules|To evaluate the feasibility and safety of a procedure path including convex Endobronchial Ultrasound (EBUS) lymph node sampling, navigation guided bronchoscopy (NB) and navigation guided transthoracic needle aspiration (N-TTNA).
62490344|NCT01663662|ACTIVE_COMPARATOR|Tolvaptan Arm|"Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing:~Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr"
62490345|NCT01663662|PLACEBO_COMPARATOR|Placebo|Placebo x 3 days and standard of care continuous infusion diuretic
62490346|NCT05649358|EXPERIMENTAL|Evaluation of non-invasive lactate sensor|To determine the efficacy and accuracy of the non-invasive lactate sensor
62490347|NCT02416934|EXPERIMENTAL|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
62694723|NCT03327129||Patients with SI|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item \>=2).
62694724|NCT00330733|PLACEBO_COMPARATOR|Placebo|Matching placebo
62694725|NCT00330733|ACTIVE_COMPARATOR|Salsalate Therapy|Salsalate
62694726|NCT06507644|ACTIVE_COMPARATOR|- Control Group (gold standard - 16% MAL with 3-hour incubation time)|Participants will be treated with 16% topical MAL photosensitizer with a 3-hour incubation period. The light source used for skin illumination will be a visible light source (LED) with a wavelength of 643nm (Hygialux LLT1601®, KLD - ANVISA registration number 10245239012).
62332666|NCT05913934||Gait analysis parameters|Twins: Gait analysis
62694727|NCT06507644|EXPERIMENTAL|Experimental Group (16% MAL incubation time - 1 hour)|Participants will be treated with 16% topical MAL photosensitizer with a 1-hour incubation period. The light source used for skin illumination will be a visible light source (LED) with a wavelength of 643nm (Hygialux LLT1601®, KLD - ANVISA registration number 10245239012).
62490348|NCT02416934|PLACEBO_COMPARATOR|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
62490349|NCT00059423||1|Individuals of African descent with benign ethnic neutropenia (BEN) at baseline
62490350|NCT00059423||2|Individuals of African descent without benign ethnic neutropenia (BEN) at baseline
62490351|NCT05694546|EXPERIMENTAL|Community Health Worker Post-Discharge Intervention|This group will be offered a community-based visit from a community health worker following hospital discharge.
62490352|NCT00584753|OTHER|1|Normal volunteers
62490353|NCT00584753|ACTIVE_COMPARATOR|2|Breast PET/CT scan
62490354|NCT00584753|ACTIVE_COMPARATOR|3|Whole body and breast PET/CT
62490355|NCT05149209|EXPERIMENTAL|Fluoride, calcium and phosphate-releasing new bioactive material (Activa™ Presto, Pulpdent®, USA).|ACTIVA Presto is a novel bioactive material with a mineral-enriched hydrophilic resin base and a patented rubberized component that resists abrasion and wear with high release and recharge of not only fluoride but also calcium and phosphate ions. It doesn't contain BIS-GMA, Bisphenol A, or BPA derivatives.
62490356|NCT05149209|ACTIVE_COMPARATOR|Fluoride-releasing hybrid restorative material (Giomer, Shofu, Japan).|Giomer is a hybrid restorative material that contains a resin base and pre-reacted glass ionomer. S-PRG (surface reaction type) technology provides some properties of GI such as fluoride release and recharge which helps prevent recurrent caries.
62136523|NCT05792956|EXPERIMENTAL|Mobile Application group|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
62490357|NCT05582343|NO_INTERVENTION|mISP|Participants who are identified as having moderate to high risk of suicide, as identified by suicide risk on the ISP, will be contacted by a mental health counselor who will engage them through the mISP encrypted interface online. The mental health counselor will offer counseling online through encryption or on the phone. Where indicated, the mental health counselor will provide the crisis hotline, and encourage participants to use their insurance provider and/or Employee Assistance Program to obtain treatment. The mental health counselor will offer to help with referrals and will bridge high-risk participants into treatment. Participants who are not identified as having moderate to high risk of suicide will be thanked for their time.
62136524|NCT05792956|NO_INTERVENTION|Control group|To the control group, the routine protocol in the clinic (Bladder training is given by the nurses after the women apply. They come to deliver the bladder diary given after the bladder training in the 3rd and 6th months. According to the results of the bladder diary, the nurses provide counseling for the problems detected regarding the symptoms they experience). After the first interview, they will be asked to fill in the required scales one day in the 3rd and 6th months.
62490358|NCT05582343|ACTIVE_COMPARATOR|mISP plus MINDSTRONG|Participants identified as having a moderate to high risk of suicide based on ISP screening will then be randomized. Participants randomized to the MINDBODYSTRONG© program (intervention) will receive the 8-session online interactive program. Reminders will be sent weekly to complete the next MINDBODYSTRONG© session and a MINDBODYSTRONG© trained coach will check in with participants by phone at baseline, weeks 3 and 5 of the on-line program to reinforce key program concepts and assess whether participants are completing the weekly skills building activities. Nurses assigned to the control group will only receive the mISP alone (aforementioned) and will be contacted for follow-up surveys.
62490359|NCT04750681|PLACEBO_COMPARATOR|Control|Each capsule contained 275mg of maltodextrin. Capsules were similar to the saffron investigation product (chlorophyll capsules).
62490360|NCT04750681|EXPERIMENTAL|Saffron|Each capsule contained 259,5mg of maltodextrin and 15,5mg of saffron extract (Saffr'activ® SAF 3C PIM) that corresponds to 1,6mg of dry saffron extract, 0,9mg of crocins (5.82%) and 0,7mg of safranal (4.6%).
62490361|NCT03958812||Gastric cancer|patients with definitive diagnosis of gastric cancer by pathology
62490362|NCT03958812||Breast cancer|patients with definitive diagnosis of breast cancer by pathology
62490363|NCT03958812||Benign gastric diseases|Gastritis or gastric ulcer
62490364|NCT03958812||Benign breast diseases|Hyperplasia of mammary glands or mastitis
62490365|NCT03958812||Normal|healthy volunteers
62490366|NCT01283763|EXPERIMENTAL|Topical Imiquimod|16 weeks topical Imiquimod
62490367|NCT01283763|ACTIVE_COMPARATOR|Conization|Large loop excision of the transformation zone
62490368|NCT04970836|EXPERIMENTAL|Low titer with two doses of HB Vaccines|anti-HBs titer 2.5-10 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
62694728|NCT06507644|EXPERIMENTAL|Experimental Group (8% MAL incubation time - 3 hour)|Participants will be treated with 8% topical MAL photosensitizer with a 3-hour incubation period. The light source used for skin illumination will be a visible light source (LED) with a wavelength of 643nm (Hygialux LLT1601®, KLD - ANVISA registration number 10245239012).
62694729|NCT06507644|EXPERIMENTAL|Experimental Group (8% MAL incubation time - 1 hour)|Participants will be treated with 8% topical MAL photosensitizer with a 1-hour incubation period. The light source used for skin illumination will be a visible light source (LED) with a wavelength of 643nm (Hygialux LLT1601®, KLD - ANVISA registration number 10245239012).
62694730|NCT06636760|PLACEBO_COMPARATOR|Herbal combination; Placebo|
62694731|NCT06636760|ACTIVE_COMPARATOR|Herbal Combination|
61937760|NCT02687373|EXPERIMENTAL|Part 1: Grp 2E - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10\^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62136525|NCT03488719|EXPERIMENTAL|Cohort 1 (Tesofensine 0.25mg)|Tesofensine 0.25 mg once daily for 23 days (loading dose of 1.0 mg for the first 3 days), plus a single dose of 25 mg, 50 mg or 100 mg metoprolol extended release (ER) in random order on Day 15, Day 18 and Day 21, respectively.
62136526|NCT03488719|EXPERIMENTAL|Cohort 2 (Tesofensine 0.50mg)|Tesofensine 0.50 mg once daily for 23 days (loading dose of 2.0 mg for the first 3 days), plus a single dose of 25 mg, 50 mg or 100 mg metoprolol extended release (ER) in random order on Day 15, Day 18 and Day 21, respectively.
62490369|NCT04970836|ACTIVE_COMPARATOR|Low titer with one dose of HB Vaccine|anti-HBs titer 2.5-10 mIU/mL with one dose of HB Vaccine at Day 0
62490370|NCT04970836|ACTIVE_COMPARATOR|Extremely low titer with two doses of HB Vaccines|anti-HBs titer lower than 2.5 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
62490371|NCT04970836|ACTIVE_COMPARATOR|Extremely low titer with one dose of HB Vaccine|anti-HBs titer lower than 2.5 mIU/mL with one dose of HB Vaccine at Day 0
62490372|NCT02942082|EXPERIMENTAL|ACP oral care geldesensitizing agent|a desensitizing agent will be applied on tooth before and /or after bleaching.
62490373|NCT02942082|PLACEBO_COMPARATOR|glycrin|glycrin will be applied on tooth before and /or after bleaching.
62490374|NCT00466167|OTHER|Pramipexole ER|
62490375|NCT00466167|OTHER|Pramipexole IR|
62490376|NCT00466167|PLACEBO_COMPARATOR|Placebo|
62694732|NCT05715320|EXPERIMENTAL|Group A|CM310, subcutaneous
62694733|NCT05715320|EXPERIMENTAL|Group B|CM310, subcutaneous
62694734|NCT06635850|ACTIVE_COMPARATOR|Mosliciguat|Participants will be randomized to receive inhaled mosliciguat or placebo daily for 24 weeks
62694735|NCT06635850|PLACEBO_COMPARATOR|Matched Placebo|Participants will be randomized to receive inhaled mosliciguat or placebo daily for 24 weeks
62694736|NCT06635850|EXPERIMENTAL|Extension|After Week 24, all participants may receive mosliciguat through an Extension period
62490377|NCT00059332|EXPERIMENTAL|Magnesium Sulfate|Magnesium sulfate (Mg) was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. The bolus-loading dose consisted of 4 grams Mg in 54 ml normal saline. The maintenance infusion contained 16 grams Mg diluted in 240 ml 0.9% normal saline, infused at 10 ml/hr for 24 hours. Paramedics in the field initiated the bolus-loading dose, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose.
62490378|NCT00059332|PLACEBO_COMPARATOR|Normal saline|Normal saline was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. Paramedics in the field initiated the bolus-loading dose of 54 ml normal saline, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose at 10 ml/hr for 24 hours.
62136527|NCT03488719|EXPERIMENTAL|Cohort 3 (Tesofensine 0.75mg)|Tesofensine 0.75 mg (0.25 mg + 0.50 mg) once daily for 23 days (loading dose of 2.0 mg \[4 tablets of 0.50 mg\] for the first 5 days), plus a single dose of 25 mg, 50 mg or 100 mg metoprolol extended release (ER) in random order on Day 15, Day 18 and Day 21, respectively.
62136528|NCT06545643|EXPERIMENTAL|Dreem headband|Participants will wear a Fitbit daily and a Dreem headband exclusively at night in their homes over a 21-day period as part of the data collection protocol. Additionally, they will maintain daily sleep and seizure diaries.
62332667|NCT03442413|EXPERIMENTAL|2-[18F]-FA PET/CT|Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
62490379|NCT00125385|EXPERIMENTAL|Cohort 1|Dose group
61937761|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 2E - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
61937762|NCT02687373|EXPERIMENTAL|Part 1: Grp 3A - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
62136529|NCT02745249|EXPERIMENTAL|A&T- intensive|A\&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention which focus on improving dietary practices, specifically improved diversity of foods and energy intakes of pregnant women, and improved intake of calcium and iron/folic acid (IFA) supplements.
62136530|NCT02745249|NO_INTERVENTION|A&T-non intensive|A\&T-non intensive aim only receive MNCH services
62332668|NCT03167086|EXPERIMENTAL|Single Session Skills-Based Pain Psychology Class|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention for chronic pain."
62490380|NCT00125385|EXPERIMENTAL|Cohort 2|Dose Group
62490381|NCT00125385|EXPERIMENTAL|Cohort 3|Dose Group
62490382|NCT00125385|EXPERIMENTAL|Cohort 4|Dose Group
62136531|NCT05092841|EXPERIMENTAL|PXT3003|Liquid oral solution, 10 mL twice a day, morning and evening with food
62136532|NCT05092841|PLACEBO_COMPARATOR|PXT3003 Placebo|Liquid oral solution, 10 mL twice a day, morning and evening with food
62332669|NCT03167086|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
62332670|NCT03167086|ACTIVE_COMPARATOR|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (ER) on 4 important factors: duration, structure, format and site.
62332671|NCT01076842|ACTIVE_COMPARATOR|A Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
62490383|NCT00125385|EXPERIMENTAL|Cohort 5|Dose Group
62490384|NCT03544242|ACTIVE_COMPARATOR|Control group|
62490385|NCT03544242|EXPERIMENTAL|Pre-Isolation Infusion|
62490386|NCT03544242|EXPERIMENTAL|Post-Isolation Infusion|
62490387|NCT02981095|ACTIVE_COMPARATOR|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
62490388|NCT02981095|PLACEBO_COMPARATOR|Saline|Saline solution (%0.9 sodium chloride), 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
62490389|NCT03766360|EXPERIMENTAL|FAP Intervention Group|All of the clients in the FAP intervention group will begin treatment at the same time and complete 3 assessments.
61937763|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 3A - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
62136533|NCT03593642|PLACEBO_COMPARATOR|Control Group|Erector spinae bilateral catheters with continuous infusion iso saline during 48h after surgery Day 0 to day 2
62332672|NCT01076842|ACTIVE_COMPARATOR|B Exenatide|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
62332673|NCT01076842|ACTIVE_COMPARATOR|C Levemir+Exenatide|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
62332674|NCT05655156|EXPERIMENTAL|Multiple Knee Ligament Injuries|"Sub-groups of n=7 incurring ligament reconstruction using OrthoPureXT in the following anatomical locations:~* Posterior cruciate ligament (PCL)~* Anterior cruciate ligament (ACL)~* Posteromedial corner including the medial collateral ligament (MCL)~* Posterolateral corner including the lateral collateral ligament (LCL)"
62490390|NCT03766360|NO_INTERVENTION|Control Group|The clients in the control group will take their assessments at the same time as those in the FAP intervention group.
62490391|NCT00189553|ACTIVE_COMPARATOR|Standard|Paclitaxel-Carboplatin
62490392|NCT00189553|EXPERIMENTAL|Experimental|Caelyx-Carboplatin
62490393|NCT05863026|EXPERIMENTAL|iDEAL group|School cluster randomization will be used to ensure administrative efficacy, lessened risk of experimental contamination, and enhancement of subject compliance. 20 standard 4 classrooms and 20 form 4 classrooms from primary and secondary school, then will be divided randomly into intervention and control group. The unit of randomization will be on a 1:1 basis in either the control or intervention group.
62490394|NCT05863026|NO_INTERVENTION|Control|School cluster randomization will be used to ensure administrative efficacy, lessened risk of experimental contamination, and enhancement of subject compliance. 20 standard 4 classrooms and 20 form 4 classrooms from primary and secondary school, then will be divided randomly into intervention and control group. The unit of randomization will be on a 1:1 basis in either the control or intervention group.
62490395|NCT01328782|ACTIVE_COMPARATOR|The group receiving oral pain medicine|This group will receive Oxycodone with Acetaminophen orally
62490396|NCT01328782|ACTIVE_COMPARATOR|The group receiving bupivacaine and oral pain medicine|This group will receive an intra-articular shot during surgery and will then be sent to the recovery room to receive pain medication as needed.
62490397|NCT01328782|ACTIVE_COMPARATOR|The group receiving ropivacaine and oral pain medicine|This group will receive an intra-articular shot of ropivacaine during surgery and will be sent to the recovery room to receive pain medicine as needed.
62490398|NCT01872676|EXPERIMENTAL|Manipulation|The experimental group received upper thoracic manipulation of the T3 vertebra. The volunteer was instructed to lie in the supine position, interlace her fingers and position her hands in the posterior region of the base of the neck. The therapist than positioned a stabilizing hand in a pistol grip immediately caudal to the T3 vertebra, pushing the volunteer's arms downward to generate flexion of the upper thoracic spine.
62490399|NCT01872676|SHAM_COMPARATOR|Sham|The placebo group was placed precisely as the experimental group, with the exception of the positioning of the therapist's hand, which remained with the palm open and not in a pistol grip. Once positioned, the volunteers were instructed to breathe deeply. The maneuver was terminated after one cycle of deep breathing.
62490400|NCT04563260|PLACEBO_COMPARATOR|Control group|Control group receives the intravenous normal saline 2 mL.
62490401|NCT04563260|EXPERIMENTAL|Palonosetron group|Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL.
62490402|NCT01023113|EXPERIMENTAL|PASCAL laser, PRP in 2-3 sitting at 3 days interval.|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by PASCAL laser
62490403|NCT01023113|ACTIVE_COMPARATOR|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by conventional laser
62136534|NCT03593642|EXPERIMENTAL|Regional analgesia group|Erector spinae bilateral catheters with continuous infusion Ropivacaine 0.1 or 0.2%, depending on age, infusion during 48h after surgeryDay 0 to day 2
62136535|NCT00629096|EXPERIMENTAL|1|All included patients are assigned to arm 1, in which they are treated by the intervention
62136536|NCT01208116||Subgroups|According to the demographic features, subjects may be divided into some subgroups.
62332675|NCT02988466|EXPERIMENTAL|Arm A: Haplo-HCT <55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients \<55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2
62332676|NCT02988466|EXPERIMENTAL|CLOSED Arm B: Haplo-HCT ≥55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
62332677|NCT02988466|EXPERIMENTAL|Arm C: Haplo-HCT HCT-CI ≤2 aged ≥55 and < 65yo|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2 aged ≥55 and \< 65 years old.
62332678|NCT02988466|EXPERIMENTAL|Arm D: Haplo-HCT aged ≥65 and ≤75yo OR any age HCT-CI ≥3|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients patients ≥65 and ≤75 years old OR any age group with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
62332679|NCT03239756|EXPERIMENTAL|60 mg single dose cohort|patients would receive a 60 mg single dose of TK006.
62332680|NCT03239756|EXPERIMENTAL|120 mg single dose cohort|patients would receive a 120 mg single dose of TK006.
62332681|NCT03239756|EXPERIMENTAL|180 mg single dose cohort|patients would receive a 180 mg single dose of TK006.
62332682|NCT03239756|EXPERIMENTAL|120 mg Q4W cohort|patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.
62332683|NCT04846751|ACTIVE_COMPARATOR|AEROBIC EXERCISE|50 min of aerobic exercise by pedaling a cycleergometer at 60% of VO2max
62332684|NCT04846751|PLACEBO_COMPARATOR|PLACEBO REST|No exercise, resting during 50 min.
62332685|NCT04005898|EXPERIMENTAL|Experimental: near-infrared cholangiography|Each subject included in the study will be subjected to a fluorescence cholangiography. The control group will be the same patient. The study consists of knowing if fluorescence is able to visualize structures that are not seen with the naked eye. For this purpose the structures are visualized with normal light and then with infrared light of the same patient. During laparoscopic cholecystectomy it will change between normal and infrared light.
62490404|NCT05539937||Patient with percutaneous aortic valve replacement via the transfemoral approach|
62490405|NCT04416750|EXPERIMENTAL|Treatment|Open label; Imatinib tablets administered once daily; Dosage: in the range of 100mg-400mg; Group evaluated: adults with PAH
62490406|NCT00508651|EXPERIMENTAL|Cohort 1 MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM Luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
62136537|NCT03459989||pregnant women|we will measure expected fetal weight by ultrasound by hadlock's formula and thigh soft tissue for each pregnant woman
62136538|NCT04337931|EXPERIMENTAL|Cohort 1|Sotigalimab administered IV at 0.3 mg/kg every 3 weeks (21 day) treatment cycles
62136539|NCT04337931|EXPERIMENTAL|Cohort 2|Sotigalimab administered IV at 0.3 mg/kg every 2 weeks (14 day) treatment cycles
62490407|NCT00508651|PLACEBO_COMPARATOR|Cohort 1 Placebo|Placebo was a frozen preparation filled into Becton Dickinson\^TM Luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
61937764|NCT02687373|EXPERIMENTAL|Part 1: Grp 3B - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
62490408|NCT02955628|EXPERIMENTAL|Ibrutinib-RICE|Patients not achieving a complete remission at time of PET-2 will receive ibrutinib and proceed on to autologous transplant if at least a partial remission is achieved. After transplantation, ibrutinib will be continued for up to 1 year. Autologous transplantation will be with BEAM conditioning.
62490409|NCT02032316|EXPERIMENTAL|Interventional|Placement of ureteral stent following post-ureteroscopy
62490410|NCT02966782|EXPERIMENTAL|Venetoclax monotherapy (Cohort 1)|
62136540|NCT04337931|EXPERIMENTAL|Cohort 3|"Metastatic melanoma participants who have failed any number of prior lines of therapy with minimum 3 measurable lesions.~Sotigalimab administered IV at 0.3mg/kg in combination with Stereotactic Body Radiation Therapy (SBRT) every 2 weeks (14-day) treatment cycles up to 16 weeks followed by sotigalimab administered IV at 0.3 mg/kg every 2 weeks (14-day) treatment cycles."
62136541|NCT03919721|EXPERIMENTAL|Learners receiving Applied Behavior Analysis therapy|All children enrolled in the study will already receiving therapy. Each BT-child pair will have worked together regularly for at least 3 months prior to the study.
62136542|NCT06364553|OTHER|Esophageal self-expandable metal stent|Esophageal self-expandable metal stent
62136543|NCT03350698|EXPERIMENTAL|active drug|Human Papilloma virus ,Gardasil, 9 valent vaccine
62136544|NCT03718013|EXPERIMENTAL|accelerated dTMS|
62136545|NCT03718013|ACTIVE_COMPARATOR|standard dTMS|
62136546|NCT02697201|EXPERIMENTAL|Intralipid Infusion, then Saline|Participants in this arm will first receive a lipid infusion. Then 4 weeks later the saline infusion.
62136547|NCT02697201|SHAM_COMPARATOR|Saline Infusion, then Intralipid|Participants in this arm will first receive a saline infusion. Then 4 weeks later the lipid infusion.
62136548|NCT03452982|EXPERIMENTAL|Patients with ovarian cancer|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection
62136549|NCT02326181|NO_INTERVENTION|control group|without inspiratory and expiratory pressure threshold training
62136550|NCT02326181|EXPERIMENTAL|inspiratory pressure training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
62136551|NCT02326181|EXPERIMENTAL|mixed training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
62136552|NCT06419777|ACTIVE_COMPARATOR|Strict Arm|The strict threshold is defined as two abnormal values or more over a one-week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated)
62136553|NCT06419777|ACTIVE_COMPARATOR|Permissive|The permissive threshold is defined as 50% of values elevated over 1 week (50% of overall fasting values, 50% of postprandial values, or 50% of overall values).
62136554|NCT00176085||healthy|healthy volunteers
62136555|NCT05475717|EXPERIMENTAL|20 µg group|Patients will receive alprostadil liposome injection at 20 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery).
62136556|NCT05475717|EXPERIMENTAL|40 µg group|Patients will receive alprostadil liposome injection at 40 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery)
62136557|NCT05475717|EXPERIMENTAL|80 µg group|Patients will receive alprostadil liposome injection at 80 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery)
62490411|NCT02966782|EXPERIMENTAL|Venetoclax + azacitidine (Cohort 2)|
62490412|NCT02966782|EXPERIMENTAL|Safety Expansion (Cohort 3)|
62490413|NCT05429944|EXPERIMENTAL|Motor Relearning Program|"MRP is a task- oriented approach to improve motor control, focusing on relearning of daily activities. Based on 4 steps~1.Analysis of task 2.Practice of missing component 3.Practice of task 4.Transference of learning"
62490414|NCT05429944|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is the neurophysiological approach in which impulses from the periphery are facilitated to the central nervous system through the stimulation of sensory receptors present in muscles and around the joints by stretch, resistance, traction, approximation and audiovisual command to the patient. The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.
62136558|NCT05475717|NO_INTERVENTION|blank control group|Patients will receive only basic hydration therapy which the experimental groups will receive.
62136559|NCT06471322|OTHER|Control Arm - Standard of Care, retrospective|Retrospective data looking at 12 patients undergoing standard of care for diabetic ketoacidosis
62136560|NCT06471322|ACTIVE_COMPARATOR|Intervention Arm - Continuous Glucose Monitoring (CGM)|12 patients with confirmed diabetic ketoacidosis upon hospital admission will receive continuous glucose monitor (CGM)
62136561|NCT03576521|EXPERIMENTAL|Ocoxin-Viusid®|The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
62136562|NCT03576521|PLACEBO_COMPARATOR|Placebo|The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.
62490415|NCT05429944|ACTIVE_COMPARATOR|Conventional Physical Therapy|Electrotherapy includes TENS, Electrical stimulation and Heat therapy. ROM . Stretching and positioning Exercises Strengthening Exercises for the weak muscles. Sensory Interventions.
62490416|NCT04345133|ACTIVE_COMPARATOR|Undersized Drilling Group|Exposed patients to the reduction of the final drill dimensions at the insertion implants protocol sequence
62490417|NCT04345133|OTHER|Conventional Drilling Group|Group with the conventional protocol recommended by the manufacturer
62490418|NCT03822130|PLACEBO_COMPARATOR|Group 1|Systemic Chemotherapy + Oral Chemotherapy Group
62490419|NCT03822130|EXPERIMENTAL|Group 2|Arterial catheter infusion chemotherapy plus oral chemotherapy group
62490420|NCT03822130|EXPERIMENTAL|Group 3|Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group
62490421|NCT05595980|EXPERIMENTAL|Probiotic|Bacillus strain spore preparation
62490422|NCT05595980|PLACEBO_COMPARATOR|Placebo|Placebo maltodextrin
61937765|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 3B - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
62332686|NCT02112994|EXPERIMENTAL|Sebelipase Alfa|Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
62332687|NCT02191241|EXPERIMENTAL|Red Vine Leaf Extract|
62332688|NCT05072548|EXPERIMENTAL|Intervention|The intervention arm will receive access to the ABCs of SLEEPING Intervention.
62332689|NCT05072548|NO_INTERVENTION|Control group|The control group arm does not receive the ABCs of SLEEPING intervention. This arm is free to access other resources while enrolled in the study. After the post-test follow up time point, the control group arm will be able to access the intervention.
62332690|NCT05662137|NO_INTERVENTION|Control group|"At the beginning of the study, data collection tools Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the control group.~No intervention will be made in the control group. Measurement tools will be applied for the posttest. Emotional Expression Scale, Toronto Alexithymia Scale and Positive and Negative Syndrome Scale will be reapplied 1 month after the last session."
62332691|NCT05662137|EXPERIMENTAL|Experimental group|"Emotion recognition and expression program is aimed to be carried out in 8-week sessions for schizophrenia patients included in the experimental group. Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the experiment. The principal investigator will lead the structured group sessions as the group leader.~The principal investigator will lead the structured group sessions as the group leader.~Each group is planned to be 60-90 minutes. Before sessions, participants are taken from their previous session's emotions so far. Homework is discussed by providing recall of the topic from the previous session, and then the current topic is moved on. At the end of each session, a general summary and evaluation is made. After the sessions in the research, measurement tools will be applied for the posttest. It will be reapplied 1 month after the last session."
62332692|NCT02018952|OTHER|Ultrasonography assessment|
62332693|NCT04207957|OTHER|IV|2 h IV infusion (Groups A/B)
62490423|NCT04020796|ACTIVE_COMPARATOR|Beetroot juice|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of beetroot juice in a single moment.
62490424|NCT04020796|PLACEBO_COMPARATOR|Mineral water|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of mineral water in a single moment.
62490425|NCT05394194||3DCRT group|In this plan, we will create plans using three dimensional conformal radiotherapy, evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
61937766|NCT02687373|EXPERIMENTAL|Part 1: Grp 3C - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
61937767|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 3C - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
62136563|NCT04155905|ACTIVE_COMPARATOR|group A fistulotomy group|35 patients with simple anal fistula subjected to fistulotomy
62136564|NCT04155905|ACTIVE_COMPARATOR|group B marsupialization group|35 patients with simple anal fistula subjected to fistulotomy and marsupialization of fistulotomy wound
62136565|NCT04504721|EXPERIMENTAL|Light therapy group|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
62136566|NCT04504721|NO_INTERVENTION|Waiting list group|Participants who are randomly assigned into the waiting list group will be told that they are on a waiting list to be enrolled in the study. Participants will be provided with light therapy after the first posttest outcome assessments are completed.
62136567|NCT00035100|EXPERIMENTAL|EPO906|
62136568|NCT04935177|EXPERIMENTAL|Imlifidase|Imlifidase, is provided as a freeze-dried powder for concentrate for solution for infusion, 11 mg per vial. After reconstitution with sterile water for injection, the concentrate contains 10 mg/mL imlifidase. Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes generally 24 hours prior to transplantation. A second dose of 0.25 mg/kg may be given if the first imlifidase dose is considered not to have had sufficient effect.
62136569|NCT04935177|OTHER|Best available treatment|Institution-specific desensitization protocol (i.e. any combination of plasma exchange (PLEX), intravenous IVIg, anti-CD20 antibody, and eculizumab) where appropriate OR remain on wait list for a more compatible organ offer
62136570|NCT06033105||Group A|35 OLP patients
62136571|NCT06033105||Group B|35 healthy controls.
62136572|NCT01053325|EXPERIMENTAL|CTX in HIV-negative women|CTX daily prophylaxis in HIV-negative pregnant women
62136573|NCT01053325|EXPERIMENTAL|CTX in HIV-positive women|CTX daily prophylaxis in pregnant women who are infected with HIV
62136574|NCT01053325|ACTIVE_COMPARATOR|SP IPT in HIV-negative women|Intermittent Preventive Treatment with SP in HIV-negative pregnant women
62332694|NCT04207957|OTHER|oral (fasted)|30 mg tablets given after an overnight fast (Groups A/B)
62332695|NCT04207957|OTHER|oral (fed)|30 mg tablets given after a high fat breakfast (Groups A/B)
62332696|NCT04207957|OTHER|oral (intact tablet)|30 mg tablets (Group C)
62332697|NCT04207957|OTHER|oral (NG tube)|30 mg tablets in water via NG tube (Group C)
62332698|NCT03537339||Observation|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on
62490426|NCT05394194||IMRT group|In this plan, we will create plans using intensity modulated radiotherapy (IMRT), evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
62694737|NCT01179555|EXPERIMENTAL|Pt. 1 Behavioral Activation|"Behavioral Activation (BA) is a behavioral technique to help people overcome avoidant tendencies through goal setting, activity scheduling, and graded task assignment. The key component of BA involves developing an Action Plan, and having the subject document each step of the plan as he or she implements it, reinforcing the steps towards goal attainment. Action Plans are easily applied to diabetes self-care tasks because the latter lend themselves to documentation of simple, step-by-step plans. In this study, a Community Health Educator (CHE) - interventionist will schedule and deliver four 45-60 minute in-home BA sessions within 3 months of randomization (i.e., one session every 2-3 weeks)."
61937768|NCT02687373|EXPERIMENTAL|Part 1: Grp 3D - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10\^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
61937769|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 3D - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62332699|NCT04146467|EXPERIMENTAL|Study Phase I|Subjects will be treated with the Renuvion APR device in the neck and submental region.
62332700|NCT04146467|EXPERIMENTAL|Study Phase II|Subjects will be treated with the Renuvion APR device in the neck and submental region.
62332701|NCT06552312||Delphi Panel|The Delphi panel will include between 20-50 international experts in critical care, cardiology, intensive care, anaesthesia, emergency medicine, perfusion and cardio-thoracic surgery.
62332702|NCT04435262||ILR Group followed with RM|Patients with unexplained syncope underwent ILR monitoring and followed with RM
62332703|NCT04435262||ILR Group followed with in-hospital visits|Patients with unexplained syncope underwent ILR monitoring and followed with in-hospital visits
62332704|NCT03055403|EXPERIMENTAL|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
62332705|NCT03055403|PLACEBO_COMPARATOR|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
62332706|NCT05475821|EXPERIMENTAL|Group 1|Participants will receive ABBV-990 Dose A or matching placebo.
62332707|NCT05475821|EXPERIMENTAL|Group 2|Participants will receive ABBV-990 Dose B or matching placebo.
62332708|NCT05475821|EXPERIMENTAL|Group 3|Participants will receive ABBV-990 Dose C or matching placebo.
62332709|NCT05475821|EXPERIMENTAL|Group 4|Participants will receive ABBV-990 Dose D or matching placebo.
62332710|NCT05475821|EXPERIMENTAL|Group 5|Participants will receive ABBV-990 Dose E or matching placebo.
62332711|NCT00620321|EXPERIMENTAL|LY2181308 sodium, idarubicin, cytarabine|
62332712|NCT00129805|EXPERIMENTAL|MCI-9042|
62332713|NCT00129805|ACTIVE_COMPARATOR|Aspirin|
62332714|NCT03706534|ACTIVE_COMPARATOR|Manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored. Radiologists also make assessment decision without any intervention from artificial intelligence. 10 radiologists review manually.
62332715|NCT03706534|EXPERIMENTAL|Review by S-Detect for Breast|The same images will be separately processed by the artificial intelligence system (S-Detect for Breast) by Samsung. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
62332716|NCT03706534|EXPERIMENTAL|Review with assistance of S-Detect for Breast|Second, the images will be reviewed by the radiologists with the help of artificial intelligence system, which is an interactive tool automatically providing recommendations on BIRADS descriptor choices that can be modified by the radiologists. The radiologists, after selecting all the descriptors of BIRADS, will decide the assessment categories. These decisions will be compared with the ground truths generated from the biopsy results or a 24-month follow-up (CADx).
62332717|NCT03165721|EXPERIMENTAL|Patients ≥ 12 Years of Age w/Wild-Type GIST|"SGI-110 administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle~Gastrointestinal stromal tumor (GIST)"
62332718|NCT03165721|EXPERIMENTAL|Patients ≥ 12 Years of Age w/PHEO/PGL with SDH-deficient PHE|"SGI-110 administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle~Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE"
62332719|NCT03165721|EXPERIMENTAL|Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca|"SGI-110 administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle~Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca"
62332720|NCT02156869|EXPERIMENTAL|Intervention arm|The intervention was the use of a decision aid.
62332721|NCT02156869|NO_INTERVENTION|Control arm|Usual care
62332722|NCT02641236|ACTIVE_COMPARATOR|Gut Decontamination with vancopoly|"* All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~* Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
62332723|NCT02641236|NO_INTERVENTION|No Gut Decontamination|"* All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~* Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
62332724|NCT05930392|ACTIVE_COMPARATOR|GINGIVAL DEPIGMENTATION USING MICROSURGERY|Surgical excision of hyper-pigmented gingival tissue using microsurgical blade (keratome 2.2) and magnification loupes under local anaesthesia. Application of periodontal dressing followed by post-operative instructions.
62332725|NCT05930392|ACTIVE_COMPARATOR|Conventional surgical technique of gingival depigmentation|Surgical excision of hyper-pigmented gingival tissue using conventional surgical blade (#15) under local anaesthesia. Application of periodontal dressing followed by post-operative instructions.
62490427|NCT05394194||VMAT plan|In this plan, we will create plans using volumetric modulated radiotherapy (VMAT), evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
62490428|NCT05303441||patients with acute coronary syndrome|patients with chronic kidney disease having chest pain with ecg, symptom or cardiac troponin levels compatible with ACS
62490429|NCT05303441||patients without acute coronary syndrome|patients with chronic kidney disease having chest pain with ecg, symptom or cardiac troponin levels NONcompatible with ACS
62490430|NCT04298216|ACTIVE_COMPARATOR|Assessment of Inferior Vena Cavae with Subcostal View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the subcostal region.
62490431|NCT04298216|EXPERIMENTAL|Assessment of Inferior Vena Cavae with Transhepatic View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the transhepatic region.
62490432|NCT06089330|EXPERIMENTAL|JMT101+SG001+ Irinotecan|
62490433|NCT06089330|EXPERIMENTAL|JMT101+Irinotecan|
62332726|NCT01606592|EXPERIMENTAL|Randomized Panic Control Treatment|Patients who have been randomized to the randomization condition are assigned to PCT
61937770|NCT02687373|EXPERIMENTAL|Part 1: Grp 3E - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10\^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
61937771|NCT02687373|PLACEBO_COMPARATOR|Part 1: Grp 3E - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
62136575|NCT01053325|ACTIVE_COMPARATOR|IPT SP in HIV-positive women|Intermittent Preventive Treatment with SP in HIV-positive pregnant women
62136576|NCT01053325|ACTIVE_COMPARATOR|CTX in HIV-positive pregnant women with CD4<350|Daily prophylaxis with cotrimoxazole in HIV-positive pregnant women with CD4\<350
62136577|NCT06082323|EXPERIMENTAL|Single Ascending Dose (SAD)|Part 1: healthy volunteer subject cohorts randomized 6:2 receiving a single dose of LT-002-158 or placebo. The first cohort will receive 50mg of LT-002-158 or placebo. Dose escalation will occur if LT-002-158 or placebo is tolerated.
62136578|NCT06082323|EXPERIMENTAL|Food effect|Part 2: A 3-treatment, 3 period crossover study will be conducted, which is composed of 12 healthy Volunteer subjects, who will be receiving a single dose of LT-002-158 in fasted, standard diet and high fat meal.
62136579|NCT06082323|EXPERIMENTAL|Multiple Ascending Doses (MAD) Study|Part 3: Healthy volunteer subject cohorts randomized 8:2 to receive LT-002-158 or placebo for 14 days continuous dosing. The first cohort will receive a dose of LT-002-15 or placebo determined to be safe based on data generated in the SAD portion and FE study.
62332727|NCT01606592|EXPERIMENTAL|Randomized Panic-Focused Psychodynamic Psychotherapy|Patients who have been randomized to the randomization condition are assigned to PFPP
62490434|NCT06089330|ACTIVE_COMPARATOR|Regorafenib (Stivarga)|
62490435|NCT03142022||SDB and lung transplantation|Polysomnography at 1 year after lung transplantation.
62490436|NCT00845130|EXPERIMENTAL|Diabetic Type II Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
61937772|NCT02687373|EXPERIMENTAL|Part 2: Group 1 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10\^6 PfSPZ per dose."
61937773|NCT02687373|EXPERIMENTAL|Part 2: Group 2 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10\^5 PfSPZ per dose."
62136580|NCT03471559|ACTIVE_COMPARATOR|Reference formulation|Cannabidiol capsule, 200 mg
62136581|NCT03471559|EXPERIMENTAL|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
62136582|NCT05877872|EXPERIMENTAL|Reduced-target resection group|Patients receive surgery according to pSTV-post-IC and adjuvant immunotherapy.
62136583|NCT05877872|ACTIVE_COMPARATOR|Full-target resection group|Patients receive surgery according to pSTV-pre-IC and adjuvant immunotherapy.
62332728|NCT01606592|EXPERIMENTAL|Self-selected Panic Control Treatment|Patients who have been randomized to the self-selection condition choose PCT
62332729|NCT01606592|EXPERIMENTAL|Self-selected Panic-Focussed Psychodynamic Psychotherapy|Patients who have been randomized to the self-selection condition choose PFPP
62490437|NCT00845130|EXPERIMENTAL|Healthy Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
62490438|NCT06004973|EXPERIMENTAL|STAR Particles|Participants will receive the 8 interventions (different application pressures) plus the control (Site and treatment will not be randomly assigned on the arm) by the investigator.
62490439|NCT03519139|EXPERIMENTAL|individual dietary counselling|three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
62490440|NCT03519139|NO_INTERVENTION|Control|standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.
62490441|NCT05285865|ACTIVE_COMPARATOR|Conventional Treatment|Thrice a day ,Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
62490442|NCT05285865|EXPERIMENTAL|Scapular Mobilization|Thrice a day Scapular mobilization (SM) along with Conventional treatment
62490443|NCT05736250||TEST group|smoker patients
62332730|NCT01606592|EXPERIMENTAL|Waiting-list|Patients who have been randomized to the waiting-list are offered sparse contact over telephone for 12 weeks and are then re-randomized to one of the other four arms
62332731|NCT00995345|EXPERIMENTAL|Dose 1: KRP-104 40 mg|Tablet, once-daily for 24 weeks
62332732|NCT00995345|EXPERIMENTAL|Dose 2: KRP-104 80 mg|Tablet, once-daily for 24 weeks
62332733|NCT00995345|EXPERIMENTAL|Dose 3: KRP-104 100 mg|Tablet, once-daily for 24 weeks
62136584|NCT02132949|EXPERIMENTAL|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m\^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m\^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m\^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams \[mg\] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram \[mg/kg\] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
62136585|NCT02132949|EXPERIMENTAL|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m\^2 intravenously (IV) q3w, epirubicin 100mg/m\^2 IV q3w, and cyclophosphamide 600mg/m\^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m\^2 in Cycle 5, then 100mg/m\^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
62136586|NCT06597279|EXPERIMENTAL|Intervention|Web-based dialysis decision support tool
62136587|NCT06597279|NO_INTERVENTION|Control|Historical controls
62136588|NCT01467128|ACTIVE_COMPARATOR|Structured expert pharmacist review|
62136589|NCT01467128|NO_INTERVENTION|Normal pharmaceutical care in hospital|
62136590|NCT03388840|EXPERIMENTAL|Adipose derived stem cells suspention|suspension rich in adipose derived stem cells plus platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
62136591|NCT03388840|ACTIVE_COMPARATOR|Platelet rich plasma|platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
62136592|NCT03807752|ACTIVE_COMPARATOR|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
62136593|NCT03807752|PLACEBO_COMPARATOR|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
62136594|NCT02968329||CVA cases|patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.
62136595|NCT02968329||CVA controls|patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.
62136596|NCT02968329||AF cases|patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF
62136597|NCT02968329||AF controls|patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration
62136598|NCT05609929|EXPERIMENTAL|Omeprazole combined with AB-106 group|
62136599|NCT05119543||Grade|The changes in myopia rate in 3 years were compared by generalized estimation equation in different grades
62136600|NCT00274261|EXPERIMENTAL|A|C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
62136601|NCT00274261|ACTIVE_COMPARATOR|B|Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
62136602|NCT04111510|EXPERIMENTAL|LN-145|LN-145 will be delivered as a single therapy in patients with Metastatic Triple Negative Breast Cancer.
62136603|NCT00532116|ACTIVE_COMPARATOR|A|EMSAM 6mg
62136604|NCT00532116|ACTIVE_COMPARATOR|B|EMSAM (Selegiline Transdermal System) 12mg
62136605|NCT02179268|ACTIVE_COMPARATOR|sertraline & control|sertraline 50-150mg tables for 1 year,Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
62332734|NCT00995345|EXPERIMENTAL|Dose 4: KRP-104 20/120mg|Tablet, once-daily for 24 weeks (dose switch from 20 to 120 mg at week 12)
62332735|NCT00995345|PLACEBO_COMPARATOR|Placebo|Tablet, once-daily for 24 weeks
62332736|NCT03920826|EXPERIMENTAL|tACS stimulation group|NEXALIN ADI transcranial alternating current stimulator
62332737|NCT03920826|SHAM_COMPARATOR|sham stimulation group|Sham stimulator provided by NEXALIN company
62332738|NCT04708652||preterm children|Our previous intervention study enrolled 178 VLBW (birth body weight less than 1,500 gm) preterm children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
62332739|NCT04708652||term children|Our previous intervention study enrolled 62 term children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
62332740|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
62332741|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
62332742|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
62490444|NCT05515458|EXPERIMENTAL|Normal Renal Function|Subjects with normal renal function will receive a single 48 mg oral dose of Chiglitazar
62490445|NCT05515458|EXPERIMENTAL|Severe Renal Impairment|Subjects with severe renal impairment will receive a single 48 mg oral dose of Chiglitazar
62332743|NCT05602441|EXPERIMENTAL|VALID - diabetes supportive clubs|VALID - diabetes supportive clubs
62490446|NCT05183282|EXPERIMENTAL|Tarsus Patch Group|All subjects will receive the Tarsus Patch to be worn and evaluated by the investigator in the clinic and to also be worn at home for 3 nights.
62694738|NCT01179555|PLACEBO_COMPARATOR|Pt. 1 Supportive Therapy|The purpose of Supportive Therapy (ST) is to explore the impact of aging and diabetes on the subject's life. In contrast to the BA intervention, the interventionist does not discuss the importance of dilated eye exams. In subsequent sessions, ST facilitates and deepens knowledge about the subject's life situation in relation to his or her health and other life difficulties. The ST therapist encourages this process and creates an accepting, nondirective, and supportive opportunity for discussion.
61937774|NCT02687373|EXPERIMENTAL|Part 2: Group 3 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10\^5 PfSPZ per dose."
62136606|NCT02179268|ACTIVE_COMPARATOR|citalopram & Control|citalopram 20-40mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
62136607|NCT02179268|ACTIVE_COMPARATOR|venlafaxine & control|venlafaxine 75-100mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
62136608|NCT02179268|ACTIVE_COMPARATOR|reboxetine & control|reboxetine 4-8mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
61937775|NCT02687373|PLACEBO_COMPARATOR|Part 2: Group 4 - Normal Saline|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals."
62136609|NCT03907306|EXPERIMENTAL|Patients after open hemorrhoidectomy (study group)|Patients to whom during a post-operation period cold argon plasma and a standard treatment will be treated. Cold argon plasma will be applied during 4 minutes at one session on the 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 14th, 21nd, 30th day after operation. The usage of antibacterial and wound healing ointments daily.
62332744|NCT01201798|EXPERIMENTAL|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
62332745|NCT01201798|ACTIVE_COMPARATOR|Pred Forte|Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period
62490447|NCT02004769|EXPERIMENTAL|Trastuzumab, Capecitabine, Docetaxel|Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.
62694739|NCT06643468|ACTIVE_COMPARATOR|beta-tricalcium phosphate + calcium sulphate bone graft and collagen membrane|will include 10 patients, in which participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate as bone graft and collagen as membrane.
61937776|NCT05077527|EXPERIMENTAL|Treatment (conditioning, axicabtagene ciloleucel)|Patients receive fludarabine IV over 30 minutes and cyclophosphamide IV over 1 hour on days -5, -4, and -3. Patients then receive axicabtagene ciloleucel IV over 30 minutes on day 0.
61937777|NCT04163497|EXPERIMENTAL|Diary reading|
62136610|NCT03907306|ACTIVE_COMPARATOR|Patients after open hemorrhoidectomy (control group)|Patients who during a post-operation period will be treated with a standard treatment.The usage of antibacterial and wound healing ointments daily.
62694740|NCT06643468|ACTIVE_COMPARATOR|beta-tricalcium phosphate + calcium sulphate bone graft and ALB- PRF membrane|will include 10 patients, in which participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate as bone graft and ALB- PRF as membrane.
61937778|NCT04163497|NO_INTERVENTION|No diary reading|
61937779|NCT05266534|ACTIVE_COMPARATOR|intramyometrial Terlipressin injection in women undergoing open myomectomy|intramyometrial Terlipressin injection
61937780|NCT05266534|ACTIVE_COMPARATOR|intramyometrial Carbetocin injection in women undergoing open myomectomy|intramyometrial Carbetocin injection
62136611|NCT04124432|EXPERIMENTAL|Active cannabis without nicotine|Smoked cannabis containing 10mg THC + No nicotine/tobacco
62136612|NCT04124432|EXPERIMENTAL|Active cannabis with own brand cigarettes|Smoked cannabis containing 10mg THC + ad-libitum use of preferred brand cigarettes
62136613|NCT04124432|EXPERIMENTAL|Active cannabis with low nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
62136614|NCT04124432|EXPERIMENTAL|Active cannabis with high nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
62136615|NCT04124432|EXPERIMENTAL|placebo cannabis with own brand cigarettes|Smoked placebo cannabis + ad-libitum use of preferred brand cigarettes
62332746|NCT01383395|EXPERIMENTAL|simvastatin/cilostazol|simvastatin 40 mg on day 1 and 6, cilostazol 100 mg from day 2 to day 6
62332747|NCT02153450|EXPERIMENTAL|Treatment (stereotactic radiosurgery, metformin hydrochloride)|"Patients receive metformin hydrochloride PO daily or BID on days -11 to -1. Patients then undergo stereotactic radiosurgery 5 days a week for 5 weeks and receive concurrent metformin hydrochloride\* PO BID for 5 weeks. Patients undergo laparotomy on week 6 (or weeks 5-7). Systemic therapy continues as soon as it is considered feasible by the treating physicians.~\*NOTE: Metformin hydrochloride should be stopped 2 days before laparotomy."
62490448|NCT01309958||intervention|design instruments and test feasibility of an intervention aimed at increasing the proportion on non-invasive treatment for early caries
62490449|NCT01926353||Vantris|Patient who categorized as who underwent endoscopic correction procedure, were patients who under general anesthesia performed by a single experienced surgeon using a 10Fr Storz® cystoscope with PPC (Vantris®) subureteral or intraureteral injection, or a combination of both techniques, depending on the anatomy of the ureteral meatus and VUR grade.
62490450|NCT01926353||Cohen reimplantation|Patient underwent surgical management were all had ureteral re-implatation with Cohen technique done by single experienced pediatric urologist.
62490451|NCT01926353||Continuous Antibiotic Prophylaxis|Group of patient treated with conservative management were children treated with culture guided antibiotics and maintained on 1st or 2nd generation cephalosporin as continuous antibiotic prophylaxis until time of 1 year follow-up.
62490452|NCT01736839||CF adults colonized with Pseudomonas aeruginosa|
61937781|NCT05266534|PLACEBO_COMPARATOR|intramyometrial saline injection in women undergoing open myomectomy procedure|intramyometrial saline injection in women
61937782|NCT05397873|EXPERIMENTAL|Group A|The patients will undergo baseline assessment and receive the intervention, being assessed after the intervention.
61937783|NCT05397873|NO_INTERVENTION|Group B|The patients will perform the same tests for assessment as in group A, however, no intervention will be done. They may enrol in the study as group B after completing group B participation.
61937784|NCT03275792|EXPERIMENTAL|Admission/Intravascular Volume Expansion|"1. Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes~2. 0.9% NS with 5% dextrose at 150% of standard maintenance volume~3. If urine output is \<0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload~4. Oral fluids ad lib along with strict input/output documentation~5. Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload~6. Daily laboratory tests and in-person assessment until inpatient discharge criteria reached:~   A) 2 - 4 days since symptom onset AND rising platelet count (\>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (\<5% decrease) documented over 48 hours in a clinically well child~7. Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge."
61937785|NCT03275792|ACTIVE_COMPARATOR|Outpatient Observation|"1. Following standard emergency department (ED) care \[volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)\], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs).~2. Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge~3. Additional health assessments as required~4. Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (\>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (\<5% decrease) documented over 48 hours in a clinically well child"
61937786|NCT06096935||Group 1|patients with type 2 diabetes complicated by active or chronic Charcot neuropathy
61937787|NCT06096935||Group 2|patients living with type 2 diabetes without active or chronic Charcot neuroarthropathy.
62332748|NCT03075462|EXPERIMENTAL|Fluzoparib + Apatinib|Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
62332749|NCT03803852|EXPERIMENTAL|0°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impress on axis 0°
62332750|NCT03803852|EXPERIMENTAL|45°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impresson axis 45°
62332751|NCT03803852|EXPERIMENTAL|90°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impress on axis 90°
62332752|NCT03803852|EXPERIMENTAL|135°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impresson axis 135°
62332753|NCT04767256|EXPERIMENTAL|DD group|co-administered intravenous dexamethasone 10 mg and dexmedetomidine 1 ug/kg
62490453|NCT03559738||Patients With Upper Ureteric Stones|Patients with upper ureteral stones more than 1cm and 1000 HU
61937788|NCT04297059|EXPERIMENTAL|Intervention group|Implementation of Ajyal Salima intervention to promote healthy eating and encourage physical activity in Lebanese school-children.
61937789|NCT04297059|NO_INTERVENTION|Control group|Group of students not receiving any intervention
61937790|NCT02595359|EXPERIMENTAL|moxifloxacin intracameral|moxifloxacin injection given at conclusion of cataract intervention
61937791|NCT06680739|EXPERIMENTAL|Control arm|Patients in this arm receive Durvalumab alone. Durvalumab is administered intravenously (IV) at a dose of 1500 mg every 4 weeks. This arm is designed to evaluate the efficacy and safety of Durvalumab monotherapy in patients with colorectal or endometrial cancer.
62332754|NCT04767256|PLACEBO_COMPARATOR|D group|intravenous dexmedetomidine 1 ug/kg
62332755|NCT01152008||healthy volunteers|
62332756|NCT02198287|EXPERIMENTAL|BIIX 1 XX, rising doses|
62332757|NCT02198287|PLACEBO_COMPARATOR|Placebo|
62332758|NCT02745223|EXPERIMENTAL|PresbiDrops (CSF-1)|Participants self-administered PresbiDrops (CSF-1), 1 drop in each eye each morning for 2 weeks.
62332759|NCT02745223|PLACEBO_COMPARATOR|Placebo|Participants self-administered placebo, 1 drop in each eye each morning for 2 weeks.
62332760|NCT04652336|ACTIVE_COMPARATOR|LSG|This group will receive standard laparoscopic sleeve gastrectomy
62332761|NCT04652336|EXPERIMENTAL|LSG with LTC|This group will receive LSG along with the novel LTC procedure
62332762|NCT04343521|EXPERIMENTAL|Targeted Indoor Residual Spraying (TIRS)|All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, epidemiological and entomological evaluation will occur in the center of each cluster
62332763|NCT04343521|NO_INTERVENTION|Control|Routine Aedes-borne virus (ABV) prevention and control, no Targeted Indoor Residual Spraying (TIRS)
62332764|NCT01913249|EXPERIMENTAL|Intervention|Seton through fistula 6 months prior to LIFT
62332765|NCT01913249|ACTIVE_COMPARATOR|Control|Seton through fistula 3 weeks prior to LIFT surgery
62694741|NCT06643468|ACTIVE_COMPARATOR|nano-crystalline putty hydroxyapatite bone graft and collagen membrane|will include 10 patients, in which participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and collagen as membrane.
62490454|NCT01404351|EXPERIMENTAL|PEAK PlasmaBlade|
62490455|NCT01404351|ACTIVE_COMPARATOR|Standard of Care|The Standard of Care arm will consist of the scalpel for the skin incision and traditional electrosurgery for subcutaneous dissection.
62490456|NCT01083329|PLACEBO_COMPARATOR|placebo|for 16 weeks
62490457|NCT01083329|ACTIVE_COMPARATOR|nicotinic acid|"for 16 weeks :~* week 1 = 375 mg per day,~* week 2 = 500 mg per day,~* week 3 = 750 mg per day,~* week 4 = 1000 mg per day,~* week 5 = 1500 mg per day,~* weeks 6 to 16 = 2000 mg per day."
62490458|NCT03100019|EXPERIMENTAL|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
62490459|NCT03100019|PLACEBO_COMPARATOR|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
62490460|NCT03100019|EXPERIMENTAL|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
62490461|NCT03100019|PLACEBO_COMPARATOR|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
62490462|NCT01608984|ACTIVE_COMPARATOR|RIPC-CABG|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.
62490463|NCT01608984|PLACEBO_COMPARATOR|Control-CABG|Control group: Coronary artery bypass grafting without RIPC protocol
62490464|NCT01608984|ACTIVE_COMPARATOR|RIPC-OPCAB|Remote ischemic preconditioning (RIPC) protocol before Off-pump coronary artery bypass surgery (OPCAB) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before first coronary artery incision and 5 to 10 Minutes after completion of the coronary anastomoses. Blood samples are taken up to 72 hours postoperatively.
62490465|NCT01608984|PLACEBO_COMPARATOR|Control-OPCAB|Control group: Off-pump Coronary artery bypass surgery without RIPC protocol
62490466|NCT03599583|EXPERIMENTAL|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
62490467|NCT03599583|NO_INTERVENTION|Control|Arm 2 will receive standard of care
61937792|NCT06680739|EXPERIMENTAL|MSI arm|Patients in this arm receive a combination of Durvalumab and Tremelimumab. They initially receive Tremelimumab as a single dose of 300 mg IV, followed by Durvalumab administered at a dose of 1500 mg IV every 4 weeks. This arm aims to assess the efficacy and safety of combining Durvalumab with Tremelimumab in patients with colorectal or endometrial cancer.
61937793|NCT06680739|EXPERIMENTAL|MSS arm|Patients in this arm also receive a combination of Durvalumab and Tremelimumab. Similar to Cohorte 1B, they receive Tremelimumab as a single dose of 300 mg IV, followed by Durvalumab administered at a dose of 1500 mg IV every 4 weeks. However, patients in this arm have tumors with microsatellite stability (MSS), unlike Cohorte 1B where patients have tumors with microsatellite instability (MSI). This arm aims to evaluate the efficacy and safety of the Durvalumab and Tremelimumab combination in patients with MSS tumors.
62332766|NCT05412719|EXPERIMENTAL|control group|". Before the procedure, the baby's pulse, blood pressure, SpO2, respiratory rate were checked by an observing nurse and recorded on the Baby Monitoring Form.~* An observer nurse will assist the doctor at the beginning of the procedure, and then the baby's upper legs are kept stable in order to maintain the stability of the baby and ensure that the doctor can see the urethral opening. The other observer nurse evaluated the respiratory rate of the baby during the procedure and recorded it in the Infant Follow-up Form after the procedure was completed.~* During the procedure, the baby was evaluated by both observer nurses according to the FLAAC pain scale.~* No pharmacological or non-pharmacological interventions were made for the baby's pain during the procedure."
62490468|NCT04763161||Experimental group|"Patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy.~Intervention is decompressive hemicraniectomy in the context of a malignant sylvian ischaemic cerebral"
62694742|NCT06643468|ACTIVE_COMPARATOR|nano-crystalline putty hydroxyapatite bone graft and ALB- PRF membrane|will include 10 patients, in which participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and ALB- PRF as membrane.
61937794|NCT05790083|EXPERIMENTAL|Body Lotion BNO 3732 + Intensive Care BNO 3731|
61937795|NCT06677567||SP AİR Q group|under general anesthesia, patients inserted Air- Q intubating airway.
61937796|NCT06677567||Proseal Group|under general anesthesia, patients inserted proseal laryngeal mask.
61937797|NCT04986644|EXPERIMENTAL|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
61937798|NCT04986644|ACTIVE_COMPARATOR|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
61937799|NCT02797015|EXPERIMENTAL|1 mg RPC1063|1 mg RPC1063 oral capsule daily
61937800|NCT02797015|EXPERIMENTAL|0.5 mg RPC1063|0.5 mg RPC1063 oral capsule daily
61937801|NCT04409600|ACTIVE_COMPARATOR|Home Based Gait Retraining + Saline Injection|
61937802|NCT04409600|EXPERIMENTAL|Home Based Gait Retraining + Botulinum Toxin Injection|
62490469|NCT04763161||Control group|"Patients not suffering from AIC, hospitalised in neurosurgery for another reason,~Patients to be opered on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach."
62490470|NCT02043392|EXPERIMENTAL|Magnamosis|Create an intestinal anastomosis using the Magnamosis Magnetic Compression Anastomosis (Magnamosis) device to re-establish intestinal continuity that would otherwise be performed using sutures or stapling devices
62694743|NCT03435107|EXPERIMENTAL|Durvalumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were refractory to fluoropyrimidines, irinotecan and oxaliplatin with or without targeted agents will be accrued.~After checking the eligibility for the study entry, patients will be entered into the study treatment with durvalumab monotherapy."
62694744|NCT06303518|EXPERIMENTAL|High normal ETCO2, Normal ETCO2, Low normal ETCO2|All patients will receive same interventions, in a randomised order.
62694745|NCT06303518|EXPERIMENTAL|High normal ETCO2, Low normal ETCO2, Normal ETCO2|All patients will receive same interventions, in a randomised order.
62694746|NCT06303518|EXPERIMENTAL|Low normal ETCO2, Normal ETCO2, High normal ETCO2|All patients will receive same interventions, in a randomised order.
61937803|NCT04409600|ACTIVE_COMPARATOR|Supervised Gait Retraining + Saline Injection|
61937804|NCT04409600|EXPERIMENTAL|Supervised Gait Retraining + Botulinum Toxin Injection|
61937805|NCT03234777|EXPERIMENTAL|Whiteboard animation video|3 minute video on treatment, management of pediatric acute gastroenteritis
62490471|NCT02244762|EXPERIMENTAL|Mild Renal Impairment|20 mg HC-ER
62490472|NCT02244762|EXPERIMENTAL|Moderate Renal Impairment|20 mg HC-ER
62490473|NCT02244762|EXPERIMENTAL|Severe Renal Impairment|20 mg HC-ER
62490474|NCT01093560|EXPERIMENTAL|young women with MetS|"1. Saturated fat (control)~2. n-3 Polyunsaturated fat (experimental)~3. monounsaturated fat"
62490475|NCT00564031|PLACEBO_COMPARATOR|1|
62490476|NCT00564031|EXPERIMENTAL|2|
62490477|NCT00564031|EXPERIMENTAL|3|
62490478|NCT00564031|EXPERIMENTAL|4|
62490479|NCT02195401||Sleeping in a cleanroom|Each child and his or her parent slept in a cleanroom for two weeks. Within 24 hours pre and post this two week experience blood and hair samples were taken from the children and the parents filled out rating scales.
62490480|NCT01246453|ACTIVE_COMPARATOR|urokinase|
62490481|NCT01246453|ACTIVE_COMPARATOR|Alteplase|
62490482|NCT03163160|EXPERIMENTAL|Pelvic floor manual therapy group|Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
62490483|NCT03163160|EXPERIMENTAL|Pelvic floor electrolysis group|Pelvic floor electrolysis technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue. The therapeutic protocol will be applied for 4 weeks.
62490484|NCT04142996|ACTIVE_COMPARATOR|Unilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
62490485|NCT04142996|ACTIVE_COMPARATOR|Bilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC and continuous TBS (cTBS) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
62490486|NCT04142996|ACTIVE_COMPARATOR|Maintenance Phase: Flexible|The flexible maintenance protocol will be based on symptom emergence. Participants will receive a fixed TBS (2x/week) schedule for the first month. For the following months (2-6), they will come in for an assessment (HRSD-17) to determine how many TBS sessions (0, 1, or 2) they receive on a flexible basis.
62136616|NCT04124432|EXPERIMENTAL|Placebo cannabis with low nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
62490487|NCT00870116|OTHER|1 - SBRT using cyberknife|SBRT using cyberknife: treatment = 2x15 Gy during 2 weeks
62490488|NCT00870116|OTHER|2 - SBRT using linear accelerator|SBRT using linear accelerator: treatment = 2x15 Gy during 2 weeks
62490489|NCT00870116|OTHER|3 - Conformational radiotherapy|Conformational radiotherapy: treatment = 5x2 Gy during 7 weeks
62694747|NCT06303518|EXPERIMENTAL|Low normal ETCO2, High normal ETCO2, Normal ETCO2|All patients will receive same interventions, in a randomised order.
62694748|NCT06303518|EXPERIMENTAL|Normal ETCO2, Low normal ETCO2, High normal ETCO2|All patients will receive same interventions, in a randomised order.
62136617|NCT04124432|EXPERIMENTAL|Placebo cannabis with high nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
62694749|NCT06303518|EXPERIMENTAL|Normal ETCO2, High normal ETCO2, Low normal ETCO2|All patients will receive same interventions, in a randomised order.
62694750|NCT04473196|ACTIVE_COMPARATOR|Weightbearing|Immediate weightbearing after surgery
62694751|NCT04473196|ACTIVE_COMPARATOR|Non weightbearing|nonweightbearing x 6 weeks post surgery
62694752|NCT03100461|ACTIVE_COMPARATOR|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
62694753|NCT03100461|ACTIVE_COMPARATOR|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
62694754|NCT03100461|EXPERIMENTAL|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
62694755|NCT03100461|ACTIVE_COMPARATOR|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
62136618|NCT01808534|EXPERIMENTAL|Treatment (palifosfamide)|Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62136619|NCT01605448|EXPERIMENTAL|MBSR|Mindfulness Based Stress Reduction
62136620|NCT01605448|NO_INTERVENTION|Control Group|Continue in Usual care; offered the intervention at the end of the study
62490490|NCT02620137|EXPERIMENTAL|Multicentrum® 3 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 3 months
62490491|NCT02620137|ACTIVE_COMPARATOR|Multicentrum® 12 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 12 months
62490492|NCT01896479|EXPERIMENTAL|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
62490493|NCT01896479|EXPERIMENTAL|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
62490494|NCT00496990|ACTIVE_COMPARATOR|control|Participants in this group receive the opportunity to attend a support group
62490495|NCT00496990|EXPERIMENTAL|Enhanced care|Participants in this arm receive the opportunity to have detoxification or methadone treatment as well as receive vouchers contingent upon drug free urine samples and individualized counseling
62490496|NCT02666482|EXPERIMENTAL|Stop Smoking SF Web App - baseline|"Online Study 1 will test the data gathering aspects of the proposed web app using a baseline, usual care intervention consisting of a static smoking cessation guide, the Guía para Dejar de Fumar, tested in printed form in the Muñoz et al. (1997) study. The print version of the guide yielded an 11% quit rate at 3 months. The investigators will utilize the content of the guide as the main element of the baseline app, so it will serve to estimate baseline utilization and quit rates when this already tested intervention is provided in a web app format. Participants can join the study online by going to: https://stopsmokingsf.org"
62694756|NCT05395338||IV rt-PA cohort|Patients who received IV rt-PA within 4.5 hours of symptom onset
61937806|NCT03234777|SHAM_COMPARATOR|Regular video|3 minute video on hand washing for infection control
62490497|NCT05832957|EXPERIMENTAL|Drive fun|The intervention will include 11 sessions and last 11-13 weeks. Seven intervention meetings will be individual sessions of one hour at the driving lab at Tel Aviv University and four 90-minute meetings will be group sessions (3-6 participants) and will be conducted remotely by Zoom. The parents will be present during the first and last individual sessions
62694757|NCT05395338||Non-reperfusion cohort|Patients who arrived or were admitted to the hospital within4.5 hours of symptom onset and did not receive any reperfusion treatment
62694758|NCT03482232||Patients visiting GP|All patients visiting GP. The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
61937807|NCT05914922|NO_INTERVENTION|FMRL CTL-PGY1 (Post Graduate Year 1) and FMRL CTL - PGY2 (Post Graduate Year 2)|This arm of participants reflects family medicine resident learners (FMRLs) who will not be exposed to the 1-20 MSK case simulations.
61937808|NCT05914922|EXPERIMENTAL|FMRL EXP - PGY1 and FMRL EXP - PGY2|This arm of participants reflects family medicine resident learners (FMRLs) who will be exposed to the 1-20 MSK case simulations.
61937809|NCT06680310||Sjogren syndrome|Ultrasound of the parotid and submandibular salivary glands in routine care of patients with Sjögren
61937810|NCT06680310||Other autoimmune diseases (Lupus/RA/Scleroderma)|Ultrasound of the parotid and submandibular salivary glands in routine care of patients with other autoimmune diseases (Lupus/RA/Scleroderma)
61937811|NCT06680310||Dry syndrome|Ultrasound of the parotid and submandibular salivary glands in routine care of patients with dry syndrome
62332767|NCT05412719|EXPERIMENTAL|intervention group|Before the procedure, the baby's heart rate, blood pressure, spo2, respiratory rate, FLACC were recorded, 5 minutes before the procedure, the finger puppet was started to be played by singing the red fish song, the baby's pulse, spo2, respiratory rate and FLACC scale were recorded during the procedure, 5 minutes after the procedure Playing more finger puppetry Evaluation of the baby's pulse, blood pressure, spo2, respiratory rate and FLAAC immediately after the procedure and five minutes later
62332768|NCT01588145|EXPERIMENTAL|HM61713|
62332769|NCT01790893|EXPERIMENTAL|intravitreal aflibercept injection|"Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.~."
62332770|NCT01790893|EXPERIMENTAL|intravitreal aflibercept|Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.
62332771|NCT00900250||Ancillary-correlative (specimen collection and baking)|"Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.~Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.~Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation."
62332772|NCT06420765|EXPERIMENTAL|VX-150|Participants will be randomized to receive a single dose of VX-150.
62332773|NCT06420765|EXPERIMENTAL|VX-548|Participants will be randomized to receive a single dose of different dose levels of VX-548.
61937812|NCT03356054|EXPERIMENTAL|Brentuximab vedotin-R-DHAP|Brentuximab vedotin added to R-DHAP
61937813|NCT04926376|EXPERIMENTAL|EYE90 Microspheres Treament|Radioembolization with Eye90 Microspheres
62332774|NCT06420765|PLACEBO_COMPARATOR|Placebo|Participants will receive single dose of non-matching placebo.
62332775|NCT04649203|EXPERIMENTAL|Group 1|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 10 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 75 days
62332776|NCT04649203|PLACEBO_COMPARATOR|Group 2|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 10 days + Placebo, 2 tablets 2 times a day, for 75 days
62332777|NCT00321100|ACTIVE_COMPARATOR|Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
62694759|NCT03482232||Patient visiting pediatricians|All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
61937814|NCT00752024|EXPERIMENTAL|1|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
61937815|NCT00752024|ACTIVE_COMPARATOR|2|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
61937816|NCT04118933|EXPERIMENTAL|MSI-H advanced colorectal cancer|
61937817|NCT06294236|EXPERIMENTAL|LN Cohort|SC291 with lymphodepleting therapy
61937818|NCT06294236|EXPERIMENTAL|ERL Cohort|SC291 with lymphodepleting therapy
61937819|NCT06294236|EXPERIMENTAL|AAV Cohort|SC291 with lymphodepleting therapy
62332778|NCT00321100|ACTIVE_COMPARATOR|Cetuximab, Oxaliplatin, Capecitabine|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
62332779|NCT02227017|EXPERIMENTAL|TPV/RTV capsules fed|
62332780|NCT02227017|EXPERIMENTAL|TPV/RTV capsules fasted|
62332781|NCT02227017|ACTIVE_COMPARATOR|TPV/RTV solutions fed|
62332782|NCT02227017|ACTIVE_COMPARATOR|TPV/RTV solutions fasted|
62490498|NCT05832957|EXPERIMENTAL|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
62490499|NCT05832957|OTHER|No Intervention|one-time short guidance on safe driving at the end of the study.
62490500|NCT04985435|ACTIVE_COMPARATOR|Choice group|50 patients will be randomized to the choice group, they will view a neutral information video on anti TNF and Filgotinib and will be given the opportunity to choose between these two treatments
61937820|NCT00147251|NO_INTERVENTION|SANDS Control Group|Standard Treatment for blood pressure and cholesterol
61937821|NCT00147251|ACTIVE_COMPARATOR|SANDS Intervention Group|FDA approved drugs to treat blood pressure and cholesterol
62332783|NCT01592279|EXPERIMENTAL|liraglutide|
62332784|NCT01592279|ACTIVE_COMPARATOR|Insulin injections|
62332785|NCT03460834||Obese asthmatic patients|Observational Cohort
62332786|NCT04346134|EXPERIMENTAL|mini-PNL group|In which percutaneous nephrolithotomy will be performed using miniature nephroscope.
62332787|NCT04346134|EXPERIMENTAL|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
62332788|NCT02433379|EXPERIMENTAL|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
62332789|NCT05059652|EXPERIMENTAL|Ischemic Preconditioning (n= 22)|"The IPC protocol will be applied in the proximal region of the thigh of the limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain.~Participants will be relaxed and comfortably seated. The same cuff used to determine the total occlusion pressure (TOP) will be used and the protocol will consist of four cycles of total ischemia (according to the TOP value determined individually) of five minutes, followed immediately by four cycles of five minutes of vascular reperfusion (0 mmHg ), totaling 40 minutes."
62332790|NCT05059652|PLACEBO_COMPARATOR|Placebo (n= 22)|The placebo protocol will be performed on the lower limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain. Participants will perform a protocol similar to the IPC, but during the four cycles of five minutes of occlusion, the cuffs will only be inflated with 10mmHg so as not to cause arterial or venous occlusion, alternating with four cycles of five minutes of reperfusion (0 mmHg).
62490501|NCT04985435|ACTIVE_COMPARATOR|Randomization group anti TNF|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with antiTNF
62490502|NCT04985435|ACTIVE_COMPARATOR|Randomization group Filgotinib|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with Filgotinib
62490503|NCT02050321|EXPERIMENTAL|Acitretin and Vemurafenib|Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
62490504|NCT00253838|ACTIVE_COMPARATOR|Restoration HA Stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating
62490505|NCT00253838|SHAM_COMPARATOR|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
62490506|NCT01782937|EXPERIMENTAL|KHK4827|
61937822|NCT06174064|ACTIVE_COMPARATOR|Protocol 1--420 and 560nm wavelengths|Broadband light treatment Patients will be treated with BBL with 420nm wavelength filter followed by 560nm wavelength filter to malar and periorbital areas once monthly for 3 months. Dry eye evaluation consisting of clinical testing as well as quality of life questionnaires will be performed at baseline and after the last BBL treatment.
61937823|NCT06174064|ACTIVE_COMPARATOR|Protocol 2--560nm wavelength|Broadband Light treatment Patients will be treated with BBL with 560nm wavelength filter to malar and periorbital areas once monthly for 3 months. Dry eye evaluation consisting of clinical testing as well as quality of life questionnaires will be performed at baseline and after the last BBL treatment.
61937824|NCT06174064|SHAM_COMPARATOR|Sham|Sham Broadband Light Treatment Patients will undergo the same preparation and procedure as for BBL treatment but the light source will be occluded. Patients will be treated with sham to malar and periorbital areas once monthly for 3 months. Dry eye evaluation consisting of clinical testing as well as quality of life questionnaires will be performed at baseline and after the last sham treatment.
61937825|NCT03903601||Ischemic changes|Patients with ischemic changes in the brain diagnosed by MRI
61937826|NCT03903601||No ischemic changes|Patients without ischemic changes in the brain diagnosed by MRI
62332791|NCT05340257|EXPERIMENTAL|Participants with CAP and ABRS|
62332792|NCT00533637|EXPERIMENTAL|1|NLA Nasal Spray
62332793|NCT00533637|ACTIVE_COMPARATOR|2|
62332794|NCT00533637|PLACEBO_COMPARATOR|3|
62332795|NCT04194658|ACTIVE_COMPARATOR|Case group|Case group will receive pretreatment letrozole 12.5 mg for 2 days before administration of misoprostol in a dosage according to ACOG guidelines based on gestational age.
62332796|NCT04194658|NO_INTERVENTION|Control group|Control group will receive only misoprostol in a dosage according to ACOG guidelines based on gestational age.
62332797|NCT03397277|EXPERIMENTAL|Screened positive intervention video|Safety behaviour promoting video
62332798|NCT03397277|SHAM_COMPARATOR|Screened positive control video|Pregnant women who screen positive for IPV using the AAS who are randomized into viewing the control video
62332799|NCT01972880|EXPERIMENTAL|tablet-1|
62332800|NCT01972880|ACTIVE_COMPARATOR|tablet-2|
62332801|NCT01774344|EXPERIMENTAL|Regorafenib|160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
62332802|NCT01774344|PLACEBO_COMPARATOR|Placebo|4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
62490507|NCT00974350|EXPERIMENTAL|Group 1: SABER-Bupivacaine|2.5 mL SABER-Bupivacaine/Once
62490508|NCT00974350|EXPERIMENTAL|Group 2: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
62490509|NCT00974350|PLACEBO_COMPARATOR|Group 3: SABER-Placebo|2.5 mL or 5.0 mL SABER-Placebo/Once
62490510|NCT00757172|OTHER|Docetaxel + Cisplatin + Panitumumab + RT|Patients received docetaxel (40 mg/m\^2), cisplatin (40 mg/m\^2) and panitumumab (6 mg/kg) on weeks 1, 3, 5, 7, and 9 with radiotherapy (RT) (5040 cGy, 180 cGy/day x 28 days) beginning week 5. Resection was planned after completing chemotherapy (CRT).
62490511|NCT05290519|EXPERIMENTAL|Group A|plant protein for 4 weeks than animal protein for 4 weeks
62332803|NCT01515995|EXPERIMENTAL|Magnesium sulfate group|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
62332804|NCT01515995|ACTIVE_COMPARATOR|Normal Saline group|15 mg albuterol in 22 ml of normal saline solution via nebulizer over one hour
62332805|NCT01152333|ACTIVE_COMPARATOR|Exendin (9-39) Acetate|Exendin (9-39) is a synthetic peptide that acts as an antagonist to the GLP-1 receptor. Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length at 600-750 pM/kg/min.
62490512|NCT05290519|EXPERIMENTAL|Group B|animal protein for 4 weeks than plant protein for 4 weeks
62490513|NCT02123823|ACTIVE_COMPARATOR|Everolimus 10mg + Exemestane 25mg|Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally
62490514|NCT02123823|EXPERIMENTAL|BI836845 + Everolimus + Exemestane|Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally
62490515|NCT02123823|EXPERIMENTAL|PhI - BI836845 + Everolimus + Exemestane|Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg
62490516|NCT04179396|EXPERIMENTAL|Arm A: Oral rucaparib and enzalutamide|
62332806|NCT01152333|PLACEBO_COMPARATOR|Saline|Saline 0.9% will be used as the control infusion.
61937827|NCT05145192|EXPERIMENTAL|COSMED K5 CPET|Participants in this arm will complete the CPET using the COSMED K5 wearable metabolic system at first visit and the ParvoMedics TrueOne® 2400 automated metabolic gas analysis system at second visit.
61937828|NCT05145192|ACTIVE_COMPARATOR|ParvoMedics CPET|Participants in this arm will complete the CPET using the ParvoMedics TrueOne® 2400 automated metabolic gas analysis system at first visit and the COSMED K5 wearable metabolic system at second visit.
61937829|NCT02326675|ACTIVE_COMPARATOR|Cryotherapy Group (Group A)|Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
62136621|NCT05048758||Individuals with AUD + varying levels of ACE|Individuals with alcohol use disorder (AUD) and varying levels of adverse childhood experiences (ACE)
62136622|NCT05920642|EXPERIMENTAL|Intrathecal morphine administration|Study subjects randomized into this arm will be administered morphine intrathecally in the dose of dose 100 ug.
62332807|NCT04349306|EXPERIMENTAL|rasburicase|rasburicase 0.20 mg/kg/day by intravenous (IV) over 30 minutes for 1 to 5 days according to the level of plasma uric acid or Investigator's clinical judgement
62332808|NCT02049255|PLACEBO_COMPARATOR|Marcaine|Rachianesthesia with marcaine or chloroprocaine
62490517|NCT04179396|EXPERIMENTAL|Arm B: Oral rucaparib and abiraterone|
62136623|NCT05920642|ACTIVE_COMPARATOR|Parenteral administration of analgesics|Study subjects randomized into this arm will receive standard postoperative pain management (parenteral administration of analgesics).
62136624|NCT04396782|EXPERIMENTAL|physiotherapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
62332809|NCT02049255|ACTIVE_COMPARATOR|Chloroprocaine|Rachianesthesia with marcaine or chloroprocaine
62332810|NCT05158452||Observational (focus group)|Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.
62490518|NCT02342509|EXPERIMENTAL|Desflurane|Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
62490519|NCT02342509|EXPERIMENTAL|Sevoflurane|Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
62490520|NCT02342509|ACTIVE_COMPARATOR|Isoflurane|Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
62490521|NCT00525746||Cases|Patients with a confirmed diagnosis of AML or MDS (cases).
62490522|NCT00525746||Controls|Patients treated for a primary malignancy (controls).
62136625|NCT04396782|ACTIVE_COMPARATOR|standard physiotherapy rehabilitation|static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.
62136626|NCT05311527|EXPERIMENTAL|All Study participants|Study participants will undergo Urolift System followed by SABR
62332811|NCT05264090|PLACEBO_COMPARATOR|Group 1|Healthy volunteers without exercise
62332812|NCT05264090|SHAM_COMPARATOR|Group 2|Healthy exercise-training volunteers
62332813|NCT05264090|ACTIVE_COMPARATOR|Group 3|Patients with ischemic coronary artery disease without exercise
62332814|NCT05264090|EXPERIMENTAL|Group 4|Patients with ischemic coronary artery disease following cardiovascular rehabilitation
62490523|NCT00620958|EXPERIMENTAL|1|Participants will receive individual cognitive behavioral therapy with parent reinforcement training.
62490524|NCT00620958|EXPERIMENTAL|2|Participants will receive individual cognitive behavioral therapy with parent relationship training.
62490525|NCT00620958|ACTIVE_COMPARATOR|3|Participants will receive individual cognitive behavioral therapy alone.
62490526|NCT02313545|EXPERIMENTAL|Experimental - IZN-6NVS Cream|Eligible women of 3 groups will be assigned to receive IZN-6NVS (IP) - 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks.
62490527|NCT05198505|EXPERIMENTAL|TQB2868 Injection|The drug was administered once every 3 weeks (administration time window: ± 3 days), the dose of each administration was 1.5-600 mg, and 3 weeks was a treatment cycle until the disease progressed or the investigator judged that it was not suitable to continue the drug use.
62490528|NCT05501158|EXPERIMENTAL|Dose adjustment of tamoxifen|Following the CPIC guidelines, those identified as Poor Metabolizers (PMs) and Intermediate Metabolizers (IMs) from our previous study are recommended to adjust their tamoxifen dosage to 40 mg per day.
62490529|NCT05501158|NO_INTERVENTION|Standard dose of tamoxifen|Those identified as Normal Metabolizers (NMs) from our previous study remain on tamoxifen 20 mg per day.
62490530|NCT00259194|ACTIVE_COMPARATOR|Alternative Observation|Moving in bed during observation after coronary angiography
62490531|NCT00259194|EXPERIMENTAL|Standard Observation|No moving in bed during observation after coronary angiography
62490532|NCT03313895|ACTIVE_COMPARATOR|Cycling Only|Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
62490533|NCT03313895|ACTIVE_COMPARATOR|Cognitive Training Only|Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
62490534|NCT03313895|EXPERIMENTAL|ACT|Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
62490535|NCT03313895|SHAM_COMPARATOR|Stretching and Mental Stimulation Activities|Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
62490536|NCT01917227|EXPERIMENTAL|Video|
62490537|NCT01715779||Patients who experienced a thromboembolic event|Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials.
61937830|NCT02326675|ACTIVE_COMPARATOR|Standard Oral Care Group (Group B)|Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
62332815|NCT04987060|OTHER|Intrastromal Fresh Human Lenticule Implantation|The aim of this study is to investigate the effect of intrastromal fresh corneal lenticule implantation using Smile module surgery after PK with primary objective to increase visual acuity by reducing irregular astigmatism according to high K values. The stromal pocket diameter was 8 mm, 2mm super incision, 140-µm cap thickness and fresh lenticular implantation is performed.
62332816|NCT00975702|NO_INTERVENTION|No RIPC Group|This group is the control group or the comparator group with RIPC
62332817|NCT00975702|EXPERIMENTAL|RIPC Group|In this group deceased donors will receive Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet of the lower limb prior to organ recovery.
62332818|NCT03628430|PLACEBO_COMPARATOR|Group C|"For patients of this group, the intervention was a Local Anesthesia with:~* 10 mL of 2% lidocaine with epinephrine 0.005mg/ml~* and 5 mL of 0.9% NaCl"
62332819|NCT03628430|ACTIVE_COMPARATOR|Group A|"For patients of this group, the intervention was a Local Anesthesia with:~* 10 mL of 2% lidocaine with epinephrine 0.005mg/ml~* and 5 mL of 4.2 % sodium bicarbonate"
62490538|NCT04792723|EXPERIMENTAL|Healthy volunteer|Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks
62490539|NCT01927380||brachytherapy|males undergoing elective laparoscopic radical prostatectomy steep trendelenburg position with pneumoperitoneum
62490540|NCT02516189|EXPERIMENTAL|Group A|group of elderly participants of strength training program
62490541|NCT02516189|NO_INTERVENTION|Group B|group of seniors who did not practice strength training program
62490542|NCT02395809|ACTIVE_COMPARATOR|LIS group|Lateral internal shincterotomy: A blade knife (No 11) was inserted between internal and external sphincter. The tip of the blade was angled medially pointing just above the dentate line and IS was divided. When the knife was felt beneath the intact mucosa, it was withdrawn.
62490543|NCT02395809|ACTIVE_COMPARATOR|TENS group|Posterior tibial nerve stimulation by transcutaneous electrical nerve stimulation by through a stimulating TENS unit.
62490544|NCT06454214||Control breast tissues (normal breast tissues)|Normal tissue contained within the surgically excised specimen
62490545|NCT06454214||Cancerous breast tissues|Tumor tissue contained within the surgically excised specimen
62490546|NCT06144398|EXPERIMENTAL|Single Use Bronchoscope|
62490547|NCT06144398|ACTIVE_COMPARATOR|Standard Bronchoscope|
62490548|NCT04262245|OTHER|irrigation activation method|Irrigation activation is a crucial stage of root canal treatment. Therefore, the effect of activation methods on post treatment is an important fact for the comfort of patients.
61937831|NCT00915356|EXPERIMENTAL|1|AZD1305 iv infusion
61937832|NCT00915356|PLACEBO_COMPARATOR|2|Placebo iv infusion
61937833|NCT03272516|ACTIVE_COMPARATOR|Control group|This group receives treatment as usual (TAU) from his/hers physician. This treatment is different for each physician, but mainly consists of cognitive therapy, personal interviews or antidepressants or anxiolytics.
62332820|NCT04397237||Systemic Lupus Erythematosus|Consecutive Systemic Lupus Erythematosus patients followed-up in each service
62332821|NCT04397237||Sjogren's Syndrome|Consecutive Sjogren's Syndrome patients followed-up in each service
62332822|NCT04397237||Axial Spondyloarthritis|Consecutive Axial Spondyloarthritis patients followed-up in each service
62332823|NCT04397237||Rheumatoid Arthritis|Consecutive Rheumatoid Arthritis patients followed-up in each service
62332824|NCT04397237||Giant Cell Arteritis|Consecutive Giant Cell Arteritis patients followed-up in each service
62332825|NCT02902172|OTHER|Acetaminophen|Patients will be monitored for change in blood pressure
62490549|NCT03563443||Bladder cancer patients|Diagnosed bladder cancer patients who are being monitored will be the experimental group to develop the LOI panel, and subsequent cohort will be used to confirm the sensitivity and specificity of this urinary analysis.
62490550|NCT03563443||Non-cancer participants|Patients being treated for other diseases but without any tumor or healthy participants will provide a negative control to provide data for developing the LOI diagnostic panel
62490551|NCT02687958|EXPERIMENTAL|A Everolimus 10mg (every cycle) until PD|Patients with stable disease, partial response or complete response after 4- 6 cycles of induction chemotherapy with Cisplatin or Carboplatin plus Etoposide or alternative first line chemotherapy according with local practice will receive maintenance therapy with Everolimus 10mg every cycle (28days) until PD or unacceptable toxicity.
62490552|NCT02687958|NO_INTERVENTION|B Observational|Patients in this arm will meet observation criteria
62332826|NCT02902172|OTHER|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
62332827|NCT03545724|EXPERIMENTAL|Neofitoroid®|Treatment is made by the application of Neofitoroid® 2 times a day for 10 days.
62332828|NCT06555705|EXPERIMENTAL|Interventional group recieveing omega 3 and the standard nutritional regimen for 3 months|The intervention group will be examined by 10 -minutes Holter and then omega 3 will be given to children( at least 400 mg eicosapentaenoic acid (EPA) and 120 mg docosahexaenoic acid (DHA) daily in addition to the standard nutritional regimen ) daily for 3 months and then reassesent of Holter will be carried out .
62332829|NCT06555705|PLACEBO_COMPARATOR|Control group receiving placebo and the standard nutritional regimen for 3 months|The control group will be examined by 10 -minutes Holter and then the standard nutritional regimen will be given daily for 3 months and then reassessment of Holter will be carried out .
62332830|NCT02370849|EXPERIMENTAL|NCS|nimotuzumab plus cisplatin and S-1
62332831|NCT02370849|ACTIVE_COMPARATOR|CS|cisplatin and S-1
62332832|NCT03867669|EXPERIMENTAL|Single Patient Room|Patients randomized to this arm will be admitted to a NICU single patient room.
62332833|NCT03867669|PLACEBO_COMPARATOR|Open Bay|Patients randomized to this arm will be admitted to the open bay NICU Unit.
62332834|NCT03955887||Experimental|Patients with severe acute lung disease requiring mechanical ventilation
62332835|NCT03955887||Control|Patients receiving routine bronchoalveolar lavage for a pathology not suspected of acute infection
62332836|NCT01068041|PLACEBO_COMPARATOR|A|Placebo
62332837|NCT01068041|ACTIVE_COMPARATOR|B|250mg active ingredient
62332838|NCT01068041|ACTIVE_COMPARATOR|C|500mg active ingredient
62490553|NCT04200872||biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
62490554|NCT04200872||without biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
62490555|NCT00944190|EXPERIMENTAL|Self-management Intervention|Telephone based self management intervention targeted at pain, fatigue, depression, and cognitive difficulties.
62490556|NCT00944190|ACTIVE_COMPARATOR|Education|Education about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
62490557|NCT01957280|EXPERIMENTAL|Process 2 patritumab|Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
62490558|NCT05092035|OTHER|COPD patients|COPD patients
62490559|NCT05092035|OTHER|ILD patients|ILD patients
61937834|NCT03272516|EXPERIMENTAL|Intervention group|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol..
62332839|NCT01068041|ACTIVE_COMPARATOR|D|1000mg active ingredient
62332840|NCT05528003||Handmade single-access port device|The homemade single-access device was composed of a wound protector, sterile surgical glove, and three trocars inserted into and secured over three digits of the glove
62332841|NCT05528003||Commercialized single-access port devices|Commercialized single-access port devices including GelPOINT® (Applied Medical, Rancho Santa Margarita, CA, USA) and LAGIPORT® (LAGIS, Taichung, Taiwan)
62332842|NCT04786873|ACTIVE_COMPARATOR|standard GHST order randomized: arginine - clonidine|"At visit 2 (V2), all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at visit 3 (V3) and visit 4 (V4).~In this arm, those subjects will be presented which will have been randomized to the arginine GHST at V3 and the clonidine GHST at V4.~At visit 5 (V5) all subjects will perform the macimorelin GHST."
62332843|NCT04786873|ACTIVE_COMPARATOR|standard GHST order randomized: clonidine - arginine|"At V2, all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at V3 and V4.~In this arm, those subjects will be presented which will have been randomized to the clonidine GHST at V3 and to the arginine GHST at V4.~At V5 all subjects will perform the macimorelin GHST."
62332844|NCT04497662|EXPERIMENTAL|KPL-404 (IV Administration)|
62332845|NCT04497662|EXPERIMENTAL|KPL-404 (SC Administration)|
62332846|NCT01679080|EXPERIMENTAL|Zolendronic acid, 3 yr + placebo teriparatide, 2 yr|yearly intravenous infusion of 5mg active zoledronic acid in 3 yr
62332847|NCT01679080|EXPERIMENTAL|teriparatide 2 yr; active zol in 3rd yr|daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.
62332848|NCT01679080|PLACEBO_COMPARATOR|No active treatment|Observation in three years, no treatment
62332849|NCT01506778|ACTIVE_COMPARATOR|Group 1(With Tenaculum)|This group consisted of the patients whose had been applied tenaculum at cervix during the endometrial sampling procedure
62332850|NCT01506778|NO_INTERVENTION|Group 2 (Without Tenaculum)|This group consisted of the patients whose had been not applied tenaculum during the endometrial sampling procedure.
62490560|NCT05092035|OTHER|non-smoker controls|non-smoker controls
62490561|NCT05092035|OTHER|smoker controls|smoker controls
62490562|NCT01151618|EXPERIMENTAL|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
62490563|NCT03082586|EXPERIMENTAL|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
62490564|NCT03082586|EXPERIMENTAL|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
62490565|NCT03082586|EXPERIMENTAL|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
62490566|NCT03082586|EXPERIMENTAL|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
62490567|NCT03082586|EXPERIMENTAL|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
62490568|NCT03082586|EXPERIMENTAL|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
62490569|NCT00694044|ACTIVE_COMPARATOR|Weekly titration|
62694760|NCT05498909||Treatment group|"Treatment group（Multidisciplinary assisted treatment model group）： Those who received any of the following treatments, as recommended by the standard medical procedure, were considered to have received the standard medical treatment; otherwise, they were not.~1. Surgical procedures: left atrial appendage ligation, left atrial appendage clip, valve repair or replacement, etc.~2. Medical procedures: atrial fibrillation radiofrequency ablation, valvular closure, left atrial appendage closure, etc.~3. Anticoagulant drug therapy: standardized anticoagulant drug therapy."
62694761|NCT05498909||Control group|"Control group（Routine diagnosis and treatment model group）:~Patients who did not agree to enter the multidisciplinary treatment mode were automatically admitted to the routine treatment mode group"
62332851|NCT02007785|EXPERIMENTAL|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
62694762|NCT06645080||Focus Group participants (health professionals)|
61937835|NCT01977937|EXPERIMENTAL|Gabapentin|Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.
62332852|NCT01986218|EXPERIMENTAL|Arm A: Dose Escalation (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
62332853|NCT01986218|EXPERIMENTAL|Arm A: Dose Expansion (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
62332854|NCT01986218|EXPERIMENTAL|Arm B: Dose Escalation (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
62332855|NCT01986218|EXPERIMENTAL|Arm B: Dose Expansion (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
62332856|NCT00978861|EXPERIMENTAL|whitening|30% Hydrogen peroxide
62332857|NCT01869114|EXPERIMENTAL|High risk Myleodysplastic Syndrome (MDS)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62332858|NCT01869114|EXPERIMENTAL|Acute Myeloid Leukemia (AML)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62332859|NCT01869114|EXPERIMENTAL|MDS or AML with prior Azacitadine therapy|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62332860|NCT01886131|EXPERIMENTAL|Synchronised video-polysomnography|
62332861|NCT01252134|OTHER|Synergi, then Biotrue, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
62332862|NCT01252134|OTHER|Synergi, then OTE, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
62332863|NCT01252134|OTHER|Biotrue, then OTE, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
62332864|NCT01252134|OTHER|Biotrue, then Synergi, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
62332865|NCT01252134|OTHER|OTE, then Biotrue, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
62332866|NCT01252134|OTHER|OTE, then Synergi, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
62332867|NCT01651052|EXPERIMENTAL|Aortic Bioprosthesis, Model 11000|Aortic valve replacement therapy
62332868|NCT01212172|ACTIVE_COMPARATOR|Soprano/SHR|Alma Soprano/SHR 810 nm Diode Laser
62332869|NCT01212172|ACTIVE_COMPARATOR|LightSheer|LightSheer Duet 810 nm diode laser
62332870|NCT05941949|EXPERIMENTAL|Active|Softgel containing: Astaxanthin, Grape Juice Extract, and All Natural Vitamin E
62490570|NCT00694044|ACTIVE_COMPARATOR|Two Week QD|
62490571|NCT00694044|ACTIVE_COMPARATOR|Two Week BID|
62490572|NCT00694044|PLACEBO_COMPARATOR|Placebo|
62332871|NCT05941949|PLACEBO_COMPARATOR|Placebo|Softgel containing: Olive Oil and Sunflower Lecithin
62490573|NCT03292705|EXPERIMENTAL|PEP+CCI|"PEP: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains.~CCI. VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention.~Intervention format and fidelity The PEP+CCI group will practice PEP for the first 4 weeks and VSOP for the following 6 weeks."
62694763|NCT06645080||Focus group participants (service users/ carers)|
62694764|NCT06645080||Delphi study participants|
62694765|NCT06439810||Tuberculous pleuritis|Patients with definite or probable tuberculous pleuritis
62694766|NCT06439810||Non-tuberculous pleuritis|Patients without tuberculous pleuritis
62136627|NCT04192773|EXPERIMENTAL|IV lidocaine|"1000mg/hour IV lidocaine administered for up to 30 minutes (500mg max). Patients will be continuously monitored by a nurse every 5 (±2) minutes to check specifically for vital signs (BP, HR, and RR), patient tinnitus levels, and reports of side effects.~The infusion is continued until any of the following criteria are met: 1) the patient has completed the 30-minute infusion; 2) the patient reports intolerable or concerning side effect, such as dizziness, nausea, or vomiting; 3) the patient experiences bradycardia \<50 and a drop of systolic blood pressure (BP) more than 20 mmHg and diastolic pressure more than 10 mmHg during the infusion; 4) the patient reports that tinnitus is resolved, or 5) the patient wishes to stop the study.~Serum lidocaine levels will be drawn by a research nurse upon completion of MRI. The Tinnitus Handicap Inventory, the Tinnitus Functional Index, and the Visual Analog Scale will be administered after IV infusion."
62332872|NCT02481726|EXPERIMENTAL|68Ga|In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10\~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
62694767|NCT03287492|EXPERIMENTAL|Group I (QPS)|Participants receive QPS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
62136628|NCT02463214|NO_INTERVENTION|Standard Room|Standard bone marrow transplant recovery, single occupancy, room
62136629|NCT02463214|EXPERIMENTAL|Engineered Room|Single occupancy bone marrow transplant recovery room, engineered with touchless devices, and surfaces coated with either copper or titanium dioxide.
62136630|NCT02143375|EXPERIMENTAL|810 Diode Laser|810 nm Diode Laser, contact, continuous wave,320micron,
62136631|NCT05927220||cohesive (I-III) worst patterns of invasion at tumor host interface|
62136632|NCT05927220||non-cohesive (IV-V) worst patterns of invasion at tumor host interface|
62136633|NCT00575419|EXPERIMENTAL|1, IV NAC|N-acetylcysteine administered intravenously
62136634|NCT00575419|EXPERIMENTAL|2, IA NAC|N-acetylcysteine administered intra-arterial
62136635|NCT03081013|ACTIVE_COMPARATOR|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
62136636|NCT03081013|EXPERIMENTAL|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
62136637|NCT00047190|EXPERIMENTAL|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62136638|NCT04228913|OTHER|Ah plus|The root canals obturated with Ah plus root canal sealer (Dentsply, Sirona) and gutta-percha cones with cold lateral condensation technique.
62136639|NCT04228913|OTHER|ROEKO GuttaFlow® 2|The root canals obturated with GuttaFlow 2 root canal sealer (Coltene,Whaledent) and single tapered gutta-percha cone with cold free flow compaction technique.
62136640|NCT04228913|OTHER|GuttaCore Obturators|The root canals obturated with GuttaCore obturators (Dentsply,Sirona) and Ah plus root canal sealer with thermoplasticized solid-core carrier technique
62694768|NCT03287492|ACTIVE_COMPARATOR|Group II (GIS)|Participants receive GIS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
62136641|NCT05176392|ACTIVE_COMPARATOR|Active rTMS with telehealth headache management therapy|Participants receive both active rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
62136642|NCT05176392|OTHER|Active rTMS with telehealth headache education control|Participants receive active rTMS treatment at the left dorsolateral prefrontal cortex and headache education
62136643|NCT05176392|OTHER|Sham rTMS with telehealth headache management therapy|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
62136644|NCT05176392|SHAM_COMPARATOR|Sham rTMS with telehealth headache education control|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and headache education
62136645|NCT03973034||Normal people|
62136646|NCT03973034||Benign breast disease patients|
62136647|NCT03973034||Breast cancer patients in early stage|
62136648|NCT04132167|EXPERIMENTAL|training group|perturbation balance training
62490574|NCT03292705|ACTIVE_COMPARATOR|control+CCI|For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks.
62490575|NCT02845336|EXPERIMENTAL|Celecoxib|Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
62490576|NCT02845336|ACTIVE_COMPARATOR|Control|Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)
62136649|NCT04132167|ACTIVE_COMPARATOR|control group|traditional physical therapy that including strengthening and stretching
62136650|NCT06275464|ACTIVE_COMPARATOR|5mg SAD|
62136651|NCT06275464|PLACEBO_COMPARATOR|5mg SAD placebo|
62136652|NCT06275464|ACTIVE_COMPARATOR|10mg SAD|
62136653|NCT06275464|PLACEBO_COMPARATOR|10mg SAD placebo|
62136654|NCT06275464|ACTIVE_COMPARATOR|5mg MAD|
62136655|NCT06275464|PLACEBO_COMPARATOR|5mg MAD placebo|
62136656|NCT06275464|ACTIVE_COMPARATOR|10mg MAD|
62136657|NCT06275464|PLACEBO_COMPARATOR|10mg MAD placebo|
62136658|NCT06125197|EXPERIMENTAL|TILT-123 and Pembrolizumab|"Patients will receive multiple administrations of TILT-123 and Pembrolizumab.~Escalation to the next dose of TILT-123 will occur when the safety data has been evaluated for patients in the preceding dose level."
62136659|NCT03375892|ACTIVE_COMPARATOR|Prone Position with DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
62136660|NCT03375892|ACTIVE_COMPARATOR|Supine Position with DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
62136661|NCT03375892|ACTIVE_COMPARATOR|Prone Position with no DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
62490577|NCT00954408||Patients with dystonia|Patients with dystonia, 21-100 years of age.
62490578|NCT05015595|ACTIVE_COMPARATOR|Memantine|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of Memantine up to 20mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Memantine will be reduced at 10mg/day due to safety reasons before the end of treatment (T5)."
62490579|NCT05015595|PLACEBO_COMPARATOR|Placebo|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of placebo 20 mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Placebo will be reduced at 10mg/day, following the study protocol, before the end of treatment (T5)."
62490580|NCT00884390|EXPERIMENTAL|ReFacto AF|
62332873|NCT04289415|EXPERIMENTAL|Individual Placement and Support|"The intervention used in this study will be a time-limited version of IPS. The employment specialist offers up until nine months job-search support and four months in-work support, giving a total of 13 months job-related support. If a participant succeeds in obtaining work before nine months has passed the remaining job-search support months may be transferred to in-work support time.~In the follow-up time while seeking employment, the employment specialists will work with the participants to identify skills and aspirations, establish contact with potential employers and ensure economic advice and help with benefits planning. The in-work support involves individual and regular contact with the participant and the employer.~All participants who receive this intervention will do so in addition to their clinical treatment. The treatment provider and the employment specialist should cooperate and clarify roles together with the patient."
62332874|NCT04289415|ACTIVE_COMPARATOR|Selv help kit and work shop|The participants in the control intervention will be offered a self-help tool kit and a following introduction course to help participants see what their opportunities are, and specific tips on how to get further help. The course will last three hours a session over four days, with the offer of an individual one hour follow up session with the course leader when the course is over. The goal of the control group intervention is to enable the participants to make use of the services offered at the ordinary labor and welfare service.
62332875|NCT02227329|EXPERIMENTAL|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
62332876|NCT02227329|ACTIVE_COMPARATOR|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
62332877|NCT02805556|EXPERIMENTAL|Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529|Single oral dose of BMS-663068 followed by Single intravenous dose of \[13C\]BMS 626529
62332878|NCT05369416|ACTIVE_COMPARATOR|Low sodium diet|-Subjects will be randomized to start a low sodium diet (1200 mg/day) for two weeks (this will be followed by a high sodium diet - crossover design)
62332879|NCT05369416|ACTIVE_COMPARATOR|high sodium diet|-Subjects will be randomized to start a high sodium diet (4200 mg/day) for two weeks (this will be followed by a low sodium diet - crossover design)
62332880|NCT06276608||Pediatric cardiac surgery patients|All patients who underwent pediatric cardiac surgery in our institution between January 1, 2019 and december 31, 2023
62332881|NCT00808691||1|Patients with sepsis
62332882|NCT00808691||2|Patient admitted for postoperative care
62332883|NCT00808691||3|Patients with ARDS
62332884|NCT00808691||4|Patients with ARF
62332885|NCT00808691||5|Patients who receive liver support treatment
62332886|NCT00808691||6|Patients wiht brain death
62332887|NCT04236479|EXPERIMENTAL|Bone marrow-derived mesenchymal stromal cell (BM-MSC)|The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10\^6, 10x10\^6, 20x10\^6, 40x10\^6, 80x10\^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD.
62136662|NCT03375892|ACTIVE_COMPARATOR|Supine Position with no DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
62694769|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI =\> 5
62694770|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI \< 5
62694771|NCT06466642|EXPERIMENTAL|Combined CogSMART and BrainHQ intervention group|Intervention: The experimental condition in this trial is a combination of CogSMART and BrainHQ. This integrated intervention helps individuals with cognitive impairment improve daily activities and achieve goals. CogSMART, a compensatory cognitive remediation (C-CR) program, employs techniques to enhance prospective memory, attention, learning/memory, and executive functioning. BrainHQ, a restorative cognitive remediation (R-CR) program, provides game-like modules targeting memory, attention, and executive functions. Together, they offer a comprehensive approach, combining C-CR with R-CR to reduce impairment and enhance problem-solving skills.
62136663|NCT04874103||EUS guided gallbladder drainage and cholecystoscopy|"EUS-GBD will be performed using LAMS (such as Hot-AxiosTM device). A 10mm x 10mm stent system will be used if the largest gallstone is smaller than 10mm in size and a 15 x 10mm stent will be used if the largest gallstone is larger than 10mm.~Colecystoscopy will be subsequently performed after at least 2 weeks using standard or therapeutic gastroscope. Lithotripsy will be performed using mechanical lithotripsy or laser lithotripsy."
62694772|NCT06466642|NO_INTERVENTION|Attention-matched Combined CogSMART and BrainHQ Control group|This control-matched approach to the CogSMART group, currently utilized in Dr. Twamley's studies, has been well received by participants, with no significant increase in dropout rates. Additionally, control participants will receive the BrainHQ component, involving Internet Navigation Training previously employed by Dr. Vance consisting of 20 sessions lasting 30 minutes each aimed to provide no therapeutic benefit.
62136664|NCT03447457|OTHER|standard oxygen group|Patients are treated with standard oxygen delivered through nasal cannula, face mask or non-rebreathing reservoir
62136665|NCT03447457|OTHER|High-flow oxygen group|Patients are treated with high-flow nasal cannula oxygen continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min
62490581|NCT05493163|EXPERIMENTAL|Catheter-Directed Thrombolysis|"Venous access should be obtained under ultrasound guidance (via the common femoral vein). The use of a double-lumen 8-Fr introducer (single access site) or two 4-Fr introducers (two ipsilateral access sites) is at the discretion of the operator.~After each thrombolytic catheter placement into left and/or right pulmonary artery, a subsequent bolus of 1mg of Alteplase (Actilyse, Boehringer Ingelheim)/catheter is administered, followed by continuous infusion at 1 mg/h/catheter for 9 h (total dose 10mg for unilateral and 20mg for bilateral PE).~Intravenous unfractionated heparin is continued to a target activated partial thromboplastin time (aPTT) of 50-60 s. After the end of local thrombolysis, the catheters are removed and anticoagulation with unfractionated heparin continues."
62694773|NCT06637007|EXPERIMENTAL|Chidamide Tablets combined with AK112|"1. Medication dosage：Chidamide Tablets（30mg,Twice a week，po），AK112（Once every 3 weeks）.~   If you experience any discomfort during the medication process, please inform your responsible doctor in a timely manner. He/she will provide appropriate treatment based on the severity of the reaction. In severe cases, the dosage of medication will be adjusted until it is stopped.~2. Medication method: The interval between two oral doses of Xidabenzamide should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), and should be taken 30 minutes after breakfast. During the research process and before the end of medication, the responsible doctor will conduct physical and laboratory examinations on you in accordance with the experimental protocol to evaluate the impact of the experimental drug on you."
62136666|NCT02477514|EXPERIMENTAL|Experimental Arm|Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)
62136667|NCT01818180|EXPERIMENTAL|Urell|
62332888|NCT02968043|ACTIVE_COMPARATOR|control group|Control group will perform generalised physiotherapy exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Generalised physiotherapy exercises consist of stretching and strengthening activities.
62332889|NCT02968043|EXPERIMENTAL|intervention group|Intervention group will perform physiotherapeutic scoliosis specific exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists with expertise in scoliosis in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Physiotherapeutic scoliosis specific exercises consist of patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living.
62332890|NCT03437772||CBT with mindfulness|
62332891|NCT03437772||Treatment as Usual: Barkley therapy|
62332892|NCT05699746|EXPERIMENTAL|CAPEOX|Drug CAPEOX (Oxaliplatin 130 mg/m2 IV day 1, Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks) for at most 8 cycles.
62332893|NCT05699746|NO_INTERVENTION|Observation|Patients undergo active surveillance
62332894|NCT02016092||Patients with Parkinson's disease|
62332895|NCT02016092||Healthy Controls|
62332896|NCT05256069|EXPERIMENTAL|Hypoxia Exposure|Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
62332897|NCT02114567|EXPERIMENTAL|PSV ventilation|AECOPD Patients who were ventilated wiht PSV, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. Pressure support was set to get the tidal volume of 6ml/kg.
62332898|NCT02114567|EXPERIMENTAL|NAVA ventilation|AECOPD patients who were ventilated with NAVA, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. NAVA level was set to get the tidal volume of 6ml/kg.
62332899|NCT05542303|EXPERIMENTAL|ZB001 for injection|Treated different dose cohorts with single intravenous injection of ZB001
62332900|NCT00219336|EXPERIMENTAL|Self-motivational Choices|Students and nonstudents were mailed a brochure prepared as part of the PHC study intervention, Making Healthy Choices for a Healthy Baby in English or Mujeres y Salud Eligiendo Opciones Saludables in Spanish. This brochure allows women to make informed decisions about preventing an AEP. The MF materials included nonstigmatizing messages about drinking and contraception embedded among other health messages. Similar to Project CHOICES, this group also received a brochure on birth control practices.
62694774|NCT04737265|EXPERIMENTAL|Biomarker Guided Arm|"NTproBNP will be monitored serially prior to start of anthracycline based chemotherapy, at each cycle of anthracycline based chemotherapy, and at 3 month intervals for a total of 12 months.~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and at standardized intervals at 3, 6, 9, and 12 months following initiation of Anthracycline chemotherapy."
62136668|NCT01818180|PLACEBO_COMPARATOR|Placebo|
62136669|NCT06282354||Face-to-face appointment|Patients allocated in face-to-face appointment after urooncologic surgical procedures
62332901|NCT00219336|ACTIVE_COMPARATOR|Information Only|Students and nonstudents were mailed a brochure prepared by the CDC. The brochure (English: Think Before You Drink: You Can Hurt Your Unborn Baby; Spanish: Piénselo Antes de Beber: Puede Lastimar a Su Futuro Bebe), available at the CDC website, targets women of childbearing-age, discusses FAS and the negative effects of a mother's drinking on her unborn child, and recommends calling Alcoholics Anonymous or an alcohol treatment program for help to stop drinking. The CDC brochure did not contain information about how to contracept effectively.
62332902|NCT04178681|EXPERIMENTAL|V-A-C|"Order of administration:~1. 100% vegetable fat blend~2. 100% Anhydrous Milk Fat (AMF)~3. 100% Cream (AMF + milk fat globular membranes)"
62332903|NCT04178681|EXPERIMENTAL|V-C-A|"Order of administration:~1. 100% vegetable fat blend~2. 100% Cream (AMF + milk fat globular membranes)~3. 100% Anhydrous Milk Fat (AMF)"
62332904|NCT04178681|EXPERIMENTAL|A-V-C|"Order of administration:~1. 100% Anhydrous Milk Fat (AMF)~2. 100% vegetable fat blend~3. 100% Cream (AMF + milk fat globular membranes)"
62332905|NCT04178681|EXPERIMENTAL|A-C-V|"Order of administration:~1. 100% Anhydrous Milk Fat (AMF)~2. 100% Cream (AMF + milk fat globular membranes)~3. 100% vegetable fat blend"
62136670|NCT06282354||Telemedicine appointment|Patients allocated in telemedicine appointment after urooncologic surgical procedures
62332906|NCT04178681|EXPERIMENTAL|C-A-V|"Order of administration:~1. 100% Cream (AMF + milk fat globular membranes)~2. 100% Anhydrous Milk Fat (AMF)~3. 100% vegetable fat blend"
62332907|NCT04178681|EXPERIMENTAL|C-V-A|"Order of administration:~1. 100% Cream (AMF + milk fat globular membranes)~2. 100% vegetable fat blend~3. 100% Anhydrous Milk Fat (AMF)"
62332908|NCT00590018|EXPERIMENTAL|1|Subjects in this arm will receive a 5 day tapering course of hydrocortisone.
62332909|NCT00590018|PLACEBO_COMPARATOR|2|Subjects in this arm will receive 5 days of placebo.
62332910|NCT04766203|NO_INTERVENTION|Global screening of high-performance athletes for REDS|This arm collects data with an online survey to assess prevalence and signs and symptoms of REDS in elite female and male elite and recreational athletes and para-athletes over the age of 15 years across the world.
62332911|NCT04766203|NO_INTERVENTION|Basic screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline blood sample and potentially (where abnormalities are present) a follow-up 6 months later.
62332912|NCT04766203|NO_INTERVENTION|Advanced screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline test for bone density (DXA scans), resting metabolic rate and exercise testing. Potentially (where abnormalities are present) a follow-up 6 months later.
62332913|NCT04766203|EXPERIMENTAL|Treatment of Canadian athletes with REDS: a holistic intervention arm|In this arm, varsity level to elite Canadian athletes and para-athletes with REDS will participate in a nutritional intervention aiming to improve energy availability and thus, REDS status.
61937836|NCT01977937|PLACEBO_COMPARATOR|Simple Syrup|Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.
62136671|NCT01643538|ACTIVE_COMPARATOR|Control Arm|"Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or charity donations in this group."
62332914|NCT02222038|OTHER|skin biopsy|4mm punch biopsy
62332915|NCT02316691||Thyroid Eye Disease|Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease. This study is observational. No interventions will be given as part of this study.
62332916|NCT04017988|EXPERIMENTAL|Ethanol Extracts of Porphyra Tenera(PTE10) group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 2.5 g/day)
62694775|NCT04737265|NO_INTERVENTION|Usual Care|NTproBNP will not be monitored while patients are on study unless clinically indicated. Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and at standardized intervals at 3, 6, 9, and 12 months following initiation of Anthracycline chemotherapy. Biomarker data will also be collected at each cycle of Anthracycline chemotherapy.
62694776|NCT05805189|EXPERIMENTAL|Heliostar group A|In this group the achievement of isolation of the pulmonary veins is evaluated with one shot tecnology Heliostar, multielecrode radiofrequency ballon catheter guided by the impedance level measured in the veins
62332917|NCT04017988|PLACEBO_COMPARATOR|Placebo group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 0 g/day)
62332918|NCT04739657||Participants|Subjects whose clinical conditions require stent implantation, and the interventional procedure of which needs the guidance of IVUS imaging.
62332919|NCT01594632|EXPERIMENTAL|Jadelle|Contraception using Jadelle implant
62332920|NCT01594632|ACTIVE_COMPARATOR|Sino-implant (II)|levonorgestrel containing subdermal contraceptive implant \[Zarin, Femplant, Trust or Simplant\]
62332921|NCT02566941|EXPERIMENTAL|Stimulated|Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
62332922|NCT02566941|NO_INTERVENTION|Control|
62332923|NCT03257930|EXPERIMENTAL|injection of ethanol|use of ethanol injection in the treatment of cystic thyroid nodule
62332924|NCT04655105|EXPERIMENTAL|Truanatomy rotary file|use of tru anatomy rotary files root canal instrumentation followed by post operative pain evaluation
62332925|NCT04655105|EXPERIMENTAL|hyflex EDM rotary file|use of hyflex EDM rotary files root canal instrumentation followed by post operative pain evaluation
62332926|NCT04655105|EXPERIMENTAL|edge endo reciprocating rotary file|use of edge endo reciprocating rotary files root canal instrumentation followed by post operative pain evaluation
61937837|NCT00586066|PLACEBO_COMPARATOR|Placebo|Placebo-matching memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to placebo-matching memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to placebo-matching memantine 5 mg in the morning and placebo-matching memantine 10 mg in the evening in Week 3; dose increase if tolerated to placebo-matching memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
62332927|NCT04655105|ACTIVE_COMPARATOR|protaper gold rotary file|use of protaper gold rotary files root canal instrumentation followed by post operative pain evaluation
62332928|NCT02844023|OTHER|Patient with giant gells arteritis|50 patients with giant gells arteritis
62332929|NCT02844023|OTHER|Control patients|50 control patients : blood from French national blood service (EFS)
62332930|NCT04430049||no visitation group|relatives cannot visit ICU patient during Covid pandemic period in France
62332931|NCT04430049||restrictive visitation group|relatives have restriction to visit ICU patient during Covid pandemic period in France
62332932|NCT04430049||open visitation group|relatives can visit ICU patient during no Covid period in France
62332933|NCT00088582|EXPERIMENTAL|Sandostatin s.c. (Octreotide)|
62490582|NCT05493163|ACTIVE_COMPARATOR|Standard Anticoagulation|Before randomization, all patients are treated with intravenous unfractionated heparin (to a target aPTT of 70-90 s) or subcutaneous LMWH (the full therapeutic dose). For patients in the CDT group, the anticoagulation treatment was is described above; among CDT patients who received LMWH, the procedure should be postponed for 8 h after the last dose of LMWH. Patients in the standard care group continue therapeutic anticoagulation with either unfractionated heparin or LMWH. Subsequent change for oral anticoagulation is at the discretion of the treating physician (not earlier than 24 hours post-randomization).
62490583|NCT03764657||"16 patients, named Hot group"|"We considered 16 sinus excision by diathermy as a case group (named Hot group)"
62136672|NCT01643538|EXPERIMENTAL|Personal Financial Incentives Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will receive $20. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
62136673|NCT01643538|EXPERIMENTAL|Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week participants will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity. Charity donation is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
62136674|NCT01643538|EXPERIMENTAL|Combined Financial Incentives & Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will receive money and/or be notified that a donation of the selected amount has been sent to the charity, depending on their selected preference. Incentives are terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
62136675|NCT03277404|EXPERIMENTAL|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium' hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
62136676|NCT03277404|ACTIVE_COMPARATOR|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
62136677|NCT06134089||Perceived Shareablility Prompt First|
62136678|NCT06134089||Perceived Effectiveness Prompt First|
62136679|NCT05254067||Device recipient|
62136680|NCT04251169|EXPERIMENTAL|Pembrolizumab + Paclitaxel|Pembrolizumab 200 mg every 3 weeks (on D1 of each 21-day cycle, beginning in Cycle 1) in combination with paclitaxel 80 mg/m2 administered at days 1, 8, 15 of each 21-day cycle beginning at cycle 2.
62136681|NCT06452212||Urologists|Health care professionals/panelist.
62136682|NCT00651859|EXPERIMENTAL|1|Bimatoprost 0.01% Ophthalmic Solution
62136683|NCT00651859|EXPERIMENTAL|2|Bimatoprost 0.03% Ophthalmic Solution
62136684|NCT00651859|PLACEBO_COMPARATOR|3|Bimatoprost Vehicle Ophthalmic Solution
62136685|NCT04420767|EXPERIMENTAL|tDCS and Go-No Go task|"Certain randomly assigned participants will receive tDCS to the DLPFC for 8 daily 20-minute sessions, with a TDCS amplitude of 2 mAmps.~During the tDCS session, individuals will perform a 10-min computerized Go-No Go task"
62136686|NCT04420767|SHAM_COMPARATOR|Sham brain stimulation and Go-No Go task|"Certain randomly assigned participants will receive Sham Stimulation to the DLPFC for 8 daily 20-min sessions. The Sham stimulation is an inactive form of stimulation.~During the sham brain stimulation session, individuals will perform a 10-min computerized Go-No Go task"
62136687|NCT05168306|NO_INTERVENTION|Standard of Care|No intervention will be administered. Subjects randomized to the Standard of Care Arm will continue using their Current standard of care device to monitor and manage their diabetes
62136688|NCT05168306|ACTIVE_COMPARATOR|Intervention|Subjects randomized to this Arm will use FreeStyle Libre 2 to monitor and manage their diabetes.
62136689|NCT02213146|EXPERIMENTAL|BioChaperone human insulin|BioChaperone Human Insulin
62136690|NCT02213146|ACTIVE_COMPARATOR|Human insulin|Huminsulin® Normal
62136691|NCT02213146|ACTIVE_COMPARATOR|Insulin lispro|Humalog®
62136692|NCT01359150|EXPERIMENTAL|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).|CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
62136693|NCT01359150|PLACEBO_COMPARATOR|Treatment Group 2:Placebo CP-690,550 (100 subjects).|Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
62136694|NCT06091449|EXPERIMENTAL|High fidelity simulation|The Faculty of Nursing has a simulation laboratory to enable students to realize their professional skills in a high-reality environment. The laboratory has all the equipment that should be found in a clinic, such as a high-reality simulation mannequin, nurse's table, patient bed, shelves, monitors, bedside oxygen systems, treatment and emergency response carts.Lab; It consists of 3 sections: application room, control room and analysis room.
62332934|NCT00088582|EXPERIMENTAL|Pasireotide (SOM230)|
62694777|NCT05805189|ACTIVE_COMPARATOR|Carto Group B|In this group the achievement of isolation of the pulmonary veins is evaluated with classic method guided by fluoroscopy
62490584|NCT03764657||"13 patients, named Cold group"|"13 procedures performed by knife as control group (named Cold group)."
62694778|NCT04938427|PLACEBO_COMPARATOR|Placebo|Soticlestat placebo-matching mini-tablets or tablets, orally or via G-tube or MIC-KEY button or J-tube, BID, up to 4 weeks during titration. Participants continued to receive soticlestat placebo-matching mini-tablets or tablets for 12 weeks during maintenance. The total duration of the treatment was up to 16 weeks (Full Treatment Period). Soticlestat matching tapering was done to maintain the blind if participants decided to discontinue the treatment.
62490585|NCT05028855||sCAS patients|Investigators plan to enroll 850 patients of symptomatic cerebral atherosclerotic stenosis (sCAS) for cerebral autoregulation assessment to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.
62490586|NCT04207333|EXPERIMENTAL|Prolonged Sitting + Mental Stress, Then Brief Sitting + Mental Stress|Participants will sit for 120 min prior to being exposed to mental stress Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 120 minutes while watching a documentary. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (brief sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Following the 10 minutes quiet rest in the seated position, participants will be subjected to a 5 minute mental arithmetic test.
62490587|NCT04207333|EXPERIMENTAL|Brief Sitting + Mental Stress, Then Prolonged Sitting + Mental Stress|Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 10 minutes. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (prolonged sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Participants will sit quietly for 120 min while watching a documentary, following which the participants will be subjected to a 5 minute mental arithmetic test.
62490588|NCT04803162||patients with eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group. EoE patients were then treated for 8 weeks with PPs - omeprazole in the dose of 20 mg twice daily. After 8 weeks, each patient in the EoE group again passed all the tests (the protocols were identical to those used for qualifying patients to the project).
61937838|NCT00586066|EXPERIMENTAL|Memantine|Re-purposed Alzheimer's drug to treat cognitive dysfunction associated with bipolar disorder. Memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to memantine 5 mg in the morning and memantine 10 mg in the evening in Week 3; dose increase if tolerated to memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
62136695|NCT06091449|EXPERIMENTAL|High fidelity simulation and virtual reality|"The modular education and virtual reality-based simulation program is currently actively available on the hadi.hacettepe.edu.tr website. Students who will benefit from this program can access the program after defining a username and password.The application of high-fidelity simulation is the same in both groups."
62136696|NCT05587699|EXPERIMENTAL|Group - A1(Part 1)|CKD-843 A 45mg
62136697|NCT05587699|EXPERIMENTAL|Group - A2(Part 2)|CKD-843 A 45mg
62332935|NCT00376597|EXPERIMENTAL|Arm I (lymphedema education)|Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.
62332936|NCT00376597|EXPERIMENTAL|Arm II (lymphedema education, physical therapy)|Description Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.
62332937|NCT05610995|EXPERIMENTAL|SENSIUM Group|Patients in the experimental group will be discharged with the device after an assessment on Day 1.
62332938|NCT05610995|NO_INTERVENTION|ERAS standard Group|Patients in the control group will receive the usual ERAS (conventional hospitalization for clinicobiological monitoring).
61937839|NCT05068310||Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors|Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors who are scheduled for skin biopsy or excision
61937840|NCT00791310|EXPERIMENTAL|TEP|Performance of of TEP coupled to scanner X
61937841|NCT02706678|EXPERIMENTAL|Tacrolimus sustained-release capsule group|Oral
62136698|NCT05587699|EXPERIMENTAL|Group - B1(Part 1)|CKD-843 A 55mg
62136699|NCT05587699|EXPERIMENTAL|Group - B2(Part 2)|CKD-843 A 55mg
62136700|NCT05587699|ACTIVE_COMPARATOR|Group - R(Part 1)|CKD-843-R
62332939|NCT05915754|EXPERIMENTAL|Hip abductors stretching and strengthening exercises|Patients will get the hip abductor stretching and strengthening exercise treatment for four weeks four times per week and will consist of four sets of 15 repetitions.
62332940|NCT05915754|EXPERIMENTAL|Posterior oblique sling strengthening exercises|Patients will get treatment plan of Hip abductors stretching and strengthening exercises plus a posterior oblique sling strengthening program for four weeks, four times per week and will consist of four sets of 15 repetitions.
62332941|NCT02215993|ACTIVE_COMPARATOR|Prasugrel|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 60 mg prasugrel followed by 10mg per day for 30 days.
61937842|NCT03048474|EXPERIMENTAL|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
62136701|NCT03877016|ACTIVE_COMPARATOR|TENS Eco2|TENS Eco2 is the classical device in patients with chronic neuropathic pain
62136702|NCT03877016|EXPERIMENTAL|actiTENS|ActiTENS is a new TENS device, that seems less cotraining.
62136703|NCT04737291|EXPERIMENTAL|Angioplasty by DCB|angioplasty of stenotic , ocluded or recoil segment using drug coated ballon
62136704|NCT02099123|EXPERIMENTAL|Atorvastatin|40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
62136705|NCT02099123|PLACEBO_COMPARATOR|Placebo|Placebo (2 x 20 mg placebo) taken orally once daily
62490589|NCT04803162||patients without eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group.
62697641|NCT06022887|EXPERIMENTAL|TRE alone|Participants will be instructed to eat ad libitum from noon - 8:00pm daily and fast from 8:00pm - noon (16-h fast) for 8 weeks. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. Participants will meet with a registered dietitian (RD) for 30 minutes at the start of the intervention to review instructions and goals and weekly thereafter. Adherence to the TRE intervention will be assessed as the number of adherent days per week.
61937843|NCT05430022|EXPERIMENTAL|Autism-adapted Group Cognitive Behavioral Therapy (Child Ratings)|Autistic adolescents (11-17 years old; middle and high school) with depression will participate in a 12-week group intervention, autism-adapted Cognitive Behavioral Therapy, to increase perception and understanding of self and to decrease the severity of depressive symptoms.
61937844|NCT05430022|EXPERIMENTAL|Autism-adapted Group Cognitive Behavioral Therapy (Parent Ratings)|One parent of each autistic adolescent (11-17 years old; middle and high school) with depression will provide ratings of their child as their child participates in a 12-week group intervention, autism-adapted Cognitive Behavioral Therapy, to decrease the severity of depressive symptoms. Parents will not participate in therapy sessions.
62136706|NCT04887337|ACTIVE_COMPARATOR|Arthroscopic stabilization|Patients will have an initial evaluation with a diagnostic shoulder arthroscopy and examination under anesthesia will be performed to confirm the degree of anterior instability and assess range of motion of the affected shoulder. Diagnostic arthroscopy will commence with the use of 3 standard shoulder portals (posterior viewing and two anterior working portals for suture passing), and a detailed arthroscopic examination will be performed. Once the soft tissue tear (including the labrum, and capsule labrum ligaments) is identified, it will be mobilized using a rasp or elevator and a burr will then be used to create a surface for a bleeding bone bed. Capsulolabral repair will then commence with the labrum fixed to the glenoid using suture anchors (the Bankart repair). Following surgery, subjects in this group will follow the same rehabilitation protocol as the comparison group.
62136707|NCT04887337|ACTIVE_COMPARATOR|Rehabilitation including a period of immobilization followed by physical therapy|Subjects in this group will use an internal-rotation shoulder immobilizer, using a standard sling for 6 weeks from the day of enrollment. Subjects will be advised to maintain range of motion (ROM) in the elbow and wrist during this period of time. The immobilizer can be removed for passive pendulum exercises and elbow ROM during the period of immobilization up to 4 times per day. Formal physiotherapy commences at 4 weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
62136708|NCT01053793|ACTIVE_COMPARATOR|Glucose Standard|
62136709|NCT01053793|EXPERIMENTAL|Potato Variety|
62136710|NCT06698874|EXPERIMENTAL|group of participants|Patients with antiplatelet drugs-related acute non-hematochezia gastrointestinal bleeding are enrolled. All enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (ds-MCE) first, followed by EGD within 24 hours.
62136711|NCT02261506|ACTIVE_COMPARATOR|7 days|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
62136712|NCT02261506|ACTIVE_COMPARATOR|14 days|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
62136713|NCT05793307|EXPERIMENTAL|Cohort 1|Single intravenous administration of GC301 at a dose of 8.0 x 10\^13 vector genomes per kilogram body weight
62136714|NCT05793307|EXPERIMENTAL|Cohort 2|Single intravenous administration of GC301 at a dose of 1.2 x 10\^14 vector genomes per kilogram body weight
62136715|NCT05793307|EXPERIMENTAL|Cohort 3|Single intravenous administration of GC301 at a dose of 1.8 x 10\^14 vector genomes per kilogram body weight
62136716|NCT06699498|EXPERIMENTAL|Treatment group|"The treatment group received neoadjuvant therapy with benmelstobart, anlotinib, cisplatin, and albumin-bound paclitaxel for a total of 3 cycles.~Surgery was performed within 2 weeks after completing neoadjuvant therapy. Adjuvant therapy was initiated within 6 weeks after surgery."
62136717|NCT06000956|EXPERIMENTAL|Jitongning tablets|
62136718|NCT06000956|PLACEBO_COMPARATOR|a simulated agent of Jitongning tablets|
62136719|NCT06389357|EXPERIMENTAL|return to school adaptation program|Counselling interviews and workshops will be held simultaneously with the children receiving the web-based training. There are 4 modules in total. The first module lasts 2 weeks. The counselling interview will start in the 2nd week. Implementation will be completed in 5 weeks.
62136720|NCT00112359|PLACEBO_COMPARATOR|Placebo three times a day (TID)|
62136721|NCT00112359|EXPERIMENTAL|AZLI 75 mg three times a day (TID)|
62136722|NCT06541522|OTHER|PEEP titrations|
62136723|NCT05310968|EXPERIMENTAL|Tirofiban group|"This group will receive tirofiban and aspirin. Day 1: Tirofiban injected intravenously for 24 hours and aspirin of 100-300 mg. Tirofiban will be injected at 4 ug/kg/ min for the first 30 minutes and 0.1 ug/kg/min for the next 24 hours.~Day 2-90: Aspirin 100mg per day."
62332942|NCT02215993|ACTIVE_COMPARATOR|Ticagrelor|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 180 mg ticagrelor followed by 90mg twice a day for 30 days.
61937845|NCT06561932|EXPERIMENTAL|Single-arm, prospective, multicenter, observational study.|.WiSE System therapy ON with Guideline Directed Medical Therapy
62136724|NCT05310968|PLACEBO_COMPARATOR|Tirofiban placebo group|"This group will receive tirofiban placebo and aspirin. Day 1: Tirofiban placebo injected intravenously for 24 hours and aspirin of 100-300 mg. The placebo will be injected at the same rate with Tirofiban group.~Day 2-90: Aspirin 100mg per day."
62136725|NCT05791162|OTHER|IgA nephropathy in follow-up (arm 1)|Diagnosis of IgA nephropathy from 2009, with a minimum follow-up for nephropathy of 5 years
62332943|NCT03057834|ACTIVE_COMPARATOR|Functionally impaired|Women with urinary incontinence and short physical performance battery score of \<9
62136726|NCT05791162|OTHER|Newly diagnosed IgA nephropathy (arm 2)|Diagnosis of IgA nephropathy during the study period
62490590|NCT05812625|EXPERIMENTAL|Interventional Group A|• Group A will receive conservative baseline treatment consisted of hot pack therapy for 10 minutes and traction for 8 minutes with Myokinetic stretching technique. Subject will be in supine lying on the plinth and the head will be placed at the edge of the plinth by the therapist. Then with one hand the therapist held the neck in cervical lateral flexion to the opposite side so as to achieve the stretching of the trapezius muscle. Myofascial release by applying sustained finger pressure for 5-10 s on the involved trapezius was given. A gentle myofascial stretching force was applied to take up slack and sustained until a release occurred .The MST protocol comprised of three sets of 4 stretches with 5 seconds rest period between the stretches. Treatment will be provided twice a week for 8 weeks.
62694779|NCT04938427|EXPERIMENTAL|Soticlestat|"Participants weighing \<45 kg: Soticlestat, mini-tablets, at the dose of 40 mg to 200 mg, orally or via G-tube or MIC-KEY button or J-tube, BID based on body weight up to 4 weeks during titration. Participants continued to receive the dose that they were on at the end of the titration, for 12 weeks during maintenance. The total duration of the treatment was up to 16 weeks (Full Treatment Period) with the dose tapered down if participants decided to discontinue the treatment.~Participants weighing ≥45 kg: Soticlestat mini-tablets or tablets with a starting dose of 100 mg BID followed by 200 mg BID and, then 300 mg BID, up to 4 weeks during titration. Participants continued to receive 300 mg BID for 12 weeks during maintenance. The total duration of the treatment was up to 16 weeks (Full Treatment Period) with the dose tapered down if participants decided to discontinue the treatment."
62694780|NCT03407950|OTHER|Group IPT+|2 sessions of IPT+ by week during 6 months
62694781|NCT03407950|OTHER|Control Group|group without specific therapy (Treatment as usual) but same number and duration of each sessions than IPT+
62694782|NCT04336969|OTHER|T1D Patients|Participants will wear a Continuous Glucose Monitor (CGM) with remote data monitoring
61937846|NCT04560790|EXPERIMENTAL|BD111 Adults single group Dose|Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.
62332944|NCT03057834|PLACEBO_COMPARATOR|Functionally normal|Women with urinary incontinence and short physical performance battery score of \> 10
62332945|NCT00137436|EXPERIMENTAL|A|SU011248 in combination with docetaxel and prednisone
62332946|NCT02481037|EXPERIMENTAL|Intervention group|Embedding a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate practitioners utilizing best-evidence; training these practices' chronic disease management (CDM) professionals to provide asthma education to children with asthma and their parents; and clinicians receiving an EMR embedded dashboard.
62332947|NCT02481037|NO_INTERVENTION|Control group|Practice will continue with routine care. Control group will be offered the intervention at study completion, if successful.
62332948|NCT06425783|NO_INTERVENTION|Blood Transfusion|It was planned to transfuse the blood at +4C temperature brought from the blood bank center in 3 hours. At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K.
62332949|NCT06425783|EXPERIMENTAL|Blood transfusıon|Blood will be warmed before transfusion. At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K.
62332950|NCT04987853||Acute COVID patients|Patients in the acute phase of the course of the disease
62332951|NCT04987853||Long Covid Patients|Patients with chronic symptoms after a previous Covid-19 (4-12 weeks)
62332952|NCT04987853||Postcovid patients|Patients with chronic symptoms after a previous Covid-19 (more than 12 weeks)
62332953|NCT01611233||DePuy ASR THA|Adults having received a Depuy ASR metal on metal hip system which is subject to a voluntary recall.
62332954|NCT02155296|EXPERIMENTAL|Schools receiving RPI|"This arm contains schools receiving RPI. RPI offers a continuum of practices that range from informal (e.g., using affective statements that communicate feelings) to formal (e.g., hosting a restorative circle where participants are encouraged to express emotions and form emotional bonds). The circles or group meetings that are designed to take place between school staff and students, are the crux of RPI. School staff are encouraged to use the restorative practices to build relationships and resolve staff issues (restorative staff community), as well as when interacting with parents (restorative approach with families). All restorative practices encourage acting with youth and setting high expectations. When a school becomes proficient in all 11 essential practices it is officially recognized as a Restorative Practices School."
62694783|NCT03295942|EXPERIMENTAL|OMP-336B11|Intravenous (in the vein) infusions of OMP-336B11
62694784|NCT04672616|EXPERIMENTAL|Group psychotherapy|Weekly group meeting w/psychotherapist: All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or problems the group members have
62332955|NCT02155296|EXPERIMENTAL|Schools not receiving RPI|This arm is the control arm and consists of schools that are not receiving RPI.
62332956|NCT00708604|EXPERIMENTAL|1|Islet transplantation
62332957|NCT04657016|EXPERIMENTAL|Tirzepatide|Participants received weekly doses of tirzepatide subcutaneously (SC) for 72 weeks, starting at 2.5 milligrams (mg) for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
62332958|NCT04657016|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo SC once weekly (QW).
62332959|NCT06369675|EXPERIMENTAL|MOB015B, MOB015B vehicle, 0.2% SLS and an inert control|All subjects will receive MOB015B, MOB015B vehicle, 0.2% SLS (positive control) and inert control (negative control) Each subject will serve as his or her own control
62332960|NCT02109094||Pregnant|
62332961|NCT02109094||Not Pregnant|
62332962|NCT03726671|EXPERIMENTAL|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62332963|NCT03726671|EXPERIMENTAL|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
61937847|NCT00997061||HYCAMTIN|
61937848|NCT01677546|EXPERIMENTAL|CSII+BC+CL|Patients using insulin pump (CSII) bolus calculator (BC) wirelessly connected with blood glucose meter Contour Link (CL)
62136727|NCT05791162|OTHER|CD163s control (arm 3)|Diagnosis of Lupus or ANCA-associated vasculitis or polycystic kidney disease
62136728|NCT06143709||Precision PCI Prospective Cohort|Patients who have undergone PCI and clinical CYP2C19 genotyping
62332964|NCT03726671|EXPERIMENTAL|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62332965|NCT03726671|EXPERIMENTAL|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62332966|NCT03726671|EXPERIMENTAL|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62332967|NCT03726671|EXPERIMENTAL|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
62332968|NCT02831634|OTHER|Blood sampling|
62332969|NCT01435239|EXPERIMENTAL|resting volume group|
62332970|NCT01435239|ACTIVE_COMPARATOR|maximum volume group|
62332971|NCT02837692|EXPERIMENTAL|Cohort 1|Participants assigned to Cohort 1 group A (elderly non-Asian), group B (young healthy non-Asian) and group C (healthy Japanese) will receive JNJ-42847922 10 mg, 3 hours after completing dinner.
62332972|NCT02837692|EXPERIMENTAL|Cohort 2|Participants assigned to Cohort 2 group A, group B and group C will receive JNJ-42847922 20 mg, 3 hours after completing dinner.
62332973|NCT02837692|EXPERIMENTAL|Cohort 3|Participants assigned to Cohort 3 group A and group C will receive JNJ-42847922 40 mg, 3 hours after completing dinner. Participants in group B will receive JNJ-42847922 40 mg, 3 hours after completing dinner in Period 1, followed by at least 7 days washout period, further followed by JNJ-42847922 40 mg, immediately after completing dinner.
62332974|NCT02837692|EXPERIMENTAL|Cohort 4|Participants assigned to Cohort 4 group B will receive JNJ-42847922 60 or 80 mg, 3 hours after completing dinner.
62332975|NCT03810690|EXPERIMENTAL|Dose Escalation Phase: Dose Level 1|mRNA-3704
62332976|NCT03810690|EXPERIMENTAL|Dose Escalation Phase: Dose Level 2|mRNA-3704
62332977|NCT03810690|EXPERIMENTAL|Dose Escalation Phase: Dose Level 3|mRNA-3704
62490591|NCT05812625|ACTIVE_COMPARATOR|Interventional Group B|• Group B will be treated by conventional baseline treatment with Post-isometric Relaxation Exercises. Cervical paraspinal post isometric relaxation will be performed with the patient supine, while the therapist will slowly lift the patient's head toward the ceiling. Once a comfortable stretch will be felt, the patient is asked to push their head back (with approximately 10% of their strength), while the therapist will resist the movement; thus, creating an isometric contraction. This position is held for 8-10 seconds. The patient will be asked to inhale deeply and, upon exhalation, will be instructed to relax while the therapist will lift the patient's head a little further towards the ceiling. The protocol will be comprised of three sets of post isometric relaxation with 5 seconds rest period. Treatment will be provided twice a week for 8 weeks.
62490592|NCT01225510|EXPERIMENTAL|Primary Cohort|
62490593|NCT01225510|EXPERIMENTAL|Exploratory Cohort|
62490594|NCT04871308|PLACEBO_COMPARATOR|Control|Placebo group using normal saline infusion
62136729|NCT02412033|ACTIVE_COMPARATOR|Misoprostol group|Going to receive 400 µg misoprostol vaginally 3 hours before IUD insertion.
62332978|NCT03810690|EXPERIMENTAL|Dose Escalation Phase: Dose Level 4 (optional)|mRNA-3704
62332979|NCT03810690|EXPERIMENTAL|Dose Expansion Phase: mRNA-3704|
62332980|NCT01727232||Standard regimen|Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab
62490595|NCT04871308|ACTIVE_COMPARATOR|Dexmedetomidine|From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.
62490596|NCT01714141|EXPERIMENTAL|Multi-component, technology based intervention|2 tailored, computer-delivered motivational interviewing sessions targeting adherence to asthma control medications + tailored text messaged reminders to take medications between sessions.
62490597|NCT01714141|ACTIVE_COMPARATOR|Asthma education active control|Control condition consists of active control matched to intervention for delivery-method and time-- 2 sessions of computer-delivered asthma education + daily text messaged facts about asthma.
62136730|NCT02412033|PLACEBO_COMPARATOR|Placebo group|Going to receive placebo.
62136731|NCT05874414|EXPERIMENTAL|GNS561+Trametinib|"Phase 1b Dose Finding Patients will receive GNS561 (50mg QD; 100mg QD; 150mg; 200mg QD) and trametinib (2mg QD; 1.5mg QD; 1mg QD) in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD) of the combination.~Experimental:~Phase 2a Patients will receive GNS561 and trametinib at the recommended dose of the combination determined during Phase 1b"
62136732|NCT03510104|EXPERIMENTAL|MRX-2843|MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
62332981|NCT01727232||Rheumatoid arthritis regimen|Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab
62332982|NCT00908206|PLACEBO_COMPARATOR|Placebo|Placebo to match GSK598809.
62332983|NCT01281683||TACE|
62332984|NCT01281683||RFA|
62332985|NCT05906134|ACTIVE_COMPARATOR|local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
62332986|NCT05906134|ACTIVE_COMPARATOR|cryo-ablation plus intercostal nerve block|Patients receiving cryo-analgesia and intercostal blocks, the patient will receive cryo-ablation prior to the intercostal block. The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
62490598|NCT06312462|EXPERIMENTAL|A:Intervention group|A group of students who receive schistosomiasis health education intervention led by community health volunteers.
62490599|NCT06312462|NO_INTERVENTION|B:Control group|A group of students who do not receive schistosomiasis health education intervention led by community health volunteers.
62490600|NCT00609557|EXPERIMENTAL|A|All subjects receive placebo for the first two weeks and then duloxetine for the next 10 weeks, but they are blind to what they are receiving.
62490601|NCT03545334|EXPERIMENTAL|Comparison result lymphoscintigraphy with ICG lymphography|"The patient first receives a standard Tc-99m-based lymphoscintigraphy. The identified lymph nodes are not marked in the patients, so that the surgeons are not affected in lymph node identification during ICG and near infrared fluorescence imaging. The surgeon also has no access to lymphoscintigraphy images.~Transcutaneous ICG lymphography is then performed by intradermal injection of ICG around the scar of the primary tumor excision and transcutaneous fluorescence evaluation with the Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD) and results are compared."
62490602|NCT01880476|EXPERIMENTAL|Home visits and group program|
62490603|NCT02155257|ACTIVE_COMPARATOR|Modafinil|Modafinil 200 mg will be administered orally one time
62490604|NCT02155257|PLACEBO_COMPARATOR|Placebo|A placebo will be administered orally one time
62490605|NCT02155257|ACTIVE_COMPARATOR|Gabapentin|Gabapentin 900 mg will be administered orally one time
62490606|NCT03279250|EXPERIMENTAL|Arm A (LHRHa, apalutamide)|Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
62490607|NCT03279250|EXPERIMENTAL|Arm B (LHRHa, apalutamide, abiraterone acetate)|Participants receive gonadotropin-releasing hormone analog and apalutamide as in arm A, abiraterone acetate PO QD, and prednisone PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
62490608|NCT04599842|NO_INTERVENTION|GROUP SA|Group SA was categorized as the group which spinal anaesthesia alone (SA) was performed
62490609|NCT04599842|ACTIVE_COMPARATOR|GROUP SA+ESP|Group SA+ESP was categorized as group which SA+ESP block was performed.
62490610|NCT03980522|EXPERIMENTAL|KPL-914: Part 1 Participants|Part 1 enrolls symptomatic participants with recurrent idiopathic pericarditis (RIP) with an elevated marker of systemic inflammation (C-reactive protein \[CRP\] \> 1mg/dL).
62490611|NCT03980522|EXPERIMENTAL|KPL-914: Part 2 Participants|Part 2 enrolls symptomatic participants with RIP with CRP ≤1 mg/dL which, in the opinion of the Investigator, can be attributed to concomitant medications (e.g., corticosteroids) and with pericardial inflammation present on cardiac magnetic resonance imaging (MRI) confirmed by the imaging core lab.
62490612|NCT03980522|EXPERIMENTAL|KPL-914: Part 3 Participants|Part 3 enrolls participants with corticosteroid-dependent RIP not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
62490613|NCT03980522|EXPERIMENTAL|KPL-914: Part 4 Participants|Part 4 enrolls symptomatic participants with recurrent post pericardiotomy syndrome (PPS) with an elevated marker of systemic inflammation (CRP \> 1mg/dL).
62490614|NCT03980522|EXPERIMENTAL|KPL-914: Part 5 Participants|Part 5 enrolls participants with corticosteroid-dependent recurrent PPS not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
62490615|NCT00393250|EXPERIMENTAL|1|Hypnosis
62490616|NCT00393250|ACTIVE_COMPARATOR|2|Control
62490617|NCT00397735|EXPERIMENTAL|N-Acetylcysteine|The subjects enrolled in our research protocol must have evidence of infection/inflammation at amniocentesis in order to receive N-acetylcysteine. Women with positive amniocentesis results The dose of N-acetylcysteine is the one recommended to be used in humans to prevent acetaminophen toxicity: 150 mg/kg loading dose (60 min), followed by 50mg/kg IV continuous infusion rate for 4 hours, and followed by 100 mg/kg IV continuous infusion rate for the following 16 hours. Acetadote (Cumberland Pharmaceuticals) is the only FDA-approved intravenous N-acetylcysteine formulation and will be used in our study.
62490618|NCT00397735|PLACEBO_COMPARATOR|Placebo|The subjects enrolled in our research protocol must have infection/inflammation in order to be randomized to receive N-acetylcysteine or placebo. Placebo-assigned patients will receive sodium chloride solution without N-acetylcysteine
62490619|NCT06465654|ACTIVE_COMPARATOR|Endurance shuttle walk test with fixed dose oxygen treatment|The participant will conduct an endurance shuttle walk test with a fixed oxygen dose of 4 liters/minute delivered by the O2matic.
62332987|NCT05906134|ACTIVE_COMPARATOR|serratus plane catheter plus intercostal nerve block|Patients receiving serratus plane catheter blocks and intercostal nerve blocks, a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on Post Operative Day (POD) #1, 2, 3, 4, and 5 by the pain service.
62490620|NCT06465654|EXPERIMENTAL|Endurance shuttle walk test with automated variable dose oxygen treatment|The participant will conduct an endurance shuttle walk test with closed loop oxygen titration using O2matic to deliver a variable oxygen dosage set at an oxygen saturation target of 90 to 94 percent and an oxygen flow of 0 - 15 liters/minute.
62490621|NCT01783392|ACTIVE_COMPARATOR|Unilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.
62490622|NCT01783392|ACTIVE_COMPARATOR|Bilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.
62490623|NCT01783392|ACTIVE_COMPARATOR|Shoulder stimulation|Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.
62490624|NCT01336088|EXPERIMENTAL|ADX48621|
62490625|NCT01336088|PLACEBO_COMPARATOR|ADX48621 Matching Placebo|
62490626|NCT02426450|EXPERIMENTAL|RFA+FOLFOX4|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).~Oxaliplatin + 5-Fluorouracil/Leucovorin:~4 weeks after RFA; Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
62490627|NCT01953458||hepatitis C and/or B|
62332988|NCT05426707|EXPERIMENTAL|RIC group|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
62332989|NCT05426707|SHAM_COMPARATOR|Sham RIC group|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
62332990|NCT01151995||Remote plus on-site|Subjects will have remote source document verification performed 2-4 weeks prior to study monitors scheduled visit and any variables that were not able to be verified remotely will be verified on-site.
62332991|NCT01151995||On-site monitoring|Traditional source document verification will be performed when study monitor is on site
62332992|NCT04288726|EXPERIMENTAL|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~* Dose Level 1: 4 × 107 CD30.CAR-EBVST cells~* Dose Level 2: 1 × 108 CD30.CAR-EBVST cells~* Dose Level 3: 4 × 108 CD30.CAR-EBVST cells"
62332993|NCT01750398|EXPERIMENTAL|ADT plus IV testosterone|"Men with castration-resistant prostate cancer will initiate androgen deprivation therapy (ADT) with an LHRH agonist (e.g. goserelin or leuprolide) for a total of 6 months. After this initial lead-in castration phase, patients will receive intermittent intramuscular testosterone cypionate or testosterone enanthate (T) at a dose of 400 mg while continuing on ADT."
62332994|NCT05901038||Cardiac patients (group 1)|Patients with prior myocardial infarction, percutaneous coronary intervention (PCI), cardiac ablation or cardiac surgery, attending a reimbursed cardiac rehabilitation programme in the cardiology department of the UZA.
62332995|NCT05901038||Coached sporters with 12-week training schedule (group 2)|Sporters attending a sports cardiology consultation and following a 12-week training schedule at Sport Medical Centre Nottebohm.
62332996|NCT05901038||Sporters without 12-week training schedule (group 3)|Sporters attending a sport medical check-up at S.P.O.R.T.S. (i.e., a multidisciplinary centre of expertise within UZA), but without standardized 12-week training schedule.
62332997|NCT00904826|EXPERIMENTAL|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.
62332998|NCT03868007|EXPERIMENTAL|RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent RIC twice daily for 14 days.And the RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
62332999|NCT03868007|SHAM_COMPARATOR|sham-RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent sham-RIC twice daily for 14 days.And the sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
62333000|NCT00793676|OTHER|A= Asthma|
62333001|NCT00793676|OTHER|B= COPD|
62333002|NCT00793676|OTHER|C= Control|
62333003|NCT01380158|EXPERIMENTAL|Pessary use during pregnancy|Device: Cup pessary
62333004|NCT01380158|NO_INTERVENTION|Expectant management|Expectant Management + weekly intramuscular progesterone injections
62333005|NCT02915367|EXPERIMENTAL|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
62333006|NCT02915367|NO_INTERVENTION|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
62333007|NCT02583945|EXPERIMENTAL|kidney treatment bundle (KDIGO)|Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
62333008|NCT02410707|EXPERIMENTAL|Nitrous Oxide Arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
62333009|NCT01026701||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
62333010|NCT01294735|EXPERIMENTAL|Part A, MK-4827 + temozolomide dose escalation cohort|
61937849|NCT01677546|EXPERIMENTAL|CSII+BC|Patients using insulin pump (CSII) bolus calculator (BC) without wireless connection with blood glucose meter (CL)
62490628|NCT04366635|EXPERIMENTAL|Mineralised Plasmatic Matrix Group|Mineralized Plasmatic Matrix (MPM) is a product of mixing of two phases: the mineral phase and the plasma phase. After centrifugation, the white blood cells are recovered and mixed with the mineral phase of bone graft that can be autogenic, allogeneic bone, or a bone substitute like Xenogeneic Bone Synthetic. We will use Beta-tricalcium phosphate as a graft material. The result of this mixture is a homogeneous single component, which is compact and stable, containing the graft, the dense fibrin network, and the promoting healing. And then we are planning to place MPM material to extraction socket of impacted third molar tooth to improve periodontal healing at the distal aspect of second molar tooth. Additional after MPM places to extraction socket, Once the MPM has been placed, it will be covered with a Platelet Rich Fibrin (PRF) membrane and sutured as a primer.
61937850|NCT01677546|NO_INTERVENTION|CSII (insulin pump only)|Patients using insulin pump (CSII) without BC and connection with CL
61937851|NCT02525276|EXPERIMENTAL|training + HT|training + HT
61937852|NCT02525276|EXPERIMENTAL|training - HT|training - HT
62136733|NCT02394106|EXPERIMENTAL|Ofatumumab|"* Drug Name: Ofatumumab~* Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~* Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~* Who provides: registered nurse~* How: Ofatumumab IV at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~* Where: in Hospital~* When and how much: once; diluted in 1000 ml of normal saline~* Tailoring: 1500 mg/1.73m2~* How well: expert nurse would assist administration"
62136734|NCT02394106|PLACEBO_COMPARATOR|Placebo|"* Drug Name: Normal Saline (NaCl 0,9%)~* Why: standard therapy could not be used as comparator for Ofatumumab, given its toxicity and lack of effectiveness. Moreover, although Rituximab, a chimeric monoclonal anti-CD20 antibody, is increasingly being used as a steroid-sparing treatment option for children with certain forms of INS (those that respond to and are dependent of steroids), this drug does not work in DR-INS and could not be used as a comparator.~* Materials and Procedures: The placebo arm will receive the same infusion as the Ofatumumab Arm with the exception of the Ofatumumab."
62136735|NCT06664151|EXPERIMENTAL|Fluzone Vaccine in Cutaneous Squamous Cell Carcinoma|"Enrolled participants will complete:~* Baseline visit~* Days 1 and 8: Flu shot injection once~* Day 15: Standard-of-care Mohs excision surgery and tissue collection.~* Day 21 follow up visit with suture removal.~* Day 38 follow up visit"
62136736|NCT00914966|EXPERIMENTAL|CINRYZE|"There were 3 potential dose escalation steps:~* Step 1: 1500 Units of CINRYZE (C1 inhibitor \[human\]) administered by IV infusion twice per week for 12 weeks~* Step 2: 2000 Units of CINRYZE (C1 inhibitor \[human\]) administered by IV infusion twice per week for 12 weeks~* Step 3: 2500 Units of CINRYZE (C1 inhibitor \[human\]) administered by IV infusion twice per week for 12 weeks"
62136737|NCT06638463|EXPERIMENTAL|My Health Coach App Group|The My Health Coach group receives the My Health Coach app at study start. The My Health Coach app is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
62136738|NCT06638463|NO_INTERVENTION|Waitlist Control Group|The Waitlist Control Group gets access to the My Health Coach app after all the study survey timepoints are complete at 12 weeks.
62136739|NCT01433315|EXPERIMENTAL|sleep restriction|restricted sleep during the experimental period
62136740|NCT01433315|NO_INTERVENTION|normal sleep|normal sleep during the experimental period
61937853|NCT02525276|PLACEBO_COMPARATOR|-training + HT|-training + HT
61937854|NCT02525276|NO_INTERVENTION|- training - HT|- training - HT
61937855|NCT02549729|NO_INTERVENTION|Control|Control group not using hormonal replacement therapy will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and up to 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
61937856|NCT02549729|EXPERIMENTAL|Exercise|Experimental group not using hormonal replacement therapy will receive supervised pelvic floor muscle training.
61937857|NCT02549729|NO_INTERVENTION|Hormone Therapy|Experimental group using hormonal replacement therapy will not receive supervised pelvic floor muscle training.
61937858|NCT02549729|EXPERIMENTAL|Exercise and Hormone Therapy|Experimental group using hormonal replacement therapy will receive supervised pelvic floor muscle training.
61937859|NCT02121990|EXPERIMENTAL|Cisplatin, Paclitaxel, bevacizumab & olaparib|All treatments will be given in the outpatient setting. A cycle is 21 days. The sequence of infusions on Day 1 will be IV paclitaxel (135 mg/m2), then IV bevacizumab (15 mg/kg, beginning Cycle 2). On Day 2 patients will receive IP cisplatin (75 mg/m2). Patients will be given twice-daily treatment with oral olaparib in cycles 1-6 for 7 consecutive days, starting on Day 2 (Days 2-8). IP paclitaxel (60 mg/m2) will be given on Day 8. Sequential cohorts of 3 patients will receive escalating doses of olaparib (50mg BID, 100mg BID, 200mg BID).
62136741|NCT02731846|EXPERIMENTAL|FF/UMEC/VI (100/62.5/25 mcg) + placebo|Subjects will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg delivered via single ELLIPTA inhaler ('closed' triple) and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
62136742|NCT02731846|EXPERIMENTAL|FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg|Subjects will receive FF/VI (100 mcg/25 mcg) and UMEC 62.5 mcg delivered via two ELLIPTA inhaler ('open' triple) once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
62136743|NCT02731846|EXPERIMENTAL|FF/VI 100 mcg/25 mcg + placebo|Subjects will receive FF/ VI (100 mcg/25 mcg) delivered via single ELLIPTA inhaler and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
62136744|NCT04644679|ACTIVE_COMPARATOR|48-hr|48-hr electrocardiographic monitoring
62490629|NCT04366635|EXPERIMENTAL|Beta-tricalcium phosphate Group|Beta-tricalcium phosphate graft will place in the extraction socket and cover with a PRF membrane.
62333011|NCT01294735|EXPERIMENTAL|Part B, MK-4827 + temozolomide melanoma cohort|
62333012|NCT01294735|EXPERIMENTAL|Part B, MK-4827 + temozolomide glioblastoma multiforme cohort|
62333013|NCT04094350|EXPERIMENTAL|ACF with a seed-and-recruit model|Active case finding with a seed-and-recruit model to be implemented by KHANA. Target group: key populations for TB (people living with HIV, TB contacts, people with diabetes, people who use/inject drugs) and presumptive TB cases
62333014|NCT04094350|EXPERIMENTAL|ACF targeting household and neighborhood contacts|Active case finding targeting household and neighborhood contacts to be implemented by CENAT. Target group: household contacts, immediate neighbors of people diagnosed with TB in the last 2 years, and other presumptive TB cases
62333015|NCT04094350|EXPERIMENTAL|ACF targeting the older population|Active case finding targeting the older population (people aged 55 and older) using mobile screening units to be implemented by CATA. Target group: elderly above age of 55 and other presumptive TB cases
62333016|NCT04094350|NO_INTERVENTION|Passive case finding|Passive case finding strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
62333017|NCT02231658|EXPERIMENTAL|Liraglutide|The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
62490630|NCT04366635|ACTIVE_COMPARATOR|Control Group|In the control group, after removal of impacted third molar tooth no material will be placed on the extraction socket. Only the extraction socket was primarily closed with non-resorbable sutures.
62490631|NCT01116505|NO_INTERVENTION|gluten-containing diet|
62490632|NCT01116505|ACTIVE_COMPARATOR|Active comparator, gluten-free diet|
62490633|NCT03024268|EXPERIMENTAL|A: interventional closure of iASD|Interventional closure of iASD (n=40) with an Figulla Flex Occluder (Occlutech)
62490634|NCT03024268|NO_INTERVENTION|B: no intervention|Best medical supportive care (n=40)
62490635|NCT00866476|EXPERIMENTAL|Vaccine-recipients|
62490636|NCT00866476|PLACEBO_COMPARATOR|Placebo|
61937860|NCT05116007|EXPERIMENTAL|Experimental|Subjects receive AK112 plus Etoposide and Carboplatin every 3- week cycle (Q3W) for 4 cycles followed by AK112 until progression.
61937861|NCT05405413|EXPERIMENTAL|Subjects evaluated by Molecular Tumor Board|Subjects whose cases are evaluated by Molecular Tumor Board
61937862|NCT02554604||Pregnant woman|Pregnant woman with identified risk factors for the development of preeclampsia
61937863|NCT00795925|EXPERIMENTAL|propiverine hydrochloride|
61937864|NCT06550271||Compounded Rapamycin|Participants in this group were receiving Compounded Rapamycin (dosages include 5, 10, or 15mg) once per week
61937865|NCT06550271||Generic Rapamycin|Participants in this group were receiving Generia Rapamycin (dosages include 2,3,6, or 8mg) once per week
62333018|NCT02231658|EXPERIMENTAL|Lixisenatide|The highest injected once daily dose will be 20µg s.c. for lixisenatide.
62333019|NCT06445101|EXPERIMENTAL|Participatory Approach (intervention)|Employees in departments allocated to the intervention group receive the PA strategy in addition to the existing range of preventive mental health measures within the organization.
62490637|NCT02305134|ACTIVE_COMPARATOR|Tipepidine Hibenzate|Tipepidine is taken orally at 30 mg/day (10 mg after breakfast, 10 mg after supper, and 10 mg before bedtime), for 4 weeks.
62490638|NCT02305134|PLACEBO_COMPARATOR|Placebo|Placebo is taken orally after breakfast, after supper, and before for 4 weeks.
62490639|NCT03201003|ACTIVE_COMPARATOR|AR101|AR101 powder provided in capsules \& sachets
62490640|NCT03201003|PLACEBO_COMPARATOR|Placebo|Placebo powder provided in capsules \& sachets
62490641|NCT04289805|ACTIVE_COMPARATOR|standard-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the French participating centres.
62490642|NCT04289805|EXPERIMENTAL|letrozole-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the Belgian participating centres.
62490643|NCT04289805|NO_INTERVENTION|non-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and who have access to the Fertility Clinics in all the participating centres but are not willing to preserve their fertility by undergoing oocyte/embryo cryopreservation.
62490644|NCT00252564|EXPERIMENTAL|Bev-FOLFOX|"(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via T connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.~Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU~Dosing on Days 1 and 15 of each 28-day cycle"
62490645|NCT00252564|EXPERIMENTAL|FOLF-CB|"(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.~Cetuximab --\> bevacizumab --\> LV --\> bolus 5-FU --\> infusional 5-FU"
62490646|NCT03734354|EXPERIMENTAL|1 mg dosing group|Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
62490647|NCT03734354|EXPERIMENTAL|2 mg dosing group|Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
62490648|NCT03734354|EXPERIMENTAL|4 mg dosing group|Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
62490649|NCT00721162|EXPERIMENTAL|Ramucirumab|
61937866|NCT03300960|EXPERIMENTAL|Provera|
61937867|NCT03300960|ACTIVE_COMPARATOR|Orgalutrán Ganirelix (GnRH antagonist)|
61937868|NCT05290207||Newly diagnosed male obese patients with type 2 diabetes|
61937869|NCT05290207||Newly diagnosed male non-obese patients with type 2 diabetes|
61937870|NCT05290207||Newly diagnosed male patients with type 1 diabetes|
61937871|NCT05290207||Healthy, non-obese men|
61937872|NCT00853034|ACTIVE_COMPARATOR|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
61937873|NCT00853034|EXPERIMENTAL|AXOS|arabinoxylan-oligosaccharides (AXOS)
62136745|NCT04644679|EXPERIMENTAL|7-day|7-day electrocardiographic monitoring
62490650|NCT01127087|EXPERIMENTAL|RYGB CaOx Stone Formers|"Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
62333020|NCT06445101|NO_INTERVENTION|Care as usual|Departments assigned to the control group receive usual strategies and therefore only have access to the existing range of preventive interventions within the organization (without the PA intervention).
62490651|NCT01127087|EXPERIMENTAL|Idiopathic Hyperoxaluria CaOx Stone Formers|"Subjects with idiopathic hyperoxaluria.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
62490652|NCT04919785|EXPERIMENTAL|Deep brain stimulation|Deep brain stimulation in the bed nucleus of stria terminalis
61937874|NCT02439879|ACTIVE_COMPARATOR|alpha lipoic acid treatment|After a decrease in the total symptoms score \>3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
61937875|NCT02439879|NO_INTERVENTION|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score \>3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
61937876|NCT04979520|EXPERIMENTAL|Brodalumab treated moderate-to-severe HS patients|Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.
61937877|NCT02549053|EXPERIMENTAL|Barrett esophagus patients|esophagus biopsies (pathologic and healthy zones)
61937878|NCT02549053|SHAM_COMPARATOR|control patients|esophagus biopsies (healthy zones)
61937879|NCT03578757|EXPERIMENTAL|intervention group|stress management program and the same usual practice (restrictive diet, physical activity and thermal spa treatment)
61937880|NCT03578757|ACTIVE_COMPARATOR|usual practice group|Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders
61937881|NCT01464944|EXPERIMENTAL|Arm 2|
61937882|NCT01464944|ACTIVE_COMPARATOR|Arm 3|
61937883|NCT01464944|ACTIVE_COMPARATOR|Arm 4|
61937884|NCT01464944|PLACEBO_COMPARATOR|Arm 5|
61937885|NCT01464944|EXPERIMENTAL|Arm 1|
61937886|NCT03293797|EXPERIMENTAL|Abbreviated Mindfulness-based Therapy|5 week, abbreviated group MBT treatment for depression and anxiety
62490653|NCT01970592|EXPERIMENTAL|POWER|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
62490654|NCT03595254|EXPERIMENTAL|Thrive Intervention|Online cognitive behavior therapy program
62694785|NCT06642194|EXPERIMENTAL|Education on sunnah of sleeping|Participants in the experimental group received education on sunnah of sleeping for two weeks. The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
61937887|NCT04137224|EXPERIMENTAL|Sequence A (IgPro20/IgPro10)|Participants received IgPro20 of a total dose of 0.5 grams per kilogram (g/kg) over 2 sessions per week as a subcutaneous (SC) injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an intravenous (IV) infusion for up to 16 weeks in Treatment Period 2.
61937888|NCT04137224|EXPERIMENTAL|Sequence B (IgPro10/IgPro20)|Participants received IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.
61937889|NCT02046733|EXPERIMENTAL|Nivolumab + Ipilimumab|"- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles~- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance"
61937890|NCT02046733|NO_INTERVENTION|Observation|no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.
61937891|NCT06681467|EXPERIMENTAL|Patients undergoing planned pulmonary function testing|"Participants will be recruited from patients attending a planned pulmonary function clinic appointment.~They will be invited to participate when they are booking into clinic. Should they agree to participate the will have the following interventions:~1. Basic medical questionnaire~2. 2x chest band devices fitted over clothing They will then undertake their planned clinic appointment. No additional resources will be required for this.~Once they have finished their clinic appointment, the investigators will ask them to read a short script whilst recording their speech. Following this the investigators will ask them to walk 75m down the hall. The devices will then be removed and the study time is over."
61937892|NCT01434407|EXPERIMENTAL|Low AGE meal|Test meal prepared by boiling/steaming the food
61937893|NCT01434407|EXPERIMENTAL|High AGE meal|Test meal prepared by frying/grilling the food
61937894|NCT06515977|EXPERIMENTAL|TXI (Group A)|Arm undergoing colonoscopy with TXI
61937895|NCT06515977|EXPERIMENTAL|TXI followed by WLI (Group B)|Arm undergoing initial inspection under TXI first, followed by second inspection with WLI
62333021|NCT00912015|EXPERIMENTAL|Tramadol OAD 200mg|
62333022|NCT00912015|EXPERIMENTAL|Tramadol OAD 300mg|
62333023|NCT00912015|EXPERIMENTAL|Tramadol OAD 400mg|
62333024|NCT00912015|OTHER|Tramadol OAD 100mg|Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
62490655|NCT03595254|NO_INTERVENTION|Waitlist Control|Wait 8 weeks before receiving program access
62333025|NCT02781467|EXPERIMENTAL|Cyclophosphamide + Fludarabine + PNK-007 + rhIL-2|Fludarabine Day -6 to -2 and Cyclophosphamide Day -5 and -4. On Day 0 PNK-007 at 4 varying dose levels followed by Human recombinant Interleukin-2 (rhIL-2) every other day, Day 0 to Day 10.
62490656|NCT01196949|ACTIVE_COMPARATOR|Manipulative and Rehabilitative Therapy|
62490657|NCT01196949|ACTIVE_COMPARATOR|Rehabilitative Therapy|
61937896|NCT06515977|ACTIVE_COMPARATOR|WLI (Group C)|Arm undergoing normal colonoscopy with WLI
62136746|NCT02550951|EXPERIMENTAL|pre-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS \[Bayer Korea\] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
62136747|NCT02550951|EXPERIMENTAL|post-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS \[Bayer Korea\] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
62136748|NCT04448561|EXPERIMENTAL|ASP8062 in combination with morphine|Participants received ASP8062 tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 dose.
62136749|NCT04448561|PLACEBO_COMPARATOR|Placebo in combination with morphine|Participants received ASP8062 matching placebo tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 matching placebo dose.
62136750|NCT01378416|EXPERIMENTAL|1|
62136751|NCT00588406|EXPERIMENTAL|B|Budesonide, 2mg, 4 doses, plus standard care
62136752|NCT00588406|PLACEBO_COMPARATOR|P|Placebo plus standard care
62136753|NCT04530630|EXPERIMENTAL|Biktarvy|Participants receive a Biktarvy tablet orally once daily with or without food.
62136754|NCT03117426|EXPERIMENTAL|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
62333026|NCT00841503||12 healthy volunteers|Healthy volunteers are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
62333027|NCT00841503||12 Participants with Type 2 diabetes|Volunteers with type 2 diabetes are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
62333028|NCT06447025|EXPERIMENTAL|CTI-1601|CTI-1601 will be administered daily
62333029|NCT02810262||First bone metastasis of adenocarcinoma lung cancer|Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.
62333030|NCT05516108|EXPERIMENTAL|Mindfulness|Mindfulness intervention involving 14 foundational audio-guided lessons plus daily brief practice prompts. Lessons train meditation techniques for 3 mindfulness skills: concentration, sensory clarity, and equanimity. Practice prompts delivered 3x daily build on the skills trained in each lesson.
62333031|NCT05516108|ACTIVE_COMPARATOR|Coping|Coping intervention involving 14 foundational audio-guided lessons plus daily brief practice prompts. Lessons train techniques for 3 coping skills: reflection, reappraisal, and problem solving. Practice prompts delivered 3x daily build on the skills trained in each lesson.
62490658|NCT04206462||Osteoarthritis|Questionnaire of eating habits, markers of oxidative stress
62490659|NCT05965908|EXPERIMENTAL|liraglutide|Saxenda® starting dose is 0.6 mg per day for 1 week.1. Patients increase the dose by 0.6 mg each week until the full maintenance dose of 3 mg is reached
62333032|NCT01503073|ACTIVE_COMPARATOR|Real stimulation|real NIBS
62333033|NCT01503073|SHAM_COMPARATOR|Sham stimulation|sham NIBS
62333034|NCT01476150||Dongcheng|
62333035|NCT01476150||Haidian|
62333036|NCT01476150||Xicheng|
62333037|NCT01476150||Chaoyang|
62333038|NCT01476150||Chongwen|
62333039|NCT01476150||Tongzhou|
62333040|NCT01476150||Fengtai|
62333041|NCT01476150||Xuanwu|
62333042|NCT04520516|EXPERIMENTAL|tVNS active device|VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
62333043|NCT04520516|SHAM_COMPARATOR|Sham tVNS device|Sham VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
62333044|NCT00635947|ACTIVE_COMPARATOR|1|isotonic solution - 1.5L
62333045|NCT00635947|ACTIVE_COMPARATOR|2|water- 1.5L
62333046|NCT00635947|PLACEBO_COMPARATOR|3|water-200mL
62490660|NCT05965908|ACTIVE_COMPARATOR|metformin|the patient is given Glucophage 1000 mg tab once daily after lunch for 1month
62490661|NCT05965908|NO_INTERVENTION|control|not given any drug
62490662|NCT03828539|EXPERIMENTAL|Erenumab|70 mg and 140 mg Erenumab
62490663|NCT03828539|ACTIVE_COMPARATOR|Topiramate|Topiramate in the highest tolerated dose (50 - 100 mg/day)
62490664|NCT00991796|EXPERIMENTAL|CS-1008|CS-1008 with carboplatin and paclitaxel
62490665|NCT00991796|PLACEBO_COMPARATOR|Placebo|Placebo with carboplatin and paclitaxel
62490666|NCT02044939|EXPERIMENTAL|Pulmonary rehabilitation|Sarcoidosis patients will realize a pulmonary rehabilitation program
62490667|NCT02044939|NO_INTERVENTION|Controls|Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.
62490668|NCT03124758|EXPERIMENTAL|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
62490669|NCT01344031|EXPERIMENTAL|Arm A (anastrozole and Akt inhibitor MK2206)|"Patients receive anastrozole PO on days 1-28. Beginning in course 2, patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
62490670|NCT01344031|EXPERIMENTAL|Arm B (Akt inhibitor MK2206 and anastrozole)|"The RPTD of Akt inhibitor MK2206 with anastrozole is determined after 3 courses, administered as in Arm A.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
62490671|NCT01344031|EXPERIMENTAL|Arm C (Akt inhibitor MK2206 and fulvestrant)|"Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, fulvestrant IM on day 1and day 15 of course 1 and then on day 1 of each course in each subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
62490672|NCT01344031|EXPERIMENTAL|Arm D (Akt inhibitor MK2206, anastrozole, fulvestrant)|"Patients receive Akt inhibitor MK2206 PO as in Arm A, anastrozole PO on days 1-28 and fulvestrant IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
62490673|NCT05812638|EXPERIMENTAL|Mental Imagery|For mental imagery, the calm and nice atmosphere isrequired for the patientsto focus on the details while sitting on a chair. The audiotape and headphones are given to the patients. The audiotape tape comprised of three phases. The first phase is relaxation phase. The patient has to do the first phase actively. In this phase patients have asked to do the deep breathing exercises while sitting on a chair and then contract their lower limb muscles from distal to proximal. The second phase is task-oriented phase. The patient has to imagine him performing the tasks.
62490674|NCT05812638|ACTIVE_COMPARATOR|Virtual Reality|"The virtual reality training will be given through Kinect connected with Xbox 360.~The Xbox games used are 20,000 water leaks, reflex ridge and river rush. The spacious environment will be given and walker are sometimes required for assistance. The LED and system are 3 feet away from patients. The VR training will be given to the both control and experimental groups"
62490675|NCT02349763|ACTIVE_COMPARATOR|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
62490676|NCT02349763|EXPERIMENTAL|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
62490677|NCT05053360|EXPERIMENTAL|Healing Touch|Subjects in this arm get a HT session post cesarean
62490678|NCT05053360|ACTIVE_COMPARATOR|Control|Subjects in this arm get a control activity of equal duration
62694786|NCT06642194|NO_INTERVENTION|Control group|While the experiment group received education on sunnah of sleeping, the control group received standard care without receiving the education on sunnah of sleeping.
61937897|NCT06515977|ACTIVE_COMPARATOR|WLI followed by TXI (Group D)|Arm undergoing initial inspection under WLI first, followed by second inspection with TXI
61937898|NCT05549219|EXPERIMENTAL|10 mg/kg GLM101|GLM101 IV infusions, given weekly
62136755|NCT03117426|ACTIVE_COMPARATOR|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
62333047|NCT01248234|ACTIVE_COMPARATOR|Propofol|Propofol alone will be used to put an elderly hypertensive patient to sleep for surgery.
62136756|NCT02957396|ACTIVE_COMPARATOR|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 20 mg intact finerenone tablet fasting
62136757|NCT02957396|EXPERIMENTAL|Adult formulation: Finerenone crushed tablet_Fasting|Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
61937899|NCT05549219|EXPERIMENTAL|20 mg/kg GLM101|GLM101 IV infusions, given weekly
62136758|NCT02957396|EXPERIMENTAL|Pediatric formulation: Finerenone suspension_Fasting|Single oral dose of 20 mg finerenone suspension fasting
62333048|NCT01248234|ACTIVE_COMPARATOR|Etomidate|Etomidate alone will be used to put an elderly hypertensive patient to sleep.
62333049|NCT01248234|ACTIVE_COMPARATOR|Propofol and Etomidate|A combination of Etomidate and Propofol will be used to put an elderly hypertensive patient to sleep for surgery.
62333050|NCT02160379||post Roux-en-Y-gastric bypass|Formerly obese females 1-5 years after gastric bypass
62333051|NCT02160379||matched controls|non-operated females age-and weight-matched to post Roux-en-Y-gastric bypass subjects
62333052|NCT02160379||healthy young controls|non overweight (BMI between 19 and 25 kg/m2) healthy females
62490679|NCT04872777|NO_INTERVENTION|Standard of care|"Standard of care (SOC) control condition: Following study group assignment, the following procedures will be completed for SOC control:~1. Digital scale provision (subjects may keep the scale)~2. Reinforcement of need to comply with SOC treatment as directed by their NASH clinician~3. Capture of available clinical information over preceding 28-days."
62490680|NCT04872777|EXPERIMENTAL|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days."
62490681|NCT03113227|ACTIVE_COMPARATOR|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
61937900|NCT05549219|EXPERIMENTAL|30 mg/kg GLM101|GLM101 IV infusions, given weekly
61937901|NCT00969813|EXPERIMENTAL|Normal hepatic function|
61937902|NCT00969813|EXPERIMENTAL|Mild hepatic impairment|
61937903|NCT00969813|EXPERIMENTAL|Moderate hepatic impairment|
62490682|NCT03113227|ACTIVE_COMPARATOR|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
62490683|NCT05252195||Participants|Participants with Multiple Sclerosis who meet eligibility criteria.
62490684|NCT03443492|EXPERIMENTAL|SLOG|800 mg/m2 gemcitabine at a fixed rate of 10 mg/m2/min followed by a 2-hour intravenous infusion of oxaliplatin on day 1 plus twice daily oral S-1 80-120 mg/day (based on BSA) and oral leucovorin 30 mg twice a day on day 1 to day 7, every 14 days as a cycle
62490685|NCT03443492|EXPERIMENTAL|mFOLFIRINOX|oxaliplatin at a dose of 85 mg/m2, given as a 2-hour infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute infusion. The treatment was immediately followed by a continuous intravenous infusion via central venous catheter of leucovorin 400 mg/m2 given as a 2-hour infusion and 5-FU 2400 mg/m2 over a 46-hour period on day 1 every 14 days/cycle.
62490686|NCT04828616|EXPERIMENTAL|DP303c injection|"Part1:Patients with HER2-expressing advanced ovarian cancer will be treated with DP303c injection at 2.0 mg/kg or 3.0 mg/kg every 3 weeks (Q3W) to determine the recommended phase 2 dose (RP2D).~Part2a:Patients with HER2-overexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D.~Part2b:Patients with HER2-lowexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D."
62490687|NCT02919462|EXPERIMENTAL|Treatment Arm A|"Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) + Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles.~Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks)."
62490688|NCT02919462|ACTIVE_COMPARATOR|Treatment Arm B|"Pemetrexed, 500 mg/m2, day 1 + Cisplatin, 75 mg/m2, day 1 every 3 weeks, for 4 cycles.~Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks).~7-10 days before treatment administration, premedication with vitamin B12 1000µg intramuscular injection (every 9 weeks) and folate 1mg every day should be commenced."
62490689|NCT02333162|EXPERIMENTAL|Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60."
62490690|NCT01167439|NO_INTERVENTION|Mild dysphagia|
62490691|NCT01167439|ACTIVE_COMPARATOR|Severe dysphagia|
62490692|NCT00491738|EXPERIMENTAL|1|
62490693|NCT00491738|PLACEBO_COMPARATOR|2|
62490694|NCT04600635||patients with a medical history of obesity|Patients included are subject who entered a structured program of care for their obesity, with or without bariatric surgery.
62490695|NCT03485118|EXPERIMENTAL|HS006+Chemotherapy|"1. Participants received six 21-day cycles of HS006(375 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).~2. Participants received six 21-day cycles of HS006(500 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles)."
61937904|NCT04300647|EXPERIMENTAL|Tiragolumab plus Atezolizumab|Participants will receive tiragolumab and atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62490696|NCT03485118|ACTIVE_COMPARATOR|Rituxan+Chemotherapy|Participants received six 21-day cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
62490697|NCT00890864|ACTIVE_COMPARATOR|1|Women aged 47-49 invited for breast screening
62490698|NCT00890864|ACTIVE_COMPARATOR|2|Women aged 71-73 invited for breast screening
62490699|NCT01939535||Women with endometriosis|Women with endometriosis with the intention of surgery - no intervention
62490700|NCT06486389|EXPERIMENTAL|distraction methods|reading fairy tales
62490701|NCT06486389|EXPERIMENTAL|distraction method|painting
61937905|NCT04300647|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab monotherapy until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
61937906|NCT06484491|ACTIVE_COMPARATOR|Arm 1 Standard care|Standard dose of IMPT
61937907|NCT06484491|EXPERIMENTAL|Arm 2 Intervention group|Dose-escalated IMPT
61937908|NCT04502979|EXPERIMENTAL|Responsive Feeding|Intervention families will receive approximately 4 hours of ASL and development specific content related to language and feeding during home visits and phone calls. The initial in-home session with families will focus on teaching ASL signs indicative of hunger, thirst, and satiety. A video and placemat of mealtime signs will be left with families at the completion of the first visit. The remaining sessions, in-home over the next 3 months and by phone monthly thereafter for 6 months total, will focus on reinforcing ASL signing in addition to focused education on particular aspects of language development (receptive language preceding expressive language and increasing intentional communication), feeding development (such as hunger and fullness cues, fear of new foods, the importance of repeated food exposures, variations in intake from meal-to-meal, and the propensity to reject bitter tastes \[many vegetables\]55\], and appropriate portion sizes and variety for healthy growth.
61937909|NCT04502979|NO_INTERVENTION|Routine Care|No intervention is provided to the families in this group; however, portions of the intervention lessons will be made available after completion of data collection.
62490702|NCT06486389|NO_INTERVENTION|Control Grup|Routine Treatment Group
61937910|NCT02290327|PLACEBO_COMPARATOR|Placebo|50 ml of 0.9% Normal Saline Intravenously once daily
61937911|NCT02290327|ACTIVE_COMPARATOR|Pantoprazole|Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
62490703|NCT02440997|PLACEBO_COMPARATOR|foot bath only|10 minute foot bath with addition of jojoba only
62490704|NCT02440997|EXPERIMENTAL|foot bath and aromatherapy|10 minute foot bath with addition of jojoba with added Mentha piperita
62490705|NCT06108557|ACTIVE_COMPARATOR|control group|Group I (Control group): which will include 20 healthy volunteers who will be selected based on their clinical examination, recent clinical history, and age and sex matching to the case group.This control group will be the basic profile for the studied group.
62490706|NCT06108557|ACTIVE_COMPARATOR|case group|Group II (Case group): which will include 70 cases, including both genders who will be admitted to Sohag University Hospital with acute organophosphate poisoning .
62490707|NCT00584103|EXPERIMENTAL|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
62490708|NCT00584103|OTHER|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
62490709|NCT04892420|ACTIVE_COMPARATOR|Group DX|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia
62490710|NCT04892420|ACTIVE_COMPARATOR|Group DM|The patients receive 20 ml plain bupivacaine(0.5%)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
62490711|NCT04892420|ACTIVE_COMPARATOR|Group M|The patients receive 20 ml plain bupivacaine(0.5%)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
62490712|NCT04892420|PLACEBO_COMPARATOR|Group C|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
62490713|NCT00937664|OTHER|AZD7762 + gemcitabine|AZD7762 administered alone and in combination with gemcitabine
62490714|NCT06447753|EXPERIMENTAL|Direct pulp capping|
62490715|NCT06447753|ACTIVE_COMPARATOR|Complete pulpotomy|
62490716|NCT04883996|ACTIVE_COMPARATOR|EXP039|At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.
62490717|NCT04883996|PLACEBO_COMPARATOR|Saline control|At Visit 1, single dose 1 drop of saline is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop EXP039 1% at Visit 2.
62136759|NCT02957396|EXPERIMENTAL|Pediatric formulation: Finerenone suspension_Fed|Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
62136760|NCT02682485|EXPERIMENTAL|Cipro, metronidazole, neomycin combo|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
62333053|NCT04495452||Study Participants|"We will be enrolling 200 participants, this will provide a large enough sampling to assure there are at least 25 patients with significant respiratory depression and 25 with insignificant respiratory depression.~The genetic data from participants with the most respiratory depression defined as having a 20-40% decrease from initial respiratory parameters will be compared with genetic data from participants with the least respiratory depression defined as having no change or less than 10% decrease from initial respiratory parameters."
62333054|NCT02918266|EXPERIMENTAL|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
62333055|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62490718|NCT04842019|EXPERIMENTAL|KRN23|KRN23 1 mg/kg administered subcutaneously (SC) every 4 weeks for 48 weeks. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
62490719|NCT03702816|EXPERIMENTAL|Alzheimer's Disease|"Alzheimer's Disease~GE180 PET Scan"
62490720|NCT03702816|EXPERIMENTAL|Parkinson's Disease|"Parkinson's Disease~GE180 PET Scan"
62490721|NCT03702816|EXPERIMENTAL|Control|"Control Group~GE180 PET Scan"
62490722|NCT03702816|EXPERIMENTAL|Mild Cognitive Impairment|"Mild Cognitive Impairment~GE180 PET Scan"
62490723|NCT01627639|ACTIVE_COMPARATOR|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
62490724|NCT01627639|PLACEBO_COMPARATOR|Placebo|Placebo
62490725|NCT05283954|EXPERIMENTAL|Combined Regime of Fluoxetine, Prednisolone and Ivermectin|"Fluoxetine: 20mg tablet; 20 mg; once daily for 10 days; oral~Prednisolone: 25 mg tablet; 25mg; once daily for 5 days; oral~Ivermectin: 3 mg tablet; 0.4 mg/kg; once daily for 5 days; oral"
62136761|NCT02682485|PLACEBO_COMPARATOR|Saline|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.
62490726|NCT05283954|OTHER|Combination of Vitamin C and Albendazole|"Vitamin C: 50 mg tablet; 1 tablet; Once daily for 10 days; Oral~Albendazole; 200 mg; 1 tablet; Once daily for 5 days; Oral~Vitamin C: 50 mg tablet; 0.13 tablet/kg\*; Once daily for 5 days; Oral~\*Same number of tablets than for Ivermectin"
62490727|NCT02125760|SHAM_COMPARATOR|Inspiratory Muscle Training (IMT)|Patients with subacute stroke in a neurorehabilitation setting.
62490728|NCT02125760|EXPERIMENTAL|High-intensity IMT|Patients with subacute stroke in a neurorehabilitation setting.
62490729|NCT00858403|EXPERIMENTAL|Treatment with Dasatinib|Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing. This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
62490730|NCT03900039|ACTIVE_COMPARATOR|Conventional Polyethylene versus metal head|This is the more conventional group bearing surfaces
62490731|NCT03900039|EXPERIMENTAL|Conventional Polyethylene versus oxidized zirconium head|This group uses the more conventional polyethylene against the newer head
62490732|NCT03900039|EXPERIMENTAL|Newer Cross linked Polyethylene metal head|In this group we continued with the conventional polyethylene, but added in the new type of head (oxidized zirconium)
62490733|NCT03900039|EXPERIMENTAL|Newer Cross linked Polyethylene versus oxidized zirconium head|In this group, we added both the new head and the new polyethylene
61937912|NCT05841836|EXPERIMENTAL|the Suture-Mediated Closure System|Produced by Zhejiang Zylox Medical Device Co., Ltd.
61937913|NCT05841836|ACTIVE_COMPARATOR|Perclose ProGlide Suture-Mediated Closure System|Perclose® ProGlide Suture-Mediated Closure System
61937914|NCT02354183|EXPERIMENTAL|Commitment|A 1-hour orientation session consisting of DBT commitment strategies plus psychoeducation. Therapists will also use commitment strategies to discuss goals related to self-harm. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
61937915|NCT02354183|ACTIVE_COMPARATOR|Psychoeducation|A 1-hour orientation session consisting of psychoeducation only. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
61937916|NCT05107427|EXPERIMENTAL|MRx0518 + Avelumab|Subjects will receive 1 capsule of MRx0518 BID throughout the treatment period and IV infusion of Avelumab every 2 weeks in 4-week cycles
61937917|NCT01163240||pediatric|
61937918|NCT05047913|EXPERIMENTAL|18F-FTX|The radioactive tracer (FAZA)
61937919|NCT03383471|EXPERIMENTAL|Invossa K Inj.|Invossa K Inj.
61937920|NCT03383471|PLACEBO_COMPARATOR|Placebo|Placebo control
61937921|NCT00876525|OTHER|Freedom SOLO stentless valve|Prospective data collection on the outcomes in patients treated with the CE Marked Freedom Solo Valve within the approved indication.
61937922|NCT05644444|EXPERIMENTAL|Lubricant A and Comparator A|"The comparator will be tested for oral assessment in the tolerance phase only. Tolerance phase includes oral assessment and vaginal assessment. A 7-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment. This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.~Treatment phase includes a 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment."
62136762|NCT01964534|ACTIVE_COMPARATOR|ARM 1 ABI-007 + Gemcitabine|ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity
62136763|NCT01964534|EXPERIMENTAL|Arm 2 ABI-007 + simplified LV5FU2|ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity
62136764|NCT00909025|EXPERIMENTAL|Claudiximab|
62333056|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62333057|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62333058|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62490734|NCT02977416|EXPERIMENTAL|patients treated withTNF blockade|22 patients treated with TNF blockade
62490735|NCT02977416|EXPERIMENTAL|patients without TNF blockade|22 patients without TNF blockade
62490736|NCT02977416|EXPERIMENTAL|healthy subjects|22 matched healthy subjects by pubertal stage and sex
62490737|NCT04712838|EXPERIMENTAL|group A|
62490738|NCT04712838|EXPERIMENTAL|group B|
62490739|NCT04712838|EXPERIMENTAL|group C|
62490740|NCT04712838|EXPERIMENTAL|group D|
62490741|NCT04712838|EXPERIMENTAL|group E|
62490742|NCT04712838|EXPERIMENTAL|group F|
62136765|NCT03947216|EXPERIMENTAL|PIMAVANSERIN|In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.
62490743|NCT04186286|ACTIVE_COMPARATOR|1st drug Ivabradine|Patients will take Ivabradine first followed by Propranolol and Placebo
62490744|NCT04186286|ACTIVE_COMPARATOR|2nd drug Ivabradine|Patients will take either Propranolol or placebo first and then Ivabradine
62490745|NCT04186286|ACTIVE_COMPARATOR|3rd drug Ivabradine|Patients will take Propranolol and placebo first and then Ivabradine
62490746|NCT03636386|EXPERIMENTAL|Percutaneous microelectrolysis group (MEP)|Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
62490747|NCT03636386|ACTIVE_COMPARATOR|Ultrasound therapy|Group treated with conventional ultrasound (US) on MTrP with 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
62490748|NCT02420353|ACTIVE_COMPARATOR|Somatropin|Somatropin of rDNA origin
62490749|NCT02420353|PLACEBO_COMPARATOR|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
62490750|NCT02677558||CFOP obese|"Transthoracic Echocardiography in pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of greater or equal 40kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia."
62490751|NCT02677558||CFOP control|"Transthoracic Echocardiography pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of less or equal 30kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia"
61937923|NCT05644444|EXPERIMENTAL|Lubricant B and Comparator B|"The comparator will be tested for oral assessment in the tolerance phase only. Tolerance phase includes oral assessment and vaginal assessment. A 7-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment. This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.~Treatment phase includes a 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment."
61937924|NCT01795638|ACTIVE_COMPARATOR|Sodium chloride|Sodium chloride 1 meq/kg (0.4 ml/kg of 2.5meq/ml formulation for injection)q6hrs on days of life 7-35. Intervention was given enterally if feedings were at least 100 ml/kg/day; otherwise medication was diluted in equal amounts of dextrose 5% water and administered intravenously.
61937925|NCT01795638|PLACEBO_COMPARATOR|sterile water|Sterile water, 0.4 ml/kg q6hrs on days of life 7-35. Placebo is given enterally when infant is tolerating at least 100 ml/kg/day; otherwise the product is diluted in equal amounts of dextrose 5% water and administered intravenously.
62136766|NCT03947216|PLACEBO_COMPARATOR|PLACEBO|In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.
62136767|NCT01379482|EXPERIMENTAL|Multimodal treatment|Neoadjuvant systemic chemotherapy followed by cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
62490752|NCT00471094|EXPERIMENTAL|Ilaprazole 5 mg QD|
62490753|NCT00471094|EXPERIMENTAL|Ilaprazole 20 mg QD|
62490754|NCT00471094|EXPERIMENTAL|Ilaprazole 40 mg QD|
62490755|NCT00471094|ACTIVE_COMPARATOR|Lansoprazole 30 mg QD|
62490756|NCT05197062|EXPERIMENTAL|14C-aticaprant|Participants in Group A (without duodenal fluid collection) and Group B (with duodenal fluid collection) will receive a single oral dose of 14C-aticaprant on Day 1.
62490757|NCT05232539|ACTIVE_COMPARATOR|Lamellar corneal transplantation type DMEK|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
62490758|NCT05232539|ACTIVE_COMPARATOR|Deep sclerectomy with implantation of subchoroidal implant Esnoper Clip|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
62490759|NCT05232539|ACTIVE_COMPARATOR|Pars plana vitrectomy with epiretinal membrane peeling|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
62490760|NCT02045108|EXPERIMENTAL|Active TDCS + Active Retraining|2.0 milliamps (mA) of TDCS applied during active alcohol avoidance retraining
62490761|NCT02045108|EXPERIMENTAL|Sham TDCS + Active Retraining|.1 mA of TDCS applied during active alcohol avoidance retraining
62490762|NCT02045108|EXPERIMENTAL|Active TDCS + Sham retraining|2.0 mA of TDCS applied during sham alcohol avoidance retraining
62490763|NCT02045108|SHAM_COMPARATOR|Sham TDCS + Sham Retraining|0.1 mA of TDCS applied during sham alcohol avoidance retraining
62490764|NCT03581630|EXPERIMENTAL|Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet|
62490765|NCT03581630|EXPERIMENTAL|Breast cancer subjects-Mediterranean Diet|
62490766|NCT03581630|ACTIVE_COMPARATOR|Healthy subjects-naltrexone/bupropion+Mediterranean Diet|
62490767|NCT04482816|EXPERIMENTAL|Physiological pacing|"Lead placed in the His-Purkinje system (his or branch) in order to achieve QRS shortening and physiologic pacing. A backup lead will be implanted in the right ventricle.~If hisian pacing is not achieved (QRS is not shortened \> 20% or QRS is not \<130ms), the left bundle branch will be paced according to the criteria established in the literature (right branch block and intrinsic deflection \<85ms).~Crossover from physiological pacing to right ventricular pacing will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (\>3.5V / 1ms); no shortening of QRS (shortening \<20%) or failure to meet non-selective HBP criteria or left bundle branch pacing criteria."
62490768|NCT04482816|ACTIVE_COMPARATOR|Right ventricular pacing|Lead placed in the right ventricle (conventional pacing).
62490769|NCT02355847|OTHER|Healthcare Worker Education|Educational Lectures
62490770|NCT02995135|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62490771|NCT01627431|OTHER|Antiplatelet therapy|Patients underwent peripheral revascularization procedures undergoing a double antiplatelet therapy
62694787|NCT05558267|EXPERIMENTAL|Standard Table Salt, then Salt Substitute|"The two intervention periods will last 16 days with a 19-day washout period in between.~During the first 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table.~Participants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing.~In addition, participants will undergo standard of care hemodialysis (typically 3x/week) and have their blood chemistries measured according to the usual standard of care during the study."
62694788|NCT05558267|EXPERIMENTAL|Salt Substitute, then Standard Table Salt|"The two intervention periods will last 16 days with a 19-day washout period in between.~During the first 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table.~Participants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing.~In addition, participants will undergo standard of care hemodialysis (typically 3x/week) and have their blood chemistries measured according to the usual standard of care during the study."
62694789|NCT00934180|EXPERIMENTAL|Ondansetron|Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
62694790|NCT00934180|ACTIVE_COMPARATOR|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg OD Tablet (test) dosed in second period
62694791|NCT06637241|NO_INTERVENTION|Usual care|Schools assigned to the usual care management group will receive a visit from one of the co-principal investigators, who will explain the project to the coaches and athletic trainers but request that they do not change their existing training plans or care practices. However, medical consultation or referral contact information will be provided if needed.
62697642|NCT06022887|EXPERIMENTAL|MBSR alone|Participants in this study will be granted access to a remote mindfulness-based stress reductions (MBSR) protocol. Participants will have access to the MBSR course, consisting of 30 audio lessons, each ranging from 9 to 14 minutes long. During the study, participants will be asked to complete four lessons per week during weeks 1-7 and two lessons during week 8.
62697643|NCT06022887|EXPERIMENTAL|TRE + MBSR|This group will follow a combined protocol of the TRE and MBSR interventions as described above.
61937926|NCT01573351|EXPERIMENTAL|QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin|"Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks"
61937927|NCT05427591|EXPERIMENTAL|Group (1A)|"30 children with 60 primary molars underwent caries removal by the CMCR method BRIX3000® (the experimental group) on one molar (n = 30)."
61937928|NCT05427591|ACTIVE_COMPARATOR|Group (1C)|30 children with 60 primary molars underwent caries removal by the traditional surgical method (the control group) on the contralateral molar (n = 30).
61937929|NCT05427591|EXPERIMENTAL|Group (2B)|"30 children with 60 primary molars underwent caries removal by the CMCR method Carie-CareTM  (the experimental group) on one molar (n = 30)."
61937930|NCT05427591|ACTIVE_COMPARATOR|Group (2C)|30 children with 60 primary molars underwent caries removal by the traditional surgical method (the control group) on the contralateral molar (n = 30).
61937931|NCT05298774|EXPERIMENTAL|Postoperative recovery with G-tech WPS|
61937932|NCT05030324|EXPERIMENTAL|XC221 100 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally in the morning (between 7:00 and 11:00) and 1 tablet of placebo in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
61937933|NCT05030324|EXPERIMENTAL|XC221 200 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally twice daily, in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
61937934|NCT05030324|PLACEBO_COMPARATOR|Placebo|Subjects will receive 1 tablet of placebo orally twice daily in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
62490772|NCT05010135||Healthy Subject|Aged 60 and over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.
61937935|NCT03572751||Vascular surgical patients|"Patient subjects are recruited from patients referred for vascular surgical procedure in Tampere University Hospital.~Bed-, wrist- and ECG-sensor monitoring"
61937936|NCT03572751||Healthy volunteers|"Healthy volunteer subjects will be recruited mainly from the students of Tampere University of Technology.~Bed-, wrist- and ECG-sensor monitoring"
61937937|NCT01848197|EXPERIMENTAL|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
61937938|NCT01848197|ACTIVE_COMPARATOR|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
61937939|NCT01438073|EXPERIMENTAL|kisspeptin, GnRH|24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
61937940|NCT02857985|EXPERIMENTAL|Patient with Myocardial Infarction|
62490773|NCT05010135||Vertebral fracture subjects|"Aged 60 or over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.~Have been diagnosed by doctors to have the vertebral fracture"
62490774|NCT01743898||Experimental|Patient taking FDA approved dose of rivaroxaban
62490775|NCT01743898||Control Group|Patient not taking any form of anticoagulation
62490776|NCT00045162|ACTIVE_COMPARATOR|1|
62490777|NCT00045162|ACTIVE_COMPARATOR|2|
62333059|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62490778|NCT05948072|EXPERIMENTAL|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62490779|NCT05948072|ACTIVE_COMPARATOR|mFOLFOX6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62490780|NCT01715077|EXPERIMENTAL|Ipilimumab|The recommended induction dose of ipilimumab is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of four doses, as guided by laboratory tests and patient assessment.
62490781|NCT03660787|PLACEBO_COMPARATOR|Placebo, 1.5 mL/kg|each subject received the placebo at the dose of 1.5 mL/kg of body weight;
62490782|NCT03660787|PLACEBO_COMPARATOR|Placebo, 2.4 mL/kg|each subject received the placebo at the dose of 2.4 mL/kg of body weight;
62490783|NCT03660787|EXPERIMENTAL|Seroguard, 1.5 mL/kg|each subject received the test drug at the dose of 1.5 mL/kg of body weight;
62490784|NCT03660787|EXPERIMENTAL|Seroguard, 2.4 mL/kg|each subject received the test drug at the dose of 2.4 mL/kg of body weight.
62490785|NCT00114504|EXPERIMENTAL|Simvastatin group|Patients with FDG-positive plaque who received simvastatin and diet therapy
62490786|NCT00114504|NO_INTERVENTION|Control group|Patients FDG-positive plaque who received diet therapy alone
61937941|NCT03835910|EXPERIMENTAL|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
61937942|NCT03835910|ACTIVE_COMPARATOR|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
61937943|NCT03835910|EXPERIMENTAL|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
61937944|NCT03835910|ACTIVE_COMPARATOR|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
61937945|NCT00559754|EXPERIMENTAL|1|
61937946|NCT01032902||Known HIV positive|Patients from HIV clinics with documented infections
61937947|NCT01032902||High Risk for Infection with HIV|Patients from defined HIV high-risk populations - i.e. intravenous drug users, or patients presenting with symptoms of sexually transmitted disease.
61937948|NCT01032902||Low-Risk for Infection with HIV|"Individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc..."
61937949|NCT00678080|EXPERIMENTAL|Metformin|Metformin therapy as prescribed by their health care provider
61937950|NCT00678080|ACTIVE_COMPARATOR|Insulin|Insulin as prescribed by their health care provider
61937951|NCT04269590|EXPERIMENTAL|Dual Task (DT) training - PD|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of patients with Parkinson's disease (PD)
62490787|NCT05767905|EXPERIMENTAL|Part 1: PF-06821497 Sequence 1|"Participants randomized to Sequence 1 will receive Treatments A, B, and C in Periods 1 through 3, respectively in the form of tablets by mouth.~Interventions:~* Drug: Single dose of PF-06821497 Treatment A~* Drug: Single dose of PF-06821497 Treatment B~* Drug: Single dose of PF-06821497 Treatment C"
62490788|NCT05767905|EXPERIMENTAL|Part 1: PF-06821497 Sequence 2|"Participants randomized to Sequence 2 will receive Treatments B, A and C in Periods 1 through 3, respectively in the form of tablets by mouth.~Interventions:~* Drug: Single dose of PF-06821497 Treatment A~* Drug: Single dose of PF-06821497 Treatment B~* Drug: Single dose of PF-06821497 Treatment C"
62490789|NCT05767905|EXPERIMENTAL|Part 2: PF-06821497 Sequence 1|"Participants randomized to Sequence 1 will receive Treatments D, E and F in Periods 1 through 3, respectively in the form of tablets by mouth.~Interventions:~* Drug: Single dose of PF-06821497 Treatment D~* Drug: Single dose of PF-06821497 Treatment E~* Drug: Single dose of PF-06821497 Treatment F"
62490790|NCT04074707|EXPERIMENTAL|oral iron supplementation|Participants go through 3 cycles of oral iron Supplementation (60mg daily vs alternate day dosing, 120mg daily vs alternate day dosing, 120mg daily vs every third-day dosing)
61937952|NCT04269590|ACTIVE_COMPARATOR|Single Task (ST) training - PD|Practice of the Swipe Slide Pattern task alone for a group of patients with Parkinson's disease (PD)
61937953|NCT04269590|EXPERIMENTAL|Dual Task (DT) training - HC|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of healthy age-matched controls.
61937954|NCT04269590|ACTIVE_COMPARATOR|Single Task (ST) training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls
61937955|NCT02428608|EXPERIMENTAL|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
62490791|NCT01131091|OTHER|Group A|Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
62490792|NCT01131091|OTHER|Group B|Subjects with severe renal impairment
62490793|NCT01131091|OTHER|Group C|Subjects with moderate renal impairment
62490794|NCT01131091|OTHER|Group D|Subjects with mild renal impairment
62697644|NCT06022887|NO_INTERVENTION|Control|The control group will not receive any of the interventions previously described. To maintain a relationship with each participant in the control group, we will contact them once a week via text message to engage them to finalize the intervention period. At the end of the intervention period and after all data is collected, the RD will meet with the participant for 30 minutes and will educate them regarding the TRE protocol and provide access to the MBSR web-based program.
61937956|NCT06101563|ACTIVE_COMPARATOR|Early|Patients will be managed by ureteroscopic lithotripsy 7 days after drainage.
61937957|NCT06101563|ACTIVE_COMPARATOR|Delayed|Patients will be managed by ureteroscopic lithotripsy 14-21 days after drainage.
61937958|NCT02193477|NO_INTERVENTION|Control|Patients were given no TEAS.
61937959|NCT02193477|EXPERIMENTAL|TEAS Treatment|Patients were given 30min of TEAS before general anesthesia induction, 1th day and 2nd day after surgery.
61937960|NCT02193477|SHAM_COMPARATOR|Sham TEAS|Patients were given 30min of sham TEAS before general anesthesia induction,1th day and 2nd day after surgery.
61937961|NCT06427759|NO_INTERVENTION|anthropometric measures|\*Group (A) Inclusion criteria of study: Anthropometric databases and studies done on females with normal BMI, In reproductive period , No history of pregnancy or weight fluctuation , No medical comorbidities .
61937962|NCT06427759|EXPERIMENTAL|arm aesthetic surgery|"* Group (B) Include patients asking for arm aesthetic surgery .~* Group B1: patients will be submitted for liposuction of arms only.~* Group B2: patients will be submitted for liposuction and brachioplasty in same setting.~* Group B3: patients will be submitted for liposuction then brachioplasty after 3 months."
61937963|NCT02946320|ACTIVE_COMPARATOR|Non-compliant balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
61937964|NCT02946320|EXPERIMENTAL|Scoring balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
62136768|NCT05122468|ACTIVE_COMPARATOR|CAF group|"Coronally advanced flap in combination with a connective tissue graft.~According to the technique(Zucchelli \& De Sanctis 2000), this procedure consists of a rotated papilla, envelope flap. Intrasulcular incisions will be performed involving all the experimental units and at least one tooth mesial and distal to the experimental teeth. From the centre of rotation the incisions will be traced in a corono-apical direction toward the mesial and toward the distal extension of the flap.~After the accurate initial incisions, the flap will be raised full thickness apical to the mucogingival junction (MGJ), exposing 1 to 2 mm of bone at the base of the recession/dehiscence defects.~A linear mesio-distal incision will then be performed to cut the periosteum, releasing any muscular tension and allow a passive coronal positioning of the flap to cover the CEJ."
62333060|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62333061|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62333062|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62490795|NCT01131091|OTHER|Group E|Healthy subjects
62490796|NCT01159873|EXPERIMENTAL|CEP-37251|
62490797|NCT01159873|PLACEBO_COMPARATOR|Placebo|
62490798|NCT05063591|EXPERIMENTAL|Intervention arm|Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment.
62490799|NCT02864836||Patients with head or neck cancer|Samples collection
62490800|NCT02864836||Patients with lymphoma|Samples collection
62490801|NCT02864836||Patients without tumoral pathology|Samples collection
62490802|NCT05804786||single group|Patients with peripheral pulmonary lesions which require histological differentiation because of the possibility of malignancy, and a biopsy can be attempted through guided bronchoscopy
62490803|NCT06158607|EXPERIMENTAL|Intervention|
62490804|NCT06158607|ACTIVE_COMPARATOR|Standard of care treatment|
62490805|NCT00629304|PLACEBO_COMPARATOR|1|standard visit at 3 and 6 months
62490806|NCT00629304|ACTIVE_COMPARATOR|2|PDA-FIT system + standard visit at 3 and 6 months
62490807|NCT00629304|ACTIVE_COMPARATOR|3|PDA-FIT system + 12 telephone visits + standard visit at 6 months
62490808|NCT05462080||Movement Disorders Patients|
62333063|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
62490809|NCT03669731|EXPERIMENTAL|Group 1|Urinary urea 24 hours and food diary
61937965|NCT02946320|EXPERIMENTAL|Cutting balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
61937966|NCT03671486||GBS-negative pregnant women|One Hundred Healthy GBS-negative pregnant women will be follow-up since the first trimester of pregnancy until one month post-delivery
61937967|NCT05598021||Ultrasound assessment|Quantitative comparison between ultrasound images performed in active self-correction and in a spontaneous position
61937968|NCT05598021||RX assessment|Quantitative comparison between radiological images performed in active self-correction and in a spontaneous position
61937969|NCT02368782||ketamine group|ketamine 2mg/kg bolus IV once
61937970|NCT02368782||propofol group|propofol 2mg/kg ıv bolus once
61937971|NCT01474369|EXPERIMENTAL|TAK-438 10 mg QD|
61937972|NCT01474369|EXPERIMENTAL|TAK-438 20 mg QD|
61937973|NCT01474369|PLACEBO_COMPARATOR|Placebo QD|
61937974|NCT00470847|OTHER|Lapatinib,Whole Brain Radiation,Herceptin|Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly
62136769|NCT05122468|EXPERIMENTAL|Tunnel group|"Tunnel technique in combination with a connective tissue graft.~When tunnelling procedures are applied, this technique consists of a supra-periosteal bed under a pedicle flap without any external incisions (Zabalegui et al. 1999). Afterwards, a connective tissue graft is placed and secured through the tunnel, covering the adjacent exposed roots.~To create a tunnel at the buccal aspect of the gingiva, sulcular partial-thickness incisions are made by means of a micro-blade through each recession area, extending the split-thickness beyond the mucogingival junction (MGJ). The partial dissection plane is then extended laterally through the papillae between the treated teeth without separating them. This incision must also be extended 3 to 5 mm mesial and distal from the lateral teeth to allow space for the connective tissue graft."
62490810|NCT03669731|EXPERIMENTAL|Group 2|Urinary urea 24 hours and food diary
61937975|NCT03668769|EXPERIMENTAL|Prevention (smoking reduction, Quitting Schedule mobile app)|"AIM I: Participants follow an individually tailored gradual reduction of smoking schedule for 5 weeks while MDACC eHealth adapts WebCASSI into a smartphone app: Quitting Schedule.~AIM II: Participants pre-test the Quitting Schedule mobile smartphone app for 5 weeks."
61937976|NCT04348461|NO_INTERVENTION|Control|Patients receiving regular respiratory distress treatment
61937977|NCT04348461|EXPERIMENTAL|Treatment|Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
61937978|NCT02360111|EXPERIMENTAL|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
62490811|NCT03669731|EXPERIMENTAL|Group 3|Urinary urea 24 hours and food diary
62490812|NCT04531969|ACTIVE_COMPARATOR|Inpatient group|Spa therapy,HP application, deep heater application, and TENS.
62490813|NCT04531969|ACTIVE_COMPARATOR|Outpatient group|Spa therapy,HP application, deep heater application, and TENS.
61937979|NCT06680609|PLACEBO_COMPARATOR|Nefopam group|
62490814|NCT02086474|EXPERIMENTAL|Hyaluronan|Hyaluronan acid Neovisc : one 6cc (viscosupplement) intra-articular injection
61937980|NCT06680609|OTHER|Placebo|
61937981|NCT04627701|EXPERIMENTAL|Omega Device|
61937982|NCT04386031||group with antifungal drug|
61937983|NCT04386031||A control group|A control group will be taken ,patients undergoing thyroidectomy or parotidectomy
61937984|NCT02239627|ACTIVE_COMPARATOR|Steroid|Epidural steroid injection
61937985|NCT02239627|EXPERIMENTAL|Clonidine|Epidural clonidine injection
62490815|NCT02086474|PLACEBO_COMPARATOR|Bupivacaine|one Marcain extra-capsular injection
62490816|NCT05026320|EXPERIMENTAL|Naproxen Topical Gel (BAYH006689)|UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
61937986|NCT02795793|EXPERIMENTAL|Non-operative management group (NOM)|Children in the NOM group will receive intravenous Piperacillin with Tazobactam (Tazocin) 100mg/kg/dose every 8 hours for at least 24 hours, and they will be observed and reassessed within 24 hours after randomisation. A further 24 hours of intravenous Piperacillin with Tazobactam therapy will be offered to children in invariable condition. A clinical decision will be made by the attending surgeon to offer OM if a patient's condition deteriorates at any time, or if a patient has failed to improve after 48 hours of intravenous antibiotic therapy. Once the patient is clinically improving and tolerating oral intake, the antibiotic regimen will be changed to oral Amoxicillin plus Clavulanic acid (Augmentin) 22.5mg/kg/dose twice per day to complete a total seven day course of antibiotics. Oral Ciprofloxacin 15mg/kg/dose twice daily and oral Metronidazole 10mg/kg/dose twice daily will be offered to children who are known to have an intolerance or allergy to Amoxicillin or Clavulanic acid.
61937987|NCT02795793|ACTIVE_COMPARATOR|Appendectomy group (Operative management, OM)|Children allocated to OM may receive preoperative antibiotic prophylaxis as clinically indicated. Appendicectomy will be performed laparoscopically, or via open surgery according to the surgeon's standard practice. Postoperative antibiotic treatment will be determined on the basis of intraoperative findings in accordance with the institutional practice. The appendix specimen will be examined by a paediatric pathologist, and the formal histopathology report will be recorded.
61937988|NCT05955053|EXPERIMENTAL|Midwifery care applied in line with Midwife-Pregnant cooperation|The group that received care in line with the midwifery care model checklist
61937989|NCT05955053|NO_INTERVENTION|Control group|The group with routine hospital protocol
61937990|NCT05007093|EXPERIMENTAL|Anlotinib hydrochloride|12 mg, 2 weeks on/ 1 week off, 21 days per cycle; treatment interruption or reduction (to 10 mg or 8 mg) was allowed
61937991|NCT00689078|ACTIVE_COMPARATOR|Pred acetate 1%|Prednisolone acetate 1.0% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
61937992|NCT00689078|ACTIVE_COMPARATOR|Pred acetate .12%|Prednisolone acetate 0.12% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
61937993|NCT00689078|ACTIVE_COMPARATOR|Lot Etab 0.2%|Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
61937994|NCT00689078|PLACEBO_COMPARATOR|Placebo|Tears Naturale (Artificial Tears) in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
61937995|NCT05492110|ACTIVE_COMPARATOR|CS Reducer implantation|
61937996|NCT05492110|SHAM_COMPARATOR|Sham procedure|
61937997|NCT03971071|PLACEBO_COMPARATOR|Placebo|After participants complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
61937998|NCT03971071|ACTIVE_COMPARATOR|Erenumab 70 mg|After participants complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
61937999|NCT03971071|ACTIVE_COMPARATOR|Erenumab 140 mg|After participants complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
61938000|NCT04893707|EXPERIMENTAL|CM310|"adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
61938001|NCT05659992|EXPERIMENTAL|treatment group|Experimental: Venetoclax combined CACAG regimen for newly diagnosed AML. All recipients in this arm received azacytidine, cytarabine.aclamycin, chidamide,venetoclax and granulocyte colony-stimulating factor.Azacytidine was uesd as 75 mg/m2/day from day-1 to day-7.Cytarabine was uesd as 75 mg/m2 bid from day-1 to day-5. Aclamycin was uesd as 10 mg/m2/day on day1,3,5). Chidamide was uesd as 30 mg/day twice per week for 2 weeks. Venetoclax was uesd as 100 mg on day 1, 200 mg on day 2, 400mg from day-3 to day-14.Granulocyte colony-stimulating factor was uesd as 5ug/kg/day from day 0 until agranulocytosis recovery.
61938002|NCT04562610|ACTIVE_COMPARATOR|Group A: All oral pre-operative analgesics|"Group A patients will be administered the following medications in the preoperative holding area:~* Acetaminophen 1,000 mg by mouth prior to operation~* Celecoxib 200mg by mouth prior to operation~* Tranexamic acid 2 grams by mouth prior to operation~* Gabapentin 600mg by mouth prior to operation"
61938003|NCT04562610|ACTIVE_COMPARATOR|Group B: Intravenous agents|"Group B patients will receive:~* Acetaminophen (Ofirmev) 1,000mg intravenous prior to operation~* Celecoxib 200mg by mouth prior to operation~* Tranexamic acid 2grams intravenous at start of operation~* Gabapentin 600 mg by mouth prior to operation"
61938004|NCT03204461||PCOS-NIH|
61938005|NCT03204461||PCOS-Rotterdam|
61938006|NCT03204461||Controls|
61938007|NCT05484778|OTHER|Case Group|This group consists of athletes whose are between the ages of 14-30 and are still active at high school or university level in sports involving sudden changes of direction and jump physically and who have a history of injury to only one lower extremity before.
61938008|NCT05484778|OTHER|Control Group|This group consists of athletes whose age range is 14-30, and who are still active at high school or university level in sports involving sudden changes of direction and jump physically and who do not have a history of lower extremity injuries.
61938009|NCT06010706|EXPERIMENTAL|Supervised Manual Physical Therapy Program|Participants will receive a supervised physical therapy program including: mobilizing exercises, stretching exercises, and strengthening exercises. 3 sessions a week for eight consecutive weeks.
61938010|NCT06010706|ACTIVE_COMPARATOR|Home based exercise program:|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance. The home-based program will include stretching, ROM and strengthening exercises
61938011|NCT01422252|EXPERIMENTAL|Persons equipped|Precocious fall detection device
61938012|NCT01422252|NO_INTERVENTION|Persons non-equipped|No fall detection device
61938013|NCT03599245|EXPERIMENTAL|Ocrelizumab|Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.
61938014|NCT00975325|ACTIVE_COMPARATOR|"Yohimbine, Yohimbine Spiegel"|
61938015|NCT00975325|ACTIVE_COMPARATOR|Yohimbine Yocon-Glenwood|
61938016|NCT01209923|EXPERIMENTAL|Body composition testing|Body composition tested using bioelectrical impedance (BC1) and the DEXA or hydrostatic weighing methods.
62490817|NCT05026320|ACTIVE_COMPARATOR|Diclofenac Diethylamine Gel|UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
62490818|NCT05026320|PLACEBO_COMPARATOR|Placebo Gel|UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
62490819|NCT06254560|EXPERIMENTAL|rituximab group|Rituximab combined with cyclosporine
62490820|NCT01698554|EXPERIMENTAL|bimatoprost formulation A solution|Bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
62490821|NCT01698554|ACTIVE_COMPARATOR|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
62490822|NCT01698554|PLACEBO_COMPARATOR|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
62490823|NCT01698554|PLACEBO_COMPARATOR|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
61938017|NCT05049681|EXPERIMENTAL|SHR-1210（Camrelizumab）+Apatinib|Apatinib 250mg, q.d.po; SHR-1210（Camrelizumab） 200 mg，Intravenous injection,q2W ,A course of treatment need 28 days.
61938018|NCT05049681|ACTIVE_COMPARATOR|SHR-1210（Camrelizumab）|SHR-1210（Camrelizumab） 200 mg，Intravenous injection. q2W ,A course of treatment need 28 days.
61938019|NCT05957978|EXPERIMENTAL|LXE408|LXE408 orally once daily for 14 days
62333064|NCT02918266|EXPERIMENTAL|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
61938020|NCT05957978|ACTIVE_COMPARATOR|Standard of care|Standard of care sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d. and paromomycin 15 mg/kg/day IM q.d. for 17 days
61938021|NCT00032032|EXPERIMENTAL|radiotherapy + paclitaxel + carboplatin|"Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.~Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years."
62333065|NCT00543569|ACTIVE_COMPARATOR|Tacrolimus/MMF/Basiliximab|Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
62136770|NCT05660356|EXPERIMENTAL|Growth Hormone|Participants will perform daily at-home subcutaneous GH injections after receiving thorough at-home education training provided by a pharmaceutical nurse before and research personnel. The GH will be provided be Pfizer. Starting doses will be 0.2 ug/L and 0.3 ug/L for women taking exogenous oral estrogen.
62333066|NCT00543569|EXPERIMENTAL|Alefacept QW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
62333067|NCT00543569|EXPERIMENTAL|Alefacept QW/Tacrolimus|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
62490824|NCT00064324|EXPERIMENTAL|Arm I|Patients receive a loading dose of oral perifosine every 6 hours for a total of 4 doses on day 1 and once daily on days 2-28 of course 1 only. For all subsequent courses, patients receive oral perifosine once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62490825|NCT02856594|EXPERIMENTAL|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
61938022|NCT03751644|EXPERIMENTAL|Electrical stimulation|After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
61938023|NCT03751644|NO_INTERVENTION|Placebo|Patients will not submitted to electrical stimulation.
61938024|NCT04021420|EXPERIMENTAL|low intensity pulsed UltraSound|SonoCloud® is an active implantable device (implantation duration until 16 weeks at maximum after inclusion). SonoCloud® delivers low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB.
61938025|NCT00894023|EXPERIMENTAL|Abciximab|IC bolus of abciximab
61938026|NCT00894023|ACTIVE_COMPARATOR|IV Abciximab|IV abciximab + infusion
61938027|NCT05030818|EXPERIMENTAL|Polypill|Patients will be receiving the polypill at the adequate doses during 3 months
61938028|NCT05030818|ACTIVE_COMPARATOR|Drugs taken separately|Patients will be receiving during 3 months the same components and at the same doses than with the polypill
61938029|NCT01354327|EXPERIMENTAL|Limicol|
61938030|NCT01354327|PLACEBO_COMPARATOR|Placebo|
61938031|NCT05389046|EXPERIMENTAL|Escitalopram|Escitalopram monotherapy (10-20 mg/day）
61938032|NCT05389046|EXPERIMENTAL|Escitalopram + omega-3 PUFAs|Escitalopram (10-20 mg/day）combined with omega-3 PUFAs （EPA 900mg，DHA 300 mg）
61938033|NCT05389046|EXPERIMENTAL|Escitalopram + Aripiprazole|Escitalopram (10-20 mg/day）combined with Aripiprazole （2.5-10 mg/day)
61938034|NCT05389046|EXPERIMENTAL|Escitalopram + omega-3 PUFAs + Aripiprazole|Escitalopram (10-20 mg/day）combined with omega-3 PUFAs （EPA 900mg，DHA 300 mg）and Aripiprazole （2.5-10 mg/day)
61938035|NCT01902238|EXPERIMENTAL|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
61938036|NCT05781373|NO_INTERVENTION|Fixed PEEP group|Protective intraoperative ventilation with: 6 ml/kg IBW tidal volume recruitment maneuver and fixed PEEP¨level of 6 cmH2O
61938037|NCT05781373|EXPERIMENTAL|Individualized PEEP group|Protective intraoperative ventilation with: 6 ml/kg IBW tidal volume recruitment maneuver and individualized PEEP¨level in order to achieve the lowest driving pressure
61938038|NCT02612038|EXPERIMENTAL|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
61938039|NCT02612038|SHAM_COMPARATOR|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
61938040|NCT04920422||Metastatic colorectal cancer patients.|Medical history data of all patients with at least 1 treatment with regorafenib will be collected retrospectively.
61938041|NCT06406790|EXPERIMENTAL|CraniSeal|CraniSeal
61938042|NCT06406790|ACTIVE_COMPARATOR|DuraSeal|DuraSeal
61938043|NCT05594810|ACTIVE_COMPARATOR|TAU only: Community Reinforcement Approach (CRA) + a regular smoking cessation program|TAU only
61938044|NCT05594810|EXPERIMENTAL|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR) + TAU (CRA)|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)
61938045|NCT01995630|EXPERIMENTAL|Hypermetropic, spherical IOL|AMO Sensar AR40e
61938046|NCT01995630|EXPERIMENTAL|Hypermetropic, aspheric IOL|AMO Tecnis ZA9003
61938047|NCT01995630|ACTIVE_COMPARATOR|Emmetropic, spherical IOL|AMO Sensar AR40e
61938048|NCT01995630|ACTIVE_COMPARATOR|Emmetropic, aspheric IOL|AMO Tecnis ZA9003
61938049|NCT02367131||JARDIANCE®|
61938050|NCT02993718|EXPERIMENTAL|Dexmedetomidine|Intraoperative sedation is performed by using dexmedetomidine.
62333068|NCT00543569|EXPERIMENTAL|Alefacept QOW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
61938051|NCT02993718|EXPERIMENTAL|Propofol|Intraoperative sedation is performed by using propofol
61938052|NCT05241431|ACTIVE_COMPARATOR|Intervention group|10 mg (oral) SGLT-2 inhibitor once daily
62136771|NCT05660356|PLACEBO_COMPARATOR|Placebo|Participants will perform daily at-home subcutaneous placebo injections after receiving thorough at-home education training provided by a pharmaceutical nurse before and research personnel. Starting doses will be 0.2 ug/L and 0.3 ug/L for women taking exogenous oral estrogen.
62136772|NCT00909961|EXPERIMENTAL|Zoledronic acid|
62333069|NCT03141086|EXPERIMENTAL|Group 1|LML134, then placebo
62333070|NCT03141086|EXPERIMENTAL|Group 2|Placebo, then LML134
61938053|NCT05241431|PLACEBO_COMPARATOR|Control group|Placebo tablet encapsulated as the active treatment.
61938054|NCT06481839|ACTIVE_COMPARATOR|Low-dose NE|
61938055|NCT06481839|ACTIVE_COMPARATOR|High-dose NE|
61938056|NCT01368432|PLACEBO_COMPARATOR|Placebo|Daily for 12 weeks
61938057|NCT01368432|EXPERIMENTAL|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks
61938058|NCT03896685|EXPERIMENTAL|endTB-Q: BeDeCLi 24 or 39 weeks|endTB-Q regimen: bedaquiline-delamanid-linezolid-clofazimine (BeDeCLi). Subjects who are randomized to this arm will be assigned to duration of 24 or 39 weeks , according to the participant's extent-of-TB-disease phenotype. Participants may take as long as 32 weeks to complete all doses of a 24-week treatment regimen, and up to 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of the experimental regimens will be oral and weight based.
61938059|NCT03896685|ACTIVE_COMPARATOR|endTB-Q: Control arm|endTB-Q is the control regimen, designed according to latest World Health Organization guidelines.
62490826|NCT02856594|PLACEBO_COMPARATOR|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
62136773|NCT02966665|EXPERIMENTAL|Healthy Young Volunteers (18-30 years)|Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
62490827|NCT01812993|NO_INTERVENTION|Control|No ventilatory treatment; standard stroke care
62490828|NCT01812993|EXPERIMENTAL|Active|Non-invasive ventilatory treatment with auto-BPAP plus standard stroke care
62490829|NCT01166464|EXPERIMENTAL|Text Messaging|A text message-based intervention for smoking cessation
62490830|NCT01166464|PLACEBO_COMPARATOR|Control|Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm. This provides a control for staff/program contact time and participant burden.
62490831|NCT02618460|EXPERIMENTAL|Whole Group|
62490832|NCT00726830|EXPERIMENTAL|Arm I: Opioid rotation to oral methadone|Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
62490833|NCT00726830|EXPERIMENTAL|Arm II: Opioid rotation to another long-acting strong opioid|Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.
62490834|NCT05251805|EXPERIMENTAL|Costal bone marrow aspiration|10 NSCLC patients undergoing surgery from which blood samples, bone marrow aspirate and lung tumor tissue will be collected
62490835|NCT06516172||Patients with cancer|Age 18+ years, indication for cancer rehabilitation
62490836|NCT06516172||Patients with cardiovascular diseases|Age 18+ years, indication for cardiovascular rehabilitation
62490837|NCT06516172||Patients with musculoskeletal diseases|Age 18+ years, indication for musculoskeletal rehabilitation
62490838|NCT06516172||Patients with pulmonary diseases|Age 18+ years, indication for pulmonary rehabilitation
62490839|NCT05643105||Colon cancer patients with intestinal anastomosis|There is a single cohort of patients, the one operated on for colon cancer with intestinal continuity construction through an anastomosis without derivative stoma construction of any kind.
62490840|NCT01993940|EXPERIMENTAL|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
62490841|NCT01993940|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo orally once daily for 12 weeks.
62490842|NCT04605835||Main group|484 children with congenital obstructive uropathies
62490843|NCT05453487|EXPERIMENTAL|Co-Ad group|"A total of 120 participants received one dose of inactivated COVID-19 vaccine and three doses of rabies vaccine.~Participants received one dose of inactivated COVID-19 vaccine and rabies vaccine on Day 0, and one dose of rabies vaccine on Day 7 and Day 28.~Blood sampling was performed on Day 0, Day 28 and Day 42."
62490844|NCT05453487|EXPERIMENTAL|COVID-19 vaccine group|"A total of 120 participants received one dose of inactivated COVID-19 vaccine on Day 0.~Blood sampling was performed on Day 0 and Day 28."
62490845|NCT05453487|EXPERIMENTAL|Rabies vaccine group|"A total of 120 participants received three doses of rabies vaccine on Day 0, Day 7 and Day 28.~Blood sampling was performed on Day 0 and Day 42."
62490846|NCT01282736|EXPERIMENTAL|Integrative Response Therapy|IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
62136774|NCT02966665|EXPERIMENTAL|Healthy Older Controls (over 65 years)|Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
62490847|NCT01282736|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy guided self-help (CBT-GSH), based on the restraint model of binge eating, has been adapted from individual format to a 10 session, group-based therapy for the purpose of this study. The book 'Overcoming Binge Eating' is employed in the present study and consists of Part 1, an educational background on BED, and Part 2, a 6 step treatment program to overcome binge eating.
62490848|NCT03584308|EXPERIMENTAL|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
62490849|NCT03584308|PLACEBO_COMPARATOR|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
62490850|NCT03008616|ACTIVE_COMPARATOR|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
62490851|NCT03008616|PLACEBO_COMPARATOR|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
62490852|NCT03246503|EXPERIMENTAL|Newborns|"Newborns will be enrolled in the study in 2 different ways. At Staged Enrollment sites, newborns will be enrolled when they are \< 48 hours old. These newborns will have a study visit when they are 48 - 167 hours old. At the study visit, a BCB will be determined and blood will be drawn for study purposes for a TSB level. At Simultaneous Enrollment sites, newborns will be enrolled and have a study visit at the time of a blood draw (+/- 2 hours) for a TSB level that is being obtained for clinical purposes. Newborns will be 0-191 hours old."
62490853|NCT02339038|OTHER|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
62490854|NCT01728480|EXPERIMENTAL|Treatment (entolimod, IMRT, cisplatin)|Patients undergo IMRT 5 times per week for 7 weeks, receive cisplatin IV once weekly for 7 weeks, and entolimod SC on days 1, 8, 15, 22, 29, 36, and 43.
62490855|NCT06182293|OTHER|Systemic sclerosis|
62490856|NCT06182293|OTHER|Controls|
62490857|NCT01772277||MMC group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy with intraoperative MMC
62490858|NCT01772277||Control group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy without intraoperative MMC
62136775|NCT02966665|EXPERIMENTAL|Coronary Angiography patients|Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
61938060|NCT05136131|EXPERIMENTAL|True cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. The unblinded non-MRP cardiologist will call out as per usual All clear, following which a shock is delivered as per the Ottawa Cardioversion Protocol in the 'shock' arm."
62333071|NCT05009459|EXPERIMENTAL|eVIS + Treatment as usual (interdisciplinary pain rehabilitation program)|Participant takes part of the unit´s program with an addition of eVIS. eVIS consists of objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
62333072|NCT05009459|NO_INTERVENTION|Treatment as usual (interdisciplinary pain rehabilitation program)|Participant takes part of the unit´s program with an addition of daily self-report of pain intensity (0-10), affect of pain on daily activities (0-10), and pharmacological consumption.
62490859|NCT02803827|EXPERIMENTAL|Rapid diagnostics and probiotic|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
62490860|NCT02803827|OTHER|Rapid diagnostics and placebo|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given placebo x 60 days.
62490861|NCT02803827|OTHER|No rapid diagnostics and probiotic|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
62490862|NCT02803827|PLACEBO_COMPARATOR|No rapid diagnostics and placebo|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given placebo x 60 days.
61938061|NCT05136131|SHAM_COMPARATOR|Sham cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. No shock is delivered in the sham shock arm."
62136776|NCT02966665|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease patients|Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
61938062|NCT04134702|EXPERIMENTAL|Acupuncture|30 patients will receive acupuncture additionally to standard pharmacological therapy of postoperative pain
62136777|NCT02966665|EXPERIMENTAL|Pulmonary Arterial Hypertension patients|Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
62333073|NCT05641792|EXPERIMENTAL|CGM pre-, intra- and postoperatively|Patients will have a Dexcom G6 system placed on admission on outer part of the arm, glycaemia will be monitored for 10 consecutive days
62333074|NCT01326052|EXPERIMENTAL|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
62333075|NCT01326052|ACTIVE_COMPARATOR|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
62333076|NCT02477722|EXPERIMENTAL|EFP-NF|Subjects are asked to change their brain activity in response to feedback they receive from the brain itself, mediated via various visual or auditory stimuli.
62333077|NCT02477722|SHAM_COMPARATOR|Sham-NF|Placebo
62333078|NCT06381518|OTHER|Cohort 1: Infliximab monotherapy|Adult patients (18-75 years old) on maintenance monotherapy of IV IFX.
62333079|NCT06381518|OTHER|Cohort 2: infliximab combination therapy|Adult patients on maintenance combination therapy of IV IFX with a thiopurine derivate or methotrexate.
62333080|NCT00997295||Heat moisture exchanger (HME)|This group was submitted to general anesthesia with low flow gas and heat moisture exchanger
62333081|NCT00997295||Low flow gas (LFG)|This group was submitted to general anesthesia with only low flow gas
62490863|NCT04506918|EXPERIMENTAL|IVR survey|Participants will receive an IVR survey
62490864|NCT04506918|EXPERIMENTAL|SMS survey|Participants will receive an SMS survey
62490865|NCT01771653||Previously treated|Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
61938063|NCT04134702|NO_INTERVENTION|No intervention|30 patients will receive just standard pharmacological therapy of postoperative pain
61938064|NCT01810432|EXPERIMENTAL|Evacetrapib (Fasted)|130 milligram (mg) oral dose of evacetrapib once daily in a fasted state for 10 days.
61938065|NCT01810432|EXPERIMENTAL|Evacetrapib (Fed)|130 mg oral dose of evacetrapib once daily following a high-fat breakfast for 10 days.
62136778|NCT02966665|EXPERIMENTAL|Heart Failure patients|Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
62333082|NCT00997295||Humidity of the respiration|"Heat and moisture group:~The first group (G1)will be submitted to low flow gas anesthesia and heat and moisture exchanger (HME)~Control group:~The second group(G2)Will be submitted to low flow gas anesthesia"
62333083|NCT00997295||HME and LFG|
62333084|NCT05284578|EXPERIMENTAL|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
62333085|NCT05284578|EXPERIMENTAL|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
62333086|NCT05284578|ACTIVE_COMPARATOR|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
62333087|NCT04620824||Trial Participants|"Overall Description of Trial Participants: The spleen organ samples included in this project will be from patients undergoing elective surgery for a lesion in the pancreas in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.~Inclusion Criteria: The samples included in this project will be from patients undergoing elective surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of spleen samples from radical surgery are adult age and presence of splenic tissue in the discarded material after hepato-pancreato-biliary surgery.~Exclusion Criteria: The main exclusion criterion is acute invasive bacterial and viral infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
62333088|NCT05594680|ACTIVE_COMPARATOR|Cilostazol and Methotrexate|Participants in this arm will receive Cilostazol 50 mg twice daily with Methotrexate for rheumatoid arthritis for 12 weeks.
62333089|NCT05594680|PLACEBO_COMPARATOR|Placebo and Methotrexate|Participants in this arm will receive Placebo with Methotrexate for rheumatoid arthritis for 12 weeks.
62333090|NCT06284018|EXPERIMENTAL|intervention group1|Group A consisted of thirty postnatal women. They were treated by progressive muscle relaxation exercises three times per week for 4 weeks.
62333091|NCT06284018|EXPERIMENTAL|intervention group 2|Group B consisted of thirty postnatal women. They were treated by pilates exercises three times per week for 4 weeks.
62333092|NCT02458079|EXPERIMENTAL|Pentoxiphylline|
62333093|NCT02458079|ACTIVE_COMPARATOR|Stool Microbiota Transplantation|
62333094|NCT00083070|EXPERIMENTAL|Temozolomide Therapy|
61938066|NCT04516369|EXPERIMENTAL|Voretigene neparvovec|1.5 E11 vg (0.3 mL subretinal injection in each eye, 6-18 days apart)
61938067|NCT00879099|ACTIVE_COMPARATOR|Paroxetine|
62333095|NCT03268070|EXPERIMENTAL|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
62333096|NCT03268070|EXPERIMENTAL|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
62333097|NCT03268070|EXPERIMENTAL|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
62333098|NCT03268070|SHAM_COMPARATOR|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
62333099|NCT03268070|EXPERIMENTAL|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
62333100|NCT05162950||SW CAH|Patients with 21-hydroxylase deficiency, salt wasting form.
62333101|NCT05162950||SV CAH|Patients with 21-hydroxylase deficiency, simple virilising form.
62333102|NCT05162950||NC CAH|Patients with 21-hydroxylase deficiency, non-classic form.
62333103|NCT05162950||Carrier CAH|Healthy individuals, heterozygous carriers a mutation in the CYP21A2 gene. Recruited among parents of patients with CAH.
62333104|NCT05162950||Control|Healthy sex and age matched controls
62333105|NCT02044159|EXPERIMENTAL|Hydrocortisone|Patients randomized to the hydrocortisone arm will receive a 2 mg/kg hydrocortisone IV bolus on enrolment followed by 1 mg/kg of hydrocortisone IV q6h until the patient has not had an escalation in therapy for at least 12 hours. If the patient meets these criteria their hydrocortisone will be weaned to 1 mg/kg every 8 hours which will be continued until they are off all vasoactive infusions for 12 hours. If following the initial hydrocortisone wean, the patient requires fluid boluses and/or an increase in their vasoactive infusion(s), their hydrocortisone will be increased back to 1 mg/kg of hydrocortisone IV q6h until they meet stability criteria again. Duration of treatment will range from a minimum of 20 hours to a maximum of 7 days of study drug.
62333106|NCT02044159|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo arm will receive a placebo solution consisting of normal saline equivalent in volume to the appropriate dose of hydrocortisone. Hydrocortisone and placebo will be identical in appearance, volume and smell as hydrocortisone is made up in normal saline and dissolves completely with no visible precipitate. The dosing regimen will be identical to the hydrocortisone arm.
61938068|NCT00879099|PLACEBO_COMPARATOR|Gelatine capsule|
61938069|NCT00879099|EXPERIMENTAL|Timolol 0.5 % eye drops|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
62136779|NCT02966665|EXPERIMENTAL|Hypertension patients|Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
62490866|NCT01771653||Previously untreated|Records of patients who have never received anti-HCV treatment.
62490867|NCT01320722|EXPERIMENTAL|Vitamin D|Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.
62490868|NCT01320722|EXPERIMENTAL|Probenecid|Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).
62490869|NCT01320722|EXPERIMENTAL|Allopurinol|Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).
62490870|NCT01320722|PLACEBO_COMPARATOR|Placebo- Vitamin D|Placebo soft gel once per week for 8 weeks.
62490871|NCT01320722|PLACEBO_COMPARATOR|Placebo- Uric Acid|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).
62490872|NCT03949062|EXPERIMENTAL|iR2|Participants received six 21-day cycles of ibrutinib, lenalidomide, and rituximab (iR2) treatment (21-day cycles).
62490873|NCT03369132|EXPERIMENTAL|Angiflash|
62490874|NCT03369132|PLACEBO_COMPARATOR|Placebo|
62490875|NCT01988636|EXPERIMENTAL|Group 1|Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
62490876|NCT01988636|ACTIVE_COMPARATOR|Group 4|Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
62490877|NCT01988636|PLACEBO_COMPARATOR|Group 5|Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24
62490878|NCT01832922|EXPERIMENTAL|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
62490879|NCT01832922|ACTIVE_COMPARATOR|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
62490880|NCT01323062|OTHER|Single-arm trial|Single-arm trial
62490881|NCT06089057|EXPERIMENTAL|Power training and monitored physical activity|This is a 16-week power-training and physical activity-focused intervention that contains in-center and at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
62490882|NCT06089057|ACTIVE_COMPARATOR|Attention control|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
62490883|NCT05895435|EXPERIMENTAL|first group|"Group (A) (Control Group):~It will be consisted of 30 patients who will receive aerobic exercise and diet for 8 successive weeks 2 sessions per week."
62490884|NCT05895435|EXPERIMENTAL|second group|"Group (B) (Study Group):~It will be consisted of 30 patients who will receive aerobic exercise and diet and radiofrequency for 8 successive weeks 2 sessions per week."
61938070|NCT00879099|EXPERIMENTAL|Timosan 0.1% eye gel|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
62136780|NCT06700226|EXPERIMENTAL|Patients treated under PFA|Single-Arm study, all patients included will undergo PFA using AblaView® Unipolar PFA System
62136781|NCT04824274|EXPERIMENTAL|Transversus abdominis plane block and intrathecal fentanyl|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + fentanyl 10 mcg. Following the completion of surgery, ultrasound-guided bilateral transversus abdominis plane block will be done with 0.375% ropivacaine 15 ml per each side.
62333107|NCT00771030|PLACEBO_COMPARATOR|Placebo SC (Cohorts 1-3)|Participants received placebo to brodalumab by subcutaneous (SC) injection once every 2 weeks for a total of six doses.
62333108|NCT00771030|PLACEBO_COMPARATOR|Placebo IV (Cohorts 5-6)|Participants received placebo to brodalumab by intravenous (IV) infusion every 4 weeks for a total of two doses.
61938071|NCT05828134|NO_INTERVENTION|Usual care group|The control group only performed routine data collection and gave them dietary suggestion.
61938072|NCT05828134|EXPERIMENTAL|Protein-enriched soup group|Protein-enriched soup /day for use as a supplement with meals and strength training /week
61938073|NCT00702689|EXPERIMENTAL|Imatinib mesylate in patients with cGVHD|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)"
62136782|NCT04824274|ACTIVE_COMPARATOR|Intrathecal morphine|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + morphine 75 mcg. Following the completion of surgery, sham block will be done using normal saline.
62333109|NCT00771030|EXPERIMENTAL|Brodalumab 50 mg SC (Cohort 1)|Participants received 50 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
62333110|NCT00771030|EXPERIMENTAL|Brodalumab 140 mg SC (Cohort 2)|Participants received 140 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
62333111|NCT00771030|EXPERIMENTAL|Brodalumab 210 mg SC (Cohort 3)|Participants received 210 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
62333112|NCT00771030|EXPERIMENTAL|Brodalumab 420 mg IV (Cohort 5)|Participants received 420 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
62333113|NCT00771030|EXPERIMENTAL|Brodalumab 700 mg IV (Cohort 6)|Participants received 700 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
62333114|NCT00932529|ACTIVE_COMPARATOR|Olanzapine|
62490885|NCT01682421|EXPERIMENTAL|Weak steroid|Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.
62490886|NCT01682421|EXPERIMENTAL|Potent steroid|Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.
62490887|NCT01904305||Patients receiving bronchoscopy|Patients suspected of having pneumonia received bronchoscopy to examine the lungs and to capture alveolar lavage culture
62490888|NCT06256224|EXPERIMENTAL|Toripalimab+CCRT|"External beam radiotherapy (EBRT) of 45-50.4Gy was delivered using intensity modulated radiation therapy (IMRT) technique to the pelvic ± para-aortic fields in 25-28 fractions, 5 days a week and was followed by brachytherapy of 24-30Gy in 3-5 fractions, once a week. Concurrent chemotherapy of cisplatin, with a dose of 40 mg/m2 by intravenous infusion, was administered once a week for 5 weeks during EBRT.~Toripalimab 240mg by intravenous infusion was administered every 3 weeks for 6 months and maintained upto 2 years for those whose lesions did not reach complete remission at six-month follow-up."
62490889|NCT06256224|ACTIVE_COMPARATOR|CCRT|EBRT of 45-50.4Gy was delivered using IMRT technique to the pelvic ± para-aortic fields in 25-28 fractions, 5 days a week and was followed by brachytherapy of 24-30Gy in 3-5 fractions, once a week. Concurrent chemotherapy of cisplatin, with a dose of 40 mg/m2 by intravenous infusion, was administered once a week for 5 weeks during EBRT.
61938074|NCT01908231||Pulmonary Embolism|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals participating in the study with clinical suspicion of PE will be considered for the study. We excluded patients with life expectancies of less than 3 months, and patients with first symptoms 15 days or more before inclusion.
61938075|NCT00629772|PLACEBO_COMPARATOR|Placebo then infliximab|Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
61938076|NCT00629772|ACTIVE_COMPARATOR|Infliximab|Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
61938077|NCT06338150||Participants with Multiple Myeloma|Participants who will undergo tumor biopsy for management of multiple myeloma (MM)
61938078|NCT04194346|EXPERIMENTAL|Determination of local pleural strain|The average Von Mises coefficient will be calculated for each recorded ultrasound loop using a non-invasive vascular elastography platform.
61938079|NCT01134315||Paricalcitol|Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
62490890|NCT06359015|EXPERIMENTAL|Metformin and Esomeprazole|Patients diagnosed with preterm preeclampsia receive expectant management with additional metformin/esomeprazole.
61938080|NCT01134315||Calcitriol|Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT). Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
62136783|NCT05856084|EXPERIMENTAL|Low dose vaccine group in adults aged 30 to 49 years|Participants aged 30 to 49 years will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62490891|NCT06359015|NO_INTERVENTION|No Intervention|Patients diagnosed with preterm preeclampsia receive expectant management only.
62490892|NCT03948854|EXPERIMENTAL|Registered dietitian education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in person by a registered dietitian
62490893|NCT03948854|EXPERIMENTAL|On-line video program education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet using an on-line video program
62490894|NCT03948854|EXPERIMENTAL|Handout education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet by a printed handout
62490895|NCT03948854|EXPERIMENTAL|Dietitian-led group education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in a dietitian-led group setting
62490896|NCT00867360|EXPERIMENTAL|Mifepristone|Receive mifepristone for 8 days
62490897|NCT00867360|PLACEBO_COMPARATOR|Placebo|Receive placebo rather than mifepristone
62490898|NCT06348888|EXPERIMENTAL|BAY2927088 + Itraconazole (ITZ)|Participant will receive single dose BAY2927088 on Days 1 and 8, will receive itraconazole daily from Day 5 to Day 11.
62490899|NCT06348888|EXPERIMENTAL|BAY2927088 + Carbamazepine (CBZ)|Participant will receive BAY2927088 single dose on Days 1 and 14, will receive carbamazepine daily from Day 3 to Day 15.
62490900|NCT05120388|EXPERIMENTAL|Dietary addition of extra virgin olive oil|WHO diet with a daily addition of extra virgin olive oil
62490901|NCT05120388|NO_INTERVENTION|No addition of extra virgin Olive Oil|WHO diet
61938081|NCT04210778|EXPERIMENTAL|CRAFT (Cognitive Training and Functional Treatment)|Over 12 weeks this group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training, in addition to a weekly 1 hour remote CO- OP (Meta cognitive strategy training) session. Each participant will set three occupational goals that will be the focus of the CO -OP treatment
61938082|NCT04210778|ACTIVE_COMPARATOR|Computerized Cognitive Training|This group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training
61938083|NCT04210778|NO_INTERVENTION|Treatment As Usual|This group will receive no intervention
61938084|NCT00569270|ACTIVE_COMPARATOR|Tiotropium 18 µg capsule, bronchodilator|tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
61938085|NCT00569270|PLACEBO_COMPARATOR|2|placebo 18ug tiotropium for 1 month
61938086|NCT05182099|OTHER|Conventional image reconstruction|Gd-EOB-DTPA enhanced liver MRI images are reconstructed using a conventional image reconstruction algorithm. It is automatically generated from a MRI console after the examination.
61938087|NCT05182099|ACTIVE_COMPARATOR|Deep learning image reconstruction|"Gd-EOB-DTPA enhanced liver MRI images are reconstructed using a deep learning based image reconstruction algorithm (AIRTM). It is additionally generated aside from the conventional images.~For obtaining the images, we will use the same MRI raw data which is used for conventional image reconstruction."
62333115|NCT00932529|ACTIVE_COMPARATOR|Quetiapine|
62333116|NCT00932529|ACTIVE_COMPARATOR|Risperidone|
62333117|NCT00932529|ACTIVE_COMPARATOR|Ziprasidone|
62333118|NCT04075201|EXPERIMENTAL|Adults-Experimental group|One dose of investigational vaccine
61938088|NCT03583723|EXPERIMENTAL|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
61938089|NCT04025983|EXPERIMENTAL|GastimunHp Plus|1 sachet of GastimunHp Plus twice daily during or after meals.
62136784|NCT05856084|EXPERIMENTAL|High dose vaccine group in adults aged 30 to 49 years|Participants aged 30 to 49 years will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62333119|NCT04075201|EXPERIMENTAL|Children-Experimental group|One dose of investigational vaccine
62333120|NCT04075201|ACTIVE_COMPARATOR|Children-Control group|One dose of control vaccine
62333121|NCT04075201|EXPERIMENTAL|Neonates-Experimenatal group|Three doses of investigational vaccine
62333122|NCT04075201|ACTIVE_COMPARATOR|Neonates-Control group|Three doses of control vaccine
62333123|NCT01686022||Pollen Allergy|Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
62490902|NCT03946787|ACTIVE_COMPARATOR|EMDR Therapy + TAU|"Patients will be submitted to 20 individual sessions of Eye Movement Desensitization and Reprocessing (EMDR) Therapy of 60 minutes each, combined to the Treatment as usual (TAU).~It's an eight-step process aimed at the traumatic events, also used to address current situations that evoke emotional disturbances so they do not trigger more symptomatic reactions. In addition, it is helpful to assist the patient in developing the specific skills and behaviors required for a healthy functional life.~Our group will adapt the EMDR protocol model specific for bipolar patients with a history of trauma, developed by Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma."
62694792|NCT06637241|EXPERIMENTAL|Risk stratification care|All baseball players at schools assigned to the injury risk-stratified care group will be categorized into high-risk, medium-risk, and low-risk groups. Baseball players in the high-risk group will receive not only sports protection education but will also be referred to a physician for further care. The sports protective education is taught by a sports injury prevention specialist from the Sports Injury Prevention System for Student Athletes of the Sports Administration. This education includes a prevention program known as the Modified Yokohama Baseball-9 (mYKB-9), which has been clinically validated to effectively reduce shoulder and elbow joint injuries in adolescent baseball players by nearly half. The program consists of nine exercises, including five stretches, two thoracic mobility exercises, and two lower limb balance exercises.
61938090|NCT04025983|PLACEBO_COMPARATOR|Placebo|1 sachet of placebo twice daily during or after meals.
61938091|NCT06665724|EXPERIMENTAL|Sonodynamic Therapy (SDT)|Patients will receive sonodynamic therapy (5 ALA combined with CV01-delivered sonication) 2 to 5 days prior to standard resection.
61938092|NCT02350673|EXPERIMENTAL|Cergutuzumab+Atezolizumab (Part I)|Participants will receive escalated IV doses of cergutuzumab amunaleukin in combination with atezolizumab. This is a Part I dose escalation phase of the study. Cergutuzumab amunaleukin will be escalated from a starting dose of 6 milligrams (mg) and dosing schedules of every week (qw) and every 2 weeks (q2w) may be explored. Atezolizumab will be administered in fixed flat doses of either 840 mg q2w or 1200 mg every 3 weeks (q3w). Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
61938093|NCT02350673|EXPERIMENTAL|Cergutuzumab +Atezolizumab (Part II)|This is a Part II expansion phase of the study. Participants will receive cergutuzumab amunaleukin at maximum tolerated dose (MTD) (or recommended dose) identified during Part I in combination with atezolizumab. Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
61938094|NCT04558281|EXPERIMENTAL|Active Treatment|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)
62333124|NCT00226681|EXPERIMENTAL|1|
61938095|NCT04558281|PLACEBO_COMPARATOR|Placebo|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline
61938096|NCT04665180|EXPERIMENTAL|Primary knee arthroplasty|Questionnaires
61938097|NCT05089162|EXPERIMENTAL|Patients with chronic HF with reduced ventricular ejection fraction coming for scheduled day|
62136785|NCT05856084|PLACEBO_COMPARATOR|Placebo group in adults aged 30 to 49 years|Participants aged 30 to 49 years will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
62136786|NCT05856084|EXPERIMENTAL|Low dose vaccine group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62333125|NCT00226681|ACTIVE_COMPARATOR|2|
62333126|NCT02302794|ACTIVE_COMPARATOR|open surgery|Conventional procedure
62333127|NCT02302794|EXPERIMENTAL|laparoscopic surgery|Minimum invasive procedure
62333128|NCT00004285|ACTIVE_COMPARATOR|Standard dose, low flux hemodialysis|
62333129|NCT00004285|EXPERIMENTAL|Standard dose, high flux hemodialysis|
62333130|NCT00004285|EXPERIMENTAL|High dose, low flux hemodialysis|
62333131|NCT00004285|EXPERIMENTAL|High dose, high flux hemodialysis|
62333132|NCT03700476|EXPERIMENTAL|Sintilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
62694793|NCT02999659||Control group|The control group implies patients with non-acute cerebral disease (e.g. cerebral aneurysm without symptoms). The pupilometer data are once collected during ambulant routine examination. The patients do not undergo any further study related examinations.
62694794|NCT02999659||Treatment group|The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
62694795|NCT06638008|EXPERIMENTAL|group will receive placental growth factor injection|
61938098|NCT02966873|EXPERIMENTAL|N-Acetylcysteine (NAC) Treatment Group|"Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication at a time from the study physician or the study coordinator. The study medication provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
61938099|NCT02966873|PLACEBO_COMPARATOR|Placebo Group|"Participant will receive 12 weeks of inactive placebo comparator daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication (placebo) at a time from the study physician or the study coordinator. The study medication (placebo) provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
61938100|NCT04102670|EXPERIMENTAL|Treatment|Subjects will receive a combination of Ultherapy, Xeomin, Beletero Balance, Dilute Radiesse and Neocutis MicroFirm Face and Neck Cream
61938101|NCT02623920|EXPERIMENTAL|Brentuximab, Bendamustine, Rituximab|Brentuximab Vedotin in Combination with Bendamustine and Rituximab
61938102|NCT03722771|EXPERIMENTAL|lavender oil group (A)|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to surgery.~Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)"
61938103|NCT03722771|SHAM_COMPARATOR|control group (B)|No application of lavender oil, prior to surgery. Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)
61938104|NCT04228783|EXPERIMENTAL|Active Vaccine: Group 1 (Ad26.ZEBOV-Lot A, MVA-BN-Filo-Lot 1)|Participants will receive Intramuscular injection (0.5 milliliter \[mL\]) of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5\*10\^10 viral particle(s) \[vp\], Lot A) on Day 1, followed by Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1\*10\^8 infectious unit(s) \[Inf U\], Lot 1) on Day 57.
61938105|NCT04228783|EXPERIMENTAL|Active Vaccine: Group 2 (Ad26.ZEBOV-Lot B, MVA-BN-Filo-Lot 2)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot B) on Day 1, followed by MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 2) on Day 57.
61938106|NCT04228783|EXPERIMENTAL|Active Vaccine: Group 3 (Ad26.ZEBOV-Lot C, MVA-BN-Filo-Lot 3)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot C) on Day 1, followed by MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 3) on Day 57.
61938107|NCT04228783|PLACEBO_COMPARATOR|Control Vaccine: Group 4 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9 percent \[%\] saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57.
61938108|NCT04228783|EXPERIMENTAL|Booster Cohort: Group 5 (Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, a single Lot) on Day 1, followed by MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, a single Lot) on Day 57 and a booster dose of Ad26.ZEBOV (at a dose of 5\*10\^10 vp, a single Lot) 4 months after Dose 2 (on Day 177).
61938109|NCT04228783|PLACEBO_COMPARATOR|Booster Cohort: Group 6 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9% saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57 and a booster dose of matching placebo on Day 177.
61938110|NCT03312998|EXPERIMENTAL|Xrays|
61938111|NCT05199493|EXPERIMENTAL|Angiotensin II|Intravenous infusion of max. 80 ng/kg/min Angiotensin II (titrated for each individual patient by effect) over 12 h after start of infusion
61938112|NCT05199493|PLACEBO_COMPARATOR|Control|Intravenous infusion placebo (matched infusion volume) over 12 h after start of infusion
61938113|NCT01436006||CT scan|patient with cancer
61938114|NCT05548309|ACTIVE_COMPARATOR|High flow nasal cannula|High flow nasal cannula (HFNC) was inserted through nasal prongs (Fisher \& Paykel Healthcare, Auckland, New Zealand) . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) .
61938115|NCT05548309|ACTIVE_COMPARATOR|oxygen face mask|Simple oxygen face mask was applied to patients starting with flow rate 6L/min .
61938116|NCT05788653|ACTIVE_COMPARATOR|Thiele Group|The group will be given Thiele Massage twice a week for 4 weeks. Thiele massage will be done with a stripping motion in the direction of the pelvic floor muscle fibers. Approximately 15-20 repetitions will be applied to each of the pelvic floor muscle groups for 30 minutes.
61938117|NCT05788653|ACTIVE_COMPARATOR|Transverse Friction Group|The group will be given Transverse Friction Massage twice a week for 4 weeks. Transverse friction massage will be applied to each tense muscle group and trigger points for 3-5 minutes, crossing the direction of the pelvic floor muscle fibers. Massage duration is approximately 30 minutes for each session.
62136787|NCT05856084|EXPERIMENTAL|High dose vaccine group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
62694796|NCT06638008|EXPERIMENTAL|group will receive platelet rich plasma injection|
62694797|NCT06638008|NO_INTERVENTION|group with only follow up|
61938118|NCT06403670|ACTIVE_COMPARATOR|Group Dex|Group Dex received 0.5 mcg/kg of dexmedetomidine IV for 10 minutes, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
61938119|NCT06403670|ACTIVE_COMPARATOR|Group Remi|Group RP received remifentanil 0.1 mcg/kg intravenously for 2 minutes, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
61938120|NCT05579925|EXPERIMENTAL|CM310|600 mg + 300 mg, subcutaneous injection, once every two weeks
62694798|NCT02097225|EXPERIMENTAL|Dose level -1 (dabrafenib, trametinib, onalespib)|"Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~There are four dose levels, plus a fallback dose. Dose escalation begins at dose level 1 (starting dose). Fallback dose level -1 is initiated if more than 1 of 6 subjects in dose level 1 (starting dose) develop DLTs.~Dose Level -1 (fallback dose):~* Dabrafenib = 75 mg~* Trametinib = 1 mg~* Onalespib = 180 mg/m\^2"
62694799|NCT02097225|EXPERIMENTAL|Dose level 1 (dabrafenib, trametinib, onalespib)|"Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~There are four dose levels, plus a fallback dose. Dose escalation begins at dose level 1 (starting dose).~Dose Level 1 (starting dose):~* Dabrafenib = 150 mg~* Trametinib = 1 mg~* Onalespib = 180 mg/m\^2"
61938121|NCT02030938|EXPERIMENTAL|SERI® scaffold implanted breasts|"SERI® Surgical Scaffold is a knitted, multifilament, bioengineered, silk mesh. It is mechanically strong, biocompatible, BIOSILK® purified, and long term bioresorbable. SERI® Surgical Scaffold is a sterile, single use only mesh and is supplied as a 10 x 25 cm sheet. SERI® Surgical Scaffold provides immediate physical and mechanical stabilization of a tissue defect through the strength and porous (scaffold like) construction of its mesh. When long term bioresorption occurs and the patient's own tissue replaces the implanted scaffold over time the mechanical integrity of the repair is maintained.~SERI® Surgical Scaffold is indicated for use as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome."
61938122|NCT04629885|EXPERIMENTAL|Oxytocin 400 IU|1mL Oxytocin 400 IU vaginal gel once daily for 12 weeks
61938123|NCT04629885|PLACEBO_COMPARATOR|Placebo|1mL Placebo vaginal gel once daily for 12 weeks
62136788|NCT05856084|ACTIVE_COMPARATOR|Shingrix® group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).
62136789|NCT05856084|PLACEBO_COMPARATOR|Placebo group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
62333133|NCT03700476|ACTIVE_COMPARATOR|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
62333134|NCT02651194|EXPERIMENTAL|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
62333135|NCT00444223|EXPERIMENTAL|fluorine F 18 FEQA + positron emission tomography|
62333136|NCT01745393|EXPERIMENTAL|Clinic Quality Improvement + Behavioral Counseling|This multilevel intervention includes advice and a referral from a pediatrician, behavioral counseling by study staff, and community systems navigation, all designed to reduce pediatric secondhand smoke exposure. Over the course of 12 weeks participants receive a home visit designed to orient them to the program and trained health counselors provide multiple individualized phone counseling sessions designed to build coping skills, urge management skills, and self-efficacy. Counseling also includes assistance with goal setting and navigation of local resources.
62333137|NCT01745393|ACTIVE_COMPARATOR|Clinic Quality Improvement + Attention Control|The attention control intervention parallels the format of the experimental group but focuses on family nutrition information. The intervention includes a home visit to orient the participant to the program and multiple phone counseling sessions conducted by a trained health counselor.
62333138|NCT05430451|EXPERIMENTAL|Brief cessation advice (AWARD) + simple physical exercise with Instant Messaging (IM) support|The integrated intervention of brief cessation advice (AWARD), and simple physical exercise practices with Instant Messaging (IM) support for craving management
62333139|NCT05430451|ACTIVE_COMPARATOR|Brief cessation advice (AWARD)|Brief cessation advice (AWARD)
62333140|NCT02932722|SHAM_COMPARATOR|Control|Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).
62333141|NCT02932722|ACTIVE_COMPARATOR|Propofol|Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.
62333142|NCT02932722|ACTIVE_COMPARATOR|Sevoflurane|Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.
62333143|NCT05803889||EC + Tax group|For the EC + Taxol arm, patients will have five visits during (neo)adjuvant chemotherapy: before the start of chemotherapy (evaluation 1), before the second EC administration (evaluation 2), before the third EC administration (evaluation 3), at the end of EC sessions and before the start of Tax (evaluation 4), and at the end of Tax administration (end of chemotherapy) (evaluation 5).
62136790|NCT00787969|EXPERIMENTAL|Treatment (rituximab, cladribine, temsirolimus)|Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62136791|NCT01630226|EXPERIMENTAL|Neoadjuvant Cisplatin Chemotherapy|
62136792|NCT01428934||Intermediate risk population|Population aged between 35 to 74 years who have an intermediate cardiovascular risk, defined as coronary risk between 5% -15% at 10 years according to the Framingham adapted risk equation or vascular mortality risk between 3-5% at 10 years according to the SCORE equation \[27\].
62490903|NCT03946787|PLACEBO_COMPARATOR|TAU (Treatment as Usual)|"Patients will receive the Treatment as Usual. TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service. Patients are expected to be euthymic (or with subsyndromal symptoms) with the same medication for at least 3 months.~Although the medications used by patients are relevant and taken into account in future analyzes, our group will not interfere with drug treatment. Thus, patients who require any type of drug intervention will be considered losses."
62333144|NCT05803889||Trastuzumab group|Patients in the Trastuzumab arm will be assessed only once at the end of treatment (on the same evaluation as the CE + Tax arm) to allow comparison with the fifth evaluation in the CE + Tax arm.
62333145|NCT02053220|EXPERIMENTAL|Intra-tumoural cohort|
62333146|NCT02053220|EXPERIMENTAL|Intra-venous cohort|
62694800|NCT02097225|EXPERIMENTAL|Dose level 2 (dabrafenib, trametinib, onalespib)|"Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~There are four dose levels, plus a fallback dose. Dose escalation begins at dose level 1 (starting dose).~Dose Level 2:~* Dabrafenib = 150 mg~* Trametinib = 2 mg~* Onalespib = 180 mg/m\^2"
61938124|NCT06533748|EXPERIMENTAL|SJALL23H Treated Patients|"All eligible patients receive intervention according to the Detailed Description section with the following:~Induction: Dexamethasone, Vincristine, Inotuzumab, Blinatumomab, Dasatinib, IT MHA.~Early Post Induction: Cyclophosphamide, Cytarabine, Inotuzumab, Methotrexate, IT MHA, Dasatinib, Blinatumomab, 6-mercaptopurine, Dexamethasone, Vincristine, Daunorubicin, Calaspargase.~Maintenance: Dexamethasone, Vincristine, Methotrexate, 6-mercaptopurine, Thioguanine, Dasatinib, IT MHA."
61938125|NCT00395772|ACTIVE_COMPARATOR|Arm 4|
62333147|NCT05220228|EXPERIMENTAL|Prucalopride|Prucalopride - 1mg for 2 days, and then increased to 2mg for a further 5-8 days. Testing will occur on day 7 ideally, but may take place up to and including day 10.
61938126|NCT00395772|EXPERIMENTAL|Arm 1|
61938127|NCT00395772|EXPERIMENTAL|Arm 2|
62136793|NCT03005119|EXPERIMENTAL|PTL201|Up to 30 mg/day (30 mg THC, 10 mg CBD), recommended to be administered after meals and if required before bed time. Patients will be instructed not to take more than 10 mg (two capsules) at a single dosing session.
62136794|NCT03005119|PLACEBO_COMPARATOR|Placebo|PTL201 and placebo capsules will be identical in appearance
62333148|NCT05220228|PLACEBO_COMPARATOR|Placebo|Placebo (sucrose / lactose) for 7-10 days
62333149|NCT04817085|EXPERIMENTAL|Visant Medical Canalicular Plug|Bilateral placement of the Visant Canalicular Plug inserted on Day 1
62333150|NCT04817085|ACTIVE_COMPARATOR|Commercially available canalicular plug|Bilateral placement of commercially available canalicular plug inserted on Day 1
62333151|NCT01847833||Patients with brain tumors|
61938128|NCT00395772|EXPERIMENTAL|Arm 3|
61938129|NCT03391310|EXPERIMENTAL|Honey dressing group|In this group, the wound will be cleaned with normal saline and then honey (medicated ) will be applied to cover the wound surface. The dressing will be changed once soiled (alternate day in most cases). The dressing will be applied for a maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
61938130|NCT03391310|NO_INTERVENTION|Standard treatment group|In this group, the wound will be first cleaned with 'povidone iodine' and then covered with hydrocolloid dressing changed alternate day for maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
62333152|NCT02388529|EXPERIMENTAL|Low dose|
62333153|NCT02388529|EXPERIMENTAL|Intermediate dose|
62333154|NCT02388529|EXPERIMENTAL|High dose|
62333155|NCT02388529|PLACEBO_COMPARATOR|Placebo|
62333156|NCT05884411|EXPERIMENTAL|LBBAP|This arm will investigate improvement in cardiac function following placement of the LBBA pacing electrode in half the patients.
62333157|NCT05884411|EXPERIMENTAL|Cardiac MRI with devices|This arm will investigate the feasibility of cardiac MRI to be used to measure cardiac function in patients with cardiac devices.
62333158|NCT01321294|ACTIVE_COMPARATOR|Nissen fundoplication|
62333159|NCT01321294|ACTIVE_COMPARATOR|Toupet fundoplication|
61938131|NCT04724980|EXPERIMENTAL|Adjuvant PRGN-2012|Four PRGN-2012 administrations (on days 1, 15, 43, and 85) via subcutaneous injection.
61938132|NCT04625790|EXPERIMENTAL|Study group|After randomization, this group will take 10 sessions of 1-Hz low frequency rTMS will be applied to the inferior frontal gyrus of the right frontal lobe for 20 minutes during the stroke treatment process before 10 days of speech therapy. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
61938133|NCT04625790|PLACEBO_COMPARATOR|Control group|This group will take 10 sessions of sham rTMS for 20 minutes during the stroke treatment process before 10 days of speech therapy. The sham therapy will consist of positioning the coil on the cranium at the same spot, but without a magnetic stimulation, only with the device open and the sounds will be audible. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
62136795|NCT04763759|EXPERIMENTAL|Dose Level 1- 6mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
62136796|NCT04763759|EXPERIMENTAL|Dose Level 2- 15mg/kg|Randomized 5:2 (TRL1068:placebo) via IV infusion
62136797|NCT04763759|EXPERIMENTAL|Dose Level 3- 30 mg/kg|Randomized 5:2 (TRL1068:placebo) via IV infusion
62136798|NCT05452525|EXPERIMENTAL|Sequence 1|Period 1: Test drug(CKD-379 I) Period 2: Test drug(CKD-379 II) Period 3: Reference drug(D759+D745+D150)
62136799|NCT05452525|EXPERIMENTAL|Sequence 2|Period 1: Test drug(CKD-379 I) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 II)
62333160|NCT03000816|EXPERIMENTAL|Experimental Arm|Patients in this arm will receive a treatment of SBRT for their oligometastatic lesions.
62333161|NCT01871896|EXPERIMENTAL|Weight Gain|Patients who previously underwent bariatric surgery who failed to lose the expected weight or regained weight.
62490904|NCT01694758||Patients with diabetes type 2|
61938134|NCT05133076|ACTIVE_COMPARATOR|Active arm|
62490905|NCT01193387|EXPERIMENTAL|IDeg (M) IM1|
62490906|NCT01193387|EXPERIMENTAL|IDeg (M) IM2|
62490907|NCT02054715|EXPERIMENTAL|Arm I (print educational)|Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
62490908|NCT02054715|EXPERIMENTAL|Arm II (multimedia psychoeducational)|Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
62694801|NCT02097225|EXPERIMENTAL|Dose level 3 (dabrafenib, trametinib, onalespib)|"Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~There are four dose levels, plus a fallback dose. Dose escalation begins at dose level 1 (starting dose).~Dose Level 3:~* Dabrafenib = 150 mg~* Trametinib = 2 mg~* Onalespib = 220 mg/m\^2"
62694802|NCT02097225|EXPERIMENTAL|Dose level 4 (dabrafenib, trametinib, onalespib)|"Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~There are four dose levels, plus a fallback dose. Dose escalation begins at dose level 1 (starting dose).~Dose Level 4:~* Dabrafenib = 150 mg~* Trametinib = 2 mg~* Onalespib = 260 mg/m\^2"
61938135|NCT05133076|PLACEBO_COMPARATOR|Placebo arm|
61938136|NCT02514603|EXPERIMENTAL|Prexasertib|Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
61938137|NCT01497327|EXPERIMENTAL|PSI-352938 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
61938138|NCT01497327|EXPERIMENTAL|PSI-352938 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
61938139|NCT01497327|EXPERIMENTAL|PSI-352938 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
61938140|NCT01497327|EXPERIMENTAL|PSI-7977 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
61938141|NCT01497327|EXPERIMENTAL|PSI-7977 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
61938142|NCT01497327|EXPERIMENTAL|PSI-7977 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
61938143|NCT05168449|NO_INTERVENTION|Control Group|Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, with an access to the previously described mobile application
61938144|NCT05168449|EXPERIMENTAL|Intervention Group|Intervention group will be provided in addition to the usual care, with an access to the mobile application
61938145|NCT06198127|EXPERIMENTAL|Experimental group; combination of core stability exercises and kinesio-taping|combination of core stability exercises and kinesio-taping were used in experimental group
61938146|NCT06198127|ACTIVE_COMPARATOR|Control group; only core stability exercises|only core stability exercises were given to control group
61938147|NCT04587544|EXPERIMENTAL|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
61938148|NCT04587544|NO_INTERVENTION|No Intervention|The participants would not receive Cold Water Intervention. However, they are allowed to received the usual care
61938149|NCT03496571|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
61938150|NCT03496571|EXPERIMENTAL|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
61938151|NCT03496571|EXPERIMENTAL|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
61938152|NCT02570841|ACTIVE_COMPARATOR|Capsaicin|Treatment with Topical High dose Capsaicin
61938153|NCT02570841|PLACEBO_COMPARATOR|Placebo|Treatment with Topical Placebo
61938154|NCT04267003|EXPERIMENTAL|DLPFC Stimulation + Task|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during cognitive task completion.
61938155|NCT04267003|EXPERIMENTAL|DLPFC Stimulation + Rest|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during rest.
61938156|NCT04267003|SHAM_COMPARATOR|Sham Stimulation + Task|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during cognitive task completion.
62490909|NCT00585741|EXPERIMENTAL|2. Head and neck|Imaging with 18F-FLT PET
61938157|NCT04267003|SHAM_COMPARATOR|Sham Stimulation + Rest|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during rest.
61938158|NCT01756053|ACTIVE_COMPARATOR|ABT-089|"During both 10-day study medication periods (Days 1-10 \& Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to active ABT-089 during study medication period 1 will take four 10mg capsules daily (40mg daily) during the 10-day medication period. During study medication period 2, these subjects will take four capsules of the matched placebo capsules."
61938159|NCT01756053|PLACEBO_COMPARATOR|Placebo|"These are matched placebo capsules manufactured by the study drug supplier.~During both 10-day study medication periods (Days 1-10 \& Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to matched placebo during study medication period 1 will take four capsules daily during the 10-day medication period. During study medication period 2, these subjects will take four 10mg capsules (40mg daily) of the active ABT-089 capsules."
61938160|NCT05305339||Group A (Control group)|Singleton pregnancies undergoing elective pre-labour CS at gestational age (34+0 to 40+0) that are otherwise healthy.
62490910|NCT00585741|EXPERIMENTAL|3. Lung|Imaging with 18F-FLT PET
62490911|NCT00585741|EXPERIMENTAL|4. prostate|Imaging with 18F-FLT PET
61938161|NCT05305339||Group B (Chronic hypertension)|It means systolic blood pressure of 140 mm Hg or more, a diastolic blood pressure of 90 mm Hg or more, or both, that is diagnosed or present before pregnancy or before 20 weeks of gestation on two occasions at least 4 hours apart. Hypertension that is diagnosed for the first-time during pregnancy and that does not resolve in the typical postpartum period also is classified as chronic hypertension
61938162|NCT05305339||Group C (Gestational hypertension)|It is usually diagnosed when systolic blood pressure is 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more, or both, on two occasions at least 4 hours apart after 20 weeks of gestation, in a woman with a previously normal blood pressure. Gestational hypertension is considered severe when the systolic level reaches 160 mm Hg or the diastolic level reaches 110 mm Hg or both.
62333162|NCT05905211||Infected COVID-19|Balance, functional mobility, activities of daily living, quality of life, fear of COVID-19, depression evaluated
62694803|NCT02956148|EXPERIMENTAL|Radioligand [18F]MNI-659|"All subjects will receive a single intravenous dose of the radioligand \[18F\]MNI-659 (investigational medicinal product \[IMP\]) and undergo PET imaging.~The radioligand \[18F\]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
61938163|NCT05305339||Group D (Preeclampsia)|Women with PE fulfilled the criteria if they had hypertension (\> 140/90 mmHg) and proteinuria (\> 0.3 gm/day or ≥ +1 by dipstick urine analysis at ≥ 20 weeks of gestation or protein-to-creatinine ratio of 0.30 or more). If no proteinuria, hypertension associated with thrombocytopenia, renal or liver impairment, or pulmonary edema was sufficient to diagnose PE as per ACOG Practice Bulletin No .202
61938164|NCT05734833|EXPERIMENTAL|Probiotic|Participants in this study arm will be receiving a 28-day supply of probiotic.
61938165|NCT05734833|PLACEBO_COMPARATOR|Placebo|Participants in this study arm will be receiving a 28-day supply of placebo.
61938166|NCT00859183|ACTIVE_COMPARATOR|1|cumulative loading dose of 8 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
61938167|NCT00859183|ACTIVE_COMPARATOR|2|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
61938168|NCT00859183|PLACEBO_COMPARATOR|3|oral placebo
61938169|NCT02781779|ACTIVE_COMPARATOR|Silverlon®|Subjects randomized to this arm will receive Silverlon® dressing postoperative.
61938170|NCT02781779|ACTIVE_COMPARATOR|AQUACEL® AG|Subjects randomized to this arm will receive AQUACEL® AG dressing postoperative.
61938171|NCT00089856|OTHER|2|Standard of care - chemotherapy
61938172|NCT00089856|EXPERIMENTAL|1|Immunotherapy
62136800|NCT05452525|EXPERIMENTAL|Sequence 3|Period 1: Test drug(CKD-379 II) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 I)
62136801|NCT05452525|EXPERIMENTAL|Sequence 4|Period 1: Test drug(CKD-379 II) Period 2: Test drug(CKD-379 I) Period 3: Reference drug(D759+D745+D150)
62136802|NCT05452525|EXPERIMENTAL|Sequence 5|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 I) Period 3: Test drug(CKD-379 II)
62136803|NCT05452525|EXPERIMENTAL|Sequence 6|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 II) Period 3: Test drug(CKD-379 I)
62136804|NCT03445364|ACTIVE_COMPARATOR|Low coronary injection-pressure, 200 psi|"Patients with STEMI who undergo Primary PCI with the use of low intracoronary dye injection pressure (of 200 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
62333163|NCT05905211||Non-Infected COVID-19|Balance, functional mobility, activities of daily living, quality of life, fear of COVID-19, depression evaluated
62333164|NCT04070768|EXPERIMENTAL|Gemtuzumab Ozogamicin(GO) + Venetoclax|Gemtuzumab Ozogamicin(GO) + Venetoclax
62333165|NCT05781815|ACTIVE_COMPARATOR|DHS|patients with trochanteric fracture treated with DHS
62333166|NCT05781815|ACTIVE_COMPARATOR|DHS with Trochanteric stabilizing plate|patients with trochanteric fracture treated with DHS with trochanteric stabilizing plate
62333167|NCT01294891||Control|Age matched healthy subjects
62333168|NCT01294891||Sickle Cell Patients|Patients with established SCD
61938173|NCT04426201|EXPERIMENTAL|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
61938174|NCT04426201|PLACEBO_COMPARATOR|Saline control|Intramuscular (IM) placebo (normal saline) at the same frequency
61938175|NCT05792423|EXPERIMENTAL|24 healthy adult volunteers|
61938176|NCT05241483||fever|Remote patient monitoring. fever values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
61938177|NCT05241483||pulse|Remote patient monitoring. pulse values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
61938178|NCT05241483||blood pressure|Remote patient monitoring. Blood pressure values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
61938179|NCT05241483||oxygen saturation|Remote patient monitoring. oxygen saturationvalues recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
61938180|NCT05241483||glucose|Remote patient monitoring. glucose values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
61938181|NCT00052780|EXPERIMENTAL|Treatment (temozolomide, O6-benzylguanine)|See Detailed Description
61938182|NCT01770028||Intervention partners|Partners of pregnant women randomized to lifestyle intervention. Note: There is no intervention in partners of pregnant women.
62333169|NCT01294891||Paroxysmal Nocturnal Hemoglobinuria patients|Patients with PNH
62333170|NCT00138034|ACTIVE_COMPARATOR|Percutaneous coronary intervention (PCI)|Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months
62333171|NCT00138034|OTHER|Dual antiplatelet therapy|Aspirin and clopidogrel for at least 6 months
62333172|NCT01152164||rectal cancer patients|
62694804|NCT06210893|ACTIVE_COMPARATOR|Conventional simple palpation|The cricoid cartilage is located with simple palpation.
62490912|NCT00585741|EXPERIMENTAL|5. esophagus|Imaging with 18F-FLT PET
62333173|NCT04069793|ACTIVE_COMPARATOR|Home Trial Condition A|Subject will use a pattern recognition controlled prosthesis that includes a powered wrist rotation, passive wrist flexion/extension, and a single DOF powered hand.
62333174|NCT04069793|EXPERIMENTAL|Home Trial Condition B|Subject will use at pattern recognition controlled prosthesis that includes a powered wrist rotation, powered flexion/extension and a single DOF powered hand.
62333175|NCT02284958|ACTIVE_COMPARATOR|Standard/Control group|Each participant will receive a one-off individualized educational session regarding the management of chronic low back pain with a Physical Therapist: includes a physical examination, standardized advice \& provision of the 'Back Book'.
62333176|NCT02284958|EXPERIMENTAL|Walking group|Each participant will receive a one-off educational session as per standard/control group followed by a 12 week graded, individually tailored, pedometer driven walking programme given by a Physical Therapist. Participants will be monitored each week and provided with encouragement and advice to increase the number of steps taken each day.
62333177|NCT03927937|EXPERIMENTAL|AUTOTRANSPLANTATION TOOTH|
62333178|NCT00682916|ACTIVE_COMPARATOR|1|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
62333179|NCT00682916|PLACEBO_COMPARATOR|2|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
62333180|NCT05685641|EXPERIMENTAL|Intervention group|All enrolled patients will be included in this arm of the study, patients will be administered all rapid diagnostic tests as part of their diagnostic work-up (this will constitute the main intervention of the study)
62333181|NCT06224699|EXPERIMENTAL|Test group|Use of toothpaste with sodium carbonate 67%
62333182|NCT06224699|PLACEBO_COMPARATOR|Control|Use of toothpaste without sodium carbonate 67%
62333183|NCT02973841|EXPERIMENTAL|Sono-ease group|insertion IJV catheter using sono-ease device
62333184|NCT03176940|EXPERIMENTAL|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
61938183|NCT01770028||Standard care partners|Partners of pregnant women randomized to Standard Care. Note: There is no intervention in partners of pregnant women.
61938184|NCT03182803|EXPERIMENTAL|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
61938185|NCT00003927|EXPERIMENTAL|High Dose chemotherapy followed by cell rescue|Doxorubicin, cyclophosphamide, Taxol, amifostine
61938186|NCT01499069|EXPERIMENTAL|Antimuscarinic agents|
61938187|NCT02159612||FSHD|A cohort of adult danish patients with facioscapulohumeral muscular dystrophy is invited to perform a MRI scan.
61938188|NCT06319638|EXPERIMENTAL|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
61938189|NCT06319638|PLACEBO_COMPARATOR|Rehabilitation therapy+placebo block|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
61938190|NCT03418623|EXPERIMENTAL|GET73|GET73 is administered at the dose of 300 mg t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of GET73: 3 capsules of GET73 on the first day of the related phase, according to randomization, and 2 capsules on the second day of each phase.
61938191|NCT03418623|PLACEBO_COMPARATOR|Placebo|Placebo is administered t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of Placebo: 3 capsules of Placebo on the first day of the related phase, according to randomization, and 2 capsules on the second day.
61938192|NCT04128371|EXPERIMENTAL|Active treatment|Participants with episodic angioedema with eosinophilia (EAE) received mepolizumab 700 mg intravenously monthly for three doses.
61938193|NCT05787288|EXPERIMENTAL|Test Group|Nebulized Mesenchymal Stem Cell Exosomes-derived extracellular vesicles twice a day (BID) for 5 days
62136805|NCT03445364|ACTIVE_COMPARATOR|High coronary injection-pressure,550 psi|"Patients with STEMI who undergo Primary PCI with the use of higher intracoronary dye injection pressure (of 500 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
62136806|NCT01108003|EXPERIMENTAL|Arm I|Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity.
62136807|NCT01108003|PLACEBO_COMPARATOR|Arm 2|Patients receive mango juice alone.
62333185|NCT03176940|EXPERIMENTAL|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
62490913|NCT00585741|EXPERIMENTAL|1.CNS|Imaging with 18F-FLT PET
62490914|NCT03284138|ACTIVE_COMPARATOR|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
62490915|NCT03284138|SHAM_COMPARATOR|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
62490916|NCT01800838|EXPERIMENTAL|Treatment (silicon phthalocyanine 4 and PDT)|Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
62490917|NCT03578822|EXPERIMENTAL|Group A|Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent
62490918|NCT03578822|OTHER|Group B|rhPro-UK simulation agent and Aspirn
62490919|NCT00438633||Early Therapy|Subjects who begin therapy immediately after diagnosis of injury.
62490920|NCT00438633||Late Therapy|Subjects who delay therapy for 3 weeks after diagnosis of injury.
62490921|NCT03141853|EXPERIMENTAL|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
62490922|NCT03141853|PLACEBO_COMPARATOR|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
61938194|NCT05787288|SHAM_COMPARATOR|Control Group|Nebulized saline solution twice a day (BID) for 5 days
61938195|NCT04906460|EXPERIMENTAL|WVE-N531|
62490923|NCT02455947|EXPERIMENTAL|Inquiry Based Stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie.It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
62490924|NCT02455947|NO_INTERVENTION|Control group|A non interventional group/ The participants completed questionnaires before and after the intervention.
62490925|NCT03028792|EXPERIMENTAL|Attention Modification Training|Attention Modification Program Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral stimuli.
62490926|NCT03028792|SHAM_COMPARATOR|Attention Control Training|Placebo Comparator: Attention Control Condition Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral stimuli or the threat stimuli.
62490927|NCT03257228||oral lichen planus and diabetes mellitus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
61938196|NCT03207893|EXPERIMENTAL|GEM+CGM|GEM lifestyle modification \& continuous glucose monitoring
61938197|NCT03207893|ACTIVE_COMPARATOR|Routine Care|Subject's current t2d treatment
61938198|NCT05273996|OTHER|Depressed|Subjects receive FDA-approved antidepressants
62333186|NCT03176940|EXPERIMENTAL|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
62333187|NCT03176940|EXPERIMENTAL|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
62333188|NCT03176940|EXPERIMENTAL|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
62490928|NCT03257228||oral lichen planus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
62490929|NCT03257228||healthy mucosa|Samples of healthy mucosa underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking mucosa samples.
62490930|NCT03811977|EXPERIMENTAL|Test group|Test group will receive investigational product - lutein syrup (2 mg/mL; daily dose 20 mg). Participants in this group will test continuous administration of investigational product for 12 weeks.
62490931|NCT03811977|PLACEBO_COMPARATOR|Placebo group|Placebo group will receive placebo product - placebo syrup (lutein 0 mg/mL; daily dose 0 mg). Continuous administration of placebo product for 12 weeks.
62694805|NCT06210893|EXPERIMENTAL|Upwards laryngeal handshake technique|The cricoid cartilage is located with upwards laryngeal handshake technique.
61938199|NCT05853120|ACTIVE_COMPARATOR|Doxycycline 100 mg|Doxycycline 100mg Participants will receive the first assigned dose of Doxycycline at the clinic on days 0 and 3 at the clinic. The other three doses of the medication will be taken at home on days 7 and 1
61938200|NCT05853120|ACTIVE_COMPARATOR|Doxycycline 200 mg|Doxycycline - 200 mg Participants will receive the first assigned dose of Doxycycline at the clinic on days 0 and 3 at the clinic. The other three doses of the medication will be taken at home on days 7 and 10
61938201|NCT05967000||Women at midlife|Women aged 45-65 years with risk factors or pre-existing CVD
61938202|NCT03815643|EXPERIMENTAL|Avelumab|
61938203|NCT01348607|EXPERIMENTAL|Arm I - methylphenidate hydrochloride|Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
61938204|NCT01348607|EXPERIMENTAL|Arm II -modafinil|Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
61938205|NCT01348607|PLACEBO_COMPARATOR|Arm III placebo|Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
61938206|NCT05233293|EXPERIMENTAL|SpyGlass group|ERCP plus SpyGlass plus RFA group
61938207|NCT05233293|ACTIVE_COMPARATOR|Cytobrush Group|ERCP plus Cytobrush plus RFA group
61938208|NCT03143543|EXPERIMENTAL|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
62333189|NCT03176940|EXPERIMENTAL|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
62333190|NCT03740841|OTHER|LUNII|The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
62333191|NCT03740841|NO_INTERVENTION|Without LUNII|Usual pre-operative visit.
62490932|NCT04560231|EXPERIMENTAL|Group intervene with Remdesivir|Review effect of Remdesivir as clinical trial among hospitalized patients with COVID-19 infection. 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
62490933|NCT05359965|EXPERIMENTAL|CPAP|Subjects randomized to the treatment arm, will receive continuous positive airway pressure (CPAP) while sleeping via an autoPAP device for 4-8 weeks.
61938209|NCT03143543|PLACEBO_COMPARATOR|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
61938210|NCT03143543|EXPERIMENTAL|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
61938211|NCT03143543|PLACEBO_COMPARATOR|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
62490934|NCT05359965|NO_INTERVENTION|No CPAP|Subjects assigned to the no CPAP group will not have any intervention for a 4-8 week period.
62490935|NCT03069976|EXPERIMENTAL|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
62490936|NCT02691676|EXPERIMENTAL|Plasmalyte|Arm 1: Plasmalyte in 5% glucose infusion solution (PL), manufactured by Baxter Healthcare as slightly alkalizing (Na+ 140; K+ 5.0; Mg2+ 1.5; Cl- 98; acetate 27; gluconate 23)
61938212|NCT05960942|EXPERIMENTAL|propofol-esketamine|
61938213|NCT05960942|ACTIVE_COMPARATOR|propofol-sufentanil|
62136808|NCT01874964|EXPERIMENTAL|Methadone Maintenance|Participants assigned to Arm 1 will be maintained on ther pre-incarceration methadone dosage during short term incarceration (6 months or less) and will be actively transferred back to their community methadone clinic upon release from incarceration. Additionally, the study will pay for the cost of methadone maintenance treatment for 10 weeks after re-enrollment post release.
62136809|NCT01874964|ACTIVE_COMPARATOR|Methadone Detoxification|Individuals assigned to Arm 2 will undergo methadone detoxification as is standard procedure at the Rhode Island Department of Corrections. They will receive active assistance with returning to their home methadone clinic upon release from incarceration and 10 weeks financial assistance to pay for treatment.
62136810|NCT01267370|ACTIVE_COMPARATOR|Soy polysaccharide fiber|Dietary fiber for treatment of chronic constipation in children
62136811|NCT01267370|PLACEBO_COMPARATOR|purified soy extract, with no fiber)|blinded control group
62136812|NCT04004494|EXPERIMENTAL|3D Reconstruction|Chest contrast-enhanced computed tomography will be performed preoperatively, and 3-dimensional reconstruction will be formed based on the data of chest CT. Video-assisted segmentectomy will be performed guided by the image of 3-dimensional CT. IPS-lung software (Shenzhen Yorktal Digital Medical Imaging Technology Company, Shenzhen, China) will be used preoperatively to construct a 3D-image to ascertain the position and structure of targeted segmental blood vessels and bronchi.
62136813|NCT04004494|NO_INTERVENTION|Chest computed tomography|Chest contrast-enhanced computed tomography will be performed preoperatively. Video-assisted segmentectomy will be performed based on the image of preoperative chest CT
62136814|NCT03580200|EXPERIMENTAL|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
62136815|NCT03580200|NO_INTERVENTION|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
62136816|NCT02387658||final TLG </=11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) \< 11 mmHg regardless if revascularization is done or not.
62136817|NCT02387658||final TLG > 11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) \> 11 mmHg regardless if revascularization is done or not.
62136818|NCT03960099|ACTIVE_COMPARATOR|Pictograph in Banner and Verification Alert|Patient Pictograph displayed in the banner (at the top of the screen) AND Pictograph displayed in a verification alert when placing electronic orders.
62136819|NCT03960099|NO_INTERVENTION|No Pictograph|No patient Pictographs displayed in the electronic health record.
62136820|NCT04505371|NO_INTERVENTION|Control - Standard Care|The control intervention is referral to standard evidence-based cessation services available nationally to Veterans, including the National VA Quitline and SmokefreeVET texting program.
62490937|NCT02691676|ACTIVE_COMPARATOR|Ringerfundin|Arm 2: Ringerfundin infusion solution (RF), manufactured by B. Braun as acid-base neutral (Na+ 145; K+ 4.0; Mg2+ 1.0; Ca2+ 2.5; Cl- 127; acetate 24; malate 5.0).
61938214|NCT01039974|EXPERIMENTAL|Cohorts 1-2|Cohorts 1 and 2 will complete both periods Period 1 GSK962040 single dose Period 2 Ketoconazole repeat dose (10 days), GSK962040 single dose
61938215|NCT04456101||Control group|healthy individuals without COVID-19
61938216|NCT04456101||Severe/Critical COVID-19 rehabilitation group|①Individuals recovering from Severe/Critical COVID-19
61938217|NCT04456101||mild/moderate COVID-19 rehabilitation group|Individuals recovering from mild/moderate COVID-19
61938218|NCT04456101||asymptomatic COVID-19 rehabilitation group|Asymptomatic COVID-19 individuals with laboratory test for SRARS-COV2 turning negative
62136821|NCT04505371|EXPERIMENTAL|Intervention - Wellness Intervention for Smokers with HIV|The experimental WISH intervention is an HIV-specific comprehensive wellness program designed to offer integrated phone and text counseling regardless of readiness to quit.
62136822|NCT06247241|EXPERIMENTAL|VMB-100 administration|intrasphincteric injection of VMB-100 in the urethra sphincter
62136823|NCT03160521|EXPERIMENTAL|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
62136824|NCT03160521|EXPERIMENTAL|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
62136825|NCT03160521|PLACEBO_COMPARATOR|Placebo|Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
62136826|NCT06360133|EXPERIMENTAL|VVN001|VVN001 Ophthalmic Solution, 5%
61938219|NCT00954304|EXPERIMENTAL|1mg group|Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
62333192|NCT04087421|EXPERIMENTAL|Transanal irrigation|Participants receiving TAI will irrigate once/day with stepwise volumes; 1. month 150 ml, 2. month 300 ml, and 3. month 500 ml.
62333193|NCT04087421|ACTIVE_COMPARATOR|Glycerol suppositories|Participants treated with glycerol suppositories will administer one glycerol suppository once/day.
62333194|NCT03032185|ACTIVE_COMPARATOR|Active TENS|Active TENS, 10 Hz/200 μs
62333195|NCT03032185|SHAM_COMPARATOR|Not Active TENS|Sham TENS
62333196|NCT03076047||end tidal CO2 (ETCO2) monitoring|We will continuously record capnography data from the patients while they are in the post-anesthesia care unit (PACU). Study personnel will visit each patient while the patient is in the PACU to promote compliance with continuous CO2 monitoring.
62333197|NCT00905307|EXPERIMENTAL|1|OPC-34712 0.25 mg arm
62333198|NCT00905307|EXPERIMENTAL|2|OPC-34712 low-dose arm
62333199|NCT00905307|EXPERIMENTAL|3|OPC-34712 mid-dose arm
62333200|NCT00905307|EXPERIMENTAL|4|OPC-34712 high-dose arm
62333201|NCT00905307|PLACEBO_COMPARATOR|5|
61938220|NCT00954304|EXPERIMENTAL|5mg group|Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15
61938221|NCT00954304|EXPERIMENTAL|10mg group|Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
61938222|NCT00954304|EXPERIMENTAL|15mg group|Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
61938223|NCT00954304|EXPERIMENTAL|60mg group|Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
61938224|NCT02979197|EXPERIMENTAL|Amlodipine+Celecoxib|OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days
61938225|NCT02979197|ACTIVE_COMPARATOR|Amlodipine+Placebo|OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
62136827|NCT06360133|PLACEBO_COMPARATOR|Vehicle|VVN001 Ophthalmic Solution, Vehicle
62136828|NCT04162457|EXPERIMENTAL|Stevia beverage|Participants receive 4 study beverages in the 4 imaging sessions in randomised and counterbalanced order.
62136829|NCT04162457|EXPERIMENTAL|Glucose beverage|330 ml of water with glucose (equal sweetness with the stevia beverage)
62136830|NCT04162457|EXPERIMENTAL|Maltodextrin beverage|330 ml of water with maltodextrin (equal amount of calories as the glucose beverage)
62136831|NCT04162457|PLACEBO_COMPARATOR|Water|330 ml water
62136832|NCT03554083|EXPERIMENTAL|Arm A - CLOSED (vemurafenib, cobimetinib, atezolizumab)|"Patients receive vemurafenib PO BID on days 1-28 and cobimetinib PO QD on days 1-21. Patients also receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15 of cycles 2 and 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
62136833|NCT03554083|EXPERIMENTAL|Arm B - CLOSED (cobimetinib, atezolizumab)|Patients receive cobimetinib as in Arm A and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62136834|NCT03554083|EXPERIMENTAL|Arm C (atezolizumab, tiragolumab)|Patients with BRAF wild-type or BRAF mutant melanoma receive atezolizumab IV over 30-60 minutes and tiragolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62136835|NCT01271309||Acute Myocardial Infarction patients|Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
62136836|NCT06251674|EXPERIMENTAL|long-axis group|The patients in the long-axis group received one session of ultrasound-guided long-axis needle release of transverse carpal ligament.
62136837|NCT06251674|ACTIVE_COMPARATOR|short-axis group|The patients in the short-axis group received one session of ultrasound-guided short-axis needle release of transverse carpal ligament.
62136838|NCT03660618|OTHER|Clinic Subjects|cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.
61938226|NCT02979197|SHAM_COMPARATOR|Placebo+Placebo|Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
62333202|NCT00905307|ACTIVE_COMPARATOR|6|Aripiprazole arm
62333203|NCT02902016|EXPERIMENTAL|Lactase expression induction by GED|
62333204|NCT02388061|EXPERIMENTAL|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds).
62333205|NCT02388061|ACTIVE_COMPARATOR|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
62333206|NCT06093035||patients with neurogenic bladder|Female patients of childbearing age with neurogenic bladder secondary to spina bifida and multiple sclerosis
62333207|NCT06093035||healthy patients|Female patients of childbearing age without neurogenic bladder secondary to spina bifida and multiple sclerosis
62333208|NCT02577406|EXPERIMENTAL|AG-221 plus Best supportive care (BSC)|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
62333209|NCT02577406|ACTIVE_COMPARATOR|Conventional care regimen (CCR)|Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
62333210|NCT06549023|ACTIVE_COMPARATOR|Single-session panretinal PRP (SS-PRP)|Administration of all panretinal photocoagulation (PRP) treatment in one comprehensive session, typically delivered in a single clinical visit.
62333211|NCT06549023|ACTIVE_COMPARATOR|Multiple-session panretinal PRP (MS-PRP)|Administration of panretinal photocoagulation (PRP) treatment over two separate visits with at least one week apart.
62333212|NCT03136549|PLACEBO_COMPARATOR|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
62333213|NCT03136549|EXPERIMENTAL|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
62333214|NCT03504774|EXPERIMENTAL|Cashew or Shrimp Oral Immunotherapy|Participants, ages 7 to 55 years, inclusive, with an allergy to Cashew or Shrimp.
62333215|NCT06253286|ACTIVE_COMPARATOR|part-time wear|Patients will be instructed to wear the aligner for 16 hours per day, then the aligner going to be changed to the next step according to its numerical order in the software
62333216|NCT06253286|ACTIVE_COMPARATOR|Full-time wear|Patients will be instructed to wear the aligner for 22 hours per day, then the aligner going to be changed to the next step according to its numerical order in the software
62333217|NCT03696069||Patients treated with immunotherapy and BRAF/MEK inhibitors|
62333218|NCT06368687|OTHER|Anorexia nervosa plus autism|The treatment model takes into account the patient's perception disorders. This means e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
62333219|NCT01926054|ACTIVE_COMPARATOR|Acthar Gel 80 IU SC BIW|80 IU administered subcutaneously BIW for 6 months
62333220|NCT01926054|ACTIVE_COMPARATOR|Acthar Gel 80 IU SC TIW|80 IU administered subcutaneously TIW for 6 months
62333221|NCT05916677|EXPERIMENTAL|Patient remediate using the virtual training method|
62333222|NCT05916677|ACTIVE_COMPARATOR|Patient remediate using the traditional training method|
62333223|NCT05428748|EXPERIMENTAL|1S|Participants will consume 1 serving/day of the test product for 28 days.
62333224|NCT05428748|EXPERIMENTAL|2S|Participants will consume 2 servings/day of the test product for 28 days
62333225|NCT05428748|EXPERIMENTAL|3S|Participants will consume 3 servings/day of the test product for 28 days
62333226|NCT05428748|PLACEBO_COMPARATOR|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
62333227|NCT03162783|EXPERIMENTAL|ADX-102 Ophthalmic Solution (0.5%)|
62333228|NCT03162783|EXPERIMENTAL|ADX-102 Ophthalmic Solution (0.1%)|
62333229|NCT03162783|EXPERIMENTAL|ADX-102 Ophthalmic Lipid Solution (0.5%)|
62333230|NCT02484196||Couples|Women, with their partners, referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
62333231|NCT02484196||Women|Women referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
62333232|NCT05279612||neoadjuvant chemoradiotherapy group|preoperative 1 circle chemotherapy(CapeOX) combined with short-course radiotherapy ，Surgical treatment(CME+D3) after four weeks of 2 circle chemotherapy(CapeOX).
62333233|NCT05279612||neadjuvant chemotherapy group|preoperative 3 circle chemotherapy(CapeOX) combined with surgical treatment(CME+D3)
62333234|NCT02680223|ACTIVE_COMPARATOR|Precision tinted lenses|Precision tinted lenses will be provided for one month.
62333235|NCT02680223|SHAM_COMPARATOR|Non-beneficial tinted lenses|Tinted lenses at a colour different from but not easily distinguishable from the precision tinted will be provided for one month.
62333236|NCT02836990|ACTIVE_COMPARATOR|Prevena|Prevena Incision Management System for vascular surgical groin wounds
62333237|NCT02836990|ACTIVE_COMPARATOR|Dermabond|Dermabond for vascular surgical groin wounds
62333238|NCT03577093||ischemic stroke|acute ischemic stroke patients within 6h after stroke onset
62333239|NCT03577093||control|healthy controls
62333240|NCT04730986|EXPERIMENTAL|Intervention Arm|This is a single-arm study with all enrolled patients receiving the same ED GOAL Nursing intervention
62333241|NCT02669004|ACTIVE_COMPARATOR|Intermittent bolus epidural morphine|"Patients who received epidural morphine with patient- controlled intermittent bolus epidural analgesia (PCIEA) represented Group 1. Epidural catheter was inserted by surgeon under direct visualization at the midpoint of the incision and advanced 5-6 cm cephalad to thoracic 4-5 before surgical closure.~Patients received morphine 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion."
62333242|NCT02669004|ACTIVE_COMPARATOR|Continuous epidural morphine|epidural morphine with patient- controlled continuous epidural analgesia (PCCEA) represented Group 2. Infusion the following initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
62333243|NCT04866537||Pregnant women who received a fetal heart ultrasound between 2015 and 2019.|Pregnant women who received a fetal heart ultrasound between 2015 and 2019.
62333244|NCT04800419|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|ACT will be conducted in a group of 10 for each session. The ACT modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
62333245|NCT04800419|EXPERIMENTAL|Mindfulness-based Stress Reduction (MBSR)|MBSR will be conducted in a group of 10 for each session. The MBSR modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
62333246|NCT04800419|NO_INTERVENTION|Control|The subjects in the control group will be assigned in the wait-list where either ACT or MBSR will be provided after the study has been completed.
62333247|NCT02949115|EXPERIMENTAL|70 mL red beetroot juice|70 mL red beetroot juice naturally containing 300 mg nitrate.
62333248|NCT02949115|ACTIVE_COMPARATOR|70 mL placebo drink plus potassium nitrate|70 mL calorie-matched placebo control drink containing 489 mg potassium nitrate to deliver 300 mg nitrate.
62333249|NCT02949115|ACTIVE_COMPARATOR|70 mL red beetroot juice without nitrate|70 mL red beetroot juice per day without nitrate.
62333250|NCT02949115|PLACEBO_COMPARATOR|70 mL placebo drink|70 mL calorie-matched placebo control drink devoid of nitrate, vitamins, minerals, and polyphenols.
62490938|NCT00591760|EXPERIMENTAL|GH|Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy
62490939|NCT00591760|NO_INTERVENTION|Placebo|PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment
61938227|NCT03728530|EXPERIMENTAL|Experimental Group|Deep /breathing exercises including Purse lip, diaphragmatic breathing and powered breathing
61938228|NCT03728530|NO_INTERVENTION|Control Group|The participants from control group did not perform any exercise.
61938229|NCT00876876|PLACEBO_COMPARATOR|Placebo QD or BID|Placebo QD or BID
61938230|NCT00876876|EXPERIMENTAL|Lixivaptan QD or BID|Lixivaptan QD or BID
61938231|NCT04108442|ACTIVE_COMPARATOR|Traditional|
61938232|NCT04108442|EXPERIMENTAL|Virtual|
61938233|NCT00729755|EXPERIMENTAL|Creatine|The subjects with major depressive disorder, treated with creatine in addition to escitalopram
61938234|NCT00729755|PLACEBO_COMPARATOR|Placebo|The subjects with major depressive disorder, treated with placebo in addition to escitalopram
61938235|NCT04263961||COPD GOLD I - II|"Inclusion for mild-moderate COPD patients (n = 100):~* Age between 45-65 years.~* GOLD classification I or II according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC \<0.7) \[2\].~* Cessation of smoking for ≥6 months.~* ≥5 packyears of smoking.~* Absence of asthma.~* Written informed consent."
61938236|NCT04263961||Controls|"Inclusion for healthy controls (n = 100):~* Age between 45-65 years.~* Absence of COPD according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC \<0.7) \[2\].~* Cessation of smoking for ≥6 months.~* ≥5 packyears of smoking.~* Absence of asthma.~* Written informed consent."
61938237|NCT05804474||Intracranial Aneurysms|
61938238|NCT05804474||Normal Vessels|
61938239|NCT01645904||Group 1|Patients participate in audiotaped focus group regarding web-based program, and fill out demographics questionnaire.
61938240|NCT01645904||Group 2|Patients come to Behavioral Research and Treatment Center (BRTC) at MD Anderson to use initial version of My Family Garden website. Completion of Website Analysis and MeasureMent Inventory (WAMMI), and demographics questionnaires.
61938241|NCT01645904||Group 3|Patients use final version of My Family Garden website, and are interviewed which will be audiotaped. Completion of Website Analysis and MeasureMent Inventory (WAMMI), questionnaire and demographics questionnaire.
61938242|NCT04609969|EXPERIMENTAL|Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
61938243|NCT01974154||Cohort I|A. Healthy nonsmokers B. Healthy smokers C. Healthy smokers/quit smoking D. COPD smokers E. COPD smokers/ quit smoking
61938244|NCT01974154||Cohort II|A. Smokers with normal spirometry and normal DLCO B. Smokers, normal spirometry, low DLCO
61938245|NCT04965051|EXPERIMENTAL|IDegAsp group|IDegAsp twice daily
61938246|NCT04965051|ACTIVE_COMPARATOR|basal insulin plus pre-prandial insulin group|basal insulin once or twice daily plus pre-prandial insulin
61938247|NCT01511965|OTHER|traitement A|Lesion 1= graft and lesion 2 = UltraViolet B
61938248|NCT01511965|OTHER|traitement B|Lesion 1 = UltraViolet B and lesion 2 = graft
61938249|NCT05804097|NO_INTERVENTION|Control|Control group
61938250|NCT05804097|EXPERIMENTAL|HBOT 20|Patients receiving 20 sessions of concurrent Hyperbaric oxygen treatment
61938251|NCT05804097|EXPERIMENTAL|HBOT 30|Patients receiving 30 sessions of concurrent Hyperbaric oxygen treatment
61938252|NCT05804097|EXPERIMENTAL|HBOT 40|Patients receiving at least 40 sessions of concurrent Hyperbaric oxygen treatment
61938253|NCT04603716|EXPERIMENTAL|Eccentric Muscle Energy Technique|conventional physical therapy Along with eccentric muscle energy technique
61938254|NCT04603716|EXPERIMENTAL|concentric muscle energy technique|Conventional physical therapy along with concentric muscle energy technique
61938255|NCT02504996|ACTIVE_COMPARATOR|Paracetamol|1 g intravenous paracetamol (Perfalga, Bristol Myers) in 100 ml saline with a rapid infusion.
61938256|NCT02504996|ACTIVE_COMPARATOR|morphine|0.1 mg/kg morphine in 100 ml saline with a rapid infusion.
61938257|NCT02504996|PLACEBO_COMPARATOR|placebo|100 ml saline
61938258|NCT04462185||Prospective Cohort|This is a prospectively enrolling cohort study and 3000 patients (1500 GGO and 1500 solid / semi solid nodules) with radiologic diagnosis of indeterminate pulmonary nodule (5-30 mm) will be recruited. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, a genomic and transcriptomic landscape analysis, at each visit.
61938259|NCT06266312|EXPERIMENTAL|multimodal lifestyle intervention|"A group receiving a multimodal prehabilitation programme consisting of three modalities:~1. MIET during neoadjuvant intravenous chemotherapy infusion~2. HITT and strength training during the last six weeks prior to surgery~3. Optimising nutritional intake throughout the total preoperative period"
61938260|NCT01460589|EXPERIMENTAL|early commencement|Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery
61938261|NCT01460589|ACTIVE_COMPARATOR|conventional commencement|Individuals who initiate the adjuvant chemotherapy after 14 days after surgery
61938262|NCT02670434|EXPERIMENTAL|NK-104-CR|Controlled release NK-104
61938263|NCT02670434|PLACEBO_COMPARATOR|Placebo|Livalo Placebo
61938264|NCT02670434|ACTIVE_COMPARATOR|Livalo® Immediate Release IR|Immediate Release Livalo®
61938265|NCT00586131|ACTIVE_COMPARATOR|Low normal pH (arterial pH 7.36-7.38)|Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
61938266|NCT00586131|ACTIVE_COMPARATOR|High Normal pH (arterial pH 7.44-7.46)|High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved
61938267|NCT01242683|EXPERIMENTAL|Case-Management for Behavior Change|Individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
61938268|NCT01242683|EXPERIMENTAL|Case-Management plus Home Visits|Community health worker lifestyle support for weight loss strategies conducted in participants' homes and neighborhood. Also, receive individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
61938269|NCT01242683|PLACEBO_COMPARATOR|Usual Primary Care|Continuation of usual primary care managed by the participants' usual physician or nurse practitioner source of care.
62490940|NCT04941313|EXPERIMENTAL|Single Dose Escalation-3D229|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
62490941|NCT04941313|PLACEBO_COMPARATOR|Single Dose Escalation- placebo|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
62490942|NCT04941313|EXPERIMENTAL|Repeat Dose-3D229|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
62694806|NCT06373120|EXPERIMENTAL|CorVad|The CorVad percutaneous ventricular assist system will offer intraoperative hemodynamic support during high-risk PCI procedures.
62694807|NCT06373120|ACTIVE_COMPARATOR|VA-ECMO|The VA-ECMO offers intraoperative hemodynamic support during high-risk PCI procedures.
62694808|NCT03559556|EXPERIMENTAL|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
62694809|NCT04576754|EXPERIMENTAL|WB001|
62694810|NCT04576754|SHAM_COMPARATOR|Comparison Condition|
62694811|NCT00088699|EXPERIMENTAL|Ketamine, Then Placebo|Ketamine and placebo infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg.
62694812|NCT00088699|EXPERIMENTAL|Placebo, Then Ketamine|Placebo and Ketamine infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg
62490943|NCT04941313|PLACEBO_COMPARATOR|Repeat Dose-placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
62490944|NCT01569854||statin|
62694813|NCT05430438|EXPERIMENTAL|Group A|Patients will undergo dialysis (4 sessions) with low dialysate sodium (137 mEq/L) and after a 2-week washout period will undergo dialysis (4 sessions) with standard dialysis sodium (140 mEq/L).
62694814|NCT05430438|EXPERIMENTAL|Group B|Patients will undergo dialysis (4 sessions) with standard dialysate sodium (140 mEq/L) and after a 2-week washout period will undergo dialysis (4 sessions) with low dialysis sodium (137 mEq/L).
62694815|NCT06157593|EXPERIMENTAL|NAVA|
62694816|NCT06157593|NO_INTERVENTION|SIMV|
62694817|NCT01522872|EXPERIMENTAL|Monotherapy TH-302 Dose Escalation|
62694818|NCT01522872|EXPERIMENTAL|TH-302 and Dexamethasone Dose Expansion|
62694819|NCT01522872|EXPERIMENTAL|TH-302 Dose Escalation and Dexamethasone with Bortezomib|
62694820|NCT01522872|EXPERIMENTAL|TH-302 Dose Escalation and Dexamethasone with Pomalidomide|
62490945|NCT03891095|EXPERIMENTAL|Intranasal oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)
62490946|NCT03891095|EXPERIMENTAL|L-DOPA|L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)
62490947|NCT03891095|PLACEBO_COMPARATOR|Placebo|Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)
62694821|NCT04603560|EXPERIMENTAL|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
61938270|NCT03845543|EXPERIMENTAL|Luminor-14 paclitaxel eluting balloon|Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
62490948|NCT01888107|EXPERIMENTAL|Risperidone Long-acting Injectable (LAI)|Risperidone LAI will be administered in dosages of 25, 37.5, and 50 mg.
61938271|NCT03260920|EXPERIMENTAL|Low Dose|
61938272|NCT03260920|EXPERIMENTAL|Medium Dose|
61938273|NCT03260920|EXPERIMENTAL|High Dose|
61938274|NCT04408131|EXPERIMENTAL|Homeless people|Blood sample
62490949|NCT02929472|EXPERIMENTAL|Physical Exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
62694822|NCT04603560|EXPERIMENTAL|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
62694823|NCT04603560|NO_INTERVENTION|Control|No intervention will be provided to physicians in the control arm.
62694824|NCT06635642|EXPERIMENTAL|Dichotic Interaural Intensity Difference Training|
62694825|NCT06596187|EXPERIMENTAL|Healthy Participants|To establish the relationship between changes in foot pressure during ankle joint movement, muscle tone, and Post-Activation Depression (PAD).
62694826|NCT06596187|EXPERIMENTAL|PD Patients|To establish the relationship between changes in foot pressure during ankle joint movement, muscle tone, and Post-Activation Depression (PAD).
62694827|NCT06596187|EXPERIMENTAL|SCI Patients|To establish the relationship between changes in foot pressure during ankle joint movement, muscle tone, and Post-Activation Depression (PAD).
61938275|NCT00496509|EXPERIMENTAL|ZD6474 (vandetanib) 100mg|
61938276|NCT00496509|EXPERIMENTAL|ZD6474 (vandetanib) 300mg|
61938277|NCT03037801|NO_INTERVENTION|Control|
61938278|NCT03037801|EXPERIMENTAL|Intrapulmonary Percussive Ventilation|15 minutes of IPV physiotherapy
62136839|NCT03351075|EXPERIMENTAL|Intervention group|Standard physical therapy program + Modern educational program
62136840|NCT03351075|ACTIVE_COMPARATOR|Control group|Standard physical therapy program + Traditional biomedical educational program
62694828|NCT04182334|EXPERIMENTAL|Slow Tempo Music|Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.
62694829|NCT04182334|SHAM_COMPARATOR|Attention Control|One-hour sessions consisting of a silence track twice daily delivered through noise-cancelling headphones for up to 7 days.
61938279|NCT05694052|EXPERIMENTAL|Multifaceted Intervention|"Lighting: a multi-channel LED Spectrum will be implemented. The spectral output covers the wavelength range from 420 nm to 730 nm. All active channels are mixed, providing a smooth (uniform in color) light with a Lambertian pattern profile.~Noise: the auditory masking system will provide a continuous background digitally generated broadband pink noise. The sound system will be placed near the head of the bed. This will be started (at 62 DB sound level) each night for 8 hours.~Nocturnal patient care activities: night-time patient care activities will be re-organized to minimize interruptions. The medication administration schedule will be organized, and the vital signs monitoring will be done continuously by medical devices without requiring to disturb the patient. Hygiene, comfort, and elective activities will be scheduled for the daytime. Emergency interventions will not be limited."
62136841|NCT00596336|ACTIVE_COMPARATOR|Group A CLL patients|Vaccination with current trispecific influenza vaccine Day 1
62333251|NCT04582734|EXPERIMENTAL|Intervention group - cognitive behavioral therapy|The intervention consists of three parts: 1) screening of hospitalised and outpatient cardiac patients at four university hospitals using the Hospital Anxiety and Depression Scale (HADS), scores ≥8 are invited to participate. (2) Assessment of type of anxiety by Structured Clinical Interview for DSM Disorders (SCID). (3) Investigator-initiated randomised clinical superiority trial with blinded outcome assessment, with 1:1 randomisation to cognitive-behavioural therapy (CBT) performed by a cardiac nurse with CBT training, plus usual care or usual care alone.The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
62333252|NCT04582734|NO_INTERVENTION|Usual Care group|The usual care group (control group) will receive usual care which consists cardiac disease control and treatment.
62490950|NCT02929472|OTHER|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
62490951|NCT04422730||pancreatectomy in cancer patients|
62490952|NCT04422730||pancreatectomy in non-cancer patients|
62490953|NCT04422730||mastectomy|
62490954|NCT04422730||Acute leukaemia|
62694830|NCT02055339|EXPERIMENTAL|Fisher & Paykel heated humidified high flow nasal cannula|For neonates randomized to HHHFNC, they will be placed on a flow rate equivalent to the pressures of nCPAP they were originally receiving based on a published chart, or stay on the same flow rate prior to randomization. When it is time for oral feeds, the Registered Nurse (RN) will turn the dial of the high flow circuit down to 2 lpm. The baby will then proceed to feed for up to one hour, and afterwards, will be turned back up to the flow rate they were on prior to feeds.
62694831|NCT02055339|ACTIVE_COMPARATOR|InfantFlow/RAM nasal continuous positive airway pressure|Neonates randomized to the nCPAP arm will remain on the nCPAP pressures they were on before recruitment into the study or match the flow rate they were receiving on high flow based on a published chart. The nCPAP circuit will only be removed when it is time for oral feeds. The respiratory therapist (RT) will exchange the circuit for a low flow nasal cannula which will be set at the flow that is optimal for the baby's gestational age saturations. The baby will then proceed to feed for up to one hour, and afterwards, will be changed back to the nCPAP circuit.
62694832|NCT02050399|ACTIVE_COMPARATOR|Healthy subjects|15 men, 45 and 65 years old. After initial evaluation, clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise protocol will be performed.
62136842|NCT00596336|EXPERIMENTAL|Group B CLL patients|Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
62136843|NCT00596336|ACTIVE_COMPARATOR|Group C volunteers|Vaccination with current trispecific influenza vaccine Day 1
62136844|NCT00100698|ACTIVE_COMPARATOR|1|recombinant human growth hormone subcutaneously once a day
62136845|NCT00100698|PLACEBO_COMPARATOR|2|placebo subcutaneously once a day
62136846|NCT04337944|EXPERIMENTAL|Patients with KPro, PPV, and endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
62136847|NCT00910832|EXPERIMENTAL|Eductyl suppository|
62136848|NCT00910832|PLACEBO_COMPARATOR|Placebo suppository|
62136849|NCT01220869|EXPERIMENTAL|Degarelix|
62136850|NCT02993211|ACTIVE_COMPARATOR|Standard resection|For patients undergoing bipolar transurethral standard resection, bladder tumour is resected in a piecemeal manner.
62136851|NCT02993211|EXPERIMENTAL|En bloc resection|For patients undergoing bipolar transurethral en bloc resection, bladder tumour is resected and removed in one piece.
62136852|NCT02392234|EXPERIMENTAL|VX-661/Ivacaftor combination|
62136853|NCT02392234|EXPERIMENTAL|Ivacaftor monotherapy|
62136854|NCT02392234|PLACEBO_COMPARATOR|Placebo|
62136855|NCT05484648|EXPERIMENTAL|Group A|Patients allocated to group A will receive ultrasound guided FICB with 0.375% ropivacaine 38 cc along with 8 mg dexamethasone in 2cc making a total injection volume of 40 cc.
62490955|NCT04567329|EXPERIMENTAL|NOV03|100% perfluorohexyloctane 4 times daily (QID)
62490956|NCT04567329|PLACEBO_COMPARATOR|Saline solution|0.6% sodium chloride solution 4 times daily (QID)
62490957|NCT04778358|EXPERIMENTAL|OOCYTE DONORS|Administration of a higher dose of Rekovelle (follitropin delta) to increase the ovarian response to 17 oocytes (the optimal range being 15 to 25 oocytes) in an oocyte donor population without compromising safety and efficacy.
62490958|NCT00838838||Group 1|
62694833|NCT02050399|EXPERIMENTAL|Coronary disease with Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease and type 2 diabetes will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood), clinical autonomic tests and isometric exercise protocol will be performed.
62694834|NCT02050399|EXPERIMENTAL|Coronary disease without Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise will be performed.
61938280|NCT05694052|NO_INTERVENTION|Standard Care|"Lighting: standard lighting system currently installed in the ICU rooms provides a fix light of 300 to 400 lux during daytime, and 0 to 30 lux during night-time. Controls depends on staff to switched on and off.~Noise: The rooms do not have noise isolation and there is no protocol for reducing environmental noise. In our ICU, isolated measurements reported mean average values of 60 dB during daytime and 50 dB during nighttime, with frequent peaks over 80 to 90 dB.~Nocturnal patient care activities: There is no specific protocol for patient care activities during the night. The activities (schedules of drug administration and intravenous infusions, non-urgent examinations, and non-urgent procedures) are organized during the morning by the patient's nurse according to their own clinical criteria. Hygiene and comfort activities are carried out in standard schedules according to the rules of the ICU. Drug administration, examinations and urgent procedures are performed when necessary."
62490959|NCT02610881|EXPERIMENTAL|Iron and Folic Acid (IFA)/Micronutrient Powders (MNP)|Participants will receive iron and folic acid (IFA) drops for one month followed by a two week washout period. Participants will then receive micronutrient powders (MNP) for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
62490960|NCT02610881|EXPERIMENTAL|Micronutrient Powders (MNP)/Iron and Folic Acid (IFA)|Participants will receive micronutrient powders (MNP) for one month followed by a two week washout period. Participants will then receive iron and folic acid (IFA) drops for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
62490961|NCT04385511|EXPERIMENTAL|supraglottic jet ventilation group|Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 \~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will put the Wei NASAL JET（WNJ）into one's nose to give the supraglottic jet ventilation with the driving pressure 0.01-0.03 megapascal (MPa), respiratory rate 15 beats per minute（BPM）, inspiratory/expiratory rate 1-1. 5.Check blood gas,stomach-ultrasound after 3 min, then do the tracheal intubation guided by visual laryngoscope.Stop jet ventilation during intubation.
61938281|NCT03911154|EXPERIMENTAL|SmartSleep Continuous Fixed Interval modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep Continuous Fixed Interval stimulation modality during sleep relative to the SHAM condition. The Continuous Fixed Interval is the delivery of auditory tones a 1 Hz inter-tone interval stimulation."
62490962|NCT04385511|NO_INTERVENTION|mask pressurized ventilation group|"Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 \~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will give them 1 min mask pressure respiration, by pressure control V - E technique after muscle relaxant. Check blood gas,stomach-ultrasound after 2 min, then do the tracheal intubation guided by visual laryngoscope."
62490963|NCT03957096|EXPERIMENTAL|SGN-CD47M|
62490964|NCT02733211|EXPERIMENTAL|Closed Loop System|MD-Logic automated insulin delivery system - all subjects wearing the study system during nights over 4 weeks
62490965|NCT02733211|ACTIVE_COMPARATOR|Sensor augmented pump therapy|Sensor augmented pump therapy - all subjects are using sensor augmented pump therapy over 4 weeks
62490966|NCT01676064|ACTIVE_COMPARATOR|liberal fluid group|during surgery 7 ml/kg/hr RL during first intraoperative hr, 5 ml/kg/hr for the subsequent hours.After surgery ( PACU) 1,5 ml/kg/hr;After operation ward on the day of surgery 1,5 ml/kg/hr; Postoperative day 1- 1,5 ml/kg/hr RL, oral fluids;Postoperative day 2-oral fluids and solid food according to surgical allowance.
62490967|NCT01676064|ACTIVE_COMPARATOR|restrictive fluid group|"during surgery-RL according to 4-2-1 4 ml/kg/hr for first 10 kg (=40ml/hr) then 2 ml/kg/hr for next 10 kg (=20ml/hr)then 1 ml/kg/hr for any kg over 20 kg of weight. This always gives 60ml/hr for first 20 kg then you add 1 ml/kg/hr for each kg over 20 kg.~After surgery (PACU):4-2-1 rule. After operation ward on the day of surgery 1,5 ml/kg/hr.Postoperative day 1:1,5 ml/kg/hr RL, oral fluids. Postoperative day 2:oral fluids and solid food according to surgical allowance."
62694835|NCT05402072|ACTIVE_COMPARATOR|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
62738571|NCT06147128||Experimental: PBP for Non-Technical emergency undocking skills|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge on NTS before continuing to the robotic surgical training element. The trainees knowledge will be assessed in a formative and summative fashion. After the trainees initial assessment, procedure-specific and validated procedure metrics will be used to teach them the steps of the emergency undocking procedure, as well as the correct (and incorrect) way to perform it. The metrics will be used to give to the trainees performance feedback with specific advice on how they might improve their performance, in the regards of non-technical skills.
61938282|NCT03911154|EXPERIMENTAL|SmartSleep Block modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep Block stimulation modality during sleep relative to the SHAM condition. The Block is the delivery of auditory tones for 5 seconds on versus 5 seconds off."
62333253|NCT03958682|EXPERIMENTAL|experimental group|During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.Patients can receive timely diagnosis and appropriate treatment
62333254|NCT04367116|EXPERIMENTAL|spinal cord stimulation|the spinal cord stimulation was performed and operated
62694836|NCT05402072|EXPERIMENTAL|Autologous matrix-induced chondrogenesis (AMIC)|Those allocated to the AMIC treatment group will also receive microfracture. Once the walls of the debrided lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The dry Chondro-Gide® matrix will be prepared by cutting it to 10% smaller than the focal defect (as it increases in size about 10% after moistening). Once the cartilage lesion is dried manually, the implant will then be secured to the defect in a press-fit fashion to the surrounding cartilage. Manual pressure is then applied to secure the implant into the defect and the hip is released from traction and rotated to facilitate further fixation of the graft. Traction is then applied to arthroscopically confirm position and fixation of the implant.
62694837|NCT03598829||Primary Total Knee Arthroplasty|All patients enrolled in this study were part of the same recruitment group who whose SMCT levels will be observed pre and postoperatively. Primary TKA patients are having their native knee replaced.
61938283|NCT03911154|EXPERIMENTAL|SmartSleep In-Phase Adjustable modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep In-Phase Adjustable stimulation modality during sleep relative to the SHAM condition. The In-Phase Adjustable is the constant stimulation with auditory tones delivered during each upstate of the slow wave."
61938284|NCT03911154|SHAM_COMPARATOR|SHAM condition|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm is the SHAM condition, during which participants wore the SmartSleep device, however no auditory tones were delivered."
61938285|NCT06677918|EXPERIMENTAL|EP395|EP395 repeated doses (oral administration). Cohort A: daily (1 capsule) for 21 days. Cohort B (optional): every other day (1 capsule) for 21 days
61938286|NCT06677918|PLACEBO_COMPARATOR|Placebo|Matched placebo capsule (oral administration). Cohort A: daily (1 capsule) for 21 days. Cohort B (optional): every other day (1 capsule) for 21 days
62694838|NCT05938946|EXPERIMENTAL|L608 Liposomal inhalation solution|Eight subjects will be enrolled in each cohort and be randomized to receive assigned dose of L608 or placebo (6:2).
61938287|NCT00085124|EXPERIMENTAL|Arm I|"Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy."
61938288|NCT00085124|EXPERIMENTAL|Arm II|"Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1 and 2.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5. Patients with a continuing CR receive a second course of consolidation therapy."
61938289|NCT04794634|EXPERIMENTAL|Alzheimer Disease|
61938290|NCT04794634|EXPERIMENTAL|Lewy body disease|
61938291|NCT04794634|ACTIVE_COMPARATOR|healthy patient|
61938292|NCT04228393|ACTIVE_COMPARATOR|Standard treatment regimen|6-mercaptopurine was administered according to the Chinese Children Cancer Group (CCCG) protocol-ALL 2015.
61938293|NCT04228393|EXPERIMENTAL|Individualized treatment regimen|6-mercaptopurine was administered on the basis of Chinese Children Cancer Group (CCCG) protocol-ALL 2015 combined with Clinical Pharmacogenetics Implementation Consortium (CPIC), genotypes and the concentrations of 6-TGN in red blood cells.
61938294|NCT05310656|EXPERIMENTAL|Mindfulness-based empowerment programme|
61938295|NCT05027672|ACTIVE_COMPARATOR|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|At the time of randomisation, patients in this arm receive a second dose of Sputnik V (rAd5) vaccine component two.
61938296|NCT05027672|EXPERIMENTAL|Gam-COVID-Vac / ChAdOx1 nCoV-19|At the time of randomisation, patients in this arm receive Astra Zeneca's vaccine (ChAdOx1 nCoV-19) as a second dose.
61938297|NCT05027672|EXPERIMENTAL|Gam-COVID-Vac / Gam-COVID-Vac (rAd26)|At the time of randomisation, patients in this arm receive a second dose of a repeat of the first component of the Sputnik V vaccine (rAd26) as a second dose.
61938298|NCT05027672|EXPERIMENTAL|Gam-COVID-Vac / mARN-1273|At the time of randomisation, patients in this arm receive as a second dose the vaccine produced by Moderna (mRNA-1273).
61938299|NCT06203574|EXPERIMENTAL|patients with solid tumors|Subjects were recruited from Huashan Hospital of Fudan University.
61938300|NCT03181893|PLACEBO_COMPARATOR|Placebo ARM|
61938301|NCT03181893|EXPERIMENTAL|PF-06823859 ARM high|
62333255|NCT02942095|EXPERIMENTAL|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
62333256|NCT02942095|EXPERIMENTAL|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
61938302|NCT03181893|EXPERIMENTAL|PF-06823859 ARM low|
61938303|NCT01457443||Observation|Patients with Pompe disease
62136856|NCT05484648|EXPERIMENTAL|Group B|Patients allocated to group B will receive ultrasound guided FICB with 0.375% ropivacaine 38 cc along with 1 µg/kg dexmedetomidine in 2cc dilution making a total injection volume of 40 cc.
62333257|NCT02942095|EXPERIMENTAL|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
62333258|NCT01506752|ACTIVE_COMPARATOR|E2020 improved 10 mg without water|
62694839|NCT05938946|EXPERIMENTAL|Placebo|Eight subjects will be enrolled in each cohort and be randomized to receive assigned dose of L608 or placebo (6:2).
62694840|NCT05870124|ACTIVE_COMPARATOR|PNS Therapy plus Conventional Medical Management (CMM)|Subjects in this arm will receive a peripheral nerve stimulator and conventional medical management
62694841|NCT05870124|ACTIVE_COMPARATOR|Conventional Medical Management|Subjects will receive only CMM
62136857|NCT05484648|NO_INTERVENTION|Group C|Patients allocated to group C will receive ultrasound guided FICB with 0.375% ropivacaine 38 cc along with 2 cc normal saline making a total injection volume of 40 cc. This will serve as the control arm.
62136858|NCT00829036|EXPERIMENTAL|Wayfinding Prototype|A Wayfinding Prototype is evaluated in terms of the time it takes subjects to use this device to walk to specific indoor locations versus baseline walking time.
62333259|NCT01506752|ACTIVE_COMPARATOR|E2020 current 10 mg without water|
62333260|NCT01506752|ACTIVE_COMPARATOR|E2020 improved 10 mg with water|
62333261|NCT01506752|ACTIVE_COMPARATOR|E2020 current 10 mg with water|
62333262|NCT01281852|EXPERIMENTAL|Treatment (paclitaxel, cisplatin, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IV over 1 hour on day 2, and veliparib PO on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62333263|NCT02797704|EXPERIMENTAL|SC Aflibercept|The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
62490968|NCT03050424|EXPERIMENTAL|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
62490969|NCT03050424|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9%
62490970|NCT05818345|NO_INTERVENTION|Control|Participants will receive a standard menu with the existing pricing structure of the restaurant
62694842|NCT01245023|ACTIVE_COMPARATOR|laparoscopy|laparoscopic adhesiolysis and application of Sprayshield spray to prevent further adhesions
62694843|NCT01245023|PLACEBO_COMPARATOR|placebo-control|anaethesia and skin incisions without laparoscopy or related procedures
62694844|NCT03888287|EXPERIMENTAL|Retrospective Phase|Patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
62694845|NCT03888287|EXPERIMENTAL|Prospective Phase-Watch Rx system|Patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
62694846|NCT03888287|EXPERIMENTAL|Retrospective Phase - Clinicians|Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
62136859|NCT06000813|EXPERIMENTAL|REACH-Es|Participants in the REACH-Es arm will receive REACH-Es short message service (SMS), as follows: 1) Daily SMS (information related to diet, exercise, self-monitoring of blood glucose, their specific diabetes medication(s), and top 4 medication adherence barriers); 2) Daily two-way SMS (diabetes medication adherence question); 3) Weekly one-way SMS (participants receive weekly feedback on Sunday regarding how many of the last 7 days they took their medicine); 4) A SMS each time an HbA1c is collected with a link to a secure website that displays the result.
62136860|NCT06000813|ACTIVE_COMPARATOR|Enhanced treatment as usual (ETAU)|Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
62136861|NCT03760913|EXPERIMENTAL|OLP-1002: Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 μg, 3 μg, 6 μg, 12 μg, 20 μg, 40 μg, 80 μg, 160 μg
62136862|NCT03760913|EXPERIMENTAL|OLP-1002: Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
62136863|NCT03760913|PLACEBO_COMPARATOR|Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
62136864|NCT03760913|PLACEBO_COMPARATOR|Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
62136865|NCT06252805||SPOCCAT|Severe Chronic Obstructive Pulmonary Disease patients in Catalonia
62136866|NCT03148652|EXPERIMENTAL|Enhanced Intervention (CBT+working memory training)|A standard, manualized cognitive behavioral therapy-based intervention for individuals interested in quitting smoking plus computerized working memory training
62136867|NCT03148652|PLACEBO_COMPARATOR|Control Intervention Condition|Participants will receive a manualized cognitive behavioral therapy-based intervention
62136868|NCT04683315|EXPERIMENTAL|Subtype diagnosis and classification: Basal|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Upon diagnosis, patients categorized as basal will receive two months of the Gemcitabine/Nab-paclitaxel Treatment Regimen.
62136869|NCT04683315|EXPERIMENTAL|Subtype diagnosis and classification: Classical|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Patients in the classical group will receive two months of the mFOLFIRINOX Treatment Regimen.
62136870|NCT04683315|EXPERIMENTAL|Basal Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response \[decline in carbohydrate antigen 19-9 (CA19-9) values\] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
62136871|NCT04683315|EXPERIMENTAL|Classical Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response \[decline in carbohydrate antigen 19-9 (CA19-9) values\] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
62136872|NCT04683315|EXPERIMENTAL|Basal Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
62136873|NCT04683315|EXPERIMENTAL|Classical Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
62333264|NCT00578864|EXPERIMENTAL|Protracted Oral Etoposide|"Protracted oral etoposide for cycles 1, 2 and 4 of induction. Etoposide will be given in combination with IV cisplatin (a standard of care agent). If a subject does not respond after cycle 2, cycle 4 will be bolus etoposide in combination with IV cisplatin.~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
62490971|NCT05818345|EXPERIMENTAL|Pricing Intervention|Participants will receive a menu where lower kcal dishes are discounted by 30%
62490972|NCT05206162|ACTIVE_COMPARATOR|continuous theta burst stimulation|cTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s.
62490973|NCT05206162|ACTIVE_COMPARATOR|intermittent theta burst stimulation|iTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in an intermittent train of 190s for iTBS, with repeated cycles of 2s stimulation and 8s pause.
62490974|NCT05206162|SHAM_COMPARATOR|sham stimulation|Sham stimulation over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s using a plastic spacer (25mm thickness) between coil and scalp, preventing effective cortical stimulation.
61938304|NCT03893175|EXPERIMENTAL|Ibuprofen|"During the double-blind stage, subjects will receive blinded ibuprofen (400 mg by mouth) when pain is at least 4/10 following third molar extraction.~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
62333265|NCT00578864|ACTIVE_COMPARATOR|IV Bolus Etoposide|"IV bolus etoposide in combination with IV cisplatin will be given for cycles 1,2, and 4 of induction chemotherapy for patients who are not eligible for the experimental arm (e.g.require emergent treatment)~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
62333266|NCT04404595|EXPERIMENTAL|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Phase 1b will include two parts, dose escalation phase (Cohort A) followed by a dose expansion phase (Cohort B). Phase 2 (Cohort C) will evaluate the chosen dose in patients with advanced gastric cancer.
62333267|NCT04183205|PLACEBO_COMPARATOR|Placebo only arm|For individuals who are placebo responders during the 2 week placebo lead in phase, they will remain on placebo for the duration of the study (i.e., the 12 weeks where the placebo non-responders are taking sertraline).
62333268|NCT04183205|ACTIVE_COMPARATOR|Sertraline arm|After the 2-week placebo lead-in phase, placebo-non responders will receive sertraline 25 mg daily for 2 weeks. Thereafter, sertraline will be increased flexibly by 25 to 50 mg per day (at a rate no higher than 50 mg per week) to achieve a total daily dose of 50 to 200 mg, based on clinical response and tolerability, with a maximum dose of 200 mg/d. Subjects unable to tolerate higher doses may be dropped back to the previous dose and remain at that dose for the remainder of the study.
62333269|NCT03699787|EXPERIMENTAL|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
62333270|NCT03699787|NO_INTERVENTION|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
62333271|NCT00884182|EXPERIMENTAL|Group 1|Participants on vaccination schedule 1 (Day 0 and Day 21)
62490975|NCT04715451|NO_INTERVENTION|Conventional Swaddle|The management of the non-intervention group is with a cotton swaddle that is standard of care. It represents a conventional standard management method using a swaddle made of cotton.
62490976|NCT04715451|EXPERIMENTAL|Novel Swaddle|The Novel Swaddle is made of fabric consisting of 85% nylon and 15% polyurethane. This fabric provides heat retention, is hygroscopic and stretches in both longitudinal and transverse directions, thus more accurately replicating the intrauterine environment. The novel material is sewed into a bag shape.
62490977|NCT05491499||Youth with Chronic pain|We will recruit 38 youth with primary and secondary chronic pain syndromes\[29; 31\] ages 10-17 years who are admitted to the Mayo Family Pediatric Pain Rehabilitation Center at Boston Children's Hospital. This longitudinal cohort study will examine responses to the OA and Fitkids Treadmill tests at 2 timepoints: 1) within 5 days of IIPT admission and 2) within 1 week of IIPT discharge. Twelve participants will complete a 3rd visit within 5 days of the first study visit to examine OA test-retest reliability.
62490978|NCT02614898||Eculizumab|The targeted population consists of pediatric and adult participants with aHUS who received eculizumab at the discretion of the treating physician.
62490979|NCT03671343|EXPERIMENTAL|Intervention : Physical rehabilitation|"The Arm Physical rehabilitation will benefit from the implementation of the Loss of Mobility Prevention program set up in the Department of Aging Medicine of the Center Hospitalier Lyon Sud (CHLS) of Pr BONNEFOY."
62490980|NCT03671343|NO_INTERVENTION|Control : optimized medical treatment|"The Arm Optimized medical treatment will not benefit from the implementation of the Loss of Mobility Prevention program."
62490981|NCT04710290|EXPERIMENTAL|Solid beverage powder|Whey portein solid beverage powder use 1 pack for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
62490982|NCT04710290|EXPERIMENTAL|Capsule|Capsules use 1 cap for every 10 kg of body weight.A total of 6 cap under 60 kg a day, an extra 1cap for each additional 10 kg over 60 kg. Use from the 7th day of the 2nd course of treatment for 5 months.
62490983|NCT04710290|PLACEBO_COMPARATOR|Placebo|placebo use 1 powder for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
62490984|NCT01989884|EXPERIMENTAL|Ortataxel|75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)
62694847|NCT03888287|EXPERIMENTAL|Prospective Phase - Clinicians|Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
61938305|NCT03893175|PLACEBO_COMPARATOR|Placebo|"During the double-blind stage, subjects will receive blinded placebo when pain is at least 4/10 following third molar extraction.~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
61938306|NCT05275478|EXPERIMENTAL|Dose Escalation|Participants with MTAP-deleted solid tumors will receive escalating doses of TNG908 to estimate the MTD
61938307|NCT05275478|EXPERIMENTAL|Dose Expansion in NSCLC|Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG908 at the identified RP2D
61938308|NCT05275478|EXPERIMENTAL|Dose Expansion in Mesothelioma|Participants with MTAP-deleted mesothelioma will receive TNG908 at the identified RP2D
61938309|NCT05275478|EXPERIMENTAL|Dose Expansion in Pancreatic Ductal Adenocarcinoma|Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG908 at the identified RP2D
61938310|NCT05275478|EXPERIMENTAL|Dose Expansion in Sarcoma|Participants with MTAP-deleted sarcoma (soft tissue and bone) will receive TNG908 at the identified RP2D
61938311|NCT05275478|EXPERIMENTAL|Dose Expansion in solid tumors|Participants with other MTAP-deleted solid tumors will receive TNG908 at the identified RP2D
61938312|NCT05275478|EXPERIMENTAL|Dose Expansion in Glioblastoma|Participants with MTAP-deleted relapsed/refractory glioblastoma will receive TNG908 at the identified RP2D
61938313|NCT03324529|EXPERIMENTAL|Participants in the NYU takotsubo registry|"10 patients with a confirmed history of takotsubo syndrome~10 age- and sex-matched healthy controls with no significant history of cardiac or neurological illness"
61938314|NCT06400212|EXPERIMENTAL|Intervention|Cardiopulmonary Exercise Testing
61938315|NCT04139473|ACTIVE_COMPARATOR|Hepaticojejunostomy|Patients undergo right lobe living donor liver transplantation will receive hepaticojejunostomy
61938316|NCT04139473|ACTIVE_COMPARATOR|Duct-to-duct anastomosis|Patients undergo right lobe living donor liver transplantation will receive duct-to-duct anastomosis
61938317|NCT05013034|PLACEBO_COMPARATOR|Placebo (Current Standard of Care)|Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
61938318|NCT05013034|EXPERIMENTAL|Basiliximab|Basiliximab in addition to Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
61938319|NCT03239158|ACTIVE_COMPARATOR|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (\> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62490985|NCT01025141|EXPERIMENTAL|MINISCREW|device
62694848|NCT06023264|NO_INTERVENTION|Control|
61938320|NCT03239158|ACTIVE_COMPARATOR|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62333272|NCT00884182|EXPERIMENTAL|Group 2|Participants on vaccination schedule 2 (Day 0 and Day 14)
62333273|NCT00884182|EXPERIMENTAL|Group 3|Participants on vaccination schedule 3 (Day 0 and Day 42)
62694849|NCT06023264|EXPERIMENTAL|dry needle|
62694850|NCT01978301|ACTIVE_COMPARATOR|Triamcinolone acetonide|Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
62694851|NCT01978301|PLACEBO_COMPARATOR|Placebo|Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
62694852|NCT01978301|NO_INTERVENTION|No treatment|Keloid(s) assigned 'No Treatment' will not receive any treatment.
62333274|NCT06108427|EXPERIMENTAL|Renin-guided arm|Renin levels will be measured prior to each follow-up appointment and MRA therapy will be titrated to achieve renin unsuppression and normokalemia. Once this is achieved, any other class of antihypertensive drugs mais be used to achieve normal BP levels.
62490986|NCT01025141|ACTIVE_COMPARATOR|Reference|dental anchorage
62490987|NCT06625255|EXPERIMENTAL|Intervention - Parent Education|Parents will participate in 2, 45 minute virtual training sessions with information and question and anwsers. Each session will provide information about child development and parent advocacy and stressors. Play as the means for promoting healthy development will be emphasized.
62490988|NCT06625255|NO_INTERVENTION|Waitlist control|Parents will have family life as usual with no education sessions.
62694853|NCT03272321|EXPERIMENTAL|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
61938321|NCT03239158|EXPERIMENTAL|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (\> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
61938322|NCT03239158|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
61938323|NCT02373722|EXPERIMENTAL|Group I (video, text message)|Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
62490989|NCT03431558|EXPERIMENTAL|Group 1|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
62694854|NCT03272321|PLACEBO_COMPARATOR|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
62694855|NCT00085735|EXPERIMENTAL|Arm I (3-7 years of age, LDCSI, IFRT)|See Detailed Description (Arm I)
62694856|NCT00085735|EXPERIMENTAL|Arm II (3-7 years of age, LDCSI, PFRT)|See Detailed Description (Arm II)
62694857|NCT00085735|EXPERIMENTAL|Arm III (3-7 years of age, SDCSI, IFRT)|See Detailed Description (Arm III)
61938324|NCT02373722|EXPERIMENTAL|Group II (educational video)|Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area
61938325|NCT02373722|EXPERIMENTAL|Group III (text message)|Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
61938326|NCT02373722|EXPERIMENTAL|Group IV (control)|Patients receive no video or text messages. Patients receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
62333275|NCT06108427|NO_INTERVENTION|Renin-blinded arm|No measurements of renin levels will be allowed during follow-up. MRA therapy will be titrated to achieve normokalemia. Once this is achieved, any other class of antihypertensive drugs mais be used to achieve normal BP levels.
62333276|NCT03703375|EXPERIMENTAL|Administration of Oral Azacitidine (CC-486)|Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
62333277|NCT03703375|ACTIVE_COMPARATOR|Investigator's choice therapy - Romidepsin|Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
62333278|NCT03703375|ACTIVE_COMPARATOR|Investigator's choice therapy - Gemcitabine|Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
62333279|NCT04527562|ACTIVE_COMPARATOR|TRAETMENT GROUP|Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
61938327|NCT04710134|ACTIVE_COMPARATOR|Reslizumab 3 mg/kg|All patients will initially receive reslizumab 3 mg/kg for at least 16 weeks.
61938328|NCT04710134|ACTIVE_COMPARATOR|Reslizumab 4 mg/kg|Patients who have uncontrolled sputum eosinophilia at 16 weeks will receive an increased dose of 4 mg/kg for the next 16 weeks. The patients with controlled eosinophilia will continue to receive 3 mg/kg.
61938329|NCT04710134|ACTIVE_COMPARATOR|Reslizumab 5 mg/kg|Patients who have uncontrolled sputum eosinophilia who were previously receiving reslizumab at 4 mg/kg at 32 weeks will receive an increased dose of 5 mg/kg for the next 16 weeks. The patients remaining patients will continue on the dose they were receiving (i.e., either 3 mg/kg or 4 mg/kg).
61938330|NCT00446420|ACTIVE_COMPARATOR|1|These patients will only receive intravenous propofol which will be titrated to an OAA/S score of 3. They will not receive fentanyl, midazolam or any other drugs
62333280|NCT04527562|PLACEBO_COMPARATOR|CONTROL /PLACEBO GROUP|"COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo.~Standard care of enrolled study patients will consist:~1. Isolation facility~2. Symptomatic treatment with Paracetamol, Fexofenadine~3. Steam inhalation/Gurgle of Lukewarm water.~4. Ensuring of hand wash (20 seconds each time) and ideally wearing mask.~5. Monitoring by the attending nurses."
62333281|NCT02615535|EXPERIMENTAL|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
62333282|NCT02615535|ACTIVE_COMPARATOR|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
62333283|NCT03682757||Severe Injury/Shock|Severely injured trauma patients presenting with shock, as defined by an Injury Severity Score (ISS)\>=25, and base deficit (BD)\>=6.
62333284|NCT03682757||Without Severe Injury/Shock|Not severely injured trauma patients presenting without shock, as defined by an Injury Severity Score (ISS)\<25, and base deficit (BD) \<6.
62333285|NCT03682757||Healthy Controls|Uninjured healthy volunteers
62333286|NCT00305006|EXPERIMENTAL|CIMT Intervention|Participants randomized to this arm were provided with 90 minutes of Constraint-Induced Movement Therapy (CIMT), which requires hand restraint and progression of unimanual tasks.
62333287|NCT00305006|EXPERIMENTAL|HABIT Intervention|Participants randomized to this arm were provided with 90 minutes of Hand-Arm Bimanual Intensive Therapy (HABIT), which requires that tasks are progressed bimanually.
62333288|NCT06287502|EXPERIMENTAL|Intervention|Subjects received resistance, aerobic, flexibility and balance exercise training; and nutritional supplement containing β-hydroxy β-methylbutyrate (HMB) during the 12-week study period.
62694858|NCT00085735|ACTIVE_COMPARATOR|Arm IV (3-7 years of age, SDCSI, PFRT)|See Detailed Description (Arm IV)
62694859|NCT00085735|EXPERIMENTAL|Arm V (8-21 years of age, SDCSI, IFRT)|See Detailed Description (Arm V)
62694860|NCT00085735|ACTIVE_COMPARATOR|Arm VI (8-21 years of age, SDCSI, PFRT)|See Detailed Description (Arm VI)
62694861|NCT04720807|EXPERIMENTAL|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
62694862|NCT04512378|EXPERIMENTAL|IU Group Treatment|Clinical intervention arm
62694863|NCT06267729|EXPERIMENTAL|AZD0754|AZD0754 monotherapy for treatment of participants with metastatic prostate cancer.
62694864|NCT05135754|OTHER|Test product - new supporting ostomy product and support service|The arm includes the newly developed supporting ostomy product (leakage notification system Heylo) used together with a support service
62694865|NCT04649749||Patients - bionic hand acquired|3 adult patients who acquired a bionic hand at the Medical University of Vienna after a traumatic brachial plexus lesion.
62694866|NCT04649749||Patients - bionic hand not yet acquired|3 patients eligible for the bionic hand prior to a possible amputation.
62694867|NCT04649749||Control subjects|Ten control subjects will be included for comparison.
62490990|NCT03431558|EXPERIMENTAL|Group 2|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 300mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
62490991|NCT03431558|PLACEBO_COMPARATOR|Group 3|"Placebo: Only Glucan-D (99.4% glucoseDose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
62490992|NCT05233254|EXPERIMENTAL|Patients with L4-5 disc herniation|In the light of the reference research, it was estimated that it could reach an effect size of 0.6 according to the sample size measurement made with at least 80% power and 0.05 margin of error, and 18 individuals with LDH (9 men, 9 women) were planned to participate in this study. Since data loss was predicted to be 20%, it was decided to include a total of 22 patients for the study.
62333289|NCT06287502|NO_INTERVENTION|Wait-list control|The waitlist control group would receive 12 weeks of conventional care. After the study period, they would receive the same intervention.
62333290|NCT01712087||MedStream System Implants|All subjects presenting for a de novo programmable pump implant or replacement of an implantable, programmable infusion pump for the treatment of severe spasticity with intrathecal Baclofen.
62333291|NCT04417777||Polynesian patient|Patient with dilatation of idiopathic bronchi
62333292|NCT04417777||Relatives of polynesian patient|Healthy
62333293|NCT05362643|EXPERIMENTAL|Acupuncture Group|Experimental groups were divided into subgroup A and B and both received a total of 9 acupuncture treatments. However Acupuncture Subgroup A received 3 acupuncture sessions over 3 weeks and Acupuncture Subgroup B received 1 acupuncture session for 9 weeks. The same selection of acupuncture points were applied to both subgroups.
62333294|NCT05362643|PLACEBO_COMPARATOR|Sham Acupuncture Group|"Sham Acupuncture groups were also divided into subgroup A and B and both received a total of 9 treatments. Sham Acupuncture subgroup A received 3 sessions over 3 weeks and Sham Acupuncture subgroup B received 1 session for 9 weeks.~Sham Acupuncture subgroups received acupuncture on non-acupuncture points."
62333295|NCT05362643|NO_INTERVENTION|Non-Acupuncture Group|Non-acupuncture treatment.
62333296|NCT01905319||Subsequent new juvenile arthritis cases|During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
62333297|NCT02197429|EXPERIMENTAL|Acupuncture|Acupuncture
62333298|NCT02197429|NO_INTERVENTION|Wait-list Control|Wait-list Control
62333299|NCT03956953|EXPERIMENTAL|Group 1: BMS-986165 Dose 1|Participants will receive Dose 1 on Day 1, and from Day 5 - 19.
62333300|NCT03956953|EXPERIMENTAL|Group 2: BMS-986165 Dose 2|Participants will receive Dose 2 on Day 1, and from Day 5 - 19.
62490993|NCT05341453|ACTIVE_COMPARATOR|Individual physiotherapy (SMA-SOC)|Individual physiotherapy will be performed according to the recommended SMA-SOC guidelines.
62490994|NCT05341453|EXPERIMENTAL|Hippotherapy by the children with cerebral palsy|Hippotherapy by the children with cerebral palsy is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators assume its effect for children with SMA.
62490995|NCT05341453|OTHER|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA.
62490996|NCT03621046|EXPERIMENTAL|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
62490997|NCT03621046|PLACEBO_COMPARATOR|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
62333301|NCT03956953|PLACEBO_COMPARATOR|Group 1: Placebo Dose 1|Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.
62333302|NCT03956953|PLACEBO_COMPARATOR|Group 2: Placebo Dose 2|Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.
62490998|NCT03508063||Healthy population|Healthy subjects receiving stimuli (thermal stimuli and stressogenic physical stimuli) at rest, and being monitored MCPM.
62490999|NCT00211562|ACTIVE_COMPARATOR|Olanzapine|
62333303|NCT01623297||Laparoscopic colon surgery|Patients over age 65 having laparoscopic colon resection for colonic adenocarcinoma
62333304|NCT01623297||Open colon surgery|Patients over age 65 having open colon resection for colonic adenocarcinoma
62333305|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
62333306|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
62333307|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
62333308|NCT01985009|OTHER|Fibroscan®|Single arm study. See intervention item for détails..
62333309|NCT06553456|EXPERIMENTAL|Group 1|The experimental drug was administered at a dose of 20 g/ day for 7 days.
62333310|NCT06553456|ACTIVE_COMPARATOR|Group 2|The positive control drug was administered at a dose of 20 g/ day for 7 days.
62333311|NCT03798912|ACTIVE_COMPARATOR|Intravenous octreotide group|Octreotide 100 mcg will be injected intravenously and serial blood samples will be collected for PK analysis
62333312|NCT03798912|EXPERIMENTAL|RaniPill A group|In 20 subjects, a RaniPill with a small balloon size will be administered and serial blood samples will be collected for PK analysis
62333313|NCT03798912|EXPERIMENTAL|RaniPill B group|In 20 subjects, a RaniPill with a larger balloon size will be administered and serial blood samples will be collected for PK analysis
62333314|NCT03798912|EXPERIMENTAL|RaniPill C group|In 20 subjects, a RaniPill with a different size will be administered and blood samples will be collected for the presence of drug
62333315|NCT02547831||Observational approach|Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression
62333316|NCT03553433|EXPERIMENTAL|Verum|Apremilast 30mg bd
62491000|NCT00211562|ACTIVE_COMPARATOR|Omega 3|
62333317|NCT03553433|PLACEBO_COMPARATOR|Placebo Oral Tablet|Excipiens
62136874|NCT04683315|EXPERIMENTAL|Basal Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
62333318|NCT05078697||early pregnancy women|According to the 2020 high-risk population score model, participants with high risks for GDM and normal health participants will be enrolled into the study.
62333319|NCT03751995|NO_INTERVENTION|Control|Participants from medical centers assigned to the control arm will receive usual care.
62333320|NCT03751995|EXPERIMENTAL|Intervention|Participants from medical centers assigned to the intervention arm will receive access to their choice of a mindfulness app or a webinar-based mindfulness course for 6 weeks.
62333321|NCT06163456|EXPERIMENTAL|low fitness|
62333322|NCT06163456|ACTIVE_COMPARATOR|moderate fitness|
62333323|NCT06163456|ACTIVE_COMPARATOR|high fitness|
62333324|NCT01423617|ACTIVE_COMPARATOR|Zenoctil|
62333325|NCT01423617|PLACEBO_COMPARATOR|Placebo|
62333326|NCT02561260||autoimmune encephalitis|
62333327|NCT02561260||unknowm encephalitis|
62333328|NCT02561260||other encephalopathy|
62333329|NCT04438889||AML|Patients with WHO 2016 diagnosis of AML
62333330|NCT04438889||MDS|Patients with WHO 2016 diagnosis of MDS
62333331|NCT04438889||CMML|Patients with WHO 2016 diagnosis of CMML
62333332|NCT04438889||PMF|Patients with WHO 2016 diagnosis of PMF
62333333|NCT03086317|ACTIVE_COMPARATOR|Standard Catheter-Directed Thrombolysis|Participants randomized to this arm will receive standard catheter-directed thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
62333334|NCT03086317|ACTIVE_COMPARATOR|Ultrasound-Accelerated Thrombolysis|Participants randomized to this arm will receive ultrasound-accelerated thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
62491001|NCT00211562|ACTIVE_COMPARATOR|Vitamin E +C|
62491002|NCT02956681|ACTIVE_COMPARATOR|Delayed Intervention Group|In this arm of the randomized delayed intervention control trial, participants randomized to delayed intervention control group were sent a brochure with information on hereditary breast and ovarian cancer and the phone number to call a cancer risk program for free genetic counseling.
62491003|NCT02956681|ACTIVE_COMPARATOR|Intervention Group|In this arm of the randomized delayed intervention control trial, those randomized to the intervention group were told that because of their family history, we were able to offer them a free genetic counseling appointment.
62136875|NCT04683315|EXPERIMENTAL|Classical Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
62333335|NCT06323915|ACTIVE_COMPARATOR|FineVision|"28 patients will be implanted bilaterally with Intensity FineVision (PhysIOL, Belgium) trifocal IOLs.~The device is CE-marked and used according to the intended purpose."
62333336|NCT06323915|ACTIVE_COMPARATOR|Artis Symbiose|"28 patients will be implanted bilaterally with Artis Symbiose (Cristalens Industrie, France) IOLs.~The device is CE-marked and used according to the intended purpose."
62333337|NCT06323915|ACTIVE_COMPARATOR|Synergy|"28 patients will be implanted bilaterally with Tecnis Synergy model ZFR00V (Johnson \& Johnson, USA) IOLs.~The device is CE-marked and used according to the intended purpose."
62333338|NCT00486538|EXPERIMENTAL|Single arm|One oral dose daily
62333339|NCT01005719|EXPERIMENTAL|Zegerid|Participants receiving Zegerid (omeprazole/sodium bicarbonate) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
62333340|NCT01005719|ACTIVE_COMPARATOR|Prevacid®|Participants receiving Prevacid® (lansoprazole) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
62333341|NCT01005719|NO_INTERVENTION|No treatment|Participants receiving No treatment in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants took approximately 2 oz of water once daily for 7 days.
62333342|NCT01351766|EXPERIMENTAL|Behavioral Activation for Smoking|"Eight 60-minute group sessions over an eight-week period. Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after treatment sessions have ended.~Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level."
62333343|NCT06330948|PLACEBO_COMPARATOR|placebo group|Placebo group (50mL/bottle)
62333344|NCT06330948|EXPERIMENTAL|SugarCut® Unripe Guava Fruit Extract|SugarCut® Guava Fruit Extract Group (50mL/bottle, each bottle contains 10g Guava Fruit Extract)
62333345|NCT00793702|EXPERIMENTAL|A|two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)
62333346|NCT00793702|EXPERIMENTAL|B|two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)
62333347|NCT00793702|EXPERIMENTAL|C|two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)
62333348|NCT00793702|EXPERIMENTAL|D|two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)
62333349|NCT00793702|EXPERIMENTAL|E|one injection 1.0 µg rdESAT-6 + rCFP-10
62333350|NCT01743963|EXPERIMENTAL|Decision Support Intervention|Clinical pharmacists mediated computerized decision support
62333351|NCT01743963|ACTIVE_COMPARATOR|Usual Care|Clinicians' typical approach for GID monitoring
62491004|NCT05062460|OTHER|1-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 1 hour after eating.
62491005|NCT05062460|OTHER|2-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 2 hours after eating.
61938331|NCT00446420|ACTIVE_COMPARATOR|2|These patients will receive propofol plus midazolam and/or fentanyl. Midazolam and fentanyl will be given in fixed doses first and propofol will be titrated to effect. All drugs will be given intravenously.
61938332|NCT02853851||France|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
62136876|NCT06190132|ACTIVE_COMPARATOR|Group A|Group A allocated to treatment with omega 3 fatty acids for 4 weeks then after 6 weeks washout period, the patients received gabapentin for 4 weeks
62136877|NCT06190132|ACTIVE_COMPARATOR|Group B|Group B allocated to treatment with gabapentin for 4 weeks then after 6 weeks washout period, the patients received omega 3 fatty acids for 4 weeks
62333352|NCT02841787|EXPERIMENTAL|Individual Internet Intervention (III)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered individually by 2 clinical psychologists.~(iCBT for late life depression without social network included.)"
62333353|NCT02841787|EXPERIMENTAL|Internet Intervention+Peer Supp.(II+PS)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered with peer support; group moderation was provided by 2 clinical psychologists.~(iCBT for late life depression with social network included.)"
62333354|NCT02841787|NO_INTERVENTION|Waitlist Control (WLC)|Waiting period, no intervention administered. WLC participants received access to the III following the 8-week waiting period.
62491006|NCT05820828|NO_INTERVENTION|Control group|Patient will during extracorporeal circulation be monitored and held in the range of \> 300 mL in the venous reservoir. Patient will recieve fluid if needed to maintain correct level (crystalloids, colloids or erytrocytes depending on patients clinical status).
62333355|NCT03798145|EXPERIMENTAL|Surgical Retinotomy|Surgical retinotomy will be constructed in the area of the scotoma.
62333356|NCT01337531|EXPERIMENTAL|gonadotropin|recombinant or highly purified gonadotropin
62491007|NCT05820828|EXPERIMENTAL|Interventional group|Patient will during extracorporeal circulation be monitored and held in the range of 200 - 300 mL in the venous reservoir. To maintain correct level of volume, any excessive fluid will be drained into a sterile infusion bag during extracorporeal circulation. After the surgery, the patient will recieve the volume to ensure correct volume status.
61938333|NCT02853851||Italy|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
61938334|NCT02853851||spain|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
61938335|NCT02853851||montreal|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
62136878|NCT05784259|NO_INTERVENTION|Control group|
62136879|NCT05784259|EXPERIMENTAL|Treatment group|Transdiagnostic single-session treatment
62136880|NCT01645566|EXPERIMENTAL|intervention|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
62136881|NCT01645566|NO_INTERVENTION|Control|No instructions
62136882|NCT06699758|EXPERIMENTAL|Intervention arm Group 1|Administration of a total of 3x106 cells administered over three 1x106cell doses.
62136883|NCT06699758|EXPERIMENTAL|Intervention arm Group 2|Administration of a total of 15x106 cells administered over three 5x106cell doses.
62136884|NCT06699758|EXPERIMENTAL|Intervention arm Group 3|Administration of a total of cumulative 30x106 cells administered over three 10x106cell doses.
62136885|NCT02155868|EXPERIMENTAL|Intervention|"Cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C.~Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it."
62136886|NCT02155868|PLACEBO_COMPARATOR|Control|Only cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C during cardiac surgery and the first six hours after it.
62333357|NCT01337531|ACTIVE_COMPARATOR|Gonadotropins|recombinant versus highly purified gonadotropin
62333358|NCT01463904||Morbid obese, diabetics|Patients with morbid obesity or severe metabolic disease
62333359|NCT03760848|OTHER|Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin|Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)
61938336|NCT00547196|EXPERIMENTAL|Regimen I (FTBI, Cyclophosphamide, Fludarabine)|Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
62136887|NCT03595969||acute leukemia group|150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
62136888|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
62136889|NCT06698926|EXPERIMENTAL|Part 1: Group 1|Participants will receive either ABBV-CLS-616 Dose A or placebo after fasting on Day 1 and will be confined for 19 days.
62333360|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
62333361|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
62333362|NCT02218658|EXPERIMENTAL|WE 941 OD|
62333363|NCT02218658|ACTIVE_COMPARATOR|Brotizolam|
62333364|NCT01520480||Non-pathological fracture|Non pathological subtrochanteric femur fractures
62491008|NCT02805114||Asthma and COPD patients|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken from the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
62491009|NCT02195544||Synvisc®|
62491010|NCT04039022|EXPERIMENTAL|AXS-05|
62491011|NCT04320563|ACTIVE_COMPARATOR|Full power treatment 4|These group of participants will receive the full power treatment 4
62491012|NCT04320563|PLACEBO_COMPARATOR|Comparative Power 1|These group of participants will receive the comparative power 1 treatment
62491013|NCT01503658|EXPERIMENTAL|Clopidogrel+Aspirin|Clopidogrel on Day 1, Aspirin on Day 2 - Day 14, Clopidogrel + Aspirin Day 15, Aspirin on Day 16 - Day 28, Clopidogrel + Aspirin Day 29
62491014|NCT02143726|ACTIVE_COMPARATOR|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62491015|NCT02143726|EXPERIMENTAL|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62491016|NCT00668551||1|Telemedicine care
62491017|NCT00668551||2|Standard of care
62491018|NCT04168307|EXPERIMENTAL|Ankle trainer device|The patients were instructed in the use of a new spring loaded ankle trainer
62491019|NCT04168307|ACTIVE_COMPARATOR|Conventional physiotherapy|The patients were instructed in passive stretching exercises by the use of a non-elastic band
62491020|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
62491021|NCT03967262|EXPERIMENTAL|Intervention|
62491022|NCT03967262|NO_INTERVENTION|Control|
62491023|NCT01953185|EXPERIMENTAL|Manual diaphragm release technique|
62491024|NCT01953185|SHAM_COMPARATOR|Control group|
62491025|NCT04146805|EXPERIMENTAL|Part 1SAD/Part 2 MAD:Active Treatment(BLD-0409)|For each cohort in both study parts, 6 subjects will be randomized to active (BLD-0409). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s)
62491026|NCT04146805|PLACEBO_COMPARATOR|Part 1SAD/Part 2 MAD:Control(Matched Placebo)|For each cohort in both study parts, 2 subjects will be randomized to control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
62491027|NCT02183727|EXPERIMENTAL|L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an investigation, interventional device intended for ACL reconstruction surgery within 18 weeks of acute rupture of the ACL and no previous surgical treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
62491028|NCT02183727|ACTIVE_COMPARATOR|Hamstring Autograft|Hamstring autograft is the active comparator for this study. Autograft tissue is the gold-standard treatment for primary ACL reconstruction.
61938337|NCT00547196|EXPERIMENTAL|Regimen II (Busulfan, Fludarabine, Melphalan)|Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
62136890|NCT06698926|EXPERIMENTAL|Part 1: Group 2|Participants will receive either ABBV-CLS-616 Dose B or placebo after fasting on Day 1 and will be confined for 19 days.
62136891|NCT06698926|EXPERIMENTAL|Part 1: Group 3|Participants will receive either ABBV-CLS-616 Dose C or placebo after fasting on Day 1 and will be confined for 19 days.
62491029|NCT03097198|EXPERIMENTAL|PbN-TED|Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
62491030|NCT03097198|EXPERIMENTAL|TED-PbN|Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
62491031|NCT02281539|EXPERIMENTAL|Treatment using myoelectric signals|Virtual- and augmented reality, are controlled by the patient's phantom limb using muscle (myoelectric) signals from the stump. The patient learns to reactivate areas in the brain related to motor control of the missing limb. The medical device is non-invasive and based on surface electromyography
62491032|NCT02766257|OTHER|children undergoing ambulatory surgery|
62333365|NCT01520480||Pathological fracture|Pathological subtrochanteric fractures
62491033|NCT01377441|EXPERIMENTAL|Ibuprofen|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo.
62491034|NCT01377441|PLACEBO_COMPARATOR|Placebo/Saline solution|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo
62491035|NCT06363799|EXPERIMENTAL|4th ventricle compression technique|"Experimental:~4th ventricle compression technique"
62491036|NCT06363799|EXPERIMENTAL|Diaphragmatic breathing technique|"Experimental:~Diaphragmatic breathing technique"
62491037|NCT06363799|PLACEBO_COMPARATOR|Sham Tecnhique|"Placebo Comparator:~Sham Technique"
62491038|NCT03708406||Children with Cleft lip and palate|Children with Cleft lip and palate
62491039|NCT03708406||Children with Cleft palate|Children with Cleft palate
62491040|NCT04436419|PLACEBO_COMPARATOR|Placebo|Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.
62694868|NCT04129021|EXPERIMENTAL|High-resolution retinal imaging through adaptive optics|High-resolution retinal imaging through adaptive optics, full field OCT and holographic systems
62491041|NCT04436419|ACTIVE_COMPARATOR|ALA|Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.
62491042|NCT04915339|EXPERIMENTAL|Group 1: physical activity then cognitive training|Using an online-computerized application, physical activities will be prescribed for one month. After a 15 days break, cognitive training activities will be prescribed the same way. A feedback by the patient will be asked fallowing each activity to control the observance.
62491043|NCT04915339|EXPERIMENTAL|Group 2: Cognitive training then physical activity|Contrary to the first group, the second one starts with cognitive training intervention then engages in physical activity in same way as the first group. A feedback by the patient will also be asked fallowing each activity to control the observance
62491044|NCT04915339|EXPERIMENTAL|Group 3 : resonance frequency breathing then combined physical activity and cognitive training|The third group takes part in a 1 month breathing exercise program. After a 15 days break (as the groups 1 and 2), a combined physical activity and cognitive training program is administrated for 1 month. As the others arms, a feedback by the patient will be asked fallowing each activity to control the observance
62491045|NCT05485662|OTHER|MIH-bearing tooth block exposed to HAP toothpaste|A block of molar incisor hypomineralization (MIH) is mounted in an oral appliance and fitted in the subject for testing with the HAP toothpaste
62491046|NCT05485662|OTHER|MIH-bearing block exposed to Sodium Fluoride toothpaste|A block of molar incisor hypomineralization (MIH) is mounted in an oral appliance and fitted in the subject for testing with the sodium fluoride toothpaste
62491047|NCT01155531|EXPERIMENTAL|Telenzepine - Group A|Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine
62491048|NCT01155531|EXPERIMENTAL|Sertraline plus Telenzepine - Group B|Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine
62694869|NCT03403179|EXPERIMENTAL|Receiving Psychosocial Intervention|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
62694870|NCT03845036|EXPERIMENTAL|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
62694871|NCT03845036|ACTIVE_COMPARATOR|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
62694872|NCT05000788|EXPERIMENTAL|Qigong Group|
62694873|NCT05000788|ACTIVE_COMPARATOR|Exercise Group|
62694874|NCT04362644|EXPERIMENTAL|PET/CT using PET ligands [18F]FDG and [18F]DPA-714|
62694875|NCT02790736|EXPERIMENTAL|Propranolol|Propranolol 40 mg capsule, given once after fear activation procedure
62333366|NCT01515306|EXPERIMENTAL|Part A: ramucirumab (IMC-1121B) and paclitaxel|Experimental: Part A: ramucirumab (IMC-1121B) and paclitaxel Cycle 1: paclitaxel administered on Day 1 of 2-week cycle. Cycle 2 and beyond : ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.
62333367|NCT01515306|EXPERIMENTAL|Part B: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.~Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4- week cycle.~\*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A."
62333368|NCT00511524|EXPERIMENTAL|Subjects receiving GW842166|Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive \[carbonyl-\^11C\]GW842166.
62333369|NCT02528097|PLACEBO_COMPARATOR|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
62136892|NCT06698926|EXPERIMENTAL|Part 1: Group 4|Participants will receive either ABBV-CLS-616 Dose D or placebo after fasting on Day 1 and will be confined for 19 days.
62136893|NCT06698926|EXPERIMENTAL|Part 1: Group 5|Participants will receive either ABBV-CLS-616 Dose E or placebo after fasting on Day 1 and will be confined for 19 days.
62136894|NCT06698926|EXPERIMENTAL|Part 1: Group 6|Participants will receive either ABBV-CLS-616 Dose F or placebo after fasting on Day 1 and will be confined for 19 days.
62333370|NCT02528097|EXPERIMENTAL|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr \> 1.0 or BUN or Cr are above baseline.
62333371|NCT04442958|EXPERIMENTAL|Convalescent Plasma Therapy Group|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
62333372|NCT04442958|NO_INTERVENTION|Non-Plasma Therapy Group|Standart critical care treatment group
62333373|NCT02638805|EXPERIMENTAL|Group 1|ITCA 650 20/60 mcg/day
62333374|NCT02638805|EXPERIMENTAL|Group 2|ITCA 650 60 mcg/day
62491049|NCT01155531|EXPERIMENTAL|Sertraline plus Telenzepine - Group C|Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine
62491050|NCT01155531|EXPERIMENTAL|Sertraline plus Telenzepine - Group D|Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine
62491051|NCT04202757|ACTIVE_COMPARATOR|Young Fresh Frozen Plasma (yFFP)|\[21CFR640.30\] Plasma from 18 - 25 year old volunteer donors
62491052|NCT04202757|PLACEBO_COMPARATOR|Saline|0.1% riboflavin in normal saline
62491053|NCT02518139|EXPERIMENTAL|TD-4208-1|88 mcg
62491054|NCT02518139|EXPERIMENTAL|TD-4208-2|175 mcg
62491055|NCT02518139|ACTIVE_COMPARATOR|Tiotropium|18 mcg
62491056|NCT00844974|OTHER|1|
62491057|NCT01750827|EXPERIMENTAL|SB-659032|Single dose open label
62491058|NCT00085501|ACTIVE_COMPARATOR|1|
62491059|NCT00085501|ACTIVE_COMPARATOR|2|
62491060|NCT06298162||RYGB, successful weight loss (TWL >35%)|TWL = total weight loss
62491061|NCT06298162||RYGB, unsuccessful weight loss (TWL <25%)|
62491062|NCT03341013|EXPERIMENTAL|Sequence 1|formulation 2 on Day 1 and formulation 3 on Day 10
62491063|NCT03341013|EXPERIMENTAL|Sequence 2|formulation 3 on Day 1 and formulation 2 on Day 10
62491064|NCT06492252|EXPERIMENTAL|Altered auditory feedback + fMRI|Participants will perform learning tasks then undergo fMRI. This procedure will be repeated on day 2. Functional connectivity patterns between regions that predict learning will be assessed. Participants then leave the laboratory and return 24 hours later to assess retention of learning.
62491065|NCT06492252|EXPERIMENTAL|Control Condition|Participants in a control condition who will undergo the same procedures, without altered feedback
62491066|NCT02943538|EXPERIMENTAL|Telemedicine group|In this group, monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
62491067|NCT02943538|EXPERIMENTAL|Telephone support group|A telephone control of their state and evolution will be made through the nursing staff of the unit.
62491068|NCT02943538|ACTIVE_COMPARATOR|Control group|Conventional care provided in the unit to patients with IBD -high moderate complexity.
62491069|NCT01300884||healthy volunteers|
62491070|NCT01300884||patients with fecal incontinence|
62491071|NCT01300884||patients with constipation|
62491072|NCT02766218||Behavioral: Lifestyle Intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
62491073|NCT02766218||No Intervention: Standard Care|
62491074|NCT00662272|EXPERIMENTAL|1|Arm includes treatment with Fluzone® vaccine mixed with study product JVRS-100 adjuvant
62136895|NCT06698926|EXPERIMENTAL|Part 2: Group 7|Participants will receive either ABBV-CLS-616 Dose G or placebo daily, starting on Day 1, for 14 days while confined for 26 days.
62333375|NCT02982304|ACTIVE_COMPARATOR|Pallidal (GPi) Deep Brain Stimulation|GPi is the standard target for treating most dystonia. This setting will be the active comparator
62333376|NCT02982304|EXPERIMENTAL|Thalamic (Vim) Deep Brain Stimulation|Vim is the standard target to treat cerebellar dysfunction in movement disorders. It is not routinely used in secondary dystonia
62136896|NCT06698926|EXPERIMENTAL|Part 2: Group 8|Participants will receive either ABBV-CLS-616 Dose H or placebo daily, starting on Day 1, for 14 days while confined for 26 days.
62136897|NCT06698926|EXPERIMENTAL|Part 2: Group 9|Participants will receive either ABBV-CLS-616 Dose D or placebo daily, starting on Day 1, for 14 days while confined for 26 days.
62136898|NCT06698926|EXPERIMENTAL|Part 2: Group 10|Participants will receive either ABBV-CLS-616 Dose E or placebo daily, starting on Day 1, for 14 days while confined for 26 days.
62136899|NCT06698926|EXPERIMENTAL|Part 2: Group 11|Participants will receive either ABBV-CLS-616 Dose F or placebo daily, starting on Day 1, for 14 days while confined for 26 days.
62136900|NCT06698926|EXPERIMENTAL|Part 3: Sequence 1|In Period 1, participants will be confined for 19 days and receive ABBV-CLS-616 Dose C on Day 1 after fasting. In Period 2, Participants will be confined for 19 days and receive ABBV-CLS-616 Dose C on Day 1, without fasting.
62333377|NCT02982304|EXPERIMENTAL|GPi + Vim (Multi-Target) Deep Brain Stimulation|Combined stimulation of GPi and Vim stimulation (both electrodes ON)
62333378|NCT01912430|EXPERIMENTAL|ICC (Integrated Care Coaching)|Received evidence-based, protocol-driven integrated care coaching intervention to improve chronic illness health outcomes (clinical, financial).
62333379|NCT01912430|EXPERIMENTAL|Control Group|Matched cohort by age and chronic illness diagnoses - no intervention
62491075|NCT00662272|ACTIVE_COMPARATOR|2|Arm includes treatment with half adult dose of Fluzone® vaccine
62491076|NCT00662272|ACTIVE_COMPARATOR|3|Arm includes treatment with full adult dose Fluzone® vaccine
62491077|NCT06028477|ACTIVE_COMPARATOR|Active stimulation|Participants will receive active stimulation between 2 hours minimum and 4 hours maximum of daily vCR or sham stimulation (2 hours twice daily) at home for the first month (30 days), followed by a minimum of 1.5 hours and a maximum of 2.5 hours of daily vCR
62491078|NCT06028477|SHAM_COMPARATOR|Sham Stimulation|Participants will receive sham stimulation between 2 hours minimum and 4 hours maximum of daily vCR or sham stimulation (2 hours twice daily) at home for the first month (30 days), followed by a minimum of 1.5 hours and a maximum of 2.5 hours of daily vCR
62491079|NCT02861560|EXPERIMENTAL|dHACM|Dehydrated human amnion/chorion membrane (dHACM)
62491080|NCT03368209|EXPERIMENTAL|OUH protocol|"The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:~* Optical Coherence Tomography (OCT)~* Optical screening on measuring site with WM3.4.~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2."
62491081|NCT03368209|EXPERIMENTAL|Home 1 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference."
62491082|NCT03368209|EXPERIMENTAL|Home 2 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference."
62491083|NCT05031455|EXPERIMENTAL|Aspirin Challenge|All subjects will undergo a standardized aspirin challenge
62491084|NCT03790163|PLACEBO_COMPARATOR|levobupivacaine at ( 23˚C)|Levobupivacine hydrochloride at ( 23˚C) will be received 3.5 ml levobupivacaine at the operating room temperature 23˚C will be administered
62491085|NCT03790163|ACTIVE_COMPARATOR|Warm levobupivacaine at (30˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (30˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
62694876|NCT02790736|PLACEBO_COMPARATOR|placebo capsule|Placebo capsule, given once after fear activation procedure
62491086|NCT03790163|ACTIVE_COMPARATOR|Warm levobupivacaine at (37˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (37˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
62491087|NCT03314857|EXPERIMENTAL|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
62491088|NCT04737239||Patient with CTS/Mild EMG|
62491089|NCT04737239||Patient with CTS/Negative EMG|
62491090|NCT01186458|EXPERIMENTAL|Fludarabine, Velcade and Rituximab|Fludarabine, Velcade and Rituximab
62491091|NCT05264896|EXPERIMENTAL|FLOT|"Patients randomized to the FLOT arm would receive perioperative FLOT~Regimen:~* Docetaxel 50mg/m2, d1~* 5-FU 2600 mg/m², d1~* Leucovorin 200 mg/m², d1~* Oxaliplatin 85 mg/m², d1~* Every two weeks 4 cycles pre-op and 4 cycles post-op~Granulocyte colony stimulating factor (GCSF) at 30 mu s.c. daily from Day 4 to Day 7 is recommended.~Two weeks after completion of the 4 cycles of pre-op chemotherapy, reassessment endoscopy and CT scan would be performed. Surgery would be performed 4 weeks after pre-op chemotherapy if no distant metastasis was found on CT scan.~Post-op adjuvant FLOT (x 4 cycles) will be started within 10 weeks after surgery."
62491092|NCT05264896|ACTIVE_COMPARATOR|XELOX|"Patients randomized to adjuvant XELOX arm would receive chemotherapy after surgery.~* Capecitabine - 1,000 mg/m² twice daily.~* Oxaliplatin - IV infusion, 130mg/m²"
62491093|NCT01704105|ACTIVE_COMPARATOR|Water Quality|100 clusters, approximately 1,000 newborns
62491094|NCT01704105|ACTIVE_COMPARATOR|Sanitation|100 clusters, approximately 1,000 newborns
62491095|NCT01704105|ACTIVE_COMPARATOR|Handwashing|100 clusters, approximately 1,000 newborns
62491096|NCT01704105|ACTIVE_COMPARATOR|Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
62136901|NCT06698926|EXPERIMENTAL|Part 3: Sequence 2|In Period 1, Participants will be confined for 19 days and receive ABBV-CLS-616 Dose C on Day 1, without fasting. In Period 2, participants will be confined for 19 days and receive ABBV-CLS-616 Dose C on Day 1 after fasting.
62136902|NCT06698926|EXPERIMENTAL|Part 4: Itraconazole|In Period 1, Participants will be confined for 19 days and receive ABBV-CLS-616 Dose C on Day 1, without fasting. In Period 2, participants will be confined for 22 days and receive ABBV-CLS-616 Dose C on Day 4 without fasting. Participants will also receive Itraconazole daily for 21 days.
62333380|NCT02405234|EXPERIMENTAL|Carbon Modular Radial Head|PyroCarbon Modular Radial Head replacement
62333381|NCT02405234|ACTIVE_COMPARATOR|Metal Radial Head|Metal Radial Head replacement
62333382|NCT02871180|OTHER|With late night snack|At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten from Type 1 diabetic patients on an intensified conventional treatment regimen.
62333383|NCT02871180|OTHER|Without late night snack|Not nutrients (No late night snack) were consumed at 10 p.m. from Type 1 diabetic patients on an intensified conventional treatment regimen..
62333384|NCT03455309|ACTIVE_COMPARATOR|NDV-3A|0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
62333385|NCT03455309|PLACEBO_COMPARATOR|Placebo|0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
62333386|NCT02430662|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Gallbladder Neoplasms
62491097|NCT01704105|ACTIVE_COMPARATOR|Nutrition|100 clusters, approximately 1,000 newborns
62491098|NCT01704105|ACTIVE_COMPARATOR|Nutrition + Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
62491099|NCT01704105|NO_INTERVENTION|Active control arm|200 clusters, approximately 2,000 newborns. Village-level promoter will visit household and will strictly engage in recording the child's MUAC, which will also be conducted in all active comparator arms as well.
62491100|NCT01704105|NO_INTERVENTION|Passive control arm|100 clusters, approximately 1,000 newborns. No intervention.
62491101|NCT05762016||incision and drainage group|patients with breast abscess who undergo incision and drainage
62333387|NCT02430662|NO_INTERVENTION|Control|The patients without treatment
62333388|NCT01216592||COPD|
62491102|NCT05762016||percutaneous drainage group|patients with breast abscess who undergo percutaneous drainage
62333389|NCT04654000|EXPERIMENTAL|Rheopheresis group|"In addition to the standards of care, the experimental group will carry out the rheopheresis in two stages:~* Stage 1: induction treatment: 3 apheresis sessions during the first week (w0; i.e. between D1 and D7) and then 2 apheresis sessions each week for 3 weeks (from w1 to w3; i.e. between D8 and D28) ;~* Step 2: maintenance treatment with 1 apheresis session per week until the 11th week (i.e. between D29 and D84)."
62333390|NCT04654000|SHAM_COMPARATOR|Sham-apheresis group|In addition to the standards of care, the comparator group will carry out Sham-apheresis sessions according to the same scheme as the rheopheresis sessions of the experimental group.
62333391|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
62333392|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
62333393|NCT01249183|EXPERIMENTAL|1- VAXIGRIP and REPEVAX concomitantly|
62333394|NCT01249183|ACTIVE_COMPARATOR|2-REPEVAX 28 days after VAXIGRIP|
62333395|NCT04523441||Parents|man or woman
62333396|NCT04523441||Professionals|health professionals in charge of monitoring children
62333397|NCT02775552|EXPERIMENTAL|A&T intervention areas|
62491103|NCT05762016||MISE group|patients with breast abscess who undergo MISE
62491104|NCT00095537|EXPERIMENTAL|Phase 1 MTD Study|
62491105|NCT02267408|EXPERIMENTAL|Fearon algorithm dosing|Warfarin adjustment using the Fearon algorithm
62491106|NCT02267408|ACTIVE_COMPARATOR|Standard dosing|Warfarin adjustment using standard dosing
62491107|NCT05475392|EXPERIMENTAL|Stretching Exercise with PIR on neck pain and muscle spasm in breastfeeding women|Experimental Group (Group A) will receive stretching with Post Isometric Relaxation and conventional treatment. Treatment will be given for five days per week for total two weeks. Pain will be assessed through VAS scale and MJM scale will be used to assess spasm. Assessment was done 2 times pretreatment and post treatment.
62694877|NCT06637293|NO_INTERVENTION|No DeepECG plateform diagnosis & recommendations|
62694878|NCT06637293|EXPERIMENTAL|DeepECG plateform diagnosis & recommendations|
62491108|NCT05475392|ACTIVE_COMPARATOR|Stretching Exercise without PIR on neck pain and muscle spasm in breastfeeding women|Active Compatitor (Group B) will receive only stretching and conventional treatment. Treatment will be given for five days per week for total two weeks. Pain will be assessed through VAS scale and MJM scale will be used to assess spasm. Assessment was done 2 times pretreatment and post treatment.
62491109|NCT02927210|PLACEBO_COMPARATOR|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
62491110|NCT02927210|EXPERIMENTAL|Dimethandrolone Undecanoate|Single doses of DMAU administered via injection intramuscularly (IM - 80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC - 50 mg, 100 mg and 200 mg)
62491111|NCT01307761||Patients with thyroid nodule received US-FNA exam|Patients with thyroid nodules which underwent head and neck ultrasound(US) examination and US-FNA cytology at Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan. No patient included in this series had a previous diagnosis of thyroid malignancy before US exam.
62491112|NCT05686993|EXPERIMENTAL|Cinnarizine and nifedipine|Drug 1 for 2 weeks, 2 weeks of washout, then Drug 2 for 2 weeks Drug 1 and 2, in no specified order, Cinnarizine 30 mg oral TDS and Nifedipine 60 mg oral daily
62491113|NCT05201235|EXPERIMENTAL|MAEVAD - DeCaLigne|The experimental group will first receive MAEVAD then the control therapy
62491114|NCT05201235|PLACEBO_COMPARATOR|DeCaLigne - MAEVAD|The control group will first receive the control therapy then MAEVAD
62491115|NCT05623228|EXPERIMENTAL|Therapy Group A|"Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~5 individuals with schizophrenia"
62491116|NCT05623228|EXPERIMENTAL|Therapy Group B|"Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~2 individuals with schizophrenia"
62491117|NCT05623228|EXPERIMENTAL|Therapy Group C|"Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~8"
62491118|NCT05623228|EXPERIMENTAL|Therapy Group D|"Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~8"
62333398|NCT02775552|ACTIVE_COMPARATOR|Comparison areas|(Receive standard government services)
62136903|NCT04566250|ACTIVE_COMPARATOR|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 20mg PO daily x 30 tabs (to be taken only while utilizing Naproxen). In the case of a Naproxen intolerance, a prescription for Meloxicam 15mg PO BID PRN x 60 tabs will be given.~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
62333399|NCT03860545||non-AKI|patient without acute kidney injury (AKI) during perioperative observation period
62491119|NCT05623228|EXPERIMENTAL|Therapy Group E|"Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~3"
62491120|NCT05623228|EXPERIMENTAL|Therapy Group F|"Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~3"
62136904|NCT04566250|OTHER|Standard of Care|The control group is standard of care, which typically includes a prescription for an opioid.
62136905|NCT04075396|EXPERIMENTAL|Part D: Outside of Korea|Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety, tolerability, efficacy and pharmacokinetics (PK) of Lazertinib.
62136906|NCT02540525|EXPERIMENTAL|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
62136907|NCT02540525|ACTIVE_COMPARATOR|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
62136908|NCT01019213|PLACEBO_COMPARATOR|Septal pacing|Septal lead will be activated.
62333400|NCT03860545||AKI|patient with diagnosis acute kidney injury (AKI) established during perioperative observation period
62491121|NCT05623228|EXPERIMENTAL|Therapy Group G|Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented 3
62491122|NCT05623228|EXPERIMENTAL|Therapy Group H|"Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~3"
61938338|NCT00547196|EXPERIMENTAL|Regimen III (TBI, Cyclophosphamide, Fludarabine)|Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
62333401|NCT05929144|OTHER|Healthy volunteers|
62136909|NCT01019213|EXPERIMENTAL|His-pacing|His lead will be activated 80 ms before septal lead
62136910|NCT00229658||Type 1|Patients with type 1 diabetes
62333402|NCT03978819||Patients with large CPA tumors|Patients with large cerebellopontine angle tumors (\>2 x 2cm) undergoing elective surgery
62333403|NCT01341652|EXPERIMENTAL|pTVG-HP vaccine with GM-CSF|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
62333404|NCT01341652|ACTIVE_COMPARATOR|GM-CSF alone|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
62491123|NCT06042296||control group|group 1 -control group normal conjunctiva from 30 patients
62491124|NCT06042296||group 2 primary pterygia|primary pterygia samples from 30 patients
62491125|NCT06042296||group 3 recurrent pterygia|recurrent pterygia samples from 30 patients
62491126|NCT04038866|EXPERIMENTAL|DUAL-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait with a dual-task program with secondary cognitive and upper limb motor tasks.~In this group, the training of the tasks (walking and cognitive or motor) was performed separately and then they were trained at the same time under a progression system. Cognitive/motor secondary tasks were different from those used in the assessment of gait.~Each training session consisted of three parts: the initial warm-up, dual-training, and back-to-calm."
62491127|NCT04038866|ACTIVE_COMPARATOR|SINGLE-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait without a dual-task program (physical and walking exercises without additional load of cognitive or upper limb motor tasks).~Each training session consisted of three parts: initial warm-up, physical exercise in single-task condition, and back-to-calm.~The objectives and walking exercises were the same as those performed in the experimental group."
62491128|NCT04471116|ACTIVE_COMPARATOR|Therapy group|Patients in the therapy group took 1 sachet of OMNi-BiOTiC® FLORA plus + (= 2 g) dissolved in 1/8 l of water once a day
62491129|NCT04471116|NO_INTERVENTION|Control group|Patients in the control group received no additional medication.
62491130|NCT03431636|EXPERIMENTAL|Immersion in cold water|"The athlete will remain submerged in a Cryo Control - Ice Bath Systems® bathtub, which allows filtration and maintenance of constant water temperature, and shoulder blade water (Getto and Golden, 2013) for 15 minutes in the 15 degrees Celsius (Machado et al, 2016)."
62491131|NCT03431636|ACTIVE_COMPARATOR|Ice pack|The athlete will remain for 20 minutes with plastic packets of 500 grams of ice each, in the region of the evaluated muscles.
62491132|NCT03431636|SHAM_COMPARATOR|Control|Group in which the athlete will be instructed to remain seated in a comfortable position, at rest, for 20 minutes.
62491133|NCT04785053|ACTIVE_COMPARATOR|Healthy young participants|a group of 20 cognitively intact younger participants (age 21-35)
62491134|NCT04785053|ACTIVE_COMPARATOR|Healthy older participants|A group of 20 cognitively intact older participants (age 55+)
62491135|NCT04785053|ACTIVE_COMPARATOR|Older MCI/mild AD participants|A group of 20 cognitively impaired older participants (age 55+)
62491136|NCT03701451|EXPERIMENTAL|decitabin and cisplatin induced chemotherapy followed by CC|Treated by demethylated drug decitabine injection combined with cisplatin induced chemotherapy followed by concurrent chemoradiotherapy
62491137|NCT03505996|EXPERIMENTAL|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
62491138|NCT05028140|EXPERIMENTAL|Piemonte association|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 tablet Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
62491139|NCT05028140|ACTIVE_COMPARATOR|Empagliflozin|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
62491140|NCT05028140|ACTIVE_COMPARATOR|Pioglitazone|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 tablet of piglitazone, oral."
62491141|NCT06203080|EXPERIMENTAL|Intervention group|An acetic acid thermoreversible gel developed by Shanghai Jinxiang Latex Products Co. will be allocated to the intervention group.
62491142|NCT06203080|ACTIVE_COMPARATOR|Controlled group|Nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be allocated to the cotrolled group.
62491143|NCT05153304|EXPERIMENTAL|anti-PD1 and personalized vaccine|
62491144|NCT02018263|ACTIVE_COMPARATOR|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
62491145|NCT02018263|ACTIVE_COMPARATOR|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
62491146|NCT02018263|ACTIVE_COMPARATOR|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
61938339|NCT00547196|EXPERIMENTAL|Regimen IV (Fludarabine, Melphalan)|Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
61938340|NCT03590873|NO_INTERVENTION|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
61938341|NCT03590873|EXPERIMENTAL|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
62136911|NCT00229658||Type 2|Patients with type 2 diabetes
62136912|NCT05814653|EXPERIMENTAL|FBT-PC delivered by a primary care provider|Subjects will receive up to 18 sessions of FBT-PC, delivered by a primary care provider, at their primary care clinic over 6 months.
62136913|NCT05814653|ACTIVE_COMPARATOR|Standard FBT|Subjects will receive up to 18 session of FBT, delivered by a specialist mental health provider at Mayo Clinic in Rochester, MN over 6 months.
62136914|NCT06268015|EXPERIMENTAL|Treatment|botensilimab + balstilimab until disease progression, then botensilimab + balstilimab + mFOLFOX6 (leucovorin, fluorouracil, oxaliplatin) + {bevacizumab or panitumumab}
62136915|NCT03763682|EXPERIMENTAL|Genio(TM) system therapy|Genio(TM) bilateral hypoglossal nerve stimulation system
62491147|NCT03284697|ACTIVE_COMPARATOR|DPC with Ca(OH)2|Direct pulp capping with Ca(OH)2.
62491148|NCT03284697|ACTIVE_COMPARATOR|DPC with MTA|Direct pulp capping with MTA
62491149|NCT06057558|NO_INTERVENTION|Observational part of the study|During this part, we will collect saliva, throat and sputum samples from cystic fibrosis patients during their routine consultations in the hospital for one year.
62491150|NCT06057558|EXPERIMENTAL|Probiotic group|Daily use of a probiotic throat spray for 4 weeks
61938342|NCT06556641|EXPERIMENTAL|Part A|"Part A : randomized, open-label, single-dose, two-sequence, two-period, cross-over~Single administration of GZR33, washout period of 14 days, followed by single administration of Insulin Degludec~Single administration of Insulin Degludec, washout period of 14 days, followed by single administration of GZR33"
62491151|NCT00690027|ACTIVE_COMPARATOR|A|"Objective: See Brief Summary, page 2. Eligibility: Patients who require \> 2 units blood transfusion for bleeding esophageal varices due to cirrhosis.~Randomization: By the blind card method to emergency portacaval shunt (EPCS) or emergency endoscopic sclerotherapy (EST) followed by long-term repetitive EST.~Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 8hr. Failure of Therapy: Bleeding requiring \>6u PRBC in first 7 days, or 8 units PRBC during 12 months, or rebleeding after varices were obliterated.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong. Data Collection on line, analysis by biostatistician Florin Vaida, PhD External Advisory, Data Monitoring and Safety Committee by 3 senior academicians."
62491152|NCT00690027|ACTIVE_COMPARATOR|B|Emergency endoscopic sclerotherapy
62491153|NCT06256562|EXPERIMENTAL|GZR18|GZR18 injection s.c.
62491154|NCT06256562|PLACEBO_COMPARATOR|Placebo|Placebo injection s.c.
62491155|NCT05722080|OTHER|simulator Eyesi - new residents|Eyesi simulator learning curve for new ophthalmology residents
62491156|NCT05722080|OTHER|simulator Eyesi/sleep deprivation -confirmed residents|See how experienced residents perform after sleep deprivation using the Eyesi simulator
62491157|NCT05646316|EXPERIMENTAL|Arm 1 (sentinel lymph node mapping)|Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study.
62491158|NCT05646316|EXPERIMENTAL|Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy)|Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study.
62491159|NCT00320684||1|Women who have had anorexia nervosa but are now maintaining a healthy weight
62491160|NCT00320684||2|Women who have never had anorexia nervosa and are maintaining a healthy weight
62491161|NCT04967469|EXPERIMENTAL|take calcitriol|End-stage renal failure patients who is Hyperparathyroid with ESRD take calcitriol
62491162|NCT04967469|EXPERIMENTAL|take alphacalcidol|End-stage renal failure patients who is Hyperparathyroid with ESRD take 1-hydroxycholecalciferol (alfacalcidol)
62491163|NCT04967469|NO_INTERVENTION|control|End-stage renal failure patients who is Hyperparathyroid with ESRD take standard treatment
62491164|NCT01531790|EXPERIMENTAL|Endostar plus pemetrexed/carboplatin|21 days as one cycle, for a total of 4-6 cycles
61938343|NCT06556641|EXPERIMENTAL|Part B|"Part B: randomized, double-blind, placebo-controlled, multiple-dose, parallel~Drug: GZR33 Injection Participants will receive once daily GZR33 Injection or placebo for 6 days, s.c.~Drug: GZR101 Injection Participants will receive once daily GZR101 Injection or placebo for 6 days, s.c."
62136916|NCT04544319|EXPERIMENTAL|Arm I|Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
62333405|NCT03703830|EXPERIMENTAL|Experimental I|Cerebellar transcranial current stimulation associated with locomotor training
62333406|NCT03703830|SHAM_COMPARATOR|Sham comparator I|Cerebellar transcranial current stimulation sham associated with locomotor training
62333407|NCT03703830|EXPERIMENTAL|Experimental II|Cerebello-spinal direct current stimulation associated with locomotor training
62333408|NCT03703830|SHAM_COMPARATOR|Sham comparator II|Cerebello-spinal direct current stimulation sham associated with locomotor training
62333409|NCT05948657|OTHER|PSMA-PET CT|Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
62333410|NCT01318473|OTHER|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
62491165|NCT01968369|ACTIVE_COMPARATOR|tomato sauce (+/- high fat meal)|80 gr for 7 days= total load 560 mg (+/- high fat meal)
62491166|NCT01968369|PLACEBO_COMPARATOR|diet without tomato (+/- high fat meal)|diet without tomato (+/- high fat meal)
62491167|NCT03097692|ACTIVE_COMPARATOR|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
62491168|NCT03097692|ACTIVE_COMPARATOR|Pharmacologic preconditioing|by sevoflurane anesthesia
62136917|NCT04544319|EXPERIMENTAL|Arm II|Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg
62136918|NCT01462149|EXPERIMENTAL|Chemotherapy|Neoadjuvant chemotherapy with docetaxel plus carboplatin
62333411|NCT01520415|ACTIVE_COMPARATOR|bupivacaine|
62333412|NCT01520415|PLACEBO_COMPARATOR|saline|
62333413|NCT04591470||General population|
62333414|NCT04591470||Pazients undergone inguinal hernia correction|
62333415|NCT03437538|ACTIVE_COMPARATOR|First MCO-HD, then High-flux-HDF|Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
62333416|NCT03437538|ACTIVE_COMPARATOR|First High-flux-HDF, then MCO-HD|Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
62333417|NCT00810719|EXPERIMENTAL|Gemcitabine and Erlotinib|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.Erlotinib will be dosed at 150mg orally (tablets) on days 2-5, 9-12, and 16-26 of a 28 day cycle.
62333418|NCT00695591||1SevereRLD,NMD|Patients with FEV1\<40%
62333419|NCT00695591||2VerySevereRLD,NMD|FEV1\<30%
62333420|NCT00695591||3NINV|FEV1\<25%,on non invasive ventilation
61938344|NCT00857883|PLACEBO_COMPARATOR|Part A|Part A: This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing doses of the study drug. Effects will be compared to those seen when a placebo is taken. Up to 4 groups of 6-9 healthy male or female volunteers will be enrolled.
62333421|NCT00695591||ModerateRLD,NMD|Patients with FEV1 40-50% of predicted
61938345|NCT00857883|ACTIVE_COMPARATOR|Part B|Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
61938346|NCT00857883|PLACEBO_COMPARATOR|Part C|Part C: A well tolerated dose selected from Parts A \& B will be used to test whether the drug has an effect on individual preferences for sugary and high fat food, when compared to placebo. Up to 32 healthy overweight male volunteers will be enrolled.
62333422|NCT00575952|EXPERIMENTAL|Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)|"Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62333423|NCT04081883|EXPERIMENTAL|Biosensor algorithm|The biosensor DIABLO algorithm is compared to Continuous Glucose Monitoring Systems (CGMS) utilisation.
62333424|NCT03292679||3D template|Subjects will have custom models of relevant portions of their facial skeleton printed and used as templates for bending and shaping plates for stabilizing the fracture(s).
62333425|NCT03491553|EXPERIMENTAL|Selgantolimod 3 mg: HBeAg-positive CHB Participants|Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
62333426|NCT03491553|EXPERIMENTAL|Selgantolimod 3 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
62333427|NCT03491553|EXPERIMENTAL|Selgantolimod 1.5 mg: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
62333428|NCT03491553|EXPERIMENTAL|Selgantolimod 1.5 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
62333429|NCT03491553|EXPERIMENTAL|Placebo: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
62333430|NCT03491553|EXPERIMENTAL|Placebo: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
62491169|NCT01866124|EXPERIMENTAL|Cash transfer|"Mothers are the primary recipient of the CT. The proposed approach will be based on monthly seasonal CTs during 5 months, from May to September, for two years (2013 and 2014). A monthly 10 000 FCFA will be transferred to the selected households.~These CTs will be done via mobile phones, in collaboration with the mobile phone company Airtel."
62491170|NCT01866124|NO_INTERVENTION|Comparison group|
62491171|NCT01026402|EXPERIMENTAL|AZD2014|AZD2014 dose escalation phase in Part A and expansion phase in Part B.
62491172|NCT02749305|OTHER|Preop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures preoperatively and annually postoperatively will occur with all metabolic and bariatric surgery patients scheduled for surgery at a participating center.
62491173|NCT02749305|OTHER|Postop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures annually postoperatively will occur with all metabolic and bariatric surgery patients who had surgery at a participating center within the preceding 12 months.
61938347|NCT04758078|EXPERIMENTAL|Corticosteroids|Patients will receive inhaled corticosteroids (Budesonide 2 mL = 1000 microgram)
61938348|NCT04758078|PLACEBO_COMPARATOR|Placebo|Patients will receive nebulized 0.9% saline
61938349|NCT05560776|EXPERIMENTAL|2 passes per target on EBUS|
61938350|NCT05560776|EXPERIMENTAL|3 passes per target on EBUS|
61938351|NCT01892865|ACTIVE_COMPARATOR|Historical means method|Operative time will be predicted using historical service means. Schedule will be constructed using this time
61938352|NCT01892865|EXPERIMENTAL|Predictive Modeling System (PMS)|Operative time will be predicted using a regression model. Schedule will be constructed using this time
61938353|NCT04203810|EXPERIMENTAL|Ectoin® Mouth and Throat Spray Althaea Honey|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
62491174|NCT05172921||Exposed|High exposure to environmental pollutants
62491175|NCT05172921||Non-exposed|Low exposure to environmental pollutants
62491176|NCT04435574|EXPERIMENTAL|Group A|group A is lactoferrin group, receiving 100mg sachet of lactoferrin once daily.
62491177|NCT04435574|ACTIVE_COMPARATOR|Group b|group B is the ferrous sulfate group, receiving 6mg/kg/ day single dose of ferrous sulfate.
62491178|NCT03488108|EXPERIMENTAL|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
62491179|NCT03488108|EXPERIMENTAL|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
62333431|NCT05728970||symptomatic|Self-reported symptoms by the subject and/or preliminary assessment of the subject by the Investigator/designee should be suggestive of COVID-19 and/or Influenza at the time of the study visit. The subject must present as symptomatic, exhibiting one or more of the following signs and symptoms: fever, cough, shortness of breath, difficulty breathing, muscle pain, headache, sore throat, chills, repeated shaking with chills, new loss of taste or smell congestion or runny nose, diarrhea, nausea or vomiting. The onset of these symptoms will be recorded and will be within the last twelve (12) days
62333432|NCT04705558|EXPERIMENTAL|group I|Continuous aerobic exercise with ketogenic diet for three month
62333433|NCT04705558|EXPERIMENTAL|group II|Ketogenic diet alone for three month
62333434|NCT05523063||Breast cancer patients followed at CAMI|The trial population concerns all adult patients with breast cancer followed at the Croix-Rousse hospital, who have been under care for less than 3 months or who are going to be treated at the CAMI.
62333435|NCT04344405|EXPERIMENTAL|Vit D|
62333436|NCT04344405|ACTIVE_COMPARATOR|control|
62333437|NCT02734719|EXPERIMENTAL|Group treated with Bonestim|The experimental group will be treated with the electrical stimulation device Bonestim.
62333438|NCT05226819|NO_INTERVENTION|H. pylori negative group|No Intervention
62333439|NCT05226819|OTHER|H. pylori positive and successful eradication group|H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed and the result show that H. pylori is eradicated. At the same time, Patients with successful eradication are instructed to conduct 13C-UBT examination after 6 months,1year and every year after drug withdrawal.
62333440|NCT05226819|OTHER|H. pylori positive and eradication failure group|H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed and the result show that H. pylori is not eradicated.
62333441|NCT02546674|EXPERIMENTAL|Nilotinib|Participants with newly diagnosed CML in chronic phase received nilotinib 300 mg BID for 24 months
62333442|NCT00422838||1|Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
62333443|NCT00422838||2|Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
62333444|NCT03702530|EXPERIMENTAL|Intervention|3x 50 L3 larvae immunisation with albendazole treatment and 2x 50 L3 larvae infection
62333445|NCT03702530|PLACEBO_COMPARATOR|Placebo|3x placebo immunisation with albendazole treatment and 2x 50 L3 larvae infection
62333446|NCT01912937|EXPERIMENTAL|DCB Arm|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
62491180|NCT02131220|EXPERIMENTAL|Prourokinase|Intracoronary bolus infusion of 20mg prourokinase using selective catheter
61938354|NCT04203810|ACTIVE_COMPARATOR|EMSER® Hals- und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
62333447|NCT06347276||PFO closure|Before PFO closure, all patients will undergo brain DW-MRI. During PFO closure, all patients will undergo right atrial angiography to opacify the PFO, and OCT is used to evaluate the PFO microstructure during angiography while the patient performs the Valsalva maneuver. The presence or absence of in situ thrombus within the PFO will be determined, and thrombus size will be measured. Postoperatively, DW-MRI will be performed 24 hours and one month after the transcatheter closure procedure.
62333448|NCT06347276||ASD closure|Before ASD closure, all patients will undergo brain DW-MRI. After the transcatheter closure of ASD, DW-MRI will be performed 24 hours and one month postoperatively.
62333449|NCT02432248|EXPERIMENTAL|Dehydroepiandrosterone|DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
62333450|NCT02432248|PLACEBO_COMPARATOR|Placebo|Medical starch is considered as medicine components. Side effects are minimal at present dosage.
62333451|NCT04848337|EXPERIMENTAL|Study Treatment Arm|Lenvatinib 20 mg Orally Day1-21 with Pembrolizumab 200 mg Intravenously (IV) over 30 minutes Day 1. Each cycle = 21 days
62333452|NCT00798213|EXPERIMENTAL|Participants with AML randomized to SCH 727965|
62333453|NCT00798213|ACTIVE_COMPARATOR|Participants with AML randomized to gemtuzumab ozogamicin|
62491181|NCT02131220|ACTIVE_COMPARATOR|Tirofiban|Intracoronary tirofiban bolus infusion using selective catheter (10ug/kg)
62333454|NCT00798213|EXPERIMENTAL|AML treated w/ SCH 727965 after prog. on gemtuzumab ozogamicin|
62333455|NCT00798213|EXPERIMENTAL|Participants with ALL treated with SCH 727965|
62333456|NCT04836455|EXPERIMENTAL|The Real Cost vaping prevention ads - Health effects theme|
62491182|NCT02131220|PLACEBO_COMPARATOR|Normal saline|Intracoronary saline bolus infusion using selective catheter (20ml)
62491183|NCT03791307|EXPERIMENTAL|Traditional Pilates group|This group will perform only exercises based on the traditional Pilates method
62491184|NCT03791307|EXPERIMENTAL|Modified Pilates group|This group will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer
62491185|NCT03791307|NO_INTERVENTION|Control group|This group will not perform any physical exercise during the trial period.
62491186|NCT04837469|EXPERIMENTAL|Universal Adhesive|universal adhesive
62491187|NCT04837469|EXPERIMENTAL|Etch-And-Rinse Adhesive|Etch-And-Rinse Adhesive
62491188|NCT03391505|EXPERIMENTAL|Treatment Group 1|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
62491189|NCT03391505|EXPERIMENTAL|Treatment Group 2|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
62491190|NCT03391505|PLACEBO_COMPARATOR|Control Group|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
62136919|NCT06415591|ACTIVE_COMPARATOR|True PENFS|Percutaneous electrical nerve stimulation applied to the ear x 4 over a 4 week period. The device is placed over the area of the ear and worn home continuously for a 5-day period, during which time it stimulates at a pre-set on/off duty cycle. At each in-person visit, the device is replaced until the device has been placed 4 times. The stimulation delivered is below the threshold of sensory perception.
62136920|NCT06415591|SHAM_COMPARATOR|Sham PENFS|A device is placed at the same points for the same amount of time and at the same intervals as the true device. This device will not deliver electrical stimulation.
62136921|NCT04663698|EXPERIMENTAL|Healthy|Lung-healthy subjects, randomized lung function testing
62333457|NCT04836455|EXPERIMENTAL|The Real Cost vaping prevention ads - Addiction theme|
62333458|NCT04836455|OTHER|Neutral vaping ads|
62333459|NCT00256048|NO_INTERVENTION|Standard Care|Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
62333460|NCT00256048|ACTIVE_COMPARATOR|Nasojejunal Arm|Patient will receive feeding via a nasojejunal feeding tube
62333461|NCT00964548|EXPERIMENTAL|Dantrolene (low dose)|
62333462|NCT00964548|EXPERIMENTAL|Dantrolene (high dose)|
62333463|NCT06004349||Participants with known or suspected autoinflammatory diseases|Participants with known or suspected autoinflammatory diseases (i.e., Probands)
62333464|NCT06004349||Family member|Family member, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease.
62333465|NCT06004349||Healthy control|
62333466|NCT05459389|NO_INTERVENTION|Group A|antibiotic regimen guided by conventional culture technique (n=24)
62333467|NCT05459389|EXPERIMENTAL|Group B|targeted antibiotics therapy guided by resistance genotyping (n=24)
62333468|NCT03226080|PLACEBO_COMPARATOR|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
62333469|NCT03226080|ACTIVE_COMPARATOR|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
62333470|NCT03017924|EXPERIMENTAL|Q collar|Subjects that will wear the Q collar during the breacher training
62333471|NCT03017924|NO_INTERVENTION|No collar|Subjects that will not wear the Q collar during the breacher training
62333472|NCT01993511||RYGB patients with type 2 diabetes|Preoperative oral glucose tolerance test with 2 h P-glucose \>11.1 mmol/L
62333473|NCT01993511||RYGB patients with IGT|Preoperative oral glucose tolerance test with 2 h p-glucose \>7.8 and \<11.1 mmol/L
62333474|NCT01993511||RYGB patients with NGT|Preoperative oral glucose tolerance test with 2 h p-Glucose \<7.8 mmol/L
62333475|NCT03685799||DHG on Barrett's esophagus|patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection
62333476|NCT05263440|EXPERIMENTAL|Experimental: Female participants with Depression|Female participants with mild to severe depression to determine if a single-session of tDCS can alter negative attention bias. The primary objective is to study if single-session tDCS will affect attention bias in depression and is not meant to treat depression.
62333477|NCT01150955|ACTIVE_COMPARATOR|Resveratrol|Dietary supplement of resveratrol 500 mg three times a day over five weeks.
62136922|NCT04663698|EXPERIMENTAL|Patient 1|COPD patients, randomized lung function testing
62333478|NCT01150955|PLACEBO_COMPARATOR|Placebo|
62333479|NCT06376214|ACTIVE_COMPARATOR|long-term daratumumab treatment group (group A)|The patient will receive the standard protocol of daratumumab combined with dexamethasone treatment, once a week for the first two months, once every two weeks for four months, and then once a month for 18 months.
62491191|NCT02227238|EXPERIMENTAL|DTG arm|Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
62136923|NCT04663698|EXPERIMENTAL|Patient 2|COPD patients, randomized lung function testing
62136924|NCT04663698|EXPERIMENTAL|Patient 3|COPD patients, randomized lung function testing
62136925|NCT04663698|EXPERIMENTAL|Patient 4|COPD patients, randomized lung function testing
62136926|NCT06548607|EXPERIMENTAL|Intervention|RD06-04
62333480|NCT06376214|EXPERIMENTAL|daratumumab combine with ASCT treatment group (group B)|This group of patients will first receive two courses of treatment with the standard protocol of daratumumab combined with dexamethasone. Subsequent patients will receive ASCT treatment, and patients who achieve VGPR or CR after transplantation treatment will be followed up for observation
62491192|NCT02227238|ACTIVE_COMPARATOR|LPV/RTV arm|Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
62491193|NCT01614288|ACTIVE_COMPARATOR|Knee Arthroscopy + HTO|
62491194|NCT01614288|ACTIVE_COMPARATOR|HTO Alone|
62491195|NCT05089903|EXPERIMENTAL|No Order|
62491196|NCT05089903|EXPERIMENTAL|No Order + Text (NO+T)|
62491197|NCT05089903|EXPERIMENTAL|Bulk Order (BO)|
62136927|NCT02644369|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
62491198|NCT05089903|EXPERIMENTAL|Bulk Order + Text (BO+T)|
62491199|NCT05089903|EXPERIMENTAL|Clinician Endorsement (CE)|
62136928|NCT00005820|EXPERIMENTAL|nitrocamptothecin|"Patients receive nitrocamptothecin orally daily for 5 consecutive days each week for 3 consecutive weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until evidence of progression or relapse for a maximum of 2 years from the date of registration."
62136929|NCT05910203|OTHER|Health belief model smoking cessation scale|Describing the thoughts and behaviors of visually impaired individuals about quitting smoking
62136930|NCT05910203|OTHER|Nicotine addiction scale|Evaluation of individuals' smoking cessation status
62136931|NCT06698978|OTHER|Simplified(PS)/Conventional(PC)|Complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months).
62136932|NCT06698978|OTHER|Conventional(PC)/Simplified (PS)|Complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS) in period 2 (3 months).
62136933|NCT04139434|EXPERIMENTAL|Dose Escalation Phase: LP-108 monotherapy|"Three to 6 subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-108 on a once daily schedule for 28 days (a Cycle) starting at a dose of 100 mg."
62136934|NCT04139434|EXPERIMENTAL|Dose Expansion Phase: LP-108 in combination with azacitidine|"Three to 6 subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-108 on a once daily schedule for 28 days (a Cycle) starting at a dose of 100 mg in combination with azacitidine at 75 mg/m2."
62491200|NCT05089903|EXPERIMENTAL|Clinician Endorsement + Text (CE+T)|
62491201|NCT05089903|EXPERIMENTAL|Standard Messaging (SM)|
62136935|NCT01638975|EXPERIMENTAL|Computerized response inhibition training|Participants in this condition receive 8 computerized training sessions over a 4 week period.
62136936|NCT01638975|NO_INTERVENTION|Waitlist Control|Participants assigned to this condition wait without an intervention until the second assessment (4 weeks after the baseline assessment).
62136937|NCT02593149|EXPERIMENTAL|Treatment|ClearGuard HD End Cap
62136938|NCT02593149|NO_INTERVENTION|Control|Tego® connector with the CurosTM for Tego disinfecting port protector
62136939|NCT05517655|EXPERIMENTAL|Pre Trikafta|129Xe MRI
62136940|NCT05517655|EXPERIMENTAL|Post Trikafta|129Xe MRI
62136941|NCT03035851|EXPERIMENTAL|Aerobic exercise|Participants will take part in a supervised 6-month-long aerobic (walk/jog) training program held 3 days/week. Each session will include a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions will follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cool-down, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise will increase from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity will be based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity will build from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
62136942|NCT03035851|OTHER|Stretch and Strength|A control group will meet on a similar schedule as the exercise group for sessions on stretching and toning but without aerobic exercise. Based on prior RCTs of similar interventions the investigators expect this control to be ineffective or minimally effective, but anticipate that it will increase participant enthusiasm and retention. All assessments will be conducted in this arm.
62136943|NCT06408077|EXPERIMENTAL|Water-Group|Intravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
62136944|NCT06408077|EXPERIMENTAL|NaCl-Group|Intravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
62136945|NCT05472207||Patients with cardiovascular diseases|Recording clinical data - especially risk parameters - from patients suffering from cardiovascular diseases
62136946|NCT03022994||NCWS patients|"Forty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2016 and February 2017 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
62491202|NCT05089903|EXPERIMENTAL|Standard Messaging (SM+T)|
62491203|NCT05376423|EXPERIMENTAL|OBI-833/OBI-821|"OBI-833 consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as a carrier protein.~OBI-821 is a purified saponin adjuvant~Dosage form: solution Dosage:30 μg OBI-833/100 μg OBI-821, subcutaneous injection, Frequency: weekly for 4 doses (weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (weeks 6, 8), then every 4 weeks for 4 doses (weeks 12, 16, 20, 24), and then every 8 weeks until disease recurrence, intolerable adverse events/toxicity, consent withdrawal, death, or up to 80 weeks from randomization."
62491204|NCT05376423|NO_INTERVENTION|Observation|Patients will be randomized into OBI-833/OBI-821 (experimental) arm or observation arm.
62491205|NCT01275664|EXPERIMENTAL|Treatment (granisetron, dexamethasone, aprepitant)|Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal \[IP\] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.
62491206|NCT04198701|EXPERIMENTAL|Pilot|First group of patients enrolled in the study.
62491207|NCT04198701|EXPERIMENTAL|Pivotal - Roll-In|First patient treated by each physician in the pivotal phase.
62491208|NCT04198701|EXPERIMENTAL|Pivotal - Paroxysmal AF|Non roll-in patients with paroxysmal AF (intermittent AF).
62491209|NCT04198701|EXPERIMENTAL|Pivotal - Persistent AF|Non roll-in patients with persistent AF (AF that lasts longer than 7 days).
62491210|NCT01807026|EXPERIMENTAL|Cohort A: 70 mg LY2886721|Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.
61938355|NCT03906136|EXPERIMENTAL|TREAT-TO-TARGET (T2T)|"Participants received secukinumab at a dose of 150 milligrams (mg) as subcutaneous (s.c.) injection at 150 mg dose at Baseline, Week 1, 2, 3, 4 and 8. From Week 12, only responders continued to receive 4-weekly doses until Week 32 if they maintained the response. In the event these patients experienced a loss of response from week 24 they were escalated to secukinumab 300 mg s.c. every 4 weeks until Week 32.~Patients who were non-responders at Week 12 will received 4-weekly secukinumab 300 mg s.c. until Week 24. From Week 24, only responders continued to receive 4-weekly secukinumab 300 mg s.c. until Week 32. Patients who are non-responders to secukinumab 300 mg at Week 24 receive biweekly of adalimumab biosimilar 40 mg s.c. until Week 34"
61938356|NCT03906136|ACTIVE_COMPARATOR|Standard-of-care (SOC)|SOC treatment up to the maximum recommended dose at the discretion of the investigator as according to current recommendation for treatment of axSpA
62136947|NCT03022994||IBS patients|"Forty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as control group. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
62333481|NCT06376214|EXPERIMENTAL|Daratumumab and Dexamethasone combined with pomalidomide (DPD) (group C)|newly diagnosed stage IIIb AL amyloidosis patients will received Daratumumab (16mg/kg), dexamethasone (40mg) and pomalidomide. The usage of Daratumumab and dexamethasone is the same as group A. Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6. The dose of pomalidomide is adjusted based on the patient's renal function and ECOG score.
62333482|NCT02278289|ACTIVE_COMPARATOR|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
62333483|NCT02278289|ACTIVE_COMPARATOR|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
62333484|NCT02665234|ACTIVE_COMPARATOR|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
62333485|NCT02665234|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
62333486|NCT02746393|EXPERIMENTAL|Intervention|Health Advocates Program
62333487|NCT02746393|ACTIVE_COMPARATOR|211 Arm|211 Information Sheet
62333488|NCT04213287|EXPERIMENTAL|Peri-Articular Injections and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine~At the end of surgery;~PAI: 30 ml 0,025% bupivacaine and~IPACK: 20 ml 0,025% bupivacaine"
62333489|NCT04213287|ACTIVE_COMPARATOR|Adductor Canal Block, and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine~At the end of surgery;~ADD: 20 ml 0,025% bupivacaine and~IPACK: 20 ml 0,025% bupivacaine"
62333490|NCT04282226|ACTIVE_COMPARATOR|active tVNS|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical
62333491|NCT04282226|PLACEBO_COMPARATOR|sham tVNS|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
62333492|NCT05453513||Neural Underpinnings of Depression Group|All participants will undergo neuroimaging and behavioral tests. during the course of the study (12 months).
62333493|NCT02514460|ACTIVE_COMPARATOR|Intervention: Stents|Stents group
62333494|NCT02514460|ACTIVE_COMPARATOR|Intervention: Atherectomy|Direct Atherectomy group
62333495|NCT04648423|EXPERIMENTAL|sodium oxybate|Sodium oxybate solution for oral administration (175 mg/mL). Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight \> 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
62333496|NCT04648423|PLACEBO_COMPARATOR|placebo|Placebo solution for oral administration. Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight \> 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
62333497|NCT01512641|EXPERIMENTAL|Children with Dissociative Disorders|Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
62333498|NCT03834571|EXPERIMENTAL|Arm I (standard care, carboplatin, paclitaxel)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62333499|NCT03834571|ACTIVE_COMPARATOR|Arm II (standard care, active monitoring)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months."
62333500|NCT02408796|EXPERIMENTAL|OTO-201|6 mg OTO-201
62333501|NCT01375504|ACTIVE_COMPARATOR|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
62333502|NCT01375504|OTHER|Mindfulness Training Program|The mindfulness training program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
62333503|NCT01496430|PLACEBO_COMPARATOR|Placebo QD|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
62333504|NCT01496430|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
62491211|NCT01807026|PLACEBO_COMPARATOR|Cohort A: Placebo|Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).
62491212|NCT01807026|EXPERIMENTAL|Cohort B: 70 mg LY2886721|Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.
62491213|NCT01807026|PLACEBO_COMPARATOR|Cohort B: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).
62491214|NCT01807026|EXPERIMENTAL|Cohort C: 280 mg LY2886721|Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.
62491215|NCT01807026|PLACEBO_COMPARATOR|Cohort C: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).
62491216|NCT02822716|OTHER|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
62491217|NCT06069037|EXPERIMENTAL|SALT surgery|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume
61938357|NCT03533101|EXPERIMENTAL|Tocilizumab 4 mg/kg|Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
61938358|NCT03533101|ACTIVE_COMPARATOR|Tocilizumab 8 mg/kg|Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation
62136948|NCT01431430|EXPERIMENTAL|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
62136949|NCT01431430|ACTIVE_COMPARATOR|Cholecalciferol 12 000 UI (Control)|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
62136950|NCT02138071||Individual|Treatment in the 'Individual group therapy' will include physiotherapy protocols usually used by physiotherapist working at Maccabi Healthcare Services (Exercises, Modalities, Maual therapy and Back Care education)
62136951|NCT02138071||group|Participants in group therapy will receive 6-8 group treatments (6-12 pateints per group) which will also include exercises and back-care education. No intervention will be done by the investigator.Therapists will use protocols commonly used in Maccabi Healthcate Services.
62136952|NCT06598553|EXPERIMENTAL|Comprehensive Sexual Education|All adolescents enrolled in intervention middle schools receive the 22 week program.
62136953|NCT06598553|NO_INTERVENTION|Usual educational program|Usual education program
62333505|NCT01496430|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
62333506|NCT01432652||vascular surgery|Patients undergoing vascular surgery
62333507|NCT02896907|EXPERIMENTAL|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62333508|NCT04671914|ACTIVE_COMPARATOR|Hyaluronic acid gel after D&C|After abortion in the II trimester, we provide D\&C and after the procedure, we apply in uterine cavity Hyaluronic acid gel.
62491218|NCT01929187|ACTIVE_COMPARATOR|Phytonail|Phytonail is a mixture of herbal active ingredients including tea tree oil, lavender oil and Australian blue cypress (ABC) oil with BioEqual carrier system.
62491219|NCT01929187|ACTIVE_COMPARATOR|amorolfine 5% nail lacquer|5% amorolfine
62491220|NCT04626440||Group 1|Group 1 \[(A) subjects who are planning to receive surgery (mastectomy or BCS) as the first-line treatment for BC and followed by adjuvant therapy, or (B) subjects with BC recurrence at screening, who had received surgery for primary BC within 3 years prior to screening, and with primary tumor FFPE tissues available\]
62491221|NCT04626440||Group 2|subjects who are planning to receive neoadjuvant therapy as the first-line treatment for BC and followed by surgery
62491222|NCT04626440||Group 3|Group 3-1 (subjects diagnosed with de novo and treatment naïve stage IV BC); or Group 3-2 \[(A) stage IV subjects with BC recurrence beyond 3 years after surgery (mastectomy or BCS) or stage IV subjects who had received or are currently receiving treatments for BC\].
62491223|NCT05871463|EXPERIMENTAL|Exosome|Standard medication + MSC-derived exosomes at a final dose of 40mg in three weeks
62491224|NCT04454307|EXPERIMENTAL|Tramadol|tramadol 100 mg twice daily for 10 days
62491225|NCT04454307|ACTIVE_COMPARATOR|standard care|standard care plus (placebo twice daily for 10 days).
61938359|NCT00167557|EXPERIMENTAL|Single Arm Study|
61938360|NCT01609231|EXPERIMENTAL|Arm A: Dalotuzumab + Irinotecan|Participants receive irinotecan intravenously (IV), 180 mg/m\^2 once every two weeks + dalotuzumab IV, 10 mg/kg once weekly, during ≥1 42-day treatment cycle(s).
61938361|NCT01609231|ACTIVE_COMPARATOR|Arm B: Cetuximab + Irinotecan|Participants receive cetuximab IV, initial dose of 400 mg/m\^2 and then 250 mg/m\^2 IV weekly + irinotecan IV, 180 mg/m\^2 once every two weeks, during ≥1 42-day treatment cycle(s).
62136954|NCT05408624||prospective group - ultrasound transvaginal drainage|Patients with TOA with ultrasound-guided transvaginal drainage with outpatient management
62333509|NCT04671914|ACTIVE_COMPARATOR|Only D&C|After abortion, in the II trimester, we provide only D\&C.
62333510|NCT05277870|ACTIVE_COMPARATOR|control|Standard eyedrops of IOP-lowering medications
62333511|NCT05277870|EXPERIMENTAL|Nanodropper|Microdrops of IOP-lowering medications using Nanodropper adaptor
62333512|NCT01627067|EXPERIMENTAL|Everolimus + Exemestane + Metformin|Patients take one 25 mg tablet of exemestane once daily, everolimus 10 mg orally per day and metformin 500 mg orally per day for three days. If there are no dose limiting toxicities, dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily. Drugs will be taken immediately after a meal at the same time each day.
62333513|NCT06064786||Group I|15 healthy patients with generalized periodontitis stage III.
62333514|NCT06064786||Group II|15 patients suffering from type 2 diabetes mellitus with generalized periodontitis stage III
62333515|NCT06064786||Group III|15 systemically healthy patients without periodontitis
62136955|NCT05408624||retrospective group - ultrasound transvaginal drainage|Patients with TOA in 2016, 2017 and 2018 with ultrasound-guided transvaginal drainage in conventional hospitalization
62136956|NCT05408624||retrospective group - laparoscopy|Patients with TOA in 2016, 2017 and 2018 with laparoscopy in conventional hospitalization
62136957|NCT01700205|ACTIVE_COMPARATOR|Type of Formula: CMF|Infants are randomized to feed standard cow milk formula during first year of life
62491226|NCT04934254||Newborn Nurses|
62491227|NCT00467597||Group 1|
62491228|NCT01961817|OTHER|Retromolar|"Patients in whom the vocal cord visualisation starts with the retromolar method, which has been randomized determined preoperatively.~The second visualization then will be performed with the conventional method."
62333516|NCT02191709|EXPERIMENTAL|Dextromethorphan syrup|Bisoltussin® Syrup
62333517|NCT02191709|ACTIVE_COMPARATOR|Dextromethorphan soft pastilles|Silomat® DMP soft pastilles
62333518|NCT01438567|EXPERIMENTAL|OXN PR tablets|
62491229|NCT01961817|OTHER|Convenvtional|"Patients in whom the vocal cord visualisation starts with the conventional method, which has been randomized determined preoperatively.~The second visualization then will be performed with the retromolar method."
61938362|NCT02140242|ACTIVE_COMPARATOR|daunorubicin 60 mg/m2|study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5
61938363|NCT02140242|ACTIVE_COMPARATOR|Double induction|study part 2: induction cycles double induction (only patients with good response)
61938364|NCT02140242|EXPERIMENTAL|Single induction|study part 2: induction cycles single induction (only patients with good response)
61938365|NCT05767970|EXPERIMENTAL|Integrated Stress Toolbox for Healthcare Providers (ISTH)|A 12-week synchronous and app-based well-being training that involves weekly 2-hour sessions for weeks 1-8 and at week 12, along with 12-weeks of app-based content delivered through a special version of the Healthy Minds Program app.
61938366|NCT05767970|NO_INTERVENTION|Wait-list control|The wait-list control group will continue with business as usual and receive the ISTH after the last data collection point.
61938367|NCT04406220|ACTIVE_COMPARATOR|Small clog size|
61938368|NCT04406220|ACTIVE_COMPARATOR|Large clog size|
61938369|NCT05149599|EXPERIMENTAL|Treated patients|
61938370|NCT04738409|EXPERIMENTAL|Ov/Ob group|PCOS subjects (Overweight/Obesity)
61938371|NCT04738409|EXPERIMENTAL|N group|PCOS subjects (Normal weight)
61938372|NCT04738409|NO_INTERVENTION|H group|Healthy control subjects
61938373|NCT05109845||Control group|Healthy volunteers
61938374|NCT05109845||Suicidal patients|Patients with a history of suicidal thoughts or behaviors
61938375|NCT05109845||Non-suicidal patients|Patients without a history of suicidal thoughts or behaviors
61938376|NCT02143700||Stable and exacerbated patients|Patients diagnosed of chronic obstructive pulmonary disease in a stable or exacerbated situation. Cognitive assessment of these patients will be performed.
62333519|NCT01438567|ACTIVE_COMPARATOR|OxyPR tablets|
62333520|NCT04088851|EXPERIMENTAL|Metformin - T2D|Participants with type-2 diabetes will intake metformin 1 g daily for 2 weeks
62333521|NCT04088851|PLACEBO_COMPARATOR|No Metformin - T2D|Participants with type-2 diabetes will pause metformin 1 g daily for 2 weeks
62333522|NCT03297099|EXPERIMENTAL|Robot-assisted Laparoscopic operation|Da Vinci surgical robot can overcome limitations of conventional laparoscopic surgery in terms of vision and instrumentation flexibility, making the minimally invasive treatment of complex hepatolithiasis possible.
62333523|NCT03297099|ACTIVE_COMPARATOR|Open surgery|The indication of laparoscopic surgery is mainly for early regional type hepatolithiasis. Open surgery is the traditional treatment method for heptolithiasis.
62333524|NCT02297334|ACTIVE_COMPARATOR|With CytoSorb device|Patients randomised to this arm are treated with the CytoSorb device during bypass.
62333525|NCT02297334|NO_INTERVENTION|Withouot device|Patients randomised to this arm are treated without the CytoSorb device during bypass.
62491230|NCT04672603|EXPERIMENTAL|Complete Preservation of Denonvilliers Fascia|Complete preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
62491231|NCT04672603|NO_INTERVENTION|Partial Preservation of Denonvilliers Fascia|Partial preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
62491232|NCT02235558|EXPERIMENTAL|Verapamil|Super-selective intra-arterial administration of 10 mg verapamil immediately following successful intra-arterial thrombolysis
61938377|NCT05377008|EXPERIMENTAL|Intervention|Parents in the intervention arm will receive one single-session intervention one month after completion of baseline measures. They will also complete a feasibility exit interview one month after completion of their data collection period (i.e., at 7 months).
61938378|NCT05377008|NO_INTERVENTION|Control|Families in the control arm will complete measures at the exact same timepoints as those in the intervention arm but will not receive the single session intervention and will not complete the feasibility exit interview. They will receive the same information as the intervention arm via an education manual at the completion of their data collection period.
61938379|NCT06228885||Children with Autism Spectrum Disorder|
61938380|NCT06228885||Typical developed children|
61938381|NCT02933112|OTHER|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
61938382|NCT01528215|EXPERIMENTAL|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
61938383|NCT01528215|ACTIVE_COMPARATOR|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
61938384|NCT01242228|EXPERIMENTAL|ASP group|Concomitant administration of ASP1941 and DPP-4 inhibitor
61938385|NCT03810144||Vectra Guided|For patients in the guided care arm, treating physicians will receive the Vectra MBDA Test score prior to the patient visit and will have a set of guidance for decision-making based on these scores. Treating physicians will be strongly encouraged to follow the guidance but will not be required to do so. For test results to be available at the time of each visit in the MBDA guided treatment arm, blood testing will be performed 7-10 days before the visit.
61938386|NCT03810144||Usual Care|For patients in the UC arm, treating physicians will not have access to MBDA scores until the end of the study.
61938387|NCT05890742|EXPERIMENTAL|Phase Ib Experimental group|In Phase Ib Experimental group，subjects will receive two cycles of neoadjuvant immunotherapy: the first cycle of IBI310 (1mg/kg) \& Sintilimab (200mg) and the second cycle of Sintilimab (200mg) only.Followed by radical surgery for colon cancer.
61938388|NCT05890742|ACTIVE_COMPARATOR|Phase Ib Control group|In Phase Ib Control group，subjects will receive two cycles of neoadjuvant immunotherapy with 200 mg of sintilimab per cycle, followed by radical surgery for colon cancer.
61938389|NCT05890742|EXPERIMENTAL|Phase III Experimental group|In Phase III Experimental group，subjects will receive two cycles of neoadjuvant immunotherapy: the first cycle of IBI310 (1mg/kg) \& Sintilimab (200mg) and the second cycle of Sintilimab (200mg) only. Followed by radical surgery for colon cancer. Adjuvant chemotherapy will be given or not according to the pathological stage after surgery.
62333526|NCT01928108||iPhone Application|"Participants using an iPhone will download the waterlogged application and use this to track daily water intake for 1 week."
62333527|NCT01928108||Android Application|"Participants using an Android cell phone will download the water your body application and use this to track daily water intake for 1 week."
62333528|NCT01996904|EXPERIMENTAL|arthroscopic repair|"Lateral-anterosuperior portal (Miracle Portal) was used to repair subscapularis tendon. Bursa anterior to the subscapularis tendon was usually removed for the accurate positioning of the suture-hook. Subscapularis tendon was released, pulled and sutured with suture-hook. One or two suture anchors of Modified Mason-Allen technique was used to secure the tendon."
62333529|NCT01996904|ACTIVE_COMPARATOR|arthroscopic debridement|Open and arthroscopic cuff debridement procedures have been described in the literatures for management of massive rotator cuff tears; these generally result in decreased pain and overall improvement in patient's function.
62333530|NCT00675558||Non-Obese (NO)|Patients with a BMI \< 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.
62491233|NCT02121184|ACTIVE_COMPARATOR|Routine Oxytocin|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
62491234|NCT02121184|EXPERIMENTAL|Half-dose Oxytocin|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
62491235|NCT03249844|EXPERIMENTAL|experimental group|Children will be treated by methylprednisolone + prednisolone and standard of care
61938390|NCT05890742|ACTIVE_COMPARATOR|Phase III Control group|In Phase III Control group, subjects will receive radical surgery without neoadjuvant therapy. Adjuvant chemotherapy will be given or not according to the pathological stage after surgery.
61938391|NCT04709354||rheumatoid arthritis patient|Skin and fingernail examination of newly diagnosed (diagnosed before 1 year) rheumatoid arthritis patients will be done. A detailed dermoscopic examination will be performed on the nails of these patients.
61938392|NCT04709354||patients with spondylopathy|Skin and fingernail examination of newly diagnosed (diagnosed before 1 year) patient with spondylopathy will be done. A detailed dermoscopic examination will be performed on the nails of these patients.
61938393|NCT04709354||psoriatic arthritis|Skin and fingernail examination of patient with psoriatic arthritis will be done. A detailed dermoscopic examination will be performed on the nails of these patients. PASI and NAPSI scores of all patients will be calculated.
61938394|NCT04709354||psoriasis patients without joint involvement|Skin and fingernail examination of patient with psoriasis patients without joint involvement will be done. A detailed dermoscopic examination will be performed on the nails of these patients. PASI and NAPSI scores of all patients will be calculated.
61938395|NCT04612582|EXPERIMENTAL|Group1|Group1 is the AL amyloidosis patients who have bortezomib-thalidomide-dexamethason-based regimens for their treatment.
61938396|NCT04612582|EXPERIMENTAL|Group2|Group2 is the AL amyloidosis patients who have bortezomib-cyclophosphamide-dexamethason-based regimens for their treatment.
61938397|NCT04048122|ACTIVE_COMPARATOR|Standard of Care (Control Group)|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
62491236|NCT03249844|NO_INTERVENTION|control group|Children will be treated by standard of care alone
62491237|NCT05759663|EXPERIMENTAL|MIRRAD|A 3 cm vertical incision is made above the umbilicus. The umbilicus is de-attached from the Linea alba so that Linea alba 5-7 cm above and 3-5cm below the umbilicus is exposed. The abdominal rectus muscle diastasis is then plicated with double layer barbed suture. The first suture line is over and over continuous suture and the second suture line continuous suture line. The umbilicus is then re-attached with a single stich .
62491238|NCT05759663|ACTIVE_COMPARATOR|Plication of the entire diastasis arm|A low transverse incision is made and the subcutaneous tissue along the Linea alba dissected. If there is any hernia present in the Linea alba, it is invaginated in a plicated suture line. The entire DRAM along the Linea alba is plicated with continuous sutures. Excessive skin and subcutaneous tissue along the incision is excised and the wound closed. The subcutaneous tissue is closed with interrupted 4-0 PDS stitches.
62491239|NCT06276660|ACTIVE_COMPARATOR|Buffalo Concussion Treadmill Test (BCTT)|"Participants in this group will complete the Buffalo Concussion Treadmill Test (BCTT). This involves individuals walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter."
61938398|NCT04048122|EXPERIMENTAL|MC4PD Strategy Training|This treatment focuses on improving functional performance by enhancing the generation and use of strategies-which can be internal (e.g., self-talk, planning) or external (e.g., checklist, alarm)-to circumvent cognitive processing limitations caused by PD. It uses a standardized approach across and within sessions for all clients while being tailored to each client's cognitive problems and goals.
61938399|NCT03848442|EXPERIMENTAL|UPART intervention group|A 1-group pretest-posttest design was conducted. Outcomes were evaluated on four occasions; twice during baseline separated by six weeks and immediately following a 12-week 'uptime' participation intervention and after a further 12 weeks (follow-up).
62333531|NCT00675558||Morbidly Obese (MO)|Patients with a BMI \> 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.
62333532|NCT00675558||Super-morbidly Obese (SMO)|"Patients with a BMI \> 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.~10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study."
61938400|NCT04867057|EXPERIMENTAL|Experimental: Trichomylin for SAD|18 out of 24 subjects were randomized to receive Trichomylin in a single dose.
61938401|NCT04867057|PLACEBO_COMPARATOR|Placebo Comparator: Placebo for SAD|6 out of 24 subjects were randomized to receive placebo in a single dose.
61938402|NCT04867057|EXPERIMENTAL|Experimental: Trichomylin for MAD|13 out of 17 subjects were randomized to receive Trichomylin in multiple doses.
61938403|NCT04867057|PLACEBO_COMPARATOR|Placebo Comparator: Placebo for MAD|4 out of 17 subjects were randomized to receive Placebo in multiple doses.
61938404|NCT01303783|EXPERIMENTAL|Nifedipine GITS 20 mg|Subjects received 20 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
61938405|NCT01303783|EXPERIMENTAL|Nifedipine GITS 30 mg|Subjects received 30 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
61938406|NCT01303783|EXPERIMENTAL|Nifedipine GITS 60 mg|Subjects received 60 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
61938407|NCT01303783|EXPERIMENTAL|Candesartan cilexetil 4 mg|Subjects received 4 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
61938408|NCT01303783|EXPERIMENTAL|Candesartan cilexetil 8 mg|Subjects received 8 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
61938409|NCT01303783|EXPERIMENTAL|Candesartan cilexetil 16 mg|Subjects received 16 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
61938410|NCT01303783|EXPERIMENTAL|Candesartan cilexetil 32 mg|Subjects received 32 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
62333533|NCT04202562|EXPERIMENTAL|Combined surgery|Participants intervened of combined ab interno trabeculectomy and cataract surgery at the same time
62333534|NCT04202562|ACTIVE_COMPARATOR|Cataract surgery|Participants intervened of cataract surgery alone
62694879|NCT05328622|EXPERIMENTAL|Adherence Incentives Program|The intervention administered to participants is an incentive program designed to motivate participants to attend to/adhere to their prescribed prenatal course of care via the Aqueduct platform.
62333535|NCT03623139|ACTIVE_COMPARATOR|Standard nutritional education|Control group
61938411|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 20/4 mg|Subjects received the combination of 20 mg of nifedipine GITS/4 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
61938412|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 20/8 mg|Subjects received the combination of 20 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
61938413|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 20/16 mg|Subjects received the combination of 20 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
61938414|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 30/8 mg|Subjects received the combination of 30 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
61938415|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 30/16 mg|Subjects received the combination of 30 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
61938416|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 30/32 mg|Subjects received the combination of 30 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
62333536|NCT03623139|EXPERIMENTAL|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
62333537|NCT05051865|EXPERIMENTAL|Camrelizumab Combined With SHR1020|Camrelizumab combined with SHR1020 for advanced melanoma.
62694880|NCT06589934|EXPERIMENTAL|Image quality|Diagnostic Test -Good and excellent rate of PI image quality is greater than or equal to 95%. PI image quality will be assessed by using the retrospective image raw data obtained from CT 5400 RT (applicable body parts include: head, neck, chest, abdomen and coronary)
61938417|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 60/16 mg|Subjects received the combination of 60 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
61938418|NCT01303783|EXPERIMENTAL|Nifedipine/candesartan 60/32 mg|Subjects received the combination of 60 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
61938419|NCT01303783|PLACEBO_COMPARATOR|Placebo|Subjects received placebo (3 tablets and 1 capsule) once daily for 8 weeks
61938420|NCT02047227|EXPERIMENTAL|Pergoveris®|
61938421|NCT02047227|ACTIVE_COMPARATOR|GONAL-f®|
61938422|NCT02148107|EXPERIMENTAL|BI 691751 Dose 1|multiple dose given over 14 days
61938423|NCT02148107|EXPERIMENTAL|BI 691751 Dose 2|multiple dose given over 14 days
61938424|NCT02148107|EXPERIMENTAL|BI 691751 Dose 3|multiple dose given over 14 days
61938425|NCT02148107|EXPERIMENTAL|BI 691751 Dose 4|multiple dose given over 14 days
61938426|NCT02148107|EXPERIMENTAL|BI 691751 Dose 5|multiple dose given over 14 days
61938427|NCT02148107|EXPERIMENTAL|BI 691751 Dose 6|multiple dose given over 14 days
61938428|NCT02148107|PLACEBO_COMPARATOR|Placebo|Placebo
61938429|NCT06680167|ACTIVE_COMPARATOR|patients of group A will receive 60mg of hyperbaric prilocaine 2% for spinal anesthesia|
62333538|NCT06552611|ACTIVE_COMPARATOR|Hand Therapy alone|Participants randomized to hand therapy alone will participate in therapy sessions three times per week, 60 minutes per session for six weeks.
62333539|NCT06552611|EXPERIMENTAL|Hand Therapy + Stimulation|Participants will receive non-invasive transcutaneous electrical spinal cord stimulation paired with hand therapy sessions three times per week, 60 minutes per session, for six weeks.
62333540|NCT05607940|EXPERIMENTAL|blood volume loss based blood transfusion|intraoperative blood transfusion begin once blood volume loss over 400ml
62333541|NCT05607940|ACTIVE_COMPARATOR|hemoglobin concentration based blood transfusion|intraoperative blood transfusion begin once hemoglobin concentration below 70g/L
62333542|NCT01361009||pramipexole group|It's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
62333543|NCT02421497||Normal Healthy Volunteer|
62333544|NCT02421497||Non-CKD Control|
62333545|NCT02421497||Chronic Kidney Disease (CKD)|
62333546|NCT02421497||Dialysis Patients|
62491240|NCT06276660|EXPERIMENTAL|Modified EXiT Test (mEXiT)|Participants in this group will complete the modified EXiT test (mEXiT). Participants will complete a 12 minute treadmill interval program followed by a dynamic circuit (10 squat jumps, 10 side to side push ups and 10 medicine ball rotations), jump ball toss, zig zag agility and arrow agility. Parameters will be recorded the same as the established dynamic EXiT test; heart rate and RPE will be recorded at 0, 2, 6:30 and 12 minutes of the treadmill program as well as after the second trial of each activity. The time to complete two trials of the zig zag agility and arrow agility will also be recorded.
62491241|NCT02886676|EXPERIMENTAL|Spirulina capsules and scaling & root planing|Patients in test group will be provided with Spirulina capsules 2gm daily, after meals for 1 month
62491242|NCT02886676|ACTIVE_COMPARATOR|Placebo capsules and scaling & root planing|Patients in test group will be provided with placebo capsules after meals for 1 month
62491243|NCT05861973|EXPERIMENTAL|Adaptive SMARTer intervention (|Smartphone application, diet and activity goals, online lessons, brief remote sessions with a Health Promotionist. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
62136958|NCT01700205|EXPERIMENTAL|Type of Formula: EHF|Infants are randomized to feed extensively hydrolyzed infant formula during first year of life
62136959|NCT04811924|ACTIVE_COMPARATOR|CXL with MMC|Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
62333547|NCT02421497||Renal Transplant Recipients|
62333548|NCT05867316|EXPERIMENTAL|Unified Protocol|Unified Protocol-based treatment, with three sessions
62333549|NCT01597427|SHAM_COMPARATOR|Clonidine|Administration of 2 μg/kg of intravenous clonidine.
62333550|NCT01597427|PLACEBO_COMPARATOR|Placebo|Injection of placebo solution.
62333551|NCT02270892|ACTIVE_COMPARATOR|Group A|Left side Ulthera treatment
62333552|NCT02270892|ACTIVE_COMPARATOR|Group B|Right side Ulthera treatment
62333553|NCT03010995|ACTIVE_COMPARATOR|18 mg nicotine|E-cigarette with 18 mg nicotine
62333554|NCT03010995|ACTIVE_COMPARATOR|9 mg nicotine|E-cigarette with 9 mg nicotine
62333555|NCT03010995|PLACEBO_COMPARATOR|0 mg nicotine|E-cigarette with 0 mg nicotine
62333556|NCT06288672|ACTIVE_COMPARATOR|True avoidance diet|Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
62333557|NCT06288672|SHAM_COMPARATOR|Sham avoidance diet|Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
62333558|NCT01263691|ACTIVE_COMPARATOR|BioThrax|BioThrax, 0.5 mL AVA per dose
62333559|NCT01263691|EXPERIMENTAL|AV7909 Formulation 1|0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
62333560|NCT01263691|EXPERIMENTAL|AV7909 Formulation 2|0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
62491244|NCT05861973|EXPERIMENTAL|Diabetes Prevention Program Participants (DPP)|Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
62491245|NCT05861973|NO_INTERVENTION|Assessments-Only (Control)|Resources educating on leading a healthier lifestyle, including information on wellness and physical activity. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, 9 months, and 12 months.
61938430|NCT06680167|ACTIVE_COMPARATOR|patients of group B will receive 12.5mg heavy bupivacaine for spinal anesthesia|
61938431|NCT05400824||general population|Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion
62333561|NCT01263691|EXPERIMENTAL|AV7909 Formulation 3|0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
62333562|NCT01263691|EXPERIMENTAL|AV7909 Formulation 4|0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
62136960|NCT04811924|PLACEBO_COMPARATOR|CXL without MMC|Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).
62136961|NCT03019835|ACTIVE_COMPARATOR|GROUP 1|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 1 response of 4 in TOF mode (Train Of Four)
62136962|NCT03019835|ACTIVE_COMPARATOR|GROUP 2|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 2 response of 4 in TOF mode (Train Of Four)
62136963|NCT03019835|ACTIVE_COMPARATOR|GROUP 3|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 3 response of 4 in TOF mode (Train Of Four)
62136964|NCT03019835|ACTIVE_COMPARATOR|GROUP 4|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 4 response of 4 in TOF mode (Train Of Four)
62333563|NCT01263691|PLACEBO_COMPARATOR|Control|Saline control
62333564|NCT03005977|OTHER|Urodynamics, pyridium pad & cough stress|"The Pelvic Floor Bother Questionnaire, a questionnaire standardized by Cleveland Clinic Florida, the Urogenital Distress Inventory (UDI-6), and the numerical analog scale are to be administered prior to and 6 weeks after the surgical intervention. (14, 15)~Prior to surgery, patients will be scheduled for a UDS performed by a qualified nurse practitioner or physician and will be given instructions in verbal and written form to undergo a 24 H pyridium pad test at least 72 hours before the UDS. Patients will be given pyridium TID and report if orange stain is noted on their pad in this period of time. A supine and a standing cough stress test will also be performed."
62333565|NCT02742272||ED Headache or Migraine Patients|The investigators will perform a prospective cohort study of patients ages 6-18 years presenting to the ED with a complaint of headache or migraine over a 12 month period.
62333566|NCT05422352|EXPERIMENTAL|intervention Group|Patients who will receive carnosine supplementation + Vitamin B complex two tablets per day
62333567|NCT05422352|NO_INTERVENTION|Control group|Patients will receive only Vitamin B Complex two tablets per day
62333568|NCT06241755|EXPERIMENTAL|Medium-risk non-muscle invasive bladder cancer (NMIBC)|Induction phase: Once weekly instillation for six consecutive times; Maintenance phase: Once every two weeks (Q2W) for three consecutive times and then once every four weeks (Q4W) for a total of 19 times.
62333569|NCT06241755|EXPERIMENTAL|High-risk non-muscle invasive bladder cancer (NMIBC)|Induction phase: Once weekly instillation for six consecutive times; Maintenance phase: Once every two weeks (Q2W) for three consecutive times and then once every four weeks (Q4W) for a total of 19 times.
62491246|NCT03002935|EXPERIMENTAL|BPM31510 Oral Nanosuspension 4%|Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days. The last study dose (morning dose only) is administered at the clinic on Day 15.
62491247|NCT04254315|EXPERIMENTAL|Cardiac rehabilitation+cognitive therapy|"The intervention group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively.~In addition, the intervention group follows a standardized group based cognitive therapy program with participation of maximum four patients, consisting of 5 sessions (each 2 hours) performed by a trained cardiac rehabilitation nurse."
62491248|NCT04254315|NO_INTERVENTION|Cardiac rehabilitation|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
62491249|NCT04254315|NO_INTERVENTION|Control group without psychological distress|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
62491250|NCT03993535|OTHER|SSRI or cognitive behavioral therapy|selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine) or cognitive-behavioral therapy, depending on availability and patient preference
62491251|NCT00009945|EXPERIMENTAL|Arm 1: Clodronate|Patient receives 2 tablets once daily for 3 years.
62491252|NCT00009945|PLACEBO_COMPARATOR|Arm 2: Placebo|Patient receives 2 tablets once daily for 3 years.
62491253|NCT03985657|ACTIVE_COMPARATOR|Baseline Sleep Study|Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.
62491254|NCT03985657|EXPERIMENTAL|CPAP Sleep Study|Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.
62491255|NCT02734758||Atrial fibrillation stroke|
62491256|NCT02734758||Non-atrial fibrillation Stroke|
62491257|NCT06316336|EXPERIMENTAL|Generic Alfuzosin Hydrochloride 10 mg|Generic Alfuzosin Hydrochloride 10 mg (test drug)
62491258|NCT06316336|ACTIVE_COMPARATOR|Xatral® XL 10 mg|Xatral® XL 10 mg (Alfuzosin Hydrochloride 10 mg (reference drug))
62491259|NCT04316962|EXPERIMENTAL|Complex rehabilitation|See intervention described elsewhere.
62491260|NCT02252016|EXPERIMENTAL|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
61938432|NCT06459765|EXPERIMENTAL|Interventional Arm|Implantation with Mi2000 TICI
62333570|NCT02413125|EXPERIMENTAL|ChitoRino irrigation solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer 1 packet of ChitoRhino irrigation solution (premixed from manufacturer containing sea salt, Chitosan, and sodium bicarbonate). An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
62333571|NCT02413125|EXPERIMENTAL|Normal saline solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer nasal saline (250mL of 0.9% sodium chloride) irrigation solution. An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
62491261|NCT02252016|PLACEBO_COMPARATOR|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
62491262|NCT01971554|EXPERIMENTAL|MK-8666 50 mg|MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
62491263|NCT01971554|EXPERIMENTAL|MK-8666 150 mg|MK-8666, 150 mg, oral, QD, for Days 1 to 14
62491264|NCT01971554|EXPERIMENTAL|MK-8666 500 mg|MK-8666, 500 mg, oral, QD for Days 1 to 14
62491265|NCT01971554|PLACEBO_COMPARATOR|Placebo|Placebo, oral, QD for Days 1 to 14
62491266|NCT01472432|PLACEBO_COMPARATOR|Placebo|In the placebo group, the dose of other concomitant hypoglycemic medication was changed to obtain a similar profile of metabolic parameters. All patients had diabetes and at least one full-thickness wound below the ankle for \>3 months. All patients were examined weekly for the first 4 weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each visit, tracings of the wound margins were made for computer planimetry to document changes in wound size, and photographs were taken for a visual record. All patients followed the regular treatment at the multidisciplinary diabetes foot clinic, included treatment of infection, debridement, off-loading, and metabolic control according to high international standards and standard good medical practice.
62491267|NCT01472432|EXPERIMENTAL|Vildagliptin|The experimental arm followed the same treatment of placebo group, but received also vildagliptin 50 mg per os b.i.d. for 4 months
62491268|NCT03805633||Sarcoidosis Patients|Patients referred to UAB Pulmonology who are diagnosed with sarcoidosis.
62491269|NCT03805633||Diabetes Patients|Patients followed by UAB Endocrinology with diabetes mellitus.
62694881|NCT06640010||Observational|Patients undergo blood sample collection and have their medical records reviewed on study.
62491270|NCT03805633||Sarcoidosis and Diabetes patients|Patients followed by UAB Pulmonary and/or UAB Endocrinology with both sarcoidosis and diabetes mellitus.
62491271|NCT03382041|EXPERIMENTAL|Carbon Fiber Implant|There is an alternative to the standard treatment, which is carbon fiber implants (tibial nails), especially in the prophylactic reinforcement of bones susceptible to pathological fractures following metastatic tumors. The new carbon fiber has also been used in the treatment of tibial non-union (non- healing bone); which has shown satisfactory outcomes.
62491272|NCT03382041|ACTIVE_COMPARATOR|Titanium Implant|The standard of practice in the treatment of fractures of the tibial shaft and other long bones has been the intramedullary nailing using titanium or stainless steel implants.
62491273|NCT02131077|EXPERIMENTAL|treatment|ALLO-ASC-TI injection
62491274|NCT02131077|PLACEBO_COMPARATOR|Placebo|Saline injection
62491275|NCT04766905|EXPERIMENTAL|Issa1|Dr.A.Sayed Issa and his team
62491276|NCT04189627||Participants Treated with GLE/PIB|Participants treated with all oral glecaprevir/pibrentasvir (GLE/PIB) and the decision to treat with GLE/PIB is made before the decision to offer an opportunity to join this study. Prescription of the treatment regimen is at the discretion of the physician and in accordance with local clinical practice and label.
62491277|NCT01298050||Extracorporeal Membrane Oxygenation|All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
61938433|NCT06413927|ACTIVE_COMPARATOR|Active Control: Online Vehicle and Driver Safety Education|Participants in this arm will receive care as usual, and also complete an online video training module on vehicle and driver safety, with a short quiz at the end to determine compliance. The training content will not teach driving skills, as in the other online driver training arm. It requires up to two hours to complete and can be done from any internet-connected computer (at home, at school, etc.).
61938434|NCT06413927|EXPERIMENTAL|Online Driver Skills Training|Participants in the Online Driver Skills Training arm will complete an online driver skill training program known as Accelerated Curriculum to Create Effective Learning (ACCEL) for novice drivers. It requires up to two hours to complete and can be done from any internet-connected computer (at home, at school, etc.).
61938435|NCT06413927|EXPERIMENTAL|Behind-the-Wheel Driver Training|Participants in the Behind-the-Wheel training arm will receive professional behind-the-wheel training course delivered in-person on the road by a local driving school instructor through our partnership with Driver Training Services.
61938436|NCT01624337|EXPERIMENTAL|DHA-piperaquine|DHA-piperaquine monthly 2 day treatment course
61938437|NCT01624337|PLACEBO_COMPARATOR|Placebo|Matching placebo control
61938438|NCT05509166|EXPERIMENTAL|LGBTQ-affirmative Cognitive Behavioral Therapy|Individuals assigned to LGBTQ-affirmative cognitive behavioral therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, delivered via telehealth. Based on the Unified Protocol, sessions will address minority stress mechanisms underlying sexual minority women's depression, anxiety, and alcohol abuse.
61938439|NCT05509166|ACTIVE_COMPARATOR|LGBTQ-affirmative Treatment-as-Usual|Individuals assigned to LGBTQ-affirmative Treatment-as-Usual will receive 10 weekly sessions from a therapist at the Institute for Human Identity who will provide their LGBTQ-affirmative therapy services via telehealth.
62136965|NCT03019835|ACTIVE_COMPARATOR|CONTROL|A control group : not receiving an antagonist (spontaneous recovery)
62333572|NCT03664193|OTHER|Single Arm|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
62333573|NCT00764400|EXPERIMENTAL|Errorless Naming Treatment|
62333574|NCT00764400|EXPERIMENTAL|Verbal+Gestural Facilitation|
62136966|NCT02241538|EXPERIMENTAL|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
62333575|NCT01472172|EXPERIMENTAL|Cryobiopsy|Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
62333576|NCT06179550|ACTIVE_COMPARATOR|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&amp;#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
62333577|NCT06179550|EXPERIMENTAL|The observation group|"Assigned by the random number table.During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with IOE according to the following procedure. The feeding content was formulated by the nutritionists based on the patient\&amp;#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62333578|NCT02375633|EXPERIMENTAL|DW-330SR2|DW-330SR(Pelubiprofen) 45mg twice a day
62333579|NCT02375633|ACTIVE_COMPARATOR|Pelubiprofen|Active Comparator(Pelubiprofen) 30mg three times a day
62333580|NCT05803720|EXPERIMENTAL|Provider Intervention|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain the knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
62333581|NCT05803720|NO_INTERVENTION|Control|No intervention control
62333582|NCT05764356||Novel oral anticoagulants cohort|
62333583|NCT05764356||Ticagrelor cohort|
62333584|NCT01924546|EXPERIMENTAL|Supplementary water|This arm receives up to 3 L of supplemental water during the course of the testing day plus encouragement to drink water.
62333585|NCT01924546|NO_INTERVENTION|Control|No additional water provided during the day. Additional water provided at the end of the school day.
62333586|NCT03047863|EXPERIMENTAL|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
62333587|NCT03047863|PLACEBO_COMPARATOR|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
62333588|NCT04507438|EXPERIMENTAL|Donepezil treatment group|Administration of 5mg or 10 mg of donepezil daily
61938440|NCT06416033||Group A :(Leprosy Group)|About 29 patients newly affected with Leprosy and The plasma irisin level of the participants will be measured by enzyme-linked immunosorbent assay (ELISA).
62136967|NCT02241538|EXPERIMENTAL|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
62136968|NCT02241538|EXPERIMENTAL|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
62136969|NCT02241538|ACTIVE_COMPARATOR|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group will not receive additional exercise.
62136970|NCT05798117|EXPERIMENTAL|YTB323|Single infusion of YTB323
62136971|NCT00940069|EXPERIMENTAL|TS high expression genotype|TS high expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
62136972|NCT00940069|EXPERIMENTAL|TS low expression genotype|TS low expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
62136973|NCT01175187||EPIDURAL FEVER|
62136974|NCT01175187||EPIDURAL WITHOUT FEVER|
62333589|NCT04507438|PLACEBO_COMPARATOR|Control group|Administration of placebo
62333590|NCT00305643|EXPERIMENTAL|Arm I: Celecoxib + Capecitabine|Celecoxib 200 mg given orally twice/day along with standard capecitabine treatment (Initial dose of 750-1500 mg/m\^2 orally twice/day).
62333591|NCT00305643|PLACEBO_COMPARATOR|Arm II: Placebo + Capecitabine|Placebo with standard capecitabine treatment (Initial dose of 750-1500 mg/m\^2 orally twice/day)
62333592|NCT01887249|EXPERIMENTAL|15 day sequential eradication therapy|the 15-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for 10 days.
62333593|NCT01887249|ACTIVE_COMPARATOR|10-day sequential eradication therapy|the 10-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five days
62333594|NCT01887249|NO_INTERVENTION|7-day PPI triple eradication therapy|7-day PPI triple therapy regimen, which consisted of esomeprazole (40mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
62333595|NCT04704999|ACTIVE_COMPARATOR|Tafenoquine standard dose (TQ-current)|"Arm 1~* \>10 kg to ≤20 kg 100 mg~* \>20 kg kg ≤35 kg 200 mg~* \>35 kg 300 mg~Tafenoquine will be given as 100 mg coated tablets. Tablets will be given, and dosing will be based on weight bands."
62491278|NCT00214682|EXPERIMENTAL|Folic acid (400mcg) + Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
61938441|NCT06416033||Group B:(Control Group)|About 29 apparently healthy individuals and The plasma irisin level of the participants will be measured by enzyme-linked immunosorbent assay (ELISA).
61938442|NCT04474249||COVID-19|Patients with PCR-confirmed COVID-19 who were treated in the intensive care unit.
61938443|NCT02242669||AIM 1|200 current DBSA participants.
62136975|NCT01175187||GROUP 1: EPIDURAL FEVER . GROUP 2 EPIDURAL WITHOUT FEVER|
62136976|NCT03175159|ACTIVE_COMPARATOR|Standard of Care (SOC)|Sexual risk-reduction counseling sessions.
62136977|NCT03175159|EXPERIMENTAL|Behavioral Activation & Risk Reduction Counseling|Behavioral activation with risk reduction counseling.
62136978|NCT04810546|EXPERIMENTAL|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
62333596|NCT04704999|ACTIVE_COMPARATOR|Tafenoquine 50% higher dose (TQ-higher)|"Arm 2~* \>10 kg to ≤20 kg 150 mg~* \>20 kg kg ≤35 kg 300 mg~* \>35 kg 600 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
62333597|NCT01523808|EXPERIMENTAL|GRASPA 25|
62333598|NCT01523808|EXPERIMENTAL|GRASPA 50|
62333599|NCT01523808|EXPERIMENTAL|GRASPA 100|
62333600|NCT01523808|EXPERIMENTAL|GRASPA 150|
62136979|NCT04810546|NO_INTERVENTION|Usual care|Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
62491279|NCT00214682|EXPERIMENTAL|Mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
62491280|NCT00214682|EXPERIMENTAL|Mental health literacy|This MHL intervention comprised 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
61938444|NCT02242669||AIM 2|60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
62136980|NCT01357018||patients with rheumatoid arthritis|
62136981|NCT01357018||patients with ankylosing spondylitis|
62333601|NCT04592432|EXPERIMENTAL|SIGN@L-A followed by SIGN@L-B|"Participants in this arm will have access to the prototype SIGN@L-A of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-B."
62333602|NCT04592432|EXPERIMENTAL|SIGN@L-B followed by SIGN@L-A|"Participants in this arm will have access to the prototype SIGN@L-B of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-A."
62333603|NCT03301766|EXPERIMENTAL|Lidocaine 5% patch|"Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
62333604|NCT03301766|ACTIVE_COMPARATOR|Non-medicated patch|"Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
61938445|NCT02242669||AIM 3|100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
61938446|NCT02457481|EXPERIMENTAL|Embryo Culture medium|Embryos from each patient are randomly allocated to culture in the commercial or experimental embryo culture medium (half of the embryos in commercial and half in experimental medium).
62136982|NCT03516370|EXPERIMENTAL|study group|Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
62136983|NCT03516370|PLACEBO_COMPARATOR|control group|Control site received placebo i.e distilled water as a mixture after scaling and root planning.
62136984|NCT06308562|EXPERIMENTAL|Fuzzy Wale Compression Stockinet|Subjects with peripheral arterial disease requiring transtibial amputation will have Fuzzy Wale Compression Stockinet applied 3-7 days pre-operatively and utilized for 4-8 weeks post operatively or until prosthetic fitting and wound has achieved full durable healing.
62136985|NCT06308562|NO_INTERVENTION|Standard of care|Subjects with peripheral arterial disease requiring transtibial amputation will receive standard of care treatment compression stockinet.
62136986|NCT02172560||Premature withdrawal from tiotropium|
62136987|NCT00790699|ACTIVE_COMPARATOR|I-PORT|Treatment group
62136988|NCT00790699|ACTIVE_COMPARATOR|standard injections|control group
62136989|NCT01120977||Male|
62136990|NCT01120977||Female|
62136991|NCT06196749|EXPERIMENTAL|Modified ultrasound-guided dynamic needle tip positioning technique group|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique
62333605|NCT06553534|EXPERIMENTAL|Site A|Site A will begin a transition period of no more than 6 months (while continuing to collect baseline data). During the transition period, the local study team will receive education about the intervention and help tailor the tools and materials to fit their institutional needs. Upon completion of the transition period, Site A will immediately begin the intervention period. They will then remain in the intervention period (using the SAMURAI Bundle) for the remaining study period.
62333606|NCT06553534|EXPERIMENTAL|Site B|Site B will begin a control period of approximately 6 months, during which they will continue to collect data while operating under their institutional standards (No SAMURAI Intervention). At the end of the control period, they will start a transition period of up to 6 months, during which time they will receive education and adapt the tools and materials to fit their institutional needs. At the conclusion of the transition period, they will begin implementing the study intervention (usage of the SAMURAI bundle) for the remaining study period
62491281|NCT00214682|PLACEBO_COMPARATOR|Placebo tablet|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
62491282|NCT00214682|ACTIVE_COMPARATOR|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
62694882|NCT02248493|EXPERIMENTAL|paracetamol and ketoprofen|"paracetamol 20 mg/kg (1% 2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
62694883|NCT02248493|PLACEBO_COMPARATOR|placebo and ketoprofen|"0.9% sodium chloride (2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
62694884|NCT06230341|EXPERIMENTAL|Learning system benefits MSPs|MSPs benefit from a learning system (described in the intervention section). MSPs are encouraged to report PSIs through the web platform provided after the initial training in each MSP and during the period of methodological support.
62136992|NCT06196749|ACTIVE_COMPARATOR|Palpation group|Perform radial arterial cannulation under palpation guidance
62136993|NCT05917015|PLACEBO_COMPARATOR|Placebo Treatment|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
62136994|NCT05917015|EXPERIMENTAL|Dietary supplement intervention|Participants were treated with 2 beta-glucan containing tablets per day for a total duration of 6 weeks.
62333607|NCT06553534|EXPERIMENTAL|Site C|Site C will begin a control period of approximately 1 year, during which they will continue to collect data while operating under their institutional standards (No SAMURAI Intervention). At the end of the control period, they will start a transition period of up to 6 months, during which time they will receive education and adapt the tools and materials to fit their institutional needs. At the conclusion of the transition period, they will begin implementing the study intervention (usage of the SAMURAI bundle) for the remaining study period.
62333608|NCT06553534|EXPERIMENTAL|Site D|Site D will begin a control period of approximately 1.5 years, during which they will continue to collect data while operating under their institutional standards (No SAMURAI Intervention). At the end of the control period, they will start a transition period of up to 6 months, during which time they will receive education and adapt the tools and materials to fit their institutional needs. At the conclusion of the transition period, they will begin implementing the study intervention (usage of the SAMURAI bundle) for the remaining study period.
62333609|NCT06553534|NO_INTERVENTION|Site E|Site E will serve as our control group for the study period, operating according to their institutional standard of care (No intervention) while continuing to collect data.
62333610|NCT01687413|EXPERIMENTAL|Radiotherapy|"* Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions).~* Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy \& cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy \& cisplatin arm) pathways"
62491283|NCT00214682|ACTIVE_COMPARATOR|Pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
62491284|NCT01338090||89Zr-bevacizumab|
62491285|NCT05305495|EXPERIMENTAL|Patients with diuretic resistance|
62694885|NCT00830336|EXPERIMENTAL|Azithromycin (test)|Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
62136995|NCT03526406|EXPERIMENTAL|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
62694886|NCT00830336|ACTIVE_COMPARATOR|Zithromax® (reference)|Zithromax® for Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in second period
62694887|NCT01673919|EXPERIMENTAL|RoActemra/Actemra|
62694888|NCT02955082|EXPERIMENTAL|Carboplatin|Patients with a germline DNA repair gene mutation identified in part 1 of the study, or who are already known to have a germline mutation will undergo assessment for inclusion in part 2 of the study to receive Carboplatin treatment.
62694889|NCT06132204|EXPERIMENTAL|HRS-7535 Tablets-Moderately renal insufficiency subjects|
62694890|NCT06132204|EXPERIMENTAL|HRS-7535 Tablets-Healthy subjects|
62694891|NCT05085847|EXPERIMENTAL|Mindfulness-based intervention (MBI)|Participants received mindfulness training for 8 weeks (two-hour meetings; 16 hours total)
62694892|NCT05085847|ACTIVE_COMPARATOR|Active control group|Participants received lectures for 8 weeks (two-hour meetings; 16 hours total)
61938447|NCT03890952|EXPERIMENTAL|Arm B Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients not undergoing salvage surgery
61938448|NCT03890952|EXPERIMENTAL|Arm A Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients undergoing salvage surgery
62333611|NCT01687413|ACTIVE_COMPARATOR|Radiotherapy, cisplatin|"* Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)~* Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).~* Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy \& cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy \& cisplatin arm) pathways"
62491286|NCT02218398|EXPERIMENTAL|Bronchodilator|Albuterol 3-4 times per day, steroids when necessary.
62491287|NCT02218398|NO_INTERVENTION|No drug|No drug
62491288|NCT05854563||Bronchoscopy subjects, current or former smokers|Bronchoscopy subjects \>=21 yo, current or former smokers
62491289|NCT05854563||Bronchoscopy subjects, never smokers|Bronchoscopy subjects \>=21 yo, never smokers
62491290|NCT03169816|EXPERIMENTAL|Lorcaserin|10 mg capsule taken twice daily of lorcaserin
62491291|NCT03169816|PLACEBO_COMPARATOR|Placebo|a placebo comparator capsule taken twice daily
62491292|NCT02119988|EXPERIMENTAL|TIPS combined with variceal embolization|"The covered stents will be used for TIPS~The gastroesophageal collaterals will be embolized during the procedure of TIPS"
62491293|NCT02119988|ACTIVE_COMPARATOR|TIPS alone|"The covered stents will be used for TIPS~No embolization of any collateral will be performed during TIPS"
62491294|NCT03248128|EXPERIMENTAL|Subjects receiving FF/VI in cohort A|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
62491295|NCT03248128|ACTIVE_COMPARATOR|Subjects receiving FF in cohort A|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
62491296|NCT03248128|EXPERIMENTAL|Subjects receiving FF/VI in cohort B|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
62694893|NCT06225544|EXPERIMENTAL|Lumasiran, treatment arm|Treatment arm with Lumasiran
62694894|NCT06225544|PLACEBO_COMPARATOR|Placebo|Placebo injection with 0.9% sodium chloride
62694895|NCT01661387||Plenadren|Modified release hydrocortisone
62694896|NCT01661387||Other Glucocorticoid Replacement Therapy|
62694897|NCT05910554|ACTIVE_COMPARATOR|Active|Patients randomized to metformin will be assigned the active arm.
61938449|NCT01614600|EXPERIMENTAL|DAILIES® AquaComfort Plus®|Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
61938450|NCT05929053|EXPERIMENTAL|Experimental|Experiment: The Vaccine Education Program based on The Integrated Change Model will be administered to the mothers in the experimental group by the researcher. The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people. Data collection forms will be applied before and after the program.
61938451|NCT05929053|OTHER|Control-waiting list|Control (waiting list): The control group of the study will be the mothers who are on the waiting list. No intervention will be made to the mothers in the control group during the education process of the experimental group. After the training process of the mothers in the experimental group is completed and the post-test data are collected, all the interventions and training will be given to the mothers in the control group.
61938452|NCT01785407|ACTIVE_COMPARATOR|80 mg FeSO4|
62333612|NCT06072872|NO_INTERVENTION|No Portable CPAP|Patients continue life as normal without portable CPAP
62333613|NCT06072872|EXPERIMENTAL|Use of portable CPAP|Patients use portable CPAP during periods of exercise
62694898|NCT05910554|PLACEBO_COMPARATOR|Placebo|Patients randomized to cellulose will be assigned the placebo arm.
61938453|NCT01785407|ACTIVE_COMPARATOR|40 mg FeSO4|40 mg FeSO4
62333614|NCT05560815||The Swedish surgical population|All adult patients (≥18 years) undergoing any surgical procedure registered in SPOR during 1 January 2015 - 31 December 2020.
62333615|NCT00403559|EXPERIMENTAL|Elidel Cream (pimecrolimus)|Elidel Cream to be applied twice daily for 4 weeks
62491297|NCT03248128|ACTIVE_COMPARATOR|Subjects receiving FF in cohort B|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
62491298|NCT05315791|EXPERIMENTAL|a: ground into pieces|0\~3mm
61938454|NCT01785407|ACTIVE_COMPARATOR|160 mg FeSO4|
61938455|NCT01785407|ACTIVE_COMPARATOR|240 mg FeSO4|
61938456|NCT06501690|NO_INTERVENTION|Habitual bedtime|For one week, children will follow their habitual bedtime.
61938457|NCT06501690|EXPERIMENTAL|Late bedtime|For one week, children will go to bed one hour later than their habitual bedtime
62491299|NCT05315791|EXPERIMENTAL|b: replace the bone|0\~3mm
62491300|NCT05315791|EXPERIMENTAL|c: turn inward|0\~3mm
62491301|NCT05315791|EXPERIMENTAL|d: ground into pieces|3\~5mm
62491302|NCT05315791|EXPERIMENTAL|e: replace the bone|3\~5mm
62491303|NCT05315791|EXPERIMENTAL|f: turn inward|3\~5mm
62491304|NCT02160613|OTHER|Open flap for periodontitis patients|Open flap debridement
62491305|NCT06026657|EXPERIMENTAL|Arm I (Gemcitabine, TGFBi)|Patients receive gemcitabine intravenously (IV) over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
62491306|NCT06026657|EXPERIMENTAL|Arm II (Gemcitabine, TGFBi x2)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 and 18 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
62694899|NCT05426083||Physiological Assessment|Prospective physiological assessment of LV work and oxygen consumption in patients with SCAI D/E cardiogenic shock due to acute coronary syndrome treated with peripheral VA-ECMO support.
62694900|NCT02233569|ACTIVE_COMPARATOR|PH|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
62694901|NCT02233569|ACTIVE_COMPARATOR|VS|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
62694902|NCT05771155|EXPERIMENTAL|PB016 (300 mg IV)|PB016 will be administered to patients with moderately to severely active UC on Weeks 0, 2 and 6, and once every 8 weeks thereafter, per the approved dosing regimen of Entyvio®
62333616|NCT00403559|ACTIVE_COMPARATOR|Ketoconazole Cream (Nizoral)|Ketoconazole Cream to be applied twice daily for 4 weeks
61938458|NCT06501690|EXPERIMENTAL|Variable bedtime|For one week, children will go to bed at a prescribed time that will vary each day within +/- 1 hour of habitual bedtime.
61938459|NCT02808377|ACTIVE_COMPARATOR|SPOP|This arm will have the soft silicone pessary inserted post operatively and it will remain in-situ for 3 weeks.
62136996|NCT03526406|PLACEBO_COMPARATOR|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
62491307|NCT06026657|EXPERIMENTAL|Arm III (Gemcitabine naxitamab, TGFBi)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle followed by naxitamab IV over 30-60 minutes on days 1, 4, and 8 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
61938460|NCT02808377|NO_INTERVENTION|Non Intervention|Routine post operative care
61938461|NCT03086278|EXPERIMENTAL|Single Ascending Dose|
61938462|NCT00263770|OTHER|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
62491308|NCT06026657|EXPERIMENTAL|Arm IV (Gemcitabine, naxitamab, TGFBi x2)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle followed by naxitamab IV over 30-60 minutes on days 1, 4, and 8 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 and 18 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
62491309|NCT05772559||Cohort 1 : Patients with acute myeloid leukemia|Patients with acute myeloid leukemia at initial diagnosis or relapse, aged less than 25 years
61938463|NCT00263770|ACTIVE_COMPARATOR|outpatient surgical procedure|where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
61938464|NCT00263770|SHAM_COMPARATOR|Sham surgery|an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
61938465|NCT06403046|EXPERIMENTAL|The Study group|all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space
61938466|NCT06403046|EXPERIMENTAL|The Control group|all patients will be subjected to routine (TMJ) arthrocentesis followed by Meloxicam injection among the patients
61938467|NCT04102943|EXPERIMENTAL|Tacrolimus1|Tacrolimus tablet Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.
61938468|NCT04102943|ACTIVE_COMPARATOR|Tacrolimus2|Tacrolimus Cap Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.
62136997|NCT06259032|EXPERIMENTAL|Mechanical alignment|
62136998|NCT06259032|EXPERIMENTAL|Functional alignment|
62136999|NCT03575624|EXPERIMENTAL|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
62137000|NCT04570358|EXPERIMENTAL|Static stretching|An 8-week home-based static stretching training for the calf muscles will be performed by group A. Altogether, 10 stretches are performed per leg 4 times a week.
62137001|NCT04570358|NO_INTERVENTION|Control|While group A performs the 8-week static stretching training, group B acts as control group performing its daily life activities as usual.
62137002|NCT04570358|EXPERIMENTAL|Proprioceptive neuromuscular facilitation stretching|After group A has finished the 8-week static stretching training, group B starts with the 8-week home-based proprioceptive neuromuscular facilitation stretching training. Altogether, 10 stretches are performed per leg 4 times a week.
61938469|NCT02648269|EXPERIMENTAL|SEL-110|Single intravenous dose of SEL-110
62137003|NCT04570358|NO_INTERVENTION|Follow-up|While group B performs the 8-week proprioceptive neuromuscular facilitation stretching, group A is in its follow-up period performing its daily life activities as usual.
62137004|NCT02369484|OTHER|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
62137005|NCT03677037|EXPERIMENTAL|Short-term MBT|The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
62137006|NCT03677037|ACTIVE_COMPARATOR|Long-term MBT|The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
62333617|NCT03982771|EXPERIMENTAL|BCD regimen|Bortezomib, cyclophosphamide and dexamethasone (the BCD regimen) would be utilized in newly diagnosed iMCD (idiopathic Multicentric Castleman's disease) patients
61938470|NCT02648269|EXPERIMENTAL|SEL-212|Single intravenous dose of SEL-110 plus SEL-037 (pegsiticase)
61938471|NCT02648269|EXPERIMENTAL|SEL-037|Single intravenous dose of SEL-037 (pegsiticase)
61938472|NCT04512170|EXPERIMENTAL|A single dose HEC585（pilot trial arm）|Healthy subjects receive a single dose of HEC585
61938473|NCT04512170|EXPERIMENTAL|Single and Mulltiple doses HEC585（ Part 1, Cohort 1）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
61938474|NCT04512170|EXPERIMENTAL|Single and Mulltiple doses HEC585（ Part 1, Cohort 2）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
62694903|NCT05771155|ACTIVE_COMPARATOR|Entyvio® (300 mg IV)|Entyvio® will be administered to patients with moderately to severely active UC on Weeks 0, 2 and 6, and once every 8 weeks thereafter, per the approved dosing regimen of Entyvio®
62694904|NCT04501120|EXPERIMENTAL|APG2575 single agent|APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.
62694905|NCT04501120|EXPERIMENTAL|APG2575+reduced-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT in R/R AML, MPAL, BPDCN, CMML.
61938475|NCT04512170|EXPERIMENTAL|Single and Mulltiple doses HEC585（ Part 1, Cohort 3）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
61938476|NCT04512170|EXPERIMENTAL|Single dose of HEC585 （Part 2，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
61938477|NCT04512170|EXPERIMENTAL|two-period study at 400 mg dose group (part 3，Fed)|Healthy subjects receive Single/multiple doses of HEC585 or matching placebo in two cycles.
61938478|NCT03624231|EXPERIMENTAL|Arm 1 - stopped after interims analyses|"Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy.~Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1)."
61938479|NCT03624231|EXPERIMENTAL|Arm 2|"Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14.~Overall patients will receive treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total)."
62137007|NCT06294756|ACTIVE_COMPARATOR|Long covid patients undergoing inhalations with sulfurous thermal water (STW)|"Adult Outpatients aged 18-75, presenting to the spa facility with an independent prescription of inhalation therapy with sulfurous water for post-COVID respiratory issues.~Active arm treatment consisted of 12 consecutive sessions of sulfurous thermal water (STW) from Visit 1 for 12 days.~Re-assessment of study analyses was performed on Visit 2 after, 14 days from Visit 1. The follow-up (Visit 3) was 90 days after Visit 1."
62137008|NCT06294756|PLACEBO_COMPARATOR|Long covid patients undergoing inhalations with Sterile Distilled non-pyrogenic Water (SDW)|"Adult Outpatients aged 18-75, presenting to the spa facility with an independent prescription of inhalation therapy with sulfurous water for post-COVID respiratory issues. Placebo arm treatment consisted of 12 consecutive sessions of Sterile Distilled non-pyrogenic Water (SDW) from Visit 1 for 12 days.~Re-assessment of study analyses was performed on Visit 2 after, 14 days from Visit 1. The follow-up (Visit 3) was 90 days after Visit 1."
62137009|NCT06581133|EXPERIMENTAL|Alarm|Patients in the alarm group will have an alarm system placed in their room, scheduled to sound at 4 timepoints during the night (specific timepoints adjusted based on patient's preferred bed times). This intervention will stop when the clinical team has collected sufficient seizures for clinical decision making.
62137010|NCT06581133|NO_INTERVENTION|Control|Patients in the control group will have an alarm system placed in their room, but the alarm system will not sound during any of the nights during their EMU admission.
62333618|NCT04917744||Ancillary-correlative (blood collection, chart review)|Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.
62137011|NCT03253367||Current/former clozapine users|This group has only one visit.
62137012|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
62137013|NCT05317390|NO_INTERVENTION|Retrospective clinical validation of DystoniaNet|Retrospective studies will (1) clinically validate the diagnostic performance of DystoniaNet compared to a normal neurological state (normative test), and (2) develop and test DystoniaNet extensions in comparison with other neurological and non-neurological conditions (differential test).
62137014|NCT05317390|EXPERIMENTAL|Prospective clinical validation of DystoniaNet|Prospective randomized studies will validate DystoniaNet performance for accurate, objective, and fast diagnosis of dystonia in the actual clinical setting.
62333619|NCT06442852||Alzheimer's disease patients|Alzheimer's patients who meet the inclusion criteria and sign an informed consent form
62333620|NCT06442852||Healthy control|Healthy volunteers who meet the inclusion criteria and sign informed consent
62491310|NCT05772559||Cohort 2 : Patients with genetic predisposition to develop acute myeloid leukemia|
62491311|NCT05772559||Cohort 3 : Patients who undergo bone marrow aspirate|Patients who undergo bone marrow aspirate as part of standard of care but without AML nor predisposition to develop AML, as controls
62491312|NCT02125149|NO_INTERVENTION|Control|Standard of care
62491313|NCT02125149|EXPERIMENTAL|Intervention|Exercise intervention from 12 week gestation until delivery
62694906|NCT04501120|EXPERIMENTAL|APG2575+ standard-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT in R/R AML, MPAL, BPDCN, CMML.
62694907|NCT04501120|EXPERIMENTAL|APG2575+ AZA|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in R/R AML, MPAL, BPDCN, CMML.
62694908|NCT04501120|EXPERIMENTAL|APG2575+ AZA(HR-MDS.)|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in HR-MDS.
62694909|NCT04501120|EXPERIMENTAL|APG2575+ AZA(Naïve AML.)|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in treatment naïve AML.
62694910|NCT02614248|EXPERIMENTAL|Coconut Oil|Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
62333621|NCT02795195|EXPERIMENTAL|CIRT Arm (3GyE per fraction)|Patients included in this arm were treated with carbon ion radiotherapy with a fraction size of 3GyE.
62491314|NCT03690349||Skin test in severe asthma exacerbation|Skin test in asthmatic children hospitalized due to severe asthma exacerbation in a preceding year
62491315|NCT03690349||skin test in outpatient|Skin test in asthmatic children without severe asthma exacerbation in a preceding year
62491316|NCT05990894||Standard treatment group|Each patient received subcutaneous low-molecular-weight heparin in adjusted doses for 10 to 14 days, followed by oral anticoagulants (warfarin or dabigatran or rivaroxaban, if warfarin was used, PT-INR was maintained between 2.0 and 3.0) for 6 months or more. The use of endovascular treatment (local thrombectomy/thrombolysis) was reserved for patients who are still progressing with adequate anticoagulant therapy.
62491317|NCT05990894||Steroid therapy group|Patients in the steroid therapy group received short-term steroids in addition to standard anticoagulant therapy.
62137015|NCT06008236|EXPERIMENTAL|Experimental Group|Researcher will be applied progressive muscle relaxation and deep breathing exercises to the students in the experimental group. This practice will be applied to students once a week for six weeks. It will be ensured that the environment is quiet, at room temperature and dim. Students will take their places in chairs at an equal distance from each other. The researcher will be located in a place where his voice is heard by all students, and computers and speakers will be used for music. In addition, black eye patches will be distributed to students to use while exercising before starting the exercises. The muscle groups that are desired to be contracted and relaxed will be as follows (hands, arms, muscles in the face, tongue, head and neck muscles, shoulders, waist, abdominal leg muscles, and feet). At the same time, Lily's Theme which was selected by using the literature and expert opinion, will be played to the students together with the exercises.
62137016|NCT06008236|NO_INTERVENTION|Control Group|No intervention will be applied to the control group. They will be expected to refill the scales at the end of six weeks and on the eighth week for follow-up purposes.
62137017|NCT03459950||Chronic Insomnia group|60 patients with chronic insomnia are included in the Chronic Insomnia group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
62137018|NCT03459950||Normal control group|60 normal people are included in the normal control group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
62137019|NCT00687414||adults|male and female with MDS and MPD and AML
62333622|NCT06514846||Patients Group|"Study Population:~Place of study: Participants will be recruited from the diabetes clinic, Sohag university hospital.~Type of the study: Cross-Sectional Comparative study.~Patients:~v Study group: participants of the study will meet the following criteria:~Ø Inclusion criteria:~ü Age: 30-55 y~ü Type of diabetes: Type 2~ü Duration of diabetes: Within 1 Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria~ü Gender: Both males \& females~Ø Exclusion criteria:~Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse."
62333623|NCT02410902|EXPERIMENTAL|CM-AT|Active substance in single unit dose powder
62333624|NCT02410902|PLACEBO_COMPARATOR|Placebo|Placebo powder of inactive substance
62137020|NCT00687414||Healthy|Healthy control group
62333625|NCT00688168||Symptom Assessments|Patients diagnosed with multiple myeloma (MM) complete questionnaires with Neurocognitive Testing and Neurosensory Testing
62333626|NCT02397993||FNA, blood collection|blood collection prior to fine needle aspiration Endoscopic ultrasonography-guided fine needle aspiration of the pancreas blood collection after to fine needle aspiration
62333627|NCT04229589||Study population|Consecutive patients undergoing pacemaker implantation for bradyarrhythmic syncope
62491318|NCT01140672|EXPERIMENTAL|Cohort 1 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
62333628|NCT03734081|EXPERIMENTAL|Gastric electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
62333629|NCT03734081|EXPERIMENTAL|Electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
62333630|NCT03734081|EXPERIMENTAL|Electrical stimulation with type 1 ODC|Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
62333631|NCT00962039|EXPERIMENTAL|Citalopram|Citalopram was initiated at 10 mg daily for one week, with dosage increased to 20 mg daily during week 2, with an optional increase to 40 mg daily at week 4 or thereafter if response was judged to be suboptimal (CGI-I or CGI-S \> 2).
62333632|NCT00962039|PLACEBO_COMPARATOR|Placebo|Placebo administered in capsules identical to those containing citalopram using microcrystalline cellulose.
62491319|NCT01140672|EXPERIMENTAL|Cohort 2 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
62491320|NCT01140672|EXPERIMENTAL|Cohort 3 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)
62491321|NCT01140672|EXPERIMENTAL|Cohort 4 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)
62491322|NCT01140672|EXPERIMENTAL|Cohort 5 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)
62491323|NCT01140672|EXPERIMENTAL|Cohort 6 (N=10) Optional cohort|Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)
62491324|NCT05758753|EXPERIMENTAL|Stage I Neurotrophic Keratopathy|Clinical findings of corneal hyperplasia and irregularity, scattered small facets of dried epithelium, decreased nerve density as assessed by in vivo confocal microscopy (IVCM), and decreased corneal sensation.
62137021|NCT04069416||Group I|175 patients who fall within the Milan criteria.
62137022|NCT04069416||Group II|36 patients who fall within up-to-7 criteria
62333633|NCT05752851||T2DM group|Collect stool and blood samples，No drugs use.
62333634|NCT05752851||Control group|Collect stool and blood samples，No drugs use.
62333635|NCT01155648|EXPERIMENTAL|PSV group.|Chest wall compression plus increase of 10 cmH2O of PSV.
62491325|NCT05758753|EXPERIMENTAL|Stage II Neurotrophic Keratopathy|Clinical findings of corneal epithelial defect with smooth and rolled edges, decreased nerve density as assessed by in vivo confocal microscopy (IVCM), and decreased corneal sensation.
62491326|NCT05758753|EXPERIMENTAL|Dry Eye Disease|Symptoms of dry eye disease for at least 3 months, supported by clinical finding of decreased tear film break-up time or ocular surface staining. Normal corneal sensation.
62491327|NCT05758753|EXPERIMENTAL|Healthy Individuals|Absence of any ocular symptoms, absence of surface findings (including corneal or conjunctival staining, corneal scar or surgical wound), and normal corneal sensation.
62491328|NCT05945472|EXPERIMENTAL|Positive reinforcement method|"The people who form the intervention groups will receive a facial cosmetic of natural components to be administered for 28 days, for which they will be given the cream.~The cream will be provided to the participants on the 1st day of the talk. The container containing the facial cosmetic will be applied twice a day, morning and evening.~Afterwards, in the experimental group, the participants will be given a talk on how to administer it according to the positive reinforcement method."
62491329|NCT05945472|ACTIVE_COMPARATOR|Standard method|"The people who form the intervention groups will receive a facial cosmetic of natural components to be administered for 28 days, for which they will be given the cream.~The cream will be provided to the participants on the 1st day of the talk. The container containing the facial cosmetic will be applied twice a day, morning and evening."
62491330|NCT05945472|NO_INTERVENTION|Control|This group will continue to use their usual cosmetics and complete the questionnaire on the first day of the study and on the last day of the study (28 days later).
62491331|NCT01214590|EXPERIMENTAL|VascuActive Treatment|
62491332|NCT04852627|ACTIVE_COMPARATOR|Exercise group|Will brisk walk 30 minutes 3 times weekly
62491333|NCT04852627|NO_INTERVENTION|Control group|No intervention
62333636|NCT01155648|ACTIVE_COMPARATOR|chest wall compression group|Chest wall compression
62491334|NCT03853187|EXPERIMENTAL|Durvalumab (MEDI4736) neo-adjuvant|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC. Patients are amendable to adjuvant chemo and/or radiation treatment, per standard-of-care. Additionally, patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and ex vivo In-111-oxine or in vivo \[89Zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
62491335|NCT01675596|EXPERIMENTAL|Test|SAPIEN XT™ valve with the NovaFlex and NovaFlex+ delivery systems.
62491336|NCT05215496|EXPERIMENTAL|[18F]fluoro-PEG-folate PET/CT scan|Patients with FIGO stage IIIB/IIIC epithelial ovarian cancer, 185 MBq of \[18F\]fluoro-PEG-folate.
62491337|NCT06252363||Practicing physiotherapists|French- or Dutch-speaking physiotherapists currently practicing their profession
62491338|NCT02934334||MDD|Major Depressive Disorder
62137023|NCT04069416||Group III|30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).
62491339|NCT03215641|NO_INTERVENTION|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
62333637|NCT02421367|EXPERIMENTAL|TDENV-PIV (0-1)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168."
62491340|NCT03215641|EXPERIMENTAL|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
62491341|NCT04448730||Group 1 (normal weight with PCOS )|35 cases
62491342|NCT04448730||overweight PCOS|38 cases
62137024|NCT05568017|EXPERIMENTAL|Y-90-DOTATOC|Patients will receive PRRT with Y-90-DOTATOC
62137025|NCT04637763|EXPERIMENTAL|Dose Escalation of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
62137026|NCT04637763|EXPERIMENTAL|Expansion of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
62137027|NCT00999336|ACTIVE_COMPARATOR|Group H|Healthy subjects matched to the renal impairment groups
62137028|NCT00999336|EXPERIMENTAL|Group A|Patients with mild renal impairment
62137029|NCT00999336|EXPERIMENTAL|Group B|Patients with moderate renal impairment
62333638|NCT02421367|EXPERIMENTAL|TDENV-PIV (0-1-6)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84."
62333639|NCT02421367|EXPERIMENTAL|TDENV-PIV (0-3)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28."
62491343|NCT03065751|ACTIVE_COMPARATOR|TPE|
62491344|NCT03065751|NO_INTERVENTION|Kontroll|
62137030|NCT00999336|EXPERIMENTAL|Group C|Patients with severe renal impairment
62137031|NCT01211184|PLACEBO_COMPARATOR|Fasting|patients undergo surgery in the fasting state
62137032|NCT01211184|ACTIVE_COMPARATOR|Water administration|Patients undergo hip surgery after receiving 800 ml water by mouth the morning 2 hours before surgery
62491345|NCT04060251|EXPERIMENTAL|Group 1, iGetBetter Group|Use only iGetBetter for the 3 months preceding surgery. After surgery, you will be given a new, Post-Op program to use for 2-3 months. For the first 3 weeks, you will only use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks.
62491346|NCT04060251|EXPERIMENTAL|Group 2, E-vive Group|You will use iGetBetter starting 3 months out from surgery. You will receive CyMedica's electrical-stimulation garment during the preoperative appointment. In addition to iGetBetter, you will wear the conductive garment two times each day for the last 3 weeks before surgery. After surgery, for the first 3 weeks you will only use the conductive garment, and will not use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to wearing the brace, approximately twice per week for the next 6-8 weeks. You will not need to return the brace after this time is up, and you may keep the brace, if you so choose, at no cost.
62491347|NCT04060251|NO_INTERVENTION|Group 3, Physical Therapy Group|You will receive only iGetBetter for the 3 months preceding surgery. After surgery, you will receive only home physical therapy, and will not use iGetBetter. After those three weeks, you will receive outpatient physical therapy approximately twice per week for the next 6-8 weeks.
62491348|NCT04070898|NO_INTERVENTION|control group|Bladder catheter removal 24 hours after surgery
62491349|NCT04070898|EXPERIMENTAL|experimental group|Removal of the bladder catheter after the surgical intervention
62137033|NCT01211184|ACTIVE_COMPARATOR|carbohydrate drink|Patients undergo hip surgery after receiving 800 ml carbohydrate drink by mouth
62137034|NCT02672033|EXPERIMENTAL|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
62333640|NCT02750800||Adalimumab and AbbVie Care 2.0|Adalimumab administered via subcutaneous (SC) injection for 12 months according to the approved EMA label and Hungarian financial protocols and supportive services via the AbbVie Care 2.0 patient support program
62333641|NCT00200252|ACTIVE_COMPARATOR|group B|women in group B will receive 10 uts oxytocin IM
62333642|NCT00200252|ACTIVE_COMPARATOR|group C|women in group C will receive oxytocin 5 uts IV
62333643|NCT00200252|ACTIVE_COMPARATOR|group A|women in group A will receive oxytocin 5 uts IM
62333644|NCT04705324|EXPERIMENTAL|Operative Hysteroscopy|Hysteroscopic separation
62333645|NCT04705324|ACTIVE_COMPARATOR|Dilation and Curettage|Curettage separation
62333646|NCT04705324|EXPERIMENTAL|Feasibility and safety|The first 15 patients recruited will not undergo randomization and will compose the preliminary safety and feasibility phase
62333647|NCT04284956|EXPERIMENTAL|Proximal group|Proximal segment of saphenous veins are harvested from the thigh by No-Touch technique and randomized to bypass the left or right territory of coronary system
62491350|NCT03416049||High-power PEMF device|20 participants with VSLU will receive PEMF therapy with a high-power PEMF device for 10 minutes twice a day for each VSLU area.
62491351|NCT03416049||Medium-power PEMF device|20 participants with VSLU will receive PEMF therapy with a medium-power PEMF device for 15 minutes twice a day per VSLU area.
62491352|NCT03416049||Low-power PEMF device|20 participants with VSLU will receive PEMF therapy with a low-power PEMF device for 30 minutes twice a day per VSLU area..
62491353|NCT03416049||Sham PEMF device|20 participants with VSLU will receive PEMF therapy with a sham PEMF device identical to the low-power PEMF device and will treat each VSLU area for 15 minutes twice a day.
62491354|NCT03472196|EXPERIMENTAL|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
61938480|NCT05982548|EXPERIMENTAL|Intervention group|"The VR intervention was created using the Unreal Engine software (Unreal Engine, 2022). The VR intervention includes the scenario of a home.~Participants will view the home as a first person character and experience psychotic phenomena including auditory hallucinations. The intervention will be delivered in one setting and lasts no more than seven minutes. It will be disseminated using smartphone inserted into VR headset equivalent of google cardboard."
62333648|NCT04284956|ACTIVE_COMPARATOR|Distal group|Distal segment of saphenous veins are harvested from the shank of the ipsilateral leg by No-Touch technique and used to bypass the right or left territory of coronary system (depending on the randomizing result of the proximal segments)
62333649|NCT02530606|EXPERIMENTAL|Diagnostic (PAI)|Patients undergo PAI over 15-30 minutes prior to the ovarian excision.
62491355|NCT03207152|EXPERIMENTAL|Influenza A/California/04/2009|Participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
62333650|NCT01819545||Alzheimer's disease|no intervention
62333651|NCT01819545||Mild cognitive impairment|no intervention
62333652|NCT01819545||Normal aging|no intervention
62333653|NCT01175278|NO_INTERVENTION|Observation Arm|Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
62333654|NCT01175278|EXPERIMENTAL|Balloon Kypholasty|
62333655|NCT01175278|ACTIVE_COMPARATOR|Control Arm|Non-surgical Management Treatment Group
62333656|NCT01675011|EXPERIMENTAL|Embozene® Microspheres|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
62333657|NCT01675011|ACTIVE_COMPARATOR|Embosphere®|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
62333658|NCT06206668|NO_INTERVENTION|Control Group|Participants will watch a video of landscapes without human or animal movement.
62491356|NCT01146080|EXPERIMENTAL|Promus Element|21 consecutive patients with Promus Element implanted to treat coronary artery lesion
62491357|NCT01146080|ACTIVE_COMPARATOR|Promus|21 consecutive patients with Promus stent implanted to treat coronary artery lesions
62491358|NCT00394303|EXPERIMENTAL|1|Intervention
62491359|NCT00394303|NO_INTERVENTION|2|Control
62491360|NCT05368753|EXPERIMENTAL|thoracic epidural analgesia|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period
62491361|NCT05526703|EXPERIMENTAL|Experimental Group|
62491362|NCT05526703|ACTIVE_COMPARATOR|Comparator Group|
62491363|NCT01687335||cancerous patients|the patients benefiting from treatment by chemotherapy.
62491364|NCT01654484|EXPERIMENTAL|Low Dose DE-117|Monotherapy
62491365|NCT01654484|EXPERIMENTAL|Medium Dose DE-117|Monotherapy
62694911|NCT02614248|ACTIVE_COMPARATOR|Standard of Care|Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
62694912|NCT04812483|OTHER|Standard Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1:~No planed further treatment. = standard therapy (without eltrombopag)"
62333659|NCT06206668|EXPERIMENTAL|Intervention Group with Referent (GIR)|Participants will observe actions whose referent has been selected by themselves based on perceived similarity. A total of 16 different videos will be used, with 4 new videos each week. The videos will gradually increase in difficulty as the study progresses. All exercises are exercises used to improve balance.
62333660|NCT06206668|ACTIVE_COMPARATOR|Standard Intervention Group (GIE)|Participants will observe actions with a standard reference. In this case, a basic digitally designed faceless doll will be used. A total of 16 different videos will be used, with 4 new videos each week. The videos will gradually increase in difficulty as the study progresses. All exercises are exercises used to improve balance.
62333661|NCT04758429||Development or Training Cohort|will provide the data to be used for algorithm development and training.
62333662|NCT04758429||Test or Validation Cohort|will provide data to be used for algorithm validation.
62333663|NCT01555112|EXPERIMENTAL|Topical AS101|15% AS101 ointment applied twice a day for treatment of external genital warts.
62491366|NCT01654484|EXPERIMENTAL|High Dose DE-117|Monotherapy
62491367|NCT01654484|EXPERIMENTAL|Low Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
62491368|NCT01654484|EXPERIMENTAL|Med. Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
62491369|NCT01654484|EXPERIMENTAL|High Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
62491370|NCT01654484|ACTIVE_COMPARATOR|0.0015% tafluprost|Monotherapy
62694913|NCT04812483|EXPERIMENTAL|Study Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2:~The subjects in the experimental arm will be treated with eltrombopag:~Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows."
61938481|NCT05982548|ACTIVE_COMPARATOR|VR control group|The VR control group will view the scenario of the same home without the simulated visual and auditory hallucinations.
62333664|NCT00307515|EXPERIMENTAL|1|Fibrin Sealant 2 (FS2)
62333665|NCT00307515|ACTIVE_COMPARATOR|2|Oxidized Regenerated Cellulose (Surgicel)
62333666|NCT04286542|EXPERIMENTAL|Provocation with cold air|Participants will be exposed to cold dry air for 15 minutes
62333667|NCT00538980|EXPERIMENTAL|All patients|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
62491371|NCT01654484|PLACEBO_COMPARATOR|Placebo|Monotherapy
62491372|NCT00096460|ACTIVE_COMPARATOR|Autologous Transplant|Cyclophosphamide and Rituximab with Filgrastim conditioning and chemotherapy or radiation therapy prior to autologous Hematopoietic Stem Cell Transplant (HSCT). Rituximab maintenance therapy following HSCT.
62491373|NCT00096460|ACTIVE_COMPARATOR|Allogeneic Transplant|Non-myeloablative conditioning regimen followed by allogeneic Hematopoietic Stem Cell Transplant (HSCT). Graft-versus-Host Disease (GVHD) Prophylaxis therapy following HSCT.
62491374|NCT00950300|ACTIVE_COMPARATOR|Herceptin IV + Chemotherapy|Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
62491375|NCT00950300|EXPERIMENTAL|Herceptin SC + Chemotherapy|Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
62491376|NCT03456544||VAN-AKI|Patients who had vancomycin associated acute kidney injury.
62491377|NCT03456544||None VAN-AKI|Patients who didn't have vancomycin associated acute kidney injury.
62491378|NCT05390255|EXPERIMENTAL|Nasal spray hormone therapy|This group of patients received nasal steroid therapy throughout the study. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
62491379|NCT05390255|EXPERIMENTAL|Nasal spray hormone therapy + oral hormone therapy|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of nasal spray hormone treatment throughout the course. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
62491380|NCT05390255|EXPERIMENTAL|Nasal spray hormone therapy + omalizumab therapy|The patients in this group were injected with omalizumab once a month under the background of nasal spray hormone therapy, for a total of 6 times. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
62491381|NCT03483818|ACTIVE_COMPARATOR|Pharmacist-Led Pathway|Assessment \& Treatment of HCV infection with oral antivirals in a community pharmacy pathway
62491382|NCT03483818|ACTIVE_COMPARATOR|Conventional Care Pathway|Assessment \& Treatment of HCV infection with oral antivirals in a conventional care pathway
62491383|NCT05856760|EXPERIMENTAL|sparsentan|Sparsentan will be administered daily as a 200-mg oral tablet. The goal is to titrate from the initial dose of 200 mg (Day 1) to the target dose of 400 mg at Week 2.
62491384|NCT05210608|EXPERIMENTAL|Working Memory Training (Active Training) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
62491385|NCT05210608|ACTIVE_COMPARATOR|Control Training (CT) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Control Condition Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
62491386|NCT03062787|EXPERIMENTAL|Cingal®|Single 4 ml intra-articular injection of Hyaluronic Acid plus Triamcinolone Hexacetonide
62694914|NCT06038175|EXPERIMENTAL|vHIT testing|For the research portion of this study, following standard of care examinations listed above, the patient would have a vHIT headset placed on their head for approximately 3-5 minutes to test if they exhibit corrective saccadic movements and to measure gain reduction to identify vestibular hypofunction. During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is \<0.8 in the presence of refixation saccades .
62694915|NCT06038175|ACTIVE_COMPARATOR|Standard of Care|The intervention group will be compared to standard of care provided to patients currently admitted for dizziness. Standard of care includes National Institute of Health Stroke Scale evaluation, evaluation by a neurologist, and a CT scan or MRI if warranted.
62694916|NCT05521269|EXPERIMENTAL|ANX1502 SAD|Participants will be administrated a single oral dose of ANX1502 at various ascending dose levels or matching placebo.
62694917|NCT05521269|EXPERIMENTAL|ANX1502 MAD|Participants will be administrated multiple oral doses of ANX1502 at various ascending dose levels or matching placebo for 14 days.
62137035|NCT06231368|EXPERIMENTAL|CNCT19 CAR T-Cell Therapy|Participants will receive CNCT19 cell infusion after preconditioning, and they need to be closely monitored for 24 hours following CAR-T cell infusion. Participants are advised to remain in the hospital for a minimum of 14 days following cell infusion. The duration of hospitalization and observation will be determined based on the researcher's comprehensive assessment of the subject's condition.
62137036|NCT05320289|EXPERIMENTAL|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
62333668|NCT02251054|EXPERIMENTAL|Avatar group|"Intervention group viewed two avatar coaches: a generic avatar coach (GAC) and a self-avatar, peer mentor (SAP)."
62333669|NCT02251054|ACTIVE_COMPARATOR|No Avatar group|The control group version (voice only) observed the identical program, including introductions, question asking, narration of animations, delivery of key points, and summary of each section with identical pre-recorded voices without the avatars.
62491387|NCT03062787|ACTIVE_COMPARATOR|Monovisc®|Single 4 ml intra-articular injection of Sodium Hyaluronate
62491388|NCT05653934|EXPERIMENTAL|Immersive reality group|patients receive care according to the usual practices of the department as well as virtual reality. Virtual reality immersion offers a visual and auditory experience during a soothing journey through visual worlds filmed in natural environments. Virtual reality headset is put on the day before the operation and in the morning just before going to the operating theatre (only on the morning of the operation for patients hospitalized the same day). The colorectal cancer surgery then proceeds as usual. In the postoperative period, virtual reality sessions are offered every day and on request without any limit in number (day and night).
61938482|NCT04148820|EXPERIMENTAL|Once daily drug administration|Patients will be given cardiovascular drugs once daily
61938483|NCT04148820|EXPERIMENTAL|Twice daily drug administration|Patients will be given cardiovascular drugs twice daily
62333670|NCT02627131|EXPERIMENTAL|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
62333671|NCT05116540|EXPERIMENTAL|Treatment|Adipose derived Mesenchymal stem cells (Autologous)
62333672|NCT05116540|PLACEBO_COMPARATOR|Placebo|Normal Saline
62333673|NCT01919333||laparoscopic ovarian cystectomy|the group who laparoscopic ovarian cystectomy are performed for endometrioma
62333674|NCT01919333||laparoscopic non- ovarian pelvic surgery|the group whom laparoscopic non- ovarian pelvic surgery are performed
62491389|NCT05653934|ACTIVE_COMPARATOR|Standard care group|patients are treated according to usual practices of the department and do not have access to virtual reality.
61938484|NCT06414408|ACTIVE_COMPARATOR|Daily Dosing|Participants will be randomized to take once daily doxycycline 200mg for six weeks.
62137037|NCT03322995|EXPERIMENTAL|Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response \[decline in carbohydrate antigen 19-9 (CA19-9) values\] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
62491390|NCT03522649|EXPERIMENTAL|Napabucasin plus FOLFIRI|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours. For patients who have failed bevacizumab with irinotecan-based chemotherapies, bevacizumab may be administered with FOLFIRI. FOLFIRI infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks, starting on C1D1. If bevacizumab is added to FOLFIRI, bevacizumab infusion should start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion. 5-FU 400 mg/ m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/ m\^2/day continuous infusion. For patients who could not tolerate FOLFIRI at the full dose previously, FOLFIRI should be started at the same dose level the patient tolerated FOLFIRI previously.
62491391|NCT03522649|OTHER|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
62491392|NCT01628887|EXPERIMENTAL|Supportive Care (BBCEI)|Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
62491393|NCT02201316|EXPERIMENTAL|Sequence 1 (ABC)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
62491394|NCT02201316|EXPERIMENTAL|Sequence 2 (ACB)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
62491395|NCT02201316|EXPERIMENTAL|Sequence 3 (BAC)|Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
62137038|NCT03322995|EXPERIMENTAL|Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
62137039|NCT03322995|EXPERIMENTAL|Restaging: Local Disease Progression|After the first restaging evaluation, further treatment will be based on treatment response. If, at the initial restaging, the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
62333675|NCT05689658|EXPERIMENTAL|Brazilian Diabetes Prevention Program Group|The program will be based on the American Diabetes Prevention Program (DPP), whose published results are used as a reference for prediabetic care patients in the Brazilian Diabetes Guideline. In order to reach the weight loss goal estimated at 0.5 to 1 Kg per week and 150 minutes of moderate physical activity per week, the program will offer individual and group visits, qualitative guidelines for improving diet, lifestyle and self-care.
62333676|NCT05689658|ACTIVE_COMPARATOR|Diet Group|Diet prescription for weight loss
62333677|NCT06053827||Frozen embryo transfer substituted cycle|In a substituted cycle, estrogen and progesterone are given and a transfer is planned when the endometrium is ready
62333678|NCT06053827||Frozen embryo transfer natural cycle|In a natural cycle no hormones are given and a transfer is planned when there is a dominant follicle apparent at the ultrasound
62333679|NCT03456713|EXPERIMENTAL|Part A: 250 mg LY3074828 (Reference)|250 mg LY3074828 administered subcutaneous (SC) as solution formulation in two prefilled syringes targeting a 5- to 10-second injection time for each injection on day 1.
62333680|NCT03456713|EXPERIMENTAL|Part A: 250 mg LY3074828 (Test 1)|250 mg LY3074828 administered SC as solution formulation in a prefilled syringe targeting a 5- to 15-second injection time on day 1.
62333681|NCT03456713|EXPERIMENTAL|Part B: 250 mg LY3074828 (Test 2 and Test 3)|"Test 2: 250 mg LY3074828 administered subcutaneous (SC) as solution formulation in an auto-injector at slow speed targeting an approximately 13-second injection time on day 1.~Test 3: 250 mg LY3074828 administered subcutaneous (SC) as solution formulation in an auto-injector at fast speed targeting an approximately 5-second injection time on day 2."
61938485|NCT06414408|ACTIVE_COMPARATOR|Three-times Weekly Dosing|Participants will be randomized to take one doxycycline 200mg dose three times a week (Monday, Wednesday, and Friday) for six weeks.
61938486|NCT06414408|ACTIVE_COMPARATOR|Weekly Dosing|Participants will be randomized to take one doxycycline 200mg dose once week.
62333682|NCT03456713|EXPERIMENTAL|Part B: 125 mg LY3074828 (Test 4 and Test 5)|"Test 4: 125 mg LY3074828 administered SC as solution formulation in an auto-injector at slow speed targeting an approximately 7-second injection time on day 1.~Test 5: 125 mg LY3074828 administered SC as solution formulation in an auto-injector at fast speed targeting an approximately 4.5-second injection time on day 2."
62333683|NCT03951857|NO_INTERVENTION|Young men|Range of age is 20-35 years, young men (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
61938487|NCT06414408|ACTIVE_COMPARATOR|Every Other Week Dosing|Participants will be randomized to take one doxycycline 200mg dose every other week.
61938488|NCT05063890|EXPERIMENTAL|Muscle Specific MET|
62491396|NCT02201316|EXPERIMENTAL|Sequence 4 (BCA)|Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
62694918|NCT05312658|EXPERIMENTAL|Routine external aortic compression|The assistant surgeon or nurse places heel of the hand or fist over the abdominal aorta immediately after the baby is born while the surgeon helps the baby out, the placenta is expulsed or fetched, and the surgeon gains control over bleeding. The compression should be held until controlled bleedning, for example until the first layer of the uterine incision is sutured. Maximum time of aortic compression is 20 minutes, then a 5 minute break is required, after which compression may be reapplied.
62694919|NCT05312658|NO_INTERVENTION|No external aortic compression|No routine aortic compression. If deemed vital to the mother, aortic compression should be exerted. Aortic compression may be exerted if bleeding exceeds 1000 ml.
62694920|NCT06645041|PLACEBO_COMPARATOR|Hypertensive Vitamin D deficient individuals receiving placebo capsule|Hypertensive Vitamin D deficient individuals receiving placebo capsules, 1 capsule/week for 8 weeks
61938489|NCT05063890|EXPERIMENTAL|Movement specific MET|
62333684|NCT03951857|NO_INTERVENTION|Young women|Range of age is 20-35 years, young women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
62137040|NCT05521386|EXPERIMENTAL|Caffeine|caffeine dose of 5 mg per kg of body mass administered orally via a gelatine capsule
62137041|NCT05521386|PLACEBO_COMPARATOR|Placebo|maltodextrin (placebo) dose of 5 mg per kg of body mass administered orally via a gelatine capsule
62333685|NCT03951857|EXPERIMENTAL|Elderly women (control)|Range of age is 65-80 years, Elderly women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
62333686|NCT03951857|EXPERIMENTAL|Elderly obese women|Range of age is 65-80 years,Elderly obese women (BMI ≥25 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
62333687|NCT03739463|EXPERIMENTAL|MAG-DHA|1500 MG of MAG-DHA per day until childbirth or for up to 2 weeks
61938490|NCT02660931|EXPERIMENTAL|AKI Risk Notification|Patients randomized to this arm will be eligible for an acute kidney injury risk notification, if their calculated risk exceeds the threshold during their inpatient encounter.
61938491|NCT02660931|NO_INTERVENTION|Usual Care|These patients will receive usual clinical care, with no acute kidney injury risk notification.
61938492|NCT01385761||Laryngeal Mask airway (LMA)|children weighing 20 to 30 kg
62137042|NCT06581965|EXPERIMENTAL|DISTINCT 1 short duration prophylaxis|Patients with a low VTE risk (predicted 3-months postoperative VTE risk \<1%) based on the TRiP(plasty) score. (Nemeth, 2024)
61938493|NCT01385761||Intubating Laryngeal Airway (ILA-SP)|Children weighing 20-30 kg
61938494|NCT01303861|ACTIVE_COMPARATOR|varenicline|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
61938495|NCT01303861|ACTIVE_COMPARATOR|Nicotine Patches only|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
61938496|NCT01303861|ACTIVE_COMPARATOR|Nicotine Patches with Nicotine Inhaler|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
61938497|NCT01303861|ACTIVE_COMPARATOR|varenicline with bupropion|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.
61938498|NCT06680440|EXPERIMENTAL|SAD Cohort 1|SAD dose 1
62137043|NCT06581965|ACTIVE_COMPARATOR|DISTINCT 1 control|Patients with a low VTE risk (predicted 3-months postoperative VTE risk \<1%) based on the TRiP(plasty) score. (Nemeth, 2024)
62137044|NCT06581965|OTHER|DISTINCT 2 observational arm|Patients with an intermediate VTE risk (predicted 3-months postoperative VTE risk ≥1%-≤1.5%) based on the TRiP(plasty) score. (Nemeth, 2024)
62137045|NCT06581965|EXPERIMENTAL|DISTINCT 3 extended prophylaxis|Patients with a high VTE risk (predicted 3-months postoperative VTE risk \>1.5%) based on the TRiP(plasty) score. (Nemeth, 2024)
62137046|NCT06581965|ACTIVE_COMPARATOR|DISTINCT 3 control|Patients with a high VTE risk (predicted 3-months postoperative VTE risk \>1.5%) based on the TRiP(plasty) score. (Nemeth, 2024)
62333688|NCT03739463|PLACEBO_COMPARATOR|Placebo|1500 MG of oleic acid per day until childbirth or for up to 2 weeks
62333689|NCT03172611|EXPERIMENTAL|Plant-based diet|A defined, plant-based diet was prescribed for 4 weeks.
62333690|NCT01614236|ACTIVE_COMPARATOR|control|patients will be randomized similarly but will undergo surgery under epidural analgesia
62333691|NCT01614236|ACTIVE_COMPARATOR|Lyrica|Patients will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
62333692|NCT04799405|EXPERIMENTAL|tDCS MDD|"A group of 5 participants with major depressive disorder (MDD).~tDCS, as a relatively simple and portable technology, is particularly well suited for remotely-supervised, home-based treatment, which would facilitate longer periods of treatment as well as offer a suitable therapeutic option at the present time as the investigators aim to deal with the COVID-19 pandemic."
62694921|NCT06645041|EXPERIMENTAL|Hypertensive vitamin D deficient individuals receiving Vitamin D supplements|Hypertensive Vitamin D deficient individuals receiving Vitamin D capsules, 25,000 IU, 1 capsule/week for 8 weeks
62694922|NCT00864279|EXPERIMENTAL|A|Cetirizine Hydrochloride 10 mg tablets, single dose
62694923|NCT00864279|ACTIVE_COMPARATOR|B|Zyrtec® 10 mg tablets, single dose
62694924|NCT04418154|EXPERIMENTAL|EC-ABX/PD-1|Patients who are treated with epirubicin hydrochloride andcyclophosphamide followed by nanoparticlealbumin-bound paclitaxel and Toripalimab
61938499|NCT06680440|EXPERIMENTAL|SAD Cohort 2|SAD dose 2
61938500|NCT06680440|EXPERIMENTAL|SAD Cohort 3|SAD dose 3
61938501|NCT06680440|EXPERIMENTAL|SAD Cohort 4|SAD dose 4
62491397|NCT02201316|EXPERIMENTAL|Sequence 5 (CAB)|Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
62491398|NCT02201316|EXPERIMENTAL|Sequence 6 (CBA)|Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
62491399|NCT04156737|EXPERIMENTAL|Investigational Lens|TECNIS Symfony plus IOL Model ZHR00V
62333693|NCT02137590|EXPERIMENTAL|Spanish Black Radish|Spanish Black Radish product
62491400|NCT04156737|ACTIVE_COMPARATOR|Control Lens|Trifocal Intraocular Lens
62333694|NCT01255046|ACTIVE_COMPARATOR|Donepezil plus STA-1|
62333695|NCT01255046|PLACEBO_COMPARATOR|Donepezil plus placebo|
62333696|NCT02125006|EXPERIMENTAL|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
62491401|NCT06627816|ACTIVE_COMPARATOR|nefopam group|• Group N (n=80) will receive nefopam 0.15 mg/kg i.v. (Nopain®, Medical Union Pharmaceuticals MUP, Ismailia, Egypt, Ampoules of 20 mg/1 ml)
62491402|NCT06627816|ACTIVE_COMPARATOR|dexmeditomidine group|• Group D (n=80) will receive dexmedetomidine 0.5 µg/kg i.v. (Precedex®, Hospira Inc, USA, Vials of 200 mg/2 ml)
62694925|NCT04540471|EXPERIMENTAL|MT group|The participants in MT group will receive music therapy 1 day per week for 1 hour with total 12hours in12 consecutive weeks after initial enrollment. Initial evaluation at the first session, including patient's vital sign, consciousness and spirit. The music therapy will consist of therapeutic singing, interpersonal communication, melody intonation therapy and rhythmic hands slapping. During therapeutic singing session, the music therapists will sing a song first and then the patients sing it after them. Interpersonal communication activity will be led by the music therapist and passed on to one patient to another patient. Melody intonation therapy will comprise communication, chatting and read aloud by using melody.
62694926|NCT04540471|PLACEBO_COMPARATOR|Control group|control groups will receive comprehensive in-patient education program for 12 consecutive weeks
62694927|NCT06638489|EXPERIMENTAL|experimental group|The experimental group received both High-Intensity-Focused-Electromagnetic-Therapy (HIFEM) combined with Pelvic-Floor-Muscle-Training (PFMT)
62694928|NCT06638489|EXPERIMENTAL|control group|the control group received only Pelvic-Floor-Muscle-Training (PFMT)
62694929|NCT06114628|ACTIVE_COMPARATOR|A. Standard TB Regimen. 2HRZE/4HR|24 weeks treatment in both Phase 2B and 2C - 8 weeks Rifampicin, Isoniazid, Pyrazinamide, Ethambutol followed by 16 weeks Rifampicin and Isoniazid.
61938502|NCT06680440|EXPERIMENTAL|SAD Cohort 5|SAD dose 5
62137047|NCT06211972|EXPERIMENTAL|Intervention|In this study, there is only one study arm, and all eligible participants will be assigned to a treatment group and will participate in three treatment sessions of the OpiVenture program, in addition to the Opioid therapy agonist treatment they are receiving through the recruiting clinic.
62137048|NCT06020352|EXPERIMENTAL|Treatment group|KN046 combined with axitinib as a neoadjuvant treatment regimen
62137049|NCT05728840|EXPERIMENTAL|Rehabilitation intervention group|Each participant of the experimental group will undergo an initial cognitive screening (pre-training) and, in addition to their standard of care, they will have 20 additional sessions with the experimental rehabilitation program. Post-treatment cognitive screening will be completed at the end of the program, then 3-4 and 6-12 months later.
62137050|NCT05728840|ACTIVE_COMPARATOR|Dose-match control group|Each participant of the experimental group will undergo an initial cognitive screening (pre-training) and, in addition to their standard of care, they will have 20 additional sessions of neuropsychological standard sessions. Post-treatment cognitive screening will be completed at the end of the program, then 3-4 and 6-12 months later.
61938503|NCT06680440|EXPERIMENTAL|SAD Cohort 6|SAD dose 6
61938504|NCT06680440|EXPERIMENTAL|MAD Cohort 1|MAD dose 1
62137051|NCT05728840|NO_INTERVENTION|Retrospective standard of care group|Each participant of the retrospective group will be included retrospectively if they were hospitalized in the study's sites between 2012 and 2022, and followed standard neuropsychological rehabilitation of attention.
62333697|NCT02125006|NO_INTERVENTION|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
62333698|NCT03059810|EXPERIMENTAL|Participating Subjects|Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.
61938505|NCT06680440|EXPERIMENTAL|MAD Cohort 2|MAD dose 2
61938506|NCT06680440|EXPERIMENTAL|MAD Cohort 3|MAD dose 3
62333699|NCT04037670|EXPERIMENTAL|SASI bypass|Patients with super obesity underwent SASI bypass
62333700|NCT05253313|NO_INTERVENTION|Conventional|Patients who are eligible for surgery are randomized to MRI scan or standard curative surgery. Patients in this arm will receive standard care according to danish standards without pre-operative MRI scans.
62333701|NCT05253313|OTHER|MRI scan|This arm includes patients who have been randomized to pre-operative MRI scans.
62333702|NCT01369316|EXPERIMENTAL|Circumferential Submucosal Incision Resection|
62333703|NCT01369316|ACTIVE_COMPARATOR|Endoscopic Mucosal Resection|Patients randomised into this arm will receive the conventional treatment Endoscopic Mucosal Resection in which the sessile lesion is injected and snared by piecemeal technique.
62491403|NCT06627816|ACTIVE_COMPARATOR|meperidine group|• Group P (n =80) will receive pethidine (meperidine) 0.5 mg/kg i.v. (Ampoules of 50 mg/1 ml).
62491404|NCT02027337|NO_INTERVENTION|Control group|Healthy women that no use combined oral contraceptives
62491405|NCT02027337|EXPERIMENTAL|20 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
62333704|NCT04680663||Non-severe complications group|where the non-complicated patients is the patients running the normal postoperative course of surgery and without any need for intervention
62333705|NCT04680663||severe complications group|any deviation from the normal post-operative course
62333706|NCT04913714|ACTIVE_COMPARATOR|Intervention|A district where the radio intervention will be broadcast.
62333707|NCT04913714|NO_INTERVENTION|Control|A district where the radio intervention will not be broadcast.
62333708|NCT04598347||Pregnant women diagnosed with SARS-CoV-2|Pregnant women diagnosed with SARS-CoV-2 infection(by PCR on nasopharyngeal aspirate or serology)that have an indication to perform an invasive technique(chorionic biopsy or amniocentesis) along thegestation.The sample size will depend on the duration of theSARS-CoV-2 pandemic.Initially we propose a study period of 18months in which we would have an approximate total of 225pregnant women with indication of invasive technique.It is planned to conduct a PCR study for SARS-CoV-2 in amniotic fluid or chorionic villi to thosepregnant women diagnosed with SARS-CoV-2 infection(approximately 5% of the total pregnant womenwith indication of invasive technique (11-12 pregnant women)).This determination is made as part of theroutine clinical practice in the context of the study of screening for perinatal infections
62333709|NCT06494878|EXPERIMENTAL|Aspirin|Low-dose aspirin (75-100 mg) once daily for 6 weeks.
62333710|NCT06494878|ACTIVE_COMPARATOR|Low-molecular-weight heparin|Site-specific low-molecular-weight heparin regimen as prescribed by the treating physician.
62333711|NCT01911572||Survivors|Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
62333712|NCT01911572||Family members|Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
62333713|NCT04698213|EXPERIMENTAL|intermittent axitinib plus Avelumab|"All patients enrolled in the trail will receive axitinib at 5 mg BID plus avelumab at 10 mg/Kg every two weeks.~Treatment will be continued until progression of disease during the first 36 weeks of therapy. At week 36, patients achieving a tumor decrease ≥ 30% will discontinue axitinib and continue avelumab until progression of disease defined as ≥ 20% increase compared to the tumor burden measured at week 36. At disease progression, axitinib will be restarted at the same dosage used before discontinuation for at least 24 weeks if progression did not occur before. Patients who achieved again tumor decrease of ≥ 30% after 24 weeks of therapy rechallenge with axitinib and avelumab may discontinue axitinib and maintain avelumab until progression of disease in an intermittent manner."
62333714|NCT03007953|EXPERIMENTAL|Intervention|This is a nurse-led telephone-based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer, who will receive therapy other than solely surgical resection. The intervention lasts for the duration of patients' primary lung cancer treatment (usually 3-4 months).
62333715|NCT03007953|NO_INTERVENTION|Usual Care|Subjects randomized to the usual care arm will receive medical oncology, radiation oncology, pulmonary, CT surgery, as indicated by the type and stage of cancer. At the completion of their primary lung cancer treatment, they will be disenrolled from the study.
61938507|NCT03343067|EXPERIMENTAL|Arm A|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24"
61938508|NCT03343067|EXPERIMENTAL|Arm C|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
62333716|NCT04502810|EXPERIMENTAL|High-level laser therapy|Real high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
62333717|NCT04502810|SHAM_COMPARATOR|Sham High-level laser therapy|Sham high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
62333718|NCT03650452|PLACEBO_COMPARATOR|Placebo|TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
62491406|NCT02027337|EXPERIMENTAL|20 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
62694930|NCT06114628|EXPERIMENTAL|Arm B. BDM|Bedaquiline, Delamanid, Moxifloxacin for 16 weeks in Phase 2B
62694931|NCT06114628|EXPERIMENTAL|Arm C. BDM + 656|Bedaquiline, Delamanid, Moxifloxacin and GSK3036656 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Moxifloxacin and GSK3036656 for 8-16 weeks in phase 2C
62694932|NCT06114628|EXPERIMENTAL|Arm D. BDZ + 656|Bedaquiline, Delamanid, Pyrazinamide and GSK3036656 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Pyrazinamide and GSK3036656 for 8-16 weeks in phase 2C
62333719|NCT03650452|EXPERIMENTAL|TAK-935|TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing \<60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
62333720|NCT02826733||Normal|"Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI).~EEG NIRS MRI"
62491407|NCT02027337|EXPERIMENTAL|30 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
62491408|NCT02027337|EXPERIMENTAL|30 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
62491409|NCT02027337|EXPERIMENTAL|35 mcg EE/2mg cyproterone|Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
61938509|NCT03343067|EXPERIMENTAL|Arm D|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
62333721|NCT02826733||cerebral neurological disease|"Group of children meeting the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological (ETF , Scanner, MRI) The children present either convulsions or a cerebrovascular accident or a neurological pain . Each condition being verified by a pathological electroencephalogram .~EEG NIRS MRI"
62333722|NCT01557608|EXPERIMENTAL|Photon stimulation|
62491410|NCT02027337|EXPERIMENTAL|35 mcg EE/2 mg cyproterone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit
62491411|NCT03528486|EXPERIMENTAL|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
62137052|NCT03554889|EXPERIMENTAL|Experimental Group|Peripheral blood lymphocytes will be collected. The NK cell will be selected and expanded ex vivo, then adaptive transfer back into patients. A total of 5.0 x 10\^8/L NK cells will be infused in one cycle.To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients. Nimotuzumab will be used 24 hours before infusion. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent.
62333723|NCT01557608|PLACEBO_COMPARATOR|Placebo treatment|
62491412|NCT03528486|ACTIVE_COMPARATOR|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
62137053|NCT04362046|EXPERIMENTAL|Hysteroscopic uterine resection|This is a prospective single-arm surgical intervention trial.
62137054|NCT00667316||A|Workers from companies and workers' health care organizations who go for their periodic medical checkup.
62137055|NCT04448652||+NSAIDs|Patients undergoing elective colorectal cancer resection before april 1st 2016 were treated with paracetamol tablets 1000 mg and ibuprofen tablets 400 mg four times a day from the day of the operation and until discharge.
62137056|NCT04448652||-NSAIDs|Patients undergoing elective colorectal cancer resection from april 1st 2016 were only treated with paracetamol tablets 1000 mg four times a day from the day of the operation and until discharge.
62137057|NCT03789071||Patient scheduled for general anesthesia with intubation|Patients in this group (only group) will have clinical airway assessment and external ultrasound assessment of the airway
62137058|NCT06074679|EXPERIMENTAL|Single-incision laparoscopic cholecystectomy|SILC was defined as laparoscopic surgery done through a single trans-umbilical incision
62491413|NCT03181386|EXPERIMENTAL|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
62491414|NCT03181386|EXPERIMENTAL|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
62491415|NCT03181386|ACTIVE_COMPARATOR|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
62491416|NCT04481451|EXPERIMENTAL|Erector spinae supplemental block|Single-shot T9/T10 operative side erector spinae block using ropivacaine 0.2%, 0.5ml/kg.
62491417|NCT04481451|ACTIVE_COMPARATOR|Quadratus lumborum supplemental block|Single-shot T9/T10 operative side quadratus lumborum (type 1) block using ropivacaine 0.2%, 0.5ml/kg.
62694933|NCT06114628|EXPERIMENTAL|Arm E. BDL + 656|Bedaquiline, Delamanid, Linezolid and GSK3036656 for 8 weeks followed by 8 weeks Bedaquiline, Delamanid and GSK3036656 in Phase 2B Bedaquiline, Delamanid, Linezolid and GSK3036656 for 8 weeks followed by 0-8 weeks Bedaquiline, Delamanid and GSK3036656 in Phase 2C
62137059|NCT06074679|ACTIVE_COMPARATOR|Conventional laparoscopic cholecystectomy|CLC was defined as three or four port surgery carried out with either French or American position.
62137060|NCT04905797||Deliberate self-harm|Individuals with psychiatric disorders and persistent DSH
62137061|NCT04905797||Clinical cases who ceased self-harm|Individuals with psychiatric disorders who have ceased DSH
62333724|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
62333725|NCT04415567||lenvatinib|high-risk patients with HBV-related HCC who took lenvatinib as adjuvant therapy after liver transplantation
62333726|NCT04415567||control|high-risk patients with HBV-related HCC who received routine treatment and follow-up after liver transplantation
62333727|NCT03871517|EXPERIMENTAL|Indobufen|Drug: Indobufen and aspirin mimetic Day 1 to 90±7: The first time : Indobufen 100mg + aspirin mimetic The second time: indobufen 100mg
62333728|NCT03871517|ACTIVE_COMPARATOR|Aspirin|Drug: Aspirin and Indobufen mimetic Day 1 to 90±7: The first time : aspirin 100mg+ Indobufen mimetic, The second time: indobufen mimetic.
62491418|NCT04633122|EXPERIMENTAL|Ripretinib|50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle.
62491419|NCT04633122|ACTIVE_COMPARATOR|Sunitinib|12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break.
62491420|NCT05405023|EXPERIMENTAL|Concentric exercises with wrist mobilization|concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements
62491421|NCT05405023|ACTIVE_COMPARATOR|Concentric exercises without wrist mobilization|concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation
62491422|NCT01230229|ACTIVE_COMPARATOR|Stenting|Active treatment group
62491423|NCT01230229|PLACEBO_COMPARATOR|Conservative treatment|Best medical treatment
62694934|NCT06114628|EXPERIMENTAL|Arm F. BPaM + 656|Bedaquiline, Pretomanid, Moxifloxacin and GSK3036656 for 16 weeks in Phase 2B Bedaquiline, Pretomanid, Moxifloxacin and GSK3036656 for 8-16 weeks in Phase 2C
62694935|NCT06114628|EXPERIMENTAL|Arm G. BDM + BTZ-043|Bedaquiline, Delamanid, Moxifloxacin and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Moxifloxacin and BTZ-043 for 8-16 weeks in phase 2C
62137062|NCT04905797||Clinical cases with no self-harm|Individuals with psychiatric disorders who never had DSH
62137063|NCT04905797||Healthy controls|Healthy controls who never had DSH
62694936|NCT06114628|EXPERIMENTAL|Arm H. BDZ + BTZ-043|Bedaquiline, Delamanid, Pyrazinamide and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Pyrazinamide and BTZ-043 for 8-16 weeks in phase 2C
62333729|NCT03466489|EXPERIMENTAL|Floraseal|The surgical site will first be cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. Once dry, the FloraSeal surgical preparatory solution will be applied per the manufacturers recommendations. The extremity will be draped in sterile fashion however adhesive drapes over the surgical site itself will not be applied.
62333730|NCT03466489|NO_INTERVENTION|Control|The operative site is first cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. The operative site will then be draped in sterile fashion. An iodine impregnated adhesive drape will then be applied to the surgical site.
62333731|NCT02210871|EXPERIMENTAL|Normal hepatic function|
62333732|NCT02210871|EXPERIMENTAL|Mild hepatic impairment|
62333733|NCT02210871|EXPERIMENTAL|Moderate hepatic impairment|
62333734|NCT02210871|EXPERIMENTAL|Severe hepatic impairment|
62333735|NCT02514928|EXPERIMENTAL|pancreatoduodenectomy & nerve resection|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
62491424|NCT00921674|EXPERIMENTAL|Ivermectin|ivermectin
62491425|NCT05826093||Patients planned for cholecystectomy|Patients planned for elective laparoscopic cholecystectomy received a peroperative ultrasound-guided transversus abdominis plane (TAP) block at the beginning of the procedure.
62694937|NCT06114628|EXPERIMENTAL|Arm I. BDL + BTZ-043|Bedaquiline, Delamanid, Linezolid and BTZ-043 for 8 weeks followed by 8 weeks Bedaquiline, Delamanid and BTZ-043 in Phase 2B Bedaquiline, Delamanid, Linezolid and BTZ-043 for 8 weeks followed by 0-8 weeks Bedaquiline, Delamanid and BTZ-043 in Phase 2C
62694938|NCT06114628|EXPERIMENTAL|Arm J. BPaM + BTZ-043|Bedaquiline, Pretomanid, Moxifloxacin and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Pretomanid, Moxifloxacin and BTZ-043 for 8-16 weeks in Phase 2C
62694939|NCT06114628|EXPERIMENTAL|Arm K. BMZ + BTZ-043|Bedaquiline, Moxifloxacin, Pyrazinamide and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Moxifloxacin, Pyrazinamide and BTZ-043 for 8-16 weeks in phase 2C
61938510|NCT03343067|EXPERIMENTAL|Arm B|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24."
62694940|NCT06114628|EXPERIMENTAL|Arm L. BD + 656 + BTZ-043|Bedaquiline, Delamanid, GSK3036656 and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, GSK3036656 and BTZ-043 for 8-16 weeks in phase 2C
61938511|NCT05095038|EXPERIMENTAL|Appethyl®|"Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.~Each capsule contain 0.5 g Appethyl®, and the daily intake is 5 g/day."
62694941|NCT05392751|EXPERIMENTAL|EA-2353|EA-2353 Ophthalmic Suspension will be administered via unilateral intravitreal injection into the Study Eye weekly for one month (4 injections)
61938512|NCT05095038|PLACEBO_COMPARATOR|Placebo|"Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.~Each capsule contain 0.5 g placebo, and the daily intake is 5 g/day."
62137064|NCT05011045||Observational (neurocognitive assessment, questionnaires, MRI)|Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.
62333736|NCT02514928|ACTIVE_COMPARATOR|pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
62333737|NCT00813514|EXPERIMENTAL|1|Open longitudinal study with observer masked analysis
62333738|NCT04217577|EXPERIMENTAL|Dried Plums|Consume dried plums daily.
62333739|NCT06468982|ACTIVE_COMPARATOR|Group A (IABP support)|Patients who are receiving intra-aortic balloon pump support during the preoperative period
62333740|NCT06468982|NO_INTERVENTION|Group B (control group; without IABP support)|Patients who did not receive intra-aortic balloon pump support in the preoperative period; control group
62491426|NCT01337427|PLACEBO_COMPARATOR|Placebo for 48 weeks, BIIB017 for 48 weeks|Placebo every 2 weeks for 48 weeks followed by 125 mcg BIIB017 SC every 2 or 4 weeks for 48 weeks.
62491427|NCT01337427|EXPERIMENTAL|BIIB017 every 2 weeks for 96 weeks|125 mcg BIIB017 SC every 2 weeks for 96 weeks.
62137065|NCT04726449||psychiatric diagnosis|psychiatric diagnosis : patients who were given a psychiatric diagnosis at the end of the follow up
62137066|NCT04726449||somatic diagnosis|somatic diagnosis: patients who were given a somatic diagnosis at the end of the follow up
62333741|NCT01994226|ACTIVE_COMPARATOR|Low-dose colchicine|500 mcg every eight hours for four days
62333742|NCT01994226|ACTIVE_COMPARATOR|Naproxen|Single initial dose of 750 mg followed by 250 mg every eight hours for up to seven days
62333743|NCT00125658|ACTIVE_COMPARATOR|Control|FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
62491428|NCT01337427|EXPERIMENTAL|BIIB017 every 4 weeks for 96 weeks|125 mcg BIIB017 SC every 4 weeks for 96 weeks.
62491429|NCT00421863|OTHER|Intensive Strategy|
62333744|NCT00125658|EXPERIMENTAL|Experimental|POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
62694942|NCT01565759|EXPERIMENTAL|Lithium|This will be a short-term longitudinal study of 4 weeks of duration. Twenty (20) healthy male subjects will be recruited and treated with lithium carbonate for 4 weeks. Lithium carbonate (150 mg, 300 mg, 600 mg) will be administered to the recruited subjects. The study will be performed in one centre at Capital District Health Authority - Dalhousie University, Halifax, Nova Scotia, Canada. Lithium serum levels will be tested at day 8, at day 14 and at the end of the treatment. Additional tests may be performed as necessary (as in the case of side effects).
61938513|NCT01828879|EXPERIMENTAL|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
61938514|NCT02276326|EXPERIMENTAL|VSL#3 sachets|VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)
61938515|NCT05333328|EXPERIMENTAL|OFS with endocrine|Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, the patients with a genomic low risk using the multigene-assay (OncoFREE®) will be included in this arm.
61938516|NCT01877018|EXPERIMENTAL|electronic reminder|Electronic reminder introduced into primary care medical health record.
61938517|NCT01877018|NO_INTERVENTION|Usual care|Usual care control group
61938518|NCT01641874|EXPERIMENTAL|Specific directional exercise|During the assessment a specific exercise will be identified for this group. The exercise will consist of a repeated specific end range movement of the knee
61938519|NCT01641874|ACTIVE_COMPARATOR|Evidence based exercise|Quadriceps strengthening and advice on aerobic exercises will be given
62491430|NCT00421863|OTHER|Usual Strategy|
62491431|NCT03577535|EXPERIMENTAL|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
62491432|NCT03577535|NO_INTERVENTION|No Oncoxin Treatment®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
61938520|NCT01641874|NO_INTERVENTION|No intervention|Patient waits on the surgeons waiting list for next appointment or for planned knee surgery
61938521|NCT06680414|EXPERIMENTAL|experimental|Supportive Vaccine Communication using Motivational Interviewing will be administered to the pregnant mothers in the experimental group by the researcher. The training will take place in 3-part and 6-sessions, one week apart, and each session will last approximately 40 minutes. The training will be carried out as group training with 3-5 people. Data collection forms will be applied before and after the program.
61938522|NCT06680414|NO_INTERVENTION|control|No intervention will be made to the pregnant mothers in the control group during the education process of the experimental group. After the training process of the pregnant mothers in the experimental group is completed and the post-test data are collected, all the interventions and training will be given to the pregnant mothers in the control group.
61938523|NCT01768767|EXPERIMENTAL|Ketamine/Lithium|Participant will receive ketamine/lithium
61938524|NCT01768767|ACTIVE_COMPARATOR|Ketamine|Participant will receive ketamine
61938525|NCT01768767|PLACEBO_COMPARATOR|Placebo|Participant will receive placebo
61938526|NCT00177996|ACTIVE_COMPARATOR|Sertaline high dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline high dose titration) are consistent with recommended FDA guidelines.
61938527|NCT00177996|ACTIVE_COMPARATOR|Sertaline low dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline low dose titration) are consistent with recommended FDA guidelines.
61938528|NCT06681285|EXPERIMENTAL|Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment|Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
62491433|NCT05223608|OTHER|ImmuCCo Cohort|"Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity.~Urine collection at initiation of immunotherapy."
62491434|NCT02041013|NO_INTERVENTION|No Talking Card|Usual care of asthma by study clinician, including evaluation of asthma using C-ACT and clinical history, treatment using asthma action planning
62491435|NCT02041013|EXPERIMENTAL|Taking Card|Usual care, as in comparison group, plus recordable Talking Card at each visit
62491436|NCT06405854|EXPERIMENTAL|Coordination-based exercise intervention|During the eight weeks, children in the coordinative exercise intervention group participated in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children.
62491437|NCT06405854|NO_INTERVENTION|Control|The control group continued their regular preschool classes without any intervention.
62491438|NCT00072514|EXPERIMENTAL|Treatment|Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
62333745|NCT04760353|EXPERIMENTAL|Probiotic|one powder portion bag of the probiotic mixture (OMNi-BiOTiC STRESS) containing 9 human bacterial strains \[Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51 Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)\] and vitamin B (B2, B6, B12), self-administered orally twice a day for 8 weeks
62491439|NCT00483743|EXPERIMENTAL|TPI 1020|TPI 1020 500 mcg BID x 42 days
62137067|NCT00145470|EXPERIMENTAL|Asenapine|Participants received asenapine as a fast-dissolving sublingual (SL) tablet, given twice daily (BID). On Day 1, participants received asenapine 5 mg, BID. On Days 2 to 84, asenapine was dosed flexibly: BID at either 5 or 10 mg. Asenapine doses were up- or down-titrated based on efficacy, safety, and tolerability.
62137068|NCT00145470|PLACEBO_COMPARATOR|Placebo|Participants received placebo on Days 1-84 as a fast-dissolving SL tablet, BID.
62333746|NCT04760353|PLACEBO_COMPARATOR|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~* Powder portion bags are suitable for participants with intolerance to yeasts or lactose~* Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
62333747|NCT02874404|EXPERIMENTAL|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62333748|NCT02874404|EXPERIMENTAL|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62491440|NCT00483743|ACTIVE_COMPARATOR|Budosenide cortico|Budesonide 800 mcg BID x 42 days
62491441|NCT00483743|PLACEBO_COMPARATOR|Placebo|Placebo inhaler
62491442|NCT02115776|NO_INTERVENTION|Control|Receiving no prophylaxis
62694943|NCT00511199|EXPERIMENTAL|NOMAC-E2|"Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive"
62694944|NCT00511199|ACTIVE_COMPARATOR|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
62694945|NCT05662722|EXPERIMENTAL|Pecutaneous electrolysis group|Subjects were treated twice (one day and one week). The technique consisted in the application of a galvanic electrical current using a needle as an electrode that will be inserted into the concha of the ear. The subjects were lying in supinus.
62694946|NCT05662722|OTHER|dry needling group|Subjects were treated twice (one day and one week). The technique consisted in the puncture with a needle in the concha of the ear. The subjects were lying in supinus.
61938529|NCT06376734|EXPERIMENTAL|TMS to random PFC location 1|Participants will receive 2 days of accelerated TMS (10 treatments per day) to a random location in the prefrontal cortex.
62333749|NCT02874404|EXPERIMENTAL|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62333750|NCT03252496|EXPERIMENTAL|Combination|250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
62333751|NCT03252496|ACTIVE_COMPARATOR|Crystalloid|250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
62333752|NCT05149794|EXPERIMENTAL|Calisthenic Exercises|The participants of this group perform calisthenic exercises.
62333753|NCT05149794|NO_INTERVENTION|Conventional Training|The participants of this group perform activities of daily routines like playing cricket, taking swings etc
62333754|NCT03741894|PLACEBO_COMPARATOR|Primary wound closure|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
62333755|NCT03741894|EXPERIMENTAL|Iodoform and wound closure|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.
62333756|NCT03741894|EXPERIMENTAL|Chlorhexidine and wound closure|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
62491443|NCT02115776|ACTIVE_COMPARATOR|Amoxicillin|Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
62491444|NCT02115776|EXPERIMENTAL|Amoxicillin-Potassium Clavulanate|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
62491445|NCT02115776|ACTIVE_COMPARATOR|Chlorhexidine (CHX)|Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
62491446|NCT02115776|EXPERIMENTAL|Amoxicillin-Potassium Clavulanate-CHX|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
62491447|NCT04050943||CRD patients|Patients with chronic pulmonary disease like COPD, asthma, bronchiectasis, and etc.
62694947|NCT05662722|SHAM_COMPARATOR|Sham group|Subjects were treated twice (one day and one week). The technique consisted in the puncture with a sham-needle in the concha of the ear. The subjects were lying in supinus.
61938530|NCT06376734|EXPERIMENTAL|TMS to random PFC location 2|After a 2-month washout following arm 1, participants will receive another two days of accelerated iTBS treatment at a different random PFC location.
61938531|NCT06376734|EXPERIMENTAL|TMS to Schizophrenia location|Patients with schizophrenia will be offered to participate in a third arm of the trial, during which participants will receive 2 days of accelerated iTBS to a schizophrenia-specific target.
62137069|NCT01335828|OTHER|echography/elastography|
62137070|NCT03234374|EXPERIMENTAL|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
62137071|NCT03234374|ACTIVE_COMPARATOR|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
62491448|NCT01954030|EXPERIMENTAL|CTO and Bevacizumab (Phase 1)|The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
62491449|NCT01954030|EXPERIMENTAL|Phase 2: CTO alone (Phase 2)|The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
62491450|NCT01954030|EXPERIMENTAL|CTO and Bevacizumab (Phase 2)|The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
62491451|NCT04323683||Low progesterone|Women with progesterone level below 15 ng/ml
62491452|NCT04323683||Normal progesterone|Women with progesterone level above 15 ng/ml
62491453|NCT02174185||bladder cancer, conduit diversion|new patients with bladder cancer scheduled for radical cystectomy and subsequent conduit diversion
62491454|NCT02174185||bladder cancer, orthotopic neobladder|new patients with bladder cancer scheduled for radical cystectomy and subsequent orthotopic neobladder
62491455|NCT01049464|PLACEBO_COMPARATOR|5%D/W|The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.
62491456|NCT01049464|EXPERIMENTAL|Magnesium sulphate|The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours
62491457|NCT02924025|EXPERIMENTAL|Case|The women in this group will receive motivational interviews approximately once every 2 weeks for half a year.
62491458|NCT02924025|NO_INTERVENTION|Control|The women in this group will have the usual guidance in weightloss with a booklet on the seven health tips from the danish government. They will not be contacted ind the half year between study onset and finish.
62491459|NCT03814850|EXPERIMENTAL|Treatment group: standard blood pressure cuff|A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.
62491460|NCT03814850|SHAM_COMPARATOR|Sham group: standard blood pressure cuff|The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.
62491461|NCT01753362|PLACEBO_COMPARATOR|placebo|subcutaneous daily injection
61938532|NCT06680141|EXPERIMENTAL|Virtual Reality Glasses|Among the women who have been admitted for a planned caesarean section, the Informed Consent Form and the Data Collection Form including Sociodemographic Characteristics, Surgical Fear Scale, Spielberg State-Trait Anxiety Scale will be applied to the women who meet the criteria and randomization will be applied. After randomization, they will be divided into a virtual reality glasses application group and a control group. All women will be applied the Spielberg State-Trait Anxiety Scale and Surgical Fear Scale in the patient room before and after the SGG application. The experimental group will be shown a video (30 minutes) of the 9-month fetal development process, with glasses on before going to surgery.
61938533|NCT06680141|NO_INTERVENTION|control|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention will perform
61938534|NCT03677908||13 high|High-Density ElectroEncephaloGraphy analysis of 13 healthy premature infants
62137072|NCT04074096|EXPERIMENTAL|Encorafenib + binimetinib + pembrolizumab|Encorafenib 450 mg oral route (PO) once daily (QD) + binimetinib 45 mg PO twice daily (BID) + pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W).
62491462|NCT01753362|ACTIVE_COMPARATOR|liraglutide|subcutaneous daily injection
62491463|NCT02364986|EXPERIMENTAL|Rebif/Avonex|Rebif® 44µg (day 1, 3, 5 and 8) s.c. Avonex 30µg (day 1 and 8) i.m.
61938535|NCT03677908||15 low|Low-Density ElectroEncephaloGraphy analysis of other 15 healthy premature infants
62137073|NCT04074096|EXPERIMENTAL|SRS followed by encorafenib + binimetinib + pembrolizumab|Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases \>5 mm); followed by encorafenib 450 mg PO QD + binimetinib 45 mg PO BID + pembrolizumab 200 mg IV Q3W. The treatment should be started more than 24 hours and less than 8 days (excluded) after the SRS
62137074|NCT04216342|EXPERIMENTAL|1|subjects entered into the trial may go thru a 0-4 weeks screening (Screening Phase). On the Intervention phase, subjects will be followed for 7 days which includes: entry criteria assessments and settling at the inpatient unit on Day 0, a single-dose I.V. infusion with data collection on Day 1 followed by 24 hours monitoring (Day 2), a 7-day and 28-day outpatient follow-up visit (Follow-Up Phase).
62137075|NCT00968149|EXPERIMENTAL|1|Montelukast
62137076|NCT00968149|PLACEBO_COMPARATOR|2|Placebo
62491464|NCT04249765|EXPERIMENTAL|Hand strength|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned.~The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer."
62491465|NCT06627985||Anthropomorphized Process Large Language Model Multidisciplinary Treatment Group|Using a locally deployed MedicalGPT, the commercially available online GPT-4o, Claude-3.5 Sonnet, GPT-4o mini, and Claude 3 Haiku, will each sequentially play the role of physicians from different departments involved in the Multi-Disciplinary Treatment Process. They will then sequentially take on the role of a summarizer to compile their recommendations into a final suggestion or treatment plan.
62491466|NCT06627985||Non-anthropomorphized Process Large Language Model Multidisciplinary Treatment Group|Using a locally deployed MedicalGPT, the commercial online GPT-4o, Claude-3.5 Sonnet, GPT-4o mini, and Claude 3 Haiku to output multidisciplinary consultation results in a single instance, without separately assuming roles for each department and then compiling the results.
62333757|NCT06004141|EXPERIMENTAL|Laguna Health Group|"* Patient and caregiver participants will have access to Laguna Health coaching and the Laguna Health mobile platform for 12 weeks after discharge from the hospital to a home environment.~* Patient participants will receive usual post-discharge care as arranged by their inpatient and outpatient oncology teams.~* Patient participants will complete study questionnaires to assess their quality of life, symptoms, and psychological outcomes.~* Caregiver participants will complete study questionnaires to assess their quality of life and caregiving burden.~* 10-20 participants will complete exit interviews to ascertain more feedback on the Laguna Health intervention."
62333758|NCT06004141|NO_INTERVENTION|Usual Care|"* Participants will receive usual post-hospital discharge care as arranged by their inpatient and outpatient oncology care teams.~* Patient participants will complete study questionnaires to assess their quality of life, symptoms, and psychological outcomes.~* Caregiver participants will complete study questionnaires to assess their quality of life and caregiving burden."
62333759|NCT05093413|EXPERIMENTAL|Fully slept first; Sleep deprived second|Participants will be fully slept during the first experimental visit and sleep deprived during the second experimental visit
62333760|NCT05093413|EXPERIMENTAL|Sleep deprived first; Fully slept second|Participants will be sleep deprived during the first experimental visit and fully slept during the second experimental visit
62333761|NCT01023399|EXPERIMENTAL|Artesunate + Amodiaquine|"Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: \>= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment"
62333762|NCT04536740|OTHER|PDL-treated PWS|PWS treated with PDL before will be treated with PDT
62333763|NCT04536740|EXPERIMENTAL|without treatment PWS|PWS without treatment before will be treated with PDT
62333764|NCT01386710|EXPERIMENTAL|Arm 2|Drug: Bevacizumab and Carboplatin
62333765|NCT01386710|EXPERIMENTAL|Arm 1|Drug: Bevacizumab and Carboplatin
62333766|NCT04068064|EXPERIMENTAL|EABM training group|about 40 individuals with IGD will be randomly assigned to the EABM training group
62333767|NCT04068064|PLACEBO_COMPARATOR|Control training group|about another 40 individuals with IGD will be randomly assigned to the control training group
62333768|NCT05261672|ACTIVE_COMPARATOR|Group QL1|quadratus lumborum block will be done. 20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
62333769|NCT05261672|ACTIVE_COMPARATOR|Group QL2|quadratus lumborum block will be done. ) 20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
62333770|NCT03311490|EXPERIMENTAL|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
62333771|NCT03311490|NO_INTERVENTION|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
62333772|NCT04321252|EXPERIMENTAL|Cohort A1: 10.5 mg/placebo|Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
62333773|NCT04321252|EXPERIMENTAL|Cohort A2: 30 mg/placebo|Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
62333774|NCT04321252|EXPERIMENTAL|Cohort A3: 75 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
62333775|NCT04321252|EXPERIMENTAL|Cohort A4: 120 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
62333776|NCT04321252|EXPERIMENTAL|Cohort A5: 210 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
62333777|NCT04321252|EXPERIMENTAL|Cohort B1: 60 mg/placebo, every 24 hours (q24h) × 5 days|Multiple iv bolus doses of KAE609 or placebo administered at the clinical site by the study personnel.
62333778|NCT04321252|EXPERIMENTAL|Cohort B2: 120 mg/placebo, every 24 hours (q24h) × 5 days|Multiple iv infusion doses of KAE609 or placebo administered at the clinical site by the study personnel.
62333779|NCT01753076|EXPERIMENTAL|Ozanezumab IV|Administered by IV route. Treatment period - 48 Weeks
62333780|NCT01753076|PLACEBO_COMPARATOR|Placebo|Normal saline by IV route. Treatment period - 48 weeks
62694948|NCT06244823|EXPERIMENTAL|Fremanezumab|"Patients will be treated with 225 mg of subcutaneous injections of Fremanezumab per month.~Patients will do four monthly additional hospital visits. During each visit, occurrence of any adverse event will be interrogated; clinical situation will be analyzed and Fremanezumab will be administered. Visits will be performed at weeks 0, 4 and 8. Last visit will be performed after 12 weeks, without Fremanezumab injection."
62694949|NCT06232954|EXPERIMENTAL|Intervention|All recruited households within the intervention arm will receive the Mossie-Go device containing transfluthrin treated discs and will be provided with refill transfluthrin discs at monthly intervals to provide sustained protection.
62333781|NCT00347854|EXPERIMENTAL|FID 105783|
62333782|NCT00347854|ACTIVE_COMPARATOR|Visine|
62333783|NCT00347854|ACTIVE_COMPARATOR|Refresh Liquigel|
62333784|NCT00347854|ACTIVE_COMPARATOR|Refresh Plus|
62333785|NCT02042729|EXPERIMENTAL|E2022- Tape Formulation|
62333786|NCT02042729|PLACEBO_COMPARATOR|Matching Placebo E2022|Matching Placebo
62694950|NCT06232954|PLACEBO_COMPARATOR|Control|All recruited households within the control arm will receive the Mossie-Go device containing untreated blank discs and will be provided with refill untreated blank discs at monthly intervals.
62333787|NCT02042729|ACTIVE_COMPARATOR|E2022- New Formulation|
62333788|NCT02042729|PLACEBO_COMPARATOR|Placebo E2022- New Formulation|Matching Placebo
62333789|NCT01331239|EXPERIMENTAL|Part l: Core cohort|Participants took an ascending dose of LCI699 (osilodrostat) from 2mg bid or 5 mg bid, up to 30 mg bid and participated in Part I of this study. 4 patients in this cohort moved to Part II of the study
62333790|NCT01331239|EXPERIMENTAL|Part II Core: Expansion cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Expansion of this study. These patients were all newly enrolled into the phase II part of the study
62694951|NCT06643273|EXPERIMENTAL|Robotic Rehabilitation|Robotic Rehabilitation of the upper limb
62694952|NCT06643273|ACTIVE_COMPARATOR|Conventional Rehabilitation|Conventional Rehabilitation of the upper limb
62333791|NCT01331239|EXPERIMENTAL|Part II Core: Follow-up cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Follow-up of this study. These patients were patients who transferred from Part I Core phase of the study
62333792|NCT03825276|EXPERIMENTAL|Mango consumption|
62333793|NCT00008138|EXPERIMENTAL|chemo/debulking surgery/IP chemo|neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)
62333794|NCT02207699|EXPERIMENTAL|Benzonatate 200 mg|
62333795|NCT02207699|EXPERIMENTAL|Benzonatate 800 mg|
62333796|NCT02207699|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|
62333797|NCT02207699|PLACEBO_COMPARATOR|Placebo|
62333798|NCT02392039|EXPERIMENTAL|Group 1 - Loratadine|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
62333799|NCT02392039|EXPERIMENTAL|Group 2 - Placebo|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
62333800|NCT05912959|EXPERIMENTAL|photo biostimulation group|"* this group will receive a photo bio stimulation (LASER) session consisting of 3 sessions using the LASER device (VECTRA GENISYS, INTELLECT LEGEND XT, Chattanooga, USA). The following parameters will be used; Power output: 300 mv, Wavelength: 820 nm, Contact area: 0.495; Powr density: 0.606 mW/ cm2, Treatment time per point: 13 seconds, Number of points are three: (GB34, LR3, LIV 3).~* in addition to the LASER, this group will receive a standard physiotherapy program designed by an experienced pediatric physical therapist"
62333801|NCT05912959|ACTIVE_COMPARATOR|standard physiotherapy group|This group will receive a standard physiotherapy program designed by an experienced pediatric physical therapist
62333802|NCT00366548|EXPERIMENTAL|1|
62333803|NCT00366548|ACTIVE_COMPARATOR|2|
62333804|NCT06472700||observation group|
62333805|NCT05787912|EXPERIMENTAL|Photobiomodulation|
62694953|NCT04419987|EXPERIMENTAL|constitutional platelet patholog|Patient and relatives having a constitutional platelet pathology
62694954|NCT06569914|NO_INTERVENTION|control group|"Routine nursing:strict implementation of the three checks and eight pairs process, strict inspection of the quality of drugs used by patients, and strict adherence to medical advice on drug dosage."
62333806|NCT05787912|EXPERIMENTAL|Hyaluronic acid gel after photobiomodulation|
62333807|NCT00611897|ACTIVE_COMPARATOR|Arm I|The NAC capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after NAC administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
62333808|NCT00611897|PLACEBO_COMPARATOR|Arm II|The placebo capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after placebo administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
62333809|NCT04002154|EXPERIMENTAL|A - papilocare alternative days|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
62333810|NCT04002154|EXPERIMENTAL|B - papilocare semiintensive|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
62333811|NCT04002154|NO_INTERVENTION|C - standard of care|Arm C: usual clinical practice: no treatment
62333812|NCT02729558|NO_INTERVENTION|observation|Watchful waiting
62333813|NCT02729558|ACTIVE_COMPARATOR|local stereotactic radiotherapy (SRT)|local SRT in three fractions of 8 Gy to the surgical cavity
62694955|NCT06569914|EXPERIMENTAL|observation group|humanistic nursing：(1) Humanized environmental care；(2) Humanized medical guidance；(3)Humanized psychological nursing；(4) Humanized and standardized management of IVGTT treatment process
62333814|NCT02930798|EXPERIMENTAL|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62333815|NCT05153941||Main Study (tier 1)|Observational Study -The main study (tier 1) comprises 3,510 subjects matched by age and gender at a group level and aged over 50 years with a study partner available to actively contribute to the study will be recruited from memory clinics and/or ongoing observational studies in 3 sites across Greece
62491467|NCT06627985||Real Doctors Multi-Disciplinary Treatment Group|In traditional multidisciplinary treatments, the results are documented in the consultation records of the patients involved, including the recommendations from doctors of various departments who participated in the consultation and the final summary by the secretary.
62694956|NCT04606290|ACTIVE_COMPARATOR|Manual|Fixed dose oxygen
62694957|NCT04606290|EXPERIMENTAL|O2matic|Automated oxygen titration
61938536|NCT06681506|EXPERIMENTAL|The new rehabilitation group|Routine drug therapy + new cardiac rehabilitation therapy, a new cardiac rehabilitation treatment reference guide requirements, according to the actual circumstance of patients treated with 1-3 months intervention.
62694958|NCT02652052|OTHER|Group 1: Observational|Standard of Care - Observation Only
62137077|NCT05928390|EXPERIMENTAL|Pasireotide s.c. 50 mcg|Pasireotide 50 mcg s.c. tid
62491468|NCT06627985||Best Large Language Model Multidisciplinary Treatment Group|After scoring the results of the Anthropomorphized Process Large Language Model Multidisciplinary Treatment Group against the outcomes of the Real Doctors' Multi-Disciplinary Treatment Group on a department-by-department basis, the best substitute models and the best summary models for each department were selected. These top models are set to assume roles in a Multi-Disciplinary Treatment consultation.
62491469|NCT00902538|EXPERIMENTAL|Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg|The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.
62491470|NCT00902538|EXPERIMENTAL|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.
62491471|NCT00902538|EXPERIMENTAL|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.
62491472|NCT00902538|EXPERIMENTAL|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)|Participants who meet their blood pressure goals in Period 3 and continued into the 8-week, double-blind Period 4 continued to receive this combination.
62491473|NCT00902538|EXPERIMENTAL|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
62491474|NCT00902538|EXPERIMENTAL|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
62491475|NCT04883164||Healthy non-immunocompromized subjects|"Healthy individuals are those with no pre-existing conditions that cause immune deficiency, and who are not receiving drugs to suppress the immune system.~•"
62137078|NCT05928390|EXPERIMENTAL|Pasireotide 100 mcg|Pasireotide 100 mcg s.c. tid
62333816|NCT05153941||Tier 2|Observational Study- Sub-study at the baseline visit (Tier 2) Amyloid Positron Emission Tomography (PET): groups (1), (2), (3), (4) as described below fluorodeoxyglucose (FDG) PET : groups (1), (2), (3), (4) as described below More than 400 subjects comprised of (1) \>100 of cognitively unimpaired with (A-, T-, (N)-) group, (2) \>100 of cognitively unimpaired with (A+, T+, (N)- or A+, T+, (N)+) groups, (3) \>100 of mild cognitive impairment with (A+, T+, (N)- or A+, T+, (N)+) groups and (4) \>100 of mild cognitive impairment with (A-, T-, (N)-) group will take Amyloid PET and FDG PET as sub-study.
62694959|NCT02652052|EXPERIMENTAL|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
62694960|NCT03991728||Alloplastic total TMJ replacement|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
62333817|NCT04999826||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10 minutes and undergo blood, urine, saliva, and fecal samples collection.
62333818|NCT02390336|EXPERIMENTAL|Real mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the real mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
62694961|NCT04770285|OTHER|Digital Therapeutic A - CT-152|Participants received digital treatment session by using the CT-152 mobile application (app) from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of Emotional Faces Memory Task (EFMT) exercises and a psychotherapy lesson. From Week 7 up to Week 10 participants continued using the CT-152 app with optional psychotherapy lesson but did not receive any new EFMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed CT-152 treatment courses.
62694962|NCT04770285|OTHER|Digital Therapeutic B - Sham|Participants received digital treatment session by using a sham mobile app from Day 1 up to Week 6 of the treatment period. Each treatment session consisted of a Shape and Memory Task (SMT) exercise only. From Week 7 up to Week 10 participants continued using the sham app but did not receive any new SMT exercises during this period. Participants continued receiving brief SMS messages during Weeks 7 to 10 as a reminder of the previously completed sham treatment courses.
62694963|NCT00174629|EXPERIMENTAL|1|
61938537|NCT06681506|ACTIVE_COMPARATOR|The traditional rehabilitation group.|Routine drug therapy + traditional cardiac rehabilitation therapy, traditional cardiac rehabilitation treatment for reference domestic and international guidelines and consensus, according to the actual circumstance of patients treated with 1-3 months intervention.
62137079|NCT05928390|EXPERIMENTAL|Pasireotide 200 mcg|Pasireotide 200 mcg s.c. tid
62137080|NCT05928390|PLACEBO_COMPARATOR|Placebo|Placebo s.c. tid
62333819|NCT02390336|SHAM_COMPARATOR|Sham mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the sham mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
62333820|NCT02520622|EXPERIMENTAL|Control|Patients use digital photographs loaded onto a mobile device
62333821|NCT02520622|EXPERIMENTAL|Reminders|Patients use digital photographs loaded onto a mobile device and receive skin exam reminders
62491476|NCT04883164||Immunocompromized|Immunocompromised subjects are those receiving immunosuppressive or immunomodulatory drugs such as those given for autoimmune disease, inflammatory bowel disease, malignancies and transplantation. Bone marrow transplant recipients and subjects with known immune deficiency diseases are also considered immunocompromised.
62491477|NCT04643691|EXPERIMENTAL|losartan / spironolactone|Losartan 50 mg and Spironolactone 25 mg pillules oral use
62491478|NCT04643691|NO_INTERVENTION|usual care|Usual care of COVID-19 infection in intensive care
62491479|NCT02169752|ACTIVE_COMPARATOR|Ambrisentan|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
62137081|NCT06534957|EXPERIMENTAL|Intervention group|The intervention group will be assessed with the study surveys at baseline (T1), will participate in the online MBSR intervention for the next 6 weeks, and will be subsequently reassessed with the study surveys at 7 weeks (T2) and at 11 weeks (T3) of follow-up.
62491480|NCT02169752|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
62333822|NCT02520622|EXPERIMENTAL|Social Support|Patients use digital photographs loaded onto a mobile device and a social support network
62491481|NCT01839539|NO_INTERVENTION|B|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
62694964|NCT00174629|ACTIVE_COMPARATOR|2|
61938538|NCT03979131|EXPERIMENTAL|Resectable GC and GEJC+avelumab+FLOT preoperative treatment|Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year.
61938539|NCT04560543|EXPERIMENTAL|McCall suture|Uterus removal by laparoscopy with usual vaginal closure and additional (McCall) suture, which is intended to prevent descent.
61938540|NCT04560543|SHAM_COMPARATOR|standard cuff closure|Uterus removal by laparoscopy with usual vaginal closure without additional (McCall) suture. (as performed so far)
61938541|NCT03285672|EXPERIMENTAL|Arm 1|FP-101
62333823|NCT02520622|EXPERIMENTAL|Combined|Patients use digital photographs loaded onto a mobile device and a social support network and receive skin exam reminders
62333824|NCT06318663|ACTIVE_COMPARATOR|Survivor Mom Companion Program|Participants in the Survivor Moms' Companion intervention will complete a minimum of 4 Survivor Moms' Companion psychoeducational modules with weekly tutor support and will then complete an ending assessment. Sessions with tutors are conducted over the phone or in person at the Buffalo Prenatal and Perinatal Network and last for 45 minutes.
61938542|NCT03285672|PLACEBO_COMPARATOR|Arm 2|Placebo Comparator
61938543|NCT00555685|ACTIVE_COMPARATOR|A|Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
62333825|NCT06318663|PLACEBO_COMPARATOR|Waitlist Control|Participants in the waitlist control group will complete the baseline assessment over the phone, wait six weeks, and then complete the ending assessment. Those on the waitlist will then be offered the Survivor Moms' Companion intervention. Sessions with tutors are conducted over the phone or in person at the Buffalo Prenatal and Perinatal Network and last for 45 minutes.
61938544|NCT00555685|PLACEBO_COMPARATOR|B|Group of patients that will receive placebo
62137082|NCT06534957|NO_INTERVENTION|Wait-list control group|"A wait-list control group will be used with the objective that all participants have the opportunity of receiving the online MBSR intervention and at the same time allow comparison of the effectiveness of the program with a group without intervention. Given that treatment-related stress has an important negative impact on patients' wellbeing, it is appropriate to offer the control group the possibility of receiving the intervention if its effectiveness is demonstrated.~The control group will be assessed with the study surveys at baseline (T1), will not participate in the online MBSR intervention for the next 6 weeks, and will be subsequently reassessed with the study surveys at the same timepoints as the intervention group at 7 weeks (T2) and at 11 weeks (T3) of follow-up. Upon completion of recruitment and follow-up of all participants, the study will end, and the control group will be able to receive the online MBSR intervention according to their preference."
62137083|NCT05986305|ACTIVE_COMPARATOR|Go Act|Go Act is structured as a small group intervention for parents, consisting of four 60-minute sessions occurring over a 4-week period.
62137084|NCT05986305|ACTIVE_COMPARATOR|Peer|Peer is structured as a small group intervention for parents, consisting of four 60-minute sessions occurring over a 4-week period.
62137085|NCT04319549|EXPERIMENTAL|group 1 ketorolac tromethamine irrigant|group 1 patients with acute irreversible pulpitis with apical periodontitis
62137086|NCT04319549|ACTIVE_COMPARATOR|group 2 sodium hypochlorite irrigant|group 2 patients with acute irreversible pulpitis with apical periodontitis
62333826|NCT05931523|EXPERIMENTAL|Stress First Aid|Fire Departments received the Stress First Aid intervention trainings, tools, and resources.
62333827|NCT05931523|NO_INTERVENTION|Wait List Control|Fire Departments in this condition did not receive any intervention or training until the end of their observation year.
61938545|NCT02297048|EXPERIMENTAL|RU 486 (mifepristone)|Subjects will receive 400 mg once a day of RU486
61938546|NCT02297048|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo once a day
61938547|NCT01154829|ACTIVE_COMPARATOR|first choice treatment|Treatment with amisulpride
61938548|NCT01154829|ACTIVE_COMPARATOR|second choice treatment|treatment with aripiprazole
61938549|NCT04894292||Adenomyosis Group|
61938550|NCT04894292||Non-adenomyosis Group|
61938551|NCT01874743|EXPERIMENTAL|Rosuvastatine 20 mg|Rosuvastatin 20 mg/day, once a day during 3 months
61938552|NCT01806558|EXPERIMENTAL|Women with lesion on MBI|Women with lesion on MBI
62137087|NCT06186375||Patients' study|Patient with planned biotherapy
62137088|NCT04340479||Absent lung ultrasound findings of active COVID infection|Absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
62333828|NCT02935634|ACTIVE_COMPARATOR|Nivolumab + Ipilimumab|
62491482|NCT01839539|EXPERIMENTAL|A|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
62491483|NCT00772408||TB|patients with pulmonary TB
62491484|NCT00772408||control|healthy controls
62694965|NCT03174067|EXPERIMENTAL|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
62694966|NCT03174067|ACTIVE_COMPARATOR|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
62694967|NCT03648892|OTHER|Main|Healthy volunteers, within three BMI strata, under controlled overnight fasting conditions following a period of dietary stabilization
62694968|NCT06498648|EXPERIMENTAL|Phase 2 Arm A (abemaciclib, gemcitabine)|Patients receive abemaciclib PO BID and gemcitabine IV on the schedule determined in phase 1 of the trial. Cycles repeat every 21 or 28 days for up to 2 years of total treatment in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients may cross over to arm B. Patients undergo blood sample collection throughout the study. Patients may also undergo tumor biopsy during screening.
61938553|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
61938554|NCT05288478|ACTIVE_COMPARATOR|Group A|First 6 weeks they will use the mouthrinse 5 times a day, following 4 week washout period.
62137089|NCT04340479||Present lung ultrasound findings of active COVID infection|Presence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
62137090|NCT06635538|EXPERIMENTAL|Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1|
62137091|NCT05928845||Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography
62333829|NCT02935634|EXPERIMENTAL|Nivolumab + Relatlimab|
62333830|NCT02935634|EXPERIMENTAL|Nivolumab + BMS-986205|
62333831|NCT02935634|EXPERIMENTAL|Nivolumab + Rucaparib|
62333832|NCT02935634|EXPERIMENTAL|Ipilimumab + Rucaparib|
62333833|NCT02935634|EXPERIMENTAL|Nivolumab + Ipilimumab + Rucaparib|
62333834|NCT02391090|EXPERIMENTAL|hypoxia|"The hypoxia group receives normobaric hypoxic air while sitting in a hypoxic chamber simulating 2800 meter above sea level.~Interventions: hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
62333835|NCT02391090|SHAM_COMPARATOR|sham hypoxia|"The sham group receives normal air while sitting in a hypoxic chamber in about 360 meter above sea level (Graz, Austria).~Interventions: sham hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
62333836|NCT05431517||Non-migration group|Cases without migration after pancreatic stenting under ERCP.
62333837|NCT05431517||Migration group|Cases with migration after pancreatic stenting under ERCP.
62333838|NCT01540916|EXPERIMENTAL|Hyperventilation|Minute ventilation will be increased of about 30% of baseline value, through an increase in respiratory rate
62333839|NCT01540916|EXPERIMENTAL|Hypoventilation|Minute ventilation will be decreased of about 30% of baseline value, through a decrease in respiratory rate
62333840|NCT06502756|EXPERIMENTAL|mobile application SOBER (digital cognitive behavioral therapy)|Participants in this group will access to the mobile app SOBER for 4 weeks. Sober is designed to provide digitalized brief-intervention and cognitive CBT-based education for high-risk drinkers. Participants are expected to engage with the app, completing tasks such as self-monitoring (daily log function that instructs participants to record their alcohol consumption, along with changes in mood, appetite and sleep quality). The app will collect data on adherence, including diary completion rates and app login frequency. Participants were also provided with a smart watch to collect biometric data throughout the duration of the study.
62333841|NCT05130164||Single group|Single group will be selected for age estimation using CBCT Scans
62333842|NCT02473159|EXPERIMENTAL|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
62333843|NCT02931695|OTHER|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum~* ECG~* circulating sex hormones levels"
62333844|NCT02931695|OTHER|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum~* ECG~* circulating sex hormones levels"
62333845|NCT06164444|EXPERIMENTAL|Intervention: Reusable drapes and gowns|"* Reusable drapes and gowns are made from cotton and polyester and are protective against fluid contamination and, to a certain extent, mechanical stress.~* Reusable drapes and gowns are usually autoclaved and laundered using pressurised steam. This ensures that bacteria and other microorganisms are killed, sterilising the fabric so it is suitable for re-use. In this pragmatic trial, a specific sterilisation protocol is not mandated, but details of the sterilisation processes in place at each hospital will be captured in the Hospital-level Questionnaire before site opening. We may report this in a paper ahead of the main trial publication."
62333846|NCT06164444|ACTIVE_COMPARATOR|Comparator: Disposable (single-use) drapes and gowns|"* Single-use surgical gowns and drapes are generally made from non-woven plastic polymers that are protective against fluid contamination and, to a certain extent, mechanical stress.~* They are intended for use during a single operation and are then disposed of as biohazard waste for incineration.~* Typically, four drapes are needed for an abdominal operation (two larger and two smaller drapes), although more may be needed for some procedures.~  * A range of disposable gowns are available. The choice of disposable gown will be at the hospital PI's discretion and will be captured in the Hospital-level Questionnaire."
62333847|NCT02528500|EXPERIMENTAL|TAMBE Device|Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
62333848|NCT01406847|EXPERIMENTAL|Spinal Manipulation|High-velocity manual technique applied to the pelvis with the participant in supine
62333849|NCT01406847|SHAM_COMPARATOR|Static Touch|Practitioner hands are placed on the lumbar spine with the participant in prone.
62333850|NCT01406847|ACTIVE_COMPARATOR|Spinal Mobilization|Oscillation of the third lumbar level performed with the participant in prone
61938555|NCT05288478|ACTIVE_COMPARATOR|Group A, second period|"After the washout period, the next 6 weeks the will use the mouthrinse twice a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
61938556|NCT05288478|ACTIVE_COMPARATOR|Group B|First 6 weeks they will use the mouthrinse twice a day, following 4 week washout period
62137092|NCT01638000|EXPERIMENTAL|Mirabegron 50 mg|Participants who received mirabegron 50 mg once daily for 12 weeks.
62137093|NCT01638000|ACTIVE_COMPARATOR|Solifenacin 5 mg|Participants who received solifenacin 5 mg once daily for 12 weeks.
62491485|NCT06529146||Troriluzole-treated SCA subjects|The BHV4157-206 study is a Phase III, multicenter, randomized, double-blind, 2-arm, placebo-controlled parallel-group study designed to assess the safety, tolerability, and efficacy of troriluzole in a population of patients with SCA. Subjects were randomized to receive placebo (QD) or troriluzole (200 mg QD). BHV4157-206 consisted of a randomization phase and an OLE phase. Subjects in the trorilzuole-treated cohort are from study BHV4157-206, were originally randomized to troriluzole, and extended an opportunity to continue treatment in an open-label extenstion (OLE) phase. All subjects had the opportunity to complete 3-years of treatment.
62491486|NCT06529146||SCA Natural History Comparator|The natural history comparison group includes SCA subjects from the CRC-SCA and EUROSCA natural history studies. The CRC-SCA study includes individuals with SCA 1, 2, 3, 6, 7, 8, and 10, with the time period of data collection spanning 2010 to present. Patients taking riluzole or troriluzole in the CRC-SCA study were not included in this analysis. The EUROSCA study included individuals with SCA genotypes 1, 2, 3, and 6, with the time period of data collection spanning 2005-2009. The natural history protocols were finalized prior to our conduct of the present analysis, as each was designed for independent research purposes.
62491487|NCT04418167|EXPERIMENTAL|Part A: JSI-1187 Monotherapy Dose Escalation|Locally advanced or metastatic solid tumors with confirmed with MAPK pathway mutation
62491488|NCT04418167|EXPERIMENTAL|Part B: JSI-1187 Plus Dabrafenib Combination Dose Escalation|BRAF V600E/K-mutated unresectable or metastatic melanoma, BRAF V600E-mutated NSCLC, or BRAF V600E-mutated locally advanced or metastatic anaplastic thyroid cancer, or other BRAF V600E-mutated unresectable or metastatic solid tumors
62491489|NCT04418167|EXPERIMENTAL|Part C: JSI-1187 Plus Dabrafenib Expansion|"Cohort 1: BRAF V600E/K-mutated unresectable or metastatic melanoma after 1-3 prior therapies for metastatic disease, including anti-PD1 therapy, with or without ipilimumab, and BRAF/MEK inhibitor treatment.~Cohort 2: BRAF V600E/K-mutated unresectable or metastatic melanoma after BRAF/MEK inhibitor adjuvant therapy for Stage 3 disease followed by 1-2 prior therapies for metastatic disease, including anti-PD-1 therapy, with or without ipilimumab, and excluding BRAF/MEK inhibitor treatment.~Cohort 3: BRAF V600E-mutated metastatic NSCLC after 1-2 prior therapies for metastatic disease."
62491490|NCT04811729|EXPERIMENTAL|Experimental Group|Intervention based on the Motivational Interview, previously receiving a training program
62491491|NCT04811729|ACTIVE_COMPARATOR|Control Group|Usual care based on a health counci
62491492|NCT00867763|EXPERIMENTAL|IVM|Early egg retrieval, in vitro maturation, then IVF
62491493|NCT00867763|ACTIVE_COMPARATOR|Mild IVF|Mild gonadotropin and conventional IVF
62491494|NCT00470379|EXPERIMENTAL|Immunization with NY-ESO-1b|Efficacy of maximal dose of topical resiquimod as immune adjuvant to intradermally administered NY-ESO-1b peptide vaccine.
62491495|NCT05348928||With oral ascorbic acid|1 g ascorbic acid orally
62491496|NCT05348928||Without oral ascorbic acid|No oral ascorbic acid is taken
62491497|NCT06339437|EXPERIMENTAL|ERAS group|ERAS protocol applied in this group
62491498|NCT06339437|NO_INTERVENTION|non ERAS group|conventional method of post op care was used
62491499|NCT02997891||intervention group|Patients with primary, unilateral hip osteoarthritis in inpatient orthopedic acute treatment, who have a medical indication of a necessary artificial hip replacement implantation.
62491500|NCT02997891||control group|Volunteers without chronic pain. As a control condition for comparing the variation in cognitive performance and everyday activity the investigators use a group of pain-free and mobility-unrestricted subjects, who do not receive or have an artificial hip.
62491501|NCT01947738|EXPERIMENTAL|VBY-891|VBY-891
62333851|NCT05955586|EXPERIMENTAL|SPR720|Healthy participants will receive SPR720 1000 mg capsule, orally, for 7 days.
62333852|NCT03114982|EXPERIMENTAL|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
62333853|NCT03114982|EXPERIMENTAL|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
62333854|NCT03114982|EXPERIMENTAL|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
62491502|NCT01947738|PLACEBO_COMPARATOR|Placebo|Capsules containing excipient but no active drug
62491503|NCT02579005|EXPERIMENTAL|Patients with a living donor|Radiation + PBMC
62491504|NCT02579005|EXPERIMENTAL|Patients with a UCB donor|Radiation + UCB
62491505|NCT01662011|EXPERIMENTAL|NAVA group|Patients ventilated with the mode of neurally adjusted ventilatory assist
62491506|NCT01662011|ACTIVE_COMPARATOR|PSV group|Patients ventilated with the mode of pressure support ventilation.
62491507|NCT05979311|EXPERIMENTAL|DTG/3TC|Participants will receive FDC of DTG/3TC once daily until Week 96.
62491508|NCT05979311|ACTIVE_COMPARATOR|BIC/FTC/TAF|Participants will receive BIC/FTC/TAF once daily until Week 96.
62333855|NCT03114982|ACTIVE_COMPARATOR|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
62491509|NCT01949532|EXPERIMENTAL|Normal Renal Function|Participants with normal renal function (creatinine clearance \[CrCl\] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
62333856|NCT01290172|EXPERIMENTAL|Somatostatin|Patients in this group receive treatment with Somatostatin for 5 days.
62333857|NCT01290172|PLACEBO_COMPARATOR|Placebo|Patients in this group receive a placebo for 5 days.
62333858|NCT05632458|EXPERIMENTAL|double stent retriever|
62333859|NCT05632458|ACTIVE_COMPARATOR|single stent retriever|
62333860|NCT00409604|EXPERIMENTAL|1|Standard PCI procedure + pacing post conditioning
62333861|NCT00409604|NO_INTERVENTION|2|Standard PCI procedure
62333862|NCT02600325|EXPERIMENTAL|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
62333863|NCT00751530||Protease Inhibitor Group|Subjects who required a protease inhibitor in their new ART regimen
62491510|NCT01949532|EXPERIMENTAL|End Stage Renal Disease|Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
62491511|NCT00796913|ACTIVE_COMPARATOR|Stop of medication after remission|"After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:~Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487."
62491512|NCT00796913|NO_INTERVENTION|Medication for 2 yrs after remission|See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
62491513|NCT00796913|EXPERIMENTAL|Se-yeast 200 Microgr/day + arm A|Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.
62491514|NCT00003953|EXPERIMENTAL|Doxorubicin and Docetaxel|
62491515|NCT01559727|NO_INTERVENTION|Control|The patients with symptomatic heart failure were treated with standard treatment.
62491516|NCT01559727|EXPERIMENTAL|15 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
62491517|NCT01559727|EXPERIMENTAL|30 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
62491518|NCT01559727|EXPERIMENTAL|60 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
62491519|NCT05616416||All ED Patient|All patients visited the emergency department during the period.
62491520|NCT02258035||DBP/Gc1f-1f genotype|Human volunteers homozygous for the 1f-1f (fast) genotype of DBP.
62491521|NCT02258035||DBP/Gc1s-1s genotype|Human volunteers homozygous for the 1s-1s (slow) genotype of DBP.
62491522|NCT02258035||DBP/Gc 2-2 genotype|Human volunteers homozygous for the 2-2 genotype of DBP.
62491523|NCT04872231|EXPERIMENTAL|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
62491524|NCT04872231|PLACEBO_COMPARATOR|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
62491525|NCT06316557|EXPERIMENTAL|rTMS group|5Hz rTMS in lesion contralateral cerebellar hemisphere
62491526|NCT06316557|PLACEBO_COMPARATOR|control group|shame rTMS in lesion contralateral cerebellar hemisphere
62491527|NCT01208194|EXPERIMENTAL|MGN1703|Study medication
62491528|NCT01208194|PLACEBO_COMPARATOR|Placebo|
62491529|NCT00963495|EXPERIMENTAL|Clioquinol|Patients will take Clioquniol at various doses depending on which dose level they come into the study at. Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
62491530|NCT02632968|ACTIVE_COMPARATOR|Pinhole surgery with orthodontic buttons|Pinhole surgery with orthodontic buttons The selected participants were assigned in test and control. In the test group orthodontic buttons were cemented on the bid-buccal region of the crown with dual cure GIC. After administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions. The sling sutures 5-0 mersilk were placed to hold the tunnel in an advanced location using orthodontic buttons as anchoring units. Inter-dental sutures with 6-0 mersilk were also placed for stabilization of the advanced gingival tissue.
62491531|NCT02632968|ACTIVE_COMPARATOR|Pinhole surgery without buttons|Pinhole surgery without orthodontic buttons The selected participants were assigned in test and control. In the control group, after administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions till the recession defects were covered. No sutures or orthodontic buttons were used in the control site.
62491532|NCT06180395||Group 1 (Ambulant )|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~1. Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~2. Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~3. Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
62491533|NCT06180395||Group 2 (Non-Ambulant )|"consisted of 38 children with CP classified to level IV and V according to GMFCS.then:~1. Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~2. Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~3. Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
62694969|NCT06498648|ACTIVE_COMPARATOR|Phase 2 Arm B (gemcitabine, docetaxel)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8 of each cycle and docetaxel IV over 60 minutes on day 8 of each cycle. Cycles repeat every 21 days for up to 2 years of total treatment in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients may cross over to arm A. Patients undergo blood sample collection throughout the study. Patients may also undergo tumor biopsy during screening.
62491534|NCT00770952|EXPERIMENTAL|Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD|
62491535|NCT00770952|ACTIVE_COMPARATOR|Glimepiride 4 mg to 6 mg QD|
62491536|NCT04964687||Transplanted patients seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
62137094|NCT01440166|EXPERIMENTAL|Cohort 1 / Dose level 1|Single dose orally: CAT-1004 Dose level 1 or placebo
62491537|NCT04964687||Transplanted patients not seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
62491538|NCT05718180|EXPERIMENTAL|Supine|Measures are performed first in the supine position and then in a flexible sacrum position
62491539|NCT05718180|ACTIVE_COMPARATOR|Flexible|Measures are performed first in a kneeling squat position and then in the supine position
62491540|NCT01345539|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT) with/without chemotherapy|"Sequence of therapy: SRS/SBRT will be used for all sites of metastatic disease in close approximation to initiation of treatment for the primary disease site (within 6 weeks). Ideally, SRS/SBRT would occur first followed by treatment to primary site. However, in some circumstances surgical resection of the primary site could precede SRS/SBRT, especially if surgical resection is required for pathological confirmation of disease.~Chemotherapy choice of agents is at the discretion of the treating medical oncologist; chemotherapy may be initiated after stereotactic radiosurgery treatment of the primary disease site has been completed."
62491541|NCT06038760||Trial Cohort|Patients with a solid primary brain tumor due to undergo surgery as standard of care
62491542|NCT03428750|ACTIVE_COMPARATOR|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
62491543|NCT03428750|PLACEBO_COMPARATOR|Placebo|
62491544|NCT03704103|EXPERIMENTAL|iSage for adjustment of insulin|The provider will prescribe the iSage app to the subject and choose a treatment algorithm within the app to make insulin dose adjustments.
62491545|NCT03704103|NO_INTERVENTION|Conventional management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet.
62333864|NCT00751530||Non-protease Inhibitor|Subjects who did not take a protease inhibitor in their regimen
62333865|NCT02047513|EXPERIMENTAL|perioperative nab-paclitaxel/gemcitabine|neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
62333866|NCT02047513|EXPERIMENTAL|adjuvant nab-paclitaxel/gemcitabine|Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
62333867|NCT02576964|EXPERIMENTAL|Capecitabine + Peginterferon alfa-2a|Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared \[mg/m\^2\] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous \[SC\] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.
62333868|NCT01542359|EXPERIMENTAL|Yoga|"The integrated yoga program was designed to: 1) include the three primary elements of yoga as most commonly practiced in western cultures (physical postures, breath control and meditation); and 2) be appropriate for those without any prior yoga experience and with pre- and Stage I hypertension. The yoga program was designed by Eddie Stern, Founder and Director of Ashtanga Yoga New York (AYNY) in consultation with Drs. Hagins and Rundle, and are in large part congruent with the yoga program we studied previously (see Preliminary Studies). The yoga class includes: instruction on yogic principles regarding moral precepts (yamas and niyamas); active postures requiring mild-moderate physical exertion; conscious control of the breath in synchrony with active postures; and meditation. We expect approximately 10-15 minutes of the integrated yoga program to consist of isolated practice of meditation (occurring independently of the moving postures, typically in seated or lying positions)."
62333869|NCT01542359|ACTIVE_COMPARATOR|Conventional Exercise|Conventional exercise such as standing toe touch with arm swings, curl ups, push ups, leg lifts, etc. All done at a relatively slow rate which will be non-aerobic and at an average rate across the session of 3 METs
62333870|NCT00579124|OTHER|1. CliniMACS CD3+/CD19+ depletion|"* 6/6 or 8/8 matched (fully matched)~* 1 antigen or allele mismatched (mismatch at A or B or DRB1)~* 2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B).~Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused."
62491546|NCT06491927||RGX-202 Recipients|Subjects who have received RGX-202 in a separate parent study.
62491547|NCT01165060|EXPERIMENTAL|Bezafibrate|All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
62491548|NCT04879927|EXPERIMENTAL|RESOURCE Matching|Participants randomized into the intervention arm will receive customized resource matching
61938557|NCT05288478|ACTIVE_COMPARATOR|Group B, second period|"After the washout period, the next 6 weeks they will use the mouthrinse 5 times a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
62333871|NCT00579124|OTHER|2. CliniMACS CD3+/CD19+ depletion|"Stratum 2. CliniMACS CD3+/CD19+ depletion:~* Haploidentical match~* 2 antigen and/or allele mismatched where one of the mismatches includes DRB1~For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum."
62333872|NCT05072769|EXPERIMENTAL|Experimental group|After the fetus and placenta are born, feeding 100 gr (5-6 pieces) dates to the experimental group
62333873|NCT05072769|NO_INTERVENTION|Control group|The group that was not attempted any intervention in the postpartum period
62333874|NCT04086563|EXPERIMENTAL|Action observation|The patients will observe a 25 minutes clip of neurodynamic exercises of the hand.
62333875|NCT04086563|EXPERIMENTAL|Mirror Therapy|With a mirror glasses, the patients will execute neurodynamic movements of their non-dominant hand during 25 minutes.
62491549|NCT04879927|ACTIVE_COMPARATOR|Usual Care|Participants randomized into the control group will receive a pre-existing pamphlet detailing DFCI resources
62491550|NCT03314376|EXPERIMENTAL|Prehabilitation program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
62491551|NCT03314376|NO_INTERVENTION|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 6-week intervention.
62491552|NCT03385863||early preterm infants with RDS|gestational age\<34 weeks
62137095|NCT01440166|EXPERIMENTAL|Cohort 2 / Dose level 2|Single dose orally: CAT-1004 Dose level 2 or placebo
62333876|NCT04086563|ACTIVE_COMPARATOR|Strength Training|Strength protocol for the dominant hand.
62333877|NCT04086563|EXPERIMENTAL|Neurodynamic exercise|Active neurodynamic exercises for the dominant hand.
62333878|NCT02108951|EXPERIMENTAL|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
62333879|NCT06503289||cytosorb therapy|18 years older patients who need cytsorb therapy due to rhabdomyolysis
62333880|NCT04783532|EXPERIMENTAL|Telehealth Mindfulness Program|Telehealth mindfulness sessions
62333881|NCT04371731|EXPERIMENTAL|Active Arm|Active cohort will use the Care4today platform to help manage their heart failure
62333882|NCT04371731|NO_INTERVENTION|Control arm|Control arm will contain standard of care heart failure treatment
62333883|NCT03725995|ACTIVE_COMPARATOR|A (Midazolam)|21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
62333884|NCT03725995|EXPERIMENTAL|B (Lidocaine-Midazolam)|21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
62333885|NCT03725995|PLACEBO_COMPARATOR|C (Placebo)|21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.
62333886|NCT00920595|EXPERIMENTAL|1|CEP-9722 alone and in combination therapy with temozolomide.
62333887|NCT03346369|EXPERIMENTAL|Experimental single arm|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.
62333888|NCT04058119|EXPERIMENTAL|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates)
62333889|NCT04058119|NO_INTERVENTION|Waiting list control group|Participants will not participate in any specific intervention, but will receive the Functional Training Program after the experimental period (6 months).
62333890|NCT03084393||study group|215 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University \[Jiangsu China\]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week after surgery without safety issue. Patients will be divided into POCD and non-POCD groups according to the two times tests.
62333891|NCT03084393||non-surgical group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
62333892|NCT01117688|ACTIVE_COMPARATOR|B - without SGW|Ureteroscopy without SGW in place.
62333893|NCT01117688|ACTIVE_COMPARATOR|A - with SGW|Ureteroscopy with SGW in place.
61938558|NCT03912064|EXPERIMENTAL|CD25/Treg-depleted DLI + Ipilimumab|"* Ipilimumab is administered intravenously every 12 weeks~* Patients will receive a defined dose of CD25hi Treg depleted DLI intravenously"
62333894|NCT04008589|EXPERIMENTAL|rtACS|repetitive transorbital ACS
62333895|NCT04008589|EXPERIMENTAL|tDCS/rtACS|Sequential tDCS - tACS
62333896|NCT04008589|SHAM_COMPARATOR|Sham stimulation|
62333897|NCT03448718|EXPERIMENTAL|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
62333898|NCT02850887|ACTIVE_COMPARATOR|general endotracheal anesthesia|an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose
62137096|NCT01440166|EXPERIMENTAL|Cohort 3 /Dose level 3|Single dose orally: CAT-1004 Dose level 3 or placebo
62333899|NCT02850887|ACTIVE_COMPARATOR|deep sedation without endotracheal intubation|local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.
62333900|NCT03632681|ACTIVE_COMPARATOR|Insulin|In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
62333901|NCT03632681|PLACEBO_COMPARATOR|Placebo|In this arm a single-dose intranasal placebo will be administrated
62333902|NCT02077634|ACTIVE_COMPARATOR|abiraterone acetate + prednisone + LHRH-therapy|Patients randomized to this group will continue their LHRH-therapy.
62333903|NCT02077634|ACTIVE_COMPARATOR|abiraterone acetate + prednisone|Patients randomized to this group will stop LHRH-therapy.
62333904|NCT01072097|ACTIVE_COMPARATOR|Atorvastatin|6 months atorvastatin 20mg/day treatment
62333905|NCT01072097|PLACEBO_COMPARATOR|Placebo|6 months placebo treatment
62333906|NCT04236206|EXPERIMENTAL|SMS Recipients|• Mobile phone SMSs will be sent to the intervention group with the aim of improving medication adherence and knowledge about diabetes, its complications, diet and physical activity.
62333907|NCT04236206|NO_INTERVENTION|Non-SMS Recipients|Control group with no intervention.
62333908|NCT05313932|EXPERIMENTAL|Sleep deprivation|Two hours of sleep deprivation (Six hours of sleep)
62333909|NCT05313932|NO_INTERVENTION|No intervention|No sleep deprivation (Eight hours of sleep)
62333910|NCT02924506|OTHER|Fixed Core|Cervical arthroplasty with fixed core prothesis
62333911|NCT02924506|OTHER|Movable Core|Cervical arthroplasty with movable core prothesis
62333912|NCT05449613|ACTIVE_COMPARATOR|acupoint application|The acupoint application is applied each stick apply time 2h, once each day. Acupoints selected: Yanglingquan, Dubi, Neixiyan. The treatment lasted for 4 weeks.
62333913|NCT05449613|PLACEBO_COMPARATOR|placebo|The placebo is applied the same acupuncture points, each stick apply time 2h, once each day. Acupoints selected: Yanglingquan, Dubi, Neixiyan. The treatment lasted for 4 weeks.
62333914|NCT02180503|EXPERIMENTAL|BI 1356 BS - low dose|
62333915|NCT02180503|EXPERIMENTAL|BI 1356 BS - high dose|
62491553|NCT03385863||near term infants with RDS|34 weeks≤gestational age\< 37 weeks
62491554|NCT03385863||term infants with RDS|Gestational age ≥ 37 weeks
62491555|NCT01376596|EXPERIMENTAL|CBT-based Intervention|Contrast the impact of a CBT intervention for the treatment of social anxiety in schizophrenia with standard care (care as usual)
62333916|NCT05323903|NO_INTERVENTION|Control Group|Postpartum Hemorrhage and Its Management course
62333917|NCT05323903|EXPERIMENTAL|Intervention Group 1- Telesimulation|Postpartum Hemorrhage and Its Management course, Telesimulation application
62333918|NCT05323903|EXPERIMENTAL|Intervention Group 2- Kahoot|Postpartum Hemorrhage and Its Management course, Kahoot game
62333919|NCT05323903|EXPERIMENTAL|Intervention Group 3-Telesimulation and Kahoot|Postpartum Hemorrhage and Its Management course, Telesimulation application and Kahoot game
62333920|NCT04666324|ACTIVE_COMPARATOR|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
62333921|NCT04666324|EXPERIMENTAL|Multilac Baby|Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10\^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
62333922|NCT01649739|EXPERIMENTAL|Levitra|
62333923|NCT06263634|EXPERIMENTAL|Home exercises group|The intervention group will perform 30-45 minutes of home exercises consisting of stretching, mobility and strengthening, 4 days a week for 8 weeks, and the patients' compliance with the exercise will be monitored by phone call once a week.
62333924|NCT06263634|NO_INTERVENTION|Control group|Patients in the control group will be on the waiting list and will be taught hand exercises when the program ends.
62333925|NCT04129749||Real-Time Analysis Interactive Lab|walk spontaneously or at prescribed speeds of cerebral palsy patient to a standstill in a virtual and secure virtual reality environment.
62333926|NCT01443455|EXPERIMENTAL|VideoDance|
62333927|NCT01443455|ACTIVE_COMPARATOR|Brisk Walking|
62333928|NCT01443455|OTHER|Delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
62491556|NCT01376596|ACTIVE_COMPARATOR|Treatment as usual|Usual care received by patients at clinic/hospital - randomized to a wait list to receive the CBT intervention at the end of the group that received the intervention immediately
62491557|NCT00686764||Group 1|Trans-femoral amputees that meet the eligibility criteria.
62491558|NCT00232687|ACTIVE_COMPARATOR|A1|
62491559|NCT00232687|ACTIVE_COMPARATOR|A2|
62491560|NCT04383249||Pathology result|Pathology result of the hernia sac
62491561|NCT03053245|EXPERIMENTAL|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
62491562|NCT03053245|ACTIVE_COMPARATOR|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
62694970|NCT06498648|EXPERIMENTAL|Phase I Part A Cohort I (abemaciclib, gemcitabine)|Patients receive abemaciclib PO BID on days 1-5 and 14-18 of each cycle and gemcitabine IV over 90 minutes on days 8 and 22 of each cycle. Cycles repeat every 28 days for up to 2 years of total treatment in the absence of disease progression or unacceptable toxicity. Patients may change to Phase 1 Part B treatment once the recommended schedule is determined. Patients also receive 18F-FLT IV and undergo PET/CT during screening and on study. Additionally, patients undergo blood sample collection during screening and on study, as well as possible tumor biopsy during screening.
62694971|NCT06498648|EXPERIMENTAL|Phase I Part A Cohort II (abemaciclib, gemcitabine)|Patients receive abemaciclib PO BID on days 1-7 and gemcitabine IV, over 90 minutes, on day 10 of each cycle. Cycles repeat every 21 days, for up to 2 years of total treatment, in the absence of disease progression or unacceptable toxicity. Patients may change to cohort I treatment schedule once the recommended schedule is determined. Patients may undergo tumor biopsy during screening and PET scan and blood sample collection throughout the study.
62333929|NCT03007745|EXPERIMENTAL|REVAMP|Veterans randomized to this arm will have access to the Remote Veteran Apnea Management Platform (REVAMP) a personalized, interactive website that allows Veterans to be evaluated for OSA without travelling to the sleep center.
62333930|NCT03007745|ACTIVE_COMPARATOR|In-person management|Veterans randomized to this arm will receive standard in-person management of their sleep apnea in the sleep center.
62333931|NCT00932152|ACTIVE_COMPARATOR|Arm B, Group 1|Best supportive care only: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support PRN
62333932|NCT00932152|ACTIVE_COMPARATOR|Arm B, Group 2|Best supportive care and Bevacizumab 15mg/kg every 21 days
62333933|NCT00932152|EXPERIMENTAL|Arm A, Group 1|Fulvestrant and anastrozole only
62491563|NCT05689541|OTHER|Single group|
62491564|NCT05588063|EXPERIMENTAL|Intervention Group|The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 3 on the dial indicator. The remaining settings will be stored in the device and will not need to be set for each treatment. Participants and guardians will be instructed to adjust intensity to highest level of tolerance each time the device is used and level will be logged.
62491565|NCT05588063|SHAM_COMPARATOR|Sham Group|The sham device will be disabled internally so that electrical stimulation is not delivered, but the device will appear to function. Externally, the sham device will look identical to the taVNS device. The participant will be told to increase the intensity until tolerated if a sensation is felt, but will be asked to stop at a maximum level of 3. This inactive sham method was chosen because previous studies have shown that stimulation with placement of the ear clip on other parts of the ear such as the earlobe, although not innervated by the vagus nerve, results in some vagus nerve activity. Inactive sham methodology has been used in previous studies.
62491566|NCT06166862|EXPERIMENTAL|Action observation and motor imagery therapy for rehabilitation|Action observation and motor imagery therapy for rehabilitation in stroke patients in addition to conventional rehabilitation programs.
62491567|NCT06166862|SHAM_COMPARATOR|Sham action observation and motor imagery therapy for rehabilitation|Sham comparator for action observation and motor imagery therapy for rehabilitation in stroke patients in addition to conventional rehabilitation programs.
62491568|NCT01360138|ACTIVE_COMPARATOR|midline approach|cervical epidural steroid injection with 18G Touhy epidural needle by midline approach
62491569|NCT01360138|ACTIVE_COMPARATOR|paramedian approach|cervical epidural steroid injection with 18G Touhy epidural needle by paramedian approach
62491570|NCT05475964|OTHER|patients with undiagnosed bile duct dilatation|patients with bile duct dilation detected by imaging studies without revealing definite cause of obstruction
62491571|NCT06267339|EXPERIMENTAL|Grasp Task|Participants will practice a fine motor grasping task for 20 min during tRNS or sham stimulation.
62491572|NCT06267339|EXPERIMENTAL|Reach Task|Participants will practice a reaching task for 20 min during tRNS or sham stimulation.
62491573|NCT02847624||ADPKD|
62491574|NCT03695354|EXPERIMENTAL|Whole body vibration plus conventional therapy group|conventional therapy + whole body vibration training for 40 minutes per day, five days per week for two-week period.
62491575|NCT03695354|ACTIVE_COMPARATOR|conventional training group|conventional therapy (passive range of motion exercise and walking exercise) for 40 minutes per day, five days per week for two-week period.
62333934|NCT00932152|EXPERIMENTAL|Arm A, Group 2|Fulvestrant, anastrozole and Bevacizumab
62333935|NCT05009316|EXPERIMENTAL|Questionnaires|Patients will answer online surveys containing different questionnaires that will evaluate psychosocial variables as well as pain variables.
62333936|NCT05631015||Artificial Intelligence support decision group|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
62333937|NCT01274442|ACTIVE_COMPARATOR|CONTROL: no dental implants lost|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, who did not lose their implants.
62333938|NCT01274442|EXPERIMENTAL|CASE: patients lost one or more implants|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, but who lost one or more implants.
62333939|NCT03914443|EXPERIMENTAL|Cohort A|"Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m\^2, every 3 week CDDP: 80 mg/m\^2, every 3 week "
62333940|NCT03914443|EXPERIMENTAL|Cohort B|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m\^2, every 3 week CDDP: 80 mg/m\^2, every 3 week "
62333941|NCT03914443|EXPERIMENTAL|Cohort C|"Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m\^2, every 3 week CDDP: 70 mg/m\^2, every 3 week DTX: 70mg/m\^2, every 3 weeks"
62333942|NCT03914443|EXPERIMENTAL|Cohort D|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m\^2, every 3 week CDDP: 70 mg/m\^2, every 3 week DTX: 70mg/m\^2, every 3 weeks"
62491576|NCT05123443||1 - Cross sectional genetics study|International, multicentre study assessing genetic predictors of chronic inflammation in 1000 MS patients with both susceptibility-based brain MRI scan and DNA from peripheral blood samples.The cross-sectional group will include 100 NUH participants who were previously scanned with iron sensitive sequences. These patients will be contacted by their clinical team and invited to participate. Blood samples will be stored in a -80° freezer until all 100 samples have been acquired. At this point, the samples will be shipped to the US for analysis, along with previously acquired MRI scans.
62491577|NCT05123443||2 - Longitudinal cohort MRI study|"The repeat MRI cohort group will be split into two phases. Phase 1: 30 participants who have consented to provide blood samples in the cross sectional genetics study will also be invited to participate by having an additional 7T MRI (funding already secured).~Phase 2: Following completion of phase 1 and securing additional funds we aim to perform more scans to complete our analysis. Exact number of phase 2 participants will be determined from analysis of pilot data."
62491578|NCT06531408||Quantitative Cohort|"UK Adult patients (\>=18) undergoing routine cholecystectomy for benign indications, including gallstone disease and gallbladder dyskinesia.~Feasibility phase will include up to 500 adult patients. Full phase is anticipated to require up to 30,000 patients, however power will be confirmed after feasibility."
62137097|NCT01440166|EXPERIMENTAL|Cohort 4/ Dose level 4|Single dose orally: CAT-1004 Dose level 4 or placebo
62333943|NCT01980121||Term pregnant patients|Term pregnant patients for scheduled elective cesarean section will be examined using a portable ultrasound machine to evaluate gastric contents.
62333944|NCT04628013|EXPERIMENTAL|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied for a single treatment in Aim 1 and after a washout period, will be applied 3x/week for 2-weeks (6 sessions) for Aim 2.
62333945|NCT03951961|EXPERIMENTAL|Midostaurin|50 mg Midostaurin bid for 12 months
62333946|NCT02616627||chronic dialysis|Patient enrolled at the National Taiwan University Hospital Jinshan branch
62333947|NCT06312449|EXPERIMENTAL|The experimental group|The second stage of delivery involves using the lateral position with peanut ball
62333948|NCT06312449|PLACEBO_COMPARATOR|Control Group A|The second stage of delivery adopts the lateral position
62333949|NCT06312449|NO_INTERVENTION|Control Group B|As usual care
62333950|NCT03647371|OTHER|Macintosh laryngoscope|direct laryngoscope - laryngoscope with Macintosh blade
62333951|NCT03647371|OTHER|McGrath videolaryngoscope|McGrath Videolaryngoscope
62333952|NCT01740037|EXPERIMENTAL|Specialized AF-clinic|Management of AF patients in specialized outpatient AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by a nurse practitioner/ physician assistant/ specialised cardiovascular nurse, cardiologist, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®). The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.
62491579|NCT06531408||Qualitative cohort|"UK Adult participants who are either~1. Patients with a history of gallbladder disease, either pre- or post cholecystectomy~2. Surgeons who undertake routine cholecystectomy~3. Healthcare professionals involved in the management or decision making of patients on biliary pathways"
62694972|NCT06498648|EXPERIMENTAL|Phase I Part B (abemaciclib, gemcitabine)|Patients receive the selected treatment schedule, Cohort 1 or Cohort 2, as above. Cycles repeat every 21 or 28 days for up to 2 years of total treatment in the absence of disease progression or unacceptable toxicity.
61938559|NCT04205253||Study|The first group is the study group. Patients aged 20 years or older and were to undergo suspension laryngoscopy procedure were eligible for inclusion in this group. Tongue areas were measured twice by submental USG. The first measurements (TA1) were done immediately after endotracheal intubation before introducing the rigid direct laryngoscope, whereas the second measurements (TA2) were done after the SL procedure and after removing the rigid direct laryngoscope just before extubation.The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
61938560|NCT04205253||Control|The second group was the control group, which included patients who did not need SL and any head and neck procedures.The tongue areas of these patients were measured twice by submental USG as in the study group. The TA1 measurements were done immediately after endotracheal intubation, whereas the TA2 measurements were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
62333953|NCT01740037|ACTIVE_COMPARATOR|Usual Care|Usual care provided by cardiologists at the regular outpatient clinic.
62333954|NCT02205437||Controls|Healthy subjects without psychotic disorder.
62333955|NCT02205437||Drug-naive patients|Drug-naive (never medicated) schizophrenia patients.
62333956|NCT02205437||Patients responder to treatment|Patients with a good clinical response to treatment (define by a marked improvement of positive symptoms) at 3 months and at 1 year.
62333957|NCT02205437||Patients non-responder to treatment|Patients with a poor clinical response to treatment at 3 months and at 1 year.
62333958|NCT02205437||Patients with metabolic side effects|Patients with metabolic side effects associated to treatment.
62333959|NCT02205437||Patients with non-metabolic side effects|Patients with no metabolic side effects associated to treatment.
62333960|NCT01201070|NO_INTERVENTION|control group|
62333961|NCT01201070|NO_INTERVENTION|no treatment|
62333962|NCT01201070|ACTIVE_COMPARATOR|TREATMENT WITH ANTITHROMBIN|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
62333963|NCT02510729|ACTIVE_COMPARATOR|SPG neurostimulation|Sphenopalatine ganglion (SPG) neurostimulation of 20 Hz
62333964|NCT02510729|PLACEBO_COMPARATOR|Sham Stimulation|Sham stimulation with amplitude=0
62137098|NCT01440166|EXPERIMENTAL|Cohort 5/ Dose level 5|Single dose orally: CAT-1004 Dose level 5 or placebo
62333965|NCT03471767|EXPERIMENTAL|AXS-05|Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
62333966|NCT03471767|ACTIVE_COMPARATOR|Bupropion SR|Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
62333967|NCT03450369|EXPERIMENTAL|NB01|"NB01 is a live probiotic containing a single strain of P. acnes, frozen, on a pad, in a single use pouch, for topical application.~Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose."
62333968|NCT06371898||ESD|Cohort of patients with giant colonic lesions resected by ESD, in which patients will be matched to group B
62333969|NCT06371898||surgery|Cohort of patients who underwent colonic surgery for T1 or T2 or in situ colon cancer
62333970|NCT01070719||Relapsing form of MS treated with natalizumab|Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.
62333971|NCT03420131||FFR-iFR-QFR group|
62333972|NCT02305901|EXPERIMENTAL|Repaglinide + Bupropion + BI 187004|repaglinide tablets and bupropion tablets with and without concomitant administration of BI 187004
62333973|NCT01641549|EXPERIMENTAL|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
62694973|NCT05149872|OTHER|TOF ratio 0.9 spontaneous recovery|TOF ratio maintained at 0.9, spontaneous recovery
62333974|NCT01641549|ACTIVE_COMPARATOR|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent
62333975|NCT01055808||Type 2 diabetes treated with insulin|
62333976|NCT03614091|ACTIVE_COMPARATOR|Paravertebral plane block group|The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
62333977|NCT03614091|ACTIVE_COMPARATOR|Erector spinae plane block group|the transducer will be placed in a transverse orientation at T5 to T6 to identify the spinous process, lamina, and transverse process .The tip of the transverse process will be centered on the ultrasound screen, and the transducer will be rotated 90 degrees into a longitudinal orientation to obtain a parasagittal view. Depending on the level imaged, 2 or 3 hypoechoic muscle layers were identiﬁed overlying the tip of the transverse processes. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes. An 8cm 22-gauge block needle will be Inserted in-plane to the ultrasound beam in a cephalad-to-caudal Direction to place the needle tip between the posterior fascia of Erector spinae and the tip of the targeted transverse process. Following which a total of 20 mL of 0.5%bupivacaine will be injected.
62491580|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
62491581|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
62491582|NCT00547794||CRT-D + AVJ Ablation|
62137099|NCT01440166|EXPERIMENTAL|Cohort 2/ Dose level 2 ( FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo
62137100|NCT01440166|EXPERIMENTAL|Cohort 3/ Dose level 3 (FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo
62491583|NCT00547794||Single-Chamber ICD + Pharmacological Therapy|
62491584|NCT05871437|EXPERIMENTAL|Huaier Granule|Huaier Granules: oral administration, 10g once, 3 times a day, used for 1 year, or intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that they no longer benefit. If the patient experiences grade 3-5 (NCI CTC AE V5.0) adverse reactions related to Huai'er granules, and the adverse reactions do not recover after 2 weeks (returning to grade 1 or 2), it can be considered to reduce dosage or stop Huai'er granules treatment. If the medication is suspended for more than 2 weeks, the medication can be interrupted according to the judgment of the researcher. If the same adverse reaction occurs again, the Huaier granules will be permanently discontinued.
62491585|NCT02962180|EXPERIMENTAL|single arm study|Dermabrasion with dermaroller of basal cell layer suspension obtained by soft trypsinisation in vitiligo lesion.
62491586|NCT02611362|EXPERIMENTAL|Intervention|"Subjects in the intervention group will each receive a smartphone with a data service plan as the active arm. The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
62491587|NCT02611362|NO_INTERVENTION|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
62137101|NCT01440166|EXPERIMENTAL|Cohort 6 / Dose level 6 (FE)|Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.
62137102|NCT01440166|EXPERIMENTAL|Cohort 7 / Dose level 7 (FE)|Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.
62137103|NCT03266081|EXPERIMENTAL|0.75% bupivacaine|
62137104|NCT04256512|EXPERIMENTAL|Prevention (Elasto Gel Therapy Mittens and Foot Wraps)|Patients wear Elasto Gel Therapy Mittens and Foot Wraps on both hands and feet 15 minutes prior to each infusion, during the entire infusion, and for 15 minutes after the completion of each infusion during their three months of treatment.
62137105|NCT01697891|EXPERIMENTAL|ALTENS|Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
62137106|NCT04175405|EXPERIMENTAL|Right side of the maxilla|The 635-nm laser parameters; dose: 10J per point (20J/cm2), time: 100 sec per point, 2 points (irradiation on a buccal, and a palatal side of the alveolus/implant), the total energy per session 20J.
62137107|NCT04175405|NO_INTERVENTION|Left side of the maxilla|
62333978|NCT05056454|OTHER|Perinatal Psychiatric Care|This treatment condition is modelled after the psychiatry-delivered treatment usually provided at the Maternal Outpatient Mental Health Services (MOMS) Clinic associated with the UCLA Westwood OB-GYN Clinic and Department of Psychiatry.
62333979|NCT05056454|EXPERIMENTAL|Screening and Treatment of Anxiety and Depression (STAND)|This treatment condition provides access to a system of care, in which type of treatment is allocated based on presenting symptomatology. Participants will learn their allocation from study staff or participants will create a secure account through STAND to learn about their allocation through the STAND online dashboard. Through their STAND online dashboard, they could also have access to their CAT-MH results over time from the start of treatment.
62491588|NCT03531060|EXPERIMENTAL|IRL790|IRL790 Capsule 10 mg, oral administration
62491589|NCT03531060|PLACEBO_COMPARATOR|Placebo|Placebo capsule, identical appearance, oral administration
62694974|NCT05149872|OTHER|TOF ratio 0.7 spontaneous recovery|TOF ratio maintained at 0.7, spontaneous recovery
62694975|NCT05149872|OTHER|TOF ratio 0.7 low dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 2 mg/kg
62694976|NCT05149872|OTHER|TOF ratio 0.7 high dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 4 mg/kg
62694977|NCT04017208|EXPERIMENTAL|ASP2713|Participants will receive a single dose of ASP2713. Up to 8 dose levels will be administered in the study.
62137108|NCT01400958|ACTIVE_COMPARATOR|A: Nuvigil®|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
62137109|NCT01400958|PLACEBO_COMPARATOR|B: Placebo|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent EBRT and TMZ, there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
62137110|NCT03402854|EXPERIMENTAL|Active tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will receive active tDCS via sponges over the scalp.
62491590|NCT05562011|EXPERIMENTAL|Caretaker Device|participants will undergo active CareTaker monitoring for 24-48 hours
62491591|NCT02144844|EXPERIMENTAL|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
62491592|NCT02144844|NO_INTERVENTION|Treatment as Usual (TAU)|Treatment as Usual (TAU) Control
62491593|NCT01635582|ACTIVE_COMPARATOR|Control group|Conventional hand exercise program
62491594|NCT01635582|EXPERIMENTAL|Experimental group|Computer gaming hand exercise regimen'
62491595|NCT00964054|EXPERIMENTAL|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
62491596|NCT00964054|ACTIVE_COMPARATOR|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
62491597|NCT04468282|EXPERIMENTAL|VGB-ST|"Name of the compound: Vigabatrin ORPHELIA Pharma (VGB-ST) Pharmaceutical form: Soluble tablet Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.~Batch N°: 16.92.042 (expiry date: 31.05.2017)"
62491598|NCT04468282|ACTIVE_COMPARATOR|Sabril|"Name of the compound: Sabril (vigabatrin) Pharmaceutical form: granules (sachet) Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.~Batch N°: 6810 (expiry date: 31.05.2019)"
62491599|NCT05086913|EXPERIMENTAL|Lifestyle medicine smartphone app|The app group will receive an app to facilitate lifestyle modification such as video demonstrations of physical activity, diet recommendations, stress and sleep management.
62491600|NCT05086913|EXPERIMENTAL|lifestyle medicine booklets|The booklet group will receive 8 lifestyle medicine and psychoeducation booklets with identical content with the lifestyle medicine app.
61938561|NCT06449417|EXPERIMENTAL|Aurora Training Group|The experimental group will receive an online class of the benefits of physical activity for breast cancer patients, followed by the delivery of the human centered design intervention program.The Aurora kit is a plastic container including a resistance band, two 2 kg dumbbells, a therapeutic ball, an arm volume measurement tape, a hydration bottle for the patient, a leaflet with a guide of recommended exercises, and the logbook journal. The intervention lasts 9 weeks.
62137111|NCT03402854|EXPERIMENTAL|Sham tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will wear the tDCS device that is worn by the active tDCS group, but in the sham group, participants will not receive stimulation during this 20 min period.
62333980|NCT03092869|EXPERIMENTAL|Experimental Group|Feet and Ankle Mobilization
62333981|NCT03092869|ACTIVE_COMPARATOR|Control Group|Proprioceptive Training
62491601|NCT05086913|SHAM_COMPARATOR|waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
62491602|NCT06186414|EXPERIMENTAL|Dose escalation-mono|BCG-unresponsive high-risk NMIBC, receiving SIM0237 monotherapy intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
62137112|NCT00575016|EXPERIMENTAL|1|botulinum toxin Type A (50U); botulinum toxin Type A (200U)
62333982|NCT02197039||The High risk group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the high risk group if they still have major stigmata of recent hemorrhage at the second-look endoscopy or have early recurrent bleeding before the schedule time for follow-up.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure \<90 mmHg, heart rate \>120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
62333983|NCT02197039||The control group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the control group if they does not have recurrent bleeding before the schedule time for follow-up, and have only minor stigmata of hemorrhage or clean ulcer base at the second-look endoscopy.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure \<90 mmHg, heart rate \>120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
62491603|NCT06186414|EXPERIMENTAL|Dose escalation-combo|BCG-unresponsive high-risk NMIBC, receiving SIM0237 and BCG intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
62491604|NCT06186414|EXPERIMENTAL|Dose expansion-Cohort 1|BCG-unresponsive CIS, receiving SIM0237 monotherapy intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
62491605|NCT06186414|EXPERIMENTAL|Dose expansion-Cohort 2|BCG-unresponsive CIS, receiving SIM0237 and BCG intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
62694978|NCT04017208|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo.
61938562|NCT06449417|NO_INTERVENTION|Control Group|The control group will receive an online class of the benefits of physical activity for breast cancer patients, followed by the delivery of the control kit.The control kit is a tote bag including a hydration bottle for the patient, and a logbook journal with blanc pages. The intervention lasts 9 weeks.
61938563|NCT01187433|EXPERIMENTAL|Dengue Vaccine Group|Participants will receive Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus vaccine
62137113|NCT00575016|EXPERIMENTAL|2|botulinum toxin Type A (100U); botulinum toxin Type A (200U)
62137114|NCT00575016|EXPERIMENTAL|3|botulinum toxin Type A (200U)
62137115|NCT00575016|OTHER|4|placebo; botulinum toxin Type A (200U)
62333984|NCT04097756|EXPERIMENTAL|Part1：dose escalation|The investigational product for this study is LX-039 tablets,which can be administered orally. 6\~8 ascending dose level until MTD and the specification included 50 mg, 100 mg, 200 mg, 400 mg, 600 mg , 800 mg,1050 mg and 1400 mg. LX-039 tablets will be administered in a therapeutic cycle of 28 days once a day orally. The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
62694979|NCT05507047|EXPERIMENTAL|Transcrestal Sinus Lifting with Emdogain|Osteotome sinus floor elevation with enamel matrix derivated
61938564|NCT01187433|PLACEBO_COMPARATOR|Control Group|Participants will receive a placebo, NaCl 0.9%.
61938565|NCT02828969|OTHER|Children and adolescents with conduct disorders|Girls and boys having less than 18 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
61938566|NCT05186285|EXPERIMENTAL|CM338 30mg, IV|30mg, single dose, IV
61938567|NCT05186285|EXPERIMENTAL|CM338 60mg, IV|60mg, single dose, IV
61938568|NCT05186285|EXPERIMENTAL|CM338 120mg, IV|120mg, single dose, IV
61938569|NCT05186285|EXPERIMENTAL|CM338 240mg, IV|240mg, single dose, IV
61938570|NCT05186285|EXPERIMENTAL|CM338 240mg, SC|240mg, single dose, SC
61938571|NCT05186285|EXPERIMENTAL|CM338 480mg, IV|480mg, single dose, IV
61938572|NCT05186285|EXPERIMENTAL|CM338 600mg, IV|600mg, single dose, IV
61938573|NCT05186285|EXPERIMENTAL|CM338 600mg, SC|600mg, single dose, SC
61938574|NCT05186285|PLACEBO_COMPARATOR|Placebo|Placebo, single dose, IV or SC
61938575|NCT02208531|NO_INTERVENTION|Control|
61938576|NCT02208531|EXPERIMENTAL|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
61938577|NCT05959083||Upadacitinib|Adolescent and adult participants will receive upadacitinib as prescribed by their physician irrespective of the study participation.
61938578|NCT04562792|EXPERIMENTAL|Patients with relapsed/refractory ALL and AML|Patients in this arm will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
61938579|NCT06681532|ACTIVE_COMPARATOR|Control group|Are treated with open flap debridement, native collagen membrane and bovine bone graft particles.
61938580|NCT06681532|EXPERIMENTAL|Study group|Are treated with open flap debridement, bovine pericardium membrane and bovine bone graft particles.
62491606|NCT06186414|EXPERIMENTAL|Dose expansion-Cohort 3|BCG-unresponsive high-risk Ta or T1, receiving SIM0237 and BCG intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
61938581|NCT01934881||group I|Voltage adjustment only
61938582|NCT01934881||group II|Multiple parameters adjustment
61938583|NCT03072732|OTHER|study arm 1 - below left axilla|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left axilla and the ZOE Fluid Status Monitor
61938584|NCT03072732|OTHER|study arm 2-upper left pectoral area|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper left pectoral area and the ZOE Fluid Status Monitor
61938585|NCT00902668|EXPERIMENTAL|Supportive care (lovastatin)|Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
61938586|NCT04181320|NO_INTERVENTION|Venous Leg Ulcer Standard of Care|Subjects will recieve standard of care treatment.
62694980|NCT05507047|ACTIVE_COMPARATOR|Transcrestal Sinus Lifting|Osteotome sinus floor elevation
61938587|NCT04181320|EXPERIMENTAL|Venous Leg Ulcer Standard of Care with Granulox|Subjects will recieve standard of care treatment with Granulox added as an adjunct therapy.
61938588|NCT02972853|EXPERIMENTAL|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study. For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, we acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional pilot fMRI study."
61938589|NCT05438784|ACTIVE_COMPARATOR|Group A (patient specific titanium implant)|(reconstruction with patient specific titanium implant)
61938590|NCT05438784|ACTIVE_COMPARATOR|Group B (preformed plate bended on stereolithographic model)|(reconstruction with preformed titanium plate preoperatively bended on stereolithographic model)
62694981|NCT04639791||Severe asthma patients|on step 4\& 5 of GINA treatment
61938591|NCT04576104|ACTIVE_COMPARATOR|Arm I (megestrol acetate)|Prior to standard of care planned procedure, patients receive megestrol acetate PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
61938592|NCT04576104|EXPERIMENTAL|Arm II (megestrol acetate, metformin hydrochloride)|Prior to standard of care planned procedure, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
61938593|NCT01162928|EXPERIMENTAL|1|3-chamber-bag combined with Oxepa
61938594|NCT01162928|ACTIVE_COMPARATOR|2|3-chamber-bag combined with Pulmocare
61938595|NCT00993876|EXPERIMENTAL|Selective serotonin reuptake inhibitor (SSRI)|citalopram
61938596|NCT00993876|EXPERIMENTAL|Serotonin-norepinephrine reuptake inhibitor (SNRI)|reboxetine
61938597|NCT00993876|ACTIVE_COMPARATOR|IPT|interpersonal psychotherapy
62491607|NCT05913115|EXPERIMENTAL|FPA144|Participants will receive escalating doses of FPA144. On completion of Cycle 1 (Cycles = 28 days in length) participants may participate in an optional Extended Treatment Period based on the Investigator's discretion, which begins on Day 1 of Cycle 2. FPA144 will be administered once every 2 weeks (Q2W) in 4-week cycles until disease progression, or until the patient meets any of the other withdrawal criteria.
62491608|NCT03648931||Pregnant or Breastfeeding Women|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
62491609|NCT03648931||Male Partners|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
62694982|NCT04139304|EXPERIMENTAL|Treatment (daratumumab, DA-EPOCH)|Patients receive daratumumab IV on days 1 (± 3 days), 8 (± 2 days), and 15 (± 2 days), of cycles 1-3, and on day 1 of cycles 4-6. Patients also receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuous over 96 hours on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for up to 6 cycles in absence of disease progression or unacceptable toxicity.
61938598|NCT01232231|ACTIVE_COMPARATOR|decolonization treatment|topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
62333985|NCT04097756|EXPERIMENTAL|Part 2：dose expansion|2\~3 selected tolerable dose will be selected according to the tolerance and FES PET results of dose escalation phase.The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
62333986|NCT06014554|EXPERIMENTAL|Stratify|Patients randomised to the 'Stratify' intervention will receive usual care and an intervention based on their subgroup assignment. The intervention will start before the third postoperative day and be delivered during the inpatient stay. Intervention components will be delivered by a physiotherapist, occupational therapist, or therapy assistant depending on staffing availability.
62333987|NCT06014554|PLACEBO_COMPARATOR|Usual care|Patients randomised to the control arm will receive usual physiotherapy and occupational therapy care.
62333988|NCT03298412|EXPERIMENTAL|Blinatumomab|"After a run-in period of up to 24 months to evaluate MRD status and assess eligibility for treatment assignment, participants received blinatumomab intravenous (IV) infusion at an initial dose of 9 μg/day for the first 7 days of treatment, escalated (dose-step) to 28 μg/day starting on Day 8 (Week 2), followed by a dose-step to 112 μg/day starting on Day 15 (Week 3) and continuing until completion of therapy (Day 57 of Cycle 1).~Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval."
62333989|NCT06116877|ACTIVE_COMPARATOR|Group (I) non modified|Five patients will receive mandibular 2-implant retained overdentures of non-modified printable acrylic resin base material.
62333990|NCT06116877|ACTIVE_COMPARATOR|Group (II) modified|Five patients will receive mandibular 2-implant retained overdentures of modified printable acrylate resin base material with zirconium oxide nanoparticles.
62333991|NCT01806246|EXPERIMENTAL|integrative rehabilitation program|28 sessions during 12 months with focus on psychoeducation, activity planning, and thoughts and feelings connected to having a serious chronic disease. From week 13 to week 32 a training programme aiming at balancing heart rate variability.
62333992|NCT05640713|EXPERIMENTAL|ThisCART19A cells infusion|In this study, allogeneic anti-CD19 CAR T cell (ThisCART19A) infusion is used to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia.
62333993|NCT03452553|EXPERIMENTAL|Open Label Treatment|Chemoembolization using LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
62333994|NCT05066828|ACTIVE_COMPARATOR|conventional obturator|Participants received conventional obturator one piece
62491610|NCT03648931||Grandmothers|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
62491611|NCT03648931||Key Informants|No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures.
62694983|NCT03315026|EXPERIMENTAL|Siltuximab|Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).
62694984|NCT05488795|OTHER|Suite TB-HBPM pre intervention|Each suite/cluster throughout the institution will begin in the baseline usual care phase in the first year.
62694985|NCT05488795|OTHER|Suite TB-HBPM throughout intervention implementation|Each suite will be randomized to implement the TB-HBPM program during one of three wedges separated by six months between each, 1.5 years later.
61938599|NCT01232231|OTHER|education|No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning
61938600|NCT06419608|EXPERIMENTAL|BHV-7000|
62333995|NCT05066828|EXPERIMENTAL|sectional obturator|two pieces obturators connected by magnet attachments
62333996|NCT04716166|EXPERIMENTAL|Volume-oriented incentive spirometry|Postoperative Volume oriented incentive spirometry 3 times a day
62491612|NCT01205035|NO_INTERVENTION|Observation|Observation; No treatment given
62491613|NCT01205035|EXPERIMENTAL|Intravitreal ranibizumab 2.0mg|Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
62694986|NCT05488795|OTHER|Suite TB-HBPM post intervention implementation|Post implementation phase of the suites 2 years after introduction of intervention.
61938601|NCT06419608|PLACEBO_COMPARATOR|Placebo|
61938602|NCT04926623|EXPERIMENTAL|CGM with Structured Education|CGM with Structured Education
61938603|NCT04926623|ACTIVE_COMPARATOR|CGM with Standard Education|CGM with Standard Education
62333997|NCT04716166|EXPERIMENTAL|Flow-oriented incentive spirometry|Postoperative Flow oriented incentive spirometry 3 times a day
62333998|NCT00760227|OTHER|1: HPI-C|Child Intervention Only Group
62333999|NCT00760227|OTHER|2: HPI-CP|Parent and Child Intervention Group
62334000|NCT00760227|NO_INTERVENTION|3: SC|Standard Care Control Group- No Intervention
62334001|NCT02300415||patient with sepsis|Patients admitted to the emergency department and with criteria of sepsis.
62334002|NCT01419483|EXPERIMENTAL|Ketogenic diet|Diet designed to maintain elevated ketone levels during therapy
62334003|NCT00051558|EXPERIMENTAL|A|Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
62334004|NCT00051558|ACTIVE_COMPARATOR|B|Alendronate 10 mg/day oral plus injection placebo, 36 months
62334005|NCT06360874|EXPERIMENTAL|ND-003 40mg|SAD（Single Ascending Dose） Cohort 1: Participants were orally administered 40mg of ND-003 or matched placebo once.
62334006|NCT06360874|EXPERIMENTAL|ND-003 80mg|SAD Cohort 2: Participants were orally administered 80mg of ND-003 or matched placebo once.
62334007|NCT06360874|EXPERIMENTAL|ND-003 160mg|SAD Cohort 3: Participants were orally administered 160mg of ND-003 or matched placebo once.
62334008|NCT06360874|EXPERIMENTAL|ND-003 240mg|SAD Cohort 4: Participants were orally administered 240mg of ND-003 or matched placebo once.
62694987|NCT02599831|EXPERIMENTAL|Electrical pudendal nerve stimulation|"Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum).~Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 times per week for 8 weeks."
62334009|NCT06360874|EXPERIMENTAL|ND-003 300mg|SAD Cohort 5: Participants were orally administered 300mg of ND-003 or matched placebo once.
62334010|NCT06360874|EXPERIMENTAL|ND-003_Dose 1|MAD （Multiple Ascending Dose）Cohort 1:The dose of ND-003 or matched placebo will be determined based on the results of the SAD. Three dose cohorts will be set and the volunteers will receive the drug once a day for 7 consecutive days.
62334011|NCT06360874|EXPERIMENTAL|ND-003_Dose 2|MAD Cohort 2: The dose of ND-003 or matched placebo will be determined based on the results of the SAD. Three dose cohorts will be set and the volunteers will receive the drug once a day for 7 consecutive days.
62334012|NCT06360874|EXPERIMENTAL|ND-003_Dose 3|MAD Cohort 3:The dose of ND-003 or matched placebo will be determined based on the results of the SAD. Three dose cohorts will be set and the volunteers will receive the drug once a day for 7 consecutive days.
62334013|NCT06360874|EXPERIMENTAL|Food effect_Cohort 1|Food effect Cohort 1: The dose of ND-003 tablets will be determined based on the results of the SAD and MAD. Participants will be orally administered in fasting condition in day 1 and then in fed condition in day 8.
62334014|NCT06360874|EXPERIMENTAL|Food effect_Cohort 2|Food effect Cohort 2: The dose of ND-003 tablets will be determined based on the results of the SAD and MAD. Participants will be orally administered in fed condition in day 1 and then in fasting condition in day 8.
62334015|NCT03617133|OTHER|Standard arm|General and specific aims of EMBRACEII as well as the multiple quantitative hypotheses are based on technical data, dose volume parameters and clinical results of the prospective observational study EMBRACEI (NCT00920920, 3 year data 2015) and the retrospective RetroEMBRACE (3/5 year data 2015). The performance of EMBRACE II interventions and clinical outcome in terms of disease- (local, nodal, systemic control, OS, CSS) and morbidity-outcome (various organs and endpoints) is thus based on recent clinical evidence with radiochemotherapy and image guided adaptive brachytherapy. The expected effect of EMBRACE II interventions on clinical outcome is estimated from comparative analyses of interventions in subgroups of Retro-/EMBRACE (partly published). Based on the Retro-/EMBRACE benchmark, the estimated outcome including a confidence interval is quantified for each clinical endpoint in the overall cohort as well as different subgroups for an overall expected patient number of 1000.
62334016|NCT03969043|EXPERIMENTAL|Young volunteers|"Volunteers between 18 ans 45 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
62334017|NCT03969043|EXPERIMENTAL|Older Volunteers|"Volunteers between 60 ans 85 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
62334018|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
62334019|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
62334020|NCT02115815|PLACEBO_COMPARATOR|Placebo|Sterile saline for human use from commercial source, liquid
62334021|NCT02115815|EXPERIMENTAL|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
62334022|NCT02115815|EXPERIMENTAL|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A \[GLA\] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
62334023|NCT02115815|EXPERIMENTAL|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
62334024|NCT02115815|EXPERIMENTAL|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
62334025|NCT02115815|EXPERIMENTAL|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
62334026|NCT02115815|EXPERIMENTAL|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
61938604|NCT04926623|ACTIVE_COMPARATOR|SMBG with Standard Education|SMBG and CGM with Standard Education
62491614|NCT05518331|EXPERIMENTAL|Avatrombopag in RAA|"After the patients met the above-mentioned inclusion conditions and signed informed consent, they began to be included in this program.~The main research objectives are to take avatrombopag conversion therapy for at least 3 months, to monitor hematological indicators, biochemical indicators and bone marrow related tests, to determine hematological responses, and to evaluate the safety of the drug.~In the 6th and 12th months after treatment, comprehensive review of bone marrow and peripheral blood was performed to evaluate the recovery of hematopoiesis, determine the curative effect, evaluate adverse events, and whether there was clonal transformation.~After the patients completed the main study observation, they were followed up for at least 3 months, that is, from the time the patients were enrolled, for a total of at least 6 months of follow-up."
62491615|NCT03911206|EXPERIMENTAL|Arm 1 : Inspirtory muscle training (IMT)|IMT exercises at home will gradually ramp up.
62491616|NCT03911206|EXPERIMENTAL|Arm 2: Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
62491617|NCT03911206|EXPERIMENTAL|Arm 3: IMT and Exercise|a combination of arm 1 and arm 3
62491618|NCT03911206|NO_INTERVENTION|Arm 4: Routine care|no interventions will occur in this group besides testing procedures and offering access to the study team in case asthma-related questions come up.
62491619|NCT04264169||• Study group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will be complicated by placenta accreta spectrum
62491620|NCT04264169||• Control group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will not be complicated by placenta accreta spectrum
62491621|NCT04584541|OTHER|case|Index cases (RA and SpA patients under immunosuppressive treatments)
62334027|NCT01419275|EXPERIMENTAL|Moyamoya|Approximately 60 Moyamoya patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
62334028|NCT01419275|EXPERIMENTAL|Acute stroke|Approximately 60 acute stroke patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
62334029|NCT01419275|EXPERIMENTAL|Healthy participants|Approximately 30 healthy participants will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
62334030|NCT01419275|EXPERIMENTAL|Diagnosis unspecified|Approximately 60 participants with diagnosis unspecified will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
62334031|NCT01082718|EXPERIMENTAL|Pregnant women|Pregnant women with P. falciparum malaria
62334032|NCT01082718|ACTIVE_COMPARATOR|Non pregnant women|Non pregnant women with P. falciparum malaria
62334033|NCT02368340||Adults with pulmonary fibrosis|This group includes adults with HPS who have known pulmonary fibrosis. Subjects in this group will provide blood and urine specimens.
62334034|NCT02368340||Adults at-risk|"This group includes adults with HPS with subtypes at-risk for pulmonary fibrosis, but who do not have known pulmonary fibrosis.~Subjects in this group will undergo chest CT and pulmonary function testing, and provide blood and urine specimens."
62334035|NCT02368340||HPS adults not at-risk|"This group includes adults with HPS subtypes considered not at-risk for pulmonary fibrosis.~Subjects in this group will provide blood and urine specimens."
62334036|NCT02368340||Children with HPS at-risk|This group includes children with HPS subtypes at-risk for pulmonary fibrosis. Subjects in this group will undergo pulmonary function testing, and provide blood and urine specimens.
61938605|NCT04409405||Cured population|• Age ≥ 5 year old
62334037|NCT05151328|EXPERIMENTAL|Plecanatide group(n=320)|The investigational products are administrated orally, each patient will take one table (Plecanatide 3.0mg) Once daily(QD) in the day before 18:00 with approximately of water. If the investigational product is not taken in the day before 18:00 then skip the dose on that day and take the next dose on the next regular time. The duration of treatment is 12 weeks.
62334038|NCT05151328|PLACEBO_COMPARATOR|Placebo group (n=320)|The investigational products are administrated orally, each patient will take one table (Placebo 3mg) QD in the day before 18:00 with approximately of water. If the investigational product is not taken in the day before 18:00 then skip the dose on that day and take the next dose on the next regular time. The duration of treatment is 12 weeks.
62334039|NCT04901065|EXPERIMENTAL|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle.
62334040|NCT04901065|SHAM_COMPARATOR|Control|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery.
61938606|NCT04409405||Contact population|"* Age ≥ 5 year old~* Contact of a participant included in cured-population cohort~* Not diagnosed with EVD"
62334041|NCT04480697|EXPERIMENTAL|SAD 10mg|A single oral dose of 10 mg
62334042|NCT04480697|EXPERIMENTAL|SAD 20mg|A single oral dose of 20 mg. Food effect will also be assessed at the same dose level.
61938607|NCT02554942|EXPERIMENTAL|Epoetin beta|Participants will receive weekly SC injection of epoetin beta (450 international units per kilogram \[IU/kg\]) for 16 weeks.
61938608|NCT02840240|EXPERIMENTAL|Gabapentin enacarbil|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
61938609|NCT02840240|PLACEBO_COMPARATOR|Placebo|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days
62334043|NCT04480697|EXPERIMENTAL|SAD 40mg|A single oral dose of 40mg
62334044|NCT04480697|EXPERIMENTAL|SAD 80 mg|A single oral dose of 80 mg
62334045|NCT04480697|EXPERIMENTAL|SAD 120 mg|A single oral dose of 120 mg
62334046|NCT04480697|EXPERIMENTAL|SAD 150 mg|A single oral dose of 150 mg
62137116|NCT06242366|EXPERIMENTAL|Intervention group|"In this arm, the participant will receive standard nursing care and the program from an investigator.~The program consisted of 2 phases: 1) Phases I during hospital admission when they are stable will receive a program total 4 times for education about stroke, self-care, rehabilitation, and complication prevention and~2) Phases II following hospital discharge within 24 hours then every 1 week until 4 weeks by Line Application visit. following self-care management, find limit to their self-care.~and Outcomes Assessor will visit to collect data 3 times~1. In-hospital period~2. after hospital discharge 4 weeks~3. after hospital discharge 12 weeks"
61938610|NCT06623149||Old policy|After referral from the general practitioner to the orthopedic department, the patient is assessed by an orthopedic surgeon in the out-patient clinic according to standard practice with a focus on symptoms, history, physical examination, radiography, and an appraisal of the patient's expectations. If an indication for knee arthroplasty (surgical joint replacement) is found, the patient is offered knee arthroplasty, and if the patient accepts the offer, he/she is scheduled according to usual practice. If a patient declines the offer, the patient is informed that the hospital cannot offer any additional service, and the patient is referred back to primary care.
62334047|NCT04480697|EXPERIMENTAL|MAD 10mg|Dose regimen is once daily 10 mg for 14 consecutive days.
62491622|NCT04584541|OTHER|controls|Members of index cases family cluster infected with the same viral strain
62491623|NCT03256396|EXPERIMENTAL|Group E|PEEP set according to esophageal pressure measured
62491624|NCT03256396|NO_INTERVENTION|Group C|PEEP set at 5 cm H2O
61938611|NCT06623149||New policy - non-surgical management|"After referral from the general practitioner to the orthopedic department, the patient is offered a 3-month non-operative treatment program. The conservative program consists of several elements that are offered on an individual basis. The program consists of 3 main elements:~* Patient education/information~* Specialized exercise supervised by a physiotherapist~* Weight loss counseling with a dietician"
62137117|NCT06242366|NO_INTERVENTION|Control group|"In this arm, the participant will receive only standard nursing care. and Outcomes Assessor will visit to collect data 3 times~1. In-hospital period~2. after hospital discharge 4 weeks~3. after hospital discharge 12 weeks"
62137118|NCT04897633|EXPERIMENTAL|Patients ON|Patients will performed Simon's task with tDCS active or sham when treatment is OFF (for standard care procedure)
62137119|NCT04897633|EXPERIMENTAL|Patients OFF|Patients will performed Simon's task with tDCS active or sham when treatment is ON (for standard care procedure)
62137120|NCT04897633|EXPERIMENTAL|Healthy volunteers|Healthy volunteers will performed Simon's task with tDCS active or sham
62137121|NCT06698575|EXPERIMENTAL|Part A: SAD Cohorts 1-5, ABI-1179|Single dose of ABI-1179 (tablet) in Part A for cohorts 1-5
62137122|NCT06698575|PLACEBO_COMPARATOR|Part A:SAD Cohorts 1-5, Placebo|Single dose of matching placebo (tablet) in Part A for Cohorts 1-5
62137123|NCT06698575|EXPERIMENTAL|Part A: (SAD) Fed Cohort 6 or 7, ABI-1179|Single dose of ABI-1179 (tablet) in Part A for Cohort 6 or 7, food effect
62137124|NCT06698575|EXPERIMENTAL|Part B: MAD Cohorts 1-4, ABI-1179|Weekly dose ofABI-1179 (tablet) in Part B for Cohorts 1-4. May have loading dose.
62137125|NCT06698575|PLACEBO_COMPARATOR|Part B: MAD Cohorts 1-4 Placebo|Weekly dose of matching placebo (tablet) in Part B for Cohorts 1-4.
62137126|NCT06645665|EXPERIMENTAL|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of IN006 or matching-placebo on Day 0
62137127|NCT06645665|EXPERIMENTAL|Cohort 2: Dose B in Younger Adults|Single injection of Dose B of IN006 or matching-placebo on Day 0.
62137128|NCT06645665|EXPERIMENTAL|Cohort 3: Dose C in Younger Adults|Single injection of Dose C of IN006 or matching-placebo on Day 0.
62137129|NCT06645665|EXPERIMENTAL|Cohort 4: Dose A in Older Adults|One injection of either Dose A of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
62137130|NCT06645665|EXPERIMENTAL|Cohort 5: Dose B in Older Adults|One injection of either Dose B of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
62334048|NCT04480697|EXPERIMENTAL|MAD 30mg|Dose regimen is once daily 30 mg for 14 consecutive days.
62334049|NCT04480697|EXPERIMENTAL|MAD 90 mg|Dose regimen is once daily 90mg for 14 consecutive days.
62334050|NCT03282903||Crohn's disease patients|1550 Crohn's disease patients who are symptomatically controlled.
62334051|NCT03282903||Ulcerative Colitis patients|1550 Ulcerative Colitis patients who are symptomatically controlled.
62334052|NCT05978830|EXPERIMENTAL|Group 1|The group of subjects underwent active Transcranial ultrasound stimulation for 2 weeks
62334053|NCT05978830|SHAM_COMPARATOR|Group 2|The group of subjects underwent sham Transcranial ultrasound stimulation for 2 weeks
62334054|NCT05148585|ACTIVE_COMPARATOR|group 1|"group 1 (get only physiotherapy) After flexor tendon repair patients start getting physiotherapy. They use static dorsal splint.~exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. Then follow-up sixth months."
62491625|NCT06405243|EXPERIMENTAL|myoinositol|patients will be treated for 12 weeks myoinositol (2gm /day) with ovulation induction by letrazole regimen for 3 consecutive cycl
62491626|NCT06405243|EXPERIMENTAL|chromium|patients will be treated for 12 weeks chromium ( 281.569 mcg/ day) with ovulation induction by letrazole regimen for 3 consecutive cycles
62491627|NCT06405243|EXPERIMENTAL|L-arginine|: patients will be treated for 12 weeks with L-arginine (500 mg once daily in the morning) with ovulation induction by letrazole regimen for 3 consecutive cycles.
62491628|NCT03145987|EXPERIMENTAL|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
61938612|NCT03945695|EXPERIMENTAL|Pneumatic Vitreolysis|All included eyes will receive one intravitreal injection of filtered sulfur hexafluoride gas (SF6).
61938613|NCT00057954|EXPERIMENTAL|Transplant|Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).
62137131|NCT06645665|EXPERIMENTAL|Cohort 6: Dose C in Older Adults|One injection of either Dose C of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
62334055|NCT05148585|EXPERIMENTAL|group 2|"group 2 (get both physiotherapy and activity-based therapy) After flexor tendon repair patients start getting physiotherapy. They use a static dorsal splint.~Exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. then follow-up sixth month. Additionally, group 2 gets activity-based therapy once a week about an hour. activities are also progressive according to the patients needs."
62334056|NCT02215421|EXPERIMENTAL|Play Mommio for 2 months|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
62334057|NCT02215421|NO_INTERVENTION|No game play|No intervention control.
62334058|NCT02730507|EXPERIMENTAL|PSR|Bras A : 167 patients in the experimental PSR group. Surgery with patient-specific rod, which are designed according to the preoperative surgical planning of the surgeon in collaboration with the manufacturer.
62334059|NCT02730507|ACTIVE_COMPARATOR|Conventional rod|Bras B: 167 patients in the experimental conventional rod group
62334060|NCT03355599|OTHER|3d camera|3d camera
62334061|NCT03284619|EXPERIMENTAL|treatment arm|Single arm study, 5 patient with bone metastasis will be enrolled for palliative treatment with the Magnetic resonance imager linear accelerator (MR-Linac).
62334062|NCT02686606|EXPERIMENTAL|Vital 1.5|200ml orally over 30 minutes
62334063|NCT02686606|ACTIVE_COMPARATOR|Ensure Plus|200ml orally over 30 minutes
62334064|NCT04242017|ACTIVE_COMPARATOR|salvage RT + 6 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 6 months ADT
62334065|NCT04242017|EXPERIMENTAL|salvage RT + 24 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 24 months ADT
62334066|NCT02307721|EXPERIMENTAL|intranasal naloxone|8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
62334067|NCT02307721|ACTIVE_COMPARATOR|Intramuscular naloxone|0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
62334068|NCT03397927|EXPERIMENTAL|orthosis|
62334069|NCT04136561|EXPERIMENTAL|CVC and Midline Catheter|Existing standard of care CVC. Midline catheter placed within 24 hours of CVC placement.
62334070|NCT04136561|NO_INTERVENTION|CVC|Standard of care CVC: case-matched controls using baseline data.
62334071|NCT05509231|EXPERIMENTAL|ASD High-intensity Exercise (Group 1a - ASD)|The high-intensity group (Group 1a - ASD). Subjects will be asked to meet 2-3 times a week for exercise training for 60-90 minutes a session. Subjects will be asked to take part in tests that measure motor skills and thinking abilities.
61938614|NCT00620347|EXPERIMENTAL|Single arm|Single arm (sunitinib arm) until PD, unacceptable toxicity, patients refused
62334072|NCT05509231|EXPERIMENTAL|Neurotypical Group (Group 1b - Neurotpical)|The high-intensity group (Group 1b - Neurotypical). Subjects will be asked to meet 2-3 times a week for exercise training for 60-90 minutes a session. Subjects will be asked to take part in tests that measure motor skills and thinking abilities.
61938615|NCT01940562|EXPERIMENTAL|Eltrombopag|"Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.~Starting doses are 100 mg/d for children \>40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children \<20 kg BW.~If unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children ≥ 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children \<20 kg BW."
61938616|NCT06202417||monotherapy group|patients received fruquintinib alone
61938617|NCT06202417||combine group|patients administered fruquintinib in combination with chemotherapy or/and anti-PD1 antibodies
62334073|NCT05509231|EXPERIMENTAL|ASD Wearable Technology (Group 2a - ASD)|ASD Wearable Technology (Group 2a- ASD). Subjects wear a glove and arm sleeve with sensors that will measure arm and hand performance. Subjects will be training 2 times a week for 20-30 minutes. The Subjects will be asked to copy a series of hand and arm gestures. Subjects will perform a series of hand exercises with the glove. The glove will record the movement data that will provide the investigators and subjects feedback on hand performance and fine motor capabilities.
62334074|NCT05509231|EXPERIMENTAL|ASD Wearable Technology (Group 2b - Neurotypical)|ASD Wearable Technology (Group 2b - Neurotypical). Subjects wear a glove and arm sleeve with sensors that will measure arm and hand performance. Subjects will be training 2 times a week for 20-30 minutes. The Subjects will be asked to copy a series of hand and arm gestures. Subjects will perform a series of hand exercises with the glove. The glove will record the movement data that will provide the investigators and subjects feedback on hand performance and fine motor capabilities.
62334075|NCT05509231|NO_INTERVENTION|Control (Group 3)|The wait-list control group will not receive the experimental intervention but will be put on a waiting list to receive the intervention after the active intervention group completes the study.
61938618|NCT06115785|EXPERIMENTAL|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy In the 2nd, 3rd, 4th, 6th, 7th and 8th weeks, IPT implementation twice a week, as two themes, for 7 weeks, with each session of 45 minutes.
62137132|NCT06518551|EXPERIMENTAL|Phase 1: Dose Escalation|"Participants will be enrolled in a standard 3+3 dose escalation design to find the Maximum Tolerated Dose (MTD) of Iberdomide, starting at Dose Level 0 and increasing to Dose Level 1~* Baseline visit~* Cycle 1 through Cycle 2:~  * Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily~ * Days 1, 8, 15, and 22 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily~ * Days 1, 8, 15, and 22 of 28 Day Cycle: Predetermined dose of Elotuzumab 1x daily~* Cycle 3 through End of Treatment:~  * Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily~ * Day 1 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily~ * Day 1 of 28 Day Cycle: Predetermined dose of Elotuzumab 1x daily~* End of Treatment visit~* 14 Day Follow Up Visit: to be in-clinic after end of treatment visit~* Follow Up: Every 28 days for up to 2 years~* Dose expansion will proceed according to dose-limiting toxicity (DLT) guidelines per the protocol"
62334076|NCT04261634|EXPERIMENTAL|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
62491629|NCT03145987|PLACEBO_COMPARATOR|Placebo|Placebo orally administered once a day for 12 weeks.
61938619|NCT06115785|NO_INTERVENTION|CST nonpharmacological intervention|CST nonpharmacological intervention Individuals in the control group will be given two sessions in the 2nd week, and they will continue their daily lives in the following weeks.
61938620|NCT02280551||Adolescents|1927 Grade 7 high school students
61938621|NCT02280551||Parent|A parent of each of the 1927 Grade 7 high school students
61938622|NCT06680999||Treated patients|All patients treated by endovascular surgery (stenting) at Hospices Civils de Lyon between March 2019 and July 2023 for superior cave syndrome, with lesions reaching the trifurcation (elective involvement of the superior vena cava)
61938623|NCT05027464|EXPERIMENTAL|Intervention Arm|The VAMC Internal Facilitator will partner with the trial External Facilitators (research team and designated External Facilitators in VISNS 16 and 21) to adapt and implement the study intervention to best meet the needs and preferences of their VAMC site. In addition, each CBOC and clinic affiliated with a VAMC in the Intervention arm will need to identify a Site Champion to provide clinic-specific information to facilitate implementation of the Vaccine Acceptance Intervention at their clinic or CBOC. In addition, for clinics and CBOCs assigned to the Vaccine Acceptance Intervention, VAMC, clinic and CBOC leadership will need to agree to release PACT staff for an initial two-hour Motivational Interviewing (MI) training, and at least one 60-minute post-training consultation session over the one-year trial period. There will be additional consultation sessions offered to intervention clinics and CBOC staff, but these will be optional.
61938624|NCT05027464|NO_INTERVENTION|Usual Care Arm|"A VAMC assigned to Usual Care will have no specific trial intervention requirements beyond their usual level of participation in national and local initiatives to improve COVID-19 vaccine acceptance. At both Intervention and Usual Care sites, the study team will perform quarterly environmental scans. The environmental scan survey will include questions about site specific barriers to COVID-19 vaccination (first dose and second dose if needed), current programs/initiatives in the clinic or local community that are improving or have had no impact on vaccination rates, and the perceived importance that the VAMC/CBOC clinic staff is placing on vaccination (Environmental Scan Survey, in preparation). At Usual Care sites, a point of contact will be chosen from each clinic and CBOC to complete the environmental scan, and at Intervention sites, the Site Champion (see below) will perform the quarterly scan."
61938625|NCT00921362||1|Schizophrenia patients under Seroquel treatment
61938626|NCT03220984|EXPERIMENTAL|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
61938627|NCT04666480|EXPERIMENTAL|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
61938628|NCT04763928|EXPERIMENTAL|VenDec|Patients will receive a combination of VENETOCLAX (400 mg per day orally on days 1 to 28 of 28-days courses) and DECITABINE (20 mg/sqm intravenously on days 1 to 5 of 28-days courses)
61938629|NCT06509139|ACTIVE_COMPARATOR|The 10-day bismuth-based quadruple therapy group for females|The female patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
61938630|NCT06509139|ACTIVE_COMPARATOR|The 14-day bismuth-based quadruple therapy group for females|The female patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
61938631|NCT06509139|ACTIVE_COMPARATOR|The 10-day bismuth-based quadruple therapy group for males|The male patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
61938632|NCT03920410|EXPERIMENTAL|stimulated serotonergic activity|
61938633|NCT03920410|EXPERIMENTAL|unstimulated serotonergic activity|
61938634|NCT02951338|ACTIVE_COMPARATOR|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
62334077|NCT04261634|ACTIVE_COMPARATOR|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
62491630|NCT04276064|EXPERIMENTAL|Patients with insomnia|Patients with insomnia disorder according to DSM-5 criteria
62491631|NCT04276064|EXPERIMENTAL|Healthy controls|Healthy controls
62491632|NCT03329924||Pre-implementation cohort|These patients are being exposed to the current standard of care, which does include some early mobilization practices, but not a formalized program.
61938635|NCT02951338|EXPERIMENTAL|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
61938636|NCT05191563|EXPERIMENTAL|Sequence 1 (Reference-Test)|Period 1: RLD2001-2 + RLD2006, Period2: HCP1904-1
61938637|NCT05191563|EXPERIMENTAL|Sequence 2 (Test-Reference)|Period 1:HCP1904-1, Period 2: RLD2001-2 + RLD2006
61938638|NCT05400863|EXPERIMENTAL|Avoid Sugary Drinks and Artificially Sweetened Drinks ( plus Metformin)|Counseling on Beverage Intake to avoid sugary sweetened and NNS (non-nutritive sweetened) drinks plus Metformin therapy (subjects will be given 12-week Metformin (500mg BID) as standard of care therapy).
61938639|NCT05400863|ACTIVE_COMPARATOR|Avoid sugary drinks only, allowed water and drinks with NNS (plus Metformin)|Counseling on Beverage Intake to avoid sugary drinks (allowed water and drinks sweetened with NNS) plus Metformin therapy (subjects will be given 12-week Metformin (500mg BID) as standard of care therapy).
61938640|NCT06162429||Flexible Thoracoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy in the Respiratory Unit, Department of Internal Medicine, Faculty of Medicine UKM
61938641|NCT06162429||Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent semi-rigid pleuroscopy using flexible bronchoscopy in the Respiratory Unit, Department of Internal Medicine, Faculty of Medicine UKM
62137133|NCT06518551|EXPERIMENTAL|Phase 2: Dose Expansion|"Participants will be enrolled and will complete study procedures as follows:~* Baseline visit~* Cycle 1 through Cycle 2:~  * Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily.~ * Days 1, 8, 15, and 22 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily.~ * Days 1, 8, 15, and 22 of 23 Day Cycle: Predetermined dose of Elotuzumab 1x daily.~* Cycle 3 through End of Treatment:~  * Days 1 through 21 of 28 Day Cycle: Predetermined dose of Iberdomide 1x daily.~ * Day 1 of 28 Day Cycle: Predetermined dose of Dexamethasone 1x daily.~ * Days 1, 8, 15, and 22 of 23 Day Cycle: Predetermined dose of Elotuzumab 1x daily.~* End of Treatment visit~* 14 Day Follow Up Visit: to be in-clinic after end of treatment visit.~* Follow Up: Every 28 days for up to 2 years"
62137134|NCT03613740|EXPERIMENTAL|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
62137135|NCT03613740|PLACEBO_COMPARATOR|Placebo|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
62137136|NCT01288443|PLACEBO_COMPARATOR|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
62491633|NCT03329924||post-implementation cohort|These patients will have been exposed to the fully executed early mobilization program.
61938642|NCT00570167|ACTIVE_COMPARATOR|2|Total cementless hip arthroplasty with metal-on-metal bearings
62137137|NCT01288443|EXPERIMENTAL|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
62137138|NCT01288443|EXPERIMENTAL|Alirocumab 100 mg Q2W|Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
62137139|NCT01288443|EXPERIMENTAL|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
61938643|NCT00570167|ACTIVE_COMPARATOR|1|Hip resurfacing
61938644|NCT04151173|EXPERIMENTAL|aspiration/electrocoagulation|
61938645|NCT04151173|ACTIVE_COMPARATOR|cystectomy|
62137140|NCT01288443|EXPERIMENTAL|Alirocumab 200 mg Q4W|Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
62137141|NCT01288443|EXPERIMENTAL|Alirocumab 300 mg Q4W|Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
62137142|NCT03092726|EXPERIMENTAL|ASP8062|Participants received 30 mg of ASP8062 orally once daily for 8 weeks.
62491634|NCT02188407|EXPERIMENTAL|Sevoflurane|Sevoflurane group (S group)- The group anaesthesied with sevoflurane
61938646|NCT04840732|EXPERIMENTAL|Experimental: Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
61938647|NCT04840732|PLACEBO_COMPARATOR|No Intervention: usual care|Chemotherapy training as usual care (for training chemotherapy skill).
62137143|NCT03092726|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo orally once daily for 8 weeks.
62137144|NCT04566263|OTHER|Successful embolization of intracranial aneurysms|Successful embolization of intracranial aneurysms defined by angiographic occlusion of greater than or equal to 90% at 6 months.
61938648|NCT00903318||Mexican American Men and Women|Rural and urban Mexican American men and women , aged 18 to 40, in urban Baytown, TX and rural Rio Grande Valley (Hidalgo County) communities along the Texas-Mexico border
62137145|NCT03529305|EXPERIMENTAL|Low frequency rTMS|Patients receive low frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the unaffected side for two weeks, 5 consecutive days each week.
62137146|NCT03529305|EXPERIMENTAL|High frequency rTMS|Patients receive high frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the affected side for two weeks, 5 consecutive days each week.
62491635|NCT02188407|ACTIVE_COMPARATOR|Propofol|Propofol 4-6 mg/kg/h iv
62137147|NCT03529305|ACTIVE_COMPARATOR|Physical therapy|Patients receive physical therapy for two weeks.
62137148|NCT02809989||Ovaleap®|Single group prospective treatment cohort
62491636|NCT03795012|ACTIVE_COMPARATOR|Eribulin monotherapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
62491637|NCT03795012|ACTIVE_COMPARATOR|eribulin plus endocrine therapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
62491638|NCT01243151|PLACEBO_COMPARATOR|A|
62491639|NCT01243151|EXPERIMENTAL|B|
61938649|NCT02395666|EXPERIMENTAL|DFMO twice daily|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
61938650|NCT03487523|ACTIVE_COMPARATOR|Intervention 1|Text message (SMS Message)
61938651|NCT03487523|ACTIVE_COMPARATOR|Intervention 2|Text message (SMS Message)
61938652|NCT03487523|NO_INTERVENTION|Intervention 3|no intervention
62137149|NCT01605409|ACTIVE_COMPARATOR|Standard ACLS|Patients in the standard ACLS group will be resuscitated until ROSC or termination of efforts. If ROSC is achieved they will be transported to the emergency department and treated according to ERC guidelines and GCP.
62137150|NCT01605409|EXPERIMENTAL|ECPB|"ACLS provided for 15 minutes by EMS personnel according to current guidelines of the ERC.~CPR during transportation will be performed by EMS personnel according to ERC guidelines.~At the ED cannulation will be performed percutaneously if feasible. The femoral artery will be cannulated with a 17-19 - Fr and the femoral vein will be cannulated simultaneously with heparin coated 19-25 - Fr catheter or a smart cannula. An antegrade 8 - Fr cannula will be placed to supply perfusion for the cannulated leg if feasible. The procedures will be performed ultrasound-guided and the size of the cannulae will be adapted according to vessel size. Correct placement of the venous cannulae will be verified via ultrasound. Cardiopulmonary bypass will be performed by using the Lifebridge(Sorin®) or the Cardiohelp(Maquet®) ECMO device, according to protocol."
62334078|NCT05980832|EXPERIMENTAL|Experimental Group 1|It will consist of 10 patients who have received psychosocial skills training by the staff of the center, and a 6-week peer-supported psychosocial skills training will be given by the peer-leaders trained by the researcher psychiatric nurse.
62137151|NCT00986375|EXPERIMENTAL|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
62491640|NCT01243151|EXPERIMENTAL|C|
62137152|NCT00986375|ACTIVE_COMPARATOR|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
62137153|NCT01503372|EXPERIMENTAL|Arm A: FLO + Pazopanib|
62137154|NCT01503372|ACTIVE_COMPARATOR|Arm B: FLO|
62137155|NCT00580866|EXPERIMENTAL|Joint Active Systems Brace (JAS Brace)|Elbow is placed in a brace to apply an extension force
62137156|NCT00580866|NO_INTERVENTION|PT Only Group|No brace is used
62137157|NCT02839395|ACTIVE_COMPARATOR|base line|First night is the base line- no exposure to computer screen illumination.
62137158|NCT02839395|EXPERIMENTAL|Acute|Second night is the acute exposure to computer screen illumination.
61938653|NCT04793698|EXPERIMENTAL|Compassion meditation|Compassion meditation is a contemplative meditation practice that fosters compassion through contemplation of common humanity.
61938654|NCT04793698|ACTIVE_COMPARATOR|Applied relaxation|Veteran.calm is an applied relaxation program that exposes participants to a variety of relaxation strategies and their application.
62137159|NCT02839395|EXPERIMENTAL|Chronic|Chronic is the effect after five nights of exposure to computer screen light illumination.
62137160|NCT00664690|EXPERIMENTAL|1|celebrex
62137161|NCT00664690|PLACEBO_COMPARATOR|2|placebo
62137162|NCT01025128|ACTIVE_COMPARATOR|group A low D|ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
62137163|NCT01025128|NO_INTERVENTION|group A high D|ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
62334079|NCT05980832|EXPERIMENTAL|Experimental Group 2|It will consist of 10 patients who have not received psychosocial skills training by the staff of the center, and a 6-week peer-supported psychosocial skills training will be given by the peer-leaders trained by the researcher psychiatric nurse.
62334080|NCT05980832|NO_INTERVENTION|Control Group 1|It will consist of 10 patients who have received psychosocial skills training by the center staff and no intervention will be applied.
62334081|NCT05980832|NO_INTERVENTION|Control Group 2|It will consist of 10 patients who have not received psychosocial skills training by the center staff and no intervention will be applied.
62334082|NCT05980832|OTHER|Peer Practitioner Training|It is the group in which psychosocial skills training will be given to 4 patients with chronic mental disorders by a researcher psychiatric nurse.
61938655|NCT06131398|EXPERIMENTAL|Group A: AMG 355 monotherapy|Specified dose on specified days
61938656|NCT06131398|EXPERIMENTAL|Group B: AMG 355 and pembrolizumab|Specified dose on specified days
61938657|NCT00634400|ACTIVE_COMPARATOR|1|
61938658|NCT00634400|PLACEBO_COMPARATOR|2|
62137164|NCT01025128|ACTIVE_COMPARATOR|group B low D|mixed population clinics patients aged 18-39 with lowest vitamin D levels
62137165|NCT01025128|NO_INTERVENTION|group B high D|mixed population clinics patients aged 18-39 with highest vitamin D levels
61938659|NCT04753307||Patients at least 45 years at-risk for cardiovascular complications|
61938660|NCT06348680|EXPERIMENTAL|Experimental group|Standard episiotomy repair training will be given to the students in the experimental group using the calf tongue simulator. After the theoretical phase is completed, the implementation phase will begin. During the application period (practical phase), students in this group will be shown a 'video recording' of episiotomy repair prepared by the researchers as educational material. Thus, students in the experimental group will be able to watch episiotomy repairs whenever and however many times they want, in addition to researcher support throughout the application, and improve their application skills.
62137166|NCT06443073|NO_INTERVENTION|Control: unhealthy|Participants with a speech disorder who do not receive the intervention and only complete the outcomes.
62137167|NCT06443073|NO_INTERVENTION|Control: healthy|Participants without a speech disorder who do not receive the intervention and only complete the outcomes.
62137168|NCT06443073|EXPERIMENTAL|Experimental groups|Four groups receiving different rates of questionnaire exposure and wording at either two or four week intervals.
62137169|NCT02910973|ACTIVE_COMPARATOR|Vagus Nerve Stimulation|Device: Vagus nerve stimulation Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
62137170|NCT02910973|SHAM_COMPARATOR|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
62334083|NCT01187108|PLACEBO_COMPARATOR|Placebo pills|
62491641|NCT01243151|EXPERIMENTAL|D|
62491642|NCT01243151|EXPERIMENTAL|E|
62491643|NCT05717790|EXPERIMENTAL|Experimental: Nimotuzumab arm|Patients will receive induction chemotherapy with nimotuzumab (200mg/w,weekly plus gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 2 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent nimotuzumab (200mg/w,weekly, 6-7 weeks) and cisplatin (100mg/m2,every 3 weeks for 3cycles )will be administered during IMRT. After 4-6 weeks of the completion of IMRT, adjuvant nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.
62491644|NCT05717790|ACTIVE_COMPARATOR|Control|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 2 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent nimotuzumab (200mg/w,weekly, 6-7 weeks) and cisplatin (100mg/m2,every 3 weeks for 3cycles )will be administered during IMRT.
62491645|NCT04475315|EXPERIMENTAL|Papillary Muscle Sling Group|Participants in the papillary muscle sling group will receive the sling technique performed in conjunction with their standard of care (SOC) Coronary Artery Bypass Grafting (CABG) surgery.
62491646|NCT04475315|ACTIVE_COMPARATOR|Controls Group|Participants in the control group will receive their SOC CABG surgery only, without any additional intervention.
62491647|NCT05754528|ACTIVE_COMPARATOR|Standard daily dosing of endocrine therapy|Standard daily dosing of endocrine therapy
62491648|NCT05754528|EXPERIMENTAL|Endocrine therapy dose-frequency escalation|Endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
62491649|NCT02429583|ACTIVE_COMPARATOR|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
62491650|NCT02429583|ACTIVE_COMPARATOR|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
62694988|NCT02599831|ACTIVE_COMPARATOR|PFM training with Transanal ES|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co. Ltd, China) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible within the patient's tolerance) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients were also required to conduct 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks.
62694989|NCT05399433|OTHER|Production of IL-23 of blood and skin dendriti cells (CD)|Simultaneously evaluate the migratory capacity and production of IL-23 of blood and skin cDC on peripheral venous blood and skin biopsies of psoriatic patients with and without type 2 diabetes and control patients (with or without type II diabetes) depending on their metabolic status.
62694990|NCT05462262|EXPERIMENTAL|intensive lipid-lowering group|Goal for LDL-C \<1.8 mmol/L or ≥50% reduction from baseline.
62694991|NCT05462262|ACTIVE_COMPARATOR|moderate-intensity lipid-lowering group|Goal for LDL-C \<2.6 mmol/L or 30%-50% reduction from baseline.
62137171|NCT03903614|EXPERIMENTAL|Sensory Motor Lateralization (SML)|This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
62137172|NCT03903614|ACTIVE_COMPARATOR|Conventional School-Based OT (CON)|This was a group of 8 junior high school students who received conventional school-based Occupational Therapy service for handwriting difficulty during the 2012-13 School Year. The participants received a like fitness exercises, fine motor speed training, and handwriting practice on their dominant hand instead.
62137173|NCT06124573|EXPERIMENTAL|Reference group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
61938661|NCT06348680|NO_INTERVENTION|Control group|Students in the control group will be given standard episiotomy repair training using the calf tongue simulator. After the theoretical phase is completed, the implementation phase will begin. Researcher support will be provided throughout the implementation period.
61938662|NCT01617525|EXPERIMENTAL|Korean Recommended Diet|A dietary pattern that follows the recommendations by the Korean Rural Development Administration.
62334084|NCT01187108|ACTIVE_COMPARATOR|Acetazolamide alone|
62491651|NCT00382187|EXPERIMENTAL|MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms|
61938663|NCT01617525|ACTIVE_COMPARATOR|US Recommended Diet|Diet based on recipes and menus developed by the USDA Dietary Guidelines for Americans intramural team.
62137174|NCT06124573|EXPERIMENTAL|Test group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
62137175|NCT02313675|EXPERIMENTAL|IV tylenol|One time intra-operative IV acetaminophen administration
62334085|NCT01187108|ACTIVE_COMPARATOR|N-acetylcysteine alone|
62334086|NCT01187108|ACTIVE_COMPARATOR|Combination of N-acetylcysteine and acetazolamide|
62334087|NCT02191787|EXPERIMENTAL|Seresis® + Placebo|"2 capsules Seresis® o.d. for 5 days~2 capsules Placebo o.d. the day before treatment with Seresis®"
62491652|NCT00382187|EXPERIMENTAL|MF59 adjuvant H5N1 influenza vaccine 15 micrograms|
62491653|NCT00382187|EXPERIMENTAL|non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen|
62491654|NCT04968951|ACTIVE_COMPARATOR|FMT with Antibiotics|Participants will receive antibiotics before receiving Fecal Microbiota Transplantation
62491655|NCT04968951|PLACEBO_COMPARATOR|FMT with placebo|Participants will receive placebo before receiving Fecal Microbiota Transplantation
62491656|NCT04106063||deaf children|All Children between 7 and 17 years old attending medical appointment for temporary or persistent deafness in our Ear, Nose and Throat (ENT) department
62491657|NCT01252758|EXPERIMENTAL|albuterol sufate DPI (TBS-7) dose 1|
62491658|NCT01252758|EXPERIMENTAL|albuterol sufate DPI (TBS-7) dose 2|
62491659|NCT01252758|EXPERIMENTAL|albuterol sufate DPI (TBS-7) dose 3|
62491660|NCT01252758|PLACEBO_COMPARATOR|placebo|
62491661|NCT01252758|ACTIVE_COMPARATOR|Ventolin HFA dose 1|
62491662|NCT01252758|ACTIVE_COMPARATOR|Ventolin HFA dose 2|
62491663|NCT00397657|ACTIVE_COMPARATOR|Extended release niacin|
62491664|NCT00397657|ACTIVE_COMPARATOR|Ezetimibe|
62491665|NCT01232049|EXPERIMENTAL|A|Pitavastatin 4mg
62491666|NCT01232049|EXPERIMENTAL|B|Valsartan 320mg
61938664|NCT01617525|ACTIVE_COMPARATOR|Typical American Diet|Diet based on data from the NHANES surveys, as summarized in the USDA report What We Eat in America.
61938665|NCT03553927|OTHER|Low Energy Diet|Commercially available diet products
61938666|NCT03553927|OTHER|NHS advice on healthy eating|Dietary / lifestyle advice programme
61938667|NCT02488850|ACTIVE_COMPARATOR|Surgery|An anatomical surgical resection of primary tumor
61938668|NCT02488850|ACTIVE_COMPARATOR|Radiotherapy|Stereotactic Ablative Radiotherapy (SABR), outpatient treatment that is typically delivered in between 3-8 fractions
61938669|NCT00914485|OTHER|Provider Communication Skills Training|Provider clinical communication training intervention
61938670|NCT05842876||Caregiver + Low Risk neonates|Participants in the nursery who are expected to be lower risk for CoA
61938671|NCT05842876||Caregiver + Medium to High Risk neonates|Participants in the NICU who are expected to be at a higher risk for CoA
61938672|NCT05842876||Nurses in the Newborn Nursery|Nurses who work at the Meriter Hospital, Inc. Newborn Nursery
61938673|NCT02444104||Patients with atrial fibrillation|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with atrial fibrillation.
62334088|NCT04190784|EXPERIMENTAL|60 seconds stretching group|"Stretching exercises for upper Trapezius and Levator scapula .~From supine position , the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times."
61938674|NCT02444104||Patients with highly reduced LV function|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with a highly reduced left ventricular function (LV function)
61938675|NCT02444104||Patients with aortic stenosis|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with severe aortic stenosis
61938676|NCT02444104||Patients with LVAD|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with left ventricular assist-device (LVAD)
62334089|NCT04190784|EXPERIMENTAL|30 seconds stretching group|The same procedures while the therapist will maintain the stretch for 30 seconds.
62334090|NCT04190784|EXPERIMENTAL|15 seconds stretching group|The same procedures while the therapist will maintain the stretch for 15 seconds.
62491667|NCT01232049|EXPERIMENTAL|C|Pitavastatin 4mg + Valsartan 320mg
62491668|NCT02092857|ACTIVE_COMPARATOR|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
62491669|NCT02092857|ACTIVE_COMPARATOR|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
62491670|NCT02092857|PLACEBO_COMPARATOR|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
62491671|NCT03898908|EXPERIMENTAL|COMBO450|"Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets~In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death."
61938677|NCT02577874||Chinese Subjects|7 blood glucose tests taken over a two hour period
61938678|NCT02577874||European Subjects|7 blood glucose tests taken over a two hour period
61938679|NCT06550687|OTHER|Phase 1:Observe communication between physicians and cancer patients|"* Observation of the 10 consultations : To ensure heterogeneous sampling, a varied panel of prescribing physicians will be selected, taking into account gender, age and specialty (oncologist versus organ specialist).~* Conduct a semi-structured interview within 10 days of the consultation with 10 new patients who have been prescribed a theranostic exome analysis by a researcher~* Thematic content analysis of 10 consultation observations by SHS researchers and 10 semi-structured interviews which will enable us to assess the degree of understanding of the information provided by the doctor, and whether it answers the patient's questions."
62491672|NCT01889758|ACTIVE_COMPARATOR|Sequence 1|Tacrolimus Hi for 1 week with full PK on Day 7, then tacrolimus Lo for 1 week with full PK on Day 14, then Prograf for 1 week with full PK on Day 21, then tacrolimus Hi with full PK on Day 28, then Prograf for 1 week with full PK on Day 35, and then tacrolimus Lo for 1 week with full PK on Day 42
62491673|NCT01889758|ACTIVE_COMPARATOR|Sequence 2|Tacrolimus Lo for 1 week with full PK on Day 7, then Prograf for 1 week with full PK on Day 14, then tacrolimus Hi for 1 week with full PK on Day 21, then tacrolimus Lo with full PK on Day 28, then tacrolimus Hi for 1 week with full PK on Day 35, and then Prograf for 1 week with full PK on Day 42
62491674|NCT01889758|ACTIVE_COMPARATOR|Sequence 3|Prograf for 1 week with full PK on Day 7, then tacrolimus Hi for 1 week with full PK on Day 14, then tacrolimus Lo for 1 week with full PK on Day 21, then Prograf with full PK on Day 28, then tacrolimus Lo for 1 week with full PK on Day 35, and then tacrolimus Hi for 1 week with full PK on Day 42
62334091|NCT04190784|PLACEBO_COMPARATOR|60 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 60 seconds
62491675|NCT02966860|EXPERIMENTAL|Oxycodone and acetaminophen (OC/APAP)|Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)
62491676|NCT02484716|EXPERIMENTAL|Timolol|Timolol 0.5% eye-drops solution packaged in a nasal spray device.
62491677|NCT02484716|PLACEBO_COMPARATOR|Placebo|NaCl solution packaged in a nasal spray device.
62491678|NCT03057535|EXPERIMENTAL|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
62491679|NCT03057535|PLACEBO_COMPARATOR|Sodium Chloride|Ingestion of sodium chloride (4 g)
61938680|NCT06550687|NO_INTERVENTION|Phase 2 : Revisit existing information media (GGC information note and video).|These materials will serve as a basis for our work, and may be adapted according to the results of phase 1 of our study. We will seek the advice of a partner patient, who will himself have benefited from a genetic analysis in the context of cancer, and who will be made aware of clinical research.
61938681|NCT06550687|OTHER|Phase 3:Assess patients' preferences with regard to 3 information modalities|"* A medical consultation, during which the doctor will provide each of the 60 patients with the standard form of information, together with the explanatory note (INFOGene study)~* Within 10 days, a semi-structured interview with 30 of the 60 patients. These 30 patients will be selected to ensure maximum socio-demographic and clinical (cancer location) heterogeneity.~* Division of the 60 patients into 3 groups of 20 stratified according to age, gender and cancer location, including 10 previously interviewed (one group will receive the information based solely on the video worked previously, one group will receive the information during a consultation, one group will receive the information first via the video and then during a consultation).~* The researcher conducts a new semi-structured interview with the 60 patients. They will provide an insight into patients' experience of the information they receive (content, form, timing)."
61938682|NCT03181815|EXPERIMENTAL|treatment arm|The patients in this arm will receive C-CAG regimen for salvage treatment,detailed as following: Cladribine 5mg/㎡，d1-5；G-CSF 300ug,d0-9; aclarubicin 10mg,d3-6;cytarabine 10mg/㎡ q12h, SC, d3-9;4 weeks a cycle
61938683|NCT06273436|NO_INTERVENTION|Usual Care|AIM (AIM Alliance for Innovation on Maternal Health) safety bundles delivered in-person
61938684|NCT06273436|EXPERIMENTAL|Usual Care plus H.E.A.R. for Mamas|H.E.A.R. for Mamas is designed to provide the AIM (Alliance for Innovation on Maternal Health) Postpartum Discharge Transition education systematically and to frequently monitor women for signs and symptoms of postpartum complications using simple, patient-centered technology (text/phone).
61938685|NCT03775031|ACTIVE_COMPARATOR|Fraxel 1927nm|Treatment setting for Fraxel 1927 nm: 20 mJ, Treatment level 8, 6 passes
61938686|NCT03775031|ACTIVE_COMPARATOR|Fraxel 1550nm|Treatment setting for Fraxel 1550 nm: 70 mJ, Treatment level 6, 6 passes
61938687|NCT03775031|ACTIVE_COMPARATOR|25% TCA Peel|25% TCA on 5 x 5 cm of sun exposed back
61938688|NCT03775031|PLACEBO_COMPARATOR|Control|Patient serves as their own control
62491680|NCT04628663|ACTIVE_COMPARATOR|DEX group|Dexmedetomidine given at a bolus dose of 1,0 μg/kg 10min before induction of anesthesia and then after as a continuous infusion 0,4-0,8 μg/kg/h until the end of the surgery.
62491681|NCT04628663|PLACEBO_COMPARATOR|Placebo group|Normal saline given as a bolus dose 10min before induction of anesthesia and then after as a continuous infusion until the end of the surgery.
62491682|NCT04688333|EXPERIMENTAL|Supportive care (iConquerFear program, questionnaires)|Patients complete 5 sessions of iConquerFear program online over 5 weeks. Patients also complete questionnaires at baseline, after the intervention, and 2 months later.
62491683|NCT02083809|PLACEBO_COMPARATOR|Placebo|500ml saline or lactated ringer without oxytocin added
62491684|NCT02083809|ACTIVE_COMPARATOR|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
62491685|NCT04428645|EXPERIMENTAL|DailyDose Decision Support|Subjects will use DailyDose decision support for 8 weeks at home.
62491686|NCT00916786||OROS-methylphenidate|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
62491687|NCT00916786||Atomoxetine group|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
62491688|NCT00916786||Control group|Healthy controls matching for the distribution of age and sex of the case groups
62491689|NCT04162171|EXPERIMENTAL|Imaging & SBRT Treatment for Ventricular Tachycardia|
62491690|NCT01828437|EXPERIMENTAL|Pyridoxine plus prednisolone|allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
62491691|NCT01828437|ACTIVE_COMPARATOR|Prednisolone|allocated patients receive prednisolone alone
62491692|NCT01164657|EXPERIMENTAL|study group|Randomized to give birth on a birthing seat
62491693|NCT01164657|NO_INTERVENTION|control group|Randomized to birth in any other position except the birthing seat
61938689|NCT06098274|EXPERIMENTAL|Motivational interviewing group based on transtheoretical model|Smartphone addiction scale will be applied to nursing department students. Those who score 31 or more on the scale for men and 33 or more for women will be considered at risk and will be invited to the study. Those who meet the participation criteria and volunteer to participate will be included in the study. Participants will be homogeneously and randomly distributed into intervention and control groups.
61938690|NCT06098274|NO_INTERVENTION|Group without transtheoretical model-based motivational interviewing (Control group)|No intervention will be made to the intervention group. After evaluating the final data, if the motivational interview and training program is found to be effective, a motivational interview and training program will also be carried out to the control group participants.
62334092|NCT04190784|PLACEBO_COMPARATOR|30 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 30 seconds
62334093|NCT04190784|PLACEBO_COMPARATOR|15 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 15 seconds
62491694|NCT01944722|EXPERIMENTAL|BD Onclarity™ HPV assay on BD Viper™ LT|The LBC specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. Colposcopy will be performed on subjects who have abnormal cytology or HPV positive test results or from a random sampling of subjects with normal cytology and HPV negative test results.
62491695|NCT05073523|OTHER|Meal A|Diet: meal proportion 1
61938691|NCT03180593|ACTIVE_COMPARATOR|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
62334094|NCT01633996|EXPERIMENTAL|Acupuncture|All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).
62334095|NCT04500314|EXPERIMENTAL|Whole body vibration plus routine physical therapy|
62334096|NCT04500314|ACTIVE_COMPARATOR|Routine physical therapy|
62334097|NCT03037658|EXPERIMENTAL|Personal - self|Participants had the opportunity to earn money for themselves by increasing their average steps per day.
62334098|NCT03037658|EXPERIMENTAL|Prosocial - loved one|Participants had the opportunity to earn money for a loved one of their choice by increasing their average steps per day.
62334099|NCT03037658|EXPERIMENTAL|Prosocial - charity|Participants had the opportunity to earn money for a charity of their choice by increasing their average steps per day.
62334100|NCT03037658|EXPERIMENTAL|Choice|Participants were given the choice to earn money either for themselves, a loved one, or a charity by increasing their average steps per day.
62334101|NCT03037658|NO_INTERVENTION|Control|Participants were not offered a financial incentive to increase their average steps per day. They simply wore the pedometer for three weeks.
62334102|NCT05120960|EXPERIMENTAL|Group A|will receive tepotinib alone
62334103|NCT05120960|EXPERIMENTAL|Group B|will receive tepotinib and osimertinib
62334104|NCT01551758|EXPERIMENTAL|FF/VI|once daily via a Novel Dry Powder Inhaler
62334105|NCT01551758|OTHER|Existing Maintenance Therapy|"Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy"
62334106|NCT01228266|EXPERIMENTAL|autologous mesenchymal stem cell|A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months
62334107|NCT01395368||Brain Speed Test|Brain Speed Test
61938692|NCT03180593|ACTIVE_COMPARATOR|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
62334108|NCT06072001|EXPERIMENTAL|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
62334109|NCT06072001|EXPERIMENTAL|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
62334110|NCT04970771|EXPERIMENTAL|Solving Wellness Platform Group|Participants will receive a 1-year membership to the Solving Wellness virtual platform containing interactive wellness resources.
62334111|NCT02423434||Corneal Confocal Microscopy subjects|
62334112|NCT02524860|EXPERIMENTAL|MRI-ultrasound fusion device|Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging
61938693|NCT04901546|EXPERIMENTAL|Infants with Esophageal Atresia|Starting at 3 weeks, infants will be administered 1 mL of their own saliva via gastrostomy tube, with each feed (8x/day) for one week.
62334113|NCT04056013|ACTIVE_COMPARATOR|Absorbable|Wound repaired with Vicryl Rapide absorbable suture
62334114|NCT04056013|NO_INTERVENTION|Nonabsorbable|Wound repaired with traditional nonabsorbable suture
62334115|NCT01613014|PLACEBO_COMPARATOR|Sugar Pill|Matched Placebo sugar pill - target dose 2 pills BID
61938694|NCT04901546|NO_INTERVENTION|Comparison Infants without Esophageal Atresia|Infants do not have EA and thus can swallow their own saliva.
61938695|NCT02604056|ACTIVE_COMPARATOR|Audit + Feedback|'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home)
61938696|NCT02604056|EXPERIMENTAL|Audit + Feedback + Educational Outreach|'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home)
61938697|NCT02121782|EXPERIMENTAL|Quadrivalent influenza vaccine(Part A)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
62334116|NCT01613014|ACTIVE_COMPARATOR|ABT-436|ABT-436 Target dose of 400 mg BID
62334117|NCT05868941|EXPERIMENTAL|Broncho Muco Cleaner|It will be applied to patients with a diagnosis of chronic bronchitis-predominant COPD, who cannot achieve adequate clinical and functional improvement despite optimal medical therapy. In patients who meet the patient selection criteria, anesthesia approval will be obtained before the procedure will be performed under general anesthesia
62334118|NCT02648958|PLACEBO_COMPARATOR|Control group|The control group received saline instead of dexmedetomidine.
62334119|NCT02648958|EXPERIMENTAL|Dexmedetomidine group|The dexmedetomidine group received the dexmedetomidine.
62334120|NCT01262300|EXPERIMENTAL|VZV vaccine|"Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection~All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels."
62334121|NCT05212168|ACTIVE_COMPARATOR|Active Vaccine Arm|Subjects receiving Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
62334122|NCT05212168|PLACEBO_COMPARATOR|Placebo Arm|Subject receiving Placebo oral tablets similar in appearance and number to active vaccine tablets
62334123|NCT04062851|NO_INTERVENTION|GRV group|Gastric residuals will be checked prior to feeds
62334124|NCT04062851|EXPERIMENTAL|NO GRV group|Gastric residuals will not be checked prior to feeds
62334125|NCT02352051|ACTIVE_COMPARATOR|Atomoxetine group|The drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
62334126|NCT02352051|ACTIVE_COMPARATOR|Methylphenidate group|The drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg.
62334127|NCT01300897||Healthy Volunteer|healthy volunteers will serve as controls. In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potentials will be measured.
62491696|NCT05073523|OTHER|Meal B|Diet: meal proportion 2
62491697|NCT05073523|OTHER|Meal C|Diet: meal proportion 3
62334128|NCT01300897||Constipated patients|Patients with chronic constipation and rectal hypersensitivity or hyposensitivity and/or dyssynergic defecation.In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potential will be measured
62334129|NCT06502470|EXPERIMENTAL|Safety Evaluation of Skin Removal Percentages and Evaluation of Healing over 14 Days.|Three participants will have the ellacor® procedure done at 4 different timepoints before their abdominoplasty surgery: -14 days, -7 days, -3 days and on day 0, just prior to the abdominoplasty procedure. At each treatment timepoint the participants will have 3 areas treated using different skin removal percent settings: 5%, 7% and 8%. The participants will have photos taken of the treatment areas and will be asked about any changes to their health or medications over the 14-day study.
62334130|NCT06382974|EXPERIMENTAL|bone grafting using atorvastatin combined with beta-TCP|the 10 volunteers will undergo cyst enucleation followed by filling the residual bone defects with atorvastatin combined with beta-TCP in the ratio of 0.1 mg: 14 mg.
62491698|NCT06466317|EXPERIMENTAL|Honey intake with walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines in addition to consuming natural honey (2ml/kg honey will be taken.. This dose will be divided into two halves, the first half will be taken at 7 am and the other half will be taken at 7 pm for 12 weeks)
61938698|NCT02121782|EXPERIMENTAL|Quadrivalent influenza vaccine(Part B)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
61938699|NCT02121782|ACTIVE_COMPARATOR|Trivalent influenza vaccine(Part B)|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
61938700|NCT03561961|ACTIVE_COMPARATOR|Moderate Hypo-fractionation|In arm 1 of the study, patients who are randomized to receive moderately hypo-fractionated RT will receive a total dose of 66-68 Gy in 25# to the primary over 5 weeks, with treatment being delivered daily. All patients will receive a dose of 50 Gy in 25# to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60-66 Gy/25# as a simultaneous integrated boost(SIB).
61938701|NCT03561961|EXPERIMENTAL|Extreme Hypo-fractionation|In Arm 2 of the study, patients who are scheduled to receive SBRT will receive a course of 5 fractions of radiation; each fraction size will be 7.00-7.25 Gy. The total dose will be 35-36.5 Gy. All patients will receive a dose of 25 Gy in 5 # to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30-35 Gy/5# as a simultaneous integrated boost(SIB).The 5 treatments will be scheduled to be delivered alternate day over approximately 7-10 days. An option of equivalent biological dose using 35-36.5 Gy in 5 weekly fractions may be allowed for multicentric accrual in the future.
61938702|NCT00187031|OTHER|1|
61938703|NCT05449769|EXPERIMENTAL|Intervention group|Those in the intervention group will receive eNutriCardio PN advice after completing the eNutriCardio FFQ at baseline only. At weeks 2, 4 and 8 of the study, participants will also receive coaching emails which includes reminders of their PN advice and questions asking them to reflect on their goal progress, if any. This will be in addition to their participation in an NHS CR programme (if they choose to join).
61938704|NCT05449769|NO_INTERVENTION|Control group|Those in the control group will not receive any PN advice from eNutriCardio and hence, will not receive any coaching emails. They will record their diet using eNutriCardio's FFQ . They will still be eligible to take part in an NHS CR programme.
61938705|NCT06557525|EXPERIMENTAL|Neurofeedback|
61938706|NCT04672720|EXPERIMENTAL|Adding l-carnitine to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. In the experimental group, the women will receive 3 tablet of L-carnitine daily (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) from day 2 of the previous menstrual cycle until pregnancy test day.
61938707|NCT04672720|PLACEBO_COMPARATOR|Adding placebo to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. The patients in the control group will receive 3 placebo tablets in similar way for 8 weeks.
61938708|NCT02438657|EXPERIMENTAL|median nerve block|"An ultrasound-guided nerve block with dextrose 5% hydrodissection is performed in each case. The first patient will receive a 2 mL local anesthetic solution. For following patients, the volume of local anesthetic depends on the clinical result of the previous patient:~* increase of the volume (0.5 mL) in case of failure,~* no change or decrease (0.5 mol) in case of success; a randomization is made in this case (BCD method, Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171-7)"
62137176|NCT02313675|EXPERIMENTAL|IV toradol|One time intra-operative IV ketorolac thromethamine administration
62137177|NCT02313675|EXPERIMENTAL|IV tylenol/toradol combination|One time intra-operative IV combination of acetaminophen/ketorolac administration
62137178|NCT02313675|PLACEBO_COMPARATOR|saline|One time intra-operative 50ml IV normal saline administration
62334131|NCT02488759|EXPERIMENTAL|Neoadjuvant Cohort|"Nivolumab intravenous infusion as specified~\*\*Not participating: Japan, Korea, and Taiwan"
62334132|NCT02488759|EXPERIMENTAL|Metastatic Monotherapy Cohort|Nivolumab intravenous infusion as specified
62491699|NCT06466317|ACTIVE_COMPARATOR|walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines for 12 weeks
62491700|NCT02117141|EXPERIMENTAL|HC-ER 20 mg capsule (fasted)|Single oral dose of a HC-ER 20 mg capsule (fasted)
62491701|NCT02117141|EXPERIMENTAL|HC-ER 20 mg capsule (fed)|Single oral dose of HC-ER 20mg capsule (fed)
62491702|NCT04727164|EXPERIMENTAL|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced melanoma and other solid tumors
62694992|NCT04868357|EXPERIMENTAL|Hypnosis|Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group hypnosis. It includes 1 hypnotic induction, multiple suggestions of relaxation and a feeling of air entering the lungs, and a closing exercise. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness. This arm is structured following the classic format of didactic hypnosis interventions, were patients discover the exercise by doing it, and receive keys to be able to recreate the hypnotic state on their own.
61938709|NCT05231044|EXPERIMENTAL|KX01 Ointment 1%|KX01 Ointment 1% is applied topically once daily for 5 consecutive days on face or scalp
62137179|NCT01880736|EXPERIMENTAL|IDeg OD Flexible Dose|
61938710|NCT05231044|PLACEBO_COMPARATOR|Placebo|Vehicle Ointment is applied topically once daily for 5 consecutive days on face or scalp
61938711|NCT04162600|EXPERIMENTAL|5 x 10^9 vp of ChAdOx2 RabG|Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10\^9 vp vaccination intramuscularly. Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine.
62334133|NCT02488759|EXPERIMENTAL|Nivolumab plus Ipilimumab Cohort|"Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified~\*\*Not participating: Belgium, France and Germany~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico~\*\*Not participating in cohort expansion: France, Germany, Korea and Taiwan"
62334134|NCT02488759|EXPERIMENTAL|Nivolumab plus Relatlimab Cohort|"Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified~\*\* Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
62334135|NCT02488759|EXPERIMENTAL|Nivolumab plus Daratumumab Cohort|"Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified~\*\*Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
62334136|NCT03838770|EXPERIMENTAL|Active|
62334137|NCT03838770|PLACEBO_COMPARATOR|Sham|
62334138|NCT03913624|EXPERIMENTAL|50 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 50 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
61938712|NCT04162600|EXPERIMENTAL|2.5 x 10^10 vp of ChAdOx2 RabG|Volunteers will receive a standalone dose of ChAdOx2 RabG 2.5 x 10\^10 vp vaccination intramuscularly. Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine.
62334139|NCT03913624|EXPERIMENTAL|35 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 35 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
61938713|NCT04162600|EXPERIMENTAL|5 x 10^10 vp of ChAdOx2 RabG|Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10\^10 vp vaccination intramuscularly. Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine.
61938714|NCT05355610|EXPERIMENTAL|Vestibular severity index improvement|Improvement in vestibular symptoms with intratympanic gentamicin
61938715|NCT05144841|EXPERIMENTAL|Arm A|Participants will receive treatment with zilovertamab vedotin 2.5 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.
61938716|NCT05144841|EXPERIMENTAL|Arm B|Participants will receive treatment with zilovertamab vedotin 2.25 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.
61938717|NCT00805701|ACTIVE_COMPARATOR|0.5mg Avodart|.5mg avodart capsule orally once a day during 13 months
62334140|NCT03913624|NO_INTERVENTION|Control group|Conventional treatment
62491703|NCT04875585|EXPERIMENTAL|Treatment Arm|neoadjuvant therapy with Pembrolizumab/Lenvatinib in combination with surgical resection of primary tumor followed by adjuvant Pembrolizumab therapy
62491704|NCT05719467|ACTIVE_COMPARATOR|Buscopan and bicarbonate|
61938718|NCT00805701|PLACEBO_COMPARATOR|Placebo|placebo capsule orally daily for 13 months
62137180|NCT01880736|EXPERIMENTAL|IDeg OD Fixed Dose|
62137181|NCT01880736|EXPERIMENTAL|IDeg OD Simple|
62137182|NCT01880736|EXPERIMENTAL|IDeg OD Stepwise|
62491705|NCT05719467|ACTIVE_COMPARATOR|Buscopan and placebo|
62491706|NCT05719467|ACTIVE_COMPARATOR|Placebo and bicarbonate|
62491707|NCT05719467|PLACEBO_COMPARATOR|Placebo and placebo|
62491708|NCT03259113|OTHER|Insertable cardiac monitor|All patients will undergo monitoring using an insertable cardiac monitor (single arm)
61938719|NCT06382831|ACTIVE_COMPARATOR|Control|
61938720|NCT06382831|EXPERIMENTAL|Opioid free anesthesia|
61938721|NCT03268837|EXPERIMENTAL|Programmed Intermittent Bolus (PIB)|For the experimental group, patients will receive 5 mL of the study solution as a bolus every hour via a PIB-capable infusion pump.
62137183|NCT03781375|PLACEBO_COMPARATOR|Methotrexate + Placebo|Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
62491709|NCT04783337|EXPERIMENTAL|HR-pQCT (high resolution computertomograph)|"This arm is the inverventional group for all collected cases. No other arms are available as comparator or control. All patients are treated the same.~Description of the intervention in the section Intervention."
61938722|NCT03268837|ACTIVE_COMPARATOR|Continuous Infusion|The control (standard care) group will receive the study solution at a rate of 5mL/h continuously via the current infusion pump.
61938723|NCT04890847||human-machine collaboration group|healthcare professionals and machine collaboration for annotation and AI model development
62491710|NCT06356077||Study cohort|Each study subject will receive an Aktiia device and will use it continuously for 3 months. Study participants will have to complete 2 different surveys: one at baseline, and one after the 3 months of Aktiia device use to give their perception on the Aktiia device use as compared to other blood pressure monitors currently on the market.
61938724|NCT04890847||pure mannual group|healthcare professionals for pure manual annotation and AI model development
61938725|NCT03634644|ACTIVE_COMPARATOR|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
62334141|NCT02273752|EXPERIMENTAL|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
62334142|NCT01052987|EXPERIMENTAL|Tranilast|Tranilast tablets
62491711|NCT03486496|EXPERIMENTAL|Gefitinib and Berberine|Experimental: Gefitinib and Berberine Patients will be treated with Gefitinib and Berberine. Gefitinib: 250 mg p.o., daily. Berberine: 50 mg p.o., tid.
62334143|NCT01052987|ACTIVE_COMPARATOR|Allopurinol|Allopurinol tablets
62491712|NCT01951209|EXPERIMENTAL|Rifaximin/Placebo|Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
62491713|NCT01951209|EXPERIMENTAL|Placebo/Rifaximin SSD|Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks
61938726|NCT03634644|PLACEBO_COMPARATOR|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
61938727|NCT00659360|EXPERIMENTAL|Arm I|Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.
62137184|NCT03781375|EXPERIMENTAL|Methotrexate + Etanercept|Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
62137185|NCT00755144|EXPERIMENTAL|1|ROCC
62137186|NCT00755144|ACTIVE_COMPARATOR|2|LCS
62137187|NCT05088798|EXPERIMENTAL|18F-Fluoro Dopa Imaging|single arm
62137188|NCT06215391|NO_INTERVENTION|commercial mask|Noninvasive ventilation delivered through a conventional mask as usual care
62137189|NCT06215391|EXPERIMENTAL|3d printed mask|"The customized mask will be obtained by merging the scanned surface with the base mask design using CAD 3D SolidWorks software, also available in the unit. In patients with edentulism, leak areas will be evaluated without dental prostheses.~3D Printing~Personalized oronasal masks will be manufactured following this procedure:~* Design and manufacture of molds for each type of base mask and the personalized mold of the scanned surface, using stereolithography technology with suitable biocompatible resin such as BioMed Clear or White from FormLABS.~* Manual injection of a biocompatible resin with a Shore A hardness of 18, such as SORTA-Clear™ 18, by joining the two molds. This Shore A hardness will provide appropriate elasticity for this type of mask, perfectly adapting to each patient's unique facial characteristics."
62334144|NCT01052987|EXPERIMENTAL|Combination|Tranilast plus Allopurinol
62334145|NCT01052987|ACTIVE_COMPARATOR|High dose Allopurinol|400 mg Allopurinol
62491714|NCT05939102|ACTIVE_COMPARATOR|Conventional bracket bonding technique|
62491715|NCT05939102|EXPERIMENTAL|V-prep combined with RMGIC for bracket bonding|
62491716|NCT01457196|OTHER|Sequencing Arm|
62491717|NCT02545179|EXPERIMENTAL|intervention|web-based daily care training 12 week interactive web based caring training education
62491718|NCT02545179|NO_INTERVENTION|control|Previous therapy
62491719|NCT01194908|EXPERIMENTAL|Arm A|Patients treated with decitabine and LBH589
62491720|NCT01622764|EXPERIMENTAL|Molecular imaging with 89Zr-RO5323441|
62491721|NCT00582244|EXPERIMENTAL|1|CBT and relaxation.
62491722|NCT00582244|EXPERIMENTAL|2|Physical activity
62491723|NCT00582244|EXPERIMENTAL|3|CBT and physical activity
62491724|NCT00582244|NO_INTERVENTION|4|Control group
62491725|NCT01151696|EXPERIMENTAL|hydroxyzine|Patients will receive intravenous hydroxyzine 1mg/kg at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
61938728|NCT01270854|EXPERIMENTAL|Plasmalyte|Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital
61938729|NCT01270854|ACTIVE_COMPARATOR|Normal Saline|Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital
61938730|NCT01147640|EXPERIMENTAL|CXA 101/tazobactam and metronidazole|
61938731|NCT01147640|ACTIVE_COMPARATOR|meropenem with matching saline placebo|
61938732|NCT00005602|EXPERIMENTAL|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days|
61938733|NCT00005602|EXPERIMENTAL|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days|
61938734|NCT00005602|EXPERIMENTAL|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days|
61938735|NCT00005602|EXPERIMENTAL|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days|
61938736|NCT05077735|EXPERIMENTAL|Treatment (hypofractionated RT)|Patients undergo hypofractionated RT over 10 fractions. Patients who achieve progression undergo up to 2 retreatment courses. Patients undergo MRI and PET-CT scan throughout the study.
62334146|NCT01052987|EXPERIMENTAL|High dose combination|Combination of Tranilast 300 mg and Allopurinol 400 mg
62334147|NCT04220489|EXPERIMENTAL|Ketamine Group|Participants will receive a 1 mg/kg dose of intravenous ketamine 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr ketamine with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
62137190|NCT04433637|EXPERIMENTAL|Nutrition Group|Pregnant women in the first experimental group were provided to consume cake and fruit juice 30 minutes before the NST procedure.
62334148|NCT04220489|PLACEBO_COMPARATOR|Placebo Group|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
62334149|NCT02594475|EXPERIMENTAL|Left lateral position|Endoscopic retrograde cholangiopancreatography is performed in left lateral position in this group.
62334150|NCT02594475|ACTIVE_COMPARATOR|Prone position|Endoscopic retrograde cholangiopancreatography is performed in prone position in this group.
62334151|NCT01755494|EXPERIMENTAL|Lower dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)
62334152|NCT01755494|EXPERIMENTAL|Higher dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)
62334153|NCT04058262|EXPERIMENTAL|Meditation presential|
62334154|NCT04058262|EXPERIMENTAL|Reiki|
62334155|NCT04058262|EXPERIMENTAL|Meditation (app)|
62334156|NCT04058262|PLACEBO_COMPARATOR|round of conversation|
62491726|NCT01151696|PLACEBO_COMPARATOR|Placebo|Patients will receive intravenous placebo at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
61938737|NCT05991388|EXPERIMENTAL|Treatment Arm I - BsAb - Odronextamab|Patients will receive odronextamab given as an intravenous infusion weekly for 12 weeks, then every two weeks until nine months, and every four weeks thereafter until progression or for a maximum of two years
61938738|NCT05991388|EXPERIMENTAL|Treatment Arm II - ADC with Standard Chemotherapy - Loncastuximab tesirine with modified R-ICE|Patients will receive loncastuximab tesirine given as a 30-minute intravenous infusion with each cycle of modified R-ICE (maximum three cycles)
62137191|NCT04433637|EXPERIMENTAL|Video Group|The video, which contains information about the developments and changes occurring in the mother and the fetus during pregnancy, was watched for 15-20 minutes during the NST procedure, accompanied by music that provided relaxation.
62137192|NCT04433637|NO_INTERVENTION|Control Group|No intervention was applied to the pregnant women in the control group.
62334157|NCT03071536|EXPERIMENTAL|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.~Urine output will be recorded hourly for 6 hours."
62334158|NCT04362904|EXPERIMENTAL|acupressure|In accordance with the acupressure protocol, each day for four weeks, taking into account the awakening and sleep periods of the individuals, acupressure applied for a total of 3 min to the each acupuncture points (one session 18 minutes) twice a day between 07:00 and 10:00 and 19:00 to 22:00 in the morning patients were asked to perform acupressure by their caregivers or on their own.
62334159|NCT04362904|NO_INTERVENTION|control|No intervention was applied to the control group.
62334160|NCT05110716|EXPERIMENTAL|Gains, Ascending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary gains in an ascending order of bundle size.
62334161|NCT05110716|EXPERIMENTAL|Gains, Descending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary gains in a descending order of bundle size.
62334162|NCT05110716|EXPERIMENTAL|Losses, Ascending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
62491727|NCT02777307|EXPERIMENTAL|Hemopatch Sealing Hemostat|
62491728|NCT02777307|NO_INTERVENTION|No Hemopatch Sealing Hemostat|
62491729|NCT03058107|EXPERIMENTAL|Nutrition Therapy (NT) group|Nutrition Therapy is intensive dietary counseling based on practical measurements of energy expenditure, rather than calculating it using theoretic formulas or no method at all.
61938739|NCT05991388|EXPERIMENTAL|Treatment Arm III - CAR T-cells - TBC|Patients will receive CAR-T cell therapy - agent TBC
61938740|NCT05857384|ACTIVE_COMPARATOR|Comparator Arm A- Reference Listed Drug/Marinol|dronabinol 5 mg, two capsules of 2.5 mg administered on an empty stomach once only in the study period
61938741|NCT05857384|ACTIVE_COMPARATOR|Comparator Arm B-Reference Listed Drug/Taro Acetazolamide|250 mg acetazolamide, one tablet administered on an empty stomach once only in the study period
61938742|NCT05857384|EXPERIMENTAL|Investigational Product Arm C-IHL42X Fasted|IHL-42X (5 mg dronabinol, 250 mg acetazolamide), one capsule administered on an empty stomach once only in the study period
62334163|NCT05110716|EXPERIMENTAL|Losses, Descending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
62334164|NCT04619121|EXPERIMENTAL|Treatment with real NIR-tPBM on top of standing pharmacotherapy|NIR t-PBM to the dorsolateral prefrontal cortex, bilaterally and simultaneously, from 20 minutes to 80 minutes a day, for 8 consecutive weeks.
62334165|NCT04619121|SHAM_COMPARATOR|Sham device on top of standing pharmacotherapy|Sham device with neglectable energy to the dorsolateral prefrontal cortex, bilaterally and simultaneously, from 20 minutes to 80 minutes a day, for 8 consecutive weeks.
62334166|NCT05304910|EXPERIMENTAL|Lu AG09222 Low Dose|Participants will receive a single dose of Lu AG09222 by subcutaneous (SC) injection on Day 1.
62334167|NCT05304910|EXPERIMENTAL|Lu AG09222 High Dose|Participants will receive a single dose of Lu AG09222 by SC injection on Day 1.
62334168|NCT05304910|PLACEBO_COMPARATOR|Placebo|Participants will receive a single dose of placebo matching LU AG0922 by SC injection on Day 1.
62334169|NCT06242067|EXPERIMENTAL|Irinotecan,Trifluridine-tipiracil in combination with Bevacizumab|
62137193|NCT06699017|EXPERIMENTAL|Patient with moderate to severe ARDS under sedation andcontinuous curarization|Patient with moderate to severe ARDS under sedation andcontinuous curarization
62334170|NCT01437670||dry mouth patients with solifenacin|dry mouth patients with solifenacin 5mg, 10mg
62334171|NCT06450691|EXPERIMENTAL|participants (SLA, healthy controls and asymptomatics)|Patients fulfilling the El Escorial criteria definite ALS or asymptomatics or Healthy controls
62334172|NCT02757066|EXPERIMENTAL|NPC-15 Granules Lower Dose|NPC-15 Granules Lower Dose group which is administered 1mg melatonin
62334173|NCT02757066|EXPERIMENTAL|NPC-15 Granules Higher Dose|NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
62334174|NCT02757066|PLACEBO_COMPARATOR|NPC-15 Placebo Granule|NPC-15 Placebo Granules group which is administered placebo melatonin
62334175|NCT02029508|ACTIVE_COMPARATOR|Epley maneuver|The group using modified Epley maneuver for PSCC BPPV
62334176|NCT02029508|ACTIVE_COMPARATOR|Semont maneuver|The group using Semont maneuver for PSCC BPPV
62334177|NCT02029508|SHAM_COMPARATOR|Sham|The group using Reverse Epley maneuver for PSCC BPPV
62334178|NCT06020274|EXPERIMENTAL|iCF-PWR Program|Parents are encouraged to review the program along with their child and then children are encouraged to complete the program 1-2 additional times (or as many times as they like). It is suggested that modules be completed at a rate of 1-2 per week, with program completion ranging from 3-6 weeks. Additional mental health resources are provided at the end of the program.
62491730|NCT03058107|ACTIVE_COMPARATOR|Control Therapy (CT) group|Control Therapy is standard dietary counseling bij state-wide recognized onco-dietitians. Energy expenditure is never measured in this standard protocol.
62491731|NCT02331511|PLACEBO_COMPARATOR|placebo|No antiplatelet drug
62491732|NCT02331511|ACTIVE_COMPARATOR|Aspirin|Aspirin 80 mg daily
61938743|NCT05857384|EXPERIMENTAL|Investigational Product Arm D-IHL42X Fed|IHL-42X (5 mg dronabinol, 250 mg acetazolamide), one capsule administered after food once only in the study period
62137194|NCT06406400|EXPERIMENTAL|Part 1a: AZD4041 (Dose 1) and Itraconazole|Healthy participants will receive a single dose of AZD4041 (Dose 1) in period 1, followed by repeat dose of itraconazole for 3 days in period 2, and a single dose of AZD4041 co-administered with itraconazole on Day 9, followed by continued itraconazole daily dosing until Day 21 in period 3.
62137195|NCT06406400|EXPERIMENTAL|Part 1b: AZD4041 (Dose 2)|Healthy participants will receive AZD4041 (Dose 2) orally as a single dose.
62137196|NCT06406400|PLACEBO_COMPARATOR|Part 1b: Placebo|Healthy participants will receive matching placebo orally as a single dose.
62334179|NCT06020274|NO_INTERVENTION|Standard Care|Participants will continue to receive their usual standard care related to CF (i.e., accessing services through their local health authority and CF clinic). Following the proposed maximum program completion time-frame (i.e., 6 weeks) and follow-up time period (i.e., 3 months), those in the standard care groups will be provided access to iCF-PWR.
62334180|NCT05505565|EXPERIMENTAL|CGM + Traditional Counseling|Subjects in this arm will receive intermittent CGM to be used for 2-weeks each month for the 6-month study period. They will be required to wear a CGM during baseline, 3-month, and 6-month periods. Additional CGM sensors will be supplied for months 1, 2, 4, and 5 and will be optional. They will be provided with a Sworkit(R) account to monitor physical activity completed through the Sworkit(R) website/platform.
62334181|NCT05505565|ACTIVE_COMPARATOR|Control|Subjects in this arm will receive standard medical care for pre-diabetes. They will be provided with a Sworkit(R) account to monitor physical activity completed through the Sworkit(R) website/platform.
62334182|NCT04510194|EXPERIMENTAL|Treatment Arm - Metformin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the metformin alone.
62491733|NCT02331511|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75mg daily
61938744|NCT06157151|EXPERIMENTAL|PRGN-2009 plus Pembrolizumab|PRGN-2009 at a dose of 5 x 10\^11 PU q3W for 3 administrations, then q6w, plus Pembrolizumab, 400mg q6w
62137197|NCT06406400|EXPERIMENTAL|Part 2: AZD4041 (Dose 3)|Participants will receive AZD4041 (Dose 3) with hydromorphone on Days 1, 2 and 3, and buprenorphine/buprenorphine + naloxone on Days 4, 5, 6 and 7.
62137198|NCT06406400|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive matching placebo with hydromorphone on Days 1, 2 and 3, and buprenorphine/buprenorphine + naloxone on Days 4, 5, 6 and 7.
62137199|NCT02564705||anterior cohort|Anterior Lumbar Interbody Fusion (ALIF)
62137200|NCT02564705||posterior cohort|"* Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)"
62137201|NCT04097145|EXPERIMENTAL|Edwards PASCAL System & OMT|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
62137202|NCT04097145|ACTIVE_COMPARATOR|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
62334183|NCT04510194|PLACEBO_COMPARATOR|Treatment Arm - Placebo Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the placebo.
62334184|NCT04510194|EXPERIMENTAL|Treatment Arm - Ivermectin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the ivermectin alone.
62334185|NCT04510194|EXPERIMENTAL|Treatment Arm - Fluvoxamine Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the fluvoxamine alone.
62491734|NCT01437735|EXPERIMENTAL|QAW039 po dose 1|
62491735|NCT01437735|EXPERIMENTAL|QAW039 po dose 2|
62491736|NCT01437735|EXPERIMENTAL|QAW039 po dose 3|
62491737|NCT01437735|EXPERIMENTAL|QAW039 po dose 4|
62491738|NCT01437735|EXPERIMENTAL|QAW039 po dose 5|
62491739|NCT01437735|EXPERIMENTAL|QAW039 po dose 6|
62491740|NCT01437735|EXPERIMENTAL|QAW039 po dose 7|
62491741|NCT01437735|EXPERIMENTAL|QAW039 po dose 8|
62491742|NCT01437735|EXPERIMENTAL|QAW039 po dose 9|
62491743|NCT01437735|EXPERIMENTAL|QAW039 po dose 10|
61938745|NCT06157151|ACTIVE_COMPARATOR|Pembrolizumab alone|Pembrolizumab, 400mg q6w
61938746|NCT00772473||1 group, usual acute triptan treatment|
62491744|NCT01437735|EXPERIMENTAL|QAW039 po dose 11|
61938747|NCT00152360|EXPERIMENTAL|Xenical (Orlistat)|Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
61938748|NCT06670365|EXPERIMENTAL|Daylong exposure to indoor overheating|Prior to and following the warm-water immersion protocol, participants will undergo a 10-hour passive heat exposure where they will remain in a climate-controlled chamber regulated at 36°C and 45% humidity (temperatures experienced indoors during extreme heat events in North America). During this time they will remain seated with the exception of hourly 5-minute breaks to stretch.
61938749|NCT03011619|ACTIVE_COMPARATOR|Control Condition|usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.
61938750|NCT03011619|EXPERIMENTAL|CBT Condition|If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
61938751|NCT02268955|PLACEBO_COMPARATOR|Control Group: Adults age 18-55 years|Saline-only control group
61938752|NCT02268955|ACTIVE_COMPARATOR|IV Ibuprofen: Adults age 18-55 years|Patients receiving intravenous ibuprofen therapy
62137203|NCT04097145|EXPERIMENTAL|Single-Arm Registry|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
62334186|NCT04510194|EXPERIMENTAL|Treatment Arm - Metformin and Fluvoxamine Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and fluvoxamine.
62334187|NCT04510194|EXPERIMENTAL|Treatment Arm - Metformin and Ivermectin Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and ivermectin.
62334188|NCT01204658|EXPERIMENTAL|10PP-LD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses (LD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD) co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
62491745|NCT01437735|EXPERIMENTAL|QAW039 po dose 12|
62491746|NCT01437735|EXPERIMENTAL|QAW039 po dose 13|
62491747|NCT01437735|ACTIVE_COMPARATOR|Montelukast po 10 mg|Comparator leukotriene receptor antagonist (LRTA)
62491748|NCT01437735|PLACEBO_COMPARATOR|Placebo|
62491749|NCT02086838|ACTIVE_COMPARATOR|Theragran Hematinic, oral iron, 120 mg elemental iron/|pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
62491750|NCT02086838|ACTIVE_COMPARATOR|low molecular weight iron dextran, total dose infusion|Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.
62491751|NCT05592808|EXPERIMENTAL|Low-Dye Taping|In addition to the ESWT applied to the participants in the control group, Low-Dye Taping will be applied to the participants in this group once a week for 3 sessions.
62491752|NCT05592808|EXPERIMENTAL|Kinesio Taping|In addition to the ESWT applied to the participants in the control group, Kinesio Taping will be applied to the participants in this group once a week for 3 sessions.
61938753|NCT05821673|PLACEBO_COMPARATOR|abutments with machine surface|abutments with machine surface characterized by circular micro-threads with a furrow of less than 2 um
62491753|NCT05592808|ACTIVE_COMPARATOR|Extracorporeal Shockwave Therapy (ESWT)|Participants in the control group will receive 3 sessions of ESWT once a week.
61938754|NCT05821673|PLACEBO_COMPARATOR|abutments with rough Ultrathin Threaded Microsurface|abutments with rough Ultrathin Threaded Microsurface with a triangular contour tread with a pitch of 50 μm
61938755|NCT05821673|EXPERIMENTAL|argon plasma pre-treated (PT) abutments|abutments with rough Ultrathin Threaded Microsurface and abutments with machine surface were pretreated with Argon Plasma
61938756|NCT05821673|PLACEBO_COMPARATOR|non treated abutments|abutments with rough Ultrathin Threaded Microsurface and abutments with machine surface without Argon Plasma pretreatment.
62491754|NCT01143337|EXPERIMENTAL|1|dose1
62491755|NCT01143337|PLACEBO_COMPARATOR|2|Placebo
61938757|NCT03701399|EXPERIMENTAL|Arm 1: BHV-4157|Troriluzole 200mg by mouth
61938758|NCT03701399|PLACEBO_COMPARATOR|Arm 2: Placebo|Placebo 200mg by mouth
61938759|NCT00591266|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD|
61938760|NCT00591266|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD|
62137204|NCT04097145|EXPERIMENTAL|Continued Access Study|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
62137205|NCT04768712|EXPERIMENTAL|Weight bearing aerobic exercise|
61938761|NCT00591266|ACTIVE_COMPARATOR|Amlodipine 5 mg QD|
61938762|NCT02927782|ACTIVE_COMPARATOR|Bed Rest|48 hours of strict bed rest after incidental durotomy during lumbar spinal surgery
61938763|NCT02927782|EXPERIMENTAL|Early Mobilization|Immediate Mobilization after incidental durotomy during lumbar spinal surgery
62137206|NCT04768712|NO_INTERVENTION|Lifestyle counseling|
62334189|NCT01204658|EXPERIMENTAL|10PP-HD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with high doses (HD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD), co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
62334190|NCT01204658|ACTIVE_COMPARATOR|Synflorix/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Synflorix™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Synflorix™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Synflorix™ and on the right side for Infanrix hexa™.
62334191|NCT01204658|ACTIVE_COMPARATOR|Prevnar 13/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Prevnar 13™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Prevnar 13™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Prevnar 13™ and on the right side for Infanrix hexa™.
62334192|NCT03230344|ACTIVE_COMPARATOR|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
62334193|NCT03230344|EXPERIMENTAL|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
62334194|NCT01853111|EXPERIMENTAL|Interleukin 2|Subjects who receive a tolerogenic drug protocol
62334195|NCT06291181|EXPERIMENTAL|cases group|wound infected patients
62334196|NCT03157154||First group|Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis
62334197|NCT03157154||Control group|Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).
62334198|NCT04807543|ACTIVE_COMPARATOR|study group|17-hydroxyprogesterone caproate (17P) (250 mg in castor oil, 1 mL total volume)intramuscular injection
62334199|NCT04807543|PLACEBO_COMPARATOR|control group|castor oil, 1 mL total volume intramuscular injection
62334200|NCT01999634|EXPERIMENTAL|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
62334201|NCT01554540|EXPERIMENTAL|Cutaneous iontophoresis of Treprostenil|
62334202|NCT01554540|PLACEBO_COMPARATOR|Cutaneous iontophoresis of placebo|
62334203|NCT04053088||SAVR patients|patients undergoing surgical aortic valve replacement (SAVR) by usage of the INSPIRIS RESILIA Aortic valve™
62334204|NCT01345877|OTHER|gender|
62334205|NCT02825264||STARflo|Patients who have been implanted with STARflo implant
62334206|NCT02979886|EXPERIMENTAL|triptorelin|GnRH-a will be given everyday to the patient undergoing IVF treatment from middle luteal phase to the day of HCG. After 14 days of injection, serum FSH/LH/E2 will be checked. Then ovarian stimulation will be started by giving daily subcutaneous injection of recombinant FSH 150\~300 IU. An appropriate dose of HMG (75\~150 IU) will be added when follicles are larger than 12\~14mm in diameter. When one leading follicle is \>18mm in diameter, or two follicles are \>17mm in diameter, or three follicles are \>16mm in diameter, final ovulation will be triggered by a single injection of HCG 4,000\~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500 IU)
62334207|NCT05621824||Solid mass|Patients with solid mass of pancreas during pancreas MR examination.
62491756|NCT04917393|EXPERIMENTAL|Multi-organ denervation|Multi-organ (Hepatic and Renal) denervation with the Integrated Radio Frequency (iRF) Denervation System
62694993|NCT04868357|ACTIVE_COMPARATOR|Relaxation|"Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group dynamic relaxation. It includes 1 exercise to liberate tension, 3 exercises to increase proprioception and calmness, and 3 exercises for calming and regulating the breath. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness.~1. Provides additional care that motivates the patients to participate in the control group.~2. Allows the controlling of number of group interventions accross arms (2).~3. Allows to control for motivation, as both arms are introduced identically: the benefits and interest of using self-relaxation techniques for complementary care in anxiety and anxiety-related dyspnea are underscored.~4. It allows the disentanglement of hypnosis and relaxation effects . This was crucial, inasmuch as hypnosis too includes physical relaxation and breathing exercises."
62137207|NCT04210037|EXPERIMENTAL|APG-1252 160 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
62334208|NCT05621824||Cystic lesions|Patients with cystic lesions or expansion of MPD during pancreas MR examination.
62334209|NCT05621824||No clear focus|Patients with no clear focus during pancreas MR examination.
62334210|NCT04489225||Observational|This single arm observational study includes all patients implanted with a Medtronic Cobalt™ XT ICD or CRT-D MRI SureScan™ (with Attain StabilityQuad™ MRI SureScan™ Model 4798 Lead (ASQ)), who are enrolled in the Medtronic CareLink (CL) Network and Product Surveillance Registry (PSR). Patients will be followed per the standard of care practices of their care provider. All patients must provide a signed informed consent.
62334211|NCT00520559||Thalassemia|
62491757|NCT04917393|SHAM_COMPARATOR|Control Arm|Subjects will recieved the sham procedure
62334212|NCT01753258||Definite diagnosis of dyspareunia|Patients who report dyspareunia, and whose dyspareunia was evaluated prior to delivery by a caregiver experienced with sexual pain disorders, with definite diagnosis.
62491758|NCT03141151|EXPERIMENTAL|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
61938764|NCT06345131|OTHER|Transverse diameter of radial artery (TDA)|The patient was placed in a supine position, the upper limb was abducted on the operative side, the palm was upward, and the wrist joint was extended at an angle of 45°.Radial artery puncture catheterization is performed within this group
61938765|NCT06345131|OTHER|vertical distance of radial artery (center) from skin (VDA)|The patient was placed in a supine position, the upper limb was abducted on the operative side, the palm was upward, and the wrist joint was extended at an angle of 45°.Radial artery puncture catheterization is performed within this group
61938766|NCT06345131|OTHER|distance of superficial branch of radial nerve relative to horizontal position of radial artery (D)|The patient was placed in a supine position, the upper limb was abducted on the operative side, the palm was upward, and the wrist joint was extended at an angle of 45°.Radial artery puncture catheterization is performed within this group
62491759|NCT03141151|ACTIVE_COMPARATOR|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
62491760|NCT00835796|EXPERIMENTAL|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
62491761|NCT00835796|ACTIVE_COMPARATOR|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
62491762|NCT03283748|EXPERIMENTAL|Measurement of Motor Movements|Wearable Accelerometer Sensors manufactured by leading manufacturers will be given to the participants to be worn around hands and legs. These sensors will be used to measure accelerations which will be impacted by the motor movements.
62491763|NCT02642809|EXPERIMENTAL|Arm 1: Pembrolizumab and Brachytherapy|"* Brachytherapy dose=16 Gy delivered in 2 fractions of 8 Gy per fraction, separated by 7-10 days between fractions.~* Pembrolizumab started within 1 week after completion of brachytherapy administered as an intravenous infusion over 30 minutes. It will be given every 3 weeks.~* Standard of care endoscopic biopsy will take place at time of enrollment and 2-6 months (optional) after pembrolizumab initiation.~* Research endoscopic biopsy for 8 consented patients will take place 1-2 weeks after initiation of brachytherapy.~* Peripheral blood will be collected: Pre-brachytherapy, Post-brachytherapy but pre-pembrolizumab (on day 1), Day 22 after the start of pembrolizumab, 3, 6, and 12 months (+/- 2 weeks) after the start of pembrolizumab, and time of progression"
62491764|NCT00235560|EXPERIMENTAL|Rapamycine|
62491765|NCT04506619||SHP607 250 mcg/kg/24 hours|Participants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
61938767|NCT02493582|OTHER|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
62491766|NCT04506619||SHP607 400 mcg/kg/24 hours|Participants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
61938768|NCT02493582|EXPERIMENTAL|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
61938769|NCT04665388||EBV-related cancer cohort|up to N=30
61938770|NCT04665388||HPV-related cancer cohort|up to N=45
61938771|NCT04665388||HCC cohort|up to N=30
62137208|NCT04210037|EXPERIMENTAL|APG-1252 240 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
62334213|NCT01753258||No definite diagnosis of dyspareunia|"Patients who report dyspareunia but were not evaluated prior to delivery or were evaluated inappropriately (i.e. yeast infection without cultures, inflammation and other vague definitions)."
62334214|NCT01753258||Patients without dyspareunia|Patients without dyspareunia- those who report non painful sexual intercourse. This group of patients will be used as a control group.
62334215|NCT04398849||14-19 year olds residing in the Northern Territory|All consenting 14-19 year olds residing in the Northern Territory in 2020-2021
62694994|NCT04201873|EXPERIMENTAL|Group A (pembrolizumab, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
61938772|NCT02759874|EXPERIMENTAL|Experimental|Intervention is pregnant women enrolled and using specialized breathalyzer device w face recognition technology linked to a cellphone
61938773|NCT02759874|NO_INTERVENTION|Control Group|No intervention. No breathalyzer given. Access granted by participant to IHE to collect data from Alberta Health Services (medical records)
61938774|NCT01356979||Patients underwent medical thoracoscopy|Patients who require medical thoracoscopy for undiagnosed exudative pleural effusion by other clinical or radiological investigations.
61938775|NCT04750603|PLACEBO_COMPARATOR|Salbutamol|Salbutamol (Salbutrim, Trima) inhaler (400 µg) via spacer + Relvar® Ellipta placebo
61938776|NCT04750603|ACTIVE_COMPARATOR|FF/VI|Placebo Salbutamol inhaler + Relvar® Ellipta (92/22 µg, GSK, UK)
61938777|NCT04253314||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label. Decision to treat with Venetoclax was made prior to offering participation in this study.
62137209|NCT04210037|EXPERIMENTAL|APG-1252 80 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
62137210|NCT03027128|EXPERIMENTAL|Cohort 1, 2x10^9 Cells haNK™|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous Infusion
62137211|NCT01894308|ACTIVE_COMPARATOR|Forearm dose|Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.
62137212|NCT01894308|ACTIVE_COMPARATOR|Chest Dose|Half of Ss will receive their dose of Testosterone on the chest.
62491767|NCT04506619||Standard Neonatal Care|Participants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
62491768|NCT06447285|ACTIVE_COMPARATOR|Autism spectrum disorders group|"All patients shall be diagnosed according to ADOS15 and DSM-517 criteria by an experienced physician. ADOS is a diagnostic tool considered the gold standard in ASD diagnostics.18,19 The children with confirmed diagnoses of autism will be assessed by a senior psychologist using the Stanford-Binet Intelligence Scales - Fifth edition (SB-5)21 to ensure that all ASD patients have an IQ of 70 or above. ASD patients with lower IQ will form a distinct group for specific evaluation.~Using sensodetect BERA technology we will in the present study pay attention to wave I-VII amplitude as well as latencies and interpeak intervals to broaden the perspective and allow a better comparison of both groups.~Group differences between autistic and TD groups will be tested intra-individually and between groups and presented."
62491769|NCT06447285|ACTIVE_COMPARATOR|totally developed group|"All patients shall be diagnosed according to ADOS15 and DSM-517 criteria by an experienced physician. ADOS is a diagnostic tool considered the gold standard in ASD diagnostics.18,19 The children with confirmed diagnoses of autism will be assessed by a senior psychologist using the Stanford-Binet Intelligence Scales - Fifth edition (SB-5)21 to ensure that all ASD patients have an IQ of 70 or above. ASD patients with lower IQ will form a distinct group for specific evaluation.~Using sensodetect BERA technology we will in the present study pay attention to wave I-VII amplitude as well as latencies and interpeak intervals to broaden the perspective and allow a better comparison of both groups.~Group differences between autistic and TD groups will be tested intra-individually and between groups and presented."
62491770|NCT03302598|OTHER|patients with enterocutaneous fistula|
62491771|NCT05070754|EXPERIMENTAL|Cold Atmospheric Plasma (CAP)|We are proposing a clinical trial of a floating electrode-dielectric barrier device (FE-DBD), a Cold Atmospheric Plasma (CAP) device for the treatment of Verrucae Vulgaris and Molluscum Contagiosum. While novel to the medical field, and especially to dermatology, there are already a number of publications regarding its use on human skin in adults and children. CAP devices utilize noble gases (such as helium) to deliver plasma state matter to the skin. As its name implies, the generated plasma stream is of near skin temperature and it exists on normal atmospheric pressure. During the generation of the plasma there is no electric contact with the patient. The treatment does not increase skin surface temperature and the used helium gas, the same as used for balloons, being a noble gas does not cause a chemical reaction with the skin. The flow of the gas is slow, thus there is no mechanical effect on the skin.
62334216|NCT02145091|EXPERIMENTAL|One all-day session|"Participants will complete on all-day study session with a moderately-high dose of psilocybin.~Preparation will include two days of screening, and an additional 8 hours of session preparation over at least 2 days. Follow-up will consist of an interview and MRI scan one day after the all-day session, a questionnaire follow-up 2 months after the all-day session, and a final follow-up 12-18 months after the all-day session."
62334217|NCT02145091|EXPERIMENTAL|Two all-day sessions|"Participants will complete two all-day study sessions, the first with placebo and the second with a moderately-high dose of psilocybin.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the second all-day session."
62491772|NCT05070754|ACTIVE_COMPARATOR|Cryotherapy|Current standard of care (SOC) for treating Verruca Vulgaris in Children is cryotherapy. Patients randomized to this arm of the study will receive SOC treatment for their identified condition.
62491773|NCT05070754|ACTIVE_COMPARATOR|Cantharidin|SOC for treatment of Molluscum Contagiosum is cantharidin. Patients randomized to this arm of the study will receive SOC treatment for their identified condition.
62491774|NCT03694236|EXPERIMENTAL|durvalumab|This study is single arm phase II study to evaluate efficacy and safety of durvalumab and chemoradiotherapy (paclitaxel and carboplatin) in treatment-naïve clinical stage II/IIIa NSCLC.
62491775|NCT04595669|EXPERIMENTAL|Personalised advice|
62491776|NCT03531450|EXPERIMENTAL|Cognitive Behavioral Therapy|Patients in the cognitive behavioral therapy group will be asked to undergo a 8-week CBT trial. An online videoconferencing link will be used to deliver CBT virtual sessions that will be approximately 60 minutes in length. Each session will be conducted by a clinical psychology doctoral student, supervised by a licensed psychologist. Patients will also undergo careful phenotyping pre- and post intervention with brain MRI, AFT, and NDT.
62694995|NCT04201873|ACTIVE_COMPARATOR|Group B (placebo, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
62694996|NCT05721079|EXPERIMENTAL|ECP with standard triple IS|
62694997|NCT05721079|ACTIVE_COMPARATOR|standard triple IS|
62694998|NCT05848817||Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK.
62694999|NCT03770611|ACTIVE_COMPARATOR|Probiotic|Subjects receiving probiotic supplementation: 2x108 CFU probiotic bacteria + prebiotic placebo per day during 3 months
62695000|NCT03770611|ACTIVE_COMPARATOR|Prebiotic|Subjects receiving prebiotic supplementation: 20 g of prebiotic fiber + probiotic placebo per day during 3 months
62695001|NCT03770611|EXPERIMENTAL|Symbiotic|Subjects receiving probiotic and prebiotic supplementation: 2x108 CFU probiotic bacteria + 20 g of prebiotic fiber per day during 3 months
62695002|NCT03770611|PLACEBO_COMPARATOR|Placebo|Subjects receiving placebo of probiotic and prebiotic per day during 3 months
62695003|NCT04972604||Duchenne and Becker muscular dystrophy|Individuals with Duchenne muscular dystrophy and Becker muscular dystrophy
62695004|NCT04972604||Carriers|Carriers of Duchenne muscular dystrophy and Becker muscular dystrophy
62137213|NCT03656042|EXPERIMENTAL|G-CSF|Subjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
62137214|NCT03656042|NO_INTERVENTION|No-treatment|No-treatment group is used to control evaluation bias and potential time effect.
62334218|NCT02145091|EXPERIMENTAL|Three all-day sessions|"Participants will complete three all-day study sessions, the first two with placebo and the third with a moderately-high dose of psilocybin. The majority of participants (over 90%) will be assigned to either one or two all-day sessions. A small minority of participants (less than 10%) will be assigned to three all-day sessions.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the third all-day session."
62334219|NCT02145091|EXPERIMENTAL|MRI of the acute effects of psilocybin|This is an optional arm consisting of two sessions where either placebo, a very-low dose of psilocybin, or a moderately-low dose of psilocybin will be administered. During each session, participants will undergo MRI scanning shortly after the administration of each dose. Study sessions may occur over one or two days. Participants who have previously completed an all-day session with psilocybin in this study will be eligible to volunteer for this arm.
62334220|NCT01966575|EXPERIMENTAL|No withdrawal bleed|No progestin prior to ovulation induction with clomiphene citrate
62334221|NCT01966575|NO_INTERVENTION|Withdrawal Bleed|Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)
62334222|NCT00937768|EXPERIMENTAL|Arm A (antihormone therapy)|Patients receive leuprolide acetate IM on day 1 OR goserelin acetate SC on day 1. Courses repeat every 3 months for 9 months in the absence of disease progression or unacceptable toxicity.
62334223|NCT00937768|NO_INTERVENTION|Arm B (no antihormone therapy)|Patients undergo observation every 3 months for 9 months.
62334224|NCT01599468|EXPERIMENTAL|tranexamic acid, post partum hemorrhage|
62334225|NCT01599468|PLACEBO_COMPARATOR|placebo|
62334226|NCT05667727|EXPERIMENTAL|epinephrine group|this arm will include the participant who will receive back to back nebulization (standard of care) plus epinephrine nebulization.
62334227|NCT05667727|ACTIVE_COMPARATOR|control group|in this arm, participant will receive the standard of care treatment (salbutamol and ipratropium, back to back) plus salbutamol as 4th nebulization.
62334228|NCT04523064|ACTIVE_COMPARATOR|SGLT2i (empagliflozin)|Empagliflozin 25 mg 1 time day for three months
62334229|NCT04523064|NO_INTERVENTION|Standard of care|Standard care treatment of diabetes patients in our center
62334230|NCT06370936|EXPERIMENTAL|Animal meats then PBMAs|For the first treatment period of 8 weeks, participants receive a standardized diet with a variety of meat products, after a 10-week washout period this is followed by a standardized diet with a variety of PBMAs for the second treatment period.
62334231|NCT06370936|EXPERIMENTAL|PBMAs then Animal meats|For the first treatment period of 8 weeks, participants receive a standardized diet with a variety of PBMAs, after a 10-week washout period this is followed by a standardized diet with a variety of meat products for the second treatment period.
62334232|NCT03176797|EXPERIMENTAL|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
62491777|NCT00326872|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
62491778|NCT04010227|EXPERIMENTAL|Acceptance and Commitment Therapy|Patients and caregivers in the ACT arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
62491779|NCT04010227|ACTIVE_COMPARATOR|Education/Support|Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
62137215|NCT03380494|EXPERIMENTAL|Overhead perturbation training technique|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied with a weight and resistance band- such that the glenohumeral joint is exposed to a perturbed stimulus and has to utilise proprioception and motor control to correct arm position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
62137216|NCT03380494|ACTIVE_COMPARATOR|Non-perturbed exercise|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied via a weight held in the hand- such that the glenohumeral joint is exposed to a load but without a perturbation of joint position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
62137217|NCT04734600|EXPERIMENTAL|aerobic training program|group a:twenty patients who will receive aerobic training program combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
62334233|NCT02509598|EXPERIMENTAL|Tc99m tilmanocept and Vital Blue Dye (optional)|0.5 mCi, 50 ug of Tc99m tilmanocept single administration. Optionally, 1-3 mL of vital blue dye, single administration (per institution's standard of care).
62334234|NCT02876770|EXPERIMENTAL|Melatonin|
62334235|NCT02876770|PLACEBO_COMPARATOR|Placebo|
62334236|NCT05781971|EXPERIMENTAL|high protein + early bedside rehabilitation|
62334237|NCT05781971|ACTIVE_COMPARATOR|high protein alone|
62334238|NCT05781971|PLACEBO_COMPARATOR|standard protein + early bedside|standard protein and rehabilitation
62334239|NCT05781971|SHAM_COMPARATOR|standard protein|only standard protein
62334240|NCT01975779|EXPERIMENTAL|Cohort A1: Lu AE58054 or placebo|
62334241|NCT01975779|EXPERIMENTAL|Cohort A2: Lu AE58054 or placebo|
62334242|NCT01975779|EXPERIMENTAL|Cohort B1: Lu AE58054|
62334243|NCT04961372||Healthcare Workers|All healthcare professionals working at Gümüşhane Şiran Government Hospital
62334244|NCT04961372||Non-Healthcare Workers|Twice the number of health workers included in the study, non-health worker volunteers
62334245|NCT01204619|NO_INTERVENTION|Conventional training group|in-center conventional training programs + two home visits
62695005|NCT06644664|EXPERIMENTAL|Arm I (Absolute Risk messages)|Participants receive AR anti-polytobacco MMS messages TIW and a check-in text message QW for a total of 6 weeks. Participants also receive smoking cessation resources via email during follow up.
62491780|NCT02439515|EXPERIMENTAL|Biofeedback training|"It consists of 15 daily sessions of voluntary cycling training augmented by functional electrical stimulation (FES) followed by 15 daily sessions of balance training (multimodal biofeedback training). Both cycling and balance training are supported by a visual biofeedback and last about 20 minutes.~In addition to cycling or balance training, subjects perform standard physical therapy in order to reach 90 minutes of training per day."
62137218|NCT04734600|ACTIVE_COMPARATOR|myofascial release technique|group B: twenty patients who will receive myofascial release technique combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
62137219|NCT02863315|EXPERIMENTAL|tsDCS|In the tsDCS group, anodal tsDCS will be applied for 20 minutes.
62491781|NCT02439515|ACTIVE_COMPARATOR|Usual Care|It consists of 30 daily sessions of standard physical therapy. Each session last about 90 minutes.
62491782|NCT02661022|EXPERIMENTAL|Phase 1, SL-401 7 µg/kg/day|Dose Level 1: single-agent SL-401 7 µg/kg/day on Days 1-5 during the initial 28-day run-in cycle followed by a combination of SL-401/pomalidomide/dexamethasone (pom/dex) if there was no dose-limiting toxicity during the run-in cycle
62491783|NCT02661022|EXPERIMENTAL|Phase 1, SL-401 9 µg/kg/day|Dose Level 2: SL-401 9 µg/kg/day in combination with pom/dex
62491784|NCT01496118|EXPERIMENTAL|Carfilzomib and Panobinostat|"Phase I:~Carfilzomib: cycle 1 - Dose is 20 mg/m\^2 IV on day 1; 27 or 36 or 45 or 56 mg/m\^2 IV on Days 8, 9, 15, 16 cycle 2 to progression - 27 or 36 or 45 or 56 mg/m\^2 IV on days 1, 2, 8, 9, 15, 16~Panobinostat: cycle 1 and cycle 2 to progression - 20 mg or 30 mg on days 1, 3, 5, 15, 17, 19~Phase II:~Carfilzomib and Panobinostat: Dose is optimal dose determined in Phase I"
62491785|NCT02119637||Study 1 TMS to S1|Cohort of healthy participants received screening, brain MRI, TMS to S1 and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
62491786|NCT02119637||Study 2 TMS targeting S2/insula|Cohort of healthy participants received screening, brain MRI before and after TMS, TMS to S2/insula and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
62695006|NCT06644664|EXPERIMENTAL|Arm II (Relative Risk messages)|Participants receive RR anti-polytobacco MMS messages TIW and a check-in text message QW for a total of 6 weeks. Participants also receive smoking cessation resources via email during follow up.
62695007|NCT06644664|ACTIVE_COMPARATOR|Arm III (control messages)|Participants receive control MMS messages on health risks of UV/sun exposure TIW and a check-in text message QW for a total of 6 weeks. Participants also receive smoking cessation resources via email during follow up.
62695008|NCT06351371|EXPERIMENTAL|Subprotocol K2 (FGFR mutation or fusion)|Patients receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study. (CLOSED TO ACCRUAL 02/25/2022)
62137220|NCT02863315|PLACEBO_COMPARATOR|sham|In sham tsDCS group, the current of anodal tsDCS will be discontinued after 30 s while the power indicator remained on for 20 minutes.
62137221|NCT04612244|EXPERIMENTAL|FARAPULSE Pulsed Field Ablation System|
62137222|NCT04612244|ACTIVE_COMPARATOR|Force Sensing Radiofrequency Ablation and Cryoballoon Ablation|
62137223|NCT05609734||Patients with an delayed traumatic intracranial hemorrhage|A total of 249 control CTs was performed, where the initial CT was normal regarding tICH. In the initial assessments 1 case of d-ICH (0,41%) was found, but after second opinion this case (case 1, Table 1) was regarded as a pictorial artefact (Table 1). Hence, no d-ICH was found.
62137224|NCT05609734||Patients without an delayed traumatic intracranial hemorrhage|A total of 249 control CTs was performed, where the initial CT was normal regarding tICH. In the initial assessments 1 case of d-ICH (0,41%) was found, but after second opinion this case (case 1, Table 1) was regarded as a pictorial artefact (Table 1). Hence, no d-ICH was found.
62137225|NCT03055559||Globifer Forte|
62137226|NCT06673511|EXPERIMENTAL|Lymph node developing group|After injecting IGG intraoperatively, the developing lymph nodes and systemic lymph nodes are resected.
62137227|NCT06673511|EXPERIMENTAL|lymph node non-developing group|After injecting IGG intraoperatively, the developing lymph nodes and systemic lymph nodes are resected
62334246|NCT01204619|EXPERIMENTAL|Intensive training group|in-center conventional training programs + an extra structured patient home visits repeatedly and regularly
62334247|NCT06503861|EXPERIMENTAL|Food Is Medicine intervention|
62334248|NCT06503861|NO_INTERVENTION|Control|
62334249|NCT01897961|OTHER|Patients whose renal disease of origin is a GEM|Patients whose renal disease of origin is a GEM
62334250|NCT01897961|OTHER|Transplanted Patients of origin is a GEM having done it again|Transplanted Patients of origin is a GEM having done it again
62334251|NCT01897961|OTHER|Transplanted patients, and having developed a GEM of novo|Transplanted patients, and having developed a GEM of novo
62334252|NCT00525148|EXPERIMENTAL|BIBW 2992|Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
62334253|NCT04611685|EXPERIMENTAL|NSAIDs|Parecoxib (iv.) for once \& Loxoprofen (po.) for routine use during the first 3 postop. days.
62334254|NCT04611685|ACTIVE_COMPARATOR|Tramadol|Tramadol (im.) for once \& Tramcontin (po.) for routine use during the first 3 postop. days.
62334255|NCT00878917|EXPERIMENTAL|Dorzolamide|
62334256|NCT01683071|EXPERIMENTAL|(Part 1) EXPAREL 67 mg|5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
62334257|NCT01683071|EXPERIMENTAL|(Part 1) EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
62334258|NCT01683071|EXPERIMENTAL|(Part 1) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
62334259|NCT01683071|PLACEBO_COMPARATOR|(Part 1) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
62334260|NCT01683071|EXPERIMENTAL|(Part 2) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
62491787|NCT03680144|EXPERIMENTAL|Diagnostic (MRI, DSC-MRI)|Participants undergo diagnostic magnetic resonance imaging (MRI) with and without contrast and treatment planning dynamic susceptibility contrast-MRI (DSC-MRI) series before receiving SRS at 4-6 weeks after SRS, and then every 3 months unless clinically indicated sooner.
62491788|NCT02485938|EXPERIMENTAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
62334261|NCT01683071|PLACEBO_COMPARATOR|(Part 2) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
62334262|NCT01251276|EXPERIMENTAL|Modified Process Hepatitis B Vaccine in Base Study|Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
62334263|NCT01251276|EXPERIMENTAL|ENGERIX-B™ Vaccine in Base Study|Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
62334264|NCT02266186|EXPERIMENTAL|Internet CBT|Intervention:Internet-based cognitive behavioural therapy.
62334265|NCT02266186|ACTIVE_COMPARATOR|Traditional CBT|Intervention:Traditional CBT given by a therapist following given modules.
62491789|NCT02485938|NO_INTERVENTION|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
62491790|NCT03914898|EXPERIMENTAL|Nurse led intervention group|"The program was four sessions; It took about 1.5-2 hours. The intervention group was divided into two groups. The author who administered the intervention previously led nurse support groups, is also an active educator in psychiatry and mental health nursing, and has training in cognitive behavioral therapy.~The group sessions were based on cognitive restructuring techniques."
62491791|NCT03914898|NO_INTERVENTION|Control Group|No intervention was applied to the control group during the study.
62491792|NCT04443049|ACTIVE_COMPARATOR|Lenvatinib +Placebo|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
61938778|NCT06060600||Natural History Cohort:|"* Treatment records from a cohort of approximately 200 patients who were hospitalized between 1901 and 1910 during the 1900-1920 HAT epidemic~* Treatment records must have sufficient information for analysis including:~  * Demographic data: age or sex must be included~ * Diagnosis: HAT diagnosis is confirmed by blood or lymph gland fluid analysis and parasites observed or HAT symptoms during the epidemic. For example, if the records state that a lymph node biopsy was performed, any result of the biopsy (e.g., documentation that trypanosomes were observed), a documentation of the HAT diagnosis, or mention of HAT symptoms such as sleepiness or excess sleeping are all acceptable. Symptoms alone are not sufficient, but a notation of biopsy and mention of HAT symptoms is acceptable.~ * Outcome: An outcome is required; any mention of a clinical outcome is acceptable."
61938779|NCT06060600||Retrospective cohort|The hospital records of TBR HAT patients will be examined for date of symptom onset (if available) and hospital admission, race, sex, age, geographic area of origin, parasites, concomitant medications and illnesses, co-infections, and disease stage. Patients are normally screened for HAT and other tropical diseases using standard parasitological World Health Organization (WHO) criteria. Briefly, blood is obtained from the patients and checked for the presence of trypanosomes using direct wet smear and capillary centrifugation technique methods. Disease stage determination is by examination of CSF using the WHO criteria which classify patients with the presence of trypanosomes in the CSF and/or a WBC count \>5 cells/mm3 as Stage 2 TBR HAT. Stage 2 patients would be disqualified from inclusion in the study.
61938780|NCT01475565||African-American women|Observational study--no intervention
61938781|NCT01475565||Caucasian women|Observational study--no intervention
61938782|NCT03886662|EXPERIMENTAL|LB-100 for Intravenous administration|Phase Ib: Escalating doses of LB-100 administered. Phase 2: Safe dose of LB-100 from phase Ib administered.
62137228|NCT04325217||Patients newly initiating Ofev®/Nintedanib Capsules|
62334266|NCT02266186|NO_INTERVENTION|Care as usual|Childbirth preparation according to local routine
62334267|NCT01625598||People with diabetes|People with diabetes who are referred to an ophthalmologist for a dilated eye examination
62491793|NCT04443049|EXPERIMENTAL|Lenvatinib and mebendazole|Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
62491794|NCT06443125|EXPERIMENTAL|Natural Psychotherapy intervention for obsessive-compulsive disorder|Inpatient naturopathic treatment was performed once a day for 45 consecutive days
62695009|NCT06186518|OTHER|Control group|
62695010|NCT06186518|EXPERIMENTAL|PİKSEÇ group|
62695011|NCT00432965|EXPERIMENTAL|VAC Therapy|Treatment of Diabetic Foot Ulcers with VAC Therapy
62334268|NCT01157416|ACTIVE_COMPARATOR|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
62334269|NCT01157416|PLACEBO_COMPARATOR|Placebo plus CBT|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
62334270|NCT06554470|EXPERIMENTAL|Systemic Methotrexate|Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
62334271|NCT06554470|EXPERIMENTAL|Local Methotrexate|Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
62334272|NCT01001455||blood pressure monitor|Cuff circumference:22cm-36cm
62334273|NCT01001455||stethoscopy|Cuff circumference: 22cm-36cm
62334274|NCT02347111|EXPERIMENTAL|flecainide 1st|flecainide x 6 months, then crossover to sotalol x 6 months
62334275|NCT02347111|EXPERIMENTAL|sotalol 1st|sotalol x 6 months, then crossover to flecainide x 6 months
62491795|NCT04090021|EXPERIMENTAL|Genotypic resistance-guided triple therapy|"In the group of genotypic resistance-guided triple therapy, a molecular assay based on DNA-strip technology was used to determine the genotypic resistance of H. Pylori to clarithromycin (23SrRNA mutations) and fluoroquinolones (gyrA mutations) from gastric biopsy specimens. According to 23SrRNA and gyrA mutational analyses, a 7-day tailored triple therapy therapy was given as follows:~Wild-type 23SrRNA: Clarithromycin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d.~23SrRNA mutated/wild-type gyrA: Levofloxacin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and levofloxacin 500 mg b.i.d.~23SrRNA mutated/gyrA mutated: Rifabutin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g t.i.d. and rifabutin 150 mg b.i.d."
61938783|NCT04863547||Exposed|Patients hospitalized for COVID-19 with SARS-CoV-2 variant 20I / 501Y.V1
62491796|NCT04090021|ACTIVE_COMPARATOR|Empirical concomitant therapy|In the empirical concomitant group, patients received esomeprazole 40mg, amoxicillin 1gr, clarithromycin 500mg and metronidazole 500mg, all b.i.d., for 10-14 days.
62491797|NCT04909970|EXPERIMENTAL|Self hypnosis|Self-hypnosis program associated to usual practice of stress management
61938784|NCT04863547||Non exposed|Patients hospitalized for COVID-19 to SARS-CoV-2 corresponding to wild type 20A variants. EU1 or 20A. EU2
62491798|NCT04909970|OTHER|control group (waiting list)|Usual practice of stress management. This group will practice self-hypnosis after the intervention group has practiced self-hypnosis (waiting list).
62491799|NCT02015832||Percutaneous Coronary Intervention|All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
62491800|NCT02133638|ACTIVE_COMPARATOR|Sevoflurane|Sevoflurane Based Volatile Induction and Maintenance of Anaesthesia
61938785|NCT04550910|OTHER|Arm A|40 Gy /15 fx / 3 weeks, 5 days per week, is a dose prescribed (after randomization ) for Breast Cancer patients indicated for adjuvant RTH after mastectomy
61938786|NCT04550910|EXPERIMENTAL|Arm B|28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy is a dose prescribed (after randomization )for Breast Cancer patients indicated for adjuvant RTH after mastectomy
61938787|NCT05797662|EXPERIMENTAL|Propranolol|Propranolol Twice Daily (BID) x 12 weeks Dosage: For ages ≤ 12 years: 3mg/kg/day divided BID; for ages \> 12 years, 120 mg BID.
61938788|NCT05353309|ACTIVE_COMPARATOR|Angioplasty DSA|"Reference procedure (DSA), comprising: production of fluoroscopy images for placement of endoluminal material and navigation, subtracted angiography with placement of flaps to reduce the field of rays (collimation ) for visualization of the arterial axis (in low dose, pulsed with maximum collimation), the realization of possible oblique incidences (external iliac), the catheterization with or without placement of a post-inflation stent, then the realization of a second subtracted control angiogram."
61938789|NCT05353309|EXPERIMENTAL|Angioplasty DSA+Fusion|Procedure under study (DSA+Fusion), including: production of fluoroscopy images for placement of the endoluminal material and navigation, 2 fluoroscopy images specifically for image fusion registration (from the images scanner), selective angiography under fluoroscopy with collimation to improve registration (in low dose mode, pulsed with maximum collimation), if possible no oblique views (3D markers of the fusion), with or without placement of post-inflation stent followed by subtracted control angiography
61938790|NCT04745923||Patients with chronic kidney disease|Having been diagnosed with chronic kidney disease
61938791|NCT04745923||Healthy individuals|Healthy individuals without chronic disease
61938792|NCT01703273|EXPERIMENTAL|low key intervention|
61938793|NCT01703273|ACTIVE_COMPARATOR|routine care|
61938794|NCT01695148|ACTIVE_COMPARATOR|White Maize Flour|Children will receive 2 meals a day (\~200 g of white maize flour), 6 days a week for 6 months.
61938795|NCT01695148|EXPERIMENTAL|β-Carotene Biofortified Maize|Children will receive 2 meals a day (\~200 g of beta-carotene biofortified maize flour), 6 days a week for 6 months.
61938796|NCT01695148|NO_INTERVENTION|Non-Intervened|Children will receive no food for the duration of the study, but families in this group will receive an equivalent ration of food items at the end of the trial.
61938797|NCT01761851||Cases|Liver cirrhosis
61938798|NCT02841436|EXPERIMENTAL|irreversible electroporation (IRE)|IRE (AngioDynamics, NY) To use 2 to 6 unipolar electrodes in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
61938799|NCT02633501|EXPERIMENTAL|Subset 1 Arm 1|One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
62491801|NCT02133638|ACTIVE_COMPARATOR|Propofol|Propofol Based Total Intravenous Anesthesia
62491802|NCT01424020|EXPERIMENTAL|questionnaire|Patients suspected of peripheral artery disease and, as such, referred for a vascular investigations and submitted the WELCH questionnaire
62491803|NCT02757287|EXPERIMENTAL|FSH-CTP + DESOGESTREL|Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation
62695012|NCT00432965|ACTIVE_COMPARATOR|Moist Wound Therapy|Moist Wound Therapy (standard of care)
62695013|NCT06639334|ACTIVE_COMPARATOR|Standard treatment|Standard pathway for THA/HE reduction
62695014|NCT06639334|EXPERIMENTAL|Fast-track treatment|Fasttrack pathway for THA/HE reduction
62695015|NCT06266351||IOP measurement with CATS|
61938800|NCT02633501|EXPERIMENTAL|Subset 1 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
61938801|NCT02633501|EXPERIMENTAL|Subset 2 Arm 1|One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
61938802|NCT02633501|EXPERIMENTAL|Subset 2 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
61938803|NCT02656914|EXPERIMENTAL|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
61938804|NCT02656914|PLACEBO_COMPARATOR|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
61938805|NCT02029170|EXPERIMENTAL|Early weightbearing|After operative reduction and fixation of the fractures, patients allocated to the early weightbearing group start weightbearing after stitch out at 2 weeks and the application of a walking cast.
61938806|NCT02029170|ACTIVE_COMPARATOR|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
62491804|NCT02790658|OTHER|Grumixama Juice|"Juice of grumixama purple fruit (Eugenia brasiliensis Lam.), which is good source of anthocyanins and ellagitannins. It was made with filtered water and sanitized fruits, with a blender. It was administered in single dose of 0.97 mg of anthocyanins and of 4.71 mg of ellagitannins per mL of juice. Which volunteers ingested 10 mL of juice per each Kg body weight.~The metabolomic approach of plasma and urine samples following acute intake of grumixama juice was done by the collection of blood samples and urine, following the intake of grumixama juice."
62334276|NCT02007330|EXPERIMENTAL|Group L|Intravenous lidocaine infusion group
62334277|NCT02007330|PLACEBO_COMPARATOR|Group C|Intravenous normal saline infusion - control group
62334278|NCT01013909|EXPERIMENTAL|Arm 1|
62334279|NCT01013909|EXPERIMENTAL|Arm 2|
62334280|NCT01013909|PLACEBO_COMPARATOR|Arm 3|
62334281|NCT01013909|PLACEBO_COMPARATOR|Arm 4|
62334282|NCT01013909|ACTIVE_COMPARATOR|Arm 5|
62334283|NCT04761887|EXPERIMENTAL|Cool Block|Ropivacaine administered at approximately 4C, via a TAP block.
62334284|NCT04761887|ACTIVE_COMPARATOR|Room Temp Block|Ropivacaine administered at approximately 20-25C, via a TAP block.
62334285|NCT04315376|EXPERIMENTAL|Exercise-Diet Group|The participants receive a personal exercise program according to Astrand-rhyming test baseline results, and a hypo-caloric diet intervention
62334286|NCT04315376|ACTIVE_COMPARATOR|Diet Group|The participants no receive a personal exercise program, only the hypo-caloric diet
62334287|NCT01959737|NO_INTERVENTION|visual contact|After initial assessment/stabilization of the VLBW infant, visual contact of mother and infant is permitted for 5 minutes.
62334288|NCT01959737|EXPERIMENTAL|skin-to-skin contact|After initial stabilization mother and preterm infant are cared for skin-to-skin for 60 minuter. SSC is supervised by the attending neonatologist.
62334289|NCT01865435|EXPERIMENTAL|new borns|
62334290|NCT05674344|EXPERIMENTAL|Masimo noninvasive temperature device|All subjects who qualify for the trial and participate in data collection will have temperature taken using the Masimo noninvasive temperature device and the reference temperature device.
62334291|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
62334292|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
62334293|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
62334294|NCT01680588|EXPERIMENTAL|[18F]NAV4694|Single intravenous injection of 8.1 millicuries of \[18F\]NAV4694
62491805|NCT03595436|EXPERIMENTAL|Pea Protein Breakfast Preload|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preloads will be standardized to \~325 kcal. The preloads will include the same fat content but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
62491806|NCT03595436|PLACEBO_COMPARATOR|Carbohydrate Control Breakfast Preload|The study participants will be provided with a control breakfast preload to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
62491807|NCT03595436|ACTIVE_COMPARATOR|Whey Protein|The study participants will be provided with an active control breakfast preload to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein amount and type and carbohydrate amount. All ingredients are GRAS listed and approved.
62491808|NCT03024801|EXPERIMENTAL|autologous platelet-rich plasma group|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
61938807|NCT03616132|EXPERIMENTAL|IBS implantation|Implantation of IBS in patients with coronary artery lesions.
61938808|NCT01358773|OTHER|Lifestyle counseling|Obese adolescents are encouraged to improve their lifestyle
61938809|NCT03793556|EXPERIMENTAL|GERDOFF® + omeprazole|"GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).~Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days)."
62334295|NCT06260644|ACTIVE_COMPARATOR|Conventional flowable nano filled resin composite|Repairing the old defective class I composite restoration by conventional nano filled flowable resin composite.
61938810|NCT03793556|ACTIVE_COMPARATOR|Omeprazole|Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
61938811|NCT01710046|EXPERIMENTAL|Cohort 1|
61938812|NCT01710046|EXPERIMENTAL|Cohort 2|
61938813|NCT04258514|EXPERIMENTAL|Virtual Reality Vasectomy|This group of men will undergo vasectomy while wearing VR goggles.
62334296|NCT06260644|EXPERIMENTAL|Self adhesive flowable resin composite|Repairing the old defective class I composite restoration by self adhering flowable resin composite.
62334297|NCT01790737|ACTIVE_COMPARATOR|A|Cyclophosphamide plus filgrastim
62334298|NCT01790737|ACTIVE_COMPARATOR|B|Filgrastim
62334299|NCT03246217|EXPERIMENTAL|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
62334300|NCT03246217|EXPERIMENTAL|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
62334301|NCT03246217|EXPERIMENTAL|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
62334302|NCT04861961|ACTIVE_COMPARATOR|Laparoscopic duodenal switch (DS)|Standard duodenal switch (double anastomoses). Roux-en-Y reconstruction.
62695016|NCT06266351||IOP measurement with GAT|
62334303|NCT04861961|ACTIVE_COMPARATOR|Laparoscopic Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S)|"Simplified duodenal switch with one anastomosis. Duodeno-ileal omega reconstruction (Billroth II-like)."
62334304|NCT04861961|ACTIVE_COMPARATOR|Laparoscopic one anastomosis gastric bypass (OAGBP)|Gastric bypass of one anastomoses. Gastro-jejunal omega reconstruction (Billroth II).
62334305|NCT00757939|EXPERIMENTAL|AD Participants|Participants with a diagnosis of mild-to-moderate AD
62334306|NCT00757939|EXPERIMENTAL|Cognitively Normal Elderly Participants|Elderly participants with no cognitive impairment
62334307|NCT03096223|EXPERIMENTAL|KHK4083|
62334308|NCT05835752|EXPERIMENTAL|RAY1225(Part A)|Escalating doses of RAY1225 administered subcutaneously (SC) once in healthy participants.
62334309|NCT05835752|EXPERIMENTAL|Placebo (Part A)|Placebo administered SC once in healthy participants.
62491809|NCT03024801|EXPERIMENTAL|normal saline group|The patients with knee cartilage injury were randomized to the normal saline group.
62695017|NCT02251041|ACTIVE_COMPARATOR|cases|the group receives a combination of drugs
61938814|NCT04258514|EXPERIMENTAL|Standard Vasectomy|This group of men will undergo a standard vasectomy without using VR goggles.
61938815|NCT00885950||Colorectal liver metastases|Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
62334310|NCT05835752|EXPERIMENTAL|RAY1225 (Part B)|Escalating doses RAY1225 administered SC once weekly for four weeks in healthy participants.
62695018|NCT02251041|PLACEBO_COMPARATOR|controls|the group do not receive a combination of drugs, but a placebo (sodium chloride solution)
62695019|NCT01163942|ACTIVE_COMPARATOR|No G-CSF, No 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
61938816|NCT00752037|OTHER|1|open label single arm
61938817|NCT03621774|EXPERIMENTAL|Mobile-assisted CBT-informed Skills Training|Psychosocial intervention combining in-person and smartphone-based CBT-informed skills training for experiential negative symptoms in schizophrenia, called Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
61938818|NCT03621774|PLACEBO_COMPARATOR|Supportive Contact|An active group leader- and device-contact control group.
62334311|NCT05835752|EXPERIMENTAL|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants.
62334312|NCT05835752|EXPERIMENTAL|RAY1225(Part C)|Three dose levels of RAY1225 administered SC once weekly for four weeks in participants with Obese.
62334313|NCT05835752|EXPERIMENTAL|Placebo (Part C)|Placebo administered SC once weekly for four weeks in participants with Obese.
62334314|NCT01636752|EXPERIMENTAL|Deprexis|Online self-help with and without e-mail-support
62334315|NCT01636752|NO_INTERVENTION|Control|
62334316|NCT05929417|EXPERIMENTAL|END-IT intervention for the community setting|The community pharmacist will distribute an educational brochure to the patient. He will also propose to the patient to communicate about a potential benzodiazepine deprescribing with his/her general practitioner through a document called pharmaceutical proposal.
62334317|NCT05929417|NO_INTERVENTION|Control|The participants will receive the usual care. The community pharmacists allocated to the control group will have access to the intervention material at the end of the study.
62334318|NCT00586391|EXPERIMENTAL|CD19CAR-28-zeta T cells|"Three dose levels of CTLs will be evaluated. Each patient will receive one injection according to their assigned dose over 1-10 minutes IV.~\*At the discretion of the attending physician, if after a 4 to 6-week evaluation period the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies); repeat infusions separated by 4 to 6 weeks (up to a maximum of 3 extra doses) of modified T cells at the same dose level or below the patient's original dose can be administered."
62491810|NCT03673514|ACTIVE_COMPARATOR|THA Posterior Approach|The posterior approach to the hip has been described by many authors and yields good results. Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
62695020|NCT01163942|ACTIVE_COMPARATOR|No G-CSF, yes 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) but they do receive early retreatment in case of no response.
62695021|NCT01163942|ACTIVE_COMPARATOR|Yes G-CSF, No 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
62695022|NCT01163942|ACTIVE_COMPARATOR|Yes G-CSF, Yes 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to receive early retreatment in case of no response.
62334319|NCT04541212||Cohort A|Prospective
62334320|NCT04541212||Cohort B|Retrospective/Prospective
62334321|NCT00521092|EXPERIMENTAL|Arm I|Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62334322|NCT01189435|EXPERIMENTAL|erlotinib|This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.
62334323|NCT02500238||Control|This group will provide 2 breath carbon monoxide (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings will be taken from this group.
62334324|NCT02500238||Smoking|This group will provide 1 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
62334325|NCT02500238||Vaping|This group will provide 2 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
62334326|NCT02069496||Subjects who receive Arepanrix®|Subjects who receive Arepanrix® as per routine practice
62695023|NCT06639919||Group 1:|Pregnant women with PPROM
62695024|NCT06639919||Group 2:|Control group pregnant women
62695025|NCT06043011||Chronic Lymphocytic Leukemia (CLL)|Patients with CLL receiving systemic treatment (physician's choice)
62695026|NCT06043011||Diffuse Large B-cell Lymphoma (DLBCL)|Patients with DLBCL receiving systemic treatment (physician's choice)
62695027|NCT06043011||Follicular Lymphoma (FL)|Patients with FL receiving systemic treatment (physician's choice)
62695028|NCT06043011||Mantle Cell Lymphoma (MCL)|Patients with MCL receiving systemic treatment (physician's choice)
62334327|NCT03140930|EXPERIMENTAL|Duodenal tastants, ileal placebo|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)
62491811|NCT03673514|ACTIVE_COMPARATOR|THA Direct anterior approach|The modified Hueter approach, based on the Smith-Peterson approach, was performed for the direct anterior minimally invasive surgery. This approach could have some advantages as it is a muscle sparing approach, hence yielding a faster recovery. A traction table was used for DAA as surgeons were trained to use this method. No intra-operative fluoroscopy was used for implant confirmation.Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
62334328|NCT03140930|EXPERIMENTAL|Duodenal placebo, ileal tastants|Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)
62491812|NCT05040737|EXPERIMENTAL|Study Arm|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
62491813|NCT05706415||patients with solid lesions of pancreas|
62334329|NCT03140930|EXPERIMENTAL|Duodenal tastants, ileal tastants|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)
62491814|NCT00286533|EXPERIMENTAL|Placed implants|
62491815|NCT03141580|EXPERIMENTAL|Study group|Subjects with carotid stent who consented to undergo near-infrared spectroscopy and intravascular ultrasound imaging.
62491816|NCT04408924|EXPERIMENTAL|200 milligram (mg) Abemaciclib Twice Daily|Participants received 200 mg abemaciclib administered orally twice daily on a continuous dosing schedule (28-day cycle) until symptomatic and/or radiographic progression, unacceptable toxicity, or until another discontinuation criterion is met.
62491817|NCT03548155|EXPERIMENTAL|berberine group|
62491818|NCT03548155|PLACEBO_COMPARATOR|control group|
62491819|NCT05261191|EXPERIMENTAL|Part 1A: Dose level 1|Single dose MGD020
61938819|NCT00073801||Chronic Pelvic Pain and Endometriosis|Women with chronic pelvic pain and endometriosis found at study surgery
61938820|NCT00073801||Chronic Pelvic Pain and No Endometriosis|Women with chronic pelvic pain and NO endometriosis found at study surgery
61938821|NCT00073801||Healthy Volunteers|Women without no chronic pelvic pain and no symptoms of endometriosis
61938822|NCT03455582|EXPERIMENTAL|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
61938823|NCT03455582|ACTIVE_COMPARATOR|Control|40 Healthy controls
61938824|NCT01948037|ACTIVE_COMPARATOR|hydrotherapy|
62137229|NCT03746613|EXPERIMENTAL|Minimally invasive robotic cochlear implantation with HEARO|
62491820|NCT05261191|EXPERIMENTAL|Part 1A: Dose level 2|Single dose MGD020
62491821|NCT05261191|EXPERIMENTAL|Part 1A: Dose level 3|Single dose MGD020
62491822|NCT05261191|EXPERIMENTAL|Part 1A: Dose level 4|Single dose MGD020
62491823|NCT05261191|EXPERIMENTAL|Part 1A: Dose level 5|Single dose MGD020
62491824|NCT05261191|EXPERIMENTAL|Part 1A: Dose level 6|Single dose MGD020
62491825|NCT05261191|EXPERIMENTAL|Part 1B: MTD/MAD -1 MGD020 and MGD014|Single dose MGD020 and MGD014
62491826|NCT05261191|EXPERIMENTAL|Part 1B: MTD/MAD MGD020 and MGD014|Single dose MGD020 and MGD014
62491827|NCT05261191|EXPERIMENTAL|Part 2: MGD020 and MGD014|Multiple doses of MGD020 and MGD014
62491828|NCT03937206|EXPERIMENTAL|Low Dose|Low Dose (300mg TG Omega-3) - 1 capsule containing 1000mg NutriterraTM per capsule + 3 capsules containing 1000mg corn oil per capsule
61938825|NCT01948037|OTHER|hot spring|30-minutes/per day;4weeks
61938826|NCT05227378|EXPERIMENTAL|neoantigen tumor vaccine|neoantigen tumor vaccine with or without PD-1/L1
61938827|NCT01033851|ACTIVE_COMPARATOR|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is an 8-week group intervention that trains participants in mindfulness meditation techniques.
61938828|NCT01033851|ACTIVE_COMPARATOR|Stress Management Education|Stress Management Education (SME) is an 8-week group intervention that educates participants about stress physiology and health lifestyle changes.
61938829|NCT01173757|EXPERIMENTAL|PF-04995274|
61938830|NCT03877731|ACTIVE_COMPARATOR|hypertrophic cariomyopathy, isolated septal myectomy|Patients with hypertrophic obstructive cardiomyopathy who will undergo isolated septal myectomy
61938831|NCT03877731|EXPERIMENTAL|hypertrophic cariomyopathy, septal myectomy + edge-to-edge|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and edge-to-edge mitral valve repair (O. Alfieri technique)
61938832|NCT03877731|EXPERIMENTAL|hypertrophic cariomyopathy, septal myectomy + sliding plasty|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and posterior leaflet sliding plasty ( A. Carpentier technique)
62137230|NCT03394534|EXPERIMENTAL|CGA group|
62137231|NCT03394534|NO_INTERVENTION|Treatment as Usual|
62137232|NCT05230264||Men|Elective AAA Repair
62137233|NCT05230264||Women|Elective AAA Repair
62137234|NCT06699238|ACTIVE_COMPARATOR|Home Exercise Group|The home exercise group performed only standard conventional exercises for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.
62334330|NCT03140930|PLACEBO_COMPARATOR|Duodenal placebo, ileal placebo|Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)
62334331|NCT02130427|OTHER|Lung Imaging|Weekly 3D/4D CT scans during radiation therapy. MRI may be used in addition to or instead of CT depending on the location of the tumor and the decision of the treating physician.
62334332|NCT00882102|EXPERIMENTAL|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m\^2 by vein (IV) over 1-1/2 hours daily for 5 days. Gemtuzumab ozogamicin 3 mg/m\^2 by vein on day 5.
62334333|NCT05647902||Healthy Group|70 systemically healthy patients; 35 healthy gingiva is divided into 2 subgroups, 35 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
62491829|NCT03937206|EXPERIMENTAL|Mid Dose|Mid Dose (600mg TG Omega-3) - 2 capsules containing 1000mg NutriterraTM per capsule + 2 capsules containing 1000mg corn oil per capsule
62491830|NCT03937206|EXPERIMENTAL|High Dose|High Dose (1200mg TG Omega-3) - 4 capsules containing 1000mg NutriterraTM per capsule
62491831|NCT03937206|PLACEBO_COMPARATOR|Placebo|Placebo (0mg TG Omega-3) - 4 capsules containing 1000mg corn oil per capsule
62491832|NCT02231957|EXPERIMENTAL|educational text message reminders|receipt of education-embedded text message vaccine reminders
62491833|NCT02231957|ACTIVE_COMPARATOR|conventional text message reminders|receipt of conventional text message vaccine reminders
62491834|NCT03323450|EXPERIMENTAL|High grade gliomas(WHO grade III or IV; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
62491835|NCT03323450|EXPERIMENTAL|Low grade gliomas(WHO grade II; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
62491836|NCT05212987|EXPERIMENTAL|Dose Escalation and Expansion|FCN-098 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
62491837|NCT02763488|ACTIVE_COMPARATOR|Standard physical therapy|These individuals will conduct physical therapy for 12 sessions as per the institutional standard physical therapy protocol
62491838|NCT02763488|EXPERIMENTAL|Blood flow restriction|These individuals will conduct physical therapy for 12 sessions with the addition of blood flow restriction interventions to their standard physical therapy
62491839|NCT02621190|NO_INTERVENTION|A|patients without CTCs or AR-V7 negative CTCs are treated according to their physician's discretion
61938833|NCT03877731|EXPERIMENTAL|hypertrophic cariomyopathy, septal myectomy + chordae|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and secondary chordae transection
61938834|NCT03877731|NO_INTERVENTION|Arterial hypertension + left ventricular hypertrophy|Patients with arterial hypertension with left ventricular hypertrophy whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
61938835|NCT03877731|NO_INTERVENTION|Control|Patients without structural heart disease whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
61938836|NCT01927627|EXPERIMENTAL|Enzalutamide|Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
61938837|NCT04223583|EXPERIMENTAL|Anrotenil hydrochloride capsule|Anrotenil hydrochloride capsule was used to treat soft tissue sarcomas with first-line chemotherapy failure (doxorubicin + ifosfamide). Oral administration was conducted on an empty stomach before breakfast (12mg), and the drug was discontinued for 2 weeks for one week (3 weeks for one cycle) until the disease progressed or became intolerable.
61938838|NCT00215683|EXPERIMENTAL|Degarelix 80 mg|Participants who completed the CS12 study in the Degarelix 80 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
61938839|NCT00215683|EXPERIMENTAL|Degarelix 120 mg|Participants who completed the CS12 study in the Degarelix 120 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
61938840|NCT00215683|EXPERIMENTAL|Degarelix 160 mg|Participants who completed the CS12 study in the Degarelix 160 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
61938841|NCT01134731|EXPERIMENTAL|paliperidone|dose escalation , levels 1-5 daily dosing ranged from 1-5mg
61938842|NCT01134731|ACTIVE_COMPARATOR|lithium|dose escalation, level 1-5 daily dosing 300-1500mg
61938843|NCT01134731|PLACEBO_COMPARATOR|placebo|1-5 placebo capsules
61938844|NCT06058403|EXPERIMENTAL|Native canola protein|20g of canola protein
61938845|NCT06058403|EXPERIMENTAL|Processed canola protein #1|20g of processed canola #1
61938846|NCT06058403|EXPERIMENTAL|Processed canola protein #2|20g of processed canola #2
62334334|NCT05647902||Myocard Infactus Group|50 patients with myocardial infarction; 25 healthy gingiva is divided into 2 subgroups, 25 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
62334335|NCT00437606|EXPERIMENTAL|1|
62491840|NCT02621190|EXPERIMENTAL|B|patients with AR-V7 positive CTCs are treated with cabazitaxel 25mg/m2 q3w
62491841|NCT01788644||No treatment (observational study)|
62491842|NCT02560051|ACTIVE_COMPARATOR|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
62491843|NCT02560051|ACTIVE_COMPARATOR|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
62491844|NCT02560051|ACTIVE_COMPARATOR|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
62695029|NCT06043011||Marginal Zone Lymphoma (MZL)|Patients with MZL receiving systemic treatment (physician's choice)
61938847|NCT06058403|ACTIVE_COMPARATOR|Whey protein|20g of whey protein
61938848|NCT04357340|EXPERIMENTAL|Pulmonary Physiotherapy Techniques group|Pulmonary physiotherapy techniques, 6 sessions during 3 days and incentive spirometer.
61938849|NCT04357340|NO_INTERVENTION|Control group|Incentive spirometer only
61938850|NCT02470416|ACTIVE_COMPARATOR|Case|Patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at Westmead hospital
61938851|NCT02470416|ACTIVE_COMPARATOR|Control|Age matched controls having VCE for OGIB/IDA at Westmead hospital.
61938852|NCT02703233|ACTIVE_COMPARATOR|Nitrous Oxide|Patients receive nitrous oxide via mask.
62334336|NCT00437606|EXPERIMENTAL|2|
62334337|NCT00437606|EXPERIMENTAL|3|
62491845|NCT06225245|EXPERIMENTAL|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
62491846|NCT02873260|EXPERIMENTAL|TetraVax-DV-TV005 + rDEN3Δ30|Participants will receive the TetraVax-DV-TV005 vaccine at Day 0 and the rDEN3Δ30 virus at Day 180.
61938853|NCT02703233|PLACEBO_COMPARATOR|Placebo (Oxygen)|Patients receive oxygen via mask.
61938854|NCT05630755|EXPERIMENTAL|DOR/ISL and Placebo to BIC/FTC/TAF|Participants will receive DOR/ISL 100 mg/0.25 mg and Placebo to BIC/FTC/TAF once daily (QD) orally from day 1 to week 144. After week 144, eligible participants may continue on DOR/ISL and continue study treatment until week 240 or to when DOR/ISL becomes commercially accessible (whichever comes first).
61938855|NCT05630755|ACTIVE_COMPARATOR|BIC/FTC/TAF and Placebo to DOR/ISL|Participants will receive BIC/FTC/TAF 50 mg/200 mg/25 mg and Placebo to DOR/ISL once daily (QD) orally from day 1 to week 144. After week 144, eligible participants may switch to DOR/ISL and continue study treatment until week 240 or to when DOR/ISL becomes commercially accessible (whichever comes first).
61938856|NCT01957254||Severe Sepsis|Patient with severe sepsis
61938857|NCT00033605|EXPERIMENTAL|octreotide + radiation|"Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.~Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
61938858|NCT00033605|ACTIVE_COMPARATOR|placebo + radiation|"Patients receive placebo SC on day 1 and IM on days 2 and 29. Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
61938859|NCT06051214|EXPERIMENTAL|Thrombogram|Blood sampling every month for 12 months
61938860|NCT04206007|EXPERIMENTAL|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
61938861|NCT05530031|EXPERIMENTAL|pediatric glaucoma patients either primary or secondary|All Cases with pediatric glaucoma prepared for trabeculotomy including Primary congenital glaucoma and secondary glaucoma as : glaucoma following cataract surgery and traumatic glaucoma
61938862|NCT04093414|ACTIVE_COMPARATOR|Selective or Non selective His Bundle Pacing|Pacemaker wires placed in Bundle of His
61938863|NCT04093414|ACTIVE_COMPARATOR|Left Bundle Area Pacing|Pacemaker wires placed in Left Bundle Branch area
61938864|NCT02224092|ACTIVE_COMPARATOR|Active|Active is a multivitamin multimineral with phytonutrient product.
61938865|NCT02224092|PLACEBO_COMPARATOR|Placebo|Placebo is a sugar pill.
61938866|NCT01024231|EXPERIMENTAL|Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
61938867|NCT01024231|EXPERIMENTAL|Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
61938868|NCT01024231|EXPERIMENTAL|Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
61938869|NCT01024231|EXPERIMENTAL|Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
62334338|NCT04451655|EXPERIMENTAL|Interventional|
62334339|NCT06141434||Pregnancies where the mother has type 1 diabetes|We will observe the risk for islet autoimmunity in the offspring where the mother has type 1 diabetes. There is no intervention in this study.
62334340|NCT06141434||Pregnancies where the mother does not have type 1 diabetes|We will observe the risk for islet autoimmunity in the offspring where the mother does not have type 1 diabetes, but the baby's father or full sibling does. There is no intervention in this study.
62491847|NCT02873260|PLACEBO_COMPARATOR|Placebo + rDEN3Δ30|Participants will receive placebo at Day 0 and the rDEN3Δ30 virus at Day 180.
62695030|NCT06043011||Waldenström's macroglobulinemia (WM)|Patients with WM receiving systemic treatment (physician's choice)
62695031|NCT04345354||Patient with continuous positive airway pressure treatment|
61938870|NCT01024231|EXPERIMENTAL|Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
61938871|NCT01024231|EXPERIMENTAL|Cohort 6: BMS-936558 (1 mg/kg)|BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
62334341|NCT06117800|EXPERIMENTAL|Team STEPPS and Patient Safety Culture|TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations. Patient safety culture means preventing unintended incidents or accidents that may happen in a certain period in serving health care to patients
62695032|NCT04345354||without continuous positive airway pressure treatment|
62334342|NCT06152250|OTHER|Liver Fine-Needle Aspiration, blood sampling and clinical evaluation|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration and blood sampling will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy and after the same local anaesthetic. Specific blood sampling will be made the same day (20mL of plasma in Ethylenediaminetetraacetic Acid Tetrasodium (EDTA) tubes and 20 mL of plasma in heparin tubes).~Clinical information will be collected in electronic Case Report Form (e-CRF). After the procedure, the patient will be monitored as part of the usual protocol. No follow-up data are expected with Profile-NASH."
62334343|NCT04185480|NO_INTERVENTION|Conventional|Historical cohort of patients that underwent axillary clearance without hemopatch.
62334344|NCT04185480|EXPERIMENTAL|Intervention|Prospective cohort of patient undergoing axillary clearance with hemopatch
62334345|NCT00916500|EXPERIMENTAL|CISPLATIN|Patients With Locally Advanced Cervical Cancer Who Underwent Concurrent Chemoradiation; Cisplatin 75mg/m2 IV Every 3 Week For 3 Cycles; External Pelvic Radiation 40 Gy; Brachytherapy Up to 85-90 Gy To Point A
62334346|NCT05742672|EXPERIMENTAL|Massage|In the experimental group, twice a day, in the morning and evening, and 30 minutes after the meal, for 15 minutes. Effusion, petrissage and vibration massage movements will be applied by the researcher for a certain period of time in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.
62334347|NCT03526003||Surgical patients|Adult patient scheduled for laparoscopic surgery under general anesthesia
61938872|NCT01024231|EXPERIMENTAL|Cohort 7: BMS-936558 (3 mg/kg)|BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
61938873|NCT01024231|EXPERIMENTAL|Cohort 8: Nivolumab+Ipilimumab|"Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks~Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks"
61938874|NCT06287190||Dental interns|Assessing dental intern confidence before and after finishing their rotation at the pediatric department
62334348|NCT01176097|EXPERIMENTAL|6 - 8 cohorts|6 patients in each cohort will receive AZD5658
62334349|NCT01176097|PLACEBO_COMPARATOR|6 - 8 cohorts|2 patients in each cohort will receive placebo
62334350|NCT02782871|NO_INTERVENTION|Control|Manual ventilation with Mapleson C-circuit
62491848|NCT02577913||FC patch low|Women taking FC Patch low, a transdermal patch releasing 60 micrograms gestodene/24 hours + 13 micrograms ethinyl estradiol/24 hours
62491849|NCT02577913||LNG-COC|Women taking levonorgestrel-containing COCs: 1) monophasic preparations containing 20 - 30mcg of ethinylestradiol; 2) multiphasic preparations containing up to 40mcg of ethinylestradiol
61938875|NCT01303354|EXPERIMENTAL|DXM 4 mg|Dexamethasone 4 mg
61938876|NCT01303354|EXPERIMENTAL|DXM 8 mg|Dexamethasone 8 mg
61938877|NCT01303354|EXPERIMENTAL|DXM 12 mg|Dexamethasone 12 mg
61938878|NCT01938872||PEB angioplasty|paclitaxel eluting balloon angioplasty in below-the-knee lesions
62334351|NCT02782871|EXPERIMENTAL|Intervention|Pneupac VR1 portable ventilator
62491850|NCT01930409|ACTIVE_COMPARATOR|Education Only|"* A 1 hour education session in the acute setting~* A toolkit with education, exercise and self management instructions for after hip fracture"
62491851|NCT01930409|EXPERIMENTAL|Education + Telephone Follow-up|"* A 1 hour education session in the acute setting~* A telephone delivered self management program , including a toolkit (education, exercise and self management instructions for after hip fracture), support to take an active role in recovery, including setting and monitoring goals, problem solving mobility barriers, and guidance on the recovery process following a hip fracture."
62491852|NCT04878211|EXPERIMENTAL|Cohort 1 - 2 WKs vaccine prior to OMB157|Participants received non-live COVID-19 mRNA vaccine at least two weeks prior to start of ofatumumab (OMB157) (20 mg subcutaneous).
61938879|NCT01400815|EXPERIMENTAL|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
61938880|NCT01400815|ACTIVE_COMPARATOR|Active Control Cigarette|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette."
61938881|NCT01285453|EXPERIMENTAL|ASA404|
61938882|NCT02447562|ACTIVE_COMPARATOR|G_AH|Usual care group
61938883|NCT02447562|OTHER|G_SP|Phone-based care
61938884|NCT02447562|EXPERIMENTAL|G_NOMHAD|Intervention group with a health platform NOMHADchronic
62334352|NCT01784601||Control Group|We will be including all patients undergoing shoulder surgery not scheduled for a nerve block.
62334353|NCT01784601||Study Group|We will be including all patients undergoing shoulder surgery scheduled for a nerve block.
62334354|NCT05265741||ArmA_Pregnant No Gestational Diabetes Mellitus|This group is composed of pregnant women divided into 3 subgroups, one of each trimester. This arm will be required to provide 2 fecal samples. One at the start of recruitment, and one at the end of a 4-week period of the trimester.
62334355|NCT05265741||ArmB_Pregnant with Gestational Diabetes Mellitus|This group is composed of pregnant women divided into 3 subgroups, one of each trimester. This arm will be required to provide 2 fecal samples. One at the start of recruitment, and one at the end of a 4-week period of the trimester.
62334356|NCT05265741||ArmC_Non- Pregnant Control|This group is composed of non-pregnant women. This arm will be required to provide 1 or more fecal samples. It will be used as a baseline for comparison of the microbiome
62334357|NCT06519006|NO_INTERVENTION|Control group - usual management|This arm will be managed as usual - without specific pelvic floor exercises after surgery, and 1, 6 and 12 months after low anterior resection, patients will be questioned about the possible development of LARS.
62334358|NCT06519006|EXPERIMENTAL|Intervention group - specific pelvic floor exercise after LAR|"This arm will be instructed to exercise pelvic floor after low anterior resection for one month and 1, 6, and 12 months postoperatively will be questioned about the possible development of LARS.~One month after surgery they will also be questioned about adherence to prescribed exercise."
62491853|NCT04878211|EXPERIMENTAL|Cohort 2 - vaccine 4 WKs after OMB157|Participants received non-live COVID-19 mRNA vaccine at least four weeks after start of ofatumumab (OMB157) (20 mg subcutaneous).
61938885|NCT01736462|EXPERIMENTAL|Mapracorat|Mapracorat ophthalmic suspension, 3%
61938886|NCT02703220|EXPERIMENTAL|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during (non-rapid eye movement sleep) NREM sleep.
61938887|NCT02703220|EXPERIMENTAL|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.
61938888|NCT02703220|EXPERIMENTAL|Finasteride|Determine the effect of oral finasteride therapy vs placebo for 1 month on SDB and the AT and chemosensitivity during NREM sleep.
61938889|NCT03276793|EXPERIMENTAL|MRI and behavioral assessment for patients receiving TMS|Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
61938890|NCT05843955||Women with Polycystic ovary syndrome (PCOS)|PCOS was diagnosed according to the revised 2003 Rotterdam Consensus as the presence of at least two of the following three criteria: (i)oligomenorrhoea or anovulation; (ii)clinical and/or biochemical signs of hyperandrogenemia and (iii)polycystic ovaries on ultrasound.
61938891|NCT00935298|EXPERIMENTAL|T|"The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation.After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*3 and \*1/\*1 ,expressors; CYP3A5\*3/\*3 nonexpressor）.~The objective is to determine the initial dosage Range of tacrolimus in Chinese renal transplantation patients by genotyping of the cytochrome P450 3A5"
61938892|NCT06679894||Single tooth edentulism right|single missed teeth
61938893|NCT06679894||single tooth edentulism left|single missed tooth
61938894|NCT04348279|ACTIVE_COMPARATOR|custom made acrylic stent|the donor sites of the participants were covered with custom made acrylic stent
61938895|NCT04348279|EXPERIMENTAL|propylene mesh|in the test group, the donor sites received propylene mesh.
61938896|NCT01417936|EXPERIMENTAL|Sym004|
61938897|NCT00882466|NO_INTERVENTION|PCI only|primary PCI only
61938898|NCT00882466|EXPERIMENTAL|EPO|
61938899|NCT06150664|EXPERIMENTAL|Dose Escalation Cohort 1|Escalating doses of CTX-8371
61938900|NCT06150664|EXPERIMENTAL|Dose Expansion Cohort 2|Dose of CTX-8371 depending on Cohort 1 data
61938901|NCT02063711|EXPERIMENTAL|Yoga Intervention|A 1-hour yoga session will take place with guided instruction provided by a registered yoga instructor. The class includes a warm up period of 5 minutes, which includes sitting with the eyes closed and slowly breathing through the nose. After which the participant will perform a series of yoga postures in coordination with her breathing for approximately 45 minutes. The last 10 minutes of class will encompass a semi-recumbent relaxation period. This is a one time intervention.
61938902|NCT02063711|NO_INTERVENTION|Control group|In order to control for 1 hour worth of time, the participants in the control group will be given a 1 hour Power Point presentation on the benefits of exercise and yoga during pregnancy.
61938903|NCT04229979|EXPERIMENTAL|Galinpepimut-S + Montanide + GM-CSF|"A maximum of 15 total injections will be administered as follows:~1. First 6 galinpepimut-S injections: every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment. The first series of 6 injections of galinpepimut-S define the initial immunization induction phase.~2. Injections 7 to 12: every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment. The second series of injections of galinpepimut-S define the early immune booster phase.~3. Injections 13 to 15: every 6 weeks (between Weeks 40 and 52). The third series of injections of galinpepimut-S define the late immune booster phase.~Note: Galinpepimut-S is admixed with Montanide adjuvant before administered as a subcutaneous injection. GM-CSF is administered one day before and on the same day as the galinpepimut-S + Montanide injection."
61938904|NCT04229979|ACTIVE_COMPARATOR|Best Available Therapy|"Four options, as monotherapy or as combination of agents listed below, (per treating investigator's choice):~1. Observation (whereby palliative management with hydroxyurea is allowed), or~2. HMA (decitabine or azacitidine), and/or~3. Venetoclax, and/or~4. Low-dose ara-C"
61938905|NCT06431737||BID group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days
62137235|NCT06699238|EXPERIMENTAL|Aerobic Exercise Group|The aerobic exercise group performed the following training: warm-up for 5 min, walking for 20 min at an intensity that would use 60-70% of the HR reserve, and cool down for 5 min. Additionally, they performed standard conventional exercises at home for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. The aerobic exercise group performed on a treadmill under the supervision of a physician.
62137236|NCT01819571|EXPERIMENTAL|Normal diastolic function group|
62137237|NCT01819571|ACTIVE_COMPARATOR|Diastolic dysfunction group|
61938906|NCT06431737||QID group|Tegoprazan 50 mg bid, amoxicillin 500 mg qid, clarithromycin 500 mg bid for 14 days
61938907|NCT05296733|EXPERIMENTAL|Part A: BI 456906: Cohort 1|Healthy subjects
61938908|NCT05296733|EXPERIMENTAL|Part A: BI 456906: Cohort 2|Patients with cirrhosis + Child-Turcotte-Pugh (CTP) Class A
61938909|NCT05296733|EXPERIMENTAL|Part A: BI 456906: Cohort 3|Patients with cirrhosis + CTP Class B
61938910|NCT05296733|EXPERIMENTAL|Part A: BI 456906: Cohort 4|Patients with cirrhosis + CTP Class C
61938911|NCT05296733|EXPERIMENTAL|Part B: BI456906: Cohort 1|Patients with overweight/obesity without cirrhosis/hepatic impairment
61938912|NCT05296733|EXPERIMENTAL|Part B: BI456906: Cohort 2|Patients with overweight/obesity with cirrhosis + CTP Class A
61938913|NCT05296733|EXPERIMENTAL|Part B: BI456906: Cohort 3|Patients with overweight/obesity with cirrhosis + CTP Class B
61938914|NCT03953417|EXPERIMENTAL|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
62137238|NCT00727909|EXPERIMENTAL|Hearing Aid Treatments|"Hearing aid treatments:~TC (Traditional Custom), RITA (Receiver-in-the Aid), and RITE (Receiver-in the-Ear)"
62137239|NCT05348603|NO_INTERVENTION|No Intervention|\*No intervention.
62137240|NCT05348603|EXPERIMENTAL|Traditional Letter Only|\*A mailed letter will invite the patient to set up a research profile in their patient portal.
61938915|NCT01334892|ACTIVE_COMPARATOR|L-CsA|Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
62334359|NCT06121700|EXPERIMENTAL|Radiotherapy, Chemotherapy and anti-PD-1 Immunotherapy followed by Surgical Resection|Participants will receive short course hypofractionated radiotherapy (HFRT) for the primary lesion, HFRT or stereotactic body radiotherapy (SBRT) for metastatic lesions, combined with systemic chemotherapy and anti-PD-1 immunotherapy. For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. Then, surgical resections of primary and metastatic lesions are performed as much as possible. For patients who need a widely invasive surgical approach or are inoperable, local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) can be alternatives. For patients undergoing surgical resections, postoperative treatment includes chemotherapy, which is determined by the researcher, and PD-1 antibody, which will be maintained until one year after surgery.
62334360|NCT01788306|ACTIVE_COMPARATOR|Intervention (OOPEN+BBCC)|Study intervention, overdose prevention, education, intervention, brief behavioral change counseling, take-home naloxone, referral to local available resources.
62334361|NCT01788306|NO_INTERVENTION|Control|Standard of care, referral to local available resources.
62491854|NCT04878211|ACTIVE_COMPARATOR|Cohort 3 - Interferon or glatiramer acetate - vaccine 4 WKs after|Participants will receive non-live COVID-19 mRNA vaccine at least 4 weeks after start of prescribed interferon or glatiramer acetate
62491855|NCT04878211|EXPERIMENTAL|Cohort 4 - Fully vaccinated and on OMB457 ≥ 4 WKs|Participants fully vaccinated with a non-live COVID mRNA vaccine and on ofatumumab for at least 4 weeks (20 mg subcutaneous)
62491856|NCT04878211|EXPERIMENTAL|Cohort 5 -Fully vaccinated, on interferon or glatiramer acetate for ≥ 4 WKs ± booster|Participants fully vaccinated with a non-live COVID mRNA vaccine, without or without a booster, and on interferon or glatiramer acetate for at least 4 weeks.
62491857|NCT04878211|EXPERIMENTAL|Cohort 6 - Fully vaccinated, currently on OMB457 for ≥ 4 WKs, + booster|Participants fully vaccinated with a non-live COVID mRNA vaccine with a booster and on ofatumumab for at least 4 weeks (20 mg subcutaneous)
62491858|NCT03675763|EXPERIMENTAL|Craniosacral therapy|Craniosacral therapy and parent information on how to manage colic.
62491859|NCT03675763|NO_INTERVENTION|Parent information|Parent information on how to manage colic.
62491860|NCT06367985|EXPERIMENTAL|Air Oxygen Concentration CAPA-IVM culture|Half of the COCs will be cultured in the CAPA step and IVM step at 37 degrees Celsius in air oxygen concentration (20%) and 6% carbon dioxide.
62491861|NCT06367985|ACTIVE_COMPARATOR|Low Oxygen Concentration CAPA-IVM culture|Half of the COCs will be cultured in the CAPA step at a low oxygen concentration (5%) and IVM step at an air oxygen concentration (20%); all two steps combine 6% carbon dioxide at 37 degrees Celsius.
62491862|NCT04535986|EXPERIMENTAL|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
62491863|NCT04535986|PLACEBO_COMPARATOR|Arm 2|Placebo Nebulized BID
62491864|NCT04827251|OTHER|Caffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume caffeinated coffee during 28 days, followed by decaffeinated coffee during more 28 days.
62491865|NCT04827251|OTHER|Decaffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume decaffeinated coffee during 28 days, followed by caffeinated coffee during more 28 days.
62491866|NCT05156086||Kidney transplant recipients with booster|Patients who received kidney-only transplant or multi-organ transplant including kidney and fully vaccinated with standard dose(s) of messenger RNA (mRNA) or vector vaccine
61938916|NCT01334892|PLACEBO_COMPARATOR|L-CsA placebo|Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)
62491867|NCT02161705|EXPERIMENTAL|Ropivacaine Group|Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
62491868|NCT02161705|PLACEBO_COMPARATOR|Saline Group|Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.
62491869|NCT04759989|ACTIVE_COMPARATOR|30cc/kg ideal body weight (IBW)|"30cc/kg intravenous fluids based on the patients calculated ideal body weight will be administered when randomized to this arm~Using Devine's formula. (men: 50kg + 2.3kg \* (height(in) - 60); women: 45.5kg + 2.3kg \* (height(in) - 60)"
62491870|NCT04759989|ACTIVE_COMPARATOR|30cc/kg adjusted body weight (AdjBW)|"30cc/kg intravenous fluids based on the patients calculated adjusted body weight will be administered when randomized to this arm~Calculated by the following formula: AdjBW = IBW + 0.4(ABW - IBW)."
62491871|NCT04759989|ACTIVE_COMPARATOR|30cc/kg actual body weight (ABW)|"30cc/kg intravenous fluids based on the patients actual body weight will be administered when randomized to this arm~Patients will receive an initial fluid bolus of 30 cc/kg of actual body weight"
62491872|NCT03681938||Intensification treatment: Autograft|
62491873|NCT03681938||Standard chemotherapy (without autograft)|
62491874|NCT05044962|EXPERIMENTAL|Aim 1a (PK study group 1)|Initiating injectable cabotegravir/rilpivirine (LA ART) and DMPA
62491875|NCT05044962|EXPERIMENTAL|Aim 1a (PK study group 2)|Initiating injectable cabotegravir/rilpivirine (LA ART) and and etonogestrel implant
62491876|NCT05044962|EXPERIMENTAL|Aim 1a (PK study group 3)|Initiating injectable cabotegravir/rilpivirine (LA ART) and levonorgestrel implant.
62491877|NCT05044962|ACTIVE_COMPARATOR|Aim 1a (PK study group 4)|Receiving injectable cabotegravir/ rilpivirine (LA ART) and not using any hormonal contraceptive method (e.g. copper IUD)
62491878|NCT05044962|ACTIVE_COMPARATOR|Aim 1a (PK study group 5)|AGYW without HIV and not exposed to antiretrovirals (e.g., for PrEP) initiating DMPA
61938917|NCT06284096|EXPERIMENTAL|Intervention group|The intervention group, on the other hand, is aimed at participating in both the psychoeducation program conducted by the researcher and these routine practices within the institution.
61938918|NCT06284096|NO_INTERVENTION|Control Group|The control group is planned to participate only in the routine Community Mental Health Center activities within the institution, such as handicraft activities, art, music, computer courses, etc.
61938919|NCT04124653|EXPERIMENTAL|PF-06842874/Placebo|Single dose administration of PF-06842874 or placebo
62695033|NCT06112275|EXPERIMENTAL|Cohort X|Cohort X will evaluate ETX101 dose level 1.
62334362|NCT04894006|EXPERIMENTAL|Home visit intervention by community health workers|The caregiver-centered, culturally and language specific home visit intervention with wearable devices (smartwatch/ring) will be delivered by trained bilingual community health workers (CHW) for Latino, Vietnamese, Korean, non-Hispanic White caregivers of PWD. The home visit intervention components will include (1) stress reduction techniques; mindful breathing and compassionate support/listening and (2) weekly education on dementia caregiving skills to handle difficult behaviors of PWD and knowledge of resources available for dementia care. The duration of the intervention will be 12 weeks that include 6 home visits (4 times for the first month and then once a month for two months) carried out in the participant's home. The on-site home visit intervention delivered by CHWs will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions.
62334363|NCT04894006|ACTIVE_COMPARATOR|Attention Control with wearable smartwatch/ring|The caregivers randomly assigned to the Attention Control (AC) group will be asked to wear smartwatch during the day time and smart ring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months asking about the WIoT technology and answering general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
62334364|NCT04894006|PLACEBO_COMPARATOR|Usual Care Group|The caregivers randomly assigned to Usual Care (UC) group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. At recruitment, the participants will be told that at the end of the 6 months they will receive a smartwatch and a smartring for their participation. CHWs will contact them monthly for 6 months by phone answering only general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
62334365|NCT05271084|EXPERIMENTAL|Citalopram + Pentoxifylline group|Citalopram (tablet): 20 mg once a day for 12 weeks + Pentoxifylline (tablet): 400 mg twice a day for 12 weeks
62334366|NCT05271084|PLACEBO_COMPARATOR|Control group|Citalopram (tablet): 20 mg once a day for 12 weeks + placebo (tablet) twice a day for 12 weeks
62334367|NCT05625386|EXPERIMENTAL|Dual-target high-dose TMS (DHT)|DHT refers to the left primary motor cortex of the lower leg (M1) and dorsolateral prefrontal cortex (DLPFC) receiving 9000 pulses/day of intermittent TBS (iTBS) for 5 consecutive days. Each iTBS sequence in the high-dose stimulation sequence released 900 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of 10 iTBS sessions was performed each day with an interval of 40 min and the daily stimulation dose was 9000 pulses. The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session.
62334368|NCT05625386|EXPERIMENTAL|Dual-target conventional-dose TMS (DCT)|DCT refers to the left M1 and DLPFC receiving 1800 pulses/day of iTBS for 5 consecutive days. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses.The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session.
62334369|NCT05625386|ACTIVE_COMPARATOR|Single-target conventional-dose TMS (SCT)|SCT refers to the left M1 receiving 1800 pulses/day of iTBS treatment for 5 consecutive days. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses.
62334370|NCT00518219|EXPERIMENTAL|immunosuppressor|TW 120mg/d，Valsartan,160mg/d
62334371|NCT02629601|EXPERIMENTAL|Active Rewards|Participant will receive the standard active rewards incentives.
62334372|NCT02629601|ACTIVE_COMPARATOR|Active Rewards Doubled|Participant will receive the standard active rewards doubled in magnitude.
62334373|NCT02629601|ACTIVE_COMPARATOR|Active Rewards & Lottery 1|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward.
61938920|NCT04124653|EXPERIMENTAL|Relative Bioavailability|Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation
61938921|NCT05822986||Individuals with stroke|Patients who were hospitalized in the Neurology Service of Pamukkale University Hospital and who had an acute stroke and who met the inclusion criteria
61938922|NCT00914173|EXPERIMENTAL|Pain/No Pain Stimuli|One Arm is used in this trial. The comparator is within the arm. The different types of stimuli levels and types are compared.
61938923|NCT06403852|EXPERIMENTAL|Image recognition task|The stimulus set will include real and scrambled images, where the scrambled images will be created by phase-shuffling a randomly chosen real image from each category to preserve category specific low-level image features. Each object category will include four unique real images and one scrambled image. Each image will be repeated 10 times (i.e., trials) for each 16-min session. The pre-stimulus interval will vary randomly from trial to trial between 4 and 8 seconds to prevent stimulus timing predictability. The stimuli will be presented in a randomized order to prevent category predictability.
62491879|NCT05044962|EXPERIMENTAL|Aim 2a (Hybrid trial intervention group)|AGYW with viral suppression on their current ART regimen to switch to cabotegravir/ rilpivirine.
62491880|NCT05044962|ACTIVE_COMPARATOR|Aim 2a (Hybrid trial comparator group)|AGYW with viral suppression to continue their oral ART regimen.
62491881|NCT06315660|EXPERIMENTAL|TAU+VR|
62491882|NCT06315660|ACTIVE_COMPARATOR|TAU|
62491883|NCT02000258|OTHER|Double-bundle ACL reconstruction|Double-bundle ACL reconstruction
62491884|NCT02000258|OTHER|Magnetic resonance imaging (MRI)|MRI of the ACL double-bundle reconstructed knee was done at 2 years after surgery.
62695034|NCT06112275|EXPERIMENTAL|Cohort Y|Cohort Y will evaluate ETX101 dose level 2.
62491885|NCT06251206|EXPERIMENTAL|ADL/Postoperative Instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated by ORIF and postoperative care. Participants in the experimental group will also receive a handout on ADL participation and postoperative care with a QR code to the video.
62491886|NCT06251206|ACTIVE_COMPARATOR|Postoperative Instruction|Participants in the control group will watch a video instructing them on postoperative care. Participants in the control group will receive a handout on postoperative care with a QR code to the video.
62491887|NCT04534985|EXPERIMENTAL|Time Restricted Feeding|Instructed to eat within an 8-hr window, beginning within 3 hrs of waking. In addition, provide current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
62491888|NCT04534985|ACTIVE_COMPARATOR|Healthy Eating Advice without Time Restricted Feeding|Curriculum for the healthy eating control group will emphasize current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
62491889|NCT05731024|EXPERIMENTAL|Close-loop synchronization controller|One-hour period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during SPONT mode.
62491890|NCT05731024|ACTIVE_COMPARATOR|Conventional|One-hour period where the synchronization of pressure support of patient effort during SPONT mode will be manually set.
62491891|NCT05319574|EXPERIMENTAL|Neoadjuvant SBRT plus immunochemotherapy|Stereotactic body radiation therapy (8Gy\*3d) followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 2 cycles before surgical resection
62491892|NCT00538863|EXPERIMENTAL|Fentanyl sublingual spray titration|Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.
62491893|NCT00538863|EXPERIMENTAL|Fentanyl sublingual spray maintenance|Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.
62491894|NCT05642130|EXPERIMENTAL|treatment group|(30) thirty patients with forward head received PIR for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks In addition to the program designed for control group.
62491895|NCT05642130|SHAM_COMPARATOR|control group|"(30) thirty patients with forward head received static stretching exercise for upper trapezius and sternocleidomastoid .~Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles 3sets of 12 repetitions with 6 sec hold. In addition to postural advices"
62491896|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
62491897|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
62491898|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
62491899|NCT05534113|EXPERIMENTAL|sequential Envafolimab therapy after Almonertinib treatment|Sequential Envafolimab therapy after patients with ctDNA EGFR mutation clearance and achieve stable radiographically deep response after treatment with Almonertinib
62491900|NCT06149962|ACTIVE_COMPARATOR|WALANT|Flexor Tendon Repair under Wide-Awake Local Anesthesia No Tourniquet
62491901|NCT06149962|ACTIVE_COMPARATOR|BRACHIAL BLOCK|Flexor Tendon Repair under Brachial Plexus Block
62491902|NCT04816227||Amyotrophic Lateral Sclerosis (ALS)|Blood draw
62491903|NCT04816227||asymptomatic carriers of ALS mutations|Blood draw
62491904|NCT04816227||patients with motor impairment other than ALS|Blood draw
62491905|NCT04816227||healthy controls|Blood draw
61938924|NCT02607007|EXPERIMENTAL|2% M.F. Milk|Breakfast meal: 250 mL 2% M.F. milk, 75 g white toast, 23.2 g strawberry jam, 100 mL water
61938925|NCT02607007|EXPERIMENTAL|2% M.F. Plain Greek Yogurt|Breakfast meal: 175 g 2% plain Greek yogurt, 75 g white toast, 23.2 g strawberry jam, 100 mL + 75 mL water
61938926|NCT02607007|EXPERIMENTAL|31% M.F. Cheddar Cheese|Breakfast meal: 30 g 31% M.F. cheddar cheese, 75 g white toast, 27.0 g strawberry jam, 100 mL + 220 mL water
62491906|NCT02285049||Urticaria Control Test|"* Evaluation by UAS28, PatGA-LS, PhyGA-LS~* Fill the UCT and DLQI questionnaire"
62695035|NCT06112275|EXPERIMENTAL|Cohort Z|Cohort Z will evaluate ETX101 dose level 3.
62695036|NCT05119335|EXPERIMENTAL|Phase 1 dose escalation|Phase 1 is designed to determine the maximum tolerated dose and/or identify the recommended Phase 2 dose of NKT2152 as a single agent administered orally once daily in ccRCC patients
61938927|NCT02607007|EXPERIMENTAL|Soy Beverage|Breakfast meal: 250 mL soy beverage, 75 g white toast, 19.3 g strawberry jam, 100 mL water
61938928|NCT02607007|EXPERIMENTAL|Water (control)|Breakfast meal: 250 mL + 100 mL water
62137241|NCT05348603|EXPERIMENTAL|Direct to Patient Message Only|\*An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research.
62491907|NCT03989141|EXPERIMENTAL|Repeated cannulation Buttonhole|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
62491908|NCT03989141|ACTIVE_COMPARATOR|Single cannulation Buttonhole|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
62491909|NCT03601845|OTHER|MRE-IA (no stimuli)|Additional sequencing only
62491910|NCT03601845|ACTIVE_COMPARATOR|MRE-IA with stimuli|Visual stimulation while using additional sequencing
62491911|NCT04203667|OTHER|EndoRotor Resection Arm|All participants enrolled in this study will undergo treatment with the EndoRotor during colonoscopy for endoscopic mucosal resection in the colon to resect and remove tissue, not intended for biopsy, of the gastrointestinal system including post-endoscopic endoscopic mucosal resection of tissue persistence with a scarred base and residual tissue from peripheral margins following endoscopic mucosal resection.
62491912|NCT01327976|ACTIVE_COMPARATOR|vBloc (Active Device)|The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
62491913|NCT01327976|SHAM_COMPARATOR|Sham (Non-active Device)|The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
62491914|NCT00862563|EXPERIMENTAL|Zonisamide|Encapsulated zonisamide with a target maintenance doses of 400 mg/day administered as 4 capsules per day.
62491915|NCT00862563|EXPERIMENTAL|Levetiracetam|Encapsulated levetiracetam with a target maintenance doses of 2000 mg/day administered as 4 capsules per day .
62491916|NCT00862563|ACTIVE_COMPARATOR|Topiramate|Encapsulated topiramate with a target maintenance doses of 300 mg/day administered as 4 capsules per day .
62491917|NCT00862563|PLACEBO_COMPARATOR|Sugar Pill|Encapsulated sugar pill with a target maintenance dose administered as 4 capsules per day.
62491918|NCT02108639|EXPERIMENTAL|DCV 3DAA FDC + BMS-791325|"Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days~Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days"
62491919|NCT03493633||EzyGain at Home|Setting up a walking device at home for people aged 60 years with partial walking disability regardless of etiology and pathology leading to walking disability.
62491920|NCT00980941|EXPERIMENTAL|Soup with no added starch|
62695037|NCT05119335|EXPERIMENTAL|Phase 2 dose expansion|Phase 2 dose expansion will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 as a single agent administered orally once daily in ccRCC patients. Patients will be randomized to one of two dosage levels being evaluated.
62334374|NCT02629601|ACTIVE_COMPARATOR|Active Rewards & Lottery 1 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward. Includes broadcasting winners (number) each week.
62334375|NCT02629601|ACTIVE_COMPARATOR|Active Rewards & Lottery 2 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 2 with a 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward. Includes broadcasting winners (number) each week.
62334376|NCT00360243|EXPERIMENTAL|flibanserin 25 mg b.i.d|25 mg twice daily for 24 weeks
62491921|NCT00980941|EXPERIMENTAL|Soup + 50 g of whole grain starch|
62491922|NCT00980941|EXPERIMENTAL|Soup + 50 g of high amylose corn starch|
62695038|NCT06571097|EXPERIMENTAL|Levofloxacin|Levofloxacin: 0.5g(500mg)/day for 2 weeks
62695039|NCT02249520|OTHER|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
62695040|NCT02249520|OTHER|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
61938929|NCT06681701|EXPERIMENTAL|Group B (experimental)|"Group B (experimental) received conventional physiotherapy and manual therapy~Rib mobilization from sitting:~Rib mobilization from supine:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Myofascial release techniques (MRT)~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:"
62334377|NCT00360243|EXPERIMENTAL|flibanserin 50mg qhs|50 mg taken once daily at bedtime for 24 weeks
62334378|NCT00360243|EXPERIMENTAL|flibanserin 50mg b.i.d.|50 mg twice daily for 24 weeks
62334379|NCT00360243|PLACEBO_COMPARATOR|placebo|twice daily for 24 weeks
62334380|NCT01763476|ACTIVE_COMPARATOR|Paclitaxel-coated balloon angioplasty|Target lesion to be treated with paclitaxel-coated balloon
62334381|NCT01763476|ACTIVE_COMPARATOR|Atherectomy + paclitaxel-balloon|Target lesion to be treated with atherectomy (TurboHawk, ev3) and paclitaxel-coated balloon
62334382|NCT01943734|EXPERIMENTAL|Lifestyle counseling|Information passed on anthropometric assessment
62491923|NCT00980941|EXPERIMENTAL|Soup + 50 g of regular corn starch|
62491924|NCT00980941|EXPERIMENTAL|Soup + 50 g maltodextrin starch|
62491925|NCT05729854|EXPERIMENTAL|acupressure group|Acupressure will be performed by the researchers of the main, hand and body parts of the women in the experimental units.In the clinic where the study will be conducted, acupressure application hours were determined considering the analgesic treatment protocol applied. Acupressure will be applied at the 18th and 24th hours postpartum.
62491926|NCT05729854|NO_INTERVENTION|control group|Acupressure will not be applied to the control group. routine midwifery care.
62491927|NCT03572582|EXPERIMENTAL|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
62334383|NCT03327753|EXPERIMENTAL|Motor control exercises|A primary goal of the motor control exercise program is to regain control and coordination of the spine and pelvis using principles of motor learning such as segmentation and simplification. The whole intervention is based on assessment of the individual patient's motor control impairments and the patient's individual treatment goals (set collaboratively with the therapist).
62491928|NCT03749707|OTHER|SLNs from early-stage cervical cancer patients|Tissue from SLNs removed from early-stage cervical cancer patients are analyzed for HPV.
62334384|NCT03327753|EXPERIMENTAL|Graded activity|A primary goal of the graded activity program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. The intervention uses cognitive behavioral approaches to deal with fear of movement and self efficacy.
62491929|NCT03166527|OTHER|Open Label study|open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
62491930|NCT05121935||MAL-ED cohort|Children initially followed from birth through 2 years old in the MAL-ED study (with some additional assessments in follow-up studies since then).
62491931|NCT00677872|EXPERIMENTAL|1|
62491932|NCT03256149|EXPERIMENTAL|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
62491933|NCT03256149|PLACEBO_COMPARATOR|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
61938930|NCT06681701|ACTIVE_COMPARATOR|Group A (control)|"Group A (control) received conventional physiotherapy~Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia."
62334385|NCT05631327|EXPERIMENTAL|Dose Finding Phase: JZP341|Participants who will receive JZP341 on Day 1 and Day 15 of each 28-day cycle.
62334386|NCT05631327|EXPERIMENTAL|Dose Expansion Phase: JZP341|Participants who will receive JZP341 at the RP2D established in the Dose Finding Phase on Day 1 and Day 15 of each 28-day cycle.
62491934|NCT05613426|ACTIVE_COMPARATOR|Intensive statin group|Rosuvastatin, 20 mg per day after randomization
62491935|NCT05613426|EXPERIMENTAL|Combined intensive statin and PCSK9 inhibitor group|Evolocumab, 140 mg twice a month after randomization, and Rosuvastatin, 20 mg per day after randomization
62491936|NCT05613426|EXPERIMENTAL|PCSK9 inhibitor alone group|Evolocumab, 140 mg twice a month after randomization
62491937|NCT00486434|ACTIVE_COMPARATOR|1|SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months
62491938|NCT00486434|PLACEBO_COMPARATOR|2|SMC021 Placebo, orally twice daily during 24 months
62491939|NCT00731367|ACTIVE_COMPARATOR|Gelled|Aquacel Ag gelled.
62491940|NCT00731367|ACTIVE_COMPARATOR|Adherent|Aquacel Ag adherent
62491941|NCT01667822|ACTIVE_COMPARATOR|Continued guided self help CBT|Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).
62491942|NCT01667822|EXPERIMENTAL|CBT individual therapy|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
62491943|NCT06462495|EXPERIMENTAL|[18F]F-PSMA-N5 and [18F]F-PSMA-1007 PET/ CT scan|Subjects PET/CT imaging: On any two days for two consecutive weeks, each subject underwent a PET/ CT scan after intravenous injection of \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007.
62491944|NCT00834158|ACTIVE_COMPARATOR|TACE|perform TACE only
62137242|NCT05348603|EXPERIMENTAL|Chatbot Only|\*A real-time, interactive chatbot on the patient portal will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests.
62137243|NCT05348603|EXPERIMENTAL|Banner Only|"\*Banner-type advertisements will appear during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
62334387|NCT06530602|EXPERIMENTAL|Group A|"3-D SPA (shoulder complex pain alignment) Moblization. Conventional therapy \& Home Plan Treatment session: 3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.~Modality: Ultrasound Mode: continuous 3 MHz, 1.5 w/cm2 for 6 min"
62334388|NCT06530602|ACTIVE_COMPARATOR|Group B|"Shoulder mobilization (kaltenborn) Conventional therapy \& Home Plan Treatment session: 3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.~Modality: Ultrasound Mode: continuous 3 MHz, 1.5 w/cm2 for 6 min"
62334389|NCT03628508|EXPERIMENTAL|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
62334390|NCT05550194|EXPERIMENTAL|Treatment|Patients with Achalasia (phenotypes II and III) with VZV DNA in saliva. Patients will be treated with valacyclovir 3 times per day. Patients found to benefit from treatment with valacyclovir will be offered Shingrix vaccine (2 - 0.5mL doses)
62491945|NCT00834158|EXPERIMENTAL|TACE+PVE|perform TACE and PVE sequentially
62491946|NCT00165919||HCV+|No group or cohort; not a clinical trial
62491947|NCT00288704|PLACEBO_COMPARATOR|Placebo|Some subjects were treated with Placebo in the Study. This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
62491948|NCT00288704|ACTIVE_COMPARATOR|rilonacept 160 mg|"If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B).~Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg."
62491949|NCT00288704|OTHER|Open-Label rilonacept 160 mg|"After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week.~Study drug is administered as a 2.0 mL subcutaneous injection once a week."
62491950|NCT03890705||postpartum women|Women aged (15-49) and had given birth in the past 12 months
62491951|NCT02835157|EXPERIMENTAL|Balanced crystalloid or multiple electrolyte solution group|After enrollment, a fluid bolus comprising of 'multiple electrolyte solution (Plasma-Lyte P)' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
61938931|NCT06565208|EXPERIMENTAL|SAT-3247|"SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.~Part A: Participants will receive one oral dose of SAT-3247 in accord with cohort assignment (1) 10 mg, (2) 50 mg, (3) 150 mg, (4) 300 mg, (5) 400 mg Part B: Participants will receive one oral dose of SAT-3247 daily for seven days in accord with cohort assignment (1) 60 mg, (2) 120 mg, (3)180 mg, (4) 240 mg Part C: Participants will receive one oral dose of SAT-3247 150 mg, following completion of Part A at the same dose Part D: All participants will receive one SAT-3247 60 mg dose once daily for 5 consecutive days of each of 4 weeks"
62137244|NCT05348603|EXPERIMENTAL|Traditional Letter + Direct to Patient Message|"* A mailed letter will invite the patient to set up a research profile in their patient portal; AND~* An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research."
62491952|NCT02835157|ACTIVE_COMPARATOR|0.9% saline or saline group|After enrollment, a fluid bolus comprising of 'saline' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
62491953|NCT04429113||G1 or Early Group|Patients treated before age 7 (Quad Helix on decidual second molars)
62491954|NCT04429113||G2 or Late Group|Patients treated between 7 and 13 years old (Quad Helix on first permanent molars)
62491955|NCT04386122|EXPERIMENTAL|FABALOFEN 60|Subjects will receive a single dose of 1 FABALOFEN 60 tablet under fed condition
62491956|NCT04386122|ACTIVE_COMPARATOR|JAPROLOX TABLET|Subjects will receive a single dose of 1 JAPROLOX® TABLETS tablet under fed condition
62491957|NCT06323616|NO_INTERVENTION|Control Group|Sevoflurane anesthesia will be applied with an endtidal agent consumption of 0.8 MACage, with 2 standard deviations for MACage:1 to the control group, as we apply in routine anesthesia practice. (During the surgery, the parameters showing the depth of anesthesia will be placed away from the anesthesiologist and covered to ensure blindness. At the end of the surgery, the data will be received via USB.)
62491958|NCT06323616|EXPERIMENTAL|Study Group|Sevoflurane anesthesia will be applied to the study group by adjusting the MAC to keep the PSI median value between 25-50 (if PSI\<25, MAC will be reduced by 0.1, if PSI\>50, MAC will be increased by 0.1).
62491959|NCT05874596|EXPERIMENTAL|Intervention|AI-aided clinical feedback system coupled with multi-aspect intervention based on the Behaviour Change Wheel model
62491960|NCT05874596|NO_INTERVENTION|Control|AI-aided clinical feedback system only
62491961|NCT04425577|OTHER|Transabdominal Ultrasound|All patients enrolled will undergo a transabdominal ultrasound at a specified time point as outlined in the protocol.
62491962|NCT04129060|EXPERIMENTAL|Mecamylamine Challenge|One of the two study days will be the oral mecamylamine.
62491963|NCT04129060|EXPERIMENTAL|Placebo Challenge|One of the two study days will be the oral placebo.
62491964|NCT03888235|EXPERIMENTAL|Immediate corrective exercises|"At this visit, participants will be examined as described in the protocol and given an exercise to correct their sacroiliac malrotation. They will use this exercise as needed for pain control. They will be reassessed one month later.~At that time they will be given the pelvic support belt and the concurrent use of both treatments will be assessed at their last visit one month after that."
62491965|NCT03888235|EXPERIMENTAL|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their pelvis. They will use this belt for activities likely to precipitate back pain. They will be reassessed one month later.~At that time they will be given the exercises and the concurrent use of both treatments will be assessed at their last visit one month after that."
62334391|NCT06552559|EXPERIMENTAL|Selinexor plus ICED|"Phase 1 part of the study:~Treatment will be repeated every three weeks.~* Selinexor: DL1 (40mg)/DL2 (60mg)/DL3 (80mg) PO, day 3, 5, 7~* Ifosfamide 1500 mg/m(2) infused over 2 h on days 1-3~* Carboplatin (5 AUC) on day 1~* Etoposide 100 mg/m(2) on days 1-3~* Dexamethasome 40 mg PO or IV on days 1-4~Phase 2 part of the study:~Treatment will be repeated every three weeks.~* Selinexor: MTD (determined by phase 1 part of the study) PO, day 3, 5, 7~* Ifosfamide 1500 mg/m(2) infused over 2 h on days 1-3~* Carboplatin (5 AUC) on day 1~* Etoposide 100 mg/m(2) on days 1-3~* Dexamethasome 40 mg PO or IV on days 1-4"
62334392|NCT03616665|OTHER|CBASPersonalized|Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient.
62334393|NCT01390116|PLACEBO_COMPARATOR|Sugar pill|looks like and is given in the same way as the experimental treatment but contains no active ingredient
62334394|NCT01390116|EXPERIMENTAL|AGE|Encapsulated aged garlic extract, 4 capsules per day, 2.56 g/day
62334395|NCT03430245|EXPERIMENTAL|VelaShape III & UltraShape Power|VelaShape III treatment with radiofrequency, infrared and massage combined with UltraShape Power treatment, using pulsed, focused ultrasound treatment.
62334396|NCT04538885|NO_INTERVENTION|control group|No intervention
62334397|NCT04538885|EXPERIMENTAL|experimental group|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)
62334398|NCT03622593|EXPERIMENTAL|A: Faricimab 6 mg Q8W|Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
62491966|NCT03888235|ACTIVE_COMPARATOR|Delayed treatment|"These participants will continue using their current therapies to deal with their low back pain for one month prior to being scheduled for a treatment visit. At the treatment visit, one month later they will be given both the exercise and the belt.~The concurrent use of both treatments will be assessed at their last visit one month after that."
61938932|NCT06565208|PLACEBO_COMPARATOR|Placebo|Part A: Participants will receive one oral dose of matched placebo in accord with cohort assignment of (1) 10 mg, (2) 50 mg, (3) 150 mg, (4) 300 mg, (5) 400 mg Part B: Participants will receive one oral dose of matched placebo daily for seven days in accord with cohort assignment (1) 60 mg, (2) 120 mg, (3)180 mg, (4) 240 mg Part C: Participants will receive one oral dose of matched placebo 150 mg, following completion of Part A at the same dose
62334399|NCT03622593|EXPERIMENTAL|B: Faricimab 6 mg PTI|Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.
62334400|NCT03622593|ACTIVE_COMPARATOR|C: Aflibercept 2 mg Q8W|Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
62334401|NCT06422351|EXPERIMENTAL|Participant Group/Arm|RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
62334402|NCT05111899|EXPERIMENTAL|Intervention|
62491967|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
61938933|NCT06612424|ACTIVE_COMPARATOR|anterior quadratus lumborum block|All blocks will be performed by the same anesthesiologist using ultrasound guidance. In the Quadratus Lumborum block group, patients will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 25 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.
61938934|NCT06612424|ACTIVE_COMPARATOR|intratechal morphine group|In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
62334403|NCT05111899|NO_INTERVENTION|Control|
62334404|NCT03664973|EXPERIMENTAL|continuous|continuous local anesthetic infusion (ropivacaine 0.2%)on the serratus plane for at least 72h adds to a Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml.
62334405|NCT03664973|ACTIVE_COMPARATOR|single-shot|Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml
62491968|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
62491969|NCT05727020||VAPOR 1 - PDAC (pancreatic ductal adenocarcinoma)|"257 treatment-naive patients with histologically-confirmed\* PDAC will be recruited to provide breath samples.~\*Patients that are due to undergo surgery for suspected PDAC (without pre-operative histological confirmation) may still be recruited despite the lack of pre-operative histological confirmation, assuming PDAC is subsequently confirmed within the resected specimen."
62491970|NCT05727020||VAPOR 1 - Control patients with benign pancreatic disorders|"257 patients with new-onset diabetes mellitus or chronic pancreatitis will be recruited to provide breath samples.~New-onset diabetes is defined as: HbA1c≥48mmol/mol (6.5%), diagnosed within the preceding 6 months."
61938935|NCT06612424|NO_INTERVENTION|control group|Participants in the control group will not receive any interventions such as intrathecal morphine or quadratus lumborum block. They will undergo cesarean sections under spinal anesthesia.
62334406|NCT06177782|ACTIVE_COMPARATOR|Tooth Modified Scan Bodies|The intraoral scanner (IOS) impression will be recorded using modified scan bodies. The IOS device will be calibrated right before the impression. The scan strategy will be consistent for all the procedures following the manufacturer guidelines.
62334407|NCT06177782|PLACEBO_COMPARATOR|Conventional Scan Bodies|The intraoral scanner (IOS) impression will be recorded using conventional implant scan bodies secured at the multiunit abutment level.
62334408|NCT03682510|ACTIVE_COMPARATOR|stepwise devascularization|routine stepwise devascularization
62334409|NCT03682510|ACTIVE_COMPARATOR|B-Lynch Transverse Compression Suture|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side."
62334410|NCT03682510|EXPERIMENTAL|N&H technique|"In the N\&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade. As follow:~(i) 100-cm Vicryl no. 1 was thrown to form two nearly equal parts (each 50 cm) on a blunt semicircular 70-mm needle, the curve of the needle was straightened.~(ii) The needle transfixed the right side of the uterine wall from anterior to posterior, about 2 cm below the hysterotomy incises posterior, then the needle transfixed the left side of the uterine wall from posterior to anterior, about 2 cm below the hysterotomy incision."
62334411|NCT00240630|PLACEBO_COMPARATOR|Arm 1|placebo to match
62695041|NCT02249520|OTHER|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
62334412|NCT00240630|EXPERIMENTAL|Arm 2|Treximet (sumatriptan/naproxen sodium)
62334413|NCT04543474|ACTIVE_COMPARATOR|Group 1|Patients starting with a low lactose diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low FODMAP diet for 3 weeks
62334414|NCT04543474|ACTIVE_COMPARATOR|Group 2|Patients starting with a low FODMAP diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low lactose diet for 3 weeks.
62695042|NCT03413995|EXPERIMENTAL|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
62695043|NCT05299320||Patients with Post-Covid|Being between the ages of 18-30, - Being a volunteer - Having had Covid-19 in the last 3 month Exclusion Criteria - Presence of neurologic and oncologic disease - Presence of orthopedic surgery - Presence of active Covid-19 disease - Any cardiopulmonary disease
61938936|NCT02699359|EXPERIMENTAL|HS-1000 recording|Study participants will receive HS-1000 ICP readings for a continuous 16 minute interval in a 30 degree supine position. Recordings will be obtained in one session. When possible, these recordings will be obtained at their initial examination and all follow-up visits. Sports Medicine staff will coordinate the HS-1000 device earplug insertion and recordings so as not to interfere with, nor marginally delay the patient's normal, routine clinical evaluation.
61938937|NCT06679829|EXPERIMENTAL|Siltuximab plus population PK-dosed melphalan|For patients randomized to Arm A, the siltuximab, 11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day). Patients will then receive 70mg/m2 of melphalan on Day -2. The melphalan will be infused over 30 minutes. Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the end of the melphalan infusion for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes. The population PK formula in the Insight Rx software will be used to calculate the melphalan dose for Day -1 to achieve a total target area under the curve (AUC) of 13 mg\*h/L (+/-1.5). The six PK samples will be collected again after the dose on Day -1 to confirm the total AUC. Patients will receive a minimum of the equivalent of 70mg/m2 and a maximum of the equivalent of 260mg/m2.
61938938|NCT06679829|ACTIVE_COMPARATOR|Standard BSA-dosed melphalan|Patients randomized to Arm B with received Standard of care (SOC) BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2 and will not receive the siltuximab. The melphalan will be infused over 30 minutes. Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the end of the melphalan infusion for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
62334415|NCT04983329|OTHER|Improvement in administration of surgical antibiotic prophylaxis.|The eight-month module will include a baseline phase, educational interventions, real-time guidance from a remote telemedicine center, regular feedback regarding adherence to protocols related to that module, and continued silent monitoring.
62491971|NCT05727020||VAPOR 1 - Control patients with non-specific GI symptoms and a normal pancreas|"257 patients with non-specific gastrointestinal symptoms but a radiologically-normal pancreas will be recruited to provide breath samples.~Imaging to confirm a normal pancreas (CT / MRI / ultrasound) must have occurred within the preceding 12 months."
62491972|NCT05727020||VAPOR Bioresource - PDAC (pancreatic ductal adenocarcinoma)|"96 treatment-naive patients with histologically-confirmed\* PDAC will be recruited to provide samples of breath, saliva, blood, urine, pancreatic tissue and duodenal aspirate.~\*Patients that are due to undergo surgery for suspected PDAC (without pre-operative histological confirmation) may still be recruited despite the lack of pre-operative histological confirmation, assuming PDAC is subsequently confirmed within the resected specimen."
62491973|NCT05727020||VAPOR Bioresource - Control patients with benign pancreatic disorders|96 patients with benign pancreatic disorders (such as intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis) will be recruited to provide samples of breath, saliva, blood, urine, pancreatic tissue and duodenal aspirate.
62491974|NCT00225641|ACTIVE_COMPARATOR|1 frequent control|Follow-up 6, 12, 18, 24 and 36 months after surgery
62491975|NCT00225641|OTHER|2 less frequent control|Follow-up 12 and 36 months after surgery
62695044|NCT05299320||Healthy Person|Being between the ages of 18-30, Being a volunteer, not having Covid-19 before
62334416|NCT00772993||1|Primary open angle glaucoma
62334417|NCT00772993||2|Normal Control
62334418|NCT00772993||3|Myopia with no evidence of glaucoma
62334419|NCT00772993||4|Myopia with evidence og glaucoma
62334420|NCT04699903||Positive SARS-Cov-2 cohort|Positive diagnosis of COVID-19 confirmed by a positive EUA SARS-CoV-2 PCR will be stratified in three subgroups 0 - 7 days since onset of symptoms 8 - 14 days since onset of symptoms 15 -90 days since onset of symptoms
62334421|NCT04699903||Negative SARS-Cov-2 cohort|Negative diagnosis of COVID-19 confirmed by a negative, EUA SARS-CoV-2 PCR test within 0-7 days of PCR sample collection will be included in the negative cohort.
62334422|NCT05436899|EXPERIMENTAL|Intensive training group|Participants in this group will undergo an intensive virtual training program twice a week
62334423|NCT05436899|ACTIVE_COMPARATOR|Non-Intensive training group|Participants in this group will undergo a non-intensive virtual training program once a week
62491976|NCT01080820|PLACEBO_COMPARATOR|Placebo + Viread|
62695045|NCT06675669|EXPERIMENTAL|Reflective thinking|"Discussion sessions will be held once a week for 7 weeks within the scope of the Professional Ethics Course for the students in the intervention group. For the discussion sessions, the students will be divided into 4 groups of 10-11 people. Separate 1-hour discussion sessions will be held with each group.~A training session will be held with the students in the intervention group in the first week (November 22,2024). In this session; the researchers will inform the students about the reflective thinking technique. In the 2nd, 3rd, 4th, 5th, 6th and 7th weeks (January 03, 2025), the students will come to class by writing an event/situation they encountered during their hospital internship in the Obstetrics and Gynecology Nursing course, which they are currently doing clinical practice. During the class hour, the researcher will determine one of the events/situations written by the students and will discuss it in the group.Follow-up data will be collected after 3 months (March 31,2025)."
62695046|NCT06675669|NO_INTERVENTION|Control|No application will be made to the students in the control group. These students will be given standard education for 7 weeks (Between November 22, 2024 and January 03, 2025).
62491977|NCT01080820|ACTIVE_COMPARATOR|Viread|
62491978|NCT01080820|EXPERIMENTAL|CMX157 + Viread|
62334424|NCT02928549||Black Women with Cancer|In this formative qualitative research study we aim to use one-on-one semi-structured interviews with Black women diagnosed with ovarian cancer to learn about their experiences and their journey to accessing care at a high-volume ovarian cancer care center (HVC).
62334425|NCT05477342|EXPERIMENTAL|İntervention 1|Experimental 1 - Board Game Group: Board game group played only board game.
61938939|NCT04871074|ACTIVE_COMPARATOR|Cognitively unimpaired|Results of most recent testing with the source cohort indicate the participant is cognitively unimpaired as judged by consensus or expert review.
61938940|NCT04871074|ACTIVE_COMPARATOR|Mild Cognitive Impairment|Abnormal cognitive status of MCI as judged by consensus or expert review using National Institute of Aging and Alzheimer's Association (NIA-AA) 2018 criteria.
62334426|NCT05477342|EXPERIMENTAL|İntervention 2|Experimental 2 - Tobacco Cessation Education Group: The Tobacco Cessation Education Group received only education according to the stages of change model.
62334427|NCT05477342|EXPERIMENTAL|İntervention 3|Experimental 3 - Combined intervention Group:Combined intervention group received both board game and tobacco cessation education.
62334428|NCT05477342|NO_INTERVENTION|Control Group|No intervention was made in the control group.
62334429|NCT02953392|ACTIVE_COMPARATOR|Arm 1|Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
62334430|NCT02953392|ACTIVE_COMPARATOR|Arm 2|Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
62334431|NCT02953392|ACTIVE_COMPARATOR|Arm 3|Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
62334432|NCT02953392|ACTIVE_COMPARATOR|Arm 4|Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
62334433|NCT03798444||Bone mineral denstiy|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry in all subjects.Accroding to The World Health Organization, we defined osteoporosis as a T-score ≤-2.5,and the non osteoporosis as T-score\>-2.5.
62334434|NCT03798444||Vertebral fractures|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray. A visual semi-quantitative method was used, with fractures defined as a vertebral height ratio \<0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra.
62491979|NCT01790685|OTHER|CRVO|Central Retinal Vein Occlusion
62491980|NCT01790685|OTHER|BRVO|Branch Retinal Vein Occlusion
62137245|NCT05348603|EXPERIMENTAL|Traditional Letter + Chatbot|"* A mailed letter will invite the patient to set up a research profile in their patient portal; AND~* A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
62334435|NCT03625362|EXPERIMENTAL|Hydrogen|1 L of hydrogen-rich water
62334436|NCT03625362|PLACEBO_COMPARATOR|Placebo|1 L of tap water
62334437|NCT00931671|OTHER|Exercise|Exercise
61938941|NCT04871074|ACTIVE_COMPARATOR|Mild dementia|Abnormal cognitive status of dementia as judged by consensus or expert review using NIA-AA 2018 criteria.
62334438|NCT03106194|OTHER|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.~Case management"
62334439|NCT06419868|EXPERIMENTAL|Intervention group|This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning.
62334440|NCT06419868|NO_INTERVENTION|Control group|Control group participants will be asked to respond to the baseline, after intervention, and four months after intervention. Once the study period is completed, and if the results show positive changes in the intervention group, they will be offered and asked to access the intervention.
62334441|NCT06323772||PDE6A patients|15 patients with mutation in PDE6A
62334442|NCT06323772||PDE6B patients|15 patients with mutation in PDE6B
62334443|NCT06323772||RHO patients|10 patients with mutation in RHO
62491981|NCT02627001|EXPERIMENTAL|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
62491982|NCT02627001|ACTIVE_COMPARATOR|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
62491983|NCT01360437|ACTIVE_COMPARATOR|Prasugrel|
62491984|NCT01360437|EXPERIMENTAL|Ticagrelor|
62491985|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
61938942|NCT03210623|EXPERIMENTAL|group A|subjects applying the stent retriever(TonbridgeMT)
61938943|NCT03210623|ACTIVE_COMPARATOR|group B|subjects applying Solitaire™
61938944|NCT03326726|EXPERIMENTAL|Chlorhexidine Gluconate|2% CHG
62334444|NCT01325480||Patients with heart failure and wide QRS|Patients undergoing a cardiac resynchronization therapy procedure
62491986|NCT06212869|EXPERIMENTAL|tDCS Group|active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
62491987|NCT06212869|SHAM_COMPARATOR|Sham tDCS Group|sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
62491988|NCT06212869|EXPERIMENTAL|Green Light Group|green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
62491989|NCT01286805|EXPERIMENTAL|Lumbar Plexus Blockade + CSE|The study group will receive a lumbar plexus blockade with 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, followed by a combined spinal-epidural.
62491990|NCT01286805|PLACEBO_COMPARATOR|Control Group|The control group will receive only a combined spinal-epidural.
62695047|NCT05860985|ACTIVE_COMPARATOR|group 1|primary vitrectomy surgery for retinal detachment
62695048|NCT05860985|ACTIVE_COMPARATOR|group 2|macular surgery: pucker, vitreomacular traction or macular hole
62695049|NCT05774041||SIS Group|Standard of care DBS surgery + use of (FDA-cleared) SIS System for preoperative target planning
62695050|NCT05774041||Control Group|Standard of care DBS surgery and preoperative target planning
61938945|NCT04291131||Veterans with COPD|Veterans with COPD who will participate in a physical activity intervention or exercise program
62137246|NCT05348603|EXPERIMENTAL|Traditional Letter + Banner|"* A mailed letter will invite the patient to set up a research profile in their patient portal; AND~* Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
62137247|NCT05348603|EXPERIMENTAL|Direct to Patient Message + Chatbot|"* An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~* A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
62137248|NCT05348603|EXPERIMENTAL|Direct to Patient Message + Banner|"* An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research AND~* Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
62334445|NCT04424355||Patients with suspected pneumonia COVID-19|"Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
62334446|NCT04424355||Patients with suspected pneumonia with COVID -19|"Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
62695051|NCT05615883|EXPERIMENTAL|AEP Group|First series of patients (10 pts) will be assigned to the Acute Exercise Protocol Group (AEP Group). The acute program consists in a single walking session on a treadmill lasting 80 minutes. The exercise session will begin with a 10-minute warm-up at the patient's self selected comfortable speed. On the ending of warm up, treadmill speed will be increased until reaching target HRR zone. Then the treadmill speed will be maintained stable throughout the exercise session. Cardiac workload will be monitored by a Sport-watch (Garmin Forerunner) and the walking biomechanics by a foot sensor (Garmin Running Dynamic Pod Sensore).
61938946|NCT01818661|EXPERIMENTAL|Tau positron emission tomography (PET)|All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.
61938947|NCT04885920||Participants With IBD|Participants diagnosed with moderately to severely active IBD (UC or CD) who initiated or are currently ongoing vedolizumab IV induction treatment in accordance with the current Summary of Product Characteristics (SmPC) or receiving vedolizumab ongoing or maintenance IV treatment with the option to switch to vedolizumab SC treatment, will be observed prospectively for at least 12 months.
61938948|NCT04112524||Patients from routine treatment|all 30 patients from Routine Treatment, only observational
61938949|NCT01841177|EXPERIMENTAL|Therapeutic Drug Monitoring|The intervention is \[1\] regular measurement of milrinone levels; \[2\]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
62137249|NCT05348603|EXPERIMENTAL|Chatbot + Banner|"* A real-time, interactive chatbot will encourage research participation and direct patients to learn more about clinical trial opportunities and trials that match their interests; AND~* Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care will inform patients of research opportunities."
62137250|NCT05348603|EXPERIMENTAL|Traditional Letter + Direct to Patient Message + Chatbot|"* A mailed letter will invite the patient to set up a research profile in their patient portal; AND~* An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~* A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
62334447|NCT02358252||Orthostatic hypotension|"Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV).~Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension."
61938950|NCT01841177|ACTIVE_COMPARATOR|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
61938951|NCT05803629|EXPERIMENTAL|68Ga-FAPI ,PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
62137251|NCT05348603|EXPERIMENTAL|Traditional Letter + Direct to Patient Message + Banner|"* A mailed letter will invite the patient to set up a research profile in their patient portal; AND~* An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~* Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
62137252|NCT05348603|EXPERIMENTAL|Traditional Letter + Chatbot + Banner|"* A mailed letter will invite the patient to set up a research profile in their patient portal; AND~* A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests.~AND~\*Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
62334448|NCT02358252||Non-orthostatic hypotension|Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension.
62491991|NCT05770011|ACTIVE_COMPARATOR|Conventional impression|Impression will be taken conventionally using rubber base open tray
62695052|NCT05615883|EXPERIMENTAL|CEP Group|Second series of patients (10 pts) will be assigned to the Chronic Exercise Protocol Group (CEP Group). The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks. The walking intensity will be defined during a treadmill test performedbefore the beginning of the exercise program. Each exercise session will beginwith a 10-minute warm-up at the patient's self selected comfortable speed. On the ending of warm up, patients will increase treadmill speed until reaching target HRR zone.Then the treadmill speed will be maintained stable throughout the exercise session. The first training session will be organized in hospital with supervision of research staff. Cardiac workload will be monitored by a Sport-watch (Garmin Forerunner) and walking biomechanics by a foot sensor (Garmin Running Dynamic Pod Sensore).
62695053|NCT05902442|EXPERIMENTAL|3DxSPLINT|
62695054|NCT05231915|OTHER|HOXB13 c.853delT mutation|Mutation is detected using Next Generation Sequencing (NGS) technique
62334449|NCT04030104|ACTIVE_COMPARATOR|Imagio IUS|Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
62334450|NCT04030104|EXPERIMENTAL|Imagio (IUS+OA)|Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.
62334451|NCT02857335|OTHER|study group|patients with benign intracranial hypertension ages 8-16 years
62334452|NCT00896753||patients with metastatic colon cancer|
62695055|NCT05148338|EXPERIMENTAL|Risk intervention group|Comprehensive risk factor management at specialized AF outpatient clinic concerning blood pressure, cholesterol, glycaemic control, physical inactivity, weight control, smoking, alcohol intake and sleep apnea.
61938952|NCT03339687|EXPERIMENTAL|Induction of Open Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer \& Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
61938953|NCT03339687|EXPERIMENTAL|Induction of a Closed Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer \& Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
61938954|NCT05922956|EXPERIMENTAL|patients with bipolar disorder 1|
61938955|NCT05922956|EXPERIMENTAL|patients with bipolar disorder 2|
61938956|NCT05922956|ACTIVE_COMPARATOR|healthy controls|
61938957|NCT03308955|ACTIVE_COMPARATOR|Grup B|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
61938958|NCT03308955|SHAM_COMPARATOR|Grup S|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
61938959|NCT05352373|ACTIVE_COMPARATOR|Rett Active Supplement|Females with clinical diagnosis of Rett syndrome treated orally daily with calcium carbonate, dose based on Dietary Reference Intake for age, for one year
61938960|NCT05352373|PLACEBO_COMPARATOR|Rett Placebo Supplement|Females with clinical diagnosis of Rett syndrome treated orally daily with sodium bicarbonate, dose based on equivalent weight for active supplement for age, for one year
61938961|NCT00250523||Traumatic injury|ICU Patients with blunt or penetrating injury
61938962|NCT00250523||2|Healthy volunteers
61938963|NCT00309478|EXPERIMENTAL|2 (CMF scheme)|6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil)
61938964|NCT00309478|EXPERIMENTAL|1 (Nol + Zol)|Zoladex (3 years) combined with Nolvadex (5 years)
61938965|NCT00494455|ACTIVE_COMPARATOR|1|Continuous subcutaneous glucose monitoring in patients without shock
62334453|NCT03857763|EXPERIMENTAL|Apatinib+Paclitaxel+Cisplatin+RT|Apatinib：250mg,po,qd, d1-35; Paclitaxel：50mg/m2 iv, d1，8，15，22，29; Cisplatin: 30mg/m2 iv, d1，8，15，22，29; Radiotherapy：41.4Gy/23f , 1.8Gy/f，5 f/w
62334454|NCT04860661|PLACEBO_COMPARATOR|N group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline
62334455|NCT04860661|EXPERIMENTAL|Es group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.
62334456|NCT00551720|EXPERIMENTAL|Standard Care|
62334457|NCT00551720|EXPERIMENTAL|Motivational Enhancement|
62491992|NCT05770011|EXPERIMENTAL|digital impression without splinting the scan bodies|Impression will be taken by intraoral scaner
62491993|NCT05770011|EXPERIMENTAL|digital impression with splinting the scan bodies|Impression will be taken by intraoral scaner
62491994|NCT02647853|EXPERIMENTAL|TAT4 Gel concentration A|TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
62695056|NCT05148338|ACTIVE_COMPARATOR|Control group|Standard of care. Treatment by cardiologist conform existing guidelines.
62695057|NCT00400322|ACTIVE_COMPARATOR|Valganciclovir|
62695058|NCT00400322|PLACEBO_COMPARATOR|Placebo|
62695059|NCT06638697|EXPERIMENTAL|exercise program|Participants will receive intervention of different physical training for 32 weeks and will be periodized in an equivalent way.
62695060|NCT06296225|EXPERIMENTAL|Vibration group|"Patients with acute stroke less than 7 days with only one paretic upper limb will be assessed for eligibility.~Patient will undergo 8 grip strength evaluation and 30 minutes of forehand muscles vibration."
62695061|NCT06630130|ACTIVE_COMPARATOR|Cohort A : T-DXd and Capecitabine combination|"Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1 and Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~-Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months) and Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"
62334458|NCT04836767||people with a history of COVID-19|"COVID-19 Group Inclusion Criteria~* Having been diagnosed with COVID-19 at least 12 weeks ago,~* Being literate,~* Being in the age range of 18-65,~* Volunteering to participate in research,~* To be clinically stable, to be under control if any accompanying comorbid conditions (such as hypertension, diabetes),~* Not having any orthopedic and neurological problems that might interfere with evaluating peripheral muscle strength, balance and exercise capacity.~COVID-19 Group Exclusion Criteria~* Those with an ICU hospitalization history due to the diagnosis of COVID-19,~* Recent myocardial infarction and pulmonary embolism.~* Having accompanying chronic diseases,~* Those who have any orthopedic or neurological disorders that will prevent walking,~* Another COVID-19 PCR Test positivity in the last 12 weeks,~* Not being able to cooperate and adapt to exercise test due to neurological influences such as cerebrovascular disease or psychiatric disorders,"
62491995|NCT02647853|EXPERIMENTAL|TAT4 Gel concentration B|TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
62491996|NCT02647853|PLACEBO_COMPARATOR|Placebo|Placebo product once daily to 50 cm2 for 14 days.
62491997|NCT04037488||Cohort: ADT patients|"All enrolled patient data entered in single group cohort. All patient who started androgen deprivation therapy for prostate cancer can included this cohort by following inclusion and exclusion criteria. We do not planned any intervention on this cohort. We measuring changes of body composition by Inbody 320 in the planned follow-up period.~We planned sub-group analysis for timing of intervention (Intervention 1) , ADT type(Intervention 2), LHRH agonist type(Intervention 3), patients age(Intervention 4), initial PSA level (Intervention 5) and Gleason Grade Group (Intervention 6)."
62491998|NCT03410030|EXPERIMENTAL|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
62491999|NCT01015287|EXPERIMENTAL|Non pre-treatment|A placebo oral loading dose is given at the time of diagnosis and a 60 milligrams (mg) oral loading dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.
62492000|NCT01015287|EXPERIMENTAL|Split Loading Dose|A 30 mg oral loading dose of prasugrel is given at diagnosis and a 30 mg oral dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days
62492001|NCT02385760|EXPERIMENTAL|Active|CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks
62492002|NCT02385760|PLACEBO_COMPARATOR|Placebo|Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks
62492003|NCT04780451|EXPERIMENTAL|Omega|
62492004|NCT04780451|PLACEBO_COMPARATOR|Placebo|
62492005|NCT02873182|EXPERIMENTAL|Autonomic nervous system monitoring|During standard intraoperative neuromonitoring, additional smooth muscle free-running and stimulated EMG will be recorded from corporal tissues (corpus spongiosum) of male and female genitalia from all patients who consent to participate in the study. EMG data and additional demographics and clinical data (e.g. operative time, adverse events) will be collected for each patient.
62492006|NCT04485806|OTHER|GPS / LM versus SPL/LM|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with light mineral oil (LM).
62492007|NCT04485806|OTHER|GPS/PO versus SPL/PO|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with paraffin oil (PO).
62492008|NCT04485806|OTHER|GPS/PO versus GPS/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 3D dishes (GPS).
61938966|NCT00494455|ACTIVE_COMPARATOR|2|continuous subcutaneous glucose monitoring in patients with shock
62492009|NCT04485806|OTHER|SPL/PO versus SPL/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 2D dishes (SPL).
62492010|NCT02559076|EXPERIMENTAL|Ten Steps Leaflet|Ten steps leaflet advice for healthy lifestyle
62492011|NCT02559076|NO_INTERVENTION|Usual care|Usual care given
62334459|NCT04836767||healthy people|"Healthy Group Inclusion Criteria~* Not having COVID-19,~* Being literate,~* Being in the age range of 18-65,~* Volunteering to participate in research. The Criteria for Not Including the Healthy Group in the Study~* Those who have any orthopedic or neuromuscular disorders that will prevent walking,~* Having any chronic illness or psychiatric conditions or mental afflictions that may interfere with cooperation or compliance with exercise tests."
61938967|NCT03633617|EXPERIMENTAL|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
61938968|NCT03633617|EXPERIMENTAL|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
62334460|NCT03188679|OTHER|mRNA sequencing|amniotic fluid for patients with CMV seroconversion during pregnancy will undergo mRNA sequencing
62492012|NCT03234907|PLACEBO_COMPARATOR|Induction Phase: Placebo|Placebo, IV, infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
62492013|NCT03234907|EXPERIMENTAL|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), IV infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
62492014|NCT03234907|PLACEBO_COMPARATOR|Maintenance Phase: Induction Placebo to Placebo Q4W|Participants who received placebo in the Induction Phase and achieved clinical response at Week 10 continued to receive placebo in the Maintenance Phase. Vedolizumab placebo-matching, IV infusion, once every 4 weeks (Q4W), from Week 14 to Week 58.
62492015|NCT03234907|EXPERIMENTAL|Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W|Participants who received placebo in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
62492016|NCT03234907|EXPERIMENTAL|Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W|Participants who received vedolizumab in the Induction Phase and achieved clinical response at Week 10 continued to receive vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching, IV infusion, Q8W, at Weeks 18, 26, 34, 42, 50 and 58 to maintain double-blind.
62492017|NCT03234907|EXPERIMENTAL|Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W|Participants who received vedolizumab in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
62492018|NCT01859260|NO_INTERVENTION|Control|
61938969|NCT03633617|EXPERIMENTAL|Part C: Dupilumab|Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
61938970|NCT00675259|EXPERIMENTAL|Neoadjuvant, Surgery, Adjuvant|Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel and carboplatin on days 1, 8, and 15. Definitive surgery with either lumpectomy or mastectomy along with axillary lymph node dissection for all pre neo adjuvant chemotherapy node-positive patients approximately 4-5 weeks after the completion of NCT. Use of additional adjuvant chemotherapy and/or radiation therapy depends upon the treating physicians' judgment. Radiation therapy should begin no sooner than 6 weeks after breast cancer surgery. All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
61938971|NCT05722457|OTHER|Investigation of the Effects of External Focused Ex. on Functionality in Individuals|Sub-branches of the study are planned as Investigation of the Effects of External Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain. Sub-branches of the study are planned as Investigation of the Effects of External Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain.
62492019|NCT01859260|EXPERIMENTAL|Intervention|CPAP/autopap
61938972|NCT05722457|OTHER|Investigation of the Effects of İnternal Focused Ex. on Functionality in Individuals|Sub-branches of the study are planned as Investigation of the Effects of internal Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain. Sub-branches of the study are planned as Investigation of the Effects of İnternal Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain.
61938973|NCT04186936|EXPERIMENTAL|Treatment Sequence AB|Participants will receive Test Product A (single dose of 2 caplets \[Combination caplet with loperamide hydrocloride \[HCl\] 2 milligram \[mg\] + simethicone 125 mg\]) orally on Day 1 followed by Reference Product B (single dose of 2 Imodium Express tablets-lyophilizate \[2\*2 mg loperamide HCl\] + 6 Espumisan capsules \[6\*40 mg simethicone\]) orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
61938974|NCT04186936|EXPERIMENTAL|Treatment Sequence BA|Participants will receive Reference product B orally on Days 1 followed by Test product A orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
61938975|NCT04794088|ACTIVE_COMPARATOR|Intravenous imatinib mesylate (Impentri®)|Patients receiving the active investigational medicinal product will be receiving imatinib 200mg b.i.d. (administered as an 8 mg/mL solution for i.v. infusion) for 7 days.
61938976|NCT04794088|PLACEBO_COMPARATOR|Placebo solution|Patients receiving the placebo comparator will be receiving the same amount of intravenous solution, however containing 0.01M acetate buffer with 1.9% glycerol.
62492020|NCT02512328|NO_INTERVENTION|Regular colonoscopy preparation|Comparison group. Regular colonoscopy preparation
62492021|NCT02512328|EXPERIMENTAL|APP supported colonoscopy preparation|APP as additional device for colonoscopy preparation
61938977|NCT04633356|EXPERIMENTAL|EUS-portal pressure gradient measurement (PPGM)|All patients would receive measurement of PPGM using the study device
61938978|NCT05229978||Patients with AD or mild cognitive impairment due to AD|All three 'arms' take part in a focus group or interview. The conversation topics will be the same (with the aim to gauge interpretations / needs / thoughts / feelings with regard data usage for research and the role health data engagement interfaces (Dynamic Consent) may play in this.
62334461|NCT02683525|EXPERIMENTAL|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
62334462|NCT05242549|EXPERIMENTAL|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance)"
62334463|NCT05242549|NO_INTERVENTION|wait-list|Routine care
62334464|NCT05029115||SGLT-2 inhibitor administration group|The group who administrated SGLT-2 inhibitor for hypoglycemic medication
62492022|NCT04768114|EXPERIMENTAL|Genetically-Informed RiskProfile|
62492023|NCT04768114|ACTIVE_COMPARATOR|Brief Cessation Advice|
62492024|NCT02533466|EXPERIMENTAL|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
62492025|NCT02533466|PLACEBO_COMPARATOR|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
62492026|NCT06262503|OTHER|Group1(Control )|Will receive conventional physiotherapy for one month and measure the pain intensity and lower extremity function
62492027|NCT06262503|EXPERIMENTAL|Group2 (Experimental)|Will receive conventional physiotherapy and Virtual Reality for phantom Pain for one month and measure the pain intensity and lower extremity function
62492028|NCT00697827|EXPERIMENTAL|1|In-Space
62492029|NCT00697827|ACTIVE_COMPARATOR|2|X STOP
62492030|NCT01446445|ACTIVE_COMPARATOR|1.A (Prophylaxis-SPC)|Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
62492031|NCT01446445|EXPERIMENTAL|1.B (Prophylaxis- PK model)|Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
62492032|NCT01446445|ACTIVE_COMPARATOR|2.A (Treatment-SPC)|Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
62334465|NCT05029115||control|The group who are not administrated SGLT-2 inhibitor
62492033|NCT01446445|EXPERIMENTAL|2.B (Treatment-PK model)|Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model
62492034|NCT04151368|EXPERIMENTAL|Robotic Nipple Sparing Mastectomy Arm|Patient cohort undergoing nipple sparing mastectomy with use of robotic dissection.
62492035|NCT05576831|NO_INTERVENTION|HPV-A VSCC|Patients with HPV-A VSCC and margins that are negative for cancer but \<8mm (regardless of in-situ (HSIL) margin status) will be eligible for the de-escalation prospective study.
62492036|NCT05576831|EXPERIMENTAL|HPV-I VSCC|If the margins are negative for cancer but \<8mm, or positive for Differentiated vulvar intraepithelial neoplasia (dVIN), and/or positive for p53 abnormality on IHC, these patients will be randomized (2:1) to further re-excision vs observation only.
62492037|NCT05065346|EXPERIMENTAL|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62492038|NCT01728987|ACTIVE_COMPARATOR|cholecalciferol|vitamin d (cholecalciferol) will be given as a capsule of 20.000 Iu twice a week
61938979|NCT05229978||Informal carers of patients with AD or mild cognitive impairment due to AD|All three 'arms' take part in a focus group or interview. The conversation topics will be the same (with the aim to gauge interpretations / needs / thoughts / feelings with regard data usage for research and the role health data engagement interfaces (Dynamic Consent) may play in this.
61938980|NCT05229978||Dementia experts/specialists|Given their expertise on dementia from a professional point of view, a focus group is conducted with dementia specialists in order to elicit their views and ideas on health data engagement interface like Dynamic Consent.
61938981|NCT03816982|ACTIVE_COMPARATOR|Bupivacaine HCl/Bupivacaine CISB|23 patients will be enrolled to receive a single-injection bupivacaine HCL interscalene block with bupivacaine CISB added.
61938982|NCT03816982|EXPERIMENTAL|Liposomal Bupivacaine Added to Interscalene Block|23 patients will be enrolled to receive a single-injection bupivacaine HCl interscalene block with liposomal bupivacaine added to same injection.
62334466|NCT05457933|EXPERIMENTAL|Dapagliflozin group|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
61938983|NCT06428682|EXPERIMENTAL|TXA group|Women undergoing immediate or delayed free flap breast reconstruction and receiving IV TXA
61938984|NCT06428682|PLACEBO_COMPARATOR|Placebo group|Women undergoing immediate or delayed free flap breast reconstruction and receiving same volume of IV saline
61938985|NCT06681168|EXPERIMENTAL|Stimulated group|"taVNS stimulation using the Parasym device or sham stimulation will be applied from the time of enrolment (between 7 to 15 days since admission in ICU) until day 90 post-enrolment.~Active stimulations will be carried out daily for 60 minutes twice daily during the acute phase and daily during the rehabilitation phase The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20)."
61938986|NCT06681168|SHAM_COMPARATOR|Control group|The Parasym device will be positioned on the patients as for the stimulated group (60 minutes twice daily during the acute phase - two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase but it won't be switched on.
62334467|NCT05457933|ACTIVE_COMPARATOR|Basal-bolus group|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
62492039|NCT01728987|PLACEBO_COMPARATOR|placebo|the placebo capsules are looking identical to the vitamin d capsules and contain medium chain triglycerides and arachis oil
62492040|NCT05753904|NO_INTERVENTION|Reverse Total Shoulder Arthroplasty|For RTSA using a deltopectoral approach, the Perform glenoid and humeral components of Tornier Stryker Reverse Shoulder system will be used for all cases. The sizes and offsets of the components will be chosen based on each patient's local anatomy which will vary among patients. The subscapularis tendon will be repaired using three transosseous nonabsorbable sutures whenever there is a reparable subscapularis tendon. After definitive implantation of the prosthesis is completed, in the 'no interventional' group, the wound will be closed in layers, and the shoulder will be immobilized in an abduction sling.
62492041|NCT05753904|EXPERIMENTAL|Reverse Total Shoulder Arthroplasty with Conjoint Tendon Resection|RTSA in the experimental group will be identical, except for that after definitive implantation of the prosthesis is completed, in the 'experimental' group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved. As mentioned above, the control group will not receive this conjoint tendon resection. Similarly, in the experimental group, the wound will be closed in layers, and the shoulder will be immobilized in an abduction sling.
62492042|NCT01812239|ACTIVE_COMPARATOR|Vaginal Progesterone|Daily administration of Vaginal Progesterone (200mg) Gel between 20 weeks of pregnancy and 34 weeks of pregnancy.
62492043|NCT01812239|PLACEBO_COMPARATOR|Placebo|Daily vaginal administration of Placebo gel (Vanicream)between 20 weeks of pregnancy and 34 weeks of pregnancy.
62492044|NCT06346535||Case1|Individuals diagnosed with major depressive disorder (MDD)
62492045|NCT06346535||Case2|Individuals diagnosed with stress induced exhaustion disorder (SED)
61938987|NCT03985111||No CVC inserted|Patients undergoing major elective colorectal resection without central venous catheter inserted pre-operatively
62334468|NCT00649649|EXPERIMENTAL|1|Quinapril Hydrochloride Tablets 40 mg
62334469|NCT00649649|ACTIVE_COMPARATOR|2|Accupril® Tablets 40 mg
62334470|NCT00736086||1|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
62334471|NCT03432910|OTHER|treatment group|Participants of the study undergo the standard stages of the clinical routine within a PAP therapy setting: a diagnostic night followed by one or two treatment nights.
62492046|NCT06346535||Control|Healthy Controls (HC) (i.e. individuals without symptoms of MDD or SED)
62492047|NCT05392959|PLACEBO_COMPARATOR|Placebo group|The patient will be treated in standard of care for type 2 diabetic mellitus and will receive a placebo (1 tablet) administered orally daily during 24 weeks
62695062|NCT06630130|ACTIVE_COMPARATOR|Cohort B : T-DXd and Capecitabine and Rilvegostomig combination|"* Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1 and Capecitabine 1000mg/m2 PO BID on D1-D14 with Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV with Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months) and Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"
62695063|NCT02556047|OTHER|Injections|"* Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length~* Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length~* Two injections of 0.1 ml saline per subject using Mantoux technique by N\&S"
62695064|NCT03751982|ACTIVE_COMPARATOR|Open-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is not synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
62695065|NCT03751982|EXPERIMENTAL|Closed-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
62695066|NCT04933708|EXPERIMENTAL|Labor Podcast Group|"1) Labor Podcast Group - Women randomized to this arm will receive access to a link to download six HUP physician created labor podcasts in addition to usual care during labor, delivery, and postpartum~o Podcast topics: Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth~* LAS-10 and Birth Satisfaction survey - Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~* EPDS - Women will receive this survey on postpartum day 7 via method they desire"
62695067|NCT04933708|NO_INTERVENTION|Usual Care|"2. Usual care Women randomized to this arm will receive usual care during labor, delivery, and postpartum with the following exceptions:~* LAS-10 and Birth Satisfaction survey Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~* EPDS Women will receive this survey on postpartum day 7 via method they desire"
62695068|NCT05115773|EXPERIMENTAL|Intraligamentary Anaesthesia|Before the restorative treatment of mandibular first molar, SOPIRA® 30 gauge extra-short cartridge needle attached to the tip of the SOPIRA® Citoject (SOPIRA® Heraeus Kulzer, Hanau, Almanya) pressure injector will be inserted into the periodontal sulcus 1-2 mm until resistance. The needle will be at an angle of 30 degrees to the long axis of the tooth. As recommended by the manufacturer, a total of 0.36 ml (mesiobuccal and distobuccal) 4% articaine solution containing 1:100,000 epinephrine (Ultracaine DS forte cartridge, Sanofi-Aventis GmbH, Almanya) will be injected slowly over 42 seconds by pressing the dosing lever 3 times for each root. If the anaesthesia will be failed, we would use the 4-point IL injection by injecting the mesiolingual sulcus and distolingual sulcus with the same technique.
62695069|NCT05115773|ACTIVE_COMPARATOR|Mandibular Anaesthesia|Before the restorative treatment of mandibular first molar, inferior alveolar nerve block will be provided using the direct standard method. The 27 gauge needle of a 2ml disposable plastic syringe (Ayset, Adana, Turkey) enters from the intersection of the internal oblique edge and the midline of the pterygomandibular raphe, and 1 ml of 4% articaine solution containing1:100,000 epinephrine (Ultracaine DS Forte ampul, Sanofi-Aventis GmbH, Almanya) will be injected slowly in 60 seconds. 15 minutes after the injection the anaesthesia of the lip/tongue will be checked by probing the labial mucosa of the ipsilateral canine tooth.
62695070|NCT04714255|EXPERIMENTAL|TICK-B group as Intervention group|Pediatric patients received TICK-B as a distraction in the TICK-B group Trace Image and Coloring for Kids-Book were conducted on the children undergoing the Cannulation procedure.
61938988|NCT03985111||CVC inserted|Patients undergoing major elective colorectal resection with a central venous catheter inserted pre-operatively
61938989|NCT04040244|EXPERIMENTAL|Exhaled Breath Analysis|Exhaled breathe condensate will be collected using R-tube and ReCIVA device over 5-10 minutes.
61938990|NCT01645137|EXPERIMENTAL|OMT|patients under usual medical care plus osteopathic treatment
61938991|NCT01645137|OTHER|control|patients under usual medical care
61938992|NCT06085794|ACTIVE_COMPARATOR|Percutaneous nephrolithotomy|the standard-PCNL group (will be performed by urologists with more than 2 years of experience of PCNL), Fluoroscopic-guided percutaneous renal access will be done for patients in the prone position.
61938993|NCT06085794|ACTIVE_COMPARATOR|Endoscopic combined intrarenal surgery|the ECIRS group (will be performed by urologists with more than 2 years of experience of PCNL and RIRS), patients will be oriented in the GMSV position.flexible ureteroscope will be inserted through the access sheath to observe the stone distributions. Under the guidance of fluoroscopy and endoscopic vision, a 18-20 Fr percutaneous tract will be established using sequential fascial dilators and a matching sheath for stone manipulation simultaneously. We use a 12-F nephroscope (Karl Storz).
61938994|NCT00072631|EXPERIMENTAL|1 erlotinib|
62334472|NCT05890287|EXPERIMENTAL|Cohort A in advanced stages of first-line ± endocrine therapy without CDK4/6 inhibitors|Chidamide tablets, specification 5mg/ tablet. Administration method: Oral, 30mg/ time, twice a week; Endocrine drugs: (TAM, AI, fluvestran, etc.) According to patients' previous endocrine treatment, different endocrine drugs were selected according to researchers' judgment, and the dosage was used according to the instructions; OFS drugs (for premenopausal patients only).
62334473|NCT05890287|EXPERIMENTAL|Late-stage first-line ± endocrine therapy with CDK4/6 inhibitors in cohort B|Chidamide tablets, specification 5mg/ tablet. Administration method: Oral, 30mg/ time, twice a week; Endocrine drugs: (TAM, AI, fluvestran, etc.) According to patients' previous endocrine treatment, different endocrine drugs were selected according to researchers' judgment, and the dosage was used according to the instructions; OFS drugs (for premenopausal patients only).
62334474|NCT02567110||Participants with Major Depression|Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
62334475|NCT02567110||Participants without Depression|Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
62334476|NCT03219593|EXPERIMENTAL|Apatinib Group|take apatinib orally (500mg/d, once a day, continuously)
62334477|NCT02364206|EXPERIMENTAL|LY2228820 + TMZ + Radiotherapy|"addition of LY2228820 to standard radiotherapy and concomitant treatment by temozolomide (TMZ).~LY2228820 will be administered orally for two 28 day cycles, from one week before the beginning of radiotherapy, and during standard chemoradiotherapy. Three dose levels of LY2228820 will be tested.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
61938995|NCT05240599|EXPERIMENTAL|Shaker|"Shaker exercises consist of isotonic and isometric contractions of the neck flexor muscles. Participants will be asked to lie on their back with their knees straight. Participants will first wait for 60 seconds by lifting their head and looking at their feet. He will repeat the movement three times in total, resting for 60 seconds in between. Then, the participants will raise their heads again, look at the toes, and put their head back on the bed without waiting. By repeating this movement 30 times in total, the exercise program will be completed.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components to be performed once, in 3 times per day."
62334478|NCT00276978|EXPERIMENTAL|Aripiprazole|Aripiprazol augmentation therapy
62334479|NCT01811849|EXPERIMENTAL|BIOD-238|Subcutaneous injection
61938996|NCT05240599|EXPERIMENTAL|Chin Tuck Against Resistance|"In this exercise, participants have to place an inflatable ball with a diameter of 12 cm between their chin and sternum. This exercise has two subcomponents, isotonic and isometric. In the isometric component, individuals must compress the ball with maximum force between their chin and sternum, hold for 60 seconds, and rest for 60 seconds. One should repeat this isometric component 3 times. In the isotonic parameter, on the other hand, the participants must slowly squeeze the ball between their chin and sternum 30 times with the maximum force they can do. Participants will perform the exercise in an upright sitting position on a back-supported chair.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components repeated 10 times in 3 setsand 3 times per day."
61938997|NCT05240599|EXPERIMENTAL|Eccentric Chin Closure|This exercise will be performed in the form of closing the chin against the manual resistance to be given from the tip of the mandible, starting from the maximum voluntary mouth opening. In this way, eccentric contraction will be created as the suprahyoid muscles will move from the shortest position to the longest position with resistance. Participants will perform the exercise by maintaining the upright posture in the upright sitting position on the back-supported chair. Volunteers will perform this exercise with 10 repetitions in 3 sets and 3 times per day.
61938998|NCT00783965|EXPERIMENTAL|Arm I|Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.
61938999|NCT00783965|EXPERIMENTAL|Arm II|Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.
61939000|NCT03049618|EXPERIMENTAL|Treatment (pembrolizumab, sEphB4-HSA)|Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
61939001|NCT02395016|EXPERIMENTAL|Nimotuzumab and Gemcitabine|"nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
61939002|NCT02395016|PLACEBO_COMPARATOR|Placebo and Gemcitabine|"placebo,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
61939003|NCT06558136|EXPERIMENTAL|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and saliva obtained.
61939004|NCT06558136|EXPERIMENTAL|Gingivitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
61939005|NCT06558136|EXPERIMENTAL|Periodontitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
61939006|NCT02830061||TYAC|Teenagers and young adults who have received a cancer diagnosis which puts them at moderate-to-high risk of fertility impairment. Semi-structured interviews will take place with each individual participant.
61939007|NCT01470859|ACTIVE_COMPARATOR|pramipexole|0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
61939008|NCT01470859|ACTIVE_COMPARATOR|Levodopa|Sinemet CR CR， Controlled Release
61939009|NCT01904058|EXPERIMENTAL|LUM001 and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
61939010|NCT01904058|PLACEBO_COMPARATOR|Placebo and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
61939011|NCT02851940|EXPERIMENTAL|A (Rubber Band Ligation)|15 patients
61939012|NCT02851940|EXPERIMENTAL|B (Hypertonic Saline Infusion)|15 patients
61939013|NCT04439149|EXPERIMENTAL|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62137253|NCT05348603|EXPERIMENTAL|Direct to Patient Message + Chatbot + Banner|"* An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~* A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests; AND~* Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
62334480|NCT01811849|EXPERIMENTAL|BIOD-250|Subcutaneous injection
62334481|NCT01811849|ACTIVE_COMPARATOR|Humalog|Subcutaneous injection
62334482|NCT01067508|EXPERIMENTAL|Fiji Water|Participants are asked to consume one liter of this silicon-rich water daily for three months.
62334483|NCT01067508|NO_INTERVENTION|Aquafina Water|Participants are asked to drink one liter of this deionized water daily for three months.
62334484|NCT06496321|EXPERIMENTAL|Conventional|26 patients will be randomized to this group. The vein harvest technique will be the conventional one.
62334485|NCT06496321|EXPERIMENTAL|No Touch|"26 patients will be randomized to this group. The vein harvest technique will be the no touch."
62334486|NCT02348411|EXPERIMENTAL|ExAblate Treatment group|
62695071|NCT04714255|NO_INTERVENTION|Standard care provided group as control group|Pediatric patients received standard care (routine care) in the control group.
61939014|NCT03054753|OTHER|Abduction brace wearing time analysis|The abduction brace wearing time analysis is performed in patients, who undergo a rotator cuff repair with postoperative abduction brace treatment
61939015|NCT05639465|EXPERIMENTAL|JoH-C19|After initial randomization, some participants will be assigned to receive JoH-C19
62137254|NCT05348603|EXPERIMENTAL|Traditional Letter + Direct to Patient Message + Chatbot + Banner|"* A mailed letter will invite the patient to set up a research profile in their patient portal; AND~* An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~* A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests; AND~* Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
62137255|NCT05543044|EXPERIMENTAL|TAY receiving peer mentor intervention|Transition age youth with EDs (n=35) will receive a peer mentor delivered transition intervention
62137256|NCT01571557||OZURDEX®|OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care.
62137257|NCT05403359||Ward (e.g., pulmonology ward, COVID-unit, etc.),|"* WP1A: Patients with WHO clinical progression scale class 4-5 (i.e., no oxygen therapy) admitted to the ward with laboratory-confirmed COVID-19.~* WP1B: Adult patients admitted to the ward with laboratory-confirmed COVID-19 and on at least oxygen therapy."
62137258|NCT05403359||Intensive Care Unit|Adult patients (≥18 years) admitted to the ICU with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) according to the Berlin definition criteria (i.e., receiving invasive mechanical ventilation).
62137259|NCT05525455|EXPERIMENTAL|Single agent TT-816|Escalating doses followed by expansion targeting advanced cancers
62137260|NCT05525455|EXPERIMENTAL|Combination TT-816 plus a PD-1 inhibitor|Escalating doses followed by expansion targeting advanced cancers
62334487|NCT00808327|ACTIVE_COMPARATOR|1|Bupivacaine alone
62334488|NCT00808327|ACTIVE_COMPARATOR|2|Bupivacaine plus Fentanyl
62334489|NCT03948659||Cirrhotic patients in intensive care unit|
62334490|NCT01982604|EXPERIMENTAL|Sequence (Group) 1|"Subjects randomized to Sequence 1 will receive TI in the following sequence:~TI-Inhalation Powder A TI-Inhalation Powder B~\*30 units (10 units + 20 units)"
62334491|NCT01982604|EXPERIMENTAL|Sequence (Group) 2|"Subjects randomized to Sequence 2 will receive TI in the following sequence:~TI-Inhalation Powder B TI-Inhalation Powder A~\*30 units (10 units + 20 units)"
62334492|NCT02617342|EXPERIMENTAL|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
62334493|NCT02617342|NO_INTERVENTION|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
62334494|NCT04628403|NO_INTERVENTION|control|
62334495|NCT04628403|EXPERIMENTAL|shock waves|
62334496|NCT04628403|EXPERIMENTAL|massage|
62334497|NCT04628403|EXPERIMENTAL|lasertherapy|
62334498|NCT05604469||Group A (liver faluire patients with pruritus)|Patients with hepatic illness (autoimmune liver diseases, chronic viral hepatitis, and drug-induced liver injury)
62334499|NCT05604469||Group B (liver faluire patients without pruritus)|Patients with hepatic illness (autoimmune liver diseases, chronic viral hepatitis, and drug-induced liver injury)
62334500|NCT05604469||Group C (renal faluire patients with pruritus)|
61939016|NCT05639465|ACTIVE_COMPARATOR|Switch off Get Active|After initial randomization, some participants will be assigned to receive Switch Off Get Active
62137261|NCT00358943||Patients in ICGG Gaucher Registry|No experimental intervention is given. A patient with Gaucher Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
62137262|NCT00358943||Pregnant women with confirmed diagnosis of Gaucher disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Gaucher disease who are participating in the ICGG Gaucher Registry and consented to participate in the Gaucher Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy and irrespective of the commercial product with which she may be treated.
62137263|NCT05508607||Pre-Implementation|
62137264|NCT05508607||Post-Implementation|
62137265|NCT00026689||1/Cohort 1|Patients suspected of having, or with biopsy proven malignant disease or patients with a benign condition for whom radiotherapy is a potential treatment
62334501|NCT05604469||Group D (renal faluire patients without pruritus)|
62334502|NCT02273050|EXPERIMENTAL|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
62334503|NCT02273050|ACTIVE_COMPARATOR|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
62334504|NCT02273050|ACTIVE_COMPARATOR|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
62695072|NCT05549622|OTHER|Low-soluble fiber diet|
62695073|NCT05549622|ACTIVE_COMPARATOR|High-soluble fiber diet|
62695074|NCT06633991|EXPERIMENTAL|instructions inducing hope and optimism|"The verbal instruction inducing more hope and optimism will be: The present therapy is a very effective one for your specific type of headache. By taking it, a large number of patients experienced significant pain relieve and improvement in functional capacity"
61939017|NCT01455831|EXPERIMENTAL|Extended peri-operative thromboprophylaxis|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
61939018|NCT01455831|ACTIVE_COMPARATOR|Standard thromboprophylaxis|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
61939019|NCT05938530|EXPERIMENTAL|Sirolimus drug-coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the graft vein junction by inflating the balloon for 2 minutes at rated burst pressure (typically 12 to 14ATM).
61939020|NCT05938530|ACTIVE_COMPARATOR|Stent graft|Stent graft is the current standard of care for treatment of arteriovenous graft malfunction. A stent graft will be deployed at the graft vein junction.
61939021|NCT02080910|EXPERIMENTAL|Psychoeducational program|Psychoeducational program consisted of (1) two inpatient sessions of face-to-face education on stroke and its caregiving; (2) six biweekly problem-solving training via telephone contacts after the discharge of stroke survivors
61939022|NCT02080910|NO_INTERVENTION|Usual care|
61939023|NCT01822704|ACTIVE_COMPARATOR|Control|This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
62695075|NCT06633991|PLACEBO_COMPARATOR|neutral instructions|"The verbal instruction inducing hope and optimism will be: The present therapy is an effective one for your specific type of headache. By taking it, a large number of patients experienced pain relieve and improvement in functional capacity."
61939024|NCT01822704|EXPERIMENTAL|Low intensity vibration|This group will receive three 45-minute whole body vibration training sessions for 10 consecutive weeks. The vibration will be of low intensity (frequency: 20 Hertz, amplitude: 1mm).
62492048|NCT05392959|EXPERIMENTAL|dapagliflozin group|The patient will be treated in standard of care for type 2 diabetic mellitus and will receive Dapagliflozin 10 mg (1 tablet) administered orally daily during 24 weeks
62492049|NCT04267692|EXPERIMENTAL|Harm Reduction Treatment Circles (HaRTC)|Participants will attend 8, weekly Harm Reduction Treatment Circles. We will not limit participants' access to other treatment or services.
61939025|NCT01822704|EXPERIMENTAL|High intensity vibration|This group will receive three 45-minute whole body vibration training sessions per week for 10 consecutive weeks.The vibration will be of higher intensity than the low intensity vibration group (frequency: 30 Hertz, amplitude: 1mm).
61939026|NCT03603054|ACTIVE_COMPARATOR|Active neck mobilization|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
61939027|NCT03603054|EXPERIMENTAL|Active Mobilization of the Sciatic nerve|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
61939028|NCT01969643|EXPERIMENTAL|LV Dose Escalation|
61939029|NCT01969643|EXPERIMENTAL|LV + Trastuzumab|
61939030|NCT01969643|EXPERIMENTAL|LV Monotherapy|LV will be given at the recommended dose (at or below the monotherapy MTD determined in the LV dose escalation arm).
61939031|NCT01869491|ACTIVE_COMPARATOR|Sodium Alginate Double Action Tablets|Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
61939032|NCT01869491|PLACEBO_COMPARATOR|Matching placebo tablets|Matching placebo tablets, 2 tablets four times daily
62137266|NCT01953224|EXPERIMENTAL|Game-based intervention|This arm will receive the game intervention, which will include provision of a mobile smartphone device, cellular data service, the game application loaded onto the device, credit to load approximately 40-50 songs onto the device, headphones, and an armband for wearing the device. Participants will also receive weekly counseling calls.
62492050|NCT04089462|OTHER|"1. Five sessions per period - Two sessions per period"|
62137267|NCT01953224|NO_INTERVENTION|Wait list control|This group will receive no intervention until after completion of the final assessment of the randomized trial. Then, they will receive the full intervention.
62492051|NCT04089462|OTHER|"2. Two sessions per period - Five sessions per period"|
62492052|NCT06170762|EXPERIMENTAL|Sodiumhexametaphosphate|
62492053|NCT06170762|ACTIVE_COMPARATOR|MTA|
62492054|NCT06402227|EXPERIMENTAL|gamified instruction|
62492055|NCT06402227|OTHER|conventional lesson lecture|
61939033|NCT00562029|EXPERIMENTAL|DJB patient|Patient has undergone a duodeno-jejunal bypass
61939034|NCT02511990|EXPERIMENTAL|Group 1A|"HIV-infected individuals Off ART, HIV-1 viral load \< 100,000 copies/ml or On ART, HIV-1 viral load \< 500 copies/ml~3 mg/kg, single dose IV administration of 10-1074"
61939035|NCT02511990|EXPERIMENTAL|Group 1B|"HIV-infected individuals Off ART, HIV-1 viral load \< 100,000 copies/ml or On ART, HIV-1 viral load \< 500 copies/ml~10 mg/kg, single dose IV administration of 10-1074"
62334505|NCT04622787||Tuscany, Italy|Infants at risk of Cerebral Palsy in Tuscany, Italy
62334506|NCT04622787||Infants at risk of Cerebral Palsy in Georgia|Infants at risk of Cerebral Palsy in Georgia
62492056|NCT06083623|EXPERIMENTAL|TNM001|
62492057|NCT06083623|PLACEBO_COMPARATOR|Placebo|
62492058|NCT03530241|EXPERIMENTAL|MRCP positive|
62492059|NCT03530241|ACTIVE_COMPARATOR|MRCP negative|
62492060|NCT00905541|NO_INTERVENTION|No treatment|Phase A: No treatment
62695076|NCT05821205|EXPERIMENTAL|Narrative Persuasion (randomized weekly, 1 of 4 options)|Narrative persuasion will be youth or provider testimonial about violence in their community and/or how SafERteens helped their development and reduced violence. Randomized weekly.
62695077|NCT05821205|EXPERIMENTAL|Reciprocity (randomized weekly, 1 of 4 options)|The reciprocity engagement strategy (ES) will be operationalized as an unsolicited $5 gift card with the SafERteens Logo. Randomized weekly.
62492061|NCT00905541|EXPERIMENTAL|simvastatin chronic|Phase B: 40 mg/day simvastatin
62492062|NCT00905541|EXPERIMENTAL|simvastatin acute-on-chronic|Phase C: 80 mg simvastatin acute-on-chronic
62492063|NCT03892343||Transplant recipients|Patients undergoing live donor kidney transplant.
62492064|NCT03892343||Non-transplanted|Patients on the deceased donor waiting list without prospect of a live donor transplant.
62137268|NCT03367338|ACTIVE_COMPARATOR|Group A|Participants in group A consumed a 2-day very low-phosphate diet with PPR of 8 mg/g, followed by a 5-day washout period in which they adhered to usual diets, and then consumed a 2-day low-phosphate diet with PPR of 10 mg/g.
62137269|NCT03367338|ACTIVE_COMPARATOR|Group B|Compared with group A, the opposite order of low-phosphate diets will be prescribed in group B.
62492065|NCT02752854||Group A|Pain threshold measurement in high altitude
62334507|NCT04622787||Sri-Lanka|Infants at risk of Cerebral Palsy in Sri-Lanka
62334508|NCT04622787||Denmark|Infants at risk of Cerebral Palsy in Denmark
62334509|NCT04622787||Infants at risk of Cerebral Palsy in the Netherlands|the Netherlands
62334510|NCT04622787||remote Queensland, Australia|Infants at risk of Cerebral Palsy in remote Queensland, Australia
62334511|NCT04622787||Medical professionals|Medical/healthcare providers from all involved geographic locations that work with infants at risk or with diagnosis of cerebral palsy will be provided opportunities for the participation in face-to-face and/or e-learning platform trainings on the the international early detection guidelines.
62334512|NCT00862849|EXPERIMENTAL|Insulin Lispro, Regular Human Insulin, rHuPH20|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C).~Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20)~Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20~Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone~There was a washout period of 3 to 14 days between interventions.~The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections."
62334513|NCT02233400|EXPERIMENTAL|Treatment|Group 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
62492066|NCT02752854||Group B|Pain threshold measurement in low altitude
62334514|NCT02233400|NO_INTERVENTION|Control|Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
62334515|NCT04369183||Study Group|Patients with primary focal segmental glomerulosclerosis or minimal change disease who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.
62334516|NCT01490268|ACTIVE_COMPARATOR|Sufentanil Group 1|Sufentanil Low Titration
62334517|NCT01490268|ACTIVE_COMPARATOR|Sufentanil Group 2|Sufentanil High Titration
62334518|NCT04520022|EXPERIMENTAL|FURESTEM-CD Inj|
62334519|NCT04838925|EXPERIMENTAL|Mobile Neurofeedback|Participants engage in the use of a mobile neurofeedback intervention, which involves using a mobile app paired with an EEG headset, to achieve a calm, relaxed state. Participants will be instructed to use the intervention at a minimum of 10 minutes a day, 4 times a week for a total of 12 weeks.
62334520|NCT05250271|OTHER|Treatment sequence 1|Sequence of the treatments: Glucose (15g) - Glucose (5g) -Protein bar
62334521|NCT05250271|OTHER|Treatment sequence 2|Sequence of the treatments: Glucose (15g) - Protein bar - Glucose (5g)
62334522|NCT05250271|OTHER|Treatment sequence 3|Sequence of the treatments: Glucose (5g) - Glucose (15g) - Protein bar
62492067|NCT00385736|EXPERIMENTAL|Adalimumab 80/40|
62492068|NCT00385736|EXPERIMENTAL|Adalimumab 160/80/40|
62492069|NCT00385736|PLACEBO_COMPARATOR|Placebo|
62137270|NCT05170620|EXPERIMENTAL|Patients|Patients with squamous intraepithelial lesions of the lower anogenital tracts will receive laser ablation.
62137271|NCT02431273|EXPERIMENTAL|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
62137272|NCT02431273|EXPERIMENTAL|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
62137273|NCT02431273|EXPERIMENTAL|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
62137274|NCT04919499|EXPERIMENTAL|Single rising dose part: low-dose BI 765128|Diabetic retinopathy (DR) patients with Diabetic Macular Ischemia (DMI) previously treated with panretinal photocoagulation (PRP) received one single intravitreal injection of low-dose BI 765128.
62492070|NCT05909436|EXPERIMENTAL|Dose escalation and expansion of GLS-012 monotherapy and combination with GLS-010|
62492071|NCT01513941|EXPERIMENTAL|Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)|All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
62492072|NCT00287053|EXPERIMENTAL|Placebo|Divalproex Sodium
62492073|NCT00287053|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Comparator
62492074|NCT03134053|EXPERIMENTAL|extracorporeal shock-wave|
62492075|NCT03134053|SHAM_COMPARATOR|massage|
62492076|NCT06010823|EXPERIMENTAL|Intervention|All the participants allocated to this group will undergo rehabilitation according to each medical center's standard rehabilitation practice. In addition, the participants will receive 12 therapy sessions incorporating error enhancement (3 session a week, for a period of 4 weeks), lasting approximately 25-30 minutes each.
62334523|NCT05250271|OTHER|Treatment sequence 4|Sequence of the treatments: Glucose (5g) - Protein bar - Glucose (15g)
61939036|NCT02511990|EXPERIMENTAL|Group 1C|"HIV-infected individuals Off ART, HIV-1 viral load \< 100,000 copies/ml or On ART, HIV-1 viral load \< 500 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
61939037|NCT02511990|EXPERIMENTAL|Group 1D|"HIV-infected individuals Off ART, HIV-1 viral load \< 100,000 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
61939038|NCT02511990|EXPERIMENTAL|Group 2A|"HIV-uninfected individuals~3 mg/kg, single dose IV administration of 10-1074"
61939039|NCT02511990|EXPERIMENTAL|Group 2B|"HIV-uninfected individuals~10 mg/kg, single dose IV administration of 10-1074"
61939040|NCT02511990|EXPERIMENTAL|Group 2C|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
61939041|NCT02511990|EXPERIMENTAL|Group 2D|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
61939042|NCT00309738|EXPERIMENTAL|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
61939043|NCT00309738|ACTIVE_COMPARATOR|Simvastatin 40 mg QD|Simvastatin 40 mg once daily
61939044|NCT04350866||Minneapolis VAMC|BBTI; ERIC strategies
61939045|NCT04350866||Philadelphia VAMC|BBTI; ERIC strategies
61939046|NCT04350866||Durham VAMC|BBTI; ERIC strategies
61939047|NCT04350866||Baltimore VAMC|BBTI; ERIC strategies
61939048|NCT04779697|EXPERIMENTAL|GLP-1a|GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
61939049|NCT04779697|PLACEBO_COMPARATOR|Placebo|Placebo pen administered weekly over 12 weeks
61939050|NCT06357312|EXPERIMENTAL|Group with distal screw|Patients who have been randomly selected for this procedure are included.
62137275|NCT04919499|EXPERIMENTAL|Single rising dose part: medium-dose BI 765128|Diabetic retinopathy (DR) patients with Diabetic Macular Ischemia (DMI) previously treated with panretinal photocoagulation (PRP) received one single intravitreal injection of medium-dose BI 765128.
62137276|NCT04919499|EXPERIMENTAL|Single rising dose part: high-dose BI 765128|Diabetic retinopathy (DR) patients with Diabetic Macular Ischemia (DMI) previously treated with panretinal photocoagulation (PRP) received one single intravitreal injection of high-dose BI 765128.
62137277|NCT04919499|EXPERIMENTAL|Multiple dose part: high-dose BI 765128|Diabetic retinopathy (DR) patients with Diabetic Macular Ischemia (DMI) previously treated with panretinal photocoagulation (PRP) received 3 single intravitreal injection of high-dose BI 765128 at week 1, 4 and 8.
62334524|NCT05250271|OTHER|Treatment sequence 5|Sequence of the treatments: Protein bar - Glucose (15g) - Glucose (5g)
62334525|NCT05250271|OTHER|Treatment sequence 6|Sequence of the treatments: Protein bar - Glucose (5g) - Glucose (15g)
62137278|NCT04919499|SHAM_COMPARATOR|Multiple dose part: Sham|Diabetic retinopathy (DR) patients with Diabetic Macular Ischemia (DMI) previously treated with panretinal photocoagulation (PRP) received 3 single intravitreal sham injection at week 1, 4 and 8.
62334526|NCT02481336||Cancer patients receiving chemotherapy|"Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage III \& high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX~1. Questionnaires~2. Peripheral nervous system examination~3. Whole Genome Sequence"
62334527|NCT01570400|EXPERIMENTAL|CBM training program variant 1 + iCBT|Cognitive bias modification training program variant 1 combined with iCBT
62334528|NCT01570400|EXPERIMENTAL|CBM training program variant 2 + iCBT|Cognitive bias modification training program variant 2 combined with iCBT
61939051|NCT06357312|EXPERIMENTAL|Group without distal screw|Patients who have been randomly selected for this procedure are included.
61939052|NCT02463968||CHRONIC CHIKUNGUNYA|Twenty participants with chronic chikungunya defined as continued knee joint effusion at least three months after diagnosis of chikungunya will be enrolled in the study.
61939053|NCT02463968||ACUTE CHIKUNGUNYA|Ten participants with acute chikungunya defined as clinical symptoms of chikungunya with acute fever and joint pain within 10 days the onset of symptoms.
61939054|NCT02463968||HEALTHY CONTROLS|Five healthy controls will have only blood drawn once.
61939055|NCT00904306|PLACEBO_COMPARATOR|Sugar pill|6 months treatment with placebo
61939056|NCT00904306|ACTIVE_COMPARATOR|low dose|600ug/day chromium picolinate for 6 months
61939057|NCT00904306|ACTIVE_COMPARATOR|high dose chromium picolinate|1000 ug/day
61939058|NCT05382533|EXPERIMENTAL|Hypertriglyceridemia intervention (group A)|"* Carbohydrates: ≤ 50 en% (sucrose + glucose + fructose ≤ 10 en%, where sucrose ≤ 5 en% and fructose ≤ 20 g/d)~* Fat: 30-35 En%~* Protein: 20 En%~* marine n3 PUFA (EPA/DHA): ≥ 4000 mg/d (10 g fish oil)"
61939059|NCT05382533|NO_INTERVENTION|Hypertriglyceridemia control (group B)|no menu plans, no study foods
61939060|NCT05382533|EXPERIMENTAL|Prediabetes intervention (group C)|"* Carbohydrates: 40 ± 2 En%~* Sucrose + glucose + fructose ≤ 10 En%~* Free sugars \< 5% of daily energy~* Fat: 40 ± 2%~* Protein: 20 ± 2 En%~* n3 PUFA: ≥ 500 mg/d"
61939061|NCT05382533|NO_INTERVENTION|Prediabetes control (group D)|no menu plans, no study foods
61939062|NCT06169293|EXPERIMENTAL|I-AM-WELL program|
61939063|NCT06169293|NO_INTERVENTION|Waitlist control|Students will receive the intervention after data is collected from all three time points
61939064|NCT01543971|ACTIVE_COMPARATOR|TXA127|(Group A) TXA127 at 300 mcg/kg once a day for 5 days
61939065|NCT01543971|ACTIVE_COMPARATOR|Neupogen|(Group B) Neupogen 10 mcg/kg once a day for 5 days
61939066|NCT01543971|ACTIVE_COMPARATOR|TXA127 and Neupogen|(Group C) both TXA127 (300mcg/kg) and Neupogen (10mcg/kg) together once a day for 5 days
61939067|NCT01296438|EXPERIMENTAL|Treatment sequence 1|
61939068|NCT01296438|ACTIVE_COMPARATOR|Treatment sequence 2|
61939069|NCT04416633|OTHER|Durvalumab|Single arm, Durvalumab , IV
61939070|NCT05750160|NO_INTERVENTION|Control|Given education only
61939071|NCT05750160|EXPERIMENTAL|Intervention|Given education and music therapy
61939072|NCT04924959||Modeling Group|
61939073|NCT04924959||Validation Group|
61939074|NCT01526772||Patients who have undergone RYGB|Patients who have undergone RYGB and have been referred for an EGD
61939075|NCT00415350|ACTIVE_COMPARATOR|Azithromycin treatment 1|
61939076|NCT00415350|PLACEBO_COMPARATOR|Placebo 2|
61939077|NCT06681129||Neonates|Any neonate or infant up to 2 years of age scheduled for an intestinal surgery or an esophogastroduodenoscopy or colonoscopy.
61939078|NCT05361421|EXPERIMENTAL|Intensive targeting group|Intensive lipid loweroing therapy with LDL-cholesterol goal of \<55mg/dL
61939079|NCT05361421|ACTIVE_COMPARATOR|Conventional therapy group|Initiate and maintain moderate intensity statin therapy
61939080|NCT00736957|EXPERIMENTAL|Tramadol HCL plus Acetaminophen|
61939081|NCT03588871|EXPERIMENTAL|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
61939082|NCT03588871|EXPERIMENTAL|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
61939083|NCT03588871|EXPERIMENTAL|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
61939084|NCT00725504|EXPERIMENTAL|Lidocaine infusion|Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.
61939085|NCT03516812|EXPERIMENTAL|Treatment (olaparib, testosterone enanthate or cypionate)|Patients receive olaparib PO BID on days 1-28 and testosterone enanthate or cypionate IM on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61939086|NCT03366012|OTHER|Cytosponge Test|This arm will include individuals without formal diagnosis of Barrett's esophagus.
61939087|NCT05131360|PLACEBO_COMPARATOR|Introduction Only|This is the control; participants only partake in one day's worth of the introduction or foundational mindfulness activities on the HMI app.
61939088|NCT05131360|EXPERIMENTAL|Purpose Only|Participants partake in the introduction or foundational mindfulness for one day and then perform purpose-based mindfulness techniques for 5 days on the HMI app.
61939089|NCT05131360|EXPERIMENTAL|Connection Only|Participants partake in the introduction or foundational mindfulness for one day and then perform connection-based mindfulness techniques for 5 days on the HMI app.
61939090|NCT05131360|EXPERIMENTAL|Connection and Purpose|Participants partake in the introduction or foundational mindfulness for one day and then perform connection and purpose-based mindfulness techniques for 5 days on the HMI app.
61939091|NCT05131360|EXPERIMENTAL|Awareness Only|Participants partake in the introduction or foundational mindfulness for one day and then perform awareness-based mindfulness techniques for 5 days on the HMI app.
61939092|NCT05131360|EXPERIMENTAL|Awareness and Purpose|Participants partake in the introduction or foundational mindfulness for one day and then perform awareness and connection-based mindfulness techniques for 5 days on the HMI app.
62137279|NCT00507884||3 Tesla MRI|Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
62334529|NCT00788775|EXPERIMENTAL|Nilotinib|Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.
62492077|NCT06010823|NO_INTERVENTION|Control|All participants allocated to this study group will undergo rehabilitation according to each medical center's standard rehabilitation practice.
61939093|NCT05131360|EXPERIMENTAL|Awareness, Purpose, and Connection|Participants partake in the introduction or foundational mindfulness for one day and then perform connection, awareness, and purpose-based mindfulness techniques for 5 days on the HMI app.
61939094|NCT05131360|EXPERIMENTAL|Awareness and Connection|Participants partake in the introduction or foundational mindfulness for one day and then perform awareness and connection-based mindfulness techniques for 5 days on the HMI app.
62137280|NCT00936182|EXPERIMENTAL|Fluconazole|
62137281|NCT00936182|PLACEBO_COMPARATOR|Placebo|Placebo capsule daily for 30 days
62137282|NCT04409470||Indication for blood gas sampling|To be eligible, patients will need to be classified as critically ill and there has to be a clear clinical indication for an arterial blood gas sampling. Enrollment will be performed in a consecutive manner at all hours.
62137283|NCT05977335||Orthostatic Intolerance Patients|
62492078|NCT03999008|ACTIVE_COMPARATOR|Budesonide|"Oral viscous budesonide will be given in apple sauce according to body weight at inclusion:~\< 10 kg: 250 mcg BID in 5 ml apple sauce 10 kg to \<15 kg: 500 mcg BID in 5 ml apple sauce \>15 kg: 1000 mcg BID in 5 ml apple sauce"
61939095|NCT04855929|EXPERIMENTAL|ANV419 single agent|
61939096|NCT04855929|EXPERIMENTAL|Ipilimumab + ANV419|
61939097|NCT04909931|EXPERIMENTAL|vitamin D supplementation group|First arm ; add on vitamin D 40,000 IU/week for 12 weeks
61939098|NCT04909931|EXPERIMENTAL|second arm|add on placebo
61939099|NCT05733377||Pregnant|Pregnant \>36 weeks gestation, 20 to 40 years old, without significant lumbar pathology, or intense labor pain, or percentile p\>97 or \<p3, or with a result of delivery-cesarean section due to risk of loss of fetal well-being
61939100|NCT03459482|EXPERIMENTAL|Group 1 - True Food Elimination Diet|Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
61939101|NCT03459482|SHAM_COMPARATOR|Group 2 - Sham Food Elimination Diet|"Group 2 (control group): Subjects will be given a Sham elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates."
61939102|NCT06019585|ACTIVE_COMPARATOR|Splint inmmobilization|Distal radius fractures fixed with volar locking plate and immobilized with an antebrachial splint for 3 weeks
61939103|NCT06019585|ACTIVE_COMPARATOR|Bandage immovilization|Distal radius fractures fixed with volar locking plate and immobilized with a compressive bandage for 3 weeks
61939104|NCT01050491|PLACEBO_COMPARATOR|sitaxsentan, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
61939105|NCT01050491|PLACEBO_COMPARATOR|placebo, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
61939106|NCT05085574|EXPERIMENTAL|Group 1 (Study Product)|Subjects will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.
62137284|NCT05387044|EXPERIMENTAL|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
62695078|NCT05821205|EXPERIMENTAL|Commitment (randomized weekly, 1 of 4 options)|Commitment will be operationalized as a pledge committing to screening and/or delivering SafERteens (depending on role). Randomized weekly.
61939107|NCT05085574|PLACEBO_COMPARATOR|Group 2 (Reference Therapy)|Subjects will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
61939108|NCT04908709|EXPERIMENTAL|Diagnostic (sMRI)|Patients undergo sMRI over less than 1 hour within 7 days prior to start of standard of care radiation therapy and at 10 weeks.
61939109|NCT04908709|ACTIVE_COMPARATOR|Group 2|Patients will undergo 3-4 sMRI scans at baseline prior to RT, 1 month, 4 months, and 7 months after RT, and/or at any time of suspected tumor recurrence.
61939110|NCT06680908||Dual stress challenge group: VR-ASD & Exercise test|"VR-ASD:~\~90 second VR scenario, subject was instructed that they are a responding officer to an active shooter, and they must find and eliminate the shooter. They then must walk down a 10 foot hallway, find the shooter, and take them out with their Glock 17 training pistol.~Exercise Test:~30 squats in 45 seconds, tempo set by metronome at 80bpm. Each rep must consist of 90 degree knee flexion with their back straight. Following, the subject then does 2 sets of 20 jump ropes."
61939111|NCT06680908||Exercise Test only|"Exercise Test:~30 squats in 45 seconds, tempo set by metronome at 80bpm. Each rep must consist of 90 degree knee flexion with their back straight. Following, the subject then does 2 sets of 20 jump ropes."
61939112|NCT01670318|EXPERIMENTAL|platinum chromium everolimus-eluting stent|
62695079|NCT05821205|NO_INTERVENTION|Engagement Strategy Control (randomized weekly, 1 of 4 options)|The control condition will involve no ES for the weekly Engagement Strategies. Randomized weekly.
62695080|NCT05821205|NO_INTERVENTION|Personalized feedback control (randomized monthly, 1 of 2 options)|The control condition will involve no personalized feedback. Randomized monthly
61939113|NCT04697056|EXPERIMENTAL|Imsidolimab|Participants received a starting dose of 400 milligrams (mg) of imsidolimab on Day 1 followed by 200 mg imsidolimab every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
61939114|NCT04697056|PLACEBO_COMPARATOR|Placebo|Participants received imsidolimab matching placebo on Day 1 and thereafter, every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
61939115|NCT06202690|ACTIVE_COMPARATOR|SP-RATS|SP-RATS Arm: 145 patients, single-port anatomical pulmonary resection will be performed using the SP robotic system. A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision.
61939116|NCT06202690|PLACEBO_COMPARATOR|SP-VATS|SP-VATS Arm: 145 patients, single-port anatomical pulmonary resection was performed using VATS. A 4-cm incision will be made at 5th intercostal space on the anterior or posterior axillary line. A chest tube will be inserted in same incision.
61939117|NCT01896336|EXPERIMENTAL|5mg sublingual Zolpidem hemitartrate|1 QD
61939118|NCT01896336|ACTIVE_COMPARATOR|10 mg oral Zolpidem hemitartrate|1 QD.
61939119|NCT03594734|EXPERIMENTAL|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
61939120|NCT03594734|ACTIVE_COMPARATOR|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
62695081|NCT05821205|EXPERIMENTAL|Personalized feedback (randomized monthly, 1 of 2 options)|The feedback ES will be operationalized as a visual graphic of their personal performance screening and/or delivering SafERteens in relation to the mean of the provider group and/or towards a pre-set standard (i.e., screening 75% of adolescents; delivery rate of 75% of eligible youth). Personalized feedback or none will be randomized on a monthly basis.
62695082|NCT03282994|EXPERIMENTAL|Treatment with cryotherapy|Dermal Cooling System
62695083|NCT06546618|EXPERIMENTAL|LCC Package with pictorial warning and no flavor|Participants will see a mock LCC package with pictorial warnings and no flavor descriptor.
61939121|NCT02919098|EXPERIMENTAL|Intervention|Two schools (all students grades 9-12) will serve as the intervention group.Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based bystander intervention program aimed at teaching students the knowledge and skills to prevent or intervene in instances in sexual harassment and violence among peers. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes. School staff and administrators will be interviewed to gather their insights on the program's feasibility and acceptability.
62137285|NCT06571695|EXPERIMENTAL|Anatomic Long Head of Biceps Tensioning Technique|Patients that are randomized to the intervention group will undergo biceps tenodesis in a standardized, step-by-step protocol as outlined in a previously published and publicly available article.
62334530|NCT02752529|EXPERIMENTAL|Tacrolimus/dose1|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
62492079|NCT03999008|PLACEBO_COMPARATOR|Placebo|Placebo: 5 ml apple sauce BID plus 1 mL saline
62492080|NCT02711644|EXPERIMENTAL|Supportive Lifestyle Counselling|Two supportive lifestyle counselling sessions with Registered Dietitian from study entry to 34 weeks.gestation.
62695084|NCT06546618|EXPERIMENTAL|LCC Package with pictorial warning and 'sweet' flavor|Participants will see a mock LCC package with pictorial warnings and a 'sweet' flavor descriptor.
62695085|NCT06546618|EXPERIMENTAL|LCC Package with text-only warning and no flavor|Participants will see a mock LCC package with text-only warnings and no flavor descriptor.
62695086|NCT06546618|EXPERIMENTAL|LCC Package with text-only warning and 'sweet' flavor|Participants will see a mock LCC package with text-only warnings and a 'sweet' flavor descriptor
62334531|NCT02752529|ACTIVE_COMPARATOR|Tacrolimus/dose2|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
62695087|NCT06335212||One group of subjects were recruited.|
62695088|NCT04731597||Cases with hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano who presented hip fracture between 2014 and 2019
61939122|NCT02919098|PLACEBO_COMPARATOR|Delayed Control|"One school (all students grades 9-12) will serve as a delayed control group. Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based health program unrelated to sexual health, sexual violence, sexual harassment, and bystander behaviors. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes.~After completing the follow-up survey, this group will follow the same procedures to deliver the bystander program and capture data outlined for the intervention group."
61939123|NCT00767949|EXPERIMENTAL|1|iSONEP
61939124|NCT01642407|EXPERIMENTAL|Sildenafil|
61939125|NCT04953351|EXPERIMENTAL|cognitive registration targeted biopsy|
61939126|NCT04953351|ACTIVE_COMPARATOR|MRI-ultrasound fusion targeted biopsy|
61939127|NCT03193190|ACTIVE_COMPARATOR|Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)|"Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria."
61939128|NCT03193190|EXPERIMENTAL|Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1-4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
61939129|NCT03193190|EXPERIMENTAL|Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
61939130|NCT03193190|EXPERIMENTAL|Cohort 1: Atezolizumab + Chemotherapy + AB928|Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
61939131|NCT03193190|EXPERIMENTAL|Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
61939132|NCT03193190|EXPERIMENTAL|Cohort 2: Atezolizumab + Cobimetinib|"Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment."
61939133|NCT03193190|EXPERIMENTAL|Cohort 2: Atezolizumab + PEGPH20|"Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
61939134|NCT03193190|EXPERIMENTAL|Cohort 2: Atezolizumab + BL-8040|"Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
61939135|NCT03193190|EXPERIMENTAL|Cohort 2: Atezolizumab + RO6874281 every 2 weeks|"Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
61939136|NCT03193190|EXPERIMENTAL|Cohort 2: Atezolizumab + RO6874281 every 3 weeks|"Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
61939137|NCT03193190|ACTIVE_COMPARATOR|Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)|"Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m\^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m\^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m\^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m\^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
62334532|NCT06088316|EXPERIMENTAL|Group-A|Group A will receive amoxicillin-esomeprazole high dose dual therapy that is amoxicillin 1gm 8 hourly after meal \& esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.
62492081|NCT02711644|ACTIVE_COMPARATOR|Standard Lifestyle Counselling|Two standard counselling sessions with Registered Dietitian from study entry to 34 weeks gestation
62492082|NCT04847401||Group 1|patients with Irritable Bowel Syndrome
62492083|NCT04847401||Group 2|normal
62695089|NCT04731597||controls without hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano without hip fracture between 2014 and 2019
61939138|NCT03193190|EXPERIMENTAL|Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab|Cohort 1: Participants will receive Tocilizumab 8 mg/kg IV infusion on Day 1 of each 28 day cycle; Atezolizumab 1680 mg IV infusion on Day 1 of each 28 day cycle; Nab-paclitaxel 125 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m\^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
61939139|NCT00718302|EXPERIMENTAL|Randomized treatment; antiglide plate|Randomized treatment; antiglide plate
61939140|NCT00718302|EXPERIMENTAL|Randomized treatment; lateral plate|Randomized treatment; lateral plate
61939141|NCT06496464|PLACEBO_COMPARATOR|control group|"Teachers randomized to the control group will participate in the following:~Basketball training as usual, which involves one 2-3 hour session delivered per week based on local school protocol~Teachers in the control group will only receive the MASTER Teaching Program after completing the study period and assessing outcome measures."
61939142|NCT06496464|EXPERIMENTAL|Intervention condition (MASTER teacher education program)|Jin Yan will train the PE teachers to complete video assessments and questionnaires. Five teachers from the intervention group will be educated in the MASTER coach education program and trained to deliver a basketball program that aligns with the MASTER framework.
61939143|NCT01066000|EXPERIMENTAL|Mircera|
61939144|NCT04288271|EXPERIMENTAL|Adherence Intervention|"The objective of the intervention is to improve medication adherence. Patient-participants will use a multi-dose electronic pillbox and adherence tracking website which can provide dose reminders. Patient will form an Adherence Support Team (AST) including the participant, a parent (or other) and the Coach (study coordinator). The Coach will guide the AST to use Action-focused Problem-solving to address personal barriers to adherence. They will then generate concrete if-then plans for how they will behave in a given situation. Intervention participants with excellent adherence will be encouraged to work on building autonomy in medication-taking instead of adherence. Action plans will be able to be modified, if desired, at the 6-week and 10-week check-ins.~HCP-participants at intervention sites will be given the option to login to the adherence tracking website to view the adherence data of their patients. They will also be alerted by study staff to critical non-adherence events."
61939145|NCT04288271|OTHER|Healthy Living Education Intervention|Patient-participants will receive a healthy living education intervention with the use of an e-pillbox. Contacts with the coach will occur at the same intervals as at adherence intervention sites. Participants will choose one of 3 healthy living topics on which they will receive education in an interactive format. The coach will engage the participant in a semi-scripted conversation on the selected topic. At check-ins, the coach will either continue the conversation on the topic selected at the outset or provide education on another topic. The coach will NOT engage in discussions about adherence and will NOT provide feedback on adherence data.
61939146|NCT02890667||Beneficiaries|Incident cancer for Beneficiaries present in the EGB on January 1, 2012.
61939147|NCT03202888|EXPERIMENTAL|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
61939148|NCT03660345|EXPERIMENTAL|PPV/MP|Study Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo pars plana vitrectomy with internal limiting membrane peeling
61939149|NCT03660345|ACTIVE_COMPARATOR|Intravitreal Injection|Control Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo intravitreal ziv-aflibercept monotherapy according to a fixed treatment schedule
61939150|NCT05863338|EXPERIMENTAL|Intervention Group|Data collection tools were applied face to face. Patient education was carried out in the polyclinic. A training booklet was given at the end of the training. Afterwards, patients were called once a week by telephone for 12 weeks. The patients were followed up by the nurse over the phone and counseling was provided to the patients. Patients were able to call the research nurse when needed. Interim evaluation was made at the 12th week. Data collection tools were applied face-to-face in the outpatient clinic. Patients 13-24. Between weeks, 12 more phone calls were made, once a week. The patients were followed up by the nurse by telephone, and the patients continued to receive counseling services. Patients were able to call the research nurse when needed. At the end of the 24th week, the research forms were applied face to face in the outpatient clinic. The research has finished.
62137286|NCT06571695|ACTIVE_COMPARATOR|Traditional Long Head of Biceps Tensioning Technique|"The control group patient will undergo biceps tenotomy and tenodesis based on surgeon feel on appropriate tensioning of the tendon (Current practice).~Of note, there is no universal method or gold standard on how the long head of the biceps should be tensioned during bicep tenodesis."
62334533|NCT06088316|ACTIVE_COMPARATOR|Group-B|Group-B patients will receive levofloxacin containing triple therapy that is Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
62334534|NCT06480305|ACTIVE_COMPARATOR|Pre-breakfast and post dinner snack (A1)|The Group A1 participants will not receive anything except for consuming a post-dinner snack. This is the control group for Prebreakfast and post-dinner snack groups.
62334535|NCT06480305|EXPERIMENTAL|Pre-breakfast and post dinner snack (A2)|The Group A2 participants will consume post-dinner snacks consisting of 7-8 peanuts, one walnut, 2 cashews, 2 almonds, and 2 pistachios, and a prepackaged dose of 25 peanuts as a pre-breakfast snack.
62492084|NCT04595591|ACTIVE_COMPARATOR|Group Ⅰ|titration dosing speeds of propofol at 2mg/kg/min
62492085|NCT04595591|ACTIVE_COMPARATOR|Group Ⅱ|titration dosing speeds of propofol at 1mg/kg/min
62492086|NCT04595591|ACTIVE_COMPARATOR|Group III|titration dosing speeds of propofol at 0.5mg/kg/min
62492087|NCT02441985|EXPERIMENTAL|Real rTMS Stimulation|rTMS will be delivered over each cerebellar hemisphere, using a 70mm figure-of-eight coil connected to a Magstim RapidStim2 machine while positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. The inion will be taken as the boundary between the posterior cerebellum and the occipital cortex. Therefore the area stimulated will be caudal to the inion to stimulate the posterior cerebellum.
62695090|NCT06637800|EXPERIMENTAL|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a single use|The Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a single use, disposable column packed with ultra-high molecular weight polyethylene (UHMWPE) beads. These beads have been modified to contain endpoint-attached heparin on the surface, thus forming a new chemical entity, the polymer now containing material of animal origin (porcine mucosa). The devices are sterilized using a standard ethylene oxide (EtO) cycle, following ISO 11135:2014.
62695091|NCT02615613|EXPERIMENTAL|High acceptability meal|A custard recipe was used as the high acceptability meal
61939151|NCT05863338|NO_INTERVENTION|Control Group|Individuals meeting the sample specifications were included in the control group in accordance with the order of numbers in the lists created by randomly assigning numbers. Data collection tools were applied face to face. Routine outpatient follow-ups continued. Interim evaluation was made at the 12th week. In the interim evaluation, data collection tools were applied face to face. Then, routine outpatient follow-up between 13 and 24 weeks continued. At the end of the 24th week, data collection tools were applied face to face. The patients were educated in the outpatient clinic. A training booklet was given at the end of the training. The research has been terminated.
61939152|NCT05460260||GLUCODAY21|Study subjects for 21-day study
62137287|NCT02251860||Participants with Rheumatoid Arthritis|Participants with active rheumatoid arthritis who are prescribed tocilizumab treatment according to the marketing authorization by their physician will be followed under routine conditions over an observation period of up to 2 years if baseline and disease characteristics data are available.
62137288|NCT05342246|EXPERIMENTAL|conservative treatment|The patent canal is retreated, no attempt to deal with the separated instrument
62334536|NCT06480305|EXPERIMENTAL|Pre-breakfast and post dinner snack (A3)|The Group A3 participants will consume post-dinner snacks consisting of 7-8 peanuts, one walnut, 2 cashews, 2 almonds, and 2 pistachios, and a prepackaged dose of 25 raisins as a pre-breakfast snack.
62334537|NCT06480305|EXPERIMENTAL|Pre-breakfast and post dinner snack (A4)|The Group A4 participants will consume post-dinner snacks consisting of 7-8 peanuts, one walnut, 2 cashews, 2 almonds, and 2 pistachios, and a prepackaged dose of 5 peanuts on one day and 25 raisins as a pre-breakfast snack on the other day.
62334538|NCT06480305|NO_INTERVENTION|Pre-breakfast but No Post dinner snack (B1)|The Group B1 participants will not receive anything not even pre-breakfast. This is the control group for Pre-breakfast and no post-dinner snacks.
62334539|NCT06480305|EXPERIMENTAL|Pre-breakfast but No Post dinner snack (B2)|The Group B2 participants will consume a prepackaged dose of 25 peanuts. Along with Pre-breakfast but no post-dinner snack.
62334540|NCT06480305|EXPERIMENTAL|Pre-breakfast but No Post dinner snack (B3)|The Group B3 participants will consume a prepackaged dose of 25 raisins. Along with Pre-breakfast but No Post dinner snack.
62334541|NCT06480305|EXPERIMENTAL|Pre-breakfast but No Post dinner snack (B4)|The Group A4 participants of the group will prepackaged dose of 25 peanuts one and the other day will consume 25 raisins. They alternate peanuts and raisins for the period of intervention. Along with Pre-breakfast but No Post dinner snack.
62695092|NCT02615613|EXPERIMENTAL|Low acceptability meal|The regular custard recipe was reformulated to yield a low acceptability version
61939153|NCT05838573|ACTIVE_COMPARATOR|Metformin group|The goal is to investigate whether adding metformin will benefit the cognitive impairment in individuals with schizophrenia.
61939154|NCT05838573|PLACEBO_COMPARATOR|Placebo group|The purpose of using placebo is to judge if the outcome is related to the study medication rather than other reasons.
61939155|NCT05838573|EXPERIMENTAL|Cross-sectional participants|"Participants do not meet any of the diagnostic criteria for metabolic syndrome: 1)abdominal obesity (i.e. central obesity): waist circumference for male≥90 cm, for female ≥85 cm; 2)fasting blood glucose ≥110 mg/dl (6.1 mmol/l) and/or plasma glucose ≥140 mg/dl (7.8 mmol/l) after glucose load; 3)at fasting state, triglyceride ≥1.7 mmol/l; 4)at fasting state, HDL-C \<1.04 mmol/L.~the other inclusion criteria and exclusion criteria are same as the intervention group."
61939156|NCT05838573|EXPERIMENTAL|Healthy volunteer|
62137289|NCT05342246|ACTIVE_COMPARATOR|traditional|All canals are retreated with attempts to retrieve the broken file
62137290|NCT03329612|EXPERIMENTAL|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
62137291|NCT03329612|SHAM_COMPARATOR|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
61939157|NCT00763048|PLACEBO_COMPARATOR|A -Control|Fluoride toothpaste (Colgate Great Regular Flavor) is the control for this study. All study toothpastes contain fluoride. The study is evaluating the additional ingredients in the other toothpastes.
62334542|NCT05196243||Study Group|Study on the genomic and molecular pathological characteristics of gastrointestinal mucosal lesions
62334543|NCT05196243||Control Group|Study on the genomic and molecular pathological characteristics of normal gastrointestinal mucosa
62334544|NCT02569411|NO_INTERVENTION|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
62334545|NCT02569411|EXPERIMENTAL|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
62334546|NCT06106633|EXPERIMENTAL|Intervention Arm|Patient will undergo UFE using PEDD
62334547|NCT01852097|EXPERIMENTAL|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
62334548|NCT01852097|NO_INTERVENTION|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
62334549|NCT03134950|EXPERIMENTAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions are in person with a trained psychologist and the following 2-4 sessions are web-based. Each web-based session is followed by phone support.
62334550|NCT03134950|NO_INTERVENTION|Medical Treatment as Usual|Medical treatment as usual
62334551|NCT05398276|EXPERIMENTAL|Behavioral Exposure For Introceptive Tolerance|The BE-FIT intervention is a cognitive-behavioral intervention and is designed to target exercise anxiety. The three main components of BE-FIT include: 1) exposure to feared bodily sensations and exercise, 2) prevention of safety behavior use before/during/after exercise, and 3) use of a wrist-worn activity monitor (Fitbit) for PA feedback and activity goal setting.
62334552|NCT05398276|ACTIVE_COMPARATOR|Health Education Control|HEC is a time-matched control intervention that will be delivered on the same delivery schedule as BE-FIT. In this arm, participants will be provided educational information about health topics relevant to healthy aging delivered through PowerPoint lectures and handouts and use a Fitbit for PA monitoring.
62334553|NCT04228120|EXPERIMENTAL|intervention group|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
62334554|NCT04228120|NO_INTERVENTION|control group|routine care
62334555|NCT00882999|PLACEBO_COMPARATOR|Placebo|Injection: Every 4 weeks in the placebo arm for 24 weeks (Weeks 0, 4, 8, 12, 16, and 20) for a total of 6 doses. Every 4 weeks in the LY2127399 arms \[4 milligrams (mg) LY2127399 / 12 weeks and 120 mg LY2127399 / 12 weeks\] for 24 weeks (except Week 0 and Week 12).
62334556|NCT00882999|EXPERIMENTAL|4 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
62334557|NCT00882999|EXPERIMENTAL|40 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
62334558|NCT00882999|EXPERIMENTAL|120 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
62334559|NCT00882999|EXPERIMENTAL|4 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
62334560|NCT00882999|EXPERIMENTAL|120 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
62334561|NCT00882999|EXPERIMENTAL|12 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
62334562|NCT02883907||Healthy volunteers|
62334563|NCT02883907||Osteoarthritis patients|
62334564|NCT03799718|EXPERIMENTAL|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
62334565|NCT00791440|EXPERIMENTAL|1|Up to 26 sessions (over a 30 week period) of weekly, individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
62334566|NCT00791440|ACTIVE_COMPARATOR|2|30 weeks of standard psychiatric treatment.
62334567|NCT06527612|EXPERIMENTAL|Exercise Group|In addition to standard medical treatment, the EGr will undergo an exercise program. The initial exercise training will be conducted in the hospital, followed by online exercise sessions via video conferencing three times a week during the first week. From the second week onwards, they will be asked to perform their exercises at home three times a week using provided exercise videos and will be monitored for one year. Compliance with the exercise regimen will be assessed through a weekly survey shared in a WhatsApp group established for the exercise group patients.
62334568|NCT06527612|NO_INTERVENTION|Control group|Patients in the CGr will receive an information brochure containing medical treatment and physical activity recommendations.
62334569|NCT04279977||Inpatient Rehabilitation Facility|Individuals post-stroke who are discharged to an inpatient rehabilitation facility.
62334570|NCT04279977||Skilled Nursing Facility|Individuals post-stroke who are discharged to a skilled nursing facility.
61939158|NCT00763048|ACTIVE_COMPARATOR|B|fluoride/triclosan/copolymer toothpaste (Colgate Total Toothpaste)
62334571|NCT05749926|ACTIVE_COMPARATOR|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|Length of use : 1 day
62334572|NCT05749926|EXPERIMENTAL|VidPrevtyn® Beta vaccine (Sanofi/GSK)|Length of use : 1 day
62334573|NCT01980108|NO_INTERVENTION|empty stomach|No fluid will be given to the patient prior to scanning.
62334574|NCT01980108|EXPERIMENTAL|50mL|50mL of water will be given to the patient prior to scanning
62334575|NCT01980108|EXPERIMENTAL|100mL|100mL of water will be given to the patient prior to scanning
62334576|NCT01980108|EXPERIMENTAL|200mL|200mL of water will be given to the patient prior to scanning
62334577|NCT01980108|EXPERIMENTAL|300mL|300mL of water will be given to the patient prior to scanning
62334578|NCT01980108|EXPERIMENTAL|400mL|400mL of water will be given to the patient prior to scanning
62334579|NCT03235570|EXPERIMENTAL|Pemigatinib|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
62334580|NCT06023173||Training Cohort|This cohort was derived from Arm A (treated with FOLFOX + bevacizumab) of the BECOME studyand was used for model construction.
62334581|NCT06023173||Negative Validation Cohort|The cohort was derived from Arm B (treated with FOLFOX) of the BECOME study , which demonstrated that the model specifically predicted the efficacy of bevacizumab.
62334582|NCT06023173||Internal Validation Cohort|The cohort was derived from an independent Zhongshan Hospital cohort with the same treatment team and imaging instrumentation as the BECOME study, differing only in patient period, and was used for internal validation of the model.
62334583|NCT06023173||External Validation Cohort|The cohort was obtained from the Zhongshan Hospital - Xiamenand the First Affiliated Hospital of Wenzhou Medical University for external validation of the model.
62695093|NCT01969058|ACTIVE_COMPARATOR|Isotretinoin Arm|Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
62334584|NCT01163253|EXPERIMENTAL|Active Treatment|"The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market.~All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion"
62334585|NCT03086200|NO_INTERVENTION|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
62334586|NCT03086200|EXPERIMENTAL|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
62334587|NCT01043185|EXPERIMENTAL|A|AZD3355 30 mg
62334588|NCT01043185|EXPERIMENTAL|B|AZD3355 90 mg
62334589|NCT01043185|EXPERIMENTAL|C|AZD3355 120 mg
62334590|NCT01043185|EXPERIMENTAL|D|AZD3355 240 mg
61939159|NCT04467931||1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
61939160|NCT04467931||1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB|Among Veterans with treated hypertension who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
61939161|NCT04467931||2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
61939162|NCT04467931||2.2 COVID-19 Hospitalized, ACEI vs. ARB|Among Veterans with treated hypertension who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
61939163|NCT01370850||Normal|Normal results from the clinical exam and free of ocular pathology.
61939164|NCT01370850||Glaucoma|Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma.
61939165|NCT01370850||Retina|Clinical exam results consistent with retina pathology.
61939166|NCT04872153|EXPERIMENTAL|Intervention Group|The patients allocated to the intervention group will conduct simultaneously combined cognitive-motor training in form of exergames using the Dividat Senso in addition to the standard rehabilitation treatment plan. Both the Dividat Senso and the training games are specifically developed considering the needs and requirements of older adults but also clinicians/therapists.
61939167|NCT04872153|NO_INTERVENTION|Control Group|The patients of the control group follow the standard rehabilitation treatment plan including: 3x 30min physiotherapy, 8x 30min group therapy, 3x 45min group therapy (group therapy includes body- focused therapy, mindfulness therapy, respiratory therapy, gymnastics, hiking etc.)
62334591|NCT01043185|PLACEBO_COMPARATOR|E|Placebo
62334592|NCT00741143|EXPERIMENTAL|1|Group that receives NaFeEDTA fortified wheat flour
62334593|NCT00741143|PLACEBO_COMPARATOR|2|Unfortified wheat flour
61939168|NCT05221307|EXPERIMENTAL|1/Children with cerebral palsy|Modified Pilates Exercises (MPEs) will be applied 3 days a week, 45 minutes a day for 8 weeks.
61939169|NCT05221307|ACTIVE_COMPARATOR|2/children with cerebral palsy|Traditional Neurodevelopmental Therapy (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks.
61939170|NCT02907580|EXPERIMENTAL|Local educational data|Local-based educational handout
61939171|NCT02907580|EXPERIMENTAL|National educational data|National-based educational handout
61939172|NCT02907580|NO_INTERVENTION|Usual care|No educational information other than provided as usual care by health care providers
62334594|NCT05429372|EXPERIMENTAL|PF-06939926|
62334595|NCT05441566||Driver gene-positive|
62334596|NCT05441566||Driver gene-negative|
62334597|NCT03695991||Study group|Patients will be recruited from out-patient clinics and in-patient sectors of Assiut Urology and Nephrology hospital
62334598|NCT06106321|EXPERIMENTAL|Transalveolar crest parietal maxillary sinus floor secondary lift|In order to achieve minimally invasive surgery (RBH≤5mm) in patients with severe deficiency of residual bone height in the posterior maxillary region and obtain reliable clinical research results, a secondary sinus floor lifting technique combining the advantages of maxillary sinus lift with the low risk of maxillary sinus lift is proposed.
62334599|NCT06106321|ACTIVE_COMPARATOR|Transalveolar crest parietal maxillary sinus floor lift|Transalveolar crest parietal maxillary sinus floor lift (OSFE) requires a residual bone height of at least 5 mm and implant placement at the same time. Its advantages are simple operation, shorter surgical time, reduced trauma and reduced postoperative complications, and the concept of minimally invasive implant surgery is reflected in OSFE.
62334600|NCT04998045|EXPERIMENTAL|Intervention arm|Youth aged 15-24 years Intervention: screening and brief intervention for substance use
62334601|NCT01401010|ACTIVE_COMPARATOR|Doripenem 500 mg|pharmacokinetics/pharmacodynamics
62334602|NCT01401010|ACTIVE_COMPARATOR|Doripenem 1000 mg|pharmacokinetics/pharmacodynamics
62695094|NCT01969058|NO_INTERVENTION|No study treatment Arm|No Isotretinoin treatment
61939173|NCT05901311|EXPERIMENTAL|[¹⁴C]-LY3537982 (Part 1)|Single dose of \[¹⁴C\]-LY3537982 administered orally.
61939174|NCT05901311|EXPERIMENTAL|[¹⁴C]-LY3537982 + LY3537982 (Part 2)|Single dose of LY3537982 administered orally followed by \[¹⁴C\]-LY3537982 administered intravenously (IV).
61939175|NCT05239442|OTHER|Patients|"Hospital Patients:~- Person hospitalized in one of the following departments: endocrinology-diabetology, geriatric medicine, pulmonology, rheumatology, dermatology, infectious diseases, internal medicine, cardiology, as well as in the rehabilitation department"
61939176|NCT05239442|OTHER|Institutional staff|Person working in the establishment where the taste commissions have been in place for at least 3 months
61939177|NCT05239442|OTHER|Residents|Patients residing in nursing home
61939178|NCT06680011||Neurosyphilis Patients|"1. Meet the diagnostic criteria for neurosyphilis in this study based on the 2015 Sexually Transmitted Diseases Treatment Guidelines published by the Centers for Disease Control and Prevention (CDC) and the 2020 European Guideline on the Management of Syphilis: ① Positive serological tests for Treponema pallidum (e.g., Treponemal tests) and rapid plasma reagin (RPR) tests; ② Positive cerebrospinal fluid tests for Treponema pallidum particle agglutination assay (TPPA), the toluidine red unheated serum test (TRUST), and the Venereal Disease Research Laboratory test (VDRL).~2. Aged 18-65 years, regardless of gender (female patients are rare in clinical practice).~3. At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.~4. No contraindications for electroencephalogram (EEG) and transcranial magnetic stimulation (TMS)."
61939179|NCT06680011||Non-neurosyphilis Syphilis Patients|"1. Positive serological tests for Treponema pallidum (e.g., Treponemal tests) and rapid plasma reagin (RPR) tests.~2. Does not meet the diagnostic criteria for neurosyphilis in this study, based on the 2015 Sexually Transmitted Diseases Treatment Guidelines published by the Centers for Disease Control and Prevention (CDC) and the 2020 European Guideline on the Management of Syphilis: ① Positive serological tests for Treponema pallidum and rapid plasma reagin tests; ② Positive cerebrospinal fluid tests for Treponema pallidum particle agglutination assay (TPPA), the toluidine red unheated serum test (TRUST), and the Venereal Disease Research Laboratory test (VDRL).~3. Aged 18-65 years, regardless of gender (female patients are rare in clinical practice).~4. At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.~5. No contraindications for electroencephalogram (EEG)."
61939180|NCT06680011||Healthy Controls|"1. Physically healthy (no mental illnesses or diseases affecting bodily organs).~2. Aged 18-65 years, regardless of gender.~3. At least a junior high school education level, with sufficient auditory and visual function to complete the necessary examinations and assessments for this study.~4. No contraindications for electroencephalogram (EEG)."
61939181|NCT06025643|EXPERIMENTAL|Cervical stimulation group|TENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
61939182|NCT06025643|EXPERIMENTAL|Plus cervical stimulation group|TENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
61939183|NCT06025643|EXPERIMENTAL|Renal stimulation group|TENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
61939184|NCT06025643|NO_INTERVENTION|Control group|This group will not receive any treatment with electrical stimulation.
61939185|NCT05862597||Health Status|Normal examination in recent six months and not fit inclusion criteria of suboptimal health status.
61939186|NCT05862597||Post-Covid syndrome|(A) Age between 20-70 years old, male or female. (B) Have a history of Covid-19 infection. (C) It has been 3 months since the day when the rapid screening test was negative. Antigen positive turn to negative (D) At least one symptom that cannot be explained by other diagnoses and lasts for at least 2 months after being infected with Covid-19.
61939187|NCT00424801|EXPERIMENTAL|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure
61939188|NCT06173934|EXPERIMENTAL|Patients with rapid gastric emptying|Patients with rapid gastric emptying
62492088|NCT02441985|SHAM_COMPARATOR|Sham rTMS Stimulation|Patients randomized to receive sham treatment will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham Magstim RapidStim2 Placebo which produces discharge noise and vibration similar to the real coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. The investigator will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp. The investigator will use an electromyography to administer electrical shocks to the scalp simultaneous to each simulated rTMS train.
62492089|NCT02293486|NO_INTERVENTION|Control|Arm that followed all the protocols with the exception of the pomegranate juice intake.
61939189|NCT06173934|EXPERIMENTAL|Patients with slow gastric emptying|Patients with slow gastric emptying
61939190|NCT03861650|EXPERIMENTAL|Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
61939191|NCT03861650|SHAM_COMPARATOR|Saline|Sham or placebo drug in the control group
61939192|NCT04932759|NO_INTERVENTION|control group|In the control group there will be no music listening
61939193|NCT04932759|EXPERIMENTAL|experimental group|In this group patients will listen to music while their dental treatments are being made.
62334603|NCT04461405|EXPERIMENTAL|Intervention Arm|INTEGRATE-D is a step-by-step blueprint that will assist practices with employing American Diabetes Association recommendations for integrating medical and psychosocial care. INTEGRATE-D consists of a set of implementation strategies that enable clinical teams to put evidence-based care in place. The intervention consists of training and education; audit and feedback materials; a facilitation implementation protocol; and health information technology support materials.
61939194|NCT00003099|ACTIVE_COMPARATOR|Arm 1 Tamoxifen + Fenretinide|Tamoxifen + Fenretinide daily for 14-28 days
61939195|NCT00003099|PLACEBO_COMPARATOR|Arm 2 Placebo|Placebo daily for 14-28 days
62334604|NCT04461405|NO_INTERVENTION|Control Arm|Usual care
62137292|NCT06458179||Proximal greater occipital nerve radiofrequency ablation (RFA)|Between January 1, 2022 and April 30, 2023, all patients diagnosed with primary unilateral occipital neuralgia who underwent US-guided diagnostic occipital nerve block and subsequent RFA of the PGON and were followed up for a minimum of one year were identified and included in the database. Patients lacking documentation or inadequate follow-up were excluded. Excluded from the study were patients with bilateral ON, secondary ON, other primary headaches, dermatitis or skin infections, and pacemakers. Based on clinical history and neurolgical examination (including Tinel's test), ON was diagnosed.
62137293|NCT03575936|ACTIVE_COMPARATOR|Standard of Care Group|Standard of Care arm. Pharmacist intervention in clinic
61939196|NCT06681493|EXPERIMENTAL|Part A|Part A Experimental: YZJ-4729 Tartrate injection; Part A Control: YZJ-4729 simulated injection
62137294|NCT03575936|EXPERIMENTAL|Home Monitoring Group|Pharmacist intervention with home INR monitoring
62334605|NCT03649321|EXPERIMENTAL|Phase 1b|bemcentinib 200 mg oral daily every 21 days. Nab-paclitaxel 100 mg/m\^2 Day 1 /8 every 21 days. Gemcitabine 800 mg/m\^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days.
62334606|NCT03649321|EXPERIMENTAL|Phase 2|bemcentinib 200 mg oral daily every 28 days. Nab-paclitaxel 125 mg/m\^2 Day 1 /8 /15 every 28 days. Gemcitabine 1000 mg/m\^2 Day 1 /8 /15 every 28 days.
62334607|NCT04745793||Thyroids|The aim is to identify and preserve the parathyroid glands during the total or partial removal of the thyroid. Repeating of the procedure for each lobe
62334608|NCT04745793||Parathyroids|The aim is to selectively remove the pathological parathyroid gland(s). Repeating of the procedure for each removed gland
62334609|NCT06250127|ACTIVE_COMPARATOR|Group 1 (Conventional facemask)|Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion.
62334610|NCT06250127|EXPERIMENTAL|Group 2 (Modified 3D printed facemask)|Modified facemask appliances will be used for growing patients who have Cl. III malocclusion.
62334611|NCT06373445|EXPERIMENTAL|Active group|The transcranial magnetic stimulation sessions were carried out using the MAGSTIM TMS equipment (Company Limited, Whitland, wales, UK). The investigators used the figure of eight or butterfly coil. The experimental group received real rTMS as follow: The intensity of the stimulus employed in treatment has used the motor threshold (MT) as the basic measure. The MT is used as a measurement index because the motor cortex is the only brain region which gives an easily detected signal \[muscle twitch\] when depolarized.The main stimulation parameters were 24 trains at120% of motor threshold for 60 seconds at 1 Hz and a 45-second interval between trains. The investigators subsequently provided a total of 1,200 pulses at each of the 20 sessions. The stimulation area was the right dorsolateral prefrontal area that was defined as the region 5 cm rostral in the same sagittal plane as the optimal site for MT production in the first dorsal interosseous
62334612|NCT06373445|SHAM_COMPARATOR|control group|The control group received sham rTMS as in the experimental group; however, sham current was with the coil placed perpendicular to the with the coil placed perpendicular to the scalp. The investigator responsible for delivering rTMS had no contact with the patients, ensuring a double-blind procedure.
62334613|NCT05233449|EXPERIMENTAL|Children anesthetized|Inhalatory general anesthesia with sevoflurane 0.9 Minimal Alveolar Concentration and alfentanil 10 µg/kg
62334614|NCT02147704|OTHER|Goup I|Group I: Fimasartan 60 mg in a low-sodium intake period --\> Fimasartan 60 mg in a high-sodium intake period
62334615|NCT02147704|OTHER|Group II|Group II: Fimasartan 60 mg in a high-sodium intake period --\> Fimasartan 60 mg in a low-sodium intake period
62334616|NCT00696657|EXPERIMENTAL|A|
62334617|NCT00696657|EXPERIMENTAL|B|
62334618|NCT00696657|EXPERIMENTAL|C|
62334619|NCT00696657|EXPERIMENTAL|D|
62334620|NCT00696657|EXPERIMENTAL|E|
62334621|NCT00696657|EXPERIMENTAL|F|
61939197|NCT06681493|EXPERIMENTAL|Part B|Subjects will receive YZJ-4729 Tartrate injection
61939198|NCT04786392|ACTIVE_COMPARATOR|Lutein supplement|"Supplement containing 5 mg powdered lutein, capsule filler microcrystalline cellulose.~To be administered once."
61939199|NCT04786392|EXPERIMENTAL|Blended food beverage|Blended food beverage containing 5 mg lutein from baby spinach. To be administered/consumed once.
61939200|NCT04786392|EXPERIMENTAL|Whole food|Consumption of 5 mg of lutein from baby spinach. To be administered/consumed once.
62137295|NCT05914896|NO_INTERVENTION|NormOsmo|This group received a priming solution with normal osmolality.
62334622|NCT00696657|PLACEBO_COMPARATOR|G1|
62334623|NCT00696657|PLACEBO_COMPARATOR|G2|
62334624|NCT00696657|PLACEBO_COMPARATOR|G3|
62137296|NCT05914896|ACTIVE_COMPARATOR|HighOsmo|This group received a priming solution with high osmolality
62137297|NCT06099548|EXPERIMENTAL|HR-PCI patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions
62137298|NCT05990452|EXPERIMENTAL|9MW2921|
62334625|NCT00696657|PLACEBO_COMPARATOR|G4|
62334626|NCT00696657|PLACEBO_COMPARATOR|G5|
62137299|NCT04347733|EXPERIMENTAL|Group A|Intra-articular injection, 20 mg (0.5 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.5 mL of normal saline
62137300|NCT04347733|EXPERIMENTAL|Group B|40 mg (1 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.0 mL of normal saline
62137301|NCT04347733|ACTIVE_COMPARATOR|Group C|20 mg (0.5 mL) of triamcinolone acetonide and 1 mL of hyaluronidase mixed with 2 mL of 2% lidocaine and 6.5 mL of normal saline
62137302|NCT05599048|EXPERIMENTAL|Part A / Phase 1: Feasibility Run-In|Participants will undergo MR imaging at a single time point. Imaging will take one day. and no follow up is planned.
62334627|NCT00696657|PLACEBO_COMPARATOR|G6|
62334628|NCT00696657|EXPERIMENTAL|H|
62334629|NCT00696657|EXPERIMENTAL|I|
62334630|NCT02987764|EXPERIMENTAL|Cord Milking|The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
62492090|NCT02293486|EXPERIMENTAL|Pomegranate Juice|Arm that followed all the protocols and the pomegranate juice intake.
62492091|NCT02293486|EXPERIMENTAL|Pomegranate Juice Dilution|Arm that followed all the protocols and the pomegranate juice dilution (1:1) intake.
62137303|NCT05599048|EXPERIMENTAL|Part B/ Phase II: Biomarker Cohort|Participants will undergo paired hyperpolarized pyruvate/metabolic MR imaging at baseline and again after approximately 21 days of the participants SOC or investigational therapy outside of this protocol.
62137304|NCT04989296|EXPERIMENTAL|Level of NF-κB translocation in lymphocyte in children with psoriasis and in comparison group|The analysis of the relative count of cells with NF-κB translocation in the lymphocyte populations the group of patients with psoriasis and in the comparison group.
62492092|NCT02754219|EXPERIMENTAL|Evogliptin|Hepatic dysfunction, Healthy control
62492093|NCT02483416||group 1|Group without 'remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
62492094|NCT02483416||group 2|Group with 'remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team
62492095|NCT00929019|EXPERIMENTAL|dendritic cell vaccination|HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
62492096|NCT00929019|NO_INTERVENTION|control arm|For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).
62137305|NCT04989296|EXPERIMENTAL|Level of NF-κB translocation in lymphocyte in children with psoriasis, based on the type of therapy|Determination of the level of NF-kB translocation in lymphocyte populations in patient groups depending on the type of therapy: Group 1 - patients receiving basic and external therapy; Group 2 - patients receiving methotrexate; and Group 3 - patients receiving therapy with biological drugs.
61939201|NCT06019949|ACTIVE_COMPARATOR|Training (RT) group|80 scTS sessions will be administered using the Neostim/Biostim (Cosyma Inc., Denver CO) device applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes. During the intervention, optimally configured scTS will be delivered based on the measures assessed during mapping sessions. The scTS with 5 mA-sub-motor threshold intensity with optimal frequency and pulse width will be delivered using 5 min on and 5 min off stimulation periods during interventional bouts. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, and respiratory rate will be closely monitored throughout stimulation sessions in the Lab by using beat-to-beat blood pressure, and respiratory kinematics monitoring.
62137306|NCT04989296|EXPERIMENTAL|Severity of psoriasis based on level of NF-κB translocation in psoriasis who received biologics|Assessment of the level of NF-kB translocation in lymphocyte populations, assessment of PASI and BSA, assessment of the effectiveness of biological drugs in patients with psoriasis. Identification of patients in the stage of regression of the disease and in the progressive stage.
62137307|NCT01576029|ACTIVE_COMPARATOR|Docetaxel|75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
62137308|NCT01576029|EXPERIMENTAL|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
62137309|NCT05728645|EXPERIMENTAL|colloid group|The participants in colloid group will received intravenous Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg before the Induction of general anesthesia.
62137310|NCT05728645|ACTIVE_COMPARATOR|crystalloid group|The participants in crystalloid group will received intravenous multiple electrolyte injection of 5ml/kg before the Induction of general anesthesia.
62137311|NCT02098837|ACTIVE_COMPARATOR|Immediate switch|Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.
62137312|NCT02098837|ACTIVE_COMPARATOR|Deferred switch|Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.
62334631|NCT02987764|NO_INTERVENTION|Observational|Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.
62334632|NCT04770610|EXPERIMENTAL|OT-101 alone|Atropine Sulfate 0.01% Ophthalmic Solution through year 4
62334633|NCT04770610|EXPERIMENTAL|OT-101 plus vehicle|Atropine Sulfate 0.01% Ophthalmic Solution through year 3 followed by vehicle for 1 year
62334634|NCT04770610|PLACEBO_COMPARATOR|Vehicle|Vehicle (Investigational Product minus active ingredient) through year 4
62334635|NCT02039180|EXPERIMENTAL|AZD3293 oral solution|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
62334636|NCT02039180|EXPERIMENTAL|AZD3293 tablet formulation A|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
62334637|NCT02039180|EXPERIMENTAL|AZD3293 tablet formulation B|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
62334638|NCT03764202|OTHER|CSEA，1μg/kg•d|"* The puerpera received combined spinal epidural anesthesia~* The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
62492097|NCT04816773||Newly or previously implanted patients|Multicenter, non-interventional prospective follow-up of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 14 months of the study index surgery. Single study group with either newly or previously implanted patients with all EVOLUTION® NitrX™ components: Non-Porous Keeled Tibia, CS/CR Non-Porous Femur component, and EVOLUTION® MP CS tibial insert
62492098|NCT05529576|EXPERIMENTAL|Major depressive disorder|Outpatients in main-center and sub-centers; meet the DSM-IV diagnosis of Major Depressive Disorder (mental examination was conducted by at least two professional doctors); available relevant HIS system biochemical data; haven't been treated with physical therapy; age between 18-65 years old; gender is not limited.
62492099|NCT05529576|ACTIVE_COMPARATOR|Bipolar disorder|Outpatients in main-center and sub-centers; meet the DSM-IV diagnosis of Bipolar disorder (mental examination was conducted by at least two professional doctors); available relevant HIS system biochemical data; haven't been treated with physical therapy; age between 18-65 years old; gender is not limited
62334639|NCT03764202|OTHER|CSEA，1.5μg/kg•d|"* The puerpera received combined spinal epidural anesthesia~* The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
61939202|NCT06019949|ACTIVE_COMPARATOR|Spinal Cord Transcutaneous Stimulation (scTS) group|Participants will undergo 80 RT sessions using standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504). Participants will be trained at the Frazier Rehab Institute and remotely to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure threshold load. The training will be initiated with a load equal to 20% of their individual Maximum Inspiratory Pressure (PImax) and Maximum Expiratory Pressure (PEmax) values with progressive increases as tolerated up to 60% of their baseline PImax and PEmax measures. The goal will be to reach the 60% load of PImax and PEmax during the last week of each month of the training.
62137313|NCT05148988||AAA patients|The entire cohort consists of patients with an abdominal aortic aneurysm eligible for endovascular repair using an Endurant II device.
62137314|NCT06352619|EXPERIMENTAL|Conservative SBP Control|
62334640|NCT03764202|OTHER|GA，1μg/kg•d|"* The puerpera received general anesthesia~* The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
62695095|NCT04516434|EXPERIMENTAL|Intraurethral Electrical Stimulation|"This procedure is specific to the urethral stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the urethra and positioned with the electrode contact 10-14 mm from the bladder neck to stimulate the proximal urethra. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be 2-20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to the proximal urethra at strong desire to void during cystometry. The participant will then be given permission to void at maximum cystometric capacity with continuous intraurethral stimulation."
61939203|NCT06019949|EXPERIMENTAL|Spinal Cord Transcutaneous Stimulation and Respiratory Training (scTS+RT) group|Participants will undergo 80 scTS combined with the RT while seated in their own wheelchairs with an approximately 45° head-up tilt. The scTS will be administered using the Neostim/Biostim (Cosyma Inc., Denver CO) and Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the RT as described for the Arms 1 and 2.
61939204|NCT02739165|EXPERIMENTAL|ART-123|
61939205|NCT02739165|PLACEBO_COMPARATOR|Placebo|
61939206|NCT05464550|EXPERIMENTAL|Eye tracking|Utilisation of a eye tracker on a screen.
61939207|NCT02443116|PLACEBO_COMPARATOR|Cohort 1 - Placebo|Cohort 1 - Placebo
61939208|NCT02443116|EXPERIMENTAL|Cohort 1 - NGM282 3mg|Cohort 1 - NGM282 3mg
61939209|NCT02443116|EXPERIMENTAL|Cohort 1 - NGM282 6mg|Cohort 1 - NGM282 6mg
61939210|NCT02443116|EXPERIMENTAL|Cohort 2 - NGM282 0.3mg|Cohort 2 - NGM282 0.3mg
62334641|NCT03764202|OTHER|GA，1.5μg/kg•d|"* The puerpera received general anesthesia~* The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
61939211|NCT02443116|PLACEBO_COMPARATOR|Cohort 2 - NGM282 1mg|Cohort 2 - NGM282 1mg
61939212|NCT02443116|EXPERIMENTAL|Cohort 2 - NGM282 3mg|Cohort 2 - NGM282 3mg
61939213|NCT02443116|EXPERIMENTAL|Cohort 3 - NGM282 1mg|Cohort 3 - NGM282 1mg
61939214|NCT02443116|PLACEBO_COMPARATOR|Cohort 4 - Placebo|Cohort 4 - Placebo
61939215|NCT02443116|EXPERIMENTAL|Cohort 4 - NGM282 1mg|Cohort 4 - NGM282 1mg
61939216|NCT02955797|EXPERIMENTAL|Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
61939217|NCT02955797|EXPERIMENTAL|Group 2 (Meningococcal Vaccine-Naive): Nimenrix®|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
62137315|NCT06352619|EXPERIMENTAL|Moderate SBP Control|
62137316|NCT06352619|EXPERIMENTAL|Intensive SBP Control|
62137317|NCT01268306|EXPERIMENTAL|B+L Biotrue MPS and B+L PureVision|Successful contact lens wearers switched to B\&L BioTrue MPS while wearing B+L PureVision lenses
62137318|NCT01917942|ACTIVE_COMPARATOR|Standard of Care|Standard of Care
62334642|NCT03764202|OTHER|CSEA，Epidural analgesia|"* The puerpera received combined spinal epidural anesthesia~* Postoperative analgesia was performed with epidural analgesia~* Speed of epidural analgesia pump ：6ml/h（0.1% ropivacaine , 0.5μg/ml sufentanil）"
61939218|NCT02955797|EXPERIMENTAL|Group 3 (MenC-Primed): MenACYW Conjugate Vaccine|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
61939219|NCT02955797|EXPERIMENTAL|Group 4 (MenC-Primed): Nimenrix®|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
61939220|NCT00836030||A|
61939221|NCT04043728|EXPERIMENTAL|Mindfulness|This module introduces mindfulness training skills, with the goal of cultivating nonjudgmental, present-focused experience of emotions, thoughts, and physical sensations related to cigarette smoking. By progressing though a series of experiential exercises (e.g., awareness of the breath, anchoring in the present), this module seeks to reduce maladaptive attempts to control negative emotions and facilitate tolerance of the physical and emotional symptoms of nicotine withdrawal.
62137319|NCT01917942|EXPERIMENTAL|Humidification|Humidification
62137320|NCT05900895|EXPERIMENTAL|Treatment Arm|Participants receive 2 cycles of olaparib in combination with 17b-estradiol and then continue to be treated with single-agent 17b-estradiol until disease progression.
62334643|NCT01192217|ACTIVE_COMPARATOR|VATS group|
62334644|NCT01192217|ACTIVE_COMPARATOR|Mini-thoracotomy group|
62334645|NCT01057719|EXPERIMENTAL|Physiotherapy in Spain|Daily inpatient physiotherapy for four weeks in a warm climate
62695096|NCT04516434|EXPERIMENTAL|Intravesical Electrical Stimulation|This procedure is specific to the bladder stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the bladder through the urethra and the electrode contacts will be positioned to be floating within the bladder. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be set at 20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to bladder sensory nerves for up to 60 minutes prior to the start of urodynamic studies.
62334646|NCT01057719|EXPERIMENTAL|Physiotherapy in Norway|Daily inpatient physiotherapy for four weeks in a cold climate
61939222|NCT04043728|EXPERIMENTAL|Interoceptive Exposure (Practice Quitting)|This module introduces interoceptive exposure, a technique in which participants purposefully and systematically complete exercises to evoke physical sensations typically associated with anxiety and distress, in order to reduce fear and avoidance of these sensations. Interoceptive exercises will focus on a gradual exposure to nicotine withdrawal symptoms, through a series of 'practice quit attempts' (i.e., brief periods of smoking abstinence without intention to permanently quit).
61939223|NCT04043728|EXPERIMENTAL|Behavioral Activation (Countering Emotional Behaviors)|This module introduces behavioral activation, which seeks to increase positive emotions by systematically introducing greater engagement with natural rewards. Treatment sessions focus on the identification of avoidance strategies, including cigarette smoking as a coping strategy for negative emotions. The goal of this treatment module is to replace smoking with adaptive coping strategies to facilitate contact with and enjoyment of reinforcing activities that are incompatible with smoking.
61939224|NCT00100061|ACTIVE_COMPARATOR|Cranberry Juice|Cranberry Juice provided by Ocean Spray
61939225|NCT00100061|PLACEBO_COMPARATOR|Placebo cranberry juice|Taken orally
61939226|NCT04754243|EXPERIMENTAL|Study group|Will receive ANTIUI protocol
61939227|NCT04754243|ACTIVE_COMPARATOR|Control group|Will receive standard protocol in IUI and unexplained infertility
61939228|NCT02484183|NO_INTERVENTION|Low-flow oxygen|Low-flow oxygen supplementation if respiratory danger signs are present or if their oxygen saturation is \<90%. Respiratory danger signs include any of the following: grunting, severe chest indrawing, very fast breathing (\>70 breaths/minute if 1-11 months; \>60 breaths/minute if 12-59 months), nasal flaring, stridor in a calm child, or apnea. Low-flow oxygen given by an oxygen concentrator with a nasal cannula. Low-flow is 0.5 liters per minute (LPM) for patients 1-2 months, and 1-2 LPM for patients 2-59 months. For 2-59 month olds oxygen can be increased to a maximum of 2 LPM to maintain a 90% saturation or treat respiratory danger signs.
61939229|NCT02484183|EXPERIMENTAL|bubble CPAP|Bubble continuous positive airway pressure (bCPAP) patients are eligible if respiratory danger signs are present or if oxygen saturation is \<90%. bCPAP will be initiated at 7 centimeters (cm) water (H20) if 1-2 months of age or 8cm H20 if 2-59 months of age using the minimum oxygen flow necessary to achieve these pressures. Gradual weaning can be attempted after 24-48 hours of treatment. All changes will be followed by 60 minutes of monitoring.
61939230|NCT05700318|EXPERIMENTAL|Neurostimulation|Neurostimulation will be delivered to target nerves.
61939231|NCT04965909|EXPERIMENTAL|Educational and therapeutic exercise program|Participants will receive a 3-month online physiotherapy program comprised of 'pain neuroscience education' (month 1) and 'gradual exposure to movement' (month 2 and 3). They will receive an informative booklet online.
61939232|NCT04965909|NO_INTERVENTION|Passive control group (usual care)|Participants will receive the 'usual care'. They will receive an informative booklet online and the possibility of receiving the therapeutic program, once the study is completed.
61939233|NCT00514423|EXPERIMENTAL|2|Psychoeducation by peer-moderators
61939234|NCT00514423|EXPERIMENTAL|1|Psychoeducation by professionals
61939235|NCT00514423|EXPERIMENTAL|3|Video-education
61939236|NCT00514423|PLACEBO_COMPARATOR|4|Control group
62137321|NCT02505191|EXPERIMENTAL|Test|St. John's wort prolonged-release tablet 500 mg
62334647|NCT00427583|EXPERIMENTAL|STI571|
62334648|NCT03754608||Diabetics/No cognitive impairment|These are individuals with diabetes who do not have vascular cognitive impairment as determined by VASCOG criteria.
62334649|NCT03754608||Diabetics with vascular cognitive impairment|These are individuals with diabetes who have vascular cognitive impairment as determined by VASCOG criteria.
62334650|NCT02006667|EXPERIMENTAL|Trastuzumab, Gemcitabine, Cisplatin|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.
62137322|NCT02505191|ACTIVE_COMPARATOR|Reference|St. John's wort film coated tablets 250 mg (Remotiv N)
62137323|NCT02988193|EXPERIMENTAL|optima4BP Medication Management|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:~1. curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;~2. medication treatment recommendation;~3. active link to access additional treatment analysis tools."
62137324|NCT02988193|NO_INTERVENTION|Usual Care Medication Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
62334651|NCT03539172|EXPERIMENTAL|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
62334652|NCT02848300|EXPERIMENTAL|All Participants|Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.
62137325|NCT03249142|EXPERIMENTAL|ARM A Durvalumab/chemotherapy association|
62137326|NCT03249142|EXPERIMENTAL|ARM B Durvalumab/Tremelimumab/chemotherapy association|
61939237|NCT05490771|EXPERIMENTAL|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment and CT or MRI at baseline, every 2 cycles for the first 26 cycles, and then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
62334653|NCT00871949|EXPERIMENTAL|Cohort 1, Sequence 1|Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
62334654|NCT00871949|EXPERIMENTAL|Cohort 1, Sequence 2|Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
62334655|NCT00871949|EXPERIMENTAL|Cohort 1, Sequence 3|Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
62334656|NCT00871949|EXPERIMENTAL|Cohort 2, Sequence 1|Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
62334657|NCT00871949|EXPERIMENTAL|Cohort 2, Sequence 2|Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
62334658|NCT00871949|EXPERIMENTAL|Cohort 2, Sequence 3|Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
62334659|NCT02829177|ACTIVE_COMPARATOR|Allopurinol|400 mg once daily, tablet treatment
62334660|NCT02829177|PLACEBO_COMPARATOR|Placebo|Identical tablet treatment
62334661|NCT03988257|EXPERIMENTAL|Experimental group|Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day.
62334662|NCT03988257|PLACEBO_COMPARATOR|Control group|A vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight.
62334663|NCT02898207|EXPERIMENTAL|Dose Level 0: Olaparib 200 mg and Onalespib 20 mg/m^2|Dose Level 0 (DL0): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200mg PO BID on days 1-28 and onalespib 20 mg/m\^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
62334664|NCT02898207|EXPERIMENTAL|Dose Level 1: Olaparib 200 mg and Onalespib 40 mg/m^2|Dose Level 1 (DL1): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200mg PO BID on days 1-28 and onalespib 40 mg/m\^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
62334665|NCT02898207|EXPERIMENTAL|Dose Level 2: Olaparib 300 mg and Onalespib 40 mg/m^2|Dose Level 2 (DL2): Patients received olaparib 300 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 300 mg PO BID on days 1-28 and onalespib 40 mg/m\^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
62334666|NCT02898207|EXPERIMENTAL|Dose Level 3: Olaparib 300 mg and Onalespib 80 mg/m^2|Dose Level 3 (DL3): Patients received olaparib 300 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 300 mg PO BID on days 1-28 and onalespib 80 mg/m\^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
62334667|NCT02898207|EXPERIMENTAL|Dose Level 2a: Olaparib 200 mg and Onalespib 80 mg/m^2|Dose Level 2a (DL2a): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200 mg PO BID on days 1-28 and onalespib 80 mg/m\^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
62334668|NCT02898207|EXPERIMENTAL|Dose Level 3a: Olaparib 200 mg and Onalespib 120 mg/m^2|Dose Level 3a (DL3a): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200 mg PO BID on days 1-28 and onalespib 120 mg/m\^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
62334669|NCT01111539|EXPERIMENTAL|Phase B: Single-blind Prospective Treatment Phase|Participants received initial dose of escitalopram 10 milligram (mg) blinded capsule (over-encapsulated tablet), orally, once daily, increased to 20 mg/day at the end of Week 1 based upon tolerability profile, for up to maximum of Week 8. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
62334670|NCT01111539|EXPERIMENTAL|Phase B+: Single-blind Phase B Responders|Participants with response (≥50% reduction in depressive symptom severity in Hamilton Depression Rating Scale {HAM-D17} Total Score; or a HAM-D17 Total Score of \<14 at Week 8 or a Clinical Global Impression of Improvement {CGI-I} Score of \<3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B, for up to maximum of Week 14, in Phase B+.
62334671|NCT01111539|EXPERIMENTAL|Phase C: Aripiprazole/Escitalopram Combination|Participants with incomplete response (less than 50% reduction in depressive symptom severity between Baseline and Week 8 measured by the HAM-D17 Total Score and HAM-D17 Total Score of ≥14 at Week 8 and CGI-I Score of ≥3 at Week 6 and 8) at Week 8 received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily at Week 9. Participants were up titrated to aripiprazole target dose of 12 mg/day at Week 10 (if initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on initial 6 mg/day dose), and thereafter received same dose up to maximum of Week 14. No dose increases were allowed for aripiprazole after end of Week 12, however, doses might be decreased at any visit based upon tolerability. In combination with aripiprazole, participants received escitalopram (10 or 20 mg/day blinded capsules) taken during final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments allowed for escitalopram during Phase C.
62492100|NCT05529576|NO_INTERVENTION|Healthy controls|Healthy controls in main-center and sub-centers; no history of psychiatric disease; age between 18-65 years old; gender is not limited.
62492101|NCT00659828|EXPERIMENTAL|Recombinant Methionyl Human Leptin|Recombinant methionyl human leptin: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss).
61939238|NCT03328156||patient with STEMI will treated by PPCI|Primary angioplasty procedure The procedure will be performed using a standard angioplasty technique. A bolus of100 IU kg of heparin will be administered intra-arterially after insertion of the vascular catheter. The target lesions will initially treated with appropriate balloon predilatation as necessary, followed by intracoronary stenting. After stent implantation, heparin will be routinely administered. The sheaths will be removed the same day.
61939239|NCT03328156||patient with STEMI will treated by Thrombolytic therapy|oral clopidogrel (300 mg), Low-flow nasal oxygen, oral acetylsalicylic acid (325 mg), Will be given to each patient. Streptokinase will be given intravenously at 1.5 million units over approximately 60 min. Reperfusion afterTT will be assessed according to clinical criteria .
61939240|NCT06175975|EXPERIMENTAL|Auricular position|Experimental group: We will position the auricula back and up first while taking body temperature in pediatric patients. And then we will take body temperature without positioning.
61939241|NCT06175975|NO_INTERVENTION|Without auricular position|Controlled group: We will not position the auricula first while taking body temperature. And then we will position the auricula back and up.
62334672|NCT01111539|EXPERIMENTAL|Phase C: Escitalopram Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received escitalopram dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
62334673|NCT01111539|EXPERIMENTAL|Phase C: Aripiprazole Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily for Week 9. Participants were up titrated to the aripiprazole target dose of 12 mg/day at Week 10 (if the initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on the initial 6 mg/day dose), and thereafter received the same dose for up to maximum of Week 14. No dose increases were allowed for aripiprazole after the end of Week 12, however, doses might be decreased at any visit based upon tolerability.
62334674|NCT01893944|EXPERIMENTAL|Virtual Reality|- Participate in this group 20 women to be treated by means of games Xbox 360 ®, attributed to this, custom applications using virtual and augmented reality to be developed.
62334675|NCT01893944|EXPERIMENTAL|Vibration therapy|- participate in this group 20 women who will undergo 15 minutes of continuous vibration by vibration of the upper mantle, with a frequency of 40 Hz, 3 function and intensity tolerable, keeping the limb supported and raised to 120 °.
62334676|NCT01893944|ACTIVE_COMPARATOR|control group|- participate in this group 20 women who are treated with conventional cinesioterapia through muscle stretching exercises, dissociation girdle, active and active-assisted exercises for groups flexors, extensors, abductors and adductors of the upper limbs, which will be three series 10 repetitions for each exercise.
62492102|NCT02364869|EXPERIMENTAL|Fructooligosaccharide|12g daily, for 12 weeks
62492103|NCT02364869|PLACEBO_COMPARATOR|Maltodextrin|12g daily, for 12 weeks
62695097|NCT06252584|EXPERIMENTAL|Multipeptide Vaccination|The vaccine cocktail will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1) as adjuvant. Two vaccinations within a 6-week interval are planned, with the option of one additional booster in case of insufficient response after the first two vaccinations. Peptide vaccination will take place in AML patients that have achieved a morphological complete remission (CR) or a complete remission with incomplete blood count recovery (CRi) with standard first line treatment. MRD positivity is permitted. Vaccination will start 4-28 weeks after last application of intensive chemotherapy). Any maintenance treatment, e.g. with oral azacytidine or midostaurin, or ongoing low intensity therapy, e.g. with HMA, venetoclax etc. is permitted, can be applied throughout the vaccination and continued after study treatment according to the treating physician's decision.
62695098|NCT06540976|EXPERIMENTAL|Experiment 1 - episodic / executive switch|"All enrolled participants will be asked to perform experiment 1, which is a cognitive task involving the switch between performing episodic memory decisions (e.g., did you eat fruit yesterday?) and executive decisions (e.g. ...does 5+3+8 = 17?). Participants will perform this computer-based task while electrical brain activity is recorded from the posterior cingulate cortex, hippocampus and prefrontal cortex. This task takes 18 minutes to complete."
62695099|NCT06540976|EXPERIMENTAL|Experiment 2 - executive decision task|All enrolled participants will be asked to perform experiment 2, which is a cognitive task involving reward-based decisions between two options. For each decision, the two options will differ in their risk and reward (e.g., 100% chance of 10 points vs. 30% chance of 50 points). Participants will perform this computer-based task while electrical brain activity is recorded from the posterior cingulate cortex, hippocampus and prefrontal cortex. This task takes 15 minutes to complete.
62492104|NCT01985724|ACTIVE_COMPARATOR|A|FEC -\> TXT
62492105|NCT01985724|EXPERIMENTAL|B|Docetaxel/Cyclophosphamide (TC)
61939242|NCT05053711|EXPERIMENTAL|rTMS+rPMS_iTBS_M|In this group, they received iTBS on affected hemisphere after following iTBS at median nerve on affected hand.
61939243|NCT05053711|EXPERIMENTAL|rTMS+rPMS_cTBS_M|In this group, they received iTBS on affected hemisphere after following cTBS at median nerve on affected hand.
61939244|NCT05053711|SHAM_COMPARATOR|rTMS+sham rPMS_M|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median nerve on affected hand.
61939245|NCT05053711|EXPERIMENTAL|rTMS+rPMS_iTBS_U|In this group, they received iTBS on affected hemisphere after following iTBS at ulnar nerve on affected hand.
61939246|NCT05053711|EXPERIMENTAL|rTMS+rPMS_cTBS_U|In this group, they received iTBS on affected hemisphere after following cTBS at ulnar nerve on affected hand.
62492106|NCT05021276|EXPERIMENTAL|ruxolitinib+basiliximab|Patients with grade 3-4 steroid-refractory aGVHD receive combined therapy of basiliximab and ruxolitinib.
62492107|NCT01492439|EXPERIMENTAL|Cognitive Remediation and Supported Education|Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
61939247|NCT05053711|SHAM_COMPARATOR|rTMS+sham rPMS_U|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at ulnar nerve on affected hand.
61939248|NCT05420792|ACTIVE_COMPARATOR|intervention group|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group
61939249|NCT05420792|NO_INTERVENTION|control group|the control group will be given a Community Mental Health Center and will also continue the treatment
61939250|NCT03078907|EXPERIMENTAL|Selexipag|Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
61939251|NCT03078907|PLACEBO_COMPARATOR|Placebo|Regimen and titration scheme similar to those in the selexipag group
61939252|NCT02298686||Observation|Patients with Sanfilippo Type A-B-C-D disease or high-grade suspicion for Sanfilippo Type A-B-C-D disease
61939253|NCT04957160||Cohort 1|
61939254|NCT04957160||Cohort 2|
61939255|NCT01638767|EXPERIMENTAL|NuvaRing|Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
61939256|NCT01638767|ACTIVE_COMPARATOR|Marvelon|Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.
62334677|NCT02147145||Observation Cohort|
61939257|NCT01863953|EXPERIMENTAL|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
61939258|NCT01863953|ACTIVE_COMPARATOR|Bimatoprost Ophthalmic Solution 0.01% and Vehicle|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
62334678|NCT00294008||001|Risperdal Consta flexible dosage for 24 months
61939259|NCT01863953|ACTIVE_COMPARATOR|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
61939260|NCT00585390|EXPERIMENTAL|Essential omega-3 fatty acid replacement|
61939261|NCT00585390|PLACEBO_COMPARATOR|Placebo|
61939262|NCT05840718||Control group|Septic shock patients treated according surviving sepsis campaign 2021 guidelines
61939263|NCT05840718||Intervention group|Septic shock patients treated according surviving sepsis campaign 2021 guidelines supplemented with thiamin 200 mg in 50 ml 5% dextrose twice daily for 7 days.
62334679|NCT03317275|EXPERIMENTAL|injection based on 18F-Fluoride-PET/MRI|One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
62334680|NCT03317275|ACTIVE_COMPARATOR|injection based on clinical practise|The control group will undergo facet injections blinded to the 18F-Fluoride-PET/MRI results, but based on current standard clinical practise (MRI and clinical correlation). Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
62334681|NCT06273657|EXPERIMENTAL|Medisinstart|
62334682|NCT06273657|NO_INTERVENTION|Control|
62334683|NCT01947049|NO_INTERVENTION|Control Arm|Participants in this arm will receive usual care (influenza testing and treatment)
62334684|NCT01947049|EXPERIMENTAL|Rapid Testing|Participants in this arm will receive rapid influenza testing with Xpert Flu.
62334685|NCT00982241|ACTIVE_COMPARATOR|normal fluid intake|1500 ml /day (+/- 300 ml) for 2,5 days
62334686|NCT00982241|ACTIVE_COMPARATOR|high fluid intake|2400 ml/day (+/- 300 ml )for 2,5 days
62334687|NCT00982241|ACTIVE_COMPARATOR|low fluid intake|fluid intake 900 ml/day (+/- 300ml) for 2,5 days
62334688|NCT01291329|EXPERIMENTAL|WJ-MSC|Wharton's jelly- Derived Mesenchymal Stem Cells Transfer
62334689|NCT06049771|EXPERIMENTAL|Intervention group|Patients who were infected caused by CRE bloodstream infection and were treated with tigecycline. Blood samples were collected.
62334690|NCT01796704||healthy and mild heart failure|diversity of patients
62334691|NCT02590445|ACTIVE_COMPARATOR|Active stimulation|Stimulator on followed by off
62334692|NCT02590445|SHAM_COMPARATOR|Sham stimulation|Stimulator off followed by on
62334693|NCT04926194|EXPERIMENTAL|Patient with MDS/MPN|DSCs will be given 1 × 10\^6 cells per kilogram of participant's body weight intravenously, administered once per week up to a maximum of six weeks depending on the clinical response.
62334694|NCT05522712|EXPERIMENTAL|Acapella user|this group will use acapella in addition to traditional chest physiotherapy , early mobility and sternal precautions.
62334695|NCT05522712|EXPERIMENTAL|Incentive spirometer user|this group will receive incentive spirometer in addition to traditional chest physiotherapy, early mobility and sternal precautions.
62334696|NCT05522712|OTHER|Control user|this group will receive traditional chest physiotherapy , early mobility and sternal precautions.
62334697|NCT03136705|ACTIVE_COMPARATOR|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
62334698|NCT03136705|ACTIVE_COMPARATOR|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
62334699|NCT03136705|ACTIVE_COMPARATOR|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
62492108|NCT01492439|ACTIVE_COMPARATOR|Supported Education Only|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
62695100|NCT06540976|EXPERIMENTAL|Experiment 3 - episodic decision task|All enrolled participants will be asked to perform experiment 3, which is a cognitive task involving memory-based decisions between two options (pictures of people). For each decision, the two pictures will differ in memory strength and reward (e.g., familiar picture for 10 points vs. unfamiliar picture 50 points). Memory strength for each picture will be defined by how many times the picture was previously shown (e.g., 2 vs. 10 presentations) prior to performing the memory decision task. Participants will perform this computer-based task while electrical brain activity is recorded from the posterior cingulate cortex, hippocampus and prefrontal cortex. This task takes 15 minutes to complete.
62695101|NCT06160167||Participants with MM treated with IMiDs|
62695102|NCT06160167||Participants with MM not treated with IMiDs|
62695103|NCT06160167||Participants with MM treated with systemic therapy|
62695104|NCT04347109||Biventricular Pacing|Patients implanted with a device enabling cardiac resynchronization therapy.
62695105|NCT04347109||Right Ventricular Pacing|Patients implanted with a right ventricular pacing device.
62334700|NCT03136705|PLACEBO_COMPARATOR|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
62695106|NCT05974176|EXPERIMENTAL|Trauma Focused CBT (TF-CBT)|Patients and families randomized to engage in TF-CBT.
62695107|NCT05974176|EXPERIMENTAL|Trauma Systems therapy (TST)|Patients and families randomized to engage in TST.
62695108|NCT06639399||Group A|Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally.
62695109|NCT06639399||Group B|Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6).
62695110|NCT06621277||Individuals received a GI tumor diagnosis > 50 years|
61939264|NCT01457820|EXPERIMENTAL|Allopurinol High dose|
61939265|NCT01457820|EXPERIMENTAL|Allopurinol Low dose|
61939266|NCT01457820|PLACEBO_COMPARATOR|Placebo|
61939267|NCT02091908|EXPERIMENTAL|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
61939268|NCT02091908|EXPERIMENTAL|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
61939269|NCT02091908|ACTIVE_COMPARATOR|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
62334701|NCT02802059|EXPERIMENTAL|EcN-Suspension|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with EcN-Suspension
62334702|NCT02802059|PLACEBO_COMPARATOR|Placebo|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with Placebo
62695111|NCT06621277||Individuals received a GI tumor diagnosis ≤ 50 years|
62695112|NCT06644365|PLACEBO_COMPARATOR|control group|Students will be given a placebo exercise on a flat yoga/exercise mat on the same days, in the same way and for the same duration as the intervention group.
62695113|NCT06644365|EXPERIMENTAL|intervention group|They will be asked to lie on the acupressure mat for 15 minutes once a day, 3 days a week (Monday, Wednesday, Friday). A reminder message will be sent on the morning of the application so that participants do not forget and are motivated. After each application, participants will be asked to fill out the session monitoring chart.
62334703|NCT05653739|EXPERIMENTAL|Mindfulness Based Intervention Group|Mindfulness Based Stress Reduction Intervention , The training consists of eight weekly group sessions with the duration of approximately 2-2.5 hours with a trained instructor. Further participants were given daily audio-guided home practice (approximately 45 min/day), and a day-long mindfulness retreat (occurring during week sixth of the 8-week program)
62334704|NCT05653739|NO_INTERVENTION|Control Group|Participants in the control group were not given any intervention in order to compare with the experimental group. At the end of the study participants in this group were also offered relaxation trainings in order to deal with the psychological distress, quality of life and distress tolerance.
62334705|NCT02786589|EXPERIMENTAL|Blood-stage infection of P. vivax|This is a single arm study that enrolls 30 patients to receive Plasmodium immunotherapy.
62492109|NCT03404921|EXPERIMENTAL|ESTD group|Use tunnelling method during ESD operation
62492110|NCT03404921|OTHER|ESD group|Use traditional method during ESD operation
62492111|NCT05536960|EXPERIMENTAL|68Ga-Dotatate PET/CT|These patients will undergo a 68Ga-Dotatate PET/CT scan.
62695114|NCT03934619|EXPERIMENTAL|Intervention|Convenient cohort, non-randomized group will be enrolled to examine the effects of the Dolores One on improving the ease of communication and intelligibility
61939270|NCT02091908|ACTIVE_COMPARATOR|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
61939271|NCT00487682|EXPERIMENTAL|1|ASP2151 low dose
61939272|NCT00487682|EXPERIMENTAL|2|ASP2151 middle dose
61939273|NCT00487682|EXPERIMENTAL|3|ASP2151 high dose
61939274|NCT00487682|ACTIVE_COMPARATOR|4|Valacyclovir hydrochloride
61939275|NCT06558084||Metastatic breast cancer patients|metastatic breast cancer patient receiving CDK4/6i in 1st or 2nd line
61939276|NCT01744431||No treatment|
62334706|NCT01008501||Experimental|Individuals with recurrent or sporadic hydatidiform moles and their first-degree family members. Sometimes additional family members are also enrolled.
62695115|NCT06639191|EXPERIMENTAL|This is a single arm trial where patients are included in successive cohorts|In the successive cohorts, increasing doses of radioactivity (177-Lu) and CD44v6-targeted antibody (AKIR001) are given. A new dose cohort is opened only when toxicity in the previous dose cohort has deemed acceptable by the trial steering committee and the independent Data Safety Monitoring Board.
62695116|NCT05670704|EXPERIMENTAL|ARGX-119|Patients receiving ARGX-119 IV or SC
62695117|NCT05670704|PLACEBO_COMPARATOR|Placebo|Patients receiving Placebo IV or SC
62695118|NCT05815498|EXPERIMENTAL|Part 1: mRNA-1283.222|Participants will receive single intramuscular (IM) injection of mRNA-1283.222 on Day 1.
61939277|NCT06680778||Cancer Patients|All patients with stomach and esophageal malignancies referred for chemotherapy of the outpatient clinic at the department of Medical Oncology at the Erasmus University Medical Center.
62334707|NCT01902277||Adult critically ill patients|All adult patients treated within study time frame on Intensive Care Units across Norfolk, Suffolk, and Cambridgshire, UK
62334708|NCT05122988||age 18|target sample 2500
62334709|NCT05122988||age 19|target sample 626
62492112|NCT01139216|EXPERIMENTAL|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
62492113|NCT01139216|EXPERIMENTAL|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
61939278|NCT06557486|EXPERIMENTAL|Mindfulness-Based Stress reduction arm|
61939279|NCT06557486|NO_INTERVENTION|Usual care|
62492114|NCT01139216|PLACEBO_COMPARATOR|Placebo|Placebo TID
62492115|NCT05665387|EXPERIMENTAL|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID
62492116|NCT05665387|EXPERIMENTAL|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID
62492117|NCT05665387|PLACEBO_COMPARATOR|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution BID
62492118|NCT03651336|OTHER|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
62492119|NCT02387034|EXPERIMENTAL|Physical activity on prescription (PAP)|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
61939280|NCT06623682|EXPERIMENTAL|JCTH+-integrated mental health services|In the intervention arm, the JCTH+ platform will be integrated into the existing services of tertiary education institutions and introduced to students through mass advertisement within the institution. After randomization, three tertiary education institutions are allocated in this arm, including Chinese University of Hong Kong (CUHK), University of Hong Kong (HKU), and Hong Kong University's School of Professional and Continuing Education (HKU SPACE). Students will be invited to join this study and give consent adhering to the declaration of Helsinki.
62492120|NCT02387034|OTHER|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about being active with cardiovascular exercise such as walking, cycling or otherwise in 30 minutes three times a week and do strength training functional during the day such as walk in stairs and getting up from a chair without hand support.
62492121|NCT00619281||Oberservation|600 consecutive patients undergoing cardiac surgery
61939281|NCT06623682|NO_INTERVENTION|Service-as-usual (SAU)|In the no-intervention group, participants will continue with their usual practice, i.e. service-as-usual (SAU), for 4 months before implementing the project. After randomization, three tertiary education institutions are allocated in this arm, including The Hong Kong Polytechnic University (PolyU), Tung Wah College (TWC) and City University of Hong Kong (CityU). The same integration procedure will be implemented after this waiting period.
61939282|NCT05686954|EXPERIMENTAL|CSO LOW|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
62334710|NCT05122988||age 20|target sample 626
62492122|NCT02501863|EXPERIMENTAL|Ropivacaine+fentanyl|"Femoral nerve block with ropivacaine+fentanyl~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
62492123|NCT02501863|EXPERIMENTAL|Ropivacaine|"Femoral nerve block with ropivacaine~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
62492124|NCT04510766||Part A|Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions
62695119|NCT05815498|EXPERIMENTAL|Part 1: mRNA-1273.222|Participants will receive single IM injection of mRNA-1273.222 on Day 1.
62695120|NCT05815498|EXPERIMENTAL|Part 2: mRNA-1283.815|Participants will receive single IM injection of mRNA-1283.815 on Day 1.
62695121|NCT05815498|EXPERIMENTAL|Part 2: mRNA-1273.815|Participants will receive single IM injection of mRNA-1273.815 on Day 1.
62695122|NCT03578315|EXPERIMENTAL|Solar lentigo|25 Patients with Solar lentigo
62695123|NCT03578315|EXPERIMENTAL|Nevus zygomaticus|25 Patients with Nevus zygomaticus
61939283|NCT05686954|EXPERIMENTAL|CSO MID|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
62334711|NCT05122988||age 21|target sample 1250
62334712|NCT00931580|PLACEBO_COMPARATOR|Placebo|placebo tablet
62334713|NCT00931580|EXPERIMENTAL|400 IU|Vitamin D3 tablet, 400 IU
62334714|NCT00931580|EXPERIMENTAL|1,000 IU|Vitamin D3 tablet, 1,000 IU
62334715|NCT00931580|EXPERIMENTAL|2,000 IU|Vitamin D3 tablet, 2,000 IU
62334716|NCT00931580|EXPERIMENTAL|4,000 IU|Vitamin D3 tablet, 4,000 IU
62334717|NCT00385268|EXPERIMENTAL|Active medication Acamprosate|1998mg/day for 8 weeks
62334718|NCT00385268|PLACEBO_COMPARATOR|Placebo|placebo pills for 8 weeks
62334719|NCT02792010|EXPERIMENTAL|T1rho MRI|Patients included had hip cartilage MRI with acquisition of T1rho MRI sequence.
62334720|NCT04567602||Participants with PAH|Participants with confirmed diagnosis of pulmonary arterial hypertension (PAH) will be enrolled in the study and the data will be collected and observed to describe the application of European ESC/ERS guidelines and related 6th WSPH proceedings on risk assessment and related treatment strategy, in clinical practice.
62334721|NCT06270693|EXPERIMENTAL|CAD WITH AP|CORONARY ARTERY DISEASE WITH APICAL PERIODONTITIS
62334722|NCT06270693|NO_INTERVENTION|CAD WITHOUT AP|CORONARY ARTERY DISEASE WITHOUT AP
62334723|NCT01458509||IVRS ( interactive voice response system) EASP|Telephone Group with Nurse Intervention
62334724|NCT01458509||Web EASP|Web Group with Nurse Intervention
62334725|NCT01458509||IVRS ( interactive voice response system) No EASP|Telephone Group without nurse intervention
62334726|NCT01458509||Web No EASP|Web Group without nurse intervention
62492125|NCT04510766||Part B|"FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for liquid biopsy will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent~(1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of liquid biopsy for future analysis."
62695124|NCT05781503|EXPERIMENTAL|Portable Rent Subsidies + Identity Capital Intervention|Young people randomized to the intervention group will receive 12 months of: portable rent subsidies, engage in a co-designed leadership guide, and be assigned a coach (one coach/10 youth).
62695125|NCT05781503|ACTIVE_COMPARATOR|Portable Rent Subsidies Only|The control group will be offered 12 months of portable rent subsidies.
61939284|NCT05686954|EXPERIMENTAL|CSO HIGH|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
61939285|NCT05686954|ACTIVE_COMPARATOR|CONTROL|Participants are given foods enriched with a mixture of oils and instructed on how to substitute study foods into their diet to maintain caloric balance.
61939286|NCT05029700|EXPERIMENTAL|Combined exercise group|Combined training consists of trunk stabilization training and aerobic training.
62137327|NCT02357966|EXPERIMENTAL|Phase I|"A phase I of the trial is a dose escalation study intended to assess the possible toxicity and to determine the recommended phase 2 dose (RP2D) of the study drug (514G3).~Randomized subjects were administered the study drug at 3 dose levels i.e. 2 mg/kg, 10 mg/kg, and 40 mg/kg or placebo."
62137328|NCT02357966|EXPERIMENTAL|Phase II|A phase 2 of the trial is a dose expansion study designed to assess the preliminary efficacy. Eligible subjects are randomized (2:1) and received a single dose of 40 mg/kg study drug (514G3) with standard IV treatment versus placebo with standard IV treatment.
62137329|NCT02040363|ACTIVE_COMPARATOR|COPD Patients ~90% VO2max|COPD Patients \~90% VO2max
62137330|NCT02040363|ACTIVE_COMPARATOR|COPD patients ~60-65% VO2max|COPD patients \~60-65% VO2max
61939287|NCT05029700|ACTIVE_COMPARATOR|Control group|Aerobic training was given to the control group.
61939288|NCT06236620|ACTIVE_COMPARATOR|Control wheat flakes|Wheat flakes made of whole derived from unprocessed wheat
62137331|NCT02040363|PLACEBO_COMPARATOR|healthy volunteers|healthy volunteers
62334727|NCT02524652|EXPERIMENTAL|Local infiltration analgesia|Infiltration of the knee by the surgeon with local anaesthetics under general anaesthesia.
61939289|NCT06236620|ACTIVE_COMPARATOR|Flakes from sprouted wheat|Wheat flakes made of whole derived from sprouted wheat
61939290|NCT06236620|ACTIVE_COMPARATOR|Flakes from hydrothermally processed wheat|Wheat flakes made of whole derived from hydrothermally processed wheat
61939291|NCT01517685|EXPERIMENTAL|Flax Oil and then Fish Oil|All people in the study will use the flax seed oil and then the fish oil.
61939292|NCT03166878|EXPERIMENTAL|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
61939293|NCT01354587|ACTIVE_COMPARATOR|Hizentra|Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra
62137332|NCT04941703|EXPERIMENTAL|Magnesium Citrate plus a Probiotic Arm:|Participants assigned to the magnesium citrate plus a probiotic arm will receive 1 bottle of magnesium citrate 296 mL PO once to be taken within a 4-hour period, (about 10 oz.). Because magnesium citrate remains within the intestinal lumen, a second bottle can be provided if there is limited bowel movement. Patients will be asked to take 2 capsules of probiotics twice daily for six days or until discharge, whichever is earlier.
62137333|NCT04941703|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive matching placebo 296 mL PO once to be taken within a 4-hour period, (about 10 oz.) and 2 cellulose capsules twice daily for six days or until discharge, whichever is earlier. The placebo will be flavored to match the taste of the interventional arm.
62137334|NCT02979184|OTHER|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
62137335|NCT05396638|EXPERIMENTAL|Contingency Management|Abstinence will be rewarded following a contingency management (CM) payment scale.
62334728|NCT02524652|ACTIVE_COMPARATOR|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist after the surgery, before awaking the patient.
62334729|NCT00400829|EXPERIMENTAL|Arm I|Patients receive 1.4 mg/m2 eribulin mesylate IV over 1-2 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62334730|NCT06146712|EXPERIMENTAL|Intervention Arm: 'Dream the night away' nighttime lotion|"The product should be applied once daily at night (30 minutes before bedtime). Participants should apply two teaspoons (one teaspoon of lotion covers approximately the size of the fingertip from tip to first knuckle) of lotion (3 mg of melatonin) and use it wherever they would usually use body lotion (paying particular attention to areas of tension in shoulders, neck, and temples, or on their legs and feet if they experience restless legs or muscle tightness).~Participants should do this for 20 nights."
62334731|NCT02356406|EXPERIMENTAL|Celiac Plexus Radiosurgery|"The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial.~All eligible patients will receive the same protocol of celiac plexus radiosurgery"
62334732|NCT02969317|EXPERIMENTAL|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
62334733|NCT06553924|EXPERIMENTAL|Macitentan and Tadalafil|Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
62334734|NCT06553924|ACTIVE_COMPARATOR|PrOpsynvi® film-coated tablets|PrOpsynvi® macitentan and tadalafil film-coated tablets 10 mg/40 mg
62334735|NCT05841550|EXPERIMENTAL|TG01|"TG01 is a sterile lyophilizate consisting of a mixture of seven peptides. The finished product is a white powder for injection, consisting only of the active substances containing 2.1 mg of peptides (individual peptides comprising 0.3 mg each). The lyophilizate is to be reconstituted with QS-21 for injection before use.~QS-21 is a naturally occurring saponin molecule purified from the South American tree Quillaja saponaria Molina. QS-21 Solution is supplied in a 2 mL CZ resin vial as a sterile, solution in PBS (phosphate buffered saline) at a concentration of 0.5 mg/mL QS-21 (500 mcg/mL) with each vial containing 0.7 mL intended single use only.~The vaccine will be given subcutaneously Treatment consists of 12 doses TG01/QS-21 vaccine given every 2 weeks in the first 12 weeks, followed by every 8 weeks until week 52.~TG01 dose 0.7 mg dose and QS-21 50 ug."
62334736|NCT01016106|ACTIVE_COMPARATOR|AA pts AD and IV|African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
62334737|NCT01016106|ACTIVE_COMPARATOR|AA patients (controls)|African American patients with no personal or family history of ichthyosis vulgaris or atopy. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
62334738|NCT06217016|EXPERIMENTAL|ICCAUT Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will undergo bladder training. The bladder training include intermittent catheter clamping and active urination to facilitate complete bladder emptying each time the catheter is released, which we called ICCAUT strategy. The training will commence at 9:00 am on the first postoperative day, and the catheter will be removed at 9:00 am on the second postoperative day.
62334739|NCT06217016|OTHER|Free Drainage Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will have their urinary catheter kept open postoperatively, and the catheter will be removed at 9:00 am on the second postoperative day.
62334740|NCT00605410|ACTIVE_COMPARATOR|1|
62334741|NCT00605410|PLACEBO_COMPARATOR|2|
62334742|NCT06122428||Group X: Ribohyal Group|Composed of 16 eyes (right or left) assigned for the use of modified hyaluronic acid, HAr® 0.1%, covalently linked to Riboflavin
62334743|NCT06122428||Group Y: (Control Group)|Composed of 16 eyes (right or left) assigned for the use of HA 0.1% alone
62334744|NCT03168256|EXPERIMENTAL|CF101 2mg|CF101 2mg, orally q12 hours
62334745|NCT03168256|EXPERIMENTAL|CF101 3mg|CF101 3mg, orally q12 hours
62334746|NCT03168256|ACTIVE_COMPARATOR|Apremilast 30mg|Apremilast 30mg, orally q12 hours
62334747|NCT03168256|PLACEBO_COMPARATOR|Placebo|Placebo control , orally q12 hours
62334748|NCT06139679||Fenestrated|Patients with ASD who underwent surgical closure of ASD with fenestrated patch
62695126|NCT00000884|EXPERIMENTAL|1|Participants will undergo treatment intramuscularly
62695127|NCT00000884|EXPERIMENTAL|2|Participants will undergo treatment orally
61939294|NCT02420158|EXPERIMENTAL|Vagal nerve stimulation|Trans-cutaneous vagal nerve electrical stimulation during 6 months
61939295|NCT00473473|EXPERIMENTAL|1|potassium bichromate
61939296|NCT00473473|PLACEBO_COMPARATOR|2|placebo
61939297|NCT05736510|EXPERIMENTAL|Binaural|Exposed to binaural sound (40 Hz) from the end of pneumoperitoneum until the eyes are open
61939298|NCT05736510|ACTIVE_COMPARATOR|Control|Applied silent files from the end of pneumoperitoneum until the eyes are open
61939299|NCT05782712||Syncope|patients referred for syncope evaluation
61939300|NCT05782712||No syncope|Subjects without syncope
61939301|NCT01522807|EXPERIMENTAL|100 mg PF-05190457|Three fasted treatments and fed with the short-duration osmotic capsule
61939302|NCT01522807|EXPERIMENTAL|100 mg PF - 05190457|Three fasted treatments and fed with the long-duration osmotic capsule
61939303|NCT01317381||ICU patients|Admitted patients to the ICU
61939304|NCT02590926||Patients|"patients with stable angina and/or documented ischemia presenting with:~* An angiographic stenosis of more than 50% and less than 90% of the left main~* Any proximal descending anterior with a stenosis of more than 50% and less than 90%~* Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%~* Single remaining patent coronary artery with stenosis \>50% and less than 90%"
61939305|NCT04634799|ACTIVE_COMPARATOR|TM5614|TM5614 30 mg tablets. 6 tablets (180 mg) taken by mouth, once daily for up to 7 days
61939306|NCT04634799|PLACEBO_COMPARATOR|Placebo|Placebo tablets. 6 tablets taken by mouth, once daily for up to 7 days
61939307|NCT02329821||HCC group|patients with hepatocellular carcinoma
62334749|NCT06139679||Non-fenestrated|Patients with ASD who underwent surgical closure of ASD with non-fenestrated patch
62334750|NCT01672996|EXPERIMENTAL|Arm 1 - Ioforminol 160mgI/mL|Single administration of Ioforminol 160mgI/mL given to the subject.
62334751|NCT01672996|EXPERIMENTAL|Arm 2 - Ioforminol 200mgI/mL|Given as a single administration to the subject
61939308|NCT02329821||donor group|patient for liver transplantation donation
61939309|NCT06046833|EXPERIMENTAL|Patients with type 1 or type 2 diabetes and gastroparesis|"Both groups will have the same intervention.~* FreeStyle Libre 3 sensor for Continuous Glucose Monitoring.~* Balanced nutritional drink (Boost plus 8 ounces/237 mL) for a standardized meal challenge."
61939310|NCT06046833|ACTIVE_COMPARATOR|Patients with type 1 or type 2 diabetes without gastroparesis|"Both groups will have the same intervention.~* FreeStyle Libre 3 sensor for Continuous Glucose Monitoring.~* Balanced nutritional drink (Boost plus 8 ounces/237 mL) for a standardized meal challenge"
61939311|NCT06337422|EXPERIMENTAL|Generic celecoxib 200 mg capsule|Generic celecoxib 200 mg capsule. The test product will be formulated using the same active ingredient with the same strength as the reference product, CELEBREX™. The test product to be used in this bioequivalence study is prepared in accordance with GMP regulations.
61939312|NCT06337422|ACTIVE_COMPARATOR|Celecoxib 200 mg capsule|Celecoxib 200 mg capsule, CELEBREX™, has been registered with Food and Drug Administration, Thailand (TFDA).
62334752|NCT01672996|ACTIVE_COMPARATOR|Arm 3 - Iopamidol 300mgI/mL|Given as a single administration to the subject
62695128|NCT00000884|EXPERIMENTAL|3|Participants will undergo treatment intranasally
62695129|NCT00000884|EXPERIMENTAL|4|Participants will undergo treatment intrarectally
62695130|NCT00000884|EXPERIMENTAL|5|Participants will undergo treatment intravaginally
61939313|NCT02502175|EXPERIMENTAL|Opium|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
62137336|NCT03411174|EXPERIMENTAL|HF-PBI|Hypofractionated partial breast irradiation was delivered to the tumor bed areas for low recurrence risk breast cancer patients, with prescription dose 40Gy in 15 fractions in 3 weeks.
62137337|NCT04797767|EXPERIMENTAL|Treatment (CLAG-M, venetoclax)|Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days 1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone, and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression or unacceptable toxicity.
62137338|NCT02101138|EXPERIMENTAL|Dexpramipexole|Dexpramipexole treatment
62137339|NCT02310152|ACTIVE_COMPARATOR|Active Treatment: CBT|Cognitive Behavioral Therapy
61939314|NCT02502175|ACTIVE_COMPARATOR|methadone|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
62137340|NCT02310152|EXPERIMENTAL|Experimental Treatment: SPACE|Parent-Based Treatment of Childhood and Adolescent Anxiety Disorders
62137341|NCT01614405|PLACEBO_COMPARATOR|Placebo|"Identical Placebo Tablets.~Duration: 6 months therapy with blinded placebo followed by 6 months open label therapy (Truvada and Kaletra). Following, there is an option for an 18-month extension study."
62137342|NCT01614405|ACTIVE_COMPARATOR|TDF/FTC/LPV/r|"TDF/FTC/LPV/r~One tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months, or less if adverse events occur.~Duration: 6 months of therapy with the option of open label for additional 18-month extension study."
62137343|NCT00012805|OTHER|Arm 1|
62137344|NCT00951691|EXPERIMENTAL|Enhanced acute medical rehabilitation|Participants will receive enhanced acute medical rehabilitation.
62137345|NCT00951691|ACTIVE_COMPARATOR|Treatment as usual|Participants will receive treatment as usual.
62137346|NCT02260024|ACTIVE_COMPARATOR|Pramipexole IR|
62137347|NCT02260024|EXPERIMENTAL|Pramipexole SR C2 in the fasted state|
62137348|NCT02260024|EXPERIMENTAL|Pramipexole SR C2A in the fasted state|
62137349|NCT02260024|EXPERIMENTAL|Pramipexole SR C2B in the fasted state|
62137350|NCT02260024|EXPERIMENTAL|Pramipexole SR C in the fasted state|
62137351|NCT02260024|EXPERIMENTAL|Pramipexole SR C2 in the fed state|
62137352|NCT04259047|EXPERIMENTAL|Diabetes Regulation for Eyesight and Memory (DREAM)|DREAM is a behavioral treatment for diabetes mellitus (DM), as well as a secondary prevention strategy for dementia. DREAM acts to reinforce DM self-care and address negative beliefs about medications and physicians, which compromise glycemic control in African Americans (AAs). In DREAM, race-concordant community health workers (CHWs) will: 1) deliver in-home DM education tailored to AAs with MCI; 2) use action plans to reinforce diabetes self-care; 3) facilitate telehealth visits with a DM nurse educator to improve DM self-care and address participants' health beliefs; and 4) increase primary care physicians' (PCP) awareness of participants' cognitive deficits and health beliefs to optimize treatment of DM. .
62137353|NCT04259047|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|EUC consists of home visits by a CHW in which general DM education is provided.
62137354|NCT06581406|EXPERIMENTAL|Test Arm: RP2 + nivolumab|RP2 (Oncolytic virus) and Nivolumab (programmed death receptor-1 (PD-1) inhibitor)
62137355|NCT06581406|EXPERIMENTAL|Control Arm (Active Comparator): ipilimumab + nivolumab|Immune Checkpoint inhibitor combination
62137356|NCT01511159|EXPERIMENTAL|NNC 90-1170, initial dose|
62137357|NCT01511159|EXPERIMENTAL|NNC 90-1170|
62137358|NCT01511159|ACTIVE_COMPARATOR|Insulin|
62137359|NCT01511159|EXPERIMENTAL|NNC 90-1170, final dose|
62137360|NCT03246724|EXPERIMENTAL|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:~• Cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~* Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~* Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
62137361|NCT03246724|EXPERIMENTAL|Retina Procedures|"The following ocular procedures will fall under this arm of the study:~* Pars plana vitrectomy~* Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~* Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~* Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
62137362|NCT03246724|EXPERIMENTAL|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:~* Descemet Stripping Endothelial Keratoplasty (DSEK)~* Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)~* Descemet Membrane Endothelial Keratoplasty (DMEK)~* Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)~* Conjunctival and/or corneal lesion excisions~* Pterygium~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~* Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~* Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
62137363|NCT03246724|EXPERIMENTAL|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:~* Ahmed valve~* Ahmed valve with cataracts~* Trabeculectomy~* Trabeculectomy with cataracts~* Baerveldt~* Baerveldt with cataracts~* Endocyclophotocoagulation~* Endocyclophotocoagulation with cataracts~* Istent~* Cataracts with istent~* Kahook~* Cataracts with kahook~* Cypass~* Cypass with cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~* Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~* Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
62334753|NCT02220348|EXPERIMENTAL|linaclotide|Linaclotide 72μg, 145 μg, or 290 μg capsules, once daily for 3 days, oral administration
62334754|NCT04929340|EXPERIMENTAL|experimental|5 drops each day before bedtime but after toothbrushing. L. reuteri DSM 17938, L. reuteri ATCC PTA 5289, with a minimum of 100 million live bacteria of each strain.
62334755|NCT04929340|PLACEBO_COMPARATOR|placebo|5 drops each day before bedtime but after toothbrushing. The placebo drops had identical composition color and taste but no probiotic bacteria.
62334756|NCT05415046||Sacral ESPB|Sacral erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
62334757|NCT06142461|EXPERIMENTAL|1: Intradermal needle-free injection|Fractional dose (2 x 0.1 mL injections) intradermal administration of Gardasil® using PharmaJet Tropis® Needle-Free Injection System.
62334758|NCT06142461|EXPERIMENTAL|2: Intramuscular needle-free injection|Full dose (0.5 mL injection) intramuscular administration of Gardasil® using PharmaJet Stratis® Needle-Free Injection System
62334759|NCT06142461|ACTIVE_COMPARATOR|3: Needle and syringe|Full dose (0.5 mL injection) intramuscular administration of Gardasil® using needle and syringe
62334760|NCT01465971||not acclimatized|no stay in an altitude above 2500 m within the last 3 Months
62334761|NCT01465971||acclimatized|stay above 2500 m with the last 14 days
62334762|NCT00883480|EXPERIMENTAL|2|The rest of the patients who do not carry the Factor Receptor mutation of Epidermal Growth will receive chemotherapy treatment individualized based on BRCA 1 m RNA levels. Function of these levels, three different subgroups of treatment: Subgroup A with low BRCA1 mRNA levels will receive treatment with gemcitabine / cisplatin Subgroup B with intermediate levels of BRCA1 mRNA: will receive treatment with docetaxel / cisplatin Subgroup C with high levels of BRCA1 mRNA: will receive treatment with docetaxel
62334763|NCT00883480|EXPERIMENTAL|1|The group of patients carrying EGFR mutation will receive treatment with Erlotinib, a selective oral Receptor tyrosine kinase inhibitor Epidermal Growth Factor
62334764|NCT03118531|EXPERIMENTAL|Coronary Stent|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm)
62334765|NCT01339949|EXPERIMENTAL|24 Gy radiation|
62334766|NCT01339949|SHAM_COMPARATOR|Sham 24 Gy radiation|
62334767|NCT01938781|ACTIVE_COMPARATOR|Entecavir monotherapy|entecavir, 0.5mg, qd, oral, for 2 years.
62334768|NCT01938781|EXPERIMENTAL|Entecavir plus peg-IFN Therapy|entecavir combined peg-IFN in the middle 1 year.
62492126|NCT00990574|ACTIVE_COMPARATOR|spinal anesthesia group (SAG)|Participants will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
62492127|NCT00990574|ACTIVE_COMPARATOR|The WSCG (wiley spinal catheter group)|The WSCG (wiley spinal catheter group) will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
62492128|NCT05278858|EXPERIMENTAL|MedJet Device|"The Med-Jet-MBX needle-free injector (Med-Jet) is a novel, needle-free drug-delivery system, which we believe may be a solution to the pain and fear associated with needles. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region (MedJet) The drug-delivery device is highly configurable allowing adjustable depth and volume parameters (MedJet). In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas (MedJet)."
62695131|NCT00000884|EXPERIMENTAL|6|Participants will undergo treatment intranasally and intramuscularly
62695132|NCT00000884|EXPERIMENTAL|7|Participants will undergo treatment intrarectally and intramuscularly
61939315|NCT03325088|OTHER|Severe Asthma|patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
61939316|NCT03325088|OTHER|Mild to moderate Asthma|patients affected with untreated mild to moderate asthma
62334769|NCT03768531|EXPERIMENTAL|Arm A: Nivolumab|
62334770|NCT03768531|EXPERIMENTAL|Arm B: Nivolumab and Cabrilizumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes, a 30 minute rest, followed by cabiralizumab every 2 weeks. (Cycle length 2 weeks).
62334771|NCT00884624||A|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
62695133|NCT06342609|ACTIVE_COMPARATOR|Colchicine|0.5 milligram (mg) per day of Colchicine orally administered over the period of 52 weeks
62695134|NCT06342609|PLACEBO_COMPARATOR|Placebo|0.5mg per day of Placebo orally administered over the period of 52 weeks
62334772|NCT02555761||Lastacaft®|One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.
62334773|NCT01301560|EXPERIMENTAL|Radiosurgery arm|Radiosurgery before palliative chemotherapy
62334774|NCT01301560|NO_INTERVENTION|Observation arm|No radiotherapy or local treatment until specific symptoms or sign developed
62334775|NCT03102944||healthy volunteers|no intervention, extra blood tube taken with blood donation at bloodbank and blood is tested on IVD away from patient.
62334776|NCT04323748|EXPERIMENTAL|rituximab|All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
62334777|NCT05744115|EXPERIMENTAL|Ga-68-PSMA-11 PET/CT|Administration of Ga-68-PSMA-11 and acquisition of PET/CT
62334778|NCT01465698|EXPERIMENTAL|Exercise|
62334779|NCT01465698|EXPERIMENTAL|Counseling|
62334780|NCT01465698|EXPERIMENTAL|Exercise and counseling|
62334781|NCT01465698|OTHER|Control group|Participants in the control group only participate in study measurements.
62334782|NCT04526756|EXPERIMENTAL|Intervention group|patients in this group will receive mechanical thrombectomy and standardized drug treatment of acute ischemic stroke
62334783|NCT04526756|NO_INTERVENTION|control group|patients in this group will receive standardized drug treatment of acute ischemic stroke
62334784|NCT03435172|EXPERIMENTAL|Treatment Group|Device-ADRCs intravenously infusion 20 million ADRCs generated by Celution device will be intraveously infused through peripheral vein. Standard care of split thickness meshed skin graft (STSG) will be used.
62695135|NCT04974476|EXPERIMENTAL|In-person exercise training group|participants in this group will receive in person exercise HIIT training 3 days a week for 12 weeks
62695136|NCT04974476|EXPERIMENTAL|Virtual exercise training group|participants in this group will receive virtual exercise HIIT training 3 days a week for 12 weeks
62334785|NCT03435172|NO_INTERVENTION|Usual Care|Standard care of split thickness meshed skin graft (STSG) will be used.
62334786|NCT02563288|ACTIVE_COMPARATOR|Esmolol|Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.
62695137|NCT00809588|EXPERIMENTAL|Melanoma Vaccine|GM-CSF Vaccine
62695138|NCT05398848|EXPERIMENTAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Antigen: NTD-RBD-foldon protein, Adjuvant (BFA03)
61939317|NCT03325088|OTHER|Controlled Sample|smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
62137364|NCT05996627|EXPERIMENTAL|Arm I (Belumosudil)|Patients receive belumosudil PO QD or BID if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study.
62334787|NCT02563288|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.
62137365|NCT05996627|PLACEBO_COMPARATOR|Arm II (Placebo)|Patients receive a placebo PO QD or BID if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study.
62137366|NCT00116649|EXPERIMENTAL|Aldara 5%|Aldara® (imiquimod) cream, 5% supplied in 250 mg single-use packets.
62137367|NCT01834846|EXPERIMENTAL|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
62137368|NCT01834846|ACTIVE_COMPARATOR|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
62137369|NCT03842085|EXPERIMENTAL|MBS301|Drug: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
62137370|NCT02696161|EXPERIMENTAL|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
62137371|NCT02696161|PLACEBO_COMPARATOR|5% dextrose|5% dextrose for hydrodissection
62137372|NCT05631808||Lowest tertile|Participants with lowest tertile of EAT volume or attenuation among all eligible participants.
62137373|NCT05631808||Intermediate tertile|Participants with intermediate tertile of EAT volume or attenuation among all eligible participants.
62137374|NCT05631808||Highest tertile|Participants with highest tertile of EAT volume or attenuation among all eligible participants.
62137375|NCT06509412|EXPERIMENTAL|LANAP surgical protocol using ND:YAG 1064 laser|
62137376|NCT06509412|EXPERIMENTAL|LANAP surgical protocol using diode 940 laser|
62137377|NCT06509412|ACTIVE_COMPARATOR|Scaling and root planing|
62137378|NCT02134262|EXPERIMENTAL|Dose Level -1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
62137379|NCT02134262|EXPERIMENTAL|Dose Level 1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
62137380|NCT02134262|EXPERIMENTAL|Dose Level 2|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
62137381|NCT02134262|EXPERIMENTAL|Dose Level 3|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
62137382|NCT06193343|EXPERIMENTAL|Interventional Group|Participants who meet study criteria and are enrolled in adaptive daily step promotion intervention
62137383|NCT06425250||Management, progression and risk factors for failure of BJI caused by Campylobacter spp.|Adult patients treated for prosthetic joint infection caused by Campylobacter spp. between 01/01/2013 and 12/31/2022
62137384|NCT00042965|EXPERIMENTAL|Gemcitabine + capecitabine|"Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
62137385|NCT06517771|EXPERIMENTAL|Online aerobic exercise group|Participants in the online aerobic exercise group performed aerobic exercises three days a week for four weeks under the online supervision of a physiotherapist using the WhatsApp application.
62137386|NCT06517771|NO_INTERVENTION|Control group|The control group did not engage in any aerobic or strengthening exercise training during the four weeks and were instructed to avoid strenuous physical activities
62137387|NCT03293914|EXPERIMENTAL|Intervention|Participants will be invited to enroll in an occupational therapy (OT) lifestyle redesign intervention focused on diabetes management. The intervention includes approximately 8 one-hour OT sessions over 4 months.
62137388|NCT03293914|NO_INTERVENTION|Usual Care Control|Participants will not be contacted; outcome data will be extracted from medical records.
62334788|NCT01968096|NO_INTERVENTION|SCI subjects|Stage 1 subjects: pilot study:understand post activation depression with spinal cord injury to avoid the influence of the suprasegmental level.
62695139|NCT05398848|PLACEBO_COMPARATOR|Placebo|Adjuvant (BFA03)
62695140|NCT06560892|EXPERIMENTAL|Bupivacaine group|Patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline
62695141|NCT06560892|EXPERIMENTAL|Bupivacaine + Dexmedetomidine group|Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml
62695142|NCT06325631|EXPERIMENTAL|Fluoroscopy|
62695143|NCT06325631|EXPERIMENTAL|Ultrasound|
62695144|NCT06325631|EXPERIMENTAL|Anatomic|
62695145|NCT03464201|EXPERIMENTAL|Enzalutamide|Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
62695146|NCT02103179||ECC patients|Extrahepatic cholangiocarcinoma patients treated by surgical treatment
62492129|NCT03504085|EXPERIMENTAL|Hatha Yoga|This arm will receive the active Hatha yoga intervention. Instructors lead participants through various yoga poses for 60-minutes, 1-2x weekly for 12 weeks, and daily home practice is recommended.
62492130|NCT03504085|ACTIVE_COMPARATOR|Restorative Yoga|This arm will receive a restorative yoga intervention. Instructors guide participants through relaxation exercises, typically with eyes closed, laying down, and minimal movement 60-minutes, 1-2x weekly for 12 weeks.
62137389|NCT01854151|NO_INTERVENTION|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
62334789|NCT01968096|NO_INTERVENTION|Incomplete SCI subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
62334790|NCT01968096|NO_INTERVENTION|Health subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
62492131|NCT05447416|ACTIVE_COMPARATOR|Hyperbaric Oxygen Therapy - HBOT|The protocol comprises of 40 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a two months' period. The HBOT group will train for 60 minutes after the HBOT sessions, 3 times per week, in a normobaric normoxic environment according to individualized training protocol
62492132|NCT05447416|ACTIVE_COMPARATOR|Intermittent Hypoxic Training - IHT|The protocol comprises of 24 consecutive Intermittent Hypoxic Training (IHT) sessions, 3 sessions per week within a two months' period. Subjects will train according to individualized training protocol.
62492133|NCT05450549|EXPERIMENTAL|DNL919 (Healthy Participant)|
62695147|NCT05007132|EXPERIMENTAL|Arm A|Trifluridine/tipiracil, 35 mg/m² body surface area (BSA), twice daily, orally on days 1-5 and 8-12 Panitumumab at 6 mg/kg bodyweight, intravenous infusion on days 1 and 15
62695148|NCT05007132|ACTIVE_COMPARATOR|Arm B|Trifluridine/tipiracil, 35 mg/m² body surface area, twice daily, orally on days 1-5 and 8-12 Bevacizumab at 5 mg/kg bodyweight, intravenous infusion on days 1 and 15
62492134|NCT05450549|PLACEBO_COMPARATOR|Placebo (Healthy Participant)|
62492135|NCT04339634||Program of All-Inclusive Care for the Elderly|The Program of All-Inclusive Care for the Elderly (PACE) provides comprehensive medical and supportive services for community-dwelling persons, mostly older adults (\>55 years), as an alternative to institutionalization. Medical services are provided by an interdisciplinary team of healthcare professionals, Tabula Rasa HealthCare being the pharmacy care provider for several PACE organizations.
62695149|NCT01092650|ACTIVE_COMPARATOR|Smoked|Deuterated Phenanthrene spiked in a study cigarette
62695150|NCT01092650|EXPERIMENTAL|Oral|Deuterated phenanthrene in an oral dose
62695151|NCT04147286|ACTIVE_COMPARATOR|Atorvastatin (Arm B)|12 weeks of 40 mg atorvastatin therapy per os daily
62695152|NCT04147286|PLACEBO_COMPARATOR|Placebo (Arm C)|Identical placebo tablet is taken per os daily
62695153|NCT03190954|PLACEBO_COMPARATOR|[11C]NNC-112|\[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
62137390|NCT01854151|EXPERIMENTAL|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
62334791|NCT01968096|EXPERIMENTAL|SCI subjects with high muscle tone (High frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(High frequency) will be executed .
62334792|NCT01968096|EXPERIMENTAL|SCI subjects with high muscle tone(low frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(Low frequency) will be executed.
62334793|NCT01968096|NO_INTERVENTION|SCI subjects with high muscle tone|Stage 3 subjects:Control subjects
62137391|NCT05738369|EXPERIMENTAL|Probiotic|Participants received treatment with Biogaia L. reuteri Prodentis® lozenges
62334794|NCT04901403|OTHER|Education intervention|Parents in the treatment group will receive information about Earned Income Tax Credit, including how to sign up for free. They will also receive help with budgeting and finances from their home visitor.
62334795|NCT04901403|OTHER|Control group|Control group families will receive home visiting services as usual.
62334796|NCT05531058|EXPERIMENTAL|AI-driven vaccine communicator intervention group|The intervention will include five modules web-based psychoeducation programme (two modules sessions weekly, each module lasts for 15-20 minutes) which includes educational materials, animations of vaccine research and development, and an MI communication skills-based AI, digital assistant.
62492136|NCT00403806|ACTIVE_COMPARATOR|1|Intravenous dexamethasone 0.05 mg per kg bodyweight
62492137|NCT00403806|ACTIVE_COMPARATOR|2|Intravenous dexamethasone 0.15 mg per kg bodyweight
62492138|NCT00403806|ACTIVE_COMPARATOR|3|Intravenous dexamethasone 0.5 mg per kg bodyweight
62492139|NCT00403806|PLACEBO_COMPARATOR|4|Intravenous saline
62492140|NCT01909713|EXPERIMENTAL|Facial Cleanser and Moisturizer SPF 30|All subjects used Cetaphil® DermaControl™ Oil Control Foam Wash and Cetaphil® DermaControl™ Oil Control Moisturizer SPF 30 at least once daily for 22 days.
62695154|NCT03190954|ACTIVE_COMPARATOR|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
62695155|NCT03190954|PLACEBO_COMPARATOR|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
62695156|NCT06611306|EXPERIMENTAL|DE-iPTV radiotherapy|Patients will undergo a radiotherapy planning scan, and an upto date MRI brain with contrast. Patients will receive 5 fractions of DE-iPTV radiotherapy over 1 week.
62695157|NCT05607576|EXPERIMENTAL|Uncovered|Dexcom G6 CGM will be uncovered during standard of care radiologic procedures.
62695158|NCT04632654|EXPERIMENTAL|PAfitME|For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention.
62695159|NCT04632654|NO_INTERVENTION|Attention Control|For 6 weeks, the attention control group will receive National Cancer Institute-based survivorship education and exergame equipment (Nintendo Switch).
62492141|NCT03789630||Monitoring arm|Monitoring subjects undergoing total knee replacement surgery using the wearable biosensor to continuously monitor physiology biomarkers.
62492142|NCT04220606|OTHER|Migraine without aura subjects|Drug: Glyceryl trinitrate (GTN)
62492143|NCT04220606|OTHER|Healthy subjects|Drug: Glyceryl trinitrate (GTN)
62492144|NCT00168233||1|No antiretroviral therapy for 12 months
62695160|NCT06638814||Patients who will undergo surgery for hemorrhoidal disease after the diagnosis of IBD|All patients with an established diagnosis of IBD who will undergo surgery for HD from January to December 2025 and followed-up for at least 1 year post-operatively will be prospectively included. Data on patient demographics and clinical characteristics, operative details and clinical outcomes will be collected.
62695161|NCT06643104||BHD|
62695162|NCT06240286|EXPERIMENTAL|Healthy Subjects|Healthy subjects will attend the the Active Wellness Office at the Dan Abraham Healthy Living Center (DAHLC) at Mayo Clinic in Rochester, Minnesota, for four consecutive days. On day one, individuals will use a sitting workstation (control); based on randomization, three active workstations (standing, stepping, or walking stations) will be randomly assigned on the following days (2-4).
61939318|NCT05883423|EXPERIMENTAL|FPCMP-Old Age group|The program mainly refers to Ha and Park (2020), and extends the development of the 12-week FPCMP-Old Age program, which combines sports and health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities). Twice a week, 2 hours each time, 12 weeks, a total of 24 times, the execution period is scheduled to be from July to the end of September.
61939319|NCT05883423|NO_INTERVENTION|usual group|Participate in the original health promotion activities of the community group
61939320|NCT05140590||Participants with a diagnosis of hypertension admitted to the emergency department|"Direct questioning about general data, medical history and about the pharmacological scheme for the treatment of hypertension.~Review of clinical records to obtain data about the admission diagnosis, drugs administered during their hospital stay, and blood pressure figures at admission, during hospital stay and at discharge.~Analysis and classification of theoretical drug interactions using the IBM Micromedex Drug Interactions and iDoctus clinical decision support systems."
62334797|NCT05531058|ACTIVE_COMPARATOR|Self-learning of COVID-19 vaccine knowledge control group|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge.
62334798|NCT04542382|EXPERIMENTAL|Placebo and Rosuvastatin|Subjects will be dosed with placebo tablet and Rosuvastatin 10mg tablet
62334799|NCT04542382|EXPERIMENTAL|Eltrombopag and Rosuvastatin|Subjects will be dosed with Eltrombopag 75mg tablet and Rosuvastatin 10mg tablet
62334800|NCT01803399|EXPERIMENTAL|GSK1322322 1200 mg Arm|Each subject will receive a single dose of GSK1322322 1200 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
62334801|NCT01803399|EXPERIMENTAL|GSK1322322 3000 mg Arm|Each subject will receive a single dose of GSK1322322 3000 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
62334802|NCT01803399|PLACEBO_COMPARATOR|Placebo Arm|Each subject will receive a single dose of GSK1322322 Placebo IV over 60 minutes on Day 1 of one of the 4 treatment periods
62334803|NCT01803399|ACTIVE_COMPARATOR|Moxifloxacin 400 mg Arm|Each subject will receive a single dose of moxifloxacin 400 mg administered orally on Day 1 of one of the 4 treatment periods
62334804|NCT02347241|NO_INTERVENTION|Control period|Assessment of resuscitation quality and clinical outcomes prior to educational intervention
62334805|NCT02347241|EXPERIMENTAL|Educational intervention|Assessment of resuscitation quality and clinical outcomes after educational intervention consisting of debriefing and rolling refreshers.
62334806|NCT04789642|EXPERIMENTAL|study group|A social group will be created on whatsapp for subjects of the intervention group and they will receive education about blood pressure measurement guidelines in 24 sessions, once per day in the form of text, image and video clips. In addition to British and Irish Hypertension Society (BIHS) blood pressure measurement auscultatory tutorials.
62334807|NCT04789642|NO_INTERVENTION|control group|The control group will not receive any intervention only their routine education that is provided by the continuous staff development team of the hospital.
62492145|NCT00168233||2|Initiating ARV therapy with an NNRTI based regimen
62492146|NCT00168233||3|Initiating ARV therapy with a PI based regimen
61939321|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
61939322|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
61939323|NCT04040270|EXPERIMENTAL|Live drama+DVD+Worksheets|Primary school students watched an interactive live drama in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
61939324|NCT04040270|EXPERIMENTAL|DVD+Worksheets|Primary school students were given DVD and worksheets and they were asked to watch the DVD and finish the worksheets with their parents. After the study finished, the students watched the live drama.
62334808|NCT01805232|EXPERIMENTAL|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
62334809|NCT01805232|ACTIVE_COMPARATOR|quinine|quinine infusion 80 mg/kg every 8 hours
62492147|NCT05146024||Formative Research|Alcohol-serving establishment owners, managers, and servers in New Mexico and Washington State.
62492148|NCT03112031|EXPERIMENTAL|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
62492149|NCT03112031|ACTIVE_COMPARATOR|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
62492150|NCT00096850|EXPERIMENTAL|1|From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
62492151|NCT02911636|EXPERIMENTAL|Arm 1|Pelvic SABR with intra-prostatic SABR
62695163|NCT03630679||Preterm|born at \<37 weeks of gestation
61939325|NCT04040270|NO_INTERVENTION|Waitlist control|Primary school students received no intervention during the 4-week study period. After the study finished, the students watched the live drama, and DVD with worksheets were distributed to students and they were encouraged to share with their parents.
62334810|NCT05924776|EXPERIMENTAL|Plasmodium immunotherapy group|This is a single arm study that is planed to enroll 30 patients with advanced ovarian cancer and each patient will be inoculated with P.vivax-infected red blood cells containing approximately 1-5 × 10\^6 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
62334811|NCT06317233|NO_INTERVENTION|Standard of Care|
62334812|NCT06317233|EXPERIMENTAL|Treatment Guide plus Standard of Care|
62334813|NCT02855411|EXPERIMENTAL|0.15 mg PF-04958242|Participants received 0.15 mg oral capsule, twice daily (BID) for 12 weeks
62334814|NCT02855411|EXPERIMENTAL|0.5 mg PF-04958242|Participants received 0.5 mg oral capsule, twice daily (BID) for 12 weeks
62334815|NCT02855411|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo oral capsule, twice daily (BID) for 12 weeks
62334816|NCT03994263|EXPERIMENTAL|iTind arm|ITind device implant
62334817|NCT03811678|EXPERIMENTAL|50 mg single dose|It includes two groups, one group is a pilot study, 2 healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet . Another group is a formal study, healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
62334818|NCT03811678|EXPERIMENTAL|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg Kangdaprevir Sodium Tablet (N=20) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
62334819|NCT03811678|EXPERIMENTAL|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
62492152|NCT02705716|EXPERIMENTAL|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million \[ppm\] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
62492153|NCT02705716|PLACEBO_COMPARATOR|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
62492154|NCT01907048||Group 1|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
62492155|NCT01907048||Group 2|Survey to measure patient awareness and understanding of the key messages in the patient card.
62492156|NCT04814628|EXPERIMENTAL|healthy volunteer subject|"A single healthy volunteer subject will participate in the study as a model of a pregnant woman in the third trimester of pregnancy, with a functional respiratory capacity reduced by 20% thanks to elastic restraints performed under the control of functional respiratory explorations.~8 obstetric anesthesiologists will participate in the 4 scenarios;"
61939326|NCT04765215||Breast or lung cancer patients receiving active chemotherapy and 2 doses of CoronaVac vaccine|
62334820|NCT03811678|EXPERIMENTAL|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
62334821|NCT03811678|EXPERIMENTAL|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
62334822|NCT03811678|EXPERIMENTAL|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
62334823|NCT03811678|EXPERIMENTAL|100 mg multiple dose|Healthy subjects, receiving 100 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
62695164|NCT03630679||Full term Term|born at \>/= 37 weeks of gestation
61939327|NCT04765215||Healthy volunteers who received two doses of coronavac vaccine|
61939328|NCT06352996|EXPERIMENTAL|power arm canine retraction|
61939329|NCT06352996|EXPERIMENTAL|canine retraction without power arm|
61939330|NCT04940325|EXPERIMENTAL|DS-1062a|All patients included in the study will receive DS-1062a at a dose of 6 mg/kg every 3 weeks until progression or until unacceptable toxicity
61939331|NCT02028312|ACTIVE_COMPARATOR|Loteprednol etabonate + Restasis|Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
62334824|NCT03811678|EXPERIMENTAL|200 mg multiple dose|Healthy subjects, receiving 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
62334825|NCT03811678|EXPERIMENTAL|400 mg multiple dose|Healthy subjects, receiving 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
62334826|NCT03354819|EXPERIMENTAL|Modified MBCT|A group-based, 10-week, 7-session modified Mindfulness Based Cognitive Therapy (MBCT) will be adopted in the MBCT intervention group with a group size of 15-20. The program includes different mindfulness activities (such as mindful eating and mindful walking) and peer sharing.
62334827|NCT03354819|ACTIVE_COMPARATOR|SIRE on dementia|The frequency of the Social Interactions and Routine Education (SIRE) program is the same as that of modified MBCT which consists of seven sessions (weekly for the first four sessions and bi-weekly for the last three sessions) and each session will last about two hours for 10 weeks with group size 15-20.
62334828|NCT05853523|EXPERIMENTAL|Gas ozone group|Participant received 32 g/m3 of gas ozone for 30 second.
62492157|NCT01050764|EXPERIMENTAL|T-reg Cell Infusion after Allogeneic Stem Cell Transplant|
62492158|NCT02808494||Affected Group|Women with a diagnosis of preeclampsia with severe features and/or fetal growth restriction.
62492159|NCT02808494||Control/Unaffected Group|Women who do not have a diagnosis of preeclampsia with severe features and/or fetal growth restriction.
62492160|NCT05704491||K+A+|diabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor present (A+)
62695165|NCT02990767||observational women|collecting maternal factors, biophysical and biochemical markers at 11-13 weeks of gestation.
62695166|NCT06640621|ACTIVE_COMPARATOR|group I|In group I(high concentration group), ropivacaine 100mg + normal saline to 20ml (0.5% ropivacaine 20ml) is used for single brachial plexus block under ultrasound guidance before general anesthesia.
62492161|NCT05704491||K+A-|diabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor absent (A-)
62492162|NCT05704491||K-A+|diabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor present (A+)
62492163|NCT05704491||K-A-|diabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor absent (A-)
62492164|NCT06562101|EXPERIMENTAL|Stromal Vascular Fraction (SVF)|Ten patients with knee OA were administered intra-articular SVF injections.
62492165|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:~1. Expression of insulin-like growth factor 1 receptor (IGF-1R)~2. Adiponectin~3. Leptin~4. Resistin~5. Osteocalcin~6. Osteoprotegerin~7. Insulin, c-peptid~8. HOMA-IR"
62492166|NCT05922306|ACTIVE_COMPARATOR|Continuous Combination Therapy Cohort|Patients with primary CHB with HBsAg ≥ 1500 IU/ml and HBV-DNA \< 500 IU/ml and patients with CHB after treatment with NAs will be enrolled. After fully informed consent, pegylated interferon alpha-2b 180µg will be administered by subcutaneous injection once a week for up to 96 weeks.
62492167|NCT05922306|EXPERIMENTAL|Pulsed Combination Therapy Cohort|Patients with primary CHB with HBsAg ≥ 1500 IU/ml and HBV-DNA \< 500 IU/ml and patients with CHB after treatment with NAs will be enrolled. After fully informed consent, pegylated interferon alpha-2b 180µg will be administered by subcutaneous injection once weekly for 8 weeks of treatment and discontinued for 4 weeks up to 96 weeks.
62492168|NCT01620840||Lacosamid-i.v. treatment|
62492169|NCT03776344|EXPERIMENTAL|Virtual Reality|Patients randomized to the experimental group will benefit from the usual standard care following surgery and during the second day the opportunity to use virtual reality for 15 minute. Along VR, they will complete the psychological and physiological measures.
62492170|NCT03776344|NO_INTERVENTION|Non-VR condition (Standard of Care)|Patients randomized to the control group will benefit from the usual standard care following surgery and during the second day will complete the psychological and physiological measures.
61939332|NCT02028312|PLACEBO_COMPARATOR|Artificial Tears + Restasis|Artificial Tears, BID 30 days Restasis, BID 45 days
61939333|NCT00643773|EXPERIMENTAL|A|Leucine supplement
62695167|NCT06640621|EXPERIMENTAL|group II|In group II (low concentration group), ropivacaine 40mg + normal saline to 20ml (0.2% ropivacaine 20ml) is used for single brachial plexus block under ultrasound guidance before general anesthesia.
62695168|NCT06539195|EXPERIMENTAL|Daily dose of DZD8586 at 25 mg|
62695169|NCT06539195|EXPERIMENTAL|Daily dose of DZD8586 at 50 mg|
62695170|NCT06539195|EXPERIMENTAL|Daily dose of DZD8586 at 75 mg|
61939334|NCT00643773|PLACEBO_COMPARATOR|B|Wheat flour
61939335|NCT06476600|ACTIVE_COMPARATOR|Opioid-based Anaesthesia|
61939336|NCT06476600|ACTIVE_COMPARATOR|Opioid-free Anaesthesia|
61939337|NCT02738632|EXPERIMENTAL|Telmisartan/Amlodipine+Hydrochlorothiazide|Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
61939338|NCT02738632|ACTIVE_COMPARATOR|Telmisartan/Amlodipine|Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide
61939339|NCT05299723|EXPERIMENTAL|Phase A - open label single-arm|"All Phase A participants randomized to the home-based CC intervention will be use a light visor to administer bright light therapy in the morning for 30 minutes after waking up (BLT), and use orange-colored glasses for blue light blocking at night from 8:00 pm until going to sleep (BLB)."
62137392|NCT05738369|PLACEBO_COMPARATOR|Sugar free lozenges|Participants received Hersheyland Ice Breakers Mints sugar free lozenges
62137393|NCT05738369|NO_INTERVENTION|Negative control|Participants received no lozenges or supplements
62137394|NCT02036177|EXPERIMENTAL|SCu300A IUB|
62137395|NCT02036177|ACTIVE_COMPARATOR|T380A copper IUD|
62137396|NCT03790215|EXPERIMENTAL|cohort for treatment|Participants enrolled are given dydrogesterone tablet of 10mg twice a day, from day 15 to day 24 of the menstrual cycle over a period of 3 months.
62137397|NCT02583113||Total and Unicompartment Knee Replacement|
62137398|NCT04010136|NO_INTERVENTION|Control group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will be given no intervention
62137399|NCT04010136|EXPERIMENTAL|Identification tool group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive access to the Identification tool Supportive and Palliative Care Indicators Tool (SPICT-PT) with a brief training on how to use it.
62137400|NCT04010136|EXPERIMENTAL|Standard Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training according to the Center Healthcare Administrative Region standard model of training.
62334829|NCT05853523|EXPERIMENTAL|Diode laser group|Participant received an application of desensitized gel, fluoride and potassium nitrate gel , and a first step of an irradiation with diode laser for 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W, not in contact. Then the second step of irradiation for 30 second in contact with dentine surface, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. Then the surface was rinsed, and the irradiation applied for a third time again without the gel as the second step.
62334830|NCT02640846|ACTIVE_COMPARATOR|Norepinephrine|Doser
62334831|NCT02640846|ACTIVE_COMPARATOR|Milrinone|Doser
62334832|NCT02640846|ACTIVE_COMPARATOR|Levosimendan|Doser
62695171|NCT06639984|ACTIVE_COMPARATOR|Psyllium (0.7 g/year of age per day) given with fructans|Participants will receive Psyllium (0.7 g/year of age per day) given with fructans (daily dose 0.5 g/kg up to 19 grams)
62695172|NCT06639984|ACTIVE_COMPARATOR|Psyllium (0.5 g/year of age per day) given with fructans|Participants will receive Psyllium (0.5 g/year of age per day) given with fructans (daily dose 0.5 g/kg up to 19 grams)
62334833|NCT03761043|NO_INTERVENTION|Pre-Intervention Arm|The nurses will have not been exposed to the behavior change intervention.
62334834|NCT03761043|EXPERIMENTAL|Post-Intervention Arm|The nurses will have been exposed to the behavior change intervention.
62492171|NCT02604641|PLACEBO_COMPARATOR|Placebo group|0 mg CoQ10 daily
62492172|NCT02604641|ACTIVE_COMPARATOR|Quvital LD group|50 mg CoQ10 daily
62492173|NCT02604641|ACTIVE_COMPARATOR|Quvital HD group|150 mg CoQ10 daily
62492174|NCT02498938||SERPINA1 gene in COPD and periodontitis|patients aged between 30-70 yrs with COPD (satisfying Gold's criteria) and chronic periodontitis (\>4mm pocket probing depth)
62492175|NCT03439085|EXPERIMENTAL|Treatment (INO-3112, durvalumab)|Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 IM and via electroporation at 1, 3, 7, and 12 weeks and durvalumab IV at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity.
62334835|NCT04824196|EXPERIMENTAL|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirror.Anterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear movements were performed for five minutes
62334836|NCT04824196|ACTIVE_COMPARATOR|propriocetion therapy|"Alternate knee flexion-extension with extended trunk posture using both hands for support.~Hip and knee flexion-extension with swiss ball between the back and wall.~Hip aises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises.~then perform all exercise on gym ball"
62334837|NCT04885491|EXPERIMENTAL|Treatment with PDNO|"Placebo treatment administered during the 120-minute observation period, followed by PDNO infusion. PDNO administered as an i.v. infusion of 5-15 minutes, respectively, for the increased planned dose titration steps: 3, 10 and thereafter steps of max 10 nmol/kg/min until the target effect on the mean pulmonary arterial pressure/pulmonary vascular resistance (MPAP/PVR) or a maximal dose of 120 nmol/kg/min is reached.~After 4 patients have been treated, the internal safety review committee (iSRC) will decide if the start dose will be increased. The new start dose could be in the interval 1 to 5 nmol/kg/min."
62492176|NCT04701216|EXPERIMENTAL|Experimental: SHR8735 cohort 1|The subjects will receive a multiple dose of SHR8735 (low dose).
62492177|NCT04701216|EXPERIMENTAL|Experimental: SHR8735 cohort 2|The subjects will receive a single dose of SHR8735 (medium dose).
62492178|NCT04701216|EXPERIMENTAL|Experimental: SHR8735 cohort 3|The subjects will receive a single dose of SHR8735 (high dose).
62492179|NCT04146090|ACTIVE_COMPARATOR|Low-pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
62492180|NCT04146090|PLACEBO_COMPARATOR|Standard pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
62492181|NCT05723796|EXPERIMENTAL|chronic HP patients|
62492182|NCT02870686|ACTIVE_COMPARATOR|ERCP without the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to the EUS guided ERCP without fluoroscopy clear all of the bile duct stones.
62492183|NCT02870686|ACTIVE_COMPARATOR|ERCP with the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to underwent ERCP with the use of fluoroscopy to clear all of the bile duct stones.
62492184|NCT03044873|EXPERIMENTAL|BMS 986165 and Rosuvastatin|
62492185|NCT00005967|EXPERIMENTAL|Arm I|Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
62695173|NCT06639984|PLACEBO_COMPARATOR|Placebo (0.7 g/year of age glucose) given with fructans|Participants will receive Placebo (0.7 g/year of age glucose) given with fructans (daily dose 0.5 g/kg up to 19 grams).
62695174|NCT04630769|EXPERIMENTAL|Monotherapy: IP FT516 at 9 x 10^7 cells/dose on Day 1, 8, and 15|
61939340|NCT05299723|EXPERIMENTAL|Phase B - active CC treatment|For all Phase B participants randomized to the active CC group, BLT will occur each morning after awakening and will last for 30 minutes and BLB at night from 8:00 pm until going to sleep throughout the 4-week intervention period. Participants in the CC group will also receive a sleep hygiene education.
62137401|NCT04010136|EXPERIMENTAL|Clinical cases based Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training using a clinical cases based model.
62334838|NCT01127126|ACTIVE_COMPARATOR|Bryophyllum|muscle relaxing substance
62334839|NCT01127126|PLACEBO_COMPARATOR|Placebo|control group postmenopausal women suffering from overactive bladder
62334840|NCT05685368|EXPERIMENTAL|Acceptance Commitment Therapy|This study will use a 10-session ACT protocol to support Black adolescents and young adults in coping with race related stress.
62334841|NCT05219422|ACTIVE_COMPARATOR|Project ALERT only|Some schools will be randomized to receive Project ALERT only for 3 years starting fall 2022.
62334842|NCT05219422|ACTIVE_COMPARATOR|Project ALERT plus GTO|Some schools will be randomized to receive Project ALERT plus Getting to Outcomes for 3 years starting fall 2022.
62334843|NCT05219422|NO_INTERVENTION|Status quo|Some schools not receive either Project ALERT or Project ALERT plus GTO until year 3 of the study.
62492186|NCT04488380|EXPERIMENTAL|high-viscosity glass ionomer restoration|One of the carious mandibular 2nd molar teeth (according to randomisation) will be restored with high-viscosity glass ionomer restoration (Equia, GC)
62492187|NCT04488380|EXPERIMENTAL|nano-hybrid composite resin|One of the carious mandibular 2nd molar teeth will be restored with nano-hybrid composite resin (GrandioSO, Voco)
62492188|NCT06375915|EXPERIMENTAL|tretament arm|Single arm treatment
62695175|NCT04630769|EXPERIMENTAL|Monotherapy: IP FT516 at 3 x 10^8 cells/dose on Day 1, 8, and 15|
62492189|NCT06040606||Group 1 (G1)|patients who acquired nosocomial omicron infection after surgery
62492190|NCT06040606||Group 2 (G2)|patients who remained uninfected with omicron during their hospitalization period
62695176|NCT04630769|EXPERIMENTAL|Monotherapy: IP FT516 at 9 x 10^8 cells/dose on Day 1, 8, and 15|
62695177|NCT04630769|EXPERIMENTAL|Safe dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6|
62695178|NCT04630769|EXPERIMENTAL|Highest dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6|
62695179|NCT05450978||Lamotrigine (LTG)|Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with lamotrigine (LTG)
62492191|NCT03264092|EXPERIMENTAL|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
62492192|NCT03264092|EXPERIMENTAL|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
61939341|NCT05299723|ACTIVE_COMPARATOR|Phase B - sleep hygiene education control group|All Phase B participants randomized to the control group will receive a sleep hygiene education alone at the start of the 4 week monitoring period.
62334844|NCT01850745||Control|Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program
61939342|NCT00737438|EXPERIMENTAL|1|"Initial chemo for ALL pts (ECX + BEV): Epirubicin 50 mg/m2 d1 every 21 days Cisplatin 60 mg/m2 d1 every 21 days, Capecitabine 625 mg/m2 po bid days 2-21 (held for 48 hours prior to FDG-PET/CT in week 3) Bev 15 mg/kg d1 every 21 days (cycle 1 \& cycle 2 only) Salvage chemotherapy for metabolic non-responders (DI + BEV): Docetaxel 30 mg/m2 d1, d8 every 21 days, CPT-11 50 mg/m2 d1, d8 every 21 days, Bev 15 mg/kg d1, cycle 2 only 2 cycles are planned prior to resection.~Pts who aren't Cisplatin candidates (i.e. Creatinine clearance 40-60/cc, older age, marginal PS,etc.) may get oxaliplatin instead of cisplatin after discus with the PI. Oxaliplatin will be admin at 130 mg/m2 on day 1 every 21 days. Pts who aren't able to get Capecitabine (i.e. insurance restriction, unable to swallow, etc.) may get infusional fluorouracil instead of capecitabine after discus with the PI. Fluorouracil will be admin at 200 mg/m2/d x 21 days (held for 48 hours prior to FDGPET/ CT scan in week 3 of cycle 1)."
62334845|NCT01850745||Validation cohort|Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
62334846|NCT01850745||Pilot cohort|Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
62334847|NCT01205672|EXPERIMENTAL|Metformin|Metformin 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
62334848|NCT02021526|EXPERIMENTAL|No Dietary Therapy|Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months
62334849|NCT02021526|EXPERIMENTAL|Ketogenic Diet|Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.
62334850|NCT04798391|EXPERIMENTAL|Dexamethasone with lignocaine|
62334851|NCT01794494||Open surgical group|Bypass surgery for critical limb ischemia
62334852|NCT01794494||Endovascular treatment|Endovascular recanalization for critical limb ischemia
62334853|NCT02172521||COPD and proven hyperinflation|Patients with COPD and proven hyperinflation receiving tiotropium bromide 18 microgram
62334854|NCT01272297|EXPERIMENTAL|LI-ESWT|Low intensity shock wave treatment- 12 sessions
62334855|NCT06254105|EXPERIMENTAL|Intervention group|Receive the HANDY programme
62334856|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness \>15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness \>15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
62334857|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure \[BP\] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
62334858|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
62492193|NCT03264092|EXPERIMENTAL|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
62492194|NCT05823662|EXPERIMENTAL|DJ stent group|A 5 Fr double J stent will be inserted and then removed after three weeks.
62492195|NCT05823662|EXPERIMENTAL|Silodosin group|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
62492196|NCT01169038|ACTIVE_COMPARATOR|Antibiotics|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
62137402|NCT04653506|EXPERIMENTAL|Paracetamol group|Women who were treated with a double-blind mechanism in an envelope containing paracetamol pills (1000 mg)
62137403|NCT04653506|EXPERIMENTAL|Ibuprofen group|Women who were treated with a double-blind mechanism in an envelope containing Ibuprofen pills (400 mg)
62334859|NCT04664595|SHAM_COMPARATOR|Group SP|The Supreme™ group
62334860|NCT04664595|ACTIVE_COMPARATOR|Group PS|The ProSeal™ group
62334861|NCT04664595|ACTIVE_COMPARATOR|Group IG|The I-gel™ group
62334862|NCT04664595|ACTIVE_COMPARATOR|Group LT|The Laryngeal Tube Suction IITM group
62492197|NCT01533038|ACTIVE_COMPARATOR|UroLift System|UroLift System procedure
62492198|NCT01533038|ACTIVE_COMPARATOR|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate surgery
62492199|NCT00414726|ACTIVE_COMPARATOR|NBO (Normobaric Oxygen)|Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
62492200|NCT00414726|PLACEBO_COMPARATOR|Room Air|Room Air, inhaled at 30-45L/min via a facemask for 8 hours
62492201|NCT00201396|ACTIVE_COMPARATOR|A arm|CCRT
62492202|NCT00201396|EXPERIMENTAL|B arm|Induction/CCRT
62334863|NCT03314441|EXPERIMENTAL|Yoga|Patients receiving Yoga lessons for 3 months
62334864|NCT01122628||DVR-A|Patients with a distal radial fracture treated with a DVR-A locking plate
62334865|NCT01438749|ACTIVE_COMPARATOR|A|
62334866|NCT01438749|PLACEBO_COMPARATOR|B|
62334867|NCT01438749|EXPERIMENTAL|C|
62492203|NCT02698345||K-POP|Patients with isolated popliteal artery disease undergoing endovascular therapy using drug-eluting balloon (In.PACT Admiral, Medtronic)
62334868|NCT06266273|OTHER|Overhead athletes with shoulder pain|"* Male and female athletes aged between 18-35,~* Engaged professionally in sports involving overhead activities for at least 3 years (volleyball, basketball, swimming, badminton, water polo, tennis, American football, handball, etc.),~* Actively participating in competitions for at least 1 year,~* Experiencing current traumatic or non-traumatic pain, or having a history of shoulder pain, or having chronic shoulder pain~* Native Turkish speakers."
62492204|NCT02637180||patients with low-energy fracture(s)|"The study will include patients from pre-defined groups of individuals (postmenopausal, perimenopausal, male, and steroid induced osteoporosis) who would be anyway eligible to receive treatment for their condition according to standard medical practice and Greek treatment guidelines.~Drug: anti-osteoporotic medication (bisphosphonates, denosumab, strontium ranelate, teriparatide, SERMs)"
62492205|NCT03655977|EXPERIMENTAL|Cervical cancer patients|This pilot study includes 25 women with histologically proven advanced stage primary cervical cancer (FIGO stages ≥IB2-IVA), planned for treatment with radio-chemotherapy.
62334869|NCT02310802|EXPERIMENTAL|OBE001 dose 1|
62334870|NCT02310802|EXPERIMENTAL|OBE001 dose 2|
62334871|NCT02310802|EXPERIMENTAL|OBE001 dose 3|
62492206|NCT06478745||Quantitative Aim|Ambispective longitudinal observational study
62492207|NCT06478745||Qualitative Aim|Focus group, semi-structured interviews and Photovoice
62492208|NCT06478745||Systematic Review Aim|Systematic literature review on the effectiveness of interventions on training, multimorbidity and polypharmacy in health professionals.
62492209|NCT06468514|EXPERIMENTAL|GRUPO 1|a Neural tension technique on the radial nerve will be performed.
62492210|NCT06468514|EXPERIMENTAL|GRUPO 2|A neural gliding technique will be performed on the radial nerve.
62492211|NCT02470260||Diabetes|Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)
62492212|NCT02470260||Pre-diabetes|Defined by HbA1c criteria (5.7 to 6.4%)
62492213|NCT02470260||Normal glucose tolerance|Defined by HbA1c criteria (\< 5.7%)
62695180|NCT05450978||Levetiracetam (LEV)|Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with Levetiracetam (LEV)
62695181|NCT04981912|EXPERIMENTAL|Arm A|HDMP + rituximab as a means of debulking prior to initiating venetoclax.
62137404|NCT03904069|EXPERIMENTAL|Comparison of different cell doses of AMG 553|Subjects will receive IV infusion of AMG 553
62137405|NCT02295189|ACTIVE_COMPARATOR|Visual analogue scale|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
62137406|NCT02295189|ACTIVE_COMPARATOR|Treatment|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
62137407|NCT05220501|ACTIVE_COMPARATOR|Micro-US Only|Subjects will undergo biopsy using micro-ultrasound only.
62137408|NCT05220501|ACTIVE_COMPARATOR|mpMRI + Micro-US|Subjects will undergo fusion biopsy using mpMRI and micro-ultrasound
62334872|NCT02310802|PLACEBO_COMPARATOR|Placebo|
62334873|NCT00563004|ACTIVE_COMPARATOR|A|Patients receive the herbal medication DBCARE for 3 months
62334874|NCT00563004|PLACEBO_COMPARATOR|B|PATIENTS RECEIVE PLACEBO PILLS
62334875|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
62334876|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
62334877|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
62334878|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
62334879|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
62334880|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
62334881|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
62334882|NCT03169010||Pulmonary Takaysu Arteritis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
62334883|NCT06281886|EXPERIMENTAL|The study group|Patients are planned to receive 2 cycles of induction immuno-chemotherapy plus apatinib, followed by concurrent chemoradiotherapy plus apatinib.
62492214|NCT00893945|EXPERIMENTAL|DC/AAT vaccine|Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.
62492215|NCT02005276|NO_INTERVENTION|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day.
62492216|NCT02005276|EXPERIMENTAL|Basic Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day."
62695182|NCT00060775||Non-Targets|Characterized by temperament - no behavioral inhibition
62695183|NCT00060775||Parents|Parents of children enrolled in the study
62695184|NCT00060775||Targets|Characterized by temperament - high/low behavioral inhibition
62492217|NCT02005276|EXPERIMENTAL|Combined Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 5 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day."
62695185|NCT01519479|EXPERIMENTAL|Palliative Care Consultation|Participant will get one palliative care consultation while in the hospital. The participants desire for subsequent palliative care visits will be determined and mutually agreed upon at the initial consultation.
61939343|NCT03169686|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive the 'WeChat WeQuit' program from the WeChat subscription account. The period for intervention was 14 weeks, including 2-week quiting preparation intervention and 12-week postquit intervention. The number of messages/pictures/audios received by participants will gradually decrease (will be intensively sent to them during 2-week prequit and 4-week postquit, and less intensively during 5-week to 12-week postquit), and follow-up questionnaires were sent only once a month in 14-28 weeks (week 16, 20, and 26 after the quit date). A WeChat group was created for answering questions from participants, and sharing the latest resources related to quitting smoking, and promoting communication between participants.
61939344|NCT03169686|NO_INTERVENTION|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 26 points.
62334884|NCT06281886|ACTIVE_COMPARATOR|The control group|Patients are planned to receive 2 cycles of induction immuno-chemotherapy, followed by concurrent chemoradiotherapy.
62492218|NCT02005276|EXPERIMENTAL|Jackpot Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day."
62492219|NCT03661151||Antireflux surgery following PPI|A single cohort with the GERD patients who had acid suppressive medication with proton pump inhibitor (PPI) followed by laparoscopic antireflux surgery
62137409|NCT05220501|ACTIVE_COMPARATOR|mpMRI Only|Subjects will undergo biopsy using mpMRI fused with regular ultrasound
62137410|NCT02118870|ACTIVE_COMPARATOR|DAPT 360 days|Treatment 360 days DAPT
62334885|NCT06383351||Peri-implant disease patients|Patients with a diagnosis of peri-implant mucositis or peri-implantitis
62334886|NCT03338751|ACTIVE_COMPARATOR|Hearing Assistance Device (HAD) First|Tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second. Participants randomized to HAD first will use a Hearing Aid Device.
62334887|NCT03338751|ACTIVE_COMPARATOR|No Hearing Assistance Device (HAD) First|Sham hearing aid device
62334888|NCT05799443|EXPERIMENTAL|SBRT followed by tislelizumab plus cetuximab and irinotecan|
62334889|NCT03765476|ACTIVE_COMPARATOR|TAU|treatment as usual
62492220|NCT03045536||Patients with TFR|Patients treated with TFR for oncologic or non-oncologic reason
62492221|NCT03031795|EXPERIMENTAL|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
62695186|NCT01519479|ACTIVE_COMPARATOR|Control|Usual care for HF patient which may include a palliative care consult if ordered by treating physician.
62334890|NCT03765476|EXPERIMENTAL|TAU plus SALIENCE|"treatment as usual plus computer-based intervention SALIENCE"
62334891|NCT03057457||Kidney Injury|
62137411|NCT02118870|ACTIVE_COMPARATOR|DAPT 90 days|Treatment 90 days DAPT
62334892|NCT01830543|EXPERIMENTAL|rivaroxaban 2.5 mg twice daily|rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
62334893|NCT01830543|EXPERIMENTAL|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
62334894|NCT01830543|EXPERIMENTAL|rivaroxaban 15 mg once daily|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
62334895|NCT02345252|EXPERIMENTAL|FTC/RPV/TAF|FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
62334896|NCT02345252|ACTIVE_COMPARATOR|FTC/RPV/TDF|FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
62334897|NCT02345252|EXPERIMENTAL|Open Label Extension Phase|After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
62334898|NCT00104494|EXPERIMENTAL|1|CF, Zinc acetate
62334899|NCT00104494|EXPERIMENTAL|2|CF, Placebo
62492222|NCT03031795|PLACEBO_COMPARATOR|placebo|look alike placebo
62492223|NCT00957762||Body Composition|120 subjects will help create the regression models. The remaining 50 subjects will be recruited to determine if the equations work for the population.
62492224|NCT02118324|EXPERIMENTAL|Exercise treatment|Participants will be instructed to use the exergaming program at home for 30 mins, 3-5 times per week.
62137412|NCT00503906|EXPERIMENTAL|Abraxane, Avastin and Gemcitabine|"Each treatment cycle is 28 days. Participants will be treated until disease progression:~* Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~* Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~* Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
62137413|NCT03555175|OTHER|Group one|This participants group must do eccentric exercise for 12 weeks
62137414|NCT03555175|OTHER|Group two|This participants group must do proprioception exercise for 12 weeks
62334900|NCT00104494|NO_INTERVENTION|3|Controls
62334901|NCT04573634||Health Care Workers|Health-care workers undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
62334902|NCT04573634||Eligible Patients|Patients undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
62334903|NCT04573634||Quarantining Individuals|Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
62334904|NCT04612062|EXPERIMENTAL|Healthy Subjects (Part A)|CEE321 0.2% (3 mg/cm2) topical cream b.i.d.
62334905|NCT04612062|EXPERIMENTAL|Atopic Dermatitis (Part B)|CEE321 0.2% (3 mg/cm2) topical cream b.i.d.
62334906|NCT01849835|EXPERIMENTAL|trans-rectal|trans-rectal to perform the prostate biopsy
62334907|NCT01849835|EXPERIMENTAL|trans-perineal|trans-perineal to perform the prostate biopsy
62334908|NCT03862690||Participants with Type 2 Diabetes Mellitus|A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.
62334909|NCT01188915|EXPERIMENTAL|intensive screening|annual breast cancer detection based on mammography, echography and RMI.
62334910|NCT00258427|EXPERIMENTAL|Marrow Isolex|Bone marrow processed using Isolex300i
62334911|NCT00258427|EXPERIMENTAL|USB arm|No processing
62334912|NCT00258427|EXPERIMENTAL|Marrow Clinimacs|Bone marrow processed using CliniMACS system
62334913|NCT00258427|EXPERIMENTAL|Sibling without CliniMacs|Sibling donor without the use of CliniMACS system
62334914|NCT03648281||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
62334915|NCT01163162|EXPERIMENTAL|Paricalcitol|After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
62334916|NCT00308438|EXPERIMENTAL|1|All subjects in the study dosed at 0.1 mg/kg teduglutide
62334917|NCT00116857|ACTIVE_COMPARATOR|Sertraline/omega-3 supplement|
62334918|NCT00116857|PLACEBO_COMPARATOR|Sertraline/corn oil|
62334919|NCT01863407|EXPERIMENTAL|DAM Solution|Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
62334920|NCT01863407|PLACEBO_COMPARATOR|Normal Saline|Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
62334921|NCT02352610|ACTIVE_COMPARATOR|LRTI without a Biotenodesis Screw|Ligament Reconstruction Tendon Interposition without a Biotenodesis Screw
62334922|NCT02352610|ACTIVE_COMPARATOR|LRTI with Biotenodesis Screw|Ligament Reconstruction Tendon Interposition with Biotenodesis Screw
62334923|NCT02623036|ACTIVE_COMPARATOR|Enalapril arm|Patients randomized to this group will receive equivalent dose enalapril to their current ACEI therapy and change the administration time to bedtime.
62334924|NCT02623036|ACTIVE_COMPARATOR|Lisinopril arm|Patients randomized to this group will receive equivalent dose lisinopril to their current ACEI therapy and change the administration time to bedtime.
62334925|NCT02817152|SHAM_COMPARATOR|Periodontal ultrasonic debridement|Periodontal pockets received ultrasonic periodontal debridement intervention.
62334926|NCT02817152|ACTIVE_COMPARATOR|Low-level laser therapy|Periodontal pockets received ultrasonic periodontal debridement plus low-level laser therapy intervention.
62334927|NCT06291116|EXPERIMENTAL|experimental|Experimental group: standard care + rotigotine at 4 mg/24 hours for 24 months.
62334928|NCT06291116|ACTIVE_COMPARATOR|Control|Control group: standard care for 24 months.
62334929|NCT00665496|EXPERIMENTAL|Arm 1|
62334930|NCT00665496|PLACEBO_COMPARATOR|Arm 2|
62334931|NCT00711269|EXPERIMENTAL|SM-13496 (lurasidone HCl) 40mg|SM-13496 40 mg was administered orally once daily.
62334932|NCT00711269|EXPERIMENTAL|SM-13496 (lurasidone HCl) 80mg|SM-13496 80mg was administered orally once daily.
62334933|NCT00711269|PLACEBO_COMPARATOR|Placebo|Placebo was administered orally twice daily.
62137415|NCT03555175|OTHER|Group 3|This participants group mustn't do exercise extra
62137416|NCT05170074||SRS implant|Surgical reconstruction of the anterior and apical compartment of the pelvic floor with an SRS implant
62334934|NCT00711269|ACTIVE_COMPARATOR|Risperidone|Risperidone was administered orally twice daily.
62334935|NCT06065527|ACTIVE_COMPARATOR|Enhanced usual care and Map Our Life|Participants will be introduced to Map Our Life, by research staff. In accordance to the Preparation for Future Care Model, PYL: (1) introduces users to long-term care (LTC) related choices (care expectation); (2) assesses the unique caregiving needs of the care recipient (awareness); (3) educates the users on locally and nationally available home-based resources (information gathering); (4) makes choices about LTC preferences (decision-making), and (5) shares those choices with others (concrete planning).This process is associated with informed and value-based decisions that fit the preferences of the care recipient and increased well-being according to the theory of proactive coping, which states that preparation for future stressors improves the ability to cope in real-time.
62334936|NCT06065527|PLACEBO_COMPARATOR|Enhanced usual care and Attention Control|"In this arm, caregivers will be referred to a website containing information from Disability and Health Information for Family Caregivers. The content in the attention control is from CDC-sponsored websites that promote healthy activities and behaviors targeting people with disabilities and their family caregivers. Additionally, the content leads users to CDC-sponsored Caregiving webpages which assist families in developing care plans. All content is available in English and Spanish."
61939345|NCT02213042|ACTIVE_COMPARATOR|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
62334937|NCT00195260|EXPERIMENTAL|Dose escalation|Dose finding study of monotherapy bosutinib in patients with advanced solid tumors.
62334938|NCT00195260|EXPERIMENTAL|Colorectal Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
62334939|NCT00195260|EXPERIMENTAL|Pancreatic Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
62334940|NCT00195260|EXPERIMENTAL|Non-Small Cell Lung Cancer (NSCLC)|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
62334941|NCT03265509|ACTIVE_COMPARATOR|Glutamine|30 g/day Glutamine supplementation for three months
62334942|NCT03265509|PLACEBO_COMPARATOR|Fantomalt|30 g/day Fantomalt supplementation for three months
62334943|NCT05218850|EXPERIMENTAL|open label intervention arm|Butyrate enemas will be administered once daily for twelve weeks.
61939346|NCT02213042|ACTIVE_COMPARATOR|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.
62137417|NCT03637296|EXPERIMENTAL|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
62334944|NCT03509207|EXPERIMENTAL|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
62334945|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
62334946|NCT00782418|ACTIVE_COMPARATOR|1|exenatide 5mcg
62334947|NCT00782418|ACTIVE_COMPARATOR|2|exenatide 1.5mcg
62334948|NCT00782418|PLACEBO_COMPARATOR|3|Placebo
62334949|NCT03018626|ACTIVE_COMPARATOR|DA-EPOCH-R|DA-EPOCH-R regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, etoposide(50 mg/m2), doxorubicin(10 mg/m2) and vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours), cyclophosphamide(750 mg/m2)/dayg IV on days 5, prednisone (60 mg/m2) given orally bid on days 1 through to 5.All patients received granulocyte colony-stimulating factor (G-CSF) beginning on day 6 and continued until the ANC was more than 5 × 109/L above the nadir level. The adjustment paradigm was based on the ANC nadir in the previous cycle as previously described(Wilson, Grossbard et al. 2002)
62334950|NCT03018626|EXPERIMENTAL|Modified R-ACVBP|R-ACVBP regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, doxorubicin (75 mg/m2) and cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1, vindesine (2 mg/m2) given on days 1 and 5, bleomycin (10 mg) given IV on days 1 and 5, prednisone (60 mg/m2) given orally on days 1 through to 5.
62334951|NCT06288776|EXPERIMENTAL|Interventional Group|Participants will be assessed for their tooth sensitivity (VAS scoring) and after giving herbal based mouthwash sensitivity will be assessed after 3 months
62334952|NCT01740440|OTHER|BMR Face treatment|BMR Face treatment used once a day for 12 weeks
62334953|NCT03540134|EXPERIMENTAL|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
62334954|NCT01104259|EXPERIMENTAL|Treatment (veliparib with cisplatin and vinorelbine tartrate)|Patients receive veliparib PO BID on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV over 1 hour on day 1 and vinorelbine ditartrate IV over 10-20 minutes on days 1 and 8. Treatment repeats every 21 days for 6-10 courses in the absence of disease progression or unacceptable toxicity. Treatment with veliparib alone may continue in the absence of disease progression or unacceptable toxicity.
62334955|NCT06006858||Moderna COVID-19 Vaccine|Clinically healthy adults aged ≥ 18 years who received Primary Moderna COVID-19 Vaccine
62334956|NCT05942937|EXPERIMENTAL|Whole-of-prison education intervention|The HepPEd Program will saturate the entire prison during a 3-month intervention phase.
62334957|NCT00471445|EXPERIMENTAL|ketamine/amitriptyline NP-H cream|Patients apply 4 grams amitriptyline (4%) and ketamine (2%) hydrochloride topical analgesic cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
62334958|NCT00471445|PLACEBO_COMPARATOR|Placebo Cream|Patients apply a placebo cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
62334959|NCT02508688|EXPERIMENTAL|thoracoscopic mesh repair group|63 patients with refractory HH (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair were included in this study.
62334960|NCT01810042|EXPERIMENTAL|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months.
62334961|NCT03533725|EXPERIMENTAL|Intervention group|Breastfeeding counseling and education services using mHealth tools
62334962|NCT03533725|NO_INTERVENTION|Comparative control group|No intervention, only standard of care
62334963|NCT00472472|PLACEBO_COMPARATOR|1|PTA
62334964|NCT00472472|ACTIVE_COMPARATOR|2|PTA with Paccocath
62492225|NCT02118324|NO_INTERVENTION|Control group|No intervention is provided.
62492226|NCT02694536|EXPERIMENTAL|Erlotinib + Gemcitabine|Participants will receive erlotinib in combination with standard of care chemotherapy (gemcitabine) until disease progression, unacceptable toxicity, or withdrawal for any reason.
62492227|NCT01712633||Volunteers|Healthy Volunteers
62695187|NCT06476509|EXPERIMENTAL|LV232|A single oral dose of 40mg LV232 (5 mg/capsule, 8 capsules each time) ，administrated in fasting state, with 240 mL water to take
62492228|NCT02570854|EXPERIMENTAL|CSJ137|In Part 1 up to 48 subjects will receive a single dose of CSJ137. In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
62492229|NCT02570854|PLACEBO_COMPARATOR|Placebo|In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
62492230|NCT04440358|EXPERIMENTAL|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to carboplatin administration.
62492231|NCT02847416|EXPERIMENTAL|Inspiratory group|the subjects will be instructed to inspire as deeply as possible with steady flow rate for 3 seconds with end-inspiratory pause for 2-3 seconds through the inspiratory circuit and follow by passive exhalation
62492232|NCT02847416|EXPERIMENTAL|expiratory group|the subjects will be instructed to inspire as deeply as possible through the nose with end-inspiratory pause for 2-3 seconds and partially forced exhalation with reach to 1/3 of expiratory reserve volume (ERV) for at least 3 seconds through expiratory circuit
62492233|NCT06098313|EXPERIMENTAL|PTCy|Patients who receive post-transplantation cyclophosphamide
62492234|NCT01127113|ACTIVE_COMPARATOR|SPIO-labelled mononuclear cells|
61939347|NCT02213042|ACTIVE_COMPARATOR|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
61939348|NCT02837068|EXPERIMENTAL|Wheelchair handrail compensator|When a patient sitting on the wheelchair, the physiotherapist put the paralysis upper limb on the handrail compensator and keep the limb in normal position for at least 60 minutes one day.
61939349|NCT02837068|ACTIVE_COMPARATOR|Ordinary wheelchair|When a patient sitting on the wheelchair, the paralysis upper limb was put on the ordinary handrail for at least 60 minutes one day.
61939350|NCT03265665|EXPERIMENTAL|ACTION Intervention|Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants during the adoptive phase (24-weeks) and 1 group session during the maintenance phase (12-weeks). Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
62137418|NCT03637296|NO_INTERVENTION|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
62137419|NCT04489355||CABG|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG)
62137420|NCT04489355||CABG with SVR|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR)
62137421|NCT04489355||CABG with mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with and mitral repair (MR)
62137422|NCT04489355||CABG with SVR and mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)
62137423|NCT03642366|ACTIVE_COMPARATOR|Active Arm 1|
62137424|NCT03642366|ACTIVE_COMPARATOR|Active Arm 2|
61939351|NCT03265665|OTHER|Enhanced usual care|Women in the Enhanced usual care arm will attend 1 asthma education/physical activity session and be given a Fitbit Charge HR to monitor their daily steps. They will be given a static step goal to achieve. Only reminder text messages for data collection visits will be sent.
61939352|NCT04683562|OTHER|Normal pregnancy group|
61939353|NCT04683562|OTHER|Placenta accreta group|
62137425|NCT03642366|SHAM_COMPARATOR|Sham Arm|
62137426|NCT05927623|EXPERIMENTAL|Misterfit online group|The Misterfit online group will receive a 12-month virtually-delivered fracture prevention intervention that includes a personalized gender-tailored strength training and balance-based exercise program, nutritional counselling and fall and fracture prevention education.
62137427|NCT05927623|OTHER|MisterFit offline group|The Misterfit offline group will act as an attention control group receiving a fracture prevention intervention with the same components as the experimental group, but the components will not be virtual, personalized or gender-tailored.
62137428|NCT01911767||Dimethyl fumarate|Exposure to dimethyl fumarate since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy
62137429|NCT01911767||Peginterferon beta-1a|Exposure to Peginterferon beta-1a since 17 days prior to the first day of her LMP prior to conception or at any time during pregnancy.
62137430|NCT01911767||Disease Modifying Therapy (DMT) Unexposed|Never received DMT therapy; discontinued treatment with any DMT at least more than 5× half-life prior to Day 1 of her LMP and throughout the entire pregnancy.
62137431|NCT02809599|NO_INTERVENTION|Pre-intervention|Patients in hospitals that have not received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess BPPV processes at the ED Index visit. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
62492235|NCT01127113|PLACEBO_COMPARATOR|Unlabelled mononuclear cells|
62492236|NCT01127113|ACTIVE_COMPARATOR|SPIO alone|
62492237|NCT00307723|EXPERIMENTAL|Regimen Level 1|Radiation/Oxaliplatin/5-FU
62492238|NCT00307723|EXPERIMENTAL|Regimen Level 2|Radiation/Oxaliplatin/Bevacizumab/5-FU
62492239|NCT05081193|EXPERIMENTAL|Oral Testosterone Therapy given until radiographic progression followed by Enzalutamide Therapy|Oral Testosterone Therapy-396 mg given twice per day on days 1-7 and 15-21 of a 28 day cycle until radiographic progression. After a 21 day washout period, Enzalutamide therapy given at 160 mg once daily will be taken for a maximum of 6 cycles while on study.
62492240|NCT03168035|EXPERIMENTAL|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
62492241|NCT03066544|ACTIVE_COMPARATOR|bupivacaine (Exparel)|subjects assigned by clinician's judgment - standard care choice A
62492242|NCT03066544|ACTIVE_COMPARATOR|naratriptan pill (Amerge)|subjects assigned by clinician's judgment - standard care choice B
62492243|NCT03066544|ACTIVE_COMPARATOR|dexamethasone tablet (Decadron)|subjects assigned by clinician's judgment - standard care choice C
62492244|NCT03066544|ACTIVE_COMPARATOR|ketorolac (Toradol)|subjects assigned by clinician's judgment - standard care choice D
62492245|NCT02136251||shoulder replacement|Subjects who had shoulder replacement surgery at The University of Nebraska and The Nebraska Medical Center at least 5 or more years ago and autologous bone graft around the anchor-peg glenoid prosthesis was used.
62492246|NCT00548431|EXPERIMENTAL|6 mercaptopurine arm|All patients received basic daily 6MP (6-mercaptopurine) (25 mg/m\^2) and in addition high-dose methotrexate(HDM) every 3rd week (3 times HDM in total) and PEG-asparaginase every 14th day. Patients increased the dose of 6MP 2 weeks after each HDM if if the myelotoxicity had been acceptable. This means 2 increments since the study stopped 2 weeks after the last HDM
62492247|NCT01820962|ACTIVE_COMPARATOR|A: heparin (Heparin LEO)|After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
62492248|NCT01820962|EXPERIMENTAL|B: concentrated citrate (Citralock)|locking the central venous catheter with concentrated citrate after each use
62492249|NCT03526484|ACTIVE_COMPARATOR|Standard of Care|The control group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will be reported to the doctor performing the procedure. The provider may require participants to take antibiotics and/or delay their procedure as a result of the urinalysis.
62492250|NCT03526484|EXPERIMENTAL|Experimental|The experimental group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will NOT be reported to the doctor performing the procedure. Instead, the provider will conduct the procedure without looking at or acting upon the results of the urinalysis. The urinalysis and urine culture results will be monitored by the research team, and the participant will be informed if the urine culture results are positive for an infection.
61939354|NCT05436275|EXPERIMENTAL|CM310|CM310 300mg is given subcutaneously (SC) every two weeks
62334965|NCT00777491|EXPERIMENTAL|5-FU and Cisplatin + BID Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction 5-fluorouracil, induction cisplatin, induction BID radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation 5-fluorouracil, consolidation cisplatin, consolidation BID radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine, adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
62492251|NCT00459407|EXPERIMENTAL|Arm I (green tea catechin extract)|"Patients receive oral defined green tea catechin extract daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
62492252|NCT00459407|PLACEBO_COMPARATOR|Arm II (placebo)|"Patients receive oral placebo daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
62492253|NCT02708758|ACTIVE_COMPARATOR|Treatment group|Medical nutrition therapy plus self monitoring capillary glucose levels and if necessary drug therapy (metformin or insulin) when goals are not met.
62492254|NCT02708758|NO_INTERVENTION|Routine care group|Prenatal routine care without medical nutrition therapy and without self monitoring capillary glucose levels and drug therapy specific for GDM.
62492255|NCT06283888|EXPERIMENTAL|CYP2C19 Genotype Guided DAPT|"Patients with CYP2C19 \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg Patients with CYP2C19 \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd~At post-PCI 3 months, monotherapy P2Y12 inhibitor (ticagrelor or clopidogrel) will be treated for a further 9 months."
62492256|NCT06283888|EXPERIMENTAL|Conventional DAPT|"Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd~At post-PCI 3 months, monotherapy P2Y12 inhibitor (ticagrelor or clopidogrel) will be treated for a further 9 months."
62492257|NCT02003391|EXPERIMENTAL|DuoTrav|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
62492258|NCT02003391|ACTIVE_COMPARATOR|Beta-blocker|Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.
62695188|NCT06476509|ACTIVE_COMPARATOR|Escitalopram|A single oral dose of 20mg Escitalopram (10 mg/tablet, 2 tablets each time) , administrated with 240 mL water
62695189|NCT03420820|EXPERIMENTAL|5% Betadine, Ocular Surface only|Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
61939355|NCT05436275|PLACEBO_COMPARATOR|Placebo|Placebo is given subcutaneously (SC) every two weeks
61939356|NCT04810481|NO_INTERVENTION|Standard Practice|Anesthesia will be provided at the discretion of the anesthesiologist following cardiovascular variables in accordance with usual clinical indications.
61939357|NCT04810481|ACTIVE_COMPARATOR|BIS Group|Anesthesia will be titrated to achieve a BIS value of 45-60 during maintenance of anesthesia. Additional intervention will be provided only if the subject is in distress.
62492259|NCT05757609|EXPERIMENTAL|tDCS combined with active physiotherapy|"transcranial Direct Current Stimulation (tDCS) will be applied for 20 min at an intensity of 2 mA with anodal stimulation targeting the left dorsolateral prefrontal cortex (DLPFC).~This will be done during a cycling session and will be followed by a physiotherapy program including strengthening and mobilisation exercises.~It will be applied 3 times a week during 3 weeks."
62492260|NCT05757609|SHAM_COMPARATOR|Sham tDCS combined with active physiotherapy|"Sham transcranial Direct Current Stimulation (tDCS) will be applied for 20 min and this induces similar sensations for the patients, but no change in excitability.~This will be done during a cycling session and will be followed by a physiotherapy programme including strengthening and mobilisation exercises.~It will be applied 3 times a week during 3 weeks."
62492261|NCT01104181|EXPERIMENTAL|swab and brush or swab and swab|we will determine which collection method is superior
62492262|NCT02941159|ACTIVE_COMPARATOR|SF2000SD|The test product is a Sondashi Formula Spray dried extract (SF2000SD). It is derived from spray drying with water the Sondashi Formula (SF2000), which is a mixture of mixture of 4 plants. SF2000SD is packaged into capsules of 500mg and six capsules are taken twice, daily for 42 days. This drug has anti-HIV properties but in this study we are just looking at safety issues.
62695190|NCT03420820|EXPERIMENTAL|10% Betadine, Ocular Surface only|Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
62334966|NCT00777491|EXPERIMENTAL|Gemcitabine + QD Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction gemcitabine and induction QD radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation gemcitabine and consolidation QD radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine and adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
62334967|NCT01226420|EXPERIMENTAL|Alefacept|Alefacept iv
62334968|NCT05329987||Parkinson Disease|Rehabilitation according to Physiotherapy and Occupational Therapy European Guidelines for Parkinson Disease.
62334969|NCT02167841|EXPERIMENTAL|Knee-Chest position|In this arm, the women will perform daily the Knee-Chest position between weeks 32-37. In week 37 the investigators will check via ultra sound if there was a successful version (if not, the woman would go to External Cephalic Version)
62334970|NCT02167841|NO_INTERVENTION|External Cephalic Version|In this group the women will perform External Cephalic Version without doing maternal Knee-Chest position before.
62334971|NCT00657852|EXPERIMENTAL|Pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
62334972|NCT00657852|PLACEBO_COMPARATOR|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
62334973|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
62334974|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
62334975|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
62334976|NCT01143493||Carrier - Other|
62334977|NCT01143493||Carrier hGR N363S Heterozygote|
62334978|NCT01143493||Carrier hGR N363S Homozygote|
62334979|NCT01143493||Carrier hGR9B A3669G Heterozygote|
62334980|NCT01143493||Carrier hGR9B A3669G Homozygote|
62334981|NCT01143493||Control|
62695191|NCT03420820|EXPERIMENTAL|10% Betadine, Ocular Surface and Adnexa|Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
62695192|NCT02586194|EXPERIMENTAL|Control (Subjects with normal hepatic function)|Oral
62334982|NCT00869765|EXPERIMENTAL|tDCS and D-CYC|Major Depression tDCS and D-cyc
62334983|NCT06552507|EXPERIMENTAL|Laminectomy with Duroplasty|Duroplasty
62334984|NCT06552507|NO_INTERVENTION|Laminectomy only|laminectomy without duroplasty
62695193|NCT02586194|EXPERIMENTAL|Mild hepatic impairment|Oral
62695194|NCT02586194|EXPERIMENTAL|Moderate hepatic impairment|Oral
61939358|NCT03227328|ACTIVE_COMPARATOR|Treatment Arm A|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
62334985|NCT05603039|EXPERIMENTAL|QL1706(5mg/kg)|QL1706(5mg/kg) Combined with Bevacizumab
62334986|NCT05603039|EXPERIMENTAL|QL1604|QL1604 Combined with Bevacizumab
62334987|NCT05603039|EXPERIMENTAL|QL1706(7.5mg/kg)|QL1706(7.5mg/kg) Combined with Bevacizumab
62334988|NCT06553326||Positive control|The image shown to the participant belongs to the same colonoscopy shown in the 10 second video-sequence.
62334989|NCT06553326||Negative control|The image shown to the participant belongs to the same colonoscopy shown in the 10 second video-sequence.
62334990|NCT06553326||EndoStyle (intervention group)|The image shown to the participant does not belong to the 10 second colonoscopy video-sequence but has been transformed with AI to simulate the style of the video.
62334991|NCT04353921||Single-Dose of Psilocybin|
62334992|NCT04353921||Niacin-Control|
62334993|NCT00753935|EXPERIMENTAL|Enteric-coated aspirin|patients received enteric-coated aspirin 81 mg qd for 2 weeks
62334994|NCT00753935|ACTIVE_COMPARATOR|Chewable aspirin|Patients received chewable aspirin 81 mg qd for 2 weeks
62334995|NCT04287998||1|PE group
62334996|NCT04287998||2|Control group
62334997|NCT04158713|PLACEBO_COMPARATOR|CTX-alone|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly placebo-DP, given as a fixed dose of 3 placebo-DP tablets daily for three days until delivery.
62334998|NCT04158713|EXPERIMENTAL|CTX-DP|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly DP, given as a fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery.
62492263|NCT02941159|PLACEBO_COMPARATOR|Placebo|The placebo arm is composed of capsule containing 500mg of inactive ingredient (Microcrystalline Cellulose PH102 -240mg; Starch - 10mg; Magnesium Stearate -10mg; and Maltodextrin Unidry 20 - 240mg).
62492264|NCT01476969|EXPERIMENTAL|Manual Tourniquet|
62492265|NCT02884986|ACTIVE_COMPARATOR|Etoricoxib|120mg of oral Etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
62492266|NCT02884986|PLACEBO_COMPARATOR|Placebo|120mg of oral Placebo the same amount as the drug administrated one hour prior to spinal anaesthesia induction
62492267|NCT01979146|EXPERIMENTAL|Provider Unrelieved Symptom Alert|Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.
62334999|NCT02328989|EXPERIMENTAL|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
62335000|NCT02328989|NO_INTERVENTION|No pessary|No pessary will be placed in the vagina.
62335001|NCT05441137|ACTIVE_COMPARATOR|A ROC with a Standing Posture for Toddlers with Mild Motor Delays (ROC-Stand(Mild))|The whole study duration will be 24 weeks, including a 12-week intervention and a 12-week follow-up. All programs will include 120 minutes/per session, 2 sessions/per week. Each week the research team will help the participant wear a wireless, head-mounted eye-tracker (46g) for recording the first 20-minute of both driving and natural play sessions in a 2-hour training session. The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary according to the previous ROC-related studies. The natural play session can be divided into two 20-to-25-minute sessions depending on the participant's condition. The head-mounted cameras worn by the participants and caregivers will record the visual and manual behaviors for 40 minutes/per week during intervention. All programs will be discussed by the family, the treating therapist and the research team.
62335002|NCT05441137|ACTIVE_COMPARATOR|A ROC with a 25-minute Standing Posture for Children with Moderate Motor Delays (ROC-Stand25(Mod))|The training guidelines and time are the same as the ROC-Stand(Mild) group, except for the participant's severity level of motor delay and using a 25-minute standing and 45-mnute sitting posture for driving. The participants will also wear the head-mounted eye tracker in one training session every week.
62335003|NCT05441137|ACTIVE_COMPARATOR|A ROC with a Sitting Posture for Children with Severe Motor Delays (ROC-Sit(Sev))|The training guidelines and time are the same as the ROC-Stand(Mild) group, except for the participant's severity level of motor delay and using a sitting posture for driving. The participants will wear the head-mounted eye tracker in one training session every week.
62492268|NCT01979146|NO_INTERVENTION|Attentional Control Usual Care Group|Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.
62492269|NCT06219980|EXPERIMENTAL|treatment group|
62492270|NCT05643833||Male recipient|
61939359|NCT03227328|EXPERIMENTAL|Treatment Arm B|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
61939360|NCT05312073|OTHER|Patients with ichtyosis|
61939361|NCT05312073|OTHER|Patients without ichtyosis|
62335004|NCT05441137|PLACEBO_COMPARATOR|Conventional Therapy for Children with Mild Motor Delays (Control(Mild))|The whole study duration will be 24 weeks, including a 12-week intervention and a 12-week follow-up. All programs will include 120 minutes/per session, 2 sessions/per week. Each participant will have the opportunity to walk on certain public space as the ROC training groups and interact with the therapist and caregivers depending on his/her motor abilities. The participants will also wear the head-mounted eye-tracker in one training session every week.
62335005|NCT05441137|PLACEBO_COMPARATOR|Conventional Therapy for Toddlers with Moderate Motor Delays (Control(Mod))|The training guidelines and time are the same as the Control(Mild) group, except for the participant's severity level of motor delay. The participants will wear the head-mounted eye-tracker in one training session every week.
62335006|NCT05441137|PLACEBO_COMPARATOR|Conventional Therapy for Toddlers with Severe Motor Delays (Control(Sev))|The training guidelines and time are the same as the Control(Mild) group, except for the participant's severity level of motor delay. The participants and caregivers will also head-mounted eye-tracker in one training session every week.
62492271|NCT05643833||Female recipient|
62492272|NCT05643833||Male donor|
62492273|NCT05643833||Female donor|
62492274|NCT02519153|PLACEBO_COMPARATOR|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
62492275|NCT02519153|ACTIVE_COMPARATOR|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
62492276|NCT04218994|EXPERIMENTAL|Group A|Subjects instructed on flossing technique.
62492277|NCT04218994|NO_INTERVENTION|Group B|No instructions for flossing provided. Subjects asked to continue their normal oral hygiene care.
62492278|NCT04594434|EXPERIMENTAL|protocol EMDR + SB / SMP protocol (adjusted)|"Association of a positive memory with the recommended therapy based on EMDR."
62492279|NCT04594434|ACTIVE_COMPARATOR|protocol EMDR (standard).|"recommended therapy based on EMDR."
62335007|NCT00660504|EXPERIMENTAL|1|Amrubicin Hydrochloride-Cisplatin combined chemotherapy
62335008|NCT00660504|ACTIVE_COMPARATOR|2|Etoposide-Cisplatin combined chemotherapy
62335009|NCT01735617|EXPERIMENTAL|Hydrocortisone Modified Release Capsules|Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
61939362|NCT04340297|EXPERIMENTAL|Experimental group|Tongjiang granules are taken orally in liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally in spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally in cold-heat complicated syndrome, one bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
61939363|NCT04340297|PLACEBO_COMPARATOR|Control group|Tongjiang placebo granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua placebo granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei placebo granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
61939364|NCT01887223|EXPERIMENTAL|Transconjunctival needling revision|Eyes with primary glaucoma surgery failure with encapsulated bleb submitted to surgical revision
61939365|NCT01887223|ACTIVE_COMPARATOR|Medical treatment|Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops)
61939366|NCT01820156|EXPERIMENTAL|HRP-PSG|First performance three nights of HRP and following one night of laboratory PSG
61939367|NCT01820156|EXPERIMENTAL|PSG-HRP|First perform laboratory PSG and following three nights of HRP
61939368|NCT03404427|SHAM_COMPARATOR|Normal sleep night|The first endurance test is the endurance motor control test after a normal sleep night.
61939369|NCT03404427|EXPERIMENTAL|Sleepless night|The first endurance test is the endurance motor test after a sleepless night.
61939370|NCT04903665||Cancer Arm|Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.
61939371|NCT04903665||Benign Arm|Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.
61939372|NCT01704521|ACTIVE_COMPARATOR|Lead-In|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin
61939373|NCT01704521|ACTIVE_COMPARATOR|No Lead-in|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin
61939374|NCT00978471|EXPERIMENTAL|experimental arm thiotepa|4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.
62137432|NCT02809599|EXPERIMENTAL|Post-intervention|Patients in hospitals that have received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess the main study outcome, behavior change in medical providers. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
62335010|NCT01220648|EXPERIMENTAL|Nilotinib in conjunction with low dose interferon alfa|
62335011|NCT04059445|EXPERIMENTAL|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
62335012|NCT04059445|ACTIVE_COMPARATOR|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
61939375|NCT00978471|OTHER|Reference arm|4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.
61939376|NCT01193660|EXPERIMENTAL|Umbilical Cord Blood & Erythropoietin & Rehabilitation|Allogenic umbilical cord blood infusion, erythropoietin injection \& active rehabilitation
61939377|NCT01193660|ACTIVE_COMPARATOR|Erythropoietin & Rehabilitation|Erythropoietin injection, active rehabilitation
61939378|NCT01193660|PLACEBO_COMPARATOR|Only Rehabilitation|Active rehabilitation
62137433|NCT04553549||Transradial approach|"The procedure will be done using standard criteria as per operator preference. All interventional cases at our institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
62335013|NCT00234858|ACTIVE_COMPARATOR|1|
62335014|NCT00234858|ACTIVE_COMPARATOR|2|
62335015|NCT04569474|EXPERIMENTAL|Dressing Group|use of sterile transparent dressing
62335016|NCT04569474|NO_INTERVENTION|Standard Group|non-sterile transparente dressing
62335017|NCT02955134|EXPERIMENTAL|Chinese medicine prescription|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in experimental group use the traditional Chinese medicine application prescription.
62335018|NCT02955134|PLACEBO_COMPARATOR|placebo|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
62335019|NCT05813171|ACTIVE_COMPARATOR|Experimental: Allicor|Dietary Supplement: Allicor 150 mg capsule by mouth two times a day during the year
62137434|NCT05420480|ACTIVE_COMPARATOR|Two-Field lymph node dissection (106recR negative by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, esophagectomy and Two-Field lymph node dissection will be performed."
62335020|NCT05813171|PLACEBO_COMPARATOR|Placebo|Placebo capsule manufactured to mimic Allicor 150 mg capsule by mouth two times a day during the year
62335021|NCT01166360||Patients 2009|Patients undergoing cardiac surgery in 2009
62492280|NCT06221124|EXPERIMENTAL|BEL-Participant|First, we will measure the size of the finger of the participant and select appropriate size of Belun Ring device and the participant will be instructed to wear it on a finger in addition to regular PSG set up on the night of sleep study. Simultaneous recording of Belun Ring data {pulse oximeter, pulse rate and actigraphy} and standard PSG will be performed for one night.
61939379|NCT05304208|EXPERIMENTAL|Treatment arm|Before standard-of-care chemotherapy, a leukapheresis will be performed and monocytes will be used for differentiation to DCs using specific cytokines. Allogeneic tumor lysate (Pheralys) loaded autologous DCs (MesoPher) will be re-injected 3 weeks after completing chemotherapy, 2 times every other week. Four weeks after the first injection with DCT, patients will undergo eP/D surgery and receive three bi-weekly injections with DCT (starting 4 weeks after surgery). If there is a surplus of vaccinations, a 6th and 7th vaccination at 3 and six months after the last vaccination could be considered by the treating physician.
61939380|NCT05816031||Ketogenic diet|Patients scheduled to right laparoscopic adrenalectomy and belonging to the case arm, will be administered a standard 21 days ketogenic diet before surgery. Ketogenic diet is based on a standard diet plus a ketogenic product to be taken once daily for 21 days. In both groups patients will undergo abdominal ultrasound before surgery.
61939381|NCT05816031||No ketogenic diet|Ketogenic diet will not be prescribed to patients belonging to control group.
61939382|NCT06680531|EXPERIMENTAL|Group A|
61939383|NCT06680531|PLACEBO_COMPARATOR|Group B|
61939384|NCT02302534|EXPERIMENTAL|patients|"2 groups with MRI :~- 8 right thoracic AIS participants (Cobb angle between 20 and 40°)"
61939385|NCT02302534|EXPERIMENTAL|controls subjects|- 8 healthy controls (no clinical scoliosis)
61939386|NCT03222011|ACTIVE_COMPARATOR|Standard endoscopic therapy|Single endoscopic dilatation
61939387|NCT03222011|EXPERIMENTAL|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
61939388|NCT04484948|EXPERIMENTAL|Systemic sclerosis group|Systemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria
61939389|NCT04603053|EXPERIMENTAL|CBot-A Group|Participants randomly assigned to this arm will receive access to CBot-A app.
62137435|NCT05420480|EXPERIMENTAL|Three-Field lymph node dissection (106recR negative by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
62335022|NCT01166360||Patients 2008|Patients undergoing cardiac surgery in 2008
62335023|NCT04105556|EXPERIMENTAL|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.~Care was given when the child and his / her parents applied to the outpatient clinic for anesthesia consultation on the working day before the operation, and care was continued in the day surgery unit. On the 1st and 3rd days after discharge, the researcher provided tele-monitoring and consultancy services. In addition, communication with the parents was maintained at all times as needed. Care was terminated on the 10th day after discharge. The time of the study was approximately 12-14 days for each child and his / her parents.~Nursing care consists of 3 types of comfort-oriented care interventions. These interventions;~1. Standard maintenance interventions,~2. Emotional focused comfort care interventions,~3. Cognitive and functional comfort care interventions."
62492281|NCT00420095|ACTIVE_COMPARATOR|1|Human insulin mix 30/70
62492282|NCT00420095|EXPERIMENTAL|2|Insulin lispro low mix
62492283|NCT06103097||Chohort of pediatric Liver transplant pacients|Patients under 18 years recipient of a Liver transplanbt followed in our Unit and under the follow-up liver biopsy protocol
62492284|NCT00139594|EXPERIMENTAL|licarbazepine|
61939390|NCT04603053|NO_INTERVENTION|Wait List Group|Participants randomly assigned to this arm will be offered the intervention after the completion of the trial.
61939391|NCT05777343|EXPERIMENTAL|Intervention 1|Participants will receive exercise, PNE and online cognitive training sessions.
62492285|NCT04518553|ACTIVE_COMPARATOR|active control|antiviraltherapy using HA using antiviralHA drugs of HA to decrease HBV-DNA load. In this group, patients with chronic hepatitis B just take antiviral drug of HAs to control hepatitis B viral without active interference.
61939392|NCT05777343|ACTIVE_COMPARATOR|Intervention 2|Participants will receive exercise and pain neuroscience education (PNE).
61939393|NCT05777343|ACTIVE_COMPARATOR|Intervention 3|Participants will receive online cognitive training sessions.
62137436|NCT05420480|OTHER|Three-Field lymph node dissection (106recR positive by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
62137437|NCT06285422|EXPERIMENTAL|SC262 Plus Chemotherapy Regimen|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC262
62137438|NCT02127749|EXPERIMENTAL|Control|Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously
62492286|NCT04518553|EXPERIMENTAL|active interference|HA+plasma purification as active interference. HA antiviral therapy using HA plus plasma purification every three months.DFT as plasma purification mode will be used. DFT therapy time lasts 2.5-3 hours each time.After three months, DFT therapy will be used if patients' HBV-DNA loads are higher than cut-off normal level.
62492287|NCT02117830|EXPERIMENTAL|Androxal 25 mg|
62492288|NCT02117830|EXPERIMENTAL|Androxal 250 mg|supratherapeutic dose
62335024|NCT04105556|NO_INTERVENTION|Routine hospital schedule|"The researcher sincerely answered all questions asked by the control group during the perioperative period.~After the post-discharge post-tests, the control group was given a gift of medal of courage, a story book and a training booklet prepared for the parents after the policlinic control on the 10th postoperative day, and the training was given to the intervention group."
62335025|NCT05595785|EXPERIMENTAL|Physical-Based Yoga Practice|"Participants attended two 50-minute class sessions per week during the four week intervention phase.~The physical-based yoga practice was Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis. The yoga class sessions included the physical postures of yoga with an emphasis on alignment, holding postures, and breathing normally.~Each yoga class session sequentially included the following physical postures of yoga: (1) standing in stillness; (2) pranayama deep breathing and warm up; (3) standing series- balance postures, wide leg postures; (4) transition from the standing postures to the floor postures with tree pose; (5) floor series - wind removing, sit up movements, cobra posture, kneeling postures; (6) cool down-stretching, spine twist, Kapalbhati breathing, and Savasana."
62335026|NCT05595785|EXPERIMENTAL|Mindfulness-Based Yoga Practice|"Participants attended two 50-minute class sessions per week during the four week intervention phase.~The mindfulness-based yoga practice included all elements of the physical-based yoga class sessions with the addition of mindfulness cues.~The mindfulness cues included body scan, mindful movement, and yoga nidra. Beyond verbal physical cues on how to control breathing and perform precise body movements during the yoga postures, verbal mindfulness cues asked participants to focus on the sensations of their breathing and body awareness non judgmentally, e.g. Feel your breathe move in through your nose and fill your lungs from bottom to top. Feel your breath exit the nose and empty lungs from top to bottom. Keep your attention on your breath and your body."
62695195|NCT06639243|EXPERIMENTAL|QTM Technique Treatment Arm|In this study, all participants will undergo the Quick Yielding Modified (QYM) technique, which combines thoracic endovascular aortic repair (TEVAR) with in situ fenestration and revascularization of the supra-aortic branches. This technique is designed to treat patients with complex aortic arch diseases, including thoracic aortic dissection, true and pseudoaneurysms, penetrating aortic ulcers, and intramural hematomas. The procedure aims to provide a minimally invasive alternative to open surgery, allowing for the effective reconstruction of the aortic arch and its branches. The study will assess the safety and efficacy of this technique, with key outcomes including the incidence of major adverse events (MAE) and the long-term success of the treatment.
61939394|NCT02275273||Patients with adnexal masses|Every patient that are at least 18 years old with a planned pelvic magnetic resonance imagery and an adnexectomy within the institution.
62137439|NCT02127749|EXPERIMENTAL|Antibiotics|Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously
62137440|NCT05260398|EXPERIMENTAL|Mightier Now|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration.
62137441|NCT05260398|NO_INTERVENTION|Mightier Later|8 weeks of wait list. Families in the Mightier Later condition will receive their Mightier shipment and will be encouraged to play Mightier after follow-up questionnaires have been completed 8 weeks after parents and teachers complete baseline questionnaires.
62335027|NCT02515864|EXPERIMENTAL|FYU-981 anticipated therapeutic dose|Drug: FYU-981, FYU-981 Placebo, Moxifloxacin Placebo (Oral)
62335028|NCT02515864|EXPERIMENTAL|FYU-981 supratherapeutic dose|Drug: FYU-981, Moxifloxacin Placebo (Oral)
62335029|NCT02515864|PLACEBO_COMPARATOR|Placebo|Drug: FYU-981 Placebo, Moxifloxacin Placebo (Oral)
62335030|NCT02515864|ACTIVE_COMPARATOR|Moxifloxacin|Drug: Moxifloxacin, FYU-981 Placebo (Oral)
62335031|NCT00216853||Patients with Recurrent UTI|
62335032|NCT00216853||Healthy controls|
62335033|NCT02491073||Eslicarbazepine acetate treated|
61939395|NCT04430192|EXPERIMENTAL|177Lu-PSMA-617 followed by prostatectomy|177Lu-PSMA-617 followed by prostatectomy
61939396|NCT02542982|EXPERIMENTAL|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
62335034|NCT02491073||Non-Eslicarbazepine acetate treated|
62492289|NCT02117830|PLACEBO_COMPARATOR|Placebo|
61939397|NCT02542982|SHAM_COMPARATOR|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
61939398|NCT06393543||Retrospective cohort|Women with isolated STIC diagnosed between 2015 and the start of the study.
61939399|NCT06393543||Prospective cohort|Women with a newly diagnosed isolated STIC
62137442|NCT05957198||Patients with fibrotic interstitial lung disease (ILD)|Patients aged ≥18 years with ≥2 fibrosing ILD diagnoses and continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date as recorded in a commercial, Medicaid, or Medicare plan, using existing administrative claims and EHR data in Optum's Market Clarity Integrated Claims + Clinical database for the patient identification period (01-Oct-2016 through 30-Jun-2022).
62137443|NCT01670474|EXPERIMENTAL|fmDLC and rt-PA (2mg/2mL actilysis)|"Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
62335035|NCT01899404|EXPERIMENTAL|18-FDG PET/CT, DWI, DCE-MRI|
62335036|NCT05342584|EXPERIMENTAL|Venetoclax plus 7+3|see detailed description
62335037|NCT03826355|ACTIVE_COMPARATOR|Stripping technique|The endometrioma is removed according to standard surgery.
62335038|NCT03826355|EXPERIMENTAL|Laser technique|The endometrioma is drained, everted and then the inner wall of the endometrioma is vaporised with CO2 laser
62335039|NCT00879814|EXPERIMENTAL|1|rLP2086 vaccine 60 mcg
62335040|NCT00879814|EXPERIMENTAL|2|rLP2086 vaccine 120 mcg
62335041|NCT00879814|EXPERIMENTAL|3|rLP2086 vaccine 200 mcg
62492290|NCT02117830|OTHER|Moxifloxacin 400 mg|positive control
61939400|NCT05184556|EXPERIMENTAL|Family-based treatment|Families will complete 2-6 hours of therapy per week for 10 - 32 weeks, on average, determined by clinical need in conjunction with insurance specifications related to coverage of home-based care
61939401|NCT05184556|ACTIVE_COMPARATOR|Integrative family therapy|Families will complete 2-6 hours of therapy per week for 10 - 32 weeks, on average, determined by clinical need in conjunction with insurance specifications related to coverage of home-based care
61939402|NCT00400231|ACTIVE_COMPARATOR|1|Metformin
61939403|NCT00400231|ACTIVE_COMPARATOR|2|Fenofibrate
62492291|NCT02339363|EXPERIMENTAL|Sitting Meditation|4 weeks (45-min sessions, 2x per week) of sitting meditation, based on MBSR. The sitting meditation condition consisted of three parts: (a) breathing techniques, (b) meditation, and (c) discussion. Participants in the sitting meditation group learned new types of sitting meditation each week. Participants in the sitting meditation group received a CD that consisted of audio meditations that they could follow along at home. The sitting meditation participants were encouraged to practice formal sitting meditation for 15 to 30 minutes every day and asked to record details of their practice on their daily home practice logs.
62492292|NCT02339363|EXPERIMENTAL|Hatha Yoga|4 weeks(45-min sessions, 2x per week) of Hatha Yoga. The adolescent hatha yoga curriculum was used with permission from Shanti Generation Yoga © (2009) created by Abby Wills. The hatha yoga sessions consisted of three parts: (a) breathing techniques, (b) yoga poses, and (c) discussion. Participants in the hatha yoga group learned a series of new yoga poses each week, as well as reviewed old poses. During the first session, participants in the hatha yoga group received a DVD that contained five yoga lessons corresponding to the yoga poses being taught in the intervention. Participants were encouraged to practice the series of yoga poses at home for 15 to 30 minutes each day and record their home practice in their daily home practice logs.
62492293|NCT02339363|NO_INTERVENTION|Waitlist Control|4-week waitlist control condition. Completed all study measures at same time points as experimental groups. Were randomly assigned to one of the two active treatment conditions after completing the waitlist period.
61939404|NCT00400231|ACTIVE_COMPARATOR|3|Fenofibrate and Metformin
61939405|NCT00400231|PLACEBO_COMPARATOR|4|
61939406|NCT06392191|OTHER|Bupivacaine liposomes group|The nerve block puncture needle was imaged and then entered into the fascial space between the rhomboid and extracostal muscles, and liposomal bupivacaine 93 mg and bupivacaine 25mg diluted to 20 ml were injected into this space.
61939407|NCT06392191|OTHER|Standard bupivacaine dexamethasone group|The nerve block puncture needle was imaged and then entered into the fascial space between the rhomboid and external intercostal muscles, and a mixture of: receive standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg was injected into this space.
61939408|NCT02994134|ACTIVE_COMPARATOR|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
62335042|NCT00879814|ACTIVE_COMPARATOR|4|Tdap vaccine - normal saline - normal saline
62335043|NCT00819533|EXPERIMENTAL|sensor|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
62335044|NCT00465855|ACTIVE_COMPARATOR|Hyperbaric Oxygen (HBO2) - 3 sessions|Subjects undergo 3 hyperbaric oxygen sessions within 24 hours following carbon monoxide poisoning.
62335045|NCT00465855|SHAM_COMPARATOR|Hyperbaric Oxygen (HBO2) - 1 session|Subjects undergo 1 hyperbaric oxygen session and then 2 sham chamber sessions within 24 hours of carbon monoxide poisoning.
62335046|NCT05137119|NO_INTERVENTION|Methicillin-resistant staphylococcus aureus (MRSA) - Standard Therapy Arm (backbone therapy)|"Vancomycin or Daptomycin - Standard Therapy Arm~Either intravenous vancomycin dosed as per Australian Therapeutic Guidelines: This includes a loading dose of 25 mg/kg (up to 3000mg) if considered appropriate by the treating clinician, initial maintenance dosing at 15-20 mg/kg q12h, with subsequent adjustment to maintain area under the concentration-time curve (AUC) of 400 to 600 mg.hr/L OR trough levels at 10-20 mg/L, and the initial level taken 48-72 hours after the initiation of the first dose. Daptomycin 8-10mg/kg per day intravenously. The choice of vancomycin or daptomycin will be at the clinician's discretion. Dosing will be based on renal function."
62335047|NCT05137119|EXPERIMENTAL|Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy)|"Vancomycin or Daptomycin (Standard Therapy) + Beta-Lactam (β-lactam) Arm~In addition to standard treatment an intravenous β-lactam will be added for the first 7 calendar days following randomisation (day 1 being the day of randomisation - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous cefazolin 2g every 8 hours. For patients with renal impairment the intravenous cefazolin administration doses will be adjusted."
61939409|NCT02994134|EXPERIMENTAL|High intensity exercise|High intensity aerobic exercise intervention (delivered at 65%-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
61939410|NCT06615739||Comprehensive Regenerex Tissue Attachment Augments|Regenerex Tissue Attachment Augments were used in combination with the Comprehensive Segmental Revision system
61939411|NCT03959072||Robotic Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
61939412|NCT03959072||Conventional (manual) Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
61939413|NCT02715401|EXPERIMENTAL|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
61939414|NCT02715401|EXPERIMENTAL|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
61939415|NCT02853344|EXPERIMENTAL|Cohort A: Clear Cell RCC|Participants with clear cell RCC receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
61939416|NCT02853344|EXPERIMENTAL|Cohort B: Non-clear Cell RCC|Participants with non-clear cell RCC receive pembrolizumab 200 mg IV Q3W for up to 35 doses (approximately 24 months).
61939417|NCT04441671|EXPERIMENTAL|Open label|Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00
61939418|NCT04638296||Physicians|surgeons, anesthesiologists, and surgical residents
61939419|NCT04638296||Nurses|OR Nurses
61939420|NCT04510376|EXPERIMENTAL|Test article|
61939421|NCT04510376|ACTIVE_COMPARATOR|Histamine Positive Skin Test Control|
62335048|NCT05137119|NO_INTERVENTION|Methicillin-susceptible staphylococcus aureus (MSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
62492294|NCT02833428|EXPERIMENTAL|patients with acute spinal cord injury|The study will be performed on patients with acute spinal cord injury between the cord next to the C2 vertebra and marrow next to the T12 vertebra. This is usually hospitalized patients in an emergency situation, brought by EMS (emergency medical services) and taken care of immediately in the recovery room by intensivists. Patients who accepted to participate to this study will got the installation bedside biomedical equipment for the project (Eclipse Nim, Medtronic®). The aim of this work is to analyze using an artificial intelligence engine (IA, Biomedical equipment (Eclipse Nim, Medtronic®)) the influence of the physiopathological environment (set of parametric data monitoring, imaging, biology etc.) of the traumatized spinal cord on spinal pain.
62492295|NCT00895050||1|Patients diagnosed with RA
62492296|NCT01055834|EXPERIMENTAL|Eszopiclone 3 mg tablet|
62492297|NCT01055834|EXPERIMENTAL|Eszopiclone 1 mg tablet|
61939422|NCT04510376|PLACEBO_COMPARATOR|Aqueous Negative Control|
61939423|NCT03999853|EXPERIMENTAL|Conventional Therapy / Butyrate|Subjects will be receiving usual therapy for the first study period (approx 1 month) then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) for approx 2 months
61939424|NCT04233463|ACTIVE_COMPARATOR|Modulen Diet|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
61939425|NCT04233463|ACTIVE_COMPARATOR|Budesonide Treatment|Crohn patients will be given Budesonide treatment
61939426|NCT05162846|ACTIVE_COMPARATOR|Arm 1 - Usual care (UC)|Participants are provided with a link to the Michigan Department of Health and Human Services (MDHHS) informational website and are instructed to follow up with their oncology provider about genetic testing.
61939427|NCT05162846|EXPERIMENTAL|Arm 2 - Virtual genetics navigator|Participants receive access to an online genetics tool, the virtual genetics navigator, to help learn why and how to seek out genetic testing for hereditary cancer syndromes.
61939428|NCT05162846|EXPERIMENTAL|Arm 3 - Motivational interviewing (MI)|Participants receive up to 2 phone calls from trained genetics health coaches who provide information about genetic testing and use motivational interviewing to encourage participants to seek out clinical genetic testing.
61939429|NCT00000304|EXPERIMENTAL|1|15/30 mg d-amphetamine
61939430|NCT00000304|EXPERIMENTAL|2|30/60 mg d-amphetamine
61939431|NCT00000304|EXPERIMENTAL|3|placebo
61939432|NCT00662688|ACTIVE_COMPARATOR|chemotherapy|chemotherapy at investigator's discretion
61939433|NCT00662688|EXPERIMENTAL|dalteparin|dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.
62492298|NCT01572623|ACTIVE_COMPARATOR|Antiplatelet before carotid artery stenting|Clopidogrel 600 mg after carotid artery stenting
62492299|NCT01572623|ACTIVE_COMPARATOR|Statin therapy before carotid artery stenting|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
62492300|NCT02290262|EXPERIMENTAL|Comprehensive phase one rehabilitation|Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education plus usual care.
61939434|NCT05600426|ACTIVE_COMPARATOR|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
61939435|NCT05600426|ACTIVE_COMPARATOR|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
61939436|NCT01069627|EXPERIMENTAL|1|
62137444|NCT01670474|ACTIVE_COMPARATOR|polyDLC and rt-PA (2mg/2mL actilysis)|"The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
62492301|NCT02290262|NO_INTERVENTION|Usual care|The control group will receive usual care alone.
62695196|NCT05727501|ACTIVE_COMPARATOR|Post isometric relaxation|This Group was treated with baseline treatment of heating for 15min and rehab protocol post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
61939437|NCT04863092|EXPERIMENTAL|Underrepresented Population|A primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty
61939438|NCT04300439|ACTIVE_COMPARATOR|Arm A: metallic reusable ancillary.|This control group will be constituted of patients who will have the GMK® prosthesis with metallic reusable ancillary.
61939439|NCT04300439|EXPERIMENTAL|Arm B: Efficiency single use ancillary.|This group will be constituted of patients who will have the GMK® prosthesis with Efficiency single use ancillary.
61939440|NCT01469234|EXPERIMENTAL|loratadine|Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
61939441|NCT01469234|EXPERIMENTAL|fexofenadine|Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
61939442|NCT01469234|PLACEBO_COMPARATOR|placebo|Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
61939443|NCT02899845|EXPERIMENTAL|elderly people with walking difficulties|subjects with proven gait disturbance and balance will be recruited from a walking speed test and a standardized geriatric assessment by a geriatrician
61939444|NCT02899845|ACTIVE_COMPARATOR|elderly people without walking difficulties|subjects with no gait disturbance and balance disorders will be recruited from a walking speed test and a standardized geriatric assessment, once the subjects with gait disturbance and balance disorders have been recruited in order to make a match on the age criterion
62492302|NCT05291195|EXPERIMENTAL|Laser-devices group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite. Afterwards, depending on allocations, in the laser devices group, adjuvant treatment approaches were be performed by means of laser devices either photodynamic therapy (HELBO, Photodynamic Systems GmbH), or high power diode laser (940nm, Biolase).
62492303|NCT05291195|EXPERIMENTAL|Sodium hypochlorite|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
61939445|NCT04470271||Patients under routine hepatitis C care|Patients who are routinely followed at the treating institution. Investigators will evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
61939446|NCT04470271||Patients with hepatitis C lost of follow-up|Patients who were lost of follow-up. Participants will be contacted to evaluate if the continued HCV care at another institution, were not routinely followed by a liver-specialist or if they died. Investigators will also evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
61939447|NCT04090073|EXPERIMENTAL|Electroacupuncture Plus Fast-track Perioperative Program|Patients who are randomized to the intervention arm will receive Electroacupuncture combined with Fast-track program. Each session of Electroacupuncture will last for 20 minutes. The patients will undergo one session of Electroacupuncture daily from day 1 till day 4, or until the time when the primary outcome has occurred, whichever is earlier.
61939448|NCT04090073|ACTIVE_COMPARATOR|Fast-track Perioperative Program|Patients who are randomized to the control arm will receive Fast-track program alone.
61939449|NCT01498978|EXPERIMENTAL|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression then receive maintenance ipilimumab IV once every 3 months for 4 additional doses.
61939450|NCT00660751|ACTIVE_COMPARATOR|1|
61939451|NCT00660751|PLACEBO_COMPARATOR|2|
62137445|NCT01670474|ACTIVE_COMPARATOR|siDLC and rt-PA (2mg/2mL actilysis)|"Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
62137446|NCT05403476|EXPERIMENTAL|FE 999049 (Follitropin Delta)|
62137447|NCT05403476|PLACEBO_COMPARATOR|Placebo|
62137448|NCT04751799|NO_INTERVENTION|Control Group (no VR)|Patients undergoing colposcopy and colposcopically-guided biopsy without further intervention
62335049|NCT05137119|EXPERIMENTAL|Methicillin-susceptible staphylococcus aureus (MSSA) - Interventional Arm (backbone therapy)|"Cefazolin - Interventional Arm~Intravenous cefazolin 2g every 6 or 8 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous cefazolin administration dose will be adjusted."
62695197|NCT05727501|ACTIVE_COMPARATOR|Post facilitation stretching|This Group was treated with baseline treatment of heating for 15min and rehab protocol post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
61939452|NCT02977130|EXPERIMENTAL|Map group|patients receiving general shared care for diabetes and the conversation map intervention
61939453|NCT02977130|ACTIVE_COMPARATOR|Control group|patients receiving general shared care for diabetes
61939454|NCT06680635|ACTIVE_COMPARATOR|Flavonoid-enriched juice and low-calorie diet for obese patients|Subjects will receive nutritional intervention by a registered dietician and a flavonoid-enriched juice supplement for 8 weeks. The dietary intervention consists of healthy dietary recommendations and hypocaloric diet if necessary (overweight, obesity).
61939455|NCT06680635|PLACEBO_COMPARATOR|Pacebo juice and low-calorie diet for obese patients|Subjects will receive nutritional intervention by a registered dietitian and a placebo in the form of juice for 8 weeks. The dietary intervention consists of healthy dietary recommendations and hypocaloric diet if necessary (overweight, obesity).
61939456|NCT06680856|EXPERIMENTAL|PRP+HA|Diabetic foot ulcers were treated with PRP+HA dressing
61939457|NCT06680856|ACTIVE_COMPARATOR|HA alone|Diabetic foot ulcers were treated with HA dressing alone
62137449|NCT04751799|EXPERIMENTAL|VR before and during colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy as well as during colposcopy.
62137450|NCT04751799|EXPERIMENTAL|VR before colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy but not during colposcopy.
62137451|NCT06698354|EXPERIMENTAL|Virtual Reality-Assisted Hypnotherapy+Physiotherapy Group|Participants in this arm will undergo a conventional physical therapy program for 3 weeks (15 sessions) supervised by physiotherapists. Additionally, during each physical therapy session, participants will receive a 20-minute Virtual Reality (VR)-assisted hypnotherapy session using the HypnoVR software.
62137452|NCT06698354|ACTIVE_COMPARATOR|Standard Treatment Group|Participants in this arm will undergo a conventional physical therapy program for 3 weeks (15 sessions) supervised by physiotherapists.
62137453|NCT05080413|EXPERIMENTAL|Parkinson disease group|A total of 10 patients in this group will walk under the same conditions (off- state of antiparkinson drugs). Participants will be instructed to walk three laps on a 10-meter track under each of the following three conditions : 1) without stimulation, 2) with visual cues using a laser shoe, 3) with auditory cues using a metronome.
62137454|NCT04436250|ACTIVE_COMPARATOR|Placebo|Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg
62335050|NCT05137119|NO_INTERVENTION|Penicillin-susceptible staphylococcus aureus (PSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
62137455|NCT04436250|EXPERIMENTAL|S-Ketamine Low dose|S-Ketamine at a dose of 0.2 mg/kg
62335051|NCT05137119|EXPERIMENTAL|Penicillin-susceptible staphylococcus aureus (PSSA) - Interventional Arm (backbone therapy)|"Benzylpenicillin - Interventional Arm~Intravenous benzylpenicillin 1.8g (3 million units) every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with critical illness the intravenous benzylpenicillin administration doses will be adjusted."
61939458|NCT03577873|PLACEBO_COMPARATOR|gallbladder preserved|Patients with stones in their bile ducts and gallbladders will keep gallbladders in stay after clearance of bile duct stones with ERCP.
61939459|NCT03577873|EXPERIMENTAL|cholecystectomy|Patients with stones in their bile ducts and gallbladders will undergo cholecystectomy after clearance of bile duct stones with ERCP.
61939460|NCT00496223|EXPERIMENTAL|1|
61939461|NCT03036904|EXPERIMENTAL|Venetoclax plus DA-EPOCH-R|Venetoclax will be given in conjunction with 6 cycles of DA-EPOCH-R (doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone, rituximab). The dosing schedule and regimen for DA-EPOCH-R will follow established protocols. Venetoclax will be administered days 1-10 of each 21-day cycle, with the exception of cycle 1, during which venetoclax dose will commence on day 3 and continue through day 12, so as to clarify attribution of any observed TLS and/or infusion reactions, and minimize tumor lysis syndrome (TLS) risk.
61939462|NCT04543825||CPET|Patients with cirrhosis who have been wait listed for liver transplant or are undergoing liver transplant evaluation and will undergo cardiopulmonary exercise testing (CPET).
61939463|NCT04962581||Group 1 : Covidien|This cohort will be monitored with the Covidien capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
61939464|NCT04962581||Group 2: General Électrique|This cohort will be monitored with the General Electrique capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
61939465|NCT04334759|EXPERIMENTAL|Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance|Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
61939466|NCT04334759|ACTIVE_COMPARATOR|Control Arm: Chemotherapy, then Observation|Standard Chemotherapy for 4 to 6 cycles, followed by Observation
61939467|NCT04334759|ACTIVE_COMPARATOR|Control Arm: Ipilimumab and Nivolumab|Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.
61939468|NCT05763212|ACTIVE_COMPARATOR|Reverse Walking+Baseline treatment|Conventional treatment was given then received Reverse Walking Training which was provided for 7 min per set, with approximately 3 min of inter-set rest, for a total training duration of 60 min/day, 3 days/week for 3 successive months .
61939469|NCT05763212|EXPERIMENTAL|Whole Body Vibration + Reverse Walking+Baseline treatment|"Conventional Physical Therapy Treatment was given as a baseline treatment which includes Stretching, Range of motion exercises, and Strengthening exercises) performed for 10 min.~Reverse Walking Training which was provided for 7 min per set, with approximately 3 min of inter-set rest, for a total training duration of 30 min/day, 3 days/week for 3 successive months After that Group received Whole Body Vibration including three vibration sessions per week for three months. The participants have to carry out each set of vibration for 2 min in the first month, and then it was increased to 3 min in the second and 5 min in the third month. The rest period between each set was 1 min in the first month, then it became half a minute in the second and third month. Total training duration is 30 min/day, 3 days/week for 3 successive months."
61939470|NCT00161473|ACTIVE_COMPARATOR|prazosin|
61939471|NCT00161473|PLACEBO_COMPARATOR|placebo (inert substance)|
61939472|NCT03585842||Pre-test group|Patients from CMP B coming for consultation or day hospital
62137456|NCT04436250|EXPERIMENTAL|S-ketamine High dose|S-ketamine at a dose of 0.4 mg/kg
62335052|NCT05137119|NO_INTERVENTION|No adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|"No adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA~Participants with either MRSA or MSSA or PSSA will have no adjunctive therapy in combination with their backbone therapy arm."
62335053|NCT05137119|EXPERIMENTAL|Adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|Adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Intravenous clindamycin (or lincomycin) 600mg every 8 hours from platform day 1 to day 5. No dosage adjustment is needed to renal impairment.
62695198|NCT06131112||Group A|22 patients with clinically suspected cardiac sarcoidosis
61939473|NCT03585842||Test group|Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
61939474|NCT02130024|EXPERIMENTAL|Ranibizumab 0.5 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity \[treat and extend\]
61939475|NCT02130024|ACTIVE_COMPARATOR|Aflibercept 2.0 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity \[treat and extend\]
61939476|NCT04968847|EXPERIMENTAL|Device: FemaSeed Localized Directional Insemination|FemaSeed (Intratubal Insemination - K231730)
61939477|NCT04635059|EXPERIMENTAL|Pacritinib|Pacritinib is an oral drug.
61939478|NCT04426708|EXPERIMENTAL|Mild hepatic impaired subjects (A)|Mild hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
61939479|NCT04426708|EXPERIMENTAL|Moderate hepatic impaired subjects (B)|Moderate hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
61939480|NCT04426708|EXPERIMENTAL|Healthy volunteers (C)|Matched healthy volunteers: to receive a single dose of HMS5552 ( 25mg ) tablet orally
61939481|NCT00333177|EXPERIMENTAL|Cog Remediation, risperidone injection|Participants will receive cognitive remediation training plus risperidone, administered via injection.
61939482|NCT00333177|ACTIVE_COMPARATOR|Healthy Behavior Training, risperidone injection|Participants will receive health behavior training plus risperidone, administered via injection.
61939483|NCT00333177|EXPERIMENTAL|Cog Remediation, oral risperidone|Participants will receive cognitive remediation training plus risperidone administered orally.
62137457|NCT05237466|EXPERIMENTAL|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive a combination of motivational interviewing and sorting practice to reduce hoarding symptoms.
62137458|NCT05237466|ACTIVE_COMPARATOR|Sorting Practice|Participants will receive sorting practice only to reduce hoarding symptoms.
62137459|NCT02523222|NO_INTERVENTION|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
62137460|NCT02523222|ACTIVE_COMPARATOR|Dextrose Gel|Infants given 40% Dextrose gel (0.5ml/kg) in the buccal mucosa after their first feed, within the first hour of life.
62492304|NCT05291195|EXPERIMENTAL|Essential oil|"Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).~Depending on allocations, in the essential oil group, the canals were be treated with adjuvant essential oil of Cymbopogon martinii and Thymus vulgaris (Herba oils, Herba doo, Belgrade, Serbia)"
62492305|NCT02391233|EXPERIMENTAL|HIV/STI Risk Reduction|This intervention tests the comparative effectiveness of E-WORTH, streamlined HIV Testing and a 5-week multimedia intervention on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
62492306|NCT02391233|ACTIVE_COMPARATOR|Streamlined HIV Testing Alone|This intervention tests the comparative effectiveness of streamlined HIV Testing alone on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
62492307|NCT01016054|EXPERIMENTAL|A. PLD plus AGS-8M4|Women with platinum resistent ovarian cancer
62492308|NCT01016054|EXPERIMENTAL|B. Carboplatin and gemcitabine plus AGS-8M4|Women with platinum sensitive ovarian cancer
62335054|NCT05137119|NO_INTERVENTION|Continue intravenous antibiotic therapies (backbone +/- adjunctive therapy) - standard of care arm|"Backbone therapy arm for MRSA or MSSA or PSSA +/- adjunctive therapy will continue on intravenous antibiotic treatment for the length of time as per usual standard of care.~Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised if not eligible then eligibility will be assess again at Day 14(+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
62335055|NCT05137119|EXPERIMENTAL|Switch to oral antibiotics at trial day 7 (+/- 2 days) or Day 14 (+/- 2 days) if eligible.|"Switch from intravenous backbone antibiotic for MRSA or MSSA or PSSA to oral antibiotics at the treating clinicians discretion on trial Day 7 (+/- 2 days) or trial Day 14 (+/- 2 days).~Participants eligibility is assessed at Day 7 (+/- 2 days). If eligible will be randomised, if not eligible then eligibility will be assessed again at Day 14 (+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
62335056|NCT05137119|NO_INTERVENTION|No PET/CT scan - standard of care arm|"Participants will not receive a PET/CT scan, in addition to their allocated treatment interventions.~Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised. If eligibility is not met then participant is excluded from this domain."
62335057|NCT05137119|EXPERIMENTAL|PET/CT scan at trial day 7 (+/- 2 days) if eligible|"Participant will receive a PET/CT scan at Day 5-12, in addition to their allocated treatment interventions.~Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised. If eligibility is not met then participant is excluded from this domain."
62335058|NCT00742443|OTHER|1|Active versus Placebo within patient
62335059|NCT00742443|OTHER|2|Active vs. Placebo within patient
61939484|NCT00333177|ACTIVE_COMPARATOR|Healthy Behavior Training, oral risperidone|Participants will receive health behavior training plus risperidone administered orally.
61939485|NCT00784641|EXPERIMENTAL|Novel Bausch & Lomb Contact Lens|Novel Bausch \& Lomb daily disposable contact lenses
61939486|NCT00784641|ACTIVE_COMPARATOR|SofLens|Bausch \& Lomb SofLens daily disposable contact lenses
62335060|NCT00742443|OTHER|3|Active vs. Active within patient
62335061|NCT01260467|EXPERIMENTAL|memantine arm|
62335062|NCT05787353|EXPERIMENTAL|Home based cardiopulmonary rehabilitation group|This was a retrospective study. 43 patients who had home based cardiopulmonary rehabilitation programme between January and July 2023, in our rehabilitation clinic.
62335063|NCT05787353|EXPERIMENTAL|Hospital based cardiopulmonary rehabilitation group|This was a retrospective study. 45 patients who had hospital based cardiopulmonary rehabilitation programme between January and July 2023, in our rehabilitation clinic.
62335064|NCT04907578||postpartum full term neonates|immediate postpartum full term neonates with no intrauterine growth restricted
62335065|NCT04907578||intrauterine growth restricted neonates|preterm or full-term intrauterine growth restricted neonates
62335066|NCT05501574|EXPERIMENTAL|Tacrolimus Inhalation Powder|Single arm open label
62335067|NCT02408055|EXPERIMENTAL|Radiolabelled TA-8995|
62335068|NCT01560728|EXPERIMENTAL|Trauma-Focused CBT|Adapted or modified Trauma-Focused Cognitive Behavioral Therapy
62137461|NCT02564536|EXPERIMENTAL|Arm 1: Pacritinib and Decitabine|"* Patients will receive one cycle of single agent pacritinib.~* Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy.~* Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced.~* Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle.~* Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle.~* Patients may continue treatment for up to 12 cycles."
62335069|NCT01560728|NO_INTERVENTION|Wait list|Monitored while waiting for intervention
62335070|NCT02636062||Follow-up CAC > 0|All patients with CAC scores of zero \> 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients that develop incident CAC.
62492309|NCT06628154|EXPERIMENTAL|losartan|oral single-dose losartan potassium (Cozaar; 50mg)
62492310|NCT06628154|PLACEBO_COMPARATOR|placebo|Microcellulose placebo in identical capsule
62492311|NCT05092464|EXPERIMENTAL|Single arm open label study|12 week-treatment of 5% natural lactic acid-enriched cream (BID)
62492312|NCT04707963|EXPERIMENTAL|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
61939487|NCT00784641|ACTIVE_COMPARATOR|Acuvue|Johnson and Johnson 1-Day Acuvue Moist contact lenses
61939488|NCT01200524|EXPERIMENTAL|AZD2423, 20mg|
61939489|NCT01200524|EXPERIMENTAL|AZD2423, 150 mg|
61939490|NCT01200524|PLACEBO_COMPARATOR|Placebo|Tablet to match the 20 mg and 50 mg AZD2423 active tablet
61939491|NCT02402829||Hemophilia Patients|Subjects diagnosed with moderate or severe Hemophilia A or B who use a central venous line (CVL) for regular prophylaxis factor infusions and are at the clinic for a standard of care visit. As part of the study all subjects will have blood drawn through their CVL and will also undergo a peripheral vein blood draw.
61939492|NCT06277492|ACTIVE_COMPARATOR|Single dose SUL-238|PART 1: Single ascending oral doses of SUL-238 (50 mg, 100 mg, 250 mg, 500 mg, 1000 mg and 2000 mg)
61939493|NCT06277492|PLACEBO_COMPARATOR|Single dose placebo|PART 1: Single oral dose of placebo
61939494|NCT06277492|EXPERIMENTAL|Single dose pharmacokinetics of SUL-238|PART 2: Single oral dose of SUL-238 (at maximum tolerated dose)
61939495|NCT06277492|ACTIVE_COMPARATOR|Multiple doses SUL-238|PART 3: Multiple ascending oral doses of SUL-238 (at maximum tolerated dose and 1 dose level lower than MTD)
61939496|NCT06277492|PLACEBO_COMPARATOR|Multiple doses placebo|PART 3: Multiple oral doses of placebo
61939497|NCT06277492|ACTIVE_COMPARATOR|Single dose pharmacokinetics of SUL-238 (food effect)|PART 2B: 2000 mg single oral dose of SUL-238
61939498|NCT06277492|PLACEBO_COMPARATOR|Single dose Placebo (food effect)|PART 2B: Single oral dose of placebo
61939499|NCT05975359|EXPERIMENTAL|Interi Manifold Drain System|Following bilateral mastectomy, stage 1 surgery for immediate implant-based breast reconstruction will be performed in each patient breast. The breast randomized to treatment with the Interi manifold (intervention arm) will have the Interi manifold placed alongside the tissue expander intra-operatively. Surgical reconstruction, closure, and post-operative management will proceed as standard. Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout recovery will also take place until removal of the Interi drain system, which typically occurs 1-3 weeks after surgery. Criteria for drain removal is defined as 2 consecutive days with drain output below 30 mL. While drains are in place, patients will be required to monitor drain output and keep a daily drain log.
61939500|NCT05975359|ACTIVE_COMPARATOR|Jackson Pratt Drain System|Following bilateral mastectomy, stage 1 surgery for immediate implant-based breast reconstruction will be performed in each patient breast. The breast randomized to treatment with the Jackson Pratt drain (active comparator arm) will have the Jackson Pratt drain placed alongside the tissue expander intra-operatively. Surgical reconstruction, closure, and post-operative management will proceed as standard. Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout recovery will also take place until removal of the Jackson Pratt drain system, which typically occurs 1-3 weeks after surgery. Criteria for drain removal is defined as 2 consecutive days with drain output below 30 mL. While drains are in place, patients will be required to monitor drain output and keep a daily drain log.
61939501|NCT03009409|ACTIVE_COMPARATOR|Ketamine Group|Participants randomized to the ketamine group will receive a 0.25 mg/kg loading dose of intravenous ketamine immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, for approximately 45 minutes, up to a maximum cumulative dose of 100 mg. This dose is in accordance with the guidelines from the recently published Clinical Practice Guidelines for the management of post-operative pain. The attending anesthesiologist will confirm whether the use of ketamine is appropriate for each patient prior to enrolling the patient in the study.
61939502|NCT03009409|PLACEBO_COMPARATOR|Control Group|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion.
61939503|NCT03025841|OTHER|Ceftaroline|Patients receive Ceftaroline 600mg BID
61939504|NCT05582031|EXPERIMENTAL|Regorafenib 90 mg + Tislelizumab 300 mg (Rego-Tisle)|The trial will include 8 cohorts of patients, with each cohort considered as a single-arm; all patients enrolled will be treated with regorafenib at a dose of 90 mg orally once daily, on days 1 to 21 of a 28 cycle in combination with tislelizumab 300 mg intravenously day 1 (of a 28 day cycle).
61939505|NCT02682771|ACTIVE_COMPARATOR|Control|Individuals were treated with Conventional Respiratory Physiotherapy (CRP), twice in immediate postoperative day and three times in first postoperative day.
61939506|NCT02682771|EXPERIMENTAL|Bilevel positive airway pressure|Individuals were treated with positive pressure, in the BIPAP mode (bilevel positive airway pressure, with inspiratory pressure:12 cmH20 and expiratory pressure: 8 cmH20) twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each
61939507|NCT02682771|EXPERIMENTAL|Load inspiratory breathing exercises|Individuals were treat with PowerBreathe, a device for inspiratory muscle, with 40% maximal inspiratory pressure, measured at preoperative, twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each.
62137462|NCT03134300|ACTIVE_COMPARATOR|Low SES|
62137463|NCT03134300|PLACEBO_COMPARATOR|Normal/high SES|
62137464|NCT02460549|EXPERIMENTAL|therapeutic education program|patients attend three sessions of therapeutic education
62137465|NCT03479411|EXPERIMENTAL|Part 1 single ascending dose|Intervention: drug Itraconzaole powder: single dose of 5mg, 10mg or 25 mg Other name: PUR1900
62335071|NCT02636062||Follow-up CAC zero|All patients with CAC scores of zero \> 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients who continue to have a CAC of zero.
62335072|NCT01887028|EXPERIMENTAL|12mmHg intraperitoneal pressure (cool, dry CO2 gas )(n=20)|
62335073|NCT01887028|OTHER|12mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
62335074|NCT01887028|OTHER|8mmHg intraperitoneal pressure with cool, dry CO2 gas (n=20)|
62335075|NCT01887028|OTHER|8mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
62335076|NCT00547378|OTHER|1|InterStim Therapy
62335077|NCT00547378|ACTIVE_COMPARATOR|2|Standard Medical Therapy
62695199|NCT06131112||Group B|22 patients with known cardiac sarcoidosis
62137466|NCT03479411|EXPERIMENTAL|Part 2 multiple ascending dose|Intervention: drug Itraconzaole powder: 10 mg or 20 mg daily for 14 days Other name: PUR1900
62137467|NCT03479411|ACTIVE_COMPARATOR|Part 3 2-period crossover single dose|Intervention: drug Itraconzaole powder: 20 mg single dose and Itraconzaole oral solution 200 mg single dose Other names: PUR1900, Sporanox
62492313|NCT04707963|ACTIVE_COMPARATOR|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
62492314|NCT02507063||study subjects|Patients age 0-18 with intracranial monitoring devices in place or requiring a VP shunt revision who receive a ocular ultrasound evaluating ONSD
62492315|NCT03956420||Study group|Implemented ERAS (Early Recovery After Surgery) elements
62492316|NCT03956420||Control group|The control group will consist of patients treated during the study in accordance with the current standards used in the Department
62335078|NCT03850327|EXPERIMENTAL|BIOMONITOR III|
62492317|NCT01710696|EXPERIMENTAL|Individual dose|
62492318|NCT01710696|EXPERIMENTAL|Fixed dose|
62492319|NCT00220844|EXPERIMENTAL|Nortriptyline|
62492320|NCT00220844|EXPERIMENTAL|Placebo|
62492321|NCT00688844||PKU subjects - baseline|Male and female subjects with PKU at baseline starting KuvanTM therapy.
62492322|NCT00657254|EXPERIMENTAL|Arm 1|
62492323|NCT00690495|EXPERIMENTAL|1|Modified propofol (Propofol 0.5%)
62492324|NCT00690495|ACTIVE_COMPARATOR|2|Propofol 1%
62137468|NCT03948542||Outcome|Nerve conduction studies (NCV) Functional assessment according to Daniels and Worthingham
62137469|NCT06477588|ACTIVE_COMPARATOR|Health Navigation|Referrals to HIV, mental health, substance use, and other supportive services
62335079|NCT03505138|EXPERIMENTAL|Group intervention|Conventional management for COPD will take place in our health care system more telematics intervention.
61939508|NCT06680583||cirrhosis|cirrhosis with gastrointestinal bleeding
61939509|NCT01722773|ACTIVE_COMPARATOR|Bipap|Bipap
61939510|NCT01722773|NO_INTERVENTION|Standard of care|No intervention
62137470|NCT06477588|EXPERIMENTAL|Health Navigation, Employment Navigation plus Contingency Management Intervention|Referrals to HIV, mental health, substance use, and other supportive services Referrals for employment including training, and career development needs; Provision of financial incentives for the uptake and achievement of specific HIV care and prevention milestones.
62137471|NCT05353894|EXPERIMENTAL|Part 1 Cohort 1|Three (3) Healthy volunteers, each receiving a single oral dose (50mg) of GNS561 tablets and capsules, after a high fat meal and with a wash-out period of seven days.
62335080|NCT03505138|ACTIVE_COMPARATOR|Group control|Is performed only conventional management of COPD in our health care system.
62335081|NCT04321317|OTHER|Undernourished Patients|All patients included will be included in the unique arm of the study
62335082|NCT04755712|EXPERIMENTAL|ropivacaine in quadratum lumburum block 2|Ropivacaine will be administrated in perineural in quadratum lumburum block 2 after the caesarian.
62335083|NCT04755712|ACTIVE_COMPARATOR|Intrathecal morphine|Morphine will be administrated in intrathecal
62335084|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
62335085|NCT04405505|EXPERIMENTAL|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
61939511|NCT06392802|NO_INTERVENTION|Control|This group follows a treatment similar to the one that a public hospital recommends. They receive a sheet of paper with the description of some exercises to do at home. These should be done in three 30-min-sessions per week, during 12 weeks.
61939512|NCT06392802|EXPERIMENTAL|Muvity - Intervention|This group follows a treatment prescribed by a therapist using Muvity, a telerehabilitation system using a depth camera. The treatment consists of some exercises guided by a virtual avatar, and some exergames to play. The computer application monitors the ranges of motion of joint angles as well as time played and deviations from theoretical trajectories. These sessions are programmed to be done in three 30-min-sessions per week, during 12 weeks (same amount as the Control group).
62335086|NCT04405505|ACTIVE_COMPARATOR|Paclitaxel for injection (albumin bound)|Paclitaxel for Injection (albumin bound) 100mg / m2 administered intravenously (IV) on Day 1, 8, 15 in 28-day cycle.
62335087|NCT02768649|EXPERIMENTAL|Cohort 1|Eligible subjects received a test dose of 0.25 risperidone prior to dosing with RBP-7000. Fifteen eligible subjects then received low dose RBP-7000
62492325|NCT05809180|EXPERIMENTAL|rituximab(100mg), orelabrutinib(50mg), pomalidomide(4mg), miniCHOP-like|"1. Phase I(induction therapy): Patients receive Rituximab on day 1, Pomalidomide on days 1-7 and oral administration of Orelabrutinib per day.~2. Phase II(stratified response therapy):~   Part A: (25% or more reduction): Patients receive Pro-miniCHOP-like regimen every 21 days for 6 cycles.(Rituximab on day 1, Pomalidomide on days 1-7, Orelabrutinib per day till progression or intolerant toxicity, Cyclophosphamide on day 2, Doxorubicin/Doxorubicin Liposome on day 2, Vindesine on day 2 and Dexamethasone on days 2-6).~   Part B: (reduction less than 25%): Patients receive R-miniCHOP-like regimen every 21 days for 6 cycles.(Rituximab on day 1, Cyclophosphamide on day 2, Doxorubicin/Doxorubicin Liposome on day 2, Vindesine on day 2 and Dexamethasone on days 2-6).~3. Phase III(maintenance and follow-up): Patients take Pomalidomide orally on days 1-7 in a cycle of 21 days for 2 years."
62492326|NCT02831920|EXPERIMENTAL|Single Arm|every patient undergoes mpMRI and targeted biopsies, CEUS and targeted biopsies and systematic biopsies. Every patient is therefore its own control.
62492327|NCT04691960|EXPERIMENTAL|Ketogenic Diet|
62492328|NCT04823533|EXPERIMENTAL|Probiotic|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
62492329|NCT04823533|PLACEBO_COMPARATOR|Placebo|Placebo formulation containing only the excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
62492330|NCT02195739||Nicotine replacement therapy cohort|Cohort defined as patients in whom nicotine replacement therapy (in any preparation) was initiated at the index smoking cessation attempt as the first recorded smoking cessation intervention.
62695200|NCT06131112||Group C|Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis
62492331|NCT02195739||Other smoking cessation therapy|Cohort defined as patients in whom other (non-nicotine replacement therapy) smoking cessation pharmacotherapy's were initiated at the index smoking cessation attempt (e.g. bupropion, varenicline) as the first recorded smoking cessation intervention
62695201|NCT06131112||Group D|22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET/CT as part of their routine diagnostic work-up or follow-up (control group)
61939513|NCT02140112|ACTIVE_COMPARATOR|Trichuris suis ova|TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks
61939514|NCT02140112|PLACEBO_COMPARATOR|Placebo|Placebo 8 doses every 2 weeks
61939515|NCT05690646|EXPERIMENTAL|NR group|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
61939516|NCT05690646|EXPERIMENTAL|UA group|ursodeoxycholic acid group, 15mg/kg/day bid for5 days
61939517|NCT05690646|EXPERIMENTAL|combination group|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days and ursodeoxycholic acid group, 15mg/kg/day bid for5 days
61939518|NCT05690646|NO_INTERVENTION|control group|No intervention
61939519|NCT02755298|EXPERIMENTAL|Acetazolamide|Twice a day 250 mg acetazolamide for 5 weeks
61939520|NCT02755298|PLACEBO_COMPARATOR|Placebo|Placebo capsule 250 mg (Mannitol) twice a day 5 weeks
61939521|NCT02059902|PLACEBO_COMPARATOR|Normal pain management|Normal saline (bolus followed by continuous infusion)
61939522|NCT02059902|EXPERIMENTAL|Lidocaine|Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)
62695202|NCT06512558|EXPERIMENTAL|Interventional|
62695203|NCT05908760|EXPERIMENTAL|CO2 Rebreathing|Participants will breathe with the rebreather in the supine position until CO2 levels increase between 5-10mmHg. Once CO2 levels are increased, participants will be tilted upright, and will continue to breathe with the rebreather during a 5-min HUT test
62695204|NCT05908760|NO_INTERVENTION|Room Air|Participants will breathe room air in the supine position and during a 5-min HUT test
62695205|NCT02738619|ACTIVE_COMPARATOR|vitamin d3|1600 UI
61939523|NCT04060849|EXPERIMENTAL|Arm I (Nozin)|Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
61939524|NCT04060849|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard of care.
61939525|NCT01192373|EXPERIMENTAL|High circulating free fatty acids|using Heparin af intralipid infusion for 8 hours
61939526|NCT01192373|ACTIVE_COMPARATOR|Low circulation free fatty acids|using hyperinsulinaemic euglycemic clamp for 8 hours
61939527|NCT03467048|EXPERIMENTAL|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
61939528|NCT03467048|ACTIVE_COMPARATOR|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
61939529|NCT03793478|EXPERIMENTAL|All Participants|All participants will receive re-induction therapy that includes fludarabine and cytarabine in combination with experimental drug quizartinib. For prophylaxis, IT chemotherapy with cytarabine, methotrexate and prednisolone/hydrocortisone will be given prior to or between re-induction cycles. After completing re-induction therapy, eligible participants may also receive optional consolidation chemotherapy which includes cytarabine, etoposide and quizartinib, if HSCT is not available immediately. After completing re-induction or HSCT successfully, eligible participants can go on to receive continuation therapy with quizartinib.
61939530|NCT01945827||DeltaMaxx treated Patients|
61939531|NCT03576365|EXPERIMENTAL|VOICE Intervention Arm|Participants participate in the online VOICE program to learn about perceived control and stress reduction to improve voice outcomes.
61939532|NCT03576365|SHAM_COMPARATOR|Information-Only Arm|Participants participate in the information only program to learn about voice problems, anatomy and physiology.
62695206|NCT02738619|PLACEBO_COMPARATOR|placebo|placebo
61939533|NCT04171765|PLACEBO_COMPARATOR|Placebo|Participants will receive a fixed dose of placebo matched to BFKB8488A.
61939534|NCT04171765|EXPERIMENTAL|Fixed Dose: BFKB8488A Dose A|Participants will receive BFKB8488A.
61939535|NCT04171765|EXPERIMENTAL|Fixed Dose: BFKB8488A Dose B|Participants will receive BFKB8488A.
61939536|NCT04171765|EXPERIMENTAL|Fixed Dose: BFKB8488A Dose C|Participants will receive BFKB8488A.
62137472|NCT05353894|EXPERIMENTAL|Part 1 Cohort 2|Six (6) healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets and capsules, after a high fat meal and with a wash-out period of fourteen days.
62492332|NCT02195739||Smoking cessation advice cohort|Cohort (control patients) defined as patients whose first recorded smoking cessation intervention involved smoking cessation advice leading to a quit attempt unassisted by pharmacological smoking cessation aids, at the index smoking cessation attempt.
61939537|NCT01346969|ACTIVE_COMPARATOR|Group 1|
61939538|NCT01346969|PLACEBO_COMPARATOR|Group 2|
62695207|NCT06535100|EXPERIMENTAL|trial (initiative will be implemented)|Art therapy artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
61939539|NCT01346969|PLACEBO_COMPARATOR|Group 3|
61939540|NCT01346969|PLACEBO_COMPARATOR|Group 4|
61939541|NCT05376943||Patients diagnosed with HCC after receiving direct acting antiviral HCV treatment|In this group there will be patients with the diagnosis of hepatocellular carcinoma, who underwent direct acting antiviral treatment. We will collect both epidemiological (age, gender, comorbidities, alcohol abuse) and clinical data (serum bilirubin, alanine, aspartate aminotransferase, gammaglutamyltransferase, alkaline phosphatase and alpha-fetoprotein level, Child-Pugh and MELD score, imaging tests, liver biopsy and elastography, if performed). The HCV infection and co-infections will be assessed and also the composition of therapy and the response to treatment will be evaluated.
62695208|NCT06535100|NO_INTERVENTION|control|standart care
62695209|NCT06550388|OTHER|Physical Activity Education|In addition to the traditional course of CBT-I, the PI will recommend patient to increase physical activity minutes per week. The increase in physical activity will be based on patient's current level of physical activity.
62695210|NCT06550388|OTHER|Nutritional Education|In addition to the traditional course of CBT-I, the PI will provide education and materials regarding the Mediterranean Diet. Patient will be provided with the Mayo Clinic booklet on Mediterranean Diet and asked to increase their daily intake in two categories assessed by the Mini-EAT.
62492333|NCT05651698|EXPERIMENTAL|HeartMan Intervention group|80 patients are in the intervention group (40 in Belgium and 40 in Italy).
62492334|NCT05651698|NO_INTERVENTION|Control group|40 patients are in the intervention group (20 in Belgium and 20 in Italy). Standard care consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year.
62695211|NCT05059327|EXPERIMENTAL|Arm A (Basimglurant/NOE-101 to Placebo)|Basimglurant to Placebo
61939542|NCT05376943||Patients diagnosed with HCC who were not receiving direct acting antiviral HCV treatment|In this group there will be patients with the diagnosis of hepatocellular carcinoma, who were not receiving direct acting antiviral treatment. We will collect both epidemiological (age, gender, comorbidities, alcohol abuse) and clinical data (serum bilirubin, alanine, aspartate aminotransferase, gammaglutamyltransferase, alkaline phosphatase and alpha-fetoprotein level, Child-Pugh and MELD score, imaging tests, liver biopsy and elastography, if performed). The HCV infection and co-infections will also be assessed.
61939543|NCT04357366|EXPERIMENTAL|Anakinra|Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.
61939544|NCT04638400|ACTIVE_COMPARATOR|Simvastatin|Obese subjects with elevated cholesterol
61939545|NCT04638400|ACTIVE_COMPARATOR|Ezetimibe|Obese subjects with elevated cholesterol
61939546|NCT05526391|EXPERIMENTAL|Early PK Cohort: TAK-341|Participants will be randomized to receive TAK-341 at 4-week intervals for up to 52 weeks.
61939547|NCT05526391|PLACEBO_COMPARATOR|Early PK Cohort: Placebo|Participants will be randomized to receive placebo at 4-week intervals for up to 52 weeks.
61939548|NCT05526391|EXPERIMENTAL|Main Cohort: TAK-341|Participants will be randomized to receive TAK-341 at 4-week intervals for up to 52 weeks.
61939549|NCT05526391|PLACEBO_COMPARATOR|Main Cohort: Placebo|Participants will be randomized to receive placebo at 4-week intervals for up to 52 weeks.
61939550|NCT06681441|EXPERIMENTAL|Treatment Group 1|Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
61939551|NCT06681441|EXPERIMENTAL|Treatment Group 2|Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
61939552|NCT06681441|EXPERIMENTAL|Treatment Group 3|Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
61939553|NCT06681441|EXPERIMENTAL|Treatment Group 4|Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
61939554|NCT06681441|EXPERIMENTAL|Treatment Group 5|Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
61939555|NCT06681441|EXPERIMENTAL|Treatment Group 6|Participants will be randomized into 1 of 6 treatment sequences in a 3-way cross-over
61939556|NCT05408013||ward patients in psychiatric hospitals|Patients in psychiatric hospitals will be assessed so that the prevalence of insomnia in psychiatric inpatients can be estimated.
61939557|NCT01736124|EXPERIMENTAL|Computerized Cognitive Training (CCT)|Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
61939558|NCT01736124|ACTIVE_COMPARATOR|Active control|Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
62137473|NCT05353894|EXPERIMENTAL|Part 2|"Nine (9) healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets or capsules (according results of Part 1), in fed condition then in fasting condition, after a wash-out period of fourteen days.~Nine (9) other healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets or capsules (according results of Part 1), in fasting condition then in fed condition, after a wash-out period of fourteen days."
62335088|NCT02768649|EXPERIMENTAL|Cohort 2|After safety and tolerability review of the data from Day 1 to Day 15 of the low dose arm, 3 subjects were dosed in Cohort 2 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
62695212|NCT05059327|PLACEBO_COMPARATOR|Arm B (Placebo to Basimglurant/NOE-101)|Placebo to Basimglurant
62695213|NCT02941055|EXPERIMENTAL|Fiber diet|50% of daily intake, 5 days a week, a diet rich in fiber, fish and probiotics will be provided to study subjects
61939559|NCT03434769|EXPERIMENTAL|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
61939560|NCT06681519|ACTIVE_COMPARATOR|Group 1|Acupoint pressure Group 1relieves pain and anxiety pain .
61939561|NCT06681519|ACTIVE_COMPARATOR|Group 2|Holding a pressure ball Group 2reduces pain and anxiety pain.
61939562|NCT06681519|SHAM_COMPARATOR|Group 3|conventional group 3 treatmente.
61939563|NCT01953861|EXPERIMENTAL|1: fasted|EC905 + fasted
61939564|NCT01953861|EXPERIMENTAL|2: low-fat breakfast|EC905 + low-fat breakfast
61939565|NCT01953861|EXPERIMENTAL|3: high-fat breakfast|EC905 + high-fat breakfast
61939566|NCT03316339|EXPERIMENTAL|Dexmedetomidine|
61939567|NCT03316339|ACTIVE_COMPARATOR|Control|
61939568|NCT06678698|EXPERIMENTAL|Panel Group|Participants who will receive full-body photobiomodulation irradiation, from a panel of LEDs
61939569|NCT06678698|SHAM_COMPARATOR|Panel Sham Group|Participants who will receive full-body photobiomodulation irradiation, with the device turned-off
61939570|NCT06678698|EXPERIMENTAL|Modified ILIB Group|Participants who will receive photobiomodulation irradiation with the transcutaneous ILIB method
61939571|NCT06678698|SHAM_COMPARATOR|Modified ILIB Sham Group|Participants who will received photobiomodulation irradiation with the transcutaneous ILIB method, with the device turned-off
62492335|NCT01808716|ACTIVE_COMPARATOR|Low-level laser therapy (LLLT) on muscle damage|Effects of low-level laser therapy (LLLT)on muscle damage
61939572|NCT06652529|EXPERIMENTAL|Dose escalation|Four dose levels will be tested. If there are no safety concerns, dose escalation may continue with up to two additional dose levels
61939573|NCT00546650|EXPERIMENTAL|A|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver \~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
61939574|NCT00546650|ACTIVE_COMPARATOR|B|Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
61939575|NCT00546650|ACTIVE_COMPARATOR|C|Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
61939576|NCT00546650|ACTIVE_COMPARATOR|D|Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
61939577|NCT00546650|EXPERIMENTAL|E|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver \~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
61939578|NCT02827916|EXPERIMENTAL|All patients|Measure of painful neuropathy for al patients with thermotest and sudoscan Devices and Neuropathic Pain Symptom Inventory.
61939579|NCT03659955|EXPERIMENTAL|Autologous blood|"Patients with severe dry eye and ocular surface disease who attend the corneal service within NHS Lanarkshire and who are unresponsive to conservative treatment measures will be considered for treatment of their condition with autologous blood.~Intervention is application of autologous blood."
61939580|NCT01148238||Diabetes type 1 older than 10 years|Blood samples will be taken from 10 patients with diabetes type 1 older than 10 years and 10 healthy age-and sexmatched controls.
61939581|NCT01148238||Newly diagnosed type 1 diabetes|Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes and 10 healthy age-and sexmatched controls.
61939582|NCT01148238||LADA|Blood samples will be taken from 10 patients with LADA and 10 healthy age-and sexmatched controls.
61939583|NCT00224848|EXPERIMENTAL|ATP III|A novel practice-based intervention, based on the ATP III Clinical Practice Guideline, which includes the use of a personal digital assistant (PDA) based decision support tool.
61939584|NCT00224848|ACTIVE_COMPARATOR|JNC 7|A novel practice-based intervention, based on the JNC-7 blood pressure Clinical Practice Guideline, which includes the use of am automated blood pressure measurement device.
61939585|NCT02337738|EXPERIMENTAL|TVP-1012 1mg|TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
61939586|NCT02337738|EXPERIMENTAL|TVP-1012 0.5mg|TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
61939587|NCT02337738|PLACEBO_COMPARATOR|Placebo|One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
61939588|NCT02575742||Young women without chronic constipation|Healthy women without chronic constipation who are aged between 18-40 years
61939589|NCT02575742||Older women without chronic constipation|Healthy women without chronic constipation who are aged between 70-90 years
61939590|NCT02575742||Young women with chronic constipation|Women with symptoms of chronic constipation who are aged between 18-40 years
61939591|NCT02575742||Older women with chronic constipation|Women with symptoms of chronic constipation who are aged between 70-90 years
61939592|NCT00532155|EXPERIMENTAL|Placebo/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
61939593|NCT00532155|PLACEBO_COMPARATOR|Aflibercept/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
61939594|NCT02415257|EXPERIMENTAL|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board"
61939595|NCT02415257|NO_INTERVENTION|Non-gentamicin|Rehabilitation exercises before and after both treatment and surgery Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board
61939596|NCT04070144|EXPERIMENTAL|IQ-Tip|At most four lumbar punctures with Injeq IQ-Tip(tm) system per participant
61939597|NCT06323954|EXPERIMENTAL|tVNS stimulation|Brief electrical current will be applied to the vagus nerve area (the tragus or cymba concha, depending on the shape and size of the ear) immediately after successful trials during finger control training.
61939598|NCT06323954|SHAM_COMPARATOR|Sham stimulation|Brief electrical current will be applied to the non-vagus nerve area (the earlobe) immediately after successful trials during finger control training.
61939599|NCT01964131|EXPERIMENTAL|D961H sachet 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets
62137474|NCT05837533|EXPERIMENTAL|Intervention group|Patients will receive information about their diagnosis, treatment and/or prognosis through the systematic communication model under study used by their oncologist during their medical consultation.
61939600|NCT01964131|OTHER|D961H HPMC capsule 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule
61939601|NCT04950023||early COPD|1) \<60 years old; 2) smoking ≥ 10 pack years. 3) with any of the following anomalies: a. Post-bronchodilator FEV1/FVC\< 0.7. b. CT image abnormalities: emphysema, air trapping or bronchial wall thickening; c.Rapid decrease of FEV1 (\>60 ml/yr).
61939602|NCT04950023||Control|1) \<60 years old; 2) Pre-bronchodilator FEV1/FVC≥70% and FEV1 ≥ 80% predicted; 3) no exposure to harmful factors such as cigarettes and dust pollution.
62137475|NCT05837533|NO_INTERVENTION|Control group|Patients will receive information about their diagnosis, treatment and/or prognosis through their usual care provided by their oncologist during their medical consultation.
62492336|NCT01808716|ACTIVE_COMPARATOR|Low-level laser therapy (LLLT) placebo on muscle damage|Effects of low-level laser therapy (LLLT) placebo on muscle damage
61939603|NCT06400251|EXPERIMENTAL|Treatment (ipatasertib)|Patients receive ipatasertib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients undergo biopsies and blood sample collection on study.
61939604|NCT02969551||Sleep apnea, Manometry and possibly DISE|Sleep apnea Patients recieved manometry measures and those who were not considered for CPAP Therapy recieved Drug induced sleep endoscopy.
61939605|NCT03862859|ACTIVE_COMPARATOR|Treatment with Warfarin|Warfarin with dosing targeting an international normalized ratio of 2-3.
61939606|NCT03862859|NO_INTERVENTION|No treatment|No treatment
61939607|NCT04855864|OTHER|BCR TKA|Patients with intact and functional ACL and PCL will be treated with the BCR design
61939608|NCT04855864|OTHER|BCS TKA|Patients with an afunctional or absent ACL and/or PCL will be treated with the BCS design
61939609|NCT04855864|OTHER|PS TKA|Patients with an afunctional or absent ACL and/or PCL will be treated with the PS design
61939610|NCT01626495|EXPERIMENTAL|CART-19 T Cells|The subject's thawed T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). The T cells will be infused over 10-15 minutes on days Days 0, and 1. Day 14 is tentative based on response.
61939611|NCT06681636|EXPERIMENTAL|Group 1 FSW|100 FSWs aged 18-26 years receiving 3 doses of Gardasil-9 vaccine at 0-6-18 months
61939612|NCT06681636|ACTIVE_COMPARATOR|Group 2 non-FSW|100 non-FSW aged 18-26 years receiving 3 doses of Gardasil-9 vaccine at 0-6-18 months
61939613|NCT06681636|ACTIVE_COMPARATOR|Group 3 FSW|100 FSW aged 18-26 years receiving 3 doses of Gardasil-9 vaccine at 0-2-6 months
61939614|NCT06276231|PLACEBO_COMPARATOR|Control Group|Patients in this group will receive the standard treatment (75mg IM Diclofenac ) + nebulized 0.9% normal saline.
61939615|NCT06276231|EXPERIMENTAL|Intervention Group|Patients in this group will receive the standard treatment (75mg IM Diclofenac ) + nebulized 10 mg of Nebulized Salbutamol.
61939616|NCT00735254|ACTIVE_COMPARATOR|Pulsed dye laser|PDL Patient will be have scar treated with pulsed dye laser.
61939617|NCT00735254|ACTIVE_COMPARATOR|Affirm laser|Patient will be have scar treated with Affirm Laser
61939618|NCT00735254|ACTIVE_COMPARATOR|combined PDL and Affirm Lasers|Patient will be have scar treated with combined Affirm + PDL
61939619|NCT00735254|PLACEBO_COMPARATOR|Placebo|Patient will be have scar treated with Placebo
61939620|NCT05449522|EXPERIMENTAL|Treatment group|Experimental group will receive 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) theoretically to achieve sufficient level of vitamin D.
61939621|NCT05449522|PLACEBO_COMPARATOR|Control group|
61939622|NCT04882046|OTHER|patients diagnosed by a clinician who suspects leptospirosis|
61939623|NCT02409810|EXPERIMENTAL|PCA-DEX Patients|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10mins by nurse staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg.
61939624|NCT04673448|EXPERIMENTAL|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-28 of cycle 1. Beginning cycle 2, patients receive niraparib PO QD on days 1-21 and dostarlimab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 6, patients receive niraparib PO QD on days 1-42 and dostarlimab IV over 30 minutes on day 1. Cycles repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo biopsy, blood sample collection, and CT or MRI throughout the study.
61939625|NCT01033188|ACTIVE_COMPARATOR|Single-bundle technique|Anatomic single-bundle technique
62137476|NCT00960141|EXPERIMENTAL|1|montelukast
62137477|NCT00960141|ACTIVE_COMPARATOR|2|loratadine
62137478|NCT00960141|PLACEBO_COMPARATOR|3|placebo
61939626|NCT01033188|ACTIVE_COMPARATOR|Double-bundle technique|Anatomic double bundle technique
61939627|NCT01147588|EXPERIMENTAL|1|lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg
61939628|NCT01147588|EXPERIMENTAL|2|omeprazole 80 mg + clopidogrel 300/75 mg
61939629|NCT01147588|EXPERIMENTAL|3|esomeprazole 40 mg + clopidogrel 300/75 mg
61939630|NCT01147588|EXPERIMENTAL|4|clopidogrel 300/75 mg alone
61939631|NCT03678883|EXPERIMENTAL|9-ING-41|Drug: 9-ING-41
61939632|NCT03678883|EXPERIMENTAL|9-ING-41 plus Gemcitabine|Drugs: Gemcitabine - 21 day cycle. 9-ING-41
61939633|NCT03678883|EXPERIMENTAL|9-ING-41 plus Doxorubicin|Drugs: Doxorubicin. 9-ING-41
61939634|NCT03678883|EXPERIMENTAL|9-ING-41 plus Lomustine|Drugs: Lomustine. 9-ING-41.
61939635|NCT03678883|EXPERIMENTAL|9-ING-41 plus Carboplatin|Drugs: Carboplatin. 9-ING-41.
61939636|NCT03678883|EXPERIMENTAL|9-ING-41 plus nab paclitaxel Gemcitabine|Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.
61939637|NCT03678883|EXPERIMENTAL|9-ING-41 plus Paclitaxel/Carboplatin|Drugs: Paclitaxel. Carboplatin. 9-ING-41.
61939638|NCT03678883|EXPERIMENTAL|9-ING-41 plus Irinotecan|Drugs: Irinotecan. 9-ING-41.
61939639|NCT04336410|EXPERIMENTAL|Group 1: INO-4800|Participants will receive one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
61939640|NCT04336410|EXPERIMENTAL|Group 2: INO-4800|Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
61939641|NCT04336410|EXPERIMENTAL|Group 3: INO-4800|Participants will receive one ID injection of 0.5 mg of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
61939642|NCT04108702|EXPERIMENTAL|VR heart|
61939643|NCT04108702|SHAM_COMPARATOR|VR control|
61939644|NCT04108702|ACTIVE_COMPARATOR|Standard control|
61939645|NCT06345092|EXPERIMENTAL|intervention group|injection of injectable platelet rich fibrin with vitamin C
62137479|NCT05224765||Geriatric patients that attended fall prevention discharge class|recidivism rates of MDMC-qualified G60 patients that attended fall prevention discharge class per hospital protocols
61939646|NCT06345092|ACTIVE_COMPARATOR|control group|injection of injectable platelet rich fibrin alone
61939647|NCT02356315||Healthy subjects|Functional magnetic resonance imaging of healthy subjects
61939648|NCT02356315||Chronic neck pain patients|Functional magnetic resonance imaging of chronic neck pain patients
61939649|NCT06235333|EXPERIMENTAL|Screening Intervention|Individuals will take part in a branching problem/responsible gambling information sharing experience before completing a multi-item brief gambling screen and receiving tailored feedback about their risk for gambling-related problems, and including problem/responsible gambling resources for their state of residence and national resources.
61939650|NCT06235333|ACTIVE_COMPARATOR|Informational Control|Individuals will take part in a limited problem/responsible gambling information sharing experience.
61939651|NCT02680509|EXPERIMENTAL|All|All patient will undergo a unilateral sympathicotomy R3. After this left and right will be compared
61939652|NCT01303328|EXPERIMENTAL|Treatment group|
61939653|NCT01303328|PLACEBO_COMPARATOR|Placebo group|
61939654|NCT05859256|EXPERIMENTAL|Experimental group|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
61939655|NCT05859256|PLACEBO_COMPARATOR|Control group|The subjects included in the control group will perform the same procedures, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
61939656|NCT03098355|EXPERIMENTAL|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10\^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
61939657|NCT02256072|EXPERIMENTAL|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
61939658|NCT02256072|OTHER|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
61939659|NCT05218668|EXPERIMENTAL|Cohort 1 - Fasudil|Oral fasudil at 180 mg/day
61939660|NCT05218668|EXPERIMENTAL|Cohort 2 - Fasudil|Oral fasudil at 300 mg/day
61939661|NCT01672229|EXPERIMENTAL|Dose-escalation|Bortezomib starting dose is 0.2 mg/m2 subcutaneously which will be given weekly with incremental increase of 0.2 mg/m2 every other week, if no improvement is seen, and no dose limiting toxicities are observed to the maximum dose of 1.6 mg/m2. Bortezomib will be administered in the outpatient clinic.
61939662|NCT03468985|ACTIVE_COMPARATOR|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61939663|NCT03468985|EXPERIMENTAL|Arm B (nivolumab, cabozantinib)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61939664|NCT03468985|EXPERIMENTAL|Arm C (nivolumab, cabozantinib, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61939665|NCT03468985|EXPERIMENTAL|Arm T (Targeted cohort; nivolumab, cabozantinib)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61939666|NCT03473951||Hyperuricemia|Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
61939667|NCT02193581||Suspicious skin lesions.|Patients with a suspicious skin lesion referred for a biopsy are tested using MDS
61939668|NCT05593471|EXPERIMENTAL|High intensity exercises|The first group (HG) received a High-intensity exercise program consisting of progressive resistance training for 30 min using dumbbells, sandbags, and TheraBand with different colors. The exercised muscles were (knee extensors, elbow flexors, chest muscles, hip adductors, abductors, abdominal muscles, back muscles, and hand grip muscles) (references). The intensity of exercise was determined by the load which was kept at 65% of the 10-repetition maximum throughout the program duration. The repetitions of each exercise were kept at a fixed value of 2 sets of 10 - 12 repetitions per session (exercises stopped if the patient reached fatigue level). For progression, the 10-repetition maximum test was performed on a weekly schedule and the amount of load was adjusted accordingly. Exercises were done in a cyclic manner where half of the selected muscles were exercised per session and the other half were exercised in the next session.
62137480|NCT05224765||Geriatric patients that did not attend fall prevention discharge class|recidivism rates of MDMC-qualified G60 patients that did not attended fall prevention discharge class per hospital protocols
62137481|NCT02000089|ACTIVE_COMPARATOR|Familial pancreas cancer relatives|"High Risk Group 2 (familial pancreatic cancer relatives):~1. \> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and~2. come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and~3. have a first-degree relationship with at least one of the relatives with pancreatic cancer.~If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
61939669|NCT05593471|EXPERIMENTAL|low intensity aerobic exercises|The second group (LG) received a low-intensity aerobic exercise program consisting of an arm ergometer, and a bicycle ergometer to train both upper and lower body muscles. Additionally, 5 minutes of regular treadmill walking was added at the beginning and the end of the exercises session as warming up and cooling down respectively. Exercises were performed in a cyclic manner where the arm and bicycle ergometers were used alternatively. The rate of perceived exertion (RPE) scale was used to monitor the intensity of the exercises to be at 3 -4 level. The actual working out time was 20 minutes plus 10 minutes for the warming up and cooling down. Sessions were performed 3 times per week for six weeks.
61939670|NCT02836275|EXPERIMENTAL|Perfusion and diffusion-weighted MRI|
61939671|NCT05514132|EXPERIMENTAL|Ceralasertib in Combination with Durvalumab|This is a sequential group treatment/dose-escalation study with 2 cohorts with no masking.
61939672|NCT04773119|ACTIVE_COMPARATOR|Pulmonary vein isolation (PVI) only|
61939673|NCT04773119|ACTIVE_COMPARATOR|PVI with substrate|
61939674|NCT02602392|EXPERIMENTAL|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
62695214|NCT02941055|ACTIVE_COMPARATOR|Protein diet|50% of daily intake, 5 days a week, a diet rich in protein, red meat and saturated fat will be provided to study subjects
62695215|NCT02264756||Ward CAP|Adult immune-competent patients admitted to ward with clinical diagnosis of community-acquired pneumonia will be potentially exposed to ASP review
61939675|NCT02602392|ACTIVE_COMPARATOR|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
62137482|NCT02000089|ACTIVE_COMPARATOR|Group 1 germline mutation carrier|"High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~10% or higher):~a. \> 50 years old or 10 years younger than the age of the youngest relative affected, if pancreatic cancer is in family, and b. The Patient is a carrier of a confirmed BRCA2, ATM or PALB2 mutation, regardless of family history of pancreatic cancer. b.\> Individual is a carrier of a confirmed FAMMM (p16/CDKN2A) mutation, age 40 years or older, regardless of family history of pancreas cancer."
62335089|NCT02768649|EXPERIMENTAL|Cohort 3|After safety and tolerability review of the data from Day 1 to Day 15 of the medium dose arm, 3 subjects were dosed in Cohort 3 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
62492337|NCT04476277|EXPERIMENTAL|Sickle Cell Disease Pre-Transplantation|Autologous cells will be collected in participants with Sickle Cell Disease Pre-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
62695216|NCT06568575|EXPERIMENTAL|experimental group of combine of exercise and music|This study held a group meeting before the formal experiment to guide all participants in advance and describe the entire experimental process in detail to them. Students who had questions were given a unified and detailed explanation. Each participant received an instruction manual and a sports smart bracelet. During the experimental stage, the researcher would remind the participants on time to conduct the music and jogging experiment. The participants were required to participate in the experiment according to the contents of the instruction manual and upload each experimental participation content in the form of video or photos to the online information collection link posted by the participants. before experiment, 4 weeks, 8 weeks and 12 weeks，this study required participants to fill out the questionnaire four times.
62695217|NCT06568575|NO_INTERVENTION|Control group|At the same time as the experimental group, a booklet about music and exercise was distributed to the participants. The control group and the experimental group had the same time to fill in the questionnaire. The control group was asked to fill in the first questionnaire before the experiment. After 4 weeks, the control group was asked to fill in the second questionnaire. After 8 weeks, the control group was asked to fill in the third questionnaire. After 12 weeks, the control group was asked to fill in the fourth questionnaire。After the study completed, the control group was also provided with the music and jogging materials for their reference. So that they received the same benefit as the experimental group.
62695218|NCT04467255|ACTIVE_COMPARATOR|group a|aerobic training
62695219|NCT04467255|ACTIVE_COMPARATOR|group b|endurance training
62695220|NCT05723263|EXPERIMENTAL|Standard Pay-it-forward|"* free gonorrhea/chlamydia testing~* minimal engagement"
62695221|NCT05723263|EXPERIMENTAL|Community engaged Pay-it-forward|"* Free gonorrhea/chlamydia testing~* Stronger engagement"
61939676|NCT03630042|EXPERIMENTAL|Pembrolizumab and Rituximab|
61939677|NCT00990353||Prism adaptation therapy|Patients receive prism adaptation therapy by protocol (Frassinetti et al., 2002)
61939678|NCT00990353||Bromocriptine pharmacotherapy|Patients receive bromocriptine pharmacotherapy by protocol (Barrett et al., 1999)
61939679|NCT03157167|EXPERIMENTAL|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
61939680|NCT03157167|EXPERIMENTAL|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
61939681|NCT03157167|EXPERIMENTAL|200 mcg/5 mCi Tc99m-Tilmanocept|Up to six subjects will receive a single subcutaneous injection and a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
62137483|NCT02000089|ACTIVE_COMPARATOR|Group 2 germline mutation carrier|"High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~5%):~1. \> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and~2. The patient is a carrier of a confirmed BRCA1 or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is \> 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
62137484|NCT02000089|ACTIVE_COMPARATOR|Hereditary pancreatitis|High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.
62137485|NCT02000089|ACTIVE_COMPARATOR|Peutz-Jeghers Syndrome|"1. At least 30 years old, and~2. at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,~3. known STK11 gene mutation carrier"
62335090|NCT01376713|EXPERIMENTAL|Ofatumumab alone|Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).
62335091|NCT01376713|EXPERIMENTAL|Ofatumumab plus Dacarbazine|Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.
62335092|NCT04169594||Stroke|Unilateral hemiplegic stroke patients
61939682|NCT01123850|ACTIVE_COMPARATOR|Single ARM - Copios Bone Filler|All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.
61939683|NCT02229331||gait analysis|gait analysis
61939684|NCT05276154|ACTIVE_COMPARATOR|thermoviscous bulk fill resin composite|
61939685|NCT05276154|ACTIVE_COMPARATOR|conventional bulk fill resin composite|
62137486|NCT02000089|ACTIVE_COMPARATOR|Negative control|"1. are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and~2. have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
62137487|NCT02000089|ACTIVE_COMPARATOR|Chronic Pancreatitis|"1. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,~2. have no clinical or radiologic suspicion of pancreatic cancer"
61939686|NCT03769298|EXPERIMENTAL|Envarsus XR|Envarsus XR (extended release) will be administered orally, once-daily, for 6 months.
61939687|NCT06307158||Intraoperative blood salvage and autotransfusion (IBSA) group|The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria included: patients under 18 years of age, presence of extrahepatic metastasis, combined kidney transplantation, reduced-size or split liver transplantation, re-transplantation, and missing data on analyzed variables. The remaining recipients were 349 in IBSA group who received salvaged blood autotransfusion during the LT.
61939688|NCT06307158||non-intraoperative blood salvage and autotransfusion (non-IBSA) group|The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria was as mentioned ahead. Recipients who did not receive salvaged blood autotransfusion during the LT were enrolled in non-IBSA group.
61939689|NCT00549874|EXPERIMENTAL|1|
61939690|NCT00549874|EXPERIMENTAL|2|
61939691|NCT05284877||Male organ transplant recipients|600 men with a solid organ transplant (heart, lung, liver, kidney or pancreas)
61939692|NCT05284877||Female organ transplant recipients|600 women with a solid organ transplant (heart, lung, liver, kidney or pancreas)
61939693|NCT05284877||Female immunocompetent controls|600 immunocompetent women without organ transplant or other immunosuppressive conditions/treatments
61939694|NCT06680427|EXPERIMENTAL|Treatment Arm|
61939695|NCT00454701||1. Amevive Exposure|Patients treated with alefacept for chronic plaque psoriasis
62137488|NCT02000089|ACTIVE_COMPARATOR|Pancreas cancer|a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)
62137489|NCT02000089|ACTIVE_COMPARATOR|Pancreas cyst, IPMN evaluation|are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).
62137490|NCT05695469|EXPERIMENTAL|ResuGlove group|Participants in the ResuGlove group will be guided by the audio feedback from the smart resuscitation glove.
62335093|NCT04169594||Amputee|Unilateral transtibial amputee patients
62335094|NCT02742870||Patients with MRI pelvic imaging|Women over 18 years old, having undergone a magnetic resonance imaging of the pelvis within the CHU Brugmann Hospital
61939696|NCT06115746|EXPERIMENTAL|iDECIDE|"Participants will...~1. Receive 4 weekly sessions of the iDECIDE drug curriculum.~2. Complete assessments and questionnaires, including self-reports of substance use and 4 urinalysis virtual visits.~3. Be video recorded for quality control."
61939697|NCT06115746|NO_INTERVENTION|Waitlist Control Group|"Participants will...~1. Not receive the iDECIDE curriculum during the weekly visits. They can choose to self-enroll in the iDECIDE curriculum at their one-month follow up visit.~2. Undergo symptom monitoring during the weekly visits.~3. Complete assessments and questionnaires, including self-reports of substance use and 4 urinalysis virtual visits."
62335095|NCT00423410|EXPERIMENTAL|EPC2407 (crinobulin)|
62335096|NCT00645567||Unassisted manual transfer|this group will use no additional aid in transfer.
62695222|NCT05723263|OTHER|Control arm|"* Test available for a fee~* No engagement"
61939698|NCT05126680|EXPERIMENTAL|Intermittent treadmill walking exercise and moderate intensity functional training|Subjects belonging to this group perform a 12-week supervised exercise therapy consisted of intermittent treadmill walking exercise and moderate intensity functional training.
61939699|NCT05126680|ACTIVE_COMPARATOR|Intermittent treadmill walking exercise|Subjects belonging to this group perform a 12-week supervised exercise therapy consisted of intermittent treadmill walking exercise.
61939700|NCT03405610|EXPERIMENTAL|Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
61939701|NCT03405610|NO_INTERVENTION|Usual Care|The Usual Care (UC) group will continue with their current medical care.
61939702|NCT00338104|EXPERIMENTAL|40% Glargine|Patients will receive a dose of glargine insulin equal to 40% of insulin drip rate.
61939703|NCT00338104|EXPERIMENTAL|60% Glargine|Patients will receive a dose of glargine insulin equal to 60% of insulin drip rate.
62335097|NCT00645567||Standard sliding board transfer|The standard transfer board is a flat surface board designed to bridge the gap that exists with transfers from wheelchair to vehicle and/or other horizontally displaced seating surfaces.
62695223|NCT06519526|EXPERIMENTAL|SHR-0302 and SHR-2554 Treatment Arm|SHR-2554 Oral administration, twice daily, with a 28-day continuous dosing as one cycle. SHR-0302: Oral administration, once daily,
62695224|NCT00153933|EXPERIMENTAL|CC-5013 in combination with bortezomib|Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
62695225|NCT05495126|ACTIVE_COMPARATOR|Standard Limbic Access|In this arm, participants will refer through the standard pathway of Limbic Access. During this process patients provide the minimal required information (e.g. demographic information) as well as some basic information about their experienced mental health symptoms (e.g. PHQ-9 \& GAD-7). This information is attached to the referral provided to the clinician before the clinical assessment.
61939704|NCT00338104|EXPERIMENTAL|80% Glargine|Patients will receive a dose of glargine insulin equal to 80% of insulin drip rate.
61939705|NCT01663168|ACTIVE_COMPARATOR|Rifabutin three times a week|Rifabutin 150mg tablet three times a week (Mon-Wed-Fri) in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
61939706|NCT01663168|EXPERIMENTAL|Rifabutin daily|Rifabutin 150mg tablet daily in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
61939707|NCT05285657|NO_INTERVENTION|Control Arm|Febrile children will be managed according to the IMCI (integrative management of childhood illnesses) and the guideline of diagnostic and treatment (GDT), which are part of the routine system existing in Burkina Faso. Treatment will be done according to the national guideline.
61939708|NCT05285657|ACTIVE_COMPARATOR|RDTs decisional Arm|The clinical examination based on IMIC will be supported by two-step malaria RDT and bacterial infections RDTs. Prescription will be left to the discretion of the healthcare workers.
61939709|NCT05285657|ACTIVE_COMPARATOR|e-algorithm Arm|Artificial intelligence integrating multiple layers of clinical information such as clinical examination, signs/symptoms and medical history, and laboratory information such as outcomes of biomarkers (CRP and WBC) and pathogen specific POCT (malaria and bacterial infections) and oximetry will be developed. The e-algorithm will serve to guide the diagnostic and management of febrile infections in children from 2 to 59 months.
61939710|NCT06359379|EXPERIMENTAL|Ropidoxuridine 960 mg|Ropidoxuridine is administered orally at 960 mg, 5 days a week for a total of 7 weeks, starting 1 week before the initiation of radiotherapy.
62335098|NCT00645567||Glide n' Go Lift|The Glide n' Go lift is a flip down power list seat that enables the person to enter and exit the vehicle by lifting them from their wheelchair up tot eh vehicle seat that they can make an easy transfer into the vehicle. Trunk stability may be required to successfully use the device.
61939711|NCT06359379|EXPERIMENTAL|Ropidoxuridine 1200 mg|Ropidoxuridine is administered orally at 1200 mg, 5 days a week for a total of 7 weeks, starting 1 week before the initiation of radiotherapy.
61939712|NCT03810391|EXPERIMENTAL|preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group A were \>11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
61939713|NCT03810391|PLACEBO_COMPARATOR|preoperative anxiety and saline|preoperative anxiety scores of patients in Group B were \>11 and received an infusion of the same volume of physiological saline
61939714|NCT03810391|EXPERIMENTAL|non-preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group C were ≤ 11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
61939715|NCT03810391|PLACEBO_COMPARATOR|non-preoperative anxiety and saline|preoperative anxiety scores of patients in Group D were ≤11 and received an infusion of the same volume of physiological saline
61939716|NCT03697057||patients|Patients scheduled for elective ambulatory gynaecological surgery, which was performed under standardised general anaesthesia
62335099|NCT00645567||Easy Reach lift|The Easy Reach lift seat allows the vehicles original seat to swivel out of the vehicle and lower to wheelchair height. the chair extends far from the vehicle to provide access for a safe, easy transfer.
62695226|NCT05495126|EXPERIMENTAL|Limbic Access with AI|In this arm, provide all information as in the standard Limbic Access pathway. Based on this information a machine-learning model is used to predict the most likely presenting problem, based on which up to two additional anxiety specific measures are administered in order to collect more tailored information about the patients' experienced mental health symptoms. All the information is attached to the referral provided to the clinician before the clinical assessment.
62695227|NCT06474013|EXPERIMENTAL|Blood Brain Barrier (BBB) Disruption|All participant in this arm will undergo 3 sessions of transcranial magnetic resonance guided focused ultrasound blood brain barrier disruption every 2 months.
62695228|NCT01218321||Antiepileptic treatment group|Group of patients treated by antiepileptic medications
61939717|NCT03697057||healthy volunteers|Female healthy volunteers matched to the patient group regarding the age
62137491|NCT05695469|ACTIVE_COMPARATOR|Traditional CPR group|Participants in the traditional CPR group will perform chest compressions without guidance from the smart resuscitation glove.
62695229|NCT03960177|EXPERIMENTAL|Treatment (glucarpidase)|Patients receive standard of care HDMTX IV over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.
62335100|NCT00645567||Ryno lift|The Ryno lift is an under-vehicle list (UVL) system. Using this lift, the wheelchair user is raised into the vehicle cab using independent controls and can then maneuver into a convenient position in the cab. The wheelchair is locked down and the lift stored beneath the vehicle chassis. This technology eliminated the need to store and retrieve a wheelchair during transit.
62335101|NCT02436577|EXPERIMENTAL|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
62335102|NCT02436577|EXPERIMENTAL|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
62335103|NCT02436577|EXPERIMENTAL|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
62695230|NCT05087342|ACTIVE_COMPARATOR|Intervention Group|"Will receive active medication semaglutide subcutaneously, once weekly, self-injection.~Month 1 - 0.24 mg SC once weekly x 4 weeks.(IE-1) Month 2- 0.5 mg SC once weekly x 4 weeks.(IE-2) Month 3 -1 mg SC once weekly x 4 weeks.(IE-3) Month 4 - 1.7 mg SC once weekly x 4 weeks.(IE-4) Month 5 - 2.4 mg SC once weekly x 4 weeks. (IE-5) Month 6 - 2.4 mg SC continue once weekly x 8 weeks.(IE-6) Month 7 - completion visit (IE-7)"
62695231|NCT05087342|PLACEBO_COMPARATOR|Control Group|Will receive placebo, subcutaneously, once weekly, self-injection throughout study duration.
61939718|NCT01836965|EXPERIMENTAL|Social Skills Intervention|The intervention is a 12-week social skills training program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session (in the form of a photography class with typically developing peers) meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the photography class. During the group therapy session adolescents will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with a typically developing peer for the photography class.
61939719|NCT01504243||Control|normal person under medical examination
61939720|NCT01504243||sepsis|SIRS plus inflammation
61939721|NCT00876746|ACTIVE_COMPARATOR|1. Supraclavicular|Patients will be randomized to placement of a nerve block in the supraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
61939722|NCT00876746|ACTIVE_COMPARATOR|2. Infraclavicular|Patients will be randomized to placement of a nerve block in the infraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
61939723|NCT06431204||Patients with postpartum hemorrhage with severe maternal morbidity|Patients with either one of severe maternal morbidity (severe hemorrhage, hypertension/neurologic, renal, sepsis, pulmonary, cardiac, intensive care unit, and anesthesia complications)
61939724|NCT06431204||Patients with postpartum hemorrhage without severe maternal morbidity|Patients without the severe maternal morbidity conditions
61939725|NCT04091009|ACTIVE_COMPARATOR|Continue Group|Those who continue taking their standard dose of buprenorphine before, during and after surgery.
61939726|NCT04091009|ACTIVE_COMPARATOR|Reduce Group|Those who are placed on a lower dose of buprenorphine starting one day before surgery and during the time period after surgery until the pain from the surgery has decreased. Once the pain from the surgery has decreased, you will be put back on your full dose of buprenorphine.
61939727|NCT03688009|EXPERIMENTAL|Mindfulness-Based Family Psycho-Education (MBFBE)|A programme focuses on non-judgmental attitudes, collaborative inquiry and self-care, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
61939728|NCT03688009|ACTIVE_COMPARATOR|Family Psycho-Education (FPE)|A programme focuses on information giving, problem-solving and mutual support, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
61939729|NCT01161732|NO_INTERVENTION|Conventional treatment|In the conventional treatment group, indications for aortic valve replacement surgery are development of symptoms, reduced left ventricular systolic function and an increase in aortic jet velocity \> 0.5 m/sec during follow-up.
61939730|NCT01161732|ACTIVE_COMPARATOR|Early Surgery|Early surgery is performed within 2 months of randomization.
61939731|NCT05907590||Patients with Fibromyalgia|Patients with fibromyalgia diagnosed using the ACR criteria (American College of Rheumatology, Wolfe et al., 2010; 2016).
61939732|NCT05907590||Healthy Controls|Healthy controls will consist of people who experience few physical complaints in daily life. The healthy controls will thus be screened for inclusion using the CSD (Checklist for Symptoms in Daily life; Walentynowicz, et al., 2018). Only volunteers with a score of 75 or lower on this questionnaire will be included
61939733|NCT02225769|EXPERIMENTAL|e-POCT|Febrile children managed using the e-POCT tool. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
61939734|NCT02225769|ACTIVE_COMPARATOR|ALMANACH|Febrile children managed using the ALMANACH algorithm. ALMANACH is an improved Integrated Management of childhood Illness (IMCI) algorithm based on mobile phones and tablets that has already been assessed for safety and efficacy.
62137492|NCT04915261|ACTIVE_COMPARATOR|Strict Arm|"The strict arm group will be given the following restrictions. These restrictions are the current institutional protocol at the study site and falls within common practice pattern across Canada:~1. No arm or shoulder movement x 24 hours~2. No movement of affected arm overhead x 8 weeks~3. No lifting anything heavier than 5 lbs (2.5kg) and avoid any kind of sports or other vigorous activities including golf, tennis, swimming or sweeping x 8 weeks~4. Avoid any kind of shovelling x 8 weeks"
62335104|NCT02436577|EXPERIMENTAL|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
62695232|NCT01112956||STD clinic patients|Patients attending sexually transmitted Disease clinics. If the initial testing result reported to the patient is confirmed by the Western Blot test, no follow-up specimens will be collected. If the initial testing result reported to the patient is different from the result by the Western Blot test, patients will be asked to provide a follow-up specimen 3-4 months after initial testing.
62695233|NCT01112956||Pregnant women|Women recruited from prenatal clinic. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
62695234|NCT01112956||Men who have Sex with men (MSM)|Men recruited from a clinic for MSM with high risk for HIV infection. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
61939735|NCT02225769|NO_INTERVENTION|Routine practice|Febrile children managed according to routine care such as provided by routine health facility health workers.
61939736|NCT00913575|EXPERIMENTAL|preoperative neuromuscular training|preoperative neuromuscular training
61939737|NCT00913575|PLACEBO_COMPARATOR|education|knee school
61939738|NCT06110572|EXPERIMENTAL|Treatment (carboplatin, atezolizumab, etoposide, TBI, H-RT)|"Description INDUCTION PHASE: Patients receive carboplatin IV and atezolizumab IV on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive TBI BID on day 18 or 19 of cycle 1 and beginning 2-3 days later, H-RT daily over 7 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive atezolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT and MRI throughout the trial."
61939739|NCT02387177|EXPERIMENTAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
61939740|NCT02387177|EXPERIMENTAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
61939741|NCT02477839|EXPERIMENTAL|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
61939742|NCT02477839|PLACEBO_COMPARATOR|Placebo|Matching placebo syrup
61939743|NCT01865188|EXPERIMENTAL|LCZ696 200 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg once daily for 8 weeks.
61939744|NCT01865188|EXPERIMENTAL|LCZ696 400 mg|Patients randomized to this treatment arm will receive LCZ696 400 mg once daily for 8 weeks.
61939745|NCT01865188|ACTIVE_COMPARATOR|Amlodipine 5 mg|Patients randomized to this treatment arm will receive amlodipine 5 mg once daily for 8 weeks.
61939746|NCT01865188|ACTIVE_COMPARATOR|Amlodipine 10 mg|Patients randomized to this treatment arm will receive amlodipine 10 mg once daily for 8 weeks.
61939747|NCT01865188|EXPERIMENTAL|LCZ696 200 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 8 weeks.
61939748|NCT01865188|EXPERIMENTAL|LCZ696 200 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 200 mg and amlodipine 10 mg once daily for 7 weeks.
61939749|NCT01865188|EXPERIMENTAL|LCZ696 400 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 5 mg once daily for 7 weeks.
61939750|NCT01865188|EXPERIMENTAL|LCZ696 400 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 10 mg once daily for 7 weeks.
61939751|NCT01865188|PLACEBO_COMPARATOR|Placebo|Patients randomized to this treatment arm will receive placebo once daily for 8 weeks.
61939752|NCT06416722|EXPERIMENTAL|Cognitive-Motor Dual Task Activities Group|Patients included in this group will be given additional cognitive tasks.
61939753|NCT06416722|EXPERIMENTAL|Motor-Motor Dual Task Activities Group|Patients included in this group will be given additional motor tasks.
61939754|NCT06416722|EXPERIMENTAL|Cognitive-Motor & Motor-Motor Dual Task Activities Group|Simultaneously with balance and large amplitude functional activities.
61939755|NCT01740973||SILC cholecystectomy|No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
61939756|NCT01740973||and conventional lap. cholecystectomy|no intervention.Patients are also mailed a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
61939757|NCT03595774|PLACEBO_COMPARATOR|Placebo|3.3 mL/kg concentrated beet root juice \*depleted of nitrate\* Other names: Beet It Sport Nitrate 400 placebo
61939758|NCT03595774|ACTIVE_COMPARATOR|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice \*depleted of nitrate\*~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
61939759|NCT03595774|ACTIVE_COMPARATOR|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate~Other names:Beet It Sport Nitrate 400"
61939760|NCT02396251|EXPERIMENTAL|HA experimental|HA experimental only
61939761|NCT02396251|ACTIVE_COMPARATOR|HA comparator|HA experimental + HA comparator
61939762|NCT05965778|EXPERIMENTAL|T2769|
61939763|NCT05965778|ACTIVE_COMPARATOR|Vismed® Multi|
61939764|NCT04209062|EXPERIMENTAL|Study device|
61939765|NCT04209062|ACTIVE_COMPARATOR|Control device|
61939766|NCT01943773|EXPERIMENTAL|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions. Sessions will occur three times weekly at the patient's home.
61939767|NCT01943773|EXPERIMENTAL|No Prehabilitation|The control group will undergo routine pre-operative management.
61939768|NCT04439279|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61939769|NCT05958732|EXPERIMENTAL|Experimental Group|The experimental group will receive body awareness therapy for 20 minutes.The following steps will be conducted, (1) Put your left hand on your right toe. (2) Put your right hand on your left toe. (3) Touch your heels. (4) Put your feet together. (5) Put your knees together. (6) Touch your right knee with your left hand. (7) Touch your left knee with your right hand. (8) Touch one knee and one foot. (9) Put your right hand on your left knee. (10) Put your left hand on your right knee. (11) Put your feet apart. (12) Touch your toes with your arms crossed. (13) Touch your thumbs to your toes. (14) Bend your knees. (15) Stamp your feet. Duration is 5 days a week for two weeks. Along with conventional therapy.
61939770|NCT05958732|OTHER|Control group|conventional training plan: (1) 5 minute warm up then, (2) static balance exercises, such as, Two leg stance, One Leg stance, and (3) dynamic balance exercises such as, sideway walking with crossover, Forward walking or running in a zigzag line, Backward walking or running in a zigzag line, Jogging end to end, (4) Coordination exercises such as, Tandem stepping, Finger to nose, Finger to finger, Sitting with Shifting weight in all directions, Rebound Phenomenon and cool down for 5 minutes.
61939771|NCT05996874|EXPERIMENTAL|Semaglutide: 50 mL water and 30 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 50 mL water and 30 minutes post-dose fasting.
62335105|NCT02436577|EXPERIMENTAL|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
62137493|NCT04915261|ACTIVE_COMPARATOR|Lenient Arm|"The lenient arm restriction group will be given the following restrictions. The justification for the selected lenient restriction is based on the current recommendations at a Canadian center as identified by the national survey:~1. No shoveling 7 days,~2. No golfing/swimming/tennis 14 days~3. No other restrictions (overhead activity and weight lifting no limitation)"
62335106|NCT02436577|EXPERIMENTAL|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
62137494|NCT06474143|EXPERIMENTAL|Epxerimental|Patients will wear the device during their polysomnographic recording
62335107|NCT00121992|ACTIVE_COMPARATOR|Arm A: FAC|FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
62492338|NCT04476277|EXPERIMENTAL|Sickle Cell Disease Post-Transplantation|Autologous cells will be collected in participants with Sickle Cell Disease Post-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
62492339|NCT04476277|EXPERIMENTAL|Sickle Cell Trait (HbAS)|Autologous cells will be collected in participants with Sickle Cell Trait (HbAS) and biotin-labeled ex vivo and reinfused to measure red cell survival
62492340|NCT04476277|EXPERIMENTAL|HbAA (Healthy volunteers)|Autologous cells will be collected in participants with HbAA (Healthy volunteers) and biotin-labeled ex vivo and reinfused to measure red cell survival
62492341|NCT02375815|EXPERIMENTAL|Statin Choice Implementation|
62492342|NCT01389713|ACTIVE_COMPARATOR|High doses|Administration of high doses of gonadotrophins to stimulate ovarian follicular growth
62695235|NCT04933422|EXPERIMENTAL|CM93 pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), pre-treatment with CM93 prior to surgical resection of recurrent glioblastoma
61939772|NCT05996874|EXPERIMENTAL|Semaglutide: 120 mL water and 30 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by dose 2 of oral semaglutide D for another 5 days with 120 mL water and 30 minutes post-dose fasting.
61939773|NCT05996874|EXPERIMENTAL|Semaglutide: 50 mL water and 60 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 50 mL water and 60 minutes post-dose fasting.
62335108|NCT00121992|EXPERIMENTAL|Arm B: TAC|TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
62335109|NCT03174821|EXPERIMENTAL|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
61939774|NCT05996874|EXPERIMENTAL|Semaglutide: 120 mL water and 60 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 120 mL water and 60 minutes post-dose fasting.
62137495|NCT01183832||Concomitant|In this group, anastrazole is concomitant to the radiotherapy
62137496|NCT01183832||Sequential|In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
62335110|NCT03174821|NO_INTERVENTION|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
62335111|NCT01260766|ACTIVE_COMPARATOR|Active Comparator: Oplon Active Patch|
62335112|NCT01260766|PLACEBO_COMPARATOR|Placebo Comparator: Placebo patch|
62335113|NCT05848830|ACTIVE_COMPARATOR|DM1 + HBEXT + MIS|Participants will be asked to undergo 16 weeks of home-based training and asked to take one dose of a multi-ingredient supplement per day.
62335114|NCT05848830|PLACEBO_COMPARATOR|DM1 + HBEXT + PLA|Participants will be asked to undergo 16 weeks of home-based training and asked to take one dose of a multi-ingredient supplement placebo per day.
62335115|NCT05848830|NO_INTERVENTION|CONTROL|Healthy control subjects who will not undergo study intervention and will be used for baseline measurements and outcomes.
62335116|NCT03673241|NO_INTERVENTION|Control Group|The Control Group will receive the standard support surface mattresses/bed surfaces and recovery chairs without the non-invasive perfusion enhancement system (The Guardian System)
62335117|NCT03673241|EXPERIMENTAL|Study Arm|The Study Arm will have the non-invasive perfusion enhancement system placed on their beds and recovery chairs. Patients will be utilizing the systems while lying in bed or sitting in the chair.
62335118|NCT04129606|OTHER|TURBT|Transurethral resection of bladder tumour
62335119|NCT03235596|EXPERIMENTAL|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
62492343|NCT01389713|EXPERIMENTAL|Clomid|Administration of Clomiphene Citrate to obtain ovarian follicular growth
62492344|NCT04364191|EXPERIMENTAL|Intervention Arm|Meaningful activity protocol during the day and Assisted Relaxation Therapy (ART) at night; includes 1) Sleep Hygiene Education; 2) Meaningful Activity Modules a) Physical Activity b) Cognitive Activity and c) Social engagement; 3) ART, a breath-based relaxation intervention that is coupled with a physical anchoring task. Participants will complete a daily sleep diary, use the activity modules daily as pre-determined times personalized to the participant, use the ART software when they get in bed to help with insomnia symptoms, and wear an actiwatch for a four-week period. Participants will have weekly to biweekly phone consultation with the research nurse.
62695236|NCT04933422|NO_INTERVENTION|No pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), no pre-treatment prior to surgical resection of recurrent glioblastoma
62695237|NCT06570616|EXPERIMENTAL|AutoCPAP|Subjects will use auto CPAP during 7 days.
62695238|NCT06570616|EXPERIMENTAL|Fixed|Subjects will start with the CPAP level obtained during auto-CPAP titration. CPAP will be decreased according to the study protocol.
62695239|NCT03774121|EXPERIMENTAL|CRYO|Subjected to Cryoneurolysis treatment and Neuromuscular training (GLA:D).
61939775|NCT05996874|EXPERIMENTAL|Semaglutide: 50 mL water and 120 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 50 mL water and 120 minutes post-dose fasting.
61939776|NCT05996874|EXPERIMENTAL|Semaglutide: 120 mL water and 120 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 120 mL water and 120 minutes post-dose fasting.
61939777|NCT03624244|EXPERIMENTAL|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
61939778|NCT03624244|OTHER|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
61939779|NCT05586646|NO_INTERVENTION|control group|100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations
61939780|NCT05586646|EXPERIMENTAL|alanyl-glutamine group|100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration).
61939781|NCT06681402|EXPERIMENTAL|FLAMOD|
61939782|NCT06681402|PLACEBO_COMPARATOR|Placebo|
61939783|NCT03461263|ACTIVE_COMPARATOR|Group A|phonophoresis treatment using pumpkin seeds oil
61939784|NCT03461263|NO_INTERVENTION|Group B|Low intensity Ultrasound
61939785|NCT03461263|NO_INTERVENTION|Group C|Placebo Low intensity Ultrasound
61939786|NCT04537195|EXPERIMENTAL|Intervention Group|ADSMP-C
61939787|NCT04537195|NO_INTERVENTION|Control Group|Wait-list control group
61939788|NCT01133041|EXPERIMENTAL|NBI observation|
61939789|NCT01133041|EXPERIMENTAL|i-Scan observation|
61939790|NCT03625934|EXPERIMENTAL|VVX001 (20 micrograms)|Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
62335120|NCT01073280||undeterminated neurological disease, cerebral endoscopy|patients without neurological diagnosis that require cerebral , meningeal diagnosis
62335121|NCT00187239|ACTIVE_COMPARATOR|AICS On|Patients in this arm have Autointrinsic conduction search programmed ON.
62695240|NCT03774121|SHAM_COMPARATOR|SHAM|Subjected to similar procedures as CRYO, but without freezing temperatures. Subjected to Neuromuscular training (GLA:D).
62695241|NCT06100731|ACTIVE_COMPARATOR|Active tDCS|Current will be ramped in/out for 15 seconds at the beginning and end of a 15-minute period and a constant current will be delivered for the 15-minutes between ramping
61939791|NCT03625934|PLACEBO_COMPARATOR|Placebo|Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
61939792|NCT06417125|EXPERIMENTAL|Dexmedetomidine group|Participants were premedicated with intranasal dexmedetomidine 2 μg/kg and oral sweet solution 0.25 mL/kg.
61939793|NCT06417125|ACTIVE_COMPARATOR|Midazolam group|Participants were premedicated with intranasal 0.9% saline 0.02 mL/kg and oral midazolam 0.5 mg/kg.
61939794|NCT06417125|PLACEBO_COMPARATOR|Placebo group|Participants were premedicated with intranasal 0.9% saline 0.02 mL/kg and oral sweet solution 0.25 mL/kg.
61939795|NCT05386576|EXPERIMENTAL|Venetoclax in Combination With Chemotherapy|All patients will complete Induction I and II of the treatment regimens, consisting of several chemotherapy agents including Peg-ASP.
62335122|NCT00187239|NO_INTERVENTION|AICS Off|Patients assigned to this arm do not have Autointrinsic Conduction Search programmed on.
62335123|NCT00319852|EXPERIMENTAL|1|
61939796|NCT04488939|EXPERIMENTAL|Bilateral treatment|
61939797|NCT04120948|EXPERIMENTAL|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
61939798|NCT04120948|ACTIVE_COMPARATOR|Tongue scraper|tongue scraping
61939799|NCT06680219|PLACEBO_COMPARATOR|Placebo controlled, randomised 4-week home use study|"The sample is Crystal Light Raspberry Lemonade~Placebo sample Usage instructions for all groups:~2. Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily (8-12 oz of water is approximately 236-354 mL of water)."
61939800|NCT06680219|ACTIVE_COMPARATOR|Active comparator for randomised 4-week home use study|"ACTIVE - Nu Biome (Formula #: 95001996; Batch #: EV24931)~Active sample Usage instructions for all groups:~1. Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily (8-12 oz of water is approximately 236-354 mL of water)."
61939801|NCT04719637|EXPERIMENTAL|PRDS-001|Renal denervation
61939802|NCT05721222|EXPERIMENTAL|PRO1160|PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B
61939803|NCT05605782||Participants initiating treatment with ozanimod|
61939804|NCT05605782||Participants initiating an sphingosine-1 phosphate (S1P) modulator|
61939805|NCT05605782||Participants initiating other non-S1P-receptor modulators disease modifying treatments (DMTs)|
61939806|NCT01315184|EXPERIMENTAL|Recovery Line Support System|Patients assigned to the Recovery Line Support System will be trained on the system and provided 24-hr access to the system for a four week period, provided with a Recovery notebook, and given reminder calls to contact the system.
61939807|NCT01315184|NO_INTERVENTION|Treatment as Usual|Patients assigned to the TAU condition will receive any services provided by their buprenorphine provider and any additional services that their provider refers or recommends that patients attend. No additional services will be provided by the study.
61939808|NCT01815983|EXPERIMENTAL|Videolaryngoscopy review.|Video review.
61939809|NCT03824418||Chromoendoscopy follow-up|
61939810|NCT03824418||Autofluorescence follow-up|
62335124|NCT00319852|ACTIVE_COMPARATOR|2|
62335125|NCT02893774|EXPERIMENTAL|cancer quality of life|All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
62695242|NCT06100731|SHAM_COMPARATOR|Shame tDCS|Current will be ramped in/out for 15 seconds at the beginning and end of a 15-minute period during which no stimulation will be delivered.
62695243|NCT06077279|EXPERIMENTAL|Horticultural Therapy|receive horticulture therapy by seven sessions within two months
62335126|NCT05822908|EXPERIMENTAL|Cohort 1|A dose of 10 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
62335127|NCT05822908|EXPERIMENTAL|Cohort 2|A dose of 20 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
62335128|NCT05822908|EXPERIMENTAL|Cohort 3|A dose of 40 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
62335129|NCT05822908|EXPERIMENTAL|Cohort 4|A dose of 70 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
62335130|NCT05822908|EXPERIMENTAL|Cohort 5|A dose of 100 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
62335131|NCT01768598||Fracture - Boys|Boys who have sustained a distal radius fracture
62335132|NCT01768598||Fracture - Girls|Girls who have sustained a distal radius fracture
62335133|NCT01768598||Non Fracture - Boys|Boys who have not sustained a distal radius fracture
62335134|NCT01768598||Non Fracture - Girls|Girls who have not sustained a distal radius fracture
62335135|NCT00074412|EXPERIMENTAL|2A|For infants: extended treatment with NVP
61939811|NCT05568537|EXPERIMENTAL|Treatment MRIs and Pylarify PSMA PET/CTs|2 MRIs and 2 Pylarify PSMA PET/CTs, occurring at mid-treatment and when testosterone level is 75% recovered or 12 months after androgen deprivation therapy (ADT), whichever comes first
61939812|NCT05403034|EXPERIMENTAL|OBPP children|OBPP children operated on to treat shoulder stiffness.
61939813|NCT04732416|EXPERIMENTAL|HM15136 active|Cohort 1 / Cohort 2
61939814|NCT01011270||Back pain|The aim of this study was to investigate the effect of rehabilitation of the dynamic ;(RDM) in balance and balance of industrial operators. The sample consisted of industrial operators, individuals with low back pain, referred to the industry of Physical Therapy
61939815|NCT01011270||Balance|the treatment with RDM reflected in significant improvement in back pain and postural balance of industrial operators.
62137497|NCT06475248|PLACEBO_COMPARATOR|Control Group|"Each volunteer selected in this group will complete a scale, in this case Hit-6, to collect data and evaluate the evolution.~Then a placebo technique will be used, which consists of imitating the contacts of the techniques without compressing or pulling the tissue, lasted 6 minutes.~This procedure will be repeated for two more sessions. One month after the first evaluation, the volunteers filled out the Hit-6 scale again."
62335136|NCT00074412|PLACEBO_COMPARATOR|2B|For infants: extended treatment with NVP placebo
61939816|NCT01488500|EXPERIMENTAL|Filtered air exposure|3 hour exposure to filtered air with intermittent exercise
61939817|NCT01488500|EXPERIMENTAL|Wood smoke exposure|3 hour exposure to dilute wood smoke generated from incomplete combustion in a wood burning stove at approximately 300 mcg/m3
61939818|NCT01488500|EXPERIMENTAL|Wood pellet smoke emission|3 hour exposure to dilute wood smoke generated from wood pellets during incomplete combustion during intermittent exercise at approximately 300 mcg/m3
61939819|NCT04363177|EXPERIMENTAL|Web-based psychosocial peer-to-peer support|"Web-based psychosocial peer-to-peer support, using Thinking Healthy two times during pregnancy"
61939820|NCT04363177|ACTIVE_COMPARATOR|Standard perinatal care|Perinatal standard care in Hong Kong, Shanghai
62137498|NCT06475248|EXPERIMENTAL|Experimental Group|"After each volunteer completes the Hit-6 scale, one of the researchers will perform the trapezius and sternocleidomastoid stretching techniques, and suboccipital inhibition. The techniques performed will only be done once, lasted 6 minutes.~This procedure will be repeated for two more sessions. One month after the first evaluation, the volunteers filled out the Hit-6 scale again."
62137499|NCT01968967|EXPERIMENTAL|Bococizumab (PF-04950615; RN316)|
62137500|NCT01968967|PLACEBO_COMPARATOR|Placebo|
62335137|NCT03215394|EXPERIMENTAL|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
62335138|NCT03215394|SHAM_COMPARATOR|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
62695244|NCT06077279|NO_INTERVENTION|Routine hospital care|doesn't receive horticulture therapy but receive routine care by hospital within conducting the research
62695245|NCT06645015|EXPERIMENTAL|AI-augmented risk-stratification|
61939821|NCT05150145|EXPERIMENTAL|Radiotherpy will be performed to thoracic and liver metastasis.|Radiotherapy for liver metastases and thoracic will be performed in paticipants with liver metastasis who achieved CR or PR after chemotherapy.
61939822|NCT05150145|NO_INTERVENTION|Radiotherpy will be performed to thoracic.|Radiotherapy performed only on the thoracic after chemotherapy of paticipants with liver metastasis who achieved CR or PR.
61939823|NCT03387683|PLACEBO_COMPARATOR|placebo|placebo tablets once daily
61939824|NCT03387683|EXPERIMENTAL|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
62492345|NCT04364191|ACTIVE_COMPARATOR|Control Arm|Study participants in the control group will also receive a tablet and watch, but the meaningful activity modules and ART software will not be accessible to them. The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education. This approach provides staff and technology interaction/attention that is comparable to the intervention arm, and thereby promotes adherence; it has been used as a placebo comparator for many insomnia treatment studies and has low attrition rates. Control subjects will also be asked to complete electronic sleep diaries and wear the actiwatch on the non-dominant wrist to monitor sleep/wake patterns. For both arms, participants will be asked to complete baseline assessments, 4-week (post-intervention) and 12-week (follow-up).
62492346|NCT01204138|PLACEBO_COMPARATOR|placebo|Patient randomized to one of two arms, either placebo, or Apremilast
62492347|NCT01204138|ACTIVE_COMPARATOR|Apremilast|Patients randomized to either placebo or apremilast
61939825|NCT03331250|EXPERIMENTAL|Eribulin|"* Eribulin administered twice per cycle intravenously~* Each cycle contains 21 days~* Dosing is per the FDA label for other cancers"
61939826|NCT05749211|EXPERIMENTAL|Huaier granule|Huaier granule is supplied as 20-g granule. Huaier granule will be administered as 20 g orally tid x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. In the absence of intolerable toxicity, a patient may continue to receive treatment with Huaier granule until disease progression, or until 24 months have elapsed.
61939827|NCT02725034|ACTIVE_COMPARATOR|Group 1|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
61939828|NCT02725034|EXPERIMENTAL|Group 2|High definition endoscopy with Optic Enhancement targeted biopsies for gastric intestinal metaplasia.
62137501|NCT06662968|EXPERIMENTAL|Lollipop group|Lollipop group patients were given lollipops for sucking in the PACU
62137502|NCT06662968|ACTIVE_COMPARATOR|Control group|Control group patients were received routine nursing treatment in the PACU.
62137503|NCT05913349|EXPERIMENTAL|The clinical response of the group cognitive behavioural therapy|A randomized controlled study of GCBT with one-month and six-month post-treatment follow-up was conducted to explore the short- and long-term efficacy of GCBT on mental sub-health
62335139|NCT03215394|OTHER|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
62335140|NCT00825383|ACTIVE_COMPARATOR|1|High Fiber Diet
62492348|NCT00746460|EXPERIMENTAL|A|Behavioral
62492349|NCT02186353|EXPERIMENTAL|Intact/minimally processed whole grains|Partial feeding study
62492350|NCT02186353|EXPERIMENTAL|Highly processed whole grains|Partial feeding study
62492351|NCT02186353|ACTIVE_COMPARATOR|Refined grains|Partial feeding study
62695246|NCT06645015|NO_INTERVENTION|Espert-based Risk-stratification|
61939829|NCT03935412|ACTIVE_COMPARATOR|ES Erector Spinae Plane Block|By the end of surgery parturient in the ESPB underwent bilateral ESPB at the level of T9 using a linear ultrasound (US) transducer (Phillips Saronno Italy) the transducer was placed vertically3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine 22-G short bevel needle (spinocan, B.Braun melsungen AG, Germany) was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml 0.5% bupivacaine was done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
62137504|NCT05913349|EXPERIMENTAL|The alterations of behavior and physiological features in the group cognitive behavioral therapy.|To understand the possible biological mechanism underlying the efficacy of group cognitive behavioral therapy by analyzing alterations of the alterations of behaviors and Physiological features in the group cognitive behavioral therapy features.
62137505|NCT05568381|EXPERIMENTAL|Digital Cognitive Behavioural therapy for insomnia|"Participants will receive a commercially available 6-week, online media-rich course of CBT-I delivered by an animated virtual therapist (Sleepio). Treatment content of this intervention includes behavioural components (sleep restriction, stimulus control, and relaxation), cognitive components (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, and 'putting the day to rest') and educational components (psychoeducation and sleep hygiene). Each of the 6 sessions lasts \~ 30 minutes and incorporates an initial progress review in relation to individualised goals, and exploration of self-reported diary data relating to the participant's current sleep status and pattern. The full program can be accessed via a website or iOS app. Participants will have access to the intervention for up to 12 weeks."
62137506|NCT05568381|ACTIVE_COMPARATOR|Sleep Health Education wait-list control|"Those in the control group will have access to three modules of the Sleep Health Education package following completion of baseline questionnaires. Each module will be delivered fortnightly with basic information about sleep health (e.g. the impact of sleep on health, creating a sleep-conducive bedroom, sleep and mood). Participants will receive a link to access each module as they are made available.~At trial completion (week 12), control participants will be offered the opportunity to engage with digital CBT-I."
62137507|NCT00090519|EXPERIMENTAL|Ruboxistaurin|32 milligrams (mg) once daily (QD) oral for up to 36 months
62137508|NCT00090519|PLACEBO_COMPARATOR|Placebo|QD oral for up to 36 months
62137509|NCT00495677|ACTIVE_COMPARATOR|PF-00232798 40 mg|
62137510|NCT00495677|ACTIVE_COMPARATOR|PF-00232798 300 mg|
62335141|NCT00825383|ACTIVE_COMPARATOR|2|Moderate Fiber Diet
62695247|NCT05694611|EXPERIMENTAL|Preterm neonates|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion at term in infants born prematurely~Other Names:~• SonoVue"
62695248|NCT05970367|EXPERIMENTAL|Intensive rehabilitation program|3 weeks of intensive rehabilitation --\> follow-up 9 months standard care
62492352|NCT05535920|OTHER|Rate Atrial fibrillation - 2.0K+ dialysate bath wo/ Lokelma to crossover|"Sequence A: standard 2.0 K+/2.5 Ca++ dialysate with no Lokelma supplementation for two (2) months, followed by a cross-over to experimental 3.0 K+/2.5 Ca++ dialysate with 5 grams powder oral suspension Lokelma supplementation (on off-dialysis days) for two (2) months.~Each two-month treatment period (both 2.0 K+/2.5 Ca++ dialysate and 3.0 K+/2.5 Ca++ dialysate with Lokelma sequences) will be preceded by a two-week run-in period, to allow the patient to adapt to the new dialysate bath. While receiving the higher K+ dialysate, patient will be treated on off-dialysis days (4 days/week) with Lokelma, titrated to maintain K+ between 4.0 and 5.5 mEq/L. Refer to section 7.2 for the initial dose and frequency details."
62492353|NCT05535920|OTHER|Rate Atrial fibrillation - 3.0K+ dialysate bath w/ 5 grams Lokelma to crossover|"• Sequence B: experimental 3.0 K+/2.5 Ca++ dialysate with 5 grams Lokelma supplementation (on off-dialysis days) for two (2) months, followed by standard 2.0 K+/2.5 Ca++ dialysate with no Lokelma supplementation for two (2) months.~Each two-month treatment period (both 2.0 K+/2.5 Ca++ dialysate and 3.0 K+/2.5 Ca++ dialysate with Lokelma sequences) will be preceded by a two-week run-in period, to allow the patient to adapt to the new dialysate bath. While receiving the higher K+ dialysate, patient will be treated on off-dialysis days (4 days/week) with Lokelma, titrated to maintain K+ between 4.0 and 5.5 mEq/L. Refer to section 7.2 for the initial dose and frequency details."
62137511|NCT00495677|ACTIVE_COMPARATOR|PF-00232798 400 mg|
62335142|NCT01671930||cardiac computed tomographic angiography|Patients refered for cardiac computed tomographic angiography by a cardiologist.
62335143|NCT00681967|EXPERIMENTAL|Cohort 1|post operative combination of gefinib and RT
62335144|NCT00681967|EXPERIMENTAL|Cohort 2|combination of gefitinib with RT and Chemotherapy in non operated patients
62335145|NCT05623904|ACTIVE_COMPARATOR|Carotid Revascularization|Carotid Artery Stenting/Carotid endarterectomy + Best Medical Treatment
62335146|NCT05623904|ACTIVE_COMPARATOR|Medical Treatment|Best Medical Treatment
62335147|NCT06093373||Comparison|
62335148|NCT06409078|EXPERIMENTAL|repeated transcranial magnetic stimulation treatment group|The rTMS group was given 1 Hz/s for 20 min for 1 week.
62335149|NCT06409078|EXPERIMENTAL|Western medicine group|The western medicine group was given pivacurium bromide tablets orally at 50 mg three times daily for 1 week.
62335150|NCT00585923|ACTIVE_COMPARATOR|Usage of Fixed hole C-Tek™ Plate|Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
62137512|NCT00495677|ACTIVE_COMPARATOR|PF-00232798 5 mg|
62335151|NCT00585923|ACTIVE_COMPARATOR|Usage of Slotted hole C-Tek™ Plate|Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.
62137513|NCT00495677|ACTIVE_COMPARATOR|PF-00232798 20 mg|
62335152|NCT04840992|EXPERIMENTAL|A1a Phase I low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
62335153|NCT04840992|PLACEBO_COMPARATOR|A1b Phase I placebo low 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
62335154|NCT04840992|EXPERIMENTAL|A2a Phase I medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
62335155|NCT04840992|PLACEBO_COMPARATOR|A2b Phase I placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
62335156|NCT04840992|EXPERIMENTAL|A3a Phase I high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
62335157|NCT04840992|PLACEBO_COMPARATOR|A3b Phase I placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
62335158|NCT04840992|EXPERIMENTAL|A4a Phase I combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
62335159|NCT04840992|PLACEBO_COMPARATOR|A4b Phase I placebo combine 2 doses|6 subjects, Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
62335160|NCT04840992|EXPERIMENTAL|A5a Phase I single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
62335161|NCT04840992|PLACEBO_COMPARATOR|A5b Phase I placebo single dose|6 subjects, Placebo containing 0 vp, 1 dose Aerogen Solo
62137514|NCT00495677|ACTIVE_COMPARATOR|PF-00232798 150 mg|
62137515|NCT00991549|EXPERIMENTAL|1|interdisciplinary weight loss intervention
62137516|NCT00991549|ACTIVE_COMPARATOR|2|Small group seminars without interdisciplinary intervention
62137517|NCT02848794|EXPERIMENTAL|Apatinib+Irinotecan|Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
62335162|NCT04840992|EXPERIMENTAL|B1a Phase II low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
62335163|NCT04840992|PLACEBO_COMPARATOR|B1b Phase II placebo low 2 doses (18-59)|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
62335164|NCT04840992|EXPERIMENTAL|B2a Phase II medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
62335165|NCT04840992|PLACEBO_COMPARATOR|B2b Phase II placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
62335166|NCT04840992|EXPERIMENTAL|B3a Phase II high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
62335167|NCT04840992|PLACEBO_COMPARATOR|B3b Phase II placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
62335168|NCT04840992|EXPERIMENTAL|B4a Phase II combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
62335169|NCT04840992|PLACEBO_COMPARATOR|B4b Phase II placebo combine 2 doses|Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
62335170|NCT04840992|EXPERIMENTAL|B5a Phase II intramuscular single dose|Ad5-nCoV containing 5E10 vp, 1 dose Intramuscular Injection
62335171|NCT04840992|PLACEBO_COMPARATOR|B5b Phase II placebo intramuscular single dose|placebo containing 0 vp, 1 dose Intramuscular Injection
62335172|NCT04840992|EXPERIMENTAL|B6a Phase II Aerogen Solo single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
62335173|NCT04840992|PLACEBO_COMPARATOR|B6b Phase II placebo Aerogen Solo single dose|placebo containing 0 vp, 1 dose Aerogen Solo
62335174|NCT05717452|EXPERIMENTAL|Blueberry drink|
62335175|NCT05717452|PLACEBO_COMPARATOR|Placebo drink|
62335176|NCT03071549|ACTIVE_COMPARATOR|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
62492354|NCT05762458|EXPERIMENTAL|Ammoxetine group-cohort 1|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.
62492355|NCT05762458|EXPERIMENTAL|Ammoxetine group-cohort 2|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.
62695249|NCT05970367|NO_INTERVENTION|Standard care|Follow-up 9 months standard care --\> 3 weeks of intensive rehabilitation
61939830|NCT03935412|SHAM_COMPARATOR|intrathecal morphine ITM|participant in the ITM group intrathecal injection of 10mg of hyperbaric bupivacaine 0.5 % in addition to 100 mcg of preservative-free morphine. Then, the parturient immediately placed in the supine position with 15° left tilt, and an oxygen mask was applied at 2 l.min-1. After ensuring sufficient anesthesia level, the surgical procedure was done with continuous hemodynamics monitoring and recording. While participants in the ITM group underwent sham blocks; Sham blocks consisted of a non-invasive ultrasound scan, while a blunt needle was gently pressed on both sides.
62335177|NCT03071549|ACTIVE_COMPARATOR|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
62335178|NCT01532063|OTHER|INTUBATION|Subjects intubed in Intensive Care Unit
61939831|NCT05216003|EXPERIMENTAL|PATH4YOU County|
61939832|NCT05216003|NO_INTERVENTION|Matched-Pair Control County|
61939833|NCT00117195||PD/PS|
61939834|NCT01690429|OTHER|OSA Patients|
61939835|NCT03107663|EXPERIMENTAL|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
61939836|NCT03203070|ACTIVE_COMPARATOR|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
61939837|NCT03203070|EXPERIMENTAL|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
61939838|NCT02585583|OTHER|Radiosurgical thalamotomy|Patients will undergo to radiosurgical thalamotomy by Cyberknife system.
61939839|NCT02216760|ACTIVE_COMPARATOR|Ripple Mapping guided VT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to identify conduction channels within the ventricular scar substrate to guide ablation lesions in patients with monomorphic VT.
61939840|NCT02216760|ACTIVE_COMPARATOR|Conventional VT Ablation|Standard substrate ablation as per local operator preference will be used to guide ablation in the ventricular scar in patients with monomorphic VT.
62335179|NCT03075176|ACTIVE_COMPARATOR|Wavefront optimized LASIK|Participants who chose to have LASIK surgery were assigned to have Wavefront optimized LASIK in one eye and Topography-guided LASIK in the other eye (randomly chosen).
62335180|NCT03075176|ACTIVE_COMPARATOR|Wavefront optimized Photorefractive Keratectomy|Participants who chose to have Photorefractive Keratectomy surgery were assigned to have Wavefront optimized Photorefractive Keratectomy in one eye and Topography-guided Photorefractive Keratectomy in the other eye (randomly chosen).
62335181|NCT03075176|ACTIVE_COMPARATOR|Topography-guided LASIK|Participants who chose to have LASIK surgery were assigned to have Topography-guided LASIK in one eye and Wavefront optimized LASIK in the other eye (randomly chosen).
62695250|NCT03901365|EXPERIMENTAL|Group 1|Patient received manual therapy in addition neuroscience pain education sessions
62695251|NCT03901365|ACTIVE_COMPARATOR|Group 2|Patient received manual therapy in addition tradition education sessions
62695252|NCT03189719|EXPERIMENTAL|Pembrolizumab + SOC|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) plus standard of care (SOC) chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
62335182|NCT03075176|ACTIVE_COMPARATOR|Topography-guided Photorefractive Keratectomy|Participants who chose to have Photorefractive Keratectomy surgery were assigned to have Topography-guided Photorefractive Keratectomy in one eye and Wavefront optimized Photorefractive Keratectomy in the other eye (randomly chosen).
62492356|NCT05762458|PLACEBO_COMPARATOR|Placebo group|The eligible subjects will receive placebo to Ammoxetine.
62492357|NCT04332484||Acute on Chronic Liver Failure|All patients of Acute on chronic liver failure according to CANONIC definition, aged more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
61939841|NCT02095067|EXPERIMENTAL|Video consultation|Patients in this arm receive video consultation from physician at the emergency medical dispatch center
62492358|NCT04332484||Cirrhosis of Liver|All patients with cirrhosis of liver with age more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
62492359|NCT05796843|EXPERIMENTAL|360 Degrees Virtual Reality-based Mirror Therapy Group|The group which will receive 360 Degrees Virtual Reality-based Mirror Therapy Group
61939842|NCT02095067|NO_INTERVENTION|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician at the emergency medical dispatch center.
61939843|NCT03835104|ACTIVE_COMPARATOR|CRP in all|"All children will undergo a CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
61939844|NCT03835104|EXPERIMENTAL|CRP in high risk children only|"Children who are positive on a clinical prediction rule for serious infections in children will undergo CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
61939845|NCT05324137|EXPERIMENTAL|Group 1: 55mg Q2W|CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)
61939846|NCT05324137|EXPERIMENTAL|Group 2: 110mg Q2W|CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)
61939847|NCT05324137|EXPERIMENTAL|Group 3: 220mg Q2W|CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)
61939848|NCT05324137|EXPERIMENTAL|Group 4: 220mg Q4W|CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)
61939849|NCT05350306|EXPERIMENTAL|Chincup|Patients will be treated with occipital chincup and bonded bite block.
62492360|NCT05796843|ACTIVE_COMPARATOR|Traditional Mirror Therapy Group|The group which will receive traditional mirror therapy using a conventional mirror
62492361|NCT05796843|ACTIVE_COMPARATOR|Conventional Physical Therapy Group|The group which will receive conventional rehabilitation for upper extremity
62695253|NCT03189719|PLACEBO_COMPARATOR|Placebo + SOC|Participants receive placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
62695254|NCT05881291|EXPERIMENTAL|group ciprofol|Patients receive ciprofol for general anesthesia
62695255|NCT05881291|ACTIVE_COMPARATOR|group propofol|Patients receive propofol for general anesthesia
62695256|NCT06637956|EXPERIMENTAL|NTG|Received a mg nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
62695257|NCT06637956|NO_INTERVENTION|Control|Control group did not receive nitroglycerine prior to laryngoscopy and intubation
62695258|NCT05702450|EXPERIMENTAL|Group P1|CM310, Subcutaneous
62695259|NCT05702450|ACTIVE_COMPARATOR|Group P2|CM310, Subcutaneous, as the parallel control group
62695260|NCT04720001||Experimental: Florbetaben F18 recipients|Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.
61939850|NCT05350306|ACTIVE_COMPARATOR|Untreated subjects|Patients will not undergone any treatment for 16 months.
61939851|NCT02276365|EXPERIMENTAL|Sequence ABC|"1. Treatment A: 50 mg BI 10773 once daily from day 1 to 5~2. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7~3. Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out"
61939852|NCT02276365|EXPERIMENTAL|Sequence CAB|"1. Treatment C: 45 mg pioglitazone once daily from day 1 to 7~2. Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out~3. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7"
61939853|NCT06422195|EXPERIMENTAL|Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA)|Ultrasound guided radial artery cannulation by Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. The ultrasound transducer is oriented transversely to the radial artery at the wrist, and the vessel appears as a circular anechoic structure in the ultrasound screen with gradual advancing of the needle till reaching the radial artery. Meanwhile, the ultrasound probe is being moved proximally in advance of the needle tip until it disappears from the ultrasound image. The cannula then advanced in the direction of the artery.
61939854|NCT06422195|ACTIVE_COMPARATOR|Long Axis Approach (LA)|Ultrasound guided radial artery cannulation in Long Axis Approach (LA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. In the LA-IP approach, an ultrasound probe is placed parallel to the radial artery and the artery appears as a tubular anechoic structure in ultrasound.
62335183|NCT04079894||LSS Participants|Patients with lumbar spinal stenosis
62335184|NCT04079894||Background population|Populationdata from existing research project
62335185|NCT04079894||LBP Participants|Patients with Low back Pain
62335186|NCT01441921|ACTIVE_COMPARATOR|Control diet|Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)
62335187|NCT01441921|EXPERIMENTAL|Pistachio diet|Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)
62335188|NCT03026413|EXPERIMENTAL|PVAM|pulomonary vein antrum modification with contact force monitoring for AF
62335189|NCT03026413|ACTIVE_COMPARATOR|Control arm|pulmonary vein isolation without contact force
62335190|NCT03129581|ACTIVE_COMPARATOR|Time Restricted|This group will receive dietary counseling.
62335191|NCT03129581|NO_INTERVENTION|Time Unrestricted|This group will not receive dietary counseling.
62335192|NCT05186883|EXPERIMENTAL|Treatment with allogenic parathyroid cells|Patients with postoperative hypoparathyroidism receiving standard treatment and allogenic parathyroid cells
62335193|NCT05186883|ACTIVE_COMPARATOR|Control|Patients with postoperative hypoparathyroidism receiving standard treatment
62335194|NCT05557773|ACTIVE_COMPARATOR|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 45 minutes.
62335195|NCT05557773|EXPERIMENTAL|Training Group|In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
62335196|NCT02623634||observation|this study measure the cuff leak volume and cuff leak ratio according to the cuff leak test with different positions and waveform,, at the same time observe the patient general condition, vital signs, oxygen saturation, cuff leak test results under different conditions and the breathing machine parameters, the diameter of the airway, the use of sedatives and hormones, after extubation stridor and intubation is happening again, the use of NPPV after extubation, patient outcomes
62335197|NCT01226355|EXPERIMENTAL|NOYA|implant NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stents Intervention: Device: stent
62335198|NCT01226355|ACTIVE_COMPARATOR|Firebird2|implant Firebird2 drug-eluting stents Intervention: Device: stent
62335199|NCT06330662|EXPERIMENTAL|Coronally advanced flap with the hyaluronic acid|The experimental group indicates the surgical intervention using a coronally advanced flap to cover multiple adjacent gingival recessions with the addition of hyaluronic acid intraoperatively (CAF+HA).
62335200|NCT06330662|OTHER|Coronally advanced flap|The control group refers to surgical intervention using a coronally advanced flap only to cover multiple gingival recessions without the addition of hyaluronic acid (CAF).
62335201|NCT06515769||Control group: healthy subjects|Subjects without rheumatoid arthritis or symptoms compatible with this disease
62335202|NCT06515769||Case group: subjects with rheumatoid arthritis|Subjects diagnosed with rheumatoid arthritis
62335203|NCT05618899|EXPERIMENTAL|HIGH INTENSITY INTERVAL TRAINING|High intensity interval training basicaaly short bursts of intense exercise alternating with low intensity recovery periods. Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
62492362|NCT03232762|ACTIVE_COMPARATOR|Diet A|high proportion of calories from refined grains as a carbohydrate source
62492363|NCT03232762|ACTIVE_COMPARATOR|Diet B|a high proportion of calories from whole grains
62492364|NCT01483820|EXPERIMENTAL|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
62492365|NCT01291095|ACTIVE_COMPARATOR|CONCURRENT CHEMO-RADIOTHERAPY ARM|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy).
62492366|NCT01291095|EXPERIMENTAL|ACCELERATED FRACTIONATION RADIOTHERAPY ARM|Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
62492367|NCT01011855|ACTIVE_COMPARATOR|Radiant warmer bed sequence 1|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
62492368|NCT01011855|ACTIVE_COMPARATOR|Radiant warmer bed sequence 2|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
62335204|NCT05618899|EXPERIMENTAL|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
61939855|NCT02883842|EXPERIMENTAL|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.
61939856|NCT02883842|NO_INTERVENTION|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
61939857|NCT02330484|EXPERIMENTAL|incentives to physicians|Give incentives to physicians according to patients' HbA1c improvement
62335205|NCT02458690|EXPERIMENTAL|eIMPACT|eIMPACT is a 12-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for cardiovascular disease risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers.
62335206|NCT02458690|ACTIVE_COMPARATOR|Usual Care|Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
62335207|NCT04391426||Patients who will undergo ERCP (case group)|
62335208|NCT04391426||Living liver transplantation donors (control group)|
62335209|NCT04056455|EXPERIMENTAL|Severe Renal Impairment: Mobocertinib 80 mg|Participants with severe renal impairment received a single dose of mobocertinib 80 mg, capsule, orally, on Day 1.
62335210|NCT04056455|EXPERIMENTAL|Normal Renal Function: Mobocertinib 80 mg|Participants with normal renal function received a single dose of mobocertinib 80 mg, capsule, orally, on Day 1.
62492369|NCT01011855|ACTIVE_COMPARATOR|Radiant warmer bed sequence 3|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
62492370|NCT01011855|ACTIVE_COMPARATOR|Radiant warmer bed sequence 4|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
62335211|NCT03420378|EXPERIMENTAL|Interventional Arm|Patients with vitamin D deficiency will receive vitamin D replacement therapy. Before and after therapy, cutaneous silent period will be measured from each upper extremity and latencies will be recorded. Their LANSS scores and Notthingham Health Profile will be recorded before and after treatment.
62695261|NCT03812848|NO_INTERVENTION|Pre program implementation|All hospitalized patients on therapeutic anticoagulant medication during the pre-implementation period of the anticoagulation stewardship program.
61939858|NCT02330484|EXPERIMENTAL|incentives to patients|Give incentives to patients according to their HbA1c improvement
61939859|NCT02330484|EXPERIMENTAL|incentives to both physicians and patients|intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement
61939860|NCT02330484|NO_INTERVENTION|Group with no incentives|
61939861|NCT06134908|EXPERIMENTAL|Multifaceted Intervention|Group in the intervention arm will receive a multicomponent intervention at the clinician- and patient-level, with a shared decision-making booklet as well as a mobile application to promote osteoporosis management and fracture practice.
61939862|NCT06134908|NO_INTERVENTION|Usual-care Control|Group in the control arm will receive a leaflet and routine medical care per their existing health care providers.
61939863|NCT02806570|EXPERIMENTAL|AccuCinch® Ventricular Restoration System|
62335212|NCT04270994|EXPERIMENTAL|Misoprostol|
62335213|NCT02023164|EXPERIMENTAL|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
62335214|NCT02023164|ACTIVE_COMPARATOR|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
62492371|NCT01011855|EXPERIMENTAL|Radiant warmer bed sequence 5|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
62335215|NCT05649618|EXPERIMENTAL|Tumor Infiltrating Lymphocytes|TIL cells (2.5×10\^9-5×10\^10) will be infused i.v. to patients with advanced solid tumors after non-myeloablative lymphocyte-depleting preparative regimen.
62335216|NCT01657448|EXPERIMENTAL|Methenamine, Methylthioninium|
62335217|NCT01657448|ACTIVE_COMPARATOR|Phenazopyridine|
62137518|NCT03155100|EXPERIMENTAL|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
62137519|NCT03923452|EXPERIMENTAL|MBSR: Mindfulness-based stress reduction|Participants will be exposed to the 9-week MBSR program, facilitated by a trained MBSR facilitator. Due to COVID-19, the program will be held virtually.
62335218|NCT02969434|EXPERIMENTAL|Sleep questionnaires assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
62335219|NCT00133237|ACTIVE_COMPARATOR|A|Sirolimus-eluting stent (Cypher)
61939864|NCT02055807|EXPERIMENTAL|PEEP and recruitment maneuvers|A PEEP of 7 cm H2O will be applied starting after intubation until the end of surgery. Recruitment maneuvers (continuous positive pressure of 30 cm H20 for 30 seconds) will be initiated following intubation and repeated every 30 minutes during surgery and immediately prior to extubation. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
61939865|NCT02055807|ACTIVE_COMPARATOR|ZEEP (Zero end-expiratory pressure)|No PEEP nor recruitment maneuvers will be used during surgery. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
61939866|NCT06655285||the U.S. National Cancer Center SEER database|SEER\*Stat software (version 8.4.3) collected 17 registries cohort data on colon cancer patients between 2010 and 2019.
61939867|NCT06655285||Chinese multi-center database|Chinese multi-center database includes patients from January 2010 to December 2021 at 3 institutions.
61939868|NCT06281938|EXPERIMENTAL|3D camera weight estimation|TBW, LBW and IBW will be automatically estimated using the 3D camera system. All relevant medical care will be based on this weight for the first 72 hours
61939869|NCT06281938|PLACEBO_COMPARATOR|Standard care weight estimation|TBW, LBW and IBW will be estimated using standard care processes. All relevant medical care will be based on this weight for the first 72 hours
61939870|NCT06254378|ACTIVE_COMPARATOR|Sinus lifting without graft (control )|Patients will receive sinus lifting with immediate implant placement without graft placement.
61939871|NCT06254378|EXPERIMENTAL|Sinus lifting with graft (intervention)|Patients will receive sinus lifting with immediate implant and allograft placement.
61939872|NCT00497315|EXPERIMENTAL|A|pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed
61939873|NCT00497315|EXPERIMENTAL|B|thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin
61939874|NCT04549961||patients admitted to intensive care units|all patients that are present on an intensive care unit on nutritionday
61939875|NCT00703196|EXPERIMENTAL|Arm I|Patients receive oral folic acid pill once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
61939876|NCT00703196|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
61939877|NCT03102112||Patients with glioma|Consecutive patients with privious MRI scans or symptoms that suggested a cerebral mass, not yet receive treatment.
61939878|NCT05780697|EXPERIMENTAL|Children presented with septic hip arthritis in Assiut University Hospitals|Surgery of Drainage of pus in septic hip arthritis
61939879|NCT04069169|EXPERIMENTAL|Intravenous lidocaine|1% preservative free lidocaine 10 mg/ml in 0.9% NaCl
61939880|NCT04069169|PLACEBO_COMPARATOR|Intravenous saline control|0.9% sodium chloride, also known as normal saline
62137520|NCT03923452|NO_INTERVENTION|WLC: Wait list Control|Participants will be asked to log their self-care activities every week.
62137521|NCT02848560||Treatment|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
62335220|NCT00133237|ACTIVE_COMPARATOR|B|Paclitaxel-eluting stent (Taxus)
62335221|NCT00619580||positive E coli|positive E coli at UPMC
61939881|NCT05271071|ACTIVE_COMPARATOR|Gluteus Maximus Group|30 patients in the gluteus maximus group will be evaluated with detailed physical examination and special clinical tests. Sensitivity with sonopalpation, piriformis and gluteus maximus thicknesses, echo intensities will be evaluated with ultrasonography. Primarily diagnostic injection test for gluteus maximus muscle is planned for the first group with lidocaine with USG guide. At the first hour after injection full examination will be repeated for all patient and will be evaluated again with Numeric Rating Scale(NRS) at rest, with movement and with deep palpation. If the NRS score persists after the first injection patients will receive a diagnostic lidocaine injection into the piriformis muscle. At the first hour after the second injection, the physical examination and clinical tests of the patients will be repeated, and their pain at rest, with movement and with deep palpation will be evaluated with NRS.
62137522|NCT02848560||Control|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients heterozygous for F508del CFTR mutation at similar timepoints to treatment group. Control subjects are not be eligible to be clinically prescribed orkambi based on FDA approval.
62137523|NCT05074810|EXPERIMENTAL|avutometinib (VS-6766)+sotorasib|To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in KRAS G12C inhibitor naïve and exposed patients
62335222|NCT00504335|EXPERIMENTAL|500 BIO 300 capsule|The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting
62335223|NCT00504335|EXPERIMENTAL|1000 BIO 300 capsule|the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program
62335224|NCT00504335|EXPERIMENTAL|1500 BIO 300 capsule|the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program
62335225|NCT00504335|EXPERIMENTAL|2000 BIO 300 capsule|the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program
62335226|NCT00878657|EXPERIMENTAL|Radiotherapy plus gemcitabine|"Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy"
62492372|NCT01011855|EXPERIMENTAL|Radiant warmer bed sequence 6|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
61939882|NCT05271071|ACTIVE_COMPARATOR|Piriformis Muscle group|30 patients in the piriformis muscle group will be evaluated with detailed physical examination and special clinical tests. Sensitivity with sonopalpation, piriformis and gluteus maximus thicknesses, echo intensities will be evaluated with ultrasonography. Primarily diagnostic injection test for piriformis muscle (piriformis syndrome) is planned for the first group with lidocaine with USG guide. At the first hour after injection full examination will be repeated for all patient and will be evaluated again with Numeric Rating Scale(NRS) at rest, with movement and with deep palpation. If the NRS score persists after the first injection patients will receive a diagnostic lidocaine injection into the gluteus Maximus muscle. At the first hour after the second injection, the physical examination and clinical tests of the patients will be repeated, and their pain at rest, with movement and with deep palpation will be evaluated with NRS.
61939883|NCT06679686|EXPERIMENTAL|Role-playing|The role play group will make an ethical analysis of a case involving an ethical problem given to them by the researchers in the classroom environment every week and will discuss the cases using the role play method in the ethics committee to be formed after the session.
61939884|NCT06679686|EXPERIMENTAL|Digital storytelling|Digital storytelling group will discuss the ethical analyses of the cases with ethical issues written by themselves outside the classroom environment. Each small group of 6-7 people will present their ethical case analyses to other group members in the classroom through digital storytelling.
61939885|NCT06679686|NO_INTERVENTION|standard education|The control group will continue the standard education.
61939886|NCT00994318|EXPERIMENTAL|FCM (high ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
61939887|NCT00994318|EXPERIMENTAL|FCM (low ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
61939888|NCT00994318|ACTIVE_COMPARATOR|Oral Iron|Ferrous sulphate 100 mg iron twice daily, continuous
61939889|NCT02001181|EXPERIMENTAL|Treatment group A|
61939890|NCT02001181|PLACEBO_COMPARATOR|Treatment B|
61939891|NCT05137704||Participant With ADHD|The record available for ADHD participants in primary care-based electronic medical records in the CPRD database linked to secondary care based episodic claims data available in HES database will be assessed.
61939892|NCT00619593|ACTIVE_COMPARATOR|2|Standard follow-up in patients without appropriate ICD therapy
61939893|NCT00619593|EXPERIMENTAL|1|Following 1st appropriate ICD therapy, the patients have to be called to the clinic for intensified clinical diagnostics and, if necessary or useful, intensified therapy.
61939894|NCT03368703|EXPERIMENTAL|COPD patients|COPD patients group
61939895|NCT03368703|ACTIVE_COMPARATOR|Healthy subjects|Healthy subject group, matched with COPD patients group on age, weight and BMI
61939896|NCT03031158|EXPERIMENTAL|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles.
61939897|NCT03031158|ACTIVE_COMPARATOR|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles.
61939898|NCT00356733|EXPERIMENTAL|EPO rise|EPO administration
62137524|NCT05074810|EXPERIMENTAL|avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients
62695262|NCT03812848|EXPERIMENTAL|Post program implementation|All hospitalized patients on therapeutic anticoagulant medication during the post-implementation period of the anticoagulation stewardship program.
61939899|NCT00356733|EXPERIMENTAL|EPO stable|EPO and stable Hemoglobin
61939900|NCT00356733|NO_INTERVENTION|control|standard treatment
61939901|NCT04351997|EXPERIMENTAL|Early cord clamping|Cord clamping at 60 seconds after birth.
61939902|NCT04351997|EXPERIMENTAL|Delayed cord clamping|Cord clamping at 180 seconds after birth,
61939903|NCT01749774|EXPERIMENTAL|Physical activity counseling|
61939904|NCT06681311|EXPERIMENTAL|Exercises Group|
61939905|NCT06681311|NO_INTERVENTION|Control Group|
61939906|NCT04759144|ACTIVE_COMPARATOR|Faster insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with faster insulin aspart for 8 weeks.~Intervention: Use of faster insulin aspart with hybrid closed-loop insulin delivery"
61939907|NCT04759144|ACTIVE_COMPARATOR|Standard insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with standard insulin aspart for 8 weeks.~Intervention: Use of standard insulin aspart with hybrid closed-loop insulin delivery"
61939908|NCT05741060|EXPERIMENTAL|Equol Arm|S-equol - 10 mg per day tablet for 24 months.
62335227|NCT04848584||Fully vaccinated|Prior receipt of 2 doses of BNT162b2 received with ≥7 days between receipt of the 2nd dose and the index date. This group will serve as the 'exposed' group evaluated in the primary objective.
61939909|NCT05741060|PLACEBO_COMPARATOR|Placebo Arm|10 mg per day for 24 months of tablets that will be of the same size/shape/color as the experimental tablet.
61939910|NCT03248336|EXPERIMENTAL|Vision therapy group|Twelve, 60-minute, weekly visits of office-based vergence/accommodation therapy will be administered by a trained therapist combined with procedures to practice at home (15 minutes, 5 times per week). This treatment sequence is a well-accepted approach for treatment of CI and has been successfully implemented in previous studies. Fifteen minutes of home-based therapy was prescribed to be performed 5 days per week, and compliance with home-based therapy was monitored at each visit by the therapist
62137525|NCT05074810|EXPERIMENTAL|avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients
62492373|NCT00575601|ACTIVE_COMPARATOR|A|
62492374|NCT00575601|PLACEBO_COMPARATOR|B|
62492375|NCT05503992|EXPERIMENTAL|Intervention arm|CHWs affiliated with intervention facilities randomized to the intervention arm will be given the intervention package.
62695263|NCT06570486||training group|For training models
62492376|NCT05503992|NO_INTERVENTION|Control arm|CHWs affiliated with control sites randomized to the control arm will continue to implement the current standard of care which includes using paper records for inventory management and dispensing.
62492377|NCT05798884|EXPERIMENTAL|Electro-acupuncture group|The electro-acupuncture intervention will be conducted for 2 sessions per week for 4 consecutive weeks before and 8 weeks during the chemotherapy. In this study eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Disposable acupuncture needles (verum acupuncture needles Hwato 0.25 x 25mm matching the Streiterger sham needles) will be inserted at a depth of 10-25mm into the points. Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
61939911|NCT03120559|NO_INTERVENTION|Control|"The dental consultation was the same for all the groups.~1. - Examination and diagnosis (15 min).~2. - Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).~3. - Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
61939912|NCT03120559|OTHER|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
61939913|NCT03120559|OTHER|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).~New Floss Holder - Gum Chucks/SMS"
61939914|NCT01514331|ACTIVE_COMPARATOR|PSV+VG|Neonates who require mechanical ventilation and randomised to pressure support + volume guarantee (PSV+VG) mode
61939915|NCT01514331|ACTIVE_COMPARATOR|SIMV+VG|Neonates who require mechanical ventilation and randomised to synchronised intermittant mandatory ventilation + volume guarantee (SIMV+VG) mode
61939916|NCT06666036|EXPERIMENTAL|Connect Community Level Enhancements|"At the community level, Connect enhancements build on standard community health worker (CHW) home visits implemented by the government and pre-existing courtyard meetings implemented by the Government of Bangladesh.~Courtyard meetings are led by CHWs and convened monthly for new mothers and their families. CHWs sensitize participants to postpartum family planning (PPFP) and share the importance of available services from facilities. Connect reinforces the regularity of these meetings. CHWs receive additional training to be sensitized to the needs of first time parents and engage first-time mothers to attend.~Home Visits: CHWs conduct home visits to women who are pregnant or recently gave birth in their catchment areas. During these visits CHWs provide basic care, information on ANC, PNC and PPFP, and provide access to FP methods. Connect targets home visits to first time mothers and those who gave birth at home. They provide print materials to support PPFP and PNC care."
61939917|NCT06666036|NO_INTERVENTION|Control|No additional Connect intervention. Pre-existing institutionalized services for expecting and new mothers.
61939918|NCT00751166|EXPERIMENTAL|1|Desloratadine
62335228|NCT04848584||Partially vaccinated|Prior receipt of 1 dose (only) of BNT162b2 received with ≥14 days between receipt of the 1st dose and the index date.
62335229|NCT04848584||Ever vaccinated|Prior receipt ≥1 dose of BNT162b2 received with ≥14 days between index date and receipt of the 1st dose
62335230|NCT04848584||Never vaccinated|never received BNT162b2. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all VE analyses
62335231|NCT04848584||Bivalent vaccinated|Receipt of the BNT162b2 BA.4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received
62335232|NCT04848584||XBB.1.5 vaccinated|Receipt of XBB.1.5-adapted monovalent vaccine with greater than or equal 14 days between receipt of vaccine and the event date.
61939919|NCT00751166|ACTIVE_COMPARATOR|2|Cetirizine
61939920|NCT00751166|PLACEBO_COMPARATOR|3|placebo
61939921|NCT02460107|PLACEBO_COMPARATOR|Normal saline|Normal saline
61939922|NCT02460107|ACTIVE_COMPARATOR|Botulinum toxin type A 50U|Botulinum toxin 50U
61939923|NCT02460107|ACTIVE_COMPARATOR|Botulinum toxin type A 100U|Botulinum toxin 100U
62137526|NCT05074810|EXPERIMENTAL|avutometinib (VS-6766)+sotorasib+defactinib|To determine the recommended phase 2 dose (RP2D) for avutometinib (VS-6766) in combination with sotorasib and defactinib in KRAS G12C inhibitor exposed patients
62137527|NCT05074810|EXPERIMENTAL|avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients
62137528|NCT05074810|EXPERIMENTAL|avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients
62335233|NCT04848584||Unexposed to XBB.1.5|Unvaccinated with XBB.1.5-adapted monovalent vaccine or any other manufacturer's XBB-adapted formulation.
62492378|NCT05798884|SHAM_COMPARATOR|sham-acupuncture group|"For subjects assigned to the sham control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, and the stimulation will be a pseudo stimulation, which will be given by connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument.The credibility and validity of this system have been well demonstrated."
62492379|NCT01506349|EXPERIMENTAL|Crossover Group 1|"Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3."
62335234|NCT00941954|EXPERIMENTAL|Lifestyle counseling|A group-based structured educational programme.
62335235|NCT00941954|ACTIVE_COMPARATOR|Control|Written Information (booklet).
61939924|NCT06680700||Healthy volunteers|Healthy adult volunteers aged 18-50, who meet strict inclusion criteria to ensure safety and consistency in the results. Participants must be in good general health, with no history of respiratory, cardiovascular, or other systemic diseases that could pose additional risks during controlled desaturation. All participants are fully vaccinated for COVID-19, fluent in English, and capable of understanding and complying with the study procedures.
62335236|NCT04721015|EXPERIMENTAL|Part 1: ABBV-637 Monotherapy|Participants will receive escalating doses of ABBV-637 in 28-day cycles.
62492380|NCT01506349|EXPERIMENTAL|Crossover Group 2|"Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3."
62492381|NCT02155153|EXPERIMENTAL|Sugar Free Chewing Gum|All patients receiving sugar free gum
61939925|NCT05734495|EXPERIMENTAL|PIRTOBRUTINIB + VENETOCLAX|"Participants will receive:~* Standard of care bone marrow aspirate \& biopsy within 90 days of Cycle 1 Day 1.~* Computed Tomography (CT) scan of chest, pelvis \& abdomen within 90 days of Cycle 1 Day 1.~* Electrocardiogram at screening.~* Cycle 1~  * Electrocardiogram.~ * Day 1-28: Predetermined dose of Pirtobrutinib 1x daily.~* Cycle 2~  -Day 1-28: Predetermined dose Pirtobrutinib \& Venetoclax 1x daily. Tumor lysis syndrome (TLS) prophylaxis, predetermined dose Allopurinol at least 72 hrs prior to 1st administration of Venetoclax and dose escalation at Day 8 \& Day 15.~* Cycles 3-24~  * Day 1-28: Predetermined dose of Pirtobrutinib \& Venetoclax 1x daily.~ * Electrocardiogram: Cycles 3, 6, 9,12,15,18,21,24~ * CT scan of chest, pelvis \& abdomen: Cycles 7, 13, End of Treatment if extramedullary disease at baseline unresolved in previous CT scan~ * Standard of care bone marrow aspirate and biopsy: Cycles 7, 13, End of Treatment~* Follow up every 12 wks for 4 yrs."
62335237|NCT04721015|EXPERIMENTAL|Part 2a: ABBV-637 + Docetaxel|Participants will receive escalating doses of ABBV-637 in combination with docetaxel in 28-day cycles.
62335238|NCT04721015|EXPERIMENTAL|Part 2b: ABBV-637 + Docetaxel|Participants will receive ABBV-637 at dose determined in Part 2a in combination with docetaxel in 28-day cycles.
62335239|NCT04721015|EXPERIMENTAL|Part 3a: ABBV-637 + Osimertinib|Participants will receive escalating doses of ABBV-637 in combination with osimertinib in 28-day cycles.
62335240|NCT04721015|EXPERIMENTAL|Part 3b: ABBV-637 + Osimertinib|Participants will receive ABBV-637 at dose determined in Part 3a in combination with osimertinib in 28-day cycles.
62335241|NCT06336551|EXPERIMENTAL|Acceptance and Commitment Therapy for insomnia (ACT-I)|In this condition, participants receive five individual face-to-face 60-minute sessions of ACT-I psychotherapy within a 7-week treatment period.
62335242|NCT06336551|NO_INTERVENTION|Waitlist control|In this condition, participants fill out assessments only during a 7-week waiting period. After completing the post-assessment, participants in the control condition receive ACT-I treatment as well.
62335243|NCT01407497|ACTIVE_COMPARATOR|IA|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
62335244|NCT01407497|PLACEBO_COMPARATOR|IB|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
62335245|NCT01407497|ACTIVE_COMPARATOR|IIA|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
62492382|NCT02155153|NO_INTERVENTION|Control|Patients receiving no intervention
62695264|NCT06570486||test group|Used to validate the model
62335246|NCT01407497|PLACEBO_COMPARATOR|IIB|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
62335247|NCT03521687|EXPERIMENTAL|Apremilast|Patients with CCCA
62335248|NCT01389648|EXPERIMENTAL|Pre Operative|Pre operative chest physiotherapy treatment
62335249|NCT01389648|NO_INTERVENTION|usual care|
62335250|NCT01425073|EXPERIMENTAL|Stop TMP/SMZ|Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.
62335251|NCT01425073|NO_INTERVENTION|Standard of care TMP/SMZ prophylaxis|Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.
62335252|NCT04313361||Smokers or Recent Smoking Quitters who Have lung Surgery|The enrolled eligible participants, that is smokers or recent smoking quitters, will be assessed for the current smoking status and smoking cessation attempts during the perioperative period, to describe postoperative complications (PCs) including postoperative pulmonary complications (PPCs) following a lung surgery, and to describe the smoking cessation methods and services participants received from their health care professionals (HCPs) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (COPD), a pulmonary lesion (example nodule, ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in China.
62492383|NCT00627731|ACTIVE_COMPARATOR|1|mPSL 240 mg per day for 5 days
62695265|NCT06570486||Prospective cohort|For the prospective validation of the model
62695266|NCT06008795|ACTIVE_COMPARATOR|Group 1 - Active - Active|Subjects randomized to Group 1 will receive an active PPF nerve block in Stage 1 followed by an active PPF nerve block in Stage 2 of the Double-Blinded Trial Phase
62695267|NCT06008795|OTHER|Group 2 - Placebo - Active|Subjects randomized to Group 2 will receive a placebo PPF-injection in Stage 1 followed by an active PPF nerve block in Stage 2 of the Double-Blinded Trial Phase
62695268|NCT06008795|PLACEBO_COMPARATOR|Group 3 - Placebo - Placebo|Subjects randomized to Group 3 will receive a placebo PPF-injection in Stage 1 followed by a placebo PPF-injection in Stage 2 of the Double-Blinded Trial Phase
62335253|NCT01710111|EXPERIMENTAL|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
62335254|NCT01710111|NO_INTERVENTION|Control Recipients|No face shield and no repeat hand hygiene measures
62492384|NCT00627731|EXPERIMENTAL|2|PSL 40mg per day for 10 days
62492385|NCT00789464|OTHER|ARM A|Probiotics drops plus placebo elixir
62492386|NCT00789464|OTHER|ARM B|TMP/SMZ elixir plus placebo drops
62695269|NCT04606472|EXPERIMENTAL|Study treatment|Participants receive SI-B003 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62492387|NCT04461587|EXPERIMENTAL|Pirfenidone [Esbriet]|"Pirfenidone recommended daily dose for patients is 801 mg three times a day with food, for a total of 2403 mg/day. Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14day period as follows:~* Days 1 to 7: a dose of 267 mg administered three times a day (801 mg/day)~* Days 8 to 14: a dose of 534 mg administered three times a day (1602 mg/day)~* Day 15 onward: a dose of 801 mg administered three times a day (2403 mg/day) It will be provided in 267mg capsules. Treatment will be for a minimum of 12 months. Treatment duration will continue until last patient enrolled received 12 months of treatment."
61939926|NCT06223919|EXPERIMENTAL|Immediate vaccination|"This vaccin is a yellowish-yellow dry preparation containing live vaccinia virus (strain LC16m8). When the accompanying solvent is added, it dissolves rapidly to form a clear or slightly cloudy yellowish-red or reddish liquid. The ingredients of this vaccin are contained in 0.5 mL of a solution of this product dissolved in 0.5 mL of the accompanying solvent (20 vol% glycerin-added water for injection).~Just one dose of vaccine will be administered according to standardized operating procedure (SOP). Briefly, the vaccine is dissolved with 0.5 mL of a diluent provided. The reconstituted vaccine is usually administered percutaneously at a dose of approximately 0.025 mL by the multiple puncture technique using a bifurcated needle. The number of punctures will be 15 times. Procedures for vaccine administration are described in detail in the SOP. The participant must be observed at the vaccination site for 30 minutes after vaccine administration to observe possible immediate reactions."
61939927|NCT06223919|ACTIVE_COMPARATOR|Delayed vaccination|The use of placebo as a control group is essential to scientifically assess the efficacy of vaccines in clinical trials and to obtain reliable evidence in preventing the onset of disease. However, the use of a placebo is unethical. Subjects are at high risk of mpox and must not be given a placebo. Therefore, a design was applied in which the immediate treatment group was evaluated with the delayed group as a control group. A period of six weeks was set aside between the immediate and delayed treatment groups to be used for logistics, such as preparations and delivery of the vaccine in the delayed treatment group. It is ethical, for the same reason, because it prevents inequities based on the abovementioned reasons.
61939928|NCT05908110|EXPERIMENTAL|Health Communication Message|Parents will review a health communication message (infographic) informing them that their child has OSA symptoms, describing both nighttime and daytime OSA symptoms, and encouraging them to speak to their child's primary care provider at the scheduled visit if they observe symptoms in their child. Primary care providers will receive an alert that the child screened positive for OSA.
62335255|NCT05737173|EXPERIMENTAL|Leukocyte-rich platelet-rich plasma|Leukocyte-rich PRP: Centrifuge at 300 G for 5 min, separate the plasma and buffy coat layers, and then centrifuge at 700 G for 17 min with calcium chloride at the ratio of 1:5 to PRP by volume.
62335256|NCT05737173|EXPERIMENTAL|Leukocyte-poor platelet-rich plasma|Leukocyte-poor PRP: Centrifuge at 123 G for 15 min, separate the plasma and buffy coat layers, and then centrifuge at 448 G for 10 min. Calcium chloride was added 1:5 to PRP by volume.
62335257|NCT05737173|EXPERIMENTAL|Corticosteroid|Corticosteroid: 1 ml of triamcinolone acetonide (40mg/ml) mixed with 0.9% NaCl to a total volume of 4 ml.
62492388|NCT01707316|EXPERIMENTAL|Sequence 1: Treatment A-B-C|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
62492389|NCT01707316|EXPERIMENTAL|Sequence 2: Treatment B-C-A|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
62492390|NCT01707316|EXPERIMENTAL|Sequence 3: Treatment C-A-B|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
62492391|NCT03181620|NO_INTERVENTION|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
62492392|NCT03181620|EXPERIMENTAL|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
62492393|NCT03773653|EXPERIMENTAL|BMT to be combined with BAT|Participants in this group will receive bilateral robotic priming and bilateral arm training or mirror therapy within the 90-minute training sessions.
62695270|NCT03449576|EXPERIMENTAL|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
62335258|NCT05792670|ACTIVE_COMPARATOR|Standard Ventilatation Mode|SV mode is defined according to the mechanical ventilator parameters (patients' age and weight) Standard ventilation mode is defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters
62335259|NCT05792670|ACTIVE_COMPARATOR|High Ventilatation Mode|Hv mode is defined as the tidal volume decreased to 6-8 mL/kg and the frequency is increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters
61939929|NCT05908110|NO_INTERVENTION|Usual Care|Like in the intervention group, parents will complete screening items and primary care providers will receive an alert if the child screens positive for OSA. However, parents randomized to this condition will not view the health communication message nor receive any information about OSA or their child's risk for OSA.
62335260|NCT05096871||Group I|patients with epilepsy
62695271|NCT03449576|ACTIVE_COMPARATOR|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
62335261|NCT05096871||Group II|apparently healthy controls with no chronic illness of matched age and sex
62335262|NCT00796601|EXPERIMENTAL|Esreboxetine|
62335263|NCT00796601|PLACEBO_COMPARATOR|Placebo|
62335264|NCT00084916|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62335265|NCT05213468|EXPERIMENTAL|Self management app as add on to standard care|PainDrainerTM App as add on to standard treatment at the physiotherapy program at the clinic PainDrainer software application: PainDrainerTM app (version 1.1.19c). ' The PainDrainer app is an investigational device, intended as a digital aid for the self-management of chronic pain for use by adults without supervision by healthcare professionals in a home setting.
62335266|NCT05213468|NO_INTERVENTION|Standard of care|Treatment as usual, standard treatment of care at the physiotherapy program at the clinic
62335267|NCT01418664|ACTIVE_COMPARATOR|Study group|Each woman in above group will recieve in addition to routine ferrous sulphate and calcium lactate, 4000IU of vitamin D
62335268|NCT01418664|NO_INTERVENTION|control group|Women in this group will recieve ferrous sulphate and calcium lactate
62492394|NCT03773653|EXPERIMENTAL|BMT to be combined with MT|Participants in this group will receive bilateral robotic priming and mirror therapy within the 90-minute training sessions.
62492395|NCT03773653|ACTIVE_COMPARATOR|BMT to be combined with IOT|Participants in this group will receive bilateral robotic priming and impairment-oriented training within one 90-minute training session.
62492396|NCT06389227|EXPERIMENTAL|dynamic-ecological approach (DEA)|The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach
61939930|NCT01578421|OTHER|FX 100 dialyzer|
61939931|NCT01578421|OTHER|Polyflux 210 H dialyzer|
61939932|NCT01578421|OTHER|FXCorDiax 100 dialyzer|
61939933|NCT06332859|EXPERIMENTAL|TakoTsubo|Individuals with TakoTsubo cardiomyopathy who participate in an inpatient rehabilitation programme receive an additional psychological intervention, specifically resilience training. This is not a common practice in such rehabilitation programmes.
61939934|NCT06332859|EXPERIMENTAL|Acute coronary event|Individuals after an acute coronary event who participate in an inpatient rehabilitation programme receive an additional psychological intervention, specifically resilience training. This is not a common practice in such rehabilitation programmes.
61939935|NCT06478706|EXPERIMENTAL|Part A - 7 day treatment period - parallel group|Twice daily doses of ETD001/placebo for 6 days, single dose on Day 7
61939936|NCT06478706|EXPERIMENTAL|Part B - 2 x 28 day treatment period - crossover|Two treatment periods of twice daily doses of ETD001/placebo for 27 days, single dose on Day 28 separated by a period of 28 days
61939937|NCT06474325|EXPERIMENTAL|Intervention via mobile app|Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
61939938|NCT03023462|ACTIVE_COMPARATOR|Transmuscular Quadratus lumborum Block|A single shot unilateral transmuscular Quadratus lumborum Block with Ropivacaine 7,5 mg/ml, 20 ml
61939939|NCT03023462|ACTIVE_COMPARATOR|TAP Block|A single shot unilateral TAP block with Ropivacaine 7,5 mg/ml, 20 ml
61939940|NCT01210131|EXPERIMENTAL|[18F]HX4|
61939941|NCT03532958|PLACEBO_COMPARATOR|Placebo|Normal saline
61939942|NCT03532958|EXPERIMENTAL|Low Dose BNZ-1|0.5 mg/kg QW
61939943|NCT03532958|EXPERIMENTAL|Moderate Dose BNZ-1|2 mg/kg QW
61939944|NCT03189485||Normal Controls and MCI|All subjects will receive 18F-AV-1451 PET scan.
61939945|NCT03521427|EXPERIMENTAL|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
62335269|NCT04393584|EXPERIMENTAL|FOLFIRINOX|Irinotecan 180mg/m2 d1, d1-2 5-FU 2450 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
62492397|NCT06389227|ACTIVE_COMPARATOR|traditional training group (TTG)|TTG followed a traditional soccer training program for the same period and number of ses-sions without any intervention attributable to the dynamic ecological approach
62492398|NCT03118063|EXPERIMENTAL|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
62492399|NCT03118063|ACTIVE_COMPARATOR|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
62492400|NCT03118063|ACTIVE_COMPARATOR|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
62492401|NCT04233060|EXPERIMENTAL|CS3005|
62492402|NCT04865471|EXPERIMENTAL|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
62492403|NCT04948619|OTHER|Arm A - Single booster vaccines|Those subjects randomized to Arm A, single dose vaccine boosters, will receive non live vaccine boosters at the 3 month visit. Boosters for live vaccines will be given at the 6 month visit. Boosters will only be given as applicable for low titers tested at the baseline assessment visit. Subjects who have negative/undetectable titers to any vaccine at the 24 month visit will receive boosters to each applicable vaccine.
61939946|NCT03521427|ACTIVE_COMPARATOR|Neurodevelopmental treatment|Ninety hours of intensive neurodevelopmental therapy
61939947|NCT05423054|EXPERIMENTAL|abdominal massage group|"* Patients will be positioned on their back while their knees will be flexed.~* Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~* The PR will be standed on the right side of the patient during the massage practice.~* The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
61939948|NCT05423054|NO_INTERVENTION|Control group|The Control group will receive routine care in the intensive care unit
61939949|NCT05898659|ACTIVE_COMPARATOR|ABFnoS then ABFS|Cochlear Implant with ABFnoS first during 6 weeks then with ABFS during 6 weeks
61939950|NCT05898659|ACTIVE_COMPARATOR|ABFS then ABFnoS|Cochlear Implant with ABFS first during 6 weeks then with ABFnoS during 6 weeks
61939951|NCT06512597|EXPERIMENTAL|Primary Intervention for Combination Therapy - IBD Coping Strategies Program|This 7-session protocol is based on Dr. Keefer's validated Project Management for Crohn's disease treatment manual. The program specifically focuses on reducing stress, building resilience, fostering self-confidence and disease acceptance, all of which have been associated with improved adjustment to disease and better self-management outcomes in CD.
61939952|NCT06512597|SHAM_COMPARATOR|Time and Attention Control Group - IBD Support Program (Standard Therapy)|This 7-session condition will serve as a Time and Attention Control to the Coping Strategies Program. The therapist will follow Dr. Keefer's previously validated control condition manual focused on supportive listening, disease education and self-reflection.
61939953|NCT00920933|EXPERIMENTAL|AIN457|
61939954|NCT00920933|PLACEBO_COMPARATOR|Placebo|
61939955|NCT00920933|ACTIVE_COMPARATOR|oral corticosteroid|
61939956|NCT02919371|EXPERIMENTAL|Sunitinib and Bevacizumab Arm|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab
61939957|NCT01076231|EXPERIMENTAL|Arm I|"Patients undergo proton beam radiotherapy over 5.5-7.5 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and days 29-33.Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 4-6 weeks after completion of chemoradiotherapy, patients may undergo surgical resection or additional chemoradiotherapy."
61939958|NCT03445520|NO_INTERVENTION|Transition Passport Comparison Group|This group will only receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide.
61939959|NCT03445520|EXPERIMENTAL|Intervention Coaching Group|This group will also receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide. This group will also receive coaching support to implement these resources. The coach will be a member of the research team who will introduce the resources to the family, briefly teach them fundamental information about the transition process, provide brief coaching phone calls, and help parents identify an appropriate person at the school or district who can work with them to complete the Student Snapshot. This group will also use ParentSquare to enhance and encourage communication between parent and members of the child's school team.
61939960|NCT02090075|ACTIVE_COMPARATOR|apixaban|apixaban 5 mg or 2.5 mg po bid
61939961|NCT02090075|PLACEBO_COMPARATOR|warfarin|warfarin with target INR of 2-3
61939962|NCT04858256|EXPERIMENTAL|Cohort 1: PTCL, NOS|Patients will receive single agent pacritinib.
61939963|NCT04858256|EXPERIMENTAL|Cohort 2: AITL/TFH PTCL|Patients will receive single agent pacritinib.
61939964|NCT04858256|EXPERIMENTAL|Cohort 3: CTCL (MF/SS)|Patients will receive single agent pacritinib.
62492404|NCT04948619|OTHER|Arm B - Staged revaccination series|Those subjects randomized to Arm B, the full revaccination series, will receive applicable vaccines when titers are low (below normal range) at baseline. When indicated, non-live vaccines will be given at the 3, 6, and 9 month visits, live vaccines will be given at the 6 and 9 month visit. Subjects who have negative/undetectable titers to any vaccine at the 24 month visit will receive boosters to each applicable vaccine.
62492405|NCT03433404|EXPERIMENTAL|Soft Tissue Mobilization|The arm will utilize a Physical Therapy technique call soft tissue mobilization.
62492406|NCT03433404|ACTIVE_COMPARATOR|Soft Tissue Massage|This arm will utilize standard soft tissue massage applied to the low back in pregnant patients complaining of third trimester low back pain.
62492407|NCT03433404|NO_INTERVENTION|No manual treatment|Group will still receive acetaminophen, heating pad application, and/or rest which is standard of care.
61939965|NCT04858256|EXPERIMENTAL|Cohort 4: Less common PTCL subtypes|Patients will receive single agent pacritinib.
61939966|NCT03277157|EXPERIMENTAL|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
61939967|NCT03277157|PLACEBO_COMPARATOR|Placebo|Placebo veggie capsule.
61939968|NCT06626360||Patients with overweight or obesity|"Inclusion criteria:~* Age 18 years or older~* Overweight (BMI of 25 kg/m² or higher)~Exclusion criteria:~* Physically or mentally unable to participate.~* Severe cognitive disorder or severe emotional instability, as assessed by the attending nurse or physician.~* Insufficient proficiency in the Dutch language to express themselves properly and no interpreter or assistant to help.~* Patient resides in a nursing or care home."
61939969|NCT03537612|EXPERIMENTAL|Opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
61939970|NCT03537612|EXPERIMENTAL|Sub-opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
61939971|NCT03537612|ACTIVE_COMPARATOR|Opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
61939972|NCT03537612|ACTIVE_COMPARATOR|Sub-opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
61939973|NCT03561753|ACTIVE_COMPARATOR|Group A (the standard 2HRZE/4HR regimen)|Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
62335270|NCT04393584|ACTIVE_COMPARATOR|FLOT|d1 Docetaxel 50mg/m2, d1-2 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m² every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
62492408|NCT05430815|EXPERIMENTAL|Enhanced Postpartum Care System|Women with a documented diagnosis of chronic diabetes, chronic hypertension, gestational diabetes, hypertensive disorder of pregnancy (gestational hypertension or preeclampsia), or pre-pregnancy obesity who are randomized to receive enhanced postpartum care.
62492409|NCT05430815|NO_INTERVENTION|Standard of Care|Women with a documented diagnosis of chronic diabetes, chronic hypertension, gestational diabetes, or hypertensive disorder of pregnancy (gestational hypertension or preeclampsia), or pre-pregnancy obesity who are randomized to receive standard postpartum care.
61939974|NCT03561753|EXPERIMENTAL|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|Group B, PRS Regimen (4EZ \[high dose\] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
62492410|NCT01799850|ACTIVE_COMPARATOR|Actos|Actos 30 mg daily
62492411|NCT01799850|PLACEBO_COMPARATOR|placebo|double blind placebo controlled
62492412|NCT02369458|EXPERIMENTAL|Cohort A: p16+ OPSCC|"* Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).~* Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
61939975|NCT03059433||AVID Intervention|175 students will be randomized via lottery by the participating high school to be part of the AVID program. These students will receive 4 surveys (8th, 9th, 10th, and 11th grade).
61939976|NCT03059433||Non AVID|175 students will be randomized via lottery by the participating high school to be part of our control group. This group of students will be similar to the AVID group, except they will not be in the AVID program. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
61939977|NCT03059433||High Performing|175 students who are identified as high performing (middle school grade point average \>3.5) by the participating high school. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
61939978|NCT05080868||Infantile hemangioma with minimal or arrested growth|Epidemiological and clinical characteristics of infantile hemangioma with minimal or arrested growth.
61939979|NCT05080868||Classic infantile hemangioma|Epidemiological and clinical characteristics of classic infantile hemangioma.
61939980|NCT06077448||cases|patients with migraine (migraineurs)
61939981|NCT06077448||controls|healthy individuals
61939982|NCT04836312|NO_INTERVENTION|Attention Control|Patients will be instructed via text message and email to fast at least 16 hours per day every day. For the next 18 weeks, they will receive a daily text message via the Way to Health platform asking if they fasted for at least 16 hours over the past 24 hours. If they fail to respond, reminder text messages will be sent. Once per week, they will receive a text message asking them to weigh themselves and check their blood pressure, and reply with the results via text message
61939983|NCT04836312|EXPERIMENTAL|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
61939984|NCT02661685|EXPERIMENTAL|autologous IKDC-like cell|Received autologous IKDC-like cells
61939985|NCT05536479|EXPERIMENTAL|Autogenous stored mineralized dentin graft (ASMDG)|Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction
61939986|NCT05536479|ACTIVE_COMPARATOR|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze
61939987|NCT02664610|NO_INTERVENTION|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
61939988|NCT02664610|EXPERIMENTAL|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
61939989|NCT02730689|EXPERIMENTAL|A group|DP-R207 \>\> rosuvastatin+ezetimibe
62137529|NCT06121479|EXPERIMENTAL|branched-chain amino acid|Oral branched-chain amino acid (BCAA) is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
62137530|NCT05166577|EXPERIMENTAL|Nanatinostat in combination with valganciclovir|
62137531|NCT05166577|EXPERIMENTAL|Nanatinostat in combination with valganciclovir and pembrolizumab|
62137532|NCT03702777|EXPERIMENTAL|ASP8302 100mg|Participants will receive ASP8302 100mg capsules orally once daily for up to 4 weeks.
62137533|NCT03702777|PLACEBO_COMPARATOR|Placebo|Participants will receive ASP8302 matching placebo orally once daily for up to 4 weeks.
62492413|NCT02369458|EXPERIMENTAL|Cohort 2: p16- HNSCC|"* Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).~* Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
62492414|NCT04720547|EXPERIMENTAL|Zolpidem, then No Treatment|Participants will be administered zolpidem for the first night study, and No Treatment during the second night study.
61939990|NCT02730689|ACTIVE_COMPARATOR|B group|rosuvastatin+ezetimibe \>\> DP-R207
61939991|NCT01387802||Non-Biologic arm|Patients that have not responded to the current treatment with an NSAID (Nonsteroidal Anti-Inflammatory Drug) and/or non - biologic DMARD (Disease-Modifying Anti Rheumatic Drug) for peripheral joint involvement and switch to or addition of another NSAID /DMARDS
61939992|NCT01387802||Biologic arm|Patients that have not responded to the current treatment with non biologic DMARDS (Disease-Modifying Anti Rheumatic Drug) /NSAID (Nonsteroidal Anti-Inflammatory Drug) and switch to or addition of adalimumab
61939993|NCT06293131|EXPERIMENTAL|ciprofol-assisted sedation 1|Adjusting the dose of ciprofol-assisted sedation in knee arthroplasty on a case-by-case basis
61939994|NCT03095833|OTHER|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
62137534|NCT03927196|EXPERIMENTAL|extended statin counseling group|Extended statins counseling. Patients are handed out information leaflets on the correction of risk factors, SMS reminders.
62137535|NCT03927196|NO_INTERVENTION|convetional statin counseling group|Сounseling on the prevention of cardiovascular diseases and the use of drugs for this purpose
62492415|NCT04720547|EXPERIMENTAL|No Treatment, then Zolpidem|Participants will be administered zolpidem for the second night study, and No Treatment during the first night study.
62492416|NCT06348979|EXPERIMENTAL|Hybrid Nano-ceramic (Grandio) CAD/CAM Endocrowns|Adding of short fiber reinforced flowable resin composite material (everX Flow, GC Europe) as a supporting base under CAD/CAM resin composite endocrowns
62335271|NCT03072121|EXPERIMENTAL|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months \& Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
62492417|NCT06348979|ACTIVE_COMPARATOR|Lithium Disilicate (e.max) Endocrowns|Lithium Disilicate (e.max) Endocrowns
61939995|NCT03095833|OTHER|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
61939996|NCT00622973|OTHER|A|Diffusion-weighted MRI
61939997|NCT00622973|OTHER|B|Sinerem (USPIO)- enhanced MRI
61939998|NCT01440452|EXPERIMENTAL|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
61939999|NCT01440452|EXPERIMENTAL|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
61940000|NCT01440452|EXPERIMENTAL|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
61940001|NCT01440452|EXPERIMENTAL|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
61940002|NCT04693117|EXPERIMENTAL|Study Group|Participants were voluntarily participated by non-probability consecutive sampling. It was a one group study with a limitation of non-randomization. The interventional group had performed interval training for 12 weeks, 3 days/week (figure 1). They sedentary conferring to activity level (≥ 30-minute, 3 days/weeks, moderate-intensity physical activity). They were not participated in any interval training program before participating in the study from six months. Written consent was taken after demonstration of the purpose, procedure, and related pros and cons. They were instructed to participate regularly in interval training.
61940003|NCT04224389||Radiotherapy|IMRT on the primitive site and the lymph nodes. +/- Concomitant chemotherapy at the discretion of the meeting multidisciplinary
61940004|NCT04224389||Surgery|transoral resection of the primary tumor, with cervical lymph node dissection. Radiotherapy complementary according to the histological criteria of severity
61940005|NCT06335134|EXPERIMENTAL|Trial Group 1: Metformin and Warfarin administered before and with XW003 treatment|Metformin will be dosed twice daily (0.5 mg per dose) in two periods of 3.5 days for a total of 7 doses before and with XW003 treatment. Single doses of warfarin (2.5 mg per dose) will be given before and with XW003 treatment. The two drugs will be separated by a washout. XW003 will be administered subcutaneously once weekly in escalating doses of 0.3 mg for 4 weeks, 0.6 mg for 4 weeks and 1.2 mg for 4 weeks.
61940006|NCT06335134|EXPERIMENTAL|Trial Group 2: Rosuvastatin and Digoxin administered before and with XW003 treatment|Single doses of rosuvastatin (10 mg per dose) and digoxin (0.25 mg per dose) will be given before and with XW003 treatment. The two drugs will be separated by a washout. XW003 will be administered subcutaneously once weekly in escalating doses of 0.3 mg for 4 weeks, 0.6 mg for 4 weeks and 1.2 mg for 4 weeks.
61940007|NCT04336358|NO_INTERVENTION|Standard Early medical abortion care|Counseling, history, instruction, family planning with clinic nurse. Ultrasound to assess gestational age.
61940008|NCT04336358|EXPERIMENTAL|Telemedicine|Online consultation questionnaire and counseling, family planning information. Instruction for the abortion received to the participants Facebook Messenger. Gestational age \<9 weeks assessed by bimanual palpation, ultrasound only in case of uncertainty.
61940009|NCT01824342|EXPERIMENTAL|Denosumab|Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.
61940010|NCT04410029|EXPERIMENTAL|Intervention|Standard counseling + Healthwise Decision Aid
61940011|NCT04410029|ACTIVE_COMPARATOR|Control|Standard counseling + a control informational handout.
61940012|NCT03714308||Patients with nAMD_Treatment-naive (anti-VEGF naive)|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
61940013|NCT03714308||Patients with nAMD_Pre-treated with IVT-AFL|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
61940014|NCT03714308||Patients with nAMD_Pre-treated with any anti-VEGF|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
61940015|NCT00550849|EXPERIMENTAL|1|RTA 402
61940016|NCT00550849|EXPERIMENTAL|2|RTA 402
61940017|NCT00550849|EXPERIMENTAL|3|RTA 402
61940018|NCT02058173|EXPERIMENTAL|chloroquine|150 mg chloroquine and lacebo , one tablet daily for 2 month
61940019|NCT02058173|EXPERIMENTAL|placebo|150 mg chloroquine and lacebo , one tablet daily for 2 month
62492418|NCT04988438||esophageal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (Chicago 3 score)."
62492419|NCT04988438||anorectal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (London protocol)."
62492420|NCT00198133|EXPERIMENTAL|Pemetrexed|Pemetrexed infusion once every 21 days (one cycle).
61940020|NCT00471146|EXPERIMENTAL|A|
61940021|NCT00471146|ACTIVE_COMPARATOR|B|
61940022|NCT04741607|ACTIVE_COMPARATOR|Control group|Delayed implant placement
61940023|NCT04741607|EXPERIMENTAL|Test group|Immediate implant placement
61940024|NCT02592122|ACTIVE_COMPARATOR|Atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Second, randomly selected into the atomization group
62492421|NCT05535998||Combined therapy group (TACE-HAIC combined with TKIs and PD-1 inhibitors)|Patients recieve combined with TKIs and PD-1 inhibitors
61940025|NCT02592122|ACTIVE_COMPARATOR|Without atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Secondly, the random selection is not the atomization group
61940026|NCT02066220|EXPERIMENTAL|PNET 5 MB-LR (low-risk)|Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.
61940027|NCT02066220|EXPERIMENTAL|PNET 5 MB-SR (standard-risk)|"Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.~Total treatment duration is 48 weeks."
61940028|NCT02066220|EXPERIMENTAL|PNET 5 MB WNT-HR|"Radiotherapy adapted to age and metastatic Status and maintenance chemotherapy adapted to age.~Total treatment duration is 39 to 48 weeks."
61940029|NCT02066220|EXPERIMENTAL|PNET 5 MB SHH-TP53|"Reduced chemotherapy with Doxorubicin, VCR, HD-MTX, Carboplatin, and MTX intraventricularly Stratification of radiotherapy according to~* presence of metastasis~* germline mutation in TP53 (including mosaicism) Maintenance chemotherapy with VBL Total treatment duration is 1 year"
61940030|NCT04357782|ACTIVE_COMPARATOR|Mild hypoxemia|S/F ratio \>250 prior to Vitamin C infusion
61940031|NCT04357782|ACTIVE_COMPARATOR|Severe Hypoxemia|S/F ratio ≤250 prior to Vitamin C infusion
62335272|NCT03072121|PLACEBO_COMPARATOR|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months \& Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
61940032|NCT02662634|EXPERIMENTAL|Sequential, no radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G)."
61940033|NCT02662634|EXPERIMENTAL|Concurrent, no radiation|"AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy \& radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G)."
61940034|NCT02662634|EXPERIMENTAL|Sequential, radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G).~Radiation therapy per PI"
61940035|NCT02662634|EXPERIMENTAL|Concurrent, radiation|"AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy \& radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy choice of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G).~Radiation therapy per PI."
61940036|NCT02524093|EXPERIMENTAL|Intervention|Participants in this arm will be given the Positive Mental Training programme. This consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly the participant needs to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
61940037|NCT02524093|PLACEBO_COMPARATOR|Control|Will receive treatment as usual for 12 weeks, when will be asked to complete rating scales again. They will then be given the Positive Mental Training programme.
61940038|NCT00561769||A|poor responder
62335273|NCT02804880|EXPERIMENTAL|Group A|HAR + AWARD + Referral Card + A4 leaflet
62335274|NCT02804880|EXPERIMENTAL|Group B|LTM + AWARD + Referral Card + A4 leaflet
62335275|NCT02804880|ACTIVE_COMPARATOR|Group C|Brief advice + 12-page booklet
62335276|NCT04740268|OTHER|Patiant without treatment|Non-Randomized patients with atrophic acne skin conditions
62492422|NCT05535998||TACE alone group|TACE alone
61940039|NCT04637646||children with MPS|
61940040|NCT01309165|EXPERIMENTAL|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
61940041|NCT01309165|ACTIVE_COMPARATOR|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
61940042|NCT04434066|EXPERIMENTAL|Abdominal Morcellation|Abdominal morcellation will occur following completion of the hysterectomy. Route of incision will be either suprapubic or umbilical incision - based on surgeon preferences. All steps and instruments have been standardized for abdominal morcellation.
61940043|NCT04434066|EXPERIMENTAL|Vaginal Morcellation|Vaginal morcellation will occur following completion of the hysterectomy. All steps and instruments have been standardized for vaginal morcellation.
61940044|NCT06288009|EXPERIMENTAL|Layered Closure with Running Locking Suture on Side A|For all participants, one wound side half will be labeled as A and the other side as B. The bottom (subcutaneous) layer of the entire wound will receive the normal stitching. For the upper (cutaneous) layer, Side A will be closed with a running locking suture, and Side B will be closed with a standard running suture.
61940045|NCT06288009|EXPERIMENTAL|Layered Closure with Running Locking Suture on Side B|For all participants, one wound side half will be labeled as A and the other side as B. The bottom (subcutaneous) layer of the entire wound will receive the normal stitching. For the upper (cutaneous) layer, Side B will be closed with a running locking suture, and Side A will be closed with a standard running suture.
61940046|NCT05209178|EXPERIMENTAL|Self-collection of specimen|Participants allocated to this arm will perform specimen collection for the antigen tests independently using written instructions and access to a video. Sampling is performed as two individual procedures from the anterior part of the nose and the oropharynx respectively.
61940047|NCT05209178|ACTIVE_COMPARATOR|Healthcare-collection of specimen|Participants allocated to this arm will initially have specimen collection for the antigen tests done by a healthcare personnel. Sampling is performed as two individual procedures from the anterior part of the nose and the oropharynx respectively.
62335277|NCT04740268|OTHER|Straberi Microneedling Treatment|Non-Randomized treatment for patients with atrophic acne skin conditions using the Straberi Microneedling device.
62335278|NCT03785886|EXPERIMENTAL|Walking group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
62335279|NCT03785886|EXPERIMENTAL|Chinese Square Dancing group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
62738424|NCT01101282|NO_INTERVENTION|'Usual care'|"Participants will receive 'usual medical care' consisting of the following:~* Medical management: Bronchodilators, corticosteroids, antibiotics and supplemental oxygen will be provided (where appropriate) in accordance with Australian and New Zealand COPD management guidelines (COPDX guidelines).~* Non-invasive ventilation: if clinically indicated and prescribed in accordance with standardised hospital guidelines.~* Physical rehabilitation: Participants will be assessed by a physiotherapist and prescribed appropriate exercises to facilitate a safe and timely discharge. Participants will perform physical rehabilitation according to a standardised protocol with an aim of maximising physical function at discharge.~* Other allied health (e.g. occupational therapy, speech pathology, dietician) assessments and interventions, as required."
61940048|NCT05570877|EXPERIMENTAL|Active group|Active group will apply ChitoCare medical Wound Healing Gel to the wound in addition to standard of care.
61940049|NCT05570877|NO_INTERVENTION|Control group|Control group will only administer standard of care to treat their wounds.
62137536|NCT00936416|EXPERIMENTAL|GFR and RBF followed by MRI|Subjects will undergo GFR and renal blood flow estimation by Inulin and PAH clearance method, followed by a MRI test. The MRI examination will be performed on the same day as the inulin/PAH procedure.
62137537|NCT04255693|EXPERIMENTAL|Change in disease manifestations|The data of all the patients will be assessed from the viewpoint of changes in the disease flow (severity and frequency of symptoms, grade of oesophagitis). They will be compared to the changes of the major factors that could influence the disease flow: adherence to anti-secretory agents, presence of concomitant medications and their doses, adherence to diet, change in physical activity. These will be compared to the initial data. Thus, it would be possible to make a multivariate comparison and try to establish the influence (and, possibly, weight) of each of the con-founder on the disease flow.
62137538|NCT04255693|ACTIVE_COMPARATOR|No change in disease flow|"To this arm patients with no change in the disease manifestations will be assigned, based on the end-point evaluation. The same as in the experimental groups factors will be analysed to establish the difference."
62335280|NCT03785886|EXPERIMENTAL|Control group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
62335281|NCT02087384|EXPERIMENTAL|Gardasil|Gardasil
62335282|NCT02087384|PLACEBO_COMPARATOR|Placebo|Intramuscular Saline 0.9% vaccination at 0, 2 and 6 months
62335283|NCT01944969|EXPERIMENTAL|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
61940050|NCT01783054|EXPERIMENTAL|chemotherapy, surgery, genetic expression|"All patients enrolled on study will start study treatment on a chemotherapy treatment regimen of Gemcitabine and abraxane. Treatment will be given on days 1, 8 and 15 of each cycle for 2 cycles over the course of 12 weeks.~Patients will move on to surgery, 4-8 weeks after chemotherapy treatment. Patients must be recovered from any adverse effects of the chemotherapy before proceeding with surgery.~As part of this study, tissue samples will be collect from each patient at the time of surgery for gene expression testing"
61940051|NCT03042325|EXPERIMENTAL|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance \[CrCl\].
61940052|NCT04636151|EXPERIMENTAL|Individual Treatment|Participants will have up to three individual sessions with a study therapist. One or more treatment modules will be presented in each session.
61940053|NCT04636151|EXPERIMENTAL|Group Treatment|Participants will have up to three group sessions with a study therapist. One or more treatment modules will be presented in each session.
61940054|NCT04636151|EXPERIMENTAL|Workshops|Participants will have one workshop with a study therapist. All three treatment modules will be presented in one session.
61940055|NCT03369470|EXPERIMENTAL|App Dexterity|
62137539|NCT05212298|PLACEBO_COMPARATOR|Control|receive placebo treatment, once a day, four pills each time.
62335284|NCT00382980|EXPERIMENTAL|7.5-|7.5 mcg of vaccine without adjuvant administered on Days 0 and 28.
62335285|NCT00382980|EXPERIMENTAL|45-|45 mcg of vaccine without adjuvant administered on Days 0 and 28.
62335286|NCT00382980|PLACEBO_COMPARATOR|Placebo|Placebo administered on Days 0 and 28.
62335287|NCT00382980|EXPERIMENTAL|15+|15 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
62335288|NCT00382980|EXPERIMENTAL|7.5+|7.5 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
61940056|NCT03369470|ACTIVE_COMPARATOR|Theraband|
61940057|NCT00968318|OTHER|Rate of seroma formation|Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion
61940058|NCT01481181|EXPERIMENTAL|zinc enriched water|zinc enriched purified water at 2-6mg/l per day
61940059|NCT01481181|NO_INTERVENTION|purified water only|non zinc enriched, purified drinking water
61940060|NCT01481181|NO_INTERVENTION|control group|group of households receiving hygiene practice recommendations and water guard (water purifying solution)
61940061|NCT01529684|EXPERIMENTAL|OSI-906|"Two Parts:~Part A: 14C-labeled OSI-906~Part B: (Optional) OSI-906 (non-labeled)"
61940062|NCT02025166|ACTIVE_COMPARATOR|Paracetamol|Pain treatment, aniline analgesics
61940063|NCT02025166|ACTIVE_COMPARATOR|lornoxicam|Pain treatment, nonsteroidal anti-inflammatory (NSAID)
62335289|NCT00382980|EXPERIMENTAL|15-|15 mcg of vaccine without adjuvant administered on Days 0 and 28.
62335290|NCT03284294|PLACEBO_COMPARATOR|Placebo|Oral placebo daily for 8 weeks
62335291|NCT03284294|ACTIVE_COMPARATOR|Vitamin D|Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
62335292|NCT03698513|EXPERIMENTAL|BMS-986177 + Aspirin + Clopidogrel (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
62335293|NCT03698513|EXPERIMENTAL|BMS-986177 (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5)
62335294|NCT03698513|PLACEBO_COMPARATOR|BMS-986177 placebo + Aspirin + Clopidogrel (Part 1)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)
62335295|NCT03698513|EXPERIMENTAL|BMS-986177 (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5)
61940064|NCT03587948||Case group|Children and adolescents with diabetes mellitus
61940065|NCT03587948||Control group|Children and adolescents without diabetes mellitus
61940066|NCT02165709|EXPERIMENTAL|Salpingectomy|Participants will be offered a risk-reducing salpingectomy, and if they choose this options the surgeon will proceed with a salpingectomy.
61940067|NCT02165709|ACTIVE_COMPARATOR|Traditional sterilization|Participants will be offered a risk-reducing salpingectomy, and those that choose a traditional sterilization will be in this treatment arm.
61940068|NCT04937855||Control group|25 gender and age matching healthy controls
61940069|NCT04937855||ARDS group 1|100 ARDS patients at the time of check in hospital
61940070|NCT04937855||ARDS group 2|100 ARDS patients at the time of 24h after check in hospital
61940071|NCT04937855||ARDS group 3|100 ARDS patients at the time of 48h after check in hospital
61940072|NCT04937855||ARDS group 4|100 ARDS patients at the time of 72h after check in hospital
61940073|NCT04423783|EXPERIMENTAL|Spider gamification app|Participants play the spider gamification app twice a day for 7 days
61940074|NCT04423783|EXPERIMENTAL|Online exposure + spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play the spider gamification app twice a day for 7 days
62137540|NCT05212298|EXPERIMENTAL|Herbal compound low-dose|once a day, two herbal compound capsules and two placebos each time. The total amount of herbal compound capsules is 557 mg.
62137541|NCT05212298|EXPERIMENTAL|Herbal compound high-dose|once a day, four capsules each time. The total amount of herbal compound capsules is 1114 mg.
62335296|NCT03698513|PLACEBO_COMPARATOR|BMS-986177 placebo + Clopidogrel (Part 2)|BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
62335297|NCT03698513|EXPERIMENTAL|BMS-986177 + Clopidogrel (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
62335298|NCT03698513|EXPERIMENTAL|BMS-986177 (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5)
62335299|NCT03698513|PLACEBO_COMPARATOR|BMS-986177 placebo + Aspirin (Part 3)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
62335300|NCT03698513|EXPERIMENTAL|BMS-986177 + Aspirin (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
62335301|NCT01465711||Control|Admission to the Intensive Care Unit (ICU) after abdominal surgery without suspicion / evidence of peritonitis.
62492423|NCT04840927|EXPERIMENTAL|Cohort 1: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 1: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 2: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 3: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
62492424|NCT04840927|EXPERIMENTAL|Cohort 2: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 4: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 5: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 6: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
62492425|NCT04392596|EXPERIMENTAL|patients|40
62492426|NCT00032227|EXPERIMENTAL|1|Surgical release of CTS
62492427|NCT00032227|ACTIVE_COMPARATOR|2|Non-surgical treatment for CTS (splint, physical therapy, ultrasound)
62492428|NCT03672916||Patients who received the Allofit IT with BIOLOX delta|Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the BIOLOX delta Taper Liners
62492429|NCT05953987|EXPERIMENTAL|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
62492430|NCT05953987|EXPERIMENTAL|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
62492431|NCT05953987|OTHER|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
62492432|NCT05452213|EXPERIMENTAL|Ribociclib|
62492433|NCT05962164|EXPERIMENTAL|Passive Heat Therapy|Patients with COPD assigned to passive heat therapy will have their lower legs immersed in a circulating hot water (\~42°C) footbath for 45 min per session.
61940075|NCT04423783|ACTIVE_COMPARATOR|Online exposure + non-spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play a non-spider gamification app twice a day for 7 days
62335302|NCT01465711||Peritonitis|Admission to the Intensive Care Unit (ICU) after abdominal surgery with suspicion / evidence of peritonitis
62335303|NCT01725152|EXPERIMENTAL|Ganaxolone then Placebo|Participants first received ganaxolone. They were first titrated up to the 12 milligram per kilogram (mg/kg) three times daily (tid) during a 2-week titration phase, then maintained on that dose for an additional 4 weeks. After a washout period of 2 weeks, participants received placebo for a duration of 6 weeks (from week 8 to 14).
62335304|NCT01725152|EXPERIMENTAL|Placebo then Ganaxolone|Participants first received placebo. They were first titrated up to the 12 mg/kg tid during a 2-week titration phase, then maintained on that dose for an additional 4 weeks. After a washout period of 2 weeks, participants received ganaxolone for a duration of 6 weeks (from week 8 to 14).
62335305|NCT03535038|EXPERIMENTAL|Inferior vena cava (IVC) diameter|subjects underwent IVC diameter measurement after VPW measurement
62335306|NCT03535038|ACTIVE_COMPARATOR|Vascular pedicle width (VPW)|Supine chest x ray was done and the VPW is assessed by radiologists.
62492434|NCT05962164|SHAM_COMPARATOR|Sham Immersion|Patients with COPD assigned to the sham condition will have their lower legs immersed in a circulating thermoneutral (\~36°C) footbath for 45 min per session.
62492435|NCT04349696|ACTIVE_COMPARATOR|T2DM with Child-Pugh A|"All subjects with T2DM with normal hepatic function received a Mitiglinide Tablets 10 mg.~Intervention: Drug: Mitiglinide Tablets 10 mg"
61940076|NCT01798420||Corticosteroid|
61940077|NCT01798420||non-corticosteroid group|
62492436|NCT04349696|EXPERIMENTAL|T2DM with Child-Pugh B|"All subjects with T2DM with moderate impaired hepatic function received a MitiglinideTablets 10 mg.~Intervention:Drug: Mitiglinide Tablets 10 mg"
62492437|NCT01939990|ACTIVE_COMPARATOR|Nebivolol|Group A will be given Nebivolol 5 to 10mg per day
62335307|NCT00446446|EXPERIMENTAL|Panitumumab|articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.
61940078|NCT03422042|ACTIVE_COMPARATOR|Short duration of antibiotic|group A: will received intravenous antibiotic until the temperature is less than 37.8 c for 72 hours, then antibiotic is discontinued
61940079|NCT03422042|ACTIVE_COMPARATOR|Standard treatment of antibiotic|group B: will received intravenous antibiotic for 7 days, and followed by oral antibiotic for 7 days, regardless of body temperature
62335308|NCT01593501|ACTIVE_COMPARATOR|High dose vitamin D|50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
62695272|NCT03162211|EXPERIMENTAL|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
62335309|NCT01593501|ACTIVE_COMPARATOR|Low dose vitamin D|800 IU vitamin D3 every day of an approximate 365-day treatment.
62695273|NCT03162211|NO_INTERVENTION|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
62695274|NCT06119477|EXPERIMENTAL|Bioceramic Putty Apical Plugs|The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger.
62695275|NCT06119477|EXPERIMENTAL|Single Cone Gutta-percha with Bioceramic Sealer|A large sized (#80 - #120, and a taper of 2%) gutta-percha cone (GC) will be inserted, measuring according to the width of the canal, to the working length, then the immature canal will be gently filled with Bioceramic sealer and the GC.
62695276|NCT06119477|EXPERIMENTAL|Combination of Bioceramic Putty and Sealer|The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP will be inserted into the canal orifice and gently plugged with hand pluggers.
62137542|NCT03959384|EXPERIMENTAL|Surfactant replacement (Curosurf)|"1. Broncho-alveolar lavage (BAL) with 25 mg / kg of Curosurf, diluted 1:10 with physiological solution, divided in two aliquots administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~2. Following supplementation of a dose of 25 mg / kg of Curosurf, diluted with physiological solution 1: 2 (1 ml = 40 mg of surfactant), given in two aliquots with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
62137543|NCT03959384|PLACEBO_COMPARATOR|Ambient Air|"1. Broncho-alveolar lavage (BAL) with air, administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~2. Following supplementation of air given with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
61940080|NCT01792271|PLACEBO_COMPARATOR|AB: 7% HS home tx, then 0.12% NaCl|"Inhaled Inhaled 7% HS (hypertonic saline) home treatment' , then 0.12% sodium chloride solution home treatment.~The intervention consists of the subject receiving both concentrations of inhaled sodium chloride solution, each during a different home treatment periods. Subjects randomized to order AB will receive inhaled 7% NaCl (sodium chloride solution) mist during the first home treatment period, then 0.12% NaCL during the second home treatment period."
61940081|NCT01792271|PLACEBO_COMPARATOR|BA: 0.12% NaCl home tx, then 7% HS|Subjects randomized to order BA will receive inhaled 0.12% NaCl mist during the first home treatment period, then Inhaled 7% HS home treatment during the second home treatment period.
61940082|NCT06331026|EXPERIMENTAL|TRR|Administration order: PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R), PEG-rhGH with present preparation (R)
61940083|NCT06331026|EXPERIMENTAL|RTR|Administration order: PEG-rhGH with present preparation (R), PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R)
61940084|NCT06331026|EXPERIMENTAL|RRT|Administration order: PEG-rhGH with present preparation (R), PEG-rhGH with present preparation (R), PEG-rhGH with new preparation (T)
62492438|NCT01939990|PLACEBO_COMPARATOR|Placebo|Group B will be given Placebo.
62492439|NCT05214677|EXPERIMENTAL|Sequence A|cross-over
62492440|NCT05214677|EXPERIMENTAL|Sequence B|cross-over
61940085|NCT05391529||Colonoscopy|Patients awaiting colonoscopy
61940086|NCT05391529||CCE|Patients awaiting colon capsule endoscopy
62695277|NCT06642636|EXPERIMENTAL|ICU-VR|Regarding the participants in the intervention group, an appointment will be scheduled with a nurse specialist of the department of pulmonology and a researcher to watch the ICU-VR intervention. During this appointment, patients will be allowed to watch the VR video as many times as desired.
62695278|NCT06642636|NO_INTERVENTION|Control|The control group will receive the usual care and no intervention.
62137544|NCT02686398|ACTIVE_COMPARATOR|Fluad|88 CKD patients were vaccinated with Fluad.
62137545|NCT02686398|ACTIVE_COMPARATOR|Agrippal|86 CKD patients were vaccinated with Agrippal.
62137546|NCT05166590|NO_INTERVENTION|Normal Sleep|Participants will sleep in the laboratory for 8 hours and then undergo the same social-rejection paradigm as the experimental group to serve as a control comparison.
62137547|NCT05166590|EXPERIMENTAL|Total Sleep Restriction|Participants will experience a night of total sleep restriction and then undergo a social-rejection task in the morning.
62137548|NCT05769816|EXPERIMENTAL|Group 1|NAs combined with anti-PD-1 antibody, followed by NAs monotherapy
62137549|NCT05769816|ACTIVE_COMPARATOR|Group 2|NAs
62335310|NCT01593501|PLACEBO_COMPARATOR|Placebo|A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
62335311|NCT00633581|EXPERIMENTAL|1|Intravenous injections of 10 grams(20ml as a solution) of vitamin C with 100ml of normal saline over 30 minutes.
62335312|NCT00633581|PLACEBO_COMPARATOR|2|Intravenous injections of 120ml of normal saline over 30 minutes.
62492441|NCT01019525||Mouth Breathing|Children aged between 8-12 years, with clinical diagnosis of mouth breathing
62492442|NCT01019525||Nasal Breathing|Children aged between 8-12 years old, with normal breathing
62492443|NCT01828112|EXPERIMENTAL|Ceritinib|Patients in this arm received 750 mg of ceritinib.
61940087|NCT06556472|EXPERIMENTAL|Continuous terlipressin infusion + Norepinephrine|"1. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.~2. Norepinephrine will be initiated @0.05mcg/kg/min and titrated upto 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.~3. IV albumin as per volume status to maintain target MAP .~4. If the target MAP is not achieved, a third vasopressor along with hydrocortisone, Adrenaline and then phenylephrine."
61940088|NCT06556472|ACTIVE_COMPARATOR|Norepinephrine|"1. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.~2. IV albumin as per volume status to maintain target MAP .~3. If the target MAP is not achieved, vasopressin along with hydrocortisone, followed by adrenaline and phenylephrine, may be added as a fourth vasopressor."
61940089|NCT02605785|EXPERIMENTAL|Tau PET Scan, F-18 AV 1451|All subjects will received a Tau PET scan.
61940090|NCT05024773|EXPERIMENTAL|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|
61940091|NCT03412708|ACTIVE_COMPARATOR|Vestibular Rehabilitation|"Vestibular Rehabilitation Program Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
61940092|NCT03412708|EXPERIMENTAL|Vestibular Rehabilitation supported with Virtual Reality|"Patients will perform the exercises in a virtual reality environment using a virtual reality goggle and a smartphone.The virtual environments consist of 2 media provided by the videos taken with a 360 camera . 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full. Exercises conducted while sitting and standing on a soft ground will happen in the 1st environment, and the ones on the treadmill will happen in the 2nd environment.~Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
61940093|NCT01544556||Prineo|An open, prospective, controlled, randomized clinical Study
61940094|NCT01544556||Steristrips|An open, prospective, controlled, randomized clinical Study
61940095|NCT01461980|ACTIVE_COMPARATOR|MCV4 + Tdap+ rLP2086|Group 1 - MCV4 + Tdap + rLP2086
61940096|NCT01461980|ACTIVE_COMPARATOR|MCV4 + Tdap + saline|Group 2, MCV4 + Tdap+ saline
61940097|NCT01461980|PLACEBO_COMPARATOR|Saline + saline + rLP2086|Group 3- rLP2086 + saline
61940098|NCT00173888|EXPERIMENTAL|A|
61940099|NCT00173888|ACTIVE_COMPARATOR|B|
62137550|NCT05834452|ACTIVE_COMPARATOR|the Epley Maneuver|Treatment of BPPV with the Epley Maneuver in the TRV chair. No kinetic energy will be used.
62137551|NCT05834452|ACTIVE_COMPARATOR|the 360 Maneuver|Treatment of BPPV with the 360 Maneuver in the TRV chair.
62492444|NCT01828112|ACTIVE_COMPARATOR|Chemotherapy|Patients in this arm received chemotherapy of either pemetrexed or docetaxel as determined by BIRC.
62492445|NCT01965093||perioperative desaturation|children aged 0-5 years who received general anesthesia and developed perioperative desaturation
62492446|NCT01965093||no perioperative desaturation|children aged 0-5 years who received general anesthesia and did not developed perioperative desaturation
61940100|NCT02315573|EXPERIMENTAL|Lidocaine with epinephrine|"Wrist block anesthesia with Lidocaine 1% with epinephrine; 10cc.~Group 1 will receive the same treatment as group 2, except that the wide-awake carpal tunnel release surgery will be performed under Lidocaine anesthesia instead of Bupivacaine anesthesia."
61940101|NCT02315573|EXPERIMENTAL|Bupivacaine with epinephrine|"Wrist block anesthesia with Bupivacaine 0.25% with epinephrine; 10cc.~Group 2 will receive the same treatment as group 1, except that the wide-awake carpal tunnel release surgery will be performed under Bupivacaine anesthesia instead of Lidocaine anesthesia."
62137552|NCT01291472|OTHER|ketorolac|Ketorolac will be given to all patients as a part of routine medical care
62137553|NCT01970553|EXPERIMENTAL|lurbinectedin (PM01183) / gemcitabine|"Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle):~- Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes,~immediately followed by:~- PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks"
62137554|NCT02455765|EXPERIMENTAL|White rice control|Subjects will consume white rice as control (50g carbohydrate)
62137555|NCT02455765|EXPERIMENTAL|co-ingest low dose of amino acid|Subjects will receive 68 ml of amino acid mixture together with white rice
62137556|NCT02455765|EXPERIMENTAL|co-ingest high dose of amino acid|Subjects will receive 136 ml of amino acid mixture together with white rice
62137557|NCT02455765|EXPERIMENTAL|pre-load low dose15 min|Subjects will receive 68 ml of amino acid mixture 15 min before consumption of white rice
62137558|NCT02455765|EXPERIMENTAL|pre-load low dose 30 min|Subjects will receive 68 ml of amino acid mixture 30 min before consumption of white rice
62137559|NCT02455765|EXPERIMENTAL|pre-load high dose 15 min|Subjects will receive 136 ml of amino acid mixture 15 min before consumption of white rice
62137560|NCT02455765|EXPERIMENTAL|pre-load high dose 30 min|Subjects will receive 136 ml of amino acid mixture 30 min before consumption of white rice
62137561|NCT03886246|EXPERIMENTAL|Spesolimab (every 6 weeks)|
62137562|NCT03886246|EXPERIMENTAL|Spesolimab (every 12 weeks)|
62137563|NCT03886246|EXPERIMENTAL|Spesolimab (every 4 weeks)|
62137564|NCT02457936|EXPERIMENTAL|Mindfulness Based Cognitive Therapy (MBCT)|This group will receive 8 weeks of Mindfulness Based Cognitive Therapy
62137565|NCT02457936|ACTIVE_COMPARATOR|Waiting list|This group will be tested twice 8-10 weeks apart and then receive 8 weeks of Mindfulness Based Cognitive Therapy
62137566|NCT00514306|EXPERIMENTAL|Schedule 1|OSI-906 days 1-3 every 14 days
62492447|NCT02739724|ACTIVE_COMPARATOR|Classic laparoscopy|Patients will undergo laparoscopy surgery with classic laparoscopy technic.
62695279|NCT06223269|EXPERIMENTAL|Skin Xenotransplant|After surgical preparation of the wound beds, subjects will receive approximately 100 square centimeters of realSKIN® at one site, and autograft at the other site, per the standard of care, in accordance with the randomization schedule.
62695280|NCT06223269|ACTIVE_COMPARATOR|Autograft|The comparator control for the study is autografting: the current standard of care procedure for the treatment of severe burns involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound to achieve complete and durable wound closure.
62695281|NCT04134936|EXPERIMENTAL|Arm A|Tafasitamab in addition to R-CHOP
61940102|NCT03814473|EXPERIMENTAL|Dietary intervention|All participants will follow an ad libitum self-administered Paleo diet for 8-weeks
61940103|NCT05264727|EXPERIMENTAL|Healthy Adults, Obese Adults, Adults with Type 2 diabetes: Saline and Glucose|Study visit: Subjects will receive a caffeine free, standardized evening meal and remain fasting overnight. An IV infusion of saline and glucose (50%) will be given the next morning and continue until the end of study. Blood draws will be collected frequently from the IV line to monitor blood glucose levels.
61940104|NCT05264727|EXPERIMENTAL|Healthy Adults, Obese Adults, Adults with Type 2 diabetes: Amino Acid and Glucose|Study visit: Subjects will receive a caffeine free, standardized evening meal and remain fasting overnight. An IV infusion of glucose (50%) will be given the next morning together with an IV infusion of Clinisol 15% (an amino acid mixture) will be given the next morning and continue until the end of study. Blood draws will be collected frequently from the IV line to monitor blood glucose levels.
61940105|NCT01051466|EXPERIMENTAL|Duloxetine|
61940106|NCT01051466|NO_INTERVENTION|Healthy Participants|
61940107|NCT05744713||Disease Cohort|
61940108|NCT05744713||Engaged Cohort|
61940109|NCT06153446||CDL PJI Database|Patients tested for PJI through the PJI Panel at CD Laboratories (CDL)
61940110|NCT02098252|ACTIVE_COMPARATOR|Interventional therapy|"Interventional therapies include:~neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).~Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization."
61940111|NCT02098252|NO_INTERVENTION|Conservative management (medical management)|The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.
61940112|NCT05738629|EXPERIMENTAL|PSC-MSC-Exo Eye Drops Treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drop intervention for 12 weeks.
61940113|NCT06556758|EXPERIMENTAL|stripping massage + conventional Therapy|"Stripping Massage Stripping massage on rhomboid major and minor active trigger point in the direction of muscle fiber from origin to insertion of muscle. Frequency: 3 minutes for 3 times/week for 4 consecutive weeks.~Conventional therapy including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set) Frequency: 3 times/ week for 4 weeks"
61940114|NCT06556758|ACTIVE_COMPARATOR|Conventional therapy|Conventional Therapy Conventional PT including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4(5 reps x 1 set ) Frequency : 3 times/ week for 4 weeks
61940115|NCT05870774|ACTIVE_COMPARATOR|First group|The patients underwent implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuberosity area of the upper jaw
61940116|NCT05870774|EXPERIMENTAL|Second group|"The patients underwent implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibro-Gide"
61940117|NCT03875768|EXPERIMENTAL|Intervention|Participants will track their daily dietary intake for six months using an app and will receive automated feedback daily via text message based on DASH nutrients. Participants in-need of coaching based on their adherence to the key nutrients in the DASH dietary pattern or engagement in the intervention will receive responsive digital coaching from Nourish registered dietitians.
61940118|NCT03875768|NO_INTERVENTION|Control|Participants will receive information about the DASH dietary pattern and will track their daily dietary intake using an app for six months.
61940119|NCT02852889||fluid responders|Patients whose stroke volume index increase by \>10% in response to a 500-ml fluid bolus was defined as fluid responders.
61940120|NCT02852889||fluid non-responders|Patients whose stroke volume index increase by \<10% in response to a 500-ml fluid bolus was defined as fluid non-responders.
62137567|NCT00514306|EXPERIMENTAL|Schedule 2|OSI-906 days 1-5 every 14 days
62137568|NCT00514306|EXPERIMENTAL|Schedule 3|OSI-906 days 1-7 every 14 days
62492448|NCT02739724|EXPERIMENTAL|Laparoscopy single port access|Patients will undergo laparoscopy surgery by single port access technic.
62137569|NCT04885257|PLACEBO_COMPARATOR|Placebo|Patient with both PTSD and recent history of stroke. Placebo control arm. The frequency will be up to twice a day, with oral dosing.
62137570|NCT04885257|EXPERIMENTAL|Methylphenidate|Patient with both PTSD and recent history of stroke. Methylphenidate active arm. The oral dosing maximum will be up to 20mg twice daily.
62137571|NCT06631183|EXPERIMENTAL|Behavioral activation group|Participants will read information and engage in exercises through the self-help tool e-couch that aim at stimulating their engagement in pleasant activities.
62137572|NCT06631183|EXPERIMENTAL|Cognitive restructuring group|Participants will read information and engage in exercises through the self-help tool e-couch that aim at tackling negative thinking.
62492449|NCT02751437|NO_INTERVENTION|Low Arginine unsupplemented|These infants identified as having low blood arginine levels will receive standard care.
62492450|NCT02751437|EXPERIMENTAL|Low Arginine supplemented|These infants identified as having low arginine levels will receive an additional arginine infusion between days 3 and 10 of life.
62492451|NCT02751437|NO_INTERVENTION|Normal Arginine|These infants identified as having normal arginine levels will receive standard care.
61940121|NCT05509751|ACTIVE_COMPARATOR|Intervention group|geriatric assessment (GAM) and remote exercise and education prior to and during curative/adjuvant or first/second line palliative chemotherapy /immunotherapy or targeted therapy
61940122|NCT05509751|NO_INTERVENTION|Waitlist control group|Wait list, receiving standard of care and option to receive intervention after treatment.
61940123|NCT05509751|EXPERIMENTAL|single arm pre-post test study for participants recruited from geriatric oncology clinic|They will receive the 12 week virtual chair-based exercise and health education intervention except no geriatric assessment
61940124|NCT01790776|ACTIVE_COMPARATOR|Conventional urethrography|Current golden standard.
61940125|NCT01790776|EXPERIMENTAL|Sono-urethrography|Experimental urethrography, which could be followed by conventional urethrography if the results are inconclusive.
61940126|NCT04676412|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
61940127|NCT04676412|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
61940128|NCT06617026|EXPERIMENTAL|Sucralfate Group|patients assigned to this group will start to use a topical rectal ointment containing Sucralfate. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days. the follow-up visits are arranged at 15, 30 and 40 days.
61940129|NCT06617026|EXPERIMENTAL|HyperOil Group|patients assigned to this group will start to use topical oil containing the combination of azadirachtin and hyperforin. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days. the follow-up visits are arranged at 15, 30 and 40 days.
61940130|NCT06617026|ACTIVE_COMPARATOR|Surgery|patients assigned to this group will be operated for fissurectomy and lateral sphincterectomy. the follow-up visits are arranged at 15, 30 and 40 days.
62335313|NCT05591898|EXPERIMENTAL|Progressive relaxation exercises group|Participants will be randomly selected by a computer based system (Block randomization was used to keep the sample size of the groups similar. Random Allocation Software (Ver. 1.0.0) will be used to allocate the patients to groups). Selected participants will be invited to a meeting which will be held face-to-face and in a quiet environment. Progressive Relaxation Exercises will be explained to this group in a step-by-step manner whose surgery date is determined to undergo bariatric surgery by the relevant researcher. After this stage, participants will be followed to do the exercises regularly for a month by a researcher. Patients will fill the Amsterdam Preoperative Anxiety and Information Score Scale preoperatively at the hospital. After the surgery, the patients will be evaluated by the researchers in terms of pain scores and analgesic usage frequency in the recovery room and 1st, 4th, 8th, 12th, 24th, 36th and 48th hours data will be collected in the postoperative service.
62492452|NCT04221048||PREG-GUCH|Pregnant women with congenital heart diseases
62492453|NCT02075385|EXPERIMENTAL|Speech pathology therapy|Pre, during and pos-treatment swallowing exercises.
62492454|NCT02075385|NO_INTERVENTION|Control group|These patients will not receive speech pathology therapy.
62492455|NCT02052817|ACTIVE_COMPARATOR|Control|Debridement and standard of care in off-loading on control patients
62492456|NCT02052817|EXPERIMENTAL|Toad Brace|Debridement and fitting of Toad Brace
62492457|NCT06627413|EXPERIMENTAL|Cohort 1|Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-E2 after a 5-day washout
62492458|NCT06627413|EXPERIMENTAL|Cohort 2|Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-E3 after a 5-day washout
61940131|NCT05211986|ACTIVE_COMPARATOR|Cohort A|Participants will receive twice weekly intramuscular (im) administration of IMM01-STEM for 4 weeks with a dose of 225μg.
61940132|NCT05211986|ACTIVE_COMPARATOR|Cohort B|Participants will receive twice weekly intramuscular (im) administration of IMM01-STEM for 4 weeks with a dose of 450μg.
61940133|NCT05211986|ACTIVE_COMPARATOR|Cohort C|Participants will receive twice weekly intramuscular (im) administration of IMM01-STEM for 4 weeks with a dose of 900μg.
61940134|NCT01454960|EXPERIMENTAL|SA, AJ, PC|"Participants are given all 3 interventions:~Suggested Alternatives, Accountable Justification, and Peer Comparison."
61940135|NCT01454960|EXPERIMENTAL|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
61940136|NCT01454960|EXPERIMENTAL|SA, PC|Participants receive the Suggested Alternatives and Peer Comparison interventions, but not the Accountable Justification intervention.
61940137|NCT01454960|EXPERIMENTAL|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternatives intervention.
61940138|NCT01454960|EXPERIMENTAL|Peer Comparison|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
61940139|NCT01454960|EXPERIMENTAL|Suggested Alternatives|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
61940140|NCT01454960|EXPERIMENTAL|Accountable Justification|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
61940141|NCT01454960|NO_INTERVENTION|Control|Participants do not receive any of the 3 interventions.
61940142|NCT04615897|EXPERIMENTAL|Experimental aging|The subjects received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
61940143|NCT04615897|NO_INTERVENTION|Control Aging|The subjects doesn´t received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
61940144|NCT04433533|ACTIVE_COMPARATOR|Rosuvastatin 20mg (Group 1)|
61940145|NCT04433533|EXPERIMENTAL|Rosuvamibe 10/10mg (Group 2)|
62492459|NCT06627413|EXPERIMENTAL|Cohort 3|Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-X2 after a 5-day washout
62492460|NCT06627413|EXPERIMENTAL|Cohort 4|Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-X5 after a 5-day washout
61940146|NCT03757338|ACTIVE_COMPARATOR|Fingolimod Reference Formulation|0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.
62492461|NCT06627413|EXPERIMENTAL|Cohort 5|Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout
62492462|NCT06627413|EXPERIMENTAL|Cohort 6|Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout
61940147|NCT03757338|EXPERIMENTAL|Fingolimod Test Formulation|0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.
62137573|NCT03287713|ACTIVE_COMPARATOR|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
62137574|NCT03287713|ACTIVE_COMPARATOR|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
62492463|NCT06627413|EXPERIMENTAL|Cohort 7|Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout
62492464|NCT06627413|EXPERIMENTAL|Cohort 8|Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> dose in Part B) of lumateperone LAI formulation (chosen from Part B) after a 5-day washout
61940148|NCT00743899|EXPERIMENTAL|1|The aggressive group
61940149|NCT00743899|EXPERIMENTAL|2|The conservative group
62137575|NCT02796729|EXPERIMENTAL|dynamic glucose enhanced MRI after D-glucose injection|"IV catheter preparation: Catheter will be placed in one arm. Fasting glucose levels measured with a glucometer using a 1-2 mL sample of blood. Only participants with normal fasting blood glucose levels (70-125 mg/dL) will proceed with the study. First IV catheter will monitor blood glucose every 10 min after bolus injection until it returns to normal. Second IV catheter is placed on the opposite arm for glucose infusion and GBCA (gadobutrol) infusion.~Glucose infusion protocol: Occurs when the participant is in the MRI. Bolus injection of hospital grade 25g of 50% dextrose solution over 1 min is to increase blood glucose concentrations to about 3-4 times the normal level. Blood glucose levels should return to normal levels within 30 to 60 min.~GBCA infusion protocol: Occurs when the participant is in the MRI; approximately 20 min after glucose infusion. Standard intravenous bolus injection of 0.1mM/kg of gadobutrol (Gadovist) at an injection rate of 5 mL/sec."
62137576|NCT03411941||Treatment-naïve nAMD patients|Patient data for whom treatment with IVT aflibercept injection was initiated as first-line treatment according to the SmPC and the SERV Guideline, in treatment-naive patients with newly diagnosed of nAMD in routine clinical practice.
62137577|NCT03048994|PLACEBO_COMPARATOR|Placebo|Placebo
62137578|NCT03048994|ACTIVE_COMPARATOR|Glutamine|Glutamine
62335314|NCT05591898|NO_INTERVENTION|Control group|This group will be the randomized selected patients who will not get any intervention. Patients will fill the Amsterdam Preoperative Anxiety and Information Score Scale preoperatively at the hospital. After the surgery, the patients will be evaluated by the researchers in terms of pain scores and analgesic usage frequency in the recovery room and 1st, 4th, 8th, 12th, 24th, 36th and 48th hours data will be collected in the postoperative service.
62335315|NCT04662242|EXPERIMENTAL|low serum selenium with selenium supplement|Patients having low serum selenium with selenium supplement given
62335316|NCT04662242|PLACEBO_COMPARATOR|low serum selenium with placebo supplement|Patients having low serum selenium with placebo given
62335317|NCT04662242|ACTIVE_COMPARATOR|non-low serum selenium with selenium supplement|Patients having normal serum selenium with selenium supplement given
62335318|NCT04662242|PLACEBO_COMPARATOR|non-low serum selenium with placebo supplement|Patients having normal serum selenium with placebo given
62492465|NCT06627413|EXPERIMENTAL|Cohort 9|Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> dose in Part B) of lumateperone LAI formulation (chosen from Part B) after a 5-day washout
61940150|NCT02301130|EXPERIMENTAL|mogamulizumab + MEDI4736 (Durvalumab)|"During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.~Part 2 (Cohort Expansion Phase)~* Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
62137579|NCT00056654|EXPERIMENTAL|1|
62335319|NCT05142514|EXPERIMENTAL|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
62335320|NCT05142514|ACTIVE_COMPARATOR|Commercial COVID-19 Vaccine|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
61940151|NCT02301130|EXPERIMENTAL|mogamulizumab + tremelimumab|"During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.~Part 2 (Cohort Expansion Phase)~* Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
62137580|NCT01174797||Patients being evaluated for active ischemia|Subjects with known or suspected CAD who are scheduled to undergo routine exercise MPI or stress echocardiography for the detection of active ischemia are eligible for enrollment.
62335321|NCT00480922|EXPERIMENTAL|1|A low glycemic load diet
62695282|NCT04134936|EXPERIMENTAL|Arm B|Tafasitamab plus lenalidomide in addition to R-CHOP
62335322|NCT00480922|ACTIVE_COMPARATOR|2|Low fat diet
62335323|NCT03226223|PLACEBO_COMPARATOR|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
62335324|NCT03226223|EXPERIMENTAL|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
62335325|NCT03641209|EXPERIMENTAL|Paracetamol|Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days
62335326|NCT03641209|PLACEBO_COMPARATOR|Placebo|0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug
62492466|NCT05032963|ACTIVE_COMPARATOR|Undisturbed Sleep|8 hours sleep - Subjects randomized to the undisturbed sleep will be instructed to go to sleep at 11pm, and awoken at 7am.
62335327|NCT03378154|EXPERIMENTAL|Tracheal Intubation in infants using Macintosh laryngoscopes|Children \< 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the Macintosh laryngoscope
62335328|NCT03378154|EXPERIMENTAL|Tracheal Intubation in infants using King vision|Children \< 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the King vision videolaryngoscope
62335329|NCT01860534|EXPERIMENTAL|Eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
62335330|NCT01860534|NO_INTERVENTION|no eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
62492467|NCT05032963|EXPERIMENTAL|Restricted Sleep|4 hours sleep - Subjects randomized to the restricted sleep will be instructed to go to sleep at 3am and awoken at 7am.
62492468|NCT04202484|EXPERIMENTAL|Toripalimab combine CT|
62492469|NCT00936351|EXPERIMENTAL|Arm 1|Mindfulness Meditation
62492470|NCT00936351|ACTIVE_COMPARATOR|Arm 2|Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support
62492471|NCT05282680||Type 2 diabetes|Subjects with a diagnosis of type 2 diabetes
61940152|NCT06680661|EXPERIMENTAL|Cy/Flu/Thio/TBI + dCBT + Tac/MMF + Abatacept|"Cyclophosphamide (Cy), fludarabine (Flu), thiotepa (Thio), and total body irradiation (TBI) is the preparative regimen for Double Umbilical Cord Transplant (dCBT).~Graft-versus-host disease prophylaxis will consist of tacrolimus (Tac) and mycophenolate mofetil (MMF). Abatacept will be administered."
61940153|NCT01262573|EXPERIMENTAL|Barbed|Vaginal cuff closure with barbed suture
61940154|NCT01262573|ACTIVE_COMPARATOR|Smooth|Vaginal cuff closure with smooth suture
61940155|NCT04383158|ACTIVE_COMPARATOR|PRGF extraction sockets (Test)|Immediately after dental extraction, the socket will be filled with Plasma Rich in Growth Factors (ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16))
61940156|NCT04383158|NO_INTERVENTION|Unassisted extraction sockets (Control)|Dental extraction sockets to be left to heal spontaneously unassisted.
61940157|NCT01556880|EXPERIMENTAL|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
61940158|NCT01556880|NO_INTERVENTION|Standard usual care|
61940159|NCT03989765|EXPERIMENTAL|Intervention arm|Municipalities in the intervention arm will, in Stage 1, be part of developing the intervention to reduce the rate of compulsion. In Stage 2 they will implement the intervention through their services.
61940160|NCT03989765|NO_INTERVENTION|Control municipality|As all outcome measures will be collected from the National Patient Register, there will be treatment as usual.
61940161|NCT06629207|EXPERIMENTAL|NUK-RB Study|
61940162|NCT05361785|ACTIVE_COMPARATOR|FMT form healthy donor|FMT from healthy donor
62492472|NCT05282680||Type 1 diabetes|Subjects with a diagnosis of type 1 diabetes
62492473|NCT05282680||Diabetic kidney disease|Subjects with diabetic kidney disease (presence of albuminuria +/- eGFR\<=60m/kg/m2) or history or presence of end stage renal disease
61940163|NCT05361785|PLACEBO_COMPARATOR|FMT plasebo|FMT plasebo
61940164|NCT05419986|OTHER|Non-opioid users|
61940165|NCT05419986|OTHER|Active opioid users|
61940166|NCT04871282|EXPERIMENTAL|Part A Main Study 1.2 mg daily|AL102 1.2 mg
61940167|NCT04871282|EXPERIMENTAL|Part A Main Study 2 mg Intermittent|AL102 2 mg
61940168|NCT04871282|EXPERIMENTAL|Part A Main Study 4 mg Intermittent|AL102 4 mg
61940169|NCT04871282|EXPERIMENTAL|Part B AL102|AL102, recommended dose regimen from Part A, 1.2 mg daily
61940170|NCT04871282|PLACEBO_COMPARATOR|Part B Placebo|Placebo to match recommended dose regimen from Part A
61940171|NCT04871282|EXPERIMENTAL|Open Label Extension|AL102, recommended dose regimen from Part A, 1.2 mg daily
61940172|NCT03425513||Hepatitis B group|
61940173|NCT04968795||Control|Participate in filling the questionnaire but NOT the meditation/wellness session (control).
61940174|NCT04968795||Wellness Group|Participate in filling the questionnaire and the meditation/wellness session
61940175|NCT06002243|EXPERIMENTAL|Intervention|Participant receiving echocardiography screening.
61940176|NCT00402272|EXPERIMENTAL|1|XIENCE V® Everolimus Eluting Coronary Stent System
61940177|NCT05625061|EXPERIMENTAL|Core Behavioral Weight Loss (BWL) Intervention|Behavioral weight loss core intervention, includes activity tracker, wireless scale, daily self-weighing, and smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback summary, and daily weight-related behavioral goals. Core intervention component is combined with each of the 7 intervention messages to be tested repeatedly over time.
61940178|NCT05625061|EXPERIMENTAL|Core BWL Intervention + BCT 1 Message (Action Planning)|"Core BWL Intervention + Message testing the Behavior Change Technique Action Planning"
61940179|NCT05625061|EXPERIMENTAL|Core BWL Intervention + BCT 2 Message (Discrepancy)|"Core BWL Intervention + Message testing the Behavior Change Technique Discrepancy Between Current Behavior and Goal"
62492474|NCT06452758||male and female rowers|Rowers will perform 2000m ergometer test.A 2,000-m time trial is a standard test used to assess performance in rowers.
62492475|NCT04835116|OTHER|Local Anesthesia|Group A patients received peri tract local anaesthesia infiltration with 0.25% Bupivacaine.
61940180|NCT05625061|EXPERIMENTAL|Core BWL Intervention + BCT 3 Message (Feedback on Outcome of Behavior)|"Core BWL Intervention + Message testing the Behavior Change Technique Feedback on Outcome of Behavior"
61940181|NCT05625061|EXPERIMENTAL|Core BWL Intervention + BCT 4 Message (Social Support)|"Core BWL Intervention + Message testing the Behavior Change Technique Social Support"
61940182|NCT05625061|EXPERIMENTAL|Core BWL Intervention + BCT 5 Message (Social Comparison)|"Core BWL Intervention + Message testing the Behavior Change Technique Social Comparison"
61940183|NCT05625061|EXPERIMENTAL|Core BWL Intervention + BCT 6 Message (Social Reward)|"Core BWL Intervention + Message testing the Behavior Change Technique Social Reward"
61940184|NCT05625061|EXPERIMENTAL|Core BWL Intervention + BCT 7 Message (Focus on Past Success)|"Core BWL Intervention + Message testing the Behavior Change Technique Focus on Past Success"
61940185|NCT05122871|EXPERIMENTAL|Scape room|
62335331|NCT02471664|EXPERIMENTAL|Single|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
62335332|NCT03251287|ACTIVE_COMPARATOR|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
62335333|NCT03251287|PLACEBO_COMPARATOR|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
62335334|NCT03815487|EXPERIMENTAL|Therapy with Hybrid Closed Loop (HCL)|"The Intervention is the specific function of the Insulin Pump from Medtronic® with the name MiniMed® 670G (MMT-1780) to deliver Insulin as medication.~This Medtronic MiniMed 670G Insulin Pump in Auto Mode is an Hybrid closed loop (HCL) system including an Auto Mode function. It provides as intervention several additional effects concerning automatically insulin delivery by pump: e.g. in case of high values (or predicted) - more insulin will be administered automatically, in case of low values (or predicted) - the insulin infusion will be decreased a suspended and resumed again. The patients will wear the pump continuously."
62335335|NCT03815487|ACTIVE_COMPARATOR|Sensor Augmented Pump (SAP) therapy|"The Intervention is the specific therapy of the Sensor Augmented Insulin Pump MiniMed® 670G (MMT-1780) without Auto Mode.~This Medtronic MiniMed 670G Insulin Pump without Auto Mode' is a Sensor Augmented Pump (SAP) therapy and means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. The patients will wear the pump also continuously, but have to respond manually after the alarm. There are no automatically steps from the pump."
62335336|NCT05188534||BOLD-fMRI|Identifying the language functional cortex in glioma patients with BOLD-fMRI
62335337|NCT05188534||ZOOMit-fMRI|Identifying the language functional cortex in glioma patients with ZOOMit-fMRI
62492476|NCT04835116|OTHER|Intravenous Analgesics|Group B patients received postoperative intravenous analgesia.
62492477|NCT03951727|OTHER|Endovascular treatment for PAD|Single group study (1 arm)
62492478|NCT02352233||colonoscopy group|consecutive patients undergoing for colonoscopy for any formal indication. Patients were submitted to colonoscopy using RETROVIEW colonoscope
62492479|NCT03997253|EXPERIMENTAL|blood, bile and urine samples|blood and urine samples at D0,D1, D3 D7, D14, M1, M3, M6 and M12
62492480|NCT01173705||Normal weight: abdominal surgery|Lean individuals undergoing elective abdominal surgery
62492481|NCT01173705||Obese: abdominal or bariatic surgery|Obese subjects undergoing elective abdominal or bariatric surgery
62492482|NCT00740896|ACTIVE_COMPARATOR|1|Participants smoke 8 cigarettes in 4 hours.
62137581|NCT05929833|EXPERIMENTAL|BETTER TBI (Traumatic Brain Injury) Transitional Care Intervention|Skilled clinical interventionists follow a manualized intervention protocol to address patient/family needs; establish goals; coordinate post-hospital care, services, and resources; and provide patient/family education and training on self- and family-management and coping skills \<16 weeks post-discharge.
62335338|NCT04220632|EXPERIMENTAL|Itacitinib+corticosteroids|Itacitinib administered in combination with corticosteroids
62492483|NCT00740896|SHAM_COMPARATOR|2|Participants are not allowed to smoke for 4 hours.
62492484|NCT04021160|ACTIVE_COMPARATOR|Active Group|A total of 16, every other day sessions of rTMS at 10 Hz frequency will be applied to 4 locations along the perilesional area (see target selection). Intensity will be 100% of motor threshold, 25 trains - 40 pulses per train with 20 seconds intertrain interval and a total of 1000 pulses per session. The coil handle will be directed downwards at 45º of the sagittal plain to ensure that the induced electric field be perpendicular to the underlying gyrus.
62492485|NCT04021160|SHAM_COMPARATOR|Sham Group|Sham group will receive the same sessions as above with the exact same parameters yet a sham coil identical in shape and size to the active coil will be used instead. The sham coil produces sounds and sensations very similar to the active one.
62492486|NCT02607826|EXPERIMENTAL|Intervention arm|
62492487|NCT02607826|NO_INTERVENTION|Standard of Care|
62492488|NCT00919711|EXPERIMENTAL|Denosumab 60 mg|
62492489|NCT00919711|ACTIVE_COMPARATOR|Risedronate 150 mg QM|
62492490|NCT05368480|EXPERIMENTAL|Senior Companion|Receives a companion to socialize with them, help with daily tasks, etc.
62492491|NCT05368480|NO_INTERVENTION|Control|Referred to other services available in the community
62492492|NCT04892147|EXPERIMENTAL|Experimental group|Randomly selected to participate first in MOBA group
61940186|NCT05122871|ACTIVE_COMPARATOR|Simulation|
61940187|NCT06383767|EXPERIMENTAL|ESG401 for injection|IV infusion on day 1, 8 and15 of each 28 day cycle
61940188|NCT06383767|ACTIVE_COMPARATOR|Treatment of Physician's Choice|"Eribulin 1.4 mg/m2, IV infusion on day 1 and 8 of each 21 day cycle~Capecitabine 1000 or 1250 mg/m2, po, from day 1 to 14 of each 21 day cycle~Vinorelbine 25 mg/m2, IV infusion on day 1 and 8 of each 21 day cycle~Gemcitabine 1000 mg/m2, IV infusion on day 1,8 and 15 of each 28day cycle"
62492493|NCT04892147|OTHER|Wait-list-control group|Randomly selected for study assessments parallel with experimental group. Participates in MOBA after completion of the experimental group
62492494|NCT06059755|EXPERIMENTAL|Group A: Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscles involved in upper limb function. It includes exercises like shoulder presses, wrist curls, elbow flexion, and triceps extensions. Among the functional movements that are the focus of motor skill training activities for non-paretic limbs are reaching, gripping, and object manipulation. Patient will be encouraged to mentally visualize themselves performing movements and tasks with the affected limb, while actively engaging the non-paretic limb. Strength will be measured using the grip strength test/ hand held dynamometer. Patients will undergo 45-minute session per day, 3 days per week for 6 weeks.
62695283|NCT04025957|EXPERIMENTAL|SHR-1501 dose escalation|SHR-1501 given subcutaneously
62695284|NCT04025957|EXPERIMENTAL|SHR-1501 dose expansion|SHR-1501 given subcutaneously
62695285|NCT05268367|EXPERIMENTAL|3-Week Baseline|Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
61940189|NCT06047925|EXPERIMENTAL|group A|First permanant molar will be prepared to receive 3D printed crown
61940190|NCT06047925|ACTIVE_COMPARATOR|group B|First permanant molar will be prepared to receive SSC
61940191|NCT05991323||Patient with prurigo nodularis|Participants aged 18 years or older who start receiving dupilumab for prurigo nodularis (according to the country-specific prescribing information) prior to and independently of their participation in the study
62137582|NCT05929833|PLACEBO_COMPARATOR|Usual Care|In alignment with U.S. usual care for patients with TBI (Traumatic Brain Injury), usual care arm activities for younger adults with TBI and their family caregivers will includes usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments).
62137583|NCT02629172||Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)|Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label
62335339|NCT01151579|ACTIVE_COMPARATOR|Levalbuterol 0.63|Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
62335340|NCT01151579|ACTIVE_COMPARATOR|Levalbuterol 1.25|Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.
62335341|NCT02131948|EXPERIMENTAL|Intranasal insulin|40 IU of intranasal insulin
62335342|NCT02131948|PLACEBO_COMPARATOR|Intranasal placebo|Placebo comparator to intranasal insulin
62335343|NCT01182623||In vivo diagnosis|Patients undergoing colonoscopy where one or more polyps up to 10mm in size are found.
62335344|NCT03446534|EXPERIMENTAL|Amoxicillin|Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.
62335345|NCT03446534|PLACEBO_COMPARATOR|Placebo|Placebo mixture 0.25ml/kg every 8 hours for 7 days
62335346|NCT04251208||Integrated Care|This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
62335347|NCT04251208||Referral-Based Care|This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
62695286|NCT05268367|EXPERIMENTAL|5-Week Baseline|Participants in this arm are randomized to a 5-week baseline period with repeated weekly assessment after the initial intake. Following the 5-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
61940192|NCT03785938|EXPERIMENTAL|Probiotic|"Participants will start the course of liquid probiotic on the first day of their course of chemotherapy. This can be taken orally, or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day"
62335348|NCT04979832|EXPERIMENTAL|Local administration of GM-CSF, fosfomycin and metronidazole in the pouch|"Local administration of 50 micrograms GM-CSF, 400 milligrams fosfomycin and 100 milligrams metronidazole in the pouch.~In a Phase A of the trial, this will be applied as a single dose during endoscopy of the pouch. In Phase B of the trial, this will be applied as a first dose during endoscopy of the pouch, followed by 6 further daily doses for a total of 7 doses."
62335349|NCT04474899|EXPERIMENTAL|Phase 1|Moxonidine 0.4mg/daily
62335350|NCT04474899|EXPERIMENTAL|Phase 2|Amlodipine 5mg
62335351|NCT05110040|EXPERIMENTAL|immunosuppressive agents|patients recruited will be treated with one or／and two immnuosuppressive agents
62335352|NCT06011746|EXPERIMENTAL|Ketamine Group|patients will receive paravertebral block (19 mL of 0.5% levobupivacaine + 1 ml ketamine (50 mg)).
62335353|NCT06011746|ACTIVE_COMPARATOR|Control Group|patients will receive paravertebral block (19 mL of 0.5% levobupivacaine + 1 ml normal saline)
62335354|NCT03427905|ACTIVE_COMPARATOR|GROUP I|lipoaspiration and transplantation of ADSVCs (for adipose-derived stromal vascular cells/primary fresh cells without culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
62335355|NCT03427905|ACTIVE_COMPARATOR|GROUP II|lipoaspiration and transplantation of ADSCs (for adipose-derived mesynchymal stem cells/after culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
62335356|NCT01480141|EXPERIMENTAL|Single Arm Study|Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
62335357|NCT02001116|EXPERIMENTAL|Pilot Hospitals|
62335358|NCT02001116|NO_INTERVENTION|Control Hospitals|
62695287|NCT00833703|PLACEBO_COMPARATOR|Placebo|0.2 mL/kg/day matching placebo solution once daily.
62695288|NCT00833703|EXPERIMENTAL|Clopidogrel 0.2 mg/kg/day|0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.
62738425|NCT01101282|EXPERIMENTAL|'Usual care' plus PEP mask therapy|"This will comprise:~* 'Usual care'~* PEP mask therapy"
62738426|NCT05648344|EXPERIMENTAL|Access to WW app for 6 months|Participants will be randomized to access the WW application for 6 months
62137584|NCT06692296|EXPERIMENTAL|Platform Group|Balance training including both conventional rehabilitation (24 sessions) and training over a stabilometric platform (20 sessions).
62137585|NCT06692296|ACTIVE_COMPARATOR|Conventional Group|Balance training including only conventional rehabilitation (44 sessions).
62137586|NCT05912218|EXPERIMENTAL|MEDI6570|Biological MEDI6570,subcutaneous injection
61940193|NCT03785938|PLACEBO_COMPARATOR|Placebo|"Participants will start the course placebo on the first day of their course of chemotherapy. This can be taken orally or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day~Placebo will be delivered in similar, packaging, appearance and taste."
61940194|NCT01318642|ACTIVE_COMPARATOR|Placebo + Gemcitabine|Arm 2: AMG479-placebo IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle
62492495|NCT06059755|EXPERIMENTAL|Group B: Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Patient will engage in specific exercises or movements using the affected limb while observing the mirror reflection. The movements will consist of forearm rotation, elbow, wrist, and finger flexion and extension movements, and hand grasping. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks.
62695289|NCT04254627|EXPERIMENTAL|Mifepristone 300 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 1 will receive one week of mifepristone at 300 mg daily.
62738427|NCT05648344|PLACEBO_COMPARATOR|Control|Participants will be randomized to receive emails with information available from myplate.gov
61940195|NCT01318642|EXPERIMENTAL|AMG 479 20 mg/kg + Gemcitabine|ARM 1: AMG 479 20mg/kg IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle.
61940196|NCT02479269|EXPERIMENTAL|intervention|Aerobic exercise+ blood sampling
61940197|NCT02479269|NO_INTERVENTION|control|Blood sampling
61940198|NCT04671524|EXPERIMENTAL|pediatric patients diagnosed with rheumatic diseases.|"Exercise group; a combination of stretching, range of motion, and strengthening exercise.~The exercise program will take 8 weeks, 3 days per week, and 45 minutes."
61940199|NCT04671524|NO_INTERVENTION|healthy controls|The healthy control group will be examined and the outcomes will be compared with the experimental group.
61940200|NCT03206437|EXPERIMENTAL|Mindfulness-Based Stress Reduction|This group will take the 8 week MBSR course within 4 weeks of their first testing visit. When the course is finished they will come in for their second testing visit. The course meets once a week in person for 2.5 hours and participants are expected to do practices at home.
61940201|NCT03206437|OTHER|Waitlist|The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
61940202|NCT05886816|EXPERIMENTAL|Mito-MES|MitoQ pills 20 mg orally daily taken during the study and initiated within 3 days post exposure.
61940203|NCT05886816|PLACEBO_COMPARATOR|Control group|Placebo pills orally daily taken during the study and initiated within 3 days post exposure.
62137587|NCT05912218|PLACEBO_COMPARATOR|Placebo|Saline Control,subcutaneous injection
62137588|NCT05868291||Group 1|"During the period going from November 2022 to March 2023, data from all the patients (approx. 500) hospitalized in the 4 closed wards will be collected (duration of stay, medication use...).~The group 1 will be exposed to the standard lighting system in Bispebjerg Hospital."
62137589|NCT05868291||Group 2|"During the period going from November 2023 to March 2024, data from all the patients (approx. 500) hospitalized in the 4 closed wards will be collected (duration of stay, medication use...).~The group 2 will be exposed to the new lighting system that will have been optimized (higher intensity and blue content in the morning and progressively dimmed light after 14:00)."
62492496|NCT02020850||Toe-Brachial and Ankle-Brachial Index|toe systolic blood pressure, ankle systolic blood pressure, brachial systolic blood pressure test
61940204|NCT05342402|EXPERIMENTAL|Somatosensory Rehabilitation Program|Includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
61940205|NCT05342402|ACTIVE_COMPARATOR|Educational Pain Management Program (PMP)|Includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
61940206|NCT05491538|EXPERIMENTAL|Social Cognition and Interaction Training-Work Edition|Social Cognition and Interaction Training-Work Edition is a group-based, skills training group that will be offered to participants after they enroll in supported employment.
61940207|NCT02910362|EXPERIMENTAL|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
61940208|NCT02910362|ACTIVE_COMPARATOR|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
62492497|NCT05248399|EXPERIMENTAL|COVID-19 Group Problem Solving plus Standard of Care|
62738428|NCT06264986|EXPERIMENTAL|KSM-66|600mg (5% withanolides) KSM-66 ashwagandha, hydroxypropyl methylcellulose capsule
61940209|NCT00826761|ACTIVE_COMPARATOR|1|High dose Lb. casei
61940210|NCT00826761|ACTIVE_COMPARATOR|2|Low dose Lb. Casei
61940211|NCT00826761|PLACEBO_COMPARATOR|3|
62137590|NCT02094560|EXPERIMENTAL|Small cell lung cancer|Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
62137591|NCT02094560|EXPERIMENTAL|Non small cell lung cancer|Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
62137592|NCT02094560|EXPERIMENTAL|biliary tract cancer|Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
62137593|NCT06131372|EXPERIMENTAL|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 milligram (mg) cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
62492498|NCT05248399|ACTIVE_COMPARATOR|Standard of Care|
62492499|NCT04285073|EXPERIMENTAL|Paclitaxel-eluting graft|Single-arm
62492500|NCT01257451|EXPERIMENTAL|Vildagliptin|
61940212|NCT00611533|ACTIVE_COMPARATOR|Atomoxetine|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
62335359|NCT06063408|EXPERIMENTAL|Cognitive Functional Therapy|"Participants will received in this group four main component:~1. Pain education, cognitive education, explanation about their health condition, self management education~2. Graded exposure to painful movements or activities~3. Movement therapy targeted to their functional integration~4. Lifestyle programme."
62335360|NCT06063408|ACTIVE_COMPARATOR|Conventional Therapy|"Participants will received in this group four main component:~1. Tens therapy~2. Massage to cervical and shoulder area~3. Relaxation techniques~4. Posture exercises~5. Workplace education"
62335361|NCT01737840|EXPERIMENTAL|pantoprazole|Intravenous pantoprazole 40 mg flacon
62335362|NCT01737840|ACTIVE_COMPARATOR|ranitidine|Intravenous ranitidine 50 mg
62335363|NCT04991844|NO_INTERVENTION|Control group|The control group did not receive any intervention, but met at three timepoints to complete study questionnaires and provide anthropometric measurements,
62335364|NCT04991844|EXPERIMENTAL|Intervention Group|This group received the study intervention protocol.
62335365|NCT03940924|EXPERIMENTAL|High Intensity Interval Training (HIIT) + Resistance Training|Subjects perform three sessions of training during 12 weeks. Session are composed of 20min HIIT program : 60 cycles of speeding up for 8s and pedaling slowly for 12s. (Intensity between 85 and 90% HRmax) + a single set circuits including 10 exercises with a load of 8-12 repetition at around 80% of maximal repetition (1RM)
62137594|NCT06131372|EXPERIMENTAL|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and placebo matched to cagrilintide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
62335366|NCT03940924|NO_INTERVENTION|Control Group|Subjects don't have training program. They keep their life style.
62335367|NCT04855565|ACTIVE_COMPARATOR|ALY688-SR|single dose subcutaneous injection
62335368|NCT04855565|PLACEBO_COMPARATOR|Matching placebo for ALY688-SR|single dose subcutaneous injection
62335369|NCT03972644|ACTIVE_COMPARATOR|Early intervention|Patients will undergo aortic valve replacement immediately
62335370|NCT03972644|NO_INTERVENTION|Watchfull waiting|Patients will be followed and treated as recommended by guidelines.
62335371|NCT01987349|OTHER|Group A: age 8-17 yo identical twins|Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)
62335372|NCT01987349|OTHER|Group B: 18-30 yo identical twins|Participants to receive FluMist® (intranasal)
62335373|NCT01987349|OTHER|Group C: 18-30 yo fraternal twins|Participants to receive FluMist® (intranasal)
62335374|NCT01987349|OTHER|Group D: 40-49 yo identical twins|Participants to receive FluMist® (intranasal)
62335375|NCT01987349|OTHER|Group E: 40-49 yo fraternal twins|Participants to receive FluMist® (intranasal)
62335376|NCT01987349|OTHER|Group F: 70-100 yo twins|Participants to receive Fluzone® (intramuscular)
62335377|NCT01987349|OTHER|Group G: 70-100 yo non-twins|Participants to receive Fluzone® (intramuscular)
62335378|NCT00527215|EXPERIMENTAL|darbepoetin alfa|
62335379|NCT01693458|EXPERIMENTAL|Lifestyle counseling|Appreciative Inquiry Change Agents (CA) Program (NAMWEZA)
62335380|NCT01693458|PLACEBO_COMPARATOR|Control group|Since the design is a stepped-wedge randomized trial, those in the control group will eventually receive the intervention later in the study.
62335381|NCT00462020|ACTIVE_COMPARATOR|1|5 days of IV antibiotics after appendectomy
62335382|NCT00462020|EXPERIMENTAL|2|home on oral antibiotics to complete 7 days of treatment when tolerating PO's
62335383|NCT01892098|ACTIVE_COMPARATOR|Zinc Sulfate|Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
62335384|NCT01892098|PLACEBO_COMPARATOR|Cellulose Pill|Subject enrolled in this arm will receive a placebo.
62335385|NCT04611295|EXPERIMENTAL|Teleneurological evaluation and support|teleneurological evaluation using a medical device certified as telemedicine system
62335386|NCT05537948|ACTIVE_COMPARATOR|pitavastatin|Pitavastatin 2 mg/d - 4 mg/d
62335387|NCT05537948|ACTIVE_COMPARATOR|PCSK9 Inhibitors|Evolocumab 140 mg once per 2 weeks or Alirokumab 150 mg once per 2 weeks
62335388|NCT03790462|EXPERIMENTAL|Music intervention group 1|"Raga A will be played for 10 minutes \& data collected."
62492501|NCT01257451|PLACEBO_COMPARATOR|Placebo|
62492502|NCT06217432|EXPERIMENTAL|Morning exercise|Three sessions per week of targeted resistance exercise targeting the quadriceps muscles performed between 6:00 and 8:00 for 12 weeks.
62492503|NCT06217432|EXPERIMENTAL|Late afternoon exercise|Three sessions per week of targeted resistance exercise targeting the quadriceps muscles performed between 16:00 and 18:00 for 12 weeks.
62492504|NCT06217432|NO_INTERVENTION|Healthy control|Healthy individuals without tendinopathy as controls for the transcriptomics and proteomics analyses.
62492505|NCT00458822|EXPERIMENTAL|All Patients|All patients treated with Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients with Systemic Light-Chain (AL) Amyloidosis
62492506|NCT04869995||Intervention|Senior abdominal and pelvic cavity surgeons (i.e., visceral surgeons, gynecologist surgeons, and urologists) having completed their robot-assisted surgery training, and commonly doing laparoscopic surgery.
62335389|NCT03790462|EXPERIMENTAL|Music intervention group 2|"Raga B will be played for 10 minutes \& data collected."
62335390|NCT03790462|EXPERIMENTAL|Music intervention group 3|"Raga C will be played for 10 minutes \& data collected."
62492507|NCT03681977|EXPERIMENTAL|Zimmer MP Persona|Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
62492508|NCT03681977|ACTIVE_COMPARATOR|Zimmer Persona Knee-PS|Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
62492509|NCT03681977|NO_INTERVENTION|Healthy Participants|The control group for the kinematic assessment
62137595|NCT06131372|EXPERIMENTAL|Cagrilintide 2.4 mg|Participants will receive cagrilintide 2.4 mg and placebo matching to semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
62335391|NCT03790462|NO_INTERVENTION|Control group|Subject relaxes without music for 10 minutes and electrophysiological parameters will be collected
62137596|NCT06131372|PLACEBO_COMPARATOR|Placebo|Participants will receive 2.4 mg placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously once weekly for 26 weeks.
62137597|NCT00488566|OTHER|Part 1|Single dose escalation
62335392|NCT01412658|EXPERIMENTAL|Milk Peptides|
62137598|NCT00488566|OTHER|Part 2|Pharmacodynamic assessment
62137599|NCT01228669|EXPERIMENTAL|A|
62137600|NCT01228669|EXPERIMENTAL|B|
62137601|NCT01228669|PLACEBO_COMPARATOR|C|
62335393|NCT01412658|PLACEBO_COMPARATOR|Placebo|Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
62335394|NCT03305094|ACTIVE_COMPARATOR|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
62335395|NCT03305094|EXPERIMENTAL|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
62335396|NCT02843373||rTMS|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered to the left DLPFC as assessed by either the 5cm rule or F3 site. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
62492510|NCT05698316||Age related macular degeneration|Collection of both retrospective and prospective data collection in 3 visits.
62492511|NCT04181736|EXPERIMENTAL|Guanfacine Treatment Group|Participants will be prescribed tabs containing guanfacine immediate release (GIR) to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg.
62492512|NCT04181736|PLACEBO_COMPARATOR|Placebo Group|Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment.
62492513|NCT03972696|ACTIVE_COMPARATOR|BA3S|Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
62492514|NCT03972696|EXPERIMENTAL|BA2|RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
62738429|NCT06264986|PLACEBO_COMPARATOR|Placebo|600mg Gluten-free chickpea powder, hydroxypropyl methylcellulose capsule
62137602|NCT01046136|ACTIVE_COMPARATOR|Mucinex|
62137603|NCT01046136|PLACEBO_COMPARATOR|placebo|
62137604|NCT00649805|EXPERIMENTAL|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
62137605|NCT00649805|ACTIVE_COMPARATOR|2|Verelan® PM extended-release capsules controlled-onset 300 mg
62137606|NCT05784194|EXPERIMENTAL|Intervention for correct discharge medication list|Identification of potential errors in medication list before discharge, information and actions to delete errors before discharge in collaboration between pharmacist (PhD student, patient and physician) on top of standard care
62137607|NCT05784194|NO_INTERVENTION|Standard care|Standard care
62137608|NCT06303674|EXPERIMENTAL|Physical activity with engaging cognitively|This experimental condition involves engaging in physical activity interspersed with rest periods based on cognitive tasks.
62137609|NCT06303674|EXPERIMENTAL|Physical activity without engaging cognitively|This experimental condition involves engaging in physical activity interspersed with rest periods (without cognitive tasks).
62137610|NCT06303674|NO_INTERVENTION|Cognitively engaging control conditions|In this condition, participants will be suggested to watch a video while seating/resting for 10 minutes.
62137611|NCT02203500|EXPERIMENTAL|Lacidipine|
62137612|NCT02203500|EXPERIMENTAL|Telmisartan|
61940213|NCT00611533|PLACEBO_COMPARATOR|Placebo|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
61940214|NCT04253912|EXPERIMENTAL|VBP-245|Topical 2% Povidone-Iodine Gel
61940215|NCT04253912|PLACEBO_COMPARATOR|Control|Placebo Gel (no Povidone-Iodine)
61940216|NCT06239025|ACTIVE_COMPARATOR|Block + multimodal analgesia|Multimodal analgesia + TTMP block with ropivacaine 0.5 %, 30 mL
61940217|NCT06239025|NO_INTERVENTION|Multimodal Analgesia|Multimodal Analgesia without a block
61940218|NCT02850354|EXPERIMENTAL|anti-g maneuvers|"Before the first parabola, pulmonary function will be evaluated. Then during each weightlessness period the subject will be instructed either to stay at rest (control condition) or to perform anti-g maneuvers (4 times each): intermittent exhalation on exertion, lower limbs and abdomen muscular contraction, combined maneuver ('intermittent exhalation on exertion' + 'muscle contraction'). Before, the exhalation on exertion, the subject will close the airway after the mouthpiece by pushing on a button actuating a pneumatic valve.~Each subject will be tested during 15 parabola where the anti-g maneuvers will be performed in randomized order. After the 15th parabola, pulmonary function will be again evaluated."
61940219|NCT02706054|PLACEBO_COMPARATOR|C-group|patients receiving an IM saline injection near the nerve root (periradicular)
61940220|NCT02706054|EXPERIMENTAL|M-group|patients receiving an IM Meloxicam injection near the nerve root (periradicular)
61940221|NCT03610451|EXPERIMENTAL|Floatation-REST|Participants will float supine in a pool of water saturated with epsom salt, in a light and sound attenuated chamber, for up to 60 minutes, on 8 separate occasions. Ratings of the experience will be collected before and after each float.
61940222|NCT03610451|OTHER|Usual care|Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.
61940223|NCT01164683|EXPERIMENTAL|Arm 1|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
61940224|NCT01164683|ACTIVE_COMPARATOR|Arm 2|Usual care
61940225|NCT00851344|ACTIVE_COMPARATOR|GSK835726 (10mg)|10mg oral dose
61940226|NCT00851344|ACTIVE_COMPARATOR|GSK835726 (50mg)|50mg oral dose
61940227|NCT00851344|ACTIVE_COMPARATOR|GSK835726 (100mg)|50mg oral dose
61940228|NCT00851344|ACTIVE_COMPARATOR|Cetirizine 10mg|10mg cetirizine as active comparator
61940229|NCT00851344|PLACEBO_COMPARATOR|placebo|placebo tablet
61940230|NCT00076206|EXPERIMENTAL|A|CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
61940231|NCT00076206|EXPERIMENTAL|B|CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
61940232|NCT00076206|EXPERIMENTAL|C|CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
61940233|NCT00076206|PLACEBO_COMPARATOR|D|Placebo dose to be taken orally daily up to 12 weeks.
61940234|NCT01054326|EXPERIMENTAL|Supervised physical therapy focusing of rotatorcuff exercises|Patients did specific exercises supervised by a physical therapists twice a week during two months. Focus was on early activation of rotator cuff and scapula stabilizers following different phases in a rehabilitation program Assessments before surgery,1 week after as well as 1,2,3 and 6 months after surgery.
61940235|NCT01054326|ACTIVE_COMPARATOR|Home exercises|Patients did home exercises following a programme during three months. Assessment considering shoulder function and pain was done before surgery, 1w after as well as 1,2,3 and 6 months after surgery,
61940236|NCT01368978|EXPERIMENTAL|Test (with the InsuPatch device)|Device use
61940237|NCT01368978|NO_INTERVENTION|Control (without the InsuPatch device)|
61940238|NCT05369676|EXPERIMENTAL|SSD8432 dose 1|SSD8432 dose 1/ritonavir or placebo
61940239|NCT05369676|EXPERIMENTAL|SSD8432 dose 2|SSD8432 dose 2/ritonavir or placebo
61940240|NCT05098704|EXPERIMENTAL|clopidogrel|
61940241|NCT05098704|PLACEBO_COMPARATOR|placebo|
61940242|NCT05741307|EXPERIMENTAL|Patients 2|"Patient aged 7 to 12 with a diagnosis of ADHD made by a child psychiatrist or neuropediatrician and followed by the child psychiatry department - Reference Center for Language and Learning Disorders of the Necker Enfants Malades Hospital.~These patients will use of the self-hypnosis application 6 weeks after inclusion : from T2 to T3."
61940243|NCT05741307|EXPERIMENTAL|Patients 1|"Patient aged 7 to 12 with a diagnosis of ADHD made by a child psychiatrist or neuropediatrician and followed by the child psychiatry department - Reference Center for Language and Learning Disorders of the Necker Enfants Malades Hospital.~These patients will use of the self-hypnosis application at inclusion : from T0 (inclusion) to T1."
61940244|NCT06229639|ACTIVE_COMPARATOR|Tracheostomy Plug|Patients receive tracheostomy plug during night 2.
61940245|NCT06229639|EXPERIMENTAL|Passy-Muir Valve|Patients receive Passy-Muir Valve during night 1.
62137613|NCT02203500|EXPERIMENTAL|Lacidipine + Telmisartan|
62137614|NCT05397262|OTHER|Standard Arm|"1 Arm: combination Treatment: Deep regional hyperthermia: 1-2/week up to 10 sessions Radiotherapy: 50.4Gy + Boost 5.4Gy (R0) or 9.0Gy (R1/2)~Chemotherapy:~5-Fluorouracil 600mg/m\^2, civ 120h; d1-5, 29-3~Chemotherapy:~Cisplatin 20mg/m\^2; d1-5, 29-33"
61940246|NCT00745940|EXPERIMENTAL|MBCT Intervention Group|The curriculum of our mindfulness intervention draws upon elements from the mindfulness-based stress reduction program, and Segal and colleagues manual for mindfulness-based cognitive therapy. It was modified by one of the investigators to address issues associated with traumatic brain injury (e.g., problems with attention, concentration, memory, fatigue). The intervention was increased to ten weeks with one and a half hour weekly sessions, along with a 20-30 minute daily meditation home practice. Further adaptations included simplified language, the use of repetition to reinforce concepts, and visual aids. More attention was paid to fostering learning conditions to encourage an environment of trust and non-judgement. Connections between learning activities was also made more explicit.
61940247|NCT00745940|NO_INTERVENTION|MBCT Control Group|Control group waited.
62137615|NCT02438007|EXPERIMENTAL|Galeterone|
62335397|NCT03791437|EXPERIMENTAL|Experiment groups|Post chest operative use Digital chest drainage system until Patient's discharge day
62335398|NCT03791437|ACTIVE_COMPARATOR|Control groups|Post chest operative use traditional drainage system until Patient's discharge day Not use Digital chest drainage system
62492515|NCT06179953|EXPERIMENTAL|Experimental group with social robot|"The emotional skills protocol aims to achieve the following objectives:~* Acquisition of appropriate emotional skills and understanding of emotions;~* Construction of functional thoughts related to emotions;~* Enhancement of interpersonal and social skills. It is aimed at a sample of children diagnosed with high-functioning autism spectrum disorder (ASD) between the ages of 5 and 10. The experimental group will carry out training through the use of social robots. The robot provides instructions and if the child requests it, it gives prompts."
62492516|NCT06179953|OTHER|Control group without social robot|"The emotional skills protocol aims to achieve the following objectives:~* Acquisition of appropriate emotional skills and understanding of emotions; Construction of functional thoughts related to emotions;~* Enhancement of interpersonal and social skills. It is aimed at a sample of children diagnosed with high-functioning autism spectrum disorder (ASD) between the ages of 5 and 10. Control group which will be conducted through traditional therapy. The therapist provides instructions, and if the child has difficulty responding, he gives prompts."
62492517|NCT05683561|ACTIVE_COMPARATOR|CoronaVac|one dose of CoronaVac on D0
62492518|NCT05683561|EXPERIMENTAL|SCTV01E|one dose of SCTV01E on D0
62492519|NCT02130180||ED T1DM and hyperglycemia without criteria for DKA|
62492520|NCT02130180||Well controlled T1DM|
62492521|NCT02130180||ED DKA|
62492522|NCT01196598|ACTIVE_COMPARATOR|PFMT group|Women who undergo to three months of a pelvic floor muscle training program.
62492523|NCT01196598|ACTIVE_COMPARATOR|HE + PFM group|Women who undergo to three months of a hypopressive exercises plus pelvic floor muscle contraction program.
62492524|NCT01196598|ACTIVE_COMPARATOR|HE group|Women who undergo to three months of a hypopressive exercises program.
62492525|NCT01196598|ACTIVE_COMPARATOR|Control|Women who undergo to a session for lifestyle advice.
62492526|NCT03408730|EXPERIMENTAL|Sci-B-Vac Lot A Hep B Vaccination|Sci-B-Vac Lot A Hepatitis B Vaccination
62492527|NCT03408730|EXPERIMENTAL|Sci-B-Vac Lot B Hep B Vaccination|Sci-B-Vac Lot B Hepatitis B Vaccination
62492528|NCT03408730|EXPERIMENTAL|Sci-B-Vac Lot C Hep B Vaccination|Sci-B-Vac Lot C Hepatitis B Vaccination
62492529|NCT03408730|ACTIVE_COMPARATOR|Comparator: ENGERIX-B Hep B Vaccination|Active Comparator: ENGERIX-B Hepatitis B Vaccination
62137616|NCT02438007|ACTIVE_COMPARATOR|Enzalutamide|
62137617|NCT01768793|EXPERIMENTAL|Parents As Teachers + Lifestyle Int.|Participants assigned to this group will receive Parents As Teachers Plus (PAT+). This will be a diet and physical activity lifestyle intervention integrated within the standard Parents As Teachers home visiting curriculum. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
62137618|NCT01768793|ACTIVE_COMPARATOR|Standard Parents as Teachers (PAT)|Participants assigned to this group will receive the standard Parents As Teachers (PAT) home visiting curriculum, focusing on parenting and child development. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
62492530|NCT02535468||Prospective Arm|
62492531|NCT02535468||Contrived Arm|
62492532|NCT02918058|ACTIVE_COMPARATOR|McGill University Health Centre|This arm is defined by the geographic cluster of all eligible participants presenting to the McGill University Health Centre (Montreal, Quebec, Canada) Montreal General Hospital or Royal Victoria Hospital during the study period. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
61940248|NCT04956926|EXPERIMENTAL|JS201|
62335399|NCT02499003|EXPERIMENTAL|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
61940249|NCT03614507|EXPERIMENTAL|FreeO2 group|Automatic oxygen flow titration
62335400|NCT00583323|EXPERIMENTAL|1|Lomotil given
62335401|NCT00583323|PLACEBO_COMPARATOR|2|Normal Saline given
62492533|NCT02918058|ACTIVE_COMPARATOR|University Health Network, Toronto|This arm is defined by the geographic cluster of all eligible participants presenting to the University Health Network (Toronto, Ontario, Canada) at the Toronto General Hospital or Toronto Western Hospital. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
62492534|NCT02918058|ACTIVE_COMPARATOR|University of Ottawa, Ottawa|This arm is defined by the geographic cluster of all eligible participants presenting to the Ottawa Hospital (Ottawa, Ontario, Canada). The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
62492535|NCT00785135|ACTIVE_COMPARATOR|Standard (Treatment)|
62492536|NCT00785135|SHAM_COMPARATOR|Placebo (control)|
62492537|NCT05471349|ACTIVE_COMPARATOR|Hope message|Participants will view a hope-based video message and flyer.
62492538|NCT05471349|ACTIVE_COMPARATOR|Fear message|Participants will view a fear-based video message and flyer.
62492539|NCT05471349|PLACEBO_COMPARATOR|Control message|Participants will view a water advertisement video and flyer.
62492540|NCT05711901|NO_INTERVENTION|No Intervention: Baseline therapy|Basic therapy - the routine practice of an institution for the treatment of patients with maternal sepsis
61940250|NCT03614507|ACTIVE_COMPARATOR|Manual group|Manual oxygen flow titration
61940251|NCT02932683|EXPERIMENTAL|MedNav assisted resuscitators|MedNav will be used to perform neonatal resuscitation on a mannequin and assessed after teaching and 7 weeks after intervention, following this a small group will be used as a cross over study.
62335402|NCT01586156|ACTIVE_COMPARATOR|Open Label Carvedilol|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
62335403|NCT01586156|PLACEBO_COMPARATOR|Placebo Arm|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.
62335404|NCT00764959||Linear Hip|Encore Linear Hip System
62335405|NCT02891798|EXPERIMENTAL|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
62335406|NCT02891798|ACTIVE_COMPARATOR|Bupivacaine Only (control arm)|Patients will receive a nerve block consisting of bupivacaine only.
62335407|NCT01003080|EXPERIMENTAL|TKA with the Aquamantys for hemostasis|This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.
62335408|NCT01003080|ACTIVE_COMPARATOR|TKA without the Aquamantys for hemostasis|This group will receive total knee arthroplasty using the standard treatment for hemostasis.
61940252|NCT02932683|NO_INTERVENTION|No MedNav resuscitators|Neonatal resuscitation will be performed on a mannequin (without the use of MedNav) and assessed after teaching and 7 weeks after intervention.
61940253|NCT04047576|EXPERIMENTAL|sirolimus group|"Sirolimus: 2 mg/day for the first 3 days and 1 mg/day thereafter. The plasma drug concentration was monitored at 14 days, 12 weeks, and 48 weeks of medication to maintain a plasma drug concentration of 4-15 ug/L.~Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until discontinuation."
61940254|NCT04047576|ACTIVE_COMPARATOR|corticosteroid group|Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until 5-7.5 mg/d.
61940255|NCT05731323|EXPERIMENTAL|D-Cycloserine|"Prior to initiating TMS therapy, participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine.~During TMS therapy, participants will orally ingest a capsule containing a weight-based dose of the antibiotic d-cycloserine (dosed 25mg/17.5kg body weight) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions)."
61940256|NCT01649388|EXPERIMENTAL|FCR001|Recipients 3-12 months post-living kidney transplantation undergo non-myeloablative conditioning followed by infusion of an enriched hematopoietic stem cell product derived from the same living donor's peripheral blood stem cells
61940257|NCT04188470|EXPERIMENTAL|person-centered care model|healthcare multidisciplinary team will review the appropriateness of medication by a person-centered care model and then the healtcare team will propose changes in the therapeutic plan to the patient or caregiver
61940258|NCT04188470|NO_INTERVENTION|usual care|the healthcare team will practice usual care
61940259|NCT01333579|ACTIVE_COMPARATOR|Active rTMS|1Hz active rTMS delivered to the unaffected hemisphere
61940260|NCT01333579|PLACEBO_COMPARATOR|Placebo rTMS|1Hz placebo rTMS delivered to the vertex
61940261|NCT00529984|EXPERIMENTAL|Cohort 1|
62335409|NCT05341505|EXPERIMENTAL|ER intervention|Cognitive-behavioral emotion regulation intervention administered twice weekly for 8 weeks.
62335410|NCT04010786|EXPERIMENTAL|Active treatment NNC0247-0829|Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment
61940262|NCT00529984|EXPERIMENTAL|Cohort 2|
61940263|NCT00529984|EXPERIMENTAL|Cohort 3|
62335411|NCT04010786|PLACEBO_COMPARATOR|Placebo|In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo
62492541|NCT05711901|EXPERIMENTAL|Experimental: Basic therapy + Efferon LPS|Basic therapy is a routine practice of the institution for the treatment of patients with maternal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)
62492542|NCT01525628|EXPERIMENTAL|Group A|Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
62492543|NCT01525628|EXPERIMENTAL|Group B|Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
62492544|NCT01525628|EXPERIMENTAL|Group C|Effect of Dual oral DAAs on tenofovir
62492545|NCT01525628|EXPERIMENTAL|Group D|Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
61940264|NCT00529984|EXPERIMENTAL|Cohort 4|
61940265|NCT00529984|EXPERIMENTAL|Cohort 5|
61940266|NCT03821207|ACTIVE_COMPARATOR|The exercise group|The group will be instructed to perform stretching exercises including the pelvic and lumbar regions 3 times a day for the first 3 days of the menstrual cycle
61940267|NCT03821207|ACTIVE_COMPARATOR|The abdominal massage group|The group will be instructed to massage the abdomen for 10 mins a day on the first 3 days of the menstrual cycle.The massage is to be applied as effleurage (light touch) clockwise over the abdomen
61940268|NCT03821207|PLACEBO_COMPARATOR|The control group|The control group will perform no exercise or massage.
61940269|NCT05103631|EXPERIMENTAL|CATCH T cells|GPC3-CAR and the IL15 (CATCH T cells) will be administered to patients with GPC3-positive solid tumors.
62335412|NCT02308345|EXPERIMENTAL|Video summary|Participants in this arm will be given online access to a 5-minute video summary of their pre-chemotherapy visit, recorded by their physician.
62335413|NCT01887899|EXPERIMENTAL|transcranial direct current stimulation|
62335414|NCT01887899|PLACEBO_COMPARATOR|sham stimulation|
62492546|NCT01525628|EXPERIMENTAL|Group E|Effect of BI 201335 and BI 207127 on raltegravir
62492547|NCT02379624|PLACEBO_COMPARATOR|EN group|5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h. Since day 7, EN was began to advance to goal energy target as quickly as possibl
62492548|NCT02379624|EXPERIMENTAL|PEC/EN group|An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday). Since day 7, EN was advanced to goal energy target as the same step
62492549|NCT02152618|EXPERIMENTAL|Treatment|
62492550|NCT02152618|NO_INTERVENTION|Comparison|
62492551|NCT05848908|EXPERIMENTAL|Telehealth Visit|telemedicine visit and follow-up surveys
62492552|NCT05128058|EXPERIMENTAL|Cohort 1|Subjects will be dosed with 50 mg Ritlecitinib on Day 1 and followed up till Day 3
62492553|NCT05128058|EXPERIMENTAL|Cohort 2|Subjects will be dosed with 200 mg Ritlecitinib on Day 1 and followed up till Day 3
62492554|NCT01070745|EXPERIMENTAL|Indomethacin for resistant PDA|Treatment with second course of indomethacin
62492555|NCT01070745|EXPERIMENTAL|Ibuprofen for resistant PDA|Ibuprofen as second course of therapy
62492556|NCT05316636|EXPERIMENTAL|Group A|Vibrational forces from onset of treatment, from weeks 0-6; then, no vibrational forces during the rest of the treatment
62492557|NCT05316636|EXPERIMENTAL|Group B|From weeks 0-6, no vibrational forces. Vibrational forces starting at 6 weeks after treatment onset and applied for 6 weeks until week 12
62492558|NCT05316636|ACTIVE_COMPARATOR|Group C|Control, no vibrational forces
62492559|NCT02232945|PLACEBO_COMPARATOR|placebo|placebo of oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules.
62492560|NCT02232945|EXPERIMENTAL|Banlangen granules & placebo|Banlangen(Radix Isatidis) granules and placebo of oseltamivir phosphate
62492561|NCT02232945|ACTIVE_COMPARATOR|oseltamivir phosphate & placebo|oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules
62492562|NCT04508205|EXPERIMENTAL|Subjects with redness and bumps and/or blemishes|Topical administration twice daily for 12 weeks
62492563|NCT05140603||Cases|Patients who received a doravirine-based regimen.
62492564|NCT05179122|EXPERIMENTAL|Surgical drain|In this arm participants a surgical drain (Redon type) will be inserted above the abdominal fascia prior to suture of the subcutaneous tissue and of the skin
62492565|NCT05179122|NO_INTERVENTION|Control|In this arm the subcutaneous tissue and the skin of the surgical wound will be sutured without insertion of any type of drain
62492566|NCT05857969||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
62492567|NCT00629057|EXPERIMENTAL|1|Lowest dose level
61940270|NCT02598726|EXPERIMENTAL|Supportive care (curcumin, piperine)|Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
61940271|NCT03629210|EXPERIMENTAL|Combination Treatment|Combination treatment: Participants will receive intravitreal Eylea (AFL, 2.0 mg) injection and OZURDEX implant (0.7 mg) injection within 0 to 8 days of each other.
62492568|NCT00629057|EXPERIMENTAL|2|Middle level dose
62492569|NCT00629057|EXPERIMENTAL|3|Highest dose level
62492570|NCT02784262|EXPERIMENTAL|botox injection|"* Preoperative medication: Paracetamol 1,5g oral, diclofenac 50mg (evt ibuprofen 600mg) oral and/or diazepam 5-10 mg oral.~* Skin and tissue inside the projected injection canal will be infiltrated with 5-10ml Marcain-Adrenalin (5mg/ml + 5microg/ml) for local anaesthesia.~* Localization will be confirmed with help of navigation before the medication will be given. Intravascular injection will be prevented by control of aspiration."
62492571|NCT06358027||pressure support ventilation group|when the patients were ready for extubation, anesthesia was terminated by one of the selected pressure support ventilation
62492572|NCT06358027||manual ventilation group|when the patients were ready for extubation, anesthesia was terminated by one of the selected manual ventilation wake-up methods at the initiative of the relevant anesthesiologist.
62492573|NCT01218360||Participants|All participants enrolled
61940272|NCT03629210|ACTIVE_COMPARATOR|Monotherapy|Monotherapy treatment: Participants will receive OZURDEX implant (0.7 mg) injection.
61940273|NCT01924507|EXPERIMENTAL|CPAP|Patients with apnea will be treated with CPAP during the night.
61940274|NCT01924507|NO_INTERVENTION|Control|One arm group will be control and will not receive CPAP treatment during the ICU admission.
62492574|NCT05440968|OTHER|A - Intervention|A - After randomization, participants will be offered information on healthy lifestyles according to their score on the FINDRISC questionnaire and subsequently a POC-A1c measurement + a confirmatory test order (Oral Glucose Tolerance Test)
62492575|NCT05440968|OTHER|B - Control|B - After randomization, will be offered the same information on healthy lifestyles according to their FINDRISC score, and will receive an order to an Oral Glucose Tolerance Test.
62492576|NCT01508065||controlled type one diabetes mellitus.|
62492577|NCT01311596||No icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the first 2 weeks of the study period~Lab -Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the first 2 weeks of the study period"
62492578|NCT01311596||Icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the last 2 weeks of the study period~Lab - Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the last 2 weeks of the study period"
61940275|NCT03523234|EXPERIMENTAL|surgery group|
61940276|NCT03523234|PLACEBO_COMPARATOR|control group|
61940277|NCT01386008|OTHER|enfilcon A + senofilcon A|Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
62492579|NCT04223349|EXPERIMENTAL|Part 1: Treatment A|Participants will receive JNJ-70033093 dose twice daily (BID) for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
62492580|NCT04223349|EXPERIMENTAL|Part 1: Treatment B|Participants will receive JNJ-70033093 dose BID for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
61940278|NCT04166500|EXPERIMENTAL|Intervention|
61940279|NCT04166500|NO_INTERVENTION|Control|
61940280|NCT01021306|ACTIVE_COMPARATOR|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner.
62335415|NCT05180110|EXPERIMENTAL|Symptoms of inflammation, Infection, tissue injury|Venous blood draw of up to 24mL and up to 6 capillary fingersticks
62335416|NCT03813719||All patients attending Rapid access Gynaecology Clinic|All patients attending Rapid access Gynaecology Clinic for the first time.
62335417|NCT05155475||Patient with jaundice|
62335418|NCT06555614||Test Group|"A prospectively selected group that will receive breast reconstruction surgery with an acellular dermal matrix called SC Derm Recon, which is processed using carbon dioxide supercritical fluid technology."
62335419|NCT06555614||Control Group|A retrospectively selected group that has undergone breast reconstruction surgery with an acellular dermal matrix processed using chemical detergents.
62335420|NCT02104804|EXPERIMENTAL|Saxagliptin 5mg|Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
62335421|NCT02104804|PLACEBO_COMPARATOR|Placebo|Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
62335422|NCT01620632||Altered gastric anatomy|Patients who have an altered gastric who need an ERCP
61940281|NCT01021306|ACTIVE_COMPARATOR|Dental Care & Self Care|Intraoral splints are removable orthopedic appliances fabricated of hard acrylic resin positioned between the remaining teeth of the patient. They are designed in theory to support the function of the TMJ and relieve associated pain. Stabilization splints are believed to function by stabilizing the intracapsular structure of the TMJ, reducing activity of masticatory muscles, distributing occlusal forces, and reducing bruxism (teeth grinding).
62335423|NCT03342482|PLACEBO_COMPARATOR|Placebo|5 g of placebo (sugar and salt) will be administered in veggie capsules
62335424|NCT03342482|EXPERIMENTAL|MSG|5 grams of MSG will be administered in veggie capsules
62492581|NCT04223349|EXPERIMENTAL|Part 1: Treatment C|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
62492582|NCT04223349|EXPERIMENTAL|Part 1: Treatment D|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
62492583|NCT04223349|EXPERIMENTAL|Part 2: Treatment Sequence EFG|Participants will receive Treatment E (JNJ-7003309 single dose in the morning in fasted condition) in treatment Period 1; followed by Treatment F (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 2; followed by Treatment G (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
62492584|NCT04223349|EXPERIMENTAL|Part 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
61940282|NCT01021306|SHAM_COMPARATOR|Sham AMCT & Self Care|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
61940283|NCT01021306|PLACEBO_COMPARATOR|Self-care only group|All patients will be offered the self-care checklist of homecare approaches at baseline. Self-care only participants successfully completing the 6 months assessment will be given the option for RIST or AMCT for one month.
61940284|NCT05933824|EXPERIMENTAL|PartA:Dose level(5mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
61940285|NCT05933824|EXPERIMENTAL|PartA:Dose level(10mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
62492585|NCT04223349|EXPERIMENTAL|Part 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
62137619|NCT04423796|EXPERIMENTAL|Robotic assisted early mobilization|Robotic assisted early mobilization started within 72 hours of ICU admission.
62335425|NCT04093518|ACTIVE_COMPARATOR|Active Comparator|Estradiol 200µg
62335426|NCT04093518|PLACEBO_COMPARATOR|Placebo Comparator|Placebo
62335427|NCT01882998|EXPERIMENTAL|Women-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled individually and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
62335428|NCT01882998|EXPERIMENTAL|Couples-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled in couples with their male partners and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
62335429|NCT01907594|ACTIVE_COMPARATOR|D-cycloserine|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
62335430|NCT01907594|PLACEBO_COMPARATOR|Gelatin Capsule|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
62492586|NCT04223349|EXPERIMENTAL|Part 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
62492587|NCT04223349|EXPERIMENTAL|Part 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
62492588|NCT04223349|EXPERIMENTAL|Part 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
62492589|NCT05470153|ACTIVE_COMPARATOR|Asthma with Obstructive Sleep Apnea on treatment|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization Continuous Positive Airway Pressure (CPAP) compliance: where acceptable compliance is defined as minimum of CPAP use of \>/= 4 hrs/70% nights (if applicable), In one month, 3month, 6 month duration Apnea/Hypopnea Index as per CPAP reading (if applicable)"
62492590|NCT05470153|NO_INTERVENTION|Asthma with Obstructive Sleep Apnea whom refused treatment|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization"
62492591|NCT05470153|NO_INTERVENTION|Asthma without Obstructive Sleep Apnea|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization"
62492592|NCT00860145|EXPERIMENTAL|radiosurgery|Radiosurgical treatment of the medial temporal lobe
62492593|NCT00860145|ACTIVE_COMPARATOR|temporal lobectomy|Resection of medial temporal lobe
62492594|NCT01971645|EXPERIMENTAL|Group D|Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block. Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
62492595|NCT01971645|PLACEBO_COMPARATOR|Group R|Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
62492596|NCT01971645|ACTIVE_COMPARATOR|Group M|Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).
62492597|NCT02050165|EXPERIMENTAL|KIND Bar|Daily inclusion of KIND Bars with almonds as a primary ingredient as part of the participant's usual diet, with diet counseling to adjust for the calories from the KIND Bars. KIND Bars that we will use in the study will include: Dark Chocolate Chili Almond; Cranberry Almond; Almond Walnut Macadamia; Pomegranate Blueberry Pistachio; Nut Delight; Fruit and Nut Delight; Almond and Apricot; Blueberry Pecan and Fiber.
61940286|NCT05933824|EXPERIMENTAL|PartA:Dose level(20mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
61940287|NCT05933824|EXPERIMENTAL|PartA:Dose level(40mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
61940288|NCT05933824|EXPERIMENTAL|PartA:Dose level(80mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
62137620|NCT04423796|ACTIVE_COMPARATOR|Early mobilization|Early mobilization started within 72 hours of ICU admission without the use of a robotic assistance. Mobilization is done by personell.
62137621|NCT01981603|EXPERIMENTAL|navigator|Kidney transplant recipients will serve as navigators to educate and assist other patients with the transplant process.
62137622|NCT01981603|NO_INTERVENTION|usual care|usual care
62137623|NCT00372775|EXPERIMENTAL|Sunitinib|
62137624|NCT03109080|EXPERIMENTAL|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
62137625|NCT05092009||All patiens|There is only one arm in this trial
62137626|NCT01000805|EXPERIMENTAL|Duloxetine|
61940289|NCT05933824|EXPERIMENTAL|PartB:Dose level(5mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
62137627|NCT01000805|PLACEBO_COMPARATOR|Placebo|
62137628|NCT01432769|ACTIVE_COMPARATOR|individualized diet|patients will receive a diet individualized to their calorie and protein requirements besides to dietary supplementation with a polymeric formula
62137629|NCT01432769|NO_INTERVENTION|standardized diet|"patients in the standardized diet will receive the dietary management established by the hospital"
62492598|NCT02050165|EXPERIMENTAL|Typical American Snack|Daily inclusion of conventional snacks (as part of the participant's usual diet, with diet counseling to adjust for the calories from the snacks. The snacks will consist of cookies considered to be conventional snack foods that are nutrient-dilute (i.e. relatively low in nutrients) and energy-dense (i.e., relatively high in kcal). Examples of conventional snack foods will include: Nabisco Snackwell Creme Sandwich 1.7 oz pack, Nabisco Newtons Fig 2 oz pack, Nabisco Cips Ahoy! Chocolate Chip 1.4 oz pack, and Nabisco Oreo Double Stuff Chocolate 1.3 oz pack.
62137630|NCT01992575||Retinal Vein Occlusion Group|Up to 35 patients diagnosed with retinal vein occlusions will be considered and evaluated for enrollment in this study.
62492599|NCT01706601||Hemorrhoids|Patient with hemorrhoids
62492600|NCT04235660|ACTIVE_COMPARATOR|Yttrium-90 Radiation Segmentectomy|
62492601|NCT04235660|ACTIVE_COMPARATOR|Stereotactic Body Radiation Therapy|
62137631|NCT06699368|EXPERIMENTAL|Ultra-High-Power Ablation Group|The ultra-high-power ablation group will use the QDOT ablation catheter with a power of 90W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g. The cold saline flow rate during ablation is 8ml/min, and the ablation device will adjust power and saline flow rate based on the electrode temperature at the tip of the QDOT ablation catheter. The target temperature is 60°C, and the cut-off temperature is 65°C, with an ablation endpoint of 4 seconds.
62137632|NCT06699368|ACTIVE_COMPARATOR|High-Power Ablation Group|The high-power ablation group will use the STSF ablation catheter with a power of 50W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g, and a cold saline flow rate of 15ml/min during ablation. The ablation endpoint for the posterior wall of the left atrium is an Ablation Index (AI) value of 360-410, for the anterior wall 450-480, and for the bottom and top of the left atrium 420-450.
62492602|NCT02583698|EXPERIMENTAL|Carvedilol|Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP \> 90 mmHg and HR \>55/min
62492603|NCT02583698|PLACEBO_COMPARATOR|placebo|
62492604|NCT01116791|EXPERIMENTAL|CRS+HIPC|Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment
62492605|NCT04203823|EXPERIMENTAL|Algorithm Testing|"The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm~The study population will be enrolled as 2 separate cohorts to test each algorithms individually"
62492606|NCT02835222|EXPERIMENTAL|Arm 2 (Selinexor) cytarabine, daunorubicin and selinexor|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2, and selinexor PO twice weekly. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3, and selinexor PO twice weekly from day 1. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
62492607|NCT02835222|ACTIVE_COMPARATOR|Standard of Care - Cytarabine and daunorubicin|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
62492608|NCT02472639|EXPERIMENTAL|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
62137633|NCT05691842|EXPERIMENTAL|HIIT intervention|Patients in this group (n=22) will undergo a HIIT training protocol for 12 weeks
62137634|NCT05691842|EXPERIMENTAL|Dual task intervention (DT)|Patients in this group (n=22) will undergo a DT training protocol for 12 weeks
62137635|NCT05691842|NO_INTERVENTION|Control group (CG)|Patients in this group (n=22) will not perform any exercise during the intervention period (12 weeks)
62492609|NCT02472639|OTHER|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
62492610|NCT05698407|EXPERIMENTAL|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine
62492611|NCT05698407|ACTIVE_COMPARATOR|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine
62492612|NCT06179641|ACTIVE_COMPARATOR|IPACK group|IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) block
62492613|NCT06179641|EXPERIMENTAL|Tibial nerve group|selective tibial nerve block
62492614|NCT03822949|EXPERIMENTAL|Experimental: Exposed to Day light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.
62137636|NCT04679675|ACTIVE_COMPARATOR|Usual Care|
62137637|NCT04679675|ACTIVE_COMPARATOR|Education|
62137638|NCT04679675|ACTIVE_COMPARATOR|Direct Mail|
62137639|NCT04679675|ACTIVE_COMPARATOR|Opt-in|
62137640|NCT02336958|ACTIVE_COMPARATOR|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
62695290|NCT04254627|EXPERIMENTAL|Mifepristone 600 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 2 will receive one week of mifepristone at 600 mg (2x300 mg) daily.
62695291|NCT06008080||Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|The Navitor valve is available in four valve sizes to cover annulus diameters from 19 mm to 27 mm. The FlexNav delivery system is available in two sizes, small and large. The Navitor loading system is an accessory used to compress and load the Navitor valve onto the FlexNav delivery system and is available in two sizes, small and large.
62492615|NCT03822949|PLACEBO_COMPARATOR|Sham Comparator: Exposed to Room light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.
62335431|NCT00078962|EXPERIMENTAL|Treatment (GTI-2040, gemcitabine hydrochloride)|"Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
62335432|NCT03907982|EXPERIMENTAL|DCCV + PVI|"DC cardioversion (DCCV) plus Pulmonary Vein Isolation (Cryoablation)~At end of pulmonary vein isolation, DCCV performed (if patient still in AF). An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure."
62492616|NCT03822949|EXPERIMENTAL|Experimental: ICU Exposed to Day light|Patients undergoing trauma or elective surgery with ICU admission: Light therapy will consist of 30 minutes intense light each morning for 5-10 days. Blood will be drawn before sunrise and after light therapy. Light therapy will be performed by a study nurse to ensure proper use. In addition, endothelial function and activity will be measured using the noninvasive Endo-pat and ActiWatch device. The patient will need to keep the box as close as possible to their eyes and not walk away during the treatment period. This will be facilities by a study nurse.
62492617|NCT03822949|PLACEBO_COMPARATOR|Sham Comparator: ICU Exposed to Room light|Patients undergoing trauma or elective surgery with ICU admission: Light therapy will consist of 30 minutes using a placebo/control device (dim/night light box) each morning for 5-10 days. Blood will be drawn before sunrise and after light therapy. Light therapy will be performed by a study nurse to ensure proper use. In addition, endothelial function and activity will be measured using the noninvasive Endo-pat and ActiWatch device.
62492618|NCT06335927|EXPERIMENTAL|HAIC-GEMOX+Cadonilimab+Regorafenib|HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
62492619|NCT01614262|EXPERIMENTAL|Continuous Glucose Monitoring|The Continuous Glucose Monitoring (CGM) arm will receive care based upon results from there CGM data; treatment decisions are based on algorithm and CGM data
61940290|NCT05933824|EXPERIMENTAL|PartB:Dose level(10mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
61940291|NCT05933824|EXPERIMENTAL|PartB:Dose level(20mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
62137641|NCT02336958|PLACEBO_COMPARATOR|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
62137642|NCT02230046|EXPERIMENTAL|Sequence 1 (ABC)|Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 1, Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 2 and Treatment C (new composition, 2\*500 mg coated tablets) in Period 3.
62137643|NCT02230046|EXPERIMENTAL|Sequence 2 (BCA)|Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 1, Treatment C (new composition, 2\*500 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 3.
62137644|NCT02230046|EXPERIMENTAL|Sequence 3 (CAB)|Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2\*500 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 2 and Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 3.
62137645|NCT02230046|EXPERIMENTAL|Sequence 4 (ACB)|Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 1, Treatment C (new composition, 2\*500 mg coated tablets) in Period 2 and Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 3.
62492620|NCT01614262|ACTIVE_COMPARATOR|Self Monitoring Blood Glucose|Subjects in the Self Monitoring Blood Glucose group will have treatment decisions based on self monitored blood glucose values and not CGM values, per current standard of care.
62492621|NCT05774522|EXPERIMENTAL|Suspicion of sleep apnea syndrome|All patients, consulting Bichat sleep center for suspected sleep apnea syndrome
62137646|NCT02230046|EXPERIMENTAL|Sequence 5 (BAC)|Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 2 and Treatment C (new composition, 2\*500 mg coated tablets) in Period 3.
62137647|NCT02230046|EXPERIMENTAL|Sequence 6 (CBA)|Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2\*500 mg coated tablets) in Period 1, Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 3.
62137648|NCT04448366|EXPERIMENTAL|Cognitive behavioral therapy group|Patients in this group will undergo a total of 7 sessions of CBT in 5 months in addition to usual care.
62137649|NCT04448366|NO_INTERVENTION|Usual care|Patients in this group will undergo usual care only.
62492622|NCT05415891|EXPERIMENTAL|Stigma-Reduction Training Arm + YouRx Prescribing Platform|"Staff working in the clinic in this arm will be offered a whole-site stigma reduction training.~Participating HIV care providers will have access to the YouRx Prescribing Platform."
62492623|NCT05415891|EXPERIMENTAL|YouRx Prescribing Platform Only|"Staff working in the clinic in this arm will not be offered a whole-site stigma reduction training. However, staff will be offered this training at the conclusion of the study.~Participating HIV care providers will have access to the YouRx Prescribing Platform."
61940292|NCT05933824|EXPERIMENTAL|PartB:Dose level(40mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
61940293|NCT05933824|EXPERIMENTAL|PartB:Dose level(80mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
61940294|NCT05933824|EXPERIMENTAL|PartB:Dose level(160mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
61940295|NCT00331422|EXPERIMENTAL|Patients Who Received Treatment|All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
61940296|NCT05413421|EXPERIMENTAL|Single Agent Dose Escalation|ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles
62137650|NCT01292863|ACTIVE_COMPARATOR|Conventional peritoneal dialysis solution|Subjects will be randomized to perform dialysis with the conventional peritoneal dialysis solution for 3 months. At the end of three months mesothelial cell shedding and apoptosis will be measured.
61940297|NCT05413421|EXPERIMENTAL|Combination Dose Escalation|ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combinations with abiraterone, apalutamide, darolutamide, or enzalutamide
61940298|NCT05413421|EXPERIMENTAL|Combination Dose Optimization|"Cohort A and C: ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combination with apalutamide~Cohort B and D: ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combination with darolutamide~Combinations with abiraterone or enzalutamide may be conducted in the future"
62137651|NCT01292863|EXPERIMENTAL|Novel biocompatible dialysis solution Delflex neutral pH|
62137652|NCT05562427|OTHER|1|Gold-standard online behavioral weight loss treatment
62137653|NCT03753932|EXPERIMENTAL|Intervention|Dentures (fixed oral prosthesis) compared with standard treatment (removable oral prosthesis).
62335433|NCT03907982|ACTIVE_COMPARATOR|DC cardioversion (DCCV)|Acute treatment of heart rhythm by cardioversion. An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure.
62335434|NCT03806179|EXPERIMENTAL|10 MBq/kg Betalutin with rituximab treatment|10 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
62335435|NCT03806179|EXPERIMENTAL|15 MBq/kg Betalutin with rituximab treatment|15 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
62335436|NCT01670214|ACTIVE_COMPARATOR|Pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions phase 1 treatment and added 6 sessions for phase 2 treatment (3 sessions per week)
62335437|NCT01670214|PLACEBO_COMPARATOR|pulsed electromagnetic field|patients are placed under off instrument while who is kept blind to know it for 6 sessions (3 sessions per week).
62335438|NCT05844345|EXPERIMENTAL|Hydrocolloid barrier group|Premature infants will firstly be assessed by two nurses with undergraduate degrees working in the clinic in terms of neonatal skin condition score, nasal injury score, neonatal stress level and comfort score before beginning NIMV support. The colloid tape will be cut to a t-shape to cover across the bridge of the nose and the nasal septum and philtrum and placed on the infant's face.
62492624|NCT05758623|PLACEBO_COMPARATOR|magnesium containing biodegradable polymer bone repair material|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd.
62695292|NCT02322840|EXPERIMENTAL|Transcatheter Mitral Valve Replacement (TMVR) Implant|Twelve TMVR Implant
62695293|NCT06569407|EXPERIMENTAL|Experimental group nurses working in the inpatient wards|The nurses in the experimental group are expected to fill in the data collection tools (Introductory Information Form for Nurses, Evidence-Based Practice Competency Scale, Clinical Decision Making Scale in Nursing) before the education and then participate in the education about evidence-based practices on the online platform and fill in the data collection tools (Evidence-Based Practice Competency Scale, Clinical Decision Making Scale in Nursing and Education Evaluation Form) 20 days after the education.
62137654|NCT03024034|ACTIVE_COMPARATOR|Cohort A|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
62335439|NCT05844345|EXPERIMENTAL|Facial Massage group|Premature infants will firstly be assessed by two nurses with undergraduate degrees working in the clinic in terms of neonatal skin condition score, nasal injury score, neonatal stress level and comfort score before beginning NIMV support. After beginning NIMV support, the researcher will perform facial massage 2 times in each 12-hour shift.
62492625|NCT05758623|PLACEBO_COMPARATOR|β- Tricalcium phosphate bioceramics|Control group application β- Tricalcium phosphate bioceramics for treatment.
62492626|NCT05182606|EXPERIMENTAL|Implementation bundle|"Participating clinics will experience integration of the Implementation Bundle into their practices."
62492627|NCT05548335|OTHER|Ocular Ultrasound|This arm includes all patients enrolled who will have an ocular ultrasound with two different probes for a total of four ultrasounds.
61940299|NCT04864418|EXPERIMENTAL|Cohort group of AST-021p for dose-escalation|"4 cohort groups for AST- 021p administration:~Group 1) 1.2mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 2) 2.4mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 3) 3.6mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 4) 4.8mg AST- 021p, Montanide ISA 51 VG and rhuGM-CSF"
61940300|NCT01898208|EXPERIMENTAL|Control|Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
62492628|NCT03819088|EXPERIMENTAL|Group I (zinc months 1 and 2)|Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.
62492629|NCT03819088|EXPERIMENTAL|Group II (zinc months 3 and 4)|Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.
62492630|NCT06399445|PLACEBO_COMPARATOR|recurrent adenotonsillitis in the age group of 3 to 7 years old, non-rocuronium group|Anesthetic management: after entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
62492631|NCT06399445|ACTIVE_COMPARATOR|recurrent adenotonsillitis in the age group of 3 to 7 years old, rocuronium group|Anesthetic management: after entering the operating room, chlidren will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths. After loss of consciousness, we will turn off Sevoflurane, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, 1 mcg/kg Fentanyl, 2.5 mg/kg Propofol and 0.6 mg/kg Rocuronium bromide (esmeron). After 2 min, orotracheal intubation will be performed.
62492632|NCT04168580|NO_INTERVENTION|OA- Older Athlete|Older adults who are regularly engaged in endurance exercise
62492633|NCT04168580|ACTIVE_COMPARATOR|OS- Older Sedentary|Older adults who are sedentary
62492634|NCT01720953||Healthy control subjects|Matched healthy control subjects will be assessed at 6 month intervals to compare changes in DNA methylation, BDNF serum levels, salivary cortisol levels, and neuropsychological test performance. Healthy control subjects will within the 1-year study period also undergo continuous assessment for comparative changes in symptoms of dissociation, depression, and personality dysfunction.
62492635|NCT01497743|PLACEBO_COMPARATOR|placebo|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
62492636|NCT01497743|ACTIVE_COMPARATOR|Probiotic|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
62492637|NCT03667963|OTHER|Low Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
62492638|NCT03667963|OTHER|High Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
62492639|NCT05521919|EXPERIMENTAL|Stress (sympathetic nervous system activation)|"Stress will be induced using the socially evaluated cold pressor test.~Participants will complete three rounds of the socially evaluated cold pressor test.~The socially evaluated cold pressor test involves submerging one hand in ice-cold water for 3 minutes while participants' reactions are filmed on camera."
62492640|NCT05521919|SHAM_COMPARATOR|No-stress|Participants will hold a hand in room temperature water for 3 minutes.
62492641|NCT01887795|EXPERIMENTAL|1. WBRT alone|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
62492642|NCT01887795|EXPERIMENTAL|2. Erlotinib concurrent WBRT|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
62492643|NCT00674908|EXPERIMENTAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
61940301|NCT01898208|EXPERIMENTAL|FilmArray test|Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
61940302|NCT01898208|EXPERIMENTAL|FilmArray plus antimicrobial stewardship|Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.
62492644|NCT00674908|ACTIVE_COMPARATOR|Easy 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
62492645|NCT00804973|EXPERIMENTAL|1|
62492646|NCT00804973|PLACEBO_COMPARATOR|2|
62492647|NCT00804973|ACTIVE_COMPARATOR|3|
62695294|NCT06569407|PLACEBO_COMPARATOR|Control group nurses working in the inpatient wards|The nurses in the control group were expected to complete the data collection tools (Introductory Information Form for Nurses, Evidence-Based Practice Competency Scale, Clinical Decision Making Scale in Nursing) before the educational booklet was given and 20 days after the education.
61940303|NCT05342792|EXPERIMENTAL|Metronomic Capecitabine with PD-1 antibody arm|Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) and Tislelizuamb (200mg, iv drip, Q3W) for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.
61940304|NCT05342792|ACTIVE_COMPARATOR|Metronomic Capecitabine alone arm|Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) alone for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.
61940305|NCT06681116|EXPERIMENTAL|Patients with idiopathic hypercalciuria Group A|Patients receiving nano-water in a daily dose of 20 mL/Kg
62137655|NCT03024034|ACTIVE_COMPARATOR|Cohort B|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
62492648|NCT01958476|ACTIVE_COMPARATOR|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
62492649|NCT01958476|ACTIVE_COMPARATOR|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
62492650|NCT04744467|EXPERIMENTAL|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
62492651|NCT04763031|EXPERIMENTAL|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy - IORT
62492652|NCT00754507|EXPERIMENTAL|1|colesevelam tablets and atorvastatin tablets
62492653|NCT00754507|PLACEBO_COMPARATOR|2|colesevelam HCl placebo tablets and atorvastatin tablets
62492654|NCT02664792|EXPERIMENTAL|Diagnosis or suspicion of non-small cell lung carcinoma|SUS patients with diagnosis or suspicion of non-small cell lung carcinoma with an indication for mediastinoscopy
62492655|NCT02331628|NO_INTERVENTION|Control|Usual care only will be provided during Baseline period and Follow-up period.
62492656|NCT02331628|EXPERIMENTAL|ESWT - Extracorporeal Shockwave Therapy|Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
62492657|NCT05579262|EXPERIMENTAL|Normal|Subjects will consume 140mL of beetroot juice per day (800mg NO3/day), taken twice a day (70mL) in the afternoon and evening.
62492658|NCT05579262|EXPERIMENTAL|Pre-diabetic|Subjects will consume 140mL of beetroot juice per day (800mg NO3/day), taken twice a day (70mL) in the afternoon and evening.
62492659|NCT04220736||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
62492660|NCT04220736||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
62492661|NCT01216254|ACTIVE_COMPARATOR|Classic electrocoagulation|Arm of the study where the classic low-frequency electrocoagulation is used during the operation
62492662|NCT01216254|EXPERIMENTAL|High Frequency electrocoagulation|Arm of the study where the tested high-frequency electrocoagulation is used during the operation
62492663|NCT03127241|ACTIVE_COMPARATOR|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
62492664|NCT03127241|ACTIVE_COMPARATOR|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
62492665|NCT00994604|EXPERIMENTAL|broccoli sprout extract|This a before and after treatment study. The subjects will consumer broccoli sprout extract (BSE) for two weeks (14d). Lung function and Chest CT will be performed before and after BSE consumption.
62492666|NCT01732328|PLACEBO_COMPARATOR|placebo|Inactive pill (microcrystalline cellulose and corn starch) taken daily
62492667|NCT01732328|ACTIVE_COMPARATOR|Calcium plus vitamin D|600mg of calcium and 200 international units (IU) vitamin D taken daily
62492668|NCT03332264|EXPERIMENTAL|Drug coated balloon catheter|"PTA with paclitaxel coated SeQuent Please OTW"
62492669|NCT03332264|ACTIVE_COMPARATOR|Drug coated stent|"PTA with paclitaxel coated Eluvia Vascular Stent System"
61940306|NCT06681116|ACTIVE_COMPARATOR|Patients with idiopathic hypercalciuria Group B|Patients receiving Hydrochlorothiazide in a daily dose of 50 mg.
62492670|NCT03332264|ACTIVE_COMPARATOR|Uncoated stent|PTA with bare nitinol stent (as commonly used in site)
62492671|NCT02151149|OTHER|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
62137656|NCT03024034|ACTIVE_COMPARATOR|Cohort C|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
62137657|NCT03024034|ACTIVE_COMPARATOR|Cohort D|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
62137658|NCT03024034|ACTIVE_COMPARATOR|Cohort E|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
62137659|NCT03024034|ACTIVE_COMPARATOR|Cohort F|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
62492672|NCT02151149|OTHER|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg\*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
62335440|NCT05844345|NO_INTERVENTION|Control group|Premature infants will firstly be assessed by two nurses with undergraduate degrees working in the clinic in terms of neonatal skin condition score, nasal injury score, neonatal stress level and comfort score before beginning NIMV support. After beginning NIMV support, no procedure apart from routine care will be performed. Routine care includes feeding every 3 hours, diaper care, position changes, changing the placement of probes and electrodes and confirming the position of the nasal cannula.
62335441|NCT04756362||Prospective cohort|A minimum of 294 patients will be included in the evaluation of 0 and 1 hour protocol (prospective evaluation).
62695295|NCT06564480|EXPERIMENTAL|treatment group|"Patients received MI-R1 lower limb walking machine assisted training device based on their condition for the following training content:~1. Center of gravity transfer training;~2. Marking time and walking training;~3. Transfer training; 15 minutes each time, once a day, at least 5 times a week."
61940307|NCT06681116|PLACEBO_COMPARATOR|Patients with idiopathic hypercalciuria Group C|Patients receiving ordinary bottled drinking water in a daily dose of 20 mL/Kg
61940308|NCT06119035|OTHER|Prediabetic|n=10, single dose of 75 grams glucose in 200ml water
61940309|NCT05092854|ACTIVE_COMPARATOR|PR Lotion Topical Solution|Dose Dependent Response: Different doses relative to the participant's body weight will be provided for provision onto the skin before beginning data collection procedures. The 'larger' dose will be composed of 0.8g/kg of the PR Lotion while the 'smaller' dose will be composed of 0.4g/kg of the PR Lotion. Participants will be instructed to apply the lotion primarily to their lower extremities and upper extremities as needed. This lotion will be applied once during the Intervention session of each phase completed and will remain on the skin for approximately 3.5 hours.
62335442|NCT04756362||Retrospective cohort|A minimum of 1,000 patients will be included in the evaluation of prognostic value of high sensitive cardiac troponin \< 5 ng/L(retrospective evaluation).
62335443|NCT04935125|ACTIVE_COMPARATOR|Standard Program|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks.
62335444|NCT04935125|EXPERIMENTAL|Strength training|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks twelve 30-minute daily sessions of supervised peripheral limb muscle training, 2 set of 6-12 repetitions
62492673|NCT06404463|EXPERIMENTAL|QL1706|QL1706 (bispecific antibody (bsAb) targeting PD-1 and CLTA-4)+nab-P-AC/EC
62492674|NCT01202253||Anidulafungin|
62492675|NCT01395017|ACTIVE_COMPARATOR|Group 1|One arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD).
62492676|NCT01395017|PLACEBO_COMPARATOR|Group 2|The other arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle) plus matched placebo by mouth once daily (QD).
62492677|NCT05356169|EXPERIMENTAL|Venetoclax combined with intensive chemotherapy|The experimental group receives two cycles of inducation chemotherapy consisting of venetoclax combined with standard DA 3+7 regimen. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks. The consolidation chemotherapy regimen consists of three cycles of intermediate （for age\>55 years）or high（for age≤ 55 years） dose cytarabine combined with venetoclax.
62695296|NCT06564480|ACTIVE_COMPARATOR|control group|"Patients received walking rehabilitation training under the guidance of therapists based on their condition for the following training content:~1. Center of gravity transfer training;~2. Single leg weight-bearing training;~3. Marking time training assisted by balance bar；~4. Walking training assisted by balance bar; 15 minutes each time, once a day, at least 5 times a week."
62695297|NCT06643429||the control group|Adults with no history of malignancy and willing to participate in this study.
62695298|NCT06643429||the colorectal cancer group|Patients with preoperative diagnosis of colorectal cancer confirmed by pathological biopsy.
62695299|NCT06643429||the colorectal adenoma group|Patients with preoperative diagnosis of colorectal adenoma confirmed by colonoscopy.
62335445|NCT03020758|EXPERIMENTAL|Dried Fruit|Daily consumption of ¾ cup blend of dried plums, figs, dates and raisins (DPFDR) for 4 weeks
62335446|NCT03020758|EXPERIMENTAL|Control|Daily consumption of isocaloric and macronutrient matched snack food for 4 weeks
62335447|NCT01979796|EXPERIMENTAL|Ecig 24 mg nicotine|Ecig 24 mg nicotine
62335448|NCT01979796|SHAM_COMPARATOR|Ecig 0 mg nicotine|Ecig 0 mg nicotine
62335449|NCT01979796|PLACEBO_COMPARATOR|Nicotine free inhalator|Nicotine free inhalator
62335450|NCT04476355|NO_INTERVENTION|control group|In the same ICU, the former(2019-12\~2020-12) patients were the control group, data collected through case system.
62335451|NCT04476355|EXPERIMENTAL|experimental group|In the same ICU, the patients in the study period were the experimental group
62335452|NCT00745368|EXPERIMENTAL|Raltegravir|Raltegravir 400 mg tablets twice daily
62335453|NCT00986427|ACTIVE_COMPARATOR|1|Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
62335454|NCT00986427|PLACEBO_COMPARATOR|2|Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
62492678|NCT05356169|ACTIVE_COMPARATOR|Intensive chemotherapy only|The control group receives two cycles of inducation chemotherapy consisting of standard DA 3+7 regimen without venetoclax. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks. The consolidation chemotherapy regimen consists of three cycles of intermediate （for age\>55 years）or high（for age≤ 55 years） dose cytarabine without venetoclax.
62492679|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
62492680|NCT05692791||ITW|
62492681|NCT05692791||Control Group|
62492682|NCT05951088||atrial fibrillation patients|AF patients hospitalised at the cardiology department or coming for an outpatient visit
62695300|NCT04144517|EXPERIMENTAL|Group 1: Nemvaleukin 3 mcg/kg + Pembrolizumab 200 mg|Participants with current stable disease (SD) or partial response (PR) (Cohorts 1 and 2) who were not progressing or further demonstrating reductions in tumor size were to receive nemvaleukin alfa 3 microgram per kilogram (mcg/kg), intravenous (IV) infusion, daily from Days 1 to 5 of the first week of each 3-week treatment cycle in combination with pembrolizumab 200 milligram (mg), IV infusion, once, every three weeks (Q3W) on Day 1 of each 21-day cycle until confirmed progression, unacceptable toxicity or met other criteria for discontinuation.
62335455|NCT04818814|EXPERIMENTAL|Mindfulness Meditation (MM) App|Participants randomized to the MM condition will be asked to download and use the free Mindfulness Coach app (available for iOS and Android platforms) developed by the Veteran Affairs National Center for PTSD. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes. Participants will attend a live videochat orientation to the study with the research coordinator (RC) to receive assistance in downloading and using the app. Participants will be asked to listen to at least one, and ideally two, audio-guided meditation exercises using the app daily for six weeks. The RC will ask participants to complete weekly logs of their MM app use via a Qualtrics survey sent via email.
62335456|NCT04818814|ACTIVE_COMPARATOR|Engagement and Distraction (ED) App|Participants randomized to the Engagement and Distraction condition will be asked to download and use the free TED Talk app (available for iOS and Android platforms). The app offers many videos of engaging and distracting presentations about technology, entertainment, and design. The research coordinator will work with the participant to create a customized list of Ted Talk videos, each lasting 6-12 minutes, based on participants' personal interests. Participants will be asked to listen to or watch at least one, and ideally two, presentations using the app daily for six weeks. The research coordinator will ask participants to complete weekly logs of their TED Talk app use via a Qualtrics survey sent via email.
62335457|NCT05463874|EXPERIMENTAL|Mindful Self-Compassion Arm|Participants in this arm will participate in an 8-week virtual mindful self-compassion program.
62335458|NCT05463874|NO_INTERVENTION|Wait-list Control Arm|Participants in this arm will receive usual clinical care and will have the opportunity to participate in the mindful self-compassion program at the end of the study.
61940310|NCT05092854|PLACEBO_COMPARATOR|Placebo Lotion Topical Solution|A dose of lotion relative to the participant's body weight will be provided for provision onto the skin before beginning data collection procedures. This dose will be approximately 0.8g/kg of the Placebo Lotion. Similar to the PR Lotion, participants will be instructed to apply the lotion primarily to their lower extremities and upper extremities as needed. This lotion will be applied once during the Intervention session of each phase completed and will remain on the skin for approximately 3.5 hours.
62492683|NCT05951088||heart failure patients|HF patients hospitalised at the cardiology department or coming for an outpatient visit
62695301|NCT04144517|EXPERIMENTAL|Group 2: Nemvaleukin Alfa 3 mcg/kg + Pembrolizumab 200 mg|Participants with progressive disease (PD) (Cohorts 3 and 4) received nemvaleukin alfa 3 mcg/kg, IV infusion, daily from Days 1 to 5 of the first week of each 3-week treatment cycle in combination with pembrolizumab 200 mg, IV infusion, once, Q3W on Day 1 of each 21-day cycle until confirmed progression, unacceptable toxicity or met other criteria for discontinuation.
62137660|NCT03024034|ACTIVE_COMPARATOR|Cohort G|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
62137661|NCT06642571|EXPERIMENTAL|Part 1a: NNC0519-0130 C and NNC0519-0130 B|Participants will start treatment with formulation NNC0519-0130 C and receive a pre-determined dose escalation regimen of NNC0519-0130 B and NNC0519-0130 C.
62137662|NCT06642571|EXPERIMENTAL|Part 1b: NNC0519-0130 B and NNC0519-0130 C|Participants will start treatment with formulation NNC0519-0130 B and receive a pre-determined dose escalation regimen of NNC0519-0130 B and NNC0519-0130 C.
62137663|NCT06642571|EXPERIMENTAL|Part 2a: NNC0519-0130 B and NNC0519-0130 C|Participants will receive a pre-determined dose escalation regimen of NNC0519-0130 B in run-in period followed by treatment with NNC0519-0130 B then NNC0519-0130 C.
62137664|NCT06642571|EXPERIMENTAL|Part 2b: NNC0519-0130 C and NNC0519-0130 B|Participants will receive a pre-determined dose escalation regimen of NNC0519-0130 B in run-in period followed by treatment with NNC0519-0130 C then NNC0519-0130 B.
62137665|NCT05320874|EXPERIMENTAL|KM257|KM257 Bispecific antibody
62137666|NCT00783497||1|Caucasian Americans
62137667|NCT00783497||2|African Americans
62137668|NCT06698341||Group 1|Age ≤50 years old irrespective of the presence of CV risk factors\* at the time of myocardial infarction
62335459|NCT04043182|NO_INTERVENTION|group control|You will not receive any type of intervention
62335460|NCT04043182|EXPERIMENTAL|treatment group (ultrasound)|Will perform protocols of 10 sessions of ultrasound in the region of abdomen
62137669|NCT06698341||Group 2|Age 51-60 years old with no more than 2 CV risk factor at the time of myocardial infarction, excluding diabetes mellitus
62137670|NCT06587919|ACTIVE_COMPARATOR|Real EEG-NF|10 EEG based neurofeedback sessions modulating the activity of the default mode network.
62137671|NCT06587919|SHAM_COMPARATOR|Sham EEG-NF|10 sessions of neurofeedback another person's EEG.
62335461|NCT04043182|PLACEBO_COMPARATOR|placebo group|It will perform protocols of 10 sessions of ultrasound in the region of abdomen, but the apparatus will be with zero intensities
62335462|NCT00133900||Cohort|Metastatic Hormone Refractory Prostate Cancer Patients
62335463|NCT01504854|EXPERIMENTAL|Resveratrol|Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
62335464|NCT01504854|PLACEBO_COMPARATOR|Placebo|Subjects will receive a matching placebo to be taken with or without food.
62137672|NCT01121965|NO_INTERVENTION|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs
62137673|NCT01121965|EXPERIMENTAL|Early vitrectomy|Pars plana vitrectomy with ILM peeling would be employed when visual symptoms occur.
62335465|NCT00208312|EXPERIMENTAL|1|Regadenoson
62335466|NCT00208312|ACTIVE_COMPARATOR|2|Adenoscan
62335467|NCT02375958|EXPERIMENTAL|Triple Negative Breast Cancer|
62335468|NCT02375958|EXPERIMENTAL|Head and Neck Cancer|
62492684|NCT05702762|ACTIVE_COMPARATOR|Gentamicin|Subjects will be given one (1) injection intramuscular gentamicin 5 mg/kg (actual body weight unless patient is \>120% ideal body weight in which case adjusted body weight will be utilized).
62492685|NCT05702762|ACTIVE_COMPARATOR|Standard of Care|Oral antibiotic prescription
62492686|NCT01049282|EXPERIMENTAL|12 TST negative volunteers antigen only|
62492687|NCT01049282|EXPERIMENTAL|12 TST negative volunteers|
62492688|NCT01049282|EXPERIMENTAL|12 BCG vaccinated volunteers|
62492689|NCT01049282|EXPERIMENTAL|12 with Latent TB infection >= 2 years ago|
62492690|NCT04058977|EXPERIMENTAL|Power training|Randomized to early power training with standardized exercise progression plus standard of care
62492691|NCT04058977|NO_INTERVENTION|Standard of Care|Standard of care
62492692|NCT04333134|EXPERIMENTAL|Dose level 1|Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.
62492693|NCT01875055|EXPERIMENTAL|NIRS derived cerebral oximetry|NIRS derived cerebral oximetry device used but data not visable to ICU caregivers
62492694|NCT01875055|ACTIVE_COMPARATOR|NIRS and Algorithm|NIRS derived cerebral oximetry device used and the caregiver in the ICU will see the data in order to guide the use of the interventional algorithm to treat the cerebral desaturation
62492695|NCT04702789|EXPERIMENTAL|Arm 1; Dorzolamide-timolol-brimonidine and latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
62492696|NCT04702789|EXPERIMENTAL|Arm 2; Dorzolamide-timolol and latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
62492697|NCT05407064|PLACEBO_COMPARATOR|Arm 1- Placebo|A substance that is designed to have no therapeutic value.
62335469|NCT02375958|EXPERIMENTAL|Esophageal Cancer|
62335470|NCT00115804|EXPERIMENTAL|Fluoxetine|All eligible patients were started on Fluoxetine at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
62492698|NCT05407064|EXPERIMENTAL|Arm 2- 25 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
62492699|NCT05407064|EXPERIMENTAL|Arm 3- 50 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
62492700|NCT05407064|EXPERIMENTAL|Arm 4- 100 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
62492701|NCT05407064|EXPERIMENTAL|Arm 5- 200 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
62335471|NCT04769635|EXPERIMENTAL|CPAP ttt|
62492702|NCT03008655|ACTIVE_COMPARATOR|Nd-YAG|ND-YAG only
62492703|NCT03008655|EXPERIMENTAL|Nd-YAG and intradermal tranexamic acid|Nd-YAG combine with intradermal tranexamic acid
62492704|NCT05539794|EXPERIMENTAL|Intervention|The intervention group will follow a physical exercise and lifestyle counselling program.
62492705|NCT05539794|NO_INTERVENTION|Control|Standard care
62492706|NCT01371617|EXPERIMENTAL|IPI-926|Single Arm, Phase 2 trial evaluating the safety and efficacy of IPI-926 in patients with myelofibrosis
62492707|NCT03590119|EXPERIMENTAL|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
62492708|NCT03590119|ACTIVE_COMPARATOR|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
62335472|NCT01085305|EXPERIMENTAL|PCIT|Provision of Parent-Child Interaction Therapy
62335473|NCT01085305|ACTIVE_COMPARATOR|TAU|Treatment as usual from other therapists in the same clinics
62335474|NCT05667155|EXPERIMENTAL|CB dualCAR-NK19/70|All subjects were intravenously administrated with CB dualCAR-NK19/70
62335475|NCT02493816|EXPERIMENTAL|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
62335476|NCT03182400|EXPERIMENTAL|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
62335477|NCT02529241|EXPERIMENTAL|Group 1: LCB01-0371|Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
62335478|NCT02529241|EXPERIMENTAL|Group 2: LCB01-0371|Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
62335479|NCT04100798|EXPERIMENTAL|Entire Papilla Preservation (EPP) technique|A minimally invasive surgical technique that involves using a vertical incision away from the defect area in order to preserve the integrity of the related interdental papilla and elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
62492709|NCT03513549||Loxapine 10 MG|ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.
62492710|NCT05191238|EXPERIMENTAL|Participants consented for IUD removal|Participants will be shown an educational video about IUD self-removal and simulation models. After the video, participants will be given the choice to either attempt IUD self-removal or to have their provider perform standard removal. If a participant elects to attempt self-removal and fails, their provider will offer standard removal.
62492711|NCT00156182|EXPERIMENTAL|1|
62492712|NCT01659073|EXPERIMENTAL|Caloric Vestibular Stimulation|Caloric vestibular stimulation performed by a modified stethescope ear attachment attached to an MRI compatible infusion pump.
62695302|NCT03009292|EXPERIMENTAL|24 mg lenvatinib|Participants will receive once daily oral dosing of lenvatinib 24 milligrams (mg)
62335480|NCT04100798|ACTIVE_COMPARATOR|Modified Minimally invasive Surgical Technique (M-MIST)|A minimally invasive surgical technique that involves using a horizontal interdental incision that extends to the buccal aspect of the two teeth adjacent to the intraosseous defect then elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
62335481|NCT04228692|ACTIVE_COMPARATOR|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary
62492713|NCT03122522|EXPERIMENTAL|ipilimumab and nivolumab|Pts will receive 2 doses of ipilimumab 3mg/kg + nivolumab 1mg/kg every 3 weeks. Week 6, if pts have achieved a favorable antitumor effect by RECIST will begin maintenance nivolumab alone at 480mg every 4 weeks for 2 doses (week 6 \& week 10) \& repeat response assessments at week 12. If pts don't achieve a favorable antitumor effect at week 6, pt will get 2 additional doses of ipilimumab + nivolumab every 3 weeks \& then will be assessed for response at week 12. If pts haven't achieved a favorable antitumor effect by week 12, if felt in the best interest for the pt as determined by the PI, pts may continue getting additional doses of ipilimumab + nivolumab with response reassessments after every 2 doses. Maintenance nivolumab will continued until unacceptable toxicity or confirmed disease progression. If pts have had an initial clinical benefit from therapy \& subsequently experience progressive disease at any time, reinduction with combination ipilimuma+ nivolumab will be allowed.
62492714|NCT03161197|EXPERIMENTAL|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
62492715|NCT01881763|EXPERIMENTAL|Ketamine|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
62492716|NCT01881763|ACTIVE_COMPARATOR|Methohexital|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
62492717|NCT03867916|EXPERIMENTAL|Health services research (Patient COUNTS)|Patients attend focus groups to help develop patient portal and navigation program. Patients use in-person navigation program. Patients also complete data collection and surveys over 15 minutes via web portal at baseline, 3 months, and 6 months and user experience survey at end of program participation.
62492718|NCT05562037|NO_INTERVENTION|Treatment as usual|"Patients referred to CR or PR are initially telephoned by a RN,RC or RA who describes the program and schedules the initial intake evaluation. The intake evaluation reflects usual care practices at both BMC and Fairview Hospital. The purpose of this initial session is to obtain the data required to design an individualized effective and safe rehabilitation program. It is performed by a RN, RC, or RA and includes performing a medical history, physical examination, and testing.~Reminder telephone calls are placed prior to the initial intake and formal reassessments visits."
62695303|NCT06637397|EXPERIMENTAL|Probiotic Group|Participants receive one sachet per day containing probiotic BC99 and maltodextrin (Week 0 to Week8).
62695304|NCT06637397|PLACEBO_COMPARATOR|Placebo Group|Participants receive one sachet per day containing maltodextrin only, serving as the placebo(Week 0 to Week8).
62335482|NCT04228692|EXPERIMENTAL|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
62335483|NCT04899791|EXPERIMENTAL|Wheat bread enriched with hydroxytyrosol|
62335484|NCT04899791|ACTIVE_COMPARATOR|Wheat bread|
62335485|NCT01104584|EXPERIMENTAL|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) \[0.1 ml/kg bw\] as an intravenous injection (i.v.) at a rate of 2 ml/sec. Unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.
62335486|NCT06530589|EXPERIMENTAL|Interventional Group|Tupler's Technique will be applied to this group. This technique includes Tupler's technique exercises and patients will also wears diastasis rehab splints. Patients will perform seated isometric exercises (elevator and contracting exercises) after wearing diastasis rehab splint. Repetitions of exercises will be 100 and whole intervention will be provided for 6 weeks.
62335487|NCT06530589|ACTIVE_COMPARATOR|Control Group|Traditional treatment protocol will be applied to this group that includes traditional exercises for diastasis rectus abdominis and this protocol will be followed 3 times per week for 6 weeks.
62335488|NCT00242385|EXPERIMENTAL|ARALAST Fr. IV-1|60 mg/kg
62335489|NCT00242385|ACTIVE_COMPARATOR|ARALAST|60mg/kg
62335490|NCT06170372|EXPERIMENTAL|Main group with nosocomial pneumonia|Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
62335491|NCT06170372|ACTIVE_COMPARATOR|Control group with nosocomial pneumonia|Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
62335492|NCT06170372|EXPERIMENTAL|Main group with community acquired pneumonia|Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
62335493|NCT06170372|ACTIVE_COMPARATOR|Control group with community acquired pneumonia|Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
62335494|NCT05364879|EXPERIMENTAL|Intervention|Circuit-based prehabilitation exercise intervention
62492719|NCT05562037|ACTIVE_COMPARATOR|Stepped Care|"The SC arm will be offered Center Based Rehabilitation (CBR) and subsequently stepped up to transportation-subsidized CBR, home-based TR, and CHW-supported home-based TR based on prespecified non-response criteria/poor adherence.~Standard of Care. Patients meeting a non-response criterion will be stepped up to transportation-subsidized CBR.~Step 1. Transportation-Subsidized CBR. Step 2. Home-Based TR. Step 3. CHW-Supported Home-Based TR."
62335495|NCT04548687|ACTIVE_COMPARATOR|carbon dioxide insufflation|patients with planned minimally invasive or repeated cardiac surgery using standard methods of deaeration of cardiac cavities, supplemented with carbon dioxide insufflation during surgery + standard methods of deaeration of cardiac cavities
62335496|NCT04548687|OTHER|no carbon dioxide|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
62335497|NCT01332812|EXPERIMENTAL|Dexamethasone, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
62335498|NCT01332812|SHAM_COMPARATOR|Control, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
62335499|NCT04579679|EXPERIMENTAL|Surufatinib|"Cohorts A, B, and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1~Cohort D:~Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1"
62335500|NCT04004533||Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
62335501|NCT01184404|EXPERIMENTAL|Treatment|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
62335502|NCT01184404|NO_INTERVENTION|Control|
62335503|NCT02030145|ACTIVE_COMPARATOR|Classic Thoracic Lymphatic Pump|Subjects begin with Classic Thoracic Lymphatic Pump, then crossover to Compressive Thoracic Lymphatic Pump after 4-week washout period.
62335504|NCT02030145|EXPERIMENTAL|Compressive Thoracic Lymphatic Pump|Subjects begin with Compressive Thoracic Lymphatic Pump, then crossover to Classic Thoracic Lymphatic Pump after 4-week washout period.
62335505|NCT03347604||Patients with abdominal obesity|Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of \> 0.85 in women, or \> 0.9 in men.
62335506|NCT04895943||Group with adjustable IGB|
62335507|NCT04895943||Group with non-adjustable IGB|
62335508|NCT02583802|NO_INTERVENTION|Control group|Control group received regular hemodialysis treatment, no given Ear pills and Shengmai capsule completed in the treatment of the first stage. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
62335509|NCT02583802|EXPERIMENTAL|Ear pills and Shengmai capsule|On regular hemodialysis based on given auricular Ear pills and Shengmai capsule
62492720|NCT03610607|ACTIVE_COMPARATOR|intense education of periodontal health maintenance|
62492721|NCT03610607|PLACEBO_COMPARATOR|No intense education of periodontal health maintenance|
61940311|NCT05092854|EXPERIMENTAL|Hydration Status|Participants will be asked to partake in 5 total Intervention trials. Upon arrival to each trial, the participant will be asked to complete an 18-24 fluid restriction protocol to ensure their arrival within a dehydrated state. Depending on the phase randomization assigned to each participant, they will either be provided fluids to consume that will bring them back to an estimated level of 1% dehydration (total of 3/5 trials completed) or they will not be given any fluids to consume during the duration of the trial (total 2/5 trials completed). Participants will be considered completed with project participation upon the completion of each of the five trials outlined.
62492722|NCT05389813|ACTIVE_COMPARATOR|Oxycodone|20 mg oxycodone hydrochloride and 10 mg naloxone hydrochloride given as 1 tablet only once, 30 minutes preoperatively.
62492723|NCT05389813|ACTIVE_COMPARATOR|Pregabalin|150 mg Pregabalin given as 1 tablet only once, 30 minutes preoperatively.
62492724|NCT05389813|PLACEBO_COMPARATOR|Multivitamin|Abecedin Multivitamins\&Minerals given as 1 tablet only once, 30 minutes preoperatively.
62492725|NCT03454737|EXPERIMENTAL|mesenchymal stem cells|
62492726|NCT03454737|ACTIVE_COMPARATOR|Pure platelet-rich plasma|
62492727|NCT01813864|EXPERIMENTAL|CASPAR Resource Guide|Treatment Enhanced/CASPAR-- All counselors in this study will receive a training and take part in the experimental arm of the study in Phase 2.
62492728|NCT00755235|EXPERIMENTAL|1|Participants will receive depression care management by secure messaging.
62492729|NCT00755235|NO_INTERVENTION|2|Participants will receive their usual care, with no additional education or care management services.
62492730|NCT01816360|EXPERIMENTAL|Aromatherapy group|20 sessions of olfactory aromatherapy using protocol.
62492731|NCT01816360|EXPERIMENTAL|Yogatherapy group|20 sessions of yogatherapy with aroma-placebo using protocol.
62492732|NCT01816360|EXPERIMENTAL|Aromatherapy-Yogatherapy group|20 sessions of yogatherapy with olfactory aromatherapy, using protocol.
62335510|NCT06405022|ACTIVE_COMPARATOR|Control (CON)|The control condition entails a six-week period. The participant will complete three regular high intensity training per week followed by 20 min of rest
62695305|NCT06101485|EXPERIMENTAL|Telerehabilitation group|The telerehabilitation group (n=104) will participate in the FP-AF program for 16 weeks. The program is administered by the AF clinics and the healthcare centers (HC) in Viborg, Skive and Silkeborg Municipalities. After enrollment, the patients will have an individual meeting with the project nurse. Here the patient (and relatives, if necessary) will be instructed in the use of the technologies and an individual plan will be formulated for the AF patient's telerehabilitation. After participation in 16 weeks the patients start a 12 weeks follow-up period, where they will only measure steps and have access to the Heartportal on their own devices.
62335511|NCT06405022|EXPERIMENTAL|Brain Endurance Training (BET)|The intervention period also entails a 6 week period but with three weekly blocks with a 20 min brain endurance training program following a regular high intensity training session.
62335512|NCT06282497|EXPERIMENTAL|Study Group|optimised neck CTV delineation
62335513|NCT06282497|ACTIVE_COMPARATOR|Control Group|standard neck CTV delineation
62335514|NCT01773135||preterm group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation \> 1 and \< 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver preterm (before 37 weeks of gestation)
62335515|NCT01773135||full term group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation \> 1 and \< 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver full term (after 37 weeks of gestation)
62335516|NCT02273440|EXPERIMENTAL|BIIL 284 BS with theophylline|
62335517|NCT02273440|PLACEBO_COMPARATOR|Placebo with theophylline|
62335518|NCT01525849|ACTIVE_COMPARATOR|Balloon Sinus Dilation|XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
62335519|NCT01525849|ACTIVE_COMPARATOR|Functional Endoscopic Sinus Surgery|Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.
62335520|NCT05485272|EXPERIMENTAL|Intervention 1|Silver Diamine Fluoride combined with Potassium Iodide (Riva Star), under High-Viscosity Glass Ionomer (EQUIA).
62335521|NCT05485272|EXPERIMENTAL|Intervention 2|Silver Diamine Fluoride (SDF), under High-Viscosity Glass Ionomer (EQUIA).
62335522|NCT05485272|ACTIVE_COMPARATOR|The comparator|High-Viscosity Glass Ionomer (EQUIA).
62335523|NCT04619875|OTHER|Lactulose|
62335524|NCT04619875|OTHER|KB5|
62335525|NCT04619875|OTHER|SG1|
62335526|NCT02833116|EXPERIMENTAL|Group Betamethasone|One ampule containing 12 mg of betamethasone in a syringe of 10 ml
62335527|NCT02833116|ACTIVE_COMPARATOR|Group Dexamethasone|One ampule containing 4 mg of dexamethasone in a syringe os 10 ml
62335528|NCT00848549|ACTIVE_COMPARATOR|ZNS|
62335529|NCT00848549|ACTIVE_COMPARATOR|CBZ|
62335530|NCT05181319||bronchopulmonary dysplasia group|infants diagnosed with bronchopulmonary dysplasia
62335531|NCT05181319||no bronchopulmonary dysplasia|infants not diagnosed with bronchopulmonary dysplasia
62335532|NCT01152567||ACE|Patients treated for hypertension with ACEs without CVD
62335533|NCT01152567||Candesartan|Patients treated for hypertension with candesartan without CVD
62335534|NCT05145075|EXPERIMENTAL|Survey group|Patients are asked to fill in a survey.
62335535|NCT03242083||Primary atrophic AMD|
62335536|NCT03242083||Secondary atrophic AMD|
62335537|NCT02364947|EXPERIMENTAL|Nalmefene hydrochloride 10 mg|
62335538|NCT02364947|EXPERIMENTAL|Nalmefene hydrochloride 20 mg|
62335539|NCT02364947|PLACEBO_COMPARATOR|Placebo|
62335540|NCT02822443|EXPERIMENTAL|TAU - EFT|This arm integrates emotion focused components (EFT; Greenberg, 2010) into psychological therapy (PT) as treatment-as-usual (TAU), aiming at clarifying and transforming maladaptive emotions. 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
62335541|NCT02822443|EXPERIMENTAL|TAU - SR|This arm focuses on the training of self-regulation strategies (SR; Carver \& Scheier, 2000) in the context of psychological therapy (PT) as treatment-as-usual (TAU). 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions.
62335542|NCT02653105|EXPERIMENTAL|OLFM4|Patient have a blood test every 6 months at the same time of the clinical exam planned in the following. The OLFM4 will be dose in the blood sample and the rate of OLFM4 compared to the result of imaging.
62335543|NCT02776657|ACTIVE_COMPARATOR|Cohort 1 (Stable Angina)|20 patients with stable angina planned to undergo elective coronary angiography will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries.
62335544|NCT02776657|ACTIVE_COMPARATOR|Cohort 2 (Acute Coronary Syndrome)|20 patients diagnosed with acute coronary syndrome will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries. If thrombus is identified, participants will be asked to undergo a repeat MRI scan at one and three months.
62335545|NCT03998475|EXPERIMENTAL|Transition preparation program|Transition preparation intervention for young adults with type 1 diabetes (T1D)
62335546|NCT02683616|EXPERIMENTAL|OSA + T2DM|CPAP treatment
62335547|NCT02683616|EXPERIMENTAL|OSA no T2DM|CPAP treatment
62335548|NCT02683616|NO_INTERVENTION|T2DM no OSA|Standard care
62335549|NCT02683616|NO_INTERVENTION|Healthy controls no ÓSA|no intervention
62335550|NCT00454155|EXPERIMENTAL|Opebacan|
62335551|NCT04196361||Ventilated72h|Patient that were ventilated for at least 72 hours
62492733|NCT01816360|NO_INTERVENTION|Control group|Control group in the waiting-list model (all volunteers were offered the treatment after the completion of data collection).
62335552|NCT02620462|EXPERIMENTAL|Wearable sensor-based exercise training|The intervention group in addition to standard of care, will receive 6 weeks of sensor-based balance training that provides real-time visual feedback of lower extremities during exercise. The visual feedback is provided on computer screen.
62335553|NCT02620462|NO_INTERVENTION|Control Group|The control group only receives standard of care.
61940312|NCT05092854|ACTIVE_COMPARATOR|aminoVITAL - Amino Acid Rehydration Supplement|Participants will be provided with 3 servings of a commercially available amino acid rehydration supplement for consumption after the completion of the dehydrated heat stress intervention. Participants will be instructed to consume each serving in a time-dependent manner over the 24-hour period after dismissal from the laboratory after completion of the Intervention session.
61940313|NCT05092854|PLACEBO_COMPARATOR|Placebo Drink Supplement Solution|Participants will be provided with 3 servings of a placebo rehydration supplement for consumption after the completion of the dehydrated heat stress intervention. Participants will be instructed to consume each serving in a time-dependent manner over the 24-hour period after dismissal from the laboratory after completion of the Intervention session.
61940314|NCT00983671||children with asthma|children with diagnosed asthma, age 6-18 years
61940315|NCT00983671||cystic fibrosis|children with cystic fibrosis, age 6-18 years
62335554|NCT05140005|OTHER|15 subjects testing themselves|15 subjects will use the Glow Test Kit to test themselves for Covid 19.
62335555|NCT05140005|OTHER|15 subjects testing someone else|15 subjects will use the Glow Test Kit to test someone else (a child) for Covid 19.
62335556|NCT05582811|EXPERIMENTAL|Dose Riociguat 2,5 or 5mg|Riociguat dose finding pilot experiment, 2,5mg and 5mg
62335557|NCT05582811|ACTIVE_COMPARATOR|Riociguat|Riociguat orally
62335558|NCT05582811|PLACEBO_COMPARATOR|Placebo|Placebo orally
62335559|NCT01002859|ACTIVE_COMPARATOR|cyclosporin|Intravenous cyclosporin injection.
62335560|NCT01002859|PLACEBO_COMPARATOR|Pacebo|Intravenous injection of NaCl solution.
62335561|NCT03740607|EXPERIMENTAL|Virtual reality during PIV placement|Randomized consented adult subjects will participate in a six-minute healthcare virtual reality software program via Samsung Gear virtual reality headsets while receiving 18 or 20-gauge peripheral intravenous catheter placement in peri-operative suite in preparation for surgery. They will be asked to rate their pain and discomfort afterwards using a graphic rating scale. They will be asked several questions about satisfaction, in order to elicit clinical significance of this intervention. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
62335562|NCT03740607|PLACEBO_COMPARATOR|Standard PIV placement|Adult control arm subjects will receive 18 or 20-gauge peripheral intravenous catheter placement according to current standard protocol, without virtual reality distraction .They will be asked to rate pain and discomfort afterwards using a graphic rating scale. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
62335563|NCT02280291|ACTIVE_COMPARATOR|Ankle Single Shot Block (SSB)|
62335564|NCT02280291|EXPERIMENTAL|Ankle OnQ (Continuos Sedation OnQ Pump)|
62335565|NCT02280291|EXPERIMENTAL|DR SSB|
62335566|NCT02280291|EXPERIMENTAL|DR OnQ|
62335567|NCT01455038||Control group|Healthy controls had no history of psychiatric disorder and had no psychiatric symptom when interviewed by a board-certified psychiatrist.
62335568|NCT01455038||Bipolar group|individual patient as being in subsyndromal depressive phase when the patient had a Montgomery-Åsberg depression rating scale score of 10 or less and Clinical Global Impression severity of 3 or less for last one month.
61940316|NCT00983671||chronic lung disease|children with chronic lung disease, also known as bronchopulmonary dysplasia, age 6-18 years
61940317|NCT00983671||pneumonia|children with clinical signs of pneumonia, age 6-18 years
61940318|NCT05626582|EXPERIMENTAL|Pain Stimulus - Learning Only|Capsaicin combined with heat applied to intact skin
61940319|NCT05626582|EXPERIMENTAL|Pain Stimulus - Learning and Retention|Capsaicin combined with heat applied to intact skin
61940320|NCT05626582|NO_INTERVENTION|No Stimulus|Nothing applied to skin
62335569|NCT01469494|ACTIVE_COMPARATOR|DIEP flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
62335570|NCT01469494|ACTIVE_COMPARATOR|SIEA flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
62335571|NCT04131517|EXPERIMENTAL|Oral contraceptive|Participants will receive oral contraceptive in Period 2 of Sequence A and Period 1 of Sequence B of Part 1 and Part 2.
62335572|NCT04131517|EXPERIMENTAL|Oral contraceptive + padsevonil|Participants will receive padsevonil + oral contraceptive in Period 1 of Sequence A and Period 2 of Sequence B of Part 1 and Part 2.
62335573|NCT03578848|ACTIVE_COMPARATOR|uAOBP & Home BP|On the scheduled visits, the uAOBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
62335574|NCT03578848|EXPERIMENTAL|CBP & Home BP|On the scheduled visits, the CBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
62335575|NCT05315232||Qualitative assessment|Survey (using validated quality of life assessment questionnaires) and one to one interviews of people and family members living with Glanzmanns Thrombasthenia
62335576|NCT05315232||Bleed diary|Daily bleed diary completion over 12 weeks
62492734|NCT04097041|ACTIVE_COMPARATOR|Surgical Arm|Surgery arm - patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).Patient has routine follow up - H\&P, 2 weeks after surgery and then H\&P, Audiometry and Tympanometry over 12 months post surgery (3rd month, 6th month and 12th month).
62335577|NCT03262597|EXPERIMENTAL|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
62492735|NCT04097041|ACTIVE_COMPARATOR|Non-Surgery|"Non surgery arm - patient has audiological consult and fitting of masking device.~The Patient has a routine follow up - H\&P, 2 weeks after masking fitting and then H\&P, Audiometry, Tympanometry over 12 months (3rd month, 6th month and 12th month). Patient cross over to change arms, at 6 months, if they have no resolution of symptoms."
62492736|NCT03893617|ACTIVE_COMPARATOR|Propranolol group|This group will receive a single oral dose (80mg) of propranolol in a blinded capsule during their acute stress study visit.
62492737|NCT03893617|PLACEBO_COMPARATOR|Placebo group|This group will receive a single blinded capsule containing no active medication during their acute stress study visit.
62492738|NCT01499043|EXPERIMENTAL|PLX3397|Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.
62492739|NCT04686435||Non-surgical treatment|Shoulder patients referred for non-surgical treatment after being diagnosed at the medical examination.
62492740|NCT04686435||Surgical treatment|Shoulder patients referred for surgical treatment after being diagnosed at the medical examination.
62492741|NCT04714060|EXPERIMENTAL|cohort 1|2.5 mg/kg UB-621 group
62492742|NCT04714060|EXPERIMENTAL|cohort 2|5 mg/kg UB-621 group
62492743|NCT02722798|EXPERIMENTAL|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks from Week 0 through Week 224
62492744|NCT02726841|EXPERIMENTAL|Hybrid TAAD repair|The group includes patients who underwent open thoracoabdominal aortic repair + abdominal stenting.
62492745|NCT02726841|ACTIVE_COMPARATOR|Conventional TAAD repair|The group includes patients who underwent classic thoracoabdominal aortic repair with dacron prosthesis.
62492746|NCT04013763|EXPERIMENTAL|Atopic dermatitis with stop using product|case wheat allergy with atopic dermatitis and stop using wheat containing skin care products
62492747|NCT04013763|EXPERIMENTAL|Atopic dermatitis with containing using product|case wheat allergy with atopic dermatitis and continue using wheat containing skin care products
62335578|NCT00863837|ACTIVE_COMPARATOR|Arm A|add pantoloc to reduce ulcer bleeding after banding ligation
62335579|NCT00863837|PLACEBO_COMPARATOR|Arm B: ligation + terlipressin 1mg q6h|Arm B, intervention: ligation + terlipressin 1mg q6h
62492748|NCT04013763|EXPERIMENTAL|Non atopic dermatitis with stop using product|case wheat allergy with normal skin and stop using wheat containing skin care products
62492749|NCT04013763|EXPERIMENTAL|Non atopic dermatitis with continue using product|case wheat allergy with normal skin and continue using wheat containing skin care products
62492750|NCT04013763|NO_INTERVENTION|Atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and has atopic dermatitis
62335580|NCT03416738|ACTIVE_COMPARATOR|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
62492751|NCT04013763|NO_INTERVENTION|Non atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and no atopic dermatitis
62492752|NCT03113396|EXPERIMENTAL|baclofen|Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
62492753|NCT03113396|PLACEBO_COMPARATOR|placebo|Patients will receive placebo for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is baclofen (10mg t.i.d) (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
62492754|NCT02671058|ACTIVE_COMPARATOR|Cortenema|Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.
62492755|NCT02671058|EXPERIMENTAL|Hydrocortisone acetate|Hydrocortisone acetate suppository 90 mg administered rectally as a single dose with the Sephure Rectal Suppository Applicator
62492756|NCT06103383|EXPERIMENTAL|Donors with history of optimal ovarian response|IVIRMA Valencia donors between the ages of 18-35 years old, with normal ovarian function, with a history of optimal ovarian response (at least 10 total oocytes and/or 8 MII) and who have already completed all their donation cycles allowed by law.
62492757|NCT05654363||Intrathecal morphine|Adult women American Society of Anaesthesiologists (ASA) physical status \<= 3, scheduled for elective laparoscopic/laparotomic hysterectomy under general anesthesia between January 1st 2019 and December 31st 2021, who consented to the execution of a preoperative spinal analgesia with intrathecal morphine (as part of our standard practice) and who did not present any contraindications to lumbar puncture.
62492758|NCT05654363||Intravenous morphine|Adult women American Society of Anaesthesiologists (ASA) physical status \<= 3, scheduled for elective laparoscopic/laparotomic hysterectomy under general anesthesia between January 1st 2019 and December 31st 2021, who did not consent to the execution of a preoperative spinal analgesia or presented contraindications to lumbar puncture (coagulopathy or incorrect discontinuation of anticoagulant drugs, increased intracranial pressure, infection at the site of injection, major spinal deformities).
62492759|NCT02812381|ACTIVE_COMPARATOR|SCS (Jones tecnique)|18 patients were treatment with straincounterstrain
62492760|NCT02812381|SHAM_COMPARATOR|KT Kinesiotaping|18 patients were treatment with neuromuscular bandage
62492761|NCT03675815|ACTIVE_COMPARATOR|Standard of care|darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd
62335581|NCT03416738|ACTIVE_COMPARATOR|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
62335582|NCT03506399|EXPERIMENTAL|Oral Contraceptive (OC)|Ethinyl estradiol and levonorgestrel administered as a single dose, orally
62335583|NCT03506399|EXPERIMENTAL|Lanabecestat|Single oral dose of lanabecestat
62335584|NCT03506399|EXPERIMENTAL|Lanabecestat and OC|A single oral dose of oral contraceptive and single daily doses of lanabecestat
62335585|NCT01622920|OTHER|ultrasound enamel thickness measurements|Enamel thickness will be measured with ultrasound
62492762|NCT03675815|EXPERIMENTAL|Dolutegravir + tenofovir (TDF) + either lamivudine (3TC) or emtricitabine (FTC)|dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd
62492763|NCT03675815|EXPERIMENTAL|Dolutegravir + darunavir|dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd
62492764|NCT01045044||Breast cancer, chemotherapy|Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
62492765|NCT01045044||Normal control|Up to 15 normal, healthy women.
62492766|NCT03161236|EXPERIMENTAL|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
62492767|NCT03161236|ACTIVE_COMPARATOR|non exercise group|• The non-exercise group will continue with their usual life style
62492768|NCT06315387|EXPERIMENTAL|4-MUST, 128 mg|Single dose: 1 tablet (128 mg). Multiple dose: 1 tablet (128 mg) 3 times a day for 3 days (first dose on an empty stomach, second and third two hours after meals), once in the morning on an empty stomach on day 4.
62492769|NCT06315387|EXPERIMENTAL|4-MUST, 256 mg|Single dose: 2 tablets (256 mg). Multiple dose: 2 tablets (256 mg) 3 times a day for 3 days (the first intake of the drug on an empty stomach, the second and third - two hours after a meal), once in the morning on an empty stomach on the 4th day.
62492770|NCT06315387|EXPERIMENTAL|4-MUST, 384 mg|Single dose: 3 tablets (384 mg). Multiple dose: 3 tablets (384 mg) 3 times a day for 3 days (the first intake of the drug on an empty stomach, the second and third - two hours after a meal), once in the morning on an empty stomach on the 4th day.
62492771|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
62492772|NCT03081624||Term Preschoolers|Term children who haven't attend school.
62492773|NCT04194333||Standard Fluoroscopy Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and standard fluoroscopy using the C-arm under general anesthesia.
62492774|NCT04194333||Cone Beam CT Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
62492775|NCT06249776|EXPERIMENTAL|Supernova revascularization device|Mechanical thrombectomy with Supernova Stent Retriever
61940321|NCT02643173||Volatile|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using volatile anesthetics as maintenance agents.
61940322|NCT02643173||Intravenous|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using intravenous anesthetics as maintenance agents.
61940323|NCT00952042|EXPERIMENTAL|Heavy slow resistance training|12 wks of heavy slow resistance training. training three times per week. each session: 3 heel-raise exercises. 12-6RM. Slow contractions.
61940324|NCT00952042|ACTIVE_COMPARATOR|Eccentric resistance training|12 wks of eccentric resistance training. 3 x 15 Eccentric heel-raises performed twice daily.
62492776|NCT05995054|EXPERIMENTAL|Intervention (Obinutuzumab)|110 enrolled subjects: one infusion
61940325|NCT03470961|EXPERIMENTAL|Anti-Tlymphocyte Globulins|intravenous，2mg/kg/d，for 5 days
61940326|NCT03470961|ACTIVE_COMPARATOR|Anti-thymocyte Globulins|intravenous，1.5mg/kg/d，for 4 days
61940327|NCT03237078|EXPERIMENTAL|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
61940328|NCT06427473|EXPERIMENTAL|DEM model|subjects participate diet, exercise and mindfulness programs
62492777|NCT05373043|EXPERIMENTAL|Exercise Rehabilitation|Participants will be assigned to the Exercise+Placebo or Exercise+Mito-Q rehabilitation interventions using block randomization (block size 10).
62492778|NCT05373043|PLACEBO_COMPARATOR|Exercise Rehabilitation with Placebo|Participants will be assigned to Exercise+Placebo rehabilitation using block randomization (block size 10)
62492779|NCT04083326|EXPERIMENTAL|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
61940329|NCT06427473|ACTIVE_COMPARATOR|DE model|subjects participate diet and exercise programs
61940330|NCT00468468|EXPERIMENTAL|CHESS Condition|Subjects who receive the CHESS (Comprehensive Health Enhancement Support System)
61940331|NCT00468468|EXPERIMENTAL|Mentor Condition|Subjects who receive access to a Human Cancer Mentor only
61940332|NCT00468468|EXPERIMENTAL|CHESS + Mentor|Subjects who receive the CHESS system plus a Human Cancer Mentor
61940333|NCT00468468|NO_INTERVENTION|Internet Only|Subjects receive routine care and nothing else
62492780|NCT04083326|NO_INTERVENTION|Conventional care group|Conventional care consists of specialist assessment in conjunction with pre-operative surgical visits and patient education. Patients in the conventional care group are provided with pre- and postoperative information face-to-face by paper-based method. Patients will be admitted and mobilised on the day of the surgery, and discharged one to three days after surgery. The follow-up visit, conducted by a physiotherapist, is conducted after 6 to 8 weeks post-discharge for patients with TKA and after 8 to 12 weeks for patients with THA.
62492781|NCT01072162|EXPERIMENTAL|Arm B|25 mg powder for oral suspension single dose fasted.
62492782|NCT01072162|EXPERIMENTAL|Arm C|25 mg powder for oral suspension administered with a meal
62492783|NCT01072162|EXPERIMENTAL|Arm D|25 mg powder for oral suspension administered 2 hours prior to meal
62492784|NCT01072162|EXPERIMENTAL|Arm E|25 mg powder for oral suspension administered 2 hours after to meal
62492785|NCT01072162|OTHER|Arm A|Commercially available eltrombopag 25 mg tablet
62492786|NCT00487695|ACTIVE_COMPARATOR|CLE followed by standard EGD|Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
62492787|NCT00487695|ACTIVE_COMPARATOR|standard EGD followed by CLE|Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.
62492788|NCT00943033|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy plus treatment as usual|
62492789|NCT00943033|NO_INTERVENTION|MBCT Waitlist plus Treatment as Usual|
62492790|NCT03103594|ACTIVE_COMPARATOR|DMSO alone|Half of the patients will undergo DMSO instillation
62492791|NCT03103594|EXPERIMENTAL|DMSO with Botox|The other half will be randomized to DMSO mixed with 200U of botulinum toxin instillation
62492792|NCT04467619|ACTIVE_COMPARATOR|Early Illusory Movements|"Phase 1: A patient enrolled in group A will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist from the start of the study (Day 1), and also FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 15).~Phase 2: From Day 16 onwards, the patient will undergo standard rehabilitation only according to the instructions of the attending surgeon and performed by an independent physiotherapist for 14 days (Day 30)."
62492793|NCT04467619|ACTIVE_COMPARATOR|Deferred Illusory Movements|"Phase 1: A patient enrolled in group B will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist, from the start of the study (Day 1) for 14 days (Day 15).~Phase 2: Then, from Day 16 onwards, in addition to standard physiotherapy, FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 30)."
62492794|NCT04983862|EXPERIMENTAL|Illuminare-1|
62695306|NCT06101485|NO_INTERVENTION|Conventional rehabilitation|The control group (n=104) will follow the conventional care regime in the AF clinic and will not have contact to the project nurse. When the AF patients are in a stable condition, they will be followed by their general practitioner (GP). The control group will be in the study for 28 weeks.
61940334|NCT02242188|EXPERIMENTAL|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
61940335|NCT02242188|PLACEBO_COMPARATOR|Placebo|"Maltodextrin prepared in sachets. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
61940336|NCT06681090|EXPERIMENTAL|Topical Steroid Therapy of Erosive oral lichen planus|topical application of 0.1% triamcinolone acetonide and photo biomodulation on erosive oral lichen planus, 3 times daily and a miconazole oral gel once daily, for 4 weeks
61940337|NCT06681090|EXPERIMENTAL|Low-Level Laser Therapy of Erosive oral lichen planus|Photo biomodulation with laser therapy twice a week for 8 sessions over 4 weeks, utilizing a 980 nm diode laser with an output power of 300 mw.
61940338|NCT06200493||Wheelchair Athletes|national squad athletes in either wheelchair rugby or wheelchair basketball
62335586|NCT03108118||Acute respiratory failure|We are enrolling patients who are intubated because of acute respiratory distress syndrome, pneumonia, septic shock, or severe acute brain injury (GCS ≤ 8 prior to intubation). This population is targeted for study because they are at relatively high risk of requiring prolonged mechanical ventilation.
62335587|NCT02140359|NO_INTERVENTION|Control Group: Usual Care|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet with case managers according to the usual procedures for new residents and will be given a standard case manager interaction.
62492795|NCT00715676|PLACEBO_COMPARATOR|Group 1|
62492796|NCT00715676|EXPERIMENTAL|Group 2|220 ng
62695307|NCT06643091|EXPERIMENTAL|Adult patients aged 18 and over with unicentric hyalino-vascular Castleman's disease|
62335588|NCT02140359|EXPERIMENTAL|Motivational Network Interview Recipients|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
62335589|NCT03029416|EXPERIMENTAL|Single Fraction of SBRT|Stereotactic Body Radiation Therapy delivered in a single session on one day
62492797|NCT00715676|EXPERIMENTAL|Group 3|440 ng
62492798|NCT04863131|EXPERIMENTAL|EXG-5003|
62492799|NCT04863131|PLACEBO_COMPARATOR|Placebo|
62492800|NCT01986725|ACTIVE_COMPARATOR|Standardized care|During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
62492801|NCT01986725|ACTIVE_COMPARATOR|Standardized care + WOMAN-PRO II program|During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
62492802|NCT05687448|EXPERIMENTAL|Experimental Group|Patients treated with apixaban 5 mg twice daily (BID)
62695308|NCT05947903||A) EUonQoL-Kit - Active Treatment module|EUonQoL-Kit questionnaire specifically designed and administered to patients undergoing/having recently completed curative treatment for early-stage cancers OR undergoing/having recently completed non-curative treatment for advanced or metastatic cancers, including disease controlling/life prolonging tumour-directed treatment.
62492803|NCT05687448|ACTIVE_COMPARATOR|Active Comparator group:|Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
61940339|NCT05378373|ACTIVE_COMPARATOR|SHEETS Arm 1|Participants will receive sleep education-related content on factors that impact sleep, like getting enough exercise.
62492804|NCT04431973|EXPERIMENTAL|Shoulder prothesis|Evaluate the performance of the Medacta Shoulder System total reverse shoulder prothesis
62695309|NCT05947903||B) EUonQoL-Kit - Survivors module|EUonQoL-Kit questionnaire specifically designed and administered to people being disease-free without evidence of active cancer, and at least one year off active treatment (with the exception of long-term adjuvant hormonotherapy).
62695310|NCT05947903||C) EUonQoL-Kit - Palliative Care module|EUonQoL-Kit questionnaire specifically designed and administered to patients with advanced cancers with projected prognosis \<12 months and Eastern Cooperative Oncology Group (ECOG) ≥2 OR referred to a specialist palliative care team for symptom control, OR receiving non-curative systemic treatment or radiotherapy purely for symptom control.
62695311|NCT06013852|OTHER|Unique arm|Without and with Boneview software use for all included patients
61940340|NCT05378373|EXPERIMENTAL|SHEETS Arm 2|Participants will receive sleep education-related content to support good sleep, like setting schedules.
61940341|NCT03397173|EXPERIMENTAL|Azacitidine + Ascorbic acid|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, (allowing for weekends, and holidays) of each 28-day cycle. Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle.
61940342|NCT00384254|NO_INTERVENTION|1|Usual Care Control: Patients receive treatment as usual
61940343|NCT00384254|EXPERIMENTAL|2|"5 A Intervention Condition: Patients in this condition receive all five A components (Ask, Advise, Assess, Assist, Arrange) recommended in the Clinical Practice Guideline: Treating Tobacco Use and Dependence."
61940344|NCT00384254|EXPERIMENTAL|3|"3 A Condition: Patients receive Ask, Advise, Arrange intervention consisting of the first two A components recommended by the Clinical Practice Guideline: Treating tobacco Use and Dependence, plus Fax-to-Quit referral to a tobacco quit line."
61940345|NCT02225197|EXPERIMENTAL|CyberKnife Radiosurgery|
61940346|NCT06679972||Cholestasis Group|This group will include all neonates born to mothers with intrahepatic cholestasis of pregnancy.
61940347|NCT06679972||Control Group|This group will include controls, defined as neonates born to mothers with no liver diseases.
61940348|NCT04199182|EXPERIMENTAL|Exercise|Progressive, multi-component supervised exercise training group.
61940349|NCT04199182|ACTIVE_COMPARATOR|Healthy Aging Attention Control|A health education program that addresses topics relevant to older adults.
62335590|NCT03029416|EXPERIMENTAL|Fractionated SBRT|Stereotactic Body Radiation Therapy delivered in three to five fractions with one fraction delivered every other day
62335591|NCT01510808||aggressive Periodontitis|Aggressive Periodontitis during maintenance
62335592|NCT01510808||aggressive periodontitis|aggressive periodontitis patients during maintenance
62335593|NCT04551573|EXPERIMENTAL|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
61940350|NCT03298373|PLACEBO_COMPARATOR|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
61940351|NCT03298373|EXPERIMENTAL|11β-MNTDC|11β-MNTDC capsules administered orally (200 mg or 400 mg).
62335594|NCT04551573|EXPERIMENTAL|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
62335595|NCT05291949|EXPERIMENTAL|ATLASense RAPHAEL monitoring|All patients receive monitoring by ATLASense RAPHAEL PolyMonitor for duration of surgery.
62335596|NCT05198752|EXPERIMENTAL|Neoantigen mRNA Personalised Cancer|This study is a 3+3 dose escalation design. Participants will receive a total of 6 cycles of SW1115C3 every 21 days.
62492805|NCT06431776|EXPERIMENTAL|molgramostim|Molgramostim 300 mcg administered once daily via nebulizer for 48 weeks.
61940352|NCT06293469|EXPERIMENTAL|Accelerated Flap Coverage|Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.
61940353|NCT06293469|ACTIVE_COMPARATOR|Standard of Care Flap Timing|The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.
61940354|NCT05522231|EXPERIMENTAL|Investigational arm|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
62492806|NCT03614728|EXPERIMENTAL|Part 1: Participants receiving GSK3326595|
62492807|NCT03614728|EXPERIMENTAL|Part 2 Dose escalation : Participants receiving GSK3326595+5-Azacitidine|
62492808|NCT03614728|EXPERIMENTAL|Part 2 Dose expansion: Participants receiving GSK3326595+5-Azacitidine|
62492809|NCT01828294|OTHER|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
62695312|NCT06644781|EXPERIMENTAL|I-DXd|Participants who are randomized to receive an intravenous infusion of I-DXd 12 mg/kg on Day 1 of every 21-day cycle (Q3W).
62695313|NCT06644781|ACTIVE_COMPARATOR|Investigator's Choice of Chemotherapy (ICC)|Participants who are randomized to receive an intravenous infusion of investigator's choice of chemotherapy (docetaxel, paclitaxel, and irinotecan).
62695314|NCT06589999||patients presenting to the imaging department in the context of inflammatory neuraxial disease|
62695315|NCT06640972|EXPERIMENTAL|Investigational drug|The effect of 12 weeks of treatment with RDX-002 on postprandial TGs, fasting levels of cholesterol, and body weight among patients who have recently discontinued treatment with the GLP-1 agonists, semaglutide or tirzepatide, for obesity.
62695316|NCT06640972|PLACEBO_COMPARATOR|Placebo|Matching placebo
62695317|NCT01166698|EXPERIMENTAL|AZD9819|Inhaled suspension
62695318|NCT01166698|PLACEBO_COMPARATOR|Placebo|Inhaled suspension
62492810|NCT01670097|EXPERIMENTAL|Dexamethasone|"Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
61940355|NCT05522231|ACTIVE_COMPARATOR|Control arm (comparator)|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion ;Everolimus, 10 mg, QD, PO, 3 weeks/cycle.
61940356|NCT05522231|OTHER|Fruquintinib monotherapy factorial study|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
61940357|NCT00759382||I|Patients with non-small cell lung carcinoma treated with curative intent
61940358|NCT01636531|EXPERIMENTAL|HCLF|
61940359|NCT01636531|ACTIVE_COMPARATOR|LyoF|
61940360|NCT03428607|EXPERIMENTAL|AZD6738+Olaparib|AZD6738 160mg QD per os administered for 7 days and olaparib 300mg BID per os administered daily. One cycle is considered of 28 days.
61940361|NCT03610360|ACTIVE_COMPARATOR|Arm A|Arm A will receive the study drug MesoPher plus best supportive care
61940362|NCT03610360|NO_INTERVENTION|Arm B|Arm B will follow best supportive care as deemed appropriate by the investigator.
61940363|NCT02503709|EXPERIMENTAL|Treatment (onalespib, CDKI AT7519)|Patients receive onalespib IV over 1 hour on days 1 and 4 (cycle 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter). Cycles repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
61940364|NCT00973674|EXPERIMENTAL|Premarin IV|Patients randomized to receive a single dose of 0.5 mg/kg Premarin® IV
61940365|NCT00973674|PLACEBO_COMPARATOR|Placebo|Patients randomized to receive a single dose of placebo IV. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with traumatic brain injury.
61940366|NCT06556524||twenty four Group|vocational school students
61940367|NCT05895071|ACTIVE_COMPARATOR|Group A Topical 5% potassium hydroxide|In group-A 30 patients were given topical 5%-potassium hydroxide solution on affected area once at night upto 4 weeks
61940368|NCT05895071|ACTIVE_COMPARATOR|Group B Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks and final assessment was done at 12th week.
61940369|NCT04452032|EXPERIMENTAL|Single arm|"The first phase of the study will consist of an evaluation of the initial dental state of each subject based on stomatological examination, orthopantomogram, bitewing radiographs, evaluation of potential risks of caries and fractures. Dental decalcification, dental care and/or avulsion if necessary, and afterwards, a dental splint will be performed before the start of RT treatment.Based on our predictive model, every tooth which potentially will receive more than 40 Gy and for which long term survival is compromised will be avulsed at least 2 weeks before the start of RT.~After RT, the subject will have clinical follow-up with dental evaluation every 6 months for 36 months in order to identify possible dental events. At each consultation, a stomatological examination will be performed as well as bitewing radiographs. Orthopantomogram will be done once a year. Periapical X-rays will be performed if there is a dental complain or to refine a lesion visible on orthopantomogram."
61940370|NCT03783975|EXPERIMENTAL|Simplified Cascade Screening|Free, mail-in, saliva-based screening for the KCNQ1 Thr224Met variant.
61940371|NCT05584332|PLACEBO_COMPARATOR|Placebo|
61940372|NCT05584332|EXPERIMENTAL|4vHPV Vaccine|
61940373|NCT05392257|EXPERIMENTAL|Arms|
61940374|NCT05688007||Cases|pregnant women with established preterm labor - gestational age: (28-36 weeks), having: Regular uterine contractions are at least 3 in 10 min each lasting 40 seconds. Progressive cervical dilatation (at least 4 cm).
61940375|NCT05688007||Controls|pregnant women not in labor - gestational age: (28- 36 weeks)
61940376|NCT00571610|EXPERIMENTAL|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
61940377|NCT05096728||Once daily Nifedipine XL 60mg|Participants will receive Nifedipine XL once daily 60 mg for 48 hours.
61940378|NCT05096728||Twice daily Nifedipine XL 30mg|Participants will receive Nifedipine XL twice daily 30 mg for 48 hours.
61940379|NCT05840731|EXPERIMENTAL|Ashwagandha|"KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.~After enrollment in the study, 50% of participants will be randomly assigned to take one capsule of KSM 66 Ashwagandha (300 mg) two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
61940380|NCT05840731|PLACEBO_COMPARATOR|Placebo|"Placebo means that the capsules will not contain Ashwagandha but some other inactive substance. By using placebo, investigators will know whether the positive results are because of Ashwagandha or are because of psychological factors. For example, the participant may feel that his or her condition is improved because he or she is expecting the capsules to be helpful.~After enrollment in the study, 50% of participants will be randomly assigned to take one capsule of placebo two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
61940381|NCT01561729|EXPERIMENTAL|Study group|This is the only arm of the study. All patients enrolled will have a nasogastric or orogastric tube placed. All will be assessed by both the RightSpot pH Indicator and chest radiograph.
62335597|NCT04142307|ACTIVE_COMPARATOR|Group A (treatment)|Each session includes 20 minutes of training each with rest as needed. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. A fixation training target (FTT) will be selected by the trainer at a perceived better fixation point. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look in the direction of the FTT and listen simultaneously to the audio feedback. As performing this task, the participant will actively control the eye movements until the audio feedback becomes more frequent and then becomes a continuous sound pattern. This continuous sound will signalize to the patient that the FTT location was reached. Participants will be given take-home efficiency reading exercises.
62695319|NCT03592264|EXPERIMENTAL|Dose escalation phase|OBI-3424 (1.0 mg/m\^2 to 14.0 mg/m\^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle or Day 1 of each 21-day cycle to determine the MTD and RP2D with a classic 3+3 dose escalation design.
62335598|NCT04142307|SHAM_COMPARATOR|Group B (control)|"The simulated biofeedback training for Group B involves the following procedure:~For four weeks, presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button. Participants will be given take-home efficiency reading exercises."
62695320|NCT03592264|EXPERIMENTAL|Cohort expansion phase|OBI-3424 (12 mg/m\^2) will be administered by IV infusion on Day 1 of each 21-day cycle.
61940382|NCT03091933|EXPERIMENTAL|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
61940383|NCT04296110|ACTIVE_COMPARATOR|Control|Participants will receive music relaxation therapy. They will be asked to listen to designated music daily for 12 weeks.
61940384|NCT04296110|EXPERIMENTAL|Biofeedback|Participants will receive a biofeedback intervention. They will be asked to practice breathing at their designated resonance frequency using provided biofeedback device daily for 12 weeks.
61940385|NCT06295536|EXPERIMENTAL|Photorefraction prototype device|- Photoretinoscopic images without cycloplegia
61940386|NCT03672643|OTHER|single arm|Crizotinib
61940387|NCT06680349|ACTIVE_COMPARATOR|Anti-CD20 alone|Lymphoma Protocol consisting of four weekly doses of 375 mg/m2 of rituximab (RTX)
61940388|NCT06680349|EXPERIMENTAL|IBCDT|Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), CYC (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
61940389|NCT06303921|EXPERIMENTAL|11C-M503 PET|Participants will undergo 11C-M503 PET scan, they may also have a brain MRI and Amyloid PET scan as well as neurological assessments.
61940390|NCT05015530||Test Medical Device|Healsea Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
61940391|NCT03318900|EXPERIMENTAL|Treatment (T-cell infusion, aldesleukin, utomilumab)|Patients undergo leukapheresis. Patients then receive cyclophosphamide IV on day -2, CD8-positive T-lymphocyte via infusion on day 0, and aldesleukin SC every 12 hours for 14 days. Beginning 24 hours after CD8-positive T-lymphocyte, patients also receive utomilumab IV over 90 minutes on days 1, 29, 57, 85, 113, and 141 in the absence of disease progression or unacceptable toxicity.
61940392|NCT05933447|EXPERIMENTAL|Rodatristat Ethyl|
61940393|NCT05933447|ACTIVE_COMPARATOR|Moxifloxacin|
61940394|NCT05933447|PLACEBO_COMPARATOR|Placebo for Rodatristat|
61940395|NCT05933447|PLACEBO_COMPARATOR|Placebo for Moxifloxacin|
62335599|NCT05763160|EXPERIMENTAL|RZL-012 50mg/ml|
62695321|NCT01352455|EXPERIMENTAL|5 days per week hemodialysis|5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session
62695322|NCT05417906|ACTIVE_COMPARATOR|Standard care|
62695323|NCT05417906|EXPERIMENTAL|Eosinophil-directed care|
62695324|NCT04593277|EXPERIMENTAL|Arm I (INSPIRE, telehealth care)|Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.
61940396|NCT03021304|EXPERIMENTAL|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
61940397|NCT00251173|ACTIVE_COMPARATOR|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
61940398|NCT00251173|ACTIVE_COMPARATOR|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's substance use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized substance treatment; or 2) provide a strategy to self-monitor substance use, consider consequences, and later seek assessment.
61940399|NCT00251173|ACTIVE_COMPARATOR|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
61940400|NCT02528175|EXPERIMENTAL|MRg-FU|Hyperthermia via magnetic resonance-guided focused ultrasound will be administered once per week for three weeks concurrent with standard radiation and chemotherapy.
61940401|NCT01114152|EXPERIMENTAL|1|Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8)
61940402|NCT01114152|PLACEBO_COMPARATOR|2|placebo given (2 subjects in each dose group)
62492811|NCT01670097|PLACEBO_COMPARATOR|Placebo|"Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
62492812|NCT04425096|EXPERIMENTAL|Skin to skin contact|The mothers and their babies in the experimental group received a 30-minute skin to skin contact immediately after birth (n:34)
62492813|NCT04425096|NO_INTERVENTION|Routine care|The babies in the control group received routine care (n:34)
62492814|NCT04348422||Symptomatic|COVID-19 RT-PCR positive patients with reported symptoms
62492815|NCT04348422||Asymptomatic|COVID-19 RT-PCR positive patients without presenting any symptoms
62492816|NCT03001934||Nephrotic syndrome patients|Patients diagnosis as nephrotic syndrome (NS)
62492817|NCT01102127||Goiter|Patients with nodular goiter
62492818|NCT05294016|OTHER|Patient group|
62492819|NCT05294016|OTHER|Control group|
62335600|NCT02581319|OTHER|Periodontal treatment|Both groups of patients (smokers and non-smokers) will receive periodontal treatment consisting of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects will be made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
62335601|NCT06128590|EXPERIMENTAL|Experimental: Photobiomodulation (Group A)|Participants will receive photobiomodulation therapy immediately before local anesthesia, in the same place where the puncture will be performed for pterygomandibular anesthesia.
62492820|NCT03917758|EXPERIMENTAL|Diabetic patients|30 diabetic patients candidate to treatment with SGLT2i in add-on to metformin.
62492821|NCT03050866|OTHER|Treatment|Treatment intervention with Cabazitaxel with premedication as necessary (antihistamine, corticosteroid, H2 antagonist, antiemetic prophylaxis)
62492822|NCT02587143|ACTIVE_COMPARATOR|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
62335602|NCT06128590|SHAM_COMPARATOR|Control: Laser Sham (Group B)|The participants will be treated in the same way as in group A. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same place as described for the experimental group, but the equipment will be switched off. So that the participant does not identify the group to which they belong, the device's activation sound (beep) will be simulated by the device itself, which makes the beep sound by pressing the activation button only once. After this, pterygomandibular anesthesia will be carried out in the same way.
62335603|NCT00458406|ACTIVE_COMPARATOR|Bi-Flex|"Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Following a baseline polysomnography, subjects in this arm will undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will be randomized to Bi-Flex or CPAP, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
62335604|NCT00458406|ACTIVE_COMPARATOR|CPAP|"Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.~Subjects in this arm received standard continuous positive airway pressure (CPAP) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will randomized to CPAP or Bi-Flex, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
62335605|NCT01552382||cardiac surgical patients|patients undergoing a cardiac surgical procedure
62335606|NCT04343079|EXPERIMENTAL|braeast cancer|breast cancer patients
62335607|NCT02557386|EXPERIMENTAL|A Levobupivacaine 5 mL|Adductor canal nerve block with levobupivacaine 0.25% 5 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
62335608|NCT02557386|EXPERIMENTAL|B Levobupivacaine 10 mL|Adductor canal nerve block with levobupivacaine 0.25% 10 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
62335609|NCT02557386|EXPERIMENTAL|C Levobupivacaine 15 mL|Adductor canal nerve block with levobupivacaine 0.25% 15 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
62335610|NCT02557386|EXPERIMENTAL|D Levobupivacaine 20 mL|Adductor canal nerve block with levobupivacaine 0.25% 20 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
62492823|NCT02587143|EXPERIMENTAL|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
62492824|NCT05200442|EXPERIMENTAL|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 (Starting Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Group 1/ Dose Level 1:~Participants in group 0 will receive the starting dose of study drugs (below):~* VS-6766 (2.4mg) orally twice a week~* cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
62695325|NCT04593277|ACTIVE_COMPARATOR|Arm II (control website)|Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.
62695326|NCT02364284||Urinary Tract Infection (cUTI)|Patients ≥18 years with diagnosis of urinary tract infection.
62695327|NCT02364284||Intra Abdominal Infection(cIAI)|Patients ≥ 18 years with diagnosis of Intra Abdominal Infection
62695328|NCT02364284||Nosocomial Pneumonia (NP)|Patients ≥ 18 years with diagnosis of Hospital acquired pneumonia
62492825|NCT05200442|EXPERIMENTAL|Phase 1(Dose-Finding Arm): Group 2- Dose Level 2 (Second Highest Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Participants in group 2 will receive the second highest dose of study drugs (below):~* VS-6766 (3.4mg) orally twice a week~* cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
62492826|NCT05200442|EXPERIMENTAL|Phase 1(Dose-Finding Arm): Group 3 - Lower Dose Level 1|"Participants in this group will received a lower dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~* VS-6766 (2.4mg) orally twice a week~* cetuximab (400mg) via intravenous (IV) needle in vein every 2 weeks"
62492827|NCT05200442|EXPERIMENTAL|Phase 1(Dose-Finding Arm): Group 4 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~* VS-6766 (2.4mg) orally twice a week~* cetuximab (300mg) via intravenous (IV) needle in vein every 2 weeks"
62492828|NCT05200442|EXPERIMENTAL|Phase 2 (Efficacy Arm/ Expansion Cohort)|"Participants in this arm will help test the efficacy of the VS-6766 and cetuximab dose established in phase 1 of the study. Participants will take the same two drugs ( VS-6766 and cetuximab) at the best tolerated dose that was found during the first phase of the study.~Participants in this group will also keep a pill diary. This helps you keep track of when you take your pills. The study team at your doctor's office will show you how to use this diary. Each time you visit the clinic, you must bring the pill diary, any remaining pills, and the pill bottle."
62492829|NCT04298151|EXPERIMENTAL|zirconomer improved|zirconia reinforced glass ionomer restoration
62492830|NCT04298151|ACTIVE_COMPARATOR|ketac molar quick aplicap|conventional viscous glass ionomer restoration
62335611|NCT02557386|EXPERIMENTAL|E Levobupivacaine 25 mL|Adductor canal nerve block with levobupivacaine 0.25% 25 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
62335612|NCT02557386|EXPERIMENTAL|F Levobupivacaine 30 mL|Adductor canal nerve block with levobupivacaine 0.25% 30 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
62335613|NCT02390115|ACTIVE_COMPARATOR|Elastic Tape|"Tape placing will consider as the initial anchor the acromioclavicular joint, and as the final one the point immediately below the insertion of the deltoid muscle. Two centimeters anchor will be considered for all the participants, and the active zone will be equivalent to the distance between two anchors. The first tape will be placed to the anterior portion of the deltoid with the shoulder at 30° passive extension. The second tape will be placed to the middle portion of the deltoid with the shoulder at 30° of passive horizontal adduction. For placing the third tape to the posterior deltoid, the limb will be positioned at 90° of passive flexion of the shoulder. The elastic tape tension will be placed as previously described as paper tension and it is equivalent to 10-15% of the total elastic tape tension."
62335614|NCT02390115|SHAM_COMPARATOR|Sham|The sham elastic tape will be placed using the same tape to the paretic shoulder. However, the rigid tape will be placed without tension with the upper limb supporting at 90 degree elbow flexion, 0 degrees abduction and adduction of the shoulder.
62335615|NCT06454604|ACTIVE_COMPARATOR|VR Passthrough|Participants in this condition wear the same VR headset as participants in the in the other arms. However, they see directly through to their laptop and are not emersed in the virtual world.
62335616|NCT06454604|EXPERIMENTAL|Virtual Reality|Participants in this condition wear the virtual reality headset. They are emersed in a virtual world that looks like a cabin room with windows. They are sitting at a desk and can see their laptop screen as part of the virtual world.
62335617|NCT06454604|EXPERIMENTAL|Virtual Reality + Feedback|Participants in this condition wear the virtual reality headset. They are emersed in a virtual world that looks like a cabin room with windows. They are sitting at a desk and can see their laptop screen as part of the virtual world. The program tracks their keyboard and mouse click data to assess how consistently they are working. A stoplight in the virtual environment is green when they are working consistently and turns red when the not.
62335618|NCT00556218|OTHER|Tibetan Meditation|
62335619|NCT00556218|OTHER|No Meditation|
62335620|NCT00319228|EXPERIMENTAL|Antithrombin III|
62492831|NCT04731324|EXPERIMENTAL|ZYIL1 Capsule|six subjects will be recruited in each cohort. safety data up to day 3 will be evaluated to determine whether progression to the subsequent dose Cohort is indicated. Single dose will be administered in ascending manner starting from 25 mg.
62492832|NCT06385301|EXPERIMENTAL|Ambient air|Patient will perform tests at University Hospital Zurich on ambient air
61940403|NCT06131723|NO_INTERVENTION|Arm 1: Standard tickler email|"Eligible, assigned participants will receive the current standard email notification (i.e., control tickler) from UCLA Health, informing patients that they have received a new message in their MyChart patient portal account, and containing links to their portal account."
62335621|NCT01085058|EXPERIMENTAL|A: lenograstim|total group
62335622|NCT04698616||Malignant lymphoma patients|Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.
62335623|NCT04387136|EXPERIMENTAL|Sublingual Sufentanil|Participants in this arm will receive the intervention.
62335624|NCT04387136|NO_INTERVENTION|Control|Participants in this arm will not receive an intervention.
62335625|NCT03272945|EXPERIMENTAL|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
62335626|NCT03272945|PLACEBO_COMPARATOR|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
62492833|NCT06385301|ACTIVE_COMPARATOR|SOT via basal cannula|Supplemental Oxygen Therapy (SOT) will be provided via nasal cannula from a small oxygen concentrator while the patient performs tests at University Hospital Zurich.
62492834|NCT04499209|EXPERIMENTAL|Period 1- XG005|XG005 capsule in 4 dose level
62492835|NCT04499209|ACTIVE_COMPARATOR|Period 2- Naproxen and Pregabalin|Combination of Naproxen and Pregabalin
62492836|NCT04499209|PLACEBO_COMPARATOR|Period 1- Placebo|XG005 matching placebo
61940404|NCT06131723|EXPERIMENTAL|Arm 2: Enhanced tickler email|"Eligible, assigned participants will receive a behaviorally informed email notification (i.e., enhanced tickler), coming from their PCP's office, informing patients that they are due for an important medical exam, and containing a direct link to the MAP Letter on their patient portal account."
61940405|NCT03138304|EXPERIMENTAL|Adventure video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
62335627|NCT01503476|EXPERIMENTAL|Healthy volunteers|healthy volunteers
62335628|NCT01503476|EXPERIMENTAL|symptomatic patients|symptomatic patients with known or suspected gastro esophageal reflux disease
62335629|NCT03191006|ACTIVE_COMPARATOR|study group: MEI BIN insoles|Participants in the study group will be prescribed with a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
61940406|NCT03138304|ACTIVE_COMPARATOR|Educational Program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
61940407|NCT02448810|EXPERIMENTAL|Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)|Subjects stratified according to their mutation status.
62335630|NCT03191006|NO_INTERVENTION|control group: without MEI BIN insoles|Participants in this control group will not receive a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
62335631|NCT01473810|EXPERIMENTAL|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
62335632|NCT01473810|EXPERIMENTAL|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
62335633|NCT01473810|EXPERIMENTAL|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
62335634|NCT01473810|PLACEBO_COMPARATOR|Zero dose|Adjuvant only, i.e. 300 µl Endocine divided into two administrations, one for each nose cavity
62335635|NCT01822041|ACTIVE_COMPARATOR|Part A - 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509
62335636|NCT01822041|ACTIVE_COMPARATOR|Part B: 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509
62335637|NCT03531177|EXPERIMENTAL|Intervention|HEAL-D diet and lifestyle education and behavioural change intervention, 7 sessions over 14 weeks.
62492837|NCT02350257|EXPERIMENTAL|ICBT|Internet-based cognitive behavior therapy
61940408|NCT02448810|EXPERIMENTAL|Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)|Subjects stratified according to their mutation status.
61940409|NCT02448810|EXPERIMENTAL|Part 2: Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
61940410|NCT02448810|EXPERIMENTAL|Part 2: Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.
62335638|NCT03531177|ACTIVE_COMPARATOR|Control|Usual care.
62335639|NCT01838967|EXPERIMENTAL|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
62335640|NCT01838967|EXPERIMENTAL|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
62492838|NCT02350257|NO_INTERVENTION|Supportive control|Control participants has weekly contact with a therapist and receives internet-based training in child directed play. Participants are informed that this training will not likely reduce anxiety.
62492839|NCT01125527|ACTIVE_COMPARATOR|Arm 1|
62492840|NCT01125527|ACTIVE_COMPARATOR|Arm 2|
62492841|NCT05004649|EXPERIMENTAL|Healthy participants|"Participants will be excluded prior to the experiment if their best-corrected visual acuity is worse than 20/40 in either eye or if they make any errors on the Ishihara plate test.~For enrolled participants, their threshold for horizontal position discrimination will be calculated based on their performance on the experimental task during their first session. Participants will be excluded after the conclusion of their first session if their horizontal position discrimination threshold in the control condition is higher than a maximum value of 0.6 degrees of visual angle, and participants excluded at this point will not participate in any further experimental sessions."
62492842|NCT01482117|ACTIVE_COMPARATOR|Clopidogrel|single oral administration of 300mg of clopidogrel
62492843|NCT01482117|ACTIVE_COMPARATOR|Cilostarole|single oral administration of 100mg of cilostazole
62492844|NCT01482117|ACTIVE_COMPARATOR|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
62492845|NCT01323127||Chronic back pain|This group of patients has had chronic back pain for longer than 3 months.
62492846|NCT01323127||Non chronic back pain|This group of patients is hospitalized for cardio physical therapy, and has no lumbar-pelvic complications. Patients are selected from the hospitalized population according to age, sex, and BMI in order to match chronic back pain patients.
62492847|NCT05702255|EXPERIMENTAL|Active acupoints group|All participants in the active group will be treated with basic acupoints Zhongwan (CV 12), Tianshu (ST25) in alternation with Sanyinjiao (SP 6), Zusanli (ST 36). Moreover according to traditional Chinese medicine diagnosis, additional acupoints will be added. The frequency of acupressure treatment will be twice a day for 4 weeks, in total 56 sets.
62492848|NCT05702255|SHAM_COMPARATOR|Sham acupoints group|All participants on the sham acupoints group will recieive sham Zhongwan (CV 12), sham Tianshu (ST25), sham Sanyinjiao (SP 6), and sham Zusanli (ST 36) acupressure. All the sham points are 2 cm outside and parallel to the actual points which do not match any recognized acupuncture points and are thought to have no therapeutic effect. The frequency of acupressure treatment will be twice a day for 4 weeks, in total 56 sets.
62335641|NCT01838967|EXPERIMENTAL|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
62492849|NCT02699866|EXPERIMENTAL|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
62335642|NCT01838967|EXPERIMENTAL|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
62492850|NCT05807958|EXPERIMENTAL|Skin Prick Automated Test|
62492851|NCT03814122|EXPERIMENTAL|ABCR Treatment Group|Group that is immediately administered action-based cognitive remediation intervention.
62492852|NCT03814122|ACTIVE_COMPARATOR|Waitlist Control Group|Group that is waitlisted (i.e., receives treatment-as-usual) and after approximately 8 weeks received action-based cognitive remediation intervention
62492853|NCT00905008||DES|Patients underwent percutaneous coronary intervention and received at least one drug-eluting stent during their index hospitalisation.
62492854|NCT00905008||BMS|Patients underwent percutaneous coronary intervention and received at least one uncoated stent during their index hospitalisation.
61940411|NCT02448810|ACTIVE_COMPARATOR|Part 2: Standard of Care- Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
61940412|NCT02448810|ACTIVE_COMPARATOR|Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
61940413|NCT04517500|EXPERIMENTAL|Home-base pulmonary rehabilitation with mindful breathing modu|Subjects will complete in a home-based pulmonary rehabilitation program and in addition will complete a mindful breathing practice using a module on a computer tablet.
61940414|NCT04517500|ACTIVE_COMPARATOR|Home-base pulmonary rehabilitation|Subjects will complete 12 week home-based pulmonary rehabilitation with health coaching
61940415|NCT04294667|EXPERIMENTAL|Dapirolizumab pegol|Subjects will receive dapriolizumab pegol througout the Treatment Period.
61940416|NCT04294667|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo througout the Treatment Period.
61940417|NCT04972149||LC|laparoscopic surgery using conventional laparoscopic instruments
61940418|NCT04972149||LW|Using wristed laparoscopic instruments (Artisential Maryland dissector, Artisential Fenestrated grasper)
62335643|NCT01838967|EXPERIMENTAL|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
61940419|NCT04972149||RC|Conventional robotic surgery
61940420|NCT04972149||RSS|Use of single site system for reduced port robotic surgery
61940421|NCT04972149||RSP|Use of da Vinci SP system for reduced port robotic surgery
61940422|NCT04972149||RRI|A new surgical robot Revo-i developed by Meerae company in Korea
61940423|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
61940424|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
61940425|NCT04747639|ACTIVE_COMPARATOR|verum 500|500 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
61940426|NCT04747639|PLACEBO_COMPARATOR|control 500|500 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
61940427|NCT04747639|ACTIVE_COMPARATOR|verum 250|250 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
61940428|NCT04747639|PLACEBO_COMPARATOR|control 250|250 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
62492855|NCT03209115|ACTIVE_COMPARATOR|calcium hydroxide and chlorhexidine|Removal of old root canal filling and placing calcium hydroxide and chlorehexidine as intracanal medication
62492856|NCT03209115|ACTIVE_COMPARATOR|calcium hydroxide|Removal of old root canal filling and placing calcium hydroxide as intracanal medication
62492857|NCT04584073|ACTIVE_COMPARATOR|Adenoidectomy|Adenoidectomy
61940429|NCT06302543|EXPERIMENTAL|bone marrow|autologous bone marrow derived mononuclear cells injected 1cc per ovary for 2 ovaries under general anesthesia under ultrasound guide
61940430|NCT02858011|ACTIVE_COMPARATOR|Control and comparison group -cash transfer program|The program is implemented during 48 months. During the first 36 months the control group does not receive any intervention. During the last 12 months eligible beneficiaries receive cash transfer and accompanying information sessions on health, child nutrition, household economics every three months (identical to experimental group).
61940431|NCT02858011|EXPERIMENTAL|Jigisemejiri cash transfer program|Unconditional cash is distributed every 3 months to beneficiaries of the Jigisemejiri program. During cash handouts, information sessions on health, child nutrition, households economics and education are organized by local NGOs.
62335644|NCT01838967|EXPERIMENTAL|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
62492858|NCT04584073|ACTIVE_COMPARATOR|Adenoidectomy and Myringotomy|Adenoidectomy and Myringotomy
62492859|NCT04584073|ACTIVE_COMPARATOR|Adenoidectomy,Myringotomy and Tympanostomy tube application|Adenoidectomy and Myringotomy and Tympanostomy tube application
62492860|NCT01300273|EXPERIMENTAL|Ketosteril|
62492861|NCT06050239|EXPERIMENTAL|Radioligand Therapy|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
62492862|NCT03214523|EXPERIMENTAL|Sleep Education|The intervention will be a brief education of the importance of sleep and healthy sleep habits. Subjects will also receive a standard sleep brochure on healthy sleep (which will also be given to the other arm).
62492863|NCT03214523|NO_INTERVENTION|Sleep Brochure|Subjects will receive a one page hand out on healthy sleep habits.
62492864|NCT04971512|EXPERIMENTAL|EDP-721 HV SAD Cohorts|EDP-721 Dose 1, Dose 2, Dose 3 and Dose 4, in one single administration
62492865|NCT04971512|EXPERIMENTAL|EDP-721 HV MAD Cohorts|EDP-721 Dose 1, Dose 2 and Dose 3, once daily for 14 days
62492866|NCT04971512|PLACEBO_COMPARATOR|EDP-721 HV SAD Placebo Cohort|Matching placebo, in one single administration
61940432|NCT02858011|EXPERIMENTAL|Jigisemejiri - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women receiving rations of fortified flour (PNP) during the last 12 months of the project
61940433|NCT02858011|ACTIVE_COMPARATOR|Control and comparison group - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women
61940434|NCT01869881|ACTIVE_COMPARATOR|Sarpogrelate|
61940435|NCT01869881|PLACEBO_COMPARATOR|Placebo|
61940436|NCT03061383|ACTIVE_COMPARATOR|8% Arginine based toothpaste|The procedure will be performed after scaling in group D1 using 8% arginine based toothpaste (Colgate Pro-relief) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
61940437|NCT03061383|ACTIVE_COMPARATOR|8% Strontium acetate based toothpaste|The procedure will be performed after scaling in group D2 using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
62335645|NCT04222439|EXPERIMENTAL|AI monitoring gastrointestinal endoscopy|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
62335646|NCT02669550|EXPERIMENTAL|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
62335647|NCT02669550|EXPERIMENTAL|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
62335648|NCT03498417||Graves' diseases|Patients with Graves' disease. No interventions foreseen
62335649|NCT03498417||Autoimmune thyroiditis|Patients with autoimmune thyroiditis. No interventions foreseen
62335650|NCT03498417||Healthy Subjects|Normal healthy subjects. No interventions foreseen
62335651|NCT06378294||Mastectomy patients|clinically node-negative T1-2 invasive breast cancer patients treated with upfront mastectomy
62492867|NCT04971512|PLACEBO_COMPARATOR|EDP-721 HV MAD Placebo Cohort|Matching placebo, once daily for 14 days
62492868|NCT04971512|EXPERIMENTAL|EDP-721+ EDP-514 HBV MAD Cohorts|EDP-721 once daily for 14 days followed by EDP-721+EDP-514 once daily for 28 days
62492869|NCT04971512|PLACEBO_COMPARATOR|EDP-721+ EDP-514 HBV MAD Placebo Cohorts|Matching placebo once daily for 42 days
62492870|NCT02933060|EXPERIMENTAL|IV fluid bolus|Patients will receive a 1000 ml bolus of normal saline, administered over 60 minutes.
62492871|NCT02933060|SHAM_COMPARATOR|Control|Patients will have an IV catheter and will be connected to an IV bag, but will receive only 10 ml of normal saline over 60 minutes.
62492872|NCT03066479|EXPERIMENTAL|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
62492873|NCT05997030|EXPERIMENTAL|Neuromodulation|Subjects meeting eligibility criteria will undergo Exablate low intensity focused ultrasound neuromodulation
62492874|NCT02867358|ACTIVE_COMPARATOR|High dose of KT07 capsule|It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).
62492875|NCT02867358|ACTIVE_COMPARATOR|Low dose of KT07 capsule|It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).
62492876|NCT02867358|PLACEBO_COMPARATOR|Placebo|It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.
62492877|NCT02469480|EXPERIMENTAL|FERRIC CARBOXYMALTOSE|max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
62492878|NCT02469480|ACTIVE_COMPARATOR|ferro sanol(R) duodenal 100 mg|200 mg ferro sanol per day over 12 weeks
62492879|NCT06559761||TYPE I|Gross classification of resected specimen: single nodule with distinct margin, usually round with complete tumour envelope
62492880|NCT06559761||TYPE II|Gross classification of resected specimen: single nodule with extranodular growth, no more than three extranodular points
62492881|NCT06559761||TYPE III|Gross classification of resected specimen: a unifocal lesion composed of confluent multiple nodules, distinct boundaries among the nodules
62492882|NCT06559761||TYPE IV|Gross classification of resected specimen: infiltrative nodule, with poor demarcated boundary and especially multiple extranodular points
62492883|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
61940438|NCT03061383|PLACEBO_COMPARATOR|tooth past without active ingredient|The procedure will be performed after scaling in group D3 control group using placebo . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
61940439|NCT01484041|EXPERIMENTAL|Dovitinib plus aromatase inhibitors|Dovitinib with aromatase inhibitor
61940440|NCT02004600|EXPERIMENTAL|patient receiving one PDT session|patient receiving one photodynamic therapy (PDT) session
61940441|NCT01466179|EXPERIMENTAL|Blinatumomab|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
61940442|NCT05088720|EXPERIMENTAL|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
61940443|NCT05088720|ACTIVE_COMPARATOR|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
61940444|NCT05662202|EXPERIMENTAL|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Red light photodynamic therapy (PDT)"
61940445|NCT05662202|PLACEBO_COMPARATOR|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Red light photodynamic therapy (PDT)
61940446|NCT06381466|EXPERIMENTAL|Part A (SAD): Cohort 1A - AZD0233 (dose 1)|Healthy participants will receive AZD0233 (dose 1) orally as a single ascending dose.
61940447|NCT06381466|EXPERIMENTAL|Part A (SAD): Cohort 2A - AZD0233 (dose 2)|Healthy participants will receive AZD0233 (dose 2) orally as a single ascending dose.
61940448|NCT06381466|EXPERIMENTAL|Part A (SAD): Cohort 3A - AZD0233 (dose 3)|Healthy participants will receive AZD0233 (dose 3) orally as a single ascending dose.
61940449|NCT06381466|EXPERIMENTAL|Part A (SAD): Cohort 4A - AZD0233 (dose 4)|Healthy participants will receive AZD0233 (dose 4) orally as a single ascending dose.
61940450|NCT06381466|EXPERIMENTAL|Part A (SAD): Cohort 5A - AZD0233 (dose 5)|Healthy participants will receive AZD0233 (dose 5) orally as a single ascending dose.
62335652|NCT06553378|NO_INTERVENTION|Usual Care|Usual care
62335653|NCT06553378|EXPERIMENTAL|Geriatric Oncology Supportive Clinic|Seen at GOSC
62335654|NCT01025817|EXPERIMENTAL|Everolimus (EVR) & low dose of tacrolimus|Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was \< 3 ng/mL, or reduced if the trough level was \> 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.
61940451|NCT06381466|EXPERIMENTAL|Part B (MAD): Cohort 1B - AZD0233 (dose 6)|Healthy participants will receive AZD0233 (dose 6) orally as a multiple ascending dose.
61940452|NCT06381466|EXPERIMENTAL|Part B (MAD): Cohort 2B - AZD0233 (dose 7)|Healthy participants will receive AZD0233 (dose 7) orally as a multiple ascending dose.
61940453|NCT06381466|EXPERIMENTAL|Part B (MAD): Cohort 3B - AZD0233 (dose 8)|Healthy participants will receive AZD0233 (dose 8) orally as a multiple ascending dose.
61940454|NCT06381466|PLACEBO_COMPARATOR|Part A (SAD): Placebo cohort|Healthy participants will receive placebo orally as a single ascending dose.
62492884|NCT02967926|EXPERIMENTAL|ERCP without Fluoroscopy|Non-fluoroscopic common bile duct stone extraction
62492885|NCT05352048|EXPERIMENTAL|Intraoperative MMG vs EMG for cortical breach detection|Participants in this arm will be assessed with both MMG and EMG during their lower spine fusion surgery.
62492886|NCT04361838|ACTIVE_COMPARATOR|Prayer|Patients will receive a daily prayer and standard of care treatment from multi-denominational group while in the ICU.
62492887|NCT04361838|NO_INTERVENTION|No Prayer|Patients will receive standard of care treatment while in the ICU.
61940455|NCT06381466|PLACEBO_COMPARATOR|Part B (MAD): Placebo cohort|Healthy participants will receive placebo orally as a multiple ascending dose.
61940456|NCT06381466|EXPERIMENTAL|Part A (SAD): Food Effect (FE) extended Cohort 3A|Healthy participants from Cohort 3A will participate in this extended cohort after a washout period of 24 hours.
61940457|NCT04156477|EXPERIMENTAL|Ketone ester|Intake of a ketogenic drink.
61940458|NCT04156477|ACTIVE_COMPARATOR|Isocaloric and -volumetric glucose drink|Intake of a taste matched glucogenic drink.
61940459|NCT04156477|PLACEBO_COMPARATOR|Isovolumetric tap water drink|Intake of a taste matched tap water drink.
61940460|NCT02976922|ACTIVE_COMPARATOR|Probiotic lozenge|Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)
61940461|NCT02976922|PLACEBO_COMPARATOR|Placebo|Placebo lozenge, one lozenge twice daily for 3 months
61940462|NCT03521219|EXPERIMENTAL|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
61940463|NCT06246760|EXPERIMENTAL|Incremental exercise test|Maximal incremental exercise test on a treadmill or a cycle ergometer until volitional exhaustion
61940464|NCT03094988|OTHER|Control|The active attention control group will receive a binder with information about personal health including sleep hygiene, nutritional changes, and stress reduction. In addition, they will participate in a control version of the cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
61940465|NCT03094988|EXPERIMENTAL|Cognitive and physical prehabilitation|The intervention group will receive the prehabilitation program consisting of a guided progressive program of home-based aerobic and resistance training exercise, which will be adapted based on kinesiologist recommendation for each individual and the individual's perceived exertion. In addition, they will have access to the full cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
61940466|NCT02635763|OTHER|PNBs1|Femoral nerve and the lateral cutaneous nerve block combined with general anesthesia
61940467|NCT02635763|OTHER|PNBs2|Lumbar plexus and sacral plexus nerve block combined with general anesthesia
62335655|NCT01025817|ACTIVE_COMPARATOR|Mycophenolate mofetil & standard dose tacrolimus|Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
62695329|NCT05385978|ACTIVE_COMPARATOR|APHD-012|Participants will receive a single dose of APHD-012 12 g daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.
62695330|NCT05385978|PLACEBO_COMPARATOR|APHD-012P|Participants will receive a single dose of APHD-012P daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.
62695331|NCT03889535|ACTIVE_COMPARATOR|Resin strip crowns|Current standard full coverage restoration provided for primary incisors. Please see intervention section for detailed description of technique.
62695332|NCT03889535|EXPERIMENTAL|Zirconia crowns|Experimental treatment under study. Zirconia crowns are an alternative restorative option. Please see intervention section for detailed description of technique.
61940468|NCT06452589|EXPERIMENTAL|Catheter ablation|Adult patients with a history of atrial fibrillation or associated atrial arrhythmias and indicated for a catheter ablation.
61940469|NCT06308419|EXPERIMENTAL|Gemcitabine + Nab-sirolimus|Participants found to be eligible to take part in this study, participants will be assigned to a dose level of gemcitabine and nab-sirolimus based on when participants join this study.
61940470|NCT06557018|EXPERIMENTAL|liposomal bupivacaine (LB) group|20cc liposomal bupivacaine (1 vial; 266 mg) added to 30 cc normal saline to a total of 50 cc solution was injected into the periarticular tissues at the conclusion of the surgical procedure.
61940471|NCT06557018|ACTIVE_COMPARATOR|traditional peri-articular injection group|From periarticular injection consisted of 400 mg ropivacaine, 5 mg morphine and 0.4 mg epinephrine in 50 cc solution.
61940472|NCT00723398|NO_INTERVENTION|Group 1: Control|Control, no intervention
61940473|NCT00723398|EXPERIMENTAL|Group 2: Raloxifene 60 Mg Oral Tablet|Raloxifene 60 mg Orally Daily
61940474|NCT00723398|EXPERIMENTAL|Group 3: Raloxifene 30 Mg Oral Tablet|Raloxifene 30 mg Orally Daily
61940475|NCT00723398|EXPERIMENTAL|Group 4: Lovaza 4 gm oral|Lovaza 4 gm/day Orally with Meals
61940476|NCT00723398|EXPERIMENTAL|Group 5: Lovaza 4gm & Raloxifene 30mg|Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily
61940477|NCT06111521|EXPERIMENTAL|LY3537982 + Digoxin & Rosuvastatin (Part 1)|Single oral doses of digoxin and rosuvastatin with or without multiple doses of LY3537982 administered orally
61940478|NCT06111521|EXPERIMENTAL|LY3537982 + Midazolam (Part 2)|Single doses of midazolam administered either orally or intravenously (IV) with or without multiple doses of LY3537982 administered orally
61940479|NCT05768802|EXPERIMENTAL|MIRA Device|All participants enrolled in the study and who meet eligibility criteria will be implanted with the MIRA device in their residual limb. There is no control group.
61940480|NCT05353179|EXPERIMENTAL|Meperizumab injection|Subcutaneous injection of meperizumab once
62695333|NCT05546866|EXPERIMENTAL|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
62695334|NCT02871440|EXPERIMENTAL|Eye drop 1|Omega 3
62695335|NCT02871440|ACTIVE_COMPARATOR|Eye drop 2|Optive Advanced
61940481|NCT05353179|ACTIVE_COMPARATOR|NUCALA®|Subcutaneous injection of NUCALA® once
61940482|NCT03020030|OTHER|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-\<15 years, WBC \< 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
61940483|NCT03020030|OTHER|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age \>=15 years, WBC \>=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1~And: No VHR characteristics~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
62335656|NCT05998954|EXPERIMENTAL|Transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block (QLESP group)|The patient was turned to the lateral decubitus position with the side to be blocked upward and a low-frequency curved array transducer was placed on the ﬂank cranially to the iliac crest to identify the transverse process of L4, quadratus lumborum muscle, erector spinae muscle, and psoas muscle. The needle was advanced to gently contact the transverse process using an in-plane technique and 15 ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. The needle was subsequently withdrawn and redirected toward the interfascial plane between the quadratus lumborum and the psoas major muscles, where 15 ml of 0.375% ropivacaine was injected with repeated negative aspiration.
62335657|NCT05998954|ACTIVE_COMPARATOR|Suprainguinal fascia iliaca block (SFI group)|With the patient in the supine position, the ultrasound transducer was placed in a parasagittal orientation over the inguinal ligament, inferior medially to the anterior superior iliac spine. Using real-time ultrasound imaging internal oblique, sartorius and iliacus muscles, covered by the fascia iliacus, were identified. With the needle tip placed beneath the fascia and above the iliacus muscle from caudad-to-cephalad direction (in-plane technique), 30 ml of 0.375% ropivacaine was injected slowly to separate the fascia iliaca from the iliacus muscle.
62695336|NCT02871440|ACTIVE_COMPARATOR|Eye drop 3|Optive
62695337|NCT00088946|EXPERIMENTAL|Arm 1|Polyphenon E plus erlotinib placebo daily for 12 months.
62695338|NCT00088946|EXPERIMENTAL|Arm 2|Erlotinib and Polyphenon E placebo daily for 12 months.
62695339|NCT00088946|PLACEBO_COMPARATOR|Arm 3|Erlotinib placebo and Polyphenon E placebo daily for 12 months.
62492888|NCT05029726|EXPERIMENTAL|Investigational|Patients will undergo regional ESPB with bupivacaine plus clonidine in the holding area of the OR immediately prior to surgery. 30mL of 0.25% bupivacaine/1:200,000 epinephrine/50mcg clonidine will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
61940484|NCT03020030|OTHER|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
62492889|NCT05029726|PLACEBO_COMPARATOR|Control|Patients will receive a placebo injection of normal saline via the same ESPB technique. 30ml of normal saline will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
62492890|NCT04516096|EXPERIMENTAL|AMX-0035 long term treatment extension|AMX0035 administered twice daily p.o.
62492891|NCT00870935|ACTIVE_COMPARATOR|Balloon catheter|Hysterosalpingography using intrauterine Balloon catheter
62492892|NCT00870935|ACTIVE_COMPARATOR|Cervical vacuum cup|Hysterosalpingography using cervical vacuum cup
62695340|NCT00684294|EXPERIMENTAL|TAG Vaccine 1 x 10^7 cells/ injection|TAG Vaccine 1 x 10\^7 cells/injection
61940485|NCT03020030|OTHER|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (\<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase \[by randomization or direct assignment\], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase \[by randomization or direct assignment\], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
61940486|NCT03020030|OTHER|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (\<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase \[by randomization or direct assignment\], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase \[by randomization or direct assignment\], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
62695341|NCT00684294|EXPERIMENTAL|TAG Vaccine 2.5 X 10^7 cells/injection|TAG Vaccine 2.5 X 10\^7 cells/injection
61940487|NCT03020030|OTHER|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (\>=0.0001) at first time point (Day 32) but low MRD (\<0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase \[by randomization or direct assignment\], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase \[by randomization or direct assignment\], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
62335658|NCT00632541|EXPERIMENTAL|Single Arm A|Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle
62335659|NCT02731391|EXPERIMENTAL|Mesh repairment|patients undergoing pelvic floor Reconstruction using mesh
62335660|NCT02731391|ACTIVE_COMPARATOR|Tradition Neoplasty|patients undergoing traditional surgical approaches
62335661|NCT01794819|EXPERIMENTAL|C-reactive protein test|"The C-reactive protein test was performed in the intervention group at both the first and second consultations.~The Afinion test system (Axis Shield) was used, which provides results within 5 minutes and before treatment was determined. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L."
62335662|NCT01316991|ACTIVE_COMPARATOR|Chewing gum|Subject will chew gum at defined intervals
62335663|NCT01316991|PLACEBO_COMPARATOR|No Gum|No chewing gum will be provided to subject
62335664|NCT02511951|EXPERIMENTAL|one-layer duct-to-mucosa anastomosis|one-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
62335665|NCT02511951|ACTIVE_COMPARATOR|two-layer duct-to-mucosa anastomosis|two-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
62492893|NCT00870935|EXPERIMENTAL|Operator choice|Hysterosalpingography is performed using either balloon catheter or cervical vacuum cup on the basis of the operator's choice
62492894|NCT00860262|EXPERIMENTAL|telmisartan and amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
62492895|NCT00860262|ACTIVE_COMPARATOR|amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
62492896|NCT00860262|ACTIVE_COMPARATOR|telmisartan|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
62492897|NCT03549897|PLACEBO_COMPARATOR|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
62492898|NCT03549897|ACTIVE_COMPARATOR|90 mcg Reference Product|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
62695342|NCT02722785|NO_INTERVENTION|Usual Care Observation Group|Patients allocated to usual care control will receive the standard patient care program as provided by the department of surgical gastroenterology, Rigshospitalet
62695343|NCT02722785|EXPERIMENTAL|Aerobic and Resistance Exercise Training|Patients allocated to this group will receive usual care plus a supervised aerobic and resistance exercise program at CFAS' facilities consisting of 2 weekly sessions of approximately 60 minutes.
62695344|NCT06053372|EXPERIMENTAL|Apple Watch|Participants will wear an Apple Watch for 6 months
62695345|NCT06570564|EXPERIMENTAL|Upper limb exercises group.|Upper limb exercises group consist of 20 patients. They received arm cranking exercise and routine physiotherapy program.
62695346|NCT06570564|EXPERIMENTAL|Lower limb exercises group.|Lower limb exercises group consist of 20 patients. They received bicycling exercise and routine physiotherapy program.
62695347|NCT06570564|EXPERIMENTAL|The control group.|The control group consisted of 20 patients. They received only routine physiotherapy program.
62492899|NCT03549897|ACTIVE_COMPARATOR|180 mcg Reference Product|One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
62492900|NCT03549897|EXPERIMENTAL|90 mcg Test Product|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
62492901|NCT01802645|ACTIVE_COMPARATOR|Cetuximab/FOLFIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)\*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks~\*reduced in UGT1A1 7/7 patients"
62492902|NCT01802645|EXPERIMENTAL|Cetuximab/FOLFOXIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),\* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~\*reduced in UGT1A1 7/7 patients"
62492903|NCT01802645|ACTIVE_COMPARATOR|FOLFOXIRI|"Irinotecan 165 mg/m² (1 h)\*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~\*reduced in UGT1A1 7/7 patients"
62492904|NCT01802645|EXPERIMENTAL|Bevacizumab/FOLFOXIRI|"Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),\* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~\*reduced in UGT1A1 7/7 patients"
62492905|NCT01777815|EXPERIMENTAL|Implanting ePTFE sutures|Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
62492906|NCT00770458||Pregnant women|Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome
62492907|NCT03347058|OTHER|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
62492908|NCT05828290|EXPERIMENTAL|Yoga Group|"The Little Yogis Doing Yoga Program was started to be implemented by the researcher for 4 weeks, 2 days a week for 30 minutes, separately for each group, in a way to form 2 groups."
62492909|NCT05828290|NO_INTERVENTION|Control Group|Children in the control group will continue their routine education at school.
62492910|NCT05554887|EXPERIMENTAL|Thrust manipulation Group|Participants undergoing thrust manipulation
62335666|NCT04907006|EXPERIMENTAL|Group-1|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
62335667|NCT04907006|EXPERIMENTAL|Group-2|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
62335668|NCT01694576|EXPERIMENTAL|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
62335669|NCT01694576|NO_INTERVENTION|Observation|Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation
62335670|NCT03699631|EXPERIMENTAL|Tacrolimus/Methotrexate/Tocilizumab|"Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant.~Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11.~Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days)."
62335671|NCT04339569||History of patellar tendinopathy|
62335672|NCT04339569||Healthy controls|
62335673|NCT04070352||clostridium difficile infection (CDI)|This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled
62335674|NCT06043206||Cases Obesity and schizophrenia|Patients with schizophrenia and obesity undergoing bariatric surgery
62335675|NCT06043206||Controls|Patients without psychiatric pathology matched by age, sex, BMI and type of surgery and in a 4:1 ratio to cases.
62492911|NCT05554887|SHAM_COMPARATOR|Sham thrust manipulation group|Participants undergoing sham thrust manipulation
62492912|NCT01825694|NO_INTERVENTION|Standard of Care|The Standard of Care condition includes: 1) an individual session with the counselor, once per week; 2) a treatment group with the counselor, twice per week; and 3) parents of youth are invited to attend parent-only educational sessions weekly.
62492913|NCT01825694|EXPERIMENTAL|Trauma-focused Substance Abuse Intervention|See Intervention Arm description.
62492914|NCT03687619|EXPERIMENTAL|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a top-down approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
62492915|NCT03687619|EXPERIMENTAL|Conductive Education|Conductive Education is a down-top approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
62492916|NCT02686567|ACTIVE_COMPARATOR|with TDT|with TDT
62492917|NCT02686567|ACTIVE_COMPARATOR|without TDT|without TDT
62492918|NCT05456451|EXPERIMENTAL|Parkinson group(pre and post treatment)|5 participants will be evaluated for tremor and autonomic dysfunction at pre and post treatment
62492919|NCT00714051|EXPERIMENTAL|Fall Prevention Training|The falls prevention training group participated in four weekly training sessions on a custom-built treadmill that produced trip-simulating perturbations (movements). While harnessed overhead to prevent actual falls, the treadmill stopped or moved suddenly. The goal for the participant was to try and prevent a fall. Each week, the level of difficulty of the task was increased.
61940488|NCT03020030|OTHER|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (\>=0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase \[by direct assignment\], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase \[by direct assignment\], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase \[by direct assignment\], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
61940489|NCT03020030|ACTIVE_COMPARATOR|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
61940490|NCT03020030|EXPERIMENTAL|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL. Closed to Enrollment.
62492920|NCT00714051|ACTIVE_COMPARATOR|Attention Control|The attention control group participated in four weekly treadmill walking sessions at a self-selected speed.
61940491|NCT03020030|OTHER|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
61940492|NCT03318666|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Both arms will receive this intervention
61940493|NCT03318666|EXPERIMENTAL|Supporting Our Valued Adolescents (SOVA)|This arm will receive the SOVA intervention in addition to Enhanced Usual Care
61940494|NCT02787265||spinal cord stimulation|Failed back surgery syndrome patients will receive high density spinal cord stimulation
61940495|NCT02373878|ACTIVE_COMPARATOR|Telecoaching plus plate|Telecoaching plus portion control plate
61940496|NCT02373878|ACTIVE_COMPARATOR|Usual Care|Usual Care
61940497|NCT04812730|OTHER|ASD with decompensated sagittal misalignment|Adults suffering from a spinal deformity with a decompensated sagittal misalignment
61940498|NCT04812730|OTHER|ASD with compensated sagittal misalignment|Adults suffering from a spinal deformity with a compensated sagittal misalignment
61940499|NCT04812730|OTHER|ASD without sagittal misalignment|Adults suffering from a spinal deformity without a sagittal misalignment
61940500|NCT04812730|OTHER|Control group|Asymptomatic adults not suffering from a spinal deformity
61940501|NCT00646789|EXPERIMENTAL|1|MK0633
61940502|NCT03576300||control|subjects without dry eye and diabetes
61940503|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
61940504|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
61940505|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
61940506|NCT02538328|ACTIVE_COMPARATOR|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
61940507|NCT02538328|PLACEBO_COMPARATOR|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
61940508|NCT02298023|EXPERIMENTAL|Mesenchymal stem cell group|Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.
61940509|NCT02298023|ACTIVE_COMPARATOR|Active control (fibrin glue) group|Received fibrin glue and normal saline.
61940510|NCT02298023|PLACEBO_COMPARATOR|Control (normal saline )group|Received only normal saline.
61940511|NCT05088395|OTHER|"Cohort 1: SENOLOC"|"Detecting residual disease after surgery is absolutely crucial in oncology, as this detection could allow the personalisation of post-operative treatments based on the presence of residual disease.~The laboratory wishes to develop a new technique for the detection of circulating tumour DNA, based on the recognition of translocation fragments in circulating DNA by shallow whole genome sequencing. This is an original approach, which to our knowledge has not been tested so far with the envisaged bioinformatics approach and could potentially be more sensitive than the techniques currently used to detect residual disease after surgical removal of localised (non-metastatic) breast cancer.~The analysis will therefore focus on the search for tumour chromosomal translocations, which will need to be differentiated from possible germline chromosomal translocations. The collection of constitutional DNA is therefore planned in this cohort."
62335676|NCT00002833|EXPERIMENTAL|Group 1A|"Group 1A - With or Without Remission + Failing Fludarabine therapy:~Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
62335677|NCT00002833|EXPERIMENTAL|Group 1B|"Group 1B: With or Without Remission, No previous Fludara Therapy~Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
62335678|NCT06100640||positive paracervical pouch|The first group will include patients in whom a paracervical pouch is detected by transvaginal ultrasound.
62335679|NCT06100640||negative paracervical pouch|the second group will include patients in whom the pouch is not detected by transvaginal ultrasound
62492921|NCT05093686|EXPERIMENTAL|RUBIES|RUBIES provides paraeducators in training on behavioral strategies based on principles of applied behavior analysis to target student disruptive behaviors in the classroom
62492922|NCT05093686|ACTIVE_COMPARATOR|Usual Care Treatment|Usual Care Treatment provides paraeducators with foundational psychoeducation on autism spectrum disorders.
62695348|NCT02683993|EXPERIMENTAL|Stone breaking|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with low frequency parameters.
62335680|NCT01413984|EXPERIMENTAL|cognitive behavioral group treatment|Helping Women Recover/Beyond Trauma integrated substance abuse and trauma treatment group. (Dr. Covington)
62492923|NCT06403423||Patients with AAA|65-year old men in Inland, Norway will be invited by mail to a screening. Patients with detected aneurysm will be followed over time with blood samples and questionnaires in addition to ultrasound measurement of the diameter of the infrarenal abdominal aortic aneurysm.
62492924|NCT06403423||Control group (no AAA)|65-year old men in Inland, Norway will be invited by mail to a screening. A matched group of individuals without AAA will be included as control patients and followed with blood samples and questionnaires.
62492925|NCT03256864|EXPERIMENTAL|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)~Other Names:~* Prograf~* Advagraf~* Zortress~* Certican"
62492926|NCT03256864|EXPERIMENTAL|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)~Other Names:~* Prograf~* Advagraf~* Zortress~* Certican"
62492927|NCT04780711||Diagnostic Group|Demographic data, symptoms for TMJ of the students will be recorded. Physical examination will be included range of motion of temporomandibular joint, right and left TMJ lateral range of motion, whether there is a gradual opening, during deflection and deviation during the opening and subluxation for palpation and measurements. Opening and closing clicks, crepitation and popping will be recorded during palpation. Deep palpation of the skin, masseter and temporal muscles will be determined, posture analysis will be recorded and dental interventions, missing teeth, orthodontic treatments and bruxism histories will be taken. An appropriate diagnosis will be determined for students who are found to have pathology as a result of all these examinations and information about this diagnosis will be provided.
62492928|NCT01546363||Validation|
62492929|NCT01546363||Testing|
62492930|NCT05036005|EXPERIMENTAL|Ontruzant + Pertuzumab (optional) + Chemotherapy|"All patients will receive 6 cycles of Ontruzant® i.v. q21d in combination with standard chemotherapy with or without pertuzumab, at the discretion of investigator's decision. Initial dose of Ontruzant® i.v. will be 8 mg/kg b.w. followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d. Clinical and bioptic tumor assessment will be performed during baseline and during surgery.~Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent. A safety follow-up is planned for 30 days after the last administration of study medication."
62492931|NCT05569109||av fistula patency loss with hperphosphatemia|hemodialysis patients with av fistula patency loss by doppler ultrasound and hyperphosphatemia
62492932|NCT05569109||av fistula patency loss with normal phosphate level|hemodialysis patients with av fistula patency loss by doppler ultrasound and normal phosphate level
62492933|NCT02218216|EXPERIMENTAL|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
62492934|NCT02218216|PLACEBO_COMPARATOR|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
62492935|NCT05418790|EXPERIMENTAL|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
62492936|NCT03734458|EXPERIMENTAL|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
62137674|NCT05455697|EXPERIMENTAL|Treatment (TRR, CHOP)|"PREPHASE THERAPY: Patients receive tafasitamab IV over 30 minutes on days 1, 8, and 15 of each cycle, rituximab and hyaluronidase human SC on day 1 of each cycle, and retifanlimab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~COMBINATION THERAPY: After completion of prephase therapy or if patients progress during prephase therapy, patients receive tafasitamab IV over 30 minutes, retifanlimab IV over 30 minutes, rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 of each cycle. Patients with an IPI score of 2-5 may receive polatuzumab vedotin IV in place of vincristine at investigator discretion. Patients also receive prednisone PO on days 1-5 of each cycle. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity."
62137675|NCT03204032|EXPERIMENTAL|Tegafur and Temozolomide|
62137676|NCT03204032|ACTIVE_COMPARATOR|Tegafur and Temozolomide combined with Thalidomide|
62335681|NCT01413984|NO_INTERVENTION|comparison group|a comparison group of incarcerated women will receive the pre and post assessments with no interventions.
62335682|NCT01154972|EXPERIMENTAL|Single arm study - Sentinel Node Localisation|
62335683|NCT04940871|EXPERIMENTAL|Favipiravir HU + SOC|Favipiravir HU + SOC
62335684|NCT04940871|PLACEBO_COMPARATOR|Placebo HU + SOC|Placebo HU + SOC
62695349|NCT02683993|EXPERIMENTAL|Stone dusting|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with high frequency parameters.
62335685|NCT06552442|EXPERIMENTAL|Main group|"Main group - 10 patients. STEMI patients with the occurrence of the no-reflow phenomenon after stenting of the infarct-related artery.~Treatment of the phenomenon: intracoronary administration of methylprednisolone."
62335686|NCT06552442|NO_INTERVENTION|Control group|"Control group - 10 patients. STEMI patients with the occurrence of the no-reflow phenomenon after stenting of the infarct-related artery.~Treatment of the phenomenon: no pharmacological intervention."
62335687|NCT02123563|EXPERIMENTAL|Ultrason Essential oils rinse|Ultrasonic debridement followed by twice daily home use of an essential-oils mouth rinse (20mL, 30 seconds for each rinse) for 3 months
62335688|NCT02123563|PLACEBO_COMPARATOR|Ultrason Placebo rinse|Ultrasonic debridement followed by twice daily home use of a placebo rinse (20mL, 30 seconds for each rinse) for 3 months
62335689|NCT01405846|OTHER|Gefitinib|Single arm study
62137677|NCT02831816|EXPERIMENTAL|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
62137678|NCT02831816|ACTIVE_COMPARATOR|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
62137679|NCT02831816|PLACEBO_COMPARATOR|ZP Vehicle|ZP without IPA
62695350|NCT06640309|EXPERIMENTAL|Nicotinamide group|Patients will receive nicotinamide 1000mg tablet once daily.in addition to their conventional therapy for three months.
61940512|NCT05088395|OTHER|"Cohort 2: Immuno-TNBC "|"The aim for this cohort is to study the role that variations in circulating tumour DNA might have as a marker associated with response during chemoimmunotherapy.~A fresh biopsy (subsequently stored frozen) is required for mutational profiling analysis (which will be used to track circulating tumour DNA in the blood). In addition, it will be used to analyse currently recognised biological tissue factors of response to chemoimmunotherapy (PD-L1 labelling, mutational load, ...) and to identify possible associations with circulating tumour DNA variations.~Constitutional DNA analysis is necessary for the determination of point mutations present in the tumour (to be differentiated from polymorphisms present at the constitutional level), as the determination of these mutations is essential to monitor circulating tumour DNA and will therefore be collected."
61940513|NCT05088395|OTHER|"Cohort 3: Trans-TNBC"|"The objective of this cohort is the development of new plasma tests, for example based on the detection of chromosomal translocations of circulating tumor DNA.~The hypothesis is that these tests would allow the detection of relapse, the prediction of treatment efficacy and the monitoring of treatment efficacy at different stages of cancer in patients with triple-negative breast cancer, either in the non-metastatic phase with planned neo-adjuvant treatment, or in the metastatic phase. The number of inclusions between these 2 populations (neo-adjuvant and metastatic) will be monitored at the operational level to avoid an excessive imbalance towards one group."
61940514|NCT05088395|OTHER|"Cohort 4: Treg"|"The purpose of this cohort, based on the previous results, is to:~1. quantify the expression level of target genes on tumor Regulatory T (Tregs) at the protein level,~2. perform multiparametric FACS analysis on blood and tumor samples from patients treated at the Institut Curie, with breast or ovary cancer and to understand the potential of these targets as biomarkers of disease.~In the context of this ALCINA-4 cohort n°4, for breast and ovary patients, 40 ml of blood will be collected and tumor fragments obtained from surgery (50 breast patients) or therapeutically required biopsy (30 ovary patients). No additional biopsy than the ones belonging to the therapeutic process will be performed in this protocol. Biopsies performed as part of standard of care will be used if sufficient material is available."
62335690|NCT02691650||polytrauma patients|Patients with severe traumatic injury, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
62335691|NCT02691650||burns patients|Patients with burns trauma, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
62335692|NCT04729582|EXPERIMENTAL|Verum Group|Participants receive primary human muscle stem cells as one-time injection into the urethral sphincter region under visual control using cystoscopy.
62335693|NCT04729582|PLACEBO_COMPARATOR|Placebo group|Participants receive placebo solution as one-time injection into the external urethral sphincter region under visual control using cystoscopy.
62335694|NCT02040883|ACTIVE_COMPARATOR|Control Group|Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
61940515|NCT05088395|OTHER|"Cohort 5: Pembro Neo"|"The purpose of this cohort is to determine the detection rate of circulating tumour DNA (ctDNA) before and after surgery in the blood of patients who received neoadjuvant treatment with chemoimmunotherapy for early triple-negative breast cancer (TNBC).~There will be two subgroups : patients who have not yet started neoadjuvant treatment (subcohort 1) and patients who have already started neoadjuvant treatment (subcohort 2).~Biopsy of a tumour lesion will be performed before the start of neoadjuvant treatment (only for subcohort 1). The collection of constitutional DNA, plasma and circulating tumour DNA are planned in this cohort at different time points."
62137680|NCT03413085|OTHER|Group A|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: multifocal soft contact lens Right eye: single vision soft contact lens"
62137681|NCT03413085|OTHER|Group B|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: single vision soft contact lens Right eye: multifocal soft contact lens"
62137682|NCT03980418|EXPERIMENTAL|all included patients will have the same procedure|After the conventional DaTSCAN SPECT/CT exam in conventional camera, all patients included will have two recordings of DaTSCAN SPECT/CT in semiconductor CZT (cadmium zinc telluride) camera; one focused on the striatum and the other focused on the total brain
62335695|NCT02040883|EXPERIMENTAL|Study Group|Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
62335696|NCT02132234|EXPERIMENTAL|Biological treatment|"Patients with high disease activity receiving biological treatment according to rheumatologic indication:~* etanercept 50 mg s.c. every week~* adalimumab 40 mg s.c. every 2 weeks~* certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks~* infliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks"
62335697|NCT02132234|PLACEBO_COMPARATOR|control group|Patients with high disease activity receiving other than biological treatment and receiving placebo.
62335698|NCT04863014|EXPERIMENTAL|evinacumab|Randomized 1:1
62335699|NCT04863014|PLACEBO_COMPARATOR|Placebo|Randomized 1:1
62492937|NCT03734458|EXPERIMENTAL|Group B - PRF only with a CAF|Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
62695351|NCT06640309|ACTIVE_COMPARATOR|control group|Patients will receive their conventional therapy only.
62695352|NCT05848297||Prolonged automated TCD|
62738430|NCT02038972|EXPERIMENTAL|Autologous Stem Cells|A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
61940516|NCT05088395|OTHER|"Cohort 6: THL"|"The main objective of this exploratory cohort is to characterize the detection rate of ctDNA before and during therapy with T-DXd (Trastuzumab deruxtecan) for patients with HER2-low metastatic breast cancer, requiring treatment with T-DXd.~Tumor biopsy will be performed after inclusion and before the start of treatment on cycle 1 day 1 for at least 30 patients. The collection of constitutional DNA, is planned in this cohort at different time points : T1 and T2 (before treatment start) are critical to evaluate the intra-patient reproducibility of liquid biomarkers. T3 will investigate the response to therapy while T4 will focus on resistance mechanisms."
61940517|NCT05088395|OTHER|"Cohort 7:CDK4/6 adjuvant"|"The purpose of this cohort is to determine the prognostic impact of circulating tumor DNA detection and monitoring in patients receiving a CDK4/6 inhibitor in adjuvant breast cancer.~50 ml of blood will be collected in EDTA tubes for constitutional DNA and plasma for research of circulating biomarkers at different time points (4 time points)."
62137683|NCT02397096|EXPERIMENTAL|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for \>=6 months with undetectable HIV-1 RNA will switch on Day 1 to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
62335700|NCT05209932|EXPERIMENTAL|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group NBP. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations. Units are highly interactive. Sessions began with a check-in in which parents responded to questions about use of the program skills and were provided with ways to address the challenges they experienced. The skill was then taught using modeling videos, interactive exercises, and testimonials from prior participants. The program then prompted parents to set times to use the skill, identify barriers to using it and select strategies to reduce these barriers. Parents were provided with tip sheets to address challenges in using the skill, downloadable sheets to record use of and competence in using the skill and a downloadable handbook that summarized what was covered in the unit.
62335701|NCT05209932|NO_INTERVENTION|wait-list control condition|Parents in the waitlist-control condition were told that they would have access to the eNBP 12 weeks after they completed the pre-test. Twelve weeks after assignment to condition, parents and children were sent links to the posttest
62335702|NCT02280928|EXPERIMENTAL|Single-task motor training group|The participants will receive only balance training which will progress from stance activities, to stance activities plus hand manipulation, then gait activities, and finally gait activities plus hand manipulation.
62335703|NCT02280928|EXPERIMENTAL|Single-task cognitive training group|The participants will receive cognitive training that will involve executive function, attention, and working memory.
62335704|NCT02280928|EXPERIMENTAL|Dual-task motor-cognitive training group|The participants assigned to the dual-task motor-cognitive training group will receive the same exercises as single-task motor training while simultaneously performing secondary tasks as those in the single-task cognitive training group.
62335705|NCT02280928|EXPERIMENTAL|Dual-task cognitive-cognitive training group|The participants in the dual-task cognitive-cognitive trainings group will receive two cognitive tasks at the same time.
62335706|NCT06290947|EXPERIMENTAL|Blood-Flow Restriction Walk Training (BFRw)|"Participants in this group will engage in a Blood-Flow Restriction Walk Training (BFRw) program designed to evaluate the efficacy of BFRw in enhancing insulin sensitivity and aerobic capacity.~Activities:~Participants will attend three weekly supervised walking sessions for eight weeks, each integrating specialized BFR cuffs calibrated to a precise pressure to restrict blood flow during exercise partially.~Purpose:~This arm is crucial for testing the study's primary hypothesis by measuring the intervention's effects against a control group."
62335707|NCT06290947|ACTIVE_COMPARATOR|Control Group Walk Training|"Participants in this group will engage in a conventional walking training program without applying BFR cuffs.~Activities:~Participants will attend three weekly supervised walking sessions for eight weeks without using BFR cuffs.~Purpose:~This group will serve as a benchmark to ascertain the effectiveness of the intervention, providing a baseline for the comparative analysis of the results obtained from the intervention group."
62335708|NCT01336179|EXPERIMENTAL|Miswak, dental plaque and gingivitis|
62335709|NCT01336179|ACTIVE_COMPARATOR|Toothbrush, dental plaque and gingivitis|
62335710|NCT02004587|EXPERIMENTAL|Mild hepatic impairment group|Mild hepatic impairment group by Child-Pugh scores
62335711|NCT02004587|EXPERIMENTAL|Moderate hepatic impairment group|Moderate hepatic impairment group by Child-Pugh scores
62335712|NCT02004587|ACTIVE_COMPARATOR|Healthy volunteers|Gemigliptin dosing in Healthy subjects
62335713|NCT04310150|EXPERIMENTAL|Treatment arm label- Collastat®|
62335714|NCT04310150|ACTIVE_COMPARATOR|Control arm label- Floseal®|an marketed product is Floseal
62335715|NCT04915677|ACTIVE_COMPARATOR|Subepithelial Connective Tissue Graft (SCTG)|Soft tissue augmentation at edentulous area with subepithelial connective tissue graft harvested from the patient's palate
62335716|NCT04915677|EXPERIMENTAL|Volume Stable Collagen Matrix (VCMX)|Soft tissue augmentation at edentulous area with xenogenic volume stable collagen matrix
62335717|NCT05276050|EXPERIMENTAL|Study group|Participants in this group will receive active F8-coil delivered rTMS.
62335718|NCT05276050|ACTIVE_COMPARATOR|Active control group|Participants in this group will receive active H-coil delivered rTMS.
62335719|NCT01928121|EXPERIMENTAL|AF expert program|Care provided by the interdisciplinary, nurse-coordinated AF expert program
62335720|NCT01928121|NO_INTERVENTION|Usual care|
62335721|NCT05224869|EXPERIMENTAL|Patients with prostate cancer|Patients undergo hydrogel rectal spacer placement on day 1. Within 2 weeks (+/-1 week) after Rectal Spacer placement, patients will be scheduled for CT simulation for external beam treatment planning. Patients will begin the SBRT of 24Gy in 5 fractions within 2 weeks (+/-1 week) from the simulation date. Within 4 weeks (+/-1 week) of last day of SBRT, patients undergo brachytherapy. Patient will return for post-implant CT-based dosimetry analysis 4 weeks (+/- 1 week) post brachytherapy,
62335722|NCT00563836|EXPERIMENTAL|1|
62335723|NCT03203889|EXPERIMENTAL|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
62335724|NCT03203889|ACTIVE_COMPARATOR|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
62335725|NCT03194152|EXPERIMENTAL|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
62335726|NCT03194152|EXPERIMENTAL|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
62492938|NCT03734458|ACTIVE_COMPARATOR|Group C - CTG with a CAF|Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
62492939|NCT02344849|EXPERIMENTAL|Mesenchymal stem cell|Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.
62335727|NCT04912037|EXPERIMENTAL|with AI-assisted system|The novice doctors are trained in colonoscopy with an artificial intelligence assisted system that can indicate abnormal lesions and the speed of withdrawal in real time, as well as feedback on the percentage of overspeed.
62335728|NCT04912037|NO_INTERVENTION|without AI-assisted system|The novice doctors receive routine colonoscopy training without artificial intelligence assistance system and no special tips
62335729|NCT05147558|EXPERIMENTAL|Pembrolizumab With Lenvatinib|Lenvatinib (20mg once daily orally) in combination with Pembrolizumab (200mg every 3 weeks, intravenously)
62335730|NCT04263142|EXPERIMENTAL|Part 1: Treatment AB|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62335731|NCT04263142|EXPERIMENTAL|Part 1: Treatment BA|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62335732|NCT04263142|EXPERIMENTAL|Part 2: Treatment CDE|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62492940|NCT00613730|EXPERIMENTAL|Gemcitabine + panitumumab|Panitumumab 6 mg/kg was administered intravenously (IV) before gemcitabine on Day 1 of Weeks 1, 3, 5, and 7, and then every 2 weeks (day 1 and 15) of each subsequent 4-week chemotherapy cycle. Gemcitabine 1000 mg/m\^2 was administered IV once weekly (on Day 1) for 7 weeks, followed by a 1-week rest period. In subsequent cycles, gemcitabine was given once weekly (on Day 1) for 3 consecutive weeks followed by 1 week of rest. Panitumumab and gemcitabine treatment continued until disease progression, unacceptable adverse events, death, or study withdrawal occurred.
62492941|NCT00972231||Thalassemia Group|Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia
62492942|NCT00972231||Sickle Cell Group|Patients with Sickle Cell Anemia and Sickle Cell Thalassemia
62492943|NCT03959150|EXPERIMENTAL|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 po qd
62492944|NCT03959150|NO_INTERVENTION|Observation|Observation
62492945|NCT04311346||Cardiac transplant|Patients exposed to cardiac transplantation
62492946|NCT03672240|EXPERIMENTAL|APL-1202|"* APL-1202 will be administered orally at daily 750 mg (250 mg, TID) for 5-7 days prior to the first intravesical BCG treatment and continue for additional 11 weeks (a total 12 weeks of dosing with APL-1202).~* Standard intravesical BCG induction course (once weekly for 6 weeks) 50 mg TICE BCG in 50 mL sterile saline (or a full dose standard vial of BCG) will be initiated on Week 2."
62492947|NCT03199196|EXPERIMENTAL|Group 1 - Intervention|"Participants given an activity tracker at the given an accelerometer at each visit. Participants instructed in use of a smartphone application at the baseline visit.~Participant emailed electronic newsletters to read that may help participant be more physically active.~Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
62738431|NCT06661655|EXPERIMENTAL|Main cohort|Patients recruited in the study will receive an ultrasound exam with Hepatoscope to collect quantitative measurements related to the severity of liver steatosis.
62738432|NCT06454279|EXPERIMENTAL|Dual Task Training|"Dual task exercises for example Crossing over the obstacles placed on their path while answering simple questions yes or no Walking while bouncing the ball with spell the word like WORLD Picking up an object from the floor. Walking on straight line while Calculation. Tandem walk while counting money"
61940518|NCT05088395|OTHER|"Cohort 8:ctDNA adjuvant "|"The purpose of this cohort is to estimate the incidence of ctDNA detection in patients with early-stage breast cancer during follow-up to detect metastatic relapse earlier in asymptomatic patients.~ctDNA analysis will be performed using various techniques, including next-generation sequencing (NGS), with or without analysis of tumor tissue, taken as part of the standard care.~40 ml of blood samples will be collected at four time points:~* enrollment,~* 6 months (+/- 15 days),~* 12 months (+/- 15 days),~* 18 months (+/- 15 days) after inclusion."
61940519|NCT05088395|OTHER|"Cohort 9:ADN-CIRC-Poumon "|"The purpose of this cohort is to:~* Generate data on the levels and nature of circulating tumor DNA under chemo-immunotherapy.~* Monitor the evolution of the circulating immune response under systemic chemo-immunotherapy.~Tumor biopsy will be performed after inclusion and before the start of treatment.~50 ml of blood samples will be collected at four time points:~* At inclusion, before starting neoadjuvant treatment~* At the start of cycle 3 (C3J1) of neoadjuvant treatment~* At the time of surgery (after neoadjuvant treatment)~* At the start of monitoring, i.e. 3 months (+/- 1 month) after surgery."
61940520|NCT05088395|OTHER|"Cohort 10: UM TENEO"|"The purpose of this cohort is to :~* Evaluate recurrence-free survival (RFS) after R0/R1 surgery~* Assess effectiveness of Tebentafusp associated with surgery for patients with uveal melanoma metastases.~  3 sub-cohorts :~* Sub-cohort 1: HLA-A\*02:01-positive patients, eligible for R0 surgery and Tebentafusp (n=20)~* Sub-cohort 2: HLA-A\*02:01-negative patients, eligible for R0 surgery and immunotherapy at next relapse (n=20)~* Sub-cohort 3: HLA-A\*02:01 positive patients, not eligible for R0 surgery but eligible for Tebentafusp (n=20).~Tumor biopsy will be performed during surgery (sub-cohorts n°1 and 2) or after inclusion (sub-cohort n°3).~40 ml of blood will be collected in EDTA tubes for constitutional DNA and circulating DNA in plasma for research of biomarkers at 4 time points."
61940521|NCT06680050|EXPERIMENTAL|Radiotherapy followed by Durvalumab+Ceralasertib|
62335733|NCT04263142|EXPERIMENTAL|Part 2: Treatment DEC|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62335734|NCT04263142|EXPERIMENTAL|Part 2: Treatment ECD|Participants will receive a single dose of GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
62335735|NCT03518099|EXPERIMENTAL|Patient|Any patient admitted for acute abdomen condition with or without ischemic causes.
62492948|NCT03199196|OTHER|Group 2 - Control|"Participants sent electronic newsletters throughout the study that may help participant be more physically active.~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
62492949|NCT04202705|EXPERIMENTAL|SYD1875|5T4-targeting Antibody-Drug Conjugate
62492950|NCT01664169||Single group|"The samples required for this study are stored in the CALGB Pathology Coordinating Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No additional samples are required from patients.~The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3, IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
62492951|NCT03174158|ACTIVE_COMPARATOR|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
62492952|NCT03174158|EXPERIMENTAL|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the Massachusetts General Hospital (MGH) tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
62492953|NCT03174158|EXPERIMENTAL|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
62492954|NCT03174158|EXPERIMENTAL|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
62492955|NCT04485208|EXPERIMENTAL|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the thalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
61940522|NCT05542199|ACTIVE_COMPARATOR|+MCNS+WL|This group receives the multicomponent nutrition supplement and the behavioral weight loss intervention.
61940523|NCT05542199|PLACEBO_COMPARATOR|-MCNS+WL|This group receives the placebo nutrition supplement and the behavioral weight loss intervention.
61940524|NCT05542199|ACTIVE_COMPARATOR|+MCNS-WL|This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes).
61940525|NCT05542199|NO_INTERVENTION|-MCNS-WL|This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes)
61940526|NCT06064266|EXPERIMENTAL|8-days plant-based preconditioning mild ketogenic controlled diet followed by a high-fat shake.|
62137684|NCT02397096|ACTIVE_COMPARATOR|Delayed Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for \>=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
62335736|NCT03518099|EXPERIMENTAL|witness|
62335737|NCT05041959|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
62335738|NCT05041959|OTHER|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
62335739|NCT03718052|EXPERIMENTAL|Early valve surgery (EVS)|Cardiac surgery as soon as possible within 72 hours of randomization
62335740|NCT03718052|ACTIVE_COMPARATOR|Conventional care|Conventional care according to the 2015 European guidelines.
62335741|NCT05909215|ACTIVE_COMPARATOR|Dexmedetomidine 0.5|Dexmedetomidine 0.5 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.
62738433|NCT06454279|EXPERIMENTAL|Task Specific Training|Picking up the card, Picking up the right color, Box and block activity, Picking up different shapes, Gait training, Sit/ standing marching.
61940527|NCT02735408|EXPERIMENTAL|100% KT Tension|100% KT Tension
62335742|NCT05909215|ACTIVE_COMPARATOR|Dexmedetomidine 0.75|Dexmedetomidine 0.75 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.
62335743|NCT05909215|PLACEBO_COMPARATOR|Placebo|20 mL of normal saline as an infusion through a syringe pump over 10 minutes followed by induction of general anesthesia.
62335744|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
62335745|NCT03077126|OTHER|Pre-surgery Ultrasound|Aixplorer® ShearWave Elastography (SWE™) Ultrasound. Participants will undergo ultrasound prep with Fleet Enema and ultrasound procedure at their pre-op visit one to two weeks before their standard of care prostatectomy.
62335746|NCT02754830|EXPERIMENTAL|LY3303560|Single IV infusion 7 milligram (mg), 21 mg, 70 mg, 210 mg, 700 mg, 1400 mg, 2800 mg, and 5600 mg of LY3303560 on Day 1 in healthy participants.
62335747|NCT02754830|PLACEBO_COMPARATOR|Saline Solution|Single IV infusion of saline solution to match LY3303560 on Day 1 in healthy participants.
62335748|NCT02754830|EXPERIMENTAL|LY3303560 Subcutaneous (SC)|Single SC injection of 210 mg LY3303560 on Day 1 in healthy participants.
62335749|NCT03608553|EXPERIMENTAL|ExAblate|ExAblate MR Guided Focused Ultrasound
62335750|NCT01818050|OTHER|Wing stent arm|There is only one arm in this study. Intervention: checking liver function tests to evaluate stent patency
61940528|NCT02735408|EXPERIMENTAL|50% KT Tension|50% KT Tension
62335751|NCT04897555|EXPERIMENTAL|LLLT Active Treatment|LLLT Therapy will be administered to the treatment site.
62335752|NCT04897555|NO_INTERVENTION|No LLLT Comparator|No LLLT Therapy will be administered to the comparator site.
62335753|NCT01062594|ACTIVE_COMPARATOR|Supervised exercise group|
62335754|NCT01062594|NO_INTERVENTION|Control group - no exercise|
62335755|NCT05705570|EXPERIMENTAL|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepleting regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
62335756|NCT06083246|EXPERIMENTAL|Hybenix gel|Clinical application of Hybenix gel.
62335757|NCT06083246|ACTIVE_COMPARATOR|Chlosite|Clinical application of Chlosite gel.
62335758|NCT05027529|EXPERIMENTAL|VA-ECMO and CytoSorb|standard ICU care WITH CytoSorb
62335759|NCT05027529|PLACEBO_COMPARATOR|VA-ECMO only|standard ICU care WITHOUT CytoSorb
62335760|NCT02194101||Supernormal oxygen delivery goal therapy|Patients will be aged over 70 yr and weight over 35 kg, and undergoing proximal femur fracture (PFF) surgery under peripheral nerve block and laryngeal mask airway anesthesia.
62335761|NCT03282357|EXPERIMENTAL|Radiesse|Subjects are randomized as to which of the two nasolabial folds is treated with Radiesse.
62335762|NCT03282357|ACTIVE_COMPARATOR|Restylane|Subjects are randomized as to which of the two nasolabial folds is treated with Restylane.
62335763|NCT04549597|EXPERIMENTAL|Cohort 1: Straight Switch|Patients stop taking phosphate binders and start tenapanor 30 mg twice daily
62335764|NCT04549597|EXPERIMENTAL|Cohort 2: Decrease Phosphate Binder by 50%|Decreases phosphate binder dose by at least 50% with the ability to switch the binder regiment from thrice daily (TID) to BID or once a day and initiates tenapanor 30 mg BID
61940529|NCT02735408|EXPERIMENTAL|0% KT Tension|0% KT Tension
61940530|NCT02735408|NO_INTERVENTION|Control (Without KT)|Control (Without KT)
61940531|NCT05842733|ACTIVE_COMPARATOR|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
62335765|NCT04549597|EXPERIMENTAL|Cohort 3: Phosphate Binder Naive|Phosphate binder naive patients are enrolled as Cohort 3 and receive tenapanor with a starting dose of 30 mg/BID
62335766|NCT05347069|ACTIVE_COMPARATOR|Aspirin|Aspirin 100 mg/day
62335767|NCT05347069|ACTIVE_COMPARATOR|No Aspirin|No Aspirin
62335768|NCT03742401|ACTIVE_COMPARATOR|Surgery|Surgery
62335769|NCT03742401|ACTIVE_COMPARATOR|HIFU (Echopulse)|HIFU (Echopulse)
62335770|NCT03562585||Efficacy of immunoassay in liver fibrosis|efficacy of immunoassay in liver fibrosis in patients with CHB
62335771|NCT00664300||2|One group with Gilles de la Tourette's Syndrome One group with healthy paired volunteers
61940532|NCT05842733|ACTIVE_COMPARATOR|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
61940533|NCT05842733|ACTIVE_COMPARATOR|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 25 hours after the first dose.
61940534|NCT04185376||group A 200 patients|patients with one or more PFDs significant psychological strain in at least one pelvic floor domain
61940535|NCT04185376||group B 200 patients|patients without any pelvic floor complaints
61940536|NCT06557135|EXPERIMENTAL|the brachial group|Patients with carotid artery stenosis will be randomly selected for carotid artery stenting via the brachial artery access.
61940537|NCT06557135|ACTIVE_COMPARATOR|the femoral group|Patients with carotid artery stenosis will be randomly selected for carotid artery stenting via the femoral artery access.
61940538|NCT06074861|ACTIVE_COMPARATOR|Test group|Patients will receive the non-surgical periodontal therapy plus three cycles of fasting-mimicking diet.
61940539|NCT06074861|NO_INTERVENTION|Control group|Patients will receive the non-surgical periodontal therapy and will continue with their normal (and ad libitum) diet.
61940540|NCT03038451|EXPERIMENTAL|s-amlodipine besylate 2,5 and 5 mg tablets|
61940541|NCT02518204|EXPERIMENTAL|BPT, NP|Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments
61940542|NCT02518204|EXPERIMENTAL|NP, BPT|Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery
61940543|NCT06681324|EXPERIMENTAL|AZD7798|AZD7798
61940544|NCT06681324|PLACEBO_COMPARATOR|Placebo|Placebo
61940545|NCT03866460||Hearing evaluation DPOAE|Post IA hearing evaluation will be allowed up until 9 months after IA completion (or roughly one year from initiation of treatment). After completion of standard treatment for RB that included IA carboplatin.
62137685|NCT06635759|EXPERIMENTAL|Experimental Group: Upper trapezius low-load endurance exercise (EE) group|Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.
62335772|NCT04013438|EXPERIMENTAL|FET cycle, discontinue estradiol after 6 gestational weeks|In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
62335773|NCT04013438|ACTIVE_COMPARATOR|FET cycle, continue estradiol till 12 gestational weeks|Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.
62492956|NCT01476904|EXPERIMENTAL|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals
62492957|NCT01476904|PLACEBO_COMPARATOR|Arm P|Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals
62492958|NCT01476904|ACTIVE_COMPARATOR|Arm A|Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals
62738434|NCT06238336|EXPERIMENTAL|CAR-T cell therapy|Dose climbing started with 1.0\*10\^6/kg back infusion, 3 patients per dose group, if there is no adverse reaction the dose can be increased to 2.0\*10\^6/kg, 4.0\*10\^6/kg, the maximum dose can be extended the study.
61940546|NCT06632691|EXPERIMENTAL|Rectosigmoidoscopy with virtual reality headset|
61940547|NCT06632691|NO_INTERVENTION|Rectosigmoidoscopy without a virtual reality headset|
61940548|NCT05180097|ACTIVE_COMPARATOR|GDP|
61940549|NCT05180097|ACTIVE_COMPARATOR|Brentuximab vedotin + Pembrolizumab|
61940550|NCT04955132|EXPERIMENTAL|E-learning|Participants (parents of food-allergic children) will use an E-learning platform on food allergies for one month.
61940551|NCT04955132|NO_INTERVENTION|Standard care|Participants (parents of food-allergic children) will receive standard allergist consulting.
61940552|NCT02913612|EXPERIMENTAL|0.25% Timolol Treatment|Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol.
61940553|NCT02913612|EXPERIMENTAL|0.5% Timolol Treatment|Subjects assigned to this arm will be randomized to 0.5% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin an alternative treatment.
61940554|NCT02913612|NO_INTERVENTION|Non-Intervention Group|Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.
61940555|NCT03009500|ACTIVE_COMPARATOR|Local Anesthetic|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve to a maximum of 20 cc
61940556|NCT03009500|ACTIVE_COMPARATOR|Local Anesthetic with steroids|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve containing steroids (methylprednisolone (Depo-Medrol) 4 mg per cc) to a maximum of 20 cc
61940557|NCT03009500|PLACEBO_COMPARATOR|Saline|Injection of 2-6 cc of saline (0.9% sodium chloride) per nerve to a maximum of 20 cc
61940558|NCT06681714||Heart Failure|Patients with heart failure
61940559|NCT06680180||Sepsis/Septic shock|According to Sepsis-3 definitions (including SARS CoV-2 as pathogen); expected to remain in ICU and survive beyond the day after tomorrow and for full, active ICU treatment; arterial and secure venous access established or imminent as part of standard care; not on oral anticoagulant/antiplatelet therapy.
61940560|NCT06680180||Severe Trauma|Admitted via the Emergency Department resuscitation bay requiring trauma team response; deemed at risk of significant blood loss and where transfusion of blood products i considered in the ED during the acute phase of the resuscitation by a senior clinician; expected to remain in ICH and survive beyond the day after tomorrow and for full, active ICU treatment; Not on oral anticoagulant/antiplatelet therapy. A clinical based inclusion approach is the most pragmatic means of patient selection and can be objectively supported by routine blood tests demonstrating poor oxygen supply to the organs. Exclusion criteria: unsurvivable head injury.
61940561|NCT06119399|EXPERIMENTAL|Breathing Exercises Plus Conventional Exercise Program for Chronic Neck Pain|Subjects will receive conventional exercise program for Chronic Neck Pain in addition to breathing exercises (diaphragmatic and pursed lip breathing) for (three sessions per week for six weeks).
61940562|NCT06119399|EXPERIMENTAL|Doming of the diaphragm plus Conventional Exercise Program for Chronic Neck Pain|Patients in this arm will receive conventional physiotherapy treatment for Chronic Neck Pain in addition to doming of the diaphragm (three sessions per week for six weeks).
61940563|NCT01461083|EXPERIMENTAL|Assess [18F]MPPF and PET imaging|To assess \[18F\]MPPF and PET imaging
61940564|NCT00326066|ACTIVE_COMPARATOR|1|
61940565|NCT00326066|PLACEBO_COMPARATOR|2|
62335774|NCT04778267|ACTIVE_COMPARATOR|TPVB (thoracic paravertebral block)|TPVB will be performed in the sitting position A high frequency linear ultrasound probe will be applied in the parasagittal plane approximately 2-3 cm lateral to the midline till identification of the 3rd thoracic vertebra (T3) in the same side of surgery. Then the transducer will be moved progressively more medially until transverse processes are identified.The image acquired will have the transverse process located superiorly and an image of lower rib located inferiorly on the screen.The needle tip is to be observed to enter through the superior costotransverse ligament and loss of resistance sensation will be experienced. After confirming the anterior displacement of pleura with 2-3 mL of local anesthetic (LA), 30 ml of 0.25% bupivacaine and 4 mg dexamethasone will be administered for the block.
62492959|NCT05907694|EXPERIMENTAL|transcatheter PFO closure + optimal medical treatment|Patients will undergoes transcatheter PFO closure (+ optimal medical treatment). Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
62492960|NCT05907694|EXPERIMENTAL|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
62492961|NCT02040961|EXPERIMENTAL|EtView|Use of ETVew double-lumen tube
62492962|NCT01690260|EXPERIMENTAL|Bone Morphogenetic Protein 2|Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.
62492963|NCT01690260|EXPERIMENTAL|Autologous bone graft|Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.
62492964|NCT03252457|EXPERIMENTAL|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
62492965|NCT03252457|ACTIVE_COMPARATOR|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
62492966|NCT00070122|EXPERIMENTAL|Arm I (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo\* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: \*As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
62492967|NCT00070122|EXPERIMENTAL|Arm II (oxaliplatin, capecitabine)|Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo\* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: \*As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
62492968|NCT00702507|ACTIVE_COMPARATOR|Miconazole Nitrate|
62492969|NCT03965065|EXPERIMENTAL|Sutureless Aortic Valve Prosthesis|Patients receiving sutureless aortic valve prostheses
62492970|NCT03965065|ACTIVE_COMPARATOR|Conventional Aortic Valve Prosthesis|Patients receiving conventional biological aortic prostheses
62492971|NCT06268457||Performed chemoembolization|
62492972|NCT02028455|EXPERIMENTAL|Phase 1 - Cohort 1A|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg
62492973|NCT02028455|EXPERIMENTAL|Phase 1 - Cohort 1B|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg
62492974|NCT02028455|EXPERIMENTAL|Phase 1 - Cohort 1C|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg
61940566|NCT05893498|EXPERIMENTAL|FFRangio|FFRangio guided revascularization
61940567|NCT05893498|ACTIVE_COMPARATOR|Pressure wire|Pressure wire-based guided revascularization (FFR or NHPR)
61940568|NCT02672228|EXPERIMENTAL|MalariaSense device|This study will involve the evaluation of a medical diagnostic device. All participants enrolled in the study will be assessed for malaria using MalariSense Technology and will aslo get rapid diagnostic tests (RDTs), microscopy, PCR
61940569|NCT01225627|EXPERIMENTAL|Coordinated discharge|Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
61940570|NCT01225627|PLACEBO_COMPARATOR|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
62492975|NCT02028455|EXPERIMENTAL|Phase 1 - Cohort 1D|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg
62492976|NCT02028455|EXPERIMENTAL|Phase 1 - Cohort 1F1|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
62335775|NCT04778267|EXPERIMENTAL|ES-PI (erector spinae-pectointercostal block)|"ESPB In the second group (ES-PI) Using a high frequency linear ultrasound probe, it will be located in a longitudinal orientation at the level of T3 spinous process and then will be placed 3 cm laterally from the midline to the side involved in the surgery. .a 22-gauge block needle will be inserted in-plane at an angle of 30-40°. 20 mL of 0.25% bupivacaine hydrochloride and 3 mg dexamethasone will be injected in the plane deeper to the erector spinae muscle.~PIPB While the patient is in the supine position, a high frequency linear probe will be placed parallel to the long axis of the sternum at a distance 2-3 cm from the attachment of the second rib and sternum to identify the Pectoralis major muscle, external intercostal muscles and the second rib in the superficial plane. by separation of fascial layers of between the external intercostal and the pectoralis muscles, a total of 10 ml of 0.25% bupivacaine and 1 mg dexamethasone will be injected."
62492977|NCT02028455|EXPERIMENTAL|Phase 1 - Cohort 1F2|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
62492978|NCT02028455|EXPERIMENTAL|Phase 2|The phase 2 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated.
61940571|NCT01031602||Psych Needs Assessment|Female Sexual Function Index (FSFI), Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire given to underserved and minority women with a gynecologic cancer or premalignant condition.
61940572|NCT06450080|EXPERIMENTAL|patients|Patients with a lingual tumor measuring less than 15 mm in long axis
61940573|NCT06450080|ACTIVE_COMPARATOR|healthy volunteers|Subjects without a history of cancer of the upper aerodigestive tract Subjects without contraindication to MRI Subjects over 18 years old Subjects who have provided free and informed written consent Subjects benefiting from a social security system
61940574|NCT04619836||segmentation type 2 diabetes patitents|Those type 2 diabetes patients, who have segmenteted for four groups to organinize cervices and self care
61940575|NCT04619836||Non-segmentation type 2 diabetes patients|Those type 2 diabetes patiets who have not segementated
61940576|NCT04619836||Segmentation substance abuse clients|Those type substance abuse clients, who have segmenteted for four groups to organinize cervices and self care
61940577|NCT04619836||Non-segmentation substance abuse clients|Those type substance abuse clients, who have not segmenteted
61940578|NCT01055522|EXPERIMENTAL|ARM 1: L19IL2 + Dacarbazin|
61940579|NCT01055522|EXPERIMENTAL|ARM 2: L19IL2 + Dacarbazin|
61940580|NCT01055522|ACTIVE_COMPARATOR|ARM 3: Dacarbazin|DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
61940581|NCT05735197|ACTIVE_COMPARATOR|Dapagliflozin group|Includes 50 patients, they will receive SGLT2i as add on drug, Dapagliflozin 10 mg will be used once daily with or without food.
61940582|NCT05735197|PLACEBO_COMPARATOR|Placebo group|Includes 50 patients, they will receive placebo plus their medication.
61940583|NCT01878409||Parkinson Disease|Patients with Parkinson Disease
61940584|NCT01878409||Healthy Subjects|Healthy Subjects
61940585|NCT01588639||Group 1|
61940586|NCT06680037|EXPERIMENTAL|Azer-cel|Participants will receive single dose of intravenous (IV) infusion of azer-cel at different dose levels, on Day 0 of the treatment period.
62335776|NCT03136185|EXPERIMENTAL|Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d|In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP). Qualifying participants could continue to receive treatment for an additional 85 days during an Additional Treatment Period (ATP) as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62492979|NCT02161263||Quality of Vision after LASIK surgery|Questionnaire
62492980|NCT01426568|ACTIVE_COMPARATOR|Course of Multi-Convergent Thearpy|
62492981|NCT01426568|NO_INTERVENTION|Waiting List for Multi-Convergent Therapy|
61940587|NCT04234997|EXPERIMENTAL|Suvorexant 20 mg|
61940588|NCT04234997|PLACEBO_COMPARATOR|Suvorexant 0mg|
62492982|NCT05746143|EXPERIMENTAL|Zolpidem|
62492983|NCT05746143|PLACEBO_COMPARATOR|Placebo|
62492984|NCT01347476||patients older than 70 years|
62492985|NCT01347476||patients 70 years or younger|
61940589|NCT05169268||MainRexult Group|Subjects with schizophrenia and related disorders receiving Abilify Maintena (aripiprazole 1 monthly depot) together with Rexulti (Brexpiprazole)
61940590|NCT05183763|EXPERIMENTAL|STAR-MAP|Interactive health coaching sessions and medication reminder tools
61940591|NCT05183763|ACTIVE_COMPARATOR|Medication App and Reminder System Medication Adherence Program (MARS-MAP)|Medication reminder tools only
61940592|NCT01512342|EXPERIMENTAL|Pacing|The pacing self-management program focussed on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), CFS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
61940593|NCT01512342|ACTIVE_COMPARATOR|relaxation therapy|Relaxation therapy comprised of education about the role of stress in CFS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
61940594|NCT03951714|OTHER|Reference|Control experience using marketed application to record medication intake without reminders from the app
61940595|NCT03951714|EXPERIMENTAL|Intervention|Full experience using marketed application, with all functionalities enabled
61940596|NCT04526938|EXPERIMENTAL|Endovascular repair|Endovascular repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms including those secondary to aortic dissection using a physician-modified endovascular graft.
61940597|NCT05504395|EXPERIMENTAL|CSTI-500 10mg|All eligible subjects will be administered a single oral dose of CSTI-500 10 mg at Visit 2
61940598|NCT00749060|OTHER|1|conventional treatment
61940599|NCT00749060|OTHER|2|kyphoplasty by balloons
61940600|NCT00749060|OTHER|3|vertebroplasty
61940601|NCT06136195|EXPERIMENTAL|Mavoglurant 1st / Placebo 2nd|Participants randomized to the Mavoglurant 1st Arm will take a single dose of 200mg mavoglurant in the morning, prior to their 1st lab session. Then after a 5-8 day washout period, participants will have their 2nd lab session where they will take a matching placebo in the morning prior to the 2nd lab session.
61940602|NCT06136195|EXPERIMENTAL|Placebo 1st / Mavoglurant 2nd|Participants randomized to the Placebo 1st Arm will take a matching placebo in the morning, prior to their 1st lab session. Then after a 5-8 day washout period, participants will have their 2nd lab session where they will take a single dose of 200mg mavoglurant in the morning, prior to their 2nd lab session.
61940603|NCT05556798|EXPERIMENTAL|Belantamab Mafodotin and Nirogacestat|There will be a 1:1 randomization betweennirogacestat 100 mg BID or 100 mg QD during the 4day run-in period prior to starting belantamab mafodotin on Cycle 1 Day 1 (days -4 to -1). The cycle length for Cycles 1-3 is 21 days (3 weeks). Treatment with nirogacestat will be 100 mg BID continuously during each cycle for all subjects. Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3 and nirogacestat 100mg BID will be administered continuously on Days 1-21 of each cycle. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg. Pomalidomide was added, 2 mg to the 1.4 mg/kg and 1.9 mg/kg dose cohorts.
61940604|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
61940605|NCT00130676|EXPERIMENTAL|mifepristone 600 mg|
61940606|NCT00130676|PLACEBO_COMPARATOR|matching placebo|
61940607|NCT04143087||Withdrawal TKIs|
61940608|NCT04143087||halve TKIs|
61940609|NCT03388385|PLACEBO_COMPARATOR|Placebo|Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.
61940610|NCT03388385|ACTIVE_COMPARATOR|Ferric carboxymaltose|Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.
61940611|NCT01498328|EXPERIMENTAL|Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.|About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
61940612|NCT01498328|EXPERIMENTAL|Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control|About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
61940613|NCT01498328|EXPERIMENTAL|Group 2 and 2C: Refractory to Bevacizumab|Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).
61940614|NCT03993470|EXPERIMENTAL|experimental|The short foot exercise daily for 4 weeks
61940615|NCT03993470|PLACEBO_COMPARATOR|Control|A placebo excercise daily for 4 weeks
61940616|NCT03899272||Osteoarthritis|All new patient present to clinic referred for osteoarthritis for considering joint replacement Present with knee pain (unilateral or bilateral) contributed by osteoarthritis
61940617|NCT05050773||Nicorandil group|Patients who are prescribed with Nicorandil with or without other concomitant medication
61940618|NCT05050773||Non-Nicorandil group|Patients who are prescribed with antianginal drugs except Nicorandil
62738435|NCT04662775|EXPERIMENTAL|Intervention group|This group received the multi-component physical activity intervention (physical activity programme, weekly behaviour change support calls, non-reply text messages)
61940619|NCT01180647|ACTIVE_COMPARATOR|Extended-release naltrexone (XR-NTX)|A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
61940620|NCT01180647|PLACEBO_COMPARATOR|Motivational Enhancement Counseling Only|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
61940621|NCT06558539|EXPERIMENTAL|Combination Therapy|Approximately 30 participants are expected to be enrolled, and they will receive a combination of standard medication and TTNS therapy for 12 weeks.
61940622|NCT06558539|EXPERIMENTAL|TTNS|Approximately 30 participants are expected to be enrolled, and they will receive TTNS therapy for 12 weeks.
61940623|NCT06558539|ACTIVE_COMPARATOR|Standard Medication Therapy|Approximately 30 participants are expected to be enrolled, and they will receive standard medication and TTNS therapy for 12 weeks.
61940624|NCT06157918|EXPERIMENTAL|Group 1-sequence ABC|Participants will sequentially receive SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A), followed by SYHA1813 oral solution (20ml:200mg) fasted (Treatment B), and SYHA1813 oral solution (2.0g:25mg) fed (Treatment C).
61940625|NCT06157918|EXPERIMENTAL|Group 2-sequence BCA|Participants will sequentially receive SYHA1813 oral solution (20ml:200mg) fasted (Treatment B), followed by SYHA1813 oral solution (2.0g:25mg) fed(Treatment C), and SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A).
61940626|NCT06157918|EXPERIMENTAL|Group 3-sequence CAB|Participants will sequentially receive SYHA1813 oral solution (2.0g:25mg) fed (Treatment C), followed by SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A), and SYHA1813 oral solution (20ml:200mg) fasted (Treatment B).
61940627|NCT05111704|EXPERIMENTAL|Balance Body Tape|Three-week treatment with Balance Body Tape (BBT).
61940628|NCT05111704|NO_INTERVENTION|Control group|Control group receiving no intervention.
61940629|NCT05977712||CIRCAME|This is the full cohort of patients that compose the CIRCAME study (N estimated = 1500)
61940630|NCT05977712||CIRCAME-EYE ancillary study|Patients from CIRCAME seen at the Fernand-Widal hospital who will also undergo an eye examination (CIRCAME-EYE, N estimated = 1100, a sub-group of CIRCAME)
61940631|NCT02416219||Cricoid Cartilage localization|The caregiver will be asked to palpate the cricoid cartilage and draw aline where he will apply cricoid pressure during rapid sequence induction
61940632|NCT05073640|ACTIVE_COMPARATOR|Pentoxifylline|Pentoxifylline (Oxopurin 400 mg)
61940633|NCT05073640|PLACEBO_COMPARATOR|Placebo|Placebo (105 mg Lactose and 510 mg Dextrose)
61940634|NCT00815399|EXPERIMENTAL|1|
62695353|NCT04280380||Mechanical ventilated patients without cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.~Inclusion criteria: (a) age \>=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
62695354|NCT04280380||Mechanical ventilated patients with cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.~Inclusion criteria: (a) age \>=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
61940635|NCT00815399|ACTIVE_COMPARATOR|2|
61940636|NCT05272462|EXPERIMENTAL|Treatment|Participants in this arm will be treated with minoxidil. This treatment will be given daily by mouth.
61940637|NCT02207023|NO_INTERVENTION|Memory Training Program|Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
61940638|NCT02207023|EXPERIMENTAL|Healthy Lifestyle Training Program|Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
61940639|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
61940640|NCT02196207|EXPERIMENTAL|Eloctate Prophylaxis|Prevention Trial, Arm A: rFVIIIFc (Eloctate) 65 IU/kg weekly will be administered by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
61940641|NCT02196207|EXPERIMENTAL|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab 1.5 mg/kg weekly (following 4-wk induction at 3 mg/kg weekly) will be administered by subcutaneous injection in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
61940642|NCT02196207|EXPERIMENTAL|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance plus Emicizumab 1.5 mg/kg weekly by subcutaneous injection in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
61940643|NCT02196207|ACTIVE_COMPARATOR|Eloctate ITI Alone|Eradication Trial, Arm B: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance alone in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
61940644|NCT00467857|ACTIVE_COMPARATOR|InteguSeal* and standard surgical preparation solutions|InteguSeal\* microbial skin sealant was applied to surgical sites prior to incision after standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
61940645|NCT00467857|OTHER|Standard surgical skin preparation alone|Prior to incision, standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
61940646|NCT05021081|EXPERIMENTAL|TEST/CONTROL|For Phase 2, eligible subjects that are enrolled will be randomized to the Test/Control contralateral sequence.
61940647|NCT05021081|EXPERIMENTAL|CONTROL/TEST|For Phase 2, eligible subjects that are enrolled will be randomized to the Control/Test contralateral sequence.
61940648|NCT04933695|EXPERIMENTAL|Sotorasib: 960 mg Daily|Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 960 mg daily. Participants will be stratified by known presence of STK11 mutation.
61940649|NCT04933695|EXPERIMENTAL|Sotorasib: 240 mg Daily|Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.
62335777|NCT03136185|EXPERIMENTAL|Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d|In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62335778|NCT03136185|EXPERIMENTAL|Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d|In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62335779|NCT03136185|EXPERIMENTAL|Ph 2b PMF: Bomedemstat 0.5 mg/kg/d|In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62738436|NCT04662775|NO_INTERVENTION|Waitlist control|Participants in the wait-list control group were asked to continue their usual PA habits and received no additional contact from the research team outside of data collection points. Following post-intervention data collection, control group participants were invited to participate in the same intervention as described above.
61940650|NCT03652883|EXPERIMENTAL|ItFits-toolkit|A generic 'Integrated Theory-based Framework for Implementation Tailoring Strategies' toolkit (the ItFits-toolkit) functions as an online self-help toolkit by which users are guided through the process of tailoring site-specific implementation strategies. The ItFits-toolkit includes four modules that implementers need to work through: 1) identifying and prioritising implementation goals and determinants of practices, 2) matching up implementation determinants to strategies, 3) designing a plan for carrying out strategies in a local context, and 4) applying strategies, and reviewing progress. In each of these four modules, evidence-informed materials such as iCBT relevant determinants of practices and implementation strategies, are included as well as methods for engaging with stakeholders.
61940651|NCT03652883|ACTIVE_COMPARATOR|Implementation as Usual|Implementation-as-Usual (IAU) refers to any existing approaches and efforts to embed and integrate iCBT within an organisation. All implementation sites included in IMA are engaged in and conducting IAU. IAU activities can be, but are not necessarily planned or guided by scientific evidence and often emerge from practice experiences and other sources of information. No standardisation in IAU across the sites is applied except for the implementation objective. That is, all implementation sites pursue the goal of increasing the number of patients treated by the iCBT service.
61940652|NCT06666127|EXPERIMENTAL|SHORT and LONG Training Protocol|Using a within subject design, participants will have the arms and legs from both left and right side of the body (divided by sagittal plane) randomly assigned to either LONG or SHORT conditions. Participants will then engage in maximal strength testing on Prime Fitness machines (1RM) as well as isokinetic strength testing (Biodex) in weeks 1 and 12. Participants will engage in the LONG and SHORT training sessions for 10 weeks in duration from week 2 until week 11.
61940653|NCT03526575|PLACEBO_COMPARATOR|10 mg Zolpidem and 10 mg Zaleplon|Experiment 1 will involve N= 14 subjects randomized to placebo , 10 mg zolpidem for males and 10 mg zaleplon in counterbalanced order. Subjects are nested into group.
61940654|NCT03526575|PLACEBO_COMPARATOR|5 mg Zolpidem and 10 mg Zaleplon|Experiment 2, which will involve N=20 subjects randomized to placebo, 5 mg zolpidem and 10 mg zaleplon. All females will be placed in experiment 2. Subjects are nested into group.
61940655|NCT02777710|EXPERIMENTAL|Combination Pexidartinib-Durvalumab|"* DURVALUMAB (MEDI4736): therapeutic Class anti-PD-L1 mAb, given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca~* PEXIDARTINIB (PLX3397): therapeutic Class Kinase inhibitor targeting CSF1-R, Flt3 and Kit. Administered daily as split dose regimen, orally. Five dose-levels possible in dose escalation part: 400mg 5 days on 2 days off (intermittent schedule), 400 mg, 600 mg, 800 mg or 1000 mg.~In this combination trial, Pexidartinib should be taken first and the Durvalumab IV infusion should be scheduled 1 hour after the Pexidartinib morning dose."
61940656|NCT02943031|EXPERIMENTAL|IPTP Group|The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
61940657|NCT02736994|OTHER|Immersion in water|water
61940658|NCT02736994|ACTIVE_COMPARATOR|Immersion in water + cleansing tablet|Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
61940659|NCT02736994|EXPERIMENTAL|Immersion in water with PIP|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium)
61940660|NCT02096237|EXPERIMENTAL|apheresis, IgE adsorber|9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
61940661|NCT02096237|NO_INTERVENTION|Conventional drug treatment|Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
61940662|NCT04500730|EXPERIMENTAL|Shaoyao Gancao Decoction Jiawei|"Shaoyao Gancao Decoction Jiawei by adding Pueraria montana, Salvia Miltiorrhiza, into Shaoyao Gancao.~The medication will be taken twice daily for 28 consecutive days. Each prescription will consist of 4 herbal granules."
61940663|NCT05390931|EXPERIMENTAL|Study group|Study group intervention consists of 6-session motivational interviews (6 times in total, once every month), a health education structured according to the health belief model, a training booklet on healthy lifestyle behavior changes at the end of the training, and 6-month follow-up.
61940664|NCT05390931|OTHER|Control group|Control group intervention consists of a health education structured according to the health belief model, a training booklet on healthy lifestyle behavior changes at the end of the training, and a 6-month follow-up.
61940665|NCT02291276||Female cancer patients with ascites|Primary epithelial ovarian female cancer patients with ascites (\> 500 ml ascites in the preoperative sonographic examination)
61940666|NCT02291276||Female cancer patients aged > 70 years|"Primary epithelial ovarian female cancer patients aged \> 70 years with at least one of the following secondary diagnoses:~* Status Post stent placement due to coronary heart disease respectively Status Post-myocardial infarction~* existing arterial Hypertension for more than 5 years~* chronic heart failure (New York Heart Association (NYHA) class II-III)~* peripheral arterial disease"
61940667|NCT00392080|PLACEBO_COMPARATOR|3|
61940668|NCT00392080|EXPERIMENTAL|1|75 mg BID
61940669|NCT00392080|EXPERIMENTAL|2|
61940670|NCT05352711|EXPERIMENTAL|active assisted exercise with Oculus Quest virtual reality (VR) group|This group includes 30 patients suffered from pain and loss of shoulder flexion ROM, The patients will treated with active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand controller ) for 30 min. 2 times per week for 4 weeks The ROM will be assessed by mobile goniometer application and Smart phone version of visual analogue scale (VAS) to assess pain and The Quality-of-Life Scale for Children to assess the psychometric properties after the 1st session, day 14 and day 28.
62335780|NCT03136185|EXPERIMENTAL|Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d|In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62738437|NCT04491682|EXPERIMENTAL|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months.Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.~Due to personal reasons, it may not be possible to accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
62738438|NCT06009991|EXPERIMENTAL|Age 45-64|Patients aged 45 to 64 years
62695355|NCT05860244|EXPERIMENTAL|Salbutamol|"Salbutamol 2mg/5ml syrup : 2mg TID salbutamol for 3 months, then 4 mg TID for 3 months~For each investigated dose (6 mg then 12 mg), the treatment will be titrated during a 4 days period:~At beginning of the first 3-month period : Month 0 D1: 2mg in the morning; D2-D3: 2 mg in the morning and 2mg in the evening for two days; From D4 and until the end of first 3-month period (until the M3 follow-up visit): 2mg in the morning, at noon and in the evening~At beginning of the second 3-month period : Month 3 D1: 4mg in the morning, 2mg at noon, 2 mg in the evening; D2: 4 mg in the morning, 2 mg at noon and 4mg in the evening; J4 and for 3 months (until the M6 follow-up visit) : 4mg in the morning, at noon and in the evening."
61940671|NCT05352711|ACTIVE_COMPARATOR|active assisted range of motion exercise group|This group includes 30 patients suffering from pain and loss of shoulder flexion ROM. Patients will recieve active-assisted ROM physical therapy 2 sessions per week for 4 weeks.
61940672|NCT04706910|EXPERIMENTAL|18F-DOPA injection|All enrolled participants will receive an intravenous injection of the investigational 18F-DOPA radiopharmaceutical
61940673|NCT05129670|EXPERIMENTAL|Calcite chewing gum|Patients with a stable pH recording after fasting for at least 6 hours will receive a refluxogenic test meal which will be consumed within 30 mins. Thirty minutes after finishing the meal, the patient will be dosed with the randomised calcite chewing gum. pH and impedance measurements will be collected throughout the treatment period from the baseline assessment to 2 hours post dose
61940674|NCT05129670|PLACEBO_COMPARATOR|Unmatched Placebo chewing gum|Patients with a stable pH recording after fasting for at least 6 hours will receive a refluxogenic test meal which will be consumed within 30 mins. Thirty minutes after finishing the meal, the patient will be dosed with the randomised unmatched placebo gum product. pH and impedance measurements will be collected throughout the treatment period from the baseline assessment to 2 hours post dose
61940675|NCT05839587|EXPERIMENTAL|Robotic TAPP|Repair of primary unilateral and bilateral hernias with robotic technology
61940676|NCT05839587|ACTIVE_COMPARATOR|Laparoscopic TAPP|Repair of primary unilateral and bilateral hernias with laparoscopic repair
61940677|NCT01826071|NO_INTERVENTION|Symptomatic Treatment|
61940678|NCT01826071|EXPERIMENTAL|Static Stretch|Home exercise program with static stretching
61940679|NCT01826071|EXPERIMENTAL|Active Elongation|Home exercise program with active elongation exercises
62335781|NCT03136185|EXPERIMENTAL|Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d|In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62335782|NCT03136185|EXPERIMENTAL|Ph 2b PMF: Bomedemstat 0.6 mg/kg/d|In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62335783|NCT03136185|EXPERIMENTAL|Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d|In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62335784|NCT03136185|EXPERIMENTAL|Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d|In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
62335785|NCT01754220|ACTIVE_COMPARATOR|Montelukast|Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks
62335786|NCT00731393|EXPERIMENTAL|Group A|Subjects aged between 6 months and 3 years.
62335787|NCT00731393|EXPERIMENTAL|Group B|Subjects aged 3 to 6 years.
62335788|NCT00731393|ACTIVE_COMPARATOR|Group C|Subjects aged between 6 months and 3 years.
62335789|NCT00731393|ACTIVE_COMPARATOR|Group D|Subjects aged 3 to 6 years.
62335790|NCT03392753|ACTIVE_COMPARATOR|Mechanochemical ablation (MOCA)|Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
62335791|NCT03392753|ACTIVE_COMPARATOR|Cyanoacrylate adhesive (CAE)|Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
62335792|NCT05966766|ACTIVE_COMPARATOR|Mozart|Subjects in this arm will listen to music from a list of pre-selected pieces by Mozart that have been previously shown to have beneficial effects on anxiety.
62335793|NCT05966766|ACTIVE_COMPARATOR|Patient preference|Subjects in this arm will listen to music from a list of pre-selected pieces of their own choosing.
62335794|NCT01847664|EXPERIMENTAL|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
62335795|NCT01847664|EXPERIMENTAL|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
62738439|NCT06009991|EXPERIMENTAL|Age 65-74|Patients aged 65 to 74 years
62738440|NCT06009991|EXPERIMENTAL|Age 75-84|Patients aged 75 to 84 years
61940680|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
61940681|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
61940682|NCT06680102|EXPERIMENTAL|Probiotic Group|"Probiotic soft candies containing Weizmannia coagulans BC99, 10 billion CFU per piece, to be chewed directly, 2 pieces daily.~Storage method: Keep away from light, seal tightly, and store in a cool, dry place."
61940683|NCT06680102|PLACEBO_COMPARATOR|Placebo Group|"Gummies without Weizmannia coagulans BC99, to be chewed directly, 2 pieces per day.~Storage method: Keep away from light, seal tightly, and store in a cool, dry place."
61940684|NCT06681038|ACTIVE_COMPARATOR|Control ARM|Systemic treatments
61940685|NCT06681038|EXPERIMENTAL|Experimental ARM|PIPAC procedure with pressurized aerosol containing oxaliplatin.
61940686|NCT05355051|EXPERIMENTAL|Pembrolizumab plus Azacitidine|Pembrolizumab by vein over about 30 minutes every 3 weeks. Azacitidine by vein over about 60-90 minutes on Days 1-7 of each 28-day study cycle
61940687|NCT04889222|EXPERIMENTAL|Pulse oximeters|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive pulse oximeter sensors.
61940688|NCT06083857|EXPERIMENTAL|Amivantamab and Tepotinib Combination|Participants will be given 2 investigational drugs (amivantamab and tepotinib) and come to the clinic for study visits every 4 weeks.
61940689|NCT03658057|ACTIVE_COMPARATOR|ROC|Neuromuscular blockade is performed in the ROC group by administering rocuronium 0.4\~0.8mg/kg before the insertion of laryngeal airway.
61940690|NCT03658057|NO_INTERVENTION|Control|Neuromuscular blockade is not performed.
61940691|NCT00112008|EXPERIMENTAL|darbepoetin alfa|
62492986|NCT03624868|EXPERIMENTAL|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
62738441|NCT06009991|EXPERIMENTAL|Age over 75|Patients aged over 85 years
62738442|NCT06244407|EXPERIMENTAL|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated tablet|Participants first received Vildagliptin and metformin HCl 50/1000 mg 1 tablet (Test product) in a fasting state. After a washout period of 7 days, they then recieved Galvus Met® 1 tablet (Reference product) in a fed state.
61940692|NCT02600351|EXPERIMENTAL|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
61940693|NCT02600351|EXPERIMENTAL|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
61940694|NCT02600351|EXPERIMENTAL|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
61940695|NCT02600351|EXPERIMENTAL|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
61940696|NCT02266498|EXPERIMENTAL|BIBB 515 BS after a standard breakfast|
61940697|NCT02266498|ACTIVE_COMPARATOR|BIBB 515 BS|
61940698|NCT03835819|EXPERIMENTAL|IMGN853 + Pembrolizumab|"* Pembrolizumab is administered intravenously once every 3 weeks~* IMGN853 is administered intravenously once every 3 weeks"
61940699|NCT06671457|EXPERIMENTAL|Active Group|To optimize stimulation parameters, electromagnetic modeling and parameter space scanning of the participant's brain are conducted. The specific method includes performing MRI scans before stimulation. MRI structural data is then used to create individualized models of the participant's brain and simulate the electromagnetic fields within biological tissues. High-density EEG is collected during the participant's sleep state, using a 256-channel stimulation-recording device (MagStim EGI, GTEN 200) to record EEG changes induced by stimulation across multiple brain regions. The type of electrical stimulation is cathodal direct current stimulation, targeting brain regions with an intensity equivalent to the traditional 2mA single-channel current, with each electrode not exceeding 200μA. Target brain regions for stimulation include the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Changes in brain
61940700|NCT06671457|SHAM_COMPARATOR|Sham Group|In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group. After the stimulation begins, the current gradually increases over 15 seconds. However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session. During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA. This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
62335796|NCT01847664|PLACEBO_COMPARATOR|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
62335797|NCT03796091|ACTIVE_COMPARATOR|Educational Brochure|Participants will read an educational brochure from the National Eating Disorder Association and will receive referral resources.
62335798|NCT03796091|ACTIVE_COMPARATOR|Body Project Traditional|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project group therapy program (Stice \& Shaw, 2001).
62335799|NCT03796091|ACTIVE_COMPARATOR|Body Project Expanded|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project Expanded group therapy program (Green et al., 2017).
61940701|NCT06556966|EXPERIMENTAL|LY03020|Subjects will take single-dose LY03020 on Day 1
61940702|NCT06556966|SHAM_COMPARATOR|Placebo|Subjects will take single-dose Placebo on Day 1
61940703|NCT00901407|EXPERIMENTAL|1|lamotrigine
61940704|NCT00901407|PLACEBO_COMPARATOR|2|placebo
61940705|NCT00528827|PLACEBO_COMPARATOR|1|
61940706|NCT00528827|EXPERIMENTAL|2|5 mcg
61940707|NCT00528827|EXPERIMENTAL|3|2.5
61940708|NCT00528827|EXPERIMENTAL|4|0.5
61940709|NCT04875429|EXPERIMENTAL|Aortic abdominal aneurysm|
62137686|NCT06635759|ACTIVE_COMPARATOR|Comparison Group: Upper trapezius stretching exercise (SE) group|Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
61940710|NCT06295757|OTHER|Continuous Smoking|"During the study visits, measures will be taken before and after participants smoke their own usual brand cigarette one continuously. Participants will be randomly assigned to continuous smoking or relight smoking conditions. Participants randomized to the continuous smoking condition will crossover to the relight smoking condition after 60 minutes on their first visit.~Visits will be separated by 7-10 days, to ensure there are 2 weekdays and 1 weekend day falling in that period for cigarette butt collection.~On the second visit, participants will begin with the second smoking condition they were assigned on their first visit. They will crossover to the remaining condition after 60 minutes. Participants initially assigned to the continuous smoking condition will begin their second visit with the relighting smoking condition and cross over to the continuous smoking condition after the 60 minutes."
61940711|NCT06295757|OTHER|Relight Smoking|"During the study visits, measures will be taken before and after participants smoke their own usual brand cigarette one continuously. Participants will be randomly assigned to continuous smoking or relight smoking conditions. Participants randomized to the relight smoking condition will crossover to the continuous smoking condition after 60 minutes on their first visit.~Visits will be separated by 7-10 days, to ensure there are 2 weekdays and 1 weekend day falling in that period for cigarette butt collection.~On the second visit, participants will begin with the second smoking condition they were assigned on their first visit. They will crossover to the remaining condition after 60 minutes. Participants initially assigned to the relighting smoking condition will begin their second visit with the continuous smoking condition and cross over to the relighting smoking condition after the 60 minutes."
61940712|NCT05165407|EXPERIMENTAL|Sintilimab Combined With IBI310 and Surufatinib|Surufatinib at a dose of 250mg QD, with Sintilimab injected intravenously 200mg per 3 weeks and IBI310 injected intravenously 1mg/kg per 6 weeks until disease progresses or unacceptable tolerability occurs
61940713|NCT00520832|EXPERIMENTAL|MC-E|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
61940714|NCT00520832|PLACEBO_COMPARATOR|MC-P|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
61940715|NCT05394350|EXPERIMENTAL|MK-1088 100 mg|Participants received MK-1088 daily (QD) orally at 100 mg on days 1-21 of each 21-day cycle for up to 35 cycles (up to \~24 months).
62137687|NCT01836445|EXPERIMENTAL|Keep It Up! Intervention|The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
62695356|NCT05860244|PLACEBO_COMPARATOR|placebo of salbutamol|"Placebo syrup : 2mg TID salbutamol for 3 months, then 4 mg TID for 3 months~For each investigated dose (6 mg then 12 mg), the treatment will be titrated during a 4 days period:~At beginning of the first 3-month period : Month 0 D1: 2mg in the morning; D2-D3: 2 mg in the morning and 2mg in the evening for two days; From D4 and until the end of first 3-month period (until the M3 follow-up visit): 2mg in the morning, at noon and in the evening~At beginning of the second 3-month period : Month 3 D1: 4mg in the morning, 2mg at noon, 2 mg in the evening; D2: 4 mg in the morning, 2 mg at noon and 4mg in the evening; J4 and for 3 months (until the M6 follow-up visit) : 4mg in the morning, at noon and in the evening."
62695357|NCT03409198|ACTIVE_COMPARATOR|Arm A|Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
61940716|NCT05394350|EXPERIMENTAL|MK-1088 200 mg|Participants received MK-1088 (QD) orally at 200 mg on days 1-21 of each 21-day cycle for up to 35 cycles (up to \~24 months)
61940717|NCT05394350|EXPERIMENTAL|MK-1088 400 mg|Participants received MK-1088 (QD) orally at 400 mg on days 1-21 of each 21-day cycle for up to 35 cycles (up to \~24 months)
61940718|NCT05394350|EXPERIMENTAL|MK-1088 600 mg|Participants received MK-1088 (QD) orally at 600 mg on days 1-21 of each 21-day cycle for up to 35 cycles (up to \~24 months)
61940719|NCT05394350|EXPERIMENTAL|MK-1088 100 mg + Pembrolizumab|Participants received MK-1088 daily (QD) orally at 100 mg on days 1-21 of each 21-day cycle plus pembrolizumab at 200 mg intravenous (IV) infusion every 3 weeks (Q3W), on Day 1 of each 21-day cycle for up to 35 cycles (up to \~24 months)
61940720|NCT05394350|EXPERIMENTAL|MK-1088 200 mg + Pembrolizumab|Participants received MK-1088 daily (QD) orally at 200 mg on days 1-21 of each 21-day cycle plus pembrolizumab at 200 mg intravenous (IV) infusion every 3 weeks (Q3W), on Day 1 of each 21-day cycle for up to 35 cycles (up to \~24 months)
61940721|NCT04677790|ACTIVE_COMPARATOR|"Very short arm (12 months)"|Very short arm (12 months): 3 months between every step. Step by step gradual introduction of egg containing food products during 12 months, unless next step can not be taken.
62137688|NCT01836445|ACTIVE_COMPARATOR|HIV Knowledge Control|The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).
62137689|NCT06580275|EXPERIMENTAL|CLAAS|In this single arm study, all eligible subjects will be assigned to receive the CLAAS device.
62137690|NCT01183767|ACTIVE_COMPARATOR|EGCG|Epigallocatechin-Gallate (EGCG)
61940722|NCT04677790|ACTIVE_COMPARATOR|"Short arm (20 months)"|Short arm (20 months): 5 months between every step. Step by step gradual introduction of egg containing food products during 20 months, unless next step can not be taken.
61940723|NCT05759611|OTHER|Control group (CTRL)|
62137691|NCT01183767|PLACEBO_COMPARATOR|Placebo|
61940724|NCT05759611|EXPERIMENTAL|Experimental group (RMT)|
61940725|NCT04821856|EXPERIMENTAL|Cannabidiol 100mg/ml|"The starting dose of cannabidiol (CBD) will be 5 mg/kg/day and will be administered orally twice daily in doses of 2.5 mg/kg (up titration phase from day 1 to 7). After one week, the dose of CBD will be increased to 10 mg/kg/day in two daily doses of 5mg/kg (8-week maintenance phase from day 8 to 63). On completion of the maintenance phase the dose of CBD will be decreased to 5mg/kg/day for one week (day 64 to 70), after which the CBD administration will cease.~A ceiling dose of 1000mg/day will be administered to all participants weighing 100kg or greater. These participants will receive a dose of 500mg/day during up- and down-titration.~Doses will be rounded to the nearest 10mg (0.1mL)."
61940726|NCT04821856|PLACEBO_COMPARATOR|Placebo|"The control group will receive placebo medium-chain triglyceride (MCT) oil which is indistinguishable from the active medication in appearance, smell and taste.~Dose will be matched for volume to the cannabidiol arm, and administered twice daily for 10 weeks (including up- and down-titration)."
61940727|NCT05061966|ACTIVE_COMPARATOR|Online Resource website|The comparator is a website that includes a list of freely available web-based resources for sexual and gender minority youth.
62137692|NCT04898569|EXPERIMENTAL|Ferinject®|
62137693|NCT04898569|PLACEBO_COMPARATOR|Normal saline|
62695358|NCT03409198|EXPERIMENTAL|Arm B|Chemo + ipilimumab + nivolumab
62492987|NCT03624868|ACTIVE_COMPARATOR|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
61940728|NCT05061966|EXPERIMENTAL|immi|The intervention is a novel and scalable web application designed to provide sexual and gender minority youth with tools for affirming their identity and coping with minority stress.
61940729|NCT02519465|ACTIVE_COMPARATOR|HEATED FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen heated .
61940730|NCT02519465|ACTIVE_COMPARATOR|COLD FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen cold
61940731|NCT05188196|ACTIVE_COMPARATOR|Collagen Membrane|ridge preservation with collagen membrane + collagenated bovine bone mineral
62492988|NCT03366428|EXPERIMENTAL|All Participants|All participants will receive DS-8201a by intravenous infusion
62492989|NCT01457092|EXPERIMENTAL|FC Nitinol SEMS|FC Nitinol SEMS
61940732|NCT05188196|EXPERIMENTAL|Collagen Sponge|ridge preservation with collagen sponge + collagenated bovine bone mineral
61940733|NCT04997915||Critical COVID-19|Critical COVID-19 patients admitted to the ICU
61940734|NCT03342014|EXPERIMENTAL|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
62335800|NCT05526794||Group 1|General anesthesia or sedation
62335801|NCT05526794||Group 2|Central Block (Spinal and Epidural Anesthesia
62335802|NCT05526794||Group 3|Peripheral Block \[Erector Spina Plane Block (ESPB), and Paravertebral Block (PVB)
62335803|NCT02061722|EXPERIMENTAL|PET Imaging with [18F]MNI-659|"All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands \[11C\]raclopride (non-investigational medicinal product \[NIMP\]) and \[18F\]MNI-659 (investigational medicinal product \[IMP\]).~The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
62335804|NCT06420648|EXPERIMENTAL|Early passive mobilization group|The modified Kleinert protocol will be used as an EPM procedure. Within 3 to 5 days following surgery, the affected hand will be placed inside the dorsal slab Kleinert splint with the wrist in 30-40 flexion; metacarpophalangeal joint (MP) in 60-70-degree flexion; PIP and DIP joints in extension. Rubber band traction will be directed to the fingernail from the wrist, with a palmar pulley system. All patients will perform passive flexion and active extension exercises with an active hold for 2-3 seconds 10 times per hour. Traction will be removed at the end of 3rd week and very gentle active flexion will start at the 4th week. The splint will be removed in the 5th-6th weeks. Blocking exercises will be started at 7th-8th weeks and resisted exercises will be started after the 8th week with the full function permitted by week 12th week .
62335805|NCT06420648|EXPERIMENTAL|Controlled active motion group|A modified CAM protocol will be used. Exercises will be performed hourly for 10 repetitions in the form of passive flexion and active extension exercises with an active hold of the fingers in the flexed position for 2-3 seconds.
62492990|NCT05128136|EXPERIMENTAL|Silicone IVR 46mm external diameter|Non-medicated 46 mm ring.
62492991|NCT05128136|EXPERIMENTAL|Silicone IVR 56mm external diameter|Non-medicated 56mm ring.
62492992|NCT05128136|EXPERIMENTAL|Silicone IVR 66mm external diameter|Non-medicated 66mm ring.
62492993|NCT01653704|EXPERIMENTAL|active management of crises scenario|participants assigned to actively manage a crisis scenario
62335806|NCT04638140||Healthy hip population|
62492994|NCT01653704|ACTIVE_COMPARATOR|Observer role in crisis scenario|Observational role in management of crises scenario
62492995|NCT03611387||Normal|Patients without any type of glaucoma
62492996|NCT03611387||Primary angle closure glaucoma|Patients with primary angle closure glaucoma
62492997|NCT03611387||Primary open-angle glaucoma|Patients with primary open-angle glaucoma
62492998|NCT00672217|PLACEBO_COMPARATOR|Behavioral Placebo Therapy|Behavioral Placebo Treatment
62492999|NCT00672217|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (CBTI)
62493000|NCT05821608|NO_INTERVENTION|Control|Participants will not receive a message before a nurse tries to contact them via a phone call.
62493001|NCT05821608|EXPERIMENTAL|Heads Up Message 1|"Participants will receive a message before a nurse tries to contact them via a phone call with the following text:~Hi @{account_firstname}, this is @{input_MEGname} at @{account_product_group}. Just a heads up, I'm calling in the next hour about your health care. Text help or stop. Msg\&DataRatesMayApply"
61940735|NCT06681844||all mature teeth presenting a tooth wear intact or presenting a tooth wear altered|Scaling of the tooth before scanning by the operator Evaluation of the tooh wear index 0 or 1 (by 2 calibrated experts )
61940736|NCT04082143|EXPERIMENTAL|Implant with prophylactic allograft|
61940737|NCT04082143|ACTIVE_COMPARATOR|Implant without prophylactic allograft|
61940738|NCT02439983|PLACEBO_COMPARATOR|Placebo|
61940739|NCT02439983|EXPERIMENTAL|Proprietary Nutritional Supplement|
61940740|NCT02232334|EXPERIMENTAL|Osteopathic manual treatment|Global Osteopathic Manual treatment: each subject will be treated according to what restrictions or areas of poor mobility are found individually. No two subjects will receive the same overall treatment.
62137694|NCT02144597|ACTIVE_COMPARATOR|2-week LCD and Roux-en-Y gastric bypass (RYGB)|A 2-week liquid formula low-calorie diet (LCD) will be administered for 2 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
61940741|NCT02232334|NO_INTERVENTION|Control--no change in current treatment of subject|The population will act as their own control prior to intervention of osteopathy, their will be a control period where the subject maintains current treatment of their gastroparesis. During that period they will fill out the GCSI measuring tool at the beginning of the control period and at the end. Those measurements will be compared to the GSCI results during the intervention period.
61940742|NCT04045548|EXPERIMENTAL|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.
61940743|NCT04045548|PLACEBO_COMPARATOR|placebo|one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.
61940744|NCT00634764||Pregnant|Pregnant women who present to MUSC's Cannon Place or Prenatal Wellness Center
61940745|NCT02282358|EXPERIMENTAL|Mocetinostat|Patients who harbor mutations for CREBBP and/or EP300 will be started on mocetinostat 70 mg orally three times per week on a 28 day schedule in cycle 1. The dose will be escalated in cycle 2 to 90 mg orally three times per week on a 28 day schedule if there are no grade 3 or higher drug related toxicities. Therapy will continue until disease progression, intolerable toxicities or death.
61940746|NCT03550664|EXPERIMENTAL|Surgical intervention|Patients undergoing a surgical intervention within the CHU Brugmann with utilisation of rocuronium.
61940747|NCT06609512|EXPERIMENTAL|Enlicitide Treatment A|Participants receive single oral dose of enlicitide after 8-hour overnight fast.
61940748|NCT06609512|EXPERIMENTAL|Enlicitide Treatment B|Participants receive single oral dose of enlicitide 4 hours after morning meal.
61940749|NCT06609512|EXPERIMENTAL|Enlicitide Treatment C|Participants receive single oral dose of enlicitide 3 hours after morning meal.
61940750|NCT06609512|EXPERIMENTAL|Enlicitide Treatment D|Participants receive single oral dose of enlicitide 2 hours after morning meal.
61940751|NCT02183142|ACTIVE_COMPARATOR|Mobic Germany|
61940752|NCT02183142|EXPERIMENTAL|Mobic China|
61940753|NCT06593106|EXPERIMENTAL|Treatment|Patients undergo 3 freeze-thaw cycles of cryodevitalization over 30 seconds or 3, 5, or 7 minutes each during standard of care robotic bronchoscopy with biopsy on study. Patients then undergo standard of care surgical resection on study. Patients also undergo a chest x-ray on study as well as CT and tissue sample collection throughout the study.
61940754|NCT00662454|ACTIVE_COMPARATOR|I|10 normal weight women (BMI \< 25 kg/m2)
61940755|NCT00662454|ACTIVE_COMPARATOR|II|10 obese women (BMI \>30 kg/m2)
61940756|NCT00904319|EXPERIMENTAL|Aquatic|Aquatic Power Training
61940757|NCT01046162|ACTIVE_COMPARATOR|Tafil Tablets 2 mg Pharmacia Upjohn|
61940758|NCT01046162|ACTIVE_COMPARATOR|Xanax Tablets 2 mg Pfizer LLC|
61940759|NCT01568515|EXPERIMENTAL|Electronic Messages|Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months
61940760|NCT01568515|NO_INTERVENTION|Standard of Care|Control group participants received standard of care at the student health center which included a card with their next appointment written on it.
62695359|NCT04469686|EXPERIMENTAL|Twice Daily - Active|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure suppository applicator
62695360|NCT04469686|EXPERIMENTAL|Once Daily - Active|Once daily 90 mg hydrocortisone acetate and once daily placebo suppository administered with Sephure suppository applicator
62695361|NCT04469686|PLACEBO_COMPARATOR|Placebo|Twice daily placebo suppository administered with Sephure suppository applicator
62695362|NCT02170519|EXPERIMENTAL|Phase 2: Inhaled Iloprost continuous|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy."
62695363|NCT02170519|EXPERIMENTAL|Phase 1: Inhaled Iloprost 3 doses|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose."
62695364|NCT06399094||Pulmonary fibrosis|
62695365|NCT06399094||Chronic Obstructive Pulmonary Disease|
62335807|NCT04638140||Hip defect population|
62335808|NCT01035255|EXPERIMENTAL|LCZ696|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
62695366|NCT06399094||Cystic fibrosis|
62695367|NCT04787809|EXPERIMENTAL|Living Well Intervention Group|Participants in the Living Well treatment group will receive a brief digital intervention informed by Acceptance and Commitment Therapy.
62695368|NCT04787809|NO_INTERVENTION|Control Group|Participants in the control group will not receive any intervention. These individuals will have the option to access the intervention at the conclusion of their study participation.
62695369|NCT06154265|ACTIVE_COMPARATOR|Default TEE|The TEE probe is placed after going under general anesthesia and a breathing tube is placed. TEE issued to take pictures of the heart before and after a CABG surgery. If randomized to this group, the TEE probe will remain in place throughout the surgery.
62695370|NCT06154265|OTHER|As-needed TEE|The TEE probe is placed only in situations where a surgeon requires information that can only be obtained by ultrasound imaging of the heart.
62738443|NCT06244407|ACTIVE_COMPARATOR|Galvus Met®|Participants first received Galvus Met® 1 tablet (Reference product) in a fed state. After a washout period of 7 days, they then recieved Vildagliptin and metformin HCl 50/1000 mg (Test product) in a fed state.
62738444|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
62738445|NCT05563311|EXPERIMENTAL|high-intensity interval training|High-intensity interval training describes physical exercise that is characterized by brief, intermittent bursts of vigorous activity, interspersed with periods of rest or low-intensity exercise
62493002|NCT05821608|EXPERIMENTAL|Heads Up Message 2|"Participants will receive a message before a nurse tries to contact them via a phone call with the following text:~Hi @{account_firstname}, this is @{input_MEGname} at @{account_product_group}. Just a heads up, I'm calling in the next hour about your health care. Text HELP for Help and Text STOP to Stop. (Note: replying STOP will stop all further texts from @{account_product_group}). Msg\&DataRatesMayApply"
62493003|NCT01977456|EXPERIMENTAL|Eptifibatide|All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
62493004|NCT00238615|EXPERIMENTAL|Chemotherapy+Radiation+Surgery|"1. Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.~2. Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.~3. No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation~4. Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support."
62493005|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
62738446|NCT04041544|ACTIVE_COMPARATOR|SN1011|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
61940761|NCT02530463|EXPERIMENTAL|Cohort I (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive nivolumab and azacitidine at the discretion of the treating physician.
61940762|NCT02530463|EXPERIMENTAL|Cohort II (ipilimumab)|Patients receive ipilimumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab and azacitidine at the discretion of the treating physician.
61940763|NCT02530463|EXPERIMENTAL|Cohort III (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes every 2 weeks (or every 4 weeks if patients receive azacitidine) in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab, nivolumab, and azacitidine at the discretion of the treating physician.
61940764|NCT02530463|EXPERIMENTAL|Cohort IV (azacitidine, nivolumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes on days 6 and 20. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
61940765|NCT02530463|EXPERIMENTAL|Cohort V (azacitidine, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and ipilimumab IV over 30 minutes on day 6. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
61940766|NCT02530463|EXPERIMENTAL|Cohort VI (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 6. Treatment with ipilimumab repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Cycles with nivolumab and azacitidine repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
61940767|NCT06469164|EXPERIMENTAL|BNT331 - Part A|Single ascending dose levels
61940768|NCT06469164|PLACEBO_COMPARATOR|Placebo - Part A|Single dose
61940769|NCT06469164|EXPERIMENTAL|BNT331 - Part B Dose 1|Fixed dose for 5 consecutive days
62335809|NCT01035255|ACTIVE_COMPARATOR|Enalapril|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period
62335810|NCT03185455|NO_INTERVENTION|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
62335811|NCT03185455|EXPERIMENTAL|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
62335812|NCT00469755|ACTIVE_COMPARATOR|1|Differin® Gel, 0.1% for 12 weeks
62335813|NCT00469755|ACTIVE_COMPARATOR|2|Tazorac® Cream, 0.1% for 12 weeks
62738447|NCT04041544|PLACEBO_COMPARATOR|SN1011 placebo|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
61940770|NCT06469164|EXPERIMENTAL|BNT331 - Part B Dose 2|Fixed dose for 5 consecutive days
61940771|NCT06469164|PLACEBO_COMPARATOR|Placebo - Part B|Multiple dose
61940772|NCT02821637|OTHER|Effort rehabilitation program|"An effort rehabilitation program designed for obese and overweight children or teens : 13 weekly sessions of 1hour30 then 1 session 2 months, 6 months and 12 months later.~This program is part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse.~Child Health Questionnaire (CHQ) of quality of life are completed by parents and children on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session.~Eurofit tests of Physical Fitness performed on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session."
62493006|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
62493007|NCT04947761|EXPERIMENTAL|modified Cheonwangbosimdan Hydrogel patch|Group receiving modified Cheonwangbosimdan Hydrogel patch
61940773|NCT03070444|EXPERIMENTAL|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
61940774|NCT03070444|ACTIVE_COMPARATOR|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
61940775|NCT05059795||Cirrhosis/ACLF of any etiology|
61940776|NCT01719783|EXPERIMENTAL|LAIV H5N2|Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
61940777|NCT01719783|PLACEBO_COMPARATOR|Placebo|two doses of placebo solution intranasal
61940778|NCT05663229||Experimental group-with rehabilitation intervention|We evaluate the static or dynamic posture stability of patients with rehabilitation intervention
61940779|NCT05663229||Control group-without rehabilitation intervention|We evaluate the static or dynamic posture stability of patients without rehabilitation intervention
61940780|NCT00590889|OTHER|St. Jude Medical (SJM) Conventional|St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff
61940781|NCT00590889|OTHER|St. Jude Medical (SJM) Silzone|St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating
61940782|NCT05755165|ACTIVE_COMPARATOR|Depression|Adolescent depression
61940783|NCT05755165|ACTIVE_COMPARATOR|Depression, adjusted|Adolescent depression, impacted by racism
61940784|NCT05755165|ACTIVE_COMPARATOR|Control|Control condition
61940785|NCT06137560|ACTIVE_COMPARATOR|Assigned Intervention 1|Single vision spectacle lens
61940786|NCT06137560|EXPERIMENTAL|Assigned Intervention 2|Single vision spectacle lens + S.T.O.P.® Kit 1
61940787|NCT06137560|EXPERIMENTAL|Assigned Intervention 3|Single vision spectacle lens + S.T.O.P.® Kit 2
61940788|NCT06137560|ACTIVE_COMPARATOR|Assigned Intervention 4|Static optical signal: single vision spectacle lens + S.T.O.P.® spectacle film
61940789|NCT06137560|EXPERIMENTAL|Assigned Intervention 5|Dynamic optical signal: single vision spectacle lens + S.T.O.P.® Kit 1 or 2
62335814|NCT00469755|ACTIVE_COMPARATOR|3|Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
62335815|NCT03412318|EXPERIMENTAL|Twisted file|Use of twisted file during cleaning and shaping of root canals
62335816|NCT03412318|ACTIVE_COMPARATOR|Mpro|Use of Mpro file during cleaning and shaping of root canals
62335817|NCT04811521|ACTIVE_COMPARATOR|Primary care follow-up|Enhanced primary care coordination
62335818|NCT04811521|ACTIVE_COMPARATOR|Online Cognitive Behavioral Therapy|Online Self-Administered Anxiety Management Program plus Peer Support Guidance
62335819|NCT04811521|ACTIVE_COMPARATOR|Therapist-Administered Cognitive Behavioral Therapy|Telehealth 8 one-hour sessions over the course of 8 to 10 weeks
62335820|NCT02822339|EXPERIMENTAL|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62493008|NCT04947761|PLACEBO_COMPARATOR|Placebo patch|Group receiving placebo patch
62493009|NCT04654429|PLACEBO_COMPARATOR|Lower OT temperature with placebo (LP)|Lower OT temperature with placebo This group function as a main control arm. Incidence of PSS will be documented usual / standard OT temperature which is 17-19 degree celsius, and without giving any pharmacological intervention to prevent PSS.
62738448|NCT01707680||Dexmedetomidine|Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
62738449|NCT01707680||Propofol|Here, patients to be included are those being sedated with propofol as primary sedative.
61940790|NCT04558593||active surveillance|220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
61940791|NCT04558593||surgery|110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
61940792|NCT05320185||Control group|CCTA images will be visually evaluated by physicians.
61940793|NCT05320185||Experiment group|CCTA images will be evaluated by physicians using RuiXin-CoronaryAI.
61940794|NCT05320185||Reference group|CCTA images will be visually evaluated by cardiologists with at least 10 years experiences, and the conclusions they offer will be used as golden standard.
61940795|NCT02617888|ACTIVE_COMPARATOR|CCTA Breast Shields|Within female subset, randomization to wearing bismuth breast shield.
61940796|NCT02617888|NO_INTERVENTION|CCTA No Breast Shields|Within female subset, randomization to wearing no bismuth breast shield (standard of care).
61940797|NCT02617888|NO_INTERVENTION|Observational Arm|Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
61940798|NCT02575131|EXPERIMENTAL|TNO whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at TNO
61940799|NCT02575131|ACTIVE_COMPARATOR|TNO whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water. at TNO
61940800|NCT02575131|EXPERIMENTAL|TNO Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams of water and consumed with 307 grams of skimmed milk at TNO
61940801|NCT02575131|ACTIVE_COMPARATOR|TNO original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at TNO
61940802|NCT02575131|EXPERIMENTAL|TNO standard breakfast|"TNO breakfast: one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at TNO"
61940803|NCT02575131|EXPERIMENTAL|Home whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
61940804|NCT02575131|ACTIVE_COMPARATOR|Home whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
61940805|NCT02575131|EXPERIMENTAL|Home Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams\* of water and consumed with 307 grams of skimmed milk at home
61940806|NCT02575131|ACTIVE_COMPARATOR|Home original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at home
61940807|NCT02575131|EXPERIMENTAL|Home standard breakfast|"one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at home"
61940808|NCT06470763|EXPERIMENTAL|ANV600 single agent|
61940809|NCT06470763|EXPERIMENTAL|ANV600 in combination with pembrolizumab (KEYTRUDA®)|
61940810|NCT04239092|EXPERIMENTAL|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
61940811|NCT04239092|EXPERIMENTAL|9-ING-41 plus Irinotecan|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days (cycle duration is 21 days).
61940812|NCT04239092|EXPERIMENTAL|9-ING-41 plus Irinotecan plus Temozolomide|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days. Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 ((cycle duration is 21 days).
61940813|NCT04239092|EXPERIMENTAL|9-ING-41 plus Cyclophosphamide plus Topotecan|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5. Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5. 9-ING-41 intravenous infusion twice weekly (cycle duration is 21 days).
61940814|NCT02651350|EXPERIMENTAL|Methylprednisolone|Participants will receive methylprednisolone from week 0 through week 48 study visit in combination with standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) in the first 12 weeks. Participants will then be followed until week 72 study visit.
61940815|NCT02651350|ACTIVE_COMPARATOR|Standard Treatment|Participants will only receive standard treatment (namely,routine liver protection drugs) including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72 study visit.
61940816|NCT02380001|EXPERIMENTAL|Dexketoprofen trometamol|A White round pill with 25 mg of dexketoprofen will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with placebo will be administered.
61940817|NCT02380001|PLACEBO_COMPARATOR|Preoperative control|A hard-gelatin capsule with placebo will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with 25mg of Dexketoprofen will be administered.
61940818|NCT02831244|OTHER|Agili-CTM|Intervention
61940819|NCT05609318||iron-deficient|patients prescribed intravenous iron infusion for the treatment of iron deficiency as part of standard clinical care
61940820|NCT04393285|EXPERIMENTAL|Abemaciclib and Letrozole|Study treatment will consist of abemaciclib 150mg orally twice a day and letrozole 2.5mg orally once a day.
61940821|NCT01050881||Positive Blood Donors|Blood donors testing positive for HIV, HBV, HCV or HTLV in 2008 and 2009. Donors notified of increased risk of vCJD in 2005.
61940822|NCT02258425|EXPERIMENTAL|FEM-CARE|Six specialized nurse case managed and health education sessions and coach-facilitated mentoring
61940823|NCT02258425|ACTIVE_COMPARATOR|Health Promotion|One brief basic health education session and coach-facilitated mentoring
62335821|NCT01763281|ACTIVE_COMPARATOR|CRH|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
62738450|NCT01707680||Midazolam|Here, patients to be included are those being sedated with midazolam as primary sedative
61940824|NCT06229418|EXPERIMENTAL|DFR AED Program|Real-time and simulated out-of-hospital cardiac arrests that occur across 6 communities (4 rural, 2 urban)
61940825|NCT05181462|EXPERIMENTAL|Phase Ib: Single-arm (dose-escalation 3+3 design).|"* Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8, every 3-week cycles.~* Gemcitabine 1000 mg/m2 IV on days 1 and 8, every 3-week cycles.~* Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8, every 3-week cycles."
61940826|NCT05181462|EXPERIMENTAL|Phase II: Randomized 1:1, non-comparative, open-label.Patients randomized to arm A|"* Carboplatin AUC 2 mg/mL/min IV on days 1 and 8, every 3-week cycles.~* Gemcitabine 1000 mg/m2 IV on days 1 and 8, every 3-week cycles.~* Nadunolimab Recommended Phase II Dose (RP2D) mg/kg IV on days 1 and 8, every 3-week cycles"
61940827|NCT05181462|ACTIVE_COMPARATOR|Phase II: Randomized 1:1, non-comparative, open-label.Patients randomized to arm B|"* Carboplatin AUC 2 mg/mL/min IV on days 1 and 8, every 3-week cycles.~* Gemcitabine 1000 mg/m2 IV on days 1 and 8, every 3-week cycles."
61940828|NCT03800173|EXPERIMENTAL|Galidesivir|Galidesivir IV infusion
61940829|NCT03800173|PLACEBO_COMPARATOR|placebo|Placebo IV infusion
61940830|NCT04113720|EXPERIMENTAL|Group A|children will receive levobupivacaine 0.25% by peritonsillar infiltration after intubation 3- 5 min before the start of surgery.
61940831|NCT04113720|ACTIVE_COMPARATOR|Group B|children will receive levobupivacaine 0.25% plus dexmedetomidine 1µg/kg diluted in 4 ml saline 0.9% and given by peritonsillar infiltration (2 ml per tonsil), after intubation 3- 5 min before the start of surgery.
62493010|NCT04654429|ACTIVE_COMPARATOR|Higher OT temperature with placebo (HP)|Higher OT temperature with placebo This group will receive one non-pharmacological intervention, which is higher OT temperature 19-22 degree celsius. The aim of this intervention is to reduce heat loss therefore incidence of PSS for obstetric population coming for lower segment cesarean section (LSCS) by reducing the temperature gradient between the body and environment.
61940832|NCT03228420|ACTIVE_COMPARATOR|HF10 therapy plus CMM|The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
61940833|NCT03228420|OTHER|CMM Alone|Conventional Medical Management
61940834|NCT06383065|EXPERIMENTAL|IMT group|In the IMT group, only IMT will be applied on the first day before surgery, and the hospital routine exercise program will be applied in addition to IMT treatment from the first day to the fourth postoperative day.
61940835|NCT06383065|NO_INTERVENTION|Control Group|Individuals in the control group will be applied only the hospital routine exercise program in the postoperative period.
61940836|NCT06680466|EXPERIMENTAL|Treatment group 1|
61940837|NCT06680466|EXPERIMENTAL|Treatment group 2|
61940838|NCT06680466|EXPERIMENTAL|Treatment group 3|
61940839|NCT06680466|EXPERIMENTAL|Treatment group 4|
61940840|NCT06680466|ACTIVE_COMPARATOR|Morphine|
61940841|NCT06680466|PLACEBO_COMPARATOR|Placebo|
61940842|NCT03211871|ACTIVE_COMPARATOR|Group D|Group D received dexmedetomidine infusion 0,5 mcg/kg/h from induction in anesthesia to extubation
61940843|NCT03211871|PLACEBO_COMPARATOR|Croup C|group C (control) received normal saline infusion
61940844|NCT01085435||EFFORTLESS Main Study|Patients implanted with a CE marked S-ICD System, not participating in Cameron Health's Investigational Device Exemption (IDE) Clinical Study.
62335822|NCT01763281|PLACEBO_COMPARATOR|Normal Saline (0.9%)|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
62335823|NCT03737006||1-(HLHS) effected pregnancies|Consent,blood draw, nose swab, stool collection,questionnaire and review of medical records.
62335824|NCT03737006||2-Other Congenital Heart Defect (OCHD)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
62335825|NCT03737006||3-Healthy Controls (UC)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
62335826|NCT02076256|NO_INTERVENTION|Control Group|
62335827|NCT02076256|EXPERIMENTAL|The helping relationships intervention program|The helping relationships intervention program will be implemented on the experimental group. And the control group will be provided with routine nursing care. Data will be collected at baseline, the sixth and the ninth month of the third year of study. Data will be analyzed using generalized estimating equation measures to evaluate the effect of the intervention program.
62335828|NCT03153735|EXPERIMENTAL|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
62335829|NCT03153735|ACTIVE_COMPARATOR|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
62335830|NCT02986893|EXPERIMENTAL|Dietary Intervention Arm|Participants will be assigned to follow a specific dietary intervention for 6 months
62335831|NCT02986893|EXPERIMENTAL|Non-dietary Intervention Arm|Participants will continue their usual diet and will be invited to attend monthly meetings at the MS Center for 6 months
62335832|NCT04264455||Biomonitor only|Patients receive a Biomonitor only
62335833|NCT04264455||Wearable Cardioverter-Defibrillator (Life Vest) + Biomonitor|Patients receive a Wearable Cardioverter-Defibrillator (Life Vest) combined with a Biomonitor
61940845|NCT01085435||Extension Phase Sub Study|The Sub-Study patients were preferably recruited from the active EFFORTLESS S-ICD patient population. Patients, who had already completed the EFFORTLESS S-ICD Registry in the past, were considered secondarily for participation in the Sub-Study.
62335834|NCT04264455||ICD Implantation|Patients receive an ICD only
62335835|NCT02445924||Control group 1|ten non smoker volunteers
62335836|NCT02445924||Control group 2|ten smoker volunteers
61940846|NCT04080440|ACTIVE_COMPARATOR|Standard of care|Clinicians decide whether to extubate or not following their ICU protocol
61940847|NCT04080440|EXPERIMENTAL|Extubation readiness clinical score|Clinicians decide whether to extubate or not following the extubation readiness clinical score
61940848|NCT05581966||Diabetic Foot Ulcer (DFU) Group|Patients with DFUs undergoing 30 day standard wound care (SWC) therapy as part of their standard of care
61940849|NCT05691036||Pregnant women with ICP|Case: Pregnant women with consistent pruritus or on medication for pruritus associated with an elevated level of serum transaminase alanine transaminase(ALT)\>40 IU/L or aspartate transaminase(AST)\>37 IU) and raised serum bile acids ≥10µmol/L will be eligible for the inclusion in the study.
61940850|NCT05691036||Pregnant women without ICP|Controls: Healthy pregnant women of the same gestational age with routine physical examinations will be enrolled as a control group.
61940851|NCT04923815||AVNRT|atrioventricular nodal reentrant tachycardia
61940852|NCT04923815||AVRT|atrioventricular reentrant tachycardia, including Wolff-Parkinson-White syndrome（WPW）
61940853|NCT02550041|OTHER|Cystic fibrosis|
61940854|NCT04483973|EXPERIMENTAL|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 14 days, with 30-day follow-up
61940855|NCT04483973|EXPERIMENTAL|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 14 days, with 30-day follow-up
61940856|NCT04483973|PLACEBO_COMPARATOR|Placebo|Oral administration of matching placebo BID for 14 days, with 30-day follow-up
61940857|NCT00072657|EXPERIMENTAL|1|Participants will partake in cognitive behavioral therapy for 12 weeks.
61940858|NCT00072657|EXPERIMENTAL|2|Participants will partake in tai chi chih for 12 weeks.
62335837|NCT02445924||NSCLC patients|twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
61940859|NCT00072657|ACTIVE_COMPARATOR|3|Participants will act as a control and attend educational sessions for 12 weeks.
61940860|NCT00107783|NO_INTERVENTION|Control|No treatment
61940861|NCT00107783|EXPERIMENTAL|Nitisinone-treated|Subjects received nitisinone 2 mg orally, once daily.
61940862|NCT06595121|EXPERIMENTAL|IMP 08P1707F0 without charcoal|Budesonide 1mg/2mL nebuliser suspension (08P1707F0) without charcoal
61940863|NCT06595121|EXPERIMENTAL|IMP 08P1707F0 with charcoal|Budesonide 1mg/2mL nebuliser suspension (08P1707F0) with charcoal
61940864|NCT06595121|ACTIVE_COMPARATOR|Pulmicort 1.0mg/2mL Suspension|Pulmicort 1.0mg/2mL Suspension (First administration)
61940865|NCT06595121|ACTIVE_COMPARATOR|Pulmicort 1.0mg/ML suspension (second administration)|Pulmicort 1.0mg/ML suspension (second administration)
62493011|NCT04654429|ACTIVE_COMPARATOR|Lower OT temperature with IV Ondansetron 4mg (LO)|Lower OT temperature with Ondansetron 4mg intravenous. This group also will receive one pharmacological intervention, which is IV ondansetron 4mg to prevent incidence of PSS under standard OT temperature 17-19 degrees.
62493012|NCT04654429|ACTIVE_COMPARATOR|higher OT temperature 19-22 and IV ondansetron 4mg (HO)|This group will receive 2 interventions - higher OT temperature 19-22 and IV ondansetron 4mg. This group is designed to see if when both intervention combined, will further reduce the incidence of PSS among obstetrics population.
61940866|NCT05435209|EXPERIMENTAL|Quadrivalent HPV Vaccine|Gardasil® 0.5 mL administered intramuscularly in the deltoid or anterolateral area of the thigh
61940867|NCT03530800|ACTIVE_COMPARATOR|Dronabinol|Subjects will receive dronabinol 5mg once daily for two weeks, 5mg twice daily for the subsequent two weeks, and 5mg three times daily for the final six weeks. Dose escalations will only be done if the investigator deems necessary.
61940868|NCT03530800|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo for 10 weeks weeks.
61940869|NCT03947203|NO_INTERVENTION|Pamphlet|Provided with only a pamphlet containing educational material about oral health
61940870|NCT03947203|EXPERIMENTAL|Social media|Provided pamphlet containing educational material about oral health and will have access to a private Facebook group, where we will share informational messages and content relating to oral health
62335838|NCT01962714|EXPERIMENTAL|Loving-Kindness Meditation|A 12-week duration, 90-minute per session Loving-Kindness Meditation (LKM) course, taught in groups of 10 participants.
62493013|NCT05789121||Healthy subjects|30 healthy subject aged between 18 and 40.
61940871|NCT03829774|EXPERIMENTAL|Primary Relief v 2.0 Device|The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
61940872|NCT03829774|PLACEBO_COMPARATOR|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
61940873|NCT06467942|NO_INTERVENTION|observation group|Observation and follow-up only, no medication
61940874|NCT06467942|EXPERIMENTAL|combined drug group|Chinese medicine 5 days + Lactobacillus 5 days
61940875|NCT06467942|ACTIVE_COMPARATOR|Single Chinese medicine group|Chinese medicine group 10 days
62335839|NCT01962714|ACTIVE_COMPARATOR|Cognitive Processing Therapy - Cognitive Only|A 12-week duration, 90-minute per session Cognitive Processing Therapy (CPT) course, taught in groups of 10 participants.
62335840|NCT01223872||Routine Patient Care|
62493014|NCT05662605|EXPERIMENTAL|W-PPMA|Participants randomized to this arm will have access to the W-PPMA mobile app throughout the 16-week study. Participants are asked to use the app for at least 5 minutes a day during the treatment phase (first 8 weeks) and then as often as they like during the follow-up phase (last 8 weeks) of the study.
62493015|NCT05662605|NO_INTERVENTION|Waitlist|Participants assigned to this group will not have access to the W-PPMA mobile app during the treatment phase (first 8 weeks) of the study. They will have access during the follow-up phase (last 8 weeks) of the study and will be instructed to use the app for at least 5 minutes a day.
62493016|NCT05274022|PLACEBO_COMPARATOR|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits.
61940876|NCT06467942|ACTIVE_COMPARATOR|Single Lactobacillus group|Lactobacillus group: 10 days
61940877|NCT00335478|EXPERIMENTAL|Daptomycin|
61940878|NCT03454685||NCSLC group|NSCLC patients,including stage I to stage IV.
61940879|NCT03454685||Healthy subjects|healthy subjects
62738451|NCT06659250|EXPERIMENTAL|PF-06414300|Participants will receive single or multiple ascending oral doses of PF-06414300
61940880|NCT05280639|EXPERIMENTAL|Simplified block protocol|subjects in this group will perform a simplified post operative rehabilitation program using a simplified wooden block protocol
61940881|NCT05280639|ACTIVE_COMPARATOR|Usual care|Subjects in this group will perform formal physical therapy or a home exercise program consistent with AAOS standards.
61940882|NCT05415683||Diabetic Foot Ulcer (DFU) Group|Patients with DFUs undergoing 30 day standard wound care (SWC) therapy as part of their standard of care
61940883|NCT06534034||Patients with Astra Tech Profile|Patients who has receive Astra Tech Profile dental implant system placement.
61940884|NCT01722396|EXPERIMENTAL|Vitamin D|
62335841|NCT01223872||Previously-enrolled REACH Clinic Patients|
62335842|NCT01223872||New REACH Clinic Patients|
62335843|NCT05271019|NO_INTERVENTION|Control group: Conventional Rehabilitation Program|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
62493017|NCT05274022|EXPERIMENTAL|Standard of Care Physical Therapy Program with Speed Walking Intervention|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. Additionally, subjects will complete the speed walking intervention. Participants will perform at 2 minute warm up followed by 1 minute of walking at their fastest tolerable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing. The subjects will perform 4 cycles of this followed by a 2 minute cool down at the end.
62493018|NCT05336669||Non-smoking|Non-smoking patients undergoing coronary angiography or percutaneous coronary intervention
62493019|NCT05336669||Smoking|Smoking patients undergoing coronary angiography or percutaneous coronary intervention
62493020|NCT02077907|ACTIVE_COMPARATOR|Super Cereal Plus (SC+)|"800 kcal/d, 215 g/d~Current protocol for treating MAM is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. In Sierra Leone, their FBF standard is Super Cereal Plus."
62493021|NCT02077907|EXPERIMENTAL|Super Cereal (SC) and oil and sugar|"200 g SC and 20 g fortified oil and 15 g sugar, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A \& D"
62493022|NCT02077907|EXPERIMENTAL|Corn Soy Blend 14 (CSB14) and fortified oil|"978 kcal/day - 150 g CSB14 and 45 g oil, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A \& D"
62493023|NCT02077907|EXPERIMENTAL|Plumpy'Sup|"500 kcal/d, 92 g/d~Ready-to-Use Supplementary Food (RUSF)"
62493024|NCT03515044|EXPERIMENTAL|Cohort 1 40 mg Rifaximin SSD once daily|40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
62493025|NCT03515044|EXPERIMENTAL|Cohort 2 40 mg Rifaximin SSD twice daily|40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
62493026|NCT03515044|EXPERIMENTAL|Cohort 3 80 mg Rifaximin SSD once daily|80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
62493027|NCT03515044|EXPERIMENTAL|Cohort 4 80 mg Rifaximin SSD twice daiy|80 mg Rifaximin sustained extended release (SER) rifaximin SSD twice daily (BID) and lactulose
62493028|NCT03515044|EXPERIMENTAL|Cohort 5 Placebo twice daily|SSD placebo twice daily (BID) and lactulose
62493029|NCT00563394|ACTIVE_COMPARATOR|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
62335844|NCT05271019|EXPERIMENTAL|Experimental group: Conventional Rehabilitation Program + Inspiratory Muscle Training (IMT)|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
62335845|NCT06411119|EXPERIMENTAL|Virtual Reality Exergaming Intervention|Participants engaged in a 20-minute session of the Beat Saber game using the Meta Oculus Quest 2™ Virtual Reality headset, which required them to perform various physical movements like lateral steps, squats, and upper limb motions. The gameplay was adjusted to a moderate difficulty level in 'no-fail' mode to maintain consistent activity and ensure an engaging experience. Physiological and psychological outcomes, including heart rate, perceived exertion, and technology acceptance, were assessed before and after the intervention.
62493030|NCT00563394|ACTIVE_COMPARATOR|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
62493031|NCT00366639||001|
62493032|NCT01334593||Rectal Cancer|
62335846|NCT02645058|EXPERIMENTAL|RIRS (retrograde intrarenal surgery)|In the first arm (RIRS) the patients will be treated by a standard retrograde ureterorenoscopy and Holmium laser lithotripsy. Preoperative exams will be abdomen ultrasound and Xray (CT in case of stones \> 15 mm), urine analysis and culture (according to all the more recent guidelines). Surgeries will be performed under general or spinal anesthesia, according to anesthesiologist evaluation. According with standard technique, ureteroscopy will be performed using both rigid and flexible ureteroscope. Lithotripsy will be performed by Holmium laser. Major stone fragments will be removed at the end of the procedure. Finally a double J ureteral stent will be push in specific cases depending on intraoperative findings (length of the procedure, macroscopic view of the ureter, residual stones etc.). RIRS will be an outpatients procedure with an hospital stay \<23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
62335847|NCT02645058|EXPERIMENTAL|ESWL (extracorporeal shockwaves lithotripsy)|In the second arm (ESWL) the patients will be treated by a standard extracorporeal shock waves lithotripsy (ESWL). Preoperative exams will be the same as first arm. No general or spinal anaesthesia will be used, but just intravenous medications if required. Ultrasound and/or X-Ray will be used to locate the stone. Power and number of shock waves will consist in 20-24 KV and 3000-3500 sw respectively, according to individual tolerance. ESWL will be an outpatients procedure with an hospital stay \<23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
62335848|NCT01672021|OTHER|PET/MRI|PET/MRI
62493033|NCT05462548|EXPERIMENTAL|treatment group|accept Luspatercept treatment
62493034|NCT06253117|PLACEBO_COMPARATOR|Placebo|Placebo
62493035|NCT06253117|EXPERIMENTAL|Pirfenidone|Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day Total duration of experimental or placebo drug treatment 6 months
62493036|NCT01020825||ASCs|Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial \[ClinicalTrials.gov identifier: NTC00475410\]
62493037|NCT01020825||Fibrin glue|Patients randomized to the control treatment (application of fibrin glue) in the FATT-1 randomized controlled trial \[ClinicalTrials.gov identifier: NTC00475410\]
62493038|NCT01020825||ASCs + Fibrin Glue|Patients randomized to the control treatment (application of fibrin glue) + intralesional injection of ASCs in the FATT-1 randomized controlled trial \[ClinicalTrials.gov identifier: NTC00475410\]
62738452|NCT06659250|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo.
62738453|NCT00351767|EXPERIMENTAL|1|
62738454|NCT00351767|EXPERIMENTAL|2|
61940885|NCT05743608||Moderate to severe COPD patients receiving Trimbow dry powder inhaler|Patients above the age of 35 years, who had been diagnosed with COPD for over a year by a pulmonologists specialist. Having a moderate or severe obstruction (30%≤FEV1\<80%) and are uncontrolled despite fixed dual combination treatment (LABA/LAMA or ICS/LABA). Therapy was changed to Trimbow® 88/5/9 µg inhalation powder maximum 1 week prior to or on the day of study inclusion and irrespective of study entry (escalation of symptomatic patient to fixed triple combination as per treatment protocol)
61940886|NCT00914680|EXPERIMENTAL|MST|
61940887|NCT05115578||Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil|Group I of 35 patients received a constant TCI effect-site target infusion of 1.5 ng/ml of remifentanil for 25 min.
61940888|NCT05115578||Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv|Group II of 35 patients received a constant TCI effect-site target infusion of 1.5 ng/ml of remifentanil for 25 min with a bolus of 1 mg of midazolam previous to the remifentanil infusion
62335849|NCT02537314|ACTIVE_COMPARATOR|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
62335850|NCT02537314|PLACEBO_COMPARATOR|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
62493039|NCT03862547|EXPERIMENTAL|Men with ED and diabetes|"A peripheral blood sample from the cubital vein~1. A collection of peripheral blood from the routinary cubital vein for hormone dosage and metabolic evaluation~2. An introverted cavernous infiltration of Prostaglandin E1 to achieve erection (Aprostadil);~3. A blood sample from both the corpus cavernosum and the cubital vein, once the erection is achieved Baseline interaction of prostaglandin E1 on the concentration of NGF released in the medium and on the expression of its receptors Evaluation of NGF and Cytokine levels Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs"
62493040|NCT00834613|EXPERIMENTAL|1|
62493041|NCT00834613|ACTIVE_COMPARATOR|2|
62493042|NCT04902963|EXPERIMENTAL|Meeting indication for short term ventilation tube placement|Adult patients meeting standard criteria for short-term ventilation tube placement were offered placement of a bioabsorbable ear tube in place of a durable ear tube that would later be removed.
62493043|NCT00840658|PLACEBO_COMPARATOR|Group A|Didactic safer injection \& sexual activity education: In each city, 75 women will participate in a 60 minute lecture-format presentation and printed materials on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). In this component, there will be no theory-driven active skill building elements oriented towards safer sex or safer injection.
62335851|NCT01325831|EXPERIMENTAL|transcranial magnetic stimluation|
62493044|NCT00840658|ACTIVE_COMPARATOR|Group B|"Interactive injection risk intervention and didactic safer sex education: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas \['Say No to Contaminated Syringes'\] counseling session. This one-on-one intervention incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared. In addition, participants will be provided a lecture-format presentation on safer sex. However, in this component, there will be no theory-driven active skill building elements oriented towards safer sex."
62493045|NCT00840658|ACTIVE_COMPARATOR|Group C|"Interactive sexual risk intervention and didactic safer injection education: In each city, 75 women will participate in the 60 minute Di No Al Sexo Inseguro \[Say No to Unsafe Sex'\] counseling session. This one on one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe sex and condom use with clients. In addition, participants will be provided a lecture format presentation on safer injection sharing. However, in this component, there will be no theory-driven active skill building elements oriented towards safer injection behavior."
62738455|NCT00351767|EXPERIMENTAL|3|
62738456|NCT00351767|PLACEBO_COMPARATOR|4|
61940889|NCT05115578||Group III Control|Group III of 30 patients. The same TCI system provided the saline solution in the control group under an equivalent simulation profile to the remifentanil administration
61940890|NCT04485910|ACTIVE_COMPARATOR|Single step media|Embryos cultured in single step media
61940891|NCT04485910|ACTIVE_COMPARATOR|Sequential media|Embryos cultured in sequential media
62335852|NCT01325831|SHAM_COMPARATOR|rTMS_sham|
62335853|NCT01545908|PLACEBO_COMPARATOR|placebo enema|Participants in this arm undergo 6 retention enemas, week 1, week 2, week 3, week 4, week 5, week 6
62335854|NCT01545908|ACTIVE_COMPARATOR|Fecal transplant from an unrelated donor|Participants in this arm undergo 6 retention enemas,week 1, week 2, week 3, week 4, week 5, week 6,using stool specimen prepared from a healthy, screened donor.
62335855|NCT04436224|EXPERIMENTAL|hydromorphone|NS 40ML+ hydromorphone(10mg , 2mg:2ml），IV-Pump，maintenance dose 0.50mg/h
62335856|NCT04436224|ACTIVE_COMPARATOR|fentanyl|NS 40ML+ fentanyl(0.5mg, 0.1mg:2ml），IV-Pump，maintenance dose 0.08-0.2mg/h
62335857|NCT04436224|ACTIVE_COMPARATOR|Butorphanol|NS 40ML+ butorphanol(10mg, 1mg:1ml），IV-Pump，maintenance dose 0.7-10mg/kg/h
62335858|NCT05194293|EXPERIMENTAL|Treatment (regorafenib, durvalumab)|Patients receive regorafenib PO QD on days 1-21 and durvalumab IV on day 1. Treatment repeats every 28 days for a maximum of 2 years from registration or until decision to proceed to surgery, disease progression, excessive toxicity, or patient withdrawal.
62738457|NCT01309997|EXPERIMENTAL|Arm I (enzyme inhibitor)|Patients receive imatinib mesylate PO QD for 6 months in the absence of progression of sclerosis or unacceptable toxicity.
61940892|NCT04952285||Normal saline（I）|Intravenous infusion of 0.9% saline when start to cut the skin，do not intravenous tranexamic acid during the surgery
61940893|NCT04952285||Tranexamic acid（II）|Intravenous infusion of tranexamic acid 1g when start to cut the skin in 1 hour
62335859|NCT05112016||TME for rectal cancer|Patients with rectal cancer treated by TME (laparoscopic TME, transanal TME, robotic TME, open TME)
62335860|NCT04861480|EXPERIMENTAL|C-4-29 cells|Infusion of C-4-29 cells by dose-escalating
62335861|NCT01749007||Veterans with HIV/AIDS|
62335862|NCT00978809|ACTIVE_COMPARATOR|Semont|BPPV patients treated by Semont maneuver by a physical therapist.
62335863|NCT00978809|NO_INTERVENTION|control|healthy volunteers.
62335864|NCT00978809|ACTIVE_COMPARATOR|Epley maneuver|BPPV patients treated with Epley maneuver by a physical therapist.
62335865|NCT05525767|EXPERIMENTAL|Assigned Interventions|Bevacizumab 10mg/Kg d1, 1/21d
62335866|NCT03302416|EXPERIMENTAL|[C-11]NOP-1A PET Scan conditions|Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition
62335867|NCT00924352|EXPERIMENTAL|Ixabepilone + Dasatinib|"Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.~Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD."
62493046|NCT00840658|EXPERIMENTAL|Group D|"Interactive injection and sexual risk intervention: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas \['Say No to Contaminated Syringes'\] and Di No Al Sexo Inseguro \[Say No to Unsafe Sex'\] counseling session. This one-on-one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy)."
62493047|NCT05344118||Parents|Parents of children undergoing orthopedic surgery
61940894|NCT04315701|EXPERIMENTAL|Treatment (cemiplimab, surgical resection)|Patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles (or up to 4 cycles for patients whose disease is unresectable after 3 cycles) in the absence of disease progression or unacceptable toxicity. Within 6 weeks of last dose of therapy, patients with potentially resectable tumors undergo surgical resection.
62493048|NCT03960762|ACTIVE_COMPARATOR|Group A = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
62493049|NCT03960762|ACTIVE_COMPARATOR|Group B = SAP group|SAP block (Group SAP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
61940895|NCT06556264|ACTIVE_COMPARATOR|Dupilumab|30 subjects undergoing ESS + dupilumab 300 (1-week post-surgery) every 2 weeks + standard of care treatment (INCS + background asthma medication) for 24 weeks
61940896|NCT06556264|PLACEBO_COMPARATOR|Placebo|30 subjects undergoing ESS + placebo (1-week post-surgery) every 2 weeks + standard of care treatment (INCS + background asthma medication) for 24 weeks.
61940897|NCT00776724|ACTIVE_COMPARATOR|1|docetaxel-epirubicin for 4 cycles before surgery
61940898|NCT00776724|EXPERIMENTAL|2|Tailored regimens, base on immunohistochemical study of the tumor biopsy tissue, for 4 cycles before surgery.
61940899|NCT04050072||Childhood Cancer Survivors (CCSS)|i. PRO-CTCAE-SCC ii.Quality of life assessment
61940900|NCT04050072||St. Jude Life (SJLIFE)|i. PRO-CTCAE-SCC ii. Quality of life assessment iii. Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation
61940901|NCT04050072||Community non-cancer control|i. PRO-CTCAE-SCC ii.Quality of life assessment
62335868|NCT05052775|ACTIVE_COMPARATOR|Chlorhexidine Group|These patients were control group given chlorhexidine mouthwash 2 times per day for 15 days
62335869|NCT05052775|EXPERIMENTAL|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
62335870|NCT05052775|EXPERIMENTAL|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
62335871|NCT05209412|EXPERIMENTAL|Drug-coated balloon|Lepu Paclitaxel coated balloon will be used
62335872|NCT05209412|ACTIVE_COMPARATOR|Drug-eluting stent|Resolute Integrity Zotarolimus eluting stents will be used
62335873|NCT00678587|PLACEBO_COMPARATOR|Placebo|placebo, once daily, oral
62335874|NCT00678587|ACTIVE_COMPARATOR|Active|75 mg, once daily, oral
62738458|NCT01309997|EXPERIMENTAL|Arm II (monoclonal antibody)|Patients receive rituximab IV on days 1, 8, 15, and 22. A second treatment cycle is repeated at 3 months for a total of 8 doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.
62738459|NCT06280768|EXPERIMENTAL|SHR-2004 injection|
61940902|NCT01291953|EXPERIMENTAL|Screening|Opportunist Screening asymptomatic patients. Taking the arterial pulse. Will invite patient to realize an ECG, if pulse is irregular
61940903|NCT01291953|ACTIVE_COMPARATOR|Control|Case finding of patient whith symptoms of atrial fibrilation. Taking the arterial pulse. ECG if pulse is irregular
61940904|NCT05067907||Control|COVID-19 ICU-admitted patients that did not received physiotherapy interventions during ICU stay.
61940905|NCT05067907||Physiotherapy|COVID-19 ICU-admitted patients that received physiotherapy interventions during ICU stay.
61940906|NCT05440188||COPD|Patients over 65 years old diagnosed with COPD in GOLD II state or higher who uses Breath Detect Platform for monitoring their respiratory health status.
62137695|NCT02144597|ACTIVE_COMPARATOR|6-week LCD|A 6-week liquid formula low-calorie diet (LCD) will be administered for 6 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
62137696|NCT02144597|OTHER|Control diet|1000 calorie diet
62335875|NCT04386564||Mild COVID-19|Pneumonia without respiratory failure
62335876|NCT04386564||Moderate COVID-19 up to 60 years|Respiratory frequency ≥30/minute, blood oxygen saturation≤93%
62335877|NCT04386564||Moderate COVID-19 over 60 years old and severe COVID-19|Pneumonia with respiratory distress syndrome
62335878|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
62335879|NCT03555851||Recipient|Cyclophosphamide
62335880|NCT03555851||Donor|Specimen collection
62695371|NCT06461494|ACTIVE_COMPARATOR|Group A: Pilates exercise|"Group A received the pilates exercise. It doesn't require any special equipment and can be done in any training center.~Week 1: Leg slides, hip release, knee to chest, spinal rotation, single knee extension, cat stretch, neutral to imprint Week 2: Imprint table top position, ab prep, Imprint table top toe touching floor, imprint table top knee extensions, spine twist, Ab prep in table top position, bridging Week 3: Half roll back, pull up; pull up with leg extension, swimming exercise, single leg extension, leg circles, and single leg stretch Week 4: Bridging on the ball, spine stretch forward, single leg lift, double knee lifts, upward dog, and shell stretch Each exercise was performed for 5 times"
62695372|NCT06461494|EXPERIMENTAL|Group B: Egoscue exercise|Static back and static back with breathing, abdominal contraction while in the static back position, abductor press, overhead extension, elbow curls on wall, static wall, upper spinal twist, pelvic tilts, supine groin progressive, and air bench Week 1: 3 times with 30 s hold time Week 2: 5 times with 30 s hold time Week 3: 15 times with 30 s hold time Week 4: 20 times with 30 s hold time
62695373|NCT04925024|EXPERIMENTAL|Lomecel B Group|Participants randomized to receive Lomecel-B injections during their Stage II palliation.
62695374|NCT04925024|NO_INTERVENTION|No Study Intervention Control Group|Participants randomized to receive no study intervention during their Stage II palliation.
62335881|NCT03730883|EXPERIMENTAL|Central line removal at 100ml/kg/day.|"In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant. After central line removal, infants in this group may continue to receive parenteral nutrition via peripheral venous access, depending on the decision of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
62335882|NCT03730883|ACTIVE_COMPARATOR|Central line removal at 140 ml/kg/day.|"In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake (full enteral intake). In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
61940907|NCT05038046|EXPERIMENTAL|TCM daycare model|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
61940908|NCT05038046|NO_INTERVENTION|Control group|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
62335883|NCT02454218|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|The intensity of the asset is little perceived and painless.
61940909|NCT00320931|EXPERIMENTAL|Hybrid PET/CT|
62738460|NCT03528122|EXPERIMENTAL|Recurrent opened macular hole|Pars plana vitrectomy with internal limiting membrane peel if not peeled in the first surgery and application of amniotic membrane graft
61940910|NCT01006460|EXPERIMENTAL|Adapt 232|
62335884|NCT02454218|PLACEBO_COMPARATOR|Simulation Transcranial Current|Will receive only simulation.
61940911|NCT01006460|EXPERIMENTAL|Arctic root group|
62738461|NCT06291012|EXPERIMENTAL|Short arm|Antibiotic therapy for 3 to 5 days depending on response
61940912|NCT01006460|ACTIVE_COMPARATOR|Ginseng group|
61940913|NCT01006460|PLACEBO_COMPARATOR|Placebo group|
61940914|NCT00121095|OTHER|1|
61940915|NCT00136123|EXPERIMENTAL|Implants|
61940916|NCT04596800|EXPERIMENTAL|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
61940917|NCT04596800|ACTIVE_COMPARATOR|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
62335885|NCT04426825|EXPERIMENTAL|Atezolizumab plus Bevacizumab|Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death.
62335886|NCT05081648|EXPERIMENTAL|Intervention group: Multiple Single Cannulation Technique (MuST)|
61940918|NCT05885854|EXPERIMENTAL|XTR003; At rest|"1. Injection with XTR003 to investigate myocardial fatty-acid metabolism in patients with known IHD.~2. Adjunct injection with 18F-FDG to investigate and trace myocardial glucose metabolism in patients with known IHD.~The study population consisted of 50 participants from the following category of patients: (1) Patients with Non-ST elevation myocardial infarction (NSTEMI) (2) Patients with old myocardial infarction (3) Patients with total occlusions of coronary arteries."
62335887|NCT05081648|OTHER|Control group: Rope-ladder cannulation technique (RL)|
62335888|NCT02820376|OTHER|All patients|"Differential renal function assessment by 4D CT:~All patients will undergo both CT and SPECT assessment of differential renal function; each patient will be his own comparator"
62738462|NCT06291012|ACTIVE_COMPARATOR|Long arm|Antibiotic therapy for 5 to 7 days depending on response
61940919|NCT02380027|EXPERIMENTAL|MRI-arm|Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.
61940920|NCT02380027|ACTIVE_COMPARATOR|TRUS-biopsy arm|Men in this arm undergo standard 12-core trans-rectal ultrasound guided prostate biopsy
61940921|NCT04087174|EXPERIMENTAL|Part A1: Capivasertib + enzalutamide|From day 1 to day 28 of this study treatment, patients will continuously enroll on a starting dose of capivasertib in combination with 160 mg enzalutamide.
61940922|NCT04087174|EXPERIMENTAL|Part A1: Capivasertib dose level 1 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+1 along with 160 mg enzalutamide.
61940923|NCT04087174|EXPERIMENTAL|Part A1: Capivasertib dose level 2 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+2 along with 160 mg enzalutamide.
61940924|NCT04087174|EXPERIMENTAL|Part A2: Capivasertib + abiraterone|Patients will continuously enroll on a starting dose of capivasertib in combination with 1000 mg abiraterone.
61940925|NCT04087174|EXPERIMENTAL|Part B1: Capivasertib + enzalutamide|This optional expansion will treat patients at the recommended dose regimen of capivasertib and enzalutamide.
61940926|NCT04087174|EXPERIMENTAL|Part B2: Capivasertib + abiraterone|This optional expansion will treat patients at the recommended dose regimen of capivasertib and abiraterone.
62335889|NCT04229498||Carbapenem resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
62335890|NCT04229498||Carbapenem hetero-resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-heteroresistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
62335891|NCT03161938|ACTIVE_COMPARATOR|Dexamethasone 48 mg|Dexamethasone 48 mg pre-operative, single shot injection
62335892|NCT03161938|ACTIVE_COMPARATOR|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative, single shot injection
62335893|NCT01308320|PLACEBO_COMPARATOR|saline|control group
62493050|NCT03816449|ACTIVE_COMPARATOR|experimental group|Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
62493051|NCT03816449|PLACEBO_COMPARATOR|control group|Control group will include about postmenopausal women who will not practice exercise program (aerobic exercise, resistance training and balance exercise) .They will continue to carry out activities of daily living, which are conducted daily before inclusion in the study. These patients will be asked to not include in any other program of physical activity and exercise during the research period (12 weeks). After this period, patients will be offered to participate in the same exercise program that had patients from the experimental group.
62493052|NCT05264207|EXPERIMENTAL|Intervention group|Participants allocated to the 'intervention group' arm will receive the usual care offered by the Public Andalusian Healthcare Service in conjunction with a 12-week nursing students' home-visit programme.
62493053|NCT05264207|ACTIVE_COMPARATOR|Control group|Participants allocated to the 'control group' arm will only receive the usual care offered by the Public Andalusian Healthcare Service for 12 weeks.
62695375|NCT05631119||Diabetic Kidney Disease|"Sample Collection:~* Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Whole blood will be collected in 4 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 million cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30"
62738463|NCT02371577|EXPERIMENTAL|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
62738464|NCT03984890|EXPERIMENTAL|Vitamin D Group|Vitamin D3 Supplementation plus traditional treatment of CGD and TB
61940927|NCT06261060|EXPERIMENTAL|Arm 1|Participants will visit the study clinic 2 times during Week 1, one (1) time during Weeks 2-4, and then 1 time every 2 weeks after that (Weeks 6, 8, 10, and so on) until Week 22 (Month 6). Then participants will have a follow-up visit at Week 24 and again at Week 52 (Month 12). Participants will take sirolimus by mouth every day, at about the same time each day. Swallow the tablet(s) whole with a full glass of water (about 1 cup). Do not crush or chew the tablet(s). Participants may take sirolimus with or without food.
61940928|NCT01747226|PLACEBO_COMPARATOR|Fluoride rinse|A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.
61940929|NCT01747226|ACTIVE_COMPARATOR|Halita|Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)
61940930|NCT01747226|ACTIVE_COMPARATOR|Meridol Halitosis|This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).
61940931|NCT01747226|SHAM_COMPARATOR|Water|To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.
62335894|NCT01308320|ACTIVE_COMPARATOR|F1 group|F1 group : fentanyl 1 mcg/kg
62335895|NCT01308320|ACTIVE_COMPARATOR|F1.5 group|F1.5 group : fentanyl 1.5 mcg/kg
62335896|NCT01308320|ACTIVE_COMPARATOR|F2 group|F2 group : fentanyl 2 mcg/kg
62335897|NCT00502307|EXPERIMENTAL|1|Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
62335898|NCT00502307|PLACEBO_COMPARATOR|2|solid oral capsule containing excipients dosed daily for three weeks per month
62335899|NCT05286073|EXPERIMENTAL|Hyflex EDm|The canals were prepared and shaped with one file (25/\~) and finished with 40/.04 using crown down technique. Torque controlled endodontic motor was used with a rotational speed of 500 rpm and torque of 2.5Ncm (25 Nm).
61940932|NCT02674776|EXPERIMENTAL|HuZhen Capsule|The main elements of HuZhen Capsule include Polygonum cuspidatum, Ligustrum lucidum etc.
61940933|NCT02674776|PLACEBO_COMPARATOR|Placebo Capsule|Placebo appearance, content color and taste should be consistent with HuZhen Capsule.
61940934|NCT06205966|ACTIVE_COMPARATOR|Probiotics|Study product containing L. reuteri (PTA5289 and DSM 17938) taken orally once in the morning and once in the evening, each time 5 drops.
61940935|NCT06205966|PLACEBO_COMPARATOR|Placebo|Placebo taken orally once in the morning and once in the evening, each time 5 drops.
61940936|NCT05689710|NO_INTERVENTION|No intervention|
61940937|NCT05689710|EXPERIMENTAL|Experimental|Dietary Supplement with inositols and alpha-lactalbumin
62335900|NCT05286073|EXPERIMENTAL|F6 SkyTaper|The canals were prepared and shaped with one file (25/\~) and finished with 40/.04 using crown down technique. Torque controlled endodontic motor was used with a rotational speed of 500 rpm and torque of 2.5Ncm (25 Nm).
62335901|NCT05286073|EXPERIMENTAL|One Shape|Canals were prepared and shaped with single rotational file system One Shape with the sequence of Endoflare (12, 0.12), One G (18, 0.03) and One Shape (12.06) connected to endodontic motor with rotational speed of 400rpm and 4 Ncm torque as recommended by manufacturer.
62335902|NCT05286073|NO_INTERVENTION|Control|In the control group, no endodontic instrumentation and shaping was done in the canals. Only the necrotic pulp tissue was extirpated from the canals with the help of barbed broaches and then the specimens were analyzed for fracture testing.
62335903|NCT04597034|EXPERIMENTAL|AN69 Oxiris|"* To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.~* To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.~* To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.~* To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
62493054|NCT05674188|EXPERIMENTAL|Augmented Reality Enhanced Simulation (Treatment group)|Participants will experience augmented simulations with a holographic mixed-reality setting based on different workplace scenarios such as medical error and workplace harassment via Augmented Reality (AR) headset.
62493055|NCT05674188|NO_INTERVENTION|Traditional In Situ Simulation (Control group)|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
62493056|NCT03756233|ACTIVE_COMPARATOR|Remifentanil gradually withdrawal group|20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes.
62493057|NCT03756233|ACTIVE_COMPARATOR|Remifentanil immediately stop group|The control group stopped remifentanil 10 minutes before the end of the operation.
61940938|NCT05906979|EXPERIMENTAL|Digital intervention|Participants will interact with PAHOLA the digital assistant of the Pan American Health Organization.
62493058|NCT00834353||Pulmonary tuberculosis patients|Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs
62493059|NCT01219140|EXPERIMENTAL|2 POMx Capsules|2 POMx Capsules daily
62493060|NCT01219140|PLACEBO_COMPARATOR|2 placebo Capsules|2 placebo Capsules daily
62335904|NCT04597034|ACTIVE_COMPARATOR|AN69 Standard|"* To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.~* To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.~* To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.~* To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
62493061|NCT04809363|EXPERIMENTAL|CDPATH™|Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.
62493062|NCT04758208||Healthy CALIPER Participants|Healthy community children and adolescents recruited through the CALIPER initiative as well as healthy children and adolescents recruited from outpatient clinics at the Hospital for Sick Children through the CALIPER initiative. Blood samples from these participants will be tested on the Mindray BC-6800Plus device to measure hematology parameters and establish reference intervals.
62738465|NCT03984890|OTHER|Control Group|Traditional treatment of CGD and TB without Vitamin D Supplementation
62738466|NCT01905943|EXPERIMENTAL|Obinutuzumab|Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide \[FC\], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
61940939|NCT05906979|EXPERIMENTAL|Digital intervention (text only)|Participants will interact with PAHOLA (text only version) the digital assistant of the Pan American Health Organization.
61940940|NCT05906979|OTHER|Information on alcohol use and risk|A PDF containing standard information on alcohol use and risk from the Pan American Health Organization.
61940941|NCT02103712||Hypospadias|
61940942|NCT06664606||Students in Rural Public Schools|This group consists of primary school students from rural public schools in Extremadura, Spain, participating in a Pain Neuroscience Education (PNE) program.
61940943|NCT06664606||Students in Urban Public Schools|This group includes primary school students from urban public schools in Extremadura, Spain, who participated in a Pain Neuroscience Education (PNE) program.
61940944|NCT06664606||Students in Special Education Schools|This group consists of students from special education schools in Extremadura, Spain, who have intellectual disabilities. These students participated in the Pain Neuroscience Education (PNE) program, with the goal of understanding program effectiveness in an inclusive educational environment tailored to students with intellectual disabilities.
62493063|NCT05485051|EXPERIMENTAL|Chlorhexidine baths|All patients in the cluster randomized to the intervention arm will receive baths using a 2% chlorhexidine digluconate solution with surface-active agents during the intervention period. All other infection control and cleaning procedures will be performed according to the current practice in each center.
62493064|NCT05485051|ACTIVE_COMPARATOR|Usual baths|All patients in the cluster randomized to the intervention arm will receive baths using soap and water according to the current practice in each center during the intervention period. All other infection control and cleaning procedures will be performed according to the current practice in each center.
62335905|NCT06536335|ACTIVE_COMPARATOR|Conventional protocol|A group of patients a group of patients to whom attachments will be bonded at the beginning of the first aligner.
62335906|NCT06536335|EXPERIMENTAL|Delayed protocol|A group of patients to whom attachments will be bonded at the beginning of the third aligner, approximately one month after the start of orthodontic treatment.
62335907|NCT01628744||Patients with mycobacterial infection|
62335908|NCT06367868|EXPERIMENTAL|Before Drainage|Optic nerve sheath diameter and intracranial pressure will be measured before CSF drainage
62335909|NCT01442740|EXPERIMENTAL|15-degree Reverse Trendelenburg Position|Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
62335910|NCT01442740|NO_INTERVENTION|0-degree Supine Position|Patients will be placed on the operating table in the standard, 0-degree supine position.
62335911|NCT02062528|EXPERIMENTAL|omega-3 fatty acids|3 capsules each day during 8 weeks
61940945|NCT06664606||Students in Regular Education Schools|This cohort includes primary school students from regular education schools in Extremadura, Spain, without intellectual disabilities. These students participated in the Pain Neuroscience Education (PNE) program, providing insights into the program's impact on general education settings and comparing outcomes with other cohorts.
61940946|NCT05529927|EXPERIMENTAL|Sustained-release Dexamphetamine|Tablets of 30 mg sustained-release dexamphetamine sulphate. Target dose: 90 mg/day, if tolerated. Tablets have to be taken daily, in the morning, per os for 24 weeks.
62335912|NCT02062528|PLACEBO_COMPARATOR|placebo|3 capsules each day during 8 weeks
62335913|NCT06523452|EXPERIMENTAL|LSI Assisted Group|"Breast reconstruction surgery will be standard clinical care, but tissue blood flow images will be available during surgery to aid surgical decision making.~The surgical procedure will take slightly longer (approximately 10-15 minutes in total) compared to the Treatment As Usual group."
62335914|NCT06523452|NO_INTERVENTION|Treatment As Usual Group|Breast reconstruction surgery will be standard clinical care
62335915|NCT01914419|ACTIVE_COMPARATOR|IV infusion|Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
62335916|NCT01914419|ACTIVE_COMPARATOR|IV bolus|Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
62493065|NCT06017427||Patients suffering from severe recurrent CRSwNP and treated with Dupilumab|Patients suffering from severe recurrent CRSwNP despite having benefited from the appropriate medical and surgical treatment and treated with Dupilumab for 6 months
61940947|NCT05529927|PLACEBO_COMPARATOR|Placebo|Identical matched placebo, dispensed under the same conditions and with similar frequency as the investigational product (see above).
61940948|NCT05883683||Colorectal Cancer|Colorectal cancer patients with advanced or recurrent tumors
62335917|NCT01914419|ACTIVE_COMPARATOR|IM injection|Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.
62335918|NCT00162305|ACTIVE_COMPARATOR|1|
61940949|NCT00560768|EXPERIMENTAL|1|
62335919|NCT00162305|ACTIVE_COMPARATOR|2|
62335920|NCT00162305|ACTIVE_COMPARATOR|3|
62335921|NCT00162305|PLACEBO_COMPARATOR|4|
62335922|NCT04336592||Patients|Patients scheduled to receive a surgical spine procedure at Mayo Clinic
62335923|NCT04336592||Clinicians|Surgeons, Physician pain specialists and allied health caring for participating patients
62335924|NCT00152815|EXPERIMENTAL|Vitamin E|alpha-tocoperol, capsules, 2 per day
62335925|NCT03397693||1|Women with unexplained infertiltiy with no treatment given
61940950|NCT04352946|EXPERIMENTAL|Hydrocholoroquine Pre-exposure prophylaxis|HCQ will be administered as 400mg orally once for 60 days.
61940951|NCT04352946|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as 400mg orally once for 60 days.
61940952|NCT04558580|NO_INTERVENTION|Standard of Care|
61940953|NCT04558580|EXPERIMENTAL|Rufinamide|
61940954|NCT01518023||Cancer gastrectomy|Patients previously submitted to partial/total gastrectomy for gastric cancer
62335926|NCT03397693||2|Women with Poly Cystic Ovary Syndrome (PCOS) who are not being treated with drugs of ovulation induction.
62335927|NCT03397693||3|Control fertile women with no treatment given.
62335928|NCT05544422|OTHER|Study Group|The Timed Up \& Go Test and 30-second Chair-Stand Tests with conventional and tele-assessment methods will be applied to the participants included in the study.
62335929|NCT05628584|EXPERIMENTAL|High FODMAP|
62335930|NCT05628584|PLACEBO_COMPARATOR|LOW FODMAP|
62335931|NCT03369106||Multiple Sclerosis siblings|Group of siblings having multiple sclerosis, n=120 Composite severity score calculation for all subjects
62335932|NCT03054077|NO_INTERVENTION|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
62335933|NCT03054077|EXPERIMENTAL|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
62335934|NCT05248087|EXPERIMENTAL|The rapid maxillary expansion|The rapid maxillary expansion will be applied using a McNamara-type (bonded) appliance.
62335935|NCT05248087|ACTIVE_COMPARATOR|The slow maxillary expansion|The slow maxillary expansion will be applied using a removable palatal expansion appliance.
62335936|NCT00966758|OTHER|1|
62335937|NCT04460690|EXPERIMENTAL|Rapid Onsite COVID-29 Testing|Community participants provide a saliva sample for a simple test to detect high concentrations of SARS-CoV-2 in saliva with assays that require no specialized equipment and can be completed in one hour.
61940955|NCT01518023||Colorectal cancer operation|Patients previously submitted to right colectomy or rectosignoidectomy for cancer
62335938|NCT05290142|ACTIVE_COMPARATOR|Self-Guided Digital Training (DT)|"Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available online on a smartphone app as well as a website that can be accessed through an internet-enabled device.~Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface."
62335939|NCT05290142|EXPERIMENTAL|Digital Training with Coaching (DT-C)|In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. Participants will also be able to send text messages to coaches.
62335940|NCT03478319|EXPERIMENTAL|Cohort 1|ACE-2494 or placebo 0.06 mg/kg SC Day 1
62335941|NCT03478319|EXPERIMENTAL|Cohort 2|ACE-2494 or placebo 0.2 mg/kg SC Day 1
62335942|NCT03478319|EXPERIMENTAL|Cohort 3|ACE-2494 or placebo 0.6 mg/kg SC Day 1
62335943|NCT03478319|EXPERIMENTAL|Cohort 4|ACE-2494 or placebo 1.0 mg/kg SC Day 1
62335944|NCT03478319|EXPERIMENTAL|Cohort 5|ACE-2494 or placebo 2.0 mg/kg SC Day 1
62335945|NCT03478319|EXPERIMENTAL|Cohort 6|ACE-2494 or placebo TBD (not to exceed 3.0 mg/kg SC) Day 1
62335946|NCT04431154|NO_INTERVENTION|Experimental: Usual care|Participants randomized to this arm will receive the standard of care (SOC) following the STAR program protocol in various sites in Johannesburg. This will include provision of an HIV self-screening test kit, the standard linkage officer follow-up call following report of a positive HIVSS test and an invitation to i) participate in study visit 1 to have their positive HIVSS result confirmed and complete blood collection for viral load PCR testing and to ii) participate in study visit 2 at 6 months for Viral Load PCR. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
62335947|NCT04431154|EXPERIMENTAL|Experimental: Incentives and linkage promotion|Participants randomized to this arm will receive the same standard HIV self-screen test kit and linkage officer follow-up call including the invitation to i) participate in study visit 1 and ii) study visit 2. In addition, they will receive a financial incentive if they complete a confirmatory HIV test at visit 1 and if they demonstrate viral suppression at study visit 2, approximately 6 months after positive HIVSS result. They will also receive monthly reminders and incentives to pick up HIV medication. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
62335948|NCT04453696||Communication before operation|Communication was established before the operation.
62335949|NCT04453696||Communication after operation|Communication was established after the operation.
62335950|NCT04453696||Communication before and after operation|Communication took place both before and after the operation.
62335951|NCT04453696||No communication|No communication.
62335952|NCT04937582|EXPERIMENTAL|Confirmed cognitive disorder|"Patients with abnormal QPC score at screening visit and confirmed cognitive disorder on the neuropsychological assessment during Visit V1.~Intervention Completed by MRI (magnetic resonance imaging), EEG (Electroencephalogram) and possible psychiatric evaluation at Visit 1B.~Follow-up 2 years after initial hospitalisation (Visit 2 : neuropsychological assessment ; if needed MRI, EEG, lumbar puncture)"
62335953|NCT04937582|EXPERIMENTAL|Absence of cognitive disorder|Patients with abnormal QPC score at screening and absence of cognitive disorder on the neuropsychological assessment during Visit V1.
62335954|NCT04891991|ACTIVE_COMPARATOR|Infliximab group|This group will receive 1 mg/0.05 mL of intravitreal infliximab at the end of standard pars plana vitrectomy.
61940956|NCT01518023||Bariatric patients|Morbidly obese participants who underwent antiobesity Roux-en-Y gastric bypass
61940957|NCT04956952|OTHER|Enhanced External Counterpulsation (EECP)|1 hour of treatment with EECP
62335955|NCT04891991|SHAM_COMPARATOR|Standard of care group|This group will undergo standard pars plana vitrectomy.
62335956|NCT05474690|ACTIVE_COMPARATOR|TCbHP chemotherapy regimen|Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
62335957|NCT05474690|EXPERIMENTAL|ECHP-THP chemotherapy regimen|(Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
62335958|NCT05342363||cardiopulmonary resuscitation during treatment with extracorporeal membrane oxygenation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) during the retrospective observation period who required mechanical cardiovascular resuscitation (CPR) during their treatment.
62335959|NCT05342363||Treatment with extracorporeal membrane oxygenation without resuscitation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) without the need for cardiovascular resuscitation during the retrospective observation period.
62335960|NCT01000194|EXPERIMENTAL|High polyunsaturated fat meal|A high fat milkshake containing 55g of fat, mainly PUFA
62335961|NCT01000194|EXPERIMENTAL|High monounsaturated fat meal|A high fat milkshake containing 55g of fat, mainly MUFA
62335962|NCT01000194|EXPERIMENTAL|High saturated fat meal|A high fat milkshake containing 55g of fat, mainly SFA
62335963|NCT05201586|ACTIVE_COMPARATOR|Conditional cash transfer|Investigators will randomize 15 patients into this intervention arm. All participants will undergo a semi-structured patient interview about how social needs impact health and self-perceptions of health at the time of enrollment and again in 6 months. All participants will receive a CCT after the first interview.
62493066|NCT01941680||ZPI|Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
61940958|NCT01527175|ACTIVE_COMPARATOR|supraclavicular|supraclavicular: supraclavicular approach for subclavian venous catheterization
61940959|NCT01527175|PLACEBO_COMPARATOR|infraclavicular|infraclavicular: infraclavicular approach for subclavian venous catheterization
61940960|NCT00097292||Annual Re-Testing/Annual Metabolic Monitoring|Participants will be monitored annually for risk of type 1 diabetes.
61940961|NCT00097292||Semi-Annual Metabolic Monitoring|Participants will be monitored every six months for risk of type 1 diabetes
61940962|NCT04042181|PLACEBO_COMPARATOR|Placebo|
61940963|NCT04042181|ACTIVE_COMPARATOR|Bifidobacterium longum|
61940964|NCT03276988|OTHER|Part B - Sequence A|Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
61940965|NCT03276988|OTHER|Part B - Sequence B|Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
61940966|NCT04138069|EXPERIMENTAL|PLB+Aerobic Bicycling|Pursed Lip Breathing + Aerobic Bicycling
62335964|NCT05201586|ACTIVE_COMPARATOR|Control|Investigators will randomize 15 patients into this control arm. All participants will undergo a semi-structured patient interview about how social needs impact health and self-perceptions of health at the time of enrollment and again in 6 months.
62335965|NCT02769845|EXPERIMENTAL|Longitudinal Portion|All enrolled children will undergo yearly TCD examination. The goal of serial examination is to help define the natural history of cerebrovascular disease, specifically to determine the incidence of new conditional or abnormal velocities. The goal is to obtain a total of 3 TCD examinations per enrolled patient, regardless of treatment status.
62335966|NCT02769845|EXPERIMENTAL|Treatment Phase|Those children with TCD velocities between 170-199 cm/sec will be eligible for protocol-directed hydroxyurea therapy. Most participants will initiate hydroxyurea treatment but those who are already on hydroxyurea and have conditional velocities will receive dose optimization. Participants will be followed until a common study termination date, defined as 3 years from the first treatment. Participants with abnormal TCD velocities ≥200 cm/sec will commence with transfusion therapy per current practice guidelines at the clinical site. Patients already on transfusion therapy identified to have conditional velocities will also be eligible for hydroxyurea and those with abnormal velocities may require re-calculation of transfusion dosing.
62335967|NCT00306917|ACTIVE_COMPARATOR|1|DuoFix HA
62335968|NCT00306917|ACTIVE_COMPARATOR|2|Porocoat porous coated
62335969|NCT04415216||ISR PCI with thin-DES|
62335970|NCT04415216||ISR PCI with DEB|
62335971|NCT03200873|ACTIVE_COMPARATOR|high impulsivity|participants with high impulsivity (BIS \>62), receiving active and sham repetitive transcranial magnetic stimulation \[intermittent theta burst stimulation (iTBS)\] in a randomised order
62335972|NCT03200873|ACTIVE_COMPARATOR|low impulsivity|participants with low impulsivity (BIS between 52 to 62), receiving active and sham repetitive transcranial magnetic stimulation \[intermittent theta burst stimulation (iTBS)\] in a randomised order
62335973|NCT02679248|EXPERIMENTAL|Neo40 Daily®|
62335974|NCT02679248|EXPERIMENTAL|Placebo|
62335975|NCT02279433|EXPERIMENTAL|DS-6051b|DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
62335976|NCT03205917|EXPERIMENTAL|Group 1A HIV-Uninfected|PGDM1400 low dose
62335977|NCT03205917|EXPERIMENTAL|Group 1B HIV-Uninfected|PGDM1400 mid dose
62335978|NCT03205917|EXPERIMENTAL|Group 1C HIV-Uninfected|PGDM1400 high dose
62335979|NCT03205917|EXPERIMENTAL|Group 2A HIV-Uninfected|PGDM1400 + PGT121 low dose
62335980|NCT03205917|EXPERIMENTAL|Group 2B HIV-Uninfected|PGDM1400 + PGT121 mid dose
62335981|NCT03205917|EXPERIMENTAL|Group 2C HIV-Uninfected|PGDM1400 + PGT121 high dose
62335982|NCT03205917|EXPERIMENTAL|Group 3A HIV-infected off ART|PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
62335983|NCT03205917|EXPERIMENTAL|Group 3B HIV-infected off ART|PGDM1400 + PGT121 at high dose; HIV + without ART
62335984|NCT04389749|EXPERIMENTAL|CPM|The experimental group will have a CPM applied in the PACU immediately post-op and it will be utilized while the patient is awake in bed for 2 hours on and 2 hours off, when not mobilizing with Physical Therapy (PT). The experimental group will also have traditional PT, including sessions 1 to 3 times a week.
62335985|NCT04389749|NO_INTERVENTION|No CPM|The control group will have typical care, including working with physical therapy 1 to 3 times a week.
62335986|NCT03179592||Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
62335987|NCT03323918|EXPERIMENTAL|ImPACT|Project ImPACT will be provided in 18 weekly intervention sessions, during which parents will learn how to stimulate their children's social imitation, social engagement, language and play skills. First, parents are taught techniques that promote interaction with the child (one technique per session, through demonstration and coaching). In the second half of the intervention, parents are taught direct teaching techniques, e.g., to promote language or play, again by means of demonstration and coaching. After completion of the program, families will receive guidance every 2-3 weeks for an additional 12 weeks, during which the support will generally not focus on social-communicative abilities, although ImPACT follow-up sessions might be given if necessary.
61940967|NCT04138069|ACTIVE_COMPARATOR|Aerobic Bicycling|Only Aerobic bicycling
61940968|NCT05510531|EXPERIMENTAL|Treatment Diabetes Survival Skills (DSS)Training|Participants in the treatment group received a 6-session 1-hour weekly literacy tailored DSS education intervention.
61940969|NCT05510531|NO_INTERVENTION|Control No intervention|Participants in the Control facility received the intervention upon completion of week twelve measurements.
61940970|NCT02187705||Patients with normotension at baseline|
61940971|NCT02187705||Patients with essential hypertension at baseline|
61940972|NCT02187705||Patients with isolated hypertension at baseline|
61940973|NCT05829993||Cohort|patients with a clinical indication to perform an ECG
61940974|NCT03503136|EXPERIMENTAL|A (TPF+P-RT)|Induction docetaxel, cisplatin, and fluorouracil plus concurrent chemoradiotherapy with cisplatin
61940975|NCT03503136|EXPERIMENTAL|B (TNF+N-RT)|Induction docetaxel, nedaplatin, and fluorouracil plus concurrent chemoradiotherapy with nedaplatin
61940976|NCT03503136|EXPERIMENTAL|C (TPX+P-RT)|Induction docetaxel, cisplatin, and capecitabine plus concurrent chemoradiotherapy with cisplatin
61940977|NCT03503136|EXPERIMENTAL|D (TNX+N-RT)|Induction docetaxel, nedaplatin, and capecitabine plus concurrent chemoradiotherapy with nedaplatin
62493067|NCT01941680||ZPI+CHOP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~CHOP-21 Day1 = day 21 (3 cycles)~Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.~day 2-Day 5 Prednisone~1mg/kg/day PO."
61940978|NCT00722800|EXPERIMENTAL|A|drospirenone and ethinyl estradiol
62493068|NCT01941680||ZPI +DHAP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
61940979|NCT00722800|PLACEBO_COMPARATOR|B|Placebo
61940980|NCT05078242|EXPERIMENTAL|Experimental: EaseVRx sessions|This is a study of patients with chronic pain to assess usability of a VR device at home. The main goals are 1) to collect data on feasibility of recruitment, 2) to collect data on daily adherence to therapy, and 3) to collect preliminary effectiveness data on pain and mood outcomes. There will be 7 sessions over one week, with each session lasting about 2-16 minutes. All patients recruited will be in the active arm; this is not a randomized pilot study.
62335988|NCT03323918|ACTIVE_COMPARATOR|TAU|Treatment as usual (TAU) will be provided at the typical frequency, which is every 2-3 weeks. TAU can include targeting eating and sleeping problems, adaptive skills, or other goals. TAU will not include forms of intervention explicitly targeting social communicative skills. However, limited guidance on social communication development can be given if explicitly asked by parents.
62335989|NCT02808312|EXPERIMENTAL|Cohort 1: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
62335990|NCT02808312|EXPERIMENTAL|Cohort 1: Normal Hepatic Function|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
62335991|NCT02808312|EXPERIMENTAL|Cohort 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
62335992|NCT02808312|EXPERIMENTAL|Cohort 2: Normal Hepatic Function|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
62335993|NCT02808312|EXPERIMENTAL|Cohort 3: Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
62335994|NCT02808312|EXPERIMENTAL|Cohort 3: Normal Hepatic Function|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
62335995|NCT02656758|EXPERIMENTAL|Executive function training|the experimental group will receive 12 sessions of intensive Executive function training weekly immediately
62335996|NCT02656758|OTHER|the waitlist group|the waitlist group will wait 12 weeks before receiving intensive executive function training for comparison.
62335997|NCT01695057|EXPERIMENTAL|Treatment (vorinostat and surgery)|Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.
62493069|NCT05779527|EXPERIMENTAL|Online Mindful Parenting Programme|Parents or carers will be invited to complete a six week online mindful parenting programme comprising online video, audio and written content plus four group support sessions via videoconferencing.
61940981|NCT00924079|EXPERIMENTAL|nalbuphine|
61940982|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
62335998|NCT03463941|EXPERIMENTAL|African American church members|
62335999|NCT03111134|NO_INTERVENTION|Routine Abdominal Closure|
62336000|NCT03111134|EXPERIMENTAL|New Abdominal Closure|modified component separation technique is used to abdomen closing.
62336001|NCT04860284|ACTIVE_COMPARATOR|Intervention arm|Participants will receive 400mg of hydroxychloroquine tablets 12-hourly on day 1 and 200mg 12-hourly on day 2 to day 5 in addition to standard of care treatment for COVID-19
62336002|NCT04860284|NO_INTERVENTION|Control arm|Participants will receive only standard of care treatment for COVID-19
62336003|NCT02393118|EXPERIMENTAL|BrainPort V200 Device|Single Arm
62336004|NCT00701727|EXPERIMENTAL|1|ezetimibe (10mg/day)for 7 weeks
62336005|NCT00701727|PLACEBO_COMPARATOR|2|Placebo control
62336006|NCT03697928||CrAT subjects|"13 healthy adult men, with a wide range of maximal aerobic capacity will be included.~Subjects will be classified as trained, physical active and untrained according to their VO2max.~Subject will perform one-legged knee extension and flexion exercise inside the MRS scanner and cycling outside the scanner"
62336007|NCT00666133|NO_INTERVENTION|2|Women in Group II (standard of care) will receive an 8 mL loading dose containing 4g magnesium sulfate administered manually per standard hospital protocol. The solution will be diluted with normal saline according to standard hospital practice, and given IV over 20 minutes. For women in Group II, the IV loading dose will be followed immediately with 20 mL treatment by IM injection, given as 10 mL (5 g magnesium sulfate) into each buttock. This dose will be followed by 10 mL treatments (5g magnesium sulfate) every four hours, injected into alternate buttock. Treatment will be discontinued when clinically indicated.
62493070|NCT01875107|EXPERIMENTAL|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
62493071|NCT00400634|EXPERIMENTAL|1|Intracerebral administration of CERE-120
62493072|NCT00400634|SHAM_COMPARATOR|2|Sham Neurosurgery
62493073|NCT00889486|PLACEBO_COMPARATOR|Placebo|Four placebo capsules taken orally once per day for 28 days
62493074|NCT00889486|EXPERIMENTAL|10 mg TZP-102|One 10 mg TZP-102 Capsule and three placebo capsules taken orally once per day for 28 days
62493075|NCT00889486|EXPERIMENTAL|20 mg TZP-102|Two 10 mg TZP-102 Capsules and two placebo capsules taken orally once per day for 28 days
62493076|NCT00889486|EXPERIMENTAL|40 mg TZP-102|Four 10 mg TZP-102 Capsules taken orally once per day for 28 days
62493077|NCT02013050|PLACEBO_COMPARATOR|Placebo|Control
62493078|NCT02013050|EXPERIMENTAL|SGX942|Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
61940983|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
61940984|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
61940985|NCT00285818|ACTIVE_COMPARATOR|Mifepristone|Patients receive mifepristone one day before and for 5 additional days after starting ECT
62336008|NCT00666133|EXPERIMENTAL|1|Women in Group I (Springfusor® arm) will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4\*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4will be administered using the Springfusor® pump. For women in Group I, the administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours for upto 24 hours postpartum.
62336009|NCT01881802||morphine or heroin dependence patients|
62336010|NCT01881802||normal control group|
62336011|NCT02218814|EXPERIMENTAL|Adductor Canal Block:|Adductor Canal Nerve Block: The patient is placed in a supine position with the extremity to be blocked slightly externally rotated. On the medial thigh, at the midpoint between the inguinal crease and the medial condyle, 13-6-MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) is placed in a transverse orientation to visualize the femoral artery in short axis deep to the sartorius muscle. Sterile field and patient sedation achieved. A 21-gauge,100 mm, short-bevel needle (Stimuplex; B Braun) is inserted under ultrasound guidance in in-plane technique to position the needle tip anterolateral to the artery and just deep to the posterior fascia of the sartorius muscle. Once in position, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
62336012|NCT02218814|ACTIVE_COMPARATOR|Femoral Nerve Block|Femoral Nerve Block. The procedure is conducted with the patient in a supine position with a 13-6 MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) applied to the skin at the level of the inguinal crease. The femoral artery, fascia iliac, and femoral nerve are visualized. Sterile field and patient sedation achieved. A 22-gauge, 50-mm, short-bevel stimulating needle (Stimuplex; B Braun, Bethlehem, Pennsylvania) connected to twitch monitor B/Braun Stimuplex DIG RC is inserted under ultrasound guidance using an in-plane technique from lateral to medial until a quadriceps motor response is elicited at a current between 0.5 and 0.2 mA with a pulse width of 0.1millisecond from a twitch monitor . After negative aspiration, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral nerve and deep to the fascia iliac, with intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
62336013|NCT04396743|ACTIVE_COMPARATOR|Periapical surgery with placement of prf high clots|Patients will undergo periapical surgery and PRF-high clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
62493079|NCT03971435||Head Start children and families - 2019|children (2,260), parents (2,260), classrooms/teachers (590), program directors (165), center directors (318)
62336014|NCT04396743|ACTIVE_COMPARATOR|Periapical surgery with placement of prf medium clots|Patients will undergo periapical surgery and PRF-medium clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
62336015|NCT00757770|EXPERIMENTAL|Group HRV Lot A|
62336016|NCT00757770|EXPERIMENTAL|Group HRV Lot B|
62336017|NCT00757770|EXPERIMENTAL|Group HRV Lot C|
61940986|NCT00285818|PLACEBO_COMPARATOR|Placebo Oral Capsule|Patients receive a placebo capsule one day before and for 5 additional days after starting ECT
61940987|NCT01863420||Rectal cancer patients|For rectal cancer patients before surgery, IMRT is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.The dose constraints for active bone marrow are V5\<95%, V10\<88%,V20\<80%,V30\<65%, V40\<45%.
62336018|NCT00757770|ACTIVE_COMPARATOR|Group Placebo|
62493080|NCT00913276|OTHER|Sevoflurane anesthesia|
62493081|NCT00913276|OTHER|Propofol anesthesia|
62493082|NCT05472415|EXPERIMENTAL|experimental group|cognicise training with insole intervention
62493083|NCT05472415|ACTIVE_COMPARATOR|control group|cognicise training
62336019|NCT00636376|EXPERIMENTAL|1|Single arm--no randomization. All subjects enrolled will have vitals collected and three ultrasounds at different levels of head of the bed elevations.
62336020|NCT02042495|EXPERIMENTAL|Metformin|"Metformin 500 mg PO TID from time of entry to study until scheduled surgical staging operation.~In cases of unresolving side effects, the metformin will be dose reduced to metformin 500 mg PO BID with evaluation after 1 week followed by withdrawal from the study if side effects persist."
62336021|NCT02149836|EXPERIMENTAL|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
62336022|NCT01123122|ACTIVE_COMPARATOR|Strict glucose control|
62493084|NCT05461157|EXPERIMENTAL|Preoperative silicone ointment|Participants will apply silicone ointment to the area where the surgical incision will be made, twice daily for 2-6 weeks prior to their scheduled surgery.
62493085|NCT05461157|PLACEBO_COMPARATOR|Preoperative placebo ointment|Participants will apply placebo ointment to the area where the surgical incision will be made, twice daily for 2-6 weeks prior to their scheduled surgery.
61940988|NCT01863420||Gastric cancer patients|For gastric cancer patients after surgery and chemotherapy,the 4500 cGy of radiation was delivered in 25 fractions, five days per week. Concurrent chemotherapy regimen is monotherapy with capecitabine 1600mg∙m2 twice a day (b.i.d.).The dose constraints for active bone marrow are V5\<90%, V10\<80%,V20\<70%,V30\<55%, V40\<35%.
61940989|NCT01743417|EXPERIMENTAL|Cognitive intervention|Children in this arm will receive computerised cognitive rehabilitation training for 24 sessions lasting 45 minutes. The Captain's log brain training software is programmed to increase in difficulty as child progresses through the training levels.
61940990|NCT01743417|ACTIVE_COMPARATOR|Active control|Children in this arm will receive 24 sessions of computerised cognitive rehabilitation training. Captain's log, the brain training software will not be programmed to increase in difficulty with each successive level in this arm.
61940991|NCT01743417|NO_INTERVENTION|Passive control|No computer training or games will be provided to this group
61940992|NCT02024555|ACTIVE_COMPARATOR|Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin|Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
61940993|NCT02024555|PLACEBO_COMPARATOR|Placebo|"Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.~The pill count will be the same as the comparator regimen."
61940994|NCT02486354|EXPERIMENTAL|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
61940995|NCT02020577|EXPERIMENTAL|combination arm|Patients to receive afatinib once daily plus weekly cetuximab infusion
61940996|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
62493086|NCT01583530|ACTIVE_COMPARATOR|Belimumab IV 240 mg|
62493087|NCT01583530|EXPERIMENTAL|Belimumab SC 2 x 120 mg|
62493088|NCT01583530|EXPERIMENTAL|Belimumab SC 1 x 240 mg|
62336023|NCT01123122|NO_INTERVENTION|Standard glucose control|
62336024|NCT06054022|EXPERIMENTAL|patient receiving high flow nasal cannula (A)|Patient will be put on high flow nasal cannula at a fixed flow of 50L/min, at Fio2 0.3% throughout surgery. Oxygen therapy will be discontinued once surgery ends. FiO2 will be titrated by 0.1 increment to a SpO2 of ≥94%.
62493089|NCT01583530|EXPERIMENTAL|Belimumab SC 1 x 200 mg|
61940997|NCT03048916|OTHER|general swallowing therapy|"including:~* oral exercises~* tactile stimulation~* compensatory techniques~* swallowing maneuvers"
61940998|NCT03048916|EXPERIMENTAL|the NMES therapy with VitalStim therapeutic device|The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS
61940999|NCT03048916|ACTIVE_COMPARATOR|: the combined NMES and general swallowing therapies|
61941000|NCT03761693|EXPERIMENTAL|Severe/classical MCADD|"Severe MCADD will be defined by ACADM mutations associated with clinical ascertainment or residual MCAD enzyme activity \< 10 %, as defined previously (Touw et al., 2012).~Interventions include fasting challenges at two and six months of age."
61941001|NCT03761693|EXPERIMENTAL|Mild MCADD|"Mild MCADD will be defined by the remaining ACADM genotype variants and residual MCAD enzyme activity ≥ 10%.~Interventions include fasting challenges at two and six months of age."
61941002|NCT02219035||stroke-ischaemic|no interventions
61941003|NCT02219035||stroke -haemorrhagic|no intervention
62493090|NCT01583530|EXPERIMENTAL|Belimumab SC 2 x 120 mg weekly|
61941004|NCT02219035||stroke: not confirmed|no intervention
61941005|NCT05657431|EXPERIMENTAL|group 1 (Ylang ylang oil)|A square cotton ball impregnated with a drop of ylang-ylang oil was placed in the participants randomized to group I (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
62336025|NCT06054022|ACTIVE_COMPARATOR|patient receiving nasoprong oxygen 2 L/min|Patient will be put nasoprong oxygen 2L/min throughout surgery. Oxygen therapy will be discontinued once surgery ends. FiO2 will be titrated by 0.1 increment to a SpO2 of ≥94%.
62336026|NCT04335266|EXPERIMENTAL|Treatment group A|Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2
62336027|NCT04335266|EXPERIMENTAL|Treatment group B|Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2
62336028|NCT03262532||Experimental|Learning TEE manipulation with a Web-based TEE simulation module
62336029|NCT03262532||Control|Learning a TEE manipulation without the Web-based TEE simulation
62493091|NCT01583530|EXPERIMENTAL|Belimumab SC 1 x 200 mg weekly|
62493092|NCT02349854||Cases|patients with scalp itch and seborrheic dermatitis who will get biopsy
62493093|NCT02349854||Controls|patients without scalp itch and without seborrheic dermatitis who will get biopsy
62493094|NCT04384224|PLACEBO_COMPARATOR|sham acupuncture + placebo tablet group|sham acupuncture point + placebo tablet
62493095|NCT04384224|EXPERIMENTAL|true acupuncture + placebo tablet group|true acupuncture point + placebo tablet
62493096|NCT04384224|EXPERIMENTAL|true acupuncture + antihistamine group|true acupuncture point + Dexchlorpheniramine (4 mg)
62493097|NCT04384224|SHAM_COMPARATOR|sham acupuncture + antihistamine group|sham acupuncture point + Dexchlorpheniramine (4 mg)
62493098|NCT01055886|ACTIVE_COMPARATOR|Nicotine Patch|Nicotine patch given pre-quit attempt at weeks 4 through 6
62493099|NCT01055886|PLACEBO_COMPARATOR|placebo patch|placebo patch given pre-quit from weeks 4 through 6
62493100|NCT01886222|EXPERIMENTAL|Long-term mild hypothermia|Focused intervention
62493101|NCT01886222|OTHER|Normothermia|Standard management
62493102|NCT04872608|EXPERIMENTAL|Letrozole, Palbociclib, and Onapristone ER|This study has two stages: a dose-finding stage and a dose expansion stage. Stage 1 of the study will utilize a standard 3+3 dose de-escalation design with a total of three dose levels of onapristone ER, 30mg PO BID, 40mg PO BID, and 50mg PO BID given on a 28-day cycle. Onapristone ER will be given in addition to letrozole 2.5mg QD and each patient's pre-enrollment dose of palbociclib.
62493103|NCT00868998|EXPERIMENTAL|Treatment|Gemcitabine, docetaxel, and capecitabine
62336030|NCT03330899|ACTIVE_COMPARATOR|15 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
62336031|NCT03330899|ACTIVE_COMPARATOR|7.5 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
62336032|NCT03330899|ACTIVE_COMPARATOR|3.75 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
62137697|NCT04875767|EXPERIMENTAL|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|Those allocated to the scaffold treatment group will have 30 ml of BMA harvested from the ipsilateral iliac crest under fluoroscopic guidance. The hip arthroscopy will then be resumed, and the damaged cartilage lesion will be debrided using a mechanical shaver to remove loose and calcified tissue. Once the walls of the lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The biodegradable HA-based scaffold (Hyalofast®; Anika Therapeutics, Bedford, MA, USA) will be prepared by cutting it to fit the focal defect. Once the cartilage lesion is dried manually, this scaffold will be implanted into the defect after it has been soaked in the BMA. The scaffold will then be secured to the defect in a press-fit fashion to the surrounding cartilage. In the case where additional fixation of the scaffold is needed, such as uncontained shoulder of cartilage, fibrin glue will be used to secure the scaffold.
62336033|NCT03330899|ACTIVE_COMPARATOR|15 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
62336034|NCT03330899|ACTIVE_COMPARATOR|7.5 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
62336035|NCT03330899|ACTIVE_COMPARATOR|3.75 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
62336036|NCT03330899|ACTIVE_COMPARATOR|15 mcg H7N9 without adjuvant|"Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
62336037|NCT03330899|PLACEBO_COMPARATOR|Placebo (PBS)|"Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
62336038|NCT03880240|EXPERIMENTAL|2 weeks of daily tACS sessions|10 daily (Monday-Friday) 1-hour sessions of tACS stimulation
62493104|NCT02396888|EXPERIMENTAL|Insulin|Half of the wound surface was treated daily with intermediate insulin. Allocation was randomized.
62493105|NCT02396888|PLACEBO_COMPARATOR|Placebo|Half of the wound surface was treated daily with normal saline. Allocation was randomized.
62493106|NCT05236062|EXPERIMENTAL|Exercise Group|"Home-based, virtually supervised via Zoom, 3x weekly for 12-weeks aerobic and resistance exercise program~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
62336039|NCT03880240|EXPERIMENTAL|4 weeks of daily tACS sessions|20 daily (Monday-Friday) 1-hour sessions of tACS stimulation
62336040|NCT03880240|EXPERIMENTAL|4 weeks of twice daily tACS sessions|20 days (Monday-Friday) of 1-hour sessions of tACS twice per day
62336041|NCT03880240|SHAM_COMPARATOR|2/4 weeks of Sham tACS sessions|10/20 days (Monday-Friday) of 1-hour sessions of tACS once/twice per day
62336042|NCT05966974||Patients treated with AGN1 LOEP|
62336043|NCT03340181|EXPERIMENTAL|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
62336044|NCT03340181|SHAM_COMPARATOR|control|patient in control group using a blood pressure cuff on an upper limb without inflating
62336045|NCT05726019|ACTIVE_COMPARATOR|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
62336046|NCT05726019|NO_INTERVENTION|Conventional treatment|The control group will follow conventional treatment guided by current guidelines.
62336047|NCT02843295|EXPERIMENTAL|Population of the study|3 stratification groups: Group 1: High immunologic risk Patients receiving a ≥ 2nd graft and/or Panel Reactive Antibody ≥ 30% and/or Human Leukocyte Antigen (HLA) mismatches ≥ 4 Group 2: High non-immunologic risk Donors over 60 years of age and/or Donor between 50 to 59 years of age who have died of stroke, or had a history of high blood pressure, or at the time of death had a creatininemia ≥ 135 µmol/L Group 3: Low risk Patients not included in Groups 1 or 2
62493107|NCT05236062|EXPERIMENTAL|Attention control Group|"Home-based, 12-week stretching program only with participants asked not to change their activity behavior.~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
62493108|NCT01214980|EXPERIMENTAL|MIST Therapy in conjunction with SOC|Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
62493109|NCT01214980|ACTIVE_COMPARATOR|Control arm|Standard of care treatment
62493110|NCT04071613|ACTIVE_COMPARATOR|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds).
62493111|NCT04071613|ACTIVE_COMPARATOR|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
62493112|NCT02392858|OTHER|influenza cohort|"Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.~1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.~Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms."
62493113|NCT02754076|EXPERIMENTAL|AX 250|In Part 1, patients will receive up to 3 escalating doses of AX 250 (30, 100 and 300 mg) via ICV infusion every week until the maximum tolerated tested dose (MTTD) is established. In Part 2, patients will receive weekly doses of AX 250 via ICV infusion that will continue for 48 weeks at the MTTD established in Part 1.
62493114|NCT01781234|EXPERIMENTAL|Intranasal Insulin|Intranasal Insulin
62493115|NCT01781234|PLACEBO_COMPARATOR|Placebo|Placebo
62493116|NCT05909696|EXPERIMENTAL|Age range of 18 to 44 years olds|Age range of 18 to 44 years olds The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium was according to the patients' myofibrillation level. If there is no myofibrillation (negative reaction), the dose of rocuronium in the next patient will be reduced until the patient has myofibrillation. If there is myofibrillation (positive reaction), the dose of rocuronium will be increased in the next patient until the patient is no fibrillation.
62493117|NCT05909696|EXPERIMENTAL|Age range of 45 to 59 years olds|Age range of 18 to 44 years olds The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium was according to the patients' myofibrillation level. If there is no myofibrillation (negative reaction), the dose of rocuronium in the next patient will be reduced until the patient has myofibrillation. If there is myofibrillation (positive reaction), the dose of rocuronium will be increased in the next patient until the patient is no fibrillation.
62493118|NCT05909696|EXPERIMENTAL|Age range of 60 to 80 years olds|Age range of 18 to 44 years olds The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium was according to the patients' myofibrillation level. If there is no myofibrillation (negative reaction), the dose of rocuronium in the next patient will be reduced until the patient has myofibrillation. If there is myofibrillation (positive reaction), the dose of rocuronium will be increased in the next patient until the patient is no fibrillation.
62493119|NCT01868243|EXPERIMENTAL|Dabigatran|Dabigatran 110 mg BID
62493120|NCT01868243|ACTIVE_COMPARATOR|Warfarin|Warfarin adjusted-dose
62493121|NCT01964950||Alogliptin|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with Sulfonylurea (SU) or without SU within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
62493122|NCT05274724|ACTIVE_COMPARATOR|Standard institutional protocol, without teleconsultation.|standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty.
62493123|NCT05274724|ACTIVE_COMPARATOR|Teleconsultation during the ambulance journey to the place of care.|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
62493124|NCT02818894|ACTIVE_COMPARATOR|Lidocaine prior to THA|Participants scheduled for Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
62493125|NCT02818894|ACTIVE_COMPARATOR|Bupivacaine prior to THA|Participants scheduled for Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
62493126|NCT03922750|EXPERIMENTAL|Insulin 287 (with 100% loading dose)|Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
62493127|NCT03922750|EXPERIMENTAL|Insulin 287 (without loading dose)|Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
62493128|NCT03922750|ACTIVE_COMPARATOR|Insulin glargine U100|Participants will receive insulin glargine U100 once daily (OD).
62493129|NCT02946424|EXPERIMENTAL|Simvastatin treatment|Simvastatin for one year time period
62493130|NCT02946424|PLACEBO_COMPARATOR|Placebo treatment|Placebo for one year time period
62493131|NCT01728116|EXPERIMENTAL|Device (EndoBarrier)|Device for glycemic control
62493132|NCT01728116|SHAM_COMPARATOR|Sham Procedure|sham procedure
62493133|NCT01485068|EXPERIMENTAL|Danubio|
62493134|NCT03475433||Beast cancer patients|All participants that suffer from breast cancer.
62493135|NCT03475433||Prostate cancer patients|All participants that suffer from prostate cancer.
62493136|NCT04956848|NO_INTERVENTION|Embryo selection supported by KIDScore™ D5|Each embryo reaching at least developmental stage of 3BB will annotated by an embryologist using the parameters required by the KIDScore™ D5. The embryo with the highest KIDScore™ will be selected proposed for transfer.
62493137|NCT04956848|EXPERIMENTAL|Embryo selection supported by iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed selected for transfer.
62493138|NCT05822726|EXPERIMENTAL|The combination of PSMA-PET/MR and p2PSA|
62493139|NCT05822726|ACTIVE_COMPARATOR|The combination of mpMRI and p2PSA|
62493140|NCT02416180|EXPERIMENTAL|SERETIDE EVOHALER|Subjects will switch from their current usual maintenance treatment of SERETIDE via DISKUS Inhaler to an equivalent dose of SERETIDE via the MDI (EVOHALER) at Visit 1. Subjects will use the MDI as 2 inhalations twice daily for approximately 14 days. Subjects will revert back to using SERETIDE DISKUS Inhaler again from Visit 2 (after 14 days) starting with the next scheduled dose.
62493141|NCT02510872|EXPERIMENTAL|18F-FDG PET combined with CT with iodinated contrast injection|18F-FDG PET combined with CT with iodinated contrast injection
62493142|NCT02510872|SHAM_COMPARATOR|18F-FDG PET combined with CT without injection|18F-FDG PET combined with CT without injection
62493143|NCT04384289|NO_INTERVENTION|''Standard Care''|''Standard Care'' group were given standard care services.
62493144|NCT04384289|EXPERIMENTAL|"Transitional Care Model"|"Transitional Care Model group were given care based on the Transitional Care Model until the post discharge 9th week starting from date of hospitalization."
62493145|NCT04163094|EXPERIMENTAL|Treatment arm|Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.
62493146|NCT02663661|OTHER|Autoantibody negative subjects|Subjects who are relatives of persons with T1DM and have tested negative for autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test.
62493147|NCT02663661|OTHER|One autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for one autoantibody will have a Metabolic Challenge Admission followed by a CGM home test..
62493148|NCT02663661|OTHER|Two or more autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for two or more autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test..
62493149|NCT01509391|EXPERIMENTAL|Keyhole-limpet hemocyanine|
62493150|NCT02096705|EXPERIMENTAL|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
62493151|NCT02096705|PLACEBO_COMPARATOR|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
62493152|NCT04129554|EXPERIMENTAL|JNJ-73763989+ JNJ-56136379+ NA|Participants will receive fixed dose of JNJ-73763989 subcutaneous injection once every 4 weeks along with fixed dose of JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir \[ETV\], tenofovir disoproxil fumarate \[TDF\], or tenofovir alafenamide \[TAF\]) once daily up to 48 weeks.
62493153|NCT04129554|PLACEBO_COMPARATOR|Placebo for JNJ-73763989+ Placebo for JNJ-56136379+ NA|Participants will receive matching placebo for JNJ-73763989 subcutaneous injection once every 4 weeks with matching placebo for JNJ-56136379 once daily and NA treatment (either ETV, TDF or TAF) once daily up to 48 weeks.
62493154|NCT00170469|EXPERIMENTAL|1|Low dose rPA vaccine
62493155|NCT00170469|EXPERIMENTAL|2|High dose rPA vaccine
62493156|NCT00170469|ACTIVE_COMPARATOR|3|Active vaccine control
61941006|NCT05657431|EXPERIMENTAL|group 2 (Lemon oil)|A square cotton ball impregnated with a drop of lemon oil was placed in the participants randomized to group 2 (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
62493157|NCT03093025|EXPERIMENTAL|TS-121 10mg|
62493158|NCT03093025|EXPERIMENTAL|TS-121 50mg|
62493159|NCT03093025|PLACEBO_COMPARATOR|Placebo|
61941007|NCT05657431|PLACEBO_COMPARATOR|group 3 (Control)|A square cotton ball impregnated with a drop of salin was placed in the participants randomized to group I (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
62493160|NCT04561115|ACTIVE_COMPARATOR|Gamunex-C|Participants received Gamunex-C by means of an infusion pump at a dose of 200 to 800 mg/kg per infusion at an infusion rate of 1 mg/kg/min or up to 8 mg/kg/min depending on participant tolerance. The participant's usual mg/kg dose (given on either a 3 or 4 week repeating schedule) was the same mg/kg dose and schedule that the participant was receiving prior to entering screening. This mg/kg dose and schedule were used throughout the study duration. Gamunex-C was administered every 3 weeks (±4 days) or 4 weeks (±4 days), depending on the participant's prior IVIG dosing schedule. The duration of Gamunex-C treatment included the Gamunex-C PK Phase (up to 4 weeks) plus the additional Gamunex-C Run-in Phase (up to 4.5 months) for participants not receiving Gamunex-C or not on a stable dose of Gamunex-C upon entering the trial. The approximate maximum duration was up to 6 months.
62493161|NCT04561115|EXPERIMENTAL|IVIG-PEG|Participants received IVIG-PEG by means of an infusion pump at a dose of 200 to 800 mg/kg per infusion at an infusion rate of 1 mg/kg/min or up to 8 mg/kg/min depending on participant tolerance. IVIG-PEG was administered every 3 weeks (±4 days) or 4 weeks (±4 days), depending on the participant's prior IVIG dosing schedule. The duration of IVIG-PEG treatment included the IVIG-PEG Treatment Phase (up to 4.5 months) and the IVIG-PEG PK Phase (up to 4 weeks), for an approximate maximum of up to 6 months.
62493162|NCT04550260|EXPERIMENTAL|Arm 1: Durvalumab + definitive CRT|Durvalumab + concurrent chemoradiation
62493163|NCT04550260|PLACEBO_COMPARATOR|Arm 2: Placebo + definitive CRT|Placebo + concurrent chemoradiation
62493164|NCT02858037|EXPERIMENTAL|HIV Open-label Prevention|"Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women~MTN-020:NCT01617096 MTN-025: NCT02858037"
62493165|NCT02387762|EXPERIMENTAL|ACP-196 + Methotrexate|Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
62493166|NCT02387762|PLACEBO_COMPARATOR|Placebo + Methotrexate|Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
62493167|NCT00550147|EXPERIMENTAL|1|Oros Methylphenidate and Quetiapine
62336048|NCT01914887|EXPERIMENTAL|allogeneic ASCs|Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
62336049|NCT05115279|OTHER|Breast conservative Surgury after neuadjvant chemotherapy|Breast conservative Surgury
62336050|NCT03591146|EXPERIMENTAL|TLC590 190mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
62336051|NCT03591146|EXPERIMENTAL|TLC590 380mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
61941008|NCT01864941|ACTIVE_COMPARATOR|Catheter Venography & Balloon Venoplasty|Patients will undergo catheter venography with balloon venoplasty procedure.
61941009|NCT01864941|SHAM_COMPARATOR|Catheter Venography Only|Patients will undergo catheter venography only.
61941010|NCT04576429|EXPERIMENTAL|experimental group|
61941011|NCT04576429|ACTIVE_COMPARATOR|comparator group|
62137698|NCT04875767|ACTIVE_COMPARATOR|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
62137699|NCT06143501||Allo-HSCT Recipients|
61941012|NCT00891007|EXPERIMENTAL|Group 1|
62336052|NCT03591146|EXPERIMENTAL|TLC590 570mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
62336053|NCT03591146|EXPERIMENTAL|TLC590 475mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
62336054|NCT03591146|ACTIVE_COMPARATOR|Naropin 150mg|Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
62336055|NCT02537301||ERCP-chat group|All the doctors who finished their ERCP training in Xijing Hospital of Digestive Diseases and were invited to join in a chatting group in a mobile social app (Wechat).
62336056|NCT04317352||Multivisceral resection (MRV)|MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
62336057|NCT04886999|EXPERIMENTAL|Inhaler A CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator."
62336058|NCT04886999|ACTIVE_COMPARATOR|Inhaler B CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator"
62336059|NCT05249088|EXPERIMENTAL|Protocolised reduction of non-resuscitation fluids|Participants receive non-resuscitation fluids according to a pre-defined protocol starting within two hours of randomization. The intervention is continued for the duration of the ICU admission up to a maximum of 90 days.
62336060|NCT05249088|OTHER|Usual Care|Participants receive non-resuscitation fluids according to local routines.
61941013|NCT00891007|EXPERIMENTAL|Group 2|
62137700|NCT06143501||Healthy Volunteers|
62336061|NCT05518734|EXPERIMENTAL|Part A: VX-708 (Cohort A1-A3)|Participants will receive multiple doses of one of different dose levels of VX-708 under fasting condition.
62336062|NCT05518734|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive placebo matched to VX-708.
62336063|NCT05518734|EXPERIMENTAL|Part A: Midazolam With or Without VX-708 (Cohort A4)|Participants will receive a single dose of Midazolam with or without VX-708 under fasting condition.
62493168|NCT03616691|EXPERIMENTAL|Atezolizumab|The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
61941014|NCT00891007|ACTIVE_COMPARATOR|Group 3|
61941015|NCT03267251|ACTIVE_COMPARATOR|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
61941016|NCT03267251|EXPERIMENTAL|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
61941017|NCT02409212|EXPERIMENTAL|Intervention|12 months of aerobic exercise training with behaviour change support
62137701|NCT01723267|ACTIVE_COMPARATOR|3D follicles assessment|During IVF treatment all ultrasound examinations will use 3D- SonoAVC technology. Timing of hCG injection and oocyte collection will be based on follicle volume and 3D-volume based diameter.
62137702|NCT01723267|ACTIVE_COMPARATOR|2D follicles assessment|During IVF treatment all ultrasound examinations will use standard 2D ultrasound. Timing of hCG injection and oocyte collection will be based on follicle diameter.
62137703|NCT03220724|EXPERIMENTAL|Part A: Group 1|Participants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
62137704|NCT03220724|EXPERIMENTAL|Part A: Group 2|Participants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
61941018|NCT02409212|PLACEBO_COMPARATOR|Comparison|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
61941019|NCT00632840|PLACEBO_COMPARATOR|P|placebo group
61941020|NCT00632840|ACTIVE_COMPARATOR|Feno|Fenofibrate
61941021|NCT00632840|ACTIVE_COMPARATOR|ATV|Atorvastatin
62493169|NCT03616691|EXPERIMENTAL|Atezolimab+Bevacizumab|Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy (stage 2). Both of drugs are administered via intravenous infusion every 3 weeks.
62493170|NCT03438643||Patient|Patients treated with ECP and corticosteroid as first-line treatment for cGVHD
62493171|NCT04554186|EXPERIMENTAL|Serratus anterior plane block|20 patients will receive SAP block with 0.4 ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
62493172|NCT04554186|ACTIVE_COMPARATOR|Thoracic Paravertebral block|20 patients will receive TPVB 0.4ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
62493173|NCT04554186|PLACEBO_COMPARATOR|Control group|20 patients will receive Fentanyl patch 50 microgram
62493174|NCT00881426|EXPERIMENTAL|1|Cefprozil 500 mg Tablets (Sandoz GmbH)
62137705|NCT03220724|EXPERIMENTAL|Part A: Group 3|Participants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
62493175|NCT00881426|ACTIVE_COMPARATOR|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
62493176|NCT04844411|EXPERIMENTAL|Arm A: JNJ-67835989 (Oral Suspension)|Participants will receive a single oral suspension dose of JNJ-67835989 on Day 1 in Part 1 and Part 2.
62493177|NCT04844411|PLACEBO_COMPARATOR|Arm B: Placebo|Participants will receive a single oral solution placebo on Day 1 in Part 1 only (except food effect cohorts).
62737588|NCT04947345|ACTIVE_COMPARATOR|Positive control group: Propofol|"Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of propofol is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.3-4.0 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and propofol, no analgesic or sedative could be used during the experimental time period.~Rescue therapy for experimental group During the treatment of the experimental group, if the RASS cannot be maintained at 0 to -2 points at the maximum Remimazolam maintenance dose of 1 mg/kg/h, a loading dose of propofol (0.2 mg/kg) can be given intravenously. If RASS fails to satisfied after three loading doses of propofol, Remimazolam is discarded and 0.3-4.0 mg/kg/h of propofol are used as rescue therapy for experimental group."
62137706|NCT03220724|PLACEBO_COMPARATOR|Part A: Group 4|Participants will receive placebo at Months 0, 2, 4, 8, and 12.
62493178|NCT04844411|EXPERIMENTAL|Arm C: JNJ-67835989 (Oral Solid Dose)|Participants will receive a single oral solid dose (tablet) of JNJ-67835989 on Day 1 in Part 3.
62493179|NCT06533215|ACTIVE_COMPARATOR|Group 1: Chlorohexidine (CHX) gel.|Application of Chlorohexidine intracanal medication in secondry endodontic infection cases
62493180|NCT06533215|ACTIVE_COMPARATOR|Group 2: Chlorohexidine loaded by silver nanoparticles (Ag-np) gel.|Application of chlorohexidine loaded by silver nanoparticles (Ag-np) gel intracanal medication in secondry endodontic infection cases
62493181|NCT06533215|ACTIVE_COMPARATOR|Group 3: Triple antibiotic-loaded chitosan nanoparticles (tachnp) gel.|Application of triple antibiotic-loaded chitosan nanoparticles (tachnp) gelintracanal medication in secondry endodontic infection cases
62493182|NCT03191305|ACTIVE_COMPARATOR|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
62493183|NCT03191305|ACTIVE_COMPARATOR|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
62493184|NCT03302949|NO_INTERVENTION|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
62137707|NCT03220724|EXPERIMENTAL|Part B: Group 5|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4, and 8. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
62137708|NCT03220724|EXPERIMENTAL|Part B: Group 6|Participants will receive CH505TF at Month 0; CH505TF and CH505w53 at Month 2; CH505TF, CH505w53, and CH505w78 at Month 4; CH505w53 and CH505w78 at Month 8. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
62137709|NCT03220724|EXPERIMENTAL|Part B: Group 7|Participants will receive CH505 M5 (admixed with GLA-SE) at Months 0, 2, 4, and 8.
62137710|NCT03220724|PLACEBO_COMPARATOR|Part B: Group 8|Participants will receive placebo at Months 0, 2, 4, and 8.
62137711|NCT03220724|EXPERIMENTAL|Part C: Group 9|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4.
62493185|NCT03302949|EXPERIMENTAL|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
62493186|NCT01749085|EXPERIMENTAL|Sequence 1|
62493187|NCT01749085|EXPERIMENTAL|Sequence 2|
62493188|NCT05912335|ACTIVE_COMPARATOR|Topical anesthetic available on the market - Lidocaine (2.5%), Prilocaine (2.5%)|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg."
62493189|NCT05912335|PLACEBO_COMPARATOR|Xanthan hydrogel 2%|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg."
62493190|NCT05912335|EXPERIMENTAL|Xanthan hydrogel (2%), Lidocaine (2.5%), Prilocaine (2.5%) in NLC|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg. Local Anesthetic encapsulated in nanostructured lipid carriers (NLC)"
62493191|NCT05912335|EXPERIMENTAL|Xanthan hydrogel (2%), Lidocaine (2.5%), Prilocaine (2.5%)|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg."
62493192|NCT04117880|EXPERIMENTAL|Ataluren|Ataluren Oral suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).
62493193|NCT01491464|EXPERIMENTAL|rhBMP-2/ACS|
62493194|NCT01491464|ACTIVE_COMPARATOR|Autogenous bone|
62493195|NCT02545530|ACTIVE_COMPARATOR|transdermal clonidine+|apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.
62493196|NCT02545530|NO_INTERVENTION|transdermal clonidine-|regular antihypertensive treatment
62695376|NCT05631119||Chronic Kidney Disease|"Sample Collection:~* Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Whole blood will be collected in 4 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 million cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am"
61941022|NCT04098848|EXPERIMENTAL|Intradialytic exercise|Cycling exercise 30 minutes a time, three times a week during hemodialysis
61941023|NCT04098848|NO_INTERVENTION|Control group|not participate in cycling exercise during hemodialysis
62336064|NCT05518734|EXPERIMENTAL|Part B: VX-708 With Itraconazole|Participants will receive a single dose of VX-708 in treatment period 1, followed by itraconazole, which will be dosed daily with a single dose of VX-708 administered in treatment period 2 under fasting conditions. A washout period of 6 days will be maintained between the 2 treatment periods.
62336065|NCT00731263|EXPERIMENTAL|1|The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
62336066|NCT03534063|ACTIVE_COMPARATOR|CYP2D6-guided opioid therapy|Participants randomized to the CYP2D6-guided arm will have their CYP2D6 genotyping completed prior to surgery (in the absence of any genotyping error) with results reported in the electronic health record (EHR). Patients will be categorized as CYP2D6 PM, IM, NM, or UM based on CYP2D6 genotype/activity score and FDA guidance on drug interactions. Strong inhibitors (e.g. bupropion, fluoxetine, paroxetine) phenoconvert patients to PMs, with moderate inhibitors (e.g. duloxetine, fluvoxamine) reducing CYP2D6 activity scores by 50%.
62336067|NCT03534063|NO_INTERVENTION|Usual Care|Participants randomized to the usual care arm will have their DNA collected at the start of the study and stored at the lab until after they have completed their surgery and the 2-week follow-up, at which time, their sample was genotyped with the results reported in the EHR.
62336068|NCT06146296|EXPERIMENTAL|Intra-epidermal Vitamin C injection|
62336069|NCT06146296|ACTIVE_COMPARATOR|Oral Vit-C supplement|
62336070|NCT06146296|NO_INTERVENTION|Control group|
62336071|NCT03237988|ACTIVE_COMPARATOR|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
62336072|NCT03237988|ACTIVE_COMPARATOR|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
62336073|NCT03237988|ACTIVE_COMPARATOR|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
62336074|NCT04136080|OTHER|chronic hypertension group|septic patients with chronic hypertension
62336075|NCT04136080|OTHER|denying chronic hypertension group|septic patients without chronic hypertension
62336076|NCT05655637|EXPERIMENTAL|Treatment Group|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
62336077|NCT05973994||Patients with significant calcific coronary artery stenosis candidate to PCI|Patients with coronary artery calcifications responsible for significant stenosis will undergo basal OCT acquistion. After intravascular lithotripsy (IVL) application, a second OCT acquisition will be made. The mean calcium density of the vessel's ROI before IVL and after IVL will be compared. Stent implantation will be performed after the second OCT acquisition.
62336078|NCT04284904||matched sibling hematopoietic stem cell transplantation|aGVHD biomarker in matched sibling donor hematopoietic stem cell transplantation
62336079|NCT04284904||unrelated allogeneic hematopoietic stem cell transplantation|aGVHD biomarker in unrelated donor hematopoietic stem cell transplantation
61941024|NCT01044706|EXPERIMENTAL|Bicalutamide 50 mg Tablet|Bicalutamide 50 mg Tablet
61941025|NCT01044706|ACTIVE_COMPARATOR|Casodex® 50 mg Tablet|Casodex® 50 mg Tablet
62336080|NCT04284904||haploidentical hematopoietic stem cell transplantation|aGVHD biomarker in haploidentical donor hematopoietic stem cell transplantation
61941026|NCT04454164|EXPERIMENTAL|PRP group|Intraarticular 5 ml single PRP injection
61941027|NCT04454164|PLACEBO_COMPARATOR|Saline group|Intraarticular 5 ml single saline injection
61941028|NCT04454164|EXPERIMENTAL|Multiple PRP group|Intraarticular 3 dose of 5 ml PRP injection (0, 1, 3 month injection)
61941029|NCT04454164|PLACEBO_COMPARATOR|Multiple saline group|Intraarticular 3 dose of 5 ml saline injection (0, 1, 3 month injection)
61941030|NCT02344862|ACTIVE_COMPARATOR|FYU-981 High dose|
61941031|NCT02344862|ACTIVE_COMPARATOR|FYU-981 Middle dose|
61941032|NCT02344862|ACTIVE_COMPARATOR|FYU-981 Low dose|
61941033|NCT02344862|PLACEBO_COMPARATOR|Placebo|
61941034|NCT04390061|EXPERIMENTAL|tofacitinib+HYQ|Tofacitinib 10mg cp twice a day + Hydroxychloroquine 200mg cp three times a day, both for 14 days
62493197|NCT03386461|EXPERIMENTAL|Exercise + Omega 3 supplementation|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly (Senior Fitness, and Faculty of Physical Education and Sport). Subjects will take 5 capsules od Calanus oil (containing approx. 250 mg EPA and DHA per day).
62493198|NCT03386461|PLACEBO_COMPARATOR|Exercise + placebo|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly. Subjects will take 5 capsules od placebo per day (provided by Calanus oil company, containing sunflower oil).
62737589|NCT02988947|EXPERIMENTAL|Intervention Group (PNE+HyP)|Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
61941035|NCT04390061|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine 200mg cp three times a day for 14 days
61941036|NCT04738487|EXPERIMENTAL|Pembrolizumab/Vibostolimab|Participants will receive pembrolizumab/vibostolimab as a coformulation (MK-7684A).
61941037|NCT04738487|ACTIVE_COMPARATOR|Pembrolizumab|Participants will receive pembrolizumab (MK-3475) alone.
61941038|NCT01785420|EXPERIMENTAL|Drug Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
61941039|NCT01785420|PLACEBO_COMPARATOR|Control|A 90 minute intravenous infusion of saline as placebo
61941040|NCT02932423|OTHER|1 - Snack|Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
61941041|NCT02932423|OTHER|2 - No snack|Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
62336081|NCT00538824|EXPERIMENTAL|DexTR (all patients)|All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.
61941042|NCT06319131|EXPERIMENTAL|TIPS group|The cirrhotic patients with persistent PVT despite 6 months of anticoagulation therapy will receive transjugular-intrahepatic-portosystemic shunt.
61941043|NCT06319131|ACTIVE_COMPARATOR|Nadroparin group|The cirrhotic patients with persistent PVT despite 6 months of anticoagulation therapy will continue with the nadroparin therapy
61941044|NCT01491971|EXPERIMENTAL|Degarelix - Cohort 1|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
62336082|NCT05366972|ACTIVE_COMPARATOR|Patients diagnosed with low back pain|Measurements of the back muscles and thoracolumbar fascia will be made by ultrasonography.
62336083|NCT05366972|ACTIVE_COMPARATOR|Healthy volunteers|Measurements of the back muscles and thoracolumbar fascia will be made by ultrasonography.
62336084|NCT01232894|EXPERIMENTAL|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
62336085|NCT01232894|ACTIVE_COMPARATOR|Long-acting beta2-agonist|Participants' current long-acting beta2-agonist (LABA) bronchodilator therapy
62336086|NCT04538092|NO_INTERVENTION|Control|Standard post op complex spine orders placed for patients undergoing deformity correction
62336087|NCT04538092|EXPERIMENTAL|ERAS|Enhanced recovery after surgery protocol is applied to the patients undergoing deformity correction
62737590|NCT02988947|NO_INTERVENTION|Control Group|No intervention / Standard care
61941045|NCT01491971|EXPERIMENTAL|Degarelix - Cohort 2|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
61941046|NCT01491971|EXPERIMENTAL|Degarelix - Cohort 3|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
61941047|NCT03737604|ACTIVE_COMPARATOR|Ropivacaine Continuous Infusion Catheter|Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg/kg) and maintained with 0.2% ropivacaine infusion 8 ml/hour via catheter.
61941048|NCT03737604|ACTIVE_COMPARATOR|Single dose liposomal bupivicaine|Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.
62336088|NCT03927508|EXPERIMENTAL|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
62336089|NCT00824187|EXPERIMENTAL|Arm 1|
62336090|NCT00824187|PLACEBO_COMPARATOR|Arm 2|
62336091|NCT01237106|EXPERIMENTAL|In Vitro Maturation (IVM)|
62336092|NCT05249231|ACTIVE_COMPARATOR|Hall technique|group of carious primary molars to be treated by hall technique
62336093|NCT05249231|EXPERIMENTAL|silver diamine fluoride|group of carious primary molars to be treated by silver diamine fluoride
62336094|NCT01037504|EXPERIMENTAL|A|Drug: AZD5423
62336095|NCT01037504|PLACEBO_COMPARATOR|B|Drug: Placebo
62336096|NCT01214746|PLACEBO_COMPARATOR|Placebo|
62336097|NCT01214746|ACTIVE_COMPARATOR|Atorvastatin|
62336098|NCT06395428|EXPERIMENTAL|Haloperidol|Haloperidol 5 mg IM haloperidol
62336099|NCT06395428|ACTIVE_COMPARATOR|Ketoralac|Ketoralac 30 mg IM
62336100|NCT03918603|EXPERIMENTAL|ultra-protective multimodal ventilation group|Patient will be diposed on ventral decubitus: one session at least more than 12 hours between inclusion and H48
62336101|NCT03918603|NO_INTERVENTION|protective ventilation group|Patient will received usual care
62336102|NCT00703755|EXPERIMENTAL|1|
62336103|NCT00703755|EXPERIMENTAL|2|
62336104|NCT00703755|EXPERIMENTAL|3|
62336105|NCT00703755|EXPERIMENTAL|4|
62336106|NCT00703755|EXPERIMENTAL|5|
62336107|NCT00703755|EXPERIMENTAL|6|
62336108|NCT00703755|PLACEBO_COMPARATOR|7|
62336109|NCT01434888|ACTIVE_COMPARATOR|Tafluprost 0.0015%|
62336110|NCT01434888|ACTIVE_COMPARATOR|Timolol 0.5%|
62695377|NCT05631119||Type 2 Diabetes|"Sample Collection:~* Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Whole blood will be collected in 8 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 mL cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am."
61941049|NCT01336296|ACTIVE_COMPARATOR|Myfortic preload|Initiation of mycophenolic acid (Myfortic) 2 weeks prior to transplantation (with Simulect induction at time of transplant)
61941050|NCT01336296|ACTIVE_COMPARATOR|Myfortic standard|mycophenolic acid (Myfortic) at time of transplant with Thymoglobulin induction
61941051|NCT04274387|EXPERIMENTAL|MBSR group|participants who receiving 8-week MBSR between the pretest and posttest
61941052|NCT04274387|NO_INTERVENTION|passive control group|participants who not undergoing any interventions for 8 weeks between the pretest and posttest
62336111|NCT01434888|EXPERIMENTAL|Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%|
62336112|NCT02351258|EXPERIMENTAL|Usual Care only, then Usual Care + 70% Isopropyl Alcohol|Usual care for central line while patients are at home and then switch to usual care plus 70% isopropyl alcohol after washout.
62336113|NCT02351258|EXPERIMENTAL|Usual Care + 70% Isopropyl Alcohol, then Usual Care only|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting and then switch to usual care only after washout.
62336114|NCT02645656|EXPERIMENTAL|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals.
62336115|NCT05397899|EXPERIMENTAL|AHT group|This group will receive Abdominal hypopressive exercises. Each AHT will be repeated 3-5 times with 1 min rest between exercises (shift to new posture, lying,sitting and standing). Between 6 and 15 hypopressive exercises (HEs) will be performed within each session based on the participant's mastery of the exercises and readiness to progress, for 6 weeks.
62336116|NCT05397899|ACTIVE_COMPARATOR|General exercise group|This group will receive general exercises (Bridging, knee to chest, Straight leg rise) these will be repeated 3-5 times with 1 min rest between exercises. Between 6 and 15 repetitions will be performed within each session based on the participant's mastery of the exercises and readiness to progress. Each exercise to be repeated 3-5 times per set, and participants will be asked to perform technique once daily for 6 weeks
62336117|NCT05468944|EXPERIMENTAL|Transanal group|Participants in this group underwent robotic surgery with transanal specimen extraction
62336118|NCT05468944|ACTIVE_COMPARATOR|Transabdominal group|Participants in this group underwent robotic surgery with transabdominal specimen extraction
62695378|NCT05631119||Healthy Matched Controls|"Sample Collection:~* Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Whole blood will be collected in 16 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 mL cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~* Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am."
61941053|NCT00921401|EXPERIMENTAL|Asthma Feedback|Each month and before all visits with their asthma care provider, participants will be encouraged to go online and answer a series of questions regarding the types of asthma medications they use and how often they use them, asthma symptoms they have experienced, emergency department visits in the past year, the care they have received for their asthma (e.g., specialist visits) in the past year, and the planned date of their next visit with their asthma care provider. Participants will receive tailored feedback about what questions they should ask their doctor during a subsequent visit, whether or not they should schedule a visit sooner, and links to read more about each recommendation.
61941054|NCT00921401|ACTIVE_COMPARATOR|Preventive Feedback|Each month and before all visits with their primary care provider, participants will be encouraged to go online and answer a series of questions regarding their preventive care. They will receive tailored feedback regarding preventive services, such as pap testing, cancer screenings, and flu shots. Participants will receive tailored feedback regarding preventive services (e.g., cancer screening) that they should discuss with their primary care provider.
61941055|NCT05272878|ACTIVE_COMPARATOR|IRBESARTAN|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit, based on clinical and biological tolerance. Treatment will be continued for 12 months, unless a side effect would occur.
62336119|NCT02704221|ACTIVE_COMPARATOR|Behavioral Parent Training (BPT)|The control group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks and 2) attend 12 weekly BPT training sessions.
62336120|NCT02704221|EXPERIMENTAL|BPT + Contingency Management (BPT+CM)|The experimental group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks, 2) attend 12 weekly BPT training sessions, and 3) receive monetary rewards for achieving weekly step-count goals.
62336121|NCT00153894|ACTIVE_COMPARATOR|Group A|Immediate Exercise
62336122|NCT00153894|ACTIVE_COMPARATOR|Group B|Delayed Exercise (delay by 16 weeks)
62336123|NCT04949841|EXPERIMENTAL|As-needed treatment with delgocitinib|Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.
62336124|NCT00835887|EXPERIMENTAL|1|Treatment with low dose flavanoids
62336125|NCT00835887|EXPERIMENTAL|2|Treatment with high dose flavanoids
62336126|NCT05005741|EXPERIMENTAL|Beinaglutide|
62336127|NCT05005741|ACTIVE_COMPARATOR|Dulaglutide|
62336128|NCT05804006|EXPERIMENTAL|HIIT-REC|High-intensity interval training program on a recumbent cycle SOLE R92 (HIIT-REC)
62336129|NCT01266655|EXPERIMENTAL|Baclofen|
62336130|NCT01266655|PLACEBO_COMPARATOR|Placebo|
62336131|NCT02702427|EXPERIMENTAL|ARM 1|Patients with Adenovirus or CMV infection after HSCT and no reduction of viral disease or stable disease with 10E6 viral copies within 2 weeks of antiviral treatment will receive a single infusion of virus-specific T-Cells
62336132|NCT00011713||Infertility patients|Patients undergoing infertility treatment at Massachusetts General Hospital Infertility Clinic.
62336133|NCT03710941|EXPERIMENTAL|REGN2477+REGN1033|Single, sequential, repeat-dose IV or matching placebo
62336134|NCT03710941|EXPERIMENTAL|Placebo|Single, sequential, repeat-dose IV
62336135|NCT04501679|EXPERIMENTAL|Nemolizumab|Participants weighing less than (\<) 90 kilogram (kg) received two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W). Participants weighing greater than or equal to (\>=) 90 kg received two SC injections of 30 mg nemolizumab (60 mg total) at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
62336136|NCT04501679|PLACEBO_COMPARATOR|Placebo|Participants weighing \< 90 kg received two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing \>= 90 kg received two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
62336137|NCT00946946|EXPERIMENTAL|Azathioprine|2.0-2.5 mg/kg/BW azathioprine tablets/day AND mesalazine placebo tablets
62336138|NCT00946946|ACTIVE_COMPARATOR|Mesalazine|4g mesalazine tablets/day AND azathioprine placebo tablets
62336139|NCT01259856|EXPERIMENTAL|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
62336140|NCT01259856|ACTIVE_COMPARATOR|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
62336141|NCT00646971|EXPERIMENTAL|1|CPAP
62336142|NCT00646971|SHAM_COMPARATOR|2|sham CPAP
62336143|NCT01604304|ACTIVE_COMPARATOR|Extracorporeal shockwave lithotripsy|stone treatment using electroconductive technology
62493199|NCT03185741|EXPERIMENTAL|UMS Strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record.~1. Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~2. Single-page, plain language medication information sheets with important medication-related information following health literacy best practices."
62493200|NCT03185741|EXPERIMENTAL|UMS Strategy + SMS Text Messaging|In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.
62493201|NCT03185741|NO_INTERVENTION|Usual Care|Patients of providers randomized to the usual care arm will receive their standard care
62493202|NCT05244928|EXPERIMENTAL|Cluster 1.|The clusters will be formed from two ambulance stations (Approximately 50 participants).
62493203|NCT05244928|EXPERIMENTAL|Cluster 2.|The clusters will be formed from five ambulance stations (Approximately 70 participants).
62493204|NCT02245503||Benign prostatic hyperplasia|Patients with symptomatic BPH to whom ALNA was prescribed
62493205|NCT01710280|ACTIVE_COMPARATOR|Native palm olein|75 g native palm olein
62336144|NCT01604304|ACTIVE_COMPARATOR|Flexible ureteroscopy|intra renal retrograde surgery with or without laser and stone extraction
62493206|NCT01710280|EXPERIMENTAL|Interesterified palm olein|75 g interesterified palm olein
62493207|NCT00695045|EXPERIMENTAL|1|patients in this group got 100mcg of intrathecal morphine.
62493208|NCT00695045|EXPERIMENTAL|2|patients in this group got 200 mcg intrathecal morphine
62493209|NCT00695045|EXPERIMENTAL|3|patients in this group given 300 mcg intrathecal morphine.
62493210|NCT00283842|EXPERIMENTAL|desvenlafaxine succinate sustained-release (DVS SR) 50mg|
62493211|NCT00283842|EXPERIMENTAL|desvenlafaxine succinate sustained-release (DVS SR) 100mg|
62493212|NCT00283842|EXPERIMENTAL|desvenlafaxine succinate sustained-release (DVS SR) 200mg|
62493213|NCT00283842|EXPERIMENTAL|desvenlafaxine succinate sustained-release (DVS SR) 400mg|
62493214|NCT00283842|PLACEBO_COMPARATOR|Placebo|
62493215|NCT01656876|EXPERIMENTAL|Mirror therapy|mirror box training with or without sham mesh glove stimulation
62493216|NCT01656876|EXPERIMENTAL|Mirror therapy + Mesh glove stimulation|Mirror therapy combined with mesh glove stimulation
62336145|NCT00715611|EXPERIMENTAL|1|This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.
62336146|NCT05948410||Study Group|Patients with an indication of invasive urodynamic study
62336147|NCT03820037|ACTIVE_COMPARATOR|OPC, Ongentys|Single oral doses of 50 mg opicapone, administered using the reference (Ongentys ®) active pharmaceutical ingredient (API) source
62336148|NCT03820037|EXPERIMENTAL|BIA 9-1067|Single oral doses of 50 mg opicapone, administered using the test (BIA 9-1067)
62336149|NCT02602938|EXPERIMENTAL|aspirin|"* The included patients will be administered with aspirin (100mg) orally once a day in 28-day cycles.~* The CTC was evaluated at baseline, and every 28 days for 2 months."
62336150|NCT01795898|EXPERIMENTAL|Fentanyl transdermal patch|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
62336151|NCT05403749|EXPERIMENTAL|IBI302 dose 2 group|Drug: Aflibercept 8mg/eye;Intraocular injection
62336152|NCT05403749|ACTIVE_COMPARATOR|Aflibercept|Drug: Aflibercept 2mg/eye;Intraocular injection
62493217|NCT01656876|ACTIVE_COMPARATOR|Controlled intervention|conventional interventions
62493218|NCT01235260||001|Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)
62737591|NCT05772689|ACTIVE_COMPARATOR|Usual Care|Standard of Care
62493219|NCT01235260||002|Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
62493220|NCT05193734|EXPERIMENTAL|Group Pertagen|
61941056|NCT05272878|PLACEBO_COMPARATOR|Placebo|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit, based on clinical and biological tolerance. Treatment will be continued for 12 months, unless a side effect would occur.
61941057|NCT03855956|EXPERIMENTAL|KB174 Arm|KB174 is a novel mixture of oligosaccharides.
61941058|NCT03855956|OTHER|Maltodextrin Arm|Maltodextrin is a commercially available easily digestible polysaccharide.
61941059|NCT02715245|EXPERIMENTAL|Experimental Group|Patients with multiple chronic disease referred to Mobile Rehabilitation and Physical therapy team (MRPTT) and Nurse-led case Management in the province of Almeria that comply the inclusion criteria; as well as their caregivers.
61941060|NCT02715245|NO_INTERVENTION|Control Group|Patients with multiple chronic disease and their caregivers belonging to health centers or areas where there is no figure MRPTT or Nurse-led case Management to reach this population
61941061|NCT01554085|EXPERIMENTAL|ALS-002158|
61941062|NCT01554085|PLACEBO_COMPARATOR|Placebo|
61941063|NCT01638364|ACTIVE_COMPARATOR|alcoholic beverage|95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
61941064|NCT01638364|PLACEBO_COMPARATOR|non-alcoholic beverage|Orange juice and tonic water.
61941065|NCT01013350||Never Exposed to Cladribine|All participants who received placebo matched to cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826 , NCT00641537, NCT00938366 and NCT00725985).
61941066|NCT01013350||Exposed to Cladribine|All participants who received cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826, NCT00641537, NCT00938366 and NCT00725985).
61941067|NCT02932215|EXPERIMENTAL|All participants|All participants will receive open label lorcaserin
61941068|NCT01800396|PLACEBO_COMPARATOR|Milk protein|Milk powder, twice daily at breakfast and dinner.
62336153|NCT05403749|EXPERIMENTAL|IBI302 dose 1 group|Drug: Aflibercept 6.4mg/eye;Intraocular injection
62336154|NCT01124201|EXPERIMENTAL|Stabilization group|In the Segmental Stabilization group exercises focused on the transversus abdominis and lumbar multifidus muscles.
62336155|NCT01124201|EXPERIMENTAL|Strengthening group|In the Superficial Strengthening group, exercises focused on the rectus abdominis, abdominus obliquus internus, abdominus obliquus externus and erector spinae muscles.
62336156|NCT01124201|EXPERIMENTAL|Stretching group|Stretching group: erector spinae, posterior connective tissues and ischiotibials muscles
61941069|NCT01800396|EXPERIMENTAL|Milk protein rich in phospholipids|Milk powder, twice daily at breakfast and dinner.
61941070|NCT03839498|EXPERIMENTAL|Axitinib (AG-013736)|Subjects with Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma will receive 16 weeks of therapy (Axitinib), and be seen in clinic every 4 weeks to monitor therapy.
61941071|NCT02337270|EXPERIMENTAL|Group 1 Aerosol|Receive 10\^6 Ad5Ag85A by aerosol at day 0
62336157|NCT04068324|NO_INTERVENTION|8 hours fasting group|Routine preoperative fasting group undergoes 8 hours of fasting before the operation.
62336158|NCT04068324|EXPERIMENTAL|Clear liquid group|"30 pediatric patients drink 3ml/kg 1 hour before the surgery. Although clear liquid suggests any drinks that do not contain any solid ingredients, but in this study we define clear liquid as water."
62336159|NCT04068324|EXPERIMENTAL|Carbohydrate containing liquid group|"Other 30 pediatric patients drink 3ml/kg of carbohydrate containing fluid 1 hour before the surgery. The product name we have is NoNPO from NewCare (South Korean company). This fluid does not contain any solid ingredients, so consuming the fluid does not exceed Nil per Os time needed before the surgery."
62493221|NCT05193734|ACTIVE_COMPARATOR|Group Control|
62493222|NCT02721563|ACTIVE_COMPARATOR|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 \~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
61941072|NCT02337270|EXPERIMENTAL|Group 2 Aerosol|Receive 2x10\^6 Ad5Ag85A by aerosol at day 0
61941073|NCT02337270|EXPERIMENTAL|Group 3 Intramuscular|Receive 10\^8 Ad5Ag85A by intramuscular injection at day 0
61941074|NCT03403374|EXPERIMENTAL|Evolocumab|Evolocumab 420 mg subcutaneous (SC) once monthly (QM) or every 2 weeks (Q2W; for participants on apheresis).
61941075|NCT02772055|EXPERIMENTAL|moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
61941076|NCT02772055|EXPERIMENTAL|smoke-free moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants and have a purification device at the top of the moxibustion to remove the moxa smoke.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
62137712|NCT04345068|EXPERIMENTAL|Calm Meditation|"The intervention will be 8-weeks in duration and will consist of a series of pre-approved meditation classes. Patients will be asked to participate in at least 10 min/day of meditation (i.e., \~70 min/week). Week 1-4 will consist of the 7 Days of Calm followed by the 21 Days of Calm, which are introductory courses offered by Calm and provide basic, introductory meditation classes for beginners. Weeks 5-8 will consist of patients participating in the Daily Calm that Calm provides, consisting of 10-12 min meditation classes that have a unique focus each day. Patients will be instructed to participate in at least 10 min/day of meditation, but will be encouraged to do more if they can."
62336160|NCT02262039|ACTIVE_COMPARATOR|Conventional Pressure|Conventional Insufflation with 15mmHg target pressure
62695379|NCT04035486|ACTIVE_COMPARATOR|Osimertinib 80mg QD|"Osimertinib (AZD9291) 80mg QD.~All patients randomized into this will only receive Osimertinib 80mg.~Dose may be reduced to allow for the management of IP related toxicity."
62493223|NCT02721563|PLACEBO_COMPARATOR|Control Group|"Placebo：dissolved in 100mlphysiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 6 weeks course.Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 \~ D5, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
62493224|NCT01465113|EXPERIMENTAL|Indefinite, LGD or no dysplasia arm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
62493225|NCT01465113|EXPERIMENTAL|high grade dysplasia|Barrett's esophagus with high grade dysplasia
62493226|NCT01465113|EXPERIMENTAL|Indefinite, LGD or no dysplasia arm:Vitamin D/Metformin Subarm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
62493227|NCT02488057|ACTIVE_COMPARATOR|Diet-induced weight loss|Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
62493228|NCT02488057|ACTIVE_COMPARATOR|Weight loss plus liraglutide|Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.
62493229|NCT04671147||Skull tong femoral traction|
62493230|NCT04671147||Cotrell longitudinal traction|
62493231|NCT03985124|EXPERIMENTAL|Intervention TIK-T|24 kindergartens will receive the full intervention. Dosage: 1 3 hour implementation session for kindergarten leaders; 1 x 2-day training workshop for kindergarten leaders and a lead resource person in each kindergarten who will support teachers in learning and implementing Emotion Coaching with children; 2 full training days for all teachers/childcare workers in Emotion Coaching; 2 x booster sessions for all teachers with the resource person in their kindergarten to assist them in using Emotion Coaching with children in their kindergartens.
62493232|NCT03985124|NO_INTERVENTION|wait list control|24 kindergartens will be in the 12-month wait list condition
62493233|NCT03596710|EXPERIMENTAL|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
62493234|NCT02582190|OTHER|Colchicine group|Colchicine add on therapy in atrial fibrillation
62493235|NCT06154993|EXPERIMENTAL|static opener with slider + Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Conventional PT includes hot pack for 10 mins and cervical isometrics."
62493236|NCT06154993|EXPERIMENTAL|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics."
62493237|NCT03651973|EXPERIMENTAL|With learning workshops|Patients in experimental arm will attend learning workshops, one before breast cancer surgey and one after surgery. Patients will be educated by physiologist to self massages and self stretching. Each workshop will last around 2 hours.
62493238|NCT03651973|OTHER|Without learning workshops|Standard follow-up. Patients randomized in this arm won't attend Learning workshops and will be followed in a standard way.
62336161|NCT02262039|EXPERIMENTAL|Low Pressure (VTI)|Valveless recirculating insufflation (VTI) with 10mmHg target pressure
62336162|NCT01968720|EXPERIMENTAL|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
62336163|NCT04524286||Public - Childbearing Women|Childbearing women living in three deprived areas in a city in the South of England.
62336164|NCT04524286||Staff - Midwives|Midwives working in caseloading teams providing continuity of care to women living in three deprived areas in a city in the South of England.
62336165|NCT06467643|EXPERIMENTAL|Group IHAN|The canal was irrigated with 5 mL room temperature 5.25% NaOCl and PUA was performed. Short vertical strokes were achieved for 30 seconds as manufacturer's instructions. After the first cycle of PUA, the canal was irrigated with 5 mL of 17% EDTA and kept in the canal for 60 seconds and then flushed out with 5 mL of saline. The root canal was filled again with 5.25% sodium hypochlorite and heated in the canal for 10 seconds using extra-fine heat carrier (0.04 taper) attached to a System B device. The temperature was fixed at 150 °C. Three consecutive cycles of PAU and intra-canal heating of sodium hypochlorite were performed. A final rinse of 5mL 17% EDTA was performed for 60 seconds followed by 5 mL of saline.
62493239|NCT04411654|EXPERIMENTAL|Low Dose|
62493240|NCT04411654|EXPERIMENTAL|High Dose|
62493241|NCT01372930|EXPERIMENTAL|Etanercept|
62493242|NCT01372930|PLACEBO_COMPARATOR|saline|
62493243|NCT04337658|EXPERIMENTAL|Trastuzumab± Pertuzumab+ Fulvestrant|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Fulvestrant(Faslodex): 500mg intramuscular injections at day 1, 15, 28 and every 4 weeks thereafter"
62695380|NCT04035486|EXPERIMENTAL|Osimertinib 80 mg QD and platinum-based chemotherapy|"Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.~Dose may be reduced to allow for the management of IP related toxicity."
62695381|NCT03287986||Suicide attempters|Depressed patients over 60 years of age with a personal history of suicide attempts scanned with MRI
62695382|NCT03287986||Patient controls|depressed patients over 60 years of age without a personal history of suicide attempt scanned with MRI
61941077|NCT06678971|ACTIVE_COMPARATOR|FIFA 11+|"The intervention program takes place at the Alqueria del Basket facilities in Valencia, Spain, during the regular season. The warm-up regimen is supervised by a performance coach with expertise in basketball. Two days before the start of the program, athletes participate in an information and familiarization session. This session includes a verbal overview and a practical demonstration of the exercises, with the coach providing guidance and corrections to ensure athletes are well-prepared and able to perform the exercises correctly.~The FIFA 11+ protocol consists of fifteen exercises organized into three segments, with three levels of difficulty. The first segment includes six running exercises, the second focuses on six exercises to enhance lower body strength, balance, and agility, and the third segment involves three running exercises aimed at activating the cardiovascular system."
62336166|NCT06467643|ACTIVE_COMPARATOR|Group R-IHAN|Each canal was prepared using Reciproc Blue nickel titanium primary file 25/08 (VDW, Munich, Germany) driven by a Xsmart IQ motor (Dentsply, Maillefer, Ballaigues, Switzerland) according to the manufacturer's instructions. Continuous checking of the canal patency was done using size 10 handfile followed by irrigation with 3 mL room temperature 5.25% sodium hypochlorite using irriflex endodontic irrigation needle mounted on a 3mL syringe each time the rotary file was removed out of the canal. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
62336167|NCT05060666|EXPERIMENTAL|Ivermectin|2 doses of ivermectin at day 0 and day 2
62336168|NCT05060666|PLACEBO_COMPARATOR|Placebo|2 doses of placebo at day 0 and day 2
62336169|NCT01446952|EXPERIMENTAL|Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent once. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
62336170|NCT02605447|EXPERIMENTAL|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
62336171|NCT04748406|ACTIVE_COMPARATOR|Peloid Therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week(16).
62336172|NCT04748406|ACTIVE_COMPARATOR|ESWT(Extracorporeal Shock Wave Therapy)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied(4).
62336173|NCT04357119|ACTIVE_COMPARATOR|CL measured from Treitz ligament|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 200 cm distal to the ligament of Treitz with the same stapler using a 60 mm blue cartridge
62336174|NCT04357119|ACTIVE_COMPARATOR|CL measured from ileocecal valve|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 300 cm proximal to the ileocecal valve with the same stapler using a 60 mm blue cartridge
62336175|NCT00039442|EXPERIMENTAL|Treatment|Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62336176|NCT02731118|EXPERIMENTAL|Placebo and Salovum|6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14
62336177|NCT02731118|EXPERIMENTAL|Salovum and placebo|6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14
62336178|NCT02875821|EXPERIMENTAL|Group IMP|Group IMP (Ipragliflozin with Metformin with Pioglitazone)
62336179|NCT02875821|ACTIVE_COMPARATOR|Group MP|Group MP (Metformin with Pioglitazone)
62336180|NCT04279379|EXPERIMENTAL|treatment arm|Sintilimab,200mg,ivdrip,day1 Decitabine 10mg d1-5, ivdrip, repeated every 3 weeks.
62336181|NCT03483506|EXPERIMENTAL|All subjects|
62695383|NCT03287986||Healthy Controls|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts, scanned with MRI
62336182|NCT05100316|OTHER|Participants with solid tumors and hematological malignancies|Participants with solid tumors and hematological malignancies will be included. No study treatment will be administered in this study.
62336183|NCT02694120||colonoscopy population|
62336184|NCT01182948|EXPERIMENTAL|Aerobic Exercise|The aerobic training group will use cardiovascular training devices.
62336185|NCT01182948|EXPERIMENTAL|Resistance Exercise|The resistance training group will perform exercises on weight machines and free weights.
62336186|NCT04825236|EXPERIMENTAL|Decision Aid Users|Patients with CF who are given access to the MyVoice:CF decision aid
62336187|NCT04825236|EXPERIMENTAL|CF Healthcare Providers|Members of the adult CF care team who interact with patients who have used the decision aid
62336188|NCT01087411|EXPERIMENTAL|Motivational Interviewing and omega 3|This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
62336189|NCT01087411|EXPERIMENTAL|Motivational interviewing and placebo|This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
62336190|NCT01087411|EXPERIMENTAL|Control and omega 3|This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
62336191|NCT01087411|PLACEBO_COMPARATOR|Control and placebo|This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
62695384|NCT04491344||Children with overweight and obesity|Overweight and obese children and adolescents visiting the adiposity outpatient clinic.
62695385|NCT04491344||adults|follow up of patients into adulthood
62695386|NCT04491344||control group|matched control group with children, adolescents and aduts without obesity
62493244|NCT04337658|ACTIVE_COMPARATOR|Trastuzumab± Pertuzumab+ Capecitabine|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Capecitabine: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination."
62493245|NCT04138251|EXPERIMENTAL|Treatment|Oral empaglifozin 5 mg 1x/day, increase up to 10 mg 1x/day if no 25% decrease of blood1,5-anhydroglucitol level
62493246|NCT06127186||Study group|Patients reporting for primary care assessment because of URTI.
62493247|NCT03396354|EXPERIMENTAL|Integrated robotic surgery|
62493248|NCT03396354|ACTIVE_COMPARATOR|Conventional laparoscopic surgery|
62493249|NCT01859936|EXPERIMENTAL|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
62493250|NCT01859936|NO_INTERVENTION|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
62493251|NCT04908540|ACTIVE_COMPARATOR|MARPE/ Conventional (Control) (Group A)|patients will open the appliance in its conventional way; 2 quarter turn (0.2 mm) in the morning, and 2 quarter turn in the evening until overcorrection achieved.
62493252|NCT04908540|EXPERIMENTAL|MARPE/ ALT-RAMEC (Group B)|Patients will open 2 quarter turn (0.2mm) in the morning, and 2 in the evening in the first week, then alternate with closing 2 quarter turn in the morning and 2 in the evening in the second week. And then continuing opening and closing till end with opening in the 7th week and continue opening until overcorrection achieved.
62493253|NCT05421039||Group (1)|With the exposure
62493254|NCT05421039||Group (2)|Without the exposure
62493255|NCT01459380|EXPERIMENTAL|Regimen I (intermittent veliparib)|Patients receive veliparib PO BID on days 1-7, and pegylated liposomal doxorubicin hydrochloride IV over 1 hour and carboplatin IV over 30 minutes on day 1.
62493256|NCT01459380|EXPERIMENTAL|Regimen II (continuous veliparib)|Patients receive veliparib PO BID on days 1-28, and pegylated liposomal doxorubicin hydrochloride and carboplatin as in Regimen I.
62493257|NCT02247687|OTHER|Counseling arm|Counseling without antiretroviral treatment modification
62493258|NCT02247687|ACTIVE_COMPARATOR|Switch arm for protease inhibitor|Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
62493259|NCT02247687|ACTIVE_COMPARATOR|Addition of Isentress® (raltegravir)|"Drug: Addition of Isentress® (raltegravir) arm~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling"
62493260|NCT02747680|OTHER|type 1 diabetes|type 1 diabetes \>5 years duration Well controlled (a1c \<7.5%)
62493261|NCT02747680|OTHER|healthy controls|healthy controls
62493262|NCT05361057|EXPERIMENTAL|venetoclax pluse azacitidine arm|azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21
62695387|NCT01950520|EXPERIMENTAL|Cohort 1|"Chamber temperature will be block randomized with low temperature and 27°C (Cohort 1 only)~Within each block, the following five interventions will be repeated:~Propranolol: Propanolol 160mg, oral, by mouth (Cohort 1 only)~Pindolol: Pindolol 20mg, oral, by mouth (Cohort 1 only)~Dantrolene: Dantrolene 100mg, oral, by mouth (Cohort 1 only)~Magnesium Sulfate: Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)~Placebo Cohort 1: Placebo, oral, by mouth (Cohort 1 only)"
61941078|NCT06678971|EXPERIMENTAL|Basket-Up|"The intervention program takes place at the Alqueria del Basket facilities in Valencia, Spain, during the regular season. The warm-up regimen is supervised by a performance coach with expertise in basketball. Two days before the start of the program, athletes participate in an information and familiarization session. This session includes a verbal overview and a practical demonstration of the exercises, with the coach providing guidance and corrections to ensure athletes are well-prepared and able to perform the exercises correctly.~The Basket-Up warm-up program is developed by a committee of experts, including the medical staff and the Performance Department of Valencia Basket Club, with detailed information previously published. This protocol is specifically designed to address the physiological, functional, and physical demands of basketball training. It is structured into three phases with progressively increasing levels of difficulty, lasting a total of 20 minutes."
61941079|NCT02292342|ACTIVE_COMPARATOR|0.1 mg/ kg BW pure (-)-epicatechin|0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
61941080|NCT02292342|ACTIVE_COMPARATOR|0.5 mg/ kg BW pure (-)-epicatechin|0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
61941081|NCT02292342|ACTIVE_COMPARATOR|1.0 mg/ kg BW pure (-)-epicatechin|1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
62493263|NCT05361057|ACTIVE_COMPARATOR|venetoclax pluse DA arm|daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
62493264|NCT04519255||Screening of clinically cured patients with severe COVID-19|①Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age \> 18 years, age \< 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
62695388|NCT01950520|EXPERIMENTAL|Cohort 2|"Interventions, in random order, will be administered during one of the six one-day stays~Caffeine: Caffeine 200mg, oral, by mouth (Cohort 2 only)~Qsymia: Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)~Topiramate: Topiramate 200mg, oral, by mouth (Cohort 2 only)~Phentermine: Phentermine 37.5mg, oral, by mouth (Cohort 2 only)~Naltrexone: Naltrexone 100mg, oral, by mouth (Cohort 2 only)~Placebo Cohort 2: Placebo, oral, by mouth (Cohort 2 only)"
62695389|NCT01950520|EXPERIMENTAL|Cohort 3|"Interventions, in random order, will be administered during one of the four overnight inpatient stays~Mirabegron 50mg: Mirabegron 50mg, oral, by mouth (Cohort 3 only)~Mirabegron 200mg: Mirabegron 200mg, oral, by mouth (Cohort 3 only)~Placebo for Mirabegron: Placebo for Mirabegron, oral, by mouth (Cohort 3 only)"
62695390|NCT00835042|EXPERIMENTAL|1|
62695391|NCT00835042|ACTIVE_COMPARATOR|2|
62336192|NCT03614442|EXPERIMENTAL|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
62336193|NCT03614442|ACTIVE_COMPARATOR|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
62336194|NCT00032019|EXPERIMENTAL|EPOCH-Rituximab|Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL
62336195|NCT00430313|EXPERIMENTAL|Electro-Stimulation (Active Site)|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
62336196|NCT00430313|EXPERIMENTAL|Electro-Stimulation (Inactive Site)|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
62336197|NCT04827836|NO_INTERVENTION|Cohort A - Room-temperature eye drops and povidone-iodine|Participants will receive a standardized topical anesthesia protocol of oxybuprocaine hydrogen chloride (HCl) 0.4% and lidocaine HCl 2% eye drops. Each drop will be instilled 3 times (one drop): At 10 minutes, 5 minutes, and just before the injection. Before the injection patients will receive cul-de-sac 5% povidone-iodine (3 drops) and the peri-ocular skin will be disinfected using a 10% povidone-iodine. A standard intravitreal injection of bevacizumab, 1.25 mg/0.05 ml will be performed through the pars plana with a 30-gauge needle, 3.5 mm from the corneal limbus, at the superior-temporal quadrant. Following the injection, a cotton swab absorbed with 5% povidone-iodine will be applied to the injection site.
62336198|NCT04827836|EXPERIMENTAL|Cohort B - Cooled eye drops and povidone-iodine|Participants will receive the same treatment as cohort A, using cooled eye drops and povidone-iodine (5 degree Celsius).
62336199|NCT01326169|ACTIVE_COMPARATOR|Standard care|No intervention
62336200|NCT01326169|EXPERIMENTAL|Counseling|Telephone-delivered counseling
62336201|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.~These patients will receive standard pain treatment until the planned surgery."
62336202|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.~These patients will receive standard pain treatment until the planned surgery."
62336203|NCT03515434|ACTIVE_COMPARATOR|ESP Block|Ultrasound-guided Erector spinae plane (ESP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
62336204|NCT03515434|ACTIVE_COMPARATOR|TAP Block|Ultrasound-guided Transversus abdominis plane (TAP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
62336205|NCT03515434|SHAM_COMPARATOR|Control|The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
62336206|NCT01591226|ACTIVE_COMPARATOR|Caffeine|6mg per kg bodyweight ingested 60min before test
62336207|NCT01591226|PLACEBO_COMPARATOR|Placebo|Sodium chloride and mannitol as placebo are ingested by the athlete
62336208|NCT01591226|ACTIVE_COMPARATOR|Sodium Citrate|sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
62336209|NCT01591226|ACTIVE_COMPARATOR|Caffeine and Sodium Citrate|sodium citrate 120-90min prior test capsules:60min prior test
62336210|NCT00960934|EXPERIMENTAL|MK-5442 2.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.
62336211|NCT00960934|EXPERIMENTAL|MK-5442 5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.
62336212|NCT00960934|EXPERIMENTAL|MK-5442 7.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.
62336213|NCT00960934|EXPERIMENTAL|MK-5442 10 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.
62336214|NCT00960934|EXPERIMENTAL|MK-5442 15 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.
62695392|NCT06643390|EXPERIMENTAL|MK-2225|Participants receive MK-2225 titrated from Dose 1, Dose 2, or Dose 3, subcutaneously (SC) once every 2 weeks (Q2W) over the course of 8 weeks based on the safety and tolerability of the previous starting dose.
62695393|NCT06643390|PLACEBO_COMPARATOR|Placebo|Participants receive placebo SC Q2W over the course of 8 weeks.
62695394|NCT05020808|SHAM_COMPARATOR|Nonessential amino acid formulation (NEAA)|"Novel non-essential amino acid blend dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.~Product Number: NEAA56812"
62336215|NCT00960934|PLACEBO_COMPARATOR|Placebo|Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.
62336216|NCT05833321|EXPERIMENTAL|Interventionnal|"Hand Grip Dynamometer Walk test SEFI Nutritional Intake Assessment Questionnaire"
62737592|NCT05772689|EXPERIMENTAL|Caregiving while Black|Caregivers of PLWD taking part in a fully self-paced asynchronous online caregiver education program.
62336217|NCT04689750||Allogeneic HSCT recipients and donors|
61941082|NCT02292342|PLACEBO_COMPARATOR|0.0 mg/ kg BW pure (-)-epicatechin|Water only (3 ml/kg BW)
62336218|NCT03440437|EXPERIMENTAL|FS118 weekly|The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design followed by an expansion cohort of participants with SCCHN and an expansion SCCHN cohort in combination with Paclitaxel.
62493265|NCT04519255||Screening of clinically cured patients with mild COVID-19|①Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age \> 18 years, age \< 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
62493266|NCT04519255||Healthy people who are not infected with COVID-19|① Volunteers who are not infected with COVID-19; ②Age \> 18 years, age \< 85 years, no gender restriction; ③ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ④ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
62493267|NCT04889365||COVID-19 positive, asymptomatic|COVID-19 positive, asymptomatic (i.e. no current symptoms of COVID-19, confirmed PCR positive for COVID-19)
62493268|NCT04889365||COVID-19 positive, symptomatic|COVID-19 positive, symptomatic (i.e. current symptoms of COVID-19, confirmed PCR positive for COVID-19)
62493269|NCT04889365||COVID-19 negative|COVID-19 negative (i.e. no current or previous symptoms of COVID-19, confirmed PCR negative for COVID-19)
62493270|NCT04372641|EXPERIMENTAL|Treatment (p97 inhibitor CB-5339 tosylate)|Patients receive p97 inhibitor CB-5339 tosylate PO QD 4 days on and 3 days off. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62493271|NCT02517424|EXPERIMENTAL|High THC/Low CBD Cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
62493272|NCT02517424|EXPERIMENTAL|High THC/High CBD cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
62493273|NCT02517424|PLACEBO_COMPARATOR|Low THC/Low CBD cannabis|Product will be administered via vaporization up to 2 grams per day as needed.
62493274|NCT00562718|EXPERIMENTAL|Surgery and Chemotherapy|Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.
62493275|NCT00197873|ACTIVE_COMPARATOR|Lactophilus|Lactophilus supplementation
62493276|NCT00197873|PLACEBO_COMPARATOR|Placebo|Placebo is administered during chemotherapy.
62493277|NCT03531645|EXPERIMENTAL|Fulvestrant + Abemaciclib|
62493278|NCT01876758|EXPERIMENTAL|Cognitive Intervention: Memory Training|Memory training before and after ECT
62493279|NCT01876758|ACTIVE_COMPARATOR|Comparable general mental stimulation|Puzzle games before and after ECT
61941083|NCT05280171|EXPERIMENTAL|Teach back|Discharge information was explained by the principal investigator. It includes pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.
61941084|NCT05280171|ACTIVE_COMPARATOR|Standard of Care|Discharge information as per the standard existing routine. Than assessed the recall and patient engagement of CLD patients in general ward regarding discharge instructions by structure questionnaires for patients recall, and PAM for patient's
62336219|NCT03238586|EXPERIMENTAL|WELL Program|Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.
62336220|NCT03238586|NO_INTERVENTION|Standard of Care|Five-week standard of care program.
62336221|NCT02080689|OTHER|Salvage setting|The clinical utility of Decipher will be evaluated for patients meeting the inclusion criteria in the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA detectable and rising on 2 or more subsequent determinations)
62336222|NCT02080689|OTHER|Adjuvant setting|The clinical utility of Decipher will be evaluated for patients in the adjuvant setting: within 12 months after surgery (in the absence of detectable PSA rise of BCR)
62336223|NCT01253044|EXPERIMENTAL|Acceptance and Commitment Therapy|12 weeks of individually delivered Acceptance and Commitment Therapy
61941085|NCT05733390|EXPERIMENTAL|JZP541|Participants who will be randomized to receive JZP541.
62336224|NCT01253044|ACTIVE_COMPARATOR|Present Centered Therapy|12 weeks of individually delivered Present Centered Therapy
61941086|NCT05733390|PLACEBO_COMPARATOR|Placebo|Participants who will be randomized to receive placebo.
61941087|NCT04193358|EXPERIMENTAL|FERTILIS HOMME® group (group A)|Group A will receive 2 FERTILIS HOMME capsules twice daily to be taken with meals for 3 months.
62336225|NCT00204997|EXPERIMENTAL|1|Laparoscopic Ovarian Transposition
62336226|NCT06324994|EXPERIMENTAL|cohort 1|Patients with relapsed refractory lymphoblastic mantle cell lymphoma who have not previously received treatment with PI3K inhibitors and BCL-2 inhibitors
62493280|NCT01876758|NO_INTERVENTION|Treatment as Usual|No memory training or puzzle games, just the study evaluations
62493281|NCT05369039|EXPERIMENTAL|Case Group|The case group will receive a 10 days course of Roflumilust in a dose of 500 mg once daily.
62493282|NCT05369039|ACTIVE_COMPARATOR|Control group|The Control group will receive a 10 days course of systemic steroids in the form of oral prednisolone in a dose of 40 mg per day.
62493283|NCT00718458||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62336227|NCT03924791|EXPERIMENTAL|Transforaminal Epidural Injection|Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3
62336228|NCT03924791|NO_INTERVENTION|Oral pain medication|Patients will receive oral pain medication according to general practitioner guidelines.
62336229|NCT02045212|EXPERIMENTAL|RPh201|3/6 month treatment schedule, consisting of bi-weekly SC administration of the RPh201
62336230|NCT02045212|PLACEBO_COMPARATOR|Placebo|3/6 month treatment schedule, consisting of bi-weekly SC administration of the Placebo
62336231|NCT02671695|EXPERIMENTAL|Group 1|chelation therapy plus Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
62336232|NCT02671695|EXPERIMENTAL|Group 2|chelation therapy plus Amlodipine in a dose of 5 mg/day orally for 3 months
62336233|NCT03664622|EXPERIMENTAL|group K|patients with a ketamine infusion intraoperative
62336234|NCT03664622|EXPERIMENTAL|group M|patients with a Morphine infusion intraoperative
62336235|NCT01337011|EXPERIMENTAL|intra-coronary administration|Application of stem cells using the intra-coronary route.
62336236|NCT01337011|EXPERIMENTAL|intra-myocardial administration|Application of stem cells using the intra-myocardial route.
62336237|NCT06553066|EXPERIMENTAL|Group DNMB ( Deep neuromascular blockage)|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)"
62336238|NCT06553066|ACTIVE_COMPARATOR|Group MNMB ( Moderate neuromascular blockage)|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block with rocuronium, titrated to obtain a TOF count of 1-3.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)"
62336239|NCT05437341|EXPERIMENTAL|bi-4SCAR-PSMA/CD70 T Cell Therapy for CD70 and/or PSMA positive cancer|
62336240|NCT03671824||Lean|BMI ≤ 30 kg/m2
62336241|NCT03671824||Obese|BMI ≥30 kg/m2
62336242|NCT04496596|EXPERIMENTAL|Suramin|
62336243|NCT04496596|PLACEBO_COMPARATOR|Placebo|
62336244|NCT03768830|EXPERIMENTAL|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
62336245|NCT03768830|NO_INTERVENTION|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
62336246|NCT03768830|EXPERIMENTAL|Healthy Exercise|Healthy individuals that will exercise-group (HE). Intervention is exercise training.
62336247|NCT03768830|NO_INTERVENTION|Healthy Control (no-Exercise)|Healthy individuals that will not exercise (HC).
62336248|NCT05882890|EXPERIMENTAL|cranoisacraltherapy receivers|"The participants will receive 5 x one hour treatment of craniosacral therapy. One treatment per week in five weeks. The treatment will follow the protocol avenue of expression end step 2c and 2c in Ten step protocol . They will, if possible be instructed in fascial self treatment for maximum 5 minutes a day. Before treatment the participants fulfill the questionnaire  Xerostomia questionnaire after 3 months - a danish standardized questionnaire of xerostomia used of hospitals. They will fulfill this questionnaire again after ending their 5 treatment sessions, and again 6 months later as a follow up. They will also fulfill a diary with any side effects experienced during the treatment period. I will take their full history the first time we meet I journal my treatment after every treatment session, and journal which effects (positive and negative) the participant has noticed."
62336249|NCT01640925|ACTIVE_COMPARATOR|Chlorhexidine gluconate bathing|Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
62336250|NCT01640925|PLACEBO_COMPARATOR|Standard bathing|Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
61941088|NCT04193358|PLACEBO_COMPARATOR|Placebo group (group B)|Group B will receive 2 placebo capsules twice daily to be taken with meals for 3 months
61941089|NCT01558739|EXPERIMENTAL|INC424|Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
62336251|NCT03503682|ACTIVE_COMPARATOR|standard treatment|Patients in this group are treated with 3000 cGy in 10 daily fractions
62336252|NCT03503682|EXPERIMENTAL|short course treatment|Patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
62336253|NCT01328249|EXPERIMENTAL|Doxorubicin and cyclophosphamide followed by eribulin mesylate|
62336254|NCT04169724|EXPERIMENTAL|Calm|Participants will be asked to download the Calm app on their smartphone. Participants will then receive an email containing login credentials to access the Calm app. Once they receive this email and they receive their study start date, they will be asked to meditate for at least 10 minutes a day for 8 weeks. This prescription mimics how a new, paying member would use the app. Participants in the intervention group will be emailed weekly reminders.
62336255|NCT04169724|NO_INTERVENTION|Waitlist|Participants randomized to the control group will be asked to maintain their normal routine for 8 weeks and to avoid using the Calm meditation app.
62336256|NCT03264482|ACTIVE_COMPARATOR|THUVAP|thulium vaporization
62336257|NCT03264482|ACTIVE_COMPARATOR|M-TURP|monopolar transurethral resection
62336258|NCT06226506|EXPERIMENTAL|Test (T)-Reference (R)|In this trial, 24 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group A: Test (T)-Reference (R), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
62336259|NCT06226506|EXPERIMENTAL|Reference (R)-Test (T)|In this trial, 24 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group B: Reference (R)-Test (T), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
62336260|NCT02415439|EXPERIMENTAL|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
62493284|NCT00718458||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
62493285|NCT01292837|EXPERIMENTAL|Levetiracetam|Twice daily (morning and evening) orally
62493286|NCT06063590|EXPERIMENTAL|MSC arm|The patients will be receiving allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in infusion solution (sodium chloride supplemented with human serum albumin) in a low intravenous infusion of 100 millions MSCs within approximately 30 min
62336261|NCT02415439|EXPERIMENTAL|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
62336262|NCT02415439|EXPERIMENTAL|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
62336263|NCT02415439|EXPERIMENTAL|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
62336264|NCT02415439|EXPERIMENTAL|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
62336265|NCT02415439|EXPERIMENTAL|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
62336266|NCT02415439|EXPERIMENTAL|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
62336267|NCT02415439|PLACEBO_COMPARATOR|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
62336268|NCT02415439|EXPERIMENTAL|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
62336269|NCT02415439|EXPERIMENTAL|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
62336270|NCT02415439|EXPERIMENTAL|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
62336271|NCT02415439|EXPERIMENTAL|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
62336272|NCT02415439|PLACEBO_COMPARATOR|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
62336273|NCT02568917|ACTIVE_COMPARATOR|Conventional Restoration|Conventional Restoration - Composite Resin (Bulk Fill)
62336274|NCT02568917|EXPERIMENTAL|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment - Ketac Molar Easy Mix
62336275|NCT03704441|OTHER|bupivacaine 6mg|bupivacaine 6mg
62493287|NCT02308241|EXPERIMENTAL|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
62493288|NCT06599619||Group 1 - Patients Treated with Pembrolizumab|Patients Treated with Pembrolizumab per Standard of Care.
62493289|NCT06599619||Group 2 - Patients Treated with Nivolumab|Patients Treated with Nivolumab per Standard of Care
62493290|NCT02082327|EXPERIMENTAL|0.3 mg/kg|IV infusion of migalastat HCl or placebo
62493291|NCT02082327|EXPERIMENTAL|1 mg/kg|IV infusion of migalastat HCl or placebo
62493292|NCT02082327|EXPERIMENTAL|10 mg/kg|IV infusion of migalastat HCl or placebo
62493293|NCT02082327|EXPERIMENTAL|150 mg IV|150 mg single IV infusion
62493294|NCT02082327|EXPERIMENTAL|150 mg oral|150 mg single oral dose
62493295|NCT02774018|EXPERIMENTAL|12 institutionalized elderly people|Mindfulness-Based Stress Reduction program.
62336276|NCT03704441|OTHER|bupivacaine 7mg|bupivacaine 7mg
62336277|NCT03704441|OTHER|bupivacaine 8mg|bupivacaine 8mg
62336278|NCT03704441|OTHER|bupivacaine 9mg|bupivacaine 9mg
62336279|NCT03704441|OTHER|bupivacaine 10mg|bupivacaine 10mg
62336280|NCT03704441|OTHER|bupivacaine 11mg|bupivacaine 11mg
62336281|NCT03704441|OTHER|bupivacaine 12mg|bupivacaine 12mg
62336282|NCT01389622|EXPERIMENTAL|Arm 1: NADA points and digital pressure|Arm 1: NADA points and digital pressure with urge.
62336283|NCT01389622|EXPERIMENTAL|Arm 2: random points + digital pressure with urge|Arm 2 (20 participants): random points + digital pressure with urge
62336284|NCT01389622|NO_INTERVENTION|Arm 3 (20 participants): NO acupressure, only advice + support|
62336285|NCT02531789||Observation|45 patients receiving elective colorectal surgery
62336286|NCT02597673|ACTIVE_COMPARATOR|Standard rehabilitation protocol|Home Exercise Program (HEP). All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
62336287|NCT02597673|EXPERIMENTAL|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
62493296|NCT00494013|EXPERIMENTAL|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
62493297|NCT00494013|ACTIVE_COMPARATOR|Detemir|Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
62493298|NCT02579577||Decision making cohort|Any people identified as being important within the network of care for children with life-limiting illnesses.
62336288|NCT02597673|EXPERIMENTAL|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
62336289|NCT02597673|EXPERIMENTAL|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
61941090|NCT05882188|EXPERIMENTAL|Tubal flushing during HSG with oil-based contrast|Tubal flushing during HSG HSG will be performed by a gynaecologist, fertility doctor or nurse according to local protocols. HSG will be performed in the follicular phase of the cycle. Preferably, HSG is performed in the next cycle after randomization, but if this is not feasible the procedure may be postponed up till one month after randomization. After cleaning the vagina and cervix, a vacuum cervix adapter will be applied to the cervix or a Lipiodol resistant balloon catheter or hysterophore will be placed through the cervix. Up to 15ml of Lipiodol Ultra Fluid will be injected into the uterine cavity and its spread directly monitored by fluoroscopy. Six to eight radiographs will be taken and assessed by a gynaecologist or radiologist. The maximum amount of oil-based contrast medium is set at 15ml.
62336290|NCT06137950|ACTIVE_COMPARATOR|Control|Interferon α2b gel treatment for 30 days.
62336291|NCT06137950|EXPERIMENTAL|Treatment|"Interferon α2b gel treatment for 30 days~+ Interferon α2b 3 MIU rectal suppository for 10 days"
61941091|NCT05882188|ACTIVE_COMPARATOR|Tubal flushing HyFoSy|Tubal flushing during HyFoSy will be performed by a gynaecologist, fertility doctor, sonographer or nurse according to local protocols. HyFoSy will be performed in the follicular phase of the cycle. Preferably, HyFosy is performed in the next cycle after randomization, but if this is not feasible the procedure may be postponed up till one month after randomization. During HyFoSy approximately 5-10cc of foam will be introduced through a little cervical balloon-less applicator into the uterine cavity. During infusion of the foam into the uterine cavity, a transvaginal ultrasound will be performed which shows whether the Fallopian tubes are patent. The assessment of the procedure will be done by the one who performed the procedure.
61941092|NCT05055128|EXPERIMENTAL|X842 25 mg BID|Patients will receive 2 tablets (X842 25mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 25 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
62336292|NCT01971489|EXPERIMENTAL|Treatment (buparlisib, gemcitabine hydrochloride, cisplatin)|Patients receive buparlisib PO QD on days 1-21, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62336293|NCT04748224|ACTIVE_COMPARATOR|group A (bupivacaine only)|Group A will be injected with 20 ml of 0. 25% bupivacaine in each side
62336294|NCT04748224|ACTIVE_COMPARATOR|group B (bupivacaine plus dexmedetomidine)|Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA).
62336295|NCT03241472|EXPERIMENTAL|Lertozole|oral tablets 5 mg start from third day cycle for 5 days
62336296|NCT03241472|ACTIVE_COMPARATOR|clomiphene plus N- acetyl cystiene|clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
62336297|NCT02406547|EXPERIMENTAL|WLE-NBI|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging (NBI). All detected polyps will be classified macroscopically and resected in each withdrawal.
62336298|NCT02406547|EXPERIMENTAL|NBI-WLE|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly Narrow Band Imaging (NBI) and secondly High Definition White Light Endoscopy (WLE). All detected polyps will be classified macroscopically and resected in each withdrawal.
62336299|NCT02125487|ACTIVE_COMPARATOR|Low-Fidelity Simulation|Teaching using traditional method
62336300|NCT02125487|EXPERIMENTAL|Hybrid Simulation|Teaching using Hybrid Simulation of breast examination
62336301|NCT03691402|EXPERIMENTAL|MCT-Silver|Metacognitive training for depression in later life is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and (re-)defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
62336302|NCT03691402|ACTIVE_COMPARATOR|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
62336303|NCT02728258|EXPERIMENTAL|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62336304|NCT00114283|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62336305|NCT06245512||With endometriosis|Women affected by endometriosis
62336306|NCT06245512||Without endometriosis|Women without any clinical sign of endometriosis
62336307|NCT04378920|EXPERIMENTAL|4L6715|exploring various doses of LEAF-4L6715
62336308|NCT04792437||glioma patients|glioma patients with routine surgery
62336309|NCT00952237|EXPERIMENTAL|IL-2 and GM-CSF for Mobilization|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
62493299|NCT05936047|EXPERIMENTAL|Experimental|The clotted vertebral bone marrow aspirate (vBMA) will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
62137713|NCT04345068|ACTIVE_COMPARATOR|Health Education Podcast|The control group will serve as an active control group and will be matched for time and attention to the intervention group. Participants assigned to the control group will be asked to listen to/view 10-min/day (i.e., \~70 min/week) of health education podcasts via a smartphone app. Topics covered in the health education control vary and will be aimed at providing useful and informative health-related information pertinent to cancer patients. The podcast app was developed by an independent app developer, and it was designed to mirror the type of functionality that the Calm app offers its users.
62336310|NCT04851717|EXPERIMENTAL|All Patients|All paediatric patients undergoing diagnostic and/or therapeutic procedures
62336311|NCT01206010|EXPERIMENTAL|Varenicline + Active Tailored Dose|
62336312|NCT01206010|PLACEBO_COMPARATOR|Varenicline + Placebo Tailored Dose|
62336313|NCT00617318|EXPERIMENTAL|A|
62336314|NCT00617318|PLACEBO_COMPARATOR|B|
62336315|NCT06291571||Liver diseases|Patients with documented liver diseases
62336316|NCT06291571||Control|Healthy volunteers without evidence of liver disease
62336317|NCT00028002|EXPERIMENTAL|Arm I|Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
62336318|NCT04404582||Klebsiella pneumoniae|patients with Klebsiella pneumoniae infection had different results of the drug sensitivity test. we compared the prognosis of these patients.
62336319|NCT04233359|ACTIVE_COMPARATOR|US-guided pleural biopsy and thoracentesis|"Pleural biopsy:~Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis."
62336320|NCT04233359|EXPERIMENTAL|LAT and thoracentesis|Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed. The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start. The patient is sedated with midazolam and morphine. Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space. A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology. Pleural parietal biopsies are taken under direct visual guidance. The recommended number of biopsies is 10-15. If no abnormalities were seen, random biopsies are taken. After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.
62336321|NCT05337527|EXPERIMENTAL|Beetroot supplementation|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
62336322|NCT05337527|PLACEBO_COMPARATOR|Placebo supplementation|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
62493300|NCT05330780|EXPERIMENTAL|All participants|The study will be single arm with intervention provided to all participants
62336323|NCT04596280||Hinchey Classification|
62336324|NCT04596280||AAST classification|
62336325|NCT04596280||WSES classfication|
62493301|NCT00393705|EXPERIMENTAL|insulin lispro LM + insulin lispro MM|Three times per day subcutaneous injection of insulin lispro mid mixture (MM) with the possibility to change the evening injection of MM to insulin lispro low mixture (LM) if fasting blood glucose target is not achieved.
62137714|NCT03532100|EXPERIMENTAL|Straight line walking|All participants will walk in a straight line while wearing the study prosthesis.
62137715|NCT03532100|EXPERIMENTAL|Circle walking with prosthesis inside|All participants will walk around a 1-meter radius circle with their prosthesis on the inside of the circle.
62336326|NCT05590741|EXPERIMENTAL|Treatment|All participants will receive a 12-session version of Emotion Regulation Therapy delivered weekly via synchronous telehealth using videoconferencing software and an asynchronous Internet-based online platform to supplement the content covered in each session.
62336327|NCT03015922|EXPERIMENTAL|Lenalidomide or pomalidomide, plus REOLYSIN|"Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.~Plus (all patients):~REOLYSIN® , intravenous infusion, maximum 3x10\^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles."
62336328|NCT01626911|EXPERIMENTAL|CRAI|CRAI of LMWH in the celiac trunk
62336329|NCT01626911|OTHER|Conservative treatment|Conservative treatment without CRAI, control group
62336330|NCT03870711|EXPERIMENTAL|group A|10% lidocaine spray
62336331|NCT03870711|PLACEBO_COMPARATOR|group B|sterile water
62336332|NCT01116219|ACTIVE_COMPARATOR|Stratum mut EGFR|"* Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression."
62336333|NCT01116219|ACTIVE_COMPARATOR|Stratum wtEGFR|"Cohort 1:~Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.~Cohort 2:~Induction chemotherapy with~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~o Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
62336334|NCT04539249|EXPERIMENTAL|Magnesium sulphate|Combination of intravenous magnesium sulphate, intravenous paracetamol and rectal diclofenac
62695395|NCT05020808|ACTIVE_COMPARATOR|Plant Protein Isolate (PPI)|"Plant protein isolate (Fava bean) dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.~Product Number: FP2011273"
62137716|NCT03532100|EXPERIMENTAL|Circle walking with prosthesis outside|All participants will walk around a 1-meter radius circle with their prosthesis on the outside of the circle.
62336335|NCT04539249|ACTIVE_COMPARATOR|Pentazocine|Combination of intramuscular pentazocine, intravenous paracetamol and rectal diclofenac
62336336|NCT01858155|EXPERIMENTAL|Melatonin|
62336337|NCT01044238|EXPERIMENTAL|active medication (methylphenidate)|Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
62336338|NCT01044238|PLACEBO_COMPARATOR|Placebo|Condition randomly assigned to receive placebo, provided to appear identical to active medication
62336339|NCT05339724||Group 1. Total cystic fibrosis patients with pulmonary exacerbation|Platelet count (PC) and mean platelet volume (MPV) during pulmonary exacerbation.
62336340|NCT05339724||Group 2. Total cystic fibrosis patients with no pulmonary exacerbation|PC and MPV during no pulmonary exacerbation
62336341|NCT05339724||Group 3. Cystic fibrosis patients with chronic colonization in acute pulmonary exacerbation|PC and MPV during chronic colonization in acute pulmonary exacerbation
62336342|NCT05339724||Group 4. Cystic fibrosis patients with chronic colonization without pulmonary exacerbation|PC and MPV during chronic colonization without pulmonary exacerbation
62336343|NCT05339724||Group 5. Cystic fibrosis patients with chronic colonization without pulmonary exacerbation|PC and MPV during chronic colonization without pulmonary exacerbation
62336344|NCT05339724||Group 6. Cystic fibrosis patients with no chronic colonization without pulmonary exacerbation|PC and MPV during no chronic colonization without pulmonary exacerbation
62336345|NCT06121336||Ischemic Stroke|100 patients admitted to a specialized stroke service because of an acute ischemic stroke due to large- or medium-vessel occlusion within 9 hours of stroke onset. BD-tau levels and other suggested markers of brain injury (e.g.. NfL) will be assessed every hour from admission to 48 hours after onset. Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization. Clinical follow-up will be performed at 3 months.
62336346|NCT01276457|EXPERIMENTAL|Upper everolimus blood target + very low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
62336347|NCT01276457|ACTIVE_COMPARATOR|Standard everolimus blood target + low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
62336348|NCT03468699|EXPERIMENTAL|Autologous BMMC transplantation|Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward
62336349|NCT01787643|EXPERIMENTAL|Standing desk|Installation of standing desk
62336350|NCT04069013|ACTIVE_COMPARATOR|Standard PCNL|Patients receive a standard PCNL procedure using a 24 fr tract
62137717|NCT06254183|ACTIVE_COMPARATOR|Gabapentin|"30 patients will represent the treatment group and will receive a single oral dose of Gabapentin 1200 mg 1 hr before the surgery.~Blood and urine samples will be collected before the surgery, then 24 hrs postoperatively."
62336351|NCT04069013|ACTIVE_COMPARATOR|Mini-PCNL|Patients receive a mini-PCNL procedure using a 16 fr tract
62493302|NCT00393705|ACTIVE_COMPARATOR|Insulin Biphasic Aspart 30/70 or Insulin Lispro LM|Twice daily subcutaneous injection of either insulin biphasic aspart 30/70 or insulin lispro low mixture (LM) (continuation of analogue formulation used before study enrollment).
61941093|NCT05055128|EXPERIMENTAL|X842 50 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
62137718|NCT06254183|PLACEBO_COMPARATOR|Placebo|"30 patients will represent the treatment group and will receive a single oral dose of Placebo 1 hr before the surgery.~Blood and urine samples will be collected before the surgery, then 24 hrs postoperatively."
62137719|NCT06274086|EXPERIMENTAL|Two-session catheter-directed sclerotherapy|Each patient received two sessions of catheter-directed sclerotherapy for endometrioma 1 day apart with the catheter left in situ overnight.
62137720|NCT05390905|EXPERIMENTAL|HSK21542|HSK21542 injection
62137721|NCT05390905|EXPERIMENTAL|tramadol|Tramadol hydrochloride injection
62336352|NCT01064024|ACTIVE_COMPARATOR|Phenazopyridine Hydrochloride Tablets, USP 200 mg|
62336353|NCT01064024|PLACEBO_COMPARATOR|Placebo|Matching placebo to the phenazopyridine hydrochloride tablets
62336354|NCT01293032|EXPERIMENTAL|Group 1 (RS < 11)|"Patients with a Recurrence Score (RS) less than 11 (RS \<11) are assigned to Group 1, neoadjuvant hormonal therapy either tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~* Neoadjuvant therapy~* Therapeutic conventional surgery~* Laboratory biomarker analysis/Correlative studies~* Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~* Hormonal therapy:~  * Tamoxifen Citrate (pre-menopausal women) OR~ * Aromatase Inhibition Therapy (post-menopausal women)"
62695396|NCT03960736|ACTIVE_COMPARATOR|Group ESPB = Erector spinae plane block group|ESP block (Group ESP) will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
62137722|NCT05390905|PLACEBO_COMPARATOR|placebo|placebo
62336355|NCT01293032|EXPERIMENTAL|Group 2 Arm 1 (RS 11-25)|"Patients with an intermediate RS (11-25) assigned to Group 2. Randomized to Arm 1, neoadjuvant hormonal therapy as in Group 1.~Treatment:~* Neoadjuvant therapy~* Therapeutic conventional surgery~* Laboratory biomarker analysis/Correlative studies~* Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~* Hormonal therapy:~  * Tamoxifen Citrate (pre-menopausal women) OR~ * Aromatase Inhibition Therapy (post-menopausal women)"
62336356|NCT01293032|EXPERIMENTAL|Group 2 Arm 2 (RS 11-25)|"Patients with an intermediate RS(11-25) assigned to Group 2. Randomized to Arm 2, neoadjuvant chemotherapy 6-8 courses of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~* Neoadjuvant therapy~* Therapeutic conventional surgery~* Laboratory biomarker analysis/Correlative studies~* Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~* Systemic chemotherapy"
62336357|NCT01293032|EXPERIMENTAL|Group 3 (RS > 25)|"Patients with a high RS (\> 25) assigned to Group 3, neoadjuvant chemotherapy as in Group 2 Arm 2.~Treatment:~* Neoadjuvant therapy~* Therapeutic conventional surgery~* Laboratory biomarker analysis/Correlative studies~* Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~* Systemic chemotherapy"
62336358|NCT03776643|EXPERIMENTAL|ILT-101 (ld-IL2)|Subcutaneous injections of ILT-101
62336359|NCT03776643|PLACEBO_COMPARATOR|placebo|Subcutaneous injections of placebo
62493303|NCT01624233|EXPERIMENTAL|80 mg ixekizumab|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
61941094|NCT05055128|EXPERIMENTAL|X842 75 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 25 mg) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 25 mg) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
62336360|NCT05974085|EXPERIMENTAL|Selinexor+RCHOP|Selinexor: 60 mg QW Rituximab: 375 mg/m2, d0 Vincristine: 4 mg, d1 Epirubicin: 75 mg/m2, d1 or Liposomal doxorubicin: 35 mg/m2, d1 Cyclophosphamide: 750 mg/m2, d1 Prednisone: 100 mg, d1-5
62336361|NCT00783341|EXPERIMENTAL|GAP-134|
62336362|NCT00783341|PLACEBO_COMPARATOR|placebo|
62336363|NCT02681380|EXPERIMENTAL|Relation learning|Participants of this group will benefit form a specific learning on relation, Balint like. They will have 7 sessions during 3 months.
62336364|NCT02681380|PLACEBO_COMPARATOR|Control group|Participants of this group will have no learning related to relation with patient.
62336365|NCT06552598|EXPERIMENTAL|KD01 treatment|The recombinant oncolytic adenovirus injection (KD01) primarily consists of a recombinant human type 5 adenovirus with a deletion in the E3 region, where the ADP gene is replaced by the tBID apoptosis protein gene. This virus exhibits a conditional replication capability, with a 27 base pair deletion in the E1A region corresponding to nucleotides 920-946 of Ad5. Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged.
62336366|NCT05900011||Patients in the pediatric population with eosinophilic eosphagitis|Patients in the pediatric population with eosinophilic eosiphagitis responding to the PedsQL eosinophilic eosophagitis module
62336367|NCT02426060|EXPERIMENTAL|Imrecoxib&Warfarin|
62493304|NCT00556673|EXPERIMENTAL|Indacaterol/mometasone - Placebo|In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
62493305|NCT00556673|EXPERIMENTAL|Placebo - indacaterol/mometasone|In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
62493306|NCT02159820|ACTIVE_COMPARATOR|DTC Arm|Patients are randomly assigned to receive lower-dose decitabine treatment followed by TC regimen (ie, DTC arm).
61941095|NCT05055128|EXPERIMENTAL|X842 100 mg BID|Patients will receive 2 tablets (X842 50 mg×2) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
61941096|NCT05055128|ACTIVE_COMPARATOR|Lansoprazole|Patients will receive 2 tablets (X842 dummy×2) and 1 capsule (Lansoprazole 30 mg) in the morning, and 2 tablets (X842 dummy×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
61941097|NCT02643030|EXPERIMENTAL|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
61941098|NCT02643030|ACTIVE_COMPARATOR|hypercapnia|Tidal volume (6ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
61941099|NCT03633136|NO_INTERVENTION|standard education|Standard of care education provided at each transplant center
62137723|NCT06176443|EXPERIMENTAL|One anastomosis gastric bypass with combined fundoplication|"One anastomosis gastric bypass with combined fundoplication FundoRing"
62137724|NCT06176443|ACTIVE_COMPARATOR|One anastomosis gastric bypass without combined fundoplication|One anastomosis gastric bypass without combined fundoplication
62137725|NCT06590064||Group T|Thyroid surgery patients under general anesthesia
62137726|NCT05723666|EXPERIMENTAL|Group watching video with virtual reality glasses|A nature video will be watched with virtual reality glasses.
62137727|NCT05723666|NO_INTERVENTION|Group not watching video with virtual reality glasses|Virtual reality glasses will not be watched. An intervention will not be applied.
62137728|NCT03414645|EXPERIMENTAL|CAM-101 10%|FD hPL 10 vol/vol %
62137729|NCT03414645|EXPERIMENTAL|CAM-101 30%|FD hPL 30 vol/vol %
62493307|NCT02159820|ACTIVE_COMPARATOR|TC regimen|Patients were randomly assigned to receive carboplatin plus paclitaxel (ie, TC arm).
62493308|NCT00704249|EXPERIMENTAL|1|Full-dose nevirapine from baseline (200 mg bid).
62493309|NCT00704249|ACTIVE_COMPARATOR|2|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
62493310|NCT05378958||Caregivers|Any health professional (medical or paramedical profession) practicing therapeutic education in distance mode by videoconferencing, regardless of the programs concerned
62493311|NCT05378958||Participants|"* Patient's caregivers or parents who have taken part in a therapeutic education session by videoconference (individual or collective) as part of a program, regardless of their age, sex or the pathology concerned by education program~* Patients: from 10 years old and only if the therapeutic education session was intended for them, regardless of gender or pathology"
62493312|NCT01044823||Adult RA|
62493313|NCT01044823||pediatric JRA|
62493314|NCT05029895||Participants Receiving Upadacitinib|Participants receiving upadacitinib for atopic dermatitis.
62493315|NCT00735696|EXPERIMENTAL|ramucirumab + paclitaxel + carboplatin|"Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle).~In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks."
62695397|NCT03960736|ACTIVE_COMPARATOR|Group TEA = Thoracic epidural analgesia group|TEA will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
62336368|NCT06400836|ACTIVE_COMPARATOR|Carbohydrate drink|All study participants will receive the carbohydrate (CHO) drink and the placebo in a randomized, doubleblind crossover fashion. The CHO drink and placebo products have similar appearance and taste.
62336369|NCT06400836|PLACEBO_COMPARATOR|Placebo|All study participants will receive the carbohydrate (CHO) drink and the placebo in a randomized, double-blind crossover fashion. The CHO drink and placebo products have similar appearance and taste.
62336370|NCT01096849|EXPERIMENTAL|plazomicin (10 mg/kg)|Patients received two intravenous (IV) infusions daily for 5 consecutive days: 10 milligrams per kilogram (mg/kg) plazomicin followed by placebo.
62336371|NCT01096849|EXPERIMENTAL|plazomicin (15 mg/kg)|Patients received two IV infusions daily for 5 consecutive days: 15 mg/kg plazomicin followed by placebo.
62336372|NCT01096849|ACTIVE_COMPARATOR|levofloxacin|Patients received two IV infusions daily for 5 consecutive days: placebo followed by 750 milligrams (mg) levofloxacin.
62336373|NCT04970524|EXPERIMENTAL|control group(conventional free gingival graft)|Conventional free gingival grafts are applied to the areas of the patients determined by randomization as suggested by Sullivan and Atkins.
62336374|NCT04970524|EXPERIMENTAL|test group(Partially de-epithelialized free gingival graft)|Partial free gingival graft is applied to the areas of the patients determined by randomization. Unlike the control group, the epithelium on the graft was partially epithelialized.
62336375|NCT04330755|PLACEBO_COMPARATOR|Group C|Control group will received saline
62336376|NCT04330755|ACTIVE_COMPARATOR|Group L|Levosimendan group will received levosimendan infusion
62336377|NCT04330755|ACTIVE_COMPARATOR|Group M|Levosimendan and Magnesium sulphate group will received both drugs
62336378|NCT02127944||FERTILE GROUP|WOMEN HAVE NO INFERTILITY PROBLEMS AND HAVE AT LEAST ONE CHILD
62493316|NCT06289296|EXPERIMENTAL|Fatty acid intake in lean males|Lean males will be studied before and after 7 days daily intake of either Medium-chain fatty acids or Long-chain fatty acids. . After a wash-out period the intervention is repeated in opposite sequence.
62493317|NCT06289296|EXPERIMENTAL|Fatty acid intake in obese males|In obese male participants will be studied before and after 7 days daily intake of either medium-chain fatty acids (MCT) or long-chain fatty acids (LCT). After a wash-out period the intervention is repeated in opposite sequence.
62493318|NCT00624351|PLACEBO_COMPARATOR|Placebo|Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
62493319|NCT00624351|EXPERIMENTAL|EMAB 600mg|600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
62493320|NCT00624351|EXPERIMENTAL|EMAB 100mg|100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
62493321|NCT00624351|EXPERIMENTAL|EMAB 400mg|400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
62493322|NCT00624351|EXPERIMENTAL|EMAB 1200mg|1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
62493323|NCT00624351|EXPERIMENTAL|EMAB 1800mg|1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
62493324|NCT05863221|EXPERIMENTAL|Group 1|ZYNRELEF® up to 200 mg/ 6mg ( 7ml vial) via instillation at all incision sites in addition to 30 ml of 0.5% Ropivacaine + 10mg dexamethasone. Postoperatively, intermittent IV acetaminophen will be administered as per need till discharge.
62493325|NCT05863221|NO_INTERVENTION|Group 2|30 ml of 0.5% Ropivacaine and 10mg dexamethasone into all surgical sites and intermittent IV acetaminophen as per need till discharge.
62493326|NCT01064960|EXPERIMENTAL|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
62336379|NCT02127944||UNEXPLAINED INFERTILE GROUP|WOMEN WITH INFERTILITY PROBLEMS,NO HISTORY OF PREGNANCY AND HAVE NO CHILDREN
62493327|NCT01756313|EXPERIMENTAL|Laser+Methylaminolevulinat|It's a single arm. Intervention as described in the detailed description.
62493328|NCT01296841|NO_INTERVENTION|Standard encounter|"Standard in-house clinical visit between patient and physician."
62493329|NCT01296841|EXPERIMENTAL|Telemedicine Encounter|Remote clinical appointment between patient and physician.
62493330|NCT06033586|EXPERIMENTAL|Open-label rusfertide|Open-label rusfertide
62695398|NCT04278924|PLACEBO_COMPARATOR|Part A: Double Blind, Placebo|TAK-079 placebo-matching injection subcutaneously (SC) once weekly (QW) for 8 weeks.
62695399|NCT04278924|EXPERIMENTAL|Part A: Double Blind, TAK-079 Dose 1|TAK-079 Dose 1, SC injection QW for 8 weeks.
62695400|NCT04278924|EXPERIMENTAL|Part A: Double Blind, TAK-079 Dose 2|TAK-079 Dose 2, SC injection QW for 8 weeks.
62493331|NCT02896296|EXPERIMENTAL|RBP-6000 (100/300 mg Flex)|"On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time.~For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator."
62493332|NCT02146690|OTHER|osteopathic manipulative treatment|newborns will receive osteopathic manipulative evaluation and treatment during the entire period of hospitalization plus usual care
62493333|NCT02146690|OTHER|sham|newborns will receive sham treatment for the entire period of hospitalization plus usual care
62493334|NCT02146690|OTHER|usual care|newborns allocated in the usual care arm will receive standard care only
62493335|NCT05636111|EXPERIMENTAL|Dose Escalation and Dose Expansion|Pariticipants will be assigned to a dose level of combined paclitaxel, bevacizumab, and lurbinectedin
62336380|NCT05347498|EXPERIMENTAL|Treatment group A|HR091506 tablets + placebo of febuxostat tablets
62493336|NCT02107469|EXPERIMENTAL|Ancient herbal treatment|"Phyllanthus niruri 3g fine dry powder 3 times a day with warm water before meals for 8 weeks~Sida cordifolia 7g coarse dry powder 2 times a day prepared as traditional decoction before meals for 8 weeks. Decoction: Take provided measurement cup full of water (112ml) and soak one portion (pe-packed) of the powder for 12 hours, then boil it until the upper level has been reduced to 1/4, filter, cool down to room temperature, drink"
62493337|NCT02107469|EXPERIMENTAL|Modern extract herbal treatment|"Phyllanthus niruri extract 2 capsules 3 times a day with warm water before meals for 8 weeks~Sida cordifolia roots extract 2 capsules 2 times a day with warm water before meals for 8 weeks"
62336381|NCT05347498|ACTIVE_COMPARATOR|Treatment group B|febuxostat tablets + placebo of HR091506 tablets
62336382|NCT00915447||Cat Allergic Rhinitis|Individuals with cat allergic rhinitis, yet without routine cat exposure
62336383|NCT05524441||Airline 1|2 conditions; 18 participants per condition (n = 36)
62493338|NCT02107469|PLACEBO_COMPARATOR|Placebo|"Phyllanthus niruri placebo 2 capsules 3 times a day with warm water before meals for 3 weeks~Sida cordifolia placebo 2 capsules 2 times a day with warm water before meals for 3 weeks"
62695401|NCT04278924|EXPERIMENTAL|Part A: Open-label Extension (OLE) Phase, TAK-079 Dose 1|Participants who received placebo in double-blind Part A and opt to receive further treatment will be randomized to receive TAK-079 Dose 1, SC injection QW for 8 weeks in OLE Phase of Part A.
62695402|NCT04278924|EXPERIMENTAL|Part A: OLE Phase, TAK-079 Dose 2|Participants who received placebo in double-blind Part A and opt to receive further treatment will be randomized to receive TAK-079 Dose 2, SC injection QW for 8 weeks in OLE Phase of Part A.
62336384|NCT05524441||Airline 2|2 conditions; 18 participants per condition (n = 36)
62336385|NCT05524441||Airline 3|2 conditions; 18 participants per condition (n = 36)
62336386|NCT05524441||Airline 4|2 conditions; 18 participants per condition (n = 36)
62336387|NCT02320695|PLACEBO_COMPARATOR|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
62336388|NCT02320695|PLACEBO_COMPARATOR|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
62336389|NCT02320695|EXPERIMENTAL|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
62493339|NCT05878132|EXPERIMENTAL|Wearable device group|Participants in the experimental group will be instructed to wear the wristwatch device five days per week for a minimum of 3 hours per day and engage in telerehabilitation, 1hour per day for 5 times per week over 4 weeks. Weekly, there will be a 30-minute therapy consultation.
62493340|NCT05878132|ACTIVE_COMPARATOR|Conventional therapy group|The participants in the conventional group will receive similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They are instructed to perform the exercises 1hour per day, 5times per week over 4 weeks. Weekly, there will be a 30-minute therapy consultation.
62493341|NCT03720548|EXPERIMENTAL|LY3372993 (Part A)|LY3372993 administered intravenously (IV) to healthy participants.
62493342|NCT03720548|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered IV to healthy participants.
62493343|NCT03720548|EXPERIMENTAL|LY3372993 (Part B)|LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.
62493344|NCT03720548|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.
62493345|NCT03345615|EXPERIMENTAL|Intensive Monitoring|30-day ambulatory cardiac event monitoir
62493346|NCT03345615|NO_INTERVENTION|Standard Care|Standard Care (no supplemental monitoring)
62493347|NCT01724762|EXPERIMENTAL|Nursing orientation|Patients who received nursing orientation and read the informative manual concerning bed bath
62336390|NCT02320695|EXPERIMENTAL|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
62336391|NCT02320695|EXPERIMENTAL|Original Ointment|Neosporin® Original Ointment (0.3 cc)
62336392|NCT02320695|EXPERIMENTAL|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
62336393|NCT02960048|ACTIVE_COMPARATOR|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
62336394|NCT02960048|EXPERIMENTAL|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
62493348|NCT01158313||Thickener|"Patients with history of swallowing difficulties associated with aging and/or neurological diseases including patients with:~* neurodegenerative diseases.~* non-progressive neurological diseases including stroke.~* older patients including nursing home patients."
62493349|NCT02064153|ACTIVE_COMPARATOR|Cool dialysate|Recruited study subject undergoes cool dialysate (35.5ºC) session.
62493350|NCT02064153|ACTIVE_COMPARATOR|Warm dialysate|Recruited study subject undergoes warm dialysate (37ºC) session.
62493351|NCT02386358|ACTIVE_COMPARATOR|Benznidazole|Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days
62493352|NCT02386358|PLACEBO_COMPARATOR|Placebo|Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days
62493353|NCT03264716|EXPERIMENTAL|HepaSphere TACE (transarterial chemoembolization)|Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis. TACE using HepaSphere load with doxorubicin.
62493354|NCT02218541|OTHER|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
62493355|NCT02218541|OTHER|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
61941100|NCT03633136|EXPERIMENTAL|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
62137730|NCT03414645|PLACEBO_COMPARATOR|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
62493356|NCT02054494||HIV patients with high CD4+ cell counts|HIV Infection, Chronic high CD4+ cell counts (\>500 /μl), No known cardiac disease
62493357|NCT02054494||HIV patients with low CD4+ cell counts|HIV Infection, Chronic low CD4+ cell counts (\<200 /μl), No known cardiac disease
62493358|NCT02054494||Control Group|No known cardiac disease.
62493359|NCT02626260|EXPERIMENTAL|Cohort 1b|The subject test one adhesive strip on the peristomal area
62493360|NCT04462276|EXPERIMENTAL|Arm A: Atezolizumab + thoracic radiotherapy|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W) Thoracic radiation therapy (TRT), 30 Gy in 10 fractions
62493361|NCT04462276|EXPERIMENTAL|Arm B: Atezolizumab|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
62493362|NCT02614196|EXPERIMENTAL|Galcanezumab 120mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
62493363|NCT02614196|EXPERIMENTAL|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
62493364|NCT02614196|PLACEBO_COMPARATOR|Placebo|Placebo given by SC injection once a month for 6 months.
62493365|NCT02614196|EXPERIMENTAL|Galcanezumab 120mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
62493366|NCT02614196|EXPERIMENTAL|Galcanezumab 240mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given by SC injection once a month for 6 months.
62493367|NCT02614196|PLACEBO_COMPARATOR|Placebo Maximum Extended Enrollment Cohort|Placebo given by SC injection once a month for 6 months.
62493368|NCT02207582|EXPERIMENTAL|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
62493369|NCT02207582|PLACEBO_COMPARATOR|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
62493370|NCT00682201||1|Healthy pregnant women
62695403|NCT04278924|PLACEBO_COMPARATOR|Part B: Double Blind, Placebo|TAK-079 placebo-matching injection SC, QW for 8 weeks.
61941101|NCT04613531||Participants with PD|patients with clinically diagnosed Parkinson's disease
61941102|NCT04613531||Participants without PD|participants clinically diagnosed without Parkinsons' Disease
61941103|NCT02286583|NO_INTERVENTION|Microwave Thermography RTM-01-RES|Microwave thermography with sensitive probe that can detect skin and up to 8 cm microwave radiation deep tissues
62493371|NCT01304979|NO_INTERVENTION|Usual care alone|Subjects receive usual care alone before and after spine fusion surgery
62493372|NCT01304979|EXPERIMENTAL|Active Intervention|Acupuncture therapies, ear seeds, acupuncture treatment and gua sha, designed to reduce pain and facilitate recovery for low back spine fusion patients.
62493373|NCT01304979|SHAM_COMPARATOR|Control Arm|Indirect therapies with same encounter time and timing as direct care group.
62493374|NCT05063630|EXPERIMENTAL|Medical treatment plus intracranial stenting (MT plus IS)|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
62493375|NCT05063630|ACTIVE_COMPARATOR|Medical treatment alone (MT)|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
62493376|NCT01353157||patients with elective cardiac surgery|
62493377|NCT05826301|EXPERIMENTAL|Percutaneous neuromodulation in tibial nerve|"Specifically, the procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.~2 times per week"
62493378|NCT05826301|ACTIVE_COMPARATOR|Percutaneous electrolysis|"The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per week"
62493379|NCT06236880|EXPERIMENTAL|Low Dose to High Dose of GM-2505|
62493380|NCT06236880|EXPERIMENTAL|Moderate Dose to High Dose of GM-2505|
62695404|NCT04278924|EXPERIMENTAL|Part B: Double Blind, TAK-079 Dose 3|TAK-079 Dose 3, SC injection QW for 8 weeks.
62493381|NCT03195387|EXPERIMENTAL|D-1/120 mg MMV390048|Treatment of cohort 1: subjects receive a single oral dose of MMV390048 on Day -1, prior to PfSPZ challenge on Day 0.
62493382|NCT03195387|EXPERIMENTAL|D-7/120 mg MMV390048|Treatment of cohort 2: subjects receive a single oral dose of MMV390048 on Day -7, prior to PfSPZ challenge on Day 0.
62493383|NCT03195387|EXPERIMENTAL|D-X/YY mg MMV390048|Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
62493384|NCT03195387|PLACEBO_COMPARATOR|Placebo|MMV390048 placebo
62493385|NCT03212651|EXPERIMENTAL|Patients with MIBC (Muscle Invasive Bladder Cancer)|Cisplatinum-ineligible patients with muscle-invasive bladder cancer
61941104|NCT00987545|PLACEBO_COMPARATOR|Placebo|
61941105|NCT00987545|EXPERIMENTAL|QAX576|
62336395|NCT06516666|EXPERIMENTAL|Depressed group|"The participants were categorized into two groups using the Patient Health Questionnaire (PHQ-9) and the 17-item Hamilton Depression Rating Scale (HAM-D). PHQ-9 is a self-report scale. PHQ-9 scores of 5 or higher represent mild and severe depression, while PHQ-9 scores of lower than 5 mean normal condition. HAM-D is a scale administered by a healthcare professional. The cut-off point of the HAM-D scale is 8, which divides normal conditions from depressive conditions. The participants first completed PHQ-9. For those with PHQ-9 scores of 5 or higher, the trained researchers interviewed them and rated their severity of depression on the HAM-D. The participants first completed PHQ-9.~For those with PHQ-9 scores ≥ 5, the trained researchers interviewed them and rated their severity of depression on the HAM-D. Those with HAM-D scores \> 8 were classified into the depressed group."
62336396|NCT06516666|EXPERIMENTAL|Non-depressed group|Those with PHQ-9 scores \< 5 or HAM-D scores ≤ 8 were classified into the non-depressed group.
62336397|NCT02681952|ACTIVE_COMPARATOR|Renamezin->Kremezin|
62336398|NCT02681952|ACTIVE_COMPARATOR|Kremezin->Renamezin|
62336399|NCT04813848|EXPERIMENTAL|Varnish fluoride|Varnish fluoride to be applied on the surface of exposed dentin
62336400|NCT04813848|ACTIVE_COMPARATOR|Bonding agent|Bonding agent to be applied on the surface of exposed dentin
62336401|NCT05506592|ACTIVE_COMPARATOR|Selenium disulfide shampoo|
62336402|NCT05506592|PLACEBO_COMPARATOR|placebo shampoo|
61941106|NCT06449898|OTHER|hemodialysis group|Undergoing hemodialysis treatment for at least 6 months.
62137731|NCT03933137||Not prolonged length of stay|Living donor patients who had ≤ 6 days length of stay after laparoscopic nephrectomy procedure
62336403|NCT00625365|OTHER|DEFINITY® (Perflutren Lipid Microsphere)|Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
62336404|NCT02710266|PLACEBO_COMPARATOR|Placebo group|hepatectomy without Gabexate Mesilate
62336405|NCT02710266|EXPERIMENTAL|Preoperative Gabexate Mesilate group|Gabexate Mesilate administered from the preoperative day
62336406|NCT02710266|EXPERIMENTAL|Intraoperative Gabexate Mesilate group|Gabexate Mesilate administered from the operative day
62336407|NCT00297362||Galantamine hydrobromide|
62336408|NCT00233259|ACTIVE_COMPARATOR|1|Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
62336409|NCT00233259|PLACEBO_COMPARATOR|2|Control group
62336410|NCT03453151|EXPERIMENTAL|Regional nerve anesthesia|
62336411|NCT03259997|ACTIVE_COMPARATOR|Probiotic supplement|
62336412|NCT03259997|PLACEBO_COMPARATOR|Placebo|
62336413|NCT03759457|EXPERIMENTAL|High Flow Nasal Cannula|High Flow Nasal Cannula is a relatively new technique able to deliver both oxygen and high flow in order to improve oxygenation and waking out CO2 from the upper airways
62336414|NCT04657952|ACTIVE_COMPARATOR|Standard medical Treatment (paracetamol)|Patients will receive paracetamol 1 gm every 6 hours daily intravenously for a day.
62336415|NCT04657952|EXPERIMENTAL|Sphenopalatine block|Patients will receive sphenopalatine block
62336416|NCT06017947|NO_INTERVENTION|standard process|
62336417|NCT06017947|EXPERIMENTAL|Musical intervention|
62336418|NCT04982120|EXPERIMENTAL|Repris Needle|Reprise sheath and needle
62336419|NCT06065267|EXPERIMENTAL|sequential|Measure eradication rate of Helicobacter pylori infection with Levofloxacien sequential based regimen
62336420|NCT06065267|ACTIVE_COMPARATOR|concomitant|Measure eradication rate of Helicobacter pylori infection with Livofloxacine concomitant based regimen
62493386|NCT02525263|EXPERIMENTAL|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
62493387|NCT02247037||Triple Negative Breast Cancers|All women eligible for this protocol will fall into this group. These women will have histologically confirmed triple negative breast cancer and be eligible for neoadjuvant chemotherapy or have evidence of metastatic disease.
62493388|NCT05646537|EXPERIMENTAL|The group to which NLP techniques will be applied|"After the participant consented to participate in the study with the Informed Consent Form, her comfort level was measured with the Postpartum Comfort Scale.~A session of NLP (30 minutes) was applied to the participant. The patient was informed about the application. The mother was asked to sit or lie down i Before the discharge of the participant from the hospital, her comfort level was evaluated once again by using the Postpartum Comfort Scale"
62493389|NCT05646537|NO_INTERVENTION|Control group|"After the participant consented to participate in the study with the Informed Consent Form, her comfort level was measured with the Postpartum Comfort Scale.~Without having any additional practice, the participant solely had the routine clinical protocol.~Before the discharge of the participant from the hospital, her comfort level was evaluated once again by using the Postpartum Comfort Scale."
62493390|NCT02528019|ACTIVE_COMPARATOR|DPP-4 inhibitors|sitagliptin (25-100mg daily), vildagliptin (50-100mg daily), alogliptin (12.5-25mg daily), linagliptin (2.5-5mg daily), teneligliptin (20-40mg), anagliptin (100-200mg daily), saxagliptin (2.5-5mg daily) or trelagliptin (50-100mg weekly)
62493391|NCT02528019|ACTIVE_COMPARATOR|SGLT2 inhibitors|ipragliflozin (50-100mg daily), dapagliflozin (5-10mg daily), luseogliflozin (2.5-5mg), tofogliflozin (20mg daily), canagliflozin (100mg daily) or empagliflozin (10-25mg daily)
62493392|NCT02528019|ACTIVE_COMPARATOR|Glimepiride|glimepiride (0.5-8mg daily)
62493393|NCT04211480|EXPERIMENTAL|γ-globin reactivated autologous hematopoietic stem cells|each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells
62493394|NCT03234309|EXPERIMENTAL|Diagnostic (ferumoxytol, MRI)|Patients undergo MRI with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol IV followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator.
62493395|NCT01301937|ACTIVE_COMPARATOR|High continuous dose|Meglumine antimoniate 20 mg/kg/day for 30 continuous days
62493396|NCT01301937|ACTIVE_COMPARATOR|Low continuous dose|Meglumine antimoniate 5 mg/kg/day for up to 120 continuous days according to clinical cure
62493397|NCT05055687|EXPERIMENTAL|Part A：FL058|a single ascending dose (SAD) of intravenous (IV) FL058(2500mg\~3000mg)
62336421|NCT03535324|EXPERIMENTAL|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
62336422|NCT03535324|OTHER|Control|There will be no intervention.
62493398|NCT05055687|PLACEBO_COMPARATOR|Part A：Placebo|FL058 Placebo
62493399|NCT05055687|EXPERIMENTAL|Part B：FL058|a multiple ascending dose (MAD) of intravenous (IV) FL058(500mg\~2000mg)
61941107|NCT03645928|EXPERIMENTAL|Cohort 1A|LN-144 therapy in combination with pembrolizumab in patients with Stage IIIC to IV unresectable or metastatic melanoma with ≤ 3 prior lines of systemic therapy, excluding checkpoint inhibitors (CPI).
62336423|NCT00364845|ACTIVE_COMPARATOR|Darbepoetin alfa|Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
62336424|NCT00364845|PLACEBO_COMPARATOR|Placebo|Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.
62336425|NCT02324179||HIV positive|people with HIV diagnosis
62493400|NCT05055687|PLACEBO_COMPARATOR|Part B：Placebo|FL058 Placebo
62493401|NCT04816851||Ozaki group|Patients undergoing aortic valve reconstruction using autologous pericardium (OZAKI technique) at Assiut University Hospitals in conjunction with Al-Nas hospital in cairo.
62493402|NCT01940445|EXPERIMENTAL|ResurFX treatment|Fractional Non Ablative (NA) treatment on one side of the face with the M22 ResurFX module
62493403|NCT01940445|EXPERIMENTAL|M22 ResurFX and QS treatment|Fractional NA treatment with the M22 ResurFX followed by Q-Switched (QS) laser treatment (SST) on one side of the face
62493404|NCT06602414||Conservative treatment|Patients treated conservatively for distal biceps tendon rupture
62493405|NCT02600676|ACTIVE_COMPARATOR|TENS, 10 weeks (active) 2 hours a day.|26 children.
62493406|NCT02600676|PLACEBO_COMPARATOR|TENS, 10 weeks (placebo) 2 hours a day.|26 children.
62493407|NCT03493919|EXPERIMENTAL|rMenB+OMV NZ Group|Participants vaccinated intramuscularly with Bexsero vaccine at Day 1 and Day 61 and blood samples were collected at Day -83, Day 8, and Day 98.
62493408|NCT03493919|EXPERIMENTAL|MenACWY 1 Group|Participants vaccinated intramuscularly with Menveo vaccine at Day 1 and blood samples were collected at Day -83, Day 8, and Day 151.
62493409|NCT03493919|EXPERIMENTAL|MenACWY 2 Group|Participants vaccinated intramuscularly with Menveo vaccine at Day 1 and blood samples were collected at Day -60, Day 31, and Day 151.
62493410|NCT03493919|EXPERIMENTAL|MenACWY 3 Group|Participants vaccinated intramuscularly with Menveo vaccine at Day 1 and blood samples were collected at Day -30, Day 61, and Day 151.
62493411|NCT04919616|EXPERIMENTAL|Single-arm|
61941108|NCT03645928|EXPERIMENTAL|Cohort 1B|LN-145-S1 therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor with or without a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.
62336426|NCT02324179||Control (HIV negative)|people without HIV
62493412|NCT05964049|EXPERIMENTAL|active rTMS treatment|5 sessions of active rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse and inter-session interval of 20 min.
62493413|NCT05964049|SHAM_COMPARATOR|sham control|5 sessions of sham rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse and inter-session interval of 20 min.
62493414|NCT03840577|NO_INTERVENTION|Sedation guided by Clinical Scales|Sedative guided by RASS (Richmond Agitation-Sedation Scale) score. Target RASS: -4 / -5.
62493415|NCT03840577|EXPERIMENTAL|Sedation guided by Bispectral Index|Sedation guided by the Bispectral Index (BIS). Target BIS between 40 to 60.
62493416|NCT05810636||ADHD group|"Inclusion criteria:~* DSM-5 Attention-deficit hyperactivity disorder~* 7\~18 years old~* Willing to carry smartwatch and smartphone most of the time during one-month study period~Exclusion criteria:~- Comorbid with major psychiatric disorders (i.e., schizophrenia, bipolar disorder) or neurodevelopmental disorders (i.e., intellectual disability, autism spectrum disorder)"
62493417|NCT05810636||Neurotypical group|"Inclusion criteria:~* 7\~18 years old without a diagnosis of Attention-deficit hyperactivity disorder~* Willing to carry smartwatch and smartphone most of the time during one-month study period~Exclusion criteria:~* Have a diagnosis of major psychiatric disorders (i.e., schizophrenia, bipolar disorder) or neurodevelopmental disorders (i.e., intellectual disability, autism spectrum disorder)~* Unable to use smartwatch and smartphone"
62493418|NCT04039230|EXPERIMENTAL|Sacituzumab Govitecan+Talazoparib|"* Sacituzumab Govitecan is administered on days 1 and 8 of a 21 day cycle.~* Talazoparib is administered daily"
62493419|NCT05228249|EXPERIMENTAL|Treatment (loncastuximab tesirine, BEAM chemotherapy)|"PART I (CONDITIONING): Patients receive loncastuximab tesirine IV on day -7, carmustine IV over 2 hours on day -7, etoposide IV over 1-2 hours BID days -6, -5, -4, and -3, cytarabine IV over 1 hour BID on days -6, -5, -4, and -3, and melphalan IV over 15-20 minutes on day -2. Patients undergo peripheral blood ASCT per standard practice on day 0.~PART II (MAINTENANCE): Beginning 30-90 days after ASCT, patients receive loncastuximab tesirine IV Q3V for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
62493420|NCT04149301||Typically developing children|Children who do not have a problem with their walking ie children who do not have cerebral palsy
61941109|NCT03645928|EXPERIMENTAL|Cohort 1C|LN-144 Generation 3 (Gen 3) therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.
62336427|NCT05088616|EXPERIMENTAL|Virtual Diabetes Wellness Classes and Medically Tailored Meals|"All participants will receive the same intervention: four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals. Additionally, participants will be paired with one to two buddies to provide support to each other."
62336428|NCT04361643|EXPERIMENTAL|Experimental|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
62336429|NCT04361643|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3, and 5.
62336430|NCT04264767||Cases Group|Peripheral blood collection via routine venipuncture
62336431|NCT04264767||Control Group|Peripheral blood collection via routine venipuncture
62336432|NCT02653976|EXPERIMENTAL|SP-02L (darinaparsin for injection)|
62336433|NCT05728086|EXPERIMENTAL|Group art therapy|Participants randomised to the intervention group receive the group art therapy intervention shortly after baseline assessment. Adherence to the intervention will be checked via an adherence questionnaire completed by therapist delivering the intervention after each session. In addition, 20% of sessions will be observed by an independent researcher for adherence checking.
62336434|NCT05728086|NO_INTERVENTION|waitlist control group|Participants randomised to the waitlist control group will complete outcomes measures at baseline and at the end of a 6 week waiting period. They will then begin the intervention (1-2 weeks after the intervention group has finished).
62336435|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
62493421|NCT04149301||Children with cerebral palsy without foot deformity|
62493422|NCT04149301||Children with cerebral palsy with mild foot deformity|
62493423|NCT04149301||Children with cerebral palsy with severe foot deformity|
62493424|NCT01675973|EXPERIMENTAL|Subjects with severe renal impairment|Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
61941110|NCT03645928|EXPERIMENTAL|Cohort 2A|LN-145 therapy in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding CPIs.
61941111|NCT03645928|EXPERIMENTAL|Cohort 3A|LN-145 therapy in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III or Stage IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding CPIs, or ≤ 4 lines if 2 or more of the lines are TKI therapy for those with tumors that harbored actionable mutations (eg, EGFR, ALK, ROS).
62336436|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
62336437|NCT02548273||Diabetics|diabetics with cataract who opted for phacoemulsification surgery
62336438|NCT02548273||controls|non-diabetics with cataract who opted for phacoemulsification surgery (subjects without corneal opacity, PXF ,high myopia, uveitis)
62336439|NCT05580055||Capillary Sample|This group donates finger prick blood samples to Entia for the purpose of development.
62336440|NCT05580055||Venous Sample|This group donates venous blood samples to Enta, taken by a registered nurse.
62336441|NCT06048237||Reliability Assessment Arm|This is a single-arm reliability assessment study. Reliability will be assessed by conducting measurements of diaphragm thickness and excursion on the same participants by the same rater (intra-rater reliability) and by different raters (inter-rater reliability) to evaluate measurement consistency.
62336442|NCT02940626|PLACEBO_COMPARATOR|Placebo|Placebo administered as 2 separate intravenous (IV) infusions
62336443|NCT02940626|EXPERIMENTAL|ASN100|ASN100 administered as 2 separate intravenous (IV) infusions
62336444|NCT01976819|EXPERIMENTAL|TW speaking valve/HME|Use of the TW speaking valve/HME
62493425|NCT01675973|EXPERIMENTAL|Subjects with normal renal function|Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
62493426|NCT02324452|EXPERIMENTAL|heterozygous carrier of DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD\*2A, c.2846A\>T, c.1236G\>A/HapB3 and DPYD\*13) that are found to be heterozygous for one of these SNPs
62493427|NCT02324452|EXPERIMENTAL|wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD\*2A, c.2846A\>T, c.1236G\>A/HapB3 and DPYD\*13) that are found to be wild type for these SNPs
62493428|NCT04721145|EXPERIMENTAL|Dexcom G6 Continuous Glucose Monitor|Children with type 1 diabetes will wear a continuous glucose monitor (CGM) for 10 days.
62493429|NCT02942810|EXPERIMENTAL|WCK 5222 (Cefepime and zidebactam combination)|IV infusion over a period of 60 minutes
62493430|NCT01834027|EXPERIMENTAL|Jazz music|Jazz music will be played through headphones to post-surgical hysterectomy patients while they are in the post anesthesia care unit.
62493431|NCT01834027|ACTIVE_COMPARATOR|No music|The patients in this group with have headphones but no music will be played.
62493432|NCT01310855|ACTIVE_COMPARATOR|Cediranib & Gefitinib|Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
62493433|NCT01310855|PLACEBO_COMPARATOR|Cediranbib & placebo|Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
62493434|NCT04150549|PLACEBO_COMPARATOR|Autologous Transplants|
62493435|NCT04150549|ACTIVE_COMPARATOR|Allogeneic Transplants|
62493436|NCT03010605|ACTIVE_COMPARATOR|Standard of care physical therapy|Patients will receive 2 weeks of in-home physical therapy consisting of 3 sessions per week followed by 4 weeks of outpatient physical therapy three times weekly.
62493437|NCT03010605|ACTIVE_COMPARATOR|MED Device|Patients will perform 10 repetitions with the MED device 3 times daily at 8am, 2pm, and 8pm and will transmit the 10th measurement of each time point to the clinicians office.
62493438|NCT06380387|EXPERIMENTAL|Meal intervention with stable isotopes|A liquid mixed meal are gived adjusted by weight. The meal consists of: Intrinsically labelled D5-Phenylalanine and D3-Leucine labelled casein protein, 13C16palmitate, 13C6-Glucose in a mix of glucose, casein protein and rape seed oil dissolved in water in an energy density of 50% CHO, 35% fat and 15% protein. Blood samples are drawn frequently to measure fat, glucose and protein metabolism.
62493439|NCT05529238|OTHER|supervised group during study|monthly physiotherapist appointment for half of the cohort including pelvic floor examination by physiotherapist including digital palpation and perineometry.
62493440|NCT05529238|NO_INTERVENTION|unsupervised group during study|No intervention. Participants to practice kegel exercises at home.
62493441|NCT05563207|EXPERIMENTAL|control group|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff. Among them, patients in the control group were given intervention for TCM health education standard path. During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
62493442|NCT05563207|ACTIVE_COMPARATOR|observation group|The patients in the observation group were given TCM health education standard path intervention. The contents of the health intervention mainly included: ① Graphic and text education;②Language education;③ Psychological education; ④Dietary education; ⑤ Complication education
62493443|NCT02190786|EXPERIMENTAL|KUX-1151, Low dose|
61941112|NCT03645928|EXPERIMENTAL|Cohort 3B|LN-145 therapy as a single agent in patients with Stage III or Stage IV NSCLC, who have previously received 1-3 lines of prior systemic therapy. Patients with known oncogene drivers (eg, EGFR, ALK, ROS) who have mutations that are sensitive to targeted therapies are not required to have received prior systemic therapy with CPIs.
62137732|NCT03933137||Prolonged length of stay|Living donor patients who had \> 6 days length of stay after laparoscopic nephrectomy procedure
62336445|NCT04942938|EXPERIMENTAL|Neubie Treatment|"Participants in this study will participate in intervention treatment with the Neubie for 6 weeks. Outcome measures objective and subjective will be collected at the beginning and end of the study. The treatments will include:~1. Manual activations to underactive, spastic or limited in sensory muscles/regions~2. Neubie Mapping mode scanning process to scan for 1) spots that stimulate movement they couldn't do before per initial assessment, 2) spots that allow movement which is a greater range than available before per initial assessment, 3) spots that lead to decreased spasticity, and 4) diminished sensation areas - drive signal to increase sensory nerves and become metabolically active.~3. Train using physical therapy exercises with Neubie in training mode and Hz current adjusted for tolerance (perceived 7/10) and ability to work through or decrease spasticity in (500 Hz) in the areas which show spasticity, contraction, are dead/diminished sensation, and hot spots."
62336446|NCT01671969|EXPERIMENTAL|very low calorie diet|
62336447|NCT05642013|EXPERIMENTAL|Prospective group|50 patients prospectively included with early prosthesis reimplantation
62336448|NCT05642013|OTHER|Retrospective group|Last 50 patients with hip or knee prosthetic-joint infection managed with classical two-stage implant exchange
62336449|NCT06032299|ACTIVE_COMPARATOR|Single Distal Femur Implant Group|Subjects will receive one of two types of implants for the distal femur fracture. The single implant will be either a plate and screws or a rod. The type of single implant used will be determined by the surgeon based on the characteristics of the fracture.
62336450|NCT06032299|EXPERIMENTAL|Dual Distal Femur Implant Group|Subjects will receive two implants for fixation of the distal femur fracture. The dual implant will be either 2 plates with screws or a plate with screws and a rod. The type of dual implant used will be determined by the surgeon based on the characteristics of the fracture.
62336451|NCT01960699||CPC < 3|Good neurological outcome
62336452|NCT01960699||CPC >/= 3|Unvavourable neurologic outcome
62336453|NCT02938585|EXPERIMENTAL|Prophylactic treatment|
62336454|NCT02938585|EXPERIMENTAL|On-demand treatment|
62336455|NCT01523119|ACTIVE_COMPARATOR|Zofran ODT|Zofran ODT (Ondansetron) Orally Disintegrating Tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
62336456|NCT01523119|EXPERIMENTAL|Ondansetron Orally Disintegrating Tablets|Ondansetron Orally Disintegrating Tablets 8 mg Manufactured By Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, USA)
62336457|NCT00184249|EXPERIMENTAL|Bipolar radiofrequency ablation|
62336458|NCT04302103|EXPERIMENTAL|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
62336459|NCT04302103|EXPERIMENTAL|RC18 240 mg|Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
62336460|NCT02330549|EXPERIMENTAL|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food for up to 24 weeks.
62336461|NCT02330549|PLACEBO_COMPARATOR|Placebo|Placebo-matching CVC, administered orally once daily and taken every morning with food for up to 24 weeks.
62336462|NCT01185145|EXPERIMENTAL|Mammosite|Accelerated Partial Breast Irradiation using Mammosite RTS
62336463|NCT01185145|EXPERIMENTAL|IMRT|Accelerated partial breast irradiation using IMRT planning technique of external beam radiotherapy
62336464|NCT03976531||Elderly cancer patients included in randomized controlled trials|
62336465|NCT06296433|EXPERIMENTAL|VR rehabilitation treatment|Daily use of VR rehabilitation program independently at home for a period of 3 weeks. Each daily session is 20 minutes.
62493444|NCT02190786|EXPERIMENTAL|KUX-1151, Middle dose|
62493445|NCT02190786|EXPERIMENTAL|KUX-1151, High dose|
62695405|NCT04278924|EXPERIMENTAL|Part B: OLE Phase, TAK-079 Dose 3|Participants who received placebo in double-blind Part B and opt to receive further treatment will receive TAK-079 Dose 3, SC injection QW for 8 weeks in OLE Phase of Part B.
62695406|NCT04697823|ACTIVE_COMPARATOR|study group|Patients receiving an embryo transfer in hyaluronan-enriched transfer medium
62695407|NCT04697823|NO_INTERVENTION|control group|Patients receiving an embryo transfer in conventional culture medium
61941113|NCT03645928|EXPERIMENTAL|Cohort 3C|LN-145 therapy in combination with ipilimumab and nivolumab in patients with Stage III or Stage IV NSCLC who have previously received 1 line of CPI monotherapy. No other systemic therapy for metastatic disease is allowed. Prior chemoradiation and/or chemotherapy in the adjuvant and/or neo-adjuvant settings are allowed.
62137733|NCT05842382|EXPERIMENTAL|IV Vitamin C (12g/day)|IV Vitamin C 3g diluted with dextrose 5% into 50ml, given every 6 hourly (12g/day), infused over 30 minutes under close monitoring, until successful extubation (minimum 16 doses, maximum 40 doses).
62493446|NCT02629640||Research Participants|Medical history questionnaire; clinical assessment and review; participant follow-up; blood or buccal sample; post mortem examination.
62336466|NCT06296433|PLACEBO_COMPARATOR|VR control treatment|Daily watching 2D video independently at home using VR headset for a period of 20 minutes.
62493447|NCT01207856|ACTIVE_COMPARATOR|group A|specific cognitive rehabilitation
62493448|NCT01207856|ACTIVE_COMPARATOR|Groupe B : non specific rehabilitation|
62493449|NCT01207856|OTHER|group C|group C for MRI, neuropsychological and ecological assessments
62493450|NCT06322251|OTHER|Use of questionnaire|Intervention I: Over a period of two months, healthcare professionals will ask standardized questions about exposure to violence using a questionnaire that measures exposure to physical, psychological, and sexual violence over the past 12 months. These questions will be verbally asked to all patients visiting the care units, regardless of the reason for their visit.
62493451|NCT06322251|OTHER|Use of virtual patient|"Intervention II: Healthcare professionals will undergo training to ask questions about violence in close relationships and practice how to utilize the answers, determine necessary care and interventions, and refer patients further. This training will utilize a virtual patient scenario where users interact with a realistic simulated patient through recorded video sequences. The training with the virtual patient will be conducted individually. On the digital platform, users will have access to the patient's medical background and other relevant information. Users can choose questions from a question bank, and based on their choices, they will receive feedback from both the patient and experts on their questions and treatment in the final part of the platform."
62493452|NCT06322251|OTHER|Combined use of questionnaire and virtual patient|Intervention III: This intervention combines Intervention I and II methods. Participants will investigate the identification of intimate partner violence over a two-month period after training with the virtual patient and in parallel with administering the violence questionnaire.
62493453|NCT03087162|EXPERIMENTAL|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
62695408|NCT04161482|EXPERIMENTAL|Cohort One|A bi-phasic delivery over 5 hours
62695409|NCT04161482|EXPERIMENTAL|Cohort 2a|Continuous infusion over 2 hours
62336467|NCT01457859|ACTIVE_COMPARATOR|Conventional sutures|
62336468|NCT01457859|EXPERIMENTAL|Antiseptic sutures|
62336469|NCT00786032||BCI Device|All participants will use the BCI System as a means of communication.
62336470|NCT02460757||Patients with COPD|
62336471|NCT02460757||Patients with interstitial lung disease|
62336472|NCT02460757||Healthy subjects|
62336473|NCT02730845|ACTIVE_COMPARATOR|Intra-articular dexmedetomidine|Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
62336474|NCT02730845|PLACEBO_COMPARATOR|Intravenous dexmedetomidine|patients will be subjected for elective knee arthroscopy under local anesthesia (i.v. dexmedetomidine + Intra-articular bupivacaine).
62493454|NCT03087162|ACTIVE_COMPARATOR|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
62493455|NCT05499728|EXPERIMENTAL|Telerehabilitation|Subjects who are randomized to telerehabilitation will be provided access to telemedicine visits with a physical therapist. Patients will have one in-person physical therapy visit before starting telerehabilitation, and another in-person visit at 3 months to assess progress. Telerehabilitation visits will be performed via secure usage of the electronic medical record (EMR). To ensure uniformity, and to allow for appropriate access to telehealth services, all telehealth visits will be carried out through the study institution's Department of Physical Therapy. It is expected most patients will complete formal physical therapy by 6 months postoperative measured by the time at which patient's regain functional range of motion or patients are satisfied with their results. Shoulder range of motion will be measured with a goniometer preoperatively, as well as 3,6, 12, and 24 months postoperatively at their regularly scheduled clinic visit.
62695410|NCT04161482|EXPERIMENTAL|Cohort 2b|Bi-phasic delivery over 2 hours
62695411|NCT04161482|EXPERIMENTAL|Cohort 3|Continuous infusion over 1 hour.
62695412|NCT04161482|EXPERIMENTAL|Cohort 4|Continuous infusion over 30 minutes.
62695413|NCT05636176|EXPERIMENTAL|Ziltivekimab|Participants will receive ziltivekimab subcutaneous (s.c.) injection once-monthly and added standard of care for up to 4 years.
62695414|NCT05636176|PLACEBO_COMPARATOR|Placebo|Participants will receive ziltivekimab placebo s.c. injection once-monthly and added standard of care for up to 4 years.
62695415|NCT02304159|EXPERIMENTAL|Group A - 16 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks
62695416|NCT02304159|ACTIVE_COMPARATOR|Group B - 24 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks
62695417|NCT05077072|EXPERIMENTAL|ARM I (CHAT)|Patients participate in CHAT counseling intervention over 45-60 minutes twice a month for up to 12 weeks.
62695418|NCT05077072|EXPERIMENTAL|ARM II (NFB)|Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.
62336475|NCT01848054|EXPERIMENTAL|BNX Sublingual Tablets Induction|"Day 1-2 (Blinded Induction): BNX sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
62336476|NCT01848054|ACTIVE_COMPARATOR|Buprenorphine Induction|"Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
62336477|NCT03209180|ACTIVE_COMPARATOR|Carvedilol IR (Immediate Release)|Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months
62336478|NCT03209180|EXPERIMENTAL|CarVeDilol-SR (Slow Release)|CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months
62336479|NCT01144078|EXPERIMENTAL|High Intensity Interval Exercise|This arms receives the High Intensity Interval Exercise intervention
62336480|NCT01144078|EXPERIMENTAL|Traditional Intensity Exercise|This arms receives the Traditional Intensity Exercise intervention
62336481|NCT03383718||DSE+/FFR+|Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation
62336482|NCT03383718||DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-|"Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Optimal Medical Treatment/OMT"
62336483|NCT03095924|ACTIVE_COMPARATOR|News with Spin|News items reporting results of RCTs with spin
62336484|NCT03095924|EXPERIMENTAL|News without spin|News items reporting results of RCTs without spin
62336485|NCT05939596|EXPERIMENTAL|SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)|100 μg /1.0 mL/dose, One booster dose 1.0mL IM injection of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021).
62336486|NCT05939596|PLACEBO_COMPARATOR|Saline|One booster dose 1.0mL IM injection of saline.
62336487|NCT05658354|EXPERIMENTAL|Computerized cognitive program|25 participants with metabolic syndrome and mild cognitive deficits; receive health advice using the World Health Organization's guidelines for Risk Reduction of Cognitive Decline and Dementia, and perform the computerized cognitive training program (BrainHQ) for 45 minutes per session, twice per week, over the 3-month intervention period.
62336488|NCT05658354|NO_INTERVENTION|Control group|25 participants with metabolic syndrome and mild cognitive deficits; receive health advice using the World Health Organization's guidelines for Risk Reduction of Cognitive Decline and Dementia.
62336489|NCT03758430||Combined Diabetes Management Data|Participants with type 1 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their continuous glucose monitor and insulin pump. Combined data will be used for diabetes management.
62336490|NCT05191823|EXPERIMENTAL|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
62336491|NCT05191823|PLACEBO_COMPARATOR|Placebo|Corn oil supplement
62336492|NCT05466266|EXPERIMENTAL|ICE group|ICE group without TEE detection before procedure
62336493|NCT05466266|ACTIVE_COMPARATOR|TEE group|TEE group with non-ICE usage at the entire procedure
62336494|NCT01658696|ACTIVE_COMPARATOR|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
62336495|NCT01658696|PLACEBO_COMPARATOR|Rabies vaccine|2 x 2.5IU Verorab
62336496|NCT02220075||spontaneous group|maintain spontaneous breathing during the operation, and recording tidal volume, ET CO2, respiratory rate, peak airway pressure, SpO2
62336497|NCT02220075||controlled group|controlled ventilation(tidal volume 8ml/kg, ET CO2 35\~40mmHg) during the operation, recording peak airway pressure, SpO2
62336498|NCT05049837||Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
62336499|NCT05049837||Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
62336500|NCT05049837||Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples.
62336501|NCT05049837||Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
62336502|NCT05049837||Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
62336503|NCT05049837||Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
62336504|NCT04593693|OTHER|Invia Motion Endure NPWT system|Use of Negative Pressure Wound Thearpy
62336505|NCT04820543|EXPERIMENTAL|Simplified Method|In this method, a uniform BTX-A injection technique with single-site injection of 2 U BTX-A (total, 4 U) at both right and left levator labii superioris alaeque nasi muscles (LLSAN) was administered. The injection points located at the muscle bulge at the uppermost part of the nasolabial fold.
62336506|NCT04820543|EXPERIMENTAL|Individualized Method|In this method, the patients were administered BTX-A after 8 months when the effect of the previous injection vanished. And A dosage and injection sites were individualized according to the degree of severity of anterior GE presented pretreatment. For mild GS (3 to\< 5mm), 2 U BTX-A was injected at bilateral LLSAN. For moderate (5 to \< 7mm) and severe GS (≥ 7mm), 3 U and 5 U of BTX-A were injected per side (total, 6 U and 10U). And The injection points located at both LLSAN and the Yonsei point, with half doses at each point.
62336507|NCT01554306||parkinson's disease, nocturnal hypokinesia, rotigotine|
62336508|NCT05414617|EXPERIMENTAL|Medical Device : Happyone|Hyaluronic acid associated with tranexamic acid ; 4.8 ml will be injected in one time
62336509|NCT05414617|EXPERIMENTAL|Medical Device : Happysoft|Hyaluronic acid associated with tranexamic acid ; 2.2 ml will be injected in three times (one injection per week)
62336510|NCT05923476|EXPERIMENTAL|Intervention arm|Lithium and ECT will be administered concomitantly to the intervention group
62336511|NCT05923476|PLACEBO_COMPARATOR|Control arm|Placebo and ECT will be administered to the control group
62336512|NCT02720016|EXPERIMENTAL|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
61941114|NCT05631600|EXPERIMENTAL|Manuka honey|The intervention in this study was conducted in a split-mouth design, meaning that after completing the NSPT for each subject, Manuka honey was administered as an adjunct to the periodontal treatment in two randomly selected quadrants of the oral cavity around the teeth with a specially designed cannula. The cannula reached the bottom of the periodontal pocket and moved circumferentially around the tooth at 6 sites, and Manuka honey was extruded until the excess of the material was observed in the sulcus.
62336513|NCT02720016|ACTIVE_COMPARATOR|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
62336514|NCT02720016|ACTIVE_COMPARATOR|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
62336515|NCT03959449|EXPERIMENTAL|Action Observation and Motor imagery|
62336516|NCT03959449|ACTIVE_COMPARATOR|Motor Imagery|
62493456|NCT05499728|NO_INTERVENTION|Traditional In-Person Physical Therapy|Subjects who are randomized to in-person therapy will present to a physical therapist of their choice with a established written protocol. The therapy protocol is developed in conjunction with the Department of Orthopaedic Surgery and the Department of Physical Therapy. Subjects are recommended to attend in-person appointments at least once a week as well as perform home exercises. Progress with therapy will be collected with weekly phone calls from the research team. It is expected most subjects will complete formal physical therapy by 6 months postoperative attending on average 5-6 visits, measured by the time at which patient's regain functional range of motion or are instructed by their therapist to discontinue. Shoulder range of motion will be measured with a goniometer preoperatively, as well as 3,6, 12, and 24 months postoperatively at their regularly scheduled clinic visit.
62493457|NCT03266276|NO_INTERVENTION|Treatment as Usual Control Group|Treatment as usual.
62493458|NCT03266276|EXPERIMENTAL|Intervention Group|Use of a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
62493459|NCT01448434|EXPERIMENTAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs
62493460|NCT01448434|PLACEBO_COMPARATOR|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
62493461|NCT03773939||Derivation cohort|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624, NCT03577405, and NCT03553069)
62493462|NCT03773939||External validation cohort|We will create a multicenter cohort based on prospectively collected data derived from the Dutch National Intensive Care Evaluation (NICE) registry
62493463|NCT02737462|EXPERIMENTAL|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
62493464|NCT02179190|EXPERIMENTAL|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
62336517|NCT03959449|EXPERIMENTAL|Exercise plus motor imagery and action observation|
62493465|NCT03449225|NO_INTERVENTION|Control Arm|The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.
62493466|NCT03449225|EXPERIMENTAL|Test Arm|• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
62493467|NCT03086941|ACTIVE_COMPARATOR|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
62493468|NCT03086941|ACTIVE_COMPARATOR|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
62336518|NCT00568958|EXPERIMENTAL|Naltrexone|Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling
62336519|NCT00568958|PLACEBO_COMPARATOR|Placebo Naltrexone|Placebo Naltrexone (targeted + daily) + BASICS Counseling
62493469|NCT02223169|EXPERIMENTAL|Egg albumin-derived peptide|Each participant will consume 1 sachet of Egg albumin-derived peptide (3 g) each day mixed with a fruit juice drink for 42 days.
62493470|NCT02223169|PLACEBO_COMPARATOR|Placebo|Participants will consume one sachet of the placebo mixed with a fruit juice drink that will appear and taste similar to the albumin derived peptide sachet.
62493471|NCT06338410|EXPERIMENTAL|KMC group|Premature infants and their mothers who will be provided with kangaroo mother care on third day of life. baby will be placed on bare chest of mother and before and after KMC urine samples will be collected from premature infants.
61941115|NCT05117333|ACTIVE_COMPARATOR|Basic letter|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed.
62137734|NCT05842382|PLACEBO_COMPARATOR|Placebo|IV dextrose 5% 50ml, given every 6 hourly, infused over 30 minutes under close monitoring, until successful extubation (minimum 16 doses, maximum 40 doses).
62493472|NCT06338410|NO_INTERVENTION|Control group|premature infants and their mothers who will be provided with same conventional incubator care in NICU on day third of life their urine samples will also be collected before and after conventional care
62493473|NCT06078176|EXPERIMENTAL|Bowel emptying|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
61941116|NCT05117333|ACTIVE_COMPARATOR|Co-pay|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland.
61941117|NCT05117333|ACTIVE_COMPARATOR|GP-Co-pay|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland, AND informs recipients that the new law did not abolish co-payments related to general practitioner visits.
62695419|NCT05077072|ACTIVE_COMPARATOR|ARM III (SOC)|Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up to 12 weeks.
62695420|NCT02284893|EXPERIMENTAL|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
62336520|NCT03532672|EXPERIMENTAL|Acute fasting|Participants will fast overnight for 10 hours (resting period), consume a santdardized breakfast, and fast during daily activities (active period) for another 10 hours.
62493474|NCT03708536|EXPERIMENTAL|bevacizumab plus s-1|
62493475|NCT03708536|ACTIVE_COMPARATOR|bevacizumab plus capecitabin|
62695421|NCT02284893|EXPERIMENTAL|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
62695422|NCT06289764|PLACEBO_COMPARATOR|Sweet almond oil|Premenstrual symptom scale will be applied to the participants who volunteered to participate in the study. Aromatherapy will be applied to people with a premenstrual symptom score exceeding 110. 3 groups will be formed from people with pms symptoms. 1st group will receive Bergamot essential oil, 2nd group will receive Grapefruit essential oil, 3rd group (placebo group) will receive sweet almond oil. Selected women will be allowed to smell 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. The aromatic oil will be put 3 drops on a cotton ball and the participants will smell it. Participants will be allowed to inhale the scent for 30 minutes in the fowler position at a distance of 15 cm.
62695423|NCT06289764|EXPERIMENTAL|Bergamot essential oil|Premenstrual symptom scale will be applied to the participants who volunteered to participate in the study. Aromatherapy will be applied to people with a premenstrual symptom score exceeding 110. 3 groups will be formed from people with pms symptoms. 1st group will receive Bergamot essential oil, 2nd group will receive Grapefruit essential oil, 3rd group (placebo group) will receive sweet almond oil. Selected women will be allowed to smell 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. The aromatic oil will be put 3 drops on a cotton ball and the participants will smell it. Participants will be allowed to inhale the scent for 30 minutes in the fowler position at a distance of 15 cm
62695424|NCT06289764|EXPERIMENTAL|Grapefruit essential oil|Premenstrual symptom scale will be applied to the participants who volunteered to participate in the study. Aromatherapy will be applied to people with a premenstrual symptom score exceeding 110. 3 groups will be formed from people with pms symptoms. 1st group will receive Bergamot essential oil, 2nd group will receive Grapefruit essential oil, 3rd group (placebo group) will receive sweet almond oil. Selected women will be allowed to smell 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. The aromatic oil will be put 3 drops on a cotton ball and the participants will smell it. Participants will be allowed to inhale the scent for 30 minutes in the fowler position at a distance of 15 cm
62695425|NCT05498090|NO_INTERVENTION|Arm 1 (Cross-sectional, Cases v. Controls)|Cases (those with Klinefelter) vs. controls (those without Klinefelter)
62695426|NCT05498090|EXPERIMENTAL|Arm 2 (Interventional with cases)|Cases (those with Klinefelter); Comparison of outcomes pre and post fenofibrate intervention, 145mg PO daily for 4 weeks
62695427|NCT05616910|EXPERIMENTAL|Group A|Subjects will receive iNO for 4 hours, followed by standard respiratory support (SRS) for 4 hours. This pattern will be reversed the next day (SRS then iNO). on the following day, the pattern will be reversed back to iNO for 4 hours and SRS for 4 hrs.
62695428|NCT05616910|EXPERIMENTAL|Group B|Subjects will receive iNO for 4 hours, followed by standard respiratory support (SRS) for 4 hours. This pattern will be reversed the next day (SRS then iNO). on the following day, the pattern will be reversed back to iNO for 4 hours and SRS for 4 hrs.
61941118|NCT05117333|NO_INTERVENTION|Control treatment|There is no intervention in the control treatment. The entire population aged 55 and above in the treatment regions will serve as a control group.
62336521|NCT04190953|EXPERIMENTAL|Twin Block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion using Twin block prior to Hyrax
62493476|NCT06282562|EXPERIMENTAL|HIIT|"The intervention group will perform High-Intensity Interval Training (HIIT), consisting of two supervised exercise sessions per week on a stationary bike, for 12 weeks.~In addition, participants will receive information on general guidelines for weekly physical activity levels and will be asked to keep an exercise diary."
61941119|NCT00657449|ACTIVE_COMPARATOR|Arm 1|
61941120|NCT00657449|ACTIVE_COMPARATOR|Arm 2|
61941121|NCT02015585|EXPERIMENTAL|Interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
62336522|NCT04190953|EXPERIMENTAL|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement using Hyrax prior to Twin block
62336523|NCT04190953|NO_INTERVENTION|Control|Patients will wait 1,5 years before the start of treatment
62336524|NCT01769417|PLACEBO_COMPARATOR|Placebo|
62336525|NCT01769417|ACTIVE_COMPARATOR|MEDI4893|
62336526|NCT06244940|OTHER|Whole Genome Sequencing (WGC) from subject samples|
62695429|NCT03847012|EXPERIMENTAL|patients with coronary artery diseases|The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
62695430|NCT06585384|EXPERIMENTAL|etanercept and repeated contrast ultrasound|
62695431|NCT05996471|EXPERIMENTAL|Participants Receiving VH3810109 Plus Cabotegravir|
62695432|NCT05996471|EXPERIMENTAL|Participants Receiving VH3810109 Plus rHuPH20 Plus Cabotegravir|
62695433|NCT05996471|ACTIVE_COMPARATOR|Participants Receiving Standard of Care (SOC) Antiretroviral Therapy (ART)|
62695434|NCT01790191|EXPERIMENTAL|RE group|Repeated consumption of artichoke purée. This group was exposed to basic artichoke puree from Exposure 1 to 10 (E1 to E10)
62695435|NCT01790191|ACTIVE_COMPARATOR|FFL group|Repeated consumption of artichoke purée. This group (Flavor-flavor learning group) was exposed to sweet artichoke puree from Exposure 1 to 10 (E1 to E10).
62695436|NCT01790191|ACTIVE_COMPARATOR|FNL group|Repeated consumption of artichoke purée. This group (Flavor-nutrient learning group) was exposed to fat, energy-dense artichoke puree from Exposure 1 to 10 (E1 to E10).
62695437|NCT06331949|EXPERIMENTAL|Experimental Group|In addition to midwifery care, training content, training videos and brochure-supported training on NST will be provided. The NST device will be inserted and, to be standard, 5 minutes after the procedure begins, the volume of the fetal heart sound coming from the device will be increased during the NST recording and the fetal heart sound will be ensured to continue. The pregnant woman who will be transferred will rest for about 2 minutes.
62695438|NCT06331949|NO_INTERVENTION|Control Group|No additional applications will be made
62695439|NCT01066910|EXPERIMENTAL|Parent-only|
62695440|NCT01066910|ACTIVE_COMPARATOR|Parent and child|
62695441|NCT06362629|EXPERIMENTAL|App group|Participants will be assisted to use the app during the process of management, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
62695442|NCT06362629|NO_INTERVENTION|Control group|The diagnosis, treatment, and follow-up of participants will be carried out according to the current routine on face-to-face basis. The time points of the participants follow-up will be determined by the responsible dermatologist, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI will be done and recorded on the day of follow-up.
62695443|NCT06105255|EXPERIMENTAL|Multipledose D-1553 on PK of single dose midazolam, caffeine, rosuvastatin, furosemide, digoxin|To evaluate the effects of multiple-dose D-1553 tablets on pharmacokinetics (PK) of single-dose midazolam, caffeine, rosuvastatin, furosemide, and digoxin in healthy male subjects.
62695444|NCT06105255|EXPERIMENTAL|Evaluate the effects of multiple-dose itraconazole on PK of single-dose D-1553|To evaluate the effects of multiple-dose itraconazole on PK of single-dose D-1553 tablets in healthy male subjects.
62695445|NCT06105255|EXPERIMENTAL|Evaluate the effects of multiple-dose omeprazole on PK of single-dose D-1553|To evaluate the effects of multiple-dose omeprazole on PK of single-dose D-1553 tablets in healthy male subjects.
62695446|NCT00086515|EXPERIMENTAL|Sitagliptin 100 mg|The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.
61941122|NCT02015585|EXPERIMENTAL|Relining complete denture base|Patients will be submitted to a procedure of relining their old dentures 30 days before the replacement of the complete dentures.
61941123|NCT02015585|ACTIVE_COMPARATOR|Only Rehabilitation|Patients will be treated with a complete denture without any kind of previous intervention
62493477|NCT06282562|NO_INTERVENTION|Waiting-list|"The control group on the waiting list will be given the option to perform High-Intensity Interval Training (HIIT) after their participation in the study.~In addition, also participants from the waiting-list control group will receive information on general guidelines for weekly physical activity levels and will be asked to keep an exercise diary."
62493478|NCT00341094||Main UkrArm|Subjects exposed to I131 before the age of 18 years
61941124|NCT05135338||answer 1|a senior emergency physician on interpretation of chest x-ray and blinded to the final diagnosis .
62137735|NCT00744913|EXPERIMENTAL|1|
62493479|NCT00341094||Ukraine in utero|Subjects exposed to I131 in utero
61941125|NCT05135338||answer 2|a resident or an intern interpretation of chest x-ray and blinded to the final diagnosis
61941126|NCT04044495|EXPERIMENTAL|Sample of 100 persons included in AMI / AMImage 2|Sample of 100 persons included in AMI / AMImage 2
61941127|NCT06022250|EXPERIMENTAL|JS207|
61941128|NCT06209437||Inhalation Anesthesia Group|After induction, anesthesia will be provided with sevoflurane (2.0 mac) and intravenous remifentanil infusion (0.05-0.2 mcg/kg/min). Depth of anesthesia will be evaluated with Bispectral Index (BIS).
61941129|NCT06209437||Total Intravenous Anesthesia Group|After induction, anesthesia will be provided with intravenous propofol infusion (50-150 mcg/kg/min) and intravenous remifentanil infusion (0.05-0.2 mcg/kg/min). Depth of anesthesia will be evaluated with Bispectral Index (BIS).
61941130|NCT02213354|EXPERIMENTAL|Group 2|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
62493480|NCT01228539|EXPERIMENTAL|TARGET|Affect regulation psychotherapy for PTSD
62493481|NCT01228539|ACTIVE_COMPARATOR|Prolonged Exposure|Cognitive behavioral therapy for PTSD with trauma memory exposure
62493482|NCT04435054|OTHER|Non invasive tests|
61941131|NCT02213354|EXPERIMENTAL|Group 6|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
62137736|NCT00744913|ACTIVE_COMPARATOR|2|
62137737|NCT05459350||Safe Discharge Positive|Safe Discharge Positive
62137738|NCT05459350||Safe Discharge Negative|Safe Discharge Negative
61941132|NCT02213354|EXPERIMENTAL|Group 5|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
62695447|NCT00086515|PLACEBO_COMPARATOR|Placebo / Glipizide 5 mg|The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.
61941133|NCT02213354|EXPERIMENTAL|Group 4|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
61941134|NCT02213354|EXPERIMENTAL|Group I|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant intramuscularly (IM) on Day 1, Day 29 and Day 169
61941135|NCT02213354|EXPERIMENTAL|Group 3|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
61941136|NCT03657446|EXPERIMENTAL|Treatment sequence ABC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
61941137|NCT03657446|EXPERIMENTAL|Treatment sequence ACB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn
61941138|NCT03657446|EXPERIMENTAL|Treatment sequence BAC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
61941139|NCT03657446|EXPERIMENTAL|Treatment sequence BCA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
61941140|NCT03657446|EXPERIMENTAL|Treatment sequence CBA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
62493483|NCT03619330|ACTIVE_COMPARATOR|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
62493484|NCT03619330|ACTIVE_COMPARATOR|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
62493485|NCT06205316|EXPERIMENTAL|Group I (SBRT)|Patients undergo SBRT over 15-20 minutes every other day for a total of 5 treatments over 1-2 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo bone scan and PET at screening and treatment failure, and undergo MRI and blood sample collection throughout the study.
61941141|NCT03657446|EXPERIMENTAL|Treatment sequence CAB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
61941142|NCT05914012|EXPERIMENTAL|Intervention Group|125 older adults aged 65 and over, who do not have any neurological, cognitive and communication problems that may affect the evaluations, and who volunteer to participate in the study and who are sedentary.
61941143|NCT05914012|NO_INTERVENTION|Control Group|125 older adults not participating in any exercise program during the study, not having any neurological, cognitive and communication problems that may prevent completing the assessments.
62493486|NCT06205316|EXPERIMENTAL|Group II (Hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy over 15-20 minutes once per day for a total of 20 treatments over 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo bone scan and PET at screening and treatment failure, and undergo MRI and blood sample collection throughout the study.
62493487|NCT02480634|ACTIVE_COMPARATOR|High dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle , a total of six cycle，Radiotherapy dose: 30Gy/10f
61941144|NCT02759484|EXPERIMENTAL|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
61941145|NCT02759484|ACTIVE_COMPARATOR|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
61941146|NCT04379544||COVID-19 Positive Patients Receiving CPUS|Adult patients (18 years) presenting to the ED or ICU with highly suspected diagnosis or confirmed diagnosis of COVID-19 in whom the clinician deems a CPUS (cardiopulmonary ultrasound) is indicated.
61941147|NCT03849807|EXPERIMENTAL|Experimental group|Chiropractic care
61941148|NCT03849807|ACTIVE_COMPARATOR|Control group|Usual health care
61941149|NCT03729466|NO_INTERVENTION|Control group|There will be no intervention for 8 weeks
61941150|NCT03729466|EXPERIMENTAL|Intervention group|clinical pilates will be given to the intervention group for 8 weeks
61941151|NCT06557720||Intractable epilepsy patients.|Based on the hybrid fusion technology of PET-fMRI-EEG, this study explores the characteristics of brain network damage in refractory epilepsy, identifies key network nodes (such as central nodes), and provides more assistance for the diagnosis of drug-resistant epilepsy.
62137739|NCT04815993|EXPERIMENTAL|SYN-020, 5 mg|6 subjects to receive a single 5 mg dose of SYN-020
62137740|NCT04815993|EXPERIMENTAL|SYN-020, 15 mg|6 subjects to receive a single 15 mg dose of SYN-020
62493488|NCT02480634|EXPERIMENTAL|Low dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle, a total of six cycle，Radiotherapy dose: 15Gy/5f
62493489|NCT04659668|EXPERIMENTAL|MMG-23-04-2019|MMG-23-04-2019 is composed by sodium hyaluronate at concentration of 2% (20 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent, in aqueous solution at physiological pH. The filler of 1ml is administered once or twice depending on the individual necessity.
62493490|NCT04965831|EXPERIMENTAL|Furmonertinib|Furmonertinib as perioperation therapy
62493491|NCT02545309||SSC-CIP|Patients with secondary sclerosing cholangitis in critically ill patients
62493492|NCT02545309||control|Patients with similar degree of critical illness who do not develop secondary sclerosing cholangitis in critically ill patients
62695448|NCT02072057|EXPERIMENTAL|Ruxolitinib|Interventional arm
62695449|NCT05110261|EXPERIMENTAL|Nirsevimab|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
61941152|NCT04423510||Recurrent pilonidal sinus|Postoperative recurrent pilonidal sinus disease
61941153|NCT00562250|EXPERIMENTAL|Arm 1|
61941154|NCT00562250|ACTIVE_COMPARATOR|Arm 2|
61941155|NCT00562250|ACTIVE_COMPARATOR|Arm 3|
62137741|NCT04815993|EXPERIMENTAL|SYN-020, 45 mg|6 subjects to receive a single 45 mg dose of SYN-020
62493493|NCT02893163|EXPERIMENTAL|CHANGE Intervention|The CHANGE intervention is a personalized approach to nutrition and exercise modification supported by a interdisciplinary team. The FD will recruit patients, complete baseline measurements and stabilize medication. The RD will create a diet plan tailored to the individual patient based on the intervention protocol. The ES will create an exercise plan tailored to the individual patient based on the intervention protocol. At the start, patients will meet weekly with the RD and ES in order to monitor progress, ascertain barriers and facilitators to change, and ensure adherence for the first 12 weeks of the intervention. Meetings will then occur monthly for the remaining 9 months of the intervention. Visits with the FD will occur every 3 months for the 12 month intervention to monitor progress, encourage behaviour change. A follow-up visit with the Research Coordinator will take place at 18 months.
61941156|NCT05054036|EXPERIMENTAL|MoviPrep|"For MoviPrep, the dose, schedule, and route of administration are as follows:~* On the evening prior to the colonoscopy, mix the powder with lukewarm water to a total volume of 32 oz. Drink 8 oz. every 15 minutes until the solution is finished. Drink 16 oz. of clear liquids before bed.~* On the morning of the procedure, repeat the above steps and make sure all fluids are consumed at least 2 hours prior to colonoscopy.~* Limit food intake to a regular breakfast, light lunch and clear soup or plain yogurt for dinner on the day prior to the colonoscopy (completed at least 1 hour prior to the first MoviPrep dose.~* Consume only clear liquids from the start of MoviPrep until after the colonoscopy."
61941157|NCT05054036|ACTIVE_COMPARATOR|GoLYTELY|"For GoLYTELY, the dose, schedule, and route of administrate are as follows:~* On the evening prior to the colonoscopy, mix powder with lukewarm water to a total volume of 4 liters. Drink 2 liters of the solution and store the rest in the refrigerator.~* Drink the remaining 2 liters on the morning of the procedure.~* Limit food intake to a light breakfast on the day prior to the colonoscopy, followed by only clear liquids until the procedure is complete.~* Avoid red and purple liquids."
61941158|NCT06135480|ACTIVE_COMPARATOR|combined subcision with platelet-rich plasma and microneedling group|
61941159|NCT06135480|ACTIVE_COMPARATOR|combined subcision with saline and microneedling group|
61978777|NCT03486132|OTHER|continous repair of mediolateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
62336527|NCT03085706|EXPERIMENTAL|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
62336528|NCT06219616|OTHER|BKV immune monitoring|"1. In this prospective cohort, the included kidney transplant recipients will receive regular post-transplantation care, including routine therapeutic drug monitoring of tacrolimus and screening for BK viremia. No extra medications beyond the standard of care will be given to the patients in this study.~2. Whole blood will be drawn from kidney transplant recipients on day 30, day 180, and at the time of BK viremia. PBMCs will be separated and incubated with BK viral peptides.~3. PBMCs will be stained for surface marker of activated T cells and intracellular cytokines 4. Phenotypic features of T cells will be analyzed under flow cytometry and correlated with the occurrence of BKV infection and immunosuppressive medications."
62336529|NCT04910724|EXPERIMENTAL|20% Energy Deficit|Energy Deficit equal to 20% total daily energy requirements.
62336530|NCT04910724|EXPERIMENTAL|40% Energy Deficit|Energy Deficit equal to 40% total daily energy requirements.
62336531|NCT04910724|EXPERIMENTAL|60% Energy Deficit|Energy Deficit equal to 60% total daily energy requirements.
62336532|NCT04710524|PLACEBO_COMPARATOR|Placebo|orally administer placebo BID for 13 weeks except on Day 91 subject receive a single dose
62336533|NCT04710524|EXPERIMENTAL|FM101 150 mg BID|orally administer FM101 150mg BID for 13 weeks except on Day 91 subject receive a single dose
62336534|NCT04710524|EXPERIMENTAL|FM101 300 mg BID|orally administer FM101 300mg BID for 13 weeks except on Day 91 subject receive a single dose
62336535|NCT06009718||Model training group|Compare the results of PCG and ECG with UCG, and conduct model training analysis
62336536|NCT06009718||Model validation group|Compare the results of PCG and ECG with UCG, and conduct model validation analysis
62493494|NCT02893163|ACTIVE_COMPARATOR|Usual Care|The usual care arm of the study will involve regular care from the patients' FD. This may involve discussions regarding nutrition and exercise. The FD will still recruit patients, complete baseline measurements and stabilize medication. Visits to the FD will occur as usual care dictates. Participating PCNs randomized to usual care will still have interdisciplinary team members available but the referral arrangements are and will continue to be ad hoc. For the study, we will mandate that control patients have follow-up with the Research Coordinator at 3, 12 and 18 months for the purpose of assessing outcomes. At these time points, appointments will not be scheduled with the FD to manage their disease; rather, the purpose of the visit is to just conduct the outcome assessment.
62493495|NCT03390244|EXPERIMENTAL|FCVB Implant|All subjects in this study are in the experimental treatment arm and will receive the FCVB implant
62493496|NCT02834962|EXPERIMENTAL|single bundle ACLR|patients undergo single bundle ACL reconstruction
62493497|NCT02834962|ACTIVE_COMPARATOR|double bundle ACLR|patients undergo double bundle ACL reconstruction
62336537|NCT00418834|ACTIVE_COMPARATOR|1|
62336538|NCT00418834|ACTIVE_COMPARATOR|2|
62336539|NCT02165800|ACTIVE_COMPARATOR|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
62493498|NCT02473393|EXPERIMENTAL|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
62336540|NCT02165800|EXPERIMENTAL|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
62336541|NCT03928431|NO_INTERVENTION|vaginally delivered|A non-randomized reference group of vaginally delivered infants.
61941160|NCT04493580|EXPERIMENTAL|iDBT Treatments|15 weekly DBT sessions. During each session, participants will be sent 30-40 PowerPoint slides including general information on particular topic, overview of skills, and homework sheets to be completed and returned to therapists. Therapists involved will be a psychiatry resident, a psychologist, and a registered nurse who will also facilitate the in-person groups. The content and format of the online program will directly corresponded with that of the in-person group. Participants will be asked to send their homework sheets back to therapists by a specific day each week. The following day, the therapist will email feedback regarding the homework submitted and send next week's PowerPoint slides, information sheets, and homework. In order to be eligible to receive the materials, participants are required to send in homework prior to deadline. If homework was not returned, reminder email will be sent. If more than two sessions are missed, participants are excluded from the program.
61941161|NCT04493580|ACTIVE_COMPARATOR|In-Person DBT Treatments|Weekly skills-building groups titled Managing Powerful Emotions (MPE) includes Mindfulness, Distress Tolerance, Emotion Regulation, and Interpersonal Effectiveness. Personality Disorders Service offers more advanced therapy groups for individuals who have successfully completed MPE and wish to continue seeking treatment modalities. Chrysalis Day Treatment Program (CDTP) is for an individual who has progress through two prior phases. In phase one, individuals will participate in a DBT-informed skill-building group (MPE). Once completed, the individual will progress to phase two which includes attending a psychotherapy group, incorporating DBT skills-building. Finally, in phase three, individuals who wish to participate in a more advanced and complex psychological treatment program, apply to participate in CDTP. The CDTP is an intensive day treatment program integrating DBT skills-building, psychodynamic psychotherapy, and a range of other group therapy modalities.
61941162|NCT06203236|ACTIVE_COMPARATOR|Natriuresis-guided group|Natriuresis-guided therapy group receiving diuretic therapy guided by natriuresis measurements.
61941163|NCT06203236|ACTIVE_COMPARATOR|Control group|Patients with matched age and sex as control group receiving diuretic therapy only.
61941164|NCT02228434|EXPERIMENTAL|Tailored intervention group|"For the monitoring session, physical activity was assessed by accelerometer and dietary was assessed by diary. Based on the monitoring information, the individual tailored prescription, including the normative feedback and process feedback, were formed and delivered to children and parents. Children were encouraged to modify the behaviors according to the prescription.~Then, next monitoring circle was followed. In total, 7 monitoring round were completed."
62493499|NCT02473393|EXPERIMENTAL|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
61941165|NCT02228434|EXPERIMENTAL|Happy 10 exercise group|All the schools participating in this group were encouraged to take two Happy 10 sessions on each school day.
61941166|NCT02228434|EXPERIMENTAL|Nutrition education group|The nutrition intervention was mainly conducted based on the nutrition knowledge through health education lectures given by researchers. The lectures were given for eight times to students and twice to parents. Each lecture session lasted no less than 40 min.
61941167|NCT02228434|NO_INTERVENTION|Control group|Receive no intervention
61941168|NCT01691898|EXPERIMENTAL|Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab|For the first 2 cycles, RTX 375 milligrams per square meter (mg/m\^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m\^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
61941169|NCT01691898|EXPERIMENTAL|Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab|For the first 2 cycles, RTX 375 mg/m\^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m\^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
61941170|NCT01691898|EXPERIMENTAL|Cohort C (FL): RTX + Polatuzumab|For the first 2 cycles, RTX 375 mg/m\^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
61941171|NCT01691898|EXPERIMENTAL|Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
62137742|NCT04815993|EXPERIMENTAL|SYN-020, 150 mg|6 subjects to receive a single 150 mg dose of SYN-020
62137743|NCT06699576|EXPERIMENTAL|Cohort 1a|HS-20093 and Anlotinib
62137744|NCT06699576|EXPERIMENTAL|Cohort 1b|HS-20093 and Epirubicin
62137745|NCT06699576|EXPERIMENTAL|Cohort 1c|HS-20093, Epirubicin and Anlotinib
62137746|NCT06699576|EXPERIMENTAL|Cohort 2a|HS-20093 and Adebrelimab
62493500|NCT02473393|EXPERIMENTAL|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
62493501|NCT02473393|EXPERIMENTAL|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
62493502|NCT03143049|EXPERIMENTAL|Pomalidomide, Cyclophosphamide, Dex (PCD)|
62493503|NCT03143049|ACTIVE_COMPARATOR|Pomalidomide, Dex (PD)|
62493504|NCT00748787|EXPERIMENTAL|1|
62493505|NCT00748787|PLACEBO_COMPARATOR|2|
62137747|NCT04053270|EXPERIMENTAL|Group A|Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300
62137748|NCT04053270|PLACEBO_COMPARATOR|Group B|Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
62137749|NCT06052332|EXPERIMENTAL|SCRT arm|"* SCRT (5 fractions of 5 Gy)~* Surgery (according to the principle of TME) or watch \& wait~* Optional adjuvant chemotherapy"
62137750|NCT06052332|ACTIVE_COMPARATOR|TNT arm|"Rapido regimen:~* SCRT (5 fractions of 5 Gy)~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~* Surgery (according to the principle of TME) or watch \& wait~Or~Rapido light regimen:~* SCRT~* Up to 12 weeks of oxaliplatin based chemotherapy~* Surgery or watch \& wait~Or~OPRA with induction chemotherapy (INCT-CRT) regimen:~* Up to 16 weeks of oxaliplatin-based chemotherapy~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~* Surgery or watch \& wait~Or~OPRA with consolidation chemotherapy (CRT-CNCT) regimen:~* CRT~* Up to 16 weeks of oxaliplatin-based chemotherapy~* Surgery or watch \& wait"
62137751|NCT04214756||Patients treated pre-MAPP|The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance
62137752|NCT04214756||Patients treated post-MAPP|The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance
62493506|NCT03242980|NO_INTERVENTION|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
62493507|NCT03242980|EXPERIMENTAL|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
62493508|NCT05453708||Autism Risk|Survey for mothers 18 years or older with a child aged 3-12 years who has an official ASD diagnosis from a clinician.
61941172|NCT01691898|EXPERIMENTAL|Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
62137753|NCT04004325|EXPERIMENTAL|Cohort A|
62336542|NCT03928431|ACTIVE_COMPARATOR|CS intervention|"A piece of gauze soaked with saline (0.9%) will be placed in the birth canal 2 hours before the CS by the study midwife, using sterile glows. Before the CS procedure begins, the gauze will be removed from the vagina and then immediately contaminated by a swab carrying maternal fecal microbiota. The swab is contaminated by introducing it 3 cm into the anal canal and by rotating it for 10-20 s.~Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding."
62493509|NCT05453708||Controls|Survey for mothers 18 years or older of children aged 3-12 years who do not have an ASD diagnosis so comparisons can be made between groups.
62493510|NCT01857687||patients with coronary artery stenosis|
62493511|NCT04104360|EXPERIMENTAL|Galacto-oligosacchardies|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
62493512|NCT04104360|PLACEBO_COMPARATOR|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin three times daily for four weeks
61941173|NCT01691898|EXPERIMENTAL|Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
61941174|NCT01297920|EXPERIMENTAL|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 3 times a day for 3 months
61941175|NCT01297920|ACTIVE_COMPARATOR|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each eye 3 times a day for 3 months
62137754|NCT04004325|EXPERIMENTAL|Cohort B|
62137755|NCT04033315|EXPERIMENTAL|Untrained Subjects with Diabetes use the L-PLUS BGMS|Untrained subjects with Diabetes test capillary fingerstick and palm blood (and study staff test subject fingerstick blood) using the L-PLUS BGMS. All blood glucose results are compared to reference method results obtained with subject capillary plasma. Also, study staff test venous blood and blood glucose results are compared to reference method results obtained from subject venous plasma.
62137756|NCT05153070|EXPERIMENTAL|Ciclosporin/ILT-101|Ciclosporin during 2 months (for all patients) followed by ILT-101 during 10 months
62137757|NCT05153070|PLACEBO_COMPARATOR|Ciclosporin/placebo|Ciclosporin during 2 months (for all patients) followed by placebo during 10 months
62137758|NCT05206240||Study group|The patients considered eligible will form the study group and will start the conventional physical therapy program and radial extracorporeal shock wave therapy delivery (rESWT).
62137759|NCT05152849|EXPERIMENTAL|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
62493513|NCT03166904|EXPERIMENTAL|AZD2014|Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle
62493514|NCT03414151||Observational - Case Arm|All participants will be placed in this arm or group if they have an eligible psychiatric diagnosis as a case (there is no randomization procedure)
62493515|NCT03414151||Observational - Healthy Control Arm|All participants will be placed in this arm if they are healthy controls (there is no randomization procedure)
62493516|NCT02472834|EXPERIMENTAL|Amino acid supplementation NephrAmine®|250 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 8 weeks plus 4 weeks of follow-up.
62493517|NCT02472834|NO_INTERVENTION|Standard-of-care|Standard-of-care does not include amino acid supplementation, but this control arm will be evaluated for the same outcomes as the experimental arm for 8 weeks plus 4 weeks of follow-up
62493518|NCT04974580|EXPERIMENTAL|CoachingOnlyArm|Phone Coaching; no Digital Coaching, no NRT: This arm will receive only the two phone counseling calls which all other arms will receive.
61941176|NCT01297920|ACTIVE_COMPARATOR|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each eye 3 times a day for 3 months
61941177|NCT03947996|EXPERIMENTAL|Stretching|Stretching
61941178|NCT03947996|EXPERIMENTAL|Walking|Walking
61941179|NCT06681779|EXPERIMENTAL|E2|Patients with a stable GCS subscore of E2, eyes opening to pain
61941180|NCT06681779|EXPERIMENTAL|E1|Patients with a stable GCS subscore of E2, eyes non-responsive to pain
61941181|NCT06681779|EXPERIMENTAL|Upper Extremity M5|Patients with a stable GCS subscore of M5, localizing, in at least one upper limb
62137760|NCT05152849|PLACEBO_COMPARATOR|Placebo|Matching Placebo administered orally BID with or without food
62137761|NCT06053424|EXPERIMENTAL|AZD7798|"Arm consists of up to 6 sequential panels:~Healthy participant panel 1, Healthy participant panel 2, Healthy participant panel 3, Crohn's disease panel 1, Crohn's disease panel 2, Optional panel"
62137762|NCT01664741|ACTIVE_COMPARATOR|Nicotine patch - transdermal|21 mg nicotine patch
62336543|NCT03928431|PLACEBO_COMPARATOR|CS placebo|See above - the gauze will be exchanged to a clean gauze (soaked with saline). Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding.
62336544|NCT01151046|EXPERIMENTAL|MM-121 (SAR256212) + exemestane|
61941182|NCT06681779|EXPERIMENTAL|Upper Extremity M4|Patients with a stable GCS subscore of M4, withdrawing, in at least one upper limb
62137763|NCT01664741|PLACEBO_COMPARATOR|Placebo NRT|Matching placebo patch
62137764|NCT01664741|NO_INTERVENTION|Healthy non-smoker comparison|Demographically-matched women and men who have never smoked
62336545|NCT01151046|PLACEBO_COMPARATOR|Placebo + exemestane|
62336546|NCT03877120|SHAM_COMPARATOR|Dexmedetomidine|"Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.~Dosage form: DEX 0.2-0.7 mcg/Kg/min."
62336547|NCT03877120|ACTIVE_COMPARATOR|Diazepam|Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam
61941183|NCT06681779|EXPERIMENTAL|Upper Extremity M3|Patients with a stable GCS subscore of M3, flexing, in at least one upper limb
62137765|NCT05127967|OTHER|Patients with neurological symptoms and two mutations in the SPG7 gene|Symptomatic patients with SPG7 mutations (homozygous or compound heterozygous)
62137766|NCT05127967|OTHER|Patients with neurological symptoms and one mutation in the SPG7 gene|Patients presenting neurological symptoms corresponding to SPG7 disease (adult onset spastic ataxia with CPEO and/or optic atrophy) with only one mutation found in the SPG7 gene
62137767|NCT05127967|OTHER|Controls|Patients without mutations in the SPG7 gene requiring spinal surgery because of a non-genetic neurologic disorders
61941184|NCT06681779|EXPERIMENTAL|Upper Extremity M2|Patients with a stable GCS subscore of M2, extending, in at least one upper limb
61941185|NCT06681779|EXPERIMENTAL|Upper Extremity M1|Patients with a stable GCS subscore of M1, no response to stimuli, in at least one upper limb
61941186|NCT06681779|EXPERIMENTAL|Lower Extremity M4|Patients with a stable GCS subscore of M4, withdrawing, in at least one lower limb
61941187|NCT06681779|EXPERIMENTAL|Lower Extremity M3|Patients with a stable GCS subscore of M3, flexing, in at least one lower limb
61941188|NCT06681779|EXPERIMENTAL|Lower Extremity M1|Patients with a stable GCS subscore of M1, no response, in at least one lower limb
61941189|NCT03090438|ACTIVE_COMPARATOR|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
61941190|NCT03090438|NO_INTERVENTION|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
61941191|NCT01845818||Ankylosing Spondylitis and Psoriatic Arthritis|Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
61941192|NCT02340507|EXPERIMENTAL|High glycemic index|The subject will consume a high glycemic index glutinous rice for breakfast (75g available carbohydrates), and a high glycemic index white bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
62137768|NCT02160119||Healthy Controls|
62137769|NCT02160119||Autism Spectrum Disorders|
62336548|NCT04887103|EXPERIMENTAL|hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
62336549|NCT04887103|NO_INTERVENTION|Control group|There will be no intervention other than routine follow-up and maintenance.
62336550|NCT00125190|EXPERIMENTAL|rhIGF-1 QD|Subjects received subcutaneous injection (SC) injections of rhIGF-1 once a day.
62493519|NCT04974580|EXPERIMENTAL|DigitalArm|Phone Coaching + Digital Coaching; no NRT: This arm will receive digital content (text messages with links to online materials) in addition to to the two phone counseling calls which all arms will receive.
62493520|NCT04974580|EXPERIMENTAL|CoachingNRTArm|Phone Coaching + NRT; no Digital Coaching: This arm will receive Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
62493521|NCT04974580|EXPERIMENTAL|DigitalNRTArm|This arm will receive digital content (text messages with links to online materials) AND Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
62493522|NCT04082741|EXPERIMENTAL|Monotherapy SAD BMS-986318 or Placebo|Single Ascending Dose (SAD)
62493523|NCT04082741|EXPERIMENTAL|Monotherapy MAD BMS-986318 or Placebo|Multiple Ascending Dose (MAD)
62493524|NCT00263458|EXPERIMENTAL|Integrated|Buprenorphine maintenance treatment delivered at an HIV primary care clinic
62493525|NCT00263458|ACTIVE_COMPARATOR|Non-integrated|Buprenorphine maintenance treatment delivered at a public health substance use disorder clinic
62493526|NCT00413049|EXPERIMENTAL|Valsartan/amlodipine 80/5 mg|
62493527|NCT00413049|ACTIVE_COMPARATOR|Amlodipine 5 mg|
62493528|NCT01282450|EXPERIMENTAL|Single arm|Eligible patients
62493529|NCT02401139|ACTIVE_COMPARATOR|Treatment arm|Ketamine
62493530|NCT02401139|PLACEBO_COMPARATOR|Placebo arm|Placebo
62493531|NCT02817828|EXPERIMENTAL|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP tablet
62493532|NCT04559841|ACTIVE_COMPARATOR|bone substitute; NanoBone® (group 1, control group)|a synthetic bone substitute consisting of nanocrystalline hydroxyapatite and silica fabricated in a sol-gel process.
62493533|NCT04559841|EXPERIMENTAL|simvastatin + NanoBone (group 2, test group)|medications used to treat hypercholesterolemia
62493534|NCT05956717||Experimental Group|Subjects wore orthokeratology lenses
62493535|NCT05956717||Control group|Subjects wore single-vision glasses group
62493536|NCT01963455|EXPERIMENTAL|MDCs transplant|The women who have stress urinary incontinency.
62493537|NCT01897064|EXPERIMENTAL|Aerobic Exercise|Up to 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric treatment.
62493538|NCT01897064|ACTIVE_COMPARATOR|Standard Psychiatric Treatment|12 weeks of standard psychiatric treatment.
62493539|NCT01751633||Surgical treatment|"Surgical treatment according to one of the following:~* Posterior open approach~* Posterior minimally-invasive surgery (MIS) approach The choice of the approach will be left upon the surgeon's discretion"
62493540|NCT01751633||Conservative treatment|Conservative treatment according to hospital's standard of care
62493541|NCT00611650|EXPERIMENTAL|Arm I|Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
62493542|NCT00611650|PLACEBO_COMPARATOR|Arm II|Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
62493543|NCT03276767|EXPERIMENTAL|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
61941193|NCT02340507|EXPERIMENTAL|Low glycemic index|The subject will consume a low glycemic index parboiled basmati rice for breakfast (75g available carbohydrates), and a low glycemic index multigrain bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
62493544|NCT03276767|ACTIVE_COMPARATOR|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
62493545|NCT05055713|EXPERIMENTAL|Secondary prevention-1|Endoscopic therapy+ beta blockers
62493546|NCT05055713|EXPERIMENTAL|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
62493547|NCT05055713|EXPERIMENTAL|Primary prevention-1|Endoscopic therapy
61941194|NCT05347277||OCB positive|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as negative for the presence of CSF OCB
61941195|NCT05347277||OCB negative|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as positive for the presence of CSF OCB
62493548|NCT05055713|EXPERIMENTAL|Primary prevention-2|Endoscopic therapy+ PSE
61941196|NCT03845751|EXPERIMENTAL|ADT protocol|ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
61941197|NCT05803473|ACTIVE_COMPARATOR|POC-arm|Subjects are monitored by point-of-care (POC) glucose testing. Diabetes management is done by usual ward nurses and guided by an in-hospital diabetes team. A blinded CGM is mounted in the POC-arm for outcome analysis.
61941198|NCT05803473|EXPERIMENTAL|CGM-arm|CGM-arm subjects are monitored by CGM viewed by the in-hospital diabetes team in addition to POC glucose testing performed by usual ward nurses. Diabetes management is done by usual ward nurses by POC glucose testing and guided by an in-hospital diabetes team with acces to CGM data.
62493549|NCT05055713|EXPERIMENTAL|Acute bleeding-1|Endoscopic therapy+somatostatin
62493550|NCT05055713|EXPERIMENTAL|Acute bleeding-2|Endoscopic therapy+PSE+somatostatin
62493551|NCT06204939|OTHER|Extended Pouch gastric bypass (EPGB)|Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.
62493552|NCT06204939|OTHER|One Anastomosis gastric bypass (OAGB)|Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.
61941199|NCT05959733|ACTIVE_COMPARATOR|Repair|This group will undergo a rotator cuff repair procedure.
61941200|NCT05959733|EXPERIMENTAL|Bridging Reconstruction using BioBrace|This experimental group will undergo bridging reconstruction using the bioinductive implant, BioBrace.
62493553|NCT03254732|EXPERIMENTAL|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
62493554|NCT01617096|EXPERIMENTAL|Dapivirine Vaginal Ring|Vaginal ring containing 25mg dapivirine
62493555|NCT01617096|PLACEBO_COMPARATOR|Placebo Ring|Vaginal ring containing no drug substance
62493556|NCT00128219|EXPERIMENTAL|GBS III-TT|A single dose of GBS III-TT vaccine administered intramuscularly (IM) containing 50 mcg of GBS III capsular polysaccharide and 32 mcg of tetanus toxoid.
62493557|NCT00128219|ACTIVE_COMPARATOR|Td|The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.
62493558|NCT04664751||Patients scheduled for general surgery with anesthesia|Patients scheduled for general surgery with anesthesia, receiving Nil-per-Oral order.
62493559|NCT06180915|EXPERIMENTAL|Experimental Group|Participants will be informed that they must answer the surveys and forms completely and appropriately, as well as attend all training sessions and fulfill their session duties. At the end of the 3-week training program (interim measurement) and 4 weeks later (post-test), the Rathus Assertiveness Inventory, Internalized Misogyny Scale and Flirting Violence Attitude Scale will be converted into an online survey via Google Forms®, the link will be sent to the participants and they will be asked to fill it out.
62493560|NCT06180915|NO_INTERVENTION|Control Group|The control group will not be subjected to any training. The Control Group will fill out the Introductory Information Form, Rathus Assertiveness Inventory, Internalized Misogyny Scale, Flirting Violence Scale and Cyber Flirting Violence Scale simultaneously with the experimental group at the beginning of the study.
62493561|NCT00362687|EXPERIMENTAL|1|Truvada 1 tablet once a day.
61941201|NCT04815278|EXPERIMENTAL|Control Group|Participants will receive usual DSS employment services that include, but are not limited to, consultation with an employments specialist, resume writing guidance, educational classes and attendance at job fairs. Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
62493562|NCT00362687|EXPERIMENTAL|2|Emtricitabine 1 capsule once a day
62493563|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
62493564|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
62493565|NCT03196817|ACTIVE_COMPARATOR|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
62493566|NCT03196817|ACTIVE_COMPARATOR|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
62493567|NCT01406639|EXPERIMENTAL|Ranibizumab|Patients treated with topical ranibizumab.
62493568|NCT01680601|EXPERIMENTAL|RIPC group|Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
62493569|NCT01680601|PLACEBO_COMPARATOR|Control|Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
62493570|NCT01401296|ACTIVE_COMPARATOR|Wait-list group|Subjects receive access to deprexis after eight weeks
62493571|NCT01401296|EXPERIMENTAL|Deprexis|Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.
62493572|NCT02409797|EXPERIMENTAL|Flexion-Distraction spinal manipulation|Participants will receive Flexion-Distraction treatment from a licensed doctor of chiropractic. During the procedure the participant lies prone on a specially designed treatment table. The table is equipped with a movable lower body section, which can be directed by the study doctor to lower the participants legs, move them from side to side, or in a traction motion. Table movements can occur in combination with other motions, depending on the diagnosis and characteristics specific to the participant's condition. During this procedure, the doctor will also touch the lower or upper part of the participants back or neck with their hands to direct treatment toward specific spinal regions.
62493573|NCT00579631||1|Questionnaire or Interview
62493574|NCT04504162||outpatient|Patients visiting a psychiatric hospital
62493575|NCT00938782|ACTIVE_COMPARATOR|Active Monitoring with SEDLine Monitor|Patient group randomized to active monitoring with SEDLine monitor for titration of anesthesia.
62695450|NCT05110261|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
62695451|NCT05689099|EXPERIMENTAL|Sequence A|Participants will be administered a single subcutaneous (s.c.) dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 2.
61941202|NCT04815278|EXPERIMENTAL|Employer Intervention Only|Participants will receive usual DSS employment services and an employer level workplace equity, job \& health supports intervention. The employer intervention will include an implicit bias workshop and supervisor support training in addition to regular supervisor check-ins every other week.
61941203|NCT04815278|EXPERIMENTAL|CDPP Only|Participants will receive the individual level CDPP intervention and no employer intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions. Content for the program will include healthy lifestyle habits, managing stress and staying motivated.
62493576|NCT00938782|NO_INTERVENTION|Blinded monitoring with SeEDLine Monitor|Patient group randomized to blinded monitoring with SEDLine monitor for titration of anesthesia. Data captured but not used for titration of anesthesia.
62493577|NCT06088095|EXPERIMENTAL|intervention group|
62493578|NCT06088095|NO_INTERVENTION|control group|
62493579|NCT03004157|EXPERIMENTAL|Two finger technique|Two finger technique TFT: the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant CPR by international CPR guidelines
62493580|NCT03004157|EXPERIMENTAL|Two thumb technique|Two thumb technique TTHT: the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
62695452|NCT05689099|EXPERIMENTAL|Sequence B|Participants will be administered a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 2.
62695453|NCT04118920|EXPERIMENTAL|Topical insulin|Patients will receive topical insulin eye drops.
62695454|NCT04118920|SHAM_COMPARATOR|Topical artificial tears|Patients will receive topical artificial tears.
62695455|NCT05836909|EXPERIMENTAL|Swisse Plus cholesterol capsules|(the main components are red yeast rice, phytosterol esters and lycopene)，the capsule is orally taken twice a day,two,tablets at a time 12 weeks
62695456|NCT05836909|PLACEBO_COMPARATOR|placebo contral|The placebo is an excipient and the colos, flavor, shape and weight are same with the Swisse plus cholesterol capsule
62695457|NCT06561087|EXPERIMENTAL|Nivolumab/Placebo|Participants will be screened for LOH and randomly assigned to trial
62695458|NCT03331354|ACTIVE_COMPARATOR|Self-help resources|a self-help vocational manual
62695459|NCT03331354|EXPERIMENTAL|Compass|a distant learning vocational program
62695460|NCT01189760|EXPERIMENTAL|onabotulinumtoxinA 44U|44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
62137770|NCT05599282|EXPERIMENTAL|Amino Acid Supplement|"Participants will be instructed to take four (4) capsules of Amino Acid Supplement with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the Investigational Product (IP). The IP must be consistently consumed immediately before nighttime sleep throughout the study.~If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the IP, that IP use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily."
62336551|NCT05445011|EXPERIMENTAL|TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Patients will receive lymphodepletion with fludarabine (25 mg/kg) and cyclophosphamide (250 mg/kg) for 3 days on day -7\~-2, followed by the infusion of TAA05 Cell with the dose of 1×10\^8, 2×10\^8 or 4×10\^8 cells on day 0. If no dose-limited toxicity(DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. After the end of dose climbing, if the maximum dose group(MTD) is still not observed, the highest dose group is defined as MTD.
62336552|NCT00285974|EXPERIMENTAL|hip prosthesis|
62336553|NCT00906074||Case|Cases will be defined as patients with elective or emergency abdominal surgery who develop severe surgical site infection (deep incisional or organ cavity type; see Center for Disease Control (CDC) criteria for definition in the Appendix), within 0-30 days of surgery.
62336554|NCT00906074||Control|Surgeon-matched controls will be patients with elective or emergency abdominal surgery who are free of surgical site infection (SSI) after 30 days from the surgery.
62336555|NCT05201274|EXPERIMENTAL|Baduanjin sequential therapy|
62336556|NCT05201274|ACTIVE_COMPARATOR|Aerobic exercise|
62336557|NCT02352792|ACTIVE_COMPARATOR|Standard therapy|Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
62336558|NCT02352792|EXPERIMENTAL|dose escalation|Standard plus 10% dose escalation to the hypoxic volume
62336559|NCT05962814|EXPERIMENTAL|fNIRS|Infants who have a test completed with EarGenie MVP in a single test session
62336560|NCT02013466|OTHER|Bolus ONS intake|Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS = oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number.
62336561|NCT01208038|EXPERIMENTAL|Testosterone|Testosterone transdermal patch 300micrograms, twice weekly for 12 weeks
62336562|NCT05201183|EXPERIMENTAL|Fludarabine + Total Marrow Irradiation|Fludarabine will be administered sequentially after the administration of TMI. TMI will be delivered on Days -11, -10, -9, -8, and -7 (1.4-2.2 gray (GY)/fraction, twice a day) followed by fludarabine on Days -6, -5, -4, -3, and -2 (150 mg/m2, 30 mg/m2/day)
62336563|NCT04695106|EXPERIMENTAL|Study population|"In the study group (both STEMI and NSTE-ACS), aspirin will be discontinued, and ticagrelor will be started at a loading dose of 180 mg, irrespective of timing and dosing of clopidogrel, and continued at a maintenance dose of 90 mg twice daily for 1 month, followed by 60 mg twice daily up to 12 months.~Dabigatran will be used as a standard-of-care. Lower dose dabigatran (110 mg twice daily) will be used in patients ≥80 years of age and will be considered in patients (i) 75-80 years of age, (ii) with creatinine clearance 30-50 ml/min, (iii) at high risk of bleeding (HAS-BLED ≥ 3), (iv) at high-risk of gastrointestinal bleeding (with esophagitis, gastritis, gastroesophageal reflux disease), and (v) treated with verapamil, in accordance with the guidelines."
62336564|NCT04695106|ACTIVE_COMPARATOR|Control group|"In the control group, aspirin and clopidogrel will be continued depending on the diagnosis (STEMI or NSTE-ACS) and bleeding risk. In patients with STEMI, aspirin will be discontinued after 1-6 months, according to a balance between the estimated risk of recurrent coronary events and bleeding. In patients at high bleeding risk aspirin will be discontinued after 1 month. Subsequently, all patients will be treated with clopidogrel and dabigatran up to 12 months. In the NSTE-ACS group, aspirin will be used up to 1 week (in-hospital period), extendable up to one month in patients at high ischaemic risk. Dual therapy will be continued up to 12 months with the possibility of shortening for patients at high bleeding risk.~Dabigatran will be used as a standard-of-care (as above)."
62336565|NCT01533935|ACTIVE_COMPARATOR|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
62336566|NCT01533935|PLACEBO_COMPARATOR|Placebo QD|placebo comparator for tiotropium + olodaterol
62336567|NCT01533935|ACTIVE_COMPARATOR|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
62336568|NCT01533935|EXPERIMENTAL|Tiotropium + olodaterol low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily
62336569|NCT01533935|EXPERIMENTAL|Tiotropium + olodaterol high dose|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily
62336570|NCT05393817||Low-dose group|Infants receiving low dose caffeine citrate (up to 10mg/kg/day)
62336571|NCT05393817||High dose group|Infants receiving high dose caffeine citrate (exceeding 10mg/kg/day)
62336572|NCT03213613|EXPERIMENTAL|Adaptive Attention Training|The training group will engage in 15 hours of at-home training on a novel iPad-based adaptive attention training program ('Engage'). Individuals will complete thirty 30-minute sessions over six weeks. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely and analyzed over secure online servers to ensure that participants are completing training as scheduled and to deal with any unexpected road-blocks in training.
62493581|NCT03004157|EXPERIMENTAL|new two-thumb technique|new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90 degrees to the chest while closing the fingers of both hands in a fist
62493582|NCT01684280||gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
62695461|NCT01189760|OTHER|onabotulinumtoxinA 24U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo (normal saline) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
61941204|NCT04815278|EXPERIMENTAL|CDPP and Employer Intervention|Participants will receive the individual level CDPP intervention and employer level workplace equity, job \& health supports intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions and check-ins. Content for the program will include healthy lifestyle habits, managing stress and staying motivated. The employer intervention will include an implicit bias workshop and supervisor support training, in addition to regular supervisor check-ins every other week..
61941205|NCT05014217||Mentalization-based Treatment|Participants who have been oriented to the mentalization-based treatment among the clinical adult population with a cluster B personality disorder.
62336573|NCT03213613|PLACEBO_COMPARATOR|Active Control|The active control group will engage in 15 hours of at-home training on an iPad game ('Boing'). Individuals will complete game play for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with research personnel, and monetary rewards. Compliance will be monitored similarly to the adaptive attention training group.
62336574|NCT03213613|PLACEBO_COMPARATOR|Low-dose Adaptive Attention Training|The low-dose training group will engage in 1 hour of at-home training on 'Engage'. Individuals will complete two 30-minute sessions at the beginning and middle of a six-week period. Compliance will be monitored similarly to the adaptive attention training group.
62137771|NCT05599282|PLACEBO_COMPARATOR|Placebo|"Participants will be instructed to take four (4) capsules of Placebo with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the placebo. The placebo must be consistently consumed immediately before nighttime sleep throughout the study.~If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the placebo, that placebo use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily."
62137772|NCT03342820|EXPERIMENTAL|Quadriceps muscle fatigue|Quadriceps muscle fatigue
62336575|NCT01954303||Troponin status|"Patients are divided into troponin positive (if hsTnT on first presentation is \<14 ng/L) and troponin negative (if hsTnT on first presentation is \>=14 ng/l)."
62336576|NCT01954303||Progress of CHD|
62336577|NCT03396250|EXPERIMENTAL|Test product + Reference product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
62336578|NCT03396250|EXPERIMENTAL|Reference product + Test product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
62336579|NCT02238496|OTHER|Surgical Cohort - cytoreductive surgery|Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
62336580|NCT02238496|OTHER|Medical Cohort - no cytoreductive surgery|No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
62336581|NCT02457182|EXPERIMENTAL|Mindfulness-based Stress Reduction|Mindfulness-based Stress Reduction (MBSR)
62336582|NCT02457182|PLACEBO_COMPARATOR|Usual Care|Usual medical therapy
62336583|NCT02304536|ACTIVE_COMPARATOR|FSH|will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day.
62493583|NCT03609749|EXPERIMENTAL|Mindfulness Training for Primary Care|"Experimental: Mindfulness Training for Primary Care For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3). For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, the investigators acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional fMRI study."
62493584|NCT00751023|EXPERIMENTAL|1|Modafinil 400 mg daily
62493585|NCT00751023|PLACEBO_COMPARATOR|2|Placebo
62493586|NCT03926416|EXPERIMENTAL|CodaVax-H1N1, low dose|Participants will receive a single dose of either CodaVax (5 x 10\^3 PFU in 200 uL) and an intramuscular injection of placebo
62137773|NCT00018096|EXPERIMENTAL|bronchoscopy|2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
62493587|NCT03926416|ACTIVE_COMPARATOR|Fluzone|Participants will receive an intranasal (IN) dose of placebo and an intramuscular (IM) dose of QuadriFlu- Tetravalent Influenza Vaccine (TIV) (Fluzone®)
62695462|NCT01189760|PLACEBO_COMPARATOR|placebo (normal saline)|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
62137774|NCT04611373|EXPERIMENTAL|A|Acetazolamide tablet 25mg/ tablet, 2 tablets a day; Levamisole 25mg/ tablet, 6 tablets/day continuous medication; Continue treatment until the disease progresses
62493588|NCT03926416|EXPERIMENTAL|CodaVax-H1N1, high dose|Participants will receive a single intranasal (IN) dose of CodaVax-H1N1 (1 x 10\^5 PFU in 500 uL)
62493589|NCT03926416|PLACEBO_COMPARATOR|Placebo|Leibovitz's L-15 medium (IN) or saline (IM)
62493590|NCT06374654|EXPERIMENTAL|Home-based Protocol|
62493591|NCT06374654|EXPERIMENTAL|Formal Physical Therapy Protocol|
62493592|NCT00452543|EXPERIMENTAL|Escitalopram plus acamprosate|
62493593|NCT00452543|PLACEBO_COMPARATOR|Escitalopram plus placebo|
62493594|NCT04546412||Fresh oocytes|Sibling oocytes not subjected to vitrification prior to assessment
62493595|NCT04546412||Vitrified-thawed oocytes|Sibling oocytes subjected to vitrification using the Cryotop® - Open System and thawing prior to assessment
62493596|NCT06116396||1|Urothelial neoplasia
62493597|NCT06116396||2|Age-matched individuals free of neoplasia
62493598|NCT01415596|PLACEBO_COMPARATOR|Placebo|
62493599|NCT01415596|ACTIVE_COMPARATOR|Salbutamol|
61941206|NCT05014217||Dialectical Behavior Therapy-inspired Treatment|Participants who have been oriented to the dialectical behavior therapy-inspired treatment among the clinical adult population with a cluster B personality disorder.
62493600|NCT05278403|ACTIVE_COMPARATOR|Control group|Conventional neurological physiotherapy treatment.
62493601|NCT05278403|EXPERIMENTAL|Experimental group|Conventional neurological physiotherapy treatment with the use of virtual reality and video games.
62493602|NCT02538211|PLACEBO_COMPARATOR|Control|"Control group - subjects will receive no antibiotics~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
62493603|NCT02538211|ACTIVE_COMPARATOR|Broad-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~* Ciprofloxacin 500mg 2dd1~* Vancomycin 250mg 3dd2~* Metronidazole 500mg 3dd1~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
62493604|NCT02538211|ACTIVE_COMPARATOR|Narrow-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~• Vancomycine 250mg 3dd2~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
62493605|NCT01944553|EXPERIMENTAL|prospective|Single Arm
62695463|NCT04958096|EXPERIMENTAL|Prefrontal Cortex (PFC)|The Prefrontal Cortex (PFC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the PFC.
61941207|NCT02937428|EXPERIMENTAL|Look away and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look away from the needle during vaccination
61941208|NCT02937428|ACTIVE_COMPARATOR|Look at needle and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look at the needle during vaccination
61941209|NCT02937428|EXPERIMENTAL|Look away and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look away from the needle during vaccination
62493606|NCT06416449|EXPERIMENTAL|participants|"the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded.~the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded.~The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests."
62493607|NCT06502951|EXPERIMENTAL|Dry Needling,Thrust Manipulation|Dry needling to the craniofacial, upper cervical, and cervicothoracic regions. High-velocity thrust manipulation to the upper cervical spine, mid/lower cervical spine, and cervicothoracic spinal regions.
61941210|NCT02937428|ACTIVE_COMPARATOR|Look at needle and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look at the needle during vaccination
61941211|NCT03309644||Peripheral nerve block|Peripheral nerve block
62137775|NCT03910855|EXPERIMENTAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
62137776|NCT03910855|ACTIVE_COMPARATOR|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
62137777|NCT01212744|EXPERIMENTAL|rAvPAL-PEG|rAvPAL-PEG in varying doses
62493608|NCT06502951|ACTIVE_COMPARATOR|Exercise,Non-thrust Mobilization|Nonthrust joint mobilization to the upper cervical spine, mid/lower cervical spine, and cervicothoracic spinal regions. Cranio-cervical flexion exercises, peri-scapular progressive resistance exercises, and electrothermal modalities
62493609|NCT01226953|ACTIVE_COMPARATOR|Arm 1|
62493610|NCT01226953|ACTIVE_COMPARATOR|Arm 2|
62493611|NCT03451747||postmenopausal hypertensive women|
62493612|NCT03451747||mached hypertensive men|
62493613|NCT04826250|EXPERIMENTAL|Hypertensive patients - nighttime medication|Hypertensive patients will be instructed to take their medication in the evening for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the morning for four weeks.
62493614|NCT04826250|EXPERIMENTAL|Hypertensive patients - morning medication|Hypertensive patients will be instructed to take their medication in the morning for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the evening for four weeks.
62493615|NCT05642936|EXPERIMENTAL|Transcendental Meditation|"The TM technique is a simple, natural, effortless mental procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. During the practice, it is reported that ordinary thinking processes settle down, and a distinctive wakeful hypometabolic state characterized by neural coherence and physiological rest is gained. The TM technique was taught in a 7-step course of instruction consisting of six 1.5-2 hour individual and group meetings taught by a certified instructor."
62695464|NCT04958096|EXPERIMENTAL|Anterior Cingulate Cortex (ACC)|The Anterior Cingulate Cortex (ACC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the ACC.
62493616|NCT05642936|ACTIVE_COMPARATOR|Health Education|The control intervention was a cardiovascular health education program designed to match the format of the experimental intervention for instructional time, instructor attention, participant expectancy, social support, and other nonspecific factors. The classroom content was based on standard, published materials. The instructors were professional health educators.
62493617|NCT02986256|NO_INTERVENTION|Conventionnal Group|No intervention for this group. Patients will be followed by a usual care.
62493618|NCT02986256|EXPERIMENTAL|"Telepied Group"|Patients will be followed by a nurse referring to ulcers of the diabetic foot.
62493619|NCT03192813||Symetis ACURATE neo™ transfemoral TAVI system|Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.
62336584|NCT02304536|ACTIVE_COMPARATOR|Ovarian drilling|70 women will have laparoscopic ovarian drilling in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
62336585|NCT00551538|ACTIVE_COMPARATOR|1|Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
62493620|NCT03192813||Medtronic CoreValve Evolut R TAVI System|Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.
62493621|NCT03201276||Drug group|patients taking glucosamine
62493622|NCT01299779|ACTIVE_COMPARATOR|PEG-ELS|
62493623|NCT01299779|ACTIVE_COMPARATOR|PEG-SD|
62493624|NCT03523650|EXPERIMENTAL|Group 1: Propranolol Group|Group 1: Propranolol - group of randomized patients will receive one propranolol pill tid for 36 months.
62493625|NCT03523650|PLACEBO_COMPARATOR|Group 2: Placebo Group|Group 2: Placebo - group of randomized patients will receive one placebo pill tid for 36 months.
62336586|NCT00551538|ACTIVE_COMPARATOR|2|Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.
62336587|NCT03487900|OTHER|Clinical remission CD|
62493626|NCT03348527|EXPERIMENTAL|Stage I: Dose = 35% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 35 % of their prostate volume.
62493627|NCT03348527|EXPERIMENTAL|Stage I: Dose = 45% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 45 % of their prostate volume.
62493628|NCT03348527|EXPERIMENTAL|Stage II: Dose = 16mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 16mL
62493629|NCT03348527|EXPERIMENTAL|Stage II: Dose = 20mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 20mL
62493630|NCT04396964||surgery|subjects undergoing multilevel lumbar fusion
62493631|NCT03945916|EXPERIMENTAL|Dark chocolate|180g/d dark chocolate
62336588|NCT03765619|EXPERIMENTAL|Aspirin|250 patients will be randomized to receive Aspirin postoperatively.
62336589|NCT03765619|NO_INTERVENTION|Non-Aspirin|250 patients will be randomized to not receive Aspirin postoperatively.
62493632|NCT03945916|PLACEBO_COMPARATOR|Placebo|180g/d of artificial dark chocolate
62493633|NCT00933140||HIV infected women|HIV infected women between ages 18 - 64 years of age due for cervical cancer screening were enrolled.
62493634|NCT05926245|PLACEBO_COMPARATOR|Placebo Group|15 adult healthy volunteers to serve as controls for the experimental group. This group will receive a placebo-topical spray with empty nanoparticles.
62493635|NCT05926245|EXPERIMENTAL|Glutathione Group|15 adult healthy volunteers will serve in the experimental group. This group will receive glutaryl treatment topical spray with nanoparticles containing GSH.
62493636|NCT05588505|EXPERIMENTAL|Cognitive Behavioral Therapy delivered in a group format|Participating students will be assessed before and after the 12-week group Cognitive-Behavioral intervention to ascertain their response to the treatment.
62493637|NCT05646238|EXPERIMENTAL|intervention group|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
62493638|NCT05646238|ACTIVE_COMPARATOR|control group|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles.
62695465|NCT06589128|ACTIVE_COMPARATOR|Astaxanthin|Oral astaxanthin supplement
62336590|NCT02370498|EXPERIMENTAL|Pembrolizumab|Participants receive 200 mg intravenous (IV) pembrolizumab on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years).
62336591|NCT02370498|ACTIVE_COMPARATOR|Paclitaxel|Participants receive 80 mg/m\^2 IV paclitaxel on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
62336592|NCT02038296|EXPERIMENTAL|Group 1|Group 1 received single-drug (doxorubicin)transarterial chemoembolization.
62336593|NCT02038296|EXPERIMENTAL|Group 2|Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization
62336594|NCT02038296|EXPERIMENTAL|Group 3|Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization.
62336595|NCT03105700|EXPERIMENTAL|Low Frequency TMS Intervention|Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
62336596|NCT03357809|EXPERIMENTAL|Endoscopic treatment|ENDOSCOPIC MUCOSAL RESECTION AT DAY 1
62695466|NCT06589128|PLACEBO_COMPARATOR|Placebo|Oral placebo supplement
62695467|NCT05166499|ACTIVE_COMPARATOR|Hydroxy Methyl Butyrate|
62695468|NCT05166499|OTHER|Balanced Amino Acid Mixture|
62695469|NCT06645002|EXPERIMENTAL|short term study|short term study (7 days) stevia leave powder 1000 mg/day
62336597|NCT02520518|EXPERIMENTAL|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
62336598|NCT02520518|EXPERIMENTAL|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
62336599|NCT02520518|PLACEBO_COMPARATOR|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
62336600|NCT02520518|PLACEBO_COMPARATOR|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
62336601|NCT02366663|EXPERIMENTAL|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
62336602|NCT02366663|ACTIVE_COMPARATOR|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
62336603|NCT01702363|EXPERIMENTAL|GSK573719|125mcg
62336604|NCT04048525|EXPERIMENTAL|CVVHD with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
62336605|NCT04048525|ACTIVE_COMPARATOR|CVVH with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
62336606|NCT04747483|ACTIVE_COMPARATOR|Extension Oriented Treatment Approach|"The EOTA intervention involves three components. The first component is a series of active extension- oriented exercises: Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension.~The second component of the EOTA is subject education. Subjects are being educated to maintain the natural lordosis of the lumbar spine while sitting, and are being instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension.The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
62336607|NCT04747483|EXPERIMENTAL|EOTA+ Mechanical Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
62336608|NCT06350344|EXPERIMENTAL|mVTEA Management Group|Patients with high-risk of VTE will be discharged with mVTEA-assisted patient-centered VTE management.
62336609|NCT04949880|EXPERIMENTAL|Group A|Neurovascular Drug-Eluting Balloon Dilatation Catheter
62336610|NCT04777643|EXPERIMENTAL|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
62336611|NCT04777643|PLACEBO_COMPARATOR|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
62336612|NCT06257498|OTHER|MRI upright open scanner|"All participants will undergo MRI scanning in the dedicated open upright 0.5T MRI research MRI scanner , with parents or guardian in attendance if desired, and with their own choice of music or video during the scan.~Immediately following the MRI scan we will collect information relating to their experience of the upright scanner using an age-appropriate questionnaire, based on similar questionnaires that we have used for paediatric MRI studies previously. A photograph of the upright MRI room will be used to prompt this discussion. The parent or carer may also be involved in prompting the child's responses.~We will also collect the views of the parent / carer using a questionnaire."
62336613|NCT04367025|ACTIVE_COMPARATOR|SOX|SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40\~60mg Bid, d1\~14, q3w; Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 2-4 cycles
62493639|NCT04188964|EXPERIMENTAL|Treatment|Pediatric subjects \> = 6 months to \< 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects \< 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
62695470|NCT06645002|EXPERIMENTAL|long term study|Long term study (60 days) stevia leave powder 1000 mg/day
61941212|NCT03309644||No peripheral nerve block|No peripheral nerve block
61941213|NCT03352310|EXPERIMENTAL|Study Group|autologous UCB transfusion
61941214|NCT03352310|OTHER|Control Group|standard care
61941215|NCT03234673|EXPERIMENTAL|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
61941216|NCT03234673|EXPERIMENTAL|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
61941217|NCT03234673|EXPERIMENTAL|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
61941218|NCT06221670|EXPERIMENTAL|Toripalimab adjuvant therapy group|Patients must be enrolled within 8 weeks of complete surgical excision and receive Toripalimab at a dose of 240 mg intravenously (IV) once every 3 weeks for a planned duration of 1 years.
61941219|NCT00580970|EXPERIMENTAL|Lovastatin for 1 yr|Lovastatin (20-80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. Lovastatin once per day for 1 year. After the implant, they are asked to return for checkups (study visits 4-13) 4 weeks, 8 weeks, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after the procedure. At 8 weeks, 4 months, 6 months, 9 months and 12 months, will also have a blood test to check their liver.
61941220|NCT05798156|EXPERIMENTAL|chemolight R-Pola-Glo treatment|
61941221|NCT02421029|EXPERIMENTAL|edetate calcium disodium|Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.
61941222|NCT03949842|EXPERIMENTAL|Subjects who inhaled non-ELLIPTA MITT|Subjects with moderate or severe exacerbation in the past year and history of use of inhaled non-ELLIPTA MITT of ICS/LABA/LAMA within a routine clinical practice setting in the 52-week retrospective pre-switch period.
61941223|NCT03949842|EXPERIMENTAL|Subjects receiving TRELEGY ELLIPTA SITT|Subjects will receive FF/UMEC/VI (100 microgram \[mcg\]/62.5 mcg/25 mcg), inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) in the 52-week prospective post-switch period.
61941224|NCT06218368|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive our vaccine toolkit intervention, which includes two main components: 1) our educational toolkit on MMR and polio vaccination in the form of a video, which will be introduced and presented to the participants from Week 12 to Week 15 of the Transform program, 2) reminding messages regarding vaccination, which will be delivered following the video session and embedded in Saving Groups program run in the communities. Additionally, participants in the intervention arm will also receive a series of 15 soap opera videos, one for each week, to complement the 15-week Transform Program's education session, which is the core intervention of the Soap Opera Trial developed and run by the ICM.
61941225|NCT06218368|NO_INTERVENTION|Control|In the control group, participants will attend the standard 15-week Transform program, with education sessions delivered through traditional lectures by health educators from ICM on the topics of income creation, education, food security, and resilience. Our educational toolkit of MMR and polio vaccination will not be provided and there will be no specific reminders or discussions regarding MMR and polio vaccinations.
61941226|NCT03813043|OTHER|Midazolam|Midazolam 2 mg as started dosage will be used for first patients and for the other patients will receive an predetermined dosage accordingly
62493640|NCT02727192|ACTIVE_COMPARATOR|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
62493641|NCT02727192|NO_INTERVENTION|Control group|No sleep apnea treatment
61941227|NCT04370223|EXPERIMENTAL|Ozone auto-hemotherapy plus standard treatment|Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days.
62137778|NCT04613713|EXPERIMENTAL|Somatocognitive physiotherapy|Somatocognitive therapy is a multi-modal physiotherapy intervention utilized for women with longstanding chronic pelvic pain and provoked vestibulodynia developed at the beginning of the 2000s as a collaboration between the department of psychosomatic medicine, Oslo University Hospital (OUH) and department of physiotherapy (OsloMet)
62493642|NCT04876716|ACTIVE_COMPARATOR|Azole monotherapy|"Azole monotherapy~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care."
62493643|NCT04876716|EXPERIMENTAL|Azole + Anidulafungin|"Azole + Anidulafungin~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care.~Anidulafungin (Ecalta) is available as an intravenous formulation only. It will be used at the licensed dose of a 200mg loading dose on day 1 and 100mg QD thereafter. No dose adjustment is needed in patients with renal or hepatic insufficiency of any grade."
62493644|NCT05033145|EXPERIMENTAL|AZVUDINE|"Experimental:~AZVUDINE 1mg tablet~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment, for up to 14 days"
62493645|NCT05033145|PLACEBO_COMPARATOR|AZVUDINE placebo|"Control:~AZVUDINE placebo~Intervention:~AZVUDINE placebo tablet, 5 tablets QD + standard treatment, for up to 14 days"
62493646|NCT01102660|OTHER|Treatment Sequence 1|
62493647|NCT01102660|OTHER|Treatment Sequence 2|
62493648|NCT01102660|OTHER|Treatment Sequence 3|
61941228|NCT04370223|NO_INTERVENTION|Standard treatment alone|Standard treatment will be the one used in each hospital participating in the trial.
61941229|NCT03704987|ACTIVE_COMPARATOR|Klinefelter|Male patients followed with the diagnosis of klinefelter
61941230|NCT03704987|ACTIVE_COMPARATOR|Control|healthy male subjects
61941231|NCT06033053|EXPERIMENTAL|Experimental|The experimental group will learn how to modulate the vmPFC-amygdala functional connectivity while being presented with pictures inducing fear.
62493649|NCT01102660|OTHER|Treatment Sequence 4|
61941232|NCT06033053|SHAM_COMPARATOR|Sham|The sham group will learn how to modulate the functional connectivity of sham ROIs while being presented with pictures inducing fear.
61941233|NCT04757246|OTHER|Cohort 1|Stable outpatients without implantable devices
61941234|NCT04757246|OTHER|Cohort 2|Stable outpatients with Boston Scientific pacemakers or defibrillators with Heart Logic capability
61941235|NCT04757246|OTHER|Cohort 3|Stable outpatients with implantable CardioMEMS devices
61941236|NCT04978597|EXPERIMENTAL|Opicapone|OPC will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
61941237|NCT04978597|PLACEBO_COMPARATOR|Matching placebo|Matching placebo will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
61941238|NCT04138004|EXPERIMENTAL|2-L PEG with LB|"PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes (sodium sulfate, sodium hydrogen carbonate, sodium chloride, and potassium chloride) and is taken by diluting one sachet into 2-L of plain water. The patients were instructed to take 250 mL every 15 min untill the entire solution was consumed.~In this group (2-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 9.00 pm and the remaining dose was given in the morning at about 5.00 to 6.00 am on the procedure day. And these patients, one 24 mcg tablet of LB was given 2 hours before PEG ingestion (at 6.00 pm of the pre-procedure day)."
61941239|NCT04138004|ACTIVE_COMPARATOR|4-L PEG|In this group (4-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 10.00 pm and the remaining dose was given in the morning at about 5.00 to 7.00 am on the procedure day.
61941240|NCT06397833||Decompensated Heart Failure Group|Patient has been admitted to hospital with decompensated heart failure, received at least one dose of an intravenous diuretic, and are awaiting discharge home following their treatment.
61941241|NCT04377243|EXPERIMENTAL|V8 850 mg|Arm 1: Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of V8
61941242|NCT04377243|PLACEBO_COMPARATOR|Placebo 850 mg|Arm: 2 Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of placebo
61941243|NCT02908451|EXPERIMENTAL|AbGn-107|AbGn-107 will be administered every 14-days or 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every continuously every 14-days or 28-days..
61941244|NCT04687995|ACTIVE_COMPARATOR|Tragal preichondrium graft|Tragal perichodrium graft for endoscopic myringoplasty as a reference graft
62336614|NCT04367025|EXPERIMENTAL|Camrelizumab+ SOX|Camrelizumab:200mg,iv drip for 1h,d1,q3w SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40\~60mg Bid, d1\~14, q3w; Neoadjuvant chemotherapy+ Camrelizumab for 2-4 cycles, adjuvant chemotherapy + Camrelizumab for 2-4 cycles.
62493650|NCT05308316|EXPERIMENTAL|Impact of Sugar Content|Participants will be ask to attend 4 laboratory sessions during which they will be asked to smoke their usual brand (UB) cigarettes and then one of three study cigarettes with low, medium and high levels of sugar in separate sessions using a within-subject design with conditions counterbalanced determined by a Latin square. In each session, smokers will be asked to smoke a cigarette in a standardized manner (10 puffs,30 second interval between puffs) and 1 hour later, ad libitum. Each of the sessions will be separated by at least 48 hours but not more than 5 days.
62493651|NCT00273013|EXPERIMENTAL|Sequence 1|Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3.
62493652|NCT00273013|EXPERIMENTAL|Sequence 2|Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3.
61941245|NCT04687995|ACTIVE_COMPARATOR|pretragal ( SMAS) fascia graft|pretragal ( SMAS) fascia graft for endoscopic myringoplasty as a new graft
61941246|NCT02155881|EXPERIMENTAL|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
61941247|NCT02155881|PLACEBO_COMPARATOR|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
61941248|NCT03115047|EXPERIMENTAL|dexmedetomidine|"Unique dose of dexmedetomidine injection:~* intravenous injection~* 0.35 mcg/kg~* in two minutes~* if shivering 5 minutes after delivery"
61941249|NCT03115047|ACTIVE_COMPARATOR|meperidine|"Unique dose of meperidine injection:~* intravenous injection~* 0.35 mg/kg~* in two minutes~* if shivering 5 minutes after delivery"
61941250|NCT06680388|EXPERIMENTAL|patients with relapsed/refractory moderately or severely active systemic lupus erythematosus (SLE)|Drug：CD19 CAR-T
61941251|NCT06680388|EXPERIMENTAL|relapsed/refractory active diffuse cutaneous systemic sclerosis (dcSSc)|Drug：CD19 CAR-T
61941252|NCT06680388|EXPERIMENTAL|relapsed/refractory antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV)|Drug：CD19 CAR-T
61941253|NCT06680388|EXPERIMENTAL|relapsed/refractory idiopathic inflammatory myopathy (IIM)|Drug：CD19 CAR-T
61941254|NCT06680388|EXPERIMENTAL|relapsed/refractory Sjogren 's syndrome (SS)|Drug：CD19 CAR-T
61941255|NCT02935231|EXPERIMENTAL|Nicotine Replacement Therapy|This experimental group receives health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
62137779|NCT04613713|ACTIVE_COMPARATOR|Treatment as usual|The participants randomized to the treatment as usual group will follow available treatment options based on the current recommendations from Vulva clinic at Oslo University Hospital, a center that is specialized in treatment of vulvar conditions.
62336615|NCT00782015|ACTIVE_COMPARATOR|almonds|3 oz/d almonds
62336616|NCT00782015|PLACEBO_COMPARATOR|Placebo|NCEP Step 2 diet
62336617|NCT02306707||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Stomach Lesions will be included in this cohort.
62336618|NCT01090089|EXPERIMENTAL|Lenalidomid, PBSCT|A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
62336619|NCT01090089|ACTIVE_COMPARATOR|Lenalidomid|A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
61941256|NCT02935231|EXPERIMENTAL|Minimal Cessation Advice & Nicotine Replacement Therapy|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
61941257|NCT02935231|EXPERIMENTAL|Minimal Cessation Advice|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet.
61941258|NCT02935231|ACTIVE_COMPARATOR|Control|This control group receives a health warning leaflet.
61941259|NCT02149875|EXPERIMENTAL|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
61941260|NCT02149875|EXPERIMENTAL|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
61941261|NCT02149875|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
61941262|NCT02949531|ACTIVE_COMPARATOR|21% oxygen|room air will be delivered via Venturi mask during cycle ergometry
61941263|NCT02949531|ACTIVE_COMPARATOR|28% oxygen|28% oxygen will be delivered via Venturi mask during cycle ergometry
61941264|NCT02949531|ACTIVE_COMPARATOR|40% oxygen|40% oxygen will be delivered via Venturi mask during cycle ergometry
61941265|NCT00537875|ACTIVE_COMPARATOR|1|
61941266|NCT00537875|PLACEBO_COMPARATOR|2|
61941267|NCT04375618|EXPERIMENTAL|EGF impregnated in collagen membrane|EGF impregnated in collagen membrane is placed in gingival recession defects
61941268|NCT04375618|ACTIVE_COMPARATOR|plain collagen membrane|plain collagen membrane is placed in gingival recession defects
61941269|NCT04746196||45 ankylosing spondylitis patients.|Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.
61941270|NCT04746196||35 controls|Healthy controls
61941271|NCT06102915||Rocuronium|Rocuronium 1mg/kg to be given at induction of anaesthesia and another 1mg/kg would be given when the patient is on hypothermic cardiopulmonary bypass
61941272|NCT06102915||Cis-atracurium|Cis-atracurium 0.2mg/kg to be given at induction of anaesthesia and another 0.2mg/kg would be given when the patient is on hypothermic cardiopulmonary bypass
62695471|NCT06437366|EXPERIMENTAL|nurse-led HeartMath training program on patients with substance use disorder|The HeartMath training program, developed by the HeartMath Institute, focuses on teaching individuals self-regulation skills that promote heart-brain coherence. This state of coherence has been associated with improved cognitive function, emotional stability, and physical health. By integrating this training into the care of patients with SUDs, nurses can play a pivotal role in addressing the complex emotional and psychological needs of this population.
61941273|NCT04597775|EXPERIMENTAL|Arm 1 hydroxychloroquine 800mg day 1 and hydroxychloroquine 400mg day 2-5|hydroxychloroquine 800mg (400mg twice daily) given orally on day 1, (loading dose) hydroxychloroquine. Then 400mg (200mg 2 tablets) on day 2,3, 4 and 5.
61941274|NCT04597775|ACTIVE_COMPARATOR|Arm 2 hydroxychloroquine 400mg day 1 and hydroxychloroquine 200mg day 2-5|hydroxychloroquine 400mg (200mg twice daily) Given orally first day (loading dose), then 200mg once daily on day 2,3, 4 and 5.
61941275|NCT04597775|NO_INTERVENTION|No Intervention|No Intervention- SARS-CoV-2 surveillance Standard control measures in the country of interest such as self isolation, good personal hygiene and good nutrition.
62137780|NCT04620200|EXPERIMENTAL|ARM A|2 courses of nivolumab 3 mg/kg in week 0 and 2 prior to standard of care
61941276|NCT06681545||young adults with severe and or uncontrolled asthma|no intervention to be administered. Participants will be asked to participate in 1-1 interviews and or focus group interviews
61941277|NCT00606255||A|Active training group: Electronic Pill-Boxes with SMS service 1/week, training material provided
62695472|NCT06437366|NO_INTERVENTION|Non-experimental patients with substance use disorder|
62738467|NCT05487677|EXPERIMENTAL|BioBrace Augmentation|During the shoulder replacement surgery (arthroplasty) in order to access the shoulder, the subscapularis is removed from its insertion in your upper arm bone. It is repaired in reverse total shoulder arthroplasty, but is sometimes not as robust as we would like based on tissue quality and other factors. A shoulder arthroplasty is when the ball and socket are replaced with prosthetic components. If randomized to the BioBrace, patient will receive BioBrace augmentation of the standard subscapularis repair.
61941278|NCT00606255||B|Passive training group: Electronic Pill-Boxes ,Training material provided
61941279|NCT00606255||C|Usual treatment group: Electronic Pill-Boxes, maintain current treatment method
61941280|NCT03130608|EXPERIMENTAL|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
61941281|NCT03130608|NO_INTERVENTION|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
61941282|NCT01669928|ACTIVE_COMPARATOR|Evening medication|Anti hypertensive medication in the evening (between 18.00 and 23.00)
61941283|NCT01669928|ACTIVE_COMPARATOR|Morning medication|Antihypertensive medication in the morning(between 06.00 and 11.00)
61941284|NCT05340374|EXPERIMENTAL|Treatment Arm|In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-617 on Day 1 of every 6 week Cycle. Cabazitaxel will be administered concurrently on Day 2 and Day 23 of each Cycle (every 3 weeks). The dose of cabazitaxel will vary in dose-escalation. Up to 6 Cycles will be given.
61941285|NCT04904575|EXPERIMENTAL|Block|"The Block group will be made up of patients who will benefit from an injection of levobupivacaine for the realization of the erector spinae plane block."
61941286|NCT04904575|PLACEBO_COMPARATOR|Placebo|"The placebo group corresponds to the reference group, that is to say that it will consist of patients who will benefit from an injection of physiological serum for the realization of the erector spinae plane block."
61941287|NCT05745623|EXPERIMENTAL|ICP-723|
61941288|NCT00734370|EXPERIMENTAL|VRET|Virtual Reality Exposure Therapy for agoraphobic participants
61941289|NCT00734370|ACTIVE_COMPARATOR|Exposure in vivo|Standard exposure in vivo for panic disorder
61941290|NCT00734370|NO_INTERVENTION|Wait-list control|Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
62137781|NCT04620200|EXPERIMENTAL|ARM B|2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care
62336620|NCT06280157||One dose of GBS-NN/NN2|Participants who participated in study MVX003 and had received one dose of GBS-NN/NN2 prior to this study.
62336621|NCT06280157||Two doses of GBS-NN/NN2|Participants who participated in study MVX002 and had received two doses of GBS-NN/NN2 prior to this study.
62336622|NCT06280157||Three doses of GBS-NN/NN2|Participants who participated in study MVX002 and MVX003 and had received three doses of GBS-NN/NN2 prior to this study.
62336623|NCT04179968|EXPERIMENTAL|Patients with suspected prostate cancer|Patients with suspected prostate cancer who have at least one PI-RADS 5 lesion, or at least one PI-RADS 4 lesion and PSA ≥10 nanograms/milliliter (ng/mL), on standard of care mpMRI of the prostate, who are scheduled for biopsy or radical prostatectomy
62336624|NCT03910998|ACTIVE_COMPARATOR|"Group M for Moderate muscle relaxation, low doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.~Rocuronium IV bolus guided by TOF that must remain between 1-3 / 4 during surgery."
62336625|NCT03910998|EXPERIMENTAL|"Group D for Deep muscle relaxation, high doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.~Bolus of rocuronium 0.1 mg/kg IV will be given during surgery to keep the TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes)."
62336626|NCT03483324|EXPERIMENTAL|Experimental|Unmanipulated umbilical cord blood plus AB-110
62336627|NCT01782456|EXPERIMENTAL|Study Oral Nutritional Supplement|2 servings per day of a complete and balanced, ready-to-drink oral nutritional supplement with a new protein blend.
62336628|NCT05632575|OTHER|Single Arm: Virtual Promotoras Intervention|Single-arm study. Pre and post intervention. Observational. Behavioral
62336629|NCT03926559|EXPERIMENTAL|Duramorph (Morphine)|2mg of Neuraxial Morphine given through epidural once after the patient has delivered.
62336630|NCT03926559|NO_INTERVENTION|No intervention|Patient does not get any intervention.
62336631|NCT05199350||Population including people with NGT, IFG and IGT and diabetes.|"Normal Glucose Tolerance (NGT) is defined as a plasma glucose concentration i.e \< 140 mg/dl.~IFG is defined by an elevated fasting plasma glucose (FPG) concentration i.e ≥ 100 and \< 126 mg/dl.~IGT is defined by an elevated post-prandial plasma glucose concentration i.e ≥140 and \< 200 mg/dl.~Presence of confirmed diabetes (HbA1c level \> 6.4 %) without complications i.e no neuropathy, no retinopathy, no nephropathy etc.~Presence of confirmed diabetes (HbA1c level \> 6.4 %) with at least one of the above complications."
62336632|NCT02124616||Neuromuscular diseases|Prospective cohort of children with inherited or acquired neuromuscular diseases.
62336633|NCT03943758|EXPERIMENTAL|prepackaged Low-residue diet group|The prepackaged Low-residue diet (Maifu Nutrition Technology Co. Ltd, Beijing, China). One package of the prepackaged Low-residue diet contained quantity of heat amounts to 268 kilocalories with 12.0 g of protein, 9.6 g of lipid, and 34.1 g of carbohydrate.
62336634|NCT03943758|ACTIVE_COMPARATOR|self-prepared Low-residue group|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy
62336635|NCT02969447|EXPERIMENTAL|Oxytocin administration after fetal expulsion|Administration of 10 units of intra venous oxytocin after fetal expulsion
62493653|NCT00273013|EXPERIMENTAL|Sequence 3|Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3.
62493654|NCT00273013|EXPERIMENTAL|Sequence 4|Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3.
62336636|NCT02969447|NO_INTERVENTION|No additional medication after fetal expulsion|
62336637|NCT02052843|EXPERIMENTAL|Steps to Success|Steps to Success enhanced home visits-including instruction for both young mothers and fathers on contraception, comprehensive sex education, and the importance of adequate birth spacing, and accompanied by group sessions on adulthood preparation topics.
62336638|NCT02052843|ACTIVE_COMPARATOR|Traditional Healthy Families|Traditional Healthy Families home visits which cover topics of parenting and child development
62336639|NCT04715230|EXPERIMENTAL|IXT-m200|IXT-m200 is a high-affinity chimeric anti-METH monoclonal antibody that is well-tolerated in healthy volunteers and in non-intoxicated people with METH use disorder. The total dose will be given over 10 min for the 0.5-g dose and over 20 min for the 1-, 1.5-, and 2-g doses.
62336640|NCT04715230|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting. Haloperidol is commonly used to treat agitation due to psychosis.
62493655|NCT00273013|EXPERIMENTAL|Sequence 5|Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3.
62493656|NCT00273013|EXPERIMENTAL|Sequence 6|Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3.
62493657|NCT01835548|EXPERIMENTAL|NT0102|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
62493658|NCT01835548|PLACEBO_COMPARATOR|Placebo|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.
62336641|NCT04478149|EXPERIMENTAL|Active Cameras|active cameras in the room
62336642|NCT04478149|SHAM_COMPARATOR|Inactive Cameras|camera in the room, not activated
62336643|NCT02391844|OTHER|Oxycodone|Xartemis XR - Oxycodone with Acetaminophen Extended Release Tablet
62336644|NCT01511419|EXPERIMENTAL|LAIV H7N3|"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.~Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.~Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.~Route of administration: Intranasal aerosol.~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28."
62493659|NCT03117244|EXPERIMENTAL|Exercise Group|
62493660|NCT03117244|ACTIVE_COMPARATOR|Exercise and NMES Group|
62493661|NCT03117244|NO_INTERVENTION|Control Group|
62493662|NCT04914546|EXPERIMENTAL|LY3819469 (Part A)|Single ascending doses of LY3819469 administered subcutaneously (SC).
62493663|NCT04914546|EXPERIMENTAL|LY3819469 (Part B)|Single doses of LY3819469 administered SC in Japanese Participants.
62493664|NCT04914546|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC.
62493665|NCT04914546|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC.
62493666|NCT02816684|ACTIVE_COMPARATOR|SET-C|Social Effectiveness Therapy for Children (SET-C; Beidel et al., 2000) includes social skills training, peer generalization experiences, and in vivo exposure.
62137782|NCT06357533|EXPERIMENTAL|Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig|Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
62336645|NCT01511419|PLACEBO_COMPARATOR|Placebo|"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.~Dose: 0.5 ml; 0.25 ml/nare~Route of administration: Intranasal aerosol~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28"
62336646|NCT06254027|EXPERIMENTAL|Forte|"Device:~One application per day for 9 months."
62336647|NCT06254027|EXPERIMENTAL|Active Cover Light|"Device:~One application per day for 9 months."
62336648|NCT06254027|ACTIVE_COMPARATOR|Loceryl 5%|Drug: Loceryl 5% One application per week for 3 months
62336649|NCT02121756|EXPERIMENTAL|Dipyridamole|ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
62336650|NCT02121756|ACTIVE_COMPARATOR|Placebo then Dipyridamole|ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
62336651|NCT03828084|EXPERIMENTAL|Formulation A|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
62336652|NCT03828084|EXPERIMENTAL|Formulation B|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
62493667|NCT02816684|EXPERIMENTAL|Pegasys-VR|SET-C SST and individual exposure sessions are the same as the active comparator. Peer generalization sessions are replaced by a virtual environment, known as Pegasys School. children engage with artificially intelligent avatars throughout the school.
62493668|NCT02985749|EXPERIMENTAL|Oxytocin- Participants ages 12-17|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
62493669|NCT02985749|EXPERIMENTAL|Oxytocin- Participants ages 18-55|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
62493670|NCT05758129||The control group|the invited recently diagnosed with epilepsy (\< 2 months) live in Wuxi, Jiangsu, China (low PM2.5 level based on previous official PM2.5 records)
62493671|NCT05758129||The PM2.5 exposure group|the invited recently diagnosed with epilepsy live in Xuzhou, Jiangsu, China (high PM2.5 level based on previous official PM2.5 records)
62493672|NCT00894764||Routine Follow Up|Monthly nasopharyngeal swab for infant. Seen during acute illness.
62493673|NCT00894764||Immunology|Monthly nasopharyngeal swab for mother and infant. Serum sample taken from Infant. Seen during acute illness.
62493674|NCT05815225||A: subjects from mental health unit|Subjects with active psychotic symptoms at the time of recruitment, attended at the Mental Health Clinical Management Unit of the Regional University Hospital of Malaga (Spain) and admitted to the Mental Health Hospitalization Unit. In turn, within this group, a cross-classification will be established according to the evolutionary staging of the disease, the concomitant presence of major affective symptoms and the consumption of substances in the weeks prior to admission.
62493675|NCT05815225||B: subjects with induced psychoses|Subjects with psychotic symptoms, diagnosed with a substance-induced psychotic episode, already recruitedand previously characterized.
62493676|NCT05815225||C: control group|Control group of volunteers extracted from the general population, without psychotic symptoms orsubstance use disorders.
62336653|NCT03828084|EXPERIMENTAL|Formulation C|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
62336654|NCT03828084|ACTIVE_COMPARATOR|Reference Formulation|3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
62493677|NCT00643305|EXPERIMENTAL|1|Skills Building with Motivational Interviewing (SB-MI)- combines education and general skills-building participants can use to reduce their at-risk behavior for HIV with increasing motivation to change HIV risk behaviors
62493678|NCT00643305|ACTIVE_COMPARATOR|2|Skills Building (SB) - provides education and general skills-building for reduction of HIV risk behaviors.
62493679|NCT02699762|EXPERIMENTAL|experimental group|self rehabilitation of upper limb in experimental group + BTI + usual physiotherapy
62493680|NCT02699762|NO_INTERVENTION|control group|BTI + usual physiotherapy
62493681|NCT03540160|EXPERIMENTAL|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
62493682|NCT00000380|EXPERIMENTAL|GHRH|Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone.
62493683|NCT00000380|PLACEBO_COMPARATOR|Placebo|Placebo
62493684|NCT04179539|EXPERIMENTAL|Intervention|"Patients with suspected acute PE undergo CTPA and V/Q PET/CT imaging within 24 hours. V/Q PET/CT images are not used for patients management.~After completion of inclusion, central readings will be independently conducted:~* CTPA will be interpreted by two radiologists, blinded to the results of any clinical information or imaging test results. The results of this interpretation will be used as a reference standard.~* V/Q PET/CT will be interpreted by two independant nuclear medicine physicians, blinded to the results of any clinical information or imaging test results (including the reference standard)."
62493685|NCT04003441|EXPERIMENTAL|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
62493686|NCT04003441|EXPERIMENTAL|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
61941291|NCT06662942|ACTIVE_COMPARATOR|Investigational product|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
62336655|NCT02444819|EXPERIMENTAL|HM61713|Subjects who entered the study will be administered HM61713 800 mg per day.
62336656|NCT00625521|EXPERIMENTAL|1|Drug: ASF 1096 0.5 % cream applied twice daily
62336657|NCT00625521|PLACEBO_COMPARATOR|2|Cream vehicle for ASF 1096 cream applied twice daily
62336658|NCT03014167|EXPERIMENTAL|Community-wide deworming|Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
62336659|NCT03014167|ACTIVE_COMPARATOR|Targeted deworming|Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.
62336660|NCT03689725|EXPERIMENTAL|Preterm music group|Music exposure with headphones
62336661|NCT03689725|NO_INTERVENTION|Preterm control group|headphones without music
62493687|NCT02898740|EXPERIMENTAL|Exercise|Structured exercise
62493688|NCT02898740|ACTIVE_COMPARATOR|Health Education|Health education
62493689|NCT00111137|ACTIVE_COMPARATOR|rHuEPO|
61941292|NCT06662942|PLACEBO_COMPARATOR|Placebo|This arm will be a sterile, transparent, water-soluble lubricating jelly that is not silicone-based.
62493690|NCT00111137|EXPERIMENTAL|Darbepoetin alfa|
61941293|NCT02970916|EXPERIMENTAL|FOLFIRI+aflibercept|
62493691|NCT05270044|EXPERIMENTAL|Arm A|Encorafenib and Binimetinib
62493692|NCT05270044|PLACEBO_COMPARATOR|Arm B|Placebo to match Encorafenib Placebo to match Binimetinib
62493693|NCT03226613|EXPERIMENTAL|Patients with suspected or known oropharyngeal cancer|Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
61941294|NCT01580358|ACTIVE_COMPARATOR|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
61941295|NCT01580358|PLACEBO_COMPARATOR|starch|Starch in the same granule as intervention group for this double-blind trial
61941296|NCT03841448|EXPERIMENTAL|Double-Blind Treatment (DBT) Period: Cemdisiran|Participants received cemdisiran, 600 milligrams (mg), subcutaneous (SC) injection, once every 4 weeks (Q4W) in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.
61941297|NCT03841448|PLACEBO_COMPARATOR|DBT Period: Placebo|Participants received cemdisiran matching placebo, SC injection, Q4W in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.
61941298|NCT03841448|EXPERIMENTAL|DBT Period: Cemdisiran to Open-Label Extension (OLE) Period: Cemdisiran|Participants who were randomized to receive cemdisiran in the DBT period continued receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.
62336662|NCT03689725|NO_INTERVENTION|Full-term control group|
62336663|NCT00712322|EXPERIMENTAL|Cohort 1 (Darifenacin 0.030 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.030 milligrams/kilogram/day (mg/kg/day) dispensed per twice a day (BID) dosing, for 14 days.
62336664|NCT00712322|EXPERIMENTAL|Cohort 2 (Darifenacin 0.0625 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.0625 mg/kg/day dispensed per BID dosing, for 14 days.
62493694|NCT04474587||OHS-NIV|Patients with obesity-hypoventilation syndrome (OHS) treated with non-invasive ventilation (NIV).
61941299|NCT03841448|PLACEBO_COMPARATOR|DBT Period: Placebo to OLE Period: Cemdisiran|Participants who were randomized to receive cemdisiran matching placebo in the DBT period started receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.
61941300|NCT03873012||OCT-guided group|OCT-guided PCI with EES or BES
62137783|NCT06357533|EXPERIMENTAL|Arm 2: Rilvegostomig Monotherapy|Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
62137784|NCT06357533|ACTIVE_COMPARATOR|Arm 3: Pembrolizumab Monotherapy|Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
62336665|NCT00712322|EXPERIMENTAL|Cohort 3 (Darifenacin 0.125 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.125 mg/kg/day dispensed per BID dosing, for 14 days.
62336666|NCT04325594|EXPERIMENTAL|Main Group|Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1×10 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy
62336667|NCT04325594|ACTIVE_COMPARATOR|Control Group|Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy
62336668|NCT00147732|ACTIVE_COMPARATOR|1|Accelerated radiotherapy
62336669|NCT00147732|EXPERIMENTAL|2|ARCON
62493695|NCT03202927|EXPERIMENTAL|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
62493696|NCT03202927|ACTIVE_COMPARATOR|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
62493697|NCT04965233||Participants recruited in Denmark|Participants recruited in Denmark will consist of 63 healthy individuals and 187 individuals with atopic dermatitis
62493698|NCT04965233||Participant recruited in the United States of America|Participants recruited in the US will consist of 125 healthy individuals, 3000 individuals with atopic dermatitis
61941301|NCT03873012||Angiography-guidance group|Angio-guided PCI with EES or BES
61941302|NCT06058559|EXPERIMENTAL|Sunflower Lecithin|Total 4800 mg sunflower lecithin per day taken in 4 softgel capsules
61941303|NCT06058559|PLACEBO_COMPARATOR|Olive Oil|Total 4000 mg olive oil per day taken in 4 softgel capsules
62336670|NCT04725370||CHOP (US)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2012 to 2019 at the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
62336671|NCT04725370||SFG (Guatemala)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2017 and 2020 with Smiles for Guatemala, Guatemala City, Guatemala.
62336672|NCT00999856|ACTIVE_COMPARATOR|Cohort 1|In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
62336673|NCT00999856|ACTIVE_COMPARATOR|Cohort 2|Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
62493699|NCT04736537|EXPERIMENTAL|Healthy Controls|
62493700|NCT03121937|EXPERIMENTAL|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
62493701|NCT03121937|NO_INTERVENTION|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
62493702|NCT00746486|EXPERIMENTAL|A|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
61941304|NCT02635776|EXPERIMENTAL|AR101 powder provided in capsules & sachets|Study product provided as peanut protein in pull-apart capsules or sachets
61941305|NCT02635776|PLACEBO_COMPARATOR|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
61941306|NCT03540030|NO_INTERVENTION|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
61941307|NCT03540030|ACTIVE_COMPARATOR|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
62695473|NCT06638255|EXPERIMENTAL|Sequence A: First Low PEEP for 12 hours, then High PEEP for 12 hours|"Arm Information~Experimental Arm Title:~Sequential PEEP Protocol - Low and High PEEP Strategies~Arm Description:~Participants in this clinical trial will be randomized into one of two pre-specified sequences to receive both high and low PEEP ventilation strategies over two sequential 12-hour periods.~Intervention for Arm 1: Participants will receive the Low PEEP protocol for the first 12-hour period, followed by the High PEEP protocol for the next 12-hour period.~Intervention for Arm 2 (Sequence B): Patients will receive High PEEP for the first 12 hours, then Low PEEP for the next 12 hours."
61941308|NCT04575454|OTHER|Comatose or post-comatose patients|
61941309|NCT04836754||Case group|Pregnant women with Covid-19
61941310|NCT04836754||Control groups|Pregnant women who do not have Covid-19
61941311|NCT03959254|EXPERIMENTAL|Intervention Group|Application of a protocol of active exercises for recovery after arthroscopic hip surgery, adapted to the femoroacetabular shock characteristics.
62336674|NCT00999856|ACTIVE_COMPARATOR|Cohort 3|Cohort 3 only differs in the used photometer from cohort 2.
62336675|NCT00999856|ACTIVE_COMPARATOR|Cohort 4|Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
62336676|NCT00999856|ACTIVE_COMPARATOR|Cohort 5|The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.
62493703|NCT00746486|ACTIVE_COMPARATOR|B|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
62493704|NCT03577561|NO_INTERVENTION|Control group A|Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving proficiency based progression training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.
62493705|NCT03577561|ACTIVE_COMPARATOR|Control Group B|Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
62695474|NCT06638255|EXPERIMENTAL|Sequence B: First High PEEP for 12 hours, then low PEEP for 12 hours|Sequence B: First High PEEP for 12 hours, then low PEEP for 12 hours
61941312|NCT03959254|ACTIVE_COMPARATOR|Control Group|Usual post-surgical general guidelines for hip interventions described by Gocen et al
61941313|NCT02808793|EXPERIMENTAL|AK002|IV dose of AK002
61941314|NCT06122116|ACTIVE_COMPARATOR|Physical Therapy (PT) Only|All participants will complete a standard of care PT program addressing individual strength, mobility, and flexibility deficits in both proximal and distal muscle groups. The provider may also use other modalities to address distal issues. If a participant has not been placed on profile at the time of consent, a profile may be written by the study medical provider to ensure limitation of activities, as appropriate.
62695475|NCT04309682|EXPERIMENTAL|crestal sinus approach technique|Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
61941315|NCT06122116|ACTIVE_COMPARATOR|PT + Platelet-Rich Plasma (PRP)|"PRP Preparation: The PRP will be prepared following standard technique by drawing 60cc blood from the participant through venipuncture and spinning the blood sample in a centrifuge (for approximately 17 minutes), adjusting for leukocyte poor-platelet rich plasma (LP-PRP). This sample will be prepared by the study provider. Any leftover blood will be safely discarded per standard protocols.~A small portion of the pre-spin whole blood (approximately 1 cc) and post-spin injectant PRP (approximately 1 cc) will be sent to MAMC Department of Pathology and Laboratory Services (DPALS) for complete blood count (CBC) cytology to monitor standardization and reproducibility. This portion will be labeled by participant ID and study. De-identified hardcopy results will be obtained from MAMC DPALS, and CBC results will be reported on Appendix G (CBC Results CRF). Post-procedural instructions will be provided in a participant handout."
61941316|NCT06122116|ACTIVE_COMPARATOR|PT + Photobiomodulation Treatment (PBMT)|"In addition to SOC PT, the PBMT group will receive PBM treatment, as outlined below.~PBM treatments will occur 3 times each week, for 3 weeks. A member of the study team will measure the treatment area according to a standard protocol and calculate the treatment time (approximately 5-20 minutes). PBMT will be delivered at 6 J/cm2 and 25W and applied in a serpentine pattern to the knee area. Participants will be asked to refrain from using perfumes or plant extracts (e.g., St. John's Wort) in the treatment area(s), as this can increase skin photosensitivity."
62695476|NCT04309682|ACTIVE_COMPARATOR|lateral sinus elevation technique|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take plac
62695477|NCT06069713|EXPERIMENTAL|Perception of Ads|Each panel will consist of 5 different advertisements for CBD. With 11 panels and 5 images each, there are a total of 55 images that will be viewed by the participants. Participants will view an image, one at a time, and answer questions about their perceptions of the advertisement.
62695478|NCT04588883|EXPERIMENTAL|Intervention Arm|Patients, adults and adolescents, will be recruited from patient registries at 7 government operated HIV clinics in Meru County, Kenya. Patients will complete validated questionnaires at baseline, 1.5 year and 3 years into a novel adaptation of a community empowerment program. The program utilizes savings- and internal-lending/group-based microfinance process to facilitate exchange of savings amongst patients and adolescent guardians. A byproduct of this process is the development of social capital, which will be used to facilitate education, peer learning, and collective problem solving to improve determinants of well-being and clinical adherence among participants. Expected outcomes include improved viral suppression, ART adherence, clinical attendance, and mental health.
62695479|NCT05576337|EXPERIMENTAL|Strict vegetarians|Strict vegetarians women
62695480|NCT05576337|EXPERIMENTAL|non vegetarians|Non vegetarians women
62695481|NCT00500331|EXPERIMENTAL|Arm 1|GSK189075
62695482|NCT00500331|PLACEBO_COMPARATOR|Arm 2|Placebo
62336677|NCT03700008|OTHER|Participants with mental illness|"Participant with pre known or actually diagnosed mental disorder, especially affective or neurodevelopmental disorder.~Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements."
62336678|NCT03700008|OTHER|Participants without any mental illness|Participant with never diagnosed mental disorder, in a healthy mental state. Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements.
62336679|NCT05272527|EXPERIMENTAL|Intervention Group|After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Within the scope of the Transition to Motherhood Program, 5-session training and phone follow-ups were made in the first week and the fourth week postpartum to the experimental group. Post-tests were applied to the experimental group at the postpartum 1st month and 4th month.
62336680|NCT05272527|NO_INTERVENTION|Control Group|After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Pretest and postpartum 1st month and 4th month posttests were applied to the control group.
62336681|NCT02200367|EXPERIMENTAL|e-mental health collaborative programme|It is a complex intervention to support primary care providers of rural primary care service to manage depressed patients. Primary care providers at the intervention sites were supported by psychiatrist using an electronic platform.Patients were monitored through a call center.
62336682|NCT02200367|OTHER|Usual Care|Patients in this arm received all the interventions that are guaranteed for the persons with depression in Chile: treatment in the primary clinics with the primary care team and referral to the regional specialized psychiatric service
62336683|NCT06053216|EXPERIMENTAL|Individualised energy delivery|Energy delivery will be guided by indirect calorimetry, with the aim to meet 80-100% of the most recent energy expenditure measurement from day 4 to 28 of hospital admission.
62336684|NCT06053216|ACTIVE_COMPARATOR|Standard care nutrition|Energy delivery will be according to predictive equation estimates and usual site practice from day 4 to 28 of hospital admission.
62336685|NCT03696303||Cases|Suspected community-acquired bacterial pneumonia
62336686|NCT03696303||Controls|Healthy children, age-matched to enrolled cases
62336687|NCT03696303||Controls with URI|Children 5 years of age or younger with upper respiratory infection (URI) (controls with URI)
62336688|NCT02854137|EXPERIMENTAL|Sunscreen / Arm 1|Subjects will be escorted to a separate room for instillation of the test materials. Test materials will be instilled in immediate succession and with a randomized order of presentation. A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the eyes of the subject forming sacs in the conjuntival tissue, apply one test product to one eye.
61941317|NCT06122116|ACTIVE_COMPARATOR|PT + PRP + PBMT|"In addition to SOC PT, the PRP and PBMT group will receive PRP treatment and PBMT treatments.~Participants in this group will start PBMT treatments on the same day after receiving the study PRP injection. On the day of the PRP injection, the participant will be instructed to rest for 5-10 minutes prior to the PBMT application and team member will ensure the participant is comfortable not in pain. Immediately following the study injection, the team member will take care not to provide the PBMT over the injected area; however, all subsequent PBMT treatments will be delivered to the knee where the PRP was injected."
61941318|NCT01460368|EXPERIMENTAL|Part A: LY2409021|Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of 300 milligrams (mg) LY2409021 administered orally. Participants enrolled in Part A will not be allowed to participate in Part B.
61941319|NCT01460368|EXPERIMENTAL|Part B: LY2409021|300 milligrams (mg) LY2409021 administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
61941320|NCT01460368|PLACEBO_COMPARATOR|Part B: Placebo|Administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
61941321|NCT01460368|ACTIVE_COMPARATOR|Part B: Moxifloxacin|400 milligrams (mg) Moxifloxacin administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
61941322|NCT05052658|ACTIVE_COMPARATOR|Palpation Group|
61941323|NCT05052658|EXPERIMENTAL|Ultrasound Group|
62336689|NCT02854137|OTHER|Control|A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the other eyes of the subject forming sacs in the conjuntival tissue, apply control materials to this eye, follow the same procedure, using a new pipet tip or steriled dropper.
61941324|NCT03897504|EXPERIMENTAL|feminizing genitoplasty using inner surface of the prepuce|Feminizing genitoplasty will be done using the prepuce as a pedicled tubularized flap to create the new vagina, the new vagina which the investigators create it from the prepuce will be sutured above to the native vagina after its separation from the urogenital sinus, and the remaining part of the urogenital sinus will be used to create the urethra, the remaining part of the prepuce will create the labia minora, clitoroplasty will be attempted in all patients.
61941325|NCT03376048|EXPERIMENTAL|Wound infiltration plus TAP|Wound infiltration placed by surgeon + TAP-LAP placed laparoscopically guided by surgeon
62336690|NCT02771249|EXPERIMENTAL|Arm B|Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + RPT and INH once weekly (days 5-19).
61941326|NCT03376048|ACTIVE_COMPARATOR|Wound infiltration|Wound infiltration placed by surgeon
62137785|NCT06292936|EXPERIMENTAL|Acceptance-Based Behavioral Intervention|Participants assigned to ABTi will receive a remotely delivered intervention consisting of 20 modules over 6 months. Based on theory derived from acceptance and mindfulness approaches, the intervention provides psychological strategies to facilitate engagement in weight control behaviors. Each module includes a video presentation of material synchronized with a slideshow illustrating session material, interactive features, quizzes that will ensure participants have mastered the material, and directed assignments to be completed throughout the week. Participants will be assigned to view each module, self-monitor their daily food intake, and weigh themselves weekly. At the completion of each module, a brief call with a coach will be scheduled to discuss and clarify the content of the session, review homework, and provide feedback on food records and weekly weights.
62336691|NCT06519552|EXPERIMENTAL|JWK008 injection|The participants will be given 5.0×10\^12vg/kg or 2.0×10\^13vg/kg body weight of JWK008
62336692|NCT04064320|EXPERIMENTAL|Intervention group|Received lullaby intervention and usual care
62695483|NCT00500331|OTHER|Arm 3|pioglitazone (active control)
62695484|NCT02168699|OTHER|Ultrasound examination|Ultrasound examination of the axillary region in children
62695485|NCT00901914|PLACEBO_COMPARATOR|1|Placebo
62695486|NCT00901914|EXPERIMENTAL|2|12.5 µg rBet v 1
62695487|NCT00901914|EXPERIMENTAL|3|25 µg rBet v 1
61941327|NCT02728622|EXPERIMENTAL|Tamoxifen|Tamoxifen 40 mg is given orally once daily until progression
62336693|NCT04064320|NO_INTERVENTION|Control group|No intervention other than usual care
62336694|NCT03085641|EXPERIMENTAL|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~* Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~* High flow rate: 40-50 L/min without additional oxygen~* Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~* High flow rate: 40-50 L/min with FiO2 of 28%"
61941328|NCT02728622|ACTIVE_COMPARATOR|Chemotherapy|Paclitaxel 80 mg/m2 is given as an 1 hour infusion every 7 days or Caelyx 40 mg/m2 is given iv, first dose over 2 hours, later doses are infused over 1 hour, administered every 4 weeks or up to a maximum dose of 550 mg/m2. Until progression
61941329|NCT05873062|EXPERIMENTAL|Experimental: AUT00201|Single dose (oral, capsule) of AUT00201
61941330|NCT05873062|PLACEBO_COMPARATOR|Experimental: Placebo|Single dose matching placebo oral capsules
61941331|NCT05175027|ACTIVE_COMPARATOR|Hypochlorosis|Hypochlorosis was used as an antiseptic for the patients
61941332|NCT05175027|ACTIVE_COMPARATOR|Povidone iodine|Povidone iodine was used as an antiseptic for the patients
62336695|NCT04719065|EXPERIMENTAL|Group A, Mitoxantrone Hydrochloride Liposome Injection, q4w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
62336696|NCT04719065|EXPERIMENTAL|Group B, Mitoxantrone Hydrochloride Liposome Injection, q3w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
62695488|NCT00901914|EXPERIMENTAL|4|50 µg rBet v 1
62695489|NCT05918029|EXPERIMENTAL|Potassium Citrate|"Potassium Citrate extended-release tablets 30 mEq twice daily. 1 mEq/kg/day divided into two doses for children to a maximum dose of 30 mEq twice daily.~OR~(for children who cannot take pills): Potassium citrate and citric acid for oral solution 1 mEq/kg/day divided into two doses to a maximum dose of 30 mEq twice daily"
62336697|NCT02976376|EXPERIMENTAL|The Box|"After randomization, patients in the intervention group will receive a box (The Box) with all the devices described above. Instructions about the installation and usage of the devices will be given. Patients will be asked to measure their weight and blood pressure once a day. Furthermore, patients will be asked to record an ECG using the AliveCor once a day. Moreover, they are asked to record an ECG in case of any symptoms of possible cardiac origin, as judged by the patient. All data will be automatically transferred to the Leiden University Medical Center. Lastly, two of the four outpatient clinical visits will be done via a video connection. The content of the interview will be comparable to the content of a regular outpatient clinic visit."
62336698|NCT02976376|NO_INTERVENTION|Control|Patients who are randomized to the control group will receive regular care.
62336699|NCT04892758||Formoterol fumarate 10 mcg|Reference Group
62336700|NCT04892758||Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Exposure Group
62336701|NCT03081286|EXPERIMENTAL|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
62493706|NCT03577561|ACTIVE_COMPARATOR|Interventional Group|"The blood sampling error rate of doctors in training provided with the intervention i.e. improved proficiency based progression training programme will be analysed from July 10th 2018 until the study ends.~The proficiency based progression training will consist of an online eLearning module to teach the doctors the correct process to take blood in the hospital. The doctors will then have to attend a face to face training day on a simulation ward where they will be asked to take blood according to a metric of 77 steps with less than 13 errors and no critical errors. Finally, the doctors will be observed taking blood on the ward and again must take it to a proficient standard."
62493707|NCT04148287|EXPERIMENTAL|APX001|APX001 IV or oral for up to 42 days
62493708|NCT05125276|EXPERIMENTAL|Interventional arm|No aspirin
62493709|NCT05125276|ACTIVE_COMPARATOR|Control arm|Aspirin (75-100 mg once daily)
62695490|NCT05918029|PLACEBO_COMPARATOR|Placebo|Placebo capsules identical to the active capsules.
61941333|NCT01882348|NO_INTERVENTION|Usual Care Control|"Control groups will receive equal number of contacts for training in preparation for enrollment and data collection for the study.~Clinicians will be given the option to receive a standard American Academy of Pediatrics tobacco control pamphlet to distribute.~Control groups have the option to receive access to the CEASE online module intervention at the conclusion of the research study which allows practitioners in this group to receive 26 continuing education credit hours."
61941334|NCT01882348|EXPERIMENTAL|Intervention|The Intervention Group will receive the CEASE Intervention
61941335|NCT00658580|ACTIVE_COMPARATOR|A|Every 3 weeks intravenous cisplatin plus etoposide
62336702|NCT03081286|SHAM_COMPARATOR|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
62695491|NCT06641518|EXPERIMENTAL|TENS|Transcutaneous Electrical Nerve Stimulation (TENS) was applied to the brachial plexus at the supraclavicular fossa (Erb's point) and to the radial nerve between the biceps and triceps in the spiral groove. The frequency was set at 10 Hz, and the intensity was adjusted to a level that elicited sensation without causing pain or muscle twitching, for a duration of 45 minutes, five days a week, totaling 20 sessions over four weeks, combined with standard upper extremity conservative occupational therapy training.
62695492|NCT06641518|SHAM_COMPARATOR|Sham TENS|Transcutaneous Electrical Nerve Stimulation (TENS) on the affected arm according to the same treatment protocol as above; however, the device was not turned on, and no electrical current was delivered (Placebo).
62695493|NCT06213480|EXPERIMENTAL|Synbiotic Group|They will receive a 3-day antibiotic (Vancomycin 500 mg/3 times/day), followed by a 3-month symbiotic. The synbiotic that will be used in this trial contains the oligosaccharide-degrading probiotics, Akkermansia muciniphila and Bifidobacterium infantis; butyrate producers such as Clostridium beijerinckii, Anaerobutyricum hallii, and Clostridium butyricum; and chicory-derived inulin, a prebiotic dietary fiber.
62695494|NCT06213480|PLACEBO_COMPARATOR|Placebo Group|They will receive a 3-day antibiotic (Vancomycin 500 mg/3 times/day), followed by a 3-month placebo.
62695495|NCT02376010|ACTIVE_COMPARATOR|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
61941336|NCT00658580|EXPERIMENTAL|B|Every 3 weeks intravenous epirubicin plus ifosfamide plus etoposide
62336703|NCT03314220|EXPERIMENTAL|standard care plus preoperative preparation|experimental group received standard care plus preoperative preparation, which included a tour, a cartoon video depicting a boy's surgical journey and familiarization with medical equipment.
62336704|NCT03314220|NO_INTERVENTION|standard care|
61941337|NCT00543543|EXPERIMENTAL|Low-dose V503|V503 (9-Valent Human Papillomavirus \[HPV\] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
61941338|NCT00543543|EXPERIMENTAL|Mid-dose V503|V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
62336705|NCT01113021|EXPERIMENTAL|LLLT and Physical Strength training in Humans|
62336706|NCT00259220|EXPERIMENTAL|drug|erythromycine
62336707|NCT00259220|OTHER|2|gastric lavage alone
62336708|NCT00259220|ACTIVE_COMPARATOR|3|erythromycine and gastric lavage
62336709|NCT01521234|EXPERIMENTAL|Feedback group|For participants assigned to the feedback group, physiotherapists will receive a summary of patients' walking activity for the previous week as a tool to guide goal planning. Physiotherapists will use the information as a 'homework checker' to determine if patients are complying with an assigned walking program. In the case of non-compliance, the physiotherapist will discuss a coping strategy for better integrating walking activity into the patients' day. In the event that the patient is meeting their specific sub-goals for walking activity, the physiotherapist will re-evaluate these sub-goals and suggest more challenging goals.
62493710|NCT04459754|EXPERIMENTAL|Fuzheng Yiliu group|
62493711|NCT04459754|NO_INTERVENTION|control group|
62493712|NCT03332433|NO_INTERVENTION|Control group|Oxygen(2L/min) supplied with nasal catheter
62493713|NCT03332433|EXPERIMENTAL|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
62493714|NCT00486993||asuriesgo|unselected outpatient population
62493715|NCT00879684|EXPERIMENTAL|1|
62695496|NCT02376010|ACTIVE_COMPARATOR|warfarin|warfarin orally once a day, titrated to INR of 2-3
61941339|NCT00543543|EXPERIMENTAL|High-dose V503|V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
62695497|NCT01220583|EXPERIMENTAL|Arm I|Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
62695498|NCT01220583|EXPERIMENTAL|Arm II|Patients undergo 3D-CRT or IMRT as in arm I.
62695499|NCT06541678|ACTIVE_COMPARATOR|Period 1: Danuglipron|Participants will receive a single 20 mg dose of danuglipron on Day 1.
62695500|NCT06541678|EXPERIMENTAL|Period 2: Cyclosporine + Danuglipron|Participants will receive a single 20 mg dose of danuglipron and a single 600 mg dose of cyclosporine on Day 1.
61941340|NCT00543543|ACTIVE_COMPARATOR|Gardasil|Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
62336710|NCT01521234|NO_INTERVENTION|No-feedback group|For participants assigned to the control group, physiotherapists will not receive accelerometer-based feedback of daily walking activity. However, physiotherapists will still discuss the achievement of walking goals with their patients. This is usual care around goal planning.
62336711|NCT03233841||Living non-HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have not undergone hematopoietic stem cell transplantation (HSCT).
61941341|NCT00646919||1|All pre-operative pediatric patients in our outpatient clinic
62336712|NCT03233841||Living HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have undergone hematopoietic stem cell transplantation (HSCT).
62493716|NCT05624424|EXPERIMENTAL|Remimazolam Besylate|Induction of anesthesia Slowly inject Remimazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS\<60, if the degree of sedation is insufficient, additional Remimazolam Besylate (0.05 mg/kg each time) is allowed. After the LoC, sufentanil 0.3\~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
62695501|NCT06541678|EXPERIMENTAL|Period 3: Itraconazole + Danuglipron|Participants will receive itraconazole daily for 6 days plus a single dose of danuglipron on Day 4.
61941342|NCT05089331||Participants will be recruited from the GERFHS/ROSE Study|Participants will be recruited who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study/Recovery and Outcomes from Stroke study, who live in the area of University of Cincinnati, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, Baptist Health Louisville and Houston Methodist. The participant's age must be18 years or greater. The participant or legal representative must be able to provide informed consent, and the racial/ethnic category of participants should be Caucasian, African American or Hispanic.
61941343|NCT02919696|EXPERIMENTAL|Abemaciclib Dose Level 1|Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
61941344|NCT02919696|EXPERIMENTAL|Abemaciclib Dose Level 2|Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
62137786|NCT06292936|NO_INTERVENTION|Control|Participants assigned to the Control condition will receive telephone contacts from the coaches on the same schedule as those who receive ABTi. The content will focus on the (re) delivery of the dietary and behavioral instruction that patients received prior to bariatric surgery. For example, participants will be reminded to consume reduced portion sizes, avoid foods higher in sugar and fat, and eat discrete meals throughout the day. They will receive a Wi-Fi scale and will be asked to weigh themselves weekly, similar to those receiving ABTi.
62336713|NCT03233841||Deceased Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are deceased (including patients who may or may not have undergone hematopoietic stem cell transplantation).
62336714|NCT04757727||EDB|Adult women (\> 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or recessive) followed at the Nice University Hospital or at the St Louis Hospital of the APHP
62336715|NCT01171404||1|Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
62336716|NCT01076634|EXPERIMENTAL|IDeg 100 U/mL|
62336717|NCT01076634|EXPERIMENTAL|IDeg 200 U/mL|
62336718|NCT05894473|ACTIVE_COMPARATOR|Motor-Motor Dual Task Physical Exercises|Motor-Motor Dual Task Physical Exercises will be given to the participants
62336719|NCT05894473|ACTIVE_COMPARATOR|Cognitive-Motor Dual Task Physical Exercises|Cognitive-Motor Dual Task Physical Exercises will be given to the participants
62336720|NCT05894473|ACTIVE_COMPARATOR|Physical exercise|Physical exercise will be given to the participants
62336721|NCT04157985|ACTIVE_COMPARATOR|Continue Treatment with PD-1/PD-L1 inhibitor|Continued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
62695502|NCT06571227||Anterior Cruciate Ligament Reconstruction Patients|Patients who will undergo anterior cruciate ligament reconstruction because of anterior cruciate ligament rupture
62695503|NCT04822883|EXPERIMENTAL|Dose-escalation - RL-007|Each cohort will include a single dose-strength. Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
62695504|NCT04822883|PLACEBO_COMPARATOR|Dose-escalation - matching Placebo|Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
62738468|NCT05487677|ACTIVE_COMPARATOR|Standard Repair with Sutures|During the shoulder replacement surgery (arthroplasty) in order to access the shoulder, the subscapularis is removed from its insertion in your upper arm bone. It is repaired in reverse total shoulder arthroplasty, but is sometimes not as robust as we would like based on tissue quality and other factors. A shoulder arthroplasty is when the ball and socket are replaced with prosthetic components. If randomized to standard repair, patient will receive the standard repair with sutures.
62137787|NCT04551651|ACTIVE_COMPARATOR|ApplTree reminder app intervention|A reminding app developed with features that, based on previous research, will increase use and ease of use for individuals with ABI when setting smartphone reminders.
62336722|NCT04157985|EXPERIMENTAL|Discontinue Treatment with PD-1/PD-L1-1 inhibitor|Discontinued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
62137788|NCT04551651|ACTIVE_COMPARATOR|Google Calendar reminder app intervention|A widely available calendar app that can be used to set reminders.
62336723|NCT01642524|EXPERIMENTAL|hypertonic saline mixed Dextran|hypertonic saline mixed Dextran
62336724|NCT01642524|PLACEBO_COMPARATOR|Placebo controlled|Saline solution
62336725|NCT01869062|OTHER|SonR CRT Optimization 'On'|CRT-D device with the SonR optimization algorithm programmed being 'on'.
62336726|NCT01869062|OTHER|SonR CRT Optimization 'Off'|CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
62336727|NCT06105424|EXPERIMENTAL|Smokers|Someone who exclusively smokes 10 - 20 combustible filtered cigarettes per day (CPD) 83 - 100 mm in length, non-menthol or menthol, for at least 3 years prior to Screening.
62336728|NCT06105424|EXPERIMENTAL|Moist Snuff Consumers|Someone who exclusively consumes ≥ 1 can of moist snuff per week for at least 6 months prior to Screening.
62336729|NCT06105424|EXPERIMENTAL|Vapers|"Someone who exclusively uses a nicotine-containing cig-a-like and/or tank system daily for at least 3 months prior to Screening."
62336730|NCT06105424|EXPERIMENTAL|Non-Tobacco Consumers|Someone who has used no tobacco or nicotine-containing products for at least the past 5 years prior to Screening and do not plan to use any tobacco or nicotine-containing products throughout the study.
62336731|NCT03247660|EXPERIMENTAL|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
62336732|NCT03247660|EXPERIMENTAL|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
62336733|NCT03247660|ACTIVE_COMPARATOR|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
62336734|NCT04671316|EXPERIMENTAL|T1T2R|"Period I: T1, DA-5209 60mg without water Period II: T2, DA-5209 60mg with 150mL water Period III: R, Lixiana 60mg with 150mL water"
62336735|NCT04671316|EXPERIMENTAL|T1RT2|"Period I: T1, DA-5209 60mg without water Period II: R, Lixiana 60mg with 150mL water Period III: T2, DA-5209 60mg with 150mL water"
62336736|NCT04671316|EXPERIMENTAL|RT1T2|"Period I: R, Lixiana 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: T2, DA-5209 60mg with 150mL water"
62336737|NCT04671316|EXPERIMENTAL|RT2T1|"Period I: R, Lixiana 60mg with 150mL water Period II: T2, DA-5209 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
62336738|NCT04671316|EXPERIMENTAL|T2RT1|"Period I: T2, DA-5209 60mg with 150mL water Period II: R, Lixiana 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
62336739|NCT04671316|EXPERIMENTAL|T2T1R|"Period I: T2, DA-5209 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: R, Lixiana 60mg with 150mL water"
62336740|NCT03009539|EXPERIMENTAL|eHealth Familias Unidas Primary Care|"eHealth Familias Unidas consists of 12 sessions: eight (12 - 15 minute) mock parent sessions in Spanish and four (30 - 45 minute) online family sessions delivered in either Spanish and/or English."
62336741|NCT03009539|NO_INTERVENTION|Treatment as Usual|Participants in this condition will not receive an intervention.
62336742|NCT01609803||Correlative studies|Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and protein overexpression by FISH and IHC.
62336743|NCT05394584|EXPERIMENTAL|CST group|A total of 64 people with mild-to-moderate cognitive impairment will receive group cognitive stimulation therapy (CST), which consists of 14 sessions of mentally stimulating activities delivered two times a week for 7 weeks by supportive staff and volunteers trained in CST, on top of their usual care in community centres or residential care homes.
62336744|NCT05394584|NO_INTERVENTION|Usual care group|A total of 64 people with mild-to-moderate cognitive impairment will receive the usual care in community centres or residential care homes.
62493717|NCT05624424|ACTIVE_COMPARATOR|Propofol|Induction of anesthesia Slowly inject Propofol 2\~2.5 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS\<60, if the degree of sedation is insufficient, additional Propofol (0.5 mg/kg each time) is allowed. After the LoC, sufentanil 0.3\~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
62137789|NCT04989842|ACTIVE_COMPARATOR|Intervention group 1|webbased aftercare
62137790|NCT04989842|NO_INTERVENTION|Control group|care as usual
62137791|NCT04989842|ACTIVE_COMPARATOR|Intervention group 2|webbased aftercare
62336745|NCT01591772||diagnosed with ovarian that recieved chemo|
62336746|NCT01591772||healthy controls|
62336747|NCT02002338||Pterygium|Patients who were operated of pterygium
62336748|NCT02811536||Diabetic retinopathy|Patients with various degrees of diabetic retinopathy
62137792|NCT04989842|ACTIVE_COMPARATOR|face-to-face aftercare|face-to-face aftercare
62695505|NCT05090865|OTHER|Liberalized dietary potassium and then restricted potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2-week run-in and liberalized potassium treatment period, then cross-over to the restricted potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional Coronavirus disease (COVID)-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet.
62695506|NCT05090865|OTHER|Restricted dietary potassium and then liberalized potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2 week run-in and then start receiving a restricted potassium treatment period, then cross-over to the liberalized potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional COVID-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet
62695507|NCT03984578|EXPERIMENTAL|Newly Diagnosed Colon cancers|Pre-operative CAPEOX 1 cycle Pre-operative Pembrolizumab 2 cycles with cycle 1 on Day 1 (concurrent with start of CAPEOX) and cycle 2 on Day 22.
62695508|NCT03984578|EXPERIMENTAL|Newly Diagnosed Rectal Cancers|Following completion of neo-adjuvant chemo-radiotherapy, 2 cycles of pre-operative Pembrolizumab administered 3 weeks apart.
62695509|NCT03984578|EXPERIMENTAL|Newly Diagnosed Colon and Rectal Cancers Referred for Pre-Operative Chemotherapy|Neoadjuvant pembrolizumab 3-weekly for a maximum of 6 doses to be administered along with XELOX chemotherapy, and additional 1 dose pembrolizumab.
62695510|NCT05309291|EXPERIMENTAL|Theranova 400 Dialyzer|1 week, 1 session in mid-week HD therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
62695511|NCT05309291|ACTIVE_COMPARATOR|FX 800 Dialyzer|1 week, 1 session in mid-week HDF therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
62695512|NCT06644677||Advanced-stage cervical cancer patients group (Stage IIIB and beyond)|
62695513|NCT06407232|EXPERIMENTAL|Letermovir for CMV in Transplant Patients|Enrolled participants will be converted from treatment with ganciclovir derivatives to letermovir
62695514|NCT06027905|EXPERIMENTAL|Remote Blood Pressure Monitoring and Social Intervention|Participants are enrolled in a remote blood pressure monitoring program and social intervention composed of remote outreach from a team of community health worker, pharmacist, nurse, and social worker for 12 weeks.
62695515|NCT05360303||Trial population|No Intervention but evaluation of the electroneuromyography at the M1 visit for patients with a clinical diagnostic of thoracic outlet syndrome.
62695516|NCT03921567|EXPERIMENTAL|Group I|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
62695517|NCT03921567|ACTIVE_COMPARATOR|Group II|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
61941345|NCT06676670|EXPERIMENTAL|real acupuncture group|"1. The patient immediately received acupuncture treatment and imaging scan on the scanning bed (acupuncture and imaging scan at the same time). Acupuncture left Hegu point to promote qi. Axial T2WI imaging for 48 seconds, fMR-BOLD imaging for 8 minutes and 11 seconds, and ASL imaging for 6 minutes and 03 seconds were simultaneously collected during acupuncture. The scanning time of each sequence was divided into 4 time periods, each time period was 1 time, each scanning sequence was 4 times, each time was 10 seconds, and the duration of acupuncture was 15 minutes and 02 seconds.~2. After acupuncture withdrawal, axial T2WI imaging was repeated for 48 seconds, fMRI-Bold imaging for 8 minutes and 11 seconds, and ASL imaging for 6 minutes and 03 seconds."
61941346|NCT06676670|SHAM_COMPARATOR|sham acupuncture group|"Control group (false acupuncture group)~1. Axial imaging of DWI was performed before the patient underwent pseudoacupuncture (12 minutes 08 seconds).~2. The patient immediately underwent a sham acupuncture and imaging scan on the scanning bed (the sham acupuncture and imaging scan were performed simultaneously). Pseudoacupuncture left Hegu point. DWI axial imaging (12 minutes 08 seconds) was collected synchronously during the fake acupuncture. The scanning time during the fake acupuncture was divided into 4 time periods, with 1 needle in each time period, 4 needles in each time period, each time for 10 seconds, and the duration of the fake acupuncture was 12 minutes 08 seconds.~3. Axial DWI imaging was repeated (12 minutes and 08 seconds) after acupuncture withdrawal."
61941347|NCT06676670|NO_INTERVENTION|healthy controls|
61941348|NCT03954132||Spiolto® Respimat®|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
61941349|NCT03954132||Triple-Therapy (LAMA/LABA/ICS)|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
62336749|NCT02811536||Retinal detachment|Patients with a history of retinal detachment
62336750|NCT02811536||Retinal vein occlusion|Patients with a history of retinal vein occlusion
62336751|NCT02811536||Arterial hypertension|Patients with a history of arterial hypertension
62336752|NCT02811536||Carotid artery occlusion|Patients with a history of carotid artery occlusion
62695518|NCT03921567|PLACEBO_COMPARATOR|The control group|will be given opioids during surgery, opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
61941350|NCT03763864|OTHER|Inherited disorders|
61941351|NCT06151431|ACTIVE_COMPARATOR|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
61941352|NCT06151431|EXPERIMENTAL|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
61941353|NCT02387710|ACTIVE_COMPARATOR|Tiagabine|Tiagabine PO 12 mg before sleep
61941354|NCT02387710|PLACEBO_COMPARATOR|Placebo|Placebo PO before sleep
61941355|NCT03200184|EXPERIMENTAL|Treatment|Subjects will receive sofosbuvir and daclatasvir
61941356|NCT01635868||umbilical hernia repair|patients having umbilical or epigastric hernia repair from 2008-2010 in Zealand
61941357|NCT02806531|EXPERIMENTAL|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in aged 6-35 months old, 28 days interval.
62137793|NCT03180541|EXPERIMENTAL|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
62336753|NCT02811536||Age related macular degeneration|Patients with a history of Age related macular degeneration
62336754|NCT02811536||Macroaneurysms|Patients with a history of retinal macroaneurysms
62336755|NCT02811536||Central serous chorioretinopathy|Patients with a history of central serous chorioretinopathy
62336756|NCT03892330|EXPERIMENTAL|liposomal doxorubicin|Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
62493718|NCT05624424|ACTIVE_COMPARATOR|Sevoflurane|Induction of anesthesia Slowly inject Etomidate 0.03 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS\<60, if the degree of sedation is insufficient, additional etomidate (0.03 mg/kg each time) is allowed. After the LoC, sufentanil 0.3\~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
62493719|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
61941358|NCT00887406|EXPERIMENTAL|Cohort 1, Period 2|GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
61941359|NCT00887406|EXPERIMENTAL|Cohort 1, period 1|Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
61941360|NCT00887406|EXPERIMENTAL|Cohort 1, period 3|GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
61941361|NCT00887406|EXPERIMENTAL|Cohort 1, period 4|GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
61941362|NCT00887406|EXPERIMENTAL|Cohort 2, period 1|Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
61941363|NCT00887406|EXPERIMENTAL|Cohort 2, period 2|GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
61941364|NCT00887406|EXPERIMENTAL|Cohort 2, period 3|GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
61941365|NCT00887406|EXPERIMENTAL|Cohort 2, period 4|GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
61941366|NCT00887406|EXPERIMENTAL|Cohort 3|GSK961081 100mcg or Placebo
61941367|NCT00887406|EXPERIMENTAL|Cohort 4|GSK961081 300mcg or Placebo
61941368|NCT05769998|EXPERIMENTAL|Acceptance and Commitment-based treatment|Acceptance and Commitment-based (ACT) treatment including a face-to-face component administered during the patient stay in the rehabilitation unit and an online component including 4 ACT modules with an estimated duration of one month. The treatment is added to the Treatment as Usual provided in the rehabilitation unit.
61941369|NCT05769998|OTHER|Treatment as usual|Usual care including pharmacological therapy and exercise therapy, administered in the rehabilitation unit independently from the project.
61941370|NCT01922557||NICOM|
61941371|NCT04354961|EXPERIMENTAL|Almonertinib 110mg PO once daily|
61941372|NCT01613365|EXPERIMENTAL|chlorhexidine gluconate|
61941373|NCT01613365|EXPERIMENTAL|placebo|
61941374|NCT06407271|EXPERIMENTAL|CAD/CAM custom ZrO2 healing abutment|Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.
61941375|NCT06407271|ACTIVE_COMPARATOR|Cylindrical ZrO2 healing abutment|Application of cylindrical, zirconium-dioxide healing abutment following immediate implantation.
61941376|NCT04666675|EXPERIMENTAL|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A once daily (QD).
61941377|NCT04666675|EXPERIMENTAL|Upadacitinib Dose B|Participants will receive Upadacitinib Dose B QD.
61941378|NCT04666675|EXPERIMENTAL|Placebo for Upadacitinib Followed by Upadacitinib Dose A|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose A QD.
61941379|NCT04666675|EXPERIMENTAL|Placebo for Upadacitinib Followed by Upadacitinib Dose B|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose B QD.
61941380|NCT01761864|EXPERIMENTAL|intervention group|academic detailing receiver
61941381|NCT01761864|NO_INTERVENTION|control group|not receiving an academic detailing intervention
61941382|NCT03144531|EXPERIMENTAL|SKIP Intervention|
61941383|NCT01924988|EXPERIMENTAL|Prostatic Embolization|Therapeutic occlusion of the prostate arteries
62137794|NCT03180541|NO_INTERVENTION|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:~* live in areas where no DBT intervention is currently available OR~* were offered a place on the DBT programme but decided not to partake at that time"
62137795|NCT06678269|EXPERIMENTAL|Participants with HR+, HER2- metastatic breast cancer|Participants will have a diagnosis of HR+, HER2- metastatic breast cancer
62336757|NCT03892330|ACTIVE_COMPARATOR|doxorubicin|Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
62336758|NCT03892330|ACTIVE_COMPARATOR|pharmorubicin|Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
62336759|NCT03892330|ACTIVE_COMPARATOR|pirarubicin|Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
62336760|NCT04774042|PLACEBO_COMPARATOR|Placebo|Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
62336761|NCT04774042|EXPERIMENTAL|HAC|Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
62695519|NCT06099002||Individuals with COPD over the age of 65 with a history of falls|Individuals with COPD who were over the age of 65 and had a history of falling were included in this group.
62695520|NCT06099002||Individuals with COPD who are over the age of 65 and have no history of falling|Individuals with COPD who were over the age of 65 and did not have a history of falling were included in this group.
62695521|NCT00780598|EXPERIMENTAL|Tosedostat|oral, once daily administration of tosedostat to evaluate its efficacy, safety and tolerability
62695522|NCT04799535||Observational (ultrasound)|"AIM 1: Participants undergo a breast ultrasound over 15 minutes.~AIM 2: Participants undergo breast ultrasounds over 15 minutes before starting the chemotherapy and/or endocrine therapy, 2 months after start of chemotherapy and/or endocrine therapy, and after the completion of chemotherapy and/or endocrine therapy before surgery. Participants may also undergo breast ultrasounds at 2 weeks after start of chemotherapy and/or endocrine therapy and 1 month after start of chemotherapy and/or endocrine therapy.~AIM 3: Patients with suspicious breast masses or known breast cancer who are scheduled for axillary lymph node biopsy undergo ultrasound over 15 minutes at the same visit of the breast mass study."
62695523|NCT06280989|EXPERIMENTAL|kinesio taping|Each female will be treated by Kinesio tape which will be applied for three days (from the first day to the end of the third day of menstrual cycle) throughout 3 consecutive cycles.
61941384|NCT04472533||CTEPH|Patients diagnosed with chronic thromboembolic pulmonary hypertension
62695524|NCT06280989|EXPERIMENTAL|myofascial release technique|Each female will be treated by myofascial relaxation technique which will be started at the third or fourth day of menstruation and continued till the onset of the next menstruation, 40 minutes, 3 times / week for 12 sessions through 3 consecutive menstrual cycle
62695525|NCT06116123|EXPERIMENTAL|Group I (Massage mattress with cube/block system)|
62695526|NCT06116123|NO_INTERVENTION|Group II (Standard of care)|
62695527|NCT06309628||Lung Transplant patients at risk for rejection|Patients who have had a lung transplant and are getting a bronchoscopy to test for rejection will provide a breathe sample. Once their rejection results come back after their sample has been collected their breathe samples will be sorted into rejection and non-rejection groups for analysis. All patients will have the same experiences in the study.
62137796|NCT04926519||Aggressive periodontitis|Patients that got the diagnosis aggressive periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
62137797|NCT04926519||Chronic periodontitis|Patients that got the diagnosis chronic periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
62137798|NCT01672333|EXPERIMENTAL|Pathological Response|
62137799|NCT00143130|EXPERIMENTAL|Single Arm|
62137800|NCT02616276|ACTIVE_COMPARATOR|Control|Control breakfast
62137801|NCT02616276|EXPERIMENTAL|Intervention 1|High glycemic index breakfast
62695528|NCT06644326|ACTIVE_COMPARATOR|Part A IkT-148009 Dry/Wet|100mg IkT-148009 Wet \& 100mg IkT-148009 Dry
62695529|NCT06644326|ACTIVE_COMPARATOR|Part B - Ikt-148009 wet/ Itraconazole|200 mg Itraconazole \& 50mg IkT-148009 Wet
62695530|NCT06640829||ADORE GAINS Participants|Children's who participated in the ADORE GAINS study were invited to participate as their body composition and dietary intake was collected during their infancy and toddlerhood.
62695531|NCT05964699|EXPERIMENTAL|Periodontal regeneration|Regeneration will be attempted during root scaling and planing with the application of Emdogain and the use of a Videoscope.
62695532|NCT05964699|PLACEBO_COMPARATOR|Control|The control group will receive standard-of-care root scaling and planing without the application of Emdogain and the use of a Videoscope.
62695533|NCT00200746|EXPERIMENTAL|2|Moderate Arginine
62695534|NCT00200746|SHAM_COMPARATOR|3|Polycose control arm
62695535|NCT00200746|EXPERIMENTAL|1|High Arginine
61941385|NCT04472533||CTED|Patients diagnosed with chronic thromboembolic disease but no evidence of pulmonary hypertension
61941386|NCT04472533||Control|Healthy control subjects
61941387|NCT05923528|EXPERIMENTAL|Group A: IPL group|participants will receive IPL treatment with 12 homogeneously spaced pulses of light to both eyes at day 0, day 14, and day 28
62137802|NCT02616276|EXPERIMENTAL|Intervention 2|Low glycemic index breakfast
62137803|NCT05460741|EXPERIMENTAL|integrated exercise approach|an integrated exercise will be used which is the exercise plan that will be formulated using strengthening and endurance exercises.
62137804|NCT05460741|EXPERIMENTAL|eumenhorreic females|strength, postural stability and biomarkers of menstrual cycle in eumenhorreic females.
62137805|NCT01741363|EXPERIMENTAL|one-day sampling with one-year interval|FIT one-day sampling with one-year interval
62695536|NCT04130347||Pancreatic resection|
62695537|NCT04130347||Liver resection|
62695538|NCT04130347||HIPEC surgery|
62695539|NCT04130347||Gynecological debulking surgery|
62695540|NCT06498479|EXPERIMENTAL|HS-20093|Participants will receive HS-20093 as an intravenous (IV) infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle until a treatment discontinuation criterion is met as specified in the protocol.
62695541|NCT06498479|ACTIVE_COMPARATOR|Topotecan|Participants will receive topotecan until a treatment discontinuation criterion is met as specified in the protocol.
62137806|NCT01741363|ACTIVE_COMPARATOR|one-day sampling with two-year interval|FIT one-day sampling with two-year interval
62137807|NCT01741363|EXPERIMENTAL|two-day sampling with one-year interval|FIT two-day sampling with one-year interval
62137808|NCT01741363|EXPERIMENTAL|two-day sampling with two-year interval|FIT two-day sampling with two-year interval
62137809|NCT01741363|EXPERIMENTAL|Hp stool antigen (HpSA)+FIT|HpSA for detection of upper gastrointestinal tract diseases and upper endoscopy for H. pylori carriers; HPSA combined with FIT
62137810|NCT01741363|ACTIVE_COMPARATOR|FIT only|HpSA + FIT compared with FIT alone
62137811|NCT06088758|EXPERIMENTAL|Liver Transplantation with Steatotic Liver|Graft will be selected if 30-60% macrosteatosis and transplanted into liver transplant recipient with MELD of 15-25.
62336762|NCT04774042|EXPERIMENTAL|Infloran|Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
62336763|NCT03533140|ACTIVE_COMPARATOR|DUCEST Neurostimulator V Group A|
62336764|NCT03533140|SHAM_COMPARATOR|DUCEST Neurostimulator V Group B|
62336765|NCT06261099|NO_INTERVENTION|Control Group|Exercises including upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group, 5 sessions per week for 6 weeks. Since the functional recovery of the upper extremity after stroke will be slow, the exercise program is planned to be 5 days a week due to the necessity of applying an intense exercise program in the early period. All patients will be asked to perform exercises under the supervision of a physiotherapist as a home program on other days of the week.
62137812|NCT06121492|EXPERIMENTAL|Branched-chain amino acid|In the branched-chain amino acid (BCAA group), participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
62137813|NCT06121492|PLACEBO_COMPARATOR|Placebo|In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
62336766|NCT06261099|EXPERIMENTAL|kontrol+ working group|Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to the control group in 5 sessions per week for 6 weeks. The telerehabilitation program will be carried out using an application that provides remote video access called Zoom. Since the functional recovery of the upper extremity after stroke will be slow, the exercise program is planned to be 5 days a week due to the necessity of applying an intense exercise program in the early period. All patients will be asked to perform exercises under the supervision of a physiotherapist as a home program on other days of the week.
62336767|NCT03878017|EXPERIMENTAL|skin marking of clipped axillary LN|all eligible patients underwent skin marking of their clipped axillary LN post neoadjuvant chemotherapy to determine the retrieval rate of the clipped nodes
62336768|NCT04586868|EXPERIMENTAL|A psychotic disorder|Patients, age 13-18 years old, diagnosed with a psychotic disorder (WHO ICD-10 )
62137814|NCT01240707|OTHER|LF tests, Fiberoptic bronchoscopy|Spirometry, Peak Expiratory Flow (PEF). Bronchoscopic assessment of soot in central airways.
62336769|NCT05252676||Patients|Patients with ground glass opacity featured lung adenocarcinoma who are candidates for surgery.
62695542|NCT00835354|EXPERIMENTAL|1|
62336770|NCT02125331||PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
62336771|NCT02125331||PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
61941388|NCT05923528|EXPERIMENTAL|Group B: HEM group|participants were applied an air-activated disposable eye mask on both closed eyes (Ocuface Medical Co., Ltd., Guangzhou, China) simultaneously for 15 minutes according to the manufacturer's instructions every day for 42 days
61941389|NCT05923528|EXPERIMENTAL|Group C: VTPS group|VTPS group, Patients will receive a single 12-minute treatment using the LipiFlow® (TearScience Inc., Morrisville, NC) on both eyes at day 0
61941390|NCT05923528|EXPERIMENTAL|Group D: EyePeace® group|Participants were followed immediately by 10 gentle squeezes of the eyelid massage device (EMD) on both eyes, and 10 gentle eyelid massaging movements using the index and middle fingers every day for 42 days.
62137815|NCT02029092||Orsiro|
62336772|NCT02594397|EXPERIMENTAL|acupoints combination 1|acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
62336773|NCT02594397|ACTIVE_COMPARATOR|acupoints combination 2|acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
62336774|NCT02594397|SHAM_COMPARATOR|sham acupoints combination|sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
62695543|NCT00835354|ACTIVE_COMPARATOR|2|
62695544|NCT04331522||Antibiotics|Children aged 0-18 years investigated for allergy to antibiotics
62695545|NCT04331522||Milk|Children aged 0-18 years investigated for allergy to milk
62695546|NCT04331522||Egg|Children aged 0-18 years investigated for allergy to egg
61941391|NCT06005597|EXPERIMENTAL|Combination Therapy|once-daily obicetrapib 10 mg and ezetimibe 10 mg fixed dose combination tablet, placebo tablet, placebo capsule
61941392|NCT06005597|EXPERIMENTAL|Monotherapy obicetrapib|once-daily obicetrapib 10 mg, placebo tablet, placebo capsule
61941393|NCT06005597|ACTIVE_COMPARATOR|Monotherapy ezetimibe|once-daily ezetimibe 10 mg capsule, 2 placebo tablets
61941394|NCT06005597|PLACEBO_COMPARATOR|Placebo|once-daily placebo tablets (2), placebo capsule
61941395|NCT00447005|EXPERIMENTAL|Open|
61941396|NCT06270329|EXPERIMENTAL|neuromuscular training program|Participants were administered the neuromuscular training program 60 min a day, 2 days a week for 8 weeks.
61941397|NCT06270329|ACTIVE_COMPARATOR|conventional physical therapy program|Participants were administered the conventional physiotherapy program 60 min a day, 2 days a week for 8 weeks.
62336775|NCT02953782|EXPERIMENTAL|Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by intravenous (IV) infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented progressive disease (PD).
62695547|NCT04331522||Peanut|Children aged 0-18 years investigated for allergy to peanut
62695548|NCT04331522||Hazelnut|Children aged 0-18 years investigated for allergy to hazelnut
62336776|NCT02953782|EXPERIMENTAL|Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
62336777|NCT02953782|EXPERIMENTAL|Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
62336778|NCT02953782|EXPERIMENTAL|Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both were given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
61941398|NCT00734123|EXPERIMENTAL|1|Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.
62336779|NCT02953782|EXPERIMENTAL|Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
62339962|NCT01021852|EXPERIMENTAL|MK-6096 2.5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for overnight polysomnography (PSG) recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive dose-matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
62493720|NCT05734716|EXPERIMENTAL|EPO Arm|participants administered subcutaneous erythropoietin injection (50 IU/kg 3x/week for 3 weeks) prior to ascent to altitutude. participants additionally administered sham intravenous treatment twice, with dosages occurring three weeks apart and final shame dose occurring 48 hours prior to ascent to altitude.
62695549|NCT04331522||Sesame|Children aged 0-18 years investigated for allergy to sesame
62695550|NCT04331522||Wheat|Children aged 0-18 years investigated for allergy to wheat
62695551|NCT04331522||walnut|Children aged 0-18 years investigated for allergy to walnut
62695552|NCT04331522||cashew|Children aged 0-18 years investigated for allergy to cashew
62695553|NCT04331522||Pistachio|Children aged 0-18 years investigated for allergy to pistachio
62137816|NCT04687033|EXPERIMENTAL|Dual-tDCS & PT|"Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about~1 hour). The current intensity is fixed at 2 mA and the current will flow continuously. Physical therapist will give an intervention program for lower limb performance."
62137817|NCT04687033|ACTIVE_COMPARATOR|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, the current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performance.
62137818|NCT03707899|EXPERIMENTAL|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
62137819|NCT03707899|ACTIVE_COMPARATOR|Group II (Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
61941399|NCT00734123|ACTIVE_COMPARATOR|2|Participants assigned to control group (2) will be followed according to the clinical standard of care.
61941400|NCT05007210|EXPERIMENTAL|Prenatal massage therapy group|Prenatal massage therapy for prenatal attachment, physiological and psychological distress, maternal and fetal well-being.
62137820|NCT05408091|EXPERIMENTAL|Dose Level 1 - 1 mg/kg|Randomized 6:2 (TRL345:placebo) via IV infusion
62695554|NCT04331522||Almond|Children aged 0-18 years investigated for allergy to almond
62137821|NCT05408091|EXPERIMENTAL|Dose Level 2 - 10 mg/kg|Randomized 6:2 (TRL345:placebo) via IV infusion
61941401|NCT05007210|NO_INTERVENTION|Control group|Pregnant women in the control group were interviewed twice (once a week for 30th and 34th week) by the same massaging midwife. No additional attempt was made except for filling out the forms and evaluating the biophysical profile by the obstetrician in these interviews. The massaging midwife's phone number was given to the pregnant women in both groups if they want to reach anytime. A phone number was set for the study, and this phone number was used by the massaging midwife. This service has been provided for pregnant women to reach her whenever they want.
62137822|NCT06244875||Patients followed in the memory clinic|
62137823|NCT05413889|EXPERIMENTAL|intervention group (IG)|The IG will consist of placing the Epic 30-day unplanned readmission risk score in the story board of providers - If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board
62336780|NCT02953782|EXPERIMENTAL|Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced colorectal cancer (CRC) who are KRAS wild type (KRASwt) and are refractory to anti-EGFRmAb therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
62493721|NCT05734716|EXPERIMENTAL|Iron Arm|participants administered intravenous iron sucrose (200mg) twice, dosages occurring three weeks apart with final dosing occurring 48 hours prior to ascent to altitude. Participants additionally administered sham subcutaneous injection (sterile saline) 3x/week for 3 weeks.
62493722|NCT05734716|PLACEBO_COMPARATOR|Placebo|participants administered sham injections (sterile saline) 3x/week for 3 weeks as well as sham intravenous infusion (sterile saline) twice with dosages occurring three weeks apart and final dosing occurring 48 hours prior to ascent to altitude.
62493723|NCT02119936|EXPERIMENTAL|Heart Rate Variability Biofeedback Tool|Intervention: Participants will be taught how to use the Heart Rate Variability Biofeedback tool (emWave 2) as a mechanism to reduce stress and anxiety, then use the tool, coupled with deep breathing exercises, to visualize their stress reduction.
62493724|NCT03748251|EXPERIMENTAL|Short fermented pizza|the patients ate a pizza that fermented for 8 hours
62493725|NCT03748251|EXPERIMENTAL|Long fermented pizza|the patients ate a pizza that fermented for 24 hours
62493726|NCT03300687|ACTIVE_COMPARATOR|Active|Subjects will receive FX-322 as an intratympanic injection
62493727|NCT03300687|PLACEBO_COMPARATOR|Placebo|Subjects will receive Placebo as an intratympanic injection
62695555|NCT04331522||Soy|Children aged 0-18 years investigated for allergy to soy
62695556|NCT04331522||Fish|Children aged 0-18 years investigated for allergy to fish
62695557|NCT04331522||Shellfish|Children aged 0-18 years investigated for allergy to shellfish
62695558|NCT04331522||Poppy seed|Children aged 0-18 years investigated for allergy to poppy seed
62695559|NCT06051357|EXPERIMENTAL|Treatment group A|
62695560|NCT06051357|EXPERIMENTAL|Treatment group B|
61941402|NCT00258284|EXPERIMENTAL|Docetaxel & Capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
61941403|NCT05496998|EXPERIMENTAL|Medtronic Intrepid™ TMVR TF System|Medtronic Intrepid™ TMVR TF System
62137824|NCT05413889|NO_INTERVENTION|control group (CG)|The CG will have the same transitional and supportive care services (TSC) orders available to them; however, they will not have the risk of readmission score present in their workflow
62137825|NCT06598423|EXPERIMENTAL|Group A|Children who are randomized to this group will wear one type of daily use, daily disposable, single-vision soft contact lens for at least four hours starting in the afternoon (after school) and another type of daily use, daily disposable, single-vision soft contact lens for the remainder of the time daily for one year.
62137826|NCT06598423|SHAM_COMPARATOR|Control group|Children who are randomized to this group will wear daily use, daily disposable, single-vision soft contact lenses full time for one year. Contact lenses will be worn for a minimum of 10 hours per day.
62137827|NCT00461019|EXPERIMENTAL|Implantation of the CardioFit system|
62695561|NCT06343974||Type 1 diabetes|Pregnant woman with type 1 diabetes.
62137828|NCT03919110||Genetically Undiagnosed SAID Patients (guSAID)|"adults and children, with different SAID of unknown pathogenesis, for which no specific mutations is identified and whose pathogenic mechanism remains unknown:~* Still Disease,~* Recurrent pericarditis,~* Neutrophilic dermatosis,~* Schnitzler,~* Vasculitis (Kawasaki disease, Behçet disease, Takayasu arteritis),~* Inflammation of unknown origin,~* Chronic/recurrent osteitis."
62137829|NCT03919110||Parents of guSAID patients|Enrollment of parents of guSAID patients is justified by the TRIO genomic analysis (patient plus two parents) of the guSAID patients without known mutations. Indeed, the TRIO based whole-exome sequencing helps to facilitate the interpretation of genotypes and improve genetic explorations
62137830|NCT03919110||Monogenic SAID patients (mSAID)|This group of patients will serve as positive control to classify other diseases and encompass the following diseases: FMF, TRAPS, HIDS, and CAPS. Investigators aim at recruiting 50 patients per disease entity.
62695562|NCT06343974||Healthy controls|Pregnant women with uncomplicated pregnancy and normal oral glucose tolerance test (OGTT).
62695563|NCT05919563||Subjects treated with GRNOPC1 in the initial dosing study CP35A007|Subjects treated with GRNOPC1 in the initial dosing study CP35A007 will be followed for 15-year long-term safety monitoring
62695564|NCT06641830||pediatric patients with cardiomyopathy|
62493728|NCT01968031|EXPERIMENTAL|Istradefylline 20 mg/day|"Istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
62493729|NCT01968031|EXPERIMENTAL|Istradefylline 40 mg/day|"Istradefylline 40 mg and placebo to match istradefylline 20 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
62493730|NCT01968031|PLACEBO_COMPARATOR|Placebo|"Placebo to match istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
62493731|NCT02931630|EXPERIMENTAL|HP/HF|Whey protein powder / High fiber bread
62493732|NCT02931630|EXPERIMENTAL|HP/LF|Whey protein powder / Low fiber bread
62493733|NCT02931630|EXPERIMENTAL|LP/HF|Maltodextrin powder / High fiber bread
62493734|NCT02931630|EXPERIMENTAL|LP/LF|Maltodextrin powder / Low fiber bread
62493735|NCT05771051||Concussed|Diagnosis of concussion
62493736|NCT05771051||Controls|Athletes with no concussion with the preceding year
62493737|NCT02046122|EXPERIMENTAL|Idarubicin + Cytarabine + DLI|Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)
62493738|NCT00526136|PLACEBO_COMPARATOR|1|Placebo (b.i.d.)
62493739|NCT00526136|EXPERIMENTAL|2|Vernakalant (oral), 150 mg (b.i.d.)
62493740|NCT00526136|EXPERIMENTAL|3|Vernakalant (oral), 300 mg (b.i.d.)
62493741|NCT00526136|EXPERIMENTAL|4|Vernakalant (oral), 500 mg (b.i.d.)
62493742|NCT01742208|EXPERIMENTAL|Sotagliflozin 400 mg - Pioneer Group|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before breakfast for 29 days; open label administration.
62493743|NCT01742208|PLACEBO_COMPARATOR|Placebo - Expansion Group|Two placebo-matching sotagliflozin tablets, once daily, orally, before breakfast for 29 days; double-blind administration.
62493744|NCT01742208|EXPERIMENTAL|Sotagliflozin 400 mg - Expansion Group|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before breakfast for 29 days; double-blind administration.
62493745|NCT03371524||Native valves_30 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop during routine cardiac echography.
62695565|NCT05195840|EXPERIMENTAL|Personalized Treatment for Eating Disorders|Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of personalized treatment for eating disorders.
62695566|NCT05195840|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Eating Disorders|Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of Cognitive Behavioral Therapy for Eating Disorders.
62695567|NCT00748605|PLACEBO_COMPARATOR|Placebo|S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
62695568|NCT00748605|EXPERIMENTAL|S-2367 1600 mg q.d. 54 weeks|S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
62695569|NCT00748605|EXPERIMENTAL|S-2367 1600 mg q.d. 60 weeks|S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
62695570|NCT06320782|EXPERIMENTAL|Dietary intervention 1|Calorie restriction and balanced distribution of macronutrients
62695571|NCT06320782|EXPERIMENTAL|Dietary intervention 2|Calorie restriction and low-carbohydrate diet
62695572|NCT06320782|EXPERIMENTAL|Dietary intervention 3|Calorie restriction and low-fat diet
62493746|NCT03371524||Native valves_30 and 60 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop and a 60 second loop during routine cardiac echography.
62493747|NCT03371524||Bioprosthesis_30 seconds loops|Patient with calcified aortic stenosis on bioprosthesis: record of a 30 second loop during routine cardiac echography.
62493748|NCT00901524|NO_INTERVENTION|PegIFN- alpha 2a + RBV|
62493749|NCT02786160|ACTIVE_COMPARATOR|HMO1|Daily bolus of HMO1
62493750|NCT02786160|ACTIVE_COMPARATOR|HMO2|Daily bolus of HMO2
62493751|NCT02786160|PLACEBO_COMPARATOR|Dextropur|Daily bolus of Dextropur
62493752|NCT02783287|EXPERIMENTAL|Medication text message|Once daily text message reminder.
62493753|NCT02783287|EXPERIMENTAL|Exercise text message|4x daily text message reminder.
62493754|NCT02783287|NO_INTERVENTION|Usual care, medication adherence|Usual care for medication adherence.
62493755|NCT02783287|NO_INTERVENTION|Usual care, exercise regimen|Usual care for exercise regimen.
62695573|NCT06320782|EXPERIMENTAL|Dietary intervention 4|Collective nutritional guidance
62695574|NCT03374956|EXPERIMENTAL|Intervention group|Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
62695575|NCT03374956|ACTIVE_COMPARATOR|Control Group|Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
62695576|NCT03329131|EXPERIMENTAL|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
62695577|NCT06641414|EXPERIMENTAL|Lisaftoclax (APG-2575) combined with Azacitidine|
62493756|NCT03019016||Robotic RC (IA)|Benign or malignant disease under going a right colectomy.
62493757|NCT03019016||Robotic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
62493758|NCT03019016||Laparoscopic RC (IA)|Patients with benign or malignant disease under going a right colectomy.
62493759|NCT03019016||Laparoscopic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
62493760|NCT04046094|EXPERIMENTAL|IV Ascorbic Acid|IV Ascorbic Acid 25 grams (g) infused 2 times a week for 4 weeks
62493761|NCT01256996|EXPERIMENTAL|Low-abrasive powder|
62493762|NCT01021657||Glaucoma|
62493763|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
62493764|NCT06462976||supine|Which group the patients will be included in will be determined by the surgical team based on the location and number of stones. The patient's values will be recorded in that position.
62493765|NCT06462976||prone|Which group the patients will be included in will be determined by the surgical team based on the location and number of stones. The patient's values will be recorded in that position.
62493766|NCT06677697|NO_INTERVENTION|Group A 30 participant received 0.5% Bupivacaine|Group A 30 participant received 0.5% Bupivacaine
62493767|NCT06677697|EXPERIMENTAL|Group B 30 participant received 0.5% rupivacaine|Group B 30 participant received 0.5% rupivacaine
62493768|NCT02017873|ACTIVE_COMPARATOR|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
62493769|NCT02017873|EXPERIMENTAL|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
61941404|NCT04619927|EXPERIMENTAL|Intervention group|The intervention includes testing of patients for carriage of the CYP2C19\*2 and \*3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
61941405|NCT04619927|ACTIVE_COMPARATOR|Comparison group|The comparison group will not be prescribed clopidogrel 75mg without preceding testing for carriage of the CYP2C19\*2 and \*3 loss-of-function alleles. CYP2C19 genotyping will be performed at the end of the study.
62493770|NCT04097444|EXPERIMENTAL|Step 1 (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~\[Induction treatment: CAPOXIRI+BEV\] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1.~\[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
62493771|NCT04097444|EXPERIMENTAL|Step 2 Arm A (FOLFOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~\[Induction treatment: FOLFOXIRI+BEV\] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~\[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks."
62493772|NCT04097444|EXPERIMENTAL|Step 2 Arm B (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~\[Induction treatment: CAPOXIRI+BEV\] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1.~\[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV\] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
62493773|NCT03005834||Atherosclerotic CVD|Atherosclerotic cardiovascular diseases (CVD) included coronary artery diseases, aortic diseases and peripheral artery diseases.
62493774|NCT03005834||Non-atherosclerotic CVD|Non-atherosclerotic cardiovascular diseases (CVD) were any CVD except atherosclerotic CVD and congenital CVD.
62493775|NCT01074827|EXPERIMENTAL|Treadmill group|Specific gait training on treadmill
62493776|NCT01074827|EXPERIMENTAL|Strength training group|Eight weeks of intensive strength training
62695578|NCT06641414|ACTIVE_COMPARATOR|Placebo combined with Azacitidine|
62336781|NCT02953782|EXPERIMENTAL|Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRAS mutation (KRASm) who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
62137831|NCT03919110||Patient Free of inflammatory disorders control subjects|In order to set a reference / baseline for the identification of biomarkers the study will need non-inflammatory samples.
62137832|NCT06290791|EXPERIMENTAL|group A (with one drain)|
62137833|NCT06290791|ACTIVE_COMPARATOR|the group B (with two drains)|
62695579|NCT04709523|EXPERIMENTAL|i-PRF enriched bovine-derived xenograft|Patients treated with i-PRF-enriched bovine-derived xenograft + resorbable membrane
62695580|NCT04709523|EXPERIMENTAL|bovine-derived xenograft|Patients treated with bovine-derived xenograft + resorbable membrane
62695581|NCT03196778|EXPERIMENTAL|Low Dose Radiation|Subjects will receive low dose body radiation for 5 weeks.
62137834|NCT05597943|EXPERIMENTAL|Malama Arm|Participants enrolled in this arm will agree to using the Malama app to track glycemic management.
61941406|NCT01558193|PLACEBO_COMPARATOR|Placebo|Two placebos consumed
62137835|NCT05597943|NO_INTERVENTION|Control|Participants enrolled in this arm agree to standard management (FS log on phone, notebook, etc)
62137836|NCT05985200|EXPERIMENTAL|BI 3032950: Dose group 1|
62137837|NCT05985200|EXPERIMENTAL|BI 3032950: Dose group 2|
62137838|NCT05985200|EXPERIMENTAL|BI 3032950: Dose group 3|
62336782|NCT02953782|EXPERIMENTAL|Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRASm who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approx. 3 hours) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approx. 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m\^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m\^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
62137839|NCT05985200|EXPERIMENTAL|BI 3032950: Dose group 4|
62137840|NCT05985200|PLACEBO_COMPARATOR|Placebo|
62137841|NCT02645942|EXPERIMENTAL|Intervention group|L-carnitine 1400 mg daily for 8 weeks
62137842|NCT02645942|PLACEBO_COMPARATOR|Placebo group|Placebo
62137843|NCT03853538|EXPERIMENTAL|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
62137844|NCT03853538|ACTIVE_COMPARATOR|Women_Hemiface Vaseline|Adult women receive the test product randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
62137845|NCT06361524||Heart failure|Adults with heart failure with reduced ejection fraction; no intervention
62336783|NCT02410850||University of Montreal|Patients from University of Montreal in Canada
62336784|NCT02410850||University of Antwerp|Patients from University of Antwerp in Belgium.
62336785|NCT02410850||University of Sydney|Patients from University of Sydney in Australia.
62695582|NCT01275378|ACTIVE_COMPARATOR|Collaborative Care Plus|Collaborative care model with specific theory-based elements to address common reasons for ADHD treatment failure
62695583|NCT01275378|ACTIVE_COMPARATOR|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
62695584|NCT05818254|EXPERIMENTAL|Routine Care Providers|Care Providers in this arm will continue seeing patients as normal in clinic.
62137846|NCT05746741|EXPERIMENTAL|Telehealth solution|Telehealth solution offered
62336786|NCT02410850||Angers University Hospital|Patients from Angers University Hospital in France.
62336787|NCT02410850||University of Gronigen|Patients from University of Gronigen in Netherlands.
62336788|NCT02410850||Kaiser Permanente|Patients from Kaiser Permanente from USA.
62336789|NCT02410850||Stanford University|Patients from Stanford University from USA.
62336790|NCT02410850||Laval University|Patients from Laval University in Canada.
62695585|NCT05818254|EXPERIMENTAL|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Providers|HOP-STEP providers will inquire and document their patients about contraceptive usage and pregnancy interest, then provide personalized guidance on family planning.
62695586|NCT05263167|EXPERIMENTAL|sodium aescinate group|Trial treatment is administered as sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
62695587|NCT05263167|PLACEBO_COMPARATOR|placebo group|Trial treatment is administered as 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
62695588|NCT05311423||Non-TB Group|QuantiFERON-TB test (QFT) negative, continue assisted reproductive treatment
62336791|NCT02410850||Cambridge University|Patients from Cambridge University in UK.
62336792|NCT02410850||Kyushu University|Patients from Kyushu University in Japan
62336793|NCT02410850||Japan Somnology Center|Patients from Japan Somnology Center in Japan.
62137847|NCT05746741|NO_INTERVENTION|Control|Usual care
62137848|NCT04046159|ACTIVE_COMPARATOR|Radiotherapy arm|Radiotherapy for ipsilateral whole breast with 50 Gy/25 fractions or 40.05 Gy/15 fractions
62137849|NCT04046159|EXPERIMENTAL|Tamoxifen arm|Tamoxifen 5 mg QD for 10 years
62137850|NCT05267769|EXPERIMENTAL|Verum|AP707 single dose oromucosal application
62137851|NCT06442748|OTHER|STANDARD|In the standard arm, patients will continue on the same dose and schedule of levetiracetam (prescribed in the range of 1000-3000 mg/ day in 2-3 divided doses) for a duration of 2 years.
62137852|NCT06442748|EXPERIMENTAL|EXPERIMENTAL|In the experimental arm, levetiracetam will be tapered by 250- 500 mg every week and then stopped.
62137853|NCT02008669||Multiple Sclerosis cases|"All patients will undergo the following interventions~* Gustatory sensitivity test using Taste strips~* Blood sampling~* Questionnaires"
62137854|NCT04207736|ACTIVE_COMPARATOR|Reproxalap Ophthalmic Solution (0.25%)|
62137855|NCT04207736|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62137856|NCT06252402|EXPERIMENTAL|Dose Level -1|EGFR+ T Cell Dose (Day 0) 5 x 10\^6 cells
62137857|NCT06252402|EXPERIMENTAL|Dose Level +1|EGFR+ T Cell Dose (Day 0) 25 x 10\^6 cells
62137858|NCT06252402|EXPERIMENTAL|Dose Level +2|EGFR+ T Cell Dose (Day 0) 50 x 10\^6 cells
62137859|NCT02848105|EXPERIMENTAL|VPA+Methyl|VPA added to standard methylpredisonlone treatment for aGVHD
62137860|NCT04865172||Patient-caregiver dyads, patients with behavioural variant frontotemporal dementia|20 patient-caregiver dyads, patients with behavioural variant frontotemporal dementia
62137861|NCT04865172||Patient-caregiver dyads, patients with Alzheimer disease|20 patient-caregiver dyads, patients with Alzheimer disease
62137862|NCT04865172||Healthy control dyads|20 healthy control dyads
62137863|NCT00635869||ARCC standard|RNs on unit receiving basic ARCC information with staff nurse champion
62137864|NCT00635869||ARCC enhanced|RNs on unit receiving ARCC standard content plus with an EBP mentor
62137865|NCT00635869||C|RNs on the unit receiving the placebo intervention
62336794|NCT02410850||Uniformed Services University|Patients from the Uniformed Services University in USA.
62336795|NCT02410850||University of British Columbia|Patients from the University of British Columbia in Canada.
62336796|NCT03151148|EXPERIMENTAL|TMT Lotion|The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to active TMT will apply 2 grams of TMT to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
62336797|NCT03151148|PLACEBO_COMPARATOR|Placebo Lotion|Placebo lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to placebo will apply 2 grams of placebo to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
62493777|NCT05842720|ACTIVE_COMPARATOR|retrospective|Consecutive patients with ASA score≥3 that underwent unsedated colonoscopy from May 2021 to August 2022 at Sheba medical center were identified by search of the computerized endoscopy database). Following an informed consent, patients were interviewed over the phone using a structured questionnaire. To assess their satisfaction, a standard Likert scale between 1 (unsatisfied) to 5 (very satisfied) was administered. Additional assessment included the maximum level of pain experienced at any point during the procedure (between 1-no pain) to 5-severe pain), and whether they would choose to perform future procedures without sedation in the future. Patients were also asked if they were able to return on the same day to their routine daily function and activities
62493778|NCT05842720|ACTIVE_COMPARATOR|prospective|"High risk patients scheduled for an anesthesiologist-assisted sedated-colonoscopy in Sheba medical center, were contacted during their clinic visit or by phone to receive explanation about the option to enroll in this unsedated colonoscopy study.~After obtaining informed consent, patients' Anxiety trait was assessed with the help of State-Trait Anxiety Inventory (STAI) questionnaire \[8\] in order to assess their level of anxiety and to investigate its predictive utility for their success in undergoing the unsedated procedure. Upon completion of the procedure in the same satisfaction questionnaire was administered, as detailed above for the retrospective part"
62493779|NCT02494505|EXPERIMENTAL|mycophenolate mofetil|
62493780|NCT02494505|PLACEBO_COMPARATOR|placebo|placebo pills
62493781|NCT05064007|EXPERIMENTAL|1|this group will be exposed to condition A first, then B, and C
62493782|NCT05064007|EXPERIMENTAL|2|this group will be exposed to condition B first, then C, and A
62493783|NCT05064007|EXPERIMENTAL|3|this group will be exposed to condition C first, then A, and B
62493784|NCT05211505|EXPERIMENTAL|WO 2707|Formulation containing WO 2707 for intravaginal application
62493785|NCT03859050|EXPERIMENTAL|LPS arm|
62493786|NCT02542462|ACTIVE_COMPARATOR|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
62493787|NCT02542462|ACTIVE_COMPARATOR|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
62493788|NCT02542462|ACTIVE_COMPARATOR|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
62493789|NCT02542462|ACTIVE_COMPARATOR|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
62493790|NCT04568707|EXPERIMENTAL|Covid-19 infection|Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
62493791|NCT00006942|EXPERIMENTAL|Treatment (bryostatin 1, cisplatin)|Patients receive bryostatin 1 IV continuously over 72 hours immediately followed by cisplatin IV over 1 hour. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression.
62493792|NCT04273295|NO_INTERVENTION|the control group|This group receives senna-based laxatives.
62493793|NCT04273295|EXPERIMENTAL|the study group|This group managed by abdominal massage with senna-based laxatives.
62493794|NCT05710588|EXPERIMENTAL|M-DTT group|This group has motor-motor dual task training-balance related tasks as primary task (e.g. marching, stepping) and motor tasks as secondary task (e.g. touching wall, popping a fidget toy).
62493795|NCT05710588|EXPERIMENTAL|C-DTT group|This group has motor-cognitive dual-task training-balance related tasks as primary task (e.g. marching, stepping) and cognitive tasks as secondary task (e.g. repeating tongue twisters, counting backwards from 100).
62493796|NCT04987645|OTHER|Water-Assisted Colonoscopy|If this intervention is chosen randomly, the trainee will use water only technique for insertion.
62493797|NCT04987645|OTHER|Water and Air Insufflation|If this intervention is chosen randomly, the trainee will use water and air insufflation technique for insertion.
62493798|NCT04266548|EXPERIMENTAL|super-selective hepatic artery ICG injection group|single arm for feasibility study of intra-hepatic artery base fluorescent segmental demarcation
62493799|NCT02233751|EXPERIMENTAL|Testosterone enanthate auto-injector - 50 mg|Testosterone enanthate auto-injector - 50 mg (SC injection)
62493800|NCT02233751|EXPERIMENTAL|Testosterone enanthate auto-injector - 200 mg|Testosterone enanthate auto-injector- 200 mg (SC injection)
62493801|NCT05838716|EXPERIMENTAL|Arm I (HDVD)|Patients receive HDVD PO throughout the study. Patients also undergo collection of blood and DXA scan on study.
62695589|NCT05311423||Latent tuberculosis infection Group|QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, acid-fast bacilli (AFB) microscopy, Mycobacterium tuberculosis (Mtb) culture, or GeneXpert MTB/RIF Ultra test results. Then assisted reproductive treatment can be continued, but follow-up for tuberculosis-related symptoms is required
62493802|NCT05838716|PLACEBO_COMPARATOR|Arm II (placebo, DXA scan, blood collection, questionnaire)|Patients receive placebo PO throughout the study. Patients also undergo collection of blood and DXA scan on study.
62493803|NCT03601585|EXPERIMENTAL|Rolly Brush|Chew for 1 minute
61941407|NCT01558193|ACTIVE_COMPARATOR|Multi-vitamin/mineral|Subjects took multi-vitamin/mineral and placebo fatty acid capsule
62493804|NCT03601585|EXPERIMENTAL|Chewing gum|Chew for 1 minute
62493805|NCT03601585|EXPERIMENTAL|Apple|Chew for 1 minute
62493806|NCT03601585|ACTIVE_COMPARATOR|Brush|brush for 1 minute
62493807|NCT01711801|PLACEBO_COMPARATOR|Part 1: Placebo|
62493808|NCT01711801|EXPERIMENTAL|Part 1: RO5545965|
62493809|NCT01711801|EXPERIMENTAL|Part 2: Food effect|
61941408|NCT01558193|ACTIVE_COMPARATOR|Docosahexaenoic acid|Subjects took docosahexaenoic acid capsule and placebo vitamins/minerals
61941409|NCT01558193|ACTIVE_COMPARATOR|DHA plus vitamins/minerals|Subjects took both fatty acid and vitamin/mineral supplements
62493810|NCT04262180|EXPERIMENTAL|Base intervention- Fitbit with EHR integration|All participants will receive a first-line intervention (i.e., Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal) and will be evaluated for response/non-response every 4 weeks until week 20.
62493811|NCT04262180|EXPERIMENTAL|Nonresponders -Stepped up to Online gym|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Online gym."
62493812|NCT04262180|EXPERIMENTAL|Nonresponders -Stepped up to Coaching calls|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Coaching calls."
62493813|NCT04727554|EXPERIMENTAL|Part 1a: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
62493814|NCT04727554|EXPERIMENTAL|Part 1b: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
62493815|NCT04727554|EXPERIMENTAL|Part 1c: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
62493816|NCT04727554|EXPERIMENTAL|Part 2: Dose Expansion|Participants will be administered with the MTD or RP2D of AMG 994 identified in the dose escalation part of the study, in combination with AMG 404.
62493817|NCT02380534|EXPERIMENTAL|active procedure|High cardiovascular risk patients will undergo H.E.L.P. apheresis.
62493818|NCT04292691|EXPERIMENTAL|Ropivacaine|A cumulative amount of approx. 40ml ropivacaine 0.5% (≙400mg (2x200mg) ropivacaine) is applied immediately before surgery. They are applied in a ring wall 10 cm cranially of the tip of the medial and lateral malleolus (N. peroneus superficialis (N. cutaneus dorsalis medius et intermedius, N. saphenus, N. suralis), as well as sonographically controlled (N. peroneus profundus and N. suralis)
62493819|NCT04292691|PLACEBO_COMPARATOR|Ringer's Lactate|Analog to the Experimental Arm, but the same amount of Ringer (40ml) will be plicated instead Ropivacaine
62493820|NCT02725515|EXPERIMENTAL|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 16 infusions
62493821|NCT02725515|PLACEBO_COMPARATOR|Placebo|Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
62493822|NCT04491838|EXPERIMENTAL|Process A|Randomized 1:1
62493823|NCT04491838|EXPERIMENTAL|Process B|Randomized 1:1
62695590|NCT05311423||Subclinical genital tuberculosis Group|QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, AFB microscopy, Mtb culture, but GeneXpert MTB/RIF Ultra positive test results. They are recommended to receive 6-month first-line standard anti-tuberculosis treatment (ATT) regimen
62695591|NCT05311423||Female genital tuberculosis Group|QFT positive. Excluded active pulmonary tuberculosis, regardless of GeneXpert MTB/RIF Ultra results, at least one of these test results, including endometrial histopathologiy, AFB microscopy, Mtb culture is positive, they will receive 6-month ATT
61941410|NCT04130984|EXPERIMENTAL|Group IO|Intraosseous assess will be established in group IO, using EZ-IO for drug or fuild resuscitation. Proximal tibia is the insertion site,locating at 1 cm medial tibial tuberosity. IO access should be retained for less than 1 day, and venous access should be established as soon as possible after winning rescue time to continue treatment. Other treatment measures refer to 2015 AHA guidelines.
61941411|NCT04130984|NO_INTERVENTION|Group IV|Intravenous access will be established in group IV, choosing any available peripheral venous for the administration of drugs or fluids.The antecubital vein is the preferred choice. If failed, the next catheterization plan will be determined by the physician in charge of the scene.Other treatment measures also refer to 2015 AHA guidelines.
61941412|NCT02368704||control|"control subjects with :~* Nondiabetic subjects (blood glucose \<7.0 mmol/l without hypoglycemic treatment).~* The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2)."
61941413|NCT02368704||case|"Diabetic patients with :~* Having type 2 diabetes for at least 6 months~* HbA1c ≤ 8%~* Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin~* No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months"
62336798|NCT00738543|EXPERIMENTAL|Whole group of 48 volunteers|The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
62336799|NCT01842308|EXPERIMENTAL|Treatment|"CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.~TRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
61941414|NCT01035580|EXPERIMENTAL|curcurim|This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.
62336800|NCT01483898|EXPERIMENTAL|ixmyelocel-T|
61941415|NCT03405896|EXPERIMENTAL|Normal subjects|
61941416|NCT01761175|ACTIVE_COMPARATOR|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block
61941417|NCT01761175|ACTIVE_COMPARATOR|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block
62336801|NCT01483898|PLACEBO_COMPARATOR|Placebo|
62336802|NCT00471536|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62336803|NCT01100996|NO_INTERVENTION|fasted control|Volunteers are fasted for 10 hours and subjected to experimental endotoxemia
62336804|NCT01100996|PLACEBO_COMPARATOR|control feeding|Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS
62336805|NCT01100996|ACTIVE_COMPARATOR|enriched feeding|volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS
62493824|NCT02582944|EXPERIMENTAL|Arm 1: Electromagnetic navigation|"* The bronchoscope will be inserted transorally into the tracheobronchial tree and a standard airway inspection will be performed.~* Following airway inspection, the bronchoscope will be removed and the tip tracked steerable catheter with optical system will be advanced transorally through the vocal cords and into the tracheobronchial tree.~* Once the tip tracked catheter has been advanced to the peripheral pulmonary target lesion, the optical SpinView system will be removed from the tip tracked catheter and the 1.4mm radial endobronchial ultrasound mini-probe will be inserted through the tip-tracked catheter into the lung periphery to confirm the presence of a peripheral pulmonary lesion and accurate navigation.~* Once target confirmation has been performed using radial probe endobronchial ultrasound, biopsy of the peripheral lesion will be performed using biopsy forceps, brushes and aspiration needles."
62493825|NCT05066334|EXPERIMENTAL|Active Arm|"Two procedures:~1. Bone marrow harvesting from the posterior superior iliac crest region~2. Single injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control"
62336806|NCT02416362|NO_INTERVENTION|Control|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
62336807|NCT02416362|EXPERIMENTAL|GE1|The GE1 (Vibration at 30 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 30 Hz.
62336808|NCT02416362|EXPERIMENTAL|GE2|The GE1 (Vibration at 50 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
62336809|NCT06064708|EXPERIMENTAL|Patients with ESRD receiving mindfulness-based intervention|Patients with ESRD who received mindfulness-based intervention: underwent hemodialysis thrice weekly, were at least 18 years old, were capable of reading and writing in Arabic, and agreed to participate. Patients under total parenteral nutrition (TPN), undergoing psychotherapy, taking psychopharmacological or anti-inflammatory drugs, and having immunocompromised and infectious illnesses were excluded from the research.
62336810|NCT06064708|NO_INTERVENTION|Control group|The control group including patients with ESRD with the inclusion criteria similar to the experimental group received usual care, comprising biomedical normative dialysis treatment (the participants in this group did not receive any kind of additional treatment or holistic components). However, upon completion of the study, audio recordings of the intervention protocol were provided and explained to participants in the control group.
62336811|NCT02233205|EXPERIMENTAL|microbubbles & platinum and gemcitabine|In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.
62336812|NCT04961814|ACTIVE_COMPARATOR|standard fasting|preoperative fasting according to 6-4-2 regimen then preoperative bedside gastric ultrasound assessment will be done
62336813|NCT04961814|EXPERIMENTAL|liberal fasting|preoperative fasting according to 6-4-0 regimen then preoperative bedside gastric ultrasound assessment will be done
62336814|NCT04768946||Adolescents with Acquired Brain Injury|Adolescents with traumatic brain injury, stroke, and other acquired brain injury ages 12 - 17 will participate in interviews about home safety. They also will have the opportunity to look at and, if desired, try the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
62493826|NCT05066334|SHAM_COMPARATOR|Sham Procedure|"Two sham procedures:~1. Simulated bone marrow harvesting without insertion into the posterior iliac crest region~2. Simulated injection under only local anaesthesia without disc injection and without placebo injection."
62493827|NCT05685550|EXPERIMENTAL|Treatment group|Etoposide capsules in combination with anrotinib and Emvollizumab
62493828|NCT05705141||Combined metabolic syndrome|HBeAg-positive CHB patients with metabolic syndrome
62493829|NCT05705141||Uncombined with metabolic syndrome|HBeAg-positive CHB patients without combined MS
62493830|NCT02926755|EXPERIMENTAL|Angiography to Assess Vulnerable Plaque|In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages \>50% in one or more of the other arteries in the heart.
62493831|NCT06403150|ACTIVE_COMPARATOR|Levetiracetam|Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes.
61941418|NCT02402101|ACTIVE_COMPARATOR|active tDCS|Intensity : 2mA Duration : 20 minutes ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
62695592|NCT04116489|EXPERIMENTAL|Wildlife Immersion Activity|We will use a single group/ modified crossover design in which each participant receives an introductory forest walk followed by 3 wildlife immersion activity experiences in different settings .
61941419|NCT02402101|PLACEBO_COMPARATOR|sham tDCS|Placebo built-in mode (30 sec ramp periods at the beginning and the end of the sham stimulation to mimic the somatosensory artifact of real tDCS) Same electrode montage than in the active group.
61941420|NCT01050543|EXPERIMENTAL|Sugammadex|
61941421|NCT01050543|ACTIVE_COMPARATOR|Neostigmine|
62493832|NCT06403150|ACTIVE_COMPARATOR|Fosphenytoin|Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min.
62493833|NCT05046951|ACTIVE_COMPARATOR|Web arm|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
62493834|NCT05046951|ACTIVE_COMPARATOR|Print Arm|The Should I Screen print-based education (included with this IRB protocol) will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
62493835|NCT03171194|EXPERIMENTAL|Drug: Low Dose Mesenchymal Stem Cells ( MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
62493836|NCT04483895|ACTIVE_COMPARATOR|The OHL method|the ETT insertion depth was estimated according to the OHL method.
62493837|NCT04483895|ACTIVE_COMPARATOR|The 7-8-9 method|the ETT insertion depth was estimated according to the 7-8-9 method.
62493838|NCT00475410|EXPERIMENTAL|ASCs|
61941422|NCT02907268|ACTIVE_COMPARATOR|Treatment Arm A|The first treatment group received onabotulinumtoxinA (Botox) on the right side of their face and abobotulinumtoxinA (Dysport) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
61941423|NCT02907268|ACTIVE_COMPARATOR|Treatment Arm B|The second treatment group received abobotulinumtoxinA (Dysport) on the right side of their face and onabotulinumtoxinA (Botox) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
62336815|NCT04768946||Caregivers of Adolescents with Acquired Brain Injury|Caregivers of adolescents with traumatic brain injury, stroke, and other acquired brain injury will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
62336816|NCT04768946||Healthcare Workers|This cohort includes health professionals involved in discharge planning and community re-integration of adolescents with ABI. Healthcare workers will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
62336817|NCT04850703|EXPERIMENTAL|Premature Ejaculation participants who receive Brain Weak Currents in IFG brain cortex|"Participants receive tRNS (weak currents \< 2 mA) sessions at IFG brain cortex for 25 minutes 2 times a day 3 times per week during 3 weeks.~After 4 hours they end the last session, a new brain mapping is performed."
62336818|NCT04850703|ACTIVE_COMPARATOR|Premature Ejaculation participants who take Dapoxetine|Participants take 1 tablet of the drug between 1 and 3 hours before the brain mapping
62336819|NCT04850703|SHAM_COMPARATOR|Placebo Group|Participants who do not take medication or receive tRNS sessions
62493839|NCT00475410|EXPERIMENTAL|ASCs+fibrin glue|
62493840|NCT00475410|ACTIVE_COMPARATOR|Fibrin glue|
62493841|NCT03655860|EXPERIMENTAL|SIMEOX|Use of the device SIMEOX to exhale
62493842|NCT00651651|EXPERIMENTAL|1|Symbicort
62493843|NCT00651651|ACTIVE_COMPARATOR|2|budesonide
62336820|NCT04850703|OTHER|Controls|44 Healthy humans not clinically not diagnosed with LPD and withouth expression the LPE endophenotype. In this way, the investigators what would be the patients diagnosed clinically with LPE who present the endophenotype or neurophysiological biomarker of LPE.
62493844|NCT00651651|ACTIVE_COMPARATOR|3|formoterol
62493845|NCT02148744|EXPERIMENTAL|XmAb7195 or Placebo|
62493846|NCT05296928|EXPERIMENTAL|umbilical incision|Placing the laparoscopic trocar by cutting the umbilicus directly at the entrance to the abdomen
62493847|NCT05296928|ACTIVE_COMPARATOR|subumbilical incision|Placing a laparoscopic trocar by making a sub-umbilicus incision at the entrance to the abdomen
62493848|NCT00595140|NO_INTERVENTION|1|patients with acromegaly on stable pegvisomant therapy
62493849|NCT00595140|ACTIVE_COMPARATOR|2|Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
62493850|NCT00595140|ACTIVE_COMPARATOR|3|Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
62493851|NCT03196557|EXPERIMENTAL|Arm A|Specified dose on specified days
62493852|NCT03196557|PLACEBO_COMPARATOR|Arm B|Specified dose on specified days
62493853|NCT03123874|EXPERIMENTAL|Sterile pump set-up first|Participants will pump with sterile pump set-ups first. Approximately 3 hours later, participants will pump with their own pump set-ups.
62493854|NCT03123874|EXPERIMENTAL|Mother's Own pump set-up first|Participants will pump with their own pump set-ups first. Approximately 3 hours later, participants will pump with sterile pump set-ups.
61941424|NCT02120612||Historical Control Group|Historical Control Group will be assessed for knowledge prior to the implementation of the educational program.
62493855|NCT02063815|ACTIVE_COMPARATOR|glass ionomer based fissure sealant|fissure sealant application
62493856|NCT02063815|ACTIVE_COMPARATOR|resin based fissure sealant|fissure sealant application
62695593|NCT02033408|EXPERIMENTAL|Antibiotics in addition to steroids|"methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:~1. PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)~2. PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks~3. PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks~4. PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks"
62493857|NCT03900013|EXPERIMENTAL|Injectable Platelet Rich Fibrin (i-PRF) with DFDBA|"In i-PRF assigned group, 10 cc of blood per intraosseous defect will be collected right after administering the anaesthesia and will be processed according to the technique proposed by Choukroun et al., 2017 (centrifuged at 700 rpm, for 2-3 minutes). The yellow part will be collected using a syringe and added to a cup that contains the bone grafting material.~The i-PRF consolidated bone graft will placed into the intraosseous defect."
62493858|NCT03900013|ACTIVE_COMPARATOR|Demineralized Freeze-Dried Bone Allograft (DFDBA) alone|After debridement and intraoperative recordings, in the control group, the bone graft material will be placed in the intraosseous defect without overfilling.
62695594|NCT02033408|ACTIVE_COMPARATOR|Steroids only|methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses
61941425|NCT02120612||Naloxone Education Intervention Group|Group to begin receiving the Naloxone Education Intervention on the signs of opioid overdose and appropriate use of naloxone.
61941426|NCT02439294|OTHER|Without Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
62137866|NCT05923190|ACTIVE_COMPARATOR|Enfortumab vedotin (EV) monotherapy|"EV will be administered at standard dose of 1.25 mg/kg IV on days 1, 8 and 15 of a 28-day cycle for 3 cycles.~First schedule de-escalation of EV will occur in patients with disease control per RECIST v1.1 (complete response/partial response/stable disease) on their first scan in the EV at 12 weeks. In these patients, EV will be administered on days 1 and 15 of a 28-day cycle.~Second schedule de-escalation of EV will occur in patients with disease control per RECIST v1.1 (complete response/partial response/stable disease) on their second scan in the EV monotherapy (at 24 weeks). EV will be administered on day 1 of a 21-day cycle."
61941427|NCT02439294|OTHER|Mild or moderate Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
62137867|NCT05923190|EXPERIMENTAL|EV/pembrolizumab|"EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles. Radiographic assessment will be conducted every 9 weeks.~Schedule de-escalation of EV will occur in patients with disease control per RECIST v1.1 (complete response/partial response/stable disease) on their first scan in the EV/pembrolizumab arm at 9 weeks. In these patients EV and pembrolizumab will be administered on day 1 of a 21-day cycle."
62137868|NCT03802994|EXPERIMENTAL|1.Aging RT|Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (\>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
62137869|NCT03802994|ACTIVE_COMPARATOR|2.Young RT|Renal transplant recipients between 35-45 years of age, on stable immunosuppression. who previously (\>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
62336821|NCT02136121|EXPERIMENTAL|da Vinci Sp Surgical System|da Vinci Sp Surgical System - Robotic - assisted single-port surgery
61941428|NCT02439294|OTHER|Severe Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
61941429|NCT02566668||Asthmatic|1 year observational follow-up
61941430|NCT02566668||Non-Asthmatic|1 year observational follow-up
61941431|NCT02422173|EXPERIMENTAL|Anodal tDCS|Participants in the acute post-stroke stage will receive anodal transcranial direct current stimulation
61941432|NCT02422173|EXPERIMENTAL|Cathodal tDCS|Participants in the acute post-stroke stage will receive cathodal transcranial direct current stimulation
61941433|NCT02422173|EXPERIMENTAL|Bilateral tDCS|Participants in the acute post-stroke stage will receive bilateral transcranial direct current stimulation
61941434|NCT02422173|SHAM_COMPARATOR|Sham tDCS|Participants in the acute post-stroke stage will receive sham transcranial direct current stimulation
62493859|NCT02702635|EXPERIMENTAL|All Subjects|All recruited subjects
62493860|NCT02233374|EXPERIMENTAL|Assessing response with MRI + PET.|"Pre-operative chemo/RT as per standard treatment. Intensity Modulated Radiotherapy (IMRT) / Volumetric Arc Therapy (VMAT) 45Gray/25 fractions with simultaneous integrated Boost of 50Gray/25 fractions + concurrent capecitabine chemotherapy.~Intervention 1 'Early MRI and PET/CT - 2 weeks after commencing chemo/RT' involves additional Multiparametric MRI + PET/CT 2 weeks into chemo/RT Intervention 2 :\\'Late MRI and PET/CT 6 weeks post chemo/RT' involves additional Multiparametric MRI + PET/CT 6 weeks post chemo/RT"
62493861|NCT02248012|EXPERIMENTAL|Everolimus/temozolomide|Everolimus 10 mg daily, temozolomide 150 mg/m2 for 7 days every 2 weeks.
62493862|NCT05878899|EXPERIMENTAL|Enoxaparin|Enoxaparin 20-60mg o.d., according to bodyweight, for 10 days postpartum.
62493863|NCT05878899|NO_INTERVENTION|No treatment|No treatment.
62493864|NCT03357380|EXPERIMENTAL|Semaglutide|Semaglutide will be initiated with a starting dose of 0.05 mg/day for the first 4 weeks. The dose will be increased every 4 weeks until the target dose of 0.4 mg/day has been reached.
62493865|NCT03357380|PLACEBO_COMPARATOR|Placebo|Placebo will be initiated with a starting volume corresponding to 0.05 mg/day of semaglutide for the first 4 weeks. The volume will then be increased every 4 weeks until the target volume corresponding to 0.4 mg/day of semaglutide has been reached.
62493866|NCT01881737|EXPERIMENTAL|Pregnenolone|Pregnenolone up to 500 mg per day
62493867|NCT05305586|ACTIVE_COMPARATOR|Packable Composite|Packable composite material was selected for splinting of luxated teeth
62695595|NCT02033408|OTHER|Open arm|either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients
62336822|NCT02474667|ACTIVE_COMPARATOR|BB3|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
62493868|NCT05305586|ACTIVE_COMPARATOR|Bulkfill composite|Bulkfill composite material was selected for the splinting of luxated teeth
62493869|NCT02599662|OTHER|Group 1: 10 Gy Low-KV IORT|10 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
62493870|NCT02599662|OTHER|Group 2: 15 Gy Low-KV IORT|15 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
62493871|NCT02599662|OTHER|Group 3: 20 GY Low-KV IORT|20 GY Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
62493872|NCT01963351||Locally advanced and metastatic nsclc|non squamous
62493873|NCT04511156|EXPERIMENTAL|Foundational Helping Skills|The Foundational Helping Skills training will be intervention to be evaluated in this study. The Foundational Helping Skills is a flexible curriculum, with an approximate 3-day (20 hour) duration to be modified based on context and personnel. The Foundational Helping Skills is a human-centered design competency-based training in foundational helping skills. The training curriculum has been developed in a modular format, with each module relating to specific foundational helping skills (e.g., non-verbal communication, confidentiality, etc). The training curriculum can be found. The general training outline includes two days of foundational helping skill modules, brief role-play competency assessments at the end of each foundational helping skills training day to inform trainers which competencies need remediation, and a half-day of training that involves a remediation of the specific foundational helping skills that have been identified via the brief role-play assessments.
62493874|NCT01234961|EXPERIMENTAL|Redesigning Daily Occupations|The ReDO intervention focuses on how people compose their everyday lives. Supporting people in how to change and modify their patterns of daily occupations is a new intervention method for people with stress-related disorders, but it has been shown to be effective in improving quality of life and self-rated health in other target groups. The basic idea is that re-structuring of an individual's lifestyle and pattern of daily occupations will lead to a healthier balance between the occupations of everyday life, and that this balance will promote wellness and improved work capacity. The program is group based and comprises 16 weeks, with sessions 2 x 2 hours per week, followed by 3-4 booster sessions.
62493875|NCT01234961|ACTIVE_COMPARATOR|Care as usual|Standard rehabilitation provided by the Social Insurance Office, such as stress management, physical therapy, mindfulness training.
62493876|NCT06223490|ACTIVE_COMPARATOR|Cryolipolysis Group|About 30 obese females with type 2 diabetes and will face cryolypolysis in addition to exercise therapy treatment
62493877|NCT06223490|ACTIVE_COMPARATOR|Group of Exercise|About 30 obese females with type 2 diabetes and will face exercise therapy treatment only.
62493878|NCT01897324|EXPERIMENTAL|The Long protocol|Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
62493879|NCT01897324|EXPERIMENTAL|The Short protocol|The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
62493880|NCT01897324|EXPERIMENTAL|The Antagonist protocol|Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
62493881|NCT01897324|EXPERIMENTAL|The Microflare protocol|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
62493882|NCT01198392|EXPERIMENTAL|S-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
62493883|NCT01198392|ACTIVE_COMPARATOR|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
62493884|NCT01519947|ACTIVE_COMPARATOR|Pre-dialysis, sea level|Participants received 50-250 mcg SC according to local label.
62493885|NCT01519947|ACTIVE_COMPARATOR|Dialysis, sea level|Participants received 50-250 mcg SC according to local label.
62493886|NCT01519947|EXPERIMENTAL|Pre-dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
62493887|NCT01519947|EXPERIMENTAL|Dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
62493888|NCT01647321|ACTIVE_COMPARATOR|Active cycling|Individuals will receive functional electrical stimulation while on the stationary bike and instructed to actively pedal.
62336823|NCT02474667|PLACEBO_COMPARATOR|Normal Saline|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
62336824|NCT05650073|EXPERIMENTAL|Immersive Soundscapes Environment|Subjects having venous ablation OR port removal with Vascular Surgery at Mayo Clinic will have relaxing music and relaxing sounds played during the procedure.
62493889|NCT01647321|SHAM_COMPARATOR|Passive cycling|Individuals will receive active functional electrical stimulation (FES) while on the stationary bike and instructed to relax their legs, allowing the FES to move their legs on the stationary bike.
61941435|NCT05194657|EXPERIMENTAL|Acrysof IQ Vivity|Patient will receive the enhanced depth of focus IOL during cataract surgery
62336825|NCT05650073|NO_INTERVENTION|Control Environment|Subjects having venous ablation OR port removal with Vascular Surgery at Mayo Clinic will have no music played during the procedure.
62137870|NCT03802994|ACTIVE_COMPARATOR|3.Healthy elderly|Healthy persons between the ages 65-75 who previously (\>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
62336826|NCT02515617|ACTIVE_COMPARATOR|Period with endotracheal tubes not allowing SSD|During this period, patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
62493890|NCT01507662|EXPERIMENTAL|BMD Result Letter and Brochure|Patients who receive the intervention - BMD result letter with brochure.
62493891|NCT01507662|NO_INTERVENTION|Control|Those who received usual care
62493892|NCT06175741|PLACEBO_COMPARATOR|Control group|this group will receive erector spinae plane block only(bupivicaine)
62493893|NCT06175741|EXPERIMENTAL|Interventional 3mg|this group will receive erector spinae plane block (bupivicaine and 3mg morphine)
62493894|NCT06175741|EXPERIMENTAL|Interventional 5mg|this group will receive erector spinae plane block (bupivicaine and 5mg morphine)
61941436|NCT05194657|EXPERIMENTAL|Acrysof IQ|Patiet will receive the monofocal IOL during cataract surgery
61941437|NCT01031706|EXPERIMENTAL|Hypertonic saline|6% NaCl, 4 ml TID via eFlow
62336827|NCT02515617|EXPERIMENTAL|Period with endotracheal tubes allowing SSD|During this period, patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
61941438|NCT01031706|PLACEBO_COMPARATOR|Placebo|0.12% x 4ml via eFlow nebulizer
61941439|NCT01464892|EXPERIMENTAL|Imagery Rescripting|
61941440|NCT01464892|ACTIVE_COMPARATOR|STAIR plus Imagery Rescripting|
62336828|NCT00696462|NO_INTERVENTION|A|Patients in Group A will undergo passive warming with a warmed cotton blanket placed over their upper extremities
62493895|NCT03214237||Participants|Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study
62493896|NCT00352196|EXPERIMENTAL|Magnetic Resonance Spectroscopy|Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
62493897|NCT00352196|OTHER|NO-MRS|Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
62493898|NCT01391650|EXPERIMENTAL|biomechanic of the knee|
61941441|NCT01464892|NO_INTERVENTION|Wait-list control|Participants from this arm are randomized to the two active conditions after 8 weeks of waiting.
61941442|NCT01135602|EXPERIMENTAL|Topiramate|1 group
62137871|NCT03802994|ACTIVE_COMPARATOR|4.Elderly DMII or HTN and normal renal function|Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (\>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
62137872|NCT03802994|EXPERIMENTAL|5.Healthy young|Healthy persons between the ages 35-45 who previously (\>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.
62137873|NCT02054351|EXPERIMENTAL|IMAB027 administration|Monotherapy - different dose Levels.
62137874|NCT00545311|EXPERIMENTAL|1|NVA237
62137875|NCT00545311|EXPERIMENTAL|2|NVA237
62137876|NCT00545311|EXPERIMENTAL|3|NVA237
62336829|NCT00696462|ACTIVE_COMPARATOR|B|Patients in Group B will have a forced-air warming device applied to the upper body above the waist at the 43 degree Celsius setting.
62336830|NCT04494633|EXPERIMENTAL|Intervention|Participants completed the pre-assessments, used the intervention, waited 2-4 weeks, and then completed the assessments again.
61941443|NCT00958789|OTHER|Triathlon TS Knee|Triathlon TS Knee System
61941444|NCT05130918|EXPERIMENTAL|Phenolmicin P3 and Bosexil|Group in which patients were administered Phenolmicin P3 and Bosexil suppositories twice a day for 5 days, then once a day for other 10 days after thulium laser enucleation of prostate was performed.
61941445|NCT05130918|NO_INTERVENTION|Controls|Group in which patients were not administered Phenolmicin P3 and Bosexil suppositories after thulium laser enucleation of prostate was performed.
61941446|NCT05203289|EXPERIMENTAL|BI 695501 40 mg/0.4 mL (T)|Participants were subcutaneously injected 40 milligram (mg)/0.4 milliliter (mL) of BI 695501 solution for injection in prefilled syringe (PFS) (Test Treatment (T)).
62137877|NCT00545311|EXPERIMENTAL|4|NVA237
62137878|NCT00545311|PLACEBO_COMPARATOR|5|Placebo
62137879|NCT01057459||Ancillary-Correlative (biomarkers and treatment outcomes)|Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
62137880|NCT05747014||Novapak Subjects|Subjects that are enrolled in the Novapak Study.
62336831|NCT04494633|NO_INTERVENTION|Wait Group|Participants completed the pre-assessments, waited 2-4 weeks, and completed the assessments again.
62336832|NCT05236881|EXPERIMENTAL|ANíMATE mobile application|Standard care protocol (3 face-to-face visits: basal, 2 and 4 months) + ANíMATE mobile application
62336833|NCT05236881|NO_INTERVENTION|Standard care|Standard care protocol (3 face-to-face visits: basal, 2 and 4 months)
62493899|NCT01458886|EXPERIMENTAL|BI 54903 LD b.i.d.|Patients receive 2 puffs b.i.d. via Respimat inhaler
62493900|NCT01458886|EXPERIMENTAL|BI 54903 MD q.d.|Patients receive 2 puffs q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
62493901|NCT01458886|PLACEBO_COMPARATOR|Placebo|Patients receive 2 puffs b.i.d. via Respimat inhaler
62493902|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
62493903|NCT05285319|EXPERIMENTAL|Prostate Only (Arm A)|Hypofractionated Intensity modulated radiotherapy (IMRT) to the prostate only to a dose of 60Gy/20fractions (3 Gy per fraction)
62695596|NCT04991142||Persons with Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c greater than or equal to 6.5%
62493904|NCT05285319|EXPERIMENTAL|Prostate and Pelvic Lymph Nodes (Arm B)|Hypofractionated Intensity modulated radiotherapy (IMRT) with elective pelvic nodes irradiation up to 44Gy/20 fractions (2.2 Gy per fraction) with a Simultaneous Integrated Boost (SIB) to the prostate to a dose of 60Gy/20fractions (3 Gy per fraction)
62493905|NCT02991846||Patients with cGVHD|All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)
62493906|NCT04815668|EXPERIMENTAL|Acupuncture group|
62695597|NCT04991142||Persons with Pre-diabetes|Venous blood draw of fasting HbA1c greater than or equal to 5.7% and less than 6.5%
62695598|NCT04991142||Persons without Pre-diabetes or Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c less than 5.7%
61941447|NCT05203289|EXPERIMENTAL|BI 695501 40 mg/0.8 mL (R)|Participants were subcutaneously injected 40 milligrams (mg)/0.8 milliliter (mL) of BI 695501 solution for injection in prefilled syringe (PFS) (Reference Treatment (R)).
61941448|NCT03539146|ACTIVE_COMPARATOR|Control yogurt|Treatment with a control yogurt with cascara but no dietary fiber.
61941449|NCT03539146|EXPERIMENTAL|Yogurt with fiber|Treatment with yogurts containing cascara and 3%, 7% and 13% of dietary fiber.
62336834|NCT05622383|EXPERIMENTAL|aromatherapy|aromatherapy will be applied
62336835|NCT05622383|EXPERIMENTAL|music concert|music concert will be applied
62336836|NCT05622383|EXPERIMENTAL|aromatherapy,music concert|aromatherapy, music concert will be applied
62336837|NCT05622383|NO_INTERVENTION|control|Routine maintenance will be applied.
62336838|NCT02555566|EXPERIMENTAL|Kidney transplant recipients|"blood sampling is done for determination of EPHX Lys55Arg and other polymorphisms status in Kidney transplant recipients.~flow-mediated distal stimulation of the forearm radial artery by cutaneous heating is assessed for evaluation of EEts level in Kidney transplant recipients."
62336839|NCT04374110||Hospitalized patients with COVID-19|Hospitalized patients with COVID-19 will be included in the study in centers around Poland.
62493907|NCT04815668|PLACEBO_COMPARATOR|Placebo acupuncture group|
61941450|NCT04087304|NO_INTERVENTION|Low Risk Group|
61941451|NCT04087304|NO_INTERVENTION|Mild Risk Group|
62336840|NCT04374110||Infected SARS-CoV-2 patients|patients with SARS-CoV-2 infection not requiring hospitalization
61941452|NCT04087304|ACTIVE_COMPARATOR|Moderate Risk Group|
61941453|NCT04087304|ACTIVE_COMPARATOR|High Risk Group|
62137881|NCT01854385|EXPERIMENTAL|Sumatriptan|Open label study of sumatriptan to treat post-traumatic headache. Subjects will use sumatriptan 100 mg at the onset of headache pain and may repeat the dose if not pain-free in 2 hours. Subjects will receive a maximum of 18 pills for use over two months. Subjects will maintain a daily headache diary.
62137882|NCT02320266||Parkinson's Disease|Patients diagnosed with Parkinson's Disease undergoing DBS surgery.
62493908|NCT04815668|OTHER|Rescue medication|
62493909|NCT01573390||1|Healthy participants.
62493910|NCT01931449|EXPERIMENTAL|Modified digestive reconstruction|Modified method of digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract with an independent intestinal loop and pancreas end.
61941454|NCT06079658|EXPERIMENTAL|Continuous Caloric Restriction (CCR) group:|Participants in this group will be placed on a diet that is prescribed a 25% reduction from maintenance calories (calories to maintain current body weight) with a dietary protein intake of 1.2 g of protein/kg body mass and remaining calories split evenly between fat and carbohydrate. In this group they will adhere to a 25% caloric reduction daily for 12 weeks.
62137883|NCT02320266||Control|Age matched controls without Parkinson's Disease and no history of mental illness.
62137884|NCT02320266||Essential Tremor|Patients diagnosed with Essential Tremor undergoing DBS surgery.
62336841|NCT04374110||Controls|structure-matched and co-existing disease matched control group from the general population.
62336842|NCT03355937|ACTIVE_COMPARATOR|UEI Sperm Chip (-)|Conventional IVF treatment and using conventional sperm selection
62336843|NCT03355937|EXPERIMENTAL|UEI Sperm Chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
62493911|NCT01931449|ACTIVE_COMPARATOR|Routine pancreatoduodenectomy|Routine digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes;Reconstruct the common bile duct-jejunum and pancreatic duct-jejunum respectively.
62336844|NCT03355937|ACTIVE_COMPARATOR|RIF sperm chip (-)|Conventional IVF treatment and using conventional sperm selection
62336845|NCT03355937|EXPERIMENTAL|RIF sperm chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
62336846|NCT02317406|ACTIVE_COMPARATOR|Probiotics|Biostime probiotics sachet children's formula, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
62336847|NCT02317406|PLACEBO_COMPARATOR|Probiotics simulation|Biostime probiotics sachet children's formula（placebo）, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
62336848|NCT05753280|EXPERIMENTAL|treatment group|pegylated interferon 180ug/week and oral vitamin D3 800IU/day for no longer than 48 weeks
62336849|NCT05753280|NO_INTERVENTION|control group|pegylated interferon 180ug/week for no longer than 48 weeks
62493912|NCT04396392|EXPERIMENTAL|VR-based training|receiving only VR intervention
62493913|NCT04396392|ACTIVE_COMPARATOR|text-based training|receiving only text-based intervention
62695599|NCT00980798|EXPERIMENTAL|001|OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks
62695600|NCT00980798|PLACEBO_COMPARATOR|002|Placebo placebo tablet once daily for 16 weeks
62695601|NCT03266783|ACTIVE_COMPARATOR|Apixaban group|10 mg orally (PO), twice a day (BID) for 1 week, then 5 mg PO BID for 3 months of treatment
62695602|NCT03266783|ACTIVE_COMPARATOR|Rivaroxaban group|15 mg orally (PO), twice a day (BID) for 3 weeks, then 20 mg PO once a day (OD) for 3 months of treatment
62695603|NCT06253312||Open surgery|Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass
62695604|NCT06253312||Hybrid repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis
62137885|NCT02320266||Dystonia|Patients diagnosed with Dystonia undergoing DBS surgery.
62137886|NCT02320266||Obsessive-Compulsive disorder|Patients diagnosed with Obsessive-Compulsive disorder undergoing DBS surgery.
62336850|NCT00004038|EXPERIMENTAL|Arm I|Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
62336851|NCT05091294|ACTIVE_COMPARATOR|Group S:33|120-second local anesthesic (% 0,5 Bupivacaine) injection time
62336852|NCT05091294|ACTIVE_COMPARATOR|Group F:34|15-second local anesthesic(% 0,5 Bupivacaine) injection time
62336853|NCT02472925|OTHER|Arm 1: Control|"MedSignals pill box will be set into quiet mode to track patient compliance. This mode sends daily adherence data to the Way to Health platform each time the participant opens the pill box, however, does not remind the participant to take the medication."
62336854|NCT02472925|EXPERIMENTAL|Arm 2: Reminders/Feedback|MedSignals pill box will track patient compliance and the Way to Health platform will allow participants to receive tailored text message reminders to take the medication if in case the interval from last cap opening is \>30 hours (greater than 6 hours overdue).
62336855|NCT02472925|EXPERIMENTAL|Arm 3: Reminders/Feedback/Incentives|MedSignals pill box will track patient compliance and in addition to reminders with missed doses and weekly adherence feedback, patients in this arm will be eligible to receive a small financial incentive each week they demonstrate perfect \>85% adherence. The weekly adherence feedback message will also alert patients whether they earned the incentive for the past week.
62336856|NCT03016299||Osteoarthritis hip joint|specimen of head of femur will be used- after total hip arthroplasty (due to Degenerative Osteoarthritis hip joint )
62336857|NCT03016299||Non-Osteoarthritis hip joint|specimen of head of femur will be used- after Hip Hemiarthroplasty -Partial replacment (due to traumatic fracture)
62336858|NCT05157451|EXPERIMENTAL|Arm I (SBRT)|Patients undergo SBRT every other day for a total of 5 days over 2 weeks.
62695605|NCT06253312||Endovascular repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
62137887|NCT06700278|EXPERIMENTAL|experimental group|
62336859|NCT05157451|EXPERIMENTAL|Arm II (Y-90 radioembolization)|Patients receive Y-90 radioembolization via injection on day 1.
62336860|NCT01078701|EXPERIMENTAL|GHB11L1|Dose levels: 6.0 log10 TCID50/volunteer, 6.5 log10 TCID50/volunteer and 7.0 log10 TCID50/volunteer
62336861|NCT01078701|PLACEBO_COMPARATOR|SPGN buffer|SPGN buffer administration by liquid nasal spray
62695606|NCT00879398||OAB-Toviaz|All patients who enrolled in this study
62336862|NCT06361329|EXPERIMENTAL|VHAG group|"Venetoclax: 100mg on day 1, 200mg on day 2, and 400mg on days 3-14, if the blast cells in bone marrow were more than 5% on day 14, the patient continued to receive venetoclax 400mg until day 28.~HHT:1.4 mg/m2,2mg maximum daily, intravenously daily from on d1-7 Cytarabine :10 mg/m2 subcutaneously every 12h on d1-14（d10-d14） G-CSF: 100ug/m2 daily on d1-14 if WBC count \<10\*10E9/L"
62336863|NCT06361329|ACTIVE_COMPARATOR|Traditional Chemotherapy Regimen group|"* VDCLP regimen~* VD(/I) CP regimen~* Hyper CVAD-A regimen~* VDLP regimen"
62336864|NCT04377594|EXPERIMENTAL|Pulmonary vein isolation plus substrate modification|Pulmonary vein isolation plus ablation of low voltage areas in the left atrium
62336865|NCT04377594|ACTIVE_COMPARATOR|Pulmonary vein isolation|Pulmonary vein isolation
62336866|NCT03370991|EXPERIMENTAL|Blueberry|22 g/day freeze-dried blueberry powder for 12 weeks
62336867|NCT03370991|PLACEBO_COMPARATOR|Control|22 g/day placebo powder for 12 weeks
62336868|NCT06337292|NO_INTERVENTION|Standard of Care Wound Care|Patients randomized to the control group will receive standard wound care.
62336869|NCT06337292|EXPERIMENTAL|Incisional Negative Pressure Wound Therapy (NPWT)|Patients randomized to the treatment group will receive wound care which includes the application of an incisional negative pressure wound vacuum.
62336870|NCT00608530|EXPERIMENTAL|Cognitive Behavioral Therapy-Psychologist-Delivered|10 hours of Cognitive Behavioral Training delivered by a psychologist over 8 weeks by telephone and face-to-face contact
62336871|NCT00608530|ACTIVE_COMPARATOR|Supportive Psychotherapy-Psychologist-Delivered|10 hours of Rogerian Psychotherapy delivered by a psychologist over 8 weeks by telephone and face-to-face contact
62336872|NCT00608530|EXPERIMENTAL|Cognitive Behavioral Therapy-Nurse-Delivered|10 hours of Cognitive Behavioral Training delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
62336873|NCT00608530|ACTIVE_COMPARATOR|Supportive Psychotherapy-Nurse-Delivered|10 hours of Rogerian Psychotherapy delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
62336874|NCT02449954|ACTIVE_COMPARATOR|morphine group|intravenous 0.1mg/kg morphine
62695607|NCT02048540|EXPERIMENTAL|bevacizumab plus DOF|patients receive bev +DOF pre and post surgery up to total 6 cycles
62137888|NCT06700278|NO_INTERVENTION|control group|Routine rehabilitation therapy for five days a week
62336875|NCT02449954|ACTIVE_COMPARATOR|tramadol group|intravenous 2 mg/kg tramadol
62336876|NCT02449954|ACTIVE_COMPARATOR|ketorolac group|intravenous30 mg ketorolac
62336877|NCT01872741|ACTIVE_COMPARATOR|Ruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
62336878|NCT01872741|ACTIVE_COMPARATOR|Unruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
62336879|NCT06280976|ACTIVE_COMPARATOR|SOC: Statin ± Aspirin (per ACC guidelines)|The SOC group: participant receive routine care as per cardiologist. Study doctor will prescribe medications that they choose themselves.
62336880|NCT06280976|EXPERIMENTAL|AT: Statin, Aspirin, Nexlizet, Leqvio, Vascepa, Jardiance, Colchicine|An AT group: FDA-approved drugs will be used to reduce cholesterol and cardiovascular risk.
62336881|NCT06347991|EXPERIMENTAL|Intervention|Those who receive the SelfBack app
62493914|NCT04396392|EXPERIMENTAL|VR- and text-based training|receiving both VR intervention and text-based intervention
62493915|NCT04396392|NO_INTERVENTION|waiting list|waiting list in phase 1 and text-based training after 3 weeks
62493916|NCT04775316||Patients with fragile skin|Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.
62493917|NCT04288076|EXPERIMENTAL|PEEP Titration Arm|
62493918|NCT03792139|EXPERIMENTAL|LY3200882|LY3200882 administered orally.
62695608|NCT02048540|ACTIVE_COMPARATOR|DOF|patients receive DOF pre and post surgery up to total 6 cycles
62695609|NCT01889251|EXPERIMENTAL|Ocriplasmin|Ocriplasmin administered as a single intravitreal injection to the study eye at baseline
62695610|NCT01889251|SHAM_COMPARATOR|Sham injection|Single sham injection to the study eye at baseline
62695611|NCT05613127|EXPERIMENTAL|Test group|Inactivated Hepatitis A vaccine
62137889|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 1, Schedule 2 (Phase 1)|Novel vaccine formulation 1
62137890|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 3 (Phase 1)|Novel vaccine formulation 2
62336882|NCT02024204|ACTIVE_COMPARATOR|Uncontrolled LRS|Patients who have uncontrolled lower respiratory symptoms (ACT \< 20) at time of Visit 1 will be provided with study Advair (Fluticasone propionate 230mcg/salmeterol 21mcg) for a total of 3 months and receive medication adherence counseling Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
62336883|NCT02024204|OTHER|Controlled LRS|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
62695612|NCT05613127|ACTIVE_COMPARATOR|Control group|Inactivated Hepatitis A vaccine
62137891|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 3, Schedule 2 (Phase 1)|Novel vaccine formulation 3
62137892|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 1, Schedule 4 (Phase 1)|Novel vaccine formulation 1
62137893|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 4 (Phase 1)|Novel vaccine formulation 2
62137894|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 3, Schedule 4 (Phase 1)|Novel vaccine formulation 3
62137895|NCT05805826|ACTIVE_COMPARATOR|C. difficile vaccine (previously studied formulation) Schedule 1 (Phase 1)|Previously studied C. difficile vaccine formulation
62336884|NCT02163304|ACTIVE_COMPARATOR|Artificial Sweetner|Artificial Sweetener
62137896|NCT05805826|EXPERIMENTAL|C difficile vaccine formulation 2, Schedule 1 (Phase 2)|Novel vaccine formulation 2
62137897|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 4 (Phase 2)|Novel vaccine formulation 2
62137898|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 5 (Phase 2)|Novel vaccine formulation 2
62137899|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 6 (Phase 2)|Novel vaccine formulation 2
62137900|NCT05805826|ACTIVE_COMPARATOR|C. difficile vaccine (previously studied formulation) , Schedule 1 (Phase 2)|Previously studied C. difficile vaccine formulation
62336885|NCT02163304|PLACEBO_COMPARATOR|Tasteless Solution|12 oz tasteless solution
62336886|NCT02163304|ACTIVE_COMPARATOR|Sucrose|12 oz 75 g sucrose beverage
62336887|NCT04641312|EXPERIMENTAL|LY3457263 - Part A|Escalating single doses of LY3457263 administered subcutaneously (SC) to healthy participants
62336888|NCT04641312|PLACEBO_COMPARATOR|Placebo - Part A|Placebo administered SC to healthy participants
62336889|NCT04641312|EXPERIMENTAL|LY3457263 - Part B|Escalating single doses of LY3457263 administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
62493919|NCT03792139|EXPERIMENTAL|Itraconazole + LY3200882|Itraconazole + LY3200882 administered orally.
62493920|NCT00686868|EXPERIMENTAL|30mg|active
62493921|NCT00686868|EXPERIMENTAL|3mg|active
62493922|NCT00686868|EXPERIMENTAL|0.3mg|active
62493923|NCT00686868|PLACEBO_COMPARATOR|placebo|placebo
62493924|NCT00686868|EXPERIMENTAL|60mg|60mg
62493925|NCT00686868|EXPERIMENTAL|100mg|100mg
62493926|NCT06371313||HA Group|Maternal hyperandrogenism of PCOS women with full-term singleton delivery were selected, and umbilical cord blood of their newborns was collected.
62493927|NCT06371313||Control Group|Healthy pregnant women with full-term singleton delivery were randomly selected, and umbilical cord blood of their newborns was collected.
62493928|NCT04133116|EXPERIMENTAL|LY3471851|Participants received single doses of 450 microgram (μg), 900 μg or 1800 μg LY3471851 administered subcutaneously (SC).
62493929|NCT04133116|PLACEBO_COMPARATOR|Placebo|Placebo matching LY3471851 administered SC.
62493930|NCT04453969||Breastfeeding mothers positive for COVID-19|
62493931|NCT01596127|EXPERIMENTAL|Intrathecal Rituximab|"Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I."
62695613|NCT03499743|EXPERIMENTAL|group1 (hyoscine Butyl-bromide group)|group1 will receive hyoscine butyl bromide 10 mg (BUSCOPAN tablets, produced by Chemical Industries Development (CID), Giza - A.R.E. under licence of Boehringer Ingelheim International GmbH - Germany) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
62137901|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 7 (Phase 2)|Novel vaccine formulation 2
62137902|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 1, (Phase 2)|Novel vaccine formulation 2
62493932|NCT05650151|EXPERIMENTAL|Vitamin D group|
62493933|NCT05650151|PLACEBO_COMPARATOR|Control group|
62493934|NCT02004717|EXPERIMENTAL|dose escalation then expansion|"Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.~Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
62695614|NCT03499743|PLACEBO_COMPARATOR|group 3 (PLACEBO GROUP)|will receive a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
62493935|NCT04837664|EXPERIMENTAL|Rose Bengal-mediated Photodynamic therapy|Participants belonging to the rose bengal mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer rose bengal was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
62493936|NCT04837664|EXPERIMENTAL|Curcumin-mediated photodynamic therapy|Participants belonging to the curcumin mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer curcumin was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
62336890|NCT04641312|PLACEBO_COMPARATOR|Placebo - Part B|Placebo administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
62336891|NCT06128798|EXPERIMENTAL|Oral Impact|Immunonutrition enriched with omega-3 fatty acids, arginine, nucleotides, and soluble fibre. Main source of protein is arginine and casein.
62336892|NCT06128798|ACTIVE_COMPARATOR|Nutren Optimum|A balanced nutritional supplement that enhance body natural defence and support recovery during illness.
62493937|NCT04837664|ACTIVE_COMPARATOR|Nystatin therapy|Participants belonging to the Nystatin group were administered the topical nystatin-based antifungal drug.
62493938|NCT04945096|EXPERIMENTAL|Acetylcysteine + decitabine|Acetylcysteine (1.2g twice a day, oral administration, from day -10 to day 365 after HSCT). Conditional regimen: decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen); semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
62493939|NCT04945096|ACTIVE_COMPARATOR|Standard Treatment|Conditional regimen: semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
62493940|NCT04136067|EXPERIMENTAL|NNC0268-0965|Participants will receive NNC0268-0965
62695615|NCT03499743|EXPERIMENTAL|group 2(celecoxib group)|group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide 2 hours before IUD insertion.
62695616|NCT06385353|EXPERIMENTAL|Association between thrombosis burden and occurrence of PTS|
62695617|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
62695618|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
62695619|NCT04501718|EXPERIMENTAL|Test group|
62137903|NCT05805826|EXPERIMENTAL|C. difficile vaccine formulation 2, Schedule 4, (Phase 2)|Novel vaccine formulation 2
62336893|NCT00849264|EXPERIMENTAL|A|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar
62336894|NCT00849264|ACTIVE_COMPARATOR|B|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with CBP and 5-FU
62336895|NCT00849264|EXPERIMENTAL|C|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar, CBP and 5-FU
62336896|NCT05412394|EXPERIMENTAL|Experimental|This is a one-arm study and the group of subjects are all experimental and will receive drug.
62336897|NCT05094999|EXPERIMENTAL|Intervention group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
62336898|NCT05094999|SHAM_COMPARATOR|Control group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
62336899|NCT05356845||PD group|
62336900|NCT05356845||Control group|
62336901|NCT00780169|EXPERIMENTAL|sorafenib +FOLFIRI|This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.
62493941|NCT04136067|ACTIVE_COMPARATOR|Insulin glargine|Participants will receive insulin glargine
62493942|NCT01348958|EXPERIMENTAL|Post-operative knee replacement|Subjects that have had a hemi knee replacement of one knee at least 8 weeks ago had the post-operative knee scanned using the orthopedic hip application and the Lunar orthopedic knee application.
62493943|NCT03937791|EXPERIMENTAL|Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells|1x10\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.
62493944|NCT02973906|OTHER|ADAPT Self Directed web|ADAPT Self Directed Web. In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum)
62493945|NCT02973906|OTHER|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
62493946|NCT02973906|OTHER|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics
62493947|NCT04668820|EXPERIMENTAL|Children who admit to Pediatric Rehabilitation outpatient clinic|Children who admit to Pediatric Rehabilitation outpatient clinic of the Department of Physical Medicine and Rehabilitation will be evaluated by face to face and virtually by using zoom application via video Pediatric Gait, Arms, Legs and Spine (V-pGALS)
62695620|NCT06639906||Group 1:|Patients with intra-abdominal adhesions
62695621|NCT06639906||Group 2:|
62336902|NCT03744884|EXPERIMENTAL|CP intervention group|Force efforts with haptic feedback in virtual reality for participants with CP.
62336903|NCT03744884|NO_INTERVENTION|CP control group|Regular activity control group, for participants with CP.
62336904|NCT03744884|EXPERIMENTAL|TD intervention group|Force efforts haptic feedback in virtual reality. The intervention will be the same as the CP intervention group but for typically developing participants.
62336905|NCT03744884|NO_INTERVENTION|TD control group|Regular activity control group, same as CP no intervention group, but for typically developing participants.
62336906|NCT04737031|NO_INTERVENTION|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice.
62137904|NCT06518486|EXPERIMENTAL|Foot-ankle exercise group|The group received intervention through health education, simulations, leaflets, and videos about foot-ankle exercise and practised independently for 12 weeks.
62137905|NCT06518486|EXPERIMENTAL|Walking exercise group|The group received intervention through health education, and leaflets about walking exercise and practised independently for 12 weeks.
62336907|NCT04737031|EXPERIMENTAL|Clinician Nudge|Clinicians will receive a nudge via Best Practice Alert within the EMR
62336908|NCT04737031|EXPERIMENTAL|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status.
62336909|NCT04737031|EXPERIMENTAL|Clinician and Patient Nudge|Both strategies described above will be used.
62695622|NCT03517605|EXPERIMENTAL|Exercise for cardiac rehabilitation|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
62695623|NCT02835105|EXPERIMENTAL|Surotomycin 0.5 g|A single oral dose of 0.5 g surotomycin in hard gelatin capsules
62695624|NCT02835105|EXPERIMENTAL|Surotomycin 1 g|A single oral dose of 1 g surotomycin in hard gelatin capsules
62695625|NCT02835105|EXPERIMENTAL|Surotomycin 2 g|A single oral dose of 2 g surotomycin in hard gelatin capsules
62695626|NCT02835105|EXPERIMENTAL|Surotomycin 4 g|A single oral dose of 4 g surotomycin in hard gelatin capsules
62695627|NCT02835105|PLACEBO_COMPARATOR|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
62695628|NCT03583294|EXPERIMENTAL|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
62695629|NCT03583294|EXPERIMENTAL|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
62695630|NCT03583294|EXPERIMENTAL|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
62695631|NCT03583294|EXPERIMENTAL|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
62695632|NCT03884257|EXPERIMENTAL|Passeo-18 Lux treatment group|These patients will be treated with the Passeo-18 Lux (Biotronik).
62695633|NCT03884257|ACTIVE_COMPARATOR|IN.PACT Admiral treatment group|These patients will be treated with the IN.PACT Admiral (Medtronic).
62137906|NCT06518486|ACTIVE_COMPARATOR|Control group|The group that received intervention in the form of health education and leaflets about DM in general.
62137907|NCT02138123|EXPERIMENTAL|IOL-shell technique|In this group, before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
62137908|NCT02138123|ACTIVE_COMPARATOR|Conventional procedure|In this group, a Sensar IOL (AMO Laboratories) was implanted in the capsular bag with the injector system after the lens material was completely removed. The nuclear fragmentation was performed using the Phaco-chop technique, which was then followed by ultrasound emulsification of the nuclear fragments piece by piece. Due to lack of cortical shell within the capsular bag, special care was taken to carry out the emulsification of the last nuclear fragment at a relatively more anterior anatomical position between the iris plan and the anterior chamber.
62336910|NCT03912025||Mild hemodynamic CHD|"Mild severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses, as outlined in the European Society of Cardiology Section on Sports Cardiology consensus guidelines (Budts W, Borjesson M, Chessa M, van Buuren F, Trindade PT, Corrado D, Heidbuchel H, Web G, Holm J, Papadakis M. 2013).~They define functional parameters such as systolic function, oxygen saturation, rhythm disorders, elevated pressure or volume load, etc. to divide patients into 3 hemodynamic groups. Based on their model, we define mild CHD as ones falling into the group that can train at High Intensity exercise levels."
62336911|NCT03912025||Moderate hemodynamic CHD|"Moderate severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses. Based on their model, we define moderate CHD as those that can train at Moderate Intensity."
62336912|NCT04720586|EXPERIMENTAL|triple procedure|lower eyelid retractors plication , transcutaneous blepharoplasty and wedge resection
62336913|NCT04720586|ACTIVE_COMPARATOR|combined procedure|lower eyelid retractors plication and transcutaneous blepharoplasty
62336914|NCT06491628||Acute decompensated heart failure (de novo or as decompensation of chronic heart failure)|This umbrella term includes patients presenting forthe first time with typical symptoms and signs of heart failure(de novo AHF) and also those with worsening of their pre-existing cardiomyopathy (acute decompensated heart failure).
62336915|NCT06491628||Pulmonary edema|It's the real clinical presentation of AHF, typically, signs and symptoms develope rapidly and patients demonstrate severe respiratory distress with tachypnea, orthopnea and pulmonary congestion
62336916|NCT06491628||Hypertensive acute heart failure|the condition is associated with elevated blood pressure with accompanying dyspnea. orthopnea and pulmonary congestion, often in patients with relatively preserved left ventricle ejection fraction
62336917|NCT06491628||cardiogenic shock|severe peripheral hypoperfusion wih subsequent end organs damage,typically it's associated with low blood pressure and low urine output
62336918|NCT06491628||Acute coronary syndrome complicated by heart failure|characterized by complex structural, hemodynamic and neurohormonal interaction need urgent referral for coronary intervention poor outcome
62493948|NCT04404725|EXPERIMENTAL|comfilcon A then samfilcon A|Subjects were randomized to wear comfilcon A for one month then Samfilcon A for one month in this randomized, bilateral cross-over study.
62493949|NCT04404725|ACTIVE_COMPARATOR|samfilcon A then comfilcon A|Subjects were randomized to wear samfilcon A for one month then comfilcon A for one month in this randomized, bilateral cross-over study.
62493950|NCT03617419|OTHER|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System~The following post-market products will be used on label:~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
62493951|NCT00674128|EXPERIMENTAL|Adhesive|Cyanoacrylate tissue adhesive.
62493952|NCT00674128|ACTIVE_COMPARATOR|Suture|Polyglactin 910 suture.
61941455|NCT06079658|EXPERIMENTAL|Intermittent Caloric Restriction (ICR) group:|"Participants in this group will be placed on a diet that is prescribed a 25% reduction from maintenance calories (calories to maintain current body weight) with a dietary protein intake of 1.2 g of protein/kg body mass and remaining calories split evenly between fat and carbohydrate. Participants will adhere to a 25% caloric deficit daily and on every 7th day they will eat their maintenance calories known as a diet refeed and then on the 3rd week they will take a diet break of eating their Maintenance calories for 7 days."
62493953|NCT02757703|ACTIVE_COMPARATOR|somatostatin group|Somatostatin (Somatosan, BAG Health Care GmbH, Lich, Germany) was given by intravenous bolus (250 μg) followed by 250 μg/hour and continued for 3 days in group S.
62493954|NCT02757703|PLACEBO_COMPARATOR|terlipressin group|Terlipressin (Glypressin, Ferring GmbH, Kiel, Germany) was started at 2mg bolus injection and followed by 1 mg infusion every 6 hours for 3 days in group T.
62493955|NCT01559116|EXPERIMENTAL|tiotropium+olodaterol FDC low dose|tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
62493956|NCT01559116|EXPERIMENTAL|tiotropium+olodaterol FDC high dose|tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
62336919|NCT06346457||premenopausal women diagnosed with breast cancer|receiving anti-estrogenic therapy
62493957|NCT01559116|ACTIVE_COMPARATOR|tiotropium low dose|tiotropium low dose; 2 inhalations once daily (a.m. dosing)
62695634|NCT01383876|ACTIVE_COMPARATOR|Collar|Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
62137909|NCT05433415|EXPERIMENTAL|Black Girls Move (BGM) Treatment Condition|BGM is guided by the Anti-Racist Public Health Critical Race Praxis with adaptive mechanisms to support Black adolescent females as they navigate a racist society. The BGM treatment condition will include mothers as active participants in all components of the weekly, 12-session intervention to test the impact of actively leveraging the daughter/mother relationship . Participants in our prior research endorsed the importance of daughters and mothers actively engaging in group meetings together on weekends. Participants set PA and diet goals and self-monitor goal attainment. Dyads participate in structured activities designed to facilitate communication, problem solving, role assignment, and relationship quality. Dyads use a variety of videos, role play, discussion, and activities to achieve session outcomes. The sessions are led by trained facilitators who follow a standardized facilitator manual.
62336920|NCT06346457||postmenopausal women diagnosed with breast cancer, with/out previous hormonal replacement therapy|receiving anti-estrogenic therapy
62336921|NCT06346457||premenopausal healthy women|before menopause
62336922|NCT06346457||postmenopausal healthy women with/out previous hormonal replacement therapy|after menopause
62493958|NCT01559116|ACTIVE_COMPARATOR|tiotropium high dose|tiotropium high dose; 2 inhalations once daily (a.m. dosing)
62336923|NCT00689819|ACTIVE_COMPARATOR|BP < 140/90 mmHg|This arm will target a blood pressure of \< 140/90 mmHg (or \< 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
62336924|NCT00689819|EXPERIMENTAL|BP < 120/80 mmHg|This arm will target a more aggressive blood pressure target of \< 120/80 mmHg.
62336925|NCT06234618||stroke patients|Stroke patients who can walk without assistance in their daily life.
62493959|NCT01559116|ACTIVE_COMPARATOR|olodaterol|one dose only; 2 inhalations once daily (a.m. dosing)
62493960|NCT01559116|PLACEBO_COMPARATOR|placebo|2 inhalations once daily (a.m. dosing)
62493961|NCT00268762|EXPERIMENTAL|Intervention|Argatroban IV Infusion 1 mcg/kg/min for 48 hours
62493962|NCT02717260|SHAM_COMPARATOR|Sham transcranial noise stimulation|subjects are stimulated 3 times with sham transcranial random noise stimulation (tRNS) (Starstim) with a 30 seconds offset
62493963|NCT02717260|ACTIVE_COMPARATOR|1 Active transcranial random noise stimulation|subjects are stimulated 1 time with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes and 2 times with sham tRNS
62493964|NCT02717260|ACTIVE_COMPARATOR|3 Active transcranial random noise stimulation|subjects are stimulated 3 times with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes
62493965|NCT01257984|EXPERIMENTAL|Arm 1|
62493966|NCT01257984|EXPERIMENTAL|Arm 2|
62493967|NCT03116776|EXPERIMENTAL|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
62493968|NCT03116776|ACTIVE_COMPARATOR|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
62493969|NCT00246662|EXPERIMENTAL|Sch A (18 mg/m2 vosaroxin initially)|Once weekly intravenous on days 1, 8, 15 up to 4 cycles
61941456|NCT05343000|EXPERIMENTAL|Severe Comorbid OSA|Newly-diagnosed severe comorbid obstructive sleep apnea subjects will use technology to facilitate remote health coaching through a home-based pulmonary rehabilitation (PR) system
62493970|NCT00246662|EXPERIMENTAL|Sch B (9 mg/m2 vosaroxin initially)|Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
61941457|NCT02685046|EXPERIMENTAL|Intervention|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
62493971|NCT00372996|EXPERIMENTAL|1|CP-751,871 + exemestane Treatment until progression or toxicity
62493972|NCT00372996|ACTIVE_COMPARATOR|2|
62695635|NCT01383876|EXPERIMENTAL|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
62695636|NCT02689557|OTHER|measures of the volumes|Measures of the volumes of the lower limbs. A measure to rest, a measure of effort (walk) and a measure recovery. Intervention.
62695637|NCT04404153|EXPERIMENTAL|Active tDCS|The active tDCS will involve 30-minutes of direct current at intensity of 2 milliamperes (mA).
61941458|NCT03225729|EXPERIMENTAL|CRYOBEAUTY MAINS ET DECOLLETE|"CRYOBEAUTY MAINS ET DECOLLETE is a new technology conceived to treat solar lentigo.~One side left, or right of neckline and/or hands is attributed to this device according to randomization protocol."
61941459|NCT03225729|ACTIVE_COMPARATOR|Liquid nitrogen|Liquid nitrogen is a classic cryotherapy device. One side, either left or right of neckline and/or hands are attributed to this device according to randomization protocol.
61941460|NCT02900976|EXPERIMENTAL|Arm I (RTX)|Patients with newly diagnosed PTLD who achieve a complete response (CR) after induction receive additional rituximab or biosimilar as in induction.
61941461|NCT02900976|EXPERIMENTAL|Arm II (LMP-TC)|Patients with newly diagnosed PTLD who do not achieve a CR to induction, all relapsed patients after induction, and all patients with refractory disease who received rituximab or biosimilar within 90 days according to institutional guidelines, receive allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes IV over 1- 2 minutes on days 0 and 7. Cycle continues for up to 42 days in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after first cycle of cycle allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes receive an additional cycle.
61941462|NCT04669327||Normal|normal subjects
61941463|NCT04669327||Scoliosis|subjects with moderate idiopathic scoliosis
61941464|NCT06271538|EXPERIMENTAL|Skal Pro|Skal Pro in the form of 2g sachet powder contains 10 billion CFU of freeze-dried Lactobacillus plantarum 299v (LP299V) and galactooligosaccharides (GOS).
61941465|NCT06271538|PLACEBO_COMPARATOR|Placebo|Placebo is an oral formulation of inert powder. Placebo and Skal Pro are identical in shape, size, colour, packaging and taste.
61941466|NCT02819869|EXPERIMENTAL|Taking both statin and metformin Group|The experimental group take Lotidon 500mg/ tablet per day and Lipitor 10mg/ tablet per day for two years or until of a recurrence.
62336926|NCT04829019|ACTIVE_COMPARATOR|whole-brain irradiation (WBI) plus Osimertinib|Osimertinib plus WBI, with Osimertinib at a dose of 80 mg once per day.
62336927|NCT04829019|ACTIVE_COMPARATOR|Osimertinib|Osimertinib with WBI sequential therapy, with Osimertinib at a dose of 80 mg once per day.
62336928|NCT03029650|ACTIVE_COMPARATOR|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
62336929|NCT03029650|EXPERIMENTAL|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
62336930|NCT00588250|EXPERIMENTAL|A|
62336931|NCT00588250|NO_INTERVENTION|B|
62336932|NCT01156038|EXPERIMENTAL|Atopy patch test|Atopy patches were applied on healthy volunteer's back for 48 hrs then the patches were removed. Reaction was evaluated 48 and 72 hrs after applying atopy patch test
62336933|NCT02085876||Patients requiring a liver biopsy|
62336934|NCT03957655|EXPERIMENTAL|SHED group|SHED transplantation via peripheral vein: 1x10E6 SHEDs/kg body weight administered via peripheral vein at week 0,4,8,12.
62336935|NCT03957655|NO_INTERVENTION|Control|Standard medication for viral hepatitis and cirrhosis
62336936|NCT02783794|EXPERIMENTAL|BP-C1|Patients randomized to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
62336937|NCT02783794|PLACEBO_COMPARATOR|Placebo|Patients randomized to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
62336938|NCT05390814|EXPERIMENTAL|PET-RMI|
62336939|NCT00870831||Islet Recipient|Subjects that have successfully received and maintained an Islet transplant at Washington University Center for Islet Transplantation
62336940|NCT00870831||Control|subjects that were similar in height, weight and age that did NOT have diabetes to act as the comparative group
62336941|NCT01453569|EXPERIMENTAL|sodium oligo-mannurarate 900mg|
62336942|NCT01453569|EXPERIMENTAL|sodium oligo-mannurarate 600mg|
62336943|NCT01453569|PLACEBO_COMPARATOR|Placebo|
61941467|NCT02819869|NO_INTERVENTION|Non- taking both statin and metformin Group|Non- taking both statin and metformin.
61941468|NCT01360528||Extremely low birth weight|Extremely low birth weight under 1000 gram
62336944|NCT01626352|EXPERIMENTAL|Bendamustine/Ofatumumab|All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
62336945|NCT01667068||Regional Ruhrgebiets Cohort|HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
62493973|NCT00397696|EXPERIMENTAL|[123I] 5-IA|To assess \[123I\] 5IA and SPECT imaging
62493974|NCT02227615|PLACEBO_COMPARATOR|Sugary beverage|Sugary beverage
62493975|NCT02227615|EXPERIMENTAL|Mango beverage|Mango polyphenolics
62493976|NCT00970788|NO_INTERVENTION|verbal group|Verbal description of goals of care.
62493977|NCT00970788|EXPERIMENTAL|Video group|Video decision aid.
61941469|NCT01360528||Very low birth weight|Between 1000-1500 gram babies
61941470|NCT01360528||Low birth weight|Between 1500-2500 gram
62336946|NCT02011126|EXPERIMENTAL|Treatment (imetelstat sodium)|Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 36 courses in the absence of disease progression or unacceptable toxicity.
62137910|NCT05433415|ACTIVE_COMPARATOR|Daughters-Only Comparison Condition (DOCC)|The DOCC runs parallel to the BGM intervention and includes daughters-only group meetings. The DOCC incorporates all components of BGM except Family Systems Theory strategies. Daughters in DOCC will receive PA and diet behavior content based on Anti-Racist Public Health Critical Race Praxis and Social Cognitive Theory with daughter-only group activities. DOCC facilitators will lead group meetings and discussions. All DOCC daughters will self-monitor their progress towards PA goals using Fitbit® and progress towards diet goals using Start Simple with My Plate®.
62137911|NCT06318728||High Performance Triathletes Groups|Triathletes who have been practicing the sport for more than 2 years, can maintain a running pace in triathlon competition below 4 minutes and 10 seconds per kilometer for men and 4 minutes and 30 seconds per kilometer for women, and have a weekly running volume exceeding 35 kilometers.
62336947|NCT02919488|EXPERIMENTAL|Exercise Condition|
62336948|NCT02919488|ACTIVE_COMPARATOR|Control Condition|
62336949|NCT01449682|ACTIVE_COMPARATOR|Ozurdex PRN|0.7 mg intravitreal DEX implant at Visit 1 then PRN for duration of trial (48 weeks) if evidence of fluid on OCT
62336950|NCT01449682|ACTIVE_COMPARATOR|Ozurdex Q16 weeks|0.7 mg intravitreal DEX implant at Visit 1 then Q16 weeks
62336951|NCT03614169|EXPERIMENTAL|Direct HIS-pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS or it is not possible to correct the LBBB, a left ventricular (LV) lead is implanted instead.
62336952|NCT03614169|ACTIVE_COMPARATOR|Biventricular pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation \< 2x pacing threshold)
62336953|NCT03407924|EXPERIMENTAL|Intervention aerobic exercise (AER)|Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
62336954|NCT03407924|ACTIVE_COMPARATOR|rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
62336955|NCT03407924|NO_INTERVENTION|control (C)|Healthy volunteers' responsiveness to exercise and activity levels will be determined to detect TBI effects.
62336956|NCT01921933|EXPERIMENTAL|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
62336957|NCT03848221|EXPERIMENTAL|Systane Complete|Subjects in this group will use Systane Complete before, during, and after contact lens use.
62336958|NCT03848221|ACTIVE_COMPARATOR|Sensitive Eyes Rewetting Drops|Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
62336959|NCT03848221|NO_INTERVENTION|No Treatment|Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
62336960|NCT04599205|EXPERIMENTAL|Microneedling group A|"Patients will be subjected to the following:~Combined laser (power=3.6 mJ) and topical tranexamic acid (TXA) (one finger unit) gel on the right half of the face.~Combined microneedling (by dermapen) and topical TXA gel only on the left half. Self application of topical TXA gel (2 finger units) on both sides on daily base."
61941471|NCT03637023|EXPERIMENTAL|Virtual Reality|Virtual Reality will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
61941472|NCT03637023|ACTIVE_COMPARATOR|Exercise Therapy|Exercise Therapy will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
61941473|NCT02081183|EXPERIMENTAL|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m\^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
62493978|NCT01677728||arm A|patients received chemotherapy alone
62137912|NCT06318728||Low Performance Triathletes Groups|Triathletes who have completed at least 2 races, maintain a running pace in triathlon competition above 4 minutes and 50 seconds per kilometer for men and 5 minutes and 10 seconds per kilometer for women, and have a weekly running volume below 30 kilometers.
62336961|NCT04599205|EXPERIMENTAL|Laser group B|"Patients will be subjected to the following:~Combined laser(power=3.6 mJ) and topical TXA gel (one finger unit) on the right half.~Laser (power=3.6 mJ) only on the left one."
62493979|NCT01677728||arm B|patients received target therapy combined with chemotherapy
62493980|NCT00594503|EXPERIMENTAL|Hyperbaric oxygen therapy-TBI|Low pressure hyperbaric oxygen therapy
62493981|NCT01712568|EXPERIMENTAL|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
62493982|NCT01712568|EXPERIMENTAL|Reference Product|Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
62493983|NCT02428348|EXPERIMENTAL|Interview|Interview of epilepsy patients and their family about their opinion on different EEG-cap models in development.
62695638|NCT04404153|SHAM_COMPARATOR|Sham tDCS|Sham stimulation consists of the direct current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining application period.
61941474|NCT02081183|ACTIVE_COMPARATOR|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m\^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m\^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
62493984|NCT04789330|ACTIVE_COMPARATOR|Norepinephrine|Norepinephrine continuous infusion as the first line vasopressor
62493985|NCT04789330|ACTIVE_COMPARATOR|Phenylephrine|Phenylephrine continuous infusion as the first line vasopressor
62336962|NCT04599205|EXPERIMENTAL|Gel group C|patients will be subjected to: Daily application of topical TXA gel (2 finger units) on both face sides.
62493986|NCT02503618||HIV-negative YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-negative
62493987|NCT02503618||HIV-positive YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-positive
62493988|NCT00660387|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
62493989|NCT00660387|ACTIVE_COMPARATOR|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
62493990|NCT05748938|EXPERIMENTAL|RD14-01 treated group|Subjects who meet the enrollment conditions will receive intravenous infusion of anti--ROR1 CAR-T Cells after lymphodepleting therapy.
62493991|NCT00414479||children 9-12 years of age|Children with schistosomiasis, malaria and anaemia
62493992|NCT02230930|ACTIVE_COMPARATOR|Massage with a spiky ball|Subjects are instructed to massage the apomorphine-induced skin reactions with a spiky ball 3 times a day for 2 minutes for 14 days.
62493993|NCT02230930|ACTIVE_COMPARATOR|Hydrocortisone cream 1%|Subjects are instructed to apply hydrocortisone cream 1% once daily for 14 days.
62137913|NCT06318728||Control Group|Physically active individuals, aged between 17 and 52 years, who do not engage in regular running.
62695639|NCT06637722||Patients with adrenal insufficiency and their relatives|
62137914|NCT02919787|ACTIVE_COMPARATOR|Surgery and then postoperative adjuvant chemotherapy|Surgery and then postoperative adjuvant chemotherapy
62493994|NCT02230930|ACTIVE_COMPARATOR|Subcutaneous hydrocortisone 10mg|Subjects are instructed to administer subcutaneous hydrocortisone (Solu-Cortef 10mg) prior to apomorphine via the subcutaneous infusion line which is used for administration of apomorphine, for 14 days.
62493995|NCT02230930|ACTIVE_COMPARATOR|Apomorphine 0.25% (2.5mg/ml)|Subjects are instructed to dilute apomorphine 0.5% (5mg/ml) with the same volume of physiologic saline (NaCl 0.9%) to 0.25% (2.5mg/ml). Apomorphine will be infused subcutaneously for 14 days.
62493996|NCT04943822|PLACEBO_COMPARATOR|conventional education service program|Including the written and verbal health education on preoperative preparation, stoma surgery and postoperative stoma care. At discharge, ET nurses offered teaching information and support for patients, including selection of pouching appliances, drug instructions, health education At each outpatient follow-up, both stomas and patients needed to be assessed. The condition of stoma and peristomal skin, nature and volume of effluent, date of pouch appliances and stoma complications were recorded by ET nurses.
61941475|NCT04378907|ACTIVE_COMPARATOR|Cigarette Smokers: 0 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
61941476|NCT04378907|EXPERIMENTAL|Cigarette Smokers: 4 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 6 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
62695640|NCT02624856|EXPERIMENTAL|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
62695641|NCT02624856|ACTIVE_COMPARATOR|Standard bupivacaine plus dexamethasone|Bupivacaine 0.5% 10 mL plus 2 mg dexamethasone for quadriceps sparing femoral nerve block and bupivacaine 0.25% 20 mL plus 2 mg of dexamethasone for posterior knee compartment periarticular injection.
62695642|NCT03085953|EXPERIMENTAL|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
62137915|NCT02919787|EXPERIMENTAL|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
62137916|NCT00370942|PLACEBO_COMPARATOR|GW823093C A|A=45 mg
62137917|NCT00370942|PLACEBO_COMPARATOR|GW823093C B|B=30 mg
62137918|NCT00370942|PLACEBO_COMPARATOR|GW823093C C|C=15 mg
62137919|NCT05027581|EXPERIMENTAL|Chondrochymal® group|Subjects will be IA injected at the target knee with 3 mL of Chondrochymal® containing 5.0 x 107 BM-MSCs in lactated Ringer's solution at Day 1.
62137920|NCT05027581|ACTIVE_COMPARATOR|Hya-Joint Plus Synovial Fluid Supplement|Hya-Joint Plus Synovial Fluid Supplement containing 60 mg/3 mL of hyaluronic acid will be IA administrated into the subject's target knee at Day 1.
62137921|NCT05321082|EXPERIMENTAL|BI 1015550 low dose|
62137922|NCT05321082|EXPERIMENTAL|BI 1015550 high dose|
62137923|NCT05321082|PLACEBO_COMPARATOR|Placebo|
62336963|NCT04838106||Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency with confirmed COVID-19 between 1st January to 1st July 2020.
62336964|NCT04838106||Non Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency without confirmed COVID-19 between 1st July 2016 and 1st July 2020.
62336965|NCT06042621||Participants|Participants will be selected from patients who are admitted to an intensive care unit (ICU) at the University of Wisconsin Hospital, Unity Point-Meriter Hospital, Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, or Northwestern Memorial Hospital.
62336966|NCT06042621||Surrogates|Surrogate participants will be the primary surrogate for an eligible patient.
62493997|NCT04943822|EXPERIMENTAL|mobile care device|The participants in the intervention group were given the same routine care as the control group pre- and postoperatively. ET nurses taught patients and their family members how to use the home care mobile app before discharge. The home care mobile app was designed and developed for the discharged stoma patients by the research team and an information technology company in March 2021. Patients could receive stoma care from ET nurses through this mobile app at home, not just going to an outpatient clinic. The Major function modules of this mobile app were as follows: (a) appointment: The app users were able to complete the basic personal and medical information and make an appointment with the ET nurse; (b) photograph diagnosis: The ET nurses could make a diagnosis based on the patients' uploaded stoma photographs; and (c) consultation: Patients were able to contact their ET nurses for help and support. This mobile app was used to supplement the outpatient follow-up.
62695643|NCT03085953|OTHER|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
62695644|NCT01128517|EXPERIMENTAL|Bahavioral|Education about complementary food given to mothers
62695645|NCT03840889||Women with a severe late PPH|Women with a severe late PPH will be recruited prospectively after verification of the inclusion criteria by a gynecologist-obstetrician or the investigating midwives, who will provide the patients information about the study and include them unless they object
62695646|NCT06638775|EXPERIMENTAL|EXPERIMENTAL GROUP|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
62695647|NCT06638775|EXPERIMENTAL|CONTROL GROUP|Globus elite intervention: is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
62695648|NCT04463355|NO_INTERVENTION|Control group: usual verbal instructions|In this group, caregivers receive, after completing the test and prior to discharge, the usual verbal information and recommendations about AGE following the guidelines of the Spanish Society of Pediatric Emergencies. The instructions are always given by one of the main investigators to provide homogeneity in the information
62695649|NCT04463355|EXPERIMENTAL|Intervention group: video discharge instructions|Additionally to the verbal information, patients are shown a short 2-minute video providing the same information about AGE that would be given by verbal information.
62695650|NCT06645379|EXPERIMENTAL|reproductive disease|Platelet-rich Plasma injection
62695651|NCT04388228|EXPERIMENTAL|Extended audit and feedback|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback."
62695652|NCT04388228|ACTIVE_COMPARATOR|Basic feedback|In the past, all GPs received basic feedback on the level of registration in the EHR and this form of feedback will still be provided in the control group. By providing all GPs a basic level of feedback, we do not change the former protocol and all GPs will receive the opportunity to improve their registration performance. Only the way of receiving feedback is more straightforward, the GP needs to login to HealthStat.be.
62695653|NCT04873557|EXPERIMENTAL|Copper Intervention|Intervention with copper-based surfaces plus copper-enriched linen
62695654|NCT04873557|NO_INTERVENTION|Control Group|Control group without copper intervention
62137924|NCT02409680|ACTIVE_COMPARATOR|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) \[also known as acetylsalicylic acid (ASA)\] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
62336967|NCT06042621||ICU Team Members|ICU Team Member participants will be members of the hospital staff providing care for an eligible patient.
62336968|NCT01583998|ACTIVE_COMPARATOR|e-MBC|Patients will receive e-MBC
62336969|NCT01583998|NO_INTERVENTION|Treatment as Usual Control|Patients receive standard treatment
62695655|NCT03579316|ACTIVE_COMPARATOR|Arm I (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62695656|NCT03579316|EXPERIMENTAL|Arm II (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61941477|NCT04378907|EXPERIMENTAL|Cigarette Smokers: 15 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
61941478|NCT04378907|EXPERIMENTAL|Cigarette Smokers: 30 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
62137925|NCT02409680|PLACEBO_COMPARATOR|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
62137926|NCT06652360|ACTIVE_COMPARATOR|Treatment|1 treatment of chemical debridement will be applied in this arm at initiation visit
62137927|NCT06652360|ACTIVE_COMPARATOR|Control|In the control arm wound debridement by curettage will be performed
62137928|NCT05719519|OTHER|Smokers|
62137929|NCT05719519|EXPERIMENTAL|Non smokers|
62137930|NCT03446521||Test group|Patients undergoing liver transplantation, no intervention (study-specific) is planed
62336970|NCT06553196|EXPERIMENTAL|Prevention group|Web-app with 6 weekly coping \& substance modules
62336971|NCT06553196|NO_INTERVENTION|Control Group|No access to web-app
62336972|NCT05388162|OTHER|coposcopy|patients undergoing colposcopy will have images taken of the cervix with a standard colposcope and the Mobile colposcope. de-identified images from both devices will then be entered into a custom colposcopic image evaluation program. Images will then be randomly evaluated by expert colposcopists as normal, abnormal or cannot evaluate. On abnormal images, the most abnormal point on the images will be marked as teh recommended biopsy site. Scoring for images from the standard colposcope will be compared with that for the Mobile Colposcope.
62493998|NCT04092595|EXPERIMENTAL|PF-06651600 and Rosuvastatin|Period 1 is 4 days in length. On Day 1 of Period 1 participants will receive a single dose of Rosuvastatin 10 mg given as a tablet orally. Period 2 is 11 days in length and will immediately follow Period 1 with no washout. In Period 2, participants will be dosed with oral 200 mg PF-06651600 once-daily (QD) for 7 days. On Day 8 of Period 2, a single dose of 10 mg Rosuvastatin oral tablet will be administered following administration of the 200-mg dose of PF-06651600. Dosing with oral 200 mg PF-06651600 QD will continue until Day 10 of Period 2.
62137931|NCT03446521||Control Group|Respective organ donors of the included liver recipients, no intervention (study-specific) is planed
62493999|NCT00635687|EXPERIMENTAL|Fibroscan|
62695657|NCT03579316|EXPERIMENTAL|Arm III (ceralasertib, olaparib)|Patient receive ceralasertib tablets by PO BID each day on Days 1-14. You will also take olaparib tablets by PO BID each day on Days 1-28.
62137932|NCT04717570|EXPERIMENTAL|TRIA Mitral Valve|Patients receiving the Foldax Mitral Valve
62137933|NCT00697060|EXPERIMENTAL|Stage 1/2|Imexon plus docetaxel
62137934|NCT01341132||Suspected Liver Disease|"1. Alpha-feto protein \> 400 ng / mL or~2. prior ultrasound with mass suspicious for hepatic malignancy or.~3. clinical risk of hepatocellular carcinoma or~4. prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma"
62336973|NCT06115161|EXPERIMENTAL|Gait Analysis|Gait analysis with the instrumented orthosis as well as a reference sysmtem (Vicon Vantage 5).
62336974|NCT02696915|PLACEBO_COMPARATOR|Placebo|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of saline 0.9%. Then intrathecal medications will be administered.
62336975|NCT02696915|ACTIVE_COMPARATOR|Bupivacaine|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of 0.25% bupivacaine. Then intrathecal medications will be administered.
62137935|NCT00674752|EXPERIMENTAL|A|
62336976|NCT03375359||cfDNA screening|Pregnant women who are referred for FTS or for further follow-up examinations in case of a suspected anomaly or increased nuchal translucency at 11-13 weeks' gestation can be recruited for this study.
62336977|NCT00252122|EXPERIMENTAL|1|Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.
62336978|NCT02078713|EXPERIMENTAL|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
62336979|NCT02078713|NO_INTERVENTION|Usual Care (Control)|Patients in this arm will receive usual family planning care.
62336980|NCT03046628|EXPERIMENTAL|Patients with diabetic feet ulcers|Each patient will be examined twice, first with TcPO2 (TCM400, Radiometer Medical ApS, Denmark) and then with a green laser (harmonic of continuous neodymium-doped yttrium aluminium garnet laser 532-nm wavelength and fast camera (PixelLink PLE531) system.
62336981|NCT02804412|ACTIVE_COMPARATOR|Control group|Patients received a standard, house-typical aphasia therapy in single and group therapy sessions
62494000|NCT00521508|OTHER|1|Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
62494001|NCT00521508|OTHER|2|Patient affected by Berger's disease with normal rate of Ig A
62494002|NCT00521508|OTHER|3|Healthy volunteers
62695658|NCT06193239|EXPERIMENTAL|OWL-EVO1|"After confirming full eligibility, individuals will all be administered the OWL-EVO1 probe intravenously.~This includes:~* Patients diagnosed with histopathologically confirmed lung cancer.~* Individuals with a CT-proven absence of lung cancer, including those with relevant comorbidities and risk factors such as smoking, COPD, asthma, extrapulmonary malignant tumours, active lung infection/inflammation and other chronic respiratory diseases."
62695659|NCT05709327|OTHER|Single-arm observational study|All participants in the study will be provided a smart ring to wear for the entire duration of the pregnancy.
62137936|NCT00674752|EXPERIMENTAL|B|
62137937|NCT00674752|PLACEBO_COMPARATOR|C|
62137938|NCT05848713|EXPERIMENTAL|Therapeutic-Dose Heparin|Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization.
62137939|NCT05848713|NO_INTERVENTION|Usual Care|Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols.
62137940|NCT04503681|ACTIVE_COMPARATOR|Standard introduction video|
62137941|NCT04503681|EXPERIMENTAL|Enhanced compassion video|
62137942|NCT00175812|EXPERIMENTAL|ATRA plus valproic acid plus theophyllin|ATRA for 14 days, continuous treatment with valproic acid and theophyllin
62137943|NCT03213145|EXPERIMENTAL|Part 1|
62137944|NCT03213145|EXPERIMENTAL|Part 2|
62137945|NCT03739866|EXPERIMENTAL|Part A: Lenacapavir 20 mg|Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
62137946|NCT03739866|EXPERIMENTAL|Part A: Lenacapavir 50 mg|Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
62137947|NCT03739866|EXPERIMENTAL|Part A: Lenacapavir 150 mg|Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
62137948|NCT03739866|EXPERIMENTAL|Part A: Lenacapavir 450 mg|Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
62137949|NCT03739866|EXPERIMENTAL|Part A: Lenacapavir 750 mg|Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
62494003|NCT03337893||Breastfed|The kids who breastfed
62494004|NCT03337893||non-breastfed|The kids who did not breastfed
62494005|NCT04797936|ACTIVE_COMPARATOR|Treatment group BNO 1030|BNO 1030
62494006|NCT04797936|OTHER|Control group|Standard care
62695660|NCT05158699|ACTIVE_COMPARATOR|topical bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week.
62695661|NCT05158699|ACTIVE_COMPARATOR|subconjunctival triamcinolone acetonide|one subconjunctival injection of 10 mg triamcinolone acetonide during cataract surgery (TA, Triesence/Vistrec) in the inferotemporal quadrant, 6mm from the limbus.
62695662|NCT05158699|ACTIVE_COMPARATOR|intracameral ketorolac|intracameral injection of ketorolac tromethamine solution during cataract surgery (Omidria). A 4ml vial of Omidria (ketorolac concentration 2.88mg/ml) is added to 500ml of the irrigation solution used during cataract surgery, resulting in a ketorolac concentration of 0.023mg/ml. At the end of the surgery, the anterior chamber will be filled with the ketorolac solution.
62336982|NCT02804412|EXPERIMENTAL|CIAT-group|Patients received constraint-induced aphasia therapy.
62336983|NCT02804412|ACTIVE_COMPARATOR|communication treatment group (CTG)|Patients received aphasia group therapy without constraints
62336984|NCT03689504|ACTIVE_COMPARATOR|Standard of Care|The standard of care is an intensive individualized home-based nutrition education program, together with a home food ration and micronutrient supplement, delivered by frontline workers for 6 months.
62336985|NCT03689504|EXPERIMENTAL|Home Garden Intervention|This arm adds an 8 month individualized home-based family garden intervention to the existing standard of care (home-based nutrition education)
62336986|NCT01488318|EXPERIMENTAL|CETUXIMAB AND DASATINIB|"Cetuximab on a standard weekly schedule (see Section 6.2). Group 1 (subjects more than 2 weeks post last dose of Cetuximab): Loading dose of 400 mg/m2 on cycle 1, day 1 then 250 mg/m2 IV weekly.~Group 2 (subjects last Cetuximab treatment within 2 weeks): Cycle 1 will start at a dose of 250 mg/m2 Dasatinib 150 mg once daily without interruption. On the FIRST cycle (1 cycle is 3 weeks) dasatinib will start 3 days after the cetuximab loading dose (i.e. cycle 1, day 4) to avoid headache as shown on the previous phase I trial.~Treatment will continue until progression."
62336987|NCT00696111|EXPERIMENTAL|1A|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive estrogen plus placebo for another 6 weeks.
62336988|NCT00696111|EXPERIMENTAL|1B|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive progesterone plus placebo for another 6 weeks.
62494007|NCT01721772|EXPERIMENTAL|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
62494008|NCT01721772|ACTIVE_COMPARATOR|Dacarbazine, 1000 mg/m^2|Participants received dacarbazine, 1000 mg/m\^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
62494009|NCT01847950|EXPERIMENTAL|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
62494010|NCT01847950|PLACEBO_COMPARATOR|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
62695663|NCT05158699|ACTIVE_COMPARATOR|subconjunctival triamcinolone acetonide & intracameral ketorolac|one subconjunctival injection of 10 mg triamcinolone acetonide \& intracameral injection of ketorolac tromethamine solution (Omidria; 0.023mg/mL) during cataract surgery.
62494011|NCT00838162|EXPERIMENTAL|TMC310911/rtv 75/100 mg twice daily|TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14
62494012|NCT00838162|EXPERIMENTAL|TMC310911/rtv 150/100 mg twice daily|TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14
62695664|NCT05963984|EXPERIMENTAL|Arm A|Participants will receive 360 mg of samuraciclib on cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onwards in combination with fulvestrant administered monthly, plus an additional dose at Cycle 1 Day 15.
62695665|NCT05963984|EXPERIMENTAL|Arm B|Participants will receive 240 mg of samuraciclib on cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onwards in combination with fulvestrant administered monthly, plus an additional dose at Cycle 1 Day 15.
62695666|NCT05963984|EXPERIMENTAL|Arm C|Participants will receive fulvestrant administered monthly, plus additional dose at Cycle 1 Day 15.
61941479|NCT03364569||Participant with tranexamic acid.|The investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects. The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
62695667|NCT02054728|EXPERIMENTAL|RHC and IMT|
61941480|NCT03364569||Participant without tranexamic acid.|This group concerns participants followed without acid tranexamic treatment. Investigators will observe the postoperative practices and complications observed, according to the surgical habits.
62336989|NCT00696111|EXPERIMENTAL|3|Randomized to receive CPAP (continuous positive airway pressure) treatment for 6 weeks.
62336990|NCT02855684|EXPERIMENTAL|Toujeo - insulin glargine (U300)|Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
62336991|NCT02855684|ACTIVE_COMPARATOR|Lantus - insulin glargine|Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
62336992|NCT06154031|EXPERIMENTAL|stroke survivors|
62336993|NCT02562248|ACTIVE_COMPARATOR|Intervention|Randomization is at the clinic level. Two clinics will be randomized to receive the revised module to screen for anxiety and ADHD among children who present with parental concern of disruptive behaviors. Parents who have concerns of disruptive behaviors will trigger the module and be administered both the Vanderbilt for ADHD and Screen for Childhood Anxiety Related Emotional Disorders (SCARED) screening tools.
62336994|NCT02562248|ACTIVE_COMPARATOR|Control|Randomization is at the clinic level. Two clinics will be randomized as the control clinics meaning that they will continue to provide care as usual for families who present to the clinic with concerns of disruptive behaviors. Currently, CHICA administers the Vanderbilt for ADHD screening tool.
62494013|NCT00838162|EXPERIMENTAL|TMC310911/rtv 300/100 mg twice daily|TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14
62695668|NCT06640530|EXPERIMENTAL|BCD-263|BCD-263 will be administered during main period and open-label period
62695669|NCT06640530|ACTIVE_COMPARATOR|Opdivo|Opdivo will be administered during main period
62695670|NCT03073512|OTHER|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
62336995|NCT02159326|EXPERIMENTAL|Arm1|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
62695671|NCT00400140|EXPERIMENTAL|A|
62695672|NCT06440837|NO_INTERVENTION|wait-list|participant in this group will not accept any psychological intervention content during experimental period. After the study, the intervention will be distributed for free.
62695673|NCT06440837|EXPERIMENTAL|IMB stress self-management health education|"Participants in this arm will receive an online IMB stress self-management health education program. The health education intervention program contains eight module topics."
62695674|NCT06014801|EXPERIMENTAL|Low intensity|12 mL/kg/hr
62695675|NCT06014801|ACTIVE_COMPARATOR|Medium intensity|25 mL/kg/hr
62695676|NCT01146821|NO_INTERVENTION|Standard care|Standard care
62695677|NCT01146821|ACTIVE_COMPARATOR|standard care + 0.20gm/kg fish oil|standard care + 0.20gm/kg fish oil
61941481|NCT03325270|EXPERIMENTAL|ferrous fumarate|labeled iron as Ferrous Fumarate
62336996|NCT02159326|EXPERIMENTAL|Arm2|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
62494014|NCT00838162|EXPERIMENTAL|TMC310911/rtv 300/100 mg once daily|TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14
62494015|NCT02586324|OTHER|global medium|
62494016|NCT02586324|EXPERIMENTAL|SSM|
62494017|NCT02484508|EXPERIMENTAL|Guli capsule|Guli capsule, the tested drug of this study
62494018|NCT02484508|ACTIVE_COMPARATOR|Kangguzengsheng capsule|Kangguzengsheng capsule, a CFDA approved drug for articular genu osteoarthritis,is adopted as active comparator in this study
62494019|NCT01790308|ACTIVE_COMPARATOR|CSII|continuous subcutaneous insulin infusion for 2-4 weeks
62695678|NCT01146821|ACTIVE_COMPARATOR|standard care + 0.50 gm/kg fish oil|standard care + 0.50 gm/kg fish oil
62695679|NCT01931410|PLACEBO_COMPARATOR|sublingual|400 microgram mısoprostol will be administered sublıngually before elective caesarean
62695680|NCT01931410|PLACEBO_COMPARATOR|rectal|rectal 600 mgr misoprostol will be administered
62695681|NCT01931410|NO_INTERVENTION|synpitan|
62695682|NCT06626516|EXPERIMENTAL|Part 1A: Safety Lead-in|"Phase I safety lead-in followed by a phase II trial with 6-month PFS rate as the preliminary efficacy endpoint.~We will conduct a single-arm of 18 patients treated with combination therapy (tebentafusp-tebn with hepatic IE with GM-CSF), with the first cohort of six patients being enrolled in a safety lead in. All patients will receive a 4-week induction course of tebentafusp-tebn alone (Cycle 1) using the approved step-up dosing regimen. Should the 4th dose be tolerated well as an outpatient, patients will receive their first IE treatment on Cycle 2 week 1 followed by continued weekly tebentafusp-tebn on weeks 2, 3, and 4 of Cycle 2. Should Cycle 2 be well tolerated, patients may receive both tebentafusp-tebn and IE on Week 1 of subsequent cycles, with tebentafusp administered alone on weeks 2-4 of subsequent cycles."
62695683|NCT06626516|ACTIVE_COMPARATOR|Part 1B: Combination|"If the safety and preliminary efficacy in Part 1A are met, we will then proceed with a randomized phase II trial.~52 patients will be randomized in a 2:1 ratio to receive tebentafusp-tebn in combination with hepatic IE or tebentafusp-tebn alone, with PFS as the primary endpoint. Patients randomized to tebentafusp-tebn + IE arm will be treated as Part 1A."
62695684|NCT06626516|ACTIVE_COMPARATOR|Part 1B: Tebentafusp-tebn alone|"If the safety and preliminary efficacy in Part 1A are met, we will then proceed with a randomized phase II trial.~52 patients will be randomized in a 2:1 ratio to receive tebentafusp-tebn in combination with hepatic IE or tebentafusp-tebn alone, with PFS as the primary endpoint. Patients randomized to tebentafusp-tebn alone will receive weekly treatment using the approved step-up dosing regimen."
62695685|NCT06626516|ACTIVE_COMPARATOR|Part 2: Efficacy of Combo|To assess the efficacy of tebentafusp-tebn in sequence with TACE in HLA-A\*0201-positive patients with metastatic uveal melanoma to the liver
61941482|NCT03325270|EXPERIMENTAL|ferrous fumarate and GOS|labeled ferrous fumarate + prebiotics
61941483|NCT03325270|EXPERIMENTAL|ferrous sulfate and GOS|labeled ferrous sulfate + prebiotics
62336997|NCT04762147|EXPERIMENTAL|Paracetamol group-P|Paracetamol 15mg/Kg was dministered 30 minutes before the start of surgery
62695686|NCT01250327|EXPERIMENTAL|Melody|insertion of a pulmonic valved stent
62695687|NCT01250327|ACTIVE_COMPARATOR|Bare stent|insertion of a bare metal stent
62336998|NCT04762147|ACTIVE_COMPARATOR|Fentanyl group-F|Fentanyl 2mcg/kg was administered at the time induction of anaesthesia
62336999|NCT05012852|EXPERIMENTAL|VagiVitalAC|
62337000|NCT05012852|NO_INTERVENTION|No treatment|
62494020|NCT01790308|ACTIVE_COMPARATOR|Liraglutide|continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks
62494021|NCT04661202|EXPERIMENTAL|Exercise training group|"* Aerobic exercise~* Resistance exercise (including pelvic floor muscle training with biofeedback)~* Stretching exercise~* Home exercise"
62494022|NCT04661202|NO_INTERVENTION|Control group|"・Usual care~After baseline assessment, the participants will receive health and lifestyle advices related to bowel symptoms, which include maintaining moderate physical activity, healthy diet, and ideal defecation posture, and establishing a personal bowel schedule and other behavioral changes that promote regular bowel movements.~Upon request, the participants will be provided with the same intervention program as the exercise training group after 8 weeks participation."
62695688|NCT01250327|ACTIVE_COMPARATOR|Surgery|conventional surgery methode.
62695689|NCT06298058|EXPERIMENTAL|SIBP-A13|SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion).
62695690|NCT04416958||CIED for cardiac resynchronisation|Patients implanted with an CIED for cardiac resynchronisation aiming to avoid pacing induced ventricular dyssynchrony, e.g. His bundle pacing, LBB-area pacing, CRT. These different implanted types of devices may be further analysed as subgroups.
62695691|NCT05050279|PLACEBO_COMPARATOR|Placebo|Delgocitinib placebo capsule
62695692|NCT05050279|EXPERIMENTAL|Active dose 1|Delgocitinib capsule (Dose 1)
62695693|NCT05050279|EXPERIMENTAL|Active dose 2|Delgocitinib capsule (Dose 2)
62494023|NCT05951205|EXPERIMENTAL|Exa-cel|Participants will receive a single infusion of exa-cel (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene) through a central venous catheter.
62494024|NCT01656915||Healthy men|Healthy male subjects with normal weight
62695694|NCT05050279|EXPERIMENTAL|Active dose 3|Delgocitinib capsule (Dose 3)
62695695|NCT05050279|EXPERIMENTAL|Active dose 4|Delgocitinib capsule (Dose 4)
62695696|NCT05583864|ACTIVE_COMPARATOR|CONDUIT Porous Titanium Spinal Cage|Solid titanium spinal cage, infused with microscopic, porous canals to allow for adhesion and proliferation of bone graft factors contributing to spinal ossification, and ultimately, spinal fusion between vertebrae demonstrating instability.
62695697|NCT05583864|ACTIVE_COMPARATOR|PROTI 360 Titanium-Coated PEEK Spinal Cage|Spinal cage composed primarily of a medical-grade polymer: poly-ether-ether-ketone (PEEK), with a titanium coating that is etched, but lacking porous features. These design features also attempt to stimulate spinal vertebrae fusion through bone-graft ossification and enhance vertebral stability.
62695698|NCT06594770|EXPERIMENTAL|ART|
62695699|NCT06594770|ACTIVE_COMPARATOR|HALL technique|
62695700|NCT06569732|EXPERIMENTAL|Homemade oral nutrition supplements|Homemade oral nutrition supplements, 200 ml/day
62695701|NCT06569732|ACTIVE_COMPARATOR|Commercial oral nutrition supplements|Commercial oral nutrition supplements, 200 ml/day
62695702|NCT03379870|EXPERIMENTAL|EAS Arm|"Subjects who receive a CI and present with a post-operative LFPTA of ≤ 75 dB HL.~Electric Acoustic Speech Processor: Electric-acoustic stimulation (EAS) fitting."
62695703|NCT03379870|EXPERIMENTAL|FES Arm|"Subjects with pre-operative low frequency hearing who receive a CI and present with a post-operative LFPTA of \> 75 dB HL.~Electric Acoustic Speech Processor: Full-electric stimulation (FES) fitting"
62494025|NCT01656915||Compromised men|pre-diabetic overweight, male subjects
62695704|NCT03170986|EXPERIMENTAL|Multisectoral Agriculture and Microfinance Arm|
62695705|NCT03170986|NO_INTERVENTION|Control Arm|
62695706|NCT03809000|ACTIVE_COMPARATOR|Salvage Radiation Therapy (SRT) + Standard androgen deprivation therapy (ADT)|"Standard ADT: 24 months of GnRH analog (any formulation) with optional 1-4 months of bicalutamide (50 mg/day).~SRT: Starting within 0-70 days of initiation of GnRH analog, 66.6-70.2 Gy as 1.8 Gy/fraction in 37-39 fractions or 66.0-70.0 Gy as 2.0 Gy/fraction in 33-35 fractions lasting approximately 7-8 weeks, and optional lymph node boost."
62695707|NCT03809000|EXPERIMENTAL|Salvage Radiation Therapy + Enhanced ADT|"Enhanced ADT: 24 months of GnRH analog (any formulation) with 24 months of enzalutamide (160 mg/day).~SRT: Starting within 0-70 days of initiation of GnRH analog, 66.6-70.2 Gy as 1.8 Gy/fraction in 37-39 fractions or 66.0-70.0 Gy as 2.0 Gy/fraction in 33-35 fractions lasting approximately 7-8 weeks, and optional lymph node boost."
62494026|NCT01731028||Somatropin|Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization
62494027|NCT04049097|EXPERIMENTAL|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
62494028|NCT06246591|ACTIVE_COMPARATOR|Extracorporeal Shockwave Therapy (Group A)|Patients of this group were invited to our department's outpatient clinics on a weekly basis, for a total of five sessions (5 weeks), lasting approximately 20 minutes each. Treatment energy and frequency were established following the recommendations and guidelines of the International Society for Medical Shockwave Treatment (ISMST).
62695708|NCT05987813|EXPERIMENTAL|FGID|Patients with a FGID
62695709|NCT05987813|EXPERIMENTAL|Non-FGID|Patients without a FGID
61941484|NCT05427162|EXPERIMENTAL|Prostacyclin Receptor Agonist|Participants in Cohort 1-7 will receive multiple doses of prostacyclin receptor agonist of formulation 1 in treatment period 1, followed by a single dose of various other formulations (formulation 2, 3, and 4) in treatment period 2. Cohort 7 will be optional. Doses in Cohorts 4, 5, 6 and cohort 7 will be based on PK, safety and tolerability data of previous 3 cohorts (preceding cohorts).
61941485|NCT02122432|EXPERIMENTAL|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association and sends them to the dermatologist using a secured email server.~Dermatologist answer is standardized."
61941486|NCT02122432|NO_INTERVENTION|Usual care|Usual care for dermatologic conditions requiring an expertise from a dermatologist involves the general practitioner 1) giving the patient a paper letter containing at least the following information: date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes) and 2) telling him to see the dermatologist of his choice (patient manages his appointments alone).
62494029|NCT06246591|ACTIVE_COMPARATOR|Mesotherapy (Group B)|Patients in this group underwent mesotherapy treatment at our outpatient clinics with Thiocolchicoside fl 4mg/2ml and Mepivacaine fl 10mg/1ml, once a week, for a total of five sessions (5 weeks), lasting about 15 minutes each.
62494030|NCT02933892|ACTIVE_COMPARATOR|Transradial Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the arm access site (transradial access).
62494031|NCT02933892|ACTIVE_COMPARATOR|Transfemoral Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the inner thigh access site (transfemoral access).
62494032|NCT00685334|EXPERIMENTAL|1|Participants will take olanzapine
62494033|NCT00685334|ACTIVE_COMPARATOR|2|Participants will take aripiprazole
62695710|NCT00811850|ACTIVE_COMPARATOR|Combigan®|Combigan® (fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
62695711|NCT00811850|ACTIVE_COMPARATOR|Cosopt®|Cosopt® (fixed combination of dorzolamide hydrochloride - timolol maleate ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
62695712|NCT03336606|ACTIVE_COMPARATOR|Cohort I|MEDI0562 administration (90mg on day 1) followed by surgical resection (day 15)
62695713|NCT03336606|ACTIVE_COMPARATOR|Cohort II|MEDI0562 administration (30mg on days 1, 3, 5) followed by surgical resection (day 15)
62695714|NCT01285232|EXPERIMENTAL|Anakinra|Anakinra 150 mg/day during four weeks
62695715|NCT01285232|PLACEBO_COMPARATOR|Placebo|Placebo during four weeks
62337001|NCT02175173||E2080|Children ages \>= 4 years: Patients weighing 15.0-30.0 kg: oral daily dose of 200 mg in two divided doses after meals for the first 2 days. The dose will be increased by up to 200 mg/day every two days. The maintenance dose should be 1000 mg/day in two divided doses after meals. The dose can be increased or decreased within a range not exceeding 1000 mg/day, and should be increased by up to 200 mg/day at intervals not less than 2 days. Patients weighing \>= 30.1 kg: Adults: oral daily dose of 400 mg in two divided doses after meals for the first 2 days, then increased by up to 400 mg/day every two days. The maintenance dose should be 1800 mg/day for patients weighing 30.1-50.0 kg, 2400 mg/day for patients weighing 50.1-70.0 kg, and 3200 mg/day for patients weighing 70.1 kg or over in two divided doses after meals. Dose can be increased or decreased within a range not exceeding the above maintenance dose, and should be increased by up to 400 mg/day at intervals not less than 2 days.
62337002|NCT03973684|ACTIVE_COMPARATOR|aPDT group|G1- 40 patient 40 patients will be included in this group. One section of Pdt will be performed with the photosensitizer (PS). PS will be applied in sufficience quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated. The apparatus shall be precalibrated at wavelength 660nm for 90 seconds per point.
62337003|NCT03973684|EXPERIMENTAL|experimental tongue scrapper group|40 patients will be included in this group. Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
62695716|NCT06316570|EXPERIMENTAL|Dual Antiplatelet Therapy|This group will receive early dual antiplatelet therapy (Ticagrelor with Aspirin) combined with intravenous thrombolysis within 6 hours of the onset.
62695717|NCT06316570|PLACEBO_COMPARATOR|Placebo|This group will receive placebo treatment (with same form and dosage) combined with intravenous thrombolysis within 6 hours of the onset.
62738469|NCT05895877|ACTIVE_COMPARATOR|Goofice®|"Active ingredient:~Elobixibat 5mg/tab~Dosage and Frequency:~Once daily before breakfast. The starting dose is total 10 mg of Goofice® (2 tablets). After 7 days of the start of the study treatment, the dosage may be adjusted according to symptoms among the dose levels of 5, 10, and 15 mg.However, the maximum daily dose is 15 mg (3 tablets)."
62337004|NCT01791114|EXPERIMENTAL|Cold water consumption|Subjects will participate in two trials as part of this protocol: a) cold water (4 °C) consumption and b) tepid (36 °C) water consumption
62337005|NCT01791114|EXPERIMENTAL|Meal consumption|Subjects will participate in two trials as part of this protocol: a) High calorie meal consumption and two weeks later b) no meal consumption.
62337006|NCT01791114|EXPERIMENTAL|Cold exposure|Participants will complete three studies: a) cold exposure study (above their individually determined shivering threshold \~ 16°C); b) Cold exposure plus 0.5mg/kg up to 40mg propranolol at the beginning of the metabolic study and again after 4-6 hrs; c) thermoneutral conditions (26 - 28°C).
62337007|NCT01791114|EXPERIMENTAL|Exercise|Subjects between 18 and 35 years old will be asked to participate in two trials: a) Exercise, i.e. four times for 10 min- at 85% VO2max (maximal oxygen consumption). with 15-min breaks between each bout b) and two weeks later rest.
62337008|NCT02913222|EXPERIMENTAL|Movement Pattern Training (MPT)|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. Movement Pattern Training (MPT) will focus on task-specific training to improve lower extremity movement patterns during basic tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Exercises will include repeated practice of tasks using optimized movement patterns. Verbal cues and visual aids will be used to assist the participant. Difficulty of the task-specific activities will be progressed by varying repetitions performed, increasing load or changing the support surface.
62337009|NCT02913222|ACTIVE_COMPARATOR|Standard Rehabilitation|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. For the Standard Rehabilitation, focus will be on progressive lower extremity and trunk strengthening and lower extremity flexibility. Patient education will include instruction to modify intensity, frequency or duration of patient-specific tasks. Using current clinical practice guidelines and previous reports, strengthening and flexibility exercises will be prescribed and progressed by varying the repetitions performed or increasing the load.
62337010|NCT04053452|EXPERIMENTAL|GBS Patients|
62494034|NCT01090245|ACTIVE_COMPARATOR|Attendance Information Group|Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
61941487|NCT01469624|EXPERIMENTAL|Test group|This group receives pentoxifylline
61941488|NCT01469624|NO_INTERVENTION|Control group|
62337011|NCT04053452|ACTIVE_COMPARATOR|Controls|
62337012|NCT01517945||Breast cancer survivors and Rare cancer survivors|This is a Cycle for Survival and Center for Translational Science Center (CTSC)-funded intervention development and pilot clinical trial of a psychosocial intervention to address fear of cancer recurrence in breast cancer survivors (BCS) and rare cancer survivors (RCS). BCS form the largest survivor cohort of any cancer, with approximately 2.5 million living in the United States. About 50 percent of people with cancer have a rare cancer. Even though they account for about half of all cancer diagnoses when combined, research aimed at supporting RCS is sparse, leaving RCS with limited support after treatment.
62494035|NCT01090245|EXPERIMENTAL|Attendance Incentive Group|Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
62494036|NCT01153438||Gastric bypass, Gastric banding|
61941489|NCT05975073|EXPERIMENTAL|Part 1: Dose Exploration of AMG 193 Combined With IDE397|Participants will receive escalating doses of AMG 193 and IDE397 administered orally (PO) in cycles of 21 days.
61941490|NCT05975073|EXPERIMENTAL|Part 2: Dose Expansion of AMG 193 Combined With IDE397|AMG 193 and IDE397 will be administered PO in cycles of 21 days.
61941491|NCT04425356|EXPERIMENTAL|Intervention Group|This group will receive the LifeXT program
61941492|NCT04425356|NO_INTERVENTION|Control Group|Wait-list control group that receives the LifeXT program after the conclusion of the study
62494037|NCT05109104|EXPERIMENTAL|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter \[mg/cm\^2\]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62494038|NCT05109104|EXPERIMENTAL|CAP Herbal Mint|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of CAP Herbal Mint will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62494039|NCT05109104|EXPERIMENTAL|CAP Mountain Berry|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of CAP Mountain Berry will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62494040|NCT05109104|ACTIVE_COMPARATOR|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
62494041|NCT02162615||Restorelle Direct Fix A|Anterior/Apical prolapse repair with Restorelle Direct Fix A
62494042|NCT02162615||Native Tissue Repair Anterior|Anterior/Apical prolapse repair with native tissue only
62494043|NCT02162615||Restorelle Direct Fix P|Posterior/Apical prolapse repair with Restorelle Direct Fix P
62494044|NCT02162615||Native Tissue Repair Posterior|Posterior/Apical prolapse repair with native tissue only
62494045|NCT02940652||Paediatric patients undergoing MRI scanning|All paediatric patients undergoing elective MRI scanning of the brain and/or brain and cervical spine
62494046|NCT03910049||Study group|The group will include all adult patients that will sign ICF and will be operated for total thyroidectomy regardless of the undelying disease
62494047|NCT01380613|ACTIVE_COMPARATOR|Workshop Control|Participants receive HIV/STDs risk reduction information.
62494048|NCT01380613|EXPERIMENTAL|Intervention Workshop|Participants learn skills to cope with depressive symptoms and stress as well as safer sex and injection skills.
62494049|NCT00985751|EXPERIMENTAL|Group 1|
62494050|NCT00985751|EXPERIMENTAL|Group 2|
62494051|NCT00985751|EXPERIMENTAL|Group 3|
62494052|NCT00985751|EXPERIMENTAL|Group 4|
62494053|NCT00985751|EXPERIMENTAL|Control Group|
62494054|NCT00850551|ACTIVE_COMPARATOR|Usual Care|Usual Care
62494055|NCT00850551|OTHER|Intervention|Twice weekly home spirometry and symptom assessment
62494056|NCT05886127||Patients undergoing ERCP with papilosphincterotomy or precut|All patients after ERCP papilosphincterotomy or precut will receive a novel hemostatic agent (Purastat®)
62494057|NCT05886127||Historical control|All patients who had ERCP with papilosphincterotomy or precut in the previous period, when a novel hemostatic gel (Purastat®) was not available.
62494058|NCT05827263|ACTIVE_COMPARATOR|Control group - non-temporomandibular disorders group.|Patients diagnosed with no temporomandibular disorders.
62494059|NCT05827263|EXPERIMENTAL|Test group - temporomandibular disorders group|Patients diagnosed with mild, moderate, or severe temporomandibular disorders.
62494060|NCT03943706||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
62494061|NCT03943706||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
62494062|NCT03682276|EXPERIMENTAL|Treatment Group|Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
62494063|NCT04715906|EXPERIMENTAL|UP-Caregiver Group|Unified Protocol (UP) Caregiver Group will receive the UP for Transdiagnostic Treatment of Emotional Disorders for Caregivers intervention via telehealth using Zoom for a minimum of 4 up to 8 sessions ideally within 8 weeks.
62494064|NCT03973151|EXPERIMENTAL|HL-085|HL-085 will be administered as BID with specified dose.
62494065|NCT02299869|OTHER|Group 1 - Verde (Competitor-control) vs. Green (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
62494066|NCT02299869|OTHER|Group 2 - Cinza (Competitor-control) vs. Grey (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
62494067|NCT02299869|OTHER|Group 3 - Esmeralda (Competitor-control) vs. Jade (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
62494068|NCT02299869|OTHER|Group 4 - Azul (Competitor-control) vs. Blue (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
62494069|NCT06045390|EXPERIMENTAL|App arm|The intervention is an in-office app that contains graphical and narrated information on a patient's specific drop regimen, and includes a quiz and a graphical print-out of their drop schedule. The patient will use the app during their clinic visit.
62494070|NCT06045390|NO_INTERVENTION|Standard arm|The standard arm will be the standard of care, which involves a provider explanation of their drop regimen (using a phone interpreter if needed).
62494071|NCT01206192||Abused Chinese women|
62494072|NCT01940159|ACTIVE_COMPARATOR|Active Comparator: SEP-363856|Dosing will be initiated at 25 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 50, 100, and 150 mg of SEP-363856
62494073|NCT01940159|PLACEBO_COMPARATOR|Placebo|Matched placebo.
62494074|NCT04993118|EXPERIMENTAL|Integrated Neuromuscular inhibition technique|Experimental group received Integrated neuromuscular inhibition technique. At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. M If pain was reproduced the pressure was maintained over the active trigger point as the position of ease was identiﬁed. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of iINIT.Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
62494075|NCT04993118|ACTIVE_COMPARATOR|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
62494076|NCT01242124|EXPERIMENTAL|side-to-side stapled esophagogastric anastomosis arm|
62695718|NCT06185751|EXPERIMENTAL|Part A Dose Escalation: WS-CART-CS1|"* Undergo apheresis procedure for WS-CART-CS1 manufacturing.~* Anti-multiple myeloma therapy may be given after leukapheresis and up to one week prior to the start of lymphodepleting chemotherapy at the discretion of the treating physician.~* Lymphodepleting chemotherapy on days -5, -4, and -3.~* Three days following the last dose of lymphodepleting chemotherapy (on Day 0), WS-CART-CS1 will be infused.~* Part A is the dose escalation portion of the study with the starting dose of 0.5 x 10\^6 cells/kg of WS-CART-CS1."
62695719|NCT06185751|EXPERIMENTAL|Part B Dose Expansion: WS-CART-CS1|"* Undergo apheresis procedure for WS-CART-CS1 manufacturing.~* Anti-multiple myeloma therapy may be given after leukapheresis and up to one week prior to the start of lymphodepleting chemotherapy at the discretion of the treating physician.~* Lymphodepleting chemotherapy on days -5, -4, and -3.~* Three days following the last dose of lymphodepleting chemotherapy (on Day 0), WS-CART-CS1 will be infused.~* Part B is the dose expansion portion of the study. The dose of WS-CART-CS1 will be determined in Part A of the study."
62695720|NCT02721732|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or toxicity. Patients with clinical response or disease stabilization may continue treatment for up to an additional 12 months.
62695721|NCT06270056||early medication abortion via telemedicine|Medication abortion up to 84 days gestation using misoprostol alone regimen consisting of three doses 800mcg (4 tablets of 200mcg misoprostol each) taken every 3 hours. An extra dose (800mcg) may also be taken if there was no bleeding after administering the earlier doses.
62695722|NCT05634174|EXPERIMENTAL|Obese Group|Single dose, 100mg oral mirabegron in Obese Insulin Resistant adults
62695723|NCT05634174|EXPERIMENTAL|Non-Obese Group|Single dose, 100mg oral mirabegron in Non-Obese adults
62337013|NCT02641366||Tremor kinetics after DBS|This group have already undergone Deep Brain Stimulation (DBS) placement and will have measurements of tremor kinetics by using the electromagnetic tracking. The electromagnetic sensors will be placed on the arm and hand while the routine outpatient neurologic examinations are being performed. The testing will be performed with the DBS system in both the on and off settings.
62137950|NCT03739866|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
62695724|NCT04977349|EXPERIMENTAL|Wind Musicians|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assesment. And the manual therapy from the Active Comparator group.
62137951|NCT03739866|EXPERIMENTAL|Part B: TAF 200 mg|Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
62337014|NCT02641366||Tremor kinetics before and after DBS|This group will have measurements of tremor kinetics by using electromagnetic tracking prior to being scheduled to undergo Deep Brain Stimulation (DBS) placement. A total of two testing sessions will be performed: the first session will be performed during the routine preoperative visit, the second session will be performed during the routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
62337015|NCT05078463|EXPERIMENTAL|Intervention A: Microneedle with 1 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 1 Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
62337016|NCT05078463|EXPERIMENTAL|Intervention B: Microneedle with 0.5 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 0.5 Finger Tip Unit (FTU) of EMLA cream containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5% (dose: approximately 0.369 g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
62494077|NCT01242124|ACTIVE_COMPARATOR|circular-stapled esophagogastric anastomosis arm|
62494078|NCT01554111|ACTIVE_COMPARATOR|Picosalax with rectal enema|This arm will receive one satchet of Picosalx and a rectal enema before the sigmoidoscopy for their bowel preparation regimen.
62494079|NCT01554111|ACTIVE_COMPARATOR|rectal enema|This group of patients will receive only a rectal enema for bowel preparation before their flexible sigmoidoscopy.
62494080|NCT01554111|ACTIVE_COMPARATOR|Pico-Salax|patient will take one sachet of pico-salax
62695725|NCT04977349|ACTIVE_COMPARATOR|Wind musicians|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, Sternocleidomastoid (ECOM), masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
62695726|NCT06298708|EXPERIMENTAL|L-HAV|Live-attenuated hepatitis A vaccine.
62137952|NCT03739866|EXPERIMENTAL|Part B: TAF 600 mg|Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
62137953|NCT06597591|EXPERIMENTAL|Serious game on VR headset ( immersive VR)|After enrolment, patients will have 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset.
61941493|NCT06193525|EXPERIMENTAL|Talazoparib|"Talazoparib Capsule, oral use~1 mg per day until PD or unacceptable toxicity"
61941494|NCT04143893||Cardiogenic shock with MCS|Patients with cardiogenic shock who underwent MCS
61941495|NCT04143893||Cardiogenic shock without MCS|Patients with cardiogenic shock who did not undergo MCS
62494081|NCT01273467|EXPERIMENTAL|001|CNTO 0007 or placebo (Stage A) a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
62695727|NCT06298708|ACTIVE_COMPARATOR|I-HAV|Inactivated hepatitis A vaccine.
62695728|NCT02135133|EXPERIMENTAL|Idelalisib & Ofatumumab|Idelalisib will be given orally continuously at 150 mg BID. On day 57, ofatumumab will begin with the 300 mg dose, given after idelalisib is taken. Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8). The overall induction treatment period will then be 8 months, comprised of two months of single agent idelalisib followed by 6 months of ofatumumab with idelalisib. After the completion of the induction treatment, idelalisib will continue indefinitely in arbitrarily defined 28 day cycles in all participants who have not had excessive toxicity and do not have progressive disease.
62695729|NCT02852837|EXPERIMENTAL|Part 1: Dose Escalation Part|Participants will receive single dose of daratumumab from Week 1 till Week 3 (Period 1 - single dosing period) followed by 6 weekly doses of daratumumab until Week 9 (Period 2 - weekly dosing period) and every 2 weeks for 8 infusions and then once every 4 weeks from Week 26 until disease progression, intolerability, or other reasons for treatment discontinuation (Period 3 - less intense dosing period). A dose of 8 milligram per kilogram (mg/kg) will be chosen as the starting dose and will be escalated to 16 mg/kg if the 8 mg/kg is determined safe and tolerated by study evaluation team (SET).
62695730|NCT02852837|EXPERIMENTAL|Part 2: Pharmacokinetic (PK) Expansion Part|Participants will receive daratumumab at 16 mg/kg in 3 periods as given in the Part 1.
61941496|NCT05996848|EXPERIMENTAL|CagriSema|Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 44 weeks.
61941497|NCT05996848|ACTIVE_COMPARATOR|Semaglutide|Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 44 weeks.
62137954|NCT06597591|EXPERIMENTAL|Serious game on tablet ( non Immersive VR)|After enrolment, patients will have 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game on a tablet.
62137955|NCT06597591|EXPERIMENTAL|Waiting Serious game on VR headset (Waiting immersive VR)|2-month after enrolment, patients will have 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset.
62137956|NCT06597591|EXPERIMENTAL|Waiting Serious game on tablet ( Waiting non Immersive VR)|2-month after enrolment, patients will have 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset.
62137957|NCT05796037||Disease Cohort|Observational
62137958|NCT05796037||Engaged Cohort|Observational
62137959|NCT05796037||Age Cohort|Observational
62337017|NCT05078463|EXPERIMENTAL|Intervention C: Microneedle with 1 Finger Tip Units (FTUs) EMLA for 15 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 15 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
62494082|NCT01273467|EXPERIMENTAL|002|CNTO 0007 or placebo (Stage B) a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
62494083|NCT00193492|ACTIVE_COMPARATOR|Rituximab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). Patients who have objective response or stable disease at week 12 reevaluation will receive 4 additional doses of rituximab (375 mg/m2) administered in months 3 (week 12), 5, 7, and 9.
61941498|NCT05996848|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 44 weeks.
61941499|NCT03830385|EXPERIMENTAL|Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or|
61941500|NCT01938573|EXPERIMENTAL|Sirolimus, cisplatin, gemcitabine|Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
62137960|NCT04874519||Participants with Fibrolamellar Carcinoma/FLC|Participants will have a personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of FLC must be confirmed at MSK or an external hospital)
62137961|NCT01611493|EXPERIMENTAL|Osseotite Prevail Implant|The Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure.
62137962|NCT01611493|ACTIVE_COMPARATOR|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
61941501|NCT05613881|EXPERIMENTAL|EXPERIMENTAL GROUP|the group to be trained and then monitored by phone
61941502|NCT05613881|NO_INTERVENTION|CONTROL GROUP|The individuals in this group will be given only education booklet by the researcher after the pre-tests are applied in the first face-to-face interview. 3 months after the first interview, the final tests will be applied.
61941503|NCT03207204|ACTIVE_COMPARATOR|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
62137963|NCT05094011|EXPERIMENTAL|Single Arm Study|Autologous MitoCell Transplantation in Subjects with Idiopathic Parkinson's Disease
62137964|NCT04543903|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62137965|NCT03358433|EXPERIMENTAL|Exercise|
62137966|NCT03358433|ACTIVE_COMPARATOR|Antidepressants|
61941504|NCT03207204|ACTIVE_COMPARATOR|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
62137967|NCT04023175|ACTIVE_COMPARATOR|In office|Patients will undergo our standard in office preoperative counseling.
62137968|NCT04023175|EXPERIMENTAL|Virtual visit|Patients will undergo preoperative counseling using telemedicine virtual visits.
61941505|NCT03207204|EXPERIMENTAL|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
62337018|NCT05078463|SHAM_COMPARATOR|Intervention D: 1 Finger Tip Unit (FTUs) EMLA only and PVA-containing PET Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of 1 cm x 1cm size will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
62337019|NCT06371651|EXPERIMENTAL|Supplement|One sachet of supplement before breakfast and dinner
62337020|NCT06371651|PLACEBO_COMPARATOR|Placebo|One sachet of inert compound before breakfast and dinner
62337021|NCT04195269|EXPERIMENTAL|Pure Green Sublingual Tablet - Daily|Subjects will take 2 tablets daily, one in the morning and one in the evening, and are able to take up to 2 additional tablets per day as needed for pain.
62337022|NCT03389061|ACTIVE_COMPARATOR|sofosbuvir/velpatasvir tablet|Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.
62494084|NCT00193492|EXPERIMENTAL|Rituximab/Bevacizumab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
62494085|NCT04576936|EXPERIMENTAL|AIRVO Device|All participants are assigned to this single-arm: Enrolled participants will be given a MyAIRVO2 Device and device stand, and asked to use their device daily, for 12 months
62494086|NCT03031951|EXPERIMENTAL|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 90-120 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
61941506|NCT03207204|EXPERIMENTAL|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
61941507|NCT03207204|EXPERIMENTAL|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
62337023|NCT03389061|EXPERIMENTAL|sofosbuvir/velpatasvir crushed|Single-dose crushed sofosbuvir/velpatasvir in a fasted state.
62337024|NCT00937560|EXPERIMENTAL|Bevacizumab + paclitaxel + carboplatin|Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = \[glomerular filtration rate + 25\] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
61941508|NCT03207204|EXPERIMENTAL|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
61941509|NCT03207204|EXPERIMENTAL|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
61941510|NCT03207204|EXPERIMENTAL|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
62137969|NCT01991275|EXPERIMENTAL|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia.
62137970|NCT01991275|PLACEBO_COMPARATOR|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia.
62137971|NCT02189772|EXPERIMENTAL|MDX (metadoxine extended release)|"Route of administration: oral~The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows:~* 40-49 kg 700 mg consisting of a 700 mg tablet~* 50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet~* 65-100 kg 1400 mg consisting of two 700 mg tablets"
62137972|NCT02189772|PLACEBO_COMPARATOR|placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
62137973|NCT03648190||Inherited qualitative platelets defect|"Clinical manifestations in the form of mucocutaneous bleeding or hemorrhage.~Bleeding patients with acquired bleeding disorders, coagulation defects, and those on antiplatelet drugs will be excluded from the study."
62137974|NCT03648190||Control|Normal healthy participants, with no manifestations of bleeding disorders.
62137975|NCT03165734|EXPERIMENTAL|Pacritinib 200 mg BID|To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food
62337025|NCT02074774|EXPERIMENTAL|IntellO2|Automated control of FiO2
62337026|NCT02074774|ACTIVE_COMPARATOR|Manual|Manual control of FiO2
62337027|NCT03598738|ACTIVE_COMPARATOR|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
62337028|NCT03598738|NO_INTERVENTION|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
62337029|NCT02560831|EXPERIMENTAL|Therapeutic exercise and Pompage|strengthening exercises, balance training and knee's pompage
62337030|NCT02560831|ACTIVE_COMPARATOR|Control|Educational lectures.
62494087|NCT03031951|NO_INTERVENTION|Control Group - Waiting List|"Participants assigned to the control group will have access to the intervention after the 12-month period - waiting list. Meanwhile, participants will receive multimedia health information fortnightly by e-mail over the first 4-month period. The health information covers healthy lifestyle topics.~During the 12 months of study participation, control group participants will be instructed to maintain their baseline level of physical activity. Individuals assigned to the control group will be asked to maintain their current nutritional practices and physical activity patterns."
62494088|NCT06066671|EXPERIMENTAL|GCO (Experimental copaiba oil resin gel)|The GCO group will receive the application of an experimental gel based on copaiba oil resin for post tooth bleaching sensitivity
62337031|NCT01269372|OTHER|PillCam Colon 2 and Standard Colonoscopy|All subjects received Capsule Endoscopy (CE) using the PillCam Colon 2 followed by a standard colonoscopy.
62494089|NCT06066671|ACTIVE_COMPARATOR|GN (Potassiun nitrate and sodium fluoride gel)|The GN group will receive the application of a potassium and sodium nitrate gel for post tooth bleaching sensitivity
62494090|NCT06066671|PLACEBO_COMPARATOR|GC|The GC group will receive the application of a placebo gel for post tooth bleaching sensitivity
61941511|NCT05684900||reservoir oxygen mask|During the sedation procedure in the endoscopy unit, patients who used a reservoir oxygen mask will be examined. No premedication will be applied to patients admitted to the endoscopy unit. As a standard, intravenous vascular access will be established with a 22 gauge intraket on the back of the left hand in all patients, 6-10 lt/minute oxygen therapy will be started with a reservoir mask, and peripheral oxygen saturation, end-tidal CO2, blood pressure arterial values will be monitored and recorded. These parameters will be monitored and recorded every five minutes during the procedure. In addition, the sedative agents applied to the patients and their doses will be recorded. After the procedure, all patients will be taken to the recovery room, where they will be observed until the modified aldrete score is 9 or higher. The recovery times of the patients, nausea, vomiting and similar symptoms will be followed and recorded.
61941512|NCT02572388|ACTIVE_COMPARATOR|Group 1|10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
61941513|NCT02572388|ACTIVE_COMPARATOR|Group 2|50µg of R21 on days 0, 28, and 56.
61941514|NCT02572388|ACTIVE_COMPARATOR|Group 3|50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
61941515|NCT02572388|ACTIVE_COMPARATOR|Group 4|2µg of R21 mixed with 50µg of Matrix-M
61941516|NCT00969254|EXPERIMENTAL|Pílulas de Lussen|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo."
61941517|NCT00969254|ACTIVE_COMPARATOR|Pyridium®|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo."
62337032|NCT01827059|ACTIVE_COMPARATOR|Bosentan|Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets
61941518|NCT03682887|ACTIVE_COMPARATOR|Cryoballoon PV isolation group|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm cryoballoon catheter will be used.~4. Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.~5. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~6. The procedure and ablation times will be evaluated.~7. The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
62494091|NCT05973331||prospective general opulation cohort|Males and females age \>= 40 years, without a personal history of PDAC or current PDAC, with at least 2 clinical encounters to the HCO within the year prior to the study start date.
61941519|NCT03682887|EXPERIMENTAL|Cryoballoon PV isolation w/ RA linear ablation group|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter as the same as cryoballoon PV isolation group.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional SVC-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local RF ablation will be followed.~5. The procedure and ablation times will be evaluated.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
61941520|NCT00586651|EXPERIMENTAL|lestaurtinib|
61941521|NCT03326739|ACTIVE_COMPARATOR|Ultrasound Guided A-Line Placement|Patients in this group will have ultrasound guided arterial line placement.
62137976|NCT03165734|ACTIVE_COMPARATOR|Physician's Choice (P/C) therapy|The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.
62337033|NCT01827059|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62337034|NCT04385914||COVID positive patients|
62337035|NCT04385914||COVID negative patients|
62337036|NCT03054467|ACTIVE_COMPARATOR|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
62337037|NCT03054467|ACTIVE_COMPARATOR|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
62337038|NCT02310828|EXPERIMENTAL|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month
62337039|NCT02310828|PLACEBO_COMPARATOR|Placebo|Patient will administer placebo capsules twice a day for one month
62494092|NCT06209996|EXPERIMENTAL|L4 weight management intervention|A weight management intervention, namely Lose Little, Live Longer (L4), is recently developed to assist overweight cancer survivors in weight loss through lifestyle modification including improved dietary quality and enhanced physical activity levels. Its underlying theoretical framework is principally derived from Social Cognitive Theory (SCT), which have been widely used in health behavioural change interventions.
62494093|NCT06209996|ACTIVE_COMPARATOR|Active control|A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging.
62137977|NCT06079164|EXPERIMENTAL|KITE-197|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-197 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-197.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-197 CAR-transduced autologous T cells at 1 or more dose-level deemed to be tolerable."
62137978|NCT03666468|EXPERIMENTAL|PlayMed|"PlayMed, a highly immersive role-playing computer game~- Focus on Paediatric Asthma and Seizure management"
62137979|NCT03666468|ACTIVE_COMPARATOR|Online Package (OP)|"Online package (OP) of NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
62337040|NCT05331950||Office workers|The office workers will do their routine job tasks and will be observed through injury predictor (functional movement screen) at baseline and after actual injuries happened 6 months
62695731|NCT02852837|EXPERIMENTAL|Part 3: Safety Expansion Part|Participants will receive daratumumab 16 mg/kg every week for 8 weeks followed by every 2 weeks for an additional 16 weeks, and then every 4 weeks thereafter. Participants will be treated with daratumumab until disease progression, intolerability, or any other reasons for treatment discontinuation.
62695732|NCT06644131|EXPERIMENTAL|Intervention group|Creatine Monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.
62695733|NCT06644131|NO_INTERVENTION|Control group|The control group will receive standard care. However, to our knowledge there is no common accepted description of standard care in the literature. In general, these participants will be advised to keep as asymptomatic as possible throughout seven weeks, and live as normal as possible.
62337041|NCT01202227|EXPERIMENTAL|Pregabalin|Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
62337042|NCT00554892|ACTIVE_COMPARATOR|1|Bowel preparation
62337043|NCT00554892|EXPERIMENTAL|2|without bowel preparation
62337044|NCT02117167|EXPERIMENTAL|Substudy 1: targeted agent|Arm A1/ targeted arm: targeted maintenance from a list of targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, olaparib tablet per os 300 mg bd continuous dosing savolitinib tablet per os 600 mg od continuous dosing
62337045|NCT02117167|ACTIVE_COMPARATOR|Substudy 1: standard maintenance therapy|Arm B1/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
62695734|NCT06644131|PLACEBO_COMPARATOR|Placebo group|Powdered sugar administered once a day for seven weeks - with 5 gram/day for the entire period.
62695735|NCT00137449|EXPERIMENTAL|A|
62695736|NCT06238973|ACTIVE_COMPARATOR|Group Low|Group Low will aim to maintain an average arterial pressure in the range of 50-57 mmHg.
62695737|NCT06238973|ACTIVE_COMPARATOR|Group Middle|The target is to keep the average arterial pressure within the range of 58-65 mmHg
61941522|NCT03326739|ACTIVE_COMPARATOR|Landmark Guided A-line Placement|Patients in this group will have landmark guided arterial line placement.
62137980|NCT03666468|PLACEBO_COMPARATOR|Paper Guidelines|"Paper NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
62695738|NCT06003504|EXPERIMENTAL|First aid training with blended learning approach|Participants follow a first aid training delivered through a blended learning approach.
61941523|NCT04986579|EXPERIMENTAL|ERIBULIN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with Eribulin.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
62137981|NCT04496388|EXPERIMENTAL|Aerobic exercise|Aerobic exercise is lasting for nearly 50 minutes each time, including warm-up and stretching for 10 minutes after exercise.
62137982|NCT04496388|EXPERIMENTAL|Aerobic exercise combined with resistance exercise|Aerobic exercise is lasting for nearly 20 minutes each time, and add resistance exercise for 20 minutes. Additional warm-up 10 minutes and stretching for 5 minutes.
62137983|NCT04496388|EXPERIMENTAL|Aerobic exercise combined with interval training|Aerobic exercise is lasting for nearly 20 minutes each time, and add moderal intensity interval training for 10 minutes. Additional warm-up 10 minutes and stretching for 15 minutes.
62137984|NCT04496388|PLACEBO_COMPARATOR|Placebo|No exercise intervention.
62137985|NCT06053606|EXPERIMENTAL|expandable cryoballoon|POLARxFIT
62137986|NCT06053606|EXPERIMENTAL|standard cryoballoon|POLARx
62137987|NCT00258830|EXPERIMENTAL|Age 18 to 59 years|Participants aged 18 to 59 years at enrollment.
62137988|NCT00258830|EXPERIMENTAL|Age 60 years and older|Participants aged 60 years and older at enrollment.
62137989|NCT01222442|EXPERIMENTAL|1|400 µg AZD3199 + moxifloxacin placebo
62337046|NCT02117167|EXPERIMENTAL|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with durvalumab for patient without actionable genomic alterations or non eligible to Targeted substudy 1, durvalumab Intra-venous 10 mg/kg, Q2W
62695739|NCT06003504|ACTIVE_COMPARATOR|First aid training with face-to-face approach|Participants follow a first aid training delivered through a conventional face-to-face approach.
62695740|NCT06003504|NO_INTERVENTION|Waitlist control|Participants do not receive any training
62137990|NCT01222442|EXPERIMENTAL|2|1200 µg AZD3199 + moxifloxacin placebo
62137991|NCT01222442|ACTIVE_COMPARATOR|3|AZD3199 placebo + moxifloxacin 400 mg
62137992|NCT01222442|PLACEBO_COMPARATOR|4|AZD3199 placebo + moxifloxacin placebo
62137993|NCT03355573|EXPERIMENTAL|Bimekizumab|Subjects will receive bimekizumab up to 4 years.
62137994|NCT02146469|EXPERIMENTAL|None varicella vaccine history|2 doses with an 3 months interval
62137995|NCT02146469|EXPERIMENTAL|1 year after first dose|A second dose with an 1 year interval
62137996|NCT02146469|EXPERIMENTAL|3 years after first dose|A second dose with an 3 year interval
62137997|NCT02146469|EXPERIMENTAL|5 years after first dose|A second dose with an 5 year interval
61941524|NCT04986579|ACTIVE_COMPARATOR|ERIBULIN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with Eribulin.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
61941525|NCT04986579|EXPERIMENTAL|SACITUZUMAB GOVITECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1 and 21 of each of their standard of care (SOC) treatment cycles with SACITUZUMAB GOVITECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
61941526|NCT04986579|ACTIVE_COMPARATOR|SACITUZUMAB GOVITECAN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with SACITUZUMAB GOVITECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
61941527|NCT04986579|EXPERIMENTAL|TRASTUZUMAB DERUXTECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with TRASTUZUMAB DERUXTECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
62137998|NCT02146469|EXPERIMENTAL|Testing group for conbined immunization|1 dose Varicella vaccine and 1 dose MMR given at the same time
62337047|NCT02117167|ACTIVE_COMPARATOR|Substudy 2: standard maintenance therapy|Arm B2/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
62337048|NCT01891760|EXPERIMENTAL|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
62337049|NCT01891760|ACTIVE_COMPARATOR|Reference Therapy|Profore - Four-layer compression bandaging therapy
62337050|NCT04975971||Dextenza recepient|A Retrospective Review DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery
62337051|NCT03838172||Parents|Parents who have a burned child
62337052|NCT00582062||1|Positive controls will include patients who have positive cytology or positive biopsy of peritoneal metastases. Cell lines which over-express these tumor markers will also be used as positive controls. Sensitivity will be defined using serial dilutions of several established gastric and pancreatic tumor cell lines. The mRNA of the tumor markers will be normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA expression.
62337053|NCT00582062||2|Patients who are scheduled to undergo laparoscopy for benign disease (e.g., laparoscopic cholecystectomy, hernia repair, or prophylactic BSO) will be recruited as negative controls. A leukemia cell line which does not express epithelial cell markers will also be used as a negative control for the RT-PCR reactions.
62337054|NCT00099359|EXPERIMENTAL|A|Standard of care ( Zidovudine only)
62494094|NCT06209996|NO_INTERVENTION|Waitlist|Participants allocated to the waitlist control arm will receive a set of pamphlets with generic, knowledge-based dietary and physical activity information. All pamphlets are developed based on the self-management framework. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
62494095|NCT01751919|OTHER|Group 1 (RT)|"* Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)~* Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
61941528|NCT04986579|ACTIVE_COMPARATOR|TRASTUZUMAB DERUXTECAN WITHOUT PAXMAN SCALP COOLING SYSTEM|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with TRASTUZUMAB DERUXTECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
62137999|NCT02146469|PLACEBO_COMPARATOR|Control group for conbined immunization|1 dose MMR
61941529|NCT00753766|EXPERIMENTAL|Multifactorial Intervention|Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
61941530|NCT00753766|NO_INTERVENTION|Usual care|Control group
62138000|NCT04122885||CRS and HIPEC|Cyroreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
62138001|NCT04122885||PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy (if CRS and HIPEC not possible)
62138002|NCT06490939|EXPERIMENTAL|Asian|Single-dose
62138003|NCT06490939|EXPERIMENTAL|Caucasian|Single-dose
62337055|NCT00099359|EXPERIMENTAL|B|Standard of care (Zidovudine) plus Nevirapine
62337056|NCT00099359|EXPERIMENTAL|C|Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir
62337057|NCT04513834|EXPERIMENTAL|Multi-faceted intervention|Patient education material on PPI deprescribing will be sent to the patients and their general practitioner (GP) will receive an educational outreach visit by a Delegue d'Assurance Maladie (DAM, healthcare representative )
62494096|NCT01751919|OTHER|Group 2 (TR)|"* Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)~* Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
62494097|NCT02928627||HCC Group|samples obtained from patients with HCC (hepatic tissue and blood)
62494098|NCT02928627||Plasma control Group (PCG)|blood samples obtained from healthy controls
61941531|NCT01683019|ACTIVE_COMPARATOR|Active Fixed Alpha Frequency Magnetic Stimulation|Sinusoidal magnetic field set to the subject's intrinsic alpha frequency (IAF).
61941532|NCT01683019|ACTIVE_COMPARATOR|Active Random Frequency Magnetic Stimulation|Magnetic field hops to random frequencies in the alpha band (8-13Hz), once per second.
61941533|NCT01683019|SHAM_COMPARATOR|Inactive Sham Treatment|Generate sound similar to active treatment, except that no magnetic field is generated.
62138004|NCT01447706|ACTIVE_COMPARATOR|Paclitaxel|Standard dosing paclitaxel: 80 mg/m2 QW intravenously)
62138005|NCT01447706|EXPERIMENTAL|MM-121 (SAR256212) + Paclitaxel|administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses
62138006|NCT03779984|EXPERIMENTAL|Red Rubber Catheter Group|Red Rubber Catheter (RRC) guided nasal tracheal intubation; a RRC securely attached to nasal tracheal tube and the rounded end of the catheter introduced into a naris.
62138007|NCT03779984|SHAM_COMPARATOR|Standard nasal tracheal intubation|The nasotracheal tube will be inserted into the nasal passage.
62138008|NCT04800042|OTHER|Patients with scheduled major surgery|Patients with scheduled major surgery
62138009|NCT06648135||Bone grafts|Immediate implant placed with bone grafts in the labial gap
62138010|NCT06648135||No bone grafts|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
62494099|NCT05856058|EXPERIMENTAL|Treatment group ARM 1|SHR0302 tablets, then SHR0302 oral solution
62695741|NCT04050839|EXPERIMENTAL|Neuroscience pain education group|Pain neuroscience education in addition medical treatment
62138011|NCT01361321||patients after GBR procedure|The study will comprise of patients who already underwent a routine Guided Bone Regeneration (GBR) procedure in order to augment a bony ridge before dental implant insertion. The patients will be followed up in order to determine bone quality and quantity formed after the usage of routinely used bone substitutes during GBR procedure.
62138012|NCT03367754|EXPERIMENTAL|1|single dose of 200 mg (IV) infusion
62138013|NCT03367754|PLACEBO_COMPARATOR|2|single dose (IV infusion)
62138014|NCT06081738|ACTIVE_COMPARATOR|Neostigmine Group|
62138015|NCT06081738|ACTIVE_COMPARATOR|Sugammadex Group|
62138016|NCT05141539|EXPERIMENTAL|Rehabilitation assessment software|This arm applies the developed rehabilitation assessment software by using two web cameras placed in the front and the side of the subject. The subject sits between two cameras. The observer asks the subject to move the head in each direction, to open the mouth, and to move the tongue. The software will measure CROM, mouth opening, and tongue movement.
62138017|NCT05141539|EXPERIMENTAL|video-fluoroscopic swallowing and FOIS.|This arm applies video-fluoroscopic swallowing (VFSS) and functional oral intake scale (FOIS) to measure the direct, dynamic view of oral, pharyngeal, and upper esophageal function during swallowing with food and liquid mixed with barium, and the functional intake of dysphagic patients, respectively.
62494100|NCT05856058|EXPERIMENTAL|Treatment group ARM 2|SHR0302 oral solution, then SHR0302 tablets
62695742|NCT04050839|ACTIVE_COMPARATOR|Control group|Medical treatment only
62695743|NCT03741855|EXPERIMENTAL|Remote-Monitoring Program|Cloud Dx kit with remote-monitoring
61941534|NCT03495427|EXPERIMENTAL|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
61941535|NCT02753933||MRI scan|Direct referral from Primary Care (GPs) to an MRI scan as the initial Secondary Care point of contact.
61941536|NCT02753933||Neurology Appointment|Referral from Primary Care (GPs) to Neurology Services in Secondary Care as the initial Secondary Care point of contact.
61941537|NCT03421340|OTHER|ERC Arm|After screening examination and confirmed presence of non-complex bile duct stone by image, patients will be randomly assigned by stratified randomization to Electroscopic Retrograde Cholangioscopy (ERC) treatment.
61941538|NCT03421340|OTHER|DSC Arm|After screening examination and confirmed presence of non-complex bile duct stone by imagine, patients will be randomly assigned by stratified randomization to fluoroscopy/radiation-free direct solitary cholangioscopy (DSC).
62695744|NCT03741855|EXPERIMENTAL|Self-Monitoring Program|Cloud Dx kit with self-monitoring
62695745|NCT03741855|NO_INTERVENTION|Standard of Care|Participants will not be provided with the Cloud DX kit or an action plan
62695746|NCT06207019|ACTIVE_COMPARATOR|Hyflex EDM|Hyflex EDM One File (25/) with variable taper was used in continuous rotation at 500 rpm and 2.5 Ncm in a circumferential brushing action in the coronal and middle thirds, then in a pecking action for three to five cycles until the WL was reached.
62695747|NCT06207019|ACTIVE_COMPARATOR|The XP-endo Shaper|The XP-endo Shaper (30/0.01) was used in rotation mode at 800 rpm and 1.0 Ncm torque. Long, gentle strokes with amplitudes of 3-4 mm were used to go down to adjusted WL in three to five cycles. After it reached the WL over the adjusted WL, it was subjected to five more up-and-down motions.
62695748|NCT06207019|ACTIVE_COMPARATOR|Primary WaveOne Gold|Primary WaveOne Gold (25/07) was applied three times in a reciprocating motion; a gradual in-and-out pecking movement was utilized as directed by the manufacturer till the WL was reached.
62138018|NCT03449771|EXPERIMENTAL|Single Arm|To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.
62138019|NCT04844879|EXPERIMENTAL|Single-arm|Patients suitable to receive Medacta GMK® Sphere system for primary TKA will be invited to take part to the study during the preoperative visit. Follow-ups are performed after 2, 6 and 12 months. Data collection includes clinical and radiological data for preoperative and postoperative assessments, as well as intraoperative details.
62138020|NCT05178420|EXPERIMENTAL|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
62138021|NCT05178420|NO_INTERVENTION|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
62138022|NCT01567605|EXPERIMENTAL|Lidocaine lubricant (then placebo)|In this arm, on the first test day subjects will use lidocaine lubricant in their normal bowel care routine (rather than standard lubricating jelly). After a washout period they will repeat testing with the placebo lubricant.
62138023|NCT01567605|PLACEBO_COMPARATOR|Placebo lubricant (then lidocaine)|In this arm, on the first test day subjects will use regular lubricant (AMG MedPro lubricating gel) in their normal bowel care routine. After a washout period they will repeat testing with a the lidocaine lubricant.
62138024|NCT02180815||ReVENT implanted group|
62138025|NCT01218841|EXPERIMENTAL|Fish oil lipid emulsion|Parenteral lipid emulsion composed by fish oil which is rich in the omega-3 polyunsaturated fatty acids eicosapentanoic and docosahexanoic.
62138026|NCT01218841|ACTIVE_COMPARATOR|MCT/LCT lipid emulsion|Parenteral lipid emulsion containing 50% of medium-chain triglycerides and 50% of soybean oil
62138027|NCT05068102|EXPERIMENTAL|Arm A|
62138028|NCT05068102|EXPERIMENTAL|Arm B|
62138029|NCT06463041|EXPERIMENTAL|Functional training group|Functional training group that will perform a short, low-intensity, 15-minute hole-body exercise program per day before the lunch break, in addition to following the getup assistance during the working day.
62337058|NCT04513834|ACTIVE_COMPARATOR|Educational outreach visit to GPs|GP will receive the educational outreach visit by a DAM (healthcare representative). Their patients will not receive any patient education material.
62494101|NCT01140607|EXPERIMENTAL|Cohort 1: normal hepatic function: cabazitaxel|"cabazitaxel 25mg/m\^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
62494102|NCT01140607|EXPERIMENTAL|Cohort 2: mild hepatic impairment : cabazitaxel|"cabazitaxel 20mg/m\^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
62738470|NCT05895877|PLACEBO_COMPARATOR|Goofice® Placebo|"Active ingredient/Excipients:~The placebo drug is identical in appearance to the Goofice ® tablet with the same excipient ingredients, but without the active compound.~Dosage and Frequency:~Once daily before breakfast. The dosage and frequency is the same as active drug"
62138030|NCT06463041|ACTIVE_COMPARATOR|Traditional training group|Traditional training group that will perform a short, low-intensity, 15-minute hole-body exercise program per day before the lunch break, in addition to following the getup assistance during the working day.
62138031|NCT06463041|NO_INTERVENTION|Negative control|Control group. A group that is not treated.
62138032|NCT06476119||Optimisation cohort|patients will be treated with surgery and adjuvant radiotherapy following local/national guidelines, while chemotherapy will be omitted
62138033|NCT06476119||Control cohort|patients will be treated with surgery, adjuvant radiotherapy and adjuvant chemotherapy following local/national guidelines
62138034|NCT04802018|EXPERIMENTAL|Monitored group|Monitoring of vital signs and following with the conventional telephone protocol
62337059|NCT04513834|NO_INTERVENTION|Control|Neither the patients nor their GP will receive any information.
62337060|NCT01294124||No Tinnitus|The absence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
62337061|NCT01294124||Tinnitus|The presence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
62337062|NCT02202096|EXPERIMENTAL|Intervention (plus usual care)|Patient education: One-on-one visit Discharge planning: Assessment of barriers to discharge Medication reconciliation: Patient medication review Appointment before discharge: Additional measure to ensure awareness of next clinic visit Transition coach Patient-centered discharge instructions: Enhanced Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology Timely follow-up: Barriers to clinic follow-up visits will be discussed Timely PCP communication Follow-up telephone call Patient hotline: 24 hour follow-up following call to Ask My Nurse number
62337063|NCT02202096|NO_INTERVENTION|Usual Care|Usual care-Standard of care that all colorectal cancer patients normally receive
62337064|NCT02263482|OTHER|Control group|patients awaiting for evaluation to cardiac rehabilitation or transplantation
62337065|NCT02263482|EXPERIMENTAL|moderate-intensity group|Patients will be submitted to a 8-weeks training program, with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with upper and lower exercises (50% of the 1-maximum repetition test).
62337066|NCT02263482|ACTIVE_COMPARATOR|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 Kg each).
62337067|NCT00603434|EXPERIMENTAL|1|Osmotic-Release Methylphenidate
62337068|NCT00603434|EXPERIMENTAL|2|Osmotic-Release Methylphenidate
62337069|NCT00603434|EXPERIMENTAL|3|Osmotic-Release Methylphenidate
62337070|NCT03044015|EXPERIMENTAL|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
62337071|NCT03044015|ACTIVE_COMPARATOR|Control|Intervention as usual
62337072|NCT00808730|EXPERIMENTAL|1|fiberoptic fibroscopy
62337073|NCT03039127|EXPERIMENTAL|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
62337074|NCT06283784|EXPERIMENTAL|Yovis Capsules|YOVIS, the Investigational Food Supplement (IFS), is an oral formulation (capsules) containing definite mix of live probiotics already marketed by Alfa-Sigma as food supplement since September 2017. it is administered to 50 patients 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
61941539|NCT05734989||Hispanic/Latinx patients at risk for CKD|Adult patients in the Hispanic/Latinx Durham community screened for CKD
62138035|NCT04802018|NO_INTERVENTION|Control group|Conventional telephone follow-up by health staff
62138036|NCT05465018|EXPERIMENTAL|Healthy volunteers|1 arm. Healthy volunteers assigned to different interventions
62138037|NCT05923606|EXPERIMENTAL|Theta-nested gamma tACS applied during passive task epochs|Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during fixation periods between consecutive task trials. EEG will be acquired before and immediately after the intervention.
62138038|NCT05923606|EXPERIMENTAL|Theta-nested gamma tACS applied during memory delays|Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. EEG will be acquired before and immediately after the intervention.
62337075|NCT06283784|PLACEBO_COMPARATOR|Placebo|Placebo is an oral formulation of inert capsules. it is administered to 50 patients 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
62337076|NCT00617006||Before (Control)|Study group representative of standard practice
62337077|NCT00617006||After(Treatment)|After treatment group with the personal hand hygiene device ie. Device Group.
62337078|NCT00717262|EXPERIMENTAL|1|HQK-1001
62337079|NCT00717262|PLACEBO_COMPARATOR|2|
62337080|NCT01606761|EXPERIMENTAL|Group 1|Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.
62337081|NCT01606761|EXPERIMENTAL|Group 2|Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
62337082|NCT01606761|EXPERIMENTAL|Group 3|Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.
62337083|NCT05580861|EXPERIMENTAL|Cohort : Patients with acute myeloid leukemia|
62337084|NCT03442829|EXPERIMENTAL|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
62494103|NCT01140607|EXPERIMENTAL|Cohort 3: moderate hepatic impairment: cabazitaxel|"cabazitaxel 10mg/m\^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
62337085|NCT03442829|ACTIVE_COMPARATOR|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
62494104|NCT01140607|EXPERIMENTAL|Cohort 4: severe hepatic impairment: cabazitaxel|"cabazitaxel 5 mg/m\^2 or 10mg/m\^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
62494105|NCT01140607|EXPERIMENTAL|Cohort 5: normal hepatic function: cabazitaxel and midazolam|"cabazitaxel 25mg/m\^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).~Midazolam is given orally in single dosing on day -1 and day 1 (crossover)"
62494106|NCT04943549|ACTIVE_COMPARATOR|Group (A)|History of addiction.
62494107|NCT04943549|PLACEBO_COMPARATOR|Group (N)|No history of addiction to any drug.
62494108|NCT05402046|EXPERIMENTAL|ProRodinki application test|Patients scheduled for excisional biopsy of skin lesion(s) will be invited to participate in this study. Photo-documentation of the skin neoplasm(s) in the ProRodinki application will be performed, and the generated report will be sent for evaluation by artificial intelligence. Following this procedure, an excisional biopsy of the lesion(s) will be scheduled. From the moment of inclusion in the study until the excisional biopsy, an interval of no more than 2-4 weeks is allowed. After excisional biopsy of the skin neoplasm(s), a routine intravital pathological examination with hematoxylin and eosin staining will be performed, if necessary, immunohistochemical and molecular genetic tests will be performed. The selected biosamples (paraffin blocks) will then be analyzed centrally by a morphologist.
62494109|NCT01540344|EXPERIMENTAL|Treatment Arm|"1. FOLFOX/FOLFIRI + cetuximab (6 cycles)~2. CRS and HIPEC~3. FOLFOX/FOLFIRI + cetuximab (6 cycles)"
62494110|NCT02346825|EXPERIMENTAL|Intensive Plus Cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
62494111|NCT02346825|EXPERIMENTAL|Intensive Plus Splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
62494112|NCT02346825|EXPERIMENTAL|Intensive no Constraint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks but will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
62494113|NCT04509232|EXPERIMENTAL|group A|- 38% Silver diamine fluoride will be applied to carious lesions by microbrush on the affected surface application time should be 1 min, Application time will be shorter in very young patients.
62494114|NCT04509232|EXPERIMENTAL|group B|"-38% Silver diamine fluoride will be applied by the same protocol as in group A~Then Glass Ionomer restoration is applied as follows~* Self cure glass ionomer restoration is applied not light cured as light causes oxidation of silver and the filling appears darker.~* Glass ionomer won't be applied immediately after SDF placement it will be applied at time ranging from 2 hours to two days.~* Conditioning of the base of the cavity is done by 3M ESPE conditioner for 10 seconds then rinsing the cavity for 10 to 20 secs.~* Applying High strength hand mix chemical self cure glass ionomer."
62494115|NCT01634685|EXPERIMENTAL|Bavituximab, Capecitabine, Radiation|one arm
62138039|NCT05923606|EXPERIMENTAL|Gamma tACS applied during memory delays|Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. The stimulation will be phase locked to the peaks of ongoing theta rhythms of the participant. EEG will be acquired before and immediately after the intervention.
62337086|NCT03132480|EXPERIMENTAL|hypovolemia|
62494116|NCT00834314|EXPERIMENTAL|Vacuum-pack|see Interventions
62494117|NCT00834314|ACTIVE_COMPARATOR|Abdominal dressing|see Interventions
62494118|NCT01135940|EXPERIMENTAL|1|2-octylcyanoacrylate (Dermabond) closure
62494119|NCT01135940|ACTIVE_COMPARATOR|2|Standard staple closure
62494120|NCT06067789|EXPERIMENTAL|Intervention|Intervention arm participants will be allocated to neuraxial anesthesia. The specific approach (spinal, epidural, or combined spinal and epidural) will be at the discretion of the treating anesthesiologist, as the underlying physiologic mechanisms and impacts are similar for both approaches. Allowing clinician discretion will reflect routine standard of care practice and support generalizability. Specific choice of neuraxial anesthetic medications, doses, and adjuncts will also be at the discretion of the attending anesthesiologist, supporting pragmatism. While existing randomized data do not suggest that the sedation level during neuraxial anesthesia leads to differences in outcomes, providers will be requested to maintain sedation at or below a 3 on the Observer's Assessment of Alertness/Sedation scale (OAAS; mild to moderate sedation consistent to responding to verbal stimuli), the same approach used in a recent large pragmatic trial of anesthesia in hip fracture patients.
62138040|NCT05923606|PLACEBO_COMPARATOR|Placebo tACS applied during task performance|Participants will receive single-session administration of placebo tACS during performance of a working memory task. EEG will be acquired before and immediately after the intervention.
62337087|NCT03375905|EXPERIMENTAL|cNEP|cNEP treatment
62337088|NCT02119884|EXPERIMENTAL|Terlipressin group|Patients receive terlipressin 2 mg IV bolus
62337089|NCT02119884|ACTIVE_COMPARATOR|High Dose Octreotide group|Patients receive Octreotide 50 μg/h with an initial bolus of 100 μg
62337090|NCT01397305|EXPERIMENTAL|Modufolin and Pemetrexed|Modufolin ( \[6R\] 5,10-methylenetetrahydrofolate) and Pemetrexed
62337091|NCT00394290|EXPERIMENTAL|PPC|Night time device for positive pulmonary pressure
62337092|NCT03683706|ACTIVE_COMPARATOR|Intervention|Participants in this arm will receive 12 sessions of LTP in My Own Way Plus interventions.
62337093|NCT03683706|NO_INTERVENTION|Treatment as Usual|Participants in this arm will be getting their usual treatment
62494121|NCT06067789|NO_INTERVENTION|Control|Control group participants will be allocated to general anesthesia. Choice of anesthetic medications and doses will be at the discretion of each anesthesiologist as per routine standard of care, again supporting conduct of a pragmatic and generalizable trial. Similarly, choice of airway management strategies and anesthetic depth will also be based on patient and provider preference, as a recent large randomized trial demonstrates that anesthetic depth is not causally linked to risk of morbidity or mortality after surgery. Details of general anesthesia management and medications will be collected for all patients.
61941540|NCT05734989||PCPs caring for Hispanic Latinx patients screened for CKD in the Durham Community|Primary Care Providers (PCPs) caring for Hispanic Latinx patients who agree to use the study guidelines and interventions for screening and monitoring their patients for CKD.
61941541|NCT02890095|EXPERIMENTAL|Arm A = Breast Cancer surgery|Arm A : women undergoing breast cancer surgery.
61941542|NCT02890095|OTHER|Arm B = Control (plastic surgery)|Arm B : women undergoing breast surgery for the purpose of plastic surgery
61941543|NCT04849104||COPD high-risk patients|age \<70 years old, long-term smoker (≥10 pack years), CT without macroscopic airway abnormalities and/or mild or moderate emphysema, air retention or bronchial thickening, normal lung function
61941544|NCT04849104||Early-stage COPD patients|"those who are younger than 70 years old, long-term smokers (≥10 pack years) and have any of the following abnormalities:~1. Forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) \<lower limit of normal value (LLN, 80%);~2. CT abnormalities: abnormal airway and/or emphysema, air retention or bronchial wall thickening;~3. FEV1 drops rapidly (≥60 mL/year);"
61941545|NCT04849104||patients with mild to moderate COPD|Patients with mild to moderate COPD: age \<75 years, FEV1/FVC\<70%, FEV1 predicted value ≥50%
61941546|NCT04799327|EXPERIMENTAL|Treatment group A|
61941547|NCT04799327|EXPERIMENTAL|Treatment group B|
61941548|NCT04799327|EXPERIMENTAL|Treatment group C|
61941549|NCT04799327|PLACEBO_COMPARATOR|Treatment group D|
61941550|NCT04543838|ACTIVE_COMPARATOR|Standard of Care|Control will include standard of care pain management during the postoperative period. Participants in this arm will not receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP).
61941551|NCT04543838|EXPERIMENTAL|EEG & SSEP monitoring|Intervention will include standard of care pain management during the postoperative period. Participants in this arm will receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP). EEG will be used to manage blood pressure.
61941552|NCT06455449|EXPERIMENTAL|Anifrolumab (subcutaneous weekly injection)|Anifrolumab subcutaneous injection once weekly
62138041|NCT03139331|EXPERIMENTAL|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
62494122|NCT04506567|EXPERIMENTAL|Dose- Fractionated Cohort|Patients will receive a single cycle of 225Ac-J591, administered as a fractionated dose on days 1 and 15. This is a dose-escalation design, with up to 4 dosing cohorts.
62494123|NCT04506567|EXPERIMENTAL|Multiple Dose Cohort|Patients will receive 225Ac-J591 every 6 weeks, with up to 4 doses. Some patients will be enrolled in a dose-escalation design, with up to 3 dosing cohorts. Additional patients will be enrolled at 2 lower dosing-cohorts.
62494124|NCT05869162|EXPERIMENTAL|SY-3505-Phase II|SY-3505 single agent, 600 mg oral capsules, QD, continuously
61941553|NCT06455449|PLACEBO_COMPARATOR|Placebo (subcutaneous weekly injection)|Matched placebo control subcutaneous injection once weekly
61941554|NCT02239354|EXPERIMENTAL|Cohort 1|2 VC-01™ Combination Product implants
61941555|NCT02239354|EXPERIMENTAL|Cohort 2|4 or 6 VC-01™ Combination Product implants
61978778|NCT03486132|OTHER|interrupted repair of lateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity"
62138042|NCT01917994|EXPERIMENTAL|Text Messages + Appointment Reminders|Participants in the intervention arm will receive supportive, informational, or motivational text messages three times a week for one year in addition to text message reminders about HIV primary care appointments.
62138043|NCT01917994|ACTIVE_COMPARATOR|Appointment Reminders|Participants in the control arm will receive text messages reminding them of HIV primary care appointments 48 hours before the scheduled appointment.
62138044|NCT05888792|NO_INTERVENTION|Single vision lens group|Subjects in single vision lens group will receive a pair of single vision lenses for the first year of study. They will then receive a pair of DG2 lenses for the second year of the study.
62138045|NCT05888792|EXPERIMENTAL|DG2 lens group|Subjects in DG2 lens group will receive a pair of DG2 lenses over the 2-year study.
62138046|NCT06700148|EXPERIMENTAL|ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197)(MCV4)|
62494125|NCT04320745|EXPERIMENTAL|Androderm® 4 mg|Participants received Androderm® 4 mg, transdermal dose, once daily (QD) for up to 16 weeks. At Day 14, if serum concentration was less than 400 nanograms per deciliter (ng/dL), the dose was increased to 6 mg, transdermal dose, QD for up to 16 weeks and if the serum concentration was more than 930 ng/dL, the dose was decreased to 2 mg, transdermal dose, QD for up to 16 weeks. The dose was not adjusted if serum concentrations were within the normal range.
62494126|NCT04127292|EXPERIMENTAL|Emotional Self Awareness Group (Clinician participants)|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
62494127|NCT04127292|NO_INTERVENTION|Emotional Self Awareness Group (Patient participants)|Patients provided care by clinicians trained in ESA
62494128|NCT04127292|SHAM_COMPARATOR|Control Group (Clinician participants)|The Control group CPs will engage in the same two VHI scenarios and will complete the TRQ-SF in response to each scenario without receiving the ESA feedback
62494129|NCT04127292|NO_INTERVENTION|Control Group (Patient participants)|Patients provided care by clinicians not receiving ESA feedback
62494130|NCT01650155|EXPERIMENTAL|BI 1005273 i.v.|single dose i.v. infusion
62494131|NCT01650155|PLACEBO_COMPARATOR|BI 1005273 i.v. Placebo|single dose i.v. infusion (Placebo)
62494132|NCT01650155|EXPERIMENTAL|BI 1005273 s.c.|single dose s.c. injection
62494133|NCT01650155|PLACEBO_COMPARATOR|BI 1005273 s.c. Placebo|single dose s.c. injection (Placebo)
61941556|NCT05655052|EXPERIMENTAL|working grup 1: Virtual Reality (VR) Group|"From the preparation stage of the IUD until the IUD application process is completed, after the internet connection is provided with a smart phone for the image, by clicking on the youtube.com link, Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video will be provided and virtual reality glasses will be provided.~Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. The practice of watching nature videos with VR during the IUD application with this device is within the framework of midwifery care practices and is not a treatment option for any treatment method, tool or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason."
62138047|NCT06700148|ACTIVE_COMPARATOR|ACYW135 Group Meningococcal Polysaccharide Vaccine (MPSV4)|
62138048|NCT03282045|EXPERIMENTAL|Lysobact Complete Sprey|"Lysobact Complete Sprey~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride."
62138049|NCT03282045|ACTIVE_COMPARATOR|Tantum Verde® Spray|"Tantum Verde® Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose."
62494134|NCT03786770|EXPERIMENTAL|Cohort 1: Dose A|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
62695749|NCT05648812|ACTIVE_COMPARATOR|Term neonates|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography, cardiac ultrasound To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with no suspected brain pathology using CEUS. Later, different patient groups could be compared to infants with no suspected brain pathology.~Other Names:~• SonoVue"
62695750|NCT05648812|EXPERIMENTAL|Neonatal asphyxia|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in neonates after birth asphyxia~Other Names:~• SonoVue"
62695751|NCT05648812|EXPERIMENTAL|Neonatal stroke|"Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion after neonatal stroke~Other Names:~• SonoVue"
62138050|NCT03282045|ACTIVE_COMPARATOR|Pharyngal® Oromucosal Spray|"Pharyngal® Oromucosal Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride."
62138051|NCT03282045|PLACEBO_COMPARATOR|Placebo|"Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times."
62337094|NCT02697513|NO_INTERVENTION|Before Period|Collection of patient-related data without interventions being made
62337095|NCT02697513|ACTIVE_COMPARATOR|After Period|Implementation of a simple infection management protocol as well as a 'Sepsis First Aid' kit to assist in the management of patients with acute infection
62337096|NCT03734367|ACTIVE_COMPARATOR|Emotional abilities training program|Intervention program on emotional abilities that will be carried out for 10 hours distributed over 5 weeks, in two and a half hour session. The work methodology will be eminently practical, working in groups including real case analysis and interactive simulation
62337097|NCT03734367|NO_INTERVENTION|Control group|Control group that will not receive the training program on emotional abilities but usual care.
62337098|NCT03496363||CHD with Hypothyroidism|
62494135|NCT03786770|EXPERIMENTAL|Cohort 2: Dose B|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
62695752|NCT05648812|EXPERIMENTAL|Other neonatal brain pathologies|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with other type (no asphyxia, stroke or preterm birth related) of brain pathology, like hydrocephalus, hemorrhage or central nervous system infection~Other Names:~• SonoVue"
62695753|NCT00522379|EXPERIMENTAL|Rotigotine 2 mg/24 hr|
62695754|NCT00522379|EXPERIMENTAL|Rotigotine 4 mg/24 hr|
62695755|NCT00522379|EXPERIMENTAL|Rotigotine 6 mg/24 hr|
62138052|NCT06026943|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62337099|NCT01889966|EXPERIMENTAL|Sildenafil|oral Sildenafil 20 mg three times a day for 90 days
62337100|NCT02529293|ACTIVE_COMPARATOR|BioChaperone Lispro U-100|injection of 2 doses of 0.2 U/kg on separate visits
62337101|NCT02529293|EXPERIMENTAL|BioChaperone Lispro U-200|injection of 2 doses of 0.2 U/kg on separate visits
62337102|NCT00354263|PLACEBO_COMPARATOR|A|PBS injected alone in step 1 or mixed with Aggripal in step 2
62337103|NCT00354263|EXPERIMENTAL|B|
62337104|NCT04200677|EXPERIMENTAL|MCN1|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
62337105|NCT04200677|EXPERIMENTAL|BCN05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve
62337106|NCT04200677|EXPERIMENTAL|BCN1|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
62337107|NCT04200677|EXPERIMENTAL|BCN2|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve
62337108|NCT04200677|EXPERIMENTAL|MCM1|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
62337109|NCT04200677|EXPERIMENTAL|BCM05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly
62494136|NCT03786770|EXPERIMENTAL|Cohort 3: Dose C|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
61941557|NCT05655052|EXPERIMENTAL|Working Group 2: Distraction Cards Implementation Group|From the preparation stage of the IUD procedure to the completion of the IUD application process, distraction cards containing five optical illusion figures, one of the distraction techniques, will be shown to the women by the researcher . Distraction cards consist of picture cards with various hidden pictures and patterns. These hidden pictures and patterns are such that individuals can only see when they look carefully. During the process, the women will focus on the cards and be distracted by asking what they see on the cards by communicating face-to-face with the researcher women about the pictures and shapes they see on the cards. Thus, it is thought that the cards with optical figures on the distraction cards will enable women to focus and reduce pain and anxiety. Display of cards will take approximately 3-5 minutes
61941558|NCT05655052|NO_INTERVENTION|Control Group|Unlike the study group, women included in the control group will not only be shown video watching applications with virtual glasses and distraction cards. The maintenance and applications in the routine IUD application will be done exactly.
61941559|NCT01749631||Difficult to Intubate (DTI) Participants|Male or non-pregnant females over 18 years of age with Mallampati score III or IV who were undergoing surgery using sevoflurane as the anesthetic agent as judged by the investigator and in compliance with the drug market authorization and approved product labeling.
62138053|NCT06284213||Normal Cognition (NC) with at least 1 vascular risk factor|"NC is defined as:~1. No diagnosis of SCD, MCI, or dementia; AND~2. CDR: Sum of Boxes = 0 AND neuropsychological testing in normal range.~Participants must have at least 1 of the following criteria prior to enrollment:~Diabetes (at least 1):~* Fasting (8-hour) blood sugar ≥126 mg/dL~* Random or Post-prandial blood sugar ≥200 mg/dL~* HbA1C ≥6.5%~* Treatment with anti-diabetic medicine~Hypertension plus (at least 2):~* Use of anti-hypertensive medications for lowering blood pressure for ≥10 years~* Current use of 2 or more anti-hypertensive meds for lowering blood pressure~* Blood pressure in a research or clinical setting in the last 2 years with SBP ≥140 or DBP ≥90~* Second blood pressure reading in a research or clinical setting in the last 2 years (different date) with SBP ≥140 or DBP ≥90~* Evidence of likely HTN end organ damage~MRI factors (at least 1):~* Peri-Ventricular Fazekas Extent Grade or Deep Fazekas Extent Grade ≥2~* ≥1 microbleeds~* ≥1 lacunar infarcts"
62138054|NCT06284213||Subjective Cognitive Decline (SCD)|"Subjective cognitive decline is defined as:~1. Cognitive concerns based on a Short eCog-12 score ≥ 3 (based on administration to participant), AND~2. Normal cognition (neuropsychological testing within normal range)."
62337110|NCT04200677|EXPERIMENTAL|BCM1|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
62337111|NCT04200677|EXPERIMENTAL|BCM2|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly
62337112|NCT04200677|EXPERIMENTAL|BC25|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly
62494137|NCT03786770|EXPERIMENTAL|Cohort 4: Dose D|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
62494138|NCT05915923|EXPERIMENTAL|Low-frequency rTMS Group|Healthy adults treated with 1Hz repetitive transcranial magnetic stimulation (rTMS)
62695756|NCT00522379|EXPERIMENTAL|Rotigotine 8 mg/24 hr|
62695757|NCT00522379|PLACEBO_COMPARATOR|Placebo|
62695758|NCT05095285|NO_INTERVENTION|The control group|• In addition to incubator cover and nesting, no other non-pharmacological intervention was applied to the control group.
62695759|NCT05095285|EXPERIMENTAL|The swaddling group|•Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.
62695760|NCT05095285|EXPERIMENTAL|The oropharyngeal colostrum group|• In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue.
62695761|NCT04946370|EXPERIMENTAL|Pembrolizumab + 225Ac-J591 + ARPI|Patients will receive one dose of 225Ac-J591 (single dose, either 65 or 90 Kbq/kg) in combination with pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule, examples of ARPI include enzalutamide and apalutamide).
61941560|NCT05693766|ACTIVE_COMPARATOR|Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes|
61941561|NCT05693766|EXPERIMENTAL|Capecitabine_Non-Luminal A subtypes|
62337113|NCT00950079|EXPERIMENTAL|Sodium bicarbonate|sodium bicarbonate
62337114|NCT00950079|ACTIVE_COMPARATOR|Saline|saline infusion
61941562|NCT03439787|ACTIVE_COMPARATOR|Active Popliteal Plexus Block|10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
61941563|NCT03439787|PLACEBO_COMPARATOR|Placebo Popliteal Plexus Block|10 ml Sodium Chloride 0.9 %
61941564|NCT02165371|EXPERIMENTAL|Sinovuyo Caring Families Programme|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly 3 hour sessions. Program is manualized.
61941565|NCT02165371|NO_INTERVENTION|No intervention|Control group receives not intervention
62337115|NCT02559154|EXPERIMENTAL|modified BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
62494139|NCT05915923|EXPERIMENTAL|High-frequency rTMS Group|Healthy adults treated with 10Hz repetitive transcranial magnetic stimulation (rTMS)
62494140|NCT05915923|SHAM_COMPARATOR|Control group|The Control group received rTMS with sham transcranial magnetic stimulation (sham-rTMS)
62695762|NCT04946370|EXPERIMENTAL|Pembrolizumab + ARPI|Patients will receive pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule) without 225Ac-J591.
62695763|NCT02154230|EXPERIMENTAL|sulphate-bicarbonate-calcium water and low-calorie diet (SW-D)|"Experimental arm: Those patients assigned to this interventional arm of the study will be asked to follow a low-calorie diet. For the first 12 weeks, the diet will cover only basal metabolism expenditure ± 10%. At the end of this 12 weeks, for the following 12 weeks, patients will follow a maintenance diet which will cover both basal metabolism and physical activity expenditure. Patients will be invited to maintain the same level of physical activity preceding enrollment throughout the entire study period. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
62738471|NCT03800524|EXPERIMENTAL|Tauroursodeoxycholic acid (TUDCA)|"* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
62695764|NCT02154230|ACTIVE_COMPARATOR|tap water and low-calorie diet (TW-D)|Active comparator: Those patients assigned to this interventional arm of the study will be asked to follow the same low-calorie diet of the experimental arm. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Rome tap water at room temperature.
62695765|NCT05691829|EXPERIMENTAL|Untreated Patients With Stage IV NSCLC|Participants will receive radiation in concert with starting chemotherapy with pembrolizumab for up to 6 cycles (18 weeks), followed by continued treatment with pembrolizumab (standard of care). Patients will be followed for 1 year following the completion of the core study period of 6 cycles.
62695766|NCT01374854|EXPERIMENTAL|Stem Cell Infusion|
61941566|NCT04436731|EXPERIMENTAL|Hypoxia Exposure|A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
61941567|NCT05046184|NO_INTERVENTION|Healthy Controls|Healthy controls will undergo clinician assessments and fMRI to compare to MDD group.
61941568|NCT05046184|ACTIVE_COMPARATOR|MDD - Ketamine|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four ketamine infusions.
62138055|NCT06284213||Mild Cognitive Impairment (MCI)|"Mild cognitive impairment is defined as:~1. There is a cognitive concern, i.e., the subject, the co-participant, or a clinician is concerned about a change in cognition compared to the subject's previous level.~2. There is impairment in one or more cognitive domains (memory, language, executive function, attention, and visuospatial skills) that is greater than would be expected for the patient's age and educational background.~3. There is largely preserved independence in functional abilities (no change from prior level of functioning or requires only extra effort and minimal aids or assistance).~4. There is no evidence of dementia (cognitive changes are mild and there is no evidence of a significant impairment in social or occupational functioning)."
62138056|NCT06284213||Mild Dementia|"Mild dementia is defined as:~1. The subject has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria:~   1. Interfere with ability to function as before at work or at usual activities?~  2. Represent a decline from previous levels of functioning?~  3. Are not explained by delirium or major psychiatric disorder? AND~2. Impairment in one\* or more of the following domains.~   1. Impaired ability to acquire and remember new information.~  2. Impaired reasoning and handling of complex tasks, poor judgment.~  3. Impaired visuospatial abilities.~  4. Impaired language functions.~  5. Changes in personality, behavior, or comportment \* In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, posterior cortical atrophy), the subject must not fulfill criteria for MCI.~   AND~3. CDR: Global Score = 0.5 or 1"
62138057|NCT04524247|EXPERIMENTAL|PMEG FEVAR|The only arm of this study will be enrolled subjects who undergo physician modified endografting as a treatment of their thoracoabdominal aortic aneurysms or complex abdominal aortic aneurysms.
62138058|NCT04858035|EXPERIMENTAL|Online Speech Training|"Participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. All participants will receive 12 sessions of perceptual training over 4 weeks. Finally, participants will complete a 3-session maintenance phase in which perception and production are probed but not treated. Perception will be measured using the identification and category goodness judgment.~Following completion of perception training all participants will complete two weeks of production training. The production training will consists of 4, 60-minute sessions. Each session will provide instruction and practice trials."
62138059|NCT03391024|EXPERIMENTAL|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
62138060|NCT06514677|EXPERIMENTAL|Ultrasonic Carbon|Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment
62138061|NCT06514677|ACTIVE_COMPARATOR|Titanium|Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
62494141|NCT05755854|EXPERIMENTAL|Patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation|A conditional chemotherapy regimen of fludarabine and cyclophosphamide will be administered, zoredronic acid depending on the patient's status, followed by investigational therapy, allogeneic γ9δ2 T Cells
62494142|NCT02359864|EXPERIMENTAL|Cohort One|An initial 15 patients will be enrolled in the first treatment scheme (5 daily fractions of 2 Gy) and will be followed for 12 months after completion of treatment to assess safety and any toxicity/adverse events associated with treatment. 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events.
62695767|NCT01374854|ACTIVE_COMPARATOR|traditional therapy control|
61941569|NCT05046184|PLACEBO_COMPARATOR|MDD - Midazolam|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four midazolam infusions.
61941570|NCT00423514|EXPERIMENTAL|cytoreduction regimen & stem cell transplant|This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).
61941571|NCT00131508|EXPERIMENTAL|2|Glutamine
61941572|NCT00131508|PLACEBO_COMPARATOR|1|
61941573|NCT01074905|ACTIVE_COMPARATOR|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
61941574|NCT01074905|ACTIVE_COMPARATOR|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
61941575|NCT01074905|EXPERIMENTAL|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
61941576|NCT06677021|OTHER|Physcial Activity Exercises|
61941577|NCT02504710|ACTIVE_COMPARATOR|Traditional Learning System|Traditional systems of manual therapy teaching
61941578|NCT02504710|EXPERIMENTAL|Kinematic Real-Time Feedback|Kinematic real time feedback to learn Manual therapy
61941579|NCT04515173|EXPERIMENTAL|Artificial intelligence group|On the basis of conventional drug therapy combined with psychotherapy robot psychotherapy, the corresponding intelligent psychotherapy module and intensity were recommended according to the results of intelligent psychological evaluation. Each module was set once a week, 50 minutes each time, a total of 12 times.
62138062|NCT06698523|NO_INTERVENTION|Tell- show-Do|Control group
62494143|NCT02359864|EXPERIMENTAL|Cohort Two|"The second treatment arm will not be used until the last patient in the first dose arm has completed all follow up. At that point patients~#16-30 will be enrolled in the second dose arm (10 daily fractions of 2 Gy). 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events."
62494144|NCT01896934|EXPERIMENTAL|Sertraline|50-200mg daily
62494145|NCT02571257|PLACEBO_COMPARATOR|Placebo|Placebo treatment on stable background statin therapy
62494146|NCT02571257|EXPERIMENTAL|Gemcabene 300 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
62494147|NCT02571257|EXPERIMENTAL|Gemcabene 900 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
61941580|NCT04515173|OTHER|General group|The subjects in this group only received routine drug therapy and routine outpatient follow-up evaluation
62138063|NCT06698523|EXPERIMENTAL|Bubble-blower|breathing exercise technique using bubble-blower
62138064|NCT06698523|EXPERIMENTAL|Pin-wheel|breathing exercise technique using Pin-wheel
62138065|NCT02189252|ACTIVE_COMPARATOR|E4:L4|Crossover Sequence
62138066|NCT02189252|ACTIVE_COMPARATOR|L4:E4|Crossover Sequence
62138067|NCT02189252|ACTIVE_COMPARATOR|E2:L4|Crossover Sequence
62138068|NCT02189252|ACTIVE_COMPARATOR|L4:E2|Crossover Sequence
62138069|NCT00860236|ACTIVE_COMPARATOR|Psycoeducation/counseling|
62138070|NCT00860236|ACTIVE_COMPARATOR|Cognitive behavioural therapy|
62337116|NCT02559154|ACTIVE_COMPARATOR|conventional BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received bortezomib (1.3mg/㎡) administration twice weekly on day 1,4, 8,11 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
62337117|NCT04868591|ACTIVE_COMPARATOR|Single session APP arm|Participants in this group will received one session with the advanced practice physiotherapist.
62337118|NCT04868591|EXPERIMENTAL|Multiple sessions APP arm|Participants in this group will received 6 sessions (in 12 weeks) with the advanced practice physiotherapist.
62337119|NCT03922360|ACTIVE_COMPARATOR|Best Practices|
62337120|NCT03922360|EXPERIMENTAL|Best Practices + Financial Incentives|
62337121|NCT01672606|EXPERIMENTAL|Rocuronium|Intravenous infusion of rocuronium with the goal of TOF 0.70 and \>0.90
62337122|NCT04759963||Group A|follow up for 6 women who gave birth through a cesarean delivery with Midline approach epidural anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
62337123|NCT04759963||Group B|follow up for 13 women who gave birth through a cesarean delivery with Midline approach spinal anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
62337124|NCT04759963||Group C|follow up for 7 women who gave birth through a cesarean delivery with general anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
62337125|NCT04759963||Group D|follow up for 12 women who are the control group (who did not experience any pregnancy or anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
62337126|NCT03446937|EXPERIMENTAL|Dexamethasone sodium phosphate injection|Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)
62337127|NCT03446937|EXPERIMENTAL|Betamethasone sodium phosphate injection|Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)
62337128|NCT03446937|PLACEBO_COMPARATOR|Water for injection|Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.
62337129|NCT04099732|EXPERIMENTAL|Part 1: Reference 1 followed by Test 1|Reference 1 - Rosuvastatin. Test 1 - Rosuvastatin + BI 1358894
62337130|NCT04099732|EXPERIMENTAL|Part 2: Reference 2 followed by Test 2|Reference 2 - Dabigatran etexilate. Test 2 - Dabigatran etexilate + BI 1358894
62337131|NCT04520763|EXPERIMENTAL|Respiratory Muscle Exercises|Two respiratory muscle exercises
62337132|NCT04520763|NO_INTERVENTION|Control|The control intervention consists of quiet sitting for 15 min
62337133|NCT02096146|OTHER|TMT Fusion Plate|Patients are treated with TMT Fusion Plate to encourage bony fusion of the 1st TMT joint.
62337134|NCT02096146|OTHER|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion .
62337135|NCT05844124|ACTIVE_COMPARATOR|Control group: Standard of care land-based walking exercise|"Participants enrolled in the land-based walking exercise program will complete a total of two community walking or normal treadmill (not LBPP) walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all).~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing."
62494148|NCT01780350|EXPERIMENTAL|ResQGARD ITD|Subjects receive a ResQGARD ITD.
62138071|NCT06699550|EXPERIMENTAL|Haptonomy|Haptonomy was conducted individually, both in a prenatal school and at home. At the beginning of the application, information was provided about the definition, purpose, and importance of haptonomy. It was stated that haptonomy would be carried out over 8 weeks, once a week for at least 30 minutes, on days and times of their choosing. In the first 4 weeks, it would be conducted under the guidance of the researchers, while in the following 4 weeks, it would be applied with the help of videos and brochures provided by the researchers, together with their partners.
62494149|NCT06453837|EXPERIMENTAL|Active ingredient incorporated into a food supplement|"The investigational product (Ref.: S-1171b) is packed on a 200ml bottle and each bottle have 50 capsules of food supplement, manufactured by Mibelle Biochemistry (Bolimattstr. 1, CH - 5033 Buchs).~Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days."
61941581|NCT01565642|EXPERIMENTAL|Decision support intervention|Decision aid and care plan meeting
62494150|NCT06453837|PLACEBO_COMPARATOR|Placebo product|"The comparator product is a placebo (Ref.: S-1171a) with the same formulation as the investigational product, except for the active ingredient, on a 200ml bottle and each bottle have 50 capsules of food supplement, manufactured by Mibelle Biochemistry (Bolimattstr. 1, CH - 5033 Buchs).~Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days."
62494151|NCT04893941|EXPERIMENTAL|CM310 75mg arm|75mg for 3 doses, every 2 weeks, SC
62494152|NCT04893941|EXPERIMENTAL|CM310 150mg arm|150mg for 3 doses, every 2 weeks, SC
62695768|NCT03967600||Hidradenitis Suppurativa Patients|Patients with physician diagnosed Hidradenitis Suppurativa
62695769|NCT03967600||Healthy Volunteers|Healthy volunteers without any skin conditions or recent history of antibiotic use.
62695770|NCT01143441|EXPERIMENTAL|Cohort A|Long-Term daclizumab cohort
62695771|NCT01143441|EXPERIMENTAL|Cohort B|New Treatment Cohort
62695772|NCT01143441|NO_INTERVENTION|Cohort C|MS Controls
62695773|NCT04845347|EXPERIMENTAL|Bright Light Therapy|
62695774|NCT04845347|SHAM_COMPARATOR|Dim Light Therapy|
62695775|NCT05516121|EXPERIMENTAL|patients|Each patient takes 100 mg single dose, after wash-out period 200 mg single dose, then, after wash-out period 200 mg single dose two following days
62138072|NCT06699550|EXPERIMENTAL|Mindfulness-Based Stress Reduction Program|Participants were introduced to each other and provided with information related to pregnancy. The Mindfulness-Based Stress Reduction Program (MBSR) was introduced. The participants shared their levels of well-being, stress, coping mechanisms for fear of childbirth, and their expectations from the MBSR program. Awareness of habitual behaviors was facilitated. Afterwards, breath-focused meditation and dried fruit meditation were practiced. Participants were encouraged to maintain awareness of activities performed at any time during the day. Lastly, body scan meditation was taught, and participants were instructed to repeat the practice throughout the week using audio recordings sent via WhatsApp.
62138073|NCT06699550|NO_INTERVENTION|Control|No use intervention.
62138074|NCT00176202|ACTIVE_COMPARATOR|Risperidone|Risperidone is an antimanic medication and is a second generation antipsychotic
62138075|NCT00176202|ACTIVE_COMPARATOR|Divalproex sodium|Divalproex sodium is an antiepileptic medication and is a mood stabilizer
62138076|NCT02787005|EXPERIMENTAL|Cohort 1: PD-L1 positive with measurable disease|Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
62695776|NCT00938574|EXPERIMENTAL|Drug Atu027|
62695777|NCT05192070|EXPERIMENTAL|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
62695778|NCT05192070|EXPERIMENTAL|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
62695779|NCT05192070|EXPERIMENTAL|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
61941582|NCT01565642|NO_INTERVENTION|Control|Attention control information on dementia care
62138077|NCT02787005|EXPERIMENTAL|Cohort 2: PD-L1 negative with measurable disease|Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
62337136|NCT05844124|EXPERIMENTAL|Intervention group 1: Lower-body positive-pressure supported low-load treadmill walking exercise|"Participants enrolled in the Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise will complete a total of two walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all). Each walking session will include 30-minute walking on a G-Trainer (AlterG Inc., Fremont, CA) under low-load walking conditions.~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing."
62494153|NCT04893941|EXPERIMENTAL|CM310 300mg arm|300mg for 3 doses, every 2 weeks, SC
62494154|NCT04893941|EXPERIMENTAL|CM310 600(1st)+300mg(2nd,3rd) arm|600mg for 1st dose, and then 300 mg for 2nd and 3rd doses, every 2 weeks, SC
62494155|NCT04893941|PLACEBO_COMPARATOR|placebo arm|placebo for 3 doses, every 2 weeks, SC
62494156|NCT01415245|EXPERIMENTAL|Treatment|Device applied to saphenous vein graft
62695780|NCT02053155|EXPERIMENTAL|computer based patient education|The patients will complete a pre module and post module set of questions to determine whether their knowledge about peri operative smoking cessation increase smoking has changed. According to their willingness and eligibility, pharmacotherapy will be given.
62695781|NCT00433186|EXPERIMENTAL|A|Mycophenolate
62695782|NCT06188741|NO_INTERVENTION|Part 1: WBMRI for NF1 patients with no known PN|To assess the incidence of asymptomatic PN in any location in participants with NF1 and no known PN
62695783|NCT06188741|EXPERIMENTAL|Part 2: Treatment randomization to selumetinib vs observation|To determine if selumetinib treatment prevents PN growth in young participants with asymptomatic tumors in high-risk locations
62695784|NCT06188741|EXPERIMENTAL|Part 3: Part 2 participants with growing or symptomatic PN|To assess the proportion of participants who are able to maintain tumor response after transition to an intermittent dosing schedule
62695785|NCT04878185|EXPERIMENTAL|Exercise|"A high-intensity, home-based, exercise program consisting of inspiratory muscle training (IMT), endurance- and functional strength exercise. The sessions will supervised by a physiotherapist during six occasions and start 2-3 weeks before surgery. IMT will be conducted with an intensity starting from 50 % of maximal capacity, with a self-reported effort of 5-7 on the Borgs CR-10 scale. Endurance and functional strength exercises will be performed at a self-reported effort of 7-8. Interval training, chair stand- and step-up exercises will be key components of the exercise program. Furthermore, the program will include task-specific exercises based on the participants self-expressed needs.~On non-supervised days, participants will perform IMT twice a day as well as endurance and strength training, 2-3 days per week with 1-2 days per week of active recovery in the form of moderate intensity walks. This will be monitored with an activity journal and an accelerometer."
61941583|NCT01135212|ACTIVE_COMPARATOR|Fimasartan 60mg|Take one tablet of Fimasartan 60mg once a day in the morning
62337137|NCT05844124|EXPERIMENTAL|Intervention group 2: Aquatic Walking exercise|"Participants enrolled in the aquatic exercise program will complete a total of two aquatic walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all). Each aquatic exercise program will include walking in the pool for 30 minutes at self-selected speeds under the guidance of an aquatic therapy instructor.~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing."
62337138|NCT03609528|EXPERIMENTAL|CamPROBE biopsy method|To be completed
61941584|NCT01135212|ACTIVE_COMPARATOR|Fimasartan 120mg|Take one tablet of Fimasartan 120mg once a day in the morning
61941585|NCT01135212|ACTIVE_COMPARATOR|Candesartan 8mg|Take one tablet of Candesartan 8mg once a day in the morning
62337139|NCT01051986|ACTIVE_COMPARATOR|SVG group|"patients who underwent off-pump coronary artery bypass using saphenous vein composite grafting based on the left internal thoracic artery~use saphenous vein as a composite graft connected to the left internal thoracic artery"
62337140|NCT01051986|ACTIVE_COMPARATOR|RITA group|"patient who underwent off-pump coronary artery bypass using right internal thoracic artery composite grafting based on the left internal thoracic artery~use right internal thoracic artery as a composite graft connected to the left internal thoracic artery"
62337141|NCT03854643|EXPERIMENTAL|Pilates group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
62337142|NCT03854643|EXPERIMENTAL|Control group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
62337143|NCT04365439|EXPERIMENTAL|Convalescent plasma|Convalescent plasma from patients after COVID-19
62337144|NCT03154398||1|case control
62695786|NCT04878185|NO_INTERVENTION|Control group|Participants in the control group receive pre- and postoperative care as usual. In addition, they will be encouraged to follow the WHO guidelines of moderate intensity aerobic physical activity for at least 150 min per week. Their activity level will be monitored with an accelerometer.
62695787|NCT06637748|ACTIVE_COMPARATOR|Acute Exacerbation Group|an acute attack, at least 1 month after attack. a. Mild acute exacerbation b. Moderate acute exacerbation c. Severe acute exacerbation, according GINA 2024.
62695788|NCT06637748|ACTIVE_COMPARATOR|Stable Asthma Group|Patients attending routine follow-up visits with well-controlled asthma
61941586|NCT04992910|EXPERIMENTAL|Functional Electrical Stimulation|
61941587|NCT04992910|ACTIVE_COMPARATOR|Standard Therapy|
61941588|NCT03883399||Colorectal surgeons|Survey among Spanish colorectal surgeons
61941589|NCT03801083|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic biliary tract cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10\^11 lymphocytes infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
61941590|NCT01908920|OTHER|OMT|Each osteopathic session is based on structural evaluation and treatment using indirect techniques.
61941591|NCT01908920|OTHER|SHAM|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. A pre-determined protocol has been used. The practitioner's attention was distracted by subtracting calculation in silence."
61941592|NCT01908920|OTHER|CONTROL|No intervention
61941593|NCT05692167|ACTIVE_COMPARATOR|Topical dexmedetomidine group|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
62337145|NCT05216406|EXPERIMENTAL|5-HTP|The dietary supplement (100 mg of 5-hydroxytryptophan; CLEANMOOD™) was provided by NURA™ (Irvine, California USA). Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
62337146|NCT05216406|PLACEBO_COMPARATOR|Control|The placebo consisted of maltodextrin. Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
62337147|NCT01360944|EXPERIMENTAL|LAS 41004, variant 1, once daily|variant 1, once daily
62337148|NCT01360944|EXPERIMENTAL|LAS41004, variant 2, once daily|variant 2, once daily
62337149|NCT01360944|EXPERIMENTAL|LAS41004, variant 3, once daily|variant 3, once daily
62337150|NCT01360944|EXPERIMENTAL|LAS41004, variant 4, once daily|variant 4, once daily
62337151|NCT01360944|EXPERIMENTAL|LAS41004, variant 5, once daily|variant 5, once daily
62337152|NCT01360944|EXPERIMENTAL|LAS41004, variant 6, once daily|variant 6, once daily
62337153|NCT01360944|PLACEBO_COMPARATOR|reference|once daily, 100microgram
62337154|NCT01360944|ACTIVE_COMPARATOR|reference, once daily|once daily
62695789|NCT05374798|EXPERIMENTAL|Heart Rate Variability-Biofeedback via Smartwatch Device Intervention|Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed.
62695790|NCT00738660|EXPERIMENTAL|A|single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.
61941594|NCT05692167|ACTIVE_COMPARATOR|Reginal dexmedetomidine group|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
61941595|NCT06009029|EXPERIMENTAL|SBRT Combined With Zimberelimab|Patients diagnosed with locally advanced pancreatic cancer are treated with SBRT combined with Zimberelimab
61941596|NCT04140838|EXPERIMENTAL|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
61941597|NCT04140838|EXPERIMENTAL|TAU + Behavioral Activation Therapy for Depression (BATD)|Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.
61941598|NCT04140838|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
61941599|NCT04828460||Kidney transplant recipients who receive Covid-19 vaccine|
61941600|NCT01132274|ACTIVE_COMPARATOR|Conventional catheter ablation|Radiofrequency catheter ablation through fluoroscopic guidance
61941601|NCT01132274|EXPERIMENTAL|Non-fluoroscopic catheter ablation|Radiofrequency catheter ablation guided by the EnSite NavX (St.Jude Medical, St Paul, MN, USA) mapping-system
61941602|NCT05971433||"Injury severity scored as severe"|"This group will include participants whose injury was scored as severe based on the recorded Injury Severity Score (ISS). Both cohorts will complete the same course of testing in this study."
61941603|NCT05971433||"Injury severity scored as minimal"|"This group will include participants whose injury was scored as minimal based on the recorded Injury Severity Score (ISS). Both cohorts will complete the same course of testing in this study."
61941604|NCT05578248||Collegiate Athletes|Group designated for collegiate athletes; see protocol for treatment plan
62138078|NCT02787005|EXPERIMENTAL|Cohort 3: Bone metastases with non-measurable disease|Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
61941605|NCT05578248||Pre-collegiate Athletes|Group designated for pre-collegiate, or high school-age, athletes; see protocol for treatment plan
61941606|NCT06220279|ACTIVE_COMPARATOR|Arm 1, oral diclofenac|Two doses of 50mg oral diclofenac 12 hours apart was administered to this arm
61941607|NCT06220279|ACTIVE_COMPARATOR|Arm 2, rectal diclofenac|100mg diclofenac was administered rectally to this arm
61941608|NCT00299182|EXPERIMENTAL|1 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m\^2; plus Cyclophosphamide 300 mg/m\^2, Vincristine 1.4 mg/m\^2, Doxorubicin (Adriamycin) 50 mg/m\^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m\^2; and, R-Ara-C/MTX is Rituximab 375 mg/m\^2, Cytarabine 3 g/m\^2 and Methotrexate 200 mg/m\^2."
61941609|NCT00299182|EXPERIMENTAL|3 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m\^2; plus Cyclophosphamide 300 mg/m\^2, Vincristine 1.4 mg/m\^2, Doxorubicin (Adriamycin) 50 mg/m\^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m\^2; and, R-Ara-C/MTX is Rituximab 375 mg/m\^2, Cytarabine 3 g/m\^2 and Methotrexate 200 mg/m\^2."
62138079|NCT02787005|EXPERIMENTAL|Cohort 4: RECIST 1.1-measureable disease|Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
62138080|NCT02787005|EXPERIMENTAL|Cohort 5: Bone metastases only or bone-predominant disease|Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
62138081|NCT03352726|EXPERIMENTAL|DBV712 Solution for Skin Prick Test|DBV712 In-House Reference Skin Prick Test preparation
62138082|NCT01664806|NO_INTERVENTION|Coag mode 30 Watts Power|Elective laparoscopic cholecystectomy will be performed with 30 Watts power coag mode which is current standard of care.
62138083|NCT01664806|EXPERIMENTAL|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform Elective laparoscopic cholecystectomy. which is the experimental arm of the study's mode.
62138084|NCT02844439|EXPERIMENTAL|Glioblastoma|The single arm design assessing progression-free survival at 6 months (PFS-6) in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
62138085|NCT06019000|ACTIVE_COMPARATOR|CYR-064 dose 1|Treatment with nasal solution of CYR-064 twice a day for 24 weeks. CYR-064 will be self-administered by patients.
62138086|NCT06019000|EXPERIMENTAL|CYR-064 dose 2|Treatment with nasal solution of CYR-064 twice a day for 24 weeks. CYR-064 will be self-administered by patients.
62138087|NCT06019000|PLACEBO_COMPARATOR|Placebo|Treatment with Placebo nasal solution for 24 weeks. CYR-064 will be self-administered by patients.
62337155|NCT04937816||EMPA-REG - Placebo|Participants of the EMP-REG OUTCOME study (1245.25) who received placebo.
62138088|NCT06067763|EXPERIMENTAL|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
62138089|NCT06067763|EXPERIMENTAL|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
62494157|NCT01415245|NO_INTERVENTION|Control|Saphenous vein graft without device support
62494158|NCT06228196||BPPV patients|Confirmed diagnosis of BPPV
62494159|NCT06228196||Healthy controls|Healthy subjects who have not had BPPV
62494160|NCT03457402|EXPERIMENTAL|Treatment|Participants in the Experimental arm will begin the Shaping Delay Tolerance behavioral intervention immediately after baseline, and this training will last for about 6 weeks.
62494161|NCT03457402|ACTIVE_COMPARATOR|Wait-list Control|After baseline, participants in the Wait-list Control arm will wait for about 6-weeks before entering the pre-treatment phase, which is a repeat of effortful control assessments and behavior questionnaires, and then they will begin training for with the Shaping Delay Tolerance behavioral intervention.
62494162|NCT04129944|PLACEBO_COMPARATOR|Placebo|
62494163|NCT04129944|EXPERIMENTAL|UBX0101 0.5 mg|
62494164|NCT04129944|EXPERIMENTAL|UBX0101 2.0 mg|
62494165|NCT04129944|EXPERIMENTAL|UBX0101 4.0 mg|
62494166|NCT01344018|ACTIVE_COMPARATOR|Surgery alone|En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.
62494167|NCT01344018|EXPERIMENTAL|Preoperative radiotherapy followed by en-bloc surgery|3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions
62494168|NCT05633251|EXPERIMENTAL|School 1|
62695791|NCT04511494|ACTIVE_COMPARATOR|OIT peanut|"Children with peanut allergy receiving peanut OIT. Peanut challenge are done before randomization and one and three years after inclusion.~n=50 patients"
62695792|NCT04511494|NO_INTERVENTION|Peanut avoidance|"Children with peanut allergy not undergoing OIT peanut. Peanut challenge are done Before randomization and one and three years after inclusion.~n=25 patients"
62337156|NCT04937816||EMPA-REG - Empagliflozin low dose|Participants of the EMPA-REG OUTCOME study (1245.25) who received a low dose of empagliflozin once daily (QD).
62337157|NCT04937816||EMPA-REG - Empagliflozin high dose|Participants of the EMP-REG OUTCOME study (1245.25) who received a high dose of empagliflozin once daily (QD).
62337158|NCT04937816||EMPEROR-Preserved - Empagliflozin|Participants of the EMPEROR-Preserved study (1245.110) who received empagliflozin once daily (QD).
62337159|NCT04937816||EMPEROR-Preserved - Placebo|Participants of the EMPEROR-Preserved study (1245.110) who received placebo once daily (QD).
62337160|NCT04937816||EMPEROR-Reduced - Empagliflozin|Participants of the EMPEROR-Reduced study (1245.121) who received empagliflozin once daily (QD).
62337161|NCT04937816||EMPEROR-Reduced - Placebo|Participants of the EMPEROR-Reduced study (1245.121) who received placebo once daily (QD).
62337162|NCT01485926|EXPERIMENTAL|Docetaxel, Carboplatin and Trastuzumab|Arm A- 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
62337163|NCT01485926|EXPERIMENTAL|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|Arm B - 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
62337164|NCT00865293||Obesity|Subjects with obesity, defined as BMI \> 30, aged 25-60
62337165|NCT00865293||Control|Subjects with a BMI 18,5-25, aged 25-60
62494169|NCT05633251|EXPERIMENTAL|School 2|
62494170|NCT05633251|EXPERIMENTAL|School 3|
62494171|NCT06465979|EXPERIMENTAL|Speech perception experiments|This arm involves experiments wherein participants listen to speech played at comfortable volumes and respond by indicating what they heard either in open-ended form or by choosing among a set of options displayed on a computer.
62494172|NCT02676973|ACTIVE_COMPARATOR|Sacral Colpopexy|Sacral Colpopexy performed via open, robotic, or laparoscopic procedure.
62494173|NCT02676973|ACTIVE_COMPARATOR|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair: Sacrospinous Ligament Suspension (SSLS) and Uterosacral Ligament Suspension (USLS)
62494174|NCT02676973|ACTIVE_COMPARATOR|Apical Transvaginal Mesh Repair|Uphold™ LITE
62494175|NCT01721551|EXPERIMENTAL|Exercise training|HD patients will receive a 9 months intradialytic exercise training program
62494176|NCT01721551|PLACEBO_COMPARATOR|No exercise|HD patients will not participate in any type of systematic exercise training
62494177|NCT00822887|EXPERIMENTAL|Vandetanib|Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
62494178|NCT06627855|ACTIVE_COMPARATOR|Manual Therapy based Fascial Distortion Model|It will conducted for forty-five minutes once a week in a clinical setting for 4 weeks.
62494179|NCT06627855|SHAM_COMPARATOR|Control|Sham application will conducted for forty-five minutes once a week in a clinical setting for 4 weeks.
62494180|NCT06300086|EXPERIMENTAL|Patient letters + no GP letter.|"Patients with CKD will receive digital nudge letters, but their associated GPs will not receive a digital nudge letter.~The letters will inform patients with CKD of the importance of GDMT in CKD and that updated Danish guidelines for the treatment of CKD are available."
62494181|NCT06300086|EXPERIMENTAL|Patient letters + GP letter.|"Patients with CKD and their associated GPs will receive digital nudge letters.~The letters will inform the recipients of the importance of GDMT in CKD and that updated Danish guidelines for the treatment of CKD are available. The letter to the GPs will also include the definition of CKD and a summary of the guidelines."
62695793|NCT04511494|NO_INTERVENTION|Healthy controls|"Control Group with non-allergic, age-matched children. No challenges are performed in this group.~n=30 patients"
62494182|NCT06300086|EXPERIMENTAL|No patient letters + GP letter|"Patients with CKD will not receive digital nudge letters, but their associated GPs will receive a digital nudge letter.~The letter will inform the GPs of the importance of GDMT in CKD and that updated Danish guidelines for the treatment of CKD are available. The letter will also include the definition of CKD and a summary of the guidelines."
62494183|NCT06300086|NO_INTERVENTION|No patient letters + no GP letter|Neither patients with CKD nor their associated GPs will receive digital nudge letters.
62494184|NCT02337322|ACTIVE_COMPARATOR|ABC+3TC+DTG|Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
62695794|NCT04511494|NO_INTERVENTION|Children not reacting at the baseline peanut challenge|"Peanut-allergic children not reacting at the baseline peanut challenge, will not be eligible for randomisation. They will have a clinical visit after 1+3 years. No more challenges in this group.~n=X patients"
62695795|NCT05810597|EXPERIMENTAL|Sequence 1: Tirzepatide by Single Dose Pen (SDP)/ Multi-use Prefilled Pen (MUPFP)|"Participants received a single dose of 5 milligrams (mg) tirzepatide administered subcutaneously (SC) via an SDP in Period 1 followed by a single dose of 5 mg tirzepatide administered SC via a MUPFP in Period 2.~There was a washout period of at least 35 days between tirzepatide dose administrations."
62695796|NCT05810597|EXPERIMENTAL|Sequence 2: Tirzepatide by MUPFP / SDP|"Participants received a single dose of 5 mg tirzepatide administered SC via a MUPFP in Period 1 followed by a single dose of 5 mg tirzepatide administered SC via an SDP in Period 2.~There was a washout period of at least 35 days between tirzepatide dose administrations."
62695797|NCT03479528||Dyspepsia|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an jiaotong university,Xijing Hospital, Tangdu Hospital, Xi'an No.3 Hospital, and received investigation.
62695798|NCT06637631|EXPERIMENTAL|SAR441566 dose 1|Participants will receive SAR441566 dose 1.
62695799|NCT06637631|EXPERIMENTAL|SAR441566 dose 2|Participants will receive SAR441566 dose 2.
62695800|NCT06637631|EXPERIMENTAL|SAR441566 dose 3|Participants will receive SAR441566 dose 3.
62695801|NCT06637631|PLACEBO_COMPARATOR|Placebo|Participants will receive SAR441566 matching placebo.
62695802|NCT03424733|ACTIVE_COMPARATOR|Current Plegridy Users|Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
62695803|NCT03424733|EXPERIMENTAL|New Plegridy Users|Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
62695804|NCT04166747|EXPERIMENTAL|Intervention Group|The participants in this group will receive virtual reality based intervention for 15 minutes at a time, twice in a week for six weeks.
62695805|NCT04166747|NO_INTERVENTION|Control Group|The participants in this group will not receive virtual reality based intervention for six weeks.
62337166|NCT03756740|EXPERIMENTAL|Telerehabilitation|After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home. The exercises will be sent as a video to his/her mobile or e-mail according to the subject's preference. The exercises will be previously recorded and accompanied with a verbal explanation and instructions on how to correctly perform the exercises, paying close attention to specific points. In total, there will be 10 videos of exercises found effective for LBP patients.. After each face to face meeting, the physical therapist will choose from these 10 videos suitable exercises for the patients.
62695806|NCT06028412|EXPERIMENTAL|Sublobar|"The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group."
62695807|NCT06028412|PLACEBO_COMPARATOR|lobectomy|lobectomy and Systematic lymph node dissection
62695808|NCT02117076|ACTIVE_COMPARATOR|gabapentin immediate release|Gabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
62695809|NCT02117076|ACTIVE_COMPARATOR|gabapentin enacarbil extended release|Horizant is the extended release form of gabapentin enacarbil. Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
62695810|NCT06565039|EXPERIMENTAL|Supira System|Ventricular support indicated for use during elective or urgent high-risk percutaneous coronary interventions.
62695811|NCT00245479|OTHER|1|
62138090|NCT06067763|ACTIVE_COMPARATOR|Educational Video control|"Participants in this arm will be assigned to watch a four-part documentary The Weight of the Nation from their home."
62138091|NCT06699836|EXPERIMENTAL|350 mg dose of leronlimab in combination with Trifluridine + Tipiracil (TAS-102) + Bevacizumab|
62138092|NCT06699836|EXPERIMENTAL|700 mg dose of leronlimab in combination with Trifluridine + Tipiracil (TAS-102) + Bevacizumab|
62138093|NCT00973505||CYP19|CYP19 genetic polymorphism
62138094|NCT02802384||Cases|People with active Paget's Disease of Bone
62138095|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
62337167|NCT03756740|ACTIVE_COMPARATOR|Control|"After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home.~subjects will receive the same exercises given to experimental group according to the results of the face to face meeting. The exercises will be shown as printed pictures on paper"
62337168|NCT03147274|EXPERIMENTAL|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
62494185|NCT02337322|ACTIVE_COMPARATOR|ABC+3TC+DRV/r|Abacavir+lamivudine+ritonavir-boosted darunavir, QD
61941610|NCT00299182|EXPERIMENTAL|10 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m\^2; plus Cyclophosphamide 300 mg/m\^2, Vincristine 1.4 mg/m\^2, Doxorubicin (Adriamycin) 50 mg/m\^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m\^2; and, R-Ara-C/MTX is Rituximab 375 mg/m\^2, Cytarabine 3 g/m\^2 and Methotrexate 200 mg/m\^2."
62695812|NCT04474873|NO_INTERVENTION|Group 1:Conventional intravenous analgesia|Conventional intravenous analgesia applied according to surgeon's preference
61941611|NCT00299182|PLACEBO_COMPARATOR|Placebo (Arm A & Arm B) with Chemotherapy|"Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy~Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m\^2; plus Cyclophosphamide 300 mg/m\^2, Vincristine 1.4 mg/m\^2, Doxorubicin (Adriamycin) 50 mg/m\^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m\^2; and, R-Ara-C/MTX is Rituximab 375 mg/m\^2, Cytarabine 3 g/m\^2 and Methotrexate 200 mg/m\^2."
61941612|NCT00299182|EXPERIMENTAL|1 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m\^2; plus Cyclophosphamide 300 mg/m\^2, Vincristine 1.4 mg/m\^2, Doxorubicin (Adriamycin) 50 mg/m\^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m\^2; and, R-Ara-C/MTX is Rituximab 375 mg/m\^2, Cytarabine 3 g/m\^2 and Methotrexate 200 mg/m\^2."
61941613|NCT00299182|EXPERIMENTAL|3 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m\^2; plus Cyclophosphamide 300 mg/m\^2, Vincristine 1.4 mg/m\^2, Doxorubicin (Adriamycin) 50 mg/m\^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m\^2; and, R-Ara-C/MTX is Rituximab 375 mg/m\^2, Cytarabine 3 g/m\^2 and Methotrexate 200 mg/m\^2."
61941614|NCT00299182|EXPERIMENTAL|10 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m\^2; plus Cyclophosphamide 300 mg/m\^2, Vincristine 1.4 mg/m\^2, Doxorubicin (Adriamycin) 50 mg/m\^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m\^2; and, R-Ara-C/MTX is Rituximab 375 mg/m\^2, Cytarabine 3 g/m\^2 and Methotrexate 200 mg/m\^2."
61941615|NCT01436916|ACTIVE_COMPARATOR|oral cholecalciferol + lifestyle counselling|will receive Oral cholecalciferol
61941616|NCT01436916|PLACEBO_COMPARATOR|Placebo + lifestyle counselling|will receive placebo
61941617|NCT04308304|EXPERIMENTAL|Donepezil|Participants receive Dose Level 1: 8-mg MK-1942 twice daily (BID) x 7 days (7D), Day 1 to Day 7; Dose Level 2: 15-mg MK-1942 BID x 7D, Day 8 to Day 14; Dose Level 3: 30-mg MK-1942 BID x 7D, Day 15 to Day 21; Dose Level 4: ≤50-mg MK-1942 BID x 7D (Provisional Dose Level), Day 22 to Day 28 All participants to receive Donepezil once daily.
61941618|NCT04308304|PLACEBO_COMPARATOR|Placebo|Placebo to MK-1942 BID x 21 \[28\] D All participants to receive Donepezil once daily.
61941619|NCT00412997|EXPERIMENTAL|LBH589|
61941620|NCT04215250|ACTIVE_COMPARATOR|Andropulous method|"Andropulous method uses equations to determine the depth of CVC insertion.~For subject with \<100 cm in height:~Depth of CVC insertion (cm) = (height (cm)/ 10)-1~For subject with \>100 cm in height:~Depth of CVC insertion (cm) = (height (cm)/ 10)-2"
61941621|NCT04215250|ACTIVE_COMPARATOR|ECG method|change in p wave from ECG
61941622|NCT04016233|EXPERIMENTAL|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, each with 3 douches. Sequence A will be 3 sequential doses of TFV douche; Sequence B will be one dose of TFV douche followed by 2 sequential non-medicated douches; Sequence C will be 2 sequential non-medicated douches followed by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by various specimen collections over 8 days according to individual sampling schedule assigned to each participant. Specimens will be collected on Days 1, 2, 4, and 8 post sequence administration.
61941623|NCT02805972|EXPERIMENTAL|Naloxone, then Placebo|4 mg / 0.1 ml Naloxone at visit 1, followed by 0.1 ml saline (Placebo) at visit 2 (with a washout period in between the two visits)
61941624|NCT02805972|EXPERIMENTAL|Placebo, then Naloxone|0.1 ml saline (Placebo) at visit 1, followed by 4 mg / 0.1 ml Naloxone at visit 2 (with a washout period in between the two visits)
62695813|NCT04474873|ACTIVE_COMPARATOR|Group 2:ESPB|A 6-13 MHz linear probe was used for ultrasound-guided ESPB (Logiq e, General Electric, USA,) performed at the T11 level. The transverse process was detected by sliding the transducer 3-4 cm laterally from the midline, and after identification of the transverse process, a 20-gauge 100mm insulated echogenic needle (Vygon locoplex, France) was used
62695814|NCT01092897||Subjects with PAH treated with Imatinib|
62337169|NCT03147274|NO_INTERVENTION|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
62337170|NCT04182256|EXPERIMENTAL|MS group|In the MS group, the MS grips the HVC through the magnet adsorbed onto the wall of the basin containing the liver. By changing the position of the MS on the wall of the basin, the surgeon is able to expose the surgical field.
62695815|NCT02553733|ACTIVE_COMPARATOR|Beetroot juice (Beet-It Organic Shot)|Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
62695816|NCT02553733|PLACEBO_COMPARATOR|Beetroot juice placebo (Beet-It Organic Placebo)|Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
62695817|NCT03662451|ACTIVE_COMPARATOR|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
61941625|NCT05543889||Patients|100 patient participants will be recruited for limbal anterior chamber depth image capture. These images will be used to develop the clinical vignette database
61941626|NCT05543889||Optometrists|50 optometrists will be recruited to undertake the clinical vignette assessment
61941627|NCT05847361||P|(P) : Preclamptic women : pregnant women diagnosed with preclampsia
61941628|NCT05847361||N|(N) : normotensive women : pregnant women without any criteria of preeclampsia
61941629|NCT06681883|EXPERIMENTAL|Action group|
61941630|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
61941631|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
61941632|NCT02128906|ACTIVE_COMPARATOR|Cisplatin-IMRT|Cisplatin 40 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
61941633|NCT02128906|ACTIVE_COMPARATOR|Docetaxel-Cetuximab-IMRT|Docetaxel 15 mg/m2 weekly x 7; Cetuximab 400 mg/m2 load, one week prior to IMRT; Cetuximab 250 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
61941634|NCT06106607|EXPERIMENTAL|Intervention group|This group will undergo a 20-week individually tailored, behavioral intervention
61941635|NCT06106607|NO_INTERVENTION|Control group|This group will be encouraged to maintain usual lifestyle and activities.
61941636|NCT00195273|EXPERIMENTAL|1|Sirolimus + Daclizumab + Mycophenolate + Corticosteroids
61941637|NCT00195273|ACTIVE_COMPARATOR|2|Cyclosporine + Mycophenolate + Corticosteroids
61941638|NCT03265301|OTHER|Office hysteroscopy|
61941639|NCT03265301|OTHER|Conventional hysteroscopy|
61941640|NCT05539131|ACTIVE_COMPARATOR|active transcranial direct current stimulation (tDCS)|daily active transcranial direct current stimulation (tDCS) use for 6 weeks
61941641|NCT05539131|SHAM_COMPARATOR|sham transcranial direct current stimulation (tDCS)|daily active transcranial direct current stimulation (tDCS) use for 3 weeks + daily sham transcranial direct current stimulation (tDCS) use for 3 weeks
62695818|NCT03662451|ACTIVE_COMPARATOR|Robotic multi-site hysterectomy|Robotic multi-site hysterectomy is performed in this arm
61941642|NCT01067066|EXPERIMENTAL|TPI 287 + Temodar|Starting dose of TPI 287 90 mg/m\^2 IV on Days 1, 8, 15 + Temozolomide (Temodar) PO at 85 mg/m\^2 on Days 1-5.
61941643|NCT02772887|EXPERIMENTAL|Citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
61941644|NCT02772887|PLACEBO_COMPARATOR|Placebo|Placebo, 3 grams once per day for 3 weeks.
61941645|NCT04523948||Cohort One|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
62695819|NCT06587659|EXPERIMENTAL|IR-TMS to the right DLPFC|IR-TMS will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the IR-TMS coil positioned using a robotic arm. In this arm, active IR-TMS will be delivered using a theta burst stimulation protocol (i.e. 1,800 pulses/session), 4 sessions per day, 5 days/week, for 2 weeks.
62695820|NCT05975450|EXPERIMENTAL|Abatacept|Participants will be assigned to a treatment regimen between 2 and 5 months after transplantation. The study drug will be administered until month 12 post-transplant; at that point, all participants will be transitioned to a physician-directed immunosuppressive regimen post-study.
61941646|NCT04523948||Cohort Two|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
61941647|NCT04523948||Cohort Three|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
61941648|NCT04523948||Cohort Four|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
61941649|NCT04523948||Cohort Five|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
61941650|NCT01833988|EXPERIMENTAL|Bi-hormonal Bionic Pancreas|Bi-hormonal Bionic Pancreas
61941651|NCT01833988|ACTIVE_COMPARATOR|Usual Care|Usual Care
61941652|NCT05816720||Initial treatment|Patients who received initial treatment with lutetium-177 DOTATATE
61941653|NCT05816720||Re-treatment|Patients who received re-treatment with lutetium-177 DOTATATE
61941654|NCT05816720||Additional re-treatment|Patients who received additional re-treatment with lutetium-177 DOTATATE
62695821|NCT06134401|EXPERIMENTAL|Treatment|Nebulised 6% Hypertonic saline
62695822|NCT06134401|PLACEBO_COMPARATOR|Control|Nebulised 0.9% normal saline
62695823|NCT06526429|EXPERIMENTAL|Dose 15|Dose 15 involved 5 cycles of blow block and restoration, each for15 seconds.
62695824|NCT06526429|EXPERIMENTAL|Dose 60|Dose 60 involved 4 cycles of blow block and restoration, each for 60 seconds.
62695825|NCT06526429|EXPERIMENTAL|Dose 120|Dose 120 involved 4 cycles of blow block and restoration, each for 120 seconds.
61941655|NCT04247776|EXPERIMENTAL|Prehab|General nutrition, relaxation, and exercise instructions. Home-based functional exercises, Fitbit goals, and nutrition supplements.
61941656|NCT04247776|ACTIVE_COMPARATOR|ERAS|Enhanced Recovery After Surgery standard of care plus Fitbit.
61941657|NCT01408797|EXPERIMENTAL|Donor specific transfusion|Subjects with uremia will undergo donor specific transfusion before transplantation
61941658|NCT01408797|EXPERIMENTAL|Clonal deletion|
61941659|NCT01408797|EXPERIMENTAL|Drugs Added When Needed|
62337171|NCT04182256|NO_INTERVENTION|MA group|In MA group, assistants use vessel forceps to pull the HVC according to the attending's requirements.
62337172|NCT03555084|EXPERIMENTAL|Device: Extension of Phonak Virto B-Titanium|The extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
62337173|NCT03555084|ACTIVE_COMPARATOR|Device: Phonak Virto B-Titanium|The Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
62494186|NCT04284007|ACTIVE_COMPARATOR|Perineural levobupivacaine with intravenous saline|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous saline.
62494187|NCT04284007|EXPERIMENTAL|Perineural dexamethasone in addition to levobupivacaine|Patients will receive levobupivacaine-dexamethasone in interscalene brachial plexus block plus intravenous saline.
62494188|NCT04284007|EXPERIMENTAL|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous dexamethasone.
62494189|NCT04090658|EXPERIMENTAL|RSV_PreF3_AS01B Group|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
62695826|NCT06526429|EXPERIMENTAL|Dose 180|Dose 180 involved 4 cycles of blow block and restoration, each for 180 seconds.
62337174|NCT04247750|EXPERIMENTAL|Open label trial|Sirolimus 0.5 mg tablets
62337175|NCT05591599||Case group|Women diagnosed with tubal pregnancy
62337176|NCT05591599||Control group|Women with the age corresponding to the case group (matched with the same age or +/- 2 years difference compared with the case group), diagnosed with spontaneous abortion or viable intrauterine pregnancy
62337177|NCT04507867|SHAM_COMPARATOR|control group|Patients who received the standard diet
62337178|NCT04507867|EXPERIMENTAL|Intervention group|Patients who received the nutritional support system (NSS) and the standard diet
62337179|NCT04136353|EXPERIMENTAL|Darolutamide|"Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
62337180|NCT04136353|PLACEBO_COMPARATOR|Placebo|"Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
62337181|NCT04664855|EXPERIMENTAL|Experimental Yoga Group|35 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
62337182|NCT04664855|NO_INTERVENTION|Control Group (No Yoga Intervention)|20 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
62337183|NCT02736292|EXPERIMENTAL|participant|
62337184|NCT04419285|EXPERIMENTAL|Retinitis Pigmentosa patients|50 patients with very severe Retinitis Pigmentosa
62337185|NCT03329651|EXPERIMENTAL|Metformin treatment|
62337186|NCT03329651|PLACEBO_COMPARATOR|Placebo treatment|
62337187|NCT02768194|EXPERIMENTAL|Test Product (0.454% stannous fluoride)|Participants will use dentifrice containing 0.454% stannous fluoride. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
62337188|NCT02768194|ACTIVE_COMPARATOR|Reference Product (0.76% sodium monofluorophosphate)|Participants will use dentifrice containing 0.76% sodium monofluorophosphate. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
62494190|NCT04090658|PLACEBO_COMPARATOR|Placebo Group|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
62494191|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
62494192|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
62494193|NCT03835845|EXPERIMENTAL|PICO7Y|PICO 7Y is a single-use NPWT System consisting of a small portable pump \& pump clip, 2 AA batteries, 2 large multisite dressings, 2 extension tubes and secondary fixation strips.
62494194|NCT02242734|EXPERIMENTAL|Mild Hepatic Impairment|20 mg HC-ER
62494195|NCT02242734|EXPERIMENTAL|Moderate Hepatic Impairment|20 mg HC-ER
62494196|NCT02242734|EXPERIMENTAL|No Hepatic Impairment|20 mg HC-ER
62494197|NCT01547728|EXPERIMENTAL|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
62494198|NCT04929821|OTHER|Study Device Treated Group|Treated with the study device, UNITY-B Biodegradable Balloon-Expandable Biliary Stent System.
62494199|NCT00684801||Usual care (control group)|Patients undergo usual care as determined by core cancer team.
62494200|NCT00684801||DMP (experimental group)|Patients undergo a systematic approach regarding specific domains related to their disease focusing on supportive care and symptom management determined by a multidisciplinary team of providers to help patients and caregivers manage.
62494201|NCT03539926|EXPERIMENTAL|Lit-control®pH Meter|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
62695827|NCT06526429|EXPERIMENTAL|Dose 240|Dose 240 involved 4 cycles of blow block and restoration, each for 240 seconds.
62695828|NCT06526429|EXPERIMENTAL|Dose 300|Dose 300 involved 4 cycles of blow block and restoration, each for 300 seconds.
61941660|NCT00860444|ACTIVE_COMPARATOR|1|Participants will take part in the basic educational and counseling program through their community health care center.
61941661|NCT00860444|EXPERIMENTAL|2|Participants will take part in the comprehensive educational and counseling program through their community health care center.
61941662|NCT00694915|EXPERIMENTAL|Mw|Mycobacterium w
61941663|NCT00694915|ACTIVE_COMPARATOR|BCG|bacillus Calmette-Guerin (BCG)
61941664|NCT01138839|PLACEBO_COMPARATOR|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery.
61941665|NCT01138839|EXPERIMENTAL|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
61941666|NCT00910273|EXPERIMENTAL|1|etanercept 50 mg/week
61941667|NCT06242600|EXPERIMENTAL|CytaCoat LIP Foley catheter|CytaCoat LIP Foley catheters will be randomized 1:1 (15 patients in each arm), to patients in need of catheterization for up to 24 hrs.
61941668|NCT06242600|OTHER|Uncoated silicone Foley catheter|Uncoated silicone Foley catheter will be randomized 1:1 (15 patients in each arm), to patients in need of catheterization for up to 24 hrs.
61941669|NCT01369160||1|Chronic Transfusion
61941670|NCT01369160||2|hydroxyurea
61941671|NCT01369160||3|matched sibling donor stem cell transplantation (MSD-SCT)
61941672|NCT01369160||4|standard comprehensive care (SCC, control)
61941673|NCT06311851|EXPERIMENTAL|Bevacizumab Transarterial Chemoembolization|The procedure commences with local disinfection and anesthesia, followed by a percutaneous right femoral artery puncture, performed using a modified Seldinger technique. A 5-F Simmons Ⅰ catheter was introduced through a vascular sheath and positioned in the common hepatic artery with the guidance of digital subtraction angiography to identify the tumor-supplying vessels. A 2.8-F microcatheter catheter was advanced into the vessel supplying the hepatic tumor. In cases of bilobar disease, the initial treatment focus was on the lobe with the greatest tumor burden, with the contralateral lobe addressed in a subsequent TACE session scheduled 4-6 weeks apart. In the standard TACE protocol ( hepaspheres are loaded with Irinotecan at 50 mg for colon metastases and Idarubicin at 10 mg for breast metastases), Bevacizumab 50 mg-loaded hepaspheres was added. The procedure was monitored under fluoroscopy until arterial flow stasis was achieved.
61941674|NCT06680752|EXPERIMENTAL|phase 1 (Dose Escalation) and phase 2 (Dose Expansion)|"In Phase 1, three escalating dose levels will be tested using the 3 + 3 design. The MTD and RP2D will be identified.~The Phase 2 will be conducted in 2 stages. In Stage I, evaluable participants from Phase 1 treated at RP2D will be enrolled. And the enrollment will continue into Stage II (additional evaluable participants) at the maximum RP2D participants for preliminary overall assessment of efficacy and safety."
61941675|NCT01066403|EXPERIMENTAL|Pergolide|Patients will be randomly assigned to a sequence of treatments of either pergolide or placebo p.o. under continuous concomitant atypical neuroleptic therapy (stable at least 2 weeks prior trial begin).
61941676|NCT00322101|EXPERIMENTAL|Arm I (Nonmyeloablative regimen)|"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96."
61941677|NCT00322101|EXPERIMENTAL|Arm II (Myeloablative regimen)|"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.~Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.~Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.~TRANSPLANTATION: Patients undergo PBSC infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
61941678|NCT04971707|ACTIVE_COMPARATOR|standard exercise training|The physical exercises intervention will include a standardized aerobic exercises training, three sessions per week for 3 months.
61941679|NCT04971707|EXPERIMENTAL|HRV-guided exercise training|The physical exercises intervention will include an individualized aerobic exercises training, three sessions per week for 3 months.
61941680|NCT06201663|EXPERIMENTAL|Interventional group|"Patients with CIT fulfilling the inclusion criteria will receive romiplostim subcutaneously weekly, either at the time of nadir of a delayed chemotherapy cycle or on the first day of the subsequent chemotherapy cycle and continue until the completion of chemotherapy for maximum 12 weeks.~Starting dose will be 3 μg/kg with the escalation of the dose weekly by 2 μg/kg (maximum dose 10 μg/kg) when the platelet increment was less than 25 x10e9/L to maintain platelet counts above 75x10e9/L."
61941681|NCT06201663|NO_INTERVENTION|Control group|"Patients with CIT fulfilling the inclusion criteria randomized to the control group will not receive romiplostim injections.~Patients are allowed to received supportive care according to the standard of care protocols."
61941682|NCT00814866|OTHER|Adalimumab|Open label
61941683|NCT05737849||Cohort 1: Participants With Positive EGFR ex20ins Detection|Participants with NSCLC having positive EGFR ex20ins detected by NGS were observed retrospectively for three years prior to leading site initiation.
61941684|NCT05737849||Cohort 2: Participants With Positive and Negative EGFR ex20ins Detection|Participants with NSCLC having positive and negative EGFR ex20ins NGS testing results were observed retrospectively for three years prior to leading site initiation.
61941685|NCT06025305||Patients who underwent coronary CT angiography and intravascular ultrasound within 3 months|
61941686|NCT06025305||Patients who underwent coronary CT angiography and optical coherence tomography within 3 months|
62695829|NCT00032513||CAEBV|Patients with chronic active Epstein-Barr virus.
61941687|NCT03416907|ACTIVE_COMPARATOR|Original|Participants will review the full-length, original consent form for the clinical trial.
62695830|NCT00032513||Hydroa vaccineforme|Patients with EBV hydro vaccineforme.
62695831|NCT03631511|EXPERIMENTAL|RetroMTA|Direct pulp capping with RetroMTA (BioMTA, Daejeon, Korea)
62695832|NCT03979001||Patients|Patients referred for polysomnography diagnosis of obstructive sleep apnea syndrome
62695833|NCT03979001||Controls|Person without obstructive sleep apnea syndrome
61941688|NCT03416907|EXPERIMENTAL|Shortened|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
61941689|NCT03416907|EXPERIMENTAL|Reordered|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
61941690|NCT03416907|EXPERIMENTAL|Highlighted|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
61941691|NCT03416907|EXPERIMENTAL|Interactive|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
61941692|NCT03316365|EXPERIMENTAL|Continuous RAS|The experimental group (continuous treatment) trained daily with RAS for 24 weeks.
62337189|NCT02768194|OTHER|Negative Control (Mineral water)|Participants will use commercially available mineral water. Appliances brushed ex situ in mineral water twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in mineral water. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
62337190|NCT02617732|EXPERIMENTAL|Tianqi capsule|a Chinese patent medicine extracted form more than10 kinds of herbs, which was approved to treat type 2 diabetes by CDFA in 2002.
61941693|NCT03316365|ACTIVE_COMPARATOR|Intermittent RAS|The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks.
61941694|NCT05047185|EXPERIMENTAL|Part 1: Low dose|BID low dose of deucrictibant
61941695|NCT05047185|EXPERIMENTAL|Part 1: High dose|BID high dose of deucrictibant
61941696|NCT05047185|PLACEBO_COMPARATOR|Part 1: Placebo|BID placebo
61941697|NCT05047185|EXPERIMENTAL|Part 2: Open-label|BID high dose of deucrictibant
61941698|NCT03594526|EXPERIMENTAL|Maternal support to become mother|"Maternal support to become mother: is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of:~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
61941699|NCT03594526|ACTIVE_COMPARATOR|Control group: usual Care|The participants will receive the usual education about the care of the mother during the puerperium, the care of the newborn, including breastfeeding.
61941700|NCT02478372|ACTIVE_COMPARATOR|Patient Controlled Epidural (PCEA)|A lumbar epidural was sited using a side-directed technique towards the side of surgery following establishment of the spinal blockade. Following the completion of the operation, patients received 4ml of 0.25% levobupivacaine prior to leaving the operating room. Thereafter they were connected to a PCEA pump (McKinley 545) with no background infusion. Patients could self-medicate with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes to control their pain until the following morning (post-operative day one) when it was stopped. Nurse-administered rescue top-ups of 4ml of 0.25% levobupivacaine were available for insufficient analgesia. The epidural catheter was removed on the morning of post-operative day two (POD2).
62337191|NCT02617732|PLACEBO_COMPARATOR|placebo|a capsule looks the same as Tianqi capsule, containing starch and other edible compositions.
62337192|NCT03586882|EXPERIMENTAL|Spinal Cord Stimulation Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
62695834|NCT06638853|EXPERIMENTAL|Distress Tolerance Skills Training|Students will participate in a series of classroom-based lessons aimed at increasing distress tolerance.
62695835|NCT06638853|NO_INTERVENTION|Standard Curriculum (Control)|Students will not participate in the distress tolerance skills training. They will receive only their standard curriculum during class time.
62695836|NCT06557863|EXPERIMENTAL|Enhanced Control + WeCareToFeedDysphagia|Participants receive usual care from their medical team and receive contact information for speech-language pathology follow-up care. Participants will also receive access to the WeCareToFeedDysphagia web tool and receive text message reminders to use the tool.
61941701|NCT02478372|EXPERIMENTAL|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine. 50ml injected following bone preparation prior to implant cementation perpendicular to the posterior femur through the posterior joint capsule in 10ml aliquots. 30ml proximal to the suprapatellar pouch down to the femur.100ml spread into subcutaneous tissues including; collateral and cruciate ligaments, fatty and connective tissue on the anterior aspect of the incision. A 16 gauge epidural catheter inserted via a medial portal, 20ml was injected via the catheter following closure of wound. Post-operatively, patients received boluses of 40ml ropivacaine 0.2% via the catheter using a mechanical McKinley 595 pump 4 hours after leaving theatre, at 22:00 and 08:00 on post-operative day one.
61941702|NCT05991700|EXPERIMENTAL|Concentrated grape powder|
61941703|NCT05991700|PLACEBO_COMPARATOR|Placebo|
61941704|NCT03761667|EXPERIMENTAL|NBI|The group of NBI inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
62337193|NCT03586882|NO_INTERVENTION|Control Group|Gait and balance testing to be administered once in healthy subjects
62337194|NCT02692014||coronary heart disease|2,400 patients who are diagnosed with CHD and have received more than 2 times of coronary angiography within 12-24 months.
62494202|NCT03539926|PLACEBO_COMPARATOR|Reactive strips|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
62494203|NCT00216060|EXPERIMENTAL|Experimental Arm|Daily oral risedronate combined with androgen deprivation
61941705|NCT03761667|NO_INTERVENTION|White light endoscopy (WLE)|The group of WLE inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
61941706|NCT00617851|EXPERIMENTAL|Influenza virus vaccine (lot A)|Lot A of the investigational influenza virus vaccine
61941707|NCT00617851|EXPERIMENTAL|Influenza virus vaccine (lot B)|Lot B of the investigational influenza virus vaccine
61941708|NCT00617851|EXPERIMENTAL|Influenza virus vaccine (lot C)|Lot C of the investigational influenza virus vaccine
61941709|NCT00617851|EXPERIMENTAL|Influenza virus vaccine (pooled)|Pooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine
61941710|NCT00617851|ACTIVE_COMPARATOR|Comparator influenza vaccine|A US licensed influenza virus vaccine
61941711|NCT06681584||Group A|Both groups of patients will receive CT scan for calcium score and Coronary angiogram, viz CTCA scan. Non-invasive FFRb will be calculated for all the patients with acceptable CTCA image quality. Based on the medical history and CTCA results, the patients may be referred for additional non-invasive tests or ICA and treated with medical therapy, PCI or CABG
61941712|NCT06681584||Group B|Both groups of patients will receive CT scan for calcium score and Coronary angiogram, viz CTCA scan. Non-invasive FFRb will be calculated for all the patients with acceptable CTCA image quality. However the FFRb results will only be given to the doctors who are taking care of the patients in Group B. Based on the medical history and CTCA with FFRb results (Group B), the patients may be referred for additional non-invasive tests or ICA and treated with medical therapy, PCI or CABG
61941713|NCT05530785|EXPERIMENTAL|treatment group|radiotherapy combined with sintilimab and bevacizumab biosimilar
61941714|NCT03644680|EXPERIMENTAL|Nasal Provocation with Birch Extract|Birch allergic patient receiving 3 consecutive nasal challenges with birch extract (Allergopharma). Total dose of 1.5ug of Bet v 1 per challenge
61941715|NCT03644680|PLACEBO_COMPARATOR|Nasal Provocation with NaCl 0.9%|Birch allergic patient receiving 3 consecutive nasal challenges with sterile NaCl 0.9%. Total dose of 100ul per nostril per challenge
61941716|NCT04343820||Breast reconstruction|Women who have had a mastectomy and want a secondary breast reconstruction by implant.
61941717|NCT06243484|EXPERIMENTAL|TOTUM-070|The experimental arm will be supplemented with TOTUM-070 twice a day
61941718|NCT06243484|PLACEBO_COMPARATOR|PLACEBO|The placebo comparator arm will be supplemented with a placebo twice a day
61941719|NCT04317404||Diabetic with Knee Osteoarthritis|HbA1c between 6.5% - 12.0% in the 3 months prior to Visit 1
61941720|NCT04317404||Pre-diabetic with Knee Osteoarthritis|HbA1c between 5.6% - 6.4% in the 3 months prior to Visit 1
61941721|NCT04317404||Non-diabetic with Knee Osteoarthritis|HbA1c \< 5.6% in the 3 months prior to Visit 1
61941722|NCT02563977||DIEP flap breast reconstruction|14 patients who have had DIEP flap breast reconstruction and preoperative CT scan of the abdomen
61941723|NCT00997880|EXPERIMENTAL|Rosuvastatin calcium 40mg|high-dose (40mg rosuvastatin)
61941724|NCT00997880|ACTIVE_COMPARATOR|Rosuvastatin calcium10mg|low-dose statin (10mg rosuvastatin)
62337195|NCT03989219||lung nodules were found by CT scanning|Plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
62494204|NCT00216060|PLACEBO_COMPARATOR|Placebo Arm|daily oral placebo combined with androgen deprivation
62695837|NCT06557863|NO_INTERVENTION|Enhanced Control|Participants receive usual care from their medical team and receive contact information for speech-language pathology follow-up care.
62695838|NCT06625372|EXPERIMENTAL|SMOF lipid|The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
62695839|NCT06625372|ACTIVE_COMPARATOR|Intralipid|intralipids
62695840|NCT06324409|ACTIVE_COMPARATOR|Reminder telephone call|A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
62695841|NCT06324409|NO_INTERVENTION|Comparison|The reminder letter in Norwegian (usual care) only
62738472|NCT03800524|PLACEBO_COMPARATOR|Reference therapy|"* Placebo capsules identical to active compound~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
61941725|NCT05342610|EXPERIMENTAL|Experimental (distant reiki) group|Reiki (complementary and integrative medicine method) was applied individually to the experimental group for 30 minutes three times a week for four weeks. Data collection forms was applied 3 times in total, before the intervention, in the fourth and the eighth week.
61941726|NCT05342610|NO_INTERVENTION|Control group|No intervention was made to women in the control group. However, data collection forms was applied 3 times in total, before the intervention, in the fourth and the eighth week.
61941727|NCT05920694|ACTIVE_COMPARATOR|CPAP Group|Participants randomized to CPAP will initiate CPAP therapy at the beginning of the study.
61941728|NCT05920694|PLACEBO_COMPARATOR|Delayed CPAP Group|Participants randomized to delayed CPAP (waitlist control) will initiate CPAP therapy immediately after 12 weeks. The investigators recognize that adherence to CPAP therapy is a common barrier to effective clinical treatment of OSA and to rigorous research on CPAP and has been significantly correlated with improvements in insulin resistance, including in a small of study of women with PCOS. After receiving this device, participants can meet with a study psychiatrist and his team within 3 days of initiating CPAP therapy and as needed for up to a month after initiating therapy. No visits in this time period will be billed to insurance.
61941729|NCT01061216|EXPERIMENTAL|Intradermal insulin infusion (ID)|
61941730|NCT01061216|ACTIVE_COMPARATOR|Subcutaneous insulin infusion (SC)|
61941731|NCT06333093|EXPERIMENTAL|Cold snare resections|Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
61941732|NCT02876094|EXPERIMENTAL|Open-label|All patients will be treated at each dose of oral once daily celecoxib (40, 80 and 160 mcg/kg) for a period of two weeks, for a total of 6 weeks (42 days) of treatment.
61941733|NCT05730699|EXPERIMENTAL|BCD-132 (divozilimab)|Intravenous infusion of BCD-132 every 24 weeks
61941734|NCT04987268||Current-smoking|exposure: smoking
61941735|NCT04987268||Smoking-cessation|exposure: smoking cessation
61941736|NCT04987268||non-smoking|exposure: none
61941737|NCT03945266|EXPERIMENTAL|Intervention group|Participants receive the allocated intervention to help manage gestational weight gain that includes education on weight regulation, healthy eating, physical activity, and goal setting.
61941738|NCT03945266|ACTIVE_COMPARATOR|Control group|Participants do not receive the allocated intervention but self-monitor their behaviors, complete study tasks and receive prenatal care as normal.
61941739|NCT04709471|EXPERIMENTAL|Switch to low nicotine e-cigarettes|Switch to e-cigarettes containing 60% of baseline e-cigarette nicotine content.
61941740|NCT04709471|EXPERIMENTAL|Reduce number of e-cigarette pods|Reduce e-cigarette use to 60% of baseline number of pods per week.
62494205|NCT04414046|EXPERIMENTAL|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
61941741|NCT04709471|NO_INTERVENTION|Use e-cigarettes as usual|Continue using usual nicotine e-cigarettes as usual.
61941742|NCT03419520|EXPERIMENTAL|Intervention group|Schools receive healthy actions aimed to reduce the risk of developing obesity, along the study
61941743|NCT03419520|NO_INTERVENTION|Control group|Schools monitored along the study but won't receive any healthy action.
61941744|NCT01562158|PLACEBO_COMPARATOR|Placebo|
61941745|NCT01562158|EXPERIMENTAL|Low dose|
61941746|NCT01562158|EXPERIMENTAL|Medium dose|
61941747|NCT01562158|EXPERIMENTAL|High dose|
61941748|NCT01408264|ACTIVE_COMPARATOR|0.035 guidewire|conventional 0.035 guidewire
61941749|NCT01408264|ACTIVE_COMPARATOR|Olympus Visiglide 0.025 guidewire|Olympus Visiglide 0.025
61941750|NCT05537896|EXPERIMENTAL|Eravacycline|Eravacycline- 1 mg/kg actual body weight IV Infusion over 60 minutes every 12 hours. Alternative dosing strategy 1.5mg/kg every 12 hourse.
61941751|NCT04979104|EXPERIMENTAL|SL Cementless|Since the trial is not comparative, the only arm implies the use of the investigational device (SL cementless femoral stem)
61941752|NCT04081324|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered orally on Day 1 and repeated doses on Days 4 to 10 (7 days of dosing).
61941753|NCT04081324|EXPERIMENTAL|50 milligram (mg) Lasmiditan|Participants received 50 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 50 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
61941754|NCT04081324|EXPERIMENTAL|100 mg Lasmiditan|Participants received 100 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 100 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
61941755|NCT04081324|EXPERIMENTAL|200 mg Lasmiditan|Participants received 200 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 200 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
61941756|NCT04134052|EXPERIMENTAL|ketamine sedation|Sedation will be performed with ketamine dose 5-20mcg / kg / min in infusion with 100 ml Na Cl solution 0.9% during surgery
61941757|NCT04134052|ACTIVE_COMPARATOR|midazolam sedation|Sedation will be performed with midazolam dose 5 - 35mcg / kg / hr in infusion with 100 ml Na Cl solution 0.9% during surgery
62337196|NCT03712566||MASST|Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head \& Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
62337197|NCT00748553|EXPERIMENTAL|All patients|All participants enrolled.
62494206|NCT03795441|EXPERIMENTAL|Ad26.RSV.preF|Participants will receive one intramuscular injection of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on Day 1.
62494207|NCT03330132|ACTIVE_COMPARATOR|Standard vaccine|Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62738473|NCT05927519|ACTIVE_COMPARATOR|morbidly obese|Class 2 (bmı \>35) weight kg/height m2 and class 3 (bmı\>40) obese men
61941758|NCT02540226|ACTIVE_COMPARATOR|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
61941759|NCT02540226|EXPERIMENTAL|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
61941760|NCT05914376|EXPERIMENTAL|hV01 intratumoral injection|"Single-dose phase (3+3 design):~Participants will receive an intratumoral injection of hV01 at one of the dose levels from 1.0×10\^7 PFU to 8.0×10\^8 PFU on Day 1 of each treatment cycle. The MTD or MAD will be determined based on the safety and tolerability outcomes of this phase.~Multiple-dose phase (3+3 design):~1. Two doses per cycle: Participants will receive two intratumoral injections of hV01 at the dose level of sub-MTD or sub-MAD on Day 1 and Day 8 of each treatment cycle.~2. Three doses per cycle: Participants will receive three intratumoral injections of hV01 at the dose level of sub-MTD or sub-MAD on Day 1, Day 8 and Day 15 of each treatment cycle."
61941761|NCT00528177|ACTIVE_COMPARATOR|O|This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
61941762|NCT00528177|ACTIVE_COMPARATOR|M|This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.
61941763|NCT03645564|ACTIVE_COMPARATOR|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
61941764|NCT03645564|NO_INTERVENTION|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
61941765|NCT00908609||1|Patients who undergo routine ultrasound guided biopsy will be studied by optical imaging technique.
62494208|NCT03330132|EXPERIMENTAL|Alternating standard vaccine & adjuvanted vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62494209|NCT03330132|EXPERIMENTAL|Alternating adjuvanted vaccine & standard vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62494210|NCT03330132|EXPERIMENTAL|Alternating standard vaccine and high-dose vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62494211|NCT03330132|EXPERIMENTAL|Alternating high-dose vaccine and standard vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62695842|NCT03267849|EXPERIMENTAL|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure or decrease eye pressure, then will have images taken a second time
62695843|NCT01775345|EXPERIMENTAL|Isotonic exercises + ST|"This group will realize 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a maximum repetition (MR)(MR is the maximum resistance that a muscle can conquer).~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
62695844|NCT01775345|EXPERIMENTAL|Isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
62337198|NCT00066625|EXPERIMENTAL|Treatment (oxaliplatin, bortezomib)|"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the MTDs are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62738474|NCT05927519|PLACEBO_COMPARATOR|nonobese|bmı\<30 weight kg/ height m2 men
62738475|NCT00438360|ACTIVE_COMPARATOR|Cyclosporine A|Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
62738476|NCT00438360|PLACEBO_COMPARATOR|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
61941766|NCT00908609||2|Patients who have advanced breast cancers and are under neoadjuvant chemotherapy treatment will be studied by optical technique.
61941767|NCT03006289||The thyroid cancer group|The postoperative pathology of thyroid is malignant
61941768|NCT03006289||The thyroid nodule group|The postoperative pathology of thyroid is benign
61941769|NCT05192733||Clinical Specialty|"We will compare responses across the following clinical specialties :~1. Neuroanesthesiologists~2. Neurosurgeons~3. Neurocritical care specialists NB: Some participants may have a double clinical specialty."
61941770|NCT05192733||Clinical Setting|"We will compare responses across the following clinical settings:~1. Cities~2. Countries~3. Number of cases per year"
61941771|NCT01431131|ACTIVE_COMPARATOR|Intrasocket graft|Positive control
62337199|NCT04081935|EXPERIMENTAL|Reduce pain and fair|To determine whether the virtual reality as a distracting intervention could reduce pain and fear in school-age children receiving intravenous injections at an emergency department.
61941772|NCT01431131|EXPERIMENTAL|Intrasocket plus facial overlay graft|Intrasocket cancellous allograft plus a facial overlay bovine xenograft
61941773|NCT04161027|EXPERIMENTAL|Pregabalin|
61941774|NCT04161027|PLACEBO_COMPARATOR|Placebo|
62337200|NCT04081935|NO_INTERVENTION|Compared|Normal treatment
61941775|NCT03179696|EXPERIMENTAL|Mobile-assisted CBT|Psychosocial intervention combining in-person and smartphone-based cognitive-behavioral therapy (CBT) for experiential negative symptoms in schizophrenia called, Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
61941776|NCT02841189|OTHER|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
61941777|NCT02043275|EXPERIMENTAL|Leg training|Lower body resistance training only
61941778|NCT02043275|ACTIVE_COMPARATOR|Arm training|Upper body resistance training only
61941779|NCT02320617|EXPERIMENTAL|DW-MRI group|To evaluate the efficacy of chemoradiotherapy in lung cancer patients by DW-MRI when compared with conventional imaging modalities(CT, ultrasound et al.)
61941780|NCT02413372|EXPERIMENTAL|Treatment Group A: BMS-986036|Administered as specified on specified days
62337201|NCT04633473|EXPERIMENTAL|SIBTime|43 primary parents were assessed at enrollment, then provided the dual-language, media-enhanced SIBTime technology for 4 weeks, and then re-assessed at 4 weeks (after treatment completion).
62494212|NCT03330132|EXPERIMENTAL|Alternating adjuvanted vaccine and high-dose vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62494213|NCT03330132|EXPERIMENTAL|Alternating high-dose vaccine and adjuvanted vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62494214|NCT03330132|EXPERIMENTAL|High-dose vaccine|Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62494215|NCT03330132|EXPERIMENTAL|Adjuvanted vaccine|Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62494216|NCT03330132|EXPERIMENTAL|Recombinant vaccine|Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
62738477|NCT05659043||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. The patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
61941781|NCT02413372|EXPERIMENTAL|Treatment Group B: BMS-986036|Administered as specified on specified days
61941782|NCT02413372|PLACEBO_COMPARATOR|Treatment Group C: Placebo|Administered as specified on specified days
61941783|NCT05276024||iFuse Bedrock technique|Multilevel lumbar fusion procedure with additional sacroiliac joint stabilization using the iFuse-3D system
61941784|NCT06556550|EXPERIMENTAL|Stereotactic Ablative Radiotherapy (SABR) arm|The method of stereotactic radiation therapy in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy T1-4, N0-3, M0-1, aged over 18 years at the time of initiation of treatment
61941785|NCT06556550|ACTIVE_COMPARATOR|Standart care arm|Palliative radiation therapy or chemotherapy alone in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy T1-4, N0-3, M0-1, aged over 18 years at the time of initiation of treatment
61941786|NCT06402643|EXPERIMENTAL|Mini-SLET.|In addition to the standard resection technique, the surgical procedure will include the application of AM with surgical adhesive at the surgical site. Following this, limbal cells will be harvested from the limbus in a resection measuring 2×2 mm, divided into six fragments, and positioned along the limbus border on the AM.
61941787|NCT06402643|ACTIVE_COMPARATOR|Conjunctival-Limbal Autograft.|Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery. In the case of CLAu, an autograft will be procured from the superior temporal bulbar conjunctiva. The autograft will be fixed to the surgical site using surgical adhesive.
61941788|NCT04375969|EXPERIMENTAL|whole body cryostimulation treatment|WBC will be performed at the Pomeranian Rheumatologic Centre in Sopot. The centre is equipped with an electric cryochamber Zimmer Medicine System, Cryochamber ELECPOL, located in a temperature- and humidity-controlled room. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
61941789|NCT04375969|EXPERIMENTAL|Connection WBC treatment and HIIT training|This group will perform HIIT protocol and WBC sessions . HIIT will be performed after 1h WBC.
61941790|NCT04375969|ACTIVE_COMPARATOR|Control Group|Control group who will be investigated (meanwhile at baseline and after the interventions)
61941791|NCT04375969|EXPERIMENTAL|HIIT training group|This group will perform only HIIT protocol without cryo-sessions
61941792|NCT03320226|OTHER|Probiotic 10 (Nature's Bounty)|The suggested dose will be two (2) pills of Probiotic 10 (Nature's Bounty) after dinner daily. Subjects will be asked to take probiotics for six (6) days after providing baseline fecal specimen. Subjects will self-report their daily GI function including the frequency of nausea, vomiting, and bowel movement(s). Then, the subjects will stop taking probiotics for two (2) days and resume taking probiotics for another six (6) days. This six (6)-day on and two (2)- day off cycle is repeated two (2) times.
61941793|NCT05698056||Women undergoing breast cancer screening with MRI|No interventions are administered. Data is retrospectively collected in an anonymized way after ethical approval at each site.
62494217|NCT03330132|EXPERIMENTAL|Alternating recombinant vaccine and adjuvanted vaccine|Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
61941794|NCT04886739|EXPERIMENTAL|CGB-400 Topical Gel|Topical administration twice daily for 12 weeks
61941795|NCT04886739|PLACEBO_COMPARATOR|Vehicle Gel|Topical administration twice daily for 12 weeks
61941796|NCT02448186|EXPERIMENTAL|ESTEEM|cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
61941797|NCT02448186|NO_INTERVENTION|Waitlist|3-month waitlist control
62494218|NCT01102907||Liquid Meal|
62494219|NCT01102907||Solid Meal|
62494220|NCT03540433||Study group|Surgical patients aged ≥70 years
62494221|NCT03540433||Control group|Healthy subjects, aged ≥70 years, American Society of Anesthesiologists (ASA) I+II+III, no surgery
62494222|NCT02465892|NO_INTERVENTION|Standard Care|Subjects in this group will continue receiving standard care from their provider team.
62494223|NCT02465892|EXPERIMENTAL|Pillars4Life|Subjects in this group will complete the Pillars4Life online coping skills curriculum.
62494224|NCT02016235|EXPERIMENTAL|Dent Disease Intervention|Dent Disease subjects will receive 2 week supplementation with phosphorus
61941798|NCT04899427|EXPERIMENTAL|orelabrutinib combined with PD-1 inhibitor|"The experimental arm will be treated orelabrutinib plus PD-1(programmed death）inhibitor every 21 days as one cycle. The responses will be evaluated every 2 cycles during the first 6 cycles and every 3 months until progression.~The investigators can choose Sintilimab Injection or Tislelizumab Injection at the beginning of treatment，but they can't exchange to another during the whole treatment."
61941799|NCT06298526||women with anorexia nervosa|DSM-V criteria for anorexia nervosa must be satisfied
62138096|NCT05115864|EXPERIMENTAL|PFMT with device (intervention) group|The patients in PFMT with device (intervention) group followed the practice program three months. During three months, the intervention group is commanded to complete the PFMT program with the vaginal device and assess the grade of type I and II pelvic floor muscle fiber strength once three weeks.
62138097|NCT05115864|NO_INTERVENTION|PFMT alone （control） group|The patients in PFMT alone (control) group are commanded to follow the same practice program three months without using the device.
62695845|NCT01775345|EXPERIMENTAL|Isotonic and isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
62695846|NCT06402162|EXPERIMENTAL|muscle architecture|
62695847|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
62695848|NCT02331303||Group1|"This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden.~This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period."
62695849|NCT05360784|EXPERIMENTAL|Brimonidine tartrate preservation-free|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
62695850|NCT05360784|ACTIVE_COMPARATOR|Lumify®|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
62695851|NCT00932607|ACTIVE_COMPARATOR|Staloral Birch|"Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
62695852|NCT00932607|EXPERIMENTAL|SUBLIVAC Birch|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
62695853|NCT05256537|EXPERIMENTAL|Open Arm|Omission of the drug mycophenolate mofetil
62695854|NCT04212923|EXPERIMENTAL|Medical Dashboard based self-management intervention|Chronic kidney disease patients in the intervention group will receive the usual care plus the tailored 'Medical Dashboard' based self-management intervention.
61941800|NCT06298526||healthy weight women|BMI range: 19-29 kg/m2
62138098|NCT06174948|EXPERIMENTAL|people with Parkinson's disease and related disorders|"Intervention~All participants with Parkinson's related disorders and the first 10 participants with Parkinson's will use the CUE1 device as follows:~* 1-2/9 weeks in the study: once a day for a continuous duration of 2 hours in the morning, 1 hour after taking the medication (if any) for PD or related disorder, every single day;~* 4-5/9 weeks in the study: once a day for a continuous duration of 8 hours, starting from morning, 1 hour after taking the medication (if any) for PD or related disorder, every single day;~* 7-8/9 weeks in the study: only at night, through all night, every single night and not during the day at all;~15-20 participants with Parkinson's disease will use the CUE1+ device at loud settings for 12 continuous weeks, as above the participants during weeks 4-5."
62138099|NCT06174948|SHAM_COMPARATOR|People with Parkinson's disease|15-20 participants with Parkinson's disease will use the CUE1+ device sat silent settings for 12 continuous weeks, as above the participants during weeks 4-5 and compared to the active CUE1+ intervention with people with Parkinson's disease only as above
62494225|NCT02016235|EXPERIMENTAL|Kidney Stone subjects|Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
62494226|NCT02016235|PLACEBO_COMPARATOR|Dent Disease Observation|Dent disease subjects will not get phosphorus
62695855|NCT04212923|NO_INTERVENTION|Usual care services|Chronic kidney disease patients in the comparison group will receive usual care consisting of personalised in- and outpatient treatment based on symptoms experienced and disease severity, as outlined in the Kidney Disease Improving Global Outcomes (KDIGO).
62695856|NCT05656040|EXPERIMENTAL|Part 1: MK-2060|MK-2060 administered as a single subcutaneous dose of 30 mg on Day 1
62695857|NCT05656040|PLACEBO_COMPARATOR|Part 1: Placebo|Placebo (normal saline) administered as a single subcutaneous dose on Day 1
62695858|NCT05656040|EXPERIMENTAL|Part 2: MK-2060|MK-2060 administered as multiple subcutaneous doses on Days 1, 2, 3, 4, 8, 15, and 22.
61941801|NCT05636826|ACTIVE_COMPARATOR|atherolive-drug|The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive) will be prescribed at a dose of 400 mg, once a day for 3 months.
61941802|NCT05636826|PLACEBO_COMPARATOR|atherolive-placebo|The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive-placebo) will be prescribed at a dose of 400 mg, once a day for 3 months.
61941803|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
61941804|NCT03565601||CTD patients with anti-Ro52 antibodies|Connective tissue disease patients with anti-Ro52 antibodies at diagnosis
62138100|NCT02859844|EXPERIMENTAL|TTNS ON|Transcutaneous tibial nerve stimulation
62695859|NCT05656040|PLACEBO_COMPARATOR|Part 2: Placebo|Placebo (normal saline) administered as multiple subcutaneous doses on Days 1, 2, 3, 4, 8, 15, and 22.
61941805|NCT03565601||CTD patients without anti-Ro52 antibodies|Connective tissue disease patients without anti-Ro52 antibodies at diagnosis
61941806|NCT04544332||Unsweetened Supplement|Infants will receive 10 exposures to the unsweetened small quantity lipid nutritional supplement (SQ-LNS) at home
61941807|NCT04544332||Sweetened Supplement|Infants will receive 10 exposures to the sweetened small quantity lipid nutritional supplement (SQ-LNS) at home
61941808|NCT06681571||TAP Group|TAP block will be performed immediately after the induction of anesthesia, under ultrasond guidence.
61941809|NCT06681571||RSB Group|RSB block will be performed immediately after the induction of anesthesia, under ultrasond guidence.
61941810|NCT05024201|EXPERIMENTAL|experimental group for effect of therapeutic touch|Therapeutic touch was applied to the experimental group for three days every other day.
61941811|NCT05024201|NO_INTERVENTION|control group for effect of therapeutic touch|No application was applied to the control group. Only pretest and posttest were done.
61941812|NCT01872897|ACTIVE_COMPARATOR|Sodium Alginate Double Action Tablets|Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose
62138101|NCT02859844|SHAM_COMPARATOR|TTNS OFF|Sham/placebo stimulation
62337202|NCT06240299|EXPERIMENTAL|Rheumatoid Arthritis - neurofeedback training|"Intervention: visual neurofeedback~Research Assessments~* EEG: relaxed state and motor imagery~* Quantitative sensory testing~Questionnaires (after each intervention session):~* visual analog scale - rate pain intensity~* pain description and pain intensity reporting~* mental strategies, affects (emotional experience) and sensations during NF~* adverse event reporting~* NASA task load index~Questionnaires (week before and week after intervention weeks)~* Routine Assessment of Patient Index Data 3 (RAPID3)~* American College of Rheumatology Fibromyalgia Scale (ACRFS)~* McGill Pain Questionnaire~* Patient-Reported Outcomes Measurement Information System (PROMIS) Depression~* PROMIS-Anxiety~* PROMIS-Fatigue~* PROMIS-Sleep related impairment~* Pain Number Rating Scale~* Generalised Self-Efficiency Scale questionnaire~* Multidimensional Health Locus of Control Scale questionnaires~Remote follow-up: semi-structured interview over the telephone"
62337203|NCT00651976|EXPERIMENTAL|treatment|
62337204|NCT01901731|EXPERIMENTAL|Embolisation of pelvic veins & treatment of leg varicose veins|Transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg varicose veins
62337205|NCT01901731|ACTIVE_COMPARATOR|Endovenous treatment of leg varicose veins alone|Endovenous treatment of legs varicose veins only
62337206|NCT05387304||COVID-19 infections|SARS-Cov-2 RNA postive
62337207|NCT02750657||Patients with advanced pancreatic ductal adenocarcinoma|
62337208|NCT03609658|EXPERIMENTAL|Nurse Navigator Pathway Group|Participants in this Nurse Navigator led ACP pathway group will participate in ACP discussions, surveys, and participant visit(s) for duration of the study (12 months)
62337209|NCT03609658|SHAM_COMPARATOR|Usual Care Group|Participants in the Usual Care group will follow usual daily living activities for the duration of the study (12 months).
61941813|NCT01872897|PLACEBO_COMPARATOR|Placebo tablets|Single dose of 4 Placebo tablets
61941814|NCT00817544|EXPERIMENTAL|ORM-12741|ORM-12741
61941815|NCT05437900|EXPERIMENTAL|Pressure Microcatheter guided strategy - PIOS-MC|Patients will be treated with the Pressure Microcatheter during PCI. After completing an angiographically successful PCI, patients will be randomized to FFR-guided stent optimization (PIOS).
61941816|NCT05437900|ACTIVE_COMPARATOR|Pressure Wire guided strategy - PIOS-PW|Patients will be treated with the Pressure Wire during PCI. After completing an angiographically successful PCI, patients will be randomized to FFR-guided stent optimization (PIOS).
61941817|NCT05437900|EXPERIMENTAL|Pressure Microcatheter guided strategy - Standard of care|Patients will be treated with the Pressure Microcatheter during PCI. After completing an angiographically successful PCI, patients will receive the standard of care treatment.
62337210|NCT01727713|EXPERIMENTAL|Aripiprazole|Aripiprazole Immediate Release Once-Daily
62337211|NCT02582580|ACTIVE_COMPARATOR|Perineal Massage|Massage is made in the perineum and vagina using your fingers to promote stretching of pelvic floor structures, making them more flexible and distensíveis, avoiding trauma during vaginal birth.
62337212|NCT02582580|ACTIVE_COMPARATOR|Vaginal Dilator|This device consists of a silicone balloon in an eight shape that, after inserted into the vagina, is inflated by manual pumping, promoting a stretching of the structures around it (hymenal edge, connective tissues and muscles perivaginal). This equipment assists the stretching of tissues around the vagina and the pelvic floor muscles, minimizing the risk of injury from the birth canal during the passage of the baby.
62494227|NCT02032927|ACTIVE_COMPARATOR|Codeine/paracetamol|"The combination codeine/paracetamol,30 mg/500 mg,1 tablet every 8 hours, paracetamol 500 mg if NRS\> 4, repeatable up to 3 times per day.~At any stage of the study, patients treated with combination codeine/paracetamol in case of ineffectiveness (NRS\> 4) despite maximal dosage (2 tablets every 8 hours) and/or side effect, will be subject to the opioid switch and will start equianalgesic therapy with oxycodone/naloxone combination."
62695860|NCT05656040|EXPERIMENTAL|Part 3: MK-2060|MK-2060 administered as a single subcutaneous dose on Day 1
62695861|NCT06570746|EXPERIMENTAL|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
61941818|NCT05437900|ACTIVE_COMPARATOR|Pressure Wire guided strategy - Standard of care|Patients will be treated with the Pressure Wire during PCI. After completing an angiographically successful PCI, patients will receive the standard of care treatment.
61941819|NCT02595138|EXPERIMENTAL|A|zoledronic acid received
62337213|NCT02582580|ACTIVE_COMPARATOR|Pelvic floor muscles training|Exercises emphasizing conscious muscle relaxation, i.e., considering a resting time based on the contraction time. The resting time was double of the sustaining time of each contraction up to the 38th week of pregnancy, after remaining fixed this relaxation time up to the moment of delivery. This time was chosen because during the expulsive labor phase, there is a need for the pelvic floor muscles to consciously relax during a long period, in order to facilitate the descendants and rotational movements of the baby's head and consequently, its passage. This exercises does not aim only muscle strength but also contraction promotion, which aims body and perineal awareness, muscle tone, coordination and appropriate motor control to allow an active muscle relaxation in the second labor stage.
62337214|NCT00674830|EXPERIMENTAL|1|professionally administered cognitive-behavioral therapy
62337215|NCT00674830|EXPERIMENTAL|2|self-administered form of cognitive behavioral therapy
62138102|NCT00047125|EXPERIMENTAL|Selective irradiation|Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks).
62138103|NCT00047125|ACTIVE_COMPARATOR|Extensive irradiation + ipsilaterals levels|Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks).
62138104|NCT05607199|EXPERIMENTAL|AUR103, 25mg to 400mg|Currently planned dose levels in Part 1 are 25 mg BID, 50 mg BID, 100 mg BID, 200 mg BID and 400 mg BID
62337216|NCT00674830|PLACEBO_COMPARATOR|3|usual care
62337217|NCT02862821|EXPERIMENTAL|validation of EEfRT task|20 healthy volunteers will be recruted to validate motivation EEfRT task which is adaptated to HR-EEG
62337218|NCT02862821|EXPERIMENTAL|biomarkers identification|20 addict online poker gamblers and 20 non-addict online poker gamblers will be recruted : After standardized questionnaires to define the socio-demographic data, the diagnosis of gambling addiction (Diagnostic and Statistical Manual of Mental Disorder 5th edition DSM-5), screening for comorbidities addictive, the level of anxiety and impulsivity, brain acvtivity will be registred (by randomisation between the 2 tasks) with HR-EEG: during the performance of a task of motivation evaluation laboratory (EEfRT) adaptated for high-resolution electroencephalography AND during a laboratory task that assesses decision making in conditions of uncertainty (IGT) with its version for high-resolution electroencephalography has already been validated in a previous study (Giustiniani et al., 2015).
62337219|NCT02862821|EXPERIMENTAL|biomarkers validation|13 online poker gamblers will be recruted, independently of their dependance profile and they will realize the same task that in precedent arm (quaestionnaires and 2 tasks adaptated to HR-EEG).
61941820|NCT02595138|NO_INTERVENTION|B|observation
62138105|NCT04593238|EXPERIMENTAL|Double antibiotic paste intra-canal medication group (n=25)|500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.
62138106|NCT04593238|ACTIVE_COMPARATOR|Calcium hydroxide intra-canal medication group (n=25)|Calcium hydroxide paste (Metapaste) placed inside the root canal for 1 week
61941821|NCT05303363||VV-ECMO|Critically ill patients with a suspected indication for VV-ECMO. ECMO will be provided according to local guidelines. In the Amsterdam UMC, location AMC, next to VV-ECMO, veno-arterial (VA-ECMO) is also provided. For this study, only patients on VV-ECMO will be included.
61941822|NCT04603612|OTHER|NMIBC patients|Patients with diagnosed bladder tumors seen the urology department (Urology and Nephrology Center, Mansoura University, Egypt) will be assessed for eligibility to the study and inclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study and will be provided with an informed consent form. Study participants will be enrolled, and the appropriate scheduled procedures will be performed.
61941823|NCT06100211||ART switch group|These are individuals who complete a planned switch of ART regimen from one class of drugs or delivery method to another.
61941824|NCT06100211||Control group|This group continue on their stable ART regimen.
61941825|NCT04743856|ACTIVE_COMPARATOR|PAT (Physical activity monitor)|Participants will receive a physical activity tracker and encouragement to increase physical activity.
61941826|NCT04743856|EXPERIMENTAL|ActiveGOALSv2|Participants will receive the ActiveGOALS online program with an integrated activity tracker.
61941827|NCT06393868|EXPERIMENTAL|Daily dose of omeprazole 20 mg|Participants randomized to the experimental arm will take one omeprazole 20 mg tablet by mouth every day for the duration of their participation in the study.
62138107|NCT06293261||Rosuampin 5/5mg (Rosuvastatin 5mg + Amlodipine 5mg)|
62138108|NCT06293261||Rosuampin 10/5mg (Rosuvastatin 10mg + Amlodipine 5mg)|
62138109|NCT06293261||Rosuampin 20/5mg (Rosuvastatin 20mg + Amlodipine 5mg)|
62138110|NCT06293261||Rosuampin 10/10mg (Rosuvastatin|
61941828|NCT06393868|PLACEBO_COMPARATOR|Daily dose of placebo|Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.
62138111|NCT06587789||Ribociclib combined with endocrine therapy group|Patients with early high-risk HR+HER2- breast cancer will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy as adjuvant therapy. During three years of follow-up, their relevant clinical data will be recorded.
61941829|NCT06448078|ACTIVE_COMPARATOR|Case group|External chest wall fixator will be applied to the rib fracture area in the case group
62494228|NCT02032927|ACTIVE_COMPARATOR|Oxycodone/Naloxone|Combination oxycodone /naloxone, 5 mg/2.5 mg, 1 tablet/day, paracetamol 500 mg if NRS\> 4, repeatable up to 3 times per day.
62494229|NCT00795158|EXPERIMENTAL|Arm 1|
62494230|NCT06076109|ACTIVE_COMPARATOR|PRONE POSITION|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
61941830|NCT06448078|NO_INTERVENTION|Control group|No intervention will be made to the control group
61941831|NCT00004195|ACTIVE_COMPARATOR|Oral eniluracil 20 mg twice daily|20 mg of eniluracil given twice daily for duration of the study. This subject may have surgery IF tumor is amenable to resection
61941832|NCT00004195|PLACEBO_COMPARATOR|Placebo|20 mg placebo that will be given for the duration of the study. This subject may have surgery IF tumor is amenable to resection
61941833|NCT04197531|EXPERIMENTAL|EndoActivator|
61941834|NCT04197531|EXPERIMENTAL|Conventional Endodontic Syringe|
62138112|NCT01025167|EXPERIMENTAL|Test|Supportan(R) (500 ml)/disease-specific enteral tube feed for oncologic patients with special key substrates
62138113|NCT01025167|PLACEBO_COMPARATOR|Control|Fresubin(R) energy fibre (500 ml)/a nutritionally complete enteral standard feed (isoenergetic)
61941835|NCT04010032|EXPERIMENTAL|PIEB (Programmed intermittent epidural bolus)|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection)
61941836|NCT04010032|ACTIVE_COMPARATOR|CEI (Continuous epidural infusion)|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device
61941837|NCT01364077|ACTIVE_COMPARATOR|Ivabradine|
61941838|NCT01364077|PLACEBO_COMPARATOR|Control|
61941839|NCT05648578|EXPERIMENTAL|Experimental|Participants received reiki application for 4 weeks.
61941840|NCT05648578|NO_INTERVENTION|Control|No intervention was applied to the participants in the control group
61941841|NCT01739361|EXPERIMENTAL|Acetaminophen|Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
61941842|NCT01739361|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
61941843|NCT01578330|EXPERIMENTAL|Fingolimod, FTY720|Patients received fingolimod 0.5 mg oral capsules daily with or without food.
61941844|NCT06463405|OTHER|Splinted implant restorations|
61941845|NCT06463405|OTHER|Non-splinted implant restorations|
62138114|NCT05047458|EXPERIMENTAL|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
62138115|NCT05047458|EXPERIMENTAL|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
62138116|NCT05047458|EXPERIMENTAL|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
62138117|NCT00993174|EXPERIMENTAL|Topical anesthesia|Patients undergo strabismus surgery for esotropia using topical anesthesia (instillation of drops plus gel)
62138118|NCT00993174|ACTIVE_COMPARATOR|Sub-Tenon's anesthesia|Patients undergo surgery for strabismus (esotropia) using sub-Tenon's administration of anesthetic (xylocaine)
62138119|NCT01333605|EXPERIMENTAL|IGEV regimen|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles
62337220|NCT02175771|EXPERIMENTAL|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62337221|NCT02175771|ACTIVE_COMPARATOR|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62494231|NCT06076109|PLACEBO_COMPARATOR|STANDARD TREATMENT|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
61941846|NCT05548673|EXPERIMENTAL|Experimental Group|Stress management training was applied to the experimental group for eight weeks in sessions of 60-90 minutes once a week.
61941847|NCT05548673|NO_INTERVENTION|Control group.|No action was taken on the students in the control group.
61941848|NCT01528033|EXPERIMENTAL|Vacuum Assisted Closure®|Negative pressure wound therapy
62494232|NCT04166058|ACTIVE_COMPARATOR|72 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
62494233|NCT04166058|ACTIVE_COMPARATOR|145 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
62494234|NCT04166058|ACTIVE_COMPARATOR|290 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
62494235|NCT00106106|PLACEBO_COMPARATOR|Placebo|For subjects randomized to placebo control, placebo doses were given every 8 hours.
62494236|NCT00106106|EXPERIMENTAL|Acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
62494237|NCT05568849|EXPERIMENTAL|OCTA measurement arm|There is only one arm in the study and patient care will not be changed. Additional measurements will be obtained over and above usual patient care in the OCTA measurement arm as detailed in the protocol.
62494238|NCT01661517|EXPERIMENTAL|Lifestyle Counseling|motivational interviewer
62494239|NCT02634736|EXPERIMENTAL|Exergame plus usual treatment|Exergame programme plus usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
62494240|NCT02634736|NO_INTERVENTION|Usual treatment|No exergame programme, just usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
62494241|NCT03243591|ACTIVE_COMPARATOR|Livionex gel|Brushing area of mucositis with Livionex gel for 30 days
62494242|NCT03243591|ACTIVE_COMPARATOR|Aquafresh gel|Brushing area of mucositis with Aquafresh gel for 30 days
62494243|NCT04464005|EXPERIMENTAL|Pads with cold magnesium sulfate 33% solution|
62494244|NCT04464005|PLACEBO_COMPARATOR|Pads with cold water|
62494245|NCT05778760|ACTIVE_COMPARATOR|Retinol|Product will be used once daily in the evening for 12 weeks. 1-2 pumps (size of quarter) of product will be applied on the face.
61941849|NCT01528033|ACTIVE_COMPARATOR|Standard conventional wound therapy|According to institutional clinical standards
62494246|NCT05778760|EXPERIMENTAL|Adapinoid|Product will be used once daily in the evening for 12 weeks. 1-2 pumps (size of quarter) of product will be applied on the face.
62494247|NCT05336487|EXPERIMENTAL|Physical Activity group (PA-group)|The intervention group. Participants with intellectual disabilities is recruited from a local daily activity center, where the participants participate in teacher-organized physical activity \~2 hours/day, 5 days/week.
61941850|NCT03956134|EXPERIMENTAL|Tapentadol Test Product 1 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
61941851|NCT03956134|EXPERIMENTAL|Tapentadol Test Product 2 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
61941852|NCT03956134|EXPERIMENTAL|Tapentadol Test Product 1 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
61941853|NCT03956134|EXPERIMENTAL|Tapentadol Test Product 2 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
61941854|NCT03956134|ACTIVE_COMPARATOR|Tapentadol PR Reference Product|Tapentadol PR tablet formulation given as single oral dose with 240 mL of still mineral water under fasting condition.
61941855|NCT03253458|EXPERIMENTAL|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
61941856|NCT05890339|EXPERIMENTAL|Laparoscopic Proximal Gastrectomy With Double-flap Technique|
62138120|NCT05766319|EXPERIMENTAL|Patients receiving the ICU-recover box containing home monitoring devices|"Treatment of subjects on the ICU will be state of the art, conform current practice, protocols and guidelines.~Patients discharged from the ICU will receive an ICU-Recover Box on one of the clinical wards of the LUMC filled with several devices after they have given informed consent. These devices are listed below and are described in further detail in section 6 of this protocol.~The ICU-Recover Box contains the following devices and tools:~* Withings BPM Connect~* Withings Body weight scale~* Withings ScanWatch, from which the following features will be used:~  * Measurement of SpO2~ * Automatic recording of heart rate~ * Automatic recording of activity (step count)"
62494248|NCT05336487|NO_INTERVENTION|Control Group (CON-group)|The control group. The participants with intellectual disabilities is recruited from daily activity centers, which does not use physical activity in their daily work with the participants.
62494249|NCT03350191|EXPERIMENTAL|SAR425899 high dose|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 20 days
62494250|NCT03350191|EXPERIMENTAL|SAR425899 low dose|Repeated once daily SC doses of SAR425899 administered over 20 days
62494251|NCT00840190|EXPERIMENTAL|P1446A-05|
62494252|NCT01992094|EXPERIMENTAL|QIVc|Influenza vaccine
62494253|NCT01992094|ACTIVE_COMPARATOR|TIV1c|Influenza vaccine
62494254|NCT01992094|ACTIVE_COMPARATOR|TIV2c|Influenza vaccine
61941857|NCT05890339|ACTIVE_COMPARATOR|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|
61941858|NCT01611610|OTHER|Ambulant SMA|
62138121|NCT06485141|ACTIVE_COMPARATOR|Control|Guardians of hospitalized children in the active comparator group will view a brief medication storage safety video produced by Safe Kids.
62494255|NCT05511935|EXPERIMENTAL|exposed to GRIN training|participates in the intervention
62494256|NCT05511935|NO_INTERVENTION|control/unexposed|no intervention
62494257|NCT00759616|EXPERIMENTAL|1|
62494258|NCT04402892|ACTIVE_COMPARATOR|Patients hospitalized for SARS-CoV-2|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
62494259|NCT04402892|ACTIVE_COMPARATOR|Patients who have recovered from CoV-2-SARS|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
62494260|NCT00695110|EXPERIMENTAL|All study participants|"Treatment Period 1: Three capsules each containing 100 mg testosterone (T) as testosterone undecanoate (TU), twice daily (BID) for 7 days.~Treatment Period 2: Two capsules each containing 200 mg T as TU and testosterone enanthate (TE), BID for 7 days.~Treatment Period 3: Two capsules each containing 100 mg T as TU, BID for 8 days.~Treatment Period 4: Two capsules each containing 150 mg T as TU and TE, BID for 7 days."
62494261|NCT06593418|EXPERIMENTAL|Radiation Therapy at 15 Gy for Ventricular Tachycardia|Post myocardial infarction patients with refractory ventricular tachycardia requiring cardio ablation, treated with 15 Gy
62494262|NCT06593418|EXPERIMENTAL|Radiation Therapy at 20 Gy for Ventricular Tachycardia|Post myocardial infarction patients with refractory ventricular tachycardia requiring cardio ablation, treated with 20 Gy
62494263|NCT06593418|EXPERIMENTAL|Radiation Therapy at 25 Gy for Ventricular Tachycardia|Post myocardial infarction patients with refractory ventricular tachycardia requiring cardio ablation, treated with 25 Gy
62494264|NCT01874041|EXPERIMENTAL|Massage group|The massage group was submitted to three weekly 30-minute sessions of massage of the muscles of mastication over four consecutive weeks.
62494265|NCT01874041|EXPERIMENTAL|The occlusal splint group|The occlusal splint group was submitted to treatment with an occlusal splint for four weeks.
61941859|NCT01611610|OTHER|Non-ambulant SMA|
61941860|NCT03353207||health Control|"1. No family history of RBD;~2. Age- and sex- matched with isolated RSWA subjects~3. Absence of dream enactment behaviors;~4. A score of RBDQ-HK less than 19;~5. Absence of RSWA as measured by v-PSG;~6. for those individuals with moderate obstructive sleep apnea (AHI \> 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
62494266|NCT01874041|NO_INTERVENTION|Control group|The control group was not submitted to any form of intervention and was evaluated on two occasions, with a four-week interval between evaluations.
62494267|NCT02288923|ACTIVE_COMPARATOR|Femoral nerve block|Femoral nerve block with 20ml 0.375% Levobupivacaine
62494268|NCT02288923|ACTIVE_COMPARATOR|Local Infiltration Analgesia|Local infiltration of knee joint using 40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
62494269|NCT01211951|EXPERIMENTAL|KCT-0809 ophthalmic solution, low dose|
62138122|NCT06485141|EXPERIMENTAL|Intervention|Guardians of hospitalized children will receive the study intervention, viewing a 3 minute educational video about the importance of secure firearm storage from the Be SMART program. Additionally, a cable gun lock will be offered to families in the intervention group along with a Frequently Asked Questions handout from Be SMART.
62138123|NCT05216796|EXPERIMENTAL|Low-carbohydrate diet|Participants assigned to the Low-carbohydrate diet will be instructed to limit carbohydrate intake to \<30 g/d.
62138124|NCT05216796|ACTIVE_COMPARATOR|Low-calorie diet|Participants assigned to the Low-calorie diet will be instructed to reduce their energy intake to match the LoCHO block (we are predicting \~1200 kcal/d for women and \~1500 kcal/d for men, following current recommendations for treatment of NAFLD).
62138125|NCT06505954||1|Participant who has lower urinary tract symptoms
62337222|NCT02175771|EXPERIMENTAL|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62494270|NCT01211951|EXPERIMENTAL|KCT-0809 ophthalmic solution, medium dose|
62494271|NCT01211951|EXPERIMENTAL|KCT-0809 ophthalmic solution, high dose|
62494272|NCT01211951|PLACEBO_COMPARATOR|Placebo|
62494273|NCT01884844|EXPERIMENTAL|Vitamin D3|Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks
62494274|NCT01884844|PLACEBO_COMPARATOR|Placebo|methylcellulose po qday for 12weeks
62494275|NCT03567551||Women w/ Preeclampsia w/o Visual Disturbances or Headache|Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: \>Systolic 160 or Diastolic 110
62494276|NCT03567551||Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: \>Systolic 160 or Diastolic 110
62494277|NCT03567551||Women w/o Preeclampsia|Normal Pregnancy Blood Pressure: \<140/90
62138126|NCT06505954||2|Participant who doesn't have lower urinary tract symptoms
62337223|NCT02175771|ACTIVE_COMPARATOR|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62337224|NCT02175771|EXPERIMENTAL|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62494278|NCT05920395|NO_INTERVENTION|Healthy control group|26 healthy volunteers without any intervention, detecting gastrointestinal hormone levels and intestinal microbiota and their metabolites.
62494279|NCT05920395|EXPERIMENTAL|PDS electroacupuncture group|Each with 26 patients who were treated with electro-acupuncture.
62494280|NCT05920395|SHAM_COMPARATOR|PDS sham electroacupuncture group|Each with 26 patients. Shallow acupuncture needles are used and then disconnected from the electrode.
62494281|NCT05920395|EXPERIMENTAL|EPS electroacupuncture group|Each with 26 patients who were treated with electro-acupuncture.
62494282|NCT05920395|SHAM_COMPARATOR|EPS sham electroacupuncture group|Each with 26 patients. Shallow acupuncture needles are used and then disconnected from the electrode.
62494283|NCT06099158|EXPERIMENTAL|HeartLogic-guided management|HeartLogic alerts will be transmitted to the study team, which will subsequently contact the participant to assess any treatment needs. Treatment needs will be assessed according to current clinical practice guidelines.
62494284|NCT06099158|NO_INTERVENTION|Standard care|The control group will receive usual HF care in the Danish health system.
62494285|NCT05228717||COVID+|"Patients with confirmed COVID-19 pneumonia as the primary diagnosis, or COVID-associated acute hypoxemic respiratory failure or hypoxia (minimum O2 requirement 3L), that are being admitted from the emergency department, who either have waiver of consent, give verbal consent to participate, or have NOK (next of kin) provide consent.~Exclusion criteria: age \<18 years old, pregnant patients, or patients that verbally refuse participation Intervention/observation: q48-72h POCUS of the lungs, heart, and IVC"
62494286|NCT06467032|EXPERIMENTAL|superficial CO2 laser resurfacing|The tested product and comparators are applied twice daily from Day2 to Day18 (except Sundays Day7 and Day14). Each subject receives a total of 30 applications of each tested product.
62494287|NCT06467032|ACTIVE_COMPARATOR|Laser untreated side|The tested product and comparators are applied twice daily from Day2 to Day18 (except Sundays Day7 and Day14). Each subject receives a total of 30 applications of each tested product.
62138127|NCT01229384|EXPERIMENTAL|Positive Airway Pressure Nebulization|Will administer nebulized medications using Positive Airway Pressure Nebulization
62138128|NCT01229384|ACTIVE_COMPARATOR|Standard Nebulization|Current standard of administering nebulized medications without positive airway pressure
62138129|NCT01185600|ACTIVE_COMPARATOR|Transfusion with washed RBC|Subject assigned to this arm will be transfused with washed RBC
62494288|NCT06498986|EXPERIMENTAL|BL-B01D1+Osimertinib Mesylate Tablets|Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62138130|NCT01185600|ACTIVE_COMPARATOR|Transfusion with unwashed RBC|Subjects assigned to this arm will be transfused with unwashed RBC
62138131|NCT05869123|EXPERIMENTAL|Online Adaptive Radiotherapy|Patients receive online adaptive radiotherapy with 5mm PTV margin. The CTV-N covered pelvic lymph nodes (common, internal and external iliac, obturator, and presacral) and CTV-V covered proximal vagina and any paravaginal or retracted parametrial tissue. A dose of 45 or 50.4Gy is delivered to CTV with online adaptive radiotherapy.
62138132|NCT05823922|ACTIVE_COMPARATOR|Clinician-delivered Cognitive Behavioral Therapy only|Participants receive treatment with a licensed clinician for 6 weeks.
62138133|NCT05823922|EXPERIMENTAL|Clinician-delivered CBT + Supplemental app|Mobile application at least two times per week for six weeks, for at least 20 minutes on each of the two days in addition to the clinician-delivered CBT
62337225|NCT02175771|ACTIVE_COMPARATOR|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62337226|NCT02175771|EXPERIMENTAL|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62337227|NCT02175771|ACTIVE_COMPARATOR|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
62138134|NCT03941665|EXPERIMENTAL|Gelronate|Tested new medical device
62138135|NCT03941665|ACTIVE_COMPARATOR|Aloevera|Current product used by the medical center
62138136|NCT00902213|NO_INTERVENTION|Minimal movement|Minimal movement group with usual care non-intervention.
62138137|NCT00902213|ACTIVE_COMPARATOR|Physical Therapy|
62138138|NCT05173987|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (up to approximately 2 years).
62138139|NCT05173987|ACTIVE_COMPARATOR|Carboplatin+paclitaxel|Participants receive a combination of paclitaxel 175 mg/m\^2 on Day 1 of each 3-week cycle (Q3W) and carboplatin AUC 5 or 6 on Day 1 Q3W for 6 cycles (up to approximately 4 months). Participants who experience a severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel 75 mg/m\^2 in place of paclitaxel on Day 1 Q3W after Sponsor consultation. Participants who experience a severe hypersensitivity reaction to carboplatin or an AE requiring discontinuation of carboplatin may receive cisplatin 75 mg/m\^2 in place of carboplatin on Day 1 Q3W after Sponsor consultation.
62138140|NCT03000257|EXPERIMENTAL|ABBV-181 plus Venetoclax|Venetoclax will be taken once daily beginning 7 days prior to cycle 1 and continuing daily for a 28 day cycle and ABBV-181 will be administered every 4 weeks.
62138141|NCT03000257|EXPERIMENTAL|ABBV-181|ABBV-181 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Based on available safety, pharmacokinetic, and pharmacodynamic data from the dose-escalation part of the study, participants will be enrolled in dose-expansion cohorts to further evaluate ABBV-181 at a dose level which is at or below the Maximum tolerated dose (MTD). In the Monotherapy Expansion portion of the study, ABBV-181 will be administered in 28-day dosing cycles at either 1 dose per cycle or 2 doses per cycle. Based on available safety, PK and PD data from the single agent dose-escalation part of the study, a dose for ABBV-181 will be selected to evaluate in combination with Rovalpituzumab Tesirine or venetoclax.
62138142|NCT03000257|EXPERIMENTAL|ABBV-181 plus Rovalpituzumab Tesirine|Rovalpituzumab Tesirine will be given once every six weeks times two doses and ABBV-181 will be administered every 3 weeks.
62138143|NCT06698744|EXPERIMENTAL|UF-KURE-BCMA T cell-based immunotherapy|Pre-infusion will include multiple myeloma testing, preCAR-T evaluation, and cells will be collected. Participants will undergo lymphodepletion and inpatient CAR T-cell infusion. Patients will be monitored closely during a 28 day dose limiting toxicity (DLT) period.
62138144|NCT01450657||Chronic Kidney Failure 3/4|
62337228|NCT01809418|EXPERIMENTAL|keePAP|
62337229|NCT02073435||Post-Implementation Group|Living Donor Liver Transplant patients with evidence based donor pain management solution.
62337230|NCT02073435||Pre-Implementation Group|Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.
62337231|NCT02689232|EXPERIMENTAL|Thromboelastography (TEG) level|
62337232|NCT02689232|ACTIVE_COMPARATOR|Coagulation Profile|
62138145|NCT05075421||Group 1 (high marker)|Patients with elevated serum markers
62138146|NCT05075421||Group 2 (normal marker)|Patients with normal value of serum markers
62138147|NCT03568175|EXPERIMENTAL|JR-141 2.0 mg/kg/week|
62138148|NCT01970007|EXPERIMENTAL|Zilver Vena Venous Self-Expanding Stent|
62138149|NCT05603182|EXPERIMENTAL|SAD Cohorts 1-8 Experimental Arm|Subjects will receive a single intravenous or subcutaneous dose of PRA052 in a dose escalation format
62138150|NCT05603182|PLACEBO_COMPARATOR|SAD Cohorts 1-8 Placebo Arm|Subjects will receive a single intravenous or subcutaneous dose of placebo
62138151|NCT05603182|EXPERIMENTAL|MAD Cohorts 1-5 Experimental Arm|Subjects will receive three subcutaneous or intravenous doses of PRA052, one dose every 2 weeks, in a dose escalation format
62138152|NCT05603182|PLACEBO_COMPARATOR|MAD Cohorts 1-5 Placebo Arm|Subjects will receive three subcutaneous or intravenous doses of placebo, one dose every 2 weeks
62494289|NCT06339424|EXPERIMENTAL|Atezolizumab and bevacizumab with photon radiotherapy|Patients undergo Atezolizumab and Bevacizumab with photon radiotherapy.
62494290|NCT02095522|EXPERIMENTAL|Colchicine|Colchicine 1mg per day for one month
62494291|NCT02095522|PLACEBO_COMPARATOR|Placebo|Placebo 1mg per day
62494292|NCT01567527|ACTIVE_COMPARATOR|1|Active Comparator: Treatment of Aripiprazole IM Depot
62494293|NCT01567527|PLACEBO_COMPARATOR|2|Placebo Comparator: Treatment of IM Depot Placebo
62494294|NCT05397977|EXPERIMENTAL|mechanical traction group|use of device chattanooga tru trac
62494295|NCT05397977|ACTIVE_COMPARATOR|manual traction group|use of manual traction with physiotherapist hands
62494296|NCT01980173|EXPERIMENTAL|With Bakri balloon|"Patients randomized to this arm will be treated using the Bakri balloon.~Intervention: Bakri balloon"
62494297|NCT01980173|ACTIVE_COMPARATOR|Without Bakri balloon|"Patients randomized to this arm will receive routine care not including the Bakri Balloon.~Intervention: Routine Care"
62138153|NCT05842603|EXPERIMENTAL|Cardiac Lifestyle Program|"Participants will complete study procedures as follows:~* Baseline in-clinic visit with research team doctor for history and physical and the completion of questionnaires.~* 6 virtual group classes alternating with 6 in-person group classes.~* Semi-structured exit interview."
62138154|NCT04989816|EXPERIMENTAL|T-DXd arm|T-DXd monotherapy
61941861|NCT03353207||Case with isolated RSWA|"1. First degree relatives of patients with iRBD;~2. Age 45 years or above;~3. Absence of dream enactment behaviors;~4. A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD;~5. Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel.~6. for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI \> 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
62337233|NCT06102252|ACTIVE_COMPARATOR|group A|will receive the TEC regimen: paclitaxel 150mg/m2 infused for 3 hours, epirubicin 50mg/m2 infused for 30 minutes, and carboplatin 4mg/ml/min for one hour on day 1 every 3 weeks.
62494298|NCT02885441|EXPERIMENTAL|Ketorolac|Ketorolac,10 mg, 3 times daily from time of enrollment until 72 hours from enrollment for up to a maximum of 9 doses, along with the standard medical treatment
62337234|NCT06102252|ACTIVE_COMPARATOR|group B|) will receive a ddTC regimen: paclitaxel 80mg/m2 for 3 hours on day 1,8,15. Carboplatin AUC 5 over one hour on day 1 repeated at 3-week intervals
62494299|NCT02885441|NO_INTERVENTION|Control|The standard medical treatment
62494300|NCT01517919|EXPERIMENTAL|Intervention: Peer Led Self-Management|Intervention: Peer Led Self-Management (PLSM) involves the DSME program followed by 12 months of peer-led ongoing self-management support
62494301|NCT01517919|NO_INTERVENTION|Diabetes Self-Management Education|Control: Diabetes Self-Management Education (DSME) involves 12 sessions of self-management training including diabetes education, one-on-one sessions, bi-weekly phone contacts, and preparation for a clinic visit.
62494302|NCT04808908|EXPERIMENTAL|N-803|All participants will receive the intervention, N-803 treatment.
62494303|NCT02943096|ACTIVE_COMPARATOR|Flavanol|Blinded treatment with either CocoaVia 500mg or placebo.
62138155|NCT01091168|EXPERIMENTAL|arm A: Vinflunine|Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.
62337235|NCT06102252|ACTIVE_COMPARATOR|group C|: paclitaxel 175 mg/m2 over 3 hours infusion on day 1-carboplatin AUC 5 over 1 hour on day 1 at 3 weeks intervals
62494304|NCT02943096|PLACEBO_COMPARATOR|Placebo|Blinded treatment with either CocoaVia 500mg or placebo.
62494305|NCT01073631||1|Patients who are indicated for use of voriconazole tablet.
62494306|NCT01638273|EXPERIMENTAL|GLA5PR GLARS tablet 150mg(mealed)|Pregabalin 150mg
62494307|NCT01638273|ACTIVE_COMPARATOR|Lyrica Capsule 75mg(mealed)|Pregabalin 75mg
62494308|NCT05284552|EXPERIMENTAL|Intervention Arm|Drug: Tinzaparin (Innohep®), solution for injection. Administration form: Subcutaneous injection. Dosage: 4500 IU (for subjects weighing below 90 kg) or 8000 IU (for subjects weighing 90 kg and above) daily for 21-28 weeks.
62494309|NCT05284552|NO_INTERVENTION|Control Arm|
62494310|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
62494311|NCT01071876|EXPERIMENTAL|BF2.649|BF2.649 capsules dosed at 5mg, 10 mg, 20mg
62494312|NCT01071876|PLACEBO_COMPARATOR|Placebo|Capsules of Placebo containing lactose with low, medium and high dosage
62494313|NCT01231737|ACTIVE_COMPARATOR|Prulifloxacin|
62494314|NCT05336994|EXPERIMENTAL|Multivitamin/mineral supplement A to B|Participants will be randomly assigned to receive Supplement A and after 5-7 days of follow-up, they will receive Supplement B.
62494315|NCT05336994|EXPERIMENTAL|Multivitamin/mineral supplement B to A|Participants will be randomly assigned to receive Supplement B and after 5-7 days of follow-up, they will receive Supplement A.
62494316|NCT01929681|EXPERIMENTAL|LFMS - active treatment|"Low Field Magnetic Stimulation (LFMS) active treatment~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present."
62494317|NCT01929681|SHAM_COMPARATOR|LFMS - sham treatment|"Low Field Magnetic Stimulation - sham treatment~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present."
62494318|NCT05076682|EXPERIMENTAL|Choline|Choline with anti-PD-1 immunotherapy
62494319|NCT05076682|EXPERIMENTAL|Sodium cromoglicate|Sodium cromoglicate with anti-PD-1 immunotherapy
62494320|NCT05076682|EXPERIMENTAL|Efavirenz|Efavirenz with anti-PD-1 immunotherapy
62494321|NCT04712903|EXPERIMENTAL|Durvalumab in Combination with Platinum-Etoposide|Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.
62494322|NCT01927016||Esophagectomy for cancer|Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
62494323|NCT01172249|EXPERIMENTAL|Glucosamine-Chondroitin Mantecorp|1 capsule three times daily before meals (drug test - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Mantecorp)
62494324|NCT01172249|ACTIVE_COMPARATOR|Condroflex|1 capsule three times daily before meals (reference medication - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Condroflex ®).
62138156|NCT01091168|ACTIVE_COMPARATOR|arm B: Alkylating agent of physician choice|Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.
62494325|NCT02895841|NO_INTERVENTION|Standard of Care|Patients will continue with their normal Standard of Care for their condition
61941862|NCT03353207||Case without isolated RSWA|"1. First degree relatives of patients with iRBD;~2. Age- and sex- matched with isolated RSWA subjects;~3. Absence of dream enactment behaviors;~4. A score of RBDQ-HK less than 19;~5. Absence of RSWA as measured by v-PSG;~6. for those individuals with moderate obstructive sleep apnea (AHI \> 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
61941863|NCT05133908|ACTIVE_COMPARATOR|Digital Sleep Hygiene and Self-Monitoring Control|Participants assigned to this condition will receive an app to track sleep and offers sleep hygiene recommendations
62494326|NCT02895841|EXPERIMENTAL|SMART app wearable device|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
62494327|NCT02489864|ACTIVE_COMPARATOR|Terlipressin and albumin|"Patients in this group received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.~albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day."
61941864|NCT05133908|EXPERIMENTAL|dCBTi-ADHD|Participants assigned to this condition will receive a 7-module digital cognitive behavioral therapy for insomnia (dCBTi) tailored for adults with ADHD
61941865|NCT05592951|PLACEBO_COMPARATOR|Placebo once daily|1 stick pack dissolved in water once daily prior to breakfast
62138157|NCT04219475||GBM patients|Newly diagnosed patients above 18 years of age with GBM receiving standard of care, i.e., maximal surgical resection possible followed by radiation therapy (RT) plus temozolomide (TMZ) therapy and maintenance TMZ.
62337236|NCT01415037||Annular Array Ultrasound|Subject with possible or with known posterior vitreous detachment. Subjects with diabetic retinopathy will receive annular array ultrasound exam.
62337237|NCT04103255|EXPERIMENTAL|High frequency and intensive prevention|"High frequency and intensive prevention program~1. Tai Chi~2. CogniFit (cognitive training)~3. SpeechCare (speech training)"
62337238|NCT04103255|ACTIVE_COMPARATOR|Control group (CogniPlus)|Computer-assisted cognitive training program
62337239|NCT04105205|EXPERIMENTAL|Apramycin injection in escalating doses|Apramycin, solution for infusion.
62337240|NCT04105205|PLACEBO_COMPARATOR|Placebo|Physiological saline, solution for infusion.
62337241|NCT01879956|ACTIVE_COMPARATOR|OGI Method|- experimental group: use the OGI method to improve the executive functioning of patients with refractory schizophrenia.
62337242|NCT01879956|PLACEBO_COMPARATOR|craft activities|- control group: use of craft activities, attend the same-number of sessions, but without the intervention of therapists.
62337243|NCT04949906||The experimental group|The application of raising serum brain granules
62337244|NCT04949906||The control group|No nourishing serum brain granules are used
62337245|NCT03510611|EXPERIMENTAL|Period 1: fed control → Period 2: fasted control|Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
62337246|NCT03510611|EXPERIMENTAL|Period 1: fasted control → Period 2: fed control|Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
62337247|NCT03150095|EXPERIMENTAL|Health coaching|Patients will work with a health coach to improve self-management skills
62337248|NCT03150095|NO_INTERVENTION|Control|Patients will receive usual pre-transplant education to improve self-management skills
62337249|NCT03364608|EXPERIMENTAL|• AS MDI 90 µg|(2 actuations of 45 µg/actuation)
62337250|NCT03364608|EXPERIMENTAL|• AS MDI 180 µg|(2 actuations of 90 µg/actuation)
62337251|NCT03364608|PLACEBO_COMPARATOR|• Placebo MDI|(2 actuations)
62337252|NCT03364608|ACTIVE_COMPARATOR|• Proventil 90 µg|(1 actuation of 90 µg/actuation)
62337253|NCT03364608|ACTIVE_COMPARATOR|• Proventil 180 µg|(2 actuations of 90 µg/actuation)
62337254|NCT01097473|ACTIVE_COMPARATOR|Exercise training|Subjects participate in a once weekly supervised exercise training group, duration of 60 min.
62337255|NCT01097473|NO_INTERVENTION|Control|Control group receives no intervention
62337256|NCT02293018|EXPERIMENTAL|0.75% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 0.75% (w/w) MTC896 Gel
62337257|NCT02293018|EXPERIMENTAL|0.75% (w/w) MTC896 Gel twice daily|Subjects will apply topically twice daily 0.75% (w/w) MTC896 Gel
62337258|NCT02293018|EXPERIMENTAL|1.5% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 1.5% (w/w) MTC896 Gel
62337259|NCT06289166|EXPERIMENTAL|Consecutive doses of STSP-0601|
62337260|NCT01838174|EXPERIMENTAL|Acthar Gel (ACTH)|15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
62337261|NCT01838174|ACTIVE_COMPARATOR|IV methylprednisolone (steroids)|3 days of IV methylprednisolone (steroids) followed by 11 days of oral prednisone
62494328|NCT02489864|PLACEBO_COMPARATOR|Albumin|Only albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day.
62494329|NCT05963750|EXPERIMENTAL|virtual reality during the surgery|Group with the use of virtual reality during the surgery
62494330|NCT05963750|NO_INTERVENTION|control|Group without the use of virtual reality during the surgery
61941866|NCT05592951|EXPERIMENTAL|Test beverage once daily|1 stick pack dissolved in water once daily prior to breakfast
61941867|NCT05592951|EXPERIMENTAL|Test beverage twice daily|2 stick packs dissolved in water, one packet at a time twice daily (after lunch and after dinner)
62337262|NCT05985122|EXPERIMENTAL|Patients|"Patients diagnosed with C3G (15 positive and 15 negative for C3NEF) at Centro Daccò, will be identified between those who provided consent to store their samples in the certified biobank (UNI EN ISO 9001:2015; certification n° 6121) of Centro Daccò (Centro di Risorse Biologiche Mario Negri - Biobanca Malattie Rare e Renali) and to share them with external laboratories."
62337263|NCT05985122|ACTIVE_COMPARATOR|Healthy controls|"Healthy donors will be identified between those who provided consent to store their samples in the certified biobank (UNI EN ISO 9001:2015; certification n° 6121) of Centro Daccò (Centro di Risorse Biologiche Mario Negri - Biobanca Malattie Rare e Renali). Subject that meet the inclusion/exclusion criteria and for which there is no enough material stored in our biobank, will be recontacted by the investigators of Centro Daccò and, if agree, will be asked for serum sampling after informed consent signature."
62337264|NCT01628250|ACTIVE_COMPARATOR|laparoscopic complete mesocolic excision|Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
62337265|NCT01628250|ACTIVE_COMPARATOR|D3 laparoscopic colectomy|Randomized group of patients receiving laparoscopic colectomy with D3-resection
62337266|NCT04258059|ACTIVE_COMPARATOR|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat \>99.9% of all bacteria, protozoa, and most viruses in water supplies.
62337267|NCT04258059|SHAM_COMPARATOR|Inactive UV Device|A device that appears identical to the active comparator device except the lamp will not emit germicidal UV.
62337268|NCT02103790|EXPERIMENTAL|Home NIV installation|
62337269|NCT04852406|EXPERIMENTAL|Intervention group|Participants in this group receive protocol-based management of perioperative antithrombotic therapy.
62337270|NCT04852406|SHAM_COMPARATOR|Control group|Participants in this group receive routine management of perioperative antithrombotic therapy.
62337271|NCT05618496|EXPERIMENTAL|Patients treated with Epipad|Epipad
62337272|NCT04962737|EXPERIMENTAL|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
62337273|NCT02324842|ACTIVE_COMPARATOR|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
62337274|NCT02324842|ACTIVE_COMPARATOR|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
62337275|NCT02324842|ACTIVE_COMPARATOR|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
62494331|NCT00427154|ACTIVE_COMPARATOR|A|
62494332|NCT00427154|ACTIVE_COMPARATOR|B|
62494333|NCT03221205|SHAM_COMPARATOR|Sham CPAP|Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
62494334|NCT03221205|EXPERIMENTAL|Therapeutic CPAP|Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
61941868|NCT05592951|EXPERIMENTAL|Test beverage three times daily|3 stick packs dissolved in water, one packet at a time three times daily (after breakfast, lunch, and dinner)
61941869|NCT01423019|ACTIVE_COMPARATOR|Advantra Z|Proprietary ingredient for: stimulating thermogenesis, reducing weight, increasing lean muscle mass to total body mass, improving athletic performance, and suppressing appetite
61941870|NCT01423019|ACTIVE_COMPARATOR|Advantra Z + Naringin + Hesperiden|
62494335|NCT01156987|EXPERIMENTAL|Healthy Volunteers|Five healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.
61941871|NCT01423019|PLACEBO_COMPARATOR|Sugar pill|Capsule contains inert ingredient.
62337276|NCT03972358|EXPERIMENTAL|Medical menstrual regulation|"Mifepristone 200 mg orally on day 1.~Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone)."
62337277|NCT03288493|EXPERIMENTAL|Phase 1: P-BCMA-101 CAR-T cells|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
62337278|NCT03288493|EXPERIMENTAL|Phase 1 P-BCMA-101 CAR-T cells (Cohort A)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
62337279|NCT03288493|EXPERIMENTAL|Phase 1 P-BCMA-101 CAR-T cells (Cohort B)|Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
62337280|NCT03288493|EXPERIMENTAL|Phase 1 P-BCMA-101 CAR-T cells (Cohort C)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
62337281|NCT03288493|EXPERIMENTAL|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
61941872|NCT05208697|EXPERIMENTAL|Tele-Harm Reduction (THR)|THR utilizes 2 components. Component 1: telehealth technology facilitated by a peer harm reduction counselor to connect the participant with medical case managers and enroll patients in Ryan White/AIDS Drug Assistance Program (ADAP). Component 2: utilizes the syringe services program (SSP)-based peer harm reduction counselor to work with participants in identifying individual-specific barriers and facilitators to medication adherence.
61941873|NCT05208697|ACTIVE_COMPARATOR|off-site linkage to HIV care|introduces the participant to an SSP HIV/HCV linkage specialist and discusses linkage to a traditional Ryan White clinic
62138158|NCT03056183|EXPERIMENTAL|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
61941874|NCT03032133|ACTIVE_COMPARATOR|Regional pain control|Regional pain catheter
62337282|NCT03288493|EXPERIMENTAL|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
62337283|NCT03288493|EXPERIMENTAL|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
62337284|NCT03288493|EXPERIMENTAL|Phase 2: P-BCMA-101 CAR-T Cells|CAR-T cells administered via intravenous infusion as a total dose
62337285|NCT02021448|OTHER|Obesity: BMI > 30 kg/m2|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires
62337286|NCT01188395||subtypes of bipolar disorders|Bipolar I Disorder with alcoholism Bipolar I Disorder without alcoholism Bipolar II Disorder with alcoholism Bipolar II Disorder without alcoholism
62337287|NCT02304315|EXPERIMENTAL|GC1102 50,000 IU|Anhepatic phase: 50,000 IU intravenous during surgery, Post-transplantation(1st week): 50,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 50,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 50,000 IU intravenous every 4 weeks.
62494336|NCT01156987|EXPERIMENTAL|Breast Cancer Patients|40 breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.
62494337|NCT01083797|OTHER|dexmedetomidine, chloral hydrate|sedation with dexmedetomidine or chloral hydrate on separate occasions in the same patients
62138159|NCT03056183|NO_INTERVENTION|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
62138160|NCT00001208||Patients|Patients 2 years and older, will be eligible for participation if they have a disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX. Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia.
62337288|NCT02304315|EXPERIMENTAL|GC1102 80,000 IU|Anhepatic phase: 80,000 IU intravenous during surgery, Post-transplantation(1st week): 80,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 80,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 80,000 IU intravenous every 4 weeks.
62337289|NCT02279524|EXPERIMENTAL|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
62337290|NCT02279524|EXPERIMENTAL|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
62337291|NCT02279524|PLACEBO_COMPARATOR|Placebo|Two tablet of Aramchol matching placebo.
62695862|NCT06570746|ACTIVE_COMPARATOR|Chemical ablation with phenol|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points. Before the procedure, the femoral artery was visualized with a linear ultrasound probe to prevent arterial injury by entering 2 cm lateral to the femoral artery. Following this, a mixture of 2.5 cc of 0.05% bupivacaine and 2.5 cc of 6% phenol was applied, and a lesion was created for 90 seconds at 80°.
62695863|NCT06434727||Thoracic Group|Anatomic Lung Resection (Segmentectomy or Lobectomy) Procedures
62695864|NCT06434727||Colorectal Group|Lower Anterior Resection Procedures
62138161|NCT05721105||ECMO|50 Patients admitted to pediatric intensive care at the University Hospital of Nantes between January 2014 and December 2022 and supported by ECMO during their hospitalization.
62337292|NCT02608437|EXPERIMENTAL|SGI-110 and Ipilimumab|SGI-110 in combination with Ipilimumab
62337293|NCT02340988|EXPERIMENTAL|Oritavancin and Warfarin|Oritavancin 1200 mg Single-Dose IV Oritavancin Diphosphate given simultaneously with 25mg dose of Warfarin
62337294|NCT02340988|EXPERIMENTAL|Warfarin 24 hours post dose|25mg dose of Warfarin given 24 hours post 1200 mg Single-Dose IV Oritavancin Diphosphate.
62494338|NCT01577173|EXPERIMENTAL|A: MEHD7945A|
62494339|NCT01577173|ACTIVE_COMPARATOR|B: Cetuximab|
62494340|NCT04484090|EXPERIMENTAL|Vertica|Treatment with Vertica RF device for improving erectile function for men with erectile dysfunction
62695865|NCT04392622|EXPERIMENTAL|d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
62695866|NCT04392622|EXPERIMENTAL|d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
61941875|NCT03032133|EXPERIMENTAL|Local pain control|Local intraarticular pain catheter
62695867|NCT04392622|EXPERIMENTAL|d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
62695868|NCT04392622|EXPERIMENTAL|d-limonene -8gram|8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation
62695869|NCT04392622|EXPERIMENTAL|de-escalation dose d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
62337295|NCT02457000||Normal, healthy volunteers|Normal, healthy volunteers without any skin pathology will be asked to undergo various procedures to evaluate their sleep and skin health.
62337296|NCT02457000||Volunteers with skin pathology|Volunteers with skin pathology including but not limited to eczema, psoriasis, acne, and other inflammatory dermatoses will be asked to undergo various procedures to evaluate their sleep and skin health.
62337297|NCT01758666|EXPERIMENTAL|Methotrexate and Calcium folinate|
62337298|NCT04246580||Indocyanine green|Women with endometrial and cervical cancer undergoing indocyanine green-guided systematic pelvic lymphadenectomy by laparoscopy or robotic surgery
62337299|NCT04246580||Control|Women with endometrial and cervical cancer undergoing systematic pelvic lymphadenectomy by laparoscopy or robotic surgery without the use of indocyanine green tracer injection.
62337300|NCT00946777|EXPERIMENTAL|Systane® Ultra|
62337301|NCT04898374|EXPERIMENTAL|Induction Arm|patients will receive three cycles of IC Gemcitabin/Cisplatin followed by radical CRT
62337302|NCT04898374|ACTIVE_COMPARATOR|Adjuvant Arm|Patients will receive radical CRT followed by three cycles of AC Gemcitabin/Cisplatin
62337303|NCT03284242|EXPERIMENTAL|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
62337304|NCT03888391|EXPERIMENTAL|Active TNS|Participants will receive trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for up to 12 months of this open-extension trial.
62337305|NCT00683241|EXPERIMENTAL|1|Subjects with stage II to IV recurrent epithelial ovarian carcinoma or recurrent primary peritoneal cancer, from whom solid tumor, ascites or pleural effusion will be harvested and available and sufficient for lysate preparation; and whose largest tumor nodule is ≤ 2.5 cm. Subjects may have undergone chemotherapy or other therapy following tumor harvesting and prior to enrollment (apheresis).
62337306|NCT03196271|OTHER|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
62494341|NCT02024230|ACTIVE_COMPARATOR|Rivaroxaban|Patients were treated over a median of 4.75 years with either rivaroxaban (10 mg once daily for patients with a creatinine clearance of 15-49 mL/min or 15 mg once daily for patients with a creatinine clearance ≥50 mL/min)
62337307|NCT02144454|ACTIVE_COMPARATOR|Meal rich in saturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in saturated fats
62337308|NCT02144454|EXPERIMENTAL|Meal rich in monounsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in monounsaturated fats
62337309|NCT02144454|EXPERIMENTAL|Meal rich in n-6 polyunsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in n-6 polyunsaturated fats
62337310|NCT04076150|EXPERIMENTAL|Patients Receiving Optimum TAV|Patients with symptomatic severe aortic stenosis that will be treated via transcatheter aortic valve implantation procedure
62337311|NCT05668260|EXPERIMENTAL|Biodegradable Stent|An internal biodegradable pancreatic stent (ArchimedesTM) will be placed at the level of the pancreatic anastomosis in patients undergoing pancreatoduodenectomy.
62494342|NCT02024230|ACTIVE_COMPARATOR|Warfarin|The dose of warfarin can be controlled with dose adjustment to achieve a target international normalized ratio \[INR\] of 2.0-3.0 or in patients aged \>70 years and having a high bleeding risk, a target INR of 1.6-2.6) according to the guideline of Japanese Circulation Society based on the following paper (Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 2013;77(9):2264-70.)
62138162|NCT05721105||Control|50 patients hospitalized at the same age, during the same time period, and sharing the same diagnostic categories as the ECMO group, but the control group never had ECMO.
62494343|NCT01664039|EXPERIMENTAL|TRAVATAN|Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
62494344|NCT01664039|ACTIVE_COMPARATOR|LUMIGAN|Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
62494345|NCT01878435|EXPERIMENTAL|SMS reminder|
62494346|NCT01878435|EXPERIMENTAL|SMS reminder and Travel subsidy|
62138163|NCT04595461|PLACEBO_COMPARATOR|Control|Standard of care patient education with verbal and written education
62138164|NCT04595461|EXPERIMENTAL|Video Group|Patient education supplemented with four short youtube videos regarding chronic rhinosinusitis and endoscopic sinus surgery
62337312|NCT05668260|NO_INTERVENTION|Non Stent|No stent will be placed at the level of the pancreatic anastomosis in patients undergoing pancreatoduodenectomy.
62494347|NCT01878435|NO_INTERVENTION|Control|
62494348|NCT01878435|EXPERIMENTAL|SMS reminder and Travel subsidy 2|
62494349|NCT01872507|ACTIVE_COMPARATOR|biofeedback training|usual treatment+12 treatment of biofeedback training
62494350|NCT01872507|NO_INTERVENTION|control|usual treatment
62494351|NCT00748696|NO_INTERVENTION|1|No intervention
62494352|NCT00748696|EXPERIMENTAL|2|patient receiving oral nutrition supplement
62494353|NCT00748696|EXPERIMENTAL|3|resistance training
62494354|NCT00748696|EXPERIMENTAL|4|patients receiving resistance training and oral nutritional supplement
62494355|NCT04657315|OTHER|The investigational drug into the Intratumoral administration|The investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery
62494356|NCT01824498|EXPERIMENTAL|Low Fat, High Fat, Low Fat High Omega 3|See Intervention Description
62494357|NCT01824498|EXPERIMENTAL|Low Fat, Low Fat High Omega 3, High Fat|See Intervention Description
62494358|NCT01824498|EXPERIMENTAL|High Fat, Low Fat, Low Fat High Omega 3|See Intervention Description
62494359|NCT01824498|EXPERIMENTAL|High Fat, Low fat High Omega 3, Low Fat|See Intervention Description
62494360|NCT01824498|EXPERIMENTAL|Low Fat High Omega 3, High Fat, Low Fat|See Intervention Description
62494361|NCT01824498|EXPERIMENTAL|Low Fat High Omega 3, Low Fat, High Fat|See Intervention Description
62494362|NCT03504020|EXPERIMENTAL|ECG Belt|The ECG Belt arm will utilize the ECG Belt Research System at implant and all follow up visits.
62494363|NCT03504020|NO_INTERVENTION|Control Arm|Standard CRT through 6 months follow-up.
62494364|NCT01361633|EXPERIMENTAL|Medication|250 mg d-cycloserine
62494365|NCT01361633|PLACEBO_COMPARATOR|Sugar Pill|
62494366|NCT01096745|EXPERIMENTAL|Gemcitabine/Cisplatin|
61941876|NCT04766710|EXPERIMENTAL|Community-based ART delivery (CAD)|The CAD model intervention will take place for 24 months. A total of 2000 registered stable people living with HIV will form into the CAD group. The investigators have developed the implementation guide, monitoring tools, quality assurance checklist, and lists of people living with HIV in selected ART clinics for the CAD model intervention. The first step will be to extract the data disaggregated by gender, age, and type of sub-populations, including adolescents, female entertainment workers, men who have sex with men, transgender women, and people who use drugs from the national database using the definitions introduced by the WHO. Once the list is completed with patient ART codes, a consultative meeting combined with the project orientation will be convened. Providers from the selected ART clinics and implementing partners at each site will divide stable people living with HIV into their respective groups based on the ART sites.
62138165|NCT06081985|ACTIVE_COMPARATOR|Active TMS|Deep TMS to the left dorsolateral prefrontal cortex with double-cone coil
62337313|NCT04260334|EXPERIMENTAL|Intervention Group|RFNP was created by researchers. RFNP comprises positive language, a positive environment, relaxation exercise and methods of coping with stress (Mete et al., 2017; Mete et al., 2015; Lazarus, 1984). This programme has a content which reducing women's anxiety and pain. Such programmes are expected to enhanced level of the knowledge about ovarian cancer and its surgery. Women are usually admitted to the clinic two days before surgery. The program duration was for 2 days each day with two sessions, of 6 hr each. There are four relaxation exercises in the program because repetition is recommended for the relaxation exercises to be effective. Deep breathing exercise, progressive muscle relaxation, and guided imagery were used in program. In addition, RFNP is divided into four sections so that the information is not intensely transferred to women.
62337314|NCT04260334|NO_INTERVENTION|Control Group|In the control group, women received routine nursing care in the hospital, and data collection tools were applied at the parallel hours as the experimental group. Usual nursing care included information about visitor and meal times, nurse call button, diet, drug administration and not to leave the hospital. Relaxation exercises were not practiced to patients in usual nursing care to reduce stress and anxiety.
62337315|NCT03361319|EXPERIMENTAL|Part 1: (Phase Ib) Dose Escalation|"A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:~Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21"
62337316|NCT03361319|EXPERIMENTAL|Part 1: Dose Expansion|In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.
62337317|NCT03361319|PLACEBO_COMPARATOR|Part 2: (Phase II)|"A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.~Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib"
62337318|NCT05837078|ACTIVE_COMPARATOR|control group|patients had ridge splitting without laser bio stimulation and received two implants supported peek overdenture
62494367|NCT01096745|EXPERIMENTAL|S-1/Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
62494368|NCT03245333|EXPERIMENTAL|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
62494369|NCT03245333|OTHER|Stage 1-negative control|observed only for 52 weeks.
62494370|NCT03245333|EXPERIMENTAL|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
62494371|NCT03245333|OTHER|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
62494372|NCT03387462|EXPERIMENTAL|DOT Diary Optimization Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
62494373|NCT04709757|ACTIVE_COMPARATOR|Intermittent Dosing HF10 30/90|Stimulation delivered at 30 seconds ON and 120 seconds OFF through patient's existing spinal cord stimulator.
62494374|NCT04709757|ACTIVE_COMPARATOR|Intermittent Dosing HF10 30/360|Stimulation delivered at 30 seconds ON and 360 seconds OFF through patient's existing spinal cord stimulator.
62337319|NCT05837078|ACTIVE_COMPARATOR|study group|patients had ridge splitting with laser bio stimulation and received two implants supported peek overdenture
62337320|NCT02902744|EXPERIMENTAL|ILUVIEN 0.19 MG|
62337321|NCT05539586|EXPERIMENTAL|Tecar group|
62337322|NCT05539586|SHAM_COMPARATOR|Sham Group|
62337323|NCT06285929||Navigated patients|Student volunteer navigation support accessing barriers to care for patients, families and caregivers with a cancer diagnosis through a social determinants of health assessment and connecting with resources with an effort to eliminate barriers.
62494375|NCT05832424|EXPERIMENTAL|UPLIFT Telehealth Intervention|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
62494376|NCT00796796|EXPERIMENTAL|Cohort 1 (Starting Dose)|"Temsirolimus 20 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
62695870|NCT04392622|EXPERIMENTAL|de-escalation dose d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
62337324|NCT06285929||non-navigated patients|Patients, families and caregivers with a cancer diagnosis without the support of student volunteer navigation and serving as the baseline and control.
62337325|NCT06285929||Student volunteers|Undergraduate or graduate students volunteering with ACS CARES program to provide navigation support to patients, families and caregivers with a cancer diagnosis.
62138166|NCT06081985|SHAM_COMPARATOR|Sham TMS|Sham TMS to the left dorsolateral prefrontal cortex with sham coil
62337326|NCT04534439|EXPERIMENTAL|APX-115|Oral administration of APX-115 400mg, daily
62337327|NCT04534439|PLACEBO_COMPARATOR|Placebo|Oral administration of APX-115-matching placebo 400mg, daily
62337328|NCT01132677|ACTIVE_COMPARATOR|Hyaluronic Acid (HA) Injection|Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
62337329|NCT01132677|ACTIVE_COMPARATOR|Corticosteroid Injection|Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
62337330|NCT02632890||Patients survey|Adult patients treated with abatacept for rheumatoid arthritis
62337331|NCT02632890||HCP survey|HCP with at least 1 patient taking abatacept
62337332|NCT02632890||Retrospective chart review study|Adult patients treated with abatacept for rheumatoid arthritis
62337333|NCT02632695|EXPERIMENTAL|FOOTFIT Plus|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports and allows regular communication with the wound care provider on progress.
62337334|NCT02632695|EXPERIMENTAL|FOOTFIT|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports. There is not regular communication with the wound care provider on progress.
62337335|NCT04765826|EXPERIMENTAL|high dose oral steroids|(20 patients) will receive high dose oral mini pulse steroids (dexamethasone 5 mg on two consecutive weekly days for 3 months).
61941877|NCT04766710|ACTIVE_COMPARATOR|ART multi-month dispensing (MMD)|A total of 2000 registered stable people living with HIV will form into the control group and received standard services under the MDD model. The control-arm participants will visit the ART clinics and collect their ARVs from the facility-based staff.
61941878|NCT03001882|EXPERIMENTAL|Combination therapy|Nivolumab + Ipilimumab
61941879|NCT03719443|EXPERIMENTAL|VIS649|A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.
62138167|NCT05298358|EXPERIMENTAL|RIC- alloBMT with high PTCy in SSc|"Days -9 Thymoglobulin 0.5 mg/kg IV~Days -8,-7 Thymoglobulin 2 mg/kg IV daily~Days -6, -5 Fludarabine 30 mg/M2 IV Cyclophosphamide 14.5 mg/kg IV~Days -4, -3-2 Fludarabine 30 mg/M2 IV~Day -1 TBI 400 cGy~Day 0 Infuse unmanipulated marrow; begin antimicrobial prophylaxis.~Days 3, 4 Cy 50 mg/kg IV and Mesna 40 mg/kg IV~Day 5 FK-506 oral and MMF oral and G-CSF~Day 30 Assess peripheral blood chimerism~Day 35 Discontinue MMF~Day 60 Assess peripheral blood chimerism~Day 180 Discontinue FK-506 Evaluate disease Assess Chimerism in peripheral blood~1 yr. Evaluate disease by peripheral blood chimerism"
62337336|NCT04765826|EXPERIMENTAL|low dose oral steroids|(20 patients) will receive low dose oral mini pulse steroids (2.5mg dexamethasone on two consecutive weekly days for 3 months
62337337|NCT04765826|EXPERIMENTAL|topical treatment|(20 patients) chosen lesions of comparable size and location in each patient in this group will receive either; super potent topical steroids once every other day, Tacrolimus ointment twice daily for 3 months, or nothing to serve as a control.
62337338|NCT06339736||M-TMD group|Patients with a diagnosis of muscular TMDs performed according to DC/TMD criteria
62337339|NCT06339736||CTRL group|A control group of subjects with a negative history for TMDs
62337340|NCT05931016||Patients with known lung disease and LTOT (long term oxygen therapy)|Patients with i.e. interstitial lung, emphysema, pulmonary hypertension or COPD with the need for LTOT
62337341|NCT04423900|EXPERIMENTAL|Plantar Fasciitis App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
62695871|NCT04392622|EXPERIMENTAL|de-escalation dose d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
61941880|NCT03719443|PLACEBO_COMPARATOR|Placebo|Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
61941881|NCT06574178|EXPERIMENTAL|Dietary Intervention|Participants will receive breakfast, lunch, and dinner in the form of fully cooked, ready-to-heat standardized meals for 6 weeks that are prepared by a commercial kitchen.
61941882|NCT06097338||MAFLD patients|MAFLD patients undergoing weight loss surgery
61941883|NCT06097338||healthy volunteers|healthy volunteers
61941884|NCT05768971||Active Crohn´s disease|Ultrasound in patients with proven active Crohn´s disease scheduled for therapy with anti tumor necrosis factor alpha antibodies
61941885|NCT05768971||Patients with Food allergy|Patients with proven food allergy
61941886|NCT05768971||Healthy controls|Healthy, food-tolerant volunteers without any abdominal complaint
61941887|NCT01680887|EXPERIMENTAL|Varenicline|Oral 1.0 mg BID.
61941888|NCT01680887|PLACEBO_COMPARATOR|Placebo|Oral 1.0 mg BID.
62494377|NCT00796796|EXPERIMENTAL|Cohort 2|"Temsirolimus 25 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
62494378|NCT01675739|ACTIVE_COMPARATOR|No-SMS group|In No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy without SMS.
62494379|NCT01675739|EXPERIMENTAL|SMS group|Patients in SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled short message service(SMS)
62695872|NCT06644066|EXPERIMENTAL|Partial pressure of Oxygen Control method|After the targeted structures were successfully dissected, the anesthesiologist manually controls pure oxygen one-lung ventilation on the surgical side until the lung is fully expand. The ventilator is disconnected, the airway is opened, and the operator uses a gauze ball to pressure the preserve lung tissue. At a SpO2 of 95%, the healthy side undergoes one-lung ventilation.
62695873|NCT06644066|NO_INTERVENTION|Modified inflation-deflation method|After the targeted structures were successfully dissected, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O, with the bronchus of the operation side open to atmosphere while continuing ventilation of the contralateral lung.
62337342|NCT04423900|EXPERIMENTAL|Achilles Tendinopathy App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
62337343|NCT04423900|EXPERIMENTAL|Plantar Fasciitis Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
62337344|NCT04423900|EXPERIMENTAL|Achilles Tendinopathy Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
62337345|NCT04423900|EXPERIMENTAL|Plantar Fasciitis Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
62337346|NCT04423900|EXPERIMENTAL|Achilles Tendinopathy Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
62337347|NCT02775760|EXPERIMENTAL|Cardiovascular endurance|Participants will undergo cardiovascular endurance training. The trainer-supervised endurance training will involve walking on a treadmill at moderate intensity
62337348|NCT02775760|ACTIVE_COMPARATOR|Strength, balance, and flexibility|Participants will undergo Strength, balance, and flexibility training.
62337349|NCT03050359|EXPERIMENTAL|TAK-438 20 mg|H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
62337350|NCT03050359|EXPERIMENTAL|Lansoprazole 30 mg|H. pylori negative (HP -) participants: lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, QD for up to 6 weeks. HP + participants: lansoprazole 30 mg, capsules, orally, BID and TAK-438 placebo-matching tablets, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed by lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, BID for up to 4 weeks.
62337351|NCT01432197|EXPERIMENTAL|Occupational therapy intervention|"Intervention group: Standard treatment and care added with an ADL intervention program: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.~Control group: Standard treatment and care. No occupational therapy intervention."
62337352|NCT01432197|NO_INTERVENTION|Standard treatment and care|Control group: Standard treatment and care. No occupational therapy intervention.
62494380|NCT05006573|EXPERIMENTAL|Benralizumab|Benralizumab will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
62494381|NCT05006573|PLACEBO_COMPARATOR|Placebo|Matching placebo solution will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
62695874|NCT03462745|EXPERIMENTAL|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
62695875|NCT03462745|NO_INTERVENTION|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
62337353|NCT03701360||Aspirin alone group|- Aspirin: 75\~100mg once per day, initial loading dose of 300\~500mg/d is allowed
62337354|NCT03701360||Aspirin + Clopidogrel resinate group|"* Aspirin: 75\~100mg once per day, initial loading dose of 300\~500mg/d is allowed~* Clopidogrel resinate: 75mg once per day, initial loading dose of 300mg/d is allowed"
62337355|NCT00414960|EXPERIMENTAL|Enzastaurin|Treatment with enzastaurin 500 milligrams (mg) orally (po) once daily (QD) given as 4 tablets (125 mg each).
62494382|NCT04492696|ACTIVE_COMPARATOR|Crashcourse|"CC uses an approach to providing concussion education informed by user-centered formative design research studies. The program features an interactive choose your own adventure approach to navigate the learner through the content, and is guided by near-peer Division I collegiate football athletes"
62494383|NCT04492696|ACTIVE_COMPARATOR|CDC Video|CDC-Vi is an online learning module developed by the CDC and the National Federation of State High School Associations Learning Center. Learners progress through the curriculum sequentially completing each unit before proceeding to the next. The primary narrator of CDC-Vi is Dr. Mick Koester, Chair of the NFHS Sports Medicine Advisory Committee
62337356|NCT00414960|PLACEBO_COMPARATOR|Placebo|Treatment with placebo po QD appearing identical to enzastaurin.
62337357|NCT00335504|EXPERIMENTAL|Arm I (atorvastatin calcium)|Patients receive oral atorvastatin once daily.
62337358|NCT00335504|EXPERIMENTAL|Arm II (sulindac)|Patients receive oral sulindac twice daily.
62337359|NCT00335504|EXPERIMENTAL|Arm III (oligofructose-enriched inulin)|Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.
62337360|NCT00335504|PLACEBO_COMPARATOR|Arm IV (placebo)|Patients receive an oral placebo twice daily.
62337361|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
62337362|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
62337363|NCT01911000|EXPERIMENTAL|RTHT|RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
62337364|NCT03106506|EXPERIMENTAL|Test-implant with graft|Patients who received a connective tissue graft around implants
62337365|NCT03106506|ACTIVE_COMPARATOR|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
62494384|NCT04492696|ACTIVE_COMPARATOR|CDC Written|"CDC-Wr consists of educational PDFs available for download from the CDC website, as part of the CDC's Heads Up brain injury awareness initiative. The PDFs used for the CDC-Wr condition were specific to high school athlete concussion education"
62494385|NCT04981457|ACTIVE_COMPARATOR|patients who recieve misoprostol alone|Group A (n =30 ) will receive only vaginal Misoprostol 800mcg (4 tablets Cytotec 200mcg ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or uterine contractions or bleeding assessed by the same doctor who made evaluation at the beginning.
62494386|NCT04981457|ACTIVE_COMPARATOR|patients who recieve misoprostol and iso sorbide mononitrate|Group B (n =30 ) will receive combined vaginal Misoprostol 800mcg (4 tablets Cytotec ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or start of uterine contractions or bleeding. with Isosorbide-5-mononitrate (20 mg). Effox 20 mg )once at the beginning with misoprostol until reaching cervical ripening or start of and uterine contractions assessed by the same doctor who made the evaluation at the beginning.
62494387|NCT05285358|EXPERIMENTAL|Treatment (gemcitabine, cisplatin, nab-paclitaxel PIPAC)|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 60 minutes on days 1 and 8. Patients also receive nab-paclitaxel via PIPAC over 5-10 minutes on day 3 of cycles 1, 3, and 5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62494388|NCT03119896|EXPERIMENTAL|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
61941889|NCT01557803||Starting ART|Adult patients starting anti retroviral therapy for the first time
61941890|NCT05108714|EXPERIMENTAL|Group 1. Left arm.|Healthy subjects, who underwent the following intervention: intradermal injection of lidocaine hydrochloride injectable solution via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein.
62695876|NCT06462456||PRECISION1 Sphere|Verofilcon A spherical soft contact lenses worn in both eyes in a real-world setting
62138168|NCT02423642|EXPERIMENTAL|AKI requring CRRT and use regional citrate anticoagulation|CRRT use regional citrate anticoagulation
62337366|NCT04989010|EXPERIMENTAL|89Zr-NY005 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3 mCi) labeled anti-CLDN18.2 mAbs (89Zr-NY005)
62337367|NCT04953650|EXPERIMENTAL|intervention group|two fasting days and five ad-libitum days followed by usual exercise.
61941891|NCT05108714|PLACEBO_COMPARATOR|Group 1. Right arm.|Healthy subjects, who underwent the following intervention: intradermal injection of sterile saline via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein.
62337368|NCT04953650|SHAM_COMPARATOR|Control group|Usual diet and usual exercise prior to the intervention.
62337369|NCT06554834|EXPERIMENTAL|CV4 + RR Group|Participants will undergo three 30-minute sessions of osteopathic therapy combining the Fourth Ventricle Compression (CV4) and Rib Raising (RR) techniques.
62337370|NCT06554834|EXPERIMENTAL|CV4 Group|Participants will receive three 30-minute sessions of osteopathic therapy focusing solely on the Fourth Ventricle Compression (CV4) technique.
62337371|NCT06554834|PLACEBO_COMPARATOR|Placebo Group|Participants will undergo a sham procedure involving an ultrasound transducer for three 30-minute sessions, with no therapeutic intervention.
62337372|NCT05433194|EXPERIMENTAL|Phase I Test group 1: ABO1009-DP|Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid region of the upper arm of subjects on D0.
62337373|NCT00304265|EXPERIMENTAL|6th Dose Pertussis Vaccine Group|Participants received 6th dose of pertussis vaccine
62337374|NCT00304265|EXPERIMENTAL|5th Dose Pertussis Vaccine Group|Participants received 5th dose of pertussis vaccine
62138169|NCT02423642|EXPERIMENTAL|AKI requring CRRT and not use regional citrate anticoagulation|CRRT not use regional citrate anticoagulation
62138170|NCT05728684|EXPERIMENTAL|CM310|CM310, subcutaneous
62138171|NCT02502461|SHAM_COMPARATOR|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
62337375|NCT04147832||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, seen at any AHF clinic within the last two years and whose care is documented in the AHF electronic health records system.
62337376|NCT04680078|ACTIVE_COMPARATOR|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop. The sutures are removed 1 week after the surgery.
62337377|NCT04680078|ACTIVE_COMPARATOR|Conventional Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop.
62337378|NCT05870644|EXPERIMENTAL|Exercise in room temperature at 25 degree Celsius.|The participants received a moderate exercise program of cycling at moderate intensity (50-60% HRR) for 60 minutes in room temperature at 25 degree Celsius.
62337379|NCT05870644|EXPERIMENTAL|Exercise in room temperature at 34 degree Celsius.|The participants received a moderate exercise program of cycling at moderate intensity (50-60% HRR) for 60 minutes in room temperature at 34 degree Celsius.
62337380|NCT01196624|ACTIVE_COMPARATOR|TMS TO RT DLPF WITH EXPOSURE|TMS TO RIGHT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
61941892|NCT05108714|EXPERIMENTAL|Group 2. Left arm.|Healthy subjects, who underwent the following intervention: intradermal injection of lidocaine hydrochloride injectable solution via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein.
61941893|NCT05108714|ACTIVE_COMPARATOR|Group 2. Right arm.|Healthy subjects, who underwent the following intervention: insertion of 18G catheter in a cubital vein at the site of antecubital fossa of the right arm, without any prior intervention.
62138172|NCT02502461|ACTIVE_COMPARATOR|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
62138173|NCT04149119|EXPERIMENTAL|Intervention arm|ATSB+LLINs+Standard Care for Malaria case management
62337381|NCT01196624|ACTIVE_COMPARATOR|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE
62337382|NCT01196624|ACTIVE_COMPARATOR|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
62337383|NCT01196624|ACTIVE_COMPARATOR|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE
62337384|NCT06555237|EXPERIMENTAL|Trametynib|Trametynib in 0,025mg/kg dose orally once daily
62337385|NCT06555237|ACTIVE_COMPARATOR|Standard therapy|Disopiramide and Beta-blocker orally
62337386|NCT03480607|ACTIVE_COMPARATOR|Dexmedetomidine group|Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block
62337387|NCT03480607|ACTIVE_COMPARATOR|Dexamethasone group|Dexamethasone in conjunction with bupivacaine f
62337388|NCT04864652|EXPERIMENTAL|Single Arm|CHILLS Procedure
62494389|NCT03119896|NO_INTERVENTION|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
62337389|NCT01043354|EXPERIMENTAL|stage-matched intervention|Transtheoretical Model-based stage-matched intervention
62337390|NCT01043354|EXPERIMENTAL|framing effects intervention|counseling based on prospect theory
62337391|NCT01043354|ACTIVE_COMPARATOR|attention placebo intervention|counseling about general health topics
62494390|NCT01676324||Inflammatory Bowel Disease|Those with Inflammatory Bowel Disease (known) and those with no Inflammatory Bowel Disease (not previously diagnosed)
62138174|NCT04149119|NO_INTERVENTION|Standard arm or arm 2|LLINs+Standard Care for MalarIA case management
62138175|NCT03500822|EXPERIMENTAL|Metronome-paced tachypnea|Dynamic hyperinflation by the method of metronome-paced tachypnea.
62337392|NCT05632627|ACTIVE_COMPARATOR|Full Spectrum Cannabidiol|Full Spectrum Cannabidiol (\<0.3% THC) Oral softgel capsule, 210mg/day
62337393|NCT05632627|ACTIVE_COMPARATOR|Broad Spectrum Cannabidiol|Broad Spectrum Cannabidiol (0.0% THC) Oral softgel capsule, 210mg/day
62494391|NCT04175587|EXPERIMENTAL|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Induction: a) RIF: 60 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR; Consolidation: a) RIF: 60 mg/kg daily, in a 4-week on 4-week off regimen for four cycles in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles
62337394|NCT05632627|PLACEBO_COMPARATOR|Hemp Seed Oil|Placebo Oral softgel capsule, 210mg/day
62337395|NCT03149666||Evaluation of bitter taste|Participants will be evaluated as to the intensity of bitter taste when performing watery mouthwash with quinine.
61941894|NCT05012657|EXPERIMENTAL|Prosthesis|Patient is temporarily fit with Point Partial partial finger prosthetic system
61941895|NCT05384678|EXPERIMENTAL|DMT 0.6 mg/min|
61941896|NCT05384678|EXPERIMENTAL|DMT 1.2 mg/min|
61941897|NCT05384678|EXPERIMENTAL|DMT 1.8 mg/min|
61941898|NCT05384678|EXPERIMENTAL|DMT 2.4 mg/min|
61941899|NCT05384678|PLACEBO_COMPARATOR|Placebo|
61941900|NCT05384678|EXPERIMENTAL|DMT 1.2 mg/min + dose titration|
61941901|NCT00469651|EXPERIMENTAL|1|15 microgramme candidate vaccine
62138176|NCT03500822|EXPERIMENTAL|Exspiratory-stenosis breathing|Dynamic hyperinflation by the method of expiratory-stenosis breathing.
62337396|NCT02002806|EXPERIMENTAL|Alcohol Injection|Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis
62337397|NCT02002806|PLACEBO_COMPARATOR|Placebo Injection|Celiac plexus injection - placebo injection
62337398|NCT04191577|PLACEBO_COMPARATOR|Placebo|Placebo to be administered once daily.
62337399|NCT04191577|ACTIVE_COMPARATOR|CVN424 (Low Dose)|Low dose of CVN424 to be administered once daily.
62337400|NCT04191577|ACTIVE_COMPARATOR|CVN424 (High Dose)|Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.
62337401|NCT01744509|OTHER|Diagnosis of CRC|All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
62337402|NCT06063252|NO_INTERVENTION|controlgroup|Usual care
62337403|NCT06063252|EXPERIMENTAL|intervention group|receive self-management intervention
62337404|NCT02493426|PLACEBO_COMPARATOR|Placebo|Saline Nasal spray designed to look and feel like the drug intervention
62337405|NCT02493426|EXPERIMENTAL|Intranasal Oxytocin|Oxytocin nasal spray designed to look as seem exactly like Placebo
62337406|NCT01428518||Patients with bipolar disorder|Patients with bipolar disorder prescribed lamotrigine tablets for the first time
62337407|NCT02096861|EXPERIMENTAL|CT-P13 - CT-P13|CT-P13 followed by CT-P13 from Week 30
62337408|NCT02096861|ACTIVE_COMPARATOR|CT-P13 - Remicade|CT-P13 followed by Remicade from Week 30
62138177|NCT02188836|EXPERIMENTAL|Electromagnetic device|The electromagnetic stimulation was performed by using a device capable of generating an electromagnetic field around the fracture site. This was applied once a day, one hour for 8 weeks.
62138178|NCT02188836|PLACEBO_COMPARATOR|Placebo device|A device with the same characteristics to the real device, except for the generation of the electromagnetic stimulation. It generates sham stimulation.
62138179|NCT05563766|EXPERIMENTAL|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
62337409|NCT02096861|ACTIVE_COMPARATOR|Remicade - Remicade|Remicade followed by Remicade from Week 30
62337410|NCT02096861|EXPERIMENTAL|Remicade - CT-P13|Remicade followed by CT-P13 from Week 30
62337411|NCT03736538|EXPERIMENTAL|Nitrous Oxide|"Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive inhaled nitrous oxide."
62337412|NCT03736538|PLACEBO_COMPARATOR|Placebo Gas|"Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive placebo gas."
62337413|NCT00463658|EXPERIMENTAL|1|Subjects in the interdisciplinary group received home care services from a team of professional service providers (CCAC Case Manager, Registered Nurse, Occupational Therapist, Physiotherapist, Registered Dietician) with experience and training in falls prevention. The team provided a comprehensive, coordinated and evidence based approach to falls prevention through regular home visits, weekly case conferencing, a single accessible fall prevention plan,and joint client visits.
62337414|NCT00463658|NO_INTERVENTION|2|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessing client's eligibility for in-home health services, arrangement and coordination of professional (i.e. nursing, occupational therapy, physiotherapy, social work, speech-language pathology, nutrition) and non-professional HSS, information and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessments with clients.
62337415|NCT01763268|EXPERIMENTAL|Trivivac|Children who receive Trivivac vaccine
62138180|NCT06459284||early use of iOCT group|Patients having undergone pars plana vitrectomy with membrane Peeling die to an epiretinal Membrane in the time period from 1.6.2014 to 31.12.2016.
62138181|NCT06459284||later use of iOCT group|Patients having undergone pars plana vitrectomy with membrane Peeling die to an epiretinal Membrane in the time period from 1.11.2020 to 31.7.2022.
62138182|NCT05340231|EXPERIMENTAL|Study group|sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy
62138183|NCT05340231|ACTIVE_COMPARATOR|Control group|neoadjuvant chemotherapy alone
62138184|NCT02823574|EXPERIMENTAL|Nivolumab and Ipilimumab|Specified dose on specified days
62138185|NCT02823574|ACTIVE_COMPARATOR|Nivolumab and Ipilimumab-placebo|Specified dose on specified days
62337416|NCT01915004|OTHER|Standard Invididual Urotherapy|Educational Intervention. Standard individual urotherapy (bladder re-training) occurs in the pediatric urology clinic.
62695877|NCT06462456||PRECISION1 Toric|Verofilcon A toric soft contact lenses worn in both eyes in a real-world setting
62337417|NCT01915004|EXPERIMENTAL|Bladder Training Video|Experimental Educational Intervention. Participants will watch a 7 minute animated bladder training video.
62695878|NCT06641557|EXPERIMENTAL|200mg|IkT-148009 will be administered as 4x50mg gelatin capsules
62337418|NCT03338517|ACTIVE_COMPARATOR|Study group|Helium Neon Laser
62337419|NCT03338517|NO_INTERVENTION|Control group|No intervention
62337420|NCT04685070|EXPERIMENTAL|HS-10296 (Almonertinib)|
62337421|NCT05688579|EXPERIMENTAL|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will treat with mineralocorticoid receptor antagonists(MRAs) (including spironolactone 20-60mg/ day, or eplerenone50-100mg/day, or finerenone 10-20mg/ day) in addition to the original antihypertensive drugs for 48 months.
62337422|NCT05688579|PLACEBO_COMPARATOR|Blank Control|Participants will be given the original antihypertensive drugs for 48 months.
62337423|NCT05520268|EXPERIMENTAL|Conventional music therapy (CMT)|Participants receive 10 weeks of CMT and standard care.
62695879|NCT03507725|EXPERIMENTAL|Usual Care + Meditation|Usual care (local anaesthesia) + audio-recorded brief mind-dody intervention for 10 minutes before and for 10 minutes during the prostate biopsy procedure
62337424|NCT05520268|EXPERIMENTAL|Digital music rehabilitation (DMR)|Participants receive 10 weeks of DMR and standard care.
62494392|NCT04175587|OTHER|Arsenic trioxide Plus Retinoic Acid|Induction: a) Arsenic trioxide: 0·15 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR Consolidation: a) Arsenic trioxide: 0.15mg/kg daily, in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles Expected Efficacy: Oral RIF plus ATRA is not inferior to intravenous arsenic trioxide plus ATRA for achieving 2-year EFS.
62494393|NCT01145157|EXPERIMENTAL|Signature Knee Guide|Total Knee Arthroplasty using the Signature Knee Guide with the Vanguard Knee System
62494394|NCT01145157|ACTIVE_COMPARATOR|Conventional Instrumentation|Total Knee Arthroplasty will be performed using Conventional Instrumentation with the Vanguard Knee System
62494395|NCT01145157|ACTIVE_COMPARATOR|Computer Assisted Navigation|Total Knee Arthroplasty will be performed using Computer Assisted Navigation with the Vanguard Knee System
62494396|NCT06352762|ACTIVE_COMPARATOR|Conventional physiotherapy|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given.
62494397|NCT06352762|EXPERIMENTAL|Robotic Rehabilitation|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. In addition, upper extremity robotic rehabilitation was applied.
62494398|NCT01310933||Kikuchi's disease|
62494399|NCT01310933||Malignant lymphoma|
62494400|NCT00924053|EXPERIMENTAL|EGT0001474|
62494401|NCT00924053|PLACEBO_COMPARATOR|Placebo|
62494402|NCT01569113|EXPERIMENTAL|ellaOne + microgynon 30|
62337425|NCT05520268|NO_INTERVENTION|Standard care|Participants receive only standard care. Standard care comprises normal care services received by the PWDs in the Finnish health care system.
62494403|NCT01569113|PLACEBO_COMPARATOR|placebo + microgynon 30|
62494404|NCT01066286||core binding factor positive|core binding factor positive acute myeloid leukemia
62494405|NCT04385251||SARS-CoV-2 infection/COVID-19|Adults who present for SARS-CoV-2 testing will be consented for this study. Participants who are enrolled will be informed that if they have SARS-CoV-2 infection/COVID-19, they will be followed for 28 days in an observational cohort study, and that if they do not have SARS-CoV-2 infection, there will be no further follow-up.
62494406|NCT04345822||normotension|patients without diagnosis or treatment for hypertension
62494407|NCT04345822||hypertension|patients with diagnosis or treatment for hypertension
62494408|NCT06632054||Text Message Reminders|Participants will receive text message reminders to complete FIT for colon cancer screening.
62494409|NCT06632054||Usual Care (Phone Call Reminders)|Participants will receive usual care (phone call reminders to complete FIT for colon cancer screening).
62494410|NCT05263635|EXPERIMENTAL|Music therapy + Standard of Care Enhanced Recovery After Surgery (ERAS)|All participants will have complete Enhanced Recovery After Surgery (ERAS) standard of care. A preoperative music intervention will be played first in the preoperative holding area, a second music intervention played immediately following the induction of anesthesia in the operating room, and a third music intervention played in the recovery room when the patient is awake and responsive.
62494411|NCT05263635|ACTIVE_COMPARATOR|Standard of Care Enhanced Recovery After Surgery (ERAS)|Participants randomized into the control group will receive complete Enhanced Recovery After Surgery (ERAS) standard of care and no music therapy sessions.
62494412|NCT03104231|EXPERIMENTAL|study group|All the patients will be shown three-dimensional (3D) movie.
62494413|NCT05434091|EXPERIMENTAL|PF-07291177 and Placebo (Cohort 1)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
62494414|NCT05434091|EXPERIMENTAL|PF-07291177 and Placebo (Cohort 2)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
62337426|NCT03134508||pregnant IBD women treated|pregnant IBD women treated by antiTNFα
62337427|NCT03134508||pregnant IBD women not treated|pregnant IBD women not treated by antiTNFα
62695880|NCT03507725|ACTIVE_COMPARATOR|Usual Care Group|Time-and-attention control group receiving usual care (local anesthesia) including optional background music in the biopsy procedure room
62695881|NCT02494492|EXPERIMENTAL|IVT of regulator T-cells|intravitreous administration of regulator T-cells
62695882|NCT06179446|EXPERIMENTAL|pdmFlu vaccine dose A|
62138186|NCT06309576|EXPERIMENTAL|Fasting-refeeding cycle|Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance, 2 days of fasting, and 2 days of ad-libitum refeeding.
62337428|NCT05297422|ACTIVE_COMPARATOR|Control|Axillary Approach to Brachial Plexus Blockade will be performed using 30ml Ropivacaine 0.5% ,without Ketamine as an adjuvant.
62494415|NCT05434091|EXPERIMENTAL|PF-07291177 and Placebo (Cohort 3)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
62494416|NCT05025033|EXPERIMENTAL|PD-1 antibody combined with apatinib and chemotherapy|PD-1 antibody: 200mg intravenous drip every 3 weeks; Apatinib: 250mg/day; Chemotherapy: Irinotecan: 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel: 150mg/m2, intravenous drip once every 3 weeks.
62494417|NCT01316432|EXPERIMENTAL|SQ Bolus Cenderitide|
62494418|NCT01316432|EXPERIMENTAL|SQ Infusion Cenderitide|24 hour SQ infusion of cenderitide
62494419|NCT01316432|PLACEBO_COMPARATOR|Placebo|24 hrs of SQ placebo infusion
62494420|NCT01110863||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
62494421|NCT02941939|ACTIVE_COMPARATOR|Ambient pressure arm|High intensity training will be completed while the subjects are breathing normal air.
62494422|NCT02941939|EXPERIMENTAL|Hyperoxic-hyperbaric arm|The high intensity training program will be carried out in a hyperbaric chamber.
62494423|NCT01851876|EXPERIMENTAL|Endometrial injury|The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
62695883|NCT06179446|EXPERIMENTAL|pdmFlu vaccine dose B|
62695884|NCT06179446|EXPERIMENTAL|pdmFlu vaccine dose C|
62695885|NCT06179446|PLACEBO_COMPARATOR|Placebo|
62695886|NCT06179446|ACTIVE_COMPARATOR|Licensed influenza vaccine|
62138187|NCT01198431|EXPERIMENTAL|Sleep restriction|Each participant will be engaged in three consecutive nights of 4 hours of sleep per night (from 3.00 a.m. to 7.00 a.m.)
62337429|NCT05297422|ACTIVE_COMPARATOR|Ketamine IV|Axillary Approach to Brachial Plexus Blockade will be performed using 30ml Ropivacaine 0.5% ,with Ketamine as an adjuvant 30mg intravenously.
62494424|NCT01851876|NO_INTERVENTION|No endometrial injury|The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.
62695887|NCT05614882|ACTIVE_COMPARATOR|Written Stroke Education|Participants in this arm will be given the current written standard of care for stroke education. Assessments will be completed during the participants inpatient stay.
62138188|NCT01198431|PLACEBO_COMPARATOR|Normal sleep duration|Each participant will be engaged in three consecutive nights of 9 hours of sleep per night (from 10.00 p.m. to 7.00 a.m.)
62138189|NCT03422549|ACTIVE_COMPARATOR|CPAP|"Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.~Intervention: Device: Drager VN500 Ventilator"
62138190|NCT03422549|ACTIVE_COMPARATOR|NHFOV|"Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date.~Intervention: Device: Drager VN500 Ventilator"
62337430|NCT05297422|ACTIVE_COMPARATOR|Ketamine Regional|Axillary Approach to Brachial Plexus Blockade will be performed using 30ml Ropivacaine 0.5% ,with Ketamine as an adjuvant 30mg regionally.
62337431|NCT04830800|EXPERIMENTAL|COVIVAC 1mcg|1mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62337432|NCT04830800|EXPERIMENTAL|COVIVAC 3mcg|3mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62337433|NCT04830800|EXPERIMENTAL|COVIVAC 10mcg|10mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62337434|NCT04830800|EXPERIMENTAL|COVIVAC 1mcg + CpG1018 1.5mg|1mcg + CpG1018 IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62337435|NCT04830800|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline (pH 7.2) for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
62337436|NCT01781429|EXPERIMENTAL|BVD-523|
62337437|NCT00859781|EXPERIMENTAL|1. 177Lu-J591 + Ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone
62337438|NCT00859781|PLACEBO_COMPARATOR|2. 111In-J591 + Ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone
62337439|NCT00798694|OTHER|New to Meds|Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
62337440|NCT00798694|OTHER|Currently on Xalatan|Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
62337441|NCT04281745|EXPERIMENTAL|Coretox®|Botulinum toxin type A to be intramuscularly injected at 4 sites of corrugator muscle and at 1 site of procerus muscle with 0.1 mL (4U) at each site, for a total of 0.5 mL (20U). The administration of the investigational product was performed once at the start of each cycle
62337442|NCT01807715||Study group|Women seeking first trimester surgical abortion
62337443|NCT04274166|EXPERIMENTAL|Experimental|2 s.c. secukinumab 150 mg injections
62337444|NCT01107756|EXPERIMENTAL|TAXOTERE (Docetaxel) + GRANOGYTE 34 (Lenograstim)|Taxotere (Docetaxel) is given as background treatment and should be administered by the treating physician in accordance with the prescribing information outlined in the package insert + Granocyte 34 (lenograstim)
62337445|NCT03772938|ACTIVE_COMPARATOR|Stem/progenitor cells transplantation|Intervention: A single intravitreal injection of autologous bone marrow-derived stem/progenitor cells will be performed.
62337446|NCT03772938|SHAM_COMPARATOR|Standard treatment of degenerative disease of retina|Symptomatic treatment of degenerative disease of retina without biologic cell-based treatment
62337447|NCT03596359|EXPERIMENTAL|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
62337448|NCT03596359|ACTIVE_COMPARATOR|Control group|The control group received routine treatment
62494425|NCT03368027|EXPERIMENTAL|Stress management program|A cognitive-behavioral program of coping with psychological stress for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
62337449|NCT01302262||Healthy smokers|Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.
62695888|NCT05614882|EXPERIMENTAL|Verbal Stroke Education|Participants in this arm will be given the experimental verbal stroke education. Assessments will be completed during the participants inpatient stay.
62337450|NCT02939924|EXPERIMENTAL|DCB treatment|Patient treated with Kanshas DCB
62494426|NCT03368027|ACTIVE_COMPARATOR|Standard intervention|Usual activities performed in the association where they attend (supervised by a psychologist) for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
62337451|NCT04743700|EXPERIMENTAL|Piezocision on Experimental Side A|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome to accelerate maxillary canine retraction
62337452|NCT04743700|EXPERIMENTAL|Micro-osteoperforations on Experimental side B|Three MOPs with the help of mini-implant screw driver,mesial and distal to canine(in a vertical line) with the help of minisrew implant driver to accelrate maxillary canine retraction
62337453|NCT03391687||Amylase Test|gastric cancer patients receiving radical gastrectomy
62337454|NCT02011984||peripheral artery disease|de novo stenotic lesions in superficial femoral artery
62337455|NCT04200716|ACTIVE_COMPARATOR|Moderate intensity continuous training - session|The volunteers perform a 30-minute moderate-intensity exercise session on the exercise bike.
62337456|NCT04200716|ACTIVE_COMPARATOR|High intensity interval training - session|The volunteers perform a session of high intensity interval exercise on the exercise bike.
62138191|NCT01070082||Adult ICU patients undergoing procedure|
62138192|NCT05089461|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced malignant tumor will receive 20 mg/m\^2 Mitoxantrone Hydrochloride Liposome by an intravenous infusion (IV) on day 1 of each treatment cycle.
62138193|NCT02034292|EXPERIMENTAL|10mg MD|APD791 10mg Multiple dose and
62337457|NCT03192527|EXPERIMENTAL|Arm A|KN015, Triptorelin
62494427|NCT05006560|EXPERIMENTAL|Usual care rehabilitation and aftercare|Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.
62138194|NCT02034292|EXPERIMENTAL|20mg MD|APD791 20mg Multiple dose
62138195|NCT02034292|EXPERIMENTAL|40mg MD|APD791 40mg Multiple dose
62138196|NCT02034292|EXPERIMENTAL|60mg MD|APD791 60mg Multiple dose
62138197|NCT02034292|PLACEBO_COMPARATOR|Placebo MD|Placebo for Multiple dose group
62138198|NCT02034292|EXPERIMENTAL|120mg SD|APD791 120mg Single dose
62138199|NCT02034292|EXPERIMENTAL|240mg SD|APD791 240mg Single dose
62138200|NCT02034292|EXPERIMENTAL|320mg SD|APD791 320mg Single dose
62138201|NCT02034292|PLACEBO_COMPARATOR|Placebo SD|Placebo for Single dose
62337458|NCT03192527|PLACEBO_COMPARATOR|Arm B|placebo, Triptorelin
62337459|NCT02678234|EXPERIMENTAL|Theraflu Aktiv powder for oral solution|Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution
62337460|NCT02678234|NO_INTERVENTION|No Treatment|Participants in this arm will not receive any medication
62337461|NCT04989907||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) induction treatment in line with local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 12 months.
62337462|NCT03861546|EXPERIMENTAL|Healthy lifestyle Shared Medical Appointment (SMA) program|South Asian (SA) adults with prediabetes and Type 2 Diabetes (T2D) that are 'information rich' and have variation in background characteristics will be identified. Dyads (spouses, parent/adolescent or young adult child, peers) will participate in a 16-week culturally-tailored, community-informed pre-post SMA intervention to improve health behaviors.
62494428|NCT05006560|EXPERIMENTAL|Rehabilitation and aftercare (aligned)|"Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.~During rehabilitation, participants already get familiarized with components of the after care program."
62138202|NCT01302600|EXPERIMENTAL|Olesoxime|100 patients in this arm. liquid suspension
62138203|NCT01302600|PLACEBO_COMPARATOR|Placebo|50 patients enrolled in this arm. liquid suspension
62138204|NCT06697132|EXPERIMENTAL|Modified antegrade stenting in laparoscopic pediatric pyeloplasty|
62494429|NCT00001469||Specimens|Specimens
62494430|NCT01013818|EXPERIMENTAL|HGS1029|
62494431|NCT03670758||Group 1|Will include 30 women with unexplained primary infertility; will be recruited from the outpatient infertility clinic
61941902|NCT00469651|ACTIVE_COMPARATOR|2|Hepatitis B vaccine
62138205|NCT06562907|EXPERIMENTAL|Part A Single-ascending Dose (SAD) in Healthy Participants|"Participants will be randomized into 5 dose escalating cohorts and will receive GS-4571 or placebo to match (PTM) GS-4571 on Day 1, to determine the maximum tolerated dose:~* Cohort 1: Dose 1 GS-4571, administered orally as a single dose, in a fasting state.~* Cohort 2: Dose 2 GS-4571, administered orally as a single dose, in a fasting state.~* Cohort 3: Dose 3 GS-4571, administered orally as a single dose, in a fasting state.~* Cohort 4: Dose 4 GS-4571, administered orally as a single dose, in a fasting state.~* Cohort 5: Dose 5 GS-4571, administered orally as a single dose, in a fasting state."
62138206|NCT06562907|EXPERIMENTAL|Part B Food/PPI Effect in Healthy Participants|"Participants will be randomized into 2 sequence groups in Cohort 6 and will receive the highest dose found to be safe and well tolerated in Part A of GS-4571 and omeprazole. The two sequential groups will receive the following treatments:~* Treatment A: Up to the highest single dose of GS-4571 evaluated in Part A, fasting.~* Treatment B: Up to the highest single dose of GS-4571 evaluated in Part A, nonfasting (high-fat/high-calorie meal).~* Treatment C: Omeprazole, once-daily (QD) for 5 days, fasting.~* Treatment D: Omeprazole followed by up to the highest single dose of GS-4571 evaluated in Part A, 2 hours later, fasting."
62337463|NCT01334372|NO_INTERVENTION|Treatment as Usual|Treatment as usual (TAU) outpatient care will consist of existing outpatient clinical practices utilized in the Mental Health Clinic.
62337464|NCT01334372|EXPERIMENTAL|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
62337465|NCT01287533|EXPERIMENTAL|Ibandronate treatment|Ibandronate 150mg PO once every 4 weeks
62337466|NCT01287533|PLACEBO_COMPARATOR|Placebo arm|Placebo PO once every 4 weeks
62138207|NCT06562907|EXPERIMENTAL|Part C Multiple-ascending Dose (MAD) in Nondiabetic Obese Participants|"Participants randomized in Cohorts 7-9 will be randomized to receive up to 4 escalating doses of GS-4571 or PTM QD for 12 weeks, as follows:~* Cohort 7: Up to dose determined from Part A of GS-4571 or PTM in obese participants, QD, in a non-fasting state~* Cohort 8: Up to 3-fold the Cohort 7 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state~* Cohort 9: Up to 2-fold the Cohort 8 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state~Cohort 10 is optional and will receive GS-4571 or PTM QD for 12 weeks in case it is opened for enrollment as follows:~• Up to 2-fold the Cohort 9 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state."
62138208|NCT06562907|EXPERIMENTAL|Part D Multiple Dose in Nonobese Participants With T2DM|Participants randomized in Cohort 11 will receive up to the highest dose of GS-4571 or PTM in T2DM, QD, in a non-fasting state for 12 weeks.
62138209|NCT01852006|EXPERIMENTAL|COPD AB ON|"Abdominal Binder ON"
62138210|NCT01852006|NO_INTERVENTION|COPD AB OFF|"Abdominal Binder OFF (control)"
62337467|NCT06376266|ACTIVE_COMPARATOR|receive a daily supplement of branched-chain amino acids combined with medium-chain triglycerides|receive a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
62337468|NCT06376266|PLACEBO_COMPARATOR|receive a daily supplement of maltodextrin of the same packaging and quantity|receive a daily supplement of maltodextrin of the same packaging and quantity
62337469|NCT03240393|EXPERIMENTAL|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
62337470|NCT03240393|EXPERIMENTAL|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and \< 6 treated with INC280 at 400 mgBID
61941903|NCT00469651|EXPERIMENTAL|3|30 microgramme MSP3 candidate malaria vaccine
61941904|NCT00469651|ACTIVE_COMPARATOR|4|Hepatitis B control vaccine
61941905|NCT05099393|EXPERIMENTAL|subject with obesity|composed of subject with obesity (Body mass index \> 30)
61941906|NCT05099393|EXPERIMENTAL|lean subject|composed of healthy volunteers (Body mass index \< 30)
61941907|NCT02634749|EXPERIMENTAL|Nordic diet|The participant in the Nordic diet group will experience three interventions: a) a systematic introduction of taste portions, b) Protein reduced complementary foods (milk cereal drinks, porridge and baby milk with reduced protein content), and c) homemade and industry manufactured main meals with a predominance of Nordic ingredients.
61941908|NCT02634749|NO_INTERVENTION|Regular diet|The participants will be given the current advice on infant feeding issued by the Swedish National Food Agency. They will also be given regular, commercially available milk cereal drinks, porridge, baby milk and industry manufactured main meals. No advice or recipes on meals will be given apart from the current recommendations.
61941909|NCT05234658|EXPERIMENTAL|PHIT|Human artificial skin created by tissue engineering, composed of a sheet of autologous adult differentiated skin keratinocytes and fibroblasts expanded in a biological fibrin-agarose matrix (PHIT).
61941910|NCT05234658|EXPERIMENTAL|PHITAH|Human artificial skin created by tissue engineering, composed of a sheet of keratinocytes and differentiated autologous adult skin fibroblasts expanded in a biological fibrin-hyaluronic matrix (PHITAH).
62337471|NCT03240393|EXPERIMENTAL|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
62337472|NCT03017248|ACTIVE_COMPARATOR|Morphine and Placebo|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an injection of Placebos (0.9% normal saline 0.05ml/kg)
62337473|NCT03017248|EXPERIMENTAL|Morphine and Ketamine 0.15|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.15mg/kg
62494432|NCT03670758||Group 2|another 30 fertile women who got pregnant and delivered at least once in the previous year with no history of recurrent abortions; will recruited from outpatient gynecology clinic as control
62494433|NCT04346680|EXPERIMENTAL|Experimental group|
62494434|NCT02650570||Head/Neck Cancer|Subjects diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC)
61941911|NCT05234658|ACTIVE_COMPARATOR|Skin Autograft|Skin autograft.
61941912|NCT02330965||Subjects Assigned to BAF312|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.
62337474|NCT03017248|EXPERIMENTAL|Morphine and Ketamine 0.3|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.3mg/kg
62337475|NCT02834546||Patients with HCC treated with sorafenib|
62337476|NCT05312710|EXPERIMENTAL|APG-157|Two pastilles (100 mg) taken three times a day (i.e. before meal time).
62337477|NCT02852148|EXPERIMENTAL|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
62337478|NCT05946889||Suture|Women with ovarian cyst who received robotic/laparoscopic ovarian cystectomy with suture
62337479|NCT05946889||Human Fibrin Glue|Women with ovarian cyst who received robotic/laparoscopic ovarian cystectomy with human fibrin glue
62337480|NCT02635737|EXPERIMENTAL|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
62494435|NCT02650570||Healthy Control|Healthy controls age matched to the Head/Neck cancer group.
62494436|NCT02107196|EXPERIMENTAL|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
61941913|NCT02330965||Subjects Assigned to Placebo (Controls)|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.
61941914|NCT00931970||Dialysis modality|Hemodialysis, Peritoneal dialysis
61941915|NCT02003365|EXPERIMENTAL|FX006 10 mg|Single 3 mL intra-articular (IA) injection
61941916|NCT02003365|EXPERIMENTAL|FX006 40 mg|Single 3 mL intra-articular (IA) injection
61941917|NCT02003365|ACTIVE_COMPARATOR|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection
61941918|NCT04574973|EXPERIMENTAL|Anodal tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
62337481|NCT01984034|EXPERIMENTAL|Educational Outreach Visits|The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.
62494437|NCT02107196|PLACEBO_COMPARATOR|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
62494438|NCT01742403|EXPERIMENTAL|R/T gating kV intrafraction monitoring|"Intervention: Recruitment will be performed in 2 phases:~Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction)."
61941919|NCT04574973|EXPERIMENTAL|Cathodal tDCS|Subjects will receive 20 minutes of active, excitatoryinhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
62138211|NCT06444607||Patients with hereditary PPGL|Blood will be collected prior and after surgery for their pheochromocytoma/paraganglioma (as planned by their treating physician). Blood will also be collected prospectively during regular follow-up appointments after 1 year and after 2 years.
62494439|NCT05694117|EXPERIMENTAL|self-determine sequence exercise program|The trial was divided into three cycles, and participants were allowed to choose any one of the a Taichi exercise program, a hybrid program of Taichi exercise and resistance training programs, and resistance training as their intervention content before the start of each cycle. Participants who chose Taichi exercise performed one hour of Taichi exercise for each session, while participants who chose a hybrid exercise program of Taichi exercise and resistance training completed Taichi exercise in the first half hour and resistance training for the second half hour. Participants who chose resistance training performed one hour of resistance training. One hour per training session, three times a week for 24 weeks
62138212|NCT06444607||Patients with sporadic PPGL|Blood will be collected prior and after surgery for their pheochromocytoma/paraganglioma (as planned by their treating physician). Blood will also be collected prospectively during regular follow-up appointments after 1 year and after 2 years.
62494440|NCT05694117|EXPERIMENTAL|resistance training|Resistance strength training for resistance exercise and aimed at promoting the greatest hypertrophy response. Training is divided into three cycles, with progressive training load. Resistance exercise intervention three times a week for 24 weeks, one hour each time.
61941920|NCT04574973|EXPERIMENTAL|Dual tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere and inhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
62494441|NCT05694117|NO_INTERVENTION|control group|The participants in the control group were introduced by nurses to education about sarcopenia and various methods for preventing it, such as consuming more protein through their diet and participating in greater physical exercise.
62494442|NCT05694117|EXPERIMENTAL|Taichi exercise and resistance training|The trial was divided into three cycles, each lasting eight weeks. Participants performed a hybrid program of Taichi exercise and resistance training of varying duration and intensity in each cycle. Each session lasted one hour, three times a week for 24 weeks.
62494443|NCT05694117|EXPERIMENTAL|Randomly selected exercise program|The trial was divided into three cycles, and participants were allowed to choose any one of the a Yijinjing exercise program, a hybrid program of Yijinjing exercise and resistance training programs, and resistance training as their intervention content before the start of each cycle. Participants who chose Yijinjing exercise performed one hour of Yijinjing exercise for each session, while participants who chose a hybrid exercise program of Yijinjing exercise and resistance training completed Yijinjing exercise in the first half hour and resistance training for the second half hour. Participants who chose resistance training performed one hour of resistance training. One hour per training session, three times a week for 24 weeks
62494444|NCT02450058|ACTIVE_COMPARATOR|FEC|5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days
62494445|NCT02450058|ACTIVE_COMPARATOR|EP|Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days
61941921|NCT04574973|SHAM_COMPARATOR|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the affected upper extremity.
62138213|NCT06444607||Asymptomatic carriers of germline mutations predisposing for PPGL|Blood will be collected at inclusion, after 1 year and after 2 years.
62138214|NCT06444607||Sex and age matched healthy volunteers|"Blood material will be obtained from healthy anonymous donors according to the protocol Donation of blood by healthy volunteers for experimental in-vitro research (Human Subjects Review Board approval number: NL84281.091.23)."
62138215|NCT02105259|EXPERIMENTAL|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for social anxiety disorder during 10 weeks and guided by a psychologist
62494446|NCT00640926|EXPERIMENTAL|1|Radezolid 300 mg
61941922|NCT00966771||IUD|Women presenting for emergency contraception who select the copper IUD
62337482|NCT01984034|ACTIVE_COMPARATOR|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
61941923|NCT00966771||Oral levonorgestrel|Women presenting for emergency contraception who select oral levonorgestrel
61941924|NCT06205615|EXPERIMENTAL|BXP154B/Right Leg Period 1; Placebo/Left Leg Period 2|Single topical application of BXP154B 6ml (right leg), treatment period 1; single topical application of Placebo 6ml (left leg), treatment period 2
62138216|NCT02105259|ACTIVE_COMPARATOR|Waiting list with support|Behavioral: supportive check-ups via the Internet during 10 weeks
62695889|NCT06152172|EXPERIMENTAL|IIM|Participants with idiopathic inflammatory myopathy will receive will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
62494447|NCT00640926|EXPERIMENTAL|2|Radezolid 450 mg
62494448|NCT00640926|EXPERIMENTAL|3|Radezolid 450 mg BID
62695890|NCT06152172|EXPERIMENTAL|DCSS|Participants with diffuse cutaneous systemic sclerosis will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
62695891|NCT06152172|EXPERIMENTAL|SLE|Participants with SLE-related nephritis will receive will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
62695892|NCT06152172|EXPERIMENTAL|AAV|Participants with ANCA-associated vasculitis will receive will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
62695893|NCT06489431|ACTIVE_COMPARATOR|Traditional Antibiotic Therapy|Preoperative antibiotic selection, method or preparation, draping, or technique;. the corpora, scrotum, and reservoir space will be irrigated with traditional antibiotics (rifampin, gentamycin, +/-fluconazole) immediately after the space is created in all cases. An additional scrotal irrigation with traditional antibiotics after all components are placed will be performed, as well. The patients will be followed and monitored for penile prosthesis infection as well as any other surgical complications for 1 year post operatively.
62695894|NCT06489431|EXPERIMENTAL|Irrisept only irrigation|Preoperative antibiotic selection, method or preparation, draping, or technique;. the corpora, scrotum, and reservoir space will be irrigated with Irrisept only immediately after the space is created in all cases. An additional scrotal irrigation with Irrisept only after all components are placed will be performed, as well. The patients will be followed and monitored for penile prosthesis infection as well as any other surgical complications for 1 year post operatively.
62695895|NCT03520114|EXPERIMENTAL|RP sling group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
62695896|NCT03520114|EXPERIMENTAL|SIS group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
62695897|NCT01629498|EXPERIMENTAL|Arm I (image-guided IMRT)|Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
62695898|NCT01629498|EXPERIMENTAL|Arm II (image-guided IMPT)|Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
62695899|NCT06636006|EXPERIMENTAL|Aerobic Exercise|Three sessions of aerobic exercise per week (outdoor walking), for 50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13), will be performed for 7 weeks. These sessions will be accompanied by a researcher responsible for data collection, who will make a daily record of the activities. The practice time will be between 5:00 pm and 7:00 pm.
61941925|NCT06205615|EXPERIMENTAL|Placebo/Right Leg Period 1; BXP154B/Left Leg Period 2|Single topical application of Placebo 6ml (right leg), treatment period 1; single topical application of BXP154B 6ml (left leg), treatment period 2
62695900|NCT06636006|ACTIVE_COMPARATOR|Digital Cognitive Behavioral Therapy (CBT-I)|Three weekly sessions of digital CBT-I will be held through the Vigilantes do Sono® application (digital therapy with the therapeutic protocol approved by ANVISA, Brazil).
62695901|NCT05708521|ACTIVE_COMPARATOR|Standardized Prescription Group (SOP)|"All participants assigned to the SOP group will be treated as per the current status quo, in which they are given the standardized analgesic prescriptions following discharge from the hospital consisting of:~1. Acetaminophen 975 mg orally every 6 hours for 7 days~2. Ibuprofen 600 mg orally every 6 hours for 7 days~3. Hydromorphone 2-4 mg orally every 6 hours as needed, with a total dispense amount of 40mg.~The participants are not given instructions on how to taper their hydromorphone medication, which is the current status quo in our department."
62695902|NCT05708521|EXPERIMENTAL|Personalized Prescription Group (POP)|"All participants assigned to the POP group will receive pre-operative education on the medications that they will be given while they are inpatients and upon discharge, along with a pain medication card to aid their understanding. Medications upon discharge will be:~1. Acetaminophen 975mg orally every 6 hours for 1 week~2. Ibuprofen 600 mg orally every 6 hours for 1 week~3. Hydromorphone - Prescribed with a personalized schedule and tapering protocol based on the participant's last 24-hour in-patient use of opioids.~Participants in this arm will also receive tapering instructions as well as an education card to assist them with their tapering protocol upon discharge."
62695903|NCT06644534|EXPERIMENTAL|TTI-0102|cysteamine-pantetheine disulfide
62695904|NCT06644534|PLACEBO_COMPARATOR|Placebo|Pearlitol® 100 SD (mannitol)
62695905|NCT01795157|EXPERIMENTAL|CCADSS|questionnaire completed using i-Pad
62695906|NCT01795157|ACTIVE_COMPARATOR|pen-paper|Questionnaire completed using pen and paper
61941926|NCT06205615|EXPERIMENTAL|BXP154B/ Left Leg Period 1; Placebo/Right Leg Period 2|Single topical application of BXP154B 6ml (left leg), treatment period 1; single topical application of Placebo 6ml (right leg), treatment period 2
61941927|NCT06205615|EXPERIMENTAL|Placebo/Left Leg Period 1; BXP154B/Right Leg Period 2|Single topical application of Placebo 6ml (left leg), treatment period 1; single topical application of BXP154B 6ml (right leg), treatment period 2
61941928|NCT04764487|OTHER|Standard follow-up|Patients will have no intervention. It is the comparator group. Patients will have the usual follow-up for clinical, biological and imaging exams.
61941929|NCT04764487|EXPERIMENTAL|KidneyPRO web-application follow up|"Patients will have to connect to the KidneyPRO web-application weekly to complete a questionnaire about their symptoms in addition to usual follow-up.~Appropriate care will be offered if necessary (depending on the symptoms assessment)"
62494449|NCT04823936|NO_INTERVENTION|control group|received the selected physical therapy program for one hour, three times weekly for two successive months including facilitation of balance and protective reactions from kneeling, half kneeling and standing position, standing alone on balance board, standing on one leg, open gait training alone (walking on the balance beam, walking on the stepper and walking on wedges), training stair climbing, and strengthening of the back and abdominal muscles.
62494450|NCT04823936|ACTIVE_COMPARATOR|study group|received the selected physical therapy program for one hour, three times weekly in addition to core stability training program for 30 minutes
62494451|NCT02070523|EXPERIMENTAL|PLD-contained VDCLD regimen|PLD 36 mg/m2 ivdrip over 60 minutes( d1、15),VCR 1.4mg/m iv(d1，8，15，22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip (d1～28).
62494452|NCT02070523|ACTIVE_COMPARATOR|DNR-contained VDCLD regimen|DNR 45 mg/m2 ivdrip over 60 minutes(d1～3),VCR 1.4mg/m2 iv(d1，d8，d15，d22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip(d1～28).
62695907|NCT04874480|EXPERIMENTAL|Treatment (tegavivint, decitabine)|"PART I: Patients receive tegavivint IV over 4 hours on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive tegavivint IV over 4 hours on days 1, 8, 15, and 22 and decitabine IV over 30-60 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62695908|NCT01587196|EXPERIMENTAL|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
62695909|NCT06564324|EXPERIMENTAL|Taletrectinib|69 ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer patients will be enrolled in Arm A and treated with talerectinib
62695910|NCT06564324|ACTIVE_COMPARATOR|Crizotinib|69 ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer patients will be enrolled in Arm B and treated with Crizotinib
62695911|NCT06637137||Prospectic cohort|patients scheduled for cardiac surgery who fulfil the inclusion criteria
62695912|NCT06637137||retrospective cohort ICARUS 1|patients scheduled for cardiac surgery (2021) with a known iron status, treated if indicated 1 or 2 days before surgery with iron supplementation.
62695913|NCT06637137||retrospective cohort|patients scheduled for cardiac surgery (2019-2020)with an unknown iron status and never treated with iron supplementation
62695914|NCT03340506|EXPERIMENTAL|dabrafenib monotherapy|"Patients in this study may receive:~- monotherapy of dabrafenib"
62695915|NCT03340506|EXPERIMENTAL|trametinib monotherapy|"Patients in this study may receive:~- monotherapy of trametinib"
62695916|NCT03340506|EXPERIMENTAL|Combination therapy (dabrafenib & trametinib)|"Patients in this study may receive:~- the combination of dabrafenib and trametinib"
62337483|NCT01603641|EXPERIMENTAL|BOTOX®|Participants received maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into a single lower limb muscles or divided between both lower limb muscles or into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment not to exceed a maximum of 8 unit per kilogram (U/kg) of body weight (not to exceed 300 U) in treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 or 8 U/kg into the lower limb in the previous study or were de novo participants who were not enrolled in the previous study.
62337484|NCT03909191||treatment-naïve|treatment-naïve patients with chronic HBV infection
62337485|NCT03909191||NAs treated CHB patients|CHB patients undergoing long-term NAs treatment
62494453|NCT01821157|ACTIVE_COMPARATOR|Flapless|Flapless: Gingivectomy and osteoplasty, as necessary, will be performed without flap elevation.
62494454|NCT01821157|ACTIVE_COMPARATOR|Open-flap|Gingivectomy and osteoplasty, as necessary, will be performed with flap elevation
62494455|NCT00664196|EXPERIMENTAL|1|
62494456|NCT02907125|EXPERIMENTAL|TSM arm|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
62695917|NCT02236910|EXPERIMENTAL|Primary Therapy with Lu-DOTA-TATE|Lu-DOTA-TATE (Lutetium-177 Octreotate) will be administered by intravenous infusion to participants who have not been previously treated with Lu-DOTA-TATE
62695918|NCT02236910|EXPERIMENTAL|Secondary Therapy with Lu-DOTA-TATE|Patients who have received previous treatment with Lu-DOTA-TATE (Lutetium-177 Octreotate) under the special access program are eligible to be treated in this study. Patients will receive Lu-DOTA-TATE by intravenous infusion.
62695919|NCT02740998||Depo Provera|Ten women ages 18-40 who elect to start a using Depo Provera for contraception.
62695920|NCT02740998||Mirena IUD|Ten women ages 18-40 who elect to start a using a Mirena IUD for contraception.
62695921|NCT02740998||Nexplanon|Ten women ages 18-40 who elect to start a using Nexplanon for contraception.
62695922|NCT02740998||Control: Tubal Sterilization|Five women ages 18-40 who elect to have a tubal sterilization.
62695923|NCT02337556|EXPERIMENTAL|Intervention Group|Peptamen Bariatric
62695924|NCT02337556|ACTIVE_COMPARATOR|Control Group|Replete
62695925|NCT03757663|EXPERIMENTAL|UV Dosimeter|UV Dosimeter will measure participants' UV exposure for two separate 3-week periods.
62695926|NCT05424276|EXPERIMENTAL|50mg IkT-148009|This arm will consist of thirty (30) patients on 50mg of active treatment.
62695927|NCT05424276|EXPERIMENTAL|100mg IkT-148009|This arm will consist of thirty (30) patients on 100mg of active treatment.
62695928|NCT05424276|EXPERIMENTAL|200mg IkT-148009|This arm will consist of thirty (30) patients on 200mg of active treatment.
61941930|NCT00989157|EXPERIMENTAL|Active drug|All subjects received drug. Single arm.
62337486|NCT04743245|EXPERIMENTAL|PCI with SSO2 therapy|AMI subjects treated with SSO2 Therapy following PCI with stenting
62695929|NCT05424276|PLACEBO_COMPARATOR|Placebo|This arm will consist of thirty (30) patients on placebo.
62695930|NCT05887401|EXPERIMENTAL|Condition 1|Core + Green Foods Monitoring + Nutrition Goals + Supportive Text Messages + All Lessons
62695931|NCT05887401|EXPERIMENTAL|Condition 2|Core + Green Foods Monitoring + Nutrition Goals + Supportive Text Messages + Weekly Lessons
62695932|NCT05887401|EXPERIMENTAL|Condition 3|Core + Green Foods Monitoring + Nutrition Goals + No Supportive Text Messages + All Lessons
62695933|NCT05887401|EXPERIMENTAL|Condition 4|Core + Green Foods Monitoring + Nutrition Goals + No Supportive Text Messages + Weekly Lessons
62695934|NCT05887401|EXPERIMENTAL|Condition 5|Core + Green Foods Monitoring + No Nutrition Goals + Supportive Text Messages + All Lessons
62494457|NCT02907125|EXPERIMENTAL|SM arm|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
62138217|NCT02013115|NO_INTERVENTION|Cursurf|The baby with respiratory distress syndrome was given Cursurf through intubation.
62138218|NCT02013115|EXPERIMENTAL|Cursurf and Budesonide|The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
62138219|NCT06025344|EXPERIMENTAL|PanCytoVir™ 1000 mg (100 mg/mL)|PanCytoVir™ oral suspension (100 mg/mL)
62337487|NCT04743245|ACTIVE_COMPARATOR|anterior AMI patients treated with PCI and stenting within 6 hours|Control group receiving PCI with stenting alone
62337488|NCT03128216|ACTIVE_COMPARATOR|Blind Local Anesthetic Infiltration|
62337489|NCT03128216|ACTIVE_COMPARATOR|Transversals Fascia Block|
62337490|NCT03128216|ACTIVE_COMPARATOR|Spinal Anesthesia|
62337491|NCT01908621|ACTIVE_COMPARATOR|G-CSF (filgrastim)|Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10\^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
62337492|NCT01908621|ACTIVE_COMPARATOR|Cytosine arabinoside + G-CSF (filgrastim)|Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10\^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
62337493|NCT02756650|EXPERIMENTAL|Canakinumab|Canakinumab was administered monthly
62337494|NCT00487084|EXPERIMENTAL|morphine - 2CP-saline (MCS)|morphine will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level; saline will be administered at skin incision
62337495|NCT00487084|EXPERIMENTAL|saline-2CP-morphine (SCM)|saline will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level;morphine will be administered at skin incision
62337496|NCT00487084|ACTIVE_COMPARATOR|saline-lidocaine-morphine (SLM)|Saline will be administered 30 min prior to epidural anesthesia; lidocaine will be used to achieve a T4 level; morphine will be administered at skin incision
62337497|NCT00646841|EXPERIMENTAL|A|
62337498|NCT06174181|EXPERIMENTAL|Experimental|Preservative-free ophtalmic lubricant emulsion countinuous during 6 month after intravitreal Injections for Age-related macular degeneration
62337499|NCT06174181|OTHER|Routine treatment|Preservative-free ophtalmic lubricant emulsion during few days after intravitreal Injections for Age-related macular degeneration
62337500|NCT04897841|PLACEBO_COMPARATOR|control arm|The control arm will receive 30 mL of bupivacaine HCl plus 50 mL of saline injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
62337501|NCT04897841|EXPERIMENTAL|Intervention: liposomal bupivacaine|The intervention arm will receive 30 mL of bupivacaine HCl plus 30 mL of saline plus 20 mL of liposomal bupivacaine injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
62337502|NCT06520319|EXPERIMENTAL|Patients will undergo a 68Ga-MGS5 PET/CTF and 68Ga-DOTATATE PET/CT|MTC Patients received 68Ga-DOTATATE PET/CT imaging and a single injection of 68Ga-MGS5 and two PET/CT scans 1 hour and 2 hours after the injection within one week.
62337503|NCT06452628|EXPERIMENTAL|Group A|This group will receive Mulligan mobilizations.
62695935|NCT05887401|EXPERIMENTAL|Condition 6|Core + Green Foods Monitoring + No Nutrition Goals + Supportive Text Messages + Weekly Lessons
62695936|NCT05887401|EXPERIMENTAL|Condition 7|Core + Green Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + All Lessons
62138220|NCT06025344|EXPERIMENTAL|Probenecid 1000 mg (2x500 mg tablets)|Probenecid 500 mg tablets
62138221|NCT04402736|EXPERIMENTAL|Modified Barthel Index-based rehabilitation nursing program|Patients received the Modified Barthel Index based rehabilitation nursing from qualified nurses.
62138222|NCT04402736|OTHER|Usual care|Patients received the usual care.
62337504|NCT06452628|ACTIVE_COMPARATOR|Group B|This group will receive the Active release technique.
62337505|NCT06452628|OTHER|Group C|This group will receive both techniques combined.
62337506|NCT04218916|EXPERIMENTAL|Rhodiola Rosea Capsule|
62337507|NCT04218916|PLACEBO_COMPARATOR|Placebo Capsule|
62337508|NCT03377010||Hematopoietic Stem Cell Transplant (HSCT) Survivor|Study participants will be administered a Dietary Intake - Food Frequency Questionnaire and a Receptivity to Participating in Diet Interventions Questionnaire.
62695937|NCT05887401|EXPERIMENTAL|Condition 8|Core + Green Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + Weekly Lessons
62695938|NCT05887401|EXPERIMENTAL|Condition 9|Core + Red Foods Monitoring + Nutrition Goals + Supportive Text Messages + All Lessons
62695939|NCT05887401|EXPERIMENTAL|Condition 10|Core + Red Foods Monitoring + Nutrition Goals + Supportive Text Messages + Weekly Lessons
62138223|NCT04325711|EXPERIMENTAL|CSPCH131 dose Escalation and expansion|"In the dose escalation part of Stage I, five dose levels will be tested according to the 3 + 3 dose-escalation design. Whether and how to carry out the follow-up study parts will be decided by the PI and sponsor on the basis of the achieved results of safety, tolerability and effectiveness of CSPCHA131."
62337509|NCT04550793||Intervention|The stroke patients who receive botulinum toxin injection at affected brachialis and/or biceps brachials.
62337510|NCT04550793||Control|The stroke patients who do not receive botulinum toxin injection at affected brachialis and/or biceps brachials in the past 3 months.
62337511|NCT05345886|EXPERIMENTAL|Hippotherapy|The experimental group will receive 30 minutes of hippotherapy once a week for 12 weeks.
62337512|NCT05345886|NO_INTERVENTION|Control|The control group will receive its rehabilitation care
62337513|NCT03594487|EXPERIMENTAL|Interventional FMT Treatment Arm|"After providing written informed consent, subjects will undergo screening and baseline assessments of stool and blood sampling, questionnaires, physical examination, MS rating scales, and MRI. Subjects will then initiate an oral antibiotic regimen for 5 days to precondition the gut for the Fecal Microbiota Transplantation (FMT) of FMP30 donor stool and optimize engraftment of the FMP30 donor stool microbiome. Following standard bowel preparation for colonoscopy, subjects will undergo the FMT procedure by an experienced gastroenterologist. Subjects will return for scheduled assessments and follow-up MRI for 12 weeks, with additional safety and biomarker follow-up for 36 weeks.~The active study time is designed to be short (12 weeks active phase) to minimize time not on other MS disease modifying therapy (DMT). This arm of the study will last for approximately 52 weeks total (4 weeks of screening + 12 weeks active treatment phase + 36 weeks of safety follow up)."
62494458|NCT02907125|ACTIVE_COMPARATOR|Comparison arm Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
62494459|NCT00967148|EXPERIMENTAL|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
62494460|NCT00967148|ACTIVE_COMPARATOR|Standard of care|The control arm will receive a subcutaneous injection of 4,500 U of tinzaparin daily beginning with the first postoperative dose and continued for the duration of hospitalization.
62494461|NCT02821208||One cohorte : patient psychogenic nonepileptic seizures|The Psychogenic nonepileptic seizures (PNESs) are paroxysmal episodes type of abnormal movements, behavior modification or alteration of the contact-like seizures. These episodes are involuntary and underpinned by an unconscious psychological processes. In the International Classification of Disease-10 (ICD-10), they are classified as dissociative phenomena as conversing syndromes in the Manual of Diagnostic and Statistical Mental Disorders-IV (DSM-IV). The participants of the study only receive the usual care they would have if they were not included (no new/different intervention allocated in the study).
62494462|NCT03074799|ACTIVE_COMPARATOR|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
62337514|NCT03594487|ACTIVE_COMPARATOR|Observational Control Arm|"Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.~After providing written informed consent, subjects will undergo screening and baseline assessments, including collection of blood and stool samples, demographic data collection, concomitant medication review, and an MS Relapse assessment. At week 2, subjects will mail in stool samples with a prepaid air bill and packaging. Weeks 4, 8, and 12 assessments will include concomitant medication review, relapse assessment, and blood and stool collection.~The duration of the study for the observational control arm will last for 12 weeks. All study procedures will be performed at the University of California, San Francisco."
62494463|NCT03074799|EXPERIMENTAL|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
62494464|NCT00504634|EXPERIMENTAL|Bortezomib|1 mg/m\^2 intravenous (IV) Days 1, 4, 8, and 11.
62494465|NCT03750357|EXPERIMENTAL|Primary Relief v 2.0 with Paracetamol|Group A will be treated with Primary Relief v 2.0(1 - 100Hz) sweep stimulation with increase in power of the stimulation for fixed interval of time.
62494466|NCT03750357|NO_INTERVENTION|Only Paracetamol|Group B will be treated with paracetamol drug.
62494467|NCT01755585||C/T-RT group|Chemotherapy (C/T) is applied in the morning. After 2-4 hrs, radiotherapy (RT) is delivered (according to the clinical practice)
62494468|NCT01755585||RT-C/T group|Radiotherapy (RT) is delivered in the morning. After 2-4 hrs, chemotherapy (C/T) is applied (according to the clinical practice).
62494469|NCT01444196|OTHER|Desloratadine dose|"1. Study group: 5 mg Desloratadine during the whole study~2. Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
62494470|NCT01444196|OTHER|Dose of Desloratadine|"1. Study group: 5 mg Desloratadine during the whole study~2. Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
62494471|NCT01977313||All study participants|All study participants
62494472|NCT02597257|PLACEBO_COMPARATOR|Normal Saline|"* normal saline~* total 250 ml~* once a week~* 4 times"
62337515|NCT06522581|EXPERIMENTAL|neonates with HIE receiving citicoline|this arm will include neonates suffering from hypoxic ischemic encephalopathy and who will be given injection citicoline
62695940|NCT05887401|EXPERIMENTAL|Condition 11|Core + Red Foods Monitoring + Nutrition Goals + No Supportive Text Messages + All Lessons
62695941|NCT05887401|EXPERIMENTAL|Condition 12|Core + Red Foods Monitoring + Nutrition Goals + No Supportive Text Messages + Weekly Lessons
62337516|NCT06522581|PLACEBO_COMPARATOR|neonates with HIE receiving placebo|this arm will include neonates who will be suffering from HIE but will recieve rotuine care in NICU but will not receive injection citicoline
61941931|NCT05143021||Pregnant Women with Sickle Cell Disease|Pregnant women with sickle cell disease from the 3 centers in Ghana
62337517|NCT05763342|EXPERIMENTAL|Adult Cochlear Implant|Adult cochlear implant recipients receiving different focused multipolar maps that are programmed using either behavioural or objective methods
62337518|NCT03779035|EXPERIMENTAL|Gemcitabine plus Capecitabine|Gemcitabine (1000 mg per square meter) on days 1 and 8 Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
62337519|NCT03779035|ACTIVE_COMPARATOR|Capecitabine|Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
62337520|NCT04958863|NO_INTERVENTION|No Mask|Runners do not use mask while running
62337521|NCT04958863|EXPERIMENTAL|Surgical Mask|Runners use surgical mask while running
62337522|NCT04958863|EXPERIMENTAL|Polyester Reusable Mask|Runners use polyester reusable mask while running
62337523|NCT03144583|EXPERIMENTAL|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
62337524|NCT02570776||observation|Cohort of patients for Endoscopy \& they are assessed for Helicobacter pylori through the histopathology \& also throgh C14 C UBT.
62337525|NCT05136248|EXPERIMENTAL|intraarticular injection|intra-articular steroid injection with the ultrasound guidance technique,
61941932|NCT05306431|EXPERIMENTAL|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant. It is non-corrosive, non-toxic and acts by disrupting cell membrane integrity. PHMB 0.2% has been recently used as a root canal irrigant in vitro and has shown promising results of antimicrobial effectiveness of \> 99.9% for both PHMB and Sodium hypochlorite
62695942|NCT05887401|EXPERIMENTAL|Condition 13|Core + Red Foods Monitoring + No Nutrition Goals + Supportive Text Messages + All Lessons
62695943|NCT05887401|EXPERIMENTAL|Condition 14|Core + Red Foods Monitoring + No Nutrition Goals + Supportive Text Messages + Weekly Lessons
62695944|NCT05887401|EXPERIMENTAL|Condition 15|Core + Red Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + All Lessons
61941933|NCT05306431|EXPERIMENTAL|Sodium Hypochloride|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter.
61941934|NCT00881673|EXPERIMENTAL|1|
62138224|NCT03703440|EXPERIMENTAL|Active|≥3 group education sessions (60 minutes per session) in addition to usual diabetes care, every 3 months for 12 months. Each group session (3-8 patients per group) will be facilitated by a diabetes nurse educator and/or dietitian. The group session content will be guided by the needs of the group participants. The group discussion will end with participants setting goals for their next appointment.
62337526|NCT05136248|ACTIVE_COMPARATOR|peng block|Ultrasound guided drug injection between to iliopubic eminentia and psoas tendon
62337527|NCT02235116||Patients who responded to the survey|
62337528|NCT01778088|OTHER|Single Group|I-131-CLR1404 Injection
62337529|NCT03108651|ACTIVE_COMPARATOR|Case|Motivational message will be administrated.
62337530|NCT03108651|NO_INTERVENTION|Control|Motivational message will not be administrated.
62494473|NCT02597257|ACTIVE_COMPARATOR|Lidocaine HCl|"* lidocaine 3 mg/kg mixed in normal saline~* total 250 ml~* once a week~* 4 times"
62494474|NCT05768087|EXPERIMENTAL|Escalated proton therapy|
62494475|NCT02321839|EXPERIMENTAL|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
62695945|NCT05887401|EXPERIMENTAL|Condition 16|Core + Red Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + Weekly Lessons
62695946|NCT06122597|EXPERIMENTAL|Test arm: ConcenTrace|"Participants should follow this weekly dosing schedule:~Week 1 - Days 1-3: take 5 drops of ConcenTrace with 8 oz of water or flavored water. Days 4-7: take 5 drops of ConcenTrace 2x daily with 8 oz of water or flavored water.~Week 2: Take 10 drops of ConcenTrace 2x daily with 8 oz of water or flavored water.~Week 3: Take 15 drops of ConcenTrace 2x daily with 8 oz of water or flavored water.~Weeks 4-12: Take 20 drops of ConcenTrace 2x daily with 8 oz of water or flavored water."
61941935|NCT00881673|ACTIVE_COMPARATOR|2|
61941936|NCT00881673|PLACEBO_COMPARATOR|3|
61941937|NCT03675620|ACTIVE_COMPARATOR|Standard Rehabilitation (Control Group)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to this group will begin with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for for the first 6 weeks of post-operative care. Standard rehabilitation will continue until discharge.
62695947|NCT04581083||Volunteer participants|Samples of volunteer participants will be collected after informed consent and classified as symptomatic, asymptomatic and negative.
62695948|NCT04715581|EXPERIMENTAL|Multicomponent prehabilitation group|Patients in the intervention group will receive nutritional optimization and exercise training before the surgery, exercise training after the surgery, and home-based rehabilitation after discharge.
62695949|NCT04715581|NO_INTERVENTION|Control group|Patients in the control group will maintain normal diet and normal activity before surgery, normal activity after surgery, and normal activity after discharge.
62695950|NCT02398799|NO_INTERVENTION|control|The dyads in the control group received care as usual including traditional care in hospital and outpatient education and support. The care is mainly focused on the patient's needs. The partner is not systematically involved in the follow-up focusing on education and psychosocial support.
62695951|NCT02398799|EXPERIMENTAL|Psycho edcuactional support|The intervention psychoeducational support to the patient-partner dyads was delivered in 3 sessions through nurse-led face-to-face counseling, a computer-based CD-ROM program and other written teaching materials. All sessions lasted at least 60 minutes and were conducted in the dyads' homes or in the heart failure clinic. The first session 2 weeks after discharge and the two remaining sessions 6- and 12-weeks following discharge. Each session included education on heart failure and development of problem- solving skills to assist the dyads in recognizing and modifying factors that contribute to psychological and emotional distress. The intervention focused on changing thoughts and behaviors and implementing strategies for self-care.
61941938|NCT03675620|EXPERIMENTAL|Blood Flow Restriction (BFR)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to the BFR group will begin combining BFR with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for the first 6 weeks post-operative care. Standard rehabilitation will continue until discharge.
61941939|NCT03145363|EXPERIMENTAL|Intervention|receive interactive text messages
61941940|NCT03145363|ACTIVE_COMPARATOR|Control|Receive informational text messages
61941941|NCT03311529|EXPERIMENTAL|Applied Relaxation|
61941942|NCT03311529|NO_INTERVENTION|usual care|
61941943|NCT00610623|EXPERIMENTAL|1|azithromycin iv 300 mg/day
61941944|NCT00610623|PLACEBO_COMPARATOR|2|Placebo
61941945|NCT06680570||smokers|"Group: smokers Smokers Description: This group consists of university students who smoke regularly. Lung capacity, physical activity levels, carbon monoxide (CO) breath values and headache frequency will be measured and evaluated. This group was included in the study to examine the effect of smoking on these health parameters.~Non-Smokers Description: This group consists of non-smoking university students. Lung capacity, physical activity levels and headache frequency of non-smokers will be measured and compared with the smoking group. This group was included to analyse the relationship between lung function and headache in non-smokers."
61941946|NCT01237938|EXPERIMENTAL|Low Glycemic Diet|
61941947|NCT03577288|EXPERIMENTAL|Experiment 1 A, B - Level of realism of EVR|Participants (50 children and 50 young adults for part A, and 50 other children and 50 other young adults) will be exposed to virtual experience having different level of realism. In one condition the realism will be high (very close to the real word) and in the second condition the realism will be low (comparable to cartoon). The stimuli of interest included in virtual experience will be of three emotional categories : negative, positive and neutral.
61941948|NCT03577288|EXPERIMENTAL|Experiment 2 - Presence and size of avatar|"Participants (50 children and 100 young adults) will be exposed to virtual experiences in which in one condition they will be part of the virtual environment in a body of an avatar and in another condition the avatar will not be present.~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar."
61941949|NCT03577288|EXPERIMENTAL|Experiment 3 - Interaction in virtual experience|Participants (50 children and 50 young adults) will be submitted to two conditions of virtual experience, one condition in which it is possible to interact with the stimuli presented in the virtual environment and another condition in which it is not possible to interact. In addition, the stimuli of interest will be of one of three emotional categories : negative, positive and neutral. Thus participants will be exposed to six short virtual experiences.
61941950|NCT03577288|EXPERIMENTAL|Experiment 4 - Animate/Inanimate nature of interactive objects|Participants (30 children and 30 young adults) will be exposed to the virtual experience during which they will be able to interact in one condition with animated (e.g., dog, bird) stimuli and in another condition with inanimate (e.g., book, jacket) stimuli. The animate and inanimate stimuli of interest will be of three emotional categories : negative, positive and neutral.
61941951|NCT01435070||Distal radius fracture|Patients aged 18 years and older with a fracture of the distal radius, within 3 cm of the radiocarpal joint
61941952|NCT03825523|EXPERIMENTAL|Group A Immediate treatment (iART)|Other: time to start the ART within 48 hours of admission to hospitalization
61941953|NCT03825523|ACTIVE_COMPARATOR|Group B Conventional treatment (cART)|Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.
61941954|NCT01341197||Subjects undergoing bidirectional endoscopy and fecal tests|Subjects participating in the health check-up at National Taiwan University Hospital (Health Management Center)
61941955|NCT01341197||Patients with screening detected GI tract cancers|Patients with screening detected GI tract cancer, such as throat cancer, esophageal cancer, gastric cancer and colorectal cancers, from other screening sites in Taiwan and were referred to the National Taiwan University Hospital for confirmatory diagnosis and treatment.
62695952|NCT05078411|OTHER|Patients without a history of tooth loss due to periodontitis (NTLP)|
62695953|NCT05078411|OTHER|Patients with a history of tooth loss due to periodontitis (TLP)|
62695954|NCT04316143|EXPERIMENTAL|50 mg zamicastat|50 mg zamicastat once daily
62695955|NCT04316143|EXPERIMENTAL|100 mg zamicastat once daily|100 mg zamicastat once daily
61941956|NCT01879514|EXPERIMENTAL|Combination Group|Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg·d, po. 48weeks
61941957|NCT01879514|PLACEBO_COMPARATOR|Placebo|Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg•d, po. 48weeks
61941958|NCT00744276|ACTIVE_COMPARATOR|1|
61941959|NCT00744276|ACTIVE_COMPARATOR|2|
61941960|NCT00744276|ACTIVE_COMPARATOR|3|
61941961|NCT00744276|PLACEBO_COMPARATOR|4|
61941962|NCT00744276|PLACEBO_COMPARATOR|5|
61941963|NCT00744276|PLACEBO_COMPARATOR|6|
61941964|NCT05248620|ACTIVE_COMPARATOR|Active|Amoxicillin/clavulanic acid 500/125mg, tablets, will be administered before each hemodialysis for 6 months
61941965|NCT05248620|PLACEBO_COMPARATOR|Placebo|Placebo tablets, similar to the active drug, will be administered before each hemodialysis for 6 months
61941966|NCT00484094||Rapamune|
61941967|NCT02000934|EXPERIMENTAL|TAK-659 60 mg (Dose Escalation)|TAK-659 60 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 49 cycles).
62138225|NCT03703440|OTHER|Control|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual diabetes care, an individual education session and written information will be provided before formal transfer.
62138226|NCT01744808|ACTIVE_COMPARATOR|EB-1020 SR1|Sustained release formulation
62695956|NCT04316143|EXPERIMENTAL|150 mg zamicastat once daily|150 mg zamicastat once daily
61941968|NCT02000934|EXPERIMENTAL|TAK-659 80 mg (Dose Escalation)|TAK-659 80 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 4 cycles).
61941969|NCT02000934|EXPERIMENTAL|TAK-659 100 mg (Dose Escalation)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 32 cycles).
61941970|NCT02000934|EXPERIMENTAL|TAK-659 120 mg (Dose Escalation)|TAK-659 120 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 41 cycles).
61941971|NCT02000934|EXPERIMENTAL|TAK-659 CCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with chronic lymphocytic leukemia (CCL) (up to 6 cycles).
61941972|NCT02000934|EXPERIMENTAL|TAK-659 DLBCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with diffuse large B-cell lymphoma (DLBCL) (up to 49 cycles).
61941973|NCT02000934|EXPERIMENTAL|TAK-659 iNHL (Dose Expansion)|Single dose TAK-659 100 mg, tablet, orally in pharmacokinetic (PK) Run-in prior to Cycle 1 followed by TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with indolent non-hodgkin lymphoma (iNHL) (up to 32 cycles).
61941974|NCT02000934|EXPERIMENTAL|TAK-659 MCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with mantle cell lymphoma (MCL) (up to 6 cycles).
61941975|NCT02000934|EXPERIMENTAL|TAK-659 PTLD (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with post-transplant lymphoproliferative disorder (PTLD) (up to 1 cycle).
61941976|NCT03991858|OTHER|Phone follow-up|Phone follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
61941977|NCT03991858|EXPERIMENTAL|Telerehabilitation follow-up|Telerehabilitation follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
61941978|NCT00332878|EXPERIMENTAL|1|Stepping Stones
61941979|NCT00332878|ACTIVE_COMPARATOR|2|A 3 hour intervention on HIV and safer sex
61941980|NCT05764408|EXPERIMENTAL|Retractor|Research team members will apply a pannus retractor adhesive according to manufacturer's directions. The sonographer will be asked to attempt all views of the detailed anatomic survey before the adhesive is removed. If the sonographer thinks that additional views could be obtained with the adhesive removed using transabdominal or transvaginal imaging, this is acceptable based on the pragmatic design of this study.
61941981|NCT05764408|NO_INTERVENTION|No retractor|The detailed anatomic survey will proceed per normal protocol. Approaches may include transabdominal and transvaginal imaging.
61941982|NCT02207465|EXPERIMENTAL|Subtrial 1-Arm A (Dose Level 1 of Abraxane)|Determine if it is safe or not (via occurrence of dose limiting toxicities) for patients to receive both Abraxane and radiation therapy.
62695957|NCT04316143|EXPERIMENTAL|200 mg zamicastat once daily|200 mg zamicastat once daily
62494476|NCT01887158|ACTIVE_COMPARATOR|bisacodyl plus 2-Liter Polyethylene glycol|Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
62494477|NCT01887158|ACTIVE_COMPARATOR|4-Liter Polyethylene glycol|Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.
62494478|NCT05136469|EXPERIMENTAL|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
62494479|NCT05136469|ACTIVE_COMPARATOR|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
62337531|NCT02221180|EXPERIMENTAL|Treatment Sequence ABDC|Treatment A (1 immediate release (IR) fixed dose combination \[FDC\] tablet containing canagliflozin 150 milligram \[mg\] and metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62494480|NCT02646488|ACTIVE_COMPARATOR|Cluster 1|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
62494481|NCT02646488|ACTIVE_COMPARATOR|Cluster 2|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
62494482|NCT02646488|ACTIVE_COMPARATOR|Cluster 3|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
62494483|NCT02646488|ACTIVE_COMPARATOR|Cluster 4|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
62494484|NCT01315717||Group 1|Healthy subjects
61941983|NCT02207465|EXPERIMENTAL|Subtrial 1-Arm B (Dose Level 2 of Abraxane: 3+4 enrollment)|Determine the maximum dose of Abraxane that is allowable and safe for patients receiving both Abraxane and radiation therapy.
61941984|NCT02207465|EXPERIMENTAL|Subtrial 2- Abraxane 125mg; Borderline get 55cGY, unresectable get 57.5cGY until next escalation|
61941985|NCT02586064|EXPERIMENTAL|Interpersonal Psychotherapy for PTSD|Relationally-focused intervention addressing PTSD symptoms and relationship dysfunctions, 12 weekly sessions
61941986|NCT02586064|ACTIVE_COMPARATOR|Prolonged Exposure|Exposure based intervention including exposure to memories and avoided places and activities
61941987|NCT05826808|EXPERIMENTAL|A|Polysomnographies will be done first for 2 nights at the sleep laboratory in Chur (600 m.a.s.l.) and after a two-week washout period for 2 nights at the participants home elevations (\>1000 m.a.s.l.).
61941988|NCT05826808|EXPERIMENTAL|B|Polysomnographies will be done first for 2 nights at the participants home elevations (\>1000 m.a.s.l.). and after a two-week washout period for 2 nights at sleep laboratory in Chur (600 m.a.s.l.).
62138227|NCT01744808|ACTIVE_COMPARATOR|EB-1020 SR2|Sustained Release Formulation
61941989|NCT03295500||Experimental Group One|In this group ,the participants receive the dose fraction of 49Gy/7f (BED 83.3Gy) by cyberknife.
61941990|NCT03295500||Experimental Group Two|In this group ,the participants receive the dose fraction of 54Gy/6f(BED 102.6Gy) by cyberknife.
61941991|NCT03295500||Control Group|In this group ,the participants receive the dose fraction of 55Gy/5f(115.5Gy) by cyberknife.
61941992|NCT04308096|EXPERIMENTAL|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks (adult) or 2 weeks (pediatric) from Week 0 through Week 140.
61941993|NCT04595331|NO_INTERVENTION|Treatment Group in pivotal study|followed for long-term safety and effectiveness with no additional treatment
61941994|NCT04595331|EXPERIMENTAL|Control Group in the pivotal study|receiving treatment in the extension study
61941995|NCT03271970||Patients with conductive hearing loss|
61941996|NCT05348473|ACTIVE_COMPARATOR|alpha group|In this group, tips of the seton will be tied as alpha-shaped
61941997|NCT05348473|SHAM_COMPARATOR|Beta group|The tips of the seton in this group will be overlapped and tied. There is no palpable free ends.
61941998|NCT05348473|EXPERIMENTAL|Comfort group|Knotless seton will be applied
61941999|NCT03509831|OTHER|INT2150-A|
61942000|NCT03509831|OTHER|INT2150-B|
62138228|NCT01744808|ACTIVE_COMPARATOR|EB-1020 SR3|Sustained Release Formulation
62494485|NCT01315717||Group 2|Patients with Mild Cognitive Impairment
62494486|NCT01315717||Group 3|Patients with Mild AD
62494487|NCT01315717||Group 4|Patients with Moderate AD
62695958|NCT05226052|EXPERIMENTAL|S. boulardii|treatment arm group (3 capsules of Floratil 200mg®/day)
61942001|NCT03860610||Patient group 1 after THA|Patients who have already received a THA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
62138229|NCT01744808|ACTIVE_COMPARATOR|EB-1020 IR|Immediate Release Formulation
62138230|NCT01744808|PLACEBO_COMPARATOR|Placebo|Placebo Formulation
62138231|NCT01102699|EXPERIMENTAL|Filgrastim, G-CSF|Single s.c. dose of G-CSF (300 microg)
62138232|NCT02922517||patients with obstructive HCM|patients with HCM (obstructive or no obstructive)
62138233|NCT02922517||controls|patients without HCM
62695959|NCT05226052|PLACEBO_COMPARATOR|Placebo|control group (3 capsules of placebo/day)
62695960|NCT06010251|EXPERIMENTAL|SCI with pain|Participants will undergo 2-4 weeks of combined intervention including transcranial direct current stimulation (tDCS) and bodily illusions (10 sessions total).
62695961|NCT01577407|EXPERIMENTAL|Nefopam|
62337532|NCT02221180|EXPERIMENTAL|Treatment Sequence BCAD|Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62337533|NCT02221180|EXPERIMENTAL|Treatment Sequence CDBA|Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62337534|NCT02221180|EXPERIMENTAL|Treatment Sequence DACB|Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62337535|NCT03965832|EXPERIMENTAL|HFNT|Patients who meet the eligibility criteria will be randomized to receive HFNT and then crossover to other device during the study procedures.
62337536|NCT03965832|EXPERIMENTAL|Standard oxygen|Patients who meet the eligibility criteria will be randomized to receive Standard oxygen and then crossover to HFNT during the study procedures.
62337537|NCT05007249|OTHER|Overweight or obese minors with intellectual disability|
62337538|NCT00007904|EXPERIMENTAL|Arm A: Combination Chemotherapy|Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.
62337539|NCT01919918|OTHER|Heart Failure Patients|Patients with heart failure will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
62695962|NCT01577407|PLACEBO_COMPARATOR|placebo|
62695963|NCT06066333|EXPERIMENTAL|Participants with Adrenocortical Carcinoma|Participants with histologically proven metastatic Adrenocortical Carcinoma/ACC with both intra-hepatic and extra-hepatic sites of disease.
62695964|NCT05940272|EXPERIMENTAL|Hematologists|Hematologists will be recruited from the lymphoma clinics at MSK
62695965|NCT05940272|EXPERIMENTAL|Participants Patients|Participant patients are being treated by a hematologic oncologist participating in this study
61942002|NCT03860610||Patient group 2 after TKA|Patients who have already received a TKA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
61942003|NCT03860610||Patient group 3 before THA|Patients with severe hip OA (N=30) scheduled to receive a THA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
61942004|NCT03860610||Patient group 4 before TKA|Patients with severe knee OA (N=30) scheduled to receive a TKA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
62337540|NCT01919918|OTHER|Control Participants|Healthy control participants will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
62337541|NCT05600192|EXPERIMENTAL|Exercise arm|Subjects perfom aerobic or anaerobic exercise in the morning or in the afternoon
62337542|NCT02733614|EXPERIMENTAL|SRX246|SRX246 160 mg BID, oral administration, capsules, daily for 8 weeks
62337543|NCT02733614|PLACEBO_COMPARATOR|Placebo|oral administration, capsules, daily for 8 weeks
62337544|NCT02648412|EXPERIMENTAL|Ketamine sedation|"Procedure scheduled under ketamine sedation. Baseline pupillary diameter measurement in alert subjects. Injection of a bolus of 1 mg/kg of ketamine. Every minute, tetanic stimulations of incremental intensities (10-20-30-40-60 milliamps), during 5 seconds.~Pupillary diameter measurement before and after each stimulation. End of study period, beginning of procedure."
62337545|NCT00755690|ACTIVE_COMPARATOR|1|"High/ Low Phosphate diet I. A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet.~II. A five-day low phosphate diet / A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder III. A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet.~IV. A five-day high phosphate diet / A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder.~V. A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet / A five-day high phosphate diet.~VI. A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet / A five-day low phosphate diet."
62337546|NCT00755690|ACTIVE_COMPARATOR|2|High/ Low Phosphate diet
62337547|NCT00755690|ACTIVE_COMPARATOR|3|High/ Low Phosphate diet
62337548|NCT05407090|EXPERIMENTAL|Probiotic|Patients will take 4 capsules of a multi-strain probiotic preparation daily. Product characteristics: 1 capsule of the preparation contains ≥2.5 x 10\^9 CFU / g of live bacteria (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidillum W23)
62337549|NCT05407090|PLACEBO_COMPARATOR|Placebo|Patients will take 4 capsules of a placebo preparation daily.
62337550|NCT02084836||Lean adolescents|
62337551|NCT03535233|ACTIVE_COMPARATOR|Intralesional group|intralesional triamcinolone acetonide 5 mg/ml monthly
62337552|NCT03535233|ACTIVE_COMPARATOR|Topical therapy group|Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night
62337553|NCT02309164|ACTIVE_COMPARATOR|Acupuncture|acupuncture
62337554|NCT02309164|SHAM_COMPARATOR|orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
62337555|NCT03106493||Primary|Singletons and 1 twin of each pair
62337556|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
62337557|NCT03106493||Tertiary|Higher order multiples and siblings
62337558|NCT01874652|EXPERIMENTAL|Light Weight Breast Implants|Assessment of Safety and Efficacy of Light Weight Breast Implant
62337559|NCT05192174|EXPERIMENTAL|NIB101 Dose Level 1|1 x 10\^7 cells/body as chimeric antigen receptor (CAR) positive viable cells will be administered intravenously on Day 0.
62337560|NCT05192174|EXPERIMENTAL|NIB101 Dose Level 2|1 x 10\^8 cells/body as CAR positive viable cells will be administered intravenously on Day 0.
62695966|NCT03832985|EXPERIMENTAL|Receive an adult-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with adult onset of disease.
62695967|NCT03832985|EXPERIMENTAL|Receive a pediatric-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with pediatric onset of disease or with risk reduction interventions that begin in childhood.
62138234|NCT02922517||patients with non obstructive HCM|patients with non obstructive HCM
62337561|NCT05192174|EXPERIMENTAL|NIB101 Expansion Cohort|Recommended dose determined on dose escalation phase will be administered intravenously on Day 0.
62337562|NCT05481203|EXPERIMENTAL|The Kaleidescope Group|Kaleidoscope Group: it and asking about the colors and shapes seen within it. This distraction procedure started before the procedure and continued until it ended.
62337563|NCT05481203|EXPERIMENTAL|The Visual Illusion Cards Group|The Visual Illusion Cards Group: Just before the nasopharyngeal swab participants were allowed to check the cards and were asked what they saw in them.
62337564|NCT05481203|NO_INTERVENTION|The Control Group|The control group received the routine nasopharyngeal swab procedure and did not receive any other nonpharmacological intervention
62337565|NCT05444972||Participants Undergoing Chart Review|Participants treated for myelofibrosis undergoing chart review.
62337566|NCT03398369|EXPERIMENTAL|Intervention|CMR-Guided CRT
62337567|NCT03398369|NO_INTERVENTION|Control|Standard CRT
62337568|NCT06216015|EXPERIMENTAL|Exercise training group|The training programs will encompass three phases, with a gradual progression in both intensity and duration. Each phase will span a duration of four weeks, culminating in a comprehensive 12-week training regimen.
61942005|NCT03860610||Healthy control group|Age-matched healthy control subjects (N=30);Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
61942006|NCT05353361|EXPERIMENTAL|SHR-A1811combined Pyrotinib|
61942007|NCT05353361|EXPERIMENTAL|SHR-A1811Combined Pertuzumab|
61942008|NCT05353361|EXPERIMENTAL|SHR-A1811Combined Adebrelimab|
61942009|NCT05353361|EXPERIMENTAL|SHR-A1811Combined Albumin-bound Paclitaxel|
61942010|NCT00502944|EXPERIMENTAL|Counselor-based HIV screening|
61942011|NCT00502944|ACTIVE_COMPARATOR|Emergency staff member-based HIV screening|
61942012|NCT06556784|EXPERIMENTAL|12-week at-home immersive virtual reality exergame|12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.
61942013|NCT06556784|NO_INTERVENTION|12-week control in awaiting|Maintaining regular eating and working habits without making significant changes throughout the 12 weeks.
61942014|NCT01367093||ICU patients admitted for severe illness|
61942015|NCT03378765||African origin adults|African origin adults from Ghana, Jamaica, Seychelles, South Africa and USA between the ages of 30- 50.
61942016|NCT00834678|EXPERIMENTAL|Bendamustine and Erlotinib|Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.
61942017|NCT02280538|EXPERIMENTAL|Intra-Articular Hyaluronic Acid|"hylan G-F 20 (high molecular weight hyaluronic acid):~* intra-articular administration~* 6 mL~* administered every 6 months~* for 2 years"
61942018|NCT02280538|PLACEBO_COMPARATOR|Placebo|"Saline solution:~* intra-articular administration~* 6 mL~* administered every 6 months~* for 2 years"
62337569|NCT06216015|NO_INTERVENTION|Control group|Control group will continue their usual care without exercise interventions.
62337570|NCT06216015|ACTIVE_COMPARATOR|Continue exercise|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.
61942019|NCT03901885|OTHER|Major women operated for deep endometriosis|Major women operated for deep endometriosis at the Lyon Sud Hospital Center (CHLS) of the Hospices Civils de Lyon (HCL).
61942020|NCT05371730|EXPERIMENTAL|NK cells|
61942021|NCT03911713|ACTIVE_COMPARATOR|Ivacaftor|Participants received IVA 150 milligrams (mg) orally every 12 hours (q12h) in the treatment period for 12 weeks.
61942022|NCT03911713|EXPERIMENTAL|VX-561: 25 mg|Participants received VX-561 25 mg orally daily (qd) in the treatment period for 12 weeks.
61942023|NCT03911713|EXPERIMENTAL|VX-561: 50 mg|Participants received VX-561 50 mg orally qd in the treatment period for 12 weeks.
61942024|NCT03911713|EXPERIMENTAL|VX-561: 150 mg|Participants received VX-561 150 mg orally qd in the treatment period for 12 weeks.
61942025|NCT03911713|EXPERIMENTAL|VX-561: 250 mg|Participants received VX-561 250 mg orally qd in the treatment period for 12 weeks.
61942026|NCT02983565|NO_INTERVENTION|Sleep study on usual long-term oxygen therapy flow rate|Participants will have a sleep study on their usual LTOT flow rate.
61942027|NCT02983565|EXPERIMENTAL|Sleep study on the intelligent oxygen therapy system|Participants will have a sleep study on the intelligent oxygen therapy system. This system will supply variable flow oxygen to match a pre-set oxygen saturation target of 93% during sleep.
61942028|NCT02149719|EXPERIMENTAL|Desensitisation to peanut|Desensitisation using boiled peanut
61942029|NCT02149719|EXPERIMENTAL|Control|Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).
61942030|NCT06681155||High-risk Plaque Group|Multimodal intravascular imaging technology is used to assess the morphological structure and stability of non-criminal lesions in plaques, categorized into high-risk and non-high-risk groups. High-risk plaques are defined as those that meet any of the following criteria: ① IVUS minimum lumen area \<4.0mm² or OCT minimum lumen area \<3.5mm², ② plaque burden \>70%, ③ presence of thin-cap fibroatheroma, ④ NIRS detects lipid-rich plaques with LRP MaxLCBI4mm \>315, and are considered high-risk if they have at least two of the above four characteristics. A patient is placed in the high-risk group if they have at least one high-risk plaque.
61942031|NCT06681155||Non-high-risk Plaque Group|Multimodal intravascular imaging technology is used to assess the morphological structure and stability of non-criminal lesions in plaques, categorized into high-risk and non-high-risk groups. High-risk plaques are defined as those that meet any of the following criteria: ① IVUS minimum lumen area \<4.0mm² or OCT minimum lumen area \<3.5mm², ② plaque burden \>70%, ③ presence of thin-cap fibroatheroma, ④ NIRS detects lipid-rich plaques with LRP MaxLCBI4mm \>315, and are considered high-risk if they have at least two of the above four characteristics. If they have no high-risk plaques, they are placed in the non-high-risk group.
61942032|NCT01501396|EXPERIMENTAL|Arm A (megestrol alone)|Megestrol acetate 800 mg PO daily x 8 weeks
61942033|NCT01501396|EXPERIMENTAL|Arm B (megestrol plus mirtazapine)|"Megestrol acetate 800 mg PO daily x 8 weeks~Mirtazapine 15 mg PO at bedtime x 1 week followed by 30 mg PO at bedtime x 7 weeks"
61942034|NCT00100178|EXPERIMENTAL|MMF and DBZ|DZB given by intravenous infusion (1 mg/kg)at baseline and 2 weeks later, and MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years.
61942035|NCT00100178|EXPERIMENTAL|MMF Alone|MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years and saline intravenous infusions given at baseline and two weeks later.
61942036|NCT00100178|PLACEBO_COMPARATOR|Placebo|Placebo pills given daily for two years and saline intravenous infusions given at baseline and two weeks later.
61942037|NCT00891462|EXPERIMENTAL|1|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
61942038|NCT00891462|EXPERIMENTAL|2|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
61942039|NCT00891462|PLACEBO_COMPARATOR|3|Inhaled placebo for 12 weeks
61942040|NCT01967433|EXPERIMENTAL|Diphenhydramine|Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
61942041|NCT01967433|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
62695968|NCT03832985|ACTIVE_COMPARATOR|Control - No result|Compare change in psychosocial outcomes and health behaviors of those without a genomic result.
62337571|NCT06216015|ACTIVE_COMPARATOR|Discontinue exercise|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
62494488|NCT05531136|EXPERIMENTAL|Foot strengthening training|12-week foot strengthening training in addition to an already joined functional exercise program. The foot strengthening training is supervised and progressing and consists of isolated and functional exercises. Participants keep a training diary.
62494489|NCT05531136|NO_INTERVENTION|Control|The control group continues the functional exercise program as usual. The subjects in this group are asked to keep a diary in which the subjects weekly report other physical activities, fall incidents and mobility related discomfort. The trainer calls the participants in the control group every week to pay attention to these topics.
62494490|NCT06626503|EXPERIMENTAL|Methadone-Based ERAS Group|Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision and 0.05 mg at the end of surgery) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
62494491|NCT06626503|ACTIVE_COMPARATOR|SOC Non-Methadone-Based Group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
62138235|NCT01626950||Cases - Stage III-IV breast cancer|The women in this group have been diagnosed with stage III-IV incident cancer.
62138236|NCT01626950||Controls: Stage I-II breast cancer|The women in this group have been diagnosed with stage I-II incident cancer.
62494492|NCT06428305|EXPERIMENTAL|The intervention group receiving planned education on genital hygiene using the teach-back method|All pregnant women diagnosed with UTI at the maternity outpatient clinic are prescribed antibiotics containing the active substance fosfomycin tromethamol, which is recommended for uncomplicated urinary tract infections of adults. The duration of the antibiotic's effect is seven days (Due date). After completing the treatment process determined according to the physician's request, training and counseling will be provided using the Genital Hygiene Training Guide based on the Tell me what you have learned method. In this context, 4 interviews will be held during the project.
62494493|NCT06428305|NO_INTERVENTION|Control Group|Control Group: Research data were collected from pregnant women who were in the control group at the December intervals with the experimental group, as shown in the Flow Chart of the study. After the completion of the study, this group will also be given an education and training booklet.
62494494|NCT01969760|NO_INTERVENTION|Wait-list control|Wait-list control. No intervention delivered until post follow-up assessment. Upon completion of the follow-up, the family was offered the full intervention.
62494495|NCT01969760|EXPERIMENTAL|Healthy Families DC Program|Healthy Families DC Program
62494496|NCT00053339|EXPERIMENTAL|trastuzumab|"Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
62494497|NCT00053339|EXPERIMENTAL|trastuzumab + tamoxifen|"Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.~In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
62337572|NCT05280041|EXPERIMENTAL|Fixed standardized - SOLENA-F|In the fixed standardized arm participants will be asked to complete the study modules of the intervention (CBT intervention itself) in a fixed standardized order from module 1 to module 10. Participants will only be able to start the following module once they complete the previous one. At the beginning and at the end of each module it is emphasized what participants will do in the following module.
61942042|NCT05462743||group for training the algorithm|This group of images is used for training the algorithm of the artifical intelligence
62337573|NCT05280041|EXPERIMENTAL|Self-tailored - SOLENA-ST|In the self-tailored arm participants will be asked to complete most of the study modules of the intervention (CBT intervention itself) in a flexible format, according to their own needs at each moment. Participants will be asked to start the intervention by completing the preparatory modules (modules 1 and 2) following a fixed order. After completion of module 2, all the remaining modules become available at the same time. At the beginning and at the end of each module, participants are invited to reflect on their own needs and to complete the modules that better meet them.
62337574|NCT05280041|NO_INTERVENTION|Waiting list control group|Participants in this group will start the intervention 10 weeks after the randomization. Participants in the waiting list control group will be randomly distributed by the fixed standardised and self-tailored arms. This arm will follow the exact same procedure of the active arms.
62337575|NCT03775018|EXPERIMENTAL|Transversus abdominis plain blockade|The patients will undergo Transversus abdominis plain blockade, associated with intravenous analgesia
62138237|NCT01905800|ACTIVE_COMPARATOR|Barbecue treatment without acceleration|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
62138238|NCT01905800|EXPERIMENTAL|Barbecue treatment with acceleartion|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
62337576|NCT03775018|ACTIVE_COMPARATOR|Intravenous analgesia|The patients will receive intravenous analgesia with Acetaminophen (1g/6h)
62337577|NCT06398366||Cooper Health System|Patients from Cooper Health System and additional sites
62695969|NCT00780585||1|Subjects who participated in previous Org 24448 trials
62695970|NCT03526172||Control|Patients undergoing HTO without the inclusion of any bone wedge
62138239|NCT01905800|PLACEBO_COMPARATOR|Placebo treatment|Positional examination of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying a rotation towards the other side.
62138240|NCT03003286|EXPERIMENTAL|UOT Students and Parents|Unstuck and on Target (UOT) provided in the classroom for students at Title 1 schools
62138241|NCT03003286|EXPERIMENTAL|PATSS Students and Parents|Parents and Teachers Supporting Students (PATSS) provided in the classroom for students at Title 1 schools
62337578|NCT00492856|EXPERIMENTAL|Post-consolidation therapy arm I|Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
62337579|NCT00492856|NO_INTERVENTION|Post-consolidation therapy arm II|Patients receive no further chemotherapy. Patients are followed every 3 months for 1 year. (Randomization and observation arm closed as of 8/15/10)
62337580|NCT00064129|EXPERIMENTAL|Treatment (monoclonal antibody, colony-stimulating factors)|Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
62337581|NCT00598195|NO_INTERVENTION|Ketamine Pharmacokinetics|The pharmacokinetic action of Ketamine used in Children having heart surgery.
62337582|NCT04037436|EXPERIMENTAL|Intervention|"At regular intervals (the steps) one cluster (i.e., one site) is randomised to cross from the control to the intervention under evaluation. This process continues until all clusters have crossed over to be exposed to the intervention. At the end of the study there will be a period when all clusters are exposed. Four sites are cluster-randomized to implement MoveSTroNg at one of four start times, each three weeks apart."
62138242|NCT06015308|EXPERIMENTAL|Amlitelimab|Participants will receive amlitelimab and vaccines as per protocol.
62138243|NCT06015308|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching amlitelimab and vaccines as per protocol.
62138244|NCT04693949|ACTIVE_COMPARATOR|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
62138245|NCT04693949|EXPERIMENTAL|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
62695971|NCT03526172||Allograft|Patients undergoing HTO with the inclusion of an allograft bone wedge
62138246|NCT05955040|ACTIVE_COMPARATOR|Treatment Group|Treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic)
62138247|NCT05955040|NO_INTERVENTION|Non-treatment Group|Non-treatment of blood pressures between 120-139 systolic and 80-89 diastolic
62138248|NCT06240741|EXPERIMENTAL|[68Ga]Ga-DOTA-TATE|All eligible participants will receive \[68Ga\]Ga-DOTA-TATE via intravenous injection at a dose of 2 MBq/kg (0.054 mCi/kg) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)
62138249|NCT01202513|EXPERIMENTAL|Bimatoprost application|
62337583|NCT04037436|OTHER|Control|Each cluster contributes observations under both control and intervention observation periods.
62337584|NCT01525927|ACTIVE_COMPARATOR|Chemotherapy non-responders|Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
62337585|NCT01525927|EXPERIMENTAL|Chemotherapy responders|Patients who respond to chemotherapy are treated with reduced dose radiotherapy.
62337586|NCT04601142||glucocorticoid sensitive (GS) group|
62337587|NCT04601142||glucocorticoid resistance (GR) group|
62337588|NCT00521651||Community Cohort|Men and Women from two Shanghai cohort studies.
62138250|NCT04814108|EXPERIMENTAL|ZN-c3 Single Agent|ZN-c3 (azenosertib) taken orally with food
62138251|NCT01025323|ACTIVE_COMPARATOR|Minimal Intervention Group|Participants in this arm receive advice and printed guidelines but no counseling or systematic instruction.
62138252|NCT01025323|ACTIVE_COMPARATOR|Enhanced Intervention Group|Participants in this group receive advice and the same printed guidelines as the Minimal Intervention Group, together with dietary and physical activity counseling provided by a dietician and/or coordinator, periodic professional reviews of their progress and systematic instruction.
62337589|NCT01413048|EXPERIMENTAL|AGSCT101|
62494498|NCT05589636|EXPERIMENTAL|Bergamot juice|Consumption of 400 cc/die of Bergamot juice (35% in water sweetened with stevia) for 12 weeks
62138253|NCT03194659|NO_INTERVENTION|Placebo|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, no additional choline chloride will be added to the cocktail.
62337590|NCT01413048|ACTIVE_COMPARATOR|Carvedilol|
62337591|NCT04400409|ACTIVE_COMPARATOR|Intervention A + site 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.~6-Minute Walk Test (6MWT) will be administered by site staff."
62494499|NCT05589636|NO_INTERVENTION|Free diet|Free diet
62494500|NCT03828435|EXPERIMENTAL|healthy control|This group does not undergo any treatment . Intervention : rTMS
62695972|NCT02796911|NO_INTERVENTION|Corticotomy alone|Group I will be treated with a modified technique of corticotomy assisted orthodontic treatment (CAOT) alone
62695973|NCT02796911|EXPERIMENTAL|Corticotomy + xenograft|group II (included 6 females and 5 males) that treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
62695974|NCT02796911|EXPERIMENTAL|Corticotomy + bioactive glass|group III (included 7 females and 4 males) that treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
62695975|NCT04169009|ACTIVE_COMPARATOR|ZVL >5 years previously|Participants have received Zostavax (ZVL) at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
61942043|NCT05462743||group for testing the algorithm|This group of images is used for testing the algorithm of the artifical intelligence
62138254|NCT03194659|EXPERIMENTAL|Supplemental Choline|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the experimental arm of the trial, supplemental choline chloride will be added to the cocktail.
62138255|NCT03206086|EXPERIMENTAL|Group|Eltrombopag
62138256|NCT00003459|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached.
62138257|NCT03241706|PLACEBO_COMPARATOR|Controls-saline|Each subject from Group 1 will undergo a metabolic study where saline is infused so as to not stimulate liver glucose uptake and glycogen deposition.
62138258|NCT03241706|ACTIVE_COMPARATOR|Controls-high fructose|A second group of control subjects will undergo a single metabolic study using a higher dose of fructose (6.5 mg/kg/min).
62138259|NCT03241706|ACTIVE_COMPARATOR|Controls-low fructose|Each subject from Group 1 will undergo another metabolic study where fructose (1.3 mg/kg/min) is infused so as to stimulate liver glucose uptake and glycogen deposition.
61942044|NCT00315146|PLACEBO_COMPARATOR|Hypocaloric diet (and placebo)|
62138260|NCT05093062|OTHER|Tian Jiu Therapy|
62138261|NCT05851495|NO_INTERVENTION|home-based exercise groups|home exercise brochures were given to the home-based exercise groups according to their diagnosis at the end of the treatment. Then, all patients were called to the hospital for control after three months and the scale prepared by us and consisting of a total of 5 (five) questions was directed to the patients and it was determined how the exercises given were performed. Five different exercises were given to patients with low back and neck pain who participated in our study. The patients were asked to do these exercises 3 times a day for 10 repetitions. Cat-camel exercises, lumbar stretching, sit-ups, bridge building and back extensor strengthening exercises were given to patients with low back pain. For patients with neck pain, neck flexion-extension, neck lateral flexion, neck rotation, shoulder capsule stretching and shoulder flexion exercises were given.
62138262|NCT05851495|EXPERIMENTAL|physiotherapists-led groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Then, all patients were called to the hospital for control after three months and the scale prepared by us and consisting of a total of 5 (five) questions was directed to the patients and it was determined how the exercises given were performed. Five different exercises were given to patients with low back and neck pain who participated in our study. The patients were asked to do these exercises 3 times a day for 10 repetitions. Cat-camel exercises, lumbar stretching, sit-ups, bridge building and back extensor strengthening exercises were given to patients with low back pain. For patients with neck pain, neck flexion-extension, neck lateral flexion, neck rotation, shoulder capsule stretching and shoulder flexion exercises were given.
62337592|NCT04400409|ACTIVE_COMPARATOR|Intervention B + site 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.~6-Minute Walk Test (6MWT) will be administered by site staff."
62494501|NCT03828435|EXPERIMENTAL|stroke patient|"this group undergoes rehabilitative therapy. It is a 24-week program and stroke patients practice the physical exercise for 1 hour each time. The intensity is three times a week.~Intervention : rTMS"
62494502|NCT00893776|ACTIVE_COMPARATOR|1 Unilateral Group|This group will wear the SaeboFlex orthosis on their affected extremity and do exercises with that extremity only. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
62695976|NCT04169009|ACTIVE_COMPARATOR|ZVL 6-12 months previously|Participants who received ZVL 6-12 months previously will be administered an intradermal dose of vOka varicella zoster virus (ZVL) in non-dominant deltoid.
62695977|NCT04169009|ACTIVE_COMPARATOR|No previous ZVL|Participants who've never received a shingles vaccine will be given the 2 standard doses of RZV. Six months later they will be given the intradermal dose of vOka varicella zoster virus (ZVL) in the non-dominant deltoid.
61942045|NCT00315146|ACTIVE_COMPARATOR|Hypocaloric diet, resist. training to maximize power, placebo|
62337593|NCT04400409|ACTIVE_COMPARATOR|Intervention A + CPC EQuIP 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
61942046|NCT00315146|ACTIVE_COMPARATOR|Hypocaloric diet and a PPAR- γ agonist (pioglitazone/Actos™)|
62337594|NCT04400409|ACTIVE_COMPARATOR|Intervention B + CPC EQuIP 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
62337595|NCT02817815|ACTIVE_COMPARATOR|Group 1|Volunteers
62337596|NCT02817815|EXPERIMENTAL|Group 2|Paroxysmal AF patients in sinus rhythm the day of inclusion
61942047|NCT00315146|ACTIVE_COMPARATOR|Hypocaloric diet,resistance training, pioglitazone/Actos™|
61942048|NCT06378151|EXPERIMENTAL|Intervention group|Attending physicians, resident physicians, or mid-level providers working in the ED who are willing to be randomized to become the study interventionists.
61942049|NCT06378151|NO_INTERVENTION|Control group|Attending physicians, resident physicians, or mid-level providers working in the ED who are willing to be randomized to become the study interventionists.
61942050|NCT01209507||Chemotherapy every 3 weeks|One treatment of chemotherapy every 3 weeks. Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV. The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
61942051|NCT01209507||Weekly chemotherapy|Chemotherapy will be given three times in a three week cycle. Chemotherapy will be given either Day 1, 8, and day 15 or Day 1,2 and day 8). Chemotherapy will either be 2 doses of 20 mg PO (12 hrs priors and immediately before treatment) or 1 dose via IV. The total dose per cycle will be 20-40 mg approximately for 18 weeks.
61942052|NCT04288180||Social Anxiety Disorder|A group of adults with social anxiety disorder will be recruited for a psychological/behavioral research study.
61942053|NCT00992277|EXPERIMENTAL|Facial|Skin rejuvenation treatments
61942054|NCT03980977|OTHER|skin and/or tumor Biopsy and blood sample|
62138263|NCT05851495|EXPERIMENTAL|home-based follow up groups|Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises. Then, all patients were called to the hospital for control after three months and the scale prepared by us and consisting of a total of 5 (five) questions was directed to the patients and it was determined how the exercises given were performed. Five different exercises were given to patients with low back and neck pain who participated in our study. The patients were asked to do these exercises 3 times a day for 10 repetitions. Cat-camel exercises, lumbar stretching, sit-ups, bridge building and back extensor strengthening exercises were given to patients with low back pain. For patients with neck pain, neck flexion-extension, neck lateral flexion, neck rotation, shoulder capsule stretching and shoulder flexion exercises were given.
62138264|NCT06337838|EXPERIMENTAL|Prophylactic intravenous tranexamic acid and prophylactic intravenous desmopressin.|"Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with estimated glomerular filtration rate (eGFR) \<25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis.~Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin intervention group will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes."
62337597|NCT02817815|EXPERIMENTAL|Group 3|Paroxysmal AF patients in atrial fibrillation the day of inclusion
62337598|NCT02817815|EXPERIMENTAL|Group 4|Persistent AF patients in sinus rhythm the day of inclusion
62337599|NCT02817815|EXPERIMENTAL|Group 5|Persistent AF patients in atrial fibrillation the day of inclusion
62337600|NCT05211011|EXPERIMENTAL|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
62337601|NCT03785496|EXPERIMENTAL|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
62337602|NCT00634959|EXPERIMENTAL|1|
62337603|NCT00634959|EXPERIMENTAL|2|
62337604|NCT00634959|EXPERIMENTAL|3|
62337605|NCT00634959|EXPERIMENTAL|4|
62337606|NCT00634959|PLACEBO_COMPARATOR|5|
62494503|NCT00893776|EXPERIMENTAL|2 Bilateral training|Members of this group will wear the SaeboFlex orthosis on the affected extremity and do exercises with the affected extremity and the non-affected extremity at the same time. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
62695978|NCT04169009|ACTIVE_COMPARATOR|SRX >5 years previously|Participants have received Shingrix at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
62337607|NCT05277649|EXPERIMENTAL|Experimental Group|Performance of a warm-up and cool-down exercise programme for the cervical and mandibular region before and after instrumental practice.
62337608|NCT05277649|NO_INTERVENTION|Control Group|"Participants in the control group will not make any changes in their instrumental practice habit.~At the end of the study, participants in the control group will be asked to perform the exercises tested in the experimental group."
62337609|NCT03056495|EXPERIMENTAL|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
62695979|NCT01556334|EXPERIMENTAL|Azithromycin|Azithromycin 1g po
62695980|NCT01556334|ACTIVE_COMPARATOR|Erythromycin|Erythromycin IV followed by po for a total of 5 days.
61942055|NCT04378127|EXPERIMENTAL|educational program + traditional medical care|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
61942056|NCT04378127|NO_INTERVENTION|traditional medical care|traditional medical care
62337610|NCT03577912|ACTIVE_COMPARATOR|TAP block administered by Surgery|transversus abdominis (TAP) plane block is performed by the surgeon at the conclusion of the surgery, still under general anesthesia, prior to removing the trocars a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under direct surgeon observed laparoscopic visualization. (Split dose 30cc/side)
62337611|NCT03577912|ACTIVE_COMPARATOR|TAP block administered by Anesthesia|transversus abdominis (TAP) plane block is performed by the anesthesiologist at the conclusion of the surgery after incisions are closed and dressing are on, prior to emergence from general anesthesia, a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under by the anesthesiologist using ultrasound visualization. (Split dose 30cc/side)
62337612|NCT02464397|EXPERIMENTAL|OPTIMAX-BAS 1|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 1 month after the index procedure.
62494504|NCT01663896||Single or multi vessel disease|Pre- and post-PCI fractional flow reserve (FFR) and OCT were performed in participants.
61942057|NCT04202471|EXPERIMENTAL|Chlorhexidine Cloth|The intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive preoperative abdominal application of 2% chlorhexidine cloths.
61942058|NCT04202471|NO_INTERVENTION|Standard Preoperative Care|The no intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive standard preoperative care.
61942059|NCT02334631|EXPERIMENTAL|High volume simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
61942060|NCT02334631|ACTIVE_COMPARATOR|Standard volume simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
61942061|NCT03719820||Intracranial Atherosclerosis|First-ever stroke patients attributed to intracranial artery stenosis (\> 50% or occlusion) who receive aggressive medical management
61942062|NCT02349542|EXPERIMENTAL|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
61942063|NCT00965809|EXPERIMENTAL|ACTIVE THC|Subjects will take 5MG of THC in 6 drops of olive oil orally.
61942064|NCT00965809|PLACEBO_COMPARATOR|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
61942065|NCT06318234||After neoadjuvant therapy for rectal cancer|(1) Pathologically confirmed as rectal adenocarcinoma, with baseline clinical staging of T3\~4 and/or N+; (2) No distant metastasis; (3) Not receiving chemotherapy or any other anti-tumor treatment before enrollment; (4) Has not received immunotherapy before enrollment and is able to adhere to the protocol during the study period (neoadjuvant therapy of short-term radiotherapy sequential chemotherapy combined with immunotherapy); (5) After neoadjuvant therapy, 18F-FAPI and 18F-FDG PET/MRI imaging were performed within 7 days before surgery, and the two scans were collected over two days; (6) Patient age ≥ 18 years old; (7) The patient voluntarily participates and signs an informed consent form.
61942066|NCT05267288|EXPERIMENTAL|afatinib plus bevacizumab|afatinib 40mg oral continually bevacizumab 15mg/kg, iv day 1, every 21days until disease progression, untolerated toxicities of patient death.
61942067|NCT03623555||E-IPV|"Women who have been exposed to intimate partner violence. Half of this group will also have a history of childhood maltreatment.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
61942068|NCT03623555||NE-IPV|"Women who have never been exposed to intimate partner violence. Half of this group will also present a diagnosis of Major Depressive Disorder.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
61942069|NCT00257608|EXPERIMENTAL|1|
61942070|NCT00257608|PLACEBO_COMPARATOR|2|
61942071|NCT03373071|EXPERIMENTAL|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
62337613|NCT02464397|ACTIVE_COMPARATOR|SYNERGY-EES 1|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 1 month after the index procedure.
62337614|NCT02464397|EXPERIMENTAL|OPTIMAX-OCT 6|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 6 months after the index procedure.
62337615|NCT02464397|ACTIVE_COMPARATOR|SYNERGY-EES 6|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 6 months after the index procedure.
62337616|NCT00850018|EXPERIMENTAL|1|Participants will receive monthly blood transfusions.
62337617|NCT00850018|ACTIVE_COMPARATOR|2|Participants will receive usual care.
61942072|NCT04238585|ACTIVE_COMPARATOR|Negative message frames|Participants will receive messages framed in a negative manner to avoid sugar-sweetened beverages
61942073|NCT04238585|ACTIVE_COMPARATOR|Sugar content information messages|Participants will receive messages framed in a positive manner to promote healthy beverage consumption
61942074|NCT04238585|PLACEBO_COMPARATOR|Attention Control-Infant Safety|Participants will receive messages with infant safety education materials-attention control group
61942075|NCT06680765|ACTIVE_COMPARATOR|Comparison group|Smart Smart and MMA are implemented in primary health centres and health posts by community health nurses, health extension workers or midwives. AGYW undergo counselling as individuals or as a group (for Nigeria through life, family and health classes- four sessions with 15-20 girls). Sessions focus on creating relevance of contraceptives as a tool for pursuing life aspirations and as a means to contribute to the household financial security through birth spacing. Girls who opt to voluntarily adopt modern contraceptive methods receive them on spot or at a later date based on their preferences and needs. For Nigeria, sessions are moderated by trained female mentors, while for Ethiopia health extension workers moderate sessions guided by a goal card.
62337618|NCT01841424|NO_INTERVENTION|Control|Subjects receive usual care for pregnancy and postpartum.
62337619|NCT01841424|EXPERIMENTAL|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
62337620|NCT06444243|EXPERIMENTAL|Psilocybin + Therapy|"* 12 weekly sessions of psychotherapy for AUD~* 2 dosing sessions - psilocybin 25mg~* Additional open-label dosing session for participants in control arm post-follow up~* 2 integration sessions following each dosing session (additional dosing session for open label dosing)~* 3 post-treatment follow-up sessions~* Total of 13 clinic sessions"
62695981|NCT01761149|ACTIVE_COMPARATOR|Remifentanil (Low dose)|remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
62695982|NCT01761149|EXPERIMENTAL|Remifentanil (High dose)|The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
62695983|NCT02133079|EXPERIMENTAL|gp96 group|autologous gp96 vaccination + basal treatment
62337621|NCT06444243|PLACEBO_COMPARATOR|Niacin + Therapy|"* 12 weekly sessions of psychotherapy for AUD~* 2 dosing sessions - niacin 250mg~* 2 integration sessions following each dosing session~* 3 post-treatment follow-up sessions~* Total of 13 clinic sessions"
62337622|NCT00305851|ACTIVE_COMPARATOR|Arm I (counseling)|Patients undergo six 1-hour sessions twice a week for 3 weeks with a trained counselor in which they choose up to 3 books on CD and listen to the book and/or discuss their impressions and thoughts about the contents with the counselor. Patients are provided with a portable CD player to listen to the books during their hospitalization.
62494505|NCT00004162|EXPERIMENTAL|Dose group 1 - dose 1 of Doxorubicin HCL Liposome|Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62494506|NCT00004162|EXPERIMENTAL|Dose group 2 - dose 2 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62138265|NCT06337838|EXPERIMENTAL|Prophylactic intravenous tranexamic acid and placebo.|"Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with eGFR \<25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis.~Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes."
62494507|NCT00004162|EXPERIMENTAL|Dose Group 3 - dose 3 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62494508|NCT00004162|EXPERIMENTAL|Dose group 4 - dose 4 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62494509|NCT00004162|EXPERIMENTAL|Dose group 5 - dose 5 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62494510|NCT00004162|EXPERIMENTAL|Dose group 6 - dose 6 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62494511|NCT00004162|EXPERIMENTAL|Dose group 7 - dose 7 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62494512|NCT00004162|EXPERIMENTAL|MTD group|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
62494513|NCT04929730|NO_INTERVENTION|Control group|Patients with an acute kidney injury in laborytory testing receive usual care. Nephrology co-supervision only on enquiry of the ward physician
62494514|NCT04929730|OTHER|Interventional group|Patients with an acute kidney injury in laborytory testing receive nephrology co-supervision in hospital and information about the importance of ambulant follow-up care.
62695984|NCT05135260|EXPERIMENTAL|Virtual Reality Therapy|Participants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.
62494515|NCT06020040|EXPERIMENTAL|Large Bone Particles|The size of the bone particles that will be used for GBR is 1-2mm.
62695985|NCT05135260|ACTIVE_COMPARATOR|Control Group|This group will not watch videos, but will continue with their normal routine as if nothing has changed.
62695986|NCT00811837|EXPERIMENTAL|Remifentail|Remifentanil Infusion
62695987|NCT00811837|ACTIVE_COMPARATOR|Midazolam|Active Placebo
62695988|NCT06643871|EXPERIMENTAL|DYNAMO-PSY program|This is a feasibility study. Therfore, there is only one arm, the experimental one, where participants will be enrolled in the DYNAMO-PSY program.
62695989|NCT06212817|EXPERIMENTAL|Fibre-UP tool: digital, personalized dietary advice to increase dietary fiber intake|Subjects will receive personalized dietary advice (PDA) based on their habitual food pattern (as assessed using a food frequency questionnaire) and preferences. Based on a previously developed algorithm, the PDA provides fiber-rich alternatives for currently used low-fiber products, close to subjects' current eating behavior, to help increase dietary fiber intake. This PDA will be provided using an online web-portal.
61942076|NCT06680765|EXPERIMENTAL|Intervention group|Smart Pathways and MMA plus are the MNCH components which are implemented alongside the respective sexual and reproductive health interventions. These interventions target AGYW (15-19 in Nigeria and 15-24 in Ethiopia). These interventions are implemented at primary health centres and health posts. Eligible women are recruited using a targeted mobilization approach by trained mobilisers. In both locations, AGYW go through sessions covering preconceptual care and nutrition, ANC education and services and referral. Intervention components are delivered by trained health providers at the health centres and posts.
61942077|NCT00946478|ACTIVE_COMPARATOR|Pimecrolimus|
61942078|NCT00946478|SHAM_COMPARATOR|Vehicle cream|
61942079|NCT04401826|EXPERIMENTAL|The conventional approach|Conventionnal ECL using piezosurgery and microsurgical tools
62138266|NCT06337838|EXPERIMENTAL|Prophylactic intravenous desmopressin and placebo.|"Within 20 minutes preceding anticipated skin incision, patients will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes. Patients will not receive prophylactic tranexamic acid.~Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group."
62138267|NCT06337838|PLACEBO_COMPARATOR|Placebo and placebo.|"Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group.~Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes."
62138268|NCT04132154||No Warming|Patients in this group were treated according to our institution's old protocol and did not receive any warming intervention during the surgical procedure.
62494516|NCT06020040|EXPERIMENTAL|Small Bone Particles|The size of the bone particles that will be used for GBR is 0.25-1mm.
62494517|NCT03306238|ACTIVE_COMPARATOR|Open/Hasson|This group will undergo initial laparoscopic port insertion by the open or Hasson approach and then undergo the remaining laparoscopic surgery as usual
62494518|NCT03306238|ACTIVE_COMPARATOR|Closed/ Veress|This group will undergo initial laparoscopic port insertion by the closed or Veress approach and then undergo the remaining laparoscopic surgery as usual
62494519|NCT04192032|EXPERIMENTAL|Preferred flavor (5% nicotine)|Preferred flavor Juul pod (5% nicotine)
62494520|NCT04192032|ACTIVE_COMPARATOR|Classic Tobacco Flavor|Control flavor (5% Classic Tobacco flavor Juul pod)
62695990|NCT06212817|EXPERIMENTAL|Vegetable product (dried chicory root) to increase dietary fiber intake|Subjects will consume 2 sachets with each 7.5 g of dried cubes of chicory root, which equals a total of 12.3 g of dietary fiber per day. Subjects can choose when and how they consume the vegetable product, for example sprinkle it over their meal, or include in existing recipes.
62695991|NCT06212817|NO_INTERVENTION|Control|Subjects will follow their habitual diet during the preoperative period.
62494521|NCT04192032|EXPERIMENTAL|Preferred flavor with HWL|Preferred flavored Juul pod (5% nicotine) with HWL
62695992|NCT04891198|EXPERIMENTAL|Subjects with TMB-H/TMB-L|Subjects receive KN035 400 mg Subcutaneously on Day 1 and day 15 of cycle 1 and on day 1 of every subsequent 4-week cycle (Q4W)
62695993|NCT02295865|EXPERIMENTAL|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
62695994|NCT02295865|EXPERIMENTAL|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
62695995|NCT02295865|EXPERIMENTAL|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
62695996|NCT02295865|EXPERIMENTAL|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
61942080|NCT04401826|ACTIVE_COMPARATOR|The intervention approach:|Conventionnal ECL with tunneling using piezosurgery and microsurgical tools
61942081|NCT01020383|EXPERIMENTAL|ALX-0081|
61942082|NCT01020383|ACTIVE_COMPARATOR|GPIIb/IIIa inhibitor|
61942083|NCT06557434|EXPERIMENTAL|Treated Cohort|Experimental: Treatment with the MIRIA Laser 3-4 experimental treatments at 4-6 week intervals. Refine usage of device
61942084|NCT02902068||Parturients undergoing cesarean section|Healthy parturients, hypertensive parturients and parturients suffering from preeclampsia above 18 undergoing cesarean section deliveries .
61942085|NCT03845777||Surgical Staff|The surgical staff group is the only group of the study. Blood samples of the surgical staff before and after the using antiseptics solution that include iodine were analyzed.
61942086|NCT00254761|EXPERIMENTAL|1|High dose cannabis (7.5% THC by weight)
62494522|NCT04192032|EXPERIMENTAL|Preferred flavor (3% nicotine)|Preferred flavored Juul pod (3% nicotine)
61942087|NCT00254761|EXPERIMENTAL|2|Low dose cannabis (3.5% THC by weight)
61942088|NCT00254761|PLACEBO_COMPARATOR|3|Placebo cannabis
61942089|NCT06015464||prospective cohort|To retrospectively collect information on DLBCL patients treated with orelabrutinib in combination with standard first-line regimens, pooled analysis of the association between recent efficacy and patient characteristics (including biomarkers) in different types of patients to assess the predictive value of ctDNA for prognosis and subsequent therapeutic adjustments during treatment
61942090|NCT06015464||Prospective cohort|Prospective observation to collect information on the efficacy of orelabrutinib in combination with standard treatment regimens in specific types of populations (with a focus on genotyped patients such as MCD, BN2 and N1 subtypes) to validate the predictive value of ctDNA in diagnosis and treatment
61942091|NCT00929123|EXPERIMENTAL|neural mobilization|manual therapy technique known to directly stress the median nerve
61942092|NCT00929123|PLACEBO_COMPARATOR|sham neural mobilization|manual therapy technique known to directly stress the median nerve without any stimulation.
61942093|NCT00929123|ACTIVE_COMPARATOR|Healthy Controls|People without carpal tunnel syndrome for comparison
61942094|NCT05938062|EXPERIMENTAL|grup 1: the group without fibrinogen concentrate (GNF)|grup 1: the group without fibrinogen concentrate (GNF)
61942095|NCT05938062|EXPERIMENTAL|Grup 2: the group with fibrinogen concentrate|Grup 2: the group with fibrinogen concentrate
61942096|NCT01751477||Probiotics (Infloran)|Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life
61942097|NCT01751477||Control|Very low birth weight Infants who did not receive Infloran (historical cohort)
61942098|NCT06002126|EXPERIMENTAL|Cervical cancer screening (single arm)|Women will be screened for cervical cancer with HPV testing that provides extended genotyping and DNA quantification. Women will also provide other samples for cervical cancer screening tests. Women will under cervical biopsies.
61942099|NCT02746172|EXPERIMENTAL|Cochlear Implant Recipients|cochlear implant recipients
61942100|NCT02746172|NO_INTERVENTION|Normal Hearing Volunteers|Normal hearing volunteers
61942101|NCT05106894|EXPERIMENTAL|smartphone application to promote nurturing care|a caregiver-directed smartphone application will directly engage first-time caregivers in providing nurturing care
61942102|NCT05106894|ACTIVE_COMPARATOR|printed caregiving materials|caregivers will receive print materials on early childhood stimulation
61942103|NCT06289985|OTHER|Endovascular Therapy (EVT) Indication Expansion Domain: Low NIHSS Strata|"Adult patients with acute cerebral ischemia within 24 hours of last known well who have large vessel occlusion (LVO) and mild deficits/low NIHSS (NIHSS 0-5) will be randomized to receive one of two strategies:~* Endovascular Therapy (EVT)~* Medical Management (MM)"
61942104|NCT06289985|OTHER|Endovascular Therapy (EVT) Indication Expansion Domain: Medium/Distal Occlusions Strata|"Adult patients with acute cerebral ischemia within 24 hours of last known who have Medium Vessel Occlusion (MVO) with Non-dominant/Co-dominant M2 occlusion or Distal Medium Vessel Occlusion (DMVO) patients with M3,4 or A1,2,3 or P1,2,3 occlusion will be randomized to receive one of two strategies:~* Endovascular Therapy (EVT)~* Medical Management (MM)"
62337623|NCT00305851|EXPERIMENTAL|Arm II (counseling and music therapy)|Patients undergo six 1-hour sessions twice a week for 3 weeks with a music therapist, designed specifically for the pre-transplant and acute phase of treatment. Phases of patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout worksheet, taking photos or making drawings for the video, viewing clip art and pictures on a computer, and sharing the final video with family members and hospital staff.
62695997|NCT04803565|EXPERIMENTAL|Custom-Made Insole|"This Group will receive a custom-made shoe insole designed on the foot shape of the subjects.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
62695998|NCT04803565|SHAM_COMPARATOR|Sham Insole|"This group will receive a Sham shoe insole without any specific custom-made design.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
62695999|NCT05879029|EXPERIMENTAL|experimental group|Jinsang Liyan Capsule: oral, 0.4g/ capsule, 4 capsules, twice a day, for 8 weeks; Rabeprazole enteric-coated tablets: taken orally before breakfast, 10mg/ tablet, 2 tablets at a time, once a day, for 8 weeks;
61942105|NCT01706796|EXPERIMENTAL|PF-06273340 Oral Solution Fasted|
61942106|NCT01706796|EXPERIMENTAL|PF-06273340 Immediate Release Tablet Fasted|
61942107|NCT01706796|EXPERIMENTAL|PF-06273340 Modified Release (MR1) Tablet Fasted|
61942108|NCT01706796|EXPERIMENTAL|PF-06273340 Modified Release (MR2) Tablet Fasted|
61942109|NCT01706796|EXPERIMENTAL|PF-06273340 Modified Release (MR1) Tablet Fed|
61942110|NCT01706796|EXPERIMENTAL|PF-06273340 Modified Release (MR2) Tablet Fed|
61942111|NCT03750461|EXPERIMENTAL|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
61942112|NCT06681298|EXPERIMENTAL|Nivolumab group|Preoperative nabuliumab combined with FLOT and trastuzumab + surgical treatment + postoperative nabuliumab combined with FLOT and trastuzumab. There were 4 cycles before and after surgery, one cycle every 2 weeks. The specific administration was: docetaxel 50mg/m2 iv,d1, oxaliplatin 85mg/m2 iv,d1, calcium leucovorin 200mg/m2 iv,d1,5-FU 2600mg/m2 iv,d1, infusion 24h; Nebulizumab 240mg iv,d2, 30 minutes per intravenous infusion, trastuzumab 4mg/kg iv,d2 (load dose 6mg /kg).
61942113|NCT06681298|ACTIVE_COMPARATOR|Control group|The control group was treated with preoperative FLOT combined with trastuzumab + surgical treatment + postoperative FLOT combined with trastuzumab. Preoperative and postoperative cycles were 4 in both groups, with one cycle every 2 weeks. Specific administration was as follows: Docetaxel 50mg/m2 iv,d1, oxaliplatin 85mg/m2 iv,d1, calcium leucovorin 200mg/m2 iv,d1,5-FU 2600mg/m2 iv,d1, infusion 24h; Trastuzumab 4mg/kg iv,d2 (load dose 6mg /kg).
61942114|NCT03636165|EXPERIMENTAL|MP plus RP group|Patients in RP/MP group will receive a peri-incisional scalp infiltration with 0.125% methylprednisolone and 0.2% ropivacaine and normal saline miscible liquids. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
62337624|NCT04626843|EXPERIMENTAL|Intermittent fasting|
62337625|NCT05968976|ACTIVE_COMPARATOR|55 patients with essential tremor receive awake DBS|
62696000|NCT05879029|PLACEBO_COMPARATOR|control group|Jinsang Liyan Capsule placebo: oral, 0.4g/ capsule, 4 capsules, twice a day, for 8 weeks; Rabeprazole enteric-coated tablets: taken orally before breakfast, 10mg/ tablet, 2 tablets at a time, once a day, for 8 weeks;
62696001|NCT05204485|ACTIVE_COMPARATOR|Fibular intramedullary nail|Randomized in the OR to ankle fracture repair with fibular intramedullary nail
61942115|NCT03636165|ACTIVE_COMPARATOR|RP group|Patients in RP group will receive peri-incisional scalp infiltration with 0.2% ropivacaine alone. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
61942116|NCT02026284||Gravid women|A questionnaire was performed to gravid women
62696002|NCT05204485|ACTIVE_COMPARATOR|Open reduction and internal fixation (ORIF)|Randomized in the OR to ankle fracture repair with ORIF
61942117|NCT02583126|EXPERIMENTAL|Music Group|Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music
61942118|NCT02583126|NO_INTERVENTION|Control Group|Prescribed medical/chemotherapy treatment plus standard care
61942119|NCT03685695|EXPERIMENTAL|Supportive care (physical activity)|Participants wear Fitbit Charge 2 to monitor physical activity for 3 courses (9-12 weeks). Participants then increase their activity minutes to 30 minutes, 5 times a week or by 30% for 6 additional months.
62696003|NCT04979143|OTHER|HoLVP with the use of Moses 2.0 technology|HoLVP with the use of Moses 2.0 technology
62696004|NCT04979143|OTHER|HoLVP without the use of Moses 2.0 technology|HoLVP without the use of Moses 2.0 technology
62696005|NCT05385289|EXPERIMENTAL|First wave with 6 participants|"Once selected, an individual online information session will be scheduled with each selected participant to explain the project and its practical implications. At this time, six of the twelve participants will be provided a link to complete online measures as the A-baseline phase, to constitute their own non-intervention control condition on the target behavior (i.e., rumination) and on positive and negative emotions. The other six participants will be entered into a 3-week waiting list period with a sequential introduction, to provide another non-intervention control condition.~The A-baseline phase length will include at least 5 measures and most 10 measures, resulting in 10 potential starting point for the B-experimental phase. This range will be determined to estimate autocorrelation and its associated bias."
62696006|NCT05385289|EXPERIMENTAL|Second wave with 6 other participants|After three weeks, the six participants on the waiting list will also begin the same A-baseline phase as the six participants of the first wave.
62696007|NCT06640725|EXPERIMENTAL|TPEx-Avelumab-Cetuximab|"Induction (TPEx regimen: up to 4 cycles Q3W) Cisplatin 75 mg/m² or Carboplatin AUC 5 every 3 weeks (±2 days). Docetaxel 75 mg/m² every 3 weeks (±2 days). Cetuximab with a loading dose of 400mg/m² at C1D1 and after 250mg/m² every week (±2 days).~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\]) Avelumab 10 mg/kg every 2 weeks (±3 days)"
62138269|NCT04132154||Active Warming|This group will include the patients treated after the implementation of the S3 Guidelines for prevention of hypothermia. For this purpose convective warming through an underbody blanket was used during the surgical procedure
62138270|NCT06213233|PLACEBO_COMPARATOR|Placebo|
62138271|NCT06213233|EXPERIMENTAL|Cannabidiol|
62696008|NCT05535569|EXPERIMENTAL|Experimental|
62138272|NCT05981352|ACTIVE_COMPARATOR|Mineral trioxide aggregate (positive control group)|": according to the manufacturing instructions as following:~* After achieving hemostasis, Mineral trioxide aggregate powder will be mixed with saline.~* Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
62138273|NCT05981352|EXPERIMENTAL|Dehydrated amniotic membrane group|"* After achieving hemostasis, a double layer of sterile processed human allograft tissue (dehydrated dual-layer dental amnion patch) will be trimmed and soaked in saline for a minute.~* Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjusted to the entire floor of the pulp chamber."
62138274|NCT05981352|EXPERIMENTAL|Hyaluronic acid group|• After achieving hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .
62337626|NCT05968976|EXPERIMENTAL|55 patients with essential tremor receive asleep DBS|
62337627|NCT01513226|EXPERIMENTAL|Dim light|Day and nighttime dim light conditions
62696009|NCT02600650|EXPERIMENTAL|Experimental|Receive daily authentic Testosterone boosting supplement
62696010|NCT02600650|PLACEBO_COMPARATOR|Placebo|Receive daily placebo supplementation
62696011|NCT05183984|EXPERIMENTAL|ARM A: carboplatin/paclitaxel + niraparib|carboplatin AUC 5-6 + paclitaxel 175 mg/m² q3w, 5 cycles, followed by niraparib 200\* or 300 mg/d for 2 years.
62696012|NCT05183984|EXPERIMENTAL|ARM B: carboplatin/paclitaxel/bevaziumab + niraparib/bevacizumab|carboplatin AUC 5-6 + paclitaxel 175 mg/m² + bevacizumab 15 mg/kg q3w, 5 cycles, followed by bevacizumab 15 mg/kg q3w for 15 months + niraparib 200\*or 300 mg/d for 2 years.
62696013|NCT06398249||Experimental|chronic mechanical low back pain
62696014|NCT06398249||control|healthy matched controls
62696015|NCT04103814|ACTIVE_COMPARATOR|Mg-CBDa cream|Subjects in this group will receive the active Mg-CBDa (magnesium-cannabidiolic acid) for topical treatment of hallux valgus or hallux rigidus.
61942120|NCT04450888|OTHER|Model A|Total cardiovascular disease (CVD)-free life expectancy gain in one's remaining life.
62138275|NCT03542279|EXPERIMENTAL|Early PE group|PE (5 times in each course) combined with intravenous methylprednisolone (IVMP) and IVIG after PE.
62138276|NCT03542279|ACTIVE_COMPARATOR|Late PE group|IVIG (0.4g/kg/d for 5 days) and IVMP immediately, followed by PE at least 2 weeks after IVIG treatment.
62138277|NCT04041219|EXPERIMENTAL|Allogeneic blood or marrow transplantation|Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota
62138278|NCT05858879|ACTIVE_COMPARATOR|Notification with a CAC image|Notification of presence of CAC with a CT scan image
62138279|NCT05858879|ACTIVE_COMPARATOR|Notification without a CAC image|Notification of presence of CAC without a CT scan image
62337628|NCT06174363|PLACEBO_COMPARATOR|Study group|Group administered Maxigesic solution
62337629|NCT06174363|EXPERIMENTAL|Control group|Group administerd 0.9% saline solution
62696016|NCT04103814|PLACEBO_COMPARATOR|Placebo cream|Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
62138280|NCT05858879|PLACEBO_COMPARATOR|Usual care|Usual care
62138281|NCT05573724|EXPERIMENTAL|Treatment Arm|"Part A:~The participants will receive a single oral dose of AZD5305 on Day 1, followed by a 2-day washout. Then Itraconazole will be dosed for 3 days \[BD\] on Day 4 and \[OD\] on Days 5 and 6, then a single oral dose of AZD5305 administered concurrently with Itraconazole on Day 7 and only Itraconazole on Days 8 to 12.~Part B:~Patients proceeding to Part B after completing Part A of the study will receive AZD5305 OD as monotherapy."
62138282|NCT03459846|EXPERIMENTAL|Arm 1: Durvalumab/Placebo|Durvalumab 1500 mg intravenous (IV) every 4 weeks (q4w) starting on week 1 day 1/Placebo orally (PO) twice a day (BID) starting on week 1 day 1.
62337630|NCT05167500||Experimental : Lorlatinib inn ALK Or ROS1 Metastatic NSCLC patient|Patients with metastatic non-small cell lung cancer treated with lorlatinib who were included in the compassionate use program in Spain between November 2016 and February 2019 for those with an ALK alteration, and between November 2016 to March 2021 for those with ROS1 alteration.
62337631|NCT03214692|EXPERIMENTAL|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
62337632|NCT06423287|EXPERIMENTAL|Lactobacillus plantarum LP-KFY04|Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
62337633|NCT06423287|PLACEBO_COMPARATOR|placebo|Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks' trial.
62337634|NCT05700071|EXPERIMENTAL|MRI examination|
62494523|NCT04192032|EXPERIMENTAL|Preferred flavor (0% nicotine)|Preferred flavored Juul pod (0% nicotine)
62494524|NCT00804011|EXPERIMENTAL|1|Automatic tube compensation plus pressure support
62494525|NCT00804011|ACTIVE_COMPARATOR|2|Pressure support alone
62494526|NCT01788709|ACTIVE_COMPARATOR|A|Fortrans (split dose) + Mentholyptus drops
62494527|NCT01788709|ACTIVE_COMPARATOR|B|MoviPrep (split dose)
62494528|NCT03261843|ACTIVE_COMPARATOR|posterior lumbar interbody fusion + platelet rich plasma|the addition of autologous platelet rich plasma to the bone graft
62494529|NCT03261843|ACTIVE_COMPARATOR|posterior lumbar interbody fusion|bone graft alone
62494530|NCT01994915|EXPERIMENTAL|Occupational therapy group|35 patients diagnosed with chronic obstructive pulmonary disease attending to the Hospital because of an exacerbation are going to be included in this group.
61942121|NCT04450888|OTHER|Model B|Average CVD-free life expectancy gain per year.
62138283|NCT03459846|EXPERIMENTAL|Arm 2: Durvalumab/Olaparib|Durvalumab 1500 mg IV q4w starting on week 1 day 1/Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
62138284|NCT05931406|EXPERIMENTAL|Emergency medical dispatchers|
62138285|NCT05931406|EXPERIMENTAL|Firefighter|
62494531|NCT01994915|NO_INTERVENTION|Control group|35 patients diagnosed with chronic obstructive pulmonary disease are going to be included in this group. They are not going to receive other than standard care (medical and physical therapy intervention).
62494532|NCT00784095|EXPERIMENTAL|Preparation and Completion|"Subjects in the first group (treatment) met with the facilitator three times for a period of forty-five minutes to one hour to discuss issues of life completion and preparation. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects discussed issues of heritage and legacy."
62494533|NCT00784095|ACTIVE_COMPARATOR|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
62138286|NCT01760382||STEMI network Primary PCI patients|Patients with STEMI brought to the Hub Hospital by the STEMI network ambulance and treated by primary PCI.
62138287|NCT01760382||STEMI Hospital ED Primary PCI patients|Patients with STEMI who reached by themselves the Hub Hospital, where they were admitted for STEMI and tretated by Primary PCI
62138288|NCT06683157||serial ultrasound 3|CCUS will be repeated on day 5±2 , day 10±2 and day 30±4. If the ICVT has propagated into the trifurcation area, the popliteal vein, or into more proximal veins therapy will be implemented according to current guidelines for proximal DVT. If no propagation to proximal veins has occurred anticoagulation will be withheld further on.
62138289|NCT00031720|EXPERIMENTAL|Arm I|All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
62138290|NCT00031720|PLACEBO_COMPARATOR|Arm II|All patients receive placebo for a 7 day run in period. Patients being treated with tamoxifen randomized to Arm II received placebo daily for 12 weeks.
62138291|NCT05213624|EXPERIMENTAL|BI 764198 - low dose|BI 764198 - low dose
62696017|NCT06040827||Group 1 (Test)|Zimmer Persona® Personalized Knee System with Canary canturioTM (CTE) tibial extension
62696018|NCT06040827||Group 2 ( Control)|Group 2 (Control): Zimmer Persona® Personalized Knee System with 14 mm +30 mm stem extension
62138292|NCT05213624|EXPERIMENTAL|BI 764198 - medium dose|BI 764198 - medium dose
62138293|NCT05213624|EXPERIMENTAL|BI 764198 - high dose|BI 764198 - high dose
62494534|NCT00784095|NO_INTERVENTION|True Control|"Subjects in the third group (true control) were exposed to no intervention or attention control."
62696019|NCT01481285||healthy adults|The study will cover 992 healthy adults. 496 men and 496 women in an age range of 18 to 65 years are planned to be recruited.
62696020|NCT04979000||Cases|Patients with a confirmed diagnosis of sinonasal cancer.
62696021|NCT04979000||Controls|Patients being seen for benign conditions at Johns Hopkins.
62696022|NCT05599165|EXPERIMENTAL|signal processing on consonant recognition|"The effects of the three processing schemes on consonant enhancement will be measured.~The results will be compared with two signal processing schemes: target-cue signal processing, and combined target and conflict-cue signal processing."
62696023|NCT06094296|EXPERIMENTAL|Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCT|
62696024|NCT06094296|EXPERIMENTAL|Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCT|
62138294|NCT05213624|PLACEBO_COMPARATOR|Placebo|Placebo
62138295|NCT05084638|EXPERIMENTAL|Ofatumumab|Ofatumumab will be provided in an autoinjector for subcutaneous administration. Dosing regimen for this study is an initial dose of 20mg at Baseline/Week 0, followed by Week 1, 2 and every month thereafter, beginning at Week 4 (Month 1) until Month 18. There will be an optional extension of dosing through month 30.
62138296|NCT05084638|NO_INTERVENTION|Healthy Control|Healthy Control arm will be age- and sex-matched subjects (to the ofatumumab treated arm) and will not receive a study treatment.
62494535|NCT02277262|EXPERIMENTAL|Treatment arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed reinforcing the suture with a swine dermis biological prosthesis positioned sublay
62494536|NCT02277262|ACTIVE_COMPARATOR|Control arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed by emi-continuous monofilament sutures with an intermediate-reabsorbable-time suture
62494537|NCT02036398|ACTIVE_COMPARATOR|Nephrostomy tube + double J stent|Standard therapy group with nephrostomy tube and double J stent left at the end of the PCNL
62494538|NCT02036398|EXPERIMENTAL|Double J stent without nephrostomy|Double J stent only left at the end of the procedure
62696025|NCT06094296|ACTIVE_COMPARATOR|Part 2: Nivolumab + Histology-based PDCT|
62696026|NCT06094296|EXPERIMENTAL|Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCT|
62696027|NCT06094296|EXPERIMENTAL|Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCT|
62696028|NCT04774445|EXPERIMENTAL|Intervention Group|Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application.
62696029|NCT04774445|NO_INTERVENTION|Usual Care Group|Individuals randomized to this arm will receive the standard clinical practice.
62494539|NCT00858416|EXPERIMENTAL|AB|First active then Sham
62494540|NCT00858416|SHAM_COMPARATOR|BA|First sham then active
62494541|NCT03336788|PLACEBO_COMPARATOR|TMS|
62494542|NCT03336788|ACTIVE_COMPARATOR|TMS with virtual reali|
62494543|NCT02689817|EXPERIMENTAL|Monitoring patch, no display|Participants in this condition will receive a padded bandage that monitors pressure over time. In this arm, healthcare providers will not be able to view the pressure data collected.
62696030|NCT05383482|EXPERIMENTAL|Afuresertib in combination with Sintilimab and Nab-paclitaxel|Afuresertib in combination with Sintilimab and Nab-paclitaxel in patients with Endometrial Cancer and Cervical Cancer
62138297|NCT06700200|ACTIVE_COMPARATOR|taVNS|The vagus nerve will be stimulated transcutaneously. The concha of the left ear will be stimulated.
62138298|NCT06700200|PLACEBO_COMPARATOR|Sham stimulation|The vagus nerve will be stimulated transcutaneously. The concha of the left ear will be stimulated. The device is inactive.
62494544|NCT01479062|EXPERIMENTAL|participation in Alive-PD|Alive-PD lifestyle intervention with multi-channel delivery
62138299|NCT00976651|ACTIVE_COMPARATOR|Recombinant FSH|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
62337635|NCT05528224|EXPERIMENTAL|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT) combined with medication|"In the main study, after individualized assessment（0 week and 3 week separately）, OCD patients will be provided with self-guided ICBT or therapist-guided ICBT through the severity of their symptoms flexibly while they will continue with the medications they already have.~In the pilot study, 23 OCD patients will be assigned to SC-ICBT group based on their autonomous will. They will begin with self-guided ICBT, followed by an assessment of their treatment outcomes at week 3, with non-responders being escalated to a higher intensity of treatment, and additional therapist-guided ICBT in the following three weeks. During the 6-week treatment they will continue with the medications they already have."
62337636|NCT05528224|ACTIVE_COMPARATOR|Cognitive Behavioral Group Therapy (CBGT) combined with medication|"In the main study, OCD patients will be provided with therapist-guided offline Cognitive Behavioral Group Therapy while they will continue with the medications they already have.~In the pilot study, 23 OCD patients will be assigned to CBGT group based on their autonomous will. They will receive the same CBGT intervention as in the main study while they will continue with the medications they already have."
62494545|NCT01479062|PLACEBO_COMPARATOR|Control|Usual care
62494546|NCT03610555||Current website|Show patient one of the website
62494547|NCT03610555||New patient centered website|Show patient another (different) of the website
62494548|NCT05590676|EXPERIMENTAL|HIE: 20 mg/kg|
62494549|NCT05590676|EXPERIMENTAL|HIE: 25 mg/kg|
62494550|NCT05590676|EXPERIMENTAL|Preterm: 15 mg/kg|
62494551|NCT05590676|EXPERIMENTAL|Preterm: 20 mg/kg|
62494552|NCT06388733|EXPERIMENTAL|Arm A: Niraparib|
62494553|NCT06388733|ACTIVE_COMPARATOR|Arm B: Temozolomide|
62494554|NCT06482606|ACTIVE_COMPARATOR|Participants with recovered depression|Participants with recovered depression will be experiencing flickering checkerboard stimulus.
62494555|NCT06482606|PLACEBO_COMPARATOR|Healthy control participants|Healthy control participants will be experiencing flickering checkerboard stimulus.
62494556|NCT01274962|EXPERIMENTAL|A - neoadjuvant chemotherapy|Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
62696031|NCT05383482|EXPERIMENTAL|Afuresertib in combination with Sintilimab and Docetaxel|Afuresertib in combination with Sintilimab and Docetaxel in patients with Gastric and Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer and Esophageal Cancer
62696032|NCT04503616|EXPERIMENTAL|HSCT Patients|Adult patients with hematological malignancies undergoing HLA-haploidentical HSCT from first-or second-degree family donors.
62696033|NCT06640127|ACTIVE_COMPARATOR|Control Group|Sinus lifting and implant placement with osteotomes
62696034|NCT06640127|EXPERIMENTAL|Test Group|Sinus lifting and implant placement with specifically designed drills
62696035|NCT03533283|EXPERIMENTAL|Atezolizumab|Participants will receive Glofitamab in combination with Atezolizumab up to the maximum tolerated dose (MTD).
62696036|NCT03533283|EXPERIMENTAL|Polatuzumab Vedotin|Participants will receive Glofitamab in combination with polatuzumab vedotin up to the MTD.
62696037|NCT03533283|EXPERIMENTAL|Imaging Sub-study|"Participants will undergo positive-emission tomography/computed tomography (PET/CT) at screening, followed by an Imaging Cycle, to replace Cycle 1 of the main study. Eligible participants will have the option roll-over to the atezolizumab arm of the main study from Cycle 2 onwards."
62696038|NCT04205786|ACTIVE_COMPARATOR|Control - Standard of Care|"Day 0:~* Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form~* Blood collection~* Continue Usual Care~Day 45:~* Repeat of baseline questionnaires with addition of vitamin B12 supplements form and investigational agent accountability record~* Blood collection~* Continue Usual Care~Day 90:~-Repeat of day 45"
62696039|NCT04205786|EXPERIMENTAL|Study Medication Group (B12)|"Day 0:~* Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form~* Blood collection~* Oral intake of Vitamin B12 Daily in the morning~Day 45~* Repeat of baseline questionnaires with addition of investigational agent accountability record~* Blood collection~* Oral intake of Vitamin B12 Daily in the morning~Day 90:~-Repeat of day 45 without additional study drug intake."
62696040|NCT01342315|EXPERIMENTAL|Active|Product 33525
62696041|NCT01342315|EXPERIMENTAL|Placebo|Product 33525 Placebo
62696042|NCT04418245||Patients positive for SARS-CoV-2|
61942122|NCT04450888|OTHER|Model C|Total CVD-free life expectancy loss that can be reclaimed in one's remaining life.
61942123|NCT04450888|OTHER|Model D|Average CVD-free life expectancy loss that can be reclaimed per year.
61942124|NCT06557538||People over the age of 18 with lower limb ulcers under Community Services|Comparison of reading between automatic and manual device ABPI scores
61942125|NCT03299270||Group 1|Elderly patiences with solid malignancy
61942126|NCT03515252|EXPERIMENTAL|Late stage lung cancer and liver cancer|Immune Killer Cells (IKC)
61942127|NCT00751218|ACTIVE_COMPARATOR|Arm 1|desloratadine
61942128|NCT00751218|PLACEBO_COMPARATOR|Arm 2|Placebo
62696043|NCT05620329||Pleural Fluid Registry|Any subject who has pleural fluid buildup from lung cancer, breast cancer, or lung infection
62696044|NCT02245659|EXPERIMENTAL|CPAP|
62696045|NCT02245659|OTHER|Nasal dilator strip|Control
62696046|NCT01798225|PLACEBO_COMPARATOR|Control|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) pills.
62696047|NCT01798225|EXPERIMENTAL|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Doxycycline 100mg x 14 pills)
62696048|NCT06643130|EXPERIMENTAL|JW0104+C2402|JW0104+C2402, 8 weeks, QD (Quaque Die)
62696049|NCT06643130|ACTIVE_COMPARATOR|JW0104+C2403|JW0104+C2403, 8 weeks, QD
62696050|NCT06643130|ACTIVE_COMPARATOR|C2402|C2402, 8 weeks, QD
62696051|NCT05085834|EXPERIMENTAL|Zinc gluconate|Patients received Zinc gluconate 45 mg capsules orally twice daily for 24 weeks.
62696052|NCT05085834|PLACEBO_COMPARATOR|Placebo|Patients received Zinc gluconate Placebo capsules orally twice daily for 24 weeks.
62696053|NCT05982678|EXPERIMENTAL|Trastuzumab-deruxtecan|5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
62696054|NCT06381102|EXPERIMENTAL|taVNS 30/30 followed by taVNS 10/10 group|Participants in the group taVNS 30/30 followed by taVNS 10/10 will be in this group for up to 6 hours.
62696055|NCT06381102|ACTIVE_COMPARATOR|taVNS 10/10 followed by taVNS 30/30 group|Participants in the group taVNS 10/10 followed by taVNS 30/30 will be in this group for up to 6 hours.
62696056|NCT00706173|EXPERIMENTAL|Hydrocortisone|
62696057|NCT00706173|PLACEBO_COMPARATOR|Placebo|
62696058|NCT02618941|EXPERIMENTAL|AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/adjuvanted
62696059|NCT02618941|NO_INTERVENTION|Control|Untreated control group
62696060|NCT05207839|PLACEBO_COMPARATOR|Milk powder without GOS|
62696061|NCT05207839|ACTIVE_COMPARATOR|Milk powder with GOS|
62696062|NCT03852420|EXPERIMENTAL|Treatment with the LUMINIZE RF Balloon Catheter|Subjects undergoing cardiac ablation procedure LUMINIZE™ RF Balloon Catheter System.
62696063|NCT05227326|EXPERIMENTAL|Treatment (PCNA inhibitor AOH1996)|Patients receive PCNA inhibitor AOH1996 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62696064|NCT03537508|EXPERIMENTAL|Group 1a|MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age
61942129|NCT00751218|ACTIVE_COMPARATOR|Arm 3|cetirizine
61942130|NCT04544085|NO_INTERVENTION|control group|Patients in the control group will not receive any noise management intervention
61942131|NCT04544085|EXPERIMENTAL|experimental group|Patients in the experimental group will receive noise management. The intervention measures mainly include the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.We will strengthen the education of medical staff to ensure the effective implementation of the noise management.
61942132|NCT02891694||recurrent corneal erosion|
61942133|NCT02891694||control patients (refractive surgery)|
61942134|NCT02744703|ACTIVE_COMPARATOR|self-etch adhesive|application of self-etch adhesive on cavities.
61942135|NCT02744703|EXPERIMENTAL|CAPE-S|CAPE before self-etch adhesive
62696065|NCT03537508|EXPERIMENTAL|Group 1b|MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age
62696066|NCT03537508|ACTIVE_COMPARATOR|Group 2a|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
62696067|NCT03537508|ACTIVE_COMPARATOR|Group 2b|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
62696068|NCT05071326|EXPERIMENTAL|HealthyLifetime Group|This project is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making.
61942136|NCT02744703|ACTIVE_COMPARATOR|total-etch adhesive|total-etch adhesive on cavities.
61942137|NCT02744703|EXPERIMENTAL|CAPE-T|CAPE before total-etch adhesive application
62696069|NCT06641388|EXPERIMENTAL|Ebronucimab 150mg (after the change)|Ebronucimab 150mg Single subcutaneous injection into the abdomen.
61942138|NCT01297075|EXPERIMENTAL|Outreach visits|Practices allocated to outreach visits may receive up to three outreach visits in order to motivate and support general practice clinics in implementing two chronic care programmes for chronic obstructive Pulmonary disease and Type 2 diabetes.
61942139|NCT01297075|NO_INTERVENTION|Control (late intervention)|These practices are allocated to outreach visits after the initial evaluation stops at 12 months.
61942140|NCT04212871|EXPERIMENTAL|watch mukbang|"In the online study, participants were assigned to watch a ramen mukbang, by Yuka Kinoshita (https://youtu.be/ArPaid2Iuck, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a hotpot mukbang by Alun (https://youtu.be/QCTOo9UGZD8, accessed: 2018-11-29)."
61942141|NCT04212871|EXPERIMENTAL|watch another food content video|"In the online study, participants were assigned to watch a donut mukbang, by Yuka Kinoshita (https://youtu.be/ntMT2y0MgHk, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a hotpot cooking show by the Cat's kitchen (https://youtu.be/EH5Ei-sMP60, accessed: 2018-11-29)."
61942142|NCT04212871|PLACEBO_COMPARATOR|watch a non-food content video|"In the online study, participants were assigned to watch a silent documentary introducing the Palace Museum by China Central Television (CCTV) (https://youtu.be/hWnm1BQOTZY, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a video introducing Cornell University is used for the non-food content video (https://youtu.be/GuM8vTq0jd4, accessed: 2018-11-29)."
61942143|NCT04525352|EXPERIMENTAL|Experimental - RP-L401|RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene
61942144|NCT00820352|ACTIVE_COMPARATOR|bosentan|Patients in this arm receive bosentan twice a day for 12 weeks
61942145|NCT00820352|PLACEBO_COMPARATOR|placebo|patients in this arm receive 12 placebo twice a day for 12 weeks
61942146|NCT05758571|EXPERIMENTAL|EGCG（Epigallocatechin-3-gallate ）|Epigallocatechin-3-gallate (EGCG) (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day. From the beginning of the diagnosis and 7 days after the signing of the informed consent form, the medication can be continued according to the wishes of the patients, but the total medication time is not more than 14 days.
62138300|NCT00976651|EXPERIMENTAL|human chorionic gonadotropin|"Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.~Histology and gene expression is studied on the endometrium"
62138301|NCT03809949|ACTIVE_COMPARATOR|Fentanyl Opioid Anesthesia|Fentanyl (1mg/kg i.v.) will be administered before general anaesthesia (GA). GA will be maintained with inhalation anaesthetics (isoflurane) at a minimum alveolar concentration of 0.7-1.3.
62138302|NCT03809949|PLACEBO_COMPARATOR|Saline Nonopioid Anesthesia|Opioid free anesthesia (syringe of saline is given instead of fentanyl) and the same general anesthesia is given as group A(muscle relaxant ,propofol, inhalation for maintance).
62138303|NCT02246946|EXPERIMENTAL|Positive Airway Pressure group|The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
62138304|NCT02246946|ACTIVE_COMPARATOR|Conventional Chest Physiotherapy group|"In the sitting position, the patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and positive airway pressure breathing with 4 mmHg via a rubber facial mask for 5 minutes in a sitting position. These patients will also walk for 100 meters.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the equipment in the room and mark the patient's skin."
62138305|NCT02246946|PLACEBO_COMPARATOR|Control group|"The patients allocated to this group will receive positive airway pressure breathing with 4 mmHg (without therapeutic value) via a rubber facial mask for 30 minutes in a sitting position.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the complete kit of equipment in the room."
61942147|NCT05931640|EXPERIMENTAL|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
62138306|NCT04976348||Consenting participants|All subjects aged ≥16 years referred to the cardiology or genetic department for heart failure like symptoms (as stated in the ESC 2016 Guidelines) or for cardiac/cardiogenetic screening.
62138307|NCT02526576|EXPERIMENTAL|Stromal Vascular Fraction|Subjects will receive stromal vascular fraction assisted fat transfer.
62696070|NCT06641388|EXPERIMENTAL|Ebronucimab 150mg (before the change)|Ebronucimab 150mg Single subcutaneous injection into the abdomen.
62696071|NCT04175015|EXPERIMENTAL|Experimental|Participants will be randomised to eat an orange coloured smartie©
62696072|NCT04175015|ACTIVE_COMPARATOR|Control Group|Participants will be randomised to eat a pink coloured smartie ©
62696073|NCT03452345|EXPERIMENTAL|MEDITOXIN|
62696074|NCT03452345|PLACEBO_COMPARATOR|Placebo|
62696075|NCT01809769|EXPERIMENTAL|Mesenchymal stem cells low-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
61942148|NCT05931640|EXPERIMENTAL|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
62696076|NCT01809769|EXPERIMENTAL|Mesenchymal stem cells mid-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
62138308|NCT02526576|ACTIVE_COMPARATOR|Biopsy for Control -regular fat transfer|Subjects will receive regular fat transfer. A biopsy procedure will analyzes the different between experimental and control groups.
62138309|NCT06406114|EXPERIMENTAL|Similar cephalosporin first|In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a similar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a dissimilar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms.
62337637|NCT05528224|ACTIVE_COMPARATOR|conventional medical treatment (TAU)|"In the main study, OCD patients will be treated as usual. Namely, they will continue with the medications they already have.~This group is not present in the pilot study, as both SC-ICBT group and CBGT group combines medications. We suppose that the mere use of SC-ICBT group compared to CBGT group (a commonly used psychotherapy in Chinese clinical practice) is sufficient to draw conclusions about the feasibility of SC-ICBT in in adults with OCD in China.~However, in order to further validate the economic benefits of SC-ICBT, we chose to set TAU group in the main study."
62337638|NCT01665755|EXPERIMENTAL|Precompression|Control arm
62337639|NCT01665755|ACTIVE_COMPARATOR|Upstroke Compression|Intervention arm
62337640|NCT03813745||early denudation|Cumulus-oocyte complexes will be denudated in 30 min after oocyte retrieval
62337641|NCT03813745||late denudation|Denudation will be done 2 hr after oocyte retrieval
62337642|NCT02315287|ACTIVE_COMPARATOR|Metformin, Sitagliptin, Pioglitazone|Thiazolidinedione
62337643|NCT02315287|ACTIVE_COMPARATOR|Metformin, Sitagliptin, Lobeglitazone|Thiazolidinedione
62337644|NCT00679679|EXPERIMENTAL|Metformin|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
62337645|NCT00679679|PLACEBO_COMPARATOR|Placebo|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
62337646|NCT04898738|ACTIVE_COMPARATOR|Alcohol-based hand sanitizer|Half the study households with receive ABHS through the course of the study
62337647|NCT04898738|NO_INTERVENTION|No Alcohol-based hand sanitizer|Half the study households with not receive ABHS through the course of the study
62337648|NCT02792322|OTHER|Trans Oral Robotic Surgery (TORS)|Patient's are having TORS surgery in a seated position
62494557|NCT01274962|EXPERIMENTAL|Arm B - adjuvant chemotherapy|Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
62494558|NCT05428696|EXPERIMENTAL|SAD - Cohort 1|Eight participants will receive a single dose of Dose Amount 1 of ALXN2080, and 2 participants will receive placebo.
62696077|NCT01809769|EXPERIMENTAL|Mesenchymal stem cells high-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
62696078|NCT06176586|EXPERIMENTAL|Exercise Group|Progressive mat Pilates exercises will be administered to by a physiotherapist in addition to the routine medical treatment.
62337649|NCT02947516|ACTIVE_COMPARATOR|Percutaneous liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol.
62337650|NCT02947516|EXPERIMENTAL|EUS-guided liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication.
62337651|NCT04817072|OTHER|Chronic inflammatory rheumatic disease|Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19
62138310|NCT06406114|EXPERIMENTAL|Dissimilar cephalosporin first|In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a dissimilar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a similar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms.
62138311|NCT06436326|OTHER|Controlled group-Blood glucose meters (BGM) group|"The participants will receive structured questionnaires and blood tests (glycated albumin, fasting plasma glucose, insulin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein) at 24-32 weeks of pregnancy, 35 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants."
62138312|NCT06436326|EXPERIMENTAL|Experimental group1-Continuous glucose monitoring (CGM) group|"The participants will receive structured questionnaires and blood tests (glycated albumin, fasting plasma glucose, insulin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein) at 24-32 weeks of pregnancy, 35 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants will receive a set of continuous glucose monitor (CGM) respectively at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set)."
62337652|NCT02290054|SHAM_COMPARATOR|Control|A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
62138313|NCT06436326|EXPERIMENTAL|Experimental group2-Continuous glucose monitoring (CGM) with nursing care group|"The participants will receive structured questionnaires and blood tests (glycated albumin, fasting plasma glucose, insulin, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein) at 24-32 weeks of pregnancy, 35 weeks of pregnancy to before delivery, and 4-12 weeks postpartum, respectively.~Participants will receive a set of continuous glucose monitor (CGM) respectively at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set).~Participants will receive perinatal nursing care for gestational diabetes."
62337653|NCT02290054|EXPERIMENTAL|Treated|"A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Auriculotherapy is performed while the patient is sleeping but before thoracic incision.~Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles."
62337654|NCT02975440|EXPERIMENTAL|Treatment|Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days
62138314|NCT03817970|EXPERIMENTAL|Granisetron|Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
62138315|NCT03817970|EXPERIMENTAL|Ondansetron|Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
62138316|NCT03817970|EXPERIMENTAL|Palonosetron|Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
62337655|NCT00122356|OTHER|Anastrozole and alendronate|Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
62337656|NCT04767633|ACTIVE_COMPARATOR|group A (PMC standard-dose)|Group A (PMC standard-dose): patients will receive two oral doses of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 17:00 and 4 hours later in the evening prior to the colonoscopy (¼ sachet for children \< 6 years, ½ sachet for children 6-12 years, and one sachet for children \>12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
62494559|NCT05428696|EXPERIMENTAL|SAD - Cohort 2|Eight participants will receive a single dose of Dose Amount 2 of ALXN2080, and 2 participants will receive placebo.
62494560|NCT05428696|EXPERIMENTAL|SAD - Cohort 3|Eight participants will receive a single dose of Dose Amount 3 of ALXN2080, and 2 participants will receive placebo.
62494561|NCT05428696|EXPERIMENTAL|SAD - Cohort 4|Eight participants will receive a single dose of Dose Amount 4 of ALXN2080, and 2 participants will receive placebo.
62494562|NCT05428696|EXPERIMENTAL|SAD - Cohort 5|Eight participants will receive a single dose of Dose Amount 5 of ALXN2080, and 2 participants will receive placebo.
61942149|NCT03901651|ACTIVE_COMPARATOR|Standard colonoscopy|"Patients submitted for screening, surveillance or diagnostic colonoscopy. A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location. Polyps will be removed before the second procedure."
61942150|NCT03901651|EXPERIMENTAL|Retroview colonoscopy|"The same group of patients. A second colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the first colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
61942151|NCT01973569|EXPERIMENTAL|Denosumab 6 months|denosumab administered subcutaneously every 6 months
62138317|NCT03069859|EXPERIMENTAL|TXA (1g)|For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site
62494563|NCT05428696|EXPERIMENTAL|SAD - Cohort 6|Eight participants will receive a single dose of Dose Amount 6 of ALXN2080, and 2 participants will receive placebo.
62337657|NCT04767633|ACTIVE_COMPARATOR|Group B (PMC split-dose)|Group B (PMC split-dose): patients will receive the first oral doses of PMC diluted in 150 ml of water (Picoprep; Ferring Italia, Milan, Italy) at 19:00 of the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy (¼ sachet for children \< 6 years, ½ sachet for children 6-12 years, and one sachet for children \>12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
62494564|NCT05428696|EXPERIMENTAL|MAD - Cohort 1|Eight participants will receive multiple doses of Dose Amount A of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.
62494565|NCT05428696|EXPERIMENTAL|MAD - Cohort 2|Eight participants will receive multiple doses of Dose Amount B of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.
62494566|NCT05428696|EXPERIMENTAL|MAD - Cohort 3|Eight participants will receive multiple doses of Dose Amount C of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.
62494567|NCT05428696|EXPERIMENTAL|MAD - Cohort 4|Eight participants will receive multiple doses of Dose Amount D of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.
62494568|NCT04552405|OTHER|FAP patients|FAP patients who underwent prophylactic total colectomy
62494569|NCT04197908|EXPERIMENTAL|EUS-guided gallbladder drainage (EGBD)|The procedure would be performed with a linear echoendoscope using a 10mm x 10mm or a 15 x 10mm stent. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder would be completely emptied by suction and irrigation until the effluent through the stent is clean.
62494570|NCT05737160|EXPERIMENTAL|Telitacicept|Participants will receive subcutaneous Telitacicept 240 mg once a week for a total of 48 doses in addition to MG SoC.
62138318|NCT03069859|PLACEBO_COMPARATOR|Placebo (0.9% saline)|For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site
62138319|NCT00944593|EXPERIMENTAL|300kcal liquid Nutrient|300kcal liquid nutrient delivered by NJ tube over 60 minutes before ingestion of a standard oral liquid nutrient test meal
62138320|NCT00944593|PLACEBO_COMPARATOR|Normal Saline|Normal Saline delivered via NJ tube over 60 minutes ahead of a standard liquid nutrient test meal
62337658|NCT02887833||XRT for Cancer induced bone pain|Will have community based assessment before and after radiotherapy to assess feasibility of using a clinical biomarker (thermal sensory testing) to predict treatment response
62337659|NCT04873024|EXPERIMENTAL|Intervention-first|Participants in this arm will receive the Intervention treatment on the first night, and the control treatment on the second night.
62337660|NCT04873024|EXPERIMENTAL|Control-first|Participants in this arm will receive the Control treatment on the first night, and the Intervention treatment on the second night.
62494571|NCT05737160|PLACEBO_COMPARATOR|Placebo|Participants will receive subcutaneous placebo once a week for a total of 24 doses (part A) and then weekly subcutaneous Telitacicept 240 mg for 24 doses (part B) in addition to MG SoC.
62494572|NCT02538549|ACTIVE_COMPARATOR|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
62494573|NCT02538549|NO_INTERVENTION|TAU Only|This group will receive only the treatment as usual.
62494574|NCT06559956||Overnight titration polysomnography cohort|A cohort of OSA patients treated with HNS that previously underwent an overnight titration PSG as part of the routine clinical care pathway
62494575|NCT06559956||Daytime titration polysomnography cohort|OSA patients treated with HNS that recently underwent or will be undergoing the newly introduced titration method, which is a daytime titration PSG.
62494576|NCT00105157|EXPERIMENTAL|1|MK0518 200 mg
62494577|NCT00105157|EXPERIMENTAL|2|MK0518 400 mg
62494578|NCT00105157|EXPERIMENTAL|3|MK0518 600 mg
62494579|NCT00105157|PLACEBO_COMPARATOR|4|Placebo
62494580|NCT02448563|EXPERIMENTAL|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
62494581|NCT02448563|NO_INTERVENTION|Control|Standard of care - one counseling visit with a study dietitian
62494582|NCT00421837||controls|household and other close contacts
62494583|NCT00421837||cases|elderly (\>55) subjects hospitalized with Influenza
62696079|NCT06176586|NO_INTERVENTION|Control Group|Patients in control group will not receive any exercise intervention. They will continue to their routine medical treatment.
61942152|NCT01973569|EXPERIMENTAL|Denosumab 3 months|denosumab administered subcutaneously every 3 months
62138321|NCT04779216|EXPERIMENTAL|Active Romosozumab 210mg Injection|Romosozumab 210mg injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
62138322|NCT04779216|PLACEBO_COMPARATOR|Placebo|Placebo injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
62138323|NCT06647511||Pregnant Refugees|Participants will complete validated questionnaires, regular blood pressure measurements, pain and trauma assessments, and clinical monitoring during this study.
62138324|NCT03394105|EXPERIMENTAL|intrapleural docetaxel administration|Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
62494584|NCT06390813|EXPERIMENTAL|Square Stepping Exercise|It is performed on a thin exercise mat divided into 40 small squares of 250 cm x 100 cm. Individuals are basically required to step in the direction of the length without stepping on the lines forming the squares. Before the CAE training, there will be a 5 minutes warm-up and then a minute cool down period. A total of 18 stepping patterns are planned to be used (6 beginner, 6 intermediate, 6 advanced). Basically, a pattern will be repeated 3-5 times and then the mirror image pattern will be repeated the same number of times. However, if the participant has difficulty in practicing the pattern, it will be repeated until he/she learns it, and after practicing the pattern 3 times without any errors, the next pattern will be used.
62494585|NCT06390813|EXPERIMENTAL|Otago Exercise Training|The exercises were performed 3 days a week for 6 weeks and 18 sessions of 60 minutes in total, including warm-up and cool-down periods of 5 minutes each session. It consists of a total of 22 exercises, including 5 warm-up movements, 5 strengthening exercises and 12 balance exercises.
62494586|NCT02346435||Active Surveillance|
62494587|NCT02346435||Immediate Intervention|May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.
62138325|NCT06514794|EXPERIMENTAL|WU-CART-007|"A CD7-directed chimeric antigen receptor (CAR) T-cell product.~A single IV infusion of WU-CART-007 Cells on Day 1 after Lymphodepletion(LD) Therapy."
62138326|NCT05357911|EXPERIMENTAL|digoxin cohort|
62138327|NCT05225753||patients treated with Affixus Zimmer-Biomet|
62138328|NCT05225753||patients treated with EBA2 Citieffe|
62138329|NCT05225753||patients treated with Proximal Femoral Nail Antirotation Synthes|
62138330|NCT06457971|EXPERIMENTAL|Robotic Ventral Hernia|Subjects undergoing robotic ventral hernia with the Anovo Surgical System.
62138331|NCT05444075||subjects with preparatory education level|Ten subjects have a preparatory education level
62337661|NCT02004912|EXPERIMENTAL|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
61942153|NCT01973569|PLACEBO_COMPARATOR|placebo|placebo administered subcutaneously to match denosumab
62138332|NCT05444075||subjects with high school education|ten subjects with a high school education or its equivalent
62138333|NCT05444075||subjects with university education|ten subjects who have a university education, or are still in a university education stage
62138334|NCT05529420||Pediatric patients rocuronium|In pediatric patients undergoing a planned general anesthesia with non-depolarizing muscle relaxants, induction of anesthesia will involve either standard intravenous (an opioid, anesthetic, muscle relaxant) or inhalational agents according to the preference of the anesthesiologist.
62138335|NCT01401231|EXPERIMENTAL|Behavioral Activation|Behavioral activation psychotherapy
62337662|NCT02004912|NO_INTERVENTION|No mentoring intervention|The no mentoring intervention arm does not have supportive visits and education to health center staff by nurse mentors.
62337663|NCT05212155|OTHER|Participating families|Parent/child dyads enrolled in the open-label program
62337664|NCT01602926|EXPERIMENTAL|conventional surgery arm|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
62337665|NCT01602926|EXPERIMENTAL|minimally invasive technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal
62337666|NCT00216099|EXPERIMENTAL|Investigational Treatment|"* Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle~* Oral Folic Acid, once per day for 7 days preceding pemetrexed dose, continued daily, and for 21 days after the last dose of pemetrexed.~* Vitamin B12, 1000ug intramuscular injection 7 days preceding pemetrexed dose, and every three cycles thereafter on the same day of pemetrexed administration"
62337667|NCT02864537|NO_INTERVENTION|Conventional treatment|Conventional anticoagulation treatment Before enrolment
62337668|NCT02864537|EXPERIMENTAL|Self-management|Trained to monitor INR and dose warfarin
62337669|NCT06268392||Expert sonographer|Expert sonographers ultrasound examination.
62337670|NCT06268392||Control Group (CG)|Control group ultrasound examination with no AI support.
62337671|NCT06268392||Feedback group 1 (FG1)|Feedback group 1 ultrasound examination with basic black box AI support.
62337672|NCT06268392||Feedback group 2 (FG2)|Feedback group 2 ultrasound examination with detailed explainable AI support.
62494588|NCT02346435||Crossover (Delayed Intervention)|Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.
62494589|NCT01939106|OTHER|One Piece Drainable Pouch|This is a one piece drainable pouch designed for the purpose of collecting stool from subjects with an ileostomy stoma
62138336|NCT01401231|PLACEBO_COMPARATOR|Usual Care|Continued care as usual
62138337|NCT04197622|EXPERIMENTAL|Hydrochlorothiazide|Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).
62138338|NCT00943917|EXPERIMENTAL|ITCA 650 20 mcg/day|
62138339|NCT00943917|EXPERIMENTAL|ITCA 650 40 mcg/day|
62138340|NCT00943917|ACTIVE_COMPARATOR|Exenatide Injection|
62138341|NCT00943917|EXPERIMENTAL|ITCA 650 20/20|
62138342|NCT00943917|EXPERIMENTAL|ITCA 650 20/60|
62138343|NCT00943917|EXPERIMENTAL|ITCA 650 40/40|
62138344|NCT00943917|EXPERIMENTAL|ITCA 650 40/80|
62138345|NCT00943917|EXPERIMENTAL|Ex Inj/ITCA 650 40|
62138346|NCT00943917|EXPERIMENTAL|Ex Inj/ITCA 650 60|
62138347|NCT03692065|ACTIVE_COMPARATOR|Apixaban film coated tablets 2.5 mg|Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.
62138348|NCT03692065|ACTIVE_COMPARATOR|Apixaban film coated tablets 5 mg|Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.
62337673|NCT02812433|ACTIVE_COMPARATOR|Sildenafil|Sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
62337674|NCT02812433|PLACEBO_COMPARATOR|Ora-Blend|Ora-Blend 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
62337675|NCT05428800|EXPERIMENTAL|Experimental|Progressive relaxation exercises will be performed for 25-30 minutes every day for 8 weeks, and at the end of 8 weeks, the group will be evaluated again with PMSS.
62337676|NCT05428800|NO_INTERVENTION|Control|They will continue their routine coping habits for 8 weeks, and at the end of 8 weeks, the group will be evaluated again with PMSS.
62337677|NCT00903032|EXPERIMENTAL|Arm 1|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
62337678|NCT00903032|ACTIVE_COMPARATOR|Arm 2|Patients will receive usual care following ACS hospital discharge
62494590|NCT02901730|EXPERIMENTAL|532nm laser group|LPI with 532nm laser.
62494591|NCT02901730|EXPERIMENTAL|561nm laser group|LPI with 561nm laser.
62138349|NCT02605850|PLACEBO_COMPARATOR|Ground beef patty + Water|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
62138350|NCT02605850|ACTIVE_COMPARATOR|Ground beef patty + Pomegranate Extract|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
62138351|NCT02605850|ACTIVE_COMPARATOR|Ground beef patty + Pomegranate Juice|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
62337679|NCT04489485||Primary Care Providers (PCP)|20 PCP who provide well child care to teens 12-18. After randomization, 10 PCPs in the enhanced care group will use the Teen Depression Module for care.
62337680|NCT04489485||Standard care teens|All teens coming for routine well child care to the control group PCPs will have routine depression screening and Youth Health Questionnaire without goals to inform treatment as usual. They will be offered a goals text messaging conversation. Suicide screening will be at the discretion of the PCP.
62138352|NCT04243915|EXPERIMENTAL|PNMES plus exercise|6-week intervention program with 3 treatment sessions of PNMES and motor control exercise program.
62138353|NCT04243915|SHAM_COMPARATOR|Sham PNMES (introducing the needle) plus exercise|Sham PNMES (introducing the needle) plus motor control exercise program
62138354|NCT04243915|ACTIVE_COMPARATOR|TENS plus exercise|6-week intervention program with 3 treatment sessions of TENS plus motor control exercise program.
62138355|NCT04243915|PLACEBO_COMPARATOR|Placebo PNMES (without inserting the needle) plus exercise|6-week intervention program with 3 treatment sessions of placebo PNMES (without inserting the needle) and exercise
62138356|NCT03745170|EXPERIMENTAL|Sintilimab+ Oxaliplatin +capecitabine|
62138357|NCT03745170|ACTIVE_COMPARATOR|placebo +Oxaliplatin + Capecitabine|
62138358|NCT01215747|EXPERIMENTAL|Kiacta (eprodisate disodium)|
62138359|NCT01215747|PLACEBO_COMPARATOR|Placebo|
62138360|NCT06517641|ACTIVE_COMPARATOR|Haploidentical transplantation|Patients receiving bone marrow transplanted from a haploidentical related donor will be included in this arm.
62138361|NCT06517641|ACTIVE_COMPARATOR|Unrelated donor transplantation|Patients receiving bone marrow transplanted from an unrelated donor will be included in this arm.
62138362|NCT05502094||Group 1|Participants who experienced Post-Covid 19 syndrome were involved in this group.
62138363|NCT05502094||Group 2|Participants who fully recovered after Covid-19 were involved in this group.
62138364|NCT05502094||Group 3|Participants who had never had Covid-19 were involved in this group.
62337681|NCT04489485||Enhanced care teens|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, as well as Youth Health Questionnaire with goals and then they will receive treatment guided by the Teen Depression Module and offered a depression text messaging conversation. Suicide screening will be conducted.
62138365|NCT05454475||Low temperature group|The temperature is 6℃-10℃.
62337682|NCT04489485||Standard care- caregivers|All caregivers of teens \<18 years old coming for routine well child care to the control group PCPs will complete a Pediatric Symptom Checklist and Short Moods and Feelings Questionnaire, plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
62494592|NCT03515473||CI532|Patients with CI532 cochlear implant
62494593|NCT03515473||CI522|Patients with CI522 cochlear implant
62494594|NCT03515473||CI512|Patients with CI512 cochlear implant
62138366|NCT05454475||room temperature group|The temperature is 20℃-24℃.
62696080|NCT06001749|EXPERIMENTAL|Psilocybin|"Participants will complete study procedures as follows:~* 2, in-clinic or remote, preparation sessions with therapists.~* In-clinic treatment session with therapists at Dana-Farber Cancer Institute. Participants will take a predetermined amount of psilocybin once. Participants will be transported home by a friend or family member.~* In-clinic integration session the day after psilocybin administration with therapists.~* In-clinic or remote, integration session with therapists 1 week after psilocybin administration.~* In-clinic or remote follow visits with therapists at week 2, 3, 5, 8, and 12 after psilocybin administration."
62138367|NCT05454475||Core temperature group|The temperature is 35℃-39℃.
62138368|NCT02697305|EXPERIMENTAL|IV BCAA test|IV application of BCAA solution
62138369|NCT02697305|EXPERIMENTAL|ORAL BCAA test|At once oral ingestion of BCAA capsules
62138370|NCT02697305|PLACEBO_COMPARATOR|ORAL PLACEBO test|At once oral ingestion of placebo capsules
62138371|NCT06307743|OTHER|RL-IPostC 30|The RL-IPostC 30 protocol involved 5 cycles of blow block and restoration, each for 30 seconds.
62138372|NCT06307743|OTHER|RL-IPostC 60|The RL-IPostC 60 protocol involved 5 cycles of blow block and restoration, each for 60 seconds.
62138373|NCT06307743|OTHER|RL-IPostC 180|The RL-IPostC 180 protocol involved 5 cycles of blow block and restoration, each for 180 seconds.
62138374|NCT05856552|EXPERIMENTAL|CBT home visits|Community resource persons will visit the elderly women once per week to deliver cognitive behavioral therapy for six weeks, followed by 3 monthly boosters.
62138375|NCT05856552|EXPERIMENTAL|CBT home visits and group activities|Community resource persons will visit the elderly women once per week to deliver cognitive behavioral therapy for six weeks, followed by 3 monthly boosters. The elderly women will also be invited to join weekly hour-long group activities for 12 weeks. Group activities will be administered by community resource persons in community spaces. A GA volunteer will be recruited by the community resource person during the intervention and trained to continue weekly meetings with elders after the intervention ends. The community resource person will attend at least 2 sessions per month for 3 months to share feedback.
62138376|NCT05856552|NO_INTERVENTION|Control|Control group
62138377|NCT05856552|EXPERIMENTAL|Group activities|The elderly women will be invited to join weekly hour-long group activities for 12 weeks. Group activities will be administered by community resource persons in community spaces. A GA volunteer will be recruited by the community resource person during the intervention and trained to continue weekly meetings with elders after the intervention ends. The community resource person will attend at least 2 sessions per month for 3 months to share feedback.
62138378|NCT06426966|EXPERIMENTAL|Gymnema sylvestre|Patients who present Obesity administrated with Gymnema sylvestre. At a dose of two 200 mg capsules before breakfast
62138379|NCT06426966|EXPERIMENTAL|Berberine|Patients who present Obesity administrated with Berberine 500 mg tablet three times a day before each meal
62138380|NCT02069613||Mild traumatic brain injury (mTBI)|Patients admitted to Huntington Memorial Hospital (HMH), Pasadena CA, Emergency Department (ED) diagnosed with mTBI by history (alteration of consciousness, post-traumatic amnesia, loss of consciousness) and normal brain computed tomography (CT).
62337683|NCT04489485||Enhanced care- caregivers|All caregivers of teens \<18 years old coming for routine well child care to the enhanced group PCPs will complete a Pediatric Symptom Checklist plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
62337684|NCT04425772|EXPERIMENTAL|Experimental Group|FNC+Standard of Care
62337685|NCT04425772|PLACEBO_COMPARATOR|Control Group|FNC dummy tablet+ Standard of Care
62337686|NCT02456870|OTHER|MA|Middle-aged overweight and obese men (age 25-40yr)
62337687|NCT02456870|OTHER|OA|Older overweight and obese men (age 55-75yr)
62337688|NCT00204425|EXPERIMENTAL|1|exercise/soy isoflavone
62337689|NCT00204425|EXPERIMENTAL|2|exercise/isoflavone placebo
62696081|NCT03917615|EXPERIMENTAL|"after women health course"|The participants will be instructed to contract the pelvic floor muscle
62138381|NCT02069613||Control|Patients admitted to HMH ED for minor extremity trauma (sprains) and no evidence of mTBI
62138382|NCT02220452|EXPERIMENTAL|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
62138383|NCT02220452|ACTIVE_COMPARATOR|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
62138384|NCT06497374|EXPERIMENTAL|Efgartigimod+IVMP group|Patients will receive efgartigimod alpha via intravenous infusion at a dose of 10 mg/kg, each infusion lasting approximately 2 hours, on Week 0, 1, 2 and 3. Efgartigimod should be administered no later than the second day after initiation of high-dose intravenous methylprednisolone therapy. This is delivered intravenously at a dosage of 1,000 mg/day for five consecutive days, which is then reduced to 500 mg/day for the next three days, followed by 240 mg/day for another three days, and then 120 mg/day for an additional three days. Subsequently, the treatment shifts to oral prednisone, starting with 60 mg daily for seven days, then decreasing to 50 mg daily for the next seven days, followed by 40 mg daily for another seven days. Afterward, the prednisone dosage is reduced by 5 mg every two weeks until it reaches 10 mg. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.
61942154|NCT01837407|OTHER|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
61942155|NCT02773290|EXPERIMENTAL|Romiplostim|Weekly Subcutaneous (SC) administration
62494595|NCT03045016|EXPERIMENTAL|Prazosin, ALPRESS® LP 2,5 et 5 mg|Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
62494596|NCT02745600|OTHER|Software assisted RFA treatment|Non-controlled, prospective, multicenter study arm, to evaluate RFA therapy simulation software.
61942156|NCT00562471|EXPERIMENTAL|1|Adhesion Prevention Gel Arm
61942157|NCT00562471|OTHER|2|Standard of Care Comparator Arm (standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure)
62337690|NCT00204425|EXPERIMENTAL|3|exercise placebo/soy isoflavone
62337691|NCT00204425|PLACEBO_COMPARATOR|4|exercise placebo/isoflavone placebo
62337692|NCT01002261||Liver cirrhosis / healthy subjects|10 patients with liver cirrhosis and 10 sex and age-matched healthy subjects
62494597|NCT01199653|ACTIVE_COMPARATOR|Non-operative treatment|Non-operative (conservative) treatment of the clavicle fracture
62138385|NCT06497374|EXPERIMENTAL|IVMP group|Patients will be treated with injectable methylprednisolone sodium succinate as described in Arm A. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.
62494598|NCT01199653|ACTIVE_COMPARATOR|Operative treatment|Operative stabilization (i.e. ORIF) of the fracture with a plate and screws.
62494599|NCT06357741||desumumab1|60mg, single injection.
62494600|NCT06357741||desumumab2|60mg, single injection.
61942158|NCT00302107|ACTIVE_COMPARATOR|Arm 1|Mirtazapine
61942159|NCT00302107|PLACEBO_COMPARATOR|Arm 2|Placebo
61942160|NCT02173938||Treatment seekers|
61942161|NCT02842307|ACTIVE_COMPARATOR|A(senior acupuncturists)|Manual acupuncture implemented by senior acupuncturists (clinical experience \>15 years)
61942162|NCT02842307|ACTIVE_COMPARATOR|B(junior acupuncturists)|Manual acupuncture implemented by junior acupuncturists (clinical experience \<5 years)
62138386|NCT06497374|OTHER|Efgartigimod group|Patients will be treated with efgartigimod alpha injection via intravenous infusion at a dosage of 10 mg/kg, with each session lasting approximately 2 hours, on Week 0, 1, 2 and 3. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.
62138387|NCT02894099|EXPERIMENTAL|Prolonged Sitting Time (PST)|Uninterrupted sitting time of 5 hours
62138388|NCT02894099|EXPERIMENTAL|PST+Light intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of light physical activity
62337693|NCT01002261||Liver cirrhosis and healthy subjects|Patients with liver cirrhosis and healthy subjects
62337694|NCT03902743|EXPERIMENTAL|Intervention group|Participants will receive an Anticipatory Care Plan
62337695|NCT03902743|NO_INTERVENTION|Control group|Usual care
62337696|NCT03545698|ACTIVE_COMPARATOR|Telehealth Intervention|
62494601|NCT06357741||desumumab 3|60mg, single injection.
62494602|NCT06357741||desumumab4|60mg, single injection.
62494603|NCT06357741||desumumab5|60mg, single injection.
62494604|NCT06357741||desumumab 6|60mg, single injection.
62494605|NCT06357741||desumumab7|60mg, single injection.
62494606|NCT06357741||desumumab 8|60mg, single injection.
62494607|NCT04541264||Model reconstruction cohort|160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group.
61942163|NCT02842307|ACTIVE_COMPARATOR|C(P6 points)|Manual acupuncture on P6 points by junior acupuncturists (clinical experience \<5 years)
61942164|NCT02842307|NO_INTERVENTION|D(no acupuncture)|No acupuncture treatment
62138389|NCT02894099|EXPERIMENTAL|PST+Moderate intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of moderate physical activity
62138390|NCT02894099|EXPERIMENTAL|PST+Moderate intensity Long bouts PA|Sitting prolonged interrupted with breaks of 10 minutes of moderate physical activity
62138391|NCT02877641|ACTIVE_COMPARATOR|Control arm (multivitamin, placebo)|Patients receive a placebo and multivitamin orally each day for 52 weeks.
62337697|NCT03545698|NO_INTERVENTION|Non-Telehealth Intervention|
62494608|NCT04541264||Internal validation cohort|40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group.
62494609|NCT04541264||External validation cohort|100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group.
62494610|NCT03242746||Control group|"1. The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.~2. a 3-years follow-up for pregnancy outcome~3. Transvaginal ultrasound for pretreatment cervical dimensions/volume"
62494611|NCT03242746||LEEP group|"1. The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.~2. a 3-years follow-up for pregnancy outcome~3. Transvaginal ultrasound for pretreatment cervical dimensions/volume~4. Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit~5. Estimation of cone dimensions/volume~6. Calculation of the proportion of volume/length excised"
62494612|NCT04008680|OTHER|Low response burden|Participants will be assigned to complete only the EQ-5D-5L questionnaire.
62494613|NCT04008680|OTHER|Low to medium response burden|Participants will be assigned to complete the General Anxiety Disorder-7 (GAD-7) questionnaire first, followed by the EQ-5D-5L questionnaire.
61942165|NCT05119673|NO_INTERVENTION|mono-plane sonographic view|Usual standard of care, in our institution, for difficult peripheral vascular access in the Emergency Department.
61942166|NCT05119673|ACTIVE_COMPARATOR|bi-plane sonographic view|
61942167|NCT00854542|ACTIVE_COMPARATOR|TCSCT|
62138392|NCT02877641|EXPERIMENTAL|Supplementation arm (multivitamin, cholecalciferol)|Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.
62138393|NCT06315985|EXPERIMENTAL|Experimental Group|This was a parallel group, randomized controlled trial. Experimental Group will listen to the music for three days.
62138394|NCT06315985|NO_INTERVENTION|Control Group|Control Group will take routine care
62138395|NCT02523170|EXPERIMENTAL|EUS guided nCLE|For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
62138396|NCT01872494|EXPERIMENTAL|Local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
62494614|NCT04008680|OTHER|Medium to high response burden|Participants will be assigned to complete the Pain Catastrophizing Scale (PCS) questionnaire first, followed by the GAD-7, and lastly the EQ-5D-5L questionnaire.
62494615|NCT04008680|OTHER|High response burden|Participants will be assigned to complete the Brief Pain Inventory (BPI) questionnaire first, followed by the PCS secondly, the GAD-7 third, and lastly the EQ-5D-5L questionnaire.
62696082|NCT03917615|ACTIVE_COMPARATOR|"before women health course"|The participants will be instructed to contract the pelvic floor muscle
61942168|NCT00854542|PLACEBO_COMPARATOR|Usual Care|
61942169|NCT02127710|EXPERIMENTAL|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
62696083|NCT06160791|EXPERIMENTAL|Treatment (ruxolitinib, dexamethasone, etoposide)|During induction therapy, participants receive ruxolitinib orally (PO) twice daily (BID) plus de-intensified HLH-94 induction with dexamethasone PO or intravenously (IV) once daily (QD) or BID for 4 weeks and etoposide IV twice a week (BIW) for 2 weeks and then based on response, once a week (QW) for another 2 weeks in the absence of disease progression or unacceptable toxicity. After induction therapy, participants receive continuation therapy with ruxolitinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for a total of up to 6 months after first administration of study drug in the absence of disease progression or unacceptable toxicity.
62696084|NCT06638983|OTHER|Cephalometric radiographs and cast impressions were collected before and after intervention.|Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment.
62494616|NCT03732833|EXPERIMENTAL|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
62696085|NCT01394185|ACTIVE_COMPARATOR|Low Dose Dronabinol, High Dose Dronabinol, and placebo|Participants were administered dronabinol (0 mg/day, 120mg/day and 240mg/day) for 12 days each in a random order
62138397|NCT01872494|ACTIVE_COMPARATOR|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
62138398|NCT01362075|EXPERIMENTAL|Local infiltration analgesia|
62138399|NCT01362075|ACTIVE_COMPARATOR|Interscalene catheter|
62337698|NCT02867345||Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10\^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
62494617|NCT03732833|EXPERIMENTAL|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
62696086|NCT06115954|EXPERIMENTAL|Synchronous Telerehabilitation|"On the basis of telerehabilitation, before starting both synchronous and asynchronous exercise therapy, a comprehensive self-management program will be provided.~Self-management training will be shared online synchronously with the participants in this exercise group. The exercise program will consist of functional exercises focused on trunk stabilization, including warm-up and cool-down periods, 3 times a week for 12 weeks, and will be performed online by the physiotherapist. Exercise training will be completed with a 10-minute warm-up exercise followed by 40-minute trunk stabilization and functional exercises for the upper and lower extremities, followed by a 10-minute cooling-down program consisting of flexibility exercises. Progression in exercise training will be done by increasing the number of repetitions and adding elastic bands to the exercises."
61942170|NCT03901547|OTHER|Education and Documentation (Tier 1)|Education only. Participants who do not wish to enroll in the behavioral observation group are followed in the education only. This includes participation in a two week palliative medicine elective which is a part of the medical trainees training and training in the serious illness communication guide (SICG). Participants can opt out of the pre and post training confidence surveys, and simulated patient encounters. Electronic documentation of the SICG by these trainees will be monitored prospectively. Participants will be provided reminders and profile information on their own documentation rate of the SICG via email and have the ability to opt out of receiving emails if they wish.
62138400|NCT02458924|ACTIVE_COMPARATOR|Schizophrenia|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
62494618|NCT03732833|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
62494619|NCT02609191|EXPERIMENTAL|The study population: first 30 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR~Intervention: Second whole body exam using the Stratos DR"
62138401|NCT02458924|ACTIVE_COMPARATOR|Bipolar disorder|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
62138402|NCT02458924|ACTIVE_COMPARATOR|First degree relatives|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
62138403|NCT02458924|ACTIVE_COMPARATOR|Health controls|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
62494620|NCT02609191|EXPERIMENTAL|The study population: last 20 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR"
62494621|NCT05207605|EXPERIMENTAL|Rhythmic Stabilization (RS)|The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended
61942171|NCT03901547|OTHER|Priming and additional measures (Tier 2)|Education and behavioral observation cohort. These participants must sign an informed consent to participate in this part of the study. In addition to all of Tier 1 activities, participants also complete psychological inventories at three time points to measure emotion regulation and burnout, and participate in a semi-structured interview.
61942172|NCT03499548|EXPERIMENTAL|Intervention|10 hours of intensive CBT for suicide will be delivered to male prisoners who are having thoughts of ending their lives. This will be delivered in 2 hours sessions, 5 times across 2 weeks.
61942173|NCT00808561|ACTIVE_COMPARATOR|1 Alternative Fistula|
61942174|NCT00808561|ACTIVE_COMPARATOR|2 Forearm AV Graft|
61942175|NCT00257465|EXPERIMENTAL|A|'Autologous, DNP-modified vaccine (M-Vax)'
62138404|NCT03500549|EXPERIMENTAL|Pegcetacoplan|1080 mg pegcetacoplan administered subcutaneously twice-weekly or every three days.
61942176|NCT00257465|EXPERIMENTAL|B|Autologous, DNP-Modified Vaccine (MVax)
61942177|NCT00257465|EXPERIMENTAL|C|Autologous, DNP-Modified Vaccine (MVax)
61942178|NCT00257465|PLACEBO_COMPARATOR|D|0 cells
62138405|NCT03500549|ACTIVE_COMPARATOR|Eculizumab|Complement (C5) Inhibitor.
62138406|NCT01736475|EXPERIMENTAL|Prophylaxis|
62138407|NCT01736475|EXPERIMENTAL|On-demand|
62494622|NCT05207605|EXPERIMENTAL|McKenzie technique|McKenzie exercises will be guided to conduct four extension exercises and three flexion exercises.
62494623|NCT00048139|EXPERIMENTAL|1|
62494624|NCT04358367|ACTIVE_COMPARATOR|Dexmedetomidine|spinal anesthesia and intravenous dexmedetomidine(1µg/kg)
61942179|NCT00864721|EXPERIMENTAL|Sunitinib Malate|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
61942180|NCT05538871||Degenerative scoliosis|Diagnosis of degenerative (De novo) scoliosis,
61942181|NCT05538871||Adult idiopathic scoliosis|Diagnosis of idiopathic scoliosis,
61942182|NCT05538871||Degenerative scoliosis - matched controls|Population sample matched to the degenerative scoliosis group.
61942183|NCT05538871||Idiopathic scoliosis - matched controls|Population sample matched to the idiopathic scoliosis group.
61942184|NCT02020187|EXPERIMENTAL|Exercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
61942185|NCT02020187|NO_INTERVENTION|Controls|Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.
61942186|NCT03442101||Treatment group|These participants are newly diagnosed with psychosis.
61942187|NCT00645723|EXPERIMENTAL|A|Intravenous colistin and nebulized colistin
61942188|NCT00645723|PLACEBO_COMPARATOR|B|intravenous colistin and saline solution nebulized
62138408|NCT05485818|EXPERIMENTAL|Low Dose|Patients in this treatment group will receive NL005 for 0.25 ug/kg respective.Continuous administration for 7 days.
62138409|NCT05485818|EXPERIMENTAL|Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
62138410|NCT05485818|EXPERIMENTAL|High Dose|Patients in this treatment group will receive NL005 for 2.0 ug/kg respective.Continuous administration for 7 days.
62138411|NCT05485818|PLACEBO_COMPARATOR|Placebo|Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.
62494625|NCT04358367|PLACEBO_COMPARATOR|Saline|spinal anesthesia and placebo (saline).
62494626|NCT02994836|ACTIVE_COMPARATOR|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
62494627|NCT02994836|PLACEBO_COMPARATOR|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
62494628|NCT01188590||Patients undergoing heart surgery|
62494629|NCT05108935|EXPERIMENTAL|Medication and telemedicine follow up|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
62494630|NCT00028925|EXPERIMENTAL|Regimen A|"Patients receive oral topotecan once daily on days 1-5, carboplatin IV over 30 minutes on day 5, and filgrastim (G-CSF) subcutaneously once daily beginning on day 6 or 7 and continuing for up to 10 days or until blood counts recover.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
62494631|NCT00028925|EXPERIMENTAL|Regimen B|"Patients receive topotecan and carboplatin as in regimen A. Patients are evaluated after the first 3-week course of chemotherapy. If no patient experiences unacceptable toxicity or febrile neutropenia, the next 33 patients receive treatment as in regimen B; otherwise, patients receive treatment as in regimen A.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
62494632|NCT00722436|EXPERIMENTAL|Tranexamic acid|Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous
62494633|NCT00722436|PLACEBO_COMPARATOR|Placebo|Saline was administered intravenously
61942189|NCT02297191|EXPERIMENTAL|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle, evaluate for spread of local anesthesia and to minimize the risk of Ropivicaine being injected intravascularly.~a. Ultrasound images will be saved using the nomenclature TLIP Anat"
62494634|NCT03155893|EXPERIMENTAL|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram \[mg\] ODV \[1\*25 mg tablet\]) and simeprevir (SMV) placebo (matching 150 mg SMV \[2\*75 mg capsules\]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram \[mg\] AL-335 \[3\*400 mg tablets\]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1\*400 mg capsule) single dose on Day 2 orally under fed conditions.
61942190|NCT01724931|PLACEBO_COMPARATOR|Placebo|Placebo once weekly
62138412|NCT02788019|EXPERIMENTAL|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
62138413|NCT02788019|ACTIVE_COMPARATOR|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
62138414|NCT04365556|EXPERIMENTAL|TASC Intervention|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
62138415|NCT04365556|NO_INTERVENTION|Treatment as Usual|Participants will not receive any intervention.
62138416|NCT05140876|EXPERIMENTAL|START mHealth Intervention|Participants randomized to receive the START mHealth intervention will have access to the mHealth application for 6 months following randomization.
62138417|NCT05140876|NO_INTERVENTION|Website referrals|Participants in this condition will receive no intervention and will have access to a website with resources related to substance use disorder treatment and HIV treatment.
62138418|NCT03234478||GBA mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
62138419|NCT03234478||non-mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
62138420|NCT03234478||GBA mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
62138421|NCT03234478||non-mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
62138422|NCT00789542|EXPERIMENTAL|Intermittent Pneumatic Compression|SCD Express device applied with thigh length sleeves for up to 30 days
61942191|NCT01724931|EXPERIMENTAL|3 mg LD-Aminopterin|3 mg LD-aminopterin once weekly
61942192|NCT01724931|EXPERIMENTAL|1 mg LD-aminopterin|1 mg LD-aminopterin once weekly
61942193|NCT05312372|EXPERIMENTAL|S095033 in combination with paclitaxel|"Dose escalation - phase 1: S095033 will be administrated at dose of 100 mg,150 mg or 200 mg everyday during a 28-day cycle. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.~Dose expansion - phase 2: Participants with MTAP-deletion and those with MTAP-wild type tumors will be evaluated in separate and independent dose expansion subpopulations.S095033 will be administrated every day during a 28-day cycle at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
62138423|NCT00789542|OTHER|Routine care|Routine care which might include: early mobilisation, adequate hydration, aspirin if ischaemic stroke and graduated compression stockings according to local protocols.
62138424|NCT03275961|EXPERIMENTAL|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
62337699|NCT02867345||Comparable group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10\^7/kg PD-1 wild-type T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
62696087|NCT06115954|ACTIVE_COMPARATOR|Asynchronous Telerehabilitation|Self-management training will be delivered to the participants in this exercise group via video and they will be asked to watch it. The exercise program will consist of functional exercises focused on trunk stabilization, including warm-up and cool-down periods, 3 times a week for 12 weeks, and will be shared with the participants through videos taken by the physiotherapist. Exercise training will be completed with a 10-minute warm-up exercise followed by 40-minute trunk stabilization and functional exercises for the upper and lower extremities, followed by a 10-minute cooling-down program consisting of flexibility exercises. Participants will be checked weekly by phone to determine exercise tracking. Progression in exercise training will be achieved with new videos that include an increase in the number of repetitions of the participants and the addition of elastic bands to the exercises.
62696088|NCT06090799|EXPERIMENTAL|Treatment group A|SHR-3032
62337700|NCT00710034|ACTIVE_COMPARATOR|Nicotine Gum|Nicotine replacement therapy (4 mg nicotine gum) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute nicotine gum for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
62696089|NCT06090799|PLACEBO_COMPARATOR|Treatment group B|SHR-3032 Placebo
62696090|NCT05998759|EXPERIMENTAL|Telitacicept plus standard therapy|Telitacicept (160mg ih qw for 24 weeks) combined with standard therapy. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.).
61942194|NCT06621719|ACTIVE_COMPARATOR|Control group (L-PRF)|The tubes will be centrifuged at (700 g for 12 min). By the end of the centrifuge cycle, the PRF clots will be extruded from the tubes with a sterile tweezer and separated from the underlying RBCs with sterile scissors.
61942195|NCT06621719|ACTIVE_COMPARATOR|Study group (Albumin-PRF)|The tubes will be centrifuged at (700 g for 8 minutes). The upper (PPR) layer will be aspirated through the unremoved plastic cap, collected in a 2-ml plastic syringe, and placed into a bio-heat device for heating at (75°C for 10 minutes) for the purpose of albumin gel formation, which will be allowed to cool for an additional ten minutes into the room temperature in a sealed dark container before being mixed with the liquid PRF and buffy coat lower layers, using a female-female luer lock connector
61942196|NCT05490407|OTHER|HGSOC|high-grade serous ovarian cancer patients (FIGO stages III and IV) with ascites, for whom neoadjuvant chemotherapy is recommended.
61942197|NCT05031273|EXPERIMENTAL|Residents moving into a congregate-living development with more features that support healthy living|Residents moving into a congregate-living development designed for older adults with more design and amenities features in the building, site, and/or neighbourhood that support physical activity, healthy eating, and social connections.
61942198|NCT05031273|NO_INTERVENTION|Residents living in a standard congregate-living development|Residents living in a standard community-based congregate-living development designed for older adults.
61942199|NCT01028885|EXPERIMENTAL|Arm I|"Patients undergo MRI and CT scan-based simulation for treatment planning with endorectal balloon target immobilization. The treatment target volumes and surrounding organs at risk are contoured, treatment plan developed and approved.~Patients then undergo 39 fractions of image-guided intensity-modulated radiotherapy over 8 weeks. Patients also undergo weekly MRI scans of the pelvis (in the planned treatment position) during radiotherapy."
61942200|NCT04849923|NO_INTERVENTION|controll group|This group has no additional strength training
61942201|NCT04849923|EXPERIMENTAL|1 training per week|This group performs one strength training session per week
62337701|NCT00710034|EXPERIMENTAL|Snus|Oral tobacco (Camel Snus) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute snus for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
62337702|NCT01404026|ACTIVE_COMPARATOR|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
62696091|NCT05998759|PLACEBO_COMPARATOR|Placebo plus standard therapy|Placebo combined with standard therapy. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.).
61942202|NCT04849923|EXPERIMENTAL|3 trainings per week|This group performs two strength training sessions per week
62337703|NCT01404026|SHAM_COMPARATOR|Sham tDCS|Subjects will undergo sham tDCS stimulation, where the current is only active for 30 seconds.
62337704|NCT02470052|EXPERIMENTAL|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
62337705|NCT02446353|EXPERIMENTAL|Megace : fed|Megace / Apetrol ES : comparator / test, fed
62337706|NCT02446353|EXPERIMENTAL|Apetrol ES : fed|Apetrol ES / Megace : test / comparator, fed, cross-over
62337707|NCT02446353|EXPERIMENTAL|Megace : fasting|Megace / Apetrol ES : comparator / test, fasting
62337708|NCT02446353|EXPERIMENTAL|Apetrol ES : fasting|Apetrol ES / Megace : test / comparator, fasting, cross-over
62696092|NCT06365463|EXPERIMENTAL|Telerehabilitation group|Remote group training to improve balance and mobility
61942203|NCT01664065|EXPERIMENTAL|AZ drug: A|200 mg Ceftaroline fosamil 1h infusion
61942204|NCT01664065|EXPERIMENTAL|AZ drug: B|600 mg Ceftaroline fosamil 1h infusion
61942205|NCT03836703|ACTIVE_COMPARATOR|Single Dose Daily Iron|single dose daily Iron'IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
61942206|NCT03836703|EXPERIMENTAL|Double dose Daily iron|Double dose daily Iron'IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
62696093|NCT05809700|EXPERIMENTAL|HA35 local injection of pain location Group|According to the ratio of 100 mg high molecular weight HA (sodium hyaluronate for injection, H20174089)/2000 units of hyaluronidase extracted from bovine testis (hyaluronidase for injection H31022111), high molecular weight HA injection and hyaluronidase injection were mixed at room temperature for 20 minutes.
62696094|NCT01117246|EXPERIMENTAL|Treated bone metastasis|Patients with bone metastasis causing pain.
62337709|NCT02239770|PLACEBO_COMPARATOR|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
62494635|NCT03155893|EXPERIMENTAL|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram \[mg\] ODV \[1\*25 mg tablet\]) and simeprevir (SMV) placebo (matching 150 mg SMV \[2\*75 mg capsules\]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram \[mg\] AL-335 \[3\*400 mg tablets\]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1\*400 mg capsule) single dose on Day 16 orally under fed conditions.
62696095|NCT00963638|EXPERIMENTAL|MagTabSR|
61942207|NCT01282658||Colorectal cancer|
61942208|NCT02785315|EXPERIMENTAL|rehabilitation & remediation approach|The intervention group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention with various compensatory strategies. Investigators will use group discussion to discuss everyday situations with memory problem and specific strategies (internal and external) related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
61942209|NCT02785315|ACTIVE_COMPARATOR|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
61942210|NCT00507923|EXPERIMENTAL|Group I (Tibetan yoga)|Participants participate in Tibetan yoga sessions consisting of deep breathing or stretching exercises over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions.
61942211|NCT00507923|ACTIVE_COMPARATOR|Group II (stretching)|Participants participate in stretching exercise sessions over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
61942212|NCT00507923|ACTIVE_COMPARATOR|Group III (usual care)|Participants receive usual care and wear actigraph activity monitor and complete a sleep diary for 7 days. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
61942213|NCT01571310|EXPERIMENTAL|Omitted Breakfast|Experimental: The patients in Omitted Breakfast day will omit the breakfast and will continue the fast until noon. Thereafter will eat Lunch at 13;30 and Dinner at 19:00
61942214|NCT01571310|ACTIVE_COMPARATOR|Breakfast|The patients in Breakfast day will consume breakfast at 8:00 and then lunch at 13;30 and dinner at 19:00
61942215|NCT00287365|EXPERIMENTAL|1-ozone|Mildly asthmatic subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects
62337710|NCT02239770|EXPERIMENTAL|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
62337711|NCT02239770|EXPERIMENTAL|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
62337712|NCT02239770|PLACEBO_COMPARATOR|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
62337713|NCT02239770|EXPERIMENTAL|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
62337714|NCT02239770|EXPERIMENTAL|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
62696096|NCT00963638|PLACEBO_COMPARATOR|Sugar Pill|
61942216|NCT03332290|ACTIVE_COMPARATOR|sport training|training course lasting 10 days. It included 10 days of multisports practice once (2h) per day.
61942217|NCT03332290|EXPERIMENTAL|diving|diving course lasting 10 days. It included 10 days of diving once (2h) per day. Diving will be carried out using air at a maximum depth of 30-meters
61942218|NCT04876144|NO_INTERVENTION|Usual care group - clinical|Usual prenatal and postpartum psychiatric care involves regular visits with a psychiatrist from the perinatal psychiatric outpatient clinic of the National Institute of Mental Health, Czechia.
61942219|NCT04876144|NO_INTERVENTION|Usual care group - general|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
61942220|NCT04876144|EXPERIMENTAL|Kogito - clinical|Usual prenatal and postpartum psychiatric care in perinatal psychiatric outpatient clinic of the National Institute of the National Institute of Mental Health, Czechia plus use of the Kogito app.
61942221|NCT04876144|EXPERIMENTAL|Kogito - general|Usual prenatal/postpartum care plus use of the Kogito app.
61942222|NCT00955318|EXPERIMENTAL|KW-6500|
61942223|NCT02236637||mCRPC patients|Patients with metastatic castration-resistant prostate cancer treated according to routine clinical practice
62337715|NCT03282708|EXPERIMENTAL|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
62696097|NCT04810624|EXPERIMENTAL|Do, Accept, Motivation Through Values, Sessions, Long-Term Food Logs,|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62696098|NCT04810624|EXPERIMENTAL|Do, Accept, Motivation through Values, Sessions, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
61942224|NCT01872221|EXPERIMENTAL|Surgery and radio-chemotherapy|Surgery (on the basis of all preoperative multimodal MRI) followed by standard radio-chemotherapy stupp protocol
62696099|NCT04810624|EXPERIMENTAL|Do, Accept, Motivation through Values, Check-Ins, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
61942225|NCT01759511|EXPERIMENTAL|Simtuzumab|Participants will receive simtuzumab.
61942226|NCT02785484|EXPERIMENTAL|Label with constituent disclosure message|
61942227|NCT02785484|OTHER|Label with litter message|
62738478|NCT05659043||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. These subjects had no history of ischemic heart disease (acute myocardial infarction, unstable angina, chronic stable angina, previous percutaneous or surgical coronary revascularization, heart failure) and received CCTA in the outpatient clinics due to suspected CAD or other causes. And the luminal diameter narrowing was estimated by CCTA at ≤30%.
62337716|NCT03282708|NO_INTERVENTION|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
62337717|NCT01848899|EXPERIMENTAL|Ioxaglate Arm|
62337718|NCT01848899|EXPERIMENTAL|Iodixanol arm|
62337719|NCT04430660|OTHER|Arm 1|Participants will have there glial acetate metabolism assessed via 13C MRS at baseline and then again 14 days later. Participants will wear blinded continuous glucose monitoring devices for \~4 weeks.
62337720|NCT01673503|ACTIVE_COMPARATOR|Carl Zeiss Meditech VisuMax laser - ReLEx flex|\>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
62337721|NCT01673503|ACTIVE_COMPARATOR|Carl Zeiss Meditech VisuMax laser - ReLEx smile|\>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
62738479|NCT06660862|EXPERIMENTAL|Darolutamide and physical activity correlation|To understand how darolutamide plus hormone therapy affects physical activity, we would like to specifically monitor the step count of men receiving these medications.
62738480|NCT02110654|ACTIVE_COMPARATOR|mometasone furoate nasal spray|mometasone furoate nasal spray,200ug qd, 6 months
62337722|NCT04402268||Low risk|Low risk of sudden cardiac death according to HCM Risk-SCD Calculator
62738481|NCT02110654|EXPERIMENTAL|mometasone furoate nasal spray combined with montelukast|montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months
62738482|NCT05657080||Cases|"This will include patients with:~* existing diagnosis of proximal GIM undergoing endoscopic surveillance~* a new diagnosis of proximal GIM requiring repeat endoscopy~* a historical diagnosis of GIM retrieved from the pathology records through retrospective analysis and lost in follow up~* gastric adenocarcinoma from upper GI multidisciplinary meeting."
62738483|NCT05657080||Controls|Controls will be patients with no known premalignant conditions of the upper GI tract and fit to undergo an upper endoscopy. They will be recruited via standard referral routes for upper GI endoscopy due to upper GI symptoms via standard referral routes. Individuals must be able to provide informed consent.
62738484|NCT05112770||Patients|Renal transplant patients whose medical follow-up is provided from 2004 to 2020 by the nephrology and adult renal transplantation department of the Necker hospital.
62738485|NCT00698438|ACTIVE_COMPARATOR|a|Implantation of Ex-PRESS mini glaucoma shunt under a scleral flap
62738486|NCT00698438|ACTIVE_COMPARATOR|b|Trabecolectomy
62696100|NCT04810624|EXPERIMENTAL|Do, Accept, Motivation through Values, Check-Ins, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62696101|NCT04810624|EXPERIMENTAL|Do, Accept, Motivation through Narratives, Sessions, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
62696102|NCT04810624|EXPERIMENTAL|Do, Accept, Motivation through Narratives, Sessions, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62696103|NCT04810624|EXPERIMENTAL|Do, Accept, Motivation through Narratives, Check-Ins, Long-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62696104|NCT04810624|EXPERIMENTAL|Do, Change, Motivation Through Values, Sessions, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
62738487|NCT04923737|ACTIVE_COMPARATOR|Dexmedetomidine group|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
62337723|NCT04402268||Intermediate risk|Intermediate risk of sudden cardiac death according to HCM Risk-SCD Calculator
61942228|NCT02248909||Patients with COPD risk factors|Group of subjects with COPD risk factors. This group will include patients aged ≥40 years, with smoking history of ≥10 pack years and long-active (not less than 3 consequent months) respiratory complaints
61942229|NCT02248909||Patients previously diagnosed with COPD|Group of patients who according to the medical records have already been diagnosed with COPD
62337724|NCT04402268||High risk|High risk of sudden cardiac death according to HCM Risk-SCD Calculator
62337725|NCT05448560|EXPERIMENTAL|Multi-level Intervention of shared model of survivorship care|"1. Patient survivorship education via telehealth with the cancer center~2. Ongoing patient-tailored education program by MyChart within the EHR patient portal~3. Structured interactive phone communication between the research RN at the cancer center and community PCP clinic~4. In-person visit with the PCP clinic for survivorship care."
61942230|NCT03368248||All neonatal resuscitation services.|All professionals in contact with children were interviewed: doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical.
61942231|NCT03913468||Received Ascorbic Acid IV|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who were treated within the first 24 hours of admission with the combination of IV ascorbic acid, IV thiamine, and IV hydrocortisone, with a duration of 4 days or until patient leaves the ICU.
61942232|NCT03913468||Control Group|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who did not receive any treatment with IV ascorbic acid.
62337726|NCT05448560|ACTIVE_COMPARATOR|"Gold standard cancer center-based survivorship clinic"|In-person visit at specialty survivorship clinic
62337727|NCT01981967|EXPERIMENTAL|Primary Vaccination Group|Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
61942233|NCT03325049|EXPERIMENTAL|The health-promoting conversations|In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
61942234|NCT03325049|ACTIVE_COMPARATOR|Control Arm|Usual Care
61942235|NCT04783818||One Stage Reconstruction With Adjuvant Radiotherapy|
61942236|NCT04783818||Two Stage Reconstruction With Adjuvant Radiotherapy|
61942237|NCT04783818||Autologous Reconstruction With Adjuvant Radiotherapy|
61942238|NCT04783818||One Stage Reconstruction Without Adjuvant Radiotherapy|
61942239|NCT04783818||Two Stage Reconstruction Without Adjuvant Radiotherapy|
61942240|NCT04783818||Autologous Reconstruction Without Adjuvant Radiotherapy|
61942241|NCT01649050|EXPERIMENTAL|BGG492|BGG492 tablets administered orally
61942242|NCT01649050|PLACEBO_COMPARATOR|Placebo|Matching placebo administered orally
62337728|NCT01981967|ACTIVE_COMPARATOR|Booster Vaccination Group|Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier
62337729|NCT01463865|PLACEBO_COMPARATOR|Placebo|Sodium chloride
62337730|NCT01463865|ACTIVE_COMPARATOR|ropivacaine|Naropin
62696105|NCT04810624|EXPERIMENTAL|Do, Change, Motivation Through Values, Sessions, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62696106|NCT04810624|EXPERIMENTAL|Do, Change, Motivation through Values, Check-Ins, Long-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62696107|NCT04810624|EXPERIMENTAL|Do, Change, Motivation Through Narratives, Sessions, Long-term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62738488|NCT04923737|PLACEBO_COMPARATOR|Control group|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
62337731|NCT02939937|EXPERIMENTAL|phenytoin|patients received phenytoin 100mg three time daily up to 3 months
62337732|NCT02939937|EXPERIMENTAL|placebo|patients received placebo 100 mg three time daily for 3 months
62337733|NCT02952326|EXPERIMENTAL|XP Endo Finisher|
62337734|NCT02952326|ACTIVE_COMPARATOR|Conventional needle irrigation|
61942243|NCT02967432|EXPERIMENTAL|Mupirocin|
61942244|NCT02967432|PLACEBO_COMPARATOR|Petroleum jelly|
61942245|NCT04798638|EXPERIMENTAL|Arm1: TY-9591 + Osimertinib + TY-9591|Participants will receive TY-9591 tablets under fasted condition in period 1 , followed by Osimeritinib Mesylate tablet under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
61942246|NCT04798638|EXPERIMENTAL|Arm2: Osimertinib + TY-9591 + TY-9591|Participants will receive Osimeritinib Mesylate tablet under fasted condition in period 1 , followed by TY-9591 tablets under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
61942247|NCT01934972|EXPERIMENTAL|CR + DCS|Subjects will receive Cognitive Remediation and active study drug.
61942248|NCT01934972|ACTIVE_COMPARATOR|CR + placebo|Cognitive Remediation and placebo
62337735|NCT02296996|EXPERIMENTAL|Dabrafenib + trametinib|Single arm study with dabrafenib + trametinib combination therapy
62337736|NCT05120934|EXPERIMENTAL|Duloxetine and Placebo|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 30mg of Duloxetine plus 30mg Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62337737|NCT05120934|EXPERIMENTAL|Duloxetine dose escalation|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 60mg of Duloxetine for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
61942249|NCT05979506|EXPERIMENTAL|Wraps (body and feet) as well as scalp care|The skin care consisting of wraps (body and feet) and scalp care, will be carried out consecutively over 3 days, in the hospital (outpatient or in day/traditional hospitalization).
61942250|NCT03082482|ACTIVE_COMPARATOR|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
61942251|NCT03082482|EXPERIMENTAL|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
62337738|NCT05120934|EXPERIMENTAL|Amitriptyline and Placebo|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 25mg of Amitriptyline plus 30mg Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
61942252|NCT02647242|EXPERIMENTAL|Patients with parkinson's disease|Patients with parkinson's disease
61942253|NCT01464996|EXPERIMENTAL|Adhesive OptiBond XTR|Adhesive OptiBond XTR will include composite restorations placed using the dental adhesive OptiBond XTR.
61942254|NCT01464996|ACTIVE_COMPARATOR|Adhesive OptiBond FL|Adhesive OptiBond FL will include composite restorations placed using the dental adhesive OptiBond FL.
61942255|NCT06391840||Patients listed for elective surgery|
61942256|NCT02403856|EXPERIMENTAL|Experimental group (Sodium Chloride 0.9%)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
62138425|NCT01296815|NO_INTERVENTION|HAART|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
61942257|NCT02403856|ACTIVE_COMPARATOR|Control group (Methylprednisolone Acetate)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
61942258|NCT04835519|EXPERIMENTAL|chimeric antigen receptor T cell treatment|
61942259|NCT05966792|EXPERIMENTAL|SGLT2 inhibitors|Intervention with henggliflozin (10mg qd) for 6 months
62138426|NCT01296815|EXPERIMENTAL|HAART+ Bevacizumab injection|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.
62337739|NCT05120934|EXPERIMENTAL|Amitriptyline dose escalation|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 50mg of Amitriptyline for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62337740|NCT05120934|PLACEBO_COMPARATOR|Placebo|Subjects will receive 30mg of Placebo for blinded period 1 (first 4 week treatment period) and 60mg of Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
62337741|NCT01767194|EXPERIMENTAL|Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)|CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.
62337742|NCT01767194|EXPERIMENTAL|Arm II (temozolomide, irinotecan hydrochloride, dinutuximab)|Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.
62337743|NCT02586233|EXPERIMENTAL|DS-1040b|Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
62696108|NCT04810624|EXPERIMENTAL|Talk, Accept, Motivation through Values, Sessions, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
62696109|NCT04810624|EXPERIMENTAL|Talk, Accept, Motivation through Values, Sessions, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
61942260|NCT05966792|PLACEBO_COMPARATOR|metformin|Intervention with metformin (500mg bid) for 6 months
61942261|NCT01254630|EXPERIMENTAL|V212-STM|Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered \~30 days apart.
61942262|NCT01254630|EXPERIMENTAL|V212-HM|Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered \~30 days apart.
61942263|NCT01254630|PLACEBO_COMPARATOR|Placebo-STM|Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered \~30 days apart.
61942264|NCT01254630|PLACEBO_COMPARATOR|Placebo-HM|Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered \~30 days apart.
61942265|NCT05412875|EXPERIMENTAL|Arm I (JUUL)|Beginning 1 month before surgery, patients receive a JUUL e-cigarette and a 1 month supply e-liquid pods. After completion of surgery, patients receive another 1 month supply of e-liquid pods.
61942266|NCT05412875|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual care.
61942267|NCT00090571||Sib Pairs|Two or more biological siblings affected with JIA.
61942268|NCT03749473|ACTIVE_COMPARATOR|Control|Participants receive a daily message with their step count on the prior day to serve as an active control for 24 weeks (daily performance feedback). No other interventions during the 24-week study
61942269|NCT03749473|EXPERIMENTAL|Choice + Immediate|Participants choose a step goal between 1000-3000 steps greater than their baseline (choice). They are asked to reach their full step goal upon intervention start (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
61942270|NCT03749473|EXPERIMENTAL|Choice + Gradual|Participants are asked to choose a step goal between 1000-3000 steps greater than their baseline (choice). They will be asked to increase their step goal by even increments of 12.5% each week for the 8 weeks of the ramp-up period (gradual). After the 8-week ramp-up period, they will be asked to maintain the step goal for the study. They may change their goal within the range at anytime. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
62337744|NCT02586233|PLACEBO_COMPARATOR|Placebo|Participants who will be randomized to receive intravenous (IV) infusion of placebo.
62337745|NCT03653403|EXPERIMENTAL|IDP-126 Gel|Component A
62337746|NCT03653403|ACTIVE_COMPARATOR|Control Gel|Gel
62337747|NCT04913961|EXPERIMENTAL|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study.
62494636|NCT03155893|EXPERIMENTAL|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram \[mg\] ODV \[1\*25 mg tablet\]) and simeprevir (SMV) placebo (matching 150 mg SMV \[2\*75 mg capsules\]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1\*25 mg tablet) and SMV 150 mg (2\*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3\*400 mg tablet) single dose on Day 15 orally under fed conditions.
62494637|NCT03155893|PLACEBO_COMPARATOR|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV \[4\*50 mg tablets\]) on Days 1 and 2; ODV placebo (matching 125 mg ODV \[2\*50 mg tablets + 1\*25 mg tablets\]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV \[2\*50 mg tablets\] on Days 8 to 14, orally once daily under fed conditions.
62494638|NCT03155893|EXPERIMENTAL|Panel 2: Treatment F|Participants will receive ODV 200 mg (4\*50 mg tablets) on Days 1 and 2; ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2\*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
62494639|NCT02404558|EXPERIMENTAL|Sarilumab|Single subcutaneous (SC) dose of sarilumab
62494640|NCT02404558|ACTIVE_COMPARATOR|Tocilizumab|Single SC dose of tocilizumab
62494641|NCT05475548|ACTIVE_COMPARATOR|Group (A): using reversed skeletally anchored PowerScope as a fixed functional appliance.|eight patients with mild to moderate Class IΙΙ malocclusion who will be treated by pre-adjusted straight wire appliance followed by reversed skeletally anchored PowerScope as a fixed functional appliance.
62494642|NCT05475548|ACTIVE_COMPARATOR|Group (B): using dentally anchored reversed PowerScope as a fixed functional appliance|eight patients with mild to moderate Class IΙΙ malocclusion who will be treated by pre-adjusted straight wire appliance followed by dentally anchored reversed PowerScope as a fixed functional appliance
62494643|NCT03099590|EXPERIMENTAL|Active Treatment, Alkontrol-herbal|Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
62494644|NCT03099590|PLACEBO_COMPARATOR|Placebo Control|Matched dextran containing capsules will serve as placebo.
62337748|NCT04913961|ACTIVE_COMPARATOR|Control|The control group will get the western medicine conventional therapy with some additional tests for the study.
62337749|NCT02628249|EXPERIMENTAL|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid made after egg protein.
62494645|NCT04121507|EXPERIMENTAL|alloSCT|defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)
62696110|NCT04810624|EXPERIMENTAL|Talk, Accept, Motivation through Narratives, Check-Ins, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
62138427|NCT04326140|EXPERIMENTAL|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
62337750|NCT02628249|EXPERIMENTAL|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid made after egg protein.
62337751|NCT02628249|EXPERIMENTAL|Base + BCAA|Base protein intake + Branched chain amino acids
62337752|NCT02628249|EXPERIMENTAL|Base + EAA|Base protein intake + essential amino acids.
62337753|NCT02628249|EXPERIMENTAL|Base + NEAA|Base protein intake + non essential amino acids
62337754|NCT02276235|EXPERIMENTAL|catgut embedding group|Catgut will be embedding in acupoints as below. Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26) Frequency: one time per week Duration: 6 weeks
62337755|NCT02276235|SHAM_COMPARATOR|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. All the procedure will be performed as in catgut embedding group.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)~The other procedure were the same as catgut embedding group Frequency: one time per week Duration: 6 weeks"
62494646|NCT01962298|PLACEBO_COMPARATOR|Single rocuronium dose - placebo|The patients will receive a single rocuronium dose, and no reversal agent.
62138428|NCT04326140|SHAM_COMPARATOR|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
62337756|NCT01648543|ACTIVE_COMPARATOR|block method: angle|The entry angle of angular method which is one method of lumbar sympathetic ganglion block is 30 degree of anterior-posterior view of C-arm.
62337757|NCT01648543|ACTIVE_COMPARATOR|block method: distance|The entry point of modified Reid method which is popular method of lumbar sympathetic ganglion block is 7\~7.5cm from midline of spinous process of lumbar spine.
62337758|NCT04423614|EXPERIMENTAL|Inspiratory Muscle Training (IMT)|Pre-operative inspiratory muscle training
62337759|NCT04423614|EXPERIMENTAL|Relaxation Breathing (RLX)|Relaxation breathing exercises
62494647|NCT01962298|ACTIVE_COMPARATOR|Single rocuronium dose - sugammadex|The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent
62494648|NCT01962298|ACTIVE_COMPARATOR|Repeated rocuronium dose - neostigmine|The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent
62494649|NCT01962298|ACTIVE_COMPARATOR|Repeated rocuronium dose - sugammadex|The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent
62337760|NCT00218855|PLACEBO_COMPARATOR|A|
62337761|NCT00218855|ACTIVE_COMPARATOR|B|
62494650|NCT01962298|ACTIVE_COMPARATOR|Continuous rocuronium dose|The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent
62494651|NCT05511662||routine follow-up|The patients were instructed to come to the hospital for routine follow-up at 1, 3, 6, and 12 months after the operation. If necessary, the investigators contacted the patients by phone for symptom follow-up and instructed them to come to the hospital for relevant examinations (eg: EKG, Holter, echocardiography, etc.)
62494652|NCT05511662||PRO follow-up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance.
62494653|NCT04651816|ACTIVE_COMPARATOR|Control PSH DPP only|This group will be enrolled the PSH DPP program. There will be two cohorts for this arm.
62494654|NCT04651816|EXPERIMENTAL|Treatment 1 Financial Incentives A|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
62494655|NCT04651816|EXPERIMENTAL|Treatment 2 Financial Incentives B|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
62494656|NCT04651816|EXPERIMENTAL|Treatment 3 Motivational Text Messaging|This group will receive text messages with motivational messages while participating in the PSH DPP program. There will be two cohorts for this arm.
62494657|NCT00003906|ACTIVE_COMPARATOR|Group 1|Tamoxifen and placebo
62494658|NCT00003906|EXPERIMENTAL|Group 2|Raloxifene and Placebo
62738489|NCT04293224|EXPERIMENTAL|DGA Mediterranean diet pattern, energy balance|Diet plan focused on energy balance (meets calorie needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
61942271|NCT03749473|EXPERIMENTAL|Assigned + Immediate|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to reach their full step goal as soon as the intervention begins (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
61942272|NCT03749473|EXPERIMENTAL|Assigned + Gradual|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to achieve their step goal of 2000 steps incrementally over the 8 weeks of the ramp-up period (gradual). After the first 8 weeks, they will be asked to maintain their full step goal of 2000 for the the study. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
61942273|NCT04576325|EXPERIMENTAL|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
62138429|NCT06328868|EXPERIMENTAL|Intermittent Oral-esophageal Tube Feeding+comprehensive rehabilitation therapy|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
62337762|NCT06145685|ACTIVE_COMPARATOR|Previous smokers - Minimally invasive|Minimally invasive non-surgical periodontal treatment
62337763|NCT06145685|ACTIVE_COMPARATOR|Previous smokers - Conventional|Conventional non-surgical periodontal treatment
62337764|NCT06145685|ACTIVE_COMPARATOR|Smoker|Conventional non-surgical periodontal treatment
62337765|NCT06145685|ACTIVE_COMPARATOR|Non-smoker|Conventional non-surgical periodontal treatment
62337766|NCT03921255|ACTIVE_COMPARATOR|TAF Incongruent (TAF-INC)|Active condition (TAF-INC) cognitive bias modification for interpretations (CBM-I), incorporates an obsessional thought meant to elicit either moral or likelihood TAF, followed by a sentence incongruent to TAF bias and meant to reduce the impact of the previous statement. Before moving on, participants must fill-in and correctly solve a key word important in the interpretation of the sentence. Participants then must correctly solve a short yes/no comprehension question to ensure understanding of the scenario.
62337767|NCT03921255|PLACEBO_COMPARATOR|TAF Congruent (TAF-CON)|Maintenance/Control condition (TAF-CON) CBM-I, differs in that participants are provided with a sentence congruent with TAF bias. Again, participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
62337768|NCT03921255|PLACEBO_COMPARATOR|Stress Management Psychoeducation|In the stress management psychoeducation (SMP) psychoeducation about stress and stress management are provided, similar in length to the obsessional thought and interpretations presented in the TAF-INC and TAF-CON. Like the other conditions there is a key word to solve, and participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
62337769|NCT00970528|EXPERIMENTAL|Arm 1|
62337770|NCT00970528|ACTIVE_COMPARATOR|Arm 2|
62337771|NCT02065622|EXPERIMENTAL|Induction (Main Study + Japan Sub-study): I-SD|Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
62337772|NCT02065622|EXPERIMENTAL|Induction (Main Study + Japan Sub-study): I-HD|Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
62337773|NCT02065622|EXPERIMENTAL|Maintenance (Main Study + Japan Sub-study): M-SD|Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
62337774|NCT02065622|EXPERIMENTAL|Maintenance (Main Study + Japan Sub-study): M-HD|Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
62494659|NCT06348277|EXPERIMENTAL|MIndfulness Plus Mood Monitoring|Mobile app that involved mood monitoring and brief mindfulness exercises.
62494660|NCT06348277|ACTIVE_COMPARATOR|Mood Monitoring Only|Mobile app that involved only mood monitoring
62696111|NCT04810624|EXPERIMENTAL|Talk, Accept, Motivation through Narratives, Check-Ins, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62696112|NCT04810624|EXPERIMENTAL|Talk, Change, Motivation Through Values, Sessions, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62138430|NCT06328868|ACTIVE_COMPARATOR|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
62696113|NCT04810624|EXPERIMENTAL|Talk, Change, Motivation Through Values, Sessions, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62696114|NCT04810624|EXPERIMENTAL|Talk, Change, Motivation through Values, Check-Ins, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
62696115|NCT04810624|EXPERIMENTAL|Talk, Change, Motivation through Values, Check-Ins, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62696116|NCT04810624|EXPERIMENTAL|Talk, Change, Motivation through Narratives, Sessions, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
62738490|NCT04293224|EXPERIMENTAL|DGA Mediterranean diet pattern, negative energy balance|Negative energy balance (\~25% calorie reduction compared to needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
62138431|NCT00612209|EXPERIMENTAL|1|
62138432|NCT01970410|EXPERIMENTAL|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
62138433|NCT05162716||LBBAP|Patients with permanent atrial arrhythmia with an indication of cardiac pacing and atrioventricular junction ablation will undergo the implantation of a single-chamber pacemaker with left bundle branch area pacing, and then atrioventricular junction ablation.
61942274|NCT04576325|PLACEBO_COMPARATOR|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
61942275|NCT05427734|EXPERIMENTAL|Jaspr2.0|Suicide prevention platform that includes evidence-based practices for suicide prevention and alcohol misuse for use in primary care. Jaspr2.0 includes psychoeducation, behavioral skills training, crisis stabilization planning, lethal means management, brief interventions for the treatment of alcohol misuse, and messages of hope, wisdom, and insights from people with lived experience (PLE). Participants in this condition will also have access to the Jaspr2.0 companion mobile app, Jaspr-at-Home.
62138434|NCT05265689|EXPERIMENTAL|Bike Club|Participants will receive a 12-hour bicycle safety education program
62494661|NCT06348277|NO_INTERVENTION|Assessment only Control|Only completed assessments
61942276|NCT05427734|ACTIVE_COMPARATOR|Active-Control app + electronic wellness resources brochure|Well-regarded suicide prevention self-help app, plus an electronic wellness resources brochure containing links to health and wellness materials, psychoeducation about suicide, depression, self-help recovery-focused resources (e.g., Alcoholics Anonymous, other 12-Step programs, Moderation Management, etc.), and phone/text information for the National Suicide Prevention Lifeline.
61942277|NCT01411618|EXPERIMENTAL|free alcohol essential oil moutwash|
62138435|NCT05265689|EXPERIMENTAL|Bike Club Plus|Participants will receive an enhanced version of the 12-hour bicycle safety education program which will include a parent training session on bicycling safety best practices, child development as it relates to bicycling, strategies for practice at home, and feedback on their adolescent's bicycling performance.
62494662|NCT03370510|EXPERIMENTAL|Pivotal Response Treatment (PRT)/oxytocin (OXT) nasal spray|Participants will receive oxytocin nasal spray 45 minutes prior to each PRT session.
62696117|NCT04810624|EXPERIMENTAL|Talk, Change, Motivation through Narratives, Sessions, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62138436|NCT05265689|NO_INTERVENTION|Control Group|The control group will not receive any bicycle safety education programming.
62337775|NCT02065622|EXPERIMENTAL|Maintenance (Main Study): TDM Regimen|Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.
62337776|NCT05439694|EXPERIMENTAL|Gelatin Sponges soaked with TXA|21 patients will have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) each sponge will be soaked with one ampoule and applied between the anterior rectus sheath and the rectus abdominis muscle, one sponge on each muscle.
62337777|NCT05439694|EXPERIMENTAL|Gelatin Sponges|2 Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2)
62337778|NCT05439694|NO_INTERVENTION|NO SPONGE|21 patients will have no sponge inserted 10 ml of saline
62337779|NCT03273205|EXPERIMENTAL|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:~Anode: Left DLPFC \[F3) Cathode: Right Supraorbital (FP2)"
62337780|NCT03273205|SHAM_COMPARATOR|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:~Anode: Left DLPFC \[F3) Cathode: Right Supraorbital (FP2)"
62337781|NCT01769079|ACTIVE_COMPARATOR|oral nitrate|In nitrate group will be provided the same prescribed dose for this drug. One group remains on nitrate use and other on placebo (same number of pills) use.
62337782|NCT01769079|PLACEBO_COMPARATOR|Placebo|In the placebo group will be given the same dose and frequency prescribed nitrate.
62337783|NCT01410266|NO_INTERVENTION|Standard of care|Standard of care includes a routine clinic visit two weeks after misoprostol administration. At the clinic visit, the woman undergoes a bimanual examination. In the event the woman fails to return for the follow-up visit, clinic procedure is followed for contacting her to determine abortion status and the need for further intervention, if any.
62337784|NCT01410266|ACTIVE_COMPARATOR|Alternative follow-up|At a clinic visit, before mifepristone administration, the woman completes a semi-quantitative pregnancy test. After mifepristone administration, she is provided with another pregnancy test and a checklist to be self-administered two weeks after she takes misoprostol. On an assigned date, the woman is contacted by phone by the clinic staff and asked to report on the results of both tests. The provider then confirms whether, based on the woman's responses, she should return for a follow-up visit.
62337785|NCT01260376|EXPERIMENTAL|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
62337786|NCT01260376|NO_INTERVENTION|Placebo|Placebo tablets will be administered 4 times previous to and during the investigation day
62337787|NCT00570752|ACTIVE_COMPARATOR|Placebo + background low to moderate dose statin|Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks
62337788|NCT00570752|EXPERIMENTAL|BMS-582949 + Background low to moderate dose statin|BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks
61942278|NCT01411618|ACTIVE_COMPARATOR|alcohol containing essential oil mouthwash|
61942279|NCT02112006|EXPERIMENTAL|distal injection|0.5% bupivacaine injected in the forearm
61942280|NCT02112006|ACTIVE_COMPARATOR|proximal injection|20-30ml of 0.5% bupivacaine
62337789|NCT00570752|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks
62337790|NCT01389141||mid-reproductive age|
62337791|NCT01389141||late reproductive age-1|
61942281|NCT02180165|EXPERIMENTAL|Cohort 1: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
61942282|NCT02180165|ACTIVE_COMPARATOR|Cohort 1: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
61942283|NCT02180165|EXPERIMENTAL|Cohort 2: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
62337792|NCT01389141||late reproductive age-2|
62337793|NCT03227562|OTHER|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
62337794|NCT03227562|OTHER|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
62337795|NCT01709786||Patients with Suspected Hemorrhage|There is a single group of patients in this study -- those with suspected hemorrhage who satisfy the inclusion and exclusion criteria. The same set of measurements will be take from each patients and those measurements will be compared with one another to determine accuracy.
62494663|NCT03370510|PLACEBO_COMPARATOR|Pivotal Response Treatment (PRT)/placebo nasal spray|Participants will receive a placebo nasal spray 45 minutes prior to each PRT session.
62494664|NCT01954212|EXPERIMENTAL|Enhanced complex oral health care intervention|The complex oral health care (OHC) intervention (SOCLE intervention) includes patient, staff and service level interventions.
62696118|NCT04810624|EXPERIMENTAL|Talk, Change, Motivation through Narratives, Check-Ins, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62696119|NCT04810624|EXPERIMENTAL|Do, Change, Motivation through Narratives, Check-Ins, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
62696120|NCT04810624|EXPERIMENTAL|Do, Change, Motivation through Narratives, Check-Ins, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
62138437|NCT06432790|EXPERIMENTAL|CHAMPION via Telehealth|"* Intensive 0-6 months: 1 individual visit monthly (virtual), 1 group visit monthly (virtual)~* Maintenance 6-12 months: 1 individual visit monthly (virtual), 2 health coaching calls per month"
62138438|NCT06432790|ACTIVE_COMPARATOR|CHAMPION via In-Person|"* Intensive 0-6 months: 1 individual visit monthly (in-person), 1 group visit monthly (in-person)~* Maintenance 6-12 months: 1 individual visit monthly (in-person), 2 health coaching calls per month"
62138439|NCT05473416|EXPERIMENTAL|1- McKenzie (Group A)|Back extension exercise. Total 10 repetitions in 1 set. Total 3 sets in a session. Total 3 sessions in a week. Total 12 sessions in a month.
62138440|NCT05473416|EXPERIMENTAL|2- Pilates (Group B)|Pelvic tilt exercise Total 10 repetitions in 1 set. Total 3 sets in a session. Total 3 sessions in a week. Total 12 sessions in a month.
62138441|NCT03807908|EXPERIMENTAL|Intervention Tape|"The intervention includes 3 strips of tape; 2 (1 on each side) placed vertically along the lumbar erectors and 1 horizontally at the posterior superior iliac spine.~Subjects will wear the tape for as long as possible up to 5-7 days."
62138442|NCT03807908|SHAM_COMPARATOR|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction.~Subjects will wear the tape for as long as possible up to 5-7 days."
62138443|NCT03169933|OTHER|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
62138444|NCT03307694||MAC-SWEI, standard SWEI, ultrasound|Participants in this group will receive all three imaging techniques
62138445|NCT03307694||Standard SWEI, ultrasound|Participants in this group will receive two imaging techniques
62138446|NCT03616015|EXPERIMENTAL|Patient|"For all patients included in the study, the following interventions will be performed :~* several blood samples (quantity collected requiring classification of this study as interventional according to French law)~* several fecal samples~* anxiety tests~* stress tests"
62138447|NCT00284752|EXPERIMENTAL|ABI-007|
62138448|NCT06699680|EXPERIMENTAL|PRX019, single dose|Specified dose on specified days
62138449|NCT06699680|EXPERIMENTAL|PRX019, multiple dose|Specified dose on specified days
62138450|NCT00945321|ACTIVE_COMPARATOR|1|aprepitant 165 mg
62138451|NCT00945321|ACTIVE_COMPARATOR|2|aprepitant 185 mg
62138452|NCT00945321|EXPERIMENTAL|3|fosaprepitant 150 mg
62138453|NCT00945321|EXPERIMENTAL|4|aprepitant with food
62138454|NCT04931524|EXPERIMENTAL|carbon-14-[14C]-ANG-3777|Administered IV as a single dose over 30 minutes on the morning of Day 1 following an 8 hour overnight fast and remain in the clinical unit until up to 168 hours after dosing (to Day 8). If mass balance criteria have not been met on Day 8, the clinical unit residency may be extended up to an additional 96 hours (to Day 12).
62138455|NCT01384890|EXPERIMENTAL|VMAT with CBCT|Volumetric modulated arc therapy (VMAT) with cone-beam computed tomography position (CBCT) verification
62138456|NCT01384890|ACTIVE_COMPARATOR|VMAT with kV-ray|Volumetric modulation arc therapy (VMAT) with kV-ray position verification
62138457|NCT05214222|EXPERIMENTAL|group A|Penpulimab plus chemotherapy with Anlotinib
62138458|NCT05214222|EXPERIMENTAL|group B|Penpulimab plus chemotherapy
62138459|NCT04357158|OTHER|Patients referred for colonoscopy|
62138460|NCT05416827|ACTIVE_COMPARATOR|PPV group|Epiretinal membrane eyes underwent PPV
62138461|NCT05416827|EXPERIMENTAL|PPV+implant Group|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
62138462|NCT01624493|EXPERIMENTAL|Phase II Arm A|Phase II Arm A will randomize patients to treatment regimen of carboplatin and gemcitabine without BNC105P
62138463|NCT01624493|EXPERIMENTAL|Phase II Arm B|Phase II Arm B will randomize patients to treatment regimen of carboplatin and gemcitabine and will include BNC105P
62138464|NCT05759260||Cases|Athletes with QT interval prolongation
62138465|NCT05759260||Controls|Athletes without QT interval prolongation
62138466|NCT00442637|EXPERIMENTAL|1|observation
62138467|NCT00442637|ACTIVE_COMPARATOR|2|capecitabine plus bevacizumab
62494665|NCT01954212|NO_INTERVENTION|Usual oral health care|"Oral health care (OHC) will be provided in the standard manner, with no change to usual care.~Provision of this standard OHC will be sampled monthly. Surveys suggest that standard oral health care (OHC) in stroke care settings comprise poorly supported OHC interventions delivered by staff that lacked access to specialist training, products, equipment, assessments, protocols and dental services."
62494666|NCT01189656|EXPERIMENTAL|Vaccine+Lamivudine group|Subjects assigned into the experimental and the controlled groups with randomization and double-blindness by a ratio of 2:1
62494667|NCT01189656|PLACEBO_COMPARATOR|Placebo+Lamivudine group|
62494668|NCT06331572||TRD|"1. age 12-18 years~2. Meet the diagnostic criteria for MDD according to the DSM-5~3. HAMD-17 score \> 13~4. currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms \<50%)"
62494669|NCT06331572||FEDN-MDD|1. age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 2. First-episode and drug-naive 4. HAMD-17 score \> 17
62494670|NCT06331572||HC|"1. age 12-18 years~2. HAMD-17 score \< 7~3. HCs without a personal history of a mental illness or family history in a first-degree relative"
62494671|NCT03944057|EXPERIMENTAL|ATG-010 + Dexamethasone|Open-label ATG-010 80mg plus Dexamethasone 20 mg
62494672|NCT03292263|EXPERIMENTAL|Mel+Nivo|Autologous Stem Cell Transplant Drug: Melphalan 140-200 mg/m\^2, Nivolumab100 mg iv days -3, +17
62494673|NCT06357416|OTHER|Main Group (MV-Eco) Sub-study|Patients seen in the Man Van, including those consenting to long-term follow-up of data.
62696121|NCT04810624|EXPERIMENTAL|Talk, Accept, Motivation through Values, Check-Ins, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (\~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62696122|NCT04810624|EXPERIMENTAL|Talk, Accept, Motivation through Narratives, Sessions, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
62494674|NCT06357416|OTHER|Point of care testing (MV-POCT) Sub-study|Patients consenting to a point of care blood test for either a PSA and/or HbA1c
62494675|NCT06357416|OTHER|Qualitative questionnaire (MV-QualQ) Sub-study|Patients consenting to participate in a qualitative study about their experience of the Man Van.
62494676|NCT06357416|OTHER|Polygenic risk scores (MV-PRS) Sub-study|Patients consenting for a polygenic risk score test.
62696123|NCT03246412|EXPERIMENTAL|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
62696124|NCT03246412|NO_INTERVENTION|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
62138468|NCT05728034|EXPERIMENTAL|Injectable PrEP information|A mock Google search results page with five search results that reflect five messaging strategies about injectable PrEP (response efficacy, social norms, exemplar, celebrity, and basic information), displayed in random order.
62337796|NCT02307669|PLACEBO_COMPARATOR|Routine inhaler adherence care|"Normal Care group This management is based on the inhaler training recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf) and medication management of the GINA management strategy.~The core features of the usual care group are:~1. The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~2. Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~3. Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~4. In follow up, medication changes in response to the above will be directed by these, as suggested by GINA management guidelines using a standardised digital script."
62494677|NCT06357416|OTHER|DNA Collection (MV-DNA) and Urinary Circulating Tumour DNA collection (MV-UctDNA) Sub-studies|Patients consenting to collection of DNA and/or urine for as yet undetermined future ethically-approved research.
62337797|NCT02307669|ACTIVE_COMPARATOR|INCA feedback|"1. The patient's treatment goal is established and used as the focus of the conversation.~2. Data from the INCA device including (1) time of use, (2) handling proficiency and (3) inhalation flow rates are discussed, with three graphs as shown in the appendix and derived as discussed. These are aimed to enhance the value of the inhaler.~3. Data from the electronic PEF and AQLQ are correlated with digitally recorded adherence so that these can be used to account for improvements or declines in these measures.~4. In follow up, medication changes in response to the above (adherence, PEF, ACT and exacerbations) are made using a standardised digital script."
61942284|NCT02180165|ACTIVE_COMPARATOR|Cohort 2: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
61942285|NCT03427671|EXPERIMENTAL|Occlusin 500 microspheres|Uterine fibroid embolization
62337798|NCT01290133|EXPERIMENTAL|Active Drug|
62337799|NCT01290133|PLACEBO_COMPARATOR|Placebo|
62337800|NCT00832546|PLACEBO_COMPARATOR|1|Placebo
62337801|NCT00832546|EXPERIMENTAL|2|Powder in solution
62337802|NCT00832546|EXPERIMENTAL|3|
62337803|NCT03933423|ACTIVE_COMPARATOR|Intervention|Educational session of pregnant mothers, blood grouping of parents and identifying risk factors for developing jaundice, screening newborns for neonatal jaundice, glucose 6-phosphate dehydrogenase deficiency and illness, Home based phototherapy and referral.
62337804|NCT03933423|NO_INTERVENTION|Control|No intervention will be deliver
62494678|NCT06357416|OTHER|Man Van patients|All patients seen within Man Van
62138469|NCT05728034|EXPERIMENTAL|Oral PrEP information (Study 1 only)|A mock Google search results page with five search results that reflect five messaging strategies about oral PrEP (response efficacy, social norms, exemplar, celebrity, and basic information), displayed in random order.
62337805|NCT04759014||Group 1|21 patients using non-articulated dynamic foot (non-articulating ankle, NAA)
62138470|NCT05779631|EXPERIMENTAL|mpMRI plus a same-day cystoscopic bladder biopsy|multiparametric MRI plus same-day cystoscopic bladder biopsy
62138471|NCT05779631|ACTIVE_COMPARATOR|TURBT|Transurethral resection of the bladder tumor
62138472|NCT05305508|PLACEBO_COMPARATOR|placebo|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
62138473|NCT05305508|EXPERIMENTAL|Calcium Dobesilate|The CaD (Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
62138474|NCT06353334|EXPERIMENTAL|Butylphthalide|Butylphthalide and Sodium Chloride Injection 100ml ivgtt bid 14days
62138475|NCT06353334|PLACEBO_COMPARATOR|Saline Solution|Saline Solution 100ml ivgtt bid 14days
62138476|NCT01979276|EXPERIMENTAL|Pomalidomide, Romidepsin, Dexamethasone|Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone
62337806|NCT04759014||Group 2|21 patients using dynamic foot with hydraulic ankle (articulating hydraulic ankle, AHA)
62337807|NCT05479409|EXPERIMENTAL|Neoadjuvant radiotherapy|Group 1:Patients undergo mastectomy or Breast conserving surgery after radiotherapy Group 2:Patients receive boost in the area of residual breast mass and regional lymph node. A total dose of 66Gy will be given.
62696125|NCT03213405|ACTIVE_COMPARATOR|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
62696126|NCT03213405|EXPERIMENTAL|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
62138477|NCT05073224|EXPERIMENTAL|Postpartum|Participants who are six months postpartum will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless Electromyography (EMG) sensors will be used to record EMG and limb steadiness (via Inertial Measurement Units (IMU). Physical activity will be measured by questionnaire and accelerometer.
62138478|NCT05073224|ACTIVE_COMPARATOR|Nulligravid|Participants who have never been pregnant will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless EMG sensors will be used to record EMG and limb steadiness (via IMUs). Physical activity will be measured by questionnaire and accelerometer.
62138479|NCT00371345|EXPERIMENTAL|Dasatinib|Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).
62138480|NCT02884245|EXPERIMENTAL|Arm E2: With estrogens pretreatment|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
62138481|NCT02884245|NO_INTERVENTION|Arm S: without estrogens pretreatment|No estrogen pretreatment will be delivered
62138482|NCT05461053|NO_INTERVENTION|Warm Compress application|The control group will receive instructions on applying warm compresses, the current standard of care. The patient or parent/guardian will be directed to apply a warm compress to the abscess or soak the area in warm water for 15 minutes. The application/soak will be done 4 times during the day.
62138483|NCT05461053|EXPERIMENTAL|LMX4-A topical anesthetic application|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
62138484|NCT03053505|EXPERIMENTAL|Recurrent CDI FMT|"Non-randomized group (R) for treatment of recurrent CDI with FMT"
62138485|NCT03053505|ACTIVE_COMPARATOR|Primary CDI antibiotic|"Randomized group (F AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)"
62138486|NCT03053505|EXPERIMENTAL|Primary CDI FMT|"Randomized group (F FMT) for the treatment of primary CDI with FMT"
62138487|NCT02620306|EXPERIMENTAL|Fimasartan(A)|
62138488|NCT02620306|EXPERIMENTAL|Fimasartan(B)|
62138489|NCT02620306|ACTIVE_COMPARATOR|Losartan(A)|
62138490|NCT02620306|ACTIVE_COMPARATOR|Losartan(B)|
62337808|NCT01691872|EXPERIMENTAL|Japanese|Retigabine 300mg single-dose
62337809|NCT01691872|EXPERIMENTAL|Caucasian|Retigabine 300mg single-dose
62696127|NCT03213405|EXPERIMENTAL|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
61942286|NCT00004857|EXPERIMENTAL|Fludarabine + Campath-1H|Standard of care induction with fludarabine followed by consolidation antibody therapy
62337810|NCT05838833|EXPERIMENTAL|Low dose|low dose ointment
62337811|NCT05838833|EXPERIMENTAL|High dose|high dose ointment
62337812|NCT05838833|PLACEBO_COMPARATOR|Placebo|same ingredient with active drug except API
62337813|NCT02497872|EXPERIMENTAL|Early Precut Sphincterectomy|Biliary stone removal using early precut: Patients enrolled in this arm received biliary drainage through a small incision on the papilla with an endoscopic needle-knife - a technique called precut sphincterotomy.
62337814|NCT02497872|ACTIVE_COMPARATOR|Pancreatic Duct Stent|Biliary stone removal using persistence of cannulation and a later pancreatic duct stent placement: Patients enrolled in this arm received conventional biliary drainage through persistent biliary cannulation. After completion of biliary drainage, a prophylactic pancreatic duct stent was placed.
62696128|NCT03213405|EXPERIMENTAL|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
62337815|NCT01160952|OTHER|long-term group|long-term group refers to prophylaxis by using itraconazole for up to 90 days
61942287|NCT04932460|EXPERIMENTAL|CEUS+blue dye|The included patients will accept essential tests and CEUS before and after neoadjuvant chemotherapy to evaluate axillary lymph nodes status. When patients finish neoadjuvant therapy, SLNB with or without axillary lymph node dissection will be performed using CEUS lymphatic mapping to mark SLN on the skin combined with blue dye.
61942288|NCT02869074||VWD Spanish Cohort|"Patients with previously diadnosis of VWD from approximately 38-40 different centers from Spain.~Samples from these patients will be analyzed locally, and also centrally for VWF and VWFgene"
61942289|NCT05925465|ACTIVE_COMPARATOR|Maxillary and mandibular nerve block (MMNB) group|receive bilateral combined maxillary and mandibular nerve block. Three mL of 0.5% isobaric bupivacaine will be injected for each nerve block after negative aspiration of blood.
61942290|NCT05925465|PLACEBO_COMPARATOR|Control (C) group|not receive any nerve block
61942291|NCT01419626|NO_INTERVENTION|Negative Control|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste.
61942292|NCT01419626|SHAM_COMPARATOR|Device with Water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
61942293|NCT01419626|EXPERIMENTAL|Device with Mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
61942294|NCT03931824|EXPERIMENTAL|PRP group|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times."
61942295|NCT03931824|SHAM_COMPARATOR|Placebo group|Injections containing saline were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used. To provide blindness, all injections were done using injectors coated with non transparent tape. All of the PRP injections were done by the same physician each time, with compliance to preventive measures against complications such as infections. Patients and the physician who applied the injection were blinded to the groups, and the solution was prepared by another researcher who was not blind to the groups.
61942296|NCT03865771|EXPERIMENTAL|EPILEPSY GROUP|"Patients with typical BECTS (benign group) or atypical BECTS or ECSWS (severe group)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography (standard of care procedure): 2h wake and whole night~Sleep diary"
61942297|NCT03865771|OTHER|CONTROL GROUP|"Patients hospitalized for non neurologic illness (diabetes, nephropathy, chronic intestinal disease)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography : 2h wake and whole night~Sleep diary"
61942298|NCT04096742|EXPERIMENTAL|Altreno|tretinoin 0.05% lotion (Altreno)
61942299|NCT04096742|SHAM_COMPARATOR|Vehicle|Vehicle lotion not containing tretinoin
61942300|NCT02298634||Observation|Patients with Farber disease or high-grade suspicion for Farber disease
61942301|NCT03118713|EXPERIMENTAL|ipragliflozin and metformin|Subjects will receive daily dosage of ipragliflozin and metformin as single tablets
61942302|NCT03118713|EXPERIMENTAL|glimepiride and metformin|Subjects will receive daily dosage of glimepiride and metformin as single tablets
62494679|NCT06357416|OTHER|Stakeholder service interviews (MV-SSI) Sub-Study|Semi-structured interviews with people involved in the running of the project or those who may help in recruiting patients. This may include but not be limited to: GPs, community leaders (e.g. church pastors), charity leaders, staff involved in delivery (nurses, co-ordinators), men who did not attend the service and relatives of men.
61942303|NCT05255211|EXPERIMENTAL|Remimazolam|IV Remimazolam tosilate 0.3mg/kg
61942304|NCT05255211|ACTIVE_COMPARATOR|propofol|IV propofol 1.2\~2.5mg/kg
61942305|NCT05255211|PLACEBO_COMPARATOR|saline|IV saline solution 10ml
61942306|NCT01475409|EXPERIMENTAL|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, tuberculin skin test (TST) and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset.
61942307|NCT02235519|ACTIVE_COMPARATOR|Azilsartan low dosage|Patients will take azilsartan 40 mg during 12 weeks
61942308|NCT02235519|ACTIVE_COMPARATOR|Azilsartan high dosage|Patients will take azilsartan 80 mg during 12 weeks
61942309|NCT01222624|EXPERIMENTAL|PankoMab-GEX™, 3-weekly|application, q3w
61942310|NCT01222624|EXPERIMENTAL|PankoMab-GEX™, 2-weekly|application q2w
61942311|NCT01222624|EXPERIMENTAL|PankoMab-GEX™, weekly|application q1w
61942312|NCT03881670|PLACEBO_COMPARATOR|Lotrafilcon B|
61942313|NCT03881670|ACTIVE_COMPARATOR|Lotrafilcon B Hydraluxe|
61942314|NCT05877573|EXPERIMENTAL|short-course radiotherapy plus chemotherapy and immunotherapy|A total of 53 patients receive 5\*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 2 cycles of CAPOX chemotherapy.
61942315|NCT01480648|EXPERIMENTAL|BI144807|Subjects receive a single oral dose of BI144807solution
61942316|NCT01480648|PLACEBO_COMPARATOR|Placebo|Subjects receive a single oral dose of placebo solution
61942317|NCT04020588|ACTIVE_COMPARATOR|Celecoxib|Celecoxib 200 mg twice a day
61942318|NCT04020588|ACTIVE_COMPARATOR|Minocycline|Minocycline 100 mg twice a day
62494680|NCT06357416|OTHER|Target product profile (MV-TPP) Sub-Study|We will develop an equity-focused Target Product Profile (TPP) that can provide a summary of the requirements for an optimal yet realistic profile of biomarker tests designed to work in mobile testing clinics, such as the Man Van.
62696129|NCT06039514|EXPERIMENTAL|GGTCA-AD mobile app|The experimental group uses the GGTCA-AD module for 14 days after the first assessment.
61942319|NCT04020588|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice a day
61942320|NCT02876627|EXPERIMENTAL|breast cancer|Effect of exercise training on breast cancer patient
62696130|NCT06039514|ACTIVE_COMPARATOR|GGNeutra mobile app|The control group uses GGNeutra for 14 days after the first assessment.
62696131|NCT06334796|EXPERIMENTAL|Virtual Assistant|Patients answer question with a virtual assistant about their recent visit to the ER.
62696132|NCT06334796|ACTIVE_COMPARATOR|ChatGPT 3.5|Patients answer question with ChatGPT about their recent visit to the ER.
61942321|NCT05089279|EXPERIMENTAL|Sequence 1|Period 1: D113/ Period 2: CKD-349
62696133|NCT06334796|ACTIVE_COMPARATOR|ChatGPT 4|Patients answer question with ChatGPT about their recent visit to the ER.
61942322|NCT05089279|EXPERIMENTAL|Sequence2|Period 1: CKD-349/ Period 2: D113
61942323|NCT00928395|ACTIVE_COMPARATOR|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
61942324|NCT02818361|EXPERIMENTAL|topical TwHF gel group|Topical TwHF gel recipe composes Tripterygium wilfordii Hook F, Mangxiao (Mirabilite), Chuanxiong (Rhizoma Ligustici), Ruxiang (Olibanum), Moyao (M yrrh) (prescription proportion is 4:4:2:2:1).Each gel is 20 gram(g). TwHF gel is applied for 1st to 5th metacarpophalangeal joints, 1st to 5th proximal interphalangeal joints, wrists, knees and ankles 20g for 1 hour, once per day from week 0 through week 4 and 10g for 1 hour, once per day from week 5 through week 8.
61942325|NCT02818361|PLACEBO_COMPARATOR|placebo group|Placebo recipe composes viscous agent which matches by the sucrose. The usage and dosage of topical TwHF and placebo are the same.
62494681|NCT02509286|EXPERIMENTAL|Perioperative Chemotherapy (FLOT):|"The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
61942326|NCT03400995|EXPERIMENTAL|Intervention Arm|Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.
62337816|NCT01160952|OTHER|short term group|short term group refers to prophylaxis by itraconazole for 30 days
62494682|NCT02509286|ACTIVE_COMPARATOR|Neoadjuvant Chemoradiation (CROSS):|"The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
61942327|NCT02600065||Study cohort|"All patients who are suffering from brain tumor of brain metastases and are willing to participate.~The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy."
61942328|NCT00169793|OTHER|A|
61942329|NCT03746171||Patients with rectosigmoid colonic polyps|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (\<5 mm) rectosigmoid polyp is detected.
61942330|NCT00658008|EXPERIMENTAL|PD 0332334 175 mg BID|
62494683|NCT04994431|EXPERIMENTAL|Perioperative Tamsulosin Hydrochloride|Participants undergoing thoracic surgery will receive 0.4mgTamsulosin Hydrochloride orally nightly for the two nights immediately prior to surgery and the morning of surgery.
62696134|NCT03411187|ACTIVE_COMPARATOR|foot-control exhaust group|The foot-control exhaust group used of the Pressure adjustable foot-control method by the way of adjustable Pressure to intermittent exhaust
62696135|NCT03411187|PLACEBO_COMPARATOR|direct exhaust group|direct exhaust group exhaust through the Trocar hole.and without use of the Pressure adjustable foot-control method
61942331|NCT00658008|EXPERIMENTAL|PD 0332334 225 mg BID|
62337817|NCT02268006|OTHER|IMRT-SIB|
62337818|NCT00217867|NO_INTERVENTION|1|Usual Care, defined as the usual hospital discharge process as delivered by nurses and doctors.
62337819|NCT00217867|EXPERIMENTAL|2|Use of animated computerized character to prepare subjects for discharge by reviewing information provided to subjects in a printed After Hospital Care Plan packet, followed by telephone system to reinforce the discharge.
62696136|NCT05966714||Group 1|Nujiang (880m)
62696137|NCT05966714||Group 2|Kunming(1800m)
61942332|NCT00658008|EXPERIMENTAL|PD 0332334 75 mg BID|
61942333|NCT00658008|ACTIVE_COMPARATOR|Paroxetine 20 mg QD|
61942334|NCT00658008|PLACEBO_COMPARATOR|Placebo BID|
61942335|NCT00705926|EXPERIMENTAL|A1|Antiretroviral therapy followed by discontinuation at Week 12.
61942336|NCT00705926|EXPERIMENTAL|A2|Antiretroviral therapy followed by discontinuation at Week 32.
61942337|NCT00705926|PLACEBO_COMPARATOR|B|No treatment.
61942338|NCT02722369|ACTIVE_COMPARATOR|Control Arm|"* IV carboplatin AUC5 (area under curve) on Day1~* IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3"
61942339|NCT02722369|EXPERIMENTAL|Investigational Arm|"* IV gemcitabine 1200mg/m2 on Day 1 and Day 8~* IV carboplatin AUC5 on Day 1~* Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)"
61942340|NCT01995643|ACTIVE_COMPARATOR|Active Capsule|Grape Seed Extract Capsule: 300 mg
61942341|NCT01995643|PLACEBO_COMPARATOR|Placebo Capsule|Placebo Capsule: Maltodextrin
62138491|NCT04105816|PLACEBO_COMPARATOR|Adult Healthy Controls|Subjects included in part I of this study will be healthy adult volunteers with no known musculoskeletal injury. Exclusion criteria will be those with identified musculoskeletal injury, non-English speaking persons, and women who are pregnant.
62696138|NCT05966714||Group 3|Lijiang(2500m)
62696139|NCT05966714||Group 4|Shangri-La (3500 m)
62696140|NCT03777605|EXPERIMENTAL|"NTG1523, rapid absorbable capsule"|"Nitroglycerine 0.4 milligram taken as ordinary tablets or NTG1523 rapid absorbable capsule once in the morning, and subsequently blood samples and observations for 2 hours are performed"
62696141|NCT01355627|EXPERIMENTAL|TachoSil®|
62696142|NCT01355627|ACTIVE_COMPARATOR|Current practice group|
62696143|NCT02527512|ACTIVE_COMPARATOR|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
62696144|NCT02527512|ACTIVE_COMPARATOR|Normal Saline|Sterile sodium chloride (NaCl) solution
62494684|NCT04994431|NO_INTERVENTION|Historical Comparator|Participants who underwent thoracic surgery (historical). Information about occurrence of Peri-Operative Urinary Retention in thoracic surgery patients will be obtained via retrospective chart review.
62494685|NCT01091363|EXPERIMENTAL|deep cultural arm|deep cultural therapy
62494686|NCT01091363|ACTIVE_COMPARATOR|standard arm|brief cessation counseling
62494687|NCT04986254||Benzylpenicillin|ICU patients receiving benzylpenicillin for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
62494688|NCT04986254||Ceftriaxone|ICU patients receiving ceftriaxone for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
62494689|NCT04986254||Meropenem|ICU patients receiving meropenem for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
62494690|NCT04986254||Piperacillin/tazobactam|ICU patients receiving piperacillin/tazobactam for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
62494691|NCT01015963||Ancillary-correlative (DNA sample analysis)|Blood samples collected on clinical trial CLB-9871 are examined via ABCC2 and SLC01B3 genotyping using TaqMan analysis. Other genes related to the pharmacokinetics and side effects of docetaxel may be considered for future genotyping. In some cases, panels of drug response SNPs on high-density arrays may be genotyped.
62494692|NCT01277510|PLACEBO_COMPARATOR|Placebo|Participants received standard of care and placebo once daily for 30 weeks during the double-blind phase. During the open-label phase, participants received cinacalcet with standard of care for an additional 30 weeks. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks up to Week 54 to a maximum dose of 4.2 mg/kg.
62494693|NCT01277510|EXPERIMENTAL|Cinacalcet|Participants received standard of care and cinacalcet once daily for 30 weeks during the double-blind phase. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks until Week 24 to a maximum dose of 4.2 mg/kg. During the open-label phase participants continued to receive cinacalcet with standard of care for an additional 30 weeks.
62494694|NCT03344120|ACTIVE_COMPARATOR|suture stent|suture stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
62494695|NCT03344120|ACTIVE_COMPARATOR|conventional double-J stent|conventional double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
62337820|NCT03939806||Oxytocin|This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
62494696|NCT01625403|EXPERIMENTAL|rhBNP treated|standard of care with rhBNP
62494697|NCT01625403|ACTIVE_COMPARATOR|standard of care|standard of care
62494698|NCT04394130|EXPERIMENTAL|CI group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~Then a continuous infusion of ropivacaine 0.2% at a flow rate of 6 ml.h-1 will be running for 48h after the bolus administration.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
62494699|NCT04394130|NO_INTERVENTION|SS group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~After the injection, the catheter will be removed.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
62494700|NCT04642781||healthy children aged 8-13years (schoolgrade 2-5)|Primary school children are asked to read a German text presented on a laptop screen
62494701|NCT04257695|EXPERIMENTAL|TapPro|Biweekly telephone and in-person visits with a clinician over three months. At each visit, a protocol adapted from the Prescription Opioid Taper Study will be provided to participants, who will learn about pain coping, distraction techniques, diaphragmatic breathing, sleep techniques, and progressive muscle relaxation techniques. All are specifically designed for patients with chronic pain on chronic opioid therapy. During visits, taper parameters will be discussed and the provider will work through a dose reduction schedule, if participants are in agreement. Additionally, urine drug screens will be obtained.
62494702|NCT04257695|NO_INTERVENTION|Usual Care|Participants randomized to the usual care arm will continue seeing their primary care providers as indicated.
61942342|NCT03344796|NO_INTERVENTION|Focus Group|"32 subjects~Focus group: It is expected that each participant will provide comments during the 2 hours of the focus group. It will take about one month to enroll the subjects. The audio files should be transcribed and the analysis completed in 60 days. The analysis will determine enablers and barriers to sun protected outdoor activities and determine strategies for achieving sun protected outdoor activities. Baseline knowledge of sun protection performed prior to and at end of focus group."
61942343|NCT03344796|NO_INTERVENTION|Usability testing|"10 subjects~Usability test with structured interview: Each participant will use the sensor for 14 days and transmit data with the app installed on their mobile phone. It will take about one month to enroll the subjects. The analysis of the structured interview is completed in one week. Baseline knowledge of sun protection performed prior to and at end of usability test."
62337821|NCT03939806||Carbetocin|This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
61942344|NCT03344796|ACTIVE_COMPARATOR|Cohort Study 1-Arm 1|"31 subjects~First cohort study: It is expected that melanoma survivors will wear the sensor and transmit data for 21 days in the warm weather months of June-Aug 2019. It will take about 2 months to enroll the subjects. Subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized in Arm 1 to receive a survey item inviting selection of strategies to achieve sun-protected outdoor activities (structured goal attainment). Baseline knowledge of sun protection performed prior to and at end of intervention."
61942345|NCT03344796|NO_INTERVENTION|Structured Interviews|20 young adults, ages 18-39 will participate in structured interviews to determine their barriers and enablers of sun exposure and sun protection. Eligible subjects will have at least one hour a day outdoors with 30 minutes of the hour being consecutive. It will take about 3 months to enroll the subjects. The audio files will be transcribed and analysis completed in 60 days. Baseline knowledge of sun protection will be performed prior to and after structured interviews.
61942346|NCT03344796|NO_INTERVENTION|Cohort Study 2|Second cohort study: 42 young adult participants will recall the number of sunburns experienced in the 28 days prior to enrolling in the study. Then, the same young adult participants will wear the UV sensor daily for 28 summer days. Participants will receive a warning on their mobile phone if the UV dose approaches the dose anticipated to cause sunburn in unprotected skin. Participants will record the number of days in which they get a sunburn. Baseline knowledge of sun protection performed prior to and at end of study.
61942347|NCT03344796|ACTIVE_COMPARATOR|Cohort Study 1- Arm 2|29 subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized in Arm 2 to submit a free text description of their strategy (unstructured goal attainment). Baseline knowledge of sun protection performed prior to and at end of intervention.
61942348|NCT02764333|EXPERIMENTAL|vaccine|Patients will receive an intradermal (ID) injection of TPIV200 (500 μg per peptide) and GM-CSF (125 μg per peptide) on Day 1 of cycles 1-6. They will also receive intravenous (IV) injections of durvalumab (750mg) on Days 1 and 15 of cycles 1-12. Radiologic tumor assessment will be repeated every 12 weeks (or 3 cycles) during and after treatment, until time of progression. Treatment will continue until progression, intolerance, withdrawal, study completion, or study termination.
61942349|NCT05143281|EXPERIMENTAL|Dexamethasone Ophthalmic Insert Day of Surgery|Day of surgery, in OR placement
61942350|NCT05143281|EXPERIMENTAL|Dexamethasone Ophthalmic Insert Day 1 Post Op|Day 1 Post-Op, In-office (HOPD)
61942351|NCT04970641|EXPERIMENTAL|3GT journaling group|Subjects will participate in the Three Good Things (3GT) Positive Psychology journaling activity daily for six weeks.
62138492|NCT04105816|EXPERIMENTAL|Adult ACL Reconstruction Patients|Subjects included in part II of the study will be adult volunteers undergoing anterior cruciate ligament reconstruction at the University of Iowa. Exclusion criteria will be non-English speaking persons, women who are pregnant, patients undergoing multi-ligament repair, patients undergoing ACL reconstruction revision, patients undergoing concomitant cartilage or meniscal repair procedures, and patients undergoing bilateral ACL reconstructions.
62138493|NCT06589024|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 5 sessions per week, \~36 minutes per session.
62138494|NCT06589024|ACTIVE_COMPARATOR|Active Comparator|Sleep hygiene education
62138495|NCT03172871|EXPERIMENTAL|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
61942352|NCT04970641|NO_INTERVENTION|Non-journaling group|Subjects will not participate in the evening journal activity.
61942353|NCT03243942|EXPERIMENTAL|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
62337822|NCT02010216|EXPERIMENTAL|tocilizumab [RoActemra/Actemra]|Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).
61942354|NCT01817231||breast cancer cases|breast cancer cases versus controls
61942355|NCT01501370|EXPERIMENTAL|ZLd|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive:~Cohort 1: ZLd association:~* Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~* Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle.~* Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
61942356|NCT01501370|ACTIVE_COMPARATOR|Ld|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~• Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
62138496|NCT03172871|ACTIVE_COMPARATOR|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
62138497|NCT01010945|EXPERIMENTAL|erlotinib, gemcitabine, nab-paclitaxel|Patients receive the following treatment in 28-day cycles: 1) erlotinib: orally once daily from days 1 through 28 continuous dosing; 2) gemcitabine (following nab-paclitaxel): intravenously over 30 minutes on days 1, 8 and 15 every 28 days; and 3) nab-paclitaxel: intravenously over 30 minutes on days 1, 8 and 15 every 28 days.
62138498|NCT03056313|EXPERIMENTAL|proactive support of labor|delayed labor; 1 cm opening and painful contractions
62138499|NCT03056313|ACTIVE_COMPARATOR|support of labor as usual|delayed labor; 3-4 cm opening of the cervix and regular contractions
62138500|NCT00978016|EXPERIMENTAL|arbaclofen placarbil-Cohort 1|"arbaclofen placarbil 20 mg QD with PPI\*~\* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
62337823|NCT01982773|EXPERIMENTAL|Virtual Hope Box Smartphone App|Use of the smartphone app, Virtual Hope Box on their personal smartphone
62138501|NCT00978016|EXPERIMENTAL|arbaclofen placarbil-Cohort 2|"arbaclofen placarbil 40 mg QD with PPI\*~\* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
62138502|NCT00978016|EXPERIMENTAL|arbaclofen placarbil-Cohort 3|"arbaclofen placarbil 20 mg BID with PPI\*~\* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
62337824|NCT01982773|ACTIVE_COMPARATOR|EnhancedTreatment As Usual|Subjects will be issued printed materials guiding them in coping with suicidal thoughts, which include information about coping strategies and emergency contact information.
62337825|NCT04752098|OTHER|premature infants and full term infants|"The study visits will be at ≥3 time points at ages: within the first 28 days after birth, 2 months, 3 months, and, if still hospitalized, at 4 months and at 6 months.~* The ultrasound machine to the nursery or neonatal intensive care unit at a scheduled time.~* The appropriate ultrasound probe will be placed on the infant's tibia and a miniature hydrophone near the probe. A series of ultrasound measurements will be obtained and the ultrasound data will be saved for offline processing.~* The Investigators will repeat the measurement in 3 locations of the infant's tibia.~* Each ultrasound measurement takes a few seconds. The complete ultrasound study will take about 15 minutes at each visit.~* All procedures will be conducted in the nursery or neonatal intensive care unit to ensure infant safety.~* The ultrasound measurement for full-term infants can be done in ultrasound lab."
62138503|NCT00978016|EXPERIMENTAL|arbaclofen placarbil-Cohort 4|"arbaclofen placarbil 30 mg BID with PPI\*~\* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
62138504|NCT00978016|PLACEBO_COMPARATOR|Placebo-Cohort 5|"Placebo dose with PPI\*~\* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
62337826|NCT04705727|EXPERIMENTAL|budesonide/formoterol Turbuhaler®|After randomization, patients in the experimental arm will receive budesonide/formoterol Turbuhaler® 100/6 μg, one inhalation every 5 minutes (Maximum 12 inhalations).
62337827|NCT04705727|ACTIVE_COMPARATOR|nebulisation of terbutaline|0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered. In case of an insufficient response, 3 additional doses will be administered for a maximum of 6 nebulisations.
62337828|NCT05312424|PLACEBO_COMPARATOR|Placebo|Placebo group: subject will take one pill (150 mg olive oil) after breakfast and another pill (150 mg olive oil) after dinner
62696145|NCT04428580|EXPERIMENTAL|Online Training|10 lectures that are self-paced with a maximum of three months to complete with each lecture bundle comprising of 5-8 short (about 4 minutes in length), didactic videos that discuss the treatment model and provide mock therapy session video clips (modeling FBT with a typical adolescent AN case), as well as supplementary readings and videotaped role-plays. Enrollees complete each lecture bundle and complete the assignments as they move through the training at their own pace, but to have completed all within the 3-month time frame. When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
62696146|NCT04428580|ACTIVE_COMPARATOR|Webinar Training|1-hour weekly webinar lectures that essentially is the FBT training that is conducted in person, just recorded. There will be lectures discussing the scientific evidence supporting FBT, how therapists set up treatment for FBT, main interventions used in FBT during each phase, and recorded role-plays illustrating interventions throughout the 3 phases. Enrollees watch each webinar video as it is released weekly over a 12 week (3 month period). When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
62138505|NCT02575924|ACTIVE_COMPARATOR|sequential medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
62337829|NCT05312424|ACTIVE_COMPARATOR|Low GG|LOW GG group: subject will take one pill (150 mg olive oil) after breakfast and another pill (150 mg GG) after dinner
62337830|NCT05312424|ACTIVE_COMPARATOR|High GG|HIGH GG group: subject will take one pill (150 mg GG) after breakfast and another pill (150 mg GG) after dinner
62337831|NCT05508438|OTHER|Treatment Group|
62337832|NCT05413005|EXPERIMENTAL|Group A (ECP regular-intensity arm)|ECP in a regular-intensity arm plus T1DM standard of care
62337833|NCT05413005|EXPERIMENTAL|Group B (ECP accelerated-intensity arm)|ECP in an accelerated-intensity arm plus T1DM standard of care
62337834|NCT05633147|EXPERIMENTAL|linaprazan glurate|"Part I: Linaprazan glurate in base form, 100 mg once daily will be administered under fasting conditions at day 1 and day 10.~Part II: Linaprazan glurate hydrochloride (HCl), 75 mg twice a day for 13 days. The morning dose will be administered under fasting conditions on Day 2 and Day 14."
62337835|NCT03136367|EXPERIMENTAL|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
62494703|NCT06441695|EXPERIMENTAL|Experimental Treatment|extended release xumXR caffeine (200mg) capsule; subject receives 2 capsules totaling 400mg
62494704|NCT06441695|ACTIVE_COMPARATOR|Control Treatment|immediate release caffeine (200mg) capsule; subject receives 2 capsules totaling 400mg
62494705|NCT03326167||Patients with or suspected coronary heart disease|
62337836|NCT03136367|EXPERIMENTAL|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
62337837|NCT03136367|NO_INTERVENTION|Arm 3: Usual Care|In the usual care arm, surgeons provided their standard information about breast cancer
62337838|NCT03639012|ACTIVE_COMPARATOR|Carbohydrate loading|Patients to receive an oral preoperative carbohydrate drink
62337839|NCT03639012|NO_INTERVENTION|No Carbohydrate loading|Current standard of care
62337840|NCT04310215|EXPERIMENTAL|Microfracture + CARTISTEM®|CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.
62337841|NCT04310215|ACTIVE_COMPARATOR|Microfracture|Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.
62494706|NCT02865824|ACTIVE_COMPARATOR|Continue thienopyridine|Patients continue dual antiplatelet therapy (DAT) before colonoscopy and all polyps are removed by cold snare polypectomy.
62494707|NCT02865824|EXPERIMENTAL|Discontinue thienopyridine|Patients discontinue thienopyridines for 1 week before colonoscopy and all polyps are removed by cold snare polypectomy.
62494708|NCT02511860|PLACEBO_COMPARATOR|Placebo|Patients will consume a placebo pill containing methylcellulose.
62494709|NCT02511860|ACTIVE_COMPARATOR|Active|Patients will consume 850 mg of burdock twice per day.
61942357|NCT04250922|PLACEBO_COMPARATOR|Arm A: SoC + placebo for LAM561|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over \~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm A will receive placebo every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance (Adjuvant) Phase will be scheduled \~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm A will receive placebo every day during the first 3 weeks of each 28-day cycle and until progression. Patients will continue with Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
61978779|NCT03486132|OTHER|continuous repair of lateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
62337842|NCT02572128|EXPERIMENTAL|Study 1|Iron fortified rice hot or cold extruded.
62337843|NCT02572128|EXPERIMENTAL|Study 2|Iron and zinc fortified rice hot extruded or coated.
62337844|NCT04556617|EXPERIMENTAL|PLX2853 + Abiraterone Acetate + Prednisone|"Phase 1b (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 15 evaluable subjects with mCRPC will be enrolled.~Phase 2a (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 19 evaluable subjects with mCRPC will be enrolled."
62337845|NCT04556617|EXPERIMENTAL|PLX2853 + Olaparib|"Phase 1b (PLX2853 + Olaparib Combination): Up to 18 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.~Phase 2a (PLX2853 + Olaparib Combination): Up to 58 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled."
62337846|NCT06316882|EXPERIMENTAL|screening endoscopy|We perform upper endoscopy, when the patient authorizes it, at the same time of their screening colonoscopy
62337847|NCT01156610|EXPERIMENTAL|Integrated Cessation Counseling|"IVR System: IVR will be used for two purposes: (1) to facilitate access to treatment for low-SES and minority smokers and (2) perform six-month outcome assessment.~Tobacco Treatment Specialist Calls: A tobacco treatment specialist will make four attempts to contact the patient by phone within 14 days. On contacting the patient, the specialist will screen the patient for readiness to quit, provide brief (10 to 15 minutes) counseling tailored to the patient's readiness to quit, and provide information and support for use of medications that could be or were prescribed and about relevant community resources.~NRT: Patients who do not have a contraindication and smoke \> 10 cigarettes per day, will be offered a free 6-week kit of generic nicotine patches (2 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches). Individuals who smoke 5-10 cigarettes/day will be offered a 6-week course, starting with the 14 mg patch. Those with a contraindication will not get NRT."
62337848|NCT01156610|ACTIVE_COMPARATOR|Usual Care|"IVR Call: Similar to the initial IVR call for the intervention arms, the initial control arm call will confirm the participant's identify and provide a brief description of the study (obtaining information about health behaviors), with the opportunity for the individual to accept or decline participation. Following this introduction, the IVR script will confirm smoking status. The phone script will collect specific information about current smoking (cigarettes/day), prior quit attempts, and motivation to quit during the next month. No further contact will be made with patients in the control clinics until the outcome assessment call. In the control practices, the IVR machine will also generate a text note documenting the information obtained for the patients' EHR for use by the patient's health care providers as part of their visit-based best practices."
62337849|NCT04445493||Device: MindRhythm Harmony|Passive recording of the head pulse
62337850|NCT05208203||stroke patients|acute ischemic stroke patients including all treatments.
62337851|NCT00893048|EXPERIMENTAL|Prednisone|Use of prednisone to decrease LOS and overall treatment time of cellulitis
62494710|NCT03820258|EXPERIMENTAL|Experimental: Cohort 1 (12 to < 18 years old), 8 Weeks|Direct-acting antiviral (DAA)-naive participants without cirrhosis in Cohort 1 (12 to \< 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 8 weeks.
62696147|NCT05509127|EXPERIMENTAL|Carious cervical lesions treated with modified universal adhesive|Preparation of class V cavity with removal of caries and beveling of margins is done followed by total etching prior to application of modified universal adhesive. The cavity is then restored with nano-filled resin composite.
62337852|NCT00893048|EXPERIMENTAL|Placebo|
62337853|NCT01107275|EXPERIMENTAL|2 primary ID doses|two doses of rabies vaccines given intradermally on days 0 and 28
62337854|NCT01107275|EXPERIMENTAL|3 primary ID doses|three doses of rabies vaccines given intradermally on days 0, 7, and 28
62337855|NCT03071705|EXPERIMENTAL|Intervention|TKI plus Metformin
62337856|NCT03071705|ACTIVE_COMPARATOR|Control|TKI
62337857|NCT01731301|EXPERIMENTAL|Ribavirin, peginterferon, boceprevir|The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
62337858|NCT04128579|EXPERIMENTAL|EQ001 Type A cohort|EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg).
62337859|NCT04128579|EXPERIMENTAL|EQ001 for Type B cohort|EQ001 administered in an unblinded single dose cohort by subcutaneous injection every two weeks for a total of 13 doses (1.6 mg/kg).
62494711|NCT03820258|EXPERIMENTAL|Experimental: Cohort 1 (12 to < 18 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 1 (12 to \< 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 12 weeks.
62494712|NCT03820258|EXPERIMENTAL|Experimental: Cohort 2 (6 to < 12 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 2 (6 to \< 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
62494713|NCT03820258|EXPERIMENTAL|Experimental: Cohort 2 (6 to < 12 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 2 (6 to \< 12 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
62494714|NCT03820258|EXPERIMENTAL|Experimental: Cohort 3 (3 to < 6 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 3 (6 to \< 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
62494715|NCT03820258|EXPERIMENTAL|Experimental: Cohort 3 (3 to < 6 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 3 (3 to \< 6 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
62494716|NCT05530811|ACTIVE_COMPARATOR|with dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
61978780|NCT01979809|SHAM_COMPARATOR|Arm 1|Untailored control website designed to support increase in fruit and vegetables with no age targeting used in previously funded MENU Choices study
62337860|NCT01503060|PLACEBO_COMPARATOR|Group 1|"* Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care~* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
62337861|NCT01503060|ACTIVE_COMPARATOR|Group 2|"* Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain~* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
62337862|NCT01503060|ACTIVE_COMPARATOR|Group 3|"* Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar~* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
62337863|NCT01503060|ACTIVE_COMPARATOR|Group 4|"* Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic~* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
62337864|NCT00532961|EXPERIMENTAL|Zylet|Zylet (loteprednol etabonate and tobramycin)
62337865|NCT00532961|ACTIVE_COMPARATOR|Tobradex|TobraDex (dexamethasone and tobramycin)
62337866|NCT02078882|EXPERIMENTAL|Abatacept 125 mg weekly|Open label treatment with Abatacept
62337867|NCT03430817|EXPERIMENTAL|Group C|Citicholine Drug
62494717|NCT05530811|PLACEBO_COMPARATOR|without dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline.
62494718|NCT03789487|EXPERIMENTAL|Non-responders to CRT|Non-responders to CRT who will undergo an electrical optimization of the settings of their device
62494719|NCT04163588|ACTIVE_COMPARATOR|Standard therapy|intravenous loop diuretics as recommended by current guidelines plus placebo
62494720|NCT04163588|EXPERIMENTAL|SNB|loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
62494721|NCT05638035||non-obese women|After obtaining demographic information for women with a BMI of 18-27.9 kg/m2 for at least 6 months, Body Mass Index (BMI) will be calculated and the relationship between rectus femoris muscle thickness, sarcopenia, gait and balance will be evaluated and will be compared with obese group.
62494722|NCT05638035||obese women|After obtaining demographic information in women with a BMI of 30-39.9 kg/m2, Body Mass Index (BMI) will be calculated and the relationship between obesity and rectus femoris muscle thickness, sarcopenia, gait and balance will be evaluated.
62337868|NCT03430817|EXPERIMENTAL|Group A|Amantadine Drug
61978781|NCT01979809|ACTIVE_COMPARATOR|Arm 2|MENU GenY age-targeted and tailored interactive website including 8 information sessions over 4 months, and options to visit over 185 recipes, videos, 4 bloggers, and information articles on dietary change topics
62337869|NCT03430817|EXPERIMENTAL|Group D|Both Citocholine and Amantadine
62337870|NCT01405443||Basic training|Theory lecture esophagogastroduodenoscopy (EGD). One hour simulator training for EGD. 30 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. One hour simulator training for Colonoscopy. 30 minutes supervised training. Supervised endoscopy. Group will be followed up for 2 weeks training time.
62337871|NCT01405443||Intermediate training|Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
62337872|NCT01405443||Extended training|Theory lecture EGD. Five hours simulator training for EGD. 90 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Five hours simulator training for Colonoscopy. 90 minutes supervised training. Supervised endoscopy. Group will be followed up for 6 weeks training time.
62337873|NCT01114958|EXPERIMENTAL|IA Cisplatin / IV Thiosulfate|Single-arm study
62337874|NCT02909842|EXPERIMENTAL|study group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of yoghurt drink, unlabelled drinking fermented milk containing probiotic, Lactobacillus paracasei (IMULUS)
62494723|NCT04429984||VPRIV: All Participants|Participants with type 1 Gaucher disease who as part of standard or routine clinical practice, have already received VPRIV retrospectively and will further receive VPRIV therapy according to the investigator's judgment for approximately 12 months will be observed prospectively in this PMS study.
62494724|NCT02323555|EXPERIMENTAL|Paramedic telephone consultation|"Establishment of a paramedic telephone consultation to the doctor to record the virtual early prescription or non-injectable cancer treatment before the arrival of the patient (Feasibility Process Optima), without changing the current practice of prescribing and dispensing of these treatments on the day of the coming of the patient."
62494725|NCT03521362|EXPERIMENTAL|MyT1DHero App|Participants in this group will receive use of the MyT1DHero app.
62494726|NCT03521362|ACTIVE_COMPARATOR|"Other T1D App"|Participants in this group will receive use of a different app with less capabilities.
62494727|NCT02174276|ACTIVE_COMPARATOR|TDF 48 weeks|Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
62494728|NCT02174276|EXPERIMENTAL|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
62494729|NCT02174276|EXPERIMENTAL|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
62494730|NCT02174276|EXPERIMENTAL|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
62494731|NCT01812603|EXPERIMENTAL|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide and in open-label manner
62494732|NCT06048848|EXPERIMENTAL|FNB|sono-guided injection with 20ml ropivacaine
62494733|NCT06048848|PLACEBO_COMPARATOR|no FNB|sono-guided injection with 20ml 0.9% saline
61978782|NCT01979809|ACTIVE_COMPARATOR|Arm 3|"Web intervention that is age targeted and tailored, identical to Arm 2, with the addition of personalized e-coaching support via email."
61978783|NCT00509782|EXPERIMENTAL|ZIO-101|
62696148|NCT05509127|ACTIVE_COMPARATOR|Carious cervical lesions treated with conventional universal adhesive|Preparation of class V cavity with removal of caries and beveling of margins is done followed by total etching prior to application of conventional universal adhesive. The cavity is then restored with nano-filled resin composite.
61978784|NCT06157723||Knee osteoarthritis participants|Participants who are registered in the Health system electronic database, with a clinical and radiographic diagnostic of knee osteoarthritis. Approximately a total of 400 participants will be enrolled in the study.
62138506|NCT02575924|ACTIVE_COMPARATOR|sequential medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
61978785|NCT01313936|EXPERIMENTAL|15 mCi/kg of 131I-MIBG|The first cohort for safety will be 3-6 patients treated with vincristine and irinotecan and 15 mCi/kg of 131I-MIBG.
62337875|NCT02909842|PLACEBO_COMPARATOR|control group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of placebo, unlabelled acidified milk with similar physical and sensory appearance to the experimental one
62337876|NCT00793819|EXPERIMENTAL|1 Silodosin|
61978786|NCT01313936|EXPERIMENTAL|18 mCi/kg of 131I-MIBG|The second cohort will be 3-6 patients at the same doses of vincristine and irinotecan and 18 mCi/kg of 131I-MIBG.
62337877|NCT00793819|PLACEBO_COMPARATOR|2 Placebo|
62337878|NCT02808533|EXPERIMENTAL|Topiramate|Topiramate will be dispensed on a biweekly basis, and pill counts conducted at each visit.
62337879|NCT02808533|PLACEBO_COMPARATOR|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
62494734|NCT04438434|EXPERIMENTAL|Hydrogen Peroxide and Hyaluronic acid mouthwash (BMG0703)|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
62696149|NCT01019915|OTHER|Heart failure patients. Intervention CRT|CRT implantation in heart failure. Effect of intervention after 6 months of treatment.
62696150|NCT04877366|ACTIVE_COMPARATOR|ARM A: Sprinkled Format REDUCOSE|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
62337880|NCT04868006|EXPERIMENTAL|End-range mobilization + proprioception training|End-range Maitland mobilization performed in end-range internal rotation of the shoulder accompanied with 8--week long proprioception training
62337881|NCT04868006|ACTIVE_COMPARATOR|Non end-range mobilization+ proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
62337882|NCT04868006|SHAM_COMPARATOR|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
62696151|NCT04877366|PLACEBO_COMPARATOR|ARM B: Placebo B: Standard Meal|A placebo matching to the test product will be used as control
62138507|NCT02575924|ACTIVE_COMPARATOR|sequential medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
62337883|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
62337884|NCT05232422|EXPERIMENTAL|Yoga-Intervention Group|This arm will participate in a hatha yoga course for a time period of 8 weeks with a frequency of at least 3 up to 5 times per week. Further they will participate in the pre- as well as the post-tests before and after the intervention.
62337885|NCT05232422|NO_INTERVENTION|Waiting Control Group|For the first 8 weeks of the study this group will not receive any intervention. After the second measurement is completed they will get the possibility to participate in a hatha yoga course as well. Further they will participate in the pre- as well as the post-tests around the same time as the Yoga-Intervention group.
62337886|NCT02367534|EXPERIMENTAL|Umbilical vein|umbilical vein catheterization
62337887|NCT03605719|EXPERIMENTAL|Arm 1|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62337888|NCT03605719|EXPERIMENTAL|Arm 2|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62337889|NCT03605719|EXPERIMENTAL|Arm 3 (expansion)|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62337890|NCT04564209|EXPERIMENTAL|Treatment|The treatment group will be exposed to the infographic intervention when they present for clinic/study visits. During their visit with the provider, the provider offer health education while using infographics.
62337891|NCT04564209|NO_INTERVENTION|Control|The control groups will receive standard health education.
62337892|NCT01947244|EXPERIMENTAL|Doula Home Visiting|Participants assigned to the intervention group receive prenatal and short-term postpartum home visitation from doulas, and support from doulas at the hospital during labor, delivery, and with early breastfeeding. Additionally, these participants receive longer-term home visiting services from family support workers during pregnancy and after the birth.
62337893|NCT01947244|ACTIVE_COMPARATOR|Case Management|Mothers in the comparison group receive low intensity case management services during pregnancy and following the birth.
62337894|NCT02635152|EXPERIMENTAL|Interpretation Bias Modification (IBM)|"Treatment consists of eight brief sessions. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive positive or negative feedback based on their response."
62696152|NCT04877366|PLACEBO_COMPARATOR|ARM C: Placebo C: Acarbose|Acarbose 100 mg tablet (provided in open-label format)
62696153|NCT05634200||Patients with haemoptysis and negative/non-diagnostic CT scan|Patients with haemoptysis and negative/non-diagnostic CT scan (i.e. with focal peripheral lung fibrosis, calcified parenchymal nodules with a maximum diameter \<5 mm, linear subsegmental atelectasis, hilar-mediastinal lymph nodes with a short axis \<1 cm, pleural thickening/pleural calcification and focal area of emphysema with a diameter \<1 cm) for whom bronchoscopy is deemed necessary to obtain an aetiological diagnosis.
62696154|NCT06456671|EXPERIMENTAL|Exclusive cigarette smokers|Exclusive cigarette smokers will be recruited and will be exposed to all of the conditions described in the intervention section.
62337895|NCT02635152|ACTIVE_COMPARATOR|Progressive Muscle Relaxation (PMR)|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove \& Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
62337896|NCT05126706|EXPERIMENTAL|Digital lifestyle management group|In the experimental group (digital lifestyle management group), 54 patients are randomly assigned to the digital lifestyle management group. The patients use this application for the first 4 months with Noom applications with 1:1 personalized coaching intervention, and then, use this app by self-help program without coaching intervention. In order to monitor the psychological state of the patients, all the patients are given daily assessment online questionnaires and additional questionnaires to evaluate the quality of life at the baseline, 4 months, and 6 months after surgery. To assess the nutritional status of the patients, we collect blood laboratory data, bioimpedance analysis for each visit.
62337897|NCT05126706|NO_INTERVENTION|Non-digital lifestyle management group|In the control group (Non-digital lifestyle management group), 26 patients are randomly assigned to the control group (Non-digital lifestyle management group). The patients follow conventional postoperative care protocol after total thyroidectomy for thyroid cancer without using Noom application. All patients are given questionnaires to evaluate the quality of life at the baseline, 4 months, and 6 months after surgery. To assess the nutritional status of the patients, we collect blood laboratory data, bioimpedance analysis for each visit.
62337898|NCT03003780|EXPERIMENTAL|Mindful Steps|Web-based behavioral intervention
62337899|NCT03003780|NO_INTERVENTION|Usual Care|
62696155|NCT06456671|EXPERIMENTAL|Dual cigarette/ nicotine vaping product users|Dual cigarette and nicotine vaping product users will be recruited and will be exposed to all of the conditions described in the intervention section.
62696156|NCT00860769|EXPERIMENTAL|ASHA Life|6-session educational group discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills.
62696157|NCT00860769|ACTIVE_COMPARATOR|Usual Care|3-session educational group focusing on HIV prevention, anti-retroviral therapy (ART) and parenting.
62696158|NCT04268147||Spinocerebellar Ataxia-1|individuals with a genetically confirmed diagnosis of SCA-1
62696159|NCT04268147||Spinocerebellar Ataxia-2|individuals with a genetically confirmed diagnosis of SCA-2
62696160|NCT04268147||Spinocerebellar Ataxia-3|individuals with a genetically confirmed diagnosis of SCA-3
62696161|NCT04268147||Spinocerebellar Ataxia-6|individuals with a genetically confirmed diagnosis of SCA-6
62696162|NCT04268147||Freidreich's Ataxia|individuals with a genetically confirmed diagnosis of FA
62696163|NCT04268147||FA Controls|Healthy, age-matched controls
61942358|NCT04250922|EXPERIMENTAL|Arm B: SoC + 12 g/day of LAM561|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over \~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm B will receive LAM561 every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance Phase will be scheduled \~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm B will receive LAM561 during the Maintenance Phase. Patients will continue to be administered with LAM561 after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
61942359|NCT02922855|NO_INTERVENTION|Contemporaneous Control|This group is our 'usual care' control group. They were not contacted for an interview and were not offered an incentive to visit their primary care physician.
61942360|NCT02922855|ACTIVE_COMPARATOR|$0 group|This group completed a baseline interview but was not offered any incentive if they visited their primary care physician.
62138508|NCT02575924|ACTIVE_COMPARATOR|one step medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
62138509|NCT02575924|ACTIVE_COMPARATOR|one step medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
62337900|NCT05008588|EXPERIMENTAL|Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment|Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
62494735|NCT04438434|ACTIVE_COMPARATOR|Chlorhexidine 0.2% mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
62696164|NCT04268147||SCA Controls|Healthy, age-matched controls
62696165|NCT00341679||Family Members|Family members need to be blood relatives of the proband with the diagnosis of an autoimmune disease
62696166|NCT00341679||IIM Patient|Adult and pediatric patients with diagnosis of myositis or a related autoimmune or rheumatic disorder (by Bohan and Peter criteria, American College of Rheumatology, or other criteria).
62696167|NCT00341679||Normal volunteers|gender and race-matched to a subset of autoimmune subjects as controls. Should be without any autoimmune disease.
62696168|NCT06642493|EXPERIMENTAL|Arm 1: Intervention Arm Title: Plasma Transfusion.|"Arm 1: Intervention Arm Title: Plasma Transfusion Description: Participants in this arm will receive fresh frozen plasma (FFP) transfusion at a dose of 10-15 mL/kg body weight.~Intervention:~Type: Biological Name: Fresh Frozen Plasma (FFP) Description: Administration of FFP to correct coagulopathy and normalize aPTT."
62696169|NCT06642493|PLACEBO_COMPARATOR|Arm 2: Control Arm Title: Standard Supportive Care|"Arm 2: Control Arm Title: Standard Supportive Care Description: Participants in this arm will receive standard supportive care without plasma transfusion.~Intervention:~Type: Other Name: Standard Supportive Care Description: Standard medical management without the administration of plasma transfusion."
62696170|NCT06644599|ACTIVE_COMPARATOR|Wireless monitoring|Wireless monitoring will be applied on patients who are at high risk, identified as having a National Early Warning Score (NEWS)-2 score of 5 or higher, patients with lower NEWS-2 scores if the clinical team has a clinical concern, patients with Critical Care Response Team (CCRT) activation regardless of NEWS-2 score and post-ICU discharges regardless of NEWS-2 score. The technology allows to have alarms for patients who meet preset thresholds for vital signs. These alarms are transmitted through a mobile device to the charge nurse of the related ward. The wireless system will be monitored 24/7 by a critical care nurse
62696171|NCT06644599|NO_INTERVENTION|Control|Usual care with no wireless monitoring.
62696172|NCT06303427|EXPERIMENTAL|Group A: (Modified constraint-induced movement therapy + electrical stimulation)|"Group A will include 17 participants. The participants in this group will receive a 60-minute session daily. Each participant will perform 96 sessions (6 times per week over 16 weeks) for 60 minutes daily.~1. Electrical stimulation for 20 minutes~2. Routine physical therapy for 10 minutes~3. Modified constraint-induced movement therapy for 30 minutes."
62696173|NCT06303427|EXPERIMENTAL|Group B: (Modified constraint-induced movement therapy)|"17 participants will be included in this group. The participants in this group will also receive a 60-minute session daily (6 times per week over 19 weeks).~1. Routine physical therapy for 10 minutes.~2. Modified constraint-induced movement therapy for 50 minutes."
62696174|NCT04756531|EXPERIMENTAL|PF-07321332 Dose 1|Dose level 1 of PF-07321332
62138510|NCT02575924|ACTIVE_COMPARATOR|one step medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
62138511|NCT05359536|EXPERIMENTAL|E-learning Intervention|Early career educators in the intervention condition will be asked to complete a 5-hour e-learning course over a two week timeframe. The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
62138512|NCT05359536|NO_INTERVENTION|Usual Practice Control|Early career educators in the control condition will be asked to continue with their usual practices. They will be invited to complete the e-learning course after the study period.
62337901|NCT05008588|EXPERIMENTAL|Umbilical cord mesenchymal stem cells treatment|Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
62337902|NCT05008588|ACTIVE_COMPARATOR|Standard treatment (control)|Neurologic and Neutrophic Drugs
62337903|NCT03886701|EXPERIMENTAL|Experimental|Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)
62337904|NCT06273306|EXPERIMENTAL|Digital care|User of mobile APP for telemonitoring
62337905|NCT06273306|NO_INTERVENTION|Traditional care|Monitoring in face-to-face visits
62337906|NCT05889507|EXPERIMENTAL|Whole body hypothermia|Whole-body hypothermia (33.5±0.5°C) will be initiated within 6 hours of birth and continued for 72 hours using a servo-controlled cooling machine at the nearest available neonatal intensive care unit (cooling centre).
62337907|NCT05889507|ACTIVE_COMPARATOR|Normothermia|The rectal temperature will be maintained at 36.5±0.5°C using servo-controlled incubators for the first 80 hours and any hyperthermia will be treated with a standardised protocol.
62337908|NCT02141646|EXPERIMENTAL|Motivational interviewing|
61942361|NCT02922855|EXPERIMENTAL|$25 group|This group completed a baseline interview and was offered $25 they visited their primary care physician within 6 months.
62138513|NCT01340066|EXPERIMENTAL|UISH001|
62337909|NCT02141646|EXPERIMENTAL|Behavioral skills training|
61942362|NCT02922855|EXPERIMENTAL|$50 group|This group completed a baseline interview and was offered $50 they visited their primary care physician within 6 months.
62138514|NCT01340066|PLACEBO_COMPARATOR|Matching placebo|
62337910|NCT04027569|ACTIVE_COMPARATOR|PSFS group|Patients in this arm will complete the patient specific functional scale (PSFS) during their visits
62337911|NCT04027569|EXPERIMENTAL|PROMIS PF group|Patients in this arm will complete the PROMIS Physical Function during their visits
62337912|NCT00264602|EXPERIMENTAL|Near Infrared Imaging|The intervention to be administered is indocyanine green dye.
62337913|NCT00230100|EXPERIMENTAL|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
62337914|NCT00230100|ACTIVE_COMPARATOR|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
62337915|NCT03712501|EXPERIMENTAL|Exercise|Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1. Participants will return the following day and consume a high fat breakfast and lunch.
62337916|NCT03712501|NO_INTERVENTION|Control|Participants will rest on day 1. Participants will return the following day where they will consume a high fat breakfast and lunch.
62337917|NCT04889573|EXPERIMENTAL|Blood sample|
62337918|NCT02316756|EXPERIMENTAL|Single Ascending Doses Cohort 1|subjects receive 3 active doses and one placebo
62337919|NCT02316756|EXPERIMENTAL|Single Ascending Doses Cohort 2|subjects receive 3 doses and one placebo
62337920|NCT02316756|EXPERIMENTAL|Cohort 3|optional cohort
62337921|NCT01502982|EXPERIMENTAL|Chemoimmunotherapy|
62337922|NCT04301921|OTHER|Group 1|Traditional puncture site + no anticoagulation
61942363|NCT06324331|EXPERIMENTAL|Non decidual sparing|uterine incision repair including suturing of the endometrium
61942364|NCT06324331|EXPERIMENTAL|Decidual sparing|uterine incision repair without including the endometrium.
61942365|NCT00431678|EXPERIMENTAL|Arm 1|
61942366|NCT00431678|ACTIVE_COMPARATOR|Arm 2|
61942367|NCT00120523|EXPERIMENTAL|1|Pimecrolimus
61942368|NCT00120523|ACTIVE_COMPARATOR|2|Topical corticosteroids
62337923|NCT04301921|OTHER|Group 2|Traditional puncture site + ACT-guided anticoagulation
62337924|NCT01554839|EXPERIMENTAL|Treatment Group|Treatment group participates in 1 hour online educational tool in addition to baseline and follow up surveys
62337925|NCT01554839|PLACEBO_COMPARATOR|Non Treatment Group|Non Treatment group participates in baseline and follow up surveys
62337926|NCT02985502||pancreatogenic diabetes|patients with pancreatogenic diabetes after pancreatectomy will be recruited
62696175|NCT04756531|EXPERIMENTAL|PF-07321332 Dose 2|Dose level 2 of PF-07321332
62696176|NCT04756531|EXPERIMENTAL|PF-07321332 Dose 3|Dose level 3 of PF-07321332
62696177|NCT04756531|EXPERIMENTAL|PF-07321332 Dose 4|Dose level 4 of PF-07321332
62696178|NCT04756531|EXPERIMENTAL|PF-07321332 Dose 5|Dose level 5 of PF-07321332
62696179|NCT04756531|EXPERIMENTAL|PF-07321332 Dose 4 (Fed)|Dose level 4 of PF-07321332 with high fat meal
62696180|NCT03421353|EXPERIMENTAL|Arm A1|Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every four weeks (Q4W). There will be a 1 week AZD9150 lead-in prior to durvalumab dosing.
62696181|NCT03421353|EXPERIMENTAL|Arm A2|Patients will receive AZD9150 once weekly (QW) + durvalumab every three weeks (Q3W) + Cisplatin on Day 1 + 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
62696182|NCT03421353|EXPERIMENTAL|Arm A3|Depending on the results of Arm A2, Arm A3 may not be conducted. If Arm A3 is conducted, patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + cisplatin on Day 1 + 5-flourouracil (5-FU) over Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
61942369|NCT01479023|EXPERIMENTAL|Cohort 1|"64Cu-DOTA-U3-1287 at a radiotracer dosage of 8-15 mCI and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~Patient will have option to continue to Part 2 (extension phase)."
61942370|NCT01479023|EXPERIMENTAL|Cohort 2|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~9.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
61942371|NCT01479023|EXPERIMENTAL|Cohort 3|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~12.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
61942372|NCT01479023|EXPERIMENTAL|Cohort 3a|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~15.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
61942373|NCT01479023|EXPERIMENTAL|Cohort 4|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~18.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
61942374|NCT01479023|EXPERIMENTAL|Cohort 5|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~TBD (to be determined) mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
61942375|NCT01479023|EXPERIMENTAL|Part 2 (extension phase)|Loading dose of 18.0 mg/kg unlabeled U3-1287 followed by 9.0 mg/kg unlabeled U3-1287 every 3 weeks.
61942376|NCT03254290|EXPERIMENTAL|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
62337927|NCT01672437|EXPERIMENTAL|Birth and parent preparation|"The following subjects will be covered in the sessions:~Session 1 (25 weeks gestation):~* Common challenges in the transition to parenthood and in the relationship~* Couple communication~Session 2 (33 weeks gestation):~* Expectations in relation to birth~* The normal course of labour~* Obstetric intervention~* Pain relief,coping strategies~* Partner support~Session 3 (35 weeks gestation):~* Feeding a newborn~* Interpreting the newborn's signs, symptoms and behaviour~* Taking care of a newborn~* Mood swings, postnatal depressive symptomatology~Session 4 (5 weeks post-partum):~* Birth experiences~* Mood swings, postnatal depressive symptomatology~* The first time at home with a newborn~* Couplehood - partner support, communication, division of household tasks"
62337928|NCT01672437|NO_INTERVENTION|control group|The control group are offered two lectures in an auditorium during pregnancy - one on breastfeeding and one on labour. This is standard care.
62337929|NCT01258972|ACTIVE_COMPARATOR|Angioplasty POBA|Side Branch balloon angioplasty with main branch DES
62337930|NCT01258972|EXPERIMENTAL|Tryton Side Branch Stent|Side Branch treated with Tryton Side Branch Stent with main branch DES
62337931|NCT06361264|EXPERIMENTAL|Karanahan|Reparative cycle of tumor cells is assessed at the preliminary stage in in vitro culture. According to the elaborated regimen, the patient receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days.
62337932|NCT05881772|ACTIVE_COMPARATOR|Experimental 1|It will be applied a dose of 30J (180J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
62337933|NCT05881772|ACTIVE_COMPARATOR|Experimental 2|It will be applied a dose of 60J (360J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
62337934|NCT05881772|ACTIVE_COMPARATOR|Experimental 3|It will be applied a dose of 90J (540J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
62337935|NCT05881772|PLACEBO_COMPARATOR|Placebo group|The placebo treatment will be performed with the equipment HTM® (model Fluence Maxx, São Paulo, Brazil) turned off.
62696183|NCT03421353|EXPERIMENTAL|Arm A4|"Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + gemcitabine on Days 1 and 8. This regimen will be repeated every 3 weeks. In addition, the following will be added to the regimen:~* For cisplatin-eligible patients: cisplatin on Day 1 (every 3 weeks for up to 12-18 weeks); or~* For cisplatin ineligible patients: carboplatin on Day 1 and Day 8 (every 3 weeks for up to 12-18 weeks)~There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing."
62696184|NCT03421353|EXPERIMENTAL|Arm A5|Patients will receive AZD9150 every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus carboplatin on Day 1 plus nab-paclitaxel on Days 1, 8, and 15 (every 3 weeks for up to 12-18 weeks). There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
62696185|NCT03421353|EXPERIMENTAL|Arm D: AZD9150 SC|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
62696186|NCT03421353|EXPERIMENTAL|Arm D: AZD9150 IV|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
62696187|NCT05518045|EXPERIMENTAL|LM-108 Dose Escalation|
61942377|NCT03254290|ACTIVE_COMPARATOR|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
62138515|NCT04555577|EXPERIMENTAL|Stage I (Peposertib, Radiation therapy, Temozolomide)|"CONCURRENT: Patients undergo standard of care radiation therapy daily (Monday-Friday) for 30 fractions. Patients also receive Peposertib PO on each day of radiation therapy and given 1-2 hours before each treatment fraction. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
62138516|NCT04555577|EXPERIMENTAL|Stage II (Peposertib, Radiation, Temozolomide, Surgery)|"CONCURRENT: Patients receive Peposertib and undergo standard of care radiation therapy as in Stage I. Within 1-14 days after the completion of radiation therapy, patients undergo surgical resection.~ADJUVANT: Patients receive temozolomide as in Stage I."
62138517|NCT05022615||Mild Non-Proliferative Diabetic Retinopathy (NPDR)|Presence of at least one retinal microaneurysm or hemorrhage as determined by clinician.
62138518|NCT05022615||Moderate NPDR|Increasing hemorrhages and microaneurysms as well as cotton wool spots, venous beading (VB) or Intraretinal microvascular abnormalities (IRMA) to a mild degree as determined by clinician
62138519|NCT05022615||Severe NPDR|"4-2-1 rule-that is, one has severe NPDR if hemorrhages or microaneurysms, or both, appear in all four retinal quadrants; venous beading appears in two or more retinal quadrants; or prominent IRMAs are present in at least one retinal quadrant as determined by clinician."
62138520|NCT05022615||Proliferative Diabetic Retinopathy (PDR)|Neovascularization, either on or within one disc diameter (DD) of the optic disc (NVD) or elsewhere in the retina (NVE); a preretinal hemorrhage (PRH); or vitreous hemorrhage (VH) as determined by the clinician.
62138521|NCT02761200||volunteer who completion of a recent ATI|
62138522|NCT01647932|ACTIVE_COMPARATOR|Loop plus thiazide-type diuretic|Loop diuretic plus hydrochlorothiazide
62138523|NCT01647932|PLACEBO_COMPARATOR|Loop diuretic plus placebo|Loop diuretic plus placebo
62138524|NCT03035084|EXPERIMENTAL|Group-2-D3|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
61942378|NCT02906904|EXPERIMENTAL|CASE (adult sleepwalking patients)|
62138525|NCT03035084|PLACEBO_COMPARATOR|Group-2-Placebo|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
62138526|NCT03035084|EXPERIMENTAL|Group-1-D2|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
62138527|NCT03035084|PLACEBO_COMPARATOR|Group-1-Placebo|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.
62138528|NCT04914403|EXPERIMENTAL|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
62138529|NCT06669611|ACTIVE_COMPARATOR|Camrelizumab with GP chemotherapy|Camrelizumab, cisplatin and gemcitabine
62138530|NCT06669611|EXPERIMENTAL|camrelizumab with nab-TPC chemotherapy|camrelizumab plus nab-TPC chemotherapy (nab-paclitaxel, cisplatin and capecitabine)
62138531|NCT03067974|EXPERIMENTAL|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
62138532|NCT04618250|EXPERIMENTAL|Coordinated, co-produced health care|
62138533|NCT04618250|NO_INTERVENTION|Care as usual|Care as usual
62138534|NCT01870830|OTHER|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1650-2590m
62138535|NCT01870830|OTHER|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1650m
62138536|NCT01870830|OTHER|C: intermediate-high-low altitude|Altitude exposure sequence C, 1650-2590-490m
62138537|NCT01870830|OTHER|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1650-490m
62138538|NCT03647241|EXPERIMENTAL|Self-Ligating Brackets|Patients will be treated using self-ligating brackets to achieve proper alignment of teeth
62696188|NCT05518045|EXPERIMENTAL|LM-108 Dose Expansion|
62696189|NCT05518045|EXPERIMENTAL|LM-108 combination dose escalation|
62696190|NCT05518045|EXPERIMENTAL|LM-108 combination dose expansion|
62696191|NCT06035887||Normative Controls|Age- and sex- matched normal controls
62696192|NCT06035887||On Hydroxychloroquine, NO retinopathy|Participants over 18 years on hydroxychloroquine without hydroxychloroquine-related retinopathy
62696193|NCT06035887||On Hydroxychloroquine, POSSIBLE retinopathy|Participants over 18 years on hydroxychloroquine with possible (indeterminate) hydroxychloroquine-related retinopathy
62696194|NCT06035887||On Hydroxychloroquine, DEFINITE retinopathy|Participants over 18 years on hydroxychloroquine with definite hydroxychloroquine-related retinopathy
62696195|NCT04605666|EXPERIMENTAL|CAR-T group|
62696196|NCT06570005|EXPERIMENTAL|Assurance Fund Intervention Arm 1|In this study arm, intervention activities will start after initial baseline data collection.
61942379|NCT02906904|EXPERIMENTAL|CONTROL (adult healthy volunteers)|
61942380|NCT00844584|OTHER|ablation|patients with atrial fibrillation underwent radiofrequency ablation with totally thoracoscope.
62138539|NCT03647241|EXPERIMENTAL|Self-Ligating Brackets with Corticotomy|Patients will be treated using self-ligating brackets with corticotomy (alveolar cortical cuts) in order to accelerate orthodontic treatment.
62138540|NCT03647241|ACTIVE_COMPARATOR|Traditionally-Ligated Brackets|Patients in this group will be treated using traditionally-ligated brackets to achieve proper alignment of teeth
62138541|NCT03387826|EXPERIMENTAL|Ticagrelor|Ticagrelor 60mg twice daily followed by Prasugrel 5mg once daily
61942381|NCT00787761|EXPERIMENTAL|ATG, Cytoxan, Bu/Flu based Allogeneic Transplant|All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
61942382|NCT05593133|EXPERIMENTAL|Pnf exercises|warm up, rhythmic stabilization, hold relax, contract relax and light exercises performed on three muscle groups
61942383|NCT05593133|EXPERIMENTAL|Gait training exercises|exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking.
61942384|NCT01469312|PLACEBO_COMPARATOR|Control|The control arm consists of the traditional pasta.
62696197|NCT06570005|EXPERIMENTAL|Assurance Fund Intervention Arm 2|The intervention activities are the same as those described in Arm 1. However, in this study arm, the intervention activities will start 6 months later than those in Arm 1. This arm will serve as a controlled comparison during those initial 6 months.
62696198|NCT06570005|EXPERIMENTAL|Assurance Fund Intervention Arm 3|The intervention activities are the same as those described in Arm 1. However, in this study arm, the intervention activities will start 12 months later than those in Arm 1. This arm will serve as a controlled comparison during those initial 12 months.
62696199|NCT06570005|EXPERIMENTAL|Non-randomized Arm|In Ghana only, there is a fourth study arm that will receive the intervention one month prior to Arm 1. This group was non-randomly selected and will primarily serve to support qualitative lessons learned from the Assurance Fund program.
62696200|NCT00543127|EXPERIMENTAL|Fulvestrant + Anastrozole|Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
62696201|NCT00543127|ACTIVE_COMPARATOR|Anastrozole|Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.
62696202|NCT06206720|EXPERIMENTAL|Deuremidevir Hydrobromide for Suspension|Deuremidevir Hydrobromide for Suspension will be orally administered at the dosing levels of 15 mg/kg BID, 20 mg/kg BID, or 20 mg/kg TID for five days according to the weight of patients.
61942385|NCT01469312|ACTIVE_COMPARATOR|Modified pasta|Dreamfields, Miracle Noodles
61942386|NCT04355507||Patients with suspicions of COVID-19 pneumonia|Patients with suspicions of COVID-19 pneumonia
61942387|NCT05780073|EXPERIMENTAL|Dasatinib|Dasatinib 70 mg/daily, orally administered, for 24 weeks
61942388|NCT05780073|PLACEBO_COMPARATOR|Placebo|Investigational Medicinal Product-like appearance capsule containing an inert substance,orally administered, once daily, for 24 weeks
61942389|NCT03576495|EXPERIMENTAL|Early Intervention Group|The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention Group). Evaluation results in the Early Intervention Group will be compared to the Delayed Intervention (Active Comparator) group at time Period 2.
61942390|NCT03576495|ACTIVE_COMPARATOR|Delayed Intervention Group|The investigators will conduct baseline testing prior to the standard residency curriculum. These results will be compared to the Early Intervention Group (Experimental Group) at time period 2.
62138542|NCT03387826|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 5m once daily followed by Ticagrelor 60mg twice daily
62138543|NCT06699901||Control Group|Patients who ideally receive no blood but may be included if they receive up to 2 units of transfused blood.
62138544|NCT06699901||Massive Transfusion Group|Patients who receive at least 3 units of blood.
62696203|NCT06206720|EXPERIMENTAL|Placebo|Placebo will be orally administered at the dosing levels of 15 mg/kg BID, 20 mg/kg BID, or 20 mg/kg TID for five days according to the weight of patients.
62696204|NCT04111354|ACTIVE_COMPARATOR|Short-term (4-hours) immobilization.|Short-term (4-hours) immobilization after primary pacemaker implantation.
62696205|NCT04111354|ACTIVE_COMPARATOR|Long-term (16-24 hours) immobilization.|Long-term (16-24 hours) immobilization after primary pacemaker implantation.
61942391|NCT05894499||Cohort 1|Participants received 2 doses of mRNA-1273 vaccine approximately 4 weeks apart.
62696206|NCT03773419|EXPERIMENTAL|Texting Intervention (T-WRITE)|Computer-based treatment targeting written language via texting (90 minutes a day, 5 days a week for 4 weeks)
61942392|NCT01620554|EXPERIMENTAL|BF2.649 5mg|
61942393|NCT01620554|EXPERIMENTAL|BF2.649 10mg|
61942394|NCT01620554|EXPERIMENTAL|BF2.649 20mg|
61942395|NCT01620554|EXPERIMENTAL|BF2.649 40mg|
61942396|NCT01620554|PLACEBO_COMPARATOR|Placebo|
61942397|NCT04087213|EXPERIMENTAL|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
61942398|NCT06651437|NO_INTERVENTION|Control|the Control group will not receive any additional information on diet
61978787|NCT03279328|ACTIVE_COMPARATOR|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
61978788|NCT03279328|ACTIVE_COMPARATOR|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
61978789|NCT03279328|ACTIVE_COMPARATOR|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
61978790|NCT02611778|EXPERIMENTAL|FYB201|FYB201 is provided as single use vials and will be administered by intra-vitreal injection.
61978791|NCT02611778|ACTIVE_COMPARATOR|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.
61978792|NCT04512209|EXPERIMENTAL|DCE-MRI|
61978793|NCT00056407|PLACEBO_COMPARATOR|Placebo Arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
61978794|NCT00056407|EXPERIMENTAL|dustasteride arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
61978795|NCT05620550|EXPERIMENTAL|ozonated oil|treatment of scar area with ozonated oil
61978796|NCT05620550|SHAM_COMPARATOR|non ozonated oil|treatment of scar area with non ozonated oil
61978797|NCT04541576|EXPERIMENTAL|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
62138545|NCT02610608||Women undergoing ART|Observation of the incidence of venous and arterial thrombosis following ovarian stimulation
62138546|NCT06327815|ACTIVE_COMPARATOR|Co-administered Dual Therapy|Dapagliflozin tablets and Metformin HCl extended-release tablets
62138547|NCT06327815|EXPERIMENTAL|FDC Regimen of Dapagliflozin/Metformin XR|Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
62138548|NCT01181154|PLACEBO_COMPARATOR|equivalent volume total (=1000 ml)|Placebo : equivalent volume total (=1000 ml)
62138549|NCT01181154|EXPERIMENTAL|rituximab (Mabthera®)|rituximab (Mabthera®), 1000 mg at day 1 and day 15
62138550|NCT05242562|EXPERIMENTAL|Pleinvue|a 1L poly ethylene glycol PEG solution with added ascorbate (Pleinvue, Norgine, active ingredients PEG 3350, Sodium ascorbate, Sodium sulfate, Ascorbic acid, Sodium chloride, Potassium chlorid)
62494736|NCT04438434|PLACEBO_COMPARATOR|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
62696207|NCT03773419|ACTIVE_COMPARATOR|HandWriting Intervention (ORLA+WTG)|Computer-based treatment targeting written language via handwriting (90 minutes a day, 5 days a week for 4 weeks)
61942399|NCT06651437|EXPERIMENTAL|Dietary educational intervention|The dietary educational intervention group received dietary education to gradually reduce salt intake (a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content). In addition, written information was provided.
61942400|NCT03018600||1|We included 15 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) to the patients every morning at 8am for at least five days.
62138551|NCT05242562|ACTIVE_COMPARATOR|Moviprep|a 2L PEG solution with added ascorbate (Moviprep, Norgine, active ingredients Macrogol 3350, Sodium Sulphate Anhydrous, Sodium chloride, Potassium chloride, Ascorbic acid, Sodium ascorbate)
62337936|NCT00242580|EXPERIMENTAL|Verteporfin and Triamcinolone 1 mg|Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
62696208|NCT04612192|EXPERIMENTAL|Active light|Active light
62696209|NCT04612192|PLACEBO_COMPARATOR|Placebo light|Placebo light
62738491|NCT04293224|EXPERIMENTAL|TAD diet pattern|Typical American Diet (TAD) with negative energy balance (\~25% calorie reduction compared to needs) which mimics intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium based on data from What We Eat in America (WWEIA).
61942401|NCT03018600||2|We included 10 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: using less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months and now treating with 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for the relapse of primary autoimmune disease for at least five days.
61942402|NCT05093140|EXPERIMENTAL|camrelizumab+R-CHOP|Induction therapy: camrelizumab in combination with rituximab Immunochemotherapy: rituximab, cyclophosphamide, hydroxyldaunorubicin, vincristine, prednisone Maintenance therapy: camrelizumab in patients achieved CR after immunotherapy
61942403|NCT06679699|EXPERIMENTAL|Trunk control exercises with Patient education program|This group have received Trunk control exercises along with patient education program.
61942404|NCT06679699|ACTIVE_COMPARATOR|Trunk control exercises|This group have received standalone trunk control exercises.
61942405|NCT04239053||ESPB block group|Patients receiving ESPB will be enrolled to this group.
62138552|NCT06612840|EXPERIMENTAL|GNC-077|Participants receive GNC-077 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62138553|NCT03234959|EXPERIMENTAL|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
62138554|NCT03234959|ACTIVE_COMPARATOR|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
62138555|NCT06509022||Before surgery|A patient with esophageal cancer before surgery
62138556|NCT06509022||Before discharge|Patients with esophageal cancer who were not discharged after surgery
62138557|NCT06509022||1 month after surgery|One month after surgery for esophageal cancer
62138558|NCT06509022||3 months after surgery|Three months after surgery for esophageal cancer
62138559|NCT06509022||6 months after surgery|Six months after surgery for esophageal cancer
62696210|NCT01080235|ACTIVE_COMPARATOR|1|Control. Forty-two residency programs randomly assigned and stratified according to size, affiliation, geographic location, and presence of geriatrics fellowship. Twenty-one in the control arm. This group will use PIM as a data collection tool during baseline and follow-up time (i.e. audit of 50-75 charts, survey from 50-75 patients, and one system survey). They will not see the summary results of the data collected; they will not be required to complete a quality improvement plan based on the summary data. Local researchers will collect the data. Individual trainees will not do data collection or audits. At both baseline and follow-up, trainees will complete pre and post test surveys of 1) geriatric and 2) quality improvement knowledge, skills, and attitudes.
62696211|NCT01080235|OTHER|2|There are 21 residency programs in intervention arm who will 1) use PIM as a data collection tool (local researchers will audit 50-75 charts, survey 50-75 patients, and complete one system survey); 2) Each trainee will audit of up to five patient charts; collect 5 patient surveys; and complete the system survey as a group; 3) Summary data from these data streams will be reviewed by group; then they will design and implement a quality improvement plan; 4) At follow-up, local researchers will re-audit same 50-75 charts, collect surveys from same 50-75 patients, and complete one system survey. At baseline and follow-up, trainees and faculty will complete surveys of geriatric and quality improvement knowledge, skills, and attitudes.
62696212|NCT06583655|EXPERIMENTAL|Sentinel Lymph Node Dissection alone , clinical low risk group|patients treated with surgery and Sentinel Lymph Node Dissection alone with positive lymph node metastasis.
62696213|NCT06583655|EXPERIMENTAL|Sentinel Lymph Node Dissection alone , clinical high risk but genomic low risk group|patients treated with surgery and Sentinel Lymph Node Dissection alone with positive lymph node metastasis.
62696214|NCT06583655|EXPERIMENTAL|Sentinel Lymph Node Dissection alone ,clinical high risk and genomic high risk group|patients treated with surgery and Sentinel Lymph Node Dissection alone with positive lymph node metastasis.
61942406|NCT03504254||CSM|A total of 50 CM patients requiring surgical decompression will be recruited. The inclusion criteria are a clinical diagnosis of CM including the signs of corticospinal lesions together with the appropriate radiographic findings. Patients with acute spinal cord injuries, prior spinal intervention or claustrophobia will be excluded.
61942407|NCT05570383|PLACEBO_COMPARATOR|In the control group|Half of the subjects（30 subjects）will be assigned to the control group，they will be using the Mometasone furoate nasal spray (Nasonex).
61942408|NCT05570383|EXPERIMENTAL|The experimental group|Half of the subjects (30) will be assigned to the experimental group. Received sublingual dust mite drops (trade name: Changdi, Zhejiang Wuwu Biotechnology Co., LTD.) for sublingual immunotherapy.
61942409|NCT03868306||Iron deficiency anaemia|Microcytic hypochromic anaemic patients with serum ferritin less than 12 Ng /ml
61942410|NCT03868306||Beta thalassemia Trait|Microcytic hypochromic anaemic patients with HBA2 more than 3.2 %
62337937|NCT00242580|EXPERIMENTAL|Verteporfin and Triamcinolone 4 mg|Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
62337938|NCT00242580|ACTIVE_COMPARATOR|Verteporfin and Pegaptanib|Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.
62337939|NCT05100654|NO_INTERVENTION|No post-operative oral antibiotics|Patients will only receive 24hr of IV peri-operative antibiotics
61942411|NCT04954287|EXPERIMENTAL|Group 1, 1 x 10^6 PFU CVXGA1 in Ages 18-55|Group 1 (Young adults aged 18 to 55 years - CVXGA1- Low Dose, no prior COVID vaccine or infection)
61942412|NCT04954287|EXPERIMENTAL|Group 2, 1 x 10^7 PFU CVXGA1 in Ages 18-55|Group 2 (Young adults aged 18 to 55 years - CVXGA1- High Dose, no prior COVID vaccine, no prior COVID vaccine or infection allowed if occurring at least 5 months prior to enrollment)
62738492|NCT04973202||Inpatients for alcohol detoxifications|French patients who were hospitalized for alcohol detoxification from 2011 to 2020
61942413|NCT04954287|EXPERIMENTAL|Group 3, 1 x 10^7 PFU CVXGA1 in Ages 18-55|Group 3 (Young adults aged 18-55 years - CVXGA1 - High Dose, prior receipt of two or more doses of COVID mRNA vaccine (Pfizer Comirnaty® or Moderna Spikevax™) at least 5 months prior to study enrollment. Prior COVID infection allowed if occurring at least 5 months prior to study enrollment).
61942414|NCT04954287|EXPERIMENTAL|Group 4, 1 x 10^7 PFU CVXGA1 in Ages 12-17|Group 4 (Adolescents aged 12-17 years - CVXGA1 - High Dose, prior receipt of two or more doses of COVID mRNA vaccine (Pfizer Comirnaty® or Moderna Spikevax™) at least 5 months prior to study enrollment. Prior COVID infection allowed if occuring at least 5 months prior to study enrollment.
61942415|NCT01365247|EXPERIMENTAL|COPE|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
61942416|NCT01365247|ACTIVE_COMPARATOR|RPT|Relapse Prevention Therapy
61942417|NCT01365247|ACTIVE_COMPARATOR|Active Monitoring Control Group|
61942418|NCT01955564|EXPERIMENTAL|Cohort 1|NW-3509a - 1mg or placebo
61942419|NCT01955564|EXPERIMENTAL|Cohort 2|NW-3509a 2mg or placebo
61942420|NCT01955564|EXPERIMENTAL|Cohort 3|NW-3509a 5mg or placebo
61942421|NCT01955564|EXPERIMENTAL|Cohort 4|NW-3509a 10 mg or placebo
61942422|NCT01955564|EXPERIMENTAL|Cohort 5|NW-3509a 20 mg or placebo
61942423|NCT01955564|EXPERIMENTAL|Cohort 6|NW-3509a 30 mg or placebo
61942424|NCT00993681|EXPERIMENTAL|1|900 subjects will receive a two vaccination regimen with an LT patch
61942425|NCT00993681|PLACEBO_COMPARATOR|2|900 subjects will receive a two vaccination regimen with a placebo patch
61942426|NCT05212519||25-hydroxyvitamin D3≥30 ng/ml|the patients were categorized as having vitamin D sufficiency if its concentrationis ≥30 ng/m
62138560|NCT01894217|EXPERIMENTAL|Genetic testing|Genetic testing and reporting for SLCO1B1\*5 allele
61942427|NCT05212519||25-hydroxyvitamin D3< 30 ng/ml|insufficiency if levels are \<30 but ≥20 ng/ml, deficiency when levels are \<20 but ≥10 ng/ml and severe deficiency with levels \<10 ng/ml
62494737|NCT00686062|EXPERIMENTAL|1|Women in this arm view the interactive, computerized, prenatal testing decision tool (PT Tool) we created.
62494738|NCT00686062|ACTIVE_COMPARATOR|2|Women in this arm view the age-appropriate computerized version of the educational pamphlet on prenatal testing developed and distributed by the State of California
61942428|NCT00747812|EXPERIMENTAL|1|Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
62696215|NCT06583655|ACTIVE_COMPARATOR|with Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)|patients treated with surgery and Sentinel Lymph Node Dissection and ALND with positive lymph node metastasis.
62696216|NCT05731245|EXPERIMENTAL|Ropeginterferon alfa-2b|"Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.~Intervention: Drug: Ropeginterferon alfa-2b"
62696217|NCT05213234|OTHER|Morning Medication Administration|Subjects are directed to take their medication between 06:00 and 10:00.
61942429|NCT00747812|SHAM_COMPARATOR|2|Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
61942430|NCT05089955|EXPERIMENTAL|Intervention group|MRI examination with Ambient Experience with paediatric content
61942431|NCT05089955|NO_INTERVENTION|Control group|MRI examination without Ambient Experience (standard of care)
61942432|NCT06681805|EXPERIMENTAL|Groups I|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine.
61942433|NCT06681805|EXPERIMENTAL|Groups II|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
61942434|NCT06681805|PLACEBO_COMPARATOR|Groups III|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine.
62337940|NCT05100654|ACTIVE_COMPARATOR|6 days of oral antibiotics|Patients will receive 24hr of IV peri-operative antibiotics and then 6 days of oral antibiotics
61942435|NCT06681805|PLACEBO_COMPARATOR|Groups IV|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
61942436|NCT06402630|EXPERIMENTAL|0.25% Dose|Once daily, STS-01 topical cream applied to affected area of the head
61942437|NCT06402630|EXPERIMENTAL|0.5% Dose|Once daily, STS-01 topical cream applied to affected area of the head
61942438|NCT06402630|EXPERIMENTAL|1% Dose|Once daily, STS-01 topical cream applied to affected area of the head
61942439|NCT06402630|EXPERIMENTAL|2% Dose|Once daily, STS-01 topical cream applied to affected area of the head
61942440|NCT06402630|PLACEBO_COMPARATOR|Placebo|Once daily, topical cream applied to affected area of the head (without API)
62337941|NCT02683226|EXPERIMENTAL|metformin and alogliptin|Vipdomet 12.5 mg/1000 mg tablets
62337942|NCT02683226|EXPERIMENTAL|pioglitasone and alogliptin|Incresync 12,5 mg/30 mg tablets
62337943|NCT05123651|PLACEBO_COMPARATOR|Control group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge Supplement looking and tasting placebo.
61942441|NCT03333304|EXPERIMENTAL|PCT group|Procalcitonin measurement and Discontinuation of antimicrobials according to Procalcitonin kinetics
62337944|NCT05123651|EXPERIMENTAL|Viable group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge(containing active L.r X253).
62337945|NCT05123651|EXPERIMENTAL|Inactivated group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge(containing inactive L.r X253).
62337946|NCT04504032|EXPERIMENTAL|Rivaroxaban|
61942442|NCT03333304|NO_INTERVENTION|Standard of care|Standard practice
61942443|NCT04314154||Study group|Group of all patients hospitalized in the SMHC and due participate in rehabilitative procedures
61942444|NCT03023787|EXPERIMENTAL|Hepalatide|Hepalatide 4.2mg, 6.3mg and 8.4mg
61942445|NCT03023787|PLACEBO_COMPARATOR|Placebo|Placebo 4.2mg, 6.3mg and 8.4mg
61942446|NCT04873700||Moderate to Severe Crohn's Disease|Participants diagnosed with moderate to severe Crohn's Disease (CD) were observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of CD.
62138561|NCT06057974||Pre-intervention|The patient and their parents who are admitted to the NICU before the NICU starts implementing the intervention.
62138562|NCT06057974||Post-intervention|The patient and their parents who are admitted to the NICU after the NICU implements the intervention.
62138563|NCT02018900|PLACEBO_COMPARATOR|Placebo|Placebo
62138564|NCT02018900|EXPERIMENTAL|Ecologic 825/scFOS|Ecologic 825/scFOS
62337947|NCT04504032|PLACEBO_COMPARATOR|Placebo|
62337948|NCT02728440||Hypogonadotropic hypogonadism patients|30 patients with idiopathic hypogonadotrophic hypogonadism
62494739|NCT02490800|EXPERIMENTAL|Phase 1 dose escalation portion|"Phase 1 dose escalation portion - an accelerated 3+3 titration design in patients with:~1. advanced or recurrent solid tumors~2. recurrent or progressive GBM / HGG"
62494740|NCT02490800|EXPERIMENTAL|Phase 2a dose expansion portion|Phase 2a expansion portion (Simon's two-stage design) - Patients with recurrent and EB1-positive GBM
62494741|NCT00772148|EXPERIMENTAL|LCP-Tacro|LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
62494742|NCT00772148|ACTIVE_COMPARATOR|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
62494743|NCT01875120||Female patients with increased risk to experience PONV.|
62494744|NCT04881188||Patients with chronic low back pain|Patients suffering from chronic low back pain (duration longer than 3 months) undergoing a multimodal pain therapy
62494745|NCT06209034|OTHER|Optic nerve sheath measurement|Optic nerve sheath diameter (ONSD) was detected 3 mm behind the entry point of the optic nerve into the globe in both eyes in each ultrasonographic measurement. ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
62138565|NCT04905004|EXPERIMENTAL|2-week reactivation interval|Replacement of elastomeric chain every 2 weeks and reestablishing a 150 g force
62494746|NCT02212457|EXPERIMENTAL|rMenB_0_2 Group|Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
61942447|NCT04873700||Mild to None Crohn's Disease|Participants diagnosed with mild to none activity of CD were observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of CD.
61942448|NCT04873700||Moderate to Severe Ulcerative Colitis|Participants diagnosed with moderate to severe Ulcerative Colitis (UC) were observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of UC.
61942449|NCT04873700||Mild to None Ulcerative Colitis|Participants diagnosed with mild to none activity of UC were observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of UC.
61942450|NCT00002651|ACTIVE_COMPARATOR|Consolidation arm I|Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
61942451|NCT00002651|EXPERIMENTAL|Consolidation arm II|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.
61942452|NCT02037958|EXPERIMENTAL|Laryngeal Mask Airway-Supreme|Patients who are randomly assigned to receive the LMA-Supreme
61942453|NCT02037958|ACTIVE_COMPARATOR|Endotracheal Tube|Patients who are randomly assigned to receive endotracheal intubation
61942454|NCT05613400|EXPERIMENTAL|Simvastatin 10mg/day|One simvastatin 10mg-tablet and one placebo tablet with the shape of ezetimibe 10mg each day.
61942455|NCT05613400|ACTIVE_COMPARATOR|Ezetimibe 10mg/day|One ezetimibe 10mg-tablet and one placebo tablet with the shape of simvastatin 10mg each day.
61942456|NCT01470937|EXPERIMENTAL|Acarbose|acarbose 100 mg once daily
61942457|NCT01470937|PLACEBO_COMPARATOR|Placebo|Matched placebo was administered for acarbose 100 mg once daily
61942458|NCT05734300|EXPERIMENTAL|CELS|The Combined Endoscopic Laparoscopic Surgery (CELS) is a hybrid procedure that enables large local excisions of the colon without segmental resection while under general anaesthesia. In our study, CELS refers only to endoscopic assisted laparoscopic resection.
61942459|NCT05734300|ACTIVE_COMPARATOR|Standard Surgery|Standard surgical resection of colonic cancer following standard oncologic principles while under general anaesthesia.
61942460|NCT01400165|ACTIVE_COMPARATOR|Desyrel/Teva-Trazodone|Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
61942461|NCT01400165|ACTIVE_COMPARATOR|Visken/Teva-Pindolol|Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
62138566|NCT04905004|ACTIVE_COMPARATOR|4-week reactivation interval|Replacement of elastomeric chain every 4 weeks and reestablishing a 150 g force
62138567|NCT04905004|EXPERIMENTAL|6-week reactivation interval|Replacement of elastomeric chain every 6 weeks and reestablishing a 150 g force
62494747|NCT02212457|EXPERIMENTAL|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
61942462|NCT01400165|ACTIVE_COMPARATOR|Seroquel/Teva-Quetiapine|Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
61942463|NCT05317624|EXPERIMENTAL|Platelet rich plasma group|participants will receive Ultrasound guided subacromial injection of 3 ml platelet rich plasma+0.5 ml of PRP activator (10% calcium gluconate)+ 1ml 0.5%bupivacaine.
61942464|NCT05317624|EXPERIMENTAL|Methylprednisolone group|participants will receive Ultrasound guided subacromial injection of 1 ml methylprednisolone+ 1ml 0.5%bupivacaine + 2.5 ml normal saline.
61942465|NCT06285331|ACTIVE_COMPARATOR|Automatic Bed|PLR will be performed by adjusting the automatic bed the patients stay on.
61942466|NCT06285331|PLACEBO_COMPARATOR|Manual|PLR will be performed by the investigators by their hands.
61942467|NCT03005418|EXPERIMENTAL|Human Acellular Vessel (HAV)|Patients with life or limb threatening traumatic injury to an arterial vessel in the limb or torso, other than the heart, will be implanted with the Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
61942468|NCT00913380|EXPERIMENTAL|Low-dose CT|
61942469|NCT00913380|ACTIVE_COMPARATOR|Standard-dose CT|
61942470|NCT05668975|EXPERIMENTAL|Training Group|Individuals with sarcopenia in this group will perform three sets of 10 repetitions, with 1-minute of rest allocated between sets, twice daily, 5 days per week for eight weeks. The first session will be performed supervised in a clinic, other sessions will be performed at home. Telephone contact will be held twice a week to ensure the completion of training and clarify any doubts. Training intensity will be set at 60% of the maximum inspiratory pressure for the first week then will be set at %70 of the maximum inspiratory pressure for the second week. After the second week, training intensity will be increased as much as participants tolerated at the start of each week.
62494748|NCT02212457|EXPERIMENTAL|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
62696218|NCT05213234|OTHER|Night Medication Administration|Subjects are directed to take their medication between 18:00 and 22:00.
62138568|NCT04905004|EXPERIMENTAL|8-week reactivation interval|Replacement of elastomeric chain every 8 weeks and reestablishing a 150 g force
62138569|NCT03236272||case group|patients with ARDS
62138570|NCT03236272||control group|patients Without ARDS
62696219|NCT04011241|EXPERIMENTAL|Reference - BI 1323495 alone|Single oral dose of 10 milligrams (mg) of film-coated tablet of BI 1323495 was administered once on day 1 in the first treatment period (period 1, visit 2) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) as reference treatment R.
62696220|NCT04011241|EXPERIMENTAL|Test - BI 1323495 + Itraconazole|Single oral dose of 200 mg itraconazole (oral solution, 20 milliliter (mL) per day with 10 mg/mL) was administered once daily with 240 mL of water after an overnight fast of 9 hours (h) from day -3 to day 7 (total: 10 doses) in the second treatment period (period 2, visit 3) together with a single oral dose of 10 mg BI 1323495 administered 1 h after itraconazole administration with 240 mL of water after an overnight fast of 10 h on the fourth day of the itraconazole treatment (day 1, period 2, visit 3) as test treatment T.
61942471|NCT05668975|SHAM_COMPARATOR|Sham Group|Individuals with sarcopenia in this group will perform two sets of 10 repetitions, with 1-minute of rest allocated between sets, one time a day, 2 days per week for eight weeks. The first session will be performed supervised in a clinic, other sessions will be performed at home. Training intensity will be set at 10 cm H₂O for all training sessions.
61942472|NCT00920634||1|Patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction (amenorrhea first grade, anovulatory cycle, polycystic ovary syndrome, oligoamenorrhea) who underwent ovulation induction
61942473|NCT01944033|ACTIVE_COMPARATOR|Group Terbutaline|Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
61942474|NCT01944033|EXPERIMENTAL|Group Terbutaline/IB|Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol
61942475|NCT03860597|ACTIVE_COMPARATOR|Memantine|
61942476|NCT03860597|PLACEBO_COMPARATOR|Placebo|
61942477|NCT01782547|EXPERIMENTAL|Telehealth Intervention|Telehealth intervention - 6 months
61942478|NCT01782547|ACTIVE_COMPARATOR|Usual care|Usual care control with comparable frequency of contact
61942479|NCT04049643|ACTIVE_COMPARATOR|Audiologist-Based|In this group, the audiologist-based fitting will be used to provide hearing aids.
61942480|NCT04049643|EXPERIMENTAL|Service-Only|In this group, hearing aids that have minimum amplification will be fitted by audiologists.
61942481|NCT04049643|EXPERIMENTAL|Device-Only|In this group, hearing aids will be provided with minimum services from audiologists.
61942482|NCT02212470|ACTIVE_COMPARATOR|Drug Eluting Balloon|Admiral In.Pact Drug Eluting Balloon
61942483|NCT02212470|ACTIVE_COMPARATOR|Nitinol Stent|Complete SE Self-expandible Nitinol stent
61942484|NCT04703387||Postextubation Success|
61942485|NCT04703387||Postextubation Distress|
61942486|NCT04622293|EXPERIMENTAL|Solriamfetol|Those who are receiving solriamfetol will receive 75 mg or 150 mg. Patients will begin at a 75 mg dose and then after three days titrate up or down as needed, determined by consultation visits with primary investigator. Solriamfetol will be taken orally.
61942487|NCT04622293|PLACEBO_COMPARATOR|Placebo|Those who are not receiving solriamfetol will receive the placebo drug, which will be encapsulated in matching capsules to reduce any bias or speculation with participants.
61942488|NCT02503410|ACTIVE_COMPARATOR|Usual care|Subjects receive physical therapy for low back pain as typically prescribed in the clinic.
61942489|NCT02503410|EXPERIMENTAL|Interactive gaming|Subjects participate in an intervention combining usual care and home-based exercises using the Valedo system.
61942490|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
62138571|NCT06610994|EXPERIMENTAL|local vibration apply group|Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. It will be applied to the most swollen part of the spastic medial gastrocnemius muscles for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.
62138572|NCT06610994|PLACEBO_COMPARATOR|placebo group|The device will be contacted to the same areas of the patients in the vibration group for only 10 minutes.
62696221|NCT05368519|EXPERIMENTAL|Right chest with Brijjit® FMTB|Patients will be assigned to have their right chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
62696222|NCT05368519|EXPERIMENTAL|Left chest with Brijjit® FMTB|Patients will be assigned to have their left chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
61942491|NCT04361825|EXPERIMENTAL|Durvalumab(MEDI4736) and AZD6738 combination|
61942492|NCT04864301|ACTIVE_COMPARATOR|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
61942493|NCT04864301|ACTIVE_COMPARATOR|Conventional Measurement technique|The control group (N=12) will receive no intraoperative ICI. Following maximal corporal dilatation, cylinder length will be estimated conventionally by adding up the internally measured distal and proximal corpora to the length of the corporotomy.
61942494|NCT02083081|EXPERIMENTAL|community intervention|Community level intervention (Social marketing campaign delivered to entire village) plus individual peer counseling sessions for enrolled pregnant women
61942495|NCT02083081|NO_INTERVENTION|usual care|Usual care provided by health aides to pregnant women
61942496|NCT05169190|ACTIVE_COMPARATOR|SGB|SGB, the experimental procedure, is the injection of 7 cc of 0.5% ropivacaine plus 0.5 cc contrast anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle
61942497|NCT05169190|SHAM_COMPARATOR|Sham|Sham, the placebo control group, is the injection of 7 cc of normal saline plus 0.5 cc contrast anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle
61942498|NCT05169190|NO_INTERVENTION|Wait-List Control (WLC)|WLC, a control for time, expectancy and safety, is all study procedures without going to the procedure room for injection
61942499|NCT02068027|EXPERIMENTAL|Clonidine Gel 0.1%|Clonidine hydrochloride topical gel, 0.1%
62337949|NCT04895163||Foreign workers|Foreign workers aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
62337950|NCT04895163||Local patients|Local patients aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
62337951|NCT00407914|EXPERIMENTAL|1|Aquamid
62337952|NCT00407914|ACTIVE_COMPARATOR|2|Restylane
62337953|NCT03105206||Low Pole Renal Calculus|patients with low pole renal calculus who are suitable to treat by flexible ureteroscopy
62138573|NCT01318694|EXPERIMENTAL|Treatment Arm A|"Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):~* Participants with a viral load below the level of detection (\< LOD) at Week 4 stop study treatment after 24 weeks~* Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment"
62337954|NCT01432262|EXPERIMENTAL|Group 1|=\> 65 years of age
62337955|NCT01432262|EXPERIMENTAL|Group 2|50 to 64 years of age
62337956|NCT02776410|EXPERIMENTAL|Intervention group|Group receiving tailored messages promoting sustainable and healthy eating through an mobile-application together with six principles of sustainable healthy eating that will be included in the mobile application,
62337957|NCT02776410|NO_INTERVENTION|Control group|Group who will not download the mobile application
61942500|NCT02068027|PLACEBO_COMPARATOR|Placebo|Placebo gel of identical appearance as active treatment
61942501|NCT00237172|EXPERIMENTAL|Imatinib Mesylate|400 mg once daily
61942502|NCT06319261|ACTIVE_COMPARATOR|guided biofilm therapy group|Sites treated with guided biofilm therapy.
61942503|NCT06319261|OTHER|conventional root debridement group|Sites treated with conventional manual instrumentation only.
61942504|NCT03873610|EXPERIMENTAL|Stress and Symptom Management Program 1|
61942505|NCT03873610|EXPERIMENTAL|Stress and Symptom Management 2|
61942506|NCT05693116||Nasal Vestibule Squamous Cell Carcinoma|Patients affected by primary squamous cell carcinoma of the nasal vestibule. Patients will be treated with upfront surgery according to the current practice and followed to identify any possible factor affecting prognosis.
61942507|NCT05824091|EXPERIMENTAL|MK-7762 (TBD09)|In Part 1 of the trial (SAD/FE), up to five sequential cohorts will be enrolled to evaluate up to five escalating single doses of MK-7762; 8 participants in each cohort will be randomized (3:1) to receive MK-7762 or placebo. A sixth cohort will evaluate the effect of food on PK of single doses of MK-7762 utilizing an open-label, two-period design in 8 participants.
62138574|NCT01318694|EXPERIMENTAL|Treatment Arm B|Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)
62138575|NCT01318694|EXPERIMENTAL|Treatment Arm C|Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks
62337958|NCT01012505||20 preterm infants|20 preterm infants without active disease
62337959|NCT02618980|EXPERIMENTAL|early endoscopy|endoscopic hemostasis
62337960|NCT02618980|NO_INTERVENTION|without early endoscopy|Patients assigned to non-endoscopic treatment group receive high dose infusional PPI therapy. If UGI bleeding subsided after medical treatment alone, diagnostic EGD will be done under stable hemodynamic and 2 weeks after ACS to confirm UGI SRH. If the SRH is not located at UGI tract, the patients will be excluded. Troponin I or T and complete ECG will be checked every 8 hours within 24 hours of interventions. APACHE II score at intervention will be calculated for each patient.
62138576|NCT01318694|ACTIVE_COMPARATOR|Treatment Arm D|ALV Placebo with PEG and RBV for 48 weeks
62337961|NCT02058134|NO_INTERVENTION|Control group|
62337962|NCT02058134|EXPERIMENTAL|Interventional group|For patients in the interventional group we use a CardioPAT cell saver intra- and postoperatively.
62337963|NCT03775096|EXPERIMENTAL|carvedilol therapy|The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125 mg twice/daily, the target dose will be 25mg twice daily (50 mg/day) and participants will take 50 mg/day carvedilol for 6 months.Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.
62337964|NCT01821820|EXPERIMENTAL|Pistachios|Pistachio treatment (3 oz/d) for two weeks; 3 oz pistachio nuts and water (1.5 oz. before, and 1.5 oz during) cycling 75 km.
62337965|NCT01821820|NO_INTERVENTION|No pistachios|No pistachios for two weeks, or before and during 75 km cycling.
62494749|NCT02212457|EXPERIMENTAL|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
61942508|NCT05824091|PLACEBO_COMPARATOR|Placebo|Participants will receive placebos matched to MK-7762 (TBD09).
61942509|NCT03878238|PLACEBO_COMPARATOR|Placebo|
61942510|NCT03878238|EXPERIMENTAL|Probiotic|
61942511|NCT04639531|EXPERIMENTAL|Orientation and Mobility Training with VR-IOMSs|Low vision subjects with Orientation and Mobility (O\&M) difficulties learning O\&M skills from Virtual Reality-base Intelligent O\&M Specialists (VR-IOMSs). VR-IOMSs are intelligent, computer-controlled automatic O\&M skill training programs in virtual streets.
61942512|NCT04639531|ACTIVE_COMPARATOR|Orientation and Mobility Training with COMS|Low vision subjects with Orientation and Mobility (O\&M) difficulties learning O\&M skills from human Certified O\&M Specialists (COMS) in real streets
61942513|NCT04639531|PLACEBO_COMPARATOR|No Orientation and Mobility Training|Low vision subjects with Orientation and Mobility (O\&M) difficulties watching low vision education videos and discuss low vision issues not related to O\&M with COMSs.
62337966|NCT04597255|EXPERIMENTAL|Holographic optical coherence tomography|Healthy phakic participants
62337967|NCT03996434|EXPERIMENTAL|Coasting group|Including 150 patients who will undergo withholding gonadotropin administration for at least 24 hours before triggering ovulation with hCG. GnRH agonist will be continued daily till the day of triggering. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml, then 5000 IU of hCG will be given.
62337968|NCT03996434|ACTIVE_COMPARATOR|Antagonist group|"Including 150 patients who will receive GnRH antagonist (subcutaneous injection Cetrorelix acetate 0.25 mg (Cetrotide, Serono, UK)) daily until the day of hCG administration.~GnRH agonist will be discontinued at the start of antagonist administration.~E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml and TVS revealed that follicles diameter is ≥ 18 mm, then 5000 IU of hCG will be given."
61942514|NCT00304239|EXPERIMENTAL|Metvix-PDT|Participants received Metvix-PDT (methyl aminolevulinate hydrochloride-Photodynamic therapy) 160 milligrams per gram (mg/g) cream on face and/or scalp for 3 hours on Day 0 and Day 7.
61942515|NCT00304239|PLACEBO_COMPARATOR|Vehicle-PDT|Participants received Vehicle cream (Vehicle-PDT) on face and/or scalp for 3 hours on Day 0 and Day 7.
61942516|NCT06132841|EXPERIMENTAL|Cohort 1|Participants will receive repeated doses of AZD6234 or placebo via SC injection
61942517|NCT06132841|EXPERIMENTAL|Cohort 2|Participants will receive repeated doses of AZD6234 or placebo via SC injection
61942518|NCT06132841|EXPERIMENTAL|Cohort 3|Japanese participants will receive repeated doses of AZD6234 or placebo via SC injection
61942519|NCT06525012||SAH of aneurysmal origin in hospitalized patients in Martinique between 2013 and 2021|
62138577|NCT05730829|EXPERIMENTAL|Pain Informed Movement and pain neuroscience education|Participants will receive a twice weekly, 8 week in-person group exercise program, consisting of exercise instruction (75 minutes) and pain neuroscience education (PNE) videos (20 to 30 minutes/week for the first 4 weeks). During the exercise sessions, the educational components and concepts such as mindfulness, muscle tension regulation, and breathing techniques will be applied by the instructor. A third home session (weekly) will be facilitated by exercise handout sheets. The exercise component will be delivered by an experienced yoga teacher that has been extensively trained. The PNE video component will cover the following topics: The purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
62138578|NCT05730829|ACTIVE_COMPARATOR|Standard neuromuscular exercise and OA education|Participants in this group will receive an 8-week in-person group exercise program held twice weekly, in which they will receive exercise instructions (60 minutes) and standard osteoarthritis (OA) education (15 to 20 minutes/week for the first 4 weeks). A third home session (weekly) will be facilitated by exercise handout sheets. The exercise component (i.e., the specific movements) of this group will be similar to those of the other group without the added techniques of breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness. The standard OA education videos will cover the following topics: common OA symptoms, risk factors associated with knee OA, and the effects of exercise and self-management tips. The exercise and education components will be delivered by a physiotherapist in the research team.
62138579|NCT02013700|EXPERIMENTAL|20 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10\^6 (20 million) cells delivered via peripheral intravenous infusion
62138580|NCT02013700|PLACEBO_COMPARATOR|Placebo|Patients will receive a matched placebo delivered via peripheral intravenous infusion
62138581|NCT02013700|EXPERIMENTAL|100 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10\^6 (20 million) cells delivered via peripheral intravenous infusion
62138582|NCT02013700|EXPERIMENTAL|200 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10\^6 (200 million) cells delivered via peripheral intravenous infusion
62138583|NCT04025255|EXPERIMENTAL|Braini|28-day oral capsules of Braini
62138584|NCT04025255|PLACEBO_COMPARATOR|Placebo|28-day oral capsule of placebo comparator
62494750|NCT02212457|EXPERIMENTAL|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
61942520|NCT05693883|EXPERIMENTAL|Pilates training|The participant completed receiving pilates training program three time a week for ten week-long (60 minutes/time)
61942521|NCT05693883|NO_INTERVENTION|Control group|
61942522|NCT01219673|PLACEBO_COMPARATOR|Placebo|Placebo by mouth 2 times every day.
61942523|NCT01219673|EXPERIMENTAL|Armodafinil|Armodafinil 150 mg by mouth once a day.
61942524|NCT01219673|EXPERIMENTAL|Minocycline|Minocycline 100 mg by muth two times a day.
62138585|NCT04172207||Results of study groups.|
62138586|NCT00104741|ACTIVE_COMPARATOR|radiotherapy alone|
62337969|NCT05437757|EXPERIMENTAL|Implantation of PCL Breast scaffold|Insertion of a 3D printed medical-grade polycaprolactone-PCL Breast scaffold with autologous fat graft for unilateral or bilateral breast implant revision and congenital defect correction surgery.
62337970|NCT00975195|EXPERIMENTAL|fluticasone high dose|fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate
62337971|NCT00975195|EXPERIMENTAL|fluticasone medium & low doses|fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate
62494751|NCT02212457|EXPERIMENTAL|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
61942525|NCT01219673|EXPERIMENTAL|Bupropion|Bupropion 100 mg by mouth two times a day.
61942526|NCT01219673|EXPERIMENTAL|Armodafinil + Minocycline|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by mouth two times a day."
62494752|NCT03628807||Retrospective 1|Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.
62494753|NCT03628807||Retrospective 2|Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.
62494754|NCT03628807||Prospective|Prospective cohort that received TIPS from 01/01/2013 onwards
62494755|NCT00960154|EXPERIMENTAL|PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
61942527|NCT01219673|EXPERIMENTAL|Armodafinil + Bupropion|"Armodafinil 150 mg by mouth once a day.~Bupropion 100 mg by mouth two times a day."
61942528|NCT01219673|EXPERIMENTAL|Minocycline + Bupropion|"Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
61942529|NCT01219673|EXPERIMENTAL|Armodafinil + Minocycline + Bupropion|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
61942530|NCT06059573|EXPERIMENTAL|Robot-guided|Implant placement by robot-guided based on a digital plan
61942531|NCT06059573|ACTIVE_COMPARATOR|Freehand surgery|Implant placement by freehand based on a digital plan
62494756|NCT00960154|ACTIVE_COMPARATOR|SOC|The SOC consists of scalpel for the skin incision and traditional electrosurgery for the entirety of the subcutaneous dissection.
61942532|NCT01604187|ACTIVE_COMPARATOR|Fentanyl|Ten minutes before the procedure fentanyl 100 mikrograms sublingual tablet will be given to the patient.
61942533|NCT01604187|PLACEBO_COMPARATOR|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
61942534|NCT04342273|EXPERIMENTAL|KW-6356 therapeutic dose|Oral administration
61942535|NCT04342273|EXPERIMENTAL|KW-6356 supratherapeutic dose|Oral administration
61942536|NCT04342273|PLACEBO_COMPARATOR|Placebo|Oral administration
62138587|NCT00104741|EXPERIMENTAL|Radiotherapy + androgene deprivation|
62138588|NCT04934995||Study Population|Adult women undergoing cesarean delivery at The Ohio State University Wexner Medical Center under spinal anesthesia, ASA physical status I-III with a BMI during pregnancy ≥ 35 kg/m2 and singleton pregnancy.
62138589|NCT04847375|EXPERIMENTAL|Nebulized Surfactant|The patients in this group will receive exogenous surfactant using nebulizer mask as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19; in addition they will receive standard care based on the national guidelines
62138590|NCT04847375|NO_INTERVENTION|Standard Care|The patients in this group will receive standard care based on the national guidelines as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19
62494757|NCT01342991|ACTIVE_COMPARATOR|Milligan-Morgan Haemorrhoidectomy|Control arm
62494758|NCT01342991|EXPERIMENTAL|Laser Haemorrhoidectomy|This new method of haemorrhoidectomy is being compared to the standard Milligan-Morgan Haemorrhoidectomy.
61942537|NCT04342273|ACTIVE_COMPARATOR|Moxifloxacin|Oral administration
61942538|NCT00871325|EXPERIMENTAL|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
61942539|NCT00871325|EXPERIMENTAL|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
61942540|NCT00871325|PLACEBO_COMPARATOR|Placebo|Placebo TID
61942541|NCT04099407|EXPERIMENTAL|Antifibrotic plus standard of care treatment|Prolonged release pirfenidone formulation in combination with standard of care treatment.
61942542|NCT04200573|EXPERIMENTAL|Normal Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with normal hepatic function
61942543|NCT04200573|EXPERIMENTAL|Mild Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment
61942544|NCT04200573|EXPERIMENTAL|Moderate Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment
61942545|NCT04200573|EXPERIMENTAL|Severe Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment
61942546|NCT01716390|ACTIVE_COMPARATOR|Drink that contains plant stanols|Dietary supplement: Plant stanol
61942547|NCT01716390|PLACEBO_COMPARATOR|Placebo drink|Dietary supplement: Placebo
61942548|NCT00970073|EXPERIMENTAL|Delayed CNI Group 1|Thymoglobulin 3mg total, administered on Days 0 and 2 (after transplant), plus MMF and corticosteroids. CNI administration delayed until 10 days post transplant. tacrolimus 3-8 (trough concentration)
61942549|NCT00970073|EXPERIMENTAL|Delayed CNI Group 2|Thymoglobulin 4.5mg total, plus MMF and corticosteroids. CNI therapy delayed until 10 days post transplant.tacrolimus 3-8 (trough concentration)
61942550|NCT00970073|ACTIVE_COMPARATOR|Early CNI / Control Arm|Standard post liver transplant therapy to include: tacrolimus 8-12 (trough concentration) initiated within 48 hours post-transplant, plus mycophenolate mofetil (MMF) and corticosteroids to be administered within 24 hours after transplant (Day 0).
61942551|NCT02624674|EXPERIMENTAL|Multi-spectral Imaging Group|All subjects in this group will undergo baseline Near Infrared Spectroscopy (NIRS) measurement points with the Multi-spectral imaging device, baseline vascular studies (including ankle-brachial index (ABI), vascular doppler (arterial and venous), and toe pressures. At the one month mark (from baseline), NIR measurement point and vascular studies will again be performed. All measurements are incorporated into the routine wound care and will not require extra trips in hospital for wound care.
62138591|NCT06215547|OTHER|The Medtronic Enterra II Model 37800 Neurostimulator|It is powered by a hermetically sealed hybrid cathode silver vanadium oxide (HCSVO) single-cell battery. To further protect the neurostimulator components from body fluids, the electronics and power source are hermetically sealed within an oval-shaped titanium shield. The neurostimulator case has an external insulating coating to prevent skeletal muscle stimulation at the neurostimulator implant site. An uninsulated area on one side of the neurostimulator (etched identification side) forms the indifferent electrode. The uninsulated side should be positioned away from muscle tissue. The neurostimulator has a self-sealing connector assembly with a corrosion-resistant titanium alloy body \& titanium setscrews. Securing the lead system requires the use of a torque wrench which is packaged with the neurostimulator.
62138592|NCT05071300|EXPERIMENTAL|Eplontersen|Eplontersen will be administered by subcutaneous (SC) injection once every 4 weeks for up to 3 years (157 weeks).
62138593|NCT03484949|EXPERIMENTAL|pre-endoscopic screening risk assessment|
62138594|NCT03484949|NO_INTERVENTION|routine screening|
62138595|NCT03202992|EXPERIMENTAL|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
62138596|NCT03202992|EXPERIMENTAL|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
62138597|NCT03202992|EXPERIMENTAL|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
62138598|NCT03202992|EXPERIMENTAL|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
62138599|NCT03202992|EXPERIMENTAL|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
62138600|NCT03202992|EXPERIMENTAL|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
62138601|NCT03202992|EXPERIMENTAL|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
62138602|NCT03202992|EXPERIMENTAL|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
62138603|NCT03202992|EXPERIMENTAL|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
62138604|NCT03202992|EXPERIMENTAL|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
62138605|NCT01645124|ACTIVE_COMPARATOR|Cytoreduction for HCT < 45%|Patients will be treated with phlebotomy and/or HU more intensively, with the goal to reach and maintain the target of hematocrit(HCT)below 45%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
62337972|NCT01628016|EXPERIMENTAL|Attentional bias modification training|"1. Attention bias modification training (ABMT) is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%.~2. ABMT intervention: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes (4 sessions a week, roughly one session every other day with for each session)."
62337973|NCT01628016|PLACEBO_COMPARATOR|Placebo training|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 218 trials, and the time to complete a PT session is approximately 10 minutes as well.
62138606|NCT01645124|EXPERIMENTAL|Cytoreduction for HCT between 45 and 50%|Patients will be treated with phlebotomy and/or HU less intensively, with the goal to reach and maintain the target of hematocrit(HCT)between 45% and 50%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
62138607|NCT03387540||Myocarditis induced by Immune check point inhibitor|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity
62138608|NCT06457516|EXPERIMENTAL|Mirror Therapy|
62138609|NCT06457516|OTHER|Music Therapy|
62337974|NCT01628016|NO_INTERVENTION|blank control|Participants only complete assessment at each point time.
62337975|NCT01778127|EXPERIMENTAL|Group A: Minimal Rewards|Participants use an activity monitor and the interactive website. They will receive minimal rewards based on their physical activity levels.
62494759|NCT05696548|EXPERIMENTAL|Lenvatinib plus Nivolumab|Step 1: 3 patients, Step 2: 48 patients
62138610|NCT06658847|EXPERIMENTAL|Intervention Cell|Investigational Night Cream plus auxiliary cleanser and sunscreen
62138611|NCT06658847|ACTIVE_COMPARATOR|No Intervention|Auxiliary cleanser and sunscreen only
62138612|NCT03295994|ACTIVE_COMPARATOR|Operative|surgery + post-operative physical therapy
62494760|NCT02188628|EXPERIMENTAL|H-Man|H-Man is a novel, portable, inexpensive end-effector upper limb robot.
62494761|NCT02188628|ACTIVE_COMPARATOR|Additional Conventional Therapy|Repetitive goals based arm therapy
62494762|NCT00292227|EXPERIMENTAL|Rotigotine|Rotigotine Patch
62494763|NCT00292227|PLACEBO_COMPARATOR|Placebo|Placebo patch
62494764|NCT02838953|EXPERIMENTAL|COPD patients|COPD patients submitted to Pulmonary Rehabilitation according to the ATS/ERS statement.
62138613|NCT03295994|ACTIVE_COMPARATOR|Non-Operative|non-operative physical therapy
62138614|NCT03604146||control group|Doctors and nurses were trained to treat chronic obstructive pulmonary disease according to the GOLD guidelines.Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
62138615|NCT03604146||Intervention group|Doctors and nurses will not receive any training from research team. Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
62138616|NCT06699745|EXPERIMENTAL|white noise group|Children in the group will be made to listen to white noise at an appropriate decibel level.
62138617|NCT06699745|EXPERIMENTAL|music group|Music will be listened at an appropriate decibel level for the children in the group.
62494765|NCT02838953|NO_INTERVENTION|Control|"Healthy individuals who will undergo the same COPD's evaluation protocol. As healthy individuals they will not participate to the Pulmonary Rehabilitation."
62696223|NCT06638034|EXPERIMENTAL|68Ga-FAPI-RGD PET/CT for scan and 177Lu-FAPI-RGD for therapy|All patients diagnosed with metastatic tumors underwent 68Ga-FAPI-RGD PET/CT scan. If the PET/CT showed high FAPI expression in tumor lesions of some patients, they would intravenously injected with the dose about 2.22-3.33 GBq (60-100 mCi) of 177Lu-FAPI-RGD for therapy.
62696224|NCT02758626|ACTIVE_COMPARATOR|Ataluren Followed By Placebo|Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
62138618|NCT06699745|NO_INTERVENTION|control group|No application was made to the control group.
61942552|NCT02359422|EXPERIMENTAL|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health program developed based upon the Message Interpretation Processing model designed to increase critical thinking skills about media messages and reduce risky sexual behaviors.
61942553|NCT02359422|NO_INTERVENTION|Wait-list control|
62138619|NCT02549807||Children muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
61942554|NCT06000397|EXPERIMENTAL|Enhanced reminders|
62337976|NCT01778127|EXPERIMENTAL|Group B: Immediate Incentives|"Participants use an activity monitor and the interactive website.~In addition to minimal rewards, participants will receive immediate incentives as they move from one level to the other on the website."
62494766|NCT01119625|EXPERIMENTAL|Synflorix™ Commercial-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of commercial lot of Synflorix™ co-administered with Rotarix™ and Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
62494767|NCT01119625|ACTIVE_COMPARATOR|Synflorix™ Clinical-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of clinical lot of Synflorix™ + Rotarix™ co-administered with Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (clinical and commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
62494768|NCT03381586|EXPERIMENTAL|Group A|1.0 mg/ml ALT-803
62494769|NCT03381586|EXPERIMENTAL|Group B|2.0 mg/ml ALT-803
61942555|NCT06000397|ACTIVE_COMPARATOR|Standard notifications|
61942556|NCT00003831|EXPERIMENTAL|Lymph node sampling|Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
62494770|NCT03126292|EXPERIMENTAL|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
61942557|NCT00003831|ACTIVE_COMPARATOR|Lymph node dissection|Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
61942558|NCT00422097|EXPERIMENTAL|Ixabepilone, 5 mg/d|If none of first 3 participants experiences a dose-limiting toxicity (DLT) during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the maximum tolerated dose (MTD). If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
61942559|NCT00422097|EXPERIMENTAL|Ixabepilone, 10 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
61942560|NCT00422097|EXPERIMENTAL|Ixabepilone, 15 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
62138620|NCT02549807||Adolescent muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured ((muscle elasticity measure)
62337977|NCT01778127|EXPERIMENTAL|Group C: Control|Participants in the control group will receive an activity monitor and educational materials, but will not have access to the interactive website. No rewards will be offered for their participation.
62494771|NCT03126292|ACTIVE_COMPARATOR|Handout|Families in the control group will receive handouts regarding child safety
62494772|NCT03511976|NO_INTERVENTION|Business as Usual (BAU)|One-third of participants will be assigned to this condition and will receive academic accommodations and interventions as deemed appropriate by their teachers, school personnel, and parents. This condition is intended to mirror current standard procedures for youth with ADHD. Thus, the specific accommodations and interventions are expected to vary across students. Some students' parents and physicians may choose to start stimulant medication with a goal of improving classroom performance.
62494773|NCT03511976|EXPERIMENTAL|Response to Intervention (RTI): Tier 1|Two-thirds of participants will be assigned to the RTI Tier 1 Arm. Teachers of students in this arm will receive consultation in RTI Tier 1 Classroom Management strategies.
62494774|NCT03511976|EXPERIMENTAL|RTI: Daily Report Card (DRC)|Students assigned to the RTI Tier 1 Arm, who do not respond to the initial RTI Tier 1 Classroom Management strategies, will move to the RTI DRC Arm of the study. Teachers of students in this arm of the study will receive consultation to implement a daily report card.
62138621|NCT02549807||Adult muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
62138622|NCT01964781|EXPERIMENTAL|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
62138623|NCT01964781|EXPERIMENTAL|topical adrenaline|adrenaline solution to be smeared on surgical wounds before closure
62138624|NCT01964781|EXPERIMENTAL|topical bupivacaine|bupivacaine to be smeared on surgical wounds before closure
62337978|NCT01348022||Xience V stent|unprotected Left Main Coronary Artery stenting treated with Xience V stent
62337979|NCT02134327|EXPERIMENTAL|Premedication with Midazolam|
62494775|NCT03511976|EXPERIMENTAL|RTI: Enhanced|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the RTI: Enhanced Arm. Students in this arm will receive a more intensive classroom behavioral intervention directed at individual target behaviors through an enhanced DRC.
62494776|NCT03511976|EXPERIMENTAL|Medication|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the Medication arm and will receive stimulant medication as an additional intervention.
62494777|NCT01476501|EXPERIMENTAL|2,000 IU/day vitamin D|2,000 IU/day vitamin D for 6 months (n=60).
62494778|NCT01476501|EXPERIMENTAL|40,000 IU/month vitamin D|40,000 IU/month for 6 months (n=60).
62494779|NCT05172687||Nursing home patients of treated study prescribers|Patients attributed to physicians who received overprescribing letters in the primary study who reside in a nursing home.
62138625|NCT01964781|EXPERIMENTAL|topical adrenaline plus tranexamic acid|tranexamic acid and adrenaline to be smeared on surgical wounds before closure
62138626|NCT01964781|PLACEBO_COMPARATOR|placebo control|saline to be smeared on surgical wounds before closure
62337980|NCT02365493|NO_INTERVENTION|Standard therapy|"Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study"
62337981|NCT02365493|EXPERIMENTAL|Standard therapy + Beta-Lactam|In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) \<10, if they desire.
62337982|NCT03656120|EXPERIMENTAL|0.2mg group|Participants are taking 0.2mg thienorphine hydrochloride table once a day for 12 weeks.
62337983|NCT03656120|EXPERIMENTAL|0.5mg group|Participants are taking 0.5mg thienorphine hydrochloride table once a day for 12 weeks.
62337984|NCT03656120|PLACEBO_COMPARATOR|placebo control group|Participants only taking placebo once a day for 12 weeks.
62337985|NCT04574609|NO_INTERVENTION|no hypnotherapy|"A control group of patients receiving the usual management for PAC and chemotherapy sessions."
62337986|NCT04574609|EXPERIMENTAL|hypnotherapy|"A hypnotherapy group of patients benefiting from hypnotherapy sessions prior to PAC and chemotherapy cures in addition to the usual management."
62494780|NCT05172687||Nursing home patients of control study prescribers|Patients attributed to physicians who received placebo letters in the primary study who reside in a nursing home.
62494781|NCT05172687||Community-dwelling patients of treated study prescribers|Patients attributed to physicians who received overprescribing letters in the primary study who reside in the community.
62494782|NCT05172687||Community-dwelling patients of control study prescribers|Patients attributed to physicians who received placebo letters in the primary study who reside in the community.
62494783|NCT06485518||5G RHS group|For all patients receiving care through the 5G-based Remote Healthcare System (5G RHS) teleconsultation platform during the specified time period
62494784|NCT05616455|EXPERIMENTAL|Propionibacterium extract gel|"The Propionibacterium extract gel is a topical product that protect the skin and mucous membranes from external agents. Its film forming property on the epidermis helps reduce inflammation, itching and pain, while the adjunct of antioxidant ingredients helps promote the healing process.~Patients were instructed to squeeze out from the aluminium tubes containing the Propionibacterium extract gel, 3 grams of gel (3 cm), applying it twice a day for 40 days in the distal anal canal and perianal area."
62494785|NCT05616455|ACTIVE_COMPARATOR|0.4% glyceryl trinitrate ointment|"0.4% glyceryl trinitrate ointment is a well-known nitric oxide donor which promotes fissure healing by decreasing resting anal pressure and increasing anoderm blood flow, via the stimulation of the intracellular cyclic GMP resulting in a consequent reduction in cytosolic calcium. The success rate is variable, with 28% of patients experiencing transient headache often leading to drug discontinuation and poor compliance to treatment.~Patients were instructed to squeeze out from the aluminium tubes containing 0.4% glyceryl trinitrate ointment approximately 1.5 mg of the ointment applying it to the distal anal canal and perianal area with a gloved finger, every 12 hours for 40 days."
62138627|NCT01964781|PLACEBO_COMPARATOR|tranexamic acid and placebo control|tranexamic acid and saline to be smeared on surgical wounds before closure
62138628|NCT06424340|EXPERIMENTAL|MB-dNPM1-TCR.1|Biological: MB-dNPM1-TCR.1
62337987|NCT00536042|EXPERIMENTAL|minocycline|addition of minocycline to standard asthma care as add-on therapy: 150 mg bid to 250 mg bid for up to one year
62337988|NCT05576948||Children with or at high risk of CP|Infants with a diagnosis of CP OR at high risk of CP as per the international Clinical Practice Guideline for early diagnosis of CP. In order to develop prognostic curves for motor function a minimum of 3 data points are required per participant. For this reason infants will be included if they are 12 months or younger (corrected age) at the time of enrolment.
62337989|NCT01066195|EXPERIMENTAL|gefitinib|
62337990|NCT01066195|ACTIVE_COMPARATOR|pemetrexed|
62494786|NCT02786953|EXPERIMENTAL|Sleep Promotion|Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.
62494787|NCT02786953|NO_INTERVENTION|Usual Care|Usual Care
62494788|NCT04898816|EXPERIMENTAL|Group A|Application of cyanoacrylate tissue adhesive over the surgical wound
62494789|NCT04898816|ACTIVE_COMPARATOR|Group B|Suturing the surgical wound using braided black silk
62494790|NCT00914654|OTHER|Healthty|10 healthy men
62494791|NCT00914654|OTHER|Asthmatics|10 male asthmatic subjects
62494792|NCT00914654|OTHER|Elite asthmatics|10 male elite athletes with asthma
62696225|NCT02758626|ACTIVE_COMPARATOR|Placebo Followed by Ataluren|Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
62696226|NCT01254214|EXPERIMENTAL|tMBSR|telephone-adapted Mindfulness Based Stress Reduction (tMBSR) is an 8-week program of training in mindfulness meditation consisting of two in-person group meetings and 6 conference calls, led by a trained meditation teacher.
62494793|NCT02230267|EXPERIMENTAL|High intensity boot camp|Each of the two HIBCs will have 10 participants (20 total) with a 1:5 physical therapist-to-patient ratio. Each HIBC session will last 1.5 hours and will be held on 4 days of the week. Participants will be required to attend 3 of those 4 days but may attend all. Because this is a pragmatic trial, therapists will have some leeway to control the intensity and the modality of the exercise. However, the basic format of the HIBC will consist of the following exercise components: A. 30 minutes of moderate-high intensity aerobic exercise at 70%+ of estimated maximum heart rate; B. 15 minutes of strengthening the major muscle groups of the trunk and upper/lower extremities; C. 15 minutes of balance training; and, D. 15 minutes of rest and stretching. Participants will rotate through these four different exercise components in a circuit fashion.
62494794|NCT02230267|ACTIVE_COMPARATOR|Usual care arm|The low intensity exercise group will participate in the Fitness Counts Exercise Program (FCEP) which is a basic low intensity, sitting and standing exercise program (10 minutes of stretching, 10 minutes of aerobic exercise (60% of heart rate maximum), and 10 minutes of strengthening). This exercise program was developed by the National Parkinson Foundation and is commonly used in PD exercise classes. The physical therapist-to-patient ratio will be 1:5. As there are two clinical sites, there will be 10 participants in each of the two boot camps (20 total). The FCEP will be 1 hour daily on four days of the week. Participants will be required to attend 3 days per week but may attend more if they are able.
62696227|NCT01254214|ACTIVE_COMPARATOR|Support Group|The Support Group is a group intervention led by a trained facilitator and designed to match the intervention for time, attention and social support
62696228|NCT06424262|EXPERIMENTAL|CI622D|Investigational Medical Device (IMD)
62696229|NCT06424262|ACTIVE_COMPARATOR|CI622|An approved medical device
61942561|NCT00422097|EXPERIMENTAL|Ixabepilone, 20 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
62337991|NCT06200987|EXPERIMENTAL|Intervention|The group randomized to use the vibrator for 9 months
62337992|NCT06200987|NO_INTERVENTION|Controls|Usual standard treatment
62337993|NCT03195855|EXPERIMENTAL|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.~1. Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).~2. Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
62337994|NCT03195855|NO_INTERVENTION|Control group of usual care including podiatry|"Control group (n=29):~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
62337995|NCT02518152|ACTIVE_COMPARATOR|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
62337996|NCT02518152|ACTIVE_COMPARATOR|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
62337997|NCT02518152|ACTIVE_COMPARATOR|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
62337998|NCT05678075|ACTIVE_COMPARATOR|Whole food plant-based nutrition education|Providers will receive an educational intervention on whole food plant based nutrition that will last 6 weeks.
62337999|NCT05678075|NO_INTERVENTION|Delayed intervention|Providers will receive a educational intervention on whole food plant based nutrition that will last 6 weeks.
62494795|NCT02979132|ACTIVE_COMPARATOR|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 90 days
62338000|NCT02878733||Albumin|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with any volume of 5% albumin
62338001|NCT02878733||Crystalloid Only|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) without any volume of 5% albumin
62338002|NCT03297307|EXPERIMENTAL|Mother-Child with Intervention|Children will attend presurgical visits with their mother
62338003|NCT03297307|NO_INTERVENTION|Mother-Child Non-Intervention|Children will not attend presurgical visits with their mother
62696230|NCT05866640|EXPERIMENTAL|Intervention|Placement of the F2 device in the aorta to cover the great cerebral vessels.
62696231|NCT05508126||Primary staging group I|All patients will be treated according to standard practice. Patients in group I are patients that will be stratified for radical gastrectomy or endoscopic resection. Group I will undergo only a primary staging. All patients will take DECT and mpMRI examination within 1 week before surgery.
62696232|NCT05508126||Restaging group II|"Patients in group II are patients that will be stratified for neoadjuvant chemotherapy.~Group II will undergo a primary staging (DECT and mpMRI) and 1-2 times restaging (DECT and mpMRI)."
62696233|NCT05410223|EXPERIMENTAL|study group|14-days therapy of Yolk antibody and ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline, bismuth
62696234|NCT05410223|ACTIVE_COMPARATOR|control group|14-days therapy of ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline, bismuth
62696235|NCT05410223|EXPERIMENTAL|the case group|14-days therapy of Yolk antibody and ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline
62696236|NCT05410223|ACTIVE_COMPARATOR|the control group|14-days therapy of ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline, bismuth
62696237|NCT05202782|EXPERIMENTAL|Treatment (zanubrutinib and CAR T-cell therapy)|"LEAD- IN PHASE: Patients receive zanubrutinib PO BID for 7-14 days in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive standard of care CAR T-cell therapy IV at 4 weeks.~MAINTENANCE PHASE: Patients receive zanubrutinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity."
62696238|NCT05019079|EXPERIMENTAL|electroacupuncture group|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation was stopped 30min later.
62696239|NCT05019079|NO_INTERVENTION|control group|The patient underwent routine anesthesia without acupuncture treatment
62696240|NCT04912518|ACTIVE_COMPARATOR|Dexmedetomidine (DEX) group|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
62696241|NCT04912518|PLACEBO_COMPARATOR|Placebo (Saline) group|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX group.
62696242|NCT01078532|EXPERIMENTAL|SMART PHR|Patients receive the active PHR
61942562|NCT00422097|EXPERIMENTAL|Ixabepilone, 25 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
61942563|NCT00422097|EXPERIMENTAL|Ixabepilone, 30 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
61942564|NCT00422097|EXPERIMENTAL|Ixabepilone, 25 mg, with famotidine|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive famotidine, 40 mg on Day 1.
61942565|NCT00422097|EXPERIMENTAL|Ixabepilone, 25 mg, with food|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive a low-fat meal on Day 1.
61942566|NCT00669396|EXPERIMENTAL|1|IUD
61942567|NCT00669396|ACTIVE_COMPARATOR|2|Oral levonorgestrel
61942568|NCT03436004|EXPERIMENTAL|Experimental|Colonoscopy with specific device with CE marking (Endocuff Vision)
61942569|NCT03436004|ACTIVE_COMPARATOR|Active Comparator|Colonoscopy with standard device of the center
61942570|NCT02239588|EXPERIMENTAL|Pure Canterbury milk powder|Oral consumption of infant formula (0-6 months) milk powder
61942571|NCT02239588|ACTIVE_COMPARATOR|Other infant formula milk powder|"Oral consumption of milk powder (other than the experimental product) selected by subjects' parents. The products including:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1: 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
62494796|NCT02979132|ACTIVE_COMPARATOR|Intravenous Iron Supplementation|Single-dose Ferinject(R) administration
62494797|NCT02979132|ACTIVE_COMPARATOR|Food Fortification with Iron|Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d
62494798|NCT04885751|EXPERIMENTAL|eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
61942572|NCT02239588|PLACEBO_COMPARATOR|Breast milk|Oral consumption of breast milk
61942573|NCT05427006||Z5-BL Dental Implants|
61942574|NCT05427006||Z5-TL Dental Implants|
61942575|NCT01148888|EXPERIMENTAL|Magnesium Sulfate|The study will be conducted in the 45 minute interval between the completion of spinal instrumentation and the completion of skin closure. Once the spinal instrumentation is complete and the integrity of the spinal cord pathways is confirmed using SEPs and MEPs, magnesium will be administered for the remainder of surgery.
61942576|NCT00810355|ACTIVE_COMPARATOR|Arm 1|Support group
61942577|NCT00810355|EXPERIMENTAL|Arm 2|Cognitive Behavior Therapy
62494799|NCT04885751|ACTIVE_COMPARATOR|rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
62494800|NCT03318133|EXPERIMENTAL|GA group|"general anesthesia(GA) group:~1. Open peripheral vein fluid infusion, radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring~2. Propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg) and sulfentanyl(0.2-0.6μg/kg) anesthesia-induced intubation, mechanical ventilation to maintain normal PETCO2~3. Use sevoflurane, propofol and sulfentanyl to maintain anesthesia, and add cis-atracurium as needed~4. Transfer to ICU after surgery"
62696243|NCT01078532|OTHER|Passive PHR|Usual PHR Care
62696244|NCT04647357|EXPERIMENTAL|SHR-1316|
62696245|NCT03298737||Correct to normal vision population|
62696246|NCT04171960||Acute Blood Biomarker Branch|Blood drawn within 12 hours or 12-24 hours following injury for i-STAT TBI Testing and in-person baseline outcome assessments.
62696247|NCT03802396|EXPERIMENTAL|CN-105|"Cohort 1: 50 Patients Dose of CN-105: 0.1 mg/kg~Cohort 2: 50 Patients Dose of CN-105: 0.5 mg/kg~Cohort 3: 50 Patients Dose of CN-105: 1 mg/kg"
62696248|NCT03802396|PLACEBO_COMPARATOR|Placebo|"Cohort 1: 17 Patients receiving placebo~Cohort 2: 17 Patients receiving placebo~Cohort 3: 17 Patients receiving placebo"
62696249|NCT03340779|EXPERIMENTAL|Norepinephrine alone|Administration of norepinephrine with increasing dose
62494801|NCT03318133|EXPERIMENTAL|CLSB group|"combined lumbar plexus and sacral plexus block(CLSB) group:~1. Open peripheral vein fluid infusion~2. In lateral position (affected side upward), ultrasound-guided lumbar plexus block (0.375% ropivacaine, Lumbar 2-3 or/and 3-4vertebral space level, 25ml), then sacral plexus block (0.375% ropivacaine, 20ml)~3. Radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring, and blockade effectiveness was evaluated 30min after nerve block~4. After reaching satisfactory blockade, target-controlled infusion of propofol was used to maintain Ramsay sedation score between 5-6 points, monitoring PETCO2 through nasopharyngeal airway, maintain autonomous respiration, and add small-dose fentanyl (10-20μg/time) as needed~5. Transfer to ICU after surgery"
62494802|NCT02417428|EXPERIMENTAL|Citrulline|Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
62494803|NCT02417428|PLACEBO_COMPARATOR|Placebo|Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
62494804|NCT02417428|EXPERIMENTAL|Exercise|Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
62696250|NCT03340779|ACTIVE_COMPARATOR|Norepinephrine plus Dobutamine|Administration of norepinephrine and dobutamine
62696251|NCT05789290||Test group|This group will receive a 30-minute cryocompression treatment to one knee using a Hilotherm device, which is set to circulate water through the cuff at a maintained temperature of 10℃. The Hilotherm device will be administered according to the manufacturer's guidelines and each participant will undergo this treatment once.
62696252|NCT03457662|ACTIVE_COMPARATOR|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
62696253|NCT03457662|EXPERIMENTAL|OMC and SDT|OMC and SDT are administrated in this arm.
62696254|NCT03611686||patient followed for metastatic prostate adenocarcinoma|patient wil be followed for metastatic prostate adenocarcinoma during 3 years
62696255|NCT06385028|EXPERIMENTAL|Physical activity promotion|The entire population will receive the physical activity promotion intervention, composed of weekly goal setting and daily notification with information about physical activity and sedentary behavior.
62696256|NCT00279695||1|Subjects with glaucoma and age-matched normals
62696257|NCT00279695||2|normal volunteers, two age groups, one 18-25 years old, one 50 years and older.
62338004|NCT03858062|ACTIVE_COMPARATOR|Open loop|14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
62338005|NCT03858062|EXPERIMENTAL|Closed loop|4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
62494805|NCT02417428|OTHER|Without exercise|Participant that will be randomized in this arm will not have an exercise program.
62696258|NCT00279695||3|subjects with tumors of the iris and ciliary body
62696259|NCT00279695||4|subjects with age-related macular degeneration and age-matched normals
62696260|NCT06263803|OTHER|control group|Participants in the control group will receive classical physiotherapy 5 days a week for 4 weeks (Tens 20 min, ultrasound 5 min, hotpack 20 min).
62696261|NCT06263803|EXPERIMENTAL|Music group|Participants in the music group will be played Pachabel Canon D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes) during the classical physical therapy session, free from external sounds (max 70 dB through headphones).
62338006|NCT03259490|EXPERIMENTAL|Test Treatment|High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
62696262|NCT06637943||time for establishing a diagnosis using SCL test|time taken to establish a diagnosis using SCL
62696263|NCT06637943||time for establishing a diagnosis using POC viscoelastic test|time taken to establish a diagnosis using POC viscoelastic test
62696264|NCT04635774|ACTIVE_COMPARATOR|Treatment Group|The treatment group will receive 40 IU via four activations of an intranasal spray.
61942578|NCT00810355|EXPERIMENTAL|Arm 3|Cognitive Behavior Therapy and Cognitive Remediation
62338007|NCT03259490|EXPERIMENTAL|Reference Treatment|Single tablets of empagliflozin + linagliptin + metformin XR
62338008|NCT01205555|NO_INTERVENTION|ultrasound alone group|Patients in the control group will have a standard ultrasound monitoring with HCG administered when the leading follicle reaches 18 mm, and IUI 36 h afterward.
62696265|NCT04635774|PLACEBO_COMPARATOR|Placebo Group|The placebo group will receive four activations of an intranasal spray containing placebo (normal saline).
62696266|NCT02572648||Participants with Heart Failure|Participants with heart failure will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
62696267|NCT02572648||Healthy Controls|Healthy controls will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
62738493|NCT03205358|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
62338009|NCT01205555|EXPERIMENTAL|LH testing combined with ultrasound monitoring|
62338010|NCT02492997|EXPERIMENTAL|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
62494806|NCT05993390|EXPERIMENTAL|Sugammadex group|Patient is intubated with etomidate 0.1\~0.2mg/kg and rocuronium 1mg/kg. 30 minutes after rocuronium administration, patient is administered sugammadex 1mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 30 minutes after administration of sugammadex. After 30 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
62494807|NCT05993390|EXPERIMENTAL|Neostigmine group|Patient is intubated with etomidate 0.1\~0.2mg/kg and rocuronium 1mg/kg. 30 minutes after rocuronium administration, patient is administered neostigmine 0.05mg/kg + glycopyrrolate 0.01mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 30 minutes after administration of neostigmine. After 30 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
62138629|NCT01616472||Incident diabetes cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with diabetes during follow-up, subsequent to SLE diagnosis.
62138630|NCT01616472||Incident diabetes controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of diabetes during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
62338011|NCT02492997|SHAM_COMPARATOR|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
62338012|NCT01070524|EXPERIMENTAL|CHF 5188 pMDI|
62338013|NCT01070524|ACTIVE_COMPARATOR|Budesonide extrafine pMDI|
62338014|NCT01070524|ACTIVE_COMPARATOR|Seretide(r) Evohaler(r)|
62338015|NCT06238245|EXPERIMENTAL|Combination of PTCy and ATG for GVHD prophylaxis|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
62494808|NCT05993390|NO_INTERVENTION|Control group|Patient is intubated with etomidate 0.1\~0.2mg/kg and rocuronium 1mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 60 minutes after intubation. After 60 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
62494809|NCT00347048|EXPERIMENTAL|1|
62494810|NCT00347048|PLACEBO_COMPARATOR|2|
62494811|NCT04784416|EXPERIMENTAL|Transcranial Photobiomodulation (t-PBM)|
62494812|NCT04784416|SHAM_COMPARATOR|Sham|
61942579|NCT02973828||A) Volunteer Imaging Studies|Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) per centre In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.
62138631|NCT01616472||Incident hypertension cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with hypertension during follow-up, subsequent to SLE diagnosis.
62138632|NCT01616472||Incident hypertension controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of hypertension during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
62138633|NCT01616472||Incident cataract cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with cataract during follow-up, subsequent to SLE diagnosis.
62138634|NCT01616472||Incident cataract controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of cataract during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
62338016|NCT01795287|ACTIVE_COMPARATOR|Spinal anesthesia|Spinal anesthesia
62338017|NCT01795287|ACTIVE_COMPARATOR|General anesthesia|General anesthesia with fentanyl, propofol and rocuronium and sevoflurane
62338018|NCT02260245|OTHER|Team training|All participating affiliates will undergo team training using the TeamSTEPPS model
62138635|NCT01616472||Incident osteoporosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with osteoporosis during follow-up, subsequent to SLE diagnosis.
62338019|NCT00913718|EXPERIMENTAL|1|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
62338020|NCT00913718|ACTIVE_COMPARATOR|2|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
62338021|NCT03808038||No Diary Group|Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
62338022|NCT03808038||Diary Start Group|Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
62338023|NCT03808038||Daily Start Group|Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
62338024|NCT02984852|EXPERIMENTAL|Treatment sequence ABC|Participants will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination \[FDC\]) Treatment A (whole tablet) as reference in session 1 then Treatment B(split tablet) as test in session 2 followed by Treatment C (crushed tablet mixed in applesauce) as test in session 3 under fed conditions (standardized breakfast) on Day 1 of each treatment session. There will be a washout period of at least 7 days between consecutive drug intakes.
62494813|NCT03036592|EXPERIMENTAL|MTNR1B CC|Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
62494814|NCT03036592|EXPERIMENTAL|MTNR1B GG|Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
62494815|NCT03036592|EXPERIMENTAL|MTNR1B CG|Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
62494816|NCT06146660||Participants receiving mavacamten for oHCM|
62494817|NCT05307276|OTHER|Healthy volunteers|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular
62494818|NCT02392689|EXPERIMENTAL|PCT-guided|"Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended"
62494819|NCT02392689|NO_INTERVENTION|Standard of Care|Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.
62494820|NCT05904639|EXPERIMENTAL|Pre-study|Baseline or pre-study arm
62494821|NCT05904639|EXPERIMENTAL|Cross-over arm|Intervention arm
62494822|NCT03645876|EXPERIMENTAL|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
62494823|NCT05457868||Salbutamol|Exposure group
62494824|NCT05457868||Long-acting muscarinic antagonists (LAMA)|Reference group
62494825|NCT05533151|EXPERIMENTAL|Bronchial asthma|This group envolves parients suffering from bronchial asthma.
62494826|NCT05533151|EXPERIMENTAL|Interstitial lung diseases|This group envolves parients suffering from interstitial lung disease.
62494827|NCT05533151|EXPERIMENTAL|Lung transplantation|This group envolves parients after lung transplantation done for a pulmonary disease.
62494828|NCT03646409||Patients with esophageal cancer receiving chemotherapy|Patients \> 18 years with esophageal cancer receiving neoadjuvant chemotherapy
62494829|NCT02707276|EXPERIMENTAL|Phase 1: Cross-Over, Active LFMS first|Phase 1 crossover: three 20 minute treatments of active low field magnetic stimulation, once per day for three consecutive days during week 1. Then repeat with three 20 minute treatments of sham LFMS, once per day for three consecutive days during week 3.
62138636|NCT01616472||Incident osteoporosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of osteoporosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
62138637|NCT01616472||Incident avascular necrosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with avascular necrosis during follow-up, subsequent to SLE diagnosis
62138638|NCT01616472||Incident avascular necrosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of avascular necrosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
62138639|NCT01141803|NO_INTERVENTION|control|
62138640|NCT01141803|ACTIVE_COMPARATOR|Apples|
62138641|NCT01141803|ACTIVE_COMPARATOR|Apple pomace|
62138642|NCT06303180||1|Patients with head and neck conditions affecting hearing, balance, smell, taste, swallowing, voice and speech.
62138643|NCT05243784|EXPERIMENTAL|Intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of 8 weeks and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
62138644|NCT05243784|NO_INTERVENTION|Control|Students in the control group (CG) will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT program once the interventions are completed.
62138645|NCT03504904|EXPERIMENTAL|Internet-delivered ACT and CFT|8 week, guided internet- delivered acceptance and commitment therapy (ACT) and compassion focused therapy (CFT)
62138646|NCT03504904|NO_INTERVENTION|Wait list control group|Wait list control group, received treatment at later point.
62138647|NCT02915315||Baseline survey period|All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
62138648|NCT02915315||Low-salt diet|All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
62138649|NCT02915315||High -salt diet|After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
62494830|NCT02707276|SHAM_COMPARATOR|Phase 1: Cross-Over, Sham LFMS first|Phase 1 crossover: three 20 minute treatments of sham low field magnetic stimulation, once per day for three consecutive days during week 1. Then repeat with three 20 minute treatments of active LFMS, once per day for three consecutive days during week 3.
62494831|NCT02707276|EXPERIMENTAL|Phase 2: Parallel, Active LFMS|Phase 2 parallel: five 20-minute active low field magnetic stimulation treatments, once per day for five consecutive days during week 1.
62494832|NCT02707276|SHAM_COMPARATOR|Phase 2: Parallel, Sham LFMS|Phase 2 parallel: five 20-minute sham low field magnetic stimulation treatments, once per day for five consecutive days during week 1.
62138650|NCT05169580|EXPERIMENTAL|FTX-6058 oral capsule(s) in Sickle Cell participants|Cohort 1 will receive 6 mg of FTX-6058 by mouth once daily. Cohort 2 will be dosed at 2 mg once daily by mouth, and cohort 3 will be dosed at 12 mg once daily by mouth. The Sponsor will reinitiate enrolment in the 3rd cohort (12 mg cohort) with the updated inclusion and exclusion criteria. Based on review of available safety and biomarker data and with the recommendation of the DMC, a subsequent 4th cohort of 20 mg and potentially a 5th cohort of 30 mg may be initiated. A total of seven cohorts may be included. Following the first cohort, doses for all subsequent cohorts will be determined following DMC review of the safety and pharmacokinetic data observed in participants from the prior and ongoing cohorts. Alternate dosing schedules may be evaluated in some of the cohorts.
62338025|NCT02984852|EXPERIMENTAL|Treatment sequence ACB|Participants will receive a single oral tablet of D/C/F/TAF \[FDC\] Treatment A in treatment session 1, then Treatment C in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
62338026|NCT02984852|EXPERIMENTAL|Treatment sequence BCA|Participants will receive a single oral tablet of D/C/F/TAF \[FDC\] Treatment B in session 1 then Treatment C in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
62338027|NCT02984852|EXPERIMENTAL|Treatment sequence BAC|Participants will receive a single oral tablet of D/C/F/TAF \[FDC\] Treatment B in session 1 then Treatment A in session 2 followed by Treatment C in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
62738494|NCT03205358|ACTIVE_COMPARATOR|Group 2: NIMENRIX®|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.
62738495|NCT01421238|EXPERIMENTAL|Resuscitation Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive resuscitation, unless their parents object. If you decline resuscitation please check the box below:~Please check if you decline resuscitation \[\]"
62738496|NCT01421238|EXPERIMENTAL|Comfort Care Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive comfort care, unless their parents object. If you decline comfort care please check the box below:~Please check if you decline comfort care \[\]"
62738497|NCT06331156|EXPERIMENTAL|Co-administration Group|Participants receive 2 doses of HRV PCV-free vaccine co-administered with the first 2 doses of IPV vaccine at Month 0.5 and Month 1.5, followed by the third dose of IPV vaccine administered at Month 2.5.
62738498|NCT06331156|ACTIVE_COMPARATOR|Staggered Group|Participants receive 2 doses of HRV PCV-free vaccine administered at Day 1 and Month 1, and 3 doses of IPV vaccine administered at Month 0.5, Month 1.5, and Month 2.5.
62738499|NCT02058316||Patients at risk for IPA|
62738500|NCT01026090|EXPERIMENTAL|Dronedarone pre-cardioversion|Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
62738501|NCT01026090|PLACEBO_COMPARATOR|Placebo pre-cardioversion|Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
62738502|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
62738503|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
62738504|NCT05366088|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|Group sessions 2 hours/week, for 8 weeks, based on the manualized protocol developed by co-I Dr. Segal and will be delivered by social workers (or equivalent) with ≥3 years of experience delivering MBCT and training for official certification from the Center for Mindfulness Studies (Toronto).
62738505|NCT05366088|ACTIVE_COMPARATOR|Health Enhancement Program|Group sessions 2 hrs/week for 8 weeks, and amount of home practice (\~30 mins/day, 6 days/week). HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin.
62738506|NCT05483699|EXPERIMENTAL|Squeezing a ball during intravenous cannulation reduces the child's pain and fear.|The soft ball has a diameter of about 8-10 cm and can return to its old form when it is squeezed.
62738507|NCT05483699|EXPERIMENTAL|Using a kaleidoscope during intravenous cannulation reduces the child's pain and fear.|Kaleidoscope includes shapes of flowers and mirrors in the shape of triangle placed with an angle of 600. While rotating one of the cylinders, various shapes and colourful eyes are formed when viewed with one eye. When the kaleidoscope is rotated, the patterns look different all the time because the colourful parts are moving, attracting the child's attention.
62738508|NCT05483699|EXPERIMENTAL|Blowing bubbles during intravenous cannulation reduces the child's pain and fear.|Children in this group were shown bubble blower before intravenous cannulation and they were shown how bubbles formed and how to blow. Children blew bubbles during intravenous cannulation
62138651|NCT04098575||Patients receiving Empagliflozin until mid Sep 2015|Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
62138652|NCT04098575||Patients receiving Empagliflozin until CV Label Change time|Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
62494833|NCT02759380|EXPERIMENTAL|Phytoestrogen-rich foods|"* Introduced to the study by a dietitian.~* Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~* Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~* Called one time during the study and perform a 24-hour recall.~* The intervention continues until the day before the surgery (at least 6 weeks).~* The patients in the experimental group will be given a package containing food with a high amount of phytoestrogens."
62138653|NCT04098575||Patients receiving Empagliflozin until last available data cut|Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3
62138654|NCT06348225|EXPERIMENTAL|Exercise + Heat Therapy|30 minutes treadmill walking at a speed and grade to elicit 55-60% of heart rate reserve, followed by 45 minutes with the legs immersed to mid-calf in water circulating at 42C
62138655|NCT06348225|EXPERIMENTAL|Heat Therapy|45 minutes with the legs immersed to mid-calf in water circulating at 42C
62138656|NCT06348225|ACTIVE_COMPARATOR|Exercise|30 minutes treadmill walking at a speed and grade to elicit 55-60% of heart rate reserve (matched between Exercise + Heat Therapy and Exercise days), followed by 45 minutes with the legs immersed to mid-calf in water circulating at 36C
62138657|NCT06348225|NO_INTERVENTION|Control|Participants will refrain from exercise or heat exposure for at least 24 hours, and perform all study analyses for a control comparison.
62138658|NCT05916144|EXPERIMENTAL|Group 1|The group in which grandparents actively participate in baby care, Grandparents with a score of 6 and above in the One Day of Life (Annex-5) questionnaire will be included.
62138659|NCT05916144|NO_INTERVENTION|Group 2|The group whose primary caregivers are mothers only
62138660|NCT04422405|EXPERIMENTAL|Patients undergoing OAGB|
62138661|NCT02448524|EXPERIMENTAL|MiStentTM|MiStentTM coronary drug eluting stent (MiStent SES) consists of four parts: a bare-metal stent (BMS), a delivery system, resorbable polymer coating and anti-proliferative drug (sirolimus).
62494834|NCT02759380|NO_INTERVENTION|Control group|"* Introduced to the study by a dietitian.~* Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~* Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~* Called one time during the study and perform a 24-hour recall.~* The intervention continues until the day before the surgery (at least 6 weeks)."
62494835|NCT05339191|EXPERIMENTAL|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
62494836|NCT01556906|EXPERIMENTAL|Lomitapide|This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses
62494837|NCT01307358|EXPERIMENTAL|Manual Toothbrush + Sonicare Interproximal Cleaning Prototype|Manual Toothbrush + Sonicare Interproximal (IP) Cleaning Prototype
62494838|NCT01307358|ACTIVE_COMPARATOR|Manual Toothbrush|Manual Toothbrush
62494839|NCT01307358|ACTIVE_COMPARATOR|Manual Toothbrush + Floss|Manual Toothbrush + Floss
62494840|NCT01307358|ACTIVE_COMPARATOR|Manual Toothbrush + Waterpik Ultra Water Flosser|Manual Toothbrush + Waterpik Ultra Water Flosser
62494841|NCT05472740|EXPERIMENTAL|Active TENS|Participants will be connected to a TENS 7000 that is turned on and working
62696268|NCT01980147|EXPERIMENTAL|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT). This integrated model focuses on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The model and techniques are adapted to an age range of 9 to 17 years, with more visual material and child friendly language options for the younger part of the age range (9-12) and more teen-relevant and interpersonal content options for the older part of the age range (13-17). The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
62696269|NCT01980147|NO_INTERVENTION|Comparison|Naturalistic comparison arm: No intervention offered, no intervention prohibited.
62138662|NCT02448524|ACTIVE_COMPARATOR|TIVOLI|TIVOLI stent is a mature and fully degradable coating on a cobalt-chromium alloy drug-eluting stent on the market, findings of four years fully demonstrated the efficacy and safety of sirolimus-coated TIVOLI stent.
62338028|NCT02984852|EXPERIMENTAL|Treatment sequence CAB|Participants will receive a single oral tablet of D/C/F/TAF \[FDC\] Treatment C in session 1 then Treatment A in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
62338029|NCT02984852|EXPERIMENTAL|Treatment sequence CBA|Participants will receive a single oral tablet of D/C/F/TAF \[FDC\] Treatment C in session 1 then Treatment B in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
62338030|NCT05176431|ACTIVE_COMPARATOR|Focused extracorporeal shock wave therapy|
62338031|NCT05176431|ACTIVE_COMPARATOR|Radial extracorporeal shock wave therapy|
62494842|NCT05472740|PLACEBO_COMPARATOR|Placebo TENS|Participants will be connected to a TENS 7000 however it will not be connected / will not be working
62494843|NCT00882245|PLACEBO_COMPARATOR|Vehicle ointment|
62494844|NCT00882245|EXPERIMENTAL|SRD441 Ointment|
62138663|NCT04198922|EXPERIMENTAL|Treatment (acalabrutinib)|Patients receive acalabrutinib 100 mg PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62138664|NCT01687751|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
62338032|NCT05176431|SHAM_COMPARATOR|Sham extracorporeal shock wave therapy|
62338033|NCT00947752|ACTIVE_COMPARATOR|F1 Glatiramer acetate 20mg/1.0ml|
62338034|NCT00947752|EXPERIMENTAL|F2 Glatiramer acetate 20mg/0.5ml|
62338035|NCT00488579|ACTIVE_COMPARATOR|routine iron prophylaxis|giving 60 mg ferrous sulphate daily (+folic acid)
62338036|NCT00488579|ACTIVE_COMPARATOR|screening and therapy|doing Hb measurement on each visit, Hb\>9g/dl giving only folic acid, Hb\<9g/dl giving 60-120 mg of ferrous sulphate daily (+folic acid)
62338037|NCT05075148||Aneurysmal bone cyst|Patient aging from 0 to 30 years with diagnosis of aneurysmal bone cyst treated by percutaneous alcolisation or endovascular embolization.
62338038|NCT03329040||Primipara mothers|Infant to primipara mothers, i.e. the first infant to the mother - No intervention
62338039|NCT03329040||Multipara mothers|Infant to multipara mothers, i.e. not the first infant to the mother - No intervention
62338040|NCT05171582|ACTIVE_COMPARATOR|Surgery 1 (Test group)|In the test group (T), bone defects will be full-filled with bovine bone substitute with HA (Cerabone plus, Botiss, Germany)
62338041|NCT05171582|ACTIVE_COMPARATOR|Surgery 2 (Control group)|In the control group (C), bone defects will be full-filled with xenograft bovine bone substitute without HA (Cerabone, Botiss, Germany).
62338042|NCT03638661|EXPERIMENTAL|n-3 fatty acid enriched formula|"Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).~vegetable (canola, flaxseed) derived n-3 fatty acid"
62494845|NCT03155867|ACTIVE_COMPARATOR|Meal replacement A|
62494846|NCT03155867|ACTIVE_COMPARATOR|Meal replacement B|
62494847|NCT03155867|ACTIVE_COMPARATOR|Meal replacement C|
62494848|NCT03155867|ACTIVE_COMPARATOR|Meal replacement D|
62494849|NCT03155867|ACTIVE_COMPARATOR|Meal replacement E|
62494850|NCT03155867|ACTIVE_COMPARATOR|Meal replacement F|
62494851|NCT06207253|EXPERIMENTAL|High concentration of diclofenac sodium|High concentration of diclofenac sodium mixed with saline
62696270|NCT05548556|PLACEBO_COMPARATOR|Placebo|Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive subcutaneous (SC) placebo every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.
62696271|NCT05548556|EXPERIMENTAL|RO7204239|Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive SC RO7204239 every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.
62696272|NCT03318627|OTHER|Tension Measuring|Measuring intraoperative tension of rotator cuff tendon with sterile spring Balance.
62696273|NCT06629103|ACTIVE_COMPARATOR|life's Omega 1035DS|
62138665|NCT01687751|ACTIVE_COMPARATOR|Midazolam|Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
62696274|NCT06629103|ACTIVE_COMPARATOR|life'sTM Omega O3020DS|
62696275|NCT06629103|ACTIVE_COMPARATOR|MEG-3TM 1812 TG|
62338043|NCT03638661|PLACEBO_COMPARATOR|soybean oil used formula|"Patients assigned to the control group received a soybean used formula by tube feeding.~soybean used formula"
62696276|NCT06629103|PLACEBO_COMPARATOR|Placebo|
62696277|NCT06642740||Platelet count: <40×10^9/L|Subjects with platelet count \<40×10\^9/L will be given 60mg/ day of avatracopal
62696278|NCT06642740||Platelet count :40-50×10^9/L|Subjects with platelet counts of 40-50×10\^9/L will be given avatracopal 40mg/ day
62696279|NCT04907084|EXPERIMENTAL|Serine 200 mg/kg/day|Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
62696280|NCT04907084|EXPERIMENTAL|Serine 400 mg/kg/day|Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
62696281|NCT04907084|EXPERIMENTAL|Fenofibrate 160 mg/day|Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.
62696282|NCT04907084|EXPERIMENTAL|Serine 200 mg/kg/day and Fenofibrate 160 mg/day|"Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
62696283|NCT04907084|EXPERIMENTAL|Serine 400 mg/kg/day and Fenofibrate 160 mg/day|"Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
62696284|NCT04907084|NO_INTERVENTION|No treatment|Control group: no investigational product taken
62696285|NCT05704803|EXPERIMENTAL|Study Groups|"Positives: Symptomatic vs. Asymptomatic Negatives: Symptomatic vs. Asymptomatic~Each broken down by age groups:~2-14 years old 15-24 years old 25-64 years old 65+ years old"
62696286|NCT05338736||Control group|Control patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, and with a nasopharyngeal swab negative for SARS-CoV-2 isolation.
62696287|NCT05338736||Asymptomatic group|Patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, with a nasopharyngeal swab positive for SARS-CoV-2 isolation, in absence of any symptoms of COVID-19
62696288|NCT05338736||Symptomatic group|Patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, with a nasopharyngeal swab positive for SARS-CoV-2 isolation, with moderate to severe symptoms of COVID-19
62138666|NCT06673368|ACTIVE_COMPARATOR|Arm 1|NRCT-101SR and low dose NRCT-202XR
62338044|NCT04676464||ultra- sound|ultra- sound assessment of their quadriceps muscle layer thickness (QMLT)
62338045|NCT03859531||CF patients planned to receive Orkambi|CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy
62138667|NCT06673368|ACTIVE_COMPARATOR|Arm 2|NRCT-101SR placebo and high dose NRCT-202XR
62696289|NCT06279182|EXPERIMENTAL|Barre Stretching Intervention|15 minute Barre stretching video two times a week for 6 weeks.
62696290|NCT06279182|NO_INTERVENTION|Control Group: No Intervention|Participants do not participate in the Barre stretching intervention.
62696291|NCT06642714|OTHER|weaning group|Patients included in the study will not be randomized individually but will be managed either according to the standard of care of the service or according to the personalized strategy (according to the stepped wedge group of the center).
62696292|NCT02174237|EXPERIMENTAL|LNP1892|Dosage Form: Tablet Two Parts. Part A: Single Ascending Dose (SAD) starting with 25 mg (Maximum 5 cohorts). Part B: Multiple Ascending Dose (MAD), 10 days dosing, Maximum 3 cohorts. Six subjects in each cohort will receive LNP1892
62696293|NCT02174237|PLACEBO_COMPARATOR|Placebo|Two subjects in each cohort will receive matching placebo.
62696294|NCT05003856|EXPERIMENTAL|Treatment (RFA)|Patients undergo ultrasound guided RFA over 1-2 hours.
62138668|NCT06673368|ACTIVE_COMPARATOR|Arm 3|NRCT-101SR placebo and low dose NRCT-202XR
62138669|NCT05922904|EXPERIMENTAL|Part A: Pembrolizumab and Brentuximab +AD|
62138670|NCT05922904|EXPERIMENTAL|Part B: De-Escalation|
62138671|NCT05922904|EXPERIMENTAL|Part C: Standard Risk Arm|
62138672|NCT02406092|EXPERIMENTAL|Rituximab|Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP \[cyclophosphamide+doxorubicin+vincristine+prednisone\], CVP \[cyclophosphamide+vincristine+prednisone\] or FC \[fludarabine+cyclophosphamide\]) during induction.
62338046|NCT00412698|EXPERIMENTAL|1|
62338047|NCT00412698|PLACEBO_COMPARATOR|2|
62338048|NCT00718757|EXPERIMENTAL|1|
62338049|NCT00677690|ACTIVE_COMPARATOR|NM+PR|Patients undergone to combination of neuromuscular stimulation and pulmonary rehabilitation (NM+PR)
62338050|NCT00677690|PLACEBO_COMPARATOR|SS+PR|Patients undergone to pulmonary rehabilitation
62494852|NCT06207253|ACTIVE_COMPARATOR|Low concentration of diclofenac sodium|Low concentration of diclofenac sodium mixed with saline
62696295|NCT03603808|EXPERIMENTAL|Treatment (VGX-3100, electroporation)|Patients receive HPV DNA plasmids therapeutic vaccine VGX-3100 IM and then undergo electroporation over 10 seconds for 4 doses in week 0, 4, 12, and 24 in the absence of disease progression or unacceptable toxicity.
62696296|NCT06501196|EXPERIMENTAL|Dose Escalation Cohort|BH-30236 monotherapy for Dose Escalation
62696297|NCT06501196|EXPERIMENTAL|Dose Expansion Cohort|BH-30236 administered at a dose(s) determined form the data of dose escalation cohort
62696298|NCT00492050|EXPERIMENTAL|Bortezomib + Rituximab|Bortezomib 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m\^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).
62696299|NCT06592079|EXPERIMENTAL|Immediate implant & Connective tissue graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
61942580|NCT02973828||B) Patient Volunteer Imaging Studies|Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.
61942581|NCT02973828||C) Pathway development studies|Pathway development studies (n = 39 - 208 per centre) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.
62338051|NCT01072539||Patients who have approved indications of Tygacil|"Approved indications of Tygacil~-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia"
62338052|NCT04496895|PLACEBO_COMPARATOR|Placebo|consume 1 sachet per day for 2 months
62494853|NCT06207253|ACTIVE_COMPARATOR|Calcium hydroxide|Calcium hydroxide paste form
62494854|NCT00714987||1: High level PEEP|
61942582|NCT02973828||D) On going imaging development & quality improvement|This stage of the study will run in parallel or subsequent to stages B and C. The purpose will be to recruit patient or non-patient volunteers to help optimise MR guided radiotherapy delivery e.g. investigate radiotherapy immobilisation and equipment for patient positioning and set up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement.
61942583|NCT02387931|EXPERIMENTAL|Vitamin D|Vitamin D3 2000 IU daily taken for 6 months
62338053|NCT04496895|EXPERIMENTAL|orange peel fermentation|consume 1 sachet per day for 2 months
62338054|NCT00448253|EXPERIMENTAL|1|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.
62338055|NCT00448253|PLACEBO_COMPARATOR|2|Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)
62338056|NCT03404596|EXPERIMENTAL|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
62494855|NCT00714987||2: Low level PEEP|
62494856|NCT05190016||Cases (Current/fresh)|Cases (current/fresh) are defined as those samples which has been tested positive by RT-PCR at IEDCR as a regular screening program and have not been stored in the freezer.
62494857|NCT05190016||Cases(stored)|Cases (stored) are defined as those samples which has been tested positive by RT-PCR at IEDCR as a regular screening program and have been stored in the -80°C freezer at IEDCR.
62494858|NCT05190016||Control (Current/fresh)|Control (Current/fresh) are defined as those samples which has been tested negative by RT-PCR at IEDCR as a regular screening program and have not been stored in the freezer.
62494859|NCT05190016||Control (stored)|Control (stored) are defined as those samples which has been tested negative by RT-PCR at IEDCR as a regular screening program and have been stored in the -80°C freezer at IEDCR
61942584|NCT02387931|EXPERIMENTAL|Fish Oil|Fish Oil 1000 mg daily for 6 months
61942585|NCT02387931|PLACEBO_COMPARATOR|Placebo|Placebo taken daily for 6 months.
61942586|NCT04275570|ACTIVE_COMPARATOR|Motivational Interview.|Repeated motivational interview during prenatal care visits
61942587|NCT04275570|NO_INTERVENTION|Usual intervention|Usual intervention
61942588|NCT00967629|OTHER|Sevelamer Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
61942589|NCT00967629|OTHER|Calcium Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
61942590|NCT03702517|EXPERIMENTAL|lateral stair walking exercise|The experimental group received 15 minutes of lateral stair walking exercise
62494860|NCT05575557|ACTIVE_COMPARATOR|His bundle pacing group|HBP was performed on the patient, and the detection of the His bundle potential during the procedure is the sign of the success of the procedure. The HB capture threshold was accepted if lower than 3.0 V at 0.42ms.
62494861|NCT05575557|ACTIVE_COMPARATOR|Left branch bundle pacing group|HBP was performed on the patient, and the detection of the His bundle potential during the procedure is the sign of the success of the procedure. During the procedure, the duration from the pacing signal to the peak of R wave (on V4-V6 lead) is measured as pacing to left ventricular activation time (p-LVAT). An eligible site of left bundle capture was confirmed if selective LBBP was demonstrated by ECG, if p-LVAT shortened abruptly \>10 ms through increasing pacing output, or if p-LVAT stayed shortest and stable at the site.
62494862|NCT05575557|ACTIVE_COMPARATOR|Right ventricular pacing group|If we could not achieve an acceptable HB or LBB capture after five attempts of lead positioning or a fluoroscopy exposure time over 30min, the lead was then placed in the RV with traditional approach.
62696300|NCT06592079|ACTIVE_COMPARATOR|Immediate implant with connective tissue graft & bone graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Xenograft will be used to fill the jumping gap.Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
62696301|NCT01516372|EXPERIMENTAL|Treatment 1|Healthy Volunteers will receive Treatments ABDC
62696302|NCT01516372|EXPERIMENTAL|Treatment 2|Healthy Volunteers will receive Treatments BCAD
62138673|NCT05697705||Population A|For evaluating second booster doses
62138674|NCT05697705||Population B|For evaluating first booster doses
62138675|NCT06532097||Intervention group|Group of patients that received the digital intervention
62338057|NCT02625324|EXPERIMENTAL|Endovascular repair|Valiant Evo Thoracic Stent Graft System
62338058|NCT01790971|ACTIVE_COMPARATOR|Intrathecal morphine|100μg of morphine will be added to the intrathecal mixture.
62494863|NCT03750591||Integrative Korean medicine treatment group|"Observation of pain, function, quality of life, satisfaction, and adverse events in inpatients with lumbar intervertebral disc herniation hospitalized at 4 Korean medicine hospitals~Interventions:~Drug: Herbal medicine Procedure/Surgery: Chuna manual therapy Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s)"
62494864|NCT04541173|ACTIVE_COMPARATOR|Arm A|TARE alone
62338059|NCT01790971|ACTIVE_COMPARATOR|No Intrathecal morphine|Morphine will not be added to the intrathecal mixture.
62338060|NCT04839770|EXPERIMENTAL|Axonpen|Subjects will receive minimally invasive endoscopic surgery using the Axonpen™ system for early hematoma evacuation (within 48 hours post-ictus).
62338061|NCT06286436|EXPERIMENTAL|Dual-task training|
62494865|NCT04541173|EXPERIMENTAL|Arm B|TARE then Bevacizumab and Atezolizumab
62494866|NCT01223755|EXPERIMENTAL|Sirolimus|
62494867|NCT01223755|ACTIVE_COMPARATOR|conventional therapy|
62696303|NCT01516372|EXPERIMENTAL|Treatment 3|Healthy Volunteers will receive Treatments CDBA
62696304|NCT01516372|EXPERIMENTAL|Treatment 4|Healthy Volunteers will receive Treatments DACB
62338062|NCT02003560|EXPERIMENTAL|Accelerated partial breast irradiation|Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy
62338063|NCT02199106|EXPERIMENTAL|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Intervention: Left temporal verum cTBS"
62494868|NCT01932905|ACTIVE_COMPARATOR|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
62696305|NCT04618276|EXPERIMENTAL|Arm A (5-ALA group)|"1. Skin swab for culture in the groin for baseline~2. PDT with 5% topical 5-ALA as the prodrug for the photosensitizer Pp IX~3. Skin swab for culture~4. Skin antisepsis~5. Skin swab for culture"
62696306|NCT04618276|EXPERIMENTAL|Arm B (Methylene Blue group)|"1. Skin swab for culture in the groin for baseline~2. PDT with 0.01% methylene blue based photosensitizer (NF-031)~3. Skin swab for culture~4. Skin antisepsis~5. Skin swab for culture"
62696307|NCT04618276|NO_INTERVENTION|Control group|"1. Skin swab for culture in the groin for baseline~2. NO PDT~3. Skin antisepsis~4. Skin swab for culture"
62696308|NCT00798408|EXPERIMENTAL|1|Participants will maintain current physical activity and take a fluid supplement.
62494869|NCT01932905|SHAM_COMPARATOR|deep rTMS-sham|patients undergoing to placebo deep rTMS
62494870|NCT01932905|ACTIVE_COMPARATOR|deep rTMS-active: H-coil|patients undergoing of deep rTMS real with H-coil
62494871|NCT02279277|NO_INTERVENTION|No physical therapy|No prescribed, supervised physical therapy prior to total knee replacement
62494872|NCT02279277|ACTIVE_COMPARATOR|Physical Therapy|Prescribed, supervised physical therapy prior to total knee replacement
62696309|NCT00798408|EXPERIMENTAL|2|Participants will maintain current physical activity and take a solid supplement.
61942591|NCT03702517|ACTIVE_COMPARATOR|traditional physiotherapy|strengthening exercise, balance training and gait training
62696310|NCT06643442|EXPERIMENTAL|Empagliflozin|All participants will receive the IMP (open-label trial, primary outcome PK)
61942592|NCT03292575||Stroke related to CAAF|
61942593|NCT05578079|NO_INTERVENTION|Control group|No music will be played to the control group.
61942594|NCT05578079|ACTIVE_COMPARATOR|Intervention 1|"The Intervention-1 group will listen to the music which determined by the researchers by examining the literature (DOI: 10.4274/jpr.24892). The music which determined by the researchers is The art of fugue by Johann Sebastian Bach."
61942595|NCT05578079|ACTIVE_COMPARATOR|Intervention 2|The Intervention-2 group will listen to lullaby.
61942596|NCT02960152||Anorexia Nervosa|interview and periodontal full-mouth examination
61942597|NCT02960152||Bulimia Nervosa|interview and periodontal full-mouth examination
61942598|NCT02960152||Control|interview and periodontal full-mouth examination
62138676|NCT06532097||Retrospective control group|Retrospectively collected group of patients from earlier versions (amendments) of the study who filled out the PHQ-9 twice with a certain interval (and were offered the intervention at a later time-point)
62138677|NCT01231971||Cognitively Normal (CN)|150 newly enrolled participants with no apparent memory problems, and CN participants followed from the ADNI1 study
62338064|NCT02199106|EXPERIMENTAL|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Intervention: Left temporal placebo cTBS"
62338065|NCT02179528|ACTIVE_COMPARATOR|etoposide,maintenance therapy|etoposide,25mg qd d1-20，repeat every 28 days
62338066|NCT02179528|NO_INTERVENTION|blank control|blank control
62338067|NCT02569619|EXPERIMENTAL|Activity Intervention|The activity intervention is MoVo-LISA (Göhner \& Fuchs, 2007). A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through physical activity and make detailed plans, how to implement activity in their everyday routine. Difficulties and barriers are discussed.
62338068|NCT02569619|ACTIVE_COMPARATOR|Healthy Diet Intervention|The healthy diet intervention is a modification of MoVo-LISA. A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through a healthy diet and make detailed plans, how to implement a healthy diet in their everyday routine. Difficulties and barriers are discussed.
62338069|NCT05081024||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood samples at baseline (before any neoadjuvant therapy), every 2 months while undergoing TNT, and then every 3 months for up to 3 years after completion of TNT. Patients' medical records are also reviewed. Patients may undergo collection of tissue sample if an archival tissue sample is not available.
62338070|NCT04471064|EXPERIMENTAL|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg; multiple dose phase
62338071|NCT04471064|EXPERIMENTAL|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg; multiple dose phase
61942599|NCT01166399||Primiparous women with an obstetric anal sphincter tear|Subjects in this trial will be primiparous women who underwent anal sphincter repair at the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized at the time of delivery as \<50% tear through the anal sphincter (modified WHO 3a), \>50% (modified WHO 3b), or complete tear through the anal sphincter (4th degree). Subjects in this study will not have receive study interventions.
61942600|NCT05788120||Patients with refractory cardiogenic shock assisted with ECMO VA|
61942601|NCT01146912|EXPERIMENTAL|Text message vaccine reminders|Receipt of text message vaccine reminders
61942602|NCT01146912|ACTIVE_COMPARATOR|automated phone call from clinic|Receipt of automated phone call from clinic
61942603|NCT04168697|EXPERIMENTAL|Controls|Control subjects undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
61942604|NCT04168697|EXPERIMENTAL|BAD|Patients with bipolar affective disorder (BAD) undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
61942605|NCT05376449|EXPERIMENTAL|Immediate start|Intervention to start immediately after first visits.
61942606|NCT05376449|ACTIVE_COMPARATOR|Delayed start|Intervention to start after 12 weeks delay.
61942607|NCT05271461|ACTIVE_COMPARATOR|Circulatory exercises group .|Circulatory exercises.
61942608|NCT05271461|EXPERIMENTAL|LLLT group .|Low level laser Therapy + circulatory exercises.
62138678|NCT01231971||Early Mild Cognitive Impairment (EMCI)|100 newly enrolled early amnestic MCI participants, and approximately 200 EMCI participants will be followed from the ADNI-GO study
62138679|NCT01231971||Late Mild Cognitive Impairment (LMCI)|150 newly enrolled late MCI participants, and LMCI participants followed from the ADNI1 study
62338072|NCT04471064|EXPERIMENTAL|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg; multiple dose phase
62338073|NCT04471064|EXPERIMENTAL|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg; multiple dose phase
62338074|NCT04471064|EXPERIMENTAL|XY0206-150mg|Drug:XY0206;Dosage form:Tablet;Dosage：150mg; multiple dose phase
62338075|NCT04471064|EXPERIMENTAL|XY0206-200mg|Drug:XY0206;Dosage form:Tablet;Dosage：200mg; multiple dose phase
62338076|NCT04471064|EXPERIMENTAL|XY0206-250mg|Drug:XY0206;Dosage form:Tablet;Dosage：250mg; multiple dose phase
62338077|NCT05385042|OTHER|Non-anaemic pregnant women|50 pregnant women who have normal haematocrit (not anaemic) at 12 weeks.
62338078|NCT05385042|OTHER|Anaemic pregnant women|100 pregnant women who have haematocrit below 33% (equates to Hb 11g/dL) in first trimester (\<14 weeks gestation) and below 30% (equates to Hb 10g/dL).
62738509|NCT02115724|EXPERIMENTAL|Antioxidant Cocktail|Following an overnight fast, blood samples, flow-mediated dilation, and nitroglycerin mediated dilation (NMD; 0.4mg sub-lingual nitroglycerin spray) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
61942609|NCT01245920|EXPERIMENTAL|FDBA + Membrane Group|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
62494873|NCT00968916|EXPERIMENTAL|1|"Level 1:~15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 2:~25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 3:~35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 4:~50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal"
62494874|NCT01087567|EXPERIMENTAL|Intensive insulin regimen|A weight based, basal bolus will be given for 12 weeks.
61942610|NCT01245920|ACTIVE_COMPARATOR|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
61942611|NCT00122109|EXPERIMENTAL|Videoteleconferencing AMT|"The experimental arm is the group condition that received the AMT treatment intervention via a videoteleconferencing modality as compared to the control condition which is the traditional face-to-face modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
61942612|NCT00122109|ACTIVE_COMPARATOR|Face to Face AMT|"The control arm is the group condition that received the AMT treatment intervention via a traditional face-to-face modality as compared to the experimental condition which is the videoteleconferencing modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
61942613|NCT02007616|EXPERIMENTAL|Non-action video game training|20 1-hour sessions of non-action video game training
61942614|NCT02007616|NO_INTERVENTION|Control|Participants in the control group did not receive non-action video game training
61942615|NCT01089673||no treatment|retrospective data analysis
61942616|NCT05501223|OTHER|Intervention|Standard care + medication review
61942617|NCT05501223|OTHER|Control|Standard care
61942618|NCT06378138|EXPERIMENTAL|ICP-248 in combination with Orelabrutinib|
61942619|NCT04862377|ACTIVE_COMPARATOR|Standard treatment group|"Infants randomised to the standard treatment arm will receive intratracheal surfactant as per usual clinical indications of respiratory distress syndrome in these preterm infants.~In that sense, and based in those clinical indications, we have developed a risk calculator for surfactant administration in preterm infants ≤32 weeks GA. We will use it to decide what patients will receive surfactant (calculator available on: https://1drv.ms/x/s!Arjkl83HIXSngP8TWh8O6oi6Ztdw3w?e=gNCMxP)."
61942620|NCT04862377|EXPERIMENTAL|Interventional treatment group|"Infants randomised to the interventional treatment arm will receive intratracheal surfactant mixed with budesonide. Indication of surfactant, as equal as for the standard treatment arm, will be decided using the calculator."
61942621|NCT04862377|NO_INTERVENTION|Control group|Infants ≤32 weeks with no indications for surfactant administration. Their clinical management will be the usual in our neonatal unit.
61942622|NCT02436681|OTHER|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
61942623|NCT05857943|EXPERIMENTAL|AEYE-DS Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy
61942624|NCT04110678|ACTIVE_COMPARATOR|NeuroEPO|The dose of NeuroEPO was a vial with a dose of 1 mL/1mg administered intra-nasally for five consecutive weeks.
61942625|NCT04110678|PLACEBO_COMPARATOR|Placebo|The dose of placebo was a vial with a dose of 1 mL/1mg of an intranasal inert solution administered intra-nasally for five consecutive weeks.
62138680|NCT01231971||Alzheimer's Disease (AD)|150 newly enrolled mild AD participants
62494875|NCT01087567|ACTIVE_COMPARATOR|Routine Care|Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
62494876|NCT02740257||Group 1 Artificial Lesions|Photos will be taken of skin lesion markings using a smartphone
62494877|NCT02740257||Group 2 high risk|A convenience sample of patients will be recruited. This population will consist of patients with known high risk to have new/changing lesions, and who fall within the Fitzpatrick skin types I-IV. High risk patients include, but are not limited to, those with dysplastic nevus syndrome, previous history of melanoma/non-melanoma skin cancer, fair skin, \>16 nevi, family history of melanoma, and/or immunosuppressed status. The first photography session will be taken by the research team in all 13 projections. After the first visit, the patient will be instructed to take photographs every month for 12 months using the TBDP app on their smart phone or tablet, and have follow-up research appointments every 6 months.
62738510|NCT02115724|OTHER|Biopsy|Following an overnight fast, a subcutaneous gluteal/hip fat biopsy sample will be obtained from each subject under local anesthesia, with adipose tissue (\~2x1.5x1.5cm) to be harvested and placed immediately in physiological saline solution (PSS): Small arteries, 100 to 150 um in diameter, will be dissected from the fat under a dissecting microscope, transferred to an arteriographic bath chamber, and cannulated for pressurized myography.
62738511|NCT00705497|EXPERIMENTAL|1|
62738512|NCT00883168|PLACEBO_COMPARATOR|placebo|
62738513|NCT00883168|ACTIVE_COMPARATOR|azelastine Hcl|
62494878|NCT02645487|EXPERIMENTAL|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
62494879|NCT01686217|EXPERIMENTAL|Dose Group 1 Treatment A|Lowest per tablet dose of ASP015K Extended Release (ER) tablets under fasted conditions
62494880|NCT01686217|ACTIVE_COMPARATOR|Dose Group 1 Treatment B|Medium per tablet dose ASP015K Immediate Release (IR) tablets under fasted conditions for comparison to lowest dose ER fasted conditions
62494881|NCT01686217|EXPERIMENTAL|Dose Group 1 Treatment C|Lowest per tablet dose of ASP015K ER tablets under fed conditions
61942626|NCT01570556|ACTIVE_COMPARATOR|Patients with positive culture, treatment group|These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
61942627|NCT01570556|NO_INTERVENTION|Patients with positive culture, observation only|These asymptomatic patients with positive urine culture, will be observed only during the study period.
61942628|NCT05158634||Cerebral Palsy|"Inclusion Criterias: Being diagnosed with Cerebral Palsy. Volunteer. Be between the ages of 6-18. Being at level 1 and level 2 according to Gross Motor Function Classification System (GMFCS) (Level 1 and 2).~To have the cognitive skills to understand and apply the evaluation parameters.~Exclusion Criterias: Cognitive impairment of participants diagnosed with Cerebral Palsy. Participants diagnosed with Cerebral Palsy have vision or hearing problems. Participants diagnosed with Cerebral Palsy must have a history of trauma such as botox or muscle relaxation operation and/or fracture at least 6 months before participating in the study."
61942629|NCT01293773|ACTIVE_COMPARATOR|Taxus Element|Patients treated with paclitaxel-eluting stent (Taxus Element, Boston Scientific, MN)
61942630|NCT01293773|ACTIVE_COMPARATOR|Xience Prime|Patients treated with Everolimus-eluting stent (Xience Prime, Abbott, IL)
62138681|NCT01231971||Significant Memory Concern (SMC)|100 newly enrolled participants with Significant Memory Concern (SMC)
62138682|NCT03331575|EXPERIMENTAL|Arm1(Hypofractionated Radiotherapy)|Hypofractionated Radiotherap（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
62338079|NCT05625529||Cohort 1|"Individuals without history of PDAC meeting any of the following criteria:~A. 2+ relatives with PDAC on same side of family; 2 are first degree related to each other and at least 1 is first degree related to subject; age ≥ 50 years or ≤10 years younger than earliest PDAC in family at diagnosis.~B. 2+ first degree relatives with PDAC; age ≥ 50 years or ≤ 10 years younger than earliest PDAC in family at diagnosis.~C. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age ≥ 50 years or ≤ 10 years younger than earliest PDAC in family at diagnosis.~D. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age ≥ 40 years.~E. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age ≥35 years.~F. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age ≥ 40 years."
62338080|NCT05625529||Cohort 2|"Individuals without history of PDAC meeting any of the following criteria:~A. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history; age ≥50 years.~B. Two or more (2+) relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age ≥50 years or ≤10 years younger than earliest PDAC in family at time of diagnosis.~C. One (1) first degree relative with PDAC at age ≤45 years; ≤10 years younger than PDAC diagnosis in family member at time of diagnosis."
62338081|NCT05625529||Cohort 3|A. Individuals meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2); age ≥ 18 years.
62494882|NCT01686217|EXPERIMENTAL|Dose Group 2 Treatment D|Medium per tablet dose of ASP015K ER tablets under fasted conditions
62494883|NCT01686217|ACTIVE_COMPARATOR|Dose Group 2 Treatment E|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to medium dose ER fasted conditions
62494884|NCT01686217|EXPERIMENTAL|Dose Group 2 Treatment F|Medium per tablet dose of ASP015K ER tablets under fed conditions
62494885|NCT01686217|EXPERIMENTAL|Dose Group 3 Treatment G|Highest per tablet dose of ASP015K ER tablets under fasted conditions
61942631|NCT01293773|ACTIVE_COMPARATOR|Integrity Resolute|Patients treated with ABT 578-eluting stent (Integrity Resolute, Medtronic, MA)
61942632|NCT04996771|EXPERIMENTAL|Surufatinib Combined With Toripalimab and Chemotherapy|
61942633|NCT04996771|EXPERIMENTAL|Surufatinib Combined With Chemotherapy|
61942634|NCT03570697|EXPERIMENTAL|Evolocumab|Participants receive evolocumab subcutaneous injection once every month (QM) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
62138683|NCT03331575|PLACEBO_COMPARATOR|Arms2（Conventional Radiotherapy）|Conventional Radiotherapy（PTV-G60Gy/30Fx,2Gy/Fx; PTV-C 50.4Gy/30Fx, 1.8Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
62494886|NCT01686217|ACTIVE_COMPARATOR|Dose Group 3 Treatment H|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to highest dose ER under fasted conditions
62494887|NCT01686217|EXPERIMENTAL|Dose Group 3 Treatment I|Highest dose of ASP015K ER tablets under fed conditions
62494888|NCT05659316||Healthy volunteers|Healthy volunteers without any patellar injury
62738514|NCT00883168|ACTIVE_COMPARATOR|fluticasone propionate|
62138684|NCT05911867|EXPERIMENTAL|combination of mobilization with movement and muscle energy techniques|"Mulligan technique (MWM) involves the therapist using a belt around the humeral head to guide appropriate gliding while the patient moves their shoulder actively through the range. The therapist applies pressure to the scapula in a counter direction.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique.~The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds."
62738515|NCT00883168|EXPERIMENTAL|azelastine Hcl /fluticasone propionate|
61942635|NCT03570697|PLACEBO_COMPARATOR|Placebo|Participants receive placebo subcutaneous injection QM for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
62696311|NCT04831229|ACTIVE_COMPARATOR|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
62138685|NCT05911867|ACTIVE_COMPARATOR|mobilization with movement|"Regarding the shoulder joint, the Mulligan technique (MWM) involves the therapist using a belt around the humeral head to guide appropriate gliding while the patient moves their shoulder actively through the range. The therapist applies pressure to the scapula in a counter direction. This technique is usually performed for five sets of five repetitions with one minute of rest between sets in a sitting position.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position."
62338082|NCT05625529||Cohort 4|A. Individuals without history of PDAC presenting for evaluation who do not meet any criteria for the other cohorts after collection of full family history and/or germline testing, eg. they have only 1 relative with PDAC; age ≥ 18 years.
62494889|NCT03277248|EXPERIMENTAL|Ublituximab + Oral Placebo|Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
62494890|NCT03277248|ACTIVE_COMPARATOR|Teriflunomide + IV Placebo|Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
62738516|NCT04432649|EXPERIMENTAL|Effectiveness of 4SCAR-276 T cells|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
62138686|NCT05911867|ACTIVE_COMPARATOR|muscle energy techniques|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applies manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
62138687|NCT06406426|EXPERIMENTAL|Patients who have failed previous standard chemotherapy in the first line|
62338083|NCT05625529||Cohort 5 - Personal history of PDAC|"Individuals with a personal history of PDAC meeting any of the following criteria (age ≥ 18 years for all subgroups):~A. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other.~B. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, STK11.~C. Diagnosed with PDAC at ≤ age 45."
62138688|NCT06406426|EXPERIMENTAL|Patients who had failed PD-1/L1 antibody combined chemotherapy in the first line|
62138689|NCT00797212|OTHER|Subjects with diabetes|Subjects with diabetes use a new Apollo Blood Glucose Monitoring System with blood obtained from the palm and forearm
62138690|NCT05941715|ACTIVE_COMPARATOR|group A: aflibercept first (part 1), switch to faricimab (part 2)|"Aflibercept 2.0mg/0.05ml intravitreal will be administered from baseline through to the first visit at or after 32 weeks in a treat-and-extend regime.~At the first visit at or after 32 weeks, faricimab 6.0mg/0.05ml intravitreal will be administered in a treat-and-extend regime through to the last visit before 56 weeks."
62138691|NCT05941715|EXPERIMENTAL|group B: faricimab monotherapy|Faricimab 6.0mg/0.05ml intravitreal will be administered from baseline through to the last visit before 56 weeks in a treat-and-extend regime.
62138692|NCT02513667|EXPERIMENTAL|ALK-inhibitor naive patients|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
62338084|NCT05625529||Cohort 6 - Pancreatic cysts|"Individuals with pancreatic cysts (age ≥ 18 years for all subgroups):~A. Individuals with a pancreatic cystic neoplasm (IPMN) and/or mucinous cystic neoplasm (MCN) and/or PanIN not meeting any criteria for Cohorts 1-3 or 6 (no personal history of PDAC, no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk present in cohorts 1C, 2A, 1D, 1E, and 1F).~B. Individuals with a pancreatic cystic neoplasm (IPMN) and/or MCN and/or PanIN without PDAC and with at least one of the pathogenic or likely pathogenic gene mutations present in cohorts 1C, 2A, 1D, 1E, and 1F and/or a first degree relative with PDAC."
62338085|NCT05625529||Cohort 7 - Acute or chronic pancreatitis|"Individuals with a personal history of pancreatitis meeting any of the following criteria (age ≥ 18 years for all subgroups):~A. Chronic pancreatitis. B. At least 2 episodes of acute pancreatitis."
62494891|NCT03138044|EXPERIMENTAL|Combined Treatment|The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.
62494892|NCT05999916|EXPERIMENTAL|60 min session of 40Hz tACS by Miamind Neurostimulator|The clinical study will enroll eight (8) participants who will undergo four (4) tACS sessions (one per day) within 4 consecutive days. The tACS intervention will last 60 min in total. The stimulation frequency will be 40 Hz with max 1 mA/electrode and total of max 2 mA across all active electrodes (peak-to-baseline).
62494893|NCT03709953|EXPERIMENTAL|apatinib|apatinib, 500 mg, po, QD; 28 days every cycle
62494894|NCT00156650|ACTIVE_COMPARATOR|1|Testosterone (T) gel for 6 months + DMPA (Depo-Medroxyprogesterone) (injected into muscle Day 0 \& at Month 3)
61942636|NCT02589405|EXPERIMENTAL|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
61942637|NCT01076920|EXPERIMENTAL|Intervention arm|
61942638|NCT05688449|ACTIVE_COMPARATOR|Epidural analgesia|Eeg monitoring will be implemented with Sedline monitor(Masimo Irvine CA) 5 minutes before epidural catheter insertion, 30 minutes after epidural catheter insertion, during surgery and 5 minutes after extubation.
61942639|NCT05688449|PLACEBO_COMPARATOR|placebo|Eeg monitoring will be implemented with Sedline monitor (Masimo Irvine CA) 5 minutes before epidural catheter insertion, 30 minutes after epidural catheter insertion, during surgery and 5 minutes after extubation.
61942640|NCT03285984|EXPERIMENTAL|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
61942641|NCT03285984|EXPERIMENTAL|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
61942642|NCT03285984|EXPERIMENTAL|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
61942643|NCT03285984|EXPERIMENTAL|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
61942644|NCT04685083||Patients with Depression in consolidation phase|
61942645|NCT04685083||Patients with Depression in acute onset|
61942646|NCT04685083||Healthy subjects|
61942647|NCT02269397||Individuals with suspected epilepsy|The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.
61942648|NCT01377571|EXPERIMENTAL|Rotavin2H|2 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 2-month separation between doses
61942649|NCT01377571|EXPERIMENTAL|Rotavin2L|2 doses of Rotavin-M1 vaccine, 106.0FFU/dose, 2-month interval between doses
61942650|NCT01377571|EXPERIMENTAL|Rotavin3H|3 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 1-month interval between doses
61942651|NCT01377571|EXPERIMENTAL|Rotavin3L|3 doses of Rotavin-M1, 106.0FFU/dose, 1-month interval between doses
61942652|NCT06680544|ACTIVE_COMPARATOR|oral voriconazole 200 mg once daily group (group A)|Patients with resistant dermatophyte infection (tinea corporis and cruris)will be given oral voriconazole 200 mg once daily
61942653|NCT06680544|ACTIVE_COMPARATOR|oral voriconazole 200 mg twice daily group (group B)|Patients with resistant dermatophyte infection (tinea corporis and cruris)will be given oral voriconazole 200 mg twice daily
61942654|NCT04940767|EXPERIMENTAL|Treatment Group A|Patients will concomitantly receive once daily treatment of oral isotretinoin and topical AMZEEQ® for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
61942655|NCT04940767|EXPERIMENTAL|Treatment Group B|Patients will receive once daily treatment of oral isotretinoin for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
61942656|NCT05838859||Female service users of childbearing age|Contraception Advice Experiences Survey - using a self-report questionnaire of female service users.
61942657|NCT05838859||Mental health care professionals|Contraception in Mental Health Survey - self-report questionnaire of professionals' current practices, attitude and knowledge
61942658|NCT05792787||Apical Periodontitis|"Patients with radiographic signs of Apical Periodontitis. The inclusion criteria of the study are healthy patients older than 40 years old, the presence of at least 24 teeth and the ability and willingness to give informed consent. Participants affected by any systemic disease or being administered either antibiotics in the last 6 months or antiaggregant, antiplatelet and antihypertensive medications are excluded from this study.~The atherosclerosis risk factors excluded in our study are signs of CVD, smoking habits, diabetes , obesity, arterial hypertension, dyslipidemia. Patients with periodontal disease and lesions other than endodontic etiology in maxilla/mandible will be also excluded from this study ). Participants that were pregnant or lactating females, non-Italian or only English speaking will also also excluded from the study, as well as those who were unable or unwilling to give informed consent."
61942659|NCT05792787||Control|"healthy individual free from clinical and radiographic evidence of AP. The inclusion criteria of the study are healthy patients older than 40 years old, the presence of at least 24 teeth and the ability and willingness to give informed consent. Participants affected by any systemic disease or being administered either antibiotics in the last 6 months or antiaggregant, antiplatelet and antihypertensive medications are excluded from this study.~The atherosclerosis risk factors excluded in our study are signs of CVD, smoking habits, diabetes , obesity, arterial hypertension, dyslipidemia. Patients with periodontal disease and lesions other than endodontic etiology in maxilla/mandible will be also excluded from this study ). Participants that were pregnant or lactating females, non-Italian or only English speaking will also also excluded from the study, as well as those who were unable or unwilling to give informed consent."
61942660|NCT02486302||Observation Group|
61942661|NCT05745012|SHAM_COMPARATOR|group A: control group|
61942662|NCT05745012|EXPERIMENTAL|group B: ARMS procedure|
61942663|NCT03613480|EXPERIMENTAL|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
61942664|NCT03613480|NO_INTERVENTION|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
61942665|NCT02653183|ACTIVE_COMPARATOR|Device Aquacel Surgical|"Aquacel Surgical is a sterile, one piece post-operative dressing from Convatec.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
61942666|NCT02653183|EXPERIMENTAL|Device Mepilex Border Post-Op|"Post-operative all-in-one self-adherent soft silicone coated foam dressing.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
61942667|NCT00082342|ACTIVE_COMPARATOR|real transcranial direct current stimulation (tDCS)|
61942668|NCT00082342|SHAM_COMPARATOR|sham transcranial direct current stimulation (tDCS)|
61942669|NCT00728650||Observation|Patients with primary or metastatic hepatic malignancies
61942670|NCT05346497||Bentall|Patients who underwent Bentall procedure for ATAAD
61942671|NCT05346497||David|Patients who underwent David procedure for ATAAD
62494895|NCT00156650|ACTIVE_COMPARATOR|2|T gel for 6 months + DMPA (Day 0 \& Month 3) + Acyline 300 mcg/kg twice monthly for 12 weeks
62494896|NCT01609270||CardioRoot|All subjects receive the CardioRoot graft at baseline implant procedure.
62494897|NCT02573662||Case subjects|Physical active non-diabetic individuals of age 18 to 50 years, who are undergoing knee surgical procedures at the Arthroscopic Center at Amager/Hvidovre Hospitals are recruited as cases for this case-control study. OGTT, blood- and urine sampling and DXA scans will be performed 3 times throughout the study period.
62494898|NCT02573662||Control group|Non-diabetic individuals matched for age, gender and physical activity are recruited as control subjects to establish a reference level likely to image the cases before they experienced their knee injury. Blood- and urine sampling, OGTT and DXA scans will be carried out 1-3 times for each control subject. No lifestyle intervention is implemented.
62696312|NCT04831229|ACTIVE_COMPARATOR|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
62338086|NCT05625529||Cohort 8 - PDAC stages I-II or clinical suspicion|"Individuals with one of the following conditions and treatment naïve (age ≥ 18 years for all subgroups):~A. Biopsy-proven, clinical stage I-II PDAC and candidate for surgical resection.~B. Clinical findings suspicious for early stage PDAC prior to biopsy."
62338087|NCT05917366|EXPERIMENTAL|Coccyx Manipulation|Manual therapy sessions, in addition to the exercise group, were performed once a week for four weeks.
62338088|NCT05917366|ACTIVE_COMPARATOR|Exercises|A total of 4 sessions were applied, 3 times a week.
62338089|NCT00736580|ACTIVE_COMPARATOR|Blunt Needles|Cesarean Delivery Performed with Blunt-tipped surgical Needles
62338090|NCT00736580|PLACEBO_COMPARATOR|Sharp Needles|Cesarean delivery performed with sharp surgical needles.
62338091|NCT03470649|EXPERIMENTAL|Treatment|Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
62338092|NCT03470649|NO_INTERVENTION|Control|Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.
62494899|NCT05659680|EXPERIMENTAL|Leadless Conduction System Pacing|Participants receive leadless conduction system pacing using the WiSE-CRT device.
62494900|NCT04224662||Patients with Gout|Patients who have been diagnosed with Gout
62494901|NCT04440696|EXPERIMENTAL|group 1:dose 1.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
61942672|NCT05346497||ARR|Patients who underwent aortic root reconstruction procedure except Bentall and David procedure for ATAAD
62494902|NCT04440696|EXPERIMENTAL|group 2:dose 3g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
62494903|NCT04440696|EXPERIMENTAL|group 3:dose 4.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
62494904|NCT04440696|EXPERIMENTAL|group 4:dose 6g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
62494905|NCT02375945|ACTIVE_COMPARATOR|current compression stocking Comprinet®|"Immediately post operatively 24 hours compression therapy starts with Elastomull Haft ®, an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts."
62494906|NCT02375945|EXPERIMENTAL|New non-elastic compression kit|"Juxta Reduction Kit ® Immediately post operative compression starts with the Juxta Reduction Kit® for the knee region, combined with an anti thrombosis stocking (Struva 2, for prevention of trombo-embolism). Both the stocking and the Juxtra Pro are used for six weeks. After 4 hours the patient ambulated and the physical therapy starts.~For the first 24 hours and longer if necessary (depending on the skills of the patient) Juxta experienced staff will apply the device and the fit and the use of the device will be checked.~In the second phase between approximately 24 hours and 6 weeks patients may adjust the Juxta-pro according to their needs and comfort by themselves."
62494907|NCT03313713|ACTIVE_COMPARATOR|Beta-glucans|Beta-glucans, 3 g per day, per 8 weeks, at breakfast
61942673|NCT00478946|EXPERIMENTAL|1|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
61942674|NCT00478946|ACTIVE_COMPARATOR|2|FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
61942675|NCT02976792||Renal Resistive Index/NephroCheck™test|Patients undergoing a transcatheter aortic valve implantation
61942676|NCT00437892|EXPERIMENTAL|Atorvastatin and lipid lowering diet|
62494908|NCT03313713|PLACEBO_COMPARATOR|Placebo|Placebo, 3 g per day, per 8 weeks, at breakfast
61942677|NCT00437892|ACTIVE_COMPARATOR|lipid lowering diet|
61942678|NCT03464877|EXPERIMENTAL|Intervention group|Standardized six-week duration multi-station full-body supervised exercise program. The frequency was 2-3 sessions per week. The duration of each session was 60 minutes.
62338093|NCT02204241|EXPERIMENTAL|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
61942679|NCT03212690|EXPERIMENTAL|Mechanically ventilated subjects|Subjects receiving invasive mechanical ventilation (Duration of ventilation \<=48 hours) will be evaluated using standard care investigations.
61942680|NCT05806086|EXPERIMENTAL|Panfoshu + conventional treatment group（program-A）|Panfoshu is commonly known as the product of bacterial dissolution. it was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
61942681|NCT05806086|EXPERIMENTAL|Panfoshu + conventional treatment group（program-B）|Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
61942682|NCT05806086|OTHER|conventional treatment group|Conventional medications are used to treat the relavant ear and nose symptoms.
61942683|NCT04429048|EXPERIMENTAL|acupressure group|The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day.
61942684|NCT04429048|SHAM_COMPARATOR|control group|The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints.
61942685|NCT04108871|EXPERIMENTAL|Transperineal Prostate Biopsy|The biopsy needed is inserted to the prostate through the perineal skin, with the assistance of an access system device known as PrecisionPoint. It utilises a single access needle cannula mounted directly on to the ultrasound probe, which acts as an access point traversing through the perineal skin. 4 - 5 cores are obtained from the anterior, mid and posterior zone of each side of the prostate.
62338094|NCT06342102||PENG + LFCN Block|group in which PENG + LFCN Block was performed
62338095|NCT06342102||FIC Block|group in which FIC Block was performed
62338096|NCT00132821|ACTIVE_COMPARATOR|A|Bupropion
62338097|NCT00132821|ACTIVE_COMPARATOR|B|Transdermal nicotine patch
62338098|NCT00132821|PLACEBO_COMPARATOR|C|
62338099|NCT00132821|PLACEBO_COMPARATOR|D|
62338100|NCT01759329|EXPERIMENTAL|test coffee|test coffee
62696313|NCT06469021|ACTIVE_COMPARATOR|Control Group:|The control group will perform the structured three-dimensional scoliosis exercise, core stabilization, and balance exercise with conventional methods at the clinic and home setting for twenty-four weeks. In the clinical setting, patients will perform their exercise for 2 days a week for 12 weeks, 1 day a week for the next 12 weeks, under the supervision of a physiotherapist. Patients will be asked to perform their exercises as a home exercise program on the remaining days (home exercise program 3 days a week for the first 12 weeks, 4 days a week after week 12).
62338101|NCT01759329|ACTIVE_COMPARATOR|control coffee|control coffee
62338102|NCT01826422|EXPERIMENTAL|EPA and DHA|Supplementation of 2.7 g/d of EPA and DHA were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes were specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.
62338103|NCT01826422|PLACEBO_COMPARATOR|Placebo Comparator|Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.
62338104|NCT01558024||C1S patients|"18 Patients with venous insufficiency: C1S patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
62338105|NCT01558024||C3 patients|"18 Patients with venous insufficiency: C3 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
62494909|NCT01220960|EXPERIMENTAL|Art Therapy intervention group|For participants who will be part of the art therapy intervention, the art therapy group will be a closed group for eight women with breast cancer who are in treatment and recently have had surgery. The group will meet once a week for two hours over a period of 8 weeks, and will focus on exploring the expressive capabilities of art making in a supportive group. This group will be held in the conference room at the Cedars Breast Clinic. Each week will revolve around a theme that pertains to the experience of women living with breast cancer, and will be guided by the women's needs in the group. A broad range of art materials will be made available and various art techniques explored. No art experience is necessary. The intervention group will also need to fill out simple questionnaires before the art therapy groups starts and after the group finishes
61942686|NCT04108871|ACTIVE_COMPARATOR|Transrectal Prostate Biopsy|The biopsy needle penetrates through the bowel (rectum) to the prostate to obtain 12 cores of prostate tissues from the lateral and medial base, midzone and apex of each side of the prostate (1 core each).
61942687|NCT03198078|EXPERIMENTAL|Brexpiprazole|Participants were administered with brexpiprazole oral tablets, daily, dose titrated up to 0.5 mg by Day 4, 1 mg by Day 7, 2 mg by Day 14, then between 2-4 mg after Day 21 up to Week 6 with a 1 mg increase or decrease, based on the Investigator's decision.
61942688|NCT03198078|ACTIVE_COMPARATOR|Aripiprazole|Participants were administered with aripiprazole oral tablets, daily, dose titrated up to 2 mg by Day 4, 5 mg by Day 7, 10 mg by Day 14, then 10, 15 or 20 mg after Day 21 up to Week 6 with a 5 mg increase or decrease, based on the Investigator's decision.
61942689|NCT03198078|PLACEBO_COMPARATOR|Placebo|Participants were administered with brexpiprazole or aripiprazole matching placebo oral tablets, daily up to Week 6.
61942690|NCT06112548|EXPERIMENTAL|TKA with pain management by multimodal periarticular injection.|Patients going TKA and getting an injection of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat before closure.
61942691|NCT06112548|EXPERIMENTAL|TKA with pain management by IV/oral analgesics.|Patients going TKA and getting a standard pain control regime of IV opioids when needed, IV ketorolac, and IV/oral paracetamol.
61942692|NCT04466176|EXPERIMENTAL|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
61942693|NCT04466176|ACTIVE_COMPARATOR|Reference Product|ADVAIR DISKUS® 250/50
61942694|NCT00792415||1|Limited continuous opioid exposure (at least 120 and less than 156 hours)
61942695|NCT00792415||2|Extended continuous opioid exposure (156 hours or more)
61942696|NCT02103907|NO_INTERVENTION|Wait list|Wait list control group. Participants will be placed on the wait list and asked to maintain their current routine and level of activity during the 10 week period. Control group participants will receive the dynamic balance training program in a single training session after the followup (second testing session at 10 weeks).
61942697|NCT02103907|EXPERIMENTAL|Treatment (balance training)|Targeted dynamic balance training. Dynamic balance training will consist of progressive exercise training over three phases, with exercises emphasising dynamic balance control, muscle strength and proprioception. Exercises will be performed four times per week for ten weeks. Exercises will be taught and supervised by a trained kinesiologist. Difficulty of exercises will be increased progressively over time by increasing resistance, time of timed exercises, and distance of walking exercises. Exercises will be progressed to different exercises in each new phase (total 3 phases). Participants will complete six treatment sessions at the university (during weeks 1, 2, 3, 5, 7, and 9) that will be included in the total number of sessions per week. All other sessions will be performed at home.
61942698|NCT04304274|EXPERIMENTAL|PTPVB-ropivacaine|Programmed intermittent bolus infusion of a thoracic paravertebral block with ropivacaine and patient-controlled analgesia with morphine
61942699|NCT04304274|PLACEBO_COMPARATOR|PTPVB-saline|Programmed intermittent bolus infusion of a thoracic paravertebral block with saline and patient-controlled analgesia with morphine
61942700|NCT00142610|EXPERIMENTAL|vitamin|500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks
61942701|NCT00142610|PLACEBO_COMPARATOR|Placebo|
61942702|NCT04977557|OTHER|single arm|"its a quasi experimental study where single group is used (self controlled clinical trial).~clinical features were compared before iand after intervention"
61942703|NCT03610438|EXPERIMENTAL|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
61942704|NCT03610438|EXPERIMENTAL|Cohort 2|Cohort 2 will enroll 38 Ph- patients
62738517|NCT04887168|EXPERIMENTAL|Compressed|Treatment delivered at higher intensity - twice weekly
62738518|NCT04887168|EXPERIMENTAL|Spaced|Treatment delivered at lower intensity - once weekly
61942705|NCT03049722|EXPERIMENTAL|AVOPT Patient|
61942706|NCT01982565|EXPERIMENTAL|Treatment Arm|NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
61942707|NCT01982565|ACTIVE_COMPARATOR|Control Arm|Standard of Care
61942708|NCT01160211|EXPERIMENTAL|Lapatinib plus trastuzumab plus aromatase inhibitor|Experimental
61942709|NCT01160211|ACTIVE_COMPARATOR|trastuzmab plus aromatase inhibitor|Active Comparator
61942710|NCT01160211|ACTIVE_COMPARATOR|lapatinib plus aromatase inhibitor|Active Comparator
61942711|NCT05931874|EXPERIMENTAL|Exp Condition 1|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
61942712|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 2|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training
61942713|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 3|Research participant receives the Core Intervention + E-Coach + Buddy
61942714|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 4|Research participant receives the Core Intervention + E-Coach
61942715|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 5|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + Buddy
61942716|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 6|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training
61942717|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 7|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training + Buddy
61942718|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 8|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training
61942719|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 9|Research participant receives the Core Intervention + General Mindfulness Training + Buddy
62494910|NCT01220960|NO_INTERVENTION|Control Group|The group not assigned to the intervention group will be asked to fill out questionnaires at two separate times (before and after the intervention group is run). The Control group will be offered the opportunity to join an open art therapy group upon completing the questionnaires.
62494911|NCT01354301|EXPERIMENTAL|Thymoglobulin and everolimus|single dose antithymocyte globulin, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
62494912|NCT01354301|EXPERIMENTAL|Basiliximabe and everolimus|basiliximab, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
62494913|NCT01354301|ACTIVE_COMPARATOR|Basiliximabe and mycophenolate|basiliximab, reduced concentration tacrolimus, mycophenolate and prednisone.
62494914|NCT04372524||Allogeneic HSC Transplant recipients|"Five possible patient scenarios are anticipated to occur in those who underwent allogeneic HSCT:~* Early event (e.g. death, non-engraftment) occurring before day 100.~* No late-acute or chronic GvHD ever develops at any time point in the first year post-transplant (regardless of whether or not classical acute GvHD develops in the first 100 days after transplant).~* Early-onset chronic GvHD (including overlap syndrome) occurred before day 60.~* Early-onset chronic GvHD (including overlap syndrome) occurred between day 60 and day 100.~* Chronic GvHD after Day 100, Late-acute GvHD (de-novo or recurrent) after day 100, or cases of overlap syndrome occurred after day 100."
62494915|NCT04260035|ACTIVE_COMPARATOR|Vasoactive Intestinal Polypeptide (VIP)|"Intravenous infusion of 8 pmol/Kg/min of Vasoactive Intestinal Polypeptide (VIP).~The infusion is administered at constant speed by an automatic pump, lasting 120 minutes."
61942720|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 10|Research participant receives the Core Intervention + General Mindfulness Training
62338106|NCT01558024||C5 patients|"18 Patients with venous insufficiency: C5 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
62338107|NCT01558024||Sedentary volunteers|18 healthy volunteers with a sedentary lifestyle (\< 2h of physical activity per week)
62494916|NCT04260035|PLACEBO_COMPARATOR|Sterile, isotonic, non-active saline (Placebo)|Intravenous infusion of sterile, isotonic, non-active saline 9 mg/ml (placebo). The infusion is administered at constant speed by an automatic pump, lasting 120 minutes.
62494917|NCT02955940|EXPERIMENTAL|Ruxolitinib|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
62494918|NCT02955940|EXPERIMENTAL|Ruxolitinib plus background cancer therapy|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
62494919|NCT02955940|EXPERIMENTAL|Background cancer therapy alone|Capecitabine and Regorafenib at the same dose provided in the parent study at the time of the rollover.
62494920|NCT01978873|EXPERIMENTAL|Arm A:|"* Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable disease or responding to up to 10 cycles. Cabazitaxel will be administered in combination with oral prednisone or prednisolone (Prednisolon 10mg 1x1)~* Hormones will be initiated in conjunction with the last cycle of chemotherapy. Consists of the administration of a luteinizing hormone-releasing hormone (LHRH) agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device. G-CSF treatment according to ASCO guidelines is recommended."
62494921|NCT01978873|ACTIVE_COMPARATOR|Arm B:|-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
62696314|NCT06469021|EXPERIMENTAL|Rehabilitative Game Based Exercise Group|The Rehabilitative Game-Based Exercise group will perform the structured three-dimensional scoliosis exercise with conventional methods similar to the control group. Differently, technology-based systems (BeCure Systems) will be used in the implementation of core stabilization and balance exercises. Patients will be asked to perform their exercises as a home exercise program on the remaining days (home exercise program 3 days a week for the first 12 weeks, 4 days a week after week 12).
62738519|NCT06262048|EXPERIMENTAL|Treatment|Tamsulosin
61942721|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 11|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training + Buddy
61942722|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 12|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training
61942723|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 13|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
61942724|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 14|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training
62738520|NCT06262048|PLACEBO_COMPARATOR|Placebo|Placebo
61942725|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 15|Research participant receives the Core Intervention + Buddy
61942726|NCT05931874|ACTIVE_COMPARATOR|Exp Condition 16|Research participant receives the Core Intervention
62338108|NCT01558024||Active volunteers|18 healthy volunteers with an active lifestyle (between 2 and 6 hours of physical activity per week)
62338109|NCT01558024||Athletic volunteers|18 healthy volunteers with an athletic lifestyle (over 6 hours of physical activity per week for at least one year)
62338110|NCT01027208|EXPERIMENTAL|Ixabepilone|
62338111|NCT04141787|ACTIVE_COMPARATOR|Ceftriaxone|Ceftriaxone 2g IV q24hvia Gravity (or q12h in the case of CNS infections) Duration dependent on site of infection, determined by treating infectious diseases (ID) clinicians based on accepted clinical guidelines.
61942727|NCT02626767|EXPERIMENTAL|Intervention|Participants were required to complete a high-intensity interval exercise training intervention, which took place three time per week for 10 weeks. The exercise sessions comprised of 4 to 7 repetitions of 45 s maximal effort exercise, based on boxing, dance, soccer and basketball drills), interspersed with 90-s rest. During each repetitions participants were encouraged to reach \>90% of their individual maximal heart rate. Participants were asked to maintain their dietary habits throughout the intervention period.
61942728|NCT02626767|NO_INTERVENTION|Control|Participants were asked to maintain their usual diet, physical education and physical activity habits during the intervention period and were not aware that an exercise intervention was taking place at other study sites.
62696315|NCT02705963|EXPERIMENTAL|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
62696316|NCT02760342|EXPERIMENTAL|ASP015K and Metformin|Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.
62696317|NCT03275987|EXPERIMENTAL|Mammography treatment|Mammography direct mail coupled with a financial incentive
61942729|NCT02650427|EXPERIMENTAL|DPPIV Inhibition|The study will include 3 weeks administration (± 7 days) of sitagliptin as monotherapy (taken orally). The study will use 3 doses: the first five patients will receive 100 mg/day, the next five 200 mg/day and the last five patients 600 mg/day. During this time, arrangements will be made for surgical resection, as per the standard of care treatment of patients. Blood samples will be obtained for immunology studies. The study will end one week after surgery. Patients will continue their treatment for HCC as prescribed by the clinician.
61942730|NCT02414659||Cesarean delivery, cord blood collected|Cesarean delivery patient who opted for cord blood collection during procedure. Cord blood was collected in-utero after delivery and after clamping of the umbilical cord. After cord blood collection operation was continued.
61942731|NCT02414659||Cesarean delivery, control|Routine cesarean delivery patients.
61942732|NCT01108120|EXPERIMENTAL|continuous intra-femoral thrombolysis group|Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 \~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
61942733|NCT01108120|ACTIVE_COMPARATOR|conventional therapy group|Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
61942734|NCT05647057|ACTIVE_COMPARATOR|A: gelofusine + ringers|Prime fluid strategy containing gelofusine and ringers
61942735|NCT05647057|ACTIVE_COMPARATOR|B: albumin + ringers|Prime fluid strategy containing albumin and ringers
62138693|NCT02513667|EXPERIMENTAL|Patients recieved prior ALK inhibitor|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
62138694|NCT05558072|EXPERIMENTAL|Group 1|Newborn
62138695|NCT05558072|EXPERIMENTAL|Group 2|adolescent
62138696|NCT06286800|EXPERIMENTAL|Personalized Transcranial direct current stimulation (ptDCS)|TDCS is a noninvasive form of cortical stimulation that uses a battery-powered device. \[67\] Weak current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the montage identified as the best in the individual stroke patient during our initial testing session during OT targeting the affected arm.
62696318|NCT03275987|ACTIVE_COMPARATOR|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
62696319|NCT03275987|EXPERIMENTAL|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
62696320|NCT03275987|ACTIVE_COMPARATOR|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
62696321|NCT03709667|EXPERIMENTAL|EX|Participants in this arm of the study will be randomized in to the exercise intervention.
62696322|NCT03709667|PLACEBO_COMPARATOR|CON|The control condition is a health-education intervention.
62696323|NCT01356147|SHAM_COMPARATOR|Sham placebo|No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
62696324|NCT01356147|ACTIVE_COMPARATOR|Dornase alfa|Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
62696325|NCT00740675|EXPERIMENTAL|1|"At post-discharge follow-up visit with PCP, PCP views:~1. Discharge medication reconciliation screen.~2. Prompts to perform post-discharge reconciliation at the first post-discharge visit."
62696326|NCT00740675|NO_INTERVENTION|Uusual care|PCPs manage the patient's medications after hospital discharge as they normally would.
61942736|NCT05647057|ACTIVE_COMPARATOR|C: ringers + retrograde autologous priming|Prime fluid strategy containing ringers combined with retrograde autologous priming
61942737|NCT06681818|EXPERIMENTAL|all participants|all participants will provide breath samples to detect carbon monoxide levels
61942738|NCT02260440|EXPERIMENTAL|Pembrolizumab and Azacitidine Arm|"9 cycles~* Pembrolizumab will be given at 200 mg every 21 days.~* Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
61942739|NCT06679881|EXPERIMENTAL|Deucrictibant|Deucrictibant
61942740|NCT04524806|ACTIVE_COMPARATOR|2 mm-thick splint group (2 mm-TSG)|The group which applied the 2 mm thick stabilization splint
61942741|NCT04524806|ACTIVE_COMPARATOR|4 mm-thick splint group (4 mm-TSG)|The group which applied the 4 mm thick stabilization splint
61942742|NCT03605212|EXPERIMENTAL|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
61942743|NCT03605212|EXPERIMENTAL|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
61942744|NCT03605212|EXPERIMENTAL|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
61942745|NCT03605212|EXPERIMENTAL|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
61942746|NCT03605212|ACTIVE_COMPARATOR|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
61942747|NCT04446572|EXPERIMENTAL|Repetitive Abortion (RA) group|Starting at day 0, women of the RA (n=21) group consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
61942748|NCT04446572|EXPERIMENTAL|Infertility (INF) group|Starting at day 0, women of the INF group (n=23) consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
61942749|NCT04446572|NO_INTERVENTION|Control group|The control group (n = 14) included fertile women having at least two children after uncomplicated term pregnancies.
61942750|NCT02935842|EXPERIMENTAL|Specific SL-therapy for PD (with and without DBS)|Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
61942751|NCT02935842|ACTIVE_COMPARATOR|rBMT for PD (with and without DBS)|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
61942752|NCT02935842|NO_INTERVENTION|PD (with and without DBS); no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
61942753|NCT02935842|NO_INTERVENTION|Healthy Controls; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
61942754|NCT02100800|EXPERIMENTAL|COPD Group|30 patients with diagnosis of COPD
61942755|NCT02100800|SHAM_COMPARATOR|Control Group|10 volunteers with extrapulmonary neoplasia
62138697|NCT06286800|PLACEBO_COMPARATOR|Sham tDCS|Same OT procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions.
62138698|NCT03890289|EXPERIMENTAL|Idelalisib Plus Obinutuzumab|"Single arm: Regimen: GAUDEALIS q28 days~* Obinutuzumab Dose: 1000 mg IV Day 1, 8, 15 (1st cycle)~* Obinutuzumab Dose: 1000 mg IV Day 1 (2nd cycle onward)~* Idelalisib Dose: 150 mg BID oral Daily (24 weeks)"
62338112|NCT04141787|ACTIVE_COMPARATOR|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Usual Antibiotics to treat methicillin-susceptible Staphylococcal infections~* Cloxacillin 2g IV q4h via Pump (dose adjusted for renal function)~* Cefazolin 2g IV q8h via Preloaded Syringe (dose adjusted for renal function)~* Daptomycin 6-10mg/kg IV daily via Gravity (dose will be determined based on the severity of infection as per discretion of the ID clinician and in accordance with most recent evidence)~* Duration dependent on site of infection, determined by treating infectious diseases clinicians based on accepted clinical guidelines."
62338113|NCT05842070|EXPERIMENTAL|Low-Intensity Protocol|Participants choose the low-cost, low-intensity egg-freezing protocol
62138699|NCT03363984|EXPERIMENTAL|Midazolam & ID-082|Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.
62338114|NCT05842070|ACTIVE_COMPARATOR|High-intensity protocol|Participants choose a routine high-intensity egg-freezing protocol
62338115|NCT05886634|EXPERIMENTAL|Participants With Dedifferentiated Liposarcoma/DDLPS|Participants will have a diagnosis of recurrent or metastatic Dedifferentiated Liposarcoma/DDLPS
62494922|NCT00466531|EXPERIMENTAL|Patients with CLL or indolent B-cell lymphoma|The first stage is a standard 3-step phase I dose escalation trial to assess the safety of 19-28z CAR expressing autologous T cells with or without prior conditioning chemotherapy.Step 1, a cohort of pts will receive the lowest planned dose of 19-28z+ modified T cells. Step 2, a cohort of pts will receive cyclophosphamide conditioning chemotherapy followed by the lowest planned dose of 19-28z+ modified T cells. If less than 33% of pts in the cohort experience unanticipated dose-limiting toxicity,Step 3, a cohort of pts will be treated with the investigator's choice conditioning chemotherapy followed by the higher dose of 19-28z+ modified T cells. If less than 33% of pts in the initial cohort (Step 3) experience unanticipated dose-limiting toxicity, the cohort in Step 3 may be expanded to include up to 15 pts. In Step 3, an additional cohort of Waldenstrom's Macroglobulinemia (WM) pts will be treated with the investigator's choice conditioning chemotherapy followed by 19-28z+ T cells.
62494923|NCT03203642|EXPERIMENTAL|Tesevatinib|Participants received tesevatinib 50 mg tablet orally once daily (QD) for up to 25.3 months.
62338116|NCT00555048|EXPERIMENTAL|Alemtuzumab|Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.
62494924|NCT03203642|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to tesevatinib tablet orally QD for up to 25.3 months.
62696327|NCT04906512|EXPERIMENTAL|3M™ Tegaderm™ CHG I.V. Securement Dressing|The primary purpose of 3M™ Tegaderm™ CHG I.V. Securement Dressing is to secure devices to skin; and secondly, the dressing contains an antimicrobial ingredient that inhibits microbial regeneration. This product is used to cover and protect the catheter sites on the body surface and to secure devices to skin and is available in a variety of models and sizes.
61942756|NCT02100579|ACTIVE_COMPARATOR|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
61942757|NCT02100579|PLACEBO_COMPARATOR|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
61942758|NCT02651831||1A: Content Validation|"Up to 4 focus groups of 6-10 cancer patients each will be conducted each lasting approximately 90 mins. An additional 10 to 15 patients will undergo individual semi-structured interviews each lasting around 60 minutes.~10-12 expert clinicians experienced in treating patients with ICMs or managing ICM toxicities will participate in a survey, and group or individual interviews."
61942759|NCT02651831||1B: Face Validity|Patients who have been and are being treated with ICMs to complete draft questionnaire (FACT-ICM). Some patients who were involved in the first round of interviews will be re-interviewed, and interview naïve patients will also be included.
61942760|NCT02651831||2A: To measure test-retest reliability|Patients to complete FACT-ICM at at two time points separated by 5 to 14 days.
62338117|NCT06302270||mother-infant dyads|
62338118|NCT06406686|ACTIVE_COMPARATOR|30 Watt|Power set to 30 Watts
61942761|NCT02651831||2B: To confirm construct validity|To evaluate discriminative properties of FACT-ICM, scores will be compared between pre-defined groups of patients where differences are expected.
62138700|NCT04761042|EXPERIMENTAL|Wilderness program|A one-week (8 days) wilderness program, 3-month online support, and a follow-up visit for four days.
62138701|NCT04761042|OTHER|Holiday program (Attention control)|A one-week (8 days) holiday program, 3-month online contact, and a follow-up visit for four days.
62338119|NCT06406686|EXPERIMENTAL|50 Watt|Power set to 50 Watts
62338120|NCT02836535||patients with complications|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential. The interview will examine the impact of complications utilizing a semi-structured script specific to each group
62338121|NCT02836535||patients without Complications (control group)|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential.
61942762|NCT02651831||2C: To determine responsiveness and MCID|"Responsiveness testing: Patients will complete FACT-ICM within a week of starting treatment, then while on treatment and within 30 days after end of treatment (EOT) with ICMs.~MCID testing: In addition to the FACT-ICM score, patients undergoing serial assessment for responsiveness will also indicate how much better or worse they are using a 5-point rating scale."
62338122|NCT01113398|EXPERIMENTAL|AMG 102 with Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg prior to AMG 102, which will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg. Subjects will receive infusions every 2 weeks.
62338123|NCT03513965|EXPERIMENTAL|Symptoms as Side Effects Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
62338124|NCT03513965|EXPERIMENTAL|Symptoms as Positive Signals Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.
62338125|NCT01333839|ACTIVE_COMPARATOR|standard exercise intervention|12 weeks of endurance exercise training
61942763|NCT00397215|EXPERIMENTAL|GSK1562902A 1 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
62138702|NCT01593020|EXPERIMENTAL|Paclitaxel + FEC or FAC Group|"ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
62138703|NCT01593020|EXPERIMENTAL|Eribulin + FEC or FAC Group|"ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
62138704|NCT03869970|ACTIVE_COMPARATOR|Rest|Discharge instructions focused on 24 - 48 hours of rest then symptom guided activity, Fitbit monitored.
62138705|NCT03869970|ACTIVE_COMPARATOR|mHealth|"Use of the resilience application on a smart phone to assess daily symptoms over 14 days and follow a self directed, symptom guided return to physical activity. Also Fitbit monitored."
62138706|NCT03869970|ACTIVE_COMPARATOR|Activity|Low intensity activity regardless of symptoms using their Fitbit to measure said activity with goals (eg. 10,000 steps/ day.
62138707|NCT03869970|ACTIVE_COMPARATOR|Both Activity and mHealth|"This group will receive both interventions and utilize the SuperBetter app. Interventions will be integrated by having research assistants support the subject to set and physical activity goals and milestones to the subject's pre-programmed general resilience goals in the SuperBetter© app (e.g. take a 30 min walk, march in place for 5 minutes, increase my step count by 2000 today, achieve 10,000 steps today)."
62138708|NCT02345603|EXPERIMENTAL|Cryo-therapy|Cryo-therapy of renal arteries
62138709|NCT02345603|NO_INTERVENTION|Control|No intervention in renal arteries
62338126|NCT01333839|ACTIVE_COMPARATOR|modified exercise intervention|combined endurance + strength exercise training
62338127|NCT01333839|ACTIVE_COMPARATOR|modified 2 exercise intervention|combined endurance + strength exercise training + oral protein supplements
62338128|NCT01940016|EXPERIMENTAL|Arm I (health coach)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and from a health coach. Participants in this arm of the study, interacted with the IVR system and had the option of interacting with the health coach.
62338129|NCT01940016|ACTIVE_COMPARATOR|Arm II (no coach condition)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system. Participants in this arm of the study only interacted with the IVR system.
62696328|NCT04906512|ACTIVE_COMPARATOR|3M™ Tegaderm™ Transparent Film Dressing 1626W|Transparent dressing, i.e. CHG-free transparent dressing, can be used to cover and protect catheter sites on the body surface and to secure devices to skin, without any antibacterial ingredients, and are the currently most commonly used transparent dressings in DVC care in China.
61942764|NCT00397215|EXPERIMENTAL|GSK1562902A 2 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
61942765|NCT00397215|EXPERIMENTAL|GSK1562902A 3 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
61942766|NCT00397215|EXPERIMENTAL|GSK1562902A 4 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
62338130|NCT03817567|EXPERIMENTAL|recombinant anti-EGFR monoclonal antibody（SCT200）|6.0mg/kg QW for 6 weeks, then 8.0mg/kg Q2W
62338131|NCT03870126|PLACEBO_COMPARATOR|Flavored Beverage Mix 1|Flavored still beverage
62696329|NCT00443014|EXPERIMENTAL|A Cognitive stimulation therapy|Patients with recently diagnosed dementia in five of the study municipality.
62696330|NCT00443014|NO_INTERVENTION|B Care as usual|
62696331|NCT02474173|EXPERIMENTAL|Treatment (onalespib, paclitaxel)|"SAFETY RUN-IN: Patients receive onalespib IV over approximately 1 hour on day -7.~TREATMENT: Patients receive paclitaxel IV over 60 minutes on day 1, 8, and 15. Patients also receive onalespib IV over 1 hour beginning on days 8 and 15 of cycle 1 and on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62696332|NCT05868811|EXPERIMENTAL|Music Together|
62696333|NCT05868811|PLACEBO_COMPARATOR|Play Group|
62696334|NCT06645223||Young Group|
62696335|NCT06645223||Elderly Group|
62338132|NCT03870126|EXPERIMENTAL|Flavored Beverage Mix 2|Flavored still beverage with polyphenols, concentration 1
62338133|NCT03870126|EXPERIMENTAL|Flavored Beverage Mix 3|Flavored still beverage with polyphenols, concentration 2
62338134|NCT03870126|EXPERIMENTAL|Flavored Beverage Mix 4|Flavored still beverage with caffeine
62338135|NCT03320291|EXPERIMENTAL|Regjoint|
62338136|NCT04873284|EXPERIMENTAL|Fosaprepitant|Patients received intravenous Granisetron plus dexamethasone followed by fosaprepitant infusion
62338137|NCT04873284|EXPERIMENTAL|Aprepitant|Patients received intravenous Granisetron plus dexamethasone followed by oral aprepitant
62338138|NCT04141852|EXPERIMENTAL|AVF surgery with device|
62338139|NCT04141852|NO_INTERVENTION|AVF surgery conventional|
62696336|NCT01765413|EXPERIMENTAL|Varilrix|Participants receive one dose of 'Varilrix' varicella-zoster vaccine.
62696337|NCT01765413|EXPERIMENTAL|Stamaril|Participants receive one dose of 'Stamaril' yellow fever vaccine.
62494925|NCT03021876|PLACEBO_COMPARATOR|ordinary group|usual intake prior to liver surgery
62696338|NCT01765413|PLACEBO_COMPARATOR|Placebo|Participants receive one injection of placebo.
62696339|NCT02989857|ACTIVE_COMPARATOR|AG-120|Participants received AG-120 500 mg, tablet, orally, once a day (QD) in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.
62696340|NCT02989857|PLACEBO_COMPARATOR|Placebo|Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.
62696341|NCT02989857|EXPERIMENTAL|After Cross over to AG-120|Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle for up to approximately 32 months.
62696342|NCT02748798|EXPERIMENTAL|Healthy Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
61942767|NCT02391675||Appendicitis patients|Patients presenting with acute appendicitis
61942768|NCT01881373|EXPERIMENTAL|CHL program|Multiple component environmentally focused intervention designed with a community engagement process.
61942769|NCT01881373|OTHER|Delayed Optimized CHL program|Comparison community that participated in community engagement process and received delayed optimized program.
61942770|NCT01881373|NO_INTERVENTION|Temporal|Communities assessed for temporal trends in anthropometry.
61942771|NCT03561363|EXPERIMENTAL|Saturated high-fat diet|"In this intervention group, subjects ingest a saturated eucaloric high-fat diet (64 E%) with total fat content being similar to the polyunsaturated high-fat diet.~The diet is enriched in saturated fat (36 E%). The main saturated fatty acids in the diet are primarily palmitic acid (C16:0) and stearic acid (C18:0). The main food sources are milk products, high-fat meat and vegetables.~Carbohydrate comprise 20 E% and protein 15 E%."
61942772|NCT03561363|EXPERIMENTAL|polyunsaturated high-fat diet|In this intervention group, subjects ingest a polyunsaturated eucaloric high-fat diet (64 E%), with total fat content being similar to the saturated high-fat diet. The diet is enriched in polyunsaturated fat (32 E%). The main polyunsaturated fatty acids in the diet are primarily linoleic acid (C18:2 n-6) and alpha-linoleic acid (C18:3 n-3). The main food sources are vegetable oils, nuts and high-fat fish (e.g. salmon). Carbohydrate comprise 20 E% and protein 15 E%.
61942773|NCT01146275|OTHER|Participants in the Pilot study 31GB0601|"This is an additional safety follow up 7-years post treatment, for subjects enrolled in a pilot study using a previous formulation of Macrolane for breast augmentation.~Radiological breast examinations - MRI of breast, mammography and ultrasound of breast"
61942774|NCT03419611|EXPERIMENTAL|Multi-Modal|3 Times Per Week for 4 weeks - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component followed by more treatment for 12 weeks
61942775|NCT03419611|EXPERIMENTAL|Multi-Modal + High Intensity Multi-Modal|3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 4 weeks, increasing to 5 times per week for 12 weeks
61942776|NCT03419611|PLACEBO_COMPARATOR|Treatment as Usual|Teacher provided with word list for 4 weeks followed by more treatment as usual for 12 weeks
61942777|NCT03419611|EXPERIMENTAL|Treatment as Usual + Multi-Modal|Teacher provided with word list for 4 weeks followed by 3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 12 weeks
61942778|NCT03419611|EXPERIMENTAL|Treatment as Usual + High Intensity Multi-Modal|Teacher provided with word list for 4 weeks followed by Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 5 times per week for 12 weeks
62696343|NCT02748798|EXPERIMENTAL|Lung Disorder Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
61942779|NCT01595672|ACTIVE_COMPARATOR|EHVCVVH group|Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
61942780|NCT01595672|ACTIVE_COMPARATOR|Control group|Patients receive conventional treatments recommended by guidelines only.
61942781|NCT06679959|EXPERIMENTAL|Cohort 1|Dose 1
61942782|NCT06679959|EXPERIMENTAL|Cohort 2|Dose 2
61942783|NCT06679959|EXPERIMENTAL|Cohort 3|Dose 3
61942784|NCT06679959|EXPERIMENTAL|Cohort 4|Dose 4
61942785|NCT06679959|EXPERIMENTAL|Cohort 5|Dose 5
61942786|NCT06681376|NO_INTERVENTION|Pre-intervention|Usual ED care
62494926|NCT03021876|ACTIVE_COMPARATOR|carnitine group|treatment with oral L-carnitine, 1500 mg/body per day for 2 weeks prior to liver surgery
62494927|NCT03324815|ACTIVE_COMPARATOR|Morphine- Methadone|Morphine 5mg/6h plus metadone: 2,5mg/12h
62494928|NCT03324815|ACTIVE_COMPARATOR|Morphine|Morphine: 5mg/6h
61942787|NCT06681376|EXPERIMENTAL|Post-intervention|Comfort menu and cart implemented
61942788|NCT06557694||Data collection|Data collected included maternal demographics, medication during pregnancy, the gestational week when COVID-19 was diagnosed, antenatal diseases occurring after COVID-19 detection during pregnancy, intrauterine growth retardation (IUGR), small for gestational age (SGA), fetal distress, intrauterine fetal demise (IUFD), intrapartum complications, gestational age (GA) at delivery, mode of delivery, postpartum hemorrhage (PPH), admission to the maternal ICU, birth weight, admission to the NICU, and the indication for NICU hospitalization
62494929|NCT03373630|EXPERIMENTAL|Midline catheter|
61942789|NCT05421871|EXPERIMENTAL|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
61942790|NCT05421871|EXPERIMENTAL|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
62494930|NCT02515487|EXPERIMENTAL|Breast cancer patients receiving chemotherapy treatment|
61942791|NCT01680965|EXPERIMENTAL|Ofatumumab|"Phase I:~Escalating dose of ofatumumab~Phase II:~Maximum tolerated dose (MTD) of Ofatumumab"
62494931|NCT02725619|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT)|CBT is dedicated to developing coping skills for managing anxiety such as emotion regulation and cognitive reappraisal. Children first learn and practice these skills during one-on-one, weekly sessions with experienced therapists and then apply this skills to navigate anxiety-producing situations as home, school and community. A key component of CBT involves exposure exercises, facing feared situations repeatedly while using the emotion regulation skills and remaining in the situations until anxiety is substantially reduced or become easy to tolerate. The feared situations are ordered from least to most distressing during therapy sessions in collaboration with the child and their parent. The unique combination of anxiety and ASD symptoms of social impairment and restricted/repetitive behavior is addressed in dedicated child and parent modules.
61942792|NCT04507100|EXPERIMENTAL|Lifestyle and environment intervention|Schools will receive the components of Salud Escolar
61942793|NCT04507100|NO_INTERVENTION|Wait-list control|Wait-list control of schools without intervention.
61942794|NCT00203073|ACTIVE_COMPARATOR|Copaxone 20 mg|Copaxone 20 mg
61942795|NCT00203073|ACTIVE_COMPARATOR|Copaxone 20mg with Novantrone induction|Copaxone 20mg with Novantrone induction
61942796|NCT02288598|EXPERIMENTAL|Anodal TDCS|Participants will receive anodal TDCS over the left inferior frontal cortex. TDCS will be delivered at 1milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
61942797|NCT02288598|SHAM_COMPARATOR|Sham TDCS|Participants will receive sham TDCS over the left inferior frontal cortex. Sham stimulation will involve 30 seconds stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
61942798|NCT01796756|EXPERIMENTAL|Handover program|Standardized handover program Dedicated place and time Template Face-to-face communication Evidence-based education session Feedback and audit
61942799|NCT01796756|NO_INTERVENTION|Usual handover practice|
61942800|NCT04359108|EXPERIMENTAL|Navigation system for users of a visual prosthesis|This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition. The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis. Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems. Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
61942801|NCT06253975|EXPERIMENTAL|AT-EV group|
61942802|NCT06253975|PLACEBO_COMPARATOR|HA group|
61942803|NCT03071159|OTHER|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
61942804|NCT01554020|ACTIVE_COMPARATOR|Multiherb product|Herbal product
61942805|NCT01554020|PLACEBO_COMPARATOR|Placebo|Maltodextrin control
61942806|NCT01074372|EXPERIMENTAL|Cohort 1|Dose 1 versus placebo
61942807|NCT01074372|EXPERIMENTAL|Cohort 2|Dose 2 versus placebo
62494932|NCT02725619|ACTIVE_COMPARATOR|Psychoeducation and Supportive Therapy (PST)|"Psychoeducation and Supportive Therapy includes learning about and discussing issues of diagnosis, treatment and educational services can also benefit children with ASD and their families. Each PST session starts with a review of events of the past week and include queries of topics such as school, interests, and family with an overarching goal of enhancing subjective well-being. The clinician, through the use of supportive, empathic and nondirective actions, will provide the participant with a sounding-board so that they can voice their concerns regarding specific problems that may require discussion and assistance. A major objective is to provide a clinical contact that enables participants to think through and discuss their concerns with a sympathetic adult. Subjects randomized to PST will be offered CBT after completion of the endpoint assessments."
62494933|NCT04485819||Cleavage stage transfer|Poor responders who transfer their embryos in cleavage stage on day 3
62494934|NCT04485819||Blast stage transfer|Poor responders who transfer their embryos on blast stage on day 5/6
62494935|NCT04498676|EXPERIMENTAL|Test product|
61942808|NCT01074372|EXPERIMENTAL|Cohort 3|Dose 3 versus placebo
61942809|NCT01074372|EXPERIMENTAL|Cohort 4|Dose 4 versus placebo
61942810|NCT01592682|NO_INTERVENTION|Usual care|Household pairs that are assessment only and receive usual care of local in-language smoking cessation resource referral including quitline.
61942811|NCT01592682|EXPERIMENTAL|Smokefree counseling|Household pairs assigned to smokefree counseling intervention, consisting of group education sessions, tobacco exposure lab report, individual follow-up phone calls.
61942812|NCT05189080|EXPERIMENTAL|Open Trial|Patients within the Wake Forest Baptist Health system who no-showed for scheduled well child visits at Pediatrics-Downtown Health Plaza, Family Medicine-Piedmont Plaza, Pediatrics-Winston East, Family Medicine-Peace Haven, and Pediatrics-Clemmons.
62138710|NCT06383390|EXPERIMENTAL|Retatrutide|Participants will receive escalated doses of retatrutide administered subcutaneously (SC) up to a maximum tolerated dose.
62138711|NCT06383390|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo administered SC.
62494936|NCT06173960||Patients with calcified femoropopliteal lesions|Patients presenting calcified femoropopliteal lesions (de novo, unique or multiple, mono or bilateral) and treated by atherectomy with Jetstream combined with Ranger between 1 December 2016 and 31 December 2020
62494937|NCT04662476|ACTIVE_COMPARATOR|Vitamin D supplement|331 children will each received 60,000IU of vitamin D once a month for 3 months.
62494938|NCT04662476|ACTIVE_COMPARATOR|Intervention|The intervention arm will receive vitamin D3.
62494939|NCT03461341||Patients post curative intent surgery for esophageal cancer|Patients post potentially curative surgery for cTxNxM0 esophageal or esophagogastric junction (Siewert type I, II and III) cancer.
62494940|NCT02093377|NO_INTERVENTION|Control|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone
62494941|NCT02093377|ACTIVE_COMPARATOR|Adaptive servo-ventilation|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI.
62494942|NCT05079230|EXPERIMENTAL|Magrolimab + Venetoclax + Azacitidine|"Participants will receive~* magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter~* venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~* azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
62494943|NCT05079230|PLACEBO_COMPARATOR|Magrolimab Placebo + Venetoclax + Azacitidine|"Participants will receive~* magrolimab placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter~* venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~* azacitidine: 75 mg/m\^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
62494944|NCT05816655|EXPERIMENTAL|Fulvestrant arm|fulvestrant + AI + ribociclib
62494945|NCT05816655|ACTIVE_COMPARATOR|Control arm|AI + ribociclib
62338140|NCT05106452||Group ANI|
62338141|NCT05106452||Group Control|
62338142|NCT02852993||Transfused patients|A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.
62338143|NCT02176395|EXPERIMENTAL|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
62338144|NCT02176395|PLACEBO_COMPARATOR|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
62338145|NCT02176395|NO_INTERVENTION|healthy volunteer|
62338146|NCT03721185|ACTIVE_COMPARATOR|LC|Lypolitic cream with hypocaloric diet and physicial activity in 51 patients
62338147|NCT03721185|PLACEBO_COMPARATOR|NLC|Hypocaloric diet and physicial activity alone in 51 patients
62338148|NCT03021291|EXPERIMENTAL|Gelesis100|Gelesis100 (2.25 g) twice daily
62338149|NCT05795114|NO_INTERVENTION|Enhanced treatment as usual|Those randomized to enhanced treatment as usual will receive brief psychoeducation about perinatal depression and the associations between ACEs and perinatal depression. Information about the collaborative care program will be provided. Individuals will be followed with monthly self-reported screens for depression, without any prevention programming for perinatal depression. Those identified to have incident depression symptoms will receive recommendations for treatment within the collaborative care model.
62338150|NCT05795114|EXPERIMENTAL|ROSE intervention|"Those randomized to the intervention will be offered 4 group-based prenatal sessions and one individual postpartum booster session guided by the Reach Out, Stand Strong, Essentials for New Mothers (ROSE) program embedded within the collaborative care model. Participants will be followed with monthly self-reported screens for depression, and those identified to have incident depression symptoms will receive treatment within the collaborative care model."
62338151|NCT06153082|EXPERIMENTAL|ROTEM Group|In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid.
62338152|NCT06153082|ACTIVE_COMPARATOR|THROMBOELASTOGRAPHY|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°
62338153|NCT05016869|EXPERIMENTAL|Experimental|fruquintinib plus capecitabine
62338154|NCT01133431|EXPERIMENTAL|CKD-501 + Glimepiride -> CKD-501 placebo + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
62338155|NCT01133431|EXPERIMENTAL|CKD-501 placebo + Glimepiride -> CKD-501 + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
62338156|NCT00568880|EXPERIMENTAL|Hydroxychloroquine Added to Bortezomib|Dose escalated by cohorts Hydroxychloroquine 200-600 mg pill every other day. Bortezomib 1.0-1.3mg/m2 IV, days 1, 4, 8, and 11 of each 21 day cycle.
62338157|NCT01987167|EXPERIMENTAL|-ACHTHAR|Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
62338158|NCT01422811|EXPERIMENTAL|Intervention|
62338159|NCT01422811|OTHER|Control|No Intervention
62338160|NCT04281160||Clinical Metric|Patients and healthy controls were evaluated by expert raters with standard clinical metrics of neurologic function.
62338161|NCT04281160||Mobile Activity Metric|Patient performed mobile activity
62338162|NCT03334162|EXPERIMENTAL|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for 12 weeks in addition to usual care.
62138712|NCT01557036||Aneurysms treated with Pipleline|Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device
62338163|NCT03334162|NO_INTERVENTION|Control group|Children in the control group will receive treatment as usual. The control group will be given the opportunity to participate in the intervention after study completion
62338164|NCT00444626|EXPERIMENTAL|DGE|Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.
62338165|NCT00444626|ACTIVE_COMPARATOR|Restylane|Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
62494946|NCT06505005|ACTIVE_COMPARATOR|Active/Treatment|Data will be collected at Baseline prior to first use of active patch (FREEDOM or REM) and then 7 days, and then at 14 days after use with the active patch. Baseline and Follow-up functional measurements will also be taken at 7 and 14 days after baseline.
62494947|NCT06505005|SHAM_COMPARATOR|Non-Active/Control|Data will be collected at Baseline prior to first use of sham patch and then 7 days, and then at 14 days after use with the sham patch. Baseline and Follow-up functional measurements will also be taken at 7 and 14 days after baseline. Control group subjects will be crossed over to crossover group after completion of control group study period.
62138713|NCT02148185|EXPERIMENTAL|MT-1303|
62138714|NCT00144040|OTHER|Arm 1|
62138715|NCT03551379||Endoscopic procedure|A double balloon endoscopic platform will be used during an ESD procedure
62138716|NCT00137800|EXPERIMENTAL|Tarceva|Chemotherapy Single Agent Systemic
62138717|NCT05014035|EXPERIMENTAL|Exercise Intervention|
62138718|NCT00781118|EXPERIMENTAL|Treatment|The Treatment arm has alerting enabled in their device during the 6-month randomization period. Treatment arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Treatment arm was re-defined as an ALARMS_ON group which included A) Control patients after the randomization period and until database lock (4/1/2014); and, b) Treatment patients both during the randomization period and after the randomization period until database lock (4/1/2014).
62138719|NCT00781118|OTHER|Control|The Control arm has alerting disabled in their device during the 6-month randomization period. Control arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Control arm was re-defined as an ALARMS_OFF group which included A) Control patients during the randomization period when the Guardian did not have alarms enabled.
62138720|NCT02339259||Febrile patients|Febrile patients admitted to CMCH who have had malaria film and scrub typhus and murine typhus rapid test will be screened for enrolment.
62138721|NCT02339259||Healthy|Healthy subjects with no recent history of fever will be recruited to provide control samples for the blood and plasma assays.
62338166|NCT02389673|NO_INTERVENTION|Without Radiotherapy|Patients just accept breast-conversing surgery without radiotherapy.
62338167|NCT02389673|EXPERIMENTAL|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
62338168|NCT01700517|SHAM_COMPARATOR|control group|Spinal anesthesia with 0.5% isobaric bupivacaine, in isolation. Punctures in the femoral and popliteal areas were made to mask the femoral and sciatic block, respectively, with no infusion of any medication.
62338169|NCT01700517|EXPERIMENTAL|Femoral nerve block|In addition to the spinal anesthesia, block of the femoral nerve guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. The technique used was femoral area puncture, at the level of the crural fold of skin, with a 0.5% (125mg) ropivacaine associated to 75 mcg of clonidine.
62338170|NCT01700517|EXPERIMENTAL|sciatic nerves block|In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
62494948|NCT06505005|ACTIVE_COMPARATOR|Crossover|Data will be collected at Baseline prior to first use of active patch (FREEDOM or REM) and then 7 days, and then at 14 days after use with the active patch. Baseline and Follow-up functional measurements will also be taken at 7 and 14 days after baseline for all arms.
62696344|NCT03215160|EXPERIMENTAL|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
62138722|NCT00818506||Late onset MDD|Patients with major depressive disorder between 50 and 70 years of age that did not suffer from depression before the age of 50.
62138723|NCT00818506||Controls|Healthy controls (matched for age, sex, and tobacco use status)
62138724|NCT01759862|EXPERIMENTAL|Aminophylline|"Patients will receive aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.~Theophylline drug levels will be monitored daily for 4 days."
62138725|NCT01759862|PLACEBO_COMPARATOR|Control|"Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.~Drug levels will be monitored daily for 4 days."
62138726|NCT02785029|EXPERIMENTAL|Normal healthy Volunteers|OCT imaging
62138727|NCT02933359||Normal Tissue|Bone fragments and their associated bone marrow will be collected from patients at the time of surgery without any additional dissection or incisions. Bone will be finely minced and then plated in tissue culture flasks as previously reported by other groups \[7\].
62138728|NCT03155113|OTHER|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
62138729|NCT05284240|EXPERIMENTAL|Auryon Laser Treatment Arm|Auryon Laser to be used on target lesion in the below the knee artery.
62138730|NCT00571298|EXPERIMENTAL|Extrapleural pneumonectomy (EPP)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
62338171|NCT04376606|EXPERIMENTAL|Left atrial appendage closure group|
62338172|NCT04376606|EXPERIMENTAL|Radiofrequency ablation group|
62138731|NCT00571298|EXPERIMENTAL|Pleurectomy/Decortication (P/DC)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
62138732|NCT00571298|EXPERIMENTAL|Tumor Debulking (TD)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
62494949|NCT05626348|EXPERIMENTAL|Methotrexate(MTX)+Iguratimod(IGU)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Methotrexate(MTX)，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response.~For RA patients with naive or csDMARDs-IR"
62494950|NCT05626348|EXPERIMENTAL|Adalimumab+Methotrexate(MTX)|"Drug: Adalimumab，40mg, iH,q2w, once two weeks (q2w) prescribed at the beginning and adjusted due to patient response.~Drug: Methotrexate(MTX)，7-10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response.~For RA patients with csDMARDs-IR"
62138733|NCT00925470||1|
62138734|NCT05070559|EXPERIMENTAL|Active Release Technique Group|Patients in this group will receive Active Release Technique along with conventional therapy
62138735|NCT05070559|EXPERIMENTAL|Graston Technique Group|Patients in this group will receive Instrumental Assisted Soft Tissue Mobilization along with conventional therapy
62338173|NCT04376606|EXPERIMENTAL|LAAC combined with radiofrequency ablation group|
62338174|NCT03224975|EXPERIMENTAL|patients|Patient who was burned will have fMRI.
62338175|NCT03224975|ACTIVE_COMPARATOR|control group|Healthy volunteers (control group) will have fMRI.
62338176|NCT01165151|EXPERIMENTAL|Small group|10-member groups
62338177|NCT01165151|ACTIVE_COMPARATOR|Large group|30-member groups
62338178|NCT04167306|EXPERIMENTAL|1) Varenicline + Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Investigational medicinal product (IMP) 2: Bupropion SR 150 mg
62338179|NCT04167306|EXPERIMENTAL|2) Varenicline + Placebo for Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Placebo capsule for IMP 2 (bupropion)
62338180|NCT04167306|EXPERIMENTAL|3) Bupropion + Placebo for Varenicline|Investigational medicinal product (IMP) 2: Bupropion SR 150 mg and Placebo capsule for IMP 1 (varenicline)
62338181|NCT04167306|PLACEBO_COMPARATOR|4) Placebo for Varenicline + Placebo for Bupropion|Placebo capsule for IMP 1 (varenicline) and Placebo capsule for IMP 2 (bupropion)
62338182|NCT00893672||1|Routine strategy of chest radiograph prescription
62494951|NCT05626348|EXPERIMENTAL|Iguratimod(IGU)+Leflunomide(LEF)+Hydroxychloroquine(HCQ)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Leflunomide(LEF)，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~For RA patients with csDMARDs-IR"
62338183|NCT00893672||2|On-demand strategy of chest radiograph prescription
62338184|NCT05502471|OTHER|ADHD|Children with ADHD
62338185|NCT05502471|OTHER|Control|Children without any psychiatric disorder
62138736|NCT03131128|EXPERIMENTAL|Mindfulness-based Intervention|2 sessions of diet nutrition education and 6 sessions of Mindfulness-based intervention, 1.5 hours each session.
62138737|NCT03131128|ACTIVE_COMPARATOR|Health Education Intervention|2 sessions of diet nutrition education and 6 sessions of Health Education, 1.5 hours each session.
62138738|NCT04290533|EXPERIMENTAL|Active HD-tDCS|
62138739|NCT04290533|SHAM_COMPARATOR|Sham HD-tDCS|
62138740|NCT04885166|EXPERIMENTAL|Web-based simulation intervention|Participants in this condition will receive psychoeducation about stimulant medication diversion, stimulant medication misuse, and will practice navigating and resisting requests for their medication with a virtual human.
62138741|NCT04885166|PLACEBO_COMPARATOR|Placebo condition|Participants in this condition will learn about psychological conditions that affect college students most often (e.g., depression), causes of those conditions, and pharmacological/behavioral treatments for those conditions.
62138742|NCT02928250|ACTIVE_COMPARATOR|Carnosine oral daily|Intervention group included pediatric patients with diabetic nephropathy receiving oral carnosine daily.
62338186|NCT06013995|EXPERIMENTAL|Cohort A: BMS-986326 Dose 1 IV|
62338187|NCT06013995|EXPERIMENTAL|Cohort B: BMS-986326 Dose 2 IV|
62338188|NCT06013995|EXPERIMENTAL|Cohort C1: BMS-986326 Dose 3 IV|
62338189|NCT06013995|EXPERIMENTAL|Cohort C2: BMS-986326 Dose 3 SC|
62338190|NCT06013995|EXPERIMENTAL|Cohort D1: BMS-986326 Dose 4 IV|
62338191|NCT06013995|EXPERIMENTAL|Cohort D2: BMS-986326 Dose 4 SC|
62338192|NCT06013995|EXPERIMENTAL|Cohort E1: BMS-986326 Dose 3 IV|
62338193|NCT06013995|EXPERIMENTAL|Cohort E2: BMS-986326 Dose 3 SC|
62338194|NCT03334669|EXPERIMENTAL|Intervention|"Sites randomized to the intervention group will receive the following:~1. Parents Connect for Healthy Living (PConnect)~2. Enhanced Nutrition Support~3. Media Resources"
61942813|NCT00994929|EXPERIMENTAL|Neumega (Oprelveken, Interleukin 11)|Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
61942814|NCT05669729||VPRIV® Home Infusion|Participants diagnosed with Gaucher disease will receive VPRIV® home infusion, administered by their caregivers and home infusion nurses will participate in the survey and complete the non-nominative web-based questionnaires on Day 1.
61942815|NCT00408460|EXPERIMENTAL|Treatment (enzyme inhibitor, chemotherapy)|Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
61942816|NCT01044251|PLACEBO_COMPARATOR|Placebo|10 days of treatment with placebo in a bid fashion that will look like the study medication.
61942817|NCT01044251|EXPERIMENTAL|Frovatriptan|Frovatriptan 2.5 mg po bid for 10 days
61942818|NCT05772208|EXPERIMENTAL|the combination of camrelizumab and standard treatment|camrelizumab 200mg q3w 2 cycle combinted with the second and third cycle neoajuvant chemotherapy and camrelizumab 200mg q3w 8 cycle starting one month after concurrent chemo-radiotherapy.
61942819|NCT05772208|EXPERIMENTAL|the combination of nimotuzumab and standard treatment|nimotuzumab 200mg qw combined with the second and third cycle neoajuvant chemotherapy and nimotuzumab 200mg qw used during chemo-radiotherapy.
61942820|NCT05772208|ACTIVE_COMPARATOR|standard treatment|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
61942821|NCT03497078|OTHER|Refered patients for scintigraphy|
61942822|NCT04767620|EXPERIMENTAL|study groups|The study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses.
61942823|NCT04767620|NO_INTERVENTION|control groups|The control group was treated with observational treatment and follow-up in outpatient clinic.
61942824|NCT03388931|EXPERIMENTAL|Study group|Increased dose of radiation therapy for locally advanced squamous cell carcinoma of the larynx or hypopharynx. Patients will also receive standard-of-care chemotherapy with the treatment regimen to be determined by the treating physicians.
61942825|NCT05153772|EXPERIMENTAL|Pb212-DOTAMTATE|investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors in PRRT naive patients (Cohort 1) and previous PRRT patients (Cohort 2)
62138743|NCT02928250|PLACEBO_COMPARATOR|Second arm received placebo oral daily|Placebo group or control patients received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
62138744|NCT05948059|EXPERIMENTAL|Part 1: SHR-2106 injection or placebo single dose, iv|
62138745|NCT05948059|EXPERIMENTAL|Part 2: SHR-2106 injection or placebo single dose, sc|
62138746|NCT03664011|EXPERIMENTAL|BI 730357 BS (C-14)|"All participants were administered an oral single dose of 50 milligram (mg) BI 730357 containing \[C-14\] BI 730357 base (BS) (pure 14C-labelled hot drug substance) and BI 730357 BS (unlabelled cold drug substance). This mixture corresponds to the warm substance BI 730357 BS (C-14) containing a radioactive dose of approximately 3.7 MegaBecquerel (MBq), (100 microcurie (µCi)), and was administered in a solution of 10 milliliter (mL) volume with 240 mL of water after an overnight fast of at least 10 hours (h)."
62338195|NCT03334669|NO_INTERVENTION|Control|Control sites will not receive any intervention components (i.e., standard practice).
62338196|NCT04484779|EXPERIMENTAL|IIM System|The IIM system is comprised of an insulin lispro pen and/or an insulin glargine pen (both U-100), an investigational mobile medical application (MMA) that transmits data to cloud storage, an investigational Bluetooth Low Energy® (BLE)-paired insulin data transmission (IDT) module and a compatible commercially available BLE-paired blood glucose meter (BGM).
62338197|NCT02040818|EXPERIMENTAL|Antibiotic Lock Solution|
62338198|NCT02040818|ACTIVE_COMPARATOR|Guide-wire Exchange|
62494952|NCT00160524|EXPERIMENTAL|Certolizumab Pegol|400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.
62494953|NCT00210639||Levofloxacin-treated cohort|Participants receiveing levofloxacin in previous levofloxacin studies will be observed.
62494954|NCT00210639||Comparator-treated cohort|Participants receiveing comparator in previous levofloxacin studies will be observed.
62494955|NCT00396630|EXPERIMENTAL|Rotarix Group|"All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
61942826|NCT06327009||fasting|100 patients who decided to fast the month of ramadan.
61942827|NCT02619669|EXPERIMENTAL|TAK-228 followed by TAK-228 plus Letrozole|"Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.~The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects."
62138747|NCT06060769||HCC group|Patients who develop HCC during follow-up
62138748|NCT06060769||non-HCC group|Patients who did not develop HCC during follow-up
62338199|NCT03349541|EXPERIMENTAL|Complex Care Curriculum Intervention|Paediatric residents who are randomized to the intervention group will participate in the complex care curriculum during an academic half-day prior to the Objective Structured Clinical Examination (OSCE).
62338200|NCT03349541|NO_INTERVENTION|No intervention|Paediatric residents who are randomized to the control group will attend the regular academic half-day unrelated to complex care prior to the Objective Structured Clinical Examination (OSCE).
62494956|NCT00396630|PLACEBO_COMPARATOR|Placebo Group|"All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
62696345|NCT03215160|ACTIVE_COMPARATOR|Classical Exercise Group|only classical exercises performed in the early post-op period
62696346|NCT00712283|PLACEBO_COMPARATOR|D|healthy volunteers
62696347|NCT00712283|ACTIVE_COMPARATOR|C|healthy volunteers
61942828|NCT02121522|EXPERIMENTAL|BI 144807|twice daily
61942829|NCT02499276|EXPERIMENTAL|PSV, PAV, NAVA, Variable-PSV|This is a crossover study in which each patient will be ventilated in the following modes of mechanical ventilation: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilator Assist (NAVA), Proportional assist ventilation (NAVA) and variable Pressure Support Ventilation (Variable-PSV), in a randomised order.
61942830|NCT02770833|EXPERIMENTAL|Salmon vs. veal and CHO with low or high GI|"In the first clinical study (Study 1), subjects will eat salmon or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~* Meat balls with salmon served with tomato sauce and other accompaniments with low GI~* Meat balls with salmon served with tomato sauce and other accompaniments with high GI~* Meat balls with veal served with tomato sauce and other accompaniments with low GI~* Meat balls with veal served with tomato sauce and other accompaniments with high GI"
61942831|NCT02770833|EXPERIMENTAL|Cod vs. veal and CHO with low or high GI|"In the second clinical study (Study 2), subjects will eat codfish or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~* Meat balls with codfish served with tomato sauce and other accompaniments with low GI~* Meat balls with codfish served with tomato sauce and other accompaniments with high GI~* Meat balls with veal served with tomato sauce and other accompaniments with low GI~* Meat balls with veal served with tomato sauce and other accompaniments with high GI"
61942832|NCT05207254||difficult airway|C-L≥3 grade
61942833|NCT05207254||none difficult airway|C-L\<3 grade
61942834|NCT04599829||Orthosis Group 1|Use of AnkleSTRONG100 device
61942835|NCT04599829||Control Group 1|Control Group of the AnkleSTRONG100 Orthosis Group - No use of the device
61942836|NCT04599829||Orthosis Group 2|Use of AnkleSTRONG500 device
61942837|NCT04599829||Control Group 2|Control Group of the AnkleSTRONG500 Orthosis Group - No use of the device
61942838|NCT04599829||Orthosis Group 3|Use of AnkleSTRONG900 device
61942839|NCT04599829||Control Group 3|Control Group of the AnkleSTRONG900 Orthosis Group - No use of the device
61942840|NCT04263831|EXPERIMENTAL|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be two dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 1.0x10\^6 IU/m\^2/day. Cohort 2: 1.25x10\^6 IU/m\^2/day."
61942841|NCT05444101|NO_INTERVENTION|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
61942842|NCT05444101|EXPERIMENTAL|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
61942843|NCT05444101|EXPERIMENTAL|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
61942844|NCT05444101|EXPERIMENTAL|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
62696348|NCT00712283|ACTIVE_COMPARATOR|B|healthy volunteers
61942845|NCT05444101|EXPERIMENTAL|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component in different orders. Total number of sessions: 4 (4 contact hours).
61942846|NCT05444101|EXPERIMENTAL|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component in different orders. Total number of sessions: 4 (4 contact hours).
61942847|NCT05444101|EXPERIMENTAL|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component in different orders. Total number of sessions: 4 (4 contact hours).
61942848|NCT05444101|EXPERIMENTAL|Mindful attention + Decentering + Values and committed action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component in different orders. Total number of sessions: 6 (6 contact hours).
61942849|NCT04686604|EXPERIMENTAL|Electron Health Record-based Provider Alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
62338201|NCT06124547|EXPERIMENTAL|Reference group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
62696349|NCT00712283|ACTIVE_COMPARATOR|A|healthy volunteers
61942850|NCT04686604|NO_INTERVENTION|Usual Care|Providers will not receive an alert and will proceed with usual care.
62138749|NCT01232959|EXPERIMENTAL|Transvaginal Surgery|Gallbladder will be removed through the vagina
62138750|NCT04381949|NO_INTERVENTION|Standard extubation Arm|
62138751|NCT04381949|EXPERIMENTAL|Positive pressure extubation arm|
62338202|NCT06124547|EXPERIMENTAL|Test group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
62696350|NCT05838248|ACTIVE_COMPARATOR|under 65 years simple appendicitis restricted duration|simple appendicitis restricted duration of no postop antibiotics
62696351|NCT05838248|ACTIVE_COMPARATOR|Under 65 simple appendicitis liberal duration|simple appendicitis liberal duration of 24 hours postop antibiotics
62696352|NCT05838248|ACTIVE_COMPARATOR|Under 65 complex appendicitis restricted duration|complex appendicitis restricted duration of 24 hours postop antibiotics
61942851|NCT05474235||ALS or Suspected ALS Patient|Subjects with clinical diagnosis of possible, laboratory-supported probable, probable or definite, ALS or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features or a blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features.
61942852|NCT05474235||Blood Relative of ALS Patient|Subjects with family history (first, second or third degree blood relative) of ALS or other motor neuron disease.
61942853|NCT05474235||Healthy Control|Subjects with no personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease
61942854|NCT06544122|ACTIVE_COMPARATOR|Effects on voice of M1 tDCS in healthy voice volunteers|The aim of this arm is to verify the effect on the voice of anodal tDCS M1 larynx target.
61942855|NCT06544122|ACTIVE_COMPARATOR|Effects on voice of S1 tDCS in vocally health volunteers|The aim of this arm is to verify the effect on the voice of anodal tDCS S1 larynx target.
61942856|NCT06544122|ACTIVE_COMPARATOR|Effects on voice of PFDLC tDCS in vocally health volunteers|The aim of this arm is to verify the effect on the voice of anodal tDCS PFDLC target.
61942857|NCT06544122|ACTIVE_COMPARATOR|Effects on voice of cerebellum tDCS in vocally health volunteers|The aim of this arm is to verify the effect on the voice of anodal tDCS cerebellum target.
61942858|NCT03274232|EXPERIMENTAL|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
61942859|NCT03926871|EXPERIMENTAL|Novices|They received ergonomic training after 1-2 days of hiring to do the work in the cutting room, and packaging sectors. They did not have experience in the refrigerator or butchers, so they had the minimum of information about tasks and risks.
61942860|NCT03926871|EXPERIMENTAL|Experienced|They received the same ergonomic training as the newbies, and should have been hired for more than 6 months in the company. In this period they had already acquired patterns of movement and self-protection to accomplish the tasks.
61942861|NCT03025009|EXPERIMENTAL|LY3192767 (Part A)|Escalating doses of LY3192767 administered subcutaneously (SC).
61942862|NCT03025009|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo matching LY3192767 administered subcutaneously (SC).
61942863|NCT03025009|EXPERIMENTAL|LY3192767 (Part B)|LY3192767 administered as a SC injection in one of three study periods.
61942864|NCT03025009|ACTIVE_COMPARATOR|Basal Insulin Peglispro (Part B)|Basal insulin peglispro administered as a SC injection in one of three study periods.
61942865|NCT03025009|ACTIVE_COMPARATOR|Insulin Glargine (Part B)|Insulin glargine administered as a SC injection in one of three study periods.
62138752|NCT00837954|ACTIVE_COMPARATOR|1|distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
62138753|NCT00837954|ACTIVE_COMPARATOR|2|distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
62138754|NCT00837954|ACTIVE_COMPARATOR|3|distal and proximal Anastomosis Lyostypt®
62138755|NCT00837954|ACTIVE_COMPARATOR|4|distal and proximal Anastomosis Surgicel®
62138756|NCT03328364||enzalutamide (mCRPC pre-chemo)|Patients treated with enzalutamide prior to chemotherapy
62138757|NCT03328364||enzalutamide and chemotherapy (mCRPC post chemo)|Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
62138758|NCT06664021|EXPERIMENTAL|Treatment group|Tislelizumab + S-1
62494957|NCT02946255|EXPERIMENTAL|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
62696353|NCT05838248|ACTIVE_COMPARATOR|Under 65 complex appendicitis liberal duration|complex appendicitis liberal duration of 4 days of postop antibiotics
62696354|NCT05838248|ACTIVE_COMPARATOR|Over 65 simple appendicitis restricted antibiotic duration|see above for under 65
62338203|NCT04912570|EXPERIMENTAL|Manual Thrombus Aspiration|Manual Thrombus aspiration in STEMI patients with Heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
62338204|NCT04912570|ACTIVE_COMPARATOR|Standard PCI|Conventional PCI according to the most recent guidelines in STEMI patients with no heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
62338205|NCT03445858|EXPERIMENTAL|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
62338206|NCT04713566|EXPERIMENTAL|Group A|will be using Salvadora Persica oral rinse
62338207|NCT04713566|EXPERIMENTAL|Group B|will be using Commercial Phenolic mouthwash.
62696355|NCT05838248|ACTIVE_COMPARATOR|Over 65 simple appendicitis liberal antibiotic duration|see above for under 65
62696356|NCT05838248|ACTIVE_COMPARATOR|Over 65 complex appendicitis restricted antibiotic duration|see above for under 65
62696357|NCT05838248|ACTIVE_COMPARATOR|Over 65 appendicitis liberal antibiotic duration|see above for under 65
62696358|NCT02801578|EXPERIMENTAL|Ibrutinib|"Participants take Ibrutinib capsules by mouth every day for 3, 28 day cycles.~During Cycle 1, participants receive the highest dose of Ibrutinib by taking 3 capsules each day. During Cycle 2, participants receive the second-highest dose and will take 2 capsules each day. During Cycle 3, participant takes the lowest dose of Ibrutinib and takes 1 capsule each day."
62696359|NCT05236023|NO_INTERVENTION|Control group|Group receiving care as usual before the intervention takes place
62696360|NCT05236023|EXPERIMENTAL|Intervention group|Group receiving zero separation and couplet care
62696361|NCT01923038|ACTIVE_COMPARATOR|Patients ventilated with zero end expiratory pressure (ZEEP)|patients undergoing gynecologic laparoscopic surgery ventilated at zero end expiratory pressure
62696362|NCT01923038|ACTIVE_COMPARATOR|Patients ventilated with positive end expiratory pressure|patients undergoing gynecologic laparoscopic surgery ventilated at PEEP
62696363|NCT01923038|ACTIVE_COMPARATOR|recruitment plus PEEP|patients undergoing gynecologic laparoscopic surgery undergoing recruitment plus PEEP
61942866|NCT01026922||SmartPill Participants|It is a single-center study, children aged 8-17 years with severe upper GI symptoms (ie, nausea, vomiting, retching, abdominal pain) referred for antroduodenal manometry (ADM) studies underwent a wireless motility capsule (smartpill) test. The scintigraphic gastric emptying study was done when clinically indicated either at the time of the ADM or at a different time within 1 year of the wireless motility capsule test. In summary, we studied symptomatic adolescents using scintigraphic gastric emptying studies, ADM, and the wireless motility capsule test, with the goal of identifying the diagnostic yield of each test and exploring how they compare in detecting motor abnormalities in the GI tract.
61942867|NCT03974360|EXPERIMENTAL|Erenumab|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
61942868|NCT02547324|EXPERIMENTAL|Slump sitting|Slump sitting flexion of lumbar spine
61942869|NCT02547324|ACTIVE_COMPARATOR|Forward bending|Forward erect bending of lumbar spine
61942870|NCT04958772|EXPERIMENTAL|Filgrastim Megalabs|Filgrastim Megalabs injectable 5 μg/Kg/day in a single subcutaneous application during 5 days
61942871|NCT04958772|ACTIVE_COMPARATOR|Granulokine|Granulokine injectable 5 μg/Kg/day in a single subcutaneous application during 5 days
61942872|NCT02969330|EXPERIMENTAL|Glucose|Glucose ingestion
62696364|NCT02244398|EXPERIMENTAL|FP and HTC services|VHTs in the intervention arm provide both family planning and HTC services between May 2012 and September 2013, then return to providing family planning only at the end of the project. Services are made available to all adults in VHTs' communities. HIV testing is done using the national rapid testing algorithm. Clients who test positive for HIV are referred to a health center for care and treatment and receive disclosure support and information on peer support groups.
62696365|NCT02244398|ACTIVE_COMPARATOR|FP services|VHTs in the control arm only provide family planning services.
61942873|NCT02969330|ACTIVE_COMPARATOR|PES|Single session of short PES treatment before glucose ingestion.
61942874|NCT05180617|EXPERIMENTAL|Individual music therapy (IMT)|"After baseline measures, each Participant will receive 6 x 1 weekly hour of music therapy. During music therapy the participants will be interacting both musically and verbally with the therapist.~Participants will be provided with both acoustic and electronic instruments to be able to improvise with the therapist. In addition, IMT participants will be provided with the opportunity to compose and write songs, take part in preferred music lyric analysis, sing and discuss/talk with the therapist.~During session 2 and 5 EEG hyperscanning of therapist and patient will be applied.~All 5 IMT participants will do the same pre-post intervention test battery."
61942875|NCT05180617|EXPERIMENTAL|Group music therapy (GMT)|"During 6 x 1 weekly hour of GMT, 5 participants will be invited to take part in a range of group music making activities.~Participants will be provided with both acoustic and electronic instruments to be able to improvise within the group setting. In addition, GMT participants will be provided with the opportunity to compose and write songs as a group, take part in preferred music lyric analysis, sing and take part in group discussions.~All 5 GMT participants will do the same pre-post intervention test battery."
61942876|NCT05180617|NO_INTERVENTION|Control Group|"CG will receive standard treatment, which includes key work sessions, other group work programmes and clinical support (e.g. prescribing).~All 5 CG participants will do the same pre-post intervention test battery."
61942877|NCT06231732|ACTIVE_COMPARATOR|treatment arm|The frequency of the stimulation was 77.5Hz and the intensity was 15mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
61942878|NCT06231732|SHAM_COMPARATOR|sham-treatment arm|The frequency of the stimulation was 77.5Hz and the intensity was 0mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
61942879|NCT00516074|EXPERIMENTAL|Exenatide Arm|This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
61942880|NCT00516074|PLACEBO_COMPARATOR|Placebo Arm|This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
62338208|NCT01217255||Brazilian Subject's|Subject's will be recruited from the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paolo (HCFMUSP); Universidade Estadual de Campinas (UNICAMP); Universidade Federal de São Paulo (UNIFESP)
62338209|NCT01217255||Canadian Subject's|Recruited from The Hospital for Sick Children
62696366|NCT06294587|EXPERIMENTAL|FGG before GBR|Free Gingival Graft(FGG) before the guided bone regeneration(GBR)
62696367|NCT06294587|EXPERIMENTAL|FGG after GBR|Free Gingival Graft(FGG) after the guided bone regeneration(GBR)
61942881|NCT04043273||Whole cohort|The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment
61942882|NCT03252119|NO_INTERVENTION|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
61942883|NCT03252119|EXPERIMENTAL|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
61942884|NCT03402113|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine consistent infusion as sedative.
62338210|NCT00991380|EXPERIMENTAL|Lifestyle counselling|
62338211|NCT00991380|ACTIVE_COMPARATOR|Usual Care|
62338212|NCT05067062|ACTIVE_COMPARATOR|new zealand blackcurrant extract|Capsules will be take daily or every other day.
61942885|NCT03402113|ACTIVE_COMPARATOR|Midazolam group|Midazolam consistent infusion as sedative.
61942886|NCT01919671|EXPERIMENTAL|Tongxinluo capsule|Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
62696368|NCT05137158|EXPERIMENTAL|iTBS stimulation|The patients in iTBS stimulation group will receive iTBS stimulation on the target of the left dorsolateral prefrontal cortex for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
62696369|NCT05137158|SHAM_COMPARATOR|Sham stimulation|The participants in sham stimulation will receive sham stimulation, as the coil vertical to the brain surface, for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
62696370|NCT05548283|OTHER|β-lactam Only (Non-AG)|Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam as selected by their treating physician. Treatment must not include an IV aminoglycoside.
62138759|NCT05513365|EXPERIMENTAL|Combined androgen blockade (CAB) + dutasteride|Patients from cohort B (ADT-resistant) will receive CAB+dutasteride.
62494958|NCT02946255|EXPERIMENTAL|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
62494959|NCT02946255|ACTIVE_COMPARATOR|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
62494960|NCT01978964|EXPERIMENTAL|ONT-10 Vaccine|
62494961|NCT05799235|EXPERIMENTAL|Telerehabilitation TAR program using a mobile application (intervention group)|Participants in the intervention group will undergo the telerehabilitation TAR program and install and utilise the application on their mobile device, and self-administer the home exercises as prescribed by their physiotherapists. The mobile application uses novel deep learning algorithm on a mobile platform to detect key landmarks on the body for human pose estimation. Participants will be able to perform their rehabilitation exercise with real-time feedback allowing for proper execution of the exercises. The participants will be instructed on the installation and use of the mobile application and will be expected to perform the prescribed exercises independently (using the application) as instructed by their Physiotherapists. This application will be used for the initial 12 weeks of post-op rehabilitation.
62696371|NCT05548283|OTHER|β-lactam and Aminoglycoside (AG)|Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam and aminoglycoside selected by their treating physician.
61942887|NCT01919671|PLACEBO_COMPARATOR|placebo capsule|placebo capsule,4 granules,t.i.d. po,for 90 days
61942888|NCT06560684|EXPERIMENTAL|Group A|Those participants assigned to Group A will start with the rectal TFV 660 mg douche for the first 8 weeks (Period 1) and then after a 2-4 week washout will switch to the on-demand oral F/TDF 200 mg/300 mg sequence for the next 8 weeks (Period 2).
61942889|NCT06560684|EXPERIMENTAL|Group B|Those participants assigned to Group B will start with the on-demand oral F/TDF 200 mg/300 mg sequence for 8 weeks and then after a 2-4 week washout will switch to the rectal TFV 660 mg douche for the next 8 weeks (Period 2).
61942890|NCT05534529|EXPERIMENTAL|Rezafungin|It is IMP.
61942891|NCT03378661|EXPERIMENTAL|BZN STD Regimen|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
62338213|NCT05067062|PLACEBO_COMPARATOR|control|no capsules will be provided.
62338214|NCT02701686|EXPERIMENTAL|quit immediately (QI)|Subjects in the QI group will receive a smoking cessation booklet plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit now, as quitting can greatly reduce risks, (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention during each telephone follow-up. The whole intervention will be limited to less than 1 min or slightly longer if necessary. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the counsellor will congratulate to the subjects who successfully quit smoking, while deliver the same brief intervention as a booster for those who continue to smoke.
62338215|NCT02701686|EXPERIMENTAL|cut down to quit (CDTQ)|Subjects in the CDTQ group will also receive the smoking cessation booklet plus a brief intervention using the AWARD model. Instead of asking them to quit immediately, they will be advised gradually cutting down on their cigarette consumption. Also, the subjects will be provided with an education card that contains reduction strategies and a suggested plan to reduce smoking. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the nurse counsellor will repeat the warning message that one out of two smokers will be killed by smoking, and remind the subjects of their next reduction target. The counsellor will congratulate subjects who quit or reduce smoking on their success. When subjects fail to quit or reduce their cigarette consumption, the counsellor will reinforce the health hazards of continued smoking and the benefits of quitting, and encourage them to try again immediately or in the near future.
62338216|NCT01091935||Lidocaine|"Adults \>18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes~Consecutive patients from two time periods:~1. June 15 to August 21, 2009~2. October 15-Dec 22,2009"
62338217|NCT01322685||Health Group|
62338218|NCT01322685||Tuberculosis Group|Tuberculosis or lung cancer group
62696372|NCT05163639|EXPERIMENTAL|1. Uninjured participants - Immediate and lasting effects of non-invasive paired stimulation|Participants will take part in the following to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
61942892|NCT03378661|EXPERIMENTAL|BZN 300 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
62138760|NCT05623436|EXPERIMENTAL|Experimental|"Ventrogluteal injection training given by virtual reality technology is effective in increasing the knowledge and skill levels of students. It also has an impact on students' motivation and anxiety levels.~Intervention: Behavioral: Education"
62138761|NCT05623436|NO_INTERVENTION|Control|Ventrogluteal injection training given by virtual reality technology doesn't effective in increasing the knowledge and skill levels of students. It also hasn't an impact on students' motivation and anxiety levels.
62138762|NCT06064669|EXPERIMENTAL|Metformin-Metformin Group|Metformin pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by metformin pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
62138763|NCT06064669|EXPERIMENTAL|Metformin-Placebo Group|Metformin pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by placebo pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
62696373|NCT05163639|EXPERIMENTAL|2. Intraoperative participants - Immediate effects of paired stimulation|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Intraoperative pairing of cortical and spinal stimulation.
62696374|NCT05163639|EXPERIMENTAL|3. Intraoperative participants - Lasting effects of SCAP|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP).
62696375|NCT05163639|EXPERIMENTAL|4. Chronic cervical SCI participants - Lasting effects of non-invasive SCAP|Participants with chronic cervical SCI will take part in the following, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
61942893|NCT03378661|EXPERIMENTAL|BZN 300 mg - 2 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
61942894|NCT03378661|EXPERIMENTAL|BZN 150 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
62138764|NCT06064669|EXPERIMENTAL|Placebo-Metformin Group|Placebo pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by metformin pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
62338219|NCT03114306|EXPERIMENTAL|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
61942895|NCT03378661|EXPERIMENTAL|BZN 150 mg - 4 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
62138765|NCT06064669|EXPERIMENTAL|Placebo-Placebo Group|Placebo pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by placebo pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
62138766|NCT02490956|EXPERIMENTAL|Rabies vaccination|"* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
62138767|NCT05048186||Decision Aid Arm|Participants in this arm will review educational material from the ADHD Decision Aid developed by the Cincinnati Children's Hospital Medical Center.
62138768|NCT05048186||Control Arm|Participants in this group will not receive any educational materials.
62138769|NCT02717611|EXPERIMENTAL|ACP-196 (acalabrutinib)|ACP-196 (acalabrutinib) 100 mg to be administered orally (PO) twice a day BID
62138770|NCT00767741|EXPERIMENTAL|with treatment|
62338220|NCT03114306|ACTIVE_COMPARATOR|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
62338221|NCT03025334|SHAM_COMPARATOR|Sham tDCS|sham tDCS (30sec ramp-up and 3sec ramp-down)
62338222|NCT03025334|ACTIVE_COMPARATOR|Real tDCS right|Real anodal tDCS (right DLPFC)
62338223|NCT03180359|EXPERIMENTAL|Patient already transplanted or waiting for a transplantation|
62338224|NCT04811469|EXPERIMENTAL|CBP-174|CBP-174 oral solution
62338225|NCT04811469|EXPERIMENTAL|Placebo|placebo oral solution
62338226|NCT02170805|EXPERIMENTAL|Substudy 1|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~1. BIBR 1048 MS capsule formulation A without pantoprazole;~2. BIBR 1048 MS capsule formulation A with coadministration of 40 mg pantoprazole (bid);~3. BIBR 1048 MS powder plus solution without pantoprazole"
62138771|NCT04840316||Post operative|Nil Intervention - observational cohort study
62138772|NCT04195919|EXPERIMENTAL|Group1|Hemodialysis patients(MDRD-eGFR ≤ 15 mL/min/1.73m2)
62138773|NCT04195919|EXPERIMENTAL|Group2|Healthy control(MDRD-eGFR ≥ 90 mL/min/1.73m2)
62138774|NCT05878288|OTHER|Cemiplimab|Cemiplimab 350 mg intravenously every 3 weeks for up to 12 weeks (up to 4 doses), or until unacceptable toxicity, disease progression, or withdrawal of consent.
62138775|NCT05240300|EXPERIMENTAL|BX005-A|twice daily topical application x 8 weeks
62138776|NCT05240300|PLACEBO_COMPARATOR|Vehicle|twice daily topical application x 8 weeks
62138777|NCT01737749||Patients undergoing cardiac surgery|
62138778|NCT03363529|PLACEBO_COMPARATOR|Standard|This study arm utilizes a standard lighting condition in the patient room
62138779|NCT03363529|EXPERIMENTAL|Dynamic|This study arm utilizes a dynamic lighting from special designed lightfixtures in the ceiling and window sill.
62138780|NCT02238769||Hepatocellular Carcinoma|18F-FluoroethylCholine PET will show the difference between HCC lesions and normal liver tissue
62138781|NCT02933294|ACTIVE_COMPARATOR|Triportal pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
62338227|NCT02170805|EXPERIMENTAL|Substudy 2|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~1. BIBR 1048 MS capsule formulation B without pantoprazole;~2. BIBR 1048 MS capsule formulation B with coadministration of 40 mg pantoprazole (bid);~3. BIBR 1048 MS powder plus solution without pantoprazole"
62338228|NCT02406768||HIV negative unexposed|HIV negative controls
62338229|NCT02406768||HIV negative exposed|HIV-negative children born to HIV-infected mothers
62494962|NCT05799235|ACTIVE_COMPARATOR|Standard rehabilitation (control group)|Participants in the control group will attend standard in person rehabilitation sessions at the outpatient clinic. Participants will be prescribed a home exercise program as per standard care.
62494963|NCT05634941|ACTIVE_COMPARATOR|Active ON-tDCS|The active group will receive the active transcranial direct current stimulation via a saline-soaked pair of surface sponges. Patients received this treatment protocol for 5 consecutive days.
62696376|NCT05163639|EXPERIMENTAL|5. Intraoperative participants - Lasting effects of SCAP at or below myelopathic region|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region.
61942896|NCT03378661|EXPERIMENTAL|BZN 300 mg (weekly) 8 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
62338230|NCT00318903|EXPERIMENTAL|Taxotere/Irinotecan|Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
62338231|NCT00296725|EXPERIMENTAL|fluoxetine / Imipramine|fluoxetine or Imipramine
62338232|NCT01996306|ACTIVE_COMPARATOR|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
61942897|NCT03378661|PLACEBO_COMPARATOR|Placebo|"Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
61942898|NCT04930822|ACTIVE_COMPARATOR|Table Top Visual Intervention|Interventions will include six, 20 minute sessions using pen and paper word search, scanning activities, and saccade visual training. All activities will be conducted with an occupational therapist/investigator.
62338233|NCT01996306|EXPERIMENTAL|XELIRI +/- Bevacizumab|Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively
62338234|NCT05092399||RYGB|Patients undergoing Roux-en-Y gastric bypass surgery
62338235|NCT05092399||SG|Patients undergoing Sleeve Gastrecomy surgery
62338236|NCT05214898||Immediate Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
62338237|NCT05214898||Delayed-Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
62338238|NCT05960019|EXPERIMENTAL|Fermented milk product|Dietary supplement (Maziwa Mala) This is a type of cultured dairy milk, that is prepared through mesophilic fermentation of milk that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
61942899|NCT04930822|EXPERIMENTAL|Bioness Integrated Therapy System Visual Intervention|Intervention will includes six sessions using the Bioness Integrated Therapy System for 20 minutes using the programs of visual scanning, visual pursuits and/or visual motor.All activities will be conducted with an occupational therapist/investigator.
61942900|NCT04925908||Control Group|Infants of mothers with suspected but negative for COVID-19
61942901|NCT04925908||Case Group|Infants Born to COVID-19 positive mothers
61942902|NCT03970642|EXPERIMENTAL|Intervention group|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will receive the video directly observed therapy smartphone app. Research staff will be able to monitor these medication adherence video on a password protected server linked to the app. Upto 50 patients will be randomly assigned to this group.
61942903|NCT03970642|NO_INTERVENTION|Control|The control group will receive current standard of care. Upto 50 patients will be randomly assigned to this group.
61942904|NCT06180746|EXPERIMENTAL|ECEMSo intervention|This group is composed of health mediators, the people living in informal housing they support and stakeholders. The ECEMSo intervention will be implemented in this group
61942905|NCT06180746|NO_INTERVENTION|Group 2 : No intervention|This group is composed of health mediators, the people living in informal housing they support and stakeholders. The ECEMSo intervention will not be implemented in this group.
61942906|NCT06180746|NO_INTERVENTION|Group 3 : No intervention|This group is composed of health workers, social workers, the people living in informal housing they support and stakeholders. The ECEMSo intervention will be implemented in this group.
61942907|NCT03643354|EXPERIMENTAL|Evaluation of prevalence of BPPV|Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device.
61942908|NCT00804622|ACTIVE_COMPARATOR|1|tenofovir disproxil fumarate 300 mg monotherapy
62338239|NCT05960019|EXPERIMENTAL|Fermented cereal based porridge|Dietary supplement (Uji) This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
62696377|NCT06459804|EXPERIMENTAL|Group A: Electro Dry Needling|Group A: will receive Electro Dry Needling along with conventional physiotherapy. The parameters for Electro dry needling will be needles of 30×0.25 mm, 50×0.25 mm sizes, Frequency 80-100 Hz, Duration 10-20 minutes and intensity as tolerated.
61942909|NCT00804622|ACTIVE_COMPARATOR|2|telbivudine 600 mg monotherapy
62696378|NCT06459804|ACTIVE_COMPARATOR|Group B: Dry Needling|Group B will receive Dry Needling along with conventional Physiotherapy in which parameters will be dry needles will be 30×0.25 and 50×0.25 mm sizes, Frequency 80-100 Hz, Duration 10-20 minutes and intensity as tolerated.
62696379|NCT02886962|EXPERIMENTAL|No anticoagulation|No oral anticoagulation, and no monitoring of the INR.
62696380|NCT02886962|ACTIVE_COMPARATOR|Oral anticoagulation with vitamin K antagonists|"VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.~Antiplatelet therapy will be provided only if recent acute coronary syndrome (\< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population."
62338240|NCT05960019|ACTIVE_COMPARATOR|Standard of Care|Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the participants prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
62338241|NCT05876858|EXPERIMENTAL|PET/CT scans|Each subject will undergo a dynamic 18F-FDG PET/CT scan and a dynamic 11C-butanol PET/CT scan on the EXPLORER total-body PET/CT system
62338242|NCT02537379||SOF+COPE|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
62494964|NCT05634941|SHAM_COMPARATOR|Sham ON-tDCS|The sham group will also receive the transcranial direct current stimulation for 5 consecutive days on sham procedure. The rationale behind this sham procedure was to mimic the transient skin sensation at the beginning of active ON-tDCS without producing any conditioning effects on the brain.
62494965|NCT00916045|OTHER|Myeloblative conditioning regimen|
62696381|NCT05967169|EXPERIMENTAL|Cohort 1|Index Procedure in OR, placement of one implant
62696382|NCT05967169|EXPERIMENTAL|Cohort 2|Index Procedure in office or OR, placement of one implant
61942910|NCT00804622|ACTIVE_COMPARATOR|3|telbivudine 600 mg and tenofovir disproxil fumarate 300 mg
61942911|NCT03029442|EXPERIMENTAL|Denosumab, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
61942912|NCT03029442|PLACEBO_COMPARATOR|Placebo, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
61942913|NCT03029442|EXPERIMENTAL|Denosumab, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
61942914|NCT03029442|PLACEBO_COMPARATOR|Placebo, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
61942915|NCT01976195|EXPERIMENTAL|Thalidomide plus HD-Dexmamethasone|Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
61942916|NCT01976195|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
62138782|NCT02933294|ACTIVE_COMPARATOR|Uniportal pulmonary resection surgery|Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
62338243|NCT04496440||Trial Group|Contracture correction therapy
62338244|NCT04496440||Control Group|No new intervention, patients continued with the previous treatment.
62494966|NCT00916045|OTHER|Reduced intensity conditioning regimen - FluCyTBI|
61942917|NCT01372228|EXPERIMENTAL|Inherited Metabolic Disorder Patients|Recipients are treated with hematopoietic stem cell infusion from living donors
62338245|NCT06279130|EXPERIMENTAL|pMMR Safety run-in 1|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 25mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
62338246|NCT06279130|EXPERIMENTAL|pMMR Safety run-in 2|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 50mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
62338247|NCT06279130|EXPERIMENTAL|dMMR Safety run-in 1|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 25mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
62338248|NCT06279130|EXPERIMENTAL|dMMR Safety run-in 2|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 50mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
62494967|NCT00916045|OTHER|Reduced intensity conditioning regimen - FluMel|
62494968|NCT01837537||no treatment|no treatment, prospective observational
62494969|NCT02002130|PLACEBO_COMPARATOR|Placebo GABA and Placebo GAD-alum|"Placebo formulation, Maltodextrin, for Gamma-Amino Butyric Acid (GABA) capsule-identical in appearance and taste, but no active medication will be taken with meals.Number of pills based on body surface area.~Placebo GAD-alum(Glutamic Acid Decarboxylase in alum) injection- identical in appearance but no active medication will be received at baseline and 1 month."
62696383|NCT05967169|EXPERIMENTAL|Cohort 3|Index Procedure in OR, placement of up to two implant
62696384|NCT00396370|EXPERIMENTAL|Group A: BCG ID/Placebo PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): Placebo ID/Placebo PO.
62696385|NCT00396370|EXPERIMENTAL|Group B: BCG ID/Placebo PO; BCG ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): BCG ID (Danish)/Placebo PO.
61942918|NCT05836181|EXPERIMENTAL|Eye Movement Desensitization and Reprocessing intervention|The goal of EMDR is to help manage physical and mental unpleasant experiences due to hypertension. The intervention group received EMDR therapy included eight phases, each lasting 60-90 minutes, and the intervention consisted of four weekly. In this study, a Nurse practitioner trained in EMDR performs an intervention in an outpatient clinic's quiet, empty room.
61942919|NCT05836181|NO_INTERVENTION|Eye Movement Desensitization and Reprocessing control|The control group received routine care and treatment as usual. They did not receive EMDR intervention or counseling.
61942920|NCT02556658|EXPERIMENTAL|Smartpilot View group|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
61942921|NCT02556658|ACTIVE_COMPARATOR|Control group|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
61942922|NCT03002363|EXPERIMENTAL|Video Modeling Intervention|The intervention group receives a video that is a behavior modeling video that walks through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment.
61942923|NCT03002363|PLACEBO_COMPARATOR|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
61942924|NCT02147184||SSRI Group|Participants within one month of starting an SSRI
61942925|NCT02147184||Unmedicated Group|No treatment with SSRIs
61942926|NCT04242550|EXPERIMENTAL|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT with executive function training, enhancing CBT with a focus on teaching compensatory strategies, habit learning, and plan for generalization to real-world behaviors.
61942927|NCT04242550|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
61942928|NCT05147935|EXPERIMENTAL|Specialist Palliative Care|All patients will be assigned to receive the intervention, consisting of two outpatient palliative care visits at Vanderbilt University Medical Center (VUMC).
61942929|NCT00353665|EXPERIMENTAL|1 - active|memantine + riluzole
61942930|NCT00353665|PLACEBO_COMPARATOR|2|riluzole + placebo
61942931|NCT03352479|OTHER|Opioids Prescribed|Each participant in the study will be given an envelope for return of unused opioids. The percentage of returned number of opioids will be calculated based on the number prescribed
61942932|NCT06680128|EXPERIMENTAL|Test group 1-1 (GBP560-A)|Low dose level(3µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.
61942933|NCT06680128|EXPERIMENTAL|Test group 1-2 (GBP560-B)|Low dose level (3µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.
61942934|NCT06680128|EXPERIMENTAL|Test group1-3 (GBP560-A)|Mid dose level (15µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.
61942935|NCT06680128|EXPERIMENTAL|Test group1-4 (GBP560-B)|Mid dose level (15µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.
61942936|NCT06680128|EXPERIMENTAL|Test group1-5 (GBP560-A)|High dose level (50µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.
61942937|NCT06680128|EXPERIMENTAL|Test group1-6 (GBP560-B)|High dose level (50µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.
61942938|NCT06680128|ACTIVE_COMPARATOR|Control group1 (IXIARO®)|Participants will receive 2 doses of one of the active comparators (IXIARO®, 6 Antigen Unit, corresponding to a potency of ≤ 460 ng ED) at 4-week intervals, respectively in Stage 1 and Stage 2.
61942939|NCT06680128|ACTIVE_COMPARATOR|Control group2 (IMOJEV®)|Participants will receive 1 dose of placebo saline and 1 dose of another active comparator (IMOJEV®, 4.0 - 5.8 log PFU) at 4-week intervals, respectively in Stage 1 and Stage 2.
61942940|NCT06680128|EXPERIMENTAL|Test group 2-1 (GBP560-A or B)|"Participants will receive 2 intramuscular injections of the test vaccines in stage 2.~1st will be on Visit 2 and 2nd will be on Visit 5, in line with the selected dose regimen in stage 1."
61942941|NCT06680128|EXPERIMENTAL|Test group 2-2 (GBP560-A or B)|"Participants will receive 2 intramuscular injections of the test vaccines in stage 2.~1st will be on Visit 2 and 2nd will be on Visit 5, in line with the selected dose regimen in stage 1."
61942942|NCT00729287|PLACEBO_COMPARATOR|Arm I|Patients receive oral placebo daily in addition to standard care.
62696386|NCT00396370|EXPERIMENTAL|Group C: Placebo ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
62696387|NCT00396370|EXPERIMENTAL|Group D: Placebo ID/BCG PO; Placebo ID/BCG PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/BCG PO (Danish).
61942943|NCT00729287|EXPERIMENTAL|Arm II|Patients receive oral selenium daily in addition to standard care.
61942944|NCT01549600|EXPERIMENTAL|psyllium|5.1 g psyllium husk in at least 8 ounces of water
61942945|NCT01549600|ACTIVE_COMPARATOR|Microcrsytalline Cellulose|1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day
61942946|NCT02250859|EXPERIMENTAL|FMX101 Minocycline 4% foam|FMX101, 4% applied to the face, upper chest, upper back and shoulders for sixsteen consecutive days in subjects either with acne or with normal skin
61942947|NCT03601078|EXPERIMENTAL|Cohort 1: BB2121 in relapsed and refractory multiple myeloma participants|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy
61942948|NCT03601078|EXPERIMENTAL|Cohort 1b: BB2121 with talquetamab in relapsed and refractory multiple myeloma participants|
61942949|NCT03601078|EXPERIMENTAL|Cohort 2a: BB2121 in multiple myeloma with Autologous stem cell transplantation participants|
61942950|NCT03601078|EXPERIMENTAL|Cohort 2b: BB2121 in multiple myeloma without Autologous stem cell transplantation participants|
61942951|NCT03601078|EXPERIMENTAL|Cohort 2c: BB2121 in multiple myeloma participants with inadequate response post ASCT|
61942952|NCT03601078|EXPERIMENTAL|Cohort 3: BB2121 with lenalidomide maintenance in newly diagnosed multiple myeloma|
61942953|NCT00599950|EXPERIMENTAL|1|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
62696388|NCT00396370|EXPERIMENTAL|Group E: BCG ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
62696389|NCT00396370|EXPERIMENTAL|Group F: BCG ID/BCG PO; BCG ID/BCG PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): BCG ID (Danish)/BCG PO (Danish).
62696390|NCT00396370|EXPERIMENTAL|Group G: Connaught strain BCG ID|Primary vaccination: Connaught strain BCG ID; secondary vaccination (1 year later): none.
62338249|NCT06279130|EXPERIMENTAL|dMMR Colorectal basket|Patients with resectable colon and rectal cancer will be treated with the regimen assesses as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If \>2 major pathological responses are observed accrual will continue to a total of 18 patients.
62338250|NCT06279130|EXPERIMENTAL|dMMR Gynaecological oncology basket|Patients with resectable endometrial, cervical and ovarian cancer will be treated with the regimen assessed as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If \>2 major pathological responses are observed accrual will continue to a total of 18 patients.
62338251|NCT06279130|EXPERIMENTAL|dMMR Upper gastro-intestinal cancer basket|Patients with resectable oesophageal (adenocarcinoma), gastro-oesophageal junction, gastric and small bowel cancer will be treated with the regimen assessed as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If \>2 major pathological responses are observed accrual will continue to a total of 18 patients.
62338252|NCT06279130|EXPERIMENTAL|"dMMR other cancers baskets"|Patients with resectable solid tumors of various origins such as but not limited to breast-, prostate-, bladder cancer, Head\&Neck SCC, oesophageal SCC and sarcoma will be treated with the regimen assessed as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If \>2 major pathological responses are observed accrual will continue to a total of 18 patients.
62338253|NCT01797510|EXPERIMENTAL|Coaching|Interventional web based coaching study
62338254|NCT01797510|NO_INTERVENTION|Usual Care|
62338255|NCT04084938|ACTIVE_COMPARATOR|Prostate operation|You will have a surgery to remove the prostate gland. The surgery will be done during general anesthesia. If your prostate gland is small the surgery will be done through a catheter into the penis. If your prostate gland is large the surgery will be through an incision in your lower abdomen.
62338256|NCT04084938|ACTIVE_COMPARATOR|Prostate artery embolization|The embolization is done in the Department of Radiology. There will be placement of a catheter into the artery in one of the groins during local anesthesia. Through this catheter small particles will be injected into the arteries of the prostate gland. When finished, the hole in the artery will be closed.
62338257|NCT04110418|ACTIVE_COMPARATOR|Methylene Blue group (Group MB)|"Methylene Blue is supplied in 1 ml or 10 mL single-dose ampules. Each 1 mL ampule contains 10 mg of methylene blue as a clear dark blue solution~* Any unused product or waste material should be disposed of in accordance with local practice,~* For administration to be diluted before use in a solution of 50 mL 5% Dextrose in Water (D5W) in order to avoid local pain, particularly in the paediatric population. Use the diluted solution immediately after preparation.~* Do not mix with sodium chloride 9 mg/mL (0.9%) solution for injection, because it has been demonstrated that chloride reduces the solubility of methylene blue."
62696391|NCT05605197|EXPERIMENTAL|U87 CAR-T cells|The Patients are enrolled into 2 dose level cohorts in sequence
62696392|NCT06644703|EXPERIMENTAL|Cryotherapy group|After the coronal pulp tissue was completely removed up to the root canal orifice with a high-speed sterile diamond bur under water cooling, hemostasis was achieved within 8 minutes using a cotton pellet moistened with 1% NaOCl. The pulpotomy area was irrigated with 2 °C saline solution for 5 minutes. Then, the pulp chamber was covered with 2-3 mm thick Bio MTA+ (Cerkamed Company, Poland) and composite restoration of the teeth (Clearfil Majesty Posterior, Kuraray Medical Inc, Tokyo, Japan) was completed in the same visit.
62696393|NCT06644703|NO_INTERVENTION|Control group|After the coronal pulp tissue was completely removed up to the root canal orifice with a high-speed sterile diamond bur under water cooling, hemostasis was achieved within 8 minutes using a cotton pellet moistened with 1% NaOCl. Then, the pulp chamber was covered with 2-3 mm thick Bio MTA+ (Cerkamed Company, Poland) and composite restoration of the teeth (Clearfil Majesty Posterior, Kuraray Medical Inc, Tokyo, Japan) was completed in the same visit.
62696394|NCT03686657|NO_INTERVENTION|Healthy adults with NGT|Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.
62696395|NCT03686657|ACTIVE_COMPARATOR|Metformin-Drug naive patients & Patients with inadequate glycemic control with Metformin|Patients receive metformin once daily
61942954|NCT00599950|PLACEBO_COMPARATOR|2|Photorefractive keratectomy (PRK)without mitomycin C.
61942955|NCT02915796|EXPERIMENTAL|G-CSF + CD133(+) cells + PTA|Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty
61942956|NCT02915796|ACTIVE_COMPARATOR|PTA + G-CSF|Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF
62696396|NCT03686657|EXPERIMENTAL|RK-01 Low|Patients receive valsartan, celecoxib and metformin (low dose) once daily
62696397|NCT03686657|EXPERIMENTAL|RK-01 High|Patients receive valsartan, celecoxib and metformin (high dose) once daily
62696398|NCT04591080|EXPERIMENTAL|GUMMETAL TiNbTaZr|"TiNbTaZr (Beta-Titanium) Alloy used to manufacture orthodontic archwires. We will be using an archwire with the size of 0.016 x 0.022"
61942957|NCT02915796|PLACEBO_COMPARATOR|Only PTA|Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection
61942958|NCT01669135|OTHER|Spinal Anesthesia with cerebral oxygen saturation monitoring|The cerebral oxygen saturation of the right and left frontal lobe as well as the thigh oxygen saturation are monitored during spinal anesthesia by means of the near-infrared spectroscopy. Hemodynamic variables were recorded at the same time points.
61942959|NCT05888454|EXPERIMENTAL|Experimental Group|Conventional treatment for T2DM + Integrative Group Program
61942960|NCT05888454|ACTIVE_COMPARATOR|Control Group|Conventional treatment for T2DM
62696399|NCT04591080|ACTIVE_COMPARATOR|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
62696400|NCT01096251|EXPERIMENTAL|CBT|CBT group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of CBT) plus 8 outpatient telephone-based sessions of CBT-oriented psychological support and monitoring with the same CBT inpatient psychotherapists.
62696401|NCT01096251|EXPERIMENTAL|BST|BST group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of BST) plus 8 outpatient telephone-based sessions of BST-oriented psychological support and monitoring with the same BST inpatient psychotherapists.
62696402|NCT04705766||COVID-19 Negative|Control group to measure progression of AKI/kidney injury overtime
62696403|NCT04705766||COVID-19 Positive|Study group to assess AKI trajectory/progression and associated risk factors of kidney injury with SARS-CoV-2 infection
62696404|NCT06271057|EXPERIMENTAL|golcadomide post CAR T-cells|0.3 mg - Per Os - every week - 6 months
62138783|NCT05779761|EXPERIMENTAL|Attention Skills Training|Participants assigned to Attention Skills Training will receive 6-weeks of self-directed, online skills training on attention regulation skills for coping with distress. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
62338258|NCT04110418|PLACEBO_COMPARATOR|Terlipressin Group (Group TP )|"The active substance is terlipressin acetate. Each ampoule contains~1 mg of terlipressin acetate in 8.5 ml solution for injection. This is equivalent to 0.12 mg terlipressin acetate per ml.~* The powder is to be dissolved in the enclosed solvent and slowly administered intravenously. Further dilution up to 10 ml with sterile isotonic sodium chloride solution is possible.~* Store in a refrigerator at 2-8˚C.~* Keep the ampoules in the outer carton in order to protect from light"
62138784|NCT05779761|EXPERIMENTAL|Attention and Reflective Thought Skills Training|Participants assigned to Attention and Reflective Thought Skills Training will receive 6-weeks of self-directed, online skills training on attention and metacognitive regulation skills for coping with distress. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
62138785|NCT05779761|EXPERIMENTAL|Health and Wellness Education Training|Participants assigned to Health and Wellness Education Training will receive 6-weeks of self-directed, online skills training on stress-reduction psychoeducation. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
62138786|NCT05873686|EXPERIMENTAL|Dose Escalation|Escalating doses of NXP900 are planned with a starting dose level of 20 mg once per day.
62138787|NCT04255212|EXPERIMENTAL|Soft tissue treatment|Participants will be treated with 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms.
62338259|NCT05087641|EXPERIMENTAL|IAB System|Patients will be treated with IAB(s)
62338260|NCT04155710|EXPERIMENTAL|Cohort 1a|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + low dose IL-2.
62338261|NCT04155710|EXPERIMENTAL|Cohort 1b|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + high dose IL-2.
62338262|NCT04155710|EXPERIMENTAL|Cohort 2|CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
62338263|NCT04155710|EXPERIMENTAL|Cohort 3|CLL/SLL patients without del 17p who progressed or progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
62696405|NCT02987140|EXPERIMENTAL|PD+FoG|PD patients with FoG
62696406|NCT02987140|ACTIVE_COMPARATOR|PD-FoG|PD patients without FoG
62696407|NCT02987140|ACTIVE_COMPARATOR|Control|age-matched non-disabled adults
62696408|NCT05298618||All Participants|All patients undergoing CPB with dNC cardioplegic arrest shall have two magnesium levels measured. The first sample shall be taken prior to magnesium administration and within 30 minutes of cross-clamp removal. The second sample will be drawn 10 +/- 5 minutes after cross-clamp removal and magnesium administration. Magnesium levels will be analyzed and compared against normally expected values.
62696409|NCT06161493|EXPERIMENTAL|Niraparib|"ZEN003694: Oral capsules - Starting dose 36 mg Dose escalated to 48 mg, following the mTPI-2/Keyboard design administered orally once daily in 28-day cycles~Niraparib: Oral tablets - Starting dose 100 mg Dose escalated to 200 mg, following the mTPI-2/Keyboard design administered once daily at the same time as ZEN003694"
62338264|NCT04982510|EXPERIMENTAL|Thermoplastic tray definitive impression|
62338265|NCT04982510|ACTIVE_COMPARATOR|Conventional tray definitive impression|
62338266|NCT01188564|EXPERIMENTAL|rhC1INH|
62338267|NCT01188564|PLACEBO_COMPARATOR|Placebo (Saline)|
62338268|NCT00856479|ACTIVE_COMPARATOR|1 Infuse|The patient will receive BMP 2 with allograft
62338269|NCT00856479|ACTIVE_COMPARATOR|2 Iliac crest autograft|Autograft from Patients Iliac Crest and allograft
62696410|NCT05847153|EXPERIMENTAL|Intervention|"The intervention arm will be comprised of:~1. Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~2. At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
62696411|NCT06563817|EXPERIMENTAL|Rapamycin treatment group|"All enrolled patients receive treatment with sirolimus (rapamycin), administered in capsule form at a dosage of 0.5 mg per capsule. The capsules, provided by North China Pharmaceutical under the trade name Yixinke, were stored at room temperature. The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.~Sirolimus (rapamycin) bioavailability can be affected by food, based on preliminary results of prior drug use. To maintain consistent blood drug concentrations, sirolimus should be taken with or without food on a constant basis. Grapefruit juice slows CYP3A4-mediated metabolism of sirolimus and potentially enhances P-gp-mediated retrograde transport of sirolimus from the small intestinal epithelium to the intestinal lumen. Therefore, it should not be consumed concurrently with sirolimus."
62696412|NCT03167060|ACTIVE_COMPARATOR|Active Rhinochill|Intranasal cooling device , using nasal cannula
62696413|NCT03167060|SHAM_COMPARATOR|Control Rhinochill|Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)
62696414|NCT02971839|EXPERIMENTAL|VX-561 20 mg|
62696415|NCT02971839|EXPERIMENTAL|VX-561 100 mg|
62138788|NCT04255212|PLACEBO_COMPARATOR|Mechaninsms explanation|Participants will be instructed with a 10 minute lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
62696416|NCT02971839|EXPERIMENTAL|VX-561 150 mg|
61942961|NCT03838146|NO_INTERVENTION|Non-Exercise Control|This group will come in regularly for measurements, but will not have an exercise intervention. If necessary for retention of participants, then we will meet with controls 3 times a week to stress reduction techniques.
61942962|NCT03838146|EXPERIMENTAL|Resistance Type of Exercise|This group will participate in resistance exercise intervention 3 times per week from enrollment to delivery.The resistance training (RT) group will perform three sets of 12-15 repetitions of 10-12 resistance exercises in a circuit, with rest of 30-60 seconds between sets as needed. Participants will use a combination of Cybex machines (Cybex International, Medway, MA), resistance bands, and free weights. Routines will change every 3 weeks to add variety and improve compliance.
61942963|NCT03838146|EXPERIMENTAL|Combination Type of Exercise|This group will participate in combination (aerobic+resistance) exercise intervention 3 times per week from enrollment to delivery. The combination (CT) group will alternate between resistance and aerobic exercises. Participants will perform 4.5 minute bouts of aerobic exercise and perform four resistance exercises of 12-15 repetition that vary between aerobic bouts\[17-19\]. The aerobic exercise bouts will be performed on the aerobic machine of the participant's choosing as described above. The resistance routine will follow similar guidelines as the resistance group.
61942964|NCT03838146|EXPERIMENTAL|Aerobic Type of Exercise|This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
62138789|NCT04255212|OTHER|Control group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
61942965|NCT06530225||Community Based Pharmacies|Community based pharmacies throughout Louisiana will be enrolled in a cohort of trained pharmacies for PrEP prescriptions for patients seeking HIV prevention medication.
62138790|NCT04255212|EXPERIMENTAL|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
62138791|NCT02002845||Robotic arm|Patient who have undergone benign non-tumor TORS procedures using the da Vinci Surgical System
62138792|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
62338270|NCT02917551|ACTIVE_COMPARATOR|Shorter duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
62138793|NCT03259269||Delamanid and companion WHO Group 5 drugs|
62138794|NCT02131584|EXPERIMENTAL|Supportive care (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
62138795|NCT02896335|EXPERIMENTAL|Cohort 1 (Palbociclib)|This arm involves screening for eligibility, study treatment and study visits, and follow up. Cohort 1 participants will receive palbociclib daily at a pre-determined dose for 21 days (Day 1-21) per 28-day cycle. Palbociclib is taken orally. Participants may receive study drug as long as they do not meet the criteria for ending treatment (no intolerable side effects and disease is not progressing). Participants will be followed for up to 2 years after their treatment with the study drug ends. Up to 30 participants will be enrolled in Cohort 1.
62338271|NCT02917551|ACTIVE_COMPARATOR|Longer duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
62338272|NCT03019770|EXPERIMENTAL|PrEP Decision Aid|All participants in the study will go through the Decision Aid with a provider.
62494970|NCT02002130|ACTIVE_COMPARATOR|GABA and placebo GAD-alum|"Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.~Patients will receive the GAD-alum( Glutamic Acid Decarboxylase in alum) placebo at baseline and 1 month."
62696417|NCT02971839|ACTIVE_COMPARATOR|Ivacaftor|
62696418|NCT02971839|PLACEBO_COMPARATOR|Placebo|
62738521|NCT01230996|EXPERIMENTAL|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
62138796|NCT02896335|EXPERIMENTAL|Cohort 2 (Palbociclib in Combination with Pembrolizumab)|Cohort 2 involves screening for eligibility, study treatment and study visits, and follow up. Participants in Cohort 2 will receive study drugs palbociclib and pembrolizumab. Palbociclib is taken orally once per day for 21 days (Day 1-21) of each 28-day cycle. Pembrolizumab will be administered as an intravenous (IV) infusion once every 21 days. Participants may receive study drugs as long as they do not meet the criteria for ending treatment (no intolerable side effects and disease is not progressing), and will be followed for up to 2 years after they stop study treatment. Up to 15 participants will be enrolled in Cohort 2.
61942966|NCT06047808|EXPERIMENTAL|Storytelling Through Music|"Participants will be randomized to either the Storytelling Through Music (STM) experimental arm or the waitlist control arm. STM is a six-week intervention that utilizes storytelling, reflective writing, self-care skills (i.e., breathing exercises, meditation, self-compassion, body scans), and songwriting. The intervention is delivered online and in a group setting. Online delivery provides convenience to participants, and the group setting provides an environment of people with shared experiences, which has been shown to decrease social isolation and feelings of being alone in their emotional experience. By the end of the intervention, participants will have written a short story and a song based on their story."
61942967|NCT06047808|NO_INTERVENTION|Waitlist Control|"Participants will receive the same Storytelling Through Music intervention once data collection from the experimental arm is complete."
61942968|NCT02985437|EXPERIMENTAL|Surfactant|Alveofact® (Bovine Lung Surfactant), 0.5 mg/ml per day (solution) all two days maximal eight times
61942969|NCT02985437|ACTIVE_COMPARATOR|Saline|0.9% Sodium chloride solution (NaCl solution), 2 ml per day (solution) all two days maximal eight times
62138797|NCT04839185|OTHER|Diagnostic: Ferumoxytol MRI|The participant will receive an infusion of an iron supplement, ferumoxytol, followed by a same day MRI scan and then a second MRI scan 3-5 days later.
62138798|NCT04549155|EXPERIMENTAL|Network-guided TMS|The study comprises one arm of five sessions. In Day 1 (\~1.5 hr session), participants fill forms, complete a neuropsychological test battery (NIH Toolbox, NACC UDS, BDI), and provide a saliva sample to be banked for future APOE genotype determination. On Day 2 (\~1 hr session), subjects will perform an initial MRI scanning session. In this session, MRI, RSFA, DWI, and fMRI are collected so they can be used for network-based targeting. In Days 3-5 (each comprising a \~2.5 hr session) a few days later participants will undergo combined TMS-fMRI sessions. In the scanner, participants complete four fMRI runs: 2 runs using either a network-based or standard target location, counterbalanced across participants. Active and Sham TMS trials are intermixed within each run.
62138799|NCT06662630|EXPERIMENTAL|CHFO group|"After checking the availability of the CHFO machine (MetaNeb® system), the inclusion and non-inclusion criteria, the patient is included. The following procedures are performed:~1. installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger)~2. continuous recording of digital and analogic data After collecting initial data from the patient within 30 minutes before CHFO treatment, successive 10-minutes CHFO were performed. At the end of the treatment, all the data is collected."
61942970|NCT06468852|EXPERIMENTAL|GDFT group|Patients in GDFT group will receive GDFT protocol, Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV\>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.
62738522|NCT03287882|NO_INTERVENTION|Standard of care|"1. Preconception period: none~2. Pregnancy period: daily iron (60 mg) and folic acid (400 µg) supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~3. Postpartum period: daily iron and folic acid supplementation to 6 months postpartum"
61942971|NCT06468852|NO_INTERVENTION|conventional fluid therapy group|Patients in conventional fluid therapy group, fluid management will be carried out according to the clinical practice routine, maintaining MAP≥65mmHg and urine output ≥0.5ml/kg/h, intraoperatively. When the anesthesiologist empirically determines that the fluid infusion is sufficient but MAP does not maintain the expected level, vasopressor or inotropic drugs are given to maintain the blood pressure.
61942972|NCT05998707||benign group|benign lesions in the lung
61942973|NCT05998707||malignant group|malignant tumor in the lung
62138800|NCT02964741|ACTIVE_COMPARATOR|Migraine Patients Active Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS\*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).~\*Active Comparator"
62138801|NCT02964741|SHAM_COMPARATOR|Migraine Patients Sham Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS\*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).~\*Sham Comparator"
62138802|NCT02964741|NO_INTERVENTION|Healthy Control Group|"Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n \</= 10) may be used from a prior study (NINDS-K23062946 project \[IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator\]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
62138803|NCT01237496|EXPERIMENTAL|1|
61942974|NCT02987842|EXPERIMENTAL|Experimental group|Patients in the experimental group will receive feedback using the TruScan Neurofeedback system in order to increase the power of EEG in the range of their individual upper alpha (as determined by the peak alpha frequency)
62138804|NCT01437319|ACTIVE_COMPARATOR|lotrafilcon A, comfilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
62138805|NCT01437319|ACTIVE_COMPARATOR|lotrafilcon A, balafilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
62138806|NCT06649708|EXPERIMENTAL|HX044|Conventional dose-escalation design with 3+3 cohort size. Patients received HX044 treatment at assigned dose level on a Q3 weekly basis.
62138807|NCT01904669||Women who are trying to conceive|Women ages 18-44 without a history of fertility problems who are in a stable relationship with a male partner who have regular access to the Internet and have been trying to conceive \<3 months.
62338273|NCT06553677|EXPERIMENTAL|Tunneled coronal advanced flap with connective tissue graft|"TCAF involves the elevation of one trapezoidal surgical papilla at the papilla with less interproximal clinical attachment loss, by a slightly divergent vertical incision extending beyond the mucogingival junction is done then a horizontal incision at a distance equal to the recession depth plus 1 mm apical to the papilla tip just as the conventional coronally advanced flap (CAF). Then a tunneling knife will be used to perform the intra-sulcular incision on the treated site and on the tooth adjacent to the papilla that will be preserved for tension-free flap advancement.~The midfacial aspect of the tooth will be elevated with tunneling knives while the surgical papilla will be elevated in a split-thickness manner.~. The anatomical papilla will be de-epithelialized, either with a surgical blade or micro scissors, while the other papilla will be gently mobilized with a tunneling instrument. .~The harvested connective tissue graft will be inserted underneath the flap"
62138808|NCT06668571|EXPERIMENTAL|Ketamine Group|Subjects will receive IV racemic ketamine at a dose of 0.5 mg per kg of the participant's actual body weight, with a maximum dose of 50 mg for individuals weighing over 100 kg.
62138809|NCT06668571|PLACEBO_COMPARATOR|Normal Saline/Placebo Group|Subjects will receive an IV infusion of normal saline over a duration of 40 minutes
62138810|NCT05962606|EXPERIMENTAL|AON-D21 plus Standard of Care|Sterile liquid formulation of AON-D21 in 4% mannitol + 0.05% EDTA in glass vials. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
62138811|NCT05962606|PLACEBO_COMPARATOR|Placebo plus Standard of Care|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
62338274|NCT06553677|ACTIVE_COMPARATOR|Coronally advanced flap with connective tissue graft|"A trapezoidal-shaped flap will be elevated with a split-full-split approach in the coronal-apical direction:~* The surgical papillae will be elevated by split thickness keeping the blade almost parallel to the root.~* The soft tissue apical to the root exposure will be elevated in a full thickness manner to expose 3-4mm of bone apical to the bone dehiscence. This was done to include the periosteum in the thickness of that central portion of the flap covering the avascular root exposure.~* The releasing vertical incisions will be elevated by split thickness keeping the blade parallel to the bone thus leaving the periosteum to protect the underlying bone in the lateral areas of the flap.~* The part of the flap apical to bone exposure will be elevated by split-thickness, this step will be done so it is possible to move the flap passively in the coronal direction.~The harvested connective tissue graft will be inserted underneath the flap"
62338275|NCT01184716|ACTIVE_COMPARATOR|Vitamin D fortified bread and milk|
62338276|NCT01184716|NO_INTERVENTION|Non-fortified bread and milk|
62338277|NCT05742087||Patients presenting with neurological symptoms and anti-GFAP antibodies in the CSF.|"This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the iological Resource Center of the Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids).~The group will be composed of patients included in the French cohort of patients with neurological syndromes and anti-GFAP antibodies in the CSF."
62338278|NCT01630096|ACTIVE_COMPARATOR|Nu-Lytely|Bowel prep solution.
62338279|NCT01630096|NO_INTERVENTION|Control|Standard of care.
62138812|NCT01303510|EXPERIMENTAL|Group A|Adults from 18 to 60 years old inclusive
62138813|NCT01303510|EXPERIMENTAL|Group B|Elderly subjects aged over 60 years
62338280|NCT05255588||Cohort|Subjects who are at high-risk (Asia Pacific Colorectal Screening Score ≥4.0) of developing CRC aged ≥40
62338281|NCT02276716|EXPERIMENTAL|Phosphatidylserine|"Phosphatidylserine titration from 300, 600 and 800 mg/day~duration: 6 months"
61942975|NCT02987842|SHAM_COMPARATOR|Sham group|Patients in the sham group will receive feedback using the TruScan Neurofeedback system for electrical static activity of a disconnected electrode.
62138814|NCT03001206||ICCU patients|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patient diagnosed with acute coronary syndrome (ACS) in the intensive cardiac care unit (ICCU) before and after planed catheterization procedure."
62138815|NCT03001206||Stress test subjects|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patients referred to stress imaging with suspected ischemia."
62138816|NCT02961868|EXPERIMENTAL|Prospective cohort|3 years follow-up
62338282|NCT02700100|EXPERIMENTAL|Pulmonary Valved Conduit (PV-001)|Bioabsorbable Pulmonary Valved Conduit (PV-001) implantation through open surgery.
62338283|NCT05097053|EXPERIMENTAL|MVC-COV1901 vaccine (3-month Interval)|There will be approximately 100 participants (Group A) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 1
62338284|NCT05097053|EXPERIMENTAL|MVC-COV1901 vaccine (6-month Interval)|There will be approximately 100 participants (Group B) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 85.
62338285|NCT05312931||Group A|students who underwent original concept of First Aid
62338286|NCT05312931||Group B|student who underwent new concept of First Aid
62338287|NCT02236728||Parkinson's disease patients|
62696419|NCT06644092|EXPERIMENTAL|Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft|"The question of our research is to determine the effectiveness of the physiotherapy and rehabilitation protocol applied in the postoperative period on the knee joint range of motion, functionality, muscle strength around the knee joint (quadriceps/hamstring ratio) and pain parameters in patients who underwent osteochondral allograft transplantation surgery and to include it in the literature. In this direction, the hypotheses of our study are; H0: The physical therapy and rehabilitation protocol to be applied after osteochondral allograft transplantation surgery has a positive contribution to the patient's knee joint range of motion, functionality, muscle strength and pain.~H1: The physical therapy and rehabilitation protocol to be applied after osteochondral allograft transplantation surgery does not have a positive contribution to the patient's knee joint range of motion, functionality, muscle strength and pain."
62696420|NCT06088667|EXPERIMENTAL|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments.
62696421|NCT06088667|EXPERIMENTAL|Control Group|The control group will receive heat application, electrical stimulation and shoulder exercises for 4 weeks.
62696422|NCT04300894|NO_INTERVENTION|Usual care group|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
62696423|NCT04300894|EXPERIMENTAL|Mamma Mia group|"Usual prenatal/postpartum care plus use of the Mamma Mia program"
62696424|NCT04300894|EXPERIMENTAL|Mamma Mia Plus group|"Usual prenatal/postpartum care plus use of the Mamma Mia program plus occasional contacts from study staff"
62338288|NCT01091987|EXPERIMENTAL|Non-pharmacological approach of insomnia|Non-pharmacological approach of insomnia based on cognitive-behavioural techniques (education on sleep, sleep hygiene, stimulus control, cognitive techniques)
62696425|NCT05745844|EXPERIMENTAL|NeuroMuscular Electro Stimulation group|Patients in the NeuroMuscular Electro Stimulation group will also have neurostimulation sessions using a CE marked medical device, in its destination, according to its instructions for use, therefore without expected clinical risk
62696426|NCT05745844|ACTIVE_COMPARATOR|Control Group|The control group (without NeuroMuscular Electro Stimulation) corresponds to the standard care routinely offered to patients in the investigating centre.
62696427|NCT05175664||MCI|Patients suffering from mild cognitive impairment (MCI) due to Alzheimer's disease.
62696428|NCT05175664||AD|Patients diagnosed with mild to moderate Alzheimer's disease (AD)
62338289|NCT01879670||Synergy|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
62696429|NCT05175664||NDD|Patients under investigation of a neurodegenerative disease (NDD)
62696430|NCT05175664||DLB|Patients diagnosed with Dementia with Lewy Bodies (DLB)
62138817|NCT05783531|EXPERIMENTAL|Intervention|This arm will receive the VMood digital mental health intervention. This consists of bibliotherapy that is delivered via a smartphone app, with coaching support provided by social workers for a duration of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
62338290|NCT01879670||Control|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.
62338291|NCT04986449|EXPERIMENTAL|Intervention group|All families will receive the culinary and nutritional intervention. Changes before-after will be assessed regarding culinary skills, knowledge and attitudes of families on cooking with plant-based foods
62338292|NCT04586114||Early corticosteroid|Corticosteroid treatment within first seven days after ICU admission
62696431|NCT05175664||VaD|Patients with vascular dementia (VaD)
62696432|NCT05175664||FTD|Frontotemporal dementia (FTD)
62696433|NCT05175664||NPH|Normal pressure hydrocephalus (NPH)
62696434|NCT05175664||Healthy Controls|Healthy Controls without brain disease
62338293|NCT04586114||Late corticosteroid|Corticosteroid treatment later than seventh day's after ICU admission
62338294|NCT04586114||No corticosteroid|No corticosteroid treatment during ICU stay
62338295|NCT05178056|ACTIVE_COMPARATOR|Respiratory Training|Research subjects with no implanted stimulator undergoing RT intervention.
62338296|NCT05178056|ACTIVE_COMPARATOR|Spinal Cord Stimulation|Research subjects with implanted stimulator undergoing stimulation intervention.
62338297|NCT05178056|EXPERIMENTAL|Spinal Cord Stimulation and Respiratory Training|Research subjects with implanted stimulator undergoing stimulation intervention in combination with respiratory training.
62338298|NCT00005096|EXPERIMENTAL|Docetaxel|Docetaxel given via iv at determined dose once a week for 4 weeks
62338299|NCT01952730|EXPERIMENTAL|Experimental Treatment Arm|GVAX, up to 6 vaccinations, administered via injection
62696435|NCT06192550|EXPERIMENTAL|Group 1: Matrix Pro|Subjects undergoing treatment with the Matrix Pro applicator.
62696436|NCT06192550|EXPERIMENTAL|Group 2: Sublime/Sublative|Subjects undergoing treatment with either 1) Sublime applicator only, 2) Sublative RF applicator only, 3) Combined treatment of Sublime and Sublative RF applicators.
62696437|NCT06192550|EXPERIMENTAL|Modified Matrix Pro|Subjects undergoing treatment with a Matrix Pro Modified applicator with lower RF power settings.
61942976|NCT05894512||Study Group (Primary Membranous Nephropathy)|"Patients with biopsy-proven primary membranous nephropathy will be included (n=20).~Samples will be collected from patients diagnosed with primary MN before starting conventional immunosuppressive therapy with calcineurin inhibitors (CNI) and corticosteroids (CS) and at 3, 6, 12, 18 and 24 months after starting the treatment.~In case of failure after treatment with CNIs and CS treatment, rituximab (RTX) is used. If patient switches to RTX, samples will be taken before and 1, 3, 6, 12, 18, and 24 months after the first dose of RTX.~If relapse occurs, sampling will be done regardless of the timing.~Treatment decisions will solely be made in line with the guidelines, and there will be no intervention."
61942977|NCT05894512||Control Group 1 (IgA Nephropathy)|"After the patient group sampling is completed, a diseased control group will be formed from patients with primary IgA nephropathy according to the distribution of age and sex (n=15).~Samples will be collected from the patients for one time only (cross-sectional sampling)."
61942978|NCT05894512||Control Group 2 (Healthy Volunteers)|"After the patient group sampling is completed, a healthy control group will be formed from healthy volunteers according to the distribution of age and sex (n=15).~Samples will be collected from healthy volunteers for one time only (cross-sectional sampling)."
61942979|NCT04122534|EXPERIMENTAL|Treatment Group|Treatment groups receives the intervention training.
61942980|NCT03617510|EXPERIMENTAL|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
61942981|NCT03617510|EXPERIMENTAL|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
61942982|NCT03617510|EXPERIMENTAL|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
61942983|NCT03617510|EXPERIMENTAL|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
61942984|NCT01268150|EXPERIMENTAL|Experimental|
61942985|NCT04234802|ACTIVE_COMPARATOR|HEAT intervention group|Workers in the intervention group will receive the HEAT training, and supervisors in the intervention group will receive the HEAT awareness application and training on how to use it.
61942986|NCT04234802|NO_INTERVENTION|Comparison group|The comparison group will not be offered HEAT trainings or the HEAT awareness application. They will be offered an alternative training on another topic.
61942987|NCT03061097|EXPERIMENTAL|Treatment (autologous fecal microbiota preparation)|"Participants randomized into the treatment arm will receive a single dose of autologous fecal microbiota preparation (auto-FMP) via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months.~Route of Administration: Enema Dosing Regimen: 125mL x 1 dose"
61942988|NCT03061097|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive a single dose of placebo FMT via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months. The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
61942989|NCT05034718|ACTIVE_COMPARATOR|Control Arm|Completion of nurse powerform and data collection only.
61942990|NCT05034718|EXPERIMENTAL|Intervention Arm|Completion of nurse powerform, data collection and physician alert/powerform with score calculation and recommendations.
61942991|NCT02145585||Robotic pharmacological system|Robotic pharmacological system/Automated anesthesia delivery system
62696438|NCT04452916|ACTIVE_COMPARATOR|Fasting|Starts immediately with 5 days of Buchinger fasting
62696439|NCT04452916|PLACEBO_COMPARATOR|Waiting list control|Starts with 5 days of Buchinger fasting after a waiting period of 12 weeks
61942992|NCT04439344|EXPERIMENTAL|Treatment (binimetinib)|Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61942993|NCT04558684|EXPERIMENTAL|radiotherapy, chemotherapy and PD1 inhibitor|Treatment will comprise 5 daily fractions of radiotherapy at 5 Gy per fraction followed by chemotherapy and immunotherapy. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard surgery.
61942994|NCT00698984|ACTIVE_COMPARATOR|1|30 mg BONISTEIN(R) 150 ug Vitamin K1 800 IU Vitamin D3 1000 mg PUFA 500 mg Calcium
62138818|NCT05783531|OTHER|Control|This arm will receive enhanced treatment as usual, which consists of regular care as provided by primary care centres and a brief introduction video about depression via the app. The control arm will receive the intervention after the intervention arm has completed the intervention period.
62696440|NCT04258631|ACTIVE_COMPARATOR|Arm I (laparotomy, liposomal bupivacaine)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine.
62138819|NCT00807313||At best response|Patients with oligometastatic colorectal cancer, who presents at best response under chemotherapy, will receive stereotactic body radiotherapy on their residual disease
62138820|NCT00807313||No indication for chemotherapy|Patients with oligometastatic colorectal cancer, who are progressive under chemotherapy or who are no candidates for (further) chemotherapy, will receive stereotactic body radiotherapy on the sites of disease.
62696441|NCT04258631|EXPERIMENTAL|Arm II (laparotomy, liposomal bupivacaine, hydromorphone)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine and hydromorphone IT.
61942995|NCT00698984|PLACEBO_COMPARATOR|2|500 mg Calcium
62138821|NCT03614663|EXPERIMENTAL|ZYN002 - Cannabidiol transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg cannabidiol Q12H or placebo.~Patients weighing greater than 35 kg will be randomized to receive 250 mg cannabidiol Q12H or placebo."
62696442|NCT04614337|EXPERIMENTAL|LUM-201 (0.8 mg/kg/day)|
62696443|NCT04614337|EXPERIMENTAL|LUM-201 (1.6 mg/kg/day)|
62696444|NCT04614337|EXPERIMENTAL|LUM-201 (3.2 mg/kg/day)|
62696445|NCT04614337|ACTIVE_COMPARATOR|rhGH (34 µg/kg/day)|
61942996|NCT02505178|EXPERIMENTAL|Problem Solving Therapy|Study participation will involve 9 study visits over a total of 12 weeks. This includes 5 sessions of Case Manager implemented PST over a period of 8 weeks (week 1, 3, 5, 7, and 9) and 4 assessment visits (baseline, week 4, week 8, and week 12).
61942997|NCT02815410|OTHER|Levetiracetam|Newly diagnosed histologically proven supratentorial glioblastoma patients received levetiracetam during and after their CCRT
61942998|NCT01319357|PLACEBO_COMPARATOR|Placebo|Placebo
61942999|NCT01319357|ACTIVE_COMPARATOR|Saxagliptin|saxagliptin 5 mg/day during 6 weeks
62696446|NCT06640036|EXPERIMENTAL|Sequence 1: Rapeseed oil, butter, coconut oil|Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals
61943000|NCT04242173|EXPERIMENTAL|Cemiplimab-rwlc treatment|Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks
61943001|NCT01229371|ACTIVE_COMPARATOR|Subjects ≥18 to ≤60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
61943002|NCT01229371|ACTIVE_COMPARATOR|Subjects >60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
61943003|NCT01229371|EXPERIMENTAL|Subjects ≥18 to ≤60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
61943004|NCT01229371|EXPERIMENTAL|Subjects >60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
61943005|NCT02727413||Infective endocarditis|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with infective endocarditis in accordance with Duke criteria and scheduled for valve surgery
61943006|NCT02727413||Valvular heart disease|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with valvular heart disease, with no signs of infection, scheduled for valve replacement surgery
61943007|NCT04127942|EXPERIMENTAL|platelet-rich plasma injection|1cc platelet-rich plasma(PRP) injection in the superior temporomandibular disk joint space by ultrasound guidance.
61943008|NCT04127942|PLACEBO_COMPARATOR|normal saline injection|1cc normal saline injection in the superior temporomandibular disk joint space by ultrasound guidance.
61943009|NCT03071146||Bard® LifeStent® 5F Vascular Stent System|Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
61943010|NCT01032174||Azithromycin SR|Acute Bacterial Maxillary Sinusitis
61943011|NCT01032174||Amoxiclav 1000 mg|Acute Bacterial Maxillary Sinusitis
62338300|NCT06431243|EXPERIMENTAL|A group|In Cohort A, subjects in the ascending-dose group received PM IV, administered at a frequency of BiW (2 times per week) for 2 weeks, i.e., on days 1, 4, 8, and 11 of each cycle, with a 1-week discontinuation to allow for a 21-day cycle (with a minimum interval of ≥48 h between each of the 2 doses within the same dosing cycle), and exemestane was administered orally once a day within 30 min after the end of breakfast as one tablet ( 25 mg). Based on the results obtained in the dose-escalation phase, the necessity of the phase IIa expansion cohort and the dose of PM to be administered will be decided after discussion by the SMC, and the phase IIa cohort expansion is expected to select 1-2 dose groups of 10-15 cases each, with a total of 19-54 cases in this cohort
62494971|NCT02002130|ACTIVE_COMPARATOR|Active Oral GABA and Active GAD-alum Injection|"Patients will receive Oral GABA(Gamma-Amino Butyric Acid) 250mg capsules. Dosage (# of capsules) based on body surface area and divided between 2 meals/day.~Patients will receive a primary (at baseline)injection of recombinant human GAD(Glutamic Acid Decarboxylase) in a standard vaccine formulation with alum, and a booster injection of the same at 1 month after baseline."
62138822|NCT03614663|PLACEBO_COMPARATOR|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
62138823|NCT01773993||Pregabalin|Subjects who are treated with pregabalin
62494972|NCT03878550||Cases|Male and female adult patients with early-stage hepatocellular carcinoma against a background of liver cirrhosis.
61943012|NCT00907712|NO_INTERVENTION|cardiovascular|cardiac echo
61943013|NCT02754154||Patients using Warfarin|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin
61943014|NCT02754154||Patients using Apixaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban
61943015|NCT02754154||Patients using Dabigatran|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran
62138824|NCT02109575||Heart Transplant Recipients|Up to 10 cc of blood will be drawn from heart transplant recipients at various time points prior to and after transplant. Blood draw is the only research activity that study participants will undergo. In addition to blood draw, data will be collected from clinical records representing the participant's transplant course such as the medical record, imaging, and biopsy slides with pathology reports.
62138825|NCT05907603|EXPERIMENTAL|Research Development 13(RD13)-02 cell infusion|drugs use generic name : RD13-02 CAR-T cell injection ; dosage form : Cell injection ; dosage : 2×10\^8 CAR+ T cells ; frequency : Once.
62494973|NCT03878550||Controls|Male and female adult patients with liver cirrhosis at risk for hepatocellular carcinoma.
62696447|NCT06640036|EXPERIMENTAL|Sequence 2: Rapeseed oil, coconut oil, butter|Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals
62696448|NCT06640036|EXPERIMENTAL|Sequence 3: Butter, coconut oil , rapeseed oil|Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals
62138826|NCT06451952|EXPERIMENTAL|Virtual darkness|Exclusive exposure to light deprived of blue wavelengths from 19.00-08.00 for 14 consecutive days as add-on to treatment as usual (TAU). This will be provided in an ordinary part of the hospital ward with circadian lightening delivered by Chromawiso. This lightening is CE approved. The intervention will be delivered in two separate patient units, each of them will include one living room, one bedroom and a bathroom, area ranging from 58m2- 60 m2. If patients are able to wear blue blocking glasses (amber lenses), they can stay outside the units from 19.00-08.00. Between 08.00-19.00 the patients in the intervention groups can stay inside or outside the units as they wish.
62338301|NCT06431243|EXPERIMENTAL|B group|In Cohort B, subjects in the ascending dose group all received PM IV drip administered at a frequency of BiW (2 times per week) for 2 consecutive weeks, i.e., on days 1, 4, 8, and 11 of each cycle, with a 1-week discontinuation for a 21-day cycle (with a minimum interval of ≥48 h between each of the 2 doses in the same dosing cycle). Tirelizumab was administered as 200 mg IV every 3 weeks, administered on the first day of each cycle. Based on the results obtained during the dose-escalation phase, the need for and the dose of the Phase IIa expansion cohort will be determined after discussion by the Safety Management Committee (SMC), and the Phase IIa cohort expansion is expected to select 1-2 dosage groups of 10-15 cases each.
62338302|NCT04144452|ACTIVE_COMPARATOR|Patient Education Session|Educational session will be given twice a day for three months. Individualized instructional booklet about back care for each patient will be designed, reviewed and finalized by operating surgeons according to the needs of patients.
62338303|NCT04144452|EXPERIMENTAL|Therapeutic exercises plus educational sessions|Trunk and lower musculature strength and endurance training will be performed twice a week for three months. Therapeutic exercises incorporating mat exercises will be performed. Progression will be made according to patient status.
62338304|NCT03458832||FSHD-COM|All participants will be asked to undergo FSHD-specific functional rating scale tests and procedures and Electrical Impedance Myography.
62338305|NCT03365427|EXPERIMENTAL|Application Group|People in this arm will be introduced to an APP on smart phone, and receive lessons on how to use it on their own phones. The APP will be installed and prepare to use before surgery. People will be asked and monitored on-line to regularly use the APP.
62338306|NCT03365427|NO_INTERVENTION|Convention Group|People in this arm receive exactly the same treatment and lessons on post-operative rehabilitation except the reach of the APP.
62696449|NCT06640036|EXPERIMENTAL|Sequence 4: Butter, rapeseed oil, coconut oil|Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals
62696450|NCT06640036|EXPERIMENTAL|Sequence 5: Coconut oil, rapeseed oil, butter|Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals
61943016|NCT02754154||Patients using Rivaroxaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban
61943017|NCT00809848|EXPERIMENTAL|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
61943018|NCT00809848|EXPERIMENTAL|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
61943019|NCT00809848|EXPERIMENTAL|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
61943020|NCT00809848|ACTIVE_COMPARATOR|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
61943021|NCT00809848|PLACEBO_COMPARATOR|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
61943022|NCT01298310|ACTIVE_COMPARATOR|Xylocaine_1mg|1 injection of Xylocaine (1 mg/mL)
61943023|NCT01298310|ACTIVE_COMPARATOR|Xylocaine_10mg|1 injection of Xylocaine (10 mg/mL)
61943024|NCT01298310|PLACEBO_COMPARATOR|Placebo|1 injection of placebo
61943025|NCT06302478|EXPERIMENTAL|5E Program|Participants in the 5E program group will receive 7-day nursing interventions.
61943026|NCT06302478|NO_INTERVENTION|Usual Care|Participants in the control group will receive 7-day usual care interventions, including health education regarding signs and symptoms of venous thromboembolism and IPC use if the participants experienced muscle power as grade 0.
61943027|NCT04046198|EXPERIMENTAL|İntervention group|Nurses working at Akdeniz University Hospital became the intervention group. The nurses who accepted to participate in the study were divided into groups of 5-15 people. Pre-test was applied to nurses who accepted the research. Nurses were given 4-hour group trainings. A booklet on the subject prepared by the researchers was given. Three interim interviews were conducted in the subsequent 3-month period. Six separate posters were posted in the clinics. Weekly reminder messages were sent via WhatsApp. At the end of the third month, post-test data were collected from the nurses.
62338307|NCT03009201|EXPERIMENTAL|Treatment (ribociclib, doxorubicin hydrochloride)|"Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62338308|NCT00895518|NO_INTERVENTION|1|Participants will receive assessments only.
62696451|NCT06640036|EXPERIMENTAL|Sequence 6: Coconut oil, butter, rapeseed oil|Diets rich in rapeseed oil, butter or coconut oil given in blinded, preprepared meals
62696452|NCT06638372|EXPERIMENTAL|caffeine gum|Chewing caffeine gum for 10 minutes
62696453|NCT06638372|PLACEBO_COMPARATOR|placebo gum|Chewing placebo gum for 10 minutes
62696454|NCT02711098|ACTIVE_COMPARATOR|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
62696455|NCT02711098|PLACEBO_COMPARATOR|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
62696456|NCT02443857|EXPERIMENTAL|ChARMin|Single-arm only
62696457|NCT05660642|EXPERIMENTAL|Arm A|
62696458|NCT05660642|EXPERIMENTAL|Arm B|
62696459|NCT05925400|NO_INTERVENTION|ET without RV|Patients who will be randomized to the control group will wait for transfer of a fresh blastocyst on the 5th day of development OR a frozen embryo on the 5th day of development according to the usual service protocol.
62138827|NCT06451952|NO_INTERVENTION|Control condition|Treatment as usual for agitation in specialized dementia health services encompasses use of psychotropic drugs (anxiolytic agents, antipsychotic agents, antidementia agents), environmental interventions, music therapy and use of medical restraints
62138828|NCT05443542|EXPERIMENTAL|Virtual Reality Group|Group 1 will play a VR game using an Oculus Quest 2 in a home setting
62338309|NCT00895518|EXPERIMENTAL|2|Participants will receive prolonged exposure therapy.
62138829|NCT05443542|ACTIVE_COMPARATOR|Active control group|The control group will be given a pamphlet containing exercises affecting working memory, attention and processing speed to be performed in a home setting
62138830|NCT04881409|EXPERIMENTAL|nasal high-flow|Patient with AECOPD is treated with NHF.
62138831|NCT04881409|ACTIVE_COMPARATOR|non-invasive ventilation|Patient with AECOPD is treated with NIV
62138832|NCT05080036|EXPERIMENTAL|Unbalanced healthy subjects|Subjects undergo an external perturbation of their balance
62138833|NCT04474496||Marshallese adults in the U.S.|Marshallese persons 18 years of age or older currently residing in the United States
62138834|NCT05324878||Population 1: Social workers/Nurses|Social workers and nurses working at participating dialysis centers. Dialysis centers will be selected based on demographic data of the center (urbanicity, population served, size of center, patients treated, etc) to provide for diversity of centers participating.
62338310|NCT05966532||Major Depressive Disorder (MDD) Participants:|"1. Male and female subjects~2. Age between 21-80 years old~3. Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnosis of major depressive disorder (MDD) based on Mini Neuropsychiatric Interview~4. Inventory of Depressive Symptomatology; Clinician Rated version (IDS-C) total score \> 14~5. Able to read, write, and comprehend English~6. Provide informed consent; willing to comply with study protocol.~Note: For individuals with MDD diagnosis: As part of the screening procedures, the Mini International Neuropsychiatric Interview (MINI-7.0 for DSM-5) will be conducted to determine eligibility. This is related to Inclusion Criteria #3."
62338311|NCT05966532||Healthy Volunteer Participants:|"1. Male and female subjects~2. Age between 21-80 years old~3. Able to read, write, and comprehend English~4. Provide informed consent; willing to comply with study protocol"
62338312|NCT05532098|ACTIVE_COMPARATOR|Control group|Patients diagnosed with ADD under this group are subjected to Dry Needling
62338313|NCT05532098|EXPERIMENTAL|Test group|Patients diagnosed with ADD under this group are administered with 1ml of PRP solution .
62338314|NCT03771417|EXPERIMENTAL|Resistance Exercise|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week.
62338315|NCT03771417|EXPERIMENTAL|RE plus Low Intensity Physical Activity|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week and regular unsupervised low intensity physical activity breaks in sedentary time 5 days per week \[6x10 min breaks/d at 2 metabolic equivalents (METS) or \~30-40% peak oxygen consumption (VO2 peak), \~500 kcal/wk above resting metabolism\].
62338316|NCT03771417|ACTIVE_COMPARATOR|RE plus Moderate IntensityExercise|Exercise Intervention: Participants will be asked to complete supervised RE 2 days per week and supervised calorically matched moderate intensity physical activity 3 days per week (50 min/session at 4 METS (\~60-75% VO2 peak), \~500 kcal/week above resting metabolism).
62338317|NCT06259279|EXPERIMENTAL|Intervention Group|Patients in the intervention group will receive a 32-week exercise-based intervention that includes supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes.
62338318|NCT06259279|NO_INTERVENTION|Control Group|standard care. Patients in the control group are referred to the municipal standard rehabilitation programs if the patient so wishes.
62696460|NCT05925400|EXPERIMENTAL|ET with RV|"The transfer and preparation in the transfer room will be done according to the usual service protocol.~Exposure to virtual reality environment exposure"
62338319|NCT01724125|EXPERIMENTAL|Case|Assigned a Personal Electronic Health Record
62338320|NCT01724125|ACTIVE_COMPARATOR|Control: Usual Care|Assigned to control arm, continued to receive care as usual in community. Was issued information on community health resources, but did not use research study personal health record.
62138835|NCT05324878||Population 2a: Patients receiving care at the dialysis center|2a. When an advance care planning conversation takes place, social worker/nurse will provide patient with an informational flyer about the HIGHway project and a postcard.
62138836|NCT05324878||Population 2b: Patients receiving care at the dialysis center|2b. Social worker/nurse will identify one patient willing to have a recording made of advance care planning conversation between social worker/nurse and patient.
62138837|NCT03836105||Group 1|This group will enroll patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) CSCC.
62138838|NCT03836105||Group 2|This group will enroll patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) BCC.
62138839|NCT05254912|ACTIVE_COMPARATOR|6% BEMT in sunscreen oil (SU E 101413 85)|"Assess the photoallergic potential of Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
62138840|NCT05254912|OTHER|Sunscreen oil Vehicle (SU E 101413 91)|"Vehicle Control: Assess the photoallergenic potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT.~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
62338321|NCT02213302|PLACEBO_COMPARATOR|Isotonic serum|placebo administration
62338322|NCT02213302|ACTIVE_COMPARATOR|Midazolam|midazolam intravenous administration 0.02mg/kg
62338323|NCT04191421|EXPERIMENTAL|Treatment spartalizumab and siltuximab Phase I dose level 1|Arm 1 (Phase I dose level 1) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 6 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62338324|NCT04191421|EXPERIMENTAL|Treatment spartalizumab and siltuximab Phase I level 2|Arm 2 (Phase I dose level 2) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 11 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62338325|NCT04191421|EXPERIMENTAL|Treatment spartalizumab and siltuximab phase I level 2a|Arm 3 (Phase I dose level 2a) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 9 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62338326|NCT04191421|EXPERIMENTAL|Treatment spartalizumab and siltuximab phase II|Arm 4 (Phase II ) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab at dose determined in Arm 1 to 3 IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62338327|NCT04202718|OTHER|Single group|Where a wearable biosensor is being considered for use in the health management of individuals at high-risk for poor health outcomes, and in the detection or prevention of adverse events within settings where traditional monitoring devices are not currently in use, the ECG interpretation will provide Arrhythmia detection which will help ensure that irregular rhythms will be reported quickly.
62338328|NCT05383729|EXPERIMENTAL|new training|"In this new learning-curve-based training modality, after participants complete 16 procedures on a high-fidelity simulator, an individual learning curve will be generated using the previously validated equation:~ln⁡(γ)=γ_0 e\^(-kn)+γ_∞ where γ is procedure time, n is previous experiences.\[2\] Other parameters and their 95% Confidence Interval (CI) can be obtained after curve fitting. And e\^(γ_∞ ) is the asymptote of this curve. Then the trainees will continue the training. If the following procedure time falls into the 95% CI of the asymptote for three consecutive times,\[6\] the individual training goal is considered achieved.\[2\]"
62494974|NCT01426334|EXPERIMENTAL|Treatment (dasatinib and cyclosporine)|Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
62494975|NCT04619225|EXPERIMENTAL|TetraGraph monitoring|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on either hand at a discretion of the anesthesiologist
62494976|NCT00494741|EXPERIMENTAL|mycophenolate mofetil|
62494977|NCT00494741|EXPERIMENTAL|azathioprine|
62494978|NCT03806491|EXPERIMENTAL|CBT-I + AUD-TAU|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
62338329|NCT05383729|ACTIVE_COMPARATOR|reference training|In this reference fixed-training-time training modality, participants will receive training with a high-fidelity simulator for 1h.
62338330|NCT06512623|NO_INTERVENTION|Control|Cardiopulmonary bypass will be conducted as per institutional protocols, without hemoadsorption (standard-of-care)
62338331|NCT06512623|EXPERIMENTAL|Hemoadsorption|Cardiopulmonary bypass (CPB) will be conducted as per institutional protocols and an HA-380® cartridge (Jafron Biomedical, Guangdong, China) will be inserted within the circuit for hemoadsorption.
62338332|NCT02667860|EXPERIMENTAL|Intracorporeal anastomosis|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
62338333|NCT02667860|ACTIVE_COMPARATOR|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
62338334|NCT02393573|ACTIVE_COMPARATOR|Metformin|Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
62338335|NCT02393573|PLACEBO_COMPARATOR|Placebo|Placebo will be administered exactly in the similar way to Metformin
62338336|NCT03819764|ACTIVE_COMPARATOR|Aerobic Exercise & Repetitive Task Practice|"Participants will perform the following:~1. 45 minutes of cycling~2. 45 minutes of upper extremity repetitive arm exercises"
62338337|NCT03819764|ACTIVE_COMPARATOR|Upper Extremity Repetitive Task Practice Only|"Participants will perform the following:~1. 90 minutes of upper extremity repetitive arm exercises"
62338338|NCT04060264|EXPERIMENTAL|BCD-148|"14 participants in BCD-148 group. During the main period (first 27 weeks), test product BCD-148 will be administered as 25- to 45-minute intravenous infusions.~After Week 27 BCD-148 900 mg will be administered biweekly as maintenance therapy."
62696461|NCT05492045|EXPERIMENTAL|Phase 1b Dose escalation of D-1553 combination therapies|Phase 1b will determine maximal tolerated dose and/or recommended phase 2 dose of D-1553 in combination with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
62696462|NCT05492045|EXPERIMENTAL|Phase 2 of D-1553 combination therapies|Phase 2 will evaluate the efficacy and safety of D-1553 combined with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
62696463|NCT00381641|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity
62696464|NCT05712109||ACL group|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8 months after the surgery
62338339|NCT04060264|ACTIVE_COMPARATOR|Soliris|"14 participants in Soliris group. During the main period (first 27 weeks), Soliris® will be administered as 25- to 45-minute intravenous infusions.~After Week 27, patients be switched to BCD-148 900 mg biweekly as maintenance therapy."
62338340|NCT01790217||Cohort|
61943028|NCT04046198|OTHER|Control group|The nurses working in the University of Health Sciences Antalya Training and Research Hospital constituted the control group. Pre-test was applied to nurses who accepted the research. Post test applied 3 months later. A booklet on the subject prepared by the researchers was given after the post test. Group training was conducted to nurses.
61943029|NCT04470778|EXPERIMENTAL|BMS-986256|
62494979|NCT03806491|ACTIVE_COMPARATOR|Sleep Hygiene + AUD-TAU|Sleep hygiene education delivered once to all participants
62696465|NCT02678377|ACTIVE_COMPARATOR|OnabotulinumtoxinA injections|100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
62696466|NCT02678377|SHAM_COMPARATOR|Saline injections|100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
62696467|NCT06241352|EXPERIMENTAL|Statin addition to chemotherapy|Chemotherapy plus atorvastatin was used in locally advanced pancreatic cancer.
62696468|NCT05271383||Study group|Male and female, major or minor, who will be treated by orthognathic surgery (maxillary, mandibular, maxillomandibular or/with genioplasty). The bone maturity of the participants (assessed by investigators) need to be sufficient for the treatment.
61943030|NCT04470778|EXPERIMENTAL|BMS-986256 + Famotidine|
61943031|NCT00199485|EXPERIMENTAL|1|Angelica Sinensis
61943032|NCT00199485|PLACEBO_COMPARATOR|2|placebo
62338341|NCT00953043|ACTIVE_COMPARATOR|Lubiprostone|Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
62338342|NCT00953043|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm received placebo medication for three days.
62338343|NCT01747278|NO_INTERVENTION|Placebo|Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).
62338344|NCT01747278|EXPERIMENTAL|TMP/SMX|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.
62338345|NCT01009788|EXPERIMENTAL|TMZ/ABT888|Combination therapy with temozolomide and veliparib
62338346|NCT04091230|EXPERIMENTAL|novel needle|TRUSbx using the 18 gauge (G) 25 centimeter(cm) novel needle with 19 millimeter (mm) sample notch and a new actuator. 12 biopsies / patient.
62338347|NCT04091230|ACTIVE_COMPARATOR|standard tru cut needle|TRUSbx using a standard tru cut biopsy needle (Mermaid Medical M-biopsy 18G 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator ( Moller Medical Blue RBG-1000-10-1000). 12 biopsies/ patient.
62338348|NCT01800006||Group 1|
62338349|NCT00358917|EXPERIMENTAL|LPV/r 800/200 mg QD Tablet|
62338350|NCT00358917|ACTIVE_COMPARATOR|LPV/r 400/100 mg BID Tablet|
62494980|NCT04891692|EXPERIMENTAL|Phasic Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's phasic setting. Treatment at 3 kHz, modulation 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
62494981|NCT04891692|EXPERIMENTAL|Combined Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's combined (tonic and phasic) setting. Treatment at 3 kHz, modulation 4 Hz and 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
62494982|NCT04893590|EXPERIMENTAL|Fatigue self-management SMS intervention|The participants will receive a 12-week fatigue self-management SMS text intervention using mobile phones to target patient activation levels in people with disabilities.
61943033|NCT01628172|EXPERIMENTAL|Biosense Webster Celcius Thermacool catheter|These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
61943034|NCT01628172|NO_INTERVENTION|renal angiogram only|Control Group: Control arm will not receive intervention but will be followed for 1 year.
61943035|NCT04398316|EXPERIMENTAL|Intravenous Lidocaine|Administered at a dose of 2 mg/kg over 5 minutes
61943036|NCT04398316|ACTIVE_COMPARATOR|Intravenous Hydromorphone|Administered at a dose of 1 mg over 5 minutes
61943037|NCT02628938|EXPERIMENTAL|Miswak extract mouth wash|50% mouthwash aqueous solution 5ml twice a day for 7 days
62696469|NCT01648933|EXPERIMENTAL|Sarcoidosis|"Rubidium PET:~Myocardial Perfusion Imaging"
62696470|NCT05516875|EXPERIMENTAL|High dose|JM-010 fixed combination drug (Group A) will be administered orally.
62696471|NCT05516875|EXPERIMENTAL|Low dose|JM-010 fixed combination drug (Group B) will be administered orally.
62696472|NCT05021848|EXPERIMENTAL|Experimental group|The experimental group (N=14) received a 90-minute partnered multicomponent exercises intervention once weekly for 12 weeks
61943038|NCT02628938|EXPERIMENTAL|Miswak sticks|Sticks twice a day for 7 days
62338351|NCT05000814||cDLT|patients using conventional double lumen tube for thoracic surgery
62338352|NCT05000814||VDLT|patients using Vivasight DLT for thoracic surgery
62696473|NCT05021848|NO_INTERVENTION|control group|The control group (N=14) carried out the usual activities without intervention. (After 12-wk, multicomponent exercises intervention will be given)
62696474|NCT06016244|EXPERIMENTAL|88% oxygen saturation threshold|Patients in this arm will receive supplemental oxygen when SpO2 falls below 88% or when other clinical symptoms indicate a need for supplemental oxygen.
62494983|NCT05358808|EXPERIMENTAL|γδ T cells (IMP, TCB008)|"After inclusion, all patients will receive lymphodepleting chemotherapy with fludarabine 30mg/m2 Day -6 to Day -3 \[total 120 mg/m2\] and cyclophosphamide 0.5g/m2 \[total 1.5 g/m2) Day -5 to Day -3,\]. This will be followed by a rest day (Day -2).~The first five patients (safety cohort) will receive 1.8mL of TCB008 (containing 3.5x10\^7 to 11.0x10\^7 cells) on Day 0.~After treatment of the first five safety patients, the remaining 48 patients will receive 5mL of TCB008 (containing 12.0x10\^7 to 23.0x10\^7 cells) on Day 0."
62138841|NCT05254912|ACTIVE_COMPARATOR|6% BEMT in petrolatum (SU E 101413 82)|"Assess the photoallergenic potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
62338353|NCT05957497||Pedestrian transport|Modality of transport currently used
61943039|NCT02628938|ACTIVE_COMPARATOR|Chlorohexidine gluconate mouth wash|0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days
62338354|NCT05957497||Drone transport|Innovative modality of transport
62338355|NCT01553916|EXPERIMENTAL|Arm 1: Lithium carbonate + prophylactic cranial irradiation|"Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.~PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium."
62338356|NCT04933721|EXPERIMENTAL|BCX7353 Capsules 150 mg once daily|Berotralstat (BCX7353) 150 mg capsule orally administered once daily.
62338357|NCT04359355||Artificial Intelligence|
62338358|NCT02176590|EXPERIMENTAL|Power PATH|Classroom PATHS Social Emotional Learning Curriculum (for preschool classrooms) plus Coping Power parent intervention (teaches parents what children are learning in the classroom PATHS program and also provides parents with mental health intervention and parenting topics to promote family well-being)
62338359|NCT02176590|ACTIVE_COMPARATOR|Head Start as usual|Head Start as usual (will measure the effects of Head Start programming as usual on the primary outcomes)
62338360|NCT05835388||Primary Study|Community dwelling adults from the South Texas area who are interested in volunteering for research studies on aging. This will facilitate the inclusion of older adults and minority in research studies and help to increase the quantity and quality of research relating to them.
62338361|NCT05835388||KAPP Sen Tissue Mapping Study|The substudy KAPP Sen TMC will enroll eligible STARR participants to undergo repeat assessments over two years. KAPP Sen TMC is a collaborative effort between UT Health San Antonio, Jackson Laboratory for Genomic Medicine (JAX-GM), Brigham and Women's Hospital, Joslin Diabetes Center, UConn Health Center on Aging and Mayo Clinic to characterize cellular senescence in terms of its presence and heterogeneity in healthy human tissues, as well as its tissue burden, spatial distribution, and biological features in a diverse study population.
62338362|NCT04108013|EXPERIMENTAL|SHR-1210+Carboplatin+Paclitaxel-albumin|Subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
62494984|NCT06257979|OTHER|Experimental group|Operated patients with positive results for their pre-operative microbiological samples.
61943040|NCT02927327|EXPERIMENTAL|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.~Zero Echo Time (ZTE) scan for head attenuation"
62338363|NCT04108013|ACTIVE_COMPARATOR|Carboplatin+Paclitaxel-albumin|Subject will receive carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
62696475|NCT06016244|ACTIVE_COMPARATOR|92% oxygen saturation threshold|Patients in this arm will receive supplemental oxygen when SpO2 falls below 92% or when other clinical symptoms indicate a need for supplemental oxygen.
61943041|NCT02927327|EXPERIMENTAL|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.~PET/MR Q Static (Q. MRAC)"
61943042|NCT01826721|NO_INTERVENTION|Standard of Care|Patients in the Standard of Care arm receive the usual in-hospital post-transplant medication teaching class led by a transplant pharmacist.
61943043|NCT01826721|ACTIVE_COMPARATOR|TMITT|Patients in this arm receive the standard of care plus the TMITT educational intervention.
61943044|NCT05380310|EXPERIMENTAL|Active alerts|"SMART ANGEL Intra-hospital System with active alerts"
61943045|NCT05380310|ACTIVE_COMPARATOR|Inactive alerts|"SMART ANGEL Intra-hospital System with inactive alerts"
61943046|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.~QoL questionnaire SF-12 and and a screening questionnaire were requested"
61943047|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
61943048|NCT06009692|EXPERIMENTAL|Upper Limb Neurodynamics Group|Upper limb Neuro-dynamics (Slider/Tensioner Technique) along with Task Oriented Training
62138842|NCT05056493|EXPERIMENTAL|Clinical Providers|Clinical provider site champions will be invited to participate in web-based quantitative surveys and a semi-structured interview
62494985|NCT06257979|OTHER|Control group|Operated patients with negative results for their pre-operative microbiological samples.
62494986|NCT01367782|ACTIVE_COMPARATOR|Active repetitive Transcranial Stimulation|Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
62494987|NCT01367782|SHAM_COMPARATOR|Sham Stimulation|The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
62494988|NCT00777855|EXPERIMENTAL|warfarin then warfarin plus rifampin|
62494989|NCT01903057|EXPERIMENTAL|Combination treatment|"Combination treatment with azithromycin, ivermectin and albendazole on day 1, followed by placebo on day 8~Placebo has same appearance and dosing as azithromycin."
62494990|NCT01903057|PLACEBO_COMPARATOR|Control (Standard of Care)|"Standard treatment with placebo, ivermectin and albendazole on day 1, followed by azithromycin on day 8~Placebo has same appearance and dosing as azithromycin."
62494991|NCT00939380|EXPERIMENTAL|P-SCIP|Arm I (Parent Social-Cognitive Intervention Program \[P-SCIP\]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
62494992|NCT00939380|EXPERIMENTAL|BPC|"Arm II (Best-recommended Psychosocial Care \[BPC\]): Participants undergo usual care and receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks."
62494993|NCT04334850|EXPERIMENTAL|Targeted antibiotic treatment according to the results of mPCR|a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
62494994|NCT04334850|OTHER|Control arm|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
62696476|NCT05718531|ACTIVE_COMPARATOR|acute coronary syndrome group1|50 patients will have triple therapy (Aspirin,75 mg once daily, clopidogrel 75 mg once daily, and Rivaroxaban 2.5mg BID) prescribed for 3 month, then clopidogrel and Rivaroxaban for the following 9 months.
62696477|NCT05718531|ACTIVE_COMPARATOR|acute coronary syndrome group 2|50 patients will be on Aspirin 75mg once daily, clopidogrel 75mg once daily for 1 year.
62138843|NCT05056493|EXPERIMENTAL|Parent/Caregivers|Patient and parent/caregiver subjects from the participating clinic sites will be enrolled. These participants are all adults - parents or caregivers of children and youth with special health care needs (CYSHCN) and adult patients with multiple chronic conditions (MCC) who are already receiving care at Duke Health.
62338364|NCT02506296|OTHER|Insulin treated T2D diagnosed >=35yrs|"split by presence or absence of severe endogenous insulin deficiency:~* Severe deficiency = fasting blood C-peptide ≤0.08nmol/L or stimulated C-peptide ≤0.2nmol/L or post meal urine C-peptide creatinine ratio ≤0.2nmol/mmol~* Retained endogenous insulin secretion = fasting blood C-peptide ≥0.25nmol/L or stimulated C-peptide ≥0.6nmol/L or post meal urine C-peptide creatinine ratio ≥0.6nmol/mmol~Groups will be compared for:~* glucose variability (via Continuous Glucose Monitoring System (CGM)) and hypoglycaemia risk (via hypoglycaemia questionnaire)~* glycaemic response to standard DPPIV inhibitor therapy"
62494995|NCT00274625|EXPERIMENTAL|1|Surgisis Gold Graft
62696478|NCT05718531|ACTIVE_COMPARATOR|chronic coronary syndrome group 1|33 patients with prescribed aspirin 75 mg once daily and Rivaroxaban 2.5 mg BID N.B: Patients with stents placement within a year will be excluded from this group
62338365|NCT02149056||Impaired Glucose Tolerance|
62494996|NCT00274625|ACTIVE_COMPARATOR|2|Control
62494997|NCT06176885|EXPERIMENTAL|Camrelizumab Group|Combined with Camrelizumab after irinotecan leucovorin and fluorouracil (FOLFIRI) chemotherapy and bevacizumab targeted induction therapy
62494998|NCT01581164||HSCT patients|Patients who have been treated with HSCT
62494999|NCT03330496||Preterm infants|preterm neonates (34-37 weeks gestational age, n=15)
62495000|NCT03330496||Term infants|term newborns (37-42 weeks gestation, n=15)
62495001|NCT03330496||Small infants|1-3 month-old infants (n=15)
62495002|NCT03330496||Older infants|3-6 month-old infants (n=15)
62495003|NCT04857593|EXPERIMENTAL|Intervention|"M4M online is a 6-week intervention for mothers with PND. The original M4M programme would be delivered face-to-face in groups of 8-12 mothers in weekly sessions lasting one hour. However, due to the current situation with COVID-19, we will therefore modify the original face-to-face intervention for this online study, as follows:~* Run groups of around 15-17 women to ensure that all participants can be visible on one screen during online delivery to create a stronger sense of community and connection~* Offer 6 weeks of intervention, also building on the evidence from the face-to-face intervention that by 6 weeks there is already a significant improvement in depressive symptoms compared with control interventions24~* Introduce a two-week lead-in period before the beginning of the six-session course, where mothers will be able to use WhatsApp and at least one (monitored) Zoom session to get to know each other."
62495004|NCT00869115|EXPERIMENTAL|1|TREATMENT 0.5 μg/kg/min
62495005|NCT00869115|EXPERIMENTAL|2|TREATMENT 1.0 μg/kg/min
62495006|NCT00869115|EXPERIMENTAL|3|TREATMENT 1.5 μg/kg/min
62495007|NCT00869115|PLACEBO_COMPARATOR|4|PLACEBO
62696479|NCT05718531|ACTIVE_COMPARATOR|chronic coronary syndrome group 2|33 patients with clopidogrel 75 mg once daily and Rivaroxaban 2.5mg BID
62138844|NCT03657316|EXPERIMENTAL|experimental school 1|"The experimental school 1 will receive the following:~* Nutritional and physical activity educational workshop~* Enhanced physical education~* Involvement of the morning broadcast~* Educational brochure will be sent to the parents~* A monthly telephone call or a text message will be sent to the parents~* Message to school administration to prevent selling of soft drinks and to sell healthy food~* A monthly session (3 months)"
62138845|NCT03657316|EXPERIMENTAL|experimental school 2|The experimental school 2 school will receive a nutritional and physical activity educational workshop; that will be held on three days through one week; one hour session each day
62138846|NCT03657316|NO_INTERVENTION|control|The control school will receive no intervention
62138847|NCT06517914|EXPERIMENTAL|YH35995|"\[Part A\] Participants will be orally administered a single dose of YH35995 in six dose groups, gradually escalating from lower to higher doses. Each cohort includes 10 participants (8 randomly assigned to the YH35995 arm and 2 randomly assigned to the placebo arm).~\[Part B\] Participants will receive multiple oral doses of YH35995 once every 4 weeks in three dose groups. Each cohort includes 12 participants (9 randomly assigned to the YH35995 arm and 3 randomly assigned to the placebo arm)."
62138848|NCT06517914|PLACEBO_COMPARATOR|Placebo|"\[Part A\] Participants will be orally administered a single dose of Placebo in six dose groups, gradually escalating from lower to higher doses. Each cohort includes 10 participants (8 randomly assigned to the YH35995 arm and 2 randomly assigned to the placebo arm).~\[Part B\] Participants will receive multiple oral doses of Placebo once every 4 weeks in three dose groups. Each cohort includes 12 participants (9 randomly assigned to the YH35995 arm and 3 randomly assigned to the placebo arm)."
62338366|NCT02575573||Admitted patients at the ED|
62338367|NCT05397223|EXPERIMENTAL|Part 1: mRNA-1345|Participants will receive single intramuscular (IM) injection of mRNA-1345 on Day 1.
62138849|NCT02893969|EXPERIMENTAL|Experimental group|Gradual reintroduction of non-contact physical activity at 72 hours post-concussion.
62138850|NCT02893969|SHAM_COMPARATOR|Control Group|Physical and cognitive rest post-injury until fully asymptomatic. Once asymptomatic participants can gradually reintroduce physical activity.
62495008|NCT03235141|EXPERIMENTAL|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
61943049|NCT06009692|ACTIVE_COMPARATOR|Upper Limb Conventional Therapy|Stretching, Strengthening exercises along with Task Oriented Training
61943050|NCT00757120||1|This group will include current and former smokers who have emphysema.
61943051|NCT00757120||2|This group will include current and former smokers who do not have emphysema.
61943052|NCT01006369|EXPERIMENTAL|FOLFOX6 + Bevacizumab + Hydroxychloroquine|"Arm A: FOLFOX6 + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 5 mg/kg in 100 cc Normal Saline every 14 days on day one.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
61943053|NCT01006369|EXPERIMENTAL|XELOX + Bevacizumab + Hydroxychloroquine|"Arm B: XELOX + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 7.5 mg/kg in 100 cc Normal Saline every 21 days.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
61943054|NCT03714802|EXPERIMENTAL|Szabo T-Stenting Technique|Patients received 2-stents implantation guided with Szabo technique in bifurcation lesion.
61943055|NCT03714802|PLACEBO_COMPARATOR|T-Stenting Technique|Patients received 2-stents implantation guided with T-stenting technique in bifurcation lesion.
61943056|NCT04961294|EXPERIMENTAL|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
62138851|NCT01540318|EXPERIMENTAL|Abdominal Ultrasound|"Patients in the experimental arm will receive a Focused Assessment with Sonography for Trauma (FAST) which includes the use of abdominal ultrasound."
62138852|NCT01540318|NO_INTERVENTION|No Abdominal Ultrasound|
62138853|NCT05677269||Colorectal endometriosis patients|Subfertile women between 21 and 40 years with colorectal endometriosis facing the choice between IVF/ICSI or laparoscopic resection of (colorectal) endometriosis.
62138854|NCT03054415|OTHER|Healthy Subjects|
62338368|NCT05397223|EXPERIMENTAL|Part 1: mRNA-1647 2-Dose|Participants will receive single IM injection of mRNA-1647 on Days 1 and 57.
62495009|NCT03235141|ACTIVE_COMPARATOR|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
61943057|NCT04961294|NO_INTERVENTION|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
61943058|NCT03491215|EXPERIMENTAL|Ruxolitinib|All pediatric participants received ruxolitinib twice a day (BID) for a planned duration of 24 weeks in either tablet, capsule or oral solution (liquid), depending on the group they were in.
62338369|NCT05397223|EXPERIMENTAL|Part 1: mRNA-1647 3-Dose|Participants will receive single IM injection of mRNA-1647 on Days 1, 57, and 169.
62338370|NCT05397223|EXPERIMENTAL|Part 2: mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1
62338371|NCT05397223|EXPERIMENTAL|Part 2: mRNA-1010|Participants will receive single IM injection of mRNA-1010 on Day 1.
61943059|NCT04863235|ACTIVE_COMPARATOR|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week, and set a physical activity goal. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Monitoring Physical Activity Session 4: Action and Coping Planning. Session 5: Self-Efficacy (master and vicarious experiences). Session 6: Self-Efficacy (modeling experiences, verbal persuasion). Session 7: Physical Activity Enjoyment and Barriers. Session 8: Making long-term Change. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, blood pressure, cholesterol, benefits of water, benefits of vitamin D, the Infodemic).
62338372|NCT05397223|ACTIVE_COMPARATOR|Part 2: FLUAD®|Participants will receive single IM injection of FLUAD® on Day 1.
62495010|NCT03622229|ACTIVE_COMPARATOR|EUS-FNB with side-fenestrated needle|"Before randomization, the endosonographer chooses the needle gauge to perform biopsy preferring the 25 gauge caliber for difficult lesions. The needle advances inside the lesion and the operator will perform some needle movements back and forth into the lesion while slowly withdrawn the stylet (slow-pull technique). If possible the direction of the needle inside the lesion will be changed during the movements (fanning technique) to sample different areas of the lesion. Three needle passes will be performed and the material acquired at each pass will be placed directly in formalin in a single vial.~Diagnostic Test: Histologic evaluation"
61943060|NCT04863235|EXPERIMENTAL|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week and set a physical activity goal. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Introduction to self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Mindfulness and Resistance. Session 6: Meeting Difficult Emotions. Session 7: Embracing the Good. Session 8: Applying Self-compassion to Physical Activity and Moving Forward.
61943061|NCT00590135|EXPERIMENTAL|AORTIC STENOSIS PATIENTS|Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis
61943062|NCT01635335|EXPERIMENTAL|HIV-specific|7-hour multiple family workshop focused on providing information and skills related to HIV prevention. Specific focus on parent-adolescent communication and parental monitoring.
61943063|NCT01635335|ACTIVE_COMPARATOR|General Health Promotion|7-hour multiple family workshop focused on providing information related to various adolescent health risk behaviors, including smoking, alcohol, violence, nutrition, and exercise.
62338373|NCT01490749|EXPERIMENTAL|XELOX/Radiation/Carboplatin/RAD001|Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
62338374|NCT02364167|EXPERIMENTAL|Verum acupuncture|Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
62338375|NCT02364167|PLACEBO_COMPARATOR|Placebo acupuncture|Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
62338376|NCT02364167|ACTIVE_COMPARATOR|Standard therapy|Each patient will receive just standard postoperative analgesia
62338377|NCT01441115|EXPERIMENTAL|ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer|ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer
61943064|NCT01595711||Thoracotomized patients|
62338378|NCT02290886|PLACEBO_COMPARATOR|Placebo|Intravenous administration of placebo
62338379|NCT02290886|EXPERIMENTAL|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
62338380|NCT02290886|EXPERIMENTAL|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
62338381|NCT02290886|EXPERIMENTAL|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
62495011|NCT03622229|ACTIVE_COMPARATOR|EUS-FNB with fork-tip needle|"Intervention: like above.~Diagnostic Test: Histologic evaluation."
61943065|NCT05062967||HAOD Cohort|"This cohort includes patients with acute hepatitis of unknown origin, meaning its origin could not be determined after screening of (at least) HAV, HAB, HAC, HAE, Epstein-Barr virus and cytomegalovirus. Patients will be recruited in 17 centres nationwide.~The research group will receive a 1mL plasma / serum sample from each patient to study the presence of Ortho-C infection"
61943066|NCT05062967||OrthoC-Tx Cohort|This cohort includes liver or kidney transplant patients under follow-up. The research group will receive a 1mL plasma / serum sample every year from each patient to study the presence of Ortho-C infection
61943067|NCT05062967||Ortho-CoRIS Cohort|"This cohort includes VIH positive patients who are in follow-up by the Spanish Network of AIDS Research.~The research group will receive a plasma / serum sample every year from each patient to study the presence of Ortho-C infection."
61943068|NCT05062967||TrazHE Cohort|"This cohort includes patients whose clinical picture is compatible with HAE infection.~The presence of Ortho-C infection will be studied in patients with positive IgM for HAE and absence of RNA-HAE."
62138855|NCT02940249|EXPERIMENTAL|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
62338382|NCT01329523||Subjects with AD|Subjects with a diagnosis of dementia
62338383|NCT01329523||Family Members|Younger biological family members of the patients with dementia
62338384|NCT01329523||Control Group|Individuals without dementia matched in age to the patients with a dementia diagnosis
62338385|NCT04073940|EXPERIMENTAL|Targeted Ballet Program|A 16-week (32 sessions of 1 hour each) ballet-based intervention targeted to improve motor function in persons with multiple sclerosis.
62338386|NCT03895944|EXPERIMENTAL|iv low dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with low dose (1x10\^6) in Leukemia or Lymphoma patients
62338387|NCT03895944|EXPERIMENTAL|iv middle dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with middle dose (3x10\^6) in Leukemia or Lymphoma patients
62338388|NCT03895944|EXPERIMENTAL|iv high dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with high dose (10x10\^6) in Leukemia or Lymphoma patients
62495012|NCT02413034|PLACEBO_COMPARATOR|Control group|no antibiotic prophylaxis group
62495013|NCT02413034|ACTIVE_COMPARATOR|Study group cefazolin|Classical antibiotic prophylaxis
62495014|NCT02238587|PLACEBO_COMPARATOR|Placebo/Ganoderma|In control group, oral placebos for 6 weeks. Then the patients in control groups are switched, Ganoderma Spores Powder Capsules are given for 6 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
61943069|NCT05062967||Ortho-C-Rodent Cohort|This cohort includes wild rats. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in wild rats (Ortho-C's main reservoir).
61943070|NCT05062967||Ortho-C-Domestic Rodent Cohort|This cohort includes domestic rats and mustelids. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in domestic rats and mustelids.
62138856|NCT02940249|EXPERIMENTAL|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
62138857|NCT02940249|EXPERIMENTAL|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
62495015|NCT02238587|EXPERIMENTAL|Ganoderma|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
62696480|NCT05718531|ACTIVE_COMPARATOR|chronic coronary syndrome group 3|34 patients with aspirin 75 mg once daily and clopidogrel 75 mg once daily.
62696481|NCT06545617|ACTIVE_COMPARATOR|Cohort 1|BAT8006 for Injection does according to protocol (frequency: Q3W)
62696482|NCT06545617|ACTIVE_COMPARATOR|Cohort 2|BAT8006 for Injection does according to protocol (frequency: Q3W)
62696483|NCT06545617|ACTIVE_COMPARATOR|Cohort 3|BAT8006 for Injection does according to protocol (frequency: Q3W)
61943071|NCT05062967||Ortho-C-Carnivore Cohort|"This cohort includes 236 wild carnivores that feed off rodents. Carnivores' cause of death is they were run over.~Feces, liver and serum samples will be taken to study the transmission of Ortho-C."
61943072|NCT04248751|EXPERIMENTAL|Graft-Augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin. Then, the graft will be delivered to the subacromial space and positioned over the bursal surface of the suprasinatus tendon, ensuring that the lateral edge of the implant will overlap with the head of the humerus. The graft will be fixed with tendon and bone staples.
61943073|NCT04248751|ACTIVE_COMPARATOR|Non-augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin.
61943074|NCT03398200|EXPERIMENTAL|Hyperbaric Oxygen Therapy|Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
61943075|NCT03398200|ACTIVE_COMPARATOR|No Hyperbaric Oxygen Therapy|Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
61943076|NCT02734082||Elevated Troponin and pathological EC|Patients with acute ischemic stroke with elevated Troponin
61943077|NCT02734082||No elevated Troponin or pathological EC|Patients with acute ischemic stroke without elevated Troponin
62696484|NCT05748769|EXPERIMENTAL|UL group|SIngle session of practicing RM sequence with the UL towards illuminating switches
62696485|NCT05748769|ACTIVE_COMPARATOR|Switches observation - SO group|Single session of observation of sequence of illuminating switches
62696486|NCT05748769|ACTIVE_COMPARATOR|(Nature observation -NO group|Single session of observation of nature movies
62696487|NCT06571877|EXPERIMENTAL|Control energy density condition|Each participant is its own control (cross-over design). Participants receive a bowl with 1000 ml food content consisting of oats, apple pie, grated nuts and milk having an energy density of 1,42 kcal/g. The participants are allowed to eat ad libitum for 45 minutes.
62696488|NCT06571877|EXPERIMENTAL|High energy density condition|Participants receive a bowl with 1000 ml food content consisting of oats, apple pie, grated nuts, milk and neutral-tasting vegetable oil having an energy density of 1,84 kcal/g.The participants are allowed to eat ad libitum for 45 minutes.
62696489|NCT04171895||Enhanced Usual Care (EUC)|
61943078|NCT02734082||Elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke with elevated Troponin T and pathological ECG and coronary angiography
61943079|NCT02734082||No elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke without elevated Troponin T and pathological ECG and coronary angiography
61943080|NCT01180101|ACTIVE_COMPARATOR|Lifestyle modification group|This group will undergo supervised exercise training 5 days per week and follow hypocaloric diet for 12 weeks. All exercise training sessions will be supervised by an Exercise Physiologist or Research Nurse, and will be conducted in the Exercise Physiology Laboratory at the CCF CRU. Exercise training will consist of walking, running on a treadmill, and stationary cycling on a cycle ergometer. Each exercise session will include a brief standardized warm-up and cool-down that include a series of stretching exercises.
61943081|NCT01180101|ACTIVE_COMPARATOR|Bariatric Surgery Group|This group will include CKD patients who undergo bariatric surgery.
61943082|NCT01180101|NO_INTERVENTION|CKD Group (control)|This group will not undergo any form of weight loss intervention
61943083|NCT02247531|EXPERIMENTAL|Lampalizumab once in every 4 weeks (Q4W)|Participants will receive 10 mg (milligrams) dose of lampalizumab by intravitreal injection, Q4W, starting at the Day 1 visit for approximately 92 weeks.
62696490|NCT04171895||Communication Training|
62696491|NCT01055340|EXPERIMENTAL|Treatment sequence 1|OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo
62696492|NCT01055340|EXPERIMENTAL|Treatment sequence 2|OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min
62696493|NCT01055340|EXPERIMENTAL|Treatment sequence 3|Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min
62696494|NCT01055340|EXPERIMENTAL|Treatment sequence 4|OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min
62696495|NCT01055340|EXPERIMENTAL|Treatment sequence 5|Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min
62696496|NCT01055340|EXPERIMENTAL|Treatment sequence 6|OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo
61943084|NCT02247531|EXPERIMENTAL|Lampalizumab once in every 6 weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab by intravitreal injection, Q6W, starting at the Day 1 visit for approximately 90 weeks.
61943085|NCT02247531|SHAM_COMPARATOR|Sham Comparator|Participants will receive sham comparator, Q4W, starting at the Day 1 visit for approximately 92 weeks or Q6W, starting at the Day 1 visit for approximately 90 weeks.
61943086|NCT05576675|EXPERIMENTAL|SN group|sufentanil 100 μ g + nalbuphine 40 mg
61943087|NCT05576675|EXPERIMENTAL|HN group|hydromorphone 10 mg+ nalbuphine 40 mg
62696497|NCT02033941|ACTIVE_COMPARATOR|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
62696498|NCT02033941|PLACEBO_COMPARATOR|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
62696499|NCT00302822|EXPERIMENTAL|Intensification|lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)
62696500|NCT00302822|ACTIVE_COMPARATOR|Standard|lopinavir or efavirenz and emtricitabine/tenofovir
62138858|NCT02940249|PLACEBO_COMPARATOR|Placebo|No polyphenols delivered in a low sugar drink.
61943088|NCT05576675|EXPERIMENTAL|S group|sufentanil 200 μ g,
62138859|NCT02925988|OTHER|EEG monitoring|Neonates will receive their aEEG monitoring as soon as the indication for monitoring is established, and cEEG electrodes will be applied in parallel, as soon as an EEG technician is available, which should usually be within less than 16 hours, in many cases within 1-4 hours.
62138860|NCT04241640|EXPERIMENTAL|Nefopam group[|
62338389|NCT03772561|EXPERIMENTAL|AZD5363+Olaparib+Durvalumab|"A traditional 3+3 design will be used during the dose escalation part of the study.~Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities."
62138861|NCT04241640|PLACEBO_COMPARATOR|placebo group|
62138862|NCT02641938|EXPERIMENTAL|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
62338390|NCT04729920||subjects with neuromuscular disease|Adult subjects with neuromuscular disease, with an active prescription of MI-E for more than 3 months
62338391|NCT00840944|EXPERIMENTAL|ZOMATRIP|GnRH agonist triptorelin plus somatropin
62338392|NCT03896789|NO_INTERVENTION|Baseline|All sites will collect usual care data from 9 months to 21 months.
62338393|NCT03896789|EXPERIMENTAL|PEGASUS Program (Intervention)|This arm (half of the sites) will receive the PEGASUS program (intervention) from 21 months to 57 months.
62696501|NCT05843604||obsessive compulsive disorder patients|
62696502|NCT05843604||Control Patients|
62696503|NCT06642090|NO_INTERVENTION|Control Group: Standard Care in Hemodialysis|This arm of the study includes 34 patients undergoing hemodialysis who will notany intervention. Participants will continue to receive the usual care provided by the hemodialysis center. No educational sessions will be delivered in this group. Clinical outcomes, including health parameters, will be assessed in comparison to those in the intervention group after the study period.
62495016|NCT04330547|ACTIVE_COMPARATOR|Analgesic administration|"The analgesic treatment will be tailored to the patient's medication and will be based on 3 levels (based on Ventafridda et al., 1985):~* Level 1 : Non-opioid analgesics~* Level 2 : Weak opioids analgesics~* Level 3 : Strong opioids analgesics~If the patient is already on pain medications, we will add the lowest effective dose of the level above the level of the regular pain medications of the patient. (e.g. if the patient has no analgesic treatment, he will be given a non-opioid analgesic (level 1). If he already has a level 1 treatment, we will go for level 2 medication. If he has level 2 treatment, we will go for level 3. And if the patient is already at level 3, we will increase the dosage by steps (reference: 5mg oxycodone as first choice for level 3 drugs)). Preferably, the medication will be administered by oral intake or gastrostomy feeding tube. If it is not possible, other routes of administration are allowed."
62338394|NCT03896789|NO_INTERVENTION|Usual Care (Control)|This arm (half of the sites) will maintain usual care. They will receive the opportunity for the PEGASUS program training (intervention) at the end of study data collection (57 months) period.
61943089|NCT01847742|EXPERIMENTAL|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
61943090|NCT01847742|NO_INTERVENTION|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
61943091|NCT02826278||Healthy female newborns|Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances
62138863|NCT02641938|PLACEBO_COMPARATOR|Normal Saline|IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
62495017|NCT04330547|PLACEBO_COMPARATOR|Placebo administration|Folavit capsules will be used as a placebo
61943092|NCT04915027|EXPERIMENTAL|Intervention i.e. with Rehabkompassen®|The participants will use the digital graphic Rehabkompassen® at follow-up.
61943093|NCT04915027|ACTIVE_COMPARATOR|Control exposure i.e. without Rehabkompassen®|"The participants will use Post-Stroke Checklist at follow-up as recommended by Socialstyrelsen."
61943094|NCT00417118|EXPERIMENTAL|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
61943095|NCT00417118|ACTIVE_COMPARATOR|Escitalopram 10 mg|Escitalopram 10 mg once daily in the morning for a maximum of 8 weeks
61943096|NCT00417118|PLACEBO_COMPARATOR|Placebo|Placebo for one week during the run in period and for a maximum of 8 weeks during the active period
61943097|NCT05303077|EXPERIMENTAL|Study Infant Formula|Infant formula supplemented with omega 3 fatty acids and inactive Bifidobacteria
61943098|NCT05303077|ACTIVE_COMPARATOR|Infant Formula|Infant formula
62138864|NCT02284113|EXPERIMENTAL|Treatment|Treatment with focused cold therapy.
62138865|NCT02284113|SHAM_COMPARATOR|Sham|Sham treatment with focused cold therapy device
62138866|NCT06698588|EXPERIMENTAL|Active intervention|Supplement
62138867|NCT06698588|EXPERIMENTAL|Placebo intervention|Supplement
62138868|NCT05521906|EXPERIMENTAL|Treatment Condition|The PRYSHM program is theoretically grounded, follows best practices for effective health behavior prevention, and includes nine, one hour sessions co-facilitated by 2 LGBTQ+ adults.
62138869|NCT05521906|NO_INTERVENTION|Control|Check-ins/provision of resources
62138870|NCT03805243|EXPERIMENTAL|test of sensors for somnonaute device|monitoring with sensors
62495018|NCT00917787||Healthy, Non-asthmatic|
62495019|NCT00917787||Asthma|
62495020|NCT02246296|ACTIVE_COMPARATOR|Standard F75 Milk|F75 with 63% of total energy from carbohydrates, including 10% of energy from lactose (standard F75).
62495021|NCT02246296|EXPERIMENTAL|Modified F75 Milk|F75 milk with 43% of total energy from carbohydrates, without any lactose, and providing the same amount of energy as standard F75 by increased lipid in the form of medium chain triglycerides.
62495022|NCT02532192|EXPERIMENTAL|Belinostat + RDHAP Chemotherapy|Belinostat administered by vein on Days 1 - 2 of a 21-day cycle. Rituximab administered by vein on Day 2. Cisplatinum administered by vein on Day 2. Cytarabine administered by vein on Day 3 during the initial cohorts, and on Day 2 in the cohort of modified DHAP scheduling. Ciprofloxacin 500 mg twice daily for 10 days and Fluconazole 100 mg daily for 10 days may be utilized at the discretion of the treating physician.
62495023|NCT03658434|EXPERIMENTAL|feasibilty|Palliative Radiotherapy
61943099|NCT05303077|ACTIVE_COMPARATOR|Breastfeed Active comparator|Infants who are breastfed
61943100|NCT00578383|SHAM_COMPARATOR|Sham (inactive) Treatment BPD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
62138871|NCT03805243|EXPERIMENTAL|test of sensors for uronaute device|monitoring with sensors
62138872|NCT03805243|EXPERIMENTAL|test of sensors for toconaute device|monitoring with sensors
62138873|NCT03805243|EXPERIMENTAL|test of sensors for cardioskin device|monitoring with sensors
62138874|NCT03805243|EXPERIMENTAL|test of sensors for neuronaute device|monitoring with sensors
62138875|NCT02138994|ACTIVE_COMPARATOR|Triple Antibiotic Ointment Neosporin|Daily direct application to the wound, covered with conventional dressing. Dressing should be changed daily or as directed by the health care provider.
62138876|NCT02138994|EXPERIMENTAL|Next Science Wound Gel|Daily direct application to the wound, covered with a conventional non-alginate dressing. Dressing should be changed daily or as directed by the health care provider.
62138877|NCT04899011||Middle ear surgery|
62138878|NCT00351299|EXPERIMENTAL|Infusion of dexmedetomidine|infusion 0.3-0.7 dexmedetomidine
62495024|NCT03492476|EXPERIMENTAL|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
61943101|NCT00578383|ACTIVE_COMPARATOR|Active LFMS treatment in BPD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
61943102|NCT00578383|SHAM_COMPARATOR|Sham LFMS Comparator: in MD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
61943103|NCT00578383|ACTIVE_COMPARATOR|Experimental LFMS: in MD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
61943104|NCT01298635|ACTIVE_COMPARATOR|trab|
62138879|NCT00351299|OTHER|Standard of Care|Standard of care per treating physician preference
62138880|NCT01940107|OTHER|Control Group (CG)|Control Group, which were subjected only to evaluations and to no exercise
62138881|NCT01940107|EXPERIMENTAL|Study Group (SG)|Study group (SG), was oriented to perform domiciliary exercises for the upper limbs.
62138882|NCT03901989|ACTIVE_COMPARATOR|zeolite|50 subjects receive the substance 3 times per day as powder
62138883|NCT03901989|PLACEBO_COMPARATOR|cellulose|50 subjects receive the substance 3 times per day as powder
62138884|NCT02524769|OTHER|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
62495025|NCT03492476|ACTIVE_COMPARATOR|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
62495026|NCT00991692|EXPERIMENTAL|Treatment dosage levels examined|
62495027|NCT02373839|OTHER|PlGF measurement|Determination of PlGF levels. If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks.
62495028|NCT02373839|NO_INTERVENTION|Controls|induction of labour at 37 weeks of gestation.
62495029|NCT04043702||on topiramate|"topiramate, conviban® group vs no treatment ( control group)."
62495030|NCT04043702||on empagliflozine|"empagliflozine, jardiance® vs no treatment ( control group)."
62495031|NCT04043702||on topiramate plus empagliflozine|all patients' vs no treatment ( control group).
62495032|NCT04043702||no treatment|all patients' vs no treatment ( control group).
62696504|NCT06642090|EXPERIMENTAL|Intervention Group|This intervention group includes 36 patients at a public hemodialysis center in the Marrakech-Safi region. this group will engage in an educational program designed to enhance their understanding of chronic kidney disease and promote self-care for venous access. The curriculum covers topics such as disease etiology, symptoms, hemodialysis principles, medication roles, and dietary recommendations. The ultimate objective is to improve treatment adherence and optimize the management of dry weight and interdialytic weight, surpassing the standard care received by the control group.
62696505|NCT05562388|EXPERIMENTAL|MAD therapy|MAD Therapy
61943105|NCT01298635|ACTIVE_COMPARATOR|phacotrab|
62138885|NCT03018561|ACTIVE_COMPARATOR|aged-gender matched healthy controls|Healthy subjects: with no MetS and no-documented coronary heart disease (CHD), both males and females, aged\>18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
62495033|NCT05545228|EXPERIMENTAL|Intervention group|Participants will receive treatment as usual plus a link work intervention to support access to dental services.
62495034|NCT05545228|NO_INTERVENTION|Treatment as usual group|Participants to receive treatment as usual and will not receive the intervention.
62495035|NCT01714284|EXPERIMENTAL|Diet and Exercise|
62495036|NCT01714284|SHAM_COMPARATOR|Informative|
62495037|NCT00766493|EXPERIMENTAL|GORE® Embolic Filter|Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
62495038|NCT02806063|OTHER|Intraoperative samples|During this study of health care procedure evaluating microbiological setting in PJI prior prosthesis implantation with one stage surgery, 3 additional perioperative samples will be performed prior prosthesis implantation for every patient.
62138886|NCT03018561|EXPERIMENTAL|patients with metabolic syndrome|Patients with MetS and no-documented CHD, both males and females, aged \> 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Metabolic syndrome (MetS) will be defined according to recent updated criteria (Alberti et al. 2005):presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides \> 1.70 mmol/l, decreased HDL-cholesterol (\< 1.0 mmol/l in men and \< 1.3 mmol/l in women), systolic blood pressure \> 130 mmHg or diastolic blood pressure \> 85 mmHg, and FPG \> 5.6 mmol/l.
61943106|NCT05972473|ACTIVE_COMPARATOR|Aflibercept|Drug: Aflibercept 2mg/eye; Intraocular injection
61943107|NCT05972473|EXPERIMENTAL|IBI302 dose 8mg|Drug: IBI302 8mg/eye; Intraocular injection
61943108|NCT03528707|ACTIVE_COMPARATOR|probiotic-omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
62495039|NCT04913545||normal group|participants with out any systemic medical problemes or oral lesions. we will only take saliva sample.
62495040|NCT04913545||potientially malignant group|participants with suspicious oral lesions without any medical diseases. we will take saliva sample and take a biopsy sample .
62495041|NCT04913545||malignant group|participants with already diagnosed oral malignant lesions without receiving any treatment yett
62495042|NCT03548480|PLACEBO_COMPARATOR|Placebo|
62495043|NCT03548480|EXPERIMENTAL|Probiotic|
62495044|NCT01529164|EXPERIMENTAL|treatment|
62495045|NCT04432077|EXPERIMENTAL|Treatment|All participants receive the DINOSAUR intervention
62696506|NCT04846946|NO_INTERVENTION|Control|Time attention control condition.
62696507|NCT04846946|EXPERIMENTAL|Intervention, Module 1 - Knowledge|20-minute module that aims to improve HIV prevention knowledge.
62696508|NCT04846946|EXPERIMENTAL|Intervention, Module 1 - Stigma|20-minute module that aims to reduce SGM- and HIV- related stigma.
62696509|NCT04846946|EXPERIMENTAL|Intervention, Module 1 - Prevention|20-minute module that aims to promote HIV prevention strategies including testing and PrEP.
62495046|NCT04951856|EXPERIMENTAL|Evolocumab + SOC|Investigational Product is open label Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
62738523|NCT03287882|EXPERIMENTAL|MMN supplementation and life skills education|"1. Preconception period: twice-weekly MMN supplementation and bi-monthly group session including life skill based education materials~2. Pregnancy period: daily MMN supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~3. Postpartum period: daily MMN supplementation to 6 months postpartum"
62495047|NCT04951856|ACTIVE_COMPARATOR|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
62696510|NCT05920252|EXPERIMENTAL|Digitally enhanced treatment supported by the Vira platform|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
62696511|NCT05920252|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
62696512|NCT02215473|EXPERIMENTAL|gingivitis mouth rinse|
61943109|NCT03528707|PLACEBO_COMPARATOR|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
61943110|NCT03239184|ACTIVE_COMPARATOR|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (\> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
61943111|NCT03239184|ACTIVE_COMPARATOR|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
61943112|NCT03239184|EXPERIMENTAL|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (\> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62138887|NCT03018561|EXPERIMENTAL|patients with coronary heart disease|CHD patients, both males and females, aged \> 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
62138888|NCT03018561|EXPERIMENTAL|patients with chronic heart failure|"Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:~* ≥18 years~* Left ventricular ejection fraction (LVEF) \<40% (measured within 6 months of their enrolment by a multigated acquisition Scan, echo or radiological ventriculography)~* NYHA functional class I-III~* Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).~* Able to perform an symptom limited exercise test.~* Capacity and willingness to sign the informed consent form."
62138889|NCT03766191|ACTIVE_COMPARATOR|Food Ads and fMRI|Exposure to food ads during an fMRI scan
62138890|NCT03766191|SHAM_COMPARATOR|Non-Food Ads and fMRI|Exposure to non-food ads during an fMRI scan
62338395|NCT05278650|OTHER|Communities Adopting Senior PharmAssist Implementation Toolkit|"Three communities will commit to learning how to implement the evidence-based, multi-component intervention, Senior PharmAssistTM (SPA), designed to improve function and quality of life of older adults with limited incomes using the SPA toolkit.~The toolkit, co-developed with community leaders, will help to create a community model for implementation that addresses equitable access to medications, medication management, and community supports that promote physical function and healthy aging in place."
62338396|NCT01718509|EXPERIMENTAL|SPD489 (Lisdexamfetamine dimesylate)|
62338397|NCT01718509|PLACEBO_COMPARATOR|Placebo|
62338398|NCT01760941|EXPERIMENTAL|Treatment (radiation therapy)|"This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment."
62338399|NCT00663728|EXPERIMENTAL|Arm 1|
62696513|NCT02215473|EXPERIMENTAL|periodontitis mouth rinse|
61943113|NCT03239184|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62138891|NCT03766191|ACTIVE_COMPARATOR|Food Ads and TV show|Exposure to food ads embedded in an age-appropriate TV program
62138892|NCT03766191|SHAM_COMPARATOR|Non-Food Ads and TV show|Exposure to non-food ads embedded in an age-appropriate TV program
62138893|NCT06682728|EXPERIMENTAL|Sacituzumab Govitecan PLUS Nivolumab|Patients eligible for this study treatment will receive combination therapy with Sacituzumab Govitecan with Nivolumab for 4 cycles, followed by single-agent Nivolumab for an additional 11 cycles.
62138894|NCT00680199||1|Primary Insomnia
62338400|NCT00663728|PLACEBO_COMPARATOR|Arm 2|
62338401|NCT02985814||patients with airway obstruction|Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC \< 0.7) willing to sign an informed consent.
62495048|NCT06144060|EXPERIMENTAL|Treatment group A：HRS-8427|
62495049|NCT06144060|EXPERIMENTAL|Treatment group B：HRS-8427|
62495050|NCT06144060|ACTIVE_COMPARATOR|Imipenem and Cilastatin Sodium|
62495051|NCT02061358|EXPERIMENTAL|Cohort 1 - 3 mg UV-4B|Subjects receiving UV-4B 3 mg oral solution or placebo
62495052|NCT02061358|EXPERIMENTAL|Cohort 2 - 10 mg UV-4B|Subjects receiving UV-4B 10 mg oral solution or placebo
62495053|NCT02061358|EXPERIMENTAL|Cohort 3- 30 mg UV-4B|Subjects receiving UV-4B 30 mg oral solution or placebo
62338402|NCT00849121|EXPERIMENTAL|1|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then every 12 weeks until disease progression.
62138895|NCT00680199||2|Good Sleepers
62138896|NCT01988649|ACTIVE_COMPARATOR|Intranasal Oxytocin|Administration of 32 units of Oxytocin administered intranasally
62138897|NCT01988649|PLACEBO_COMPARATOR|Placebo (saline)|Administration of 4 sprays intranasally of normal saline.
62138898|NCT06509243|ACTIVE_COMPARATOR|SLIT HDM|Patients received sublingual allergen immunotherapy (Acarizax), adding to symptomatic therapy for atopic dermatitis (according to recommendations).
62696514|NCT02215473|ACTIVE_COMPARATOR|gingivitis no mouth rinse|
62138899|NCT06509243|ACTIVE_COMPARATOR|biologic|Patients received dupilumab, added to symptomatic therapy for atopic dermatitis (according to recommendations.)
62138900|NCT06509243|ACTIVE_COMPARATOR|Combi therapy|Patients received sublingual allergen immunotherapy (Acarizax) and dupilumab, added to symptomatic therapy for atopic dermatitis (according to recommendations).
62138901|NCT06509243|PLACEBO_COMPARATOR|cyclosporine|Patients received cyclosporine added to symptomatic therapy for atopic dermatitis (according to recommendations).
62138902|NCT04856085|EXPERIMENTAL|Cohort 1a (VIR-2218 + VIR-3434)|Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
61943114|NCT04651985||Injured Achilles tendon participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
61943115|NCT04651985||Healthy Achilles tendon (contralateral) of participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
62138903|NCT04856085|EXPERIMENTAL|Cohort 2a (VIR-2218 + VIR-3434)|Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
62138904|NCT04856085|EXPERIMENTAL|Cohort 3a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
61943116|NCT01090284||Heavy weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene heavy weight mesh.
62138905|NCT04856085|EXPERIMENTAL|Cohort 4a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
62138906|NCT04856085|EXPERIMENTAL|Cohort 5a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
62138907|NCT04856085|EXPERIMENTAL|Cohort 6a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
62338403|NCT00849121|EXPERIMENTAL|2|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then given every 2-week, 4-week, or 3-month intervals as dictated by cellular immune response measurement.
62338404|NCT01237808|ACTIVE_COMPARATOR|Standard arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA
62138908|NCT04856085|EXPERIMENTAL|Cohort 7a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks
62138909|NCT04856085|EXPERIMENTAL|Cohort 8a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks
62138910|NCT04856085|EXPERIMENTAL|Cohort 1b (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 44 weeks
62138911|NCT04856085|EXPERIMENTAL|Cohort 2b (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 20 weeks
62138912|NCT04856085|EXPERIMENTAL|Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)|Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks
62495054|NCT02061358|EXPERIMENTAL|Cohort 4 - 90 mg UV-4B|Subjects receiving UV-4B 90 mg oral solution or placebo
62495055|NCT02061358|EXPERIMENTAL|Cohort 5 - 180 mg UV-4B|Subjects receiving UV-4B 180 mg oral solution or placebo
62696515|NCT02215473|ACTIVE_COMPARATOR|periodontitis no mouth rinse|
61943117|NCT01090284||Light weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene light weight mesh.
61943118|NCT00398411|EXPERIMENTAL|Moxifloxacin|moxifloxacin 400 mg tablets once daily
61943119|NCT00398411|PLACEBO_COMPARATOR|Placebo|identical appearing placebo
61943120|NCT04737928|EXPERIMENTAL|latanoprost switch to tafluprost|POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP\>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months.
61978798|NCT02848183|EXPERIMENTAL|Pediatric de novo acute myeloid leukemia|"I. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide~II. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning"
62138913|NCT04856085|EXPERIMENTAL|Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)|Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks
62138914|NCT04856085|EXPERIMENTAL|Cohort 1d (VIR-3434 + PEG-IFNα)|Participants will receive multiple doses of VIR-3434 + PEG-IFNα for 48 weeks
62138915|NCT05063864|EXPERIMENTAL|Nursing Support Program|the group that applied the nursing support program
62138916|NCT05063864|NO_INTERVENTION|No Nursing Support Program|the group that did not receive a nursing support program
62138917|NCT06601504|EXPERIMENTAL|Group A: HMPL-760 planned dose 1 once daily (QD) in combination with R-GemOx regimen|Group A: Patients will receive HMPL-760 planned dose 1 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
62338405|NCT01237808|EXPERIMENTAL|Investigational arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)
62338406|NCT04729491|ACTIVE_COMPARATOR|Dutasteride|Dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
62495056|NCT02061358|EXPERIMENTAL|Cohort 6 - 360 mg UV-4B|Subjects receiving UV-4B 360 mg oral solution or placebo
62338407|NCT04729491|PLACEBO_COMPARATOR|Placebo|Placebo q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
62495057|NCT02061358|EXPERIMENTAL|Cohort 7 - 720 mg UV-4B|Subjects receiving UV-4B 720 mg oral solution or placebo
62495058|NCT02061358|EXPERIMENTAL|Cohort 8 - 1000 mg UV-4B|Subjects receiving UV-4B 1000 mg oral solution or placebo
62495059|NCT05841693|ACTIVE_COMPARATOR|Experimental ( Carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake.Solid food and drinking will be forbidden after 24:00 p.m the day before surgery. The Carb group will consume carbonhydrate fluid two hours before the surgery.
62495060|NCT05841693|PLACEBO_COMPARATOR|Standard Care (Non-carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food and drinking will be forbidden after 24:00 p.m the day before surgery.The Non-carb Group will consume same amount of placebo fluid as Carb Group two hours before the surgery
62495061|NCT05497557|EXPERIMENTAL|Omeprazole + Sotorasib|
62495062|NCT02092701|EXPERIMENTAL|cholecalciferol|
62495063|NCT01726803|ACTIVE_COMPARATOR|Usual Care|Usual care arm will receive management as recommended by practice guidelines and directed by the primary care provider. The recommended stepped care approach is used with initial management of advice and education only and no referral to physical therapy during the initial 4 weeks.
62495064|NCT01726803|EXPERIMENTAL|Early Physical Therapy with Usual Care|The Early Physical Therapy arm will receive the same advice and education intervention received by the usual care group and will be referred to receive 4 sessions of physical therapy during the first 4 weeks. The physical therapy protocol involves spinal manipulation and exercise.
62495065|NCT02086617|OTHER|ultrasound of aorta|
62495066|NCT05237830||Use|Patients in whom the cell saver was effectively used
62495067|NCT05237830||Not Use|Patients in whom the cell saver wasn't effectively used
62495068|NCT02378909|ACTIVE_COMPARATOR|Group 1|Diabetic Neuropathy with electrical stimulation device and standard of care.
62138918|NCT06601504|PLACEBO_COMPARATOR|Group B: HMPL-760 placebo planned dose 1 once daily (QD) in combination with R-GemOx regimen|Patients will receive HMPL-760 placebo planned dose 1 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
61943121|NCT03844100|EXPERIMENTAL|Patients with Refractory Functional Dyspepsia|"Patients with FD diagnosed by the Rome IV criteria, patients with Refractory Functional Dyspepsia~* Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week~* Person with above symptoms that started at least 6 months before and continused for minimum 3 months~* Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease~* Person who do not respond to at least 2 general treatments for FD~* Dyspepsia symptoms that can disrupt daily life (global overall symptom scale score =\>5)"
61943122|NCT05761041|EXPERIMENTAL|Naf + MI|Sodium Fluoride Varnish 5% (Applied biannually) + two MI sessions: baseline face-to-face session and phone call after 3months.
62338408|NCT00621855|EXPERIMENTAL|Dabigatran etexilate 50mg|twice daily dosing,
62338409|NCT00621855|EXPERIMENTAL|Dabigatran etexilate 75mg|twice daily dosing, patients with moderate renal impairment allocated 50mg bid
62495069|NCT02378909|NO_INTERVENTION|Group 2|Diabetic neuropathy with standard of care.
62495070|NCT02378909|ACTIVE_COMPARATOR|Group 3|Diabetic neuroischemia with electrical stimulation device and standard of care.
62495071|NCT02378909|NO_INTERVENTION|Group 4|Diabetic neuroischemia with standard of care.
62495072|NCT01427036|EXPERIMENTAL|MISS surgery group|hip screw MISS® (Minimally Invasive Screw System) : minimally invasive approach
62495073|NCT01427036|ACTIVE_COMPARATOR|PHS surgery group|PHS® hip screw design for standard approach
62495074|NCT05598398|ACTIVE_COMPARATOR|Control (Wet-to-dry dressings)|Subjects randomized to the control group with receive standard of care (wet-to-dry dressings) for treatment of their pressure sore.
61943123|NCT05761041|ACTIVE_COMPARATOR|SDF|Silver Diamine fluoride 38% (Applied biannually)
61943124|NCT00137215|ACTIVE_COMPARATOR|A|
62338410|NCT00621855|EXPERIMENTAL|Dabigatran etexilate 110mg|twice daily dosing, patients with moderate renal impairment allocated 75mg bid
62338411|NCT00621855|EXPERIMENTAL|dabigatran etexilate 150mg|twice daily dosing, patients with moderate renal impairment allocated 110mg bid
62338412|NCT00621855|PLACEBO_COMPARATOR|placebo|matched placebo
62338413|NCT03279783|NO_INTERVENTION|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
62338414|NCT03279783|ACTIVE_COMPARATOR|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
62338415|NCT05607017|EXPERIMENTAL|Radiation Therapy and Losartan|Participants will receive radiation therapy 5x weekly over 1-6 weeks. Participants will receive Losartan 1x daily during radiation therapy and for up to 6 months afterward then be followed for 1 year
62495075|NCT05598398|EXPERIMENTAL|Treatment (NPWT with Instillation)|Subjects who are randomized into the treatment arm (NPWT with Instillation) will receive the V.A.C. VeraFlo™ Cleanse Choice Dressing Systems for treatment of their pressure sore.
62495076|NCT02269735|EXPERIMENTAL|Part I: MK-2640 (Panel A)|Part I: Lowest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
62495077|NCT02269735|EXPERIMENTAL|Part I: MK-2640 (Panel B)|Part I: Low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
62495078|NCT02269735|EXPERIMENTAL|Part I: MK-2640 (Panel C)|Part I: Medium-low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
62495079|NCT02269735|EXPERIMENTAL|Part I: MK-2640 (Panel D)|Part I: Medium dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
62495080|NCT02269735|EXPERIMENTAL|Part I: MK-2640 (Panel E)|Part I: Medium-high dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
62495081|NCT02269735|EXPERIMENTAL|Part I: MK-2640 (Panel F)|Part I: High dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
62495082|NCT02269735|EXPERIMENTAL|Part I: MK-2640 (Panel G)|Part 1: Highest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
62696516|NCT01334879|ACTIVE_COMPARATOR|With Loading Doses|5 patients will receive intravitreal injections every 30 days (+/- 7 days) for the first 4 months and every month thereafter until month 12 (maximum of 12 injections)
61943125|NCT05224414|EXPERIMENTAL|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program up to 12 sessions of a digital cognitive training targeting interpretation bias
61943126|NCT05224414|SHAM_COMPARATOR|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program up to 12 sessions of digitized psychoeducation
61943127|NCT04118842|EXPERIMENTAL|Savolitinib and/or Rifampicin|Treatment Period 1 consists of 16 days starting with admission on Study Day -1, followed by a single dose administration of savolitinib on Day 1, followed by a washout period of at least 14 days. Subjects will be discharged from the Study Centre on Study Day 3, after the last PK sample is collected Treatment Period 2 consists of 6 days, starting with admission on Study Day 14, followed by QD dose administrations of rifampicin for 5 consecutive days (Study Day 15 to Study Day 19) Treatment Period 3 consists of 4 days, starting immediately after Treatment Period 2, comprising of a single dose administration of savolitinib on Study Day 20 and QD dose administration of rifampicin on Study Day 20 and Study Day 21. Subjects will be discharged from the Study Centre on Study Day 22, after the last PK sample is collected
61943128|NCT00721123|EXPERIMENTAL|Tocilizumab 8 mg/kg|All participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.
61943129|NCT01030068|EXPERIMENTAL|Yoga|Yoga plus smoking cessation
61943130|NCT01030068|ACTIVE_COMPARATOR|Wellness|Health \& Wellness classes plus smoking cessation therapy
61943131|NCT05516277|EXPERIMENTAL|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep provided in individual 60-minute sessions for 5 weekly sessions.
61943132|NCT05516277|EXPERIMENTAL|General Sleep Education Intervention|Manual-based education program focusing on general sleep provided in individual 60-minute sessions for 5 weekly sessions.
61943133|NCT05767125|EXPERIMENTAL|APRV Group|Patients with moderate-to-severe ARDS were supported with APRV.
61943134|NCT05767125|ACTIVE_COMPARATOR|LTV Group|Patients with moderate-to-severe ARDS were supported with LTV.
61943135|NCT04879225|EXPERIMENTAL|Intervention 1: Fruit, dessert, mint, menthol, tobacco|All participants receive all interventional e-liquid flavors on separate days.
62338416|NCT02049749|NO_INTERVENTION|Delayed CARE|40 child-caregiver pairs will be randomized to usual treatment plus delayed CARE (control). Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual. Following the final interview (3-4 months after enrollment for each subject) all participants randomized to the control arm (usual treatment plus delayed CARE) will receive the CARE training, if desired.
62338417|NCT02049749|EXPERIMENTAL|Immediate CARE|40 child-caregiver pairs will be randomized to usual treatment plus immediate CARE. The trainings are administered to groups of 4-10 caregivers at a time and are led by two mental health providers trained in the CARE curriculum. The children do not attend the training; however, caregivers are expected to practice the skills that they learn in CARE with their child between sessions. The curriculum involves 6 sessions over 6-8 weeks. Each session will be 1-2 hours.
62338418|NCT05344144|EXPERIMENTAL|Emotional freedom technique group|Emotional freedom technique group pregnant women who have experienced prenatal loss, who were included in the emotional freedom technique group with randomization method, will be given a counseling program including psychosocial care and emotional freedom technique application in addition to the routine.
62338419|NCT05344144|EXPERIMENTAL|Music group|Music group pregnant women who have experienced prenatal loss, who were included in the music group with randomization method, will be given a counseling program including music application in addition to the routine.
62338420|NCT05344144|NO_INTERVENTION|Control|control group standard care group
62338421|NCT01156597|ACTIVE_COMPARATOR|Pioglitazone Group|This is a baseline versus treatment study comparing subjects on pioglitazone to a matched group of subjects treated with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level
62338422|NCT01156597|NO_INTERVENTION|Comparator Group|This group of subjects will be maintained on standard treatment with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level as group treated with pioglitazone.
62338423|NCT03319615|NO_INTERVENTION|Habitual dietary intake|Habitual dietary intake
62338424|NCT03319615|EXPERIMENTAL|Energy Restriction|Match period (to comparator) of dietary energy restriction
62338425|NCT00864422|EXPERIMENTAL|1|
62338426|NCT00864422|ACTIVE_COMPARATOR|2|
62338427|NCT02547636||Subjects/specimens that meet the inclusion criteria|Subjects/specimens that meet the inclusion criteria
62338428|NCT03666858||Neosaldina|Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
61943136|NCT04879225|EXPERIMENTAL|Intervention 2: Mint, menthol, and tobacco|All participants receive all interventional e-liquid flavors on separate days.
61943137|NCT04879225|EXPERIMENTAL|Intervention 3: Menthol and Tobacco|All participants receive all interventional e-liquid flavors on separate days.
62338429|NCT02860533|EXPERIMENTAL|Blood pressure measurement|six repetitive blood pressure measurements with iPhone and conventional oscillometric cuff device during stress testing will be performed
62338430|NCT03187912|ACTIVE_COMPARATOR|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
61943138|NCT04879225|EXPERIMENTAL|Intervention 4: Only tobacco|All participants receive all interventional e-liquid flavors on separate days.
61943139|NCT06044389||People suffering from fructose intolerance|
61943140|NCT04902131|EXPERIMENTAL|MENOPUR pen|
61943141|NCT04902131|ACTIVE_COMPARATOR|MENOPUR powder|
61943142|NCT05059639|EXPERIMENTAL|Almond (2 ounces)|Consume 2 ounces almond daily for 8 weeks
61943143|NCT05059639|ACTIVE_COMPARATOR|Pretzel|Consume comparative amount of pretzel for 8 weeks
61943144|NCT02778087|EXPERIMENTAL|TAU plus 30 minutes of BT.|Intervention: Subjects randomized to the 30 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently two times per day in addition to their treatment as usual.
61943145|NCT02778087|EXPERIMENTAL|TAU plus 60 minute of BT.|Intervention: Subjects randomized to the 60 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently four times per day in addition to their treatment as usual.
61943146|NCT02778087|SHAM_COMPARATOR|TAU plus 30 minutes of sham BT.|Intervention: Subjects randomized to the control (sham) group will perform the above Sham Mirror Box Therapy intervention independently two times per day. The control group will be using a mirror box with an opaque surface as opposed to a reflective mirror.
61943147|NCT03643159|EXPERIMENTAL|Abilify MyCite|Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
61943148|NCT03643159|ACTIVE_COMPARATOR|Virtual Matched Controls|Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.
62495083|NCT02269735|EXPERIMENTAL|Part II: MK-2640 followed by RHI|Part II: MK-2640 infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
62495084|NCT02269735|EXPERIMENTAL|Part II: RHI followed by MK-2640|Part II: RHI infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
62495085|NCT02269735|EXPERIMENTAL|Part III: MK-2640 followed by RHI|Part III: MK-2640 infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
62495086|NCT02269735|EXPERIMENTAL|Part III: RHI followed by MK-2640|Part III: RHI infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
62495087|NCT03136562||Kidney transplanted patients|Kidney transplanted patients in prednisolone treatment. Adrenal function is assessed by a synacthen test.
62495088|NCT03136562||Control group|Patients in dialysis not in prednisolone treatment. Adrenal function is assessed by a synacthen test.
61943149|NCT06248060|ACTIVE_COMPARATOR|Before preanaesthetic teleconsultation implementation|
61943150|NCT06248060|EXPERIMENTAL|After preanaesthetic teleconsultation implementation|
61943151|NCT01976676|EXPERIMENTAL|5-methyltetrahydrofolate|1 mg 5-methyltetrahydrofolate per day
61943152|NCT01976676|ACTIVE_COMPARATOR|folic acid|1 mg Folic acid per day
61943153|NCT04326829|EXPERIMENTAL|QL1604 Injection|
62138919|NCT06601504|EXPERIMENTAL|Group C: HMPL-760 planned dose 2 once daily (QD) in combination with R-GemOx regimen|Patients will receive HMPL-760 planned dose 2 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
62338431|NCT03187912|ACTIVE_COMPARATOR|Riboflavin with HPMC|Riboflavin drops with HPMC
62696517|NCT01334879|ACTIVE_COMPARATOR|Physician Discretion|5 patients will receive intravitreal ranibizumab every 30 days (+/- 7 days) on as needed basis based on the criteria defined in the study.
62696518|NCT06642805||Cohort bilious|
61943154|NCT05183815|EXPERIMENTAL|massage|
61943155|NCT06449521|OTHER|Single arm- stepped wedge implementation|All participants enrolled in the study will receive intervention in a stepped wedge fashion. This means that every three months, four clusters will transition to the intervention phase until all clusters (a total of 20) in the study have received intervention. Participants will receive routine usual care when their clusters are in the control phase. This includes the Government of Nepal's (GoN) current protocols at the home/community level. CHWs will monitor for CMD and NCD symptoms and red flags every three months, provide health education, and refer individuals to health facilities.
61943156|NCT02350569|EXPERIMENTAL|LDV/SOF|Participants with genotype 1 or 4 HCV who are undergoing liver transplant will receive one dose of LDV/SOF prior to the transplant and then will receive LDV/SOF once daily for 4 weeks following the transplant.
62338432|NCT02712372|EXPERIMENTAL|Part 1, Dose Level 1|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
62495089|NCT02260258|EXPERIMENTAL|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous intravenous (IV) infusion as per standard intensive care unit practice.~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
62495090|NCT02260258|PLACEBO_COMPARATOR|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
62495091|NCT02552082||Scorpio NRG|
62696519|NCT01064726|EXPERIMENTAL|Ibuprofen|
62696520|NCT01064726|EXPERIMENTAL|Fluticasone propionate|
62696521|NCT01064726|PLACEBO_COMPARATOR|Placebo|
61943157|NCT04928443||Scar dressing group|Patients planning to treat surgical scar with scar dressing
61943158|NCT04928443||Regular care group|Patients treated with adhesive tapes or strips or did not take care of surgical scar.
61943159|NCT01092507|EXPERIMENTAL|JE-CV Group|Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
62138920|NCT06601504|PLACEBO_COMPARATOR|Group D: HMPL-760 placebo planned dose 2 once daily (QD) in combination with R-GemOx regimen|Patients will receive HMPL-760 placebo planned dose 2 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
62338433|NCT02712372|EXPERIMENTAL|Part 1, Dose Level 2|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
62338434|NCT02712372|EXPERIMENTAL|Part 1, Dose Level 3|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
62138921|NCT03572257|EXPERIMENTAL|Quetiapine (0.5 mg/kg TID x 10 days)|This study group will receive treatment with quetiapine after diagnosis of pediatric delirium. Group assignment will be blinded.
62138922|NCT03572257|PLACEBO_COMPARATOR|Placebo|This study group will receive a placebo treatment after diagnosis of pediatric delirium. Group assignment will be blinded.
62338435|NCT02712372|EXPERIMENTAL|Part 1, Dose Level 4|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
62338436|NCT02712372|EXPERIMENTAL|Part 1, Dose Level 5|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
62338437|NCT02712372|EXPERIMENTAL|Part 1, Dose Level 6|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
62338438|NCT02712372|EXPERIMENTAL|Part 2, Dose Level 1|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
62338439|NCT02712372|EXPERIMENTAL|Part 2, Dose Level 2|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
62338440|NCT02712372|EXPERIMENTAL|Part 2, Dose Level 3|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
62338441|NCT02712372|PLACEBO_COMPARATOR|AZD4831 Placebo|"Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.~Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12"
62338442|NCT02513368|EXPERIMENTAL|Bio-Oss®, Bio-Gide®|augmentation procedure with Bio-Oss® and Bio-Gide®
62338443|NCT02513368|ACTIVE_COMPARATOR|connective tissue graft|augmentation procedure with connective tissue graft
62138923|NCT05510700|EXPERIMENTAL|Acupuncture group|"Participants will be given sleep hygiene instructions. Participants will receive acupuncture treatment at Nei Guan (PC 6), Shen Men (HT 7), Shen Ting (GV 24), Yin Tang (GV 29), Zhong Wan (CV 12), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62). Among the above acupoints, Nei Guan (PC 6), Shen Men (HT 7), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62) are all taken from both sides.~Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 12 sessions over the course of four weeks. The follow-up observation will be recorded on week 8 and 16."
62338444|NCT03021434|EXPERIMENTAL|Standard Testing|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Household-specific water quality information will be delivered to households within 72 hours, and households will be informed whether their drinking water was found to be contaminated. A study team member will review the information from the laboratory tests with the household and review information covered in the informational materials on safe water handling, storage, and use behaviours.
62338445|NCT03021434|EXPERIMENTAL|Test Kits|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. Data collectors will demonstrate the use of the low-cost microbiological water test kits and test household stored drinking water. A study team member will return to the household within 72 hours and review the household-specific water quality information from the initial test with household members. Households will be given 10 water test kits to use at their discretion over the 1-2 month follow up period. They will be appropriately trained in how to both perform the test and interpret the results. Households will also review information on safe water handling, storage, and use behaviours.
62338446|NCT03021434|ACTIVE_COMPARATOR|Comparison|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Results from this analysis will be returned to the household at project endline. A study team member will return to the household within 72 hours to review the information on safe water handling, storage, and use behaviours.
62338447|NCT05665621|EXPERIMENTAL|Training group|Eight-week in-school strength and balance training program
62338448|NCT05665621|NO_INTERVENTION|Control|No intervention, normal activities.
62338449|NCT05370313|EXPERIMENTAL|Cigarette smokers - Tobacco Parity|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Tobacco Parity Tax Condition described in the intervention section.
62338450|NCT05370313|EXPERIMENTAL|Cigarette smokers - Nicotine-Content|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Nicotine-Content Tax Condition described in the intervention section.
61943160|NCT01092507|ACTIVE_COMPARATOR|SA14-14-2 vaccine Group|Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)
61943161|NCT00347360|EXPERIMENTAL|lisinopril|lisinopril
61943162|NCT00347360|EXPERIMENTAL|carvedilol|carvedilol controlled release formulation
61943163|NCT02405780|EXPERIMENTAL|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
61943164|NCT02405780|ACTIVE_COMPARATOR|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
61943165|NCT04269707|OTHER|IV Iron|The primary objective in this study is to allow participants who were randomized to receive oral iron in the 1VIT17044 trial and who had an unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol, increase in erythropoietin for any reason \[Day 0 thru Day 35 of study protocol 1VIT17044\], change in IBD treatment) to receive one course of FCM. This course of FCM will consist of two doses of FCM at 15 mg/kg (maximum single dose of 750 mg), separated by seven days.
61943166|NCT01355120|EXPERIMENTAL|a human immunoglobulin|Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
61943167|NCT04729621|EXPERIMENTAL|TVB-009 main treatment period|TVB-009 (denosumab) pre-filled syringe, administered at weeks 1 and 26
61943168|NCT04729621|ACTIVE_COMPARATOR|PROLIA main treatment period|Prolia® (denosumab) pre-filled syringe, administered at weeks 1 and 26
61943169|NCT04729621|EXPERIMENTAL|TVB-009 main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to TVB-009 in the main treatment period
61943170|NCT04729621|ACTIVE_COMPARATOR|PROLIA main / PROLIA transition period|Prolia® (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
61943171|NCT04729621|EXPERIMENTAL|PROLIA main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
61943172|NCT03815539|EXPERIMENTAL|dry eye group|Part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
61943173|NCT02116231|EXPERIMENTAL|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy: IMRT was given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy.
61943174|NCT02116231|ACTIVE_COMPARATOR|IMRT alone|IMRT is given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume.
61943175|NCT01975051|EXPERIMENTAL|Miltefosine|Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
61943176|NCT00768183|EXPERIMENTAL|Regimen A|KADIAN Capsule + alcohol (under fasting conditions)
61943177|NCT00768183|EXPERIMENTAL|Regimen B|KADIAN Capsule + alcohol (under fed conditions)
61943178|NCT00768183|EXPERIMENTAL|Regimen C|KADIAN Capsule + water (under fasting conditions)
61943179|NCT00768183|EXPERIMENTAL|Regimen D|Morphine sulfate IR oral solution + water (under fasting conditions)
61943180|NCT05829031|EXPERIMENTAL|Music listening vs. No music listening|Every participant will be randomly assigned (50:50) to one of the following two conditions: Music listening after a stressful and/or discriminatory event (i.e., intervention condition) or no music listening after a stressful and/or discriminatory event (i.e., control condition).
61943181|NCT04406974||Patients with local recurrence|
61943182|NCT04406974||Patients with advanced colorectal cancer|
61943183|NCT05677022|EXPERIMENTAL|Adapted motor activity|
61943184|NCT05530798|EXPERIMENTAL|Contrast Enhanced Ultrasound Arm|
61943185|NCT01811225|EXPERIMENTAL|Low-Dose Contraceptive, then High-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the high dose progesterone, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM)."
61943186|NCT01811225|EXPERIMENTAL|High-Dose Contraceptive, then Low-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the high progesterone dose, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM)."
61943187|NCT01914757|EXPERIMENTAL|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
61943188|NCT01914757|EXPERIMENTAL|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
61943189|NCT01914757|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
61943190|NCT04275557||Retrospective Cohort|Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases
62338451|NCT05370313|EXPERIMENTAL|Cigarette smokers - Harm-Reduction|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Harm-ReductionTax Condition described in the intervention section.
61943191|NCT04275557||Prospective Cohort|Blood, tumor tissue samples and data will be collected.
61943192|NCT01772160||Herpes Zoster Group|Male or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode.
61943193|NCT05051995|PLACEBO_COMPARATOR|Open-label placebo ABAB Sequence|The N-of-1 trial will, on the level of the individual patient, test whether open-label placebo reduces negative side effects caused by discontinuation of antidepressants compared to no treatment. After antidepressant discontinuation, subjects will be randomized to 2 arms differing in the treatment order (ABAB; BABA). Subjects in this arm (ABAB) will start with open-label placebo (A) for 2 weeks; they will then crossover to no treatment (B) for 2 weeks and repeat this sequence once again.
61978799|NCT01002703|EXPERIMENTAL|RBP|Lenalidomide and Bendamustine and Prednisone
61978800|NCT06275568|ACTIVE_COMPARATOR|Usual care Fresh Connect cardholder engagement|
61978801|NCT06275568|EXPERIMENTAL|Usual care Fresh Connect cardholder engagement plus Enhanced engagement communication|
61943194|NCT05051995|PLACEBO_COMPARATOR|Open-label placebo BABA Sequence|The N-of-1 trial will, on the level of the individual patient, test whether open-label placebo reduces negative side effects caused by discontinuation of antidepressants compared to no treatment. After antidepressant discontinuation, subjects will be randomized to 2 arms differing in the treatment order (ABAB; BABA). Subjects in this arm (BABA) will start with no treatment (B) for 2 weeks; they will then crossover to open-label placebo (A) for 2 weeks and repeat this sequence once again.
61943195|NCT03502096|EXPERIMENTAL|100% portion size|100% portion sizes of all foods served (baseline). To-go container and controls received this meal.
61943196|NCT03502096|EXPERIMENTAL|125% portion size|125% of baseline portions served. To-go container and controls received this meal.
61943197|NCT03502096|EXPERIMENTAL|150% portion size|150% of baseline portions served. To-go container and controls received this meal.
61943198|NCT03502096|EXPERIMENTAL|175% portion size|175% of baseline portions served. To-go container and controls received this meal.
61943199|NCT00904397|EXPERIMENTAL|Lidoderm|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
61943200|NCT00904397|ACTIVE_COMPARATOR|Celecoxib|Celecoxib (Celebrex®, G.D. Searle \& Co., Chicago, IL), one 200 mg oral capsule QD
61943201|NCT00451451|EXPERIMENTAL|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
61943202|NCT00451451|EXPERIMENTAL|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
61943203|NCT00451451|PLACEBO_COMPARATOR|Placebo|Participants received two placebo capsules orally three times daily (TID)
61943204|NCT00451451|ACTIVE_COMPARATOR|Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)|Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
61943205|NCT06557915||Neonates and Infants Subjected to CPAP|"* Detection and Screening of different nasal complications of using CPAP in neonates and infants~* reach a consensus about minimizing nasal problems of CPAP in neonates and infants"
61943206|NCT00607815|ACTIVE_COMPARATOR|Cognitive Processing Therapy|Cognitive Processing Therapy
61943207|NCT00607815|ACTIVE_COMPARATOR|Present Centered Therapy|Present Centered Therapy
61943208|NCT03320317||Colorectal cancer|
61943209|NCT05616273||MMTT Visit 1, AST Visit 2|Mixed Meal Tolerance Test (MMTT) Visit 1 and Arginine Stimulated Test (AST) Visit 2
61943210|NCT05616273||AST Visit 1, MMTT Visit 2|Arginine Stimulated Test (AST) Visit 1 and Mixed Meal Tolerance Test (MMTT) Visit 2
61943211|NCT03724786|EXPERIMENTAL|Calculated collection|"Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the 6-hour collection will be multiplied by four, and the result will serve as the calculated collection, for pregnancy management. The additional 18 hour collection will serve for: 1. Patient blinding. 2. Calculation of the total 24-hour protein collection for reference."
61943212|NCT03724786|NO_INTERVENTION|Control collection|Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the total 24-hour collection will serve for pregnancy management. The initial 6-hour collection will serve for patient blinding.
61943213|NCT01634061|EXPERIMENTAL|Dose escalation: BEZ235 + Zytiga®|BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
61943214|NCT01634061|EXPERIMENTAL|Dose escalation: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
61943215|NCT01634061|EXPERIMENTAL|Dose expansion: BEZ235 + Zytiga®|"BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate~Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label"
61943216|NCT01634061|EXPERIMENTAL|Dose Expansion: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
61943217|NCT04828239|EXPERIMENTAL|Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
61943218|NCT04828239|ACTIVE_COMPARATOR|Manual Acupuncture Group|Acupuncture point: PC-6 and PC-7 Responses elicited: de qi sensation Manual: twirling with lifting-thrusting method stimulation Needles retained for 30 min Needle type: C\&G, gauge and size: 0.25x40mm
61943219|NCT04828239|SHAM_COMPARATOR|Sham Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 Sham laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
61943220|NCT02486666|EXPERIMENTAL|Experimental Arm|"Experimental Arm:patients will not have any dose titration regardless of anti-Xa level.~Premature neonates will receive enoxaparin 2.0 mg/kg/dose rounded to nearest whole mg twice daily, while term neonates will receive enoxaparin 1.7 mg/kg/dose rounded to nearest whole mg twice daily. Children≥1 month corrected age will receive 1.5 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing) while children≥2 month corrected age will receive 1.0 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing)."
61943221|NCT02486666|OTHER|Control Arm|Control Arm: patients who will have dose titration based on anti-Xa levels to maintain a therapeutic range of 0.5-1.0 u/mL (standard of care).
61943222|NCT01923987|EXPERIMENTAL|SCRT/ChemoTx with Delayed Surgery|Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis
61943223|NCT03051750|ACTIVE_COMPARATOR|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
61943224|NCT03051750|EXPERIMENTAL|Kinesio Taping|Kinesio Taping during three weeks
62495092|NCT04457115|EXPERIMENTAL|TPV Block|Thoracic paravertebral block performed at thoracic level T2-T3 and T4-T5 with administration of Ropivacaine 0.7% 8 ml for each level.
61943225|NCT02947555||DM+/AT+|Patients with type 2 diabetes mellitus and atherosclerotic event in history
61943226|NCT02947555||DM+/AT-|Patients with type 2 diabetes mellitus without atherosclerotic event in history
61943227|NCT02947555||DM-/AT+|Non-diabetic patients with atherosclerotic event in history
61943228|NCT02947555||DM-/AT-|Non-diabetic patients without atherosclerotic event in history
61943229|NCT01807039||patients after surgery with isolated proximal femur fracture|Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
61943230|NCT00513656|ACTIVE_COMPARATOR|Oxycodone Hydrochloride Tablets|
61943231|NCT00513656|EXPERIMENTAL|Oxycodone Naloxone Tablets|
62138924|NCT05510700|SHAM_COMPARATOR|Sham acupuncture group|"Participants will be given sleep hygiene instructions. To match the true acupuncture points, sham treatment at sham Nei Guan (PC 6), Shen Men (HT 7), Shen Ting (GV 24), Yin Tang (GV 29), Zhong Wan (CV 12), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62) will be used.~Participants will have the same needle retention time, treatment time, and follow-up time as the acupuncture group."
62138925|NCT02681900|EXPERIMENTAL|Self-affirmation|Participants in the self-affirmation arm write about their most important value, reasons why is important and an example of when they enacted that value. This is the Self-affirmation manipulation task as described in the intervention.
62338452|NCT05370313|EXPERIMENTAL|Cigarette smokers - Modified Risk Tobacco Products (MRTP)|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the MRTP Tax Condition described in the intervention section.
62338453|NCT05094921|EXPERIMENTAL|Group A (Halliwick method group)|Under water exercise program according to halliwick concept which will be applied as three sessions per week for three successive months. Underwater exercises will be performed under the supervision of a certified aquatic therapist. This practitioner will instruct the child in proper techniques for performing exercises while ensuring child's safety by using flotation devices, body boards or float belts when necessary. Also the pool where the children will perform underwater exercises will be equipped with ramps, chair lifts, stairs, and handrails to facilitate a child's ability to access the pool.
62338454|NCT05094921|ACTIVE_COMPARATOR|Group B (conventional physical therapy group)|Conventional selected exercise program for 60 minutes , three sessions per week for three successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises, (3) improving postural responses, (4) Flexibility exercises, (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles) and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
62338455|NCT00726817|PLACEBO_COMPARATOR|1|enemas, once daily, containing saline
62338456|NCT00726817|EXPERIMENTAL|2|enemas, once daily, containing 50mM butyrate
62495093|NCT04457115|EXPERIMENTAL|ESP Block|Erector spinae plane block performed at thoracic level T2 and T5 with administration of Ropivacaine 0.5% 12 ml for each level.
61943232|NCT01997853|ACTIVE_COMPARATOR|Test Group|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
61943233|NCT01997853|PLACEBO_COMPARATOR|Control Group|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
61943234|NCT04668573|EXPERIMENTAL|Trunk exercise group|Participants received trunk exercise for 30 minutes per session, twice a week for 12 weeks.
61943235|NCT04668573|NO_INTERVENTION|Control group|Participants remained their regular activities.
61943236|NCT06083077|EXPERIMENTAL|Infant < 6 months with severe bronchiolitis|"Infant will be recorded successively in 6 conditions (10 min each) :~* Without chest wall strapping at PEEP 0 and PEEP 7~* With chest wall strapping at PEEP 0 and PEEP 7~* again without chest wall strapping at PEEP 0 and PEEP 7."
61943237|NCT01422174||ICD implantation|Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
61943238|NCT01422174||Non ICD implantation|Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
62338457|NCT00726817|EXPERIMENTAL|3|enemas, once daily, containing 100mM butyrate
61943239|NCT04288752|EXPERIMENTAL|VR101 Lubricating Intravaginal Ring|VR101 is a clear, flexible, torus-shaped lubricating intravaginal ring (IVR) manufactured from hollow tubing formed from Excipient Grade Thermoplastic Urethane Pathway® Polymer PY-PT42DE35 by hot-melt extrusion. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
61943240|NCT04288752|SHAM_COMPARATOR|Sham Ring|"Performance of VR101 will be compared to that of an inactive ring. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.~Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added."
61943241|NCT06426433|OTHER|Wrist Proprioceptive Exercises and General Upper Extremity Exercises|Wrist Proprioceptive Exercises are neuromuscular exercises for wrist stabilization and control.
61943242|NCT06426433|OTHER|General Upper Extremity Exercises|These exercises are traditional rehabilitation exercises.
61943243|NCT05015439|EXPERIMENTAL|Cannabidiol|Participants will receive cannabidiol, starting at 100 mg twice daily, and increased to 200 mg twice daily by week 3. This arm will last six weeks.
61943244|NCT05015439|PLACEBO_COMPARATOR|Placebo|Participants will receive six weeks of placebo.
61978802|NCT03102021|ACTIVE_COMPARATOR|1|erythropoeitin
61978803|NCT03102021|PLACEBO_COMPARATOR|2|saline placebo
62138926|NCT02681900|ACTIVE_COMPARATOR|Control|Participants in this arm complete a control equivalent of the self-affirmation task, where they write about their least important value, reasons why is may be important to someone else and an example of when another person may have enacted that value. This is the Control task as described in the intervention.
62495094|NCT05467540|EXPERIMENTAL|Pain reduction in patients with vertebral metastatic lesions treated with SPINERY System|
62495095|NCT01656564||Healthy Controls|Individuals with no known history of HIV
62495096|NCT01656564||Healthy Controls - Questionnaire Group|Individuals with no known history of HIV
62495097|NCT01656564||HIV|Individuals who acquired HIV in early life
61943245|NCT02548533|ACTIVE_COMPARATOR|Region 1|Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
61943246|NCT02548533|EXPERIMENTAL|Region 2|Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.
61943247|NCT04708379|EXPERIMENTAL|Intervention group|Nutrition education and physical activity education.
61943248|NCT04708379|NO_INTERVENTION|Control group|No specific intervention.
62138927|NCT05980559|EXPERIMENTAL|One Group|Patients will be injected with 50 MU of botulinum toxin and Surface qualitative Electromyography, maximum bite force and visual pain scale will be taken before and after 1, 3 months
62138928|NCT06046859|EXPERIMENTAL|Subjects randomized to get Fluoxetine therapy|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
62138929|NCT06046859|ACTIVE_COMPARATOR|Subjects randomized to Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
62138930|NCT00457119|EXPERIMENTAL|Step 1 Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel
62338458|NCT03331666|ACTIVE_COMPARATOR|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.
62696522|NCT03999424|EXPERIMENTAL|Autologous human Schwann cells|All participants will receive autologous human Schwann cells harvested from their own sural nerve.
62138931|NCT00457119|EXPERIMENTAL|Step 1, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel
62338459|NCT03331666|PLACEBO_COMPARATOR|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.
62338460|NCT03164512|PLACEBO_COMPARATOR|Placebo|Placebo oral and vapor
62338461|NCT03164512|EXPERIMENTAL|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
62495098|NCT06074757|OTHER|cohort 1|Test (25mg) vs RLD (500mg) to assess the safety and tolerability of the test dose
62495099|NCT06074757|EXPERIMENTAL|cohort 2|Test 100 mg
62495100|NCT06074757|EXPERIMENTAL|cohort 3|Test 250 mg
62696523|NCT03622983||Collection of sample and data|Collection of biological samples and clinical data
62696524|NCT00757016|PLACEBO_COMPARATOR|B|0.99 ml saline solution 9mg/ml and 0.01 ml fat emulsion will be given once to the sacrospinous ligament insertion.
62696525|NCT00757016|ACTIVE_COMPARATOR|A|1 ml triamcinolone 20mg/ml (Lederspan), Meda AB, Solna, Sweden) and 1 ml lidocaine hydrochloride 10mg/ml (Xylocain), Astra Zeneca, Södertälje, Sweden)
61943249|NCT04743076|EXPERIMENTAL|Intervention group|Standard medical treatment plus endovascular treatment
62696526|NCT06595290|ACTIVE_COMPARATOR|Usual care|Patients will be managed by their cardiologist according to their usual practice. Follow-up appointments will be scheduled as per the cardiologist's instructions. Participants will return to the recruiting study site for clinical outcome assessment by study investigators at 90 and 180 days post-discharge.
61943250|NCT04743076|ACTIVE_COMPARATOR|Control group|Standard medical treatment alone
61943251|NCT01039870|EXPERIMENTAL|PVB|Paravertebral block initiated at the later part of thoracotomy is used for postoperative pain control
61943252|NCT01039870|ACTIVE_COMPARATOR|TEA|Thoracic epidural block initiated before the surgical incision is used for postoperative pain control.
61943253|NCT01572350|ACTIVE_COMPARATOR|Grid laser|It's a reference standard as the treatment which is currently accepted for NTDDME
61943254|NCT01572350|EXPERIMENTAL|Triamcinolone 4 mg|
61943255|NCT01572350|EXPERIMENTAL|Bevacizumab|
61943256|NCT03897023||Stable patient|Stable patients who admitted to ICU for observation.
61943257|NCT01988220|EXPERIMENTAL|sensory retraining|sensory identification and discrimination training. using different attention and sensation modalities for sensory retraining
62138932|NCT00457119|EXPERIMENTAL|Step 2, Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
62138933|NCT00457119|EXPERIMENTAL|Step 2, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab
62138934|NCT00429338|EXPERIMENTAL|AIR-MRSI|Endorectal MRSI with Air
62138935|NCT00429338|EXPERIMENTAL|PFC-MRSI|Endorectal MRSI with PFC
62138936|NCT04700410|EXPERIMENTAL|Pure-Vu|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System (single arm)
62338462|NCT03164512|EXPERIMENTAL|Vaporized Cannabidiol|100mg cannabidiol in vapor
62338463|NCT03164512|EXPERIMENTAL|Oral Cannabidiol|100mg oral cannabidiol
62338464|NCT02014935|EXPERIMENTAL|Low intensity laser|"So that this research recrutarou 30 subjects with spastic hemiparesis sequel, post stroke who have gone through three phases, with three evaluations. If this conformation is necessary, therefore, it is a search for intergroup analysis, and the values found in Phase I were faced with the values found in Phases II and III.~The phases comprise:~* Phase I (1st Cycle): Individuals treated with LLLT not only performed the evaluation of muscle activity, torque and lactic acid level.~* Phase II (2nd Cycle): Individuals undergoing the application of LLLT, with the same off, and assessment of muscle activity, torque and lactic acid level.~* Phase III (3rd Cycle): Individuals undergoing the application of LILT and evaluation of muscle activity, torque and lactic acid level."
61943258|NCT01988220|ACTIVE_COMPARATOR|repeated exposure to sensory input|
61943259|NCT04442113|ACTIVE_COMPARATOR|Control group|Pulmonary vein isolation alone (by catheter ablation)
62338465|NCT04872816|EXPERIMENTAL|Continuous airway positive pressure|All participants in continuous airway positive pressure arm will use CPAP (model S10-Resmed®) with expiratory relief and nasal mask.
62495101|NCT06074757|EXPERIMENTAL|cohort 4|Test 500mg
62495102|NCT01402128|EXPERIMENTAL|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
62495103|NCT01402128|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62138937|NCT06221969|EXPERIMENTAL|CagriSema|Participants will receive cagrilintide dose 1 and semaglutide dose 2 subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 68 weeks.
62338466|NCT04872816|SHAM_COMPARATOR|SHAM continuous airway positive pressure|Individuals in SHAM continuous airway positive pressure arm will use CPAP (model S7-Resmed®) with expiratory relief and nasal mask. The Sham-CPAP consists of a modified CPAP so that the pressure in the mask was less than 1 cm H2O. In this study, the Sham-CPAP equipment includes an increase in the expiratory orifice of the CPAP mask to eliminate airflow resistance, and a resistor with a small orifice was placed between the CPAP and the circuit. The noise produced by the ventilator and the airflow through the mask will be very similar to that of the effective CPAP. The diameter of the expiratory orifice was 10 cm H2O, and a 4 mm diameter resistor was placed between the trachea and the CPAP flow generator.
62495104|NCT04218487|EXPERIMENTAL|XFZY group|2.4g (6 capsules) three times daily for 12 weeks
61943260|NCT04442113|EXPERIMENTAL|STAR guided ablation group|Pulmonary vein isolation plus ablation guided by STAR MappingTM
61943261|NCT04232774|EXPERIMENTAL|Treated by the study device|
61943262|NCT03216187|EXPERIMENTAL|Pregabalin|Pregabalin 150 mg twice daily, starting from the evening before surgery, continuing with two times 150mg per day for 12 days, and ending with one 150mg capsule every evening for the final 3 days.
61943263|NCT03216187|PLACEBO_COMPARATOR|Placebo|Identical placebo capsules twice daily, starting from the evening before surgery, continuing with two capsules per day for 12 days, and ending with one capsule every evening for the final 3 days.
62495105|NCT04218487|PLACEBO_COMPARATOR|Control group|2.4g (6 capsules) three times daily for 12 weeks
62696527|NCT06595290|EXPERIMENTAL|High intensity care|This arm follows a structured algorithm for initiating and uptitrating all four pillars of HFrEF oral medications post-randomization (pre-discharge) and during at least 4 visits over 6 weeks post-discharge.
62696528|NCT06565325|EXPERIMENTAL|Experimental group|Terminal Knee Extension Exercise with Audible Cues
61943264|NCT00881257|EXPERIMENTAL|1|GRST Peripheral Catheter System
61943265|NCT02798146|OTHER|hormonal levels|Blood samples are collected for analysis of LH, E2, hCG and progesterone.
61943266|NCT02325648||HIPEC cytoreductive surgery|
61943267|NCT02234570|EXPERIMENTAL|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
61943268|NCT02234570|EXPERIMENTAL|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
61943269|NCT02234570|EXPERIMENTAL|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
61943270|NCT02234570|EXPERIMENTAL|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
62138938|NCT06221969|ACTIVE_COMPARATOR|Tirzepatide|Participants will receive tirzepatide dose 1 subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 68 weeks.
62138939|NCT02757469|EXPERIMENTAL|Yasmin|Pregnancies will occur while the women are taking oral contraceptives (Yasmin). The possible role of exogenous estrogens in sensitizing the granulosa cells to the effect of follicle-stimulating hormone and thereby inducing ovulation and conception in some women with premature ovarian failure is examined.
62138940|NCT03709706|EXPERIMENTAL|Arm A: lete-cel monotherapy|In Arm A, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel monotherapy. Participants who subsequently progress by Week 25 will be offered pembrolizumab.
62696529|NCT06565325|ACTIVE_COMPARATOR|Control group|Terminal Knee Extension Exercise without Audible Cues
62696530|NCT01738412||Study population|Stroke patients
61943271|NCT02234570|EXPERIMENTAL|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
61943272|NCT02234570|EXPERIMENTAL|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
61943273|NCT02234570|EXPERIMENTAL|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
61943274|NCT05623839|EXPERIMENTAL|LY3305677|LY3305677 administered subcutaneously (SC)
61943275|NCT05623839|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
61943276|NCT00993993||"group early intervention"|
61943277|NCT00993993||"group late intervention"|
62138941|NCT03709706|EXPERIMENTAL|Arm B: lete-cel plus pembrolizumab|In Arm B, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
62138942|NCT03709706|EXPERIMENTAL|Arm C: lete-cel plus pembrolizumab|In Arm C, participants with NSCLC (with actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
62138943|NCT04139005|EXPERIMENTAL|Awareness-Connection|
62138944|NCT04139005|EXPERIMENTAL|Awareness-Insight|
62138945|NCT04139005|NO_INTERVENTION|Wait list|
62138946|NCT02139813|EXPERIMENTAL|Laparoscopic Omega Loop Bypass|Laparoscopic Mini-gastric bypass
62138947|NCT02139813|ACTIVE_COMPARATOR|Laparoscopic Roux-en-Y Gastric ByPass|Procedure of reference in bariatric surgery
62495106|NCT03924154|EXPERIMENTAL|RVT-1201|RVT-1201 600 mg immediate-release tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=24 \[Anticipated\])
62495107|NCT03924154|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=12 \[Anticipated\])
62495108|NCT03900234||Residents of the single rural settlement|No interventions will be administered
62495109|NCT04162327|EXPERIMENTAL|Ia stage - IBI315 Dose escalation|
62495110|NCT04162327|EXPERIMENTAL|Ib stage - IBI315 monotherapy|
62696531|NCT06637891|EXPERIMENTAL|Mandala coloring group|Mandala painting will be applied to postpartum women who have postpartum blues
62696532|NCT06637891|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce postpartum blues symptoms.
62696533|NCT00420537|ACTIVE_COMPARATOR|mycophenolate|Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
62696534|NCT00420537|ACTIVE_COMPARATOR|Everolimus|Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
62696535|NCT06073067|EXPERIMENTAL|Fractionated grid radiation therapy|Subjects with resectable extremity soft tissue sarcoma received neoadjuvant grid radiation therapy (GRID), followed by standard-of-care conventional radiotherapy (XRT) and tumor resection.
62696536|NCT05463341|EXPERIMENTAL|Intervention Arm|Each participant in the intervention arm will receive one-on-one education on the purpose, benefits, and limitations of fentanyl test strip (FTS) testing and undergo a brief 20-minute FTS educational intervention (including a 2-3-minute video and hands-on demonstrations on how to use FTS). They will also receive a supply of 10 FTS upon enrollment and continued supply upon request throughout the 2-year follow up period.
61943278|NCT03584061|EXPERIMENTAL|Fat grafting/fat transplant.|Each patient receives fat grafting to the site of dermal pain. Fat is to be harvested for either the abdomen or the thigh.
61943279|NCT03349931||Hematological patients|Hematological patients at high risk for invasive aspergillosis
61943280|NCT00839852|EXPERIMENTAL|Cariprazine 1.5mg|Participants received cariprazine 1.5 mg capsule once, twice or three times a day depending on their response and tolerability
61978804|NCT02485301|EXPERIMENTAL|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
62138948|NCT02157116|EXPERIMENTAL|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
62338467|NCT02919124|EXPERIMENTAL|Echoclip device|Ultrasonography using the echoclip device
62338468|NCT02649543|ACTIVE_COMPARATOR|Primary Closure|Primary Closure is made after surgery.
62338469|NCT02649543|ACTIVE_COMPARATOR|Delayed Primary Closure|Delayed Primary Closure is made after at least 7 days.
62338470|NCT02649543|ACTIVE_COMPARATOR|Vacuum Assisted Closure|Vacuum Assisted Device is used in the wound.
62338471|NCT02942316|EXPERIMENTAL|Pupil dilation reflex measurement|Four measurements of PDR during surgery at standardized times
62338472|NCT00948662|EXPERIMENTAL|1|active arm/healthy young
62338473|NCT00948662|PLACEBO_COMPARATOR|2|placebo arm
62338474|NCT00948662|OTHER|3|ketoconazole interaction evaluation
62338475|NCT02517827|ACTIVE_COMPARATOR|Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.
62338476|NCT02517827|ACTIVE_COMPARATOR|Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy
62338477|NCT05582265|EXPERIMENTAL|Neoadjuvant Tislelizumab + Reduction of Cycles of Chemotherapy (Arm A)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1; Cisplatin (IV), dose=75 mg/m2, or Carboplatin (IV), AUC=5, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Cycle2、3（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1.~Following surgical resection, high risk participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Low risk participants receive 200 mg Tislelizumab Q3W plus radiotherapy as adjuvant therapy."
62338478|NCT05582265|EXPERIMENTAL|Neoadjuvant Tislelizumab + Chemotherapy (Arm B)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1、2、3（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1; Cisplatin (IV), dose=75 mg/m2, or Carboplatin (IV), AUC=5, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Following surgical resection, high risk participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Low risk participants receive 200 mg Tislelizumab Q3W plus radiotherapy as adjuvant therapy."
62338479|NCT05582265|OTHER|Up-front Surgery (Arm C)|Following surgical resection, high risk participants receive chemoradiotherapy as adjuvant therapy. Low risk participants receive radiotherapy as adjuvant therapy.
62338480|NCT03791645|EXPERIMENTAL|SKY Intervention|Participants in the intervention group will get to participate in the SKY program, for 5 days with each day session taking 3 hours/day. SKY program involves a) specific breathing exercises and social interaction with other participants in the program. Following completion of the program, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use. After completion of the 5 day SKY program, participants will practice SKY every day at home for 30 days. They will also need to attend 4 weekly group sessions during this period and each session is expected to last 1 hour. At the end of the 30 day period, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use.
62338481|NCT03791645|NO_INTERVENTION|Usual treatment|Participants assigned to the control group will not have access to the SKY program but will continue with usual care. They will also complete questions after 5 days and again after 30 days.
62338482|NCT01890070|PLACEBO_COMPARATOR|STANDARD DIET|"each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats \< 30% e 30 g of fiber)~Three weeks of washout to avoid additive effects on treatments to follow."
62338483|NCT01890070|EXPERIMENTAL|STANDARD DIET WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats \< 30% e 30 g of fibers) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
62338484|NCT01890070|EXPERIMENTAL|STANDARD DIET WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats \< 30% e 30 g of fibers) with 200 ml of Italian organic Red Wine.~Three weeks of washout to avoid additive effects on treatments to follow."
62696537|NCT05463341|NO_INTERVENTION|Non-Intervention Arm|Fentanyl test strip (FTS) education and a supply of FTS will be offered to participants in the non-intervention arm of the study during the final quarter of year 5.
62696538|NCT06421350|EXPERIMENTAL|Acute and Subacute Phases of CRPS|Participants diagnosed with acute and subacute phases of CRPS will be assigned to this group.
62696539|NCT06421350|EXPERIMENTAL|Chronic Phase of CRPS|Participants diagnosed with chronic CRPS will be assigned to this group.
62696540|NCT00943137|EXPERIMENTAL|5-FU dosage adjustments|The dose of continuous infusion 5-FU will be adjusted every cycle until patients reached the therapeutic plasma range (450 to 550 microgram/L).
62696541|NCT05960604||Low cardiac reserve/efficiency|Patients who were identified as having low cardiac reserve and efficiency, based on PRAM parameters.
62696542|NCT05960604||Normal cardiac reserve/efficiency|Patients who were identified as having normal cardiac reserve and efficiency, based on PRAM parameters.
62495111|NCT02048696|EXPERIMENTAL|Exercise training|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
62495112|NCT02048696|NO_INTERVENTION|control|Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction.
62495113|NCT05908617|NO_INTERVENTION|Paper Discharge Instruction|Patient will be given paper discharge instructions
62138949|NCT04634682|EXPERIMENTAL|MYODM|MYODM, three times a day, orally
62495114|NCT05908617|EXPERIMENTAL|Video Discharge Instructions|Patient will be given Video discharge instructions
62495115|NCT06195865|ACTIVE_COMPARATOR|Randomised DIEP flap|
62495116|NCT06195865|ACTIVE_COMPARATOR|Randomised implant-based|
62495117|NCT06195865|ACTIVE_COMPARATOR|Preference DIEP-flap|
62495118|NCT06195865|ACTIVE_COMPARATOR|Preference implant-based|
62495119|NCT02864524|EXPERIMENTAL|Manipulative and Massage Therapy|"Ten sessions (2/week):~* High speed and low amplitude technique to lower cervical spine (C3-C4).~* Dog technique flexion for high thoracic area (T1-T4).~* Dog technique flexion for mid-thoracic area (T5-T8).~* Dog technique flexed to low thoracic (T6-T12).~Classic Massage Therapy during 40 minutes (2 time / week):"
62495120|NCT02864524|ACTIVE_COMPARATOR|Exercise Program|Ten sessions (2 time/ week): Initial heating and continuing with aerobic and muscle stretching exercises.
62495121|NCT00990041||PBMC|
62696543|NCT01550510|EXPERIMENTAL|Ascorbic Acid + Irinotecan|Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks
62338485|NCT01890070|EXPERIMENTAL|STANDARD DIET WITH CHESTNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats \< 30% e 30 g of fibers) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
62495122|NCT00990041||periodontitis|
62495123|NCT03025451|EXPERIMENTAL|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
62495124|NCT04038645|ACTIVE_COMPARATOR|Experimental Group (laser)|"The patients (n=18) will receive infrared LEDs in 6 points (3 on the right side and 3 on the left side) using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt (mW) . The LED light outputs will be positioned in direct contact with the skin. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
62495125|NCT04038645|PLACEBO_COMPARATOR|Control group (Placebo)|The patients (n=18) will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days (by the same evaluator), as well as the evaluation of serum CRP.
62696544|NCT01550510|ACTIVE_COMPARATOR|Standard of Care (irinotecan alone)|350mg/m2 irinotecan once a week every 3 weeks
62495126|NCT02810223|EXPERIMENTAL|Single dose of CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
62495127|NCT03790241|EXPERIMENTAL|Young males of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
62495128|NCT03790241|EXPERIMENTAL|Young females of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
62495129|NCT03790241|EXPERIMENTAL|Aged males of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
62495130|NCT03790241|EXPERIMENTAL|Aged females of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
62495131|NCT03790241|EXPERIMENTAL|Obese young males|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
62696545|NCT04518228||Component 1: Arm 1.1: Bictegravir (BIC) 50 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving bictegravir (BIC) 50 mg once daily (q.d.), and their infants
62696546|NCT04518228||Component 1: Arm 1.2: Doravirine (DOR) 100 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving doravirine (DOR) 100 mg q.d., and their infants
62696547|NCT04518228||Component 1: Arm 1.3: Tenofovir alafenamide (TAF) 10 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving tenofovir alafenamide (TAF) 10 mg q.d. boosted with cobicistat, and their infants
62696548|NCT04518228||Component 1: Arm 1.4: TAF 25 mg q.d. without boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. without boosting, and their infants
61943281|NCT03864770|EXPERIMENTAL|Extracorporeal shock wave therapy and general physical therapy|In this arm, the subjects will receive the intervention of extracorporeal shock wave therapy and general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
61978805|NCT02485301|PLACEBO_COMPARATOR|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
62138950|NCT04634682|NO_INTERVENTION|No intervention|Patients will follow the same evaluation schedule but will not receive MYODM
62138951|NCT00421759|EXPERIMENTAL|1|85 elderly individuals with somatosensory deficits
62495132|NCT03790241|EXPERIMENTAL|Obese young females|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
62495133|NCT03790241|EXPERIMENTAL|Obese aged males|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
62495134|NCT03790241|EXPERIMENTAL|Obese aged females|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
62495135|NCT06036927|EXPERIMENTAL|TQC2731 injection 210 mg|TQC2731 injection 210 mg combined with Mometasone Furoate Aqueous Nasal Spray, 28 days as a treatment cycle.
62495136|NCT06036927|EXPERIMENTAL|TQC2731 injection 420 mg|TQC2731 injection 420 mg combined with Mometasone Furoate Aqueous Nasal Spray, 28 days as a treatment cycle.
62495137|NCT06036927|PLACEBO_COMPARATOR|TQC2731 matching placebo|TQC2731 matching placebo combined with Mometasone Furoate Aqueous Nasal Spray, 28 days as a treatment cycle.
62495138|NCT03397667|OTHER|Control|Primary Care
62138952|NCT00421759|EXPERIMENTAL|2|85 elderly individuals with recurrent falls
62495139|NCT03397667|EXPERIMENTAL|Intervention|Primary Care plus ABC ANSWERS intervention
62495140|NCT00748137|ACTIVE_COMPARATOR|Fixed dose|Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
62495141|NCT00748137|EXPERIMENTAL|ezy-BICC dose calculation card|variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
62495142|NCT03736460|EXPERIMENTAL|Mindfulness-based intervention|
62495143|NCT03736460|ACTIVE_COMPARATOR|Physical training|
62495144|NCT03736460|NO_INTERVENTION|Wait-list|
62495145|NCT06353724|PLACEBO_COMPARATOR|conventional positioning stent|The Oral positioning stent were constructed according to the conventional technique
62495146|NCT06353724|ACTIVE_COMPARATOR|Digital positioning stent|The Oral positioning stent will be constructed digitally
62495147|NCT01523236|EXPERIMENTAL|Investigational Test Product|Mometasone furoate anhydrous 50 mcg/actuation Nasal Spray (Teva)
62495148|NCT01523236|ACTIVE_COMPARATOR|Reference Listed Drug|Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray (Schering)
62495149|NCT01523236|PLACEBO_COMPARATOR|Placebo|Saline Placebo Nasal Spray
62495150|NCT00139815|ACTIVE_COMPARATOR|Enoxaparin|
62696549|NCT04518228||Component 1: Arm 1.5: TAF 25 mg q.d. with boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. boosted with cobicistat or ritonavir, and their infants
62696550|NCT04518228||Component 2: Arm 2.1: CAB LA|Women ≥ 24 weeks gestation who received at least one dose of long-acting injectable formulation of cabotegravir (CAB LA) any dose during pregnancy, and their infants
62138953|NCT05359796||long-term T1D|Subjects who has the T1D duration ≥10 years, with or without diabetic complications.
62495151|NCT00139815|EXPERIMENTAL|Fondaparinux|
62696551|NCT04518228||Component 3: Arm 3.1: Dolutegravir (DTG) 50 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving dolutegravir (DTG) 50 mg twice daily (b.i.d.) when combined with RIF or 50 mg q.d. if RIF is not part of the TB regimen, and their infants
62696552|NCT04518228||Component 3: Arm 3.2: ATV/r or DRV/r|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving atazanavir/ritonavir (ATV/r) ≥ 300/100 mg q.d. or darunavir/ritonavir (DRV/r) ≥ 600/100 mg b.i.d., and their infants
62696553|NCT04518228||Component 3: Arm 3.3: Lopinavir/ritonavir (LPV/r) 800/200 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving lopinavir/ritonavir (LPV/r) 800/200 mg b.i.d., and their infants
62738524|NCT05308407|OTHER|Aim 1. Focus Groups|"Healthcare providers (n=16-24 participants in 4 focus groups) from MD Anderson Cancer Center (MDACC).~AYAs with primary benign or malignant central nervous system tumors (n=16-24 participants in 4 focus groups) treated at MDACC."
62138954|NCT04584866|ACTIVE_COMPARATOR|Study Intervention|Endonasal endoscopic pituitary surgery in semi-sitting position
62138955|NCT04584866|ACTIVE_COMPARATOR|Control Intervention|Endonasal endoscopic pituitary surgery in supine position
62138956|NCT00872872|ACTIVE_COMPARATOR|AZT/3TC 1 week after delivery|AZT/3TC 1week after delivery
62138957|NCT00872872|EXPERIMENTAL|AZT/3TC 2 weeks after delivery|AZT/3TC 2 weeks after delivery
62138958|NCT02673216||Spontaneous abortion|Women attending for suspected spontaneous abortion
62495152|NCT05366231|EXPERIMENTAL|Kesuting syrup group|Kesuting syrup, the tested drug of this study.
62495153|NCT05366231|ACTIVE_COMPARATOR|LianHuaQingWen Granules Control group|"LianHuaQingWen Granules, referring to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9), a NMPA approved drug for light and common patients with novel coronavirus during medical observation and clinical treatment,is adopted as active comparator in this study."
62495154|NCT01285076||All Enrolled Participants|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU + MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist, or family practice doctor.
62495155|NCT02359539|EXPERIMENTAL|PRF|Platelets rich fibrin,
62495156|NCT02359539|EXPERIMENTAL|MPP|Marginal periosteal pedicle
62495157|NCT01398787|EXPERIMENTAL|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear
62495158|NCT01398787|ACTIVE_COMPARATOR|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear
62495159|NCT04900623|EXPERIMENTAL|LOW RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~* NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what radiation dose received . The specimens will be de-identified. The specimens will be banked for future use.~* Radiation Therapy: Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.~* Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~  * Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~ * Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
62338486|NCT01890070|EXPERIMENTAL|STANDARD DIET WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats \< 30% e 30 g of fibers) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
62338487|NCT01890070|EXPERIMENTAL|STANDARD DIET WITH WILD MIXED GREEN|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats \< 30% e 30 g of fibers) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
62338488|NCT01890070|EXPERIMENTAL|STANDARD DIET WITH OLIVE OIL|"Intervention type: each patient is administered a food plan for four weeks. Every patient patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats \< 30% e 30 g of fibers) with 100g of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
62338489|NCT01890070|PLACEBO_COMPARATOR|HIGH FAT DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)~Three weeks of washout to avoid additive effects on treatments to follow."
62338490|NCT01890070|EXPERIMENTAL|HIGH FAT WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 40g of Italian hazelnuts from Piedmont with Protected Geographical Indication Certification.~Three weeks of washout to avoid additive effects on treatments to follow."
61943282|NCT03864770|ACTIVE_COMPARATOR|Only general physical therapy|In this arm, the subjects will only receive the intervention of general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
61943283|NCT02160990|EXPERIMENTAL|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
61943284|NCT02160990|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
61943285|NCT03307785|EXPERIMENTAL|Part A: TSR-042 and niraparib 200 mg QD|Patients will receive TSR-042 500 milligram (mg), intravenous (IV) infusion on Day 1 of every cycle (every 3 weeks \[Q3W\]) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (every 6 weeks \[Q6W\]) beginning on Day 1 of Cycle 5 along with niraparib 200 mg, once daily (QD), orally on Days 1 to 21 repeated Q3W.
61943286|NCT03307785|EXPERIMENTAL|Part A: TSR-042 and niraparib 300 mg QD|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg, QD, orally on Days 1 to 21 repeated Q3W.
61943287|NCT03307785|EXPERIMENTAL|Part B: TSR-042 and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 milligram per square meter (mg/m\^2), IV infusion on Day 1 Q3W administered for 4 to 6 cycles.
61943288|NCT03307785|EXPERIMENTAL|Part C: TSR-042, niraparib 200 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 200 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kilogram (kg), IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
62138959|NCT02673216||Normal pregnant women|Normal pregnant women attending for nuchal translucency scan
62138960|NCT05711693|EXPERIMENTAL|Technique comparison|All patients will undergo successively LDV heart to carotid PWV and ascending aorta PWV by MRI, for comparison
62696554|NCT04518228||Component 4: Arm 4.1: Second-line TB treatment drugs|"Women ≥ 20 weeks gestation receiving at least one of the following second-line TB treatment drugs, and their infants:~* Levofloxacin (LFX) 750mg - 1000mg q.d.~* Clofazimine (CFZ) 100mg q.d.~* Linezolid (LZD) 300mg - 600mg q.d.~* Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~* Delamanid (DLM) 100mg b.i.d.~* Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study"
62338491|NCT01890070|EXPERIMENTAL|HIGH FAT WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
62338492|NCT01890070|EXPERIMENTAL|HIGH FAT WITH CHESTNUT|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
62696555|NCT04518228||Component 5: Arm 5.1: ATV/r|Women post-delivery receiving ATV/r, and their infants
62696556|NCT04518228||Component 5: Arm 5.2: DRV/r|Women post-delivery receiving DRV/r, and their infants
62696557|NCT04518228||Component 5: Arm 5.3: LPV/r|Women post-delivery receiving LPV/r, and their infants
62696558|NCT01751880|EXPERIMENTAL|Exercise Group|
61943289|NCT03307785|EXPERIMENTAL|Part C: TSR-042, niraparib 300 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
61978806|NCT03566927|EXPERIMENTAL|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter, then a standard balloon angioplasty, followed by a Lutonix® drug-coated balloon (DCB).
61978807|NCT01361464|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive tipifarnib orally twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61943290|NCT03307785|EXPERIMENTAL|Part D: TSR-042, carboplatin-paclitaxel and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m\^2, IV infusion on Day 1 Q3W administered for 4 to 6 cycles; and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
61943291|NCT03307785|EXPERIMENTAL|Part E: TSR-042 and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W and pemetrexed 500 mg/m\^2, IV infusion on Day 1 Q3W (with vitamin supplementation) administered for 6 cycles (each cycle is 21 days).
61943292|NCT03307785|EXPERIMENTAL|Part F: TSR-042, TSR-022, and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); and TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W administered for 5 cycles (each cycle is 21 days); and pemetrexed 500 mg/m\^2, IV infusion on Day 1 Q3W (with vitamin supplementation).
61943293|NCT03307785|EXPERIMENTAL|Part G: TSR-042 and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m\^2, IV infusion on Days 1, 8 and 15 (every week \[Q1W\]) of every 3 week cycle for 4 to 6 cycles.
62138961|NCT04615416|EXPERIMENTAL|Emotion Regulation Training via Telehealth|All participants will receive 9 sessions of Emotion Regulation Training delivered via telehealth. These individualized therapy sessions are 1-hour in length and occur semi-weekly over the course of four weeks.
61943294|NCT03307785|EXPERIMENTAL|Part H: TSR-042, TSR-022, and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m\^2, IV infusion on Days 1, 8 and 15 (Q1W) of every 3 week cycle for 4 to 6 cycles.
61943295|NCT03307785|EXPERIMENTAL|Part I: TSR-042, TSR-022, and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m\^2, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days).
61943296|NCT03239600|EXPERIMENTAL|Part I & II: GSK2618960 2 milligram per kilogram (mg/kg)|GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)
61943297|NCT03239600|PLACEBO_COMPARATOR|Part II: Placebo|Placebo will be administered IV with MTX
61943298|NCT05215886||Surgery|Patients scheduled for or have already completed Weight Loss Surgery at UC Davis Medical Center
61943299|NCT04597229|ACTIVE_COMPARATOR|Instant multigrain|Oral instant multigrain supplement
61943300|NCT04597229|NO_INTERVENTION|Standard care|Standard care without oral instant multigrain supplement
61943301|NCT00406718|EXPERIMENTAL|PharmCAT|Participants will receive PharmCAT in addition to Treatment as usual, Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
62138962|NCT00571649|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
62696559|NCT05175157||General practitioner|Answer the Gut Fellings questionnaire
61943302|NCT00406718|ACTIVE_COMPARATOR|Med-eMonitor|Participants will receive Med-eMonitor™ in addition to treatment as usual. Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
61943303|NCT00406718|ACTIVE_COMPARATOR|Treatment as Usual|Participants will receive standard treatment as usual which is medication management and limited case management provided by the CMHC.
61943304|NCT00068328||Group 1|"Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.~Patients are followed annually for at least 5 years."
61943305|NCT04156360||Healthy Volunteers|
61943306|NCT04156360||Patients With Pulmonary Nodule|
61943307|NCT00922233|EXPERIMENTAL|Levonorgestrel|0.75 mg of levonorgestrel within 24 hours of sex
61943308|NCT03760055||Glaucoma and glaucoma suspects|Patients with at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits. Patients considered suspects for glaucoma must have an intraocular pressure (IOP) greater than 21 millimeters of mercury (mmHg) or suspicious appearance of the optic nerve head but with reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
61943309|NCT03760055||Age-related macular degeneration|"Patients will be considered as having AMD if one or more of the following are present on posterior biomicroscopy (fundoscopy), indirect ophthalmoscopy or Optical Coherence Tomography (OCT) exams:~1. Presence of at least intermediate-size drusen (63µm or larger in diameter)~2. Retinal pigment epithelium (RPE) abnormalities such as hypopigmentation or hyperpigmentation~3. Reticular pseudodrusen (also called sub retinal drusenoid deposit)~4. Presence of any of the following features: geographic atrophy of the RPE, choroidal neovascularization (exudative, wet), polypoidal choroidal vasculopathy, or retinal angiomatous proliferation."
62696560|NCT05175157||Internal|Answer the Gut Fellings questionnaire
61978808|NCT00755157|EXPERIMENTAL|1|Docetaxel(metronomic)/Bevacizumab
61978809|NCT01902264|EXPERIMENTAL|EE20/DRSP/L-5-MTHF|
62138963|NCT00571649|ACTIVE_COMPARATOR|Enoxaparin|Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
62138964|NCT04516057|EXPERIMENTAL|Nabilone Arm|Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.
62696561|NCT00023595|ACTIVE_COMPARATOR|H01: Medication|Medical therapy alone to treat Coronary Artery Disease
62495160|NCT04900623|EXPERIMENTAL|INTERMEDIATE RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~* NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what dose of radiation received. The specimens will be de-identified. The specimens will be banked for future use.~* Radiation Therapy: Higher risk participants will receive standard radiation dose for up to 7-8 weeks~* Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~  * Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~ * Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
62495161|NCT01341405|EXPERIMENTAL|CG100649 2 mg|capsule, once daily for 28 days
62495162|NCT01341405|EXPERIMENTAL|CG100649 4 mg|capsule, once daily for 28 days
62495163|NCT01341405|ACTIVE_COMPARATOR|celecoxib 200 mg|capsule, once daily for 28 days
62495164|NCT00716625||sunitinib malate|Patients taking sunitinib malate
62495165|NCT04898504|NO_INTERVENTION|Next line chemotherapy only|Next line chemotherapy is the current standard treatment for patients with CRLM and progression on chemotherapy. We will include 18 patients in this treatment arm.
62495166|NCT04898504|ACTIVE_COMPARATOR|Liver transplant|Liver transplant (LTX) has emerged as a possible solution for some patients with unresectable CRLM who otherwise have good prognosis based on available scorings systems. We will include 9 patients in this treatment arm. They will be given next line chemotherapy followed by Liver-Tx.
62696562|NCT00023595|ACTIVE_COMPARATOR|H01: Medication + CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
61943310|NCT03760055||Other eye diseases|Patients with other retinal degenerations such as retinitis pigmentosa or with other diseases affecting the visual pathways such as tumors, ischemic neuropathy or optic neuritis may also be included. Their diagnosis will be extracted from their clinical visits.
61943311|NCT03760055||Healthy subjects|To be considered healthy, subjects have to have IOP \< 22 mmHg with no history of elevated IOP and with at least two reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
61943312|NCT03599388|EXPERIMENTAL|SASI|"* Sleep Diaries (daily)~* Fitbit 24/7~* Phone/videoconference (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)"
61943313|NCT01601132|EXPERIMENTAL|theophylline|300mg (80mg/15ml elixir) theophylline
62138965|NCT04516057|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to the placebo arm will receive placebo capsules.
62138966|NCT01785446|ACTIVE_COMPARATOR|P 1|"In this group patients were aged from 20 to 45. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
62138967|NCT01785446|ACTIVE_COMPARATOR|P 2|"In this group patients were aged from 46 to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
62495167|NCT04898504|ACTIVE_COMPARATOR|Hepatic artery infusion (HAI) chemotherapy|The biological rationale for intra-arterial chemotherapy is that the hepatic artery rather than the portal vein is responsible for most of the blood supply to liver tumors. We will include 18 patients in this arm
62696563|NCT00023595|ACTIVE_COMPARATOR|H02: Medication+CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
62696564|NCT00023595|ACTIVE_COMPARATOR|H02: Medication+CABG+SVR|CABG plus Medication and Surgical ventricular reconstruction (SVR)
62495168|NCT01781117|EXPERIMENTAL|HoLEP group|Holmium Laser Enucleation of the Prostate (HoLEP)
62495169|NCT02697708|PLACEBO_COMPARATOR|Control Diet|Control (no additional potassium added to diet): Arm will consist of a 16 day balance period with a basal diet set at \~2340mg K/day; based on average American intake.
62495170|NCT02697708|ACTIVE_COMPARATOR|Potassium Supplement Diet|Potassium gluconate: Arm will consist of a 16 day balance period with the basal (control) diet plus the addition of 1000mg of K/day from potassium gluconate (12 tablets).
62495171|NCT02697708|EXPERIMENTAL|Potato Diet|Potato diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg of K/day from white potatoes.
62696565|NCT06057090|EXPERIMENTAL|Therapy Dog|This group will have a certified therapy dog present in the treatment room throughout the procedure. Prior to the procedure, the participant will be briefly introduced to the therapy dog and handler, who will remain in the room until the end of the procedure.
61943314|NCT01601132|EXPERIMENTAL|Colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
61943315|NCT04135742|EXPERIMENTAL|active tACS+ Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
61943316|NCT04135742|SHAM_COMPARATOR|sham tACS+Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min."
61943317|NCT04135742|SHAM_COMPARATOR|active tACS+ sham Cognitive Training group|"Subjects will watch neutral pictures on iPad for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
62495172|NCT02697708|EXPERIMENTAL|French fries Diet|French fry diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg K/day from French fries.
62495173|NCT04955015||patients|patients with caotid atherosclerosis refering to carotid endarterectomy
62495174|NCT04587258||Breast Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using mammograms.
62495175|NCT04587258||Colorectal Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using colonoscopies
62696566|NCT06057090|NO_INTERVENTION|Control|The control group receives standard of care and does not have a therapy dog present in the room during their treatment.
62696567|NCT04281940|EXPERIMENTAL|Permanent Implant|Insertion of the Chordal Repair System tethering the mitral leaflets to the left ventricle.
62696568|NCT01969409|PLACEBO_COMPARATOR|Placebo|These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.
61943318|NCT03830632|EXPERIMENTAL|Plyometric Training Program|The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
61943319|NCT03830632|ACTIVE_COMPARATOR|Traditional Training|"AEROBIC TRAINING - A minimum of two low-intensity sessions a week consisting of 1 hour running. .~SHUTTLE SPRINTS - Placed two cones roughly 25 yards apart. Ask cricketer to sprint as fast as back and forth between the cones 12 times, for a total of six round-trips. ask them to finish in one minute. give rest for up to five minutes, then repeat once or twice."
61943320|NCT04569656|EXPERIMENTAL|treatment|6 week treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg
61943321|NCT02708901|ACTIVE_COMPARATOR|GI Vivomixx®|25 children with GI symptoms
62138968|NCT01785446|ACTIVE_COMPARATOR|P 3|"In this group patients were aged from 66 to 85. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
62138969|NCT01785446|ACTIVE_COMPARATOR|D|"In this group patients were aged from 46to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Dexmedetomidine infusion is started at induction,a bolus dose of 0.5 µg/kg is given over the first hour which is followed by infusion of 0.4 µg/kg/hr.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
62338493|NCT01890070|EXPERIMENTAL|HIGH FAT WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
62338494|NCT01890070|EXPERIMENTAL|HIGH FAT WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
62495176|NCT00496067|EXPERIMENTAL|1|DUAO Device
62495177|NCT02340962|EXPERIMENTAL|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
62495178|NCT02340962|EXPERIMENTAL|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
62495179|NCT05006131||Patients who are at high-risk for pancreatic cancer|Patients that meet the eligibility criteria based on CAPS3 or updated national pancreatic cancer screening guidelines
62495180|NCT04553406|EXPERIMENTAL|SPR720 low dose|SPR720 500 mg administered orally once daily for 28 days.
62495181|NCT04553406|EXPERIMENTAL|SPR720 high dose|SPR720 1000 mg administered orally once daily for 28 days.
62495182|NCT04553406|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once daily for 28 days
62696569|NCT01969409|EXPERIMENTAL|Rituximab|Rituximab i.v. given on two occasions, with 14 days between doses.
62696570|NCT01728896|EXPERIMENTAL|Patient-controlled oral refeeding|Patients will be allowed to drink and eat hospital food freely as tolerated.
62696571|NCT01728896|NO_INTERVENTION|Conventional management|
61943322|NCT02708901|PLACEBO_COMPARATOR|GI Placebo|25 children with GI symptoms
61943323|NCT02708901|ACTIVE_COMPARATOR|NGI Vivomixx®|25 children without GI symptoms
61943324|NCT02708901|PLACEBO_COMPARATOR|NGI placebo|25 children without GI symptoms
61943325|NCT01453725|EXPERIMENTAL|Golimumab→Golimumab|In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
62696572|NCT05368935|EXPERIMENTAL|Healthy Control Match (RF ≥ 90 mL/min)|500 mg Twice Daily for 7 days
62696573|NCT05368935|EXPERIMENTAL|Mild Renal Impairment (RF ≥ 60 to < 90 mL/min)|500 mg Twice Daily for 7 days
62696574|NCT05368935|EXPERIMENTAL|Moderate Renal Impairment (RF ≥ 30 to < 60 mL/min)|500 mg Twice Daily for 7 days
62696575|NCT05368935|EXPERIMENTAL|Severe Renal Impairment (RF < 30 mL/min and not on dialysis)|500 mg Twice Daily for 7 days
61943326|NCT01453725|PLACEBO_COMPARATOR|Placebo→Golimumab|In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)
61978810|NCT06456151||Patients with suspected invasive candidiasis|Patients with suspected invasive candidiasis will be enrolled in this study arm.
62338495|NCT01890070|EXPERIMENTAL|HIGH FAT WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 of Italian organic Olive oil~Three weeks of washout to avoid additive effects on treatment following."
62338496|NCT01890070|PLACEBO_COMPARATOR|LOW CARBOHYDRATE DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%)~Three weeks of washout to avoid additive effects on treatments to follow."
61943327|NCT01436396|EXPERIMENTAL|CYD Dengue Vaccine Group|Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month \[M\] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
61943328|NCT01436396|EXPERIMENTAL|Placebo Group|Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
61943329|NCT04833673|EXPERIMENTAL|PMR|"The PMR intervention involving tensing and relaxing the body muscles accompanied with deep breathing. The researchers told each~participant to sit in a soundless and breathable room and in a comfortable position before each session at their home. The participants performed tensing and relaxing for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed with deep breathing. The participants were instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Moreover, throughout this exercise, the participants imagined a wave of relaxation flowing over their body."
61943330|NCT04833673|EXPERIMENTAL|BRT|Within the scope of this technique, first of all, the participants were asked to focus on a word that relieves them such as love, health or well-being. And so, the participants were asked to be in comfortable position in a silent and breathable room with the closed eyes, relax their muscles from the sole of their feet and progressing up to their face gradually, keep them relaxed, accompanied with deep breathing, be aware of their breathing, exhale gently. They continue these practices for 20 minutes and try to relax their muscles. After finishing the duration, they sit quietly for several minutes with eyes closed and later with eye opened.
61943331|NCT04833673|NO_INTERVENTION|CG|"Regarding CG, the participants were invited to the same room and received only a single time attention-matched education on Living with MS; including definition of MS, dietary advices for MS patients. The attention-matched education was performed face to face and lasted for 10 min. All participants in the three study groups also received usual treatment and care."
61943332|NCT02606084|EXPERIMENTAL|Cohort 1|Participants with mild renal impairment (Measured Creatinine Clearance \[CLCR,m\] greater than or equal to \>= 50 to 79 milliliter/minute \[mL/min\]) will self-administer esketamine 28 milligram (mg) intranasally on Day 1.
62138970|NCT05292521|EXPERIMENTAL|Group A (QOL fact sheet)|Patients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).
62138971|NCT05292521|ACTIVE_COMPARATOR|Group B (usual care)|Patients receive usual care during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT.
62495183|NCT04553406|ACTIVE_COMPARATOR|Standard of Care (SOC)|Standard of Care regimen per the Investigator's discretion.
62495184|NCT04125134|EXPERIMENTAL|Hypertonic Saline Responders|Subjects who qualify as hypertonic saline responders will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
62495185|NCT04125134|EXPERIMENTAL|Hypertonic Saline Non-responders|Subjects who qualify as hypertonic saline non-responders will be dispensed the same instructions and treatment as the Hypertonic Saline Responders. They will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
62495186|NCT05002660|EXPERIMENTAL|Group 1 (Intervention)|"For Change Club members (CCM) only: CCM will participate in meetings of the Change Club and continue implementation of a change to the community environment for up to an additional 24 months. Change Club members will also be asked to recruit 10 or more friends and family members (FFM) to participate in the research study.~In addition, 100 community residents (CR) will be recruited into the study. Family members, friends and community residents do not participate in the Change Club, but may hear about Change Club activities in their community."
62495187|NCT05002660|EXPERIMENTAL|Group 2 (Control)|Control group participants will participate in no intervention activities during the 3-year research study.
62495188|NCT03250117|EXPERIMENTAL|Cohort 1|Requip; One Ropinirole Implant
62495189|NCT03250117|EXPERIMENTAL|Cohort 2|Requip; Two Ropinirole Implants
62495190|NCT03250117|EXPERIMENTAL|Cohort 3|Requip; Three Ropinirole Implants
62495191|NCT03250117|EXPERIMENTAL|Cohort 4|Requip; Four Ropinirole Implants
62495192|NCT04255849|EXPERIMENTAL|9-valent HPV vaccine|Participants receive 9-valent HPV vaccine 0.5mL at entry, Month 2 and Month 6
61943333|NCT02606084|EXPERIMENTAL|Cohort 2|Participants with moderate renal impairment (CLCR,m \>=30 to 49 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
61943334|NCT02606084|EXPERIMENTAL|Cohort 3|Participants with severe renal impairment (CLCR,m less than \[\<\] 30 mL/min), not on dialysis will self-administer esketamine 28 mg intranasally on Day 1.
61943335|NCT02606084|EXPERIMENTAL|Cohort 4|Participants with normal renal function and no evidence of kidney damage (CLCR,m \>= 80 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
61943336|NCT04348643|EXPERIMENTAL|CEA+ CAR-T|CAR-T cell reinfusion is carried out in 1\~3 times
61943337|NCT00316992|EXPERIMENTAL|Ramelteon 8 mg and Placebo|
61943338|NCT06167564|ACTIVE_COMPARATOR|Routine allergy tests|Routine allergy tests (prick tests, specific IgE detection) will be done to establish the sensibilization of the patient.
61943339|NCT06167564|EXPERIMENTAL|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system will be used to establish the sensibilization of the patient.
61943340|NCT00722332|EXPERIMENTAL|1|HBV-related liver transplant patients
62495193|NCT04255849|PLACEBO_COMPARATOR|Saline Placebo|Participants receive 0.9% NaCl 0.5 mL at entry, Month 2 and Month 6
62495194|NCT05530291||ESA hyporesponsive CKD patients|A cohort of patients who meets ESA hyporesponsiveness criteria as well as other common criteria will be created from the Fresenius Medical Care´s proprietary clinical database called EuCliD.
62495195|NCT05530291||ESA responsive CKD patients|A cohort of patients who meets ESA responsiveness criteria as well as other common criteria will be created from the Fresenius Medical Care´s proprietary clinical database called EuCliD.
62495196|NCT06678529|ACTIVE_COMPARATOR|active tDCS|TDCS(transcranial direct current stimulation) at 2 mA were received for 20 min, beginning with a 30-s current rise phase and ending with a 30-s current fall phase.
62495197|NCT06678529|SHAM_COMPARATOR|sham tDCS|Subjects received only a 30-s current rise phase at the beginning of each session and a 30-s current fall phase at the end of each session without a constant current of 2 mA for 20 min.
62138972|NCT01606813|ACTIVE_COMPARATOR|Brief physician counseling (BPC) + Usual care (UC)|The participant will receive standard care. They will receive BPC from their PCP on weight loss by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss.
62495198|NCT02034513|EXPERIMENTAL|IDeg OD + IAsp followed by IGlar OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
62495199|NCT02034513|ACTIVE_COMPARATOR|IGlar OD + IAsp followed by IDeg OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
62495200|NCT02583048|EXPERIMENTAL|Arm 1: Bedaquiline|"Participants received 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
62696576|NCT01505088|EXPERIMENTAL|Iontophoretic Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
61943341|NCT02827227||Primary HIV- Infected patients|Primary HIV- Infected patients with a minimum of 2 years of effective cART.
61943342|NCT06503055||General population|The questionnaire will target a convenience sample of the general population in the Gharbia governorate.
61943343|NCT06503055||Healthcare professionals|The questionnaire will target a convenience sample of healthcare professionals in the Gharbia governorate including physicians with different specialties, pharmacists, medical students, and nursing staff.
61943344|NCT02108782|EXPERIMENTAL|Treatment (dovitinib lactate)|Patients receive dovitinib lactate PO on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62138973|NCT01606813|EXPERIMENTAL|BPC + Internet Weight Control Program (IWCP)|The participant will receive BPC from their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program.
62138974|NCT01606813|EXPERIMENTAL|BPC + IWCP + Follow up email notes from PCP|The participant will receive BPC form their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program. And they will receive brief follow up email notes from PCPs on how their weight loss is going (from data collected from the weight loss website).
62138975|NCT04790331|EXPERIMENTAL|verapamil group|verapamil group who will receive verapamil 80 mg PO 3 hours preoperative
62338497|NCT01890070|EXPERIMENTAL|LOW CARBOHYDRATE DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
62338498|NCT01890070|EXPERIMENTAL|LOW CARBOHYDRATE DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
62495201|NCT02583048|EXPERIMENTAL|Arm 2: Delamanid|"Participants received 100 mg of delamanid twice a day for 24 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
62696577|NCT01505088|ACTIVE_COMPARATOR|Prednisolone Acetate Ophthalmic Suspension (1%)|Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
61943345|NCT02884882|OTHER|Emotional induction in stroke population|Six films are presented, each after a relaxation period after which the basal score is measured.
61943346|NCT02884882|PLACEBO_COMPARATOR|Emotional induction in healthy volunteers|Six films are presented, each after a relaxation period after which the basal score is measured.
61943347|NCT04148690|EXPERIMENTAL|Group ANC Intervention|Clinics in the group ANC intervention arm offer group Antenatal Care to women who present for their initial visit prior to 24 weeks provided that they intend to remain in the area for the duration of the pregnancy, and agree to participate in GANC. Women not enrolled in group ANC will receive standard ANC per ministry of health protocols.
61943348|NCT04148690|ACTIVE_COMPARATOR|Routine ANC|Clinics will offer only standard ANC per ministry of health protocols.
61943349|NCT05748080|EXPERIMENTAL|Apple intervention|the eating of 2 apples a day for a period of 6 weeks
61943350|NCT06255184|EXPERIMENTAL|Serenity GROUP|40 geriatric patients for the serenity group. They will receive the routine care in addition to the serenity therapy which included 8 sessions (1 introductory session, 4 face to face sessions at dialysis unit , and 3 mobile based sessions at home).
61943351|NCT06255184|NO_INTERVENTION|Control group|The control group received only the routine care provided at the dialysis unit with no extra interventions.
61943352|NCT05868759|EXPERIMENTAL|patients|Candidates for an ankle prosthesis
61943353|NCT02954250|NO_INTERVENTION|Control|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as usual
61943354|NCT02954250|EXPERIMENTAL|Mindfulness Group|The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
62696578|NCT06554639|EXPERIMENTAL|MK-5684 Period 1|On Day 1 a single dose of MK-5684 will be administered under fasting conditions and a single dose of HRT (prednisone and fludrocortisone) will be administered under fed conditions approximately 4.5 hours after MK-5684 dosing.
62696579|NCT06554639|EXPERIMENTAL|MK-5684 Period 2|There will be a washout of at least 5 days between MK-5684 dosing in Period 1 and the first diltiazem dosing in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 6 consecutive days with a single dose of MK-5684 coadministered on Day 2 under fasting conditions. HRT (prednisone and fludrocortisone) will be administered under fed conditions QD on Days 2 through 5, approximately 4.5 hours after MK-5684 and/or diltiazem dosing.
61943355|NCT05640804|EXPERIMENTAL|CTTTQ Dasatinib tablet|Subjects receive CTTQ dasatinib tablet under fasting/fed
61943356|NCT05640804|EXPERIMENTAL|Sprycel Sprycel|Subjects receive Sprycel under fasting/fed
61943357|NCT03105804|EXPERIMENTAL|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
61943358|NCT03105804|EXPERIMENTAL|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
61943359|NCT03105804|EXPERIMENTAL|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
61943360|NCT03105804|EXPERIMENTAL|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
62138976|NCT04790331|EXPERIMENTAL|Ditiazim|Diltiazim group will receive Diltiazim 90mg PO 3 hours preoperative
62138977|NCT04790331|EXPERIMENTAL|placebo group|Placebo oral tablet
62138978|NCT03771066|EXPERIMENTAL|Diet plus bisphenol A|Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.
62138979|NCT03771066|PLACEBO_COMPARATOR|Placebo|Participants will receive a 4-day diet plus no bisphenol A.
62138980|NCT06698510||arPZQ distributed through Platform 1 (NTD programmes)|Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine schistosomiasis mass drug administration campaigns led by the national NTD programmes.
62138981|NCT06698510||arPZQ distributed through Platform 2 (child health days/nutrition programmes)|Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine vitamin A distribution/child health days campaigns led by the national nutrition programmes.
62138982|NCT01291628|EXPERIMENTAL|socks containing copper-oxide fibers|
62138983|NCT06522893|EXPERIMENTAL|Percutaneous neuromodulation|"Patients assigned to this group (n=35) will receive three weekly sessions of percutaneous neuromodulation for a total of 6 weeks, with each session lasting 30 minutes.~For the treatment application, the patient will be positioned in a prone decubitus position, leaving the dorsal-cervical area exposed, and we will apply skin disinfectant (chlorhexidine). Subsequently, and under ultrasound guidance, we will perform the technique using a 30 x 40 mm acupuncture needle, which will be inserted at three vertebral levels and bilaterally; the greater occipital nerve and the posterior root of the C3 and C7 levels.~Once the needles are correctly positioned, we will connect alligator clip electrodes segmentally, connecting them to an electrotherapy device (TensMed S82-Enraf Nonius) applying a TENS current. The parameters used will be set to low-frequency (2 Hz) symmetric biphasic pulsed current with a pulse width of 120 μs and an intensity described by the patient as mild to moderate."
62138984|NCT06522893|ACTIVE_COMPARATOR|Therapeutic Exercise|"These participants (n=35) will engage in resistance training for the cervical flexor muscles, following a progressive exercise program in a supine position with the head comfortably supported, as described by Falla et al. (2008).~Participants will perform these exercises with a frequency of 3 days a week for 6 weeks, with each session lasting 30 minutes."
62138985|NCT04922242|EXPERIMENTAL|Population 1: NICU Study Staff|Interdisciplinary Professional Clinical Staff who are employed to work as a nurse, therapist, social worker or physician in the NICU.
62138986|NCT04922242|EXPERIMENTAL|Population 2: Mother-infant dyads in NICU|Parent and infant dyads admitted to a NICU for over 72 hours.
62696580|NCT06062485|EXPERIMENTAL|Experimental|
61943361|NCT04534972|NO_INTERVENTION|Pre-Implementation|The control (pre-implementation) group will be burn patients admitted to the burn unit in ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
61943362|NCT04534972|ACTIVE_COMPARATOR|Post-Implementation Targeting Normoxemia in Burn ICU|The intervention (post-implementation) group will be patients admitted to the burn unit in ICU during the targeting normoxemia intervention period of the stepped-wedge design implementation process (up to 19 months).
62696581|NCT06644105|EXPERIMENTAL|subjects took cefditoren pivoxil tablets 200mg after a meal|take cefditoren pivoxil tablets 200mg after a meal
62696582|NCT05628480||POD group|According to RASS and CAM-ICU scales, patients who suffer from post-cardiac surgery delirium in ICU will be include into POD group
61943363|NCT00333801|ACTIVE_COMPARATOR|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited
61943364|NCT00333801|EXPERIMENTAL|Individual Placement and Support (IPS)|Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.
61943365|NCT05273333|OTHER|Ultra-gyn®|ovule
61943366|NCT02830178||Any Paracetamol|Participants with age 18 and over who received a first prescription of single-ingredient paracetamol or ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
62696583|NCT05628480||Non-POD group|According to RASS and CAM-ICU scales，patients who do not judge as post-cardiac surgery delirium in ICU will be include into non-POD group
62696584|NCT05713487|EXPERIMENTAL|preventive treatment group|
62338499|NCT01890070|EXPERIMENTAL|LOW CARBOHYDRATE DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
62495202|NCT02583048|EXPERIMENTAL|Arm 3: Bedaquiline and Delamanid|"Participants received 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They then received 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
62495203|NCT04244643||Patients with soft contact lenses|
62495204|NCT04698551||16 pregnant women and their spouses|16 pregnant women and their spouses
62696585|NCT05713487|NO_INTERVENTION|control group|
62338500|NCT01890070|EXPERIMENTAL|LOW CARBOHYDRATE DIET CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
62338501|NCT01890070|EXPERIMENTAL|LOW CARBOHYDRATE DIET WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
62338502|NCT01890070|EXPERIMENTAL|LOW CARBOHYDRATE DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
62338503|NCT01890070|PLACEBO_COMPARATOR|HIGH PROTEIN DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%)~Three weeks of washout to avoid additive effects on treatments to follow."
62338504|NCT01890070|EXPERIMENTAL|HIGH PROTEIN DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification"
62338505|NCT01890070|EXPERIMENTAL|HIGH PROTEIN DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
62338506|NCT01890070|EXPERIMENTAL|HIGH PROTEIN DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
62338507|NCT01890070|EXPERIMENTAL|HIGH PROTEIN DIET WITH CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
62338508|NCT01890070|EXPERIMENTAL|HIGH PROTEIN DIET WITH ITALIAN ORGANIC WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
62495205|NCT01118767|EXPERIMENTAL|Cell phone intervention|Participant receives short text messages
62495206|NCT01118767|NO_INTERVENTION|Standard of care|Participant receives standard of care support but not short text messages
62495207|NCT04589364|EXPERIMENTAL|abobotulinum toxin A|"Abobotulinum Toxin Type A (Dysport) dose was investigated:~dose: 100 units ( various units each site depend on clinical )"
62495208|NCT04589364|EXPERIMENTAL|neubotulinum toxin A|"Neubotulinum Toxin Type A (Neuronox) dose was investigated:~dose: 33.33 units ( various units each site depend on clinical )"
62495209|NCT06129123|EXPERIMENTAL|Intervention|"Participants will be asked to complete a 30-minute intervention that is accessible on a mobile device, delivered via a webpage, and personalized to their individual vaping behavior and beliefs (based on the baseline surveys). The intervention will contain personalized normative feedback (PNF), Motivational Enhancement (ME), and education.~Participants will complete assessments at baseline as well as 2-weeks, 4-weeks, and 8-weeks post randomization."
62495210|NCT06129123|NO_INTERVENTION|Waitlist Control|Participants will complete assessments at baseline as well as 2-weeks, 4-weeks, and 8-weeks post randomization. They will not receive the intervention during the active study phase, lasting 8 weeks. Participants will have the option to access the intervention once this active study phase is over.
62495211|NCT05514340|ACTIVE_COMPARATOR|Normal Saline + Standard of care|Patients will receive the best available standard of care. Normal saline will be administered as an intravenous bolus over one minute every 3 hours on day 1, day 3, and day 6 post randomizations.
62696586|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
62696587|NCT05161195|OTHER|Ribociclib|All participants will receive ribociclib in combination with other drugs at the same dose/schedule as in the parent study.
62696588|NCT05896371|EXPERIMENTAL|Cohort A|Lower risk of toxicity (no risk factor)
62696589|NCT05896371|EXPERIMENTAL|Cohort B|Extensive bone metastasis
62696590|NCT05896371|EXPERIMENTAL|Cohort C|Decreased bone marrow reserve
62696591|NCT05896371|EXPERIMENTAL|Cohort D|Renal function impairment
62696592|NCT05896371|EXPERIMENTAL|Cohort E|Higher risk of toxicity (more than one risk factor and others)
62696593|NCT05974800||Cancer patients|All adult patients with solid or hematological malignancies and receiving systemic therapy or having received systemic therapy within the last 3 months that are admitted to the emergency department of the Erasmus medical center for the oncology, hematological, lung- and neuro-oncology medical unit are eligible for inclusion.
62696594|NCT01405196|OTHER|10 mg of PF-04236921|
62696595|NCT01405196|OTHER|50 mg of PF-04236921|
62696596|NCT01405196|OTHER|200 mg of PF-04236921|
62696597|NCT01405196|OTHER|Placebo|
62696598|NCT03440411|ACTIVE_COMPARATOR|ARM pom-dex Early (A-I)|Patients will receive treatment at biochemical relapse with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
62696599|NCT03440411|EXPERIMENTAL|ARM pom-cyclo-dex Early(B-I)|Patients will receive treatment at biochemical relapse with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
62696600|NCT03440411|EXPERIMENTAL|ARM pom-dex Late (A-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
62696601|NCT03440411|ACTIVE_COMPARATOR|ARM pom-cyclo-dex Late (B-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-cyclo-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
62138987|NCT06638099|EXPERIMENTAL|Healthcare Prescribers Exposed to CGM Prescriber Toolkit Training|Participants in this arm will include qualified healthcare prescribers (MDs, DOs, PAs, NPs, etc.) and staff who treat patients with Type 2 diabetes in primary care settings who will receive in depth training using a study-developed prescriber toolkit. The toolkit covers important information including current clinical practice guidelines, eligibility criteria, provider documentation requirements and scripts for discussing CGM use with their patient population. The impact of the training will be evaluated by examining changes in CGM prescription rates for patients with Type 2 diabetes seen in primary care before and after the training is delivered. Secondarily, Participants will be surveyed pre- and post-training to elicit prescribing knowledge and attitudes towards CGM use.
62138988|NCT06638099|NO_INTERVENTION|Healthcare Prescribers Not Exposed to CGM Prescriber Toolkit Training|Participants in this arm are prescribers (MDs, DOs, PAs, NPs, etc.) and staff who will NOT receive in depth training using a study-developed prescriber toolkit.
62138989|NCT05211232|EXPERIMENTAL|GP combined with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for eight cycles after radiotherapy
62138990|NCT05211232|PLACEBO_COMPARATOR|GP combine with Placebo neoadjuvant therapy+CCRT+Placebo adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and Placebo(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with Placebo(200mg) every three weeks for eight cycles after radiotherapy
62696602|NCT02137343|EXPERIMENTAL|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
62696603|NCT02137343|PLACEBO_COMPARATOR|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
62696604|NCT03275337|EXPERIMENTAL|Anodal tDCS|Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
62696605|NCT03275337|EXPERIMENTAL|Cathodal tDCS|Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
62696606|NCT03275337|ACTIVE_COMPARATOR|Sham tDCS|Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
62696607|NCT04183712|EXPERIMENTAL|Afatinib with GEMOX|Patients will receive targeted therapy(Afatinib 40mg orally from day 1 to day 21 combined with GEMOX chemotherapy(gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion)
62696608|NCT04183712|ACTIVE_COMPARATOR|GEMOX|Patients will receive conventional GEMOX chemotherapy (gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion）
62738525|NCT05308407|OTHER|Aim 2. Pilot randomized controlled trial:|AYAs with primary benign or malignant central nervous system tumors (n=80 patients approached, with n= 40 participants consented and randomized to the intervention (n=20) or usual care control group (n=20)) treated at MDACC, any gender and race, who are ≤1-year post-surgery for a central nervous system tumor.
62338509|NCT01890070|EXPERIMENTAL|HIGH PROTEIN DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 of Italian organic Olive Oil~This is followed by a 3 week wash out period, to neutralize any additive effects."
62338510|NCT01426607|EXPERIMENTAL|AMO|Adjustable mandibular repositioning appliance
62338511|NCT01426607|PLACEBO_COMPARATOR|placebo|placebo device in upper jaw
61943367|NCT02830178||Ibuprofen|Participants with age 18 and over who received a first prescription of single-ingredient ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
61943368|NCT04633733|EXPERIMENTAL|Single arm|"This single arm is conducted in fixed-sequence(Treatment A -\>(washout period) -\> Treatment B -\> Treatment C -\> Maintenance treatment).~Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days"
62338512|NCT00946530|EXPERIMENTAL|Bright Light|received bright light
62495212|NCT05514340|EXPERIMENTAL|Sovateltide + Standard of care|Patients will receive the best available standard of care. Dose of sovateltide (0.3 µg/kg) will be administered as an intravenous bolus over one minute every 3 hours on day 1, day 3, and day 6 post randomizations.
62495213|NCT00370851|EXPERIMENTAL|1|Intravitreal injection of Avastin
62495214|NCT00370851|SHAM_COMPARATOR|2|
62338513|NCT00946530|PLACEBO_COMPARATOR|Control|received regular light
62338514|NCT02032745||Chemo-insensitive|Non-responders to chemotherapy (Probability for pathological negative nodal status)
62338515|NCT02032745||Chemo-sensitive|Responders to chemotherapy (Probability for pathological negative nodal status)
62338516|NCT03498781|EXPERIMENTAL|Exercise-only intervention|Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
62338517|NCT03498781|SHAM_COMPARATOR|Control intervention|Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.
62338518|NCT02231450|EXPERIMENTAL|Patients with mild hepatic impairment (Group1)|8 patients with mild hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054
62495215|NCT06447441|PLACEBO_COMPARATOR|Placebo|Enteral supplementation of placebo in 3 days
62495216|NCT06447441|EXPERIMENTAL|Vitamin D3 group|Enteral supplementation of 1,728,000 IU vitamin D3 in 3 days
62495217|NCT00668395|OTHER|CYP2B6*1/*1 genotype|Efavirenz clearance in this genotype was compared with the other genotypes
62495218|NCT00668395|OTHER|CYP2B6*1/*6|Efavirenz clearance in this genotype was compared with the other genotypes
62495219|NCT00668395|OTHER|CYP2B6*6/*6|Efavirenz clearance in this genotype was compared with the other genotypes
62495220|NCT02178891|OTHER|short implants|
61943369|NCT00108173|OTHER|Arm 1|
61943370|NCT00936611|EXPERIMENTAL|LBH589|"30 mg three days a week (Mondays, Wednesdays and Fridays).~1 cycle was 28 days~Dose modifications for attributable toxicities allowed for reduction to:~* 25 mg, 20 mg three times a week every week~* Or 20 mg three times a week every other week. No dose re-escalation was allowed.~  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose."
61943371|NCT01891110|EXPERIMENTAL|ES of the abdominal muscles|ES with surface electrodes, fixed stimulation parameters and individual mA
61943372|NCT01891110|EXPERIMENTAL|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
61943373|NCT01891110|EXPERIMENTAL|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
61943374|NCT03725215|EXPERIMENTAL|Split-Belt Treadmill Training 1:2|Split-Belt Training with a steady ratio of 1:2.
61943375|NCT03725215|EXPERIMENTAL|Split-Belt Treadmill Training 3:4|Split-Belt Training with a steady ratio of 3:4.
61943376|NCT03725215|EXPERIMENTAL|Split-Belt Treadmill Training Changing|Split-Belt Training with changing ratios between 3:4 to 1:2.
61943377|NCT03725215|ACTIVE_COMPARATOR|Split-Belt Treadmill Training Tied-Belt|Split-Belt Training with tied belts.
61943378|NCT06306989||High-risk groups|
61943379|NCT06306989||Low to medium risk group|
61943380|NCT05171543|EXPERIMENTAL|Periapical surgery with placement of an allograft and a membrane|Patients will undergo periapical surgery and an allograft and a membrane will be placed inside the bony crypt and over the denuded root surface respectively before closure of the flap.
61943381|NCT05171543|NO_INTERVENTION|Periapical surgery with no placement of any graft or membrane|Patients will undergo periapical surgery with no placement of any graft or membrane in the control group.
61943382|NCT05744011|EXPERIMENTAL|Tango group|"Tango intervention 2 times/week~1 hour During 3 months Conducted by care staff who previously received training in therapeutic tango from the University of Burgundy."
61943383|NCT05744011|ACTIVE_COMPARATOR|Physical activity group|"Physical activity intervention 2 times/week~1 hour During 3 months No music Conducted by physical activity professor assisted by care staff"
61943384|NCT02758314||Cases / NSCLC patients|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 150 NSCLC, free treatment by flow cytometry.~Evaluate the expression of PD-1 / PD-L1 in tumor tissue obtained by biopsy of patients with NSCLC by immunohistochemistry.~The patients for the enrollment have to be diagnosed with advanced Non-Small Cell Lung Adenocarcinoma (clinical stages IIIA, IIIB and IV), treated at the Instituto Nacional de Cancerología (INCan) who had not received radiotherapy and / or chemotherapy prior to obtaining samples to analyze. ECOG performance status 0-2 and present evidence of measurable disease."
61943385|NCT02758314||Control / Healthy subjects|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 50 samples, by flow cytometry.~Healthy subjects blood cells will be obtained from the blood bank at the Instituto Nacional de Cancerología (INCan)"
61943386|NCT01230723|ACTIVE_COMPARATOR|Arm 1|Everolimus-Eluting Stent
61943387|NCT01230723|ACTIVE_COMPARATOR|Arm 2|Zotarolimus-Eluting-Stent
61943388|NCT05182866|EXPERIMENTAL|Single Arm|ASP-1929 640 mg/m\^2 treatment by intravenous (IV) infusion followed approximately 24 hours later by illumination (also termed as photoimmunotherapy \[PIT\]) of tumor(s) using the PIT690 Laser System with a 690 nm light dose of 50 J/cm\^2 for superficial illumination and 100 J/cm of diffuser length for interstitial illumination. During the illumination procedure, fluorescence of the IR700 component of ASP-1929 will be imaged with a Shimadzu Fluorescence Imaging System camera. Patients will undergo standard of care surgery with or without chemotherapy or radiation approximately 21 days after ASP-1929 PIT treatment.
61943389|NCT02154737|EXPERIMENTAL|erlotinib and gemcitabine|"Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg~Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle."
61943390|NCT01781754||Diabetic patients|Un balanced diabetic patients
61943391|NCT05269433|ACTIVE_COMPARATOR|PSE + OCAT-sham|Psycho-education video + an active placebo training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is an undirected scrambled sentences task with online contingent feedback (only) on the speed with which the sentences were made. In this condition, participants will not receive feedback on emotional attention.
61943392|NCT05269433|EXPERIMENTAL|PSE + OCAT|Psycho-education video + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
62495221|NCT03699150||Postmenopausal women|Outpatients referred to the Gynecologic Endocrinology, FTGM
61943393|NCT05269433|EXPERIMENTAL|PSE + OCAT+|Psycho-education video + short motivational video before each training session + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
61943394|NCT05352178|ACTIVE_COMPARATOR|MDT alone|Metastasis-directed therapy alone
61943395|NCT05352178|EXPERIMENTAL|MDT + 1 month of ADT|Metastasis-directed therapy plus one month of androgen deprivation therapy (gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im)
61943396|NCT05352178|EXPERIMENTAL|MDT + 6 months of ADT + anzalutamide|Metastasis-directed therapy plus 6 months of androgen deprivation therapy (gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im) and enzalutamide (4 x 40 mg each day during 6 months )
62696609|NCT03097640|EXPERIMENTAL|CHAMP|Participants enrolled in CHAMP are followed by a team of a social worker and physician across the care continuum. CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
61943397|NCT00601198|EXPERIMENTAL|Treatment Period|The chemotherapy regimen will be given for 2 consecutive days. On day #1, pt. will be premedicated with drugs to prevent nausea and vomiting in addition to intravenous fluids. Then they will receive amifostine intravenously followed by oxaliplatin, 5FU and leucovorin. This will be followed by an infusion of 5FU given in a pump over 22 hours. If the doctor decides on giving the pt. Avastin, this will be given on day #1. On day #2, they will receive the same treatment except for oxaliplatin.
61943398|NCT01892215|EXPERIMENTAL|Cephalad-caudad|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
61943399|NCT01892215|EXPERIMENTAL|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
61943400|NCT01389271||Group 1|
61943401|NCT04200560|EXPERIMENTAL|Healthy Adult Subjects|Healthy adult subjects (18 - 30 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise
61943402|NCT04200560|EXPERIMENTAL|Healthy Older Adult Subjects|Healthy older adult subjects (\> 60 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise and after Chronic Exercise Training.
61943403|NCT04275934||Cohort|This project will evaluate the impact of self-insured employers implementing an innovative care model utilizing pharmacist-delivered MTM services for health plan beneficiaries with high blood pressure.
61943404|NCT00775073|EXPERIMENTAL|Treatment|Bevacizumab (Avastin) \& Everolimus (RAD001)
61943405|NCT02269748|EXPERIMENTAL|Root coverage with Tunnel (TT)|The tunnel technique with subepithelial connective tissue graft (TT+SeCTG) will be utilized to cover the denude root surface
61943406|NCT02269748|ACTIVE_COMPARATOR|Coronally advanced flap (CAF+SeCTG)|The Coronally advanced flap with subepithelial connective tissue graft (CAF+SeCTG) will be utilized to cover the denude root surface
61943407|NCT02123173||non-intubated|VATS, non-intubated
61943408|NCT02123173||intubated|VATS, intubated
61943409|NCT05962671|ACTIVE_COMPARATOR|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
61943410|NCT05962671|ACTIVE_COMPARATOR|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
61943411|NCT06315023||As Treated|All patients that have received the therapy; patients treated within and outside the IFU criteria subgroups; male and female subgroups; and duplex imaging subgroups for arterial and venous observations.
61943412|NCT06315023||Imaging Cohort|Sites that are performing (arterial and venous) duplex ultrasound assessments according to the institution's standard practice will be asked to participate in the DUS imaging cohort. The Imaging sub-study will consist of 55 female and 55 male subjects from these sites. Duplex imaging at 1-, 12-, 24-, and 36-months post-procedure will be collected to assess the endpoints of graft patency and venous thrombus within the vein containing the graft (n=110).
62495222|NCT02791958|EXPERIMENTAL|CV Fixed Dose Combination Pill AAR|Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).
61943413|NCT04273373|ACTIVE_COMPARATOR|Standard dose albumin+SOC|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours. SOC (Standard of Care)
62696610|NCT03097640|NO_INTERVENTION|Standard Care|Individuals in the standard care arm will receive care as they do normally when hospitalized, including medical and inpatient social work services, as well as outpatient care from their providers.
62696611|NCT06564064|ACTIVE_COMPARATOR|study group Study group(Group1)|25 participant will be in study group (abdominal binders)
62696612|NCT06564064|PLACEBO_COMPARATOR|Control group (Group 2)|25 participants will be in control group
61943414|NCT04273373|EXPERIMENTAL|Low dose albumin+SOC|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg. after 48 hours SOC (Standard of Care)
61943415|NCT02397031|EXPERIMENTAL|Mindfulness|As proposed in dialectical behavioral therapy, mindfulness training consist of a set of behavioral skills that aim at improving patient's attentional control and emotional regulation.
61943416|NCT02397031|ACTIVE_COMPARATOR|Interpersonal effectiveness|Interpersonal effectiveness skills are focused on improving interpersonal relationships and enhancing patient's ability to display social effective behavior.
61943417|NCT06529406|EXPERIMENTAL|Ozanimod de-escalation of anti-CD20 treatment|Ozanimod will be started 6-12 months after the last anti-CD20 infusion or 30-180 days from their last ofatumumab injection. Ozanimod will be provided by the study.
61943418|NCT06529406|NO_INTERVENTION|Continued anti-CD20 treatment|Patients will continue to receive anti-CD20. Propensity score matched to the experimental arm.
61943419|NCT01286727|PLACEBO_COMPARATOR|Normal Saline|Placebo
61943420|NCT01286727|ACTIVE_COMPARATOR|BB3|
61943421|NCT01542073|EXPERIMENTAL|68Ga-BNOTA-PRGD2 cardiac PET/CT scanning|We will perform 68Ga-BNOTA-PRGD2 cardiac PET/CT scanning on myocardial infarction patients to determine its value.
62495223|NCT02791958|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 40 mg (Lipitor®).
62495224|NCT02791958|ACTIVE_COMPARATOR|Ramipril|Ramipril 10 mg (Altace®).
62495225|NCT04685681|EXPERIMENTAL|Hiking Challenge|This group receives access to the local hiking challenge after completion of baseline measure
61943422|NCT02245984|EXPERIMENTAL|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
61943423|NCT02245984|EXPERIMENTAL|electronic nursing process|for two weeks students in this group will be implemented electronic nursing process for patients.
61943424|NCT02124486|ACTIVE_COMPARATOR|Dietetic Intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers diet programme.
62138991|NCT05737602|EXPERIMENTAL|3RP-VHL|"* An adapted version of the 3RP (3RP-VHL) for individuals with VHL. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.~* Complete pre- and post-intervention surveys."
62138992|NCT03758391|NO_INTERVENTION|Traditional Didactic Education|Education will be provided to fellows using the traditional didactic approach (lecture-based).
62138993|NCT03758391|EXPERIMENTAL|Flipped Classroom Education|Education will be provided to fellows using the flipped classroom approach.
62138994|NCT01258036||Fractured Mothers|Fractured Mothers and their daughters
62138995|NCT01258036||Non fractured mothers|Mothers non fractured and their daughters
62138996|NCT02707666|EXPERIMENTAL|Pembrolizumab+Surgery+Chemotherapy|Neoadjuvant pembrolizumab, followed by surgery, followed by adjuvant pemetrexed and cisplatin
62138997|NCT06221215||Traumatic brain injury Group|The levels of related hormones (growth hormone, pituitary prolactin, ACTH, cortisol, FSH, thyroid hormone, etc.) were measured in patients with traumatic brain injury on the 1st, 7th and 14th day.
62138998|NCT06221215||Spontaneous cerebral hemorrhage roup|The levels of related hormones (growth hormone, pituitary prolactin, ACTH, cortisol, FSH, thyroid hormone, etc.) were measured in patients with spontaneous craniocerebral injury on the 1st, 7th and 14th day.
62138999|NCT00475241|EXPERIMENTAL|Prolonged Exposure Therapy|Prolonged exposure therapy for PTSD
62139000|NCT00475241|ACTIVE_COMPARATOR|Present Centered Therapy|Present centered therapy for PTSD
62139001|NCT01471691|EXPERIMENTAL|intravitreal ranibizumab 0.5mg|
62139002|NCT01471691|EXPERIMENTAL|intravitreal ranibizumab 1.0mg|
62139003|NCT02313350|EXPERIMENTAL|Chemonucleolysis with Discogel|Discogel® is a class III medical device (CE0459 mark on 28/09/2007) constituted by a radiopaque jellified ethanol. Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia. A volume of 0.9 ml of Discogel® is finally slowly injected during 10 to 15 minutes
62495226|NCT04685681|ACTIVE_COMPARATOR|Activity list|This group receives access to a resource sheet with activity ideas after completion of baseline measure and does not receive the main resource of interest (hiking challenge) until after the post-test (delayed intervention)
62139004|NCT02313350|ACTIVE_COMPARATOR|Open discectomy|surgery : The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root
62139005|NCT03452254|ACTIVE_COMPARATOR|Experimental Group|Active bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
62139006|NCT03452254|SHAM_COMPARATOR|Control Group|Sham bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
62139007|NCT04029090|EXPERIMENTAL|Sequence 1|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
62139008|NCT04029090|EXPERIMENTAL|Sequence 2|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
62139009|NCT04029090|EXPERIMENTAL|Sequence 3|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
62139010|NCT03903965||diabetic patients after cataract surgery|diabetic patients after cataract surgery
62139011|NCT03903965||non-diabetic patients after cataract surgery|non-diabetic patients after cataract surgery
62139012|NCT01858285||BCH Children's Rare Disease Cohort (CRDC)|Individuals with epilepsy, onset at any age. Must be followed clinically at Boston Children's Hospital. Research trio-based exome and/or whole genome with CLIA confirmation of diagnostic findings. Exclusions include presence of existing genetic diagnosis or known cause for epilepsy, presence of structural brain malformation.
62495227|NCT01774058|EXPERIMENTAL|Ilomedin, bloodflow volume, measurement,|Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
62338519|NCT02231450|EXPERIMENTAL|Patients with moderate hepatic impairment (Group 2)|8 patients with moderate hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054.
62338520|NCT02231450|EXPERIMENTAL|Healthy subjects (Group 3)|8 healthy subjects will be administered a single oral dose of 60 mg Lu AE58054.
61943425|NCT02124486|EXPERIMENTAL|Bariatric surgery|Patients randomised to the bariatric surgery arm will be referred to the bariatric surgery pathway and, if judged suitable according to the bariatric surgery clinic's screening processes, undergo bariatric surgery.
61943426|NCT02124486|NO_INTERVENTION|Matched obese control group|To evaluate the baseline difference in ICP between IIH patients and a matched obese control cohort we will recruit 20 obese but otherwise healthy participants who will undergo the same baseline visit as the main trial participants and then exit the study.
61943427|NCT02124486|NO_INTERVENTION|MRI Test run|5 patients will undergo double baseline MR scans to validate the novel MR sequences being used in the main trial.
62495228|NCT05604651||dry eye disease|Dry eye disease was diagnosed according to the Tear Film and Ocular Surface Society (TFOS) DEWS II criteria: (1) Ocular Surface Disease Index (OSDI) score ≥ 13 and (2) one of these signs; fluorescein tear breakup time (TBUT) \<10 sec; abnormal ocular surface staining (\>5 corneal spots or \> 9 conjunctival spots).
62495229|NCT05604651||control|The controll group enrolled healthy participants without ocular and systemic diseases.
62495230|NCT05187884|EXPERIMENTAL|Intervention|Darovasertib 300mg bd
61943428|NCT01088750|OTHER|surgery alone|watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL
61943429|NCT01088750|EXPERIMENTAL|CVP Chemotherapy|3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)
61943430|NCT02641132|EXPERIMENTAL|Pterygium surgery: Head and body.|Application of Mitomycin C 0.02% after excision of the body and the head of the pterygium.
61943431|NCT02641132|ACTIVE_COMPARATOR|Pterygium surgery: Body.|Application of Mitomycin C 0.02% after excision of the body only of the pterygium.
61943432|NCT02671409|PLACEBO_COMPARATOR|Control group|The exercise program will be drawn from the recommendations of the American College of Physicians and the American Pain Society for the treatment of low back pain. The exercise protocol consist of: Strengthening the abdominal muscles and erector spinae: will be three sets of 15 repetitions for each exercise with rest time between 2 minutes series; - Proprioceptive Neuromuscular Facilitation (PNF). The PNF technique will be the contract-relax the hamstrings by 6/2. Stretching the erector muscles of the spine, iliopsos, hamstrings, quadriceps and sural triceps: will be three three repetitions, with 30 seconds support time each stretch and rest time between sets 1 minute.
61943433|NCT02671409|EXPERIMENTAL|MOB Group|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
61943434|NCT05493332|EXPERIMENTAL|HAIC-Donafenib-Toripalimab Group|HAIC(FOLFOX)+Toripalimab+Donafenib
61943435|NCT00169754|OTHER|cohort|mapping and data collection
61943436|NCT02856698|EXPERIMENTAL|midazolam|The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
61943437|NCT02856698|ACTIVE_COMPARATOR|morphine|The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
61943438|NCT03677427|EXPERIMENTAL|5 fractions|
61943439|NCT03677427|EXPERIMENTAL|15 fractions|
61943440|NCT06121180|EXPERIMENTAL|Cemiplimab + Ziv-Aflibercept|"One cycle consists of 3 weeks during which:~Cemiplimab 350 mg administered IV every 3 weeks given with Ziv-Aflibercept 4 mg/kg administered IV every 2 weeks."
61943441|NCT01254292|EXPERIMENTAL|LCS12 (Skyla, BAY86-5028)|Participants received LCS12 (low dose levonorgestrel \[LNG\] intrauterine delivery system \[IUS\]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
61943442|NCT01254292|ACTIVE_COMPARATOR|EE30/DRSP (Yasmin, BAY86-5131)|Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
62139013|NCT01858285||Gene-STEPS (Shortening Time of Evaluation in Paediatric Epilepsy Services)|"Collaborative effort of consortium including BCH, Great Ormond Street Hospital, Royal Children's Hospital Melbourne and Murdoch Children's Research Institute, and The Hospital for Sick Children.~For BCH cohort, eligibility limited to individuals presenting clinically at BCH with seizure onset at less than 12 months of age. Must be enrolled within six weeks of first seizure-related presentation to BCH. Clinical trio-based rapid whole genome sequencing in a CLIA laboratory.~Exclusions include:~Simple febrile seizures, provoked seizures, genetic or acquired cause already identified, MRI findings consistent with specific genetic etiology."
62495231|NCT04817969|OTHER|Persona Ti-Nidium|Primary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System
61943443|NCT01161784|PLACEBO_COMPARATOR|Nutrient drink|
61943444|NCT01161784|EXPERIMENTAL|Probiotics|
61943445|NCT04330274||Group 1|Unilateral transtibial amputee
61943446|NCT04330274||Group 2|Unilateral transfemoral amputee
61943447|NCT03178331||Grade 1 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
62338521|NCT00617409|ACTIVE_COMPARATOR|Standard of Care|Arm A - Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy
62495232|NCT02707016|OTHER|High dose sevoflurane|"Inhaled sevoflurane 8% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
62495233|NCT02707016|OTHER|Low dose sevoflurane|"Inhaled sevoflurane 5% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
61943448|NCT03178331||Grade 5 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
61943449|NCT02777619|PLACEBO_COMPARATOR|Propofol and 0.0ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
61943450|NCT02777619|EXPERIMENTAL|Propofol and 0.4ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
61943451|NCT02777619|EXPERIMENTAL|Propofol and 0.6ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
61943452|NCT02777619|EXPERIMENTAL|Propofol and 0.8ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
61943453|NCT02694809|EXPERIMENTAL|Arm I (conjugated estrogens/bazedoxifene)|Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
61943454|NCT02694809|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
61943455|NCT05158608|ACTIVE_COMPARATOR|Cyclophosphamide on day +3,+4 at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
61943456|NCT05158608|EXPERIMENTAL|Cyclophosphamide on day +3,+4 at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
61943457|NCT01388595|ACTIVE_COMPARATOR|Fluticasone Proprionate|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
61943458|NCT01388595|ACTIVE_COMPARATOR|Salmeterol|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
61943459|NCT01388595|PLACEBO_COMPARATOR|placebo|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
61943460|NCT01015144||Atorvastatin|
61943461|NCT01015144||No statin|
62139014|NCT01858285||Epilepsy Core|Individuals with epilepsy, onset at any age. Research trio-based exome and/or whole genome. Exclusions include presence of existing genetic diagnosis or known cause for epilepsy, presence of structural brain malformation.
62139015|NCT01858285||Phenotyping Cohort|Individuals with diagnosed genetic epilepsies, including but not limited to PRRT2, SCN1A, SCN2A, SCN8A, PCDH19, SYNGAP1, DEPDC5, KCNQ2, CACNA1A.
62139016|NCT05185245|EXPERIMENTAL|Liver Transplantation|
62139017|NCT06699082|EXPERIMENTAL|Experimental Group: 1|"Experimental group was treated with kinesiotaping along with Kaltenborn mobilization AP and PA glides. The treatment protocol was administered in 10 reps' and 3 sets, and AP and PA glide were given.~Kinesiotaping: First the deltoid area was dried and cleansed, excessive hair were trimmed, the KT was cut into Y-shape and I- shape, after that whole length of the thumb was used to stretch the tape for about 15% to 25% and then from 25% to 50%. The tape was rubbed vigorously for few seconds, heat activates glue. The whole procedure takes about 15 to 20 minutes."
61943462|NCT04459624|ACTIVE_COMPARATOR|ESP block|Intervention: Erector Spina Plane Block will administer with 20 ml of % 0.25 bupivacaine
61943463|NCT04459624|ACTIVE_COMPARATOR|QLB 2 block|Intervention: Quadratus Lumborum Block 2 will administer with 20 ml of % 0.25 bupivacaine
62139018|NCT06699082|ACTIVE_COMPARATOR|Control Group: 2|Control was treated with Kaltenborn mobilization AP and PA glides along with conservative treatment and Home plane exercises.
62139019|NCT06696105|EXPERIMENTAL|Resin infiltration arm|resin infiltration will be applied on white spot lesion of anterior teeth
62139020|NCT06696105|EXPERIMENTAL|vanish xt varnish arm|vanish xt will be applied on white spot lesion of anterior teeth
61943464|NCT02424448||Metastatic CRPC|Patients with metastatic prostate cancer post maximal androgen blockade (MAB) with primary or metastatic cancer deposits amenable to biopsy. Patients will have biopsies, blood and urine samples taken.
62139021|NCT04752072|EXPERIMENTAL|ESTAIR|ESTAIR (Cloitre et al., 2019) will consist of up to 25 sessions, organized in 4 modules of 6 sessions targeting symptoms of PTSD and disturbances in self-organisation (AD: affective dysregulation; NSC: negative self-concept; and DR: disturbances in relationships).
62338522|NCT00617409|EXPERIMENTAL|Ad.p53-DC Vaccines|Arm B - Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy
62139022|NCT04752072|ACTIVE_COMPARATOR|Treatment as usual (TAU)|At present, there are no recommended treatments for CPTSD. TAU will consist of a treatment package that could include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, resembling established protocols for treating PTSD.
62338523|NCT00617409|EXPERIMENTAL|Ad.p53-DC Vaccines + ATRA|Arm C - Experimental: Ad.p53-DC vaccines + All -trans Retinoic Acid (ATRA) + Second Line Chemotherapy
62338524|NCT00256087|PLACEBO_COMPARATOR|Standard Care|Two capsules containing placebo will be given 12 hourly
62338525|NCT00256087|ACTIVE_COMPARATOR|First active treatment|Two capsules containing probiotic lactobacillus fermentin given 12 hourly
62338526|NCT00256087|ACTIVE_COMPARATOR|Second active reatment|Two capsules containing probiotic lactobacillus acidiphilus given 12 hourly
62338527|NCT02892565|EXPERIMENTAL|Cases|Patients with SLE and/or APL and first vein thrombosis episode
62338528|NCT02892565|OTHER|Controls|age-matched; Patients with SLE and/or APL
62338529|NCT02208817||Ill patients|Ill patients who require Paediatric Intensive Care or Paediatric High Dependency Care
62338530|NCT02208817||Well Controls|Matched controls who are well (PEWS\<3)
61943465|NCT01904227|EXPERIMENTAL|Inpatient Adaptation of DBT|"Patients are in treatment 5 days a week, during 12 weeks. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.~Patients also receive daily mindfulness classes, 2 hours of drama therapy, psycho educational classes about sexuality, substance abuse and medication, and the possibility to get help in applying principles of validation and behavioral analysis skills."
61943466|NCT01904227|ACTIVE_COMPARATOR|Outpatient DBT|Control condition: Standard outpatient DBT
61943467|NCT03414281|EXPERIMENTAL|TMQLB group 1|0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
61943468|NCT03414281|EXPERIMENTAL|TMQLB group 2|0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
61943469|NCT03414281|ACTIVE_COMPARATOR|TPVB group|0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.
61943470|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep \[10 from New York City (NYC); 10 from Rhode Island (RI)\] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
61943471|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step \[10 from NYC; 10 from RI\] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
61943472|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
61943473|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep \[10 from NYC; 10 from RI\] will review the intervention providing feedback on its appropriateness and utility.
61943474|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step \[10 from NYC; 10 from RI\] will review the intervention providing feedback on its appropriateness and utility in small groups.
61943475|NCT02296281|EXPERIMENTAL|treatment group|
61943476|NCT06203379|EXPERIMENTAL|Neuromuscular Exercise Training|
61943477|NCT06203379|ACTIVE_COMPARATOR|Exercise Training|
61943478|NCT02664545|EXPERIMENTAL|Bridge-Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into.
61943479|NCT02664545|ACTIVE_COMPARATOR|Tendon Graft|ACL reconstruction is when a tendon graft (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee) is taken and used to replace the torn ACL.
61943480|NCT01561378|EXPERIMENTAL|Insulin|Aspart Insulin 40 IU intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
61943481|NCT01561378|PLACEBO_COMPARATOR|Normal saline|Normal saline (0.9% sodium chloride solution) intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
61943482|NCT06680973|EXPERIMENTAL|Hospital-Based Resistance Training Group|Participants will undergo resistance training using a weight training station and elastic equipment (elastic bands and tubes).
61943483|NCT06680973|EXPERIMENTAL|Home-Based Resistance Training Group|Participants will undergo resistance training at home using elastic equipment (elastic bands and tubes).
61943484|NCT06680973|NO_INTERVENTION|Control Group|No training will be provided to the participants.
61943485|NCT05479331||sarcopenia|CKD patients with sarcopenia, meeting the following two criteria (1) male LTI (lean tissue index)\< 7.0 kg/m2, female LTI \< 5.7 kg/m2; (2) Male HGS)(handgrip strength \< 26 kg, female HGS \< 18 kg.
62338531|NCT02208817||Parent feedback|Feedback from parents/carers of children recruited into the PRefill study
62495234|NCT02521051|EXPERIMENTAL|Alectinib and Bevacizumab.|"Phase 1~* Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~* Alectinib, orally, twice a day, per cycle~* Bevacizumab, iv, once per cycle~Phase II In the phase II portion of this study, the investigators will evaluate the combination of alectinib plus bevacizumab in ALK-positive patients with untreated or progressive, asymptomatic brain metastases. Eligible participants will receive alectinib plus bevacizumab at the recommended phase II doses determined in the phase I portion of the study."
61943486|NCT05479331||non-sarcopenia|CKD patients with non-sarcopenia
62338532|NCT02208817||Healthcare professionals feedback|Feedback from healthcare professionals who have cared for a child with the device on
62338533|NCT04757909|EXPERIMENTAL|Monthly Haemoglobinometry|
62338534|NCT04757909|NO_INTERVENTION|Routine monitoring|
62495235|NCT00724958||Remicade|Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.
61943487|NCT02788760|OTHER|6 weeks|This group of patients will be treated for 6 weeks with a cervical collar (Miami J collar - Össur)
61943488|NCT02788760|OTHER|12 weeks|This group of patients will be treated for 12 weeks with a cervical collar ( (Miami J collar - Össur)
61943489|NCT01122433|EXPERIMENTAL|C-MAC|After a maximum of three failed intubation attempts using direct laryngoscope the C-MAC video laryngoscope is used as an emergency airway device.
61943490|NCT06558097|EXPERIMENTAL|XXB750 s.c 1 mg|Single SC dose of XXB750 1 mg
61943491|NCT06558097|EXPERIMENTAL|XXB750 s.c 3 mg|Single SC dose of XXB750 3 mg
61943492|NCT06558097|EXPERIMENTAL|XXB750 s.c 10 mg|Single SC dose of XXB750 10 mg
61943493|NCT06558097|EXPERIMENTAL|XXB750 s.c 30 mg|Single SC dose of XXB750 30 mg
62338535|NCT01743014|ACTIVE_COMPARATOR|ramipril|Ramipril 10 mg tablets. Each dose will be taken orally with water once daily.
62338536|NCT01743014|ACTIVE_COMPARATOR|clopidogrel and ramipril|clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily
62338537|NCT02512068|EXPERIMENTAL|Trelagliptin 25 mg|Trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period I + II)
61943494|NCT06558097|EXPERIMENTAL|XXB750 s.c 60 mg|Single SC dose of XXB750 60 mg
61943495|NCT06558097|EXPERIMENTAL|XXB750 s.c 120 mg|Single SC dose of XXB750 120 mg
62495236|NCT01156441|EXPERIMENTAL|surgical mitral valve repair|Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree. Mitral valve repair will be performed with mitral valve annuloplasty via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia.
62495237|NCT01156441|NO_INTERVENTION|control: medical management|Clinical observation will be continued without surgery. Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree.
62495238|NCT02089516||Frail elderly|Measuring movement activity in frail elderly (GFI score ≥ 4) of 75 years and older using DynaPort.
61943496|NCT06558097|EXPERIMENTAL|XXB750 s.c 240 mg|Single SC dose of XXB750 240 mg
61943497|NCT06558097|PLACEBO_COMPARATOR|Placebo|Placebo to XXB750
61943498|NCT06558097|EXPERIMENTAL|XXB750 s.c 240 mg Japanese cohort|Single SC dose of XXB750 240 mg in the Japanese cohort
61943499|NCT06558097|PLACEBO_COMPARATOR|Placebo for Japanese cohort|Placebo to XXB750 in the Japanese cohort
62338538|NCT02512068|EXPERIMENTAL|Placebo and Trelagliptin 25 mg|Placebo tablet, orally, once weekly before breakfast for up to Week 12 (Period I), followed by trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period II)
62338539|NCT01933165|OTHER|LipiView|
62338540|NCT05522673|OTHER|Subjects with major depression disorder (MDD)|Participants with major depressive disorder received 20 mCi of \[11C\](R)-rolipram intravenously for two PET scans, prior to and after ketamine infusion as well as brain MRI
62338541|NCT01317667|EXPERIMENTAL|Group 1|RVEc vaccine 20 μg/dose x 3 doses
62338542|NCT01317667|EXPERIMENTAL|Group 2|RVEc vaccine 50 μg/dose x 3 doses
62338543|NCT01317667|EXPERIMENTAL|Group 3|RVEc vaccine 100 μg/dose x 1 dose
62338544|NCT01536002|EXPERIMENTAL|Pharmacokinetics|Propofol pharmacokinetics
62338545|NCT00904540|EXPERIMENTAL|Lidoderm®|Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
62338546|NCT01219517|EXPERIMENTAL|Study Group|All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
62338547|NCT02586753|EXPERIMENTAL|Paclitaxel plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug Paclitaxel plus Cisplatin
62495239|NCT02581527|ACTIVE_COMPARATOR|Rifampicin 150mg (Control)|2 months daily 4FDC - Rifampicin 150mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 4 months daily 2FDC - Rifampicin 150mg and Isoniazid 75mg (continuous phase)
62495240|NCT02581527|EXPERIMENTAL|Rifampicin 1200mg (Regimen 1)|2 months daily 4FDC - high dose Rifampicin 1200mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1200mg and Isoniazid 75mg (continuous phase)
62495241|NCT02581527|EXPERIMENTAL|Rifampicin 1800mg (Regimen 2)|2 months daily 4FDC - high dose Rifampicin 1800mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1800mg and Isoniazid 75mg (continuous phase)
61943500|NCT06558097|EXPERIMENTAL|XXB750 s.c 450 mg (HBP)|Single SC dose of XXB750 450 mg (High Blood Pressure Cohort)
61943501|NCT06558097|EXPERIMENTAL|XXB750 s.c 600 mg (HBP)|Single SC dose of XXB750 600 mg (High Blood Pressure Cohort)
61943502|NCT06558097|PLACEBO_COMPARATOR|Placebo to High Blood Pressure cohort|Placebo to XXB750 in High Blood Pressure cohorts
61943503|NCT01261936||women with a diagnosis of CBD|women in the fertile age, with an ascertained diagnosis of CBD, followed up for heavy periods and needing a specific treatment.
61943504|NCT00659048|ACTIVE_COMPARATOR|1|Ciclesonide 200µg
61943505|NCT00659048|PLACEBO_COMPARATOR|2|Placebo
61943506|NCT03321266||Patients treated for a anorectal fistula|Patients who were treated for a anorectal fistula with a Biodesign Fistula plug
61943507|NCT04642612||Treatment Arm|Patients ages 18-85 years old presenting with orthopedic shoulder surgery with indication to receive preoperative insertion of interscalene nerve block.
62338548|NCT02586753|EXPERIMENTAL|S1 plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug S1 plus Cisplatin
62338549|NCT06256783|EXPERIMENTAL|Treatment group|Once enrolled, participants will be administrated Baozhu Keli and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
62495242|NCT00569660|EXPERIMENTAL|Azacitidine|75 mg/m\^2 Subcutaneous Daily for 7 days every 4 weeks
62495243|NCT01228552|ACTIVE_COMPARATOR|Topical, intra-oral ketoprofen gel|
61943508|NCT05396846|ACTIVE_COMPARATOR|Eating Plan 1|This group will receive a pamphlet from the American Institute for Cancer Research (AICR) on dietary prevention and the results of their own breath test, Veggie Meter score and anthropometric measures.
61943509|NCT05396846|EXPERIMENTAL|Eating Plan 2|This group will receive the MyBestGI App and User Manual that encourages limiting four food groups: three or less foods each day made with refined flour, no more than 8% of calories from added sugars, no processed meats and less than 18 oz./week red meat. They will also receive the results of their own breath test, Veggie Meter score and anthropometric measures.
62139023|NCT05794659|EXPERIMENTAL|AST-301|"AST-201 with rhuGM-CSF (3-week interval, 3 cycles in total)~Standard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)~\* Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles"
62338550|NCT03487640||Transanal rectal mucosa resection|TARMR: Transanal resection of rectal mucosa for at least 5cm in length.
62338551|NCT03487640||Laparoscopic rectal suspension and colectomy|LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
62338552|NCT02687230|EXPERIMENTAL|Cohort 1|Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
62338553|NCT02687230|EXPERIMENTAL|Cohort 2|Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
62338554|NCT02687230|EXPERIMENTAL|Cohort 3|Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
61943510|NCT05396846|EXPERIMENTAL|Eating Plan 3|This group will receive a version of the MyBestGI App and User Manual that encourages meeting 11 food group goals: four food groups to limit and seven food groups to encourage. The 7 groups to encourage are: 3-4 cups/day fruits and vegetables, at least one dark orange or dark green vegetable daily, daily allium and culinary herbs, 3-6 oz./day whole grains, 6-8 oz./week foods high in omega-3 fatty acids, 8-10 tsp./day olive oil or the equivalent from other foods high in monounsaturated fats and at least ½ cup/day of legumes or 1 TB/day nut butter. Some of the goals are personalized based on calculated energy needs. They will also receive the results of their own breath test, Veggie Meter score and anthropometric measures.
61943511|NCT02905149|EXPERIMENTAL|Serrato|Standard anesthesia+serratus plane block.
61943512|NCT02905149|PLACEBO_COMPARATOR|Control|Standard anesthesia
61943513|NCT04306029|NO_INTERVENTION|Pre-Intervention|
61943514|NCT04306029|EXPERIMENTAL|Post-Intervention|"Postpartum staff has received the Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
61943515|NCT02081131|ACTIVE_COMPARATOR|Laparoscopic Surgery|patients will be randomized to laparoscopic pancreatoduodenectomy group
61943516|NCT02081131|ACTIVE_COMPARATOR|Open Surgery|Patients will be randomized to Open pancreatoduodenectomy
61943517|NCT03221699|PLACEBO_COMPARATOR|control|Formula without ZnO
61943518|NCT03221699|ACTIVE_COMPARATOR|intervention|Formula with ZnO
61943519|NCT04069962|NO_INTERVENTION|Control group|Patients in the control group will receive CGA coordinated by the oncology team as standard of care, including geriatric recommendations for interventions communicated to the treating physician (eg. referral to the social worker, psychologist, dietician).
61943520|NCT04069962|EXPERIMENTAL|Intervention group|Patients in the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching.
61943521|NCT03012971|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
61943522|NCT03012971|PLACEBO_COMPARATOR|Control group|Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
62495244|NCT01228552|PLACEBO_COMPARATOR|Placebo gel|
62495245|NCT04581122|EXPERIMENTAL|Selective lymphadenectomy|
61943523|NCT04820517|EXPERIMENTAL|Experimental Group|The Roy Adaptation Model Based Empowerment Program, which consists of 12 sessions that will create awareness of social media and its effects in students and contribute to students gaining and maintaining a healthy lifestyle by providing controlled and purposeful use of social media with behavioral change, will be held with online group sessions for 12 weeks to the students in the experimental group. .
61943524|NCT04820517|NO_INTERVENTION|Control Group|No intervention will be made to the students in the control group. When the research is completed, student nurses in the control group will be informed about social media addiction and its effects.
61943525|NCT01580800||Breast cancer survivors|Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.
62338555|NCT05674838|EXPERIMENTAL|Experimental Intervention - Leg Elevation Arm|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
62495246|NCT04581122|NO_INTERVENTION|Systematic lymph node dissection|
62495247|NCT01467362|EXPERIMENTAL|V0034CR01B|
62495248|NCT01467362|PLACEBO_COMPARATOR|Vehicle cream|
62495249|NCT02835755|ACTIVE_COMPARATOR|Group I (Control)|Patients receive standard information about HPV and HPV vaccine, such as the VIS, on a mobile-friendly website study portal.
62495250|NCT02835755|EXPERIMENTAL|Group II (mHealth HPV vaccine)|Patients receive the mHealth HPV vaccine intervention consisting of content about HPV and HPV vaccine on the study portal for 15 minutes and vaccination reminders sent by the portal via text or e-mail.
61943526|NCT04634383|EXPERIMENTAL|WFMA Cortical Visual Prosthesis Single-arm Study|The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.
61943527|NCT00424450||PAD patients|30 PAD patients
62495251|NCT05575245|ACTIVE_COMPARATOR|Intervention: Drug-eluting Stent|Drug-eluting Stent group
61943528|NCT06412224|EXPERIMENTAL|RRG001|Frequency of administration: one time injection.
61943529|NCT03815474|EXPERIMENTAL|anlotinib & epirubicin& ifosfamide|interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
61943530|NCT02563665||advanced chronic kidney disease|Subjects on dialysis with GFR (Glomerular Filtration Rate) \> 30
61943531|NCT02563665||Renal replacement therapy.|Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) \< 15
61943532|NCT01662843||BRIPPED scan|Patients presenting with undifferentiated shortness of breath who receive the ultrasound scan in addition to standard of care
62338556|NCT05674838|NO_INTERVENTION|Control - No Leg Elevation Arm|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge. She will remain in this position for approximately 40 minutes.
62495252|NCT05575245|EXPERIMENTAL|Intervention: Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon group
62495253|NCT00438750|EXPERIMENTAL|Independent Home Exercises|Subjects who learn their therapy exercises from the surgeon and practice them independently at home.
62495254|NCT00438750|EXPERIMENTAL|Formal Therapy|Subjects who follow the conventional protocol of seeing a therapist to learn and guide them in their exercises.
61943533|NCT01662843||Control|Patients who only receive the standard of care for undifferentiated shortness of breath
62495255|NCT03538262||former phase 3 PD trial participants|The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.
62495256|NCT04238962|EXPERIMENTAL|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
62495257|NCT04238962|ACTIVE_COMPARATOR|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
62495258|NCT00965731|ACTIVE_COMPARATOR|Erlotinib|
62495259|NCT00965731|EXPERIMENTAL|Erlotinib + PF-02341066|
62495260|NCT00614276||Phase I - Focus Groups|
62495261|NCT00614276||Phase II TENDRILS|Phase II - TENDRILS Program only.
62495262|NCT00614276||Phase II TENDRILS + Counseling|Phase II - TENDRILS + Sexual Counseling Sessions.
62495263|NCT06152848||Patients affected by malnutrition|Patients affected by malnutrition due to deficiency or excess
61943534|NCT06105931|EXPERIMENTAL|Young adults with T1D who have a body mass index <25 kg/m2|Young adults with T1D who have a body mass index \<25 kg/m2 will have: abdominal MRI, hyperinsulinemic-euglycemic clamp wtih stable isotope tracer, DEXA scan and a High Fat Mixed Meal Tolerance Test.
62139024|NCT05794659|PLACEBO_COMPARATOR|Placebo|"Placebo with rhuGM-CSF (3-week interval, 3 cycles in total)~Standard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)~\*Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles"
62338557|NCT05578235|ACTIVE_COMPARATOR|stapled side-to-side anastomosis|Standard procedure for CD, ileocolic resection with side-to-side anastomosis is done according to local practice with a linear stapler either aniso- or isoperistaltic as advised by the ECCO guidelines
62338558|NCT05578235|ACTIVE_COMPARATOR|Handsewn anastomosis: handsewn end-to-end or Kono-s anastomosis|"* Kono-S (anti-mesenteric functionel end-to-end handsewn) anastomosis is done according to the description by Kono~* End-to-end handsewen anastomosis is fashioned either by enlarging the small bowel diameter by an antimesenteric incision to fit the large bowel lumen or by tailored resection of a part of the staple line of the cross stapled colon"
62495264|NCT06152848||Sex- and age- matched healthy controls|Sex- and age- matched healthy controls not affected by any pathology and/or malnutrition due to deficiency or excess
62495265|NCT00697619|EXPERIMENTAL|Test Group|Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
62495266|NCT00697619|NO_INTERVENTION|Contorl Group|Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.
62495267|NCT04517526|EXPERIMENTAL|1|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles , followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites
62495268|NCT01567319|EXPERIMENTAL|Allergic Subjects|
62495269|NCT01567319|ACTIVE_COMPARATOR|Atopic Subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
62495270|NCT01567319|ACTIVE_COMPARATOR|No Atopic Subjects|Healthy volunteers.
62495271|NCT06458868|NO_INTERVENTION|bath puva|Patients received the standard protocol of bath PUVA with standard psoralen plus tap water in combination with a phototherapy regimen.
62495272|NCT06458868|EXPERIMENTAL|salt water uva|Patients received saline solution (3% NaCl) in addition to UVA with standard phototherapy regimen.
62495273|NCT06458868|EXPERIMENTAL|tap water uva|Patients received tap water in addition to UVA with standard phototherapy regimen.
62495274|NCT02336633|EXPERIMENTAL|1|Resveratrol (80mg/j = 4 capsules/day)
62139025|NCT06511284|EXPERIMENTAL|High protein group|100% of the energy requirements measured by indirect calorimetry (IC) or estimated, and a protein intake of 2.0 g/kg, will be prescribed
62139026|NCT06511284|OTHER|Usual protein group|100% of the energy requirements measured by IC or estimated, and a protein intake of 1.5 g/kg, will be prescribed.
62139027|NCT06243575|EXPERIMENTAL|Multimodal Intraosseous Femoral Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
62139028|NCT06243575|EXPERIMENTAL|Multimodal Intraosseous Tibial Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
62495275|NCT02336633|PLACEBO_COMPARATOR|2|Placebo (4 capsules/day)
62495276|NCT03977441|PLACEBO_COMPARATOR|control group|treated with Pramipexole 0.75mg/d（0.25mg tid)+placebo 25mg qn \*2weeks than Pramipexole 0.75mg/d（0.25mg tid)+placebo 50mg qn \* 10 weeks
62495277|NCT03977441|EXPERIMENTAL|experimental group|treated with Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine25 mg qn \*2weeks than Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine 50mg qn \* 10weeks
62495278|NCT04473326|EXPERIMENTAL|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
62495279|NCT04473326|NO_INTERVENTION|Control Arm|Up to daily, untailored text messages.
62495280|NCT04400292|EXPERIMENTAL|SLN mapping by NIR with ICG|Patients will undergo ICG injection and NIR imaging for lymphatic mapping. Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy. The SLN biopsy procedure will be performed as described below. Although NIR with ICG is used to assess conduit perfusion in all esophagectomies performed at MSK, its use for lymphatic mapping is considered experimental in esophageal cancer.
62495281|NCT02417571|EXPERIMENTAL|ABPM group|"Ambulatory blood pressure monitoring (ABPM) performed at 3, 6 months after randomization; adjusting drugs/doses based on ABPM results.~Target BP: daytime ABP \< 135/85 mm Hg according to British NICE clinical guideline 127."
62495282|NCT02417571|NO_INTERVENTION|Office BP group|"Conventional BP management using office BP according to KDIGO guideline on BP management.~Target BP: \<140/90 mm Hg."
62495283|NCT05158660|EXPERIMENTAL|patients assessed by transcranial duplex sonography|
62495284|NCT01420614|EXPERIMENTAL|Radial|group of patients undergoing primary angioplasty by transradial approach
62696613|NCT02341274|ACTIVE_COMPARATOR|Fresh Brand Name Tacrolimus (Prograf®)|Oral administration of 5 mg capsule of fresh brand name tacrolimus (Prograf®) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
62696614|NCT02341274|ACTIVE_COMPARATOR|Fresh Generic Tacrolimus|Oral administration of 5 mg capsule of fresh generic tacrolimus to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
62139029|NCT02355041|EXPERIMENTAL|Meal Replacement-based Weight Loss Diet|Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
62139030|NCT02355041|ACTIVE_COMPARATOR|Educational Video|"Control participants will view The Weight of the World, a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web."
62696615|NCT02341274|ACTIVE_COMPARATOR|Low Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 10-30% crystallized generic tacrolimus (Low Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
62139031|NCT06697106|EXPERIMENTAL|Nonsteroidal anti-inflammatory drugs|Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
62139032|NCT06697106|PLACEBO_COMPARATOR|Control group|Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.
62139033|NCT02432274|EXPERIMENTAL|Cohort 1: Single-Agent Dose-Finding|Children and adolescents with relapsed or refractory solid malignant tumors.
62696616|NCT02341274|ACTIVE_COMPARATOR|High Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 40-60% crystallized generic tacrolimus (High Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
61943535|NCT05574998|EXPERIMENTAL|Recombinant Human Endostatin(Endostar) in Combination With Platinum-Based Doublet Chemotherapy|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
61943536|NCT06057077|ACTIVE_COMPARATOR|60 early type 1 diabetes with semaglutide and degludec basal bolus insulin|degludec administered once daily bolus insulin three times daily and time in range and Semaglutide once weekly
62139034|NCT02432274|EXPERIMENTAL|Cohort 2A: Single-agent Expansion (DTC)|Children and adolescents with 131 iodine-refractory DTC.
62139035|NCT02432274|EXPERIMENTAL|Cohort 2B: Single-agent Expansion (Osteosarcoma)|Participants with relapsed or refractory osteosarcoma.
62139036|NCT02432274|EXPERIMENTAL|Cohort 3A: Combination Dose-finding|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
62139037|NCT02432274|EXPERIMENTAL|Cohort 3B: Combination Expansion|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
62139038|NCT05824871|EXPERIMENTAL|Sudapyridine (WX-081) Group|Participants in this group will receive Sudapyridine (WX-081) combined with background regimen (BR). Treatment starts with a loading dose of Sudapyridine for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days). This is followed by a maintenance dose of 150 mg once daily from Week 3 to Week 24. During the 24-week treatment period, participants will also receive a placebo for bedaquiline and continue their background regimen (BR). After the 24-week treatment period, participants will enter the background regimen phase and continue BR until Week 72.
62139039|NCT05824871|ACTIVE_COMPARATOR|Bedaquiline Group|Participants in this group will receive Bedaquiline combined with background regimen (BR). Treatment starts with a loading dose of Bedaquiline for 2 weeks (400 mg once daily), followed by a maintenance dose of 200 mg three times per week (with at least 48 hours between doses) from Week 3 to Week 24. During the 24-week treatment period, participants will also receive a placebo for Sudapyridine and continue their background regimen (BR). After the 24-week treatment period, participants will enter the background regimen phase and continue BR until Week 72.
62139040|NCT04973163|EXPERIMENTAL|Monotherapy Arm|Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
62139041|NCT04973163|EXPERIMENTAL|Combination Therapy Arm|Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
62338559|NCT02312817|NO_INTERVENTION|Group 1|Individuals randomized to Group 1 will receive usual medical care and will not be directly contacted at any point of the trial. Study data and outcomes will be abstracted from the EMR.
62338560|NCT02312817|EXPERIMENTAL|Group 2|Individuals randomized to Group 2 will receive mailed outreach invitation.
62139042|NCT03821506|EXPERIMENTAL|Dynamic light|The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
61943537|NCT06057077|NO_INTERVENTION|60 early type 1 diabetes with degludec basal bolus insulin with regular standard of care|60 patients' Basal insulin degludec administered once daily according to the SMBG and continuous plan at the clinic bolus insulin three times daily according to the meals and time in range and carbohydrate index Dosing adjusted based on SMBG results
62139043|NCT03821506|PLACEBO_COMPARATOR|Usual care|The usual care is constant standard LED-light with two elements: two ceiling mounted lamps and a wall mounted lamp.
62139044|NCT02142751|EXPERIMENTAL|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
62139045|NCT02142751|ACTIVE_COMPARATOR|Meropenem intravenous|1g every 8 hours (15-30 min infusion)
61943538|NCT06680804||Group I: Successful VBAC group|Successful VBAC group whose take chance for vaginal delivery.
62139046|NCT02142751|OTHER|Ceftriaxone intravenous|1g every 24h (2-4 min)
62139047|NCT06515691|EXPERIMENTAL|Group M = M-TAPA Block group|M-TAPA block will be performed andd standard postoperaive pain management protocols will be applied.
62139048|NCT06515691|ACTIVE_COMPARATOR|Group K = control group|Standard postoperative pain management protocols will be applied. No plane block will be applied.
62139049|NCT03600844|EXPERIMENTAL|Phase 1 Intervention|Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.
62495285|NCT01420614|ACTIVE_COMPARATOR|Femoral|group of patients undergoing primary angioplasty by transfemoral approach
62696617|NCT03981510|EXPERIMENTAL|Children being investigated with 3D-transit|"4 groups of each 20 children will be investigated with respectively one or two capsules:~* Healthy children (1)~* Children with chronic constipation (2)~* Children with neurofibromatosis type 1 (2)~* Children with cancer receiving treatment with Vincristine (1)"
62696618|NCT05946551|EXPERIMENTAL|HRA Treatment Arm|Participants randomized to Treatment Arm will receive dual histamine receptor antagonists: famotidine and cetirizine daily.
62696619|NCT05946551|PLACEBO_COMPARATOR|Placebo Arm|The compounding study pharmacy will provide placebo capsules to the patients randomized to Placebo. These capsules are manufactured to match each treatment drug for oral administration.
62696620|NCT05977439||Healthy Participants|Endorse good health with no history of mental or physical illness or implanted metal
61943539|NCT06680804||Group II: Failed VBAC group|Failed VBAC group whose take chance for vaginal delivery.
62139050|NCT03600844|ACTIVE_COMPARATOR|Phase 1 Comparison/Phase 2 Intervention|During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.
62495286|NCT01528293|ACTIVE_COMPARATOR|ActiVAC System+ Compression therapy|ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
62495287|NCT01528293|OTHER|Compression therapy only|Standard of Care compression therapy only
62495288|NCT02678780|EXPERIMENTAL|Cohort A|"Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.~Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)"
62696621|NCT05977439||Depressed Participants|Endorse current depression, identified via the Hamilton Depression Rating Scale (HAM-D scores ≥ 17), but no history of psychosis or mania, determined via the Quick Structured Clinical Interview for DSM-5 Disorders (SCID).
62696622|NCT01554904|OTHER|Facial-Flex|The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.
62696623|NCT00582296||1|multi-organ follow-up
62696624|NCT00582296||2|control follow-up
61943540|NCT00736814|ACTIVE_COMPARATOR|Arm I|Patients receive standard chemotherapy of docetaxel and carboplatin.
61943541|NCT00736814|EXPERIMENTAL|Arm II, Genotype A1|Patients receive docetaxel and vinorelbine ditartrate.
61943542|NCT00736814|EXPERIMENTAL|Arm II, Genotype A2|Patients receive gemcitabine hydrochloride and vinorelbine ditartrate.
61943543|NCT00736814|EXPERIMENTAL|Arm II, Genotype B1|Patients receive docetaxel and carboplatin.
61943544|NCT00736814|EXPERIMENTAL|Arm II, Genotype B2|Patients receive gemcitabine hydrochloride and carboplatin.
62139051|NCT01333800|ACTIVE_COMPARATOR|Ciclesonide|
62139052|NCT01333800|PLACEBO_COMPARATOR|Beclomethasone|
62139053|NCT03936660|NO_INTERVENTION|Control|Clinics provided with existing clinical care guidelines.
62139054|NCT03936660|ACTIVE_COMPARATOR|Intervention|Clinics provided with existing clinical care guidelines as well as a multifaceted educational intervention to support development of an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
62139055|NCT00736463|ACTIVE_COMPARATOR|1|Aimvastatin 80 mg
62139056|NCT00736463|ACTIVE_COMPARATOR|2|Atorvastatin 80 mg
62139057|NCT00352599|ACTIVE_COMPARATOR|Lovastatin|Lovastatin
62139058|NCT00352599|PLACEBO_COMPARATOR|Placebo pill|Placebo pill
62139059|NCT03737409|EXPERIMENTAL|Oxygen therapy with POC (AOT group)|Patients will receive ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
62696625|NCT02756585|OTHER|ct perfusion|All participants will undergo the imaging protocol with CTP of head at the time of initial diagnostic imaging upon hospital arrival.
62495289|NCT02678780|EXPERIMENTAL|Cohort B|Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
62495290|NCT04883450||Risk of pancreatic cancer|Subjects with an increased predicted 18-month risk of pancreatic cancer
62495291|NCT00000136|EXPERIMENTAL|Foscarnet|The induction dose for foscarnet is 60 mg/kg every 8 hours. Full dose maintenance therapy for foscarnet is 90 mg/kg/day
62495292|NCT00000136|EXPERIMENTAL|Ganciclovir|The induction dose for ganciclovir is 5 mg/kg every 12 hours. Full dose maintenance therapy for ganciclovir is 5 mg/kg every 24 hours, 7 days a week.
62495293|NCT03755596|EXPERIMENTAL|Treatment|Oral treatment with single-dose 160mg Z. officinale extract in tablet form.
62495294|NCT01625390|EXPERIMENTAL|Arm 1|
62495295|NCT01625390|ACTIVE_COMPARATOR|Arm 2|
62495296|NCT01625390|EXPERIMENTAL|Arm 3|
62495297|NCT03513224|EXPERIMENTAL|eDosette|
62696626|NCT04788693|EXPERIMENTAL|Motor imagery and gait training group|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise (cues). In an interspersed way, motor imagery exercises will be carried out where participants must rehearse or simulate mentally each gait exercise that will be developed in the session."
61943545|NCT02186873|EXPERIMENTAL|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
62139060|NCT03737409|SHAM_COMPARATOR|Sham oxygen therapy with POC (air group)|Patients will receive sham ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
62139061|NCT03874819|ACTIVE_COMPARATOR|Control group|Conventional Hemodialysis using a high-flux dialyzer
62139062|NCT03874819|EXPERIMENTAL|Experimental group|Conventional Hemodialysis using a medium cut-of dialyzer
62139063|NCT04379557|EXPERIMENTAL|High power ablation|Ablation Index guided high power ablation (radio frequency energy: Left atrium anterior segment and roof: 40W, Left atrium inferior/posterior: 30W, near esophagus: 25W)
62338561|NCT02312817|EXPERIMENTAL|Group 3|Individuals randomized to Group 3 will receive mailed outreach invitation and patient navigation.
62338562|NCT03745196|EXPERIMENTAL|PC945|PC945 5mg once-daily, nebulized
62139064|NCT04379557|ACTIVE_COMPARATOR|Conventional ablation|Conventional ablation applying 30-35W strategy for Left atrium anterior segments.
62338563|NCT03745196|PLACEBO_COMPARATOR|Placebo|Placebo, nebulized
62495298|NCT05089890|OTHER|Sorbact® Compress|Patients already assigned to start treatment with Sorbact® Compress as it is judged by the investigator to be the most suitable for their wounds
62495299|NCT05089890|OTHER|Sorbact® Gel Dressing|Patients already assigned to start treatment with Sorbact® Gel Dressing as it is judged by the investigator to be the most suitable for their wounds
62495300|NCT05089890|OTHER|Sorbact® Ribbon Gauze|Patients already assigned to start treatment with Sorbact® Ribbon Gauze as it is judged by the investigator to be the most suitable for their wounds
62495301|NCT05114668|EXPERIMENTAL|Stage 1|- Stage 1 (Dose Escalation Cohorts): Stage 1 is a multiple ascending dose escalation of EVT801 in patients with advanced solid tumours to evaluate the safety and tolerability of EVT801 and to determine MTD / RP2D for further investigation.
62495302|NCT05114668|EXPERIMENTAL|Stage 2|- Stage 2 (Biomarker Expansion cohorts): A biomarker expansion cohort, in which all subjects will receive EVT801 at the MTD / RP2D, will be recruited to explore pharmacodynamic outcomes and further elucidate tolerability, activity, and pharmacokinetics.
61943546|NCT02186873|EXPERIMENTAL|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
61943547|NCT01234831|OTHER|Active Screening|Patients randomized to active screening will have two nasal swabs collected daily for 3 days, for both nucleic acid amplification and culture (CHROMagar)assays.
62338564|NCT02038218|EXPERIMENTAL|DM-CHOC-PEN|"Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
62338565|NCT05059418|ACTIVE_COMPARATOR|Clonazepam|Topical treatment of oral mucosa with a 3-min lozenge tablet with clonazepam (0.5 mg), three times a day.
62495303|NCT00867919|EXPERIMENTAL|1|Participants will receive a cognitive behavioral family therapy for adolescent depression to be developed in this study.
62495304|NCT00867919|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual 1 year prior to the experimental treatment group.
62495305|NCT04728620|EXPERIMENTAL|Intervention|Participants will have access to a new feature within an established patient portal native app on mobile devices. The new feature aims to address diabetes care gaps.
62495306|NCT01380522|EXPERIMENTAL|A|Subjects received kali product under fed conditions
62495307|NCT01380522|ACTIVE_COMPARATOR|B|Subjects received Searle product under fed conditions
62139065|NCT05950867|OTHER|1 arm including patients with CAP and/or SFN|"1 arm including patients with chronic axonal length-dependent polyneuropathy and/or small-fiber neuropathy.~All participants will be screened with ECG and echocardiography. All participants will be asked to complete questionnaires about there polyneuropathy and cardiological symptoms."
62139066|NCT01224613|ACTIVE_COMPARATOR|Intanza - self-administered|Self-administered intradermal influenza vaccine
62139067|NCT01224613|ACTIVE_COMPARATOR|Intanza - nurse-administered|Nurse-administered intradermal influenza vaccine
62338566|NCT05059418|ACTIVE_COMPARATOR|Capsaicin|Topical treatment of oral mucosa with capsaicin rinsing solution (XXXX IE) for three min three times a day.
62338567|NCT05059418|PLACEBO_COMPARATOR|Placebo|Topical treatment of oral mucosa with rinsing solution without capsaicin for three min three times a day.
62338568|NCT00834704|OTHER|1|Dose determination
62139068|NCT02955407||Low back pain patients|Low back pain since more than 3 months Age: 18-65 Caucasian race
62139069|NCT02955407||Controls without low back pain|no low back ain Age: 18-65 Caucasian race
62139070|NCT06246110|EXPERIMENTAL|Cohort A - Participants with non-squamous NSCLC|Participants in this arm will receive EIK1001 + Standard of Care (SOC).
62139071|NCT06246110|EXPERIMENTAL|Cohort B - Participants with squamous NSCLC|Participants in this arm will receive EIK1001 + Standard of Care (SOC).
62338569|NCT00209521|EXPERIMENTAL|fospropofol|
62139072|NCT01602913||Patients with diagnosis of Type II Diabetes|Patients indicating T2DM after the index date (ICD-9-CM 250.x), or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date
62139073|NCT01602913||Patients without diagnosis of Type II Diabetes|Patients not indicating T2DM
62139074|NCT06698419|EXPERIMENTAL|RADA16 Group|Participants will undergo canal wall down mastoidectomy in standard fashion. All participants will have absorbable gelatin sponge placed into the mastoid cavity which is standard care. Only participants in this arm will receive RADA16 gel into the mastoid cavity before placement of the gelatin sponge.
62139075|NCT06698419|NO_INTERVENTION|Control Group|Participants will undergo canal wall down mastoidectomy in standard fashion. All participants will have absorbable gelatin sponge placed into the mastoid cavity which is standard care. Participants in this arm will not receive RADA16 gel.
62139076|NCT05386108|EXPERIMENTAL|Phase 1b Cohort 1|Elacestrant 300 mg once daily (QD) + abemaciclib 100 mg twice daily (BID)
62139077|NCT05386108|EXPERIMENTAL|Phase 1b Cohort 2|Elacestrant 400 mg QD + abemaciclib 100 mg BID
62139078|NCT05386108|EXPERIMENTAL|Phase 1b Cohort 3|Elacestrant 400 mg QD + abemaciclib 150 mg BID
62139079|NCT05386108|EXPERIMENTAL|Phase 2|Elacestrant in combination with abemaciclib at the recommended phase 2 dose (RP2D) determined in phase 1b
62139080|NCT00293397|EXPERIMENTAL|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|Patients undergo DEB-TACE procedures utilizing LC Beads, polyvinyl alcohol microspheres with diameters of 100-300um or 300-500um, which are loaded with 100mg of doxorubicin hydrochloride and mixed with an equal volume of nonionic contrast media.
62139081|NCT06699329|EXPERIMENTAL|Enlicitide Decanoate and Semaglutide|"Period 1: Participants receive an oral dose of enlicitide decanoate every day for 1 week.~Period 2: Participants receive an oral dose of semaglutide every day for 6 weeks.~Period 3: Participants receive an oral dose of both enlicitide decanoate and semaglutide every day for 1 week."
62338570|NCT00209521|ACTIVE_COMPARATOR|propofol|
62338571|NCT04558788||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
62338572|NCT04558788||Colitis|Patients with active colitis
62338573|NCT04558788||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
62338574|NCT05557955||Neoadjuvant chemoradiotherapy group|All patients will receive standard fractionation radiation therapy (RT) scheme: 40-50.4 Gy in 20-28 fractions over 4-6 weeks using intensity-modulated radiotherapy, concurrently with platinum- or taxane-based chemotherapy, with or without PD-1 inhibitors. All patients will undergo esophagectomy 6-8 weeks after the completion of neoadjuvant CRT. Dynamic breathing testing was performed before, during, and after radiotherapy.
62338575|NCT05557955||Definitive chemoradiotherapy group|All patients will receive standard fractionation radiation therapy (RT) scheme: 50-50.4 Gy in 25-28 fractions over 5-6 weeks using intensity-modulated radiotherapy, concurrently with platinum- or taxane-based chemotherapy, with or without PD-1 inhibitors. Dynamic breathing testing was performed before, during, and after radiotherapy.
62338576|NCT03001310|EXPERIMENTAL|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of AAV - CNGB3
62139082|NCT06264869|EXPERIMENTAL|IGCT + CTG|Interdental guided creeping technique (IGCT) + Connective tissue graft (CTG)
62139083|NCT06264869|EXPERIMENTAL|IGCT + CM|Interdental guided creeping technique (IGCT) + Collagen membrane (CM)
62139084|NCT01467934||Trivalent inactivated influenza vaccine|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1
62139085|NCT01467934||TIV and PCV13 together|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
62139086|NCT01467934||13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
62338577|NCT03001310|EXPERIMENTAL|Biological-Medium dose AAV - CNGB3|Subretinal administration of a single intermediate dose of AAV - CNGB3
62338578|NCT03001310|EXPERIMENTAL|Biological-High dose AAV - CNGB3|Subretinal administration of a single high dose of AAV - CNGB3
62338579|NCT01605591|ACTIVE_COMPARATOR|the DLT bending to the right|
62338580|NCT01605591|ACTIVE_COMPARATOR|the DLT bending to the left|
62338581|NCT02913352|ACTIVE_COMPARATOR|Latarjet procedure|Open Latarjet-Patte procedure. Surgery. Anterior glenoid bone graft from coracoid. Fixation with 2 screws.
62338582|NCT02913352|EXPERIMENTAL|Modified Eden-Hybinette Procedure|Surgery. Modified Eden-Hybinette surgery, with capsular repair on the iliac bone Anterior glenoid bone graft from iliac bone. Fixation with 2 screws.
62338583|NCT01021072|EXPERIMENTAL|MTD|The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
62495308|NCT03447691|EXPERIMENTAL|DES Group|"Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min~DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
61943548|NCT01234831|OTHER|Passive Screening|Patients randomized to passive screening will not actively be identified for testing but may be tested using culture-based algorithm by care team.
62338584|NCT02281903|EXPERIMENTAL|Chest compression of manikins chest|Compression of pediatric manikins chest according European Resuscitation Council 2010 guidelines for cardiopulmonary resuscitation.
62338585|NCT03629041|EXPERIMENTAL|Treatment A - Microneedle patch|The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
62338586|NCT03629041|SHAM_COMPARATOR|Treatment B - Patch with no microneedles|The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
62338587|NCT04820556||Arterial hypertension|
62338588|NCT04820556||Atherosclerosis occlusive disease|
62338589|NCT04820556||Heart failure with preserved ejection fraction|
62338590|NCT04820556||Heart failure with reduced ejection fraction|
62338591|NCT04820556||Diabetes mellitus, type 2|
62338592|NCT04820556||Chronic obstructive pulmonary disease and asthma|
62338593|NCT04820556||Nonalcoholic fatty liver disease|
62495309|NCT03447691|ACTIVE_COMPARATOR|TIVA Group|"Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.~TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
61943549|NCT05516589|EXPERIMENTAL|Treatment Cohort|"Participants will receive~* TP chemotherapy every 3 weeks x 2 cycles (Nab-paclitaxel 260mg/m\^2 IV on day1, Cisplatin 75mg/m\^2 IV on days 1-3);~* Tislelizumab 200mg IV every 3 weeks x 2 cycles;~* Afatinib 30mg PO everyday x 6 weeks."
61943550|NCT01342276|EXPERIMENTAL|vHFC|Patients will get to participate in the interactive heart failure website (vHFC).
61943551|NCT01342276|NO_INTERVENTION|Usual Care|Patients will not get to participate in the interactive heart failure website (vHFC).
61943552|NCT05363410|EXPERIMENTAL|MagnéVie B6®|Each film coated tablet contains 100mg magnesium citrate and 10mg pyridoxine hydrochloride.
61943553|NCT05363410|PLACEBO_COMPARATOR|Placebo|Each identical film coated tablet contains inert materials.
61943554|NCT02366988|ACTIVE_COMPARATOR|Endoscopic Biliary Stenting|Temporary self-expandable metallic covered stent
61943555|NCT02366988|ACTIVE_COMPARATOR|Surgical treatment|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
61943556|NCT04903756||Patients|Adult patients where major lower limb amputation is being considered.
62338594|NCT04820556||Control group|
62495310|NCT02243137|ACTIVE_COMPARATOR|prasugrel and acetylsalicylic|single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally
62495311|NCT02243137|EXPERIMENTAL|lysine acetylsalicylate and prasugrel|single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous
62495312|NCT04196296|ACTIVE_COMPARATOR|Psychoeducation|
62495313|NCT04196296|EXPERIMENTAL|Psychoeducation plus Motivation Enhancement|
61943557|NCT04903756||Healthcare professionals|Surgeons, anaesthetists, and allied health professionals involved in decision making with patients where a major lower limb amputation is being considered.
61943558|NCT02524405||Normal Controls|Upto 85 normal elders, 50-90 years old who are within normal limits on the study neuropsychological battery will be enrolled. All patients involved in the study will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET.
61943559|NCT02524405||Alzheimer's Disease (AD)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
61943560|NCT02524405||Mild Cognitive Impairment (VCI)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association criteria for amnestic or multi-domain MCI with MoCA score ≥18 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
62338595|NCT01560897|EXPERIMENTAL|C13|The dose of sodium \[1-13C\] acetate is calculated according to patient weight (27mg/kg) or (0.33 mmol / kg).
62338596|NCT02871115|EXPERIMENTAL|Pharmacy Intervention|"Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will~* Perform detailed medication reconciliation~* Obtain allergy and vaccination history~* Evaluate and document polypharmacy (number of medications)~* Document their findings in the medical record and discuss their recommendations (in-person, phone call, email) with each patient's oncology team"
62338597|NCT02871115|ACTIVE_COMPARATOR|Usual Care|"Participants receiving Usual Oncology Care will not meet with the pharmacist unless indicated as part of their routine clinical care~* Study staff will obtain all patient-reported measures from the patient.~* Remind participant to complete self-report measures"
62338598|NCT05633134|EXPERIMENTAL|Precision preoperative embolization|60 patients with pelvic tumors will undergo arteriography and receive transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
62338599|NCT05633134|ACTIVE_COMPARATOR|Control group|60 patients with pelvic tumors will undergo arteriography and without transcatheter arterial embolization of pelvic tumors prior to surgery.
61943561|NCT02524405||Subcortical Vascular Impairment (VCI)|Sixty-five subjects meeting the American Heart Association-American Stroke Association (AHA-ASA) criteria for probable vascular dementia (VaD) or probable vascular mild cognitive impairment (VaMCI) due to subcortical ischemic vascular disease , and probable or possible Cerebral Amyloid Angiopathy using the Modified Boston Criteria116 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
61943562|NCT02524405||LBD Spectrum|Sixty- five subjects with: Dementia with Lewy Bodies (DLB) meeting the criteria for probable Dementia with Lewy Bodies with MMSE score ≥20; or PD-MCI meeting the proposed Level I criteria for Mild Cognitive Impairment in Parkinson's Disease with MoCA score 18-24; or; PDD meeting the criteria for probable Parkinson's Disease - Dementia and MMSE score ≥20 will be enrolled. All patients involved will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
62495314|NCT01363817|EXPERIMENTAL|Escalation Phase: BMS-906024|BMS-906024 escalating doses starting at 0.3 mg solution for intravenous (IV) administration once weekly continuously until disease progression or unacceptable toxicity
61943563|NCT01355926|EXPERIMENTAL|Flexible Fiber-based CO2 Laser|In the CO2 excised group, the resection will be performed at 15W, at a distance of 1cm from the tissue. Here too, if required, the bipolar will be used to achieve hemostasis The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
62139087|NCT05086432|EXPERIMENTAL|Sputum-guided management|During Weeks 0 to 16, participants randomized to the intervention arm will receive open-label sputum-guided management of airway inflammation (Table 1 in protocol) identified during screening (Figure 2 in protocol). Airway eosinophilia will be treated with regular inhaled corticosteroids based on the severity of eosinophilic inflammation. In participants with airway neutrophilia, as per the standard of care, sputum culture and sensitivity will be sent, and pathogenic organisms treated. Those participants with airway neutrophilia with negative cultures will be treated with thrice weekly Azithromycin (250mg). Combined eosinophilia and neutrophilia will receive treatment with both ICS and Azithromycin as per Table 2 in protocol.
62139088|NCT05086432|ACTIVE_COMPARATOR|Standard of Care|Participants in this arm will receive standard of care treatment as determined by their ILD specialist who will be blinded to the results of the sputum analysis.
62139089|NCT05568082|EXPERIMENTAL|AMG 510 + Itraconazole|
62338600|NCT04061681|EXPERIMENTAL|Behavioral Intervention (BIPAMS)|Participants will complete a 16-week behavioral intervention to increase physical activity levels.
62338601|NCT04061681|NO_INTERVENTION|Waitlist Control|Participants will have 16-weeks of no intervention or interaction.
62338602|NCT00278772|EXPERIMENTAL|1|Divalproex
62338603|NCT00278772|PLACEBO_COMPARATOR|2|
62338604|NCT02458157|EXPERIMENTAL|Forced Fluid Removal|"The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP \< 50 or mottling beyond the edge of kneecaps).~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated."
62338605|NCT02458157|ACTIVE_COMPARATOR|Usual Care|Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).
62338606|NCT02704676||control patients|normal pregnant women, 3rd trimester
62338607|NCT02704676||mild pre-eclampsia|patients with albuminuria +1 and blood pressure \>140/90 and \<160/110
62338608|NCT02704676||sever pre-eclampsia|patients diagnosed as sever pre-eclampsia according to criteria done by ACOG
62338609|NCT04065087|EXPERIMENTAL|GX-I7|GX-I7 administered until Progression of Disease
62338610|NCT04065087|PLACEBO_COMPARATOR|Placebo|Placebo administered until Progression of Disease
62495315|NCT01363817|EXPERIMENTAL|Expansion Phase: BMS-906024 + Dexamethasone|BMS-906024 maximum tolerated dose (To be determined) solution for IV administration once weekly and Dexamethasone 20mg/day tablet by mouth (Oral) for 3-4 days every week for 3-4 weeks per cycle continuously until disease progression or unacceptable toxicity
62495316|NCT01451541|ACTIVE_COMPARATOR|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37mcg once daily
62338611|NCT01623531|ACTIVE_COMPARATOR|RiaSTAP|Intravenous fibrinogen(RiaSTAP) will be administered according to FIBTEM based calculation formula
62338612|NCT01623531|PLACEBO_COMPARATOR|Intravenous saline|Intravenous saline (placebo) will be calculated according to FIBTEM based calculation formula
62338613|NCT06473285|ACTIVE_COMPARATOR|Healthy brain volunteers|
62338614|NCT06473285|EXPERIMENTAL|Patients with prolonged disorders of consciousness|
62338615|NCT01968954|EXPERIMENTAL|Bococizumab (PF-04950615;RN316)|
62338616|NCT01968954|PLACEBO_COMPARATOR|Placebo|
62338617|NCT02796391|EXPERIMENTAL|Study 1: Immediate Reduction|"Participants will receive cigarettes with the lowest nicotine dose (.03 mb nicotine yield). They will receive a targeted intervention workbook (Count down: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with one-on-one counseling."
62338618|NCT02796391|EXPERIMENTAL|Study 1: Gradual Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4.They will receive a targeted intervention workbook (Count down: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with one-on-one counseling."
62338619|NCT02796391|EXPERIMENTAL|Study 2: Targeted/Immediate Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4.They will receive a targeted intervention workbook (Count down: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with one-on-one counseling."
62495317|NCT01451541|ACTIVE_COMPARATOR|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg once daily
62495318|NCT01451541|PLACEBO_COMPARATOR|Placebo|
62495319|NCT04580615|EXPERIMENTAL|Inpatients subjects|Inpatients subjects diagnosed with a Respiratory disease/impairment or subjects with no known Respiratory disease/impairment
62495320|NCT03555136||Patients initiating vortioxetine treatment|Patients with major depressive disorder initiating treatment with vortioxetine
62696627|NCT04788693|ACTIVE_COMPARATOR|Gait training group without motor imagery|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise (cues). In the periods that the experimental group performs the motor imagery exercises, the control group will take breaks."
62696628|NCT06641739|ACTIVE_COMPARATOR|• Laser-treated group|Ten patients will be treated the simplified papilla preservation flap with laser therapy performed into the defect site. The laser used in the study is diode lasers ( 940nm), with an output power of 3 W in the contact mode.
62696629|NCT06641739|ACTIVE_COMPARATOR|platelets Rich Fibrin Graft|Ten patients will be treated with simplified papilla preservation flap with platelet-rich fibrin grafted into the defect site.
62696630|NCT06361173||Spanish-speaking caregivers|Spanish-speaking caregivers recruited from Nationwide Children's Hospital and Columbia University Irving Medical Center to pilot test a Spanish a transcreated version of the BMT4me app
62696631|NCT06639841|EXPERIMENTAL|Virtual Reality facilitated Psychotherapy for Performance Anxiety|Participants in this arm will undergo Virtual Reality (VR) facilitated Psychotherapy aimed to alleviate performance anxiety. The sessions will combine cognitive-behavioural therapy (CBT), exposure therapy and relaxation within VR environments. The program will be provided by a qualified integrative psychotherapist, 2-3 times per week, each lasting 30-60 minutes, over 4 weeks. The programme will be individualized for each participant, based on their anxiety levels and progression, including in-depth experiences to promote performance resilience.
62696632|NCT06639841|EXPERIMENTAL|Yoga Training for Performance Anxiety|Participants in this arm will undergo a Yoga-based intervention for performance anxiety. This therapy includes facilitated yoga sequences consisting of breathing (Pranayama), exercises (Asanas) and meditation, for body-mental relaxation. The course will be led by expert yoga instructors for 2x60 to 90 min sessions, twice per week, within 2 to 4 weeks. The trainers will focus on promoting mindfulness, reducing anxiety, and improving focus to help participants manage daily performance stressors.
62696633|NCT02695277|EXPERIMENTAL|Hybrid Procedure|Endoscopic epicardial surgical ablation (first stage) combined with endocardial catheter ablation (second stage) performed between 91 and 180 days post index procedure.
62696634|NCT02695277|ACTIVE_COMPARATOR|Catheter Procedure|Standard catheter ablation with pulmonary vein (PV) isolation (minimum lesion set) and optional additional lesions (index procedure). When required due to AF recurrence, ablation may be repeated within 6 months after the index-procedure according to clinical indications and consistent with the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Consensus Statement
62696635|NCT01014312|EXPERIMENTAL|Depression Care Management (DCM)|Participants will receive Depression Care Management.
62696636|NCT01014312|ACTIVE_COMPARATOR|Enhanced Care|Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.
62696637|NCT05901207||Case|
62696638|NCT04978415|EXPERIMENTAL|subtenon's block|we use the subtenon cannula to inject the local anesthetic mixture
62696639|NCT04978415|EXPERIMENTAL|peribulbar block|we use the usual 25G sharp needle to inject the local anesthetic mixture
62696640|NCT02168556|PLACEBO_COMPARATOR|Standard of Care|Patient underwent urodynamic testing by receiving only standard of care with mailed information and during test teaching.
62696641|NCT02168556|ACTIVE_COMPARATOR|Music|Patient underwent urodynamic testing while listening to music that was 60 beats per minute and received standard of care information and teaching.
62338620|NCT02796391|EXPERIMENTAL|Study 2: Targeted/Gradual Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4. Participants will also receive targeted materials (booklet series entitled (Count down: Preparing to Quit Smoking with low-Nicotine Cigarettes) as well as one-on-one counseling."
62338621|NCT02796391|EXPERIMENTAL|Study 2: Generic/Immediate Reduction|"Participants will receive VLNC (very low nicotine cigarettes) with the lowest nicotine dose (.03 mb nicotine yield). Participants will also receive the generic (Clearing the Air) materials, as well as one-on-one counseling."
62338622|NCT02796391|EXPERIMENTAL|Study 2: Generic/Gradual Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4. Participants will also receive the generic (Clearing the Air) materials, as well as one-on-one counseling."
62338623|NCT02388022||degenerative disc disease|Patients who have had a transforaminal lumbar interbody fusion at 1-2 contiguous levels with the CALIBER® expandable spacer and have completed at least 2 year follow-up.
62338624|NCT05149248|OTHER|Group 1: MSM|Arm 1: HPV vaccination in an alternative schedule for MSM of 1 dose (M0). Arm 2: HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6) Arm 3: a control group will be screened for high-risk HPV and vaccinated at 12 months
62495321|NCT03599921||Family-based Treatment|Participants will receive family-based treatment.
62495322|NCT03599921||Enhanced Cognitive behavioral therapy|Participants will receive enhance cognitive behavioral therapy.
62495323|NCT03599921||Family-based Treatment for ARFID|Participants will receive family-based treatment modified for Avoidant/Restrictive Food Intake Disorder (ARFID).
62495324|NCT03599921||FBT + UP for ARFID|Participants will receive family-based treatment with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents, named FBT + UP for ARFID.
62696642|NCT02168556|ACTIVE_COMPARATOR|Video|Patient watched an informational video prior to urodynamic testing.
62139090|NCT01750684|PLACEBO_COMPARATOR|Saline|Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
62139091|NCT01750684|ACTIVE_COMPARATOR|AC105|Patients randomized (1:1) to the active drug arm will receive an initial intravenous infusion of AC105 for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
62139092|NCT05786235||pregnant patients with primary APS|Diagnosis of primary APS, according to international classification criteria
62338625|NCT05149248|OTHER|Group 2: TRANSGENDER WOMEN|Arm 1: Transgender women
62338626|NCT05149248|OTHER|GROUP 3: WOMEN AND MEN LIVING ON THE STREET|Arm 1: Women and men living on the street
62495325|NCT04072003||IVUS-guided PCI|In this group, intravascular ultrasound(IVUS) in addition to coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
62495326|NCT04072003||CAG-guided PCI|In this group, coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
62495327|NCT02889393|EXPERIMENTAL|Standard of Care followed by Teduglutide|"Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure."
62495328|NCT02889393|EXPERIMENTAL|Teduglutide followed by Standard of Care|"Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure"
62696643|NCT04805593|EXPERIMENTAL|WaveLight EX500 excimer laser system|Laser-assisted in situ keratomileusis (LASIK) surgery using the WaveLight EX500 excimer laser system
62338627|NCT05149248|OTHER|GROUP 4: WOMEN AND MEN WHO HAVE SUFFERED RAPE|Women and men who have suffered rape
62338628|NCT05149248|OTHER|GROUP 5: WOMEN WHO ARE SEX WORKERS|Female sex workers
62338629|NCT02964286|EXPERIMENTAL|Acupressure group|The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
62338630|NCT02964286|NO_INTERVENTION|Control group|The patients of the control group are not admitted any acupoints press-related interventions, only take clinical treatment protocol as usual.
62338631|NCT05674045|EXPERIMENTAL|EG017 3mg|
62338632|NCT05674045|EXPERIMENTAL|EG017 6mg|
62338633|NCT05674045|EXPERIMENTAL|EG017 9mg|
62696644|NCT06541951|ACTIVE_COMPARATOR|Services as usual|Services as usual before maternal health equity implementation efforts
61943564|NCT01355926|EXPERIMENTAL|electrocautery resection|In the electrocautery excised group, the cut and coagulation modes used will be each at 25 Malis power setting. First, cut mode will be used to mark out the lesion. Subsequently, coagulation mode will be used for excision. Bipolar cautery will then be used at 25 Malis for hemostasis. The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
61943565|NCT05098899|EXPERIMENTAL|MyGeneMyDiet® Recommendations for Weight Management|A set of nutrition and lifestyle advice for weight management derived from genetic information
62139093|NCT05786235||pregnant patients who do not have APS|Patients with at least one previous full-term pregnancy No diagnosis of APS, according to international classification criteria
62139094|NCT04100538|EXPERIMENTAL|Intervention group|The intervention group will receive the technology-assisted program by health coach twice a week during the 10-week treatment period. The health coach will be an experienced master-prepared nurse who has extensive and in-depth knowledge about fibromyalgia and has previously worked in direct contact with patients with fibromyalgia in a research project.
62139095|NCT04100538|NO_INTERVENTION|control group|The control group will receive technology-assisted informational support twice a week during the 10-week treatment period. Each technology-assisted informational support will last for approximately 10-30 min consisting of 15-min questions-and-answers regarding the educational materials and 15-min debriefing.
62338634|NCT05674045|PLACEBO_COMPARATOR|Placebo Comparator: matching placebo|
62338635|NCT00683475|EXPERIMENTAL|IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone|
62139096|NCT02972359|EXPERIMENTAL|Neridronic acid|Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
62338636|NCT00683475|EXPERIMENTAL|IMC-A12 + Mitoxantrone + Prednisone|
62338637|NCT05125536|EXPERIMENTAL|Experimental group|"Before the application, the Descriptive Characteristics Data Form and Assessment Scale of Adaptation Difficulty in Elderly were administered to the experimental group by the investigator through face-to-face interviews. A cd containing songs in Nihavent theme (instrumental), computer and sound system were used during the application. The patients in the experimental group were informed about the music session in advance. The sessions lasted 12 weeks in total and there were two sessions per week (Monday and Wednesday), and each session took approximately 50 minutes to complete. One week after the last music session (end of 12th week), the Assessment Scale of Adaptation Difficulty in the Elderly was re-administeredto the experimental group ."
62338638|NCT05125536|NO_INTERVENTION|Control group|No intervention was performed for the patients in the control group.
62338639|NCT06249256|EXPERIMENTAL|Fast CAR T cells|The safety and efficacy of BZT2312 will be assessed in a standard 3+3 dose escalation approach. Three doses of CAR T cells will be evaluated in this study: 5×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 5×10\^6 CAR+ T cells/kg.
62338640|NCT04880538||Asymptomatic patients for any motility disorder|Asymptomatic patients for any motility disorder
62338641|NCT04880538||Patients with gastrointestinal dysmotility|Patients with gastrointestinal dysmotility
62495329|NCT01541215|EXPERIMENTAL|Lira + Met|
62495330|NCT01541215|PLACEBO_COMPARATOR|Placebo + Met|
61943566|NCT05098899|ACTIVE_COMPARATOR|Usual Standard of Care for Weight Management|A set of standard nutrition and lifestyle advice for weight management without genetic information
62495331|NCT02132650|EXPERIMENTAL|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
62495332|NCT02132650|ACTIVE_COMPARATOR|SS|Rehabilitation of walking using typical steady state (SS) walking
61943567|NCT06358131|ACTIVE_COMPARATOR|propofol arm|
61943568|NCT06358131|ACTIVE_COMPARATOR|midazolam arm|
62495333|NCT03485027|EXPERIMENTAL|The rechallenge regimens|"XELOX ± BEV, repeating every 3 weeks.~FOLFOX ± BEV, repeating every 2 week~FOLFOX ± Cetuximab, repeating every 2 week~FOLFIRI ± BEV, repeating every 2 weeks.~FOLFIRI ± Cetuximab, repeating every 2 weeks.~IRI ± BEV, repeating every 2 weeks.~IRI ± Cetuximab, repeating every 2 weeks.~Raltitrexed ± BEV, repeating every 3 weeks.~Raltitrexed ± Cetuximab, repeating every 2 weeks."
62495334|NCT06147258|EXPERIMENTAL|Expressive writing|Participation in a 10 weekly virtual expressive writing with 1 session per week
61943569|NCT01982578|EXPERIMENTAL|Product: Genistein|60 mg of genistein BID for 360 days. Intervention: Product: Genistein
61943570|NCT01982578|PLACEBO_COMPARATOR|Product: Placebo|1 placebo capsule BID for 360 days. Intervention: Product: Placebo
61943571|NCT05520099||Participants suspected of or diagnosed with Stage III or IV/metastatic cancer|"Subjects suspected or diagnosed with Stage III or IV:~* Bladder: Urothelial Carcinoma (UC)~* Kidney: Clear Cell Renal Cell Carcinoma (ccRCC)~Subjects suspected or diagnosed with Stage IV/metastatic:~* Colon and Rectum: Microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) Colorectal Cancer (CRC)~* Head and Neck: Squamous Cell Carcinoma (HNSCC), excluding nasopharyngeal and salivary gland cancers~* Lung: Non-small cell lung cancer (NSCLC)~* Skin: Cutaneous Melanoma, excluding Uveal Melanoma~* Uterus: endometrial cancer~Subjects suspected or diagnosed with:~* Any metastatic solid tumor with high TMB, MSI-High or dMMR and are being considered for treatment with ICI therapy.~* Any metastatic solid tumor that the clinician plans to treat with ICI therapy."
61943572|NCT04048187|EXPERIMENTAL|Phone Application|
61943573|NCT05351021|EXPERIMENTAL|Group I (metformin group)|who will receive adjuvant paclitaxel in addition to metformin tablets (1700 mg daily) during the chemotherapy treatment duration.
62139097|NCT04650191||Mild COVID-19 infection|Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.
62495335|NCT06147258|NO_INTERVENTION|Waitlist control|Participation in usual daily activities
62495336|NCT03567122|EXPERIMENTAL|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
62139098|NCT04650191||Moderate COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.
62139099|NCT04650191||Severe COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.
62139100|NCT04724759|EXPERIMENTAL|Opioid-free Anesthesia|Patients in this arm will not receiving opioids but the total intravenous anesthetic during surgery. Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics.
62139101|NCT04724759|NO_INTERVENTION|Standard Anesthesia|Patients in this arm will undergo the standard of care and receive opioids as part of their anesthetic regimen.
62139102|NCT06175299|EXPERIMENTAL|Cognitive Training with Social Function|To promote adherence and reduce social isolation, participants will be asked to use home-based cognitive training program on a tablet for 30 minutes per day for 5 days a week for 1 month, then use it freely for another month. The cognitive training program has a chat function and a leadership board to allow interaction between participants.
62338642|NCT04823208|EXPERIMENTAL|LY3437943|LY3437943 administered subcutaneously (SC)
62338643|NCT04823208|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
61943574|NCT05351021|PLACEBO_COMPARATOR|Group II (control group)|who will receive adjuvant weekly paclitaxel.
61943575|NCT04537143||Control|Non-AMD eyes
61943576|NCT04537143||AMD|AMD eyes
61943577|NCT00003591|EXPERIMENTAL|Pacilitaxel + External Beam Radiation Therapy (PXRT)|Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.
61943578|NCT03509883|EXPERIMENTAL|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets
61943579|NCT03509883|ACTIVE_COMPARATOR|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
61943580|NCT02640573|EXPERIMENTAL|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
61943581|NCT06061341||TruGraf|Group who will have immunosuppression (IS) assessed utilizing TruGraf Liver Gene Expression test to serially monitor liver transplant recipients with autoimmune disease and alter IS based on these results.
62338644|NCT02299063|PLACEBO_COMPARATOR|Placebo (0.9% Saline)|0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.
62495337|NCT03567122|EXPERIMENTAL|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
62139103|NCT04639869|EXPERIMENTAL|Phenyramydol then Cabral|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
62139104|NCT04639869|ACTIVE_COMPARATOR|Cabral then Phenyramydol|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
62139105|NCT04639869|EXPERIMENTAL|Phenyramydol then Cabral Replicate|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
62139106|NCT04639869|ACTIVE_COMPARATOR|Cabral then Phenyramydol Replicate|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
62139107|NCT04558723|EXPERIMENTAL|ICD group|Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.
62338645|NCT02299063|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.
62338646|NCT02084784|EXPERIMENTAL|Indocyanine green & methylene blue,|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%
62338647|NCT06430112|EXPERIMENTAL|Liposomal Bupivacaine group|Liposomal Bupivacaine was used in the group
62139108|NCT04558723|NO_INTERVENTION|Optimal HF care group|Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.
62139109|NCT05167318|EXPERIMENTAL|every 3-4 hour oral care|Infants will receive standardized oral care every 3-4 hours for 4 weeks
62139110|NCT05167318|NO_INTERVENTION|every 12 hour oral care|Infants will receive standardized oral care every 12 hours for 4 weeks
62338648|NCT06430112|ACTIVE_COMPARATOR|Ropivacaine group|Ropivacaine was used in this group
62139111|NCT00556478|ACTIVE_COMPARATOR|Double-Blind Active|Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
62139112|NCT00556478|PLACEBO_COMPARATOR|Double-Blind Placebo|Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
62139113|NCT00556478|ACTIVE_COMPARATOR|Open Label Phase|Subjects will all receive PSD502 if they wish to continue in the trial.
62696645|NCT06541951|EXPERIMENTAL|Scale-up implementation approach|An implementation approach for scaling up bundled equity-focused maternal health safety guidelines in community care settings county-wide, co-developed with partners.
62338649|NCT02521961|EXPERIMENTAL|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
62338650|NCT02521961|ACTIVE_COMPARATOR|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
62338651|NCT04467177|EXPERIMENTAL|Glucose group|Neonates will receive 30% oral glucose
62338652|NCT04467177|PLACEBO_COMPARATOR|Placebo group|Neonates will receive sterile water
62338653|NCT05294211|EXPERIMENTAL|M•care™ System + CTG|The M•care System and standard of care CTG (cardiotocography) will be applied for fetal and maternal monitoring
62495338|NCT03567122|ACTIVE_COMPARATOR|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
62338654|NCT04552379|ACTIVE_COMPARATOR|Interferon|Peginterferon beta-1alfa will be made available from Biogen Inc. Switzerland. 125 micrograms of pegylated IFNß1alfa (PLEGRIDY, Biogen) administered on Study Days 1, 6 and 11 (i.e. for a total of 3 doses) via subcutaneous injection.
62495339|NCT03886363|EXPERIMENTAL|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
62495340|NCT03886363|NO_INTERVENTION|Wait-list control|Usual practice
62338655|NCT04552379|NO_INTERVENTION|Standard of Care|Standard of Care; following national guidelines regarding self-isolation and infection prevention
62139114|NCT01189929|EXPERIMENTAL|Gemcitabine and demcizumab With or Without Abraxane®|Gemcitabine and demcizumab With or Without Abraxane®
62139115|NCT05081804|NO_INTERVENTION|Non-diabetic Control|Patients without diabetes. No intervention will be administered - standard care.
62139116|NCT05081804|EXPERIMENTAL|Non-diabetic CHO Drink|Patients without diabetes. Commercially available preoperative carbohydrate drink will be administered two hours prior to cesarean section.
62139117|NCT05081804|NO_INTERVENTION|Diabetic Control|Patients with diabetes. No intervention will be administered - standard care.
62139118|NCT05081804|EXPERIMENTAL|Diabetic CHO Drink|Patients with diabetes. Commercially available preoperative carbohydrate drink will be administered two hours prior to cesarean section.
62139119|NCT04630899|EXPERIMENTAL|Active Joint Mobilization|
62139120|NCT04630899|EXPERIMENTAL|Passive Joint Mobilization|
62139121|NCT06319430|EXPERIMENTAL|robots|Participants will be randomly allocated to groups A or B. Those in group A will co-design and build their LEGO™ robot, using the researcher's assistance, as led by the child. A go-along interview will be conducted during the co-design with the child . The co-design session will be video recorded to provide context, visual data, and to inform the qualitative analysis. Videos will be deleted right after analysis. A research assistant (RA) will visit the participant's home twice a week for 30 to 45 minutes (after school or on the weekend) to play with the child and their built LEGO™ robots for four weeks (4 sessions total).
62139122|NCT06319430|EXPERIMENTAL|conventional toys|Group B will engage in the same process of 4 play intervention sessions over four weeks with the research assistant; however, they will receive conventional play tools. The RA will carry a prepared play pack for the play intervention session.
62139123|NCT01693822|EXPERIMENTAL|Axitinib|Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
62139124|NCT06121375|ACTIVE_COMPARATOR|Participants receiving OCA|Participants will be randomized to receive OCA (starting at 1.5 milligrams \[mg\] adult equivalent dose \[AED\]) orally, with water, once daily. Dose will be titrated every 2 weeks in a stepwise manner for the first 6 weeks, starting at 1.5 mg AED and titrating through 3 mg AED to a maximum of 5 mg AED, as tolerated; a discussion with the Medical Monitor is encouraged when determining uptitration if considerable signs or symptoms have arisen. Following the 6-week dose titration phase, participants will continue at the tolerated dose for approximately 24 months in Age Expansion Treatment Phase.
62139125|NCT06121375|PLACEBO_COMPARATOR|Participants receiving Matching placebo|Participants will be randomized to receive matching placebo orally, with water, once daily. Dose will be titrated every 2 weeks in a stepwise manner for the first 6 weeks, starting at 1.5 mg AED and titrating through 3 mg AED to a maximum of 5 mg AED, as tolerated; a discussion with the Medical Monitor is encouraged when determining uptitration if considerable signs or symptoms have arisen. Following the 6-week dose titration phase, participants will continue at the tolerated dose for approximately 24 months in Age Expansion Treatment Phase.
62139126|NCT01583868|EXPERIMENTAL|B&L RD2135-01 lens C|Investigational Silicone hydrogel soft contact lens
62338656|NCT06555211|OTHER|Group randomized to begin with MRI|Group is randomized to begin with MRI and have PET/CT performed later on the same day
62338657|NCT06555211|OTHER|Group randomized to begin with PET/CT|Group is randomized to begin with PET/CT and have MRI performed later on the same day
62338658|NCT02648724|EXPERIMENTAL|Part 1: 6 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 6 mg/kg. A substitute or an additional dose level could potentially be evaluated.
62338659|NCT02648724|EXPERIMENTAL|Part 1: 12 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 12 mg/kg. A substitute or an additional dose level could potentially be evaluated.
62139127|NCT01583868|EXPERIMENTAL|B&L RD2135-01 lens D|Investigational Silicone hydrogel soft contact lens
62139128|NCT01583868|ACTIVE_COMPARATOR|PureVision2|Bausch \& Lomb High definition soft contact lenses
62139129|NCT01583868|ACTIVE_COMPARATOR|Ciba Vision Air Optix Aqua|Ciba Vision Air Optix Aqua soft contact lens
62338660|NCT02648724|EXPERIMENTAL|Part 1: 18 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 18 mg/kg. A substitute or an additional dose level could potentially be evaluated.
62338661|NCT02648724|EXPERIMENTAL|Part 1: 24 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 24 mg/kg. A substitute or an additional dose level could potentially be evaluated.
62338662|NCT02648724|EXPERIMENTAL|Part 2: Basket Cohort|Patients with KRAS WT advanced solid tumor malignancies with MET-amplification were to receive Sym015 at the RP2D. Included in this group was a subset of patients who have received prior therapy with a MET-targeting TKI.
62338663|NCT02648724|EXPERIMENTAL|Part 2: NSCLC MET-Amplified Cohort|Patients with advanced NSCLC with MET-amplification were to receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
62338664|NCT02648724|EXPERIMENTAL|Part 2: NSCLC METex14del Cohort|Patients with advanced NSCLC with METex14del were to receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
62338665|NCT06129318|EXPERIMENTAL|Clinical Pharmacist Led Pharmaceutical Care|In addition to usual care services, the intervention group was provided with pharmaceutical care by a clinical pharmacist.
62338666|NCT06129318|NO_INTERVENTION|Control Group|Usual Care
62338667|NCT04790552|ACTIVE_COMPARATOR|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
62338668|NCT04790552|EXPERIMENTAL|Night Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will consume a Fast Bar 3 hours after the dinner and then fast overnight. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
62338669|NCT04790552|EXPERIMENTAL|Bar + Coffee Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
62338670|NCT04790552|EXPERIMENTAL|Bar + Tea Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with tea on day 2.
62338671|NCT01160341|EXPERIMENTAL|Testosteron, secondary hypogonadism|
62338672|NCT05265130|EXPERIMENTAL|YQFM group|YQFM 5.2g in 0.9% Normal Saline 250ml IV, about 40 drops per min, once a day.
62338673|NCT05265130|PLACEBO_COMPARATOR|Placebo group|0.9% Normal Saline 250ml IV, about 40 drops per min.
62338674|NCT03477617|EXPERIMENTAL|Intraoperative Hemodynamic Algorithm|In the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
62495341|NCT06655337|EXPERIMENTAL|Intervention Arm: medidux App|Participants in this arm will use the medidux™ smartphone application to monitor their symptoms and vital signs for 7 days following discharge from the Acute Admission Unit (AAU). The app provides health monitoring features, prompts for symptom tracking, and guidance on whether further medical consultation is required. Participants will log daily health data and receive automated reminders. The app aims to reduce post-discharge readmissions and emergency hospitalizations by providing real-time support. Follow-up assessments will be conducted at day 7 and day 28 post-discharge to evaluate symptom progression and healthcare utilization.
62495342|NCT06655337|NO_INTERVENTION|Control Arm: Standard Post-Discharge Care|Participants in this arm will receive standard post-discharge care as currently practiced in the Acute Admission Unit (AAU). This may include follow-up calls or appointments with healthcare providers to monitor symptoms and progression after discharge, but participants will not use the medidux™ app for symptom tracking or monitoring. Follow-up assessments will be conducted at day 7 and day 28 post-discharge to evaluate symptom progression and healthcare utilization.
62495343|NCT04483349||Observational (survey administration)|Patients and healthcare providers complete a survey over 10-15 minutes.
62495344|NCT04364763|EXPERIMENTAL|RBT-9 (90 mg)|RBT-9 (90mg) will be administered intravenously over a 120-minute period on Day 1.
62495345|NCT04364763|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride (normal saline) will be administered intravenously over a 120-minute period on Day 1.
62495346|NCT04661280|NO_INTERVENTION|Cognitive remediation|Non-drug treatment, cognitive remediation, cognitive stimulation
62495347|NCT04661280|EXPERIMENTAL|Cognitive remediation + Donepezil|Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
62495348|NCT00657787||PTSD|Combat-exposed men and women with PTSD deployed to OIF/OEF.
62495349|NCT00657787||High Utilizers|A comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD
62495350|NCT00657787||Not OIF/OEF|A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones
62495351|NCT04358627||DEXMEDETOMIDINE|Patients receiving dexmedetomidine continuous infusion since their admittance to ICU. Continuous checking of the primary and secondary outcomes
62495352|NCT04358627||No-DEXMEDETOMIDINE|Historical Control patients matched for ICU admittance diagnosis, age, and concomitant disease and medication state. No Dexmedetomidine. CONtinuous checking of primary outcomes
62495353|NCT02382601||Small for Gestational Age Pregancies (controls)|Small for gestational age (SGA) pregnancies that do not develop IUGR will be considered controls. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
62495354|NCT02382601||IUGR Pregnancies (cases)|Small for gestational age (SGA) pregnancies that do develop IUGR will be considered cases. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
62495355|NCT05269563|EXPERIMENTAL|Double flap technique to secure macular hole closure.|Single ILM flap technique is already performing worldwide; however, sometimes it is associated with flap displacement. To overcome this issue, the double flap technique was tried.
61943582|NCT06061341||Matched historical control group|Group who will have immunosupression (IS) assessed utilizing traditional clinical parameters for IS management.
62338675|NCT03477617|ACTIVE_COMPARATOR|Usual Hemodynamic Management|In the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
62338676|NCT03840083|EXPERIMENTAL|Sleep|Individuals will either nap (Exps 1, 4) or have overnight sleep (Exps 2, 3, 5, 6)
62338677|NCT03840083|NO_INTERVENTION|Wake|Individuals will stay awake for the same amount of time as they slept in the sleep condition
62338678|NCT05542329|NO_INTERVENTION|Control|Standard of care
62338679|NCT05542329|EXPERIMENTAL|Tele-Medecine|The experimental group will be given a case of connected devices dedicated to telemedicine allowing them to closely monitor their state of health during the 3 months following discharge from hospital
62495356|NCT02500615|EXPERIMENTAL|0 PG: 100 VG|
61943583|NCT04295551|EXPERIMENTAL|Experimental group of ordinary COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
61943584|NCT04295551|ACTIVE_COMPARATOR|Control group of ordinary COVID-19|ritonavir/ritonavir treatment
62338680|NCT00786136|EXPERIMENTAL|1|perioperative rosuvastatin administration for at least 5 dosages
62338681|NCT00786136|PLACEBO_COMPARATOR|control|blank control of perioperative statin administration
62338682|NCT05099146|EXPERIMENTAL|pictorial|brushing technique taught by using pictures
62338683|NCT05099146|EXPERIMENTAL|video|brushing technique taught by showing video
62495357|NCT02500615|EXPERIMENTAL|30 PG: 70 VG|
62495358|NCT02500615|EXPERIMENTAL|50 PG: 50 VG|
62495359|NCT02500615|EXPERIMENTAL|70 PG: 30 VG|
62495360|NCT02500615|EXPERIMENTAL|100 PG: 0 VG|
62338684|NCT05099146|EXPERIMENTAL|control|only oral hygiene instructions provided
62338685|NCT04788108|ACTIVE_COMPARATOR|Dydrogesterone|dydrogesterone 10 mg by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
61943585|NCT04295551|EXPERIMENTAL|Experimental group of severe COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
62338686|NCT04788108|PLACEBO_COMPARATOR|Placebo|placebo by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
62338687|NCT03041909|EXPERIMENTAL|Single Arm|Single Arm / open label
62495361|NCT06385158|EXPERIMENTAL|GS1-144 tablet|
62495362|NCT06385158|PLACEBO_COMPARATOR|placebo controlled study|
62495363|NCT04219527|EXPERIMENTAL|Dual-Target injection|Corticosteroid injection into the subacromial bursa and biceps tendon
62495364|NCT01994018||Control Group (Vitamin D level)|Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
62696646|NCT06643156|EXPERIMENTAL|GP681 powder for oral suspension 10mg/20mg/40mg|"All patients will receive a single oral dose of GP681 dry suspension dissolved in approximately 10 mL of warm water. The mixture will be stirred thoroughly before administration, and then the cup will be rinsed twice with an additional 10-20 mL of warm water (about 40°C) to ensure the full dose is taken.~The dosage of GP681 in patients 2-18 years of age is a single weight-based dose displayed in the following table.~Dosage Patients 40mg Aged 5-18years(exclusive)，weight≥40kg 20mg Aged 5-18years(exclusive)，20kg≤weight\<40kg 40mg Aged 5-18years(exclusive)，20kg≤weight\<40kg 10mg Aged 2-5years(exclusive)，10kg≤weight\<20kg 20mg Aged 2-5years(exclusive)，10kg≤weight\<20kg"
62139130|NCT01231438|EXPERIMENTAL|Renvela|Treatment for 2 weeks
62139131|NCT01231438|EXPERIMENTAL|Etalpha|Vit D Treatment for 2 weeks
62139132|NCT06698549|EXPERIMENTAL|Subjects with Severe Renal Impairment|Subjects with severe renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.
62338688|NCT02572258|EXPERIMENTAL|Nutritional oats cookie and educational session|Nutritional cookie with oats and nuts
62139133|NCT06698549|EXPERIMENTAL|Subjects with Normal Renal Function|Subjects with normal renal function will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.
62139134|NCT06698549|EXPERIMENTAL|Subjects with Mild Renal Impairment (Optional)|Subjects with mild renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.
62139135|NCT06698549|EXPERIMENTAL|Subjects with Moderate Renal Impairment (Optional)|Subjects with moderate renal impairment will receive oral doses of 300 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.
62139136|NCT01526954|EXPERIMENTAL|TissuGlu Surgical Adhesive|Experimental Arm: standard of care plus TissuGlu Surgical Adhesive and no drains
62139137|NCT01526954|NO_INTERVENTION|Control- Standard of Care|Control Arm: standard of care plus drains and no TissuGlu Surgical Adhesive
62139138|NCT05166057|EXPERIMENTAL|Telerehabilitation Group (TG)|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
62338689|NCT02572258|NO_INTERVENTION|Educational session only|
62338690|NCT05700747|EXPERIMENTAL|Health Through Activity (HTA) Intervention|"Participants will undergo study procedures as outlined:~* Complete a baseline survey regarding activity level and quality of life.~* Attend 6 weekly study visits at the MGH Institute of Health Professions IMPACT Practice Center.~* Attend final study visit and complete the Satisfaction survey and an individual, semi-structured interview with site staff to supply feedback about the program.~* After six weeks, complete the Satisfaction survey again."
62338691|NCT03953261|EXPERIMENTAL|Curcumin|
62338692|NCT03953261|PLACEBO_COMPARATOR|Placebo|
62338693|NCT05248971||Children screened for trauma and/or posttraumatic stress|Children were screened for trauma exposure and posttraumatic stress at one of the first meetings at the child and adolescent mental health clinic. For participants receiving TF-CBT, posttraumatic stress was also assessed during and after therapy.
62338694|NCT02257164|ACTIVE_COMPARATOR|femoral nerve block|20 ml injection of 2 mg/ml ropivacaine in femoral nerve
62338695|NCT02257164|EXPERIMENTAL|obturator nerve block and intraarticular injection|10 ml injection of 2 mg/ml ropivacaine in obturator nerve intraarticular injection : 10 ml of chlorhydrate ropivacaine (2 mg/ml) and 10ml of magnesium sulfate
62338696|NCT01511835|EXPERIMENTAL|Myo-inositol powder|
62338697|NCT01511835|EXPERIMENTAL|Myo-inositol soft gel capsules|
62338698|NCT01511835|PLACEBO_COMPARATOR|Folic acid|
62338699|NCT00790738|EXPERIMENTAL|1|liothyronine (T3)
62338700|NCT00790738|PLACEBO_COMPARATOR|2|placebo
62338701|NCT03360539|EXPERIMENTAL|Treatment-NFP|NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.
62495365|NCT01994018||MS Group|RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
62495366|NCT01994018||Retrospective Chart Review|RR-MS patients treated with a FDA approved immuno-modulatory drug for MS.
62495367|NCT01169272|EXPERIMENTAL|CRT-SonR 9770|Active implantable defibrillator with ability to cardiac resynchronization therapy
62139139|NCT05166057|EXPERIMENTAL|Video Group (VGr)|After 1 session of online simultaneous exercise training in the company of a physiotherapist via a smart phone videoconference to the VGr group, an exercise video including the exercises will be sent and the participants will be asked to do exercises 3 days a week. The cases will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
62139140|NCT05166057|EXPERIMENTAL|Standard pulmonary rehabilitation group (SGr)|The SGr group will be applied the pulmonary rehabilitation program with supervision in the hospital 2 days a week, and participants will be asked to do exercises at home for 1 day. The exercise period will be 8 weeks for both groups.
62139141|NCT01663454|EXPERIMENTAL|Cogmed Robomemo working memory training|Participants will complete 25 sessions (5 weeks) of Cogmed Robomemo (Pearson assessment) working memory training
62139142|NCT00808405|ACTIVE_COMPARATOR|acyclovir|
62338702|NCT03360539|NO_INTERVENTION|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
62495368|NCT03610386|ACTIVE_COMPARATOR|Control|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...).One of two biopsies will be left in culture for 24 hours and then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes .
62139143|NCT00808405|PLACEBO_COMPARATOR|placebo|
62139144|NCT02534285|SHAM_COMPARATOR|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
62139145|NCT02534285|ACTIVE_COMPARATOR|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
62139146|NCT04110301|EXPERIMENTAL|MIL62 + Lenalidomide|MIL62 plus Lenalidomide
62495369|NCT03610386|EXPERIMENTAL|Treatment with menthoxypropanediol|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. Thy will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...).One of two biopsies will be left in culture for 24 hours. Then the menthoxypropanediol (200 µM) will be applied topically on this explant and left for 6 hours. Then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes.
62139147|NCT00309166|EXPERIMENTAL|Cervarix Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
62139148|NCT00309166|ACTIVE_COMPARATOR|Engerix-B Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
62139149|NCT04623554|ACTIVE_COMPARATOR|Intervention arm|Prehabilitation program
62139150|NCT04623554|NO_INTERVENTION|Control arm|Usual care
62139151|NCT05159453|EXPERIMENTAL|Main Experimental|Type 2 Diabetic patients regulating blood glucose with daily injections as basal and/or post-prandial interventions. Patients will receive transdermal product formulated at 100 IU/mL of equivalent International Units of Human Insulin dosed at the same amount as current injected therapies with timing adjusted for the Absorption, Distribution, Metabolism \& Elimination (ADME) of human insulin with maximum effect at 3 hours post dose so mid morning before lunch, late afternoon before dinner and before bedtime.
62139152|NCT06510764|EXPERIMENTAL|Traditional Chinese Medicine+acupuncture|Subjects in this group will be treated with traditional Chinese medicine and intradermal acupuncture point stimulation for 6 months.
62139153|NCT06510764|ACTIVE_COMPARATOR|Traditional Chinese Medicine|Subjects in this group will be treated withTraditional Chinese Medicine for 6 months.
62139154|NCT05274321|ACTIVE_COMPARATOR|Pediatric Participant's Eyes Using Standard Pupilary Dilation|Consenting pediatric participants will undergo standard pupillary dilation in one eye.
62139155|NCT05274321|EXPERIMENTAL|Pediatric Participant's Eyes using Nanodropper attachment|Consenting pediatric participants will undergo pupillary dilation in the second eye using the Nanodropper attachment.
62139156|NCT02574611|EXPERIMENTAL|SCI observational|"Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
62139157|NCT02574611|EXPERIMENTAL|Able-bodied observational|"Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
62139158|NCT02574611|ACTIVE_COMPARATOR|SCI drug group|Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.
62139159|NCT02574611|PLACEBO_COMPARATOR|SCI placebo group|Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).
62338703|NCT01518712|EXPERIMENTAL|Treatment Sequence AB|
62495370|NCT03359941|EXPERIMENTAL|Integrative Treatments|This study's arm is single, so all participants will receive acupuncture treatments.
62495371|NCT00828828||Sarcoidosis|Sarcoidosis patients who are assigned to receive influenza vaccine
62338704|NCT01518712|EXPERIMENTAL|Treatment Sequence BA|
62338705|NCT04510350||MS CIS+|
62338706|NCT04510350||Healthy volunteers|
62495372|NCT00828828||Healthy Controls|Healthy controls who are assigned to receive influenza vaccine
62495373|NCT03212820|EXPERIMENTAL|Biologic drilling|drilling at low speed
62495374|NCT03212820|ACTIVE_COMPARATOR|conventional drilling|drilling at conventional or high speed
62338707|NCT04786041||underwent Appendectomy during march-april of 2019|all patients who underwent Appendectomy during the period of march-april of 2019
62696647|NCT03562156|EXPERIMENTAL|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
62139160|NCT03235856||Keratoconus patients|This study involves a retrospective analysis of data recorded during routine clinical follow-up of keratoconus patients. As such, the impact for the patient is minimal as no additional tests need to be performed
62696648|NCT03562156|PLACEBO_COMPARATOR|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
61943586|NCT05237232||Patients|Newborns, infants and children hospitalized in pediatric intensive care unit (PICU) at Trousseau Hospital, having been treated with jugulocarotid ECMO and weaned alive off ECMO.
61943587|NCT05237232||Controls|Newborns treated for hypoxic-ischemic encephalopathy in the PICU of Trousseau Hospital.
61943588|NCT02291874|EXPERIMENTAL|Ipragliflozin group|Ipragliflozin treatment
61943589|NCT05143450|EXPERIMENTAL|Experimental Group|Before the procedure, manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher.
61943590|NCT05143450|NO_INTERVENTION|Control Group|No intervention will perform to reduce pain in the control group.
61943591|NCT00808483|EXPERIMENTAL|Walking skill training group|Participation in the supervised walking skill training program.
62139161|NCT01515241|OTHER|Open label single arm study of CER-001|Open label single arm study of CER-001
62139162|NCT01285999|EXPERIMENTAL|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System (PROMUS Element)
62139163|NCT01285999|ACTIVE_COMPARATOR|TAXUS Liberté DES|TAXUS Liberté Paclitaxel-Eluting Coronary Stent System (TAXUS Liberté)
62139164|NCT06482112|ACTIVE_COMPARATOR|Efinopegdutide Q1W 10 mg|Participants will receive efinopegdutide Q1W via subcutaneous (SC) injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for up to 16 weeks.
62139165|NCT06482112|EXPERIMENTAL|Efinopegdutide Q2W 10 mg|Participants will receive efinopegdutide Q2W via SC injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for up to 16 weeks.
62139166|NCT06482112|EXPERIMENTAL|Efinopegdutide Q2W 15 mg|Participants will receive efinopegdutide Q2W via SC injection for 28 weeks in a dose-escalating regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, 10 mg for 4 weeks, and 15 mg for up to 12 weeks.
62139167|NCT03987243|OTHER|Intervention|Two interventions will be provided. The first intervention is a structured education regarding pressure ulcer prevention through weight shifts at start of study. The second intervention is the use of a mobile seat interface pressure map (IPM), which will occur during two intervention phases.
62338708|NCT04786041||underwent Appendectomy during march-april of 2020 (during covid pandemic)|all patients who underwent Appendectomy during the period of march-april of 2020 (during the COVID19 pandemic lockdown)
62139168|NCT04446481|EXPERIMENTAL|MCI patients|Vets with mild cognitive impairment
62139169|NCT04446481|ACTIVE_COMPARATOR|NC|Normal healthy Veterans
62338709|NCT01643759|EXPERIMENTAL|buprenorphine transdermal system|buprenorphine transdermal system
62495375|NCT05363241|NO_INTERVENTION|Conservative group (CG)|The patients will receive standard pharmacological treatment (oral analgesics, intra-articular injection with corticosteroids) and physiotherapy for 6 months, where the end of the study occurs. After this period, the patient is guaranteed to undergo the cooled radiofrequency procedure, with medical indication.
62696649|NCT06418308|ACTIVE_COMPARATOR|Dexmedetomidine|receiving the addition of 5 mcg of dexmedetomidine to the standard spinal medication mixture.
62696650|NCT06418308|ACTIVE_COMPARATOR|Epinephrine|receiving the addition of 200 mcg of epinephrine to the standard spinal medication mixture
62696651|NCT02774694||observational cohort|patients undergoing interventional pain management procedures
62696652|NCT04821310|ACTIVE_COMPARATOR|Arm 1 Full Dose Pantoprazole and matching placebo|Full Healing Dose of pantoprazole
61943592|NCT00808483|NO_INTERVENTION|Control group|No participation in the supervised walking skill training program
61943593|NCT00400738|EXPERIMENTAL|1|different dose per arm
61943594|NCT00400738|EXPERIMENTAL|2|different dose per arm
61943595|NCT00400738|EXPERIMENTAL|3|different dose per arm
61943596|NCT00400738|EXPERIMENTAL|4|different dose per arm
62139170|NCT03813524|EXPERIMENTAL|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
62139171|NCT05925699||All patients with new-onset cerebrovascular disease from January 1, 2016 to July 1, 2049|
62139172|NCT02631369|EXPERIMENTAL|inter- & intrarater reliability study|pre-study: inter- and intrarater reliability study in 30 healthy subjects, interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
62139173|NCT02631369|EXPERIMENTAL|cyclotorsion in forth nerve palsy|measurement of cyclotorsion on SLO-fundusphoto in 20 patients forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
62139174|NCT02631369|EXPERIMENTAL|cyclotorsion in healthy subjects|measurement of cyclotorsion on SLO-fundusphoto in 30 healthy subjects to be compared to patients with forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
62338710|NCT00361127|EXPERIMENTAL|CMPD patients|Patients with CMPD with evaluation of ACE I/D polymorphism
62338711|NCT02438995|EXPERIMENTAL|Cetuximab with Radiation Therapy|For subjects receiving radiation therapy, the treatment schedule will consist of a re-irradiation dose of approximately 70 Gy over 6-7 weeks. This experimental treatment arm will add IA Cetuximab administration every three weeks up to 2 doses to this radiation schedule.
62696653|NCT04821310|ACTIVE_COMPARATOR|Arm 2 Half Dose Pantoprazole and matching placebo|Half Healing Dose of pantoprazole
62696654|NCT00835172|EXPERIMENTAL|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
62696655|NCT00835172|ACTIVE_COMPARATOR|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
62139175|NCT00817154|EXPERIMENTAL|Hopes-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
62139176|NCT06698952|EXPERIMENTAL|Intervention group|The chatbot-delivered structured psychological intervention (SPI-Bot)
62139177|NCT06698952|ACTIVE_COMPARATOR|Control group|Attention control group
62139178|NCT05491135|EXPERIMENTAL|HMB002|All patients will receive HMB002 infusion into the peritoneal cavity.
62139179|NCT06665022|EXPERIMENTAL|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode). For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
62139180|NCT06665022|PLACEBO_COMPARATOR|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
62338712|NCT02438995|EXPERIMENTAL|Cetuximab Alone|For subjects who are not candidates for re-irradiation, this experimental treatment arm will include only IA Cetuximab administration every three weeks up to 2 doses.
62338713|NCT04673617|EXPERIMENTAL|Phase 1: Dose confirmation of AB-101 as mono, ritux combo (including DLBCL specific) & BR combo|Phase 1: Dose confirmation of AB-101 as monotherapy, in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab
62338714|NCT04673617|EXPERIMENTAL|Phase 2: AB-101 given with rituximab or with BR to patients with B-cell NHL at the R2PD|Phase 2: AB-101 given with rituximab or with bendamustine and rituximab to patients with B-cell NHL at the R2PD
62338715|NCT04019275|EXPERIMENTAL|ENGAGE|The intervention blends social learning, guided discovery, and skill training to promote community participation after stroke. The intervention is delivered in a group format and comprises group learning activities and individual action planning activities that address barriers to community participation after stroke.
62338716|NCT05062941|ACTIVE_COMPARATOR|Control group|Conventional therapy (CT) was applied to all participants. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS) in conventional mode, 5 minutes of ultrasound (1.5 W/cm2, 1 MHz), 20 minutes of interference current with vacuum electrodes (80 Hz pulse frequency, 1/1 rectangular spectrum), and exercises (all exercises were applied as 1 set of 10 repetitions in each direction: Codman exercises (3-directions), wand exercises (4-directions), exercises using the shoulder wheel (2-directions), exercises with exercise band (5-directions), exercises on the finger ladder (1 set of 10 repetitions in both directions); and shoulder capsule stretching exercises performed (1 set of 12 repetitions) by asking the subjects to wait 20 seconds where the tension was felt).
62338717|NCT05062941|ACTIVE_COMPARATOR|Study group|"Same conventional therapy (CT) that was applied to control group was also applied to all participants in this group. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and the same exercises.~In addition to the CT program, only study group has received HILT (BTL 6000, BTL Industries, Inc., USA) application to the shoulder area (analgesic mode, 25 Hz,10 W, 12 j/cm2) for 2 minutes."
62338718|NCT01661218||complications|catheter-related venous thrombosis catheter-related infections
62338719|NCT00651404|EXPERIMENTAL|Ezetimibe|
62338720|NCT00651404|PLACEBO_COMPARATOR|Placebo|
61943597|NCT02019277|EXPERIMENTAL|Trastuzumab SC, Pertuzumab, and Taxane|Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
62338721|NCT03007017|EXPERIMENTAL|Arm 1|Patients selected for this arm will receive the left kidney from the new method of organ retrieval.
62338722|NCT03007017|ACTIVE_COMPARATOR|Arm 2|Patients selected for this arm will receive the normal standard of care operational kidney from retrieval.
62338723|NCT01975233||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 75 years requiring treatment for intracranial aneurysms.
62338724|NCT02352805||(1) veno-venous ECMO|ECMO - Patients being connected to veno-venous extracorporeal membrane oxygenation (ECMO)
62338725|NCT02352805||(2) veno-arterial ECLS|ECLS - Patients being connected to veno-arterial extracorporeal life support (ECLS)
61943598|NCT02001103|ACTIVE_COMPARATOR|Memantine 10 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
61943599|NCT02001103|ACTIVE_COMPARATOR|Memantine 20 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
61943600|NCT02001103|PLACEBO_COMPARATOR|Placebo|Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
62495376|NCT05363241|EXPERIMENTAL|Radiofrequency cooled group with classical targets (CRF-CT)|The patients will undergo the CRF procedure using the classical therapeutic targets (medial superior genicular nerve, lateral superior genicular nerve, medial inferior genicular nerve). So that patients do not know in which group of the study they are included, the probe will be placed in the aforementioned genicular nerves and also in the recurrent fibular nerve and in the infra-patellar branch of the saphenous nerve, but will not receive radiofrequency in the recurrent fibular nerve nor in the infra-patellar branch of the saphenous nerve, receiving radiofrequency only in the genicular nerves. Oral analgesics will be prescribed for the patient to use if necessary.
62495377|NCT05363241|EXPERIMENTAL|Radiofrequency cooled group with revised targets (CRF-RT)|The patients will undergo the CRF procedure using the revised therapeutic targets (medial superior genicular nerve, lateral superior genicular nerve, medial inferior genicular nerve, recurrent fibular nerve and in the infra-patellar branch of the saphenous nerve). So that patients do not know in which group of the study they are included, the probe will be placed in all the aforementioned nerves and will receive radiofrequency in all of them. Oral analgesics will be prescribed for the patient to use if necessary.
62696656|NCT05840250|EXPERIMENTAL|Continuous Glucose Monitoring and Education Support Group|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
62696657|NCT03988218|EXPERIMENTAL|Anorexia|Subjects with anorexia nervosa
62696658|NCT03988218|ACTIVE_COMPARATOR|Control|Subjects without eating disorders
62696659|NCT03731429|EXPERIMENTAL|Intervention|Group that receives a 1 mg/kg single bolus of 2% IV lidocaine
62696660|NCT03731429|PLACEBO_COMPARATOR|Placebo|group that receives 0.9% saline solution
62696661|NCT04049474|EXPERIMENTAL|Bronchoscopic Cryo-Immunotherapy (BCI)|BCI is performed by advancing a flexible cryoprobe through a bronchoscope to reach a peripheral tumor. The cryoprobe is activated to freeze a portion of the tumor. The cryoprobe is allowed to thaw to prevent removal of lung or airway tissue. The tumor must be located by radial EBUS and a guide sheath placed prior to cryoablation.
62696662|NCT05866302||Cohort 1: Newly diagnosed chronic GVHD|All subjects will undergo a non-contrast, high resolution CT scan with inspiratory and expiratory imaging, pulmonary function testing (PFT) and serologic biomarker studies upon entry. A total of 300 subjects (200 adults, 100 pediatric) will be enrolled. Patients in cohort 1 who develop CLD prior to the 12-month period will transition to cohort 2 at that time. PFT is recommended every 3 months over a 12 month period. Plasma samples will be collected at entry and at 12 months.
62696663|NCT05866302||Cohort 2: Newly diagnosed chronic lung disease (CLD)|All subjects will undergo a non-contrast, high resolution CT scan with inspiratory and expiratory imaging, pulmonary function testing (PFT) and serologic biomarker studies upon entry. A total of 75 subjects (50 adults, 25 pediatric) will be enrolled. PFT is recommended every 3 months over a 12 month period. Plasma samples will be collected at entry and at 12 months.
62696664|NCT05172297|EXPERIMENTAL|Immediate Intervention Group|The immediate intervention group will take part in the online parent training program called the Parent Web (PW). This immediate intervention group are parents of PATHS children who took part in a social emotional curriculum (PATHS) at age 4 to 5 years old and during the PW trial will be 11 to 13 years old. Parents are participating in the Parent Web.
62696665|NCT05172297|OTHER|Wait-List Control Group|This is a group of parents who are in a wait-list control group and will receive the Parent Web, after pre and post testing.
62139181|NCT03136172||Premature infant|premature infants with 32 weeks or less gestational age or 1,500 g or less birth weight, who born in the Inha university hospital and admit to the neonatal intensive care unit of the Inha university hospital
62139182|NCT05660174||Patient with a digestive surgery procedure|
62139183|NCT05660174||Patient with a vascular surgery procedure|
62338726|NCT02352805||(3) LVAD (Heart Mate II)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate II)
61943601|NCT06558487||Cancer patients|All adult patients with an active cancer diagnosis who visit the emergency department (ED) of the Erasmus University Medical Centre (Erasmus MC).
61943602|NCT01499758|EXPERIMENTAL|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
61943603|NCT01499758|ACTIVE_COMPARATOR|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
62139184|NCT05489913|EXPERIMENTAL|Web based Cardiac Rehabilitation program and follow-up telephone|"The website was created under the name of Cardiac Rehabilitation Support Program. The language of the website is Turkish. Designed for computer, tablet and mobile phone use. Patients must be registered to access the website. After creating a six-digit password during registration, they log in to the website with their e-mail address and this password. The password is determined specifically for the patient. There is a welcome text on the home page of the website. The main headings in the menu section; trainings, disease management questions, questionnaires, ask questions to the researcher."
62139185|NCT05489913|NO_INTERVENTION|Standard care|patients received their training before discharge from the hospital and no intervention was made for 12 weeks.
62338727|NCT02352805||(4) LVAD (Heart Ware)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Ware)
62338728|NCT02352805||(5) LVAD (Impella)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Impella)
62338729|NCT02352805||(6) Dialysis system|Patients being connected to a dialysis system
62338730|NCT02352805||(7) LVAD (Heart Mate III)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate III)
62338731|NCT02352805||(8) HLM|HLM = Heart Lung Machine - patients undergoing coronary artery bypass grafting surgery and / or aortic valve replacement with cardiopulmonary bypass
61943604|NCT05438888||Warfarin cohort (Reference)|Patients with NVAF treated with warfarin
61943605|NCT05438888||Apixaban cohort|Patients with NVAF treated with apixaban
61943606|NCT06451848|EXPERIMENTAL|Test preparation（T）|Genakumab Solution for Injection (T, liquid formulation)
62338732|NCT04199208|ACTIVE_COMPARATOR|Standard Care Arm|Standard perioperative care is given.
62338733|NCT04199208|EXPERIMENTAL|Interventional Arm|Intervention of prehabilitation and immunonutrition is given prior to surgery
62495378|NCT03612973|ACTIVE_COMPARATOR|non cirrhotic HCV patients|"* complete blood picture~* Liver and renal function tests~* Prothrombin time and concentration~* HCV quantitative polymerase chain reaction~* Hepatitis B surface Ag~* lipid profile~* fasting blood glucose level~* fasting insulin level~* homeostasis model for the assessment of insulin resistance (HOMA-IR)~* fibrosis (FIB- 4) index~* Aspartate aminotransferase (AST)/platelet ratio index (APRI)~* Abdominal ultrasound to assess liver and spleen~* Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
62338734|NCT03489616|EXPERIMENTAL|Radiotherapy+chemotherapy+ rhGM-CSF|Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be\> 4Gy per time（or BED \>45Gy） from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.
62338735|NCT03489616|EXPERIMENTAL|Single agent maintenance therapy|Maintenance treatment by single agent in a cycle of 21 days.
62696666|NCT01427478|EXPERIMENTAL|AFATINIB|Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
62696667|NCT01427478|PLACEBO_COMPARATOR|PLACEBO|Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
62139186|NCT06191016|EXPERIMENTAL|nVNS Group|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
62338736|NCT04649073|EXPERIMENTAL|OPC-415 (up to 1×10^7cells/kg)|
62696668|NCT06528418||pulmonary disease|Individuals with abnormalities in lung CT imaging and clinically diagnosed with lung cancer, lung infection, chronic obstructive pulmonary disease (COPD), bronchitis, pulmonary fibrosis, pulmonary embolism, pulmonary arterial hypertension, tuberculosis, lung abscess, emphysema, radioactive lung injury, cystic fibrosis of the lung, Bronchial Asthma, Bronchiectasis, interstitial lung disease (ILD), preserved ratio impaired spirometry (PRISm) etc .
62696669|NCT06528418||normal individual|Individuals with no abnormalities detected in lung CT imaging.
62338737|NCT03335852|EXPERIMENTAL|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
62338738|NCT02815241|EXPERIMENTAL|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62338739|NCT06441136|EXPERIMENTAL|Phonation Resistance Training Exercises (PhoRTE) Voice Therapy Program|PhoRTE is a voice therapy program administered by a speech language pathologist for participants with presbyphonia. During sessions, participants perform five vocal exercises at individualized target vocal intensity. Goals of therapy are to increase muscular workload on vocal mechanism and target the respiratory and laryngeal muscular deficits that result from aging. Participants practice 6 days per week at home and meet with speech pathologist weekly for 4 weeks.
62338740|NCT03378726|EXPERIMENTAL|Standard Counseling and Micronutrients|Participants will receive standard services provided by the Ministry of Health, including powder micronutrients. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old.
62696670|NCT05022719|EXPERIMENTAL|PillCam Colon2 procedure with MB-MMX|PillCam Colon2 procedure with MB-MMX
62696671|NCT04943757|EXPERIMENTAL|PTBCy graft-versus-host disease prophylaxis|Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration
61943607|NCT06451848|EXPERIMENTAL|Reference preparation（R）|Genakumab Powder for solution for Injection (R, lyophilized formulation)
61943608|NCT04004546|EXPERIMENTAL|Intervention group|At baseline: video and education booklet. 2-weeks after enrollment: telephone call by nurse.
62696672|NCT06048029|OTHER|Laparoscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for laparoscopic cholecystectomy compared to open cholecystetcomy
62696673|NCT06048029|OTHER|Open Cholecystectomy in children|Evaluate preoperative and operative risk factors for open cholecystectomy compared to laparoscopic cholecystetcomy
62696674|NCT04531579|EXPERIMENTAL|VPA plus SOC|A single dose of 140 mg/kg of VPA plus standard of care
62696675|NCT04531579|PLACEBO_COMPARATOR|Placebo plus SOC|A single dose of isotonic saline solution plus standard of care
62696676|NCT05411900|EXPERIMENTAL|Experimental group: BoNT-A arms|Subjects randomized in experimental group will receive intradermal injections of BoNT-A into the wrist and skin area of the hand where the pain is located.
62696677|NCT05411900|PLACEBO_COMPARATOR|Control group: Placebo arms|Subjects randomized in control group will receive intradermal injections of placebo.
62696678|NCT06192420|EXPERIMENTAL|Test product|Traumed® gel (human gel galenic form of Traumeel®)
62696679|NCT06192420|ACTIVE_COMPARATOR|Reference product|Diclofenac sodium gel 1%
62696680|NCT06192420|PLACEBO_COMPARATOR|Placebo therapy|Corresponding placebo gel
61943609|NCT04004546|NO_INTERVENTION|Control group|Usual care
62139187|NCT06191016|ACTIVE_COMPARATOR|Sham Group|control will receive sham stimulation to vagal nerve along with prescribed medications.
62139188|NCT02285270|OTHER|Single group assignment|Diagnostic test/procedure - FDG PET/CT
62139189|NCT04643574|EXPERIMENTAL|NeoTIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (fludarabine and cyclophosphamide), Low Dose Irradiation (LDI), ex vivo expanded Tumor Infiltrating Lymphocyte (TIL), enriched for tumor antigen specificity (NeoTIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
62338741|NCT03378726|EXPERIMENTAL|SPOON Group Counseling with SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group counseling, which is a new form of social communication in which participants will learn relevant lessons in a group format. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
62338742|NCT03378726|EXPERIMENTAL|Group, Interpersonal Counseling, SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group and interpersonal counseling, which will consist of both participants learning relevant lessons in group format as well as in formats in which participants will work one-on-one with an instructor. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
62139190|NCT05829512||Patients group|Individuals with dysmenorrhea
62139191|NCT00831688|ACTIVE_COMPARATOR|1|Local overpressure treatment
62338743|NCT06365515|EXPERIMENTAL|Women in EF|Healthy women in the early follicular menstrual cycle phase
62338744|NCT06365515|EXPERIMENTAL|Women in ML|Healthy women in the mid-luteal menstrual cycle phase
62338745|NCT06365515|EXPERIMENTAL|Men|Healthy men
62338746|NCT03007485|NO_INTERVENTION|Standard of Care|Standard pulmonary rehabilitation
62338747|NCT03007485|EXPERIMENTAL|Intervention|Telehealth delivered pulmonary rehabilitation
62338748|NCT02819895|EXPERIMENTAL|Intervention|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive their usual care (an immunization card). In addition they will received automated text, calls and emails (if applicable) reminders through a customized windows® software application when their child's immunization visit is due.
62338749|NCT02819895|NO_INTERVENTION|Control|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive usual care (an immunization card)
62338750|NCT04017442|EXPERIMENTAL|Morphine|2mg preservative free morphine
62338751|NCT04017442|PLACEBO_COMPARATOR|Saline|4 mL preservative free saline
62338752|NCT01908959|EXPERIMENTAL|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
62338753|NCT01908959|NO_INTERVENTION|Attention-control|"Participants in the attention receive monthly brief telephone calls by research technicians and collection of study data on-site at the Maricopa Medical Center and other community based sites at baseline, 6, and 12 months (T1, T3, T5). The staff did not give advice or support specific to walking, which enabled a valid evaluation of the intervention effect. The content given to the attention-control group did not include the active ingredients of the Madres para la Salud intervention. The attention-control group received monthly mailings of health-related information regarding common postpartum or newborn concerns, such as breastfeeding, infant sleep, sibling rivalry, emotional support related to new parenthood, and early childhood development topics."
62338754|NCT03481127|ACTIVE_COMPARATOR|Arm 1: Usual Care|-No psychosocial care in clinic
62338755|NCT03481127|EXPERIMENTAL|Arm 2: Integrated Care|-Those who receive integrated care will receive a one-page care plan completed by Dr. Vanderlan including their scores from screening questionnaires , recommendations for coping strategies and available supportive resources.
62139192|NCT00831688|PLACEBO_COMPARATOR|2|Placebo treatment
62338756|NCT01911845|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, plus RBV|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
62495379|NCT03612973|ACTIVE_COMPARATOR|cirrhotic HCV patients|"* complete blood picture~* Liver and renal function tests~* Prothrombin time and concentration~* HCV quantitative polymerase chain reaction~* Hepatitis B surface Ag~* lipid profile~* fasting blood glucose level~* fasting insulin level~* homeostasis model for the assessment of insulin resistance (HOMA-IR)~* Fibrosis (FIB- 4) index~* Aspartate aminotransferase (AST)/platelet ratio index (APRI)~* Abdominal ultrasound to assess liver and spleen~* Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
62495380|NCT00325182|EXPERIMENTAL|Intervention: Levetiracetam|Levetiracetam dose schedule Days 1-4 250 mg bid Days 5- 19 500 mg bid Days 20 -70 1000 mg bid Days 71-78 500 mg bid Days 79-85 250 mg bid Days 86-91
62495381|NCT00325182|PLACEBO_COMPARATOR|Historical controls|Historical controls from COMBINE study who receive a placebo
62495382|NCT03483350|EXPERIMENTAL|1- 1st group|1- 1st group will include 30 patients will receive intravenous granisetron 10 μg/kg after induction of anesthesia and before start of surgery
62696681|NCT04941885|EXPERIMENTAL|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab(8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days) plus cyclophosphamide metronomic chemotherapy(50mg once a day orally) plus aromatase(once a day orally).
62495383|NCT03483350|EXPERIMENTAL|2- 2nd|2- 2nd group will include 30 patients will receive intravenous midazolam 50 μg/kg after induction of anesthesia and before start of surgery
62696682|NCT00966667||cancer survivor|cancer survivor
62139193|NCT00995592|EXPERIMENTAL|Mentor mothers|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
62696683|NCT00751231|ACTIVE_COMPARATOR|Arm 1|300mg or 600mg loading dose of Clopidogrel followed by once daily dosing of 75 mg Clopidogrel for up to 120 days.
62139194|NCT00995592|NO_INTERVENTION|Control|Control cases were visited and their infants were weighed 4 times over one year period. After one year, mothers were provided Philani nutrition intervention program.
62139195|NCT01860079|ACTIVE_COMPARATOR|Early discharge group|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
62139196|NCT01860079|NO_INTERVENTION|Standard discharge group|Patients who stay longer (96-120 hours) as of a standard procedure
62696684|NCT00751231|EXPERIMENTAL|Arm 2|IV bolus of PRT060128 prior to PCI and twice daily administration of 50 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
62338757|NCT00077610|EXPERIMENTAL|RO0503821 (1x/2 Weeks)|Participants received RO0503821 (Mircera \[methoxy polyethylene glycol-epoetin beta\]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram \[mcg\]) that was based on the Epoetin dose (\<8000, 8000-16000, \>16000 International units \[IU\]/Week) administered during the week preceding the switch to the study drug.
62696685|NCT00751231|EXPERIMENTAL|Arm 3|IV bolus of PRT060128 prior to PCI and twice daily administration of 100 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
62338758|NCT00077610|EXPERIMENTAL|RO0503821 (1x/4 Weeks)|Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (\<8000, 8000-16000, \>16000 IU/Week) administered during the week preceding the switch to the study drug.
62139197|NCT03983668|EXPERIMENTAL|CMP-001 plus pembrolizumab|Intratumoral administration of CMP-001 and intravenous administration of pembrolizumab
62139198|NCT00912964|PLACEBO_COMPARATOR|Placebo|Participants received matching mirabegron placebo tablets orally once a day for 12 weeks.
62338759|NCT00077610|ACTIVE_COMPARATOR|Epoetin (1-3x/Weeks)|Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.
62338760|NCT04093817||on pump CABG|patients under going CABG with cardiopulmonary bypass machine
62139199|NCT00912964|EXPERIMENTAL|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
62696686|NCT00751231|EXPERIMENTAL|Arm 4|IV bolus of PRT060128 prior to PCI and twice daily administration of 150 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
62696687|NCT04595292||older adults, assessment|
62139200|NCT00912964|EXPERIMENTAL|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.
62139201|NCT06142409|ACTIVE_COMPARATOR|Active arm|Enzyme-containing lozenge
62696688|NCT05664529||healthy children aged 6-36 months|120 healthy children with or without any feeding difficulties reported by the mothers will be included. A 20-minute videotaped feeding session will be evaluated by Chatoor Feeding Scale to examine mother-infant relationship during feeding.
62139202|NCT06142409|PLACEBO_COMPARATOR|Placebo arm|Placebo lozenge
62139203|NCT06539312|EXPERIMENTAL|SBHC group|
62338761|NCT04093817||off pump CABG|patients under going CABG without cardiopulmonary bypass machine
62338762|NCT04980924||Pulmonary Embolism without reccurence or complication|Pulmonary Embolism without reccurence or complication
62338763|NCT04980924||Pulmonary Embolism with reccurence or complication|Pulmonary Embolism with reccurence or complication, in particular occurrence of pulmonary hypertension.
62338764|NCT03990519|EXPERIMENTAL|Cohort1: JNJ-2636682/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
62338765|NCT03990519|EXPERIMENTAL|Cohort 2: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
62338766|NCT03990519|EXPERIMENTAL|Cohort 3: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2.
62338767|NCT02074306|EXPERIMENTAL|UROSHIELD®|Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
62338768|NCT02074306|SHAM_COMPARATOR|SHAM UROSHIELD®|same as abouve but with Sham device.
62338769|NCT00094887|EXPERIMENTAL|Inhaled Nitric Oxide|Participants receive Inhaled nitric oxide (INO)
62338770|NCT00094887|PLACEBO_COMPARATOR|Placebo|Participants receive Nitrogen gas
62696689|NCT04728230|EXPERIMENTAL|Treatment (chemo-immunotherapy, radiation therapy)|See detailed description.
62696690|NCT06274177|EXPERIMENTAL|Treatment with BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator)
62696691|NCT02759133|ACTIVE_COMPARATOR|A - A standard Localization technique|A standard Localization technique : Metal wire as localization technique for breast cancer surgery
61943610|NCT06680882|EXPERIMENTAL|study group|The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
61943611|NCT06680882|OTHER|control group|also consisting of 30 patients, was administered prucapride as a monotherapy.
61943612|NCT00968890|EXPERIMENTAL|Pandemrix+Fluarix and Pandemrix+Placebo|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
62139204|NCT06539312|NO_INTERVENTION|PCP group|
62139205|NCT04777357|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo over a 6 week treatment period.
62139206|NCT04777357|EXPERIMENTAL|Cariprazine|Participants will receive flexible dose Cariprazine over a 6 week treatment period.
62139207|NCT05528549|EXPERIMENTAL|Dynamic Exercise|The investigators will look at leg blood flow during a seated leg-kicking test that is similar to biking. Leg blood flow will be measured in both the active and inactive legs. These measurements will be taken to examine how blood is directed (or controlled) during exercise.
62139208|NCT05528549|EXPERIMENTAL|Static Exercise|The investigators will look at blood pressure responses to a sustained leg kick. Blood pressure should increase during the sustained contraction for people without Down syndrome.
62139209|NCT00640588|EXPERIMENTAL|1|Telbivudine
62139210|NCT00640588|ACTIVE_COMPARATOR|2|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
62139211|NCT03107169|ACTIVE_COMPARATOR|Vancomycin|Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days
62139212|NCT03107169|EXPERIMENTAL|FMT-FURM|Patients in this arm receive FMT-FURM
62139213|NCT01146522|EXPERIMENTAL|LCQ908|
62139214|NCT01146522|PLACEBO_COMPARATOR|Placebo|
62338771|NCT02145741|EXPERIMENTAL|Xentuzumab|Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)
62495384|NCT03483350|EXPERIMENTAL|3- 3rd group|3- 3rd group will include 30 patients will receive combination intravenous granisetron 5 μg/kg with midazolam 25 μg/kg after induction of anesthesia and before start of surgery
62696692|NCT02759133|EXPERIMENTAL|B - Experimental Localization technique|Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery
62139215|NCT06696599||Serum and corporal irisin in diabetic patients|Penil duplex ,serum irisin ,corporal irisin
62139216|NCT06696599||Serum irisin in normal persons|Serum irisin
62139217|NCT02531841|ACTIVE_COMPARATOR|Arm A|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)"
62139218|NCT02531841|ACTIVE_COMPARATOR|Arm B|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment High-dose chemotherapy~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \*if not available at study site, Busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)"
62139219|NCT05619705|EXPERIMENTAL|Healthy for Two-Health Coaching (H42)|Those assigned to the intervention group will receive the 8 to 11 month H42 health coaching intervention in addition to usual home visiting and usual prenatal and postpartum care clinical services. Intervention duration will depend on the participant's gestational age at the of enrollment. Participants can be enrolled as early in pregnancy as 20 weeks gestation and as late as 33 weeks gestation. All participants would be enrolled for 6 months postpartum. Therefore, the minimum time in the intervention would be 8 months and maximum would be 11 months.
62338772|NCT01955850|EXPERIMENTAL|Internet-delivered CBT for insomnia|Online Cognitive behavioral treatment for insomnia
62338773|NCT01955850|EXPERIMENTAL|Face-to-face CBT for insomnia|Face-to-face Cognitive behavioral treatment for insomnia
62338774|NCT01955850|NO_INTERVENTION|Waiting-list|Waiting-list
62338775|NCT06166914|EXPERIMENTAL|Treatment group|Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml) during pars plana vitrectomy and silicone oil injection with scleral buckle in children under 14 years of age with high-risk PRRD
62338776|NCT06166914|PLACEBO_COMPARATOR|Control group|Group B received infusion of normal saline during pars plana vitrectomy and silicone oil injection with scleral buckle in children under 14 years of age with high-risk PRRD
62495385|NCT05955326|EXPERIMENTAL|Sovateltide (Tyvalzi™) + Standard treatment|A total of 80 patients will be enrolled in the experimental arm. Three doses of sovateltide (each dose of 0.3 μg/kg body weight) will be given as an IV bolus in each patient (randomly assigned to this group) over one minute at an interval of 3 ± 1 hours on day 1, day 3, and day 6 (total dose/day: 0.9 μg/kg body weight). All patients will receive standard stroke treatment as provided by the specific hospital setup. Patients will be closely monitored for the qualifying stroke, followed for 3 months, and assessed for safety and efficacy parameters. Efforts will be made to administer the drug at the same time on days 1, 3, and 6.
62495386|NCT05955326|PLACEBO_COMPARATOR|Normal Saline (Dose: Equal volume) + Standard Treatment|A total of 80 patients will be enrolled in this arm. Three doses of an equal volume of normal saline will be administered as an IV bolus in each patient (randomly assigned to this group) over one minute at an interval of 3 ± 1 hours on day 1, day 3, and day 6. All patients will receive standard stroke treatment as provided by the specific hospital setup. Patients will be closely monitored for the qualifying stroke, followed for 3 months, and assessed for safety and efficacy parameters. Efforts will be made to administer the drug at the same time on days 1, 3, and 6.
62495387|NCT05846256||Infertile male|Men with unexplained infertility
62495388|NCT05846256||Donors (control)|Fertile sperm donors
62495389|NCT02037854|PLACEBO_COMPARATOR|Placebo|A nutrient formulation without the active ingredient
62495390|NCT02037854|EXPERIMENTAL|Nutrient formulation|Nutrient formulations with variable amounts of active ingredients.
62696693|NCT06500585|EXPERIMENTAL|Mill's Manipulation and Muscle Energy Technique|Group A will receive (Mills Manipulation + Muscle Energy Technique + Conventional therapy).
62696694|NCT06500585|OTHER|Mill's Manipulation|Group B will receive (Mills Manipulation + Conventional therapy).
62338777|NCT05915338||Experimental Group|"-Pre-test data were obtained by using the descriptive information form, İUBGF, VAS, and HRAS.~The patients were asked to self-administer a dose of insulin that day, and the ability of the patients to administer the insulin dose was recorded in the IUBGF as the 1st follow-up by the researchers. Afterwards, individual insulin use training was given and the Educational Manual on the Use of Insulin for Individuals with Type 2 Diabetes was given to the patients and the first follow-up was completed.~-2 weeks later, post-test data were obtained from the patients using IUBGF, VAS, and HRAS. The ability of the patients to administer the insulin dose was recorded in the IUBGF as the second follow-up by the researchers.~After 8 weeks, post-test data were obtained by using IUBGF, VAS, and HRAS as retention tests. The ability of the patients to administer the insulin dose was recorded by the researchers as the 3rd follow-up retention test in IUBGF."
62696695|NCT04932772|EXPERIMENTAL|Group A (kinesiotaping group)|include 24 women will receive kinesiotaping combined with abdominal exercise (2sessions /week for eight weeks).
62696696|NCT04932772|ACTIVE_COMPARATOR|Group B (abdominal exercise group)|include 24 women will receive abdominal exercise only.
62696697|NCT00723632||Peginterferon alfa-2b and ribavirin|All participants included in the study
62338778|NCT05915338||Control Group|"-Pre-test data were obtained by using the descriptive information form, İUBGF, VAS, and HRAS.~The patients were asked to self-administer a dose of insulin that day, and the ability of the patients to administer the insulin dose was recorded in the IUBGF as the 1st follow-up by the researchers.~-2 weeks later, post-test data were obtained from the patients using IUBGF, VAS, and HRAS. Patients were asked to self-administer a daily dose of insulin. The ability of the patients to administer the insulin dose was recorded in the IUBGF as the second follow-up by the researchers.~After 8 weeks, post-test data were obtained by using IUBGF, VAS, and HRAS as retention tests. Patients were asked to self-administer a daily dose of insulin. The ability of the patients to administer the insulin dose was recorded in IUBGF as the 3rd follow-up retention test by the researchers."
62338779|NCT03052842|EXPERIMENTAL|Arm 1A: 9.2 mg C16G2|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
62495391|NCT00515216|EXPERIMENTAL|Oxaliplatin/Leucovorin/5-FU|"Good risk patients with the TSER\*2/\*2 or \*2/\*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks."
62495392|NCT02297087|OTHER|Pilot|Obtain the necessary tumor biopsies to yield sufficient DNA and RNA for Genome-Wide Sequencing (GWS).
62495393|NCT01613937|EXPERIMENTAL|Lifestyle|12 once weekly Lifestyle training program
62495394|NCT00776867|EXPERIMENTAL|perifosine|This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
62495395|NCT02597049|EXPERIMENTAL|1.5 mg Dulaglutide|1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.
62495396|NCT02597049|EXPERIMENTAL|0.75 mg Dulaglutide|0.75 mg dulaglutide given SC once a week for 24 weeks.
62495397|NCT02597049|PLACEBO_COMPARATOR|Placebo|Placebo given SC once a week for 24 weeks.
62495398|NCT03213548|EXPERIMENTAL|Alar facial groove Incision|Alar Base surgical modification with surgical inions in the alar facial groove
62495399|NCT03213548|ACTIVE_COMPARATOR|Alar facial groove spared|Alar Base surgical modification with surgical incisions 1mm above the alar facial groove
62495400|NCT03594617|EXPERIMENTAL|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
62495401|NCT03594617|NO_INTERVENTION|Control institutions|The control institutions do not receive any intervention.
62495402|NCT04317638||breastfed group|Infants on exclusive breast feeding for the first 6 months of life and their mothers
62495403|NCT04317638||formula fed group|Infants on exclusive formula feeding for the first 6 months of life
62495404|NCT04317638||mixed fed group|Infants on mixed feeding (formula \& breast feeding) and their mothers
62495405|NCT01008709|PLACEBO_COMPARATOR|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur
62495406|NCT01008709|ACTIVE_COMPARATOR|Aesculap U-Clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur.
62495407|NCT04513327|EXPERIMENTAL|Digital Healthcare System Rehabilitation|
62495408|NCT04513327|ACTIVE_COMPARATOR|Conventional Rehabilitation|
62495409|NCT03770130|EXPERIMENTAL|Dexmedetomidine treatment group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an initial loading dose of dexmedetomidine of 1μg/kg over 10 min after the induction of anaesthesia followed by a continuous infusion of 0.5μg/kg/h until the end of surgery.
62495410|NCT03770130|PLACEBO_COMPARATOR|Control group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an equal volume initial loading dose of 0.9% saline over 10 min after the induction of anaesthesia followed by an equal volume continuous infusion until the end of surgery.
62495411|NCT03039816|ACTIVE_COMPARATOR|Active|The patients were randomly assigned to active (Nasaleze cellulose powder) or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
62495412|NCT03039816|PLACEBO_COMPARATOR|Placebo|The patients were randomly assigned to active or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
62495413|NCT04956289|EXPERIMENTAL|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
62495414|NCT06445478|EXPERIMENTAL|Group 1 (Resistant exercise with blood flow restrictive exercise (BFR-RE Group ))|Resistant exercise with blood flow restrictive exercise (BFR-RE) training will be given 2 days a week for 8 weeks. Each exercise session will consist of 4 sets. There will be 30 repetitions in the first set and 15 repetitions in the next 3 sets, for a total of 75 repetitions. There will be a minimum of 30 seconds and a maximum of 60 seconds of rest intervals between sets. Since the application will be performed for the lower extremity muscle groups, a cuff will be placed on the proximal part of the lower extremity. Exercise load will be determined as 20-40% of 1 RM.
62495415|NCT06445478|EXPERIMENTAL|Group 2 (Resistant exercise with isokinetic device (ID-RE Group))|Resistant exercise with isokinetic device (ID-RE) training will be given 2 days a week for 8 weeks. During the training, leg press, squat and knee extension movements will be improved by increasing the resistance or changing the position depending on the athlete's condition.
62495416|NCT02646800|EXPERIMENTAL|Micafungin group|Intravenous (IV)
62696698|NCT05103332|EXPERIMENTAL|Zilebesiran (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period. Upon implementation of Amendment 3, the open-label extension (OLE) period will be closed and participants will not receive any further treatment with zilebesiran in the OLE period.
62696699|NCT05103332|EXPERIMENTAL|Placebo (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period. Upon implementation of Amendment 3, the OLE period will be closed and participants will not receive any further treatment with zilebesiran in the OLE period.
61943613|NCT00968890|EXPERIMENTAL|Pandemrix+Placebo and Pandemrix+Fluarix|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
61943614|NCT05377879|EXPERIMENTAL|OPTIVF predicted drug dosage|In our study, we will be using the patient's age and day three serum day AMH and FSH levels to decide the starting dose for the patient's cycle. We will use the first two days of data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient with the help of the decision support tool OPTIVF for this intervention in the clinical trial.
61943615|NCT05377879|NO_INTERVENTION|Traditional drug treatment|Patients where drug dosage is decided by the physician based on ultrasound and estrogen levels for each day of the cycle.
62139220|NCT05619705|ACTIVE_COMPARATOR|Maintain Health in Pregnancy and Postpartum (mHIPP)|"Those assigned to the usual home visiting plus comparison group, called maintain health in pregnancy and postpartum (mHIPP), will receive the typical, evidence-based experience in participants' home visiting program in addition to the participants' usual prenatal and postpartum care clinical services. In addition, the investigators will provide a brief (less than 5 minutes) maternal warning signs educational video that is available in English or Spanish. The video was developed for a home visiting client audience and is publicly available, https://mdmom.org/warningsigns."
62139221|NCT00895609|EXPERIMENTAL|Sugammadex|Sugammadex in doses: 0 (placebo), 0.0625, 0.125, 0.25, 0.5 and 1 mg/kg
62139222|NCT00895609|ACTIVE_COMPARATOR|Neostigmine|Neostigmine in doses: 0 (placebo), 5, 8, 15, 25, 40 mg/kg
62139223|NCT01160354|EXPERIMENTAL|Plerixafor 240 mcg/kg + Clofarabine|"Plerixafor 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before hour IV administration of Clofarabine fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).~Phase II: Plerixafor at the highest dose tolerated in Phase I.~Plerixafor was dose-escalated in a 3+3 design, starting at 240 mcg/kg, and proceeding to dose levels of 320 mcg/kg, and 400 mcg/kg."
62139224|NCT01262963|EXPERIMENTAL|Study Medication|GSK2118436 suspension
62139225|NCT02457806|EXPERIMENTAL|Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart
62696700|NCT05103332|EXPERIMENTAL|Zilebesiran (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period. Upon implementation of Amendment 3, the OLE period will be closed and participants will not receive any further treatment with zilebesiran in the OLE period.
62696701|NCT05103332|PLACEBO_COMPARATOR|Placebo (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period. Upon implementation of Amendment 3, the OLE period will be closed and participants will not receive any further treatment with zilebesiran in the OLE period.
61943616|NCT05661409|ACTIVE_COMPARATOR|Sugammadex 2 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
62139226|NCT02457806|ACTIVE_COMPARATOR|Kovacaine Mist and Placebo|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart
62139227|NCT02457806|ACTIVE_COMPARATOR|Placebo and Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart
62139228|NCT02457806|PLACEBO_COMPARATOR|Placebo spray|3 sprays of placebo in each nostril administered 4 minutes apart
62139229|NCT01611337|OTHER|insight evaluation|insight evaluation using the Q8 scale
62139230|NCT03357926||Observation Group|
62139231|NCT04621435|EXPERIMENTAL|CLOSED - 68Ga-Dosimetry population (Cohort 1a)|PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if clinically indicated.
62139232|NCT04621435|EXPERIMENTAL|CLOSED - 64Cu-Dosimetry population (Cohort 1b)|PET imaging will begin 60±15 minutes, 240±30 minutes after injection,and 24±2 hours after injection of 64Cu-FAP-2286. Contrast may be administered if clinically indicated.
62338780|NCT03052842|PLACEBO_COMPARATOR|Arm 1B: 9.2 mg Placebo|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
62139233|NCT04621435|EXPERIMENTAL|Participants with metastatic disease (Cohort 2)|Participants with metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if clinically indicated.
62338781|NCT03052842|EXPERIMENTAL|Arm 2A: 18.4 mg C16G2|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
62338782|NCT03052842|PLACEBO_COMPARATOR|Arm 2B: 18.4 mg Placebo|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
62338783|NCT03052842|EXPERIMENTAL|Arm 3A: 36.8 mg C16G2|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
62338784|NCT03052842|PLACEBO_COMPARATOR|Arm 3B: 36.8 mg Placebo|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
62139234|NCT04621435|EXPERIMENTAL|Participants without metastatic disease (Cohort 3)|Participants without metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if if clinically indicated.
62338785|NCT04183699|EXPERIMENTAL|MRI targeted + systematic random biopsy|
62338786|NCT06364982||Inter-implant distance ≤ 3mm|Presence of an inter-implant distance ≤ 3mm
62338787|NCT06364982||Inter-implant distance ≥ 3mm|Presence of an inter-implant distance ≥ 3mm
62338788|NCT05970744|EXPERIMENTAL|RSV/Flu-01E low dose 18-59|Participants aged 18 to 59 years will receive single injection of low dose RSV/Flu-01E Vaccine
62338789|NCT05970744|EXPERIMENTAL|RSV/Flu-01E high dose 18-59|Participants aged 18 to 59 years will receive single injection of high dose RSV/Flu-01E Vaccine
62338790|NCT05970744|PLACEBO_COMPARATOR|Placebo 18-59|Participants aged 18 to 59 years will receive single injection of Placebo
62338791|NCT05970744|EXPERIMENTAL|RSV/Flu-01E high dose over 60|Participants aged over 60 years will receive single injection of high dose RSV/Flu-01E Vaccine
62338792|NCT05970744|PLACEBO_COMPARATOR|Placebo over 60|Participants aged over 60 years will receive single injection of Placebo
62338793|NCT02858154|OTHER|HFNC and low flow oxygen by nasal cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (low flow oxygen by nasal cannula)
62139235|NCT01083134||percentage of stenosis|
62139236|NCT01223924|EXPERIMENTAL|M2ES 7.5-90mg|M2ES dose escalating
62139237|NCT01223924|PLACEBO_COMPARATOR|Placebo|placebo contract
62139238|NCT04611334|EXPERIMENTAL|experimental group|HRV biofeedback
62139239|NCT04611334|NO_INTERVENTION|control group|routine care
62338794|NCT05583981||Observational (interview)|Participants participate in interview over 30-60 minutes.
62139240|NCT01591694||FamilyLive|Families with a history of intergenerational trauma (maltreatment, violence exposure, domestic violence, substance abuse, etc.)
62139241|NCT01591694||Yoga Based Psychotherapy|Children with a history of maltreatment and/or violence exposure
62139242|NCT01591694||Biofeedback|Children with a history of maltreatment and violence exposure and their caregivers
62338795|NCT04813159|ACTIVE_COMPARATOR|Remote Ischaemic Conditioning (RIC)|Consented STEMI participants presenting \< 24 hours who are randomised to the RIC protocol, will receive blood pressure cuff inflation by the automated RIC blood pressure device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
62338796|NCT04813159|SHAM_COMPARATOR|Sham-control|Consented STEMI participants presenting \< 24 hours who are randomised to the sham protocol will receive low-pressure cuff inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff. The sham control protocol will be repeated daily for the next 2 days.
62338797|NCT04813159|NO_INTERVENTION|Observational|Consented STEMI participants presenting \> 24 hours but within 72 hours of MI onset will be recruited into the observational arm of the study which will have the same study endpoints as the RCT. These participants will not be randomised or receive any trial intervention.
62495417|NCT03368391|OTHER|Sequence 1|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 1 participants will receive the drugs in the following sequence: 1) tetracaine HCl and oxymetazoline HCl 2) 3% mepivacaine 3) 2% lidocaine with 1:100,000 epi"
61943617|NCT05661409|EXPERIMENTAL|Sugammadex 1 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
61943618|NCT05661409|EXPERIMENTAL|Sugammadex 0.5 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
62139243|NCT01591694||TST-SA|Trauma Systems Therapy for Adolescent Substance Abuse
62139244|NCT06334666|EXPERIMENTAL|Active Comparator: Encourage using pedometer group.|MASLD patient who received pedometer recording and was encouraged to use actively.
62139245|NCT06334666|NO_INTERVENTION|Placebo comparator: Discourage using pedometer group|MASLD patient who received pedometer recording but without encouraged to use.
62139246|NCT05484661|EXPERIMENTAL|Exercise + BCAA|Exercise will include a 3x/wk for eight weeks exercise protocol is designed to provide a high-volume, moderate-intensity whole body training stimulus. BCAA will include \~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
62139247|NCT05484661|PLACEBO_COMPARATOR|Exercise + Placebo|Exercise will include a 3x/wk for eight weeks exercise protocol is designed to provide a high-volume, moderate-intensity whole body training stimulus. Placebo will include \~7-10 g of maltodextrin (100 mg/kg) daily for eight weeks.
62139248|NCT01420497|ACTIVE_COMPARATOR|methylprednisolone,infiltration|
62338798|NCT05273008||Active hockey players|Observational study on 180 Hockey players
62338799|NCT04650958|ACTIVE_COMPARATOR|STN DBS stimulation group|In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts). If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.
62139249|NCT01420497|ACTIVE_COMPARATOR|epidural injection|
62139250|NCT05365191|OTHER|Multispectral near infrared imaging|The participants will be assigned to one single arm that accepted both near infrared zone I and near infrared zone II imaging during the near infrared fluorescence navigated sentinel lymph node biopsy procedure. Imaging quality will be compared between different spectrums.
62139251|NCT04003259|EXPERIMENTAL|Overweight and obese subjects|1-year lifestyle programme
62139252|NCT03812874|EXPERIMENTAL|PTX-9908 Injection group|IV injection.
62338800|NCT04650958|SHAM_COMPARATOR|Sham stimulation group|In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation. After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.
62338801|NCT03420716|EXPERIMENTAL|functional yogurt|Participants are given the symbiotic yogurt daily (180 ml)
62495418|NCT03368391|OTHER|Sequence 2|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 2 participant will receive the drugs in the following sequence: 1) 2% lidocaine with 1:100,000 epi 2) tetracaine HCl and oxymetazoline HCl 3) 3% mepivacaine"
62139253|NCT03812874|PLACEBO_COMPARATOR|Placebo/Vehicle group|IV injection
62139254|NCT00262782|EXPERIMENTAL|Fludarabine|
62495419|NCT03368391|OTHER|Sequence 3|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 3 participants will receive the drugs in the following sequence: 1) 3% mepivacaine 2) 2% lidocaine with 1:100,000 epi 3) tetracaine HCl and oxymetazoline HCl"
62495420|NCT00222040|EXPERIMENTAL|1|Levovist
62495421|NCT00222040|NO_INTERVENTION|2|No specific intervention
62495422|NCT01390948|EXPERIMENTAL|Bevacizumab + TMZ Young Patient Cohort (YPC)|Participants aged greater than or equal to (\>/=) 6 months and less than (\<) 3 years will receive 10 milligrams per kilogram (mg/kg) Bevacizumab every 2 weeks and 150 to 200 milligrams per meter squared (mg/m\^2) of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m\^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m\^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
62495423|NCT01390948|EXPERIMENTAL|Main Cohort: Chemoradiation + Bevacizumab + TMZ|Participants will receive a total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m\^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m\^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m\^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m\^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle. Bevacizumab will be given concomitantly at a dose of 10 mg/kg every 2 weeks throughout the entire treatment period.
62495424|NCT01390948|ACTIVE_COMPARATOR|Main Cohort: Chemoradiation + TMZ|Participants will receive a total dose of 54 Gy units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m\^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m\^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m\^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m\^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
62495425|NCT04840355||Subjects with no irAEs|
62495426|NCT04840355||Subjects with degree 1-2 irAEs|
62495427|NCT04840355||Subjects with degree 3-4 irAEs|
62495428|NCT00522223||Questionnaire|Questionnaire
62495429|NCT02156453||Total knee arthroplasty|Patients undergoing uncomplicated total knee replacement
62495430|NCT03417427|ACTIVE_COMPARATOR|Decitabine and Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive decitabine (15mg/m2 d1-5) combined with high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
62495431|NCT03417427|PLACEBO_COMPARATOR|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
62495432|NCT00588783||1|
62495433|NCT00588783||2|
62495434|NCT01841060|EXPERIMENTAL|Radiofrequency ablathermy|Percutaneous radiofrequency ablation (RFA)
62495435|NCT05682963|ACTIVE_COMPARATOR|Square-Stepping Exercise Program Group|Square stepping exercise is performed on a thin exercise mat divided into 40 small squares of 250 cm x 100 cm. Participants practice a set of step patterns on the mat. Square step exercises are a low-cost, highly accessible and fun exercise method. It is known that it improves motor performance and muscle strength in healthy young individuals, and has positive effects on functional fitness and gait parameters in individuals with osteoarthritis. It is known to have positive effects on balance, fall risk, walking ability, physical and cognitive function in elderly individuals. It will be applied to examine the effects on mobility, balance and position sense in individuals with multiple sclerosis.
62139255|NCT00262782|NO_INTERVENTION|watch & wait|
62139256|NCT02652585|ACTIVE_COMPARATOR|Naltrexone|"1 capsule naltrexone 25 mg per day, oral use, day 1 to day 3;~1 capsule naltrexone 50 mg per day, oral use, day 4 to day 28"
62139257|NCT02652585|PLACEBO_COMPARATOR|Placebo|1 capsule placebo, oral use, day 1 to day 28
62338802|NCT03420716|EXPERIMENTAL|control yogurt|Participants are given the control yogurt daily (180 ml)
62338803|NCT03209635|PLACEBO_COMPARATOR|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
62495436|NCT05682963|ACTIVE_COMPARATOR|Home Exercise Program Group|The home exercise program group will implement a protocol of frenkel's coordination exercises developed for balance and coordination therapy. The exercise protocol, which includes frenkel's coordination exercises, will be delivered to the patient in the form of a brochure and in the form of a Compact Disc (CD) with video images.
62495437|NCT00869713|OTHER|primary vaccination with boost|Inactivated, Dried (TSI-GSD 200), RVF Vaccine
62495438|NCT01573819|EXPERIMENTAL|Cohort 1|A dose of 2mg per day for 10 days
62696702|NCT05103332|PLACEBO_COMPARATOR|Zilebesiran (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period. Upon implementation of Amendment 3, the OLE period will be closed and participants will not receive any further treatment with zilebesiran in the OLE period.
62338804|NCT03209635|EXPERIMENTAL|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
62338805|NCT02790671|EXPERIMENTAL|single study arm|DS-8500a and itraconazole
62338806|NCT05608317|EXPERIMENTAL|Supportive Care with Non-Bordered Foam Dressing|All Subjects will use a non-bordered foam dressing as the absorbent primary dressing.
62139258|NCT01368744||OSNA Breast Cancer System|
62139259|NCT05467813|EXPERIMENTAL|clinic-setting MT preceding AR-first group|In the experimental group, the participants will receive clinic-based rehabilitation first. After a 3-week washout period, the participants will receive home-based rehabilitation.
62338807|NCT00670397|EXPERIMENTAL|Treatment (PDT)|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62139260|NCT05467813|ACTIVE_COMPARATOR|home-based MT preceding AR-first group|The comparison group will receive home-based rehabilitation first. After a 3-week washout period, the participants will receive clinic-based rehabilitation.
62139261|NCT05467813|ACTIVE_COMPARATOR|clinic-setting MT preceding conventional therapy group|The control group will receive clinic-based rehabilitation first. After a 3-week washout period, the participants will receive clinic-based rehabilitation.
62139262|NCT03978728||ECMO patients|Patients with ECMO support
62139263|NCT03951142|EXPERIMENTAL|Study A: Recurrent glioblastoma (denoted 'AR')|"Patients with recurrent glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 12 cycles will be administered for a total of 6 weeks (42 days) to 24 weeks (168 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy (temozolomide or lomustine tablets)."
62139264|NCT03951142|EXPERIMENTAL|Study A: Newly diagnosed glioblastoma (denoted 'AN')|"Patients with newly diagnosed glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 17 cycles will be administered for a total of 6 weeks (42 days) to 34 weeks (238 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving adjuvant chemotherapy (Temozolomide tablets)."
62139265|NCT03951142|EXPERIMENTAL|Study B: Brain metastases (denoted 'BM')|"Patients with brain cancer from non-small cell lung cancer (N=45) with all receive a dose of 50mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 3 months (90 consecutive days) defined as a treatment cycle. A minimum of one cycle and a maximum of three cycles will be administered for a total of 3 months (90 days) to 9 months (270 days), respectively.~A stepped-wedge randomized design (ratio 1:1:1 over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy alone (carboplatin in combination with vinorelbin or pemetrexed or equivalent analogs) or in combination with pembrolizumab (2mg/kg/3rd week)."
62139266|NCT02463994|EXPERIMENTAL|MPDL3280A + HIGRT|
62139267|NCT02022800|OTHER|PET 18FDOPA|PET 18FDOPA
62139268|NCT00862043|EXPERIMENTAL|Sildenafil Citrate|Sildenafil Citrate 40 mg t.i.d. oral
62139269|NCT00862043|PLACEBO_COMPARATOR|Placebo|Sildenafil-matched oral placebo 40 mg t.i.d
62139270|NCT00354237|OTHER|B|No intensive treatment
62139271|NCT00354237|EXPERIMENTAL|A|Intensive insulin treatment
62139272|NCT05912738||PHN Patients (Self-Controlled Design)|This cohort comprises the affected and unaffected side muscles in postherpetic neuralgia (PHN) patients. These muscles will undergo elasticity ultrasound assessment at baseline and post-treatment. Additionally, muscle biopsies will be performed at specific time points during the treatment period, including during interventional therapy, to analyze pathological changes and elucidate the treatment's pathophysiological effects on the affected muscles.
62139273|NCT05302076|EXPERIMENTAL|electric current|Electric current will be applied in this group of patients using removable device.
62139274|NCT05302076|ACTIVE_COMPARATOR|Traditional treatment|No acceleration method will be performed in this group.
62139275|NCT02347332|EXPERIMENTAL|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
62139276|NCT02347332|ACTIVE_COMPARATOR|Methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
62338808|NCT05971004|EXPERIMENTAL|Collagen Peptide Group|The Collagen Peptide Group (31 patients) received oral pain relievers (paracetamol and anti-inflammatory NSAIDs) for 3-7 days (if the pain was severe) and one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point (femoral condyle).
62338809|NCT05971004|ACTIVE_COMPARATOR|Cortison Group|The Cortison Group (31 patients) received oral painkillers (paracetamol and anti-inflammatory NSAIDs) for 3-7 days (if the pain was severe) and one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
62139277|NCT02500147|EXPERIMENTAL|Metformin|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
62139278|NCT02500147|PLACEBO_COMPARATOR|Placebo|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Subjects randomized to placebo will be instructed to take one pill daily by mouth for one week and then to take one pill daily by mouth for the remainder of six months.
62139279|NCT05676346||LUTS|Patients with lower urinary tract symptoms with CACV \> 3 and/or IPSS \> 7.
62338810|NCT00579501|EXPERIMENTAL|Trabectedin|Trabectedin at a dose of 1.5 milligram per meter square (mg/m\^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.
62338811|NCT05989490|EXPERIMENTAL|Static stretching to the point of pain|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of pain.
62495439|NCT01573819|EXPERIMENTAL|Cohort 2|A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg
62495440|NCT01573819|EXPERIMENTAL|Cohort 3|a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
62495441|NCT05606328|EXPERIMENTAL|Implementation Period|ED leadership at each site will identify 5-10 delirium champions (nurse educators and managers, bedside nurses) based on their interest in delirium and commitment to program participation, including training of nurses by champions. The implementation period will take place over a period of 3 months. No data analysis will take place during the implementation period.
62495442|NCT05606328|NO_INTERVENTION|Intervention Period|The intervention period will take place 3-9 months after implementation of the ED-DDP program over a 15 month period, depending on when a site is randomized to receive the ED-DDP intervention.
62495443|NCT02028416|ACTIVE_COMPARATOR|ATG-Fresenius 3 Days|In one group Injection ATG-Fresenius will be given @ 10mg/kg will be given for 3 days along with Capsule Cyclosporin 5mg/kg for 6 months followed by very slow tapering of dose
62495444|NCT02028416|EXPERIMENTAL|ATG-Fresenius 5 Days|In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
62495445|NCT00474188|EXPERIMENTAL|Single Arm|
62495446|NCT02664350|EXPERIMENTAL|Genotype Arm|Participants in this arm will have genotyping performed for CYP2D6 variants. Based on the CYP2D6 the treating physicians will be provided with an interpretation of genotype results, and a recommendation will be provided by a pharmacist on the UF Health Personalized Medicine team through one-on-one consultation with the physician for the type of pain medication. These participants will also be genotyped for OPRM1 variants at the end of the study which is performed for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
62495447|NCT02664350|ACTIVE_COMPARATOR|Traditional Arm|Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
62495448|NCT03478007|NO_INTERVENTION|Usual Treatment|Usual standard of care (exercises)
62495449|NCT03478007|EXPERIMENTAL|Intervention Technology Only|Exercises with technology alone
62495450|NCT03478007|EXPERIMENTAL|Intervention Technology Plus Coaching|Exercises with technology plus coaching
62495451|NCT04301817||Prone position|Patients undergoing surgery in prone position
62696703|NCT05103332|PLACEBO_COMPARATOR|Placebo (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period. Upon implementation of Amendment 3, the OLE period will be closed and participants will not receive any further treatment with zilebesiran in the OLE period.
61943619|NCT05661409|EXPERIMENTAL|Sugammadex 0.25 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
61943620|NCT05661409|EXPERIMENTAL|Sugammadex 0.125 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
62139280|NCT04389385|EXPERIMENTAL|COVID-19 STCs -Exo therapy|"In addition to the best available treatment, participants will receive inhaler COVID-19 STCs -Exo therapy \*.~Biological: Inhaler CSTH-Exo treatment will be applied daily x 5 times (2.0 x 108 nano vesicle / 3 ml; on day 1 to day 5).~\* If the improvement contribution is observed in the parameters, this application period could be extended"
62495452|NCT06103760|OTHER|Participants with Major Depressive Disorder|Intranasal esketamine to be self-administered by participants under direct supervision of a healthcare professional. First initial dose is 56mg and subsequent doses will be 56mg or 84mg. Esketamine will be administered twice weekly for weeks 1-4, once weekly for weeks 5-8, and once weekly/once fortnightly/once monthly as clinically indicated for weeks 9-25. After each treatment phase, participants will be re-assessed through a comprehensive battery of assessments and dose adjustments will be performed by the study psychiatrist base on tolerability, treatment response, and ongoing consent.
62495453|NCT04793633||Patients at increased risk for developing pancreatic cancer|Patients being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes) or have signs or symptoms of disease and are undergoing other imaging diagnostic tests to determine if they have pancreatic cancer
62495454|NCT00493883|OTHER|TheraSphere|"Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver~--------------------------------------------------------------------------------"
62495455|NCT02399891||Retrospective|MI prior to December 11, 2011
62495456|NCT02399891||Prospective|MI on or after December 11, 2011
62495457|NCT03318289|EXPERIMENTAL|Ving Tsun (VT) group|Participants in the VT group will receive VT exercise intervention for 12 weeks.
62495458|NCT03318289|NO_INTERVENTION|Control group|No intervention but can continue daily activities.
62495459|NCT04618172|EXPERIMENTAL|Exercising group|This group practises 30 minute long exercises twice a week besides filling out the questionnaires.
62495460|NCT04618172|NO_INTERVENTION|Control group|This group fills out the questionnaires without practising 30 minute long exercises twice a week.
62495461|NCT04600739||AVD Patients|Patients suffering from aortic valve stenosis receiving replacement of the diseased valve using a TAVI procedure.
62495462|NCT00509301|EXPERIMENTAL|1|1.5 mCi/cc
62495463|NCT00509301|EXPERIMENTAL|2|2.0 mCi/cc
62495464|NCT00509301|EXPERIMENTAL|3|2.5 mCi/cc
62696704|NCT06645444|ACTIVE_COMPARATOR|immediate implant placement with customized composite healing abutment|"* extraction of the Posterior teeth will be done with minimally invasive technique using periotome.~* Then, the digital surgical guide will be placed, and will be checked the affinity of the reference window with other teeth accurately in the optimal position. The osteotomies will be prepared with a surgical-guided surgery kit through a digital surgical guide and drill direction will be ensured by radiographic taking. Implant fixture insertion will be performed through this digital surgical guide.~* All patients will receive a bone-level implant with varying diameter and length in each case. After implant placement, the operator will scan the surrounding gingiva with a scan body immediately for a post-extraction digital model.~* Then the spaces between the implant fixture and alveolar bone wall will be filled with locally harvested autogenous bone and xenograft grafting material (OsteoBiol Gen-Os, Sweden)."
61943621|NCT05661409|PLACEBO_COMPARATOR|Placebo|The inclusion of a placebo group would allow the study team to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
62338812|NCT05989490|EXPERIMENTAL|Static stretching to the point of discomfort|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort.
62495465|NCT05198973|EXPERIMENTAL|Bumblebee Breath group|Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face. this group will be 28 patients to receive half an hour daily for ( 1 month)
62495466|NCT05198973|NO_INTERVENTION|control group|this group (28 patients) will receive no training
62495467|NCT04795245||patients treated with afatinib|
62495468|NCT01134822||Idiopathic pulmonary fibrosis (IPF)|
61943622|NCT06679946|EXPERIMENTAL|Vutrisiran 25 mg|Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M).
61943623|NCT03172819|EXPERIMENTAL|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
62338813|NCT00663455|OTHER|A|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
62338814|NCT00663455|NO_INTERVENTION|B|Standard CSA-dosing without reduction. Therapy control by C2-monitoring.
62338815|NCT00740883|ACTIVE_COMPARATOR|1|18 months of active warfarin therapy
62495469|NCT04153825|ACTIVE_COMPARATOR|Active TENS Group|Ten sessions of active conventional TENS and hydrocollator hot-pack.
62495470|NCT04153825|ACTIVE_COMPARATOR|Active IFC Group|Ten sessions of active interferential current and hydrocollator hot-pack.
62495471|NCT04153825|SHAM_COMPARATOR|Sham TENS Group|Ten sessions of sham TENS and hydrocollator hot-pack.
62495472|NCT04153825|SHAM_COMPARATOR|Sham IFC Group|Ten sessions of sham IFC and hydrocollator hot-pack.
62495473|NCT04540211|EXPERIMENTAL|Atezolizumab + Tiragolumab + PC|Participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
62495474|NCT04540211|PLACEBO_COMPARATOR|Placebo + PC|Participants will receive atezolizumab matching placebo and tiragolumab matching placebo on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
62495475|NCT06527547|EXPERIMENTAL|taVNS Group|Using the Huatuo Electronic Acupuncture Treatment Instrument (Model SDZ-IIB, Suzhou Medical Appliance Factory Co., Ltd.) for auricular vagus nerve stimulation, place the electrostimulating ear clip on the concha area where the auricular branch of the vagus nerve is located. Set the pulse type to intermittent waves, with a frequency of 20Hz; pulse width to 0.2ms ± 30%; and current ≤ 50mA (500Ω load impedance). The intensity should be at a tolerable level and not cause pain. Under the guidance of a professional physician, the patient learns how to operate the acupuncture device, and then take it home for treatment. The treatment is performed twice daily, once in the morning and once in the evening, treating both ears simultaneously for 30 minutes each session. This treatment is conducted 5 days a week with a 2-day rest period, for a total of 4 weeks.
62495476|NCT06527547|PLACEBO_COMPARATOR|Sham Stimulation Group|Using the Huatuo Electronic Acupuncture Treatment Instrument (Model SDZ-IIB, Suzhou Medical Appliance Factory Co., Ltd.). Place the sham stimulation ear clip on the scaphoid fossa, an area without the distribution of the auricular branch of the vagus nerve. Set the pulse frequency to dense-dispersed waves, with a frequency of 20Hz; pulse width to 0.2ms ± 30%; and current ≤ 50mA (500Ω load impedance). The intensity should be at a tolerable level and not cause pain. Under the guidance of a professional physician, the patient learns how to operate the acupuncture device and then takes it home for treatment. The treatment is performed twice daily, once in the morning and once in the evening, treating both ears simultaneously for 30 minutes each session. This treatment is conducted 5 days a week with a 2-day rest period, for a total of 4 weeks.
62495477|NCT01195220|ACTIVE_COMPARATOR|HIV-T|"Group 1, the control, will be the current standard of care, consenting video and testing for HIV alone (HIV-T).~This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test"
62495478|NCT01195220|EXPERIMENTAL|STI/HIV-T|"Group 2 will add routine STI testing for CT and GC, (STI/HIV-T).~This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED."
62495479|NCT01195220|EXPERIMENTAL|STI/HIV-Plus|"Group 3, in addition to combined STI/HIV testing, will add a behavioral video encouraging safer sex, which is chosen for participants based on their answers to a brief measure on stage of change (STI/HIV-PLUS).~This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes"
62338816|NCT00740883|PLACEBO_COMPARATOR|2|18 months of placebo of warfarin
62495480|NCT03310593|EXPERIMENTAL|Cannabidiol|Cannabidiol 150-300mg per day for 12 weeks.
62495481|NCT03310593|PLACEBO_COMPARATOR|Placebo|Cannabidiol comparator for 12 weeks.
62495482|NCT00999284|PLACEBO_COMPARATOR|Placebo|Sham infusion of sodium chloride 0.9%
62495483|NCT00999284|ACTIVE_COMPARATOR|Low dose arm|Infusion of 0.3 mg/kg/h ZK200775 over 4 hours
62495484|NCT00999284|ACTIVE_COMPARATOR|High dose arm|Infusion of 0.75 mg/kg/h ZK200775 over 4 hours
62495485|NCT05493358||Open distal gastrectomy|An incision of 15\~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth I, Billroth II or Roux en Y method was used for gastric reconstruction.
62495486|NCT05493358||Laparoscopic distal gastrectomy|"5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.~The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6.~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.~The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7.~The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3.~As a general rule, Billroth I, Billroth II or Roux en Y method was used for gastric reconstruction."
62495487|NCT03595241|EXPERIMENTAL|Group A - active treatment|
62495488|NCT03595241|NO_INTERVENTION|Group B - conservative management|
62495489|NCT03467737|EXPERIMENTAL|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
62338817|NCT02526758|EXPERIMENTAL|beclomethasone / formoterol|beclomethasone 100ug and formoterol 6ug , 2 inhalations, twice daily ,for three months
62338818|NCT02526758|ACTIVE_COMPARATOR|budesonide / formoterol|budesonide 160ug and formoterol 4.5ug, 2 inhalations ,twice daily ,for three month
62338819|NCT01374776|EXPERIMENTAL|intravenous iron carboxymaltose|intravenous iron carboxymaltose infusion
62338820|NCT04435145|EXPERIMENTAL|Intervention|Sugar-sweetened beverage warning label
62495490|NCT03467737|EXPERIMENTAL|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
62495491|NCT03467737|EXPERIMENTAL|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
61943624|NCT05247593||Dayingpian exposure group 1|The exposure of interest is Dayingpian. Patients in this group take Dayingpian combined with conventional mood stabilizers. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
62495492|NCT03467737|EXPERIMENTAL|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
62495493|NCT03467737|EXPERIMENTAL|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
62495494|NCT03467737|EXPERIMENTAL|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
62139281|NCT03861052|EXPERIMENTAL|5 mg Tirzepatide|Participants received 5 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 52 weeks.
62139282|NCT03861052|EXPERIMENTAL|10 mg Tirzepatide|Participants received 10 mg tirzepatide administered SC once weekly for 52 weeks.
62338821|NCT04435145|NO_INTERVENTION|Control|No label
62338822|NCT02723604|EXPERIMENTAL|Experimental: Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
62338823|NCT03231085|ACTIVE_COMPARATOR|Ferrous fumarate or ferrostrane|"The oral treatment should begin 21 days before surgery.~Recommended Dosage ferrous fumarate according to the SPC in force:~* 5 to 8 kg: 2 cd rases / d or 200mg of ferrous fumarate~* 8 to 10 kg: 3 cd rases / d or 300mg of ferrous fumarate~* 10 to 12kg: 4 cd rases / d or 400mg of ferrous fumarate~Ferrostrane ® (syrup) Laboratory TEOFARMA SRL Either 34mg of iron per teaspoon~Recommended dosage according to the SPC in force:~* Infant 5 to 8 kg (about 1 to 6 months): 2 teaspoons a day,~* Infant from 8 to 12 kg (about 6 to 30 months): 3 teaspoons a day."
62139283|NCT03861052|EXPERIMENTAL|15 mg Tirzepatide|Participants received 15 mg tirzepatide administered SC once weekly for 52 weeks.
62139284|NCT03861052|ACTIVE_COMPARATOR|0.75 mg Dulaglutide|Participants received 0.75 mg dulaglutide administered SC once weekly for 52 weeks.
62139285|NCT03018067|PLACEBO_COMPARATOR|Placebo|Microcrystalline Cellulose (MCC), 2 g qd. Subjects assigned to the Placebo group will be randomly assigned in a 1:1:1 ratio to receive either one, two, or three bottles of drug per day.
62139286|NCT03018067|EXPERIMENTAL|10 g qd|RDX227675, 10 g qd
62139287|NCT03018067|EXPERIMENTAL|20 g qd|RDX227675, 20 g qd
62139288|NCT03018067|EXPERIMENTAL|30 g qd|RDX227675, 30 g qd
62139289|NCT04797468|EXPERIMENTAL|HLX23|HLX23 administered IV.
62139290|NCT05282966||Prospective Cohort with QSant Testing|2,000 participants will be enrolled across sites within 90-days post-kidney transplant and followed for 24-months
62139291|NCT05282966||Retrospective Control Cohort without QSant Testing|2,000 site-matched controls from UNOS database who underwent a kidney transplant no more than 5 years prior to the study completion date
62139292|NCT06575725|EXPERIMENTAL|Arm BB (botensilimab, balstilimab)|Patients receive botensilimab IV over 60 minutes on day 1 of each cycle and balstilimab IV over 30 minutes on days 1, 15, and 29 of each cycle. Cycles repeat every 42 days for up to 2 cycles of botensilimab and up to 2 years of balstilimab in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and blood sample collection throughout the trial. Patients also undergo tumor biopsy during screening and on study.
62139293|NCT06575725|EXPERIMENTAL|Arm BBR (botensilimab, balstilimab, regorafenib)|Patients receive botensilimab IV over 60 minutes on day 1 of each cycle, balstilimab IV over 30 minutes on days 1, 15, and 29 of each cycle, and regorafenib PO QD on days 1-7, 15-21, and 29-35 of each cycle or on days 1-5, 15-19, and 29-33 of each cycle. Cycles repeat every 42 days for up to 2 cycles of botensilimab and up to 2 years of balstilimab and regorafenib in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and blood sample collection throughout the trial. Patients also undergo tumor biopsy during screening and on study.
62139294|NCT03204357|EXPERIMENTAL|Fresh Autologous whole blood transfusion|The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
62139295|NCT03204357|ACTIVE_COMPARATOR|Standard of Care Expectant Management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
62338824|NCT03231085|EXPERIMENTAL|Ferric carboxymaltose|The single intravenous treatment the day of the inclusion. Dosage according to: 15mg / kg iron (to dilute in 3 ml / kg of Nacl 0.9% (SSI), to pass in 15 minutes.
62338825|NCT03412474|ACTIVE_COMPARATOR|Bupivacaine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).
62338826|NCT03412474|ACTIVE_COMPARATOR|Dexmedetomidine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
62495495|NCT04011787|ACTIVE_COMPARATOR|Intervention|bolus NGT feeding
62139296|NCT05835375|ACTIVE_COMPARATOR|EQ-778|"1. capsule to be taken daily after breakfast (in case no URTI episode)~2. capsules to be taken daily after breakfast (in case of URTI episode)"
62139297|NCT05835375|PLACEBO_COMPARATOR|Placebo|"1. capsule to be taken daily after breakfast (in case no URTI episode)~2. capsules to be taken daily after breakfast (in case of URTI episode)"
62139298|NCT06699316|NO_INTERVENTION|Cohort 1|Current general counselling on life expectancy
62139299|NCT06699316|EXPERIMENTAL|Cohort 2|Individualized prognostic counselling on life expectancy
62139300|NCT01758549|EXPERIMENTAL|Aggressive Intravenous Hydration Group|Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.
62139301|NCT01758549|ACTIVE_COMPARATOR|Standard Fluids Arm|Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.
62139302|NCT05288959|EXPERIMENTAL|Healthy participants|"All participants participate in five core sessions. Session 1 consists of MRI scans (T1-weighted, T2-weighted, diffusion MRI, resting-state fMRI). Thereafter, there are four TMS-EEG sessions. Session 2 delivers uni-focal spTMS to various cortical targets while EEG is recorded to determine inter-regional conduction delays. Thereafter, Sessions 3 - 5 deliver bi-focal TMS (PAS), each session using a different asynchrony (shorter, equal to, or longer than the conduction delay). The three PAS sessions are at least one week apart. Each of the PAS sessions have three segments: (a) TMS-EEG-behavioral recordings before PAS, (b) the PAS modulation, and (c) TMS-EEG-behavioral recordings after PAS.~In addition to these core sessions, some participants may be invited for additional sessions for parameter optimization and for assessing test-retest repeatability."
62139303|NCT02148705|EXPERIMENTAL|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (\~ surface of an adult palm) for four hours.
62139304|NCT02148705|PLACEBO_COMPARATOR|Gel Vehicle|Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (\~ surface of an adult palm) for four hours.
62338827|NCT04669041|EXPERIMENTAL|Single pill combination (SPC)|Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks
62338828|NCT04669041|ACTIVE_COMPARATOR|Rosuvastatin|Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks
62338829|NCT04058054|EXPERIMENTAL|KeraStat® Cream|KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.
62495496|NCT04011787|OTHER|Control|Continuous NGT feeding (standard care)
62338830|NCT04058054|EXPERIMENTAL|KeraStat® Gel|KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.
62338831|NCT04058054|EXPERIMENTAL|Biafine|Wound dressing for management of partial and full thickness wounds.
62338832|NCT04058054|ACTIVE_COMPARATOR|Histamine|Histamine is provided as a solution of histamine base (6.0 mg/mL).
62696705|NCT06645444|EXPERIMENTAL|immediate implant placement with customized PEEK healing abutment|"* an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery."
62696706|NCT06638684|ACTIVE_COMPARATOR|Moderate intensity exercise|Subjects will participate in a 100 min bout of exercise led by an exercise physiologist doing the same exercises as the high-intensity group, but at a lower effort level. Exercise consists of of a mix of running activities (≤ 400 m); body weight exercises, such as burpees and lunges; and exercises, such as crunches and squats utilizing 20.4 kg weight plates, but performed at a pace allowing for in-session recovery. Scheduled 5 min rests will be included at 30, 60, and 85 min and MI subjects will be similarly encouraged to consume water and/or the carbohydrate/electrolyte drink. The researchers will obtain a blood sample from you prior to and immediately following the exercise, as well as one, four and six hours post-exercise.
61943625|NCT05247593||Non-exposure group|The non-exposure group is the patients who do not take Dayingpian. Patients in this group take conventional mood stabilizers. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
61943626|NCT05247593||Dayingpian exposure group 2|The exposure of interest is Dayingpian. Patients in this group take Dayingpian as monotherapy for bipolar disorder. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
61943627|NCT02121626||Chemotheraphy Treatement|The study will be limited to NHS patients to reduce complications associated with the need for additional funding authorisations from private health care providers for algorithm-instigated investigations. It is not envisaged that participation in other studies running within the GI unit at The Royal Marsden Hospital will preclude entry into this study except in the event of those rare studies where the study is specifically measuring toxicity of treatment as the primary end point.
61943628|NCT03140228|EXPERIMENTAL|I-Gel group|I-gel will be used for maintenance of airway during general anaesthesia
61943629|NCT03140228|ACTIVE_COMPARATOR|LMA ambu auraonce group|LMA ambu auraonce will be used for maintenance of airway during general anaesthesia
61943630|NCT03109730|EXPERIMENTAL|Cohort B1|ABI-H0731 or Placebo in varying doses by mouth for 28 days
61943631|NCT03109730|EXPERIMENTAL|Cohort B2|ABI-H0731 or Placebo in varying doses by mouth for 28 days
61943632|NCT03109730|EXPERIMENTAL|Cohort B3|ABI-H0731 or Placebo in varying doses by mouth for 28 days
61943633|NCT03109730|EXPERIMENTAL|Cohort B4|ABI-H0731 or Placebo in varying doses by mouth for 28 days
61943634|NCT03109730|EXPERIMENTAL|Cohort B5|ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days
62139305|NCT02148705|ACTIVE_COMPARATOR|Standard of Care (SOC)|Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.
62495497|NCT02293616|EXPERIMENTAL|Nitrate Rich|A nitrate rich beetroot juice supplement (Beet It Shot®, James White Drinks, UK) high in nitrates will be provided to the subjects. Subject's diet will be supplemented once daily while hospitalized up to 14 days with one 70 ml bottle containing 300 mg of dietary nitrate.
61943635|NCT03109730|EXPERIMENTAL|Cohort B6|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
61943636|NCT00357357|PLACEBO_COMPARATOR|Group1|4x 7 day rising dose
61943637|NCT00357357|PLACEBO_COMPARATOR|Group2|4x, 7 day rising dose
61943638|NCT00357357|PLACEBO_COMPARATOR|Group3|28 day fixed lower dose
61943639|NCT00357357|PLACEBO_COMPARATOR|Group4|28 day fixed upper dose
61943640|NCT04324619|EXPERIMENTAL|Immediate|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning immediately.
62338833|NCT04058054|SHAM_COMPARATOR|Saline|Saline (sterile) is provided as a 0.9% NaCl solution.
62338834|NCT02370355||Group I (retrospective analysis)|Previously collected plasma samples are analyzed for ctDNA via PCR and NSG.
62338835|NCT02370355||Group II (prospective analysis)|Patients undergo collection of blood samples before and following systemic therapy for analysis of CTC enumeration, RNA expression, and ctDNA via PCR and NSG.
62338836|NCT05834764|EXPERIMENTAL|Pyrotinib|pyrotinib 400mg orally daily for one year
62338837|NCT03179280|ACTIVE_COMPARATOR|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
62338838|NCT03179280|NO_INTERVENTION|Healthy adolescents|3 standard meals with varying composition were consumed
62338839|NCT02144558|EXPERIMENTAL|Spinal cord injured (SCI) men, para or tetraplegic|SCI men will have 4 medical visits associated to sperm retrieval (penile vibratory stimulation (PVS) or masturbation)
62338840|NCT06295016|NO_INTERVENTION|Regular training|Participants maintain their regular training habits for 3 weeks.
62338841|NCT06295016|EXPERIMENTAL|High-intensity intensive training|Participants increase their regular regular training volume by 10% each week for 3 weeks.
61943641|NCT04324619|EXPERIMENTAL|3 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 3 months.
62338842|NCT06295016|EXPERIMENTAL|Taper|Participants gradually reduced to 55% of their regular training volume for 1 week.
62338843|NCT04081597|EXPERIMENTAL|STAR-101|Doses in two of three crossover periods
62338844|NCT04081597|PLACEBO_COMPARATOR|Placebo|Matching placebo in one of three periods
62338845|NCT00783211|EXPERIMENTAL|1|desloratadine
62338846|NCT00783211|ACTIVE_COMPARATOR|2|fexofenadine
62495498|NCT02293616|PLACEBO_COMPARATOR|Nitrate Depleted|This group will consume a beetroot juice supplement (Beet It Shot®, James White Drinks, UK) that has had the nitrate removed from the beverage by the manufacturer. Patient's diet will be supplemented once daily with one 70 ml bottle while hospitalized up to 14 days.
62338847|NCT00783211|PLACEBO_COMPARATOR|3|placebo
62338848|NCT01895816|EXPERIMENTAL|fertility coated tablet|700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
62338849|NCT04143620|OTHER|Neovascular glaucoma|Neovascular glaucoma patients underwent triple procedure
62338850|NCT02694211|EXPERIMENTAL|Intervention group ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
62338851|NCT02694211|NO_INTERVENTION|Control group|No intervention, business as usual
62338852|NCT00363246||Group 1|Older veterans who use a wheelchair for their primary means of mobility.
62338853|NCT03443843|EXPERIMENTAL|Sequence 1|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
62338854|NCT03443843|EXPERIMENTAL|Sequence 2|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
62495499|NCT03291145|EXPERIMENTAL|Beta Blockers|With and without Beta Blockers
61943642|NCT04324619|EXPERIMENTAL|6 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 6 months.
61943643|NCT04324619|EXPERIMENTAL|12 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 12 months.
61943644|NCT06145373|EXPERIMENTAL|fitusiran|"The pre-fitusiran treatment period is defined as the transition period up to the first fitusiran administration. Participants will receive on demand or prophylactic treatment with intravenous clotting factor concentrates (IV CFCs) or bypassing agents (BPAs) from Month-2 until Day 1.~Fitusiran treatment period: Participants will receive subcutaneous (SC) fitusiran prophylaxis once every 2 months (Q2M) or once monthly (QM) from Day 1 until Month18.~Participants may receive IV antithrombin concentrate (ATIIIC) upon investigator's judgement.~AT FU period: Participants will be followed up until AT activity levels recover to at least 60% (per central laboratory).~In case of bleeding events participants will receive IV CFCs or BPAs. Participants may receive IV ATIIIC upon investigator's judgement."
62338855|NCT03443843|EXPERIMENTAL|Sequence 3|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
62338856|NCT03443843|EXPERIMENTAL|Sequence 4|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
62338857|NCT04051151|EXPERIMENTAL|Gameification Arm|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game.
62338858|NCT04051151|NO_INTERVENTION|Education Arm|Participants and partners that randomized to the control group will receive standard of care educational resources on the importance of physical activity in Parkinson's patients.
62495500|NCT03291145|EXPERIMENTAL|Spironolactone|With and without Spironolactone
62338859|NCT00465491|EXPERIMENTAL|1|Picoplatin
62338860|NCT00465491|OTHER|2|BSC
62338861|NCT04434820|NO_INTERVENTION|standard dressing group|patients will receive sterile wound dressing of gauze and tape for 4 days.
62338862|NCT04434820|ACTIVE_COMPARATOR|External negative pressure dressing system group|patients will receive placement of a sterile dressing of gauze and occlusive adhesive over the closed incision. The dressing's tubing will then be attached to a compact, portable negative-pressure therapy unit (Yuwell 7E-A portable suction unit) that will deliver -80 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
62495501|NCT00453258||Study Subject|Subjects receiving eye examination
62495502|NCT04817514|EXPERIMENTAL|specific shoulder rehabilitation protocol group (SRG);|
62495503|NCT04817514|EXPERIMENTAL|specific protocol of shoulder rehabilitation plus aerobic exercise group (ARG)|
62495504|NCT03634735|ACTIVE_COMPARATOR|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
62495505|NCT03634735|PLACEBO_COMPARATOR|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
62495506|NCT02571530|EXPERIMENTAL|Intra-arterial Cerebral Infusion of Trastuzumab|Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption
62495507|NCT04153539|EXPERIMENTAL|Walking along a busy road|Participants in this group will be asked to walk along a busy road for 4.5 hours.
61943645|NCT01173939|ACTIVE_COMPARATOR|Active comparator: Standard Pravastatin Group|
61943646|NCT01173939|ACTIVE_COMPARATOR|Intensive Rosuvastatin Group|
61943647|NCT02650635|EXPERIMENTAL|Treatment (CTX, pegfilgrastim, TLR8 agonist VTX-2337)|Patients receive cyclophosphamide IV over 30 minutes on day 1, pegfilgrastim SC on day 2, and TLR8 agonist VTX-2337 SC on day -6 of course 1 only and on days 9 and 16. Patients achieving CR, PR, or SD may continue therapy every 21 days for 3 additional courses. Treatment may then continue in the absence of disease progression or unacceptable toxicity.
61943648|NCT02540109|EXPERIMENTAL|High-Definition tDCS (Active)|
61943649|NCT02540109|EXPERIMENTAL|High-Definition tDCS (Sham)|
61943650|NCT03039192|EXPERIMENTAL|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.
61943651|NCT03039192|PLACEBO_COMPARATOR|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.
61943652|NCT02162316|ACTIVE_COMPARATOR|H.Pylori eradication therapy|A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
61943653|NCT02162316|EXPERIMENTAL|Motilitone®|30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
61943654|NCT06366100|EXPERIMENTAL|Dialectical Behavior Therapy for Substance Use Disorders (DBT-SUD)|In the first phase of the study, a three-day workshop (20 hours) online training on DBT-SUD intervention will be provided to professionals. In the second phase, participants will implement DBT-SUD in group that will consist of applying the skills training mode of DBT for 3 months (12-14 sessions, two hours each). Regarding the specific contents, they will be based on the program published by Maffei´s team (DBT certified trainer and therapist in Italy), which has shown good results in improving the severity and frequency of alcohol use and emotional dysregulation with a 3-month program. Four modules of the skills training program will be applied: mindfulness, distress tolerance, skills to deal with addiction and emotional regulation skills. A self-management and rehabilitation module will be also included.
61943655|NCT06366100|EXPERIMENTAL|Unified Protocol (UP)|In the first phase of the study, a a three-day workshop (20 hours) online training on UP intervention will be provided to professionals. In the second phase, participants will implement the UP program that will consist of 8 treatment modules that include training in 5 core skills of emotional regulation: mindfulness training, cognitive flexibility, identification/oppositional behavior of emotional behaviors, interoceptive exposure and emotional exposure. Our team has adapted the UP to be implemented in 12 group sessions, one per week, lasting 2 hours, in specialized mental health care services of the national health system. Additional recommendations to adapt UP to alcohol addiction will be included.
61943656|NCT03458975|ACTIVE_COMPARATOR|Selected liver metastases of the patient|Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy
62338863|NCT02504268|EXPERIMENTAL|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
61943657|NCT03458975|PLACEBO_COMPARATOR|Not-selected liver metastases of the patient|Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm
62338864|NCT02504268|ACTIVE_COMPARATOR|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
61943658|NCT02219438|EXPERIMENTAL|RIGHT side BOLUS and left side basal|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours
61943659|NCT02219438|ACTIVE_COMPARATOR|RIGHT side BASAL and left side bolus|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours. For the left catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours.
62338865|NCT02504268|PLACEBO_COMPARATOR|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
62338866|NCT02504268|PLACEBO_COMPARATOR|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
62338867|NCT03670316|EXPERIMENTAL|Algorithm Treatment plus referral to quitline (AT)|will be assigned a pharmacotherapy treatment regimen recommended to their provider.
62338868|NCT03670316|ACTIVE_COMPARATOR|Quitline (eTAU)|will be referred to quitlines, telephone-based tobacco cessation services.
62338869|NCT02148822||Malnourished|Children with either height for age z score or body mass index for age z score below 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
62338870|NCT02148822||Not malnourished|Children with either height for age z score or body mass index for age z score equal or higher than 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
62338871|NCT00628953|EXPERIMENTAL|1|
62338872|NCT00628953|PLACEBO_COMPARATOR|2|
62338873|NCT01260363|ACTIVE_COMPARATOR|Naropin, Adrenalin, applicationsite|
61943660|NCT00286507|ACTIVE_COMPARATOR|ILM peeling|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
61943661|NCT00286507|ACTIVE_COMPARATOR|No ILM peeling|combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
61943662|NCT00895232|EXPERIMENTAL|Cohort I|500 mg dose Venofer over 4 hours
61943663|NCT00895232|EXPERIMENTAL|Cohort II|500 mg Venofer infusion over 4-6 hours on Day 0 and repeated on Day 2 to 7
62338874|NCT01260363|ACTIVE_COMPARATOR|Femoral nerve block|
62338875|NCT05524870|EXPERIMENTAL|Mobilization|Mobilization with movement plus exercise.
62338876|NCT05524870|PLACEBO_COMPARATOR|Sham mobilization|Sham mobilization with movement plus exercise
62338877|NCT05524870|ACTIVE_COMPARATOR|Control|Exercise alone
62338878|NCT05045924||Intervention group|20 patients with decompensated liver cirrhosis monitored using a wrist-watch wearable device, with associated smart weighing scales and blood pressure cuff, along with a smartphone application (including economic smartphone in those patients if not available), to facilitate home monitoring.
62338879|NCT05045924||Control group|20 patients with decompensated liver cirrhosis receiving standard quality of care.
62338880|NCT02223455|PLACEBO_COMPARATOR|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
62495508|NCT04153539|ACTIVE_COMPARATOR|Walking in a traffic-free park|Participants in this group will be asked to walk in a traffic-free park for 4.5 hours.
62495509|NCT06285448||Patients with Alzheimer's disease|Patients with Alzheimer's disease eligible to receive lecanemab infusions at HealthPartners clinics and their care partners.
62495510|NCT05727579|OTHER|low-sodium diet; placebo|
62495511|NCT05727579|OTHER|low-sodium diet; ertugliflozin 15 once daily|
62495512|NCT05727579|OTHER|high-sodium diet; placebo|
62495513|NCT05727579|OTHER|High-sodium diet; ertugliflozin 15 mg once daily|
61943664|NCT00895232|EXPERIMENTAL|Cohort III|500 mg Venofer over 6 hours, followed within 24 hours by 500 mg Venofer over 6 hours
62139306|NCT04263610|EXPERIMENTAL|Non-Germany: Dimethyl fumarate standard scheme|"Part 1: Participants will receive Dimethyl fumarate (DMF) standard scheme from baseline to Week 16.~Part 2: Participants achieving a Psoriasis Area and Severity Index (PASI) 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
62338881|NCT02223455|ACTIVE_COMPARATOR|Hand Hygiene Signs Changed Monthly|Intervention: Hand Hygiene Signs Changed Monthly Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
62338882|NCT02223455|ACTIVE_COMPARATOR|Hand Hygiene Signs Changed Weekly|Intervention: Hand Hygiene Signs Changed Weekly Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
62338883|NCT01621152|OTHER|Conventional management arm|Patients with AKI receive standard of care in the conventional manner by the primary clinicians
62338884|NCT01621152|ACTIVE_COMPARATOR|AKI sniffer instigated AKI management|primary clinicians for the AKI patients in this arm receive a verbal alert and reminder of KDIGO guidelines.
62495514|NCT06000579|EXPERIMENTAL|Experimental Group|EFT will be applied to individuals with premenstrual syndrome.
62495515|NCT06000579|NO_INTERVENTION|Control Group|Individuals in the control group will not be interfered with.
62495516|NCT04791007|EXPERIMENTAL|Single dose administration (Part 1)|the dose of the drug (4g OB-002H (8.0 mg/g)) administrated once vaginally or rectally
62139307|NCT04263610|EXPERIMENTAL|Germany: Dimethyl fumarate standard scheme|Part 1: Participants will receive DMF standard scheme from Baseline to Week 16. Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40.
61943665|NCT03812653|EXPERIMENTAL|Intervention Arm: CPAP with Usual Care.|6 months of CPAP plus usual medical therapy.
61943666|NCT03812653|NO_INTERVENTION|Control Arm: Usual Care.|6 months of usual medical therapy alone.
61943667|NCT02829073|EXPERIMENTAL|Oasis™ device|Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.
61943668|NCT02829073|PLACEBO_COMPARATOR|Placebo device|Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.
61943669|NCT01329536||AD Patients with Agitation|Patients with a diagnosis of probable Alzheimer's Disease who show signs of agitation based on the Cohen-Mansfield Agitation Inventory
61943670|NCT01329536||AD Patients without Agitation|Patients with a diagnosis of probable Alzheimer's Disease who do not show signs of agitation based on the Cohen-Mansfield Agitation Inventory and are matched in both age and gender to the AD Patients with Agitation
61943671|NCT06181591|EXPERIMENTAL|Hibero SR (Mirabegron) 50 mg|Subjects aged between 5 and 18 years will receive a daily dose of IP orally starting from baseline to week 8.
61943672|NCT06181591|ACTIVE_COMPARATOR|Ditropan (Oxybutynin Chloride) 10 mg|Subjects aged between 5 and 18 years will receive a daily dose of active comparator orally starting from baseline to week 8.
61943673|NCT00810472|EXPERIMENTAL|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
61943674|NCT00810472|PLACEBO_COMPARATOR|Random graft assignment|
61943675|NCT05556330|EXPERIMENTAL|horizontal ridge augmentation by computer guided autogenous cortical shell technique|
61943676|NCT05556330|ACTIVE_COMPARATOR|horizontal ridge augmentation by free hand autogenous cortical shell technique|
62139308|NCT04263610|EXPERIMENTAL|Germany: Dimethyl fumarate simplified scheme|"Part 1: Participants will receive DMF simplified scheme from Baseline to Week 16.~Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
62139309|NCT04150042|EXPERIMENTAL|Chemotherapy/stem cell treatment|
62495517|NCT04791007|EXPERIMENTAL|Multidose administration (Part 2)|the dose of the drug (4g OB-002H (8.0 mg/g)) or placebo administered vaginally through five consecutive days
62495518|NCT03255980|EXPERIMENTAL|Xonrid®|Xonrid® is a medical device for radiation dermatitis
61943677|NCT00631696|EXPERIMENTAL|1|
61943678|NCT00631696|PLACEBO_COMPARATOR|2|
61943679|NCT05147584|EXPERIMENTAL|Interventional/Observational|The internal and external oxygen sensors will be used to record fetal oxygen during active labor and these will be be compared to the CTG retrospectively.
61943680|NCT05661110||Prospective Sample Collection|Prospective sample collection from participants treated with HIPEC combined PD1/PDL1inhibitor at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University under standard of care treatment. Blood and tissue samples will be collected prior to initiation of conversion therapy. And thereafter at the four time points: before and after surgery(±7 days), before the start of the second cycle of adjuvant, tumour progression, blood sample will be collected too.
61943681|NCT02309593||PROFEMUR® Xm Femoral Stems|Single study group either previously implanted or will be implanted with the following combination of components: PROFEMUR® Xm Femoral Stems, with any type of Acetabular Shells.
61943682|NCT03833960||1-cN0/pN0|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was ypN0.
61943683|NCT03833960||2-cN+/pN0|Patients with initially clinically involved axilla (cN1-2), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was complete axillary remission (ypN0).
62139310|NCT03064594||cornuostomy|cornuostomy
62139311|NCT03064594||wedge resection|wedge resection
62139312|NCT04720794|OTHER|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
62495519|NCT03255980|ACTIVE_COMPARATOR|Standard of Care|Standard of care suggested by MASCC guidelines
62495520|NCT02451696|EXPERIMENTAL|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
62495521|NCT02451696|NO_INTERVENTION|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
61943684|NCT03833960||3-cN0/pN+|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within SLNB was done, followed by ALND because of positive pathological report of sentinel node(s).
61943685|NCT03833960||4-cN+/pN+|Patients with initially clinically positive axilla (cN1-3) submitted to neoadjuvant treatment, followed by surgical procedure within ALND was done and the final pathological report was ypN1-3.
61943686|NCT01931618|ACTIVE_COMPARATOR|Usual care|"Receives two interventions:~1. Online screening and feedback.~2. Online booklet."
61943687|NCT01931618|EXPERIMENTAL|Extended follow-up|"Receives two interventions:~1. Online screening and feedback.~2. Online multi session follow-up."
62338885|NCT05821621||Cashew nut allergy|"Inclusion criteria:~* Patients under 18 years of age with a proven allergy to cashew nut and followed in the pediatric allergology unit of Nancy University Hospital.~* Patients having received oral cashew immunotherapy for at least 18 months at 28/02/2023~Non-inclusion criteria:~* Patients who have received oral cashew immunotherapy for less than 18 months.~* Patients lost to follow-up for more than 3 years (last consultation in 2020 or earlier)"
62139313|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
62495522|NCT00113919|EXPERIMENTAL|Busulfan|study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days
62495523|NCT01450800|ACTIVE_COMPARATOR|Nitrofurantoin|Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
62495524|NCT01450800|PLACEBO_COMPARATOR|Placebo|Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
61943688|NCT05955625|EXPERIMENTAL|TIMELY intervention and care as usual|The intervention group will receive the TIMELY intervention including wearable monitoring devices and app in addition to care as usual for a duration of 6 months.
61943689|NCT05955625|NO_INTERVENTION|Care as usual|The care as usual group will receive the standard care as they would receive without being enrolled in the current trial.
62338886|NCT01734486|EXPERIMENTAL|Low dose|
62338887|NCT01734486|EXPERIMENTAL|High dose|
62338888|NCT04300062|EXPERIMENTAL|Rebiopsy|
62338889|NCT05782179|EXPERIMENTAL|Cohort 1 - Active|Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
62338890|NCT05782179|PLACEBO_COMPARATOR|Cohort 1 - Placebo|Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
61943690|NCT03805425|EXPERIMENTAL|Photorefractive intrastromal corneal crosslinking (PiXL)|Patients undergo PiXL where the UVA light is delivered in customized patterns and corneal changes are achieved. For hyperopia, a ring shape irradiation is used to steepen the central cornea. An oxygen mask is used to enhance the crosslinking efficacy. A dedicated riboflavin formulation penetrates the corneal stroma. Pulsed UVA light with oxygen triggers the covalent bonds of collagen strands in riboflavin soaked cornea.
62338891|NCT05782179|EXPERIMENTAL|Cohort 2 - Active|Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
62338892|NCT05782179|PLACEBO_COMPARATOR|Cohort 2 - Placebo|Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
61943691|NCT04172896|ACTIVE_COMPARATOR|Intraperitoneal Group|Vaginal intraperitoneal uterosacral ligament suspension group
61943692|NCT04172896|ACTIVE_COMPARATOR|Extraperitoneal Group|Vaginal extraperitoneal uterosacral ligament suspension group
61943693|NCT05929131|EXPERIMENTAL|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
61943694|NCT05929131|PLACEBO_COMPARATOR|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
61943695|NCT05929131|EXPERIMENTAL|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
61943696|NCT02400177|EXPERIMENTAL|Emotion regulation training|This is a 4 sessions group workshop and 1 session individual pre-screening about parental emotion regulation and emotion co-regulation. In this study the facilitators will give information about efficient strategies to regulate parent emotions and their children's emotions.
61943697|NCT02400177|NO_INTERVENTION|Control group|"In this condition we will take all the measurement before and after the waiting list period.~This group will go through the workshop after the measurements will be taken."
62338893|NCT05782179|EXPERIMENTAL|Cohort 3 - Active|Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
62338894|NCT05782179|PLACEBO_COMPARATOR|Cohort 3 - Placebo|Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
62338895|NCT05782179|EXPERIMENTAL|Cohort 4 - Active|Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
62338896|NCT05782179|PLACEBO_COMPARATOR|Cohort 4 - Placebo|Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
62338897|NCT04772664|EXPERIMENTAL|Participants with Major Depression receiving a multi-strain probiotic|Participants with Major Depression receiving a multi-strain probiotic
61943698|NCT00358423|EXPERIMENTAL|A|
61943699|NCT00358423|PLACEBO_COMPARATOR|B|
61943700|NCT05663502||Observational (biospecimen collection)|Patients undergo collection of fresh blood and/or tumor tissue samples
61943701|NCT03748108|EXPERIMENTAL|lidocaine|A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
61943702|NCT03748108|PLACEBO_COMPARATOR|Placebo|A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.
61943703|NCT03996759||Critically ill patients|Patients admitted in ICU
62139314|NCT03961451||Group With Recommendations (GAR)|Patients in the GAR group will receive several recommendations and will have access to an online tool to increase motivation to engage in physical activity.
62139315|NCT03961451||Control Group (GC)|No recommendation given
62338898|NCT04772664|PLACEBO_COMPARATOR|Participants mit Major Depression receiving a placebo|Participants mit Major Depression receiving a placebo
62338899|NCT04772664|EXPERIMENTAL|Healthy volunteers receiving a multi-strain probiotic|Healthy volunteers receiving a multi-strain probiotic
62338900|NCT04772664|PLACEBO_COMPARATOR|Healthy volunteers receiving a placebo|Healthy volunteers receiving a placebo
62338901|NCT03195062|EXPERIMENTAL|Test meal|The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
62338902|NCT05380674||quality of life|The short questionnaire of healthy habits for adults of the PASOS (Physical Activity, Sedentarism and Obesity in Spanish Youth) study was used, which collects sociodemographic data, weight, height, and physical activity, self-reported.
62338903|NCT01382043||Endeavor Segment group|
62338904|NCT01382043||Excel Segment Group|
62495525|NCT00325780|EXPERIMENTAL|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
61943704|NCT02642302|EXPERIMENTAL|HIIT With 60 sec Rest|The experimental (1) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 60 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
61943705|NCT02642302|EXPERIMENTAL|HIIT With 120 sec Rest|The experimental (2) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 120 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
61943706|NCT02642302|ACTIVE_COMPARATOR|Control|Continuous exercise at 50-55% of VO2max with similar total work
61943707|NCT06134492|EXPERIMENTAL|Treatment group|Aciclovir therapy
61943708|NCT06134492|NO_INTERVENTION|Comparison group|No study-specific treatment measures
61943709|NCT04853030|EXPERIMENTAL|Minimed 670G 4.0 closed loop with Faster Insulin aspart|
61943710|NCT04853030|ACTIVE_COMPARATOR|Minimed 670G 4.0 closed loop with Standard Insulin aspart|
61943711|NCT05099081|EXPERIMENTAL|diode laser|diode laser application
61943712|NCT05099081|ACTIVE_COMPARATOR|sclerotherapy|intra-lesional injection of ethanolamine oleate
61943713|NCT00789009||Group 1|Consist of HIV positive patients recruited from the Washington DC metropolitan area who will receive long-term care for their HIV infection through the NIAID/CCMD HIV clinic
61943714|NCT00789009||Group 2|Patients with known or suspected HIV infection, referred to a NIAID/CCMD investigator for reasons such as testing to diagnose or exclude HIV disease or assistance with HIV-related problems.
61943715|NCT02796703|PLACEBO_COMPARATOR|Control Group|Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
61943716|NCT02796703|ACTIVE_COMPARATOR|Treatment Group|"Dietary Supplement: Heat Inactivated Probiotics~1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula."
61943717|NCT01884532||2 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62495526|NCT01981044|EXPERIMENTAL|SERI® Surgical Scaffold|It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.
61943718|NCT01884532||3 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
61943719|NCT01884532||4 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
61943720|NCT01884532||5 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62338905|NCT04209777|ACTIVE_COMPARATOR|Antibiotics|The antibiotic group is provided with amoxicillin capsules 500mg and metronidazole tablets 400mg three times a day for 7 days along with the placebo of probiotics twice daily for 30 days.
62696707|NCT06638684|EXPERIMENTAL|High intensity exercise|Subjects in this group will participate in an exercise session that is representative of a training event experienced by cadets preparing for military competitions. All exercises will consist of a mix of running activities (≤ 400 m); body weight exercises, such as burpees and lunges; and exercises, such as crunches and squats utilizing 20.4 kg weight plates; with rapidly occurring exercise transitions to prevent recovery. The exercise bout will last a total of 100 min. Scheduled 5 min rests will be inserted at 30, 60, and 85 min. During the scheduled rest periods, subjects will be encouraged to consume water and/or the carbohydrate/electrolyte drink. The researchers will obtain a blood sample from you prior to and immediately following the exercise, as well as one, four and six hours post-exercise.
62696708|NCT05018507||total knee arthroplasty patients|data collection only
61943721|NCT01884532||6 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
61943722|NCT00971880||Patients receiving blood transfusions|All the patients with blood disorders that require blood transfusions
61943723|NCT02299882|EXPERIMENTAL|Vancomycin|Patient will receive Vancomycin powder to the incision just before skin closure
61943724|NCT02299882|NO_INTERVENTION|no vancomycin|Patient will be randomized to either vancomycin powder or no vancomycin powder. This arm the patient will not have the powder placed in the incision before skin closure.
61943725|NCT01524757|EXPERIMENTAL|pantoprazol|
61943726|NCT01524757|PLACEBO_COMPARATOR|placebo|
61943727|NCT05322733|EXPERIMENTAL|Treatment (oFCG)|See Detailed Description.
61943728|NCT00526942|NO_INTERVENTION|I|No contact control (NCC)
62139316|NCT00918333|EXPERIMENTAL|Treatment (panobinostat and everolimus)|Patients receive panobinostat PO QD or on days 1, 3, 5, 15, 17, and 19 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62696709|NCT02496000|PLACEBO_COMPARATOR|Placebo Comparator|three identical capsules containing placebo
61943729|NCT00526942|EXPERIMENTAL|II|Computerized, SAAGE-designed, visual memory-based cognitive training
61943730|NCT02639546|EXPERIMENTAL|Phase I (Tablet) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
61943731|NCT02639546|EXPERIMENTAL|Phase I (Tablet) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
62696710|NCT02496000|EXPERIMENTAL|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
62495527|NCT00897676|OTHER|Vehicle first, then Exendin-(9-39)|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
62696711|NCT02496000|EXPERIMENTAL|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
62696712|NCT06424002|EXPERIMENTAL|RTS,S/AS01 Vaccine|Three doses of the vaccine will be administered, each with one month interval. RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01.
62338906|NCT04209777|EXPERIMENTAL|Probiotics|The probiotic group is provided with Lactobacillus-reuteri probiotics (2x10(8)CFU) twice daily after brushing for 30 days.
62338907|NCT02019394|EXPERIMENTAL|Lu AE58054|
62338908|NCT01699620|EXPERIMENTAL|Dermatome|BAHA implant insertion with Dermatome technique
62338909|NCT01699620|EXPERIMENTAL|Linear incision|BAHA implant insertion with linear incision
62338910|NCT01610648||Patients presenting for a diagnostic sleep study|Patients presenting to the TMC sleep center for sleep study
62338911|NCT03294928|EXPERIMENTAL|progressive increasing of PEEP level|four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level.
62338912|NCT03365804|EXPERIMENTAL|3D Printed Brace|This group will receive 3D printed brace
62338913|NCT03365804|NO_INTERVENTION|Traditional Brace|This group will receive the traditional brace
62338914|NCT03408951||Interventions (recording)|Patients requiring Intracardiac defibrillator (ICD) implantation or Defibrillation Test (DFT) or Electrophysiology (EP) study with high probability of supra ventricular tachyarrhythmia.
62338915|NCT04634773|EXPERIMENTAL|Group 1: Early Degeneration ('Disease')|Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
62338916|NCT04634773|ACTIVE_COMPARATOR|Group 2: No Degeneration ('Healthy')|Those who have posterior subluxation of the humeral head and show no signs of degeneration.
62338917|NCT03635398|EXPERIMENTAL|Intranasal Midazolam by SipNose device|
62338918|NCT03635398|ACTIVE_COMPARATOR|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
62338919|NCT03635398|ACTIVE_COMPARATOR|oral administration of midazolam|
62338920|NCT05514652|EXPERIMENTAL|First group|Multimodal low-opioid protocol provided for induction of anesthesia with intravenous (iv) propofol administration using the dosage of 1.5-2 mg/kg at 40 mg in interval of 10-15 seconds, iv fentanyl dosage 1-1.5 μg/kg and iv pipecuronium bromide dosage of 0.1 mg/kg. Before intubation of the trachea, a lidocaine 1 mg / kg bolus was added intravenously, with the simultaneous establishment of a continuous infusion at a dose of 1.5-2 mg/kg/h. All patients were administered a bolus of ketamine (0.5 mg/kg) and were started continuous infusion dexmedetomidine at a dose 0.7 μg/kg/h. If indicated fentanyl was used as additional analgesic during surgery by bolus injection. Depth of anesthesia was monitored with bispectral index; the dosage of sevoflurane from 1,5vol% to 2,5vol% was titrated to maintain BIS values from 40 to 60.
62338921|NCT05514652|ACTIVE_COMPARATOR|Second group|Routine opioid protocol of anesthesia provided for induction of anesthesia with the iv administration of propofol dosage of 1.5-2 mg/kg at 40 mg in interval of 15-20 seconds, iv fentanyl at a dose of 1-1.5 μg/kg and iv pipecuronium bromide dosage of 0.1 mg/kg. For analgesia, bolus injections of fentanyl were used at a dose of 8-10 μg/kg for the entire duration of the operation, muscle relaxation - pipecuronium bromide at a dose of 0.1 mg/kg. Depth of anesthesia was monitored with bispectral index; the dosage of sevoflurane from 1,5vol% to 2,5vol% was titrated to maintain BIS values from 40 to 60.
62495528|NCT00897676|OTHER|Exendin-(9-39) first then Vehicle.|"An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.~."
62495529|NCT04943107||healthy control|adults without glaucoma history or hypertension history
62495530|NCT04943107||glaucoma patients|adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history
62495531|NCT04943107||hypertension patients|adults with primary hypertension history; without glaucoma history
62495532|NCT04943107||glaucoma+hypertension|adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history
62696713|NCT06424002|EXPERIMENTAL|RTS,S/AS01 Vaccine plus artemether-lumefantrine|RTS,S/AS01 Vaccine will be provided with a therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine). Artemether-lumefantrine will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
61943732|NCT02639546|EXPERIMENTAL|Phase I (Tablet) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
62338922|NCT01941524|ACTIVE_COMPARATOR|Poractant goup|Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.
62338923|NCT01941524|ACTIVE_COMPARATOR|Beractant group|Newborns who will be monitored by aEEG and NIRS during beractant instillation
62338924|NCT01970514|EXPERIMENTAL|ARO Spinal System|ARO Spinal System
62338925|NCT00803010|ACTIVE_COMPARATOR|Tacrolimus / Rapamycin (TAC/RAPA)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year."
62338926|NCT00803010|ACTIVE_COMPARATOR|Tacrolimus / Methotrexate (TAC/MTX)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant."
62338927|NCT01930812|EXPERIMENTAL|18F-NaF PET Imaging for Bone Scintigraphy|All participants will receive PET/CT Imaging using the investigational drug 18F-NaF and a 99mTc-medronate whole body bone scan with SPECT to compare the diagnostic ability of the two methods for the presence of bone metastases.
62696714|NCT06424002|EXPERIMENTAL|Artemether-lumefantrine only|A therapeutic dose of artemether-lumefantrine will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
62495533|NCT05492292|EXPERIMENTAL|Long Covid19 patient group|Patients with Long Covid19 undergoing perfusion brain scintigraphy
62495534|NCT03735706|ACTIVE_COMPARATOR|Control group - 120 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.~The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV."
62495535|NCT03735706|EXPERIMENTAL|90 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.~A radiation dose reduction from 120 to 90 kV.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1."
62495536|NCT03735706|EXPERIMENTAL|100 kV - 0.417 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.~The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg."
62696715|NCT06424002|NO_INTERVENTION|Vitamin A|This is the control group where Vitamin A will be given.
62139317|NCT05605925|ACTIVE_COMPARATOR|Control arm|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
62139318|NCT05605925|EXPERIMENTAL|Intervention arm|IVN 600 mcg/kg/day for 3 days + 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
62139319|NCT04870398|ACTIVE_COMPARATOR|MTA partial pulpotomy|Profound local anesthesia of the tooth and the surrounding tissues will be achieved The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of MTA. After the placement of MTA, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
62338928|NCT01743872|EXPERIMENTAL|iOCT|"Arterial access will performed by the operating surgeon. An aortic and infrainguinal angiogram using the standard method of intravenous iodinated contrast under digital subtraction fluoroscopy will be conducted in the usual manner according to the vascular surgeon. A 54 mm section of Superficial Femoral Artery will be chosen for study imaging. An intervention sheath or injection catheter will be placed just proximal to the area of interest. An 0.014 wire will be passed distal to the area of interest. The patient will then undergo OCT of this 54mm section with each of the three mediums below using a continuous flushing method through injection catheter. All OCT imaging will be collected at a rate of 25mm/sec. In the event of a subsequent procedure, OCT imaging will again be performed"
62338929|NCT05874453|EXPERIMENTAL|Intervention Group|Eye care protocol to be appliedevaluation.
62338930|NCT05874453|NO_INTERVENTION|Control Group|Routine intensive care Eye care protocol to be applied
62696716|NCT06189573|OTHER|Quadriceps Tendon graft|Patients with ACL reconstruction with the use of quadriceps tendon graft
62696717|NCT06189573|OTHER|Bone Patellar Tendon Bone Graft|Patients with ACL reconstruction with the use of bone patellar tendon bone graft
62696718|NCT04621877|EXPERIMENTAL|"Volunteer-delivered Behavioral Activation - Do More, Feel Better"|"Do More, Feel Better (DMFB) is a streamlined, simplified version of Behavioral Activation (BA) delivered by lay volunteers to depressed senior center clients."
62696719|NCT04621877|ACTIVE_COMPARATOR|Master's Level Clinician-delivered Behavioral Activation|Traditional Behavioral Activation (BA) delivered by master's level mental health clinicians
62338931|NCT01912716|EXPERIMENTAL|high-dose indomethacin|200mg rectal indomethacin
62338932|NCT01912716|ACTIVE_COMPARATOR|standard dose indomethacin|100mg rectal indomethacin
62338933|NCT06553950|EXPERIMENTAL|Botox injection group|"Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants, and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle"
61943733|NCT02639546|EXPERIMENTAL|Phase I (Suspension) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
61943734|NCT02639546|EXPERIMENTAL|Phase I (Suspension) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
61943735|NCT02639546|EXPERIMENTAL|Phase I (Suspension) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
61943736|NCT02639546|EXPERIMENTAL|Phase I (Suspension) Cobimetinib (1.33 mg/kg)|Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
61943737|NCT02639546|EXPERIMENTAL|Phase II (Suspension) Cobimetinib (1 mg/kg)|Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
61943738|NCT00769522|EXPERIMENTAL|FCR|
61943739|NCT00769522|EXPERIMENTAL|BR|
61943740|NCT04568421||Treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
62338934|NCT06553950|EXPERIMENTAL|Mandibular stabilization splint group|Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
62696720|NCT05024162|EXPERIMENTAL|Prospective Cohort|Sixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).
62696721|NCT06607770|EXPERIMENTAL|Experimental group|Patients were started on Carrelizumab in combination with Apatinib 2-3 weeks after cryoablation. Karelizumab 200 mg, q3w, and Apatinib 250 mg, qd. Every 3 weeks is a treatment cycle.
62696722|NCT05697380|EXPERIMENTAL|Experimental: Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
62338935|NCT06553950|ACTIVE_COMPARATOR|Control group|Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
62696723|NCT05603637|ACTIVE_COMPARATOR|Radiofrequency ablation arm|Patients will undergo pulmonary vein isolation by means of radiofrequency energy. The ablation will be done using SmartTouch ablation catheter (Biosense Webster, USA).
62696724|NCT05603637|EXPERIMENTAL|Pulsed- field ablation arm|Patients will undergo pulmonary vein isolation by means of pulsed-field ablation. The ablation will be done using Farawave ablation catheter (Boston Scientific, USA).
62696725|NCT05507333|OTHER|Gedea pessary|Gedea pessary administration
62696726|NCT05052684|EXPERIMENTAL|Leaflex™ Performer|
62696727|NCT05497024||Surveys|Participants may answer questions that are sensitive in nature.
62696728|NCT05497024||Interviews|The interview may occur over phone, web conferencing, or in-person.
62338936|NCT02607358||Clopidogrel|Clopidogrel non-responders (HOTPR) Blood sampling for HOTPR-testing
62338937|NCT02607358||Acetacylicacid|Acetcylicacid non-responders (HOTPR), Blood sampling for HOTPR-testing
62338938|NCT04724382|EXPERIMENTAL|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
62338939|NCT04724382|ACTIVE_COMPARATOR|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
62338940|NCT03775772|OTHER|Oral Health - Test Group|- study population is randomly assigned to control and test group
62338941|NCT03775772|OTHER|Bite Force/Chewing Efficacy-Test Group|- study population is randomly assigned to control and test group
62495537|NCT03735706|EXPERIMENTAL|90 kV - 0.365 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg."
62495538|NCT01767753|EXPERIMENTAL|Triggerfish|Device: Sensimed Triggerfish
62495539|NCT01435928|EXPERIMENTAL|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
62495540|NCT01435928|PLACEBO_COMPARATOR|Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
62495541|NCT03470116|EXPERIMENTAL|MacGrath MAC video laryngoscopy|Patients will benefit MacGrath MAC video laryngoscopy for intubation after curarization
62495542|NCT03470116|ACTIVE_COMPARATOR|direct laryngoscopy|Patients will benefit direct laryngoscopy for intubation after curarization
62696729|NCT05765175|ACTIVE_COMPARATOR|Repeat catheter ablation (CA)|
62696730|NCT05765175|EXPERIMENTAL|Varian Cardiac Radioablation (CRA)|
62696731|NCT06645171|EXPERIMENTAL|Arm 1|ONS including fibre (300 kcal, 12gr protein, 125 mL, 4.5 g fibre), The subjects will use study products twice daily for 4 weeks starting at V1.
62696732|NCT06645171|EXPERIMENTAL|Arm 2|ONS without fibre (300 kcal, 12gr protein, 125 mL, 0 g fibre), The subjects will use control products twice daily for 4 weeks starting at V1.
62696733|NCT06077214|EXPERIMENTAL|Experiemental|Subjects will be treated with liposomal bupivacaine (study drug) after undergoing bariatric surgery.
62696734|NCT06077214|ACTIVE_COMPARATOR|Standard of Care|Subjects will be treated with standard bupivacaine after undergoing bariatric surgery.
62338942|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
62338943|NCT06206278|EXPERIMENTAL|Infigratinib|Infigratinib 125 mg orally daily, 3 weeks on, 1 week off. . In patients with mild liver function abnormalities or mild renal impairment, the starting dose is 100 mg.
62495543|NCT05685472|EXPERIMENTAL|MEDI5752 monotherapy|
62495544|NCT02082834|EXPERIMENTAL|EVAR|
62495545|NCT06536049|EXPERIMENTAL|Treatment (epcoritamab, ibrutinib)|Patients receive ibrutinib PO QD on days -7 to 28 of cycle 1 and on days 1 to 28 of remaining cycles, as well as epcoritamab SC on days 1, 8, 15 and 22 of cycles 1-3, days 1 and 15 of cycles 4-9, and on day 1 of remaining cycles. Treatment repeats every 28 days for up to 6 cycles of ibrutinib and up to 12 cycles of epcoritamab in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT and PET/CT throughout the study. Patients may also undergo bone marrow aspiration and biopsy on study.
62338944|NCT04398199|EXPERIMENTAL|Hypofractionated Radiation Therapy|Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.
62696735|NCT06610890|EXPERIMENTAL|Healthy subject|Midazolam maleate tablets 15 mg were taken orally in the morning on Day1, and Hemay005 tablets were taken daily on Day3-Day9, twice a day, 60mg once. Midazolam maleate tablets 15 mg+Hemay005 tablets 60mg were taken orally in the morning of Day10
62696736|NCT05588323|EXPERIMENTAL|Cohort 1: ≥ 12 to < 18 Years|Participants will receive 0.05 milligrams (mg) to 0.2 mg naldemedine based on their body weight once daily for 7 days.
62696737|NCT05588323|EXPERIMENTAL|Cohort 2: ≥ 6 to < 12 Years|Participants will receive 0.05 mg to 0.2 mg naldemedine based on their body weight once daily for 7 days.
61943741|NCT04568421||Not treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases not treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
61943742|NCT02380144|EXPERIMENTAL|Orange Fruit - Orange Juice|"Sequence of test foods during the intervention period:~1st: Orange fruit; 2nd: Orange juice"
61943743|NCT02380144|EXPERIMENTAL|Orange Juice - Orange Fruit|"Sequence of test foods during the intervention period:~1st: Orange juice; 2nd: Orange fruit"
61943744|NCT05626816|EXPERIMENTAL|All interventions, Sham applied first|These participants will have all interventions applied, but will be randomly designated to have sham stimulation applied before effective stimulation. This will balance any issue with order of presentation of multiple stimulation sessions.
61943745|NCT05626816|EXPERIMENTAL|All interventions, effective stim applied first|These participants will have all interventions applied, but will be randomly designated to have effective stimulation applied before sham stimulation. This will balance any issue with order of presentation of multiple stimulation sessions.
61943746|NCT02645097|ACTIVE_COMPARATOR|Proximal saphenous nerve block|The anesthesiologist will administer a saphenous proximal nerve block if specified in the randomization envelope.
61943747|NCT02645097|ACTIVE_COMPARATOR|Distal saphenous nerve block|The anesthesiologist will administer a saphenous distal nerve block if specified in the randomization envelope.
61943748|NCT01482273|ACTIVE_COMPARATOR|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
61943749|NCT01482273|ACTIVE_COMPARATOR|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
61943750|NCT00223171|ACTIVE_COMPARATOR|Arm 1 : 36 months AB + RT|Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
61943751|NCT00223171|EXPERIMENTAL|Arm 2 : 18 months AB + RT|Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
61943752|NCT05598008||GLP-1 Group|"GLP-1 Group: receiving GLP-1 analogues for weight management in addition to conventional weight management (= lifestyle intervention plus GLP-1 analogues).~Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support.~Participants in the GLP-1 group will inject the medication themselves."
61943753|NCT05598008||Lifestyle group|"Lifestyle group: using conventional weight management (= lifestyle intervention only).~Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support."
61943754|NCT04783038|ACTIVE_COMPARATOR|Distance Reiki|Subjects will be scheduled for once a week session of distance Reiki for 4 weeks.
61943755|NCT04783038|SHAM_COMPARATOR|Sham Reiki|Subjects will be scheduled for once a week session of Sham distance Reiki for 4 weeks.
62338945|NCT00620971|EXPERIMENTAL|1|NC/Avastin-\>DG/Avastin
62696738|NCT05588323|EXPERIMENTAL|Cohort 3: ≥ 2 to < 6 Years|"Participants will be enrolled in this cohort after the safety and PK data has been evaluated for cohorts 1 and 2.~Participants will receive 0.05 mg to 0.2 mg naldemedine based on their body weight once daily for 7 days."
61943756|NCT04783038|NO_INTERVENTION|Standard of Care|Subjects will not receive any Reiki treatment
61943757|NCT03959631|EXPERIMENTAL|Intervention group|The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
61943758|NCT03959631|NO_INTERVENTION|Control group|The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.
61943759|NCT03134833|EXPERIMENTAL|Automated Messaging & Monitoring|"Youth randomized to the Automated Messaging and Monitoring Intervention (AMMI) arm will receive daily texts to motivate, inform, and refer youth to health care and HIV services. Message banks will focus on the HIV Prevention Continuum, with libraries of text messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for young men-who-have-sex-with-men (MSM) and non-MSM.~Youth will also receive a weekly monitoring survey that covers seven domains, including: use of PrEP/PEP, condomless sex, potential symptoms of acute HIV infection, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
62338946|NCT00620971|EXPERIMENTAL|2|DG/Avastin
62338947|NCT01012193|ACTIVE_COMPARATOR|adjunctive cilostazol|adjunctive cilostazol 100mg bid to dual antiplatelet therapy
62338948|NCT01012193|ACTIVE_COMPARATOR|high maintenance-dose clopidogrel|double dose of clopidogrel 150mg/day
62338949|NCT01547910|EXPERIMENTAL|Fish oil|Children will receive fish oil capsules according to age as described in the protocol
62338950|NCT01547910|PLACEBO_COMPARATOR|Placebo|Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
62338951|NCT02338791|EXPERIMENTAL|Manual Mobilization|Grade I, II and III manual mobilizations in the inferior, posterior and distractive directions.
61943760|NCT03134833|EXPERIMENTAL|Peer Support|Youth randomized to the Peer Support arm will be enrolled in private, online peer support groups, where they can post information and have discussions with other participants, guided broadly by topics relevant to the HIV Prevention Continuum. Peer Supporters will post to encourage and broadly guide discussion, while Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content. All youth will also receive AMMI messages.
61943761|NCT03134833|EXPERIMENTAL|Coaching|Youth randomized to the Coaching arm will have access to a dedicated Coach for crisis management, problem-solving, linkage to HIV and related services, and care coordination. The Coach's primary means of contact with youth will be electronic - using e-mail, social media, text messages - and phone calls. In person contacts may also occur. AMMI is also provided to all youth.
61943762|NCT03134833|EXPERIMENTAL|Coaching + Peer Support|Youth randomized to the Coach + Peer Support arm will be enrolled in online, private peer support groups and have access to a Coach. As well as AMMI messages.
61943763|NCT01120535|EXPERIMENTAL|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
61943764|NCT05682365|EXPERIMENTAL|prevANS intervention|In this arm, participants will receive an online personalized intervention to prevent anxiety disorders based on a risk predictive algorithm (predictA).
61943765|NCT05682365|NO_INTERVENTION|Control group|In this arm, participants will continue receiving the usual care from their health providers. However, they will not receive any intervention, but they will fill out the same questionnaires as in the intervention group.
61943766|NCT04295785||autoimmune necrotizing myopathy beginning before 18|
61943767|NCT02806245|EXPERIMENTAL|Biventricular pacing|Patients will be randomized pre-operatively to either the pacing group or to the control group. Patients randomized to receive pacing will 1st undergo an acute pacing phase where the order of the pacing mode will be randomized and then will continue to an extended pacing phase of biventricular pacing.
61943768|NCT02806245|NO_INTERVENTION|Control|Controls will receive standard of care treatment consisting of placement of 2 pacing leads (right atrial and right ventricular), monitoring of the study outcomes, monitoring of oxygen consumption and echocardiography, but no pacing.
61943769|NCT06681142|NO_INTERVENTION|Usual Care (Control) Group|"Pharmacists will provide a general educational pamphlet and will inform the primary care physician of patient participation and referral for further assessment of knee OA.~Participants randomized to this group will be offered physiotherapy and/or pharmacy interventions (individual or GLA:D program 3 months after enrollment) and pharmacy options (comprehensive medication review). It will be explained to participants that usual care is 'conservative therapy'.~Usual care participants will be eligible to opt in for a comprehensive medication review (pharmacist) and/or the physiotherapy sessions and will be evaluated at 9-months after enrollment."
61943770|NCT06681142|EXPERIMENTAL|Intervention Group|"Pharmacists will provide comprehensive 1:1 patient care, including a SCHOLAR assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide comprehensive patient education/resources. Pharmacists will refer to physiotherapy clinics located nearby for patient convenience and to establish community pharmacy/physiotherapy clinic relationships.~Participants will be offered a physiotherapy assessment at a nearby physiotherapy clinic within 2 weeks of being assessed by the pharmacist. After the physiotherapy assessment session, participants who are diagnosed with symptomatic knee OA will be offered 1) up to 5 individual physiotherapy sessions within a 6-week period, or 2) the GLA:D program for knee OA which includes 6-weeks of neuromuscular exercises along with 2 education session in a group format."
61943771|NCT06228274||ARTHRUM 2.5% single injection|
61943772|NCT00417508|EXPERIMENTAL|Nutritional supplement|2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
61943773|NCT00417508|ACTIVE_COMPARATOR|Dietary advice|ordinary dietary advice with a recommendation of four meals per day or similar dietary advice
61943774|NCT01852305|EXPERIMENTAL|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
61943775|NCT01852305|ACTIVE_COMPARATOR|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI\>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
61943776|NCT04680052|EXPERIMENTAL|Arm A : tafasitamab + rituximab + lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
61943777|NCT04680052|PLACEBO_COMPARATOR|Arm B : placebo+rituximab+lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
62139320|NCT04870398|ACTIVE_COMPARATOR|Total Fill partial pulpotomy|The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of Total Fill BC. After the placement of the material, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
62139321|NCT00640159|EXPERIMENTAL|Selegiline|Open label switch from current oral selegiline dose to orally disintegrating selegiline (Zelapar) titrated to a dose of 2.5 mg QD.
62338952|NCT04253977|EXPERIMENTAL|HEALTH-P2|Along with PAT National Center, parent educators affiliated with PAT sites in HEALTH-P2; with be trained to use the HEALTH-P2 training curriculum (implementation strategy).
62338953|NCT04253977|ACTIVE_COMPARATOR|Usual Care|Participants at usual care PAT sites will receive PAT as usual.
62338954|NCT00228306|EXPERIMENTAL|1|
62338955|NCT00228306|NO_INTERVENTION|2|Control Group
62696739|NCT03044795|EXPERIMENTAL|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
62696740|NCT03044795|EXPERIMENTAL|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
61943778|NCT02148159|EXPERIMENTAL|Cachexia Acupuncture-A|"Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period.~Acupuncture needles: Single-use, sterile stainless steel and disposable \[acupuncture needles-Peace Classic Needles®, Acu-Market\] Other name: Mechanism based acupuncture"
62495546|NCT03786705||Trauma patients' SBP ≥ 90 mm Hg with EMS|Only patients who were transferred by emergency medical service from the accident site with a systolic blood pressure ≥ 90 mm Hg at the ER were included in this study. The enrolled trauma patients divided into 2 groups, those who had received blood transfusion ≥ 10 U (massive transfusion) and those who had not (non-massive transfusion).
62495547|NCT05044533||Cohort 1|Participants with atrial fibrillation (AF) experiencing a bleed
62495548|NCT03901690|EXPERIMENTAL|Arm Betaglucin|It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.
62495549|NCT03901690|ACTIVE_COMPARATOR|Arm Imiquimod|51 individuals between the ages of 18 and 50 will receive 5% imiquimod.
62495550|NCT04077125||Cirrhosis no MHE|Patients with liver cirrhosis without signs of minimal hepatic encephalopathy
62495551|NCT04077125||Cirrhosis MHE|Patients with liver cirrhosis with minimal hepatic encephalopathy
62696741|NCT05234216|EXPERIMENTAL|Comfort Group|Centers evaluating patients after surgery requiring postoperative opioid treatment with an ICU comfort scale.
62696742|NCT05234216|OTHER|Pain Group|Centers evaluating patients, after surgery requiring postoperative opioid treatment, with a pain numerical verbal scale in the postoperative care service.
62696743|NCT06163404|EXPERIMENTAL|Investigational Device|Treatment with the Spirair Septal correction device and delivery system for correction of cartilaginous nasal septal deviation.
62696744|NCT06637202|ACTIVE_COMPARATOR|postoperative radiotherapy|Patients were treated with radiotherapy to 50 Gy in 25 fractions
62696745|NCT06637202|NO_INTERVENTION|control|Patients received no further treatment after surgery
62696746|NCT00655655|EXPERIMENTAL|Arm I|See Detailed Description
62139322|NCT03898505|PLACEBO_COMPARATOR|Placebo|Placebo powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour. Participants in the placebo group will ingest 1 scoop of the placebo material per day (30-35g). Placebo powder is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Placebo will be consumed once per day for 60 days.
62338956|NCT02634099|OTHER|hemoglobine monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
62338957|NCT05298696|ACTIVE_COMPARATOR|Intervention|Cilostazol 100 mg twice daily for treatment period
62338958|NCT05298696|PLACEBO_COMPARATOR|Control|placebo twice daily for treatment period
62338959|NCT03800862||CTP and CT-FFR|"This will be a prospective, observational study designed to include a convenience sample of all qualifying patients undergoing myocardial CTP and CT-FFR.~The study will enroll patients who have chest discomfort and will require further evaluation for the presence of coronary artery disease. Patients in the study will include those who have had a clinically indicated CCTA for suspicion of coronary artery disease and are determined to have a coronary stenosis ≥50% and ≤99%. However, patients with Left main disease greater than 50% and occluded vessels Coronary Artery Disease Reporting and Data System (CAD RADS 5) will be excluded from the study. CCTA is a clinically indicated and standard of care procedure at Lancaster General Hospital.~."
62338960|NCT05249816|EXPERIMENTAL|NVX-CoV2373|NVX-CoV2373 (5 μg): Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg antigen and 100 μg adjuvant per mL. The vaccination regimen will comprise of 1 intramuscular (IM) injection on Day 0 of 0.5 mL injection volume at a dose of 5 μg of antigen with 50 μg Matrix-M adjuvant.
62338961|NCT05249816|ACTIVE_COMPARATOR|BBIBP CorV|Sinopharm BBIBP-CorV vaccine administered per manufacturer instructions as a single intramuscular injection.
62338962|NCT04050098|ACTIVE_COMPARATOR|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
62495552|NCT04077125||Controls|Healhty subjects
62495553|NCT03349632|OTHER|DD T2/Oasys 1-Day|Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized
62495554|NCT03349632|OTHER|DD T2/MyDay|Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
62495555|NCT03349632|OTHER|DD T2/Moist|Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
62495556|NCT05327322|EXPERIMENTAL|Low Glycemic Load|This group will be prescribed a daily GL of \<45 points/1000 kcal and 25% of daily calorie intake from carbohydrates. This group will be provided few processed foods. During the first 16 weeks, this group will eat enough calories to maintain baseline weight, and will reduce daily calorie intake by 500 kcal/day in the second 16 weeks.
62338963|NCT04050098|ACTIVE_COMPARATOR|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
62696747|NCT04239703||Kidney transplant biopsies for cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care.
62696748|NCT06636942|EXPERIMENTAL|Intermittent pneumatic compression|30 minutes of intermittent pneumatic compression at 200mmHg
61943779|NCT02148159|SHAM_COMPARATOR|General Acupuncture-B|"General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted.~Acupuncture needles: single-use, sterile stainless steel and disposable needles \[Peace Classic Needles®, Acu-Market\] Other name: General acupuncture"
61943780|NCT03855228|EXPERIMENTAL|MFNS 200 µg + Loratadine 10 mg|Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
61943781|NCT03855228|ACTIVE_COMPARATOR|MFNS 200 µg|Daily administration of 200 µg of MFNS plus oral placebo tablet.
61943782|NCT03855228|ACTIVE_COMPARATOR|Loratadine 10 mg|Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
61943783|NCT03855228|PLACEBO_COMPARATOR|Placebo|Daily administration of placebo nasal spray plus oral placebo tablet.
61943784|NCT01787422|EXPERIMENTAL|Telemedicine Visit|Patients who are seen by use of an off-site telemedicine physician.
61943785|NCT01787422|ACTIVE_COMPARATOR|Traditional Visit|Patients who are seen in followup with a traditional in-office visit.
61943786|NCT05096052|EXPERIMENTAL|ProLectin M|Active chewable tablets containing galectin inhibitor complex carbohydrate
61943787|NCT05096052|PLACEBO_COMPARATOR|PLACEBO|Placebo chewable tablets not containing galectin inhibitor complex carbohydrate
61943788|NCT06069531|PLACEBO_COMPARATOR|Lactobacillus johnsonii,|heat-killed Lactobacillus johnsonii TCI250
61943789|NCT06069531|EXPERIMENTAL|White pomegranate extract|White pomegranate extract, dosage of 500mg
61943790|NCT03458962||Genetic Enrollees|Enrollment of patients for whom WGS may be beneficial. Patients who are ill and for whom a genetic diagnosis is suspected but not yet established.
62338964|NCT06186752|EXPERIMENTAL|MyIBD|Each participant randomized to the intervention arm (MyIBD) will receive an individually tailored MyIBD document within a week of a scheduled outpatient clinic visit. The MyIBD document will be prepared by the patient's usual, assigned nurse coordinator together with the study's clinical champion (a nurse practitioner in the IBD program). Participants will receive a copy of the MyIBD document with language suggesting that they use it to guide decisions about care in between appointments. Each participant's primary care provider will also receive a copy of the MyIBD document. The nurse coordinator will send reminder messages to intervention-group participants (using the electronic patient portal) to access and use their MyIBD document at 1-2 months, 3-4 months, 7-8 months, and 11-12 months after initial plan creation.
61943791|NCT03813667|NO_INTERVENTION|Control|The control patients have standard care given through the WVU hospital and outpatient clinics, prescribed by the patient's pulmonologist and recorded in the medical record
61943792|NCT03813667|EXPERIMENTAL|Intervention|The FamPALcare intervention group receives all standard care plus 2 weeks of home EOLPC coaching by community nurses experienced in end-of-life palliative care.
61943793|NCT05994365||Anlotinib group|Anlotinib hydrochloride capsules: 12 mg once daily for 2 weeks, followed by a discontinuation of 1 week (21 days as a cycle)
61943794|NCT05994365||Observation group|Observation: prospectively and retrospectively collect data of patients who did not receive anlotinib hydrochloride capsules or similar small-molecule antivascular inhibitors.
62338965|NCT06186752|NO_INTERVENTION|Usual Care|Each participant randomized to the control group will receive usual care in the pediatric IBD program. They will be eligible to receive a MyIBD document after completing the study (12 months after enrollment).
62696749|NCT06636942|PLACEBO_COMPARATOR|Placebo|A hydrant cream on a pad will be placed on participants quadriceps stating that they are using an inovative recovery cream.
62696750|NCT04023110|EXPERIMENTAL|Carvedilol|"Carvedilol will be initiated at 3.125mg twice daily and uptitrated as tolerated in a stepwise fashion to a maximum dose of 25mg twice daily or to a systolic blood pressure (SBP) of 110-120mmHg or heart rate (HR) of 50-55 beats per minute (bpm). Patients will start carvedilol in the evening after first dose of chemotherapy and will continue on medication for 12 months.~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months."
61943795|NCT02231697||XLMTM patients - deceased|Non-interventional, retrospective medical chart review
61943796|NCT02231697||XLMTM patients - living|Non-interventional, retrospective medical chart review
61943797|NCT06292104||POTS (Postural Orthostatic Tachycardia Syndrome)|Patients meeting clinical criteria for postural orthostatic tachycardia syndrome who meet other criteria for inclusion.
61943798|NCT06292104||Healthy matched controls|Age and sex matched controls
61943799|NCT00149734|EXPERIMENTAL|Ondansetron followed by placebo|Participants will take ondansetron then placebo plus an atypical antipsychotic drug
61943800|NCT00149734|EXPERIMENTAL|Placebo followed by Ondansetron|Participants will take placebo then ondansetron plus an atypical antipsychotic drug
61943801|NCT04046237|NO_INTERVENTION|Usual treatment - Control group|"The patient is referred to his treating dentist with a diagnosis report of his oral state including his periodontal status.~The usual care usually includes the extraction of non-preservable teeth, the dental prosthesis to replace them and at least one descaling session."
62139323|NCT03898505|EXPERIMENTAL|Low Dose|All Participants randomized to the low dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 50 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the low dose group will ingest 1 scoop of this test product per day (30-35g). Low dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Low dose test product will be consumed once per day for 60 days.
61943802|NCT04046237|EXPERIMENTAL|Periodontal treatment - Intervention group|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit at M9.~Briefly, the intervention group includes initial therapy with information on oral hygiene techniques, scaling and surfacing of dental roots. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
61943803|NCT02885207|OTHER|Focal epilepsy of unknown cause|
61943804|NCT01515878|EXPERIMENTAL|Dialysis with BVT|Dialysis using the BVT monitor biofeedback called Hemocontrol
61943805|NCT01515878|NO_INTERVENTION|Conventional dialysis|Conventional dialysis without blood volume tracking or similar therapies
61943806|NCT02890927|EXPERIMENTAL|Cardio-geriatric co-management|A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.
61943807|NCT02890927|NO_INTERVENTION|Standard of care|The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.
61943808|NCT00802087|EXPERIMENTAL|Egalet® hydrocodone treatment A|Single Dose administration
61943809|NCT00802087|EXPERIMENTAL|Egalet® hydrocodone Treatment B|Single Dose Administration
61943810|NCT00802087|EXPERIMENTAL|Egalet® hydrocodone Treatment C|Single Dose Administration
61943811|NCT00802087|EXPERIMENTAL|Egalet® hydrocodone Treatment D|Single Dose Administration
61943812|NCT00802087|ACTIVE_COMPARATOR|Active Comparator|Single Dose Administration
62696751|NCT04023110|NO_INTERVENTION|Usual Care|Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months.
61943813|NCT01212107|EXPERIMENTAL|Part A: 2 mg FGF Receptor QD|"Part A: Dose escalation~2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
62338966|NCT01173796|EXPERIMENTAL|PMFL ablation|Radio-frequency catheter ablation of the mitral isthmus only
62338967|NCT01173796|EXPERIMENTAL|Repeat PVAI and triggers ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
62338968|NCT03072641|EXPERIMENTAL|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
62495557|NCT05327322|ACTIVE_COMPARATOR|Standard Glycemic Load|This group will be prescribed a daily GL of \>75 points/1000kcal and 60% of daily calorie intake from carbohydrates. This group will be provided more processed foods than the low GL group. During the first 16 weeks, this group will eat enough calories to maintain baseline weight, and will reduce daily calorie intake by 500 kcal/day in the second 16 weeks.
62696752|NCT05214573||Aims 1, 2B, and 3 Groups|De-identified administrative claims with linked laboratory results, electronic health record (EHR), and mortality data from the OptumLabs Data Warehouse (OLDW) and Medicare fee-for-service data (Medicare parts A, B, D) will be utilized to identify adults (≥21 years) with T2D (established using validated Healthcare Effectiveness Data and Information Set criteria) who first filled any study drug GLP-1RA, SGLT2i, DPP-4i, or SU between 1/1/2014-12/31/2021.
62696753|NCT05214573||Aim 2A Group|Adults with Type 2 diabetes treated with one or more of the study medications (GLP-1RA, SGLT2i, DPP-4i, or SU) and not treated with insulin who receive medical care at Mayo Clinic Rochester, Mayo Clinic Health System in Minnesota or Wisconsin, or Emory University/Grady Hospital.
62696754|NCT05668624|EXPERIMENTAL|Full Subsidy Arm|This arm receives free LPG and stove for cooking following the baseline measures, for the duration of the 3-year follow-up period. For those households in Government of Rwanda designated areas for solar microgrids, this arm will also be connected to and provided free access to solar electricity for lighting.
62696755|NCT05668624|NO_INTERVENTION|Control Arm|This arm will remain using traditional forms of energy for cooking and lighting.
62696756|NCT05668624|EXPERIMENTAL|Discount Subsidy Arm|This arm will be randomized to a discounted price (at baseline and every 6-months during the 3-year study) for solar electricity (in areas marker for solar grids by the Government of Rwanda) and LPG gas in a pay-as-you-go (PAYG) service model (i.e., pre-pay an affordable amount through mobile money, a common form of currency transactions in Rwanda). For example, this arm will be asked to cook as normal and decide whether or not to cook with the discounted LPG or their traditional stove (i.e., they will not be required to pay for LPG).
61943814|NCT01212107|EXPERIMENTAL|Part A: 4 mg FGF Receptor QD|"Part A: Dose escalation~4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
61943815|NCT01212107|EXPERIMENTAL|Part A: 10 mg FGF Receptor QD|"Part A: Dose escalation~10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
61943816|NCT01212107|EXPERIMENTAL|Part A: 10 mg FGF Receptor QD + Phosphate Binders|"Part A: Dose escalation~10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
62338969|NCT03072641|NO_INTERVENTION|Control|
62338970|NCT01647659|EXPERIMENTAL|GSK1120212 tablet|GSK1120212 tablet
62338971|NCT01647659|EXPERIMENTAL|GSK1120212 powder for oral solution|GSK1120212 powder for oral solution
62338972|NCT04821973|ACTIVE_COMPARATOR|Control Respiratory Monitoring Group|
62338973|NCT04821973|EXPERIMENTAL|Experimental Respiratory Monitoring Group|
62338974|NCT01344837||Observational|Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).
62338975|NCT06049290|EXPERIMENTAL|LBL-034|LBL-034 for Injection; Initial dose - MTD; Q2W
62338976|NCT00001345||1|Members of families that have had relatives diagnosed with a disease of mineral metabolism. Participants will be asked to give blood samples for DNA extraction.
62338977|NCT04987541|EXPERIMENTAL|Active|"Participants received the real intervention of TBS (iTBS 600) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).~\*iTBS = intermittent theta burst stimulation"
62338978|NCT04987541|SHAM_COMPARATOR|Sham|Participants received the sham intervention of TBS (sham-coil) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).
62338979|NCT01917110|EXPERIMENTAL|omafilcon A|Contact Lens Group
62338980|NCT01917110|ACTIVE_COMPARATOR|Spectacle Group|Prescription at Baseline
62338981|NCT01364350||TODAY cohort|The cohort of participants diagnosed with type 2 diabetes ages 10 to \<18 and obese at time of diagnosis who participated in the TODAY clinical trial are recruited, consented and followed.
62338982|NCT04646980|EXPERIMENTAL|Biobran/MGN-3|This arm consisted from 20 males and 20 females. Biobran/MGN-3 was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
62338983|NCT04646980|PLACEBO_COMPARATOR|Placebo|This arm consisted from 20 males and 20 females. Placebo, with the same appearance and taste, was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
62338984|NCT03280641||Dabigatran Group|Patiets with atrial fibrillation received dabigatran (110mg, bid).
62338985|NCT03280641||Warfarin Group|Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
62338986|NCT04018196|EXPERIMENTAL|Experimental group|Patient aged over 80 years old will be included. They will have motor imagery training of manual task and motor imagery training of motor task.
62338987|NCT04018196|ACTIVE_COMPARATOR|Control group|Patient aged over 80 years old will be included. They will have emotionally neutral film as training of manual task and emotionally neutral film as training of motor task.
62338988|NCT03993964|EXPERIMENTAL|Experimental: Pyrotinib + SHR6390|Pyrotinib combine with SHR6390 should be administrate to all subjects. pyrotinib 400mg qd combined with SHR 6390 125mg qd
62338989|NCT02426593||Subjects without heart failure|
62338990|NCT03134651|ACTIVE_COMPARATOR|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
62495558|NCT04884724|EXPERIMENTAL|Adaptive Dance Exercise Group|"In addition to the routine physiotherapy programs received in the rehabilitation center for children and adolescents with cerebral palsy, an adaptive dance exercise program will be applied 2 days a week in the rehabilitation center for 5 weeks and online for 3 weeks in the presence of a physiotherapist. The duration of each session of the adaptive dance exercises to be applied is planned to be 45-60 minutes. It is planned that the adaptive dance exercises to be applied will be accompanied by the selected song.~Before and after the 8-week exercise program, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests."
62495559|NCT04884724|NO_INTERVENTION|Control Group|Children and adolescents diagnosed with Cerebral Palsy will continue their routine physiotherapy and rehabilitation programs in the rehabilitation center. At the beginning of the study and after 8 weeks, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests.
62495560|NCT02227550|EXPERIMENTAL|Apixaban|Xa group: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose)
62495561|NCT02227550|ACTIVE_COMPARATOR|Vitamin K antagonist|VKA group: any Vitamin K antagonist (VKA), INR 2-3 , min. 30 days prescribed as in clinical routine
62495562|NCT01540045||BASELINE|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study
62696757|NCT05585294|EXPERIMENTAL|Water based perturbation exercise group|"In both groups, the participants screened for Treatment-based classification of back pain and based on TBC interventions were provided. From second week, water based perturbation exercise were initiated personalized to the level of participants.~Treatment-based classification of back pain intervention was gradually tapered in orderly fashion during 6 weeks, concurrently introduced land based perturbation exercise gradually phased from level 1 to level 4."
62696758|NCT05585294|ACTIVE_COMPARATOR|Land based perturbation exercise group|All procedures were followed similar to Water based perturbation exercise group except perturbation based exercises were provided in land.
62338991|NCT03134651|ACTIVE_COMPARATOR|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
62338992|NCT04054349|EXPERIMENTAL|Low FODMAP Diet Group|The parent/caregiver was given detailed nutrition education by the investigator concerning the low FODMAP diet and was asked to implement for 2 weeks.
62338993|NCT04054349|NO_INTERVENTION|Control Group (Habitual Diet)|The parent/caregiver was asked to continue their child's usual dietary intake for 2 weeks.
62338994|NCT05116514|EXPERIMENTAL|Case manager group|
62338995|NCT05116514|NO_INTERVENTION|Control|
62338996|NCT01766882|EXPERIMENTAL|Treatment|"1. Lower sodium intervention:~   Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day~   Lower dialysate sodium at 137 mmol/L.~2. Progressive Challenge to Post Dialysis Weight:~The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments."
62696759|NCT03332056|ACTIVE_COMPARATOR|Belladonna and Opium (B&O) suppository|A single belladonna and opium suppository, dose-weight calculated, administered immediately following patient positioning prior to instrumentation. The pharmacologically active ingredients that are present in the belladonna extract consist of atropine and scopolamine. Opium is compound drug that is composed of 20 alkaloids. The principle alkaloid that derives the majority of its effect is its morphine content and acts as a narcotic analgesic by increasing the pain threshold or the magnitude of stimulus required to evoke pain.
62696760|NCT03332056|PLACEBO_COMPARATOR|Placebo Suppository|placebo suppository
62696761|NCT05750784|OTHER|total knee arthroplasty using the active robotic system using the kinematic alignment concept|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
62696762|NCT05750784|OTHER|total knee arthroplasty using the active robotic system using the mechanical alignment concept|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
62696763|NCT04906343|NO_INTERVENTION|Group 1 (2 years)|Group 1, surveillance colonoscopy in two years after the last complete colonoscopy in SPS patient.
62696764|NCT04906343|ACTIVE_COMPARATOR|Group 2 (3 years)|Group 2, surveillance colonoscopy in three years after the last complete colonoscopy in SPS patient.
62696765|NCT03969030|EXPERIMENTAL|Intervention|"Participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery."
62696766|NCT03969030|NO_INTERVENTION|Control|Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club).
62696767|NCT05618925|EXPERIMENTAL|Arm A|Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab
62696768|NCT05618925|EXPERIMENTAL|Arm B|Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab (cohort A) or in combination with rituximab and N-803 (cohort B).
62696769|NCT05797623|EXPERIMENTAL|Trappa ethanolamine tablets combined with ciclosporin|
62495563|NCT05909163||Pakinson's disease without cognitive impairment|"* Age 50-90 years~* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank criteria) made by a movement disorders specialist~* Under the care of a movement disorders specialist for a minimum of 1-year duration~* Native monolingual English speaker~* Hoehn \& Yahr score between 1.5 and 4~* Grade 10 education, or higher~* Sufficient vision and hearing (aided or unaided) for all experiment tasks~* Montreal Cognitive Assessment (or MoCA-converted MMSE score) greater than or equal to 25~* No subjective complaints of cognitive difficulty or word finding issues"
62495564|NCT05909163||Pakinson's disease with cognitive impairment|"* Age 50-90 years~* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank criteria) made by a movement disorders specialist~* Under the care of a movement disorders specialist for a minimum of 1-year duration~* Native monolingual English speaker~* Hoehn \& Yahr score between 1.5 and 4~* Grade 10 education, or higher~* Sufficient vision and hearing (aided or unaided) for all experiment tasks~* Montreal Cognitive Assessment (or MoCA-converted MMSE score) greater than or equal to 17~* Subjective complaints of cognitive difficulty or word finding issues, without significant impact on activities of daily living"
62495565|NCT05259956|EXPERIMENTAL|"3 plus 1 multidimensional exercise therapy"|The intervention consists of a Schroth-based exercise session and a manipulative therapy of pelvic asymmetry.
62696770|NCT05797623|PLACEBO_COMPARATOR|Placebo combined with ciclosporin|
62696771|NCT06571162|ACTIVE_COMPARATOR|Usual Care|Patients will receive usual care for their LDL-C management.
62696772|NCT06571162|EXPERIMENTAL|Clinical Pharmacy Team|Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.
62696773|NCT04190472||IOP VPH test|Immediately after the LEEP, a cervical sample is token for the IOP-HPV test
62696774|NCT04905407|EXPERIMENTAL|Part 1: Tamibarotene/Venetoclax/Azacitidine|"Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination as follows: Azacitidine (intravenously or subcutaneously) at 75 milligrams (mg)/square meter (m\^2) once daily, on Days 1 through 7 of each 28-day therapy cycle (per VIDAZA USPI). Alternative dosing of azacitidine (Days 1 through 5, 8, and 9) will be permitted throughout the study.~Venetoclax (orally) daily on Days 1 through 28 per standard of care. Standard of care daily dosing is 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and beyond.~Tamibarotene 6 mg twice daily (BID) orally, on Days 8 through 28 of each 28-day therapy cycle. Tamibarotene will only be administered to participants who have been confirmed as RARA-positive."
62696775|NCT04905407|EXPERIMENTAL|Part 2: Tamibarotene/Venetoclax/Azacitidine|Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination at the dose and regimen selected in Part 1.
62696776|NCT04905407|ACTIVE_COMPARATOR|Part 2: Venetoclax/Azacitidine|Participants will receive the venetoclax/azacitidine combination at the dose and regimen selected in Part 1.
61943817|NCT01212107|EXPERIMENTAL|Part A: 8 mg FGF Receptor BID|"Part A: Dose escalation~8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
62338997|NCT01766882|NO_INTERVENTION|Control|Usual care in addition to Blood pressure monitoring and and Hydration status monitoring
62338998|NCT02921919|EXPERIMENTAL|Talazoparib|
62338999|NCT04761029|ACTIVE_COMPARATOR|grup R|Unilateral Rhomboid intercostal and subserratus block + intravenous patient-controlled analgesia
62696777|NCT04905407|EXPERIMENTAL|Part 3: Tamibarotene/Venetoclax/Azacitidine|Part 2 participants treated with venetoclax/azacitidine who experience progressive disease, relapse after initial CR or CRi response, or treatment failure may begin subsequent treatment in Part 3, where tamibarotene will be added to their regimen.
61943818|NCT01212107|EXPERIMENTAL|Part A: 10 mg FGF Receptor BID|"Part A: Dose escalation~10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
61943819|NCT01212107|EXPERIMENTAL|Part A: 14 mg FGF Receptor BID|"Part A: Dose escalation~14 FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
61943820|NCT01212107|EXPERIMENTAL|Part A: 18 mg FGF Receptor BID|"Part A: Dose escalation~18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
61943821|NCT01212107|EXPERIMENTAL|Part A: 24 mg FGF Receptor BID|"Part A: Dose escalation~24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
61943822|NCT01212107|EXPERIMENTAL|Part A: 18 mg FGF Receptor BID Extension|"Part A: Dose escalation~18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
61943823|NCT01212107|EXPERIMENTAL|Part A: 16 mg FGF Receptor BID|"Part A: Dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
62696778|NCT00541424||PET/CT Scanning|Patients that have newly diagnosed mantle cell lymphoma will first undergo CT colonography (CT or CTC) and PET followed by conventional colonoscopy.
61943824|NCT01212107|EXPERIMENTAL|Part B: 16 mg FGF Receptor BID|"Part B: Dose determined by part a dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
62139324|NCT03898505|EXPERIMENTAL|High Dose|All Participants randomized to the high dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 200 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the high dose group will ingest 1 scoop of this test product per day (30-35g). High dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. High dose test product will be consumed once per day for 60 days.
62139325|NCT06171711|EXPERIMENTAL|Exposure Therapy|Exp-AN will effectively target anxiety related to eating and weight gain via inhibitory learning, and improve treatment outcomes.
61943825|NCT06391125|EXPERIMENTAL|Lidocaine + Benzathine Penicillin G Arm|0.5ml 1% lidocaine solution added to prefilled 1.2 million units Benzathine Pencillin G syringe which will be injected once into the gluteal muscle of the study participant, the side (left or right) to be randomly assigned with the control assigned to the other gluteal muscle.
62139326|NCT01562834|EXPERIMENTAL|Somatropin|
62139327|NCT01562834|PLACEBO_COMPARATOR|Placebo|
62696779|NCT06603493||Headache Group|individuals diagnosed with migraine and tension-type headache according to the International Classification of Headache Disorders (International Classification of Headache Disorders, 3rd edition) will be placed in the headache group
61943826|NCT06391125|PLACEBO_COMPARATOR|Normal Saline + Benzthine Penicillin G Arm|0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe which will be injected once into the gluteal muscle of the study participant, the side (left or right) to be randomly assigned with the study arm assigned to the other gluteal muscle.
61943827|NCT04332133|ACTIVE_COMPARATOR|group 1|group 1 of DME which treated by SML
61943828|NCT04332133|ACTIVE_COMPARATOR|group 2|Group 2 of DME which treated by intravitreal injection of Ranibizumab
61943829|NCT04332133|NO_INTERVENTION|group 3|control group of diabetic patients received no treatment
61943830|NCT02717273|ACTIVE_COMPARATOR|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
62139328|NCT03800914|EXPERIMENTAL|High Intensity Interval Training|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
62139329|NCT03800914|ACTIVE_COMPARATOR|Traditional pulmonary rehabilitation|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
62139330|NCT06699511|ACTIVE_COMPARATOR|pilates exercise|pilates exercise
62139331|NCT06699511|ACTIVE_COMPARATOR|Home exercis|Home exercise
62139332|NCT06699472|EXPERIMENTAL|Chemotherapy+Trilaciclib|Receive VDC+IE alternating chemotherapy combined with Trilaciclib, with 3 weeks as one course of treatment, for a total of 17 cycles or until disease progression and intolerable toxicity occur.
62139333|NCT06699472|ACTIVE_COMPARATOR|Chemotherapy|Receive VDC+IE alternating chemotherapy with 3 weeks as one course of treatment, for a total of 17 cycles or until disease progression and intolerable toxicity occur.
62139334|NCT01096472|EXPERIMENTAL|LAS41003|Once daily
62696780|NCT06603493||Control Group|Individuals aged 18-65 without headaches will be placed in control group.
62696781|NCT04695366||Diffuse large B-cell lymphoma patients in year 1 and 2 of clinical follow-up|Patients (Diffuse Large B-cell Lymphoma) in complete remission after primary treatment and entering the regular follow-up program at the clinic. Baseline is defined as date of end-of-treatment visit.
62696782|NCT06386107|EXPERIMENTAL|Patients with cancer associated thrombosis under curative anticoagulant treatment|Patients with cancer associated thrombosis under curative anticoagulant treatment.
62696783|NCT01506726|EXPERIMENTAL|Active drug - oral salsalate|Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.
62696784|NCT01506726|PLACEBO_COMPARATOR|Placebo Arm|Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.
62696785|NCT05755269||Observational (blood collection, genotyping, surveys)|Patients complete a survey and undergo collection of a blood sample for PRS genotyping at baseline. Patients receive their PRS results and complete another survey 6 weeks to 6 months after baseline and then complete surveys annually over 10 years on study.
62696786|NCT06100120|EXPERIMENTAL|Hybrid implants|Hybrid implants will be placed in this group
62696787|NCT06100120|ACTIVE_COMPARATOR|Fully etched implants|Fully etched implants will be placed in this group
62696788|NCT05427929|EXPERIMENTAL|NVR 4mm Edi Catheter|
62696789|NCT05128903|EXPERIMENTAL|Participants|Participants who meet the eligibility criteria in the study will receive Translocation Protein (TSPO) Positron Emission Tomography (PET) for longitudinal, quantitative assessment of brain neuroinflammation following whole brain radiation therapy.
61943831|NCT02717273|EXPERIMENTAL|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
61943832|NCT01757327|EXPERIMENTAL|Arm I (erismodegib [LDE225])|400 mg daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
61943833|NCT01757327|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
62696790|NCT06063876|EXPERIMENTAL|Implants with history of peri-implantitis|Implant(s) treated previously for peri-implantitis with or without exposed polished surface, no PD \> 4 mm and \< 50% bone loss.
62696791|NCT06483113||DAILIES TOTAL1 Sphere|Delefilcon A spherical soft contact lenses worn in both eyes in a real-world setting
62696792|NCT06483113||DAILIES TOTAL1 Toric|Delefilcon A toric soft contact lenses worn in both eyes in a real-world setting
61943834|NCT01753141|EXPERIMENTAL|Active|Cognitive Behavioral Therapy for smoking cessation plus anxiety sensitivity reduction.
61943835|NCT01753141|ACTIVE_COMPARATOR|Control|Cognitive Behavioral Therapy for smoking cessation.
61943836|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
62139335|NCT01096472|ACTIVE_COMPARATOR|LAS189962|Once daily
62696793|NCT06483113||DAILIES TOTAL1 Multifocal|Delefilcon A multifocal soft contact lenses worn in both eyes in a real-world setting
62139336|NCT01096472|ACTIVE_COMPARATOR|LAS189961|Once daily
62139337|NCT05419466|EXPERIMENTAL|melatonin and zinc bioavailability|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm
62696794|NCT04280588|EXPERIMENTAL|Treatment group|
62696795|NCT04280588|NO_INTERVENTION|Control group|
62696796|NCT03286361|EXPERIMENTAL|BeGraft Peripheral + Stent Graft System|Patients treated with the BeGraft Peripheral Plus Stent Graft System
62696797|NCT04708847|EXPERIMENTAL|Pre-immobilization active drug group|Subjects will receive a single subcutaneous dose of GYM329 on Day 1 and a single subcutaneous dose of placebo on Day 15.
62696798|NCT04708847|EXPERIMENTAL|Post-immobilization active drug group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of GYM329 on Day 15.
62696799|NCT04708847|PLACEBO_COMPARATOR|Placebo group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of placebo on Day 15.
62696800|NCT04943848|EXPERIMENTAL|"Lead In: rHSC-DIPGVax Monotherapy"|rHSC-DIPGVax for 8 total doses
62696801|NCT04943848|EXPERIMENTAL|Part A: rHSC-DIPGVax in Combination with BALSTILIMAB (Anti-PD1)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB), the study will proceed to Part B."
62696802|NCT04943848|EXPERIMENTAL|Part B: Dose Escalation of ZALIFRELIMAB (Anti-CTLA4)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB), the study will proceed to Part C."
62139338|NCT02208414|EXPERIMENTAL|Crab or shrimp|Intervention: treated with crab and shrimp energy signature vial using NAET
62139339|NCT02208414|PLACEBO_COMPARATOR|Placebo|Treated with water vial
62139340|NCT03477305|EXPERIMENTAL|BerryCare Participants|Subjects will be recruited to participate in a community gardening program where they will learn the benefits of both physical active gardening and consuming homegrown foods through blackberry consumption.
62139341|NCT04329221|EXPERIMENTAL|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
62696803|NCT04943848|EXPERIMENTAL|Part C: Dose Expansion|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity."
62696804|NCT00642759|EXPERIMENTAL|Chemotherapy|Carboplatin, nab-paclitaxel, and bevacizumab
62696805|NCT00936650|EXPERIMENTAL|cinacalcet|
62696806|NCT00936650|PLACEBO_COMPARATOR|placebo|
61943837|NCT05859685|EXPERIMENTAL|Experimental group|"The patients included in the experimental group will undergo the following manual therapy techniques:~* Talar dorsal sliding technique. A dorsal mobilization of the talus will be performed, with the patient in the supine position and dorsiflexion of the ankle, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~* Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
61943838|NCT05859685|PLACEBO_COMPARATOR|Control group|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
61943839|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
61943840|NCT02925832|EXPERIMENTAL|Group B|Deep Topical Fornix Nerve block anesthesia using bupivacaine and proparacaine
61943841|NCT02925832|EXPERIMENTAL|Group R|Deep Topical Fornix Nerve block anesthesia using ropivacaine and proparacaine
61943842|NCT05221710|NO_INTERVENTION|Acupuncture Group|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling)"
61943843|NCT05221710|EXPERIMENTAL|Electroacupuncture Group|On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation
61943844|NCT05221710|NO_INTERVENTION|Neuromuscular Electrical Stimulation Group|Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points
61943845|NCT05357638|EXPERIMENTAL|Physical Training Group 1 (n=16)|High Intensity Interval Training
62139342|NCT04329221|PLACEBO_COMPARATOR|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
62139343|NCT03443700|ACTIVE_COMPARATOR|sLT|Standard neurorehabilitation locomotor training during the whole study period (8 weeks).
62139344|NCT03443700|EXPERIMENTAL|sLT + EX-T|Standard neurorehabilitation locomotor training (sLT) during the whole study period (8 weeks), plus a training with a new-generation robotic anthropomorphic exoskeleton (EKSO-GT locomotor training) during the first 4 study weeks.
62139345|NCT06699173|EXPERIMENTAL|İntervention Group|"Experimental :~Heat application was not applied routinely to the intervention group, and unlike the intervention group, heat application was not applied only with thermophor to the control group. However, the scales and forms were evaluated and blood pressure and pulse rate were measured during the same period. Incollecting data; 'Individual Introduction Form', 'Information Form Regarding the Cystoscopy Procedure', 'Visual Comparison Scale (VAS)', 'Data Recording Form', 'State Anxiety Scale' and 'General Comfort Scale Short Form' were used.~Thermophor Prosedure~Before the cystoscopy procedure, the temperature of the water was measured as 40-45°C. Approximately two-thirds of the bag was filled with hot water and the air in the bag was removed. The bag was dried and checked for leakage, then wrapped with the bag's cover and placed on the patient's lower abdomen body area 5 minutes before the cystoscopy procedure."
62139346|NCT06699173|NO_INTERVENTION|Control Group|The scales and forms were evaluated and blood pressure and pulse rate were measured during the same period. Incollecting data; 'Individual Introduction Form', 'Information Form Regarding the Cystoscopy Procedure', 'Visual Comparison Scale (VAS)', 'Data Recording Form', 'State Anxiety Scale' and 'General Comfort Scale Short Form' were used.
62139347|NCT01440933|ACTIVE_COMPARATOR|Magnesiumsulphate|
62139348|NCT01440933|PLACEBO_COMPARATOR|Physiologic saline|
62139349|NCT06698666|OTHER|The Control Group|The Control Group will receive the standard treatment of depression including SSRI (Sertraline) only
62139350|NCT06698666|EXPERIMENTAL|The Interventional group|the interventional group will receive the standard treatment of depression including SSRI (Sertraline) in addition to the10 mg/day rosuvastatin
62139351|NCT03340909|EXPERIMENTAL|Prednisolone|Prednisolone tablets 5 mg
62139352|NCT03340909|PLACEBO_COMPARATOR|Placebo|Placebo tablets with identical appearance to the experimental drug.
62139353|NCT06025318|EXPERIMENTAL|PanCytoVir™ 1000 mg fasted|Single oral dose of PanCytoVir™ 1000 mg (100 mg/mL suspension) following an overnight fast
62139354|NCT06025318|EXPERIMENTAL|PanCytoVir™ 1000 mg fed|Single oral dose of PanCytoVir™ 1000 mg (100 mg/mL suspension) following a standard, high-fat, high-calorie breakfast
62495566|NCT05259956|ACTIVE_COMPARATOR|Schroth based scoliosis specific exercise|The intervention consists of the Schroth-based exercise session.
62495567|NCT03428945|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine compound for oral use
62696807|NCT00539500|EXPERIMENTAL|Transplantation CD133+ cells|Stem Cell Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan
61943846|NCT05357638|EXPERIMENTAL|Physical Training Group 2 (n=16)|Continuous Aerobic Training
62495568|NCT03428945|PLACEBO_COMPARATOR|Placebo|Placebo tablet matching active drug
62696808|NCT06471010||B-DIT|
62696809|NCT04666740|EXPERIMENTAL|Cohort A: Core HRD|Patients with either pathogenic germline or somatic alterations of 3 core homologous recombination-genes (HR-genes) - (BRCA1/2, or PALB2) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort A.
61943847|NCT05357638|EXPERIMENTAL|Physical Training Group 3 (n=16)|Movement Advice
61943848|NCT01820065||Patients undergoing phacoemulsification|Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)
61943849|NCT01931930|EXPERIMENTAL|Perilla extract|Experimental arm: Perilla extract
61943850|NCT01931930|PLACEBO_COMPARATOR|Maltodextrin|Placebo arm: Maltodextrin
61943851|NCT05788900|ACTIVE_COMPARATOR|Reference Drug|Healthy participants using intravenous Heparin Sodium Injection, USP (Fresenius Kabi) to assess the pharmacodynamic profile
61943852|NCT05788900|EXPERIMENTAL|Test Drug|Healthy participants using intravenous Heparin Test to assess the pharmacodynamic profile
61943853|NCT06680024|ACTIVE_COMPARATOR|Intercostal tube|Intercostal tube as a primary intervention for treatment of second stage empyema
61943854|NCT06680024|ACTIVE_COMPARATOR|Video assisted thoracoscope|Video assisted thoracoscopic evacuation as a primary intervention for treatment of nd stage empyema
62495569|NCT03852745|OTHER|Cognitive Behavioral Therapy|Online cognitive behavioral therapy intervention for 2 hours a week for 12 weeks.
62495570|NCT04947150|EXPERIMENTAL|LOCATION TRIGGERED MESSAGING|Weekly message is triggered when arriving at grocery store.
62495571|NCT04947150|EXPERIMENTAL|COACH MONITORING|Coaches view grocery purchases via web portal, send weekly messages about purchases they observe, and conduct three brief phone calls to discuss purchases.
62495572|NCT04947150|EXPERIMENTAL|BENEFITS OF CHANGE|Attend an extra workshop session and three phone calls to identify and reflect on benefits of dietary change. Content added to standard weekly messages about benefits of change.
62495573|NCT04947150|EXPERIMENTAL|HOUSEHOLD SUPPORT|An adult household member attends one workshop session and three phone calls with the index participant. This household member receives weekly text messages for 20 weeks about program goals and ways to support the index participant.
62495574|NCT00841620|ACTIVE_COMPARATOR|1|Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids
62495575|NCT00841620|ACTIVE_COMPARATOR|2|Stapled anopexy for grade 3-4 haemorrhoids
62495576|NCT02976064|EXPERIMENTAL|PreHab_Intervention|Experimental group of the prehabilitation trial
61943855|NCT04925726|ACTIVE_COMPARATOR|Land based exercise|Land based exercise
61943856|NCT04925726|ACTIVE_COMPARATOR|Water based exercise|Water based exercise
62139355|NCT06090513||Control/Standard|Standard patient group: advanced cancer patients receiving limited and acceptable care without access to advanced genetic testing tools or expertise; patients at facility prior to deployment of TSO500, ELIA, and molecular tumor boards.
62139356|NCT06090513||Test group|Same patient population at the same facility after deployment of TSO500, ELIA, and molecular tumor board support.
62495577|NCT02976064|NO_INTERVENTION|PreHab_Control|Control group of the prehabilitation trial
61943857|NCT04047329||Without post-operative myocardial infarction|Patients without post-operative myocardial infarction after first admission for transurethral resection of the prostate
61943858|NCT04047329||With post-operative myocardial infarction|Patients with post-operative myocardial infarction after first admission for transurethral resection of the prostate
61943859|NCT03384888|EXPERIMENTAL|ano-M1-cat-SO5 tDCS|Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.
61943860|NCT03384888|EXPERIMENTAL|ano-M1-cat-SO10 tDCS|Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.
62139357|NCT05968170|EXPERIMENTAL|Patients receiving allogeneic hematopoietic stem cell transplants|"The test product is an αβ+/CD19+ T-cell depleted stem cell product using the CliniMACS system. The test product is given intravenously over a period of time as dictated by the final volume of the infused product (5mL/kg/hour).~The target dose of CD34+ cells is 20-40 x 10\^6/kg, but a minimum of 5 x 10\^6/kg is required. The target dose of TCRαβ+ T-cells and CD19+/CD20+ T-cells is ≤ 1 x 10\^5/kg."
62139358|NCT02736851|NO_INTERVENTION|Control group|Usual care
62139359|NCT02736851|ACTIVE_COMPARATOR|Home-based telemedicine group|Nurse-tutor support at home for 6 months
62495578|NCT02976064|EXPERIMENTAL|Chronic patients_Intervention|Experimental group of the Rehabilitation in chronic stable patients in primary care trial
62495579|NCT02976064|NO_INTERVENTION|Chronic patients_Control|Control group of the Rehabilitation in chronic stable patients in primary care trial
62495580|NCT02976064|EXPERIMENTAL|Citizens & mild disease_Intervention|Experimental group of the Rehabilitation in mild chronic patients and citizens at risk trial
62495581|NCT02976064|NO_INTERVENTION|Citizens & mild disease_Control|Control group of the Rehabilitation in mild chronic patients and citizens at risk trial
62495582|NCT02134639||Patient who is suspected of endocrine tumors|According to symptomatology, biology or imaging or pathological context
62495583|NCT02405793|EXPERIMENTAL|Meloxicam low dose test capsule|Meloxicam SoluMatrix Capsules - low dose QD
62495584|NCT02405793|EXPERIMENTAL|Meloxicam high dose test capsule|Meloxicam SoluMatrix Capsules - high dose QD
62495585|NCT02405793|ACTIVE_COMPARATOR|Meloxicam tablets|Meloxicam Tablets QD
62495586|NCT03510312||Long-term follow up, observational|This cohort does not involve interventions, just follow up of prognosis of ischemic stroke/transient ischemic attack patients.
62495587|NCT03105193|EXPERIMENTAL|Intraperitoneal Lignocaine|IP Lignocaine
62495588|NCT03105193|EXPERIMENTAL|Intravenous lignocaine|IV lignocaine
62495589|NCT00797576||1/Cases|Subjects whom had cardioversion aborted due to LAA thrombus or suspicion of LAA thrombus on TEE.
62495590|NCT00797576||2/Controls|Subjects with underlying atrial fibrillation undergoing elective TEE as clinically indicated for any reason.
61943861|NCT03384888|SHAM_COMPARATOR|Sham tDCS|Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.
61943862|NCT06557928||Doctors to Tibet from Peking Union Medical College Hospital in 2024|
61943863|NCT06557928||Doctors to Tibet from Peking Union Medical College Hospital in 2025|
61943864|NCT06104176|ACTIVE_COMPARATOR|CBT group|
61943865|NCT06104176|EXPERIMENTAL|VRET group|
61943866|NCT00268788|ACTIVE_COMPARATOR|1|Subcutaneous Ig given twice a week.
61943867|NCT00268788|ACTIVE_COMPARATOR|2|Intravenous Ig
62495591|NCT05712564||MFS_cohort|Adult patients with Marfan syndrome
61943868|NCT01219998||NGAL Kinetics in neonates|to describe postoperative kinetics of urinary NGAL in neonates and to identify the threshold for accurate prediction of severe AKI requiring RRT in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass
61943869|NCT02654847|ACTIVE_COMPARATOR|Norepinephrine 3 micrograms/mL|1mL of a solution of norepinephrine, containing 3 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
61943870|NCT02654847|ACTIVE_COMPARATOR|Norepinephrine 4 micrograms/mL|1mL of a solution of norepinephrine, containing 4 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
61943871|NCT02654847|ACTIVE_COMPARATOR|Norepinephrine 5 micrograms/mL|1mL of a solution of norepinephrine, containing 5 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
61943872|NCT02654847|ACTIVE_COMPARATOR|Norepinephrine 6 micrograms/mL|1mL of a solution of norepinephrine, containing 6 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
61943873|NCT02654847|ACTIVE_COMPARATOR|Norepinephrine 7 micrograms/mL|1mL of a solution of norepinephrine, containing 7 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
61943874|NCT02654847|ACTIVE_COMPARATOR|Norepinephrine 8 micrograms/mL|1mL of a solution of norepinephrine, containing 8 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
61943875|NCT00885053|EXPERIMENTAL|Fish oil|
61943876|NCT00885053|PLACEBO_COMPARATOR|Olive oil|
61943877|NCT03824184|ACTIVE_COMPARATOR|Hysteroscopic evaluation|Hysteroscopic evaluation Active group : infection Manipulation of endometrium with saline
62495592|NCT05712564||EDS_cohort|Adult patients with Ehlers-Danlos syndrome
62495593|NCT05459116|EXPERIMENTAL|Overall group|Placement of a nasogastric balloon
61943878|NCT03824184|OTHER|control group|Hysteroscopic evaluation Control group : No infection
61943879|NCT01788046|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
61943880|NCT01788046|EXPERIMENTAL|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.
62696810|NCT04666740|EXPERIMENTAL|Cohort B: Non core HRD|Patients with either pathogenic somatic or germline non-core 14 HR-gene alterations (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort B.
61943881|NCT02585154|EXPERIMENTAL|Closed-loop Deep Brain Stimulation|Closed-loop Deep Brain Stimulation
62139360|NCT00843934|EXPERIMENTAL|anti-cancer agent|
62339000|NCT04761029|PLACEBO_COMPARATOR|Group P|intravenous patient-controlled analgesia
62495594|NCT03064867|EXPERIMENTAL|V+RICE|"Venetoclax given in combination with R-ICE chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide)~Phase I part of this study is a 3 + 3 design, with 3 dose levels, a minimum of 6 participants (maximum of 18) will be required to identify the recommended phase 2 dose (RP2D).~Phase II involvs two stages: In stage I, a total of 16 participants will be accrued. If there are 7 or fewer complete responses (CR), the study will be stopped. Otherwise, an additional 30 participants will be accrued in stage II.~The maximum number of treatment cycles with V+RICE is three. Participants who achieve complete remission at the interim response assessment after 2 cycles may omit cycle 3 in order to proceed to subsequent consolidation therapy with autologous stem cell transplant (AHSCT).~Participants will proceeed to other treatment including RICE, other chemotherapy, peripheral blood stemm cell collection, and ASCT per institutional guidelines."
62495595|NCT01505049||Previously received all three doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received their third dose of vaccine three or more years ago. Recruitment of this group was completed in Sept 2012.
62696811|NCT04666740|EXPERIMENTAL|Cohort C: Platinum sensitive|Patients without any of the above HR-gene alterations included in Cohort A and B who have platinum-sensitivity, which is defined as a partial response (PR) or complete response (CR) for the best overall response (BOR) during at least 4 months on platinumbased therapy. Variants of unknown significance of candidate HR-genes from Cohort A or B will be eligible for Cohort C if they meet the partial response to platinum criterion.
61943882|NCT02585154|ACTIVE_COMPARATOR|Open loop Deep Brain stimulation|Open loop Deep Brain stimulation
61943883|NCT02585154|OTHER|No Deep Brain Stimulation|No Deep Brain Stimulation
61943884|NCT05192473|EXPERIMENTAL|Lithotripsy Treatment|"Pulse Intravascular Lithotripsy System~Device: Pulse Intravascular Lithotripsy Catheter"
62139361|NCT03985774||Patients requiring carotid revascularization|Symptomatic patients, male or female, with atherosclerotic extracranial internal carotid stenosis (ICA) with or without involvement of the contiguous common artery (CCA), that require carotid revascularization.
62139362|NCT06699693|ACTIVE_COMPARATOR|Group1 Injection+Mobilization|Group 1 patients underwent ultrasound-guided PENG block (20 cc of a solution containing 0.25% bupivacaine hydrochloride and 6 mg betamethasone) by an experienced algologist (BU) before starting mobilization treatment
62139363|NCT06699693|ACTIVE_COMPARATOR|Group 2 Mobilization|only mobilization therapy on shoulder pain, function, and kinesiophobia in patients with AC resistant to conservative treatment,
62139364|NCT04038424|EXPERIMENTAL|Study group|The intervention group (n = 30) will receive Routine Hospital Management (RHM), conventional rehabilitation activity and AT (painting, coloring, listening to music and Hand Therapy Ball Exercises). Overall 9 sessions over a period of three weeks will be performed and each session will take around 30 min.
62339001|NCT04719676|EXPERIMENTAL|Core strength training using unstable surface|The experimental group will use Core strength training using unstable surface
62339002|NCT04719676|ACTIVE_COMPARATOR|The stable surface would be gym floor.|The control group will use stable surface.
62339003|NCT02076321|OTHER|Acetaminophen|control group
62339004|NCT02076321|OTHER|NSAID (Ibuprofen)|Study group
61943885|NCT05522452|EXPERIMENTAL|Telerehabilitation group|"The telerehabilitation group will participate in the treatment in their homes. While the participants are performing the activities in their own homes, applications will be made via webcam-based software (Zoom) and synchronous access via video and audio from the physiotherapist's computer screen. The activities determined by the physiotherapist will be directed to the family, and the activities will be adapted and implemented according to the child's needs and functional level.~Physiotherapy program will include the following applications:~* Tone regulation~* Active stretching and strengthening exercises~* Gross and fine motor activities to improve bilateral hand use~* Daily living activities to improve upper extremity functional skills such as dressing, eating, and buttoning.~* Arts and crafts activities"
61943886|NCT05522452|ACTIVE_COMPARATOR|Face to face group|"The face-to-face group will be treated in the clinic. To this group; The activities determined by the physiotherapist will be applied face to face.~Physiotherapy program will include the following applications:~* Tone regulation~* Active stretching and strengthening exercises~* Gross and fine motor activities to improve bilateral hand use~* Daily living activities to improve upper extremity functional skills such as dressing, eating, and buttoning.~* Arts and crafts activities"
61943887|NCT00113087|ACTIVE_COMPARATOR|Enalapril|Enalapril (angiotensin converting enzyme inhibitor)
62696812|NCT03162627|EXPERIMENTAL|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.~When maximum tolerated dose reached, Dose Expansion Phase begins."
62139365|NCT04038424|NO_INTERVENTION|Control group|The control group (n = 30) will receive only the Routine Hospital Management (RHM) and the department conventional rehabilitation activity.
61943888|NCT00113087|PLACEBO_COMPARATOR|Placebo|Placebo (Ora-Plus and Ora-Sweet)
62495596|NCT01505049||Previously received two doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received two doses of the HPV vaccine. The second dose must have been received six or more months ago.
61943889|NCT02256371|EXPERIMENTAL|Hypnotic analgesia|"Hypnosis sessions:~Hypnosis will consist of 45 minutes hypnosis session with a trained hypnotherapist"
62139366|NCT00562614|EXPERIMENTAL|1|SLx-2101
62495597|NCT01505049||Unvaccinated Cohort|This group will consist of 45 women who have not received their HPV vaccination. Women ages 18-26 are eligible for this cohort. Recruitment for this group was completed in January 2013.
62495598|NCT01181830|ACTIVE_COMPARATOR|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
62495599|NCT01181830|PLACEBO_COMPARATOR|placebo|administration of 8.1 mmol bid of placebo for 8 weeks
62139367|NCT00562614|PLACEBO_COMPARATOR|2|Comparative Placebo Dose
62139368|NCT05774704|ACTIVE_COMPARATOR|Low curcumin group|
62139369|NCT05774704|ACTIVE_COMPARATOR|High curcumin group|
62139370|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
62139371|NCT01611545||Clopidogrel|Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
62495600|NCT00697918|EXPERIMENTAL|001|RWJ-333369100 mg to 400 mg twice daily
62495601|NCT00493727|OTHER|1|
62495602|NCT03699254|ACTIVE_COMPARATOR|Control|"Control Group (universal prophylaxis + pre-emptive therapy; 6+6): The recommendation of the Spanish Consensus Document will be followed according to the strategy described below:~* Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +6. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend on each center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of patients will depend oneach center's clinical practice.~* Pre-emptive therapy guided by viral load from month +6 to month +12. For a viral load above\> 38 copies/mL (\> 35 IU/mL) and depending on each center's clinical practice, treatment with valganciclovir may be initiated (900 mg/12h, corrected for renal function)."
62495603|NCT03699254|EXPERIMENTAL|Experimental|"Experimental Group (reduced prophylaxis + immuno-guided prophylaxis; 3+9):~* Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +3. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend oneach center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of the patients will depend on the each center's clinical practice.~* Immuno-guided prophylaxis. This will consist of a monthly determination of cellular immunity by QF-CMV from month +3 to month +12."
62696813|NCT03162627|EXPERIMENTAL|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
62696814|NCT03162627|EXPERIMENTAL|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
62696815|NCT03162627|EXPERIMENTAL|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
62696816|NCT03162627|EXPERIMENTAL|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
62696817|NCT05914129|SHAM_COMPARATOR|Control Group (GC)|To each volunteer, after 2 questionnaires, sham techniques will be performed to this group. The investigator will mimic the technique contacts without actually performing any type of tissue traction or compression, maintaining contact for the same amount of time described in the refered techniques. Following the technique, volunteers will answer the same 2 questionnaires shown previously.
62139372|NCT00523419|EXPERIMENTAL|Pemetrexed|Participants received pemetrexed 500 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
62139373|NCT06075017|EXPERIMENTAL|Zirconia|Two-piece zirconia dental implant will be placed to replace a single missing tooth.
62139374|NCT06075017|ACTIVE_COMPARATOR|Titanium|Two-piece titanium dental implant will be placed to replace a single missing tooth.
62139375|NCT06698484|EXPERIMENTAL|Patient will infuse with autologous CD19 CAR-T cells|CD19 CAR-T cells
62139376|NCT05500690|EXPERIMENTAL|Folic Acid|5 mg folic acid supplement by mouth once a day for 12 weeks
62339005|NCT05601024|EXPERIMENTAL|Experimental Group|"1. After obtaining permission from the participants, patients will be called by phone and questions will be asked about Rosenberg Self-Esteem Scale, sociodemographic characteristics, City of Hope Quality of Life Ostomy.~2. Participants in this group will receive a 4 week of laughter therapy. Laughter therapy will be conducted on whatsapp.~3. After laughter therapy (after 1 month): Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy.~4. After 3 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy."
62696818|NCT05914129|EXPERIMENTAL|Experimental Group A (GEA)|To each volunteer, after 2 questionnaires, Diaphragm Stretching, Lower stomach mobilization and Liver pump techniques will be performed to this group. The diaphragm technique is performed 2 times with 1 minute interval, with the duration of 10 respiratory cycles. The lower stomach mobilization and liver pump techniques are performed one time, for 5 minutes each. Following the technique, volunteers will answer the same 2 questionnaires shown previously.
61943890|NCT02256371|EXPERIMENTAL|Relaxation|"Relaxation group:~Relaxation will be conducted in 45 minutes sessions with a trained psychotherapist."
61943891|NCT02256371|NO_INTERVENTION|Routine care|The patients will receive their usual pain treatments throughout the study
61943892|NCT03930758|EXPERIMENTAL|Uphill exercise before the meals|40 minutes of uphill treadmill exercise at +6o slope completed 1 hour before eating the meal
61943893|NCT03930758|EXPERIMENTAL|Uphill exercise after the meals|40 minutes of uphill treadmill exercise at +6o slope started 1 hour after eating the meal
61943894|NCT03930758|EXPERIMENTAL|Downhill exercise before the meals|40 minutes of downhill treadmill exercise at -6o slope completed 1 hour before eating the meal
61943895|NCT03930758|EXPERIMENTAL|Downhill exercise after the meals|40 minutes of downhill treadmill exercise at -6o slope started 1 hour after eating the meal
61943896|NCT03930758|SHAM_COMPARATOR|Sedentary trial|A trial with no exercise
62139377|NCT00702884|EXPERIMENTAL|Sunitinib|Sunitinib 37.5 mg daily for a 4 week cycle
62139378|NCT05224024|ACTIVE_COMPARATOR|Retzius-repairing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-repairing technique as prostate cancer patients with robot assisted radical prostatectomy.
62139379|NCT05224024|PLACEBO_COMPARATOR|Retzius-sparing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-sparing technique as prostate cancer patients with robot assisted radical prostatectomy.
62139380|NCT06669351|EXPERIMENTAL|Single Arm|"Part 1:~A pilot study of pharmacokinetics, safety, and efficacy was conducted in children (5-11 years old, weight ≥20kg) with uncomplicated influenza. A total of 12 subjects were planned to be enrolled. (Pharmacokinetic and safety data from at least 8 children are required.)"
62495604|NCT04391517|EXPERIMENTAL|Study Population|Included patients will be evaluated by an anaesthesiologist according to national and international guidelines as it is routine at the pre-operative clinic. In addition, all included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
62696819|NCT05914129|EXPERIMENTAL|Experimental Group B (GEB)|To each volunteer, after 2 questionnaires, Lower stomach mobilization and Liver pump techniques will be performed to this group. These 2 techniques are the same ones as described for the experimental group A. Following the technique, volunteers will answer the same 2 questionnaires shown previously.
62696820|NCT06602011||Triple Therapy|
62696821|NCT05787041|EXPERIMENTAL|High-fat diet group|A single dose of AD16 tablets was taken orally after a high fat diet
62696822|NCT05787041|EXPERIMENTAL|Fasting group|A single dose of AD16 tablets was taken orally under fasting conditions
61943897|NCT03659539|ACTIVE_COMPARATOR|CLADS group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with propofol, with its administration controlled with CLADS tuned to consistent anesthetic depth (BIS-50) feedback from the patients.
61943898|NCT03659539|ACTIVE_COMPARATOR|Desflurane group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
61943899|NCT01790932|EXPERIMENTAL|BKM120|"BKM120: 100 mg capsule once daily each day of a 28 day cycle .~Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons."
61943900|NCT00183820|EXPERIMENTAL|1|
61943901|NCT00801320|EXPERIMENTAL|Cohort 1|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF
61943902|NCT00801320|EXPERIMENTAL|Cohort 2|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF and topical Imiquimod at site of vaccination
62139381|NCT04566861|EXPERIMENTAL|Anxious pregnant women - intervention group|100 pregnant women who have at least mild anxiety will be randomized to the intervention group where they will receive six one-on-one core sessions of Cognitive Behavioral Therapy during pregnancy (plus possible booster sessions)
62139382|NCT04566861|NO_INTERVENTION|Anxious pregnant women - enhanced usual care group|100 pregnant women who have at least mild anxiety will be randomized to the enhanced usual care group. Reminder calls were given, provider visits were facilitated (shorter wait times), and transportation to assist participants in attending appointments and medically indicated ultrasounds were paid for (as in the other group).
62139383|NCT04566861|NO_INTERVENTION|Non-anxious pregnant women - healthy control|100 pregnant women who do not have symptoms of anxiety or depression be followed in the healthy control group. Reminder calls were given, provider visits were facilitated (shorter wait times), and transportation to assist participants in attending appointments and medically indicated ultrasounds were paid for (as in the other groups).
62139384|NCT05564468|EXPERIMENTAL|Group I (Peacefully's)|Patients receive Peacefully's web-based tool to help with end-of-life planning on day 7.
61943903|NCT04937946|EXPERIMENTAL|Fentanyl|Fentanyl will be given within 24 hours from the initiation of mechanical ventilation at an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
61943904|NCT04937946|NO_INTERVENTION|Placebo|Will receive continuous infusion of IV fluid up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
61943905|NCT06450262|EXPERIMENTAL|Empagliflozin/ Metformin HCl Film Coated Tablet|Empagliflozin/ Metformin HCl 12.5mg/1000 mg Film Coated Tablet (12.5mg Empagliflozin / 1000mg Metformin HCl)
61943906|NCT06450262|ACTIVE_COMPARATOR|Synjardy® film-coated tablets|Synjardy® 12.5mg/1000mg film-coated tablets (12.5mg Empagliflozin / 1000mg Metformin HCl)
61943907|NCT05403658|EXPERIMENTAL|Family Navigation + Usual Care|Participants assigned to this arm will receive the Family Navigation (FN) intervention in addition to standard pediatric obesity management (Usual Care).
61943908|NCT05403658|ACTIVE_COMPARATOR|Usual Care|Participants assigned to this arm will standard pediatric obesity management only.
61943909|NCT00413244|EXPERIMENTAL|Androgel treatment|"Androgel 5 grams~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
61943910|NCT00413244|PLACEBO_COMPARATOR|Placebo|Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
61943911|NCT01050855|EXPERIMENTAL|RIC: Distal Campath|"Day Treatment~Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) (subcutaneously) over 2 hours~Day - 21 to-19 Alemtuzumab IV/ SQ (subcutaneously)~Day - 7 to -3 Readmission to hospital Fludarabine IV~Day - 2 Melphalan IV~Day - 1 Begin cyclosporine infusion~Day 0 Transplant: Bone marrow or cord blood infusion"
61943912|NCT01050855|EXPERIMENTAL|RIC:Intermediate Campath|"Day Treatment~Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 to -3 Fludarabine IV~Day - 2 Melphalan 140 mg/m2 IV~Day - 1 Cyclosporine infusion starts~Day 0 Transplant: Bone marrow or cord blood infusion"
61943913|NCT01050855|EXPERIMENTAL|RIC: Mini Busulfan|"Day Treatment~Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV~Day - 3 Fludarabine IV~Day - 2 Fludarabine IV Cyclosporine infusion~Day - 1 Rest~Day 0 Transplant: Bone marrow or cord blood infusion"
61943914|NCT00843531|EXPERIMENTAL|RAD001 and erlotinib|"Each 28 day cycle:~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)"
61943915|NCT05038943|EXPERIMENTAL|SherpaPak|cardiac allografts recovered from donors after circulatory determined death using thoracoabdominal normothermic regional perfusion will be transported to the recipient center in Paragonix SherpaPak Cardiac Transport System
61943916|NCT02812173|ACTIVE_COMPARATOR|suprapubic tube ex 2 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 2th day after the surgery
61943917|NCT02812173|ACTIVE_COMPARATOR|suprapubic tube ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 5th day after the surgery
62139385|NCT05564468|ACTIVE_COMPARATOR|Group II (standard of care)|Patients receive standard care.
62696823|NCT06241846|EXPERIMENTAL|Part 1|To evaluate the safety and efficacy of YL201 in patients with mCRPC and to determine the recommended dose of YL201 for the pivotal clinical study (n ≈ 60)； Cohort 1: YL201 2.0 mg/kg iv Q3W ； Cohort 2: YL201 1.6 mg/kg iv Q3W； Cohort 3: YL201 2.4 mg/kg iv Q3W； Cohort 4: YL201 1.2 mg/kg iv D1, D8 Q3W； Cohort 5: YL201 1.0 mg/kg iv D1, D8, Q3W；
61943918|NCT02812173|ACTIVE_COMPARATOR|transurethral catheter ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a transurethral catheter, which was withdrawn on the 5th day after the surgery
61943919|NCT05920278||Healthy Adult Volunteers|Minimum of ten (10) subjects meeting the eligibility criteria.
61943920|NCT04781504|EXPERIMENTAL|standard care + moderate-intensity continuous exercise training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min
61943921|NCT04781504|EXPERIMENTAL|standard care + high-intensity interval training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min
61943922|NCT01268020|EXPERIMENTAL|[18F]-FMH3-01 PET Imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
61943923|NCT03920748||Difficult laryngoscopy (Group D)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 3-4 are classified as difficult laryngoscopy ( Group D).
62139386|NCT05860504||Normal left ventricular systolic function|Patients with normal echocardiographic systolic function, defined as having left ventricular ejection fraction ≥ 50% and no regional hypokinesia
62495605|NCT02805517|EXPERIMENTAL|PEAL laparoscopic nephrectomy|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy using 3 mm instruments.
62495606|NCT04621617|ACTIVE_COMPARATOR|Albumin + Midodrine + SMT|Human albumin plus oral midodrine
62495607|NCT04621617|ACTIVE_COMPARATOR|Albumin + SMT|Human albumin plus placebo of midodrine
62495608|NCT04621617|PLACEBO_COMPARATOR|SMT|standard medical therapy plus placebo of midodrine
62696824|NCT06241846|EXPERIMENTAL|Part2|To evaluate the safety and efficacy of YL201 in patients with mCRPC and to determine the recommended dose of YL201 for the pivotal clinical study (n ≈ 40)； Recommended dose and method of administration
62696825|NCT06634498|EXPERIMENTAL|real rTMS on the dlPFC|rTMS on the DLPFC Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline functional magnetic resonance imaging (fMRI) study for regulation of craving using a separate sample. During the intervention, each participant will receive an iTBS mode intervention on this DLPFC region.
62696826|NCT06634498|SHAM_COMPARATOR|sham rTMS on the dlPFC|Each participant will also receive a sham rTMS intervention as a controlled condition.
62339006|NCT05601024|NO_INTERVENTION|Control Group|"1. After obtaining permission from the participants, patients will be called by phone and questions will be asked about Rosenberg Self-Esteem Scale, sociodemographic characteristics, City of Hope Quality of Life Ostomy.~2. After 2 weeks: Patients will be called by phone and asked if they have any complaints about their disease.~3. After 1 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy.~4. After 3 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy."
62339007|NCT02643186|ACTIVE_COMPARATOR|misoprostol group|preoperative vaginal misoprostol in decreasing blood loss in transabdominal myomectomy
62339008|NCT02643186|ACTIVE_COMPARATOR|uterine artery ligation group|bilateral uterine artery ligation in decreasing blood loss in transabdominal myomectomy
62339009|NCT01952457|EXPERIMENTAL|Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.
62339010|NCT01952457|ACTIVE_COMPARATOR|prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.
62339011|NCT06330597||Patients admitted to CICU|The study population will be composed of patients admitted to the Coronary Intensive Care Unit (CICU) requiring hemodynamic assessment using pulmonary artery catheter (PAC) as standard of care.
62339012|NCT03348852|ACTIVE_COMPARATOR|Active tDCS|Active transcranial direct current stimulation
62339013|NCT03348852|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation
62339014|NCT03395275|EXPERIMENTAL|Intrathecal Pump Therapy Participants|Patients eligible for intrathecal pump therapy will undergo quantitative sensory tests and surveys during various stages of the treatment process.
62339015|NCT03102177|EXPERIMENTAL|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
62339016|NCT02067091|ACTIVE_COMPARATOR|BVS|Implantation of bioresorbable vascular scaffold in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
62339017|NCT02067091|ACTIVE_COMPARATOR|DES|Implantation of drug eluting stent in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
62339018|NCT00668655||1|Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea
62339019|NCT05610852|ACTIVE_COMPARATOR|Transvesical Single Port Robotic Partial Prostatectomy|Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to Prostatectomy. Prostatectomy consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.
62495609|NCT02751424|EXPERIMENTAL|GSK3342830 single dose in Part 1|Enrolled subject will receive single escalation dose of GSK3342830. The escalating doses will be evaluated in six cohorts as A- 250 mg, B-500 mg, C-1000 mg, D-2000 mg, E-4000 mg, and F-=\<6000 mg. In each cohort 6 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 36 subjects will receive GSK3342830. Dose escalation will be based on evaluation of the preceding dose levels in the study.
62495610|NCT02751424|PLACEBO_COMPARATOR|Placebo single dose in Part 1|Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
62495611|NCT02751424|EXPERIMENTAL|GSK3342830 repeat Dose in Part 2|Enrolled subject will receive repeat escalating dose of GSK3342830. GSK3342830 as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. The escalating doses will be evaluated in three cohorts as G-1000 mg, H-2000 and I-4000 mg. In each cohort 8 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 24 subjects will receive GSK3342830. The starting dose and maximum dose may change based on clinical safety and PK findings in Part 1 or earlier doses in Part 2 respectively.
62495612|NCT02751424|PLACEBO_COMPARATOR|Placebo repeat Dose in Part 2|Enrolled subject will receive repeat escalation dose of placebo. Placebo as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 6 subjects will receive placebo.
62339020|NCT05610852|ACTIVE_COMPARATOR|High-intensity focused ultrasound (HIFU)|Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to HIFU. HIFU consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.
62339021|NCT05346913|EXPERIMENTAL|Caregivers of Persons with Spinal Cord Injury (mTBI)|
62339022|NCT02225873|EXPERIMENTAL|strength-endurance exercises|Group 1 (experimental) will carry out motor control exercises through cranio-cervical flexion training and strength-endurance exercises.
62339023|NCT02225873|PLACEBO_COMPARATOR|strength-endurance and proprioception|Group 2 (control) will carry out exercises to improve muscle strength-endurance and proprioception.
62495613|NCT02986139|EXPERIMENTAL|Sequence AB|Participants received a single 50 mg subcutaneous (SC) dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 1 (Treatment A) followed by a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 8 (Treatment B).
62495614|NCT02986139|EXPERIMENTAL|Sequence BA|Participants received a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 1 (Treatment B) followed by a single 50 mg SC dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 8 (Treatment A).
62495615|NCT03239145|EXPERIMENTAL|Pembrolizumab + Trebananib|Part 1 Standard 3+3 Dose Escalation
62495616|NCT03239145|EXPERIMENTAL|Pembrolizumab + Trebananib (Melanoma)|Part 2 Dose Expansion
62495617|NCT03239145|EXPERIMENTAL|Pembrolizumab + Trebananib (Ovarian)|Part 2 Dose Expansion
62495618|NCT03239145|EXPERIMENTAL|Pembrolizumab + Trebananib (Colorectal)|Part 2 Dose Expansion
62495619|NCT03239145|EXPERIMENTAL|Pembrolizumab + Trebananib (Renal Cell Carcinoma)|Part 2 Dose Expansion
62495620|NCT02121717|EXPERIMENTAL|Arm 1|Patients administrate Chiglitazar 32mg once daily for 52 weeks
62495621|NCT02121717|EXPERIMENTAL|Arm 2|Patients administrate Chiglitazar 48mg once daily for 52 weeks
61943924|NCT03920748||Easy laryngoscopy (Group E)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 1-2 are classified as easy laryngoscopy ( Group E).
62495622|NCT02121717|PLACEBO_COMPARATOR|Arm 3|Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.
62339024|NCT04153617|PLACEBO_COMPARATOR|Control honey|"Orange blossom honey.~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.~Short term trial: 20g/day in a single day."
62495623|NCT01127776|EXPERIMENTAL|Apos System|
62495624|NCT01127776|PLACEBO_COMPARATOR|CONTROL|
62495625|NCT05449080||Cases|subjects with type 2 5-alpha reductase deficiency
62495626|NCT06297408|EXPERIMENTAL|Relma-cel|Evaluate the safety and tolerability of Relma-cel in moderate to severe active systemic lupus erythematosus (SLE) and determine the Phase II Recommended Dose (RP2D)
62495627|NCT00982228|EXPERIMENTAL|IDeg OD|
62495628|NCT00982228|ACTIVE_COMPARATOR|IGlar OD|
62495629|NCT05546398||Physicians|Office-based cardiologists (OBCs) and lipid management specialists (LMSs) who are qualified for study participation regarding experience in lipid management therapy and treating a sufficient number of patients.
62495630|NCT05546398||High and Very High Cardiovascular Patients|Patients at high and very high cardiovascular risk as assessed by the office-based cardiologists and lipid management specialists with hypercholesterolemia or mixed dyslipidemia who received a prescription of bempedoic acid 180 mg fixed dose combination with ezetimibe 10 mg (FDC).
62495631|NCT02229084|EXPERIMENTAL|Part 1 - Chemovax Schedule A|Feasibility - Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
62495632|NCT02229084|EXPERIMENTAL|Part 1 - Chemovax Schedule B|Feasibility - Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
62495633|NCT02229084|EXPERIMENTAL|Part 1 - Chemovax Schedule C|Feasibility - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
62495634|NCT02229084|EXPERIMENTAL|Part 1 - Chemovax Schedule D|Feasibility - Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
62495635|NCT02229084|EXPERIMENTAL|Part 1 - Chemovax Schedule E|Feasibility - Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
62495636|NCT02229084|EXPERIMENTAL|Part 2 - Chemovax Schedule C|Primary Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
62495637|NCT02229084|EXPERIMENTAL|Part 3 - Chemovax Schedule C|Expanded Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
62495638|NCT01896492|ACTIVE_COMPARATOR|N-acetyl cystien and clomiphen citrate|N-acetyl cystien and clomiphen citrate,in induction of ovulation in newly diagnosed PCOS,1-2gm schats of NAC PLUS 100 mg of cc in the therd day of the cycle till day 8,with monitoring of follicular growth usin ultrasonography.HCG is giving to trigger of ovulation fo follicular size 18mm or more.
62495639|NCT01896492|PLACEBO_COMPARATOR|Clomiphen citrate and placebo|CC plus placebo compared to cc and NAC in induction of ovulation in PCOS new cases.
62495640|NCT01896492|NO_INTERVENTION|N-acetyl cystien|In addition to the CC, each patient was selected randomly to receive either NAC (Sedico, Cairo, ARE), in a dose of 1.2 g/d orally, or a placebo (sugar) of the same volume twice daily from day 3 until day 7
62339025|NCT04153617|EXPERIMENTAL|Modified honey with soluble fiber and polyphenols|"Honey modified with soluble fiber and polyphenols~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.~Short term trial: 20g/day in a single day."
62339026|NCT01711684|EXPERIMENTAL|Diphenylcyclopropenone (DPCP)|Subjects will have DPCP in a topical gel formulation applied to their cutaneous metastatic lesions.
62339027|NCT01321931|EXPERIMENTAL|NRT 60|A 6 mg dose of an experimental Nicotine Replacement Therapy (NRT) given every hour for 11 hours, with a 36-hour washout between visits
62339028|NCT01321931|ACTIVE_COMPARATOR|NFG 60|A 4 mg dose of a marketed Nicotine Fruit Gum (NFG) given every hour for 11 hours, with a 36-hour washout between visits
62139387|NCT05860504||Left ventricular dysfunction|Patients with echocardiographic left ventricular systolic dysfunction, defines as having left ventricular ejection fraction \< 50% or left ventricular regional hypokinesia in at least two adjacent segments
62339029|NCT01321931|EXPERIMENTAL|NRT 90|A 6 mg dose of NRT given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
62339030|NCT01321931|ACTIVE_COMPARATOR|NFG 90|A 4 mg dose of NFG given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
62339031|NCT01321931|ACTIVE_COMPARATOR|NIQ 60|A 4 mg dose of marketed nicotine mint lozenge (NIQ), given every hour for 11 hours, with a 36-hour washout between visits
62339032|NCT01592409|ACTIVE_COMPARATOR|Active cannabis|In this condition, participants will receive a cigarette containing 12.5% active THC.
62339033|NCT01592409|PLACEBO_COMPARATOR|Placebo|In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
62339034|NCT03589105|EXPERIMENTAL|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
62339035|NCT03611322|EXPERIMENTAL|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
62339036|NCT03611322|ACTIVE_COMPARATOR|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
62139388|NCT06700005||Stroke Survivors|Participants have had a left-hemisphere stroke, or a stroke elsewhere in the brain causing aphasia or alexia (i.e., reading difficulties). They are given a series of standardized and in-house tests of reading, language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
62339037|NCT00819585|EXPERIMENTAL|Core study: Canakinumab 25 mg|Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
62339038|NCT00819585|EXPERIMENTAL|Core study: Canakinumab 50 mg|Canakinumab 50 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
62339039|NCT00819585|EXPERIMENTAL|Core study: Canakinumab 100 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
62339040|NCT00819585|EXPERIMENTAL|Core study: Canakinumab 200 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
62339041|NCT00819585|EXPERIMENTAL|Core study: Canakinumab 300 mg|Canakinumab 300 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
62339042|NCT00819585|EXPERIMENTAL|Core study: Canakinumab q4wk|Canakinumab 50 mg sc at Days 1, and 29 followed by canakinumab 25 mg sc on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
62339043|NCT00819585|ACTIVE_COMPARATOR|Core study: Colchicine 0.5 mg|Colchicine 0.5 mg capsule orally once daily throughout the whole treatment phase of 16 weeks plus placebo matching canakinumab s.c. at Days 1, 29, 57, and 85. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
62339044|NCT00819585|EXPERIMENTAL|Extension study: Group A|Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.
62339045|NCT00819585|EXPERIMENTAL|Extension study: Group B|Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.
62495641|NCT03043040|EXPERIMENTAL|Telephone follow up|"Patients discharged from hospital A and B after a suicide attempt receive a protocolized telephone follow which is added to their usual treatment (TAU). Calls are made by nurses at weeks 1,2,4,12 and 24 after the index suicide attempt.~TAU: Includes whatever treatment the doctor decides to offer to that patient (psychopharmacology, psychotherapy etc)."
62139389|NCT06700005||Controls|Participants are matched to the stroke cohort in age, educational background, race, and gender but have no history of brain injury. They are also given a series of standardized and in-house tests of reading, language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
62339046|NCT00819585|EXPERIMENTAL|Extension study: Group C|Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.
62495642|NCT03043040|ACTIVE_COMPARATOR|Control|Patients discharged from hospital C after a suicide attempt receive treatment as usual (whatever treatment the doctor decides to offer to that patient: psychopharmacology, psychotherapy etc).
62495643|NCT04817995|EXPERIMENTAL|Intervention group|The intervention group will get a 6-week internet-based stress recovery intervention.
62495644|NCT04817995|NO_INTERVENTION|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
62139390|NCT03872063|EXPERIMENTAL|Myofascial|Each session will last 17 minutes, taking place for 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the technique of myofascial induction and eccentric exercises will be performed.
62339047|NCT00819585|EXPERIMENTAL|Extension study: Group D|Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.
62339048|NCT01029886|EXPERIMENTAL|1|
62339049|NCT01029886|ACTIVE_COMPARATOR|2|
62139391|NCT03872063|ACTIVE_COMPARATOR|Eccentric|Each session will have a duration of 9 minutes, taking place during 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the eccentric exercises will be performed.
62139392|NCT06693648|EXPERIMENTAL|AMZ001 diclofenac gel|
62339050|NCT03590522||Group I:|Thirty heart failure patients
62696827|NCT06272890|EXPERIMENTAL|intervention group|The intervention group will receive online motivational interviewing (MI) consisting of five sessions. The sessions are planned to take place on the same day and time every week. Each session will last an average of 40 minutes. In the literature, PD sessions with groups of 5-8 people have been evaluated as adequate and effective. Before the MG, a WhatsApp group will be established to provide faster and easier communication to the intervention group and communication about the sessions will be handled in this group.
62696828|NCT06272890|NO_INTERVENTION|control group|No treatment will be applied to the control group during the study period.
62696829|NCT02478281|EXPERIMENTAL|Methylene Blue Injection, USP|Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
62696830|NCT06449118|ACTIVE_COMPARATOR|Mindfulness Stress Reduction|Mindfulness Stress Reduction Program
61943925|NCT04789239|EXPERIMENTAL|SZC + MRA treated heart failure patients|"Optimal dose of SZC, which is an approved drug for hyperkalemia in Sweden.~The subject is treat with 5 mg daily however it can be reduced to once every second day, or inreased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with a mineralcorticoid receptor antagonist (spironolacton or eplerenon), 25 mg or 50 mg depending on what dose they could tolerate."
61943926|NCT04789239|PLACEBO_COMPARATOR|Placebo + MRA treated heart failure patients|The subject is treat with placebo drug, 5 mg once daily, however it can be reduced to once every second day, or increased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with the dose of mineralcorticoid receptor antagonist (spironolacton or eplerenon) 25 mg or 50 mg depending on what dose they could tolerate.
62696831|NCT06449118|NO_INTERVENTION|Control|No intervention
62696832|NCT05905146|EXPERIMENTAL|interventional group|benefiting from a multi-professional intervention around the strong opioid treatment with the aim of setting up a personalized pharmaceutical plan
61943927|NCT02505295|ACTIVE_COMPARATOR|selenium|vial selenium (selenase 500 microgr ) 2000 microgram stat and 1000 microgram daily for 5 days
61943928|NCT02505295|PLACEBO_COMPARATOR|normal saline|40 cc normal saline stat and 20 cc daily for 5 days( in vials like selenase vial)
62139393|NCT06693648|PLACEBO_COMPARATOR|Placebo gel|
62139394|NCT01178372|ACTIVE_COMPARATOR|lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
62139395|NCT01178372|ACTIVE_COMPARATOR|probiotics|
62139396|NCT01957332|EXPERIMENTAL|Molecular imaging|All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET. On the same day or the day after 18F-FES injection 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
62139397|NCT04776239|EXPERIMENTAL|Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group|Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).
62339051|NCT03590522||Group II:|Twenty healthy controls
62339052|NCT04875338|ACTIVE_COMPARATOR|saline injection|2ml %0.9 NACI(Saline )injection to effected lateral epicondyle
62339053|NCT04875338|ACTIVE_COMPARATOR|platet riched plasma injection|2 ml prp )injection to effected lateral epicondyle
62339054|NCT04875338|ACTIVE_COMPARATOR|betametazon injection|2 ml betametazon )injection to effected lateral epicondyle
62339055|NCT05940727|ACTIVE_COMPARATOR|Usual macroalgae consumption|Crossover design with habitual macroalgae consumption at baseline
62339056|NCT05940727|EXPERIMENTAL|Cessation of macroalgae consumption|Cessation of macroalgae consumption as an experimental intervention.
62339057|NCT01893658|ACTIVE_COMPARATOR|Omalizumab and Prednisone|"Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone~Standard clinical therapy with prednisone.~* Day 1-14: 60 mg/day 14 days (2 weeks)~* Day 15-28: 40 mg/day (2 weeks)~* Day 29-35: 30 mg/day (1 week)~* Day 36-42: 20 mg/day (1 week)~* Day 43-49: 10 mg/day (1 week)~* Day 50-56: 5 mg/day (1 week)~* Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
62339058|NCT01893658|ACTIVE_COMPARATOR|Prednisone|"Standard clinical therapy with prednisone.~* Day 1-14: 60 mg/day 14 days (2 weeks)~* Day 15-28: 40 mg/day (2 weeks)~* Day 29-35: 30 mg/day (1 week)~* Day 36-42: 20 mg/day (1 week)~* Day 43-49: 10 mg/day (1 week)~* Day 50-56: 5 mg/day (1 week)~* Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
62339059|NCT02431468|EXPERIMENTAL|Bryostatin 1 20ug|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
62339060|NCT02431468|EXPERIMENTAL|Bryostatin 1 40ug|Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
62495645|NCT02711527|ACTIVE_COMPARATOR|Acupunture group A|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total) Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation , all needles will be retained for 30 minutes."
62339061|NCT02431468|PLACEBO_COMPARATOR|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
62339062|NCT02094872|EXPERIMENTAL|Arm I (molecularly targeted therapy)|Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
62139398|NCT04776239|EXPERIMENTAL|Group 2: Placebo Group|Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.
62139399|NCT05739370|EXPERIMENTAL|Ger-iPST|Prospective participants will be contacted by telephone to confirm eligibility, explain the study protocol, and obtain informed consent. An in-person or videoconference assessment will be used to administer baseline PHQ-9 to confirm enrolment criteria and will be asked questionnaire to gather demographic information. Participants will then be provided with an email link to access the Online Psycho Therapy Tool (OPTT). PHQ-9 will be collected again at the mid-point (4 weeks) and after completing the program through OPTT. Caregivers will be invited to assist the participant if required in completing Ger-iPST modules, and weekly telephone support calls by a research assistant will be provided to assist with any difficulty navigating technical aspects of the Ger-iPST platform.
62339063|NCT06518512||AVIGA2|Eye gaze tracking using the AVIGA tool
62339064|NCT03034759|EXPERIMENTAL|All participants|+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention.
62339065|NCT02294409|EXPERIMENTAL|Cognitive-behavioral therapy (CBT)|Manualized group cognitive-behavioral therapy for social anxiety in first episode psychosis
62339066|NCT02294409|ACTIVE_COMPARATOR|Computer assisted Cognitive Remediation therapy (CACRT)|Group computer assisted cognitive remediation therapy
62495646|NCT02711527|ACTIVE_COMPARATOR|Acupunture group B|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total). Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes."
62696833|NCT05905146|NO_INTERVENTION|control group|routine management, including medication reconciliation at entry and exit and pharmaceutical analysis of prescriptions
62139400|NCT02613403|EXPERIMENTAL|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
62139401|NCT02613403|EXPERIMENTAL|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily for 24 weeks.
62139402|NCT02613403|EXPERIMENTAL|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
62139403|NCT02613403|EXPERIMENTAL|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily for 24 weeks.
62139404|NCT02613403|EXPERIMENTAL|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 \[50 mg\]) + UPR (MK-3682 \[225 mg\]) + RZR (MK-8408 \[30 mg\]), administered as 2 tablets once daily for 16 weeks.
62339067|NCT01879176|EXPERIMENTAL|CytoSorb|For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
62495647|NCT01717040|EXPERIMENTAL|Pioglitazone|
62495648|NCT01717040|PLACEBO_COMPARATOR|Placebo|
62696834|NCT06209619|EXPERIMENTAL|Treatment (rituximab, CC-99282)|Patients receive rituximab IV on day 1 of each cycle and CC-99282 PO QD on days 1-14 of each cycle. Treatment repeats every 28 days for up to 6 cycles of rituximab and up to 24 cycles of CC-99282 in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and collection of blood samples throughout the trial. Patients may undergo biopsy at screening.
62696835|NCT05487391|EXPERIMENTAL|QL1706 plus Platinum-based chemotherapy|QL1706(5mg/kg Q3W IV) plus Platinum-based chemotherapy
62139405|NCT06029842|OTHER|the intervention group|this group received the collaborative care between the clinical pharmacist and physicians in a medical center
62339068|NCT01879176|NO_INTERVENTION|Control|No filter will be installed on the CPB machine.
62339069|NCT02034604|EXPERIMENTAL|Naftopidil Group|Naftopidil medication patients
62339070|NCT02034604|ACTIVE_COMPARATOR|Tamsulosin Goup|Tamsulosin medication patients
62339071|NCT03488121|EXPERIMENTAL|Poster Only|This arm will only receive motivational posters.
62339072|NCT03488121|EXPERIMENTAL|Thank-you Letter Only|This arm will only receive thank-you letters.
62339073|NCT03488121|EXPERIMENTAL|Double Incentive|This arm will receive both motivational posters and thank-you letters.
62339074|NCT03488121|NO_INTERVENTION|Control|This arm will not receive any intervention.
62339075|NCT01368393|EXPERIMENTAL|Electroacupuncture|
62339076|NCT01368393|ACTIVE_COMPARATOR|Sham acupuncture|
62339077|NCT04348591|EXPERIMENTAL|Misophonia Group|Participants who endorse Misophonia will undergo a neuroimaging session to identify different neurostimulation targets. Then Misophonic participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
62339078|NCT04348591|ACTIVE_COMPARATOR|Emotional Dysregulation Clinical Group|Participants who self report high emotional dysregulation and who meet diagnostic criteria for a DSM disorder will undergo a neuroimaging session to identify different neurostimulation targets. Then these participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
62495649|NCT05881733|OTHER|Study population|This study will have only a single arm. Patients will undergo pulmonary vein isolation using the 31 mm balloon size of POLARx FIT. High-definition 3D maps will be constructed before and after cryoablation to assess the antral lesion size.
62139406|NCT06029842|NO_INTERVENTION|the control group|this group received the standard care of physicians in a medical center without clinical pharmacist interventions
62339079|NCT04958616||Patients sensitive to HDM|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled.Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
62339080|NCT04958616||Patients not sensitive to HDM allergy.|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled .Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation).
62339081|NCT05899387||BC, mastectomy and implant|Women with first diagnosis of breast cancer or DCIS and planned skin-sparing mastectomy and implant placement
62339082|NCT05899387||BC and mastectomy|Women with first diagnosis of breast cancer or DCIS and planned simple mastectomy
62339083|NCT05899387||High risk for BC|healthy women with high risk for breast cancer and planned bilateral risk-reducing mastectomy and implant reconstruction
62339084|NCT05899387||Cosmetic breast surgery|healthy women planned for plastic breast implant surgery
62339085|NCT05384158|ACTIVE_COMPARATOR|Cognitive behavioral therapy|cognitive behavioral therapy for depression, anxiety, and/or anhedonia
62339086|NCT05384158|ACTIVE_COMPARATOR|Valuation with instruction|repeat laboratory sessions of a reward/loss learning computer game with specific instructions
62339087|NCT05384158|ACTIVE_COMPARATOR|Valuation without instruction|repeat laboratory sessions of a reward/loss learning computer game without specific instructions
62339088|NCT04217889||Adherent patient|This group is composed of adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
62339089|NCT04217889||Not-adherent patient|This group is composed of not-adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
62339090|NCT02173496||Colour contrast sensitivity|Colour contrast sensitivity
62339091|NCT05465031|EXPERIMENTAL|Experimental: Sacubitril/Valsartan|After assessment of the tolerance of the drug during the single-blind period, during the which the starting dose of the drug of 100 mg b.i.d. should be increased after two weeks to the target dose 200 mg b.i.d, the patients will be randomized in 1:1 ratio to either intervention or placebo group. In the experimental arm, the patients after randomization will receive the dose 200 mg b.i.d of sacubitril/valsartan for the course of the study. If the patients does not tolerate the target dose of 200 mg b.i.d., the reduction of the drug dose to 100 mg b.i.d. will be possible at the discretion of the physician-in-charge.
62339092|NCT05465031|PLACEBO_COMPARATOR|Placebo|After assessment of the tolerance of the drug during the single-blind period, during the which the starting dose of the drug of 100 mg b.i.d. should be increased after two weeks to the target dose 200 mg b.i.d, the patients will be randomized in 1:1 ratio to either intervention or placebo group. In the placebo arm, the paitents will receive the matching placebo with an identical strategy of dose reduction as in the intervention group, at the discretion of the physician-in-charge.
62339093|NCT06483516||OPEN REPAIR|Patient operated for AAA by conventional surgery
62339094|NCT06483516||ENDO REPAIR|Patient operated for AAA by Endovascular exclusion (EVAR/F-BEVAR)
62339095|NCT03192072||Subjects with Acute Respiratory Illness|Patients with acute respiratory illness identified in the Emergency Department
62339096|NCT03574935|EXPERIMENTAL|External Chinese medicine|"External Chinese medicine include 3 kinds of formula，including:~Qin, Hua and Bu will be applied to cover the participants' lesions in wet dressing form. Dosage form:5g/ml; frequency:qd; duration:2months."
62696836|NCT05487391|PLACEBO_COMPARATOR|Placebo plus Platinum-based chemotherapy|Placebo(5mg/kg Q3W IV) plus Platinum-based chemotherapy
62696837|NCT05386472|EXPERIMENTAL|Cohort 1|Pregnant women in their second trimester
62696838|NCT05386472|EXPERIMENTAL|Cohort 2|Pregnant women in their third trimester
62696839|NCT05386472|EXPERIMENTAL|Cohort 3|Non-pregnant women
62696840|NCT06040255|ACTIVE_COMPARATOR|Arm A|Treat all children with suspected FCA with corticosteroids as soon as the diagnosis is made.
62696841|NCT06040255|ACTIVE_COMPARATOR|Arm B|Treat only the subset of children that develop evidence of FCA disease progression.
62139407|NCT06603623|EXPERIMENTAL|BHV-2100 75 mg|
62139408|NCT06603623|EXPERIMENTAL|BHV-2100 150 mg|
62139409|NCT06603623|PLACEBO_COMPARATOR|Placebo|
62139410|NCT05304624|ACTIVE_COMPARATOR|Group 1: ErCr:YSGG laser|"Waterlase iPlus,Biolase-USA Er,Cr:YSGG laser (2780nm) was set at frequency 50Hz, power of 2.5W and 1562.5 W/cm2. MZ6 (400µm fiber tip) was used in contact mode for de-epitelization procedure.~Another visit of laser ablation was performed after 7 days to remove the remaining pigmentation. The same laser settings were used."
62696842|NCT04172220|EXPERIMENTAL|PECS + Opioid-free GA|Loco-regional anesthesia with PEC I and serratus plane block with an echoguided technique and opioid-free general anesthesia
62696843|NCT04172220|ACTIVE_COMPARATOR|GA|General anesthesia
62696844|NCT06498258|EXPERIMENTAL|experimental group|positive psychotherapy balance model based psychoeducation intervention
62696845|NCT06498258|NO_INTERVENTION|control group|positive psychotherapy balance model TRAINING
62339097|NCT03574935|ACTIVE_COMPARATOR|External Western medicine|Ethacridine Lactate Solution, 1% Sulfadiazine Silver Cream and rb-bFGF will be applied to cover the participants' lesions. Dosage form:3g/ml; frequency:qd; duration: 2months.
62339098|NCT00884468||1|Patients with PsA that fulfill the eligibility criteria of the study
62339099|NCT04703348|OTHER|Healthy patients|Healthy patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
62339100|NCT04703348|OTHER|Complex regional pain syndrome patients|Complex regional pain syndrome patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
62339101|NCT04703348|OTHER|Musculoskelettal disorders patients|Musculoskelettal disorders patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
62339102|NCT02509494|EXPERIMENTAL|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
62339103|NCT02509494|EXPERIMENTAL|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
62339104|NCT02509494|EXPERIMENTAL|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
62339105|NCT02509494|ACTIVE_COMPARATOR|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
62339106|NCT02509494|ACTIVE_COMPARATOR|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.
62339107|NCT03212664|OTHER|Exercise|Schroth-based physical therapy exercises for patients who agree to participate in exercises. Will be compared to observation-only treatment
62339108|NCT06429878|ACTIVE_COMPARATOR|no-MRI|received no MRI before prostatectomy
62339109|NCT06429878|EXPERIMENTAL|MRI|received MRI before prostatectomy
62339110|NCT04693442||Burn patients|with the condition
62339111|NCT04693442||Control group|without the condition (blood sampling only for adults) and children undergoing general anaesthetic procedures that involve skin resections (blood sampling and excised skin)
62339112|NCT06554002|EXPERIMENTAL|Control|Flavoured beverage powder with 3g glucose, twice a day
62339113|NCT06554002|EXPERIMENTAL|Treatment|Flavoured beverage powder with 20g resistant dextrin, twice a day
62339114|NCT00622869|EXPERIMENTAL|Everolimus + reduced tacrolimus|Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
62339115|NCT00622869|EXPERIMENTAL|Tacrolimus elimination|Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
62339116|NCT00622869|ACTIVE_COMPARATOR|Tacrolimus control|Control dose tacrolimus + corticosteroids.
62339117|NCT01262755||African Americans|Consists of 450 African Americans living in the zip code surrounding Temple Hospital between the ages of 18 and 80.
62696846|NCT06125405|EXPERIMENTAL|Telitacicept group|Weekly administration (administration time can be within 1 week + 3 days). Body weight and dosage: for subjects with body weight greater than 10kg and less than or equal to 20kg, the dose of Telitacicept is 40mg; for subjects with body weight greater than 20kg and less than or equal to 40kg, the dose of Telitacicept is 80mg; for subjects with body weight greater than 40kg and less than or equal to 60kg, the dose of Telitacicept is 120mg; for subjects with body weight greater than or equal to 60kg, the dose of Telitacicept is 160mg. Treatment duration: 52 weeks.
62339118|NCT05944991|EXPERIMENTAL|Olive oil message|Give olive oil message 2 times per day
62339119|NCT06250894|EXPERIMENTAL|Neoadjuvant immunotherapy-chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive Sintilimab (PD-1 inhibitor) and combined with preoperative chemoradiotherapy and operation.~generic name：PD-1; dosage form：Injection; dosage：200mg (20ml)； frequency：every 3 weeks； duration：3 times before operation and 3-5 times after operation"
62339120|NCT00649376|EXPERIMENTAL|1|Fexofenadine Tablets 180 mg
62339121|NCT00649376|ACTIVE_COMPARATOR|2|Allegra® Tablets 180 mg
62696847|NCT00610220|ACTIVE_COMPARATOR|1|
62339122|NCT02173210||Prior preterm birth|Pregnant women with a prior preterm birth, eligible to receive 17 hydroxyprogesterone caproate (17OHPC)
62339123|NCT00733382|EXPERIMENTAL|1|
62339124|NCT00733382|ACTIVE_COMPARATOR|2|
62339125|NCT01047761|EXPERIMENTAL|exercise|Multimodal exercises that include walking, breathing exercises, dynamic balance, and core strengthening.
62339126|NCT03051087|EXPERIMENTAL|Ganilever (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
62339127|NCT03051087|ACTIVE_COMPARATOR|Orgalutran (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
62339128|NCT00694954|EXPERIMENTAL|1|Wireless capsule endoscopy
62339129|NCT00694954|ACTIVE_COMPARATOR|2|Standard Care
62339130|NCT05986097|EXPERIMENTAL|Very low-carbohydrate breakfast|Materials will encourage eating a very low-carbohydrate breakfast (or first meal of the day), with no more than about 5-10 non-fiber (net) grams of carbohydrates each.
62339131|NCT05606224|EXPERIMENTAL|iMIED+TAU: internet-based mindfulness intervention for emotional distress plus treatment as usual|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
62495650|NCT04254809|EXPERIMENTAL|Re-Evaluating Suicidal Thoughts|Participants in this condition will complete the experimental intervention at the baseline appointment.
62339132|NCT05606224|NO_INTERVENTION|TAU-only: treatment as usual|In the current study, TAU consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therapy.
62339133|NCT03991364|EXPERIMENTAL|Constant gait speed group|experimental group that applied the speed of the robot-assisted gait training constantly
61943929|NCT06681480|EXPERIMENTAL|Intervention/treatment|figure-of-eight active rTMS coil rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at low frequency 0,5Hz Device: figure-of-eight active rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil, optic navigation system
61943930|NCT06681480|SHAM_COMPARATOR|Control arm|figure-of-eight active rTMS coil rTMS is administered using the figure-of-eight sham coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at sham stimulation Device: figure-of-eight sham rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight sham rTMS coil, optic navigation system
61943931|NCT06680960|ACTIVE_COMPARATOR|Trunk Stabilisation Exercise Group|
61943932|NCT06680960|ACTIVE_COMPARATOR|Respiratory Exercise Group|
61943933|NCT02175628|EXPERIMENTAL|Acoustic Angiography|All breast patients will be included in the experimental group.
61943934|NCT02175628|EXPERIMENTAL|Healthy Volunteers|A volunteer group was added to the study to perfect the image acquisition techniques.
61943935|NCT01161108|ACTIVE_COMPARATOR|Group A: Fast Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
61943936|NCT01161108|ACTIVE_COMPARATOR|Group B: Timed Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
61943937|NCT01739114|EXPERIMENTAL|"SI group"|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cm H2O.~After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cm H2O and PEEP of 5 cm H2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided."
61943938|NCT01739114|ACTIVE_COMPARATOR|IPPV group|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
61943939|NCT02325986|EXPERIMENTAL|Weekly PF with radiation|4 cycles of weekly cisplatin and fluorouracil (cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3, repeated weekly for 4 weeks) concurrently with Intensity-modulated radiation therapy (60Gy/28fr).
61943940|NCT02212795|EXPERIMENTAL|A Group|1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg
61943941|NCT02212795|EXPERIMENTAL|B Group|1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg
62339134|NCT03991364|OTHER|Increasing gait speed group|control group that applied the gradual increase of the speed of the robot-assisted gait training
62495651|NCT04254809|SHAM_COMPARATOR|Healthy Social Living|Participants in this condition will complete the sham control intervention at the baseline appointment, and given the option to complete the experimental intervention at the conclusion of the follow-up period.
62495652|NCT05676008|NO_INTERVENTION|Waitlist control|
62495653|NCT05676008|EXPERIMENTAL|Treatment|
62495654|NCT05134571|EXPERIMENTAL|Aldurazyme (laronidase)|Aldurazyme (laronidase) treatment at approved dose and regimen, administered every week as an IV infusion
61943942|NCT02212795|EXPERIMENTAL|C Group|1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg
61943943|NCT02284542||Patients with successful trial implant|Patients who have had a successful SCS trial and are indicated for permanent implantation will be approached to participate in this study prior to permanent implantation. Patients will be recruited and enrolled by physicians at any one of the involved sites. Each Investigator will only use one method (awake or non-awake) according to his/her typical practice. Patients will receive treatment from their enrolling physician.
61943944|NCT00909896||Robotic Surgery candidates|Group of patients receive Robotic approach for endometrial cancer staging
61943945|NCT00909896||Open Laparotomy Surgical Candidates|Patients receiving open laparotomy for endometrial cancer surgical staging
61943946|NCT00819299|EXPERIMENTAL|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.
61943947|NCT03714620|ACTIVE_COMPARATOR|0.15 mg/kg IV Ketamine|
61943948|NCT03714620|ACTIVE_COMPARATOR|0.3 mg/kg IV Ketamine|
62339135|NCT03627910|EXPERIMENTAL|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
62495655|NCT04715139||All Products listed in Descriptions|"* ProStop~* BioCompression Screw~* TRIM-IT Drill Pin/TRIM-IT Spin Pin~* Headless Compression Screw/Compression FT Screw~* DynaNite Nitinol Staple~* Beveled Headed FT Screw"
62495656|NCT00662194||1|HIV-HBV co-infected and receiving anti-retroviral therapy (ART) and CD4 count \> 500cells/mm3
62495657|NCT00662194||2|HIV-HBV co-infected and receiving ART and CD4 count 200-500 cells/mm3
62495658|NCT00662194||3|HIV-HBV co-infected and receiving ART and CD4 count \<200cells/mm3
62495659|NCT00662194||4|HIV-HBV co-infected and not receiving ART
62495660|NCT00662194||5|HIV-HCV co-infected \& receiving anti-retroviral therapy (ART) and CD4 count \> 500cells/mm3
62495661|NCT00662194||6|HIV-HCV co-infected and receiving ART and CD4 count 200-500 cells/mm3
62495662|NCT00662194||7|HIV-HCV co-infected and receiving ART and CD4 count \<200cells/mm3
62495663|NCT00662194||8|HIV-HCV co-infected and not receiving ART
62495664|NCT06677723|EXPERIMENTAL|RUN_1*60|exercise training including one weekly running session (60-min long) for 3 weeks
62696848|NCT00610220|EXPERIMENTAL|2|
61943949|NCT01570296|EXPERIMENTAL|Gefitinib and BKM120|"Patients with NSCLC who progress on treatment with single-agent EGFR TKI (e.g., gefitinib or erlotinib), and meet the clinical definition of EGFR TKI resistance (Jackman et al., 2010):~1. A tumour that harbours an EGFR mutation known to be associated with drug sensitivity~2. Previous objective clinical benefit from treatment with an EGFR TKI~Patients should have systemic progression of disease (by RECIST) while on continuous treatment with gefitinib or erlotinib. Patients that have previously progressed on EGFR TKI (not in the preceding line of treatment) may also be enrolled and will receive gefitinib and BKM120 sequentially.~Patients with any solid tumour-type and activated PI3 kinase pathway and historically known to over express EGFR may also be recruited.~Once the RP2D is reached, an expansion cohort of 40 patients will be accrued for extended safety experience and to ascertain preliminary activity."
61943950|NCT02469740|EXPERIMENTAL|Ticagrelor|Patients in this group will be prescribed ticagrelor 90 mg BD for 4 weeks.
61943951|NCT02469740|ACTIVE_COMPARATOR|Clopidogrel|Patients in this group will be prescribed clopidogrel 75 mg OD for 4 weeks
61943952|NCT01175460|EXPERIMENTAL|Chemoradiotherapy|Thoracic radiation 60Gy over 30 fractions.Concurrently, nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 was given on Days 1-14,repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
61943953|NCT06307873|ACTIVE_COMPARATOR|patients undergone Sacrospinous Fixation operation|
61943954|NCT06307873|ACTIVE_COMPARATOR|patients undergone V-notes Lateral Suspension Operation|
61943955|NCT04389216|EXPERIMENTAL|Radiofrequency|Radiofrequency Ablation of breast cancer tumour by Cool-tip electrode.
61943956|NCT00676338|EXPERIMENTAL|Exenatide Once Weekly|
61943957|NCT00676338|ACTIVE_COMPARATOR|Metformin|
62495665|NCT06677723|EXPERIMENTAL|RUN_4*15|exercise training including 4 weekly running sessions (15-min long) for 3 weeks
62696849|NCT00443456|EXPERIMENTAL|Single|
61943958|NCT00676338|ACTIVE_COMPARATOR|Sitagliptin|
61943959|NCT00676338|ACTIVE_COMPARATOR|Pioglitazone|
61943960|NCT01709565||No hepatic dysfunction|No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
61943961|NCT01709565||Hepatic dysfunction|Hepatic dysfunction, total plasma bilirubin \> 2.0 mg/dl
61943962|NCT03896165|EXPERIMENTAL|Teaching Reiki|Parent-adolescent pairs will be in the study for a total of nine weeks from enrollment to the follow up visit. During Week 1, the parent will receive Reiki training, a poster with suggested hand positions and a commercially-available book about Reiki in the home. During Week 2 the parent will receive a Reiki booster session with a repeat of the training and may ask questions in the home. At the end of Week 4, measures will be repeated either in person or by phone. During Week 8, measures will be repeated, another hair sample obtained and the parent will participate in a qualitative interview. The qualitative interview will be administered in person by trained Ohio State University College of Nursing study staff as part of the interview session. Interviews will be audio recorded using a hand-held audio recording device. Audio recording is voluntary and participants can choose to not have their interview recorded and still be a part of the study.
61943963|NCT02002832|EXPERIMENTAL|Lurasidone group|
62139411|NCT05304624|EXPERIMENTAL|Group 2: Diode laser|"Ilase, Biolase-USA Diode laser (940nm) was set at power of 1.2W and 750 W/cm2. 400µm fiber tip was used in contact mode and continuous-wave for de-epitelization procedure.~Another visit of laser ablation was performed after 7 days to remove the remaining pigmentation. The same laser settings were used."
62495666|NCT06677723|NO_INTERVENTION|CONTROL|control group
62696850|NCT04873908|OTHER|conventional rehabilitation|
61943964|NCT02002832|ACTIVE_COMPARATOR|Risperidone group|
61943965|NCT05420597|EXPERIMENTAL|Induction chemotherapy and Toripalimab|Induction chemotherapy TP regimen combined with Toripalimab, followed by cisplatin-based concurrent chemoradiation.
61943966|NCT01932359|ACTIVE_COMPARATOR|rapidly absorbable suture (Vicryl Rapide)|
61943967|NCT01932359|ACTIVE_COMPARATOR|non-absorbable suture (Ethilon)|
62139412|NCT01501617|EXPERIMENTAL|HSC- Hair Stimulating Complex|Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
62495667|NCT05797480|EXPERIMENTAL|Experimental: Real Dry needling|1 dry needling treatment per week for 6 consecutive weeks
62495668|NCT05797480|SHAM_COMPARATOR|Sham: Non penetrating dry needling|1 non penetrating dry needling per week for 6 consecutive weeks
62495669|NCT00951535|OTHER|Arm A|Treatment will be delivered in 1.8 Gy fractions; dose escalation will be in 1.8 Gy increments from 75.6 Gy to a maximum 81 Gy.
62696851|NCT04873908|EXPERIMENTAL|Modified constraint-induced therapy|
62696852|NCT04873908|EXPERIMENTAL|Proprioceptive Training|
62696853|NCT02438969||AUD/ELS-|Treatment seeking or non-treatment seeking individuals with AUD without ELS exposure
62696854|NCT02438969||AUD/ELS+|Treatment-seeking or non-treatment seeking individuals with AUD and early life stress (ELS) exposure
62696855|NCT02438969||non-AUD/ELS-|non-AUD controls without ELS exposure
62696856|NCT02438969||non-AUD/ELS+|Non-AUD controls with ELS exposure
61943968|NCT05780190|EXPERIMENTAL|CABA group|new artificial liver CABA system (BS330+CA280) combined with plasma exchange
61943969|NCT05780190|EXPERIMENTAL|control group|BS330 combined with plasma exchange
61943970|NCT00482027|ACTIVE_COMPARATOR|1 AAV-2 HIV Vaccine|64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization
61943971|NCT00482027|PLACEBO_COMPARATOR|2|16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES
61943972|NCT04680130||Neurodegenerative symptoms|
62696857|NCT04466007|PLACEBO_COMPARATOR|Control arm|0.9% physiological saline
62696858|NCT04466007|EXPERIMENTAL|Low dose treatment arm|Low dose allogeneic mesenchymal stem cells derived from adipose tissue
62696859|NCT04466007|EXPERIMENTAL|High dose treatment arm|High dose allogeneic mesenchymal stem cells derived from adipose tissue
62495670|NCT06113549|EXPERIMENTAL|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame. KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
62495671|NCT06113549|ACTIVE_COMPARATOR|Knee Prosthesis|KP is indicated and surgically implanted according to regular clinical practice (can be a total- or unicompartmental KP, in line with local practice in consultation with the patient and conform the national guideline by Dutch orthopaedic society (NOV)).
62495672|NCT06343688||Case Group|"The Gross Motor Function Classification System (GMFCS) will be used to classify children's gross motor levels, the Manual Abilities Classification System (MACS) for hand skills, the Communication Function Classification System (CFCS) for communication skills, and the Eating and Drinking Ability Classification System (EDACS) for feeding skills. Additionally, the Gross Motor Function Measure (GMFM-88) items D and E will be used to assess motor skills, the Wii Balance Board for testing balance, the Pediatric Berg Balance Scale, and the functional reach test will be utilized. The balance and gross motor functions of the included children will be evaluated in two different ways: with and without DAFO."
62339136|NCT03627910|ACTIVE_COMPARATOR|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
62339137|NCT05202093|EXPERIMENTAL|Electric toothbrush A|Use Oclean electric toothbrush A to brush teeth twice daily for 8 weeks
62339138|NCT05202093|ACTIVE_COMPARATOR|Manual toothbrush|Use Oral B manual toothbrush to brush teeth twice daily for 8 weeks
62495673|NCT01494090|ACTIVE_COMPARATOR|Rosuvastatin|
62495674|NCT01494090|PLACEBO_COMPARATOR|placebo|
62495675|NCT01608906|EXPERIMENTAL|continuous low dose intravenous heparin infusion|titrated to a PTT of 40-45
62495676|NCT01608906|ACTIVE_COMPARATOR|subcutanous heparin 5000 units 3 times/day|standard of care
62495677|NCT00659815|ACTIVE_COMPARATOR|ReNu in Currently Marketed Bottle|Bausch \& Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
62495678|NCT00659815|EXPERIMENTAL|ReNu in Clear Resin Bottle|Bausch \& Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
62495679|NCT01181596||Arm 1: observational ultrasound|Collection of image data with the ultrasound probe.
62495680|NCT04631133||Participants with low-back pain and degenerative lesions of grade II, III, IV (Pfirrmann MRI class)|Participants with low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification)
62495681|NCT06381323|EXPERIMENTAL|Finerenone|Recruitment of diagnosed patients with PA from multiple centers, confirmation of subject eligibility according to inclusion criteria and exclusion criteria, and signing of informed consent forms. All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
62495682|NCT04572854|EXPERIMENTAL|Group 1|Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
62495683|NCT04572854|OTHER|Group 2|No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
62495684|NCT00089973|EXPERIMENTAL|SB-715992|Females with advanced or metastatic breast cancer were administered Ispinesib
62495685|NCT02213887|EXPERIMENTAL|Start Pantoprazole|"Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.~Intervention: Days 2-8"
62495686|NCT02213887|EXPERIMENTAL|Stop Pantoprazole|"Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.~Intervention: Days 2-8"
62495687|NCT02625311|EXPERIMENTAL|MIS|Minimal invasive surgery for placement total knee prosthesis
62495688|NCT02625311|ACTIVE_COMPARATOR|conventional approach|"conventional open surgery for placement total knee prosthesis."
62495689|NCT02156219||Under separation|Exposure to the separation of women and men in the metro of Mexico City.
62495690|NCT02156219||No treatment|Non exposure to the separation of women and men in the metro of Mexico City.
62495691|NCT00794053|EXPERIMENTAL|study group|The members in this group will undergo intervention by having surgery and lymph node detection by dye staining
62495692|NCT02414464|EXPERIMENTAL|35% hydrogen peroxide|Volunteers of this group will receive a gel with 35% hydrogen peroxide - Whiteness HP 35% for whitening treatment.
62495693|NCT02414464|EXPERIMENTAL|35% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 35% for whitening treatment.
62495694|NCT02414464|EXPERIMENTAL|20% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 20% for whitening treatment.
62495695|NCT06200376|EXPERIMENTAL|T3011|
62495696|NCT05564845||Severe SCD genotypes|Children between 6 and 18 years of age of genotypes HbSS, HbSβº
62339139|NCT05202093|EXPERIMENTAL|Electric toothbrush B|Use Oclean electric toothbrush B to brush teeth twice daily for 8 week
62339140|NCT05519046|EXPERIMENTAL|Cardiac Contractility Modulation Group - CCM Group|CCM implantation.
62339141|NCT05519046|ACTIVE_COMPARATOR|Cardiac Resynchronization Therapy Group - CRT Group|CRT implantation
62339142|NCT02456545||help-seekers at-risk|"persons consulting collaborating Early Recognition Centers presenting with hints for ≥ 1 potential risk factor for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse, ADHD)~anticipated n = 500"
62339143|NCT02456545||patients with depressive syndrome|"in- and outpatients with depressive syndrome (SCID)~anticipated n = 500"
62339144|NCT02456545||patients with ADHD|"in- and outpatients with Attention-Deficit/Hyperactivity-Disorder (ADHD)~anticipated n = 150"
62339145|NCT02456545||representative population cohort|"representative population cohort from the IMAGEN study~anticipated n = 500"
62339146|NCT05364905||Cohort 1|Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
62696860|NCT06564194|EXPERIMENTAL|Investigational product|Subjects randomized to this arm will be given the investigational product (JCXH-108).
61943973|NCT01771042|EXPERIMENTAL|Normal glucose tolerant|"Weight loss attained by 25% caloric restriction.~This arm will be both a glycemic and time control. Initially they will undergo a 4-month weight maintenance phase (acting as time control), followed by 4 month weight loss."
61943974|NCT01771042|EXPERIMENTAL|Impaired glucose tolerant|"Weight loss using 25% caloric restriction.~Impaired glucose tolerant subjects will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
61943975|NCT01771042|EXPERIMENTAL|Type 2 diabetic hyperinsulinemic|"Weight loss using 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
61943976|NCT01771042|EXPERIMENTAL|Type 2 diabetic hypoinsulinemic|"Weight loss via 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
61943977|NCT03716193|EXPERIMENTAL|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
61943978|NCT03716193|EXPERIMENTAL|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
61943979|NCT03716193|EXPERIMENTAL|Cohort 3|Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
61943980|NCT03716193|EXPERIMENTAL|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
61943981|NCT01745185||Fabry disease switch group|Subjects will include individuals with Fabry disease who are switching from agalsidase alfa to agalsidase beta
61943982|NCT01745185||Control Group|Controls will include individuals with Fabry disease who have only received agalsidase beta as treatment in their lifetime.
61943983|NCT00423722|EXPERIMENTAL|Hydration: Normal Saline (salt water)|Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily
61943984|NCT00423722|PLACEBO_COMPARATOR|Placebo: Lower Saline|Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
61943985|NCT06117397|EXPERIMENTAL|Text4Moms|Texts will include video links that reinforce information relevant to Interpersonal Psychotherapy (IPT).
61943986|NCT06117397|NO_INTERVENTION|Educational Control|The control condition will be limited to texts related to pregnancy, nutrition and sleep. We will avoid elements that have behavioral therapeutic effects. Although this condition is meant to constitute time and attention control, we will include material on recognizing depression and links to ways to attain depression treatment and suicide hotline information.
61943987|NCT03808129|ACTIVE_COMPARATOR|ESP Group: Bupivacaine and lidocaine|ESP Group: Bupivacaine and lidocaine: Erector Spinae Plane Block : (1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine) was administered.
62139413|NCT01501617|PLACEBO_COMPARATOR|Dulbecco's Modified Eagle Medium, DMEM|Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.
62139414|NCT02170337|EXPERIMENTAL|AMG 282|AMG 282 administered as subcutaneous and intravenous doses.
62139415|NCT02170337|PLACEBO_COMPARATOR|Placebo|No active drug
62139416|NCT06699043|ACTIVE_COMPARATOR|nanocrystalline hydroxyapatite in putty form|• Group I: in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of nanocrystalline hydroxyapatite in putty form as grafting material.
62139417|NCT06699043|ACTIVE_COMPARATOR|Demineralized Bone Matrix allograft putty as grafting material|group II in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of Demineralized Bone Matrix allograft putty as grafting material.
62139418|NCT00613405|EXPERIMENTAL|Stress + cue exposure|Individuals were exposed to the Trier Social Stress Test (TSST) as well as neutral cues and marijana cues.
62696861|NCT06564194|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will be given a placebo.
62696862|NCT05656664|PLACEBO_COMPARATOR|Placebo|Placebo daily 12 weeks
62696863|NCT05656664|EXPERIMENTAL|Folic Acid|Folic acid 800 ug/day 12 weeks
61943988|NCT03808129|NO_INTERVENTION|control group|Control Group:
61943989|NCT01228474|EXPERIMENTAL|SET|Single embryo transfer
61943990|NCT01228474|ACTIVE_COMPARATOR|DET|Double embryo transfer
61943991|NCT05742711|EXPERIMENTAL|Treatment Group|The group who have received PENS treatment using PrimaryRelief in addition to Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS\>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.
61943992|NCT05742711|SHAM_COMPARATOR|Control Group|The group who have received a sham device along with Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS\>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.
62139419|NCT00613405|EXPERIMENTAL|No stress + cue exposure|Individuals were not exposed to a stress test, but were exposed to neutral cues and marijuana cues.
62139420|NCT01756599|EXPERIMENTAL|leukaemia during childhood or adolescence|
62339147|NCT05364905||Cohort 2|Patients in second line treatment (after one prior systemic chemotherapy) in 2019
62696864|NCT06642025|EXPERIMENTAL|CAR-T Cell Injection|
62696865|NCT02971163|EXPERIMENTAL|SynDA|The research coordinator will print the appropriate version of the SynDA based on the patient's individualized risk score and the corresponding estimated probability of a serious medical event within 30 days.
62696866|NCT02971163|NO_INTERVENTION|Control|Patients in the control arm will receive usual emergency care pertaining to syncope.
62696867|NCT06000787|OTHER|Diffuse Midline Glioma|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B
62696868|NCT06000787|OTHER|Neuroblastoma|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B
62696869|NCT06365502|EXPERIMENTAL|DCB treatment|Non-flow limited vulnerable plaque will be treated by drug-coated balloon when the enrolled individual is randomized into DCB treatment group. The individual located in DCB treatment will receive guideline-directed medical treatment.
62339148|NCT06175962|EXPERIMENTAL|Experimental Group|"At the beginning of the research, the Introductory Information Form, the Attitudes Towards Menopause Scale (MITÖ), and the Spirituality Index Well-Being Scale will be applied to the experimental group. Later, menopause health education will be given to women within the scope of the menopause adaptation program prepared based on Meleis's transition theory. Then, the women will be taught the baduanjin exercise for 4 weeks by the researcher who has a Qigong practitioner certificate. All training will be held online. After making sure that the women have learned the baduanjin exercise, they will be asked to do the baduanjin exercises at home 3 times a week for 8 weeks.~During this process, counseling services will be provided and women will be followed. The study will be completed in 14 weeks, after which posttest data will be collected."
62339149|NCT06175962|NO_INTERVENTION|Control Group|"At the beginning of the research, the Introductory Information Form, Attitudes Towards Menopause Scale (MITÖ), and Spirituality Index Scale will be applied to the control group.~No intervention will be made to the control group."
62339150|NCT06373042|EXPERIMENTAL|Tirofiban|Intraarterial and intravenous tirofiban
62339151|NCT06373042|PLACEBO_COMPARATOR|Placebo|Intraarterial and intravenous placebo
62339152|NCT02154126|OTHER|Accuracy assessment|
62339153|NCT04702217|EXPERIMENTAL|POTS patients|All POTS patients in the study will perform a 16 week-training program. The present study will be using longitudinal comparisons, meaning that the 100 POTS patients are their own controls. The questionnaires and exercise capacity will be compared before and after the 16-weeks training program.
62339154|NCT01647464||Contrast administration|Patients undergoing contrast-enhanced echo.
62339155|NCT02730936|EXPERIMENTAL|Antimicrobial Hernia Repair Device|Antimicrobial hernia repair device for repair of ventral or incisional hernias in Class II and III surgical fields.
62339156|NCT02998060|ACTIVE_COMPARATOR|Robot-guided|Robotic guidance (SpineAssist®or Renaissance® (Mazor Robotics Ltd. Caesarea, Israel) will be used for navigation and insertion of pedicle screws.
62339157|NCT02998060|ACTIVE_COMPARATOR|Navigated|A computer-assisted method of navigation (CT- or 3D-Fluoroscopy-based) will be used for navigation and insertion of pedicle screws.
62339158|NCT02998060|ACTIVE_COMPARATOR|Freehand|Pedicle screws will be inserted using the freehand technique under fluoroscopic control.
62339159|NCT00138424|EXPERIMENTAL|Cidofovir|32 subjects will be randomized to 1 of 3 possible cohorts. Cohort I will receive dose 0.25 mg/kg; Cohort II will receive 0.5 mg/kg, Cohort III will receive 1.0 mg/kg. Maximum tolerated dose is to be determined.
62339160|NCT00138424|PLACEBO_COMPARATOR|Placebo|16 subjects to receive placebo.
62495697|NCT05564845||Not severe SCD genotypes|Children between 6 and 18 years of age of genotypes HbSβ+, and HbSC and more
62696870|NCT06365502|ACTIVE_COMPARATOR|Guideline-directed medical treatment|Non-flow limited vulnerable plaque will be left with no intervention when the individual is randomized into guideline-directed medical treatment group. The individual will receive guideline-directed medical treatment alone.
61943993|NCT05887232|ACTIVE_COMPARATOR|Fractional Co2 laser|Patient in group A received FCL treatment's four sessions four weeks apart.
62696871|NCT00850330||Hospitalized patients|Patients elder than 65 years old hospitalized for any reason.
62696872|NCT04130191||Participants with hereditary angioedema (HAE)|Participants who initiate treatment with lanadelumab according to current product labelling will be enrolled and followed for up to 24 or 36 months (depending on their enrollment date).
62696873|NCT05322005|EXPERIMENTAL|Arm A: augmentation to surgery|Patients will be surgically treated with partial meniscectomy combined with an intraarticular and intra-meniscal injection of polynucleotide gel, during an arthroscopic procedure. After 6 weeks the patients attend a second injection session, during an ambulatorial visit. At 8 weeks from the surgery the patients attend the third ambulatorial injection session
61943994|NCT05887232|ACTIVE_COMPARATOR|Platelet Rich Plasma|Group B received fractional CO2 with four Platelet Rich Plasma sessions,4 weeks apart.
62339161|NCT00501215|EXPERIMENTAL|Parathyroidectomy + Observation|
62339162|NCT00501215|OTHER|Observation Alone|
62339163|NCT03611517|EXPERIMENTAL|Sexual rehabilitation programme|The intervention exists of a nurse-led sexual rehabilitation programme, which is provided in addition to the care as usual. The intervention consists of four one-hour sessions at 1 month, 3, 6, and 12 months after RT. Women treated with RTBT will receive an additional appointment with the nurse (2 months after RTBT). Furthermore, the latter group receives a vaginal dilator set.
62339164|NCT03611517|NO_INTERVENTION|Care as usual|The control group receives the optimal care as usual, according to each participating hospital's guidelines. Additionally, all patients receive an information booklet including information concerning sexuality after RT for GC. Patients who underwent RTBT also receive a vaginal dilator set.
62495698|NCT00310492|ACTIVE_COMPARATOR|Subcutaneous immunotherapy|Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
62696874|NCT05322005|EXPERIMENTAL|Arm B: conservative treatment|The patients are going to receive three injections session (polynucleotide gel) performed with a time interval of 2 weeks.
62696875|NCT05708859|ACTIVE_COMPARATOR|Tirzepatide|Tirzepatide 15mg Prefilled pen for weekly subcutaneous injection over 52 weeks
62696876|NCT05708859|PLACEBO_COMPARATOR|Placebo|Placebo Prefilled pen (volume matched) for weekly subcutaneous injection over 52 weeks
61943995|NCT02601599|EXPERIMENTAL|Intervention|Motivational interviewing The medical student will deliver a 15 minute consultation with the patient. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, educate the patient about effective behavioral and pharmacological cessation strategies, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy. Patients who elect to receive this consult with have a coloured sticker placed by the medical student on the medical chart requesting a consultation.
62339165|NCT00165646|EXPERIMENTAL|1|
62495699|NCT00310492|PLACEBO_COMPARATOR|Subcutaneous injections|placebo injections
62495700|NCT00645944|EXPERIMENTAL|Eszopiclone Group|Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
62696877|NCT05878795|EXPERIMENTAL|Written Exposure Therapy-for Suicide Prevention (WET-SP) +TAU|Participants randomized into this arm will be offered WET-SP which will consist of 5 treatment sessions, conducted daily while the participant is hospitalized, allowing for the largest dose of treatment possible while inpatient. If a patient is discharged prior to the completion of WET-SP, the remaining sessions will be conducted in outpatient sessions. Participants in this arm will also be offered TAU.
62696878|NCT05878795|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Participants randomized into this arm will be offered TAU which consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). Participants will engage with the provider team daily throughout the duration of hospitalization.
61943996|NCT02601599|NO_INTERVENTION|Usual care|This group will not receive student contact, but may be counselled by the smoking cessation officer or other Connolly staff as per normal procedures.
61943997|NCT01173354|EXPERIMENTAL|COPD patients only|Free balanced amino acid mixture or free essential amino acid mixture
61943998|NCT05531331|EXPERIMENTAL|Intervention Group|After discharge, the individuals in the experimental group were given training by the researcher through training booklets prepared by the Association of Wound Ostomy Incontinence Nurses and video conference in four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month.
61943999|NCT05531331|NO_INTERVENTION|Control Group|Individuals with stoma in the control group received the training of the company representative that sells stoma materials routinely in the hospital.
61944000|NCT01825525|EXPERIMENTAL|Cardiac device patients.|Exposure to ScopeGuide - patients with cardiac devices exposed to ScopeGuide as per study protocol
61944001|NCT04238546|EXPERIMENTAL|Sirolimus-coated group|
61944002|NCT04238546|ACTIVE_COMPARATOR|Uncoated group|
61944003|NCT01330680|EXPERIMENTAL|Coffee|
61944004|NCT01330680|ACTIVE_COMPARATOR|Decaffeinated coffee|
61944005|NCT02037360|ACTIVE_COMPARATOR|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
61944006|NCT02037360|EXPERIMENTAL|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
61944007|NCT00630370|PLACEBO_COMPARATOR|1|2 Placebo tablets, TID, orally, 58 days
61944008|NCT00630370|EXPERIMENTAL|2|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
61944009|NCT00630370|EXPERIMENTAL|3|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
61944010|NCT00630370|EXPERIMENTAL|4|2 ATI 40mg tablets, TID, orally, 58 days
62139421|NCT05971979||Critically ill patients with presumed or confirmed lower respiratory tract infection|Non-interventional. Admitted to intensive care unit. Presumed or confirmed lower respiratory tract infection. Receiving either piperacillin/tazobactam or meropenem. Participants will have samples collected during an antimicrobial dose cycle.
62696879|NCT06626126|ACTIVE_COMPARATOR|LDL-C guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
62696880|NCT06626126|EXPERIMENTAL|ApoB-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets.
61944011|NCT05613309||patients with acute varicose hemorrhage in Renmin Hospital of Wuhan University in recent 10 years|In this study, patients with liver cirrhosis and acute variceal bleeding in Renmin Hospital of Wuhan University in the past 10 years will be selected as the research objects. Patients will be divided into survival and death groups according to whether they died 6 hours after admission. The differences in clinical data between the two groups will be compared and analyzed to decide the risk factors for early death and establish a mortality risk prediction model.
61944012|NCT05568407||Patients with Advanced or Metastatic Urothelial Cancer|Patients with Advanced or Metastatic Urothelial Cancer
61944013|NCT05283278|ACTIVE_COMPARATOR|Lactoferrin Bovine group|Group A (20 preterm neonates) which will receive lactoferrin (100mg/day)
61944014|NCT05283278|ACTIVE_COMPARATOR|Lactoferrin Bovine with probiotics group|Group B (20 preterm neonates) which will receive lactoferrin (100mg/day) in combination with the probiotic
61944015|NCT05283278|PLACEBO_COMPARATOR|Placebo group|Group C (40 preterm neonates) which is a placebo group.
61944016|NCT05928260|ACTIVE_COMPARATOR|Real time CGMS(rt-CGMS)|Medtronic Guardian Connect sensor 3 will be applied for 2 weeks at the beginning of this study in this arm for blood glucose monitoring and insulin dose adjustments for glycemic control.
62139422|NCT05596331|OTHER|Group of adult subjects without ASD (Autism Spectrum Disorders)|Age between 18 and 50 years
62339166|NCT00165646|EXPERIMENTAL|2|
62339167|NCT00165646|PLACEBO_COMPARATOR|3|
62339168|NCT05047159|EXPERIMENTAL|drug therapy group|Drug: drug therapy There is no restriction on the choice of therapeutic drugs.
62495701|NCT00645944|PLACEBO_COMPARATOR|Placebo Group|"Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study."
61944017|NCT05928260|ACTIVE_COMPARATOR|Intermittently scanned CGMS(is-CGMS)|Abott Freestyle Libre Sensor will be applied for 2 weeks at the beginning of this study in this arm for blood glucose monitoring and insulin dose adjustments for glycemic control.
62139423|NCT05596331|OTHER|Group of children without ASD|Age between 2 and 12 years
62139424|NCT05596331|OTHER|Group of children with ASD|Age between 2 and 12 years Conformity with the diagnostic criteria of ASD according to DSM-V, ICD-10 or ICD-11
62139425|NCT05596331|OTHER|Group of children without NDD (NeuroDevelopmental Disorders)|Age between 0 and 12 years
62139426|NCT05596331|OTHER|Group of children with NDD, or whose diagnosis is in progress|Conformity to the diagnostic criteria of NDD
62139427|NCT01157299||Hemodynamic instability|Hypotension and/or evidence of end-organ hypoperfusion
62696881|NCT02706392|EXPERIMENTAL|Treatment (ROR1 CAR-specific autologous T-lymphocytes)|Patients receive chemotherapy comprising fludarabine phosphate and cyclophosphamide as determined by the referring physician in consultation with the protocol PI. Beginning within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive ROR1 CAR-specific autologous T-lymphocytes IV over 20-30 minutes. Patients may receive a second infusion of ROR1 CAR-specific autologous T-lymphocytes with or without additional cytoreductive therapy at the same (for those that received the highest cell dose) or up to the next highest dose level and there is persistent disease, there were no toxicities attributed to the first infusion, and the patient is at least 21 days from the first T cell infusion.
62696882|NCT05136495|EXPERIMENTAL|Caffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
62495702|NCT05919901|EXPERIMENTAL|HPV Intervention|
62696883|NCT05136495|EXPERIMENTAL|Decaffeinated coffee|Drink decaffeinated coffee one morning and drink caffeinated coffee the other morning
62696884|NCT06460155|EXPERIMENTAL|Experimental group|
62696885|NCT05409794||Suicide attempters/ideations|Patients currently suffering from a major depressive disorder and reporting at least one suicidal event (suicide attempt or hospitalization for suicidal ideation) over the last 12 months.
62696886|NCT05409794||Affective controls|Patients currently suffering from a major depressive disorder and reporting no suicidal event (suicide attempt or hospitalization for suicidal ideation) over the last 12 months.
62696887|NCT05549362|PLACEBO_COMPARATOR|ad libitum Control|No treatment control condition.
62696888|NCT05549362|ACTIVE_COMPARATOR|Traditional CR|A 25% calorie restriction (CR) intervention delivered via traditional in-person sessions.
62696889|NCT05549362|ACTIVE_COMPARATOR|Adaptive CR|A 25% calorie restriction (CR) intervention delivered via a remote, adaptive, and technology-driven intervention program.
62139428|NCT01157299||Hemodynamic stability|"Normotension and end-organ normoperfusion along with~* Vasopressor, vasodilator or inotropic therapy~* Edema and/or evidence of hypervolemia"
62139429|NCT01157299||"Hemodinamically normal"|"Normotension and end-organ normoperfusion along with~* Non vasopressor, vasodilator or inotropic therapy~* Normohydration state~* Non Systemic Inflammatory Response Syndrome~* Spontaneous breathing and PEEP, or CPAP, equal or less than 5 cm H2O"
62139430|NCT05769244|EXPERIMENTAL|testicular torsion|
62139431|NCT05769244|ACTIVE_COMPARATOR|other testicular pathology|
62139432|NCT05769244|SHAM_COMPARATOR|healthy patients|
62139433|NCT01458600|ACTIVE_COMPARATOR|diclofenac|12 months treatment with diclofenac 50 mg 1x2 in addition to regular treatment for thyrotoxicosis.
62139434|NCT01458600|OTHER|without diclofenac|12 months treatment without diclofenac in addition to regular treatment for thyrotoxicosis.
62696890|NCT05549362|ACTIVE_COMPARATOR|Traditional TRE|An eight-hour time restricted eating (TRE) intervention delivered via traditional in-person sessions.
62696891|NCT05549362|ACTIVE_COMPARATOR|Adaptive TRE|An eight-hour time restricted eating (TRE) intervention delivered via a remote, adaptive, and technology driven intervention program.
62696892|NCT06418061|EXPERIMENTAL|IBI3005|
62495703|NCT05919901|ACTIVE_COMPARATOR|Active Control|
62696893|NCT06637930|EXPERIMENTAL|Cobalt chromium(COCR) group|The secondary crowns and the framework were fabricated using milled Cobalt chromium alloy
62696894|NCT06637930|EXPERIMENTAL|Polyetheretherketone(PEEK) Group|The secondary crowns and the framework were fabricated using milled PEEK material
62696895|NCT03947463|EXPERIMENTAL|PECS block group|20ml of 0.25% bupivacaine was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualised on the ultrasound screen. similarly, in Serratus plane block, ultrasound probe was placed over the mid-axillary region of the thoracic cage in a sagittal plane. Ribs were identified inferiorly and laterally, until the identification of the 3rd rib in the mid axillary line. 10 ml of 0.25% bupivacaine was infiltrated in between Serratus anterior muscle and Latissimus Dorsi muscle
62696896|NCT03947463|NO_INTERVENTION|Control group|Patient were given multimodal analgesia without the regional block
62696897|NCT02239237||Compound Kuh-seng Injection|Compound Kuh-seng Injection will be given to the patients, and the investigators will record all the information including ADR, application of Compound Kuh-seng Injection and the combined medications, etc.
62696898|NCT05706350|EXPERIMENTAL|Plant stanol group (2 grams per day)|Dietary Supplement: 4 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
62696899|NCT05706350|EXPERIMENTAL|Plant stanol group (3 grams per day)|Dietary Supplement: 6 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
62696900|NCT05706350|EXPERIMENTAL|Plant stanol group (4 grams per day)|Dietary Supplement: 8 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
62139435|NCT00474799|EXPERIMENTAL|A|MNS075 7.5mg q1h
62139436|NCT00474799|EXPERIMENTAL|B|MNS075 15mg q3h
62139437|NCT00156507|EXPERIMENTAL|1|Parents of children in the experimental group receive asthma education prior to NICU discharge.
62139438|NCT05750043||Population of selected villages in Maridi county|A total of 2,511 households containing 17,652 individuals were visited in 2018, and 2,254 households containing 14,402 individuals in 2022.
62139439|NCT01749319|ACTIVE_COMPARATOR|Oral Baclofen|
62139440|NCT01749319|EXPERIMENTAL|Intervenous baclofen|Crossover study that eacg subject is given both oral and intervenous baclofen
62139441|NCT04291027|EXPERIMENTAL|Aquatic Group Exercise|
62139442|NCT04291027|ACTIVE_COMPARATOR|Land Based Group Exercise|
62139443|NCT00290537|EXPERIMENTAL|Part One: ZD6474|First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m\^2 IV over 3 hours on Day 1 every 3 weeks.
62139444|NCT00290537|EXPERIMENTAL|Part Two A: ZD6474 300 mg|Second part of study where participants randomized to receive 300 mg of ZD6474 daily (group A)
62139445|NCT00290537|EXPERIMENTAL|Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel|Second part of study where participants randomized to receive 100 mg of ZD6474 daily plus carboplatin AUC 6.0 IV over 15-30 minutes and paclitaxel 200 mg/m\^2 IV over 3 hours on Day 1 every 3 weeks (group B).
62696901|NCT05706350|PLACEBO_COMPARATOR|Placebo group|Dietary Supplement: 6 placebo soft chews Soft chews that do not contain plant stanols
62339169|NCT05047159|EXPERIMENTAL|drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group|"Device: rTMS Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
62339170|NCT05047159|EXPERIMENTAL|drug therapy combined with light therapy group|"Device: light therapy Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
62339171|NCT05047159|EXPERIMENTAL|drug therapy combined with electroconvulsive therapy (ECT) group|"Device: ECT The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
62339172|NCT05047159|EXPERIMENTAL|drug therapy combined with magnetic seizure therapy (MST) group|"Device: MST A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
62339173|NCT01732185|OTHER|Patient|congenital cystic adenomatoid malformations
62339174|NCT00988741|EXPERIMENTAL|ARQ 197|
62339175|NCT00988741|PLACEBO_COMPARATOR|placebo|
62339176|NCT02095236|EXPERIMENTAL|experimental|Radioopaque fiducial markers or electro-magnetic transponders will be implanted into or in close proximity of the tumor. During a radiotherapy treatment session image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors The data will help to characterize tumor and organ motion during one treatment session which may in fact have impact on dose distribution
62339177|NCT03936816||GBS screened positive|150 patients that were screened positive by culture at 35-37 weeks gestational age.
62339178|NCT03936816||GBS unknown with risk factors|150 patients that were not screened for GBS and have risk factors for GBS prophylaxis.
62339179|NCT00987233|EXPERIMENTAL|triamcinolone acetonide aqueous nasal spray|
62339180|NCT00987233|ACTIVE_COMPARATOR|Nasacort® AQ Nasal Spray|
62339181|NCT00987233|PLACEBO_COMPARATOR|Placebo|
62339182|NCT02857114|OTHER|massage|
62339183|NCT03208725||Hospitalized children with severe wasting or kwashiorkor (SWK)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
62339184|NCT03208725||Community reference participants (CP)|Children recruited from the community who are seen a single appointment in the community.
62339185|NCT03208725||Hospitalized children with moderate wasting (MW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
62339186|NCT03208725||Hospitalized children without wasting (NW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
62139446|NCT01608568|ACTIVE_COMPARATOR|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
62339187|NCT02860806|EXPERIMENTAL|Part 1: Period 1 (JNJ-63623872 100 mg or Placebo)|Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) \[3 milligram per milliliters (mg/mL) solution\] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
62339188|NCT02860806|EXPERIMENTAL|Part 1: Period 2 (JNJ-63623872 200 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
62339189|NCT02860806|EXPERIMENTAL|Part 1: Period 3 (JNJ-63623872 300 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
62696902|NCT06493253||Non-Liver Related Event|Absence of any of the liver events described in the second group in the patient clinical follow-up.
62696903|NCT06493253||Liver Related Event|Liver-related events include liver-related death, hepatic decompensation events (variceal hemorrhage, ascites, hepatic encephalopathy), and hepatocellular carcinoma.
62696904|NCT04907955|ACTIVE_COMPARATOR|panoptix PANFOCAL intraocular lens|panoptix PANFOCAL intraocular lensis a single-piece aspheric non-apodized diffractive panfocal IOL that distributes light energy to three focal points in both small and large pupil conditions
62339190|NCT02860806|EXPERIMENTAL|Part 2: Group 1 (EFG)|Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2\* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G). Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
62339191|NCT02860806|EXPERIMENTAL|Part 2: Group 2 (FGE)|Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
62339192|NCT02860806|EXPERIMENTAL|Part 2: Group 3 (GEF)|Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
62339193|NCT02860806|EXPERIMENTAL|Part 2: Group 4 (GFE)|Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
62339194|NCT02860806|EXPERIMENTAL|Part 2: Group 5 (FEG)|Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
62339195|NCT02860806|EXPERIMENTAL|Part 2: Group 6 (EGF)|Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
62696905|NCT04907955|ACTIVE_COMPARATOR|Trifocal Diffractive the AT LISA intraocular lens|Trifocal Diffractive the AT LISA is a preloaded single-piece aspheric diffractive trifocal IOL and made of hydrophilic acrylic with a hydrophobic surface with an ultraviolet absorber. This aspheric IOL is aberration -correcting in order to reduce and compensate for corneal spherical aberrations.
61944018|NCT05928260|PLACEBO_COMPARATOR|Self Monitoring of Blood Glucose(SMBG)|This group will monitor blood glucose using glucometer and needle pricks throughout the study duration and insulin doses will be adjusted based on these readings as per the standard management of Type-1 Diabetes Mellitus patients endorsed by American Diabetic Association in 2023.
62495704|NCT04011098|ACTIVE_COMPARATOR|Control Group (No Additional Epidural Fentanyl Bolus)|The Control group will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
62495705|NCT04011098|EXPERIMENTAL|Fentanyl bolus group|The Fentanyl bolus group will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
62495706|NCT01845064|EXPERIMENTAL|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
62495707|NCT01845064|EXPERIMENTAL|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
62495708|NCT01845064|EXPERIMENTAL|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
62495709|NCT01845064|EXPERIMENTAL|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
62495710|NCT01845064|PLACEBO_COMPARATOR|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
62495711|NCT01845064|PLACEBO_COMPARATOR|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
62495712|NCT01845064|PLACEBO_COMPARATOR|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
62495713|NCT01845064|PLACEBO_COMPARATOR|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
62495714|NCT04975724|EXPERIMENTAL|Group A Liposom Forte + Citalopram|Liposom Forte (2 ampoules of 28mg/2 ml) for 30 days + citalopram (10mg) for 90 days
62495715|NCT04975724|EXPERIMENTAL|Group B Placebo + Citalopram|Placebo (2 ampoules of 2 ml) for 30 days + citalopram (10mg) for 90 days
62495716|NCT00709137|ACTIVE_COMPARATOR|1|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)
62495717|NCT00709137|ACTIVE_COMPARATOR|2|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)
62696906|NCT04907955|ACTIVE_COMPARATOR|Symphony EDOF (extended depth of focus) intraocular lens|SYMPHONY EDOF intraocular lens is a single-piece aspheric biconvex hydrophobic acrylic IOL with a 6.0 mm optic and an 13.0 mm overall diameter. This IOL consists of a wavefront-designed anterior aspheric surface (negative spherical aberration of -0.27 mm to counterbalance the net positive spherical aberration from cornea) and a posterior achromatic diffractive surface with echelette design.
61944019|NCT01826773|EXPERIMENTAL|Stress only CardioPET™|"Group I will consist of 15-20 patients and will have CardioPET™ imaging performed with a repeat identical stress component at ≥ 48 hours and ≤ 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.~The analysis of the acquired imaging data will determine if CardioPET™ is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET™ imaging group is to measure blood flow at near maximal stress."
62696907|NCT06043154|EXPERIMENTAL|Anorexia nervosa|
62696908|NCT05470686|OTHER|HEART SURGERY PATIENTS with cardio pulmonary bypass|
62696909|NCT01172392|EXPERIMENTAL|PegIFN + Nucleosidic or Nucleotidic Analog|
62696910|NCT01172392|ACTIVE_COMPARATOR|Nucleosidic or Nucleotidic Analog|
62139447|NCT01608568|ACTIVE_COMPARATOR|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
62139448|NCT04745156|EXPERIMENTAL|RNS System Implantation|This is a device feasibility study, therefore participants will only be enrolled into the investigational arm and will receive the RNS System Implantation.
62139449|NCT05593107|EXPERIMENTAL|[68Ga]N188|Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-N188 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
62139450|NCT01094106|ACTIVE_COMPARATOR|Ropivacaine 0,75%|Postoperative wound infusion 15 mg /h / 48h
62139451|NCT01094106|PLACEBO_COMPARATOR|NaCl 0,9%|Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h
62696911|NCT00672035|EXPERIMENTAL|1|7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
62139452|NCT05437770|EXPERIMENTAL|BFR (Blood-Flow Restricted exercise)|The BFR training intervention group will perform low load blood-flow restricted exercise. Training twice a week for 12 weeks. The group will also attend a two hours education lecture with osteoarthritis information.
62696912|NCT00672035|EXPERIMENTAL|2|7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
62696913|NCT00672035|EXPERIMENTAL|3|22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
62696914|NCT00672035|EXPERIMENTAL|4|22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
62696915|NCT00672035|EXPERIMENTAL|5|37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
62696916|NCT00672035|EXPERIMENTAL|6|37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
62696917|NCT00672035|EXPERIMENTAL|7|50µg LT Dose placed at the Deltoid on Day 0 and Day 21
62495718|NCT02584166||Intervention group|38 maternity units with allocated to the intervention group: coordinating team disseminated protocols related to the management of cases, and organized mortality morbidity conferences (MMC) in each unit with staff concerned. These MMC were realized by the same outside medical binomial composed of a midwife and an obstetrician (outreach visit with a leader ship). Among the 38 maternity units, MMC were performed with the medical binomial and professionals of human science in 20 units to identify the defense mechanisms manifested by medical staff which could disturb the decision making. In the others 18 units, MMC were performed with only the outside medical binomial. Coordinating team defined with teams the area of improvement before each MMC. 3 or 4 MMC were performed according to their activity.
62495719|NCT02584166||Control group|No intervention in 57 maternity units
62495720|NCT00907205|EXPERIMENTAL|SF1126|Twice weekly IV infusion
62495721|NCT04988737|EXPERIMENTAL|CDS Group|Clinicians complete tasks using the CDS prototype. Briefly, the clinician scans the barcode on the syringe label immediately prior to medication administration. The scan triggers the CDS to display a dosing window with pertinent patient-specific information and/or alert(s) when necessary to prevent a medication error (ME) prior to the medication being administered. Medication data are then sent from the CDS application to the patient's anesthesia record for automatic documentation in real-time, eliminating the need to manually document the medication in the Anesthesia Information Management System (AIMS). When necessary, the CDS application generates alerts to prevent medication errors. Upon receiving an alert, the anesthesia clinician may accept the alert and revise the action that generated the alert, or override the alert and continue with the planned action.
62495722|NCT04988737|NO_INTERVENTION|Control Group|Clinicians complete tasks using the conventional medication administration and documentation workflow in anesthesia.
61944020|NCT01826773|EXPERIMENTAL|Rest only CardioPET™|"Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating ≥2 segments of ischemia. These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.~CardioPET™ imaging in these subjects must be performed ≥ 48 hours and ≤ 10 days from the initial stress (stress MPI or echocardiography) at rest only. An angiography must be scheduled to be performed within 30 days."
62495723|NCT03409315||Moxifloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.
62495724|NCT03409315||Levofloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin
62495725|NCT03409315||Moxifloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.
61944021|NCT06050369|EXPERIMENTAL|GTS group|This arm will be studied to get some electrophysiological marker of tics. The patients will be their own control (periods with symptoms vs. free symptoms periods).
61944022|NCT06050369|EXPERIMENTAL|OCD group|This arm will be studied to get some electrophysiological marker of compulsions. The patients will be their own control (periods with symptoms vs. free symptoms periods).
61944023|NCT03645590|EXPERIMENTAL|Stroke Ready Community intervention|We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
61944024|NCT03920787|EXPERIMENTAL|Inositol|Administration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month
62139453|NCT05437770|ACTIVE_COMPARATOR|Standard rehabilitation|The standard rehabilitation group will be offered participation in the Good Life with osteoArthritis in Denmark programme (GLA:D). The programme includes supervised team group training twice a week for 8 weeks and an education lecture. The GLA:D programme will be followed by 4 weeks of team group training continuing the exercises from the GLA:D programme.
61944025|NCT03920787|PLACEBO_COMPARATOR|Placebo|Administration of placebo. 2 capsules every day for 1 month
62139454|NCT01006772|NO_INTERVENTION|Control Group|Control group patients receive usual clinical practice provided by Stroke Unit at Stobhill Hospital in Glasgow. They receive physiotherapy and early mobilisation as deemed appropriate to treat their oown impairments.
62139455|NCT01006772|EXPERIMENTAL|Experimental group|Intervention Group patients receive custom made solid ankle foot orthosis (AFO)treatment.
62495726|NCT03409315||Levofloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.
62495727|NCT04161950||Tested device model (EG-UR5-S50 )|Tested device model: The EG-UR5 echoendoscope manufactured by SonoSscope Medical Crop. That used with the HD-500 image processor, HDL-500X light source and S50 ultrasonic processor.
62495728|NCT04161950||Compared device model (GF-UE260-ME2)|Compared device model: The GF-UE260 echoendoscope manufactured by Olympus and its compatible light source, image processor and ME2 ultrasonic processor.
62139456|NCT02221505|EXPERIMENTAL|LOP628 - Solid Tumor|with LOP628
62495729|NCT02836587|EXPERIMENTAL|interventional|Experimental group will undergo balance training for 8 weeks.
62495730|NCT02836587|NO_INTERVENTION|control|Control group will have no assigned intervention.
62696918|NCT00672035|EXPERIMENTAL|8|50µg LT Dose placed at the Lower Back on Day 0 and Day 21
61944026|NCT04824976|ACTIVE_COMPARATOR|Blueberry|Freeze-dried pure blueberry powder
61944027|NCT04824976|PLACEBO_COMPARATOR|Placebo|Maltodextrin powder.
61944028|NCT01274650|OTHER|Decubitis Ulcer|Patients admitted to the hospital with decubitus ulcers in the ischial, sacral, or coccyx area.
62139457|NCT02221505|EXPERIMENTAL|LOP628 - AML|With LOP628
62139458|NCT02221505|EXPERIMENTAL|LOP628 - Solid Tumor Expansion|With LOP628
62139459|NCT06522438|EXPERIMENTAL|Test Group|Non-surgical periodontal treatment (NSPT) plus Hyaluronic Acid (HA) and Octenidine gel.
62139460|NCT06522438|ACTIVE_COMPARATOR|Control Group|Non-surgical periodontal treatment (NSPT) alone.
62139461|NCT05620472|EXPERIMENTAL|[99mTc]Tc(CO)3-(HE)3-Ec1 1000 μg|At least five (5) evaluable subjects with solid tumor.
62139462|NCT05620472|EXPERIMENTAL|[99mTc]Tc(CO)3-(HE)3-Ec1 2000 μg|At least five (5) evaluable subjects with solid tumor.
62139463|NCT05620472|EXPERIMENTAL|[99mTc]Tc(CO)3-(HE)3-Ec1 3000 μg|At least five (5) evaluable subjects with solid tumor.
62696919|NCT00672035|PLACEBO_COMPARATOR|9|Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21
62139464|NCT02674841|EXPERIMENTAL|Feedback group|Receives live feedback on TUT and pulling force during exercises.
62495731|NCT03825198|ACTIVE_COMPARATOR|ESB group|"Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.~Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea."
62495732|NCT03825198|SHAM_COMPARATOR|SHAM group|Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
62495733|NCT04194008|EXPERIMENTAL|Nerivio device treatment|Treatment with active Nerivio device
62495734|NCT01089530|NO_INTERVENTION|Standard care|
62495735|NCT05423873|OTHER|Vitamin C Serum and Moisturizing Sunscreen SPF 45|"Dual Regimen:~Vitamin C Serum Tinted Moisturizing Sunscreen SPF 45"
62495736|NCT03458845||Group 1|This group consists of cirrhotic patients with any abdominal hernia
61944029|NCT02863276|EXPERIMENTAL|Intensified insulin group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target\<6 mmol\*l-1) via an continuous insulin infusion.
61944030|NCT02863276|NO_INTERVENTION|Control group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target \<10 mmol\*l-1) via subcutaneous insulin boluses
61944031|NCT06285461|EXPERIMENTAL|Non-palatable meal|Acute intake of a non-palatable meal, i.e., with low-hedonic reward, followed by PET/CT scans with three different radiotracers (\[15O\]H2O, \[15O\] oxygen, and \[11C\]-carfentanil.
61944032|NCT06285461|EXPERIMENTAL|Palatable|Acute intake of a palatable meal, i.e., with high-hedonic reward, followed by PET/CT scans with three different radiotracers (\[15O\]H2O, \[15O\] oxygen, and \[11C\]-carfentanil.
62139465|NCT02674841|ACTIVE_COMPARATOR|Control group|Receives no feedback on TUT but on pulling force during exercises.
62139466|NCT03398876|EXPERIMENTAL|Part 1; Treatment Sequence ABDC|Participants will receive Treatment A (one spray of oromucosal nicotine spray \[ONS\]) at Visit 1, then Treatment B (2 consecutive sprays of ONS at Visit 2, then Treatment D (1 cigarette \[10 puffs\]) at Visit 3, followed by Treatment C (nicotine gum) at Visit 4. The visits will be separated by a period of at least 7 calendar days.
62495737|NCT03458845||Group 2|This group consists of cirrhotic patients without any hernias
62696920|NCT00672035|PLACEBO_COMPARATOR|10|Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21
62139467|NCT03398876|EXPERIMENTAL|Part 1; Treatment Sequence BCAD|Participants will receive Treatment B at Visit 1, then Treatment C at Visit 2, then Treatment A at Visit 3 followed by Treatment D at Visit 4. The visits will be separated by a period of at least 7 calendar days.
62495738|NCT04758390|EXPERIMENTAL|IMARA intervention arm|Participants randomized to the IMARA arm will receive the IMARA intervention (i.e., the intervention group).
61944033|NCT05073978||Case group|Case group with certain pregnancy outcome, e.g., miscarriage, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
61944034|NCT05073978||Control group|Control group without certain pregnancy outcome,e.g., miscarriage, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
62139468|NCT03398876|EXPERIMENTAL|Part 1; Treatment Sequence CDBA|Participants will receive Treatment C at Visit 1, then Treatment D at Visit 2, then Treatment B at Visit 3 followed by Treatment A at Visit 4. The visits will be separated by a period of at least 7 calendar days. The visits will be separated by a period of at least 7 calendar days.
62495739|NCT04758390|EXPERIMENTAL|Health promotion control arm|Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
62495740|NCT01531023||ESBL producing E. coli bacteria|Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
62495741|NCT01531023||Non-ESBL E.coli urinary tract infection|E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
62495742|NCT03742063||Huvos group I|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade I is 0% to 49%.
62495743|NCT03742063||Huvos group II|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade II is 50% to 89%.
62495744|NCT03742063||Huvos group III|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade III is 90% to 99%.
62696921|NCT03471845|EXPERIMENTAL|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
62696922|NCT03624075|NO_INTERVENTION|control group|The control group had a protocol of a health education / self-gestation session lasting 60 minutes. This session should include topics such as definition of knee OA, guidance on knee anatomy and physiology, prayer over articulation, rehabilitation and practice of exercises, and as volunteer to receive an educational and self explanatory primer with all the content that is exposed during a lesson .
61944035|NCT04300231|ACTIVE_COMPARATOR|Thoracic epidural|1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.
62339196|NCT02860806|EXPERIMENTAL|Part 3: JNJ-63623872 300 mg|Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10. Duration of infusion and dose will be selected after Part 2 of this study is completed.
62339197|NCT06447324|EXPERIMENTAL|Fender Mate matrix group|Twenty primary molars will be restored with composite restoration using the Fender Mate matrix
62339198|NCT06447324|EXPERIMENTAL|Conventional T-band matrix group|Twenty primary molars will be restored with composite restoration using T-band matrix
62339199|NCT05574335|EXPERIMENTAL|Adults with T1D 0.08 mg/kg SQ dose|Cohort 1 Group1: 0.08 mg/kg SQ dose for a total of 12 weeks
62339200|NCT05574335|EXPERIMENTAL|Adults with T1D 0.12 mg/kg SQ dose|Cohort 1 Group 2: 0.12 mg/kg SQ dose for a total of 12 weeks
62339201|NCT05574335|EXPERIMENTAL|Adults with T1D 0.18 mg/kg SQ dose|Cohort 1 Group 3:0.18 mg/kg SQ dose for a total of 12 weeks
62339202|NCT05574335|EXPERIMENTAL|Adults with T1D 0.22 mg/kg SQ dose|Cohort 1 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks
62339203|NCT05574335|EXPERIMENTAL|Children with T1D 0.08 mg/kg SQ dose|Cohort 2 Group 1:0.08 mg/kg SQ dose for a total of 12 weeks
62339204|NCT05574335|EXPERIMENTAL|Children with T1D 0.12 mg/kg SQ dose|Cohort 2 Group 2:0.12 mg/kg SQ dose for a total of 12 weeks
62339205|NCT05574335|EXPERIMENTAL|Children with T1D 0.18 mg/kg SQ dose|Cohort 2 Group 3: 0.18 mg/kg SQ dose for a total of 12 weeks
62339206|NCT05574335|EXPERIMENTAL|Children with T1D 0.22 mg/kg SQ dose|Cohort 2 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks
62339207|NCT05109013||NT group - normotensive children|
62339208|NCT05109013||HT group - hypertensive children|
61944036|NCT04300231|ACTIVE_COMPARATOR|Rectus Sheath Block|2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected into 4 locations below the rectus abdominis muscle.
61944037|NCT04300231|ACTIVE_COMPARATOR|Surgeon Infiltration with Liposomal Bupivacaine (LB)|3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.
61944038|NCT04300231|ACTIVE_COMPARATOR|Surgeon Infiltration|4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.
61944039|NCT06438939|ACTIVE_COMPARATOR|White Light Oral Examination (WLOE)|Patients will undergo commone WLOE examination prior to do a required biopsy (see protocol for patients characteristics).
62339209|NCT00489840|EXPERIMENTAL|anecortave acetate|
62339210|NCT06108869|EXPERIMENTAL|1|6 Week ABT intervention as described.
62339211|NCT06108869|EXPERIMENTAL|2|6 Week ABT intervention as described.
62339212|NCT06108869|EXPERIMENTAL|3|6 Week ABT intervention as described.
62339213|NCT06108869|EXPERIMENTAL|4|6 Week ABT intervention as described.
62339214|NCT06108869|EXPERIMENTAL|5|6 Week ABT intervention as described.
62339215|NCT06108869|ACTIVE_COMPARATOR|6|Delayed intervention group
62339216|NCT06108869|ACTIVE_COMPARATOR|7|Delayed intervention group
62339217|NCT06108869|ACTIVE_COMPARATOR|8|Delayed intervention group
62339218|NCT06108869|ACTIVE_COMPARATOR|9|Delayed intervention group
62339219|NCT06108869|ACTIVE_COMPARATOR|10|Delayed intervention group
62339220|NCT06108869|EXPERIMENTAL|11|ABT intervention as described
62339221|NCT06108869|EXPERIMENTAL|12|ABT intervention as described
62339222|NCT06108869|EXPERIMENTAL|13|ABT intervention as described
62339223|NCT06108869|EXPERIMENTAL|14|ABT intervention as described
62339224|NCT06108869|EXPERIMENTAL|15|ABT intervention as described
62339225|NCT06108869|ACTIVE_COMPARATOR|16|Delayed Control group
62495745|NCT03742063||Huvos group IV|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade IV is 100% necrosis.
61944040|NCT06438939|EXPERIMENTAL|Narrow Band Imaging (NBI)|Patients will have their biopsy guided by NBI (see protocol for patients characteristics).
61944041|NCT03081975|ACTIVE_COMPARATOR|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
61944042|NCT03081975|ACTIVE_COMPARATOR|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
62339226|NCT06108869|ACTIVE_COMPARATOR|17|Delayed Control group
62339227|NCT06108869|ACTIVE_COMPARATOR|18|Delayed Control group
62339228|NCT06108869|ACTIVE_COMPARATOR|19|Delayed Control group
62339229|NCT06108869|ACTIVE_COMPARATOR|20|Delayed Control group
62339230|NCT01155297|SHAM_COMPARATOR|Control Group|At the control group, with 34 subjects, will be performed stretching and metabolic exercises. This group will make the assessments before and the reassessments after the end of the program.
62339231|NCT01155297|ACTIVE_COMPARATOR|Training group|At the training group, with 34 subjects, will be performed stretching, physical training and resistance. This group will make the assessments before and the reassessments after the end of the program.
62339232|NCT05105438|ACTIVE_COMPARATOR|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
62339233|NCT05105438|EXPERIMENTAL|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
62495746|NCT00778453|EXPERIMENTAL|Hospital-based mCIT|Hospital-based modified constraint-induced therapy(mCIT)
62139469|NCT03398876|EXPERIMENTAL|Part 1; Treatment Sequence DACB|Participants will receive Treatment D at Visit 1, then Treatment A at Visit 2, then Treatment C at Visit 3 followed by Treatment B at Visit 4. The visits will be separated by a period of at least 7 calendar days.
62139470|NCT03398876|EXPERIMENTAL|Part 2; Treatment Sequence EF|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment E (two consecutive sprays of ONS once every 30 minutes until 11.5 hours) at Visit 5, followed by Treatment F (two consecutive sprays of ONS once every 1 hour until 11 hours) at Visit 6. The visits will be separated by a period of at least 7 calendar days.
62339234|NCT04635072|EXPERIMENTAL|Stabilised Whole Rice Bran (SWRB)|"Patients with mild AD will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, one time per day.~Patients with moderate disease will be instructed to use SWRB as a cleanser as above. In addition, they will also use SWRB as an emollient after constituting it into a paste as in instructions, apply at night and leave it overnight."
62339235|NCT02607254|EXPERIMENTAL|Pregabalin Treatment phase|All patients will be initially treated with pregabalin in a single blind fashion
62339236|NCT02607254|EXPERIMENTAL|Withdrawal phase|After finishing the treatment phase, some patients will be randomized to the placebo or continue on pregabalin for the 4 weeks of withdrawal phase.
62339237|NCT00648193|EXPERIMENTAL|1|Paroxetine hydrochloride 40 mg tablet
61944043|NCT00289016|EXPERIMENTAL|Talimogene Laherparepvec|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque forming units (PFU)/mL injected into 1 or more tumors with maximum total volume of 4 mL (up to 2 mL per tumor). Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks for up to 15 weeks. After the initial 8 doses, if indications of biological activity were observed, treatment could continue for up to 16 additional doses.
61944044|NCT02838446|EXPERIMENTAL|Cognitive Therapy|Graded motor imagery program was applied in only intervention group for 8 weeks.
62339238|NCT00648193|ACTIVE_COMPARATOR|2|Paxil® 40 mg Table
62339239|NCT02012608|ACTIVE_COMPARATOR|Glutamine|Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day
62339240|NCT02012608|PLACEBO_COMPARATOR|Placebo|Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day
61944045|NCT02838446|ACTIVE_COMPARATOR|Control|Rehabilitation program applied in both groups for 8 weeks. Frequency of the treatment was 2 days in per week and its duration was approximately one hour in one session.
62339241|NCT02065310|NO_INTERVENTION|Diabetes, Non-diabetes|
62339242|NCT03925818|EXPERIMENTAL|B.I.D. TMPPI + Lactobacillus-10|pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
62339243|NCT03925818|ACTIVE_COMPARATOR|B.I.D. Bismuth|pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days
62495747|NCT00778453|EXPERIMENTAL|Hospital-based BIT|Hospital-based bilateral isokinematic training (BIT)
62495748|NCT00778453|EXPERIMENTAL|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
61944046|NCT03166059|EXPERIMENTAL|Single arm|CaveoVasc® Thrombolysis Protection System
61944047|NCT03330288||Participants with Stage I-III Knee osteoarthritis (KOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
61944048|NCT03330288||Participants with Stage I-III Hip osteoarthritis (HOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
62339244|NCT01948284|ACTIVE_COMPARATOR|maximal suction pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
62339245|NCT01948284|ACTIVE_COMPARATOR|half-maximal pressure|The pressure level of the suction unit will be set at the half-maximal (-35 cm Hg).
62339246|NCT05948371|EXPERIMENTAL|High Intensity interval Training|
62339247|NCT05948371|ACTIVE_COMPARATOR|Continuous Aerobic training|
62339248|NCT03927248|EXPERIMENTAL|Nivolumab and PAC-1|Patient will be accrued and started on dose 1 level of PAC-1 (500 mg). If no DLT is observed in first cycle of therapy (28 days), dose of PAC-1 will be escalated to 625 mg in second cycle of therapy for the same patient. If patient remains on study and has no dose limiting toxicities, then in third cycle, dose will be escalated to 750 mg and continue in following cycles, if no dose adjustment is needed because of toxicities. Nivolumab will be administered by IV infusion at a dose of 480 mg.
62339249|NCT00916370|EXPERIMENTAL|Core size registry (CSR)|Core size indicates the range of diameters of the stents used.
62339250|NCT00916370|EXPERIMENTAL|Long lesion registry (LLR)|Use of long lesion stents.
62495749|NCT00778453|EXPERIMENTAL|Home-based BAT|Home-based bilateral arm training(BAT)
62495750|NCT00778453|EXPERIMENTAL|Home-based TR|Home-based traditional rehabilitation (TR)
62339251|NCT06148896|EXPERIMENTAL|Group Exercise with acceptance and commitment therapy|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapist (GrExPACT)
62339252|NCT06148896|ACTIVE_COMPARATOR|Group Physiotherapy Exercise alone|Group Physiotherapy exercise alone (GrEx)
62339253|NCT02660333|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62339254|NCT02660333|ACTIVE_COMPARATOR|Prebiotic|Fructooligosaccharide
62495751|NCT00778453|EXPERIMENTAL|Home-based mCIT|Home-based modified constraint-induced therapy (mCIT)
62495752|NCT00658034|ACTIVE_COMPARATOR|1|Acupuncture
62495753|NCT00658034|SHAM_COMPARATOR|2|Placebo Acupuncture
62696923|NCT03624075|PLACEBO_COMPARATOR|Placebo group|The placebo group will simultaneously receive two techniques of applying tensionless KT. The first technique that will be applied is inverted 'Y' on the rectus femoris. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
62696924|NCT03624075|EXPERIMENTAL|intervention group|The intervention group will receive the same protocol as the placebo group, differing only in relation to the tension of the bandage. According to Kase et al (2003), the techniques recommend the relief of pain and edema and performance. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
62696925|NCT04278781|EXPERIMENTAL|Chondrosarcoma|Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma
62696926|NCT04925284|EXPERIMENTAL|XB002 Single-Agent Dose-Escalation Cohorts|Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
62696927|NCT04925284|EXPERIMENTAL|XB002 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer \[NSCLC\] (Cohort B), epithelial ovarian cancer (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F), pancreatic cancer (Cohort G), Esophageal SCC (Cohort H), metastatic castration-resistant prostate cancer (Cohort I), triple-negative breast cancer (Cohort J), hormone-receptor positive breast cancer (Cohort K), endometrial cancer (Cohort L) and tumor agnostic tissue factor-expressing solid tumors (Cohort M).
62696928|NCT04925284|EXPERIMENTAL|XB002 + Nivolumab Dose Escalation Cohorts|Subjects (Cohort AN) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
62696929|NCT04925284|EXPERIMENTAL|XB002 + Nivolumab Dose Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer \[NSCLC\] (Cohort BN), SCCHN (Cohort FN), Esophageal SCC (Cohort HN).
62696930|NCT05976633|EXPERIMENTAL|Consumption of 1 of 3 rice products|This arm will provide 1 of the 3 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
62696931|NCT05976633|EXPERIMENTAL|Consumption of 2 of 3 rice products|This arm will provide the consumption of the second randomly assigned rice product. There will be a minimum of three days separating each visit.
62696932|NCT05976633|EXPERIMENTAL|Consumption of 3 of 3 rice products|This arm will provide the third consumption of the randomly assigned rice product. There will be a minimum of three days separating each visit.
62696933|NCT05976633|ACTIVE_COMPARATOR|Consumption of the control rice product|This arm will provide the white rice control product.
62339255|NCT02660333|ACTIVE_COMPARATOR|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
62696934|NCT05976633|EXPERIMENTAL|Consumption of 1 of 3 rice products with different preparation method|This arm will provide the blends product via a different cooking method (microwave).
62696935|NCT03618407||Oral oseltamivir group|Patients with influenza virus positive and early oral oseltamivir capsules
62696936|NCT03618407||Oral Lotus Capsules group|Patients with positive influenza virus and early oral administration of lotus extract capsules
62696937|NCT03618407||other group|Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early
62339256|NCT06396780||Participants who meet the inclusion/exclusion criteria will be invited to complete the questionnaire|Children will be invited to complete the Medication Adherence Questionnaire, Medication Literacy Questionnaire, and Medication Beliefs Specific Questionnaire. Caregivers will be invited to complete the Helicobacter pylori Knowledge Questionnaire, Medication Beliefs Specific Questionnaire, and Medication Support Questionnaire.
62339257|NCT01927133||FIBROFRANCE Project|
62339258|NCT06081998|EXPERIMENTAL|Sleep deprivation|This subproject will be conducted in two sessions separated by three nights of sleep deprivation. Each session will last approximately 2 hours. At the beginning of the first visit and after the last visit, 9 ml of blood will be drawn, and plasma will be isolated. After plasma isolation, the CRP concentration will be analyzed. In each forearm of the participant, a 4x4 cm area will be selected as Area of Interest (AOI). In these selected areas, itch will be induced in both sessions using histamine and cowhage and several tests will be conducted.
62339259|NCT00213928|NO_INTERVENTION|Control|
62339260|NCT00213928|ACTIVE_COMPARATOR|Horse Chestnut Seed Extract|Horse chestnut seed extract (escins, aesins)
62495754|NCT01877122|EXPERIMENTAL|Proflex® Mesh|Device: Partially absorbable lightweight mesh Intervention: Mesh implantation
62495755|NCT01877122|ACTIVE_COMPARATOR|Marlex® Mesh|Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation
62696938|NCT05810480||Autoimmune Hepatitis|This group includes patients with a diagnosis of Autoimmune Hepatitis according to the simplified diagnostic criteria by Hennes et al. made by the local treating physician. The diagnosis of autoimmune hepatitis additionally requires steroid dependency \> six months for this study to discriminate Autoimmune Hepatitis from autoimmune like drug-induced liver injury (DILI) which are hard to discriminate at diagnosis and with the latter often being treating with a short course of corticosteroids less than six months. One serum sample will be stored for anonymized evaluation of serum autoantibodies
62696939|NCT05810480||non-autoimmune hepatitis liver disease|This group includes patients with a diagnosis of any non-viral liver disease that is not autoimmune hepatitis and whose diagnosis necessitated a diagnostic liver biopsy in the work-up of the liver disease for local care. One serum sample will be stored for anonymized evaluation of serum autoantibodies
62696940|NCT06468137|OTHER|Swedish I-ACE|Participants choosing to take part in the Swedish I-ACE as follow-up.
62696941|NCT06468137|OTHER|Clinical visit|Participants choosing a clinical visit as follow-up.
62696942|NCT06468137|OTHER|No follow-up|Participants choosing no follow-up.
62696943|NCT06625710|EXPERIMENTAL|Part A-1|GV1001 2.24 mg SAD or Placebo
62696944|NCT06625710|EXPERIMENTAL|Part A-2|GV1001 4.48 mg SAD or Placebo
62139471|NCT03398876|EXPERIMENTAL|Part 2; Treatment Sequence FE|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment F at Visit 5 followed by Treatment E at Visit 6. The visits will be separated by a period of at least 7 calendar days.
62696945|NCT06625710|EXPERIMENTAL|Part B-1|Part B-1: GV1001 0.56 mg MAD (6 treatments for 2 weeks)
62696946|NCT06625710|EXPERIMENTAL|Part B-2|GV1001 1.12 mg MAD or Placebo (6 treatments for 2 weeks )
62696947|NCT06625710|EXPERIMENTAL|Part B-3|GV1001 2.24 mg MAD or Placebo (6 treatments for 2 weeks)
62696948|NCT06625710|EXPERIMENTAL|Part B-4|GV1001 4.48 mg MAD or Placebo (6 treatments for 2 weeks)
62696949|NCT06625710|EXPERIMENTAL|Extra Cohort|GV1001 1.12 mg MAD or Placebo (6 treatments for 2 weeks ), Caucasian Only
62696950|NCT04077502|ACTIVE_COMPARATOR|stimulated group|The group stimulated by real coil of rTMS.
62139472|NCT02502526|EXPERIMENTAL|CVS with 45° Balanced Tip|Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
62339261|NCT04738825|NO_INTERVENTION|Treatment as Usual (TAU)|Participants randomized to TAU will receive a health handout on HIV risk reduction approaches, including PrEP and OUD-related care, and where to access such services. They will receive standard care as provided by the community-based organization and by their medical provider.
62339262|NCT04738825|EXPERIMENTAL|Contingency Management with stepped care to PrEP Adherence and Support Services (CoMPASS)|"Participants randomized to Compass will also receive a health handout on HIV risk reduction approaches. They will also receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12, will be stepped up to receive PrEP adherence and support services (n=5)."
62339263|NCT01346371|PLACEBO_COMPARATOR|Refresh Tears® eye drops|Must add drops twice a day every day during trial enrollment.
62339264|NCT01346371|EXPERIMENTAL|Bepreve® 1.5% solution|Must add drops twice a day every day while enrolled in trial.
62696951|NCT04077502|SHAM_COMPARATOR|controle group|The group stimulated by sham coil of rTMS.
62696952|NCT01649869|ACTIVE_COMPARATOR|Active|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive valganciclovir HCl 16.0 mg/kg orally twice a day for 6 weeks
62696953|NCT01649869|PLACEBO_COMPARATOR|Placebo|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive placebo orally twice a day for 6 weeks
62696954|NCT05650866|EXPERIMENTAL|Implanted group|The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday.
62696955|NCT05650866|NO_INTERVENTION|Control group|Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device.
62696956|NCT03193580|EXPERIMENTAL|Anodal Conventional tDCS|The intervention will be anodal conventional tDCS. Anodal tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0 milliamp. Anode positioned over the right primary motor cortex, and the cathode over the contralateral supraorbital area.
62696957|NCT03193580|EXPERIMENTAL|Anodal High Definition tDCS|The intervention will be anodal high definition-tDCS. Anodal HD-tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0milliamp. Anode entered over the right primary motor cortex, and four cathodes placed in a ring formation surrounding the anode.
62696958|NCT03193580|SHAM_COMPARATOR|Sham tDCS|Sham subjects will undergo exactly the same anodal conventional tDCS protocol as outlined above. This includes the initial stimulation sequence of ramp up of 30 seconds, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist after 120 seconds of stimulation to automatically ramp down to 0milliamp over 30 seconds.
62696959|NCT06602830||Patients undergoing laparoscopic surgery|Measurement of primary and secondary outcome parameters at different time points during the procedure.
62696960|NCT06317597|EXPERIMENTAL|Short time interval group:|Bowel preparation for colonoscopy was performed using oral sulfate solution as a laxative
62696961|NCT06317597|ACTIVE_COMPARATOR|Standard time interval group|Bowel preparation for colonoscopy was performed using oral sulfate solution as a laxative
62696962|NCT02116335|EXPERIMENTAL|Bosentan|Sub-Chronic (3 days) Bosentan 250mg/day.
62696963|NCT02116335|PLACEBO_COMPARATOR|Placebo|Stress response and endothelial function will be determined following a three day treatment of placebo
62696964|NCT03923335||high-risk group|patients with any of the four genes hypermethylated
62696965|NCT03923335||low-risk group|patients with none of the four genes hypermethylated
62696966|NCT02891356||Anorexia patient|Dual Energy X-ray Absorptiometry (DEXA)
62696967|NCT04199390|ACTIVE_COMPARATOR|Clinic-based Physical Therapy|
62696968|NCT04199390|ACTIVE_COMPARATOR|Home-based Physical Therapy|
62696969|NCT06496724|EXPERIMENTAL|Albumin paclitaxel/neutrophil drug|Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. Then the drug will be infused intravenously into patients. The number of neutriphil cells will be more than 1.0E10.
62696970|NCT00163293|PLACEBO_COMPARATOR|Placebo|
62696971|NCT00163293|ACTIVE_COMPARATOR|Ciclesonide 100 µg|Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
62696972|NCT00163293|ACTIVE_COMPARATOR|Ciclesonide 200 µg|Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
62696973|NCT06640205|ACTIVE_COMPARATOR|MTA Pulpotomy|using MTA as pulpotomy capping agent in mature permanent teeth
62696974|NCT06640205|EXPERIMENTAL|I-PRF pulpotomy|using I-PRF as pulpotomy capping agent in mature permanent teeth
61944049|NCT03515083|EXPERIMENTAL|Experimental|"In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget.~The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully."
62495756|NCT05100680|ACTIVE_COMPARATOR|Multicomp group|Food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
61944050|NCT03515083|NO_INTERVENTION|Control|"Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study.~During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication."
61944051|NCT02103231||Full Term Birth|History of full term birth (\>37 weeks gestation) including sub-group with diagnosis of hypertension
61944052|NCT02103231||Preterm Birth|History of preterm birth (\<37 weeks gestation) including subgroup with diagnosis of hypertension
61944053|NCT02645201|ACTIVE_COMPARATOR|Probiotic|Children in probiotic group will receive chewable tablets containing 4x108 CFU of Gastrus. Subjects will take 1 tablet twice a day for 21 days
61944054|NCT02645201|PLACEBO_COMPARATOR|Placebo|Children in placebo group will receive placebo tablets of similar appearance and taste as Gastrus tablets. Subjects will take 1 placebo tablet twice a day for 21 days
61944055|NCT04743466||Observational (biobank review)|Patients' records from institutional or national biobanks are reviewed.
61944056|NCT03102333|ACTIVE_COMPARATOR|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
61944057|NCT03102333|ACTIVE_COMPARATOR|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
61944058|NCT00365222|EXPERIMENTAL|1|
61944059|NCT05517551||normal flow anesthesia|A fresh gas flow of 3 L/min will be applied continuously
62339265|NCT02225444||OsteoAMP treatment group|The OsteoAMP treatment group contains patients randomized to receive their own bone (retrieved from the surgical site) augmented with the OsteoAMP growth factor to assist with posterolateral arthrodesis at 1 or 2 adjacent levels between L1-S1.
62696975|NCT06640205|EXPERIMENTAL|I-PRF combined with Nano MTA pulpotomy|using nano MTA mixed with I-prf as pulpotomy capping agent in mature permanent teeth
62696976|NCT06355297|EXPERIMENTAL|Education about PF|Education about PF. Participants will attend three 60-minutes educational online sessions.
62696977|NCT06355297|NO_INTERVENTION|Control|Despite the fact that all females will be invited to participate in the study, those who did not attend the educational sessions will be considered as control group. These participants will not receive any educational session or information about PF prior to be evaluated.
62696978|NCT05990491||Septic shock group|Patients 18-80 years of age who meet the definition of septic shock. Vasopressor requirement should be maintained for a period \>24 hours and should require ICU stay for a duration of \> 7 days. Patient should recover from shock and be planned for discharge from the ICU.
62696979|NCT05990491||Non-septic shock group|Patients 18-80 years of age who planned for discharge from the ICU.with stay for a duration of \>7 days. Also, they should not have received vasopressor for.a period of \>24 hours
62696980|NCT02631785|EXPERIMENTAL|Anxious group|Youth diagnosed with anxiety disorder will receive Cognitive Behavioral Therapy for reducing anxiety symptoms.
62339266|NCT02554253|ACTIVE_COMPARATOR|ketamine|Ketamine induction
62339267|NCT02554253|ACTIVE_COMPARATOR|Propofol|Propofol induction
62696981|NCT02631785|NO_INTERVENTION|Control group|Healthy youth will be recruited for comparison but their participant in the study will not include intervention.
62696982|NCT00553254|EXPERIMENTAL|1|
62696983|NCT06645275|EXPERIMENTAL|POCT group|
62696984|NCT06645275|NO_INTERVENTION|pyrosequencing group|
62696985|NCT05131256|EXPERIMENTAL|patients suffering from obesity with BED|
62696986|NCT05131256|ACTIVE_COMPARATOR|patients suffering from obesity without BED|
62696987|NCT05131256|ACTIVE_COMPARATOR|healthy participants|
62696988|NCT06631534|ACTIVE_COMPARATOR|Group GD|Anesthesia induction and maintenance with sevoflurane inhalational anesthesia in addition dexmedetomidine diluted in normal saline (NS) to a concentration of 4ug/ml (in a 50 ml syringe) bolus dose will be administered through the IV catheter at 1 ug/kg over 10 minutes, followed by an infusion rate of dexmedetomidine 0.5ug/kg/hr with use of a syringe pump.
62696989|NCT06631534|PLACEBO_COMPARATOR|Group GS|Anaesthesia induction and maintenance with sevoflurane inhalational anaesthesia in addition a 50 ml syringe admisinstered at the same initial rate and maintenance rate as would a vloume-matched dexmedetomidine syringe. Syringes will be prepared by an independent party.
62696990|NCT06616155|EXPERIMENTAL|Treatment (ruxolitinib, enzalutamide)|Patients receive ruxolitinib PO BID and enzalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT and bone scan throughout the study. Patients may also undergo a tissue biopsy on study.
62696991|NCT04198012|EXPERIMENTAL|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
62339268|NCT00751114|EXPERIMENTAL|Insulin Glargine|Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\<FPG≤100mg/dL (3.9mmol/L\<FPG≤5.5mmol/L).
62339269|NCT00751114|ACTIVE_COMPARATOR|Sitagliptin|Dose of 100 mg once a day administered with or without food.
62696992|NCT05671666|OTHER|Healthy controls|
62696993|NCT06277284|EXPERIMENTAL|MG-K10 humanized monoclonal antibody injection (prefilled syringe)|single injection
62696994|NCT06277284|ACTIVE_COMPARATOR|MG-K10 humanized monoclonal antibody injection|single injection
62696995|NCT04662450|EXPERIMENTAL|Affective pain stimuli group|affective/neutral word pairs
62696996|NCT04662450|EXPERIMENTAL|Sensory pain stimuli group|sensory/neutral word pairs
62696997|NCT04662450|PLACEBO_COMPARATOR|Control group|affective/neutral and sensory/neutral word pairs
62696998|NCT06637345||Retrospective cohort|Patients treated with RT with radical intent from 01 January 2014 to the date of study approval
62696999|NCT06637345||Prospective cohort|Patients eligible for radical intent radiotherapy treatment radical, from the date of study approval
62139473|NCT02502526|ACTIVE_COMPARATOR|CVS with 45° MFK Tip|Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
62339270|NCT05339243|ACTIVE_COMPARATOR|ES 1|Two capsules orally once daily after breakfast for 84 days
62697000|NCT00761137|EXPERIMENTAL|Tropicamide placebo|subject received (blinded) each of the 4 drug doses at different visits - 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
62697001|NCT00761137|EXPERIMENTAL|Tropicamide 0.3 mg|subject received (blinded) each of the 4 drug doses at different visits - 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide
62697002|NCT00761137|EXPERIMENTAL|Tropicamide 1 mg|subject received (blinded) each of the 4 drug doses at different visits - 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide
62139474|NCT02502526|ACTIVE_COMPARATOR|IVS with 45° MFK Tip|lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
62339271|NCT05339243|ACTIVE_COMPARATOR|HT ES1|Two capsules orally once daily after breakfast for 84 days
62339272|NCT05339243|PLACEBO_COMPARATOR|Placebo|Two capsules orally once daily after breakfast for 84 days
62339273|NCT01842607|EXPERIMENTAL|Mepolizumab Arm|Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
62339274|NCT05768841||endurance athletes|participants that have or are participating in endurance sports
62495757|NCT05100680|PLACEBO_COMPARATOR|Placebo group|Placebo - 2 capsules / day containing modified starch
62697003|NCT00761137|EXPERIMENTAL|Tropicamide 3 mg|subject received (blinded) each of the 4 drug doses at different visits - 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide
62139475|NCT04305197|EXPERIMENTAL|Lower Dose|
62139476|NCT04305197|EXPERIMENTAL|Medium Dose|
62139477|NCT04305197|EXPERIMENTAL|Higher Dose|
62139478|NCT04305197|PLACEBO_COMPARATOR|Placebo|
62697004|NCT03796104||Deficiency of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency
62697005|NCT03796104||Presence of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production
62697006|NCT03231267||"Carrierof Ec-BLSE/EPC or Kp-BLSE/EPC"|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
62697007|NCT03231267||Non-Carrier of Ec-BLSE/EPC orKp-BLSE/EPC|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
62697008|NCT04480866|OTHER|First-void urine collection|Women self-collect three first-void urine samples (random order) at home.
62697009|NCT04204915|ACTIVE_COMPARATOR|Group A: Aortic valve replacement|Participants randomised to AVR will be investigated and managed according to local protocols and standard practice. Participants will be placed on the waiting list with the aim that surgery will be performed within 3 months, dependent on local hospitals' waiting lists.
62697010|NCT04204915|NO_INTERVENTION|Group B: Expectant management|Participants randomised to expectant management will continue to have regular monitoring of their condition in line with the procedures and standard practices of their hospital.
62697011|NCT02831049|EXPERIMENTAL|1|alcohol retrieval / alcohol extinction
62697012|NCT02831049|ACTIVE_COMPARATOR|2|soft-drink retrieval / alcohol extinction
62697013|NCT02831049|ACTIVE_COMPARATOR|3|alcohol retrieval / soft-drink extinction
62495758|NCT01937689|EXPERIMENTAL|Pyrotinib|Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days.
62697014|NCT03826472|EXPERIMENTAL|Almond Butter|Participants will consume one ounce per day (\~32 g) of almond butter as an evening snack (i.e., after dinner and before sleep).
62697015|NCT03826472|NO_INTERVENTION|No-snack Control|Participants will consume nothing besides water after dinner/bed sleep.
62697016|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
62697017|NCT06119204|EXPERIMENTAL|Intervention (Oviva ODR-I programme)|The intervention arm will follow Oviva ODR-I programe: a 12-week TDR of approximately 850 calories per day through four TDR products daily, supported by the digital scales, CBG meters and link to the OVIVA app.
62697018|NCT06119204|ACTIVE_COMPARATOR|Control (NHS 12 weeks programme)|The control group will follow usual care, which will be the NHS 12-week digital weight-loss programme
62697019|NCT03662607|NO_INTERVENTION|Control|Standard pre-procedural education for cardiac catheterization.
62697020|NCT03662607|EXPERIMENTAL|Treatment|Standard pre-procedural education plus virtual reality experience for cardiac catheterization.
62697021|NCT04227379|EXPERIMENTAL|DD-TXT|Participants in this group were signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol consisted of the same daily educational content as the DSE arm augmented by the following: regular two-way check-in messages about diabetes self-management behaviors, an invitation to receive messages written by other Veterans living with diabetes on demand, and a menu of optional and customizable modules (e.g., medication reminders, blood sugar and blood pressure monitoring,: physical activity reminders, weight management, and goal setting) from which participants could select messaging that supported their diabetes self-management goals. Patients could customize the timing and frequency of their messages. DD-TXT participants also received a once monthly message asking whether the messages had been helpful.
62697022|NCT04227379|ACTIVE_COMPARATOR|DSE|"Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE was comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSE messages could not be customized. There was no interactive content for the DSE arm other than a once monthly message asking whether the messages had been helpful."
61944060|NCT05517551||low flow anesthesia|A fresh gas flow of 3 L/min will be applied for the first 20 minutes after intubation , and then it will be reduced to 1 L/min.
61944061|NCT05637879|ACTIVE_COMPARATOR|Active Drug|Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
61944062|NCT05637879|PLACEBO_COMPARATOR|Placebo|Placebo, 3 oral tablets once daily for 8 weeks.
61944063|NCT05978778|OTHER|controlled group|Nine children will be randomly allocated to control group who receive only pre-hand writing skills.
61944064|NCT05978778|EXPERIMENTAL|Experimental group|Nine children will be randomly allocated to experimental group who receive active video gaming along with pre-hand writing skills.
62495759|NCT02924649|EXPERIMENTAL|Early Intensive mobilisation|As early as possible the experimental group will receive mobilisation on a tilt table for up to 20 minutes 5 days a week for four weeks using an ERIGO tilt table. If orthostatic hypotension occur the patient is moved to supine until parameters are stable again. Hereafter the mobilisation will continue until the patient has completed 20 minutes of standing exercise.
62495760|NCT02924649|NO_INTERVENTION|Standard care group|The standard care group will receive daily mobilisation to the seated position.
62495761|NCT02627274|EXPERIMENTAL|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
62697023|NCT04779008|EXPERIMENTAL|Experimental Group 1|Routine treatment + interventions:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) before surgery, then normal surgery, and RIPC was performed on the second day and Once RIPC/day after CABG for one year.
62697024|NCT04779008|EXPERIMENTAL|Experimental Group 2|Routine treatment + interventions:Patients underwent a RIPC before surgery, and then normal medical procedures were performed with no additional intervention.
61944065|NCT04222231|EXPERIMENTAL|Blood-flow restriction resistance training|Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.
61944066|NCT04222231|EXPERIMENTAL|Classical resistance training|Resistance training with high loads (60-80% RM).
62139479|NCT05340452|EXPERIMENTAL|Test Group|Single oral dose of 20 ml of Test (Klaribact 125mg/5ml Suspension) will be given with the aid of graduated cup.
62139480|NCT05340452|ACTIVE_COMPARATOR|Reference Group|Single oral dose of 20 ml of Reference (Klaricid 125mg/5ml Suspension) will be given to volunteers with the aid of graduated cup.
62697025|NCT04779008|NO_INTERVENTION|Control group|routine treatment, no RIPC
62697026|NCT03682484|EXPERIMENTAL|MA-0211 Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
62697027|NCT03682484|PLACEBO_COMPARATOR|Placebo Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
62697028|NCT03682484|EXPERIMENTAL|MA-0211 Single Ascending Dose (food effect)|A single cohort of 8 participants will be started on a fixed single dose of MA-0211, within 30 minutes after the start and 5 minutes after the completion of an US Food and Drug Administration (FDA) high fat breakfast.
62697029|NCT03682484|EXPERIMENTAL|MA-0211 Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
62697030|NCT03682484|PLACEBO_COMPARATOR|Placebo Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
62697031|NCT01323374|EXPERIMENTAL|Droxidopa 200mg TID|
62697032|NCT01323374|EXPERIMENTAL|Droxidopa 400mg TID|
62697033|NCT01323374|EXPERIMENTAL|Droxidopa 600mg TID|
62697034|NCT01323374|ACTIVE_COMPARATOR|Carbidopa 25mg TID|
62697035|NCT01323374|ACTIVE_COMPARATOR|Carbidopa 50 mg TID|
62697036|NCT01323374|EXPERIMENTAL|Droxidopa/carbidopa 200mg/25mg TID|
62697037|NCT01323374|EXPERIMENTAL|Droxidopa/carbidopa 400mg/25mg TID|
62697038|NCT01323374|EXPERIMENTAL|Droxidopa/carbidopa 600mg/25mg TID|
62339275|NCT04240288|OTHER|Control Arm|Participants randomized to the control arm will be managed with the current standard of care including daily white blood cell count and vital sign documentation. The control group will also have daily procalcitonin levels drawn but the results will not be used to make decisions regarding antibiotic duration. Antibiotics will be given orally or intravenously at the discretion of the treating physician and will be given for a 10-day course, the current standard of care.
62697039|NCT01323374|EXPERIMENTAL|Droxidopa/carbidopa 200mg/50mg TID|
62697040|NCT01323374|EXPERIMENTAL|Droxidopa/carbidopa 400mg/50mg TID|
62697041|NCT01323374|EXPERIMENTAL|Droxidopa/carbidopa 600mg/50mg TID|
62697042|NCT01323374|PLACEBO_COMPARATOR|Placebo TID|
62697043|NCT03452202|EXPERIMENTAL|Active Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
62697044|NCT03452202|SHAM_COMPARATOR|Sham Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
62697045|NCT06094621||Pre-operative Visit Arm|Eligible participants for the interview and surveys will be those who have undergone a virtual visit by the head and neck surgery nurse practitioners before their scheduled surgical procedure.
62697046|NCT06094621||No Pre-operative Visit Arm|Patients who also underwent surgical resection for head and neck cancer with free flap reconstruction at the University of Michigan through the Department of Otolaryngology but did NOT receive a pre-operative virtual visit. This cohort is a retrospective chart review study
62697047|NCT04950439|OTHER|Myocardial CT|The investigator will collect the usual clinical history and data. Risk factors and cardiovascular events are identified. A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
62697048|NCT02290912|EXPERIMENTAL|Treatment|Health education program; informational website, experiential classes in various help domains, custom smart phone application, and wearable technology
62697049|NCT02290912|NO_INTERVENTION|Control|No intervention
62697050|NCT05022316|NO_INTERVENTION|Control Arm|Control clinics will not receive an intervention.
62697051|NCT05022316|EXPERIMENTAL|Intervention Arm|Intervention clinics will have the CDS tools turned on in their EHR.
62697052|NCT04623593|ACTIVE_COMPARATOR|ACDF|Anterior cervical discectomy and fusion.
62697053|NCT04623593|EXPERIMENTAL|ACDA|Anterior cervical discectomy with arthroplasty.
62697054|NCT00951639|EXPERIMENTAL|5g Cassia cinnamon|Experimental treatment group
62697055|NCT00951639|ACTIVE_COMPARATOR|50 minutes endurnace exercise|Endurance exercise treatment known to influence blood glucose
62697056|NCT00951639|PLACEBO_COMPARATOR|5g Cellulose|Placebo equivalent in weight and appearance to experimental treatment
62697057|NCT03982316|EXPERIMENTAL|Telehealth Behavioral Migraine Management|Participants will receive weekly online education sessions in the following categories: Relaxation, Early Warning Signs, Triggers, Medication Adherence, Reducing Migraine Impact, Stress Management, Biofeedback, and Relapse Prevention. Participants will receive four monthly 50-minute telehealth sessions with a doctoral psychology student in a clinical health psychology program covering these topics, and three check-ins to enhance adherence to behavior change strategies. Participants will complete a daily headache diary throughout the course of treatment.
62697058|NCT03985527|EXPERIMENTAL|Transvenous nerve stimulation|
62697059|NCT05580042|EXPERIMENTAL|Patients with Granuloma Annulare|4-week treatment and 2-week follow-up period (without treatment)
62697060|NCT03462602|EXPERIMENTAL|NGT group|NGT group
62697061|NCT03462602|EXPERIMENTAL|non-NGT group|non-NGT group
62697062|NCT04379830|EXPERIMENTAL|Very Low Energy Diet|VLED in its entirety is composed of the following for 3-weeks preoperatively: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
62697063|NCT05349604|EXPERIMENTAL|Garlic extracts|Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)
62697064|NCT05349604|PLACEBO_COMPARATOR|placebo|As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.
62697065|NCT03508674|EXPERIMENTAL|Intervention|Levita Magnetic Surgical System
62697066|NCT04100018|EXPERIMENTAL|Arm A: Nivolumab + docetaxel + prednisone|
62697067|NCT04100018|PLACEBO_COMPARATOR|Arm B: Placebo + docetaxel + prednisone|
61944067|NCT01967342|EXPERIMENTAL|Pain Ed|Pain Education: A psychosocial treatment group focusing on providing core pain education to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
61944068|NCT01967342|EXPERIMENTAL|CBT for Pain|Cognitive-Behavioral Therapy for Pain: A psychosocial treatment group focusing on providing core pain education and cognitive-behavior skills to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
62139481|NCT03195803|EXPERIMENTAL|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
62139482|NCT03195803|ACTIVE_COMPARATOR|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
62139483|NCT02433587|EXPERIMENTAL|Short Term|The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
62495762|NCT02627274|EXPERIMENTAL|Part B: RO6874281 in Combination with Trastuzumab|Dose Escalation: RO6874281 will be administered as an IV infusion. RO6874281 will be administered QW for the first 4 administrations, then Q2W. The standard dose for trastuzumab will be a loading dose of 6 milligrams per kilogram (mg/kg) followed by a maintenance dose of 4 mg/kg from Cycle 2 in a Q2W regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.
62697068|NCT04789941|EXPERIMENTAL|Single arm of patients with locally advanced cancer cervix|"Single arm study to assess the efficacy and safety of use of neoadjuvant cisplatin and irinotecan in treatment of patients with locally advanced cancer cervix.~A combined regimen of intravenous infusion of cisplatin 80mg/m2 on day 1 with irinotecan 60mg/m2 on day 1 and day 8 of every 21- day cycle for 3 cycles.~Then, MRI pelvis will be used for assessment of disease response. According to RECIST criteria, patients who will develop at least stable disease, will be sent for radical hysterectomy. Afterwards, 6 weeks after the surgery, another 3 cycles of the same regimen will be given to the participants as adjuvant treatment."
62139484|NCT02433587|EXPERIMENTAL|Long Term|The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
62139485|NCT01903109|ACTIVE_COMPARATOR|Cevimeline first, the Evoxac|Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
62139486|NCT01903109|ACTIVE_COMPARATOR|First Evoxac, then cevimeline|Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
62139487|NCT03022968|EXPERIMENTAL|Alzheimer disease|\[18F\]T807 PET
62139488|NCT03022968|EXPERIMENTAL|Benson disease|\[18F\]T807 PET
62697069|NCT06624995|NO_INTERVENTION|traditional nurse-led education|
62139489|NCT03022968|EXPERIMENTAL|Healthy volunteer|\[18F\]T807 PET
62697070|NCT06624995|EXPERIMENTAL|chatbot education|
62139490|NCT06260670|EXPERIMENTAL|EGF Mapping|"Subjects will be treated with catheter ablation of atrial fibrillation as is clinically indicated according to standard hospital ablation procedures (pulmonary vein isolation in de novo, pulmonary vein isolation touch-up in redo).~In addition, subjects will receive electrographic flow mapping (EGF) and concomitant high density mapping to collect electrogram patterns and morphology using both mapping methods."
62139491|NCT02403375|EXPERIMENTAL|Continuous Subcutaneous Insulin Infusion (CSII)|Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
62697071|NCT01283984|EXPERIMENTAL|1|AZD2115
62697072|NCT01283984|PLACEBO_COMPARATOR|2|Placebo to AZD2115
62697073|NCT04850456||trial group|Human Gamma Globulin
62697074|NCT04850456||control group|conventional treatment
62697075|NCT05929313|EXPERIMENTAL|OrbusNeich Scoreflex TRIO|OrbusNeich Scoreflex TRIO Scoring PTCA catheters
62697076|NCT05929313|ACTIVE_COMPARATOR|OrbusNeich Scoreflex NC|OrbusNeich Scoreflex NC Scoring PTCA catheters
62697077|NCT02825667|EXPERIMENTAL|Experimental group|"Patients included in this group will receive treatment over a period of three weeks, receiving 3 physiotherapy sessions lasting approximately 30 minutes each.~The treatment program includes 8 maneuvers that must be administered bilaterally: maneuver longitudinal sliding on the fascial surface plant, maneuver induction of the plantar fascia, maneuver longitudinal surface sliding on the anterolateral compartment of the leg, induction maneuver ankle anterior compartment, maneuver pressure and sliding on the posterior region of the leg, technical release of the popliteal fascia, maneuver induction sural triceps, and lower extremity telescopic technique."
62697078|NCT02825667|NO_INTERVENTION|Control group|Patients included in this group will not receive any physiotherapy treatment. However, will be evaluated under the same conditions that patients in the experimental group (pretreatment evaluation, post-treatment and follow-up).
62139492|NCT00442104|EXPERIMENTAL|ganaxolone|
62139493|NCT00680771||1|Primary Insomnia
62139494|NCT00680771||2|Good Sleepers
62139495|NCT04373694|ACTIVE_COMPARATOR|Standard hysteroscopy|morcellation hysteroscopy with intravenous sedation and paracervical bloc
62139496|NCT04373694|EXPERIMENTAL|Vaginoscopy|morcellation hysteroscopy with only intravenous sedation
62139497|NCT03975400|NO_INTERVENTION|Pre-Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States prior to campaign initiation.
62139498|NCT03975400|ACTIVE_COMPARATOR|Active Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States during the active campaign initiation.
62697079|NCT03750019|EXPERIMENTAL|Satisfying rehearsal|Participants completed the satisfying rehearsal task where they rehearsed the satisfying aspects of the lunchtime meal.
62697080|NCT03750019|EXPERIMENTAL|Dissatisfying rehearsal|Participants completed the dissatisfying rehearsal task where they rehearsed the dissatisfying aspects of the lunchtime meal.
62697081|NCT03750019|ACTIVE_COMPARATOR|Neutral rehearsal|Participants completed the neutral rehearsal task where they rehearsed their journey to campus that day.
62697082|NCT02602145||Peripheral artery disease patients|Patients with peripheral artery disease who were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have a stent in their femoropopliteal artery) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for 6-12 months. During the follow-up, a post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
62697083|NCT04318938|ACTIVE_COMPARATOR|Standard Arm with any available ALK TKI|"1. st line: Any approved 2nd-generation TKI according to investigator's choice~2. nd line: Any available ALK TKI according to investigator's choice (patients from the standard Arm A can be offered brigatinib in the 2nd line)"
62697084|NCT04318938|EXPERIMENTAL|Experimental Arm with Brigatinib|"1. st line: 90 mg brigatinib once daily p.o. for the first 7 days (lead-in) followed by 180 mg brigatinib once daily p.o. afterwards, starting with day 8~2. nd line: Any available ALK TKI according to investigator's choice"
62697085|NCT02903147|EXPERIMENTAL|Functional Meta-Cognitive Intervention|The intervention is aimed to improve human factors of professional bus drivers
62697086|NCT02903147|ACTIVE_COMPARATOR|Control group|The control group had the employer's training - The company holds routine covert inspections, summons to conversations with the security offices and records in the drivers' personal files.
62697087|NCT02592863|EXPERIMENTAL|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
62697088|NCT02592863|PLACEBO_COMPARATOR|Placebo|Patients will take placebo 3 times per day for 12 weeks
62697089|NCT06377319||Patients at risk of developing heart failure|Individuals at risk of developing HF ≥45 years of age sub-divided into two categories i.e., (i) patients with current or prior symptoms or signs of HF, but without structural, biomarker, or genetic markers of heart disease but have evidence of one of the following: hypertension, cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, known exposure to cardiotoxins and family history of cardiomyopathy and (ii) Patients with current or prior symptoms or signs of HF and have evidence of one of the following - structural heart disease (e.g. Left ventricular (LV) hypertrophy, chamber enlargement, wall motion abnormality, valvular disease), abnormal cardiac function (e.g., reduced LV or right ventricular systolic function, evidence of increased filling pressures or abnormal diastolic function), elevated natriuretic peptide or elevated cardiac troponin on exposure to a cardiotoxin. Willing to visit the clinical research facility and able to provide written informed consent.
62697090|NCT06377319||Patients diagnosed with heart failure|Patients with confirmed diagnosis of HF (heart failure reduced ejection fraction; heart failure mildly reduced ejection fraction; heart failure improved ejection fraction; and heart failure preserved ejection fraction) over the previous 24 months or hospitalisation due to HF ≥45 years of age; willingness to visit the clinical research facility and able to provide written informed consent.
62139499|NCT04437043|OTHER|Laparoscopic ventral hernia repair with closure of the defect|In laparoscopic intraperitoneal onlay mesh or IPOM repair, the mesh is inserted intra-abdominally and fixed to the peritoneum / abdominal wall. The general steps include safe entry into the peritoneum, insufflation and placement of the trocars to gain access and visibility (via laparoscope) of the defect. Careful adhesiolysis is performed, which is the removal of scar tissue connecting tissues and organs. The content of the hernia, which may include intestine and fatty tissue, is returned into the abdominal cavity. After closure of the hernia defect, a wide intraperitoneal mesh is fixed over the defect. Desufflation releases the gas from the abdomen. The trocars will be removed and the incisions are closed.
62697091|NCT05179577|ACTIVE_COMPARATOR|Arbaclofen Extended-Release|Extended-release oral tablet, twice daily dosing (80 mg/day)
62339276|NCT04240288|EXPERIMENTAL|Treatment Arm|These participants will be managed with procalcitonin-guided antibiotic therapy. An index procalcitonin will be drawn within 24 hours of admission followed by daily procalcitonin levels. Per standard of care, patients will have daily white blood cell counts drawn and regular vital sign documentation. Antibiotics will be given orally or intravenously at the discretion of the treating physician. Antibiotics in this arm will be stopped once the procalcitonin value drops to ≤80% of its index value or to \<0.5 ng/ml. Extension of antibiotics for more than 24 hours past this time will be documented.
62697092|NCT05179577|PLACEBO_COMPARATOR|Placebo|Extended-release oral tablet, twice daily dosing
62697093|NCT01542203||Breast Cancer, Various BMIs|18 female breast cancer patients who are normal weight (body mass index \[BMI\] \< 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI \> 35 kg/m2).
62697094|NCT05787249|NO_INTERVENTION|Usual care (no nudge)|Usual standard of care, no nudging.
62697095|NCT05787249|EXPERIMENTAL|Provider nudge only|Nudge sent to provider through EHR.
62697096|NCT05787249|EXPERIMENTAL|Patient nudge only|Nudge sent to the patient through text messaging.
62697097|NCT05787249|EXPERIMENTAL|Patient and provider nudge|Nudge sent to both provider through EHR, and to patient through text messaging.
62697098|NCT01202084|EXPERIMENTAL|Formoterol/Fluticasone Eurofarma|formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks
62697099|NCT01202084|ACTIVE_COMPARATOR|Foraseq®|formoterol + budedonide (12/400 mcg) twice a day per 12 weeks
62697100|NCT01202084|ACTIVE_COMPARATOR|Fluticasone|fluticasone (500 mcg) twice a day per 12 weeks
62697101|NCT00939185||Azithromycin group|
62495763|NCT02627274|EXPERIMENTAL|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW for the first 4 administrations, then Q2W. Cetuximab will be administered Q2W at 500 milligrams per square meter (mg/m\^2). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.~Extension Phase: The MTD for RO6874281 was determined to be 10mg and therefore patients in the extension will be treated with 10mg RO6874281. Cetuximab and R06874281 will be administered weekly during induction phase (cycle 1 and cycle 2). Both IMPs will be administered Q2W starting in cycle 3."
61944069|NCT01967342|ACTIVE_COMPARATOR|Usual Care|Usual Care (Medical Treatment-as-Usual: A control/comparison condition in which patients receive on-going standard care at the federally qualified health center partnering in this research. Facets of care may include medication, surgery, chiropractic, and physical therapy, among others, which are available to all patients in all arms.
61944070|NCT06680518|ACTIVE_COMPARATOR|Arm with tourniquet|The surgeon will use the tourniquet as usual.
62495764|NCT02418754|EXPERIMENTAL|REGN2176-3 (1 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
62495765|NCT02418754|EXPERIMENTAL|REGN2176-3 (3 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
62495766|NCT02418754|EXPERIMENTAL|Intravitreal Aflibercept Injection (IAI) 2 mg|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
62495767|NCT02418754|EXPERIMENTAL|REGN2176-3 (3 mg: 2 mg) to IAI 2 mg|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
62697102|NCT06527274|EXPERIMENTAL|Myopic defocus soft lens design (MDSL)|This arm involves the wear of a daily disposable soft contact lens (nesofilcon A) designed with a myopic defocus zone. This is a 14.2mm total diameter lens with a 4.2mm central zone for distance vision correction. This is followed by an abrupt transition zone of 1.2mm with no optical power. Then a higher convex power zone covers the surface to the edge of the optical zone (8mm). The rest of the lens (up to 14.2 mmOAD) supports the lens on the eye surface and has no power nor refractive effect. The power of the add area is calibrated to the central power to achieve a net add power of +5D. For example: -1.00D central power is surrounded by a +6D convex area; -2D is surrounded by a +7D area, and so on.)
62697103|NCT06527274|ACTIVE_COMPARATOR|Single vision soft lens design (SVSL)|This arm involves the wear of a daily disposable soft contact lens (nesofilcon A) designed as a regular optical device to compensate for refractive error. In the case of this study, this lens will be made available from -1.00D to -4.00D. This lens is already in regular use in the US (K113703) and Canadian markets. Its design includes a central optical zone of 8mm that is powered to correct distance vision. The rest of the lens is supported on the ocular surface and has no power.
62339277|NCT04161274|ACTIVE_COMPARATOR|Traditional method: Electrosurgery|"Local anaesthesia and excision with a scalpel connected to the electric current, according to the voltage. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
62339278|NCT04161274|ACTIVE_COMPARATOR|Traditional method: Cryotherapy|"Application of liquid nitrogen to cause freezing. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
62339279|NCT04161274|ACTIVE_COMPARATOR|Traditional method: Silver nitrate|"Excision is made with the scissors and a rod is applied containing silver nitrate with caustic power on the wound.~Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
62339280|NCT04161274|EXPERIMENTAL|Moist healing environment|"Excision is made with the scissors, afterwards pressure, clorhexidine and a hydrocolloid dressing when the skin is dry.~Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
62339281|NCT00523614||1: Cases|
61944071|NCT06680518|EXPERIMENTAL|Arm without tourniquet|The surgeon will operate without the aid of a tourniquet
61944072|NCT00961649|EXPERIMENTAL|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
61944073|NCT00961649|ACTIVE_COMPARATOR|Brinz|Brinzolamide ophthalmic suspension, 1% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
61944074|NCT00961649|ACTIVE_COMPARATOR|Brim|Brimonidine tartrate ophthalmic solution, 0.2% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
62339282|NCT00523614||2: Controls|
62339283|NCT04569331|NO_INTERVENTION|Control group|"Patients undergoing anterior rectal resection with protective ileostomy will follow routine clinical practice.~During hospital admission for ileostomy closure surgery, the stoma therapist reinforces the information on the possibility of anterior resection syndrome (ARS) and hygienic-dietary measures. At the level of the ARS, the patient is informed of the possibility of increased frequency of bowel movements, evacuation dysfunction, such as urgency to defecate or feeling of incomplete emptying. At the level of diet, an astringent diet is recommended during the first week after ileostomy closure to avoid liquid stools. It is also recommended at the level of perineal hygiene to use a cleanser with a pH similar to that of the skin, applying the least possible force on the skin, dry gently after each bowel movement and apply a skin protection product to avoid dermatitis associated with incontinence."
62339284|NCT04569331|EXPERIMENTAL|Stimulation of efferent loop and rehabilitation pelvic floor|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened every 48-hours the first two weeks and once daily the thrid week.~Rehabilitation of pelvic floor: 3 months after the ileostomy closure surgery, patient will be referred to the pelvic floor unit for pelvic floor rehabilitation."
62339285|NCT02694094||Adults on Chronic ketogenic diets|Adults who have been on Modified Atkins or ketogenic diets for over 1 year
62339286|NCT02694094||Adults naive to ketogenic diets|Adults who have never been on Modified Atkins or ketogenic diets
62339287|NCT02548572|EXPERIMENTAL|Treatment group|Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks
62339288|NCT02548572|PLACEBO_COMPARATOR|Sham group|Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks
62339289|NCT06460077||Patients with Multiple Sclerosis|Patients who have previously participated in PET-imaging studies and from whom slowly expanding lesions as well as TSPO-rim-positive lesions and iron rims at the edge of lesions are found
62339290|NCT04585217|ACTIVE_COMPARATOR|Plain gut suture on right eyelid|Plain gut suture closure of blepharoplasty incision
62339291|NCT04585217|ACTIVE_COMPARATOR|Polypropylene suture on right eyelid|Polypropylene suture closure of blepharoplasty incision
62495768|NCT02418754|EXPERIMENTAL|IAI 2 mg to REGN2176-3 (3 mg:2 mg)|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
62495769|NCT03428542|NO_INTERVENTION|Control arm|Instructed not to practice any yoga or mindfulness during the five-week study period.
62697104|NCT02923167|EXPERIMENTAL|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
62697105|NCT05697588||MCI progression|MCI-P (Compared with the baseline, MMSE score declined \> 4 points per year)
62697106|NCT05697588||MCI stabilization|MCI-S (Compared with the baseline, MMSE score decreased \< 4 points per year）
62697107|NCT00830531|EXPERIMENTAL|1|Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
62697108|NCT00830531|PLACEBO_COMPARATOR|2|Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
62697109|NCT06468553|EXPERIMENTAL|Prediabetes Care Program|Intervention composed of an interdisciplinary care team, patient-centered care approach for behavior change for the adoption of healthy eating and physical activity
62697110|NCT03333187|EXPERIMENTAL|Arm A|Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
62697111|NCT03333187|ACTIVE_COMPARATOR|Arm B|Treatment with Ruxolitinib continuous therapy
62697112|NCT05006755|EXPERIMENTAL|control group|the group of primary molar teeth that will be treated in furcal perforation with Mineral Trioxide Aggregate
61944075|NCT00961649|ACTIVE_COMPARATOR|Brinz+Brim|Brinzolamide ophthalmic suspension, 1% and brimonidine tartrate ophthalmic solution, 0.2%: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
61944076|NCT03866486||IVUS-guidance group|The patients who underwent drug-eluting stents implantation with IVUS guidance.
61944077|NCT03866486||Angiography-guidance group|The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS.
62139500|NCT04437043|OTHER|Open ventral hernia repair with closure of the defect|An open retromuscular ventral hernia repair involves an incision through the abdominal wall. Adhesiolysis is performed and the content of the hernia is returned into the abdominal cavity. The posterior rectus sheath is separated from the rectus muscle and closed, which closes the abdominal cavity. The mesh is then placed behind the muscle and anterior to the re-approximated posterior rectus sheath. Preperitoneal mesh extension is allowed via transversus abdominis release (TAR). The anterior rectus sheath is closed over the mesh, which closes the hernia.
62339292|NCT02779452||GDM newborns|Newborns from gestational diabetes mellitus pregnancy
61944078|NCT05736471||Test Group|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
61944079|NCT03820271|OTHER|SuperMELD|
62339293|NCT02779452||No GDM newborns|Newborn from a normal pregnancy
62339294|NCT01928043|EXPERIMENTAL|adjunctive curcumin|Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.
61944080|NCT04123652|OTHER|Lidocaine and ketamine infusion|
62339295|NCT00724724|EXPERIMENTAL|1|Butylphthalide Soft Capsules + Aspirin
62339296|NCT00724724|ACTIVE_COMPARATOR|2|Aspirin
62339297|NCT03731364|ACTIVE_COMPARATOR|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (5 mg), was prepared at 0.05 mg/mL CA-008 (vocacapsaicin)
62339298|NCT03731364|PLACEBO_COMPARATOR|Placebo - Cohort 1|"Placebo for Cohort 1~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
62339299|NCT03731364|ACTIVE_COMPARATOR|CA-008 10 mg (0.1 mg/mL) Cohort 2|Cohort 2 (10 mg), was prepared at 0.1 mg/mL CA-008 (vocacapsaicin)
62339300|NCT03731364|ACTIVE_COMPARATOR|CA-008 15 mg (0.15 mg/mL) Cohort 3|Cohort 3 (15 mg), was prepared at 0.15 mg/mL CA-008 (vocacapsaicin)
62495770|NCT03428542|ACTIVE_COMPARATOR|Yin yoga intervention arm|"The Yin yoga intervention arm will receive Yin yoga, a calm-paced practice that uses seated and lying down positions.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
61944081|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
61944082|NCT03546062||T2DM patients treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant. 41 patients recluted from January 2015
61944083|NCT03546062||T2DM Metformin treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant in metformin therapy. 35 patients recluted from January 2015
61944084|NCT03546062||Non-diabetic patients treated by HTx|Authors will include a population of non-diabetic patients with advanced heart failure treated by heart transplant. 82 patients recluted from January 2015
61944085|NCT05458934||Lung-/Airway diseases|Patients with lung-/airway diseases
62697113|NCT05006755|EXPERIMENTAL|experimental group|the group of primary molar teeth that will be treated in furcal perforation with Biodentine
61944086|NCT05458934||Controls|Participants without lung-/airway disease
61944087|NCT02863744|EXPERIMENTAL|CAF+SCTG|
61944088|NCT01842100|ACTIVE_COMPARATOR|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
61944089|NCT01842100|ACTIVE_COMPARATOR|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
61944090|NCT04351854||Patients with SARS-CoV-2-infection|Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED
61944091|NCT04351854||Control group|Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.
61944092|NCT00621959|PLACEBO_COMPARATOR|Placebo|Matched placebo tablets once daily
61944093|NCT00621959|EXPERIMENTAL|LCTZ|5 mg levocetirizine dihydrochloride tablet
62139501|NCT04437043|OTHER|Robotic ventral hernia repair with closure of the defect|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar closure of the hernia defect and similar retromuscular mesh placement as for the open approach. Preperitoneal mesh extension is allowed via TAR. The da Vinci System is a robotic-assisted surgical device that allows the surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of the abdominal cavity. Rather than one long incision with open repair, four to six small incisions are made along the outer part of the abdomen between the rib cage and the hip.
62339301|NCT03731364|PLACEBO_COMPARATOR|Placebo - Cohorts 2 and 3|"Placebo - Cohorts 2 and 3~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
62339302|NCT00592852|EXPERIMENTAL|Fluoxetine|
62339303|NCT06187116|EXPERIMENTAL|Physiotherapist led orthopaedic triage|Patients who are randomised to PT led triage will be scheduled for a consultation with a physiotherapist (PT) at a rehabilitation clinic in primary care in the Region Västra Götaland.
62339304|NCT06187116|ACTIVE_COMPARATOR|Usual care|Patients who are randomised to usual care will be sceduled according to standard procedure for an orthopaedic surgeon (OS) consultation at the orthopaedic department of a hospital in the Region Västra Götaland.
62495771|NCT03428542|ACTIVE_COMPARATOR|YOMI program intervention arm|"The YOMI intervention arm will receive stress education + yoga, and bring together education about stress, mindfulness and yoga practice. It will involve weekly group meetings, homework, and yoga postures. Stress education and mindfulness will make up one portion of the intervention. This will take place in a group lecture format and shall be conducted by a mental health professional(s). Yoga practice in a group format will make up the second portion of the intervention.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
62339305|NCT00148733|EXPERIMENTAL|Zinc|Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water
62697114|NCT00835367|EXPERIMENTAL|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
62697115|NCT00835367|ACTIVE_COMPARATOR|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period
61944094|NCT01284101|ACTIVE_COMPARATOR|Forceps delivery of donor graft|Using the forceps to insert the donor graft.
61944095|NCT01284101|EXPERIMENTAL|Tan Endoglide for insertion of the donor graft|Use of the Tan Endoglide for insertion of the donor graft.
62139502|NCT01943669|EXPERIMENTAL|ReWalk™ device|Self-controlled group; single cohort.
62139503|NCT05717127|EXPERIMENTAL|Intermittent fasting (time restricted feeding)|Intermittent fasting (IF) study arm consisting of time restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
62339306|NCT00148733|PLACEBO_COMPARATOR|Placebo|Placebo
62339307|NCT01902082|EXPERIMENTAL|Mesenchymal stem cell arm|Patients received one dose of 1x 10\^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.
62339308|NCT01902082|PLACEBO_COMPARATOR|Placebo|Patients received one dose of normal saline.
62339309|NCT02008838|ACTIVE_COMPARATOR|Synbiotic|Each synbiotic capsule (Protexin, UK) contained 2 × 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS \[Fructooligosaccharide\]), and probiotics culture (Magnesium stearate \[source: mineral and vegetable\], and vegetable capsule \[hydroxypropyl methyl cellulose\])
61944096|NCT02833350|EXPERIMENTAL|Cohort 1: GDC-0853 High Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
61944097|NCT02833350|EXPERIMENTAL|Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
61944098|NCT02833350|EXPERIMENTAL|Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
61944099|NCT02833350|ACTIVE_COMPARATOR|Cohort 1: GDC-0853 Placebo + Adalimumab|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
61944100|NCT02833350|PLACEBO_COMPARATOR|Cohort 1: GDC-0853 Placebo + Adalimumab Placebo|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
62697116|NCT02671292|EXPERIMENTAL|Interpersonal Psychotherapy (IPT-WG)|IPT-WG targets the difficult social functioning and stressful events that are associated with loss of control eating and that are highly relevant to the adolescent children of military personnel.
62697117|NCT02671292|ACTIVE_COMPARATOR|Health Education (HE)|HE improves knowledge on various health topics including, alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
62139504|NCT05717127|ACTIVE_COMPARATOR|Standard lifestyle|Standard lifestyle recommendation as per the Diabetes Canada guidelines, where participants are encouraged to maintain regularity in timing and spacing of means with no specific recommendations regarding the hours of fasting
62139505|NCT04886674||Remuverol|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for \< 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
62139506|NCT06699199|ACTIVE_COMPARATOR|Arresting Treatment 1|Management of dental caries in children between the ages of 4 and 10 by arresting the lesion using standard Treatment for caries arrest, which is silver diamine fluoride %38
62339310|NCT02008838|PLACEBO_COMPARATOR|Placebo|250 mg Maltodexterin
62339311|NCT04021394||Non-metastatic, high-risk hormone sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
62339312|NCT04021394||Low-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
62339313|NCT04021394||High-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
62697118|NCT04951193|EXPERIMENTAL|Goal2QuitVaping|Participants in the Goal2QuitVaping group will be asked to download the Goal2QuitVaping app to their smartphone. Goal2QuitVaping focuses on mood management as well as on quitting vaping nicotine. Participants will be asked to use Goal2QuitVaping regularly, at least once per day, for the study duration. Participants will also be asked to complete questionnaires weekly for 4 weeks.
62339314|NCT04021394||Metastatic castrate-resistant prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
62339315|NCT02357849|ACTIVE_COMPARATOR|Aripiprazole|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).
62495772|NCT03757520|ACTIVE_COMPARATOR|Regular user group|Their number: 300; female and male students, will earn 39 points or less of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
62697119|NCT04951193|OTHER|Treatment as Usual|Participants in the treatment as usual group will be provided with educational material about quitting vaping nicotine and it will be suggested that they discuss any questions about mood management and about quitting vaping with their primary care provider. The educational material is from the National Cancer Institute's SmokeFree Teen website and includes information on recognizing reasons for quitting vaping, avoiding dual use of e-cigarettes and other tobacco products, setting a quit date, understanding triggers, and accessing social support.
61944101|NCT02833350|EXPERIMENTAL|Cohort 2: GDC-0853 High Dose|Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
61944102|NCT02833350|PLACEBO_COMPARATOR|Cohort 2: GDC-0853 Placebo|Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
61944103|NCT01690585|EXPERIMENTAL|Ferinject 1000 mg|Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
61944104|NCT01690585|PLACEBO_COMPARATOR|Placebo|Intravenous administration of 250 ml of sodium chlorure 0.9 %
61944105|NCT04442139||Mini-Gastric Bypass|Patients reported completing survey following Mini-Gastric Bypass
61944106|NCT04365920|NO_INTERVENTION|Re-Entry as Usual|The type and level of services provided to individuals at re-entry will vary across jails and will be carefully documented. For the most part, individuals released to the community will receive a referral to an opioid treatment provider (OTP) for treatment with MOUD, and a subset may potentially be mandated to participate in community based treatment and/or recovery programs such as recovery coaching, and/or sentenced to varying levels of probation.
61944107|NCT04365920|EXPERIMENTAL|Recovery Management Checkups (RMC)|In the RMC condition, participants will have access to services provided as a part of re-entry as usual. In addition, checkups will be provided on a fixed schedule that includes face-to-face monthly checkups for the initial 3 months, and quarterly for the rest of the two years. Participants will have access to referrals and services provided by the jail and linkage to an OTP as part of their usual re-entry procedures. Individuals will meet with a Linkage Manager (LM) upon study enrollment and during each quarterly checkup, during which they will complete a Brief Treatment Needs Assessment, receive motivational interviewing, linkage assistance, or a check-in on continuing care and recovery support. The priority is to engage the individual into treatment with MOUD as soon as possible at the time of release, however, if individuals express a preference for another form of SUD treatment, the LM will work with that individual to link, engage, and retain them in that form of treatment.
61944108|NCT04365920|EXPERIMENTAL|RMC-Adaptive|In the RMC-Adaptive condition, checkups will be provided based on the participant's current need for treatment and will be adapted in three ways. First, the interval between RMC-A check-ups will vary (in 1-month increments) depending upon the individual's assessed need for treatment at the prior check-up. Second, in cases where participants have 3 consecutive checkups in which they need treatment, the LM and treatment provider will discuss how to better meet the participant's needs, e.g., a different treatment provider, different type of MOUD or other types of treatment, and/or additional services. Third, if RMC-A participants are re-incarcerated at the time of their checkup, the LM will meet with the individual while incarcerated to discuss a recovery plan, which may include initiation of treatment with MOUD while incarcerated and re-linkage to an OTP upon release.
61944109|NCT02386631|EXPERIMENTAL|Orthotic|Custom made orthotic provided for study
61944110|NCT01999751||MRI Scan|Patients with implantable cardioverter-defibrillator or pacemaker who undergo an MRI scan
61944111|NCT05225649|EXPERIMENTAL|Behavior Change Intervention|Participants will receive health coaching, patient-directed behavior change support by mobile health, and usual clinical care.
61944112|NCT05225649|NO_INTERVENTION|Control|Participants will receive usual clinical care.
61944113|NCT03041987||Chronic Kidney Disease|"Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR \<60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with nephrotic range proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR\<60 ml/minute per 1.73m(2) is set for enrollment."
61944114|NCT03656770|NO_INTERVENTION|V1: Control|This version of the survey questionnaire depicts a young woman with no symptoms of mental illness.
61944115|NCT03656770|EXPERIMENTAL|V2: Schizophrenia|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic schizophrenia."
61944116|NCT03656770|EXPERIMENTAL|V3: Schizophrenia + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with complete response."
61944117|NCT03656770|EXPERIMENTAL|V4: Schizophrenia + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with partial relapse."
61944118|NCT03656770|EXPERIMENTAL|Version 5: Bipolar|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic bipolar disorder."
62139507|NCT06699199|EXPERIMENTAL|Arresting Treatment 2|Management of dental caries n children between the ages of 4 and 10 by arresting the lesion using an alternative Treatment by using the combination of Silver diamine fluoride 38% + potassium iodide (SDF+KI), Both products reported as materials with an anti-microbial effect
62139508|NCT06668623|ACTIVE_COMPARATOR|Reiki Group|Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second-level training.
62697120|NCT04392076||Radiofrequency Ablation (RFA) of RCC|Patients following image guided radiofrequency ablation (RFA) of renal cell carcinoma (RCC)
61944119|NCT03656770|EXPERIMENTAL|V6: Bipolar + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with complete response."
61944120|NCT03656770|EXPERIMENTAL|V7: Bipolar + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with partial relapse."
61944121|NCT03656770|EXPERIMENTAL|V8: Depression|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic major depressive disorder."
61944122|NCT03656770|EXPERIMENTAL|V9: Depression + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with complete response."
61944123|NCT03656770|EXPERIMENTAL|V10: Depression + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with partial relapse."
61944124|NCT05983588|EXPERIMENTAL|Verum|RAVICTI 1.1 g/ml oral liquid (glycerol phenylbutyrate (GPB)) Duration of Treatment: 26 weeks, twice daily
61944125|NCT05983588|PLACEBO_COMPARATOR|Placebo|Matching Placebo, oral liquid Duration of Treatment: 26 weeks, twice daily
61944126|NCT03676998|OTHER|Measurement of diaphragm function|Patients will be followed up from admission to weaning with twice a week a diaphragm function multimodal evaluation (ultrasound, phrenic nerves stimulation technique)
61944127|NCT04676698|EXPERIMENTAL|Three Good Things|"Three times weekly for three weeks, participants will receive a text-based survey asking them to type or dictate three good things."
61944128|NCT04676698|ACTIVE_COMPARATOR|Waitlist Control Arm then Three Good Things|Participants will have surveys in the waiting period for 3 months and then be crossed over to the treatment arm Three Good Things.
61944129|NCT04532502||Study group|All female assistants in anesthesia
61944130|NCT01858376|OTHER|Capros dietary supplement|Subjects will take Capros supplement (1 capsule) twice a day for 12 weeks.The subjects then will have blood drawn seven times throughout the course of the study.
61944131|NCT02526446|EXPERIMENTAL|Self-administered acupressure|The intervention consists of a total of 28 hours over a period of 8 weeks. It comprises of individual learning and practice, self-practice at home, and home follow-up.
62339316|NCT02357849|ACTIVE_COMPARATOR|Fluoxetine|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
61944132|NCT02526446|OTHER|Wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
61944133|NCT02472873|EXPERIMENTAL|study group - sclerotherapy|Aspiration and Sclerotherapy of endometriomas.
61944134|NCT02472873|OTHER|control group - cystectomy|cystectomy of endometriomas.
61944135|NCT06556511|EXPERIMENTAL|zinc group|Children with diagnosis of sepsis. Patients who received standard therapy with zinc for 10 days
62139509|NCT06668623|SHAM_COMPARATOR|Sham Reiki Group|In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.
62339317|NCT06310096|ACTIVE_COMPARATOR|TLF fascial stretching exercise|The study group received a 4-week TLF fascial stretching exercise (10 times per day) in addition to the conventional physiotherapy program, while the control group only received a conventional physiotherapy program
62495773|NCT03757520|ACTIVE_COMPARATOR|Heavy user group|Their number: 300; female and male students, will earn 40 points or more of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
62495774|NCT00850447|EXPERIMENTAL|Cognitive Remediation Therapy|
62139510|NCT06668623|NO_INTERVENTION|control group|For four weeks, patients will not receive any treatment. Individuals will continue to receive their normal treatments.
62495775|NCT00850447|PLACEBO_COMPARATOR|Videogames|
62495776|NCT04252716||VISTHESIA 1.5|Ophtalmologic surgery supported by Visthesia OVD
62495777|NCT04252716||ProVisc|Ophtalmologic surgery supported by Provisc OVD
62495778|NCT05889039|SHAM_COMPARATOR|OMT + BEMER PLACEBO|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
62495779|NCT05889039|ACTIVE_COMPARATOR|Experimental: Bio Electro-Magnetic Regulation (BEMER) Therapy|Participants receiving BEMER therapy laid supine on the BEMER mat (BEMER International AG). The BEMER was set at intensity 3 for week 1, intensity 4 for week 2, and intensity 5 for week 3. The B.Pad (BEMER International AG) was placed under their cervical region. B.Pad® settings were set at Program 1 (8 minutes long) in week 1 through week 3. These settings were selected based on the manufacturer's recommendations.
61944136|NCT06556511|PLACEBO_COMPARATOR|placebo group|Children with diagnosis of sepsis. Patients who received standard therapy with placebo for 10 days
61944137|NCT03868761|OTHER|Single Arm|21 male and female teenage participants will be randomized to one of three varying baseline assessment periods of two, four, or six weeks. Multiple baseline is a type of single-case experimental design (SCED) that is a time- and cost-effective method for evaluating efficacy of a new treatment, Sonoma Rises. The randomization of participants to baseline periods of varying lengths enables assessment of whether symptom changes occur when, and only when, the intervention is applied.
61944138|NCT04032652|ACTIVE_COMPARATOR|1200 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 1200 mg asacol
61944139|NCT04032652|ACTIVE_COMPARATOR|2400 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 2400 mg asacol
61944140|NCT03867279|EXPERIMENTAL|Flossing|The subjects included in this group will perform a protocol of reeducation exercises plus the application of the Flossing technique. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
61944141|NCT03867279|ACTIVE_COMPARATOR|Reeducation exercises|The subjects included in this group will carry out a protocol of reeducation exercises. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
61944142|NCT01181908|EXPERIMENTAL|GSK1144814|Subjects will receive either GSK1144814 or placebo at each treatment arm.
61944143|NCT01181908|PLACEBO_COMPARATOR|placebo|Subjects will receive either GSK1144814 or placebo at each treatment arm.
61944144|NCT00618683|OTHER|Study Arm|Mapping and Ablation
61944145|NCT05722093|EXPERIMENTAL|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
61944146|NCT05722093|PLACEBO_COMPARATOR|placebo group|Administration cycle of Manzhi Guben granules simulator: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
61944147|NCT05021263|EXPERIMENTAL|Magnesium Group|The magnesium group (Mg) will receive a bolus of 50 mg/kg of IV magnesium prior to incision and an infusion of 15 mg/kg/hr, with no preoperative oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
61944148|NCT05021263|PLACEBO_COMPARATOR|Control Group|The control group (Ct) will receive saline solution and no IV magnesium or oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
62697121|NCT04392076||Microwave Ablation (MWA) of RCC|Patients following image guided microwave ablation (MWA) of renal cell carcinoma (RCC)
62697122|NCT04392076||Cryoablation (CRYO) of RCC|Patients following image guided cryoablation (CRYO) of renal cell carcinoma (RCC)
61944149|NCT04796545|EXPERIMENTAL|SING IMT System model NG SI IMT 3X|All participants will be implanted with the SING IMT System model NG SI IMT 3X.
61944150|NCT06215807|ACTIVE_COMPARATOR|Femtosecond laser arcuate keratotomy|femtosecond laser arcuate keratotomy will be designed using Donnenfeld nomogram.
61944151|NCT06215807|ACTIVE_COMPARATOR|Toric intraocular lens implantation|The Toric IOL power and alignment axis were calculated using the online calculator available at https://www.tecnistoriccalc.com
61944152|NCT00651391|EXPERIMENTAL|Ezetimibe + Simvastatin|
61944153|NCT00651391|ACTIVE_COMPARATOR|Simvastatin|
61944154|NCT00651391|PLACEBO_COMPARATOR|Placebo|
62495780|NCT05889039|ACTIVE_COMPARATOR|OMT (Osteopathic Manipulative Treatment)|Participants receiving OMT were treated with a standardized sequence to the areas where somatic dysfunctions were found.
62697123|NCT03131479|EXPERIMENTAL|Mild|Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
62697124|NCT03131479|EXPERIMENTAL|Moderate A|Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
62697125|NCT03131479|EXPERIMENTAL|Moderate B|Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
62697126|NCT03131479|EXPERIMENTAL|Severe|Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
62697127|NCT03131479|EXPERIMENTAL|Normal|Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.
61944155|NCT01457573|EXPERIMENTAL|One (single arm)|All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg (1 tab) and Solifenacin (Vesicare) 5 mg (1 tab) orally at the same time.
61944156|NCT01149837||residual blood donor samples|Protocol describes testing an HTLV-I/II antibody reactive population from this cohort using the InnoLIA HTLV I/II Score line immunoassay
61944157|NCT00522015|ACTIVE_COMPARATOR|1|patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
61944158|NCT06389500|EXPERIMENTAL|HAIC+Immune-targeted therapy|Hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib
61944159|NCT05059171|ACTIVE_COMPARATOR|Rotary motion using OneShape single file|File size 25 with a taper of 0.06 was mounted to a 6:1 speed-reduction headpiece powered by X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). The speed and torque were set to 400 rpm and 1 N.cm torque, respectively. In a picking motion without pressure, mechanical preparation began with the first RC two-thirds followed by the next 3 mm followed by the full WL.
61944160|NCT05059171|ACTIVE_COMPARATOR|Reciprocating motion using WaveOne Gold single file|A Primary file size 25 a taper of 0.07 was installed to pre-programmed reciprocation angles and speed for the WaveOne system handpiece of an endomotor (X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). After ensuring a passive fit of the hand file along the predetermined WL, the RC coronal two-thirds was initially instrumented then followed by the full WL.
61944161|NCT02949700|EXPERIMENTAL|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
61944162|NCT05820373|EXPERIMENTAL|Intervention group|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course.
61944163|NCT05820373|ACTIVE_COMPARATOR|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course.
61944164|NCT05820373|PLACEBO_COMPARATOR|Passive control group|The passive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group.
61944165|NCT03082261|OTHER|All enrolled subjects|All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite Implantable Pulse Generator (IPG).
61944166|NCT01612858|EXPERIMENTAL|Metformin|
61944167|NCT01612858|EXPERIMENTAL|Pioglitazone|
61944168|NCT01628705|SHAM_COMPARATOR|Nutritional intervention|The subjects were undergoing nutritional intervention.
61944169|NCT01628705|EXPERIMENTAL|Nutritional intervention with green tea|The subjects were undergoing nutritional intervention complemented with green tea.
61944170|NCT03055182|EXPERIMENTAL|Low back pain patients|Subjects included in physical rehabilitation program.
62139511|NCT05891132|ACTIVE_COMPARATOR|Group I comprised 30 women who will receive 10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
62339318|NCT06310096|ACTIVE_COMPARATOR|conventional physiotherapy program|The study group received a 4-week TLF fascial stretching exercise (10 times per day) in addition to the conventional physiotherapy program, while the control group only received a conventional physiotherapy program.
62339319|NCT00849251|EXPERIMENTAL|Treatment (chemotherapy and enzyme inhibitor)|Patients receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62339320|NCT01836887|PLACEBO_COMPARATOR|Intervention 1|Very low polyphenol fruit based drink (control)
62339321|NCT01836887|ACTIVE_COMPARATOR|Intervention 2|Polyphenol-enriched fruit-based drink - low
62339322|NCT01836887|ACTIVE_COMPARATOR|Invervention 3|Polyphenol-enriched fruit-based drink - high
62495781|NCT05889039|EXPERIMENTAL|OMT+BEMER|Participants receiving BEMER therapy laid supine on the BEMER mat (BEMER International AG). The BEMER was set at intensity 3 for week 1, intensity 4 for week 2, and intensity 5 for week 3. The B.Pad (BEMER International AG) was placed under their cervical region. B.Pad® settings were set at Program 1 (8 minutes long) in week 1 through week 3. These settings were selected based on the manufacturer's recommendations. OMT was performed prior to BEMER therapy for those in the combined group. Participants were treated with a standardized sequence to the areas where somatic dysfunctions were found.
62495782|NCT06340698|EXPERIMENTAL|Resilience intervention|Participants (mother-child dyads) will receive two biweekly sessions of dyadic resilience intervention.
61944171|NCT03055182|NO_INTERVENTION|Control subjects|No intervention administered
62339323|NCT04980976|ACTIVE_COMPARATOR|Conventional blind insertion technique.|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
62339324|NCT04980976|EXPERIMENTAL|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique to advance into esophagus under direct vision.
62339325|NCT00513097|EXPERIMENTAL|Smoking Prevention & Cessation Program|
62339326|NCT04209647|ACTIVE_COMPARATOR|Continuous Exercise|At %60 of maximal heart rate, 30-60 minutes exercise
61944172|NCT03531359|EXPERIMENTAL|TIBD Tablet-based video distraction|Children will receive of tablet-based interctive games in preoperatory room
61944173|NCT03531359|ACTIVE_COMPARATOR|Midazolam|Children will be premedicated with usual treatmente (midazolam)
61944174|NCT04185948|EXPERIMENTAL|Mediterranean diet plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
61944175|NCT04185948|ACTIVE_COMPARATOR|Eatwell guide plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
61944176|NCT04404062||Trial Participants|Male and female participants aged 5-70 years
62339327|NCT04209647|EXPERIMENTAL|REHIT Exercise|At %100 of heart rate 15 seconds, after this period 15 sec recovery period for all step
62339328|NCT05251454|EXPERIMENTAL|Electrical stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase). They will always be tested beforehand to ensure that they do not cause participants any discomfort or distress.
61944177|NCT04875663|EXPERIMENTAL|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
61944178|NCT04875663|EXPERIMENTAL|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
62339329|NCT05782335||Arm 1: Abatacept Initiator|RA patients of any disease duration, 18 years or older who are starting ABA (either IV or subcutaneous at standard doses) for the first time. Concomitant non-biologic medications (for e.g., standard conventional synthetic (cs)DMARDs, one of which must be MTX as typically used in routine care, or if MTX was not tolerated leflunomide will be acceptable) will be allowed as long as the dose has been stable for at least 3 months.
62495783|NCT06340698|EXPERIMENTAL|Adherence intervention|Participants (mother-child dyads) will receive two biweekly sessions of dyadic adherence intervention.
62495784|NCT06340698|NO_INTERVENTION|Control|Participants will receive usual medical treatment.
62495785|NCT00890916|EXPERIMENTAL|Neuroprosthesis System|Receives implanted device for hand function.
62495786|NCT02386007|EXPERIMENTAL|DW-3101_150mg|150mg a day
61944179|NCT04875663|NO_INTERVENTION|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
61944180|NCT04823182||Cases|Cases - Recent COVID-19 infection ≥ 6 weeks and ≤ 12 months before enrolment, as evidenced by positive reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 swab
61944181|NCT05504473|EXPERIMENTAL|Patients with facial nerve palsy and lagophthalmus|There is only one arm in this study. The investigators examine if the medical device can achieve a painless blinking in patients with facial nerve palsy and lagophthalmus.
61944182|NCT00381550|EXPERIMENTAL|Arm I|Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61944183|NCT00427947|EXPERIMENTAL|1|Continuous sciatic nerve bloc : ropivacaine infusion
61944184|NCT00427947|PLACEBO_COMPARATOR|2|Continuous sciatic nerve bloc : NaCl Infusion
62697128|NCT05829044|EXPERIMENTAL|Testing non-visual light impacts on pupil response, circadian timing, and hormones|"1. Pupillometry on day 1 in afternoon and evening and on day 2 in morning and evening. Participants will be randomized to one of 8 different light stimuli within the pupillometry~2. Red light exposure on night 1 to determine circadian timing~3. Blue/green light exposure on night 2 to compare hormone response during blue/green light to that during red light on night 1"
62697129|NCT05377411|EXPERIMENTAL|Optimized tDCS + Cognitive Training|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of up to 4.0mA direct current through two biocarbon rubber electrodes covered with at least 5mm-thick conductive electrode paste buffer, and placed over the optimized locations based on the international 10-20 system by using a combination of 10-20 EEG cap measurement and a stereotactic neuronavigation system. Stereotactic neuronavigation will be used as needed and may not be used on all participants.
61944185|NCT02359344|EXPERIMENTAL|CNV1014802|CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8
61944186|NCT02359344|PLACEBO_COMPARATOR|Placebo|Placebo tid 7 days plus a single dose on day 8
61944187|NCT01474083|EXPERIMENTAL|GK1-399, low dose|
61944188|NCT01474083|EXPERIMENTAL|GK1-399, high dose, once per day|
61944189|NCT01474083|EXPERIMENTAL|GK1-399, high dose, twice per day|
61944190|NCT01474083|PLACEBO_COMPARATOR|Placebo|
61944191|NCT06061354|EXPERIMENTAL|Teriparatide|"Access to the maxillary sinus will be done through osteotomy, using a piezosurgery . Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material Bio-Oss® mixed with Forteo® will be delivered for placement on the sinus floor maxilla below Schneider's membrane.~Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed"
61944192|NCT06061354|PLACEBO_COMPARATOR|Placebo|"Access to the maxillary sinus will be done through osteotomy, using a piezosurgery . Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material, Bio-Oss® mixed with saline solution, will be delivered for placement on the sinus floor maxilla below Schneider's membrane.~Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed"
61944193|NCT05366517|OTHER|Group|LiST active treatment group
61944194|NCT03646825||Treatment group|Male patients exposed to antioxidant for 12 weeks
61944195|NCT04184544|EXPERIMENTAL|Maternal and Newborn health districts|Group one included maternal and newborn health districts. These districts are further divided into three sub groups. Sub group 1 will receive only interventions focusing on maternal health (1 district (Sangher)); sub group 2 will receive interventions focusing only on newborn health (1 district (Nasirabad)); sub group 3 will receive combined maternal and newborn interventions (two districts (, Lasbila and Badin).
61944196|NCT04184544|EXPERIMENTAL|Child Health|Group two will receive child health interventions focusing on the implementation of the global action plan for pneumonia and diarrhea (GAPPD \[4districts, Qamabar Shahdadkot Muzaffargarh, Rahim Yar Khan Jafferabad).
61944197|NCT02888301||Basic science (18F-clofarabine biodistribution)|Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
62495787|NCT02386007|EXPERIMENTAL|DW-3101_300mg|300mg a day
62495788|NCT02386007|EXPERIMENTAL|DW-3101_600mg|600mg a day
61944198|NCT06321562|EXPERIMENTAL|Group 1: TimoD implant-Dose 1 (low dose)|Participants in the Group 1 will receive a low dose of TimoD implant in the study eye on Day 1.
61944199|NCT06321562|EXPERIMENTAL|Group 2: TimoD implant-Dose 2 (intermediate dose)|Participants in Group 2 will receive an intermediate dose of TimoD implant in the study eye on Day 1 if all participants in Group 1 have completed a 4-week treatment period with the lowest dose of TimoD implant, providing there are no safety issues in Group 1.
61944200|NCT06321562|EXPERIMENTAL|Group3: TimoD implant-Dose 3 (high dose)|Participants in Group 3 will receive a high dose of TimoD implant in the study eye on Day 1 if all participants in Group 2 have completed a 4-week treatment period with the intermediate dose, providing there are no safety issues in Group 2.
61944201|NCT03890315||Neuropathic pain|Adult patients with upper extremity neuropathic pain due to radiculopathy Duration of \>1 month Unilateral extremity pain will be recruited
61944202|NCT03890315||Control|Age and gender matched control patients will also be recruited to show whether differences exist in outcome measures.
61944203|NCT03468803|EXPERIMENTAL|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
61944204|NCT03141593|ACTIVE_COMPARATOR|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
61944205|NCT03141593|ACTIVE_COMPARATOR|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
61944206|NCT03141593|ACTIVE_COMPARATOR|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
61944207|NCT03141593|ACTIVE_COMPARATOR|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
61944208|NCT01727401|EXPERIMENTAL|Fondaparinux|Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
62495789|NCT02386007|PLACEBO_COMPARATOR|a tablet same as experimental agents in formation and shape|Placebo
62495790|NCT05386134||Study Subjects|Approximately 175 Study Subjects
62495791|NCT05386134||Control Group|Approximately 25 Control group
62697130|NCT05377411|SHAM_COMPARATOR|Sham tDCS + Cognitive Training|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of up to 4 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
61944209|NCT04624854|PLACEBO_COMPARATOR|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
61944210|NCT04624854|EXPERIMENTAL|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
62697131|NCT05299424|EXPERIMENTAL|Phase 1, Dose escalation|There are 14 dose groups in dose escalation part ( Phase 1 study).
62697132|NCT05299424|EXPERIMENTAL|Phase 2, Dose expansion|Based on the data of phase 1, the dose level recommended for the phase 2 study (RP2D) will be evaluated.
62697133|NCT03323255|ACTIVE_COMPARATOR|cTBS stimulation|continuous theta-burst TMS stimulation (1200 pulses, 50Hz, separated in two sequences of 600 pulses)
61944211|NCT04292769|EXPERIMENTAL|Decitabine combined with DC-CIK|Test group: decitabine combined with autologous DC-CIK cells infusion: decitabine 10mg / d, intravenous administration of d-5 to d-1, autologous DC-CIK cells infusion: first course: d1-d3 The second course: d14-d16; the total number of cells is about 5-10 × 109; IL-2: 200,000 IU / d subcutaneous injection, the first course: d0-d4, the second course: d13-d17, every 2 weeks 1 course of treatment, 2 courses in total.
61944212|NCT04292769|ACTIVE_COMPARATOR|DC-CIK|Control group: autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109; One course: d0-d4, the second course: d13-d17, 1 course every 2 weeks, a total of 2 courses.
61944213|NCT01501331||RRT diagnostic tool|Patients implanted with an Energen device or successor.
61944214|NCT01669499|PLACEBO_COMPARATOR|Placebo|Placebo on day 0-3
62697134|NCT03323255|SHAM_COMPARATOR|SHAM stimulation (placebo)|SHAM stimulation
62697135|NCT06396559|NO_INTERVENTION|placebo|Student nurses will undertake internships included in their curriculum.
62697136|NCT06396559|EXPERIMENTAL|mobil application|Student nurses will undertake internships included in their curriculum. They will use the patient safety mobile application during the internship.
62697137|NCT06414031|EXPERIMENTAL|Tranexamic acid|Intravenous administration of tranexamic acid (1 g bolus 10 minutes prior to skin incision followed by continuous infusion 125 mg / hour until skin closure)
61944215|NCT01669499|ACTIVE_COMPARATOR|Dexamethasone acetate day 0|8 mg dexamethasone on day 0
61944216|NCT01669499|ACTIVE_COMPARATOR|Dexamethasone acetate day 0-3|8 mg dexamethasone on day 0-3
61944217|NCT05254808|ACTIVE_COMPARATOR|Fosfomycin in a single dose of 3000mg on day 1|Fosfomycin-trometamol Single dose scheme: 3000mg taken orally once (arm A)
61944218|NCT05254808|EXPERIMENTAL|Extended dosing of 3000mg fosfomycin on day 1 and 3|Fosfomycin-trometamol Extended dosing scheme: 3000mg taken orally on day 1 and day 3 (arm B)
62697138|NCT06414031|PLACEBO_COMPARATOR|Placebo|Intravenous administration of placebo (normal saline), 50 ml bolus 10 minutes prior to skin incision followed by continuous infusion of 6.25 ml / hour until skin closure.
62697139|NCT06639685||CKD|Chronic Kidney Disease
62697140|NCT06223152|EXPERIMENTAL|deaf children and parents|
62697141|NCT04138355|EXPERIMENTAL|Extracorporeal shock wave therapy group|. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
62697142|NCT04138355|NO_INTERVENTION|conventional manual therapy|the same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy.
62697143|NCT05748210|EXPERIMENTAL|Intervention group|Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.
61944219|NCT05254808|ACTIVE_COMPARATOR|Nitrofurantoin 100mg bid (slow release) for 5 days|Nitrofurantoin 100mg b.i.d. in slow release form (Furabid) taken orally for 5 days (arm C)
61944220|NCT06309186||Midwives|The study involves a convenience sample of midwives registered with the two Orders of the Midwifery Profession in Friuli-Venezia Giulia Region (Italy)
61944221|NCT03950011||ERP|Any patient requiring oncologic surgery, including hysterectomy or curettage, posterior pelvectomy, conventional laparoscopic or assisted robotic surgery, or laparotomy for cervical or cervical cancer or ovarian cancer, body or cervix uterus and ovaries as well as benign pathologies or borderline malignancy.
62139512|NCT05891132|ACTIVE_COMPARATOR|Group II will have lidocaine prilocaine cream 15gm application on the perineum|lidocaine-prilocaine cream 15gm application on the perineum at 8 cm of cervical dilatation and then an additional dose every 1 hour until delivery is achieved, then another dose of the cream will be applied before repairing the episiotomy and finally daily 3 doses every 8 hours at the site of episiotomy for the first week post-partum
62139513|NCT02616926|EXPERIMENTAL|Hepatic resection|"Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.~Intervention: Hepatic resection"
61944222|NCT02277730|EXPERIMENTAL|vasopressor delivery automated system|vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
61944223|NCT02277730|ACTIVE_COMPARATOR|manual vasopressor delivery|manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
61944224|NCT02371304|ACTIVE_COMPARATOR|Total Mesorectal Excision|After local excision patients will receive additional TME surgery
61944225|NCT02371304|EXPERIMENTAL|Adjuvant chemoradiotherapy|After local excision. Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
61944226|NCT05270122|EXPERIMENTAL|ThrombX Retriever|Access to the involved vasculature and preform mechanical thrombectomy using the ThrombX Retriever.
61944227|NCT05551208|EXPERIMENTAL|maintenance treatment|after 4-9 cycles chemotherapy containing platinum and bevacizumab, fluzopanib and bevacizumab were used for maintenance treatment
62495792|NCT06534164|EXPERIMENTAL|Full/High-tech TeleRehab DSS|5x/week x 12 weeks All TeleRehab DSS components: multisensory balance exercises, AR avatar, real-time feedback, AR gamified activities, sensor-monitored exercise performance and additional cognitive training.
61944228|NCT04945577||Experimental: Mild Clinical Group|patients showing mild clinical symptoms without pneumonia.
61944229|NCT04945577||Experimental: Moderate Clinical Group|patients with fever, other respiratory symptoms, and pneumonia findings based on radiological imaging
61944230|NCT04945577||Experimental: severe/critical clinical group|severe one of these as follows; patients with hypoxia (≤93% oxygen saturation), respiratory distress (RR \>30 times per minute), partial pressure of arterial blood oxygen (PaO 2 )/the fraction of inspired oxygen (FiO 2 ) ≤ 300 mmHg, patients whose chest imaging shows that lung damage develops significantly within 24 to 48 hours, or critical one of these as follows; respiratory failure requiring mechanical ventilation, signs of septic shock with multiple organ failure requiring intensive care unit admission.
61944231|NCT00395733|EXPERIMENTAL|Gadobutrol, then Gadopentate dimeglumine|Period 1: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged; Period 2: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged
62339330|NCT05782335||Arm 2: csDMARD/TNFi Treated|RA patients, 18 years or older and on stable doses of conventional DMARDs (MTX with or without hydroxychloroquine, sulfasalazine, with or without leflunomide therapy, where leflunomide therapy can be an alternate to MTX). Patient's disease activity can be controlled or near controlled (CDAI \<=12) or active if a recent DMARD or TNFi has been added, though they will have been on MTX at doses of at least 15mg weekly or leflunomide 10 mg or more for 4 weeks or more. A combination of csDMARDs at stable doses for 4 or more weeks with \>= MTX 10 mg weekly or ± MTX 10 mg weekly for at least 4 weeks with any dose of a conventional TNF inhibitor (stable dose + TNFi) is permitted.
62339331|NCT05782335||Arm 3. Healthy Controls|Healthy individuals over 18 y.o. without RA, SLE, juvenile arthritis, psoriasis or psoriatic arthritis or other inflammatory auto-immune rheumatic disease, who are receiving care at the HSS or volunteers from the community. Participants will be recruited to serve in the control population for this study. Given that the range of age for most RA patients is between 40-70, we will aim to recruit control volunteers in this age range, ensuring that at least 60% - 70% are female, ensuring an age range and sex that is proportionately similar to the RA population at HSS.
62495793|NCT06534164|EXPERIMENTAL|Basic/Low-tech TeleRehab DSS|"5x/week x 12 weeks With depth camera, motion sensors and tablet for multisensory balance exercises, real time feedback, sensor monitored exercise performance and cognitive games.~No exergames, no smartwatch, no mobile phone."
62495794|NCT06534164|ACTIVE_COMPARATOR|OTAGO Home Exercise programme|"3x/week x 12 weeks a balance exercise programme developed by a research group at University of Otago, New Zealand \[12\]. The OTAGO HEP will be provided to all individuals in the control arm who report falls/are at risk of falls. The OTAGO group participants will receive a pamphlet with instructions for home exercises within the programme, resistance bands and an exercise diary.~The OTAGO HEP booklet is available at https://www.livestronger.org.nz/assets/Uploads/acc1162-otago-exercise-manual.pdf"
62697144|NCT05748210|ACTIVE_COMPARATOR|Wait-list control group|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
62697145|NCT05497934|EXPERIMENTAL|Treatment arm|Subjects will be imaged with OCT and endoscopy before treatment of the tympanic membrane with topical glycerol, after treatment of the tympanic membrane with topical glycerol and after rinsing the tympanic membrane with saline
62697146|NCT03716596|EXPERIMENTAL|SBRT and PD-1|Stereotactic body radiotherapy, radiation dose is 40-50 Gy in total. Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
61944232|NCT00395733|EXPERIMENTAL|Gadopentate, dimeglumine then Gadobutrol|Period 1: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged; Period 2: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged
61944233|NCT05877768||Coronary Artery Disease|Patients with suspected coronary artery disease and those with known coronary artery disease and the suspicion of progressive disease who undergo clinically indicated Coronary Computed Tomography Angiography on the Photon-Counting Detector CT will be enrolled after written consent. All data from the CT scan and potential additional investigations (e.g. invasive coronary angiographies) will be collected. There will be no additional investigations for the purpose of the study. After 1, 2 and 5 years, participants will be asked to answer a health questionaire.
61944234|NCT04037046|EXPERIMENTAL|Screening HCV with DBS at primary care centers|Patients assigned to the strategy 1 will receive an invitation letter for HCV screening with DBS at the primary care center to be performed by the general practitioner
61944235|NCT04037046|ACTIVE_COMPARATOR|Screening HCV and CCR with FOT at primary care centers|Patients assigned to the strategy 2 will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
61944236|NCT04037046|ACTIVE_COMPARATOR|Self-testing at home for screening HCV and CCR|Patients assigned to the strategy 3 will receive an invitation letter for self-testing at home for HCV screening with DBS, and CCR screening with FOT
61944237|NCT02622620||Patients with glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
61944238|NCT05297201|EXPERIMENTAL|CPL500036 low dose|Patients will receive 20 mg of CPL500036 administered once daily for 28-days treatment period.
61944239|NCT05297201|EXPERIMENTAL|CPL500036 high dose|Patients will receive 40 mg of CPL500036 administered once daily for 28-days treatment period.
61944240|NCT05297201|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo administered once daily for 28-days treatment period.
61944241|NCT01693848||Patients|Patients with metastatic colorectal cancer scheduled for metastatic surgery
61944242|NCT01693848||Control patients|Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
62697147|NCT03070665|EXPERIMENTAL|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
62339332|NCT01149642|EXPERIMENTAL|Oral immunomodulatory solution|The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.
62495795|NCT06534164|ACTIVE_COMPARATOR|Vestibular rehabilitation programme|"Daily x 12 weeks For participants with problems chronic (lasting \>3 months) dizziness/imbalance due to chronic vestibular disorder (affecting the vestibular /balance system) or due to long Covid). The vestibular rehabilitation group participants will receive a booklet with vestibular exercises which have been individualised based on the assessment by the research team member. The exercise booklet is a validated and widely used intervention for vestibular disorder \[17\]. This will be provided to all individuals in the control arm with chronic dizziness/imbalance (\>3 months) without falls/risk of falls (FGA\>22).~The booklet has descriptions and diagrams of the exercises and instructions on how to progress these as well as an exercise log, available at: https://www.menieres.org.uk/files/pdfs/balance-retraining-2012.pdf"
62495796|NCT01468688|EXPERIMENTAL|STI571 (imatinib mesylate) and BKM120|The study will comprise of 2 parts. A dose escalation and a dose expansion part. Patients will receive increasing doses of BKM120 (40, 60, 80, 100 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. 35 patients will enter the expansion phase with 18 patients having a pharmacokinetic (PK) run-in period of 8 days receiving imatinib monotherapy or BKM120 monotherapy.
62495797|NCT01468688|EXPERIMENTAL|STI571+BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
62495798|NCT01468688|EXPERIMENTAL|STI571 monotherapy run-in|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
62495799|NCT04474145|ACTIVE_COMPARATOR|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
62495800|NCT04474145|ACTIVE_COMPARATOR|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
61944243|NCT03417219|EXPERIMENTAL|Mobile Media Education and Skill-Building Rehabilitation Int|The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
61944244|NCT03417219|ACTIVE_COMPARATOR|Usual Care|"Usual Care (plus supplemental educational materials). Participants randomized to the Usual Care (UC) group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
61944245|NCT05981430|ACTIVE_COMPARATOR|Fecal microbiota transplant|This group's subject will receive an infusion of 125mL fecal suspension via enema.
61944246|NCT05981430|PLACEBO_COMPARATOR|Sham fecal microbiota transplant|This group's subject will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food colouring 204 (Americolorcorp) as a sham procedure.
61944247|NCT06284902|EXPERIMENTAL|Treatment Sequence Group 1|
61944248|NCT06284902|EXPERIMENTAL|Treatment Sequence Group 2|
61944249|NCT06284902|EXPERIMENTAL|Treatment Sequence Group 3|
61944250|NCT06284902|EXPERIMENTAL|Treatment Sequence Group 4|
61944251|NCT06284902|EXPERIMENTAL|Treatment Sequence Group 5|
61944252|NCT06284902|EXPERIMENTAL|Treatment Sequence Group 6|
62339333|NCT01149642|PLACEBO_COMPARATOR|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
62339334|NCT04102878|ACTIVE_COMPARATOR|Transcutaneous anaesthetic|
62697148|NCT03070665|NO_INTERVENTION|Control group|Patients received normal ESD manipulation.
62697149|NCT01542944|EXPERIMENTAL|TevaGastrim|treatment with TevaGastrim for allogeneic stem cell collection
61944253|NCT01332331|EXPERIMENTAL|Low Dose Ambrisentan|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
61944254|NCT01332331|EXPERIMENTAL|High Dose Ambrisentan|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
61944255|NCT04448938||optic neuritis|
61944256|NCT04448938||control|
61944257|NCT05328674|ACTIVE_COMPARATOR|Microfracture method|
61944258|NCT05328674|EXPERIMENTAL|Method of autogenous PRP (Auto Cart-Arthrex) cartilage transplant|
61944259|NCT05565131|EXPERIMENTAL|PAtients requiring pedicle screw implantation|
61944260|NCT04668807|EXPERIMENTAL|Connected Medical Device|"SMART ANGEL Intra-hospital System 's Connected Medical Device (DMC) measuring physiological parameters in the operating room"
61944261|NCT04668807|ACTIVE_COMPARATOR|Traditional system|Traditional wired transmission system between the sensor and the data processing device in the operating room
61944262|NCT06258395||Nursing 2st year|second year nursing students
61944263|NCT06258395||Nursing 3st year|third year nursing students
61944264|NCT06258395||Nursing 4st year|fourth year nursing students
62339335|NCT04102878|ACTIVE_COMPARATOR|Transconjunctival anaesthetic|
62339336|NCT05845918|EXPERIMENTAL|PRISEM CEP (in-person)|The Cognitive Empowerment Program (CEP) is an in-person lifestyle intervention program in which participants participate in individual or group-based activities that address cognitive, physical, social, and functional independence, education, and well-being goals.
62339337|NCT05845918|EXPERIMENTAL|PRISEM Remote|PRISEM Remote is a remote-based lifestyle intervention program in which participants will attend 17 core online sessions via Zoom from the evidence-based Diabetes Prevention Program curriculum with remaining post-core sessions to reinforce strategies and activities introduced in the core program for the duration of 6 months.
61944265|NCT06681610|EXPERIMENTAL|TPS|The stimulation will be 20 min duration as indicated in the CE mark approval. Each session involves 6,000 pulses in the hand region of the motor cortex with 3,000 on each side of the brain. The system uses a low energy flux density maximum of 0.25 mJ/mm2 accordingly with EMA and FDA guidelines (high energy is defined as \> 0.5 mJ/mm2). The standard therapy involves 6 sessions in 2 weeks as indicated in the CE mark.
61944266|NCT06681610|SHAM_COMPARATOR|sham|The transcranial pulse stimulation with the same device and the same protocol uses a membrane on the device that blocks the sound waves. Participants' motor cortex is not stimulated.
61944267|NCT04971421||Benign ovarian tumors|All histological proven benign ovarian tumors
61944268|NCT04971421||Malignant ovarian tumors|All histological proven malignant ovarian tumors
61944269|NCT04971421||Borderline ovarian tumors|All histological proven borderline ovarian tumors
62139514|NCT02616926|ACTIVE_COMPARATOR|TACE + RFA|"TACE is performed as a primary treatment for hepatocellular carcinoma. RFA will be performed two weeks later if necessary.~Intervention: TACE; RFA"
62339338|NCT04403984||Patients with Luminal A breast cancer|Patients confirmed with Luminal A breast cancer sub type
62339339|NCT04403984||Patients with Luminal B breast cancer|Patients confirmed with Luminal B breast cancer sub type
62339340|NCT05912855||BPS（Behavioral Pain Scale）and physiological index monitoring guided analgesia group|
62339341|NCT05912855||Analgesia group guided by qNOX|
62339342|NCT04580394|EXPERIMENTAL|AD109|Oral capsule administered before sleep
62339343|NCT04580394|ACTIVE_COMPARATOR|Atomoxetine|Oral capsule administered before sleep
62339344|NCT04580394|ACTIVE_COMPARATOR|R-oxybutynin|Oral capsule administered before sleep
62339345|NCT04580394|PLACEBO_COMPARATOR|Placebo|Oral capsule administered before sleep
62339346|NCT01897181|ACTIVE_COMPARATOR|Hearing aids|Patients who agree to use hearing aids
62495801|NCT02579226|EXPERIMENTAL|Part A|Part A dose-escalation will evaluate the safety and tolerability of AZD2811 monotherapy at increasing doses in patients with advanced solid tumours. Patients will receive AZD2811 on Days 1 and 4 of a 28-day cycle or Day 1 only in cycles of either 21 or 28 days.
61944270|NCT00905827|EXPERIMENTAL|Intervention 1: in person CAMS|In person Collaborative Assessment and Management of Suicidality (CAMS) training for providers
61944271|NCT00905827|EXPERIMENTAL|Intervention 2: e-learning CAMS|Online Collaborative Assessment and Management of Suicidality (CAMS) training for providers
62339347|NCT01897181|NO_INTERVENTION|No hearing aids|Patients who did not agree to use hearing aids
62339348|NCT01922284|EXPERIMENTAL|Group 1 - Combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.~At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm."
61944272|NCT00905827|NO_INTERVENTION|Control: no training|Control Group: no training
61944273|NCT01403311|EXPERIMENTAL|ALA|5-Aminolevuline Acid (ALA)
62139515|NCT03927651|EXPERIMENTAL|Administration of ICG|ICG will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. Near infrared fluorescence imaging will be used to illuminate the ICG. The extent of perfusion will be determined using digital imaging software. ICG will be stored at the NM Investigational Pharmacy and administered intravenously by the anesthesiologist at the direction of the surgeon during surgical procedure.
62139516|NCT03477968||PE|"Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.~Enrolment completed for this group : 13th February 2020"
62139517|NCT03477968||DVT|"Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.~Enrolment on going"
62139518|NCT02414633||Humira|Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
62339349|NCT01922284|ACTIVE_COMPARATOR|Group 2 - Non-combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.~At weeks 16 \& 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm."
62339350|NCT02854904|EXPERIMENTAL|Dexmedetomidine intervention|Dexmedetomidine (1 ug/kg/hr) during anesthesia.
62339351|NCT02854904|PLACEBO_COMPARATOR|Placebo|Infusion of normal saline during anesthesia.
62339352|NCT03270150|EXPERIMENTAL|BTL-899 Therapy Arm|BTL-899 therapy, 3 therapies
62339353|NCT03972124|ACTIVE_COMPARATOR|CBD 100 mg OD|The lower dose CBD group will start with CBD capsules 10 mg OD, then increase the dose every 4 days until on the target dose of 100 mg OD.
62495802|NCT02579226|EXPERIMENTAL|Part B|Part B will include patients with relapsed or refractory small-cell lung cancer (SCLC). Patients will receive AZD2811 monotherapy at the recommended Phase 2 dose (RP2D).
61944274|NCT00477178||chronic non-malignant pain codeine|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - on long-term codeine therapy
61944275|NCT00477178||chronic non-malignant pain|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - NOT on long-term codeine therapy
61944276|NCT00477178||healthy|healthy controls
61944277|NCT04213482||oncology patients|For this study, panoramic images were taken from pediatric patients who received radiotherapy and/or chemotherapy because of any oncologic disease.
61944278|NCT04213482||healthy|panoramic images of patients(pediatric) who have no systemic disease were collected from the archive of dental radiology clinic of the university hospital.
62339354|NCT03972124|EXPERIMENTAL|CBD 200 mg OD|The higher dose CBD group will start with CBD capsules 10 mg OD and will increase every 4 days until on a target dose of 200 mg OD.
62339355|NCT03972124|PLACEBO_COMPARATOR|Placebo|
62339356|NCT01261806|EXPERIMENTAL|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up: 10 session intervention in foster families' homes designed to enhance parental nurturance, synchrony, and provide skills such that parents can help children calm down when overwhelmed.
62339357|NCT01261806|ACTIVE_COMPARATOR|Developmental Education for Families|10 session intervention in foster families' homes that targets cognitive and motor skills of children
62339358|NCT02985905|EXPERIMENTAL|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate,every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
62339359|NCT02985905|NO_INTERVENTION|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment
62339360|NCT01366066|ACTIVE_COMPARATOR|TMNS treatment - Stress incontinence|Women with stress incontinence treated with active TMNS (vibration)
62339361|NCT01366066|NO_INTERVENTION|No treatment - stress incontinence|Women with stress incontinence NOT treated with TMNS (vibration)
62339362|NCT01366066|ACTIVE_COMPARATOR|TMNS treatment - Urge incontinence|Women with stress incontinence treated with TMNS (vibration)
62339363|NCT01366066|NO_INTERVENTION|No treatment - urge incontinence|Women with urge incontinence NOT treated with TMNS (vibration)
62339364|NCT03482323|EXPERIMENTAL|Exercise intervention|Exercise class will run twice a week for 12 weeks. Participants will be encouraged to maintain their exercise beyond the intervention. An exercise trainer will lead the classes. The main activity of the classes includes aerobic exercises of walking on treadmill, or out-doors depending on group preference and weather, at a set pace individually tailored for moderate intensity of exercise, determined by baseline physical functioning assessment and modified based on Rated Perceived Exertion (RPE), or cycling on a stationary bike, using a set resistance to the physical functioning assessment and RPE. A set of four strengthening exercises are included in one of the exercise classes each week. These exercises are chosen to increase strength in the leg, arm, abdomen and improve trunk stability. Weights for the strengthening exercise will be set to give participants a moderate level of intensity of exercise.
62339365|NCT03482323|EXPERIMENTAL|Tai-chi intervention|The classes will run twice a week for 12 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 12 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
62339366|NCT03482323|NO_INTERVENTION|Control group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 12 weeks, 6 months and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
62339367|NCT00127530|PLACEBO_COMPARATOR|Placebo- sugar pill|Placebo control
62339368|NCT00127530|EXPERIMENTAL|Fampridine-SR|10 milligram (mg) tablet b.i.d.
62339369|NCT04637945|PLACEBO_COMPARATOR|placebo|The placebo will be delivered in softgels consisting of colorant, olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, glycerin and water.
62339370|NCT04637945|EXPERIMENTAL|ACRB|The ACRB product will be delivered in softgels consisting of anthocyanin-rich blend. Each softgel will contain: i) 49 mg bilberry extract; ii) 101 mg black currant extract; and iii) 303 mg black rice extract. The high ACRB will deliver at least 108 mg anthocyanins. The product will also contain olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, and water.
62339371|NCT05896618|EXPERIMENTAL|Group I|TPA group
62339372|NCT05896618|EXPERIMENTAL|Group II|Nance group
62339373|NCT05637723|EXPERIMENTAL|schroth exercise group|Included participants will be included in the Schroth exercise program by a Schroth-trained physiotherapist 3 days a week for 6 weeks, after being evaluated at the start of treatment.
62339374|NCT05637723|ACTIVE_COMPARATOR|traditional scoliosis exercise group|Included participants will be included in the traditional scoliosis exercise program by a physiotherapist 3 days a week for 6 weeks, after being evaluated at the start of treatment.
62339375|NCT05637723|NO_INTERVENTION|control group|Any exercise program for scoliosis will not be applied to this group.
62339376|NCT05830513|ACTIVE_COMPARATOR|Group A|Women will be randomly allocated to undergo OPU either with the use of Virtual reality(group A)
62495803|NCT04540068||Patients with Lumbar Disc Herniation|Patients with a lumbar disc herniation on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
62495804|NCT04540068||Patients with Lumbar Spinal Stenosis|Patients with a lumbar spinal stenosis on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
62495805|NCT01126606|EXPERIMENTAL|Group 1|Dermacyd Silver Frutal followed by Dermacyd Silver Frutal+PH_DESYLSTY_FR followed by wash out followed by Glycerine Vegetal Soap Granado Traditional
61944279|NCT02041767|EXPERIMENTAL|group A|One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
61944280|NCT02041767|EXPERIMENTAL|group B|One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
62139519|NCT05121259|EXPERIMENTAL|Exercise Guide|Single group feasibility group. Single group (intervention group) will be given access to the intervention (Exercise Guide UK) for eight-weeks.
62139520|NCT03582566|EXPERIMENTAL|Phonological Awareness|Children will play games to practice their rhyming, sound sequencing, and letter-sound knowledge. These games are all implemented in the Earobics program.
62495806|NCT01126606|EXPERIMENTAL|Group 2|Glycerine Vegetal Soap Granado Traditional followed by wash out followed by Dermacyd Silver Floral followed by Dermacyd Silver Floral + PH_DESYLSTY_FR
62139521|NCT03582566|EXPERIMENTAL|Working Memory|Children will play games designed to help them hold and manipulate objects in memory. These games are implemented in Cogmed.
62139522|NCT03582566|EXPERIMENTAL|Phonological Awareness + Working Memory|Children will practice both their sound skills (Earobics) and their memory skills (Cogmed).
62139523|NCT03582566|ACTIVE_COMPARATOR|Active Control|Children will play games to practice their addition and subtraction skills (Splashmath).
62339377|NCT05830513|NO_INTERVENTION|Group B|Women will be randomly assigned to an OPU in the control group with standard treatment, withouth analgesia (Group B).
62339378|NCT02725827|ACTIVE_COMPARATOR|HA group|One the day of frozen-thawed embryo transfer, frozen embryos will be thawed and incubated for at least 10 minutes in embryo transfer medium. For women allocated to the HA group, EmbryoGlue (Vitrolife), a hyaluronan-enriched embryo transfer medium, will be used as embryo transfer medium. EmbryoGlue contains a higher concentration of hyaluronan than the control medium.
62339379|NCT02725827|ACTIVE_COMPARATOR|Control group|For women allocated to the control group, the usual transfer medium used in the study centers will be used and will serve as control. The main difference between the two media is that EmbryoGlue contains a higher concentration of HA.
62339380|NCT02197936||Peristalsis adenomyosis|with adenomyosis
62339381|NCT02197936||Peristalsis control|No adenomyosis
62339382|NCT05334680||COVID-19|Individuals experiencing COVID-19 like symptoms.
62339383|NCT05334680||Healthy Controls|Individuals without any known significant health problems
62339384|NCT01869751||Prucalopride|Slow-transit constipation with treatment with prucalopride
62339385|NCT04459702|EXPERIMENTAL|Dual Therapy|Dual Therapy utilizing hydroxychloroquine and azithromycin.
62697150|NCT03782493|EXPERIMENTAL|Enhanced Milieu Teaching-Sentence Focus|The study intervention is a behavioral intervention which will include individually teaching caregivers to use the intervention strategies from the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention using a manualized protocol (Teach-Model-Coach-Review). Caregivers will participate in 66 intervention sessions across 18 months, targeting vocabulary and grammar as well as the transition to decontextualized language.
62697151|NCT03782493|NO_INTERVENTION|Business-as-usual control|Caregivers in the control group will participate in community-based intervention services and receive the same printed intervention instructions, books, and toys at the same intervals as the treatment group, but will not receive EMT-SF intervention.
62697152|NCT02929732|EXPERIMENTAL|Willis-Ekbom disease patients (CASE)|
62339386|NCT04459702|EXPERIMENTAL|Quadruple Therapy|Quadruple therapy utilizing hydroxychloroquine, lopinavir, ritonavir, and azithromycin
62339387|NCT03215654|EXPERIMENTAL|Sensitization Program (SP)|Include the concepts of mental health and mental disorder, healthy and risky behaviors of mental health, and use of health services. Duration 1 hour.
62339388|NCT03215654|EXPERIMENTAL|Mental Health Literacy Program (MHL)|MHL module contents are: 1) Our emotions. Definitions of mental health and mental disorders. Mental health multidisciplinary team network; 2) Healthy and risky behaviors of mental health; 3) Social skills and antisocial behavior, bullying and cyberbullying; 4) Anxiety, depression, self-harm, and suicidal behaviors; 5) Eating and behavioral disorders; 6) Substance abuse (alcohol and cannabis), an psychotic disorder. Duration 6 hours.
62339389|NCT03215654|EXPERIMENTAL|MHL more Stigma Reduction (ER)|Includes the six teaching units of MHL and a first contact presentation with lived experience of any mental disorder, who will be delivered by a voluntary member of Activament Catalunya Associació (http://www.activament.org/es), a non-profit group specialized in reducing stigma. Duration 7 hours.
62339390|NCT03215654|NO_INTERVENTION|Control group|Control group will be a waiting list condition and they will receive the full program of 7h at the next year of academic course
62339391|NCT00459485|EXPERIMENTAL|Zinc supplement (20 mg)|Daily intake of 20 mg supplementary zinc
61944281|NCT00485433|ACTIVE_COMPARATOR|Bupivacaine HCl 105mg|Bupivacaine HCl given during hernia repair
62139524|NCT05321992|NO_INTERVENTION|Usual Care Community|Participants in this arm will not be given the eCHEC program
62139525|NCT05321992|ACTIVE_COMPARATOR|eCHEC Community|Participants in this arm will be given the eCHEC program as their intervention
62339392|NCT00459485|EXPERIMENTAL|Zinc supplement (10 mg)|Daily intake of 10 mg supplementary zinc
62339393|NCT00459485|PLACEBO_COMPARATOR|Placebo supplement|Daily intake of placebo supplement
62339394|NCT02498561|ACTIVE_COMPARATOR|obese-chronic periodontitis patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
62339395|NCT02498561|PLACEBO_COMPARATOR|obese-periodontally healthy controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
62339396|NCT02498561|ACTIVE_COMPARATOR|normal weight-CP patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
62339397|NCT02498561|PLACEBO_COMPARATOR|normal weight-PH controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
62339398|NCT02727270||Parkinson's - High Stress *FULL NOT RECRUITING|Parkinson's disease patients with self-reported high strain/stress.
62339399|NCT02727270||Parkinson's - Low Stress *FULL NOT RECRUITING|Parkinson's disease patients with self-reported low strain/stress.
62697153|NCT02929732|EXPERIMENTAL|Healthy volunteers (CONTROL)|
62697154|NCT04652297|EXPERIMENTAL|HS-10356 single dose|Single oral dose of HS-10356 ascending dose
62139526|NCT01337141|EXPERIMENTAL|Interventional telematic|80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
62139527|NCT01337141|OTHER|Control|80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
62139528|NCT01540591|PLACEBO_COMPARATOR|control|Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
62139529|NCT01540591|EXPERIMENTAL|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
62697155|NCT04652297|PLACEBO_COMPARATOR|placebo single dose|Single oral dose of placebo ascending doses
62697156|NCT04652297|EXPERIMENTAL|HS-10356 multiple doses|Multiple oral doses of HS-10356 ascending doses
62697157|NCT04652297|PLACEBO_COMPARATOR|Placebo multiple doses|Multiple oral doses of placebo ascending doses
62495807|NCT03576053|EXPERIMENTAL|Histamine+cowhage+heat|
62495808|NCT03576053|EXPERIMENTAL|Histamine+cowhage+serotonin+pre-heating|
61944282|NCT00485433|EXPERIMENTAL|SKY0402 low dose|SKY0402 low dose given during hernia repair
62697158|NCT05229705|EXPERIMENTAL|Resistance exercise|Exercises will be completed in Kevin Shoemaker's (Co-I) exercise lab in the Health Sciences Building. Participants will use the programmable weight machines along with free weights to target the primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. We will record the number of sets completed and the load lifted for each exercise for each participant at every class.
62697159|NCT05229705|NO_INTERVENTION|Control (balance and tone exercise)|Exercises will be completed in the Health Science Exercise lab. These will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation (Liu-Ambrose et al., 2010; Liu-Ambrose et al., 2012; Nagamatsu et al., 2012; Nagamatsu et al., 2013).
62697160|NCT02956473|EXPERIMENTAL|Supine MRI|"* Standard MRI will be performed~* Supine MRI will be performed~* Participant will receive mammography and ultrasound~* Breast Radiologist will take a brief survey.~* Patients will undergo upfront surgery or receive Neoadjuvant Therapy per standard of care~* Standard of care will be performed"
61944283|NCT00485433|EXPERIMENTAL|SKY0402 Middle dose|SKY0402 middle dose given during hernia repair
61944284|NCT00485433|EXPERIMENTAL|SKY0402 High dose|SKY0402 high dose given during hernia repair
61944285|NCT01612104|EXPERIMENTAL|Psychological First Aid|Psychological material developed for children and adolescents, based on cognitive behavioral theory, used to structure therapeutic conversations and/or for self-help.
61944286|NCT00065208|EXPERIMENTAL|Reiki|Energy therapy
61944287|NCT00065208|SHAM_COMPARATOR|Pretend Reiki|
61944288|NCT00065208|OTHER|Rest / Guided Imagery|Rest for pre-surgery outcomes Guided Imagery for post-surgery outcomes
62139530|NCT03259984||Aim 1|This experiment will use the next generation sequencing reduced representation bisulfite sequencing to define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. The investigators will test the hypotheses that: (a) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (b) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (c) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance.
62339400|NCT02727270||Controls - High Stress *FULL NOT RECRUITING|Healthy controls (no neurological disease) with self-reported high strain/stress.
62339401|NCT02727270||Controls - Low Stress *FULL NOT RECRUITING|Healthy controls (no neurological disease) with self-reported low strain/stress.
62339402|NCT02727270||Huntington's - High Stress *FULL NOT RECRUITING|Huntington's disease patients and/or Huntington's disease gene carriers with self-reported high strain/stress.
62339403|NCT02727270||Huntington's - Low Stress *FULL NOT RECRUITING|Huntington's disease patients and/or Huntington's disease gene carriers with self-reported low strain/stress.
62339404|NCT02727270||Parkinson's Disease - ReEnrollment (COVID-19) *FULL NOT RECRUITING|Parkinson's disease patients that had previously completed the study.
62339405|NCT06012045|EXPERIMENTAL|Enhanced Cue Exposure Therapy|This is the experimental arm. Participants will receive the 6-session enhanced cue exposure therapy.
62339406|NCT06012045|ACTIVE_COMPARATOR|Behavioral Lifestyle Intervention|This is the active control arm. Participants will receive the 6-session behavioral lifestyle intervention.
62339407|NCT02222454|EXPERIMENTAL|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for pressure ulcers.
62339408|NCT05279989|EXPERIMENTAL|Seated Tai Chi Qigong|Participants will receive daily text messages and emails to distribute videos and record which sessions were completed. Participants can participate in 10-, 20-, or 30- min TCQ practices. Total weekly practice time will be recommended between 50-150 minutes/week (\~10-30 min/day on most days). A library of existing TCQ videos will be used. All videos will demonstrate seated practice with discussions on how to accommodate mobility limitations of various types.
62339409|NCT05279989|PLACEBO_COMPARATOR|Control|The control arm will receive text messages and emails with links to health information videos for the same time lengths as the intervention group. Existing video content will be reviewed and adapted to assure avoidance of topics that can impact outcome variables.
62495809|NCT03576053|PLACEBO_COMPARATOR|lidocaine and saline+heat|
62495810|NCT05259852|EXPERIMENTAL|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|
62495811|NCT05259852|ACTIVE_COMPARATOR|Food Assistance and Cessation Resources Navigation|
62495812|NCT03867773|EXPERIMENTAL|4-hour Time restricted feeding|4-h TRF subjects will consume food ad libitum between 3pm and 7pm (4-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 3pm (20-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
62697161|NCT00843960|ACTIVE_COMPARATOR|1|intervention group
61944289|NCT06146205|ACTIVE_COMPARATOR|Direct lateral approach|
61944290|NCT06146205|EXPERIMENTAL|Spaire approach|
61944291|NCT05590494|OTHER|Repair a partially torn rotator cuff|Subjects will undergo an ultrasonic tenotomy to repair a partially torn rotator cuff per standard of care as clinically indicated
61944292|NCT01967173|EXPERIMENTAL|Crossover sequence 1|Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
61944293|NCT01967173|EXPERIMENTAL|Crossover sequence 2|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
61944294|NCT01967173|EXPERIMENTAL|Crossover sequence 3|Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
61944295|NCT01967173|EXPERIMENTAL|Crossover sequence 4|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
61944296|NCT01967173|EXPERIMENTAL|Crossover sequence 5|Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
61944297|NCT01967173|EXPERIMENTAL|Crossover sequence 6|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
61944298|NCT01967173|EXPERIMENTAL|Crossover sequence 7|Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
62139531|NCT03259984||Aim 2|This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and (b) Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise.
62339410|NCT03201146|EXPERIMENTAL|Apatinib 750mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
62339411|NCT03201146|EXPERIMENTAL|Apatinib 500mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
62339412|NCT03201146|EXPERIMENTAL|Apatinib 250mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
62339413|NCT03201146|EXPERIMENTAL|Apatinib|Phase 2 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
62339414|NCT03201146|ACTIVE_COMPARATOR|AP or AC|Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum-based doublet chemotherapy, as the control group in the phase 2 study.
62339415|NCT04347317|ACTIVE_COMPARATOR|Low Intensity IMT|
62339416|NCT04347317|EXPERIMENTAL|High Intensity IMT|
62697162|NCT00843960|NO_INTERVENTION|2|control group
62697163|NCT06527677|EXPERIMENTAL|ANT3310 and Meropenem|"Participants with mild, moderate, or severe renal function impairment (Panel A, B, and D) and participants with normal renal function (Panel C and F) will receive 1 single dose of a combination of ANT3310 and meropenem.~Participants with End Stage Renal Disease (Panel E) will receive 2 times a single dose of a combination of ANT3310 and meropenem: one single dose during dialysis-free interval (off- dialysis) and one single dose on the day of dialysis (on-dialysis). The same dose will be given in both periods with a washout interval of at least 7 days between administrations."
61944299|NCT01967173|EXPERIMENTAL|Crossover sequence 8|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
62697164|NCT03584490|ACTIVE_COMPARATOR|Pen-and-paper format|Based on randomization, participants in this group will receive traditional pen-and-paper questionnaires about health.
61944300|NCT05467371|EXPERIMENTAL|Parenting Action Plan|The parenting action plan is a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby. Maternal caregivers will receive the booklet via mail and a trained research staff member will virtually go over the booklet using motivational interviewing strategies
61944301|NCT05467371|ACTIVE_COMPARATOR|Safe Kids Home Safety Checklist|The Safe Kids Home Safety Checklist is a handout with information that focuses on home safety for parents of young children. Maternal caregivers will receive the handout via mail and a trained research staff member will virtually go over the handout with the parent using educational strategies.
61944302|NCT02280070|ACTIVE_COMPARATOR|SOX (S-1 + L-OHP)|"S-1 (80 mg/m2, p.o.) (day1-14）, L-OHP (130 mg/m2)(day 1): repeated every 3 weeks until 4 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
62139532|NCT03259984||Aim 3|This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes, (b) There is altered methylation of genes involved in inflammation and cytoskeletal structure.
62139533|NCT05030415|EXPERIMENTAL|Ixekizumab|ixekizumab 80 mg injection, 160 mgs injected subcutaneously on week 0, 80 mgs injected subcutaneously every two weeks
62139534|NCT02386098|EXPERIMENTAL|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
62139535|NCT02386098|OTHER|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
62139536|NCT02386098|EXPERIMENTAL|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
62139537|NCT02386098|EXPERIMENTAL|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
62339417|NCT03157973|EXPERIMENTAL|Education intervention|
62339418|NCT03157973|NO_INTERVENTION|Standard of Care|
62339419|NCT04116476|EXPERIMENTAL|Moderate Hepatic Impairment|
62339420|NCT04116476|EXPERIMENTAL|Normal Healthy Matches|
62339421|NCT04116476|EXPERIMENTAL|Mild Hepatic Impairment|
62339422|NCT03105596|EXPERIMENTAL|Chidamide plus DICE regimen|Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) regimen
62339423|NCT00311181|EXPERIMENTAL|2.5/3.5/4.5 ms defibrillation waveform|
62339424|NCT05172193|EXPERIMENTAL|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|One booster dose 0.5 mL IM injection of SARS-COV-2 Vaccine (Vero Cell) Inactivated
62339425|NCT03629418|EXPERIMENTAL|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
62697165|NCT03584490|EXPERIMENTAL|Computerized Talking Touchscreen|"This group will receive the Computerized Talking Touchscreen intervention.~Based on randomization, participants in this group will receive a computerized talking touchscreen version of our health questionnaires, which allows the participant to have questions and answer choices read aloud to them by the computer."
61944303|NCT02280070|ACTIVE_COMPARATOR|mFOLFOX6|"L-OHP (85 mg/m2) and l-LV (200 mg/m2) by IV infusion drip for 2hr at day 1. 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards (day 1-2: repeated every 2 weeks until 6 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
62339426|NCT03629418|ACTIVE_COMPARATOR|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
62339427|NCT00037635|EXPERIMENTAL|AMG 073|
62339428|NCT00037635|PLACEBO_COMPARATOR|placebo|
62339429|NCT02938052|EXPERIMENTAL|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
62339430|NCT03258346|EXPERIMENTAL|Exercise and Pomegranate Juice|Exercise training with daily consumption of pomegranate juice containing polyphenols
62339431|NCT03258346|PLACEBO_COMPARATOR|Exercise and Placebo|Exercise training with daily consumption of pomegranate juice with polyphenols removed
62339432|NCT04414176||Case|Patients with coronary artery stenosis more than 75% (or left-main stenosis more than 50%) are defined as case group
62339433|NCT04414176||Control|Patients with normal angiography are considered as control group.
62339434|NCT04825145||Preeclamptic women|Pregnant women who is diagnosed with preeclampsia during anytime of pregnancy.
62339435|NCT04825145||Healthy pregnant women|Pregnant women without preeclampsia. Will be matched for body mass index, gestational age and age.
62339436|NCT04673136|EXPERIMENTAL|Colonoscopy assisted by GI-GENIUS|
62339437|NCT04673136|PLACEBO_COMPARATOR|Standard colonoscopy|
62339438|NCT04606654|EXPERIMENTAL|Handgrip strength training with Blood flow restriction|"Three sessions per week will be given to individual subject. and training will be with Blood flow restriction.~Subjects will be followed for two weeks for;~* Hand grip strength~* Forearm circumference"
62339439|NCT04606654|ACTIVE_COMPARATOR|Handgrip strength training without Blood flow restriction|"Three sessions per week will be given to individual subject and training will be without Blood flow restriction.~Subjects will be followed for two weeks for;~* Hand grip strength~* Forearm circumference"
62697166|NCT05380947|EXPERIMENTAL|Treatment sequence 1: R - T1 - T2 - T3|"Treatments:~R: TF1 fasted T1: NF fasted T2: NF fed T3: NF fasted + rabeprazole"
62697167|NCT05380947|EXPERIMENTAL|Treatment sequence 2: T1 - T3 - R - T2|
62697168|NCT05380947|EXPERIMENTAL|Treatment sequence 3: T2 - R - T3 - T1|
62339440|NCT01035242|EXPERIMENTAL|"association splitting"|Association splitting (6 sessions) delivered by psychologists.
62339441|NCT01035242|ACTIVE_COMPARATOR|cognitive remediation|CogPack training(6 sessions) delivered by either psychologists or psychology students at an advanced master level.
62339442|NCT03103906|EXPERIMENTAL|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
62339443|NCT03103906|OTHER|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
62339444|NCT00743600|EXPERIMENTAL|1|Patients with shoulder pain who were clinically referred to Ultrasound for evaluation
62339445|NCT00743600|ACTIVE_COMPARATOR|2|healthy volunteers who do not have shoulder pain
62339446|NCT06521957|EXPERIMENTAL|Cognitive Behavioral Therapy|Structured, short-term psychological treatment in the field of cognition that aims to shape adaptive thoughts and behavior.
62697169|NCT05380947|EXPERIMENTAL|Treatment sequence 4: T3 - T2 - T1 - R|
62697170|NCT06395935|NO_INTERVENTION|conventional group|In the control group, participants will be asked to complete written questionnaires in the outpatient clinic before surgery and at 1, 3, and 6 months after surgery. Based on the questionnaires, a clinician will provide a solution at an outpatient clinic. However, the Wecare® platform was not provided. .
61944304|NCT04686214|EXPERIMENTAL|study group|
62339447|NCT06521957|NO_INTERVENTION|Treatment As Usual|Administration of information and education regarding in vitro fertilization according to each patient's needs and current stage of treatment.
62339448|NCT01089582||AD patients|
62339449|NCT01367301|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.~RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16."
62339450|NCT06342388||Live Outreach|People in this cohort will receive a live outbound call from a Navigator
62339451|NCT06342388||Pre-recorded Outreach|People in this cohort will receive a pre-recorded outbound call providing a hotline number
61944305|NCT04686214|NO_INTERVENTION|control group|
62697171|NCT06395935|EXPERIMENTAL|Wecare group|In the intervention group, participants will be asked to use the Wecare® platform (Figure 2). The Wecare® platform administers QoL questionnaires, including the KOQUSS-40 and EORTC QLQ-C30, following gastrectomy to treat gastric cancer. Based on participants' responses, The platform automatically generates expert recommendations from gastric cancer specialists based on participants' responses according to the timing of surgery after gastrectomy. Furthermore, the Wecare® platform offers educational materials on gastric cancer to address participants' questions about the disease. Participants will be free to use the platform but will be asked to visit the Wecare® platform at least once a month and answer questionnaires. Participants will visit an outpatient clinic before surgery and at 1, 3, and 6 months after surgery.
62697172|NCT00839579|EXPERIMENTAL|4x4min|4x4minutes interval group
61944306|NCT04512950|ACTIVE_COMPARATOR|Ringer's lactate|administered as infusions or boluses as per the treating physician
61944307|NCT04512950|ACTIVE_COMPARATOR|0.9% Saline|administered as infusions or boluses as per the treating physician
61944308|NCT03047655|ACTIVE_COMPARATOR|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
61944309|NCT03047655|ACTIVE_COMPARATOR|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
61944310|NCT01497717|EXPERIMENTAL|Adalimumab, Behcet with arthritis|
61944311|NCT04875962|EXPERIMENTAL|Cohort 1 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
61944312|NCT04875962|EXPERIMENTAL|Cohort 2 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
61944313|NCT04875962|PLACEBO_COMPARATOR|Cohort 1 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
61944314|NCT04875962|PLACEBO_COMPARATOR|Cohort 2 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
61944315|NCT04032392|EXPERIMENTAL|Autologous γδT cells|"Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions.~Dose escalation subjects will receive 6 infusions with dose of γδT cells escalation from 1×10e9 to 6×10e9.~Constant dose subjects will have single infusion intravenously at a target dose of 1\~2×10e9 γδT cells."
61944316|NCT02197273|ACTIVE_COMPARATOR|Standard of care analgesia|"Total Hip Arthroplasty (THA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine~Injection into capsular tissue after placement of the acetabular component:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Knee Arthroplasty (TKA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc~Injection into posterior capsule of the knee:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Shoulder Arthroplasty (TSA):~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
61944317|NCT02197273|EXPERIMENTAL|Liposomal bupivacaine|"THA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue~TKA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue~TSA:~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
61944318|NCT06205823||T cell engager|
61944319|NCT06205823||Standard-of-care|
61944320|NCT05818098|EXPERIMENTAL|Intravascular Lithotripsy System|Subjects in experimental group will be treated with the Intravascular Lithotripsy System manufactured by Shanghai Microport Rhythm Co. Ltd.
61944321|NCT01810731|EXPERIMENTAL|Quadrivalent Influenza Vaccine (QIV)|"15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
61944322|NCT01810731|ACTIVE_COMPARATOR|Inactivated Polio Vaccine|A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
61944323|NCT01810731|EXPERIMENTAL|Double Dose QIV|"30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
61944324|NCT01197664|EXPERIMENTAL|Arm I (paricalcitol and chemoradiotherapy)|Patients receive paricalcitol PO daily. Patients also receive standard care chemoradiotherapy with fluorouracil PO.
61944325|NCT01197664|ACTIVE_COMPARATOR|Arm II (chemoradiotherapy)|Patients receive standard care chemoradiotherapy as in Arm I.
61944326|NCT05746494|EXPERIMENTAL|Active anodal tDCS first, then Sham tDCS|Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); sham stimulation (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing.
62139538|NCT02386098|OTHER|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
62139539|NCT03524755|EXPERIMENTAL|Training Group|Warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. A leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. All exercises were performed with 8-12 repetitions and 3 sets. 3 training sessions (30min for each session) per week for during the course of radiotherapy (\~6 weeks).
62139540|NCT03524755|NO_INTERVENTION|Control Group|The control group received usual care.
62339452|NCT06342388||No outreach|People in this cohort will not receive outreach of any kind
62339453|NCT04629612|EXPERIMENTAL|Regional anesthesia|Regional block applied according to surgical area
62339454|NCT04629612|NO_INTERVENTION|No Regional anesthesia|No regional anesthesia applied
62339455|NCT01717664|EXPERIMENTAL|RHB-104|5 RHB-104 capsules administered orally BID
62495813|NCT03867773|NO_INTERVENTION|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits. Controls will visit the research center at the same frequency as the TRF groups (for outcome measurements).
61944327|NCT05746494|SHAM_COMPARATOR|Sham tDCS first, then Active anodal tDCS|Sham tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing Intervention.
61944328|NCT04529915||Lung cancer|
61944329|NCT04529915||Healthy|
61944330|NCT04899102|EXPERIMENTAL|Time-Restricted, Intermittent Fasting Group|Special type of diet for 6 weeks, called time-restricted, intermittent fasting.
61944331|NCT06078410||TA-BSM|patients received transapical beating-heart septal myectomy
62697173|NCT00839579|EXPERIMENTAL|1x4min|
62697174|NCT02772302|EXPERIMENTAL|Patients|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
61944332|NCT06078410||Cardiac surgery involving left heart operation|patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect
61944333|NCT03898258||neurogenic bladder|individuals with chronic (≥12 months) neurogenic lower urinary tract dysfunction due to spinal cord injury (SCI)
61944334|NCT01136031|EXPERIMENTAL|Paclitaxel and irinotecan|
61944335|NCT01127035|EXPERIMENTAL|SLIT|sublingual immunotherapy biologically standardized
61944336|NCT01127035|PLACEBO_COMPARATOR|placebo|same preparation of SLIT without the allergen
61944337|NCT02008175|EXPERIMENTAL|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
61944338|NCT00860288|EXPERIMENTAL|Vildagliptin Dose 1|
61944339|NCT00860288|EXPERIMENTAL|Vildagliptin Dose 2|
61944340|NCT00860288|PLACEBO_COMPARATOR|Placebo|
61944341|NCT00860288|ACTIVE_COMPARATOR|Sitagliptin|
61944342|NCT05454501|ACTIVE_COMPARATOR|Exercise Training|8-week real-time online exercise training will be provided. The content of the training will be aerobic based exercises, strength and flexibility exercises with warm up and cool down phases.
61944343|NCT05454501|ACTIVE_COMPARATOR|Patient Education|Patients will be given face-to-face education about their disease, the importance of physical activity and how to do it safely. They will be followed up with information leaflets and weekly phone calls.
61944344|NCT03731845|EXPERIMENTAL|patient|
61944345|NCT00760500||1|
61944346|NCT06204978|OTHER|scFOS Dose 1|scFOS 10g
62139541|NCT05516745|EXPERIMENTAL|arm with intervention (AioCare spirometry)|50 participants with DMD aged 7-17 years, subjected to home electronic monitoring
62339456|NCT05041452||Noncirrhotic portal hypertension (NCPH)|Patients with non-cirrhotic portal hypertension (NCPH) with pre-sinusoidal (e.g., porto-sinusoidal vascular disease, portal vein obstruction, congenital hepatic fibrosis, biliary diseases,), sinusoidal (e.g., sinusoidal destruction in the setting of acute hepatic injury, inflammatory or toxic fibrosis, non-alcoholic steatohepatitis), or post-sinusoidal causes (Budd-Chiari syndrome, sinusoidal obstruction syndrome).
62339457|NCT05041452||Cirrhotic portal hypertension|Patients with cirrhosis and portal hypertension.
62697175|NCT02772302|EXPERIMENTAL|Healthy Controls|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
62697176|NCT02892279|EXPERIMENTAL|Diesel exhaust exposure|A single arm study in which first a baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute diesel exhaust will start.
61944347|NCT06204978|OTHER|scFOS Dose 2|scFOS 20g
61944348|NCT05375708|ACTIVE_COMPARATOR|Systemic maintenance therapy|
62697177|NCT06511778|NO_INTERVENTION|No Application of Hemoblast Hemostatic Agent|"Patients who are randomized to control will not receive application of the Hemoblast hemostatic agent during on pump sternotomy surgery."
61944349|NCT05375708|EXPERIMENTAL|Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)|
61944350|NCT02214407|EXPERIMENTAL|ARM A: DECITABINE (DACOGEN)|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days.~Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.~Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L."
61944351|NCT02214407|EXPERIMENTAL|ARM B: HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains \> 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by \> 30 X 109/L (if initially below 100 X 109L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation."
61944352|NCT05869760||Observational Group|Children will be followed from 4-24 months of age.
61944353|NCT03993132||Patients with type 2 diabetes|
61944354|NCT02173873|EXPERIMENTAL|one injection of ziv aflibercept intravitreal route|Intervention: Inject 0.05 ml of zaltrap into the vitreous of blind eyes with various diseases (AMD, CRVO) and monitor vision and OCT 1 day and 1 week after injection
61944355|NCT04402060|EXPERIMENTAL|180 mg APL-9 IV plus SOC|
61944356|NCT04402060|PLACEBO_COMPARATOR|Isotonic saline plus SOC|
62139542|NCT05516745|EXPERIMENTAL|arm with intervention (AioCare spirometry with telerehabilitation)|50 participants with DMD aged 7-17 years, subjected to home electronic monitoring with the AioCare device and pulmonary rehabilitation exercises
62139543|NCT05516745|EXPERIMENTAL|arm with intervention (telerehabilitation)|50 participants with DMD aged 7-17 years, subjected to pulmonary rehabilitation exercises
62139544|NCT05516745|NO_INTERVENTION|control arm (no intervention)|50 participants with DMD aged 7-17 years, subject to a standard of care
62339458|NCT02467647|EXPERIMENTAL|A|Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
62339459|NCT02467647|ACTIVE_COMPARATOR|B|Arm B: Thalidomide 100mg oral once per day for 6 months
62339460|NCT02056535|NO_INTERVENTION|Screened Only|Screened only and met criteria for eligibility for study
62339461|NCT02056535|NO_INTERVENTION|Screened and Assessed|Screened as eligible for the study and received baseline assessment
62339462|NCT02056535|ACTIVE_COMPARATOR|Intervention|Screened eligible, received baseline assessment and intervention
62339463|NCT03684291||Group V|The patients in this group are ventilated using VCV (Volume Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute, I/E ratio: 1/2, PEEP not applied)
62495814|NCT03867773|EXPERIMENTAL|6-hour Time restricted feeding|6-h TRF subjects will consume food ad libitum between 1pm and 7pm (6-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 1pm (18-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
62495815|NCT02658435|EXPERIMENTAL|Tafenoquine 300 milligram (mg) single dose|Participants will receive single dose of TQ (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
62495816|NCT02658435|PLACEBO_COMPARATOR|Matched Placebo 300mg single dose|Participants will receive single dose of matched placebo (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
62495817|NCT00158925|EXPERIMENTAL|EASYTRAK EPI Lead|Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.
62495818|NCT00730652|EXPERIMENTAL|MDX1411|An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.
62495819|NCT04348955||women with adjuvant breast cancer|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
61944357|NCT02210650|OTHER|Symptomatic stone removal|Group 1 will receive the standard treatment of having only the symptomatic stone removed
61944358|NCT02210650|OTHER|Asymptomatic kidney stones and symptomatic stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the symptomatic stone
61944359|NCT03110926|EXPERIMENTAL|Induction Chemotherapy /Chemoradiation|mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles - Carboplatin AUC 2mg/mL/min, Paclitaxel 50 mg/m2 and radiation therapy.
61944360|NCT05412095||Cardiology patient|Patient requiring cardiac surgery with bypass
61944361|NCT05412095||Pneumology patient|Patient requiring lung surgery with resection of at least one lobe
61944362|NCT01248208|EXPERIMENTAL|FluMist (LAIV) group|FluMist influenza vaccine 0.2 mL intranasal vaccine once
62139545|NCT04995588|OTHER|Blood test|Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes
62495820|NCT05772858|EXPERIMENTAL|Family Therapy Training and Implementation Platform (FTTIP)|Participants will be trained for 20 hours on an online platform practicing family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
62495821|NCT05772858|ACTIVE_COMPARATOR|Traditional in person Training as Usual|Participants will attend 20 hours of a traditional in person training learning about the family therapy evidenced based treatment.
62495822|NCT05772858|EXPERIMENTAL|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|All of the 150 families will receive Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format.
62697178|NCT06511778|ACTIVE_COMPARATOR|Application of Hemoblast Hemostatic Agent|"Patients who are randomized to treatment will receive application of the Hemoblast hemostatic agent during on pump sternotomy surgery."
62697179|NCT01676870|EXPERIMENTAL|1x4 aerobic interval training|1x4min aerobic interval training (1-AIT), 3 times a week
62697180|NCT01676870|EXPERIMENTAL|4x4 aerobic interval training|4x4min aerobic interval training (4-AIT), vigorously exercise according to today's guidelines, 3 times a week
61944363|NCT01248208|ACTIVE_COMPARATOR|Flu shot (TIV) group|"Patients 6 months to 2 yrs or \> 49 years or WITH a history of asthma symptoms / treatment within the past 12 months will receive intramuscular influenza vaccination. History/Treatment of asthma in the past 12 months is defined as follows:~1. wheezing in the past 12 months~2. use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months~3. emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months."
61944364|NCT03530358|EXPERIMENTAL|Technology-aided rehabilitation|The technology-aided upper limb rehabilitation include reinforced feedback in virtual environment (RFVE), or robotic therapy.
61944365|NCT03530358|ACTIVE_COMPARATOR|Conventional rehabilitation|The conventional upper limb rehabilitation program will be based on traditional rehabilitation techniques aimed at restoring upper limb motor functions.
61944366|NCT02046902||Heart disease|Adults with a diagnosis of coronary artery disease and may have had a percutaneous coronary intervention.
61944367|NCT02046902||Healthy adults|Adults without a diagnosis of coronary artery disease. Focus groups will be held.
61944368|NCT06238271|EXPERIMENTAL|UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
62139546|NCT03507972|OTHER|Ankle ultrasound & ankle MRI|Ankle ultrasound performed on the day of emergency consultation member MRI (without injection of contrast products) performed within 7 days following the trauma
62139547|NCT06455683||Glaucoma|Glaucoma or Ocular Hypertension patients with sub-optimal intraocular pressure (IOP) on multiple topical medications
62139548|NCT01333007||Cohort|
62139549|NCT02493166|ACTIVE_COMPARATOR|patients with Multiple sclerosis Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
62495823|NCT05772858|EXPERIMENTAL|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|Agency leaders assigned to this condition will complete an online assessment of agency readiness, participate in a webinar and live discussion, complete an online meeting with leaders and clinical supervisors
62495824|NCT05772858|ACTIVE_COMPARATOR|Agency Engagement and Orientation as Usual|Agency leaders assigned to this condition will receive a traditional engagement of leadership at their agency including a description of study procedures and engagement with study team.
62495825|NCT05436626|EXPERIMENTAL|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without controlling the abdominal sepsis
62495826|NCT05436626|EXPERIMENTAL|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury after controlling the abdominal sepsis
62495827|NCT05436626|ACTIVE_COMPARATOR|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury a
62495828|NCT01144845||Thoracic surgical patients|Patients with pulmonary malignancies
62339464|NCT03684291||Group P|The patients in this group are ventilated using PCV-VG (Volume Guaranteed Pressure Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute (EtCO2 kept between 35-40 mmHg), Pressure limit: 30 cm H2O, I/E:1/2, PEEP not applied)
62339465|NCT02413619|ACTIVE_COMPARATOR|Start cataract|Patients start having cataract surgery. After one month they undergo vitrectomy
62339466|NCT02413619|ACTIVE_COMPARATOR|start vitrectomy|Patients start having vitrectomy. After one month they undergo cataract surgery.
62339467|NCT02413619|ACTIVE_COMPARATOR|combined surgery|Combined cataract surgery and vitrectomy at the same time
62339468|NCT05509218|EXPERIMENTAL|Personalized feedback plus incentive|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided. Participants in this group will receive $1 per day for submitting their daily survey.
62339469|NCT05509218|EXPERIMENTAL|Personalized feedback without incentive|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided. Participants in this group will NOT receive $1 per day for submitting their daily survey.
62339470|NCT05509218|NO_INTERVENTION|Control|Participants in this arm will only complete baseline and follow-up surveys.
62339471|NCT02997449||NSCLC, SABR, nodal staging|Patients with a clinical or pathological diagnosis of Non-Small Cell Lung Cancer (NSCLC), and who are medically inoperable or refuse surgery, are eligible if Stereotactic ablative radiotherapy (SABR) is recommended by a multi-disciplinary tumor board. All patients undergo complete mediastinal and hilar staging procedure (EBUS+EUS-B). Pre endoscopy imaging data will be compared with endosonography data.
62339472|NCT06281782|ACTIVE_COMPARATOR|topical retinoid and platelet-rich plasma (PRP) group|
62339473|NCT06281782|ACTIVE_COMPARATOR|topical retinoid group|
62339474|NCT03147339|EXPERIMENTAL|AGEs restricted diet|Low calorie diet + AGEs restricted diet
62339475|NCT03147339|NO_INTERVENTION|control|Low calorie diet
62339476|NCT04765137|EXPERIMENTAL|Atorvastatin 40 mg|Participants receive 40 mg atorvastatin orally daily in the evening.
62339477|NCT06281145|EXPERIMENTAL|Standard of care + HRV biofeedback intervention|"Experimental: Heart-rate variability (HRV) biofeedback intervention + standard of care Deep paced breathing with the HRV monitoring performed three times a day for seven minutes during three months with standard of care.~Cohort A- breast cancer, Cohort B- colon cancer"
62339478|NCT06281145|NO_INTERVENTION|Standard of care|Cohort A- neoadjuvant chemotherapy +/- targeted therapy +/- immunotherapy defined standard of care in current European Society For Medical Oncology (ESMO) guideline in the defined disease subtype Cohort B- adjuvant chemotherapy +/- targeted therapy +/- immunotherapy defined standard of care in current ESMO guideline in the defined disease subtype
62339479|NCT03177980||Fentanyl|All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
62339480|NCT03177980||Fentanyl and Clonidine|Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
62339481|NCT03166865|EXPERIMENTAL|Intervention group|Intraarticular injection of 2×10\~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
62339482|NCT03166865|OTHER|Control group|Intraarticular injection of hyaluronic acid
62339483|NCT05509153|EXPERIMENTAL|NAC|1g N-Acetylcysteine capsules, taken orally twice a day.
62339484|NCT05509153|PLACEBO_COMPARATOR|Placebo|Coated Placebo capsules, taken orally twice a day
62339485|NCT04501198|EXPERIMENTAL|Moxibustion with characteristic lifestyle intervention of TCM|Participants will receive moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine.In this study, xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course, and the intervention of Xiusheng Decoction and Traditional exercises will last for 8 weeks.While the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
62339486|NCT04501198|EXPERIMENTAL|moxibustion with lifestyle intervention|Participants will receive moxibustion combined with lifestyle intervention. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course,while the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
62339487|NCT04501198|OTHER|lifestyle intervention|Participants will receive lifestyle intervention which includes modern dietary exercise modifications. Participants will receive this treatment for a 8-session treatment course and 4-session follow-up course.
62339488|NCT02159469|EXPERIMENTAL|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
62339489|NCT00914602|ACTIVE_COMPARATOR|Treatment Period A|Treatment Period A: Sinemet® 25-100 treatment After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
62339490|NCT00914602|EXPERIMENTAL|Treatment Period B|Multiple-Dose XP21279 (with Lodosyn®) treatment. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
62697181|NCT01676870|ACTIVE_COMPARATOR|traditional moderate training|traditional moderate training (CME), moderate exercise at least 30 min, 5 days a week or more, according to today's guidelines
62339491|NCT00516633|NO_INTERVENTION|CG|The control group had regular individual information and support in connection with ordinary clinical follow-ups
62339492|NCT00516633|EXPERIMENTAL|IG|The intervention group had extra support and information in the form of four group discussions with parents
62339493|NCT03587480|OTHER|TME+LLND group|Total Mesorectal Excision plus Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.
62339494|NCT03587480|OTHER|TME+nCRT group|Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.
62339495|NCT01761721||RAHL|Women suspected of endometrial cancer planned to be treated by robotic assisted laparoscopy hysterectomy
62697182|NCT05197842|EXPERIMENTAL|Group A|BDB-001 injection low dose plus reduced dose glucocorticoids in combination with cyclophosphamide
62339496|NCT06525545|EXPERIMENTAL|Mobilizzazione Precoce|early motion of the ankle
62495829|NCT02929927|EXPERIMENTAL|Control group|Rubber dam isolation, tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, then take the sample again, drying the canal and fill the canal with a commercial calcium hydroxide-based paste. After 2 weeks, the canals were filled with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
61944369|NCT06260813|EXPERIMENTAL|PTTD patients (PTTD I, II and III)|75 patients with PTTD (25 patients in Stage I, 25 patients in Stage II, 25 patients in Stage III)
62339497|NCT06525545|ACTIVE_COMPARATOR|Immobilizzazione Con Stivaletto Gessato|standard treatment
62339498|NCT06495307|EXPERIMENTAL|Treatment|
62339499|NCT01998269||Adult patients with diabetes and hypertension|
62339500|NCT03529136|EXPERIMENTAL|MSC group 1|Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
62339501|NCT03529136|EXPERIMENTAL|MSC group 2|Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).
62339502|NCT03529136|EXPERIMENTAL|Control group|Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up.
62339503|NCT02958397|EXPERIMENTAL|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62339504|NCT00302718|EXPERIMENTAL|Physician-level incentives|Examines the effect of physician-level financial incentives on hypertension quality of care
62339505|NCT00302718|EXPERIMENTAL|Practice-level incentives|Examines the effect of practice-level financial incentives on hypertension quality of care
62339506|NCT00302718|EXPERIMENTAL|Physician- and practice-level incentives|Examines the effect of physician- and practice-level financial incentives on hypertension quality of care
62339507|NCT00302718|NO_INTERVENTION|No incentives (control)|Physician participants in this arm received only audit and feedback performance reports as did the participants in the intervention arms.
62339508|NCT01665521|EXPERIMENTAL|HEART Pathway|The HEART Pathway will be used for real time clinical decision making. Physicians will receive care recommendations according to the HEART Pathway, based on HEART score and serial cardiac biomarkers. This will help physicians identify low-risk patients for early discharge with no objective cardiac testing.
62339509|NCT01665521|NO_INTERVENTION|Usual Care|Conventional Care cardiac testing. Patients will undergo cardiac testing as determined by their treating physicians.
62339510|NCT00539253|OTHER|Gadobenate Dimeglumine (Multi Hance)|If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
62339511|NCT03247205|EXPERIMENTAL|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
62495830|NCT02929927|EXPERIMENTAL|Experimental group|Rubber dam isolation，tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO for 1 min, then 17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, drying the canal, aPDT, then take the sample again. then dried the canals and filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
62697183|NCT05197842|EXPERIMENTAL|Group B|BDB-001 injection high dose plus reduced dose glucocorticoids in combination with cyclophosphamide
61944370|NCT06260813|EXPERIMENTAL|Healthy control group|25 healthy volunteers
62139550|NCT02493166|ACTIVE_COMPARATOR|Healthy volontiers Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
62139551|NCT01267643|EXPERIMENTAL|Alefacept|
62339512|NCT03363412|EXPERIMENTAL|Underdilated TIPS|Patients will be treated with PTFE-covered stent grafts balloon-dilated to less than 8 mm.
62139552|NCT05868304|ACTIVE_COMPARATOR|Group 1 - Standard strengthening group (no BFR)|"Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
62339513|NCT03625427|PLACEBO_COMPARATOR|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
62339514|NCT03625427|EXPERIMENTAL|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
62339515|NCT03625427|EXPERIMENTAL|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
62339516|NCT03873402|EXPERIMENTAL|Nivolumab + ipilimumab|
62339517|NCT03873402|EXPERIMENTAL|Nivolumab + ipilimumab placebo|
62339518|NCT03615469|ACTIVE_COMPARATOR|Neuromusclar electrical stimulation|"NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time."
61944371|NCT05265715|EXPERIMENTAL|Low AGE dietary intervention|"* Patients will complete a food frequency questionnaire, \& if found to have a high AGE diet at baseline, will then begin the study the 24-week low AGE dietary intervention. Patients will complete a 3 day food record prior to receiving remotely delivered education on AGEs on how to adhere to a low AGE diet by the study dieticians prior to starting. This session will provide education on dietary AGE \& how to prepare \& choose low AGE meals~* Subsequent sessions with the dieticians will be conducted remotely \& will be 30-60 minutes in duration, with the exception of sessions scheduled for weeks when a study blood draw is required, when visits with the dietician may occur in person. These sessions will occur at the following schedule: weekly during the first 2 months (8 sessions), every other week during the next 2 months (4 sessions, aka step down sessions), monthly for the remaining 2 months (2 sessions)~* 3 day food records will be collected at 12 \& 24 weeks, in addition to baseline."
61944372|NCT06283524||Single cohort of MS patients with EDSS 1.0-8.0|Confirmed diagnosis of MS with an EDSS score ranging from 1.0 and 8.0.
61944373|NCT02697487||No Treatment|This is a longitudinal observational study involving individuals who are depressed, depressed with other comorbidities and non-depressed individuals. The primary aim of this study is to describe the longitudinal course of illness and real world treatment outcomes for depressed patients receiving routine care from their providers. Health outcomes and biospecimens along with the functional and economic burden of depression will be characterized and compared amongst three groups: (1) depressed patients, (2) depressed patients with comorbid illnesses, and (3) non-depressed patients.
62339519|NCT03615469|SHAM_COMPARATOR|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation
62697184|NCT05197842|ACTIVE_COMPARATOR|Group C|Standard dose glucocorticoids in combination with cyclophosphamide
62697185|NCT05197842|EXPERIMENTAL|Group D|BDB-001 injection low dose in combination with cyclophosphamide
62697186|NCT05197842|EXPERIMENTAL|Group E|BDB-001 injection high dose in combination with cyclophosphamide
61944374|NCT02680535|EXPERIMENTAL|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to ultrasound-guided laser irradiation using a FDA cleared laser and an interstitial optical fiber.
61944375|NCT02488161||Patients with colorectal cancer|One cohort of patients with colorectal cancer, studied before the intervention, and one month, one year, two years, three years and five years after.
62139553|NCT05868304|EXPERIMENTAL|Group 2 - Low-load BFR group|"Participants will warm up on a stationary bike for 5 minutes BFR will be applied to non-dominant limb (dominant limb is determined as the preferred leg for kicking a ball)~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
62139554|NCT03590899||Healthy patients|Healthy volunteers without retinal disease, glaucoma, previous ocular surgery, laser photocoagulation, or optical media opacities that would disturb imaging.
62697187|NCT04347967|EXPERIMENTAL|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
61944376|NCT02248831|EXPERIMENTAL|Doppler ultrasound|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
61944377|NCT01415895|EXPERIMENTAL|ATNC05 - a study drug capsule|Naltrexone and Clonidine Combination (ATNC05)
61944378|NCT01415895|PLACEBO_COMPARATOR|placebo|
61944379|NCT04365868|EXPERIMENTAL|belapectin 2 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
61944380|NCT04365868|EXPERIMENTAL|belapectin 4 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
61944381|NCT04365868|PLACEBO_COMPARATOR|Placebo|"Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)"
61944382|NCT04977921|EXPERIMENTAL|Elsiever clinical skill platform|
61944383|NCT04234074|OTHER|Breathing test or sleep study|infants undertaking cardiorespiratory polysomnography
61944384|NCT05246397|EXPERIMENTAL|Cardiac surgery patients|Patients undergoing cardiac surgery
61944385|NCT03014557||WATCHMAN|subjects with non-valvular atrial fibrillation intended to be implanted with a WATCHMAN left atrial appendage closure device
61944386|NCT04067752|EXPERIMENTAL|High Dialysate Na|high dialysate sodium concentration (138 mEq/L)
61944387|NCT04067752|ACTIVE_COMPARATOR|Low Dialysate Na|Low dialysate sodium concentration (132 mEq/L)
61944388|NCT02231918|EXPERIMENTAL|MIRAPEX® - low|
61944389|NCT02231918|EXPERIMENTAL|MIRAPEX® - medium|
62139555|NCT02304614||Group 1|Patients who have undergone Breast conserving Therapy
62339520|NCT01042613|OTHER|Group A|Research participants are randomly assigned into group A (Accuvein AV300 assisted intravenous catheter insertion)
62139556|NCT06642584|EXPERIMENTAL|Sequence 1: Semaglutide J then Semaglutide L|Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide L in treatment period 2.
62139557|NCT06642584|EXPERIMENTAL|Sequence 2: Semaglutide L then Semaglutide J|Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide L then semaglutide J in treatment period 2.
62339521|NCT01042613|OTHER|Group B|(standard technique of insertion of the intravenous cannula)
62339522|NCT04486963|EXPERIMENTAL|Sanhuangjingshimingwan group|Sanhuangjingshimingwan,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
62339523|NCT04486963|PLACEBO_COMPARATOR|Sanhuangjingshimingwan Placebo group|Sanhuangjingshimingwan placebo,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
62339524|NCT01469806||1 - PFJ|Patients who require primary partial knee arthroplasty of the patello-femoral joint.
62339525|NCT03802838|ACTIVE_COMPARATOR|Acupuncture|Acupuncture+Amisulpride
62339526|NCT03802838|OTHER|Amisulpride|Amisulpride only.
62697188|NCT02699411|ACTIVE_COMPARATOR|dry needling|Dry needling on the vastus is performed in patients undergoing ACL fortnight after the intervention and then evaluated. REL dry needling while supplies last twenty insertions before treatment, at midnight, a week and five weeks.
61944390|NCT02231918|EXPERIMENTAL|MIRAPEX® - high|
61944391|NCT05249101|EXPERIMENTAL|Ivaltinostat plus Capecitabine|Ivaltinostat plus Capecitabine
61944392|NCT05249101|ACTIVE_COMPARATOR|Capecitabine Monotherapy|Capecitabine Monotherapy
61944393|NCT02151695|ACTIVE_COMPARATOR|Panretinal photocoagulation|
61944394|NCT02151695|EXPERIMENTAL|Aflibercept intravitreal injections|
61944395|NCT01784757|EXPERIMENTAL|ODM-201 Tablet A|ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
61944396|NCT01784757|EXPERIMENTAL|ODM-201 Tablet B|ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
61944397|NCT03939754||Adult attendance to Dedalo activities|Adult attended one Dedalo's activity
61944398|NCT03939754||Adult living in Vercelli|Adult aged 40-75
61944399|NCT06450158|EXPERIMENTAL|Experimental Group I|Participants in this group will be between the ages of 7 and 18 years old and have a diagnosis of cerebral palsy. Amadeo will be used to train the more-affected hand of participants in this group. The training will last approximately 1 hour per day for 14 successive days. Participants will be asked to first do active finger and passive finger moving, then receive haptic vibration, and finally play interactive games.
61944400|NCT06450158|NO_INTERVENTION|Control Group I|Participants in this group will be between the ages of 7 and 18 years old and have a diagnosis of cerebral palsy.
61944401|NCT06450158|EXPERIMENTAL|Experimental Group II|Participants in this group will be between the ages of 7 and 18 years old and have no history of neurological disorder or brain injury. Amadeo will be used to train the non-dominant hand of participants in this group. The training will last approximately 1 hour per day for 14 successive days. Participants will be asked to first do active finger and passive finger moving, then receive haptic vibration, and finally play interactive games.
61944402|NCT06450158|NO_INTERVENTION|Control Group II|Participants in this group will be between the ages of 7 and 18 years old and have no history of neurological disorder or brain injury.
61944403|NCT06149026|NO_INTERVENTION|Control group|The control group will receive written, detailed, and standardized instructions on nutritional recommendations and physical activity at visit 1. Patients will have follow-up evaluations by a physician to reinforce adherence and make necessary adjustments for compliance with nutritional requirements. Nutritional intake reminder surveys will be conducted during the last 24 hours (E24H) at weeks 0, 4, 8 and 12.
61944404|NCT06149026|EXPERIMENTAL|Intervention group|Intervention group consisting of physical therapy guided by a kinesiologist for 10 sessions during which the patient will be trained to maintain physical activity three times a week. In addition, patients will be evaluated by a nutritionist who will give specific indications regarding the quality, quantity, and timing of food intake, as well as the daily frequency of food consumption. Patients will have two follow-ups by a nutritionist (week 4 and 8) to check adherence and make the necessary adjustments to meet nutritional requirements. Nutritional intake reminder surveys will be conducted during the last 24 hours (E24H) at weeks 0, 4, 8 and 12.)
62139558|NCT06642584|EXPERIMENTAL|Sequence 3: Semaglutide J then Semaglutide M|Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide M in treatment period 2.
62139559|NCT06642584|EXPERIMENTAL|Sequence 4: Semaglutide M then Semaglutide J|Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide M then semaglutide J in treatment period 2.
62139560|NCT06642584|EXPERIMENTAL|Sequence 5: Semaglutide J then Semaglutide N|Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide N in treatment period 2.
62139561|NCT06642584|EXPERIMENTAL|Sequence 6: Semaglutide N then Semaglutide J|Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide N then semaglutide J in treatment period 2.
62139562|NCT02191891|EXPERIMENTAL|BI 836845 + afatinib|BI 836845 low or high dose (weekly IV infusion), afatinib 30mg or 40mg (once daily oral dosing)
62139563|NCT01280513|EXPERIMENTAL|High Protein intake|
62139564|NCT01280513|EXPERIMENTAL|Low Protein intake|
62697189|NCT02699411|ACTIVE_COMPARATOR|Stability and propioception|Proprioception and stability exercises in patients undergoing ACL fortnight after the intervention and then evaluates performed before treatment, at midnight, a week and five weeks.
61944405|NCT01103336|EXPERIMENTAL|Nicorandil in saline|
61944406|NCT01103336|PLACEBO_COMPARATOR|saline|
61944407|NCT01604915|PLACEBO_COMPARATOR|Group R|Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered.
61944408|NCT01604915|EXPERIMENTAL|Group DR|Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
61944409|NCT03519971|EXPERIMENTAL|Arm 1: Durvalumab + platinum-based chemotherapy and radiation|"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~* cisplatin/etoposide~* carboplatin/paclitaxel~* pemetrexed/cisplatin~* pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
62339527|NCT03777722|EXPERIMENTAL|Aim 1: Active Intervention then Placebo|Tailored Lighting intervention (TLI). The active TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The active lighting intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the placebo control intervention for 8 weeks.
62697190|NCT01533987|EXPERIMENTAL|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
62697191|NCT01533987|PLACEBO_COMPARATOR|Placebo|The placebo consists of microcrystalline cellulose,dicalcium phosphate, magnesium stearate, and FD \& C yellow #6.
62139565|NCT05706246|OTHER|Children with perioperative hypersensitivity|Children with perioperative hypersensitivity
62139566|NCT06698562|ACTIVE_COMPARATOR|Group IIa Tell- Show-Do|Placebo topical anesthesia + LLLT + Local anesthesia
62139567|NCT06698562|PLACEBO_COMPARATOR|Group IIb Tell- Show-Do|Topical anesthesia + placebo LLLT + Local anesthesia
62139568|NCT06698562|ACTIVE_COMPARATOR|Group Ia Distraction (VR)|Placebo topical anesthesia + LLLT + Local anesthesia
62139569|NCT06698562|PLACEBO_COMPARATOR|Grup Ib Distraction (VR)|Topical anesthesia + placebo LLLT + Local anesthesia
62697192|NCT06368206|OTHER|Aktiia G2C and references/ comparators for Blood Pressure and Pulse Rate monitoring|All study participants will test the investigational device (Aktiia G2C) and other marketed devices for blood pressure and pulse rate measurements (Aktiia Bracelet G2, Double auscultation, oscillometric monitors, finger pulse oximeter).
62339528|NCT03777722|EXPERIMENTAL|Aim 1: Placebo Intervention then Active|The placebo lighting intervention is designed to have no effect on the circadian system. The control intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the active tailored lighting intervention for 8 weeks.
62697193|NCT01483170|EXPERIMENTAL|Fexinidazole|
62697194|NCT01483170|PLACEBO_COMPARATOR|Placebo fexinidazole|
62697195|NCT06405269||Adjuvant chemotherapy group（Hormone receptor negative breast cancer）|Patients receiving adjuvant chemotherapy after surgery for hormone receptor-negative breast cancer
62697196|NCT06405269||Adjuvant chemotherapy group（Hormone receptor positive breast cancer）|Patients receiving adjuvant chemotherapy after surgery for hormone receptor-positive breast cancer
61944410|NCT03519971|PLACEBO_COMPARATOR|Arm 2: Placebo + platinum-based chemotherapy and radiation|"Placebo in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~* cisplatin/etoposide~* carboplatin/paclitaxel~* pemetrexed/cisplatin~* pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment."
61944411|NCT05602350|EXPERIMENTAL|Treatment|Survey respondents will self-administer three survey sections in a tablet: (1) antisocial behaviors, (2) depression symptoms, and (3) anxiety symptoms
61944412|NCT05602350|PLACEBO_COMPARATOR|Control|Survey respondents will have the survey questions on the three sections administered by an enumerator
62339529|NCT01429792|EXPERIMENTAL|Single Arm|
62339530|NCT01794481|NO_INTERVENTION|Usual Care|Participants allocated to usual care will receive their usual treatment program which will include dietician counseling as needed. As part of standardized care, participants will not be encouraged to begin a new exercise program(patients needing physical therapy at time of enrollment will be excluded.
62339531|NCT01794481|EXPERIMENTAL|Resistance Exercise Training|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
62339532|NCT03864718||complex anal fistula|
62339533|NCT01575405|EXPERIMENTAL|Rectal-specific formulation (RF) stage|During this stage, participants will receive seven rectally-administered doses of the rectal-specific formulation (RF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
62339534|NCT01575405|ACTIVE_COMPARATOR|Vaginal formulation (VF) stage|"During this stage, only one exposure to the vaginal formulation (VF) will be administered (as the seventh dose in the stage), but it will be coupled with six preceding exposures to the Universal HEC Placebo Gel to balance it out against the other three stages in the study.~First and last doses will be administered in clinic, and after the administration of the last dose, various specimens will be collected, including blood, vaginal and rectal fluid, and endoscopic biopsies. Additional blood and fluids will be collected at 2, 4, and 24 hours post seventh dose administration."
62339535|NCT01575405|ACTIVE_COMPARATOR|Reduced Glycerin Vaginal Formulation (RGVF) stage|During this stage, participants will receive seven rectally-administered doses of the reduced glycerin vaginal formulation (RGVF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
62339536|NCT05152472|EXPERIMENTAL|Imatinib + Atezolizumab|Imatinib per os 400 mg daily continuously associated with intravenous administrations of atezolizumab at the fixed dose of 1 200 mg every 3 weeks (up to 12 months)
62339537|NCT05152472|ACTIVE_COMPARATOR|Imatinib alone|Imatinib alone, per os 400 mg daily continuously (up to 12 months)
62697197|NCT06405269||Without adjuvant chemotherapy group（Hormone receptor positive breast cancer）|Patients without adjuvant chemotherapy after surgery for hormone receptor-positive breast cancer
61944413|NCT03830242|EXPERIMENTAL|<Sup>18<Sup>F-FDG PET/CT study group|\<Sup\>18\<Sup\>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scan The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
62697198|NCT04164927|ACTIVE_COMPARATOR|Kinesio Taping|Lymphatic correction method is applied via Kinesiotaping depending on the size of the leg two or three fan-cut tape was applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Certified Kinesio Tape practitioner applied Kinesiotaping on the second day (day 2) post-surgery and once a week.
62697199|NCT04164927|ACTIVE_COMPARATOR|Manual Lymphatic Drainage|A standardized 30-minute manual lymphatic drainage (MLD) treatment is applied to MLD group. On the second day (day 2) post-surgery, patients allocated to the MLD group underwent a standardized 30 minute MLD treatment on the operated limb by an experienced remedial massage therapist trained in delivering MLD.
61944414|NCT03830242|OTHER|B-ultrasonography group|B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
62697200|NCT04164927|NO_INTERVENTION|Control|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
62697201|NCT06095050|EXPERIMENTAL|Embolization|"Angiography will be performed to identify hyperemic neovasculature arising from one or more of branch shoulder arteries. After localizing the abnormal neovessels a microcatheter will be inserted coaxially and selectively placed in the targeted artery(ies). The abnormal vessels will be embolized with Lipiodol emulsion (Guerbet, Villepinte, France) The embolic agent will be used under an investigational device exemption from the FDA. The embolic will be injected in small volume increments until blood flow stagnates in the target artery(ies).~Angiography and embolization will be repeated until the hyperemia is markedly reduced as demonstrated on digital subtraction angiography.~Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12."
62697202|NCT06095050|ACTIVE_COMPARATOR|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
62697203|NCT01865032||Skin Ulcers|Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.
61944415|NCT05615779|PLACEBO_COMPARATOR|Randomized pectin diet|
61944416|NCT05615779|PLACEBO_COMPARATOR|Randomized B-fructan diet|
61944417|NCT05615779|EXPERIMENTAL|Personalized pectin diet|
61944418|NCT05615779|EXPERIMENTAL|Personalized B-fructan diet|
61944419|NCT05005910|EXPERIMENTAL|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours) then vonoprazan 20 mg oral once daily for 28 days
61944420|NCT05005910|ACTIVE_COMPARATOR|PPIs|PPIs IV infusion for 72 hours then oral PPIs twice per day for 28 days
61944421|NCT02215096|EXPERIMENTAL|Phase 1-Dose Escalation|Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination. If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated. If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated. Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK. Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).
61944422|NCT02215096|EXPERIMENTAL|Phase 2- Dose Expansion|Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate
61944423|NCT02848404|EXPERIMENTAL|Categorical Language Fluency Smartphone Application|Smartphone game application specifically aimed at training categorical language fluency
61944424|NCT05634031|EXPERIMENTAL|Patients with INOCA|Patients to undergo coronary angiogram and/or coronary CT angiogram for suspected ischemic symptoms of angina and dyspnea but do not have obstructive epicardial coronary artery disease.
61944425|NCT02319512|EXPERIMENTAL|Chewing gum|Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.
61944426|NCT02319512|SHAM_COMPARATOR|Control|Controls received standard care and sips of glucose, in total 3.6g/day in a 12-ml mixture per day, the same amount of glucose per day as the treatment group received via the chewing gum
61944427|NCT03144765|EXPERIMENTAL|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
62697204|NCT06265415|ACTIVE_COMPARATOR|group A|(20 patients) will receive Labetalol intravenous infusion. The starting infusion rate is 5mg/h,the infusion rate will be changed 1mg/h up every 10 minutes until the desired goal achieved which is a decrease in systolic blood pressure (SBP) to 120 - 140 mmHg and a decrease in diastolic blood pressure (DBP) to 80 - 90 mmHg every 10 minutes
61944428|NCT05744908|ACTIVE_COMPARATOR|With Hunner's ulcer|Pentosan Polysulfate 100 mg
61944429|NCT05744908|ACTIVE_COMPARATOR|Without Hunner's ulcer|Pentosan Polysulfate 100 mg
61944430|NCT04768075|EXPERIMENTAL|Camrelizumab group|"subject will receive Camrelizumab intravenously(IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by Camrelizumab ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
61944431|NCT04768075|PLACEBO_COMPARATOR|placebo group|"subject will receive placebo intravenously (IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by placebo ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
61944432|NCT00715455|ACTIVE_COMPARATOR|Unfractionated Heparin|Unfractionated Heparin
61944433|NCT00715455|EXPERIMENTAL|REG1 Partial Rev.|REG1 with partial reversal
61944434|NCT00715455|EXPERIMENTAL|REG1 Total Rev.|REG1 with total reversal
61944435|NCT06223074|ACTIVE_COMPARATOR|Standard Intravenous Methylprednisolone treatment in relapsing-remittent multiple sclerosis|"Intravenous methylprednisolone is the standard treatment for a multiple sclerosis relapse. Thus, 40 randomly enrolled patients aged 18-65 years with relapsing-remitting multiple sclerosis that assist to the hospital and confirmed with a relapse, will be treated with intravenous methylprednisolone, 1000 mg, once a day for 3 days for moderate relapses or 5 days for severe ones.~A written informed consent will be obtained from each participant or a legal representative whenever the participant could not provide consent."
61944436|NCT06223074|EXPERIMENTAL|Intranasal Methylprednisolone administration in relapsing-remittent multiple sclerosis|"Nasal Methylprednisolone Administration For this group, 40 randomly enrolled patients aged 18-65 years with relapsing-remitting multiple sclerosis that assist to the hospital and confirmed with a relapse, will be treated with intranasal methylprednisolone administration (1000 mg once a day for 3 days for moderate relapses or 5 days for severe ones) using a Mucosal Atomization Device (MAD Nasal).~A written informed consent will be obtained from each participant or a legal representative whenever the participant could not provide consent"
61944437|NCT04685967|EXPERIMENTAL|Glass-ionomer|Equia Forte HT, GC, Tokyo, Japan (EHT)
62697205|NCT06265415|ACTIVE_COMPARATOR|group B|(20 patients) will receive calculated dose of Nitroglycerine started as intravenous infusion, The starting infusion rate is 4.8mg/h ,the infusion rate will be changed 1mg/h every 10 minutes up until the therapeutic goal achieved, which is a decrease in systolic blood pressure (SBP) to 120 - 140 mmHg and a decrease in diastolic blood pressure (DBP) to 80 - 90 mmHg
62697206|NCT06265415|ACTIVE_COMPARATOR|group C|, (20 patients) will receive calculated dose of nifedipine the content (100 µL) of a 10 mg capsule of nifedipine was drawn up into an insulin syringe and deposited sublingually, every 30 min.( Maximum dose of nifedipine 120 mg/day) ) until the therapeutic goal achieved, which is a decrease in systolic blood pressure (SBP) to 120 - 140 mmHg and a decrease in diastolic blood pressure (DBP) to 80 - 90 mmHg
62697207|NCT01404247|EXPERIMENTAL|OCT imaging in neonates|OCT imaging of all neonates, 38-42 weeks, enrolled in this study
62697208|NCT06639971||ITR group|hepatocellular carcinoma patients treated with immunotherapy and targeted therapy combined with radiotherapy
62697209|NCT06639971||IT group|hepatocellular carcinoma patients treated with immunotherapy and targeted therapy alone
62697210|NCT00829465|ACTIVE_COMPARATOR|control|
62697211|NCT00829465|EXPERIMENTAL|therapy|
62697212|NCT00296712|EXPERIMENTAL|escitalopram + bupropion|patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d
62139570|NCT05598957||uninfected Sars-CoV-2 group (Group 1)|The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: no viral RNA detected, uninfected Sars-CoV-2 patients (Group 1)
61944438|NCT04685967|EXPERIMENTAL|Bulk-Fill|SonicFill2, Orange, CA, USA (SBF)
62697213|NCT06564766|NO_INTERVENTION|Control group|Both groups (EG and CG) received BTI training in a short 2.5-hour format in groups of 13-16 students. The content included: 1) general information and epidemiology of smoking, 2) passive smoking, 3) evidence of the effectiveness of tobacco interventions, and 4) the approach to smoking cessation in Primary Care as proposed by the WHO using the 5 As and 5 Rs model to help patients quit smoking (World Health Organization, 2014). This model outlines the five main steps of the 5 As (Ask, Advise, Assess, Assist, and Arrange) for providing brief intervention in primary care settings and the 5 Rs (Relevance, Risks, Rewards, Roadblocks, and Repetition) to address with smokers who are not yet ready to quit.
62697214|NCT06564766|EXPERIMENTAL|Experimental group|
62697215|NCT02758028|OTHER|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach. Counsellors will emphasizes the identification, use, and modification of personally relevant coping strategies. Advice will be provided on overcoming expected difficulty, withdrawal symptoms and relapse prevention during quitting.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
62697216|NCT01324973|EXPERIMENTAL|eWellness program|A comprehensive program that delivers web-based, evidence-based weight management; and structured peer supports. The program is designed to meet the needs of individuals with mental illness.
62697217|NCT01324973|NO_INTERVENTION|Control group|Care as usual
62697218|NCT03456076|EXPERIMENTAL|Alectinib|
61944439|NCT06333301||TIME-ZZZ|Group will complete several surveys
61944440|NCT05498012|PLACEBO_COMPARATOR|Placebo group|Dental gel applied by dentist after oral hygiene (no cannabidiol). Toothpaste for daily use as needed for patients (no cannabidiol).
61944441|NCT05498012|EXPERIMENTAL|CBD group|Dental CBD (cannabidiol) gel applied by dentist after oral hygiene. CBD toothpaste for daily use as needed for patients.
62139571|NCT05598957||mild Sars-CoV-2 group (Group 2)|The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: viral RNA detected but asymptomatic disease, ambulatory mild disease (Group 2)
62139572|NCT05598957||moderate to severe Sars-CoV-2 group (Group 3)|The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: hospitalized moderate disease, moderate to severe Sars-CoV-2 patients (group 3)
62697219|NCT03456076|ACTIVE_COMPARATOR|Platinum-Based Chemotherapy|
62697220|NCT04012450|ACTIVE_COMPARATOR|Epidural Anesthesia|Women in labor receiving epidural anesthesia
62697221|NCT04012450|ACTIVE_COMPARATOR|Spinal-epidural|Women in labor receiving spinal-epidural anesthesia
62697222|NCT05038839|EXPERIMENTAL|Treatment (cabozantinib, pamiparib)|Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61944442|NCT05498012|ACTIVE_COMPARATOR|Corsodyl group|Corsodyl dental gel applied by dentist after oral hygiene. Toothpaste for daily use as needed for patients (no cannabidiol).
61944443|NCT02643602|EXPERIMENTAL|Bicarbonate and theophylline|Hydration with bicarbonate in addition to theophylline
61944444|NCT02643602|ACTIVE_COMPARATOR|Sodium and theophylline|Hydration with sodium chloride in addition to theophylline
61944445|NCT03350165|EXPERIMENTAL|Treatment Group|K-877 (pemafibrate) tablet twice daily.
62697223|NCT02943161|EXPERIMENTAL|L-Citrulline|In this pilot study subjects with asthma that have an increased body mass index compatible with being obese, will be invited to participate in a short open-label treatment with 15g/day of L-citrulline for two weeks. Study participants will be asked to do lung function testing and donate blood before and after taking the supplement. L-citrulline is safe and well tolerated and has been used at much higher doses without significant side effects.
62697224|NCT04984200||AB|
62697225|NCT06639035||Patients with External Oblique Intercostal Plane Block|At the end of the surgery, the application of the EOIP block involves the patient being in a supine position, with either the clavicle or mid-axillary line palpated to locate the 6th rib. An ultrasound probe is placed 1-2 cm lateral to the midclavicular line over the 6th rib. Under aseptic conditions, a 22-gauge 25-50 mm block needle is advanced to the 6th rib using the in-plane technique. Two ml of saline is injected for hydrodissection to ensure accurate placement. Avoiding subperiosteal injection, hydrodissection is performed between the external oblique muscle and the 6th rib. Subsequently, 20-30 ml of 0.25% bupivacaine is injected into this area. The block is then repeated on the other side.After apply EOIPB intravascular analgesia will be administered with PCA.
62697226|NCT06639035||Control group|Patient will not apply any block only use patient control analgesia with tramadol will be administered with PCA.
62697227|NCT06477692|EXPERIMENTAL|Standard radiotherapy with elective neck irradiation (ENI)|"The elective neck dose is 56 Gy in 35 fractions Lymph nodes measuring 17 mm or greater in any dimension, or showing FDG above adjacent blood pool, may receive 63 Gy in 35 fractions per physician discretion.The elective neck field is determined by the primary site.~The Oropharynx:~Node-positive side: Levels IB-V and RP nodes Node-negative side: Levels II-IV, RP at discretion of physician For ipsilateral tonsil decision-making, see 4.1.1.6.3~The Larynx:~Node-positive side: Levels IB-V Node-negative side: Levels II-IV Subglottic extension: Level VI~Hypopharynx:~Node-positive side: Levels IB-V and RP nodes Node-negative side: Levels II-V and RP nodes Pyriform sinus involvement: Level VI"
62697228|NCT06477692|EXPERIMENTAL|Involved and suspicious lymph node delineation and targeting|After the involved and suspicious nodes are contoured, the physician will contour remaining nodes that are present on more than one CT slice and submit them to the AI-Radiomics module for assessment.The nodal gross tumor volume (GTVn, GTVns and GTVnps for involved, suspicious nodes or potentially suspicious) will be contoured on the planning CT, using radiographic and clinical information to define its extent. The total dose for GTVns is 63 Gy in 35 fractions, and the total dose for GTVnps is 56 Gy in 35 fractions. For lymph nodes identified as potentially suspicious by the AI- Radiomics module that are outside of the expected primary draining zone, physicians may not treat the lymph node if the module assesses its estimation uncertainty as greater than 50%.
62495831|NCT00070239|EXPERIMENTAL|Treatment|"PART 1 (closed to accrual as of 8/2005): Patients receive alvocidib IV over 1 hour on days 1, 8, and 15.~Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD\* is determined.~PART 2: Patients receive alvocidib IV over 1 hour at or below the MTD determined in part 1 and then receive a maintenance dose of alvocidib IV over 1-6 hours on days 1, 8, and 15. Cohorts of 3-6 patients receive escalating durations of the maintenance dose of alvocidib until the MTD\* is determined. An additional cohort of 10-20 patients receives alvocidib over 1 hour on days 1 and 15 at the MTD.~NOTE: \*The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both parts, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
61944446|NCT03350165|PLACEBO_COMPARATOR|Control Group|placebo tablet twice daily.
61944447|NCT04489459|ACTIVE_COMPARATOR|colistin-tigecycline|this group received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12h
61944448|NCT04489459|ACTIVE_COMPARATOR|colistin-meropenem|received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
62495832|NCT06348576|EXPERIMENTAL|Test group|AD-209+AD-2091 Placebo
62697229|NCT05026801|ACTIVE_COMPARATOR|Azithromycin plus hydroxychloroquine|Azithromycin 500 mg plus hydroxychloroquine 600 mg by mouth daily for six consecutive days
62697230|NCT05026801|PLACEBO_COMPARATOR|Placebo|Placebo
62697231|NCT05575440||Observational (18F-TFB PET/CT)|Patients receive fluorine F18 tetrafluoroborate IV and undergo PET/CT scan on study.
62697232|NCT00283166|EXPERIMENTAL|A|Tailored Coaching and Education
62697233|NCT00283166|OTHER|B|Active Control
62697234|NCT04678258|ACTIVE_COMPARATOR|Group 1: MVG ablation|Group 1 - MVG: high-resolution mapping and maximum voltage guided stepwise CTI ablation (stepwise voltage guided approach (SVG)).
62697235|NCT04678258|ACTIVE_COMPARATOR|Group 2 - control: linear ablation|Group 2 - control: conventional bipolar mapping and conventional linear CTI ablation.
62697236|NCT01847014|EXPERIMENTAL|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
62697237|NCT02310269||Cohort 1/new use cohort|Subjects who initiated pasireotide s.c. at time of study entry (on or after the signing of the informed consent or acknowledging an equivalent document -for example, written information- as per country regulation).
62697238|NCT02310269||Cohort 2/prior use cohort|Subjects who initiated pasireotide s.c. prior to study entry.
61944449|NCT00912860|EXPERIMENTAL|1|serum-free avonex given IM
62139573|NCT06108635|ACTIVE_COMPARATOR|Group A|McKenzie exercises with moist heat therapy will be given as intervention to experimental group. 2 sets of 5 reps will be given then progressed to 3 sets of 10 repetitions .Participants will be given Hot pack for 15 minutes.
62697239|NCT06004037|EXPERIMENTAL|delpazolid|In addition to background therapy for MABC, patients will be given orally three tablets (400 mg/tablet) of LCB01-0371 for 12 weeks.
61944450|NCT04088643|EXPERIMENTAL|tACS group|NEXALIN ADI transcranial alternating current stimulator
62495833|NCT06348576|ACTIVE_COMPARATOR|Control group|AD-2091+AD-209 Placebo
62495834|NCT02196467|EXPERIMENTAL|Myoblast transplantation & strength|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
61944451|NCT04088643|SHAM_COMPARATOR|sham stimulation group|Sham stimulator provided by NEXALIN company
61944452|NCT04757285||control group|25 healthcare personnel volunteers not working in quarantine hospitals of matched age
62339538|NCT03670914|EXPERIMENTAL|WatchPAT 200 and In-Lab Study|Patients who are referred to the sleep center for an overnight study that are narcotic users will be offered to the opportunity to participate in the study. Patients who fulfill the inclusion exclusion criteria and have given informed consent will undergo a standard in-lab polysomnography while simultaneously wearing the WatchPAT200 device.
62339539|NCT01563640|PLACEBO_COMPARATOR|normal school uniforms|washing only
62339540|NCT01563640|EXPERIMENTAL|insecticide-treated school uniforms|washing and insecticide treatment
62339541|NCT04445402||Heme/Non-Sickle Cell Disease|Subjects with a diagnosis of hemoglobinapathy except Sickle Cell Disease
62339542|NCT04445402||Heme/Sickle Cell Disease|Subjects with a diagnosis of Sickle Cell Disease
62697240|NCT01758120|EXPERIMENTAL|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months)
62697241|NCT01758120|EXPERIMENTAL|prednisone alone|prednisone alone: prednisone(0.5mg/kg/day\*6 months)
62697242|NCT06098573|EXPERIMENTAL|Program 1: High Alert|High Alert
62697243|NCT06098573|ACTIVE_COMPARATOR|Program 2: Information condition|Active Control- Information condition
62697244|NCT06098573|PLACEBO_COMPARATOR|No contact|Passive control- No contact
62697245|NCT04039347|EXPERIMENTAL|L-CsA 5 mg plus Standard of Care|L-CsA 5 mg twice daily plus Standard of Care for up to 144 weeks for patients post Single Lung Transplant
62697246|NCT04039347|EXPERIMENTAL|L-CsA 10 mg plus Standard of Care|L-CsA 10 mg twice daily plus Standard of Care for up to 144 weeks for patients post Double Lung Transplant
62697247|NCT03578055|ACTIVE_COMPARATOR|BDD with UDCA|Postoperative BDD with UDCA treatment
62697248|NCT03578055|PLACEBO_COMPARATOR|Placebo|Placebo
62697249|NCT06637150|ACTIVE_COMPARATOR|standard endocrine therapy|standard endocrine therapy
62697250|NCT06637150|EXPERIMENTAL|standard endocrine therapy plus dalpicilib|standard endocrine therapy plus dalpicilib
62697251|NCT02494115|EXPERIMENTAL|subcutaneous drainage|This local treatment consists in inserting in lower limbs several catheters draining into enclosed bags in order to evacuate lymph fluid and to lower local pressure.
62697252|NCT06059898|EXPERIMENTAL|NOVAMag membrane|GBR procedure / membrane placement
62697253|NCT06059898|ACTIVE_COMPARATOR|Jason membrane|GBR procedure / membrane placement
62697254|NCT00685295|EXPERIMENTAL|Arm 1 / Fentora|"Intervention Group:~Subject receives:~1. placebo oral/swallowed pill~2. Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet"
62495835|NCT02196467|SHAM_COMPARATOR|Saline injection & strength|The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
62697255|NCT00685295|ACTIVE_COMPARATOR|Arm 2 / Percocet/Prevacid|"Active Comparator Group:~Subject receives:~1. Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill~2. Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet"
62339543|NCT04445402||Neuro-Oncological Disease|Oncology diagnosis with involvement of the neurological system
62697256|NCT00960245|EXPERIMENTAL|1|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
62339544|NCT04445402||Oncology/Non-Neuro-Oncological|Subjects with any oncology diagnosis except those that involve the neurological system.
62339545|NCT04445402||Transplant patients|Subjects who have received or are intending to have a stem cell transplant for treatment of disease.
62339546|NCT00578799|ACTIVE_COMPARATOR|Kyo-Dophilus|Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)
62339547|NCT00578799|PLACEBO_COMPARATOR|Placebo|placebo capsules (potato starch)
62339548|NCT04365985|PLACEBO_COMPARATOR|Placebo|Placebo by mouth 1 time per day for patients with stage I or stage 2A COVID-19
62339549|NCT04365985|EXPERIMENTAL|Naltrexone|Naltrexone 4.5 mg by mouth 1 time per day for patients with stage I or stage 2A COVID-19.
62339550|NCT04365985|EXPERIMENTAL|Ketamine|Ketamine IV infusion (0.15 mg/kg based on total body weight for maximum 20 mg every 6 hours) for patients with stage 2B or stage 3 COVID-19; may be increased to 0.3 mg/kg based on total body weight for a maximum of 30 mg every 6 hours if needed. Patients entering this arm from the placebo or naltrexone arms remain on those medications as well.
62339551|NCT04651725|ACTIVE_COMPARATOR|Exercise group 1: Exercise via mechanical horse-riding simulator|All patients in both groups were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
62697257|NCT00960245|ACTIVE_COMPARATOR|2|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
62697258|NCT03962647|EXPERIMENTAL|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
62697259|NCT03962647|ACTIVE_COMPARATOR|Letrozole Control|
62697260|NCT06160245|EXPERIMENTAL|core stability exercise|This group will receive core stabilization exercises ( MCGILL 2008), in addition to postural correction exercises described by (HARMAN 2005)
62697261|NCT06160245|ACTIVE_COMPARATOR|traditional exercise|This group will receive only postural correction exercises described by (HARMAN 2005)
62697262|NCT06637163|EXPERIMENTAL|Benmelstobart combined with radiochemotherapy|Benmelstobart + Paclitaxel + Carboplatin + Radiotherapy
62697263|NCT06637163|ACTIVE_COMPARATOR|radiochemotherapy|Paclitaxel + Carboplatin + Radiotherapy
62697264|NCT03934294|EXPERIMENTAL|Treatment group: specific acupuncture group(Acu)|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G.~Acupuncture doctor will disinfect the acupoints with alcohol and will perform acupuncture on the marked points with needle Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor."
62697265|NCT03934294|PLACEBO_COMPARATOR|Control group: non-specific acupuncture group (Con-Acu)|"Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related pathologies, and are not reported to improve digestive function.~Acupuncture doctor 1 will disinfect the marked acupoints with alcohol and will perform acupuncture on the marked points. Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor"
62697266|NCT00887887||liver surgery|patients with benign or malignant hepatobiliary disease requiring partial hepatic resection
62495836|NCT03492567|EXPERIMENTAL|Blood monocyte precursors/osteoclasts|Blood test
62495837|NCT03033030||Tomosynthesis|Patients undergoing Digital Breast Tomosynthesis
62339552|NCT04651725|ACTIVE_COMPARATOR|Exercise group 2: Home exercises|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
62339553|NCT00352755|EXPERIMENTAL|Peritonectomy + IP5FU + FOLFOX|"* Surgical debulking with peritonectomy~* IP 5FU 600 mg/m\^2 over 30-60 minutes with patient rotating every 15 minutes. Repeated every 2 weeks for a total of 9 cycles.~* FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy. Oxaliplatin 85 mg/m\^2 over 2 hours with leucovorin at 400 mg/m\^2 and IV 5-FU at 2400 mg/m\^2 over 46 hours. Repeated every 2 weeks for a total of 8 cycles."
62339554|NCT05941351|OTHER|Running|Group 1: Flap fixation after mastectomy with running sutures.
62339555|NCT05941351|OTHER|Individual|Group 2: Flap fixation after mastectomy with interrupted sutures.
62339556|NCT01449201|EXPERIMENTAL|PF-00299804|
62339557|NCT06140069||Experimental: Patient treated at the Toulouse University Hospital for an abortion|Patient treated at the Toulouse University Hospital for an abortion between 14 and 16 weeks (dating by ultrasound) presenting with a single and evolving pregnancy.
62339558|NCT06310785|EXPERIMENTAL|Esketamine group|Esketamine group was induced with esketamine 0.5 mg/kg, propofol 2 mg/kg, and rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and esketamine 0.5 mg/kg/h.
62339559|NCT06310785|ACTIVE_COMPARATOR|opioid group|Anesthesia induction in the opioid group Sufentanil 0.5 ug/kg, propofol 2 mg/kg, rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and remifentanil 1 ug/kg/h.
62339560|NCT01409031|EXPERIMENTAL|Intravenous Sildenafil|
62339561|NCT01409031|PLACEBO_COMPARATOR|Placebo|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
62339562|NCT00923819|EXPERIMENTAL|Group A|Laparoscopic Gastric Bypass
62339563|NCT00923819|ACTIVE_COMPARATOR|Group B|Standard conservative treatment. Patients from Child Obesity Registry of Vestfold.
62495838|NCT01216540||Patients receiving vancomycin|
62495839|NCT02445846||Pregnant women|Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
62495840|NCT04305470|EXPERIMENTAL|Single Arm|Open-label, single-arm
62495841|NCT02591849|ACTIVE_COMPARATOR|Glucagon-like peptide-1 (GLP-1)|Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
62495842|NCT02591849|PLACEBO_COMPARATOR|Isotonic saline|The included patients will receive concomitant intravenous infusion of isotonic saline on one of the two experimental days
62495843|NCT02319603|ACTIVE_COMPARATOR|Low dose WenXin keli|"Low dose group (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
62495844|NCT02319603|EXPERIMENTAL|High dose WenXin keli|"High dose group(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
62697267|NCT06571864|EXPERIMENTAL|anti-CD38|Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
62697268|NCT06419504||SAP block group|Before the surgery, US-guided SAP block will be performed
62697269|NCT06419504||PECS II block group|Before the surgery, US-guided PECS II block will be performed
62697270|NCT06419504||ESP block group|Before the surgery, US-guided ESP blockwill be performed
62697271|NCT06419504||Control group|No intervention
62697272|NCT02266771|ACTIVE_COMPARATOR|NPWT with Instillation|Negative Pressure Wound Therapy with Instillation.
62697273|NCT02266771|PLACEBO_COMPARATOR|NPWT without Instillation|Negative Pressure Wound Therapy without Instillation
62339564|NCT06554028|EXPERIMENTAL|Tislelizumab and Induction Chemotherapy Followed by Radiotherapy or Adaptive Surgery|"Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.~Response rate of primary tumor or lymph nodes is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If the primary lesion reaches CR/PR and the lymph nodes reach CR, chemoradiotherapy based on cisplatin is conducted. If the primary lesion reaches CR/PR and lymph node PR/PD, cervical lymph node dissection will be performed, followed by radiotherapy/concurrent chemoradiotherapy. If the primary lesion is SD/PD, regardless of the condition of the lymph nodes, primary lesion resection and lymph node dissection should be performed, followed by adjuvant radiation/chemoradiation.~Interventions:~Drug: chemotherapy TP regimen combined with Tislelizumab"
62339565|NCT04709302||COVID-19 positive, HIV-positive with ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV who are on ART
62339566|NCT04709302||COVID-19 positive, HIV-positive without ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
62339567|NCT04709302||COVID-19 positive, HIV-negative|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
62697274|NCT01434940|EXPERIMENTAL|Alzheimer|Patients suffering of Alzheimer disease
62697275|NCT01434940|EXPERIMENTAL|Depression|Patients suffering from depression
62697276|NCT01434940|EXPERIMENTAL|Healthy|Healthy volunteers
62697277|NCT06570369|EXPERIMENTAL|SP-624|SP-624 oral capsule, once daily for 2 weeks
62697278|NCT06570369|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule, once daily for 2 weeks
62697279|NCT00937105|ACTIVE_COMPARATOR|ReNu Multiplus and lotrafilcon A lenses|ReNu Multiplus contact lens care solution
62697280|NCT00937105|ACTIVE_COMPARATOR|Clear Care solution and lotrafilcon A lenses|Clear Care Contact Lens Care Solution
62697281|NCT01215331|ACTIVE_COMPARATOR|Insulin|Rapid acting insulin and long acting insulin
62697282|NCT01215331|EXPERIMENTAL|Oral Hypoglycemic Agents|Metformin + glyburide + insulin if needed
62697283|NCT05382130|EXPERIMENTAL|Test All|MNCH, HIV, and TB clinic attendees are offered SARS-CoV-2 testing regardless of symptoms.
62697284|NCT05382130|NO_INTERVENTION|Screen and Test|Populations are screened and tested for SARS-CoV-2 according to the MOH testing guidelines model.
62697285|NCT05752487|EXPERIMENTAL|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants with drug refractory, paroxysmal atrial fibrillation (PAF) who are candidates for catheter ablation will be enrolled with ablation system which uses THERMOCOOL SMARTTOUCH SF (STSF) catheter and TRUPULSE generator to deliver RF or PF energy during cardiac ablation procedures.
62697286|NCT06316765||With stylet group|Intubation performed with stylet.
62697287|NCT06316765||Without stylet group|Intubation performed without stylet.
62697288|NCT06637020|EXPERIMENTAL|HDM1005 injection 0.5mg|HDM1005 injection or pleacebo 0.5mg qw subcutaneous injection, 4weeks
62139574|NCT06108635|EXPERIMENTAL|Group B|The patients will be given Maitland mobilization (central glide on effected cervical spinous process) with McKenzie exercises. Grade i and ii mobilizations will be given in week 1 and then progressed to grade iii and iv in week 2. The total time duration will be 25-30 minutes. Participants will be given Hot pack for 15 minutes.
62139575|NCT06163300||Control|Healthy volunteers
62495845|NCT04735172|EXPERIMENTAL|de novo PD patients|"Patients will be included:~* suffering from idiopathic Parkinson's disease according to UKPDSBB criteria (Gibb \& Lees, 1988; Hughes et al., 1992),~* the stage of the disease is I-II according to the Hoehn and Yahr scale,~* which do not receive dopaminergic treatment,~* duration of disease development: 5 years,~* without major cognitive impairment (Moca \> 24)~* men or women aged 18 to 75,~* having understood and signed the informed consent form,~* members of a social security scheme."
62495846|NCT04735172|EXPERIMENTAL|control subjects|"* subjects male or female aged 18 -75 years~* subjects affiliated to a social security scheme.~* volunteers who have given their written consent. They will be matched to de novo PD patients according to age, sex and level of education."
62495847|NCT03860441|EXPERIMENTAL|Intervention group|Participants in the intervention group received 24 sessions of computerized cognitive training, with a total time of 960 min.
62495848|NCT03860441|ACTIVE_COMPARATOR|Active control group|Participants in the control group attended activities separate activities, such as learning about healthy lifestyle, had cooking and other social lessons for the same amount as the intervention group performed cognitive training.
62339568|NCT02526719|NO_INTERVENTION|Standard Nipple-Sparing Mastectomy|Patients in the control group will receive usual care. The surgical oncologist will perform the NSM and sentinel lymph node biopsy if indicated (active breast cancer or DCIS). We will submit a nipple core biopsy and a 1cm thick biopsy of immediately retro-areolar ductal tissue for permanent section pathology for control patients, and all patients will have the mastectomy specimen submitted for permanent section pathology. Under the same general anaesthesia, the plastic surgeon will perform the IBR (2-stage tissue expander to implant or 1-stage direct to implant). Patients who later have a positive nipple core and retro-areolar biopsy will have a discussion with the surgical oncologist regarding the need for revision breast surgery to excise the NAC, as is current practice.
62495849|NCT03827005|PLACEBO_COMPARATOR|placebo|3 grams cornstarch once per day for one day.
62495850|NCT03827005|EXPERIMENTAL|L-arginine|3 g L-arginine once per day for one day.
62495851|NCT00721955|PLACEBO_COMPARATOR|Inhaled Placebo|Inhaled Staccato Placebo, may repeat after 2 hours x 2
62495852|NCT00721955|EXPERIMENTAL|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
62495853|NCT00721955|EXPERIMENTAL|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
62139576|NCT06163300||Disease|Patients affected by disease
62339569|NCT02526719|EXPERIMENTAL|Nipple Delay Intervention|Patients in the experimental group will have a nipple-delay intervention in addition to usual care. The nipple delay procedure will be performed by the plastic surgeon in the minor clinic procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
62495854|NCT04070222||Natural labour group|
62139577|NCT03501303|EXPERIMENTAL|No touch|No touch technique. Patients are randomized to no touch vein harvesting. The technique is used as routine in Medical care by some hospitals.
62139578|NCT03501303|OTHER|Control|Control technique. Patients are randomized to Control vein harvesting. The technique is used as routine in Medical care.
62495855|NCT04070222||Cesarean scar group|
62495856|NCT04070222||Cesarean with diverticulum (PCSD) group|
62495857|NCT01160640|PLACEBO_COMPARATOR|Ceftriaxone/Doxycycline/Placebo Oral Cap|ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo oral capsule PO bid x 14 days
62495858|NCT01160640|ACTIVE_COMPARATOR|Ceftriaxone, Doxycycline, Metronidazole|ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days
62495859|NCT02856776|EXPERIMENTAL|Arm 1: 600 IU vitamin D|Subject will receive 600 IUs of vitamin D3/day for 24 weeks.
62495860|NCT02856776|EXPERIMENTAL|Arm 2: 4,000 IU vitamin D|Subject will receive 4,000 IUs of vitamin D3/day for 24 weeks
62495861|NCT02856776|EXPERIMENTAL|Arm 3: 10,000 IU vitamin D|Subjet will receive 10,000 IUs of vitamin D3/day for 24 weeks
62495862|NCT02856776|EXPERIMENTAL|Arm 4: Mixed vitamin D dosages|Subject will receive 600 IUs of vitamin D3/day for the first 8 weeks, 4,000 IUs of vitamin D3/day for the next 8 weeks, and 10,000 IUs of vitamin D3/day for the final 8 weeks.
62495863|NCT02316457|EXPERIMENTAL|ARM1 IVAC_W_bre1_uID|Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
62139579|NCT05776888||Early Treatment Cohort (Cohort 1)|Patients that, before initiation of Ofatumumab, were either treatment naive or have started their treatment for RMS with another disease modifying therapy (BRACE, teriflunomide or fumarates). Non-naive patients in this cohort must have started the use of Ofatumumab within 3 years after first DMT initiation.
62139580|NCT05776888||Later Treatment Cohort (Cohort 2)|Patients that have been on BRACE and/or Teriflunomide and/or fumarates for at least three years or longer before the switch to Ofatumumab has been initiated.
62139581|NCT04376775||Transplant patient|This study will involve all the transplant centres in France. The investigator will use patient-completed surveys for all participants. Wait Listed Transplant Candidates and Transplant Recipients (liver, kidney, pancreas, heart, lung) will be contacted by the all French transplant centres and patient's associations.
62697289|NCT06637020|EXPERIMENTAL|HDM1005 injection 1.0mg|HDM1005 injection or pleacebo 1.0mg qw subcutaneous injection, 4weeks
62697290|NCT06637020|EXPERIMENTAL|HDM1005 injection 2.0mg|HDM1005 injection or pleacebo 2.0mg qw subcutaneous injection, 4weeks
62697291|NCT06637020|EXPERIMENTAL|HDM1005 injection 4.0mg|HDM1005 injection or pleacebo 2 mg/2 mg/4 mg/4 mg, 2mg subcutaneously administered once weekly, for 1 time; subsequently increased to 4 mg once weekly for 2 times.
62697292|NCT06637020|EXPERIMENTAL|HDM1005 injection 8.0mg|HDM1005 injection or pleacebo 2 mg/2 mg/4 mg/8 mg, 2mg subcutaneously administered once weekly, for 1 time; increased to 4 mg once weekly, for 1 time; subsequently increased to 8 mg once weekly, for 2 times.
62697293|NCT05911165|ACTIVE_COMPARATOR|Control group|Resident participants who do not receive video-based surgical coaching
62139582|NCT03695549|ACTIVE_COMPARATOR|intervention|CAF+ APRF
62495864|NCT02316457|EXPERIMENTAL|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|Patients enrolled in ARM2 will optionally receive the WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
62495865|NCT02316457|EXPERIMENTAL|ARM3 IVAC_W_bre1_uID + RBLTet.1|Patients enrolled in ARM3 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient. RBLTet.1 RNA will be added to each RNA applied.
62495866|NCT02745860|EXPERIMENTAL|Sequence AB|Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
62495867|NCT02745860|EXPERIMENTAL|Sequence BA|Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2
62495868|NCT05210049|OTHER|Patients undergoing routine screening via upper endoscopy (EGD)|All enrolled patients will complete upper endoscopy for screening for Barrett's esophagus and esophageal adenocarcinoma.
62495869|NCT01710358|PLACEBO_COMPARATOR|Placebo|"Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50.~At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
62697294|NCT05911165|EXPERIMENTAL|Comparison group|Resident participants who do receive video-based surgical coaching
62697295|NCT03074669|EXPERIMENTAL|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
62697296|NCT03074669|NO_INTERVENTION|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
62697297|NCT05478837|EXPERIMENTAL|Treatment (KIND T cells, cyclophosphamide, fludarabine)|Patients receive fludarabine IV on days -4, -3, and -2 and cyclophosphamide IV on day -2 in the absence of disease progression or unacceptable toxicity for the conditioning regimen. Patients also receive KIND T cells IV at dose level 1 (2 x 106 dextramer®+ CD8+ cells/kg) on day 0. If no DLTs are reported, newly enrolling participants may receive dose level 2 of KIND T cells on day 0.
62697298|NCT04578041|EXPERIMENTAL|Arm 1: TRPMS + Aerobic Physical Activity Program|
62697299|NCT04578041|ACTIVE_COMPARATOR|Arm 2: TRPMS + Adaptive Cognitive Training|
62697300|NCT06541132||Non-CAD group|non-coronary artery disease group
62697301|NCT06541132||CAD group|coronary artery disease group
62697302|NCT06541132||SS≤22 group|SYNTAX score ≤22
62697303|NCT06541132||SS≥23 group|SYNTAX score ≥23
62697304|NCT03384966|EXPERIMENTAL|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
62697305|NCT03384966|EXPERIMENTAL|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
62697306|NCT03384966|PLACEBO_COMPARATOR|Placebo|Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
62139583|NCT03695549|ACTIVE_COMPARATOR|control|CAF+SCTG
62139584|NCT06699524||drug-sensitive group|Organoid resistance and sensitivity are indicated by an IC50 value ≥23.815 μmol/L and \< 23.815 μmol/L, respectively. According to the PDTO drug testing, 42 patients were classified into the drug-sensitive group, and 80 patients into the drug-resistant group。
62697307|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
62495870|NCT01710358|EXPERIMENTAL|Baricitinib|"Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50.~Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
62495871|NCT01710358|ACTIVE_COMPARATOR|Adalimumab|"Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
62495872|NCT04385043|EXPERIMENTAL|plasma-hyperimmune|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with plasma hyperimmune add on to the standard therapy
62495873|NCT04385043|ACTIVE_COMPARATOR|standard therapy|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with the standard therapy
62495874|NCT01095887|EXPERIMENTAL|eculizumab|Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.
62495875|NCT04436718|EXPERIMENTAL|Daily POCUS|Patients are assessed by facility experts with daily chest ultrasound and findings of interstitial syndrome and IVC measurement are reported to primary care providers.
62495876|NCT04436718|NO_INTERVENTION|Usual care|Patients are assessed daily by primary care providers per usual care.
62495877|NCT00530348|EXPERIMENTAL|Alemtuzumab|
62697308|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
62697309|NCT04733079|EXPERIMENTAL|E-mail follow-up group|Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging
62697310|NCT04733079|ACTIVE_COMPARATOR|Usual follow-up group|Adaptation and follow-up of ULT according to referring physician's habits
62697311|NCT00321932|ACTIVE_COMPARATOR|Arm I (control)|Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
62339570|NCT06553508|ACTIVE_COMPARATOR|Unrepaired bursa group|As a routine procedure in our centre, the trochanteric bursa is left unrepaired after a hip arthroplasty. The conventional joint closure is performed after reduction and the layers are closed in a routine fashion.
62697312|NCT00321932|EXPERIMENTAL|Arm II (treatment)|Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
62697313|NCT05006248|ACTIVE_COMPARATOR|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions.
62697314|NCT05006248|EXPERIMENTAL|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
62339571|NCT06553508|EXPERIMENTAL|Repaired Bursa group|For the experimental arm, the trochanteric bursa is repaired after a hip arthroplasty. The conventional joint closure is performed after reduction and then the bursa is retrieved and repaired. Layers are then closed in a routine fashion.
62339572|NCT01397552|ACTIVE_COMPARATOR|Dexamethasone|Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
62339573|NCT01397552|ACTIVE_COMPARATOR|methylprednisolone acetate|Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded
62339574|NCT05796505|NO_INTERVENTION|Treatment as usual|Participants receive standard interventions currently in use (treatment as usual).
61944588|NCT05909683|EXPERIMENTAL|MODIFY strategy|These patients will start antibiotics according to standard practice of the attending physicians. It is anticipated that attending physicians will be informed in maximum 5 hours after randomization about the results of BCID2 including carriage of resistance genes and of the Reveal Rapid AST in the case of Gram-negative isolates. Physicians and investigators receiving this information are obliged to change the empirically prescribed antibiotics according to the rule provided in Box 1. The attending physicians and investigators will be allowed to decide for any change of antimicrobial treatment based on the results of conventional blood cultures provided to them by the central lab or any other culture provided to them by their hospital. PCT will be measured on day 1 and then daily starting from day 5. Attending physicians will be advised to discontinue antimicrobials on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml.
61944589|NCT03468829|EXPERIMENTAL|ALX-0171 Dose 1|
61944590|NCT03468829|EXPERIMENTAL|ALX-0171 Dose 2|
61944591|NCT03468829|PLACEBO_COMPARATOR|Placebo|
61944592|NCT06049043|EXPERIMENTAL|Intervention to Help Orient Men to Excel (IN-HOME)|Professional development training for CHWs on African American and Latino male caregiver needs
61944593|NCT06049043|OTHER|Control|"AARP's English Care at Home resource webpage"
61944594|NCT01910948|EXPERIMENTAL|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
61944595|NCT05047068||OCS DBD Heart Primary Analysis Population|"200 adult primary heart transplant recipients of OCS perfused DBD donor hearts that meet the FDA-approved indication for use except for the following recipient exclusion criteria:~* Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant; or~* On renal dialysis at time of transplant"
61944596|NCT05047068||OCS DCD Heart Primary Analysis Population|"150 adult primary heart transplant recipients of OCS perfused DCD donor hearts that meet the FDA-approved indication for use except for the following recipient exclusion criteria:~* Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant; or~* On renal dialysis at time of transplant~* Transplanted with DCD heart with warm ischemic time \> 30 minutes (warm ischemic time is defined as: Time from when mean systolic blood pressure (SBP) is \< 50 mmHg or peripheral saturation \< 70% to aortic cross-clamp and administration of cold cardioplegia in the donor)."
61944597|NCT05047068||Other OCS Heart Analysis Population|Any/all other recipients of OCS Heart perfused donor hearts outside of the DBD and DCD indications above will be collected in the respective arm of this registry until the enrollment of the PAP of that arm is completed (200 for DBD and 150 for DCD).
61944598|NCT06022601|EXPERIMENTAL|DNA Nudge|DNA Nudge wearable and app, DNA-based dietary advice
61944599|NCT06022601|NO_INTERVENTION|Control|Fitbit, standard dietary advice
61944600|NCT04265053|EXPERIMENTAL|Male NOS|Males visit MRI twice. Once for indomethacin visit (hypoxia + hypercapnia), and once for placebo visit (hypoxia + hypercapnia). We will conduct these 2 MRI visits in a double-blind placebo controlled design. CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
61944601|NCT04265053|EXPERIMENTAL|Male COX|Males visit MRI twice. Once for indomethacin visit (hypoxia + hypercapnia), and once for placebo visit (hypoxia + hypercapnia). We will conduct these 2 MRI visits in a double-blind placebo controlled design. CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
61944602|NCT04265053|EXPERIMENTAL|Female NOS|Females visit MRI twice. Once for indomethacin visit (hypoxia + hypercapnia), and once for placebo visit (hypoxia + hypercapnia). We will conduct these 2 MRI visits in a double-blind placebo controlled design. CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
61944603|NCT04265053|EXPERIMENTAL|Female COX|Females visit MRI twice. Once for indomethacin visit (hypoxia + hypercapnia), and once for placebo visit (hypoxia + hypercapnia). We will conduct these 2 MRI visits in a double-blind placebo controlled design. CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
61944604|NCT03273543|EXPERIMENTAL|Nasal Tip Projection|
61944605|NCT03273543|EXPERIMENTAL|Upper Lip Position|
61944606|NCT03128034|EXPERIMENTAL|Treatment (211^At-BC8-B10, PBSC)|Patients receive 211\^At-BC8-B10 IV over 6-8 hours on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and PBSC transplant on day 0. Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 and then tapered to day 180, or continuing to day 96 and then tapered to day 150. Patients receive mycophenolate mofetil PO or IV (first dose to occur 4-6 hours after PBSC infusion) every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on day 0 and then reduced to every 12 hours on days 30-150 then tapered to day 180 (for patients with unrelated donors).
61944607|NCT02043314|ACTIVE_COMPARATOR|Isoniazida-LAQFA®|3 coated tablet of 100mg
61944608|NCT02043314|EXPERIMENTAL|Isoniazida|coated tablet of 300mg
61944609|NCT02540616|EXPERIMENTAL|Transcranial Electrical Stimulation-Real|The participant will perform real TES. The forms of TES used in this study will include transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS). Each stimulation session will last for 20-minutes.
61944610|NCT02540616|SHAM_COMPARATOR|Transcranial Electrical Stimulation-Sham|The participant will perform sham TES for 20-minutes. The form of sham TES will depend on the active arm, e.g. if tACS is on the active arm, then the sham tACS will be a different frequency of stimulation. If tDCS is the active arm, then a short ramp up of tDCS followed by a ramp down (about 60-seconds) will be used as the sham arm.
62164403|NCT01124916|EXPERIMENTAL|Robotic Assisted Laparoscopic (RASC)|Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
62539181|NCT05792579|ACTIVE_COMPARATOR|late closure of stoma|Detection complications of late closure of stoma.
62164404|NCT05199701|EXPERIMENTAL|Investigational Mammogram Exam|All subjects that are indicated for a screening or diagnostic mammogram or breast biopsy.
62539182|NCT06524453|EXPERIMENTAL|Exercise group|A 20-session structured rehabilitation exercise program for individuals with SCI
62539183|NCT06524453|NO_INTERVENTION|Control group|Maintain their daily lives without any intervention
62539184|NCT00062985|NO_INTERVENTION|Control|
62539185|NCT00062985|EXPERIMENTAL|Mail-based weight loss intervention|
61944611|NCT06180291|EXPERIMENTAL|Intervention group|PRECOP group: screening and early treatment. CAMSP (Centre d'Action Médico-Sociale Précoce) orientation upon discharge from neonatology for immediate follow-up according to PRECOP protocol: early multidisciplinary care, with targeted objectives according to the child's needs.
62496029|NCT06678594||Patient treatment will follow a standardised algorithm for calcium modification|"All patients will have coronary angiography (QCA) and intravascular ultrasound (IVUS) imaging with 60MHz HD IVUS of the calcified lesion at baseline. The lesion will be characterized based on calcium distribution and morphology as assessed by HD IVUS. Depending on the specific lesion characteristics, the appropriate method for calcium modification will be chosen and performed in line with the CYCLOPES calcium modification algorithm included in the study protocol.~The calcific lesion will be imaged for a second time by 60MHz HD IVUS following calcium modification. The operator will then proceed, if no further lesion preparation is required, to deploy a bioabsorbable polymer Everolimus eluting stent using standard stenting techniques, post dilatation will be performed at the operator's discretion. The treated lesion will be assessed again using intravascular ultrasound following stent deployment and optimization."
62496030|NCT05255549|EXPERIMENTAL|Group I|
62496031|NCT05255549|SHAM_COMPARATOR|Group II|
62496032|NCT04099433|EXPERIMENTAL|Oral Bacteriotherapy Arm|Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria). Probiotic sachets are indistinguishable from placebo
61944612|NCT06180291|NO_INTERVENTION|Control group|Standard of care group: in the control centers, care includes specialized consultations organized by the perinatal network with a hospital and/or community pediatrician belonging to the network until the child is 2 years old. Cerebral palsy screening is based on clinical examination.
61944613|NCT01801826||Treatment|Treatment with CryoTouch IV device
61944614|NCT04017000|ACTIVE_COMPARATOR|BlaST study|"Patients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding.~The participants Urodynamic clinic will run according to routine care."
61944615|NCT04017000|OTHER|Calibration Sub Study|"Any patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study.~Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound.~Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change."
61944616|NCT02029001|EXPERIMENTAL|Arm A: Maintenance treatment|"Patients will continue targeted treatment matching the molecular alterations identified in their tumor~* for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion or a discontinuation criteria (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) is met for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib.~* until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) or for up to 2 years duration for patients with CR/PR/SD with the possibility of rechallenge in case of PD after IT cessation for durvalumab + tremelimumab"
61944617|NCT02029001|NO_INTERVENTION|Arm B:Interruption of targeted treatment|"Targeted treatment received during induction period will be discontinued until a first documented off-treatment disease progression occurs. At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval).~Treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib or until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met for durvalumab + tremelimumab.~If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study."
61944618|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SLIGHT TISSUE DAMAGE|
61944619|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH MODERATE TISSUE DAMAGE|
61944620|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SUBSTANTIAL TISSUE DAMAGE|
61944621|NCT06041490|EXPERIMENTAL|multi-kinase inhibitors in combination with bevacizumab|TKI (Sorafenib 400mg, bid, po or Lenvatinib 8mg, qd, po if bodyweight less than 60 kg,12mg, qd, po if bodyweight more than 60kg or Donafenib：200mg, bid, po) + bevacizumab：7.5mg/kg, infusion, Q3w
62496033|NCT04099433|PLACEBO_COMPARATOR|Placebo Arm|Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day). Placebo sachets are indistinguishable from probiotic
62496034|NCT04031560|EXPERIMENTAL|Experimental|Integrative treatment
62496035|NCT04031560|NO_INTERVENTION|Control|The control group (62 patients) will not receive any type of add-on psychotherapy.
62496036|NCT05793645|EXPERIMENTAL|Personalized care plan|A personalized care plan will be deployed according to patient profile/ disease characteristics
62496037|NCT05450809||Ambulatory, outpatient Mayo Clinic ECG lab patients|Patients who are undergoing routine clinical evaluation with a 12 lead ECG recording ordered at the Mayo Clinic ECG lab.
61944622|NCT06041490|NO_INTERVENTION|Without adjuvant therapy|No intervention.
61944623|NCT03301701|EXPERIMENTAL|Arm 1|Radical prostatectomy
61944624|NCT03301701|ACTIVE_COMPARATOR|Arm 2|Radiotherapy
61944625|NCT00627549|ACTIVE_COMPARATOR|1|
61944626|NCT00627549|ACTIVE_COMPARATOR|2|
62164405|NCT01685307|EXPERIMENTAL|intense cooking process|Test meal: 150g of beef cooked at intense temperature. Beef proteins are intrinsically labelled with 15 N protein
62164406|NCT01685307|EXPERIMENTAL|mild cooking process|Test meal: 150 g of beef cooked at moderate intensity. Beef proteins are intrinsically labeled with 15N.
62496038|NCT03710551|EXPERIMENTAL|Experimental Infant Formula|Experimental Infant Formula with a new fat blend plus L. reuteri
62539186|NCT00062985|EXPERIMENTAL|Telephone-based weight loss intervention|
61944627|NCT05476458||Red Dichromatic Imaging|Per-oral endoscopic myotomy will be performed using novel Evis X1 endoscopy(Olympus corporation, Tokyo, Japan) system. RDI mode 1 and Mode 2 will be used during the procedure. Submucosal bleb will be created by injecting mixture of indigo carmine and normal saline. RDI mode 2 will be used for submucosal injection and Mucosal incision. RDI Mode 2 helps in detection of deep mucosal or submucosal vessels which are the major cause of bleeding. Submucosal dissection and myotomy will be performed under white light. However when there is bleeding, RDI mode 1 will be used for the detection of bleeding point. Bleeding will be controlled with spray coagulation or using Coagrasper. Hemostasis treatment will be performed by switching to RDI only at the time of bleeding during the procedure.
62496039|NCT03710551|ACTIVE_COMPARATOR|Standard Infant Formula|Standard bovine milk-based infant formula.
62496040|NCT05462717|EXPERIMENTAL|RMC-6291|Dose Escalation and Dose Expansion
61944628|NCT05476458||White light imaging|Per-oral endoscopic myotomy will be performed using CV-190 Gastroscope (Olympus corporation, Tokyo, Japan). White light imaging is used during entire procedure. Submucosal bleb will be created by injecting mixture of indigo carmine and normal saline. Initial submucosal injection and Mucosal incision will be performed under white light. RDI Entry point bleed and ease of entry into the tunnel will be marked by trainee at the end of the procedure. Submucosal dissection and myotomy will be performed under white light. When there is bleeding, bleeding point is identified with white light and hemostasis is achieved
62139695|NCT05503368|ACTIVE_COMPARATOR|Follicle cell suspension added t NCES|• Under local anesthesia, 1 mm punch will be used to extract hair-follicles from occipital scalp behind the ear. Depending on the area to be transplanted, one hair follicle will be etracted for each 1 cm2. The extracted hair-follicles are washed with phosphate buffered saline (PBS) for about 3 times. The hair-follicles are then incubated with 0.25% trypsin - 0.05% ethylene diamine tetra acetic acid (EDTA) at 37°C for 90 min to prepare the single cell suspension. Within 15-20 min of incubation, the cells start loosening from each other. The hair-follicles are subsequently placed in another tube of trypsin and EDTA. At the end of three such cycles, a thin keratinous shaft is left behind. The cell suspensions of all the tubes are added in a single tube. The final cell pellet is obtained by centrifuging the combined cell suspension at 1000 rpm for 5 min. The resulting suspension will be added to NCES and placed on a comparable derma braded lesion
62139696|NCT05503368|ACTIVE_COMPARATOR|Non cultured epidermal suspension (NCES)|Melanocyte keratinocyte pellet will be prepared. Donor skin will be harvested from the gluteal region ; using a sterile shaving blade mounted on a Kocher's forceps. Cell Suspension will be prepared by placing the donor skin in 0.25% trypsin-EDTA (GIBCO) solution for 40 minutes at 37 ᴼC. sample and trypsin will be poured into a labelled petri dishes then neutralized using ringer's lactate. All the steps will be performed in a laminar air flow bench under strict aseptic conditions. The epidermis will be detached from the dermis which will be discarded. Then the epidermis will be cut into tiny pieces and scrapped so that no pigment is left on the surface. Afterwards, they will be transferred to sterile falcon tubes and centrifuged for 10 minutes at 1,000 rpm. The floating epidermal fragments and supernatant fluid will be removed, leaving the cell pellet containing epidermal cells rich in melanocytes and Keratinocytes at the bottom.
62339966|NCT01021852|EXPERIMENTAL|MK-6096 10 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
62496041|NCT04609397|EXPERIMENTAL|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.
61944629|NCT01391754|EXPERIMENTAL|SafeCare with Coached Implementation|Home-based services with the SafeCare model, implemented with in vivo provider coaching as quality control
61944630|NCT01391754|EXPERIMENTAL|SafeCare without Coaching|Home-based services using the SafeCare model, implemented without in vivo coached implementation quality control
61944631|NCT01391754|EXPERIMENTAL|Services As Usual with Coaching|Usual home based services, with in vivo coached implementation quality control
61944632|NCT01391754|ACTIVE_COMPARATOR|Services As Usual Without Coaching|Usual home based services without in vivo coached quality control
61944633|NCT05244993|EXPERIMENTAL|AK105+Anlotinib Hydrochloride+Albumin Paclitaxel|AK105 200mg IV Day 1 Anlotinib Hydrochloride 12mg PO once daily on Days 1-14 Albumin paclitaxel 125mg/m2 IV Days 1, 8 Cycled every 21 days until disease progression, death or toxicity is intolerable (for subjects who can continue to tolerate the treatment, albumin paclitaxel lasts for at least 6 cycles)
61944634|NCT01663220||obese individuals with type 2 diabetes mellitus|
61944635|NCT01689103|EXPERIMENTAL|Alliance Feedback to Therapist|Alliance feedback provided to therapist
62139697|NCT04407884|EXPERIMENTAL|study arm|Subjects will receive an active study device.
62139698|NCT05660434|EXPERIMENTAL|Intervention Group|Adults (\>18 years) who are currently receiving treatment for SUD in the outpatient treatment program at West Virginia University Chestnut Ridge Center (WVUCRC) (n = 340 approx.). In addition, participants can be at any level of treatment, including peer recovery coach program. Inclusion criteria are patients diagnosed with SUD who have completed intensive acute phase 1 treatment, and who desire to pursue continuous recovery phases (per facility protocol). All participants must be alert and oriented, provide written consent, and be able to read and write English. Exclusion criteria are patients diagnosed with severe mental illness (who cannot consent to participate), have a medical history of asthma or other serious respiratory disease, and known allergy to citrus.
62496042|NCT04609397|EXPERIMENTAL|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.
61944636|NCT01689103|PLACEBO_COMPARATOR|No alliance feedback to therapist|No alliance feedback provided to therapist
61944637|NCT04882280|EXPERIMENTAL|Low room|Low intensity (80 lux) room light
61944638|NCT04882280|EXPERIMENTAL|Normal room|Normal intensity (150 lux) room light
61944639|NCT04882280|EXPERIMENTAL|Bright room|High intensity (500 lux) room light
61944640|NCT04882280|EXPERIMENTAL|Bright|Very high intensity (1000 lux) room light
61944641|NCT02083614|EXPERIMENTAL|clamping|to clamp or release the catheter for 2 days before removal
61944642|NCT02083614|NO_INTERVENTION|no clamping|
61944643|NCT05329532|EXPERIMENTAL|Patients with TNBC, advanced/unresectable SCCHN, high grade serous ovarian carcinoma, or RCC|
61944644|NCT05329532|EXPERIMENTAL|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; monotherapy)|
61944645|NCT05329532|EXPERIMENTAL|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; combination)|
61944646|NCT05538533|EXPERIMENTAL|46 Gray (Gy)|46 gy of radiation therapy will be administered in 10 fractions.
61944647|NCT05538533|EXPERIMENTAL|40 Gray (Gy)|40 gy of radiation therapy will be administered in 7 fractions.
61944648|NCT05538533|EXPERIMENTAL|35 Gray (Gy)|35 gy of radiation therapy will be administered in 5 fractions.
62139699|NCT05660434|NO_INTERVENTION|Control Group|Adults (\>18 years) who are currently receiving treatment for SUD in the outpatient treatment program at West Virginia University Chestnut Ridge Center (WVUCRC) (n = 340 approx.). In addition, participants can be at any level of treatment, including peer recovery coach program. Inclusion criteria are patients diagnosed with SUD who have completed intensive acute phase 1 treatment, and who desire to pursue continuous recovery phases (per facility protocol). All participants must be alert and oriented, provide written consent, and be able to read and write English. Exclusion criteria are patients diagnosed with severe mental illness (who cannot consent to participate), have a medical history of asthma or other serious respiratory disease, and known allergy to citrus.
62496043|NCT04609397|PLACEBO_COMPARATOR|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.
62496044|NCT01097694|ACTIVE_COMPARATOR|Imatinib mesylate|Group on active imatinib treatment
62496045|NCT01097694|PLACEBO_COMPARATOR|Placebo|Group on Placebo treatment
61944649|NCT00842582|EXPERIMENTAL|Single group assignment|Patients will receive Azacitidine at 20, 40, or 75 milligrams per meter squared subcutaneous once daily for 7 days.
61944650|NCT01751893|EXPERIMENTAL|Henna arm|Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
61944651|NCT01751893|PLACEBO_COMPARATOR|Placebo|Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hours and then the mixture will be rinsed with fresh water.
61944652|NCT03788629|EXPERIMENTAL|Study Group 1|Bobath Concept+ Talocrural joint Mulligan MWM techniques were applied to this group.
61944653|NCT03788629|ACTIVE_COMPARATOR|Study Group 2|Subtalar joint Mulligan MWM techniques were applied to this group in addition to Bobath Concept+ Talocrural joint Mulligan MWM techniques
61944654|NCT04509869|EXPERIMENTAL|pre-operative and postoperative|the patients who will undergo the operation to treat the pain
61944655|NCT01349231|EXPERIMENTAL|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of ketamine.
61944656|NCT04696523|ACTIVE_COMPARATOR|Air/Oxygen|Control arm: air/oxygen with standard of care
61944657|NCT04696523|EXPERIMENTAL|xenon|Xenon arm: xenon inhalation in air/oxygen with standard of care
61944658|NCT06239831||Postoperative monitoring|ActivPAL accelerometer will be placed on the chest and thigh, an ExSpiron monitor placed on the chest, and the patient will be observed for three days, until fully ambulatory (able to walk 30 meters without assistance with or without a walker), or until discharge; whichever comes earlier.
61944659|NCT03420625|ACTIVE_COMPARATOR|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
62139700|NCT03345095|EXPERIMENTAL|Experimental Arm|Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
62139701|NCT03345095|ACTIVE_COMPARATOR|Standard Arm|Radiotherapy + Temozolomide followed by adjuvant Temozolomide
61944660|NCT03420625|ACTIVE_COMPARATOR|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
61944661|NCT03420625|ACTIVE_COMPARATOR|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
61944662|NCT03420625|ACTIVE_COMPARATOR|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
61944663|NCT01954160|OTHER|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
61944664|NCT01954160|OTHER|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
61944665|NCT05314738|EXPERIMENTAL|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 1 / Cohort 1|Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
61944666|NCT05314738|ACTIVE_COMPARATOR|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2A|Riboflavin Solution + Exposure to NXL system to achieve total energy level 1
62496046|NCT06321055||Advanced Gastro-intestinal soft-tissue tumors (GIST) patients|Adult GIST patients with evidence of regorafenib treatment initiation among commercially insured or Medicare patients in the Merative MarketScan database.
62496047|NCT02374216|OTHER|Dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 and August 31st 2017
61944667|NCT05314738|ACTIVE_COMPARATOR|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2A|Riboflavin Solution + Exposure to NXL system to achieve total energy level 2
61944668|NCT05314738|ACTIVE_COMPARATOR|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2A|Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
61944669|NCT05314738|ACTIVE_COMPARATOR|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2B|Riboflavin Solution + Exposure to NXL system to achieve total energy level 1
61944670|NCT05314738|ACTIVE_COMPARATOR|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2B|Riboflavin Solution + Exposure to NXL system to achieve total energy level 2
61944671|NCT05314738|ACTIVE_COMPARATOR|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2B|Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
61944672|NCT05314738|SHAM_COMPARATOR|Placebo Group 2 / Cohort 2B|Sham Solution with no exposure to NXL System
61944673|NCT01566734|EXPERIMENTAL|Cefazolin|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
61944674|NCT01566734|EXPERIMENTAL|Normal Saline|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients
61944675|NCT01566734|NO_INTERVENTION|Control|
62496048|NCT03950674|EXPERIMENTAL|Pembrolizumab with Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and Pemetrexed|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression. Participants who receive pembrolizumab 200 mg IV Q3W for up to 2 years, but experience disease progression, are eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to another year.
62496049|NCT03950674|ACTIVE_COMPARATOR|Placebo with Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression. Participants who receive saline placebo, but experience disease progression, can switch over to pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 2 years. The participants who switch over to pembrolizumab 200 mg IV Q3W, but experience disease progression, are eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to another year.
62496050|NCT04520243|EXPERIMENTAL|English alphabet illiterate group|Individuals with no self-reported understanding of English alphabet and recognition of \<6/10 Sloan Letters
61944676|NCT00644189|OTHER|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
61944677|NCT01941693|EXPERIMENTAL|Integrated care|"Integrated care:~Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders."
62339967|NCT01021852|EXPERIMENTAL|Placebo/MK-6096 10 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
61944678|NCT01941693|ACTIVE_COMPARATOR|Usual care|Usual care
61944679|NCT02084212|OTHER|Patients about to undergo epiretinal membrane surgery|
61944680|NCT03882190|NO_INTERVENTION|group 1|
62496051|NCT04520243|ACTIVE_COMPARATOR|English alphabet literate group|Individuals with self-reported understanding of English alphabet and recognition of ≥6/10 Sloan Letters
62496052|NCT05001191|EXPERIMENTAL|Gentle Human Touch Group|
62496053|NCT05001191|NO_INTERVENTION|Control group|
61944681|NCT03882190|EXPERIMENTAL|group 2|
61944682|NCT02112344|EXPERIMENTAL|Total mucosal irradiation|
61944683|NCT03511664|EXPERIMENTAL|177Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)|Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used
61944684|NCT03511664|OTHER|Best supportive/best standard of care (BS/BSOC) alone|Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator
61944685|NCT00002561|ACTIVE_COMPARATOR|Radiotherapy or ABVD + Radiotherapy|Radiotherapy
61944686|NCT00002561|ACTIVE_COMPARATOR|ABVD Alone|ABVD Alone
61944687|NCT06453902|EXPERIMENTAL|Experimental: TGRX-678|All patients with CML-AP to be treated with TGRX-678. Patients with T315I mutation or without T315I mutation will be assigned into separate cohorts for evaluation
61944688|NCT04644003|EXPERIMENTAL|STP1 Low Dose|1 capsule and 1 tablet per intake
61944689|NCT04644003|EXPERIMENTAL|STP1 High Dose|1 capsule and 1 tablet per intake
61944690|NCT04644003|PLACEBO_COMPARATOR|Placebo|1 placebo capsule and 1 placebo tablet per intake
61944691|NCT03516825|EXPERIMENTAL|Musical Neglect Training (MNT)|A single-subject design was used. All participants took Musical Neglect Training.
61944692|NCT02840721|EXPERIMENTAL|PF-06480605|PF-06480605 500 mg IV Q2W X 7 doses
62139702|NCT05967858||gastroenterological|Consecutive admissions - n= 43 - 34 operated (79%) - 10 patients acutely admitted Diseases in Esophagus (8), gastric cavity (8), pancreas (7), colon/rectum (8), bile (4), small intestine (3), IBD (5) No interventions in the treatments, just observation
62496054|NCT03645616|EXPERIMENTAL|Functional Tests|Participants undertook 6-minute walk test, 10 meters walk test and 30 second sit to stand test.
62496055|NCT01120691|EXPERIMENTAL|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
62496056|NCT01120691|ACTIVE_COMPARATOR|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
62496057|NCT01120691|ACTIVE_COMPARATOR|open-label tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
62496058|NCT01510509|EXPERIMENTAL|Titanium bare metal stent|Titanium bare metal stent (Titan2®, Hexacath, Paris, France)
62496059|NCT01510509|EXPERIMENTAL|Everolimus Drug Eluting Stent|Xience-V®, Abbott Vascular, Santa Clara, California, USA
61944693|NCT01497275|EXPERIMENTAL|Zevalin + Velcade|"Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi."
61944694|NCT02429843|EXPERIMENTAL|Standard treatment + TRC105|In addition to standard treatment of paclitaxel, carboplatin, and bevacizumab, dosing of TRC105 will begin at 8 mg/kg. However a lower dose level has also been included (6 mg/kg) and will be enrolled if 8 mg/kg is found to exceed the maximum tolerated dose. Following the appropriate pre-medication regimen, the first weekly TRC105 dose (cycle 1 day 8) will be split into two doses whereby 3 mg/kg is administered on cycle 1 day 8 and the balance (e.g., 5 mg/kg for Dose Level 1) is administered on cycle 1 day 11. Beginning with cycle 1 day 15 and thereafter, the full TRC105 dose will be administered intravenously each week during the 21-day cycle. Intra-patient dose reductions are allowed beginning in cycle 2.
61944695|NCT01414608|EXPERIMENTAL|Arm I (cisplatin, radiation therapy, brachytherapy)|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.
61944696|NCT01414608|EXPERIMENTAL|Arm II (cisplatin, radiation therapy, brachytherapy, chemo)|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
61944697|NCT02259101|EXPERIMENTAL|CBT-I Treatment Condition|The CBT-I treatment condition will be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total CBT-I groups occurring over the course of two years will be implemented, with at total of 40 participants enrolled for the CBT-I condition.
61944698|NCT02259101|ACTIVE_COMPARATOR|SH Comparison Condition|The SH comparison condition will also be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total SH groups over the course of two years will be conducted, with a total of 40 participants enrolled for the SH condition.
61944699|NCT03980431|EXPERIMENTAL|FBY in suspected malignant brain tumor|This arm investigates the metabolic characteristics of FBY in suspected malignant brain tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after FBY PET scan.
61944700|NCT03980431|EXPERIMENTAL|FBY in suspected recurrent glioma|This arm investigates the value of FBY to differentiate tumor progression from pseudoprogression. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operation, MRI follow up or change of treatment strategy, according to specific conditions, will be recommended for the definitive diagnosis as well as the management of patients.
61944701|NCT05616975||reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests
61944702|NCT05616975||validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests
61944703|NCT05616975||normative|Collection of normative SWAY Balance, Functional, and Cognitive data
61944704|NCT02474381|EXPERIMENTAL|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
61944705|NCT02474381|ACTIVE_COMPARATOR|Single PTA|Angioplasty of arteries below tibial plateau level only
62496060|NCT03807830|OTHER|One arm feasbility study|
62496061|NCT05778890|EXPERIMENTAL|Intervention group|The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Intervention group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form. These exercises were not given to the control group.
62496062|NCT05778890|ACTIVE_COMPARATOR|control group|Control group is physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. This group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
62496063|NCT03247686|PLACEBO_COMPARATOR|Placebo|Placebo
62496064|NCT03247686|ACTIVE_COMPARATOR|RSLV-132|Experimental drug
62496065|NCT00338390|NO_INTERVENTION|1|Maintain antiretroviral treatment
62496066|NCT00338390|EXPERIMENTAL|2|Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.
62496067|NCT00338390|EXPERIMENTAL|3|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
62539187|NCT04007653||Patients treated with heparin+edoxaban for VTE|Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
61944706|NCT05027061||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Warfarin
61944707|NCT05027061||Cohort 2|NVAF participants receiving oral anticoagulant - Apixaban
61944708|NCT05027061||Cohort 3|NVAF participants receiving oral anticoagulant - Dabigatran
61944709|NCT05027061||Cohort 4|NVAF participants receiving oral anticoagulant - Edoxaban
61944710|NCT05027061||Cohort 5|NVAF participants receiving oral anticoagulant - Rivaroxaban
61944711|NCT05027061||Cohort 6|NVAF participants not receiving oral anticoagulants
61944712|NCT03626168|ACTIVE_COMPARATOR|Consumption of 100% watermelon juice|Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
61944713|NCT03626168|PLACEBO_COMPARATOR|Consumption of a placebo beverage|Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
61944714|NCT04171154|EXPERIMENTAL|Expectation|Participants are asked to think of three strength which have helped them in prior stressful events. They then have to think of ways how these strength may help them in future stressful situations, i.e. a test in this experiment.
61944715|NCT04171154|EXPERIMENTAL|Acceptance|Participants listen to an audio-instruction on cognitive defusion. They shall observe the thoughts and feelings of stress and, with the help of the instruction, distance themselves from it.
61944716|NCT04171154|NO_INTERVENTION|Control|Participants wait for the stress-test to start.
61944717|NCT02328417||Control|Consecutive radical cystectomies up to 94 patients in 13 participating hospitals in Madrid, Spain. These patients will be taken care of as it is done regularly in each of participating hospitals. All study variables will be prospectively collected in this group
61944718|NCT02328417||Active Treatment|"After recruiting cotrol group, another consecutive radical cystectomies up to 94 patients in 13 participating hospitals will be recruited and the following measures will be followed with them:~I.-PREOPERATIVE MEASURES: (eight measures according to Protocol) II.- INTRAOPERATIVE MEASURES: (six measures according to Protocol) III.- POSTOPERATIVE MEASURES: (eight measures according to Protocol)"
62139703|NCT05967858||head and neck cancer|Consecutive admissions - n=8 - 7 radiation therapy - 1 operated Locations: 2 Larynx, 1 oro-pharynx, 4 tonsillar, 1 tung No interventions in the treatments, just observation
62139704|NCT04379375|ACTIVE_COMPARATOR|Inertia|"Participants simply receive and subsequently have default access (i.e., readily and immediately available) to handwashing (HW) materials. This condition will functionally serve as a control comparison. As the term implies, inertia capitalizes on minimizing effort necessary (e.g., going to the grocery store) to engage in HW behavior in one's personal environment."
62339968|NCT01021852|EXPERIMENTAL|MK-6096 20 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
62339969|NCT01021852|EXPERIMENTAL|Placebo/MK-6096 20 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
62339970|NCT02145923|OTHER|allogeneic MMSCs infusion|Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion.
62339971|NCT03241563|ACTIVE_COMPARATOR|without triamcinolone|sodium Deoxycholate without triamcinolone
62339972|NCT03241563|ACTIVE_COMPARATOR|with triamcinolone|sodium Deoxycholate with triamcinolone
62339973|NCT02619318|EXPERIMENTAL|The Balancing Everyday Life (BEL) intervention|The BEL was developed on the basis of previous research on lifestyle interventions made by our own group and other researchers \[1, 2\]. It is a group-based programme (5-8 participants) with 12 sessions, one session a week, and 2 booster sessions with two-week intervals. The themes for the group sessions are, e.g., activity balance, healthy living, work-related activities, and social activities. Each session contains a main group activity and a home assignment to be completed between sessions. The main group activity starts with analysing the present situation and proceeds with identifying desired goals and finding strategies for how to reach them. The home assignment is aimed at testing one of the proposed strategies. Self-analysis, setting goals, finding strategies and evaluating the outcome of tested strategies form a process for each session, but also for the BEL intervention as a whole.
61944719|NCT01663025|EXPERIMENTAL|Hand Reflexology|Participants in this condition will receive hand reflexology, performed by a trained reflexologist during their treatment. This will be in addition to usual standard care therefore the surgeon will speak to the participant occasionally to ensure they are comfortable.
61944720|NCT01663025|NO_INTERVENTION|Control|Participants in condition will form the control group for the study. They will receive usual standard care during treatment which will involve the surgeon speaking to them occasionally to ensure that they are comfortable.
62339974|NCT02619318|ACTIVE_COMPARATOR|Care as usual (standard occupational therapy)|Standard occupational therapy involves support to open-market employment and support in managing everyday life in general.
62339975|NCT02344407|EXPERIMENTAL|2|ChAd3-EBO Z
62339976|NCT02344407|EXPERIMENTAL|3|VSVG-ZEBOV
62339977|NCT02344407|PLACEBO_COMPARATOR|1|Placebo (Saline)
61944721|NCT01596387|EXPERIMENTAL|Propofol|20 obese patients(IMC\>35 kg m-2) scheduled for laparoscopic bariatric surgery.
61944722|NCT05249699|EXPERIMENTAL|Positive TSPOT results with clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
61944723|NCT05249699|PLACEBO_COMPARATOR|Negative TSPOT results with clinical risk factors group|patients receive no additional therapy
61944724|NCT05249699|EXPERIMENTAL|Clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
61944725|NCT05636644||Group A|anthracyclines+cyclophosphamide+other paclitaxel drugs
61944726|NCT05636644||Group B|anthracyclines+cyclophosphamide+nab paclitaxel
61944727|NCT05769309|ACTIVE_COMPARATOR|Erector spinae block group|the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
61944728|NCT05769309|OTHER|control group|no block will be done but only IV analgesia.
62496068|NCT04065646|EXPERIMENTAL|Intervention|The intervention group will receive daily text messages with information on: (i) HMM stop locations and schedule; (ii) information on HMM weekly produce specials and sales; (iii) motivational messages encouraging use of the HMM; and (iv) links to produce coupons that they can exchange at HMM- $5 coupons received weekly for the four-week texting period.
62496069|NCT04065646|NO_INTERVENTION|Control|The control group will receive the same dosage of daily text messages covering free activities taking place at the Hartford Public Library and other community locations. The control group will not receive incentive coupons.
62496070|NCT00656539|EXPERIMENTAL|1|AzaSite®
62496071|NCT00656539|NO_INTERVENTION|2|
62496072|NCT04054258|EXPERIMENTAL|App support programme group|In addition to the usual care, the participant and one family member will receive a CHD app and a briefing from a trained research nurse (A). The reason to invite an additional family member to install the app is to ensure that he/she can be informed automatically when the patient presses an icon during a chest pain attack. The patient may be too stressed during an angina attack and may not be able to follow the 'Things to Do List' quickly. In addition, automatic reminders of the individual's medication times and follow-up times will be pre-set in the app for individual use.
62496073|NCT04054258|ACTIVE_COMPARATOR|Telephone support group|In addition to the above usual care, bi-weekly 20-minute telephone follow-ups will be provided by a trained research nurse (B) for up to 3 months. Patients can ask about related health problems if any. The nurse will address their problem by providing advice or referring them to the ED follow-up clinic. The team has set up a telephone advice guide to support the research nurse in giving phone advice.
62496074|NCT04733313|ACTIVE_COMPARATOR|quadratus lumborum-2|
62496075|NCT04733313|ACTIVE_COMPARATOR|quadratus lumborum-3|
62496076|NCT01632306|EXPERIMENTAL|LY2090314 + Gemcitabine|LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m\^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
62496077|NCT01632306|EXPERIMENTAL|LY2090314 + FOLFOX|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
62496078|NCT01632306|EXPERIMENTAL|LY2090314 + Gemcitabine + Nab-paclitaxel|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m\^2 gemcitabine + 125 mg/m\^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.
62496079|NCT05549687|EXPERIMENTAL|Group I (Pack Health Program)|Patients participate in the Pack Health Program which includes up to 60 scheduled touch points via phone, text, email and a mobile application and weekly interaction with a health coach over 3 months. They also have access to standard of care support services at MD Anderson including a telephone triage line 5 days a week between 8 a.m. and 5 p.m.
62496080|NCT05549687|ACTIVE_COMPARATOR|Group II (standard of care support services)|Patients receive standard of care support services with a telephone triage line available 5 days a week between 8 a.m. and 5 p.m.
62496081|NCT05762653||Case|Cases are adult patients with type-2 diabetes, who undergo endoscopic ultrasound examination for any non-pancreatic indication.
62496082|NCT05762653||Control|Controls are adult, non-diabetic patients, who undergo endoscopic ultrasound examination for any non-pancreatic indication.
62496083|NCT05280080|ACTIVE_COMPARATOR|Regular Task|Knee extensions.
62496084|NCT05280080|EXPERIMENTAL|Dual Task|Knee extensions while also doing a self-regulated mathematical dual-task.
62496085|NCT05975112||cesarean section|"maternal blood is drawn immediately after the baby's cord is cut and analyzed using thrombelastography with the addition of tranexamic acid. In addition, the following parameters are examined:~* Levels of Factor 1 (Fibrinogen) and Factor 2 (Thrombin)~* Level of hs-D-Dimer~SpHb is measured before discharge from the delivery room in order to estimate blood loss and to be able to make a comparison with the level of Hb measured in the laboratory as part of clinical routine."
62496086|NCT05975112||vaginal delivery|"maternal blood is drawn immediately after the baby's cord is cut and analyzed using thrombelastography with the addition of tranexamic acid. In addition, the following parameters are examined:~* Levels of Factor 1 (Fibrinogen) and Factor 2 (Thrombin)~* Level of hs-D-Dimer~SpHb is measured before discharge from the delivery room in order to estimate blood loss and to be able to make a comparison with the level of Hb measured in the laboratory as part of clinical routine."
61944729|NCT02954627||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
61944730|NCT04686695|EXPERIMENTAL|Transcutaneous Auricular Vagus Nerve Stimulation|
61944731|NCT03270644|EXPERIMENTAL|Lasmiditan Reference|Single oral dose of lasmiditan 200 mg on Day 1 as reference treatment.
61944732|NCT03270644|ACTIVE_COMPARATOR|Propranolol Reference|Twice-daily oral doses of propranolol 80 mg on Days 4-10 as reference treatment.
62339978|NCT00186056|EXPERIMENTAL|Mifepristone|Patients received mifepristone for 6 days
61944733|NCT03270644|EXPERIMENTAL|Lasmiditan + Propranolol Test|Single oral dose of lasmiditan 200 mg + two oral doses of propranolol 80 mg on Day 9 as test treatment.
61944734|NCT04141046|SHAM_COMPARATOR|Sham Stimulation|This is a sham/placebo arm that receives some stimulation, mimicking the skin sensations associated with tACS to enhance success of patient blinding.
62339979|NCT00186056|PLACEBO_COMPARATOR|placebo|Patients received placebo for 6 days
61944735|NCT04141046|ACTIVE_COMPARATOR|Theta-tACS|This arm targets theta oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
61944736|NCT04141046|EXPERIMENTAL|Alpha-tACS|This arm targets alpha oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
61944737|NCT01934244||Per Protocol|All enrolled patients in which all inclusion/exclusion criteria were met and the NovaSure endometrial ablation was completed.
61944738|NCT01934244||Primary|All enrolled patients in whom the Novasure device was inserted.
61944739|NCT01934244||Intent to treat|All enrolled patients in which NovaSure device was attempted.
61944740|NCT01287078|EXPERIMENTAL|Inhaled Cyclosporine in Lung Transplant and HSCT Recipients|Subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.
61944741|NCT03124446|EXPERIMENTAL|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
61944742|NCT03124446|ACTIVE_COMPARATOR|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
61944743|NCT06432231|EXPERIMENTAL|Low glycemic index diet treatment|Children with drug-resistant epilepsy were treated with a low glycemic index diet for 3 months.
61944744|NCT05583565|EXPERIMENTAL|study group|receiving sensory integration approach
61944745|NCT05583565|ACTIVE_COMPARATOR|control group|receiving conventional physical therapy
61944746|NCT02666885|EXPERIMENTAL|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
61944747|NCT03545100|EXPERIMENTAL|experimental group|motor control therapy
61944748|NCT03545100|ACTIVE_COMPARATOR|control group|regular physical therapy
61944749|NCT00462631|EXPERIMENTAL|1|paclitaxel eluting balloon followed by bare metal stent
62697645|NCT06188806|ACTIVE_COMPARATOR|PROXİMAL ADDUKTOR CANAL BLOCK GROUP|Patients are placed in the supine position and a high-frequency linear probe is inserted for a cross-sectional image of the groin and thigh. The femoral nerve is identified in the short axis near the inguinal crease and the ultrasound transducer is placed caudally beyond the femoral triangle. The location of the proximal block is determined where the superficial femoral artery passes under the medial border of the sartorius muscle (usually 8-12 cm distal to the inguinal crease). Using the in-plane technique, a 100 mm peripheral nerve block needle is advanced until the tip of the needle passes the sartorius muscle and enters the adductor canal from the lateral side of the superficial femoral artery, and 20 mL 0.375% Bupivacaine is administered. To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.
61944750|NCT00462631|ACTIVE_COMPARATOR|2|Paclitaxel eluting stent
61944751|NCT01910961|EXPERIMENTAL|limb RIPC|limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
61944752|NCT01910961|NO_INTERVENTION|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia.The control group had an uninflated cuff placed on the left upper arm for 30 min.
61944753|NCT00292396|ACTIVE_COMPARATOR|1|Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks
61944754|NCT00292396|ACTIVE_COMPARATOR|2|Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks
61944755|NCT00292396|ACTIVE_COMPARATOR|3|Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks
62139705|NCT04379375|EXPERIMENTAL|Anchoring|"Involves once again providing default access to HW materials as above, but adds an explicit written cue to wash hands at a rate of (15) times per day, which is placed directly on the soap dispenser. The stimulus is intended to deliberately prime participant thinking (and subsequent behavior) towards a higher reference point that overshoots a desired target rate of 10+ daily HWs."
62339980|NCT04969133|ACTIVE_COMPARATOR|TAP Block|"Transverse abdominal block is realisated at the beginning of the surgery with ultrasound guided technique with levobupivacaine 2.5mg/mL, 0.3mL/kg each side.~The patient receives usual analgesia protocol."
61944756|NCT00292396|ACTIVE_COMPARATOR|4|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks
61944757|NCT00292396|ACTIVE_COMPARATOR|5|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks
61944758|NCT00292396|PLACEBO_COMPARATOR|6|placebo, 12 doses
61944759|NCT03656107|EXPERIMENTAL|Cognitive training|Participants selected to brain training will be given instructions on how to access and use the program at home for 15-30minutes, 3-5 times per week for 8-12 weeks.
61944760|NCT03656107|NO_INTERVENTION|Waiting-list control|Control participants will be waiting listed to receive the brain training program at the end of the study. control participants will undergo usual care.
61944761|NCT00853346|EXPERIMENTAL|1|Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
61944762|NCT00853346|ACTIVE_COMPARATOR|2|Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
61944763|NCT05061706|EXPERIMENTAL|Lumateperone 42 mg|
61944764|NCT05061706|PLACEBO_COMPARATOR|Placebo|
61944765|NCT04223973|EXPERIMENTAL|Active Group|Using the Medtrum Pump A7+ during 3 months
62496087|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
62496088|NCT00622362|ACTIVE_COMPARATOR|A|Subcutaneous administration
62496089|NCT00622362|EXPERIMENTAL|B|Sublingual administration
61944766|NCT04223973|ACTIVE_COMPARATOR|Control Group|using the usual Insulet Patch pump
61944767|NCT04553679||Stroke survivors|Participants who have had a stroke
61944768|NCT04553679||Caregivers|Participants who are caring for someone who have had a stroke
61944769|NCT02291354|PLACEBO_COMPARATOR|FMT + Placebo|Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.
61944770|NCT02291354|EXPERIMENTAL|FMT + Pectin|Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.
61944771|NCT03078400|EXPERIMENTAL|Safety Phase|"Six to 12 subjects~* Cohort 1 SPL-108 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles~* Cohort 2 SPL-108 BID injection + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles"
61944772|NCT03078400|EXPERIMENTAL|Exploratory Expansion Phase|"Up to 12 subjects~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."
61944773|NCT03804008|ACTIVE_COMPARATOR|Fundamental advice and a heel cup|
61944774|NCT03804008|ACTIVE_COMPARATOR|Fundamental advice and a heel cup plus exercise|
61944775|NCT03804008|ACTIVE_COMPARATOR|Fundamental advice and a heel cup plus exercise and injection|
61944776|NCT04725422||disease modifying anti-rheumatic drug, DMARD|"1. Methotrexate 1 mg/kg (max 25 mg) PO or SQ weekly~2. Sulfasalazine 30 mg/kg (max 1000 mg) PO twice daily~3. Leflunomide 10-20 mg PO daily"
61944777|NCT04725422||tumor necrosis factor inhibitor, TNFi|"1. Adalimumab (subcutaneous) 10-40 mg SQ every other week~2. Etanercept (subcutaneous) 12.5-50 mg SQ every week~3. Infliximab (intravenous) 10 mg/kg (max 1000 mg) i.v. at week 0,2, 6 then every 4 weeks~4. Golimumab (subcutaneous or intravenous) 2 mg/kg (max 200 mg) at every 4 weeks"
61944778|NCT04725422||bisphosphonate|"1. Pamidronate 1 mg/kg (max 90 mg) (intravenous)\*:~   Option 1: every month Option 2: 3 consecutive days every 3 months~2. Zoledronic acid 0.0125-0.05 mg/kg (max 4mg) (intravenous): every 3-6 months. \* Both options may use lower dose of 0.5 mg/kg at the initiation of the treatment. All options allow concurrent use of NSAIDs."
61944779|NCT04725422||non-steroidal anti-inflammatory drugs|"1. Naproxen 10 mg/kg (max 500 mg) PO twice daily~2. Indomethacin 1 mg/kg (max daily dose 150 mg) PO twice or three times daily~3. Meloxicam 0.1-0.3 mg/kg (max 15 mg) PO daily~4. Piroxicam 10-20 mg PO daily~5. Ibuprofen 10 mg/kg (max 800 mg) PO 3-4 times daily"
62139706|NCT04090632|EXPERIMENTAL|closed kineTic chain upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
62139707|NCT03856619|EXPERIMENTAL|Aubagio®/Teriflunomide|Single dose of Aubagio® to be taken orally, once daily in the morning
62139708|NCT02555345||classic asthma/No intervention|Patients with classic asthma were stable.Chest X-ray or CT scan was normal.Fenofibrate(FeNO) was performed.Spirometry was needed. The leicester cough questionnaire (LCQ) was offered to physicians.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
62496090|NCT00622362|PLACEBO_COMPARATOR|C|Sublingual administration
62496091|NCT05241314|EXPERIMENTAL|Phase 1 Youth Focus Group|Intervention adaptation and Community Health Worker Interventionist (CHWI) training through the delivery of the intervention to an adolescent focus group. CHWI from WellShare International will lead the recruitment of adolescent youth from the existing cohort of families and up to two Zoom focus groups will be held.
62496092|NCT05241314|EXPERIMENTAL|Phase 2 Youth|One randomly selected index youth per participating Karen family. Community health worker interventionists (CHWI) will deliver 7 weeks of home-based intervention with optional post-intervention focus groups to examine the feasibility of the community-based participatory research approach and intervention delivery by CHWIs.
62496093|NCT05241314|EXPERIMENTAL|Phase 2 Caregivers/Adults|Maternal and paternal caregivers (if present) of participating Karen family. Community health worker interventionists (CHWI) will deliver 7 weeks of home-based intervention with optional post-intervention focus groups to examine the feasibility of the community-based participatory research approach and intervention delivery by CHWIs.
62539188|NCT04007653||Patients treated with heparin+VKA for VTE|Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
62539189|NCT04170751|EXPERIMENTAL|group N|In group N, 16 mcg / cc of norepinephrine was infused to patients.
62539190|NCT04170751|EXPERIMENTAL|group V|In group V, 0.4 unit / cc of vasopressin was infused to patients.
61944780|NCT01118871|ACTIVE_COMPARATOR|Standard of care|
62139709|NCT02555345||CVA/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered to physicians. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
62139710|NCT02555345||EB/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
62139711|NCT02555345||Healthy/No intervention|Chest X-ray or CT scan was normal.FeNO was performed.Spirometry was needed. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
62139712|NCT01401790|EXPERIMENTAL|Telehomecare|3 month use of a new telehomecare program
62139713|NCT01401790|ACTIVE_COMPARATOR|Control|3 month regular education program and follow up at the Diabetes Clinic
61944781|NCT01118871|EXPERIMENTAL|NRTI sparing arm|
61944782|NCT00407160||Group 1 Standard Immunosuppression|"Anti-thymocyte Globulin (Rabbit)\] ,tacrolimus, mycophenolate mofetil and prednisone~Patients with End Stage Renal Disease (ESRD) and high Panel Reactive Antibody (PRA) who randomize to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.~They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone."
62697646|NCT06188806|ACTIVE_COMPARATOR|DİSTAL ADDUKTOR CANAL BLOCK GROUP|Patients are placed in the supine position, the mid-thigh point is determined as half the distance between the groin crease and the top of the patella. After the mid-thigh mark is marked with a sterile marking pen, the ultrasound transducer is positioned for a transverse view of the adductor canal into the mid-thigh. Under USG imaging, the femoral artery and saphenous nerve are identified. The distal position is determined where the USG probe moves away from the sartorius muscle of the femoral artery and proceeds deep into the adductor hiatus, and a 100 mm block needle passes the sartorius muscle with an in plane technique and 20 mL 0.375% Bupivacaine is administered to the lateral side of the femoral artery and saphenous nerve.
62697647|NCT06188806|SHAM_COMPARATOR|CONTROL GROUP|No nerve block procedure is applied to patients.
62697648|NCT06565130|OTHER|Attention Skills Training|Intervention plan, which will begin by talking about the importance of attention in sports; It will consist of different tasks that include sub-parameters of attention, such as maintaining attention, shifting attention, focusing attention and splitting attention.
61944783|NCT00407160||Group 2 Campath Immunosuppression|"Alemtuzumab,tacrolimus~Patients with ESRD and high PRA who randomize to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy)."
62339981|NCT04969133|ACTIVE_COMPARATOR|local infiltration of the trocar wounds|"local infiltration of the trocar wounds is realisated at the end of the surgery by the surgeon with levobupivacaine 2.5mg/mL 0.6mL/kg distributed in each trocar opening.~The patient receives usual analgesia protocol."
62697649|NCT01990040||Teduglutide treated|SBS participants who have been treated with teduglutide.
62697650|NCT01990040||Non-teduglutide treated|SBS participants who have not been treated with teduglutide.
62697651|NCT01230411|PLACEBO_COMPARATOR|placebo|IV saline administration as placebo
62697652|NCT01230411|EXPERIMENTAL|Ibuprofen|IV ibuprofen
62697653|NCT00938626|EXPERIMENTAL|Armed-activated T cells/Immunotherapy|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
62697654|NCT06036368|EXPERIMENTAL|Peroneal eTNM arm|All patients will receive treatment with peroneal eTNM
62697655|NCT01117779||Kidney lesions amenable to cryoablation|Kidney lesions treated with cryoablation.
62697656|NCT06563167||CXR receipients|Patients who will receive CXR after lung biopsy
62697657|NCT04935593|EXPERIMENTAL|Renew Intervention Group|Participants in the group will receive training to help children strengthen social, emotional and behavioral knowledge and resilience.
62697658|NCT04935593|NO_INTERVENTION|Parallel Control Group|Participants in the group will receive the usual bible lessons and activities
62697659|NCT06005948|ACTIVE_COMPARATOR|control group|No exercise will be given after surgery
62697660|NCT06005948|EXPERIMENTAL|exercise group|Dynamic neuromuscular stabilization exercises will be performed for 8 weeks after surgery.
62697661|NCT04861701|EXPERIMENTAL|Stretching exercise group (SE)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
62697662|NCT04861701|NO_INTERVENTION|Control group (CON)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
62697663|NCT03659825|PLACEBO_COMPARATOR|Placebo + Normoxia|Taste, volume and appearance matched drink given before cognitive testing in normoxia
62697664|NCT03659825|PLACEBO_COMPARATOR|Placebo + Hypoxia|Taste, volume and appearance matched drink given before cognitive testing in hypoxia
62697665|NCT03659825|EXPERIMENTAL|Ketone Ester + Normoxia|Ketone ester drink given before cognitive testing in normoxia
61944784|NCT01715935|EXPERIMENTAL|everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
62139714|NCT06098105|ACTIVE_COMPARATOR|Ultrasound-guided transversus abdominis plane block|This group will receive Ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
62139715|NCT06098105|EXPERIMENTAL|Laparoscopic-assisted transversus abdominis plane block|Patients will receive Laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
62697666|NCT03659825|EXPERIMENTAL|Ketone Ester + Hypoxia|Ketone ester drink given before cognitive testing in hypoxia
62697667|NCT05573308|EXPERIMENTAL|Clear Aligners with Dental Monitoring|"Experiment group: DM (Remote Dental Monitoring approach). Remote Dental Monitoring by DMTM will be implemented in the patient's orthodontic treatment. Pretreatment, 3D digital intra-oral scans will be uploaded to the DMTM dashboard, so they serve as the baseline for 3D tracking of tooth movement. Patients will be trained on how to use the DMTM application and do DM remote scans using their smartphones DM scan box and rector.~They will be instructed to do the DM scan after the initial tray insertion. Replacement of the aligners trays will be based on DM GO tracking function, which is specifically targeted at clear aligner treatment."
62697668|NCT05573308|ACTIVE_COMPARATOR|Clear Aligners replaced every 7 days|Group 2:Control group. All subjects will have conventional aligner treatment with aligners replaced every 7 days, and standard in-office visits every 8 weeks.
61944785|NCT03334110|EXPERIMENTAL|LIMA-GSV-SCVBG Group|Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
61944786|NCT03334110|OTHER|BIMA-SCVBG Group|The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
61944787|NCT03929510|EXPERIMENTAL|Period A|Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).
62339982|NCT03360136|OTHER|Multi-professional CBT-rehabilitation|24 weeks CBT-based multi-professional rehabilitation.
62697669|NCT05573308|ACTIVE_COMPARATOR|Clear Aligners replaced every 14 days|Group 3: (n=40) Control group. All subjects will have conventional aligner treatment with aligners replaced every 14 days, and standard in-office visits every 8 weeks.
61944788|NCT03929510|EXPERIMENTAL|Period B|Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).
61944789|NCT04391491||Heart failure with preserved ejection fraction|Patients of both sexes and \> 18 years with a confirmed diagnosis of HFpEF (Symptoms of HF (NYHA II-IV); LVEF \>50%; Elevated levels of natriuretic peptides (NT-pro BNP \> 300 pg/ml in sinus rhythm, \>600 pg/ml in AF);Relevant structural heart disease (Left ventricle hypertrophy (LVH) and/or Left atrium enlargement (LAE); left atrial volume index (LAVI) \>34 mL/m2 or a left ventricular mass index (LVMI) =115 g/m2 for males and =95 g/m2 for females)
61944790|NCT04391491||Microvascular angina|Patients of both sexes and \> 18 years with a confirmed diagnosis of MVA (Angina-like chest pain: signs of exercise-induced ischemia (ST-depression on exercise ECG (\>1 mm down-sloping or rectilinear ST-segment depression in \>2 leads)); No fixed stenosis (\>50%) in epicardial coronary arteries or branches at baseline coronary arteriography)
61944791|NCT04391491||Pulmonary hypertension|Patients of both sexes and \> 18 years with a confirmed diagnosis of secondary PH due to left heart disease (Left ventricular systolic dysfunction, left ventricular diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow obstruction and congenital cardiomyopathies) or chronic thromboembolic pulmonary hypertension defined by echo when peak tricuspid regurgitation velocity =2.8 m/s and presence of other echo 'PH signs'
62496094|NCT05241314|EXPERIMENTAL|Phase 1 Community Leadership Board (CLB)|Intervention adaptation and community health worker interventionist (CHWI) training through the delivery of the intervention to Community Leadership Board (CLB) members. The CLB will be made up of 4-7 Karen professionals representing prominent local organizations supporting Karen refugees in resettlement. Representatives will have lived cultural and historical expertise as well as professional expertise supporting the resettled community from mental health and social services perspectives. The expertise of the board ensures culturally centered preparations for intervention dissemination. The CLB will take an active role in the adaptation of the intervention.
62697670|NCT03559530||Patients|Patients with microbiologically proven A. baumannii-related osteomyelitis
62697671|NCT04409431|EXPERIMENTAL|Adrenal Artery Ablation|Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol.
62697672|NCT04409431|NO_INTERVENTION|Spironolactone|Patients in this group will be treated with aldosterone 20-80mg daily according to blood pressure
62697673|NCT01047865||pancreas-kidney transplant|pancreas-kidney transplant recipients with type 1 diabetes.
61944792|NCT04391491||Heart failure with redused ejection fraction|Patients of both sexes and \> 18 years with a confirmed diagnosis of HFrEF (Symptomatic HF (NYHA class II-IV), left ventricular ejection fraction ≤ 35% (at any time in the past))
61944793|NCT01856907|EXPERIMENTAL|Sitagliptin-Metformin|50 mg/1000 mg twice a day (BID)
61944794|NCT01856907|PLACEBO_COMPARATOR|Placebo pill|1 pill/BID for 16 weeks
61944795|NCT01856907|ACTIVE_COMPARATOR|Metformin|1000 mg BID
62139716|NCT06098105|EXPERIMENTAL|Laparoscopic-assisted intraperitoneal instillation|This group will receive Laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
62139717|NCT04379869|EXPERIMENTAL|NNZ-2591 Single dose Cohort 1|Single dose of oral NNZ-2591 in healthy volunteers
62496095|NCT01388257|EXPERIMENTAL|Surgery|Seton drain removal is associated with proctological surgery.
61944796|NCT04203329||Paroxysmal A-Fib|
61944797|NCT04203329||Persistent A-Fib|
61944798|NCT04203329||A-Fib|
61944799|NCT02910115|OTHER|Control Group|Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.
61944800|NCT02910115|EXPERIMENTAL|Study Group|"Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol.~Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician."
61944801|NCT02439190|ACTIVE_COMPARATOR|Treatment A: BMS-986120|BMS-986120 on specified days
61944802|NCT02439190|ACTIVE_COMPARATOR|Treatment B: Aspirin and Clopidogrel|Aspirin and Clopidogrel on specified days
61944803|NCT05155150|EXPERIMENTAL|Intervention group|Providing patient-reported outcome: patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
61944804|NCT05155150|NO_INTERVENTION|Control group|Family meetings take place as usual.
62139718|NCT04379869|EXPERIMENTAL|NNZ-2591 Single dose Cohort 2|Single dose of oral NNZ-2591 in healthy volunteers
62139719|NCT04379869|EXPERIMENTAL|NNZ-2591 MAD Cohort 1|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
62697674|NCT06482996||group A|Frail scale:Non frail
62697675|NCT06482996||group B|Frail scale: Pre frail/frail
62697676|NCT04855799|EXPERIMENTAL|Aquamin®|
62697677|NCT04714177|EXPERIMENTAL|Edaravone Dexborneol|Edaravone Dexborneol injection
62697678|NCT04714177|PLACEBO_COMPARATOR|Placebo|Edaravone Dexborneol matching injection
62697679|NCT03664544|EXPERIMENTAL|Subjects with severe hepatic impairment|HP PK MCI-186
62697680|NCT03664544|EXPERIMENTAL|Subjects with normal hepatic function|NHV PK MCI-186
62697681|NCT06172023|EXPERIMENTAL|Silver Nanoparticles Irrigant|
62697682|NCT06172023|EXPERIMENTAL|Chitosan Nanoparticle Irrigant|
62697683|NCT06172023|ACTIVE_COMPARATOR|2.6% NaOCl and 17% EDTA sol|
62697684|NCT04752826|EXPERIMENTAL|Phase I, Part A - Dose escalation and safety of BI-1808 alone|Dose escalation with repeated administrations of BI-1808 infusions as a single agent, in patients with advanced malignacy.
62339983|NCT04668001|EXPERIMENTAL|Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
62697685|NCT04752826|EXPERIMENTAL|Phase I, Part B - Dose escalation and Safety of BI-1808 in combination with pembrolizumab|Dose escalation and safety with repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in patients with advanced malignacy.
62697686|NCT04752826|EXPERIMENTAL|Phase IIa - Part A Expansion cohorts of BI-1808 alone|Repeated administrations of BI-1808 infusions as a singel dose in 3 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer , Cutaneous T-cell lymphoma (Sézary Syndrome and Mycosis Fungoides).
62697687|NCT04752826|EXPERIMENTAL|Phase IIa, Part B - Expansion cohorts of BI-1808 in combination with pembrolizumab|Repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in 2 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer.
61944805|NCT01001013|EXPERIMENTAL|LC15-0444 200 mg|LC15-0444 200 mg
61944806|NCT01001013|EXPERIMENTAL|Pioglitazone 30 mg|Pioglitazone 30 mg
61944807|NCT01001013|EXPERIMENTAL|LC15-0444 200 mg + pioglitazone 30 mg|LC15-0444 200 mg + pioglitazone 30 mg
61944808|NCT00646074|EXPERIMENTAL|1|Self-Care TALK
62139720|NCT04379869|EXPERIMENTAL|NNZ-2591 MAD Cohort 2|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
62496096|NCT01388257|OTHER|Simple seton drain removal|
62139721|NCT06192043|EXPERIMENTAL|Experimental treatment group|"Experimental Group:~Participants in the experimental group would receive 6-8 sessions of Psychoeducational based program~Waitlist Control group:~Participants in the control group would not receive a psychoeducational-based Program"
62339984|NCT04668001|PLACEBO_COMPARATOR|Sham Transcranial Photobiomodulation (tPBM-Sham)|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
61944809|NCT00646074|NO_INTERVENTION|2|
61944810|NCT04674202||Pharmaceutical interview|This group will benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
61944811|NCT04674202||No pharmaceutical interview|This group will not benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
61944812|NCT04746222|EXPERIMENTAL|Treatment|Single dose of 30 oral capsules containing FMT from a stool bank
61944813|NCT04746222|PLACEBO_COMPARATOR|Placebo|Single dose of 30 oral placebo capsules
61944814|NCT05024604||study group|women receiving mini pills as a method of contraception with symptoms not diagnosed with us
61944815|NCT05024604||Control group|women attending to office hysteroscopy unit and not taking hormonal therapy
62139722|NCT06192043|NO_INTERVENTION|No intervention Control Group|"Control Group:~Participants in the control group didn't receive any Psychoeducational Intervention or any treatment"
62139723|NCT06698770|EXPERIMENTAL|Start medication - Lower chance of future health problems|Participants read a hypothetical scenario where a doctor recommends starting a new medication to lower their chances of experiencing significant health problems.
62139724|NCT06698770|EXPERIMENTAL|Start medication - Higher risk without medication|Participants read a hypothetical scenario where a doctor recommends starting a new medication because they could experience a higher risk of serious health problems without it
62339985|NCT04677621|EXPERIMENTAL|Nurse Telehealth Intervention|Allocated to tele-intervention
62496097|NCT05430464|EXPERIMENTAL|1726nm Laser Treatment|
62496098|NCT05430464|SHAM_COMPARATOR|Sham Laser Treatment|
62697688|NCT01587560|ACTIVE_COMPARATOR|Pyrocarbon|Patients receiving a shoulder surface replacement implant made of pyrocarbon (the PyroTITAN Humeral resurfacing Arthroplasty)
62697689|NCT01587560|ACTIVE_COMPARATOR|CoCr|Patients receiving a shoulder surface replacement implant made of Cobalt-Chrome(CoCR) (the TITAN Humeral Resurfacing Arthroplasty)
62339986|NCT04677621|ACTIVE_COMPARATOR|Standard Deep Brain Stimulation (DBS)|Allocated to conventional approach
62339987|NCT05353166|EXPERIMENTAL|Group A|Randomized 1:1; limited to participants with heart failure with reduced ejection fraction (HFrEF) not taking sacubitril/valsartan
62496099|NCT01394133||HIV+ Female|HIV infected women between 21-40 years of age, not receiving oral contraceptives.
62496100|NCT04425031|EXPERIMENTAL|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
62697690|NCT06640140|NO_INTERVENTION|Usual care|Patients allocated to this arm will receive the usual care plus explicit recommendations for home-based aerobic and strength training.
62697691|NCT06640140|ACTIVE_COMPARATOR|Supervised aerobic plus strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and strength training.
62697692|NCT05229666|OTHER|Cognitive Challenge|
61944816|NCT00595465|ACTIVE_COMPARATOR|IC51 Batch A|
61944817|NCT00595465|ACTIVE_COMPARATOR|IC51 Batch B|
61944818|NCT00595465|ACTIVE_COMPARATOR|IC51 Batch C|
61944819|NCT04424810|EXPERIMENTAL|Video group|Patients selected to be in the intervention group will be asked to watch a high-quality, physician created video describing their condition and the operative treatment they are about to undergo.
61944820|NCT04424810|PLACEBO_COMPARATOR|Control group|Patients selected to be in the control group will not be asked to watch a video prior to surgery.
61944821|NCT01232777|ACTIVE_COMPARATOR|Bevacizumab (Avastin) 0.75mg/0.03cc|1/3 of study participants will be randomized to this treatment in one eye (study eye) and the other eye will receive laser (fellow eye)
61944822|NCT01232777|ACTIVE_COMPARATOR|Bevacizumab (Avastin) 0.625mg/0.025cc|1/3 of patients will be randomized to this treatment in 1 eye (study eye) and the other eye will receive laser (fellow eye).
62339988|NCT05353166|EXPERIMENTAL|Group B|Randomized 1:1; limited to participants with HFrEF taking sacubitril/valsartan
62339989|NCT05353166|EXPERIMENTAL|Group C|Randomized 1:1; limited to participants with heart failure with preserved ejection fraction (HFpEF) not taking sacubitril/valsartan
61944823|NCT01232777|ACTIVE_COMPARATOR|Laser ablation|1/3 of study participants will be randomized to this treatment in both eyes (study eye and fellow eye)
62496101|NCT04425031|ACTIVE_COMPARATOR|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
62496102|NCT00555893|EXPERIMENTAL|Active Drug|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
62496103|NCT00555893|PLACEBO_COMPARATOR|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
62496104|NCT03414073|SHAM_COMPARATOR|Group A Phase 1|"Conventional flossing technique using commercially available Reach® Floss One third of sample are randomly assigned to Group A and are to utilise conventional finger flossing technique in the first phase of 4-weeks. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
61944824|NCT02008630|EXPERIMENTAL|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
61944825|NCT02008630|EXPERIMENTAL|Animal-assisted therapy|30 minutes group session with animal-assisted therapy twice a week for 12 weeks in groups of 4-6 participants
61944826|NCT02008630|NO_INTERVENTION|Control|Control group with treatment as usual
61944827|NCT06324383|OTHER|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
61944828|NCT05634915|EXPERIMENTAL|Individual dose of ATG|The total individual ATG dose was calculated based on population pharmacokinetic modeling. ATG was intravenously infused every day from day -5 to day -2.
61944829|NCT05634915|ACTIVE_COMPARATOR|ATG 10mg/kg|The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2.
62139725|NCT06698770|EXPERIMENTAL|Stop medication - Lack of benefit|Participants read a hypothetical scenario where a doctor suggests stopping the medication due to a lack of benefit.
62139726|NCT06698770|EXPERIMENTAL|Stop medication - Potential for harm|Participants read a hypothetical scenario where a doctor suggests stopping the medication due to the potential for harm.
62139727|NCT02765711||the use of ticagrelor in hospital|
62539191|NCT01421511|EXPERIMENTAL|TR-701 FA|• TR-701 FA IV followed by TR-701 FA tablets
61944830|NCT02422472|NO_INTERVENTION|Standard|Standard of care ultrasound guided peripheral IV placement
61944831|NCT02422472|EXPERIMENTAL|Experimental|Ultrasound guided peripheral IV placement with the use of a guidewire
61944832|NCT05100901|EXPERIMENTAL|Oral nutritional supplement|Oral nutritional supplement that contains MAG oil
61944833|NCT04225546||Patient group|Patients with hemiplegic and diplegic cerebral palsy between 4 - 10 years of age
61944834|NCT04225546||Control group|Healthy volunteer typically developing peers
61944835|NCT05169996|EXPERIMENTAL|Real Food|Participants are exposed to a tangram game with puzzle pieces from chocolate.
61944836|NCT05169996|EXPERIMENTAL|Real Nonfood|Participants are exposed to a tangram game with puzzle pieces from wood.
61944837|NCT05169996|EXPERIMENTAL|Virtual reality Food|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) chocolate.
61944838|NCT05169996|EXPERIMENTAL|Virtual reality Nonfood|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) wood.
61944839|NCT05169996|EXPERIMENTAL|Virtual reality Food Branded|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) chocolate. In the background of the puzzle, a brand is shown.
61944840|NCT03848065|EXPERIMENTAL|V114-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of V114 on Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age). Infant participants will receive a single 0.5 mL SC injection of concomitant study vaccine \[Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV) at the same time as V114-SC.
61944841|NCT03848065|EXPERIMENTAL|V114-IM|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age). Infant participants will receive a single 0.5 mL SC injection of concomitant study vaccine (DTaP-IPV) at the same time as V114-IM.
61944842|NCT03848065|ACTIVE_COMPARATOR|PCV13-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of pneumococcal 13-valent conjugate vaccine (PCV13) at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age). Infant participants will receive a single 0.5 mL SC injection of concomitant study vaccine (DTaP-IPV) at the same time as PCV13-SC.
61944843|NCT01462643|EXPERIMENTAL|variant1|topical ointment, once daily application
61944844|NCT01462643|EXPERIMENTAL|variant 2|topical ointment, once daily application
61944845|NCT01462643|EXPERIMENTAL|variant 3|topical ointment, once daily application
62139728|NCT03607175|ACTIVE_COMPARATOR|Steroid-eluting implant (Propel)|Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
62339990|NCT01820078|EXPERIMENTAL|Paricalcitol, Daily treatment, CKD|Experimental Arm
62339991|NCT01820078|OTHER|Daily treatment for CKD|Comparator Arm
62339992|NCT06207422|EXPERIMENTAL|Moderate intensity training program|
62339993|NCT06207422|EXPERIMENTAL|High intensity training program|
61944846|NCT01462643|EXPERIMENTAL|variant4|topical ointment, once daily application
61944847|NCT01462643|EXPERIMENTAL|variant 5|topical ointment, once daily application
61944848|NCT01462643|PLACEBO_COMPARATOR|variant 6|topical ointment, once daily application
61944849|NCT01462643|ACTIVE_COMPARATOR|control positive|topical ointment,once daily application
61944850|NCT01880619|PLACEBO_COMPARATOR|Group A|Patients in this group will receive placebo
61944851|NCT01880619|ACTIVE_COMPARATOR|Group B|Patients in this group will receive Tamsulosin
61944852|NCT01880619|ACTIVE_COMPARATOR|Group C|Patients in this group will receive Solifenacin
61944853|NCT04845477|NO_INTERVENTION|internal hip rotation pre measurement|with knee and hip flexion at 90º, internal hip rotation will be performed
61944854|NCT04845477|EXPERIMENTAL|internal hip rotation post experimental application measurement|with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
61944855|NCT04845477|PLACEBO_COMPARATOR|internal hip rotation post placebo application measurement|with Placebo tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
61944856|NCT04140097||COPD patients with acute exacerbation|
61944857|NCT04140097||COPD patients without acute exacerbation|
61944858|NCT05861869||PLA2R-induced membranous nephropathy group|"1. Pathological examination showed that patients with membranous nephropathy were positive for PLA2R by immunohistochemistry, and the symptoms were not completely relieved; (24 h urine protein quantification\<0.3g or urine protein /creatinine (uPCR)\<300mg /g is regarded as complete remission)~2. In patients with nephrotic syndrome (serum albumin ≤ 30.0g /L, clinical manifestations show moderate to large amount of proteinuria (urine protein\>3.5g /L or urine protein /creatinine ratio ≥ 3500mg /g), and their serum anti PLA2R antibody detection shows positive."
61944859|NCT05861869||Secondary membranous nephropathy group|"1. Patients in nephrology department who have ruled out primary membranous nephropathy.~2. the patient has the remaining serum samples of normal test, and the serum volume of the sample is not less than 1ml."
61944860|NCT06033144||"Non Tapia group"|Patients without Tapia's syndrome
62339994|NCT03509272|NO_INTERVENTION|Control Group|
62339995|NCT03509272|EXPERIMENTAL|remote monitoring group|
62339996|NCT04452227||eumenorrheic healthy women|women with a regular menstrual cycle for three months, predictable, and a period between 24-38 days that lasts less than 8 days.
62339997|NCT06380361|EXPERIMENTAL|All patients will be allocated to the same study arm.|During the bronchoscopic biopsy procedure, the study device will be entered through the bronchoscope to the level of the lesion. At lesion level, the BioSpy System sensor will make several measurements of the tumors and peripheral lung nodules and masses.
62339998|NCT05790785||Children with Type 1 diabetes|children recruited within 14 weeks of type 1 diabetes diagnosis and followed for 24 months.
62339999|NCT01200615|OTHER|Explanation about common side effects|50 patients started on SSRI's will be updated about its common side effects
62340000|NCT01200615|OTHER|Explaning side effects and the nocebo effect|subjects started on SSRI's will be updated about its common side effects and the nocebo effect
62340001|NCT01200615|OTHER|explanation about the nocebo effect|3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects.
61944861|NCT06033144||"Tapia group"|Patient with Tapia's syndrome
61944862|NCT05295056||Permanent atrial fibrillation|Known to have permanent atrial fibrillation
61944863|NCT05295056||Healthy control|Healthy controls
61944864|NCT05194865||CMR viability study group|"Diagnostic Test: CMR Basic CMR data including LV and RV volumes, SWMA reported, EF and wall thinning will be collected.~* SWMA from SSFP sequences will be reported and numbered according to the usual (1 normal, 2 hypokinetic, 3 akinetic, 4 dyskinetic, 5 aneurysmal).~* Data of viability assessed with LGE imaging with scar measurement using standard deviation method with SD of 4-5 will be used.~* AHA 17 segment model will be used as a reference for LV segmentation.~* Viability scoring will be calculated for each segment based on the transmurality index, in a semiautomated method, with no scar given 0, 1-25% subendocardial scar given score 1, 25-50% given 2, 50-75% given 3, \>75% as 4.~* Wall thinning will be given 0 or 1 score for each segment, with 1 given for \<6 mm thickness."
61944865|NCT05194865||direct revascularization group|Direct Coronary revascularization
61944866|NCT04433663|EXPERIMENTAL|Mentalization-based Intervention|Participants in the intervention group, received mentalization-based psychotherapy with the developed ECOSA axis. Therapist received mentalization-based supervision.
61944867|NCT04433663|ACTIVE_COMPARATOR|IPT-Inter Personal Therapy|The control group's participants received IPT - interpersonal psychotherapy that focused on resolving interpersonal problems and symptomatic recovery. The control group's therapist received regular supervision - with no emphasis on mentalization or tool's usage.
61944868|NCT00763529|EXPERIMENTAL|Arm 1|
61944869|NCT00763529|ACTIVE_COMPARATOR|Arm 2|
61944870|NCT04108234|EXPERIMENTAL|Treatment group A|HR071603,nasal spray,dose escalation.
61944871|NCT04108234|PLACEBO_COMPARATOR|Treatment group B|Placebo, nasal spray
61944872|NCT01332084|EXPERIMENTAL|hypoallergenic wheat cereals|HA wheat cereal used in a SOTI test
61944873|NCT02570360|ACTIVE_COMPARATOR|exercise|Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
61944874|NCT02570360|PLACEBO_COMPARATOR|treatment-as-usual|Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
61944875|NCT03242889|EXPERIMENTAL|DARA SC|Participants will receive DARA SC (daratumumab 1800 milligram \[mg\] with Recombinant Human Hyaluronidase \[rHuPH20\] 30,000 units \[U\] that is 2000 U/milliliter \[U/mL\]) subcutaneous (SC) injection once weekly for the first 8 weeks in Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks in Cycles 3 to 6 (Days 1 and 15) for the following 16 weeks and then every 4 weeks (from Cycle 7 \[Day 1\]) in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
62539192|NCT01421511|ACTIVE_COMPARATOR|Linezolid|• Linezolid IV followed by Linezolid Tablets
61944876|NCT06282393|OTHER|FibriCheck recordings|
61944877|NCT05258643|OTHER|Covid-19 patients|Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection
61944878|NCT05258643|OTHER|Controle|Whole blood and serum samples will be collected during the same period
61944879|NCT04569253|EXPERIMENTAL|All study participants|Subjects will receive treatments with the RF device on one flank. The other flank will be left untreated to serve a control.
62340002|NCT06484439|ACTIVE_COMPARATOR|Acetaminophen, Ibuprofen, Hydrocodone Control arm|The control arm will be 650 mg Acetaminophen PO scheduled q6h, 600mg Ibuprofen PO scheduled q6h and 5 mg Hydrocodone PO PRN q6h.
61944880|NCT01254331|EXPERIMENTAL|Single arm|
61944881|NCT05485155|EXPERIMENTAL|Active Drug|Zemaira alpha-proteinase inhibitor
62340003|NCT06484439|EXPERIMENTAL|Ketorolac, Acetaminophen, Oxycodone Study arm|The study arm will be 10 mg Ketorolac PO q6h, 650 mg Acetaminophen PO scheduled q6h, and 5 mg Oxycodone PO PRN q6h.
62496105|NCT03414073|ACTIVE_COMPARATOR|Group B Phase 1|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss One third of sample are randomly assigned to Group B and are to utilise knotted floss technique in the first phase of 4-weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
62496106|NCT03414073|SHAM_COMPARATOR|Group C Phase 1|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes One third of sample are randomly assigned to Group C and are to utilise conventional interdental brushing technique in the first phase of 4-weeks twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
62496107|NCT03414073|ACTIVE_COMPARATOR|Group A Phase 2|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group A will use the knotted floss technique in the second phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
62714733|NCT02208219|EXPERIMENTAL|Music-supported Therapy (n=40)|Participants in this group will receive a Music-supported Therapy training at the Hospital during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
61944882|NCT01825070|EXPERIMENTAL|low dose|Montmorency cherry concentrate, 30 mls
61944883|NCT01825070|EXPERIMENTAL|higher dose|Montmorency cherry concentrate, 60 mls
61944884|NCT01691274|EXPERIMENTAL|PF-04895162|
62340004|NCT02498756|EXPERIMENTAL|IP plus CIK|Patients receive ipilimumab and CIK.
62340005|NCT02498756|ACTIVE_COMPARATOR|IP alone|Patients receive ipilimumab alone.
62340006|NCT01658579|EXPERIMENTAL|HOE901-U300 Morning Then Evening|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
62340007|NCT01658579|EXPERIMENTAL|HOE901-U300 Evening Then Morning|HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
62340008|NCT01658579|ACTIVE_COMPARATOR|Lantus Morning Then Evening|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
62340009|NCT01658579|ACTIVE_COMPARATOR|Lantus Evening Then Morning|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
61944885|NCT01691274|PLACEBO_COMPARATOR|Placebo|
61944886|NCT01899664|OTHER|Primary Study Population|Study participants (primary study population) will include patients with spinal cord injury at the mid cervical level who are undergoing evaluation for possible surgical treatment with nerve transfers and or tendon transfer/tenodesis to improve their upper extremity function. All enrolled participants will receive the same standard of care surgical procedures.
61944887|NCT03148314|ACTIVE_COMPARATOR|hospital- based vaginal misoprostol|hospital- based vaginal misoprostol
61944888|NCT03148314|ACTIVE_COMPARATOR|extended low dose oral misoprostol|extended low dose oral misoprostol
61944889|NCT03608371|EXPERIMENTAL|BTRX-246040 Cohort 1|BTRX-246040 will be administered orally 40 mg (1capsule) in Cohort 1
61944890|NCT03608371|EXPERIMENTAL|BTRX-246040 Cohort 2|BTRX-246040 will be administered orally 80 mg (2 capsules) in Cohort 2
61944891|NCT03608371|EXPERIMENTAL|BTRX-246040 Cohort 3|BTRX-246040 will be administered orally120 mg (3 capsules) in Cohort 3
61944892|NCT03608371|PLACEBO_COMPARATOR|Placebo Cohorts 1-3|Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
61944893|NCT01768052||functional Near Infrared Spectroscopy|Noninvasive functional Near Infrared Spectroscopy (fNIRS) monitoring will take place during patients' clinical rTMS treatment sessions.
61944894|NCT01966601|EXPERIMENTAL|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
61944895|NCT01966601|EXPERIMENTAL|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
61944896|NCT01966601|EXPERIMENTAL|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
62340010|NCT05851339||PCNL|PCNL group applicants will answer SF-36 questionnaire
62340011|NCT05851339||RIRS|RIRS group applicants will answer SF-36 questionnaire
61944897|NCT01966601|PLACEBO_COMPARATOR|Placebo|Placebo via continuous IV infusion
61944898|NCT00437931||A|patients with subclinical hypothyroidism
61944899|NCT00437931||B|patients with subclinical hyperthyroidism
61944900|NCT00437931||C|patient with normal thyroid function.
61944901|NCT05043675|EXPERIMENTAL|[18F]APN-1607|For the injection, subjects will receive a target dose of 0.1\~0.15mCi/Kg \[18F\]APN-1607 as a bolus injection.
61944902|NCT00834223|OTHER|Aquashunt|Open label, all subjects receive device.
61944903|NCT04516330|ACTIVE_COMPARATOR|unifocal breast cancer|patients having unifocal breast cancer
61944904|NCT04516330|ACTIVE_COMPARATOR|multicentric breast cancer|patients having multicentric breast cancer
61944905|NCT02221024|EXPERIMENTAL|Flushing every 24 hours|Flushing with positive pressure with normal saline every 24 hours
61944906|NCT02221024|ACTIVE_COMPARATOR|Flushing every 12 hours|Flushing with positive pressure with normal saline every 12 hours
61944907|NCT03084731|EXPERIMENTAL|Goup 1:Children with moderate stunting and wasting|Test 3 prototype MDCFs and the current rice-lentil RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week 2x /day intervention, with a 2 week post-intervention phase to assess durability of MDCF-induced changes in the microbiota.
61944908|NCT03084731|EXPERIMENTAL|Goup 2:Children with moderate stunting and wasting|Select most efficacious MDCF from study 1 and compare with 2 additional MDCF prototypes using the same design used in study 1.
61944909|NCT03084731|EXPERIMENTAL|Goup3:Children with moderate stunting and wasting|Select lead MDCF from studies 1, 2 and conduct final 'bake-off' vs current RUSF and also examine the impact of 1x vs 2x per day administration with a 4 week post-intervention period to provide additional information on the durability of MDCF-sponsored changes in the microbiota.
61944910|NCT03084731|NO_INTERVENTION|Healthy controls|In order to construct a library of gut microbiota of healthy growing children of the same community, one spot fecal sample (1-2 gm) and spot blood sample (2 mL) will be collected from 30 children each who would be aged 12-18 months of either sex, having WLZ and LAZ : \>-1
62496108|NCT03414073|SHAM_COMPARATOR|Group B Phase 2|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group B will use the conventional interdental brushing technique in the second phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
62496109|NCT03414073|SHAM_COMPARATOR|Group C Phase 2|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the conventional finger flossing technique in the second phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
61944911|NCT00331864|EXPERIMENTAL|Ranibizumab|Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
61944912|NCT04185064|EXPERIMENTAL|Cryopnematic Device (Randomized Component)|Game Ready shoulder wrap is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises.
62340012|NCT02941913|EXPERIMENTAL|Fixed Dose Palonosetron group|patient will receive a fix dose of 75 μg of palonosetron
62340013|NCT02941913|EXPERIMENTAL|Bodyweight-adjusted Dose Palonosetron|patient will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron
62340014|NCT01862445||Study group|Patients receiving Chlorambucil plus Rituximab
62340015|NCT00608439|PLACEBO_COMPARATOR|Placebo|Placebo CAST
61944913|NCT04185064|ACTIVE_COMPARATOR|Standard Care|Ice is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the ice will be applied by the patient or a health care provider; as cold as comfortable; 30 min on:60 min off; use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off; use minimum of twice/day. The patients in the control group will receive pain management strategies as would be normally dictated by the physician/therapist. This may include the use of ice, ice packs and compression bandages, as well as pain medications, range of motion, and positioning exercises
62340016|NCT00608439|ACTIVE_COMPARATOR|Centella asiatica selected triterpenes|Active CAST
62340017|NCT05124795|EXPERIMENTAL|IMU-935 - low dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
62340018|NCT05124795|EXPERIMENTAL|IMU-935 - medium dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
62340019|NCT05124795|EXPERIMENTAL|IMU-935 - high dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
62539193|NCT03546920|NO_INTERVENTION|Control Phase|Usual care for patients admitted to the SNF.
62539194|NCT03546920|EXPERIMENTAL|ALIGN Intervention Phase|ALIGN Intervention delivered by Palliative Care Social Workers in the SNF setting. The intervention consists of aligning patient/caregiver goals of care, completing advance care planning, and connecting to community resources and services to ensure smooth transition from facility to home setting.
62697693|NCT05406713|EXPERIMENTAL|Experimental Group|"Cycles 1-2 (Pembrolizumab): 400 mg of Pembrolizumab intravenously (Administered Day 1 of 42 day Cycle)~If complete response of treatment is observed then maintenance therapy will be given. All other patients will receive with standard of care local therapy (cystectomy or chemo-radiation) as per their treating physicians followed by adjuvant pembrolizumab.~Cycle 3-9 (Maintenance or Adjuvant Single agent Pembrolizumab): 400 mg of Pembrolizumab intravenously (Administered Day 1 of 42 day Cycle)"
62697694|NCT03880019|EXPERIMENTAL|Treatment (olaparib, temozolomide)|Patients receive olaparib PO BID and temozolomide PO QD on days 1-7 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial and undergo tumor biopsy at screening and on study.
61944914|NCT04185064|OTHER|Cryopneumatic Device (Observational Cohort)|Game Ready® shoulder wrap is applied in the operating room and used in the recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises
61944915|NCT06352983|EXPERIMENTAL|Veneered high-translucent zirconium dioxide fixed dental prosthesis|Core material: high translucent zirconium dioxide (BruxZir, Glidewell, Newport Beach, Canada) Buccal veneer: porcelain (GC initial Zr, GC Corporation, Tokyo, Japan).
62340020|NCT01861288||Adults and children with and without IBD|"The study includes adult and pediatric patients with and without IBD who, as part of an ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children: colonoscopy).~Inclusion of adult patients, age 15-67 years: 50 patients with UC in remission, 50 patients with active UC, 50 patients without IBD~Inclusion of pediatric patients, \<15 years: We expect to include: 10 UC / CD patients in remission,10 UC / CD patients in relapse,10 non-IBD patients."
61944916|NCT06352983|ACTIVE_COMPARATOR|Monolithic high-translucent zirconium dioxide fixed dental prosthesis|High translucent zirconium dioxide (BruxZir, Glidewell, Newport Beach, Canada)
61944917|NCT01585870|EXPERIMENTAL|Sorafenib + Eribulin|
62539195|NCT02549586|EXPERIMENTAL|Autologous HSCT|Eligible participants will undergo an Autologous Hematopoietic Stem Cell Transplant (HSCT) as a two-step intervention.
61944918|NCT06681233|EXPERIMENTAL|HyperSight Imaging Arm|
61944919|NCT03727607|ACTIVE_COMPARATOR|Gass|DESFLURANE ANESTHESIA
61944920|NCT03727607|ACTIVE_COMPARATOR|TIVA|TOTAL INTRAVENOUS ANESTHESIA
61944921|NCT04394611||Fetal Growth Restriction (FGR)|FGR will be defined as an estimated fetal weight (grams) less than the 10th percentile for gestational age. Hadlock I formula will be used to calculating estimated fetal weight percentiles
61944922|NCT04394611||Control|healthy pregnancies will be selected for the control group.
61944923|NCT03088371|OTHER|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
61944924|NCT03088371|OTHER|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
61944925|NCT05627297||SR|
61944926|NCT05627297||RFA|
61944927|NCT04307784|EXPERIMENTAL|Vitamin D3 alone Group|Treated with VD3 (50.000 IU/week)
61944928|NCT04307784|EXPERIMENTAL|Omaga-3 alone Group|Treated with (1000 mg) wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
61944929|NCT04307784|EXPERIMENTAL|Vitamin D3 and Omega-3 Combination, Group|Treated with 50.000 IU VD3 per week and 1000 mg wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
61944930|NCT04307784|EXPERIMENTAL|Control Group|No intervention was given.
61944931|NCT04245072|ACTIVE_COMPARATOR|Ranibizumab|Arm 1
62539196|NCT03761264|EXPERIMENTAL|Intra-canal Odontopaste®|Single visit placement of Odontopaste®
61944932|NCT04245072|ACTIVE_COMPARATOR|Aflibercept|Arm 2
61944933|NCT04195282|ACTIVE_COMPARATOR|Plasma exchange group|10 patients will receive conventional treatment plus plasma exchange
61944934|NCT04195282|EXPERIMENTAL|RL-1 Novel Human-derived Bio-artificial Liver treatment group|10 patients will receive conventional treatment plus RL-1 Novel Human-derived Bio-artificial Liver treatment
61944935|NCT00579592|EXPERIMENTAL|1|Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine
61944936|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.~Inclusion Criteria:~Patients included in the study will be:~* \> 18 years of age~* Non-cardiac patients~* Non-obstetric patients~* Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
61944937|NCT01117948|EXPERIMENTAL|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
61944938|NCT01117948|PLACEBO_COMPARATOR|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
61944939|NCT03584100|EXPERIMENTAL|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
61944940|NCT03584100|ACTIVE_COMPARATOR|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
61944941|NCT04711434|EXPERIMENTAL|Prevention group|Toripalimab: 240mg IV every 3 months for a year
61944942|NCT04711434|NO_INTERVENTION|Follow-up group|Routine follow-up, no intervention
61944943|NCT01291680||Pre - delivery pregnant women|Participants in the study will be pregnant women attending the obstetric ER for routine term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The current study will focus on women attending a regular followup, not considered to be at high risk.
62697695|NCT04391569|PLACEBO_COMPARATOR|IV Placebo|Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
62697696|NCT04391569|EXPERIMENTAL|IV ganaxolone active|Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
62697697|NCT01497730||CR FB|Subjects receiving a Cruciate Retaining Fixed Bearing implant configuration
61944944|NCT00515177|EXPERIMENTAL|MBSR|A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
61944945|NCT00515177|ACTIVE_COMPARATOR|PCT Sleeping Pills|A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.
62340021|NCT06008249|EXPERIMENTAL|Lithium carbonate|Lithium carbonate 400 mg capsules will be taken once daily, starting with one capsule (400 mg daily) initially titrated up to two or three capsules daily, depending on blood lithium levels. The target range for the lithium plasma level will be between ≥0.4 mmol/l and ≤ 0.8 mmol/l. Maximum duration is 24 months.
61944946|NCT02188771|EXPERIMENTAL|RegenoGel SP 2ml|"RegenoGel-SP is a new viscosupplement intended for the intra-articular treatment of OA.~Following signing the Informed Consent form (Visit 1), subjects who conform to the inclusion criteria will be evaluated for vital signs, blood hematology, chemistry, INR, aPTT and ECG, and will be subjected to a 30-40ml blood withdrawal that will be used for the production of autologous RegenoGel-SP. Subjects randomized to receive RegenoGel-SP will receive a single, intra-articular injection (Visit 2)."
61944947|NCT04562467|EXPERIMENTAL|Icosapent Ethyl + Standard of Care|Icosapent Ethyl 1000 MG Oral Capsule \[Vascepa\] 2 x 1g capsules BID (4g total) as per REDUCE-IT
61944948|NCT04562467|NO_INTERVENTION|Standard of Care|Standard of care therapy (including statin therapy as per inclusion criteria)
61944949|NCT00529334|EXPERIMENTAL|1|CyberKnife Partial Breast Irradiation (PBI)
61944950|NCT02059252|EXPERIMENTAL|SmartMatrix scaffold|SmartMatrix dermal replacement scaffold
61944951|NCT00698048||1|Controls
61944952|NCT00698048||2|Sepsis
61944953|NCT00698048||3|Septic Shock
61944954|NCT01678261||1a Turner syndrome 45,X|Blood from 50 persons with Turner syndrome an karyotype 45,X
61944955|NCT01678261||1b Controls for TS 45,X|50 healthy aged female controls matched to the TS 45,X cohort
61944956|NCT01678261||2a Turner syndrome 45,X mosaics|Blood from 50 persons with Turner syndrome an karyotype 45,X mosaics
61944957|NCT01678261||2b Controls for TS 45,X mosaics|50 healthy aged female controls matched to the TS 45,X mosaics cohort
61944958|NCT01678261||3a Paraffin embedded aortic tissue TS|3a Paraffin embedded samples of aortic tissue from 10 persons with TS
61944959|NCT01678261||3b Paraffin embedded aortic tissue from 10 controls|3b Paraffin embedded samples of aortic tissue from 10 controls who did not die from aortic aneurism
61944960|NCT01678261||4a 70 47,XXY men|4a Blood from 70 men with Klinefelter syndrome (47,XXY)
61944961|NCT01678261||4b 70 controls matching group 4a|4b 70 male controls matching group 4a with respect to age.
61944962|NCT01678261||5a 5 persons with double Y-syndrome|5a Blood from 5 persons with double Y-syndrome (47,XYY)
61944963|NCT01678261||5b 20 controls matching 5a|5b 20 healthy controls matching group 5a with respect to age
61944964|NCT01678261||6a 5 persons with triple X-syndrome|6a Blood from 5 persons with triple X-syndrome (47,XXX)
62340022|NCT06008249|PLACEBO_COMPARATOR|Placebo|Patients start with 1 capsule to be taken once daily, with subsequent sham dose adjustments made to patients on placebo to maintain blinding in clinical sites.
62340023|NCT05291598|ACTIVE_COMPARATOR|Ketorolac group|Participants will receive the institution specific joint replacement pain protocol, including ketorolac.
62697698|NCT01497730||PS FB|Subjects Receiving a Posterior Stabilized Fixed Bearing implant configuration
61944965|NCT01678261||6b 20 controls matching 6a|6b 20 healthy controls matching group 6a with respect to age.
61944966|NCT01678261||7 10 biological parents of cohort 1a.|7 Blood from 10 biological parents of individuals in cohort 1a
61944967|NCT00053573|EXPERIMENTAL|1|
61944968|NCT01265251||Test-retest|Forty-four healthy elderly 60-82 years old
61944969|NCT01265251||Validity|Twenty six patients with various diseases and various ages
61944970|NCT01265251||Feasibility|Twenty seven patients under the preoperative investigation for INPH
61944971|NCT04948515||group 1 patients with severe covid 19 respiratory infections|Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17
61944972|NCT04948515||group 2 patients with non severe covid 19 respiratory infections|Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17
61944973|NCT04231890|EXPERIMENTAL|IPI group|IPI monitoring
61944974|NCT04231890|NO_INTERVENTION|Control group|Standard monitoring
61944975|NCT04531839|EXPERIMENTAL|Intervention period|The 1.5-year period during which all six participating centers receive evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation, and collaborative learning
61944976|NCT04531839|NO_INTERVENTION|Baseline period|The 2-year period before the collaborative quality improvement intervention
61944977|NCT01448161||Pediatric and Adult ICU patients|Pediatric and Adult ICU patients
62340024|NCT05291598|EXPERIMENTAL|IV meloxicam group|Participants will receive the institution specific joint replacement pain protocol, however with IV meloxicam substituted for ketorolac.
62340025|NCT01015482|EXPERIMENTAL|Remifentanil|Remifentanil Infusion
62697699|NCT01497730||CR RP|Subjects receiving a Cruciate Retaining Rotating Platform implant configuration
62697700|NCT01497730||PS RP|Subjects receiving a Posterior Stabilized Rotating Platform implant configuration
62714734|NCT02208219|EXPERIMENTAL|home-based Music-supported Therapy(n=40)|Participants in this group will receive a Music-supported Therapy training at home during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
62697701|NCT05902741|EXPERIMENTAL|Resilience, Stress, and Ethnicity (RiSE) program|"Resilience, Stress, and Ethnicity (RiSE) program is an 8-session weekly group-based intervention that integrates cognitive-behavioral strategies focused on the biopsychosocial impact of racism, racial identity development, and empowerment. RiSE has three primary components:~1. processing and sharing experiences related to race based stress,~2. psychoeducation on the biopsychosocial impact of racism,~3. skill building and empowerment."
61944978|NCT05649566|EXPERIMENTAL|Virtual Reality Game Group|"A total of 24 interventions will be carried out for each participant, separated by 2 each week for 3 months. Each intervention will consist of a VR session lasting 30 minutes. Each participant must play for 30 minutes in the game Beat know. The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
61944979|NCT05649566|NO_INTERVENTION|Control Group|No intervention during 12 weeks.
62697702|NCT05902741|ACTIVE_COMPARATOR|Health Education Program (HEP)|Health Education Program
61944980|NCT06170892|EXPERIMENTAL|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
61944981|NCT06558474||Pre-intervention/implementation cohort|In the first phase, data additional to the national PCI registry will be analyzed retrospectively from all patients receiving PCI from January 2021 to January 2022. Data on the percentage of use of post-dilatation using high-pressure non-compliant (HPNC) balloon by the individual interventional cardiologist will be collected. This will establish a benchmark from which individual interventional cardiologists must increase their use of post-dilatation.
61944982|NCT06558474||Post-intervention/implementation cohort|"During this implementation phase, all individual PCI operators of the participating centres will be informed to liberally use post-dilatation for stent optimization during PCI. Operators are requested to increase their use of post-dilatation with at least 20% or use post-diltation in at least 85% of the PCI's. Throughout the project, individual participating operators will receive individual feedback on the percentage use of post-dilatation with prospective data collection after 2, 4, 6, 9 and 12 months. Based on this result, the implementation process will be refined as necessary. The duration of this phase will be approximately 1 year per centre.~Eventually a retrospective observational anlaysis, comparing the two cohorts, will be conducted to evaluate whether adopting this strategy has led to improved clinical outcomes after PCI in terms of MACE."
61944983|NCT00788073|ACTIVE_COMPARATOR|STX209|STX209 variable dose from 1mg bid to 10mg tid, capsule, oral, 4 weeks
61944984|NCT00788073|PLACEBO_COMPARATOR|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
61944985|NCT02295410||Engaged in Home-Based CPT|Home-Based Telemental Health-Patients undergoing Home-Based CPT for PTSD
61944986|NCT02295410||Comparison|Treatment as Usual (TAU) Patients NOT receiving regular CPT or other evidence-based therapy for PTSD.
61944987|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
61944988|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
61944989|NCT04930978||TB patients with SARS-CoV-2 PCR+|50 TB patients with SARS-CoV-2 PCR+ will be recruited in group 1
61944990|NCT04930978||TB patients with SARS-CoV-2 Ab+|100 TB patients with SARS-CoV-2 Ab+ will be recruited in group 2
61944991|NCT04930978||TB patients negative for SARS-CoV-2 PCR and Ab|100 TB patients with SARS-CoV-2 PCR and Ab negative will be recruited in group 3
61944992|NCT04043975||Cohort 1|Participants with advanced or metastatic renal cell carcinoma (aRCC) receiving the combination of nivolumab plus ipilimumab as the first line of systemic therapy
61944993|NCT02651467|EXPERIMENTAL|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
61944994|NCT02651467|EXPERIMENTAL|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
61944995|NCT02651467|PLACEBO_COMPARATOR|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
61944996|NCT02235805|EXPERIMENTAL|Magnesium Citrate|
61944997|NCT02235805|PLACEBO_COMPARATOR|Placebo|
61944998|NCT03401736|EXPERIMENTAL|Group M：received midazolam|Patients who requires the mechanical ventilation allocated to the midazolam group (group M) were treated with an infusion bolus of 0.05 mg/kg and continuous infusion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted to achieve the desired level of sedation.
61944999|NCT03401736|ACTIVE_COMPARATOR|Group D: received dexmedetomidine|Patients who requires the mechanical ventilation allocated to the dexmedetomidine group (group D) received an infusion bolus of 1 ug/kg within 10 minutes and continuous infusion of 0.25 to 0.75 ug/kg/hour, with the dosage adjusted to achieve the desired level of sedation.All patients maintained BIS between 65\~85 and the Ramsay score was 3 to 4.
62340026|NCT01015482|ACTIVE_COMPARATOR|Midazolam|Active Placebo
62496110|NCT03414073|SHAM_COMPARATOR|Group A Phase 3|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group A will use the conventional interdental brushing technique in the third phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
62496111|NCT03414073|SHAM_COMPARATOR|Group B Phase 3|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group B will use the conventional finger flossing technique in the third phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
61945000|NCT03431766|PLACEBO_COMPARATOR|control group A|on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
62340027|NCT02843646|EXPERIMENTAL|Walk Aide training|This group of children will receive six weeks of Walk Aide training. During training, children will wear the Walk Aide. This device triggers ankle dorsiflexion, and controls the timing and duration of personal nerve stimulation during the swing phase of gait. The duration of the stimulus is gradually increased along with the wearing of the Walkaide. Subjects will begin by wearing the prosthesis for 30 minutes. The wearing time will be increased to waking hours of the subject, depending on their age. The electrodes will be placed on the client before the session is to begin, and taken off immediately after WalkAide usage. The skin will be checked before and after WalkAide electrode usage. The skin will be cleaned with an alcohol wipe before the electrodes are applied.
61945001|NCT03431766|EXPERIMENTAL|test group B|on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
61945002|NCT00535457|EXPERIMENTAL|1|"Children will watch tricks (magic) before anesthesia induction"
61945003|NCT01025154|EXPERIMENTAL|Clofarabine, Cytarabine + Idarubicin|Induction Cycle: Clofarabine 20 mg/m\^2 intravenous (IV) daily for 5 days; Idarubicin 10 mg/m\^2 IV daily for 3 days; Cytarabine 1 g/m\^2 IV daily for 5 days
62340028|NCT02843646|PLACEBO_COMPARATOR|Delayed Walk Aide training|This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
62340029|NCT00910429|EXPERIMENTAL|Arm 1|
62340030|NCT05120999||Dominant hand|Application of either TetraGraph or TOFScan device on dominant hand
62340031|NCT05120999||Non-Dominant hand|Application of either TetraGraph or TOFScan device on non-dominant hand
62340032|NCT03176277|EXPERIMENTAL|ONO-7475 3mg once daily|Part A Initial dose level
62340033|NCT03176277|EXPERIMENTAL|ONO-7475 6mg once daily|Part A 2nd dose level
62340034|NCT03176277|EXPERIMENTAL|ONO-7475 10mg once daily|Part A 3rd dose level
62340035|NCT03176277|EXPERIMENTAL|ONO-7475 6mg + Venetoclax (70-400mg)|Part D ONO-7475 + Venetoclax combination
62340036|NCT05400005|NO_INTERVENTION|Normal protein diet (control)|"Subjects are to consume normal-protein diet based on the My Healthy Plate diet (launched by Health Promotion Board of Singapore) for the duration of the 16-week study."
62496112|NCT03414073|ACTIVE_COMPARATOR|Group C Phase 3|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the knotted floss technique in the third phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
62496113|NCT05481931||Safety Population|The safety population will consist of all patients who receive at least one treatment of NUCEIVA.
62496114|NCT05481931||Botulinum Toxin Naïve|Sub-population of patients that have never been treated with botulinum toxin
62496115|NCT05481931||Botulinum Toxin Exposed|Sub-population of patients that have previously been treated with botulinum toxin
62496116|NCT01211262|EXPERIMENTAL|IMCgp100 weekly dosing regimen|Weekly intravenous (IV) infusions of IMCgp100 over treatment cycles of 8 weeks each.
62496117|NCT01211262|EXPERIMENTAL|IMCgp100 daily dosing regimen|Daily IV infusions of IMCgp100 administered on days 1 to 4 and days 22 to 25 of a six-week treatment cycle.
62496118|NCT04880876|EXPERIMENTAL|Open Label 6-11 years of age: Eluxadoline 50mg|Eluxadoline two 25mg tablets, oral administration, twice daily with food. Take at approximately the same time each day.
62496119|NCT04880876|EXPERIMENTAL|Open Label 12-17 years of age: Eluxadoline 100 mg|Eluxadoline one 100mg tablet, oral administration, twice daily with food. May use 25mg tablets to administer 100mg dose. Take at approximately the same time each day.
61945004|NCT00630643|PLACEBO_COMPARATOR|1|
61945005|NCT00630643|EXPERIMENTAL|2|
62340037|NCT05400005|EXPERIMENTAL|High protein diet (soy)|"Subjects are to consume higher-protein diet by following the My Healthy Plate diet (launched by Health Promotion Board of Singapore) and 20g of soy protein isolate for the duration of the 16-week study."
61945006|NCT01512212|NO_INTERVENTION|single group|FNAB will be perform first with standart technique and after with new FNAB apparatus
61945007|NCT03437512|EXPERIMENTAL|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
61945008|NCT03437512|SHAM_COMPARATOR|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
61945009|NCT03971123|EXPERIMENTAL|AC-SD-03 (for Part 1)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
61945010|NCT03971123|EXPERIMENTAL|AC-LMP-01 (for Part 1)|Tricaprilin LMP formulation, single dose (20g tricaprilin). Administered orally.
61945011|NCT03971123|EXPERIMENTAL|AC-SD-03P (for Part 1)|Placebo formulation, single dose. Administered orally
61945012|NCT03971123|EXPERIMENTAL|AC-1202 (for Part 2)|Tricaprilin SD formulation, single dose (20g caprylic triglyceride). Administered orally.
61945013|NCT03971123|EXPERIMENTAL|AC-SD-03 (for Part 2)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
61945014|NCT03459261||POM|post-traumatic osteomyelitis group (POM), the participants who developed post-traumatic osteomyelitis after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4). Patients were included in POM group after additional assessment of meeting the CDC/NHSN surveillance definition criteria for osteomyelitis: positive intraoperative withdrawal bone and soft tissue sample, types of cultured bacteria, histopathologic proof of osteomyelitis and clinical signs of surgical site infection.
61945015|NCT03459261||NO POM|No POM group, the participants who did not develop postraumatic osteomyelitis to tibia after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4) in follow up interval of 6 months /control group/. Patients were included in No POM group after assessment of not meeting the CDC/NHSN surveillance definition criteria for osteomyelitis.
62139729|NCT03607175|EXPERIMENTAL|Triamcinolone-impregnated CMC foam|Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
62139730|NCT06486012|EXPERIMENTAL|Study group|Standard oral hygiene and home-use of Lumoral Treatment aPDT device.
62139731|NCT06486012|ACTIVE_COMPARATOR|Control group|Standard oral hygiene
62496120|NCT04880876|EXPERIMENTAL|Double Blind 6-11 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
61945016|NCT01492569|EXPERIMENTAL|Arm I (TAPS at the P6 point)|Patients undergo TAPS at the true acupuncture point (P6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm II for the second course of chemotherapy.
61945017|NCT01492569|SHAM_COMPARATOR|Arm II (TAPS at a non-P6 point)|Patients undergo TAPS at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm I for the second course of chemotherapy.
61945018|NCT03687112||Alzheimer desease and related disorders|Alzheimer desease and related disorders
61945019|NCT01363648|EXPERIMENTAL|Choline alfoscerate|choline alfoscerate 400mg, 3 times a day, for 12 weeks.
61945020|NCT01363648|PLACEBO_COMPARATOR|placebo (for choline alfoscerate )|placebo tablet, 3 times a day, for 12 weeks.
61945021|NCT00181155|EXPERIMENTAL|Allopurinol|One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
61945022|NCT00181155|PLACEBO_COMPARATOR|Placebo|One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
61945023|NCT01446926|EXPERIMENTAL|Group 1: Adults High Dose (Formulation 1)|Adults who will receive a single injection of high dose investigational Pneumococcal vaccine
61945024|NCT01446926|PLACEBO_COMPARATOR|Group 2: Adults Placebo|Adult participants who will receive an injection of placebo
61945025|NCT01446926|EXPERIMENTAL|Group 3: Toddlers High Dose (Formulation 1)|Toddlers who will receive a single injection of high dose Pneumococcal vaccine
61945026|NCT01446926|PLACEBO_COMPARATOR|Group 4: Toddlers Placebo|Toddlers who will receive a single injection of placebo
61945027|NCT01446926|EXPERIMENTAL|Group 5: Infants Low Dose (Formulation 2)|Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine
61945028|NCT01446926|PLACEBO_COMPARATOR|Group 6: Infants Placebo|Infants who will receive 3 injections of placebo
61945029|NCT01446926|EXPERIMENTAL|Group 7: Infants Middle Dose (Formulation 3)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
62139732|NCT04015505|EXPERIMENTAL|Intervention|Participants will receive 5 sessions of a psychological (talking therapy) intervention based on the wisdom enhancement 'timeline technique' within cognitive behavioural therapy for older adults.
62139733|NCT02262299|PLACEBO_COMPARATOR|Placebo|Receive placebo tablets
62539197|NCT03761264|ACTIVE_COMPARATOR|Intra-canal Pulpdent|Single visit placement of Pulpdent
62539198|NCT03761264|ACTIVE_COMPARATOR|Oral Amoxicillin|Amoxicillin 15mg/kg tds for 5 days
62139734|NCT02262299|ACTIVE_COMPARATOR|Pirfenidone|Upon enrollment, subjects will be randomized to either the treatment group (Pirfenidone) or to the placebo group (1:1 ratio). The trial medication will be administered as 267-mg oral capsules and titrated to a maintenance dose of 2403 mg/d (3 capsules TID, for a total of 9 capsules/day).
62139735|NCT05338567||Open/laparoscopic surgery|Small bowel length measurement by laparoscopy or laparotomy
62139736|NCT05338567||3D reconstruction|Small bowel length measurement by 3D digital model
62164407|NCT02548052|EXPERIMENTAL|GSK2981278, Vehicle, Betamethasone valerate|All subjects will receive all six treatments (GSK2981278 ointment 0.03%, 0.1%, 0.8%, 4%, vehicle to match GSK2981278 ointment and betamethasone valerate 0.1% cream); with random assignment of the treatments to 6 test fields on identified stable plaque(s) on the upper extremities, thighs and/or trunk. Subjects will be treated once-daily (except Days 7 and 14) over 19 days (a total of 16 applications) under semi-occlusive conditions (covered by an adhesive non-woven fabric).
61945030|NCT01446926|EXPERIMENTAL|Group 8: Infants Middle Dose (Formulation 4)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
61945031|NCT01446926|PLACEBO_COMPARATOR|Group 9: Infants Placebo|Infants who will receive 3 injections of placebo
61945032|NCT01446926|EXPERIMENTAL|Group 10: Infants High Dose (Formulation 1)|Infants who will receive 3 injections of high dose Pneumococcal vaccine
61945033|NCT01446926|PLACEBO_COMPARATOR|Group 11: Infants Placebo|Infants who will receive 3 injections of placebo
62496121|NCT04880876|EXPERIMENTAL|Double Blind 6-11 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
62697703|NCT06011733|EXPERIMENTAL|bimekizumab|Study participants randomized to this arm will receive bimekizumab (BKZ) dosage regimen 1 in the Initial Treatment Period (16 weeks) and switch to dosage regimen 2 and placebo to maintain the blinding in the Maintenance Treatment Period (16 weeks).
62697704|NCT06011733|PLACEBO_COMPARATOR|placebo|Study participants randomized to this arm will receive placebo comparator in the Initial Treatment Period (16 weeks) and switch to bimekizumab dosage regimen 1 in the Maintenance Treatment Period (16 weeks).
61945034|NCT03914482|OTHER|Patients at risk of FLD|Patients who choose to participate in the study that meet the inclusion criteria
62697705|NCT04430010|EXPERIMENTAL|Implementation|Teachers will implement the BEST in CLASS treatment in their classrooms
62697706|NCT05094609|EXPERIMENTAL|Aerosol Ad5-triCoV/Mac dose level 10e5|Single dose by inhalation of 10e5 Ad5-tri-CoV/Mac
62164408|NCT02332096||Patients with Atrial Fibrillation|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
62697707|NCT05094609|EXPERIMENTAL|Aerosol ChAd-tri-CoV/Mac dose level 10e5|Single dose by inhalation of 10e5 ChAd-triCoV/Mac
62697708|NCT05094609|EXPERIMENTAL|Aerosol Ad5-triCoV/Mac dose level 10e6|Single dose by inhalation of 10e6 Ad5-triCoV/Mac
62697709|NCT05094609|EXPERIMENTAL|Aerosol ChAd-triCoV/Mac dose level 10e6|Single dose by inhalation of 10e6 ChAd-triCoV/Mac
62496122|NCT04880876|EXPERIMENTAL|Double Blind 12-17 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
62697710|NCT05094609|EXPERIMENTAL|Aerosol Ad5-triCoV/Mac dose level 10e7|Single dose by inhalation of 10e7 Ad5-triCoV/Mac
62697711|NCT05094609|EXPERIMENTAL|Aerosol ChAd-triCoV/Mac dose level 10e7|Single dose by inhalation of 10e7 ChAd-triCoV/Mac
61945035|NCT06240130|ACTIVE_COMPARATOR|Sodium hypochlorite lavage group|3% sodium hypochlorite lavage will be done after pulp amputation
61945036|NCT06240130|EXPERIMENTAL|Chlorhexidine lavage group|2% Chlorhexidine lavage will be done after pulp amputation
62164409|NCT04546360||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement based on two-dimensional shear wave elastography, gallbladder wall thickness, spleen thickness, spleen long diameter and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, albumin, prothrombin time, international normalized ratio).
62697712|NCT05094609|EXPERIMENTAL|Aerosol Ad5-triCoV/Mac dose level 3x10e7|Single dose by inhalation of 3x10e7 Ad5-triCoV/Mac
62697713|NCT05094609|EXPERIMENTAL|Aerosol ChAd-triCoV/Mac dose level 6x10e7|Single dose by inhalation of 6x10e7 ChAd-triCoV/Mac
62164410|NCT03441789|EXPERIMENTAL|Otezla plus Enstilar foam|Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
62697714|NCT05094609|EXPERIMENTAL|Aerosol ChAd-triCoV/Mac dose level 1x10e8|Single dose by inhalation of 1x10e8 ChAd-triCoV/Mac
62697715|NCT05094609|EXPERIMENTAL|ChAd-triCoV/Mac at a dose level of 3x10e7|Single dose by inhalation of 3x10e7 Ad5-triCoV/Mac
62697716|NCT06638788|EXPERIMENTAL|Constant Torque Biodex Dynamometer|Participants will perform their intervention on the constant torque Biodex Dynamometer
62697717|NCT06638788|EXPERIMENTAL|Variable Torque Standerd Knee Extension|Participants will perform their intervention on the variable torque standerd knee extension machine
62697718|NCT02583815||Cancer Patients|This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
62697719|NCT00323622|EXPERIMENTAL|Cohort 1-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
61945037|NCT05316285|EXPERIMENTAL|Yoga Group|It will consist of students who choose the Yoga for a Healthy Life lesson. For 14 weeks, one day a week and 60 minutes a day, theoretical and practical yoga training will be applied.
61945038|NCT05316285|NO_INTERVENTION|Control Group|The control group will consist of students who chose the Fashion and Beauty lesson.
61945039|NCT03484637||Lifestyle-medicine intervention|Photographic follow-up every 4 weeks
62164411|NCT03441789|PLACEBO_COMPARATOR|Otezla plus vehicle foam|Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
62164412|NCT02627534|ACTIVE_COMPARATOR|Ultrasonic Debridement (UD)|Ultrasonic Debridement (UD) (n=20)
62164413|NCT02627534|EXPERIMENTAL|UD + Antimicrobial Photodynamic Therapy|Ultrasonic Debridement + aPDT (UD+aPDT) (n=20)
62164414|NCT02014298|OTHER|Control|One area assessed as a control area, compared to the laser-treated area
62164415|NCT02014298|ACTIVE_COMPARATOR|Non-ablative Laser treatment|3 Non-ablative fractional laser treatments of one area
62164416|NCT05631379||All patients meeting inclusion criteria|All patients meeting inclusion criteria
61945040|NCT01890746|EXPERIMENTAL|Eltrombopag arm|Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
61945041|NCT01890746|PLACEBO_COMPARATOR|Placebo arm|Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
62164417|NCT05631379||Subgroup of patients with available preoperative CT/MRI scans|Subgroup of patients with available preoperative CT/MRI scans will be detected and body composition measurements will be assessed min order to detect nutrition-related syndromes
62496123|NCT04880876|EXPERIMENTAL|Double Blind 12-17 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
62164418|NCT01179659|ACTIVE_COMPARATOR|Protonix|Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)
62340038|NCT05400005|EXPERIMENTAL|High protein diet (Micellar Casein)|"Subjects are to consume higher-protein diet by following the My Healthy Plate diet (launched by Health Promotion Board of Singapore) and 20g of micellar casein isolate for the duration of the 16-week study."
62340039|NCT05016648||PEARS patients|Patients who underwent the personalized external aortic root support procedure at the AMC. Cerebral monitoring measurements (NIRS, EEG, TCD and blood pressure) are used for the study.
62496124|NCT04880876|EXPERIMENTAL|Double Blind 12-17 years of age: Eluxadoline 100mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
62496125|NCT00702793|EXPERIMENTAL|1|Smoking cessation drug - varenicline
62496126|NCT00021541|EXPERIMENTAL|Tipifarnib (R11577)-Arm I|Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m\^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62496127|NCT00021541|PLACEBO_COMPARATOR|Placebo-Arm II|Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m\^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.
62496128|NCT06381622|ACTIVE_COMPARATOR|Control group: Ropi-5|30 ml Ropivacaine 5 mg/ml (equivalent to 150 mg Ropivacaine)
62697720|NCT00323622|EXPERIMENTAL|Cohort 1-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
62697721|NCT00323622|EXPERIMENTAL|Cohort 2-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
62714735|NCT02208219|ACTIVE_COMPARATOR|Conventional treatment (n=40)|Participants in this group will receive the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy). In order to balance the number of treatment hours between arms, this group will receive extra time of Conventional Treatment during 1 month.
62340040|NCT03508635|EXPERIMENTAL|SAD Cohorts 1 through 6|Participants will receive single doses of 5 mg up to 400 mg of CORT125134 (capsule) in a dose escalation format. The doses selected will be subject to amendment based on emerging data.
62340041|NCT03508635|PLACEBO_COMPARATOR|SAD Cohorts 1 through 6 Placebo|Participants will receive single doses of Matching Placebo of CORT125134 (capsule).
62496129|NCT06381622|EXPERIMENTAL|Intervention group 1: Ropi-5+Lido-20|20 mL Ropivacaine 5 mg/ml + 10 mL Lidocaine-Epinephrine (20 mg + 5 µg) /ml (= 100 mg Ropivacaine + 200 mg Lidocaine)
62496130|NCT06381622|EXPERIMENTAL|Intervention group 2: Ropi-7.5+Lido-20|20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 µg) /ml (= 150 mg Ropivacaine + 200 mg Lidocaine)
62496131|NCT05492448|PLACEBO_COMPARATOR|Placebo|
62496132|NCT05492448|EXPERIMENTAL|L. salivarius AP-32 and L. reuteri GL-104|
62496133|NCT05492448|EXPERIMENTAL|L. reuteri GL-104|
62496134|NCT04531527|EXPERIMENTAL|Phototoxicity reaction test|Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.
62714736|NCT04750421|EXPERIMENTAL|Transillumination Venolux®|Transillumination using Venolux was used to visualize veins in the hemiface before hyaluronic acid injections
61945042|NCT04374071||Pre-Corticosteroid protocol|Patients with moderate or severe disease who presented to HFHS within the first week of the COVID epidemic in Detroit were initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases Physicians and Pharmacists. The institutional guidelines were developed by consensus, and based on the available literature, experience from Wuhan, China and other centers around the world affected by COVID-19 before Michigan. Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated patients. On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the COVID-19 institutional protocol.
62139737|NCT06029244|ACTIVE_COMPARATOR|EyeControl-Pro assisted active intervention arm|The device will be placed on patient's heads. Once the device is properly positioned, patient's will undergo a training session/tutorial lasting 2-3 minutes to orient them to the device usage. Personalized family messages recorded by LARs or others will be played at regular intervals up to 5 times per day (between 08:00-18:00) (8 am to 6 pm). Personalized music/brown noise will be played for 15 minutes every 4 hours, which will be modulated according to your reactions/choices. A study team member will assess patient's mental status by asking thinking and memory questions twice a day (AM and PM). The device will perform the same assessments within 30 minutes of those performed by the study team. The device will be removed at 1800/2000 hrs to ensure adequate sleep. Patient's will be in this study arm for up to 7 days of start of study. The device will be removed on day 7 or sooner if patient's do not need ventilator support and standard care will continue as before device usage.
62164419|NCT01179659|EXPERIMENTAL|Pantoprazole 40 mg DR Tablet|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
62164420|NCT01193088||CMT1A|Families/people with genetically defined CMT1A
62164421|NCT01193088||Genetically undefined CMT|Families/people with genetically undefined CMT with common causes ruled out.
62496135|NCT02207153||Chronic Hemodialysis|Initiation of chronic hemodialysis or currently undergoing chronic hemodialysis at one of the study centres
62340042|NCT03508635|EXPERIMENTAL|Food Effect Cohort 7|Participants will receive a single dose of CORT125134 (capsule) with a standard high fat breakfast. The dose will be chosen such that it has been previously administered in a prior SAD cohort.
62496136|NCT02207153||Peritoneal Dialysis|Initiation of chronic peritoneal dialysis or currently undergoing chronic peritoneal dialysis at one of the study centres
62496137|NCT04186130||SB|Children over 3 years old and under 12 years old who have been diagnosed with spinal bifida with spinal MRI. They should not have known inflammatory bowel disease or cloacal anomaly
62496138|NCT04186130||Control|Children over 3 years old and under 12 years without known inflammatory bowel disease or cloacal anomaly
62496139|NCT01152112|EXPERIMENTAL|Treatment, Office Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in an office setting
62340043|NCT03508635|EXPERIMENTAL|Pharmacological Effect Cohort 8|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
62496140|NCT01152112|EXPERIMENTAL|Treatment, Hospital Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
62496141|NCT03505008|EXPERIMENTAL|MTX-Monotherapy Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the maximum tolerated dose (MTD) of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and simple disease activity index (SDAI) remission is achieved at Week 24, the MTX therapy will continue until Week 48.
62496142|NCT03505008|EXPERIMENTAL|ADA/MTX-Maximum Tolerated Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to the MTX therapy until Week 48.
62496143|NCT03505008|EXPERIMENTAL|ADA/MTX-Reduced Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to low-dose MTX (6 to 8 mg/week) treatment until Week 48.
62496144|NCT00046839|EXPERIMENTAL|Phase I: Celecoxib 200mg BID + RT|"COX-2 Inhibitor: Celecoxib 200 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
62496145|NCT00046839|EXPERIMENTAL|Phase I: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
62496146|NCT00046839|EXPERIMENTAL|Phase II: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
62496147|NCT03059329||Fycompa-treated epilepsy participants|Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
62496148|NCT06249451|NO_INTERVENTION|Retrospective control group (n= 62)|Analysis of patients with the diagnosis of S. aureus-bacteraemia between 01.10.2022-01.10.2023
62496149|NCT06249451|OTHER|Prospective quality-improvement group (n= 62)|Analysis of patients with the diagnosis of S. aureus-bacteraemia between 22.01.2024-22.01.2025
61945043|NCT04374071||Corticosteroid Protocol|"As a result of observed poor outcomes, clinical rationale based upon immunology, clinical course of COVID-19, and more recently best available evidence, the HFHS corticosteroid protocol was developed. We hypothesized that early corticosteroids would combat the inflammatory cascade leading to respiratory failure, ICU escalation of care, and mechanical ventilation. The corticosteroid protocol became the institutional standard on March 20, 2020. Patients with confirmed influenza infection were not recommended to receive corticosteroids.~Patients with moderate COVID-19 who required 4 liters or more of oxygen per minute on admission, or who had escalating oxygen requirements from baseline, were recommended to receive IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days. Patients who required ICU admission were recommended to receive the above regimen of hydroxychloroquine and IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 to 7 days."
61945044|NCT00821483|PLACEBO_COMPARATOR|1: placebo|
61945045|NCT00821483|ACTIVE_COMPARATOR|2 Frovatriptan|
61945046|NCT06436261|EXPERIMENTAL|Split-Face Application of Active|"Active (Experimental) Post-Procedure Cream~Dosage Form: reverse emulsion (water in oil) cream containing bioactive ingredients, botanical actives, peptides, and antioxidants.~Frequency of Dosage: Three times daily (morning, afternoon, and evening). Subjects were asked to apply to the face, forehead, under eyes, cheeks, upper lips, chin, and nose. The product was labelled with Right or Left depending on split-face randomization.~Study Duration: 14 days. Active Post-Procedure Cream duration 14 days."
61945047|NCT06436261|ACTIVE_COMPARATOR|Split-Face Application of Comparator|"COMPARATOR:~Dosage Form: moisturizer formulation~Comparator Moisturizer Frequency of Dosage: Three times daily (morning, afternoon, and evening). Subjects were asked to apply to the face, forehead, under eyes, cheeks, upper lips, chin, and nose. The product was labelled with Right or Left depending on split-face randomization.~Study Duration: 14 days. Comparator duration 14 days."
61945048|NCT04587271|EXPERIMENTAL|Lactating Mothers (Moringa)|Lactating mothers.
61945049|NCT04587271|EXPERIMENTAL|Breastfeeding Infants (Moringa)|Breastfeeding infants from lactating mothers
61945050|NCT04587271|EXPERIMENTAL|Children (Moringa)|Children from 6-59 months of age.
61945051|NCT04587271|PLACEBO_COMPARATOR|Lactating Mothers (placebo)|Lactating mothers.
61945052|NCT04587271|PLACEBO_COMPARATOR|Breastfeeding Infants (placebo)|Breastfeeding infants from lactating mothers
61945053|NCT04587271|PLACEBO_COMPARATOR|Children (placebo)|Children from 6-59 months of age.
61945054|NCT06404671|EXPERIMENTAL|delayed interval cytoreduction surgery (DICS)|delayed interval cytoreduction surgery after six courses of intravenous carboplatin and paclitaxel every 3 weeks
61945055|NCT06404671|ACTIVE_COMPARATOR|Early interval cytoreduction surgery (EICS)|Early interval cytoreduction surgery after three courses of intravenous carboplatin and paclitaxel every 3 weeks
61945056|NCT03159117|EXPERIMENTAL|PF 06688992|This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
61945057|NCT04414748|ACTIVE_COMPARATOR|Antagonist group|Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
61945058|NCT04414748|EXPERIMENTAL|PPOS group|Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
61945059|NCT06680713|EXPERIMENTAL|Progressive exercise test|The incremental effort test will be performed. Thus, on a cycle ergometer, each participant will begin the test with a pedaling cadence of 60-70 RPM at 30W load. Every 3 minutes, this load will increase by 30W, always maintaining the same pedaling cadence. Heart rate, blood pressure, rating of perceived effort, pulse oximetry and muscle oximetry will be monitored throughout the test.
61945060|NCT04604314|EXPERIMENTAL|Endocrown Onlay Restoration|Endocrown onlay preparation = Buccal and lingual walls are intact with an occlusal-gingival height at least equal to half the original crown height of the tooth. Remaining buccal and lingual walls maintain a thickness ≥ 2.0 mm.
61945061|NCT04604314|EXPERIMENTAL|Endocrown Shoulder Restorations|Endocrown shoulder preparation = Buccal and/or lingual walls are less than half the original occlusal-gingival height of the tooth or the buccal or lingual surfaces were previously prepared axially due to a prior restoration.
62340044|NCT03508635|EXPERIMENTAL|Proof of Concept (POC) Cohort 9|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg of prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. An oral glucose tolerance test will be administered on each study day. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
61945062|NCT02789631||chronic neck pain|experiencing neck pain for at least 3 months in the last year
61945063|NCT02789631||without neck pain (asymptomatic)|no history of neck pain
61945064|NCT05181033|ACTIVE_COMPARATOR|Control arm|intramuscular (IM) fulvestrant 500mg on day 1 and day 15 during cycle 1, then day 1 only from cycle 2 onwards of every 4-weekly cycle
61945065|NCT05181033|EXPERIMENTAL|Experimental arm|oral (PO) letrozole 2.5mg daily plus lenvatinib 14mg daily
61945066|NCT03101787|NO_INTERVENTION|CCPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.~No special preparations for the trial are needed before the patient's arrival."
61945067|NCT03101787|EXPERIMENTAL|ECPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).~Time from arrest to start of cannulation is \< 60 minutes."
61945068|NCT01488305|NO_INTERVENTION|Only government regular program|One arm is control arm, in this arm no additional program is added in government regular program
62164422|NCT02390752|EXPERIMENTAL|Phase I|take oral drug daily for a 28 day cycle
62164423|NCT00711776|EXPERIMENTAL|Subjects receiving new formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
62340045|NCT03508635|EXPERIMENTAL|MAD Cohorts 10 and 11|Participants will receive the selected dose of CORT125134 (capsule) following receipt of data from Cohorts 1-9 up to a maximum frequency of twice a day for a total of 14 days.
62496150|NCT01096641|OTHER|Fatigued patients: Immediate start CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
62496151|NCT01096641|OTHER|fatigues patients: delayed CBT (after 6 months)|The fatigued patients on the waiting list will start with CBT after 6 months
62496152|NCT01096641|NO_INTERVENTION|non-fatiqued controls|Non-fatigued control group. This group is not included in the randomization.
62496153|NCT04274829||PTMC|Patients with papillary microcarcinoma of the thyroid
62496154|NCT00787605|ACTIVE_COMPARATOR|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
61945069|NCT01488305|EXPERIMENTAL|AAMA arm (HFP and IYCF BCC)|Second arm is AAMA project intervention which includes HFP activities, ENA and BCC activities
61945070|NCT01488305|EXPERIMENTAL|MNP added in AAMA|It is actually a intervention arm
61945071|NCT01823146|EXPERIMENTAL|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
61945072|NCT01823146|PLACEBO_COMPARATOR|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
61945073|NCT03883360|EXPERIMENTAL|Cannabidiol (CBD)|Participants receive CBD daily for 12 weeks.
61945074|NCT03883360|PLACEBO_COMPARATOR|Placebo|Participants receive vehicle not containing any drug daily for 12 weeks.
61945075|NCT03463174|EXPERIMENTAL|Single-implant mandibular overdenture|Participants allocated to this group will have a dental implant placed in the mandibular midline followed by the immediately insertion of a ball attachment and the incorporation of a retention matrix to the mandibular denture.
62164424|NCT00711776|ACTIVE_COMPARATOR|Subjects receiving current formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
62340046|NCT03508635|PLACEBO_COMPARATOR|MAD Cohorts 10 and 11 Placebo|Participants will receive Matching Placebo of CORT125134 (capsule) up to a maximum frequency of twice a day for a total of 14 days.
62340047|NCT03508635|EXPERIMENTAL|MAD of PoPE Cohorts 12 and 13|Proof of Pharmacological Effect (PoPE+POC). Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the selected dose of CORT125134 (capsule) for a total of 13 days. Participants may either receive a higher dose level than previously administered or a repeat of a dose level given in 1 of the previous 2 MAD Cohorts. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
62340048|NCT03508635|PLACEBO_COMPARATOR|MAD of PoPE Cohort 12 and 13 Placebo|Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the Matching Placebo of CORT125134 (capsule) for a total of 13 days. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
62340049|NCT00062114|EXPERIMENTAL|rituximab + yttrium Y 90 ibritumomab tiuxetan|"Patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV (for imaging) over 10 minutes on day 1. Patients undergo 1 (or 2 if needed) imaging scan between days 2-5. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
62340050|NCT04395352||Pre-ECV|Patients having undergone colonoscopy prior to the introduction of ECV (November 1 2018 to April 30 2019).
62340051|NCT04395352||ECV|Patients having undergone colonoscopy after the introduction of ECV (June 1 2019 to November 30 2019).
62340052|NCT01277341|EXPERIMENTAL|2% Twice a day|Bepotastine Besilate Nasal Spray 2% Twice a day
62340053|NCT01277341|EXPERIMENTAL|3% Twice a day|Bepotastine Besilate Nasal Spray 3% Twice a day
62496155|NCT00787605|EXPERIMENTAL|Aliskiren / HCTZ|Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
61945076|NCT03463174|ACTIVE_COMPARATOR|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment besides the new set of conventional complete dentures. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
61945077|NCT01975961|EXPERIMENTAL|FDC YH16410|"Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).~Subjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
62164425|NCT00711776|EXPERIMENTAL|Subjects receiving new formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
62164426|NCT00711776|ACTIVE_COMPARATOR|Subjects receiving current formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
62340054|NCT01277341|EXPERIMENTAL|4% Twice a day|Bepotastine Besilate Nasal Spray 4% Twice a day
62164427|NCT00711776|EXPERIMENTAL|Subjects receiving new formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
62340055|NCT01277341|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray
62496156|NCT05920954|EXPERIMENTAL|Urgent ERCP|Urgent ERCP (\<24 Hours).
62496157|NCT05920954|EXPERIMENTAL|Early ERCP|Early ERCP(24 to 48 Hours).
62496158|NCT03774199|OTHER|Pulse oximeter calibration population|
62496159|NCT04587245||Physicians|Physician or healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients
62496160|NCT05103644|EXPERIMENTAL|study|breast cancer patient received Atorvastatin 80 mg
62496161|NCT05103644|PLACEBO_COMPARATOR|control group|breast cancer patient received placebo
62496162|NCT01937806|EXPERIMENTAL|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
62496163|NCT01937806|ACTIVE_COMPARATOR|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
62496164|NCT05341492|EXPERIMENTAL|Treatment|Patients will receive 2\*10e6/kgCAR-T cells.
62697722|NCT00323622|EXPERIMENTAL|Cohort 2-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 of the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
62697723|NCT00323622|ACTIVE_COMPARATOR|Cohort 1-Prevnar-Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
62697724|NCT00323622|ACTIVE_COMPARATOR|Cohort 1-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
61945078|NCT01975961|ACTIVE_COMPARATOR|Co-administration|"Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).~Subjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
61945079|NCT06556355||Overall patients|Consecutive patients with locally advanced thoracic ESCC who underwent nCRT and surgery at our center between 1 January 2015 and 31 December 2020.
61945080|NCT04027829|EXPERIMENTAL|Dexmedetomidine|Intravenous infusion of dexmedetomidine for 50 min after surgery at intensive care unit
61945081|NCT01578070|EXPERIMENTAL|ViscoGel® and 0.2μg Act-HIB®|
61945082|NCT01578070|EXPERIMENTAL|0.2μg Act-HIB®|
61945083|NCT01578070|EXPERIMENTAL|ViscoGel® and 2μg Act-HIB®|
61945084|NCT01578070|EXPERIMENTAL|2μg Act-HIB®|
61945085|NCT01578070|ACTIVE_COMPARATOR|10μg Act-HIB®|
62139738|NCT06029244|SHAM_COMPARATOR|Sham Control|The device will be placed on patient's heads. Once the device is properly positioned, patient's will undergo a training session/tutorial lasting 2-3 minutes to orient them to the device usage. Patient's will not receive any of the orientation or family messages and no music will be played through the earphones of the device. A study team member will assess patient's mental status by asking thinking and memory questions twice a day (AM and PM). The device will perform the same assessments within 30 minutes of those performed by the study team. The device will be removed at 1800/2000 hrs to ensure adequate sleep. Patient's will be in this study arm for up to 7 days of start of study. The device will be removed on day 7 or sooner if patient's do not need ventilator support and standard care will continue as before device usage.
62164428|NCT00711776|ACTIVE_COMPARATOR|Subjects receiving current formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
62697725|NCT00323622|ACTIVE_COMPARATOR|Cohort 2-Prevnar- Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
62714737|NCT04750421|NO_INTERVENTION|Comparator group|No vascular exploration methods were used on the other hemiface
61945086|NCT01172262||Bothered Tinnitus|Either responds with a Global Tinnitus Scale of Moderately or Severely Bothered. Score \>30 on the Tinnitus Handicap Index (THI).
61945087|NCT02842359|EXPERIMENTAL|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
61945088|NCT02842359|ACTIVE_COMPARATOR|Irbesartan|Irbesartan will be given orally daily for 28 days
61945089|NCT02842359|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin will be given orally daily for 28 days
62496165|NCT04409054||Patients undergoing the cough and Valsalva protocol|Patients over 18 years old, consulting in neuro urology departement, undergoing ano rectal manometry in order to explore ano rectal disorders
61945090|NCT04471246|EXPERIMENTAL|High Dose Cephalexin|The intervention is high-dose cephalexin (1000mg PO QID) for seven days
61945091|NCT04471246|ACTIVE_COMPARATOR|Standard Dose Cephalexin|The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days
61945092|NCT05704231|EXPERIMENTAL|Experimental: Intervention Group|Motivational Interviewing with WhatsApp video call The individuals in the intervention group will be given a smoking cessation education and motivational interview with a WhatsApp video call for 3 months. The motivational interview will be applied every two weeks, 6 times in total. Self-efficacy scale and smoking behavior scale will be administered again at 3, 6 and 12 months after the intervention. tumor recurrence and progression will be checked by cystoscopy at 3rd and 12th months
61945093|NCT05704231|NO_INTERVENTION|No Intervention: Control Group|the control group received the routine care/education provided in the hospital. Self-efficacy scale and smoking behavior scale will be administered again at 3, 6 and 12 months after the routin hospital care. Both intervention and control groups' tumor recurrence and progression will be checked by cystoscopy at the 3rd and 12th months
61945094|NCT05401968|EXPERIMENTAL|Intervention group|Osteoporosis patients who have participated in patient education
61945095|NCT05401968|NO_INTERVENTION|Control group|Osteoporosis patients who have not participated in patient education
61945096|NCT05330572||Oral lichen planus|No interventions were administered to this group of patients as a part of the study.
61945097|NCT05330572||Oro-vulvovaginal lichen planus|No interventions were administered to this group of patients as a part of the study.
61945098|NCT04314934|EXPERIMENTAL|Active|ANAVEX2-73
62164429|NCT01493947|EXPERIMENTAL|Ivermectin 1% cream|
61945099|NCT00647361|EXPERIMENTAL|NAVA|
62496166|NCT05614115|EXPERIMENTAL|Empagliflozin 10mg|Empagliflozin10mg oral: Those randomized to 10 mg daily dose will be treated with 10 mg QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
62496167|NCT05614115|EXPERIMENTAL|Empagliflozin 25mg|Empagliflozin 25 mg oral: Those randomized to 25 mg daily dose will be treated with 10 mg QD for the first 2 weeks before escalating the dose to 25 mg QD in week 3, based on tolerability. At the end of the dose-escalation phase (weeks 3-4), participants will continue the randomized assignment for additional 8 weeks (weeks 5-12, treatment phase), for a total of 12 weeks.
62139739|NCT04755179||Complex appendicitis without abscess or mass formation|All children (\<18 years old) that present with a suspicion of complex appendicitis without clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
62139740|NCT04755179||Complex appendicitis with abscess or mass formation|All children (\<18 years old) that present with a suspicion of complex appendicitis with clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
62139741|NCT03933540||Pediatric Asthma Patients|"Participants are ages 8 years through 17 years and have partially controlled or uncontrolled asthma.~No intervention is included in this study."
62496168|NCT05614115|PLACEBO_COMPARATOR|Placebo|Encapsulated placebo with an identical appearance to empagliflozin: Those randomized to placebo will be treated with an oral placebo QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
62496169|NCT00640341|EXPERIMENTAL|PureVision|PureVision Contact Lens
62496170|NCT00640341|ACTIVE_COMPARATOR|Acuvue Oasys|Acuvue Oasys Contact Lens
62496171|NCT00640341|ACTIVE_COMPARATOR|O2Optix|O2Optix Contact Lens
62496172|NCT04158427|EXPERIMENTAL|Fecal transplant|A single dose fecal transplant is given (via colonoscopy) from a healthy donor
62496173|NCT04158427|PLACEBO_COMPARATOR|Placebo|A single dose patient's own feces is given (via colonoscopy)
62496174|NCT00949091|EXPERIMENTAL|1|
62496175|NCT02015351|EXPERIMENTAL|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.~Immunosuppression: cyclosporine and/or azathioprine"
62496176|NCT00625157|EXPERIMENTAL|1|
62139742|NCT06039059||Receiving PCI with nonintervened coronary lesion|Patients who received PCI with nonintervened coronary lesion.
62139743|NCT00756574|ACTIVE_COMPARATOR|1. Surgical|surgical mask
62139744|NCT00756574|ACTIVE_COMPARATOR|2. N95 Respirator|N95 respirator
62139745|NCT05838781|NO_INTERVENTION|General/control|Standard of care.
62139746|NCT05838781|EXPERIMENTAL|General/intervention|Standard of care plus 14-days continuous ECG monitoring using an ECG patch.
62139747|NCT05838781|EXPERIMENTAL|Risk prediction model/control|Standard of care.
62139748|NCT05838781|EXPERIMENTAL|Risk prediction model/intervention|Standard of care plus 14-days continuous ECG monitoring using an ECG patch.
62139749|NCT01568359||Group 1 - Acromegaly, Group 2 - control|Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)
62139750|NCT03884413||Breast cancer survivors|Study of spontaneous fertility outcomes following breast cancer history
62139751|NCT03884413||Control group|Study of spontaneous fertility outcomes in healthy volonteers population
62139752|NCT04447287|EXPERIMENTAL|ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of ASP8062 concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
62164430|NCT01493947|ACTIVE_COMPARATOR|Metronidazole 0.75% cream|
62164431|NCT00391521|ACTIVE_COMPARATOR|1|Regimen 1
62164432|NCT00391521|ACTIVE_COMPARATOR|2|Regimen 2
62164433|NCT00391521|ACTIVE_COMPARATOR|3|Regimen 3
62164434|NCT04301843|EXPERIMENTAL|Eflornithine (DFMO)|"In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.~Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed.~DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study."
62164435|NCT05483192|PLACEBO_COMPARATOR|Comparison between placebo and active treatment|"120 subjects were planned. Screening data was reviewed to determine subject eligibility. Subjects who met all inclusion criteria and none of the exclusion criteria were enrolled into the study.~The following investigational products were used:~* Test product: Dichrostachys glomerata extract (Dyglomera™) at a dose of 400 mg~* Control product: Placebo at a dose of 400 mg Subjects were assigned to the test group or placebo group in random order. Each subject was administered a single 400 mg dose of Dyglomera or placebo once daily, before lunch or dinner. Measurements were taken at baseline and at the beginning of each of the 5 study visits."
62164436|NCT05483192|ACTIVE_COMPARATOR|Comparison of baseline to final outcome|The effect of Dyglomera on body fat and blood parameters were compared at baseline and at the end of the intervention period.
62164437|NCT00100945|EXPERIMENTAL|gefitinib|"Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease recurrence or unacceptable toxicity.~Quality of life is assessed at baseline, 4 weeks, every 12 weeks during study treatment, and then at the end of study treatment.~Patients are followed every 3 months for up to 5 years."
62164438|NCT02316145|OTHER|'Habilitation (Internet-based support)|Before the individual started with the internet-based support and coaching (IBSC), a meeting with the coach was compulsory to discuss what specific issues they were going to work with during the period of IBSC. The IBSC was offered at fixed times twice a week during an eight-week period. Two meetings between the individual and the coach were included. Between chat sessions the individuals and the coaches could get in touch using the programme's e-mail. The content of the support and coaching was individualised based on each individual's requirement. Once a fortnight a meeting was held with the head of the project and coaches. Issues regarding ongoing support and coaching were addressed.
62164439|NCT03547648|ACTIVE_COMPARATOR|Group I ( 30 cm H2O)|Patients will be applied 30 cm H2O peak airway pressure manually at the end of the surgery
62164440|NCT03547648|ACTIVE_COMPARATOR|Group II( 40 cm H2O)|Patients will be applied 40 cm H2O peak airway pressure manually at the end of the surgery
62697726|NCT00323622|ACTIVE_COMPARATOR|Cohort 2-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
62697727|NCT06571526|EXPERIMENTAL|EXT|
62697728|NCT06571526|ACTIVE_COMPARATOR|CON|
62697729|NCT06443632|EXPERIMENTAL|Sleep Adjustment|For eligible children aged 0-4, inform parents about the condition and sign an informed consent form. Explain the specific sleep adjustment plan to help parents prepare the child for positioning and radiotherapy appointments.
62697730|NCT06443632|NO_INTERVENTION|Sedation|For eligible children aged 0-4, administer chloral hydrate rectally or orally before positioning and radiotherapy implementation, allowing the child to enter a sedated state for accurate positioning and completion of the radiotherapy session.
62697731|NCT05220202|NO_INTERVENTION|Waitlist Control Group|The waitlist control group will continue with usual care management of musculoskeletal pain and depression. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, midpoint, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the intervention once they have completed the end outcomes assessment.
61945100|NCT02406183|EXPERIMENTAL|Treatment (SBRT, Ipilimumab)|"Drug: Ipilimumab Dosage: Ipilimumab will be administered intravenously at 3 mg/kg every 3 weeks for 4 cycles,~Radiation: Stereotactic Body Radiotherapy Radiation therapy 24 Grays in 8 Grays fractions, Radiation therapy 30 Grays in 10 Grays fractions, Radiation therapy 36 Grays in 12 Grays fractions"
61945101|NCT03010670|EXPERIMENTAL|Oxytocin (OT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OT (3 puffs of 4 IU per nostril).
61945102|NCT03010670|PLACEBO_COMPARATOR|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
61945103|NCT03678025|ACTIVE_COMPARATOR|Arm I (SST)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone.
61945104|NCT03678025|EXPERIMENTAL|Arm II (SST, prostatectomy or radiation therapy)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization.
62340056|NCT05098548||patients with Chronic limb threatening ischemia|"All patients with Chronic limb threatening ischemia present with one or more of the following:~1. Rest pain (Rutherford category 4)~2. Minor tissue loss (Rutherford category 5) admitted to the department of Vascular surgery for Endovascular Intervention with provided written informed consent."
61945105|NCT03678025|ACTIVE_COMPARATOR|Step 1 (pre-randomization)|Standard treatment data collection prior to randomization
62139753|NCT04447287|PLACEBO_COMPARATOR|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of placebo concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
62139754|NCT01588951|EXPERIMENTAL|No Leukemia Stem Cells - Consolidation|Without LSC, standard cytarabine consolidation
62139755|NCT01588951|EXPERIMENTAL|Leukemia Stem Cells - Consolidation|LSC present, randomized to cytarabine consolidation
62340057|NCT05164406||With blood salvage|Patients undergoing oncologic liver surgery with systematic use of blood salvage therapy
62340058|NCT05164406||Without blood salvage|Patients undergoing oncologic liver surgery without any blood salvage therapy
62340059|NCT04121312|EXPERIMENTAL|Facilitation Intervention|"A brief, web-based facilitation guide (called Weight Loss Your Way Kickoff Materials) that encourages initial and sustained engagement in online tracking and social network tools for weight loss.The intervention also includes 8 emails sent over 12 weeks to further motivate use of the online tools and weight loss."
62340060|NCT04969497|EXPERIMENTAL|Sequence ABC|Receives interventions in the sequence, A, B, C.
62340061|NCT04969497|EXPERIMENTAL|Sequence CAB|Receives interventions in the sequence, C, A, B.
62340062|NCT04969497|EXPERIMENTAL|Sequence BCA|Receives interventions in the sequence, B, C, A.
62340063|NCT04969497|EXPERIMENTAL|Sequence CBA|Receives interventions in the sequence, C, B, A.
62340064|NCT04969497|EXPERIMENTAL|Sequence BAC|Receives interventions in the sequence, B, A, C.
62340065|NCT04969497|EXPERIMENTAL|Sequence ACB|Receives interventions in the sequence, A, C, B.
61945106|NCT03869983|ACTIVE_COMPARATOR|Active Comparator|Omnipaque™ (iohexol) Injection, 755 mg/mL iohexol (350 mgI/mL)
61945107|NCT03869983|EXPERIMENTAL|Experimental|CE-Iohexol Injection, 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL
61945108|NCT05895617||Research Study|Is the Occuity pachymeter non inferior in it's measurement of central corneal thickness compared to the ultrasound pachymeter, Lenstar and Pentacam.
61945109|NCT05466929|EXPERIMENTAL|TeACH System Resources|Patients who screen positive for anxiety will receive stakeholder-informed feedback and resources (i.e., psychoeducation and mental health recommendations).
62139756|NCT01588951|EXPERIMENTAL|Leukemia Stem Cells - Transplant|LSC present, randomized to allogeneic transplant
62496177|NCT00625157|PLACEBO_COMPARATOR|2|
61945110|NCT05466929|NO_INTERVENTION|Evidence-based Resources|Patients who screen positive for anxiety will receive a link to a webpage providing psychoeducation about anxiety and possible treatment options.
62139757|NCT05935046|EXPERIMENTAL|Premenopausal Status|
62139758|NCT05935046|EXPERIMENTAL|Peri Menopausal status|
62139759|NCT05935046|EXPERIMENTAL|Menopausal status|
62139760|NCT03205566|ACTIVE_COMPARATOR|Arm A Raltegravir, then Raltegravir/Lamivudine|7 days Raltegravir 400mg bd followed by minimum 4 weeks wash out and then 7 days Raltegravir 400mg/lamivudine 150mg (oral tablets) bd.
62496178|NCT03494933|EXPERIMENTAL|CRT-P group|Intervention: CRT-P implantation
61945111|NCT06681753|EXPERIMENTAL|the Breastfeeding Consultancy and Baby Friendly Hospital Training Program|The project consultant (PT) who is a Breastfeeding Consultant and National Baby Friendly Hospital evaluator and a nurse working in the Neonatal Intensive Care Unit and who participated in the Breastfeeding Consultancy and Baby Friendly Hospital Training Program of the Ministry of Health, will provide 6 hours of theoretical and 2 hours of practical training on Breastfeeding and Breastfeeding support. The training content will include the following topics: Breastfeeding Status in Turkey and the World, Effective Communication and Consultancy Skills, Composition of Breast Milk, Lactation and Relaxation, Breastfeeding Positions, Feeding of Babies with Special Conditions, and Benefits of Breastfeeding.
62496179|NCT03494933|ACTIVE_COMPARATOR|CRT-D group|Intervention: CRT-D implantation
62496180|NCT01898845|EXPERIMENTAL|LEE011|LEE011
62496181|NCT01589835|EXPERIMENTAL|Lifestyle counseling|Green prescription with facilitator support
61945112|NCT06681753|NO_INTERVENTION|Control|
61945113|NCT03591185|EXPERIMENTAL|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
61945114|NCT00934479|NO_INTERVENTION|Healthy Subjects|Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
61945115|NCT00934479|EXPERIMENTAL|Constipated Subjects|"Subjects with constipation included those with chronic constipation (CC) and those with constipation predominant irritable bowel syndrome (C-IBS). They completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing.~Following baseline test and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.~Following the 4-weeks treatment with lubiprostone, they completed another stool diary, fasting breath test, and stool sample for pyrosequencing."
61945116|NCT01706978|EXPERIMENTAL|Soft Tissue Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
61945117|NCT01706978|ACTIVE_COMPARATOR|Bone Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
61945118|NCT02218255|ACTIVE_COMPARATOR|Day 3 eSET combined with Eeva|Traditional Morphology + Eeva™ results
61945119|NCT02218255|ACTIVE_COMPARATOR|Day 5 eSET combined with Eeva|Traditional Morphology + Eeva™ results
61945120|NCT02218255|NO_INTERVENTION|Day 5 eSET with Traditonal Morphology|
61945121|NCT02515396|EXPERIMENTAL|Treatment Group A|MMI-0100 Inhaled, once daily x 5, followed by 3 week washout period, followed by Placebo Inhaled, once daily x 5
61945122|NCT02515396|EXPERIMENTAL|Treatment Group B|Placebo Inhaled, once daily x 5, followed by 3 week washout period, followed by MMI-0100 Inhaled, once daily x 5
62139761|NCT03205566|ACTIVE_COMPARATOR|Arm B Raltegravir/Lamivudine, then Raltegravir|Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days followed by a minimum of 4 weeks wash out and then 7 days Raltegravir 400mg bd.
62139762|NCT02268708||COPD|"Patients:~\>18 years old COPD: FEV/FEV1\<80% in respiratory evaluation who have un oncological pulmonary resection in Cochin Hospital Paris France"
62164441|NCT03547648|ACTIVE_COMPARATOR|Group III(50 cm H2O)|Patients will be applied 50 cm H2O peak airway pressure manually at the end of the surgery
62496182|NCT01589835|OTHER|Usual care|
62496183|NCT06678711|EXPERIMENTAL|Minimal invasive surgery arm|Patients in minimal invasive surgery arm will receive minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion.
62697732|NCT05220202|EXPERIMENTAL|Behavior Intervention Group (MOTIVATE)|For participants assigned to the intervention arm, trained health coaches will deliver the 8 session intervention via telephone. MOTIVATE users motivational interviewing techniques, values elicitation and physical activity based goal setting. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, midpoint, final assessments) conducted by a blinded research assistant.
62340066|NCT00448916|EXPERIMENTAL|Pregabalin|Orally-administered pregabalin
62496184|NCT06678711|ACTIVE_COMPARATOR|Open atlantoaxial fixation and fusion arm|Patients in open atlantoaxial fixation and fusion arm will receive atlantoaxial fixation and fusion using the Goel-Harms technique.
62496185|NCT01092169||Sickle cell beta|
62496186|NCT03294122||PCa patients - Discovery cohort|External beam radiotherapy for prostate cancer
62496187|NCT03294122||HNCa patients - Discovery cohort|External beam radiotherapy for head and neck cancer
62496188|NCT03294122||PCa patients - Validation cohort|External beam radiotherapy for prostate cancer
62496189|NCT03294122||HNCa patients - Validation cohort|External beam radiotherapy for head and neck cancer
62496190|NCT04997551|ACTIVE_COMPARATOR|Colchicine|EC Experimental group: colchicine for 2 weeks orally added to standard treatment.
62496191|NCT04997551|PLACEBO_COMPARATOR|Placebo|Control group: placebo for 2 weeks added to standard treatment.
62697733|NCT06645197|EXPERIMENTAL|3 single Ascending Dose Levels|The study will be open-label with an initial plan to explore 3 dose levels of SNUG01 in approximately 7 to 10 Participants in total. Each Participant will receive a single dose of SNUG01 delivered via intrathecal (IT) infusion and will be followed for up to 5 years after administration.
62496192|NCT03727763|EXPERIMENTAL|FIVC group|Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)
62496193|NCT02340780|EXPERIMENTAL|Buparlisib|100mg daily orally every 28 days
62496194|NCT02508870|EXPERIMENTAL|Cohort A: Atezolizumab - HMA R/R MDS|Participants with MDS who are HMA R/R will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a partial response (PR) or hematological improvement (HI) after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
62539199|NCT03929276|EXPERIMENTAL|high-intensity laser therapy & exercises|High-intensity laser therapy application with iLux Laser device + exercise program
62697734|NCT04567251||Noona® mobile healthcare application|All patients will be instructed to report pre-defined, non-life-threatening cognitive symptoms as often as relevant through the Noona® application for 17 weeks.
62697735|NCT03005002|EXPERIMENTAL|Treatment (durvalumab, tremelimumab)|Patients receive durvalumab IV over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
61945123|NCT00333840|EXPERIMENTAL|imatinib (STI571)|In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
61945124|NCT00333840|ACTIVE_COMPARATOR|IFN-a+Ara-C|In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
62340067|NCT02391350|ACTIVE_COMPARATOR|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
62340068|NCT02391350|EXPERIMENTAL|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
62340069|NCT01136421|ACTIVE_COMPARATOR|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
62340070|NCT01136421|EXPERIMENTAL|Magnesium sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
62340071|NCT00264849|EXPERIMENTAL|OAT + Omalizumab|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.
62340072|NCT00264849|ACTIVE_COMPARATOR|Optimized Asthma Treatment (OAT)|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.
62340073|NCT05408312|EXPERIMENTAL|Experimental group 1|
62340074|NCT05408312|EXPERIMENTAL|Experimental group 2|
62340075|NCT05408312|EXPERIMENTAL|Experimental group 3|
62340076|NCT05408312|PLACEBO_COMPARATOR|placebo group|
62340077|NCT05181020|EXPERIMENTAL|Maternal Voice Exposure|Infants enrolled will be exposed to maternal voice for 20 min immediately prior to being offered oral feedings. This exposure will be conducted 2 times a day until infant starts taking all enteral feeds orally.
62340078|NCT01665248|OTHER|stable angina pectoris or acute coronary syndrome|
62340079|NCT03783052|OTHER|Healthy volunteers|11 Healthy volunteers
62340080|NCT03783052|OTHER|Obese volunteers|11 Obese Volunteers
62539200|NCT03929276|PLACEBO_COMPARATOR|Shame laser & exercises|Sham high-intensity laser therapy application with iLux Laser device + exercise program
62539201|NCT03929276|ACTIVE_COMPARATOR|control - exercises only group|exercise program
62697736|NCT02956564|OTHER|exposure group|subjects in this group are those who accept intrauterine intervention
62697737|NCT02956564|NO_INTERVENTION|control group|subjects in this group are those who do not accept intrauterine intervention
62697738|NCT05812859|EXPERIMENTAL|Device Use|Patient's will use vaginal orthosis daily from the start of week 2 post-operative to week 12 post-operative.
62697739|NCT05812859|NO_INTERVENTION|Standard of Care|Patient's will proceed with normal standard of care post-operative management which is pelvic rest and light acitvity.
62697740|NCT04255381|EXPERIMENTAL|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Use Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system
62697741|NCT04789317||Stable CAD or stabilized NSTEMI (ACS) with significant epicardial lesions defined as FFR≤0.80.|The PPG Global Registry an investigator-initiated, observational, multicenter study of patients with an indication for PCI based on coronary angiography and FFR ≤0.80. After confirmation of intention to treat with PCI, a manual pullback with PPG analysis will be performed. A second level of decision making is then performed concerning PCI, coronary artery bypass grafting (CABG) or medical therapy (OMT). Patients will undergo PCI at operator discretion and post-PCI FFR will be measured. Clinical follow-up will be performed at 1, 2 and 3 years.
61945125|NCT04289623||Standard email|This email mentions the cost-saving benefits of enrollment by participants who met their 2018 goals. It also includes the message that registration can be completed quickly (in less than five minutes). Finally, it also includes reward incentive information, wherein registering by a March deadline provides qualified recipients with the potential to win prizes. This information is contained in all other emails.
61945126|NCT04289623||Loss frame email|"In addition to the content of the generic email, the subject line and content of the loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. This email further frames the reward as something recipients will miss out on if they do not sign up.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
61945127|NCT04289623||Testimonial (medical expert) email|"In addition to the content of the generic email, the testimonial (medical expert) email includes a testimonial from a doctor, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a presumed authority figure. Recipients may be more likely to enroll for this program if they see a physician - who would be seen as an authority on health and wellness - talking about the medical benefits of the program. It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
62139763|NCT05085704||Adolescents and adults with Glut1 deficiency|"1. Adolescents and adults with previously documented diagnosis of Glut1 Deficiency with diagnosis genetically confirmed or confirmed by PET scan of the brain.~2. Ages 16 to 65~3. Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included."
62139764|NCT05085704||Normal healthy adolescents and adults|"1. Adolescents or adults in good general health.~2. Ages 16 to 65.~3. Persons with dental fillings, dental crowns, and short (max. 4 cm) dental retainer wires can be included."
62139765|NCT06699251|ACTIVE_COMPARATOR|Enhanced Usual Care|When the online consent/assent form is completed, the teen will be sent a personalized link to complete their baseline survey. Upon survey completion, the teen will receive a link that has their electronic gift card payment, and the case manager will be notified that a particular ID has completed the survey. The case manager will be informed by study staff whether to schedule that ID for enhanced usual care (EUC) or the Chat intervention. If they are randomized as EUC, the informational brochure for the EUC will be handed to the teen during the visit or securely emailed to them. Whether the teen completes EUC or Chat, every teen will be followed by the RAND Survey Research Group to complete their paid follow-up web-based surveys based on timing of completion of their baseline survey.
62139766|NCT06699251|EXPERIMENTAL|Chat Intervention|When the online consent/assent form is completed, the teen will be sent a personalized link to complete their baseline survey. Upon survey completion, the teen will receive a link that has their electronic gift card payment, and the case manager will be notified that a particular ID has completed the survey. The case manager will be informed by study staff whether to schedule that ID for enhanced usual care (EUC) or the Chat Intervention. If they are randomized as Chat Intervention, Chat will take place either via a virtual or in-person visit. Whether the teen completes EUC or Chat, every teen will be followed by the RAND Survey Research Group to complete their paid follow-up web-based surveys based on timing of completion of their baseline survey.
62139767|NCT04690738||Post Pancreas Transplant Patients|Pancreas transplant recipients
62139768|NCT02597920||Switch patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
62139769|NCT02597920||New AF patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
62139770|NCT04629313||periodontal disease group|"Gingivitis: BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.~SI Periodontitis: interdental AL of 1-2 mm, PD≤4 mm and no tooth loss SII Periodontitis: interdental AL of 3-4 mm, PD≤5 mm and no tooth loss SIII Periodontitis: interdental AL ≥5 mm, PD≥6 mm SIV Periodontitis: interdental AL ≥5 mm teeth, radiographic bone lose extending to middle or apical third of the root,"
62139771|NCT04629313||periodontal healthy group|consisted of individuals with clinically healthy gingiva
62139772|NCT04142255|EXPERIMENTAL|FMT|20 subjects will be enrolled in this arm to receive FMT treatment.
62139773|NCT05786872|EXPERIMENTAL|dual-target deep brain stimulation|This is a single arm, prospective, open label clinical study, participants who fit inclusion/exclusion standards, completed physical anti-addiction treatments and surgical implantation standard will start DBS system stimulation and adjust parameters after 10-14 days of implantation. Then after stimulation for 9-32 weeks, they will be evaluated for treatment efficacies. This study is extendable, with agreements from participants, long term efficacy and safety follow-up study will be performed after 32 weeks ± 7 days of following, once every 2-3 months.
62340081|NCT03783052|OTHER|Roux-en-Y Gastric Bypass patients|6 volunteers with a Roux-en-Y Gastric Bypass
62340082|NCT03783052|OTHER|Sleeve Gastrectomy patients|6 volunteers with a Sleeve Gastrectomy
62340083|NCT03783052|OTHER|Volunteers with obesity|6 obese volunteers
62340084|NCT06303947|EXPERIMENTAL|Intermittent Oro-esophageal Tube+comprehensive rehabilitation therapy|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding"
62340085|NCT06303947|ACTIVE_COMPARATOR|Nasogastric Tube+comprehensive rehabilitation therapy|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines."
61945128|NCT04289623||Testimonial (rank-and-file) email|"In addition to the content of the generic email, the testimonial (rank-and-file) email includes a testimonial from a customer care specialist, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a peer (relative to most Geisinger employees). Recipients may be more likely to enroll for this program if they see a rank-and-file employee talking about the program as this person would be more relatable (relative to a doctor). It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
61945129|NCT04289623||Social norms (percentage) email|"In addition to the content of the generic email, the social norms (percentage) email will include communication about the percentage of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a majority of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. The use of percentages makes it clear that this behavior is indeed being done by most people in the group. It is unclear in the current context and population if a message using percentages or numbers would be more effective."
62496195|NCT02508870|EXPERIMENTAL|Cohort B: Atezolizumab+Azacitidine - HMA R/R MDS|Induction: Participants with MDS who are HMA R/R will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 milligrams per square meter (mg/m\^2) subcutaneously (SC) on Days 1 to 7 of 28-day cycle, for 6 cycles. Maintenance: Participants who complete induction treatment will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
62340086|NCT03548038||Bariatric surgery patients|All subjects will be patients scheduled for bariatric surgery. There is only one arm in this study.
61945130|NCT04289623||Social norms (number) email|"In addition to the content of the generic email, the social norms (number) email will include communication about the number of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a large number of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. While the use of numbers does not indicate that this behavior is being done by a majority, using a large number can be more convincing just in showing sheer quantity."
61945131|NCT06556290|EXPERIMENTAL|Nutritional Intervention|Group with 3 months of a gluten free and casein free diet
61945132|NCT01735760||Palpation|The group using palpation as primary attempt at localizing the cricothyroid membrane
62340087|NCT00288860|EXPERIMENTAL|Telephone Monitoring|Biweekly monitoring and support by telephone (up to 6 calls over 3 months) as augmentation to mental health care as usual.
62340088|NCT00288860|ACTIVE_COMPARATOR|Treatment-As-Usual|Mental health Treatment As Usual, potentially including case management, pharmacotherapy, and individual and/or group psychotherapy.
62340089|NCT04105244|NO_INTERVENTION|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post-enrollment plus the current standard of care, whereby caregivers phone their healthcare providers when they have questions or concerns
62496196|NCT02508870|EXPERIMENTAL|Cohort C1: Atezolizumab+Azacitidine - HMA-Naive MDS|Participants with MDS who are HMA-naive will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m\^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
62496197|NCT02508870|EXPERIMENTAL|Cohort C2: Atezolizumab+Azacitidine - HMA-Naive MDS|If the participants enrolled in Cohort C1 fulfil the dose limiting toxicity (DLT) criteria, then additional participants with MDS who are HMA-naïve will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m\^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
62496198|NCT02508870|EXPERIMENTAL|Cohort A2: Atezolizumab - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
62697742|NCT06207942|ACTIVE_COMPARATOR|Sedation, temperature device and high MAP|
62697743|NCT06207942|ACTIVE_COMPARATOR|Sedation, no temperature device and high MAP|
62697744|NCT06207942|ACTIVE_COMPARATOR|Sedation, temperature device and low MAP|
62697745|NCT06207942|ACTIVE_COMPARATOR|Sedation, no temperature device, and low MAP|
61945133|NCT01735760||Ultrasonography|The group using ultrasound for their primary approach to localizing the cricothyroid membrane
61945134|NCT01903031|EXPERIMENTAL|NuvaRing and no ART (Arm A)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days).
61945135|NCT01903031|EXPERIMENTAL|NuvaRing with EFV plus ≥2 NRTIs (Arm B)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). EFV is a non-nucleoside reverse transcriptase inhibitor taken at a dose of 600 mg once daily.
61945136|NCT01903031|EXPERIMENTAL|NuvaRing with ATV/r plus TDF + ≥1 NRTIs (Arm C)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). ATV/r is a combination protease inhibitor taken at a dose of 300/100 mg once daily. Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) taken at a dose of 300 mg daily.
61945137|NCT05531383|NO_INTERVENTION|Control group (group 1)|Patients in the control group (group 1) No memantine administration
61945138|NCT05531383|ACTIVE_COMPARATOR|Treatment group (group 2)|in addition to the standard treatment, they will receive memantine (30 mg) twice daily, either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital. The memantine dose administered in our study was based on the maximum dose of 60 mg/day reported in prior human studies
61945139|NCT03451578|OTHER|Advanced Dry macular degeneration|
61945140|NCT01022749|EXPERIMENTAL|2|patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
61945141|NCT01022749|EXPERIMENTAL|3|patients with IBD receiving immunosuppressants including TNF blockers (n=100)
61945142|NCT01022749|EXPERIMENTAL|1|patients with IBD not receiving immunosuppressant (n=100)
61945143|NCT01022749|ACTIVE_COMPARATOR|4|patients with IBD receiving immunosuppressants including TNF blockers (n=20)
61945144|NCT04798456||Patients with DoC|
61945145|NCT04798456||Caregivers/ legal guardian of patients with DoC|
61945146|NCT02637154|ACTIVE_COMPARATOR|Motivational Interviewing|With 30 patients Motivational Interviewing method will be used during each visit
61945147|NCT02637154|ACTIVE_COMPARATOR|Standard Education|With 30 patients Standard Education material will be used during each visit
61945148|NCT05485454|ACTIVE_COMPARATOR|Aria Health Aria Free|An Aria Free therapy session on the study lower limb.
61945149|NCT05485454|ACTIVE_COMPARATOR|Traditional PCD|A therapy session using the traditional PCD on the study lower limb.
61945150|NCT02437812|EXPERIMENTAL|Paclitaxel, carboplatin and metformin|"Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)~The regimen will be administered as a dose dense schedule."
61945151|NCT00241358|ACTIVE_COMPARATOR|Subcutaneous (SC) Treatment Plan - Donor|"* Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis~* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
61945152|NCT00241358|EXPERIMENTAL|Intravenous (IV) Treatment Plan - Donor|"* Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis~* Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis~* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
61945153|NCT00241358|OTHER|Recipients|"* Conditioning Regimen~  * Cyclophosphamide 60mg/kg/day on Days -3 and -2~ * TBI 550cGy on Day -1~* GVHD prophylaxis~  \*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100~* PBSC transplant on Day 0"
61945154|NCT04659720|ACTIVE_COMPARATOR|summers' osteotome technique for closed sinus lift|Implant stability will be evaluated after closed sinus lift using summer's osteotome technique in posterior edentulous maxilla
61945155|NCT04659720|ACTIVE_COMPARATOR|Patient satisfaction evaluation after closed sinus lifting using summers' osteotome technique|"* Will be assessed numerically using a patient satisfaction chart .~* Time of assessment: immediately after surgery"
62139774|NCT03110536||2h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 2 hours.
62697746|NCT06207942|ACTIVE_COMPARATOR|Minimal sedation, temperature device, and high MAP|
61945156|NCT05515315|EXPERIMENTAL|Tislelizumab combined with chemothapy|
61945157|NCT01361568|EXPERIMENTAL|CR845|Peripheral kappa opioid receptor agonist
61945158|NCT01361568|PLACEBO_COMPARATOR|Placebo|Matched Placebo
61945159|NCT01373489|NO_INTERVENTION|Usual Care|The usual care group received the current standards of care at the study clinics.
61945160|NCT01373489|EXPERIMENTAL|Technology Assisted Case Management|The TACM group used the FORA 2-in-1 Telehealth system for diabetes management intervention to link a case manager to patients with poorly controlled type 2 diabetes in real time.
61945161|NCT02545257|ACTIVE_COMPARATOR|Active comparator|In addition to normal, standard care, participants allocated to intervention group will receive a coordinated medication management model containing prescription review, drug-related problems (DRP) risk assessment and required action based on the DRP risk assessment.
61945162|NCT02545257|NO_INTERVENTION|Control group (standard care)|Normal, standard care (control group)
61945163|NCT06201442||Patients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)|4 - 5 visits: Clinical examination, magnetic resonance imaging (MRI), 3D motion analysis, Strength assessment, EOS radiography (full leg X-ray scan), X-ray scan knee, Blood sample, Questionnaires and Activity monitoring.
61945164|NCT06201442||Healthy controls without previous Anterior Cruciate Ligament (ACL) injury|2 visits: Clinical examination, MRI, 3D motion analysis, Strength assessment, EOS radiography, X-ray scan knee, Blood sample, Questionnaires and Activity monitoring.
61945165|NCT05136287||Diabetes mellitus 2 patients with obesity|Patients that meet criteria to start treatment with GLP-1 receptor agonists (dulaglutide; exenatide; liraglutide; lixisenatide )
62697747|NCT06207942|ACTIVE_COMPARATOR|Minimal sedation, no temperature device and high MAP|
62697748|NCT06207942|ACTIVE_COMPARATOR|Minimal sedation, temperature device and low MAP|
61945166|NCT01817244|EXPERIMENTAL|care management type 1|2-month care management
61945167|NCT01817244|ACTIVE_COMPARATOR|care management type 2|6-month care management
62139775|NCT03110536||4h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 4 hours.
62139776|NCT03110536||6h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 6 hours.
61945168|NCT02551861|ACTIVE_COMPARATOR|Daclatasvir + Sofosbuvir|Daclatasvir 60mg tablet and Sofosbuvir 400mg tablet oral dosing once daily for 8 weeks
61945169|NCT02551861|ACTIVE_COMPARATOR|Daclatasvir + Sofosbuvir + Ribavirin|Daclatasvir 60mg tablet + Sofosbuvir 400mg tablet+ Ribavirin 1000-1200mg tablet(weight based dosing) oral dosing split into am and pm once daily for 8 weeks
61945170|NCT01538511|EXPERIMENTAL|BIAsp 70|
61945171|NCT01538511|EXPERIMENTAL|BIAsp 30|
61945172|NCT05132634|EXPERIMENTAL|Arms|"Experimental Group:~Braden Risk Assessment Scale was completed on the first day of admission to the Intensive Care Unit and every morning in the morning.~Since the care hours were between 08:00_10:00 in the morning and 20:00-22:00 at night, classical hand massage was applied to the patient by the researcher between the time zones specified daily.~It was followed up with the Pressure Wound Staging Form.~Control Group:~The Braden Risk Assessment Scale was completed on the first day of admission to the Intensive Care Unit and every morning in the morning.~It was followed up with the Pressure Wound Staging Form."
61945173|NCT05748197|EXPERIMENTAL|ADCLEC.syn1 CAR T cells|The dose escalation cohort size of 3 patients in each cohort will be infused with escalating doses of ADCLEC.syn1 CAR T cells to inform the RP2D. There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells. After dose escalation, one or two dose levels will be selected for dose expansion cohort(s).Two to 7 days following completion of the conditioning chemotherapy, the frozen CAR T cells will be thawed and administered. Conditioning chemotherapy may occur either outpatient or inpatient, and T cell infusions will occur as inpatient. Up to approximately 12 additional patients each if two doses are selected or approximately 16 additional patients, if one dose is selected, will be treated in the dose expansion phase to determine RP2D.
61945174|NCT01495975|NO_INTERVENTION|Usual Care|Usual care for diabetes in the 1 month after discharge.
61945175|NCT01495975|EXPERIMENTAL|Diabetes Transitions Tool Kit|Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
61945176|NCT03918473|EXPERIMENTAL|Mobilization with Movement|A weight- bearing mobilization directed to the talocrural joint in a standing position.
62139777|NCT02861456|ACTIVE_COMPARATOR|Standard Care Group|Patient in the treatment arm will receive the Standard Model of Care as prescribed for their condition by their physician including but not limited to Advanced imaging, Rest, Bracing, Physical Therapy, and Medication.
62139778|NCT02861456|EXPERIMENTAL|Functional Progression Group|Patients who are randomized to the alternative model of care to guide treatment will not have advanced imaging done and will be referred directly to physical therapy care . If the patient is able to functional progress through phase I and II of physical therapy within 3 weeks and phase III within 5 weeks then they return to sport. If patient are unable to progress the are put on rest as a presumed vertebral injury (spondylolysis).
61945177|NCT03918473|EXPERIMENTAL|Thrust Mobilization|A high velocity, low amplitude thrust mobilization directed to the talocrural joint with the participant in a non-weight bearing position.
61945178|NCT01520597||Case|Patient with culture-proven listeriosis
62139779|NCT05335044|EXPERIMENTAL|Sequence A|"Period 1: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 3: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-331 - A single oral dose of 2 tablets under fasting condition"
62139780|NCT05335044|EXPERIMENTAL|Sequence B|"Period 1: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 2: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 4: EX5619 - A single oral dose of 1 tablet under fasting condition"
62164442|NCT06030258|EXPERIMENTAL|Experimental group|IN10018 in combination with Tislelizumab, carboplatin and etoposide as the first-line treatment in ES-SCLC.
62340090|NCT04105244|EXPERIMENTAL|Resourcefulness Training Intervention©|The Resourcefulness Training© arm will receive (a) individually tailored instruction on personal and social resourcefulness skills via the Resourcefulness Video and intervention nurse, (b) journal-writing instruction to describe resourcefulness application, (c) access to the study website with videotape vignettes and Resourcefulness Video, and (d) boosters at 2 and 4 months post-enrollment that will include reinforcement of skills learned and additional journal writing.
62340091|NCT02815293|EXPERIMENTAL|AGN-195263|
62697749|NCT06207942|ACTIVE_COMPARATOR|Minimal sedation, no temperature device and low MAP|
61945179|NCT01520597||Control|Patient above the age of 18 years with medical background and clinical features compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp \> 38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile symptom leading to empiric amoxicillin prescription.
61945180|NCT01681940|EXPERIMENTAL|Lamazym|1 mg/kg body weight
61945181|NCT05310448|EXPERIMENTAL|Treatment (tumor treating fields)|After completion of standard of care radiation therapy, patients wear the Optune device for 18 hours per day for 12 months in the absence of disease progression or unacceptable toxicity.
61945182|NCT04211402||Obsessive-Compulsive Disorder|Patients with obsessive-compulsive disorder
61945183|NCT00375037|EXPERIMENTAL|Hand hygiene|Hand hygiene promotion
61945184|NCT00375037|ACTIVE_COMPARATOR|Usual care|usual care
61945185|NCT03439917|EXPERIMENTAL|Carnitine and Meal Replacement Drink|2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
62164443|NCT06030258|ACTIVE_COMPARATOR|Control group|Tislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC
62164444|NCT00278395|EXPERIMENTAL|Arm I|Patients receive oral vorinostat (SAHA) twice daily on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may have the option of continuing treatment beyond 52 weeks at the discretion of the investigator.
62164445|NCT01425541|EXPERIMENTAL|estrogen, progesterone|Estrace, 0.5-1 mg once a day Micronized progesterone powder (Spectrum Chemical Manufacturing Corporation, Irving, CA), Three times a day at 0700, 1500, and 2300 hr
61945186|NCT03439917|PLACEBO_COMPARATOR|Placebo and Meal Replacement Drink|2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
61945187|NCT03643575|EXPERIMENTAL|Treatment A: Vicks Cough Syrup for Chesty Coughs|Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
61945188|NCT03643575|EXPERIMENTAL|Treatment B: Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
61945189|NCT03643575|EXPERIMENTAL|Treatment C: Organ-I- NR tablet|Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
61945190|NCT02973490|EXPERIMENTAL|Transanal Tube Drainage|patients with transanal tube drainage after ESD
61945191|NCT02973490|NO_INTERVENTION|Without Transanal Tube Drainage|patients without transanal tube drainage after ESD
61945192|NCT05952596|EXPERIMENTAL|Test group|DTaP-HepB-IPV-Hib vaccine
61945193|NCT05952596|ACTIVE_COMPARATOR|Control group|DTaP-HepB-IPV-Hib vaccine
61945194|NCT06462638||Triad - Newborn, mother and father|"The study involves triads of mother, father, moderately/late preterm born infant, admitted to the NICU. The population of moderately preterm infants admitted to a Neonatal Intensive Care Unit (NICU) and their parents are individuals who face a unique and complex set of challenges. These infants are at a stage when many of their organs and body systems are not yet fully developed. This incomplete development makes them particularly vulnerable to various medical complications.~As for the parents of these infants, the experience of having a baby admitted to the NICU is often a source of great emotional and psychological stress. Preterm birth, which is generally unexpected, can generate feelings of anxiety, fear and uncertainty about their baby's short- and long-term health. They need clear and understandable informational support to help them feel more involved and less helpless in their baby's care."
61945195|NCT06175130||Healthy children (6-12 years)|Healthy children (6-12 years), no illness or disease
62697750|NCT06205069|ACTIVE_COMPARATOR|Intervention group|"The floss band will be applied to the knee of the dominant lower limb in the intervention group (IG). While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.~After applying the floss band, passive mobilization will be performed - 20 repetitions of knee flexion and extension and an active movement task - 20 squats. Participants will be instructed to perform knee flexion and extension to their extreme range of motion and to complete the mobility exercises within two minutes. After two minutes, the floss band will be removed and participants will be instructed to stand up and walk for a minute to allow blood to flow back to the foot."
62697751|NCT06205069|NO_INTERVENTION|Control group|For the CG, after initial assessment, participants without a floss band will perform the same two functional movement tasks (active and passive) with 20 repetitions as the GI for 2 minutes. After two minutes, participants will be instructed to get up and walk for one minute like the intervention group.
61945196|NCT06175130||Healthy Women of reproductive age (15-50 years)|Healthy Women of reproductive age (15-50 years), no illness or disease
61945197|NCT03676283|EXPERIMENTAL|Web-based psycho-educational support for family caregivers|Gaining access to the website (närstående.se) with supportive films and texts
61945198|NCT01374828|EXPERIMENTAL|Ketolorac|
61945199|NCT01633073|ACTIVE_COMPARATOR|LMA Supreme|
61945200|NCT01633073|ACTIVE_COMPARATOR|i-gel|
61945201|NCT05034562|EXPERIMENTAL|Diagnostic (gallium Ga 68-labeled PSMA-11, PET/CT, PET/MRI)|Patients receive gallium Ga 68-labeled PSMA-11 IV. 50-100 minutes after injection, patients then undergo a PET/CT scan or PET/MRI scan over 60 minutes.
61945202|NCT06266689|OTHER|Intervention|Participants in this group will receive the standard infant dietary guidance packet via email or mail and will additionally be presented with their infant's own dietary DNA metabarcoding data from stool samples collected as part of Project HOPE 1000 and this study. Diet data will be returned via electronic report or a paper report mailed to the participant following the visit.
61945203|NCT06266689|OTHER|Control|"Participants in this group will receive a dietary information packet via mail or email, which will consist of the sections of the DGA relevant to 12-24 month old children (Included as a supplemental document, Standard dietary guidance). This dietary guidance will also be provided at the 18- and 24-month visits. Please note that participants in this arm will receive their personalized diet information at the conclusion of the study."
61945204|NCT01085474||1|1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
61945205|NCT01085474||2|Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
62340092|NCT02815293|PLACEBO_COMPARATOR|Vehicle|
62697752|NCT05264402||PICCline group|Patients needing a vascular approach using PICCline catheters
62697753|NCT05264402||Midline group|Patients needing a vascular approach using Midline catheters
62697754|NCT00572559|EXPERIMENTAL|1|
62697755|NCT00572559|EXPERIMENTAL|2|
62697756|NCT06135064|EXPERIMENTAL|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets affected by PTSD.
62697757|NCT06135064|SHAM_COMPARATOR|Sham stimulation|Sham stimulation that applies the device in the same way as verum but only delivers auditory sounds correspoding to the ultrasonic pulses.
61945206|NCT02432742|EXPERIMENTAL|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
61945207|NCT02432742|ACTIVE_COMPARATOR|Restylane|Single injection and optional touch up injection with Restylane in NLF
61945208|NCT01132365||knee arthroplasty|
61945209|NCT01545804|EXPERIMENTAL|Lenalidomide|
61945210|NCT01615666||Healthy volunteers|Healthy volunteers who will undergo functional MRI (fMRI) to obtain fMRI index
61945211|NCT01615666||Alzheimer's disease|Individuals with Alzheimer's disease who will undergo functional MRI (fMRI) to obtain fMRI index
61945212|NCT01615666||Non-Alzheimer's dementia|Individuals with Non-Alzheimer's dementia who will undergo functional MRI (fMRI) to obtain fMRI index
61945213|NCT01615666||Amnestic mild cognitive impairment|Individuals with Amnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
61945214|NCT01615666||Nonamnestic mild cognitive impairment|Individuals with Nonamnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
61945215|NCT05185323|EXPERIMENTAL|Breastfeeding usual known aids and osteopathic treatment|The osteopathic treatment consists of manual listening without intention, without thrust. The hands follow the spontaneous movements of the patients. The end of the treatment is perceived by an overall relief and a feeling of balance for the baby and his mother
61945216|NCT05185323|ACTIVE_COMPARATOR|Breastfeeding usual known aids|Breastfeeding usual known aids in usual care
61945217|NCT01322659|ACTIVE_COMPARATOR|Helmet NPPV|Weaning from mechanical ventilation with noninvasive positive pressure ventilation (NPPV)delivered by means of the helmet
61945218|NCT01322659|SHAM_COMPARATOR|ETT IMV|Weaning from mechanical ventilation with standard invasive mechanical ventilation (IMV) delivered by means of the endotracheal tube (ETT)
61945219|NCT06345352||Elegible population|All adult patients presenting to the emergency department with non-specific cardiopulmonary or abdominal manifestations, represented by one or more of the following symptoms: chest pain, abdominal pain, dyspnoea, transient loss of consciousness.
61945220|NCT02201849|EXPERIMENTAL|Study Drug|Oral capsules
61945221|NCT02201849|ACTIVE_COMPARATOR|Active Control|Oral capsules
61945222|NCT02201849|PLACEBO_COMPARATOR|Placebo|Oral capsules
61945223|NCT05486754|EXPERIMENTAL|Cognitive behavioral stress management group|Participants received the cognitive behavioral stress management intervention for 10 weeks.
61945224|NCT05486754|ACTIVE_COMPARATOR|Health promotion group|Participants received the health promotion group for one day.
61945225|NCT02030704||Atherosclerotic Plaque|
61945226|NCT03907228|EXPERIMENTAL|RHT-3201|Lactobacillus rhamnosus IDCC 3201, Tyndallization (RHT-3201) (100 billion Colony Forming Units/sachet)
61945227|NCT03907228|PLACEBO_COMPARATOR|Placebo|Dextrose Anhydrous
61945228|NCT04067882||Cervix cancer|Women older than 18 years with histopathological diagnosis of cervical cancer clinical stage I2-IVA, candidates to receive standard treatment with chemotherapy followed by brachytherapy.
62697758|NCT02670291|ACTIVE_COMPARATOR|active cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); active cTBS (80% of RMT);
61945229|NCT02308189|ACTIVE_COMPARATOR|Exercise|Low load resistance exercise training
61945230|NCT02308189|EXPERIMENTAL|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
61945231|NCT05175508|EXPERIMENTAL|Azacytidine Combined With ARTA|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle with ATRA 20mg tid by po on days 1-21 of every cycle 28 days
61945232|NCT05175508|EXPERIMENTAL|Azacytidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle
61945233|NCT05991167||EndeavorRx Users|All participants with an active EndeavorRx prescription. Treatment regimen is as directed by their prescribing healthcare provider.
61945234|NCT00121381|EXPERIMENTAL|1|Pimecrolimus 1 % cream plus topical corticosteroid (TCS)
61945235|NCT00121381|PLACEBO_COMPARATOR|2|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
62139781|NCT05746234|EXPERIMENTAL|Music-Based ER module|"The program will involve the following modules: a) VALUES \& SETTING GOALS FOR ENHANCING MOTIVATION, b) MODULE 2. UNDERSTANDING EMOTIONS, c) MODULE 3. MINDFUL EMOTION AWARENESS AND RELAXATION, d) MODULE 4. THINKING FLEXIBLY, e) MODULE 5. COUNTERING INAPPROPRIATE BEHAVIORS.~The rationale of the training was built based on the framework of Unified Protocol (Barlow, et al. 2018) and training activities were selected and adapted from a compilation of foundational works on contemporary evidence-based approaches, (i.e. Cognitive Behavioral approach, Acceptance and Commitment approach, and Dialectical Behavior approach). Activities were adapted using core components of music-based interventions (Dingle \& Fay, 2016; McFerran, 2016; Saarikallio, 2019) with emphasis on emotion recognition in music, regulation of stress and negative emotions through active music listening, and self-reflective awareness of emotional responses to music."
62139782|NCT05746234|ACTIVE_COMPARATOR|Standard ER module|Participants will receive the same training modules in the same chronological order as the music-based group. The only difference is that modules will be mainly text/language based (instead of using music methodologies).
62139783|NCT02022670|PLACEBO_COMPARATOR|Placebo|inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
62139784|NCT02022670|EXPERIMENTAL|Sodium Nitrite 80 mg/d|80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
62139785|NCT02022670|EXPERIMENTAL|Sodium Nitrite 160 mg/d|160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
62139786|NCT04617574||AEON Endostapler|Stapling performed with AEON Endostapler
62139787|NCT04617574||Endo GIA Reloads with Tri-Staple Technology|Stapling performed with Endo GIA Reloads with Tri-Staple Technology
61945236|NCT01081288|ACTIVE_COMPARATOR|Women aged 47-49 invited for breast screening|
61945237|NCT01081288|ACTIVE_COMPARATOR|Women aged 71-73 invited for breast screening|
61945238|NCT05128318|EXPERIMENTAL|Patients with BMI < 30 kg/m2|Collection of subcutaneous and visceral adipose tissue pieces of 1-2 cm3 during abdominal surgery procedures
61945239|NCT03015857|ACTIVE_COMPARATOR|phenylephrine,|- Phenylephrine group (n=100): will receive 100 mcg phenylephrine as a single bolus just after intrathecal injection of 10 mg bupivacaine plus 20 mcg fentanyl. The dose will be diluted in 5 mL and given over seconds. A continuous infusion with placebo (normal saline) will start after the first bolus.
61945240|NCT03015857|ACTIVE_COMPARATOR|norepinephrine|- Norepinephrine group (n=100): will receive bolus of norepinephrine (10 mcg) directly after spinal block using 10 mg bupivacaine plus 20 mcg fentantanyl followed by continuous infusion of norepinephrine with a rate of 0.1 mcg/kg/min till delivery of the fetus.
61945241|NCT05755438|PLACEBO_COMPARATOR|Vehicle Cream BID|Participants apply ruxolitinib matching vehicle cream topically to the affected areas as a thin film twice daily (BID) for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will apply ruxolitinib 1.5% cream topically during the open label extension (OLE) period for up to 40 weeks.
61945242|NCT05755438|EXPERIMENTAL|Ruxolitinib 1.5% Cream|Participants apply ruxolitinib 1.5% cream topically to the affected areas as a thin film BID for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will apply ruxolitinib 1.5% cream the open label extension (OLE) period for up to 40 weeks.
62139788|NCT02072499|EXPERIMENTAL|KTP Green Light Prostatectomy|Device
62139789|NCT02072499|ACTIVE_COMPARATOR|Open prostatectomy|Surgical procedure
62139790|NCT02695134|OTHER|Intervention Group|This group will receive 6 Healing Touch treatments over 3 weeks
61945243|NCT03814083|EXPERIMENTAL|Active-tDCS and Sham-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, for sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
61945244|NCT03814083|ACTIVE_COMPARATOR|Active-tDCS and wait-list|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, participants in the wait-list control group will not receive any intervention.
61945245|NCT03814083|SHAM_COMPARATOR|Sham-tDCS and wait-list|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode. On the other hand, participants in the wait-list control group will not receive any intervention.
61945246|NCT00833820|ACTIVE_COMPARATOR|A|Patients receiving real rTMS
61945247|NCT00833820|SHAM_COMPARATOR|B|patients receiving sham stimulation
62496199|NCT02508870|EXPERIMENTAL|Cohort B2: Atezolizumab+Azacitidine - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m\^2 SC on Days 1 to 7 of 28-day cycle, for 6 cycles during induction. Participants who complete induction treatment will receive maintenance atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
62496200|NCT04305535|ACTIVE_COMPARATOR|Peptidic+Probiotic|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and mix of probiotics during 6 months
62496201|NCT04305535|ACTIVE_COMPARATOR|Peptidic+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
62496202|NCT04305535|PLACEBO_COMPARATOR|Polymeric+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
61945248|NCT01888757|EXPERIMENTAL|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
62496203|NCT04809714|ACTIVE_COMPARATOR|Routine Post-operative Physical Therapy|The control group will undergo routine post-op and undergo a modified version of the graduated therapy protocol.
62496204|NCT04809714|EXPERIMENTAL|Routine Physical Therapy + Blood Flow Restriction and Neuromuscular Electrical Stimulation (NMES)|The intervention group will start with a Delfi tourniquet system cuff set on a limb occlusion pressure (LOP) of 60-100%. The intervention group will also use a neuromuscular electrical stimulation device at therapeutic level in addition to BFR.
62697759|NCT02670291|SHAM_COMPARATOR|Sham cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); sham cTBS;
61945249|NCT01888757|ACTIVE_COMPARATOR|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
61945250|NCT01769989|ACTIVE_COMPARATOR|Eletrodermabrasion|The side treated with electrodermabrasion will be burned with an electric cautery machine to remove the outermost layer of skin as well as the lumps and bumps and a small area of surrounding skin.
61945251|NCT01769989|ACTIVE_COMPARATOR|Dermabrasion|The side treated with dermabrasion will be scraped with a sterile piece of sandpaper until the outermost layer of skin and lumps and bumps have been removed and a small layer of surround skin.
62139791|NCT02695134|NO_INTERVENTION|Control Group[|This group will continue with their usual medical treatments but receive NO Healing Touch
62496205|NCT04537520|EXPERIMENTAL|Experimental Group|treatment with the device Kerecis Omega3 Wound
62496206|NCT04537520|NO_INTERVENTION|Control Group|treatment with SOC treatment
62496207|NCT01390051|ACTIVE_COMPARATOR|Innohep|Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
62496208|NCT01390051|NO_INTERVENTION|no treatment|
62697760|NCT02304185|EXPERIMENTAL|gp140, 50 mcg|
62697761|NCT02304185|EXPERIMENTAL|gp140, 50 mcg + Adjuvant|
62697762|NCT02304185|PLACEBO_COMPARATOR|Placebo 1|
62697763|NCT02304185|EXPERIMENTAL|gp140, 250 mcg|
62340093|NCT05381012|OTHER|Chronic migraine|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3).
62340094|NCT05381012|OTHER|Fibromyalgia syndrome|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3), and patients with fibromyalgia syndrome .
62697764|NCT02304185|EXPERIMENTAL|gp140, 250 mcg + Adjuvant|
62697765|NCT02304185|PLACEBO_COMPARATOR|Placebo 2|
62697766|NCT06398197|EXPERIMENTAL|Nourish Intervention then No Intervention|Subjects first participate in 8 weeks of weekly cooking classes, then no intervention for 8 weeks.
62697767|NCT06398197|EXPERIMENTAL|No Intervention then Nourish Intervention|Subjects receive no intervention for 8 weeks, then participate in 8 weeks of weekly cooking classes.
62697768|NCT01631500|OTHER|Conventional treatment|Patients receive usual treatments provided at primary care settings, e.g. antidepressants, sessions with a curator or psychotherapist and physiotherapy.
62697769|NCT01631500|EXPERIMENTAL|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
61945252|NCT01536743|EXPERIMENTAL|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
62139792|NCT03293875|OTHER|HIV testing promoted by members of the social network|Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.
62139793|NCT03293875|OTHER|Peer network behavioral intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.
62139794|NCT03510169|EXPERIMENTAL|NeoVest|Negative pressure ventilation using NeoVest
62139795|NCT02095366|EXPERIMENTAL|IN Sufentanil AND IV Placebo|Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration
62139796|NCT02095366|ACTIVE_COMPARATOR|IV Morphine AND IN Placebo|Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray
61945253|NCT06473948|EXPERIMENTAL|Cohort 1|Participants will receive JMKX001899 500 once on Day 1
61945254|NCT06473948|EXPERIMENTAL|Cohort 2|Participants will receive JMKX001899 750 once on Day 1
61945255|NCT06473948|EXPERIMENTAL|Cohort 3|Participants will receive JMKX001899 1000 once on Day 1
61945256|NCT00547547|EXPERIMENTAL|Treatment (high-selenium therapy and chemotherapy)|
61945257|NCT02360995|ACTIVE_COMPARATOR|Total Toothpaste|Triclosan/fluoride toothpaste
62139797|NCT02189759|ACTIVE_COMPARATOR|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
62139798|NCT02189759|SHAM_COMPARATOR|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
62139799|NCT02189759|ACTIVE_COMPARATOR|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
62139800|NCT02189759|SHAM_COMPARATOR|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
62139801|NCT05430087|EXPERIMENTAL|Vitamin D + Placebo|The first group received 400 IU cholecalciferol (Nature Plus) t.i.d (three times a day) and placebo (Saccharum lactis) t.i.d.
62139802|NCT05430087|EXPERIMENTAL|Curcumin-Piperine + Placebo|The second group received a tablet containing curcumin (632 mg) - piperine (15,800 mg) (Bioglan) one time daily and a placebo (Saccharum lactis) t.i.d.
62139803|NCT05430087|EXPERIMENTAL|Vitamin D + Curcumin-Piperine|The third group received 400 IU cholecalciferol (Nature Plus) t.i.d and curcumin (600 mg) - piperine (15,800 mg) (Bioglan) one time daily
62139804|NCT06697431|EXPERIMENTAL|Anakinra|Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day
62139805|NCT06697431|ACTIVE_COMPARATOR|Intravenous immunoglobulins|IVIG 2g/kg administered in 10-12 hours as per local standard of care
62139806|NCT05532072|EXPERIMENTAL|The group of Meprednone combined with Rapamycin|The specific dose of methylprednisolone pulse therapy is 500mg / week \* 6 + 250mg / week \* 6. RAPA has rich experience in the application of renal transplantation, and the recommended maintenance amount for renal transplant patients is 2 mg / day. The efficacy benefits of doses above 2 mg are unclear, and the overall safety of Rapa 2 mg is better than that of patients taking Rapa 5 mg daily. Therefore, based on the clinical experience and clinical research data of RAPA, we would select the dose of Rapamycin as 2mg / day. The experimental group received rapamycin 2 mg/day orally for 24 weeks on the basis of methylprednisolone pulse therapy, and monitor the blood concentration of Rapa at the end of the first week and the end of the 12th week.
62139807|NCT05532072|OTHER|The group of Meprednone alone|The specific dose of methylprednisolone pulse therapy is 500mg / week \* 6 + 250mg / week \* 6. The effect of methylprednisolone pulse therapy on moderate and severe active Tao has been widely verified in clinical work. EUGOGO will take methylprednisolone pulse therapy as the first-line treatment of moderate and severe active Tao in 2020.
62139808|NCT02730624|EXPERIMENTAL|piperacillin/tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h
62139809|NCT06100159|EXPERIMENTAL|Tympanostomy tube|Insertion of tympanostomy tubes after 3 months observation for chronic otitis media with effusion (OME) according to the National guidelines in Denmark. Sleep measurements with accelerometer 7 nights before and 7 nights after intervention. Caregivers report use of paracetamol during nights with sleep measurements.
62340095|NCT03736954|EXPERIMENTAL|ICU doulas intervention|specially trained ICU doulas will provide critically ill intubated patients with early psychological support on a daily basis
62697770|NCT01631500|ACTIVE_COMPARATOR|Terapeutic acupuncture|Therapeutic acupuncture alone, eight individual sessions, once a week. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
62697771|NCT05897775|EXPERIMENTAL|Coordinated Reset DBS Setting (CR-DBS)|Coordinated Reset DBS settings
62697772|NCT05897775|OTHER|Clinically Optimized DBS Setting (T-DBS)|Traditional DBS settings
62340096|NCT01728883||Diagnosed DR/DME requiring treatment|Patients diagnosed as diabetic retinopathy(DR) and/or diabetic macular edema (DME) and requiring treatment at the time they are recruited into the Study. Patients will be home vision monitoring using myVisionTrack®.
62340097|NCT02289482|EXPERIMENTAL|GSK2838232 Part A: Single Dose Escalation|During Part A, subjects will receive GSK2838232/ placebo (3:1) in 4-period (period 1: GSK2838232 200mg, period 2: GSK2838232 500mg), single dose escalation design. Subjects randomized to placebo will receive placebo in all four periods. Following completion of Period 2 PK assessments at 96hr post-dose, subjects will begin daily dosing of RTV 100mg (period 3: GSK2838232 20 mg + RTV 100 mg, period 4: GSK2838232 50 mg + RTV 100 mg) for a total of 26 days.
62340098|NCT02289482|EXPERIMENTAL|GSK2838232 Part B: Single Dose, 3-Period Crossover, Relative B|During Part B, subjects will receive GSK2838232/ placebo, in an open-label, unbalanced, 3-period, cross-over design; subjects will be randomized (1:1) to each sequence. The relative bioavailability of single 100 mg doses of powder in a bottle (PIB) Active Pharmaceutical Ingredient (API) of GSK2838232 versus PIB Spray-Dried Dispersion (SDD) will be assessed (Period 1: SDD GSK2838232 100 mg vs GSK2838232 API 100 mg; period 2: GSK2838232 API 100 mg Vs SDD GSK2838232 100 mg ). A single dose of GSK2838232 will be co-administered on the 10th day of RTV dosing (period 3:GSK2838232 10 mg + RTV 100 mg); RTV dosing will continue for an additional 4 days (total of 14 days).
62340099|NCT04774679|EXPERIMENTAL|Biopsy Arm|All patients who underwent EUS Guided biopsy
62340100|NCT02840890|EXPERIMENTAL|experimental|Patients will have a visceral osteopathic technique perform with continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
62340101|NCT02840890|PLACEBO_COMPARATOR|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
62340102|NCT04982159||Invasive Fusariosis|Patients hospitalized with an invasive fusariosis diagnostic in the stablished period of study.
62340103|NCT05338957|EXPERIMENTAL|MRG002+HX008|"MRG002 will be administrated via intravenous infusion at 1.8，,2.2, or 2.6 mg/kg , (if appropriate) once on Day 1 of every 3 weeks (21-day cycle), up to 24 months.~HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day- cycle), up to 24 months."
62340104|NCT00444509|EXPERIMENTAL|Treatment 1|Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
62340105|NCT00444509|EXPERIMENTAL|Treatment 2|Subjects will receive GW685698X 800 mcg containing magnesium stearate inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
62340106|NCT03403543||1|This cohort study only set up a group. We will follow up and observe the pregnant women's lifestyle during pregnancy in order to find the risk factors of adverse pregnancy outcomes. We will divide the participants into more than one group according to the variables（e.g. age, smoking status, drinking status, sleep pattern .etc.）
62340107|NCT05349058||ICI patients|Patients receiving an Immune Checkpoint Inhibitor as treatment for their malignancy
62340108|NCT04636008|EXPERIMENTAL|Experimental arm|Sintilimab+Hypofractionated radiotherapy
62340109|NCT01434381|EXPERIMENTAL|Pfs25-EPA/Alhydrogel|Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
62340110|NCT04622085|EXPERIMENTAL|ANIMERS Chiara LA|
62340111|NCT04622085|ACTIVE_COMPARATOR|JUVÉDERM VOLUMA®|
62340112|NCT05243394|EXPERIMENTAL|Gamified virtual reality environtment + tDCS + treadmill gait training|The first group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill. They will also receive tDCS for the first 20 minutes of each session.
62340113|NCT05243394|EXPERIMENTAL|Gamified virtual reality environtment + treadmill gait training|The second group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill.
62340114|NCT05243394|ACTIVE_COMPARATOR|Treadmill gait training|The third group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last.
62340115|NCT04941352|EXPERIMENTAL|Experimental: Study group|Study group intervention consists 6-session Interpersonal Relations Theory-Based Motivational Interviews and 3-month follow-up.
62340116|NCT04941352|NO_INTERVENTION|No Intervention: Control group|Control group receives general care and the training booklet at the end of the study. Also includes 3-month follow-up.
62340117|NCT06490419|EXPERIMENTAL|electrolipolysis group|The participants will be treated by electrolipolysis, in addition to the low-caloric diet of 1200 kcal/day.
62340118|NCT06490419|EXPERIMENTAL|ultrasound cavitation group|The participants will be treated by ultrasound cavitation, in addition to the low-caloric diet of 1200 kcal/day.
62697773|NCT06323421|EXPERIMENTAL|Mindfulness|8-week group and individual mindfulness training and practice
62340119|NCT01238315|OTHER|HuCNS-SC|
62697774|NCT06121752|EXPERIMENTAL|Device assisted endoscopic full thickness resection (EFTR)|The steps of EFTR are as follows. Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed. The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device. After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning. The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4).
61945258|NCT02360995|ACTIVE_COMPARATOR|Toothpaste + Mouthwash|Stannous fluoride toothpaste \& cetylpyridinium chloride Mouthwash
62340120|NCT05883553|EXPERIMENTAL|Epithesis group|Participants receive an Elator device which was measured to the size of their phallus.
62496209|NCT03058640|EXPERIMENTAL|Karate Intervention|Participants will be enrolled into PKSA karate classes which includes at least two, standardized 1-hour classes per week for 12 weeks. Participants must attend at LEAST 20/24 classes. Attendance sheets will be signed by parents at each site. Practice at home will also be encouraged. Log sheets will be provided to participants to log their practice
62496210|NCT03058640|NO_INTERVENTION|Standard Care|Participants will have no initial intervention. Investigators will request that participants do not enroll in a structured martial arts class during the one-year period. Participants will, however, be given the option of receiving the structured karate program at 6 months, once measurements are completed
62496211|NCT01452035|EXPERIMENTAL|Exercise|
62496212|NCT01452035|NO_INTERVENTION|Sedentary Control|
62496213|NCT01134367||1|Patients with GERD
62496214|NCT00892749|EXPERIMENTAL|1. ASP1585|
62496215|NCT02906917|EXPERIMENTAL|IDegAsp|
62496216|NCT02906917|ACTIVE_COMPARATOR|IGlar + IAsp|
62496217|NCT06273709||OCT scans without clinical/dermoscopic photographs|OCT scans will be used from a pre-existing registry. The OCT scans are made of lesions clinically suspect for BCC. All patients underwent punch biopsy conform regular care.
62496218|NCT06273709||OCT scans with clinical/dermoscopic photographs|The same OCT scans will be used . OCT assessment is performed in conjunction with clinical and dermoscopic photographs.
62496219|NCT06058806|EXPERIMENTAL|Multimodal Physical Therapy|Patients in this group will receive Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises.
62496220|NCT03365063|EXPERIMENTAL|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
62496221|NCT03365063|NO_INTERVENTION|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
62340121|NCT05883553|ACTIVE_COMPARATOR|Prosthesis group|Participants receive a Zephyr ZSI 475 FTM internal erection prosthesis device as the current standard of care in our hospital. A healing phase of at least six weeks is respected.
62340122|NCT05667792|EXPERIMENTAL|Study Group- 4-11 age|
62340123|NCT05667792|PLACEBO_COMPARATOR|Control Group-4-11 age|
62496222|NCT00844350|NO_INTERVENTION|letrozole+hCG|
61945259|NCT02360995|PLACEBO_COMPARATOR|Control group|fluoride toothpaste +fluoride mouthwash
62340124|NCT05667792|EXPERIMENTAL|Study Group- 12-18 age|
62340125|NCT05667792|PLACEBO_COMPARATOR|Control Group-12-18 age|
62340126|NCT00675103|EXPERIMENTAL|pegloticase|
62340127|NCT05178251||Control group without Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2018 to December 14, 2018 and from March 17, 2019 to December 14, 2019
62340128|NCT05178251||Test group with Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2020 to December 14, 2020
62340129|NCT05068193|OTHER|Sequence 1|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.~\*Sequence 1~\[Period I\] Administration of BR2008-1 (single dose)~- Wash out for 2 weeks~\[Period II\] Administration of BR2008 (single dose)"
62340130|NCT05068193|OTHER|Sequence 2|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.~\*Sequence 2~\[Period I\] Administration of BR2008 (single dose)~* Wash out for 2 weeks~\[Period II\] Administration of BR2008-1 (single dose)"
62340131|NCT01945333|ACTIVE_COMPARATOR|Brain Basics for Impaired Tone Matchers|Cognitive remediation includes sensory processing training
62340132|NCT01945333|ACTIVE_COMPARATOR|Brain Basics for Intact Tone Matchers|Cognitive remediation includes sensory processing training
62496223|NCT00844350|NO_INTERVENTION|letrozole+oxytocin|
62496224|NCT00844350|NO_INTERVENTION|letrozole+oxytocin+hCG|
62496225|NCT00844350|NO_INTERVENTION|clomiphene citrate +oxytocin|
62340133|NCT01945333|ACTIVE_COMPARATOR|Brain Training for Impaired Tone Matcher|Cognitive remediation does not include sensory processing training
62496226|NCT00844350|NO_INTERVENTION|clomiphene citrate +oxytocin+hCG|
61945260|NCT02624960|EXPERIMENTAL|Accucinch Implant|Accucinch Implant procedure is completed
61945261|NCT02688049|EXPERIMENTAL|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients receive NeuroRegen scaffold with mesenchymal stem cells transplantation after spinal cord injury.
61945262|NCT02688049|EXPERIMENTAL|NeuroRegen scaffold/neural stem cells transplantation|Patients receive NeuroRegen scaffold with neural stem cells transplantation after spinal cord injury.
61945263|NCT01874600||Epilepsy Patients|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
62496227|NCT03141216|EXPERIMENTAL|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
62496228|NCT03141216|EXPERIMENTAL|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
62496229|NCT00625339|EXPERIMENTAL|A|entecavir 0.5 mg QD
62496230|NCT00625339|ACTIVE_COMPARATOR|B|lamivudine 100 mg QD
62496231|NCT02713139|EXPERIMENTAL|Colpistatin 5DT|
62496232|NCT02713139|ACTIVE_COMPARATOR|Gynecological Flagyl|
62496233|NCT02713139|ACTIVE_COMPARATOR|Gino-Canesten 3|
62496234|NCT03448692|EXPERIMENTAL|PF-06730512 Cohort 1|Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
62496235|NCT03448692|EXPERIMENTAL|PF-06730512 Cohort 2|Subjects in cohort 2 will receive dose 2 IV infusion.
62496236|NCT03448692|EXPERIMENTAL|PF-06730512 Cohort 3 (optional)|Subjects in cohort 3 will receive dose 3 IV infusion.
62496237|NCT02604680|EXPERIMENTAL|BLI1100-1|Topical gel
62496238|NCT02604680|EXPERIMENTAL|BLI1100-2|Topical gel
62496239|NCT02604680|EXPERIMENTAL|BLI1100-3|Topical gel
62496240|NCT02604680|EXPERIMENTAL|BLI1100-4|Topical gel
62697775|NCT06121752|ACTIVE_COMPARATOR|Endoscopic submucosal dissection (ESD)|ESD will be performed using the standard technique under general anaesthesia. The steps of the procedure are as follows: a) marking of the lesion using closed tip of DualKnife J in soft coagulation mode (Effect 4, 80W), b) submucosal lifting injection using saline mixed with indigocarmine dye, c) circumferential mucosal incision (Dry Cut, Effect 2, 30W), d) submucosal dissection (SwiftCoag, Effect 2, 30W), removal of the lesion using suction or a polypectomy snare, f) closure of the defect using endoclips or loop and endoclips.
62697776|NCT06641609|EXPERIMENTAL|Dose-Escalation (Phase Ia)|"Intervention Name: CFT8919 capsule Intervention Type: Drug Intervention Description: Participants will receive CFT8919 at different dose levels in a 3+3 dose-escalation design, starting from 150 mg BID, increasing to 300 mg, 600 mg, and up to 900 mg BID."
62697777|NCT06641609|EXPERIMENTAL|Dose-Expansion (Phase Ib)|After the MTD is determined in Phase Ia, participants will receive CFT8919 at the recommended Phase II dose (RP2D). The primary objective is to further evaluate the safety and preliminary antitumor activity of the drug at the RP2D
61945264|NCT02351999|EXPERIMENTAL|TSP Crosser Transseptal Access System|The TSP Crosser Transseptal Access System is a novel integrated system combining an extendable radiopaque loop wire to aid in localizing the fossa ovalis (FO); an innovative flexible needle to enable controlled selection of the FO puncture site; and a steerable sheath for enhanced maneuvering and orientation of catheters during LA navigation.
62697778|NCT06641609|EXPERIMENTAL|Cohort-Expansion (Phase Ic)|Participants will be enrolled based on their EGFR mutation status into separate cohorts. Each cohort will receive CFT8919 at the RP2D to evaluate its efficacy, safety, and pharmacokinetic profile in specific EGFR mutation populations, including those with L858R and other EGFR-resistant mutations after EGFR-TKI treatment.
62697779|NCT06042491|EXPERIMENTAL|Intervention|The intervention includes 3 aspects (exercise, nutrition and breathing). Our intervention is a home-based multimodal prehabilitation program supported through an online platform.
61945265|NCT02124161|OTHER|13vPnC+SIIV/Placebo|
61945266|NCT02124161|OTHER|Placebo+SIIV/13vPnC|
61945267|NCT04601402|EXPERIMENTAL|GEN-001 with avelumab|"Dose Escalation Cohort includes patients with advanced or metastatic solid tumors who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination) will be enrolled. 3 or 6 patients will be enrolled per escalating or de-escalating dose levels.~Dose Expansion Cohort includes patients with advanced or metastatic NSCLC, SCCHN, and UC who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)will be enrolled."
61945268|NCT03498066|EXPERIMENTAL|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
61945269|NCT03498066|ACTIVE_COMPARATOR|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
61945270|NCT01658631||Anesthesia|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during the induction of anesthesia
61945271|NCT01658631||Intensive Care Unit patients|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during a passive legs raising test
61945272|NCT04948788|EXPERIMENTAL|SHR1459 + YY-20394 (Stage 1)|
61945273|NCT04948788|EXPERIMENTAL|SHR1459 + YY-20394 (Stage 2)|
61945274|NCT04948788|EXPERIMENTAL|GemOx (Stage 2)|
62340134|NCT01945333|ACTIVE_COMPARATOR|Brain Training for Intact Tone Matchers|Cognitive remediation does not include sensory processing training
62340135|NCT02090192|EXPERIMENTAL|WBV training|"Whole-body vibration training was performed on a commercial Galileo machine (Germany). Participants were required to stand on the moveable rectangular platform and positioned their feet at an equal and standardized distance from the axis of rotation so that the vertical vibration amplitude was 1-3 mm. The frequency was set at 6-26 Hz. The vibration protocol consisted of four to five bouts (60 seconds for each bout), and three to five times a week for 12 weeks. The positions taken by the subjects differed according to their function. Participants who could stand independently were instructed to adopt a partial squat position with slight flexion at the hips, knees, and ankle joints to damp the vibrations approximately at the pelvic level."
62340136|NCT02090192|EXPERIMENTAL|WBV+ PRT training|
62496241|NCT02604680|PLACEBO_COMPARATOR|Placebo|Topical gel
61945275|NCT02410551|EXPERIMENTAL|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
61945276|NCT02552784|EXPERIMENTAL|patients and their parents with inherited metabolic diseases|The population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases .
61945277|NCT02846545|EXPERIMENTAL|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).
61945278|NCT02846545|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive a matching placebo to golimumab.
62496242|NCT01693887||empirical therapy|immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
61945279|NCT01557049|EXPERIMENTAL|Postural Reeducation Group|The participants, after obtaining a written informed consent, were randomized for one of the two groups: In the Global Postural Reeducation group (GPR), they were submitted 1 time per week, during 12 weeks, at GPR sessions. The duration of sessions was 60 minutes each, with the same physical Therapist of the study. After the intervention, subjects returned to assessment 3 months after, with the blinded assessor. All the 6 postures from GPR were used during the study. All outcomes measurements, in both groups, were validated for Portuguese language and applicable at baseline, 3 months and 6 months after baseline.
62496243|NCT01693887||preemptive therapy|Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。
61945280|NCT01557049|NO_INTERVENTION|Control Group|In the control group, no physical intervention was given during the study. After the study, 6 months after, all participants from control group received the same treatment given in GPR group, according to the Unifesp Ethics Committee orientations. All participants, of both groups, have a doctor from the study, if necessary.
61945281|NCT04945512|EXPERIMENTAL|Study group; Epidural catheter and PCA|Epidural catheter will be placed in the preoperative period. After induction, 10 ml of 0.25% bupivacaine will be administered through the epidural catheter and bupivacaine PCA will be started.
61945282|NCT04945512|NO_INTERVENTION|Control group; No block, IC PCA|Postoperative pain control will be achieved with intravenous morphine PCA.
61945283|NCT02154074|ACTIVE_COMPARATOR|N1 group: Isoflurane & saline|for normal patients: inhale Isoflurane + the same volume of saline during operation
61945284|NCT02154074|EXPERIMENTAL|N2 group: Isoflurane & Dexmedetomidine|for normal patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
61945285|NCT02154074|ACTIVE_COMPARATOR|D1 group: Isoflurane & saline|for diabetes patients: inhale Isoflurane + the same volume of saline during operation
61945286|NCT02154074|EXPERIMENTAL|D2 group: Isoflurane & Dexmedetomidi|for diabetes patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
61945287|NCT01126086|EXPERIMENTAL|Mild impairment|Patients with mild hepatic impairment
61945288|NCT01126086|EXPERIMENTAL|Moderate impairment|Patients with moderate impairment
61945289|NCT01126086|EXPERIMENTAL|Healthy subjects|Matched healthy subjects
62496244|NCT05361408|ACTIVE_COMPARATOR|Denosumab short-term user|Denosumab injection less than 5 times
62697780|NCT06042491|NO_INTERVENTION|Control|To support blinding, improve enrollment and reflect usual care, widely available physical activity (World Health Organization Recommendations for Physical Activity for ages 18-64 and \>65) and healthy eating recommendations (Canada's Food Guide Snapshot) documents will be provided to control participants (without active or online support).
62697781|NCT06116175|EXPERIMENTAL|lateral epicondylitis|chronic patients of tennis elbow
62697782|NCT06054308|EXPERIMENTAL|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
62697783|NCT04514835|EXPERIMENTAL|Cisplatin+Capecitabine+Sintilimab|Cisplatin+Capecitabine+Sintilimab
62697784|NCT05817786|EXPERIMENTAL|BP PNS (experimental group)|Patients with refractory upper limb neuropathic pain treated by chronic electrical stimulation of the brachial plexus nerve roots
62697785|NCT05817786|ACTIVE_COMPARATOR|sham stimulation (control group).|Patients with refractory upper limb neuropathic pain treated by sham stimulation
62697786|NCT06101420|EXPERIMENTAL|Arm 1 Vonoprazn Triple Therapy Arm|Fifty eight participants.The patients received (Clarithromycin 500 mg tablets twice daily\[BID\]+ Amoxicillin 1gm capsules BID + Vonoprazan 20 mg tablets BID) for 14 days
62697787|NCT06101420|ACTIVE_COMPARATOR|Arm 2 Proton Pump Inhibitor Triple Therapy Arm|Fifty eight participants.The patients received the classic triple therapy (Clarithromycin 500 mg tablets BID + Amoxicillin 1gm capsules BID + Esomeprazole 20 mg tablets BID) for 14 days
62697788|NCT06101420|EXPERIMENTAL|Arm 3 Vonoprazan Quadruple Therapy Arm|Fifty eight participants.The patients received a non-bismuth quadruple therapy (Levofloxacin 500 mg tablets once daily\[OD\] + Vonoprazan 20mg tablets BID + Nitazoxanide 500mg tablets BID +Doxycycline 100mg capsules OD) for 14 days.
62697789|NCT06101420|ACTIVE_COMPARATOR|Arm 4 Proton Pump Inhibitor Quadruple Therapy Arm|Fifty eight participants.The patients received a non-bismuth quadruple therapy (Levofloxacin 500 mg tablets OD + Esomeprazole 20mg tablets BID + Nitazoxanide 500 mg tablets BID +Doxycycline 100mg capsules OD) for 14 days
61945290|NCT03622814|EXPERIMENTAL|Treatment - Partners at Meals (PAM)|People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (\~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
62139810|NCT06100159|NO_INTERVENTION|Control|"No tympanostomy tube treatment up to 1 month after enrollment in control group. Sleep measurements with accelerometer 7 nights at time of inclusion. Caregivers report use of paracetamol during nights with sleep measurements.~After 1 month tympanic tube insertion is allowed if still chronic OME. If tympanostomy tubes are needed the children will undergo same evaluation as the intervention group."
62139811|NCT01662505|EXPERIMENTAL|Volasertib|Patient to receive escalating dose of volasertib
62139812|NCT01331642||Observation|Patients with Gaucher disease or high-grade suspicion for Gaucher disease
62340137|NCT02090192|ACTIVE_COMPARATOR|PRT training|
62340138|NCT02090192|PLACEBO_COMPARATOR|Control group|
62340139|NCT05806047|EXPERIMENTAL|chidamide combined with fulvestrant|chidamide combined with fulvestrant
62496245|NCT05361408|ACTIVE_COMPARATOR|Denosumab long-term user|Denosumab injection more than 5 times
62496246|NCT00522041|EXPERIMENTAL|Cellegesic (nitroglycerin 0.4%)|Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
62496247|NCT00522041|PLACEBO_COMPARATOR|Placebo 375 mg|Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
62697790|NCT06500156||Septic shock|Septic shock patients within the first 24 hours of ICU admission, and selected by the attending physician for performing a fluid challenge (FC) due to suspected tissue hypoperfusion.
62697791|NCT02657343|EXPERIMENTAL|Cohort A: Ribociclib + T-DM1 [3+3 Design]|"* Ribociclib will be given orally once day (day 5-18) at a pre-determine dose for two weeks of a 21 day cycle. During dose escalation, patients received doses of ribociclib of Period 1: 300 mg (n = 3), Period 2: 400 mg (n = 3), Period 3: 500 mg (n = 3), and Period 4: 600 mg (n = 3). Maximum dose-escalation of Ribociclib will be up to 600 mg. Dose-escalation will stop if DLT exceed limit.~* T-DM1 will be given as IV infusions on Day 1 of a 3 week cycle at a pre-determined dose over pre-determined period of time."
62697792|NCT02657343|EXPERIMENTAL|Cohort B: Ribociclib + Trastuzumab [Phase 1b/2 Study]|"* Ribociclib will be given orally once day (400 mg per day on a continuous schedule) for a 21-day cycle of treatment.~* Trastuzumab will be given as IV infusions over 6 mg/kg every 3 weeks."
62697793|NCT02657343|EXPERIMENTAL|Cohort C: Ribociclib + Trastuzumab + Fulvestrant [Phase 1b/2 Study]|"* Ribociclib will be given orally once a day continuously for a 28-day cycle of treatment (except at Dose Level -1, when Ribociclib is given Days 1-21 of a 28 day cycle).~* Trastuzumab will be given as IV infusions over a pre-determined period of time and dose. Fulvestrant will be dosed approximately every 28 days as per standard of care."
61945291|NCT03622814|PLACEBO_COMPARATOR|Enhanced Usual Condition (EUC)|In the non-treatment respite care centers, an Enhanced Usual Condition will be delivered to caregivers of People with Dementia (PWD). This program consists of enhanced training in caregiving using components from a module of the evidence-based Savvy Caregiver program (K. Hepburn) given in a group setting with opportunity for a question and answer period; the program is given for new enrollees and every 6 months. The PI (EJA), the nutritionist (KM) or the Program Manager (MCP) will lead these groups. Weight of the PWD is measured initially and monthly (x5); amount of food consumed will be measured using the Samsung tablets, also initially and monthly (x5).
61945292|NCT06005896||Success|Patients who were alive and free from RRT 7 days after interrupting RRT.
61945293|NCT06005896||Failure|Patients who were not alive or who needed to dialyse again after interrupting RRT for at least 48h.
61945294|NCT01330784||hMG-HP|Patients with a condition
61945295|NCT01015599|EXPERIMENTAL|HOP'N After-School Program|After-school program with daily physical activity following CATCH guidelines, daily fruit/vegetable snack, and weekly nutrition and physical activity education based on social cognitive theory.
61945296|NCT03307642|NO_INTERVENTION|SLIV + usual communication|Parents receive usual communication from school (paper consent packets \& automated voice mails) about SLIV
61945297|NCT03307642|ACTIVE_COMPARATOR|SLIV + usual communication + text|Parents receive usual communication from school (paper consent packets \& automated voice mails) about SLIV plus a series of text messages informing them about the usual communication for SLIV
61945298|NCT05736614|NO_INTERVENTION|Stage 1 Standard of Care (SOC) Control Condition|SOC participants will receive an informational pamphlet about the PrEP as a form of HIV prevention and referrals to local PrEP Prescribers.
61945299|NCT05736614|EXPERIMENTAL|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
61945300|NCT05736614|NO_INTERVENTION|Stage 2 SOC Control Condition|Research staff will show a brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission. Participants will continue to see their PrEP prescriber for routine clinical care.
62139813|NCT04434651|EXPERIMENTAL|Block group (A)|"26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line \<10 mm evaluated by CT scan \[computerized tomography\] . SPGB will be performed using 2 % lidocaine before induction of anesthesia.~The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes."
62139814|NCT04434651|SHAM_COMPARATOR|control sham group (B)|26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line \<10 mm evaluated by CT scan \[computerized tomography\] . SPGB will be performed using normal saline.The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes
62139815|NCT04310449|EXPERIMENTAL|Dual zone concept and customized healing abutment|Immediate implant placement with bone grafts in the dual zone and customized healing abutment.
62139816|NCT04310449|ACTIVE_COMPARATOR|Connective tissue graft and customized healing abutment|immediate implant placement with CTG and customized healing abutment
62139817|NCT02182479|EXPERIMENTAL|Berodual® via Respimat®, high dose|
62496248|NCT01206439|EXPERIMENTAL|Nebivolol 5 or 10 mg, oral, daily|Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
61945301|NCT05736614|EXPERIMENTAL|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
61945302|NCT03652740|EXPERIMENTAL|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
61945303|NCT03652740|EXPERIMENTAL|Additional Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
62139818|NCT02182479|EXPERIMENTAL|Berodual® via Respimat®, low dose|
62139819|NCT02182479|ACTIVE_COMPARATOR|Berodual® via MDI, high dose|
62340140|NCT04342182|EXPERIMENTAL|Convalescent plasma|Standard of care plus 300mL of convalescent plasma from COVID-19 recovered donors
62340141|NCT04342182|NO_INTERVENTION|Standard of care|standard of care (supportive care, oxygen, antibiotics)
62340142|NCT01679093|ACTIVE_COMPARATOR|ONDANSETRON (OS)|patients receiving ondansetron at the beginning of the surgery to prevent postoperative nausea and vomiting (PONV); and paracetamol at the end of the surgery for postoperative analgesia.
62496249|NCT04848688|EXPERIMENTAL|Moxidectin|8 mg Moxidectin at day 0 administered orally
61945304|NCT04805762||Children with overweight or obesity following the lifestyle intervention YCND|Children with overweight or obesity that are participant of the lifestyle intervention YCND
61945305|NCT02681601|ACTIVE_COMPARATOR|Diet + Nutrawell Powder with Fish Oil|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
61945306|NCT02681601|ACTIVE_COMPARATOR|Dietary Intervention Only|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.
61945307|NCT01407822|EXPERIMENTAL|Erlotinib arm|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
61945308|NCT01407822|ACTIVE_COMPARATOR|Chemo arm|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
62496250|NCT04848688|EXPERIMENTAL|Ivermectin|200 ug/kg Ivermectin at day 0 administered orally
61945309|NCT05157438|EXPERIMENTAL|Group I (virtual reality group)|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, the system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment.
61945310|NCT05157438|ACTIVE_COMPARATOR|Group II (screen program group).|the screens shows such as cartoons, animation movies or recorded video games are used for distraction during dental treatments. They could be seen on tablets, iPads or LCD screen.
61945311|NCT03631875|PLACEBO_COMPARATOR|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LM conditions insertion.
61945312|NCT03631875|ACTIVE_COMPARATOR|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LM conditions insertion.
62139820|NCT02182479|PLACEBO_COMPARATOR|Placebo via Respimat®|
62139821|NCT02182479|PLACEBO_COMPARATOR|Placebo via MDI|
62139822|NCT06375278|EXPERIMENTAL|Safety Study|Aim 1: Ascertain the safety of the system and device in patients undergoing cochlear implantation (CI). Mild therapeutic hypothermia will be delivered to the subjects during CI surgery via the ear canal.
62139823|NCT06375278|EXPERIMENTAL|Efficacy Study Cooling|Aim 2: Ascertain the applicability and efficacy of the device and system in patients undergoing cochlear implantation (CI). Half of the candidates will receive mild therapeutic hypothermia via the ear canal during cochlear implant surgery.
62139824|NCT06375278|NO_INTERVENTION|Efficacy Study Control|Aim 2: Ascertain the applicability and efficacy of the device and system in patients undergoing cochlear implantation (CI). Half of the candidates will receive standard of care (no cooling) during cochlear implant surgery.
62139825|NCT06400537|EXPERIMENTAL|A-319 intervention|A-319 will be preset with 3 escalation dose levels: dose A, dose B, dose C, total course of treatment: 4 weeks.
62139826|NCT06161259|EXPERIMENTAL|Child-Pugh A|8 participants with mild hepatic impairment (Child-Pugh A) will be given 400mg of Leritrelvir(RAY1216)
62139827|NCT06161259|EXPERIMENTAL|Child-Pugh B|8 participants with mild hepatic impairment (Child-Pugh B) will be given 400mg of Leritrelvir(RAY1216)
62139828|NCT06161259|EXPERIMENTAL|Normal hepatic function|8 participants with normal hepatic function will be given 400mg of Leritrelvir(RAY1216)
62139829|NCT05490732|EXPERIMENTAL|Therapeutic drug monitoring of methadone|6 samplings per subject: 3 venipunctures and 3 microsamplings
62139830|NCT03433794|PLACEBO_COMPARATOR|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
62139831|NCT03433794|ACTIVE_COMPARATOR|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
62340143|NCT01679093|ACTIVE_COMPARATOR|DROPERIDOL (DRO)|patients receiving droperidol at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
62340144|NCT01679093|ACTIVE_COMPARATOR|DEXAMETHASONE (DEXA)|patients receiving dexamethasone at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
62340145|NCT06426199|ACTIVE_COMPARATOR|Intra-Articular Injection of Hyaluronic Acid|Arthroscope-guided intra-articular injection of Hyaluronic Acid in patients with TMJ anterior disc displacement without reduction.
62496251|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
62697794|NCT02102945|OTHER|Computed tomography perfusion|Participants will undergo CT perfusion of the head after cooling following cardiac arrest.
61945313|NCT05473208|NO_INTERVENTION|Control Group|Participants randomly assigned to control group will not wear an exoskeleton during working hours.
62496252|NCT05204537||Patients who developed in-hospital COVID-19 thoracic complications, surgically managed.|"The study population consists of patients who have been surgically treated for COVID-19 thoracic complications.~Thoracic complications have been defined as any condition involving the thorax, directly or indirectly consequence of COVID-19, including either pathologies strictly related to the infection, or iatrogenic effects of therapeutic attempts to treat it. Since the wide span of diagnosis, the novelty of this pathology and the different protocols adopted by participating centers, it is not possible to identify common criteria for surgical indications. A wide variety of pleuro/parenchimal surgical procedures are included. Patients undergone chest tube placement alone are not included in the study."
62496253|NCT04000945|EXPERIMENTAL|BTL-899 Therapy Arm|
62496254|NCT04000945|SHAM_COMPARATOR|Sham Arm|
62496255|NCT06468904|EXPERIMENTAL|cervical stabilization exercises and integrated neuromuscular inhibition technique|"patients received cervical stabilization exercises and integrated neuromuscular inhibition technique for 3 sessions / week for 4 weeks. Cervical stabilization included chin tucks, isometric holds, ball squeeze.~Integrated neuromuscular inhibition technique included:~1. ischemic compression: therapist applied an intermittent ischemic compression on upper trapezius trigger point by thumb for 90sec.~2. Strain counter-strain: therapist applied pressure at trigger point. patient's head was laterally flexed towards the affected side passively by one hand of the therapist. The other hand held the subject's forearm and moved the affected shoulder to 90degree of abduction and external rotation for 90 secs.~3. Muscle energy technique: patient laterally flexed the neck to opposite side patient was moved the stabilized shoulder and ear towards each other. The contraction was maintained for 10 sec followed by 5 seconds of relaxation. The muscle was stretched for 30 secs."
62496256|NCT06468904|ACTIVE_COMPARATOR|Integrated neuromuscular inhibition technique|"patients received integrated neuromuscular inhibition technique for 3 sessions / week for 4 weeks.it included Ischemic compression, Strain counter-strain and muscle energy technique.~1. ischemic compression. therapist applied an intermittent ischemic compression on upper trapezius trigger point by thumb for 90 sec.~2. Strain counter-strain: therapist applied pressure at trigger point. patient laterally flexed towards the affected side passively by one hand of the therapist. The other hand held the subject's forearm and moved the affected side shoulder passively to 90degree of abduction and external rotation for 90 secs.~3. Muscle energy technique: patient was asked to laterally flex the neck to opposite side. patient was requested to move the stabilized shoulder and ear towards each other. The contraction was maintained for 10 sec followed by 5 seconds of relaxation. The muscle was stretched for 30 secs."
62496257|NCT01956565|EXPERIMENTAL|Inspiratory muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
62496258|NCT01956565|NO_INTERVENTION|Declining Inspiratory muscle training|No intervention. Interview and baseline assessment only.
62496259|NCT01067521|EXPERIMENTAL|GA 40 mg / GA 40 mg|Also referred to as the 'Early Start' treatment arm, participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the Double-Blind Period, and then continued that treatment as open-label therapy until the drug was commercially available or development stopped.
62496260|NCT01067521|PLACEBO_COMPARATOR|Placebo / GA 40 mg|Also referred to as the 'Delayed Start' treatment arm, participants were administered placebo subcutaneous injections three times a week for 12 months during the Double-Blind Period, and then switched to GA 40 mg/mL subcutaneous injections three times a week as open-label therapy until the drug was commercially available or development stopped.
62697795|NCT04070703|EXPERIMENTAL|Cognitively enhanced Tai Ji Quan|Participants in this arm will exercise a series of Tai Ji Quan-based movements with configurations that are specifically designed for older adults to improve cognitive function, dual-task ability, strength/balance, and mobility.
62697796|NCT04070703|ACTIVE_COMPARATOR|Standard Tai Ji Quan|Serving as an active comparison arm, participants in this intervention will exercise a series of Tai Ji Quan-based movements that are specifically designed for older adults to improve strength/balance, cognitive function, and mobility.
61945314|NCT05473208|EXPERIMENTAL|Exoskeleton Group|Participants randomly assigned to exoskeleton group will be given instructions and explanations on how to use/adjust/loosen the exoskeleton, and after a period of familiarisation, they will be wearing an exoskeleton during their working hours for a period of one year.
61945315|NCT04356742|EXPERIMENTAL|Dapagliflozin 10mg + Evogliptin 5mg + Metformin|
62139832|NCT03433794|EXPERIMENTAL|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
61945316|NCT04356742|PLACEBO_COMPARATOR|Dapagliflozin Placebo + Evogliptin 5mg + Metformin|
61945317|NCT04495933|EXPERIMENTAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|SARS-CoV-2 Sclamp antigen 5 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart.(Cohorts 1 \& 4)
61945318|NCT04495933|EXPERIMENTAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|SARS-CoV-2 Sclamp antigen 15 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 2 \& 5)
61945319|NCT04495933|EXPERIMENTAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|SARS-CoV-2 Sclamp antigen 45 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 3 \& 6)
62697797|NCT04070703|SHAM_COMPARATOR|Stretching|Serving as a control arm, participants in this intervention will engage in a series of light exercise activities consisting of breathing, stretching, and body relaxation.
62697798|NCT04084366|EXPERIMENTAL|OBI-999 Escalation phase|Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).
61945320|NCT05553314|EXPERIMENTAL|Carvedilol-group|Patients receiving carvedilol
61945321|NCT05553314|PLACEBO_COMPARATOR|Placebo-group|Patients receiving placebo
62496261|NCT06504355|EXPERIMENTAL|Experimental group|Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session. The participants underwent pre-, mid- and post-training measures of the outcome parameters which includes body weight, body mass index, basal metabolic rate, skeletal muscle rate, body fat percentage, flexibility, balance and agility.
62697799|NCT04084366|EXPERIMENTAL|OBI-999 Expansion Phase|Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.
62697800|NCT06222684|EXPERIMENTAL|Intervention Group|Women in the intervention group applying for mammography screening will listen to music for 5 minutes before, during and after the procedure.
62697801|NCT06222684|NO_INTERVENTION|Control Group|Women in the control group applying for mammography screening will not receive any intervention other than routine mammography screening.
61945322|NCT04862429|EXPERIMENTAL|Contrast enhanced mammography guided biopsy|"Patients will be subjected to CESM; the two orthogonal mammographic projections, after intravenous administration of iodized contrast-enhancement (Omnipaque), will be performed.~Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the experimental procedure."
61945323|NCT04862429|ACTIVE_COMPARATOR|mammography guided biopsy|"Patients will be subjected to stereotactic biopsy Mammotome as normal clinical practice.~Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the standard procedure."
61945324|NCT01049568|EXPERIMENTAL|Cell Phone Intervention|
61945325|NCT01049568|NO_INTERVENTION|Control|"Control group participants will participate in all on-study evaluations, except the intervention exit interviews.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
61945326|NCT05890950|EXPERIMENTAL|K-757 and K-833 combination|
61945327|NCT05890950|PLACEBO_COMPARATOR|Placebo|
62340146|NCT06426199|ACTIVE_COMPARATOR|Intra-Articular Injection of chitosan-hyaluronate gel mixture|Arthroscope-guided intra-articular injection of chitosan-hyaluronate gel mixture in patients with TMJ anterior disc displacement without reduction
62496262|NCT06504355|NO_INTERVENTION|Control group|The participants in the control group underwent no any special training but maintain daily work and leisure routines. They underwent pre-, mid- and post-experimental measures of the outcome parameters which was the same as those measured in the experimental group.
62697802|NCT05814159|EXPERIMENTAL|Anakinra|100 mg/day or 2 mg/kg/day of subcutaneous anakinra for those with a body weight ≥50 kg or \<50 kg, respectively.
62697803|NCT05814159|PLACEBO_COMPARATOR|Placebo|Corresponding volume to 100 mg/day or 2 mg/kg/day
61945328|NCT04402918|OTHER|pregnancy patients diagnosed with SARS Cov2 during pregnancy|Delivery day biological samples from the mother and the newborn will be performed
62139833|NCT03569774|EXPERIMENTAL|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
62340147|NCT03164226|OTHER|Patient consulting for chest Pain in ED|Any patient ≥ 25 years consulting for chest pain in the emergency department from 8:00 am to 8:00 pm (for the unavailability of the endopat device during the guard).
62340148|NCT00808249|EXPERIMENTAL|A-AZD7325 2mg|AZD7325 2mg BID
62697804|NCT02458729|PLACEBO_COMPARATOR|Placebo Group|Primary total knee replacement with 0.9% normal saline 20ml administration intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
62697805|NCT02458729|ACTIVE_COMPARATOR|One-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously five minutes before deflation of the tourniquet. and then 0.9% normal saline 20ml administration intravenously 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
61945329|NCT00806975|OTHER|usability and preference|
61945330|NCT05820607||Type A atrophic gastritis|Gastroscopy and histopathology showed no significant atrophy of antrum mucosa, but significant atrophy of the body or fundus mucosa, accompanied by positive blood and/or gastric fluid anti-parietal cell antibodies and/or anti-internal factor antibodies.
61945331|NCT05820607||Type B atrophic gastritis|Gastroscopy and histopathological examination showed multifocal atrophy of gastric mucosa, mainly antrum involved.
61945332|NCT05820607||Chronic non-atrophic gastritis|Gastroscopy and histopathology showed chronic inflammation of gastric mucosa with infiltration of lymphocytes and plasma cells, and no intrinsic glandular reduction.
61945333|NCT04112420|OTHER|Group A|200 Participants more than 60 yrs old having Trans-esophageal Echocardiography examination upon admission to ICU
61945334|NCT01613534|EXPERIMENTAL|APC plus oral sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) administration for four weeks.
61945335|NCT01613534|PLACEBO_COMPARATOR|APC plus placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks.
62340149|NCT00808249|EXPERIMENTAL|B-AZD7325 5mg|AZD7325 5mg BID
61945336|NCT04905966|EXPERIMENTAL|Nutrition education + Physical activity intervention|Physical Activity and Nutrition Education: An additional 45 minute weekly physical education class and 5 weekly active break sessions of 10 minutes each will be added to the provisions of the children's curriculum. In addition, schools will receive high intensity nutrition education, that is, 3 weekly nutrition education classes of one hour in each session over a period of 6 months.
61945337|NCT04905966|NO_INTERVENTION|Control|Schools receiving a lower intensity nutrition education served as control. This group received 3 sessions of 1 hour with a total of 3 educational sessions over the 6 month period. The educational material was the same as the intervention group but the development of lessons was not as specific and deep as the intervention group.
61945338|NCT06390033||K2 or above prosthesis|Unilateral transtibial amputees will engage in both indoor and outdoor activities, utilizing a K2 or above prosthesis.
61945339|NCT06390033||A low-cost prosthesis|Unilateral transtibial amputees will engage in both indoor and outdoor activities, utilizing a low-cost prosthesis
61945340|NCT05653193|ACTIVE_COMPARATOR|Antifungal|Any oral triazole antifungal as per routine care
61945341|NCT05653193|EXPERIMENTAL|Antifungal plus inteferon gamma|Any oral triazole antifungal as per routine care plus interferon-gamma three times weekly subcutaneously 50 micrograms/m2 for 3 months
61945342|NCT03730675|EXPERIMENTAL|irradiation stent plus TACE|Portal irradiation stent placement will be performed before TACE procedures.
61945343|NCT03730675|ACTIVE_COMPARATOR|Sorafenib plus TACE|TACE will be performed in patients randomized to Arm B, with sequential sorafenib.
61945344|NCT01276600|EXPERIMENTAL|Arm 1|1 tablet orally weekly
61945345|NCT01276600|EXPERIMENTAL|Arm 2|One tablet orally twice weekly
62139834|NCT03569774|ACTIVE_COMPARATOR|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
62340150|NCT00808249|EXPERIMENTAL|C-AZD7325 10mg|AZD7325 10mg QD
62340151|NCT00808249|EXPERIMENTAL|D-Placebo|Placebo
62340152|NCT05085028|ACTIVE_COMPARATOR|6 weekly|6 weekly pembrolizumab, 400mg intravenous
62340153|NCT05085028|EXPERIMENTAL|9 weekly|9 weekly pembrolizumab, 400mg intravenous
62340154|NCT05085028|EXPERIMENTAL|12 weekly|12 weekly pembrolizumab, 400mg intravenous
62340155|NCT05085028|EXPERIMENTAL|15 weekly|15 weekly pembrolizumab, 400mg intravenous
62340156|NCT05085028|EXPERIMENTAL|18 weekly|18 weekly pembrolizumab, 400mg intravenous
62340157|NCT04382898|EXPERIMENTAL|Part 1 (mCRPC) - dose titration|"BNT112 monotherapy~Enrollment into this arm is completed."
62340158|NCT04382898|EXPERIMENTAL|Part 2 Arm 1A (mCRPC) - expansion cohort|"BNT112 in combination with cemiplimab~Enrollment into this arm is completed."
62340159|NCT04382898|EXPERIMENTAL|Part 2 Arm 1B [1] (mCRPC) - expansion cohort|"BNT112 monotherapy~Enrollment into this arm is completed."
62340160|NCT04382898|EXPERIMENTAL|Part 2 Arm 2 (LPC) - expansion cohort|BNT112 in combination with cemiplimab
62340161|NCT04382898|EXPERIMENTAL|Part 2 Arm 3 (LPC) - expansion cohort|BNT112 monotherapy
61945346|NCT01276600|EXPERIMENTAL|Arm 3|Two tablets orally twice weekly
61945347|NCT01276600|EXPERIMENTAL|Arm 4|One tablet orally daily
62139835|NCT05892562||RA combined with depression or anxiety|
62139836|NCT05892562||RA without comorbid depression or anxiety|
62139837|NCT05680857|PLACEBO_COMPARATOR|Placebo|The placebo group will receive a product in sachet form that doesn't have marine collagen peptide and Coenzyme Q10.
62340162|NCT04382898|EXPERIMENTAL|Part 2 Arm 1B [2] (mCRPC) - expansion cohort|"Following progression after BNT112 monotherapy, patients in Arm 1b have the option to be treated with cemiplimab monotherapy~Enrollment into this arm is completed."
62340163|NCT03296865|NO_INTERVENTION|Without taping|Evaluations without taping
62340164|NCT03296865|EXPERIMENTAL|Kinesio taping|Kinesio taping was apllied only one time. It was removed after intervention.
62139838|NCT05680857|EXPERIMENTAL|Product containing marine collagen peptide and Coenzyme Q10.|This group will receive the product containing marine collagen peptide from the fish origin and Coenzyme Q10 in sachet form.
62340165|NCT03296865|PLACEBO_COMPARATOR|Placebo|Placebo was apllied only one time. It was removed after intervention.
62340166|NCT01911234|EXPERIMENTAL|TNF-Kinoid|TNF Kinoid + ISA51
62340167|NCT01911234|PLACEBO_COMPARATOR|Placebo|Placebo + ISA51
61945348|NCT04203498|EXPERIMENTAL|Nabiximols|
61945349|NCT04203498|PLACEBO_COMPARATOR|Placebo|
61945350|NCT02537028|EXPERIMENTAL|MSC2364447C 25 mg|
61945351|NCT02537028|EXPERIMENTAL|MSC2364447C 75 mg|
61945352|NCT02537028|PLACEBO_COMPARATOR|Placebo|
61945353|NCT06253884|EXPERIMENTAL|Coronary Artery Disease (CAD) Subjects|Subjects with a of coronary artery disease will undergo computer-controlled gas challenges.
61945354|NCT05095454|EXPERIMENTAL|Percutaneous Epidural Stimulation|Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
61945355|NCT05095454|EXPERIMENTAL|Transcutaneous Epidural Stimulation|Transcutaneous spinal stimulation will be delivered via skin surface-level electrodes during rehabilitation. The effects of transcutaneous stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
61945356|NCT00075218|PLACEBO_COMPARATOR|B|
61945357|NCT00075218|ACTIVE_COMPARATOR|A|
61945358|NCT02293161|EXPERIMENTAL|Cohort A GSK2618960|Subjects will receive GSK2618960 0.6 milligram per kilogram (mg/kg)
62340168|NCT01211964|EXPERIMENTAL|LEO 22811 oral solution 1.5 mg (fasted state)|
62340169|NCT01211964|EXPERIMENTAL|LEO 22811 single tablet 1.5 mg (fasted state)|
62340170|NCT01211964|EXPERIMENTAL|LEO 22811 single tablet 1.5 (fed state)|
62340171|NCT04771052||CORE program|Patients admitted to a dedicated COVID-19 units (CHUS Hôtel-Dieu de Sherbrooke - CIUSSS de L'Estrie - CHUS) with medical clearance (physical deconditioning; hemodynamically stable; oxygen therapy by nasal cannula \< 4 L/min for saturation \> 92%; resting respiratory rate \< 24; and heart rate between 50 and 120 beats per minute).
62340172|NCT04771052||Control|Patients admitted to a dedicated COVID-19 units (CHAUR de Trois-Rivières, CIUSSS de la Mauricie-et-du-Centre-du-Québec) receiving usual care, matched to CORE a patient with similar characteristics (sex, age, preadmission provenance).
62697806|NCT02458729|ACTIVE_COMPARATOR|Two-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
61945359|NCT02293161|PLACEBO_COMPARATOR|Cohort A Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
61945360|NCT02293161|EXPERIMENTAL|Cohort B GSK2618960|Subjects will receive GSK2618960,planned dose being 2mg/kg. However, actual dose level for Cohort B may be adjusted based on the emerging data on safety, tolerability, PK and RO from Cohort A. The maximum dose will not exceed 2.4 mg/kg (i.e. a 4-fold dose escalation from 0.6 mg/kg)
62340173|NCT00370695|EXPERIMENTAL|Precision Spinal Cord Stimulation System|Single arm Precision Spinal Cord Stimulation System.
61945361|NCT02293161|PLACEBO_COMPARATOR|Cohort B Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
61945362|NCT05942300|EXPERIMENTAL|CPI-0209 (150 mg) + carboplatin|CPI-0209: 150 mg (oral dosing) carboplatin administered intravenously as per institutional standards
61945363|NCT05942300|EXPERIMENTAL|CPI-0209 (200 mg) + carboplatin|CPI-0209: 200 mg (oral dosing) carboplatin administered intravenously as per institutional standards
61945364|NCT05942300|EXPERIMENTAL|CPI-0209 (250 mg) + carboplatin|CPI-0209: 250 mg (oral dosing) carboplatin administered intravenously as per institutional standards
62139839|NCT06112600|NO_INTERVENTION|Control Group|No attention-diverting method was applied to the children in this group and routine vaccination was administered.
62139840|NCT06112600|EXPERIMENTAL|Virtual Reality group|The VR group received a VR application using the Oculus Quest 2 while being vaccinated.
62139841|NCT06112600|EXPERIMENTAL|Kaleidoscope group|In the Kaleidoscope group, children were given a kaleidoscope toy while being vaccinated.
62139842|NCT05030493||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
62139843|NCT05030493||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg mFOLFOX6 + bevacizumab combination therapy, once every two weeks
62139844|NCT03665532|EXPERIMENTAL|Interactive 2-way texting|Biweekly text message communications with counselors for problem solving
62139845|NCT03665532|ACTIVE_COMPARATOR|Passive text reminders|Automated weekly text message health care reminders
62340174|NCT04903119|EXPERIMENTAL|Level 1|Patients in this group will receive 100mg Nilotinib PO BID.
62697807|NCT03729609||Brentuximab vedotin 1.2 mg/kg (body weight)|Brentuximab vedotin 1.2 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every two weeks (up to 12 times). The dose should be adjusted depend on the participant's condition. Participants received interventions as part of routine medical care.
62697808|NCT03463681|EXPERIMENTAL|Cabozantinib|all subjects will recieve open label Cabozantinib 60 mg orally once daily
62697809|NCT03779620|EXPERIMENTAL|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
61945365|NCT06206642|EXPERIMENTAL|18F-FAPI-04|18F-FAPI-04 PET-CT is injected through the patient's elbow vein without special preparation at a dose of 2.96-5.55 megabecquerels (MBq) /kg (0.08-0.15 millicurie/kg).
61945366|NCT06206642|EXPERIMENTAL|18F-FDG|Before the 18F-FDG PET/CT examination, all patients should fast for at least 4-6 hours, and the fasting blood glucose should be controlled to less than 9.0mmol/L to avoid difficulties in image analysis due to poor blood glucose in patients. 18F-FDG is administered via the patient's elbow vein at a dose of 2.96-5.55 megabecquerels (MBq) /kg (0.08-0.15 millicurie/kg).
61945367|NCT02107404|EXPERIMENTAL|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCA Experimental therapy
62697810|NCT04724837|EXPERIMENTAL|Zibotentan Dose A + Dapagliflozin|Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.
62697811|NCT04724837|EXPERIMENTAL|Zibotentan Dose B + Dapagliflozin|Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.
61945368|NCT02107404|NO_INTERVENTION|Standard Therapy|No Intervention
62139846|NCT01088841|ACTIVE_COMPARATOR|75 g glucose + 150 ppm lactisole|
62139847|NCT01088841|ACTIVE_COMPARATOR|75 g glucose + 300 ppm lactisole|
62139848|NCT01088841|ACTIVE_COMPARATOR|75 g glucose + 450 ppm lactisole|
62139849|NCT01088841|PLACEBO_COMPARATOR|75 g glucose|
62139850|NCT03674515|PLACEBO_COMPARATOR|placebo|"Smartphone application placebo"
62139851|NCT03674515|ACTIVE_COMPARATOR|"Bouge"|"Smartphone equipped with the application Bouge"
62697812|NCT04724837|EXPERIMENTAL|Placebo + Dapagliflozin|Participants will receive once daily oral dose of dapagliflozin 10 mg and placebo for 12 weeks.
62139852|NCT01974843||Group BT|Bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg
62139853|NCT01974843||Group LT|Levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg, resulting in a total volume of 1 ml/kg.
62139854|NCT05782894|EXPERIMENTAL|Remimazolam besylate|Remimazolam besylate
62139855|NCT05782894|ACTIVE_COMPARATOR|Propofol|Propofol
62139856|NCT03938337|EXPERIMENTAL|Cohort 1 Not Previously Treated|Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
62139857|NCT03938337|EXPERIMENTAL|Cohort 2 Treated Previously|Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
62139858|NCT01778842|EXPERIMENTAL|Prasugrel low dose|Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
62139859|NCT01778842|EXPERIMENTAL|Clopidogrel standard dose|Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.
62139860|NCT02660476||QUDOS 1|Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care
62340175|NCT04903119|EXPERIMENTAL|Level 2|Patients in this group will receive 200mg Nilotinib PO BID.
62340176|NCT04903119|EXPERIMENTAL|Level 3|Patients in this group will receive 300mg Nilotinib PO BID.
62340177|NCT04903119|EXPERIMENTAL|Level 4|Patients in this group will receive 400mg Nilotinib PO BID.
62139861|NCT02660476||QUDOS 2|To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).
62496263|NCT02059811|EXPERIMENTAL|DASH Diet|"All participants will be provided a control diet for a 7-day run-in period followed by the DASH dietary intervention for a 14-day intervention period. Participants will consume the largest meal of the day in a supervised setting at the study center and all other meals and snacks will be provided in to-go packages. Weight will be held constant by measuring participant weight daily and adjusting caloric content of meals. Adherence will be monitor by review of daily food diaries."
62697813|NCT02843399||Exenatide once weekly (EQW)|EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015.
62697814|NCT02843399||Insulin Glargine (IG)|IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015
62697815|NCT05545059|EXPERIMENTAL|sacubitril/valsartan group|The experimental group will be sacubitril/valsartan group. Patients assigned to this group will receive sacubitril/valsartan 200mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
62697816|NCT05545059|ACTIVE_COMPARATOR|valsartan group|The control group will be valsartan group, which patients will receive valsartan 160mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
62139862|NCT05063006|EXPERIMENTAL|LVAD pump speed dynamically adjusted|
62139863|NCT05063006|ACTIVE_COMPARATOR|LVAD pump at optimal resting speed|
62139864|NCT06700187|EXPERIMENTAL|Interrupting sitting|Participants will engage in low-intensity walking breaks in different frequencies for 4.5 hours
62139865|NCT06700187|NO_INTERVENTION|Control|Paticipants will remain seated for 4.5 hours
62340178|NCT02905942|EXPERIMENTAL|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
61945369|NCT02866708|EXPERIMENTAL|Intermittent negative pressure (INP) therapy|"At baseline, the participants will be randomized into 2 groups: 1) INP therapy or 2) control with no INP therapy.~The 1) patients randomized to INP therapy will start with 8 weeks INP therapy two hours per day divided into timed sections (1-3 times per day or use the device as many times as practical for the individual as long as the total time is two hours). After 8 weeks of INP therapy, final measures will be performed at the Vascular lab before the participants starts their 8-week control period."
62139866|NCT03385031||group 1|whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment
62340179|NCT02905942|ACTIVE_COMPARATOR|rhG-CSF|Patients in control group received rhG-CSF day +1 after transplantation.
62340180|NCT01569425|EXPERIMENTAL|Lifestyle counseling|Lifestyle counseling, with high calorie breakfast
62340181|NCT01569425|ACTIVE_COMPARATOR|Life Counseling|Diet with high calorie dinner
62496264|NCT01643434|ACTIVE_COMPARATOR|Spironolactone|
62496265|NCT01643434|ACTIVE_COMPARATOR|Clonidine|
62697817|NCT05855694|EXPERIMENTAL|Intervention Arm - Therapeutic Setting|Photobiomodulation Helmet, Therapeutic setting, 35mW/cm2 = 42J/cm2, 3 x Sessions per week for 6 weeks
62139867|NCT03385031||group 2|simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment
62139868|NCT03385031||group 3|patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment
62139869|NCT04044781|EXPERIMENTAL|Test Group|Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
62139870|NCT03220074|OTHER|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
62139871|NCT03315065|OTHER|Patients diagnosed with Lung cancer|patients diagnosed with Lung cancer and Thoracic radiotherapy
62139872|NCT05388045|EXPERIMENTAL|Recovery PROM|All study participants will complete the Recovery PROM instrument.
62139873|NCT01170208|OTHER|Group I|Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting and insulin dose software.
62139874|NCT01170208|OTHER|Group II|Type 2 diabetes treated with basal-bolustherapy and insulin dose software.
62139875|NCT01170208|OTHER|Group III|Type 2 diabetes treated with biphasic insulin and insulin dose software.
62139876|NCT05144984|EXPERIMENTAL|2.4 mg semaglutide + 2.4 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
62139877|NCT05144984|PLACEBO_COMPARATOR|Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
62139878|NCT05144984|EXPERIMENTAL|2.4 mg semaglutide + 7.2 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
62340182|NCT00935519|OTHER|ceramic bearing|Survival rate of THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
62340183|NCT05902546|EXPERIMENTAL|High intensity interval training (group A)|30 Diabetic patients (Type 2 Diabetes Mellitus) will receive high intensity interval training
62340184|NCT05902546|EXPERIMENTAL|moderate intensity aerobic exercise (group B)|30 Diabetic patients (Type 2 Diabetes Mellitus) will receive moderate intensity aerobic exercise
62340185|NCT05235217|EXPERIMENTAL|Test product (T) 40 mg Hard Gelatin Capsules|Single oral dose of 40 mg capsule
62340186|NCT05235217|ACTIVE_COMPARATOR|Reference product (R) 40 mg Hard Gelatin Capsules (first dose)|Single oral dose of 40 mg capsule
62496266|NCT00190541|ACTIVE_COMPARATOR|1|Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
62496267|NCT00190541|EXPERIMENTAL|2|Procedure/Surgery: Mesorectal excision without lateral lymph node excision
61945370|NCT02866708|NO_INTERVENTION|Control|The participants randomized to control will continue their usual wound care for 8 weeks without INP therapy. The control group will start INP therapy after 8 weeks. After 8-weeks without intervention, the participants allocated to the control-group will be asked to start with INP therapy for 8 weeks before a final examination. The participants in the control group will receive vascular assesment at baseline, week 8 (end of control).
61945371|NCT00723580|EXPERIMENTAL|Sleep and Activity by Treatment Condition|Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.
61945372|NCT01171040||Consecutive patients received echocardiographic examinations|Consecutive patients received echocardiography are willing to participate in this study.
61945373|NCT00867685|EXPERIMENTAL|Treatment A|Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state.
61945374|NCT00867685|EXPERIMENTAL|Treatment B|Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state.
61945375|NCT00867685|EXPERIMENTAL|Treatment C|Single oral dose of 40 mg (2x20mg tablets) in a fed state.
61945376|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
61945377|NCT00776282|EXPERIMENTAL|1|loratadine 10 mg orally disintegrating tablets
61945378|NCT00776282|ACTIVE_COMPARATOR|2|loratadine 10 mg orally disintegrating tablets
61945379|NCT01423578|ACTIVE_COMPARATOR|Hatha Yoga (HY)|Exercise and Smoking Cessation Counseling
61945380|NCT01423578|EXPERIMENTAL|Cardiovascular Exercise (CE)|Exercise and Smoking Cessation Counseling
61945381|NCT01423578|OTHER|Smoking Cessation Counseling Only|Control Group - Smoking Cessation Counseling
61945382|NCT04436159|ACTIVE_COMPARATOR|Nissen fundoplication|Addition of 360 fundoplication after crural closure
61945383|NCT04436159|ACTIVE_COMPARATOR|Toupet fundoplication|Addition of 180 posterior fundoplication after crural closure
61945384|NCT06076954|EXPERIMENTAL|Planned therapist feedback iCBT|Participants in the planned therapist feedback iCBT condition will receive the iCBT intervention with planned feedback after each completed module. The therapist may spend a max. of 15 minutes giving feedback per module.
62496268|NCT04962139|EXPERIMENTAL|ON101 Cream plus Standard of Care|ON101 cream will be applied twice daily for up to 20 weeks to the Target Ulcer. The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.
61945385|NCT06076954|EXPERIMENTAL|On-demand therapist feedback iCBT|Participants in the on-demand therapist feedback iCBT condition will receive the intervention with on-demand feedback that is participant-initiated. The therapist may spend a max. of 15 minutes giving feedback per module.
61945386|NCT05626062|EXPERIMENTAL|Intervention group|30 adults with learning disabilities with incontinence will be offered a 12-week personalised toilet training plan, which promotes prompted voiding in a toilet
61945387|NCT02777333|EXPERIMENTAL|Simulation training|Addition of simulation training during usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
61945388|NCT02777333|NO_INTERVENTION|Non-simulation/Routine training|Usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
61945389|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
61945390|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
61945391|NCT02389062|EXPERIMENTAL|Placebo controlled group|This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.
61945392|NCT02389062|EXPERIMENTAL|High dose gluten capsules|This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
61945393|NCT02389062|EXPERIMENTAL|Low dose gluten capsules|This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
61945394|NCT06248567|EXPERIMENTAL|Experimental 1: participants with severe renal impairment|8 participants with severe renal impairment will be given 600mg of ZSP1273
61945395|NCT06248567|EXPERIMENTAL|Experimental 2: healthy participants|8 participants with normal renal function will be given 600mg of ZSP1273
61945396|NCT02758132|ACTIVE_COMPARATOR|Alliance A031201|Denosumab plus enzalutamide, abiraterone and prednisone
62496269|NCT04962139|PLACEBO_COMPARATOR|Vehicle Cream plus Standard of Care|"Vehicle cream will be applied twice daily for up to 20 weeks to the Target Ulcer.~The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary."
61945397|NCT02758132|ACTIVE_COMPARATOR|Standard of Care|Denosumab plus enzalutamide alone
61945398|NCT03269604|ACTIVE_COMPARATOR|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
61945399|NCT03269604|ACTIVE_COMPARATOR|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
61945400|NCT03269604|EXPERIMENTAL|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
61945401|NCT02817074|ACTIVE_COMPARATOR|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
61945402|NCT02817074|PLACEBO_COMPARATOR|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
61945403|NCT02623140|EXPERIMENTAL|Biofreedom|Biofreedom stent treatment at index procedure
62496270|NCT05469958|EXPERIMENTAL|Intervention group|a bundle of hypothermia prevention measures will be applied
62496271|NCT05469958|ACTIVE_COMPARATOR|Control group|Conventional care with textile blankets under patient demand.
61945404|NCT02623140|ACTIVE_COMPARATOR|Orsiro|Orsiro stent treatment at index procedure
61945405|NCT01724879|EXPERIMENTAL|Dasatinib and chemotherapy|Dasatinib, QD p.o. administration, day 1 to EOS
61945406|NCT01072422|EXPERIMENTAL|counseling based on answers in TTQ|40 participating primary health care nurses will be randomly assigned to this arm. Each nurse will identify 5 consecutive patients with COPD who smoke (n = 200 total patients). The nurses will ask the patients to fill in the assessment protocol, TTQ. The nurses will then provide an intervention to each patient in the form of individual treatment on the basis of that patient's answers to the TTQ.
61945407|NCT01699490|EXPERIMENTAL|Fluoxetine + Valsartan|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to 40 mg per day of valsartan"
61945408|NCT01699490|ACTIVE_COMPARATOR|Fluoxetine + Placebo|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to placebo"
61945409|NCT02061618|NO_INTERVENTION|Usual Care|
61945410|NCT02061618|EXPERIMENTAL|Bollywood Dance Exercise|Participants in the Bollywood Dance Exercise group will take part in an 8-week dance intervention. The dance classes will take place 2 times per week, approximately 60 minutes per class, for 8 weeks total.
61945411|NCT03439059|EXPERIMENTAL|intervention- reducing SB|prompted to do 10min of light physical activity 3x/day
61945412|NCT03439059|NO_INTERVENTION|Control|go about their normal daily living
61945413|NCT03582878|ACTIVE_COMPARATOR|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
61945414|NCT03582878|EXPERIMENTAL|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
61945415|NCT04324931|EXPERIMENTAL|Biomechanical corrections|In this group, biomechanical correction will be perform with the help of mobilization with movement to correct biomechanical misalignment and along with this conventional treatment, in which Hydrocollatoral packs for 20 minutes, Interferential Therapy for 15 minutes with beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program for 3 sessions of 20 minutes on alternative days for 3 weeks. Which will be given for three days a week for three weeks.
61945416|NCT05646095|EXPERIMENTAL|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|Brief, behavioral sleep intervention for children and caregivers
61945417|NCT05646095|ACTIVE_COMPARATOR|Delayed Intervention|Waitlist families will be monitored for 1 month before receiving the B-SAFE intervention
61945418|NCT04734951|ACTIVE_COMPARATOR|Power/resistance exercise|Participants on a power/resistance exercise program
61945419|NCT04734951|EXPERIMENTAL|Power/resistance exercise + HMB|Participants on combined power/resistance exercise program + HMB oral supplementation
61945420|NCT05825781|EXPERIMENTAL|Pertuzumab (manufactured by Mabscale, LLC)|Eligible subjects (57 healthy men) will receive once Pertuzumab 420 mg/14 ml in 250 ml 0,9 % NaCl intravenous on the Visit 2. The following visits are the visits of safety and pharmacokinetics visits.
61945421|NCT05825781|ACTIVE_COMPARATOR|Perjeta®|Eligible subjects (57 healthy men) will receive once Perjeta® 420 mg/14 ml in 250 ml 0,9% NaCl intravenous on the Visit 2. The following visits are the visits of safety and pharmacokinetics visits.
61945422|NCT00946361||Diagnostic|
62496272|NCT00544167|EXPERIMENTAL|Intervention|All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated.
62697818|NCT05855694|SHAM_COMPARATOR|Control Arm - Non-Therapeutic Setting|Photobiomodulation Helmet, Non-Therapeutic setting, 0mW/cm cm2 = 0J/cm2, 3 x Sessions per week for 6 weeks
62697819|NCT06196905|EXPERIMENTAL|MT-2990|MT-2990 will be administered intravenously every 4 weeks for a total of 6 doses.
61945423|NCT04260711|EXPERIMENTAL|Discontinuation of DMT|Discontinuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
62139879|NCT05144984|EXPERIMENTAL|2.4 mg semaglutide + 12.0 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
62139880|NCT05144984|EXPERIMENTAL|2.4 mg semaglutide + 21.6 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
62697820|NCT05260242|EXPERIMENTAL|Conversation|Scripted interaction
62697821|NCT05260242|NO_INTERVENTION|No Conversation|Control Group
62697822|NCT05158010|OTHER|HELIX's follow-up|
61945424|NCT04260711|NO_INTERVENTION|Continuation of DMT|Continuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
61945425|NCT03368534|EXPERIMENTAL|Skin Wound Patients|Patients will receive ART for wound healing and will be followed for 28 days to determine success of the procedure.
61945426|NCT02364622|SHAM_COMPARATOR|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by traditional fiberoptic bronchoscopy.
61945427|NCT02364622|EXPERIMENTAL|Modified fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by modified fiberoptic bronchoscopy.
61945428|NCT02364622|EXPERIMENTAL|Flexible Trachway intubating stylet|We used Flexible Trachway intubating stylet to facilitate the accurate placement of left-sided double lumen endobronchial tube into the left main bronchus.
61945429|NCT02437383|ACTIVE_COMPARATOR|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
62697823|NCT02208765|OTHER|Study cohort|Any patient referred to the Nuclear Cardiology Laboratory of the University Hospital of Grenoble for myocardial perfusion imaging for diagnosis or prognosis evaluation of suspected or know coronary artery disease
61945430|NCT02437383|PLACEBO_COMPARATOR|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
61945431|NCT03080454|PLACEBO_COMPARATOR|Sham Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
61945432|NCT03080454|ACTIVE_COMPARATOR|Anodal Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
61945433|NCT02017418|EXPERIMENTAL|zeaxanthin|placebo zeaxanthin
61945434|NCT02017418|ACTIVE_COMPARATOR|combinatory supplement|placebo combinatory supplement
61945435|NCT05879601|OTHER|control group- immediate retainer delivery|Retainer will be given to the patients immediately \[ Just after debonding\]
61945436|NCT05879601|ACTIVE_COMPARATOR|experimental group- delayed retainer delivery|Retainer will be given to the patient 24 hours post debonding.
61945437|NCT02527993|EXPERIMENTAL|Glucobay|Tablet Glucobay (acarbose) 50 mg x 6 daily for 7 days.
61945438|NCT02527993|EXPERIMENTAL|Januvia|Tablet Januvia (sitagliptin) 100 mg orally O.D for 7 days.
61945439|NCT02527993|EXPERIMENTAL|Verapamil|Tablet Verapamil 120 mg orally O.D for 7 days.
61945440|NCT02527993|EXPERIMENTAL|Victoza|Subcutaneous injection of Victoza (liraglutide) 0,6-1,2 mg O.D for three weeks.
61945441|NCT02527993|EXPERIMENTAL|Signifor|Subcutaneous injection of Signifor (pasireotide) 300 µg as a single dose prior to a meal tolerance test.
61945442|NCT05444517|ACTIVE_COMPARATOR|Interscalene Block|Patients randomized to receive an interscalene block.
61945443|NCT05444517|EXPERIMENTAL|Infraclavicular-Anterior Supraescapular Nerve Blocks|Patients randomized to receive a combined infraclavicular plus anterior suprascapular nerve blocks.
61945444|NCT04165473||Intervention Group|Study participants having finished the following course in the past will be assigned to the intervention group: During a 6-module course, with four 3-day modules and two 5-day modules in the timeframe of one year, participants learn ways to strengthen their personal resources to establish effective social relationships and to develop skills as a social being. In between the module courses, the participants take 5 single sessions with an instructed trainer and document 10 conversations/social situations where they successfully applied the new skills.
61945445|NCT04165473||Control Group|Individuals without intervention
61945446|NCT03352973|EXPERIMENTAL|active tDCS on the dlPFC|tDCS on the DLPFC Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline functional magnetic resonance imaging (fMRI) study for regulation of craving using a separate sample. During the intervention, each participant will receive an active transcranial direct current stimulation (tDCS) intervention on this DLPFC region (1.5 mA for 20 minutes).
61945447|NCT03352973|SHAM_COMPARATOR|sham tDCS on the dlPFC|Each participant will also receive a sham tDCS intervention as a controlled condition. The sham tDCS only include a 30-s ramp up and a 30-s ramp down.
61945448|NCT06558058|EXPERIMENTAL|Test Rivaroxaban 10 mg PT Dexa Medica|Rivaroxaban 10 mg Film-coated Tablet, produced by PT Dexa Medica, Indonesia
61945449|NCT06558058|ACTIVE_COMPARATOR|Reference Xarelto 10 mg Bayer|Xarelto 10 mg Film-Coated Tablet, manufactured by Bayer AG, Germany, imported by PT Bayer Indonesia, Indonesia
61945450|NCT06405958||Liver transplant patients|Patients who have undergone liver transplantation
61945451|NCT06405958||Kidney transplant patients|Patients who have undergone kidney transplantation
61945452|NCT06405958||Pancreas transplant patients|Patients who have undergone pancreas transplantation
61945453|NCT06405958||Heart transplant patients|Patients who have undergone heart transplantation
61945454|NCT06405958||Lung transplant patients|Patients who have undergone lung transplantation
61945455|NCT06557902|EXPERIMENTAL|Group 1 (10 to less than 13 years)|Lumateperone capsule once daily: 10.5 mg on Days 1 and 2; 10.5 mg or 21 mg on Day 3; 10.5 mg or 21 mg on Days 4 and 5
61945456|NCT06557902|EXPERIMENTAL|Group 2 (5 to less than 10 years)|Lumateperone ODT once daily: 5 mg on Days 1 and 2; 5 mg or 10.5 mg on Day 3; 5 mg or 10.5 mg on Days 4 and 5; dosing regimen may be adjusted after the first 6 patients dosed and will not exceed 21 mg in subsequent patients
61945457|NCT05948787|OTHER|Intervention Group|Intervention group' Families take part in weekly sessions of Strong Families for 3 weeks. All family's complete measures again (Time 2, two weeks post intervention). All family's complete measures again (Time 3, 6 weeks post intervention)
61945458|NCT05948787|EXPERIMENTAL|Waitlist group' Families take part in weekly sessions of Strong Families after the data measures|Families in the RCT will be randomized to implementation of the Intervention or Waitlist group . Families will be allocated using online software (www.sealedenvelope.com). We are aware that randomization before recruiting participants can influence recruitment and dropout in the control arm. To minimize these issues, we have included costs for compensating families for participation in study measure completion and will instruct staff not to reveal family allocation until families have agreed to take part and before signing informed consent. This is an un-blinded trial. Research assistants, staff and families will be aware of participants' allocated condition during the trial.
61945459|NCT02974478|EXPERIMENTAL|Orange juice with meals|Effect of orange juice consumption with three meals per day (without snacking) on glucose metabolism and antioxidative status
61945460|NCT02974478|EXPERIMENTAL|Orange juice between meals|Effect of orange juice consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
61945461|NCT02974478|EXPERIMENTAL|Sugar sweetened beverage between meals|Effect of sugar sweetened beverage consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
61945462|NCT04545385|EXPERIMENTAL|TEV-48574|Participants will receive the investigational medicinal product (IMP) loading doses on the day of randomization and the subsequent corresponding IMP maintenance doses every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
62496273|NCT02837913|EXPERIMENTAL|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
62496274|NCT02837913|PLACEBO_COMPARATOR|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
62496275|NCT01278641|EXPERIMENTAL|1|Intervention i arm 1 comprises graded strength resistance training, 75 minutes twice a week for 12 weeks.
62496276|NCT01278641|EXPERIMENTAL|2|Intervention in arm 2 comprises low intensive temperate pool exercise 50 minutes, twice a week for 12 weeks.
62496277|NCT01278641|NO_INTERVENTION|3|Reference group, continues with normal activities during the study period of 12 weeks.
62496278|NCT05586386|EXPERIMENTAL|Cherry group|Obese adults were asked to consume 200 mL of DSC juice supplemented with 3g of DSC powder twice / day for 30 days.
62496279|NCT05586386|EXPERIMENTAL|Placebo group|Obese adults were asked to consume 200 mL of placebo juice supplemented twice / day for 30 days.
61945463|NCT04545385|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to TEV-48574 SC every 2 weeks for a total of 8 doses.
62496280|NCT05215873|ACTIVE_COMPARATOR|misoprostol group|25µg misoprostol oral tablet every 4 hours with maximum200 µg
61945464|NCT03808831|EXPERIMENTAL|Experimental groups|Subjects in the experimental group will wear the fall detection and prevention system on the lower back. The system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
61945465|NCT03808831|SHAM_COMPARATOR|Sham group|In the sham group, subjects wear a sham system with record but no alert function.
61945466|NCT02108873||Retrospective Cohort|Adult patients who had scheduled an appointment for outpatient primary care. Patients were divided into two groups, including those who attended their scheduled appointment and those who missed it.
61945467|NCT04136366|EXPERIMENTAL|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
61945468|NCT04136366|ACTIVE_COMPARATOR|Standard surgical care procedure|Standard procedure performed.
61945469|NCT01717911|ACTIVE_COMPARATOR|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
61945470|NCT01717911|EXPERIMENTAL|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
62139881|NCT05144984|EXPERIMENTAL|NNC0480-0389 + placebo (semaglutide)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide)
62139882|NCT05144984|PLACEBO_COMPARATOR|Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
62139883|NCT05144984|PLACEBO_COMPARATOR|Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
62496281|NCT05215873|ACTIVE_COMPARATOR|oxytocin group|"oxytocin infusion according to ASUMH local protocol: Put 3IU oxytocin (3000mIU) +50ml of normal saline in syringe pump= (60mIU/ml). Commence at 1ml/hour (1mIU/min) for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 2 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 4 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 6 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy increase by 2ml/hr. for max. 27ml/hour.~At any point there's fetal or maternal distress (e.g. pathological FHR pattern, antepartum hemorrhage, etc.) the study intervention will be stopped, and the maternal/fetal condition will be managed by cesarean section."
62496282|NCT00942721|EXPERIMENTAL|Web-based CBT for PPD|Participants will receive Web-based CBT for PPD.
62496283|NCT06630897|EXPERIMENTAL|Microsupport|
62496284|NCT06630897|NO_INTERVENTION|No Microsupport|
61945471|NCT01717911|EXPERIMENTAL|Insulin|In the insulin therapy group (Insulin glargine), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Daily dose was administrated before breakfast.
62496285|NCT00757705|EXPERIMENTAL|Paliperidone Extended-Release (ER)|
61945472|NCT05751044|EXPERIMENTAL|Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide + cytarabine|"Sub-study B~Each cycle lasts 28 days.~Cycle 1: All patients in cycle 1 will receive 28 days of of dasatinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 3) and two blocks of four consecutive days of cytarabine (days 5 to 8 and days 12 to 15). A 1-day venetoclax ramp-up is proposed in this study.~Cycle 2 and subsequent cycles: Dasatinib and ventoclax one a day (day 1-28); one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 1) and two blocks of four consecutive days of cytarabine (days 3 to 6 and days 10 to 13).~Patients in dose level -1, receive a lower dose of venetoclax. Patients in dose level 2 receive a higher dose of venetoclax.~All patients receive age adapted intrathecal chemotherapy."
62139884|NCT05144984|PLACEBO_COMPARATOR|Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
62139885|NCT05144984|EXPERIMENTAL|Semaglutide 2.4 mg + placebo (NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide.
62139886|NCT02417792||control|group of healthy participants
62496286|NCT01201694|EXPERIMENTAL|Surface-Controlled Water Soluble Curcumin Group|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
62496287|NCT01201694|EXPERIMENTAL|Surface-Controlled Water Soluble Curcumin Expansion|Following finding of MTD surface-controlled water soluble curcumin, escalating dose levels
62496288|NCT00391534|EXPERIMENTAL|Oxcarbazepine MR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
62697824|NCT04165109||Trial Ready Cohort|Non-demented adults with Down syndrome (DS)
61945473|NCT06419738|ACTIVE_COMPARATOR|Cognitive behavioral treatment (CBT)|Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.
61945474|NCT06419738|EXPERIMENTAL|Low level laser therapy combined with CBT (LLLT+CBT)|LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.
61945475|NCT06419738|ACTIVE_COMPARATOR|Occlusal Splint combined with CBT (OS+CBT)|Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks. In addition, patients are still instructed CBT as group 1.
61945476|NCT03123367|ACTIVE_COMPARATOR|Group 1: Nella VuSleeve|Sleeve
61945477|NCT03123367|ACTIVE_COMPARATOR|Group 2: Nella NuSpec|Speculum
61945478|NCT03123367|ACTIVE_COMPARATOR|Group 3: NellaSpec|Speculum
61945479|NCT03123367|ACTIVE_COMPARATOR|Group 4: Nella Insert|Sleeve
61945480|NCT06101550|EXPERIMENTAL|partial pulpotomy in immature permanent teeth|partial removal of coronal pulp tissue
61945481|NCT06101550|ACTIVE_COMPARATOR|complete pulpotomy in immature permanent teeth|complete removal of pulp in pulp chamber
62139887|NCT02417792||Topical psoriasis treatment|Group of patients who are treated with topical medications for psoriasis
61945482|NCT02597231|EXPERIMENTAL|Melatonin Group|Patients in this group will receive melatonin 3mg orally at 9pm.
61945483|NCT02597231|PLACEBO_COMPARATOR|Placebo Group|Patient in this group will receive a matching placebo pill orally at 9pm.
61945484|NCT00687895|EXPERIMENTAL|1|training in clinical algorithm plus microscopy
61945485|NCT00687895|EXPERIMENTAL|2|clinical algorithm
61945486|NCT00687895|NO_INTERVENTION|3|Control
61945487|NCT01126333||Long term Sirolimus or Tacrolimus|"Ths study cohort will consist of participants who successfully completed two years of the original Spare the Nephron (STN) study, a two year prospective multi-center study where participants were assigned to receive either center-specific CNI regimen (assigned at the time of transplantation) or were switched to replace the CNI with Sirolimus therapy.~In this current long-term follow-up study, we will approach patients who previously enrolled in the STN study and offer them the opportunity to enroll to be followed-up for another 3 years. There will be no change in immunosuppression unless clinically indicated. The majority of effort is standard care with every 6 month follow-up appointments.Participants will be required to consent to participate in the three year extension study."
61945488|NCT03950479||primiparous group|women who will give birth to their first baby
62139888|NCT02417792||Systemic psoriasis treatment|Group of patients who are treated with systematic medications for psoriasis
62139889|NCT02469441||Arm A|Arm A (treatment arm: coffee): patients after colorectal surgery receive coffee in addition to the regular infusion therapy and/or alimentation
62139890|NCT02469441||Arm B|Arm B (control arm: water / tea): patients after colorectal surgery receive water or tea (excluding black tea) and no coffee until the first bowel movement in addition to the regular infusion therapy and/or alimentation
62139891|NCT03934567|EXPERIMENTAL|Abexinostat 80 mg bis in die (BID)|Experimental: Abexinostat 80 mg BID
62139892|NCT01553487|EXPERIMENTAL|Excercise|The forearm vibration training
62139893|NCT01553487|NO_INTERVENTION|Control|Patients will be treated by routine fracture treatment methods (fixation and rest).
62139894|NCT04975217|EXPERIMENTAL|Treatment (FMT, FMT capsules)|Patients undergo FMT during colonoscopy. Patients also receive FMT capsules PO QW for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection of tumor(s).
62139895|NCT04975087||Patients group|Individuals with primary Sjögren's syndrome
62139896|NCT02506270|ACTIVE_COMPARATOR|AirSeal Trocar valveless|patients are treated with the AirSeal-CO2-insufflator and trocar-system
62139897|NCT02506270|SHAM_COMPARATOR|Conventional trocar|patients are treated with a conventional insufflation and trocar system
62139898|NCT00686595|EXPERIMENTAL|Infliximab 5 mg/kg|Infliximab 5 mg/kg intravenous (IV) infusion administered at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
62139899|NCT02845466|EXPERIMENTAL|Becaplermin/Promagran Dressing|Topical Becaplermin with a protease inhibitor wound dressing.
62139900|NCT02845466|ACTIVE_COMPARATOR|Becaplermin/Placebo Dressing|Topical Becaplermin with a placebo wound dressing.
62139901|NCT06698679||cohort 1|women without breast cancer or other malignancies；breast cancer patients.
62139902|NCT06698679||cohort 2|patients diagnosed with breast cancer who received standard neoadjuvant therapy.
62139903|NCT06698679||Cohort 3|patients who have been discharged after breast cancer treatment.
62139904|NCT01558544|OTHER|Use of high dose chemotherapy|Use of chemotherapy without removal of the disease ovary.
62340187|NCT05235217|ACTIVE_COMPARATOR|Reference product (R) 40 mg Hard Gelatin Capsules (second dose)|Single oral dose of 40 mg capsule
62340188|NCT04078672|EXPERIMENTAL|AMD|NOTAL-OCT V3.0 scan
62340189|NCT03359694|EXPERIMENTAL|DT group|Pegylated liposomal doxorubicin and Docetaxel Treatment group Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
62340190|NCT03359694|ACTIVE_COMPARATOR|ET group|Conventional doxorubicin and Docetaxel Treatment group Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
62496289|NCT00391534|ACTIVE_COMPARATOR|Oxcarbazepine IR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
62496290|NCT04022941|EXPERIMENTAL|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.
61945489|NCT03726944|OTHER|Group 1 - Meditation1+Meditation2|8 weeks in total; 4 weeks of unnamed consumer-based meditation app + 4 weeks of Calm meditation app
61945490|NCT03726944|OTHER|Group 2 - Meditation2+Meditation1|8 weeks in total; 4 weeks of Calm meditation app + 4 weeks of unnamed consumer-based meditation app
62340191|NCT03359694|EXPERIMENTAL|NX group|Navelbine and Xeloda treatment group in group of Non-pCR patients Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d×4
62340192|NCT03359694|NO_INTERVENTION|Control group|"no treatment group of Non-pCR patients after DT or ET neoadjuvant chemotherapy.~No drugs treatment in this group."
61945491|NCT03726944|OTHER|Group 3 - Control+Meditation1|8 weeks in total; 4 weeks of educational control + 4 weeks of unnamed consumer-based meditation app
61945492|NCT03726944|OTHER|Group 4 - Control+Meditation2|8 weeks in total; 4 weeks of educational control + 4 weeks of Calm meditation app
62340193|NCT01417065|EXPERIMENTAL|Temsirolimus|Starting dose 0.02 mg intravenous administered once.
62340194|NCT03144323|EXPERIMENTAL|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
62340195|NCT03144323|NO_INTERVENTION|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
62340196|NCT03624517|EXPERIMENTAL|24-hour octreotide infusion|Patients will receive octreotide infusion over 24 hours
62340197|NCT03624517|ACTIVE_COMPARATOR|72-hour octreotide infusion|Patients will receive octreotide infusion over 72 hours
62340198|NCT04628728||Current referral letters|One letter will be chosen from the selection of current referral letters (of average quality according to the results of the study mentioned above). Any data that would allow identification of the respective patient (i.e. name, date of birth, social insurance number, address) will be anonymised (not blackened in order not to disturb fluent reading).
62340199|NCT04628728||New referral letters|The other one will be a corrected version of the first letter according to the ELGA (Elektronische Gesundheitsakte) requirements and the identified needs of patients and stakeholders (see Previous Work 1).
62340200|NCT02981277|ACTIVE_COMPARATOR|Transcricoid|Lignocaine delivery using transcricoid injection
62340201|NCT02981277|ACTIVE_COMPARATOR|Spray as You go|Lignocaine delivery using spray as you go method
62340202|NCT06389188|EXPERIMENTAL|Experimental: MAN Group|MAN-Group were treated with cervical spine manipulation with SAT. Patients received a total of 3 sessions of treatment over a month (days 1, 15 and 30 after the beginning of the study).
62496291|NCT04022941|PLACEBO_COMPARATOR|Placebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
62340203|NCT06389188|ACTIVE_COMPARATOR|MAN Group|MAN-Group were treated with cervical spine manipulation with SAT. Patients received a total of 3 sessions of treatment over a month (days 1, 15 and 30 after the beginning of the study).
62340204|NCT04575272|EXPERIMENTAL|Continuous Deep Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately deep to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
62496292|NCT04836182|EXPERIMENTAL|IONIS-AGT-LRx|IONIS-AGT-LRX by subcutaneous injection once-weekly
62496293|NCT04836182|PLACEBO_COMPARATOR|Placebo|Matching placebo by subcutaneous injection once-weekly
62496294|NCT04122027|ACTIVE_COMPARATOR|Control|Patients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.
62496295|NCT04122027|ACTIVE_COMPARATOR|Intervention|Patients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.
62496296|NCT04392934|EXPERIMENTAL|flat shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
62496297|NCT04392934|EXPERIMENTAL|curved shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
62496298|NCT04392934|EXPERIMENTAL|hooked shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
62496299|NCT00616993|PLACEBO_COMPARATOR|2|Vehicle
62496300|NCT00616993|EXPERIMENTAL|1|Difluprednate
62496301|NCT04237350||severe visual impairment group|"The severe visual impairment group is defined as the BCVA of at least one eye outside the 99% referenced range or worse than light perception with structural abnormalities or other examination results."
61945493|NCT00111982|EXPERIMENTAL|Liatermin|Bilateral continuous infusion of liatermin for up to 24 months.
61945494|NCT05552755|PLACEBO_COMPARATOR|Placebo (Part 1)|Participants will receive placebo PO dosed once daily
61945495|NCT05552755|EXPERIMENTAL|REC-4881 4mg (Part 1)|Participants will receive REC-4881 4mg PO dosed once daily
61945496|NCT05552755|EXPERIMENTAL|REC-4881 4mg (Part 2)|Participants will receive REC-4881 4mg PO dosed once daily
61945497|NCT05552755|EXPERIMENTAL|REC-4881 8mg (Part 2)|Participants will receive REC-4881 8mg PO dosed once daily
61945498|NCT05552755|EXPERIMENTAL|REC-4881 12mg (Part 2)|Participants will receive REC-4881 12mg PO dosed once daily
61945499|NCT00761631|EXPERIMENTAL|Single|Open label
62496302|NCT04237350||likely healthy group|"For the likely healthy group, the visual acuity of both eyes is in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology \& Visual Science. 36(3):671 (1995)"
62496303|NCT04237350||mild visual impairment group|"The mild visual impairment group is defined as the BCVA in the 99% referenced range in both eyes with abnormalities of structure or other examination results."
62496304|NCT04912063|EXPERIMENTAL|Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
62340205|NCT04575272|ACTIVE_COMPARATOR|Continuous Superficial Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately superficial to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
61945500|NCT04384783||GH group|GH group: Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
61945501|NCT04384783||NGH group|NGH (non-GH) group: Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
61945502|NCT03882112|EXPERIMENTAL|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
61945503|NCT03882112|EXPERIMENTAL|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
61945504|NCT02423109|EXPERIMENTAL|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
61945505|NCT02423109|ACTIVE_COMPARATOR|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
62139905|NCT03607591|ACTIVE_COMPARATOR|Active rTMS group|One daily session: active 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
62139906|NCT03607591|PLACEBO_COMPARATOR|Placebo rTMS group|One daily session: inactive 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
62139907|NCT04068506|EXPERIMENTAL|Group A|Gabapentin 600 mg Tab
62340206|NCT00426517|EXPERIMENTAL|Matched related donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 10 mg/kg total dose given intravenously over 2 days
62340207|NCT00426517|EXPERIMENTAL|Matched unrelated donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
61945506|NCT04584970|EXPERIMENTAL|Virtual reality device|Participants will be offered a virtual reality (VR) device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
61945507|NCT04584970|ACTIVE_COMPARATOR|iPad device|Participants will be offered an iPad device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
61945508|NCT02891109||patients group|Adults patients with chronic immune thrombocytopenia
61945509|NCT02891109||control group|Adults without immune thrombocytopenia
61945510|NCT05101642|EXPERIMENTAL|Guided Creeping Technique (GCT)|Novel minimally invasive guided creeping technique
61945511|NCT04167969|EXPERIMENTAL|Prostate cancer patients|Patients will receive an intravenous (IV) injection of approximately 5 mCi (+/- 10%) of PSMAtargeting C' dot tracer up to 48 hours before surgery. Patients will then undergo serial preoperative PET/MR imaging to help characterize the safety, biodistribution/pharmacokinetics, and dosimetry of this agent. To assess total radioactivity in whole blood/plasma and urine samples, as well as radioactive metabolites, blood and urine samples will be collected at approximately 30 min post-injection as well as before each imaging session
61945512|NCT05384964||Nurses|
61945513|NCT01381484|NO_INTERVENTION|Placebo|This group received placebo gel and requested to apply periorbital area and over the face for 3 months.
62139908|NCT04068506|ACTIVE_COMPARATOR|Group B|Paracetamol 1000 mg Tab
62139909|NCT03235518||Structure Interviews with FSW|Structured interviews with 200 purposively sampled FSW will be conducted. These interviews will be conducted prior to focus group discussion (FGD) and in-depth qualitative interview (IDI) with FSW. Structured interviews will take approximately 45-60 minutes to complete and will be administered privately in Kiswahili, Dholuo or English by trained female research staff. Quantitative interviews will be administered to conduct an assessment of FSW sociodemographics, sexual behaviour patterns and HIV-related knowledge, attitudes and practices regarding HIV prevention and other factors that might affect initiation and adherence to PrEP use, ability to use PrEP covertly, HIV testing history, mobility patterns, social networks, pregnancy intentions, ability to use condoms consistently with clients, and regular partners, and interpersonal violence from clients, regular partners and the police.
62340208|NCT00426517|EXPERIMENTAL|Matched unrelated donor stem cell transplant (MUD-non CGD)|Conditioning with ATG 40 mg/kg total dose over 4 days IV, Busulfan 5 mg/kg total dose over 2 days IV, and TBI 300 cGy in two fractions at day -2
62340209|NCT00426517|EXPERIMENTAL|Matched unrelated donor transplant (MUD-CGD) cord blood|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
62340210|NCT02612389|EXPERIMENTAL|MM Intervention taught via DVD|Receive Meditative Movement training via DVD with pre and post interventional testing.
62496305|NCT04912063|EXPERIMENTAL|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
62496306|NCT04912063|EXPERIMENTAL|Lemzoparlimab + Azacitidine in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
62496307|NCT04912063|EXPERIMENTAL|Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
62496308|NCT04912063|EXPERIMENTAL|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
62496309|NCT04912063|EXPERIMENTAL|Lemzoparlimab Monotherapy in AML (Japan Only Escalation)|Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
62496310|NCT04912063|EXPERIMENTAL|Lemzoparlimab Monotherapy in MDS (Japan Only Escalation)|Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
61945514|NCT01381484|EXPERIMENTAL|Study group|This group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.
61945515|NCT00579098|ACTIVE_COMPARATOR|Atorvastatin|Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
61945516|NCT00579098|PLACEBO_COMPARATOR|Placebo|Placebo (dummy) tablet taken once daily by mouth for 90 days
61945517|NCT01462487||Pregnancy outcomes analysis group|Pregnant women evaluated for the following pregnancy outcomes: elective termination, spontaneous abortion (defined as spontaneous fetal loss at \< 20 weeks' gestation), fetal death (defined as death of a fetus at \> 20 weeks' gestation), premature birth (defined as a birth occurring at \< 37 weeks' gestation), and live birth at term
61945518|NCT01462487||Congenital anomalies analysis group|Infants evaluated for congenital anomalies
61945519|NCT01462487||Treatment-emergent diagnoses analysis group|Pregnant women evaluated for treatment-emergent diagnoses
61945520|NCT05928793|EXPERIMENTAL|Mindfulness|
62139910|NCT03235518||Focus Group Discussions with FSW|Three to five FGDs of up to 10 FSW per group will be conducted. These FGD will take place prior to FSW IDI. FSW who participated in FGDs will be ineligible for participation in the IDI. All group discussions will last approximately 1.5 to 2 hours and be conducted in Kiswahili, Dholuo or English. Each group discussion will be facilitated by trained female research staff and held in a private space at a pre-specified location. The themes that will be explored in the FGDs include: FSW social networks, participation in PrEP studies, barriers and facilitators to PrEP use and use of resource transfers for PrEP adherence. In addition, participants will complete a brief demographic survey.
62340211|NCT02612389|NO_INTERVENTION|MM Intervention Waitlist Control|Testing at same frequency as Meditative Movement interventional subjects.
61945521|NCT05928793|NO_INTERVENTION|Control|
61945522|NCT05712434|EXPERIMENTAL|Long CHG Intervention|2 months of iodine protocol, followed by 4 months of CHG protocol, followed by 6 months of CHG plus protocol.
61945523|NCT05712434|EXPERIMENTAL|Mid-length CHG Intervention|4 months of iodine protocol, followed by 4 months of CHG protocol, followed by 4 months of CHG plus protocol.
61945524|NCT05712434|EXPERIMENTAL|Short CHG Intervention|6 months of iodine protocol, followed by 4 months of CHG protocol, followed by 2 months of CHG plus protocol.
61945525|NCT06005571|ACTIVE_COMPARATOR|Control: traditional acid etch treatment group|Traditional acid etching to the tooth and old restoration surfaces and then adhesive application.
61945526|NCT06005571|EXPERIMENTAL|Silane-Adhesive treatment group|Acid cid etching of prepared tooth tissues and old restoration surfaces, silane solution application, and then adhesive application.
61945527|NCT06005571|EXPERIMENTAL|Sandblast-Silane-Adhesive treatment group|First sandblasting the old composite filling surfaces, then acid etching of prepared tooth tissues the restoration, then silane application followed by adhesive application.
61945528|NCT05405465||UC patients with exposure to golimumab|The investigators retrospectively analyzed all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
61945529|NCT05875571|ACTIVE_COMPARATOR|Ketorolac|The group of patients will receive IV Ketorolac before placement of IUD under sedation.
61945530|NCT05875571|PLACEBO_COMPARATOR|Placebo|The group of patients will receive placebo before placement of IUD under sedation.
62340212|NCT03050671|ACTIVE_COMPARATOR|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
61945531|NCT05446441|EXPERIMENTAL|Intervention;|Endoscopic thyroidectomy was performed in a standardized fashion by multi-institutional Chinese experienced surgeons using the same gasless unilateral transaxillary approach.
61945532|NCT05446441|ACTIVE_COMPARATOR|Control|Conventional open surgery was performed in a standardized fashion by multi-institutional Chinese experienced surgeons.
61945533|NCT00689780|EXPERIMENTAL|1|AZD1940 + Placebo
61945534|NCT00689780|OTHER|2|
61945535|NCT02428023||GrThalasaemia|estimation of IMT of the carotides arteries and calcium scoring
62340213|NCT03050671|ACTIVE_COMPARATOR|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
62496311|NCT02660541|ACTIVE_COMPARATOR|Betafoam|Brand name: Betafoam® This is a medicated device (dressing) consisting of 3% povidone iodine.
62496312|NCT02660541|ACTIVE_COMPARATOR|Allevyn Silver dressing|Brand name: Allevyn® Silver
61945536|NCT02428023||GrNormal|estimation of IMT of the carotides arteries and calcium scoring
62496313|NCT01787929|OTHER|Cemented hemiarthroplasty|hemiarthroplasty surgery with cement for displaced femoral neck fractures
62496314|NCT01787929|OTHER|Uncemented hemiarthroplasty|hemiarthroplasty surgery without cement is a surgery for displaced femoral neck fractures
62496315|NCT02505035|ACTIVE_COMPARATOR|Default ordering of palliative consult|Hospitals randomized to the intervention arm will adopt a system whereby eligible patients are identified by the electronic health record, a consultation is ordered by default, and physicians may cancel the order after being alerted to it, and patients or family members may decline such services.
62496316|NCT02505035|NO_INTERVENTION|Usual care|There will be no trial-driven approach to care. Inpatient palliative care consultative services will be actively requested by physicians as in usual care.
62496317|NCT04012216||The study population|Patients consulting for persistant, moderate-to-severe rhinitis and meeting eligibility criteria.
62496318|NCT01866644|EXPERIMENTAL|N-acetylcysteine|At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).
62496319|NCT01866644|PLACEBO_COMPARATOR|Saline|With usual technique
62496320|NCT02172469|EXPERIMENTAL|Tiotropium & Placebo|
62496321|NCT02172469|ACTIVE_COMPARATOR|Atrovent & Placebo|
62496322|NCT03885336||Both-Quit Group|Couples in which both individuals smoke and both individuals would like to quit smoking.
62496323|NCT01485718|ACTIVE_COMPARATOR|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
62496324|NCT01485718|PLACEBO_COMPARATOR|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
62496325|NCT05002140|EXPERIMENTAL|XRD-0394 40 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
62496326|NCT05002140|EXPERIMENTAL|XRD-0394 80 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
62496327|NCT05002140|EXPERIMENTAL|XRD-0394 160 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
62496328|NCT05002140|EXPERIMENTAL|XRD-0394 (Dose TBD)|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT. A single biopsy will be performed in each subject (either after RT alone or after XRD-0394 and RT).
62496329|NCT00862212|EXPERIMENTAL|Brief Alcohol Intervention|Half of the subjects will be randomly assigned to receive a brief physician-delivered alcohol intervention designed by the NIAAA to be delivered by primary care and mental health providers.
62496330|NCT00862212|NO_INTERVENTION|Control Group|
62496331|NCT00409942|EXPERIMENTAL|1|Torasemide prolonged released
62496332|NCT00409942|ACTIVE_COMPARATOR|2|Furosemide
62496333|NCT05721157|EXPERIMENTAL|Intervention|Patients randomized to intervention will have access to the screening tool.
62496334|NCT05721157|NO_INTERVENTION|Control|Patients randomized to control will continue routine practice.
62496335|NCT04880954|EXPERIMENTAL|Soft Tissue Mobilization|
62496336|NCT04880954|EXPERIMENTAL|Rehabilitation|
62496337|NCT04880954|EXPERIMENTAL|Soft Tissue Mobilization and Rehabiliation|
62496338|NCT06317402||patient|Adult patients hospitalized at Pitié Salpêtrière in conventional hospitalization wards
62496339|NCT02832167|EXPERIMENTAL|Nivolumab|
62496340|NCT04416854|EXPERIMENTAL|Chemotherapy plus surgery|Chemotherapy plus surgery: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to surgery group. Patients receive palliative resection of Primary tumor. Then the rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
62496341|NCT04416854|ACTIVE_COMPARATOR|Chemotherapy alone|Chemotherapy alone: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to chemotherapy group. The rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
62496342|NCT02577133|ACTIVE_COMPARATOR|Lactobacillus reuteri group|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
62496343|NCT02577133|PLACEBO_COMPARATOR|Placebo group|Placebo (5 drops) for 28 days
62496344|NCT03757468|ACTIVE_COMPARATOR|RME (rapid maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with the standard hyrax expansion screw anchored on second deciduous molars
62496345|NCT03757468|EXPERIMENTAL|Leaf (leaf maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with Leaf Expander appliance anchored on second deciduous molars.
62496346|NCT00083772|EXPERIMENTAL|1|Nesiritide
62496347|NCT06226259|EXPERIMENTAL|GABA supplement group|"The experimental group was given a kind of GABA supplement already on the market, with 100mg of GABA in the unit package.~Take orally every night before sleep for 14 days."
61945537|NCT04923464||ELX/TEZ/IVA|CF participants who are currently on a stable regimen of commercially available ELX/TEZ/IVA will be evaluated for the performance of wearable technology devices. Wearable devices include a wrist-worn actigraphy sensor and an ambulatory cough monitoring system.
61945538|NCT02272478|ACTIVE_COMPARATOR|Arm A|"Patients not known adverse karyotype~Randomise between~Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy~Versus~CPX-351 100 units/m2 on days 1, 3 and 5"
62496348|NCT06226259|PLACEBO_COMPARATOR|placebo group|Placebo ,Take orally every night before sleep for 14 days.
62496349|NCT03400774|OTHER|Control|Oral glucose tolerance test with no stair-climbing
62496350|NCT03400774|EXPERIMENTAL|1 minute|Oral glucose tolerance test with 1 minute of stair-climbing
62496351|NCT03400774|EXPERIMENTAL|3 minutes|Oral glucose tolerance test with 3 minutes stair-climbing
62496352|NCT03400774|ACTIVE_COMPARATOR|10 minutes|Oral glucose tolerance test with 10 minutes stair-climbing
62496353|NCT01713166|ACTIVE_COMPARATOR|Plasmalyte solution|Plasmalyte solution infusion to meet the fluid requirements.
62496354|NCT01713166|EXPERIMENTAL|Hextend|6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
62496355|NCT02179151|PLACEBO_COMPARATOR|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
62496356|NCT02179151|EXPERIMENTAL|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
62496357|NCT02179151|EXPERIMENTAL|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
62496358|NCT05065619|EXPERIMENTAL|MT-2766 High dose (3.75 µg)|
62496359|NCT05065619|PLACEBO_COMPARATOR|Placebo|
62496360|NCT05065619|EXPERIMENTAL|MT-2766 Low dose|
62496361|NCT05205096|EXPERIMENTAL|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
62340214|NCT03508141|EXPERIMENTAL|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC
62340215|NCT03508141|ACTIVE_COMPARATOR|Cryoprecipitate|Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate
62697825|NCT05309629|EXPERIMENTAL|QL1706+chemotherapy|Participants received intravenous infusions of QL1706 5mg/kg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 mg/mL/min followed by etoposide 100 mg/m\^2 on Day 1 of every 21-day cycle for 4-6 cycles. On Days 2 and 3 of every 21-day cycle, etoposide 100 mg/m\^2 was administered alone for 4-6 cycles. Thereafter, participants received maintenance QL1706 5mg/kg on Day 1 of every 21-day cycle until progressive disease, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
61945539|NCT02272478|ACTIVE_COMPARATOR|Arm B|"Patients with known adverse karyotype~5 cycles of Vosaroxin and Decitabine therapy"
61945540|NCT02272478|ACTIVE_COMPARATOR|Arm C|"Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1~Randomise between~Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)~Versus~Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive~Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive~Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)~And Randomisation to receive AC220 or not"
61945541|NCT02272478|ACTIVE_COMPARATOR|Arm D|"Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomisation to receive AC220 or not"
61945542|NCT02272478|ACTIVE_COMPARATOR|Arm E|"Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1~Randomisation between~CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)"
61945543|NCT02272478|ACTIVE_COMPARATOR|Arm F|"Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)~versus~Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)"
61945544|NCT02550262|EXPERIMENTAL|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
61945545|NCT02550262|EXPERIMENTAL|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62496362|NCT03953664|EXPERIMENTAL|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
62697826|NCT03246880|EXPERIMENTAL|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
62697827|NCT03246880|ACTIVE_COMPARATOR|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
62697828|NCT03246880|ACTIVE_COMPARATOR|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
62139911|NCT03235518||In-Depth Qualitative Interviews with FSW|30 IDI will be conducted with FSW. FSW who participated in FGDs will be ineligible for participation in the IDI. All in-depth interviews will be conducted by trained female research staff using a semi-structured interview guide. All interviews will be held in a private space at a pre-specified location within the community. The topics that will be discussed in the IDI with FSW include demographics, social support, dynamics of sex work, HIV prevention methods (including condom use), perception of HIV risk and development of PrEP intervention.
62139912|NCT03235518||In-Depth Qualitative Interviews with MC|30 IDI will be conducted with MC. All IDI will last approximately 60-90 minutes and be conducted in Kiswahili, Dholuo, or English. Each interview will be conducted by a trained male research staff using semi-structured interview guide. All interviews will be held in a private space at a pre-specified location. Topics include demographics, relationships with FSW, HIV prevention methods (including use of condoms), perception of HIV risk and development of PrEP intervention.
62139913|NCT03235518||In-Depth Qualitative Interviews with HCPs|30 IDI will be conducted with health care provider (HCP). All IDI will last approximately 60-90 minutes and be conducted in English. Each interview will be conducted by trained research staff using a semi-structured interview guide. Interviews will be held in a private space at the health facility where they work or another venue preferred by the HCP. Topics include demographics, health care needs of FSW and sources of care, HIV prevention needs of FSW, PrEP for FSW and training needs for HCP.
62139914|NCT02238041||GlucoClear System|
62139915|NCT02961075|EXPERIMENTAL|Cricothyroid|local surface anesthesia by Cricothyroid
62139916|NCT02961075|EXPERIMENTAL|Laryngeal tube|local surface anesthesia by Laryngeal tube
62139917|NCT03552276|EXPERIMENTAL|SUNPG18_07 q4 weeks, high dose|Tildrakizumab 200 mg q4 Weeks
62139918|NCT03552276|EXPERIMENTAL|SUNPG18_07 q12 weeks, high dose|Tildrakizumab 200 mg q12 Weeks
62139919|NCT03552276|EXPERIMENTAL|SUNPG18_07 q12 weeks, low dose|Tildrakizumab 100 mg q12 Weeks
62340216|NCT03998020|OTHER|chronic sleep disorders|Subjects with chronic sleep disorders responsible of hypersomnolence measured by a scale of severity of sleep disorder, and blood parameters (blood sample)
62496363|NCT03953664|EXPERIMENTAL|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
62496364|NCT03953664|EXPERIMENTAL|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
62496365|NCT03585309|EXPERIMENTAL|Laparascopy comper with coagulation and without coagulation|
62139920|NCT03552276|EXPERIMENTAL|SUNPG18_07 q4 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose|Tildrakizumab 200 mg q4 weeks switched to tildrakizumab 100 mg q12 weeks
62496366|NCT04020016|EXPERIMENTAL|Part 1 Single Ascending Dose|Impaired liver function subjects and healthy liver subjects single ascending dosing up to 162 mg BID of Nalbuphine ER
62496367|NCT04020016|EXPERIMENTAL|Part 2 Multiple Ascending Dose|Impaired liver function subjects will receive multiple ascending dosing up to 162 mg BID of Nalbuphine ER
62496368|NCT01586208|ACTIVE_COMPARATOR|40mg/kg intial valproate bolus|Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
62496369|NCT01586208|ACTIVE_COMPARATOR|20mg/Kg intial bolus valproate|Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
62496370|NCT01775722|OTHER|Pulsed Dye Laser|port wine stain treatment using Pulse Dye Laser
62496371|NCT01775722|EXPERIMENTAL|Bipolar Radiofrequency&Pulsed Dye Laser|Port wine stain using Combined Bipolar Radiofrequency\&Pulsed Dye Laser
62496372|NCT02308696|EXPERIMENTAL|Peer-to-peer support (non-randomized)|225 older adults that are currently receiving peer-to-peer support
62496373|NCT02308696|ACTIVE_COMPARATOR|Standard Services (non-randomized)|225 older adults will continue receiving standard community services
62496374|NCT00027417|ACTIVE_COMPARATOR|Liothyronine Sodium/Triiodothyronine|bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function.
62496375|NCT00027417|PLACEBO_COMPARATOR|Placebo|bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses
61945546|NCT02550262|EXPERIMENTAL|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
62139921|NCT03552276|EXPERIMENTAL|SUNPG18_07 q12 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose|Tildrakizumab 200 mg q12 weeks switched to tildrakizumab 100 mg q12 weeks
62139922|NCT04580459|EXPERIMENTAL|CARE Parenting Group Treatment|Participants receive the CARE mentalizing-focused group parenting intervention.
62139923|NCT04580459|OTHER|Treatment as Usual (TAU)|Participants continue to receive treatment as usual in the outpatient child mental health clinic.
62139924|NCT01540305|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation|Actual transcranial magnetic stimulation of supplementary motor areas bilaterally.
62340217|NCT05638906|EXPERIMENTAL|single-arm study with intra-subject comparisons|Study eyes of subjects with uncontrolled (IOP \> 20 mmHg) open-angle glaucoma (OAG), where IOP is not controlled when using maximum tolerated glaucoma medications.
62340218|NCT00572325||1|"Inclusion criteria~* Histological or cytological proven NSCLC~* UICC stage I-III~* Performance status 0-2~* FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~* Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~* stage IV~* performance status 3 or more~* FeV 1 or DLCO\< 30% of the age-predicted value"
62340219|NCT03321214|EXPERIMENTAL|Light use of Nima|Ten participants will be randomized to receive 12 capsules every other month (18 capsules for the 3 months which is considered light use).
62340220|NCT03321214|EXPERIMENTAL|Moderate use of Nima|Ten participants will be randomized to receive 12 capsules per month (36 capsules for the 3 months which is considered moderate use).
62340221|NCT03321214|EXPERIMENTAL|Heavy use of Nima|Ten participants will be randomized to receive 24 capsules per month (72 capsules for the 3 months which is considered heavy use).
62340222|NCT02471001||Heart Surgery Using Heart-lung Machine|All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being two additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
62340223|NCT03277144|EXPERIMENTAL|TST-TriStaple(3lines stapler)Technology|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device.
62340224|NCT03277144|ACTIVE_COMPARATOR|OCT (other conventional techniques)|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples.
62340225|NCT04359082|PLACEBO_COMPARATOR|Placebo|Placebo for 8 straight days
62340226|NCT04359082|EXPERIMENTAL|Bioflavanol|Bioflavanol supplementation for 8 days at 900 mg flavanol per day
62496376|NCT03008941|EXPERIMENTAL|FMT|"Fecal microbiota capsules (provided by Openbiome).~Dosage:~* Induction: 10 capsules (single dose)~* Maintenance: 5 capsules, weekly, during 7 weeks."
62496377|NCT03008941|PLACEBO_COMPARATOR|Placebo|"Placebo capsules (provided by Openbiome).~Dosage:~* Induction: 10 capsules (single dose)~* Maintenance: 5 capsules, weekly, during 7 weeks."
62496378|NCT02011451|EXPERIMENTAL|95% Pure ECGC capsules 200mg|95% Pure ECGC capsules 200mg three times a day with food for 6 months
62496379|NCT02011451|PLACEBO_COMPARATOR|Sugar pill|Matched placebo capsules
62496380|NCT01447758|EXPERIMENTAL|LEO 29102 2,5 mg/g cream|
62496381|NCT01447758|PLACEBO_COMPARATOR|LEO 29102 Cream Vehicle|
62496382|NCT03183141|EXPERIMENTAL|SER-109|Received oral dose of SER-109
62496383|NCT00650780||1|All of the subjects will have measurements of Gc concentration and phenotype
62496384|NCT04763096|EXPERIMENTAL|tacrolimus|conversion to Advagraf
62496385|NCT05921812||control|apparently healthy individuals with no chronic illness
62496386|NCT05921812||cases|newly diagnosed Non-Hodgkin's lymphoma patients
61945547|NCT02550262|EXPERIMENTAL|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
61945548|NCT04567823|EXPERIMENTAL|Microalgae I|Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans)
61945549|NCT04567823|EXPERIMENTAL|Microalgae II|Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans)
61945550|NCT04567823|PLACEBO_COMPARATOR|Smoothie|Smoothie (without microalgae) and standardised background diet (defined menu plans)
61945551|NCT04567823|NO_INTERVENTION|Control|no intervention (no smoothie, no menu plans)
61945552|NCT02083965|EXPERIMENTAL|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
62340227|NCT02397694|EXPERIMENTAL|BIC + F/TAF|"Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks.~* Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
62496387|NCT03098693||Sero-discordant Couple Cohort|We will enroll and track a cohort of 60 serodiscordant couples (120 individuals). The HIV-positive couple members will be offered anti-retroviral therapy (ART) and the HIV-negative couple members will be offered pre-exposure prophylaxis (PrEP). We will monitor monthly clinic visits for the couple and will conduct in-depth behavioral surveys at baseline, 6-, 12-, and 18-months.
62697829|NCT00668642|EXPERIMENTAL|A: Dutasteride During First Off-Cycle|Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle
62697830|NCT00668642|PLACEBO_COMPARATOR|B: Placebo During First Off-Cycle|Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle
62697831|NCT05712681|EXPERIMENTAL|Sequence 1|T → Washout period(7-14days) → R
61945553|NCT02083965|EXPERIMENTAL|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
61945554|NCT03870100|EXPERIMENTAL|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
61945555|NCT03870100|EXPERIMENTAL|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
61945556|NCT03870100|EXPERIMENTAL|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
61945557|NCT03870100|EXPERIMENTAL|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
61945558|NCT03870100|EXPERIMENTAL|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
61945559|NCT06125548|EXPERIMENTAL|Lactation Management Model-Experimental|The women in the experimental group were told about the care technique in accordance with the Lactation Management Model and were asked to apply it regularly for 3 days.The content of the Lactation Management Model includes skin-to-skin contact, hot application to the breast, relaxation and breast massage, and process monitoring.In this regard, the mother should apply skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes manual milking, 2 minutes . nipple stimulation, stroking for 3 minutes).
61945560|NCT06125548|NO_INTERVENTION|Non-application group- Control|No treatment was performed on women in the control group.
61945561|NCT01765907|EXPERIMENTAL|HIFU|
61945562|NCT05285800|EXPERIMENTAL|Saddle group|After administration of 12mg of 0.5 % Hyperbaric Bupivacaine intrathecally, Patient is advised to remain in Sitting position for the next 5minutes and then take supine position
61945563|NCT05285800|ACTIVE_COMPARATOR|Spinal group|After administration of 12mg of 0.5% Hyperbaric Bupivacaine intrathecally, Patient is advised to take Supine position immediately.
61945564|NCT05235087|EXPERIMENTAL|Bovine Atelocollagen Skin Sensitization Test|Volunteer cohort tested for hypersensitivity towards intradermal injection of bovine atelocollagen.
61945565|NCT00697788|EXPERIMENTAL|Ascending dose study|Ascending doses of dexmedetomidine (as per protocol)
61945566|NCT01418313||DCE-MRI|Magnetic resonance imaging (MRI) with and without FDA approved contrast agents: MRI is a non invasive imaging technique used to visualize the internal structure of the body in detail. The MRI machine is an oversized magnet that is always on. It will be used in this study to provide anatomical and functional (MRI with contrast) information about atherosclerotic plaques.
62139925|NCT01540305|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation over the supplementary motor areas.
62496388|NCT03853499||Successful vacuum extraction|Patients for whom vacuum extraction was successful
62496389|NCT03853499||Failed vacuum extraction|Patients who had an emergency caesarean section after failed vacuum extraction
62496390|NCT06679595||Children|Children up to the age of 18 with a chronic condition included in a pilot project for paediatric transmural care
62496391|NCT06679595||Parents|Parents/ legal guardians of children included in a pilot project for paediatric transmural care
62496392|NCT06679595||Healthcare professionals|Project coordinators and healtcare professionals involved in a pilot project for paediatric transmural care
62496393|NCT01077505|EXPERIMENTAL|albiglutide|albiglutide 50mg weekly
62697832|NCT05712681|EXPERIMENTAL|Sequence 2|R → Washout period(7-14days) → T
61945567|NCT01418313||PET/CT and PET/MR|Positron emission tomography (PET)/ computer tomography (CT): PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. Nowadays PET imaging is most useful in combination with anatomical imaging, such as CT scanners, thereby PET scanners are now available with integrated high-end multi-detector row CT scanners. Because the two scans can be performed in immediate sequence during the same session and with the patient not changing position between the two scans, areas of abnormality on PET images can be directly correlated with anatomy on the CT images.
61945568|NCT01418313||PET/MR|Positron emission tomography (PET)/MRI: PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. To avoid the additional radiation deriving from the CT scan during PET/CT imaging, nowadays PET imaging can be paired with MR anatomical images.
61945569|NCT05012033||Group A|Patients started acutely on high dose prednisolone (\>30mg for any inflammatory condition)
61945570|NCT05012033||Group B|Patients on longer term anti-inflammatory doses of prednisolone to treat any medical condition warranting their use, including post COVID.
61945571|NCT05012033||Group C|Patients receiving multiple high doses of methylprednisolone or dexamethasone in association with oral prednisolone.
61945572|NCT04741711|EXPERIMENTAL|Interventional group|The heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava
61945573|NCT04741711|OTHER|Control group|Usual care (i.e. without ultrasound guidance) will be provided.
61945574|NCT00667160|EXPERIMENTAL|1|
61945575|NCT00667160|ACTIVE_COMPARATOR|2|
61945576|NCT02389985|EXPERIMENTAL|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
61945577|NCT06558591|EXPERIMENTAL|Chronic disease patients|The only intervention group (chronic disease patients) will use the ADEPINA device as part of their conventional treatment.
61945578|NCT01638221||heavy weight mesh|Surgipro mesh is a heavier weighted mesh with less flexibility after surgery
61945579|NCT01638221||light weight mesh|UltraPro mesh is a lighter weighted mesh with theoretically less stiffness and more flexibility compared to heavier weighted meshes
61945580|NCT02006888|EXPERIMENTAL|IBI-10090 low dose|IBI-10090 low dose
61945581|NCT02006888|EXPERIMENTAL|IBI-10090 med dose|IBI-10090 med dose
61945582|NCT02006888|PLACEBO_COMPARATOR|Placebo|Placebo
62496394|NCT01916694|EXPERIMENTAL|Smart phone app glucose monitoring|Home blood glucose monitoring results directly transmitted via a bluetooth enabled smart phone app to a central database to be reviewed by clinicians
62496395|NCT01916694|ACTIVE_COMPARATOR|Standard glucose monitoring|Home blood glucose monitoring results recorded by hand in a paper diary by the patient and reviewed by the clinical team in the outpatient clinic.
62496396|NCT02910687||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
62496397|NCT00694486||1|Healthy adult volunteers
61945583|NCT05431660|EXPERIMENTAL|tele-rehabilitation group|1st group within the scope of diabetic foot school, and an exercise program aiming to increase the mobility and strength of the foot will be implemented through video calls twice a week, face-to-face once a week for 8 weeks.
61945584|NCT05431660|ACTIVE_COMPARATOR|face to face training group|The 2nd group will be given a booklet covering this training and they will be followed up with video calls 1 day a week for 8 weeks.
61945585|NCT04970784||Patients cared for by the adult sector|Patients admitted to emergencies, non-hospitalized and cared for by the adult sector of emergencies (classical emergencies)
61945586|NCT04970784||Patients cared for by the geriatric sector|Patients admitted to emergencies, non-hospitalized and cared for by the geriatric sector of emergencies
61945587|NCT01529242|EXPERIMENTAL|Desloratadine + Prednisolone|desloratadine 0,5 mg/ml + prednisolone 4 mg/ml - oral solution
61945588|NCT01529242|ACTIVE_COMPARATOR|Dexchlorpheniramine + Betamethasone|dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution
61945589|NCT03395392|EXPERIMENTAL|NRX-101|Following study enrollment and randomization, subjects will receive twice daily NRX-101
61945590|NCT03395392|ACTIVE_COMPARATOR|Lurasidone|Following study enrollment, subjects will receive twice daily lurasidone
61945591|NCT04846842|EXPERIMENTAL|Gimatecan group|In Phase II study, patients will receive gimatecan at fixed dose level (0.8mg/m2/d, oral, every 4 weeks) until progressive disease (PD)、complete remission（CR）).
61945592|NCT04221178||MRD-Negative Participants|
61945593|NCT04057508|ACTIVE_COMPARATOR|Stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order .
61945594|NCT04057508|SHAM_COMPARATOR|Sham stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order.
61945595|NCT02104752|EXPERIMENTAL|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
61945596|NCT02104752|PLACEBO_COMPARATOR|Sugar Pill|Matched placebo, 2 capsules twice daily.
61945597|NCT05490303|OTHER|Patients|Patient with an echocardiography examination
61945598|NCT01649804|EXPERIMENTAL|RoActemra/Actemra single arm|
61945599|NCT04578483||PCA group|Patients receiving patient-controlled analgesia (PCA) will be allocated to PCA group.
62496398|NCT01183884|EXPERIMENTAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.
62697833|NCT03242447|EXPERIMENTAL|e-Practice Self-Regulation (e-PS-R)|e-Practice Self-Regulation (e-PSR) is the treatment condition. e-PS-R is a 'blended learning' intervention, combining online and face-to-face instruction. e-PS-R aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
62496399|NCT06105580|EXPERIMENTAL|Conduction system pacing|"Pacing the His-Purkinje system.~Crossover to biventricular pacing allowed in case of failed conduction system pacing: failed His bundle pacing and failed Left bundle branch pacing (high thresholds (\>3.5V / 1ms); no left bundle branch pacing criteria; no left bundle branch correction).~Electrocardiographic optimization allowed in order to obtain the narrowest QRS."
62496400|NCT06105580|ACTIVE_COMPARATOR|Biventricular pacing|"Pacing from the right ventricular and coronary sinus lead. Electrocardiographic optimization with fusion-optimized intervals (FOI).~Crossover from biventricular pacing to conduction system pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
62496401|NCT01466374|EXPERIMENTAL|Cohort 1: Induction|Placebo
62496402|NCT01466374|EXPERIMENTAL|Cohort 2: Induction|Anti-IP-10 Antibody
61945600|NCT04578483||ERDS group|Patients receiving one dose of extended-release dinalbuphine sebacate (ERDS) by ultrasound-guided muscle injection will be allocated to ERDS group.
62340228|NCT02397694|ACTIVE_COMPARATOR|DTG + F/TAF|"Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks.~* Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
62340229|NCT02397694|EXPERIMENTAL|Open Label Extension Phase|After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.
62496403|NCT01466374|EXPERIMENTAL|Cohort 3: Induction|Anti-IP-10 Antibody
61945601|NCT04578483||PRN group|Patients receiving analgesics other than ERDS and PCA will be allocated to PRN group.
61945602|NCT00659750|ACTIVE_COMPARATOR|1|Ciclesonide 200µg
61945603|NCT00659750|PLACEBO_COMPARATOR|2|Placebo
61945604|NCT01565720|EXPERIMENTAL|Group 1|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole low dose once a day (QD) for 11 days
61945605|NCT01565720|EXPERIMENTAL|Group 2|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole high dose once a day (QD) for 11 days
61945606|NCT01565720|PLACEBO_COMPARATOR|Group 3|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 11 days
61945607|NCT01565720|ACTIVE_COMPARATOR|Group 4|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 10 days and then moxifloxacin on Day 13
61945608|NCT05058716||COVID-19 positive patients|
61945609|NCT05058716||COVID-19 negative patients|
61945610|NCT00115648|ACTIVE_COMPARATOR|A|Single dose NVP + ZDV daily for the first week.
61945611|NCT00115648|EXPERIMENTAL|C|Arm A plus NVP + ZDV daily to age 14 weeks.
61945612|NCT00115648|EXPERIMENTAL|B|Arm A plus oral NVP daily to age 14 weeks.
61945613|NCT04520412|EXPERIMENTAL|GV-971|
61945614|NCT04520412|PLACEBO_COMPARATOR|Placebo|
62340230|NCT00740168||TG|Bevacizumab treatment group with metastasized cancer
62496404|NCT01466374|EXPERIMENTAL|Cohort 1: Maintenance|Placebo
62496405|NCT01466374|EXPERIMENTAL|Cohort 2: Maintenance|Anti-IP-10 Antibody
62496406|NCT01466374|EXPERIMENTAL|Cohort 3: Maintenance|Anti-IP-10 Antibody
62496407|NCT01466374|EXPERIMENTAL|Cohort 1: Open Label|Anti-IP-10 Antibody
62496408|NCT05302193|EXPERIMENTAL|Blood pressure and heart rate measurement|Calm measurement of blood pressure and heart rate simultaneously by smartwatch and vital signs monitor. Each participant will undergo this measurement a total of 6 times.
62496409|NCT04380233|EXPERIMENTAL|Investigational Drug Group|A 8-weeks double-blind treatment period with a Proprietary Chinese Medicine (consists of 4 kinds of Chinese herbs at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
62496410|NCT04380233|PLACEBO_COMPARATOR|Placebo Group|A 8-weeks double-blind treatment period with Placebo Capsules (at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
62496411|NCT02668991||Cohort 1|It will consist of planned 100 children and adults with Autism Spectrum Disorder (ASD) aged 6 years and older with no requirements regarding concurrent therapies or treatments.
62340231|NCT05483621|EXPERIMENTAL|Hormonal therapy Group|Administration of hormonal therapy (as Beta HCG (5000 IU I.M) twice weekly for three months
62340232|NCT05483621|OTHER|L-carnitine Group (Control)|Administration of L-carnitine 1000 mg twice daily for three months
61945615|NCT06144892|EXPERIMENTAL|Intervention first|Patients will undergo proactive therapy first, followed by the buffer period, and finally the conventional APAP therapy.
61945616|NCT06144892|EXPERIMENTAL|Control first|Patients will undergo the conventional APAP therapy first, followed by the buffer period, and finally the proactive therapy.
61945617|NCT00887653|EXPERIMENTAL|Raltegravir|This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
61945618|NCT05819281|EXPERIMENTAL|Probiotic blend group|Volunteers supplemented with the probiotic product (n=57) (Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 10e10 CFU/day).
61945619|NCT05819281|PLACEBO_COMPARATOR|Placebo group|Placebo Group (n=57): Volunteers supplemented with placebo (maltodextrin)
61945620|NCT02256657|EXPERIMENTAL|Step 1: Toolkit Implemented in Month 4|Quality Improvement Toolkit
61945621|NCT02256657|EXPERIMENTAL|Step 2: Toolkit Implemented in Month 8|Quality Improvement Toolkit
61945622|NCT02256657|EXPERIMENTAL|Step 3: Toolkit Implemented in Month 12|Quality Improvement Toolkit
61945623|NCT02256657|EXPERIMENTAL|Step 4: Toolkit Implemented in Month 16|Quality Improvement Toolkit
61945624|NCT02256657|EXPERIMENTAL|Step 5: Toolkit Implemented in Month 20|Quality Improvement Toolkit
61945625|NCT02592525|EXPERIMENTAL|Cluster A|IP-SDM training for health professionals (intervention at 4 months)
62340233|NCT02307071|EXPERIMENTAL|Cefaly Kit Arnold|Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.
62496412|NCT02668991||Cohort 2|It will consist of planned 50 children and adults aged 6 and older who, as part of their standard care, happen to be beginning a behavioral intervention within 2 weeks after the baseline visit of the study. This intervention can be an applied behavior analysis (ABA) program or similar or a social skills program or a school-based autism program and must be intended to last at least throughout the duration of the study.
62496413|NCT02668991||Cohort 3|It will consist of planned 30 normally developing children and adults. These participants will only have a single visit wherein they will undergo a single session with the task battery and biosensors. There should be 5 participants aged 6-9 years, 5 aged 10-12 years, 5 aged 13-17 years, and 5 aged 18 years and older. This cohort should approximate the male:female ratio in Cohorts 1 \& 2, with approximately 1 female for every 5 males.
62496414|NCT00945438|EXPERIMENTAL|Group 1|Participants aged 18 to 59 years at enrollment.
62496415|NCT00945438|EXPERIMENTAL|Group 2|Participants aged 60 years or older at enrollment.
61945626|NCT02592525|EXPERIMENTAL|Cluster B|IP-SDM training for health professionals (intervention at 11 months)
61945627|NCT02592525|EXPERIMENTAL|Cluster C|IP-SDM training for health professionals (intervention at 18 months)
61945628|NCT02592525|EXPERIMENTAL|Cluster D|IP-SDM training for health professionals (intervention at 25 months)
62139926|NCT03462485|EXPERIMENTAL|Golf intervention|The golf intervention will be an eight-week golf programme in which participants will be taught to play golf in two 150-min sessions each week. Each session will begin with 30 minutes of socialising, then 90 minutes playing golf, followed by another 30 minutes socialising. The golf sessions will progress from putting, to chipping, and then a full swing, with sessions taking place on a nine-hole golf course.
62496416|NCT01745887|ACTIVE_COMPARATOR|EBI-005-2 5mg/ml|Administration: 3 times per day
62496417|NCT01745887|ACTIVE_COMPARATOR|EBI-005-2 20 mg/ml|Administration: 3 times per day
62496418|NCT01745887|PLACEBO_COMPARATOR|EBI-005-2 Placebo|Administration: 3 times per day
62496419|NCT02407496||ADHD|Adults with Attention Deficit Hyperactivity Disorder (ADHD)
62496420|NCT02407496||Control|Healthy individuals without ADHD
62496421|NCT02342938|EXPERIMENTAL|Patient|
62496422|NCT02342938|EXPERIMENTAL|Volunteers|
62496423|NCT02039635|EXPERIMENTAL|Korean Red Ginseng|"Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Dietary Supplement: Korean Red Ginseng"
61945629|NCT04693455|EXPERIMENTAL|Experimental: Cohort 1, Dose 1 of ZD03 or Placebo|Dose 1 of ZD03 or matching Placebo capsules by mouth
61945630|NCT04693455|EXPERIMENTAL|Experimental: Cohort 2, Dose 2 of ZD03 or Placebo|Dose 2 of ZD03 or matching Placebo capsules by mouth
61945631|NCT04693455|EXPERIMENTAL|Experimental: Cohort 3, Dose 3 of ZD03 or Placebo|Dose 3 of ZD03 or matching Placebo capsules by mouth
61945632|NCT04693455|EXPERIMENTAL|Experimental: Cohort 4, Dose 4 of ZD03 or Placebo|Dose 4 of ZD03 or matching Placebo capsules by mouth
61945633|NCT04693455|EXPERIMENTAL|Experimental: Cohort 5, Dose 5 of ZD03 or Placebo|Dose 5 of ZD03 or matching Placebo capsules by mouth
61945634|NCT04693455|EXPERIMENTAL|Experimental: Cohort 6, Dose 6 of ZD03 or Placebo|Dose 6 of ZD03 or matching Placebo capsules by mouth
61945635|NCT04693455|EXPERIMENTAL|Experimental: Cohort 7, Dose 7 of ZD03 or Placebo|Dose 7 of ZD03 or matching Placebo capsules by mouth
62139927|NCT03462485|NO_INTERVENTION|Control|Control participants will continue their normal activities.
62139928|NCT04452383|ACTIVE_COMPARATOR|propofol (P)|patients will receive only propofol intravenous for sedation
62139929|NCT04452383|ACTIVE_COMPARATOR|propofol ketamine (pk)|patients will receive ketamine in addition to propofol intravenous for sedation
62139930|NCT00186446|EXPERIMENTAL|Bupropion|
62139931|NCT04919811|EXPERIMENTAL|Taletrectinib|Single-arm trial whereby all consented, enrolled, eligible patients receive taletrectinib
62139932|NCT02972034|EXPERIMENTAL|A: MK-8353 BID Continuous+Pembro|Participants receive MK-8353 orally (PO) two times each day (BID) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab (pembro) 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 35 cycles.
62139933|NCT02972034|EXPERIMENTAL|B: MK-8353 QD Continuous+Pembro|Participants receive MK-8353 PO once each day (QD) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62139934|NCT02972034|EXPERIMENTAL|C: MK-8353 QD 1 Week On/1 Week Off+Pembro|Optional Arm: Participants receive MK-8353 PO QD on Days 1 to 7, Days 15 to 21 and Days 29 to 35 PLUS pembrolizumab 200 mg IV on Day 1 and Day 22 of each 42-day period (based on 2 cycles of 21 days) for up to 35 cycles.
62139935|NCT02972034|EXPERIMENTAL|D: MK-8353 QD Run-in→MK-8353 QD Continuous+Pembro|Optional Arm: Participants undergo an MK-8353 PO QD run-in period from Day -14 to Day -1 prior to Cycle 1 during which they receive MK-8353 PO QD. After the run-in period, participants receive MK-8353 PO QD on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 36 cycles.
62139936|NCT05494866|EXPERIMENTAL|Arm 1|CYP3A Inhibitor Cobicistat and the cytostatics Gemcitabine and nab-Paclitaxel
62139937|NCT04094519|EXPERIMENTAL|digoxin plus rosuvastatin and enzalutamide|Participants will receive a single oral dose cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin on Day 1 and 64. A single oral dose of placebo to match enzalutamide will be given on Day 1 and 160 mg enzalutamide once daily on Days 8 through 71.
62496424|NCT02039635|PLACEBO_COMPARATOR|Placebo|"Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Other: Placebo"
62496425|NCT00115869|NO_INTERVENTION|No-intervention control|
62496426|NCT00115869|EXPERIMENTAL|Social influences school-based smoking prevention curriculum|
62139938|NCT04984889|EXPERIMENTAL|TAK-662 80 IU/kg|TAK-662 80 international unit (IU)/kg, single intravenous infusion over 15 minutes on Day 1. In the extension part, dose of TAK-662 will be modified per participants. TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C.
62139939|NCT05577624|EXPERIMENTAL|AMG 510 + Rifampin|
62139940|NCT06698835|EXPERIMENTAL|school girls aged 10-12 years (case group)|It includes turnip consumption, and qigong exercise. Also, they will receive health education about the importance of weight loss. Educational program aged from 10 to 12 years. they will receive the nursing educational program which will be implemented in 2 small groups (5) in the primary school
62496427|NCT00127166|EXPERIMENTAL|Montelukast/Salmeterol|Period I - Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
62496428|NCT00127166|EXPERIMENTAL|Salmeterol/Montelukast|Period I - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
62496429|NCT02360007|EXPERIMENTAL|Interim Buprenorphine Treatment|IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
62496430|NCT02360007|NO_INTERVENTION|Waitlist Control|WLC participants will remain on the waitlist for their treatment of choice but complete the same scheduled follow-up assessments as IBT participants.
61945636|NCT06427824|EXPERIMENTAL|Participants Who Watch Educational Videos Before Surgery|Participants in this group will attend an educational session in a conference room that includes 4 learning modules on strategies to reduce mobility loss, improve medication management, prevent delirium, and to document what matters most before and after surgery (cystectomy). These learning modules will be in video format. Participants will watch videos to learn about pre/post surgical strategies and they will receive informational handouts after watching the videos. The study team will also ask participants to fill out questionnaires/surveys before and after surgery.
61945637|NCT06427824|EXPERIMENTAL|Participants Who Watch Educational Videos Before Surgery and Receive Geriatric Follow Up Services|"Participants in this group will also attend an educational session in a conference room that includes 4 learning modules on strategies to reduce mobility loss, improve medication management, prevent delirium, and to document what matters most before and after surgery (cystectomy). These learning modules will be in video format. Participants will watch videos to learn about pre/post surgical strategies and they will receive informational handouts after watching the videos. The study team will also ask participants to fill out questionnaires/surveys before surgery.~In addition to attending the educational program (via video) and receiving informational handouts, participants in this group will also meet with the study doctor and/or members of the study team after surgery to help plan their hospital discharge and reinforce/use the strategies they learned in the educational session after surgery."
62139941|NCT06698835|NO_INTERVENTION|school girls aged 10-12 years (control group)|it includes ten students as control group who will not receive any intervention
62139942|NCT04923035||Case|"Children aged 5 years and below with clinically diagnosed pneumonia and attending the outpatient's department or admitted as a hospital inpatient at three sentinel sites. Pneumonia. Suspected pneumonia cases will be identified by a family physician or paediatrician based on medical history and clinical symptoms.~Pneumonia is defined as (WHO Fact Sheet 2019) patient with history of:~1. cough and/or~2. difficulty/rapid breathing and/or~3. intercostal recession,~4. with or without fever. and supported by chest x-ray findings."
62139943|NCT04923035||Control|Healthy children aged 5 years and below without any intercurrent respiratory illness and who is in good health as determined by a brief medical history and/or clinical judgement of the investigator whose parent/LAR is willing and able to give informed consent.
62139944|NCT02052440|EXPERIMENTAL|Baclofen 10mg three times daily|Baclofen 10mg by mouth three times daily
62139945|NCT02052440|PLACEBO_COMPARATOR|Sugar Pill given three times daily|Placebo sugar bill
62139946|NCT01505166|EXPERIMENTAL|Vigil™|Patients will receive 1 x 10\^7 cells (Group A) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses (vaccine) starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
62139947|NCT01505166|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo (Group B) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
62139948|NCT01505166|EXPERIMENTAL|Vigil™ Vaccine (6 patient run-in)|Six patients will be enrolled into the Part 1 of the study to receive intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations).
62139949|NCT05500170|EXPERIMENTAL|Intervention|Participants in the intervention group will receive 500mg of NR twice daily
62139950|NCT05500170|PLACEBO_COMPARATOR|Placebo|Participants in the intervention group will receive 500mg of sham placebo twice daily
62139951|NCT03150875|EXPERIMENTAL|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
62139952|NCT03150875|ACTIVE_COMPARATOR|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
62139953|NCT01630824|OTHER|Education|Kidney transplant recipients, who undergo the structured education program
62139954|NCT01630824|NO_INTERVENTION|Control|Kidney transplant recipients without structured education programm
62139955|NCT02890524|EXPERIMENTAL|Night guard|the night guard made of EVA
62139956|NCT02890524|PLACEBO_COMPARATOR|Placebo night guard|Placebo night guard made of EVA
62139957|NCT02625818||acute psychiatric condition|
62139958|NCT04561089||COVID-19 asymptomatic population|COVID-19 asymptomatic Illumina personnel
62340234|NCT04143672|EXPERIMENTAL|study group|"The following tests will be performed on the study subjects.~1. Pain catastrophizing scale~2. Hospital Anxiety and Depression scale-Anxiety Subscale (HADS-A)~3. Pain sensitivity questionnaire~4. Pain pressure threshold using electronic digital pressure algometer"
62340235|NCT00330863|EXPERIMENTAL|Injectable|Participants assigned to receive long-acting injectable risperidone
62340236|NCT00330863|ACTIVE_COMPARATOR|Oral|"Participants assigned to receive oral atypical antipsychotic medication"
62340237|NCT03966105||Patients with LSS surgery indication|
61945638|NCT02938429|OTHER|Participants with Fontan circulation|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
61945639|NCT02938429|OTHER|Age and gender matched controlled|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
61945640|NCT06043882||the relation between COVID-19 infection and the development of sarcoidosis .|All patients were subjected to the following : history taking , clinical examination , radiological assessment by CT chest , fiberoptic bronchoscopy where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination and if the patient had past history of COVID-19 infection with previous positive RT-PCR.
61945641|NCT01042678|EXPERIMENTAL|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
61945642|NCT01042678|EXPERIMENTAL|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
62139959|NCT03284359|EXPERIMENTAL|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
62139960|NCT03284359|NO_INTERVENTION|Standard Consent|Arm 2 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
62496431|NCT05790460|EXPERIMENTAL|Telehealth|Patients in the intervention arm will be scheduled for an enhanced synchronous telehealth visit with a trained lung cancer nurse navigator prior to tissue biopsy. The enhanced synchronous telehealth visit will ideally occur between the initial clinical appointment and diagnostic biopsy (typically a period between two and seven days). In addition to the activities conducted as part of usual care, the nurse navigator will: 1) provide more detailed and individualized education on lung cancer and the rationale for comprehensive molecular testing, including plasma-based tests; and 2) if the patient agrees to testing, pend a default order for plasma-based molecular testing (if not already ordered) for the clinician to sign and arrange for phlebotomy to be performed at the time of the patient's tissue biopsy.
61945643|NCT01042678|EXPERIMENTAL|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
62139961|NCT01235936|EXPERIMENTAL|AKB-6548|
62139962|NCT00828126||PET-CT Scan|
62139963|NCT03903692|EXPERIMENTAL|Marine polysaccharide dressing|
62139964|NCT03903692|ACTIVE_COMPARATOR|Carboxymethylcellulose dressing|
62139965|NCT03699163||Non cancer control patients|Patients who are attending hospital for a colonoscopy as part of their routine clinical care, or as part of the Bowel Cancer Screening Programme, will be asked to give a sample of their breath prior to the procedure. Those without a finding of colorectal adenocarcinoma will go into this group.
62496432|NCT05790460|NO_INTERVENTION|Usual Care|Patients in the usual care arm will receive a telephone call from a trained lung cancer nurse navigator after biopsy, as is typical at Penn Medicine, to 1) review the roles of clinicians on the medical oncology care team; 2) provide brief education on lung cancer; and 3) review the patient's diagnostic history and coordinate collection or completion of imaging required for guideline-recommended cancer staging. At the initial in-person oncology visit, the oncologist may choose to order plasma-based testing if appropriate (and if not already ordered or pending).
62139966|NCT03699163||Colorectal cancer patients|Patients who have known pre-diagnosed colorectal cancer (adenocarcinoma) attending hospital as part of their clinical care will be asked to give a breath sample prior to their cancer operation. Patients who are attending hospital for a colonoscopy as part of their routine clinical care, or as part of the Bowel Cancer Screening Programme, will be asked to give a sample of their breath prior to the procedure. Those with a finding of colorectal adenocarcinoma will go into this group.
62139967|NCT03421249|ACTIVE_COMPARATOR|Group A - Intervention|Submitted to knee and hip muscle strengthening exercises and electromagnetic field therapy with Magnetron ® (Meditea - ARG) using the coplanar technique
62139968|NCT03421249|ACTIVE_COMPARATOR|Group B - exercises|Performed exercises to strengthen the hip and knee muscles
62496433|NCT05900323|EXPERIMENTAL|Enteral Nutrition Guidelines Group|It will include 34 patients who will receive enteral nutrition guidelines.
62496434|NCT05900323|NO_INTERVENTION|Routine Enteral Nutrition Unit Care Group|It will include 34 patients who will receive routine enteral nutrition unit care.
62496435|NCT05232487|EXPERIMENTAL|Swiss low back acupuncture group|Participants in this group will be treated with the Swiss low back acupuncture method.
62496436|NCT05232487|ACTIVE_COMPARATOR|Standard acupuncture group|Participants in this group will be treated with the standard acupuncture method.
62139969|NCT03421249|PLACEBO_COMPARATOR|Group C - Placebo|Performed hip and knee strengthening exercises and electromagnetic field therapy with the coplanar Magnetron® technique, but with the device switched off
62139970|NCT03421249|ACTIVE_COMPARATOR|Group D - Apparatus|Only use electromagnetic field therapy with the coplanar Magnetron® technique
62496437|NCT02157896||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
61945644|NCT01042678|EXPERIMENTAL|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
61945645|NCT01042678|EXPERIMENTAL|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
61945646|NCT01042678|EXPERIMENTAL|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
61945647|NCT03259217|EXPERIMENTAL|stem cell product|stem cell transplant
61945648|NCT05072704|ACTIVE_COMPARATOR|Control group|Sufentanil IV injection
62139971|NCT02920034|ACTIVE_COMPARATOR|Radiofrequency main renal artery|Renal sympathetic denervation of the main renal artery using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
62496438|NCT05129189|EXPERIMENTAL|ASC22 group|ASC22 1mg/kg hypodermic injection Q4W+Chidamide 10mg PO BIW
61945649|NCT05072704|EXPERIMENTAL|OFA group|Dexmedetomidine IV infusion
61945650|NCT04610385||ileal conduit|
61945651|NCT04610385||cutaneous ureterostomy|
61945652|NCT02357979|EXPERIMENTAL|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
61945653|NCT02357979|ACTIVE_COMPARATOR|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
62139972|NCT02920034|EXPERIMENTAL|Radiofrequency main and branches|Renal sympathetic denervation of the main renal artery, its branches and accessories using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
62139973|NCT02920034|EXPERIMENTAL|Ultrasound main renal artery|Renal sympathetic denervation of the main renal artery using the ultrasound-based Paradise™ catheter (ReCor, CA, USA)
62139974|NCT01060306||Bare metal stent 1 month|Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation
62139975|NCT01060306||Biodegradable polymer stent 6 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)
62496439|NCT05547048|EXPERIMENTAL|Athena Strategy|Virtual care model that includes direct synchronous videoconferencing with a provider, telephone/ texting communication, electronic health records, e-prescribing for the purposes of delivering PrEP and medications for opioid use disorder. This is combined with a decision aid for PrEP
61945654|NCT03945214|EXPERIMENTAL|Meditation group|Participants in the meditation intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks.
61945655|NCT03945214|EXPERIMENTAL|Healthy eating group|Participants in the healthy eating group will be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
61945656|NCT03945214|EXPERIMENTAL|Mediation + Healthy eating group|Participants in the meditation + healthy eating intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks. They will also be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
61945657|NCT03945214|NO_INTERVENTION|Waitlist control condition|Waitlist control group participants will continue their normal activities and not add any form of mediation during the study period.
61945658|NCT02202525||Essential arterial hypertension|Patients with essential arterial hypertension needing a new antihypertensive therapy
61945659|NCT04857957|EXPERIMENTAL|Cohort 1|300 mg oral dose TID
62139976|NCT01060306||Biodegradable polymer stent 7 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)
62496440|NCT05547048|ACTIVE_COMPARATOR|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
62496441|NCT02824757||known diabetes|Participants have been diagnosed diabetes.
62496442|NCT02824757||known prediabetes|Participants have been diagnosed impaired glucose tolerance or impaired fasting glucose before.
62496443|NCT02824757||normal glucose tolerance|Participants have done the oral glucose tolerance test and been confirmed the normal glucose tolerance.
62496444|NCT02824757||unclear glucose tolerance condition|Participants who have not done oral glucose tolerance test or been diagnosed diabetes before.
61945660|NCT04857957|EXPERIMENTAL|Cohort 2|600 mg oral dose TID
61945661|NCT04857957|EXPERIMENTAL|Cohort 3|800 mg oral dose TID
61945662|NCT04857957|EXPERIMENTAL|PDN cohort|Dose based on safety in healthy Cohorts 1-3
61945663|NCT01083485|EXPERIMENTAL|Tablets Oxycodone Naloxone (OXN)|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)
61945664|NCT01083485|ACTIVE_COMPARATOR|Oxycodone|Oxycodone PR 20mg or 10mg (twice a day) BID for 2.5 days (total 5 dosages)
61945665|NCT03278756|EXPERIMENTAL|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
61945666|NCT03278756|ACTIVE_COMPARATOR|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
61945667|NCT01733784|EXPERIMENTAL|Viscoelastic properties of the airway|
61945668|NCT01854996|EXPERIMENTAL|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
62496445|NCT01071551|EXPERIMENTAL|Lifestyle and health promotion|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
62496446|NCT01071551|ACTIVE_COMPARATOR|Physical activity only|Children allocated to this group will attend physical activity classes only.
61945669|NCT01854996|EXPERIMENTAL|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
61945670|NCT01854996|EXPERIMENTAL|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
61945671|NCT04354103|EXPERIMENTAL|patients with Tourette's syndrome|Atomoxetine in Patients With Tourette's Syndrome
61945672|NCT04154930|EXPERIMENTAL|Restylane-L Treatment|Restylane-L® injected with optional touch-up at 1 month and optional retreatment at 12 months.
61945673|NCT04154930|NO_INTERVENTION|No Treatment Control|No treatment control with optional treatment at 12 months.
62340238|NCT03096002||Lifestyle change (one-treatment group)|The lifestyle change program is a 3-week program that will introduce participants to a regular healthy lifestyle that includes exercising at least three times per week and the program will highlight simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 12 months after the program has concluded.
62340239|NCT02864966|OTHER|Other|This is a safety study where a marketed product will be placed on healthy adult skin.
62340240|NCT06015802||Pituitary neuroendocrine tumors|Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection.
61945674|NCT05544812||experimental|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
61945675|NCT02652065|ACTIVE_COMPARATOR|Healthy skin|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin.~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
61945676|NCT02652065|EXPERIMENTAL|Psoriasis plaque|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back).~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
61945677|NCT02318875|EXPERIMENTAL|Kritech group|Subjects take 1 Kritech capsule per day (dose of 300mg)
61945678|NCT02318875|PLACEBO_COMPARATOR|Placebo group|Subjects take 1 placebo capsule per day
62139977|NCT03877354||Paediatric patients anaesthesia|Paediatric patients who underwent diagnostic or surgical procedure under general anaesthesia with the need for mechanical ventilation in the selected time period.
62340241|NCT05869487|OTHER|X-ray|Whole body x-ray absorptiometry for measurement of appendicular muscle mass in kilograms. Only one measurement per participant.
62340242|NCT03328585|ACTIVE_COMPARATOR|CBT-I in person|
62340243|NCT03328585|EXPERIMENTAL|CBT-I via telemedicine|
62340244|NCT03328585|OTHER|Waitlist Control|Patients in this arm will receive in person CBT-I treatment after conclusion of the study.
62340245|NCT01032993|ACTIVE_COMPARATOR|Coenzyme Q10|600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
62340246|NCT01032993|PLACEBO_COMPARATOR|Placebo|Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
62340247|NCT03496467|ACTIVE_COMPARATOR|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
62340248|NCT03496467|PLACEBO_COMPARATOR|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
62714738|NCT06068517|EXPERIMENTAL|Closed incision negative pressure wound therapy|At the completion of the surgical procedure, the skin will be closed with staples at a distance of two centimeters from each other. After skin closure, ciNPWT will be applied, using a commercially available device. The device will be left in place for 7 days.
61945679|NCT05224089|EXPERIMENTAL|Liposomal Bupivacaine/Bupivacaine HCL|20mL 1.3% Exparel (266mg) + 60mL 0.25% bupivacaine (150mg) + 20mL normal saline. Total 100mL divided into 10mL syringes, 30 mL left TAP, 30mL right TAP, 20mL left rectus, 20mL right rectus.
61945680|NCT05224089|ACTIVE_COMPARATOR|Regular Bupivacaine Arm|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL of normal saline. Total 100mL divided into 10mL syringes, 30mL left TAP, 30mL right TAP, 20mL left rectus, 20mL right rectus.
61945681|NCT04325646||CORSER-1a|Subjects who had been to China in the weeks before the outbreak began
61945682|NCT04325646||CORSER-1b|Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
61945683|NCT04325646||CORSER-2a|Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
61945684|NCT04325646||CORSER-2b|Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
61945685|NCT04325646||CORSER-2c|"Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation.~* study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise~* study among pupils from 5 to 12 and their parents in elementary schools located in Oise~* study among choir members"
61945686|NCT04325646||CORSER-2d|Staff of health care institutions
61945687|NCT04325646||CORSER-2e|Subjects in care, hospitalized or residing in health care facilities
62340249|NCT04254783|EXPERIMENTAL|Cytochrome P450 (CYP) + Risankizumab|In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
62496447|NCT05998980|ACTIVE_COMPARATOR|Componeer Prefabricated Veneers|Componeer veneers (device 1) were randomly applied to patients. The teeth were evaluated in terms of color and size matching in order to select the correct veneers. Componeer sizing guide was used for size selection. Prefabricated veneers were adapted to the teeth' surfaces. Then, the inner surfaces of the prefabricated veneers were roughened to obtain better mechanical retention. Then the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were rinsed and dried. An adhesive system was applied to the teeth. Prefabricated veneers' inner surfaces were cleaned with alcohol, and One Coat dental adhesive was applied. Synergy D6 nanohybrid resin composite was placed on the inner surfaces of the veneers and transferred to the teeth. The restorations were light-cured for 40 s Gingival borders were adapted with contouring and polishing discs (intervention 1).
62496448|NCT05998980|ACTIVE_COMPARATOR|Essentia resin composite venners|Direct resin composite restorations were randomly applied to patients. Essentia resin composite (device 2) shade guide was used for color selection. After the preparation, the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were then rinsed and dried. An adhesive system G-Premio Bond was applied to the teeth. Then Essentia micro-hybrid resin composite with dentin shade was placed on labial surfaces of teeth and was light-cured. Then enamel shade was placed on the tooth. After that, the resin composite veneer was light-cured for 20 s from each surface. Proximal surfaces were polished using proximal sandpaper strips (intervention 2).
62340250|NCT00509496|EXPERIMENTAL|anti-gp100:154-162 TCR PBL + HD IL-2|"1. fludarabine phosphate-25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days~2. cyclophosphamide-60 mg/kg/day x 2 days intravenous~3. Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.~4. aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
62496449|NCT03750695|EXPERIMENTAL|Acute Resistance Exercise|One acute exercise session of 40 minutes of resistance exercise
62496450|NCT03750695|EXPERIMENTAL|Acute Aerobic Exercise|One acute session of 40 minutes of aerobic exercise
62496451|NCT03750695|PLACEBO_COMPARATOR|Acute Resting Session|One session of 40 minutes of quiet rest
62496452|NCT02653235|ACTIVE_COMPARATOR|Typhoid vaccination|Salmonella typhi vaccination
62496453|NCT02653235|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride
62496454|NCT01769222|EXPERIMENTAL|Ipilimumab 25 mg (Phase 1)|Participants receive ipilimumab intratumorally on Day 1
62496455|NCT01769222|EXPERIMENTAL|Ipilimumab 25 mg and radiation therapy (Phase 2)|Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions
62496456|NCT05852873|ACTIVE_COMPARATOR|Nirmatrelvir-ritonavir|Participants will receive a standard 5-day treatment course nirmatrelvir plus ritonavir in addition to standard of care. The participants will receive 2 tablets nirmatrelvir 150 mg twice daily and 1 tablet ritonavir 100mg twice daily, both for a duration of 5 days. The tablets have been encapsulated to maintain blinding.
62496457|NCT05852873|PLACEBO_COMPARATOR|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets in addition to standard of care. The participants will receive 3 tablets twice daily for 5 days. The placebo tablets have the same shape and appearance as the active comparator product. The tablets containing placebo and active comparato have both been encapsulated in the same way to maintain blinding.
62496458|NCT04742608||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples on the day of surgery following anesthesia but prior to incision and at the first routine blood test following surgery. Patients who undergo remnant ablation after total thyroidectomy with radioactive iodine have an additional blood sample collected. Patients also undergo collection of tissue samples following surgical resection of thyroid nodule or thyroid cancer. Patients' medical records are also reviewed.
62496459|NCT05198635||Group 1|
62496460|NCT05198635||Group 2|
62496461|NCT00218335|EXPERIMENTAL|Intervention Condition|Participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
62496462|NCT00218335|ACTIVE_COMPARATOR|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
61945688|NCT04325646||CORSER-3|Subjects returning from a humanitarian mission that started before 31/01/2020
61945689|NCT04325646||CORSER-2f|Subjects with two symptomatic episodes of SARS-CoV-2 infection
61945690|NCT04325646||CORSER-4|Subjects being vaccinated against COVID-19
62496463|NCT04711317|EXPERIMENTAL|Preoxygenation with nasal high flow oxygen|Preoxygenation with nasal high flow oxygen
61945691|NCT04325646||CORSER-5|Subjects with acute SARS-CoV-2 infection and uninfected controls
61945692|NCT04894695||healthy control (HC)|healthy control
61945693|NCT04894695||Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus
61945694|NCT04894695||lupus nephritis (LN)|lupus nephritis
61945695|NCT00810108|EXPERIMENTAL|Whole Then Crushed Tablets|These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.
61945696|NCT00810108|EXPERIMENTAL|Crushed Then Whole Tablets|These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.
61945697|NCT03917459|EXPERIMENTAL|LCZ696|LCZ696 200 mg (sacubitril/valsartan 97 mg/103 mg bid)
61945698|NCT03917459|ACTIVE_COMPARATOR|Enalapril|Enalapril 10 mg
61945699|NCT00238888|EXPERIMENTAL|Asthma control awareness|Multifaceted intervention to increase the patient awareness of the leve of asthma control
61945700|NCT00238888|ACTIVE_COMPARATOR|Usual care|Usual care
61945701|NCT00074984|PLACEBO_COMPARATOR|Placebo|Patients randomized to placebo
61945702|NCT00074984|ACTIVE_COMPARATOR|Fabrazyme (agalsidase beta)|Patients randomized to Fabrazyme (agalsidase beta).
62496464|NCT04711317|NO_INTERVENTION|Control group|Standard preoxygenation according to hospital protocol with tight fitting facemask
62496465|NCT03968016|PLACEBO_COMPARATOR|Healthy|Control group
61945703|NCT05235451|EXPERIMENTAL|Intervention group|The 2 HAI intervention reading groups will receive visits from a registered canine team during children's small group reading sessions twice a week over 12 weeks.
61945704|NCT05235451|NO_INTERVENTION|Control group|The 2 control reading groups will receive care as usual and offered a 1-time visit from the dog at the end of the study (after T3 completed).
61945705|NCT05193552|NO_INTERVENTION|Control Group|11 subjects will be treated for 6 months at their current dose of Hizentra
62340251|NCT00509496|EXPERIMENTAL|anti-gp100:154-162 TCR TIL + HD IL-2|"1. fludarabine phosphate-25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days~2. cyclophosphamide-60 mg/kg/day x 2 days intravenous~3. Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes~4. aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
62340252|NCT02969850|EXPERIMENTAL|Vitamin D Supplementation|Participant will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
62496466|NCT03968016|ACTIVE_COMPARATOR|Stable heart disease|Stable heart disease and non-hospitalized
62496467|NCT04064827|EXPERIMENTAL|Participants Receiving Paricalcitol|Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks
62496468|NCT06253481||Group I: patients diagnosed with various types of ASCVD|Group I: Patients diagnosed with various types of ASCVD (\> 50% stenosis caused by atherosclerotic plaque) of various vascular beds (coronary vessels, carotid arteries, mesenteric arteries, lower extremities, and kidneys) (case; n=6500).
62496469|NCT06253481||Group II: patients with no clinically significant ASCVD (control, n=3500)|Group II: patients with no ultrasound/ angiography findings of ASCVD (control, n=3500)
62496470|NCT02991313|EXPERIMENTAL|Endocardial Ablation Procedure|ablation with Linear type catheter
62496471|NCT01418235|EXPERIMENTAL|Group 1: MVA-C + gp140/MF59|
62496472|NCT01418235|EXPERIMENTAL|Group 2: MVA-C + gp140/MF59|
62340253|NCT02969850|PLACEBO_COMPARATOR|Placebo|Participant will receive a placebo. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
62340254|NCT04958421|NO_INTERVENTION|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
61945706|NCT05193552|EXPERIMENTAL|Treatment Group|11 subjects will have their level of immunoglobulin replacement therapy increased by the equivalent of 0.05 gm/kg in dose per 4 weeks, adjusted for bioavailability as per manufacturer's instructions. On average, rounded up to the nearest gram, this will typically increase their dose of Hizentra by 2 gm per week.
61945707|NCT03221270|EXPERIMENTAL|tACS Treatment & tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 20 minutes twice daily during 5 consecutive days of stimulation. 10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.
62340255|NCT04958421|EXPERIMENTAL|PiCSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
62340256|NCT01123577|EXPERIMENTAL|Intervention|
62340257|NCT01123577|NO_INTERVENTION|Control|Participants receive usual care by providers.
62496473|NCT01418235|EXPERIMENTAL|Group 3: DNA-C2 + MVA-C|
62496474|NCT01418235|EXPERIMENTAL|Group 4: DNA-C2 + MVA-C + gp140/MF59|
62496475|NCT00998595|EXPERIMENTAL|Promotora|This group receives additional education and proactive follow-up by removing barriers to already existing services and reminders by a lay community health workers (Promotora)
62496476|NCT00998595|NO_INTERVENTION|Standard of Care|These subjects receive the routine standard of postpartum care
62496477|NCT04807062|EXPERIMENTAL|DTPFs treated with structural bicortical autologous ICBG combined with TBTM|
62496478|NCT06562543|EXPERIMENTAL|Fruquintinib 5 mg|Participants will receive fruquintinib capsule at a dose of 5 mg, orally (PO), once daily (QD), for the first 21 days of each 28-day treatment cycle until progressive disease (PD), unacceptable toxicity, or other discontinuation criteria are met.
62496479|NCT01239498|EXPERIMENTAL|Saline + Lidocaine/Adrenaline|
62496480|NCT01239498|PLACEBO_COMPARATOR|Lidocaine/Adrenaline only|
62139978|NCT03877354||Paediatric patients intensive care|Paediatric patients admitted to the paediatric intensive care unit with the need for mechanical ventilation in the selected time period
62496481|NCT01223027|EXPERIMENTAL|Dovitinib + best supportive care (BSC)|Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.
62496482|NCT01223027|ACTIVE_COMPARATOR|Sorafenib + BSC|Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.
62496483|NCT05485727|EXPERIMENTAL|RG(Robotic group= study group)|14, Robotic-assisted gait training group (RG) will receive Lokomat gait training and conventional physiotherapy
62496484|NCT05485727|ACTIVE_COMPARATOR|& CG( Control group)|control group (CG) will only receive conventional physiotherapy
62496485|NCT04754555||subacute phase|between 7 days and 6 months post-stroke;
62496486|NCT04754555||chronic phase|minimum 6 months post-stroke
62496487|NCT03969108|EXPERIMENTAL|Indocyanine Green|
62496488|NCT02408536||Single cohort|Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
62340258|NCT01934894|EXPERIMENTAL|cabazitaxel and lapatinib combination|"* Cabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)~* Lapatinib PO once daily (dose to be determined)~Treatment cycles will be repeated every 3 weeks."
62340259|NCT00983840|EXPERIMENTAL|Family Eats|8-session program on health eating
62340260|NCT00983840|ACTIVE_COMPARATOR|Family eats- plain|Family eats without role model stories and goal setting
62340261|NCT01684475|EXPERIMENTAL|Treatment with CJH1|
62496489|NCT04204096|EXPERIMENTAL|Vi-DT Multi-dose|"* 750 participants (6 mo - 45 yrs)~* Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~* Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (multi-dose formulation Vi-DT contains preservative 2 PE)~* Mode of Administration: Intramuscular injection~* Frequency of administration: Once"
62496490|NCT04204096|EXPERIMENTAL|Vi-DT Single-dose|"* 750 participants (6 mo - 45 yrs)~* Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~* Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (single dose formulation Vi-DT without any preservative)~* Mode of Administration: Intramuscular injection~* Frequency of administration: Once"
61945708|NCT03221270|SHAM_COMPARATOR|Sham tACS Treatment & Sham tACS Maintenance|10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation. 10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation once weekly for 8 weeks of maintenance stimulation.
61945709|NCT03221270|OTHER|Sham tACS Treatment & tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.
61945710|NCT03221270|OTHER|tACS Treatment & Sham tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 20 minutes twice daily during 5 consecutive days of stimulation. 10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation once weekly for 8 weeks of maintenance stimulation.
61945711|NCT00033774||1|Eligible healthy volunteers 18 and older
61945712|NCT05433012|OTHER|Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T|
61945713|NCT03314142|EXPERIMENTAL|Glucose as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61945714|NCT03314142|EXPERIMENTAL|White bread as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62139979|NCT04271774||Infants with ASD-affected sibling|Infants, enrolled at 0-6 months of age, who have a sibling diagnosed with ASD.
62340262|NCT02622724|EXPERIMENTAL|FP-1201-lyo 10 μg|"FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
62340263|NCT02622724|PLACEBO_COMPARATOR|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection."
62340264|NCT02856685|EXPERIMENTAL|PLM60|Mitoxantrone Hydrochloride Liposome
62340265|NCT05392894|ACTIVE_COMPARATOR|Standard of care|The comparator arm is standard medical care for this patient population. Standard medical care may include all currently available non-trial therapies for SCD.
62340266|NCT05392894|EXPERIMENTAL|Haploidentical stem cell transplantation|Participants receiving Haploidentical Stem Cell Transplantation will receive the transplant conditioning regimen as per the standard transplant protocol. Stem cells from a haploidentical donor will be infused on Day 0 according to standard institutional practices. Bone marrow is the preferred stem cell source however peripheral blood may be used as an alternative where required due to donor reasons.
62340267|NCT02276521||Zero dose group|Participants that did not received any HPV vaccine previously.
62496491|NCT04204096|ACTIVE_COMPARATOR|Control|"* 300 participants (6 mo - 45 yrs)~* Dose: 0.5mL, Locally available Meningococcal conjugate vaccine~* Dosage form: Lyophilized white powder~* Mode of Administration: Intramuscular injection~* Frequency of administration: Once (For participants 6 months to 1 year, one more dose will be provided after the study unblinding)"
62496492|NCT06075849|EXPERIMENTAL|PB101|A total of 6 cohorts are planned, and each dose escalation will proceed in a traditional 3+3 scheme.
62496493|NCT02349022|EXPERIMENTAL|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
62496494|NCT04666753||ImmunoFormulation cohort|"Patients treated\* with IMUNO TF® with a combination of nutraceuticals.~\*Without restrictions on the adjuvant treatment received."
62496495|NCT04666753||Control cohort|"Control cohort: patients not treated\* with IMUNO TF® with a combination of nutraceuticals.~\*Without restrictions on the adjuvant treatment received."
62340268|NCT02276521||One dose group|Participants that received one dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
62340269|NCT02276521||Two dose group|Participants that received two dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
62340270|NCT02276521||Three dose group|Participants that received three dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
62697834|NCT03242447|ACTIVE_COMPARATOR|Video Health Group|The Video Health Group is the control counterfactual condition. Youth assigned to the control group will view a video on a non-sexual health topic (the hazards of smoking).The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes. The informational video uses both narration and interviews to educate viewers on the dangers that cigarettes pose.
62697835|NCT02015130|EXPERIMENTAL|individual treatment|Individualized treatment
62697836|NCT02015130|NO_INTERVENTION|control group|treatment according to current national guidelines
62697837|NCT02714751|NO_INTERVENTION|Observational group|
62340271|NCT02366754|EXPERIMENTAL|Active rTMS|The intervention consists of 30 active rTMS sessions. Each session is comprised of 300 trains of paired pulses with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Pulse intensity will be set at 110% of each participant's motor threshold. Active rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left dorsolateral prefrontal cortex. Two Magstim-2002 units and a Bistim2 module will be used to administer active rTMS. Participants assigned to the active rTMS group will receive a total of 1.8 seconds of stimulation. Active rTMS will be administered 2 times daily with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
61945715|NCT03314142|EXPERIMENTAL|Bread enriched with coarse wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62340272|NCT02366754|SHAM_COMPARATOR|Placebo rTMS|The intervention consists of 30 placebo rTMS sessions. Each session is comprised of 300 paired-pulse trains with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Placebo rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left DLPFC. Two Magstim-2002 units and a Bistim2 module will be used to administer placebo rTMS. The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. Participants assigned to the placebo rTMS group will receive 0 seconds of stimulation. Placebo rTMS will be administered with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
62340273|NCT04343313|EXPERIMENTAL|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
62340274|NCT04742270|EXPERIMENTAL|SIMEOX+ respiratory physiotherapy telecare|Use the device for 3 months in addition to usual care
62340275|NCT04676945||untreated control group|NO MDS disease modifying therapy
62340276|NCT04676945||treated patients|ANY MDS disease modifying therapy
62340277|NCT00717366|EXPERIMENTAL|MIRCERA Group 1: Intermediate-Conversion-Factor Group|Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 \* previous weekly epoetin dose \[international units {IU}\]/250 or 4 \* previous weekly darbepoetin alfa dose \[micrograms {mcg}\]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
62340278|NCT00717366|EXPERIMENTAL|MIRCERA Group 2: High-Conversion-Factor Group|Participants will receive MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 \* previous weekly epoetin dose \[IU\]/125 or 4 \* previous weekly darbepoetin alfa dose \[mcg\]/0.55) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with Hb within ± 1 g/dL of their baseline Hb and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
61945716|NCT03314142|EXPERIMENTAL|Bread enriched with fine wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62139980|NCT06117085|EXPERIMENTAL|Percutaneous Treatment Arm|CellFX Percutaneous Treatment under ultrasound guidance using nanosecond Pulse Field Ablation (nsPFA)
62139981|NCT00856700|EXPERIMENTAL|GLP-1 infusion|Patients with metabolic syndrome
62340279|NCT02550314|EXPERIMENTAL|NPC-18,FBG-18|"Intervention drug:~NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue~Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane"
62496496|NCT04846686||preeclampsia group|"25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized.~Placenta pathological examination will be performed."
62697838|NCT02714751|OTHER|Group after information intervention|Control group after daily information to healthcare team
62697839|NCT00480727|PLACEBO_COMPARATOR|Control|No fortnightly re-tensioning. Placebo treatment utilises the re-tensioning procedure, pt experiences clicking sensation, however, the pin is not tightened.
62697840|NCT00480727|EXPERIMENTAL|Treatment (Re-tensioning) Group|Pins are re-tensioned fortnightly back to initial fitting tension of 8lb/inch.
62697841|NCT04200963|EXPERIMENTAL|IK-175 Single Agent Dose Escalation|Approximately 5 dose escalation steps are planned during the Single Agent Treatment dose escalation phase of the study. (COMPLETE)
62697842|NCT04200963|EXPERIMENTAL|IK-175 Single Agent Dose Expansion|A Single Agent Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D. (COMPLETE)
61945717|NCT03314142|EXPERIMENTAL|Bread enriched with fine wheat and carob|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61945718|NCT04172623|EXPERIMENTAL|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
61945719|NCT04172623|ACTIVE_COMPARATOR|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
61945720|NCT03600701|EXPERIMENTAL|Treatment (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1, and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Patients also undergo a CT scan, MRI, biopsy, and collection of blood throughout the trial.
61945721|NCT01413061|ACTIVE_COMPARATOR|AlloStem Live Cellular Allograft|AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.
61945722|NCT01413061|ACTIVE_COMPARATOR|Control: Autologous Bone Marrow Aspirate|Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.
61945723|NCT04046055|EXPERIMENTAL|Sham and Experimental Sessions|"50% of participants will have a unilateral cerebellar montage with the anode (active electrode) three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode (return electrode) on the ipsilateral cheek. 50% of participants will have a bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned (2 mA) on for the 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.~A unilateral cerebellar montage will be applied. tDCS intensity will be 2 mA. Bilateral cerebellar tDCS will be applied. tDCS intensity will be 2 mA. A unilateral cerebellar montage will be applied. tDCS intensity will be 4 mA. Bilateral cerebellar tDCS will be applied. tDCS intensity will be 4 mA."
61945724|NCT01846390|EXPERIMENTAL|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
62496497|NCT04846686||control group|"10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized.~Placenta pathological examination will be performed."
61945725|NCT04726670||A Comparison of Pain Levels|A Comparison of Pain Levels at different time intervals according to the Irrigation Activation Protocols
61945726|NCT04726670||The evaluation of postoperative pain (Mean Rank) within the group according to time periods|The evaluation of postoperative pain (Mean Rank) within the group according to time periods
61945727|NCT01384942|EXPERIMENTAL|Meaning-Based Bereavement Group|
61945728|NCT01384942|ACTIVE_COMPARATOR|Conventional Bereavement Group|
61945729|NCT01570088|ACTIVE_COMPARATOR|Folic acid|
61945730|NCT01570088|EXPERIMENTAL|L-5-MTHF|
61945731|NCT01570088|PLACEBO_COMPARATOR|Placebo|
61945732|NCT02508831|EXPERIMENTAL|Bilateral amputation of upper limb|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
62139982|NCT00428805|EXPERIMENTAL|intervention 1|This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
62139983|NCT00428805|NO_INTERVENTION|control 2|measurement only control arm
62496498|NCT03275623|ACTIVE_COMPARATOR|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
62496499|NCT03275623|ACTIVE_COMPARATOR|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
62139984|NCT02408887|ACTIVE_COMPARATOR|Arm 2/Total Thyroidectomy (TT) Plus Prophylactic Central Neck Dissection (pCND)|TT plus pCND
62139985|NCT02408887|ACTIVE_COMPARATOR|Arm 1/Total Thyroidectomy (TT) alone|TT alone
62697843|NCT04200963|EXPERIMENTAL|IK-175 and nivolumab Combination Dose Escalation|Approximately 2 dose escalation steps are planned during the Combination Treatment dose escalation phase of the study. (COMPLETE)
62697844|NCT04200963|EXPERIMENTAL|IK-175 and nivolumab Combination Dose Expansion|A Combination Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D. (COMPLETE)
62139986|NCT03158415|EXPERIMENTAL|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
62139987|NCT04535856|EXPERIMENTAL|Low-dose group|"Low-dose group (5 x 10\^7cells):~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 2 vials for low-dose group"
62496500|NCT05726162|ACTIVE_COMPARATOR|Control|Patients sleep as usual with noise-canceling earplugs
62496501|NCT05726162|EXPERIMENTAL|Biofeedback-based music|Patient is provided with a biofeedback-based music program using a smart device application for sleep.
62496502|NCT01711567|ACTIVE_COMPARATOR|entecavir|standard drugs
62496503|NCT01711567|ACTIVE_COMPARATOR|tenofovir|study drugs
62697845|NCT02979990|PLACEBO_COMPARATOR|Control Video|Subjects will have access to general videos on the in vitro fertilization process. They will not have access to instructional videos related to the administration of controlled ovarian stimulation.
61945733|NCT05901454|OTHER|intervention arm|yellow fever vaccine arm (all participants receive the standard yellow fever vaccine (Stamaril)
61945734|NCT02279446||20/20ND group|This group will have 20/20 visual acuity both in distant and near.
61945735|NCT02279446||20/20D group|This group will have 20/20 distant visual acuity and variable near visual acuity.
61945736|NCT02279446||20/20N group|This group will have 20/20 near visual acuity and variable distant visual acuity.
61945737|NCT02279446||s20/20ND group|This group will have variable near and distant visual acuity (both less than 20/20)
61945738|NCT03343379|OTHER|Healthy cohort|Core stability test
61945739|NCT01978418|PLACEBO_COMPARATOR|Placebo|Placebo is administered once, at 30-60 minutes of age
61945740|NCT01978418|ACTIVE_COMPARATOR|Intervention|Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age
61945741|NCT00214760|EXPERIMENTAL|PGET|
61945742|NCT00214760|ACTIVE_COMPARATOR|PMMA|
61945743|NCT03027102|EXPERIMENTAL|Patient Arm|Patients will receive DNT cells from healthy donors.
62340280|NCT04257955||Pancreatic cancer|"Outpatients seen at the Gastroenterology, Pancreatic Surgery and Oncology Clinics of the Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele, Milan (Italy) will be considered includable if:~1. Adult patients (≥18 years);~2. Of Italian mother tongue;~3. Have a histologic diagnosis of PDAC obtained during the 4 weeks before the visit~4. The visit is the first visit after completion of diagnostic procedures and is set to communicate the diagnosis and treatment strategies~5. Give full, written informed consent~The following exclusion criteria will be applied:~1. PDAC recurrence after previous diagnosis and treatment~2. poor performance status (ECOG ≥ 3);"
62340281|NCT00668304|EXPERIMENTAL|Arm 1|
62340282|NCT03754062|PLACEBO_COMPARATOR|Placebo|Placebo control
61945744|NCT03027102|NO_INTERVENTION|Donor Arm|Healthy volunteer donors will donate blood.
62496504|NCT00942734|EXPERIMENTAL|RAD001 + Erlotinib|RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.
62697846|NCT02979990|EXPERIMENTAL|Experimental Video|Subjects will be asked to view instructional videos related to the administration of controlled ovarian stimulation medication during their own controlled ovarian stimulation
61945745|NCT03380715|ACTIVE_COMPARATOR|right nostril in patients with rhinitis|Intervention : Administration of either 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity or
61945746|NCT03380715|NO_INTERVENTION|Left nostril in patients with rhinitis|No nasal decongestion administration into the left nostril
61945747|NCT03380715|ACTIVE_COMPARATOR|Right nostril in patients with rhinitis|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
62340283|NCT03754062|EXPERIMENTAL|Haloperidol 3mg|Haloperidol
62496505|NCT00929006|EXPERIMENTAL|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
62496506|NCT00929006|PLACEBO_COMPARATOR|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
62496507|NCT02285491|EXPERIMENTAL|bupivacaine group|This is the group of patients that will receive 10ml of bupivacaine 0.5% injection in both angles of the rectus sheath incision
62496508|NCT02285491|PLACEBO_COMPARATOR|saline group|This group will receive saline injections as placebo into both angles of the rectus sheath incision
62496509|NCT02285491|EXPERIMENTAL|bupivacaine and saline group|This group will receive saline injection in one angle and 10ml of bupivacaine 0.5% injection in the opposite angle.
61945748|NCT04354142|EXPERIMENTAL|iSpy|In addition to usual care, participants in the intervention group will receive the iSpy intervention.
62340284|NCT03754062|EXPERIMENTAL|L-Dopa 150 mg & Domperidone 10mg|L-Dopa
61945749|NCT04354142|NO_INTERVENTION|Control|The control group participants will continue to use their usual method of carbohydrate counting for a 3-month period.
61945750|NCT03177057|EXPERIMENTAL|Arm I (self-monitoring)|ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.
61945751|NCT03177057|EXPERIMENTAL|Arm II (text messages)|ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.
61945752|NCT03177057|EXPERIMENTAL|Arm III (self-monitoring, text messages)|ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.
61945753|NCT03177057|SHAM_COMPARATOR|Arm IV (questionnaire administration)|ARM IV (CONTROL GROUP): Patients complete study assessments.
61945754|NCT04811378|ACTIVE_COMPARATOR|HaemoCer|
61945755|NCT04811378|NO_INTERVENTION|No HaemoCer|
61945756|NCT04139668|EXPERIMENTAL|Vivitrol + MET/CBT|All participants will receive three 4ml doses of extended-release naltrexone 380mg (Vivitrol), administered by intramuscular injection. Three injections will be administered to each participant; one injection every 4 weeks for 12 weeks of treatment. In addition, all participants will receive weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy for 12 weeks.
61945757|NCT01141452||IPDA FP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as fluticasone via metered dose inhaler
61945758|NCT01141452||IPDA HFA-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as extra-fine hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
62340285|NCT00247182|OTHER|Step 1|Minimal Intervention
62340286|NCT00247182|ACTIVE_COMPARATOR|Step 2-A|Brief motivational intervention (BMI)
62340287|NCT00247182|ACTIVE_COMPARATOR|Step 2-B|Assessment-only control
62496510|NCT05984823|EXPERIMENTAL|Intervention group|Body weight exercise with blood flow restriction
62496511|NCT05984823|ACTIVE_COMPARATOR|Exercise only group|Body weight exercise only
61945759|NCT01141452||IPDA CFC-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
61945760|NCT01141452||IPDI CFC-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
62496512|NCT06679218|EXPERIMENTAL|Activity Coaching Programme|
62496513|NCT06679218|ACTIVE_COMPARATOR|Standard medical care and leaflet education|
62496514|NCT03142620|ACTIVE_COMPARATOR|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
62496515|NCT03142620|ACTIVE_COMPARATOR|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 10 days"
62496516|NCT03142620|ACTIVE_COMPARATOR|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 28 days"
62496517|NCT02364258|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
62496518|NCT02364258|EXPERIMENTAL|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
62496519|NCT00365690|ACTIVE_COMPARATOR|1|Participants will receive individual therapy upon request
61945761|NCT01141452||IPDI HFA-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
61945762|NCT01141452||IPDI FP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as fluticasone propionate via metered dose inhaler
62496520|NCT00365690|ACTIVE_COMPARATOR|2|Participants will receive telephone-administered supportive-expressive group therapy
62139988|NCT04535856|EXPERIMENTAL|High-dose group|"High-dose group (1 x 10\^8 cells):~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 4 vials for High-dose group"
62340288|NCT00815906|EXPERIMENTAL|SBI-087 0.15 mg IV|
62340289|NCT00815906|EXPERIMENTAL|SBI-087 0.5 mg IV|
62340290|NCT00815906|EXPERIMENTAL|SBI-087 100 mg SC|
62340291|NCT00815906|EXPERIMENTAL|SBI-087 200 mg SC|
62340292|NCT00240188|OTHER|1|
62340293|NCT02059213|ACTIVE_COMPARATOR|ADT Alone|Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
62340294|NCT02059213|EXPERIMENTAL|ADT + Ibrance®|Ibrance® (125mg taken daily by mouth days 1-21 of a 28 day cycle) in addition to Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
62139989|NCT04535856|PLACEBO_COMPARATOR|Control group (placebo)|"Control group (placebo):~No Drug substance: 4 vials for Place group"
62139990|NCT02080585|NO_INTERVENTION|Control group without advice|Control group receives no intervention or physical activity advice.
62139991|NCT02080585|EXPERIMENTAL|Computer-tailored physical activity advice|Subjects receive computer-tailored physical activity advice.
62139992|NCT03958019|EXPERIMENTAL|Intervention Group|12 week multidisciplinary program consisting of; i) supervised and home-based aerobic and resistance training, ii) 1:1 dietary counselling, and iii) group education sessions.
62139993|NCT03958019|NO_INTERVENTION|Control|Usual care control group
62139994|NCT01818869|EXPERIMENTAL|AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
62139995|NCT01818869|PLACEBO_COMPARATOR|Placebo to match AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
62139996|NCT06258044||maligant|Thyroid nodules with surgical or puncture biopsy-confirmed pathological findings of malignancy in the TI-RADS4 category
62139997|NCT06258044||benign|Thyroid nodules with surgical or puncture biopsy-confirmed pathological findings of benign TI-RADS4 category
62340295|NCT01666691|PLACEBO_COMPARATOR|Placebo|ZGN-440 sterile diluent
62340296|NCT01666691|EXPERIMENTAL|0.3 mg Beloranib|0.3 mg ZGN-440 for injectable suspension
62340297|NCT01666691|EXPERIMENTAL|0.6 mg Beloranib|0.6 mg ZGN-440 for injectable suspension
62340298|NCT01666691|EXPERIMENTAL|1.2 mg Beloranib|1.2 mg ZGN-440 for injectable suspension
62340299|NCT01666691|EXPERIMENTAL|2.4 mg Beloranib|2.4 mg ZGN-440 for injectable suspension
62340300|NCT01666691|EXPERIMENTAL|3.2 mg Beloranib|3.2 mg ZGN-440 for injectable suspension
62340301|NCT01746888||Older Adults|Adults 65 years and older who present to the Emergency Department.
62496521|NCT00365690|EXPERIMENTAL|3|Participants will receive telephone-administered coping improvement group therapy
62496522|NCT04002869||Active TB suspicion|This study will include both adults and children with suspicion of different degrees of severity of active TB (pulmonary and extrapulmonary) to bring the investigator's study population into line with the routine clinical practice and to avoid the spectrum bias
62496523|NCT04002869||Latent TB infection|Individuals with latent TB infection (adults and children), with positive TST and/or IGRAs; without any sign or radiological evidence of TB disease or any clinical picture compatible with the criteria defined in the section TB cases.
62496524|NCT04002869||NTM infection|Adult and pediatric patients with lymphadenopathies caused by NTMs or individuals with chronic respiratory diseases with a NTM microbiologically confirmed by culture isolation.
62496525|NCT04002869||Uninfected control|Both adult and children without active TB and no immunologic evidence of M. tuberculosis infection, with negative TST and/or IGRAs
62697847|NCT04660344|EXPERIMENTAL|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
61945763|NCT03267836|EXPERIMENTAL|Avelumab + Proton Therapy|"* Avelumab will be started concurrently with proton therapy (up to 3 days before or after is permissible) and administered every 2 weeks for 3 months~* Proton therapy 20 CGE (cobalt gray equivalent) will be given over 5 daily fractions of 4 CGE per day during weekdays~* After 3 months of avelumab, patient will have a brain MRI evaluation, and radiological response will be assigned based on the iRANO criteria. Surgery will be performed as per routine clinical care~* If the brain MRI after 3 months of avelumab shows complete response with no signs of residual tumor, no surgery will be indicated, and the patient may continue to take adjuvant avelumab for an additional 3 months.~* After the patient has recovered from the surgery and if deemed medically eligible by the treating physician to receive additional immunotherapy, avelumab will be restarted and administered every 2 weeks for an additional 3 months"
61945764|NCT01235624|OTHER|patient|Patient suffering of adRP that accept to participate at this study have a blood prelevement for genetic analysis (intervention)
61945765|NCT01937754|ACTIVE_COMPARATOR|Nitric Oxide supplement|
61945766|NCT01937754|PLACEBO_COMPARATOR|Placebo|
61945767|NCT06438302||Major mechanically ventilated patients intubated orotracheally|The study population will be adult patients with acute respiratory failure who are orally intubated and sedated. These patients should be free of neurological and psychiatric diseases prior to ICU admission. The choice of this particular population is justified by its exposure to mechanical ventilation and continuous sedation, which are recognized risk factors for brain damage.
61945768|NCT02182102|EXPERIMENTAL|BIBF 1120 + Pemetrexed|
61945769|NCT03715101|EXPERIMENTAL|Rosuvastatin 20 mg PO|Rosuvastatin 20 mg daily for 21 days
61945770|NCT02249442|EXPERIMENTAL|Scheme A, mild hepatic subjects|multi-dose
61945771|NCT02249442|EXPERIMENTAL|Scheme B, moderate hepatic subjects|single dose
61945772|NCT03764007|EXPERIMENTAL|18F-Fluorocholine PET|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
62139998|NCT04759833|PLACEBO_COMPARATOR|Part A: Placebo|Participants weighing \<50 kilograms (kg) will draw equal volumes from two bottles of placebo oral solution to account for the daily dose assigned or participants weighing ≥ 50 kg will receive two placebo oral tablets, once daily (QD), during 12 weeks in Part A. Prucalopride matching placebo (oral solution or tablet) will be dosed depending on the participant's body weight (BW) at the randomization visit.
62340302|NCT03488914|OTHER|Intervention|The YMHP intervention is a 4 session Motivational Interviewing (MI) intervention. In session 1, youth will choose which behavior to discuss first (substance use or sexual risk behavior), and the Health Educator counselor will elicit the client's view of the problem using standard MI techniques, building motivation for change by eliciting and reinforcing change talk, and clarifying the youth's own personal goals for maintaining their sexual health/considering changes in their substance use. The second session follows the same format for the second target behavior. In the subsequent two sessions, the counselor will discuss Pre-exposure Prophylaxis (PrEP) uptake as part of a change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
62340303|NCT03488914|OTHER|Enhanced Treatment as Usual|The Enhanced Treatment as Usual arm involves referring youth to standard of care services available at the community based organization for substance use and sexual health. This includes available services for Pre-exposure prophylaxis.
62340304|NCT06324279||term pregnant women with Singleton living fetus attending for induction of labor|
62340305|NCT02236949|EXPERIMENTAL|Pain Practice Change Booster|Pain Practice Change Booster Intervention: 12 months after the EPIQ intervention, and every 4 months for 2 years, a 30-60 minute standardized booster session was delivered to a small group of champions in each hospital unit randomized to the intervention group. Two co-facilitators familiar with the EPIQ intervention conducted all booster sessions via teleconference. Booster sessions included reviewing the effectiveness knowledge translation strategies champions implemented over the past four months to sustain and improve targeted pain practices; determining the sustainability of the pain practice changes, developing a commitment to change plan of action for the next four months.
62340306|NCT02236949|NO_INTERVENTION|Usual Care Group|No interventions associated with the study were conducted on these units.
62340307|NCT05864183||case group|prediabetic
62340308|NCT05864183||control group|non prediabetic
62340309|NCT01325324|OTHER|Study group|Study group
62340310|NCT03225716|EXPERIMENTAL|Phase 1 Dose level 1: Ibrutinib + Ulocuplumab 400mg Cycle 1 and 800mg Cycles 2-6|"* Ibrutinib administered orally once daily for 48 cycles~* Ulocuplumab administered intravenously at 400mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 800mg for Cycles 2-6 on Days 1 and 15."
62340311|NCT03225716|EXPERIMENTAL|Phase 1 Dose level 2: Ibrutinib + Ulocuplumab 800mg Cycle 1 and 1200mg Cycles 2-6|"* Ibrutinib administered orally once daily for 48 cycles~* Ulocuplumab administered intravenously at 800mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 1200mg for Cycles 2-6 on Days 1 and 15."
62340312|NCT03225716|EXPERIMENTAL|Phase 1 Dose level 3: Ibrutinib + Ulocuplumab 800mg Cycle 1 and 1600mg Cycles 2-6|"* Ibrutinib administered orally once daily for 48 cycles~* Ulocuplumab administered intravenously at 800mg for Cycle 1 on Days 1, 8, 15, and 22. Ulocuplumab administered IV at 1600mg for Cycles 2-6 on Days 1 and 15."
61945773|NCT01479127|EXPERIMENTAL|Levodopa-carbidopa intestinal gel|"Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks.~The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms."
61945774|NCT06199336|EXPERIMENTAL|Treatment Group|Single injection with JHM03 in glabellar lines
61945775|NCT06199336|ACTIVE_COMPARATOR|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
61945776|NCT06199336|PLACEBO_COMPARATOR|Placebo-Controlled Group|Single injection with Placebo in glabellar lines.
62496526|NCT04002869||Other respiratory diseases|Subjects with ARIs, and subjects with lung cancer; without any clinical picture compatible with the criteria defined in TB cases section. Patients with ARIs will be identified as individuals with clinical signs, symptoms and radiology of respiratory infections, and microbiological confirmation of non-TB origin. Patients with lung cancer will be identified as those with a high clinical suspicion, a suggestive chest X-ray/computed tomography scan, and a confirmed histopathological/cytological diagnosis
62340313|NCT04086069|EXPERIMENTAL|Standard Training+Sit-to-stand trainer|Training using a sit-to-stand trainer device in addition to standard training of standing-up with the help of a physiotherapist
62496527|NCT00052949|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
62496528|NCT02355262||Arm I (Independent Tool Implementation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline.
61945777|NCT01227317||Acute dyspnea in ED|Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
62340314|NCT04086069|NO_INTERVENTION|Standard Training|Standard training of standing-up with the help of a physiotherapist
62340315|NCT01238133|EXPERIMENTAL|Treatment (RO4929097, paclitaxel, carboplatin, surgery)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17, paclitaxel IV over 60 minutes on days 1, 8, and 15 (day -1 of course one), and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after completion of neoadjuvant therapy, patients undergo definitive breast surgery.
62340316|NCT04429685|EXPERIMENTAL|Low Dose Ketamine|
62340317|NCT04429685|PLACEBO_COMPARATOR|Saline (placebo)|
62340318|NCT05328856|ACTIVE_COMPARATOR|Vital shower|Participants receive the installation of a shower prototype from Hansgrohe and training including a handout. After installation, participants are asked to shower daily for four weeks according to a predefined shower protocol with alternating warm and cold water application.
62340319|NCT05328856|NO_INTERVENTION|Regular shower|Participants are advised not to change their showering behaviour; at the end of the study, the participants receive an offer of a shower head for free.
62340320|NCT02261012||30 healthy probands|group without the condition of interest
62340321|NCT02261012||30 CRPS patients|group with condition of interest
62340322|NCT02261012||30 CTS patients|group with a different type of pain on the upper limbs
62340323|NCT05825209|ACTIVE_COMPARATOR|Food-Grown Magnesium|Food-grown magnesium in capsule form - taken as 2 capsules, orally with water 1 hour before sleep.
62340324|NCT05825209|PLACEBO_COMPARATOR|Microcrystalline cellulose|Microcrystalline cellulose in capsule form - taken as 2 capsules, orally with water 1 hour before sleep.
62340325|NCT04835558||Group I|Subjects with obesity hypoventilation sydrome (30 \< body mass index \< 40 kg/m2)
62496529|NCT02355262||Arm II (Tool Implementation with Interactive Facilitation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. Participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation.
62496530|NCT03573336|EXPERIMENTAL|Vilaprisan (BAY1002670) 2 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg
62496531|NCT03573336|EXPERIMENTAL|Vilaprisan (BAY1002670) 4 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg
61945778|NCT03949972||A - Pediatric Cohort|Pediatric patients until 18 years of age presenting with or diagnosed with idiopathic nephrotic syndrome or a biopsy-proven diagnosis of MCD or FSGS.
61945779|NCT03949972||B -Adult Cohort|Adult patients 18 years and above with a biopsy-proven diagnosis of primary or secondary FSGS or MCD.
61945780|NCT02005731||Shockwaves|Low intensity linear focused shockwave device ('Renova')
62340326|NCT04835558||Group II|Subjects with obesity hypoventilation sydrome (body mass index \> 40 kg/m2)
62340327|NCT04835558||Control Group|Age and sex-matched obese subjects (30 \< body mass index \< 40 kg/m2) with low risk of obstructive sleep apnea (STOP-BANG score \< 3)
62340328|NCT02507193|ACTIVE_COMPARATOR|Open reduction internal fixation(ORIF)|This surgical intervention is performed using a plate and screws.Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
62340329|NCT02507193|ACTIVE_COMPARATOR|Intermedullary (IM) Nail|This surgical intervention is performed using an intermedullary nail. Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
62340330|NCT05210205|EXPERIMENTAL|EAA-enhanced food products|Consume approximately 1500 calories of EAA-enhanced food products plus ad libitum consumption of 3 combat rations each day during training.
62340331|NCT05210205|EXPERIMENTAL|Energy dense food products|Consume approximately 1500 calories of energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
62340332|NCT05210205|ACTIVE_COMPARATOR|Control food products|Consume approximately 1500 calories of low energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
62340333|NCT06461611|PLACEBO_COMPARATOR|Control Group|Patients in the control group will receive traditional health education, which consist of routine oral health education and oral health instructions during their visits for orthodontic treatment.
62340334|NCT06461611|EXPERIMENTAL|Intervention Group|Patients in the intervention group will receive a health diary to plan and clock for their fixed orthodontic self-management behaviors in addition to the traditional health education.
62340335|NCT02738996|EXPERIMENTAL|60-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 30 min
62496532|NCT03573336|PLACEBO_COMPARATOR|Placebo group|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1
62496533|NCT01173536|ACTIVE_COMPARATOR|A|
62496534|NCT01173536|ACTIVE_COMPARATOR|B|
62496535|NCT01173536|EXPERIMENTAL|C|
61945781|NCT02040948|EXPERIMENTAL|Surgical patients|"* Nexfin (Pulse Pressure Variation)~* Radical 7 (Pleth Variability Index)~* CardioQ (stroke volume)"
61945782|NCT04748146|OTHER|Intervention and Control group|Each patient will receive electrical and sham stimulation, meaning that each patient will act as their own control.
61945783|NCT04111809||intravenous biphosphonate|Patients treated with intravenous bisphosphonate until 12 months in routine care
61945784|NCT01984983|EXPERIMENTAL|VEEV DNA Vaccine 0.5 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
61945785|NCT01984983|EXPERIMENTAL|VEEV DNA Vaccine 0.5 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
61945786|NCT01984983|EXPERIMENTAL|VEEV DNA Vaccine 2.0 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
62139999|NCT04759833|EXPERIMENTAL|Part A: Low Dose Prucalopride|Participants weighing \<50 kg will receive 0.04 milligrams per kilogram (mg/kg) of prucalopride oral solution (will draw the required volume from one bottle of 0.4 milligram per milliliter \[mg/mL\] and one bottle of placebo oral solution), QD or participants weighing ≥50 kg will receive one 2 milligram (mg) of prucalopride oral tablet and one placebo oral tablet, QD, during 12 weeks in Part A. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
62140000|NCT04759833|EXPERIMENTAL|Part A: High Dose Prucalopride|Participants weighing \<50 kg will receive 0.08 mg/kg of prucalopride oral solution (will draw the required volume from two bottles of 0.4 mg/mL to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive two 2 mg of prucalopride oral tablets, QD, during 12 weeks of treatment period in Part A. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
62140001|NCT04759833|EXPERIMENTAL|Part B: Low Dose Prucalopride|Participants weighing \<50 kg will receive 0.04 mg/kg of prucalopride oral solution (will draw the required volume from one bottle of 0.4 mg/mL and one bottle of placebo oral solution to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive one 2 mg of prucalopride oral tablet and one placebo oral tablet, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
62496536|NCT01900457|ACTIVE_COMPARATOR|Volunteer healthy|healthy volunteers
62496537|NCT01900457|EXPERIMENTAL|patients|vestibular defective patients
62496538|NCT04174118|EXPERIMENTAL|belcesiran|Healthy volunteers will be administered a single dose of belcesiran.
61945787|NCT01984983|EXPERIMENTAL|VEEV DNA Vaccine 2.0 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
61945788|NCT01984983|PLACEBO_COMPARATOR|Placebo: 0.9% saline|0.9% saline
62496539|NCT04174118|PLACEBO_COMPARATOR|Placebo|Healthy volunteers will be administered a single dose of matching placebo.
61945789|NCT02398656|EXPERIMENTAL|Tenecteplase (tNK)|Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
61945790|NCT02398656|ACTIVE_COMPARATOR|Control (Antiplatelet Agents)|Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.
61945791|NCT03214315||Prostatectomy|Visceral adipose tissue specimen sample
61945792|NCT06557044|EXPERIMENTAL|Verum Group|20 ml ropivacaine 0.5%
62140002|NCT04759833|EXPERIMENTAL|Part B: High Dose Prucalopride|Participants weighing \<50 kg will receive 0.08 mg/kg of prucalopride oral solution (will draw the required volume from two bottles of 0.4 mg/mL to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive two 2 mg of prucalopride oral tablets, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
62140003|NCT05636293|ACTIVE_COMPARATOR|Ritlecitinib|10g gluten + 200mg of Ritlecitinib
62140004|NCT05636293|PLACEBO_COMPARATOR|Placebo|10g gluten + placebo
62140005|NCT05179187|EXPERIMENTAL|Parkinson disease patients|Participants diagnosed with Parkinson's disease
62496540|NCT04640194|EXPERIMENTAL|Part 1: Alteplase low dose|0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Part 1 subjects were randomized equally (1:1:1) across the three Part 1 arms.
62496541|NCT04640194|EXPERIMENTAL|Part 1: Alteplase high dose|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Part 1 subjects were randomized equally (1:1:1) across the three Part 1 arms.
61945793|NCT06557044|PLACEBO_COMPARATOR|Placebo Group|20 ml physiological saline
61945794|NCT01611155|EXPERIMENTAL|Arm I (management of therapy complications)|Patients receive venlafaxine PO BID beginning on day 1 of and continuing through completion of FOLFOX.
61945795|NCT01611155|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.
61945796|NCT00608660|EXPERIMENTAL|A|staging acupuncture for treating Bell's Palsy
61945797|NCT00608660|EXPERIMENTAL|B|staging acupuncture and moxibustion for treating Bell's Palsy
61945798|NCT00608660|EXPERIMENTAL|C|staging electroacupuncture for treating Bell's Palsy
61945799|NCT00608660|EXPERIMENTAL|D|staging acupuncture along Yangming musculature for treating Bell's Palsy
61945800|NCT00608660|EXPERIMENTAL|E|non-staging acupuncture for treating Bell's Palsy
61945801|NCT02883686|EXPERIMENTAL|Alma Mentoring plus usual care|Alma peer-mentoring
61945802|NCT02883686|NO_INTERVENTION|Enhanced Usual Care|Usual care for depression within the Kaiser Permanente of Colorado healthcare system plus study monitoring of depression symptoms and feedback.
61945803|NCT02391701|EXPERIMENTAL|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
61945804|NCT02391701|NO_INTERVENTION|Control|No intervention
62340336|NCT02738996|EXPERIMENTAL|30-15 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 15 min
62496542|NCT04640194|OTHER|Part 1: Standard of Care|Standard of Care included best possible treatment regimen established locally and was in line with current guidelines for Acute respiratory distress syndrome treatment. Part 1 subjects were randomized equally (1:1:1) across the three Part 1 arms.
62496543|NCT04640194|EXPERIMENTAL|Part 2: Alteplase high dose - non-invasive mechanical ventilation (NIV) patients|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Non-invasive mechanical ventilation (NIV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 6. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
62496544|NCT04640194|OTHER|Part 2: Standard of Care - non-invasive mechanical ventilation (NIV) patients|Standard of Care included best possible treatment regimen established locally and was in line with current guidelines for Acute respiratory distress syndrome treatment. Non-invasive mechanical ventilation (NIV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 6. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
62496545|NCT04640194|EXPERIMENTAL|Part 2: Alteplase high dose - invasive mechanical ventilation (IMV) patients|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Invasive mechanical ventilation (IMV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 7, 8 or 9. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
61945805|NCT05730283|EXPERIMENTAL|High Dose ORC-13661|This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 150mg followed by a daily dose of 30mg. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
61945806|NCT05730283|EXPERIMENTAL|Low Dose ORC-13661|This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 60mg capsules followed by a daily dose of 12mg capsules. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
61945807|NCT05730283|PLACEBO_COMPARATOR|Placebo|This arm is a daily treatment regimen of a placebo with a loading dose and a daily dose of placebo capsules to match the treatment arms. Placebo regimen will run concurrently with treatment with IV amikacin. Placebo regimen will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
61945808|NCT05915221|NO_INTERVENTION|Control group|The control group was chosen to be the group that did not receive SMS.
61945809|NCT05915221|EXPERIMENTAL|SMS group|The intervention group was chosen to be the group that received SMS messages.
61945810|NCT06012487|OTHER|Ambulatory Blood Pressure Monitor (ABPM)|"Participants on antihypertensive pharmacotherapy in the highest decile of BPV will be offered enrollment based on inclusion/exclusion criteria. Patient's will undergo a 48 hour ABPM to determine baseline BPV. Next, each patient's primary care physician will be guided through titrations to antihypertensive medications to a low BPV regimen (Amlodipine and Indapamide, with doses titrated to reach target blood pressure). Following this, patients will undergo repeat 48h ABPM to evaluate change in BPV. All medication decisions will be at the ultimate discretion of the treating physician.~The optional sub-study will test the hypothesize that ABPM and SKNA data can be simultaneously captured and that BPV will be positively correlated with SKNA. Participants who enroll in the optional sub-study will be fitted with a single patch ECG which will capture high-fidelity ECG tracings from which SKNA can be determine in post-test analysis."
61945811|NCT05334914|OTHER|Intervention Arm|Participants will complete the baseline session, a 1:1 motivation building session, and 8 weeks of ACT group therapy. They will then complete a final study visit and a follow-up study visit to occur 6 month after the end of therapy.
61945812|NCT00645749|EXPERIMENTAL|Helminth ova|Subjects serving as their own controls (baseline - end-of-treatment) will receive a dose of 2,500 ova, in liquid form, every 2 weeks
61945813|NCT04962620||Longidaze|75 patients receiving combination therapy: Longidaze + dienogest
61945814|NCT04962620||Control|74 patients receiving only Dienogest.
61945815|NCT05679518|EXPERIMENTAL|ConquerFear intervention|Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.
61945816|NCT05679518|EXPERIMENTAL|CALM intervention|Participants in the CALM intervention group will receive a semi-structured, manualized, individual psychotherapy intervention consisting of 3-6 individual therapy sessions.
62140006|NCT05179187|ACTIVE_COMPARATOR|Healthy adults|Healthy adult age-matched controls
62140007|NCT03388736|NO_INTERVENTION|No lavender|No mist will be diffused into the environment.
62340337|NCT02738996|EXPERIMENTAL|15-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 60 min
62340338|NCT02738996|EXPERIMENTAL|60-15|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 15 min
62340339|NCT02738996|EXPERIMENTAL|30-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 60 min
61945817|NCT05679518|ACTIVE_COMPARATOR|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.
61945818|NCT03781427|ACTIVE_COMPARATOR|Standard care|Cardiac resynchronization therapy: Usual output programming
61945819|NCT03781427|EXPERIMENTAL|High output|Cardiac resynchronization therapy: High output programming
61945820|NCT02433561|ACTIVE_COMPARATOR|Intraplexic catheter|Intraplexic approach (Patients will have the catheter placed within the plexus, classical approach)
61945821|NCT02433561|EXPERIMENTAL|Extraplexic catheter|Extraplexic approach (Patients will have the catheter placed out of the plexus.)
61945822|NCT04035109|OTHER|Anakinra (Period 1) then Placebo (Period 2)|Subjects randomized to this arm will receive a single injection of anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their first allergen challenge (Period 1), followed by the matching saline placebo after their second allergen challenge (Period 2).
61945823|NCT04035109|OTHER|Placebo (Period 1) then Anakinra (Period 2)|Subjects randomized to this arm will receive a single injection of saline placebo administered subcutaneously after their first allergen challenge (Period 1), followed by anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their second allergen challenge (Period 2).
61945824|NCT00709657|EXPERIMENTAL|1|patients with age-related macular degeneration, which are already scheduled for intravitreal anti-VEGF therapy in one eye are measured before and after treatment.
61945825|NCT05146310|EXPERIMENTAL|Treated eye|Eye is treated at Baseline visit (V1)
61945826|NCT05686889|EXPERIMENTAL|Success|Symptomatic improvement present
61945827|NCT05686889|EXPERIMENTAL|Failure|Symptomatic improvement absent
61945828|NCT00227006|EXPERIMENTAL|Taste-Based Goal Setting|6-month intervention (14 lifestyle counseling classes)
61945829|NCT00227006|ACTIVE_COMPARATOR|Smart Consumers|6-month intervention (14 lifestyle counseling classes)
61945830|NCT00227006|ACTIVE_COMPARATOR|Community Access|Can enroll in behavioral treatment programs available in the community that do not include medication or very-low calorie diets
61945831|NCT05395689|EXPERIMENTAL|Active substance|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae solution administered by the subcutaneous route for 12 months using a rush schedule
61945832|NCT05395689|PLACEBO_COMPARATOR|Placebo|Saline solution administered by the subcutaneous route for 12 months using a rush schedule
61945833|NCT01497431|EXPERIMENTAL|Arm I (Se-methyl-seleno L-cysteine)|Participants receive Se-methyl-seleno L-cysteine on days 1-84.
61945834|NCT01497431|EXPERIMENTAL|Arm II (selenomethionine)|Participants receive selenomethionine PO on days 1-84.
61945835|NCT01497431|PLACEBO_COMPARATOR|Arm III (placebo)|Participants receive placebo PO on days 1-84.
61945836|NCT01816529|EXPERIMENTAL|Topical Diltiazem Hydrochloride 2% Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
61945837|NCT01816529|PLACEBO_COMPARATOR|Vehicle Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
61945838|NCT01816529|ACTIVE_COMPARATOR|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
61945839|NCT01816529|PLACEBO_COMPARATOR|0.9% Saline|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
62496546|NCT04640194|OTHER|Part 2: Standard of Care - invasive mechanical ventilation (IMV) patients|Standard of Care included best possible treatment regimen established locally and was in line with current guidelines for Acute respiratory distress syndrome treatment. Invasive mechanical ventilation (IMV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 7, 8 or 9. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
61945840|NCT01513096|NO_INTERVENTION|Split-dose PEG|Bowel preparation using split dose PEG without prokinetics
61945841|NCT01513096|ACTIVE_COMPARATOR|Split dose PEG with prokinetics|Bowel preparation using split-dose PEG with prokinetics
61945842|NCT03567577|EXPERIMENTAL|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
61945843|NCT03567577|EXPERIMENTAL|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
61945844|NCT03567577|EXPERIMENTAL|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
61945845|NCT03567577|PLACEBO_COMPARATOR|Placebo|0,9% saline solution
61945846|NCT05060848||ADRD|"Participants in the ADRD group will have a score of greater than or equal to 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory.~Subgroups based on sex and race categories will also be examined."
61945847|NCT05060848||Control|Participants in the control group will have a score of less than 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory
62697848|NCT04660344|PLACEBO_COMPARATOR|Arm B: Placebo|Placebo will be administered intravenously on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
61945848|NCT06400303|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)|Dosing with KYV-101 CAR T cells
61945849|NCT06400303|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)|Recommended Phase 2 Dose
61945850|NCT01328431|NO_INTERVENTION|Standard Care|Subjects receive a brochure for the state's Smokers' Quitline only.
61945851|NCT01328431|EXPERIMENTAL|SBIRT+NRT|Subjects receive a 6 week course of NRT, a motivational Brief Negotiated Interview, and a facilitated referral to the state's Smokers' Quitline.
61945852|NCT06295107||Spastic leg|Children with spastic hemiplegic cerebral palsy.
61945853|NCT06295107||Non spastic leg|Children with spastic hemiplegic cerebral palsy.
62496547|NCT00380588|EXPERIMENTAL|Gemcitabine + Cisplatin|"Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.~Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal."
62496548|NCT00380588|EXPERIMENTAL|Gemcitabine|Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
62140008|NCT03388736|ACTIVE_COMPARATOR|0,1 lavender|0,1 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
62340340|NCT02738996|EXPERIMENTAL|15-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 30 min
62340341|NCT00702156|EXPERIMENTAL|1|Bisoprolol
62340342|NCT00702156|PLACEBO_COMPARATOR|2|Identical appearance matching placebo
62340343|NCT04400539|EXPERIMENTAL|Malignant Pleural Mesothelioma patients|
62340344|NCT02757781|NO_INTERVENTION|Control Group|Group of healthcare professionals that NOT receive the intervention (community of practice)
62340345|NCT02757781|EXPERIMENTAL|Intervention group|Group of healthcare professionals that receive the intervention (community of practice)
62340346|NCT00885417|EXPERIMENTAL|Cravit-based sequential therapy|Cravit-based sequential therapy Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
62340347|NCT04726293|EXPERIMENTAL|Mango beverage|Mango composite served as a frozen drink
62340348|NCT04726293|PLACEBO_COMPARATOR|Control beverage|Energy matched Control frozen drink
62340349|NCT02477228|ACTIVE_COMPARATOR|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
62340350|NCT02477228|ACTIVE_COMPARATOR|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
62340351|NCT05926258|EXPERIMENTAL|Chloroprocaine 3% gel|The assigned investigational product (2 drops) will be instilled in both eyes of each subject. Administrations will be performed at the clinical centre by the Investigator or his/her deputy on study day 1. For each administration, the 2 drops will be instilled one at the time, at a 1 min interval.
62340352|NCT05926258|ACTIVE_COMPARATOR|Oxybuprocaine 0,4% solution|The assigned active comparator (2 drops) will be instilled in both eyes of each subject. Administrations will be performed at the clinical centre by the Investigator or his/her deputy on study day 1. For each administration, the 2 drops will be instilled one at the time, at a 1 min interval.
62340353|NCT03365479|EXPERIMENTAL|Study cohort|The study comprises a 1-day Screening period, followed by a right heart catheterization with a single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
62340354|NCT03585322|EXPERIMENTAL|APG-1387 for Injection|APG-1387 will be explored sequentially using a escalation scheme at the dose escalation phase.
62340355|NCT02985268|ACTIVE_COMPARATOR|MitraClip/Optimal Medical Therapy (OMT) and CRT ON|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON
62340356|NCT02985268|ACTIVE_COMPARATOR|MitraClip/OMT and CRT OFF|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON
62340357|NCT02985268|ACTIVE_COMPARATOR|OMT and CRT ON|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to ON"
62496549|NCT03993080|EXPERIMENTAL|Virtual reality relaxation|Virtual reality relaxation using virtual landscape and audio features and sound
62140009|NCT03388736|ACTIVE_COMPARATOR|0,3 lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
62140010|NCT03792061|EXPERIMENTAL|Strategy Training|Strategy training is an activity intervention training approach developed based on the theoretical tenets of metacognitive training. The purpose of strategy training is to guide individuals to generate problem-solving skills to address challenges that they identify in daily activities.
62340358|NCT02985268|ACTIVE_COMPARATOR|OMT and CRT OFF|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON"
62340359|NCT02385877|EXPERIMENTAL|Protocol 1: [18F]4F-MHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and receive a 90 minute PET scan.
62140011|NCT03792061|NO_INTERVENTION|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
62140012|NCT00977249|ACTIVE_COMPARATOR|varenicline|"Varenicline for 12 weeks.~The treatment schedule for varenicline is:~Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks"
62140013|NCT00977249|PLACEBO_COMPARATOR|placebo|Placebo for 12 weeks
62140014|NCT04334005|ACTIVE_COMPARATOR|Usual care|Prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations.
62140015|NCT04334005|EXPERIMENTAL|Intervention group|25000 UI of vitamin D supplement in addition to the above-mentioned drug recommendations.
62140016|NCT00609050|ACTIVE_COMPARATOR|1|Self-Regulated Exercise with Telephone Reinforcement
62140017|NCT00609050|ACTIVE_COMPARATOR|2|Attention Control
62140018|NCT02977832|EXPERIMENTAL|odyliresin|Odyliresin (Iresine celosia) 2 ml
62140019|NCT02977832|EXPERIMENTAL|alphalytic|alpha-antagonist (alfuzosin 10 mg)
62140020|NCT01465152|EXPERIMENTAL|Met|
62140021|NCT01465152|ACTIVE_COMPARATOR|Rep|
62140022|NCT01465152|ACTIVE_COMPARATOR|Met+Rep|
62140023|NCT06162702|EXPERIMENTAL|FMT Responder|
62496550|NCT03993080|NO_INTERVENTION|Treatment as usual|Seated in similar environment as experimental group for same time
62496551|NCT00676169||Observational|Pa negative or concurrently enrolled in the EPIC Clinical Trial
62496552|NCT01781416||1|
62496553|NCT00827840|EXPERIMENTAL|1. Paliperidone ER|New antipsychotics
62697849|NCT05704088|ACTIVE_COMPARATOR|study group|Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one year.
61945854|NCT03766568|EXPERIMENTAL|Diagnostic with JGG endoscope|
62140024|NCT06162702|EXPERIMENTAL|FMT non-Responder|
62140025|NCT01253213|EXPERIMENTAL|BR55|
62140026|NCT06148740|EXPERIMENTAL|Pro Vitality Daily Restorative Face Serum|"Participants will be required to apply the test product in the morning and before sleeping at night.~After thoroughly cleansing and toning the face, the participants will apply 2-3 drops onto clean dry fingers and massage over the entire face until fully absorbed.~The product should be followed with the participants' preferred moisturizer."
62340360|NCT02385877|EXPERIMENTAL|Protocol 1: [18F]3F-PHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG) and receive a 90 minute PET scan.
62340361|NCT02385877|EXPERIMENTAL|Protocol 2: Biodistribution Studies|Subjects (n = 4) will be injected one time with 6.5 mCi of either \[18F\]4F-MHPG or \[18F\]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
62340362|NCT04281342|EXPERIMENTAL|Aprocitentan 25 mg|Therapeutic dose level
62340363|NCT04281342|EXPERIMENTAL|Aprocitentan 100 mg|Supratherapeutic dose level
62340364|NCT04281342|PLACEBO_COMPARATOR|Matching placebo|
62340365|NCT04281342|OTHER|Moxifloxacin|
62340366|NCT04253041|EXPERIMENTAL|Control|The control group will be exposed to 15 different appearance-neutral images of interior design, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was most prevalent in the previous image?) regarding characteristics of the last image they were exposed to.
62340367|NCT04253041|EXPERIMENTAL|Fitspiration|Participants assigned to the Fitspiration condition (n=30) will be exposed to 15 different fitspiration images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
62340368|NCT04253041|EXPERIMENTAL|Body Positive|Participants assigned to the Body Positive condition (n=30) will be exposed to 15 different body positive images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
62340369|NCT02922634||older surgical patients|Older surgical patients presenting for elective spine surgery
62340370|NCT02155764|EXPERIMENTAL|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
62340371|NCT02155764|ACTIVE_COMPARATOR|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
62697850|NCT05704088|PLACEBO_COMPARATOR|control group|Control group: will receive placebo as add on drug once daily with or without food for one year.
61945855|NCT05373277|PLACEBO_COMPARATOR|Placebo|The subjects will be given orally placebo twice a day for 2 days, and a single 10 mg dose of rosuvastatin.
61945856|NCT05373277|ACTIVE_COMPARATOR|Ticagrelor|The subjects will be given orally 90 mg ticagrelor twice a day for 2 days, and a single 10 mg dose of rosuvastatin.
61945857|NCT03499925|EXPERIMENTAL|Test Group|Telephone consultation effectiveness and cognitive behaviors
61945858|NCT03499925|NO_INTERVENTION|Comparison Group|Routine product inspection
61945859|NCT01024335|ACTIVE_COMPARATOR|Naltrexone and placebo|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
62140027|NCT03768466|EXPERIMENTAL|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
62340372|NCT02155764|ACTIVE_COMPARATOR|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
62340373|NCT03824925|PLACEBO_COMPARATOR|Placebo oral zinc capsules|Group A: It was the control group. Participants were advised to start taking placebo capsule of Zinc in a look alike preparation on their first day of chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended
62340374|NCT03824925|EXPERIMENTAL|Zinc Sulfate 220 MG|Group B: Cap zinc 220 mg (equivalent to 50 mg of elemental zinc) on 1st day of their chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended.
62340375|NCT02675153|EXPERIMENTAL|Upper gastrointestinal strictures|Patients with upper gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
62496554|NCT00827840|ACTIVE_COMPARATOR|2 Risperidone|
62697851|NCT06052358||Patients with a history of AF and GI bleeding who will undergo LAAC|This is group of patients who will undergo LAAC with Watchman FLX device and have a history of AF and GI bleed.
62697852|NCT06052358||Patients with a history of AF and GI bleeding without LAAC|This is a historical cohort of patients with AF and recurrent GI bleeding without LAAC.
62697853|NCT02394067||Idiopathic Intracranial Hypertension|All participants of our study will be in this arm. These will be patients with a diagnosis of IIH. These patients will be followed throughout their standard of care treatment, with neuro-radiological imaging.
62697854|NCT03896581|EXPERIMENTAL|Bimekizumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen.
62140028|NCT04068272|EXPERIMENTAL|Treatment|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
62140029|NCT04068272|PLACEBO_COMPARATOR|Placebo|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
62140030|NCT04174339|EXPERIMENTAL|camrelizumab plus apatinib and POF|Participants will receive camrelizumab in combination with apatinib plus POF until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62697855|NCT03896581|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo.
62140031|NCT02551237|ACTIVE_COMPARATOR|Radiochemotherapy|"Patients who will be treated with~* radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with~* oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
62340376|NCT02675153|EXPERIMENTAL|Lower gastrointestinal strictures|Patients with lower gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
62340377|NCT04955002||Healthy UK adults|Healthy UK adults
62340378|NCT01951235|EXPERIMENTAL|Imeglimin (Dose 1)|
62340379|NCT01951235|EXPERIMENTAL|Imeglimin (Dose 2)|
62340380|NCT01951235|EXPERIMENTAL|Imeglimin (Dose 3)|
62340381|NCT01951235|EXPERIMENTAL|Imeglimin (Dose 4)|
62340382|NCT01951235|PLACEBO_COMPARATOR|Placebo|
62340383|NCT05764018|PLACEBO_COMPARATOR|Normoxia-Placebo|Participants will be breathing room air, and ingest a flavoured drink containing only a trivial amount of maltodextrin.
62340384|NCT05764018|EXPERIMENTAL|Normoxia-Caffeine|Participants will be breathing room air, and ingest a flavoured drink containing a trivial amount of maltodextrin and 6 mg/kg body mass caffeine.
62340385|NCT05764018|PLACEBO_COMPARATOR|Hypoxia-Placebo|Participants will be breathing a 13% oxygen gas mixture, and ingest a flavoured drink containing only a trivial amount of maltodextrin.
62340386|NCT05764018|EXPERIMENTAL|Hypoxia-Caffeine|Participants will be breathing a 13% oxygen gas mixture, and ingest a flavoured drink containing a trivial amount of maltodextrin and 6 mg/kg body mass caffeine.
62340387|NCT02323321|EXPERIMENTAL|OCS Preservation|OCS Preservation and Assessment
62340388|NCT03245723|ACTIVE_COMPARATOR|Preterm|"Participants born premature either registered on the National Lung Project (currently in their late twenties) or not registered on the National Lung Project Cohort (current age ranges 18-35 years).~All the participants in this group will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging."
62340389|NCT03245723|PLACEBO_COMPARATOR|Term - Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
62140032|NCT02551237|EXPERIMENTAL|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
62140033|NCT05001126|EXPERIMENTAL|HIFT 1x/week|HIFT exercise performed one time per week.
62140034|NCT05001126|EXPERIMENTAL|HIFT 2x/week|HIFT exercise performed two times per week.
62140035|NCT05001126|EXPERIMENTAL|HIFT 3x/week|HIFT exercise performed three times per week.
62140036|NCT04304937||Cohort 1|test-retest at baseline and 7 days later
62140037|NCT04304937||Cohort 2|test at baseline and 8 weeks post treatment
62340390|NCT02486887|EXPERIMENTAL|telemonitoring|telemonitoring of weight, arterial pressure and heart rate at home with connection to a medical platform to monitor the evolution.
62340391|NCT02486887|NO_INTERVENTION|conventional follow-up|conventional follow-up
62340392|NCT00406783|EXPERIMENTAL|5-mg Desloratadine tablet|
62340393|NCT00406783|PLACEBO_COMPARATOR|Placebo tablet|
62340394|NCT05653297||Group A (Control Group)|will undergo conventional dressing daily until the wound is ready for reconstruction, Then coverage of the wound with conventional tie over for 4 days.
62140038|NCT04642287|EXPERIMENTAL|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
62340395|NCT05653297||Group B (Experimental Group)|NPWT (MEDWAY GROUP VAC) will be applied on a continuous mode between -75 \& -150 mm Hg for 4 days per session for indefinite number of sessions until the wound is ready for reconstruction, Then it will be applied after coverage of the wound for 1 session.
62340396|NCT03230474|ACTIVE_COMPARATOR|group 1|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
62340397|NCT03230474|ACTIVE_COMPARATOR|group 2|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
62340398|NCT05598294|NO_INTERVENTION|Control Group|Standard treatment and mobilization recommendations will be given to this group.
62340399|NCT05598294|EXPERIMENTAL|Mobilization Group|Mobilization of patients will be encouraged.
62340400|NCT04412382||covid-19|Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION.
62340401|NCT04412382||control|Control group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer.
62340402|NCT04515043|EXPERIMENTAL|INVAC-1|All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.
62340403|NCT02601066|EXPERIMENTAL|EPS and ECG holter monitor|Electrophysiological study (EPS) and ECG holter monitor implantation
62697856|NCT02019849||Plasmafit® Total Hip Arthroplasty|
62697857|NCT03409809|EXPERIMENTAL|Training Alone|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website.
62697858|NCT03409809|EXPERIMENTAL|Training and Technical Assistance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies, and communication.
62496555|NCT06241157|EXPERIMENTAL|Pediatric Quiz Game|"Behavior Guidance Technique (BGT) group (Pedo-Quiz group) Whereas, with the novel BGT so called The Pediatric-Quiz Game (PQ), dentists start interacting with children in the waiting room before entering the operating room. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child. Each child will be asked to fill out the Facial Shape Scale and the Venham Picture Test before the procedure. After the session, the Frankl Behavior Scale and the Patient Evaluation Form will be filled out by the dentist. Their families (parents/guardians) will be asked to fill out the Child Fear Assessment Scale-Dental Subscale (CFSS-DSc) before the session. 35 children will be included in the study.Main goal in this sesion is to evaluate in which dental practice step can be progressed in an anxious child by using this new behavior managament technique."
62496556|NCT06241157|NO_INTERVENTION|Control|"This group is the control group. Tell-show-do technique, which is a frequently used behavioral management techniques will be used.~In this group, each child will be asked to fill out the Facial Shape Scale and the Venham Picture Test before the procedure. After the session, the Frankl Behavior Scale and the Patient Evaluation Form will be filled out by the dentist. Their families (parents/guardians) will be asked to fill out the Child Fear Assessment Scale-Dental Subscale (CFSS-DSc) before the session. 35 children will be included in the study. Main goal in this sesion is to evaluate in which dental practice step can be progressed in an anxious child by using classical behavior managament technique."
62496557|NCT03261817|EXPERIMENTAL|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
62496558|NCT03261817|SHAM_COMPARATOR|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
62496559|NCT03261817|ACTIVE_COMPARATOR|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
62496560|NCT03261817|SHAM_COMPARATOR|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
61945860|NCT01024335|EXPERIMENTAL|Naltrexone and dronabinol|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
61945861|NCT04234607|EXPERIMENTAL|TQB2450+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62340404|NCT06371014|EXPERIMENTAL|Ondansetron mouth soluble film|Drug: ondansetron plus dexamethasone Ondansetron oral membrane lysis group, oral administration 30 minutes before chemotherapy, 8 mg bid for children over 12 years old, 4mg/ time for children 4-11 years old, bid; Dexamethasone was administered intravenously at 0.225 mg/(kg·d) 30 minutes before chemotherapy until 2 days after the end of the last dose of chemotherapy
62340405|NCT06371014|EXPERIMENTAL|Ondansetron tablet|Ondansetron tablet group, oral administration 30 minutes before chemotherapy, 5mg/m2 q12h po; Dexamethasone was administered intravenously at 0.225 mg/(kg·d) 30 minutes before chemotherapy until 2 days after the end of the last dose of chemotherapy
61945862|NCT04234607|EXPERIMENTAL|TQB2450（blank）+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+ Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62340406|NCT02503631||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or a pre-malignant colorectal lesion with large enough residual lesion to require subsequent surgical excision or complex colonoscopic polypectomy.
62340407|NCT03368131|EXPERIMENTAL|Trastuzumab XELOX and radiotherapy|Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. XELOX：Capecitabine 825\~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45 Gray (unit)Gy/25f （1.8Gy/f/d，5 f/w）
62340408|NCT03368131|ACTIVE_COMPARATOR|XELOX and radiotherapy|Capecitabine：825\~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
62340409|NCT02819115||Healthy adults group|Healthy adults aged 18 to 59 years
62340410|NCT02819115||Elderly group|Elderly over 60 years old.
62496561|NCT00645827|EXPERIMENTAL|Insulin infusion conversion equation|Insulin infusion conversion equation is used to determine subcutaneous insulin dosing for first 24 hours after cessation of an IV insulin infusion.
62496562|NCT00645827|ACTIVE_COMPARATOR|Control|Judgment of patient's healthcare provider is used to determine subcutaneous insulin dosing for first 24 hours after cessation of IV insulin infusion.
62496563|NCT06377007|ACTIVE_COMPARATOR|IOLMaster 700|IOLMaster 700 represents the gold standard for measuring ocular biometry before cataract surgery, employing a single refractive index.
62496564|NCT06377007|EXPERIMENTAL|ARGOS|ARGOS is a new device used to measure ocular biometry. It employs distinct refractive indices for different eye components such as the cornea, lens, and vitreous.
62496565|NCT03920449|ACTIVE_COMPARATOR|Botulinum toxin injection|
62496566|NCT03920449|ACTIVE_COMPARATOR|Posterolateral internal sphincterotomy|
62140039|NCT04642287|PLACEBO_COMPARATOR|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
62140040|NCT06695806||osteopath|Participants should be osteopaths or students in osteopathy. They need to understand french and give their consent before answering questionnaire.
62496567|NCT01923818|ACTIVE_COMPARATOR|aspirin|Receiving a 100-mg dose of aspirin and placebo rivaroxaban from day 1 to day 30
62496568|NCT01923818|EXPERIMENTAL|Rivaroxaban 5mg|Receiving a 5-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
62496569|NCT01923818|EXPERIMENTAL|rivaroxaban 10mg|Receiving a 10-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
62496570|NCT02684539|EXPERIMENTAL|tilt table Erigo®|observation of physiological parameters, tilting table with onset of syncope
62496571|NCT04045015|ACTIVE_COMPARATOR|glycyrrhizic acid 1.5 mg/kg body weight|Liqourice corresponding to 1.5 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
62496572|NCT04045015|ACTIVE_COMPARATOR|glycyrrhizic acid 3.0 mg/kg body weight|Liqourice corresponding to 3.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
62496573|NCT04045015|ACTIVE_COMPARATOR|glycyrrhizic acid 6.0 mg/kg body weight|Liqourice corresponding to 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
62714739|NCT06068517|ACTIVE_COMPARATOR|Standard dressing|At the completion of the surgical procedure, the skin will be closed with staples at a distance of two centimeters from each other. After skin closure, conventional dry dressings will be applied. Conventional dressings will be changed according to clinical practice in the participating study centers.
62340411|NCT05359406|EXPERIMENTAL|unresectable group|Patients will receive tislelizumab in combination with radiotherapy and targeted therapy. 2 weeks after large fractionated radiotherapy for primary rectum lesion and metastasis, patients will be treated with systemic treatment including chemotherapy combined with targeted therapy and immunotherapy. Patients will be evaluated by MDT every 2 months since the beginning of the treatment. Those who are regarded as NED will be treated surgically/locally. Those in stable or partial remission will continue with combination therapy. Those with progressive disease will be withdrawn from study. Patients who are not surgically treatable will continue with combination therapy until disease progression or receiving surgical treatment.
62340412|NCT04263948|EXPERIMENTAL|Picado Arm|All the patients undergo multidimensional tele monitoring for 7 weeks using an upgraded version of the Picado internet platform
62340413|NCT01666418|OTHER|Pazopanib/Paclitaxel|
62340414|NCT04118114|EXPERIMENTAL|PRL3-ZUMAB Monotherapy|
62340415|NCT03769935|EXPERIMENTAL|experimental arm|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
62340416|NCT03769935|ACTIVE_COMPARATOR|active comparator|cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
62340417|NCT01093755|ACTIVE_COMPARATOR|dexlansoprazole|Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
62340418|NCT01093755|ACTIVE_COMPARATOR|omeprazole|Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
62340419|NCT02561299|EXPERIMENTAL|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
62340420|NCT02561299|ACTIVE_COMPARATOR|DCB angioplasty|014 Drug Coated Balloon angioplasty
62340421|NCT05869539|EXPERIMENTAL|Tumor-infiltrating lymphocyte transfer combined with ANV419|"Patients have excisional biopsy/surgical resection of tumor lesion(s) (tumor collection) and TILs are expanded from this lesion/these lesions (TIL expansion).~The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to patient and first administration of ANV419 at day 0."
62340422|NCT05394740|EXPERIMENTAL|Regorafenib, Nivolumab+CapeOX/FOLFOX|Regorafenib and Nivolumab+CapeOX (Cohort A) / Nivolumab+FOLFOX (Cohort B)
62340423|NCT04346264||General Cohort|Population general cohort from the Austrian LEAD Study
62340424|NCT04068311|NO_INTERVENTION|Pre Implementation|Adult patients \>65 years of age in the Emergency Department Observation Unit.
62340425|NCT04068311|ACTIVE_COMPARATOR|Post Implementation|Adult patients \>65 years of age in the Emergency Department Observation Unit.
62340426|NCT04123717|ACTIVE_COMPARATOR|Arm1 - IV Ibuprofen|Patients will receive IV Ibuprofen 10 mg/kg to a maximum of 400 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with 100 ml normal saline.
62340427|NCT04123717|ACTIVE_COMPARATOR|Arm 2 -IV Paracetamol|Patients will receive 15 mg/kg IV Paracetamol to a maximum of 1000 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with normal saline.
62340428|NCT04123717|ACTIVE_COMPARATOR|Arm 3- Both IV Paracetamol and IV Ibuprofen|Patients will receive an infusion of both IV Paracetamol and IV Ibuprofen. They will initially receive IV Ibuprofen and the IV catheter will then be flushed with 10 ml of normal saline, and the patient will receive IV Paracetamol
62496574|NCT04495959||68Ga-HTK03149 PET/MRI DWB scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
62140041|NCT02745990|EXPERIMENTAL|EPO group|In EPO group, The recombinant human erythropoietin (rhEPO) will be given by 500 U/kg/dose intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
62496575|NCT00434590|EXPERIMENTAL|Full Dose Myfortic® and Reduced Dose Neoral®|The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
62496576|NCT00434590|ACTIVE_COMPARATOR|Standard Dose of Myfortic® and Standard Dose of CsA-ME|Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.
62496577|NCT06143527|EXPERIMENTAL|Treatment Group (AlloRx)|Intravenous infusion
62496578|NCT01920750|EXPERIMENTAL|Group 2|5 subjects will receive d single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLCwA and one of mock antigen equally in two arms
62496579|NCT01920750|EXPERIMENTAL|Group 1|5 subjects received single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLSA-LAM and one of mock antigen equally in two arms
62496580|NCT05993754|EXPERIMENTAL|Intervention group|Frail and pre-frail elderly people over 65 years of age who underwent elective non-cardiac surgeries who receive non-pharmacological interventions by the nursing team
61945863|NCT04234607|ACTIVE_COMPARATOR|TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib (blank) capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules (blank) 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
61945864|NCT02655133|ACTIVE_COMPARATOR|Pentaglobin®|Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).
61945865|NCT02655133|PLACEBO_COMPARATOR|Physiologic Solution|Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)
61945866|NCT05488171|EXPERIMENTAL|Methylone|Methylone (3,4-methylenedioxy-N-methylcathinone) 200 mg, single dose, oral administration
61945867|NCT05488171|ACTIVE_COMPARATOR|3,4-methylenedioxymethamphetamine (MDMA)|MDMA (3,4-methylenedioxymethamphetamine) 100 mg, single dose, oral administration
61945868|NCT05488171|PLACEBO_COMPARATOR|Maltodextrin|Placebo, single dose, oral administration
61945869|NCT04157543|EXPERIMENTAL|electroacupuncture|electroacupuncture at points after surgery
61945870|NCT04157543|SHAM_COMPARATOR|electroacupuncture non-point|electroacupuncture at non-points after surgery
61945871|NCT04157543|NO_INTERVENTION|Control group|only injection painkiller were used before surgery
62340429|NCT04123717|ACTIVE_COMPARATOR|Arm 4 -PO Brufen|Patients will receive PO ibuprofen given as a 100mg/5ml syrup or 200 mg tablets to a maximum of 400 mg. The treating nurse will ask the parental preference to use syrup or tablets. If they vomit the medication within 15 minutes of administration, another full dose will be administered.
62340430|NCT04273399|EXPERIMENTAL|Crohn's Disease|Twelve week jumping based exercise intervention
62340431|NCT04273399|ACTIVE_COMPARATOR|Controls|Age and sex matched controls will undertake the same twelve week intervention for active comparison between groups
62340432|NCT03838068|ACTIVE_COMPARATOR|Mineral trioxide aggegate|white mineral trioxide aggregate (MTA) calcium silicate-based cement
62340433|NCT03838068|EXPERIMENTAL|Biodentine|calcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
62340434|NCT03911336|EXPERIMENTAL|Group A - test|Group A (Test) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
62340435|NCT03911336|ACTIVE_COMPARATOR|Group B - Control 1|Group B (Control 1) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3- day period, starting the regime at 2 PM on the day of the extraction.
62697859|NCT03409809|EXPERIMENTAL|Training, Tech. Assist., Qual. Assurance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies and communication. Furthermore, this condition will have 1 year of technical assistance, coaching, and quality assurance to enhance implementation skills and sustainability.
61945872|NCT01980940|EXPERIMENTAL|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
61945873|NCT01980940|EXPERIMENTAL|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
61945874|NCT01980940|EXPERIMENTAL|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
61945875|NCT01980940|EXPERIMENTAL|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
61945876|NCT01980940|EXPERIMENTAL|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose \[OD\]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
61945877|NCT01980940|OTHER|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
62340436|NCT03911336|ACTIVE_COMPARATOR|Group C - Control 2|Group C (Control 2) - Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
62340437|NCT02200471|EXPERIMENTAL|VeinViewer|VeinViewer will be used in conjunction with routine cosmetic dermatology procedures. Patients and physicians will complete questionnaires.
62340438|NCT01522040|ACTIVE_COMPARATOR|Magnesium|Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
62340439|NCT01522040|PLACEBO_COMPARATOR|Control|Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
61945878|NCT01980940|EXPERIMENTAL|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
61945879|NCT01980940|PLACEBO_COMPARATOR|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
61945880|NCT04279405|EXPERIMENTAL|YY-20394|treatment with YY-20394 will be continued until tumor progression or development of unacceptable toxicity.
61945881|NCT03477123|EXPERIMENTAL|Intervention|Walking therapy with Exo-H2 exoskeleton
61945882|NCT03477123|NO_INTERVENTION|Control|Group receiving conventional walking therapy without robotic exoskeleton
61945883|NCT00589901|EXPERIMENTAL|A|phase II trial of capecitabine and cyclophosphamide in the management of metastatic breast cancer
61945884|NCT04806503|EXPERIMENTAL|UNR844 5 mg/mL|UNR844 5 mg/mL ophthalmic solution; one drop twice-a-day for three months
62340440|NCT02043223|EXPERIMENTAL|Early postpartum vitamin A suppl.|Single dose 200,000 IU vitamin A supplementation at \<3-day and placebo supplementation at 6-wk postpartum.
62340441|NCT02043223|EXPERIMENTAL|Late postpartum vitamin A suppl.|Placebo supplementation at \<3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
62340442|NCT02043223|EXPERIMENTAL|Early & late postpartum vitamin A suppl|200,000 IU vitamin A supplementation, both at \<3-day and 6-wk postpartum
62340443|NCT02043223|EXPERIMENTAL|No postpartum vitamin A suppl.|Placebo supplementation, both at \<3-day and 6-wk postpartum.
62340444|NCT01341379|EXPERIMENTAL|N-carbamylglutamate (Carbaglu)|
62340445|NCT04288479|EXPERIMENTAL|Doing a single HIT session in gestational week 22-36|
62340446|NCT01161082|EXPERIMENTAL|Group 1 with atorvastatin|Dose 1 versus placebo
62340447|NCT01161082|EXPERIMENTAL|Group 2 with atorvastatin|Dose 1 versus placebo
62340448|NCT01161082|EXPERIMENTAL|Group 3 with atorvastatin|Dose 2 versus placebo
62340449|NCT01161082|EXPERIMENTAL|Group 4 with atorvastatin|Dose 2 versus placebo
62340450|NCT01161082|EXPERIMENTAL|Group 5 with atorvastatin|Dose 3 versus placebo
62340451|NCT01161082|EXPERIMENTAL|Group 6 with atorvastatin|Dose 3 versus placebo
62340452|NCT01161082|EXPERIMENTAL|Group 7 without atorvastatin|Dose 3 versus placebo
62340453|NCT01161082|EXPERIMENTAL|Group 8 with atorvastatin|Dose4 versus placebo
62496581|NCT05993754|NO_INTERVENTION|Control group|Frail and pre-frail elderly people over 65 years of age undergoing elective non-cardiac surgeries who will receive traditional care.
62697860|NCT06415240|EXPERIMENTAL|Facilitated Tucking|A non pharmacological intervention to be implemented during arterial prick.
62697861|NCT06415240|EXPERIMENTAL|Gentle Human Touch|A non pharmacological intervention to be implemented during arterial prick.
61945885|NCT04806503|EXPERIMENTAL|UNR844 13.3 mg/mL|UNR844 13.3 mg/mL 1 ophthalmic solution; one drop twice-a-day for three months
61945886|NCT04806503|EXPERIMENTAL|UNR844 23 mg/mL|UNR844 23 mg/mL ophthalmic solution; one drop twice-a-day for three months
61945887|NCT04806503|EXPERIMENTAL|UNR844 30 mg/mL|UNR844 30 mg/mL ophthalmic solution; one drop twice-a-day for three months
62140042|NCT02745990|PLACEBO_COMPARATOR|Normal saline|Normal saline is administered the same volume with EPO, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
62697862|NCT06415240|NO_INTERVENTION|Usual Care|Usual Care
61945888|NCT04806503|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution|placebo ophthalmic solution; one drop twice-a-day for three months
61945889|NCT06556771|EXPERIMENTAL|Group A|"Gongs mobilization and conventional therapy , sessions 3 per week , mobilization for 5 minutes and 30 minutes session for total 4 weeks. exercise 3 sets for 10 repetitions.~Modality (Hydrocollator pack, TENS for 15 minutes with pulse frequency of 10-200 Hz, pulse width 100 - 250 micro seconds."
62140043|NCT06104423|ACTIVE_COMPARATOR|Nebivolol 5 mg|Single dose Phase (4 weeks): patients will be treated with Nebivolol 5 mg. Combination Phase (12 weeks): uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5 mg and Ramipril 2.5 mg for 4 weeks. Ramipril 2.5 mg will switched to Ramipril 5 mg in uncontrolled patients for further 4 weeks while controlled patients will continue with Nebivolol 5 mg/Ramipril 2.5 mg therapy. After 8 weeks Ramipril 5 mg will be switched to Ramipril 10 mg in the uncontrolled patients as well as Ramipril 2.5 mg will be switched to Ramipril 5 mg. Controlled patients will continue same therapy.
62340454|NCT03146052|EXPERIMENTAL|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
62340455|NCT03146052|ACTIVE_COMPARATOR|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
62340456|NCT05439460|EXPERIMENTAL|Phenylephrine|Phenylephrine will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery.
62340457|NCT05439460|EXPERIMENTAL|Epinephrine|Epinephrine will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery.
62340458|NCT05439460|EXPERIMENTAL|Arginine Vasopressin|Arginine Vasopressin will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery.
62340459|NCT04507620||cervical neck collar|
62340460|NCT04507620||head blocks strapped on the backboard|
62340461|NCT04914078||Mepolizumab treated patients|Severe eosinophil severe asthmatic patients treated with anti IL-5 monoclonal antibody Mepolizumab
62340462|NCT01953536|EXPERIMENTAL|Vintafolide|Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.
62340463|NCT01953536|EXPERIMENTAL|Vintafolide + Paclitaxel|Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
62340464|NCT01953536|ACTIVE_COMPARATOR|Paclitaxel|Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
62340465|NCT00119730|EXPERIMENTAL|Fludarabine, Mitoxantrone, Rituximab, Zevalin|Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression.
62340466|NCT01562704|EXPERIMENTAL|paracetamol|
62340467|NCT01562704|PLACEBO_COMPARATOR|placebo|
61945890|NCT06556771|EXPERIMENTAL|Group B|"Kaltenborn mobilization along with cervical traction and conventional therapy:~Intervention will be given 3 times/week 5 minutes mobilization Exercise 3 sets for 10 repetitions and 30 minutes session for 4 consecutive weeks.~Modality including (Hydrocollator pack, TENS for 15 minutes with pulse frequency of 10-200 Hz, pulse width 100 - 250 micro seconds. Intensity tolerated by patients."
62496582|NCT05700890||Implementation Team|"The Implementation Group will complete two surveys at the beginning of the study, then at five different points during the HPC Toolkit's use, and again three months post-intervention. The surveys are the Safe Surgery Checklist Culture Survey and the SSC Use and Attitudes Survey and a series of user experience surveys.~They will also do interviews pre- and post-HPC toolkit, and we will observe the Implementation Team's meetings as they work through the toolkit."
61945891|NCT05446896|EXPERIMENTAL|AR group|participants in the AR group were guided by AR-based instructions and requested assistance with the head-mounted device.
61945892|NCT05446896|NO_INTERVENTION|manual group|Participants in the manual group used a printed manual and made a phone call for assistance.
61945893|NCT01422018|EXPERIMENTAL|one arm for Anastin injection|intravitreal Avastin injection
61945894|NCT01404273|EXPERIMENTAL|Meditation/Relaxation Response Training|
61945895|NCT03020173||BMI above 30|Oocytes and granulosa of infertile women with BMI above 30
61945896|NCT03020173||BMI below 30|Oocytes and granulosa of infertile women with BMI above 30
61945897|NCT04555421|EXPERIMENTAL|Lumen device usage and diet guidelines|
61945898|NCT05768074||Therapists|20 therapists who were already trained will participate in a qualitative interview to gather perceptions and experiences of the therapists about the process of learning and practicing specific CIFFTA competencies from the therapy training platform (time 1 interview) and later, about their unique experiences related to implementation of the Evidenced Based Treatment (EBT), delivery of competencies learned, and the application of EBT in a real-world context (time 2).
61945899|NCT05768074||Agency leaders|16 agency leaders from the main study will participate in qualitative interviews to 2) gain a deeper understanding from leaders of their experiences in facilitating EBTs at their agencies, the identification of barriers that can be addressed by the organizational readiness work (time 1), and later regarding their agencies experience with the platform, consultation process, perceived cost-benefit, and agency readiness (at time 2).
61945900|NCT01951222|EXPERIMENTAL|V0162 dose1|
61945901|NCT01951222|EXPERIMENTAL|V0162 dose2|
61945902|NCT01951222|PLACEBO_COMPARATOR|placebo|Placebo
61945903|NCT01310153|ACTIVE_COMPARATOR|Prone Positioning|Newly born infant placed in prone position (face up) for the first 30 60 seconds of life after delivery by Cesarean birth.
61945904|NCT01310153|ACTIVE_COMPARATOR|Supine Positioning|newly born infant placed in supine position (face down) for the first 30 60 seconds of life after delivery by Cesarean birth.
61945905|NCT05837585|EXPERIMENTAL|Air quality sensors|The experimental group will use the air quality sensors during 2 weeks pre-test and 12 weeks trial period.
61945906|NCT00635375|EXPERIMENTAL|1|LED fiberoptic blanket phototherapy
61945907|NCT00635375|EXPERIMENTAL|2|metal halide phototherapy
61945908|NCT00635375|ACTIVE_COMPARATOR|3|LED bank phototherapy
61945909|NCT00635375|EXPERIMENTAL|4|Combination metal halide phototherapy plus LED fiberoptic blanket phototherapy
61945910|NCT02704260|EXPERIMENTAL|GENETIC ANALISYS|GENETIC ANALYSIS AND RESEARCH OF GENETIC BLOOD SAMPLE
61945911|NCT01278836|OTHER|fascio-cutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
61945912|NCT02387138|EXPERIMENTAL|SIRINOX|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).~Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle G-csf : d8 to d13 systematically"
61945913|NCT04609371|EXPERIMENTAL|self-care tools|"Arms Assigned Interventions Experimental: self-care tools~The tools are adapted from those successfully deployed in the DIRECTsc depression self-care project focusing on patients with depressive symptoms, but abbreviated to meet the needs of the proposed short-term intervention for a broader sample of patients to include those with anxiety symptoms and with minimal symptoms. Tools will include individual chapters of the Antidepressant Skills Workbook; the mood monitoring tool; a workbook on managing worry; relaxation audio files and information on exercise and healthy eating. In view of the short duration of the intervention (8 weeks), a maximum of 2 tools will be sent to each participant.~An algorithm will determine which self-care tools, matched to the specific mental health symptoms reported by participants, will be sent to the participants."
62140044|NCT06104423|ACTIVE_COMPARATOR|Ramipril 2.5/5/10 mg|Single dose Phase (4 weeks): patients will be treated with Ramipril 2.5 mg. Combination Phase (12 weeks): uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5 mg and Ramipril 2.5 mg for 4 weeks. Ramipril 2.5 mg will switched to Ramipril 5 mg in uncontrolled patients for further 4 weeks while controlled patients will continue with Nebivolol 5 mg/Ramipril 2.5 mg therapy. After 8 weeks Ramipril 5 mg will be switched to Ramipril 10 mg in the uncontrolled patients as well as Ramipril 2.5 mg will be switched to Ramipril 5 mg. Controlled patients will continue same therapy.
62496583|NCT05700890||OR Team|The OR members will complete the same pre- and post-intervention surveys (Safe Surgery Checklist Culture Survey and the SSC Use and Attitudes Survey) and do interviews before and after the IT has worked through the HPC toolkit.
62496584|NCT05700890||Surgical Patients|Surgical patients will be invited to participate in focus groups on their experiences from the time they enter the hospital on the day of their surgery to the moment they are put under anaesthesia.
61945914|NCT04609371|EXPERIMENTAL|coaching|Participants will receive the algorithm-determined self-care tools, matched to the specific mental health symptoms reported by participants as in the first arm. They will ALSO be offered up to 3 coach calls. Coaching by a trained lay coach will be structured and guided by a manual. Trained lay coaches will call participants in the week following delivery of the toolkit to guide them through the self-care toolkit over an 8-week period. Coaches will contact participants a maximum of 3 times, with calls expected to average 15-20 minutes. Call content will be guided by a structured coaching manual adapted from those used in the team's previous two RCTs of the self-care materials. The coaches will follow structured agendas, keep records of all contacts.
61945915|NCT04977674|EXPERIMENTAL|A: Visit 1) Naltrexone + Ketamine, Visit 2) Placebo + Ketamine|"Participants randomly assigned to arm A:~VISIT 1) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~VISIT 2) Placebo before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
61945916|NCT04977674|EXPERIMENTAL|B: Visit 1) Placebo + Ketamine, Visit 2) Naltrexone + Ketamine|"Participants randomly assigned to arm B:~VISIT 1) Placebo before the administration of ketamine 0.5mg/kg.~VISIT 2) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
61945917|NCT03948581|ACTIVE_COMPARATOR|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
61945918|NCT03948581|EXPERIMENTAL|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
61945919|NCT02317588|ACTIVE_COMPARATOR|Flax Oil|Flax oil 4 grams of ALA per day for 28 days (4 weeks).
61945920|NCT02317588|ACTIVE_COMPARATOR|Fish Oil|Fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day for 28 days (4 weeks).
61945921|NCT00494299|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.
61945922|NCT00494299|PLACEBO_COMPARATOR|Placebo|Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).
61945923|NCT01848730|EXPERIMENTAL|CNV2197944|CNV2197944 75mg tid 21 days
61945924|NCT01848730|PLACEBO_COMPARATOR|Placebo|Placebo tid 21 days
61945925|NCT04053322|EXPERIMENTAL|Study Arm|
61945926|NCT03086993|EXPERIMENTAL|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
61945927|NCT03086993|ACTIVE_COMPARATOR|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
62340468|NCT03796182|EXPERIMENTAL|Sequence 1|Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
62340469|NCT03796182|EXPERIMENTAL|Sequence 2|Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
62496585|NCT05692115||case|Coronary Artery Ectasia patients
62496586|NCT05692115||control|Normal coronary artery patients
61945928|NCT05776368|EXPERIMENTAL|Sub-study E1, arm 1, patients and tool motor training|patients undergo a 30 minutes tool motor training and two linguistic tasks (one before and one after).
61945929|NCT05776368|EXPERIMENTAL|Sub-study E1, arm 2, patients and hand motor training|patients undergo a 30 minutes hand motor training and two linguistic tasks (one before and one after).
61945930|NCT05776368|EXPERIMENTAL|Sub-study E1, arm 3, patients and no motor training (control group)|patients only undergo two linguistic tasks separated by a 30-minutes break (without motor activity (control group)).
61945931|NCT05776368|EXPERIMENTAL|Sub-study E1, arm 4, healthy volunteers and tool motor training|healthy volunteers undergo a 30 minutes tool motor training and two linguistic tasks (one before and one after).
61945932|NCT05776368|EXPERIMENTAL|Sub-study E1, arm 5, healthy volunteers and hand motor training|healthy volunteers undergo a 30 minutes hand motor training and two linguistic tasks (one before and one after).
61945933|NCT05776368|EXPERIMENTAL|Sub-study E1, arm 6, healthy volunteers and no motor training (control group)|healthy volunteers only undergo two linguistic tasks separated by a 30-minutes break (without motor activity (control group)).
61945934|NCT05776368|EXPERIMENTAL|Sub-study E2, arm 1, single case design|patients undergo 4 weeks of tool motor training according to an on/off design.
61945935|NCT05776368|EXPERIMENTAL|Sub-study E3, arm 1, patients and 4 week experimental sensorimotor protocol|patients undergo 4 weeks of tool motor training
61945936|NCT05776368|EXPERIMENTAL|Sub-study E3, arm 2, control group of patients|aphasic patients receiving the standard treatment as a control group
61945937|NCT03386474|EXPERIMENTAL|Brolucizumab|Brolucizumab 6 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8, and Week 16 or Week 20
61945938|NCT03386474|OTHER|Aflibercept|Aflibercept 2 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8 and Week 16 to maintain the masking of the extension trial only.
61945939|NCT04205981|EXPERIMENTAL|Aerobic exercise|Exercise intervention. The experimental group increased their energy expenditure according to American College of Sports Medicine and WHO-based physical activity recommendations for all adults to promote clinically significant weight loss and for additional health benefits: 300 min of moderate-intensity aerobic training throughout the week (WHO, 2010; Swift et al. 2014). Participants underwent five 60 min moderate-intensity cycling sessions per week for a period of 8 weeks, 40 sessions in total. Each session involved 5 min of warm up at 40 Watts, cycling for 50 min at a speed that increased their HR to a target HR obtained at 50-60% of peak VO2, and a 5 min of cool down at 40 Watts.
61945940|NCT04205981|NO_INTERVENTION|Control|. In the control group, participants did not undergo any intervention and were instructed to maintain their regular physical activity and diet regime for 8 weeks.
62496587|NCT02694861||Registry Group|Patients previously enrolled in the ANGINA RELIEF Registry who are eligible for a 1-year, prospective follow-up (date of ANGINA RELIEF Registry TMR procedure performed within 12-18 month follow-up window).
62496588|NCT02694861||Prospective Group|A group of up to 100 new, prospectively enrolled patients from active centers that receive TMR with the CardioGenesis Laser System and complete a 30-day and 1-year follow-up.
62496589|NCT02324335|PLACEBO_COMPARATOR|Placebo Comparator Oral Rinse|Water for Injection
62496590|NCT02324335|ACTIVE_COMPARATOR|Active Comparator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
62340470|NCT06317077|OTHER|Treatment group|All participants of the clinical investigation undergo the standard stages of the clinical routine within an initial PAP therapy setting: a diagnostic night followed by a titration night (or if necessary two titration nights) with prescribed titration scheme. All participants use a full face mask of Löwenstein Medical.
61945941|NCT01744873|EXPERIMENTAL|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
61945942|NCT01744873|ACTIVE_COMPARATOR|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
61945943|NCT04135365||Pediatric T1D|A sample of 20 children with Type 1 Diabetes and their caregivers will be asked to stay after their diabetes clinic appointment to complete enrollment, or they may choose to come back for a study visit. Trained study staff will describe the study in detail to interested families. They will be encouraged to ask questions before giving consent. After obtaining informed consent/assent, children and caregivers will schedule time for a neurocognitive assessment and neuroimaging assessment. Children and caregivers will complete assessments again approximately 12 months later.
61945944|NCT04135365||Comparison|Children with no known chronic medical conditions or intellectual disability will undergo the same procedure listed for the Pediatric T1D group
61945945|NCT02640859||Normal cohort|Normal cohort for biobank
61945946|NCT04230395|EXPERIMENTAL|CAP (Counseling on Alcohol Problems)|The CAP intervention is an up to 4-session alcohol reduction intervention that uses a combination of Motivational Enhancement Therapy and Cognitive Behavioral Therapy. The intervention will also include 3 booster sessions.
61945947|NCT04230395|OTHER|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
61945948|NCT02552589|EXPERIMENTAL|Test group|Amine fluoride toothpaste
61945949|NCT02552589|PLACEBO_COMPARATOR|Control group|Placebo Sodium monofluorophosphate toothpaste
61945950|NCT01068834||KIF6 tested|Recruited subjects, completing a valid KIF6 test with results
61945951|NCT01068834||KIF6 test naïve|Database matched cohort not receiving a KIF6 test
61945952|NCT04045275|EXPERIMENTAL|Calm|"The intervention will occur across 8 weeks. During Week 1, it is suggested to intervention participants that they complete 7 days of Calm meditation series (7 meditations, each approximately 10 minutes long, created to help users learn the basics of mindfulness meditations. For the remaining weeks (Week 2- Week 8) intervention participants will be asked to meditate for 10 minutes per day using any of the meditation sessions/features. Throughout the intervention, participants not completing 30 minutes of meditation per week will be sent reminders texts/emails."
61945953|NCT04045275|NO_INTERVENTION|Control|This group is a wait-list control group who will receive the intervention following the 8-week waiting period. Participants in this condition are instructed not to start meditating before the waiting period. After the 8-week waiting period, waitlist participants will receive the same intervention as described in the Calm Arm.
61945954|NCT02508857|ACTIVE_COMPARATOR|ketorolac|intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
61945955|NCT02508857|EXPERIMENTAL|magnesium|intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
61945956|NCT02508857|PLACEBO_COMPARATOR|saline|intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).
61945957|NCT00799422|ACTIVE_COMPARATOR|ReNu MultiPlus|ReNu MultiPlus used as specified in the protocol for contact lens care. In this crossover study, ReNu MultiPlus was dispensed in randomized order with Complete Easy Rub and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
61945958|NCT00799422|ACTIVE_COMPARATOR|Complete Easy Rub|Complete Easy Rub used as specified in the protocol for contact lens care. In this crossover study, Complete Easy Rub was dispensed in randomized order with ReNu MultiPlus and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
61945959|NCT00799422|ACTIVE_COMPARATOR|Clear Care|Clear Care used as specified in the protocol for contact lens care. In this crossover study, Clear Care was dispensed in randomized order with Complete Easy Rub and ReNu MultiPlus. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
61945960|NCT00456248|EXPERIMENTAL|1|Infergen 15 ug QD plus RBV for 36 weeks
61945961|NCT00456248|EXPERIMENTAL|2|Infergen 15 ug QD plus RBV for 48 weeks
61945962|NCT00456248|ACTIVE_COMPARATOR|3|
62340471|NCT04764409||Group 1|This group includes patients who underwent chemoembolization of hepatic arteria
61945963|NCT05069610|EXPERIMENTAL|Standard of care + AD17002 (3 weekly doses)|Received 3 weekly doses of AD17002 20 μg/dose of AD17002 by intranasal route
61945964|NCT05069610|PLACEBO_COMPARATOR|Standard of care + Placebo (3 weekly doses)|Received 3 weekly doses of Placebo Formulation buffer by the intranasal route
61945965|NCT05069610|EXPERIMENTAL|Standard of care + AD17002 (3 doses in 5 days)|Received 3 doses of AD17002 in 5 days 20 μg/dose of AD17002 by the intranasal route on days 1, 3, and 5
61945966|NCT05069610|PLACEBO_COMPARATOR|Standard of care + Placebo (3 doses in 5 days)|Received 3 doses of Placebo in 5 days Formulation buffer by the ntranasal route on days 1, 3, and 5
61945967|NCT02544646|OTHER|trabeculectomy|
62340472|NCT04764409||Group 2|This group includes patients who underwent chemoinfusion of hepatic arteria
62340473|NCT01592669|EXPERIMENTAL|passive leg group|bilateral PLR was achieved by raising the patient's legs to a 45 angle.
62340474|NCT01592669|NO_INTERVENTION|control|supine baseline position
62340475|NCT03579953|EXPERIMENTAL|Real cTBS to MPFC|One session of real cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
62340476|NCT03579953|SHAM_COMPARATOR|Sham cTBS to MPFC|One session of sham cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
62496591|NCT00176891|EXPERIMENTAL|Laronidase ERT Treatment|Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
62496592|NCT05543551|EXPERIMENTAL|Diaphragmatic breathing with Resistance Training|"Diaphragmatic breathing with Resistance Training:~Wall press-up: Attempt 3 sets of 5 to 10 repetitions. Dumbbell biceps curls: Attempt 3 sets of 5 to 10 repetitions. Back squats: 1 set of 10 repetitions Leg press:1 set of 10 repetitions"
62496593|NCT05543551|ACTIVE_COMPARATOR|Diaphragmatic breathing exercises without Resistance Training|"Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
62496594|NCT05343273||Healthy|
62496595|NCT05343273||Periodontitis|
62496596|NCT03061903|EXPERIMENTAL|Prevena|Subjects will receive PREVENA after surgery.
62496597|NCT03061903|ACTIVE_COMPARATOR|Aquacel|Subjects will receive AQUACEL Ag after surgery.
62496598|NCT01597349|EXPERIMENTAL|FP01 High dose|
62496599|NCT01597349|EXPERIMENTAL|FP01 Low dose|
62496600|NCT01597349|PLACEBO_COMPARATOR|Placebo|
62697863|NCT06616610|EXPERIMENTAL|The Experimental Arm|"Participants included in arms are children with the following inclusion criteria:~* Diagnosed with cerebral palsy~* Classified as GMFCS level IV or higher, indicating an inability to walk or operate a powered wheelchair.~* Under 12 years old.~* Must be affiliated to a center whose facilities guarantee a proper navigation experience~The participants will be randomly assigned to two equal-sized arms: the control arm, in which participants will continue with the traditional therapy, and the experimental arm, where the children will use the platform.~The experimental arm receives an intervention (procedure) that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities."
62340477|NCT05554471|EXPERIMENTAL|Mynx Control Venous Closure|204 (2:1 randomized - 136 VCD:68 manual compression)
62340478|NCT05554471|ACTIVE_COMPARATOR|Manual Compression|204 (2:1 randomized - 136 VCD:68 manual compression)
62340479|NCT01356836||Good-poor collateral|Patients who had good and poor collaterals formed 2 groups
62496601|NCT00948909|PLACEBO_COMPARATOR|A. Sugar Pill|
62496602|NCT00948909|EXPERIMENTAL|B. ABT-126|
62340480|NCT01356836||Good collateral, Poor collateral|
62340481|NCT04448093|EXPERIMENTAL|Treatment group|Treated group (53) that answered quality of life questionnaires before, after and with 45 days of treatment.
62340482|NCT04448093|NO_INTERVENTION|Group control|Untreated group (68) that answered quality of life questionnaires before, after and with 45 days of treatment.
62496603|NCT00948909|EXPERIMENTAL|C. ABT-126|
62496604|NCT00948909|ACTIVE_COMPARATOR|D. donepezil|
62496605|NCT05562648|EXPERIMENTAL|Manual therapy techniques|Myofascial release is a soft tissue method that provides removal of adhesions and tissue tension in tissues due to overload and repetitive use. These adhesions and unbalanced tissue tensions in the tissues can cause muscle weakness, numbness, pain, tingling and burning sensation. The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
62496606|NCT05562648|ACTIVE_COMPARATOR|Electrophysical agents|Evidence levels for approaches commonly used in the clinic for the treatment of chronic low back pain were generally very low to moderate. TENS (Transcutaneous Electrical Nerve Stimulation) is the most preferred application in the treatment of chronic pain in patients who receive conventional treatment in the clinic. TENS is a physiotherapy modality used to inhibit pain by stimulating the sensory nerves by applying a low frequency electrical current.
62496607|NCT02212236|EXPERIMENTAL|Psychological preparation + TAU|TAU=treatment as usual
62496608|NCT02212236|NO_INTERVENTION|Treatment as usual|Usual care including medication, nursing, and psychologist support.
62496609|NCT01984606|EXPERIMENTAL|Empagliflozin|Empagliflozin once daily
62496610|NCT01984606|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin once daily
62340483|NCT03065634|EXPERIMENTAL|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
62340484|NCT03065634|ACTIVE_COMPARATOR|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
62340485|NCT01693133|OTHER|Control|Standard of Care: Moist Wound Therapy and Offloading
62340486|NCT01693133|EXPERIMENTAL|EpiFix plus Standard of Care|Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
62340487|NCT01450046|EXPERIMENTAL|Phase I Dose Escalation|Each investigator will be provided with adequate supplies of Vitamin E δ -Tocotrienol, which will be supplied as 100-mg, 200-mg, and 400-mg capsules. Vitamin E δ-Tocotrienol will be administered orally once. The dose administered to each subject will be fixed and based on cohort assignment. Doses will be administered at the clinical site during each protocol-defined visit.
62340488|NCT00006604|EXPERIMENTAL|Step I: Group 1|"Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m\^2, 620 mg/m\^2; Final Dose: Not Established"
62496611|NCT01198873|EXPERIMENTAL|Dronedarone|Dronedarone 400 mg twice a day
62496612|NCT01198873|PLACEBO_COMPARATOR|Placebo|Placebo (for Dronedarone) twice a day
62496613|NCT01226693|EXPERIMENTAL|Sequence 1|
62496614|NCT01226693|EXPERIMENTAL|Sequence 2|
62496615|NCT01226693|EXPERIMENTAL|Sequence 3|
62496616|NCT01226693|EXPERIMENTAL|Sequence 4|
62496617|NCT01226693|EXPERIMENTAL|Sequence 5|oral, 6mg, single dose
62496618|NCT01226693|EXPERIMENTAL|Sequence 6|oral, 6mg, single dose
62496619|NCT01155427||entecavir|Patients initiating special antiviral treatments for CHB
62496620|NCT01155427||tenofovir|Patients initiating special antiviral treatments for CHB
62496621|NCT01155427||lamivudine|Patients initiating special antiviral treatments for CHB
62496622|NCT01155427||telbivudine|Patients initiating special antiviral treatments for CHB
62496623|NCT01155427||adefovir|Patients initiating special antiviral treatments for CHB
62496624|NCT04784169|EXPERIMENTAL|free middle turbinate flap group|A free middle turbinate flap is used to repair the leakage
62496625|NCT04784169|ACTIVE_COMPARATOR|vascularized nasoseptal flap|A vascularized nasoseptal flap is used to repair the leakage
62340489|NCT00006604|EXPERIMENTAL|Step I: Group 2|"Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m\^2, 620 mg/m\^2; Final Dose: Not Established"
62496626|NCT01552330|EXPERIMENTAL|Group A|Primaquine only followed by Pyronaridine-Artesunate and followed by Primaquine together with Pyronaridine-Artesunate.
62496627|NCT01552330|ACTIVE_COMPARATOR|Group B|Primaquine only followed by Primaquine together Pyronaridine-Artesunate and followed by Pyronaridine-Artesunate only.
61945968|NCT03509311||Asthma Group|"That group consists from patients who had diagnosed as asthma by doctors from Chest Diseases Department of Gazi University Hospital.~Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment, depression and anxiety level assesment and asthma management knowledge assesment apply to this group."
61945969|NCT03509311||Healthy Group|That group consists from participants who do not have any diagnosed disease. Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment and depression and anxiety level assesment apply to this group.
61945970|NCT04575623||Study group|It will consist of 120 patients suffering from migraine according to international classification of headache
61945971|NCT06151132||Patients with atrial fibrillation|Direct current cardioversion
61945972|NCT02543580|EXPERIMENTAL|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
61945973|NCT02543580|EXPERIMENTAL|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
62496628|NCT02197416|EXPERIMENTAL|dabigatran etexilate|
62496629|NCT03206749|EXPERIMENTAL|VX-150|
62496630|NCT03206749|ACTIVE_COMPARATOR|Hydrocodone Bitartrate/Acetaminophen (HB/APAP)|
62496631|NCT03206749|PLACEBO_COMPARATOR|Placebo|
61945974|NCT02543580|EXPERIMENTAL|sham electroacupuncture|electrode attached but no stimulation
61945975|NCT05291325|EXPERIMENTAL|3L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 3L polyethylene glycol solution combined with 3-day linaclotide.
61945976|NCT05291325|ACTIVE_COMPARATOR|3L PEG alone|Bowel preparation for colonoscopy was performed with 3L polyethylene glycol solution without linaclotide.
61945977|NCT05291325|EXPERIMENTAL|2L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 2L polyethylene glycol solution combined with 3-day linaclotide.
61945978|NCT04875169|EXPERIMENTAL|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
62340490|NCT00006604|EXPERIMENTAL|Step I: Group 3|"Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m\^2, 415 mg/m2, 520 mg/m\^2; Final Dose: 520 mg/m\^2"
62340491|NCT00006604|EXPERIMENTAL|Step I: Group 4|"Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m\^2, 520 mg/m\^2, 620 mg/m\^2; Final Dose: 620 mg/m\^2"
61945979|NCT04875169|EXPERIMENTAL|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
62340492|NCT00006604|EXPERIMENTAL|Step I: Group 5|"Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m\^2; Final Dose: 310 mg/m\^2"
62340493|NCT00006604|EXPERIMENTAL|Step I: Group 5a|"Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m\^2; Final Dose: 310 mg/m\^2"
62340494|NCT00006604|EXPERIMENTAL|Step I: Group 6|"Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m\^2; Final Dose: 310 mg/m\^2"
62340495|NCT00006604|EXPERIMENTAL|Step I: Group 7|"Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m\^2, 205 mg/m\^2; Final Dose: 205 mg/m\^2"
62340496|NCT00006604|EXPERIMENTAL|Step I: Group 8|"Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m\^2, 205 mg/m\^2; Final Dose: 205 mg/m\^2"
62340497|NCT02156492|EXPERIMENTAL|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
62340498|NCT02156492|EXPERIMENTAL|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
62340499|NCT02156492|ACTIVE_COMPARATOR|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
62496632|NCT03232450|ACTIVE_COMPARATOR|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
62496633|NCT03232450|OTHER|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
62496634|NCT04232540|EXPERIMENTAL|Patient participants|Patient and provider will view and discuss results of the MedViewer test.
62496635|NCT04232540|EXPERIMENTAL|Provider participants|Patient and provider will view and discuss results of the MedViewer test.
62340500|NCT02156492|EXPERIMENTAL|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
62496636|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
62340501|NCT02156492|ACTIVE_COMPARATOR|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
62340502|NCT02156492|EXPERIMENTAL|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
62496637|NCT01610050|EXPERIMENTAL|LFA102|
61945980|NCT04875169|PLACEBO_COMPARATOR|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
61945981|NCT04875169|EXPERIMENTAL|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
61945982|NCT04875169|EXPERIMENTAL|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
61945983|NCT02514525|OTHER|CryoBalloon Ablation System|Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
62340503|NCT03204435|OTHER|Traditional therapy|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented by stages.
61945984|NCT01193699|EXPERIMENTAL|P1101|
61945985|NCT04813640|PLACEBO_COMPARATOR|Single Vision Spectacles|Commercially available conventional single vision spectacles
62340504|NCT03204435|EXPERIMENTAL|Hybrid operation|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented in one-stage in hybrid operating theater.
62496638|NCT00096005|EXPERIMENTAL|Treatment (chemotherapy and enzyme inhibitor therapy)|"Patients receive tanespimycin IV over 1-2 hours and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 12 additional patients are treated as above\* at the MTD.~NOTE: \*Bortezomib is not administered on day 1 of course 1 only. Patients are followed at 3 months."
62496639|NCT06411392|EXPERIMENTAL|Stereotactic Antiarrhythmic Radiotherapy|Stereotactic antiarrhythmic radiotherapy for refractory ventricular arrhythmia
61945986|NCT04813640|ACTIVE_COMPARATOR|Commercially available myopia control spectacles|Commercially available myopia control spectacles
61945987|NCT04813640|EXPERIMENTAL|Novel Myopia control spectacles - Prototype I|Experimental myopia control spectacles
62496640|NCT06282406|EXPERIMENTAL|Paired, Sub-Threshold Stim|Sub-threshold stimulation paired with successful task repetitions
61945988|NCT04813640|EXPERIMENTAL|Novel Myopia control spectacles - Prototype II|Experimental myopia control spectacles
61945989|NCT03364933|EXPERIMENTAL|Primary intensivist and nurses|Patients randomized to the experimental arm will have a primary intensivist and a team of primary nurses assigned to them.
62340505|NCT03115476|EXPERIMENTAL|Ingenol disoxate gel 0.018%|
62340506|NCT03115476|EXPERIMENTAL|Ingenol disoxate gel 0.037%|
62340507|NCT03115476|PLACEBO_COMPARATOR|Vehicle gel|
62340508|NCT01265420|EXPERIMENTAL|Injectable clostridial collagenase|Patients with thumb 1st web contracture secondary to Dupuytren's disease will be treated with 0.58mg of collagenase
62340509|NCT06527456|NO_INTERVENTION|usual practice|the doctor will use their usual practices to encourage screening.
62340510|NCT06527456|EXPERIMENTAL|Intervention|the general practitioner or one of the professionals on their team will contact the patient (phone call, SMS, email, etc.), to encourage them to make an appointment to carry out the screening
62340511|NCT03446430|EXPERIMENTAL|Hypertensives|PWV measurement by LDV
62340512|NCT05142540||blood and saliva sampling|blood and saliva samples will be taken
62340513|NCT05682586|NO_INTERVENTION|standard therapy|Participants will receive standard therapy, including oxygen therapy，glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.
62340514|NCT05682586|ACTIVE_COMPARATOR|Paxlovid treatment|Participants will receive paxlovid treatment on the basis of standard therapy.
62340515|NCT05682586|EXPERIMENTAL|UC-MSCs treatment|Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment.
62496641|NCT06282406|EXPERIMENTAL|Paired, Supra-Threshold Stim|Supra-threshold stimulation paired with successful task repetition
62496642|NCT06282406|EXPERIMENTAL|Unpaired, Sub-Threshold Stim|Sub-threshold stimulation after successful task repetition
62496643|NCT06282406|EXPERIMENTAL|Unpaired, Supra-Threshold Stim|Supra-threshold stimulation after successful task repetition
61945990|NCT03364933|NO_INTERVENTION|Control|Patients who are randomized to the control group will receive usual care and not be assigned a primary intensivist or nurses.
61945991|NCT02758769||ORENCIA with Exposure|ORENCIA with Exposure
61945992|NCT03530527|ACTIVE_COMPARATOR|ERCP with biliary stenting|Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.
62496644|NCT06282406|SHAM_COMPARATOR|Sham|No stimulation
62496645|NCT06070545|EXPERIMENTAL|İntervention Group|Modified supine position care
62697864|NCT06616610|ACTIVE_COMPARATOR|The Control Arm|Participants included in arms are children with the following inclusion criteria: - Diagnosed with cerebral palsy - Classified as GMFCS level IV or higher, indicating an inability to walk or operate a powered wheelchair. - Under 12 years old. - Must be affiliated to a center whose facilities guarantee a proper navigation experience The participants will be randomly assigned to two equal-sized arms: the control arm, in which participants will continue with the traditional therapy, and the experimental arm, where the children will use the platform. The control arm participants continue with their regular therapy. Regular cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
62697865|NCT01542788|EXPERIMENTAL|SOF+RBV|Participants were randomized to receive SOF+RBV for 12 weeks.
62697866|NCT01542788|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.
62697867|NCT06638450|EXPERIMENTAL|DCEAS+BA group|Subjects assigned to Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA) group will receive DCEAS+BA treatment, twice weekly for 8 weeks, in addition to their current interventions and medications as usual.
62697868|NCT06638450|SHAM_COMPARATOR|MAS group|Subjects assigned to Minimal Acupuncture Stimulation (MAS) group will receive MAS treatment, twice weekly for 8 weeks, in addition to their current interventions and medications as usual.
62697869|NCT04344912||COVID19- Population|Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan
62697870|NCT04344912||COVID19+ Population|Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan
62697871|NCT03131193|NO_INTERVENTION|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
62340516|NCT02998424|EXPERIMENTAL|Propofol 1 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 1 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
62697872|NCT03131193|EXPERIMENTAL|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
61945993|NCT03530527|ACTIVE_COMPARATOR|EUS guided biliary drainage|Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.
62340517|NCT02998424|EXPERIMENTAL|Propofol 2 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 2 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
62340518|NCT02998424|EXPERIMENTAL|Propofol 3 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 3 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
62340519|NCT05323292||Leukoplakia due to hyperkeratosis with dysplasia|Biopsy-confirmed diagnosis of hyperkeratosis with dysplasia.
62340520|NCT05323292||Leukoplakia due to hyperkeratosis with no dysplasia|Biopsy-confirmed diagnosis of hyperkeratosis with no dysplasia.
62340521|NCT05323292||Control group|Laryngoscopy showing no evidence of vocal fold epithelial disease.
62340522|NCT03414762|EXPERIMENTAL|PICO Dressing|PICO Negative Pressure Wound Therapy (Smith and Nephew Healthcare, Hull, United Kingdom) is a non-significant-risk, FDA Class II, medical device commercially available in the USA. The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.
62340523|NCT03414762|ACTIVE_COMPARATOR|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing.
62340524|NCT01634321|EXPERIMENTAL|Luphere|
62340525|NCT03570034||Obalon Balloon System|Obalon Balloon System with moderate intensity Weight Loss Behavioral Modification Program
62340526|NCT00343291|ACTIVE_COMPARATOR|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)|"Cycles 1-6:~* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~* Paclitaxel 200 mg/m² on day 1 of every 3 week cycle~* Carboplatin area under curve (AUC=6 min\*mg/mL) on day 1 of every 3 week cycle~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
62340527|NCT00343291|ACTIVE_COMPARATOR|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)|"Cycles 1-6:~* Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~* Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Cycles 1-3:~* Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles~* Carboplatin AUC=6 min\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
62496646|NCT06070545|NO_INTERVENTION|Control Group|Standard Care
62496647|NCT05995769|EXPERIMENTAL|High Dose (25mg)|PEX010 (Oral Psilocybin), 25mg; single dose administered 24hrs prior to first of 5 weekly MET sessions
62496648|NCT05995769|ACTIVE_COMPARATOR|Low dose (1mg)|PEX010 (Oral Psilocybin), 1mg; single dose administered 24hrs prior to first of 5 weekly MET sessions
62496649|NCT02883439|EXPERIMENTAL|Investigational product|MP29-02 137
62496650|NCT02883439|ACTIVE_COMPARATOR|Non-investigational product|fluticasone propionate
62496651|NCT01992406||Transrectal hybrid-NOTES anterior resection|
62496652|NCT01942278|NO_INTERVENTION|Usual Care|Care is delivered according to baseline standard practice
61945994|NCT02837146|EXPERIMENTAL|Tocilizumab (TCZ) + Methotrexate (MTX)|"Induction phase:~From week 0 to week 24, all subjects will receive TCZ and MTX~Maintenance phase:~From week 24 to week 54, all subjects will receive MTX"
61945995|NCT01500031|EXPERIMENTAL|OffRoad Re-entry catheter|Participants treated with OffRoad Re-entry Catheter System
62140045|NCT03987646|EXPERIMENTAL|xenograft cortical flexible sheet|a-traumatic tooth removal , socket lavage and curettage, performing a vestibular access horizontal incision corresponding to the socket 3-4 mm apically from the muccogingival junction , a tunnel is then created from the socket office and extended apically till it connects with the vestibular access incision, a computer guided surgical template is then used to deliver the implant in its optimal position, a slowly resorbable membrane shield is then introduced through the tunnel and stabilized with a membrane tac , it is a sturdy fixable membrane barrier placed above the labial plate
62340528|NCT02518308|EXPERIMENTAL|Arm I (MBSR intervention)|Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
62340529|NCT02518308|NO_INTERVENTION|Arm II (control)|Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.
62340530|NCT04224285|EXPERIMENTAL|Early Dayzz|Participants receive a Sleep Health and Wellness education session and download the Dayzz app. Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries.
62340531|NCT04224285|NO_INTERVENTION|Late Dayzz|Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries. At the end of nine months, participants have the opportunity to receive a Sleep Health and Wellness education session.
61945996|NCT03872154|EXPERIMENTAL|Intervention|"In this group (intervention), physicians will conduct checklist-guided shared decision making to determine the patient's code status. Additionally, physicians will be given a decision aid, which they are told to use to illustrate impact and outcome of in-hospital cardiac arrests.~Ancillary project (patients considered as futile): In this group (intervention), physicians will conduct checklist-guided communication."
61945997|NCT03872154|NO_INTERVENTION|Usual Care|In this group (control), physicians will conduct code status discussions as usually.
61945998|NCT02343107|EXPERIMENTAL|1|Subgroup of subjects who benefit of the e-coaching
62140046|NCT05364385|EXPERIMENTAL|S/B group- infants|Infants randomized to the study group (S/B group) will receive surfactant and Budesonide - 0.5 mg -1mL
62140047|NCT05364385|PLACEBO_COMPARATOR|S/P group- control / placebo comparator|Infants randomized to the control group (S/P group) will receive surfactant and placebo (Normal Saline -1mL)
62340532|NCT04108585||HFO group|HFO therapy
62140048|NCT04060212|EXPERIMENTAL|All Participants|All participant will eat 6 meals of tuna fish. All participants will take a prebiotic dietary supplement.
62340533|NCT04108585||CPAP group|CPAP therapy
62340534|NCT03030911|ACTIVE_COMPARATOR|Dexmedetomidine group|"* Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~* Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1)~* Intervention: indirect calorimetry"
62340535|NCT03030911|PLACEBO_COMPARATOR|midazolam group|"* Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~* Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1.~* Intervention: indirect calorimetry"
62496653|NCT01942278|EXPERIMENTAL|BHOMA|Care is delivered according to the BHOMA intervention
61945999|NCT02343107|NO_INTERVENTION|2|Subgroup of subjects who are asked to follow the conventional nutritional recommendations of the treatment of abdominal obesity and diabetes
61946000|NCT01631110|EXPERIMENTAL|Elderly subjects aged over 60 years|
61946001|NCT01631110|EXPERIMENTAL|Adults from 18 to 60 years old inclusive|
61946002|NCT02053870|EXPERIMENTAL|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
61946003|NCT02053870|ACTIVE_COMPARATOR|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
61946004|NCT00627185|EXPERIMENTAL|1|Intervention group (dental practices) that received the interactive motivational website for patient tobacco cessation
61946005|NCT00627185|PLACEBO_COMPARATOR|2|Control group (dental practices) that did not receive any materials or resources on tobacco cessation. This is a wait-list control.
61946006|NCT05559398|PLACEBO_COMPARATOR|Placebo|
61946007|NCT05559398|EXPERIMENTAL|Glenzocimab|
62140049|NCT01329952||Current intravenous drug users|Those who were actively injecting drugs at the time of their hepatitis C treatment.
62140050|NCT01329952||Past drug users|Those who stopped injecting drugs intravenously at least 6 months prior to the start of treatment for hepatitis C
62140051|NCT01370928|EXPERIMENTAL|Prototype colonoscope|The new colonoscope to be tested
62140052|NCT01370928|ACTIVE_COMPARATOR|Standard colonoscope|The standard colonoscope used world-wide today.
62140053|NCT06118307||Ambispective patient cohort|Patients attending the oncology department require differential diagnosis of ovarian cancer.
62140054|NCT06118307||High-risk population cohort|Family members of ovarian cancer patients; family history of BRCA mutation-related disease; abnormal findings on ovarian cancer screening; history of ovarian disease and other risk factors.
62340536|NCT03076190|NO_INTERVENTION|Active Control Group (Health Education)|"Prior to surgery:~* Demographics survey~* Baseline surveys~* Participants receive online information regarding nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery.~* Follow-up questions about the handouts (detailed above)~Post-surgery:~* Daily surveys (detailed above)~* Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
62697873|NCT03131193|EXPERIMENTAL|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
62697874|NCT03131193|EXPERIMENTAL|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
62697875|NCT03131193|EXPERIMENTAL|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
61946008|NCT00098956|EXPERIMENTAL|Treatment (topotecan hydrochloride, UCN-01)|Patients receive topotecan IV over 30 minutes on days 1-5 and UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR receive 2 additional courses beyond CR or PR.
61946009|NCT04745000||Pulmonary Hypertension Participants|Children with Primary Pediatric Pulmonary Arterial Hypertension
61946010|NCT04745000||Control Participants|Children with a healthy heart and lungs
61946011|NCT04958668|ACTIVE_COMPARATOR|Volatile procedere|Intensive care treatment with demand-adapted sedation with volatile anaesthetics
62697876|NCT03131193|EXPERIMENTAL|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
61946012|NCT04958668|NO_INTERVENTION|Conventional procedere|Conventional Intensive care treatment with demand-adapted sedation with intravenous sedatives
61946013|NCT05276596|ACTIVE_COMPARATOR|Control group|The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
61946014|NCT05276596|EXPERIMENTAL|Test group|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
61946015|NCT03319173|EXPERIMENTAL|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
61946016|NCT03319173|ACTIVE_COMPARATOR|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
62340537|NCT03076190|EXPERIMENTAL|My Surgical Success Treatment Group|"Prior to surgery:~* Demographics survey~* Baseline surveys~* Intervention:~  * 90-minute psychoeducational My Surgical Success video that emphasizes catastrophizing treatment.~ * audio file~ * personalized plan that incorporates the information learned in the video.~* Follow-up questions about the video (detailed above)~Post-surgery:~* Daily surveys (detailed above)~* Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
62340538|NCT01337063|NO_INTERVENTION|Pre-intervention|Usual care regarding medication reconciliation as currently practiced at each participating site.
62340539|NCT01337063|EXPERIMENTAL|Intervention|Improved medication reconciliation process using continuous quality improvement methods, mentored implementation, and an implementation guide.
62340540|NCT04173442||Cohort 1: Dupilumab-Exposed Cohort|Pregnant women with approved indications exposed to dupilumab during pregnancy
62697877|NCT06236646|EXPERIMENTAL|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
62140055|NCT06118307||Healthy control cohort|Healthy women with normal health examination results.
62140056|NCT03524131|EXPERIMENTAL|risk-framed leaflet|Patients sent 2-sided risk-framed leaflet with NHS Health Check invitation
62340541|NCT04173442||Cohort 2: Disease-Matched Comparison Cohort|Pregnant women with approved indications not exposed to dupilumab during pregnancy
62340542|NCT04173442||Cohort 3: Healthy Comparison Cohort|Pregnant women who are not diagnosed with any dupilumab-approved indications, and not exposed to dupilumab during pregnancy
62496654|NCT00709514|EXPERIMENTAL|DCB-WH1 ointment|DCB-WH1 ointment 1.25%, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
61946017|NCT06361160|ACTIVE_COMPARATOR|Active TMS sessions|For a given patient, the 6 sessions (out of 12) in which the TMS is active.
62140057|NCT03524131|EXPERIMENTAL|benefits-framed leaflet|Patients sent 2-sided benefits-framed leaflet with NHS Health Check invitation
61946018|NCT06361160|SHAM_COMPARATOR|Sham TMS sessions|For a given patient, the 6 sessions (out of 12) in which the TMS is a sham.
61946019|NCT03074955|ACTIVE_COMPARATOR|Control|"leg wrapping without tension \& maintain supine position~1. Apply elastic bandages to both legs without tension.~2. Maintain supine position after injecting propofol.~3. After 3 minutes from propofol injection, remove elastic bandages~4. induction using propofol 2mg/kg~5. After bispectral index (BIS) goes below 60 \& patient become unconsciousness, inject rocuronium 0.6mg/kg~6. intubate patient between 3 and 4 minutes after propofol injection~7. measure blood pressure ( systolic, diastolic, mean ) \& heart rate at 1,2,3,4,5 minutes after propofol injection~8. phenylephrine injection if hypotension develops"
61946020|NCT03074955|EXPERIMENTAL|Trendelenburg only|"leg wrapping without tension \& apply Trendelenburg position~1. Apply elastic bandages to both legs without tension.~2. After injecting propofol, apply Trendelenburg position ( 10 degree )~3. After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~4. induction using propofol 2mg/kg~5. After bispectral index (BIS) goes below 60 \& patient become unconsciousness, inject rocuronium 0.6mg/kg~6. intubate patient between 3 and 4 minutes after propofol injection~7. measure blood pressure ( systolic, diastolic, mean ) \& heart rate at 1,2,3,4,5 minutes after propofol injection~8. phenylephrine injection if hypotension develops"
61946021|NCT03074955|EXPERIMENTAL|Trendelenburg & leg wrapping|"leg wrapping with tension \& apply Trendelenburg position~1. Apply elastic bandages to both legs with tension.~2. After injecting propofol, apply Trendelenburg position ( 10 degree )~3. After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~4. induction using propofol 2mg/kg~5. After bispectral index (BIS) goes below 60 \& patient become unconsciousness, inject rocuronium 0.6mg/kg~6. intubate patient between 3 and 4 minutes after propofol injection~7. measure blood pressure ( systolic, diastolic, mean ) \& heart rate at 1,2,3,4,5 minutes after propofol injection~8. phenylephrine injection if hypotension develops"
61946022|NCT06680622|EXPERIMENTAL|Cohort 1|bemarituzumab plus SOC treatment with irinotecan
61946023|NCT06680622|EXPERIMENTAL|Cohort 2|bemarituzumab plus SOC treatment with paclitaxel plus ramucirumab
61946024|NCT06680622|EXPERIMENTAL|Cohort 3|bemarituzumab plus SOC treatment with trifluridine/tipiracil
61946025|NCT04941560||Algorithm training and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to training and validate the algorithm for CAD detection based on facial photos.
61946026|NCT04359667||tocilizumab|one infusion of TCZ 8 mg/kg i.v., with a maximum dose of 800 mg, and SOC treatment according to local guidelines (hydroxychloroquine or/and lopinavir/ritonavir or/and remdesivir).
62496655|NCT00709514|PLACEBO_COMPARATOR|Placebo|Placebo, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
61946027|NCT00691223||Experimental|Individuals with Goltz syndrome and their first degree relatives.
62496656|NCT05635630|EXPERIMENTAL|ctDNA positive|
62140058|NCT03524131|ACTIVE_COMPARATOR|control|Patients sent 4-sided current national leaflet with NHS Health Check invitation
62140059|NCT02927249|EXPERIMENTAL|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
62140060|NCT02927249|PLACEBO_COMPARATOR|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
62140061|NCT06078696|EXPERIMENTAL|Siplizumab|Participants will receive 5 infusions of siplizumab. The first dose is given 14 days prior to the infusion of stem cells; the second dose is given 6 days before infusion; and doses 3, 4, and 5 are given on the day before, day of, and day after stem cell infusion.
62140062|NCT00505336|EXPERIMENTAL|1|Eplerenone
62140063|NCT00505336|ACTIVE_COMPARATOR|3|no additional treatment
62140064|NCT00505336|EXPERIMENTAL|2|Atorvastatin
62140065|NCT01065649|EXPERIMENTAL|Nortriptyline|20 NERD patients will be treated with nortriptyline 10 mg a day in the first 7 days and 25 mg a day in the following 14 days
62140066|NCT01065649|PLACEBO_COMPARATOR|Placebo|Placebo arm
62140067|NCT02334917|EXPERIMENTAL|Absorbable suture closure|Patients will have half of their surgical wound closed using one kind of absorbable superficial sutures, and the other half with a different kind of absorbable superficial suture. Which half receives which suture will be randomly determined.
62140068|NCT02082652|ACTIVE_COMPARATOR|Control group (No ART)|Etonogestrel implant in participants not yet receiving ART (control group)
62496657|NCT05635630|EXPERIMENTAL|ctDNA negative|
62496658|NCT03588260||Idiopathic pulmonary fibrosis|The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic.
62496659|NCT03588260||Healthy subjects|The healthy adults without additional disease
62496660|NCT04381741|EXPERIMENTAL|CD19-7×19 CAR-T plus PD1 monoclonal antibody|
62496661|NCT06669754|EXPERIMENTAL|Active|Deucrictibant 40mg extended-release tablet by mouth once daily
62496662|NCT06669754|EXPERIMENTAL|Placebo|Placebo 1 tablet by mouth once daily
62496663|NCT06167850|EXPERIMENTAL|Intervention group|Group doing the Copenhagen plank
62496664|NCT06167850|NO_INTERVENTION|Control group|Group doesn't do Copenhagen plank
62496665|NCT01086969|EXPERIMENTAL|Study Group|Participants in three age cohorts - Children: 2 - 11 years of age; Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age will be enrolled.
62496666|NCT01285505|ACTIVE_COMPARATOR|Alprazolam commercial sublingual tablet|
62496667|NCT01285505|EXPERIMENTAL|Alprazolam test sublingual tablet|
62496668|NCT05141474|EXPERIMENTAL|NEXTGEN-TIL|Subjects will receive a therapy based on Tumor-infiltrating Lymphocyte (NEXTGEN-TIL product) preceded by a preparative non-myeloablative lymphodepleting (NMA-DL) regimen and followed by IL-2 infusion. Patients will be followed-up for 2 years, assessed at weeks 2, 3, 4, 6, 9, 12, 18, 24, 30, 36 (9 months), and then at 1 year, 1,5 and 2 years.
62496669|NCT05107739|EXPERIMENTAL|Safety Run In|Patients with gynecological malignancies
62496670|NCT05107739|EXPERIMENTAL|EOC|Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma
62496671|NCT05107739|EXPERIMENTAL|Cervical|Recurrent, metastatic, or persistent cervical carcinoma
62496672|NCT05107739|EXPERIMENTAL|Endometrial|Advanced or recurrent endometrial cancer
62496673|NCT03565562|NO_INTERVENTION|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the 12 first months. Free access to StopBlues.
62496674|NCT03565562|ACTIVE_COMPARATOR|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). Free access to StopBlues.
62496675|NCT03565562|ACTIVE_COMPARATOR|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
62496676|NCT04860349|EXPERIMENTAL|High Intensity Interval Training|20 minutes of High Intensity Interval Training for experimental group.
62496677|NCT04860349|NO_INTERVENTION|Control|No intervention for the control group.
62496678|NCT06331650|EXPERIMENTAL|cadonilimab|
62496679|NCT02849106|EXPERIMENTAL|biopsy to obtain a chemogram|
61946028|NCT01034150|ACTIVE_COMPARATOR|Somatosensory stimulation|Active group
62340543|NCT04245527|EXPERIMENTAL|Study Arm|20 minutes Joovv Solo every day for 8 weeks.
62340544|NCT04116450|OTHER|primary congenital glaucoma|Glaucolight illuminated microcatheter trabeculotomy in primary congenital glaucoma
62340545|NCT06022978|NO_INTERVENTION|EUS only|The enrolled patients will accept ordinary EUS only.
62340546|NCT06022978|EXPERIMENTAL|EUS+SSI|The enrolled patients will be accepted submucosal injection of saline（SSI）,then EUS will be performed.
62340547|NCT06022978|EXPERIMENTAL|BLI+ME/EUS+SSI|The enrolled patients will be accepted ordinary endoscope using blue laser Imaging and magnified ensocope system(BLI+ME), firstly. If B3 type intra pillary capillary loops (IPCL) was observed, then the procedure would be finished (no EUS or EUS+SSI) . If B1 or B2 type IPCL was observed, then EUS+SSI would be performed.
62496680|NCT03646162|EXPERIMENTAL|Veru-944 10 mg|Veru-944 10 mg daily
62496681|NCT03646162|EXPERIMENTAL|Veru-944 50 mg|Veru-944 50 mg daily
62496682|NCT03646162|PLACEBO_COMPARATOR|Placebo|Placebo daily
62496683|NCT02771392|EXPERIMENTAL|Tetracaine Group|Patients with he primary diagnosis of corneal abrasion will be treated with ophthalmic tetracaine. Tetracaine will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of preservative-free, undiluted 1% tetracaine hydrochloride (a total of 1.5 mL or approximately 50 drops will be provide to avoid overuse). Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
62496684|NCT02771392|PLACEBO_COMPARATOR|Normal Saline Group|Patients with the primary diagnosis of corneal abrasion will be treated with normal saline eye drops. Normal saline will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of normal saline. Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
62496685|NCT01603667|EXPERIMENTAL|PG2 Injection 500 mg|PG2 Injection 500 mg
62496686|NCT01603667|PLACEBO_COMPARATOR|Placebo|Placebo
62496687|NCT06110819|EXPERIMENTAL|Workgroup|.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health.
62496688|NCT06110819|OTHER|Control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
62496689|NCT06324305|ACTIVE_COMPARATOR|Group 1|drainage of sub-retinal fluid from the original (primary) break
62496690|NCT06324305|ACTIVE_COMPARATOR|Group 2|drainage of sub-retinal fluid using perfluorocarbon (PFC) and removing sub-retinal fluid through the original break or peripheral retinotomy
62496691|NCT06324305|ACTIVE_COMPARATOR|Group 3|drainage of sub-retinal fluid through formation of a posterior drainage retinotomy only.
62496692|NCT05165654|EXPERIMENTAL|Active Stimulation with TDCS|10 tDCS; Two, twenty-minute sessions of tDCS to the rSTS for 5 days (10 total sessions).
62140069|NCT02082652|ACTIVE_COMPARATOR|Nevirapine-based ART group|Etonogestrel implant in participants receiving nevirapine (NVP)-based ART
61946029|NCT01034150|PLACEBO_COMPARATOR|Control group|Placebo stimulation
61946030|NCT04394975|EXPERIMENTAL|Test group|Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orraly twice daily.
62340548|NCT02652507|OTHER|Anesthesia for MRI|"All patients will receive the same drugs.~A loading dose of dexmedetomidine of 2 mcg/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h. Bolus dose 2 mg/kg of ketamine will be given after the initial set of research images have been taken."
62340549|NCT00667251|ACTIVE_COMPARATOR|Lapatinib|Plus taxane based chemotherapy
62340550|NCT00667251|ACTIVE_COMPARATOR|Trastuzumab|Plus taxane based chemotherapy.
62340551|NCT03685669||Lung nodule group|
62340552|NCT03685669||Healthy Control group|
62340553|NCT05270850|ACTIVE_COMPARATOR|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
62340554|NCT05270850|EXPERIMENTAL|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula.
62340555|NCT01948388|ACTIVE_COMPARATOR|corticotrophin 80 units|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) weekly
62340556|NCT01948388|ACTIVE_COMPARATOR|corticotrophin 80 units twice a week|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) twice a week
62697878|NCT06236646|SHAM_COMPARATOR|Control (CON)|The CON group did not have any intervention but usual care.
62697879|NCT04252664|EXPERIMENTAL|Remdesivir group|active remdesivir
62496693|NCT05165654|SHAM_COMPARATOR|SHAM Stimulation|10 passive sham control; Two, twenty-minute sessions of passive sham control to the rSTS for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).
62496694|NCT01251393|EXPERIMENTAL|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
62496695|NCT01251393|PLACEBO_COMPARATOR|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
62496696|NCT00856349||Analysis cohort|Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.
62140070|NCT02082652|ACTIVE_COMPARATOR|Efavirenz-based ART group|Etonogestrel implant in participants receiving efavirenz (EFV)-based ART
62140071|NCT04383067|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|
61946031|NCT04394975|ACTIVE_COMPARATOR|Control group|Sunitinib monotherapy. Participants receive sunitinib 50mg orally once daily for 4 weeks and then are off treatent for 2 weeks, or once daily for 2weeks and then are off treatent for 1 week.
62140072|NCT01730456|EXPERIMENTAL|RoActemra/Actemra|
62140073|NCT04455204||non-pregnant women (group 1)|20 non-pregnant women who serve as a control group (group 1)
62140074|NCT04455204||pregnant women (group 2)|20 pregnant women with normal pregnancy at their third trimesters (group 2)
61946032|NCT04001933|EXPERIMENTAL|Intervention Arm|CPOP Intervention (see below).
61946033|NCT04001933|NO_INTERVENTION|Control Arm|Usual care.
61946034|NCT05714059|EXPERIMENTAL|MiniMed™ 780G system with DS5|Subjects with type 1 diabetes wearing the MiniMed™ 780G insulin pump in combination with the DS5 CGM.
62140075|NCT04455204||pregnant women with Preeclampsia (group 3)|20 pregnant women with Preeclampsia in their third trimester (group 3) will be screened to fit the inclusion and exclusion criteria.
62140076|NCT04942184|EXPERIMENTAL|Group 1- 15 Mild AD and 15 MCI due to AD|In Group 1, for the first 2 weeks participants will be taught memory strategies and reminded to use them each day from week 0 to week 2. Weeks 3-4, participants will be advised to keep using the strategies both on the tablet and in their daily life even though they will not be reminded each time they start the task.
62140077|NCT04942184|ACTIVE_COMPARATOR|Group 2- 15 Mild AD and 15 MCI due to AD|"In Group 2, for the first 2 weeks participants will be reminded to try hard to remember the items although they will not be given any specific strategies. At week 2 the subjects will be taught memory strategies and reminded to use them each day from week 2 to week 4."
62140078|NCT01788605|EXPERIMENTAL|ramosetron|
62340557|NCT02753036||Chemotherapy|patients with ovarian cancer and paclitaxel + carboplatin combination chemotherapy as well as patients with breast cancer and paclitaxel +/- carboplatin combination chemotherapy
62340558|NCT02753036||Healthy control|patients with benign gynecological tumors after laparoscopic surgical resection
62340559|NCT02753036||Tumor control|patients with breast cancer with anti-hormonal and/or localized radiation treatment but no chemotherapy
62340560|NCT01511679||Alcohol-naive adolescents|A general population longitudinal cohort of alcohol-naïve (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o).
62340561|NCT01511679||Treatment sample|A sample of adolescents who have a \>1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan
62340562|NCT01511679||High risk sample|High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)
61946035|NCT02169479|EXPERIMENTAL|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
62340563|NCT00661245|EXPERIMENTAL|TOGA|The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.
62340564|NCT00661245|SHAM_COMPARATOR|Control|A gastric sleeve is not formed.
62340565|NCT02951390|ACTIVE_COMPARATOR|High-definition white-light endoscopy|High-definition white-light endoscopy without indigo carmine instilation
62340566|NCT02951390|NO_INTERVENTION|High-definition chromoendoscopy|High-definition indigo-carmine chromoendoscopy
62340567|NCT02680886||Novosyn® Quick|Skin closure using rapid absorbable suture material
62340568|NCT00799344||Stent|Catania Stent
62340569|NCT05266794|NO_INTERVENTION|Control|25 hemodialysis patients who received their routine therapy only.
62340570|NCT05266794|ACTIVE_COMPARATOR|Selenium|23 hemodialysis patients who received Selenium 200µg once daily with their routine therapy just after the dialysis sessions for 3 months.
62340571|NCT05266794|ACTIVE_COMPARATOR|Alpha Lipoic acid|20 hemodialysispatients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
62340572|NCT01098838|EXPERIMENTAL|Weekly dosing of LCL161|by mouth (oral)
62340573|NCT01098838|EXPERIMENTAL|Comparison of LCL161|tablet versus liquid
62340574|NCT01098838|EXPERIMENTAL|Twice daily dosing of LCL161|by mouth for 4 days followed by a 3-day rest period every week
62340575|NCT01029431|EXPERIMENTAL|1|All subjects will have both Air-Q ILA \& PLMA
62340576|NCT01173341||Subgroup 2|Subgroup2 represents will undergo trastuzumab therapy only
62340577|NCT01173341||Subgroup 1|Subgroup 1 are anthracycline only treated patients.
62340578|NCT01173341||Subgroup 3|Subgroup 3 are patients that will undergo trastuzumab therapy with anthracyclines.
62340579|NCT01722487|EXPERIMENTAL|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
62340580|NCT01722487|ACTIVE_COMPARATOR|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
61946036|NCT02169479|EXPERIMENTAL|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
61946037|NCT02169479|EXPERIMENTAL|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
61946038|NCT02169479|EXPERIMENTAL|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
61946039|NCT04667481|EXPERIMENTAL|Arm I (aerobic exercise)|Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
61946040|NCT04667481|EXPERIMENTAL|Arm II (resistance exercise)|Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
61946041|NCT04667481|EXPERIMENTAL|Control Group (digital exercise interventions)|After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
61946042|NCT01323959|EXPERIMENTAL|BOOSTRIX POLIO GROUP|Healthy subjects who had received one booster dose Boostrix™ Polio vaccine in the NCT01277705 study received one additional booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
61946043|NCT01323959|EXPERIMENTAL|BOOSTRIX+POLIORIX GROUP|Healthy subjects who had received one booster dose of the co-administered Boostrix™ and Poliorix™ vaccines in the NCT01277705 study received one booster dose Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
61946044|NCT01323959|EXPERIMENTAL|REVAXIS GROUP|Healthy subjects who had received one booster dose of Revaxis® vaccine in the NCT01277705 study received one booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
61946045|NCT05592262|EXPERIMENTAL|Treatment group A|
61946046|NCT05592262|EXPERIMENTAL|Treatment group B|
61946047|NCT02761070|ACTIVE_COMPARATOR|Bevacizumab (BEV) alone|Bevacizumab 10 mg/kg, day 1 div, every 2 weeks
61946048|NCT02761070|EXPERIMENTAL|Dose Dense Temozolomide Followed by BEV|Temozolomide (120 mg/m2, po, 7 days on/7 days off, every 2 weeks per cycle) up to 48 cycles. The dose will be escalated to 150 mg/m2 at 3rd cycle if the defined conditions are met throughout the first 2 cycles. At recurrence or progression, bevacizumab alone(10 mg/kg, day 1 div, every 2 weeks)
61946049|NCT01484275|EXPERIMENTAL|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
61946050|NCT01484275|PLACEBO_COMPARATOR|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
61946051|NCT01713608|EXPERIMENTAL|OZ439 Dose level 1 (300mg)|• Cohort 1 (12 subjects: 8 Active \[A\] and 4 on Placebo \[P\]) Active dose will consist of 300mg OZ439 drinking solution administered once daily for 3 days
61946052|NCT01713608|EXPERIMENTAL|OZ439 Dose level 2|• Cohort 2 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
61946053|NCT01713608|EXPERIMENTAL|OZ439 dose level 3|Cohort 3 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
61946054|NCT04789083|EXPERIMENTAL|Group 1 (Propolis)|Medical therapy and propolis
61946055|NCT04789083|EXPERIMENTAL|Group 2 (Nurse Coaching/ Nursing education)|Medical treatment and nurse coaching
61946056|NCT04789083|PLACEBO_COMPARATOR|Group 3 (Plassebo)|Medical treatment and plassebo will be applied.
61946057|NCT05975879|ACTIVE_COMPARATOR|ARTNEO|1 capsule 1 time per day for 6 months
61946058|NCT05975879|PLACEBO_COMPARATOR|Placebo|1 capsule 1 time per day for 6 months
61946059|NCT02002273|EXPERIMENTAL|Patients with regulated suction mode|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
61946060|NCT02002273|EXPERIMENTAL|regulated seal mode (-8 cmH2O).|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O and patients of group 2 are switched to -20 cm H2O. After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
61946061|NCT00436241|EXPERIMENTAL|1|
61946062|NCT00044083|PLACEBO_COMPARATOR|Placebo Arm|Placebo one week
61946063|NCT00044083|ACTIVE_COMPARATOR|Tolcapone Arm|Tolcapone one week
62496697|NCT04713982|EXPERIMENTAL|Deutetrabenazine|The mode of administration is oral. Subjects will be started on deutetrabenazine at a dose of 6mg/day. Dosing will be up-titrated in increments of 6mg/day per week to achieve optimal chorea control.
61946064|NCT01593410|EXPERIMENTAL|Lenalidomide and dexamethasone|Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
61946065|NCT04206059|EXPERIMENTAL|CLASS-D Cohort|Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.
61946066|NCT02242266|EXPERIMENTAL|Tiotropium low dose|oral inhalation via the blue HandiHaler®
62496698|NCT03929328|NO_INTERVENTION|Spontaneous breathing trial with T-piece|Patients were randomized to undergo a spontaneous breathing trial with T-piece that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
62496699|NCT03929328|EXPERIMENTAL|Spontaneous breathing trial with high flow oxygen therapy|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
61946067|NCT02242266|EXPERIMENTAL|Tiotropium medium dose|oral inhalation via the blue HandiHaler®
62140079|NCT05480540|EXPERIMENTAL|Serious game|A serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which was prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group.
62140080|NCT05480540|ACTIVE_COMPARATOR|Video|The video prepared on sterile dressing and surgical instrument preparation training will be shown to the students in the control group for 2 weeks.
62140081|NCT02955563|EXPERIMENTAL|CSDM Tool|Surrogate will complete educational sessions on CSDM tool prior to each family meeting with clinical team.
62140082|NCT02955563|NO_INTERVENTION|Control|Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
62140083|NCT06358755|EXPERIMENTAL|Low dose atropine plus DIMS|This group will receive 0.01% atropine (twice per day: 1 drop in the morning and 1 drop at night before bedtime) and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
62140084|NCT06358755|EXPERIMENTAL|Low dose atropine|This group will receive 0.01% atropine (twice per day: 1 drop in the morning and 1 drop at night before bedtime) and single vision spectacle lenses
62140085|NCT04495426||Presence of symptomatic ataxic disease|Presence of symptomatic ataxic disease with definite molecular diagnosis of SCA10 or whose first-degree relative has a molecular diagnosis of SCA10.
62340581|NCT03926767|EXPERIMENTAL|Pain Neuroscience Education + orofacial and neck exercises|All participants in this arm will initially receive two additional sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
62340582|NCT03926767|ACTIVE_COMPARATOR|Orofacial and neck exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
62340583|NCT01858610|OTHER|Irbesartan alone|Irbesartan 300 mg alone
62340584|NCT01858610|OTHER|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
62340585|NCT01858610|OTHER|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
62340586|NCT02742350|EXPERIMENTAL|IMT+Exercise|The inspiratory muscle training protocol (IMT) high intensity is achieved with a device with linear load pressure (POWERbreathe Plus Light Resistance®, SP, BR) that allows loads up to -90cmH2O. IMT is performed for 36 sessions (12 weeks) with weekly frequency of three times a week under supervision prior to the cardiac rehabilitation. The training protocol consists of five series with 10 repetitions each set until the 8th week with increase in the number of sets of repetitions of the 8th to 12th week, with two minutes or according to patient feedback using the modified Borg scale . Aerobic training lasts 40 minutes (5 minutes heating 30 minute workout and 5 minutes desaqueciemento. During training vital signs such as heart rate, blood pressure (BP) and peripheral oxygen saturation (SpO2) are evaluated and the feeling of effort the patient should not exceed the level of 8 according to the modified Borg scale.
62340587|NCT02742350|NO_INTERVENTION|Exercise Control|Aerobic Exercise and Stretching
62340588|NCT05044260|EXPERIMENTAL|Direct Sinus elevation using SLA Kit|
62340589|NCT01897922|ACTIVE_COMPARATOR|Marketed routine infant formula|
62340590|NCT01897922|EXPERIMENTAL|Infant formula containing a probiotic source|
62340591|NCT02875847|ACTIVE_COMPARATOR|HMO1|Daily bolus of HMO1
61946068|NCT02242266|ACTIVE_COMPARATOR|Spiriva® HandiHaler® high dose|oral inhalation via the grey HandiHaler®
62340592|NCT02875847|ACTIVE_COMPARATOR|HMO2|Daily bolus of HMO2
62340593|NCT02875847|PLACEBO_COMPARATOR|Dextropur|Daily bolus of dextropur
62496700|NCT02336308|ACTIVE_COMPARATOR|Ketamine|Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
62697880|NCT04252664|PLACEBO_COMPARATOR|Control group|Placebos matched remdesivir
62697881|NCT03970031|ACTIVE_COMPARATOR|MSDC-0602K|MSDC-0602K one tablet per day taken orally
61946069|NCT02242266|PLACEBO_COMPARATOR|Placebo|
61946070|NCT02138773|EXPERIMENTAL|Fed, formulation-A|drug administered at 0.5h after the start of a standard breakfast
61946071|NCT02138773|EXPERIMENTAL|Fed, formulation-B|drug administered at 0.5h after the start of a standard breakfast
61946072|NCT02138773|EXPERIMENTAL|Fasted, formulation-A|drug administered under fasted condition (fasting for at least 10 hours)
62140086|NCT04495426||Premanifest for SCA10|Asymptomatic participants of either sex aged ≥18 with definite molecular diagnosis of SCA10 (Premanifest carriers)
62140087|NCT04495426||At risk for SCA10|Asymptomatic participants of either sex, aged ≥18 whose first-degree relative has a molecular diagnosis of SCA10 (50%-at-risk relatives\*).
62140088|NCT04495426||Non-carrier for SCA10 (Control)|At risk participants who test negative for the SCA10 mutation will serve as non-carriers. Exclusion criteria described above also applies to non-carrier subjects. If the number of non-carriers were less than 10, we will recruit additional participants from normal population to supplement the controls.
61946073|NCT02138773|EXPERIMENTAL|Fasted, formulation-B|drug administered under fasted condition (fasting for at least 10 hours)
61946074|NCT03482765|EXPERIMENTAL|Probiotic 1|Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: \> 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
61946075|NCT03482765|EXPERIMENTAL|Probiotic 2|Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: \> 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
61946076|NCT03482765|PLACEBO_COMPARATOR|Placebo|The Placebo contains MCC.
61946077|NCT01395667|EXPERIMENTAL|Bevacizumab + CCRT followed by surgery|Bevacizumab 5 mg/kg every 2 weeks + radiotherapy 45\~55 Gy/25 fractions, followed by total mesorectal excision
61946078|NCT02210546|EXPERIMENTAL|Magnetic Resonance Imaging (MRI)|Patients will undergo MRI yearly
61946079|NCT02210546|OTHER|Mammography (Mx) + ultrasonography (US)|Patients will undergo yearly two-view (Mx) and breast US
61946080|NCT00270439|EXPERIMENTAL|single arm|Removed omentum of patients with type 2 diabetes
61946081|NCT05352100|EXPERIMENTAL|Hospitalized patients|This phase will recruit hospitalized bedridden patients who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. They may receive multiple 5 minute episodes of various vibration frequencies.
61946082|NCT02028143|EXPERIMENTAL|Study arm|The study arm group will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
61946083|NCT02028143|ACTIVE_COMPARATOR|Control arm|The control arm group will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
61946084|NCT04088942|EXPERIMENTAL|High-intensity group|"Will receive high-intensity intervention, which is a combination of pharmacological (varenicline) and behavioural support, described later."
61946085|NCT04088942|ACTIVE_COMPARATOR|Low-intensity group|Encouraged to quit smoking via own doctor and is prescribed varenicline.
61946086|NCT02564549|ACTIVE_COMPARATOR|Group 1 (TRUS-guided biopsy)|"* Baseline and annual systematic TRUS-guided biopsy performed as per standard of care by urologists for a total of one baseline diagnostic biopsy and two active surveillance systematic biopsies.~* mpMRI at the end of the 2nd year with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~* Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~* Patients will be followed, as per standard of care, for any potential infections from biopsies.~* Annual PSA tests performed as per routine standard of care."
61946087|NCT02564549|EXPERIMENTAL|Group 2 (mpMRI with targeted biopsy)|"* Baseline systematic transrectal ultrasound-guided biopsy performed as per standard of care by urologists.~* Baseline and annual mpMRI with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~* Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~* Patients will be followed, as per standard of care, for any potential infections from biopsies.~* Annual PSA tests performed as per routine standard of care."
62140089|NCT06490718|ACTIVE_COMPARATOR|Group ESPB|"For USG ESPB, 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline will be drawn in a 25 ml syringe with a sterile label (available in a sterile package) displaying 'study drug for ESPB'.~For IV infusion, 30 ml 0.9% saline will be drawn in a 50 ml syringe with a sterile label displaying 'study drug for IVI'. Both these syringes will be stored under strict aseptic precautions in a sterile tray until administration."
62140090|NCT06490718|EXPERIMENTAL|Group IVLI|"For USG ESPB, 25 ml of 0.9% saline will be drawn in a 25 ml syringe with a sterile label (available in a sterile package) displaying 'study drug for ESPB'.~For IV infusion, 30 ml 2% lidocaine will be drawn in a 50 ml syringe with a sterile label displaying 'study drug for IVI'. Both these syringes will be stored under strict aseptic precautions in a sterile tray until administration. The 30 ml volume for 2% lidocaine is decided as it can cover for a 70kg patient for a 3-hour surgical period."
62340594|NCT06233734||Robot Assisted Gait Training|This group of stroke patients will receive their standard care. For these participants, at this site (University Hospitals Dorset NHS Foundation Trust), this includes robot-assisted gait training.
62340595|NCT06233734||Conventional care|This group of stroke patients will receive their standard care. For these participants, at this site (Hampshire Hospitals NHS Foundation Trust), this does not include any robot-assisted gait training.
61946088|NCT03000933||Young same-sex attracted men|Same-sex attracted men aged 16 to 20
61946089|NCT03363997|EXPERIMENTAL|Test 1 vaginal ring|Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days
61946090|NCT03363997|EXPERIMENTAL|Test 2 vaginal ring|Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days
61946091|NCT03363997|EXPERIMENTAL|Test 3 vaginal ring|Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days
61946092|NCT02856646||Population with Condition|Community Sample
61946093|NCT05276531|EXPERIMENTAL|subcutaneous progesterone|PROLUTEX® 25 mg Solution for injection, IBSA Group, Lugano, Switzerland
62340596|NCT01783717|EXPERIMENTAL|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
62697882|NCT03970031|PLACEBO_COMPARATOR|Placebo|Placebo one tablet per day taken orally
62697883|NCT06511024||COVID-19|"* Patients in the community~* Patients at hospital admission~* Rapidly deteriorating patients~* Ventilated, critically ill patients With confirmed COVID-19 infection"
61946094|NCT05276531|ACTIVE_COMPARATOR|vaginal progesterone|LUTINUS® 100 mg vaginal tablets, Ferring GmbH Wittland/Kiel/Germany
61946095|NCT01177930||Feeding with milk with DHA and ARA|
62496701|NCT02336308|PLACEBO_COMPARATOR|Placebo|Placebo will be 10mL of normal saline in the syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
61946096|NCT01177930||Feeding with milk without DHA and ARA|
61946097|NCT00469378|EXPERIMENTAL|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
61946098|NCT01854242||Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
61946099|NCT02211625|EXPERIMENTAL|TRV734 125 mg|Part A, open-label will evaluate the the safety, PK and PD profile of a 125mg dose of TRV734 in which subjects are fasted, fed a standard meal, or fed a high-fat meal. Part A will also inform the dosing paradigm for Part B.
61946100|NCT02211625|ACTIVE_COMPARATOR|Multiple ascending dose study, active and placebo comparators|Part B will assess the safety, tolerability, PD and PK of TRV734. Subjects will be randomized in a ratio of 3:1:1 to receive either multiple doses of TRV734, oxycodone IR 10mg or placebo.
61946101|NCT03524742|EXPERIMENTAL|Avocado-Mediterranean Diet|Avocado based Mediterranean diet with intake of ½ portion of a Hass avocado per day, during 3 months.
61946102|NCT03524742|ACTIVE_COMPARATOR|Control-Group Diet|Control-Group Diet consists of a low fat-high complex carbohydrate diet, during 3 months.
61946103|NCT02502318|EXPERIMENTAL|Lobectomy or segmentectomy using video-thoracoscopy|
61946104|NCT02502318|ACTIVE_COMPARATOR|Lobectomy or segmentectomy using thoracotomy|
61946105|NCT01424709|EXPERIMENTAL|Arm 1|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
61946106|NCT01424709|ACTIVE_COMPARATOR|Arm 2|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
61946107|NCT03938467|EXPERIMENTAL|Antiseptic Cleanser|Standard prophylaxis will be administered by Irrisept patients as would individuals in the control group. In addition, these Irrisept study subjects will be supplemented with the use of Irrisept irrigation by the study surgeon during the patient's surgical procedure. Standard times for irrigation will include immediately after incision through the dermal layer, and immediately prior to implantation of any prosthetic components. Final irrigation will be performed just prior to closure of the deltopectoral interval.
61946108|NCT03938467|NO_INTERVENTION|Standard of Care Prophylaxis|Standard prophylaxis includes use of chlorhexidine wipes (Sage cloth) the night before and morning of surgery on the surgical site over the anterior shoulder.
61946109|NCT02824237|EXPERIMENTAL|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
61946110|NCT05475561|ACTIVE_COMPARATOR|Group (P)|
61946111|NCT05475561|ACTIVE_COMPARATOR|Group (E)|
61946112|NCT06367361|EXPERIMENTAL|Oxfendazole single dose|Oxfendazole 100 mg capsules at 20 mg/kg of body weight as a single oral dose administered with a lipid containing meal under direct observation.
62140091|NCT06698393|ACTIVE_COMPARATOR|Suture 3.0 Group|Coronally Advanced Flap Combined with a Connective Tissue Graft Harvested from the Palate for the Treatment of RT1 Gingival Recession. The flap was repositioned using a non-resorbable polyamide suture with a diameter of 3.0
62496702|NCT05414162||CAR T-cell Therapy Group|Hematooncological patients undergoing CAR T-cell therapy with Tisagenlecleucel, Axicabtagen-ciloleucel, Idecabtagen-vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel or Ciltacabtagene Autoleucel (dosages, frequency and duration to be determined by the treating oncologist).
62697884|NCT06511024||Control|No clinical suspicion of COVID-19 infection
62697885|NCT04648085|EXPERIMENTAL|Pre and Post Treatment with Trigeminal Nerve Stimulation (TNS)|Individuals will receive treatment with trigeminal nerve stimulation for 20 minutes at a frequency of 100 Hertz (Hz). Ocular pain intensity will be recorded prior and after the use of therapy.
61946113|NCT06367361|EXPERIMENTAL|Oxfendazole two doses|Oxfendazole 100 mg capsules at 20 mg/kg of body weight per dose in two oral doses separated 24 hours each administered with a lipid containing meal under direct observation.
61946114|NCT06367361|ACTIVE_COMPARATOR|Triclabendazole|Triclabendazole 250 mg tablets at 10 mg/kg of body weight per dose in two oral doses separated 24 hours each administered with a lipid containing meal under direct observation.
61946115|NCT06340516|EXPERIMENTAL|NT-proBNP instead of ECHO/MUGA at 6 months and 12 months|Replacement with measurement of plasma levels of NT-proBNP at 6 months and 12 months instead of ECHO/MUGA for monitoring of trastuzumab-induced cardiotoxicity
61946116|NCT05927584||Local excision|"* Patients older than 18 years~* Diagnosis of rectal cancer~* Inferior edge of the tumour not further than 2 cm above the anorectal ring~* Clinical TNM staging T1N0M0"
61946117|NCT05393011||Pregnant group|A female is considered pregnant when an explicit gestational sac inside the uterus is seen by ultrasound 4 weeks after embryo transfer.
61946118|NCT05393011||Non-pregnant group|A female is considered not pregnant when no explicit gestational sac is seen inside the uterus by ultrasound 4 weeks after embryo transfer.
61946119|NCT01252004||TT Syndrome|Will be included over a period of one year, prospectively, all patients newly diagnosed
61946120|NCT06157255|EXPERIMENTAL|AZD4604|In Part 1, one 30 ug dose of \[14C\]AZD4604 Solution for Infusion 6 ug/mL (NMT 37.0 kBq/5 mL) and one 3 mg dose of AZD4604 Inhalation Powder, 1 mg (as 3 x 1 mg). In Part 2, one 4 mg dose of \[14C\]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq).
61946121|NCT04948489|EXPERIMENTAL|LNG IUD+ Norethindrone Acetate|All eligible participants will have the LNG-IUD. Experimental participants will also receive norethindrone acetate 5 mg by mouth daily for 12 months.
61946122|NCT04948489|PLACEBO_COMPARATOR|LNG IUD+Placebo|All eligible participants will have the LNG-IUD. Participants in the placebo comparator group will also receive a placebo tablet, 1 tablet by mouth daily for 12 months.
61946123|NCT00917501|PLACEBO_COMPARATOR|Placebo|Placebo to the Omega-3 given in other group taken twice a day.
62697886|NCT02081703|EXPERIMENTAL|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
61946124|NCT00917501|ACTIVE_COMPARATOR|Omega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA \& will be taken twice a day.
61946125|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
62496703|NCT01894009|ACTIVE_COMPARATOR|Foot manipulation|"Asymmetry of the feet was treated by thrusting of the cuboid bone and the subtalar joint was treated with gapping thrust. Mobilisation of the distal tibia-fibula was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given with morning exercises. Four types of exercises were recommended: 1) Foot training with pro-and supination of the feet from dorsal to plantar flexion. 2)Caterpillar walk. 3) Training the take off of the great toes along a normal walking line and 4) Mobility of lateral malleoli and the talo-crural joint by dorsal flexion of feet while bending the knees."
61946126|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
61946127|NCT02213640|EXPERIMENTAL|Arm A Anodal tDCS and prismatic adaptation|anodal tDCS over the primary motor cortex : stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
61946128|NCT02213640|PLACEBO_COMPARATOR|Arm B: control|Prismatic adaptation with placebo stimulation
61946129|NCT02322073||Lean healthy controls|Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair.
61946130|NCT02322073||Obese|Obese BMI 35-55 Laparoscopic Roux-en-Y gastric bypass or Sleeve gastrectomy Phenotype according to cardiometabolic status
61946131|NCT05403788|EXPERIMENTAL|Intervention with virtual reality|Each subject will receive a single session of exercises with the OCULUS QUEST2 (OCULUS VR, USA) and a hand tracking software (Hand Physics Lab, Holonautic, Switzerland). Brain function monitoring will be made by an EEG system ENOBIO 20 (Neuro-electrics, Spain) positioned over subject head. Intervention consisted of exercises with upper limbs and visual feedback. These activities were projected stereoscopically on VR googles.
61946132|NCT03088839||30 ALS patients|
61946133|NCT03088839||30 healthy controls|
61946134|NCT02883959|EXPERIMENTAL|music therapy|Music therapy
61946135|NCT02883959|NO_INTERVENTION|control arm|No music
62140092|NCT06698393|EXPERIMENTAL|Suture 6.0 Group|Coronally Advanced Flap Combined with a Connective Tissue Graft Harvested from the Palate for the Treatment of RT1 Gingival Recession. The flap was repositioned using a non-resorbable polyamide suture with a diameter of 6.0
62697887|NCT02081703|PLACEBO_COMPARATOR|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
62140093|NCT03798574||IMD Case|No intervention
62340597|NCT01069523|PLACEBO_COMPARATOR|Placebo|Patients will be started on 1 mg of guanfacine extended release matching placebo tablets at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
62697888|NCT02081703|EXPERIMENTAL|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
62697889|NCT02081703|PLACEBO_COMPARATOR|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
61946136|NCT00657358|EXPERIMENTAL|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
61946137|NCT02961673|EXPERIMENTAL|HU-014 Inj(Phase 1 and 2)|HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
61946138|NCT02961673|ACTIVE_COMPARATOR|Botox Inj(Phase 2)|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
61946139|NCT06134960|EXPERIMENTAL|KD-496 cell infusion|
61946140|NCT05945628|EXPERIMENTAL|Experiment 1|Subjects with iEEG electrodes implanted will perform an eye-tracking memory task in which they view pictures of naturalistic scenes and later undergo memory testing for these scene pictures. For the memory test, studied scenes will be repeated and presented along with novel (foil) scenes. Subjects will attempt to discriminate studied from novel scenes using button press responses. Eye movements will be remotely (noninvasively) tracked using a camera during both study and test. This memory task will take about 1.5 hours to complete. 20 subjects undergoing iEEG recordings as part of epilepsy treatment will be assigned to this study experiment condition.
61946141|NCT05945628|EXPERIMENTAL|Experiment 2|Subjects with iEEG electrodes implanted will perform an eye-tracking memory task in which they view arrays of everyday objects arranged as a grid and later undergo memory testing for these object image arrays. Half of the object-image arrays are studied actively (subjects view objects in any order they wish) and half are studied passively (viewing patterns are predetermined and subjects must follow along). For the memory test, subjects attempt to pick studied objects from among novel (foil) objects and replace them at studied locations using the computer mouse. Eye movements will be remotely (noninvasively) tracked using a camera during the study phases. This memory task will take about 1.5 hours to complete. 20 subjects undergoing iEEG recordings as part of epilepsy treatment will be assigned to this study experiment condition.
62140094|NCT03798574||Control|No intervention
62140095|NCT05645068|EXPERIMENTAL|Optical Coherence Tomography Angiography|
62140096|NCT04738656||Mediterranean-style diet plan|"Mediterranean-style diet plan (6 months): 22% proteins, 53% carbohydrates, and 25% of lipids.~52 participants."
62140097|NCT04738656||Open protein diet plan|"Open protein presents (6 months) 40% of proteins, 29% carbohydrate and 31% of lipids.~26 participants."
62140098|NCT04000750|EXPERIMENTAL|Time Restricted Eating (16:8)|Participants will consume all calories within an 8 hour window each day.
62340598|NCT01069523|EXPERIMENTAL|Guanfacine Extended Release|Patients will be started on 1 mg of guanfacine extended release at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
62340599|NCT01782794||Cohort A|Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
62140099|NCT04000750|ACTIVE_COMPARATOR|Control|Participants will consume all calories within a \~12 hour window each day (4 separate meals + needed snacks).
62140100|NCT05011292|ACTIVE_COMPARATOR|Control Group|The control group includes parents that will view an educational video about a topic other than infant SCB consumption.
62697890|NCT05530733|OTHER|Pacifier only|Participants in the pacifier-only group will get a pacifier five minutes prior to tube feeding. During feedings, a pacifier will be employed. Five minutes following the end of tube feeding, the pacifier application will be discontinued. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the volume of gastric residue will be controlled.
62697891|NCT05530733|OTHER|Pacifier with breast milk|Five minutes prior to tube feeding, participants in the pacifier with breast milk group will get their own breast milk dripping pacifier. During feedings, a pacifier will be employed. Five minutes following the end of tube feeding, the pacifier application will be discontinued. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the amount of gastric residue will be controlled.
62697892|NCT05530733|NO_INTERVENTION|standard care (no pacifier)|The premature babies in the standard care (no pacifier) will get standard care while being fed through an orogastric tube. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the amount of gastric residue will be controlled.
61946142|NCT05945628|EXPERIMENTAL|Experiment 3|The same 20 subjects with iEEG electrodes implanted who perform Study Experiment Condition 2 will perform the same eye-tracking memory task described for Study Experiment Condition 1. For these subjects, high-frequency electrical stimulation will be delivered through the iEEG electrodes on a subset of study trials, with half of stimulated trials receiving stimulation of the hippocampus and the other half receiving stimulation of the amygdala. This memory task will take about 1.5 hours to complete and will be performed on a different day of their inpatient visit than the procedures for Study Experiment Condition 2.
61946143|NCT05945628|EXPERIMENTAL|Experiment 4|The same 20 subjects with iEEG electrodes implanted who perform Study Experiment Condition 1 will perform the same eye-tracking memory task described for Study Experiment Condition 2. For these subjects, high-frequency electrical stimulation will be delivered through the iEEG electrodes on a subset of study trials, with half of stimulated trials receiving stimulation of the hippocampus and the other half receiving stimulation of the amygdala. This memory task will take about 1.5 hours to complete and will be performed on a different day of their inpatient visit than the procedures for Study Experiment Condition 1.
61946144|NCT05945628|EXPERIMENTAL|Experiment 5|Subjects with iEEG electrodes implanted will perform the same eye-tracking memory task as described for Study Experiment Condition 1. This is a different group of iEEG subjects selected based on having iEEG electrodes implanted in the hippocampus as well as in at least one location of the Dorsal Attention Network (DAN), which is a region of interest for the experiment condition. 20 subjects undergoing iEEG recordings as part of epilepsy treatment will be assigned to this study experiment condition.
61946145|NCT05945628|EXPERIMENTAL|Experiment 6|The same group of 20 iEEG subjects that are included in Study Experiment Condition 5 will perform the same eye-tracking memory task as described for Study Experiment Condition 2. This experiment condition will be performed on a different day of the inpatient visit than participation in Study Experiment Condition 5.
61946146|NCT02716805|EXPERIMENTAL|Cohort 1|"Subjects received Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on \~Day -10, melphalan (200 mg/m\^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
61946147|NCT02716805|EXPERIMENTAL|Cohort 2|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on \~Day -10, melphalan (200 mg/m\^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
62140101|NCT05011292|EXPERIMENTAL|Intervention Group|The intervention group will include those parents who participate in the study after the control data has been collected and two SCB reduction-related videos have been introduced (one for showing at the 4-month visit and one for the 12-month visit).
62140102|NCT04415307|EXPERIMENTAL|Acupuncture|Acupuncture over acupoints.
62140103|NCT04415307|EXPERIMENTAL|Far-Infrared|Far-Infrared heat-patch attachment over acupoints.
62140104|NCT04415307|EXPERIMENTAL|Combination of Acupuncture and Far-Infrared|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
62140105|NCT04415307|PLACEBO_COMPARATOR|Placebo (no Acupuncture nor Far-Infrared)|Far-Infrared heat-patch attachment over acupoints without electric current passing.
62140106|NCT02103556|ACTIVE_COMPARATOR|Mineral oil|4ml daily (adjusted as needed), for 4 weeks
62140107|NCT02103556|ACTIVE_COMPARATOR|Olive oil|4ml daily (adjusted as needed), for 4 weeks
62140108|NCT02103556|ACTIVE_COMPARATOR|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
62140109|NCT03500523|EXPERIMENTAL|1-study group|study group: pregnant women
62140110|NCT03500523|EXPERIMENTAL|2-control group|control group: healthy non pregnant women
62140111|NCT04185181|ACTIVE_COMPARATOR|virtual reality|
62140112|NCT04185181|ACTIVE_COMPARATOR|propreoceptive neuromuscular facilitation|
62140113|NCT02246075|EXPERIMENTAL|EVP-6124, low dose|Low dose, Tablet, Once Daily, Day 1 through Day 168
62340600|NCT01782794||Cohort B|Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
62697893|NCT06443814|EXPERIMENTAL|Transcendental Meditation|The TM technique is practiced for 20 minutes twice a day. Participants were instructed by a certified teacher in 7-step course to learn how to meditate according to previously standardized and validated procedures.
62697894|NCT06443814|ACTIVE_COMPARATOR|Health Education|The health education group was matched for instructor time and attention to the TM group. The classroom-based health education group received AHA-based guidelines for healthy diet, exercise and control of substance use. No stress management techniques are taught in this group.
62496704|NCT01894009|SHAM_COMPARATOR|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
62496705|NCT01937767|ACTIVE_COMPARATOR|Propofol|Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.
62496706|NCT01937767|EXPERIMENTAL|Remimazolam 6 mg/kg/hr|Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
62496707|NCT01937767|EXPERIMENTAL|Remimazolam 12 mg/kg/hr|Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
62496708|NCT03450629|EXPERIMENTAL|PDP-716|
62496709|NCT03450629|ACTIVE_COMPARATOR|Brimonidine Tartrate Ophthalmic Solution|
62496710|NCT03794245|EXPERIMENTAL|Men-Centered HIV Testing|Mobile HIV testing is conducted at sites in the community where men gather.
62496711|NCT03794245|ACTIVE_COMPARATOR|Clinic-based HIV Testing|Men are referred to the nearest clinic for HIV counseling and testing
62496712|NCT03794245|EXPERIMENTAL|Linkage to Care for HIV+ Men|The patient coordinator arranges an appointment time at the clinic and accompanies the patient to the initial visit
62496713|NCT03794245|ACTIVE_COMPARATOR|Clinic Referral for HIV+ Men|Men diagnosed with HIV are referred to the nearest clinic for treatment of HIV
62496714|NCT06292364|OTHER|control group|beggs wrap around Retainer will be given to the patients immediately \[Just after debonding\].
62496715|NCT06292364|ACTIVE_COMPARATOR|experimental group|beggs wrap around Retainer will be delivered to the patients 7 days post debonding.
62496716|NCT04804839|EXPERIMENTAL|First research arm (Combined group)|Combined group with 8 weeks of pelvic floor muscle training, knack maneuver and lifestyle recommendations.
62496717|NCT04804839|EXPERIMENTAL|Second research arm [PFMT (including knack maneuver) group]|Only 8-week PFMT (including knack maneuver)
62496718|NCT04804839|ACTIVE_COMPARATOR|Third research arm (PFMT alone group)|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
62496719|NCT01681862|EXPERIMENTAL|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
62496720|NCT05421260||Adult onset SCI|Spinal cord injury accident when the patient is over the age of 18 years old.
62496721|NCT05421260||Paediatric onset SCI|Spinal cord injury accident when the patient is under the age of 18 years old.
62496722|NCT01348633||Sub-study 1|The Quantitative, Doppler SD-OCT Blood Flow Technology will be validated and calibrated by manipulating end-tidal blood gases using the computer-controlled gas sequencer (Slessarev et al, 2005) in 15 healthy controls. Homeostatic inner retina blood flow values and the magnitude of vascular reactivity will be compared between Doppler SD-OCT blood flow technology and the Canon Laser Blood Flowmeter, an established standard, at specific locations within the retinal vascular tree.
62697895|NCT04010344|EXPERIMENTAL|Enhanced Usual Care Group|All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
62340601|NCT05425875|EXPERIMENTAL|Manual suction|A 50-mL syringe will be used to apply the suction.
62496723|NCT01348633||Sub-study 2|The Quantitative, Hyper-Spectral Imaging Derived Oxygen Saturation Maps of the major retinal vessels and capillary beds will be validated and calibrated in human volunteers using our novel and exact technique that allows the precise control of the partial pressure of oxygen (PO2) to induce controlled and safe levels of hypoxia. Oxygen saturation values will be compared to measured PO2 values (i.e. recognized standard) for various levels of hypoxia and will be used to provide in-sight into the properties of the data output e.g. effective operating range, linearity of response. At the end of the study, subjects will be returned to normoxic conditions to assess reproducibility of oxygen saturation maps.
62340602|NCT05425875|EXPERIMENTAL|Manual suction with tubing|A 50-mL syringe with a 15-cm rubber tubing.
62340603|NCT05425875|ACTIVE_COMPARATOR|Wall mount suction|A negative pressure of \<100 mmHg will be applied using continuous wall suction.
62340604|NCT06197932|OTHER|Routine exercise and running training|15 participants were in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol. In pre measurements I assessed the strength of big toe of right and left feet, using the hip and toe dynamometer in kilograms. Further I assessed height of vertical jump in centimeters, than I assessed horizontal jump in centimeters. For balance Y -balance test is measured, test is measured for agility T test I measured, after assessment of all variables I gave them plan for big toe strengthening ask them to do repetitions about 15 in three sets twice a day, for 4 weeks after pre measurements, with intensity should be moderate. Asked them to perform 5 exercises twice a day. After 4 weeks measured all variable in same units and used the same instruments that used in pre measurements.
62140114|NCT02246075|EXPERIMENTAL|EVP-6124, high dose|High dose, Tablet, Once Daily, Day 1 through Day 168
61946148|NCT02716805|EXPERIMENTAL|Cohort 3|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on \~Day -10, melphalan (200 mg/m\^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
61946149|NCT02716805|EXPERIMENTAL|Cohort 4|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on \~Day -10, melphalan (200 mg/m\^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
62697896|NCT04010344|ACTIVE_COMPARATOR|Usual Care|Patients in this arm of the study will receive usual care as determined by their providers. Usual care in the region typically involves at least one visit every 2-3 months for review of adherence to treatment, blood pressure control, and prescriptions for medication refills. Similar to the intervention group, participants will have a total of three follow-up visits which will be separate from their regular appointments during which study outcomes will be assessed.
62697897|NCT04402216|NO_INTERVENTION|Current standard of care, no formal preparation|Participants in this group will receive the standard of care with no formal preparation. MRI technologist will meet patient prior to scan introducing role of patient, role of MRI technician, and give verbal discussion of MRI process. MRI technologist will offer opportunity for patient to watch a movie as alternative focus/distraction during MRI scan. The child life specialist will not meet with the caregiver or child during their visit.
62697898|NCT04402216|EXPERIMENTAL|Child Life-led preparation|Participants will meet with a child life specialist who will provide psychological preparation utilizing photos, MRI sounds, verbal discussion of MRI process, and discuss various coping strategies such as deep breathing or stress ball and option to watch a movie for alternative focus/distraction during the scan.
62697899|NCT04402216|EXPERIMENTAL|MRI preparation video|Participants will be shown an MRI preparation video by the research coordinator in the MRI dressing room prior to MRI scan. The MRI preparation video will walk the patient through the MRI experience with a mock patient explaining all the steps of MRI process from check in to discharge. The child life specialist will not meet with the caregiver or child during their visit.
62697900|NCT04402216|EXPERIMENTAL|Child Life preparation with VR|Participants will be provided MRI preparation with a child life specialist using the Kind VR device. The VR (virtual reality) session will consist of an audio and visual MRI experience designed to serve as an opportunity for the patient to practice their scan prior to MRI. The VR session will take place once during the Radiology admission and will be approximately 15 minutes in duration. The VR software was developed by Kind VR and was designed specifically for the purpose of preparation for brain MRI. The interactive VR experience walks patients through each step of an MRI. Patients can practice holding still for the MRI and will get feedback from the VR headset when they are moving their head. Along with VR practice session CCLS will discuss various coping strategies such as deep breathing and/or stress ball and option to watch a movie for alternative focus/distraction during the scan.
62697901|NCT04363892|EXPERIMENTAL|Receiving optical and infrared imaging|This is the only arm of the study. All patients will have optical and infrared images acquired of skin on the treated and contralateral sides.
61946150|NCT02031796|EXPERIMENTAL|CAVAREC images|CAVAREC images from x-ray angiography
62496724|NCT01348633||Sub-study 3|Subjects with symptoms of branch and central retinal artery and vein occlusion within the past 2 months will be used to validate the Doppler SD-OCT blood flow technology and the hyperspectral imaging derived oxygen saturation maps. In cases of central retinal vein and artery occlusion, imaging values (i.e. inner retinal and choroidal blood flow, oxygen saturation values of the major retinal vessels and the capillary beds of the retina and ONH) will be compared between the affected and unaffected eyes. In cases of branch occlusion, imaging values will be compared between the affected and unaffected quadrants of the affected eye and between the affected and unaffected eyes. The difference in inner retinal and choroidal blood flow for each eye will be calculated and compared between eyes.
62697902|NCT01600651|SHAM_COMPARATOR|Recruitment maneuver (RM) sham group|when recruitment maneuver sequence precedes a sham evaluation period
62697903|NCT01600651|SHAM_COMPARATOR|Sham Recruitment (RM) maneuver group|a group in which patients receive a sham sequence before the RM sequence
62697904|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
62697905|NCT03158246|EXPERIMENTAL|Yigu Group|"a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
62697906|NCT03158246|ACTIVE_COMPARATOR|Aclasta Group|"a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
62697907|NCT04148209|EXPERIMENTAL|Treatment|Participants receiving PF-07081532
62496725|NCT01348633||Sub-study 4|Calibration for retinal melanin, crystalline lens absorption, macular pigment, morphological variation and pre-retinal autofluorescence in healthy subjects (n=20 per decade, range 40 to 80yrs). Established reflectometric techniques to derive absorption values and autofluorescence techniques will be used to calculate correction values for each parameter that influences the hyper-spectral retinal and ON oxygen saturation imaging data (Keilhauer and Delori, 2006; Delori et al, 2007).
62496726|NCT01348633||Sub-study 5|Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
61946151|NCT02765269|EXPERIMENTAL|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
62140115|NCT02246075|PLACEBO_COMPARATOR|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 168
62140116|NCT00268723|EXPERIMENTAL|1|levalbuterol HFA MDI 90 mcg QID
62140117|NCT00268723|PLACEBO_COMPARATOR|2|Placebo MDI QID
62140118|NCT03615352|EXPERIMENTAL|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
62496727|NCT05917119|EXPERIMENTAL|BLT|Bright light therapy delivered via glasses
62140119|NCT03615352|EXPERIMENTAL|ovarian cyst aspiration and coagulation|laparoscopic ovarian endometrioma aspiration and coagulation
62340605|NCT06197932|EXPERIMENTAL|Big Toe Strengthening Exercise|Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for 4 weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
62340606|NCT00759980||Platelet Number|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to the total number of platelets
62340607|NCT00759980||Platelet Mass|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to a combination of platelet number and platelet size (mass)
62340608|NCT02760017|PLACEBO_COMPARATOR|placebo|capsules containing placebo for B forticata
62340609|NCT02760017|EXPERIMENTAL|B. forficata|capsules of B. forficata containing 200 mg of plant extracts
62340610|NCT05640674|ACTIVE_COMPARATOR|Opioid Pain Management|Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Hydrocodone/Acetaminophen (liquid, 0.135mg Hydrocodone/kg/dose every 6 hours) will be used as needed for breakthrough pain.
62340611|NCT05640674|EXPERIMENTAL|Non-Opioid Pain Management|Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Acetaminophen (liquid, 15mg/kg/dose every 6 hours) will be used as needed for breakthrough pain.
62340612|NCT01492283||NAFLD|Non alcoholic fatty liver disease without type 2 diabetes
62340613|NCT01492283||NAFLD+T2D|Non alcoholic fatty liver disease with type 2 diabetes
62340614|NCT01492283||T2D|Type 2 diabetics without non alcoholic fatty liver disease
62340615|NCT01492283||cirrhosis|Patients with liver cirrhosis
62340616|NCT01492283||Kontrol groups|Healthy control subjects
62340617|NCT05725382|EXPERIMENTAL|NOL-guided remifentanil dosing|"Remifentanil dosing will preferentially be guided by the NOL index, but blood pressure and heart rate will be monitored and considered concurrently.~* If the NOL index is \> 25, remifentanil infusion will be increased.~* If the NOL index is \< 10 the remifentanil infusion rate will be reduced"
62340618|NCT05725382|NO_INTERVENTION|Standard care remifentanil dosing|Remifentanil dosing will be administered according to standard care per institutional practice.
62340619|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
62340620|NCT04156932|ACTIVE_COMPARATOR|OUC|Origin uterine artery closure
62340621|NCT04156932|ACTIVE_COMPARATOR|IUC|Cervical-isthmic uterine artery closure
62340622|NCT01694420|EXPERIMENTAL|Quad FDC|FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
62340623|NCT04182698|EXPERIMENTAL|Experimental|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
62340624|NCT00844649|EXPERIMENTAL|Albumin-bound paclitaxel (ABI-007)/Gemcitabine|ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
62340625|NCT00844649|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
62340626|NCT02517593|OTHER|PRS|Providing polygenic risk score (PRS)
62496728|NCT05917119|SHAM_COMPARATOR|s-BLT|Sham Bright light therapy
62496729|NCT00907816||intervention|PCPs at MGH who receive display of utilization and quality during computer order entry
62496730|NCT00907816||control|
62496731|NCT04789733|EXPERIMENTAL|Tight pressure management|"Patients assigned to tight blood pressure control angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.~Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication.~The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days."
62496732|NCT04789733|OTHER|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
62496733|NCT02995187|EXPERIMENTAL|Apatinib Mesylate tablet|Patients received oral apatinib 500 mg in tablet once daily, a treatment cycle was defined as 28 days (4 weeks).
62496734|NCT00769496|EXPERIMENTAL|Arm 1|
62496735|NCT04345016|EXPERIMENTAL|All Participants|Eligible participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) during the intervention/treatment phase. Each was followed for one year or until study disenrollment, health plan disenrollment, death, or end of the study and follow-up period. Outcomes data from eligible participants from the two years prior to the intervention/treatment phase and the period of time after the intervention ended through the analysis date (2020-01-01) were evaluated. For this period, these participants received standard medical and diabetic foot care.
62496736|NCT01378013||Elective sugery|"Patients entering into elective surgery. These will be divided into three subgroups:~A. Patients with cancer. This will include patients with malignancy of the gastrointestinal and colorectal tract (including those excised by microsurgery) cancer of the breast or solid tumours of the kidney.~B. Patients with benign diseases of the bowel requiring surgery e.g. inflammatory bowel disease C. Benign surgical conditions, usually operated on in a day surgery setting. These will specifically be of the biliary tree (gall stones) and the anterior abdominal wall (e.g. Hernia surgery)"
62496737|NCT01378013||Acute (emergency) surgery|"Patients presenting to Accident and emergency under the care of the general surgery on call team will be recruited into this study group. This study group will have the following subgroups:~A. Acute abdominal pain, as per the previous ethical clearance B. Patients with acute sepsis thought to be of surgical origin. C. Patients suffering major trauma with an Injury severity score of \>15, multiple injuries, who require surgery or who have \>1 organ system that is failed or who are admitted to the intensive care department."
62496738|NCT05121441|EXPERIMENTAL|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
62496739|NCT05121441|PLACEBO_COMPARATOR|Placebo Comparator|Placebo arm matching active arm ARD-101, 200 mg BID
62496740|NCT02941523|EXPERIMENTAL|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
61946152|NCT02765269|NO_INTERVENTION|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
61946153|NCT04592978|EXPERIMENTAL|Pain-Alcohol Personalized Feedback Intervention|
61946154|NCT04592978|ACTIVE_COMPARATOR|Control Personalized Feedback Intervention|
62340627|NCT01930994||Cohort 1|Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
62340628|NCT01930994||Cohort 2|TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
62340629|NCT01930994||Cohort 3|Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
62340630|NCT01930994||Cohort 4|Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
62340631|NCT01930994||Cohort 5|Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
62340632|NCT01930994||Cohort 6|Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
62340633|NCT01062074||Korean Participants Vaccinated with GARDASIL|Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
62340634|NCT05127421|EXPERIMENTAL|Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID|Participants will be treated with ruxolitinib cream 1.5% or vehicle cream twice a day (BID) in a double-blind fashion.
62340635|NCT05127421|EXPERIMENTAL|Open Label Extension: Ruxolitiib cream 1.5%|Patients will be treated with Ruxoltinib cream 1.5% twice per day (BID) during the open label extension period. Participants who complete the double-blind period will continue into this open-label extension period for an additional 4 weeks of treatment.
62340636|NCT06191120|EXPERIMENTAL|One [18F]-ALF-FAPI-74 PET/CT scan|For patients presenting with metachronous disease, or synchronous disease without the need for two separate surgical sessions for removal of all lesions (i.e. separate liver and primary cancer surgery), and who do not receive any chemotherapy before surgery, only one pre-surgical \[18F\]-ALF-FAPI-74 PET/CT will be performed.
62340637|NCT06191120|EXPERIMENTAL|Two [18F]-ALF-FAPI-74 PET/CT scans|For patients presenting with synchronous disease who require two separate surgical sessions (i.e. separate liver and primary cancer surgery), and who do not receive pre-surgical chemotherapy, an \[18F\]-ALF-FAPI-74 PET/CT will be performed before each surgical session.
62340638|NCT06191120|EXPERIMENTAL|Pre-treated group, two [18F]-ALF-FAPI-74 PET/CT scans|For patients presenting with metachronous disease, or synchronous disease without the need for two separate surgical sessions for removal of all lesions (i.e. separate liver and primary cancer surgery), and who receive pre-surgical chemotherapy, two \[18F\]-ALF-FAPI-74 PET/CTs are performed: one before chemotherapy and one before surgery.
62340639|NCT06191120|EXPERIMENTAL|Pre-treated group, three [18F]-ALF-FAPI-74 PET/CT scans|For patients presenting with synchronous disease who require two separate surgical sessions (i.e. separate liver and primary cancer surgery), and who do receive pre-surgical chemotherapy, three \[18F\]-ALF-FAPI-74 PET/CTs will be performed: one before chemotherapy and one before each surgical session.
62340640|NCT05018117|EXPERIMENTAL|Young (18-28 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
62340641|NCT05018117|EXPERIMENTAL|Old (60-85 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
62340642|NCT05018117|PLACEBO_COMPARATOR|Young (18-28 years) participants - placebo gum|placebo gum, one time before fMRI measurements
62340643|NCT05018117|PLACEBO_COMPARATOR|Old (60-85 years) participants - placebo gum|placebo gum, one time before fMRI measurements
62340644|NCT04389580|ACTIVE_COMPARATOR|13 cis retinoic acid doses orally plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
62496741|NCT02941523|EXPERIMENTAL|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
62496742|NCT02941523|EXPERIMENTAL|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
62496743|NCT01706809||Biomarkeres|
62496744|NCT00379509|EXPERIMENTAL|GW572016|
62496745|NCT04018690|EXPERIMENTAL|Experimental|24 patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.
62496746|NCT04018690|ACTIVE_COMPARATOR|Control Group|24 patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine
62496747|NCT04915222|EXPERIMENTAL|Natural apophyseal glides|This group receives natural apophyseal glides along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
62496748|NCT04915222|ACTIVE_COMPARATOR|Cervical manual traction|This group receives cervical manual traction along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
62496749|NCT00966628|ACTIVE_COMPARATOR|Ringer's lactate|
62496750|NCT00966628|EXPERIMENTAL|Hypertonic sodium lactate|
62496751|NCT02980172||Pain triage complaint|Patients admitted at GUH ED triaged with a main complaint requiring a pain evaluation.
62496752|NCT05971524|PLACEBO_COMPARATOR|Placebo|An oral placebo capsule once daily for 4 weeks
62697908|NCT04148209|PLACEBO_COMPARATOR|Placebo|Participants receiving Placebo
62496753|NCT05971524|EXPERIMENTAL|2mg 6-BT|2 mg of 6-BT as an oral capsule once daily for 4 weeks
62496754|NCT05971524|EXPERIMENTAL|4mg 6-BT|4 mg of 6-BT as an oral capsule once daily for 4 weeks
62496755|NCT05971524|EXPERIMENTAL|8mg 6-BT|8 mg of 6-BT as an oral capsule once daily for 4 weeks
62496756|NCT05913817||Adalimumab Reference Product to AVT-02|Patients switching from the high-volume, low concentration, citrate containing Adalimumab reference product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar.
62496757|NCT05913817||Other Adalimumab Biosimilar to AVT-02|Patients switching from another high-volume, low concentration, citrate-containing or citrate-free Adalimumab biosimilar product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar.
62697909|NCT06634069|EXPERIMENTAL|Group 1|Patients suffering from septic shock who require fluid resuscitation get 0.5M HSL (containing 504mM of sodium and lactate)
62697910|NCT06634069|ACTIVE_COMPARATOR|Group 2|Patients suffering from septic shock who require fluid resuscitation get 3% NaCl (containing 513mM of sodium and chloride)
62697911|NCT01232140|EXPERIMENTAL|CRP-guided antibiotic treatment|If CRP\> 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment is withheld.
62697912|NCT01232140|OTHER|GOLD strategy-antibiotic treatment|According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.
62697913|NCT02444247|OTHER|High Dose Exercise vs Sedentary Option|Relative Reinforcing Value of high dose exercise (300 kcal expenditure per session) versus sedentary activity will be determined.
62496758|NCT01332968|ACTIVE_COMPARATOR|Rituximab+Chemotherapy|Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
62496759|NCT01332968|EXPERIMENTAL|Obinutuzumab+Chemotherapy|Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
62496760|NCT06678451|EXPERIMENTAL|Sugammadex group|When T2 appeared, the sugammadex group was given 2mg/kg of sugammadex intravenously (adjusted body weight)
62496761|NCT06678451|ACTIVE_COMPARATOR|Neostigmine group|When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
62496762|NCT02228889|EXPERIMENTAL|Strattice|Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
62496763|NCT02228889|EXPERIMENTAL|XenMatrix|Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
62496764|NCT02988882|EXPERIMENTAL|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
62496765|NCT02988882|PLACEBO_COMPARATOR|PV|PV (placebo drug delivery vehicle)
62496766|NCT04602741|EXPERIMENTAL|A4i Intervention|"App4Independence (A4i)~Experimental: A4i Intervention App4Independence (A4i) The study intervention is the digital health platform A4i. A4i operates on the individual's own phone with or without data.~Specific A4i functionality includes:~* Addressing social isolation and cognitive challenges through personalized prompts, scheduling of activities, and connections to a range of resources.~* Fostering illness self-management through evidence-informed content.~* A peer-peer engagement platform that facilitates strategy/tip sharing between users (anonymous and moderated).~* Daily wellness and goal attainment check-ins.~* An ambient sound detector with an oscilloscope-type indicator that assists individuals with auditory hallucinations separate hallucinations from real sounds.~* Passively collected data on phone use as a proxy for sleep.~* A provider dashboard. Both control and experimental condition participants will be receiving standard outpatient care (TAU)."
61946155|NCT03412526|EXPERIMENTAL|ACT TIL|"1. Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day~2. Preparation and administration of unselected or 4-1BB enriched TIL~3. Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
61946156|NCT03801460|NO_INTERVENTION|SOC|Standard of Care
61946157|NCT03801460|EXPERIMENTAL|RAPR|Remotely administered physiological reconditioning program
62340645|NCT04389580|ACTIVE_COMPARATOR|13 cis retinoic acid doses Aerosolized plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of tamoxifen therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
62340646|NCT04389580|NO_INTERVENTION|No Intervention:|No study treatment Arm No Isotretinoin or Tamoxofien treatment
62340647|NCT03935165|EXPERIMENTAL|Indocyanine Green arm|"All the patients to be enrolled have to meet the inclusion criteria. All enrolled patient is subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions are described.~Subsequently, 0.25 mg /(kg BW) Indocyanine Green is administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision is made, in order to identify the fluorescent lesions. All the lesions are described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged."
62340648|NCT02557360|EXPERIMENTAL|S-adenosyl-L-methionine|Patients with primary biliary cirrhosis will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
62340649|NCT00313950|EXPERIMENTAL|Group 1|
62340650|NCT00313950|EXPERIMENTAL|Group 2|
62340651|NCT00313950|EXPERIMENTAL|Group 3|
62340652|NCT01096043|PLACEBO_COMPARATOR|Placebo|Each Strata of the study will have a placebo control. In strata A, the chance of getting active drug is 4 out of 5, in Strata B the chance of getting active drug is 3 ot of 4, and in Strata C, the chance of getting active Drug is 4 out of 5. In the event that a patient is allocated to receive placebo, the treatment may be stopped if the patient's condition fails to improve or worsens during the placebo infusion.
62340653|NCT01096043|EXPERIMENTAL|Strata 1 CXL-1020|Patients assigned to CXL-1020 in strata one will have their dose increased from the initial dose 2 times during the study period. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
62340654|NCT01096043|EXPERIMENTAL|Strata 2 CXL-1020|In strata 2, patients who are assigned to active treatment will receive one of up to 3 possible fixed dose levels of CXL-1020 for a period of 6 hours. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
62340655|NCT01096043|EXPERIMENTAL|Strata 3 CXL-1020|In strata 3, patients assigned to receive CXL-1020 will receive a fixed dose of CXL-1020 for 6 hours, and then the dose may be increased or decreased, based on the investigators assessment of the patient. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
62340656|NCT06460636|EXPERIMENTAL|Progressive muscle relaxation therapy + Aquatic therapy|Participants in group B will receive progressive muscle relaxation therapy and aquatic therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
62340657|NCT06460636|ACTIVE_COMPARATOR|Progressive muscle relaxation therapy|Participants in group A will receive progressive muscle relaxation therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
62340658|NCT03284008|EXPERIMENTAL|Manual manoeuver + stretching|Patients will receive a manual manoeuver treatment and education to perform stretching exercises at home.
62340659|NCT03284008|ACTIVE_COMPARATOR|stretching exercise|Patients will receive education to perform stretching exercises at home.
62340660|NCT03294408|OTHER|Imaging|multimodal imaging and clinical assessment
62496767|NCT04602741|NO_INTERVENTION|Treatment As Usual|Treatment as usual participants will be recieving outpatient mental health care through the standard supports (most typically, case management and psychiatric support) that are available in a large, Canadian, urban centre.
62496768|NCT03868631|ACTIVE_COMPARATOR|Soy protein group|
61946158|NCT00981240|EXPERIMENTAL|Dose escalation|Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
61946159|NCT02605304|EXPERIMENTAL|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
61946160|NCT02605304|EXPERIMENTAL|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
61946161|NCT01483300|EXPERIMENTAL|lobaplatin|gemcitabine plus lobaplatin
61946162|NCT01483300|ACTIVE_COMPARATOR|cisplatin|gemcitabine plus cisplatin
61946163|NCT03495037|EXPERIMENTAL|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
61946164|NCT03495037|ACTIVE_COMPARATOR|Psychosocial Education|Group sessions including education on brain health.
62140120|NCT02205515|OTHER|Radiotherapy|SBRT or EBRT
62496769|NCT03868631|ACTIVE_COMPARATOR|Whey protein group|
62496770|NCT02556853|EXPERIMENTAL|Ultrasound|Determination of correct placement of the double lumen tube by lung ultrasound.
61946165|NCT06334458|OTHER|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups|Early diagnosis for pancreatic cancer in first degree healthy/asymptomatic relatives of patients with exocrine pancreatic cancer (high-risk asymptomatic subject groups)
61946166|NCT05023707|EXPERIMENTAL|CAR-T infusion|FLT3 positive relapsed or refractory acute myeloid leukemia
61946167|NCT02229383|EXPERIMENTAL|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
61946168|NCT02229383|PLACEBO_COMPARATOR|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
61946169|NCT01923831|EXPERIMENTAL|Magnesium group|
61946170|NCT01923831|ACTIVE_COMPARATOR|Dexamethasone group|
61946171|NCT03638622|EXPERIMENTAL|Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)|Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.
61946172|NCT04647864||Group 1|Edwards Sapien 3 and Edwards Sapien 3 Ultra
61946173|NCT04647864||Group 2|Medtronic Corevalve Evolut R and Medtronic Corevalve Evolut PRO
61946174|NCT04647864||Group 3|Boston Scientific Acurate neo and Boston Scientific Acurate neo2
61946175|NCT04647864||Group 4|St. Jude Medical Portico
61946176|NCT04339686||Suspicion of COVID 19|
61946177|NCT03650556|EXPERIMENTAL|Ablation|Enrolled subjects who had the investigational catheter inserted into their vasculature for pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE).
61946178|NCT05376462|EXPERIMENTAL|Quantra System with the QStat Cartridge|Decisions regarding transfusion of blood products will be made based on information derived from the Quantra System with the QStat Cartridge.
61946179|NCT05376462|ACTIVE_COMPARATOR|Standard Laboratory Coagulation Testing|Decisions regarding transfusion of blood products will be made based on the site's standard of care which is information derived from standard laboratory coagulation tests.
61946180|NCT06540027||Control group|Patients with rectal cancer, open surgery
61946181|NCT06540027||Study group 1|Patients with rectal cancer, laparoscopic surgery
61946182|NCT06540027||Study group 2|Patients with rectal cancer, robotic surgery
61946183|NCT06029738|EXPERIMENTAL|Experimental group|Intervention (Metacognitive Education for Obsessive-Compulsive Disorder (MCT-OCD)): MCT-OCD is a group education for OCD patients
61946184|NCT06029738|NO_INTERVENTION|Control group|
61946185|NCT01444131|PLACEBO_COMPARATOR|Varenicline and Placebo Patch|Varenicline and Nicotine Patch (placebo)
61946186|NCT01444131|ACTIVE_COMPARATOR|Varenicline and Nicotine Patch|Varenicline and Nicotine Patch 15mg
61946187|NCT01701921|EXPERIMENTAL|Pregabalin 75|Pregabalin 75mg by mouth one hour before surgery
61946188|NCT01701921|ACTIVE_COMPARATOR|Pregabalin 150|Pregabalin 150mg by mouth one hour before surgery
61946189|NCT01701921|PLACEBO_COMPARATOR|Sugar pill|Placebo : Sugar pill manufactured to mimic pregabalin capsule by mouth one hour before surgery
62140121|NCT02383043|EXPERIMENTAL|Active Treatment|Cocaine choice during d-amphetamine maintenance
62140122|NCT02383043|PLACEBO_COMPARATOR|Placebo Treatment|Cocaine choice during placebo maintenance
62140123|NCT03861234|EXPERIMENTAL|0.06 mg BI 836880 - SRD part|
62140124|NCT03861234|EXPERIMENTAL|0.18 mg BI 836880 - SRD part|
62140125|NCT03861234|EXPERIMENTAL|0.5 mg BI 836880 - SRD part|
62140126|NCT03861234|EXPERIMENTAL|1 mg BI 836880 - SRD part|
62140127|NCT03861234|EXPERIMENTAL|2 mg BI 836880 - SRD part|
62496771|NCT02556853|ACTIVE_COMPARATOR|Clinical|Determination of correct placement of the double lumen tube by clinical examination.
62697914|NCT02444247|OTHER|Low Dose Exercise vs Sedentary Option|Relative Reinforcing Value of low dose exercise (150 kcal expenditure per session) versus sedentary activity will be determined.
62140128|NCT03861234|EXPERIMENTAL|1 mg BI 836880 - cohort 1 MRD part|
61946190|NCT05306392|EXPERIMENTAL|Moderate Hypothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of moderate hypothermia during 48 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
61946191|NCT05306392|SHAM_COMPARATOR|Control - Normothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
61946192|NCT02086292|EXPERIMENTAL|2 milliliter lidocaine|2 ml 1% Lidocaine in one ring finger, 1 ml 2% Lidocaine in the other ring finger
61946193|NCT02086292|EXPERIMENTAL|1 milliliter lidocaine|1 ml 1% Lidocaine in one ring finger, 2 ml 2% Lidocaine in the other ring finger
61946194|NCT04638660|EXPERIMENTAL|Phentolamine Ophthalmic Solution 0.75%|One drop in both eyes at or near bedtime (8PM to 10PM)
61946195|NCT04638660|PLACEBO_COMPARATOR|Phentolamine Ophthalmic Solution Vehicle|One drop in both eyes at or near bedtime (8PM to 10PM)
61946196|NCT03949439||Non-Frail|non-frail (frailty score 1\~3) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
61946197|NCT03949439||Pre-Frail|Pre-frail (frailty score 4) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
62140129|NCT03861234|EXPERIMENTAL|2 mg BI 836680 - cohort 2 MRD part|
62140130|NCT03861234|EXPERIMENTAL|2 mg BI 836680 - cohort 3 MRD part|
62140131|NCT05374694||Group 1|Macrovasculature + (FFR ≤ 0.80) / Microvasculature + (IMR ≥25)
62140132|NCT05374694||Group 2|Macrovasculature + (FFR ≤ 0.80) / Microvasculature - (IMR \<25)
62140133|NCT05374694||Group 3|Macrovasculature - (FFR\>0.80) / Microvasculature + (IMR ≥25)
62340661|NCT00077376|EXPERIMENTAL|Treatment (trastuzumab, ixabepilone, carboplatin)|"Induction therapy: Patients receive trastuzumab (Herceptin®) IV over 30 minutes\* on days 1, 8, 15, and 22 and ixabepilone IV over 1 hour and carboplatin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of unacceptable toxicity.~NOTE: \*Trastuzumab is given over 90 minutes on day 1 of course 1 (induction therapy) only.~Maintenance therapy: Patients receive trastuzumab IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
62496772|NCT05892731||age-related hearing loss with depression|According to Hamilton depression scale, age-related hearing loss patients were divided into two groups, namely age-related hearing loss with depression and age-related hearing loss without depression.
62496773|NCT05892731||age-related hearing loss without depression|According to Hamilton depression scale, age-related hearing loss patients were divided into two groups, namely age-related hearing loss with depression and age-related hearing loss without depression.
62496774|NCT02069951|EXPERIMENTAL|Practice two procedures on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises.~Participants randomised to the intervention group will practice two procedures on a simulator. First a procedural module A (a laparoscopic appendectomy) to a predefined proficiency level. Upon reaching proficiency for procedural module A the participants will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
61946198|NCT01031381|OTHER|Rad001/Bevacizumab|Patients will receive RAD001 by mouth everyday and Bevacizumab IV every 14 days until clinical progression.
61946199|NCT00981201|EXPERIMENTAL|Celecoxib + Placebo|
61946200|NCT00981201|EXPERIMENTAL|Celecoxib + Celecoxib|
62697915|NCT02444247|OTHER|No Exercise vs Sedentary Option|Relative Reinforcing Value of no exercise (0 kcal expenditure per session) versus sedentary activity will be determined.
61946201|NCT00981201|ACTIVE_COMPARATOR|Placebo + Celecoxib|
62140134|NCT05374694||Group 4|Macrovasculature - (FFR\>0.80) / Microvasculature - (IMR \<25)
62340662|NCT05963295|ACTIVE_COMPARATOR|patient with hematlolgical malignancies|
62340663|NCT05963295|ACTIVE_COMPARATOR|control group|
62340664|NCT03766802|ACTIVE_COMPARATOR|Wearable watch training group.|"Aerobic exercises Strengthening exercises Stretching exercises Balance exercises Dose was increased as person is able to tolerate. Form:intervention is trackable and notifiable if patients don't exercise with smartwatch.~Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
62340665|NCT03766802|ACTIVE_COMPARATOR|Mobile application training group.|"Aerobic exercises Strengthening exercises Stretching exercises~Balance exercises Form:intervention is trackable and notifiable if patients don't exercise with smartphone Dose was increased as person is able to tolerate. Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
62340666|NCT03766802|SHAM_COMPARATOR|Supervised exercise training group|Aerobic exercises Strengthening exercises Stretching exercises supervised by a physical therapist
62340667|NCT06411249|EXPERIMENTAL|Belimumab (GSK1550188)|Participants will receive GSK1550188.
62340668|NCT03180489|EXPERIMENTAL|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
62697916|NCT02531256|EXPERIMENTAL|LMA Protector|Single Use Supraglottic Airway Device with 2 ports for gastric access (male and female port)
62697917|NCT06643676|EXPERIMENTAL|Targeted Endodontic Microsurgery using trephine drill and 3d printed surgical guide|Endodontic Microsurgery using 3d printed static surgical guide using patient's cbct data
61946202|NCT00981201|PLACEBO_COMPARATOR|Placebo + Placebo|
61946203|NCT04799574|EXPERIMENTAL|music therapy activity|The music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle.
61946204|NCT04799574|PLACEBO_COMPARATOR|Health education lecture|routine activities of community
61946205|NCT00532324|NO_INTERVENTION|A|Pregnant women not receiving CA-MRSA decolonization therapy.
61946206|NCT00532324|OTHER|B|Pregnant women receiving CA-MRSA decolonization therapy.
61946207|NCT05968131|ACTIVE_COMPARATOR|Conventional Physical Therapy|Conventional Physical Therapy will consist of application heat pack, ROM exercises, stretching, and strengthening exercises
61946208|NCT05968131|EXPERIMENTAL|Conventional Physical Therapy with Proprioceptive Training Exercises|Conventional Physical Therapy with Proprioceptive Training Exercises
61946209|NCT03404232|ACTIVE_COMPARATOR|Group 1|patients with their first surgical intervention at the lumbar spine receive the Dynesys DTO device (Zimmer Spine, Inc.).
61946210|NCT03404232|ACTIVE_COMPARATOR|Group 2|patients with a previous surgical decompression but non-fusion procedure after lumbar spinal stenosis surgery receive the Dynesys DTO device (Zimmer Spine, Inc.).
61946211|NCT03404232|ACTIVE_COMPARATOR|Group 3|patients with the medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment receive the Dynesys DTO device (Zimmer Spine, Inc.).
62140135|NCT05374694||Group 5|"Microvascular spasm (\<90% diameter contraction, Chest pain, ECG changes) or Macrovascular spasm (\>90% diameter contraction, Chest pain, ECG changes)~\*Only patients in groups 3 and 4 will undergo the acetylcholine test."
62140136|NCT01034306|EXPERIMENTAL|CF101 1 mg|piclidenoson (CF101) 1 mg tablet oral, Q12h for 12 weeks
62140137|NCT01034306|PLACEBO_COMPARATOR|Placebo|placebo tablet to match the active, oral dosage, Q12h for 12 weeks
62140138|NCT01357694|EXPERIMENTAL|psychotherapeutic contacts|
62140139|NCT01357694|NO_INTERVENTION|control group|
62340669|NCT03180489|PLACEBO_COMPARATOR|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
62340670|NCT03499821|EXPERIMENTAL|Study population|EDOF ICL implanted into both eyes of eligible subjects.
61946212|NCT06349018|EXPERIMENTAL|High nitrate|High nitrate isotonic drink
61946213|NCT06349018|ACTIVE_COMPARATOR|No nitrate|No nitrate isotonic drink
62340671|NCT01755195|EXPERIMENTAL|Cabozantinib|60 mg tablets orally once a day in a 28-day cycle.
62340672|NCT01324622|ACTIVE_COMPARATOR|Laminectomy|Control
61946214|NCT05916820|EXPERIMENTAL|Tanzberger Exercises|It consist of patients who will receive Tanzberger exercises 3 sessions per week for 4 weeks.
61946215|NCT05916820|EXPERIMENTAL|Pelvic floor muscle training|It consists of patients who will receive pelvic floor muscle training 3 sessions per week for 4 weeks.
61946216|NCT02128932|EXPERIMENTAL|Semaglutide 0.5 mg/week|
61946217|NCT02128932|EXPERIMENTAL|Semaglutide 1.0 mg/week|
61946218|NCT02128932|ACTIVE_COMPARATOR|Insulin glargine|
61946219|NCT05406362|EXPERIMENTAL|30 mg|30 mg VAD044
61946220|NCT05406362|EXPERIMENTAL|40 mg|40 mg VAD044
61946221|NCT05406362|PLACEBO_COMPARATOR|Placebo|Placebo
61946222|NCT00519454||Female Lupus patients|Females who are still childbearing age, not on hormones, with Systemic Lupus Erythematosus, still cycling.
61946223|NCT00827528|EXPERIMENTAL|SIS graft|this group will use a biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
61946224|NCT00827528|ACTIVE_COMPARATOR|2|this group will use a traditional repair on correction of anterior vaginal wall prolapse.
61946225|NCT03488355|EXPERIMENTAL|Modified Reporting|Modified laboratory report
61946226|NCT03488355|NO_INTERVENTION|Standard Reporting|Standard laboratory report
61946227|NCT03555760||Surgery patient|Observation of informed consent form readings of all patients who are scheduled for surgery
61946228|NCT00785928|EXPERIMENTAL|Placebo|
61946229|NCT00785928|EXPERIMENTAL|1 mg LY2127399|
61946230|NCT00785928|EXPERIMENTAL|3 mg LY2127399|
61946231|NCT00785928|EXPERIMENTAL|10 mg LY2127399|
61946232|NCT00785928|EXPERIMENTAL|30 mg LY2127399|
61946233|NCT00785928|EXPERIMENTAL|60 mg LY2127399|
61946234|NCT00785928|EXPERIMENTAL|120 mg LY2127399|
61946235|NCT06462885||Living alone|1,624 patients undergoing elective total hip arthroplasty who were living alone at the time of admission.
61946236|NCT06462885||Living with others|1,624 patients undergoing elective total hip arthroplasty who were living with others at the time of admission.
61946237|NCT02264639|EXPERIMENTAL|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
61946238|NCT02264639|EXPERIMENTAL|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
61946239|NCT02264639|EXPERIMENTAL|Cohort 3|Repeated Dose 180 mg/day
61946240|NCT02264639|EXPERIMENTAL|Cohort 4|Repeated Dose 270 mg/day
61946241|NCT03363269|EXPERIMENTAL|ID1201 100mg|
61946242|NCT03363269|EXPERIMENTAL|ID1201 200mg|
61946243|NCT03363269|EXPERIMENTAL|ID1201 400mg|
61946244|NCT03363269|PLACEBO_COMPARATOR|Placebo|
61946245|NCT06435728||STEMI|Patients with STEMI who underwent primary PCI and were hospitalized at Peking University Third Hospital between January 2017 and March 2022
61946246|NCT03490708|EXPERIMENTAL|Tranilast|Subjects who were treated with tranilast
61946247|NCT00263731||Group 1 (Experimental Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will receive 13-C-glucose prior to surgery
61946248|NCT00263731||Group 2 (Control Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will not receive 13-C-glucose prior to surgery
61946249|NCT00263731||Group 3 (Healthy Subjects)|250 healthy subjects (must be at least 30 years of age and have no prior history of diagnosed lung cancer) will provide 1 blood sample and 1 urine sample.
61946250|NCT05265416|EXPERIMENTAL|Piezosurgery|Piezocision will be applied in this group of patients using a piezosurgery knife.
61946251|NCT05265416|EXPERIMENTAL|Low-level laser therapy|Low-level laser therapy will be applied in this group of patients using a diode laser device.
61946252|NCT05265416|ACTIVE_COMPARATOR|Traditional treatment|No acceleration method will be performed in this group.
62140140|NCT06698458|EXPERIMENTAL|Patients with locally advanced pancreatic adenocarcinoma|Patients will begin mFOLFIRINOX treatment and will undergo DaRT placement during the first 4 cycles. Follow-up will continue up to 6 months after enrollment.
61946253|NCT06097182|EXPERIMENTAL|Post-biotic, colonic delivery|n=25, 250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
61946254|NCT06097182|ACTIVE_COMPARATOR|Post-biotic, regular administration|n=25, 250mg post-biotic once daily in a regular uncoated vegan gelatine capsule
61946255|NCT06097182|PLACEBO_COMPARATOR|Placebo|n=25, 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
61946256|NCT05075460|EXPERIMENTAL|Tucidinostat, Azacitidine combined with CHOP|Tucidinostat, Azacitidine combined with CHOP
61946257|NCT05075460|ACTIVE_COMPARATOR|CHOP|CHOP
61946258|NCT02683720|EXPERIMENTAL|ONS1|new product
61946259|NCT02683720|ACTIVE_COMPARATOR|ONS2|usual care
61946260|NCT06277596|EXPERIMENTAL|Supervise clinical Pilates group|Clinical Pilates exercises will be performed 10 repetitions, 3 days a week, for 6 weeks, under the supervision of a physiotherapist. The exercise program will be progressed as basic stabilization exercises in the first 3 weeks, advanced stabilization exercises in the last 3 weeks, as recommended in the literature, and a 30-second rest will be given between sets.
61946261|NCT06277596|ACTIVE_COMPARATOR|Clinical Pilates as home exercise|The same exercises will be shown to the home exercise group and it will be ensured that they are performed correctly. Patients will be given an illustrated and descriptive exercise program brochure containing information about exercise position, number of repetitions, contraction duration, rest time between sets, frequency, and an exercise diary for exercise tracking. In the 3rd week, new exercises will be shown to individuals. It will be applied 10 times, 3 days a week, for 6 weeks. The exercise program will be progressed as basic stabilization exercises in the first 3 weeks, advanced stabilization exercises in the last 3 weeks, as recommended in the literature, and a 30-second rest will be given between sets.
61946262|NCT02243969|EXPERIMENTAL|flaxseed oil (rich in α-linolenic acid )|
61946263|NCT02243969|PLACEBO_COMPARATOR|high oleic sunflower oil|
61946264|NCT00932126|EXPERIMENTAL|1|
61946265|NCT03493620|EXPERIMENTAL|Device arm|Gastric endosuturing will be performed until the entire gastric body is sutured in the form of a tube.
61946266|NCT03493620|SHAM_COMPARATOR|Sham arm|Group II is a control group (only the endoscopist will know which group each patient belongs to)
61946267|NCT05476367||patients with normal uric acid level|The uric acid level is below 420 μmol/L in men and 360 μmol/L in women
61946268|NCT05476367||patients with high uric acid level|The uric acid level is higher than 420 μmol/L in men and 360 μmol/L in women.
62496775|NCT02069951|NO_INTERVENTION|Practice one procedure on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises. Each exercise has to be passed twice within five consecutive attempts.~Participants randomised to the control group will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
62496776|NCT05705791|EXPERIMENTAL|166Holmium SIRT arm|"166Holmium selective internal intra-arterial radiation therapy (QuiremSpheres®, experimental medical device) in combination with approved first line therapy:~* Atezolizumab1200mg Q3W IV~* Bevacizumab 15mg/kg Q3W IV"
62496777|NCT00374361||Caucasian Adolescents|Caucasian Adolescents
62496778|NCT00374361||African-American Adolescents|African-American Adolescents
61946269|NCT03155282||Cirrhotic group|30 patients with cirrhosis will be evaluated by EUS-E to measure liver and spleen stiffness. Different cirrhosis etiologies will be included like cirrhosis induces by alcohol, virus, autoimmune, nonalcoholic steatohepatitis (NASH), cryptogenic, primary sclerosing cholangitis and primary biliary cirrhosis. The cirrhotic status will be determinate by clinical, biochemical and/or imaging methods (abdominal ultrasound or CT scan).
61946270|NCT03155282||Control group|30 normal patients with no history of liver disease (negative hepatitis B virus and hepatitis C virus serology, insignificant alcohol intake, normal ultrasound and laboratory), in whom a EUS has to be performed to evaluate a esophageal or gastric subepithelial lesion, chronic pancreatitis, will be evaluated by EUS-E to measure liver and spleen stiffness.
61946271|NCT03711318|EXPERIMENTAL|Short-term treatment with buprenorphine|Short-term treatment with buprenorphine
61946272|NCT05447897|OTHER|Stakeholder Advisory Group|"To co-design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke.~Convene a stakeholder advisory group (CHC providers, quality improvement specialists, community engagement staff, and specialty providers) to review the results of the literature review and quantitative analysis of deidentified data in order to select a set of implementation strategies from a menu of strategies to implement. The team will meet with the stakeholder advisory group four times for 1-2 hours each."
61946273|NCT03468101||Dairy farmers COPD|
61946274|NCT03468101||Non farmers COPD|
61946275|NCT00594048|EXPERIMENTAL|1|15 hypertensive patients use the Resperate for 9 weeks and measure their blood pressure before and after using this device
61946276|NCT00594048|ACTIVE_COMPARATOR|2|15 patients use a discman with freely chosen music for 9 weeks and measure their blood pressure before and after use of this device
61946277|NCT02699593|EXPERIMENTAL|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
61946278|NCT02699593|ACTIVE_COMPARATOR|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
62340673|NCT01324622|ACTIVE_COMPARATOR|Laminoplasty|Treatment group
62496779|NCT05331625|EXPERIMENTAL|Intervention|Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic at which time they will be offered additional resources to promote symptom management. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
62496780|NCT05331625|NO_INTERVENTION|Usual Care|Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic where they will receive symptom management and supportive care. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
62496781|NCT01853176|EXPERIMENTAL|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
62496782|NCT01853176|ACTIVE_COMPARATOR|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
62140141|NCT06698458|EXPERIMENTAL|Patients with metastatic pancreatic adenocarcinoma|Patients will begin mFOLFIRINOX treatment and will undergo DaRT placement during the first 4 cycles. Follow-up will continue up to 6 months after enrollment.
62340674|NCT04536337|EXPERIMENTAL|ALG-000184|Oral tablet(s) of ALG-000184 in HV or CHB subjects once daily for up to 4 weeks
62340675|NCT04536337|PLACEBO_COMPARATOR|Placebo|Oral tablet(s) of placebo in HV or CHB subjects once daily for up to 4 weeks
62496783|NCT04894409|EXPERIMENTAL|Experimental group|The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution.
62496784|NCT04894409|ACTIVE_COMPARATOR|Control group|"The control group was instructed to do mouthwashes and nose rinse in a conventional way."
62496785|NCT05595720|EXPERIMENTAL|treatment group|
62496786|NCT05595720|NO_INTERVENTION|control group|
62496787|NCT04781244|ACTIVE_COMPARATOR|EndWarts® FREEZE in Soft keratin|EndWarts® FREEZE were treated to 11 patients with wart at soft keratin
62697918|NCT06643676|ACTIVE_COMPARATOR|Conventional Endodontic microsurgery using burs|Conventional Endodontic microsurgery using carbide bur and free hand conventional procedure
61946279|NCT02835742|ACTIVE_COMPARATOR|Group1|Treatments for Group 1 include GM-CSF inhalation with 250 mcg/day/body of sargramostim (125 mcg BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
61946280|NCT02835742|PLACEBO_COMPARATOR|Group2|Treatments for Group 2 include placebo inhalation (Placebo BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
61946281|NCT02864602|EXPERIMENTAL|Dexamethasone 2mg|The experimental intervention in this arm will be an IV infusion of 2mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
62340676|NCT04536337|ACTIVE_COMPARATOR|Entecavir in combination with ALG-000184|
62496788|NCT04781244|ACTIVE_COMPARATOR|EndWarts® FREEZE in Hard keratin|EndWarts® FREEZE were treated to 11 patients with wart at hard keratin
62496789|NCT04781244|ACTIVE_COMPARATOR|Liquid nitrogen in Soft keratin|Liquid nitrogen were treated to 11 patients with wart at soft keratin
61946282|NCT02864602|EXPERIMENTAL|Dexamethasone 4mg|The experimental intervention in this arm will be an IV infusion of 4mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
61946283|NCT02864602|EXPERIMENTAL|Dexamethasone 8mg|The experimental intervention in this arm will be an IV infusion of 8mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
62496790|NCT04781244|ACTIVE_COMPARATOR|Liquid nitrogen in Hard keratin|Liquid nitrogen were treated to 11 patients with wart at hard keratin
62496791|NCT02861833||Patients with a cancerous wound|major patients followed in a cancer ward and holders of a cancerous wound.
62496792|NCT02966730|EXPERIMENTAL|Follicular Lymphoma|Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
62496793|NCT00483145|ACTIVE_COMPARATOR|1|Long-pulsed dye laser (Candela)
62496794|NCT00483145|ACTIVE_COMPARATOR|2|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
61946284|NCT03270371|EXPERIMENTAL|MCO Dialysis|Theranova Dialyzer
61946285|NCT03270371|ACTIVE_COMPARATOR|Standard High Flux Dialysis|Standard High Flux Dialyzer
61946286|NCT04997278|EXPERIMENTAL|Coordinated Reset- Spinal Cord Stimulation|All subjects will undergo spinal cord stimulation (SCS) implantation and will be optimized on standard SCS (sSCS) settings using the standard clinical protocol, including paresthesia mapping, threshold finding, and adjustment of stimulation parameters to provide reduction in pain. Therapeutic sSCS will be maintained for a minimum of one month prior to baseline assessment. Following a washout period of three hours assessments will be performed and Coordinated Reset- spinal cord stimulation (CR-SCS) will be enabled by means of a firmware upgrade. Personnel from Boston Scientific will perform this upgrade. The simulator will then be programmed to deliver CR-SCS. At the end of one month of CR-SCS (with stimulation parameters similarly held constant for the last 7 days), baseline assessment will be repeated after a three hour washout period. Finally, a firmware downgrade will be performed by Boston Scientific Personnel, and patients will be treated with sSCS at their previous settings.
61946287|NCT04046692||children in hospital school in contact with outside school|children experience school's lesson with the hospital teacher in the school's room or into their bedrooms and the investigator give before/after the lesson 2 questionnaire (PANAS-C and PH-C) and the VAS to evaluate the aim's study. Then, the investigator asks the children to make 2 paintings: one about the hospital school experience (what is for him/her the hospital school) and one about the outside school (what he/she do/did outside during school).
61946288|NCT04046692||children in hospital school NOT in contact with outside school|"it's the same of the previous group (children experiencing hospital school still in contact with outside school); the only difference of this group is that children are not in contact with the outside school."
61946289|NCT04046692||hospital teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
61946290|NCT04046692||outside teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
61946291|NCT04046692||Parents|parents have to answer some questions (qualitative interview)
61946292|NCT02125968|ACTIVE_COMPARATOR|interactive video game|"Participants in interactive video game group receive six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min interactive video game intervention, for 3 times per week for a 2-week duration.~Short- and medium-term therapeutic effects of interactive video game intervention for patients with chronic low back pain will be assessed."
61946293|NCT02125968|SHAM_COMPARATOR|therapeutic exercise|"Participants received six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min supervised therapeutic exercise,for 3 times per week for a 2-week duration.~short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain will be evaluated."
61946294|NCT03108274|EXPERIMENTAL|Part 1: Danicopan and Midazolam|"Period 1: Participants received a single dose of midazolam.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of midazolam.~Scheduled pharmacokinetics (PK) blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
62340677|NCT04946799|EXPERIMENTAL|Low-intensity training combined with blood flow restriction group (LI-BFR)|
62340678|NCT04946799|ACTIVE_COMPARATOR|High-intensity aerobic exercise group (HI)|
62340679|NCT04946799|PLACEBO_COMPARATOR|Low intensity group (LI)|
62496795|NCT04598633|ACTIVE_COMPARATOR|Lactobacillus reuteri Prodentis®-lozenges|
62496796|NCT04598633|PLACEBO_COMPARATOR|Placebo-lozenges (BioGaia)|
62496797|NCT01990807|ACTIVE_COMPARATOR|Idarubicin(IDA)|philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times
62496798|NCT01222364|ACTIVE_COMPARATOR|Standard Cord Clamping|
62496799|NCT01222364|EXPERIMENTAL|Delayed Cord Clamping|
62496800|NCT02763696||normal women|Composition of Viginal flora of Child-Bearing women in normal woman
62496801|NCT02763696||vaginitis women|Women of childbearing age with vaginitis
62496802|NCT00613041||1|Patients with one or more pulmonary nodules 5-15 mm in diameter.
62496803|NCT06504121||Device Closure|PFO closure with septal occluder device.
62496804|NCT04149509||Exposed|Infants born ≥ 37 weeks gestation with second or third trimester opioid exposure as determined by maternal urine toxicology screen at delivery; maternal history; and/or infant urine, meconium, or umbilical cord toxicology screen.
62496805|NCT04149509||Unexposed - Controls|Infants born ≥ 37 weeks gestation with no antenatal drug exposure as determined by maternal urine toxicology screen at delivery and/or maternal history. We will match control infants to exposed infants based on Clinical Site and up to 60 days after the date of birth of the exposed infant , recruiting 1 control for every other exposed infant at each site.
62496806|NCT02180230|OTHER|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
62340680|NCT00193219|EXPERIMENTAL|Intervention|"Bevacizumab 5 mg/kg IV~Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8~5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)~Leucovorin 350 mg IV~Oxaliplatin 85 mg/m2 IV"
62340681|NCT04930783|EXPERIMENTAL|CDX-301 + Neovax + Nivolumab|"* Participants will have vaccine made from tissue collected from metastatic tumor biopsy or surgical resection, or from previously collected archival biopsy or surgical tissue.~* Participants will receive Nivolumab at a flat dose every 4 weeks up to two years.~* Participants will receive CDX-301 at a predetermined dose dependent on the number of participants previously enrolled for 5 days starting 2 days before the initiation of NeoVax. CDX-301 will then be administered at a predetermined dose dependent on the number of participants previously enrolled 2 days before and for 5 days coinciding with the administration of NeoVax on days 50 and 78."
61946295|NCT03108274|EXPERIMENTAL|Part 2: Danicopan and Fexofenadine|"Period 1: Participants received a single dose of fexofenadine.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of fexofenadine.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
61946296|NCT03108274|EXPERIMENTAL|Part 3: Danicopan and MMF|"Period 1: Participants received a single dose of MMF.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of MMF.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
61946297|NCT03227185|EXPERIMENTAL|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
61946298|NCT03227185|EXPERIMENTAL|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
61946299|NCT03592654|EXPERIMENTAL|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
61946300|NCT06452238|EXPERIMENTAL|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block .
61946301|NCT06452238|EXPERIMENTAL|Transversus Abdominis Plane Block|Patients will receive ultrasound guided transversus abdominis plane block.
61946302|NCT01595633|ACTIVE_COMPARATOR|Adefovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Adefovir 10mg
61946303|NCT01595633|EXPERIMENTAL|Tenofovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Tenofovir 300mg
61946304|NCT03604484|ACTIVE_COMPARATOR|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
61946305|NCT03604484|NO_INTERVENTION|No Tricuspid annuloplasty|Control patients
62340682|NCT04930783|EXPERIMENTAL|CDX-301 + Neovax + Pembrolizumab|"* Participants will have vaccine made from tissue collected from tumor biopsy, or from previously collected archival biopsy or surgical tissue.~* Participants will receive neoadjuvant Pembrolizumab for 3 doses every 3 weeks, then undergo standard-of-care surgical resection.~* Participants will receive adjuvant NeoVax and CDX-301. CDX-301 will be administered at a predetermined dose, dependent on the number of participants previously enrolled, for 5 days starting 2 days before the initiation of NeoVax. CDX-301 will then be administered at a predetermined dose dependent on the number of participants previously enrolled 2 days before and for 5 days coinciding with the administration of NeoVax on days 50 and 78.~* Participants will receive adjuvant Pembrolizumab for 15 doses every 6 weeks."
62496807|NCT00752076|EXPERIMENTAL|1|We collected malignant pleural effusion for NSCLC cell lines with different EGFR mutations development and then we can compare the difference responses and signal pathways in these cell lines. We can also explore the detailed mechanism of TKI responsive cancer cell and try to develop other agent to enhance the pathways.
62496808|NCT03168906|EXPERIMENTAL|NEOD001|Study Drug given IV every 28 days at 24mg/kg
62496809|NCT03168906|PLACEBO_COMPARATOR|Placebo|Placebo
62496810|NCT04302935||chronic pain patients|
62496811|NCT04703751|EXPERIMENTAL|CIRCULATE Catheter|CIRCULATE Catheter will be used to deliver nitroglycerin and CardioCell to evaluate safety and efficacy of the device
62496812|NCT03581994|NO_INTERVENTION|Standard Practice|Not receiving any intervention/educational materials on drug-drug interaction testing
62496813|NCT03581994|EXPERIMENTAL|Compulsory DDI Testing|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
62496814|NCT03581994|EXPERIMENTAL|Optional DDI Testing|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
62496815|NCT02528409|PLACEBO_COMPARATOR|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
62496816|NCT02528409|EXPERIMENTAL|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
62496817|NCT02687789|EXPERIMENTAL|Medical Device: WO3191|The vaginal suppository is used for the reduction and/or inhibition of vaginal biofilms that were shown to be related to recurrent bacterial vaginosis.
62697919|NCT02578251|EXPERIMENTAL|Paracetamol|Patients will receive paracetamol intravenously (1 g in 100 mL) over 15 minutes (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
62697920|NCT02578251|ACTIVE_COMPARATOR|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
62340683|NCT01086150|OTHER|Healthy control patients|Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
61946306|NCT03854110|EXPERIMENTAL|GP-2250 Monotherapy|GP-2250 in doses of 250 mg up to 30 grams intravenously on Days -7, 1, 8, 15 (Cycle 1) and Cycle 2 and all subsequent cycles on Days 7, 8, 15 of a 28-day cycle with gemcitabine 1000 mg/m2 on Days 1, 8, 15 days of the cycle.
61946307|NCT05263375|EXPERIMENTAL|MV replacement with Innovalve TMVR system|MV replacement with Innovalve TMVR system
61946308|NCT03375008|EXPERIMENTAL|Imaging diagnostic and biopsy|47 subjects who are suspected NASH from June 2016 to December 2017.
61946309|NCT01250431|EXPERIMENTAL|EFT (Emotional Freedom Techniques)|10 sessions of EFT.
61946310|NCT01250431|NO_INTERVENTION|Wait List|10 week wait period.
62496818|NCT02687789|ACTIVE_COMPARATOR|Medical Device: Vagisan® Lactic Acid|It is used for the maintenance and restoration of a natural pH level in the vagina. The acidification of the vaginal milieu with lactic acid promotes the growth of typical vaginal flora (lactic acid bacteria) and is unfavourable for the growth of pathogens in the vagina. Vagisan® Lactic Acid is used in the post-treatment of bacterial vaginosis.
62496819|NCT04158687|PLACEBO_COMPARATOR|Placebo|Participants received CTP-692 matched-placebo powder for oral solution, once daily (QD) for up to 12 weeks.
62496820|NCT04158687|EXPERIMENTAL|CTP-692 1 gram QD|Participants received CTP-692 1 gram powder for oral solution, QD for up to 12 weeks.
62496821|NCT04158687|EXPERIMENTAL|CTP-692 2 grams QD|Participants received CTP-692 2 grams powder for oral solution, QD for up to 12 weeks.
62496822|NCT04158687|EXPERIMENTAL|CTP-692 4 grams QD|Participants received CTP-692 4 grams powder for oral solution, QD for up to 12 weeks.
62496823|NCT02763631|EXPERIMENTAL|Run In Phase|Eligible patients will have 6-Minute Walk Test (6-MWT) on self ventilation and on CPAP
62496824|NCT02763631|EXPERIMENTAL|Treatment|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Treatment arm - Patients will be setup onto portable CPAP during the day"
62496825|NCT02763631|SHAM_COMPARATOR|Standard Care Arm|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Control Arm - Standard care arm."
62496826|NCT00381849|ACTIVE_COMPARATOR|Cystone then sugar pill|Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
62496827|NCT00381849|PLACEBO_COMPARATOR|Sugar pill then Cystone|Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
62496828|NCT00381849|EXPERIMENTAL|Open-label Cystone|All subjects will receive Cystone for 46 weeks in the open-label period.
62496829|NCT00002923|EXPERIMENTAL|KRN5500|
62340684|NCT01086150|OTHER|Type I or Type II diabetes with painful diabetic neuropathy|18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
62340685|NCT01086150|OTHER|patients with non-painful diabetic peripheral neuropathy|18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
62496830|NCT02257437|EXPERIMENTAL|LNS + borbor|Lipid-based nutrient supplement (LNS) added to borbor
62496831|NCT02257437|ACTIVE_COMPARATOR|Corn-soy blend ++ (CSB++)|CSB++ porridge
62496832|NCT02257437|ACTIVE_COMPARATOR|Sprinkles|Sprinkles added to borbor
61946311|NCT01264783|EXPERIMENTAL|RNS60|RNS60
61946312|NCT01264783|PLACEBO_COMPARATOR|Placebo|Placebo
61946313|NCT05197621||Vaccine Arm|Pregnant women who are planning to receive an mRNA COVID vaccine (Pfizer of Moderna), and/or a third booster vaccine, who consent to maternal blood collection before receipt of the vaccine and at 6 time points after receiving the vaccine and/or booster.
61946314|NCT05197621||Sample Collection at Delivery Arm|Pregnant patients who have tested positive for COVID during their pregnancy or have a positive COVID test at the time of admission to Labor \& Delivery, who consent to collection of maternal blood, cord blood, placenta, and breast milk samples, as well as neonatal blood and stool samples. Patients testing negative for COVID at the time of admission to Labor \& Delivery can be enrolled in the study as controls.
62340686|NCT00929734|EXPERIMENTAL|Rosuvastatin|
62340687|NCT00929734|PLACEBO_COMPARATOR|Placebo|
62340688|NCT02311699|EXPERIMENTAL|Women Only|Groups of women will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by female facilitators.
62496833|NCT02257437|ACTIVE_COMPARATOR|LNS snack|LNS eaten as snack
62496834|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
62697921|NCT05704647|EXPERIMENTAL|Relatlimab+Nivolumab|Participants will receive nivolumab in combination with relatlimab by vein over about 30 minutes on Day 1 of each 28-day study cycle. You may receive up to 25 doses of the study drugs.
62697922|NCT04017312|ACTIVE_COMPARATOR|HFCWO group|Subjects in this arm of treatment will use The Vest® as their primary airway clearance modality for the duration of the study.
62697923|NCT04017312|ACTIVE_COMPARATOR|OPEP group|Subjects in this arm of treatment will use the Acapella® as their primary airway clearance modality for the duration of the study.
62496835|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
62496836|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
62496837|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
62496838|NCT03076645|EXPERIMENTAL|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
62496839|NCT06232837||Macintosh blade size 3|Patients intubated using Macintosh blade size 3
62496840|NCT06232837||Macintosh blade size 4|Patients intubated using Macintosh blade size 4
62697924|NCT05505500||Parent/Guardian of child with Nephrotic Syndrome (NS)|This group will help create the Observer Reported Outcome (ObsRO) tool.
62496841|NCT01008306||Renal transplanted children and young adults|"Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006.~Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards."
62496842|NCT03563885|EXPERIMENTAL|RYGB or SG|Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
62496843|NCT03563885|NO_INTERVENTION|Lean|Lean control subjects doing baseline testing only.
62496844|NCT00398073|EXPERIMENTAL|mouse gp100 DNA via PMED|patients will be randomized to mouse gp100 DNA delivered via gold particles using the PowderMed delivery system (ND10, described above). Two actuations/day will be administered every two weeks for 4 months for a total of 16 actuations. Each actuation consists of 2 μg of plasmid DNA coated onto 1000 μg of gold. The total dose of plasmid DNA given will be 32 μg DNA on 16,000 μg gold.
62496845|NCT00398073|EXPERIMENTAL|mouse gp100 DNA injections intramuscularly|patients will be injected with 1000 μg of mouse gp100 plasmid DNA intramuscularly. Two injections/day will be administered every two weeks for 4 months (4000 ug of mouse gp100 plasmid/month) for 16 vaccinations.
62496846|NCT01652508|PLACEBO_COMPARATOR|Control|Participants are given printed self-help leaflet on smoking cessation developed by the Department of Health, Hong Kong.
62496847|NCT01652508|EXPERIMENTAL|Acceptance and Commitment Therapy|All participants are given a self-help leaflet on smoking cessation. Participants are also given an initial session of face-to-face ACT at a primary health service clinic. In addition, two more subsequent ACT sessions are provided by telephone at one week and one month after the initial intervention.
62496848|NCT06349096|EXPERIMENTAL|Laser treatment|Treatment of facial skin wrinkles using the Alma Harmony platform with the ClearLift high power Q-switched (QS) 1064nm Nd:YAG laser module
62496849|NCT02466087|EXPERIMENTAL|Mg Cl|500mg Mg Cl per day for 6 weeks
62496850|NCT02466087|NO_INTERVENTION|Control|No intervention
62496851|NCT01237080|EXPERIMENTAL|Fastrach|50 persons beeing intubated using the Fastrach.
62496852|NCT01237080|EXPERIMENTAL|GlideScope|50 persons beeing intubated using the GlideScope.
62496853|NCT01941069|ACTIVE_COMPARATOR|Internalizing Disorders|Students identified as being at-risk for or meeting criteria for Internalizing Disorders will assigned to this intervention arm. They will receive the FRIENDS for Life intervention. FRIENDS is a group Cognitive Behavioral Therapy (CBT) intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
62496854|NCT01941069|ACTIVE_COMPARATOR|Externalizing Disorders|Students identified as being at-risk for or meeting criteria for Externalizing Disorders will be assigned to this intervention arm. They will receive the Coping Power Program (CPP) intervention. CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
62496855|NCT02336906|ACTIVE_COMPARATOR|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
62496856|NCT02336906|OTHER|Urotherapy alone|This group will receive standard behavioral urotherapy alone.
62496857|NCT00002727|ACTIVE_COMPARATOR|Radiation therapy - conventional fractionation|Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
62496858|NCT00002727|EXPERIMENTAL|Radiation therapy - hyperfractionation|Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
62496859|NCT02046317|EXPERIMENTAL|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
61946315|NCT02727842|EXPERIMENTAL|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
62340689|NCT02311699|EXPERIMENTAL|Men Only|Groups of men will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by male facilitators.
62496860|NCT02046317|ACTIVE_COMPARATOR|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
62496861|NCT01407484|EXPERIMENTAL|Treatment|Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
62496862|NCT01407484|PLACEBO_COMPARATOR|Placebo|Placebo
62496863|NCT04903652|EXPERIMENTAL|Pyrotinib plus Vinorelbine|
62496864|NCT00107016|EXPERIMENTAL|RAD001 + letrozole 2.5mg|
62496865|NCT00107016|ACTIVE_COMPARATOR|Letrozole 2.5mg|
62496866|NCT06383091|ACTIVE_COMPARATOR|Neck Manual, Stretches, Pain Neuroscience Education with Voice Exercise and Scar Massage Arm|Patients will receive direct manual massage to the anterior neck, general neck stretches and pain neuroscience education along with voice exercises and scar massage with a trained Speech-Language Pathologist
62496867|NCT06383091|PLACEBO_COMPARATOR|Voice Exercises and Scar Massage with placebo Manual/Stretching and Pain Education|Patients will be given voice exercise and scar massages with a trained Speech Language Pathologist, alongside placebo manual/stretching and placebo pain education.
62496868|NCT03910361|EXPERIMENTAL|Evogliptin|evogliptin 5mg
62496869|NCT03910361|ACTIVE_COMPARATOR|Pioglitazone|pioglitazone 15mg
62496870|NCT02587806|EXPERIMENTAL|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
62496871|NCT02871050||Castleman Disease Patients|Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.
61946316|NCT03985306|EXPERIMENTAL|Feasibility trial group|Every trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
62340690|NCT02311699|EXPERIMENTAL|Couples|Couples will receive the behavioural intervention to reduce IPV and HIV. Sessions will be led by a male and a female facilitator.
61946317|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
62340691|NCT02311699|NO_INTERVENTION|Control Group|Community members in the control villages will receive a short informational session on violence reduction.
61946318|NCT05600660|EXPERIMENTAL|OR-MTX|Experimental arm will be treated with OR-MTX regimen(Orelabrutinib plus Rituximab and Methotrexate) for 6 cycles as initiate induction. After 6 cycles of induction chemotherapy, autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be performed for transplantation eligible patients . Thereafter, Orelabrutinib maintenance chemotherapy will be given up to one year. Follow-ups should be taken up to the first 2 years. The primary endpoint is objective response rate (ORR) and secondary endpoint includes Progression free survival (PFS), overall survival (OS), and adverse events.
61946319|NCT02528604|ACTIVE_COMPARATOR|Catheter Ablation|Left atrial catheter ablation for persistent atrial fibrillation and implantable loop recorder.
61946320|NCT02528604|ACTIVE_COMPARATOR|Pacemaker and AV node ablation|Participants will have a permanent pacemaker implant followed by AV node ablation
61946321|NCT02528604|ACTIVE_COMPARATOR|DC cardioversion|Participants will have electrical cardioversion with concomitant anti-arrhythmic therapy and implantable loop recorder.
61946322|NCT01781364|EXPERIMENTAL|Cognitive Training|Brain Fitness Training, Posit Science SF
61946323|NCT06556381|EXPERIMENTAL|Group A,|women who received TAP block.
62496872|NCT01476358|ACTIVE_COMPARATOR|Vitamin A|Capsule containing oil vehicle with Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
62496873|NCT01476358|PLACEBO_COMPARATOR|Placebo|Capsule containing oil vehicle withOUT Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
62496874|NCT03271996|EXPERIMENTAL|Primary closure|Excision of sinus and paramedian closure according to modified Karydakis technique
62496875|NCT03271996|EXPERIMENTAL|Fistulectomy|Removal / fistulectomy by scalpels or trephines of primary and drainage orifices and healing of the wound by second intention
61946324|NCT06556381|ACTIVE_COMPARATOR|Group B|Received Usual modality of analgesics (Paracetamol, Tramadol, and Pethidine).
61946325|NCT02875912|NO_INTERVENTION|Usual Care|Family members are surveyed at enrollment, day 5 (if patient is still in ICU), and 90 days post ICU discharge for symptoms of PTSD, depression, and anxiety as well as for concordance of care at enrollment and ICU day 5. Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed to establish baseline data
61946326|NCT02875912|EXPERIMENTAL|Family Care Rituals Intervention|At enrollment, family members are given a handout/pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so. The families are then surveyed in the same way as they were during the usual care, with nursing completing the same surveys as well to compare against the baseline data
62340692|NCT06215222||Healthy patients|Healthy Patients
61946327|NCT01845142|ACTIVE_COMPARATOR|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
61946328|NCT01845142|PLACEBO_COMPARATOR|intramuscular placebo|intramuscular 0.9% sodium chloride
61946329|NCT01845142|ACTIVE_COMPARATOR|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
61946330|NCT01845142|PLACEBO_COMPARATOR|subcutaneous placebo|subcutaneous 0.9% sodium chloride
62340693|NCT06215222||IBS/Functional GI diasease|Patients with IBS or Functional GI disease (bloating, diarrhea, constipation)
62340694|NCT03976115|EXPERIMENTAL|1. healthy volunteers|3x single dose of DDO-3055 and placebo
62340695|NCT03976115|EXPERIMENTAL|2. Patients with chronic kidney disease|3x single dose of DDO-3055 and placebo
62340696|NCT01062568|EXPERIMENTAL|Obese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
62340697|NCT01062568|EXPERIMENTAL|Nonobese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
62340698|NCT04502550||Parkinson's Disease patients with DBS, no stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
62496876|NCT03920280|EXPERIMENTAL|LID015385|LID015385 contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
62496877|NCT03920280|ACTIVE_COMPARATOR|Biofinity|Comfilcon A contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
62496878|NCT02004067|ACTIVE_COMPARATOR|Refresh Endura|Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.
62496879|NCT02004067|EXPERIMENTAL|Restasis|Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months
62496880|NCT02132624|EXPERIMENTAL|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
62697925|NCT05505500||Person with Nephrotic Syndrome (NS)|This group will help create the Patient Reported Outcome (PRO) tool.
62697926|NCT05745961||PAH|
62697927|NCT05745961||Healthy volunteer|
61946331|NCT02123342|NO_INTERVENTION|Exercise programme only|Participants randomized in this condition will not receive SMS reminders to execute the myPAtHS exercise programme.
61946332|NCT02123342|EXPERIMENTAL|SMS reminder|Participants in this study arm will receive SMS reminders to motivate them to execute the myPAtHS exercise programme.
62496881|NCT04293354|ACTIVE_COMPARATOR|Serratus Plane Block|The Serratus plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
61946333|NCT04736082|EXPERIMENTAL|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive the following infant formula: Infant formula manufactured from extensively hydrolyzed proteins and containing pre- and probiotics.
61946334|NCT04736082|ACTIVE_COMPARATOR|Control Group: Infant Formula with intact protein|Infants will receive the following infant formula: Infant formula manufactured from intact proteins and containing pre- and probiotics.
61946335|NCT04736082|NO_INTERVENTION|Breast Fed Group|Exclusively breast milk
61946336|NCT01689636|EXPERIMENTAL|Single-center, open-label|"The study was designed as a single-center, open-label clinical study to evaluate the safety, pharmacokinetics, dosimetry and metabolism of Tc 99m EC20 in normal volunteers and in patients with known or suspected ovarian cancer.~Eight subjects were to be enrolled at one center: four normal subjects, four patients with ovarian cancer. Each subject was to receive a single injection of Tc 99m EC20 complex composed of 0.1 mg ligand (EC20) and 15 - 20 mCi of Tc 99m. Two (2) of the 4 normal subjects and 2 of the 4 patients were to receive an injection of 0.25-2.0 mg folic acid 1-2 minutes prior to the injection of Tc 99m EC20."
61946337|NCT02758704|EXPERIMENTAL|High-Stress (HS)|In the HS environment, the resident will be exposed to various stressors. There will be the presence of audio alarms as well as the presence of a senior physician who will be supervising the performance of the resident. In addition, the mannequin will be slightly unstable which will be reflected in its oxygen saturation dropping throughout the first 30 seconds the procedure.
61946338|NCT02758704|ACTIVE_COMPARATOR|Low-Stress (LS)|In the LS environment, there will be absence of audio (alarms), physical (third-party supervisor, nurse and respiratory therapist) and situational (unstable infant) stressors.
61946339|NCT03302650|EXPERIMENTAL|Angiotensin group|Patients will receive Angiotensin II at a starting dose of 20 ng/Kg/min. During the first 30 minutes after randomization, the angiotensin II infusion will be titrated to achieve a mean arterial pressure of 65-75 mmHg while the norepinephrine infusion will be withdrawn and stopped. Following a stabilization of 60 minutes, the angiotensin II infusion is titrated to achieve a mean arterial pressure of 85-95 mmHg. Following a 30 minutes wash-in period and a 60 minutes stabilization period, a third set of measurements will be taken. Then, the angiotensin II infusion will be withdrawn in small steps and replaced by a norepinephrine infusion which will then be titrated to achieve a mean arterial pressure of 65-75 mmHg. Then, the final set of measurements will be taken.
61946340|NCT03302650|PLACEBO_COMPARATOR|Normal saline group|Patients will receive normal saline infusion in addition to norepinephrine infusion. The same mean arterial pressure levels (65-75 mmHg \> 85-95 mmHg \> 65-75 mmHg) will be achieved by titration of the norepinephrine infusion. Identical wash-in and stabilization periods will be kept as in the study group. Measurements will be taken at the same time points as in the study group. The maximum dose of norepinephrine applied will be 0.7 mcg/kg/min.
61946341|NCT03024879|ACTIVE_COMPARATOR|Erythromycin|40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml
61946342|NCT03024879|PLACEBO_COMPARATOR|Placebo|a saline solution of 100 ml will be administered intravenously over a period of 20 min
62340699|NCT04502550||Essential Tremor patients with DBS|"This cohort will serve as a control group (no basal ganglia pathology). A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a TCI system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
62340700|NCT04502550||Parkinson's Disease patients with DBS, Gpi stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads during propofol induced loss of consciousness."
62340701|NCT04502550||Parkinson's Disease patients with DBS, Gpe stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads during propofol induced loss of consciousness."
62496882|NCT04293354|SHAM_COMPARATOR|Control|No block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
62496883|NCT04411173|ACTIVE_COMPARATOR|Rice Protein|Rice Protein - 24 grams, chocolate, powder
62496884|NCT04411173|ACTIVE_COMPARATOR|Whey Protein|Whey Protein - 24 grams, chocolate, powder
62496885|NCT03023137|ACTIVE_COMPARATOR|Walking & dietary modification (W&D)|W\&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W\&D at enrolment and at each consultation.
62496886|NCT03023137|NO_INTERVENTION|Controls|No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
62496887|NCT05324891|ACTIVE_COMPARATOR|Fentanyl|Neonates received fentanyl infusion during postoperative phase.
62496888|NCT05324891|ACTIVE_COMPARATOR|Dexmedetomidine|Neonates received dexmedetomidine infusion during postoperative phase.
62496889|NCT00267124||1|elderly people who have normal cognition
62496890|NCT00267124||2|elderly people who have mild to moderate Alzheimer's disease
62496891|NCT02328040|PLACEBO_COMPARATOR|Part A|Placebo and Insulin monotherapy via CL
62496892|NCT02328040|ACTIVE_COMPARATOR|Part B|Sitagliptin and insulin/novolog via CL
62496893|NCT01759251||vestibular vertigo|Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label
62697928|NCT02881554|EXPERIMENTAL|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.~* In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.~* In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
61946343|NCT04639700|EXPERIMENTAL|Psycho-educational intervention|All participants will receive receive 4 individual sessions with an interventionist in addition to the standard post-hospital HSCT information for patient follow-up care as provided by the patient's oncologist
61946344|NCT02326662|EXPERIMENTAL|Paraplegics Acute|Acute \[1-6 mo.\] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
61946345|NCT02326662|EXPERIMENTAL|Paraplegics Sub-chronic|Sub-chronic \[6-12 mo.\] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
61946346|NCT02326662|EXPERIMENTAL|Paraplegics Chronic|"Chronic \[1- 5 years\]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
61946347|NCT02326662|EXPERIMENTAL|Tetraplegics Acute|Acute \[1-6 mo.\] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
61946348|NCT02326662|EXPERIMENTAL|Tetraplegics Sub-chronic|"sub-chronic \[6-12 mo.\] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
61946349|NCT02326662|EXPERIMENTAL|Tetraplegics Chronic|Chronic \[1- 5 years\]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation \& Biomatrix
61946350|NCT04732143|EXPERIMENTAL|Incentive Spirometry|Participants will undergo inspiratory muscle training using an incentive spirometer daily for 14 days prior to surgery.
61946351|NCT04732143|NO_INTERVENTION|Standard Care|Participants will not undergo any inspiratory muscle training prior to surgery.
61946352|NCT04120441|EXPERIMENTAL|Group mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
61946353|NCT04120441|NO_INTERVENTION|Routine care/control|Study participants randomized to control will receive information about community resources. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
61946354|NCT05138107|EXPERIMENTAL|Skin Graft Burn Patients Experimental Site|Both placebo and active cosmetic scar spray will be applied to different parts of the same scar on each participant. The active and the placebo spray will both be applied to the designated area of each scar twice per day. The amount sprayed will cover the designated area of the scar and then be massaged into to scar and surrounding skin with each application. This will be done twice daily for the nine-month duration of the study.
61946355|NCT05138107|PLACEBO_COMPARATOR|Skin Graft Burn Patients Placebo Site|Both placebo and active cosmetic scar spray will be applied to different parts of the same scar on each participant. The active and the placebo spray will both be applied to the designated area of each scar twice per day. The amount sprayed will cover the designated area of the scar and then be massaged into to scar and surrounding skin with each application. This will be done twice daily for the nine-month duration of the study.
62340702|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpe stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
62496894|NCT04129255|OTHER|OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)|OCT LAR is already registered By FDA for USA, by EMA for Europe and , also, by AIFA for Italy.
62496895|NCT02509260|EXPERIMENTAL|Prevena™ incisional NPWT|Prevena wound management system: Post op application of the Prevena™ wound management system will be applied.
62496896|NCT02509260|ACTIVE_COMPARATOR|Standard Wound Dressings|Standard Wound Dressings: Control patients with standard wound dressings will have gauze and tape dressings applied.
62496897|NCT03330860|EXPERIMENTAL|Neuromarketing strategy|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
62496898|NCT03330860|ACTIVE_COMPARATOR|No-capsule group|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
62496899|NCT03890757||serratus anteriorblock|Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe
61946356|NCT04826523||Participants treated with Venetoclax|Participants who were prescribed venetoclax for the treatment of Acute Myeloid Leukemia (AML) will be enrolled for this study.
61946357|NCT05780684|EXPERIMENTAL|Study Arm|All patients in this single-study arm will be exposed to the FOX regimen, an adaptively dose-escalated chemotherapy regimen. The FOX regimen is comprised of oxaliplatin 85 mg/m2 IV on Day 1; leucovorin calcium 350 mg IV on Day 1; and infusional 5-FU IV over 46 hours (Days 1 and 2) - starting at a dose of 2,400 mg/m2 and adaptively adjusted toward a maximum dose of 3,200 mg/m2 over Cycles 2-4 using a clinical algorithm.
61946358|NCT02284516|EXPERIMENTAL|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
61946359|NCT02284516|PLACEBO_COMPARATOR|Placebo|Placebo to match active treatment, BID for 84 days
61946360|NCT05807230|NO_INTERVENTION|Conventional therapy: three-level rehabilitation treatment, Chinese medicine and acupuncture|Patients received conventional three-level rehabilitation treatment, conventional Chinese medicine and acupuncture treatment.
61946361|NCT05807230|EXPERIMENTAL|Conventional therapy and three-level network rehabilitation services|Three months after received conventional three-level rehabilitation treatment, conventional Chinese medicine and acupuncture treatment, patients continued to receive three-level network rehabilitation services within the medical alliance.
61946362|NCT02677064||Patients with Acute Leukemia (Arm A)|Follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
62697929|NCT03509779||NSCLC|NSCLC localized disease treated by surgery
62697930|NCT05301764|EXPERIMENTAL|LVGN6051 combined with Anlotinib|LVGN6051 Dose Escalation in the combination treatment with Anlotinib
61946363|NCT02677064||Patients with MDS and MPN (Arm B)|Follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
61946364|NCT02677064||Patients with Acute Leukemia or MDS/MPN who Relapse After First Allografts (Arm C)|Follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
61946365|NCT04935281||percutaneous repair with an intraoperative assissted ultrasound|a radiologist did an intraoperative ultrasound before the repair for identification the course of sural nerve and outline the medial and lateral edges of torn tendon.
61946366|NCT04935281||percutaneous repair without an intraoperative assissted ultrasound|the course of the sural nerve was determined according to the technique described by Blackmon et al .This technique depends on the leg length for location the point where the nerve crosses the lateral edge of the tendon
61946367|NCT02168127|EXPERIMENTAL|Active drug group|PRC-063 - Active methylphenidate hydrochloride extended-release capsules drug group
61946368|NCT03558087|EXPERIMENTAL|Gemcitabine, Cisplatin and Nivolumab|Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m\^2 IV ,Cisplatin 70mg/m\^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with \> cTa status will undergo cystectomy.
61946369|NCT01272973|EXPERIMENTAL|Oral 1|
61946370|NCT01272973|EXPERIMENTAL|Oral 2|
62496900|NCT03258996|EXPERIMENTAL|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
62496901|NCT03258996|ACTIVE_COMPARATOR|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
61946371|NCT01272973|EXPERIMENTAL|Oral 3|
61946372|NCT01272973|ACTIVE_COMPARATOR|S.c.|
61946373|NCT01102270|ACTIVE_COMPARATOR|Eszopiclone|Eszopiclone 3mg prior to sleep (1 night)
61946374|NCT01102270|PLACEBO_COMPARATOR|Sugar Pill|Sugar Pill (placebo) prior to sleep (1 night)
62697931|NCT01796847||PTEN, hyperglycemia|
62697932|NCT02317419|EXPERIMENTAL|Part A MAD Phase RO6927005 Monotherapy|RO6927005 given as a single agent in participants with tumors known to be mesothelin expressing and with mesothelin-positive tumors. MAD = multiple ascending dose.
62697933|NCT02317419|EXPERIMENTAL|Part A Extension Phase Group 1|RO6927005 given as a single agent in participants with mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA)
62697934|NCT02317419|EXPERIMENTAL|Part A Extension Phase Group 2|RO6927005 given as a single agent in participants with mesothelin-positive metastatic and/or advanced PDA
62697935|NCT02317419|EXPERIMENTAL|Part B MAD Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with mesothelin-positive metastatic and/or advanced PDA
62697936|NCT02317419|EXPERIMENTAL|Part B Extension Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with PDA
61946375|NCT03862560|EXPERIMENTAL|Experimental group|Female soccers that perform a strength training
61946376|NCT03862560|NO_INTERVENTION|Control group|Female soccers that do not perform a strength training
61946377|NCT04590131|EXPERIMENTAL|Hubrid revaskularization|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.
61946378|NCT04590131|ACTIVE_COMPARATOR|Endovascular treatment|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
61946379|NCT01669265||OSNA|Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
61946380|NCT06217380|EXPERIMENTAL|Masimo SafetyNet Alert (MSNA)|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Masimo SafetyNet Alert (MSNA)
61946381|NCT03867344|ACTIVE_COMPARATOR|Hypoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute hypoglycemic hyperinsulinemic clamp procedure (50mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
62496902|NCT02802462|EXPERIMENTAL|High intensity-interval (HIT)|
62496903|NCT02802462|EXPERIMENTAL|moderate intensity-continuous (MCT)|
61946382|NCT03867344|PLACEBO_COMPARATOR|Normoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute normoglycemic hyperinsulinemic clamp procedure (90mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
61946383|NCT05727436|EXPERIMENTAL|Group 1 - probiotic|"Experimental: Group 1 - probiotic The use of Streptococcus salivarius M18 containing tablets (Dentoblis, registration number: AM.01.06.01.003.R.000061.07.20; 15.07.2020, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: basic active ingredients - Streptococcus salivarius M18 (≥5×108 CFU in 1 tablet), Vitamin D (320 IU (8 mcg) in 1 tablet); excipients - isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
61946384|NCT05727436|PLACEBO_COMPARATOR|Group 2 - placebo|"The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
61946385|NCT00004635|EXPERIMENTAL|Thalidomide|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received thalidomide orally 200 mg a day. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received the placebo for thalidomide once a day.
61946386|NCT00004635|EXPERIMENTAL|Placebo|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received placebo for thalidomide. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received thalidomide 200 mg once a day.
61946387|NCT04932993|NO_INTERVENTION|Standard care|Will not write down goals their goals for their medical care (usual care).
61946388|NCT04932993|EXPERIMENTAL|Writing down goals|Will write down goals their goals for their medical care.
61946389|NCT01468675|EXPERIMENTAL|Intervention|The intervention is completion of a validated, web-based risk assessment used to assess personalized risk and generate a risk report
61946390|NCT01468675|NO_INTERVENTION|Control|Usual Care
61946391|NCT01263977|EXPERIMENTAL|Thermodilution controlled volume management|Volume management based on parameters: GEDI, ELWI, CI
62697937|NCT05834738|EXPERIMENTAL|Sequence AB|Once daily oral administration of 0.75 mg atrasentan for 12 weeks (Period A) followed by once daily oral administration of placebo for 24 weeks (Period B)
61946392|NCT01263977|ACTIVE_COMPARATOR|Volume management based on surviving sepsis campaign|volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2
61946393|NCT00685542|EXPERIMENTAL|1|Diacerein 50mg bid
61946394|NCT00685542|PLACEBO_COMPARATOR|2|placebo 50mg bid
61946395|NCT05783375|OTHER|ADUNU Participants|Individuals and healthcare providers residing and working in the involved Ugandan Districts.
61946396|NCT00549380|EXPERIMENTAL|1|
61946397|NCT05904912|ACTIVE_COMPARATOR|Group PENG = PENG block|PENG block will be performed
61946398|NCT05904912|OTHER|Group C = Control group|Local infiltration will be applied.
61946399|NCT06259123|EXPERIMENTAL|Oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging|Patients with oligometastatic PCa diagnosed using \[68Ga\]Ga-PSMA-11 imaging defined as M1a and/or M1b positive with ≤5 osseous metastases and/or M1c ≤3 lung metastases will receive 2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy.
61946400|NCT05664074|EXPERIMENTAL|Rectal indomethacin|"Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
61946401|NCT05664074|EXPERIMENTAL|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
61946402|NCT04594343|EXPERIMENTAL|Disulfiram|
61946403|NCT04594343|PLACEBO_COMPARATOR|Placebo|
61946404|NCT03866954|EXPERIMENTAL|Intravenous administration of EE-TP|Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
61946405|NCT04789499|EXPERIMENTAL|Theophylline|400mg theophylline capsule diluted in 240 mL isotonic nasal saline lavage twice daily for six weeks.
61946406|NCT04789499|PLACEBO_COMPARATOR|Placebo|500mg lactose capsule diluted in 240 mL isotonic nasal saline lavage twice daily for six weeks.
61946407|NCT01497457|EXPERIMENTAL|MR saline peritoneography|Patients that will undergo MR saline peritoneography
61946408|NCT02037022|EXPERIMENTAL|Pivotal Response Treatment Package|Pivotal Response Treatment Package (PRT-P)
61946409|NCT02037022|NO_INTERVENTION|Delayed Treatment Group|Delayed Treatment Group (DTG)
61946410|NCT05952817|EXPERIMENTAL|virtual reality treatment|Virtual reality treatment
61946411|NCT05952817|OTHER|Exercise programs|Congenital physical therapy exercise
61946412|NCT04771312|ACTIVE_COMPARATOR|Information-only intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the information-only condition could respond to daily questions in a diary.
61946413|NCT04771312|EXPERIMENTAL|Social support network intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the social support condition could use an online chatting tool where they can send messages to their own network.
61946414|NCT03127046|EXPERIMENTAL|Group 1|Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole
61946415|NCT03127046|EXPERIMENTAL|Group 2|Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole
61946416|NCT03127046|EXPERIMENTAL|Group 3|Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac
62697938|NCT05834738|EXPERIMENTAL|Sequence BA|Once daily oral administration of placebo for 12 weeks (Period B) followed by once daily oral administration of 0.75 mg atrasentan for 24 weeks (Period A)
62496904|NCT02802462|NO_INTERVENTION|control (CTL)|
62697939|NCT00849992|OTHER|Imiquimod 5%|Patients randomized to this arm will receive treatment with imiquimod 5%
61946417|NCT03127046|EXPERIMENTAL|Group 4|Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac
61946418|NCT03127046|EXPERIMENTAL|Group 5|Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole
61946419|NCT03127046|EXPERIMENTAL|Group 6|Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole
62496905|NCT02769741|OTHER|Crossover 1: Control Diet followed by Active Diet|Treatment Period 1: Controlled diet without cashew nuts; Treatment Period 2: Controlled diet with cashew nuts
62496906|NCT02769741|OTHER|Crossover 2: Active Diet followed by Control Diet|Treatment Period 1: Controlled diet with cashew nuts; Treatment Period 2: Controlled diet without cashew nuts
62496907|NCT00024154|EXPERIMENTAL|Treatment (trastuzumab, gefitinib)|"Phase I (completed): Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1.~Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.~Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity."
62697940|NCT00849992|OTHER|Photodynamic therapy|Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.
62697941|NCT04198402||Patient with digestive neuroendocrine tumor|naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment
61946420|NCT02819739|EXPERIMENTAL|normoxia|During cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.
61946421|NCT02819739|ACTIVE_COMPARATOR|hyperoxia|During cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.
61946422|NCT03094403|EXPERIMENTAL|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
61946423|NCT03094403|ACTIVE_COMPARATOR|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
61946424|NCT03094403|PLACEBO_COMPARATOR|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
61946425|NCT01549678|EXPERIMENTAL|Intervention foot orthoses|Ethyl Vinil Acetate EVA insole shaped in the cast of the patient's foot.
61946426|NCT01549678|PLACEBO_COMPARATOR|Placebo insole|EVA flat insole.
61946427|NCT05097612|EXPERIMENTAL|Healthy participant|This is a repeated measures design. All participants receive both the intervention and the placebo comparator.
62697942|NCT04198402||Patient without tumor|Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.
61946428|NCT01809730||Cardiovascular risk|patients with CV disease
61946429|NCT04112407|EXPERIMENTAL|Control|Standard preparation of the surgical site without P. acnes pretreatment
61946430|NCT04112407|EXPERIMENTAL|BPO Group|Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry.
61946431|NCT04112407|EXPERIMENTAL|BPO and Phototherapy|2 days of benzoyl peroxide washes and 3 treatments of blue light phototherapy. Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry. The blue light phototherapy is administered to the shoulder for 3 minutes on three occasions; 2 days before, the day before surgery and in the preoperative area by the patient.
61946432|NCT01033812||Index Recruiter|Young African American or Latina women who served as index recruiters in ATN 067 and members of their female friendship network members who tested HIV positive based on HIV screening and a confirmatory test result that was conducted in ATN 067.
61946433|NCT01033812||Male Sexual Partners|Any male partner who engaged in at least one episode of oral, vaginal or anal sex during the course of their lifetime with an 084 index recruiter.
62496908|NCT05648539|EXPERIMENTAL|The clinical response of the music therapy|To assessthe efficacy of music therapy of MT group compared to Waiting group in mental subhealth.
62496909|NCT05648539|EXPERIMENTAL|The alterations of acoustic features in the music therapy|To understand the possible biological mechanism underlying the efficacy of music therapy by analyzing alterations of acoustic features.
62697943|NCT03014115|ACTIVE_COMPARATOR|combination ARA+ DHA|combination 0.76% ARA+ 0.4% DHA in infant formula per day
62697944|NCT03014115|EXPERIMENTAL|DHA|0% ARA +0.4% DHA in infant formula per day
62697945|NCT03755427|EXPERIMENTAL|15μg H7N9 Vaccine|Participants will be inoculated with 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
62697946|NCT03755427|PLACEBO_COMPARATOR|Aluminum hydroxide adjuvant|Participants will be first inoculated with one dose of seasonal influenza vaccine and followed with one dose of aluminum hydroxide adjuvant at 21-day intervals.
62697947|NCT04223271||Acutely Decompensated Heart Failure Patients|Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing. Testing with the Indicor device will occur every day during hospitalization, and twice a day for up to 30 days after discharge.
61946434|NCT02583282|EXPERIMENTAL|Doxycycline|Intrapleural doxycycline
61946435|NCT02583282|ACTIVE_COMPARATOR|Iodopovidine|Intrapleural iodopovidine
61946436|NCT01228864|EXPERIMENTAL|Brody Belt|
61946437|NCT01228864|ACTIVE_COMPARATOR|Conventional Urinary Drainage bag|
61946438|NCT05969808|ACTIVE_COMPARATOR|control group|"The control group will participate in regular activities and routines typically provided to children with developmental delays. These activities may include general playtime, basic gross motor activities, and free play with toys for 3 times a week for 45mins for 12 weeks. The control group will not receive any specific intervention targeted at improving visual motor integration, manual dexterity, or intra-limb coordination.~Experimental group"
61946439|NCT05969808|ACTIVE_COMPARATOR|experimental group|The Experimental group will receive the baseline treatment as Control group. Adaptive Physical Activities will perform for to improve Visual Motor Integration 3 times a week for 45mins for 12 weeks. Pre and post assessment will be performed by using box and boll test, box and block test, Discrete Vertical Finger Tapping Test (DVFTT), discrete horizontal finger tapping test and discrete vertical tapping test with ball.
61946440|NCT05235048|PLACEBO_COMPARATOR|Standard of care control|Tooth extraction and spontaneous healing
62697948|NCT03524157|EXPERIMENTAL|PRO-087|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
61946441|NCT05235048|EXPERIMENTAL|Socket seal with CT graft|Tooth extraction and socket sealing with autologous connective tissue graft
61946442|NCT05235048|EXPERIMENTAL|Socket seal with CT graft and bone replacement graft|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket
61946443|NCT05235048|EXPERIMENTAL|Tooth extraction and socket sealing and BRG with membrane|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket and positioning of collagen membrane
61946444|NCT04687384|EXPERIMENTAL|Robotic-assisted surgery|Patients undergoing robotic-assisted colectomy for colonic neoplasm
61946445|NCT04687384|ACTIVE_COMPARATOR|Laparoscopy|Patients undergoing conventional laparoscopic colectomy for colonic neoplasm
61946446|NCT04730687|PLACEBO_COMPARATOR|Traditional non-surgical mechanical therapy|Mechanical instrumentation in all groups continued with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany) until the clinician gently felt that the surface was sufficiently debrided.There is no laser application. The laser tip is placed in the peri-implant sulcus but not activated.
61946447|NCT04730687|ACTIVE_COMPARATOR|Diode laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) has been applied with the aid of a 300 µm diameter optical fiber tip (E3-9 mm) placed approximately 1 mm above the most apical part of the peri implant pocket, parallel to the implant surface. Pocket irrigation was performed with 3% hydrogen peroxide solution for 10 seconds before and after diode laser application.The fiber was moved in apico-coronal and mesial-distal directions for a total of 30 seconds during laser light emission.The laser tip was checked every 7-8 seconds and wiped with sterile saline in order to prevent a possible coagulation or temperature increase.The laser was used in continuous pulse mode, at a power of 0.8 Watt (W), an energy density of 3J / cm2 and a spot diameter of 1 mm. Pulse width and pulse interval were applied as 20 milliseconds.
61946448|NCT04730687|ACTIVE_COMPARATOR|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) was applied in short pulse '' H '' mode, water cooled with a non-contact sweeping motion for 30 seconds parallel to the implant surface.The settings used are: 1.5 W power, 30 Hz frequency, 50% water, 40% air, 140 s pulse duration and 1 cm spot size.
61946449|NCT01172522|EXPERIMENTAL|Fexofenadine left; placebo right|"Topical treatment active versus placebo.~Double blind randomized placebo controlled split face intrasubject comparison."
62340703|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpi stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
62697949|NCT03524157|ACTIVE_COMPARATOR|Xyel Ofteno|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
62697950|NCT03524157|ACTIVE_COMPARATOR|Systane ultra|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc.
62340704|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, no stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will not receive any stimulation via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
62340705|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
62340706|NCT04620915|EXPERIMENTAL|High-level construal|"Participants will be sent messages asking them to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014)."
62340707|NCT04620915|EXPERIMENTAL|Effortful down-regulation of craving for cigarettes|"Participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences)."
62340708|NCT04620915|EXPERIMENTAL|Up-regulation of goal energization|Participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking.
62340709|NCT05414305|OTHER|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
61946450|NCT01172522|EXPERIMENTAL|Fexofenadine right; placebo left|Split face double blind
61946451|NCT01953107|EXPERIMENTAL|Ferrous Fumarate 300 mg + Vitamin C|300 mg once a day of Oral Ferrous Fumarate
61946452|NCT01953107|PLACEBO_COMPARATOR|Placebo + Vitamin C|300 mg of Placebo
61946453|NCT05004714||Head Start Staff|Head Start staff including teachers, family advocates, directors, and others
61946454|NCT05004714||Head Start Children with Asthma|Children enrolled in Head Start program with physician diagnosed asthma
61946455|NCT03924635|ACTIVE_COMPARATOR|SYMBICORT as maintenance and reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 twice a day (BID) for maintenance and as needed (PRN) for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance and PRN for relief.
61946456|NCT03924635|ACTIVE_COMPARATOR|SYMBICORT as maintenance, salbutamol as reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief.
61946457|NCT05379777|EXPERIMENTAL|Remimazolam|A maintenance dose of remimazolam is administered for sedation
61946458|NCT01517620|EXPERIMENTAL|Total Glucosides Paeony, Capsules|
61946459|NCT01517620|NO_INTERVENTION|no intervention|
61946460|NCT04805177|EXPERIMENTAL|hematoma evacuation|Early minimally invasive image guided hematoma evacuation
62140142|NCT06523699|EXPERIMENTAL|CYT107 + Melphalan + AHCT|All patients on this protocol will be treated with standard of care melphalan conditioning followed by autologous hematopoietic stem cell transplant (AHCT). After AHCT, if patients are randomized to the experimental arm, CYT107 will be initiated and will continue for 4 weeks. CYT107 will be administered subcutaneously starting on D+1. Two doses will be given during the first week, and then CYT107 will be administered weekly for 3 more weeks for a total of 5 doses.
62140143|NCT06523699|ACTIVE_COMPARATOR|Melphalan + AHCT|All patients on this protocol will be treated with standard of care melphalan conditioning followed by autologous hematopoietic stem cell transplant (AHCT).
62140144|NCT00998725||HIV+ARV+|
62697951|NCT00329420|EXPERIMENTAL|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
62140145|NCT00998725||HIV+ARV-|
62140146|NCT00998725||HIV negative|
62140147|NCT06251336|EXPERIMENTAL|Uroial Plus Arm|UroialTM Plus sachets one sachet daily at night before going to bed after urinating for 30 days
62140148|NCT06251336|PLACEBO_COMPARATOR|Placebo Arm|one placebo sachet daily at night before going to bed after urinating for 30 days
62140149|NCT00392899|ACTIVE_COMPARATOR|UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
62140150|NCT00392899|NO_INTERVENTION|Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
62140151|NCT00708045|EXPERIMENTAL|All patients|All participants enrolled.
62340710|NCT00930605|EXPERIMENTAL|Alemtuzumab combination with CHOP and ESHAP|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
62340711|NCT02787642|EXPERIMENTAL|Olaparib in association with concomitant radiotherapy|Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
62697952|NCT00329420|EXPERIMENTAL|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
62697953|NCT00329420|EXPERIMENTAL|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
61946461|NCT05554588|ACTIVE_COMPARATOR|Intrathrombus thrombolysis|Intrathrombus thrombolysis with microcatheter or pierced bolloon during PPCI
61946462|NCT05554588|ACTIVE_COMPARATOR|Aspiration thrombectomy|Aspiration thrombectomy during PPCI
61946463|NCT04745884|EXPERIMENTAL|Monitoring|Imaging guided by monitoring results
61946464|NCT01570166|EXPERIMENTAL|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
62140152|NCT05380089|EXPERIMENTAL|Experimental group|"Over a 4-day period, participants randomly assigned to the experimental group will be instructed to maintain normal solid food choices, but to increase water intake to achieve a total water intake of ≥45ml/kg/day. Prepared bottles of water with the required amount will be given to each participant every morning and collected empty the following day. Instructions to drink small amounts of water every hour be transmitted.~Adherence to instructions regarding water intake will be determined by the return of drinking bottles, analysis of daily food records, assessment of water flux (i.e., collecting urines after subjects being dosed with deuterium), and daily screening questions. These samples will be delivered on a subsequent morning during a daily laboratory visit to collect urine and saliva samples, as well as BI assessment. On the 4th day, participants will perform a neuromuscular function assessment."
62140153|NCT05380089|NO_INTERVENTION|Control group|Participants randomly assigned to the control group will be instructed to maintain normal solid food choices and water intake based on their average intake reported on the food records. Adherence to instructions regarding water intake will be determined and assessments performed will occur as mentioned previously for the experimental group.
61946465|NCT01570166|EXPERIMENTAL|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
61946466|NCT02903641|NO_INTERVENTION|Control|All households in the study were given general child nutrition educational messaging, immediately after the baseline survey and prior to any treatments. This messaging focused on appropriate feeding habits complemented by breastfeeding and ways to maintain proper hygiene during food preparation and consumption.
61946467|NCT02903641|EXPERIMENTAL|Personalized information only|Household received the personalized information about the index child's height.
61946468|NCT02903641|EXPERIMENTAL|Labeled cash transfer only|Household received the labeled cash transfer.
61946469|NCT02903641|EXPERIMENTAL|Personalized information and labeled cash transfer|The household received both the personalized information intervention and labeled cash transfer intervention.
61946470|NCT02451111|ACTIVE_COMPARATOR|Rituximab/Ibrutinib|Ibrutinib capsules for 24 months (104 weeks) daily (always at the same time) in a dose of 560 mg (4 x 140 mg capsules)
61946471|NCT02451111|PLACEBO_COMPARATOR|Rituximab/Placebo|Placebo as comparator for 24 months (4 capsules daily always at the same time)
61946472|NCT00239590|EXPERIMENTAL|Testosterone|oral testosterone undecanoate, 80mg twice daily (Andriol Testocaps, Organon, The Netherlands) for 8 weeks
61946473|NCT00239590|PLACEBO_COMPARATOR|Placebo|identical to active medication, taken in an identical way to the active arm
61946474|NCT00216710|EXPERIMENTAL|Home Visited Mothers|Mothers randomized to the home visited group received AK State-funded home visiting services. Frequency of home visits was determined by home visiting staff based on mothers' needs. Mothers could receive home visiting services until their child turned 3 years old
61946475|NCT00216710|NO_INTERVENTION|Control Mothers|Mothers randomized to the control group did not receive home visiting services, but were offered referrals to other community-based services, as was usual protocol with home visiting agencies were operating at capacity.
61946476|NCT06556420||controls|
61946477|NCT06556420||patients with S. pyogenes infection|
61946478|NCT06556420||patients with other respiratory infections|
61946479|NCT00654121|ACTIVE_COMPARATOR|1|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
61946480|NCT00654121|NO_INTERVENTION|2|
62697954|NCT04416711|ACTIVE_COMPARATOR|Services As Usual|Participants assigned to the SAU condition will receive services as usual at their university, which include required programming related to heavy episodic drinking and sexually aggressive behavior either online or through new-student orientation.
61946481|NCT00607984|EXPERIMENTAL|single|
61946482|NCT06068023||Intestinal-type ampullary adenocarcinoma intervention|This cohort consist of patients with intestinal-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy.
61946483|NCT06068023||Intestinal-type ampullary adenocarcinoma control|This cohort consist of patients with intestinal-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy but due to logistics or patient preference, are not willing to receive adjuvant chemotherapy.
61946484|NCT06068023||Pancreatobiliary/mixed-type ampullary adenocarcinoma intervention|This cohort consist of patients with Pancreatobiliary/mixed-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy.
61946485|NCT06068023||Pancreatobiliary/mixed-type ampullary adenocarcinoma control|This cohort consist of patients with Pancreatobiliary/mixed-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy but due to logistics or patient preference, are not willing to receive adjuvant chemotherapy.
61946486|NCT00261456||BRCA1/2 carriers|Carriers of a BRCA1 or BRCA2 mutation.
61946487|NCT00261456||BRCA1/2 non Carriers|Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.
61946488|NCT00261456||Mismatch Repair gene mutation carriers|Carriers of a MSH2, MSH6 or MLH1 mutation.
61946489|NCT00261456||Mismatch Repair gene mutation non-carriers|Do not carry a mutation in either the MLH1, MSH2 or MSH6 genes that has been found in other members of the family.
61946490|NCT06362070|ACTIVE_COMPARATOR|DaVinci® Surgical System|"Robot-assisted total or subtotal Gastrectomy is carried out through daVinci platform.~(10 patients enrolled for phase 1 of the study and 15 patients for phase 2)"
61946491|NCT06362070|EXPERIMENTAL|Hugo™ RAS System|"Robot-assisted total or subtotal Gastrectomy is carried out through Hugo platform.~(10 patients enrolled for phase 1 of the study and 15 patients for phase 2)"
61946492|NCT06362070|EXPERIMENTAL|Versius® Robotic Surgery System|"Robot-assisted total or subtotal Gastrectomy is carried out through Versius platform.~(10 patients enrolled for phase 1 of the study and 15 patients for phase 2)"
61946493|NCT05824988||Patients with MAC lung disease|
61946494|NCT00808626|EXPERIMENTAL|99mTc-rBitistatin|
61946495|NCT05894226|EXPERIMENTAL|laparoscopic ventral mesh rectopexy arm|those who were underwent laparoscopic ventral mesh rectopexy for rectocele.
61946496|NCT00867620||1|case group: patients with urothelial carcinoma
62140154|NCT04463654|EXPERIMENTAL|Zero Self-Harm|When randomized to the Zero Self-Harm app the participants will receive an introduction to the app through videos in the app, which explains, amongst others, how to review previous crisis situations and possible strategies for future crisis. This will ensure the navigation and knowledge of the technicalities of the app, in addition to ensure the app can be used privately without personal guidance from e.g a therapist.
62697955|NCT04416711|EXPERIMENTAL|Personalized Feedback and Cognitive Training|The prevention program will target heavy episodic drinking, sexually aggressive behavior, and risky sexual behavior through 2 sessions that integrate personalized feedback and cognitive training components.
61946497|NCT00867620||2|control group: those without previous history of any malignancy
62697956|NCT04894864|ACTIVE_COMPARATOR|Opioid-Based Anesthesia Analgesia|Premedication: IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg and Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/kg. Anesthesia maintenance: Desflurane set at approximately 1 MAC, Morphine 0.1-0.12mg/kg, Fentanyl 1-2mcg/kg during induction and 50-100mcg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, along with Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. ICU stay sedation: Remifentanil infusion, until removal of the endotracheal tube. Surgical ward: PCA pump with Morphine for the first 3 postoperative days. Additional postoperative analgesia: Paracetamol 1g x3 +/- Dexketoprofen trometamol 50mg x2. Rescue therapy only: Tramadol 50-100mg.
62697957|NCT04894864|ACTIVE_COMPARATOR|Opioid-Free Anesthesia Analgesia|Premedication: Pregabalin 50-150mg x2, IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Dexdmedetomidine 0.5-1mcg/kg, Lidocaine 1mg/kg, Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg, Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/kg, Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg. Anesthesia maintenance: Desflurane set at \~1 MAC, Dexmedetomidine 0.2-1.2mcg/kg/h, Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, and Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. ICU sedation: Dexmedetomidine + Lidocaine infusions, until removal of the ETT. Surgical ward: PCA pump with Ketamine, Lidocaine, Clonidine and Midazolam for the first 3 postoperative days. Additionally, Pregabalin 50mg per os x1 and 25mg x1, up to x2, Paracetamol 1g x3 +/- Dexketoprofen trometamol 50mg x2. Rescue therapy only: Tramadol 50-100mg.
61946498|NCT02210923||Resistant hypertensive patients with Rheos system|"We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:~* 20 Hz, 3 Volts, 480 microseconds~* 20 Hz, 6 Volts, 480 microseconds~* 50 Hz, 3 Volts, 480 microseconds~* 50 Hz, 6 Volts, 480 microseconds~* 90 Hz, 3 Volts, 480 microseconds~* 90 Hz, 6 Volts, 480 microseconds"
61946499|NCT04478981||SELENON- or LAMA2-related muscular dystrophy|Participants diagnosed with congenital myopathy/muscular dystrophy due to mutations in the SEPN1 (SELENON) or LAMA2 gene
61946500|NCT02846324|EXPERIMENTAL|GBT440 600 mg Dose|Parts A and B
61946501|NCT02846324|EXPERIMENTAL|GBT440 900 mg Dose|Part A
61946502|NCT02846324|EXPERIMENTAL|GBT440 1500 mg Dose|Part B
61946503|NCT02846324|PLACEBO_COMPARATOR|Placebo|Parts A and B
61946504|NCT04763785||Patients with keratoconus corneas|Corneal tomography on patients with keratoconus diagnosis
61946505|NCT04763785||participants with healthy corneas|Corneal tomography on healthy participants
61946506|NCT04763785||retrospective part|fully anonymised Picture data of existing 4500 patients
61946507|NCT06189690|EXPERIMENTAL|rTMS 5 Hz group|Two-session/day 5-Hz rTMS will be administered by two week (weekdays) with a 30-minutes inter-session interval. A total of 20 sessions will be administered. Then two sessions per week along 12 weeks will be administered as maintenance phase. Parameters are considered as follow: 10 s. train, 10 s. inter-train interval, 2500 pulses per session at 100% of motor threshold (MT).
61946508|NCT06189690|SHAM_COMPARATOR|Sham group|Two-session/day sham 5-Hz rTMS will be administered by two week (weekdays) with a 30-minutes inter-session interval. A total of 20 sessions will be administered. Then two sessions per week along 12 weeks will be administered as maintenance phase. Parameters are considered as follow: 10 s. train, 10 s. inter-train interval, 2500 pulses per session at 100% of motor threshold (MT).
61946509|NCT06189690|NO_INTERVENTION|no rTMS control group|The patients on this group will receive any rTMS intervention. The purpose of this gruop is to compare all clinical, cognitive variables and BDNF levels under conditions of no cocaine/crack consumption, i.e., controlled environments, without rTMS.
61946510|NCT00677482||1|Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.
61946511|NCT05952934|ACTIVE_COMPARATOR|Candin vaccine|Seven Candida (Candin). The route of administration is intradermal injection at subject's limbs at 0.5 mL/injection. The schedule is 1 injection every three weeks for the first 4 injections, and then one injection every 3 months until a total of 7 injections has been given.
61946512|NCT05952934|PLACEBO_COMPARATOR|Placebo|Seven placebo injections (sterile 0.9% Normal Saline). The route of administration is intradermal injection at subject's limbs at 0.5 mL/injection. The schedule is 1 injection every three weeks for the first 4 injections, and then one injection every 3 months until a total of 7 injections has been given.
61946513|NCT00731068|EXPERIMENTAL|1|PRGF
62697958|NCT02510924|ACTIVE_COMPARATOR|Tracheal intubation with Airtraq sp|Tracheal intubation with Airtraq sp.
62496910|NCT02834390|EXPERIMENTAL|Quizartinib 20 mg/day|"Participants who received 20 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m\^2/day IV) and either idarubicin (12 mg/m\^2/day IV infusion) or daunorubicin (60 mg/m\^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m\^2/12 hours IV) was co-administered with quizartinib."
61946514|NCT00731068|PLACEBO_COMPARATOR|2|
61946515|NCT03967301|EXPERIMENTAL|Probiotic isolated intestinal bacteria (active)|Patients randomized to active arm, will consume 5ml every 12 hours per day of a suspension of probiotics (Bioflora ® Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis y Bifidobacterium brevis) for 14 days.The content of each bottle is reconstituted up to 50 ml (10 doses) with drinking water The prescription of the intervention will be carried out and monitored through the electronic medical record. In the hospital setting, the probiotic is reconstituted by the nursing staff. If the patient is discharged before this period the patient and family will be instructed to perform the reconstitution at home.
61946516|NCT03967301|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo arm, will consume 5ml every 12 hours per day of a suspension of placebo for 14 days. The prescription of the intervention will be carried out and monitored through the electronic medical record.
61946517|NCT03566862||Lung cancer|Individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough.
61946518|NCT03566862||COPD|Individuals with a confirmed diagnosis of COPD according to established criteria.
61946519|NCT03566862||Other (non-COPD) chronic lung disease|Individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma).
62697959|NCT02510924|EXPERIMENTAL|Tracheal intubation with Airtraq Mobile|Tracheal intubation with Airtraq Mobile
62697960|NCT03604744|EXPERIMENTAL|LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
61946520|NCT03566862||Normal smokers|Individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment).
61946521|NCT04213729|ACTIVE_COMPARATOR|Crohn's Disease (CD) Control Group|Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
61946522|NCT04213729|EXPERIMENTAL|Experimental CD Low Fat Diet (LFD) Group|Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
61946523|NCT04213729|EXPERIMENTAL|Experimental CD LFD + DPS Group|Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
61946524|NCT01521546|ACTIVE_COMPARATOR|eplerenone|active study drug
61946525|NCT01521546|PLACEBO_COMPARATOR|sugar pill|placebo
61946526|NCT03623841|EXPERIMENTAL|Dual-task training group|Participants in dual-task training group will execute dual-task training via exer-game which combined with treadmill, 3 times per week, least 8 weeks.
61946527|NCT03623841|ACTIVE_COMPARATOR|Treadmill training group|Participants in treadmill training group will do treadmill training only, 3 times per week, least 8 weeks.
61946528|NCT01748266||microcirculatory reactivity|Patients were studied during the first 48 postoperative hours. Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
61946529|NCT04403360|EXPERIMENTAL|Erector Spinae plane Block (ESPB) group|The ultrasound-guided ESPB was realized at T12 level (levo bupivacaine 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)after the induction of anesthesia but before the start of the surgery.
61946530|NCT04403360|ACTIVE_COMPARATOR|Local anesthesia infiltration by the surgeon|The surgeon infiltrates the surgical site after skin incision with local anesthetics (Levo Bupivacaïne 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)
62340712|NCT06214572|ACTIVE_COMPARATOR|Systemic therapy|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~1. Gemcitabine plus cisplatin:~   Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~2. Gemcitabine plus oxaliplatin:~   Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~3. Gemcitabine plus cisplatin plus Durvalumab:~   Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~4. Gemcitabine plus cisplatin plus nab-paclitaxel:~Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w.~duration: 3 months"
62340713|NCT06214572|ACTIVE_COMPARATOR|RT (Radiation therapy)|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy arm"
62697961|NCT03604744|PLACEBO_COMPARATOR|LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62697962|NCT03604744|PLACEBO_COMPARATOR|Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62697963|NCT03604744|PLACEBO_COMPARATOR|Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62697964|NCT03604744|PLACEBO_COMPARATOR|Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
62697965|NCT02085980|EXPERIMENTAL|Laser Treatment|Laser Treatment
62697966|NCT03685149|ACTIVE_COMPARATOR|Flecainide|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
61946531|NCT04641858|ACTIVE_COMPARATOR|BCG-Denmark|Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the right upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
61946532|NCT04641858|PLACEBO_COMPARATOR|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color and appearance as the resuspended BCG vaccine.
61946533|NCT05508711||Group 1|"1. st cardiac output measurement (horizontal supine position): Transesophageal echocardiographic cardiac output measurements, data recorded and in the meantime the data of the FloTrac system (© Edwards Lifesciences) monitor recorded also.~2. nd cardiac output measurement (Trendelenburg position): The operating table was then tilted in - 30 ° Trendelenburg (head-down) position. Echocardiographic measurements and FloTrac system (© Edwards Lifesciences) data were recorded.~3. rd cardiac output measurement: The patients were positioned from Trendelenburg to reverse-Trendelenburg, the above-described data were recorded again."
62340714|NCT04287101|EXPERIMENTAL|home PAC|A home PAC team will care for patients in his/her home within 3 weeks after acute hospitalization. The patient will get a physical therapy (PT) or occupational therapy (OT) 1 to 6 session(s) per week.
62340715|NCT04287101|ACTIVE_COMPARATOR|hospital PAC|A rehabilitation PAC team will care for patients in the hospital within 3 weeks after acute hospitalization. The patient will have 1 to 2 session(s) of PT or OT on weekdays, and a daily physician visit and nurse care.
62340716|NCT04287101|NO_INTERVENTION|conventional care group|usual care
62340717|NCT00484536|EXPERIMENTAL|CDP323 1000 mg/day|
62697967|NCT03685149|PLACEBO_COMPARATOR|Placebo|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
62697968|NCT02878863|EXPERIMENTAL|Paeoniflorin + phosphatidylcholine or silymarin|Paeoniflorin tablets(600mg, tid)combination of phosphatidylcholine or silymarin
62697969|NCT02878863|ACTIVE_COMPARATOR|Phosphatidylcholine or silymarin|Phosphatidylcholine or silymarin
62697970|NCT01313676|EXPERIMENTAL|fluticasone furoate/vilanterol|Combination of both products in one inhaler
62697971|NCT01313676|EXPERIMENTAL|fluticasone furoate|comparator of individual component
62340718|NCT00484536|EXPERIMENTAL|CDP323 500 mg/day|
62340719|NCT00484536|PLACEBO_COMPARATOR|Placebo|
62697972|NCT01313676|EXPERIMENTAL|vilanterol|comparator of individual component
62697973|NCT01313676|PLACEBO_COMPARATOR|placebo|once daily via inhaler
62697974|NCT00480532|EXPERIMENTAL|Doxycycline 100bid x5 days|
62697975|NCT00480532|PLACEBO_COMPARATOR|placebo bid x 5 days|
62697976|NCT00480532|EXPERIMENTAL|Subantimicrobial doxycycline daily|
62697977|NCT00480532|PLACEBO_COMPARATOR|placebo daily|
61946534|NCT05508711||Group 2|"1. st cardiac output measurement (horizontal supine position): Transesophageal echocardiographic cardiac output measurements, data recorded and in the meantime the data of the FloTrac system (© Edwards Lifesciences) monitor recorded also.~2. nd cardiac output measurement (reverse Trendelenburg position): The operating table was then tilted in + 30 ° reverse Trendelenburg (head-up) position. Echocardiographic measurements and FloTrac system (© Edwards Lifesciences) data were recorded.~3. rd cardiac output measurement: The patients were positioned from reverse Trendelenburg to Trendelenburg, the above-described data were recorded again."
61946535|NCT00764296||no treatment|The information obtained by the evaluation of both acute and chronic wounds is pivotal to truly understanding the intercellular tactics used by wound biofilms which work to disrupt host tissue and to evade the host's immune system.
61946536|NCT02285647|EXPERIMENTAL|Rolapitant - Oral|Investigational Product: Rolapitant Dose: 200 mg (4 x 50mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
61946537|NCT02285647|EXPERIMENTAL|Rolapitant - IV|Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
61946538|NCT05968456||Thoracic surgery|Patient undergoing thoracic surgery
61946539|NCT05968456||Cardiac surgery|Patient undergoing cardiac surgery
61946540|NCT05968456||Vascular surgery|Patient undergoing vascular surgery
62340720|NCT00377611|EXPERIMENTAL|FLUARIX 50-64 YEARS GROUP|Adult subjects aged between and including 50-64 years who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
62496911|NCT02834390|EXPERIMENTAL|Quizartinib 40 mg/day|"Participants who received 40 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m\^2/day IV) and either idarubicin (12 mg/m\^2/day IV infusion) or daunorubicin (60 mg/m\^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m\^2/12 hours IV) was co-administered with quizartinib."
62496912|NCT00560326|EXPERIMENTAL|1|
62697978|NCT02976805|EXPERIMENTAL|Regimen A|4L PegLyte + 15 mg bisacodyl
62697979|NCT02976805|EXPERIMENTAL|Regimen B|6L PegLyte + 15 mg bisacodyl
62697980|NCT00732888|OTHER|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Tasigna® once daily on days 1 and 15 (i.e., Tasigna® alone on day 1, and combination of Tasigna® and calcium supplement on day 15).
62697981|NCT00732888|OTHER|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Tasigna® once daily on days 1 and 15 (i.e., combination of Tasigna® and calcium supplement on day 1, Tasigna® alone on day 15).
62697982|NCT06177184|EXPERIMENTAL|Donor Human Milk|Infants randomized to the intervention group will receive DHM each time supplementation is required for the first 7 days of life.
62697983|NCT06177184|NO_INTERVENTION|Standard Care (Infant Formula)|Infants randomized to the standard care group will receive formula each time supplementation is required for the first 7 days of life.
61946541|NCT03611491|EXPERIMENTAL|Princess® FILLER Lidocaine|Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point
61946542|NCT05619250|EXPERIMENTAL|Unsupervised home-based exercise group without motivational intervention (UNSUP)|Participants will use a mobile application to perform a home-based training program autonomously, without the face-to-face supervision of a specialist during its execution.
61946543|NCT05619250|EXPERIMENTAL|Unsupervised home-based exercise group with motivational intervention (UNSUP+)|"Participants will use a mobile application to perform a home-based training program autonomously, without the face-to-face supervision of a specialist during its execution. As opposed to the UNSUP group, the UNSUP+ group will receive a motivational intervention."
62340721|NCT00377611|EXPERIMENTAL|FLUARIX 65+ YEARS GROUP|Elderly subjects aged 65 and over who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
62340722|NCT03327181|EXPERIMENTAL|COPD|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
62496913|NCT06678464|EXPERIMENTAL|Moiz MM|"1. Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
62496914|NCT06678464|EXPERIMENTAL|Moiz XL|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
62496915|NCT06678464|EXPERIMENTAL|Moiz LMF 48|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day or as often as needed Route of Administration: Topical"
62697984|NCT05650996|EXPERIMENTAL|ADL video/Cast Care|ADL/cast care instructional video ADL/cast care handout
62697985|NCT05650996|ACTIVE_COMPARATOR|Cast Care Video|Cast care instructional video Cast care handout
62697986|NCT02772692|EXPERIMENTAL|Squatting pan|Defecation using a squatting pan
62697987|NCT02772692|NO_INTERVENTION|Toilet|defecation using a standard-sized toilet
62697988|NCT02314923|EXPERIMENTAL|3x10^3 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10\^3 pfu in the deltoid on Day 0.
61946544|NCT05619250|EXPERIMENTAL|Supervised center-based exercise group without motivational intervention (SUP)|Participants will perform a center-based training program in small groups with a maximum of 8 participants per session, being supervised by an exercise professional.
61946545|NCT05619250|EXPERIMENTAL|Supervised center-based exercise group with motivational intervention (SUP+)|"Participants will perform a center-based training program in small groups with a maximum of 8 participants per session, being supervised by an exercise professional. As opposed to the SUP group, the SUP+ group will receive a motivational intervention."
61946546|NCT05619250|NO_INTERVENTION|Control group (CON)|Participants will not perform any type of exercise program during the intervention period and will be advised to maintain their usual lifestyle.
61946547|NCT01050283|EXPERIMENTAL|1|\[18F\]-FDG-PET/CT (Computed Tomography) Imaging
61946548|NCT02829060|ACTIVE_COMPARATOR|1a: Indwelling drains (48 hr)|"This group has indwelling urinary tubes/drains and a negative urine culture~* Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~* All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
61946549|NCT02829060|ACTIVE_COMPARATOR|1b: Indwelling drains (7d)|"This group has indwelling urinary tubes/drains and a negative urine culture~* Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~* All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
61946550|NCT02829060|ACTIVE_COMPARATOR|2a: +UCx with Oral Options (48hr)|"This group has a positive pre-operative urine culture with oral antibiotic options~* Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~* If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin \> sulfamethoxazole-trimethoprim \> doxycycline\> ciprofloxacin \> cephalexin \> cefpodoxime.~* All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
61946551|NCT02829060|ACTIVE_COMPARATOR|2b: +UCx with Oral Options (7d)|"This group has a positive pre-operative urine culture with oral antibiotic options~* Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~* If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin \> sulfamethoxazole-trimethoprim \> doxycycline\> ciprofloxacin \> cephalexin \> cefpodoxime.~* All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
61946552|NCT02829060|ACTIVE_COMPARATOR|3a: +UCx No Oral options (48hr)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~* 48 hour course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~* Gentamicin (80 mg) preferred if sensitive~* All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
61946553|NCT02829060|ACTIVE_COMPARATOR|3b: +UCx No Oral options (7d)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~* 7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~* Gentamicin (80 mg) preferred if sensitive~* All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
61946554|NCT04539353||chronic pain|Patients with chronic pain, regardless of the cause of the pain.
61946555|NCT02998983|EXPERIMENTAL|Racotumomab|Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
62140155|NCT04463654|NO_INTERVENTION|Treatment as usual|The control group will continue their present course of treatment and/or counseling at non-profit organizations, service centers in the municipalities, at outpatient treatment services for psychiatric disorders and/or care, attention at emergency departments. They will receive no treatment on the nature of NSSI. Participants in the control group will be offered a possibility to download the Zero Self-Harm app after they have completed the last questionnaire at six months, which will be stressed at the initial appointment as well as after collection of all data.
62140156|NCT02588443|EXPERIMENTAL|Arm1|Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
62340723|NCT03327181|ACTIVE_COMPARATOR|Healthy older adults|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
62340724|NCT02571751|EXPERIMENTAL|Breast Augmentation|
62340725|NCT04822857||1|AMH \> cut-off point
62340726|NCT04822857||2|AMH \< cut-off point
62340727|NCT05108220||R-101|CBD oil, 30 mg CBD per serving, 0% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
62340728|NCT05108220||R-102|CBD oil, 20 mg CBD per serving, 0% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
62340729|NCT05108220||R-103|CBD oil, 30 mg CBD per serving, \<0.3% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
62340730|NCT05108220||R-104|CBD oil, 20 mg CBD per serving, \<0.3% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
62340731|NCT05108220||R-105|CBD capsule, 15 mg CBD per serving, 0% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
62340732|NCT05108220||R-106|CBD capsule, 25 mg CBD per serving, 0% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
62340733|NCT05108220||R-107|CBD capsule, 15 mg CBD per serving, \<0.3% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
62697989|NCT02314923|EXPERIMENTAL|3x10^4 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10\^4 pfu in the deltoid on Day 0.
62496916|NCT03201341|OTHER|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
62496917|NCT03201341|OTHER|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
62496918|NCT03201341|OTHER|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
62697990|NCT02314923|EXPERIMENTAL|3x10^5 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10\^5 pfu in the deltoid on Day 0.
62340734|NCT05108220||R-108|CBD capsule, 25 mg CBD per serving, \<0.3% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
62697991|NCT02314923|EXPERIMENTAL|3x10^6 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10\^6 pfu in the deltoid on Day 0.
62697992|NCT02314923|EXPERIMENTAL|9x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 9x10\^6 pfu in the deltoid on Day 0.
62697993|NCT02314923|EXPERIMENTAL|2x10^7 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 2x10\^7 pfu in the deltoid on Day 0.
62697994|NCT02314923|EXPERIMENTAL|1x10^8 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 1x10\^8 pfu in the deltoid on Day 0.
62697995|NCT02314923|PLACEBO_COMPARATOR|Placebo Cohort 1|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
62697996|NCT02314923|EXPERIMENTAL|3x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 3x10\^3 pfu in the deltoid on Day 0.
62697997|NCT02314923|PLACEBO_COMPARATOR|Placebo Cohort 2|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
62697998|NCT05617885|EXPERIMENTAL|Phase 1 Lead In in CRPC|Standard 3+3 dose escalation scheme with 3 dose levels of abemaciclib and a constant dose of darolutamide, per protocol, for 6, 28-day cycles
62140157|NCT02588443|EXPERIMENTAL|Arm2|Arm II provides one dose of RO7009789 two days after one dose of nab-paclitaxel and one dose of gemcitabine prior to surgery. Nab-paclitaxel and gemcitabine are given on day 1. RO7009789 will be given on day 3. Patients will recover from any toxicities and will then have their disease surgically resected. Patients will receive four cycles of these same medications in an adjuvant fashion after recovering from surgical resection. A cycle will consist of nab-paclitaxel (125mg/m²), gemcitabine (1000mg/m²) given on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle.
62697999|NCT05617885|EXPERIMENTAL|Phase 2 - Neoadjuvant Darolutamide and ADT prior to Radical Prostatectomy|per protocol, for 6, 28-day cycles
62698000|NCT05617885|EXPERIMENTAL|Phase 2 - Neoadjuvant Darolutamide, Ademaciclib, and ADT prior to Radical Prostatectomy|per protocol, for 6, 28-day cycles
62698001|NCT04892589||Active Comparator: Control group|Thumb orthosis at night and day for 3 to 4 hours during Activities of Daily Living that included thumb metacarpophalangeal joint (MCP) for three months. In addition to a classic home exercise program.
61946556|NCT00805246||Pulmonary Embolism (PE)|Subjects diagnosed with PE by CT will be recruited.
62140158|NCT02298842|ACTIVE_COMPARATOR|Platelets Stored in Plasma|Platelets stored in Plasma
61946557|NCT03944031|EXPERIMENTAL|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by \[18F\]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.
61946558|NCT05667987|NO_INTERVENTION|General anesthesia without intravenous lidocaine administration|
61946559|NCT05667987|EXPERIMENTAL|General anesthesia with intravenous lidocaine administration|
61946560|NCT02762578|EXPERIMENTAL|IDegAsp BID|
61946561|NCT02762578|ACTIVE_COMPARATOR|BIAsp 30 BID|
62340735|NCT05108220||Control|Waitlist control; no product
62340736|NCT04910763|EXPERIMENTAL|Resistance Exercise|Resistance exercise will be training all major muscle groups 2x/week (2 days upper body, 2 days lower body) at 40-50% 1 repetition max (RM; estimated from 10 RM baseline testing) for 3 sets of 10-12 reps. This equals 4x/week for the 3 week intervention period.
62340737|NCT01829061||No Treatment|
62340738|NCT03386656|EXPERIMENTAL|Amchafibrin|Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.
62340739|NCT03386656|PLACEBO_COMPARATOR|Saline Solution 0,9%.|Comparator of tranexamic acid
62340740|NCT04124536|EXPERIMENTAL|Intervention|In addition to standard partner notification services, the intervention arm will receive HIV self-test kits and structured counseling about HIVST, regardless of HIV status.
62340741|NCT04124536|NO_INTERVENTION|Control|Standard partner notification services, regardless of HIV status.
62340742|NCT00101491|EXPERIMENTAL|1|
62340743|NCT00101491|OTHER|2|Attention Control Comparator
62340744|NCT03501745|OTHER|Management Group|
62340745|NCT03501745|OTHER|control group|
62340746|NCT01115738|PLACEBO_COMPARATOR|Placebo and 60 milligram (mg) Prasugrel|Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
62496919|NCT03201341|OTHER|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
62496920|NCT03201341|OTHER|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
62496921|NCT03930849|EXPERIMENTAL|AIMS Intervention|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol.
62496922|NCT03930849|NO_INTERVENTION|No Intervention|Participants randomized to the no intervention arm will not be enrolled in the Annie text messaging program.
62496923|NCT03930849|EXPERIMENTAL|AIMS Intervention Plus|Participants randomized to the AIMS Intervention Plus arm will be enrolled in VA's Annie text messaging program/study protocol and receive a weekly phone call.
62496924|NCT02672761|EXPERIMENTAL|MBSR|Subjects enrol and complete a standardized and licensed meditation program developed by Jon Kabat-Zinn. The program includes a weekly 200 min group session, daily meditation training from 20-40 min and one 4 h retreat within the study period. The individual daily and overall training volume is noted in min.
62496925|NCT02672761|EXPERIMENTAL|MBT|Subjects while being on the waiting list for MBSR are allocated to a web-based training program (MBT- My Brain Training) for working, episodic and general memory functions. The individual daily and overall training volume is noted in min.
62496926|NCT02672761|ACTIVE_COMPARATOR|Wellness|Subjects while being on the waiting list for MBSR are allocated to a free accessable wellness program including sessions in a computerized chair delivering Shiatzu massage and relaxation music. The individual daily and overall training volume is noted in min.
62496927|NCT02672761|PLACEBO_COMPARATOR|Control|Subjects while being on the waiting list for MBSR are requested to do no special program for stress reduction or memory improvement. The individual daily and overall training volume of sports or recreational activity is noted in min.
61946562|NCT03254979|EXPERIMENTAL|Sequential engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a sequential engagement of professional categories, initiated in nursing, which finally involves the whole professional groups of the center (eg. physicians, etc), will be followed
62496928|NCT05123053|EXPERIMENTAL|Treatment Arm|subjects will be given active drug and titrated up in 10mg increments (with max single dose being 30mg) until a change or drug side effect is noticed.
62496929|NCT00613158||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with significant subclinical atherosclerosis (SA) and a low Framingham risk score
62496930|NCT00613158||2|Participants from MESA with no SA and a low Framingham risk score
62140159|NCT02298842|EXPERIMENTAL|Test Platelets Stored in InterSol|Platelets stored in InterSol
62496931|NCT00613158||3|Healthy participants from Northwestern University
62496932|NCT02825316|EXPERIMENTAL|Group A|Patients with active Crohn's disease that will be allocated to the Mediterranean diet group.
62496933|NCT02825316|EXPERIMENTAL|Group B|Patients with active Crohn's disease that will be allocated to the low residue diet group.
62496934|NCT05770804|EXPERIMENTAL|Intervention group|Face to face group
62698002|NCT04892589||Experimental: Experimental group|The experimental group will receive thumb orthosis at night and daytime use for 3 to 4 hours during Activities of Daily Living that included the thumb MCP for three months. In addition to a classic home exercise program and a proprioceptive home exercises program divided in three phases.
62698003|NCT03592017|EXPERIMENTAL|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
62698004|NCT03592017|EXPERIMENTAL|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
62698005|NCT01920113|EXPERIMENTAL|DR group|In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
62698006|NCT01920113|ACTIVE_COMPARATOR|PR group|In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).
62698007|NCT02692534||Cocaine negative|Patients with preoperative urine cocaine negative results
62496935|NCT05770804|NO_INTERVENTION|Control Group|Control Group
62496936|NCT06676813|EXPERIMENTAL|ADF|Experimental: Alternate day fasting, along with standard medical management.
62496937|NCT06676813|NO_INTERVENTION|Control arm|Standard medical management.
62140160|NCT05254392|NO_INTERVENTION|Usual Care|Participants in the UC arm received the usual/conventional care offered by the hospitals which included: hospital visits on appointment or a sick day, consultations with the physicians, prescription of drugs and routine laboratory tests, review of diagnosis and medications, refilling of prescriptions by patients and referral.
62496938|NCT06048783|EXPERIMENTAL|Program of systematic and periodic spiritual accompaniment and care|A minimum of 3 sessions of spiritual accompaniment by trained volunteers, considering a 1:1 ratio (patient:companion). The topics that will be proposed during the sessions are: sense of suffering, uncertainty, death, life after life, ideas about healing, forgiveness and guilt, etc. In addition, the spiritual needs of the participants will be explored through an instrument specially designed for this purpose and culturally adapted in Chile (FICA). The spiritual accompaniment sessions will be implemented preferably at a distance, using zoom or video call.
62698008|NCT02692534||Cocaine positive|Patients with preoperative urine cocaine positive results
62496939|NCT06048783|NO_INTERVENTION|Standard Care|It correspond to spiritual care currently offered by the hospital. This consists of the possibility of being assisted by a Catholic priest or being contacted by pastors from Protestant churches.
61946563|NCT03254979|ACTIVE_COMPARATOR|Global engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a global strategy of engagement with the participation of all professionals from the beginning, will be followed
61946564|NCT05652881|NO_INTERVENTION|Standard of care|Standard of care treatment for axially unstable tibial pilon fracture will include temporary external fixation followed by delayed definitive fixation. Arthrocentesis of the injured and uninjured ankles will be performed at the time of initial temporary external fixation and again at the time of definitive fixation.
61946565|NCT05652881|EXPERIMENTAL|Intervention|Additional intra-articular joint lavage with 1L normal saline will be performed at the time of initial temporary external fixation in addition to standard of care treatment.
62698009|NCT06583343|ACTIVE_COMPARATOR|Conventional Physical Therapy Group|Conventional rehabilitation, personalized and administered under the guidance of a physiotherapist
62698010|NCT06583343|ACTIVE_COMPARATOR|Botulinum toxin injection group|Administration of botulinum toxin injection prior to the conventional rehabilitation program
62698011|NCT01807884|EXPERIMENTAL|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
61946566|NCT00875979|EXPERIMENTAL|Trastuzumab emtansine 3.0 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
61946567|NCT00875979|EXPERIMENTAL|Trastuzumab emtansine 3.6 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
61946568|NCT03549169|EXPERIMENTAL|TOMAS|Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
61946569|NCT03549169|OTHER|Standard or regular attention|Regular attention is centered on education for therapeutic adherence
61946570|NCT03400566|EXPERIMENTAL|Narrative (target)|Children will receive the story featuring the target vegetable and NO sensory experience.
61946571|NCT03400566|EXPERIMENTAL|Narrative+ experiential (target)|Children will receive the story featuring the target vegetable and experiential learning with the target vegetable.
61946572|NCT03400566|ACTIVE_COMPARATOR|Narrative (control)|Children will receive the story featuring the control vegetable and NO sensory experience.
61946573|NCT03400566|ACTIVE_COMPARATOR|Narrative+ experiential (control)|Children will receive the story featuring the control vegetable and experiential learning with the control vegetable.
61946574|NCT05645354|EXPERIMENTAL|SmokefreeSGM|
61946575|NCT05645354|ACTIVE_COMPARATOR|SmokefreeTXT|
61946576|NCT01573260|EXPERIMENTAL|Argentinean Tango|A biweekly class of argentinean tango for a period of 3-months the intervention for this arm
61946577|NCT01573260|PLACEBO_COMPARATOR|A 'wait-list' control group|Intervention: Patient will receive information about exercise in PD. After 12 weeks, these patients will then start the same 12-weeks tango program.
61946578|NCT06126926|EXPERIMENTAL|Intervention arm|32-week group therapy
61946579|NCT06126926|ACTIVE_COMPARATOR|Control group|Treatment as Usual
62340747|NCT01115738|EXPERIMENTAL|600 mg Clopidogrel and 60 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
62698012|NCT01807884|PLACEBO_COMPARATOR|Routine oral care|Oral suction followed by mouth care and tracheal suction
61946580|NCT06364475|ACTIVE_COMPARATOR|16:8 Time-Restricted Intermittent Fasting Group|88 people were included in the 16:8 time-restricted intermittent fasting group with an 8-hour window for food consumption, with an eating plan of 400 kcal lower than the total daily energy requirement.
62340748|NCT01115738|EXPERIMENTAL|600 mg Clopidogrel and 30 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
62340749|NCT02117596|OTHER|Sirolimus|Single arm
62340750|NCT01973452|EXPERIMENTAL|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
62340751|NCT01973452|PLACEBO_COMPARATOR|Placebo|continuous infusion of 0.4 mcg/kg/hr
62340752|NCT04973592||Child with Blunt Abdominal Trauma|
62340753|NCT00261326|ACTIVE_COMPARATOR|B|simvastatin tablets 80 mg daily
62340754|NCT00261326|PLACEBO_COMPARATOR|A|calcium tablets 80 mg
62340755|NCT05025735|EXPERIMENTAL|Phase 2 study of Fulvestrant, alpelisib and dapagliflozin|"A cycle length is defined as 28 days.~Fulvestrant 500 mg intramuscular, Cycle 1, Day 1 and Day 15; Cycle 2 and beyond 500 mg Intramuscular Day 1.~Alpelisib 300 mg by mouth, daily, continuously beginning on Cycle 1, Day 1.~Dapagliflozin 10 mg by mouth, daily, continuously beginning Cycle 1, Day 3."
62340756|NCT00022971|EXPERIMENTAL|1|Apolizumab followed by rituixmab every 4 weeks
62340757|NCT00848250|EXPERIMENTAL|ACE inhibitor|Patients already on an ACE inhibitor will continue it until the day of surgery
62698013|NCT05446207|ACTIVE_COMPARATOR|Group A|This group will receive routine physiotherapy with task oriented training. This protocol will be given for 3 alternative days per week. Each session will be of 45 minutes. Data will be collected at baseline, at 4th week and at 8th week.
62340758|NCT00848250|EXPERIMENTAL|No ACE inhibitor|Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery
62496940|NCT05048862||Neuromuscular disorder|Patients age at least 20 years, and have been diagnosed as neuromuscular disorders by the neurologist. Patients who are unable to read the questionnaire, fail to accept all the examinations, and refuse to provide inform consent are excluded from this study.
62496941|NCT05048862||Normal group|The normal group (age at least 20 years) who had no neurological symptoms or signs were also recruited. The neurological examination performed by the board neurologist must be normal in the normal group.
62496942|NCT04385745|EXPERIMENTAL|Elastic Stable Intramedullary Nailing|BIN (biodegradable intramedullary nailing) method will be compared with the ESIN (elastic stable intramedullary nailing)
62496943|NCT04385745|EXPERIMENTAL|Biodegradable intramedullary nailing|BIN method will be compared with the ESIN.
62496944|NCT03282539||LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents.
61946581|NCT06364475|ACTIVE_COMPARATOR|Energy-Restricted Six-Meal Group|86 people were included in the energy-restricted six-meal group. This group have an eating plan three meal and three snack of 400 kcal lower than the total daily energy requirement.
61946582|NCT01539083|EXPERIMENTAL|Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]|Bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
61946583|NCT01539083|EXPERIMENTAL|Thalidomide + Prednisolone [TP Consolidation]|Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
61946584|NCT01539083|EXPERIMENTAL|Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]|Bortezomib 1.3 mg/m\^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
62496945|NCT03282539||LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
62496946|NCT01867190|OTHER|ASCT01|ASCT01 (Autologous Stem Cell Transplantation)
62496947|NCT04857333||Pulmonary Nodule|Patients are recommended for using antibiotics, solely follow-up or surgical resection according to the current clinical guideline for management of indeterminate pulmonary nodule. No intervention is administered for this observatory study.
61946585|NCT01784848|EXPERIMENTAL|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
61946586|NCT01784848|ACTIVE_COMPARATOR|Clinical treatment|Optimized clinical treatment including medical management of hypertension.
61946587|NCT05997550|ACTIVE_COMPARATOR|Pursed Lip Breathing Exercise Group|During the first interview, the training and demonstration of pursed lip breathing exercise is performed by the thesis student in a single session. After this information session, the pursed lip breathing exercise taught from the patients; They are asked to do it in their own homes, 3 days a week on Monday, Wednesday and Friday, for about 30 minutes each session, for a total of eight weeks. In addition, one day a week (on a day determined by the patient, Monday, Wednesday or Friday), the thesis student makes a video call to the patient on WhatsApp, and the practice of pursed lip breathing exercise is performed during the video call.
62496948|NCT00997477|EXPERIMENTAL|Formoterol and Budesonide|
62496949|NCT05014880|PLACEBO_COMPARATOR|ICR (Intensive Cardiac Rehabilitation)|"20 patients will be randomly assigned to the standard of care group, which will receive the standard health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR group."
62496950|NCT05014880|EXPERIMENTAL|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|"20 patients will be randomly assigned to the Time-Restricted Eating (TRE) group which will be asked to limit the number of hours they eat in a day to 10 hours in addition to receiving the standard of care health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR x TRE group."
62496951|NCT04449341|EXPERIMENTAL|Standard care venipuncture with additional of virtual reality|Patients undergoing blood draw while interacting with VR application Ocean Rift while wearing Oculus Go headset
62496952|NCT04449341|NO_INTERVENTION|Standard care venipuncture without addition of virtual reality|Patients undergoing blood draw while wearing Oculus Go headset that is turned off
62698014|NCT05446207|EXPERIMENTAL|Group B|This group will receive passive music therapy and routine physiotherapy with task oriented training. This protocol will be given for 3 alternative days per week. Each session will be of 60 minutes. Data will be collected at baseline, at 4th week and at 8th week.
62698015|NCT05905302|EXPERIMENTAL|Experimental Arm|Two modes of high intensity exercise
62496953|NCT03256227|EXPERIMENTAL|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
62496954|NCT03256227|ACTIVE_COMPARATOR|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
62496955|NCT02761720||MyPennMedicine (MPM)|Participants assigned to this arm downloaded only the MyPennMedicine mobile app.
62496956|NCT02761720||MPM and Ginger iO|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app.
62698016|NCT04139291|EXPERIMENTAL|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema
62698017|NCT04432623|EXPERIMENTAL|Low dose|A low dose, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks
62698018|NCT04432623|EXPERIMENTAL|Middle dose|A middle dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 weeks
61946588|NCT05997550|ACTIVE_COMPARATOR|Laughter Therapy Group|During the first interview, laughter therapy training and demonstration is carried out by the thesis student in a single session. After this information session, the laughter therapy taught from the patients; They are asked to do this in their own homes, 3 days a week on Monday, Wednesday and Friday, 30 minutes each session, for a total of eight weeks. . In addition, once a week (on a day determined by the patient, Monday, Wednesday or Friday), the thesis student makes a video call to the patient on WhatsApp, and laughter therapy is practiced during the video call.
62496957|NCT02761720||Lottery|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app. They were also given a lottery incentive if they completed 70% of the daily mood ratings.
62698019|NCT04432623|EXPERIMENTAL|High dose 3 days per week|Highest dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 to 24 weeks
62698020|NCT04432623|EXPERIMENTAL|High dose 5 days per week|The highest dose, by mouth once per day on 5 days per week for 24 weeks
62698021|NCT04432623|EXPERIMENTAL|Sickle Cell Disease Arm|The most active dose given once per day on the most active regimen for up 24 weeks
61946589|NCT05997550|PLACEBO_COMPARATOR|Control Group|"Attention-match training is given to the patients in the control group. During the first interview, attention matching training is carried out by the thesis student for one time, about Lung structure and functioning, lasting approximately 20 minutes. In addition, a brochure about lung structure and functioning is given to patients. The patients in the control group are not subjected to any other interventions throughout the study."
61946590|NCT04040205|EXPERIMENTAL|Abemaciclib|Subjects will be treated with abemaciclib 200 mg twice daily by mouth.
61946591|NCT04198116|EXPERIMENTAL|Varenicline + Guanfacine ER|Varenicline (2mg/day) + Guanfacine extended release (6mg/day ER). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Guanfacine ER (6mg/day) administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM for both medications.
62340759|NCT03677895|EXPERIMENTAL|patients with rotator cuff disorders|patients with rotator cuff disorders, including impingment, rotator cuff disorders and rotator cuff tear receiving hyaluronic acid injection over subacromial bursa
62340760|NCT06298461|ACTIVE_COMPARATOR|OSS|
62340761|NCT06298461|ACTIVE_COMPARATOR|2L PEG|
62340762|NCT00979446|EXPERIMENTAL|Guided|
62340763|NCT00979446|ACTIVE_COMPARATOR|Self-directed|
62340764|NCT02163993|EXPERIMENTAL|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
62340765|NCT02163993|EXPERIMENTAL|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
62340766|NCT02163993|EXPERIMENTAL|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
62340767|NCT02163993|EXPERIMENTAL|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
62340768|NCT02163993|PLACEBO_COMPARATOR|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
62340769|NCT04802980|EXPERIMENTAL|HB002.1T + Oxaliplatin+ Capecitabine|21-24 patients with advanced gastric cancer administeredHB002.1T+ Oxaliplatin+ Capecitabine combination every 3 weeks in a 21-day cycle, total 18cycles
62340770|NCT04802980|EXPERIMENTAL|HB002.1T + Paclitaxel + Carboplatin|21-24 patients with advanced ovarian cancer, cervical cancer, head and neck cancer or lung cancer (not limited to the above tumor types) administered HB002.1T + Paclitaxel + Carboplatin combination every 3 weeks in a 21-day cycle, total 18cycles
62340771|NCT04802980|EXPERIMENTAL|HB002.1T + Gemcitabine + Cisplatin|21-24 patients with advanced biliary tract tumor, pancreatic cancer, bladder cancer or nasopharyngeal carcinoma (not limited to the above tumor types) administered HB002.1T + Gemcitabine + Cisplatin combination every 3 weeks in a 21-day cycle, total 18cycles
62340772|NCT01044680|EXPERIMENTAL|Nutriose|17 g NUTRIOSE consumed twice daily for 12 weeks
62340773|NCT01044680|PLACEBO_COMPARATOR|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
62340774|NCT06163365||Cohort 1. Li Fraumeni (TP53 mutations carriers)|Patients with a germline TP53 alteration included in this study will undergo their usual surveillance with their treating team. In addition to their routine scans or examinations, they will provide blood samples at enrollment, during the study (optional) and at the end of their participation (at 12 months). The results of any radiological scan undergone during this period will be collected retrospectively and added to their data collection, which will allow for a correlative analysis between the genetic and epigenetic results and radiological outcomes.
62340775|NCT06163365||Cohort 2. Gastro-intestinal (GI) cohort|"Patients with underlying germline conditions at high risk of developing a GI malignancy (approximately 40-50 patients)~* Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM genes)~* PTEN~* STK11 (Peutz-Jeghers syndrome)~* CDH1 and APC gene alterations carriers prior to their risk-reducing surgery if such is performed.~* SMAD4~* MUTYH\* (\*biallelic variants)~Carriers of CDH1 and APC pathogenic mutation are invited to give blood and optional urine samples before and after their surgery, if they undergo this intervention, with no need for sequential samples. Samples should be taken when convenient for the patient prior to and post-surgery."
62340776|NCT05829616|EXPERIMENTAL|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
62340777|NCT02559713|EXPERIMENTAL|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.
62496958|NCT06394492|EXPERIMENTAL|Treatment group 1: SHR-A1921|
62496959|NCT06394492|ACTIVE_COMPARATOR|Treatment group 2: Investigator's choice of chemotherapy|
62496960|NCT02913287|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62496961|NCT02913287|EXPERIMENTAL|Aquamin/Aquamin MG|Aquamin/Aquamin MG mix
62496962|NCT04409379||acute leukemia group|300 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
62698022|NCT05250908|EXPERIMENTAL|INTIBIA Therapeutic|Implanted with INTIBIA device and programmed to therapeutic stimulation for the duration of the study.
62698023|NCT05250908|EXPERIMENTAL|INTIBIA Non-Therapeutic|Implanted with INTIBIA device and programmed to non-therapeutic stimulation for the first 3 months, then to therapeutic stimulation for the duration of the study.
62698024|NCT05793502||Permanent pacemaker implantation or cardiac resynchronization therapy|Patients with an indication for permanent pacemaker implantation or CRT
61946592|NCT04198116|ACTIVE_COMPARATOR|Varenicline|Varenicline (2mg/day). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
62496963|NCT02398734|EXPERIMENTAL|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
62496964|NCT02398734|SHAM_COMPARATOR|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
62496965|NCT03481517|EXPERIMENTAL|Wound with local anesthesia|5 mL Bupivacaine is injected into subcutaneous area near surgical wound
62496966|NCT03481517|NO_INTERVENTION|Wound without local anesthesia|Nothing is injected into subcutaneous area near surgical wound
62496967|NCT04167358|EXPERIMENTAL|Participants receiving linerixibat|Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER \[Group 1\]) and Phase 3 study (212620 GLISTEN \[Group 2\]), will receive linerixibat.
61946593|NCT02370381||Epistaxis|Patients with active anterior epistaxis
61946594|NCT05000723||PJI patients|"Patients (older than 18 years) with PJI of a total hip replacement treated at University Hospitals Leuven.~Diagnosis of PJI of the hip is made based on the EBJIS 2021 criteria. Patients will receive standard of care."
61946595|NCT02436304|EXPERIMENTAL|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
61946596|NCT02436304|EXPERIMENTAL|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
61946597|NCT02436304|ACTIVE_COMPARATOR|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
61946598|NCT02122458|ACTIVE_COMPARATOR|Immediate Hearing Aid Treatment: Blast-exposed Only|This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were negative for significant PTSD. They were fitted with open-fit hearing aids that provided mild high-frequency amplification and were monitored for 6 months.
61946599|NCT02122458|ACTIVE_COMPARATOR|Immediate Hearing Aid Treatment: Blast-exposed with PTSD|This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were comorbid for significant PTSD. They were fitted with open-fit hearing aids that provided mild high-frequency amplification and were monitored for 6 months.
61946600|NCT02122458|ACTIVE_COMPARATOR|Delayed Hearing Aid Treatment: Blast-exposed Only|This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were negative for significant PTSD. They were fitted with hearing aids after a 6-month delay. Their performance was monitored 6-months pre-fitting and for the 6 months after the fitting.
61946601|NCT02122458|NO_INTERVENTION|Non-treatment Diagnostic Testing: Normal|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group included neurotypical Veterans with normal hearing and were negative for blast-exposure and PTSD.
61946602|NCT02122458|NO_INTERVENTION|Non-Treatment Diagnostic Testing: Blast-exposed Only|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. They were negative for significant PTSD.
61946603|NCT02122458|NO_INTERVENTION|Non-treatment Diagnostic Testing: Blast-exposed with PTSD|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were comorbid for significant PTSD.
61946604|NCT02122458|NO_INTERVENTION|Non-treatment Diagnostic Testing: PTSD Only|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group was negative for blast-exposure and hearing loss but positive for significant PTSD.
62164446|NCT03701581|EXPERIMENTAL|Group A: Investigational Treatment|"* FDA-approved 10mg dalfampridine (generic Ampyra)~* Subjects will not take more than 2 tablets in a 24-hour period~* Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.~* The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.~* Study drug can be taken with or without food.~* If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.~* Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine)."
62496968|NCT03380325|EXPERIMENTAL|Iloprost first|Cross-over starts with iloprost intervention, then second clamp without iloprost.
62496969|NCT03380325|EXPERIMENTAL|Iloprost second|Cross-over starts without iloprost intervention, then second clamp with iloprost.
62496970|NCT00654641|EXPERIMENTAL|Negative pressure wound closure|Negative Pressure wound closure
62496971|NCT00654641|ACTIVE_COMPARATOR|Standard wound closure|Standard Wound Closure
62496972|NCT00380796||Cohort 1|
62496973|NCT05696327|EXPERIMENTAL|Experimental Group|tyler twist wrist extensor strengthening exercises Treatment protocol will be followed for thrice a week for 4 weeks. The session will be of approximately 20 minutes. The initial Conventional therapy program will be the same as discussed in the control group except strengthening exercise which is excluded in experimental group because of Tyler twist exercise which is being used as a strengthening protocol.
62496974|NCT05696327|ACTIVE_COMPARATOR|Control Group|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.) The treatment will continue for 4 weeks and 3 sessions/ week i.e. thrice a week. The session will be of approximately 20 minutes.
62496975|NCT01876745||NovoSeven® (activated recombinant factor VII)|
62496976|NCT02656316|EXPERIMENTAL|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
62496977|NCT02656316|SHAM_COMPARATOR|Sham tDCS|The Sham tDCS - an inactive stimulation.
62496978|NCT02775058||patients|The subjects enrolled in this CI just received dental grafting by the device under evaluation and in any case will be subject to the same procedures foreseen for this CI for the dental implant surgery.
61946605|NCT05248737||Group 1 - DHA/EPA bioenhanced poultry (n=24)|Participants will be asked to consume two meals of chicken, one meal will contain chicken that has been fed omega-3 fatty acids so the chicken contains omega 3 (DHA/EPA) fatty acids and the other meal will consist of non enhanced chicken and a DHA supplement. Each participant will be asked to eat both of these forms of chicken in random order. Each study is expected to take 9-hours and the two visits will be separated by a period of two weeks. A total of 5 blood samples will be collected over a 9-h period.
62698025|NCT05755958|SHAM_COMPARATOR|HIFU SHAM|"The patient placed in the right lateral decubitus position under general anesthesia or spinal anesthesia on the operating table. An endorectal probe is inserted in the patient's rectum. The probe includes an imaging transducer to visualize the endometriosis lesions and locate areas to be treated and an ultrasound therapy transducer to administer the HIFU treatment. After identification of the treatment area, HIFU shots will not be delivered on the lesion to be treated in a blinded manner.~Patients randomized to this arm will received exactly the same procedure as patients in the HIFU group with the exception of the HIFU shots."
62140161|NCT05254392|EXPERIMENTAL|Pharmacists' Intervention|Participants in the PI arm received routine usual care plus pharmacists' interventions for 12 months. The PI arm received usual care plus face-to-face education on CKD, hypertension as a co-morbidity and its management, and antihypertensive medication adherence at baseline (group education), 6 months and 12 months (individualized according to each patient's needs), CKD patient educational infographic leaflet at baseline, a calibrated sphygmomanometer digital BP monitor (Chidalex®) for HSMBM, a BP logbook at baseline for the recording of BP values daily and hands-on training on BP self-measurement. Also, antihypertensive medication adherence and HSMBM reminder cell phone text messages were sent biweekly throughout the trial period, while phone-in inquiries from the participants and phone-out reinforcement interventions were utilized throughout the trial period
61946606|NCT05248737||Group 2 - 25(OH)D bioenhanced poultry (n=36)|Participants will be asked to consume 1 serving of 25-hydroxyvitamin D (25(OH)D enhanced chicken or non-fortified chicken that does not contain additional 25(OH)D and a vitamin D supplement every day for 21 days. Your participation in the study is expected to last 3 weeks. On Monday-Friday you will be asked to eat lunch in the HMRU on the Cornell campus. On weekends you will be given packaged chicken to eat at home. At 4 timepoints over the 3-week study, a blood draw will be collected to measure vitamin D status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit should last about 30 minutes. The total time needed to complete study visits in the HMRU is 10 hours over the 21-day period.
62140162|NCT06510166|EXPERIMENTAL|normal nebulizer + mask + distraction technique|"Inclusion criteria is below:~1. Parent and child volunteer to participate in the study,~2. The child is between 3-6 years old,~3. Presentation due to upper and lower respiratory tract infection,~4. Inhaler treatment will be applied with a nebulizer,~5. No request for any other intravenous, intramuscular or invasive treatment,~6. The child does not have any genetic, congenital, chronic or metabolic disease"
62140163|NCT06510166|ACTIVE_COMPARATOR|toy type nebulizer + toy mask|"Inclusion criteria is below:~1. Parent and child volunteer to participate in the study,~2. The child is between 3-6 years old,~3. Presentation due to upper and lower respiratory tract infection,~4. Inhaler treatment will be applied with a nebulizer,~5. No request for any other intravenous, intramuscular or invasive treatment,~6. The child does not have any genetic, congenital, chronic or metabolic disease"
62496979|NCT02319850||Reference Group|18 - 29 years of age; apparently healthy younger participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
62496980|NCT02319850||Comparison Group|55 - 75 years of age; apparently healthy older participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
62496981|NCT06488469|EXPERIMENTAL|intervention|The interventions will be provided at regular intervals of 2 months and adherence to the interventions will be monitored. The children along with the caregivers will attend the Endocrinology OPD where they will be educated as per prepared modules by the diabetic educators and will be monitored for adherence to diet and insulin. They will also be directed to the Child Psychologist to give module- based interventions. The interventions will be provided for a period of 6 months. Follow up of patients for reinforcement of interventions will happen on 2-monthly basis.
62496982|NCT06488469|ACTIVE_COMPARATOR|Usual Care|Routine standard of care is given to all patients with Hypoglycemia unawareness, irrespective of the randomized group to which they belong. This include treatment of hypoglycaemia, mandatory avoidance of hypoglycaemia for 2 weeks, Review of drugs and diet every 3 months (which is routinely done at our centre) and exploring the causes of hypoglycaemia. The control group will receive education on Dietary modification, advise on individualized targets and warning signs of hypoglycemia.
62496983|NCT02786927|EXPERIMENTAL|ELLIPTA - HANDIHALER; HANDIHALER Questionnaire Version 1|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
61946607|NCT05248737||Group 3 - DHA/EPA and 25(OH)D bioenhanced poultry (n=24)|Participants will be asked to consume chicken that contains both omega3 (DHA/EPA) fatty acids and vitamin D (25(OH)D) for a 3week period. On the first day, you will be asked to spend around 9h in the HMRU, and will be fed a breakfast containing this chicken. A total of 5 blood samples will be collected over the 9h period. You will be asked to stay in the HMRU for this 9h study and will be fed breakfast, lunch and dinner. For the next 3w you will be asked to eat this chicken at lunch in the HMRU on the Cornell campus on weekdays (Monday-Friday). On weekends you will be given two packaged frozen chicken servings to eat at home (one serving per day). At 4 timepoints over the 3-week study, a blood draw will be collected to measure (25(OH)D) status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit to the HMRU should last about 30 minutes. The time needed to complete this study in the HMRU is 10 hours over the 3w period.
61946608|NCT03096483|EXPERIMENTAL|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
61946609|NCT06025825||Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl)|Before extraction, buccal and palatal infiltration anesthesia with articaine will perform. Following anesthesia, extraction will carry out.
62140164|NCT06510166|NO_INTERVENTION|control group|"Inclusion criteria is below:~1. Parent and child volunteer to participate in the study,~2. The child is between 3-6 years old,~3. Presentation due to upper and lower respiratory tract infection,~4. Inhaler treatment will be applied with a nebulizer,~5. No request for any other intravenous, intramuscular or invasive treatment,~6. The child does not have any genetic, congenital, chronic or metabolic disease"
62140165|NCT01290003|EXPERIMENTAL|Antibiotic Group|Neonates randomized to intervention Group(Antibiotic group)will receive the first line antibiotics (Piperacillin-Tazobactam and Amikacin) as per the unit policy for 72 hours. These neonates will also be monitored by performing sepsis screens and blood culture for development of sepsis.
62496984|NCT02786927|EXPERIMENTAL|ELLIPTA - HANDIHALER; Questionnaire Version 2|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
62496985|NCT02786927|EXPERIMENTAL|HANDIHALER - ELLIPTA; Questionnaire Version 1|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
62496986|NCT02786927|EXPERIMENTAL|HANDIHALER - ELLIPTA; Questionnaire Version 2|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
62496987|NCT02992548|EXPERIMENTAL|pravastatin group|Use of pravastatin 20mg to 40mg
62496988|NCT01639664|EXPERIMENTAL|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
62496989|NCT01639664|NO_INTERVENTION|Control group|standard practice
62496990|NCT02301741|EXPERIMENTAL|Game Condition|Participants in the GAME condition will complete laboratory sessions on five consecutive days. Session 1 (baseline) and Session 5 (post-test) will be used to assess lumbar spine motion and expectations of pain and harm during standardized reaching tasks. In sessions 2 through 4 they will play the virtual dodge ball game.
62496991|NCT02301741|NO_INTERVENTION|Control Condition|Participants in the CONTROL condition will complete baseline and post-test standardized reaching tasks, but will not play the game in the intervening three days.
62496992|NCT01170715|EXPERIMENTAL|Experimental Group|Enbrel (etanercept): started with self-injection of 50 mg subcutaneous twice weekly for 12 weeks, followed by self-injection of 50 mg subcutaneous weekly for 40 weeks.
62496993|NCT04920058|EXPERIMENTAL|Wellness Program combined with Continuous Glucose Monitoring (CGM)|Continuous Glucose Monitoring (CGM) sensor combined with Levels CGM software that provides real-time visualization, analysis and feedback will be added to a Wellness Program incorporating a low carbohydrate diet (\<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
62496994|NCT04920058|ACTIVE_COMPARATOR|Wellness Program|Wellness Program incorporating a low carbohydrate diet (\<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
62698026|NCT05755958|ACTIVE_COMPARATOR|HIFU TREATMENT|The patient placed in the right lateral decubitus position under general anesthesia or spinal anesthesia on the operating table. An endorectal probe is inserted in the patient's rectum. The probe includes an imaging transducer to visualize the endometriosis lesions and locate areas to be treated and an ultrasound therapy transducer to administer the HIFU treatment. After identification of the treatment area, HIFU shots will be delivered on the lesion to be treated in a blinded maner.
62698027|NCT02177162|OTHER|Intervention= education peer review group|For this controlled trial a group of physiotherapists will recieve specific education about optimal exercise therapy for patioents with knee OA in early stage
62698028|NCT05769036|ACTIVE_COMPARATOR|Cardiac Resynchronization Therapy with Biventricular Pacing|Patients in this group will be implanted with a cardioverter-defibrillator with a resynchronization function using the biventricular pacing
62496995|NCT00660491|NO_INTERVENTION|1|Control
62496996|NCT00660491|NO_INTERVENTION|2|moderate exercise training group
62698029|NCT05769036|EXPERIMENTAL|Cardiac Resynchronization Therapy with Left Bundle Branch Pacing|Patients in this group will be implanted with a cardioverter-defibrillator with a resynchronization function using the left bundle branch pacing
62698030|NCT00356187|EXPERIMENTAL|Propranol Treatment|
62698031|NCT00356187|NO_INTERVENTION|Standard of Care|
62698032|NCT00526799|EXPERIMENTAL|Phase I|Topotecan 3.5 mg/m\^2 + Sorafenib dose escalation:
62698033|NCT00526799|EXPERIMENTAL|Phase II|Topotecan 3.5 mg/m\^2 + Sorafenib 400 mg po daily.
62698034|NCT04452877|EXPERIMENTAL|Dabrafenib in combination with trametinib|Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
62698035|NCT01828060|EXPERIMENTAL|Jobelyn™|Dietary supplement Jobelyn™, 500mg daily for 8 weeks Jobelyn is a sorghum bicolor extract marketed as dietary supplement Other Name: Sorghum bicolor extract
62496997|NCT00660491|EXPERIMENTAL|3|high intensity exercise group
62496998|NCT04405908|PLACEBO_COMPARATOR|Adult Group 1|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg.
62496999|NCT04405908|PLACEBO_COMPARATOR|Adult Group 2|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
62497000|NCT04405908|PLACEBO_COMPARATOR|Adult Group 3|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
62497001|NCT04405908|PLACEBO_COMPARATOR|Adult Group 4|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg .
62497002|NCT04405908|PLACEBO_COMPARATOR|Adult Group 5|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
62497003|NCT04405908|PLACEBO_COMPARATOR|Adult Group 6|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
62497004|NCT04405908|PLACEBO_COMPARATOR|Adult Group 7|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg .
62497005|NCT04405908|PLACEBO_COMPARATOR|Adult Group 8|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
62497006|NCT04405908|PLACEBO_COMPARATOR|Adult Group 9|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
62497007|NCT04405908|PLACEBO_COMPARATOR|Elderly Group 10|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
62497008|NCT04405908|PLACEBO_COMPARATOR|Elderly Group 11|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
62497009|NCT04405908|PLACEBO_COMPARATOR|Elderly Group 12|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
62497010|NCT04405908|PLACEBO_COMPARATOR|Elderly Group 13|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
62497011|NCT04405908|PLACEBO_COMPARATOR|Elderly Group 14|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
62497012|NCT04405908|PLACEBO_COMPARATOR|Elderly Group 15|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
62698036|NCT01828060|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62698037|NCT03227549|EXPERIMENTAL|Direct Superior Approach|The intervention being tested is the surgical approach.
61946610|NCT06025825||Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl)|Before extraction, buccal and palatal infiltration anesthesia with lidocaine will perform. Following anesthesia, extraction will carry out.
62698038|NCT03227549|ACTIVE_COMPARATOR|Posterior Approach|
61946611|NCT06025825||Buccal infiltration anesthesia (5 minutes waiting time with articaine HCl)|Before extraction, buccal infiltration anesthesia with articaine will perform. After 5 minutes, extraction will carry out.
61946612|NCT06025825||Buccal infiltration anesthesia (5 minutes waiting time with lidocaine HCl)|Before extraction, buccal infiltration anesthesia with lidocaine will perform. After 5 minutes, extraction will carry out.
61946613|NCT06025825||Buccal infiltration anesthesia (8 minutes waiting time with articaine HCl)|Before extraction, buccal infiltration anesthesia with articaine will perform. After 8 minutes, extraction will carry out.
62497013|NCT04405908|PLACEBO_COMPARATOR|SARS-CoV-2 Seropositive Group 16|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg.
62497014|NCT04405908|PLACEBO_COMPARATOR|SARS-CoV-2 Seropositive Group 17|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg with AS03 adjuvant.
62497015|NCT04405908|PLACEBO_COMPARATOR|SARS-CoV-2 Seropositive Group 18|SARS-CoV-2 Seropositive subjects receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
62497016|NCT04405908|PLACEBO_COMPARATOR|Adjuvant Dose Modification: Adult Group 19|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
62497017|NCT04405908|PLACEBO_COMPARATOR|Adjuvant Dose Modification: Adult Group 20|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
62497018|NCT04405908|PLACEBO_COMPARATOR|Adjuvant Dose Modification: Elderly Group 21|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
62497019|NCT04405908|PLACEBO_COMPARATOR|Adjuvant Dose Modification: Elderly Group 22|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
62497020|NCT04405908|PLACEBO_COMPARATOR|Alum Only Adjuvant Group 23|Subjects receive SCB-2019 9 µg with Alum adjuvant only.
62497021|NCT04405908|PLACEBO_COMPARATOR|Dose Expansion Phase: Adult Group 24|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
62497022|NCT04405908|PLACEBO_COMPARATOR|Dose Expansion Phase: Adult Group 25|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
62497023|NCT04405908|PLACEBO_COMPARATOR|Dose Expansion Phase: Elderly Group 26|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
62497024|NCT04405908|PLACEBO_COMPARATOR|Dose Expansion Phase: Elderly Group 27|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
62497025|NCT04432207|EXPERIMENTAL|Dose Escalation: Monotherapy Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
62497026|NCT04432207|EXPERIMENTAL|Dose Escalation: Monotherapy Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
62497027|NCT04432207|EXPERIMENTAL|Dose Escalation: Monotherapy Cohort 3|100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
62698039|NCT00815633|EXPERIMENTAL|Alefacept|Treatment Group (only one group)
62698040|NCT06408233|EXPERIMENTAL|Performance coaching|All clinics will receive the performance coaching intervention. There is only one arm to this study.
62698041|NCT03926013|EXPERIMENTAL|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-63898081. Ascending dose levels will be sequentially tested.
62698042|NCT03926013|EXPERIMENTAL|Part 2: Dose Expansion|Participants with mCRPC or renal cell carcinoma (RCC) will receive JNJ-63898081 at the recommended Phase 2 dose (RP2D) determined in Part 1.
62698043|NCT04621188|EXPERIMENTAL|Lorlatinib|100 mg once daily
62698044|NCT05214118|NO_INTERVENTION|Brochure|
62497028|NCT04432207|EXPERIMENTAL|Dose Expansion Monotherapy|mOBD (TBD) dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
62497029|NCT04432207|EXPERIMENTAL|Dose Escalation Arm 1: Combination with atezolizumab Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI or Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
62497030|NCT04432207|EXPERIMENTAL|Dose Escalation Arm 1: Combination with atezolizumab Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI or Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
62497031|NCT04432207|EXPERIMENTAL|Dose Escalation Arm 1: Combination with atezolizumab Cohort 3|Cohort 3: 100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI or Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
62497032|NCT04432207|EXPERIMENTAL|Dose Escalation Arm 2: Combination with atezolizumab and chemotherapy Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
62497033|NCT04432207|EXPERIMENTAL|Dose Escalation Arm 2: Combination with atezolizumab and chemotherapy Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
62497034|NCT04432207|EXPERIMENTAL|Dose Escalation Arm 2: Combination with atezolizumab and chemotherapy Cohort 3|100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
62497035|NCT04432207|EXPERIMENTAL|Dose Expansion Arm 1: Combination with atezolizumab|cOBD (TBD) dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
61946614|NCT06025825||Buccal infiltration anesthesia (8 minutes waiting time with lidocaine HCl)|Before extraction, buccal infiltration anesthesia with lidocaine will perform. After 8 minutes, extraction will carry out.
61946615|NCT03231657|EXPERIMENTAL|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:~* sFlt1/PlGF ratio \>38: pre-eclampsia risk~* sFlt1/PlGF ratio \>85: pre-eclampsia~* ISSHP pre-eclampsia definition + ratio \>210: severe PE~* ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio \>600: consider deliver"
62698045|NCT05214118|EXPERIMENTAL|Technology-based program|
61946616|NCT03231657|NO_INTERVENTION|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
61946617|NCT02016573|NO_INTERVENTION|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
61946618|NCT02016573|EXPERIMENTAL|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
61946619|NCT04198597|EXPERIMENTAL|Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
61946620|NCT04198597|EXPERIMENTAL|Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
61946621|NCT04198597|EXPERIMENTAL|Process-based treatment, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
61946622|NCT04198597|EXPERIMENTAL|Process-based treatment, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
61946623|NCT05823532|EXPERIMENTAL|Infliximab|Subjects will be stratified by sex and randomized prior to this visit in preparation for the infusion. Vitals and safety labs will be drawn at this visit as well as urine testing for drugs of abuse and pregnancy testing for all biological females. Patients will receive breakfast followed by a double-blinded infusion of infliximab (5mg/kg body weight) in the GCSTA Clinical Research Center at Emory University Hospital. The infusion will last 3 hours, and subjects will be monitored during the infusion and for one hour after completion for the possible development of anaphylaxis, which occurs in less than 1% of patients receiving an initial dose of infliximab
62497036|NCT04432207|EXPERIMENTAL|Dose Expansion Arm 2: Combination with atezolizumab|cOBD (TBD) dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI, TPS/TC ≥50% or IC ≥10%
62497037|NCT04432207|EXPERIMENTAL|Dose Expansion Arm 3: Combination with atezolizumab and chemotherapy|cOBD (TBD) dose IMU-201 as a 05 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
62497038|NCT01547507|ACTIVE_COMPARATOR|KimVent Turbo-Cleaning Closed Suction System Kimberly clark|
62497039|NCT01547507|ACTIVE_COMPARATOR|Airway Medix Closed Suction System|
62497040|NCT03436316|EXPERIMENTAL|SAD Cohort 1 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 1) and 2 participants will receive placebo.
62698046|NCT05849467|EXPERIMENTAL|Multiple Sclerosis|"MS cohort- Three study visits. (1) Baseline; (2) Day 0: MRI brain/spinal cord (with gadolinium) followed by an intravenous injection of anti-CD8 minibody (akaPET/CT tracer); (3) Day 1: PET/CT scan"
61946624|NCT05823532|PLACEBO_COMPARATOR|Placebo|Subjects will be stratified by sex and randomized prior to this visit in preparation for the infusion. Vitals and safety labs will be drawn at this visit as well as urine testing for drugs of abuse and pregnancy testing for all biological females. Patients will receive breakfast followed by a double-blinded infusion of saline in the GCSTA Clinical Research Center at Emory University Hospital. The infusion will last 3 hours, and subjects will be monitored during the infusion and for one hour after completion for the possible development of anaphylaxis, which occurs in less than 1% of patients receiving an initial dose of infliximab
62497041|NCT03436316|EXPERIMENTAL|SAD Cohort 2 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 2) and 2 participants will receive placebo.
62698047|NCT05849467|EXPERIMENTAL|Progressive Multifocal Leukoencephalopathy|"PML cohort- Up to five study visits. (1) Baseline; (2) Day 0: MRI brain (with gadolinium) followed by an intravenous injection of anti-CD8 minibody (aka PET/CT tracer); (3) Day 1: PET/CT scan; (4) Study visit 4 (optional; time-period between study visit 3 and 4 is variable): MRI brain (with gadolinium) followed by an intravenous injection of anti-CD8 minibody (aka PET/CT tracer) following clinical, radiological and/or laboratory-defined immune reconstitution (spontaneous or facilitated); (5) Study visit 5: PET/ CT scan"
62698048|NCT06003712|EXPERIMENTAL|Mindfulness Exercise Group|Subjects will participate in a one-month mindfulness breathing-exercise program
61946625|NCT02882412||patient group|
61946626|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
61946627|NCT04213417|EXPERIMENTAL|Bobath therapy plus Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the Bobath therapy was applied to the affected side of the body and lower extremity for 60 minutes in each session.
61946628|NCT04213417|ACTIVE_COMPARATOR|Bobath therapy|Both groups were treated with the Bobath therapy as a neurodevelopmental therapy.
61946629|NCT04786938|EXPERIMENTAL|Saccharomyces boulardii|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34) plus S. boulardii CNCM I-745 (approximately 22.5 x109 CFU
61946630|NCT04786938|NO_INTERVENTION|No intervention|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34)
61946631|NCT01138774|PLACEBO_COMPARATOR|Control group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
61946632|NCT01138774|EXPERIMENTAL|EPA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
61946633|NCT01138774|EXPERIMENTAL|Lipoic acid group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
61946634|NCT01138774|EXPERIMENTAL|EPA+LA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
61946635|NCT02487433|EXPERIMENTAL|Tofacitinib MR 22 mg Fed|Single dose of tofacitinib MR 22 mg administered under fed conditions
61946636|NCT02487433|EXPERIMENTAL|Tofacitinib MR 22 mg Fasted|Single dose of tofacitinib MR 22 mg administered under fasted conditions
61946637|NCT03451266|EXPERIMENTAL|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (vitamin C arm).
61946638|NCT03451266|PLACEBO_COMPARATOR|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (placebo arm).
61946639|NCT04903678|EXPERIMENTAL|intrathecal chemotherapy in patients with central metastases|Systemic chemotherapy and intrathecal chemotherapy are performed every 3 weeks. After three treatment cycles, the treatment response is comprehensively evaluated including cerebrospinal fluid, intracranial and orbital tumors. If necessary, local radiotherapy and arterial interventional chemotherapy are performed for local solid tumors. Cerebrospinal fluid is detected in each treatment cycle. If RB tumor cells still exist in cerebrospinal fluid, chemotherapy and intrathecal chemotherapy are continued until the end event. If cerebrospinal fluid was negative, intrathecal chemotherapy is supplemented for another 2 cycles with a total of 6 cycles of systemic chemotherapy. The patients are followed up after treatment.
62497042|NCT03436316|EXPERIMENTAL|SAD Cohort 3 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 3) and 2 participants will receive placebo.
62497043|NCT03436316|EXPERIMENTAL|SAD Cohort 4 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 4) and 2 participants will receive placebo.
62698049|NCT06352463|ACTIVE_COMPARATOR|2-week waiting period|Children and parents have to wait 2 weeks between baseline 1 and the start of the treatment. In the first week, they fill in ESMs daily.
62698050|NCT06352463|ACTIVE_COMPARATOR|4-week waiting period|Children and parents have to wait 4 weeks between baseline 1 and the start of the treatment. In the first and third week, they fill in ESMs daily.
61946640|NCT03875404|EXPERIMENTAL|Deep Brain Stimulation subjects|
61946641|NCT05038670|ACTIVE_COMPARATOR|PERSONA|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet PERSONA system
61946642|NCT05038670|ACTIVE_COMPARATOR|Journey II|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Smith\&Nephew Journey II system
61946643|NCT01551901|EXPERIMENTAL|Luna Interbody System|
61946644|NCT04605042|EXPERIMENTAL|WET First group|COOK ECHO-HD 22-C EchoTip Procore needle biopsy in WS-SNP-WS-SNP sequence
61946645|NCT04605042|EXPERIMENTAL|STANDARD first group|COOK ECHO-HD 22-C EchoTip Procore needle in SNP-WS-SNP-WS sequence
61946646|NCT01522508||propofol/remifentanil|patients receive standardized propofol and changing remifentanil concentrations
61946647|NCT01522508||sevoflurane/remifentanil|patients receive standardized sevoflurane and changing remifentanil concentrations
61946648|NCT02030418|EXPERIMENTAL|Leadless Pacemaker|VVIR pacing
61946649|NCT06323187||Pregnant Participants|Pregnant participants will be randomly assigned to provide a cervical sample using one of the devices/procedures for cervical fluid collection.
62497044|NCT03436316|EXPERIMENTAL|SAD Cohort 5 (Part 1)|"6 Participants will receive AZD8154 (single inhaled small particle dose 5) and 2 participants will receive placebo.~Participants in this Cohort will return for a second Treatment Period after a minimum washout period of 7 to 14 days. All 6 subjects will receive an inhaled dose of AZD8154 (large particle size)."
62497045|NCT03436316|EXPERIMENTAL|SAD Cohort 6 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 6) and 2 participants will receive placebo.
62497046|NCT03436316|EXPERIMENTAL|Cohort 1 (Part 2)|All participants in this cohort will receive single IV dose of AZD8154 in Treatment Period 1 and then after washout period, will receive inhaled AZD8154 (small particle size) in Treatment Period 2.
62698051|NCT06352463|ACTIVE_COMPARATOR|6-week waiting period|Children and parents have to wait 6 weeks between baseline 1 and the start of the treatment. In the first, third, and fifth week, they fill in ESMs daily.
62698052|NCT06634771|EXPERIMENTAL|10Hz bi-frontal tACS|"For Session 3, participants will complete a Habitual Association between Images Task (HABIT) Test Session in the Howell Hall Neurostimulation Core Lab or electroencephalogram (EEG) Core Lab, which is located one floor below the Boettiger Lab. Participants will receive either 10Hz bi-frontal transcranial alternating current stimulation (tACS) or sham tACS.~10 Hz bi-frontal tACS: Alternating current stimulation is delivered by an XCSITE 100 device (Pulvinar Neuro, Chapel Hill, NC), through three conductive carbon-rubber electrodes. Electrodes are placed over the apex of the head (Cz) and the prefrontal cortex bilaterally (F3 and F4). Stimulation is delivered during the second half of the HABIT Test session. Stimulation parameters: 2mA peak-to-peak 10Hz sine-wave flanked by 10 second linear envelope ramps in and out for a total duration of 30 min and 20 seconds."
62698053|NCT06634771|SHAM_COMPARATOR|sham tACS|Sham transcranial alternating current stimulation (tACS): The procedure for sham stimulation will be identical, but the actual stimulation will last for 2 minutes instead of 30 minutes. Participants generally report that stimulation is felt most strongly at the beginning of active stimulation, before they adjust to the sensation. Sham stimulation is meant to mimic this progression in terms of tactile salience. Stimulation is delivered for 2 minutes at the beginning of the HABIT reversal task, flanked by 10 second linear envelope ramps. The stimulating electrodes are left on the head until completion of the HABIT task, as is the case in active stimulation. There is no visual or auditory indication to the participant or researcher when the 2-minute sham stimulation period has ended, allowing the sham stimulation condition to feel similar to active stimulation.
62698054|NCT04414943|EXPERIMENTAL|S-katamine group|For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
61946650|NCT06323187||Non-Pregnant Participants|Non-pregnant participants will be randomly assigned to provide a cervical sample using one of the devices/procedures for cervical fluid collection.
61946651|NCT01162070|ACTIVE_COMPARATOR|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
61946652|NCT01162070|EXPERIMENTAL|Experimental strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
61946653|NCT04464057|EXPERIMENTAL|experimental group|The patients in the experimental group would be given early oral feeding within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
62340778|NCT02673892|EXPERIMENTAL|PODS intervention|The PODS intervention is administered during the discharge process which includes discharge teaching. In the acute settings, discharge teaching is provided by a nurse navigator, resident physician, or other members of the care team. In the rehabilitation setting, discharge teaching is provided by a multi-disciplinary team. PODS is used as a useful add-on to the usual discharge teaching process. The PODS form used during the study will be a fillable pdf. Members of the healthcare team will fill it out electronically, then print it out and give the paper to the patient. After the discharge teaching is finished, patients take the completed PODS home with them as a post-discharge reference and guide.
62340779|NCT02673892|NO_INTERVENTION|Usual Care|Patients randomized to this arm will receive usual discharge care. At UHN, this involves receiving a discharge summary with information pertaining to hospital course including investigations performed and medications used, as well as follow-up care suggested. It is intended to be, unlike PODS, a document for the primary care physician seeing the patient after discharge to refer to. As to discharge instructions provided for the patient, there is no standard procedure and sometimes follow-up instructions are included for the patient. Patient education may or may not be provided to the patient verbally by their nurse, resident, physician, or pharmacist. Moreover, follow-up with the primary care physician may be set up prior to or following discharge with the nurse navigator.
62340780|NCT01899859|ACTIVE_COMPARATOR|Cohort 1|Patient receives dose of GR-MD-02 or placebo
62340781|NCT01899859|ACTIVE_COMPARATOR|Cohort 2|Patient receives dose of GR-MD-02 or Placebo
61946654|NCT04464057|NO_INTERVENTION|control group|The control group would be given early oral feeding within 4-5 days after intestinal anastomosis. Start taking it at 4-5 days after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
61946655|NCT01145625|EXPERIMENTAL|5% MTF|5% Minoxidil Topical Foam
61946656|NCT01145625|ACTIVE_COMPARATOR|2% MTS|2% Minoxidil Topical Solution
61946657|NCT01743183|EXPERIMENTAL|threshold|Held inspiratory muscle strengthening for 5 weeks with Threshold, charging 30% of maximal inspiratory pressure, 7 days a week, one supervised and unsupervised 6.
61946658|NCT00216476|EXPERIMENTAL|001|Risperidone Long Acting Injectable (LAI) 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
61946659|NCT00216476|ACTIVE_COMPARATOR|002|Quetiapine Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
61946660|NCT00216476|OTHER|003|Aripiprazole 10-30 mg oral once daily for 104 weeks
62340782|NCT01899859|ACTIVE_COMPARATOR|Cohort 3|Patient receives dose of GR-MD-02 or placebo
62340783|NCT02150473|EXPERIMENTAL|Adalimumab|receive adalimumab 40 mg eow injections in combination with MTX for 24 weeks
62340784|NCT02150473|PLACEBO_COMPARATOR|Placebo|receive placebo injections in combination with MTX for 24 weeks
62340785|NCT03054948|EXPERIMENTAL|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
62340786|NCT03054948|ACTIVE_COMPARATOR|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
62340787|NCT02915952|ACTIVE_COMPARATOR|Zip Closure Device|The Zip device is a non-invasive, single use, sterile medical device for closure of the skin layer for surgical incisions or laceration repair.
62340788|NCT02915952|ACTIVE_COMPARATOR|Conventional Sutures|Conventional subdermal (subcuticular) absorbable sutures
62340789|NCT00383721|EXPERIMENTAL|MF/F MDI 400/10 mcg BID|
61946661|NCT05073211|EXPERIMENTAL|SJW-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
61946662|NCT05073211|ACTIVE_COMPARATOR|IAA-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
61946663|NCT00579878|ACTIVE_COMPARATOR|Leflunomide alone vs combination therapy|Group A: Leflunomide alone
61946664|NCT00579878|ACTIVE_COMPARATOR|Methotrexate-Sulfasalazine-Hydroxychloroquine|Methotrexate, Sulfasalazine, Hydroxychloroquine.
61946665|NCT00579878|ACTIVE_COMPARATOR|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide-Sulfasalazine-Hydroxychloroquine
62698055|NCT04414943|PLACEBO_COMPARATOR|Placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
61946666|NCT03047876||All neonates and infants undergoing aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
61946667|NCT01975714|EXPERIMENTAL|Latanoprost (Period I) + Bimatoprost (Period II)|"Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
61946668|NCT01975714|EXPERIMENTAL|Bimatoprost (Period I) and Latanoprost (Period II)|"Preservative-free bimatoprost 0.03% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free latanoprost 0.005% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
61946669|NCT03250221||Robotic or laparoscopic myomectomy|Women who received robotic or laparoscopic myomectomy
61946670|NCT02670720|EXPERIMENTAL|avoralstat|Five avoralstat capsules (100 mg) to be taken three times daily by mouth
61946671|NCT00074269|EXPERIMENTAL|treatment|
61946672|NCT00147212|EXPERIMENTAL|1|ET-743
62698056|NCT06296498|ACTIVE_COMPARATOR|Group OFD + L-PRF|Open flap debridement (OFD) with L-PRF is used during periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
61946673|NCT02296073|EXPERIMENTAL|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
61946674|NCT02296073|EXPERIMENTAL|Dexmedetomidine1|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
62140166|NCT01290003|NO_INTERVENTION|No Antibiotic Group|Neonates randomized to 'No antibiotic group' will receive supportive treatment as per standard unit protocol. These neonates will be monitored by performing sepsis screens and blood culture for development of sepsis.
62140167|NCT01406106|EXPERIMENTAL|Liquid yoghurt with plant stanol esters|"Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).~It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg."
62698057|NCT06296498|OTHER|Group OFD|Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
62698058|NCT05034081|EXPERIMENTAL|group A|to know the effect of post-bariatric body contouring surgery on weight loss and metabolism
62698059|NCT05034081|NO_INTERVENTION|group B|compare this group of patients with group A to detect weight changes and metabolic changes without any post-bariatric intervention
62698060|NCT05396014|ACTIVE_COMPARATOR|Treatment Period 1: Enhanced Self-Care (ESC)|"This arm includes participants who are randomized to ESC in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on ESC or be randomized to augment ESC with an additional treatment during Treatment Period 2."
62698061|NCT05396014|ACTIVE_COMPARATOR|Treatment Period 1: Acceptance and Commitment Therapy (ACT)|"This arm includes participants who are randomized to ACT in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on ACT, augment ACT with an additional treatment, or switch to a new treatment during Treatment Period 2."
61946675|NCT02296073|EXPERIMENTAL|Dexmedetomidine2|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
61946676|NCT02296073|EXPERIMENTAL|Dexmedetomiding3|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
61946677|NCT06465095||Healthy|Individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP \< 10%, probing depth ≤ 3 mm.
62140168|NCT01406106|PLACEBO_COMPARATOR|Yoghurt without plant stanol esters|Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
62140169|NCT04715269|EXPERIMENTAL|Alprazolam Arm|0.5mg Alprazolam will be given to the patient at the time of presentation
62140170|NCT04715269|PLACEBO_COMPARATOR|Placebo Arm|The empty capsule will be given to the patient at the time of presentation
62140171|NCT02401711|ACTIVE_COMPARATOR|Online training|Residents randomized to the control group will only participate in the Breakthroughs in Patient Safety (BIPS) online training (Education - BIPS course). All residents in the comparison arm will receive evaluations on their non-technical skills, but the results will not be fed back to them until after the study has been completed.
62698062|NCT05396014|ACTIVE_COMPARATOR|Treatment Period 1: Evidence-Based Exercise and Manual Therapy (EBEM)|"This arm includes participants who are randomized to EBEM in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on EBEM, augment EBEM with an additional treatment, or switch to a new treatment during Treatment Period 2."
62698063|NCT05396014|ACTIVE_COMPARATOR|Treatment Period 1: Duloxetine|"This arm includes participants who are randomized to Duloxetine in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on Duloxetine, augment Duloxetine with an additional treatment, or switch to a new treatment during Treatment Period 2."
61946678|NCT06465095||Stage III Grade B Periodontitis|Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 will be included.
61946679|NCT06465095||Stage III Grade C Periodontitis|Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is \>1 will be included.
61946680|NCT00697359|EXPERIMENTAL|1|There is only one group in this cohort study.
61946681|NCT03948243|EXPERIMENTAL|G.Glabra|single arm
61946682|NCT03540212|EXPERIMENTAL|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
61946683|NCT01805128|EXPERIMENTAL|schizophrenia|child with a DSM-IV diagnosis of schizophrenia
61946684|NCT01805128|EXPERIMENTAL|autism spectrum disorder|child with a DSM-IV diagnosis of autism spectrum disorder
61946685|NCT01805128|EXPERIMENTAL|Healthy|child having no DSM-IV diagnosis of schizophrenia spectrum disorder or autism
61946686|NCT05657925|ACTIVE_COMPARATOR|Ondansetron|ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
61946687|NCT05657925|PLACEBO_COMPARATOR|Placebo|Matching placebo will be identical in appearance to the active treatment pill.
61946688|NCT02855073|EXPERIMENTAL|ReJoinTM Group|Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.
61946689|NCT02855073|ACTIVE_COMPARATOR|Sodium Hyaluronate Group|subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22.
61946690|NCT05850065|OTHER|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp will used for the retraction.
62140172|NCT02401711|EXPERIMENTAL|Online training & Safety curriculum & Evaluation and feedback|Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
62698064|NCT06109324|EXPERIMENTAL|Robotic Rehabilitation|
62698065|NCT06109324|ACTIVE_COMPARATOR|Conventional treatment|
62698066|NCT00912717||Pancreatic Cancer|individuals who have been diagnosed with pancreatic cancer
62698067|NCT00912717||Unaffected|individuals who have not been diagnosed with pancreatic cancer
61946691|NCT05850065|OTHER|dental floss using the simple knot tie method|Dental floss using the simple knot tie method will used for the retraction.
61946692|NCT05850065|OTHER|Using Hu-Friedy 212 clamp and dental floss using the simple knot tie method together|Using Hu-Friedy 212 clamp and dental floss using the simple knot tie method together will used for the retraction.
61946693|NCT05850065|OTHER|Coltene B4 clamp|Coltene B4 clamp will used for the retraction.
61946694|NCT04311775||video laryngoscopy|video laryngoscope is a camera laryngoscope system used to see the larynx with camera
61946695|NCT04311775||laryngoscopy|laryngoscopy is a method used to see the larynx.
61946696|NCT04715425|ACTIVE_COMPARATOR|Thoracoscopic ablation|Thoracoscopic ablation
61946697|NCT04715425|ACTIVE_COMPARATOR|Catheter ablation|Catheter ablation
61946698|NCT01034189|EXPERIMENTAL|Targeted therapy|Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy
61946699|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
61946700|NCT00762216|OTHER|Toric|Implantation with the AcrySof® Toric intraocular lens
61946701|NCT05797259|EXPERIMENTAL|Danosumab|Danosumab 60mg subcutaneous once at diagnosis
61946702|NCT05797259|PLACEBO_COMPARATOR|Placebo|Similar Volume, and consistency placebo (Normal Saline) subcutaneous once at diagnosis
61946703|NCT05381844||HIV-1-infected, untreated|Patients recently diagnosed with chronic HIV-1-infection with detectable HIV-1 RNA in plasma, sampled before treatment initiation
61946704|NCT05381844||HIV-1-infected, undetectable viral load|Patients with chronic HIV-1 infection on antiretroviral treatment for less than a year, with a plasma HIV-1 RNA \< 50 copies/ml plasma since at least 6 months
61946705|NCT01540266|EXPERIMENTAL|first year psychology_structured|First year psychology students who watched the video where the physician gives structured information to the patient
61946706|NCT01540266|ACTIVE_COMPARATOR|First year psychology_non-structured|First year psychology students who watched the video where the physician gives non-structured information to the patient
61946707|NCT01540266|EXPERIMENTAL|First year medical_structured|First year medical students who watched the video where the physician gives structured information to the patient
61946708|NCT01540266|ACTIVE_COMPARATOR|First year mediclal_non-structured|First year medical students who watched the video where the physician gives non-structured information to the patient
61946709|NCT01540266|EXPERIMENTAL|Third year medical_structured|Third year medical students who watched the video where the physician gives structured information to the patient
61946710|NCT01540266|ACTIVE_COMPARATOR|Third year medical_non-structured|Third year medical students who watched the video where the physician gives non-structured information to the patient
61946711|NCT02345226|EXPERIMENTAL|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks.
61946712|NCT02345226|ACTIVE_COMPARATOR|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
62340790|NCT00383721|EXPERIMENTAL|MF/F MDI 200/10 mcg BID|
62340791|NCT00383721|EXPERIMENTAL|MF MDI 400 mcg BID|
62497047|NCT03436316|EXPERIMENTAL|MAD Cohort 1 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 8) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 8) or placebo once daily from Day 4 to Day 12.
62497048|NCT03436316|EXPERIMENTAL|MAD Cohort 2 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 9) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (Inhaled dose 9) or placebo once daily from Day 4 to Day 12.
62497049|NCT03436316|EXPERIMENTAL|MAD Cohort 3 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 10) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 10) or placebo once daily from Day 4 to Day 12.
61946713|NCT02345226|EXPERIMENTAL|Open Label Extension Phase|After the Week 96 visit, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead elects to discontinue the study, whichever occurs first.
61946714|NCT00839722|EXPERIMENTAL|1|fertility after embolization
61946715|NCT06534684|ACTIVE_COMPARATOR|Intermittent Theta Burst Stimulation|Stimulation will be performed with a Mag \& More PowerMag EEG 100 system with a double PMD70 p-cool (fluid-cooled) figure-of-eight coil.
61946716|NCT06534684|PLACEBO_COMPARATOR|Sham Intermittent Theta Burst Stimulation|Sham stimulation will be performed by the Mag \& More PowerMag EEG 100 system double PMD70 p-cool figure-of-eight coil Sham system.
61946717|NCT01630057|EXPERIMENTAL|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
61946718|NCT01630057|ACTIVE_COMPARATOR|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
61946719|NCT02705872|EXPERIMENTAL|Programmed intermittent boluses|Epidural analgesia performed with programmed intermittent boluses.
61946720|NCT02705872|ACTIVE_COMPARATOR|Continuous perfusion|Epidural analgesia performed with a continuous perfusion.
61946721|NCT00778544|EXPERIMENTAL|1|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension of Ranbaxy
61946722|NCT00778544|ACTIVE_COMPARATOR|2|Augmentin ES-600
61946723|NCT05775354|EXPERIMENTAL|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
61946724|NCT05775354|NO_INTERVENTION|Usual primary care|No measurements
61946725|NCT02194855|EXPERIMENTAL|laparoscopic operation on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
61946726|NCT02194855|EXPERIMENTAL|laparoscopic operation on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
62497050|NCT01710670|EXPERIMENTAL|Ethanol + Brivaracetam|Treatment A: Ethanol + Brivaracetam
62497051|NCT01710670|EXPERIMENTAL|Ethanol Placebo + Brivaracetam|Treatment B: Ethanol Placebo + Brivaracetam
62698068|NCT04344873|EXPERIMENTAL|Older Adult participants|Older adult participants (ages 55-75) will be assessed for arterial function using FMD analysis, PWV calculations, T Cell phenotyping, and proportion of inflammatory biomarkers after injections of placebo and abatacept.
62698069|NCT02041273|EXPERIMENTAL|Palbociclib given to healthy volunteers|
61946727|NCT02194855|EXPERIMENTAL|conventional open surgery on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
61946728|NCT02194855|EXPERIMENTAL|conventional open surgery on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
61946729|NCT06272201|EXPERIMENTAL|Treatment|POSE2.0 Treatment with Lifestyle Modification
61946730|NCT06272201|NO_INTERVENTION|Control|Lifestyle Modification alone
61946731|NCT00142935|EXPERIMENTAL|Pre-Release Initiation MMT|Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
62140173|NCT00355888|EXPERIMENTAL|Open label study of MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
62340792|NCT00383721|ACTIVE_COMPARATOR|Formoterol MDI 10 mcg BID|
62340793|NCT00383721|PLACEBO_COMPARATOR|Placebo MDI BID|
62340794|NCT00364325||001|
62340795|NCT04417725||Chronic kidney disease|Adult patients (≥18 years of age) with CKD were identified in Alberta during the case ascertainment period (April 1, 2010, to March 31, 2019), based on a validated algorithm incorporating ICD-9-CM/ICD-10-CA coding, estimated glomerular filtration rate, and albuminuria laboratory tests. This is a non-interventional, observational study, and thus, no intervention was administered.
62698070|NCT06558578|ACTIVE_COMPARATOR|Cases|"Children with migraine (cases) Inclusion criteria Age: children between 6 and 16 years old. Both sexes. children who suffering from migraine.~Exclusion criteria:~Age: children below 6 years old\& children above 16 years old. Children suffering from epilepsy, Mental retardation, autism, attention deficient hyperactivity disorder."
61946732|NCT00142935|EXPERIMENTAL|Post Release Initiation of MMT|Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
61946733|NCT00142935|ACTIVE_COMPARATOR|Standard of Care Plus|Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
61946734|NCT05534685|EXPERIMENTAL|intratracheal administration of surfactant/budesonide on the incidence of bronchopulmonary dysplasia|Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg.
61946735|NCT05534685|EXPERIMENTAL|intratracheal administration of surfactant on the incidence of bronchopulmonary dysplasia|Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
61946736|NCT02298231|EXPERIMENTAL|Group 1|Standard of Care Balance (SCB) Treatment
62698071|NCT06558578|OTHER|Control|Healthy children (control) healthy children not suffering from migraine or any neurological diseases.
62698072|NCT06275867|NO_INTERVENTION|Control group|In this group, participants will have free access to government facilities (usual care)
62698073|NCT06275867|EXPERIMENTAL|Convenient group|In this group, for the duration of the study, participants will be given free access to a small number of private providers located relatively close by (less than 30 minutes).
61946737|NCT02298231|EXPERIMENTAL|Group 2|Mystic Isle (MI) Balance Training
61946738|NCT02298231|EXPERIMENTAL|Group 3|Mystic Isle (MI) Dual Task Training
61946739|NCT05332730|EXPERIMENTAL|BAT2506|BAT2506 injection, 50 mg, subcutaneous administration. Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
61946740|NCT05332730|ACTIVE_COMPARATOR|Simponi® (EU commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
61946741|NCT05332730|ACTIVE_COMPARATOR|Simponi® (US commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
61946742|NCT03774758||Cohort 1A: Benign nodule on screening CT|"High-risk patients eligible for lung cancer screening but with negative radiographic findings on CT screening (Lung RADS ≤2).~1. ≥30 pack-year history of cigarette smoking~2. ≥55 years of age~3. Current smoker or quit within the past 15 years"
61946743|NCT03774758||Cohort 1B: Incidental benign nodule|"Patients with lung nodules ≥ 6 mm on routine (non-lung cancer screening) CT evaluation deemed suspicious for malignancy by initial physician judgment but not malignant by ≥2 years of radiographic stability and consensus clinical opinion.~1- Age ≥40 years."
61946744|NCT03774758||Cohort IC: Presumed lung cancer|"Patients with lung cancer (histologically proven or presumed by consensus opinion of tumor board); prior to definitive therapy.~1- Age ≥40 years."
61946745|NCT03774758||Cohort 2A: Suspicious nodule|"High-risk patients with newly diagnosed suspicious nodule of Lung RADS ≥3 on CT screening.~1. ≥30 pack-year history of cigarette smoking~2. ≥55 years of age~3. Current smoker or quit within the past 15 years"
61946746|NCT03774758||Cohort 2B: Suspicious incidental nodule|"Patients with newly diagnosed incidentally-found lung nodules ≥ 6 mm on routine CT evaluation deemed suspicious for malignancy by physician judgment.~1- Age ≥40 years."
61946747|NCT03774758||Cohort 2C: Post-treatment lung cancer|"Patients with previously treated lung cancer (histologically proven or by consensus opinion); status-post completion of definitive therapy (resection +/- chemotherapy or SBRT with curative intent) within the previous year with no current evidence of disease.~1- Age ≥40 years."
61946748|NCT03253575||Squamous Carcinoma of the Head and Neck (HNSCC)|"1st line metastatic/locally advanced~* 2nd line metastatic/locally advanced"
61946749|NCT03253575||Triple Negative Breast Cancer (TNBC)|1. Triple Negative Breast Cancer (TNBC) A 1st line metastatic/locally advanced B ≥2nd line metastatic/locally advanced
61946750|NCT03253575||Non-small Cell Lung Cancer (NSCLC)|1. Non-small Cell Lung Cancer (NSCLC) A ≥2nd line Stage 3B or 4
61946751|NCT03253575||Epithelial Ovarian Cancer (EOC)|1. Epithelial Ovarian Cancer (EOC) A 2nd line platinum-resistant Stage 3 or 4 B 2nd line platinum-sensitive Stage 3 or 4 C ≥3rd line platinum-sensitive Stage 3 or 4
61946752|NCT03253575||Colorectal Cancer (CRC)|1. Colorectal Cancer (CRC) A 1st line Stage 4 B Recurrent or progressive disease following treatment with both oxaliplatin- and irinotecan-containing regimens
61946753|NCT01780571|NO_INTERVENTION|Control group|Neutral pressure breathing after 2 min preoxygenation
61946754|NCT01780571|ACTIVE_COMPARATOR|Active group|CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation
62340796|NCT04417725||Type 2 diabetes mellitus|Adult patients with T2DM were identified in Alberta during the case ascertainment period (April 1, 2010 to March 31, 2018), based on a validated algorithm incorporating ICD-9-CM and ICD-10-CA codes. This is a non-interventional, observational study, and thus, no intervention was administered.
62698074|NCT06275867|EXPERIMENTAL|Inconvenient group|In this group, for the duration of the study, participants will be given free access to a small number of private providers located relatively far (about one hour).
62497052|NCT01710670|EXPERIMENTAL|Ethanol + Brivaracetam Placebo|Treatment C: Ethanol + Brivaracetam Placebo
62497053|NCT00351117|EXPERIMENTAL|1|St. John's wort 300mg PO TID
62698075|NCT06484881|ACTIVE_COMPARATOR|Topical Minoxidil 5% + Multivitamin Oral Supplement|Topical Minoxidil 5% + Multivitamin Oral Supplement
62698076|NCT06484881|EXPERIMENTAL|Placebo Spray + Daniel Alain Probiotic Treatment for Androgenetic Alopecia|Placebo Spray + Daniel Alain Probiotic Treatment for Androgenetic Alopecia
61946755|NCT03632200|EXPERIMENTAL|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
61946756|NCT03632200|NO_INTERVENTION|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
61946757|NCT01358851|EXPERIMENTAL|1|Drug Las41005
62497054|NCT00351117|PLACEBO_COMPARATOR|2|Lactose in capsule matching the St. John's wort. 300mg PO TID
62497055|NCT02557217|EXPERIMENTAL|NP202|1000mg oral NP202 daily for 90 days
62497056|NCT02557217|PLACEBO_COMPARATOR|Placebo|Oral placebo daily for 90 days
62497057|NCT04729101|EXPERIMENTAL|Treatment A (vonoprazan)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Vonoprazan will be administered via 20 mg oral tablet once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
62497058|NCT04729101|ACTIVE_COMPARATOR|Treatment B (lansoprazole)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Lansoprazole will be administered via 30 mg oral capsule once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
62497059|NCT00376740|EXPERIMENTAL|Immediate zoledronic acid|Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
62497060|NCT00376740|ACTIVE_COMPARATOR|Delayed zoledronic acid|Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
62497061|NCT01969864|EXPERIMENTAL|HRSA Video Intervention|5-minute video on organ donation from U.S. Department of Health and Human Services
62698077|NCT05949957|EXPERIMENTAL|Intervention group|"LvL UP App (Smarphone-based conversational agent-delivered holistic lifestyle intervention for the prevention of type 2 diabetes, and common mental disorders \[anxiety, depression\]).~HAPPY App (Health promotion information, and display health data collected)~Oura ring and Oura App (activity-tracking wearable that collects lifestyle data \[physical activity, sleep and heart rate\])."
62698078|NCT05949957|ACTIVE_COMPARATOR|Control group|"HAPPY App (Health promotion information, and display health data collected)~Oura ring and Oura App (activity-tracking wearable that collects lifestyle data \[physical activity, sleep and heart rate\])."
61946758|NCT01358851|OTHER|2|Cryotherapy
61946759|NCT00760422||With fever|
61946760|NCT00760422||Without fever|
61946761|NCT03909646|ACTIVE_COMPARATOR|Surgical excision|Standard surgical excision with 5 mm safety margin
61946762|NCT03909646|ACTIVE_COMPARATOR|Photodynamic therapy|PDT with application of methyl aminolevulinate (MAL) cream followed by two illuminations with a one-week interval
61946763|NCT03909646|ACTIVE_COMPARATOR|5% 5-Fluorouracil|5FU cream, which has to be applied by the patient twice daily for 4 weeks.
61946764|NCT06454435|EXPERIMENTAL|Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel|
62140174|NCT05036837|EXPERIMENTAL|OZOPROMAF_SEQ1|"OZOPROMAF consists of: local superficial anesthesia by application of EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (O2O3) mixture by 26Gx 1⁄2 - 0.45x13mm needle into mucosal margin surrounding bone exposure or around situs evidenced by CT scans.~Pain intensity and/or other symptoms are assessed at each visit and the day after by a questionnaire (numerical rating scale).~OZOPROMAF is applied on 7-15 days, depending on patient compliance, until the resolution (i.e. formation of sequestrum and clinical healing -T1).~Follow-up visits are scheduled to confirm healing at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5). Radiographic evaluations of bone healing are scheduled at T3/ T4/T5.~Positive outcomes~at T1/T2 clinical healing (no signs of acute phlogosis and no symptoms compatible with MRONJ);~at T3/ T4/T5 clinical healing and no radiological signs of MRONJ."
62140175|NCT05485116||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
62497062|NCT01969864|EXPERIMENTAL|PI Video Intervention|5-minute video on organ donation created in part by the principal investigator.
62497063|NCT01969864|PLACEBO_COMPARATOR|CDC Health Website Intervention|This control intervention will include text from the CDC website on health and wellness.
62497064|NCT04260854|ACTIVE_COMPARATOR|Bupivacaine HCl|Immediately prior to surgical wound closure, participants randomized to the bupivacaine arm will be injected with bupivacaine HCl along the closure site.
62497065|NCT04260854|PLACEBO_COMPARATOR|Saline|Immediately prior to surgical wound closure, participants randomized to saline, will receive saline injections along the closure site.
62497066|NCT01402934|EXPERIMENTAL|fluid infusion|
62497067|NCT03990233|EXPERIMENTAL|Step 1 (Dose escalation) : Cohorts A|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
62497068|NCT03990233|EXPERIMENTAL|Step 1 (Dose escalation) : Cohorts B|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
62698079|NCT01661673|EXPERIMENTAL|Arm 1|10 mg EVP-0962 Orally administered once daily for 14 days
62698080|NCT01661673|EXPERIMENTAL|Arm 2|50 mg EVP-0962 Orally administered once daily for 14 days
62698081|NCT01661673|EXPERIMENTAL|Arm 3|100 mg EVP-0962 Orally administered once daily for 14 days
61946765|NCT06454435|ACTIVE_COMPARATOR|Sintilimab + S-1 plus nab-paclitaxel|
62698082|NCT01661673|EXPERIMENTAL|Arm 4|200 mg EVP-0962 Orally administered once daily for 14 days
62698083|NCT01661673|PLACEBO_COMPARATOR|Arm 5|Placebo orally administered for 14 days
62698084|NCT00476645|EXPERIMENTAL|Fulvestrant|
62140176|NCT05485116||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
62497069|NCT03990233|EXPERIMENTAL|Step 2 (Expansion Cohorts) : Cohort C1|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic colorectal cancer
62497070|NCT03990233|EXPERIMENTAL|Step 2 (Expansion Cohorts) : Cohort C2|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic endometrium cancer
62698085|NCT05154734|EXPERIMENTAL|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
62698086|NCT05408780|EXPERIMENTAL|Part A - Food Effect Assessment|Subjects will be randomized before administration of the first dose of active or matching placebo IMP in a 1:1:1:1 ratio to 1 of 4 treatment sequences (ABCD, BACD, ABDC, BADC) so that all subjects receive Regimens A, B, C and D across the 4 periods.
62698087|NCT05408780|EXPERIMENTAL|Part B - Titration Tolerability|"Subjects will be dosed BID in the morning and afternoon (approximately 5 h apart) on Days 1 to 27. Both doses of active or matching placebo IMP will be administered in the fed state either 30 min after completion of a standard-fat and calorie content breakfast or 30 min after a standardized-fat and calorie content lunch.~Participants will be randomised to either study drug or the matching placebo."
62698088|NCT01631266|EXPERIMENTAL|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
62140177|NCT03703414||Control|Healthy controls
62340797|NCT04417725||Comorbid type 2 diabetes mellitus and chronic kidney disease|The derived T2DM cohort was used to identify patients with comorbid T2DM/CKD (stages 1-3) during the same case ascertainment period (April 1, 2010 to May 31, 2018). The study cohort included T2DM patients with comorbid CKD (stages 1-3) identified in Alberta within the two years prior or after their T2DM index date, using the T2DM index date as the index date for this cohort. This is a non-interventional, observational study, and thus, no intervention was administered.
62340798|NCT04936724|EXPERIMENTAL|Condition A (Lesser-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting lesser-known harms of tobacco use.
62340799|NCT04936724|EXPERIMENTAL|Condition B (Well-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting the well-known harms of tobacco use.
62340800|NCT05902013|ACTIVE_COMPARATOR|Video|using video laryngoscopy for endotracheal intubation
62340801|NCT05902013|ACTIVE_COMPARATOR|Direct|using direct laryngoscopy
62340802|NCT04836819|ACTIVE_COMPARATOR|Group L|IV lidocaine infusion (1-2 mg/kg/h) up to postoperative 12 hours.
62340803|NCT04836819|ACTIVE_COMPARATOR|Group K|IV ketamine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
62340804|NCT04836819|ACTIVE_COMPARATOR|Group D|IV dexmedetomidine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
62340805|NCT05929924|NO_INTERVENTION|Control|This group will not receive intervention
62340806|NCT05929924|ACTIVE_COMPARATOR|Extra-virgin olive oil|This group will receive extra-virgin olive oil (EVOO) as intervention
62340807|NCT06068322|EXPERIMENTAL|Supramaximal high-intensity interval training (Supramaximal HIIT)|Each HIIT session consists of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIIT is initially 20 min, including warm-up (5 min) and cool-down (5 min). The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
62340808|NCT06068322|ACTIVE_COMPARATOR|Moderate-intensity continuous training (MICT)|Each MICT session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is initially 30 min, including warm-up (5 min) and cool-down (5 min). The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
62497071|NCT03624777|EXPERIMENTAL|Stroll Safe Program|
62497072|NCT03624777|ACTIVE_COMPARATOR|Outdoor Fall Prevention Brochure|
62698089|NCT01631266|ACTIVE_COMPARATOR|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
62140178|NCT03703414||ECT|MDD patients receiving ECT treatment
62140179|NCT03703414||SSRI|MDD patients receiving SSRI treatment
62140180|NCT04051060||Patients with Bronchial Asthma|
62140181|NCT04051060||Healthy individuals|
62140182|NCT06639997|EXPERIMENTAL|Cohort 1 - AZD5148 IM|"Biological: AZD5148 (Cohort 1)~・Single dose of AZD5148 IM"
62140183|NCT06639997|PLACEBO_COMPARATOR|Cohort 1 - Placebo IM|Biological: Placebo (Cohort 1) Single dose of Placebo IM
62140184|NCT06639997|EXPERIMENTAL|Cohort 2 - AZD5148 IV|"Biological: AZD5148 (Cohort 2)~・Single dose of AZD5148 IV"
62140185|NCT06639997|PLACEBO_COMPARATOR|Cohort 2 - Placebo IV|Biological: Placebo (Cohort 2) Single dose of Placebo IV
62140186|NCT02063659|EXPERIMENTAL|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
62497073|NCT05788250|EXPERIMENTAL|Subacromial spacer implantation|
62497074|NCT05788250|ACTIVE_COMPARATOR|Rotator Cuff Repair|
62497075|NCT05080140||Simvastatin|
62497076|NCT05080140||Ezetimibe|
62497077|NCT05080140||Omega -3 fatty acids-|
62497078|NCT05080140||Simvastatin+ Ezetimibe|
62497079|NCT05080140||Simvastain + ezetimibe + omega|
62497080|NCT02519543|PLACEBO_COMPARATOR|Placebo|Placebo comparator to be given twice daily, once with breakfast and once with supper
62497081|NCT02519543|EXPERIMENTAL|Metformin|Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper
62497082|NCT04629170|EXPERIMENTAL|MAD HV: SYNB8802 (1 x 10^11 live cells)|HV subjects receive SYNB8802 (1 x 10\^11 live cells) TID for 5 days in the MAD study (Part 1).
62497083|NCT04629170|EXPERIMENTAL|MAD HV: SYNB8802 (3 x 10^11 live cells)|HV subjects receive SYNB8802 (3 x 10\^11 live cells) TID for 5 days in the MAD study (Part 1).
62497084|NCT04629170|EXPERIMENTAL|MAD HV: SYNB8802 (1 x 10^12 live cells)|HV subjects receive SYNB8802 (1 x 10\^12 live cells) TID for 5 days in the MAD study (Part 1).
62497085|NCT04629170|EXPERIMENTAL|MAD HV: SYNB8802 (optional cohort 1)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
62497086|NCT04629170|EXPERIMENTAL|MAD HV: SYNB8802 (optional cohort 2)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
62497087|NCT04629170|PLACEBO_COMPARATOR|MAD HV: Placebo|HV subjects receive placebo TID for 5 days in the MAD study (Part 1).
62497088|NCT04629170|OTHER|Crossover Arm 1: SYNB8802 crossover to Placebo|In Part 2 subjects will be randomized (1:1) to receive SYNB8802 TID for 6 days and then, following a washout period, receive Placebo TID for 6 days.
62140187|NCT02063659|EXPERIMENTAL|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
62497089|NCT04629170|OTHER|Crossover Arm 2: Placebo crossover to SYNB8802|In Part 2 subjects will be randomized (1:1) to receive Placebo TID for 6 days and then, following a washout period, receive SYNB8802 TID for 6 days.
62497090|NCT06217276|ACTIVE_COMPARATOR|COPD Group|
62497091|NCT06217276|ACTIVE_COMPARATOR|Healthy Group|
62497092|NCT04791345|EXPERIMENTAL|Methylprednisone single-dose|Subjects receive a single dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
62497093|NCT04791345|EXPERIMENTAL|Methylprednisone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 7 days after administration in 20 fractions.
62698090|NCT06639425|EXPERIMENTAL|Lactobacillus paracasei LC19 supplementation|
62140188|NCT02063659|PLACEBO_COMPARATOR|Placebo|Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
62497094|NCT04791345|EXPERIMENTAL|Deflazacort single-dose|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
62497095|NCT04791345|EXPERIMENTAL|Dexamethasone single-dose|"Subjects receive a single-dose treatment. Urine samples will be collected until 13 days after administration in 11 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h, 120-144h post-administration.~Blood samples will be collected until 9 days after administration in 6 fractions: pre-administration and 24h, 48h, 72h, 120h and 192h post-administration."
62698091|NCT06639425|PLACEBO_COMPARATOR|Placebo probiotic milk powder|
62140189|NCT06120855|EXPERIMENTAL|Regulated cannabis from authorized pharmacies (intervention group)|Multimodal intervention of authorized, regulated cannabis sale in combination with counselling on reducing harms for recreational cannabis users in Swiss pharmacies (intervention group).
62140190|NCT06120855|ACTIVE_COMPARATOR|Cannabis from the illicit market (control group)|The control group receives no intervention and is expected to continue purchasing cannabis from the illicit market.
62140191|NCT03937804||asthmatics|persons with asthma
62340809|NCT06068322|NO_INTERVENTION|Usual care|The passive control group will receive usual care alone and a standardized phone call every three months including assessments of health status (CAT), disease specific quality of life (CRQ) and questions on symptoms of exacerbations. We will match the participants in the standard care group to those randomized to HIIT or MICT by age, sex, disease severity, educational level, and physical activity.
62497096|NCT04791345|EXPERIMENTAL|Dexamethasone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 10 days after administration in 34 fractions. Blood samples will be collected until 13 days after the first administration.
62340810|NCT01405313|EXPERIMENTAL|Modified ASV|Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
62698092|NCT02558868|EXPERIMENTAL|Oxaliplatin + Irinotecan|Irinotecan：160 mg/m2，iv 120 min，d1 q2w oxaliplatin: 85 mg/m2，iv 120 min，d1 q2w
62340811|NCT01405313|ACTIVE_COMPARATOR|Conventional ASV|Conventional ASV This is the current (predicate) ASV algorithm.
62698093|NCT02558868|ACTIVE_COMPARATOR|Irinotecan|Irinotecan：180 mg/m2，iv 120 min，d1 q2w
62698094|NCT06632171|EXPERIMENTAL|psychoeducation 1|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62698095|NCT06632171|EXPERIMENTAL|psychoeducation 2|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62698096|NCT06632171|EXPERIMENTAL|psychoeducation 3|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62698097|NCT06632171|EXPERIMENTAL|psychoeducation 4|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62340812|NCT05519371|EXPERIMENTAL|remimazolam group|For induction of anesthesia, rimazolam benzoate was pumped at a rate of 12 mg/kg/h; for maintenance of anesthesia, 1.0-2.0 mg/kg/h rimazolam was given as a continuous pump.
62698098|NCT06632171|EXPERIMENTAL|psychoeducation 5|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62698099|NCT06632171|EXPERIMENTAL|psychoeducation 6|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62340813|NCT05519371|ACTIVE_COMPARATOR|propoful group|For induction of anesthesia, propofol medium-length chain fatty milk injection 2 mg/kg was given by intravenous push; for maintenance of anesthesia, 6-8 mg/kg/h propofol medium-length chain fatty milk injection was given by continuous pumping.
61946766|NCT03992014|EXPERIMENTAL|Linerixibat + [14C]-linerixibat|Subjects will receive a single oral dose of linerixibat 90 milligram (mg) (2\*45 mg) tablets concomitantly with \[14C\]-linerixibat 100 microgram (approximately 9.25 kilobecquerel; 250 nano curie) IV infusion for 3 hours, after an overnight fast that continues for 2 hours after the oral dose/start of IV infusion, small standard high-fat meal will be given on Day 1 in treatment Period 1; followed by a single oral dose of \[14C\]-linerixibat 90 mg (approximately 4.96 megabecquerel; 134.1 micro curie) solution on Day 1 in treatment Period 2. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
61946767|NCT03179527|EXPERIMENTAL|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
61946768|NCT03179527|OTHER|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
61946769|NCT04640857|EXPERIMENTAL|Test group: Silk'n Toothwave with vibration and electromagnetic field|Silk'n Toothwave with vibration and electromagnetic field use twice a day for 3 months.
61946770|NCT04640857|SHAM_COMPARATOR|Control group: Silk'n Toothwave with-out an electromagnetic field ( only vibration)|Silk'n Toothwave without an electromagnetic field (only vibration ) use twice a day for 3 months.
61946771|NCT04640857|ACTIVE_COMPARATOR|Silk'n Toothwave with an electromagnetic field and without vibration|Silk'n Toothwave with an electromagnetic field and without vibration use twice a day for 3 months.
61946772|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
61946773|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
61946774|NCT04225962||Women with cystic fibrosis|Women with cystic fibrosis
61946775|NCT01830231|EXPERIMENTAL|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
61946776|NCT01830231|ACTIVE_COMPARATOR|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation~* 280 mg/m2 in patients aged \>75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years."
61946777|NCT02178085|EXPERIMENTAL|Flow imaging|Glaucoma patients and healthy subjects who will undergo ocular flow imaging
61946778|NCT05491109|EXPERIMENTAL|Venous Assistance and Contracture Management System (VACOM)|Venous Assistance and Contracture Management System (VACOM) + Inpatient rehabilitation (daily Physiotherapy therapy and Occupational therapy)
61946779|NCT05491109|ACTIVE_COMPARATOR|Intermittent Pneumatic Compression (IPC)|Intermittent Pneumatic Compression (IPC) which is the standard care + Inpatient rehabilitation (daily Physiotherapy therapy and Occupational therapy)
61946780|NCT00579137|EXPERIMENTAL|Participants With SCID or Primary Immunodeficiency Disorder|all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45
61946781|NCT02912078|EXPERIMENTAL|Pocket-warmed epidural medication|This arm will consist of pocket-warmed epidural medications to be administered per standard protocol to patients randomized to this group; this group is the pocket-warming group.
61946782|NCT02912078|ACTIVE_COMPARATOR|Room-temperature epidural medication|This arm will consist of room-temperature epidural medications to be administered per standard protocol to patients randomized to this group. This group has no experimental intervention; standard of care labor epidural.
61946783|NCT02617043|EXPERIMENTAL|HF-WBI|Hypofractionated whole breast irradiation for early breast cancer with prescription dose 40Gy in 15 fractions in 3 weeks. Tumor bed is simultaneously integrated boosted to 48Gy.
62340814|NCT00434512|EXPERIMENTAL|SB732461 adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose \[LD\] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
62340815|NCT00434512|EXPERIMENTAL|SB732461 adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose \[MD\] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
61946784|NCT04195906|EXPERIMENTAL|SNF472 (Double-Blind Period)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
61946785|NCT04195906|PLACEBO_COMPARATOR|Placebo (Double-Blind Period)|Matching placebo (saline) diluted in 100 mL physiological saline.
62140192|NCT03937804||control|persons without asthma
62340816|NCT00434512|EXPERIMENTAL|SB732461 adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose \[HD\] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
62340817|NCT00434512|EXPERIMENTAL|SB732461 non-adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose \[LD\] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
62340818|NCT00434512|EXPERIMENTAL|SB732461 non-adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose \[MD\] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
62340819|NCT00434512|EXPERIMENTAL|SB732461 non-adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose \[HD\] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
62340820|NCT05098158|EXPERIMENTAL|Single arm pain treatment|Arm includes usual pain care plus the chosen two telehealth interventions x 6 weeks
61946786|NCT04195906|EXPERIMENTAL|SNF472 (Open-Label)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
61946787|NCT04027543||Neoadjuvant chemoradiotherapy|Patients who had chemoradiotherapy before surgery.
61946788|NCT04027543||Neoadjuvant chemotherapy|Patients who had chemotherapy before surgery.
61946789|NCT04027543||Surgery alone|Patients who only had oesophagectomy. Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic. The appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
62140193|NCT04314375|EXPERIMENTAL|Low Dose Budesonide|
62140194|NCT04314375|EXPERIMENTAL|High Dose Budesonide|
62140195|NCT04314375|PLACEBO_COMPARATOR|Placebo|
62340821|NCT01938963|NO_INTERVENTION|Care as usual|
62497097|NCT05598164|EXPERIMENTAL|main group|Patients of main group are treated with injection in internal sphincter Botulinum toxin type A.
61946790|NCT06034847|ACTIVE_COMPARATOR|Conservative management|Mechanical thrombectomy of large vessel occlusions with or without administration of IV thrombolytics
62140196|NCT06514391|EXPERIMENTAL|compressive one piece implants with bar attachment|All patients received 4 mandibular inter-foraminal single piece compressive implants, bar attachment connecting 4 implants was then cemented and complete mandibular overdenture was attached to bar via peek clips
62140197|NCT03440996|EXPERIMENTAL|Clinpro™ 5000|Participants will use Clinpro™ 5000 to brush their teeth for two minutes twice daily for 4 months.
62140198|NCT03440996|EXPERIMENTAL|Clinpro™ Tooth Crème|Participants will use Clinpro™ Tooth Crème to brush their teeth for two minutes twice daily for 4 months.
62140199|NCT03440996|ACTIVE_COMPARATOR|MI-Paste Plus|Participants will use MI-Paste Plus to brush their teeth for two minutes twice daily for 4 months.
62340822|NCT01938963|EXPERIMENTAL|Collaborations in Health (COACH)|COACH integrates the care provided by the older person's primary care provider (PCP) with that delivered by an Aging Worker (AW; a lay member of the village's Aging Association), supervised by a psychiatrist consultant. Based on chronic disease management principles, the PCP is trained to use evidence based practice guidelines for treatment of both HTN and depression, and provided with access to mental health consultation regarding optimal management of the patient's depression. The AW is trained to conduct a systematic assessment of the older person's social context to identify and reduce social and environmental barriers to treatment adherence and response. AWs participate with the PCP in developing multi-disciplinary care plans for their shared patients, reinforce treatment adherence and adoption of healthy behaviors, and emphasize activation and engagement of the older person in activities designed to improve their connectedness to others and to the community.
62340823|NCT02719470|EXPERIMENTAL|normal cognition|Group 1: patients with normal cognitive profile, assessed with MMSE (27 ≤ correct score ≤ 30) undergoing MIRT
62340824|NCT02719470|EXPERIMENTAL|mildly impaired cognition|Group 3: patients with middle cognitive decline, assessed with MMSE (20 ≤ correct score \< 27) undergoing MIRT
62340825|NCT02719470|EXPERIMENTAL|moderately-severely impaired cognition|Group 2: patients cognitive decline, assessed with MMSE (correct score \< 20) undergoing MIRT
62340826|NCT02719470|EXPERIMENTAL|patients with normal executive functions|Group 4: patients with pathological executive functions, assessed with FAB (FAB ≥ 13.8) undergoing MIRT
62340827|NCT02719470|EXPERIMENTAL|pathological executive functions|Group 5: patients with pathological executive functions, assessed with FAB (FAB \< 13.8) undergoing MIRT
62340828|NCT01000727|EXPERIMENTAL|Darapladib 160 mg|Single daily oral tablet
62340829|NCT01000727|PLACEBO_COMPARATOR|Placebo|Single daily oral tablet
62497098|NCT05598164|EXPERIMENTAL|control group|In the control group, the fissure is excised in combination with a injection in internal sphincter Botulinum toxin type A.
62497099|NCT03824834|EXPERIMENTAL|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) with supervised exercise training.
62497100|NCT03824834|PLACEBO_COMPARATOR|Exercise training with placebo|Placebo treatment with supervised exercise training.
62497101|NCT01580046|EXPERIMENTAL|Iodixanol|
62497102|NCT01580046|ACTIVE_COMPARATOR|iopromide|
62497103|NCT05263505|EXPERIMENTAL|Baricitinib|4mg daily
62497104|NCT05263505|ACTIVE_COMPARATOR|Antiproliferative|methotrexate, azathioprine, or mycophenolate
62497105|NCT04280224|EXPERIMENTAL|NK Cells Treatment Group|Conventional treatment plus NK cells. Participants will receive conventional treatment plus twice a week of NK cells (0.1-2\*10E7 NK cells/kg body weight).
62340830|NCT05246176|EXPERIMENTAL|Cases|group of patient with inoperable malignant obstructive jaundice with failed internal drainage.
62340831|NCT00601796|EXPERIMENTAL|Combination Immunotherapy|Vaccine + Cytoxan + ATRA as outlined in Detailed Description
62497106|NCT04280224|NO_INTERVENTION|Conventional Control Group|Participants will only receive conventional treatment.
62698100|NCT06632171|EXPERIMENTAL|psychoeducation 7|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62340832|NCT00752167||Case|all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
62340833|NCT00752167||Control|control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
62340834|NCT06130852|EXPERIMENTAL|Behavioral Parent Training|"This program includes 10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.~This program combines knowledge about ADHD with behavioral and cognitive techniques."
62340835|NCT06130852|NO_INTERVENTION|control group|no behavioral parent training
62340836|NCT00808782|SHAM_COMPARATOR|Sham rTMS|Sham 5Hz rTMS.
62497107|NCT04046562|ACTIVE_COMPARATOR|PAW plus standard of care|Each PAW session will include handouts and worksheets to assist with new strategies as well as homework. Strategies taught within PAW will be integrated with the skills taught in weight management. For example, pain diaries will be kept along with food and exercise logs to examine relationships among pain, eating and activity.
62497108|NCT04046562|PLACEBO_COMPARATOR|Pain education plus standard of care|For those randomized into the information-only group, sessions will be delivered in the same manner. Sessions will cover general pediatric pain management but no behavioral or cognitive skills training will be taught.
62497109|NCT02276625|EXPERIMENTAL|A - ID|Intradermal administration. 20% dose in a single visit.
62497110|NCT02276625|EXPERIMENTAL|B - ID|Intradermal administration. 40% dose in a single visit.
61946791|NCT06034847|ACTIVE_COMPARATOR|Rescue therapy|In addition to conservative management, rescue therapy in distal occlusions consisting of either mechanical thrombectomy with small stent retrievers with or without contact aspiration, or intra-arterial pharmacotherapy with tPA (tissue Plasminogen Activator), uPA (urokinase Plasminogen Activator) or tenecteplase.
61946792|NCT05510375|ACTIVE_COMPARATOR|Cocoa extract + multivitamin|Two capsules/day for 600 mg/day of cocoa flavanols One tablet/day of multivitamin
62497111|NCT02276625|EXPERIMENTAL|C - ID|Intradermal administration. 60% dose in a single visit.
62497112|NCT02276625|ACTIVE_COMPARATOR|D - IM|1x IM
62497113|NCT06348316|NO_INTERVENTION|Control|
62698101|NCT06632171|EXPERIMENTAL|psychoeducation 8|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
61946793|NCT05510375|ACTIVE_COMPARATOR|Cocoa extract + multivitamin placebo|Two capsules/day for 600 mg/day of cocoa flavanols Multivitamin placebo
61946794|NCT05510375|ACTIVE_COMPARATOR|Cocoa extract placebo + multivitamin|Cocoa extract placebo One tablet/day of multivitamin
61946795|NCT05510375|PLACEBO_COMPARATOR|Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo Multivitamin placebo
61946796|NCT04980781|EXPERIMENTAL|Participants receiving PED-t|"Participants, i.e. females with bulimia nervosa or binge eating disorder, are recruited for therapy in the trained ERC. The treatment program consists of 20 behavioral therapy sessions covering 16 weeks, and with single follow-up sessions at 2-, and 4- months post-therapy.~Participants are interviewed on the expectations to- and experiences from having therapy in the ECR, and monitored and evaluated on therapy effectiveness (i.e. diagnostic outcomes)."
61946797|NCT04980781|EXPERIMENTAL|Therapists and management in ERC offering PED-t|"Employees in the ECR and the management will be trained in giving PED-t in their facility, and will then perform therapy with a single group of participants recruited.~Therapists/employees trained in PED-t will be interviewed about their expectations to- and experiences from giving the PED-t, and also being monitored according to therapy manual fidelity.~The management at the facility offering PED-t will be interviewed about their experiences on administration and implementation of the PED-t in their facility."
61946798|NCT00414271|EXPERIMENTAL|Docetaxel and Capecitabine in gastric cancer|Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
61946799|NCT03472651|EXPERIMENTAL|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
61946800|NCT03472651|EXPERIMENTAL|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
62340837|NCT00808782|EXPERIMENTAL|rTMS|Active 5Hz deep TMS.
62340838|NCT06167499|EXPERIMENTAL|Therapeutic Education Group.|Medical follow-up every 6 months for 18 months (inclusion, M6, M12, M18) associated with therapeutic education consultations conducted by nurses in the month following inclusion (between D0 and M1), M3, M9 and M15
62340839|NCT06167499|NO_INTERVENTION|Standard|Medical follow-up every 6 months for 18 months (Inclusion, M6, M12, M18) :usual practice
62340840|NCT00669916|EXPERIMENTAL|AIN457|AIN457A 3mg/kg was administered intravenously as a single dose.
62698102|NCT06632171|EXPERIMENTAL|psychoeducation 9|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
61946801|NCT01601860|ACTIVE_COMPARATOR|Control|Active Comparator: Control Group Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
61946802|NCT01601860|EXPERIMENTAL|Intervention Group|Experimental: Intervention Group Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: Walking (with cervical dilation between 4 and 5 cm) Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm) Shower (with dilation\> 7 cm);
62340841|NCT00669916|PLACEBO_COMPARATOR|Placebo|Placebo was administered intravenously as a single dose.
62340842|NCT04914741|EXPERIMENTAL|Glofitamab plus R-CHOP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by R-CHOP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
61946803|NCT03542123|EXPERIMENTAL|NeuroTronik CANS Therapy® System|
62340843|NCT04914741|EXPERIMENTAL|Glofitamab plus polatuzumab vedotin-RCHP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by polatuzumab vedotin-RCHP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
62340844|NCT06110299|EXPERIMENTAL|patients with obstructed ureters|
62497114|NCT06348316|EXPERIMENTAL|Half swaddle|
62497115|NCT06348316|EXPERIMENTAL|Kangaroo care|
62497116|NCT06348316|EXPERIMENTAL|Half swaddle+Kangaroo care|
61946804|NCT02495831|EXPERIMENTAL|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
61946805|NCT02495831|ACTIVE_COMPARATOR|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
61946806|NCT03823508|ACTIVE_COMPARATOR|anodal tDCS|Patients will receive anodal tDCS (left dorsolateral prefrontal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
61946807|NCT03823508|PLACEBO_COMPARATOR|sham tDCS|Patients will receive sham tDCS (15 secondes of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
62340845|NCT03829865||Water-perfused HREM|Healthy volunteers examined with water-perfused high resolution esophageal manometry
62340846|NCT03829865||Solid-state HREM|Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter
62497117|NCT05543395||The group accepting to report|
62497118|NCT05543395||The group refusing to report|
62497119|NCT05654025||Non-surgical group: Refractive change, ocular parameter changes, and prognosis without surgery|To evaluate the long-term changes in refractive state, ocular parameter, ocular development and visual prognosis in patients without congenital ectopia lentis surgery.
62698103|NCT06632171|EXPERIMENTAL|psychoeducation 10|Cognitive behavioral therapy- based and motivational interviewing supported psychoeducation will be applied to obese individuals in this group.
62698104|NCT06570161|EXPERIMENTAL|SEEUS95|Transparent mask developed by SEEUS95
62698105|NCT06570161|EXPERIMENTAL|CrystalGuard|Transparent mask developed at BWH
62698106|NCT06570161|ACTIVE_COMPARATOR|N95|Standard N95 face mask
61946808|NCT02754557|EXPERIMENTAL|Breath-Focused Meditation|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation.
61946809|NCT02754557|EXPERIMENTAL|Breath-Focused Meditation + Physiological Feedback|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation and physiological feedback.
61946810|NCT00431288|EXPERIMENTAL|DASH intervention|The DASH diet used in this intervention was slightly modified from the original version of the DASH diet for adults to more closely conform to the unique nutritional needs of adolescents. Details of the intervention have been published (Couch, SC et al. J Pediatrics 2008; 152: 494-501)
61946811|NCT00431288|OTHER|Routine Care|Routine care did not deviate from the nutrition counseling that was routinely given to all new patients at the Cincinnati Children's Hypertension Clinic. Details of routine care have been published (Couch, SC et al. J Pediatrics 2008; 152: 494-501)
61946812|NCT03789396||Pre-implementation|The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
61946813|NCT03789396||Post-implementation|The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.
62497120|NCT05654025||Surgical group: Safety and efficacy of different congenital ectopia lentis surgeries|To compare the safety and efficacy of different congenital ectopia lentis surgeries, including phacoemulsification， phacoemulsification + Intraocular lens (IOL) implantation， phacoemulsification + IOL implantation + Capsular Tension Ring implantation or phacoemulsification + IOL implantation + transscleral fixation.
62698107|NCT05175729||Pregnant Group|First trimester pregnant group would be included and will be followed up in second, third trimesters and after pregnancy
62698108|NCT05175729||Control group|Age-, sex-matched healthy volunteers
62698109|NCT01422577|ACTIVE_COMPARATOR|Bright Narrow Band Imaging|Bright Narrow Band Imaging
62698110|NCT01422577|ACTIVE_COMPARATOR|White Light Endoscopy|White Light Endoscopy
62698111|NCT06645418|ACTIVE_COMPARATOR|Diabetic group|100 randomly selected older adults with DM II, of both sexes who are attending endocrine outpatient clinics in governmental hospitals.
62698112|NCT06645418|ACTIVE_COMPARATOR|non diabetic group|100 older adults non diabetic, of both sexes who are attending endocrine outpatient clinics in governmental hospitals.
62698113|NCT05837481|EXPERIMENTAL|Meditation Group|Two sessions of guided meditation on the day of surgery, both to occur before the start of surgery
62698114|NCT05837481|NO_INTERVENTION|Control Group|Standard of care, which does not involve any meditation programs
62698115|NCT06138418|EXPERIMENTAL|Longitudinal cohort study|Longitudinal cohort study
62698116|NCT04197232||exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
62698117|NCT04197232||not exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
62698118|NCT06547632|ACTIVE_COMPARATOR|1. RIRS WITH VACUUM-ASSISTED URETERAL ACCESS SHEATH|"In Arm 1, participants will undergo RIRS with ClearPetra™ vacuum-assisted ureteral access sheath.~Participants will undergo RIRS per standard of care."
62698119|NCT06547632|NO_INTERVENTION|2. RIRS WITH TRADITIONAL APPROACH|"In Arm 2, participants will undergo RIRS a traditional approach (no sheath or non-vacuum-assisted sheath). The treating investigator will decide whether to use a regular UAS based on their preference and/or availability.~* No ureteral access sheath~* Navigator™ Ureteral Access Sheath 11/13 Fr (Boston Scientific®)~* Navigator™ Ureteral Access Sheath 12/14 Fr (Boston Scientific®)"
62698120|NCT06643065||Group-1|normal microbiome
62698121|NCT06643065||Group-2|dysbiotic microbiome
62698122|NCT05488522|EXPERIMENTAL|study treatment plan|Patients will be enrolled in a Rolling 6 clinical trial design1. This study design retains sensitivity to identifying DLTs while having the benefit of decreasing accrual time given the long DLT period required to assess radiation toxicity. In this trial design, up to 6 patients can be enrolled at a time onto a dose level while awaiting DLT assessment. Established rules guide the decision for enrolling onto the current, next highest, or previous dose level based on the number of participants currently enrolled in a given cohort, the number of radiation-attributable dose-limiting toxicities (ra-DLTs) observed, and the number of patients with immature toxicity data. If the MTD is not reached after 6 patients have enrolled on dose level 3 (three 17Gy fractions of SBRT) and have completed toxicity evaluations, then the recommended phase 2 dose will be determined based on an analysis of the efficacy of the combination
61946814|NCT02869607||Patients with breast cancer diagnosis|
61946815|NCT05491720|EXPERIMENTAL|tDCS group|TDCS intervention protocol consists of 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days. Anodal electrode will be placed over the left dorsolateral prefrontal cortex and cathodal electrode will be placed over the right supraorbital area.
61946816|NCT05491720|EXPERIMENTAL|Medication group|Participants in this group will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
61946817|NCT05491720|PLACEBO_COMPARATOR|Control group|Participants in this group undergo 10 daily sessions of sham tDCS concurrent with placebo tablets ( Galenus pharmaceutical company) for 10 consecutive days.
61946818|NCT03821909||Pancreatic cancer|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology.
61946819|NCT03821909||Benign pancreatic diseases|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology, e.g. PCLs.
61946820|NCT01811680|EXPERIMENTAL|supervised treadmill training|Supervised treadmill training on variable sensing treadmill.
61946821|NCT02261454|NO_INTERVENTION|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
62698123|NCT06230913|EXPERIMENTAL|Kinesiotaping group|To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
62698124|NCT06230913|ACTIVE_COMPARATOR|Pressure garment group|The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
61946822|NCT02261454|ACTIVE_COMPARATOR|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
61946823|NCT00569465|PLACEBO_COMPARATOR|A|
62497121|NCT02463630|EXPERIMENTAL|Compression distraction reduction|All the participants in this group will be performed Posterior Compression Distraction Reduction Technique for reduction of basilar invagination and atlantoaxial dislocation
62497122|NCT03236363|EXPERIMENTAL|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
62698125|NCT04723719|EXPERIMENTAL|SIESTA training + treatment as usual for ADHD|We developed a cognitive behavioral therapy for sleep problems in adolescents with ADHD. This includes seven individual sessions with the adolescent and two individual sessions with the parent(s)/guardian(s). Participants receive this CBT training called SIESTA next to their treatment as usual for ADHD symptomatology (mostly ADHD-medication).
62497123|NCT03236363|NO_INTERVENTION|Control|No intervention
62698126|NCT04723719|ACTIVE_COMPARATOR|Treatment as usual for ADHD only|Participants continue their treatment as usual for ADHD (mostly ADHD-medication).
62698127|NCT06565013||CHEERS main|"Switch from daily oral ART to Cabenuva, administered IM every two months.~* Cabotegravir: 200mg/ml, 3ml per dose~* Rilpivirine: 300mg/ml, 3ml per dose"
62698128|NCT06516198|EXPERIMENTAL|Experimental Group|"A random number card will be drawn in sequence from a box. Even numbered cards will assign the patient to the experimental group, odd numbered cards will assign the patient to the control group.~o Intervention group seed points:~1. Shen Men (anxiety, depression, stress, pain)~2. Point 0 (homeostasis, energy, mood)~3. Endocrine (hormonal homeostasis)~4. Subcortex (insomnia, anxiety, pain, inflammation)~5. Autonomic (autonomic balance, pain)"
61946824|NCT00569465|EXPERIMENTAL|B|
61946825|NCT01865097|EXPERIMENTAL|Relaxation guided imagery|
61946826|NCT01865097|ACTIVE_COMPARATOR|Relaxing music|
61946827|NCT02601027|EXPERIMENTAL|0.125% Bupivacaine|0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter
61946828|NCT02601027|PLACEBO_COMPARATOR|Placebo|Saline infusion (sham) via transversus abdominis plane (TAP) catheter.
61946829|NCT03455127|NO_INTERVENTION|Classic Public Works as Usual|Half of the sample will be eligible to receive or be receiving the Government of Rwanda's (GOR) flagship social protection programming, Vision 2020 Program (VUP). One component of this program is to provide cash for work opportunities for labor endowed vulnerable households, i.e. one able bodied adult. Vulnerable households are those in Poverty Level 1 category, the GOR's poverty classification system. Furthermore, this study will require households in the control group receiving classic public works as usual to have at least one child between the ages of 6 months to 36 months.
61946830|NCT03455127|EXPERIMENTAL|Classic Public Works + FSI ECD|Half of the sample will receive the FSI ECD home visiting parenting program alongside the GOR's classic public works programming. These households will be in Poverty Level 1 with an able-bodied adult, thus eligible to receive or be received the GORs public works programming. They will have a child between 6 and 36 months at enrollment. Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
62140200|NCT01412606|EXPERIMENTAL|Scrathcing|scratching of endometrium on day 21-26 of a spontaneous menstrual cycle
62140201|NCT01412606|PLACEBO_COMPARATOR|Control|Uterine sounding on day 21-26 of a spontaneous menstrual cycle
62497124|NCT03236363|EXPERIMENTAL|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
62497125|NCT06316180|NO_INTERVENTION|Control|Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
62497126|NCT06316180|ACTIVE_COMPARATOR|Intervention|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
62497127|NCT00834236|EXPERIMENTAL|gastric cancer|gastric cancer patients
62497128|NCT00834236|ACTIVE_COMPARATOR|normal subject|healthy subject
62698129|NCT06516198|SHAM_COMPARATOR|Control Group|"A random number card will be drawn in sequence from a box. Even numbered cards will assign the patient to the experimental group, odd numbered cards will assign the patient to the control group.~o Control group sham seed points:~1. Inside edge, center of tragus~2. Helix midway between apex and tubercle~3. Helix 1 cm anterior to apex~4. 5 mm anterior to Shen Men~5. Covered, 5 mm anterior and superior to endocrine~For the sham intervention (Sham Type II, same intervention with seeding and intermittent pressing) the seeds are placed at nonacupressure points for the control group."
62698130|NCT01334255|EXPERIMENTAL|0.5 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
61946831|NCT06292234|EXPERIMENTAL|patient specific implants|Custom made designed implants
62140202|NCT04603508|EXPERIMENTAL|Berlim 25/10|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
62497129|NCT00725764|EXPERIMENTAL|Single Arm|Participants who qualified for study entry received 240 mg of GSK1363089 (foretinib) on a 5-day on 9-day off schedule every 2 weeks.
62497130|NCT03947398|EXPERIMENTAL|Treatment with BLIMP first|
61946832|NCT06292234|ACTIVE_COMPARATOR|miniplates|Over the counter miniplates
61946833|NCT03022435|OTHER|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
61946834|NCT03022435|OTHER|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
61946835|NCT03022435|OTHER|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
61946836|NCT03022435|OTHER|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
61946837|NCT03022435|OTHER|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
61946838|NCT00537004||PPA (Primary Progressive Aphasia)|Individuals with primary progressive aphasia
61946839|NCT00537004||Control|Individuals with no diagnosis of any type of dementia
61946840|NCT00752102|ACTIVE_COMPARATOR|Calcitriol|"Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Calcitriol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/ml of calcitriol. All dosage forms contain butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) as antioxidants.~Subjects taking calcitriol started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels."
61946841|NCT00752102|ACTIVE_COMPARATOR|Paricalcitol|"Paricalcitol, USP, the active ingredient in Zemplar® Capsules, is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Zemplar is available as soft gelatin capsules for oral administration containing 1 mcg, 2 mcg or 4 mcg of paricalcitol. Each capsule also contains medium chain triglycerides, alcohol, and butylated hydroxytoluene.~Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels."
61946842|NCT05070195|EXPERIMENTAL|The DDI of SKLB1028 and Midazolam|Eligible subjects received a single dose of Midazolam 15 mg on Day 1, and took a single dose of Midazolam 15 mg and a single dose of SKLB1028 150 mg with dosing interval of 0.5 h on Day 3.
62698131|NCT01334255|EXPERIMENTAL|2.0 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
62698132|NCT06312930|EXPERIMENTAL|Real TPS group|"1. Healthy adults aged 18-65 years old will receive one single session of real TPS on the primary motor cortex.~2. Before and after TPS, participants will perform two visuomotor tasks (a simple reaction time task and a nine-hole peg test).~3. The stimulation target on the primary motor cortex will be determined by transcranial magnetic stimulation (TMS). Measurements of the resting motor threshold by TMS will be conducted for each participant before the real TPS session."
62698133|NCT06312930|SHAM_COMPARATOR|Sham TPS group|"Sham stimulation comprises TPS on the vertex as the control region (sham control).~Stimulation duration, intensity, as well as pre- and post stimulation assessments are the same as in the experimental arm.~In this cross-over study, the order of the real and sham stimulation conditions will be randomized and separated by 24 hours."
61946843|NCT05406648|EXPERIMENTAL|Intervention|20g of Morus nigra concentrate administration for 12 weeks
61946844|NCT05406648|NO_INTERVENTION|Control|No intervention throughout the study
61946845|NCT02718066|EXPERIMENTAL|HBI-8000 in combination with nivolumab|HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.
61946846|NCT01952145|EXPERIMENTAL|Insulin degludec/liraglutide OD plus metformin|
61946847|NCT01952145|ACTIVE_COMPARATOR|Insulin glargine OD plus metformin|
61946848|NCT01810861||Serotype distribution (this is a non-interventional study)|Serotype distribution both in pediatrics and adults (this is a non interventional study)
61946849|NCT02044445|ACTIVE_COMPARATOR|36 h group|Oocyte retrieval will be performed 36 hours after hCG administration
61946850|NCT02044445|ACTIVE_COMPARATOR|38 h group|Oocyte retrieval will be performed 38 hours after hCG administration
61946851|NCT02081287|ACTIVE_COMPARATOR|Lamotrigine|As adjunct to lithium therapy
61946852|NCT02081287|EXPERIMENTAL|IP6|As adjunct to lithium therapy
61946853|NCT05138211|EXPERIMENTAL|Hemiparetic patients|Patients with hemiparetic gait who will be assisted by the exoskeleton action
61946854|NCT04442412|EXPERIMENTAL|Arm B (Experimental):|"Patients randomized to Arm B will receive a prephase with oral prednisone and a prephase therapy with VitD according to the below reported schedule followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~Schedule for VitD supplementation: 25,000 U/day starting on day -6:~daily loading dose for 7 days if 25 VitD baseline level 20-40 ng/ml daily loading dose for 14 days if 25 VitD baseline level \< 20 ng/ml followed by weekly maintenance supplementation of 25,000 U for the entire duration of immunochemotherapy (6 courses every 21 days - 18 weeks), regardless of the baseline level of 25 VitD."
62140203|NCT04603508|ACTIVE_COMPARATOR|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association placebo, oral;~1 tablet empagliflozin , oral;~1 tablet rosuvastatin calcium, oral."
62140204|NCT01332175|ACTIVE_COMPARATOR|Provent|
62140205|NCT01332175|PLACEBO_COMPARATOR|Placebo-Provent|
62698134|NCT02743741|EXPERIMENTAL|Lutetium-177 Octreotate|Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
62140206|NCT01332175|ACTIVE_COMPARATOR|CPAP|
62698135|NCT04073420||Surgical Valve Replacement and/or Repair Patients|
62698136|NCT01531335|ACTIVE_COMPARATOR|Standard care|Patients will receive normal nutritional regime of around 25 kcal per kg.
62698137|NCT01531335|EXPERIMENTAL|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg
62698138|NCT00600496|EXPERIMENTAL|1|AZD6244 + docetaxel
62140207|NCT02111096|EXPERIMENTAL|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
62140208|NCT02111096|ACTIVE_COMPARATOR|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
62698139|NCT00600496|EXPERIMENTAL|2|AZD6244 + Dacarbazine
62497131|NCT03947398|ACTIVE_COMPARATOR|Treatment with low-profile balloon first|
62698140|NCT00600496|EXPERIMENTAL|3|AZD6244 + Erlotinib
62497132|NCT02888743|EXPERIMENTAL|Cohort 1, Arm A (tremelimumab, durvalumab, HD-RT)|Patients receive tremelimumab and durvalumab and as in Arm C. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.
62497133|NCT02888743|EXPERIMENTAL|Cohort 1, Arm B (tremelimumab, Durvalumab, LD-RT)|Patients receive tremelimumab and durvalumab and as in Arm C. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.
62698141|NCT00600496|EXPERIMENTAL|4|AZD6244 + Temsirolimus
61946855|NCT04442412|OTHER|Arm A (Standard arm)|"Patients randomized to Arm A will receive a prephase with oral prednisone followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~If patients randomized to arm A are already on VitD, they are allowed to continue receiving VitD supplementation at a dose that can be considered part of the standard of care and does not exceed the maximum standard VitD dose recommended for general adult and elderly population , up to 10,000 U/week VitD"
61946856|NCT02555774|EXPERIMENTAL|cognitive training|Cognitive training programs 2 times a week for 3 months (totally 24 sessions) for 90 minutes per session. Lifestyle modification is educated first, then weekly phone call for lifestyle modification is done by investigators.
61946857|NCT02555774|ACTIVE_COMPARATOR|lifestyle modification|This group receives only lifestyle modification for 3 months. Lifestyle modification is educated at the first, then weekly phone call for lifestyle modification is done by investigators. The method of lifestyle modification is same with the first arm.
61946858|NCT02555774|NO_INTERVENTION|No intervention|This group receives no intervention.
61946859|NCT05409495|EXPERIMENTAL|The control group treated with open flap debridement (OFD)|The control group periodontal intrabony defects were treated with open flap debridement (OFD) only.
61946860|NCT05409495|EXPERIMENTAL|The test group treated with OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF)|The test group periodontal intrabony defects were treated with open flap debridement (OFD) with autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF) combined.
61946861|NCT00876421|PLACEBO_COMPARATOR|P|
61946862|NCT00876421|ACTIVE_COMPARATOR|A|
61946863|NCT00876421|EXPERIMENTAL|E1|
61946864|NCT00876421|EXPERIMENTAL|E2|
61946865|NCT00876421|EXPERIMENTAL|E3|
61946866|NCT00968864|EXPERIMENTAL|CliniMACS® (T cell depletion)|Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
61946867|NCT04150055|EXPERIMENTAL|Intervention|Everyone in the study will get Mindfulness Coach and an orientation session. Mindfulness Coach is a self-guided mHealth intervention designed to help individuals learn MT, an evidence-based treatment to enhance health, wellness and mental health. The intervention will be introduced during 1 in-person session by a trained research assistant with 1-2 booster instructional phone call at 7 and 14-days to ensure that the participant knows how and is encouraged to use the app. The participant will also be provided with a laminated card that provides the basic instructions. We will encourage the participant to use Mindfulness Coach weekly for 8 weeks, or more if desired, as this treatment dose is commensurate with most in-person MT psychotherapy treatment protocols.
61946868|NCT05834569|EXPERIMENTAL|Maxigesic group|
61946869|NCT05834569|PLACEBO_COMPARATOR|Control group|
61946870|NCT05660226|EXPERIMENTAL|Intervention|Home blood pressure monitoring + E-coaching
61946871|NCT05660226|PLACEBO_COMPARATOR|Control|Standard care in patients with hypertension
61946872|NCT04104230||Individuals Affected With Pancreatic Cancer|Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
61946873|NCT04104230||Individuals Affected with Related Cancer|Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
61946874|NCT04104230||Individuals Affected With Pancreatic Neoplasm|Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
61946875|NCT04104230||High-Risk Individuals|Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
62140209|NCT02111096|PLACEBO_COMPARATOR|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
61946876|NCT04104230||Healthy Controls|Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
61946877|NCT03277690|EXPERIMENTAL|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
61946878|NCT03277690|PLACEBO_COMPARATOR|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
61946879|NCT01858571|EXPERIMENTAL|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
62497134|NCT02888743|EXPERIMENTAL|Cohort 1, Arm C (tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.
62497135|NCT02888743|EXPERIMENTAL|Cohort 2, Arm A (tremelimumab, durvalumab, HD-RT)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.
62497136|NCT02888743|EXPERIMENTAL|Cohort 2, Arm B (tremelimumab, durvalumab, LD-RT)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.
62497137|NCT05544656|EXPERIMENTAL|Tolperisone|Tolperisone 3 times 150 mg daily, i.e. a daily dose of 450 mg. Treatment lasts for 14 days
61946880|NCT01858571|PLACEBO_COMPARATOR|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)~* Capsules of same size and color as used in metronomic therapy Best supportive care~* Management of pain as per WHO standard for pain management"
61946881|NCT01660204|ACTIVE_COMPARATOR|Betalactam monotherapy|Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone
61946882|NCT01660204|ACTIVE_COMPARATOR|Betalactam combination with macrolide|Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin
61946883|NCT01660204|ACTIVE_COMPARATOR|Quinolone monotherapy|Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin
61946884|NCT02423993|EXPERIMENTAL|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
61946885|NCT02423993|ACTIVE_COMPARATOR|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
61946886|NCT02423993|EXPERIMENTAL|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
61946887|NCT02423993|ACTIVE_COMPARATOR|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
61946888|NCT03028103|EXPERIMENTAL|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
61946889|NCT04915898|ACTIVE_COMPARATOR|Oral Care Hygiene Intervention Group|Providing oral care kits designed to facilitate adherence to brushing teeth after meals and before sleep. Providing continuous education and feedback on performance to team members on the interventional units. Encouraging patients to brush their teeth and use the kits or own materials if desired.
61946890|NCT04915898|NO_INTERVENTION|Control group - standard of care oral care on units|These units will perform their 'usual' or standard of care for oral hygiene practices without use of the oral care kits, no encouragement to perform outside of usual care
61946891|NCT02153333||HRV Group|Subjects who had received 2 doses of HRV vaccine in previous studies.
61946892|NCT02153333||Placebo Group|Subjects who had received 2 doses of placebo in previous studies.
61946893|NCT03282370|EXPERIMENTAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
62497138|NCT05544656|PLACEBO_COMPARATOR|Placebo|Matching placebo 3 times daily. Treatment lasts for 14 days
62497139|NCT03908307|EXPERIMENTAL|Study Eye|OZURDEX implant 700 μg
62698142|NCT05493657|ACTIVE_COMPARATOR|Aspirin group|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
61946894|NCT03282370|ACTIVE_COMPARATOR|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
61946895|NCT06541847|EXPERIMENTAL|HLX-1502|Participants will take an oral dose three times a day (with or without food) for 12 cycles. A cycle is defined as 28 days. Participants with a partial response or stable disease with a previously progressive tumor and/or clinical improvement can continue therapy for an additional 12 cycles for a total of 24 cycles.
61946896|NCT03951155|EXPERIMENTAL|ADHD Group|Muscle Relaxation technique for behavioral management
61946897|NCT03951155|NO_INTERVENTION|Tell Show Do Group|Tell Show Do Technique for behavioral management
62340847|NCT05801809|EXPERIMENTAL|Active taVNS|TaVNS will be administered by an earset, with conductive eartips placed on the auricular concha of the ears, connected to a stimulator, and during active stimulation, we stimulate both the cymba conchae and external auditory canal of both left and right ears with the following parameters: 30Hz, 200-250 us, and with adjustable intensity for 60 min.
62340848|NCT05801809|SHAM_COMPARATOR|Sham taVNS|Sham condition will have the same device, with an earset, and conductive eartips placed in the same location of the active stimulation; however during 60 min there will be no current and the device will be turned off.
61946898|NCT02505763|EXPERIMENTAL|Strategy with thoracic ultrasound|"* Use of thoracic ultrasound for the treatment of pleural effusion, treatment and monitoring.~* Use of other examinations like chest CT if necessary"
62340849|NCT01600768|ACTIVE_COMPARATOR|intermittent infusion|
62340850|NCT01600768|EXPERIMENTAL|extended infusion|
62340851|NCT06211530|EXPERIMENTAL|SpO2 Measurements - All Subjects|Participants participating in this study will be connected to eight (8) Portrait Mobile P-SA01PL/P-SP01PL prototype sensors provided by GEHC and two reference monitors, Nellcor N-600X V 1.6.0.0 and a forehead sensor, used as standard operating procedures at the site. Data will be collected using the Portrait Hub patient monitor. The participants are exposed to a desaturation protocol that sequentially decreases the SpO2 in a stepwise fashion. The goal is to achieve six stable oxygenation plateaus between 100 and 70% SpO2, while recording simultaneous SpO2 readings from the prototype and reference devices. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
62340852|NCT04832919|EXPERIMENTAL|Nurse-Community Health Worker-Family Partnership|The experimental arm will receive the Nurse-Community Health Worker-Family Partnership intervention
62497140|NCT04859140|EXPERIMENTAL|Foam rolling|The foam rolling routine consisted in unilateral exercises alternatively performed on both legs and bilateral exercises on lower and back muscles. All participants started with the feet in a standing up position with a lacrosse ball. Then, participants performed on the ground the foam rolling exercises with the foam roller targeting leg and back muscles.
62698143|NCT05493657|EXPERIMENTAL|Clopidogrel group|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
61946899|NCT02505763|NO_INTERVENTION|Strategy without thoracic ultrasound|"* Usual care : without thoracic ultrasound~* Use of chest radiography or chest CT scan if necessary, as for treatment and monitoring.~Usual care: without the use of ultrasound Using either chest radiography or TDM if necessary, as for treatment and monitoring."
62698144|NCT05025865|PLACEBO_COMPARATOR|HA35 Placebo Group|12 study participants will be given a placebo capsule to take once per day in the morning with breakfast for 3 days.
61946900|NCT00251212|ACTIVE_COMPARATOR|1|Therapist delivered adapted motivational enhancement therapy and skills training
61946901|NCT00251212|ACTIVE_COMPARATOR|2|Computer delivered adapted motivational enhancement therapy and skills training
61946902|NCT00251212|NO_INTERVENTION|3|3: Control brochure
61946903|NCT02400229|EXPERIMENTAL|Computed Tomography Angiography (CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography
61946904|NCT02400229|ACTIVE_COMPARATOR|Invasive coronary angiography (ICA)|Invasive coronary angiography
61946905|NCT04628741|ACTIVE_COMPARATOR|Dynamic Coaching Model|The Dynamic Coaching Model is an established treatment approach that entails training college students with executive function impairments (e.g., those with a history of traumatic brain injury) to rely on their own executive functions in order to problem solve and reason in real-life situations requiring them to do so (e.g., taking college classes).
61946906|NCT04628741|EXPERIMENTAL|Apprenticeship Approach for College Students|The Apprenticeship Approach is a novel treatment approach that incorporates explicit education about: (a) traumatic brain injury definition; (b) traumatic brain injury symptomatology; and (c) individuals who may be able to provide assistance to the individual with traumatic brain injury into the existing Dynamic Coaching Model.
61946907|NCT05856188|EXPERIMENTAL|Group I (Test group):|Will include twenty patients receiving Glutamine oral suspension (5 grams of glutamine and 5 g maltodextrin dissolved in cold water) 30 min before a meal, 3 times per day through swish and swallow technique25 throughout the radiotherapy period.
61946908|NCT05856188|PLACEBO_COMPARATOR|Group II (Control group)|Included twenty patients receiving maltodextrin oral suspension (5 g maltodextrin dissolved in cold water) 30 min before a meal, 3 times per day through swish and swallow technique throughout the radiotherapy period along with general measures as well as analgesic drugs according to the WHO scale.
61946909|NCT00810914|EXPERIMENTAL|1|Continuous epidural infusion of medication for method of pain relief
61946910|NCT00810914|EXPERIMENTAL|2|continuous epidural infusion in conjuction with patient controlled anesthesia (PCA)
61946911|NCT00810914|EXPERIMENTAL|3|patient controlled anesthesia only this arm has pt controlled medication delivery. (PCA)
61946912|NCT01685944|PLACEBO_COMPARATOR|Placebo|
61946913|NCT01685944|EXPERIMENTAL|Live Pediococcus pentosaceus LP28|
61946914|NCT01685944|EXPERIMENTAL|Heat-killed Pediococcus pentosaceus LP28|
61946915|NCT05708170|EXPERIMENTAL|Intravenous iron therapy group|This group will receive intravenous iron calculated based on body weight and level of anaemia (hemoglobin concentration), as per the iron therapy's SPC.
61946916|NCT05708170|ACTIVE_COMPARATOR|Active Control Group|This group will receive oral ferrous sulphate prescribed by their GP Randmisation: Simple randomisation/parallel assignment/single-blinded
61946917|NCT03985254|ACTIVE_COMPARATOR|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]), and in subsequent weeks the goal will be the development of muscle strength (load\> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
61946918|NCT03985254|EXPERIMENTAL|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]). However, in subsequent weeks the goal will be to develop strength (load\> 70% 1RM) and muscle power (load between 40-60% 1RM).
61946919|NCT05414877|EXPERIMENTAL|Ephedrine|receive ephedrine (configured concentration 2 mg/mL). The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
61946920|NCT05414877|EXPERIMENTAL|Phenylephrine|receive intravenous infusion of phenylephrine (configured concentration 0.1 mg/mL) The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
61946921|NCT05414877|EXPERIMENTAL|norepinephrine|intravenous infusion of norepinephrine (configured concentration of 6 μg/ml).The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
61946922|NCT02609828|EXPERIMENTAL|Arm 1|Tanezumab 20 mg subcutaneously
61946923|NCT02609828|PLACEBO_COMPARATOR|Arm 2|Placebo matched to active treatment subcutaneously
61946924|NCT05462483|EXPERIMENTAL|Rice sock and instructions to heat quadriceps|Receives heating device and instructions to heat the quadriceps musculature.
61946925|NCT05462483|NO_INTERVENTION|No heating device or instructions to heat quadriceps|WIll not receive heating device or instructions to heat quadriceps musculature.
62497141|NCT04859140|EXPERIMENTAL|Manual massage|Participants in the manual massage group received manual massage by a professional physiotherapist who was blinded to the purpose of the experiment (20 years of registered practice). Participants were lying in the prone position on a massage table. To facilitate the physiotherapist's maneuvers, massage oil was used. The manual massage protocol reproduced several features of the foam rolling intervention, i.e., order of the areas massaged, massage time per muscles and total duration of the session.
62698145|NCT05025865|ACTIVE_COMPARATOR|HA35 Treatment Group|12 study participants will be given an HA35 capsule to take once per day in the morning with breakfast for 3 days.
61946926|NCT02281773|EXPERIMENTAL|dose 1|
61946927|NCT02281773|EXPERIMENTAL|dose 2|
61946928|NCT02281773|EXPERIMENTAL|dose 3|
61946929|NCT02281773|EXPERIMENTAL|dose 4|
61946930|NCT02281773|PLACEBO_COMPARATOR|placebo|
61946931|NCT01529047|EXPERIMENTAL|In-person PFI|In-person personalized feedback intervention
61946932|NCT01529047|EXPERIMENTAL|Web-based PFI|Web-based personalized feedback intervention
61946933|NCT01529047|NO_INTERVENTION|Assessment Only|Complete online survey assessments only.
61946934|NCT03358797|EXPERIMENTAL|intervention-HPP|Community participants will participate in a group-based lifestyle intervention based on the CDC Diabetes Prevention Program, and adapted to the Arabic language, Arab culture, Mediterranean Diet, and adapted to include empowerment, leadership and emotion regulation.
61946935|NCT03358797|EXPERIMENTAL|CBLI+RT|based on randomization, group that will be assigned to CBLI+RT will receive the CBLI curriculum (as described in the intervention-HPP arm) in addition to the resiliency training
61946936|NCT03358797|EXPERIMENTAL|Attention control (CBLI-)|The attention control group will receive the core curriculum of the CBLI (as described in the intervention-HPP arm) only without the resiliency training. The sessions of the resiliency training will be replaced with sessions on health topics that do not contribute to our outcome (increased resiliency) (i.e. breast cancer, osteoporosis)
61946937|NCT03358797|EXPERIMENTAL|Pilot|This group will not be randomized. The group will receive the CBLI content (as described in the intervention-HPP arm) in addition to the resiliency training. The aim of this pilot is to create a resiliency training manual to be implemented in the following groups that will be assigned to receive the CBLI+RT
61946938|NCT01919138||severe sepsis, septic shock|
61946939|NCT02713373|EXPERIMENTAL|Arm I (cetuximab and pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.
61946940|NCT02829255|EXPERIMENTAL|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
62340853|NCT04832919|NO_INTERVENTION|Standard of Care|The control arm will receive standard access to NYC Department of Health COVID-19 testing sites and standard COVID-19 public health messaging
62497142|NCT04859140|ACTIVE_COMPARATOR|Autogenic relaxation|Participants in the relaxation group listened to a 16 min relaxation audio tape, based on the autogenic training method. Participants were lying on the massage table in supine position, wearing headphones. During this desensitization-relaxation technique, they were guided to visualize bodily perceptions of heaviness and warmth in their arms, thorax and legs. To facilitate concentration, participants were left alone in a dark room.
62497143|NCT01704534|EXPERIMENTAL|Ustekinumab|Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28
61946941|NCT04511104|ACTIVE_COMPARATOR|Standard of Care|"Standard of care treatment:~- including passive / assisted / active movements, stretching, functional exercise, scar treatment~Duration: up to 8 weeks"
61946942|NCT04511104|EXPERIMENTAL|Exercise|"Standard of care + added exercises~Exercise type: resistance and aerobic exercise~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)~Duration: up to 8 weeks"
61946943|NCT02965300||Primary lung cancer|patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
61946944|NCT02965300||Benign lung lesion|Patients diagnosed with pulmonary benign diseases.
61946945|NCT02965300||Healthy control|Patients without any pulmonary abnormal symptoms or diseases
61946946|NCT05324722|EXPERIMENTAL|PPCS|Novel intervention
61946947|NCT05324722|ACTIVE_COMPARATOR|CBS|Cross arm stretch gave to individuals
61946948|NCT03745807|EXPERIMENTAL|Combination|NKTR-214 + nivolumab
61946949|NCT06009731||adult patients undergoing mechanical ventilation|
61946950|NCT05231304||Total Talus Replacement|
62698146|NCT02985944||Standard scope-short time|Standard colonoscopy with unmonitored withdrawal time
62698147|NCT02985944||FUSE scope-short time|Wide-angle colonoscopy with unmonitored withdrawal time
62698148|NCT02985944||Standard scope-long time|Standard colonoscopy with monitored withdrawal time
62698149|NCT02985944||FUSE scope-long time|Wide-angle colonoscopy with monitored withdrawal time
62698150|NCT04272034|EXPERIMENTAL|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
61946951|NCT05231304||Total Ankle Total Talus Replacement|
61946952|NCT05231304||Total Ankle Total Talus Replacement + Subtalar Fusion|
61946953|NCT05231304||Total Talus Replacement + Subtalar Fusion|
61946954|NCT06322069|EXPERIMENTAL|Self-compassion intervention group|The intervention group was granted access to a 14-day course focused on the theme of self-compassion. Participants within this group were encouraged to engage with one module per day, and completion of the entire course within a 21 days.
61946955|NCT06322069|NO_INTERVENTION|waitlist group|The waitlist group received no course.
62140210|NCT06383572|EXPERIMENTAL|Phase 1 (Dose Escalation and Dose Expansion)|"Participants will be assigned to a dose level of the NK cell treatment based on when you join this study. Up to 4 dose levels of the treatment will be tested.~The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of the NK cell treatment is found."
62340854|NCT01523314|EXPERIMENTAL|dexamethasone - Cyclodextrin|
62340855|NCT01523314|ACTIVE_COMPARATOR|Avastin/Laser|
62497144|NCT04850027||Lower rectal cancer patients with a LLN ≥ 5mm|Patients with lateral lymph node short diameter ≥ 5mm evaluated by MRI were included.
62497145|NCT01643239|EXPERIMENTAL|Hospital-based mCIT with individualized intervention|Hospital-based modified constraint-induced therapy(mCIT)
62497146|NCT01643239|EXPERIMENTAL|Hospital-based mCIT with group therapy|Hospital-based modified constraint-induced therapy(mCIT)
62497147|NCT01643239|OTHER|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
62497148|NCT04763473|PLACEBO_COMPARATOR|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
62497149|NCT04763473|EXPERIMENTAL|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
62497150|NCT05003882||Arm A|Commercially available, orally ingestible CBD product A
62497151|NCT05003882||Arm B|Commercially available, orally ingestible CBD product B
62497152|NCT05003882||Arm C|Commercially available, orally ingestible CBD product C
62497153|NCT05003882||Arm D|Commercially available, orally ingestible CBD product D
62497154|NCT05003882||Arm E|Commercially available, orally ingestible CBD product E
62497155|NCT05003882||Arm F|Commercially available, orally ingestible CBD product F
62497156|NCT05003882||Arm G|Commercially available, orally ingestible CBD product G
62497157|NCT05003882||Arm H|Commercially available, orally ingestible CBD product H
62698151|NCT04272034|EXPERIMENTAL|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
62698152|NCT04272034|EXPERIMENTAL|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
62698153|NCT02626884|EXPERIMENTAL|Ibrutinib|All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
62698154|NCT06642727|EXPERIMENTAL|the group undergoing laughter yoga|"Laughter Yoga is a complementary therapy that combines fake and genuine laughter with yoga and breathing exercises, including neck and shoulder exercises. It does not involve humor and is non-pharmacological and non-invasive.~A session of laughter yoga lasts about 40 minutes and consists of four sections. The first section includes deep breathing exercises, the second section consists of warm-up exercises, the third section involves childlike games, and the fourth section includes laughter exercises.~The experimental group will consist of 25 participants. Before starting laughter yoga, the Maslach Burnout Inventory and the Nurse Job Stress Scale will be used to measure burnout and stress levels. Subsequently, a total of eight laughter yoga sessions will be conducted twice a week for one month, after which burnout and stress levels will be measured again using the scales."
62698155|NCT06642727|NO_INTERVENTION|control group|"The control group will consist of 25 participants, whose burnout and stress levels will be measured only using the Maslach Burnout Inventory and the Nurse Job Stress Scale. No intervention will be applied to the participants."
62698156|NCT02985723|EXPERIMENTAL|939MP|AT LISA tri toric 939MP intraocular lens
62698157|NCT03599765|EXPERIMENTAL|Arm I (LCT, routine therapy)|Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.
62497158|NCT05003882||Arm I|Commercially available, orally ingestible CBD product I
62497159|NCT05003882||Arm J|Commercially available, orally ingestible CBD product J
62497160|NCT05003882||Arm K|Commercially available, orally ingestible CBD product K
62497161|NCT05003882||Arm L|Commercially available, orally ingestible CBD product L
62497162|NCT05003882||Arm M|Commercially available, orally ingestible CBD product M
62698158|NCT03599765|EXPERIMENTAL|Arm II (routine therapy)|Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.
62698159|NCT03374306|EXPERIMENTAL|Atropine 0.01%|Group receiving atropine treatment for 18 months
62698160|NCT03374306|PLACEBO_COMPARATOR|Artifical tear|Group receiving placebo for 18 months
62698161|NCT04839640|ACTIVE_COMPARATOR|reinforced acrylic resin denture teeth|Shufo acrylic denture teeth
62698162|NCT04839640|EXPERIMENTAL|Composite resin denture teeth|Bredent denture teeth
62698163|NCT02729415|EXPERIMENTAL|Stromal Vascular Fraction Cells (SVF Cells)|The participants will undergo a standard tumescent liposuction to harvest adipose tissue. The adipose tissue will then be processed for obtain the Stromal Vascular Fraction Cells (SVF Cells) for a single injection for the treatment of androgenetic alopecia. Before the procedure, hair measurements will be performed in the 2cm x 2cm site for density (number of hairs per square centimeter) and thickness (mm) of the hair to compare to the measurements after the procedure at pre-procedure, 6 weeks, 3 months and 6 months.
62698164|NCT06564857|EXPERIMENTAL|REMI-arm|Bolus of remifentanil at anaesthesia induction
62497163|NCT05003882||Control|Waitlist control
62497164|NCT01691612|EXPERIMENTAL|D. pteronyssinus allergens|Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments
62497165|NCT02937207|EXPERIMENTAL|Hanxiao treatment group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
62497166|NCT02937207|PLACEBO_COMPARATOR|Hanxiao control group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
62497167|NCT02937207|EXPERIMENTAL|Fengtanxiao treatment group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture and Xie Wu Capsule oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
62497168|NCT02937207|PLACEBO_COMPARATOR|Fengtanxiao control group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture placebo and Xie Wu Capsule placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
62497169|NCT02937207|EXPERIMENTAL|Rexiao treatment group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
62497170|NCT02937207|PLACEBO_COMPARATOR|Rexiao control group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
62497171|NCT02937207|EXPERIMENTAL|Xuxiao treatment group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule and Bu Shen Na Qi Granule oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
62698165|NCT06564857|ACTIVE_COMPARATOR|ROCU-arm|Bolus of rocuronium at anaesthesia induction
61946956|NCT06285708|EXPERIMENTAL|Prolonged exposure with crisis response plan|In the enhanced prolonged exposure condition, participants will complete a CRP instead of a safety plan. The CRP is another recommended standard care practice with suicidal patients that includes many of the same elements as the safety plan (i.e., warning signs, self-management strategies, sources of social support, crisis services), but is created collaboratively by the patient with active input of their clinician rather than being self-guided. The CRP also includes a section focused on the participant's reasons for living, an addition that has been shown to increase positive emotional states (e.g., hope, optimism) and lead to faster reductions in suicidal intent. The CRP will be administered during the first therapy session.
61946957|NCT06285708|ACTIVE_COMPARATOR|Prolonged exposure with safety plan|In the standard prolonged exposure condition, participants will complete a safety plan, a procedure that includes personal warning signs for a suicidal crisis, self-management strategies, sources of social support, and contact information for professional resources and crisis services within the participant's local community, as well as the National Suicide Prevention Lifeline phone number. As a recommended standard care practice with suicidal patients, the combination of PE and safety plan represents treatment as usual. The safety plan will be administered during the first therapy session.
61946958|NCT02761733|EXPERIMENTAL|mPOWR System|Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
61946959|NCT02761733|NO_INTERVENTION|Control|Treatment as usual
61946960|NCT02390908|EXPERIMENTAL|Site 1 Immediate PLUS intervention|Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
61946961|NCT02390908|ACTIVE_COMPARATOR|Wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
61946962|NCT02390908|EXPERIMENTAL|Site 2 Immediate PLUS intervention|Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
62497172|NCT02937207|PLACEBO_COMPARATOR|Xuxiao control group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule placebo and Bu Shen Na Qi Granule placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
62497173|NCT04721418||Cocaine Use Disorder|
62497174|NCT04721418||Healthy Control|
62497175|NCT04190706|EXPERIMENTAL|bioactive components fortified food products|
62497176|NCT04190706|PLACEBO_COMPARATOR|control food products|
62497177|NCT03484234|EXPERIMENTAL|Ultimaster stent|
62497178|NCT03484234|ACTIVE_COMPARATOR|Xience alpine stent|
61946963|NCT02390908|EXPERIMENTAL|Site 3 Immediate PLUS intervention|Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
61946964|NCT04537429|EXPERIMENTAL|Eptinezumab|
62698166|NCT02629107||Healthy Volunteers|Healthy volunteers, age 18-34.
61946965|NCT05511194|EXPERIMENTAL|Experimental Group|Experimental Group: scheduled nausea and vomiting prophylaxis the first postoperative 24 hours, start liquid diet 8 hours postoperative, if tolerated, advance to a soft diet in the next shift, double IV antibiotic scheme (ceftriaxone, metronidazole) for at least 3 days and change to oral route upon discharge to complete 10 days of antibiotics, discharge upon accomplish discharge criteria (at least 3 days with IV antibiotic scheme, tolerance to feeding, tolerance to postoperative pain and 24 hours without the presence of fever).
62140211|NCT05840887|EXPERIMENTAL|Knee Ostetomy combined with meniscal allograft transplantation|The treatment group will perform osteotomy and meniscal allograft transplantation to restore the meniscal deficiency.
62340856|NCT04345926|EXPERIMENTAL|Dose-response|"1. - Concentration of propofol at the loss of consciousness (LOS) will be recorded in the presence of remifentanil (7.5 ng/mL) (LOS time).~2. - Patients will be intubated and remifentanil will be decreased to 4 ng/mL.~3. - Concentration of propofol that caused the LOS will be maintained for 20 minutes (Baseline time).~4. - Propofol will be increased in steps of 0.3 mcg/mL for 7 minutes until an episode of burst suppression will be observed (Burst suppression time).~EEG activity will be acquired using a SedLine® monitor during the complete protocol."
62340857|NCT05204511|EXPERIMENTAL|Post-COVID/Long-COVID endurance training group|Participants affected by Post-COVID/Long-COVID that carry out a 12-week thrice weekly endurance training intervention
62340858|NCT05204511|EXPERIMENTAL|Post-COVID/Long-COVID concurrent training group|Participants affected by Post-COVID/Long-COVID that carry out a 12-week thrice weekly concurrent training intervention
62497179|NCT03647722||Lemtrada treated - 6 month|Patients that received their first course of treatment with Lemtrada approximately 6 months prior.
62497180|NCT03647722||Lemtrada treated - 12 month|Patients that received their first course of treatment with Lemtrada approximately 12 months prior but who have not received the second course of treatment.
62497181|NCT03647722||Lemtrada treated - 18 month|Patients that received their first course of treatment with Lemtrada approximately 18 months prior and their second course of treatment with Lemtrada approximately 6 months prior.
62497182|NCT03647722||Lemtrada treated - 24 month|Patients that received their first course of treatment with Lemtrada approximately 24 months prior and their second course of treatment with Lemtrada approximately 18 months prior and who have not received any further treatment.
62497183|NCT03647722||Lemtrada qualified - untreated|Patients that are qualified to start treatment with Lemtrada but have not yet being untreated.
62698167|NCT04961255||Control group|Healthy individuals will be evaluated only once throughout the study. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated.
62497184|NCT01746654|EXPERIMENTAL|P128-0.1 mg|Three healthy adult volunteers will be enrolled to P128-0.1 mg single dose-cohort 1 (Part A) Three healthy adult volunteers will be enrolled to P128-0.1 mg multiple doses-Cohort 4 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.1 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.1 mg single dose (Part D)
62497185|NCT01746654|EXPERIMENTAL|P128-0.3 mg|Three healthy adult volunteers will be enrolled to P128-0.3 mg single dose-Cohort 2 (Part A) Three healthy adult volunteers will be enrolled to P128-0.3 mg multiple doses-Cohort 5 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.3 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.3 mg single dose (Part D)
61946966|NCT05511194|OTHER|Control Group|Control Group: use of antiemetic only in case of nausea or vomiting, start of liquid diet when presenting intestinal transit data (channeling of gases or presence of evacuation), if they tolerate advancing to a soft diet in the next shift, triple IV antibiotic regimen (ampicillin, amikacin, metronidazole) for at least 5 days and change to oral route upon discharge to complete 10 days of antibiotics, discharge upon accomplish discharge criteria (at least 5 days with IV antibiotic regimen, tolerance to feeding, tolerance to postoperative pain and 24 hours without the presence of fever).
61946967|NCT03691181|EXPERIMENTAL|Open Ambulatory Ventilation|"monitoring with the use of the Life2000 Open Ventilation System for a period of six months with measures of nutrition, feeling of breathlessness, exercise tolerance, and quality of life.~BODE Index B - BMI - BMI stands for body mass index, a calculation made by comparing height vs weight.~O - Airway obstruction - Airway obstruction is measured by evaluating FEV1 - the amount of air that can be forcefully exhaled in 1 second after a deep breath.~D - Dyspnea - Dyspnea refers to the degree of breathlessness someone experiences while living with COPD.~E - Exercise tolerance - Exercise testing refers to how well some does on a 6-minute walk test.~Modified Medical Research Council Dyspnea Scale"
61946968|NCT00704678|EXPERIMENTAL|1|1g bid
61946969|NCT00704678|ACTIVE_COMPARATOR|2|0.8 g tid
61946970|NCT00704678|EXPERIMENTAL|3|1.5 g tid
61946971|NCT00704678|ACTIVE_COMPARATOR|4|1.6 g tid
61946972|NCT00413400|PLACEBO_COMPARATOR|Placebo|
62140212|NCT05840887|ACTIVE_COMPARATOR|Knee Osteotomy|The control group will consist of patients who will perform an isolated osteotomy.
62140213|NCT02091752|EXPERIMENTAL|Ruxolitinib|All participants received ruxolitinib.
61946973|NCT00413400|ACTIVE_COMPARATOR|Etanercept|
61946974|NCT02389517|EXPERIMENTAL|Arm I (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
61946975|NCT02389517|ACTIVE_COMPARATOR|Arm II (lenalidomide)|Patients receive lenalidomide PO as in Arm I.
61946976|NCT03534362|ACTIVE_COMPARATOR|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
61946977|NCT03534362|ACTIVE_COMPARATOR|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
61946978|NCT06319378|EXPERIMENTAL|psilocybin 25 mg (active)|
61946979|NCT06319378|ACTIVE_COMPARATOR|psilocybin 1 mg|
61946980|NCT02867150|EXPERIMENTAL|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
61946981|NCT06422767|EXPERIMENTAL|Participants receiving Bepirovirsen|
61946982|NCT06422767|PLACEBO_COMPARATOR|Participants receiving Placebo|
61946983|NCT05773443||Ambroxol: Digital biomarkers|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550))
61946984|NCT05773443||Placebo: Digital biomarkers|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
61946985|NCT05773443||Caregivers|Primary family caregivers to participants
61946986|NCT02506465|EXPERIMENTAL|iTind arm|iTind implant is implant during the study for 5-7 days.
61946987|NCT02506465|SHAM_COMPARATOR|Sham arm|Foley catheter is used during the study
62140214|NCT06699095|EXPERIMENTAL|Interventional, telemedicine group|Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital
62140215|NCT06699095|NO_INTERVENTION|Control group|Patients will perform a 12 weeks maintenance rehabilitation program as usual care (TAU treatment as usual) at home after intensive rehabilitation in hospital
62140216|NCT06555575|EXPERIMENTAL|coQ10 A|Eligible subjects will be receiving ubiquinone 200 mg prior to their in vitro fertilization (IVF) cycle.
62140217|NCT06555575|EXPERIMENTAL|coQ10B|Eligible subjects will be receiving ubiquinol 100 mg prior to their IVF cycle.
62140218|NCT06555575|NO_INTERVENTION|Control|Subjects are not receiving coQ10 supplementation.
62140219|NCT02235298|EXPERIMENTAL|Dapagliflozin and Metformin Group|Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.
62140220|NCT02235298|ACTIVE_COMPARATOR|Metformin and Placebo Group|Participants in this group will receive Metformin and Placebo for 6 months.
62140221|NCT06699121|EXPERIMENTAL|LB-P8 low-dose|Oral capsule, 1×10\^10 CFU/day
62140222|NCT06699121|EXPERIMENTAL|LB-P8 high-dose|Oral capsule, 1×10\^11 CFU/day
62140223|NCT06699121|PLACEBO_COMPARATOR|Placebo|Oral capsule, placebo
62140224|NCT04694937||metabolic healthy obese|Demographic, clinical laboratory and heart rate variability assesment
62140225|NCT04694937||metabolic unhealthy obese|Demographic, clinical laboratory and heart rate variability assesment
62340859|NCT05204511|NO_INTERVENTION|Post-COVID/Long-COVID control group|Participants affected by Post-COVID/Long-COVID that don't carry out an exercise intervention
62340860|NCT06065358|EXPERIMENTAL|Interventional, prospective, monocentric|
62340861|NCT01272843||Carotid endarterectomy patients|
62340862|NCT01272843||Lumbar stenosis laminectomy patients|
62497186|NCT01746654|EXPERIMENTAL|P128-1.0 mg|Three healthy adult volunteers will be enrolled to P128-1.0 mg single dose-Cohort 3 (Part A) Three healthy adult volunteers will be enrolled to P128-1.0 mg multiple doses-Cohort 6 (Part B) Ten chronic kidney disease patients will be enrolled to P128 1.0 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-1.0 mg single dose (Part D)
62497187|NCT01746654|PLACEBO_COMPARATOR|Placebo|Three healthy adult volunteers will be enrolled to placebo single dose-Cohort 1-3 (Part A) Three healthy adult volunteers will be enrolled to placebo multiple doses-Cohort 4-6 (Part B) Ten chronic kidney disease patients will be enrolled to placebo multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to placebo single dose (Part D)
62497188|NCT03673592||Euploid embryos analyzed by PGT-A|Embryos with a normal chromosome copy number. This embryos will be transferred to the uterus.
62497189|NCT03673592||Low-grade mosaic embryos (PGT-A)|Embryos with a lower aneuploidy percentage (\<50%). This embryos will be considered for transfer to the uterus.
62497190|NCT03673592||High-grade mosaic embryos (PGT-A)|Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
62497191|NCT03673592||Aneuploid embryos analyzed by PGT-A|Embryos with an abnormal number of chromosomes. This embryos will be discarded for transfer.
62497192|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:~* ≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy~* Clinician's diagnosis based on his/her assessment~* Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
61946988|NCT02058693|PLACEBO_COMPARATOR|Group 1(A): Placebo/MSA|"Phase I (3 weeks) placebo adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine controlled release (CR) 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlafaxine extended release (XR) 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT (as in Phase I)."
61946989|NCT02058693|ACTIVE_COMPARATOR|Group 2(B): MSA/MSA|"Phase I (3 weeks) mixed salts amphetamine adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine controlled release (CR) 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlafaxine extended release (XR) 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT (as in Phase I)."
61946990|NCT00534066||Admitted|Patients presenting to the ED with acute exacerbation of CHF who require admission to the hospital directly from the ED
61946991|NCT00534066||Observational|Patients who present to the ED for acute exacerbation of CHF who are transferred to the Observation Unit from the ED for up to 24 hours.
61946992|NCT02476201|EXPERIMENTAL|MPP ON|To activate the Multipoint Pacing (MPP) feature to ON in all patients
61946993|NCT03336034||IBS-C|Constipation-predominant irritable bowel syndrome
61946994|NCT06141018|ACTIVE_COMPARATOR|Cross-linked intra-articular hyaluronic acid|Cross-linked intra-articular hyaluronic acid (90 mg 3 ml cross-linked hyaluronic acid)
61946995|NCT06141018|PLACEBO_COMPARATOR|Placebo|Intra-articular isotonic saline solution (3 ml 0.9% isotonic saline) at the same dose as the treatment arm
61946996|NCT03414229|EXPERIMENTAL|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
61946997|NCT03414229|EXPERIMENTAL|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
61946998|NCT03414229|EXPERIMENTAL|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
61946999|NCT03414229|EXPERIMENTAL|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
61947000|NCT04534543|OTHER|Imaging|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
61947001|NCT01870050|ACTIVE_COMPARATOR|dapsone gel - verum|dapsone gel - verum
61947002|NCT01870050|PLACEBO_COMPARATOR|dapsone gel - vehicle only|
61947003|NCT01723657|OTHER|Risk-adapted postremission treatment.|Ara-C, G-CSF, Autologous peripheral blood stem cell transplantation, Allogeneic matched related or unrelated donor transplant, G-CSF Priming, CD34+ selection, Myeloablative or reduced intensity conditioning, Mylotarg purging before autologous PBSC transplantation.
61947004|NCT03012009|ACTIVE_COMPARATOR|Full ablative CO2 laser + MAL PDT|The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.
62140226|NCT04626206||Imaging to asess treatment response post-SRS|"There will be only one group. All recruited patients will have 3 scans, the multi-parametric MRI, contrast-clearance analysis MRI (TRAMs) and 18F-choline-PET/CT.~This is a non interventional study. Only the results of the contrast-clearance analysis MRI (TRAMs) will be used to make clinical decisions (as this is the current standard of care at the recruiting site). The multi-parametric MRI and 18F-choline PET/CT will be treated as research scans."
62497193|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
62497194|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
62497195|NCT04532996|EXPERIMENTAL|Trauma-focused psychodynamic psychotherapy|Twice-weekly psychotherapy for 20-24 sessions.
62497196|NCT02393560||Gout subjects on stable dose of allopurinol (at least 300mg)|
61947005|NCT03012009|ACTIVE_COMPARATOR|Fractional ablative CO2 laser+ MAL PDT|The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.
61947006|NCT00370071|EXPERIMENTAL|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
61947007|NCT05944211|EXPERIMENTAL|Hetrombopag|The study in a 1:1 randomization ratio (36 subjects to experimental group). The treatment group received Herteppa Ethanolamine tablets and platelet transfusion.
61947008|NCT05944211|NO_INTERVENTION|Control|The study in a 1:1 randomization ratio (36 subjects to control group). The control group did not receive other platelet raising therapy except platelet transfusion.
61947009|NCT03827265|EXPERIMENTAL|TMS on SFG|"Device: repetitive transcranial magnetic stimulation (real)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the superior frontal gyrus (SFG).~Other Name: rTMS (active stimulation)"
61947010|NCT03827265|EXPERIMENTAL|TMS on PPC|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the posterior parietal cortex (PPC).~Other Name: rTMS (active stimulation)"
61947011|NCT03827265|EXPERIMENTAL|TMS on dlPFC|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the dorsolateral prefrontal cortex (dlPFC).~Other Name: rTMS (active stimulation)"
61947012|NCT03827265|PLACEBO_COMPARATOR|TMS on v5|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target visual cortex (v5).~Other Name: rTMS (sham stimulation)"
61947013|NCT02906332|EXPERIMENTAL|Pembrolizumab + lenalidomide|"This is an open label study.~* Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.~* This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
61947014|NCT04032548|PLACEBO_COMPARATOR|Placebo|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
61947015|NCT04032548|EXPERIMENTAL|Propolis|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
61947016|NCT04032548|ACTIVE_COMPARATOR|Chlorhexidine|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
61947017|NCT05815173|EXPERIMENTAL|Advanced NSCLC Patients|Patients with KRASG12C mutant NSCLC will receive ladarixin and sotorasib in combination.
61947018|NCT05668429|EXPERIMENTAL|Single dose of [14^C]-Ibrexafungerp|Each subject will receive a dose of \[14C\]-Ibrexafungerp at 12 h intervals for 7 doses in total.
61947019|NCT04852770|EXPERIMENTAL|Trial-Based Cognitive Therapy|TBCT (de Oliveira, 2008) is a novel transdiagnostic approach (Wenzel, 2017). It has been shown to be effective for depression (Hemanny et al., 2019), social anxiety disorder (Neufeld et al., 2020; Caetano et al., 2018; de Oliveira et al., 2011; Powell et al., 2013), and PTSD (Duran et al., 2020). TBCT differs from other CBT approaches in that it introduces a new, organized, and systematic approach to change dysfunctional negative core beliefs, and allows cognitive, emotional, and experiential work to be done simultaneously (de Oliveira, 2016). Interestingly, it incorporates a courtroom metaphor to challenge dysfunctional core beliefs conceptualized as self-accusations (de Oliveira, 2016). TBCT is an example of assimilative psychotherapy integration that relies on Beckian CBT (de Oliveira, 2016). It incorporates and integrates components of other psychotherapies (Delavechia et al., 2016).
61947020|NCT04852770|ACTIVE_COMPARATOR|Mindfulness-Based Health Promotion|The Mindfulness-Based Stress Reduction (MBSR) program was created by Jon Kabat-Zinn and colleagues at the University of Massachusetts Medical Center in 1979, and it is an intervention whose effects on mental health and quality of life has produced several studies worldwide, both in clinical and non-clinical populations. Several protocols have been developed based on the MBSR aimed at specific publics, such as the Mindfulness-Based Health Promotion (MBHP) program developed by the Mente Aberta - Brazilian Center for Mindfulness and Health Promotion. The MBHP program was inspired by the original MBSR model but adapted to the context of the Brazilian Health Care (SUS) system, addressing chronic conditions and mental disorders as well (TROMBKA et al., 2018; LOPES et al., 2019; SALVO et al., 2018).
62140227|NCT02739100|EXPERIMENTAL|Triferic via Hemodialysate|"Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.~Intervention Drug: Triferic"
62140228|NCT02739100|EXPERIMENTAL|Triferic via IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via the unused heparin infusion line (pre-dialyzer).~Intervention: Drug: Triferic"
62140229|NCT02739100|EXPERIMENTAL|Triferic IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via an infusion port (post-dialyzer).~Intervention: Drug: Triferic"
62140230|NCT00743574|EXPERIMENTAL|Vitamin D plus Calcium (Ca) supplementation|
62140231|NCT04870775|EXPERIMENTAL|Experimental group|The intervention administered to the experimental group will be a mindfulness training program
62497197|NCT01614184|EXPERIMENTAL|All patients|All patients enrolled in study.
62497198|NCT04370444|EXPERIMENTAL|Experimental (PLR)|Participants will be given the OhNut Phallus Length Reducer (PLR) for use during the study period.
62497199|NCT04370444|OTHER|Control (Waitlist)|Participants will not have a PLR during the study period. They will be placed on a waitlist to receive the PLR at the end of the study period.
62497200|NCT05258630|EXPERIMENTAL|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
62497201|NCT05258630|ACTIVE_COMPARATOR|Enhanced usual care|Brief diabetes educational session by a diabetes wellness coach.
62497202|NCT01201486||Pregnant women|Pregnant females in the 2nd trimester.
62497203|NCT06117241|NO_INTERVENTION|Comparison|Participation will be for six months. Participants will meet staff at three timepoints (baseline, 3 months, 6 months) to complete questionnaires, online dietary assessment, body measures, have blood pressure measured, provide blood and stool samples, and wear an activity monitor for a week at each time point.
62698168|NCT04961255||COVID-19 positive participants who had moderate symptoms group|"These participants will be evaluated 4 times throughout the study.~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
61947021|NCT04852770|ACTIVE_COMPARATOR|Positive psychotherapy|Positive psychotherapy (PPT) seeks to understand positive emotions, psychological potentialities and healthy human / social / institutional functioning, and to apply this knowledge to help people and institutions, with a focus on prevention and promotion of mental health (SELIGMAN et al., 2005). Originally, PP focused on happiness and subjective well-being (SELIGMAN, 2010; SELIGMAN; CSIKSZENTMIHALYI, 2000). Then, the studies gained a broader view of psychological well-being and another similar proposal entitled PERMA, which is composed of the following five spheres: positive emotions - P; engagement - E; relationships - R; meaning - M; and achievement - A. (RYFF, 2013; SELIGMAN, 2012). Although positive psychology aims to be a way of looking at life, some psychotherapeutic proposals, such as positive psychotherapy (PPT), have been developed, and clinical studies have been replicated in different clinical and cultural contexts (RASHID; SELIGMAN, 2019; RICHES et al., 2016).
61947022|NCT03502460|OTHER|ORFALU|"Lung ultrasound consists of the application of a high-frequency ultrasound probe type Trans Thoracic Echography (ETT) on the anterior and lateral chest of the patient. Since air and bone do not pass through the US, it is the artefacts due to these structures that constitute ultrasound lung semiology.~Esophageal Doppler is a means of monitoring cardiac output measuring stroke volume (SV)."
62140232|NCT04870775|NO_INTERVENTION|Control group|The control group will not receive any intervention
62698169|NCT04961255||COVID-19 positive participants who had severe symptoms group|"These participants will be evaluated 4 times throughout the study.~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
61947023|NCT06556654|EXPERIMENTAL|Prospective Arm|Prospectively treated subjects who undergo two-stage implant-based breast reconstruction with the TRBR Device (TRBR Device group)
62698170|NCT06638411|EXPERIMENTAL|ADHD information workshop|
62698171|NCT06638411|EXPERIMENTAL|ADHD information workshop with nocebo education|
62698172|NCT06638411|ACTIVE_COMPARATOR|Sleep and dreams workshop|
62698173|NCT06312059|ACTIVE_COMPARATOR|Market leader- Competitor Cow Milk based infant formula|Intervention with Competitor product currently in market- Control.
62698174|NCT06312059|EXPERIMENTAL|Test product Cow Milk based infant formula|Intervention with Test product product - Test arm.
62698175|NCT06312059|EXPERIMENTAL|Test product Goat Milk based infant formula|Intervention with Test product product - Test arm.
62698176|NCT01827020|ACTIVE_COMPARATOR|Group L (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.
61947024|NCT02051231|NO_INTERVENTION|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with oxytocin.
61947025|NCT02051231|EXPERIMENTAL|Oxytocin|Samples from each patient will be exposed to oxytocin and then allowed to rest for 30, 60 or 90 minutes.
62140233|NCT03478969|EXPERIMENTAL|Group A: Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
62140234|NCT03478969|EXPERIMENTAL|Group B: MDI, then Accu-Chek® Solo|Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
62698177|NCT01827020|ACTIVE_COMPARATOR|Group K (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg plus lidocaine 2% 1 mg/kg of the intranasal cavity.
62698178|NCT01827020|PLACEBO_COMPARATOR|Group S (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.
62698179|NCT04432779||Women tested positive to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~Follow up end at 1 month post delivery."
62698180|NCT04432779||Women tested negative to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~No follow up after delivery."
62140235|NCT03478969|EXPERIMENTAL|Group C: mylife™ OmniPod®, then Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
62140236|NCT05033522|EXPERIMENTAL|AlloStim®|AlloStim® is a formulation of living allogeneic Th1-like cells with anti-CD3/CD28 microbeads attached derived from precursors purified from healthy screened blood donors that are differentiated and expanded ex-vivo. AlloStim® is formulated at 10-7 cells/ml in 0.5ml for ID administration and 3ml for IV administration
62140237|NCT05033522|ACTIVE_COMPARATOR|Physician's Choice|Physician's Choice is sorafenib or levantinib or FOLFOX4 monotherapy
62497204|NCT06117241|EXPERIMENTAL|Intervention|Participation will be for six months. Participants will meet staff at three timepoints (baseline, 3 months, 6 months) to complete questionnaires, online dietary assessment, body measures, have blood pressure measured, provide blood and stool samples, and wear an activity monitor for a week at each time point. In addition, participants will attend weekly classes for 12 weeks and one class per month for three months. These classes will include cooking, movement, and stress reduction.
62497205|NCT02783326|EXPERIMENTAL|COPD Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
62698181|NCT04432779||Newborns from women tested positive|"Newborns born to mothers who had a positive nasal swab or a positive serology during pregnancy or at delivery and who consented the follow up study.~Follow up end at 3 years of age."
62698182|NCT04432779||Newborns from women tested negative|"Newborns born to mothers who had no COVID-19 infection during pregnancy or at delivery and who consented the follow up study. These control children will be matched with children from the other group for gestational age and ethnicity.~Follow up end at 3 years of age."
62698183|NCT06637709||Experimental group: patients with symptomatic knee osteoarthritis (OA)|Experimental group includes a subgroup: OA patients from the experimental group requiring primary TKA due to the failure of conservative treatment, thus undergoing surgical intervention.
61947026|NCT04635189|ACTIVE_COMPARATOR|Experimental Arm: Cycle 1-4 All subjects|"Subjects will be treated with the following:~* Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~* Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~* Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
61947027|NCT04635189|EXPERIMENTAL|Experimental Arm: Cycle 5+ Partial Response or Better|"Subjects will be treated the following:~* Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~* Lenalidomide 25 milligrams/kilograms daily days 1-21 out of a 28 day cycle"
61947028|NCT04635189|ACTIVE_COMPARATOR|Experimental Arm: Cycle 5+ Less than Partial Response|"Subjects will be treated the following:~* Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~* Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~* Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
61947029|NCT05882357|EXPERIMENTAL|Part A|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
61947030|NCT05882357|EXPERIMENTAL|Part B|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.
61947031|NCT02701699|EXPERIMENTAL|18-F-FAZA Scan|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
62140238|NCT03759249|EXPERIMENTAL|Treatment group|Standard Treatment of Sleep disorder according to applicable guideline
62140239|NCT03759249|NO_INTERVENTION|Waiting list|Continuation of former treatment, after completing the study standard treatment of Sleep disorder according to applicable guidelines
62340863|NCT05685667|EXPERIMENTAL|Laser-induced microjet injector (Mirajet)|The left/right assignment was sealed in a nontransparent envelop.
62497206|NCT02783326|ACTIVE_COMPARATOR|Control Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
62698184|NCT06637709||Control group: subjects without any chronic pain|subjects undergoing occupational health surveillance matched by age, sex and psychological profile with the experimental group patients
62140240|NCT06687226|OTHER|Stool samples + consumption of powdered food|Each participant will submit a baseline stool sample, consume a single dose of a study-specific powdered food (reconstituted in water) differing from their usual diet, and provide the subsequent five stool samples. If five samples are collected in fewer than five days, an additional sample will be obtained on the fifth day post-consumption
62140241|NCT05716113|EXPERIMENTAL|RD13-02 cell infusion|
62140242|NCT02533232|PLACEBO_COMPARATOR|placebo|Matching placebo for Minocycline
62140243|NCT02533232|EXPERIMENTAL|Minocycline|Minocycline 200mg once a day orally
62140244|NCT03568409|EXPERIMENTAL|Group A: ABO-GLYC|Libramed
62140245|NCT03568409|PLACEBO_COMPARATOR|Group B: Placebo|
62140246|NCT03901781|EXPERIMENTAL|Cohort One|Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
62140247|NCT03901781|EXPERIMENTAL|Cohort Two|Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
62340864|NCT05685667|ACTIVE_COMPARATOR|Needle injection (control)|The left/right assignment was sealed in a nontransparent envelop.
62340865|NCT01021605|EXPERIMENTAL|Hemolung Respiratory Assist System|
62497207|NCT02054754|EXPERIMENTAL|Dexanabinol Dose Level 1|Single oral dose of dexanabinol
62497208|NCT02054754|EXPERIMENTAL|Dexanabinol Dose Level 2|Single oral dose of dexanabinol
62497209|NCT02054754|EXPERIMENTAL|Dexanabinol Dose Level 3|Single oral dose of dexanabinol
62497210|NCT02054754|EXPERIMENTAL|Dexanabinol Dose Level 4|Single oral dose of dexanabinol
62497211|NCT02054754|EXPERIMENTAL|Dexanabinol Dose Level 5|Single oral dose of dexanabinol
62497212|NCT02054754|PLACEBO_COMPARATOR|Placebo|Single oral dose of matching placebo
62497213|NCT04231292|EXPERIMENTAL|Experimental Group A +Group a|Group A: 0.8μg/kg RD01, once every two weeks, Day 1\~ 18th week;Group a: refers to the weekly dose at the end of the first stage , once every two weeks, 19th\~46th week
61947032|NCT02231632|EXPERIMENTAL|Live attenuated Poliomyelitis vaccine (human diploid cell)|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
61947033|NCT02231632|EXPERIMENTAL|Poliomyelitis（Live）Vaccine(Monkey Kidney Cell),Oral|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
61947034|NCT02760797|EXPERIMENTAL|Part I (Dose-Finding Stage)|Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
62140248|NCT03901781|EXPERIMENTAL|Cohort Three|Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
62497214|NCT04231292|EXPERIMENTAL|Experimental Group B +Group b|Group B: 1.2μg/kg RD01, once every two weeks, Day 1\~ 18th week; Group b: refers to the weekly dose at the end of the first stage , once every four weeks, 19th\~46th week
61947035|NCT02760797|EXPERIMENTAL|Part II (Dose Expansion Stage)|Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
62497215|NCT04231292|EXPERIMENTAL|Experimental Group C +Group c|Group C: 1.6μg/kg RD01, once every two weeks, Day 1\~ 18th week; Group c: refers to the weekly dose at the end of the first stage , once every six weeks, 19th\~46th week
62497216|NCT04231292|EXPERIMENTAL|Experimental Group D +Group d|Group D: 0.8μg/kg RD01, once every two weeks, Day 1\~ 18th week; Group d: refers to the weekly dose at the end of the first stage , once every four weeks, 19th\~46th week
62497217|NCT04231292|ACTIVE_COMPARATOR|Experimental Group E +Group e|Group E: 150IU/kg rHuEPO, once a weeks, subcutaneous administration, Day 1\~ 18th week; Group e: refers to the weekly dose at the end of the first stage , once a weeks, intravenous administration, 19th\~46th week
62698185|NCT06541197|ACTIVE_COMPARATOR|Robotic rehabilitation combined with Functional Electrical Stimulation (FES) bicycle ergometry group|Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks. For FES bicycle ergometry, a current-controlled six-channel stimulator (RT 300-SLSA; Restorative Therapies, Baltimore, MD, USA) will be used. The quadriceps, hamstring and tibialis anterior muscles will be stimulated bilaterally with six channels through 3 × 4 cm2 adhesive surface electrodes. Stimulation intensity will be adjusted according to palpable muscle contraction and sensory discomfort felt by patients with incomplete SCI. The pedaling cadence range will be set to 40-50 rotations per minute. Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. FES bicycle ergometry will be performed in 30-minute sessions for 4 weeks for a total of 20 sessions under the supervision of a physician before robotic rehabilitation.
62698186|NCT06541197|ACTIVE_COMPARATOR|Robotic rehabilitation|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks.
62698187|NCT06507618|EXPERIMENTAL|Intervention Arm|90 days of pre-ET (endocrine therapy - tamoxifen or aromatase inhibitor) before Breast Cancer Surgery
62698188|NCT06507618|NO_INTERVENTION|Control Arm|Will proceed directly to Breast Cancer Surgery
62698189|NCT03738228|EXPERIMENTAL|Arm A (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days -21, 0, and 21 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy IV over 90 minutes on days 0, 7, 14, 21, 28, and 35. Beginning on day 0, patients also receive standard of care radiation therapy once daily (Monday-Friday) for a total of 25 fractions with image guided brachytherapy beginning in week 4, 5, or at the end of radiation therapy.
62140249|NCT03632876|ACTIVE_COMPARATOR|Lower Dose Vitamin A|Subjects with SCD-SS in the lower dose Vitamin A arm receive 3000IU of retinyl palmitate daily for 8 weeks.
62340866|NCT03733873|EXPERIMENTAL|desmopressin plus Suoquan|Drug1. name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months Drug2 name:Suoquan mixture form:liquid dosage:10ml/time frequence:bid duration:3 months
62340867|NCT03733873|ACTIVE_COMPARATOR|desmopressin|name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months
62340868|NCT06502444|EXPERIMENTAL|Moving Forward Together Activity Intervention|This is a single-arm project. All participants receive the same experimental intervention. The intervention is a gentle program encouraging greater participation in physical activity and healthy regulation of emotions.
62340869|NCT02193815|EXPERIMENTAL|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
62340870|NCT00747396|EXPERIMENTAL|Foster Care Placement Group|Children randomized to this group were placed in high quality foster care developed for the study.
62340871|NCT00747396|NO_INTERVENTION|Care As Usual Group|Children randomized to this group remained in institutional care.
62340872|NCT02822404|EXPERIMENTAL|Urinary and blood sample|Urinary and blood samples for cystatin C dosage
62497218|NCT04231292|PLACEBO_COMPARATOR|Experimental Group F +Group f|Group F: 8μl placebo, once every two weeks, for 6 weeks; 150 IU/kg rHuEPO, once week, subcutaneous injection, 7th \~ 18th week; Group f: refers to the weekly dose at the end of the first stage , once a weeks, subcutaneous administration, 19th\~46th week
61947036|NCT00734474|EXPERIMENTAL|3.0 mg LY2189265|"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
62497219|NCT04231292|EXPERIMENTAL|Experimental Group G|Group G: 1.6μg/kg RD01, once every four weeks, Day 1\~ 28th week;
62497220|NCT02284139|PLACEBO_COMPARATOR|Placebo|Placebo ointment dose not contain EGF.
62497221|NCT02284139|ACTIVE_COMPARATOR|Arm EGF ointment 1ppm|Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration
62497222|NCT02284139|ACTIVE_COMPARATOR|Arm EGF ointment 20ppm|Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration
62497223|NCT02357927|PLACEBO_COMPARATOR|control|simple general telephone call
62497224|NCT02357927|EXPERIMENTAL|Mini-AFTERc Intervention|20-30 minute structured conversation with breast cancer patient using Mini-AFTERc Manual
62497225|NCT05040139||Malone procedure|The percutaneous caecal access is performed surgically
62497226|NCT05040139||Percutaneous Endoscopic Caecostomy|The percutaneous caecal acces is performed endoscopically.
62497227|NCT04746976||Diroximel Fumarate|Participants with RMS who are receiving diroximel fumarate orally in routine clinical practice will be enrolled.
62497228|NCT03171064|EXPERIMENTAL|Experimental intervention arm (EX)|The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
62497229|NCT03171064|NO_INTERVENTION|Wait list - control group (UC)|Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.
62497230|NCT03563560|EXPERIMENTAL|ACM regimen|ACM regimen is for Japanese patients with relapsed or refractory AML.
61947037|NCT00734474|EXPERIMENTAL|2.0 mg LY2189265|"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
62497231|NCT03563560|EXPERIMENTAL|A+7+3 regimen|A+7+3 regimen is for Japanese newly diagnosed AML patients.
61947038|NCT00734474|EXPERIMENTAL|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
61947039|NCT00734474|EXPERIMENTAL|1.0 mg LY2189265|"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
62497232|NCT01897077|EXPERIMENTAL|Peanut Allergic|Only one intervention will be given. Peanut allergic study subjects, will receive gradually increasing doses of the dissolving peanut film.
62497233|NCT01897077|ACTIVE_COMPARATOR|Healthy Volunteers|Healthy volunteers will receive active peanut dissolving films in an expedited manner in order to determine safety dissolving films.
62497234|NCT00105040|EXPERIMENTAL|Levetiracetam (LEV)|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
62497235|NCT00105040|PLACEBO_COMPARATOR|Matching Placebo (PBO)|Oral tablets and oral solution.
62497236|NCT01329458||Focal liver lesions|Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound
62698190|NCT03738228|EXPERIMENTAL|Arm B (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy, radiation therapy, and image guided brachytherapy as in Arm A.
62698191|NCT06361836|EXPERIMENTAL|SBT777101 Dose Level 1|Low dose SBT777101
62698192|NCT06361836|EXPERIMENTAL|SBT777101 Dose Level 2|Mid dose SBT777101
62698193|NCT06361836|EXPERIMENTAL|SBT777101 Dose Level 3|High dose SBT777101
62698194|NCT02026167|NO_INTERVENTION|Usual Care|No intervention, usual care
62698195|NCT02026167|EXPERIMENTAL|Intervention|Collaborative care with Health Care Assistant
62698196|NCT04921865||Patients treated with the DPS VA-LCP® Clavicle Plate 2.7 System or Hook Plate 2.7 System|Any patient undergoing surgical treatment for the fixation of clavicle bone fragments and acromioclavicular joint dislocations using the DPS VA-LCP® Clavicle Plate 2.7 System or DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 .
62698197|NCT05479370|EXPERIMENTAL|Frequently vaccinated Group 1: QIV-R|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Flublok Quadrivalent vaccine, intra-muscularly, at Day 0.
62698198|NCT05479370|EXPERIMENTAL|Frequently vaccinated Group 2: QIV-E|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Fluarix Quadrivalent vaccine, intra-muscularly, at Day 0.
62698199|NCT05479370|EXPERIMENTAL|Frequently vaccinated Group 3: QIV-C|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Flucelvax Quadrivalent vaccine, intra-muscularly, at Day 0.
62698200|NCT05479370|EXPERIMENTAL|Infrequently vaccinated Group 4: QIV-R|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Flublok Quadrivalent vaccine, intra-muscularly, at Day 0.
62698201|NCT05479370|EXPERIMENTAL|Infrequently vaccinated Group 5: QIV-E|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Fluarix Quadrivalent vaccine, intra-muscularly, at Day 0.
61947040|NCT00734474|EXPERIMENTAL|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
62140250|NCT03632876|ACTIVE_COMPARATOR|Higher Dose Vitamin A|Subjects with SCD-SS in the higher dose Vitamin A arm receive 6000IU of retinyl palmitate daily for 8 weeks.
62497237|NCT06291454||Stage III Grade B periodontitis group (Group 1)|Stage III Grade B periodontitis patients and systemically healthy
62497238|NCT06291454||Stage III Grade C periodontitis group (Group 2)|Stage III Grade C periodontitis patients and systemically healthy
62497239|NCT06291454||Control group (Group 3)|Periodontally healthy (control group) and systemically healthy patients
62497240|NCT05274191|EXPERIMENTAL|A single arm, open-label Phase II clinical study.|"All subjects enrolled will receive the following treatment：Pyrotinib±standard treatment.~Pyrotinib 400 mg/ D (once a day, at the same time each day) until the progression of disease; Chemotherapy regimens follow the programme cycle recommended by the guidelines or as determined by the investigator.~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
62497241|NCT03329209|EXPERIMENTAL|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
62497242|NCT00987480|EXPERIMENTAL|chemotherapy-based cytoreductive regimen plus a CD34+ selected|This phase II trial is designed to investigate the safety and efficacy of a chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease.
62497243|NCT04795466|EXPERIMENTAL|Canakinumab|increasing doses of sub-cutaneous injections
62497244|NCT04795466|PLACEBO_COMPARATOR|Placebo|Matching placebo sub-cutaneous injections
62497245|NCT01044433|EXPERIMENTAL|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.
62497246|NCT02093962|EXPERIMENTAL|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
62497247|NCT02093962|ACTIVE_COMPARATOR|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
62497248|NCT04624594|EXPERIMENTAL|Artificial Intelligence (AI) Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the AI group then performed 10 more practice repetitions with real-time audiovisual feedback from the app followed by one minute of rest. The AI's design provided one piece of feedback, if necessary, with a vocal statement and on-screen video per repetition (e.g. when a participant performed a squat repetition with their neck flexed downward, AI suggested keeping their head up with on-screen instruction). Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
62497249|NCT04624594|ACTIVE_COMPARATOR|Physical Therapist Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the PT group (n=15) also performed 10 practice repetitions with one piece of feedback per repetition, if necessary, from the PT followed by one minute of rest. Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
62497250|NCT02571582||Patients died|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
62497251|NCT02571582||living patients|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
61947041|NCT00734474|EXPERIMENTAL|0.5 mg LY2189265|"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
62140251|NCT03632876|NO_INTERVENTION|Healthy Comparison Arm|Healthy subjects receive no intervention and undergo comparisons to the two vitamin A supplementation arms at baseline.
62497252|NCT03105297|EXPERIMENTAL|All participants (Baseline phase)|All the participants were applied nasal dilator strip during the sleep laboratory night on Day 1.
62497253|NCT03105297|EXPERIMENTAL|All Participants (Active Phase)|All the participants wore nasal dilator strip over a 1 month in-home use period and returned for sleep laboratory nights after 7 (Day 8) and 28 days (Day 29) of treatment
62497254|NCT03105297|EXPERIMENTAL|All Participants (Nasal Resistance Phase)|The participants were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip' on 2 sleep laboratory nights (on Day 30 and Day 31) based on the randomization schedule
62698202|NCT05479370|EXPERIMENTAL|Infrequently vaccinated Group 6: QIV-C|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Flucelvax Quadrivalent vaccine, intra-muscularly, at Day 0.
62698203|NCT06099665|EXPERIMENTAL|Automated alert|Providers that will receive an automated alert sent via the EHR.
62698204|NCT06099665|NO_INTERVENTION|Control|Care providers in the control arm will not receive an automated alert.
62698205|NCT06570252|EXPERIMENTAL|Experimental Group - nasal aPDT|"1. Swabbing the formulation applicator (soft swab pre-saturated with the photosensitizer formulation) inside the patient's nostrils.~2. Connection of the nasal light illuminator to the light source and insertion of the nasal light illuminator into the patient's right and left nostrils.~3. Experimental group: Activation of the light source and illumination of the nose and nasopharynx for 2 minutes.~4. Repetition of steps 1.-3. to complete photo disinfection of all nasal regions.~Duration of study intervention: 14 minutes~Intervention is performed during preparations prior to surgery and followed by regular disinfection of oral cavity (not nasal cavity) according to hospital standards after nasal swab test."
62497255|NCT04327336|ACTIVE_COMPARATOR|Manual|In this group non invasive mechanical ventilation will be manually titrated during a polysomnography. The Philips A40 ventilator will be used in Spontaneous-Timed (ST) mode.
62497256|NCT04327336|ACTIVE_COMPARATOR|Automatic|In this group the ventilator will run in an automatic mode (AVAPS) with the same Phillips A40 ventilator.
61947042|NCT00734474|EXPERIMENTAL|0.25 mg LY2189265|"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
62497257|NCT06030128|EXPERIMENTAL|Core stabilization exercise group|All participants will undergo 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6 - 8per class. Subjects will be divided into experimental and control groups.
62698206|NCT06570252|ACTIVE_COMPARATOR|Control Group - no light activation|"1. Swabbing the formulation applicator (soft swab pre-saturated with the photosensitizer formulation) inside the patient's nostrils.~2. Connection of the nasal light illuminator to the light source and insertion of the nasal light illuminator into the patient's right and left nostrils.~3. no activation of light source~4. Repetition of steps 1.-3. to complete control intervention.~Duration of treatment: 14 minutes~Intervention is performed during preparations prior to surgery and followed by regular disinfection of oral cavity (not nasal cavity) according to hospital standards after nasal swab test."
62698207|NCT03563001|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease Group|Patients with diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Disease(GOLD 2018) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
62698208|NCT03563001|EXPERIMENTAL|Asthma-Chronic Obstructive Pulmonary Disease Overlap Group|Patients with diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
61947043|NCT00734474|ACTIVE_COMPARATOR|Sitagliptin|"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
62497258|NCT06030128|NO_INTERVENTION|waiting list control group|Participants in the control group will not receive exercise training at first but were evaluated at the same time as participants in the experimental group.
62497259|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
62497260|NCT02451644|EXPERIMENTAL|high risk for PTD with pedometer|Patient with high risk for preterm delivery including short cervix or rapture of membranes
62497261|NCT05098951|EXPERIMENTAL|Patients with stiffness of joint receive acupuncture therapy|This is a single arm study. All the enrolled patients will receive acupuncture twice weekly for 6 weeks then once weekly for another 6 weeks.
61947044|NCT00734474|PLACEBO_COMPARATOR|Placebo/Sitagliptin (Baseline Through 104 Weeks)|"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Placebo: tablet, administered orally, once daily for 26 weeks~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
61947045|NCT01298531|ACTIVE_COMPARATOR|etanercept|Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
62497262|NCT02090933|EXPERIMENTAL|Treatment (celecoxib)|Participants undergo UV-irradiation to the right buttock at baseline, receive celecoxib PO BID for 10 days, and then undergo UV-irradiation to the left buttock.
62497263|NCT02297230|EXPERIMENTAL|Arm 1 Capecitabine and RT|Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
62497264|NCT02297230|EXPERIMENTAL|Arm 2 Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
62497265|NCT02297230|EXPERIMENTAL|Arm 3: Paclitaxel and RT|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
62698209|NCT03671226|EXPERIMENTAL|Supportive Care (questionnaire)|Patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.
62698210|NCT00391716|EXPERIMENTAL|gabapentin 900mg daily|900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
62698211|NCT00391716|EXPERIMENTAL|gabapentin 1800mg daily|1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
62698212|NCT00391716|PLACEBO_COMPARATOR|placebo daily|placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
62698213|NCT06268847|PLACEBO_COMPARATOR|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
61947046|NCT01298531|PLACEBO_COMPARATOR|etanercept-placebo|Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.
61947047|NCT01428271||Herniorrhapy with caudal block|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorrhapy under general anesthesia with caudal block
61947048|NCT04209192|ACTIVE_COMPARATOR|Control group (Amikacin)|"Patients in the control group will receive amikacin as prophylactic antibiotic. It will be administered intravenously 30 minutes before procedure. Patients with an estimated glomerular filtration rate (EGFR) greater or equal than 70 ml/min will receive 1 gram of Amikacin. Patients with an EGFR less than 70 ml/min will received a calculated dose following the next parameters.~Patients with EGFR between 69-40 ml/min should receive: the calculated GFR x 0.18 = mg/kg.~Patients with EGFR less than 40 ml/min should receive: the calculated GFR x 0.36 = mg/kg."
62140252|NCT03387254|EXPERIMENTAL|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
62140253|NCT03387254|SHAM_COMPARATOR|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
62698214|NCT06268847|EXPERIMENTAL|ACT01|The test product is a food supplement presented as a capsule containing a fish hydrolysate.
62698215|NCT06268847|EXPERIMENTAL|ACT02|The test product is a food supplement presented as a capsule containing a fish hydrolysate.
62698216|NCT05781308|OTHER|Arm A: paclitaxel + bevacizumab|Bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
62698217|NCT05781308|EXPERIMENTAL|Arm B: paclitaxel + bevacizumab + atezolizumab|Atezolizumab 1200 mg, bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
62698218|NCT03888027|NO_INTERVENTION|Control|Patients receive no intervention
62698219|NCT03888027|ACTIVE_COMPARATOR|WalkMORE group|"Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:~1. Standard of care; or~2. WalkMORE Ambulation program + Standard of care. Patients will ambulate with a trained WalkMORE volunteer two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge. Patients randomized to the WalkMORE intervention will be assessed daily by the Research Coordinator to ensure patients remain fit for independent ambulation. The duration of each walking session will be determined daily by the RC and the medical team."
62698220|NCT05437419|EXPERIMENTAL|Cohort 1|The patient will receive Dose A of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
62698221|NCT05437419|EXPERIMENTAL|Cohort 2|The patient will receive Dose B of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
61947049|NCT04209192|EXPERIMENTAL|Intervention group (Fosfomycin)|Patients in the intervention group will receive Fosfomycin trometamol as prophylactic antibiotic. It will be administered orally in the night before procedure. Patients must be on fasting and will receive 3 grams.
62698222|NCT05437419|EXPERIMENTAL|Cohort 3|The patient will receive Dose C of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
62698223|NCT05437419|EXPERIMENTAL|Cohort 4|The patient will receive Dose D of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
62698224|NCT03014258|ACTIVE_COMPARATOR|Control Cohort 1|Immunologic malaria-naïve subjects will undergo CHMI #2 with 5 NF54 P. falciparum-infected mosquitoes at months 8-9. n=6.
62698225|NCT03014258|ACTIVE_COMPARATOR|Control Cohort 2|Immunologic malaria-naïve subjects will undergo a CHMI #3 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #2. n=6.
62698226|NCT03014258|ACTIVE_COMPARATOR|Control Cohort 3|Immunologic malaria-naïve subjects will undergo a CHMI #4 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #3. n=6.
62698227|NCT03014258|ACTIVE_COMPARATOR|Control Cohort 4|Immunologic malaria-naïve subjects will undergo a CHMI #5 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #4. n=6.
62698228|NCT03014258|EXPERIMENTAL|Repeat CHMI|Subjects will initially be challenged with 5 uninfected mosquitoes (mock), followed by 5 challenges (CHMI # 1-5) with 5 NF54 P. falciparum-infected mosquitoes 2, 8, 14-20, and 20-32, and 32-36 months later. n=10.
61947050|NCT02598960|EXPERIMENTAL|BMS-986156: Dose Escalation|
61947051|NCT02598960|EXPERIMENTAL|BMS-986156 + nivolumab (nivo): Dose Escalation|
61947052|NCT02598960|EXPERIMENTAL|BMS-986156: Dose Expansion|
61947053|NCT02598960|EXPERIMENTAL|BMS-986156 + nivolumab (nivo): Dose Expansion|
61947054|NCT02598960|EXPERIMENTAL|BMS986156 + Nivo: Cohort Expansion|
61947055|NCT01206166|EXPERIMENTAL|Enteral Nutrition + Parenteral Nutrition|Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
61947056|NCT01206166|NO_INTERVENTION|Enteral Nutrition Only|Enteral nutrition only - no intervention
62698229|NCT06139354|EXPERIMENTAL|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
62698230|NCT06459778|EXPERIMENTAL|Piezo-ICSI group, Oocytes in this group will be fertilized with Piezo-ICSI|The Piezo-ICSI technique involves the use a piezoelectric actuator to create high speed movement of the injection pipette. These fine movements allow precise microdrilling of the zona and smooth penetration of injection pipette into the cytoplasm and a single Piezo pulse facilitates breakage of the membrane, with the spermatozoa deposited into the cytoplasm without the need for cytoplasmic aspiration or agitation. Since the initial reports of the use of Piezo-ICSI in human oocytes, there have been notable improvements made to the technique, including a change in the operating fluid, leading to a safe and effective technique suitable for clinical use. In addition, when this technology was utilized in patients with poor outcomes, including low fertilization, high degeneration or low utilization in previous cycles, it resulted in improved fertilization, degeneration, embryo utilization and pregnancy rates compared with conventional ICSI.
62698231|NCT06459778|NO_INTERVENTION|Control group, Oocytes in this group will be fertilized with conventional ICSI|
62698232|NCT02552264|ACTIVE_COMPARATOR|Immediate intervention|Acceptance and Commitment Therapy
61947057|NCT05567315|ACTIVE_COMPARATOR|Oocyte puncture with local anaesthesia alone|
61947058|NCT05567315|EXPERIMENTAL|Oocyte puncture with local anaesthesia and additional virtual reality hypnosis|
61947059|NCT02095418|EXPERIMENTAL|Mycophenolate mofetil, Corticosteroids|"* Mycophenolate mofetil: 500-1500mg/day, bid, PO~* Corticosteroids: 500mg for the first dosage. It will be tapered at least 5mg for 14days and withdrawn"
61947060|NCT02095418|ACTIVE_COMPARATOR|Corticosteroids, Mycophenolate mofetil|"* Mycophenolate mofetil: 500-1000mg/day, bid, PO~* Corticosteroids 500mg for the first dosage. It will be tapered at least 5mg for 3months(± 2 weeks) and withdrawn."
61947061|NCT02740439|EXPERIMENTAL|Intervention Meal|Intervention meals will contain 1 large avocado and be consumed daily for 12 weeks.
61947062|NCT02740439|PLACEBO_COMPARATOR|Control Meal|Control meals will be isocaloric to the intervention meals but without avocado. They will also be consumed daily for 12 weeks.
61947063|NCT01979965|ACTIVE_COMPARATOR|Active drug|Ranolazine therapy for three months
61947064|NCT01979965|PLACEBO_COMPARATOR|Sugar Pill|sugar pill therapy for three months
62497266|NCT02297230|EXPERIMENTAL|Arm 4: Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery \& thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
62497267|NCT05380726|EXPERIMENTAL|Experimental group|"A pilot study will be conducted for 2 months with a sample of 10 participants, in order to gather initial data to test the algorithm from the eHealth tool. During the QUAN phase the algorithm will provide individualized feedback and responses to the patients based on their different variables analyzed in real-time by the wrist receiver device: cardiovascular parameters, sleep quality and structure of sleep, physical activity, oxygen saturation.~The eHealth tool will contain all the educational materials developed by the researchers of the study. Depending on the information received from the electronic wrist device the eHealth tool will make recommendations of educational topics as hygienic-dietary measures, sleep related habits, or physical activity. The information provided in this regard will be dependent upon the subjects' knowledge gaps/beliefs identified in the QUAL phase and the parameters measures by the electronic wrist device in each subject."
62497268|NCT05380726|ACTIVE_COMPARATOR|Control group|In the control group, the participants will be provided with the same electronic wrist device and access to the eHeatlh tool as the experimental group. However, the electronic wrist device will not provide feedback based on the parameters of each individual. The information provided by the eHealth tool will be general information from the sleep unit of the Arnau de Vilanova - Santa María Hospital instead of the materials developed from the QUAL phase.
62497269|NCT02697617|PLACEBO_COMPARATOR|Placebo Arm|Subject will be on placebo
62497270|NCT02697617|ACTIVE_COMPARATOR|Pioglitazone Arm|Subject will be on pioglitazone
62698233|NCT02552264|PLACEBO_COMPARATOR|Waitlist control|Acceptance and Commitment Therapy
62698234|NCT00375713|EXPERIMENTAL|Levocetirizine|Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
62140254|NCT03865875|EXPERIMENTAL|Multimodal Prehabilitation Program|"Pretreatment exercise program and nutrition program~-The prehabilitation intervention will include the following components: (1) a standardized fitness program and (2) nutritional counseling and optimization. Patients are enrolled in the program within 8 weeks of being diagnosed and continued until operation"
62497271|NCT03892291||Civilian mTBI|Civilians with persistent symptoms from mTBI
62497272|NCT03892291||Civilian Control|Civilian healthy controls
62497273|NCT03892291||Active Duty Control|Active duty service member healthy controls
62497274|NCT03892291||Active Duty mTBI|Active duty service members with persistent symptoms from mTBI who are referred for physical therapy due to their symptoms
62497275|NCT01096602|EXPERIMENTAL|Group 1|DC AML Fusion Vaccine
62497276|NCT05157750||IBD patients with endoscopic remission|No intervention will be administered. All patients with endoscopic remission will be monitored for the future development of major clinical events. Diagnostic performances of endoscopic remission for predicting major clinical events will be calculated.
62497277|NCT05157750||IBD patients with histologic remission|No intervention will be administered. All patients with histologic remission will be monitored for the future development of major clinical events. Diagnostic performances of histologic remission for predicting major clinical events will be calculated.
62497278|NCT05157750||IBD patients with barrier healing|No intervention will be administered. All patients with barrier healing will be monitored for the future development of major clinical events. Diagnostic performances of barrier healing for predicting major clinical events will be calculated.
62497279|NCT06024148||patients hospitalized in the Geriatric Rehabilitation Department|patients aged 75 and over, admitted with a severe osteoporotic post-fracture, having received a first dose of antiosteoporotic treatment between the day of fracture and discharge from Geriatric Rehabilitation Department
62698235|NCT00375713|ACTIVE_COMPARATOR|Cetirizine|Cetirizine + Levocetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
62698236|NCT03404713|ACTIVE_COMPARATOR|Standard Behavioral Weight Loss (BWL) Treatment|All participants will participate in 4 weeks of group based behavioral weight lost treatment in the intervention called Pathways to Health. Based on early treatment response (improvement in binge eating), participants will be assigned to either continue in this arm for the remaining 12 weeks of treatment (early strong responders) or be assigned to the 2nd arm of this study.
62140255|NCT06114069|ACTIVE_COMPARATOR|all on four group|4 patients received 4-implant supported fixed prosthesis
62140256|NCT06114069|ACTIVE_COMPARATOR|all on six group|4 patients received 6-implant supported fixed prosthesis
62140257|NCT02073500||Observational study|Patients diagnosed with PSM undergoing CRS with HIPEC.
62140258|NCT06100198|EXPERIMENTAL|Intervention group|A one-group pretest-posttest design was adopted. Participants participated in 3 nutrition and exercise courses, each lasting 2 hours (including 1 hour nutrition course and 1 hour exercise course) with an interval of 1 week between each course. All subjects underwent anthropometric measurements and completed questionnaires one week before the start of the course and one week after the end of the course. A repeat assessment was conducted 6 months after the course intervention.
62140259|NCT03542305|EXPERIMENTAL|Mild|Mild renal impairment
62140260|NCT03542305|EXPERIMENTAL|Moderate|Moderate renal impairment
62140261|NCT03542305|EXPERIMENTAL|Severe|Severe renal impairment
62140262|NCT03542305|OTHER|Normal|Normal renal function
62140263|NCT01898754|EXPERIMENTAL|Pre-ART Oligonucleotide Assay (OLA)|Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
62140264|NCT01898754|NO_INTERVENTION|No OLA (Standard of Care [SOC])|The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
62698237|NCT03404713|EXPERIMENTAL|Acceptance-Based Binge Eating Treatment|After 4 weeks of standard BWL treatment, early weak responders will be assigned to individual acceptance-based treatment for the remaining 12 weeks of treatment.
61947065|NCT00740571|ACTIVE_COMPARATOR|1|Strategy in which patient starts with amitriptyline
61947066|NCT00740571|ACTIVE_COMPARATOR|2|Strategy in which patient starts with pregabalin
62497280|NCT06678009|ACTIVE_COMPARATOR|The isokinetic training group with blood flow restriction (BFR Group)|For the BFR, the occlusion pressure was set to 80% of arterial occlusion pressure as determined. The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
62497281|NCT06678009|OTHER|The isokinetic training group without blood flow restriction (Control Group)|The isokinetic training group without blood flow restriction. The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions
62497282|NCT04397640|OTHER|Sonovue|ICU patients with sepsis and septic shock who are eligible for myocardial contrast echocardiography with sulphur hexafluoride microbubbles contrast Sonovue (Bracco, Milan, Italy) injection.
62497283|NCT06435325|EXPERIMENTAL|Intervention arm|The intervention arm will receive a hypocaloric Mediterranean-style diet (TEE - 500kcal, macronutrient distribution: 45 - 55% carbohydrates, 15 - 25% protein, and 25 - 35% fat) with dietary recommendations based on the participant's gene expression profile.
61947067|NCT02587793||Barcelona Clinic Liver Cancer (BCLC) staging|The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D.
61947068|NCT01601730|PLACEBO_COMPARATOR|Placebo|
61947069|NCT01601730|ACTIVE_COMPARATOR|Modafinil 200 mg + Escitalopram 20 mg|
61947070|NCT01601730|ACTIVE_COMPARATOR|Modafinil 200 mg|
61947071|NCT01601730|ACTIVE_COMPARATOR|Escitalopram 20 mg|
61947072|NCT01518348|EXPERIMENTAL|Patch Test|
61947073|NCT05243355|EXPERIMENTAL|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w. Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles. Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total.
61947074|NCT02725931|EXPERIMENTAL|Activity group|Pulmonary rehabilitation plus physical activity intervention
61947075|NCT04346082|EXPERIMENTAL|online mindfulness group|
61947076|NCT00747461|EXPERIMENTAL|Cryospray Ablation|Experimental CSA (Cryospray Ablation)
61947077|NCT04752683||Organisation 1|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
61947078|NCT04752683||Organisation 2|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
61947079|NCT02904993|OTHER|L2 paravertebral block|regional anesthetic nerve blocks using an L2 paravertebral block with ropivacaine
61947080|NCT02904993|ACTIVE_COMPARATOR|periarticular injection group|periarticular local injection into the periarticular soft tissues at the time of hip replacement using a combination of ropivacaine, epinephrine, ketorolac and morphine sulphate (periarticular injection group).
61947081|NCT01868503|EXPERIMENTAL|Lapatinib Plus Radiation Therapy|Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.
62497284|NCT06435325|ACTIVE_COMPARATOR|Control arm|The control arm will receive a hypocaloric Mediterranean-style diet (TEE - 500kcal, macronutrient distribution: 45 - 55% carbohydrates, 15 - 25% protein, and 25 - 35% fat) personalized to the participant's dietary and lifestyle habits.
62497285|NCT04338334|ACTIVE_COMPARATOR|CONTROL GROUP|Control group includes physical therapy protocol composed of manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active arm therapeutic exercises.
62497286|NCT04338334|EXPERIMENTAL|COHESIVE BANDAGE GROUP|Cohesive bandage is a self-adherent lightweight bandage, made of a porous nonwoven polyester material. A single self-adherent inelastic bandage will be directly applied at full stretch on cleaned and dried skin (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States) in a spiral method around the limb, starting at the hand and a layer overlap of 50%, so that the greatest compression was located at the distal points, gradually decreasing toward the proximal shoulder part. Cohesive latex-free bandages will be available for those allergic women. Women will do progressive active arm therapeutic exercises with bandaging.
61947082|NCT06555497|EXPERIMENTAL|topical 1% methotrexate gel|topical 1% methotrexate gel 2x a day for 6 weeks
61947083|NCT06555497|ACTIVE_COMPARATOR|clobetasol propionate 0.05% ointment|clobetasol propionate 0.05% ointment 2x a day for 6 weeks
61947084|NCT02515448|EXPERIMENTAL|Gentamicine injectable(day 1+2)and then gentamicine inhalation|
61947085|NCT06261918||Patients without metabolic syndrome|Pre/postmenopausal patients diagnosed with breast cancer undergoing NCT and subsequent surgery with long follow-up
61947086|NCT06261918||Patients with metabolic syndrome|"Pre/postmenopausal patients diagnosed with breast cancer undergoing NCT and subsequent surgery with long follow-up~Metabolic syndrome evaluated on the basis of the following criteria:~1. BMI≥30~2. Glycosylated hemoglobin/baseline blood glucose~3. Triglycerides~4. Hypertension~5. Lipid profile"
61947087|NCT05133752|EXPERIMENTAL|Nemonoxacin|
61947088|NCT06487416|EXPERIMENTAL|Tiotropium Bromide Inhalation Powder|"Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 microgram (mcg), as tiotropium, equivalent to 22.5 microgram of tiotropium bromide monohydrate).~The subjects randomly received single oral dose of tiotropium bromide inhaling powder"
61947089|NCT06487416|EXPERIMENTAL|Spiriva®Handihaler®|"Reference Product (Spiriva®Handihaler®, Strength: 18 microgram, as tiotropium, equivalent to 22.5 microgram of tiotropium bromide monohydrate).~The subjects randomly received single oral dose of Spiriva®Handihaler®"
61947090|NCT01435902|ACTIVE_COMPARATOR|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
61947091|NCT01435902|ACTIVE_COMPARATOR|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
62497287|NCT03685617|ACTIVE_COMPARATOR|Dual chamber pacemaker|"1. Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~2. Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~3. Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
62497288|NCT03685617|EXPERIMENTAL|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
62497289|NCT00973050|EXPERIMENTAL|Bicalutamide (test)|Bicalutamide Tablet, 50 mg
62497290|NCT00973050|ACTIVE_COMPARATOR|Casodex® (reference)|Casodex® Tablet, 50 mg
62497291|NCT05561257|PLACEBO_COMPARATOR|Group 1 (control group)|300 ml NaCl infusion
62497292|NCT05561257|EXPERIMENTAL|Group 2 (750 mg Vitamin C)|295 ml NaCl + 5 ml (750 mg) Vitamin C
62497293|NCT05561257|EXPERIMENTAL|Group 3 (7.5 g Vitamin C)|250 ml NaCl + 1 x 50 ml (7.5 g) Vitamin C
62497294|NCT05561257|EXPERIMENTAL|Group 4 (15 g Vitamin C)|200 ml NaCl + 2 x 50 ml (2 x 7.5 g) Vitamin C
62698238|NCT05039307|EXPERIMENTAL|Intervention group (Educational and motivational strategy)|The intervention group will be provided with a multi-component intervention entailing the following components distributed over the 24-months study: 4 individualized education sessions at the household, 4 group activities (2 group education sessions and 2 physical activity sessions) at the healthcare center, and 4 focus groups at the healthcare center as well. The motivational components of goal setting and the use of a pedometer will be incorporated in the individualized education sessions. Moreover, community activities will be incorporated in the second year of the study after exploring whether the activities are feasible and acceptable by the community. The topics covered by the intervention are healthy diet, physical activity, weight control strategies and knowledge and awareness of T2DM and GDM. Additionally, at baseline participants will be provided with a healthy lifestyle brochure with general recommendations.
62698239|NCT05039307|NO_INTERVENTION|Comparison group (Basic educational strategy)|The comparison group will be limited to receive the healthy lifestyle brochure with general recommendations at baseline only.
62698240|NCT05053061|EXPERIMENTAL|Telerehabilitation Arm|
62698241|NCT06637579|EXPERIMENTAL|Group A|Group A received universal exercise unit therapy with task-oriented strength training.
62698242|NCT06637579|EXPERIMENTAL|Group B|Group B received task-oriented training for gross motor functioning.
62698243|NCT02071589|EXPERIMENTAL|Nifedipine oral solution|Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose
62698244|NCT02071589|ACTIVE_COMPARATOR|Nifedipine soft gelatine capsules|Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose
62698245|NCT06526273|EXPERIMENTAL|PILI 'Āina|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. The participating households will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. The investigators will provide seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks). All lessons will be delivered by a trained community health worker .
62497295|NCT04933240|ACTIVE_COMPARATOR|Tamoxifen|tamoxifen 10mg daily for 7 days
62497296|NCT04933240|ACTIVE_COMPARATOR|Estradiol|estradiol 1mg daily for 7 days
62497297|NCT04933240|PLACEBO_COMPARATOR|placebo|placebo daily for 7 days
62497298|NCT06099964|ACTIVE_COMPARATOR|Pain Coping Information|
62497299|NCT06099964|EXPERIMENTAL|Mindful Pain Management|
62497300|NCT03799224|EXPERIMENTAL|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for recurrent and refractory acute leukemia at the time of HLA-mismatched HSCT~Details:~The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2"
62497301|NCT03799224|EXPERIMENTAL|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD (minimal residual disease) at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3."
62497302|NCT02199119|EXPERIMENTAL|Control|Sitting quietly for 30 min No TV No exercise
62497303|NCT02199119|EXPERIMENTAL|TV viewing only|watching TV for 30 min
62497304|NCT02199119|EXPERIMENTAL|Exercise only|exercising for 30 min
62497305|NCT02199119|EXPERIMENTAL|TV viewing and Exercise|30 min of moderate exercise on a treadmill while watching TV
62497306|NCT00904280|EXPERIMENTAL|Oxymorphone ER|
62497307|NCT05667597|EXPERIMENTAL|Residents and staff from nursing homes from the previous PICOV-VAC study|
62497308|NCT05667597|EXPERIMENTAL|Healthy adults from the previous REDU-VAC study|
62497309|NCT05667597|EXPERIMENTAL|Kidney transplant and dialysis patients from the previous NEPHRO-VAC study|
62497310|NCT05667597|EXPERIMENTAL|Lung transplant patients from the previous LUNG-VAC study|
62497311|NCT03316157|EXPERIMENTAL|Rehabilitation|Advanced cancer patients will receive an 8 week rehabilitation intervention consisting of physical exercise and nutritional supplementation, along with standard care
62497312|NCT03316157|NO_INTERVENTION|Waiting list Control|Standard care alone for the 8 week trial period, followed by participants being offered the rehabilitation programme
62497313|NCT01824576|EXPERIMENTAL|ITPR|Use of the ITPR for 120 minutes.
62497314|NCT03358147|EXPERIMENTAL|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
61947092|NCT02831140|OTHER|Common arm : for both groups :|"* In preoperative phase~* In peroperative phase~* In postoperative phase"
62497315|NCT03358147|EXPERIMENTAL|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
62497316|NCT03358147|EXPERIMENTAL|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
62497317|NCT03358147|PLACEBO_COMPARATOR|Placebo MDI|Taken as 2 inhalations BID
62497318|NCT03358147|OTHER|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
62497319|NCT06492551|EXPERIMENTAL|Experimental group|Exercise protocol to be performed through Trak. Trak is a rehabilitation tool and, therefore, the product of investigation.
62497320|NCT06492551|ACTIVE_COMPARATOR|Control Group|Exercise protocol with conventional methods in the Asunción Klinika gym.
62497321|NCT05355519|ACTIVE_COMPARATOR|Curriculum and Instructor-Led Course|Participants first complete an online cognitive assessment. Once complete, staff email the electronic curriculum for participants to read. On a specific day, participants will go to the designated center to participate in an instructor-led course and simulated medical scenarios and complete megapode and online cognitive assessment. After a washout period of six months, participants return to the designated center to participate in simulated medical scenarios and complete the online cognitive assessment again. After a second washout period of six months, participants will take the online cognitive assessment again.
62497322|NCT05355519|PLACEBO_COMPARATOR|Placebo|On a specific day, participants will go to a designated center to complete an online cognitive assessment and participate in simulated medical scenarios. Once complete, study staff will email the electronic curriculum for participants to read. After a washout period of six months, participants will return to the designated center to participate in an instructor-led course and simulated medical scenarios and complete a megapode and online cognitive assessment. After a second washout period of six months, participants will take an online cognitive assessment again.
62497323|NCT00999362||Early kidney-transplant recipients|Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.
62497324|NCT00999362||stable kidney transplant recipients|Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation
62497325|NCT03519438||Lateral 3/4 of treatment field|placement of Mepitel on the lateral ¾ of the treatment field
62497326|NCT03519438||Medial 3/4 of treatment field|placement of Mepitel on the medial ¾ of the treatment field
62497327|NCT03252717|EXPERIMENTAL|blood sample|Pre-treatment blood samples will be collected: 8 samples
62497328|NCT00881231|EXPERIMENTAL|1|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
62497329|NCT00881231|ACTIVE_COMPARATOR|2|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
62497330|NCT05694260|EXPERIMENTAL|Cohort 1|Patients at 16 to \<30 kg body weight at screening receiving once daily 60 mg bempedoic acid for 8 weeks followed by 90 mg bempedoic acid for 8 weeks.
62497331|NCT05694260|EXPERIMENTAL|Cohort 2|Patients at 30 to 60 kg body weight at screening receiving once daily120 mg bempedoic acid for 8 weeks followed by 150 mg bempedoic acid for 8 weeks.
62497332|NCT05694260|EXPERIMENTAL|Cohort 3|Patients at greater than 60 kg body weight at screening receiving once daily 180 mg bempedoic acid for 8 weeks.
62497333|NCT00547625|PLACEBO_COMPARATOR|1|Placebo run in followed by 5 mg treatment phase 1 and then 20 mg treatment phase 2 which both include a placebo control.
62497334|NCT00547625|ACTIVE_COMPARATOR|2|Treatment phase 1 includes 5 mg tadalafil 6 weeks then treatment phase 2 which includes 20 mg tadalafil for 6 weeks.
62497335|NCT00691704|EXPERIMENTAL|High-risk Multiple Myeloma|Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy
62497336|NCT04479735|EXPERIMENTAL|VR goggle with venipuncture|Virtual reality goggles SamsungGearVR supplied by KindVR will be placed on patients at least 2 min prior to venipuncture. All patients will also receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture.
62497337|NCT04479735|NO_INTERVENTION|no VR goggle with venipuncture|Patients will receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture but NO virtual reality goggles.
62497338|NCT00666354|ACTIVE_COMPARATOR|1|
62497339|NCT00666354|ACTIVE_COMPARATOR|2|
62497340|NCT00666354|ACTIVE_COMPARATOR|3|
62497341|NCT03241186|EXPERIMENTAL|Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV|"Cycles 1-4: Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV Day 1 of each Cycle Each Cycle = 21 days~Cycles 5-15: Nivolumab IV 480 mg Day 1 of each Cycle Each Cycle = 28 days"
62497342|NCT01214239|EXPERIMENTAL|Linagliptin|once a day
62497343|NCT01214239|PLACEBO_COMPARATOR|Placebo|once a day
62497344|NCT06677736|EXPERIMENTAL|conventional scaling and debridement young age patient|conventional scaling and debridement young age patient
62497345|NCT06677736|EXPERIMENTAL|conventional scaling and debridement old age patient|conventional scaling and debridement old age patient
62497346|NCT06677736|EXPERIMENTAL|diode laser as adjunctive to scaling and debridement young age patient|diode laser as adjunctive to scaling and debridement young age patient
62497347|NCT06677736|EXPERIMENTAL|diode laser as adjunctive to scaling and debridement old age patient|diode laser as adjunctive to scaling and debridement old age patient
62497348|NCT01780467|EXPERIMENTAL|patients with and without treatment by L dopa)|to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
61947093|NCT02831140|EXPERIMENTAL|FTR protocol group (A)|"A. Experimental : FTR protocol group :~Early exercises after a thoracic surgery : removing urinary probe and all catheters as well as alimenting ."
62497349|NCT01780467|OTHER|healthy paired control|to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
62497350|NCT03318757|EXPERIMENTAL|Group 1- Bupivacaine extended release liposome injection|Bupivacaine extended release liposome injection (Exparel TM) is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.
62497351|NCT03318757|ACTIVE_COMPARATOR|Group 2- Bupivacaine HCl|Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area in which the drug is applied.
62497352|NCT05419505|EXPERIMENTAL|Cohort 1: CCH-aaes Dose Evaluation|Participants will be administered CCH-aaes at different doses. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
62497353|NCT05419505|EXPERIMENTAL|Cohort 2: CCH-aaes Concentration Evaluation|Participants will be administered CCH-aaes at different concentrations. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
62497354|NCT05419505|EXPERIMENTAL|Cohort 3: CCH-aaes Injection Depth Evaluation|Participants will be administered CCH-aaes using different injection depths. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
62698246|NCT06526273|ACTIVE_COMPARATOR|Control|Participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers markets, cultural events, and physical activity events.
61947094|NCT02831140|NO_INTERVENTION|Control group (B)|Traditional, conventional care group with first get up and alimentation permission in 24 hours at the postoperative.
61947095|NCT01971242|ACTIVE_COMPARATOR|Exenatide|Bydureon- 2mg administered subcutaneously once weekly
61947096|NCT01971242|PLACEBO_COMPARATOR|Placebo|Placebo, 2mg administered subcutaneously once weekly
61947097|NCT00499239|EXPERIMENTAL|GS-9219|Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m\^2) until determination of the maximum tolerated dose (MTD)
61947098|NCT00089414|EXPERIMENTAL|1|Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
61947099|NCT00089414|ACTIVE_COMPARATOR|2|Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
61947100|NCT00089414|ACTIVE_COMPARATOR|3|Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
61947101|NCT01971996||Lumbar spine surgical patients|Patients undergoing lumbar spine surgery in the prone position
61947102|NCT05571670||Patients treated with PI3K/AKT/mTOR inhibitors for cancer|Patients with cancer being treated with PI3K/AKT/mTOR inhibitors will be studied prospectively for the impact of treatment on bile acid metabolism as a function of drug-induced acute insulin resistance. Treatments will be selected by patients' treating oncologist based on standard of care.
61947103|NCT02927886|EXPERIMENTAL|Per-oral Endoscopy Pyloromyotomy (G-POEM)|
61947104|NCT02927886|PLACEBO_COMPARATOR|Intrapyloric injection of botulinum toxin|
61947105|NCT06281574||Patients with shoulder arthroplasty|Including all surgical interventions (anatomic total shoulder arthroplasty, humeral head hemi arthroplasty or reversed shoulder arthroplasty) for patients with shoulder arthroplasty
62140265|NCT00933270|EXPERIMENTAL|SUPERA® Nitinol Stent System|Implantation of SUPERA nitinol stent using the SUPERA® Nitinol Stent System
62497355|NCT05419505|EXPERIMENTAL|Cohort 4: CCH-aaes Injection Method Evaluation|Participants will be administered CCH-aaes using different injection methods. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
62497356|NCT05419505|EXPERIMENTAL|Cohort 5: CCH-aaes and Diluent Additive Evaluation|Participants will be administered CCH-aaes and diluent additive. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
62497357|NCT05419505|EXPERIMENTAL|Cohort 6: CCH-aaes Dose, Concentration, and Treatment Schedule Evaluation|Participants will be administered CCH-aaes using a different treatment schedule and different doses and concentrations. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
62497358|NCT05419505|EXPERIMENTAL|Cohort 7: CCH-aaes and Antifibrinolytic Agent|Participants will be administered CCH-aaes and an antifibrinolytic agent. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
62497359|NCT04411017|ACTIVE_COMPARATOR|1L PEG|
62497360|NCT04411017|ACTIVE_COMPARATOR|2L PEG|
62497361|NCT04411017|ACTIVE_COMPARATOR|2L sodium picosulfate|
62497362|NCT04619862|EXPERIMENTAL|Medication|"Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.~The starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: \< 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day."
62698247|NCT04581395|OTHER|Not pretreated|Succinylcholine administration with no Rocuronium pre-treatment
62497363|NCT04619862|PLACEBO_COMPARATOR|Placebo|Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.
62497364|NCT02753465|EXPERIMENTAL|left colic artery group|Laparoscopic D3 Lymph Node Dissection with preservation of the left colic artery
62698248|NCT04581395|ACTIVE_COMPARATOR|Pre-treated 1 minute before succinylcholine administration|Succinylcholine administration 1 minute following Rocuronium pre-treatment
62698249|NCT04581395|ACTIVE_COMPARATOR|Pre-treated 2 minutes before succinylcholine administratjion|Succinylcholine administratjion 2 minutes following Rocuronium pre-treatment
61947106|NCT05345977|EXPERIMENTAL|Unified Protocol|The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
61947107|NCT02358681|EXPERIMENTAL|Ketorolac, intranasal|"1. Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.~2. Placebo, intravenous."
61947108|NCT02358681|ACTIVE_COMPARATOR|Ketorolac, intravenous|"1. Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.~2. Placebo, intranasal."
62340873|NCT04315610|EXPERIMENTAL|Access to mobile application|This application will help parents to recognize symptoms of reduced health status in their infant, provide decision-making support, increase their communication skills with health professionals, and provide easier access to quality assured information. At first login, the diagnosis, treatment, and contacts in the health service are registered to provide parents with personalized information that is adapted to their infant's needs. Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application.
62497365|NCT02753465|ACTIVE_COMPARATOR|High ligation group|Laparoscopic D3 Lymph Node Dissection with high ligation
61947109|NCT03473171|EXPERIMENTAL|Nasal non-invasive ventilation with RAM cannula|
62497366|NCT02569528||Patients|Patients of consenting providers will complete a short survey and interview.
61947110|NCT04871971|PLACEBO_COMPARATOR|Glucose|Glucose 50 g available carbohydrate
61947111|NCT04871971|EXPERIMENTAL|10 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 10 g NUTRALYS®S85 Plus pea protein
62497367|NCT02569528||Providers|Physicians treating patients with atrial fibrillation will complete a short survey and interview.
62497368|NCT05317806|EXPERIMENTAL|Metformin Treatment Group|Subjects with PAI-1 deficiency with or without cardiac fibrosis, receiving daily treatment with metformin for a daily range of 500-2000mg
62497369|NCT05317806|NO_INTERVENTION|Observation Group|"Subjects with PAI-1 deficiency with or without cardiac fibrosis, not receiving treatment with metformin~Subjects are allowed to switch between the two groups"
62497370|NCT05995873|SHAM_COMPARATOR|treatment|Half of the participants will receive sham. Treatment will be 2 times a week for 4 weeks, then once a week for 20 weeks and then a followup 1 week later. The sham device is identical to the active device except that it has foil over the LED.
62698250|NCT05388487|EXPERIMENTAL|Dose escalation cohort 1: HF1K16 given QOD at 45 mg/m²|The first dosing group (45 mg/m²) will include a sentinel subject receiving one dose followed by a 7-day safety evaluation interval. Three or more subjects will receive 7 doses of HF1K16 QOD at 45 mg/m2 per cycle of 21 days.
62698251|NCT05388487|EXPERIMENTAL|Dose escalation cohort 2: Oral ATRA followed by HF1K16 QOD at 90 mg/m²|The second dosing group will receive oral ATRA at 45mg/m², and three days later HF1K16 QOD at 90 mg/m2 for 7 times per cycle of 21 days.
61947112|NCT04871971|EXPERIMENTAL|20 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 20 g NUTRALYS®S85 Plus pea protein
61947113|NCT04871971|EXPERIMENTAL|10 g Whey protein concentrate|50 g available carbohydrate Glucose + 10 g Whey protein concentrate
61947114|NCT04871971|EXPERIMENTAL|20 g Whey protein concentrate|50 g available carbohydrate Glucose + 20 g Whey protein concentrate
61947115|NCT05124535||Persons aged 18-29|
61947116|NCT05124535||Persons aged 30-39|
61947117|NCT05124535||Persons aged 40-65|
61947118|NCT00837356|EXPERIMENTAL|Advate®/turoctocog alfa|
61947119|NCT04382300|EXPERIMENTAL|Treatment arm|pyrotinib 400mg p.o. qd, combined with thalidomide 200mg p.o. qd
61947120|NCT03888586|EXPERIMENTAL|Dry Needling|Participants were administered trigger point dry kneedling technique 6 times for 1 month, once every 5 days. The subject was positioned prone and the arm position was slightly changed related with the muscle. After the skin inspection it was cleaned with the alcohol. .
62497371|NCT05995873|EXPERIMENTAL|Active treatment|Participants in this group will receive a 4-minute unilateral transcranial photobiomodulation treatment.
62497372|NCT06375187|EXPERIMENTAL|Treatment Arm|Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL)
62497373|NCT05533034|EXPERIMENTAL|Home based exercises|1 supervised session in the outpatient rehabilitation department with respiratory, aerobic and muscles strengthening exercises, followed by 3 months of self-manage personalized home exercises program. Cardiac frequency and adherence to exercise will be monitored using an activity tracker (Garmin© watch).
62497374|NCT05797870|EXPERIMENTAL|188Re-SSS lipiodol SIRT|Patients in the experimental arm will be treated with 188Re-SSS lipiodol Selective Internal Radiotherapy (SIRT).
62497375|NCT05760261|EXPERIMENTAL|GSK3882347 and MDZ|Period 1: Participants will receive MDZ on Day 1. Period 2: Participants will receive 14-days of repeat dosing of GSK3882347 Followed by one dose of MDZ co-administered with GSK3882347 on Day 15.
62497376|NCT00377156|ACTIVE_COMPARATOR|Arm I|Patients undergo stereotactic radiosurgery (SRS)
62698252|NCT05388487|EXPERIMENTAL|Dose escalation cohort 3: HF1K16 QOD at 120 mg/m²|The cohort 3 will receive 7 doses of HF1K16 QOD at 120 mg/m² per cycle of 21 days.
62698253|NCT05388487|EXPERIMENTAL|Dose escalation cohort 4: HF1K16 QOD at 160 mg/m²|The cohort 4 will receive 7 doses of HF1K16 QOD at 160 mg/m² per cycle of 21 days.
62698254|NCT05388487|EXPERIMENTAL|Dose escalation cohort 5: HF1K16 QOD at 120mg or180 mg|The cohort 5 will receive 7 doses of HF1K16 QOD at 120 mg or 180mg per cycle of 21 days.
62698255|NCT02160808|ACTIVE_COMPARATOR|Secretin|Stimulate pancreatic secretion
62698256|NCT02160808|PLACEBO_COMPARATOR|Saline|Placebo should not stimulate the pancreas to release its fluids
62698257|NCT01979185|ACTIVE_COMPARATOR|Simvastatin|Administered as a single oral 20 mg dose on Day 1.
62698258|NCT01979185|EXPERIMENTAL|Simvastatin + SSP-004184SS|Simvastatin (20 mg) + SSP-004184SS (30 mg/kg) administered concomitantly as a single oral dose on Day 1.
61947121|NCT03888586|EXPERIMENTAL|Deep Friction Massage|Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
62698259|NCT04198428|EXPERIMENTAL|Receives OUD-CDS|Clinics will have access to the OUD-CDS (Opioid Wizard)
62698260|NCT04198428|NO_INTERVENTION|Does not Receive the OUD-CDS|"Clinics will not have access to the OUD-CDS (Opioid Wizard). These will be usual care clinics."
62698261|NCT00553085||Anx group|
62698262|NCT00553085||ADHD group|
62698263|NCT00553085||Nonanx/nonadhd group|
62698264|NCT00095576|EXPERIMENTAL|Trivalent MRKAd5 HIV-1 gag/pol/nef|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10\^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
62698265|NCT00095576|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.
62698266|NCT05414799|OTHER|Control Group|in control group,33 participants (17=male, 16=female) performed figure eight vision exercise for 30 seconds once a day for 4 to 5 days per week for total duration of 4 week.
62698267|NCT05414799|EXPERIMENTAL|Experimental Group|in experimental group, 33 participants (17=male, 16=female) performed figure eight vision exercise for 30 seconds followed by chin nodding for 20 second and followed by self neck stretching for 20 seconds. All the exercises are performed once a day for 4 to 5 days per week for total duration of 4 week.
62698268|NCT04921267|EXPERIMENTAL|trained group|group receives training with sounds that correspond to simulated hearing protection
62698269|NCT04921267|NO_INTERVENTION|Control|group receives no training
62340874|NCT04315610|ACTIVE_COMPARATOR|Treatment as usual|This group receives traditional oral and written information about their child's heart defect and further follow-up.
61947122|NCT05081765||Patients with diabetes mellitus|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
61947123|NCT05081765||Patients with hyperglycemia,|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
61947124|NCT05081765||Patient with normal glucose level|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
61947125|NCT00865670|EXPERIMENTAL|1|Azithromycin Monohydrate 600mg Tablets
61947126|NCT00865670|ACTIVE_COMPARATOR|2|Zithromax (azithromycin dihydrate)600mg Tablets
61947127|NCT05562687||Control group|subjects who do not have any heart disease, hypertension, or other chronic \&inflammatory diseases, and their coronary arteries are normal
61947128|NCT05562687||CAD group with essential hypertension|subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have high blood pressure
61947129|NCT05562687||CAD group without essential hypertension|subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have normal blood pressure
62340875|NCT00262080|EXPERIMENTAL|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
62340876|NCT00262080|PLACEBO_COMPARATOR|Placebo|Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
62340877|NCT03294668|EXPERIMENTAL|KONTAKT Australia|A social skills group training
62698270|NCT03141437|ACTIVE_COMPARATOR|Arm I (standard of care)|Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
62698271|NCT03141437|EXPERIMENTAL|Arm II (standard of care, decision-making website)|Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
62698272|NCT06077357|ACTIVE_COMPARATOR|COPD Patients|Having COPD. Older than 65 years old and not having any communication problems.
61947130|NCT05562687||Hypertension group without CAD|the subjects were characterized by the normal coronary artery and high blood pressure
61947131|NCT00066638|EXPERIMENTAL|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
61947132|NCT04673968|ACTIVE_COMPARATOR|prehabilitation (P)|inhospital exercise training 5 times/week, 5\~6 weeks during nCRT (neoadjuvant chemoraiotherapy); home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
61947133|NCT04673968|NO_INTERVENTION|control group (C)|no prehabilitation
62340878|NCT03294668|ACTIVE_COMPARATOR|Super Chef|A social cooking group
62698273|NCT06077357|ACTIVE_COMPARATOR|Asymptomatic Patients|Not having a diagnosis of COPD and being over 65 years old and not having any communication problems.
62698274|NCT06638528|EXPERIMENTAL|Walking apnea|Walking apnea at High Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes.
62698275|NCT06638528|ACTIVE_COMPARATOR|Walking normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes.
62698276|NCT05456087|EXPERIMENTAL|Single treatment with Xeomin® (incobotulinumtoxin A)|Individual balding scalps will be outlined and mapped to include up to 30 injection sites evenly distributed within the hair loss area. At each site, 5 Units of Xeomin® will be injected with a maximum of 150 Units total per subject. This will be a single, one-time treatment session.
62698277|NCT06563934|EXPERIMENTAL|Experimental: Lenvatinib + PD-1 monoclonal antibody + Enterobacterium capsules|"1. Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day. PD-1 monoclonal antibody 200mg i.v. once every 3 weeks.~2. Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days, and then discontinued to the next course of treatment."
62497377|NCT00377156|EXPERIMENTAL|Arm II|Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.
62497378|NCT00633698|ACTIVE_COMPARATOR|1|Nicotinic acid (niacin)
62497379|NCT00633698|PLACEBO_COMPARATOR|2|Placebo
62497380|NCT05820919|OTHER|Control (each NH acts as its own control):|Each nursing home serves as its own control. Control data will be collected for 1 week (then the intervention will begin).
62497381|NCT05820919|EXPERIMENTAL|Intervention (all NHs receive the intervention):|The intervention arm includes a ten-week active intervention phase, then a five-week sustainment phase.
62497382|NCT00926367|EXPERIMENTAL|Clinidamycin/ Benzoyl Peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).
62497383|NCT00926367|ACTIVE_COMPARATOR|Benzoyl peroxide and adapalene|Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene
62497384|NCT02214563|ACTIVE_COMPARATOR|Thrice-weekly cholecalciferol|Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
62497385|NCT02214563|ACTIVE_COMPARATOR|Monthly cholecalciferol|Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
62497386|NCT02214563|PLACEBO_COMPARATOR|Thrice-weekly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
62497387|NCT02214563|PLACEBO_COMPARATOR|Monthly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
62497388|NCT03324217|EXPERIMENTAL|Motor Imagery Group|The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
62497389|NCT03324217|EXPERIMENTAL|Action Observation Group|The participants in the action observation group were given instructions to perform a daily training comprised of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant simply watched a video that showed a forearm performing the task, placed in the standard position and with the tennis ball in the hand. Once that first set was completed, the participant took a 2-minute break before starting the second set, in which they performed the 10 isometric contractions with the tennis ball while they watched the video.
62497390|NCT03324217|ACTIVE_COMPARATOR|Control Group|The participants in the control group were given instructions to perform a daily training of a single set. The set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions.
62698278|NCT06563934|PLACEBO_COMPARATOR|Lenvatinib + PD-1 monoclonal antibody + Enterobacterium capsules placebo|"1. Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day. PD-1 monoclonal antibody 200mg i.v. once every 3 weeks.~2. Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days, and then discontinued to the next course of treatment."
62698279|NCT06570980||Group A- type 2 diabetic patients having sulfonylurease with metformin|"Sulfonylurease- gliclazide(30/60/80mg), glimepiride (1/2/3/4mg), glibenclamide (5mg), glipizide (5mg)~metformin - 500/850/1000mg"
62698280|NCT06570980||Group B- type 2 diabetic patients having DPP4 inhibitors with metformin|"DPP4 inhibitors- Linagliptin (2.5/5mg), Sitagliptin (50mg), Vildagliptin (50mg)~metformin - 500/850/1000mg"
62698281|NCT03986892||COmPLETE-Health|No intervention
62698282|NCT03986892||COmPLETE-Heart|No intervention
62698283|NCT03232567|EXPERIMENTAL|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
62698284|NCT03232567|EXPERIMENTAL|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
62698285|NCT03232567|EXPERIMENTAL|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
62698286|NCT03232567|PLACEBO_COMPARATOR|Placebo|Normal saline administered by intranasal spray at a single dose
62698287|NCT03810807|EXPERIMENTAL|Dacomitinib and Osimertinib|"Patients will begin on combination dacomitinib and osimertinib at the prescribed doses.~A cycle will be 28 days in duration. The study will use a standard 3+3 dose escalation design. Per MD discretion, telemedicine visits may be utilized for cycles where imaging is not collected, and physical exam, vital sign and labs collection will only be required concurrent with imaging visits."
62698288|NCT06068621|EXPERIMENTAL|Venetoclax Combined With CACAG Regimen|Venetoclax combined with CACAG regimen for newly diagnosed AML. Recipients were randomized and those entering the experimental group received azacytidine, cytarabine,aclacinomycin,chidamide,venetoclax and granulocyte colony-stimulating factor. Azacytidine was used as 75 mg/m2/day from day 1 to day 7. Cytarabine was used as 75-100 mg/m2 bid from day 1 to day 5. Aclacinomycin was used as 20 mg/day on days 1,3,5. Chidamide was used as 30 mg/day on days 1,4,8,11. Venetoclax was used as 400 mg/day from day 1 to day 14;Combined with posaconazole, reduced to 100 mg/day;Combined with voriconazole, reduced to 200 mg/day.Granulocyte colony-stimulating factor was used as 300 μg/day from day 0 until agranulocytosi recovery .
61947134|NCT01897714|EXPERIMENTAL|Phase I: Melflufen 15 mg + Dexamethasone|Intravenous (IV) infusion of 15 milligram (mg) melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
61947135|NCT01897714|EXPERIMENTAL|Phase I: Melflufen 25 mg + Dexamethasone|IV infusion of 25 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
62140266|NCT05555628|EXPERIMENTAL|Mandibular Exercise|At the beginning of the treatment, the therapist will perform a soft tissue massage to the patient's muscles. Then, an exercise protocol for specific muscles (masseter, temporal muscles, mandibular region muscles) will be administered. This group, the exercise will focus only on the chin area, not general like posture.
62497391|NCT04960761|EXPERIMENTAL|Intervention Group|Pre-operative training will be given by the clinic nurse with audio and picture book. Training content with audio and picture book; Before the operation, the procedures performed during the admission of the patient to the service (introducing the clinic and staff to the patient), what are the preoperative preparations (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown), wearing a patient tag on the wrist, taking him to the operating room on a stretcher), which will be used during the operation anesthesia techniques and how to provide sedation (the anesthetic agent can be given by mask or IV catheter, the reasons are the clothes worn by doctors and nurses in the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.).
62497392|NCT04960761|NO_INTERVENTION|Control Group|Routine training will be given by a nurse working in the clinic during the preoperative period. The content of the routine training: What are the procedures performed during the admission of the patient to the service before the operation (introducing the clinic and the staff to the patient), what the preoperative preparation is (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown, wearing a patient tag on the wrist, with a stretcher. being taken to the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.), there may be some medical materials that were applied to the patient during the surgery (nasogastric tube, IV catheter, types of drains placed in the wound site) includes information such as
62698289|NCT06068621|ACTIVE_COMPARATOR|"3+7 Regimen"|Idarubicin+cytarabine(IA) regimen or daunorubicin+cytarabine(DA) regimen for newly diagnosed AML.Recipients were randomized and those entering this group received IA or DA induction chemotherapy. With the IA regimen,recipients received idarubicin(8-10 mg/m2) for three days and cytarabine(75-100 mg/m2, every 12 hrs) for seven days. With the DA regimen,recipients received daunorubicin(60 mg/m2)for three days and cytarabine(75-100 mg/m2,every 12 hrs)for seven days.
61947136|NCT01897714|EXPERIMENTAL|Phase I: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
61947137|NCT01897714|EXPERIMENTAL|Phase I: Melflufen 55 mg + Dexamethasone|IV infusion of 55 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
61947138|NCT01897714|EXPERIMENTAL|Phase I + II: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day or 28-day treatment cycles, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycles. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each treatment cycle.
61947139|NCT01897714|EXPERIMENTAL|Phase II: Melflufen 40 mg (Single Agent)|IV infusion of 40 mg melflufen on Day 1 of each 28-day treatment cycle.
61947140|NCT03397615|ACTIVE_COMPARATOR|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
61947141|NCT03397615|NO_INTERVENTION|Non betadine douches|subjects didnot received a vaginal preparation prior to caesarean delivery
61947142|NCT00671333|ACTIVE_COMPARATOR|1|(LRTI) Ligament reconstruction and tendon interposition
61947143|NCT00671333|ACTIVE_COMPARATOR|2|Ascension PyroDisk
61947144|NCT01047670|EXPERIMENTAL|1|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
61947145|NCT01047670|PLACEBO_COMPARATOR|2|placebo
61947146|NCT02759497||Serum amyloid A level in SBP|serum amyloid A level
61947147|NCT02759497||Serum amyloid A level in cirrhosis|Serum amyloid A level
62714792|NCT05659849|EXPERIMENTAL|Manual therapy with Neuromuscular training|"Manual physical therapy is intended to improve musculoskeletal function and pain by addressing impaired kinematics of the joint. Passive Joint Mobilization (PJM) was applied to knee distraction and dorsal glides, ventral glides, and patellar glides in all directions, which were applied at a rate of two to three oscillations per second for 1-2 min. Each direction was repeated three to six times.~Neuromuscular training (NEMEX-TJR training program):~(2 times per week for 6 weeks) The neuromuscular training program consists of 3 parts: warming up, a circuit program, and cooling down. The program is performed twice a week for 6 weeks, with each session lasts for 60 minutes."
61947148|NCT05203432|EXPERIMENTAL|Red Light Intervention|Repeated Low-Level Red-Light Therapy
61947149|NCT05203432|ACTIVE_COMPARATOR|Low concentration atropine|0.01% atropine
61947150|NCT04074031|EXPERIMENTAL|minimally invasive method for performing thalamotomy|We will study patients with essential tremor with significant disability despite well-conducted drug therapy who have a contraindication to deep brain stimulation or who refuse treatment. In this population, unilateral thalamotomy of Vim by radiosurgery is already considered a valid indication and performed routinely with proven efficacy and morbidity deemed acceptable. It is therefore the population of choice to evaluate for the first time in France the efficacy and safety of a new, minimally invasive method for performing thalamotomy: targeted ultrasound thermal injury at high intensity. This same population will also make it possible to study, for the first time in humans in this indication, the potential of neuromodulation by low frequency low frequency ultrasound beams to improve the guidance before the lesion is achieved.
61947151|NCT03798197|ACTIVE_COMPARATOR|30 mg estetrol (E4) without food (fasted)|Treatment A (reference): One 30 mg E4 tablet administered orally following an overnight fast of at least 10 hours.
61947152|NCT03798197|EXPERIMENTAL|30 mg estetrol (E4) with food (fed)|Treatment B (test): One 30 mg E4 tablet administered orally 30 min after the start of an FDA prescribed high-fat breakfast preceded by at least a 10 hours overnight fast.
61947153|NCT04736693||Raloxifene|Reference Group
61947154|NCT04736693||Zoledronic Acid|Exposure Group
61947155|NCT01524731|PLACEBO_COMPARATOR|Placebo|Placebo group
61947156|NCT01524731|ACTIVE_COMPARATOR|4 mg dexamethasone|4 mg dexamethasone group
61947157|NCT01524731|ACTIVE_COMPARATOR|Dexamethasone 8 mg|Dexamethasone 8 mg group
61947158|NCT03822182|OTHER|Control/Bupivicaine +DMSO|Group 1 will serve as the control and receive the standard injection consisting 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone.
61947159|NCT03822182|ACTIVE_COMPARATOR|Liposomal bupivicaine|Group 2 will receive a block with 15ml 0.5% bupivacaine and 10ml (133mg) of liposomal bupivicaine (Exparel) and 5.4ml of Normal Saline
62698290|NCT05329831|EXPERIMENTAL|Experimental|"Patients will be asked to fill out the Introductory Information Form, the Numerical Rating Scale, the Oxford Happiness Scale Short Form, and the Life Activities Scale scales. Then, the educational needs of the patients in the experimental group will be determined. Trainings will be planned individually for each patient according to the needs of the patients.~After the patients go to their homes, telehealth will be implemented. Patients included in the experimental group will continue their routine physician appointments and prescriptions. In addition, telehealth education initiative will be made for the patients. Structured training will be applied to the patients once a week for 12 weeks, each training will be 20-40 minutes. The researcher will develop a trusting relationship with the patient and evaluate the patient's compliance with treatment, obstacles to happiness, information needs related to pain management, and difficulties in life activities."
62698291|NCT05329831|NO_INTERVENTION|Control|No application will be made by the researcher to the patients in the control group. Patients will continue with their prescriptions and physician visit routines. The scales will be administered to the patients in this group at the beginning of the study and at the 4th, 8th, and 12th weeks.
62698292|NCT06283212|EXPERIMENTAL|Cohort X|Cohort X will evaluate ETX101 dose level 1.
61947160|NCT03822182|ACTIVE_COMPARATOR|Liposomal Bupivicaine +DMSO|Group 3 will receive 15ml of 0.5% bupivicaine and 10ml (133mg) of Liposomal Bupivicaine (Exparel) and 0.4ml (4mg) dexamethasone and 5ml normal saline
61947161|NCT02520830|ACTIVE_COMPARATOR|Blueberry Group|Dietary Supplement: 22 gram freeze-dried blueberry powder per day
61947162|NCT02520830|PLACEBO_COMPARATOR|Placebo Group|blueberry polyphenol deprived powder 22 gram per day
61947163|NCT05413070||Lowest Performing Practices|This is the group of 5 to 10 primary care practices that incurred the highest amount of low-value back pain imaging based on claims data reports. This group will receive the survey and the intervention (brief training sessions in existing quality improvement meetings, performance reports, etc.).
61947164|NCT05413070||Highest Performing Practices|This is the group of 5 primary care practices that incurred the lowest amount of low-value back pain imaging based on claims data reports. This group will only receive the survey.
61947165|NCT00573937|ACTIVE_COMPARATOR|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
61947166|NCT00573937|ACTIVE_COMPARATOR|Morphine|Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.
61947167|NCT01014000|ACTIVE_COMPARATOR|Empirical|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
61947168|NCT01014000|EXPERIMENTAL|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
61947169|NCT04034836|EXPERIMENTAL|The scalp blocks group|The scalp blocks group will receive scalp blocks with ropivacaine, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine (5 ug/mL) and i.v. saline 2ml;
61947170|NCT04034836|ACTIVE_COMPARATOR|The i.v. group|The i.v. group will receive scalp blocks with ropivacaine 20ml, plus saline 2ml with epinephrine (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously.
62140267|NCT05555628|EXPERIMENTAL|Mandibular and Postural Exercise|The patients will perform posture exercises, including stabilization of the upper body and cervical region, accompanied by a physiotherapist. A theraband suitable for the patient's muscular strength will be used for posture exercises,. The appropriate therabant selection will be decided by a maximum repetition method.
62497393|NCT04189120|ACTIVE_COMPARATOR|Thoracic epidural analgesia (TEA)|Under full aseptic conditions and wearing sterile gloves while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine, then an 18-G Epidural needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal or IV injection. After negative response, 15 ml of 0.25% epidural bupivacaine will be injected and the patient will be turned to the supine position.
62698293|NCT06283212|EXPERIMENTAL|Cohort Y|Cohort Y will evaluate ETX101 dose level 2.
62698294|NCT06283212|EXPERIMENTAL|Cohort Z|Cohort Z will evaluate ETX101 dose level 3.
62698295|NCT03747367|NO_INTERVENTION|Baseline|8 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab. Repeated for visit 1 and visit 2.
62698296|NCT03747367|EXPERIMENTAL|Insufficient Sleep|3 days with 3 hour sleep opportunities in lab, immediately following baseline on both visit 1 and visit 2.
62698297|NCT06560736|OTHER|Immediate Intervention Group|
62698298|NCT06560736|OTHER|Wait List / Delayed Intervention Group|
62698299|NCT06055751||Transcatheter aortic valve replacement (TAVR) with Boston Scientific Loop Recorder|This is a group of patients who have undergone TAVI procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473).
61947171|NCT04034836|ACTIVE_COMPARATOR|The control group|The control group will receive scalp blocks with ropivacaine, 20ml, plus saline 2ml with epinephrine (5 ug/mL) and i.v. saline 2ml;
61947172|NCT01199172|NO_INTERVENTION|Control|
61947173|NCT01199172|EXPERIMENTAL|voice hygiene|Subjects will receive training in voice hygiene
61947174|NCT01199172|EXPERIMENTAL|VH + VP|
61947175|NCT05369767|EXPERIMENTAL|SAD, SHR-2004|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 injection
61947176|NCT05369767|PLACEBO_COMPARATOR|SAD, SHR-2004 placebo|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 placebo injection
61947177|NCT04337268|ACTIVE_COMPARATOR|human glucagon-like peptide-1|"Intervention:~Drug: human glucagon-like peptide-1 Other names: GLP-1"
61947178|NCT04337268|PLACEBO_COMPARATOR|Placebo|"Intervention:~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1"
61947179|NCT01354457|EXPERIMENTAL|Epratuzumab and 90Y-Epratuzumab|Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
62497394|NCT04189120|ACTIVE_COMPARATOR|Ultrasound-guided superficial serratus plane block (SSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. The muscles will be identified easily overlying the fifth rib, the latissimus dorsi , teres major and serratus muscles . A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle beneath the latissimus dorsi. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected
62497395|NCT04189120|ACTIVE_COMPARATOR|Ultrasound-guided deep serratus plane block (DSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane between the posterior border of the serratus anterior muscle and the corresponding surface of the rib. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected deep to the serratus muscle separating the serratus anterior muscle from the external intercostal muscle.
62497396|NCT04476563||ChILI|Patients who are already on CPI therapy and have developed liver injury
62497397|NCT04476563||Control|Patients with cancer who are starting on checkpoint inhibitors
62497398|NCT02571634|OTHER|Open label|Open label, no blinding, everyone receives Lazanda.
62497399|NCT03439995|EXPERIMENTAL|Open Lung Protective Ventilation|Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect
62497400|NCT03439995|ACTIVE_COMPARATOR|Conventional Ventilation|Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect
62497401|NCT05959616|EXPERIMENTAL|Group 1 Shigella sonnei 53G 1500CFU (N=10)|"Dose finding group~Group 1 will receive lyophilised S. sonnei 53G strain at a dose of 1500CFU.~Group 1 will receive curative treatment of Ciprofloxacin."
62497402|NCT05959616|EXPERIMENTAL|Group 2 Shigella sonnei 53G 2000CFU (N=10)|"Dose finding group~Group 2 will receive lyophilised S. sonnei 53G strain at a dose of 2000CFU.~Group 2 will receive curative treatment of Ciprofloxacin."
62497403|NCT05959616|EXPERIMENTAL|Group 3 Shigella sonnei 53G 2500CFU (N=10)|"Dose finding group~Group 3 will receive lyophilised S. sonnei 53G strain at a dose of 2500CFU.~Group 3 will receive curative treatment of Ciprofloxacin."
62497404|NCT05959616|EXPERIMENTAL|Group 4 Shigella sonnei 53G 3000CFU (N=10)|"Dose finding group~Group 4 will receive lyophilised S. sonnei 53G strain at a dose of 3000CFU.~Group 4 will receive curative treatment of Ciprofloxacin."
62497405|NCT05959616|EXPERIMENTAL|Group 5 Shigella sonnei 53G TBDCFU (N=15)|"Dose verification group~Group 5 will receive lyophilised S. sonnei 53G strain at a dose TBD.~Group 5 will receive curative treatment of Ciprofloxacin."
62497406|NCT05959616|EXPERIMENTAL|Group 6 Shigella sonnei 53G TBDCFU (N=15)|"Dose verification group~Group 6 will receive lyophilised S. sonnei 53G strain at a dose TBD.~Group 6 will receive curative treatment of Ciprofloxacin."
62497407|NCT00691041|EXPERIMENTAL|1|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
62497408|NCT00691041|NO_INTERVENTION|2|HIV/STI counseling and testing and a single 15 minute session of resources available in the community
61947180|NCT02620722|EXPERIMENTAL|LOP Measurement|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument and the gold-standard technique with the handheld Doppler ultrasound.
61947181|NCT01548287|EXPERIMENTAL|AZD5213 doseA|AZD5213 doseA daily
62497409|NCT05252234||Group 1|Patients undergoing elective surgeries with past history of COVID-19 infection during the past six months
62497410|NCT01833754|EXPERIMENTAL|Group 1: Stage 4 Renal Impairment|Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate \[eGFR\] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
62497411|NCT01833754|EXPERIMENTAL|Group 2: ESRD Requiring Hemodialysis|Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
62497412|NCT01833754|EXPERIMENTAL|Group 3: Healthy Participants|Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
62497413|NCT02630316|PLACEBO_COMPARATOR|Placebo|Matching placebo inhaled using an ultrasonic nebulizer four times daily
62497414|NCT02630316|ACTIVE_COMPARATOR|Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily
62497415|NCT05848440|EXPERIMENTAL|Part A|Participants will be administered single ascending SC doses of AZD9550 or a placebo.
62698300|NCT03236883|EXPERIMENTAL|GEM plus GPBSC|Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)\*10\^8/kg
62698301|NCT03236883|OTHER|Gemcitabine|
62698302|NCT03236883|OTHER|GPBSC|
62698303|NCT03552029|EXPERIMENTAL|Part 1 - Quizartinib + Milademetan|Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
61947182|NCT01548287|EXPERIMENTAL|AZD5213 doseB|AZD 5213 doseB daily
61947183|NCT01548287|EXPERIMENTAL|AZD5213 doseC|AZD5213 doseC daily
61947184|NCT01548287|PLACEBO_COMPARATOR|Placebo|Placebo daily
61947185|NCT03491267|EXPERIMENTAL|Subjects with alopecia-- area treated|One area will be treated
61947186|NCT03491267|EXPERIMENTAL|Subjects with alopecia-- area un-treated|One area will be un-treated
62497416|NCT05848440|EXPERIMENTAL|Part B|Participants will be administered one SC dose of AZD9550 or a placebo.
62497417|NCT05848440|EXPERIMENTAL|Part C|Participants will be administered one IV dose of AZD9550 or a placebo.
62497418|NCT03700190||Control|Healthy child
62497419|NCT03700190||Experimental|Patients with Autism Spectrum Disorder
62497420|NCT00564343||ChSt, water training, Observation|Subjects suffer from chronic hemiplegia (a year or more post stroke) that upon questioning was judged to meet the following inclusion criteria: (a) able to stand independently 90 seconds; (b) able to walk 10 meters (with cane if necessary); (c) able to understand verbal instructions. The exclusion criteria will be: (a) Serious visual impairment; (b) Inability to ambulate independently (cane acceptable, walker not). (c) Severely impaired cognitive status (score less then 24 in Mini Mental State Examination). (d) Persons with impaired communication capabilities.
62497421|NCT05389241|EXPERIMENTAL|Method A|Subjects in this arm will perform the task on the liver phantom with Method A (2D-CT). Then they will do the NASA task load index questionnaire. After that they will perform the tasks with Method B (2D-CT + 3D augmented reality model). After that again a NASA Task load index questionnaire is performed
62497422|NCT05389241|EXPERIMENTAL|Method B|Subjects in this arm will perform the task on the liver phantom with method B (2D-CT + 3D augmented reality model). Then they will do the NASA task load index questionnaire. After that they will perform the tasks with Method A (2D-CT). After that again a NASA Task load index questionnaire is performed
62497423|NCT04188808|EXPERIMENTAL|Popliteal artery aneurysm|Asymptomatic popliteal artery aneurysm patients will undergo surgery with a femoropopliteal/femorodistal bypass
62497424|NCT04188808|ACTIVE_COMPARATOR|Peripheral artery disease|Patients with peripheral artery disease defined as (ankle - brachial index, ABI \<0.5 or typical symptoms); intermittent claudication (IC), or resting pain and/or minor tissue loss. Will undergo surgery with a femoropopliteal/femorodistal bypass
62497425|NCT01557751|OTHER|Total knee arthroplasty subjects who are genotyped|All patients will have whole blood drawn for genotyping, and participate in the various assessments (psychosocial questionnaires, qualitative sensory testing, etc).
62497426|NCT01513395|NO_INTERVENTION|Immediate|"Participants randomized to the Immediate or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time)."
62497427|NCT01513395|EXPERIMENTAL|Interval|"Participants randomized to the Interval or experimental arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time"
62698304|NCT03552029|EXPERIMENTAL|Part 2 - Cohort 1|Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
62698305|NCT03552029|EXPERIMENTAL|Part 2 - Cohort 2|Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
62698306|NCT05991713|EXPERIMENTAL|Modifying Exploration|Individuals will be asked on certain days to increase their levels of exploration, and some days be asked to decrease their levels of exploration. Participants will do this for up to six months.
61947187|NCT02213523|EXPERIMENTAL|Plant concentrate A|Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
61947188|NCT02213523|EXPERIMENTAL|Plant concentrate B|Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
61947189|NCT02213523|EXPERIMENTAL|Plant concentrate C|Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
61947190|NCT02213523|EXPERIMENTAL|Plant concentrate D|Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
62340879|NCT03449316|EXPERIMENTAL|Inhaler technique education|This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
62340880|NCT03449316|NO_INTERVENTION|Usual Care|"This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.~If any adjustments are made in drug classes or device types in every participants, this information will be recorded."
62340881|NCT03571256|EXPERIMENTAL|TEV-50717 High-Dose|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
62340882|NCT03571256|EXPERIMENTAL|TEV-50717 Low-Dose|TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
62340883|NCT03571256|PLACEBO_COMPARATOR|Placebo|Placebo matched to TEV-50717 for a total of 8 weeks
62497428|NCT00943813||Patients in clinic waiting room|When patients are approached in the clinic, they will be given the permission form and asked to participate in the assessment through allowing video-recording and completing the survey. Procedures will be similar to our current operations, with the RSA starting the video-recording equipment before the fellow enters the room and stopping it when the fellow leaves the room. One additional step will be added: When the RSA goes into the room to turn off and remove the video-recording equipment, she will also give the patient the survey, to complete. We expect this survey to take no longer than 5 minutes. In our experience, it is usually at least 10 minutes from when the fellow leaves the room until the attending comes back into the room. Thus, we believe there will be sufficient time for the patient to complete the survey.
62497429|NCT06439394||OM3|Participants will receive 1 drop of OM3 on Day 1. After Day 1, participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15.
62497430|NCT01524016|EXPERIMENTAL|68Ga-DOTATATE, PET/CT scan|We will perform 68Ga-DOTATATE PET/CT scanning on subjects
62497431|NCT01507233|ACTIVE_COMPARATOR|IV morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
62497432|NCT01507233|EXPERIMENTAL|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
62497433|NCT06090708|NO_INTERVENTION|Control group|Children with acute gastroenteritis received standard hospital care and the prescribed medication of control group for acute gastroenteritis.
62497434|NCT06090708|EXPERIMENTAL|Probiotic Study Group|Children with acute gastroenteritis received fresh probiotic yogurt (1st day of production) for three consecutive days in addition to standard hospital care and prescribed medication for acute gastroenteritis.
62497435|NCT04096651|OTHER|PSP Classic|"15 patients with a classical form of PSP are recruited to realize all the tests of the multimodal approach."
62497436|NCT04096651|OTHER|Caribbean PSP|"15 patients with a Caribbean PSP are recruited to realize all the tests of the multimodal approach."
62497437|NCT04096651|OTHER|Healthy controls|15 persons with no PSP are recruited to realize all the tests of the multimodal approach.
62497438|NCT02752334|NO_INTERVENTION|group Bupivacaine|patients will receive 23 mL of Bupivacaine HCL 0.5% (Marcaine, 5 mg per mL; Hospira, USA) in addition to 2 mL normal saline using Ultrasound-guided Supraclavicular Brachial Plexus Block
62497439|NCT02752334|ACTIVE_COMPARATOR|group Bupivacaine Magnesium|patients will receive 23 mL of Bupivacaine HCL 0.5% in addition to 2 mL (100 mg) Magnesium Sulphate (Magnesium Sulphate 50 %, 500 mg per mL; Hospira, USA) diluted with normal saline. using Ultrasound-guided Supraclavicular Brachial Plexus Block
62497440|NCT05384457|EXPERIMENTAL|High intensity training (HIT)|Each participant will follow 24 therapy sessions (2 x 1.5 hours/week). The experimental group will perform a multimodal HIT protocol. Cardiorespiratory training will consist of a high-intensity interval training protocol on a cycle ergometer. After a five-minute warm-up, interval training will start, consisting of five one-minute bouts (110 RPM at 100% VO2max workload), separated by one minute of active rest (75 RPM at 50% VO2max workload). Limb strength training will consist of a circuit of three upper-body (vertical traction, chest press, arm curl) and three lower-body exercises (leg curl, leg press, leg extension) executed at 80% of the one repetition maximum. Core muscle training will consist of a circuit of six static core exercises (glute bridge, glute clam, superman back extension, adapted plank, adapted side plank, shoulder retraction with hip hinge) at 60% of the maximal voluntary contraction.
62698307|NCT02729519|OTHER|Group A|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation)
62698308|NCT02729519|EXPERIMENTAL|Groupe B|standard procedure TAVI performed without pre dilatation (Without prior balloon dilatation)
62698309|NCT05530525||Test-retest reliability and responsiveness group (All of the data was collected from medical record)|All the participants received conventional rehabilitation (e.g., occupational therapy, physical therapy, or speech therapy) or other interventions (e.g., acupuncture).
62340884|NCT06216938|EXPERIMENTAL|Vusolimogene oderparepvec (RP1)|Patients will receive 3 doses of RP1 (1.0 mL/injection; 10e6 PFU/mL for the first dose, and 10e7 mL for the subsequent 2 doses). The drug will be injected into the skin at the tumor biopsy site at baseline (day 1), day 15, and day 21, 4-5 weeks prior to SOC WLE and SLNB. Definitive surgery will occur up to 28-35 (± 2 days) days from first injection, to avoid treatment delay.
62340885|NCT05216848||nulliparas with no existing complications in the third trimester|"The investigators involve every nullipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language"
62340886|NCT05216848||multiparas with no existing complications in the third trimester|"The investigators involve every multipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language, previous caesarean section"
62340887|NCT00356863|EXPERIMENTAL|Explanation on cardiac rehabilitation|Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
62340888|NCT00356863|NO_INTERVENTION|Usual care with no intervention|Patients recruited to the study received the usual care without any additional explanation on cardiac rehabilitation, and no effort to increase their awareness or the ward's awareness to cardiac rehabilitation was done.
62340889|NCT01524367|PLACEBO_COMPARATOR|saline group|We administrate the saline single bolus (0.01ml/kg,intravenously) at time of oral cavity sealing.
62340890|NCT01524367|EXPERIMENTAL|dexmedetomidine group|We administrate the dexmedetomidine single bolus (1ug/kg, intravenously) at time of oral cavity sealing.
62340891|NCT00490763||Active Surveillance|Patients with low-risk prostate cancer who choose to undergo active surveillance.
62698310|NCT03388827|EXPERIMENTAL|Laminaria|Laminaria tent was introduced in the cervical canal
62698311|NCT03388827|ACTIVE_COMPARATOR|Laminaria plus Misoprostol|Laminaria and Misoprostol were introduced
62698312|NCT04344795|EXPERIMENTAL|TPST-1495 monotherapy dose escalation|Subjects will receive escalating doses of TPST-1495 administered orally twice daily until maximum tolerated dose is reached or until disease progression
62497441|NCT05384457|ACTIVE_COMPARATOR|Moderate intensity training (MIT)|Each participant will follow 24 therapy sessions (2 x 1.5 hours/week). The control group will perform a multimodal MIT protocol. Cardiorespiratory training will consist of a moderate-intensity continuous training protocol on a cycle ergometer. After a five-minute warm up, participants start continuous training comprising of 14 minutes of moderate-intensity cycling (90RPM at 60%VO2max workload). The duration will increase weekly with 1'40'' up to 22'40''. Limb strength training will consist of a circuit of three upper-body (vertical traction, chest press, arm curl) and three lower-body exercises (leg curl, leg press, leg extension) executed at 60% of the one repetition maximum. Core muscle training will be identical to the protocol described in 'Core muscle training HIT' with the exception of the exercise intensity. Only exercises with low relative core muscle activation will be used.
61947191|NCT04776109|ACTIVE_COMPARATOR|(Group of continous thoracic epidural bupivacaine infusion [CEI])|Group I : An epidural catheter will be inserted via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T8 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine (sunny-bupivacaine) infusion. Proper placement of the catheter will be verified through an aspiration test and a test dose (2 ml) of lidocaine 2% with adrenaline. At the end of surgery, a 0.2 ml/kg bolus of bupivacaine 0.25% will be administered through the catheter and then an infusion of bupivacaine 0.125% at a rate of 0.1 ml/kg/h will be administered immediately postoperative and continued for 48 hours.
61947192|NCT04776109|ACTIVE_COMPARATOR|(Group of continous bilateral erector spinae bupivacaine infusions[CESI])|Group II : Bilateral erector spinae catheters will be placed at T8 level. Surface anatomy or ultrasound (counting up from the 12th rib) will be used to identify the level of T8 after skin sterilization with the patient on the lateral position. Then a high frequency linear-array ultrasound transducer (Sono Site MW, Bothell, WA, USA) covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. Next, 2-3 ml of 2% lidocaine will be infiltrated. A catheter will be inserted and secured. The procedure will be repeated on the contralateral side. 20 ml of bupivacaine 0.25% solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours.
61947193|NCT04594811|EXPERIMENTAL|Dose escalation|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.~Nivolumab will be administered on Day 1 of every 4 week cycle (Q4W)."
62497442|NCT00003700|EXPERIMENTAL|Daunorubicin, ara-C, & MTX Therapy|daunorubicin during induction, increasing doses of cytarabine during consolidation followed by methotrexate in place of cranial irradiation for treatment of ALL
62497443|NCT01112891|EXPERIMENTAL|1|
62497444|NCT01112891|EXPERIMENTAL|2|
62497445|NCT01112891|EXPERIMENTAL|3|
62497446|NCT00844870|ACTIVE_COMPARATOR|1|stabilization training group
62497447|NCT00844870|EXPERIMENTAL|2|auditory response training group
62497448|NCT06423196|EXPERIMENTAL|Experimental group|The intervention of the experimental group will consist of performing an exercise protocol after carrying out the blood flow restriction. A total of 6 muscle strength exercises will be performed for the proximal (triceps brachii) and forearm (epitrochlear and epicondylar muscles).
62497449|NCT06423196|NO_INTERVENTION|Control group|Patients included in the control group will continue with their pre-study training and activities, without modifying their routine.
62497450|NCT02413008|EXPERIMENTAL|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
62497451|NCT02413008|PLACEBO_COMPARATOR|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
62497452|NCT01732679||stroke patients|specialized rehabilitation in a multidisciplinary team, Sunnaas International Network
62497453|NCT05814068|EXPERIMENTAL|Intervention|diagnosis and treatment of high blood pressure
61947194|NCT04594811|EXPERIMENTAL|Phase 2: NT-I7 and Nivolumab|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W) at the recommended phase 2 dose (RP2D) identified during Dose escalation phase.~Nivolumab will be administered on Day 1 of every 4 week cycle (Q4W)."
62497454|NCT05333653|EXPERIMENTAL|Continous Supportive Care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.
61947195|NCT02465645|EXPERIMENTAL|Carvedilol + Simvastatin|"Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.~Simvastatin will be administered orally at a start dose of 20 mg for 15 days followed by 40 mg OD for the next 3 months. Along with Simvastatin, Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min."
61947196|NCT02465645|ACTIVE_COMPARATOR|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
62698313|NCT04344795|EXPERIMENTAL|TPST-1495 monotherapy dose and schedule optimization|Subjects will receive alternative TPST-1495 administration schedules until RP2D for the selected schedule is determined or until disease progression.
62698314|NCT04344795|EXPERIMENTAL|TPST-1495 monotherapy dose expansion|Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression
62497455|NCT05333653|EXPERIMENTAL|Control|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
62497456|NCT03740191|OTHER|Proton Therapy of Prostate Cancer|"Patients with low and intermediate risk are included. The following interventions are performed:~* 'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire~* kV x-ray images~* Conebeam CT"
62497457|NCT02910596|EXPERIMENTAL|A|"* Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~* In bethanechol chloride arm arm should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~* Remove urethral catheter on 5thpostoperative day. Void volume and postvoid residual urine were record. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
62497458|NCT02910596|EXPERIMENTAL|B|"* Early bladder training Start on 3rd - 5th postoperative day~* Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
62497459|NCT02910596|EXPERIMENTAL|C|"* Early bladder training and Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~* should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~* Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
62497460|NCT02910596|OTHER|D|-Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative
62497461|NCT01209988|EXPERIMENTAL|Tamsulosin 0.4mg|Perioperative tamsulosin 0.4mg daily
62497462|NCT01209988|PLACEBO_COMPARATOR|Control|No medication
62698315|NCT04344795|EXPERIMENTAL|TPST-1495 in combination with pembrolizumab dose and schedule optimization|Subjects will receive alternative TPST-1495 administration schedules in combination with pembrolizumab until RP2D for the selected schedule is determined or until disease progression.
62698316|NCT04344795|EXPERIMENTAL|TPST-1495 in combination with pembrolizumab dose expansion|Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression
62698317|NCT01417767|EXPERIMENTAL|CHG regimen|one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)
61947197|NCT06374212|EXPERIMENTAL|Anifrolumab|Participants will receive anifrolumab (loading dose of 900mg) intravenously at the first visit, week 4 and week 8. Anifrolumab (maintenance dose of 600mg) will be administered intravenously for weeks 12, 16, and 20.
62140268|NCT05555628|ACTIVE_COMPARATOR|Occlusal Splint|"The patients assigned to this group will be treated by the occlusal splint administered by the dentist and the recommendations that they should pay attention to in daily life.~Occlusal splints will be prepared according to previously published criteria by Okeson and other researchers. Occlusal splint measurement and production will be done by technicians with 5 years of experience. Using the models obtained from the maxillary measurements of the patients, 0.5 mm thick thermoplastic rigid splints will be prepared and adjusted according to the patient's occlusion. Occlusal splints will be prepared for night use only. Patients will use splints every night for 6 weeks. Splint use of the patients and possible side effects or plaque-related disorders will be followed up with phone calls to be made every 2 weeks."
62340892|NCT04300634||Children whose parents are physiotherapists|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
62340893|NCT04300634||Children whose parents are athletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
62698318|NCT01417767|ACTIVE_COMPARATOR|Decitabine|one course of Decitabine (5-aza-deoxycytidine,Dacogen)
62698319|NCT04458857|EXPERIMENTAL|Fremanezumab Dose A|Participants weighing \<threshold weight will receive fremanezumab SC at dose A for 3 months.
62698320|NCT04458857|EXPERIMENTAL|Fremanezumab Dose B|Participants weighing ≥threshold weight will receive fremanezumab SC at dose B for 3 months.
62698321|NCT04458857|PLACEBO_COMPARATOR|Placebo|Matching placebo
61947198|NCT04652427|EXPERIMENTAL|Use Dexmedetomidine Hydrochloride to maintain a sedative|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
61947199|NCT04652427|PLACEBO_COMPARATOR|Sedative were maintained with a 0.9% sodium chloride injection|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
61947200|NCT00169546|EXPERIMENTAL|Arm 1|
61947201|NCT00747331|EXPERIMENTAL|A|
61947202|NCT00747331|PLACEBO_COMPARATOR|B|
61947203|NCT01422460|EXPERIMENTAL|Platelet Rich Plasma|intra articular injection 2ml of platelet-derived preparation rich in growth factors
61947204|NCT06297317||Experienced long-distance trail runners|"All the participants of the First 'Trail Scientifique de Clécy 2021. This was a multidisciplinary protocol to investigate the mechanisms that contribute to performance during an ultradistance trail race (156-km)"
61947205|NCT05342935|EXPERIMENTAL|IDA treatment|Each subject will be treated with his prescribed manual PD for 14 days, followed by a treatment period of 14 days with the investigational IDA system, and concluding with additional 14 days of treatment with the manual PD.
61947206|NCT00737243|EXPERIMENTAL|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
61947207|NCT00737243|OTHER|Treatment determined by physician|Other treatment determined by physician based on molecular profiling assay
62140269|NCT03874169||High-Risk of GI Bleed|Patients that have a high risk of having a gastrointestinal bleed upon admission into the ICU based on their medical history and symptoms. These patients will have a biosensor watch, the E4 wristband, placed on them to monitor their vital signs.
62140270|NCT01283568||1 - Gamaline+Hipericin - fertile women|
62497463|NCT05983523|EXPERIMENTAL|PEP07 Monotherapy|"The dose escalation stage of PEP07 monotherapy consists of an accelerated dose escalation followed by a standard 3+3 dose escalation. The accelerated titration will enroll 1 patient in each dose cohort until 1 patient experiences a DLT or a total of 2 patients experience any ≥ grade 2 PEP07-related AE during Cycle 1, and then the dose escalation will be switched to the 3+3 scheme to enroll 3 to 6 patients at the dose cohort where the DLT or the second ≥ grade 2 PEP07-related AE is observed.~To confirm the safety and evaluate the preliminary efficacy of PEP07, expansion cohorts with 12 patients will be opened for PEP07 monotherapy at RP2D once efficacy signal is observed in the dose escalation."
62497464|NCT06678386|EXPERIMENTAL|50% sugar reduction|Participants were advised by a dietitian to reduce their daily caloric intake from sugars by 50% for 12 weeks.
62497465|NCT06678386|NO_INTERVENTION|unmodified diet|Participants maintained an unmodified diet.
62140271|NCT01283568||2- Gamaline+Hipericin - climateric women|
62140272|NCT01283568||3- Gamaline- control - fertile women|
62140273|NCT01283568||4 - Gamaline control - climateric women|
62140274|NCT02148575|EXPERIMENTAL|Self-Management Group|"Managing Cancer Care: A Personal Guide (MCC) is a set of magazine-format, printed modules that includes information about key self-management topics, worksheets, conversation starters, and targeted links to local and internet resources, among other features."
62497466|NCT04997720|OTHER|Training|The course will be theoretical-practical, lasting eight hours, divided into two meetings with a theoretical class and practical exercises in microsurgery of increasing complexity. The course will also have an initial and final evaluation.
62497467|NCT03208517|EXPERIMENTAL|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
62497468|NCT03208517|EXPERIMENTAL|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
62698322|NCT00875446|EXPERIMENTAL|Subjects receiving GSK1223249|"Eligible subjects will receive sequential dose of intravenous infusion of GSK1223249 with a starting dose of 0.01 milligram per kilogram followed by 0.1, 0.5,~1, 2.5, 5, 7.5, and 15 milligrams per kilograms."
61947208|NCT01902823|NO_INTERVENTION|No Nurse Navigator Services|
61947209|NCT01902823|EXPERIMENTAL|Services from a Nurse Navigator|
61947210|NCT00246753|OTHER|Single Arm Trial|Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.
61947211|NCT01758523|EXPERIMENTAL|dutasteride|4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
61947212|NCT01758523|PLACEBO_COMPARATOR|Sugar Pill|Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
61947213|NCT00472719|EXPERIMENTAL|1|Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
62140275|NCT02148575|ACTIVE_COMPARATOR|Symptom Management Group|Participants in the Symptom Management Group will be given a symptom management toolkit that provides information on the most commonly experienced symptoms and side effects of cancer treatment, including fatigue, nausea, and sleep problems, among others. Each chapter includes information on when and why the symptom may occur, how the symptom can be managed, and when to call a provider.
62140276|NCT05456932|EXPERIMENTAL|Intravenous iron|Intravenous iron therapy
62497469|NCT03208517|NO_INTERVENTION|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
62497470|NCT04551183|EXPERIMENTAL|OnlyGroup|Patients are their own witnesses
62497471|NCT04194151|ACTIVE_COMPARATOR|2 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol
62497472|NCT04194151|ACTIVE_COMPARATOR|2 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol
62497473|NCT04194151|ACTIVE_COMPARATOR|2 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol
62497474|NCT04194151|ACTIVE_COMPARATOR|1 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol
62497475|NCT04194151|ACTIVE_COMPARATOR|1 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol
62497476|NCT04194151|ACTIVE_COMPARATOR|1 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol
62497477|NCT02005562|EXPERIMENTAL|Mycophenolate Mofetil, Adapted Dose|Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours \[q12h\]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
62497478|NCT02005562|ACTIVE_COMPARATOR|Mycophenolate Mofetil, Fixed Dose|Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
62497479|NCT01087034||Milwaukee brace|Children with an infantile scoliosis requiring Milwaukee bracing
62497480|NCT01087034||Cheneaux brace|Children with an infantile scoliosis requiring Cheaneaux bracing
61947214|NCT00472719|EXPERIMENTAL|2|Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
61947215|NCT00472719|EXPERIMENTAL|3|Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
62140277|NCT05456932|EXPERIMENTAL|Ferric maltol|Treatment with oral ferric maltol
62140278|NCT05456932|EXPERIMENTAL|Ferrous fumarate|Treatment with oral ferrous fumarate
62497481|NCT05189691|EXPERIMENTAL|behavior change and walking exercise|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale, Short Form 36 (SF-36) scales and continuously recorded step counts will be evaluated at week 0, 4 and at the end of week 12.
61947216|NCT00472719|EXPERIMENTAL|4|Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
61947217|NCT05432375|EXPERIMENTAL|Tinostamustine|Infusion delivered over 60 minutes
61947218|NCT06558175|EXPERIMENTAL|Recovery factor levels|Radiation therapy - recovery factor levels Level 1: 6 months (10%) and 0.75%/month Level 2: 6 months (15%) and 0.75%/month Level 3: 6 months (15%) and 1.00%/month Level 4: 6 months (20%) and 1.00%/month Level 5: 6 months (20%) and 1.25%/month Level 6: 6 months (25%) and 1.40%/month
62140279|NCT05180838||BioSticker|This cohort will place BioStickers at least 3 days prior to completion of standard of care therapy and discharge home post therapy.
62140280|NCT03085433|EXPERIMENTAL|Microfluidic sperm sorting|Couples undergoing in vitro fertilization randomized to microfluidic sperm sorting will have raw semen sorted by the microfluidics chip prior to fertilization with IVF/ICSI.
62140281|NCT03085433|ACTIVE_COMPARATOR|Conventional sperm preparation|Couples undergoing in vitro fertilization randomized to conventional methods for sperm processing will undergo separation of semen by density gradient centrifugation prior to IVF/ICSI.
61947219|NCT04812171||smoker participants|"Current cigarette smokers older than 18 years, without previously reported systemic disease, not taking medications influencing imunological system or bone metabolism.~Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment."
61947220|NCT04812171||non-smoker participants|Healthy non-smokers paired with smoker group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
61947221|NCT04812171||diabetic participants|Participants reporting diabetes melitus type II, having gycated hemoglobin test, not taking medications influencing imunological system or bone metabolism, non-smokers Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
62497482|NCT05189691|NO_INTERVENTION|behavior change|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) scales will be evaluated at week 0, 4 and at the end of week 12.
62497483|NCT05941611|EXPERIMENTAL|Partisipants|
62497484|NCT06604195|EXPERIMENTAL|Group 1: MSNM|The participants in this group are treated with modified sciatic nerve mobilization.
62497485|NCT06604195|ACTIVE_COMPARATOR|Group 2: DHMS|The participants in this group are treated with dynamic hamstring muscle stretching.
62497486|NCT03670719|EXPERIMENTAL|Manual Therapy and Exercise Group|Combination of manual therapy and exercises for chronic cervical pain
62497487|NCT03670719|ACTIVE_COMPARATOR|Exercise Group|Only exercises for chronic cervical pain
62698323|NCT00875446|PLACEBO_COMPARATOR|Subjects receiving placebo|Eligible subjects will receive intravenous infusion of placebo.
61947222|NCT04812171||non-diabetic participants|Healthy non-smokers paired with diabetic group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
61947223|NCT04689269|ACTIVE_COMPARATOR|McGrath-King Vision|The participants will attempt double-lumen tube intubation using the McGrath (X-blade) laryngoscope then they will use the King Vision (channelled blade size 3) in the same order.
61947224|NCT04689269|ACTIVE_COMPARATOR|King Vision-McGrath|The participants will attempt double-lumen tube intubation using the King Vision (channelled blade size 3) then they will use the McGrath (X-blade) laryngoscope in the same order.
61947225|NCT01307982|ACTIVE_COMPARATOR|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
61947226|NCT01307982|ACTIVE_COMPARATOR|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
61947227|NCT03695744|EXPERIMENTAL|Daratumumab Bortezomib Dexamethasone|IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
61947228|NCT05687175||Neuropathic pain|Questionnaire administration and socio-demographic data collection
61947229|NCT05687175||Nociceptive pain|Questionnaire administration and socio-demographic data collection
61947230|NCT01457222|ACTIVE_COMPARATOR|Mindfulness|Mindfulness intervention 10 minutes daily
62497488|NCT06363240|EXPERIMENTAL|Treatment Arm|Each subject will receive Broadband light treatment
62497489|NCT03541239|ACTIVE_COMPARATOR|non-ischemic preconditioning|The participants will have the cuff attached to the arm, however not be inflated for the 4 cycles of remote ischemic conditioning: 1 cycle is 5 minutes of inflation followed by 5 minutes of deflation. The ischemic reperfusion injury was induced by cuff inflation by the Single Cuff Tourniquet 8000 to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
62497490|NCT03541239|EXPERIMENTAL|ischemic preconditioning|The blood supply to the distal part of the arm will be occluded by inflation of a single cuff to 200mmHg, by the help of the Single Cuff Tourniquet 8000, for 5 minutes separated from 5 minutes of deflation, a cycle that happens 4 times in total. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
62698324|NCT06061757|EXPERIMENTAL|Arm 1 - TEE Primary imaging guidance|TEE is the primary imaging guidance with 4D ICE is the secondary
62497491|NCT04939558||Chronic Obstructive Pulmonary Disease|245 participants - GOLD 1, 2, 3 / A, B, C
62497492|NCT04939558||Asthma|55 participants - Mild to moderate, not labelled as severe.
62497493|NCT04939558||Congestive cardiac failure|55 participants
62497494|NCT04939558||Anaemia|55 participants - with at least 50% of participants recruited having no history of chronic cardiorespiratory conditions
62497495|NCT04939558||Bronchiectasis|55 participants - Acquired or genetic, e.g. cystic fibrosis or other primary ciliary dyskinesias
62698325|NCT06061757|EXPERIMENTAL|Arm 2 - ICE Primary Imaging Guidance|4D ICE is the primary imaging guidance and TEE is the secondary
62736495|NCT02901249|EXPERIMENTAL|Sertraline|"Group Started: sertraline (50mg-200mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.~Second step: Sertraline 200mg + lithium (900mg-1500mg)~Non responsive patients: 3rd step.~Third step: Nortriptyline 100mg~Non responsive patients: 4th step.~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)~Non responsive patients : 5th step~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
62736496|NCT01808872||Heart Failure|
61947231|NCT01457222|ACTIVE_COMPARATOR|Music relaxation|Music intervention 10 minutes daily
61947232|NCT01457222|NO_INTERVENTION|Business as usual|No intervention - control group.
61947233|NCT06045780||Sepsis|disease
61947234|NCT06045780||Healthy controls|healthy
61947235|NCT05830773|EXPERIMENTAL|App Trial|Use of the smartphone app
62140282|NCT03489369|EXPERIMENTAL|Sym022|Sym022 will be administered at up to 4 planned dose levels.
62497496|NCT04939558||Lung cancer|55 participants - including rare types e.g. mesothelioma
62497497|NCT04939558||Interstitial Lung Disease|55 participants - including pulmonary fibrosis pneumoconiosis, asbestosis, sarcoidosis, amyloidosis
62497498|NCT04939558||Long COVID|55 participants
62497499|NCT04939558||Upper airway obstruction disorder|55 participants
62497500|NCT04939558||Healthy|55 participants - with no previous or current chronic cardiorespiratory diagnoses
62497501|NCT03711357|ACTIVE_COMPARATOR|laser|980 nm diode laser (maximum output of 3 watts and coupled with a fiber optic tip of 200 µm diameter) will be used for four irradiations, of 5 seconds each, after chemo-mechanical preparation procedures.
62497502|NCT03711357|PLACEBO_COMPARATOR|Placebo|After chemo-mechanical preparation procedures, the diode laser fiber optic tip will be inserted inside the root canals but not activated.
62497503|NCT05701124|ACTIVE_COMPARATOR|Aggressive ROP|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant.
62497504|NCT05701124|ACTIVE_COMPARATOR|Type 1 prethreshold ROP|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant.
62497505|NCT01227070||Asthmatic|
62497506|NCT01227070||Healthy Control|
61947236|NCT03026361||oral lichen planus (OLP)|"Histopathologically confirmed samples of OLP underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OLP changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
62497507|NCT04192929|PLACEBO_COMPARATOR|High definition white light endoscopy|colonoscopy performed using high definition equipment
62497508|NCT04192929|ACTIVE_COMPARATOR|Chromoendoscopy|indigo carmine is sprayed on the colon mucosa during withdrawal phase
62497509|NCT04192929|EXPERIMENTAL|Narrow band imaging|Narrow band imaging is used during withdrawal phase
62497510|NCT05580887||Patients with luminal A breast cancer|
62497511|NCT05580887||Patients with high risk luminal B breast cancer|
62497512|NCT05580887||Patients with high pancreatic cancer|
62698326|NCT06645236|OTHER|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|"The therascreen® KRAS RGQ PCR Kit functions as part of this system, using the QIAamp DSP DNA FFPE Kit as a clinical sample concentrator, the Rotor-Gene Q MDx (RGQ) instrument as the platform on which PCR is performed, and KRAS specific software for PCR analysis and result reporting. The kit contains a Positive Control (PC) and a No Template Control (NTC) which are used to determine the validity of the test.~The therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx (US) instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE), colorectal cancer (CRC) tissue"
62698327|NCT05828173|EXPERIMENTAL|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Treatment|
62140283|NCT03852069|PLACEBO_COMPARATOR|Placebo|16 g maltodextrin/day + recipes based on vegetables poor in inulin-type fructans
62497513|NCT06570278|NO_INTERVENTION|control procedure|In-silico analysis of a panel of validated genes (ISApanel). Patients recruited along control procedure will stay in their arm using current genetic diagnosis practices and standard of care that may differ from one center to another
62497514|NCT06570278|EXPERIMENTAL|intervention procedure|WGS coupled with MCM
62497515|NCT00397254|ACTIVE_COMPARATOR|Clinical Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a clinical limit of study medication received Rizatriptan 10mg ODT: 27 tablets per month."
62497516|NCT00397254|ACTIVE_COMPARATOR|Formulary Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a formulary limit of study medication received Rizatriptan 10mg ODT: 9 tablets per month."
62497517|NCT04966962||Bladder cancer|Patients who diagnosis with incident or recurrent bladder cancer
62497518|NCT04966962||benign disease of urinary system|Patients who clinically diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia.
62497519|NCT01058122||Patients on the ward|
62497520|NCT05125809|EXPERIMENTAL|Low Dose Setrusumab -> Open-Label (OL) Setrusumab Selected Dose|"Single-blind setrusumab low dose during phase 2 followed by open-label setrusumab selected dose~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
62698328|NCT04492384||inpatients|Patients treated from COVID-19 in hospital
62140284|NCT03852069|EXPERIMENTAL|Inulin|16 g inulin/day + recipes based on vegetables rich in inulin-type fructans
62497521|NCT05125809|EXPERIMENTAL|High Dose Setrusumab -> OL Setrusumab Selected Dose|"Single-blind setrusumab high dose during phase 2 followed by open-label setrusumab~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
62497522|NCT05125809|EXPERIMENTAL|Setrusumab Selected Dose -> OL Setrusumab Selected Dose|"Double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
62497523|NCT05125809|PLACEBO_COMPARATOR|Placebo -> OL Setrusumab Selected Dose|"Double-blind placebo during phase 3 followed by open-label setrusumab~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
62497524|NCT03860025||Single dislocation.|Patients with a single postoperative hip dislocation without subsequent revision surgery.
62698329|NCT04492384||outpatients|Patients treated from COVID-19 at home
62698330|NCT06424743|EXPERIMENTAL|1 set|"Training A Bench press, Pull front, Leg press and seated flexor~1 series 10 repetitions with 60% 1RM, 2' minute interval"
62698331|NCT06424743|EXPERIMENTAL|2 sets|Training B Bench press, Pull front, Leg press and seated flexor 2 series 10 repetitions with 60% 1RM, 2' minute interval
62140285|NCT00210106|EXPERIMENTAL|Intraoperative radiofrequency ablation (IRFA)|IRFA treatment, either with or without resection, was performed at laparotomy within 28 days of inclusion in the study. The type of IRFA current generator and probes, and whether or not resection was performed, was at the discretion of the surgeon.
62140286|NCT06157554|EXPERIMENTAL|Intervention group|Respiratory exercises will be applied in addition to conventional treatment for frozen shoulder patients.
62140287|NCT06157554|OTHER|Control Group|For frozen shoulder patients, 15 conventional treatment programs will be applied.
62497525|NCT03860025||Recurrent dislocation.|Patients with two or more postoperative hip dislocations without subsequent revision surgery.
62497526|NCT03860025||Revision due to dislocation.|Patients with one or more postoperative hip dislocations with subsequent revision surgery due to recurrent instability.
62497527|NCT03860025||Controls.|Matched patients without postoperative hip dislocation or revision of any reason.
62497528|NCT06150079|NO_INTERVENTION|PEEP Group|After endotracheal intubation, an esophageal balloon is placed and calibrated for accurate positioning and inflation pressure. Continuous monitoring of end-expiratory esophageal pressure (Pes_ee) is conducted. Fixed PEEP of 3 cmH2O is applied throughout the procedure without lung recruitment maneuvers.
62497529|NCT06150079|EXPERIMENTAL|Pes-Guided PEEP Group (PEEPPtp)|After endotracheal intubation, an esophageal balloon is placed and calibrated for accurate positioning and inflation pressure. Continuous monitoring of end-expiratory esophageal pressure (Pes_ee) is conducted. Lung recruitment is performed at each time point. After lung recruitment, ventilation is adjusted based on the target PEEP. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (Ptp_ee = PEEP - Pes_ee). PEEP titration following lung recruitment should be performed within 1 hour after endotracheal intubation or any procedure that may cause lung collapse, such as pneumoperitoneum, deflation or inflation of the endotracheal tube cuff, changes in position, or endotracheal suctioning.
62497530|NCT03668457|EXPERIMENTAL|Intervention to Patients|Only patients receive intervention
62497531|NCT03668457|EXPERIMENTAL|Intervention to Psychiatrists|Psychiatrists receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
62497532|NCT03668457|EXPERIMENTAL|Mixed Intervention|Patients and Psychiatrists associated with these patients receive intervention
61947237|NCT03026361||oral squamous cell carcinoma (OSCC)|"Histopathologically confirmed samples of OSCC underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OSCC changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
61947238|NCT03026361||healthy mucosa|"Archival samples of healthy oral mucosa underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of healthy mucosa taken during alveolotomy underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
62497533|NCT03668457|OTHER|Control|Psychiatrists provide the usual care Patients receive usual care
62497534|NCT02641873|EXPERIMENTAL|BBI608 + FOLFIRI +Bevacizumab|
62497535|NCT04233866|EXPERIMENTAL|Arm A (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62497536|NCT04233866|EXPERIMENTAL|Arm B (fluorouracil, leucovorin, liposomal irinotecan)|Patients receive fluorouracil IV over 46 hours starting on day 1. Patients also receive leucovorin IV over 90-120 minutes and liposomal irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62497537|NCT02305407|EXPERIMENTAL|surgical revascularization|Patients will be assigned to either surgical or conservative treatment depending on their clinical symptoms and radiological assessment.
62497538|NCT02305407|EXPERIMENTAL|conservative treatment|Normal conservative treatment without surgical intervention.
62497539|NCT02111109||Traumatic injury|
62497540|NCT01562132|EXPERIMENTAL|5FC plus fluconazole|Combination therapy with oral fluconazole and flucytosine
62497541|NCT01562132|ACTIVE_COMPARATOR|fluconazole alone|Fluconazole monotherapy
62497542|NCT02219009|EXPERIMENTAL|MIND1 System|
62497543|NCT05079555|NO_INTERVENTION|Control group|The control group consisted of patients who followed conventional therapy.
62698332|NCT06424743|EXPERIMENTAL|3 sets|Training C Bench press, Pull front, Leg press and seated flexor 3 series 10 repetitions with 60% 1RM, 2' minute interval
62497544|NCT05079555|EXPERIMENTAL|Intervention group|The intervention group consisted of patients rehabilitated using the robotic platform.
62497545|NCT01003951|EXPERIMENTAL|Acupuncture|Each patient will receive two acupuncture treatments each week for four consecutive weeks. At the end of four weeks, the intervention will be complete.
62497546|NCT05777694|ACTIVE_COMPARATOR|Group 1: 25 gauge spinal needle|Group 1: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle ( Pencan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
62497547|NCT05777694|ACTIVE_COMPARATOR|Group 2: 26 gauge spinal needle|Group 2: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle ( Atraucan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
62698333|NCT02712203||12 months|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age
62698334|NCT02712203||13 months|MMR vaccine / MMRV vaccine : administration of the first dose at 13 months of age
62698335|NCT02712203||14 months|MMR vaccine / MMRV vaccine : administration of the first dose at 14 months of age
62497548|NCT05777694|ACTIVE_COMPARATOR|Group 3: 27 gauge spina needle|Group 3: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle ( Pencan ® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
62497549|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
62497550|NCT03110380|EXPERIMENTAL|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet + dolutegravir (DTG) placebo tablet + emtricitabine/tenofovir alafenamide (F/TAF) placebo tablet administered without regard to food for at least 48 weeks.
62497551|NCT03110380|ACTIVE_COMPARATOR|DTG + F/TAF|DTG 50 mg tablet + F/TAF FDC tablet + B/F/TAF placebo tablet administered without regard to food for at least 48 weeks.
62497552|NCT03110380|EXPERIMENTAL|Open-label Phase B/F/TAF from B/F/TAF|Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
62698336|NCT02712203||15 months or more|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age or older
62698337|NCT04605276||Pre-biopsy cohort|"Male patients of age ≥18 suspected for prostate cancer who are scheduled for systematic and/or targeted biopsy after mpMRI examination.~No intervention study"
61947239|NCT01130675|ACTIVE_COMPARATOR|eight ounces of caffeinated coffee for breakfast and lunch|
61947240|NCT01130675|NO_INTERVENTION|standard care|
61947241|NCT06429488||chron's disease patients|patients diagnosed with CD at the department of Gastroenterology were collected from hospital records, and all patients were contacted and accepted to be part of this study
61947242|NCT06429488||Healthy controls|Healthy Controls with no medical illness or mental illness before were invited to fill in the same questionnaire, the controls were relatives of patients attending the hospital for clinics not related to the gastrointestinal tract or psychiatry
61947243|NCT00493623|EXPERIMENTAL|1|
61947244|NCT00493623|PLACEBO_COMPARATOR|2|
61947245|NCT02698878|ACTIVE_COMPARATOR|Control Group|Control Group consisting of six healthy male subjects wearing only the HEPHAISTOS ORTHOSIS for lower leg unloading (60 days).
61947246|NCT02698878|EXPERIMENTAL|Intervention Group|Intervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
61947247|NCT03789214|PLACEBO_COMPARATOR|Placebo|Placebo sleep medication (Placebo oral capsule)
61947248|NCT03789214|ACTIVE_COMPARATOR|Low Dose Suvorexant|Low dose sleep medication
61947249|NCT03789214|ACTIVE_COMPARATOR|High Dose Suvorexant|High dose sleep medication
61947250|NCT02023593|EXPERIMENTAL|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
61947251|NCT00510497|EXPERIMENTAL|Autologous HIV-1 ApB DC Vaccine|Subjects who will receive ApB Dendritic cell vaccine
61947252|NCT04752969||Hypothyroidia|20 subjects diagnosed with hypothyroidism
61947253|NCT04752969||Hyperthyroidia|20 subjects diagnosed with hyperthyroidism
61947254|NCT04752969||Healthy|20 age-matched healthy control subjects
61947255|NCT05469191|EXPERIMENTAL|Group 5 STS|Group 5 STS will perform the same protocol as group 10 STS, only the number of repetitions between each set will change.
61947256|NCT05469191|EXPERIMENTAL|Group 10 STS|Group 10 STS will perform the same protocol as group 5 STS, only the number of repetitions between each set will change.
61947257|NCT05469191|NO_INTERVENTION|Control group|Control group, no intervention.
61947258|NCT00369824|EXPERIMENTAL|Cervarix + Boostrix/Menactra Group|Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.
61947259|NCT00369824|EXPERIMENTAL|Cervarix + Menactra/Boostrix Group|Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.
61947260|NCT00369824|EXPERIMENTAL|Cervarix + Boostrix + Menactra Group|Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.
61947261|NCT00369824|EXPERIMENTAL|Boostrix/Cervarix Group|Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.
61947262|NCT00369824|EXPERIMENTAL|Menactra/Cervarix Group|Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.
61947263|NCT00369824|EXPERIMENTAL|Cervarix Group|Subjects received Cervarix at Months 0, 1 and 6.
62340894|NCT04300634||Parents of children who are atletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
61947264|NCT06322680|EXPERIMENTAL|Main pancreatic duct and biliary duct external drainage|"Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve."
61947265|NCT06322680|EXPERIMENTAL|Main pancreatic duct and biliary duct internal drainage|"Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures."
61947266|NCT03479073||Stroke group|Patients who experienced stroke or systemic embolic event following catheter ablation for AF.
61947267|NCT03479073||Control group|Patients who did not experienced stroke or systemic embolic event following catheter ablation for AF.
61947268|NCT03406767|EXPERIMENTAL|GLA:D Canada Program|GROUP 1: GLA:DTM CANADA GROUP (STANDARDIZED EXERCISE PROGRAM)
61947269|NCT03406767|EXPERIMENTAL|JointEffort Program|GROUP 2: JOINTEFFORT GROUP (INDIVIDUALIZED EXERCISE PROGRAM)
61947270|NCT05202028|EXPERIMENTAL|Classic abdominal massge|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Classic abdominal massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
62140288|NCT02628015||preschool children preterm|born 2010 or 2011 Birthweight \<1500g
61947271|NCT05202028|EXPERIMENTAL|Connective tissue massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
61947272|NCT05202028|EXPERIMENTAL|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
61947273|NCT05449548|EXPERIMENTAL|Intervention with lenalidomide|All subjects will be treated with lenalidomide 10mg/day.
61947274|NCT02018068|EXPERIMENTAL|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
61947275|NCT02018068|ACTIVE_COMPARATOR|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
61947276|NCT04901676|EXPERIMENTAL|Leronlimab|Leronlimab subcutaneously once a week (up to 4 doses) until hospital discharge. The first dose will be of 700 mg, followed by weekly doses of 350 mg.
61947277|NCT04901676|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneously once a week (up to 4 doses) until hospital discharge
61947278|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR \<60ml/min/1.73m2, including those on dialysis
61947279|NCT03285854||Healthy age and gender matched children|"1. All children \<18 years~2. Normal renal function (eGFR 90-120ml/min/1.73m2 \[calculated by Schwartz formula\] in children \>1 year and serum creatinine \<35μMol/L in children \<1 year)~3. Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
61947280|NCT00005044|EXPERIMENTAL|TAS x 8 weeks|Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
61947281|NCT00005044|EXPERIMENTAL|TAS x 28 weeks|TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
61947282|NCT06558331||ESP Group|After the patients are taken to the operating table and the necessary ASA monitoring is performed, erector spinae plane block (ESP) is performed on the side where surgery will be performed from the T4-T5 thoracic vertebrae level for peroperative analgesia with ultrasound (USG), depending on the clinician's experience and the USG image.
61947283|NCT06558331||Paravertebral Group|After the patients are taken to the operating table and the necessary ASA monitoring is performed, paravertebral block is performed on the side where surgery will be performed from the T4-T5 thoracic vertebrae level for peroperative analgesia with ultrasound (USG), depending on the clinician's experience and the USG image.
61947284|NCT02702453|EXPERIMENTAL|Development and Testing|Develop an online interactive, tailored intervention to address the needs of men and partners interested in sexual recovery after treatment for localized prostate cancer during the first 6 months after treatment. The intervention will undergo content testing through 4 focus groups with prostate cancer survivors and partners and usability testing with 5 survivors and partners
61947285|NCT02549534||Women with Breast Cancer (WBC)|"Defined as women who:~* Are 18 to 85 years old at the time of enrollment;~* Have histologically-confirmed, first-time, non-metastatic breast cancer (Stage I-IIIB);~* Have no history of neurotoxic chemotherapy or radiation treatment at the time of enrollment;~* Will be receiving weekly paclitaxel (Taxol® or generic paclitaxel), 80-100mg/m2, or bi-weekly (i.e., dose-dense) Taxol, 175 mg/m2, as a part of their treatment regimen OR~* Will be receiving an anthracycline and cyclophosphamide (AC) therapy followed by weekly or bi-weekly (i.e., dose-dense; 175 mg/m2) paclitaxel (Taxol® or generic paclitaxel, 80-100mg/m2);~* Are willing to participate in up to four study sessions."
61947286|NCT02549534||Healthy Female Controls (HCs)|"Defined as women who:~* Are 18 to 85 years old at the time of study enrollment;~* Can read, write, and understand English,~* Are willing to participate in three planned study sessions."
61947287|NCT02158975|EXPERIMENTAL|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
61947288|NCT01629992|EXPERIMENTAL|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
61947289|NCT01629992|NO_INTERVENTION|Control|The control group received no preoperative counseling either oral or written.
62140289|NCT02628015||preschool children full-term|born 2010 or 2011 born after 38 weeks
62140290|NCT02628015||school children preterm|same children from the preschool group will be tested 2 years later again
62698338|NCT04605276||Pre-radical prostatectomy cohort|Male patients of age ≥18 diagnosed with prostate cancer who are scheduled for radical prostatectomy
62698339|NCT01596023|EXPERIMENTAL|NIOV Ventilator|Breathe NIOV Ventilator under various volume augmentation settings
62140291|NCT02628015||school children full-term|same children from the preschool group will be tested 2 years later again
62140292|NCT02628015||youths preterm|born 2001 or 2002 Birthweight \<1500g
62698340|NCT05991453|ACTIVE_COMPARATOR|Propofol total intravenous anesthesia (TIVA)|No administration of inhaled agent.
62698341|NCT05991453|ACTIVE_COMPARATOR|inhaled volatile general anesthesia (INVA)|Must administer inhaled agent.
62698342|NCT01052779|EXPERIMENTAL|Ferumoxytol|Participants received an IV injection of ferumoxytol (510 milligrams \[mg\], 17 milliliters \[mL\]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
62736497|NCT03316573|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks for 35 cycles
62736498|NCT04154293|PLACEBO_COMPARATOR|Vehicle Ointment (Control)|Topical, BID (Twice daily)
61947290|NCT04903444|EXPERIMENTAL|with AI navigation system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
61947291|NCT04903444|NO_INTERVENTION|without AI navigation system|The endoscopists in the contrpl group performs ERCP routinely without special prompts.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
62698343|NCT01052779|ACTIVE_COMPARATOR|Iron Sucrose|"Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g."
61947292|NCT01171417||Cohort 1|1st-line Faslodex 500 mg
61947293|NCT01171417||Cohort 2|2nd-line Faslodex 500 mg
61947294|NCT01171417||Cohort 3|3rd- line Faslodex 500 mg
61947295|NCT01171417||Cohort 4|patients on exemestane
61947296|NCT02302807|EXPERIMENTAL|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
61947297|NCT02302807|ACTIVE_COMPARATOR|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m\^2), paclitaxel 175 mg/m\^2, or docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
61947298|NCT05986786|EXPERIMENTAL|AVT06 (proposed aflibercept biosimilar) PFS|IVT injection with a PFS containing the proposed aflibercept biosimilar AVT06
61947299|NCT01552993|EXPERIMENTAL|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and sucrose
61947300|NCT01552993|PLACEBO_COMPARATOR|placebo|pacifier and sucrose only
61947301|NCT04149379|EXPERIMENTAL|Treatment group|One group of 6 patients undergoing 20 sessions of hyperbaric therapy at table 14/90.
61947302|NCT06326099|EXPERIMENTAL|Brief Online Binge Eating and Drinking Intervention|The intervention is a 30 minute mobile phone program designed to address binge eating and drinking. The program addresses underlying loss of control, impulsivity, and emotion regulation common to both binge drinking and binge eating through videos, interactive activities, and psychoeducation.
61947303|NCT06326099|NO_INTERVENTION|Resources Only|Campus-specific resources for how to access the university's counseling office (i.e., student mental health services), information about the Eating Disorders program at the university, and information on accessing the university's alcohol and drug awareness offices.
61947304|NCT03710005|EXPERIMENTAL|Ascent Intervention Treatment|Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
61947305|NCT03710005|ACTIVE_COMPARATOR|Standard Treatment|Standard treatment arm will receive a standard Corticosteroid injection
61947306|NCT05708209||Group A|20 patients with a diagnosis suggestive of OSCC
62497553|NCT03110380|EXPERIMENTAL|Open-label Phase B/F/TAF from DTG + F/TAF|Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
62497554|NCT05024487|EXPERIMENTAL|Experimental group|The correlation between blood pressure level, dermal resistance level, and subjective symptoms caused by triggered AD below the level of the lesion will be performed in a group of SCI people.
62497555|NCT00473616|EXPERIMENTAL|1|AZD7762 monotherapy followed by AZD7762 + irinotecan
61947307|NCT05708209||Group B|20 age-and-sex-matched healthy individuals, as normal controls.
61947308|NCT05335629|ACTIVE_COMPARATOR|Intervention arm|"30 patients will receive standard of care in addition to the SGLT2 Dapagliflozin 10 mg daily for 4 Weeks~Interventions:~Drug: Dapagliflozin 10 mg oral tablets Standard of care: Dual antiplatelet therapy, Statin, anticoagulation therapy"
61947309|NCT05335629|NO_INTERVENTION|Control arm|30 patients will receive standard of care (Dual antiplatelet therapy, Statin, anticoagulation therapy) for 4 weeks
61947310|NCT06022393|EXPERIMENTAL|Cognitive Reappraisal|The intervention group completes CBT-training to improve their cognitive reappraisal and emotion-regulation-skills.
61947311|NCT06022393|SHAM_COMPARATOR|Reflection|The control group completes tasks based on reflection about their daily lifes, which should have no impact on their emotion-regulation-skills or functional motor disorder.
61947312|NCT00531973|EXPERIMENTAL|A|Liposomal doxorubicin
61947313|NCT00531973|ACTIVE_COMPARATOR|B|epirubicin
61947314|NCT01453361|EXPERIMENTAL|Vigil™ Vaccine|Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
62140293|NCT02628015||youths full-term|born 2001 or 2002 born after 38 weeks
62140294|NCT02628015||adults preterm|Birthweight \<1500g
62140295|NCT02628015||adults full-term|born after 38 weeks
62140296|NCT01319838|EXPERIMENTAL|isotretinoin prolongation|Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
62497556|NCT05317858|EXPERIMENTAL|Pembrolizumab with Exablate BBBD|Using Exablate Model 4000 Type 2 for the treatment of NSCLC brain metastases in subjects who are undergoing planned pembrolizumab monotherapy.
62698344|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
62698345|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
62736499|NCT04154293|EXPERIMENTAL|TMB-001 Ointment, 0.05%|Topical, BID ( twice daily)
62698346|NCT03018873|EXPERIMENTAL|long-term RIPC group|"routine treatment + interventions interventions: once preoperative RIPC and once RIPC/day after PCI for one year. Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention(PCI).~Once RIPC/day after PCI for one year:Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg."
62698347|NCT03018873|ACTIVE_COMPARATOR|preoperative RIPC group|routine treatment + Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention.
62698348|NCT03018873|NO_INTERVENTION|control group|routine treatment, no RIPC
62698349|NCT06503185||Prehabilitation|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise was prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
62698350|NCT06503185||Control|The control group received the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
61947315|NCT05799170|EXPERIMENTAL|intervention|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment.
61947316|NCT05799170|NO_INTERVENTION|usual care|usual care/standard of care no intervention implemented
61947317|NCT05058235|EXPERIMENTAL|Active Release Technique|Hot pack, TENS, Quadriceps Isometric strengthening, Active Release Technique
61947318|NCT05058235|ACTIVE_COMPARATOR|Bent leg raise|Hot pack, TENS, Quadriceps Isometric strengthening, Bent leg raise
61947319|NCT02364726|EXPERIMENTAL|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
61947320|NCT00660673|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel|"Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL.~Participants will receive LCIG until it is commercially available."
61947321|NCT01021722|EXPERIMENTAL|Modified suture technique|Sutured in a modified manner
62140297|NCT03916341|EXPERIMENTAL|Non-user|Non- users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
62698351|NCT00618787|ACTIVE_COMPARATOR|Arm 1|
62698352|NCT00618787|ACTIVE_COMPARATOR|Arm 2|
62698353|NCT05339555|OTHER|IUD Self-Removal|
62698354|NCT03632044|EXPERIMENTAL|Suprazygomatic maxillary nerve blockade|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.
62698355|NCT03632044|SHAM_COMPARATOR|25 Gauge needle|Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
62698356|NCT01993732|EXPERIMENTAL|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
62698357|NCT00505687|EXPERIMENTAL|Rotigotine|Rotigotine
61947322|NCT01021722|NO_INTERVENTION|Historical sphincter group|The outcome of historical sphincter tears
61947323|NCT01021722|NO_INTERVENTION|Normal primaparous deliveries|Normal deliveries
62140298|NCT03916341|EXPERIMENTAL|Chronic EC user|Chronic EC users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
62140299|NCT03916341|EXPERIMENTAL|Chronic TC smoker|Chronic TC smokers will use, in a randomized, crossover fashion with a 4 week washout, a 1) TC with nicotine (own brand), 2) research TC with very low level nicotine, and 3) a straw (control)
62140300|NCT01928459|EXPERIMENTAL|Metastatic breast cancer|Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.
62140301|NCT01928459|EXPERIMENTAL|Solid tumor arm 1|Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.
62497557|NCT05317858|ACTIVE_COMPARATOR|Control Arm (Pembrolizumab only)|subjects will undergo planned pembrolizumab monotherapy.
62497558|NCT06249893||Included patients|
62497559|NCT05609695||Immunotherapy group|Treatment based on immunotherapy.
62736500|NCT04154293|EXPERIMENTAL|TMB-001 Ointment, 0.1%|Topical, BID (Twice daily)
62340895|NCT04300634||Parents of children who are physiotherapist|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
62340896|NCT03780556|ACTIVE_COMPARATOR|Lornixicam|Patients received lornoxicam 8 mg intravenous to control pain
61947324|NCT04342377|EXPERIMENTAL|Selective Targeted Sampling|"During patients' Endobronchial Ultrasound (EBUS) procedure, they will first undergo:~Selective Targeted Sampling - endosonographic assessment of at least 3 mediastinal lymph node stations (4R, 4L, and 7) using the four criteria of the Canada Lymph Node Score (predictor of nodal disease during Endobronchial Ultrasound). Each lymph node will be assigned a CLNS ranging from 0 to 4. Triple Normal lymph nodes will be defined as those that appear normal on CT (diameter \< 1 cm), AND normal on PET (SUV \< 2.5), AND normal on EBUS (CLNS \< 2). Lymph nodes that are found to be Triple Normal will be marked as Not for Biopsy, whereas all other lymph nodes will be biopsied."
61947325|NCT04342377|ACTIVE_COMPARATOR|Systematic Sampling|"Upon completion of Systematic Targeted Sampling, all patients will crossover and receive the standard of care:~Systematic Sampling - all lymph nodes previously marked as Not for Biopsy will be biopsied.~At the conclusion of the EBUS procedure, all nodal stations would have been sampled as is mandated by current guidelines."
61947326|NCT00391729|PLACEBO_COMPARATOR|1|
61947327|NCT00391729|EXPERIMENTAL|2|
61947328|NCT00408629|EXPERIMENTAL|adalimumab group|
61947329|NCT00408629|EXPERIMENTAL|placebo group|
61947330|NCT01828736|ACTIVE_COMPARATOR|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance \> 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance \< 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
61947331|NCT01828736|EXPERIMENTAL|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance \> 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance \< 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
61947332|NCT01861860|EXPERIMENTAL|New OPERA Criteria|TAXUS™ Element long stent
61947333|NCT04014946|OTHER|ICD implantation|Implantation of a Lumax 540 single/dual chamber ICD or successor according to local practice within 3 months after enrolment. The patient will be implanted with a single or dual chamber device according to ESC guidelines.
61947334|NCT06557291||Dabrafenib and Trametinib Combination Therapy Cohort|Adult BRAF V600 patients with resected stage III/IV melanoma that relapsed during or after CPI as their first adjuvant therapy and were again rendered free of disease and received adjuvant dab/tram combination therapy.
62340897|NCT03780556|ACTIVE_COMPARATOR|Pethidine|Patients received pethidine 50mg intravenous to control pain
61947335|NCT03812120|PLACEBO_COMPARATOR|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
62340898|NCT03490357|ACTIVE_COMPARATOR|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
62497560|NCT05901116|OTHER|SPSIPB|SPSIPB is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle. Tramadol (intravenous analgesic drug) at a concentration of 4 mg per 1 ml was administered with patient-controlled analgesia (PCA) device (max dose: 400 mg /day)
62497561|NCT06428955|EXPERIMENTAL|Bilateral implantation of investigational device|Monofocal IOL
62497562|NCT01757379|EXPERIMENTAL|13C-labeled acetate|
61947336|NCT03812120|ACTIVE_COMPARATOR|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
61947337|NCT03849248|EXPERIMENTAL|Intervention|This group of babies will have a maternal scented cloth placed under their heads
61947338|NCT03849248|NO_INTERVENTION|Control|This group of babies will have a clean non- maternal scented cloth placed under their head
61947339|NCT02573688|EXPERIMENTAL|Interdisciplinary Therapy|The Therapy includes: Physical Exercise (three times week - 180 minutes); Nutrition, Psychology, Physiotherapy (once a week - 60 minutes each one)
62497563|NCT01757379|EXPERIMENTAL|13C-labeled propionate|
62736501|NCT02044952|EXPERIMENTAL|Mesalazine, Tripterygium glycosides|Mesalazine 4g/d and Tripterygium glycosides 2mg/kg/d for 12 weeks
62736502|NCT00873821|EXPERIMENTAL|1|MK-0941
61947340|NCT03344133|EXPERIMENTAL|Exercise|4-week moderate intensity exercise programme
61947341|NCT03344133|NO_INTERVENTION|Control|4 weeks of habitual life style
61947342|NCT00766025|EXPERIMENTAL|Rosuvastatin Calcium|
61947343|NCT04708106|EXPERIMENTAL|RELX ENDS Tobacco Flavor|Switch from combustible cigarettes to RELX ENDS Tobacco Flavor for 56 days
61947344|NCT04708106|EXPERIMENTAL|RELX ENDS Menthol Flavor|Switch from combustible cigarettes to RELX ENDS Menthol Flavor for 56 days
61947345|NCT04708106|EXPERIMENTAL|RELX ENDS Tobacco and Menthol Flavors|Switch from combustible cigarettes to RELX ENDS Tobacco and Menthol Flavor for 56 days
61947346|NCT04708106|NO_INTERVENTION|Continue-smoking|Continue smoking combustible cigarettes for 56 days
61947347|NCT00933829|PLACEBO_COMPARATOR|Non-absorbable arm|uses non-absorbable suture such as Prolene to repair lacerations
61947348|NCT00933829|ACTIVE_COMPARATOR|Absorbable Suture Arm|uses absorbable sutures to repair lacerations
62340899|NCT03490357|EXPERIMENTAL|Quadratus Lumborum Block|Quadratus lumborum nerve block
62736503|NCT00873821|PLACEBO_COMPARATOR|2|Placebo Comparator
62497564|NCT01757379|EXPERIMENTAL|13C-labeled butyrate|
61947349|NCT02676115|ACTIVE_COMPARATOR|Control Group|Standard Post Operative Skin Care
61947350|NCT02676115|EXPERIMENTAL|Treatment Group|Medipore Tape will be applied to ACL reconstruction Incision
62340900|NCT06196957|EXPERIMENTAL|Buteyko technique|"GROUP A'(Buteyko technique)~Participant in group A will be instructed to perform the Buteyko breathing exercise.~Patient either on the sitting position or standing position.~Patient will be relaxed the shoulder and rest lower back against the back of chair.~Close the mouth while only breathing through nose.~Breath into the diaphragm and chest should be still.~Exhale slowly, then hold the breath.~Use the index finger and thumb to plug the nose, Hold the breath until there is urge to breath Then inhale~Repeat several times. With in 15 minutes."
61947351|NCT01790425|EXPERIMENTAL|water colonoscopy|The water (study) method: Warm water (body temperature) will be infused into colon to open the lumen for water infusion colonoscopy. Higher rate of complete colonoscopy will be achieved.
62340901|NCT06196957|ACTIVE_COMPARATOR|Senobi technique|"GROUP B (Senobi techniques)~Senobi breathing exercise will be performed from standing, Arms will be extended firmly,~The neck was extended so as face the ceiling. And the patient instructed to avoid over exertion~Take a deep breath, hold for 3 second and then exhale through mouth.~The time of exercise will be 15 minutes."
62497565|NCT01757379|EXPERIMENTAL|Inulin|
62497566|NCT04190927|EXPERIMENTAL|Treatment|All patients will be symptomatic peri or post menopausal and will all be started on the same protocol. The Dosing schedule of topical estradiol and topical progesterone will be modified for each subject in the first three months to address individual symptoms. The dosing will be relatively unique to each patient. Patients will remain on their dosing schedule for the remainder of the three year study and will be assessed during at the end of the study for changes in mood, symptoms of menopause, breast health, BMD and thickness of uterine lining .
62698358|NCT03563079|EXPERIMENTAL|trial group|The treatment will be performed using two pieces of Instrument Assisted Soft Tissue Mobilization (IASTM) stainless steel in the neck, bilaterally, which comprise the following muscles: Upper Trapezius, Splenius, scalenes and Sternocleidomastoid. An established time of 3 minutes will be used in each region, using an angle of 30 to 60º with the instrument. As it is observed, through the instrument, regions of greater adhesion, the researcher will use most of this time to release this condition.
62698359|NCT03563079|ACTIVE_COMPARATOR|group control|Treatment will be performed using manual Myofascial Release techniques. Release the upper Trapezius muscle bilaterally, sliding using roller with the dorsum of the fingers and ending with myofascial release. Sternocleidomastoid, sliding using roller with the dorsum of the fingers, ending with myofascial release. Afterwards the release of the scalenes muscles will be performed, with the fingers sliding and ending with the myofascial release. Soon afterwards techniques will be performed for the Splenius muscles, using finger slips and ending with posterior cervicothoracic release. The same time of 3 min will be used for the treatment bilaterally in each region.
62698360|NCT01107496|EXPERIMENTAL|IR Viloxazine|Treatment A: immediate-release (IR) viloxazine capsules administered orally 3 times a day
62698361|NCT01107496|PLACEBO_COMPARATOR|Placebo|Treatment B: Placebo capsules administered orally 3 times a day
61947352|NCT01790425|ACTIVE_COMPARATOR|Air Colonoscopy|The air (conventional) method: Air is pumped gently (insufflation) into the colon will be used to open the inside space of the colon and aid in colonoscope insertion
62698362|NCT06215378|EXPERIMENTAL|Systematic heparine antagonization with protamine sulphate|Complete reversal of the Heparin administered during the TAVI achieved through the infusion of a protamine solution until the ACT returns to its baseline level.
61947353|NCT05586893|EXPERIMENTAL|Electroacupuncture|The acupuncture electrical stimulation was performed by the EL 608 electroacupuncture device (NKL, Brusque - SC, Brazil, ANVISA 80191680002). For the stimulation of the acupuncture points, we selected a biphasic wave, 2 HZ of frequency, 6 mA of wavelength, and 5 seconds at resting time. The total stimulation time was 20 minutes.
61947354|NCT05586893|EXPERIMENTAL|Acupuncture therapy|"The acupuncture points were bilaterally punctured by a stainless steel acupuncture needle (length 30mm x diameter 0.25) (Dongbang, Boryeong, Chungnam- Korea). We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
61947355|NCT05586893|NO_INTERVENTION|Control Group|Infrared images were captured at the first assessment (P0), 10 minutes later (P10), 20 minutes later (P20) and 30 minutes after the first assessment (P30). All analyzes were performed using QuickReport software, version 1.2 (FLIR Systems). No application of interventions between assessments.
62140302|NCT01928459|EXPERIMENTAL|Solid tumor arm 2|Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3
62140303|NCT01928459|EXPERIMENTAL|Dose escalation|To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.
62340902|NCT04568941|EXPERIMENTAL|Preoperative Vacuum-Assisted Biopsy|Preoperative vacuum-assisted biopsy was performed within 10 days before final surgery. The tumor were excised almost.
62340903|NCT04568941|EXPERIMENTAL|Preoperative Core Needle Biopsy|Preoperative core needle biopsy was performed within 10 days before final surgery. The needle biopsy were performed with 3 needles.
62340904|NCT04568941|EXPERIMENTAL|Intraoperative Excisional Biopsy|The tumor was excised intraoperatively.
62340905|NCT05790473||Case|Fetuses with brain anomalies
62340906|NCT05790473||Controls|Normal with normal brain
62340907|NCT05552534|EXPERIMENTAL|Intervention group|
62340908|NCT05552534|NO_INTERVENTION|Control group|
62340909|NCT06102811|EXPERIMENTAL|Low Concentration Local Anesthetic Fascia Iliaca Compartment Block|Patients will be submitted to a Suprainguinal Fascia Iliaca Block with low concentration local anesthetic (Ropivacaine 0.075%)
62497567|NCT01467596|EXPERIMENTAL|Elderly population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
62497568|NCT01467596|ACTIVE_COMPARATOR|Middle aged population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
62140304|NCT04719026||Cases|Patients for the case study group will be recruited from those hospitalized for acute myocardial infarction on the Cardiology Ward and Coronary Care Unit at Aberdeen Royal Infirmary. All patients will be diagnosed using current clinical criteria for type-1 myocardial infarction according to the ESC guidelines10 and recruited within 3 days of admission. Recruitment of this arm is now complete.
62497569|NCT02913755|EXPERIMENTAL|Intervention group|Repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
62497570|NCT02913755|ACTIVE_COMPARATOR|Lagged Control Group|2 week period of treatment as usual followed by repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
62497571|NCT04959032|EXPERIMENTAL|Lumateperone 42 mg|
62497572|NCT04959032|PLACEBO_COMPARATOR|Placebo|
62497573|NCT06678308|EXPERIMENTAL|Magic Glue®|Embolisation of the prostatic arteries will be performed with Magic Glue® combined with lipiodol
62497574|NCT06678308|ACTIVE_COMPARATOR|Embosphere®|Embolisation of prostatic arteries will be performed with 300-500 micron trisacryl particles (Embosphere®)
62497575|NCT04323215||Support system users|Usual care (behavioral treatment) plus the support system for self-monitoring of weight and communication with the clinic during one year of treatment.
62497576|NCT04323215||Control group|Children treated with usual care according to regular treatment routines registred in BORIS the Swedish childhood obesity treatment register
62497577|NCT01878773|OTHER|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI Scan.
62497578|NCT04622930|EXPERIMENTAL|Experimental: Smartphone-delivered CBT for SAD|12-week Smartphone delivered CBT for SAD.
62497579|NCT04622930|OTHER|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for SAD following the 12-week waitlist control).
62497580|NCT03435341||Patients diagnosed with AML|The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
62497581|NCT04085744|NO_INTERVENTION|control group|In this group any drug will be applied on the cuff of the intubation tube
62497582|NCT04085744|ACTIVE_COMPARATOR|lidocaine group|10% lidocaine spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
62497583|NCT04085744|ACTIVE_COMPARATOR|steroid group|mometasone furoate spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
62497584|NCT06677619|EXPERIMENTAL|intrusion by reverse curve in cervical position|double slot bracket with reverse curvein cervical slot
62497585|NCT06677619|EXPERIMENTAL|intrusion with reverse curve in incisal position|double slot bracket reverse curvein incisal slot
62497586|NCT04006873|ACTIVE_COMPARATOR|Tezacaftor/Ivacaftor in combination with Ivacaftor|"A film-coated tablet containing 100mg tezacaftor and 150mg ivacaftor will be taken in the morning.~A film-coated tablet containing 150mg ivacaftor will be taken in the evening.~Participants will take these tablets for 28 days.~All tablets are licensed for use in the EU."
62497587|NCT04006873|PLACEBO_COMPARATOR|Placebo|A visually matched placebo to the active drugs will be taken in the morning and in the evening for 28 days.
62698363|NCT06215378|NO_INTERVENTION|No Systematic heparine antagonization with protamine sulphate|No administration of protamine solution unless a participant encounters a bleeding event requiring a surgery or percutanous intervention.
62497588|NCT01774682|OTHER|6-minute walk test|the 6-minute walk test is performed for each patient prior to the surgery and 6 months after by a specialist.
62497589|NCT06332092|ACTIVE_COMPARATOR|Arm A|FID-007 (75 mg/m2) plus Cetuximab (500 mg/m2)
62497590|NCT06332092|ACTIVE_COMPARATOR|Arm B|FID-007 (125 mg/m2) plus Cetuximab (500 mg/m2)
62497591|NCT04164030|ACTIVE_COMPARATOR|Nutrition Education Control|An evidence-based nutrition program entitled Eating Smart Being Active. Delivered in a group: Meets weekly for 2 hours for 9 weeks.
62497592|NCT04164030|EXPERIMENTAL|Nutrition Education +OT+Yoga|9 week group that meets twice a week for two hours each. Group occupational therapy and group yoga will be added to the nutrition program.
62497593|NCT05645315|EXPERIMENTAL|TQB2618 injection+TQB2450 injection|TQB2618 injection combined with TQB2450 injection, 21 days as a treatment cycle.
62698364|NCT05713292|EXPERIMENTAL|Pirfenidone|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
62698365|NCT05713292|PLACEBO_COMPARATOR|Placebo|Pirfenidone placebo 200mg tid for first week; subsequently, 400mg tid for 2 months
62140305|NCT04719026||Controls|A control group of dental patients matched for age (±3 years), gender, and risk factors for CAD (hypertension, obesity, diabetes, smoking, hypercholesterolaemia and family history) but with no history of myocardial infarction will be selected at Aberdeen Dental School or from the SHARE register or via the NHS Research Scotland Primary Care Network on an invitation basis. Thr recruitment of this arm of the study is ongoing.
62497594|NCT01932190|EXPERIMENTAL|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
62497595|NCT01932190|EXPERIMENTAL|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria"
62497596|NCT05761392|EXPERIMENTAL|Precise management|"Participants will be asked to take daily pain state and monthly health condition assessments.~A warning for the physicians will be given when participants reach daily assessment threshold. Remote interventional meeting will be scheduled and stimulation parameters will be adjusted accordingly.~Participants will also be asked to take conventional follow-up at 1-, 3-, and 6-month post-operative."
62497597|NCT05761392|NO_INTERVENTION|Conventional management|Participants will be only asked to take conventional follow-ups at 1-, 3-, and 6-month post-operative. During these follow-ups, they will be asked to score VAS based on general pain state, and take questionnaires including EQ-5D-5L, PSQI, PGIC, CGI-I.
62497598|NCT03160079|EXPERIMENTAL|Blinatumomab + Pembrolizumab|"Drug: blinatumomab Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days~Other Names:~Blincyto~Drug: pembrolizumab Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Other Names:~* Keytruda~* MK-3475"
62497599|NCT01256697|EXPERIMENTAL|Alga Dunaliella Bardawil|
62497600|NCT01256697|PLACEBO_COMPARATOR|Sugar pill|
61947356|NCT03774264||Xiaflex group|"Patients will be evaluated in our urology clinic at baseline for possible inclusion in our study. All patients at baseline evaluation will be evaluated for duration of symptoms, relationship stability, IIEF and PDQ. All patients will obtain a penile Doppler ultrasound with the aid of a vasoactive substance by a specially trained technician. During this visit, plaque measurements will be taken: location of plaque, distance of plaque from the tip of the penis, degree of curvature measured by goniometer.~Ultrasound characteristics will be documented: Type (Type 1: The plaque appears as a thickening of the tunica albuginea without acoustic shadowing. Type 2: A moderately calcified plaque with a typical ultrasound shadow. Type 3: A severely calcified plaque with typical ultrasound shadowing) and Grade of calcification (grade 1 (\<0.3 cm), grade 2 (\>0.3 cm, \<1.5 cm), grade 3 (\>1.5 cm; or ≥ 2 plaques \>1.0 cm). Sample data sheet attached as appendix 2."
62140306|NCT05142215|ACTIVE_COMPARATOR|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO).
62340910|NCT06102811|ACTIVE_COMPARATOR|High Concentration Local Anesthetic Fascia Iliaca Compartment Block|Patients will be submitted to a Suprainguinal Fascia Iliaca Block with high concentration local anesthetic (Ropivacaine 0.25%)
62340911|NCT01363713|EXPERIMENTAL|1|
62340912|NCT01953328|PLACEBO_COMPARATOR|A5 Placebo Q2W|Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
62698366|NCT06457087||Patients with peripheral pulmonary lesions|A total of 150 patients with peripheral pulmonary lesions who meet the inclusion and exclusion criteria will be prospectively enrolled, of which 100 patients will be used for the development of CLE interpretation criteria, and 50 patients will be used for the validation of the criteria.
62698367|NCT05601869|EXPERIMENTAL|Intervention|Participants in this arm receive a new prosthesis system designed to improve footwear options.
62698368|NCT05629520||Participants with Major Depressive Disorder including TRD|Treatment resistant depression (TRD) participants are defined as participants with Major Depressive Disorder (MDD) who fail to respond to at least two lines of antidepressant medication treatment interventions.
62698369|NCT03592355|EXPERIMENTAL|Intervention|"If enrolled in the intervention arm, the following steps will occur:~* The Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~* The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
62698370|NCT03592355|NO_INTERVENTION|Control|"If enrolled in the control arm, the following steps will occur:~* Three months from the time of the follow-up email, the Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~* The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
62140307|NCT05142215|PLACEBO_COMPARATOR|Placebo percutaneous coronary intervention|Placebo procedure for chronic total occlusion (CTO).
62140308|NCT03738709|EXPERIMENTAL|Occupational therapy group sessions|In the collective experimental group, the care includes 6 group sessions of one hour each, programmed over 2 weeks and progressive courses.
62140309|NCT03738709|ACTIVE_COMPARATOR|Individual Occupational therapy sessions|In the individual control group, care consists of 6 individual sessions of 45 minutes each, not programmed over 2 weeks and progressive courses.
62340913|NCT01953328|PLACEBO_COMPARATOR|A5 Placebo QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
62340914|NCT01953328|EXPERIMENTAL|A5 Evolocumab Q2W|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62340915|NCT01953328|EXPERIMENTAL|A5 Evolocumab QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
62340916|NCT01953328|PLACEBO_COMPARATOR|A20 Placebo Q2W|Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
62340917|NCT01953328|OTHER|A20 Placebo QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
62698371|NCT03506360|EXPERIMENTAL|Treatment (ixazomib citrate, pembrolizumab, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62140310|NCT04890938|EXPERIMENTAL|Sputum-guided management and comprehensive care management|The intervention consists of 6-months of CCM and sputum biomarker-directed treatment of airway inflammation, including hospital and clinic visits. Clinic visits at 2, 6, and 16 weeks. The key elements of CCM will be provided, including case management, self-management education, and coordination of community/hospital resources (1). Clinic nurse will review inhaler technique with the patient. Sputum (spontaneous) biomarkers will be measured with results used to direct therapy at the time of AECOPD and during clinic visits after hospital discharge, at both sites.
62140311|NCT04890938|ACTIVE_COMPARATOR|Usual Care|This group will also receive clinic visits at 2, 6, and 16 weeks with a study physician, and also education material, inhaler technique assessment and education, and case management from the clinic personnel. The study physician will pursue further investigation and/or further intervention if they see fit.
62340918|NCT01953328|EXPERIMENTAL|A20 Evolocumab Q2W|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62340919|NCT01953328|EXPERIMENTAL|A20 Evolocumab QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
62698372|NCT00867152|EXPERIMENTAL|Cohort 2|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
62497601|NCT06400225|EXPERIMENTAL|Treatment (BVD-523FB [ulixertinib])|Patients receive BVD-523FB (ulixertinib) PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI and blood sample collection throughout the trial. Patients also undergo ECHO or nuclear study (MUGA or similar scan) during screening and on study. Patients may also undergo biopsies on study.
62698373|NCT00867152|EXPERIMENTAL|Cohort 1|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
62698374|NCT05316844||Office Employees Group|Office Employees with neck pain
62698375|NCT03512730|EXPERIMENTAL|Titanium brush, H2O2 3%, plastic curettes|
61947357|NCT04188587|EXPERIMENTAL|177Lu-PSMA-I&T|177Lu-PSMA-I＆Tradioligand therapy with 2.0-8.0GBq in every circle were performed. And then 177Lu-PSMA post-therapy scans were performed at 24 h and 48 h respectively, and the fusion phenomenon was performed at the second day to pre evaluate the efficacy of the patients.
61947358|NCT05614232||Positive group|chest radiographs with the specific target radiologic findings (Atelectasis, Calcification, Cardiomegaly, Consolidation, Fibrosis, Mediastinal Widening, Nodule/Mass, Pleural Effusion, Pneumoperitoneum, Pneumothorax)
61947359|NCT05614232||Negative group|chest radiographs with no target radiologic findings
61947360|NCT05708274|EXPERIMENTAL|CPH + hand training|A single dose of Cyproheptadine (CPH) (8 mg) will be administered. Supplied as 2 over-encapsulated pills of 4 mg each.
61947361|NCT05708274|EXPERIMENTAL|CD-LD + hand training|A single dose of IR Carbidopa-levodopa (CD-LD) (50/200 mg) will be administered. Supplied as 2 over-encapsulated pills (25 mg carbidopa / 100 mg levodopa each).
61947362|NCT05708274|EXPERIMENTAL|ATX + hand training|A single dose of Atomoxetine (ATX) (40 mg) will be administered. Supplied as 1 over-encapsulated pill of 40 mg plus 1 placebo capsule.
61947363|NCT05708274|PLACEBO_COMPARATOR|Placebo + hand training|A single dose of Placebo will be administered. Supplied as 2 gelatin capsules, identical in number, size, shape and color, filled with microcrystalline cellulose.
61947364|NCT03117920|EXPERIMENTAL|Minnelide|0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
61947365|NCT04785092|EXPERIMENTAL|Treatment - All Autologous Cartilage Regeneration|
62340920|NCT03216317|ACTIVE_COMPARATOR|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
62340921|NCT03216317|NO_INTERVENTION|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
62340922|NCT05299814|EXPERIMENTAL|Behavior Therapy|8 sessions of an evidence based parenting program to address oppositional behaviors and ADHD symptoms at home. All participants are in this arm.
62340923|NCT02178176|EXPERIMENTAL|Education, encouragement, card sort|
62340924|NCT02178176|ACTIVE_COMPARATOR|Education, encouragement|
62340925|NCT05966844|EXPERIMENTAL|Mindfulness and Virtual Reality|This group will receive questionnaires at the beginning and end of the trial. In addition, they will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
62340926|NCT05966844|NO_INTERVENTION|No intervention|This group will only receive questionnaires at the beginning and end of the experiment
62340927|NCT02060344||Hispanic/Latinos residing in the US|The cohort consists of over 16,400 persons of Hispanic/Latino origin, ages 18-74, specifically Cuban, Puerto Rican, Mexican, and Central/South American, to be recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami.
62340928|NCT05294822|EXPERIMENTAL|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|
62698376|NCT03512730|ACTIVE_COMPARATOR|H2O2 3%, plastic curettes|
62698377|NCT05011383|EXPERIMENTAL|ATM|Patients with castration resistant prostate cancer which contains ATM alterations are treated with high dose testosterone
62698378|NCT05011383|EXPERIMENTAL|CDK12|Patients with castration resistant prostate cancer which contains CDK12 alterations are treated with high dose testosterone
62140312|NCT03683576|PLACEBO_COMPARATOR|Placebo|Placebo once per day (QD) for 24 weeks
62340929|NCT06224881|ACTIVE_COMPARATOR|Vitamin C group|Ascorbic acid (Vitamin C) was given parenterally (2 gm every 8hrs) for 4 days.
62340930|NCT06224881|PLACEBO_COMPARATOR|Control group|No vit C given
62340931|NCT05138783|OTHER|PRECISION1, then Biotrue|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for 8 -0/+3 days. A fresh pair of lenses will be worn each day.
62340932|NCT05138783|OTHER|Biotrue, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for 8 -0/+3 days. A fresh pair of lenses will be worn each day.
62340933|NCT02055430|ACTIVE_COMPARATOR|percutaneous nephrostomy|percutaneous nephrostomy insertion (6-8 Fr in size) for initial urinary drainage followed by definitive stone management.
62340934|NCT02055430|ACTIVE_COMPARATOR|Bilateral double J ureteric stents|double J ureteric stent insertion (4.8-6 Fr JJ in size) for initial urinary drainage followed by definitive stone management.
62698379|NCT05011383|EXPERIMENTAL|CHEK2|Patients with castration resistant prostate cancer which contains CHEK2 alterations are treated with high dose testosterone
62698380|NCT04641026|ACTIVE_COMPARATOR|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
62497602|NCT02578641|EXPERIMENTAL|Arm A|"4 cycles\* of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T cells every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.~\*Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion.~As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days"
62140313|NCT03683576|EXPERIMENTAL|GB001 20 mg|GB001 20 mg QD for 24 weeks
62497603|NCT02578641|ACTIVE_COMPARATOR|Arm B|6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.
62698381|NCT04641026|ACTIVE_COMPARATOR|Deuterium oxide-labeled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
62698382|NCT04641026|PLACEBO_COMPARATOR|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
62698383|NCT04641026|PLACEBO_COMPARATOR|Deuterium oxide-labeled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
62698384|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
62698385|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
62140314|NCT03683576|EXPERIMENTAL|GB001 40 mg|GB001 40 mg QD for 24 weeks
62140315|NCT03683576|EXPERIMENTAL|GB001 60 mg|GB001 60 mg QD for 24 weeks
62140316|NCT05309200|PLACEBO_COMPARATOR|OCE-205 Cohort 1|Placebo, intravenous infusion
62140317|NCT05309200|EXPERIMENTAL|OCE-205 Cohort 2|OCE-205, 8 µg/hr, intravenous infusion
62140318|NCT05309200|EXPERIMENTAL|OCE-205 Cohort 3|OCE-205, 15 µg/hr, intravenous infusion
62340935|NCT05909605||Ultrasound blood pressure sensor|
62340936|NCT05494541||Overall cohort|All the patients who met the base inclusion criteria were included in the cohort.
62340937|NCT05494541||Three-month cohort (3m cohort)|Patients with stability and eligibility in IQVIA Patient Centric Medical Claims Database (Dx) and stability and eligibility in IQVIA Longitudinal Prescription Database (LRx) during the 3 months following the index date were included in the cohort.
62140319|NCT05309200|EXPERIMENTAL|OCE-205 Cohort 4|OCE-205, 30 µg/hr, intravenous infusion
62340938|NCT05494541||Six-month cohort (6m cohort)|A subset of patients from the 3m cohort with stability and eligibility in Dx and stability and eligibility in LRx during the 6 months following the index date were included in this cohort.
62698386|NCT01980264|EXPERIMENTAL|Diagnostic imaging|Harmonic Generation Microscopy
62698387|NCT01683812|EXPERIMENTAL|Cranial Cup Arm|Single arm
62698388|NCT06107699|EXPERIMENTAL|Patient Navigator|
62698389|NCT06107699|NO_INTERVENTION|Standard of Care|
62698390|NCT04950153|OTHER|HIV Testing Intervention|Combination HIV testing and linkage to care intervention includes social media engagement and peer navigation
62140320|NCT05309200|EXPERIMENTAL|OCE-205 Cohort 5|OCE-205, 50 µg/hr, intravenous infusion
62140321|NCT05940740|EXPERIMENTAL|INTERFERENCE (EXPERIMENT)|"1. Giving patients with colorectal cancer about 20-30 minutes of training during chemotherapy with the mobile health application and answering face-to-face questions about the use of mobile health application.~2. Sending a reminder message about the use of mobile health application via phone once a week. Answering the questions about the mobile health application and the training given during the chemotherapy application every two weeks / summarizing the training"
62698391|NCT04950153|OTHER|HIV Treatment Intervention|Combination HIV treatment outcomes (retention, ART adherence and viral suppression) intervention includes SMS text messaging and peer navigation
62698392|NCT03454347|EXPERIMENTAL|Protein Supplementation Group|Participants in this group will complete two weeks of lower limb suspension and receive 75g/day of supplemental protein in addition to education aimed at increasing protein intake through their diet.
62698393|NCT03454347|ACTIVE_COMPARATOR|Non-Supplemental Group|Participants in this group will complete two weeks of lower limb suspension and will receive no supplementation or nutritional education.
62698394|NCT01716000|EXPERIMENTAL|2 mL vaginal gel|2 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
62140322|NCT05940740|NO_INTERVENTION|CONTROL|"1. Giving approximately 20-30 minutes of routine treatment and care and answering questions during premedication application to colorectal cancer patients when they come to the unit to receive 1st cure chemotherapy.~2. Pre-test-post-test at the beginning of the 1st course of treatment and at the end of the 3rd cycle of treatment"
62140323|NCT03977194|ACTIVE_COMPARATOR|Arm A : standard treatment|Carboplatine + paclitaxel (4 cycles of 28 days)
62340939|NCT01320111|ACTIVE_COMPARATOR|Arm 1: PA|patient is treated with paclitaxel only
62340940|NCT01320111|EXPERIMENTAL|Arm 2: PASO|patient is treated with paclitaxel AND sorafenib
62340941|NCT02850991|EXPERIMENTAL|High-dose|"concurrent chemoradiotherapy High-dose RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
62497604|NCT04084990|EXPERIMENTAL|aPAP|Nightly use of aPAP when sleeping through the date of delivery
62497605|NCT04084990|NO_INTERVENTION|No aPAP|No use of aPAP (standard of care)
62140324|NCT03977194|EXPERIMENTAL|Arm B : standard treatment + immunotherapy|Carboplatine + paclitaxel (4 cycles of 28 days) + atezolizumab (every 21 days) until progression or toxicity
61947366|NCT01706822|EXPERIMENTAL|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy
61947367|NCT04029506||medical staff group|medical staff in Qilu Hospital who recieveing endoscopy for physical examination
62140325|NCT04070963||Cohort|We propose a prospective, observational single-centre pilot study in the PAC (SGH), on participants aged 21 years and above. A HbA1c test will be added to their routine preoperative blood tests. The incidence of newly-diagnosed DM/pre-diabetes (HbA1c ≥6.1%) and poorly controlled DM (HbA1c ≥ 8%), demographic details and presence of significant comorbidities will be analysed.
62698395|NCT01716000|EXPERIMENTAL|4 mL vaginal gel|4 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
61947368|NCT04029506||general population group|general population who recieveing endoscopy for physical examination in Qilu Hospital
61947369|NCT02318537|EXPERIMENTAL|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
61947370|NCT02318537|PLACEBO_COMPARATOR|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
61947371|NCT06142708|EXPERIMENTAL|Dual trigger (GnRH-agonist plus hCG)|Participants in this arm will be administered a GnRH-agonist trigger plus hCG (dual trigger) for final maturation
62698396|NCT02382146|EXPERIMENTAL|dexamethasone and ondansetron|dexamethasone 8 mg with ondansetron 4mg administered in group DO
62698397|NCT02382146|ACTIVE_COMPARATOR|dexamethasone and dimenhydrinate|dexamethasone 8 mg with dimenhydrinate 1mg/kg administered in group DD
61947372|NCT06142708|ACTIVE_COMPARATOR|Gn-RH-agonist only trigger|Participants in this arm will be administered a GnRH-agonist trigger only for final maturation
61947373|NCT04548583|EXPERIMENTAL|remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 150 million cells into the submucosal layer of the colon wall at baseline~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)"
61947374|NCT04548583|EXPERIMENTAL|remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
61947375|NCT04548583|PLACEBO_COMPARATOR|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L, at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
61947376|NCT06132516|EXPERIMENTAL|High Intensity Interval Training (HIIT)|HIIT 16 sessions of 12 to 30 minutes, over 6 weeks.
61947377|NCT06132516|PLACEBO_COMPARATOR|Low Intensity Group Training (LIGT)|LIGT 16 sessions of 12 to 30 minutes, over 6 weeks.
61947378|NCT02201875||Healthy subjects|male, aged 18-65 moderately trained healthy, no treatment
61947379|NCT02201875||obstructive sleep apneas|patients with apnea/hypopnea index \> 15 BMI \< 30 Age \< 50 yrs
61947380|NCT02201875||cardiac failure|NYHA class I to III ejection fraction \< 40% age \< 65 yrs BMI \< 30
61947381|NCT01907997|EXPERIMENTAL|Group L|Intravenous lidocaine infusion group
61947382|NCT01907997|PLACEBO_COMPARATOR|Group C|Intravenous normal saline infusion - control group
61947383|NCT02620657||Non interventional study|The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
61947384|NCT02315989|OTHER|safety|proton therapy
61947385|NCT01595035|EXPERIMENTAL|counselling|Patients who receive the Pain booklet and support by telephone
61947386|NCT01595035|NO_INTERVENTION|Control|Standard care
61947387|NCT03314194|EXPERIMENTAL|Plant Based Diet Group|Study aims for two cohorts of 20 females each, being tested over 6 days in two conditions: habitual diet versus plant based diet.
62140326|NCT03515369|EXPERIMENTAL|Hepatectomy plus Babaodan|Surgical removal of all lesions and take Babaodan oral capsule after operation
62140327|NCT03515369|PLACEBO_COMPARATOR|Hepatectomy plus Placebo|Surgical removal of all lesions and take Placebo oral capsule after operation
61947388|NCT00993902|SHAM_COMPARATOR|Single IUI|Single IUI will be carried on after 36-38 hours of HCG administration
61947389|NCT00993902|ACTIVE_COMPARATOR|Double IUI|
61947390|NCT04330053|EXPERIMENTAL|Experimental|Information - Education about falls and Exercise for Fall Prevention
61947391|NCT04330053|ACTIVE_COMPARATOR|Control|Information - Education about falls without Exercise for Fall Prevention
61947392|NCT02293057|ACTIVE_COMPARATOR|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
62140328|NCT00255372|EXPERIMENTAL|1|
62140329|NCT00255372|ACTIVE_COMPARATOR|2|
61947393|NCT02293057|PLACEBO_COMPARATOR|Girl Health Group (Attention Control)|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
62164447|NCT03701581|PLACEBO_COMPARATOR|Group B: Placebo|"Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by a licensed compounding pharmacy. The Investigational Drug Service at Banner University Medical Center will manage the placebos.~The placebo will be tooled to look similar to the investigational treatment using Coni-Snap #00 White/White (Opaque) capsules manufactured by Medisca and CapsOral filler manufactured by Specialized Rx."
62698398|NCT03864328|EXPERIMENTAL|RVT-1601 Low Dose|
62497606|NCT00540358|ACTIVE_COMPARATOR|Arm G/C|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
62497607|NCT00540358|EXPERIMENTAL|Arm G/C/I|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
62497608|NCT00812318|EXPERIMENTAL|Treatment A|GSK1265744 10mg oral solution
62497609|NCT00812318|EXPERIMENTAL|Treatment B|GSK1265744 5mg tablet, fasted
62497610|NCT00812318|EXPERIMENTAL|Treatment C|GSK1265744 5mg tablet, fed
62497611|NCT00428831||1|Patients with respiratory illnesses.
62497612|NCT04009876|EXPERIMENTAL|Chemotherapy + Surgery|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection
62497613|NCT04009876|EXPERIMENTAL|Chemotherapy + Watch-and-wait|"Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and watch-and-wait surveillance protocol."
61947394|NCT06429111||low-risk pregnant women who freely chooses to use epidural analgesia during labor|"* Pregnant women at term with normal pregnancy without the presence of maternal and neonatal risk factors who meet criteria according to the protocol for the use of water and who choose epidural analgesia at the time of admission to the dilatation room in active labor.~* Over 17 years of age~* Psychic and cognitive capacity for decision making~* Willingness to take part in the study and signature of the informed consent form.~* Absence of ideomatic barrier"
62497614|NCT04734782||Protective Mothers (high IGG titers)|Protected group Newborns with congenital heart disease + high titers of anti-RSV IGG in the mother's serum before birth
62497615|NCT04734782||Non-protective mothers (low IGG titers)|Unprotected group Newborn with congenital heart disease + negative anti-RSV IGG titers in the mother's serum before birth.
62497616|NCT01590199|EXPERIMENTAL|RAD001 + SOM230|
62497617|NCT05551741|EXPERIMENTAL|Cohort 1|IBC-Ab002 low dose or placebo
62497618|NCT05551741|EXPERIMENTAL|Cohort 2|IBC-Ab002 mid low dose or placebo
62497619|NCT05551741|EXPERIMENTAL|Cohort 3|IBC-Ab002 mid dose or placebo
62698399|NCT03864328|EXPERIMENTAL|RVT-1601 Mid Dose|
62698400|NCT03864328|EXPERIMENTAL|RVT-1601 High Dose|
62140330|NCT05112549|EXPERIMENTAL|intrathecal Nivolumab|"This is a prospective, interventional, open label, multicenter phase I trial in leptomeningeal disease in subjects with solid tumor that have a registered indication for intravenous treatment with PD1 antibody. Subject will undergo 6 cycles each 14 days in duration and a safety visit 7 days after the 3th dosage and 7 days after the 6th dosage. The Follow-up phase will start four weeks after the last dose and will continue monthly (up to 4 Follow-up visits in total).The study consists of two parts:~Part I dose - escalation phase (3 + 3 design) with 4 cohorts and each subject will receive an intrathecal nivolumab treatment with a fixed predefined dose (20 mg, 30 mg, 40 mg or 50 mg). On each dose level, exposure of subjects to intrathecal nivolumab will follow a staggered approach. Part II dose expansion phase: subjects will receive an intrathecal PD1 treatment with a fixe dose, depending on the results from Part I."
62140331|NCT04918875||Patients 12 years of age or older with suspected or confirmed COVID-19, deemed to require oxygen.|
62140332|NCT03428633|ACTIVE_COMPARATOR|Group A|Thoracic paravertebral block using ropivacaine
62140333|NCT03428633|ACTIVE_COMPARATOR|Group B|Morphine IV
62497620|NCT05551741|EXPERIMENTAL|Cohort 4|IBC-Ab002 mid high dose or placebo
62497621|NCT05551741|EXPERIMENTAL|Cohort 5|IBC-Ab002 high dose or placebo
62497622|NCT06168903|EXPERIMENTAL|EOI block Group (n=25):bilateral US-guided external oblique intercostal block.|"Patient in a supine position. A linear ultrasound probe will be placed in paramedian sagittal orientation between the midclavicular and anterior axillary lines at the level of the sixth rib, visualizing the external oblique and intercostal muscles. Local anesthetics are injected under the external oblique muscle.~A 22-gauge needle will be advanced in the superomedial-to-inferolateral direction into the fascial plane between the external oblique and intercostal muscles at the caudal end of the sixth rib and between the sixth and seventh ribs.The location of the needle tip will be confirmed by hydrodissection of inter-fascial planes with 3 ml of normal saline. After negative aspiration, a total of 20 mL of bupivacaine 0.25% will be injected in the fascial plane incrementally, aspirating every 5 ml, and the block will be repeated on the other side."
62497623|NCT06168903|ACTIVE_COMPARATOR|ESPB Group (n=25): bilateral US-guided erector spinae plane block|Patient in a lateral position. A curvilinear ultrasound probe (5-7 MHz) will be placed transversely to identify tip of T9 transverse process 2.5-3 cm from the midline, then it will be rotated longitudinally to get a parasagittal view, visualizing the transverse process as a hyperechoic curvilinear structure with prominent finger-like acoustic shadowing beneath , lamina , spinous process, and costochondral junction medially and laterally. The erector spinae muscles are identified superficially to the tip of the T9 transverse process.The location of the needle tip will be confirmed by hydrodissection of the erector spinae muscle from the tip of the transverse process. After negative aspiration, a total of 20 mL bupivacaine 0.25% will be injected under the fascial plane incrementally, aspirating every 5 ml and the block will be repeated on the other side
62698401|NCT03864328|PLACEBO_COMPARATOR|Placebo|
62698402|NCT06459440|EXPERIMENTAL|Group Task Oriented Training|"All session will be give 4 days a week~1.Week 1-2: Warm-up (10 mins) Core strengthening (10 mins) Posture training (10 mins) Balance training (10 mins)~Week 3-4:~Gross motor skills (10 mins) Fine motor skills (10 mins) Gait training (10 mins)~Proprioception training (10 mins) Week 5-6 Activities of daily living (10 mins)"
62497624|NCT03237156|EXPERIMENTAL|TAK-906 50 mg; Cohort 1|TAK-906 50 milligram (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
62497625|NCT03237156|PLACEBO_COMPARATOR|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
62736504|NCT06520696|EXPERIMENTAL|Intervention group: MILC application|Eligible Hispanic participants in their third trimester will be recruited for the study. The intervention group will receive standard WIC services plus the MILC application.
62736505|NCT06520696|EXPERIMENTAL|Control Group: Usual Care|Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program.
62497626|NCT03237156|EXPERIMENTAL|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
62497627|NCT03237156|PLACEBO_COMPARATOR|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
61947395|NCT06429111||low-risk pregnant woman who freely chooses the use of water during childbirt|"Pregnant women at term with normal pregnancy without the presence of maternal and neonatal risk factors who meet criteria according to the protocol for the use of water and who choose immersion water at the time of admission to the dilatation room in active labor.~* Over 17 years of age~* Psychic and cognitive capacity for decision making~* Willingness to take part in the study and signature of the informed consent form.~* Absence of ideomatic barrier"
61947396|NCT01101373||1|All subjects who received BAC for treatment resistant depression between 2000 and 2009
62140334|NCT03733275|EXPERIMENTAL|local anesthetic group|local aensthetic group receive preopetaive lidocaine spray and lidocaine-bupivacine mixture-soaked nasal pacing after nasal reduction surgery
62698403|NCT06459440|ACTIVE_COMPARATOR|Routine Treatment|"1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes) (26)."
62698404|NCT05703763||GCA group|Definite confirmation of GCA will occur 6 months after study inclusion, following the phone follow-up, and will be require all the following features: 1) initial symptoms and clinical evolution consistent with GCA; 2) at least one positive test for cranial GCA (ultrasound of temporal arteries, temporal artery biopsy, cranial MRI, cranial PET); and 3) satisfies the 2022 ACR-EULAR classification criteria for GCA.
61947397|NCT03041857||GMK Sphere|Subjects with a unilateral Medacta GMK Sphere TKA
61947398|NCT03041857||GMK PS|Subjects with a unilateral Medacta GMK Primary PS Fixed Bearing TKA
61947399|NCT03041857||GMK UC|Subjects with a unilateral Medacta GMK Primary UC Fixed Bearing TKA
61947400|NCT02899299|EXPERIMENTAL|Nivolumab and Ipilimumab|Specified dose on specified days
61947401|NCT02899299|ACTIVE_COMPARATOR|Pemetrexed and Cisplatin (or Carboplatin)|Specified dose on specified days
61947402|NCT02351375|EXPERIMENTAL|high protein, low carbohydrate|a high-protein/low-carbohydrate diet (26,7E% protein, 38.2E% carbohydrate)
61947403|NCT02351375|EXPERIMENTAL|low protein, high carbohydrate|a low-protein/high-carbohydrate diet (7E% protein, 59.6E% carbohydrate)
61947404|NCT05642988||Adult patients being discharged from hospital following intra-abdominal or pelvic surgery|Patient compliance with wearable biosensor monitoring after major intracavity surgery. The remote monitoring is made up of a wearable biosensor and a data-enabled relay device which will detect vital sign observations (ECG, heart rate, temperature and respiratory rate) and a health status assessment questionnaire.
61947405|NCT06535165|EXPERIMENTAL|Red Beetroot Juice|daily oral supplementation with 200 mL beetroot juice for 14 days
61947406|NCT06535165|PLACEBO_COMPARATOR|Control|Placebo (a solution containing 7 g of sugar, 180 mL of water, and 20 mL of beetroot juice, to show the same color as the active treatment) for 14 days
61947407|NCT05143541||AEON Endostapler|Stapling performed with AEON Endostapler
61947408|NCT04432259|EXPERIMENTAL|Arm B: Oral Dexamethasone|Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days
61947409|NCT04432259|PLACEBO_COMPARATOR|Arm A: Placebo|Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days
61947410|NCT05361161|EXPERIMENTAL|Transarterial Chemoembolization With Lipiodol for Initial Unresectable Gastric Cancer|
62698405|NCT05703763||Non-GCA group|Participants who do not meet the criteria (above) for GCA at month 6.
61947411|NCT03616275|EXPERIMENTAL|HRV biofeedback group|8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education
61947412|NCT03616275|NO_INTERVENTION|control group|1 session of healthy lifestyle education
61947413|NCT03847714|ACTIVE_COMPARATOR|Probiotic|Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water
61947414|NCT03847714|PLACEBO_COMPARATOR|Placebo|3g of a similar looking and tasting powder, twice daily
61947415|NCT05520112|EXPERIMENTAL|Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC|Experimental: Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC
62140335|NCT03733275|PLACEBO_COMPARATOR|control group|control group receive preoperative normal saline spray and normal saline-soaked nasal packing after nasal reduction surgery
61947416|NCT05520112|ACTIVE_COMPARATOR|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
61947417|NCT01880281|ACTIVE_COMPARATOR|Meat diet without any vegetables or fruits|"The volunteers will follow a diet of 3 days with at least 400g of meat per day. The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 50meq of ammonium chlorid over a period of one hour in order to avoid the effect of nausea."
62140336|NCT06371456|EXPERIMENTAL|epidural anesthesia|
62140337|NCT06698783|EXPERIMENTAL|Intervention group|
62140338|NCT01754051||Treatment by the PC 400 coils|Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use.
62140339|NCT03074032|EXPERIMENTAL|ONC1-0013B 40 mg|ONC1-0013B 40 mg per os daily
62140340|NCT03074032|EXPERIMENTAL|ONC1-0013B 80 mg|ONC1-0013B 80 mg per os daily
62140341|NCT03074032|EXPERIMENTAL|ONC1-0013B 160 mg|ONC1-0013B 160 mg per os daily
62140342|NCT03074032|EXPERIMENTAL|ONC1-0013B 320 mg|ONC1-0013B 320 mg per os daily
62497628|NCT03237156|EXPERIMENTAL|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
62497629|NCT03237156|PLACEBO_COMPARATOR|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
62497630|NCT04099680|ACTIVE_COMPARATOR|Partial-thickness bed preparation|Partial-thickness bed preparation for free gingival graft procedure.
62698406|NCT04558736|EXPERIMENTAL|Haploidentical HCT|"To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability.~Cells for infusion are prepared using the CliniMACS System."
61947418|NCT01880281|ACTIVE_COMPARATOR|Vegetarian diet without any sources of protein|"The volunteers will follow a diet of 3 days with at least 600g of fruits and vegetables per day without any proteins (animal or vegetal like soybean). The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 1g of bicarbonate."
61947419|NCT02436746||Neurofibromatosis type I (NF1)|Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I
61947420|NCT02436746||Tuberous Sclerosis Complex (TSC)|Monozygotic twin pairs with genetically confirmed Tuberous Sclerosis Complex
61947421|NCT00887874||A|
61947422|NCT03998566|EXPERIMENTAL|TraceIT Tissue Spacer|
61947423|NCT06110078|EXPERIMENTAL|Group 1|Daily oral acetazolamide mouth rinse 10 ml
61947424|NCT06110078|EXPERIMENTAL|Group 2|Twice daily oral acetazolamide mouth rinse 10 ml
61947425|NCT06110078|PLACEBO_COMPARATOR|Group 3|Placebo mouth wash daily 10 ml
61947426|NCT06110078|PLACEBO_COMPARATOR|Group 4|Twice daily placebo mouth wash 10 ml
61947427|NCT02800343||Cardiovascular surgery|All adult patients undergoing elective or emergency cardiovascular surgery at the study site
61947428|NCT05049616|EXPERIMENTAL|Hctz/Lisinopril|Hctz/Lisinopril for postpartum management of hypertension. either a combined pill of ACE inhibitors and diuretics (Hydrochlorothiazide/Lisinopril)
61947429|NCT05049616|ACTIVE_COMPARATOR|Extended release nifedipine|calcium channel blocker (Nifedipine
61947430|NCT01252381|ACTIVE_COMPARATOR|Vitamin D|
61947431|NCT01252381|PLACEBO_COMPARATOR|Calcium tablet|
61947432|NCT01172236|EXPERIMENTAL|Lactoferrin|
61947433|NCT00775346||Polysomnography (PSG) Subjects|Subjects who have been prescribed with needing a polysomnography (PSG) will be enrolled into the study.
62140343|NCT04178213|EXPERIMENTAL|ADAPT 3D ALR|Patients treated with ADAPT 3D ALR
62140344|NCT01371994|EXPERIMENTAL|Solifenacin succinate|Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
62340942|NCT02850991|ACTIVE_COMPARATOR|Standard-dose|"concurrent chemoradiotherapy Standard-dose RT:50.4 Gy in 28 fractions, 1.8Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
61947434|NCT00795847|EXPERIMENTAL|1. Preminent|Patients with blood pressure self-measurement-proven morning hypertension are treated with Preminent 1T qd for 3 months.
61947435|NCT00795847|ACTIVE_COMPARATOR|2. High-dose losartan|Patients with blood pressure self-measurement-proven morning hypertension are treated with losartan 100 mg qd for 3 months.
61947436|NCT04859673|ACTIVE_COMPARATOR|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
61947437|NCT04859673|SHAM_COMPARATOR|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy. Stimulation will not deliver as the transmitter head will be removed. The patients will receive the same frequency of air pressure and sound
61947438|NCT02022020||Group 1|
61947439|NCT04477889||COVID-19 Cohort|Patients treated at MHS facilites for COVID-19
61947440|NCT04477889||Synopsis for COVID Bariatric, Hepato-Biliary and Colorectal surgery study|"30 Day Mortality after surgery in patients with COVID19 infection who undergo elective bariatric, hepato-biliary and colorectal surgery.~* Patients diagnosed with COVID-19 at the time of surgery up to seven days before surgery~* Patients diagnosed with COVID-19 within 30 days after surgery"
61947441|NCT00779740|EXPERIMENTAL|New Formulation Group|
61947442|NCT00779740|ACTIVE_COMPARATOR|Old Formulation Group|
61947443|NCT05072782|OTHER|Status quo arm|"If the patient received no prophylactic therapy after resection, no treatments will be started.~If the patient received a prophylactic therapy after resection, the same will be continued at the same dose."
62140345|NCT01371994|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets once a day for 12 weeks.
61947444|NCT05072782|EXPERIMENTAL|Therapy escalation arm|Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.
61947445|NCT04412434|OTHER|patients with acute ischemic stroke|This open-label prospective study will be conducted in the single medical center (RAMBAM Medical Center) and will include at least 200 patients with acute ischemic stroke resulted from MCA or ICA occlusion.
61947446|NCT04920344|ACTIVE_COMPARATOR|GROUP I - Low Risk Recurrence (transoral surgery, clinical observation))|After standard of care transoral surgery, patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation.
61947447|NCT04920344|EXPERIMENTAL|GROUP II - Medium Risk Recurrence (transoral surgery, EBRT 50Gy)|Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) RT 50Gy for 5 weeks in the absence of disease progression or unacceptable toxicity.
61947448|NCT04920344|EXPERIMENTAL|GROUP III - High Risk Recurrence (transoral surgery, EBRT 60Gy, cisplatin 30 mg/m2)|"Patients whose tumor has a positive margin, which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT RT 60 Gy for 6 weeks and receive cisplatin intravenously (IV) weekly 30mg/m2 for 6 weeks in the absence of disease progression or unacceptable toxicity."
62140346|NCT03876457|EXPERIMENTAL|Endovascular Thrombectomy plus Medical Management|
62497631|NCT04099680|EXPERIMENTAL|Full-thickness bed preparation|Full-thickness bed preparation with bone screw placement for anchoring the sutures.
62497632|NCT01677650|ACTIVE_COMPARATOR|Methadone 0.5 mg/kg|Methadone 0.5 mg/kg
62497633|NCT01677650|EXPERIMENTAL|Methadone 0.4 mg/kg|Methadone 0.4 mg/kg
62497634|NCT01677650|ACTIVE_COMPARATOR|Methadone 0.3 mg/kg|Methadone 0.3 mg/kg
62497635|NCT01677650|ACTIVE_COMPARATOR|Methadone 0.2 mg/kg|Methadone 0.2 mg/kg
62497636|NCT01677650|ACTIVE_COMPARATOR|Methadone 0.15 mg/kg|Methadone 0.15 mg/kg
62497637|NCT05894031|EXPERIMENTAL|Intervention|The intervention group was instructed to perform the Wim Hof Method daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
62497638|NCT05894031|NO_INTERVENTION|Control|The control group received noch intervention throughout the intervention period.
62497639|NCT05427994||Patients with age-related macular degeneration|Patients with age-related macular degeneration who fill out the quality of life questionnaire, and answer questions about social support and reliability of social support
62497640|NCT01201668||Persistent Tooth Pain|
61947449|NCT03831789|ACTIVE_COMPARATOR|Unilateral cerebellar rTMS|
61947450|NCT03831789|EXPERIMENTAL|Bilateral cerebellar rTMS|
61947451|NCT02256592|EXPERIMENTAL|Fecal microbiota transplant (FMT)|Donor fecal suspension will be delivered during colonoscopy to HIV+ individuals.
61947452|NCT02470832|EXPERIMENTAL|Combination therapy RG1662 + itraconazole|Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food
61947453|NCT02470832|EXPERIMENTAL|RG1662 Monotherapy|Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)
61947454|NCT02470832|EXPERIMENTAL|itraconazole Monotherapy|Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)
61947455|NCT05106387||REGN5459 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5459 in study R5459-RT-1944.
61947456|NCT05106387||REGN5458 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5458 in study R5459-RT-1944.
62140347|NCT03876457|ACTIVE_COMPARATOR|Medical Management|
62340943|NCT00442013|EXPERIMENTAL|Lansoprazole|Participants in this group will receive lansoprazole on a daily basis for 6 months. There are two doses of Lansoprazole solutab provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
62340944|NCT00442013|PLACEBO_COMPARATOR|Matching placebo|Participants in this group will receive a matching placebo on a daily basis for 6 months. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
62340945|NCT04371952|EXPERIMENTAL|Doxycycline 100mg|Doxycycline capsule containing 2 tablets doxycycline 100mg over-encapsulated. Doxycycline is given at 200 mg once a day and administered per os during 2 weeks
62340946|NCT04371952|PLACEBO_COMPARATOR|Doxycycline placebo|Doxycycline Placebo capsule 200 mg, containing 1 capsule of a marketed placebo = RODAEL placebo ( lactose, 380 mg / capsule). Doxycycline placebo is given once a day and administered per os during 2 weeks
62340947|NCT04479917|EXPERIMENTAL|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg 2 tablets
62340948|NCT04479917|EXPERIMENTAL|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet+ Placebo 10mg tablet
62340949|NCT04479917|EXPERIMENTAL|TPN171H 20mg group|TPN171H 10mg 2 tablets + Placebo 5mg tablet
62340950|NCT04479917|PLACEBO_COMPARATOR|Placebo group|Placebo 5mg tablet+ Placebo 10mg 2 tablets
62340951|NCT05611359|EXPERIMENTAL|Thermal Ablation|In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, thermal ablation and chemotherapy are administered.
62340952|NCT05611359|ACTIVE_COMPARATOR|Chemotherapy|In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, chemotherapy is administered.
62497641|NCT04442854|EXPERIMENTAL|cognitive behavioral group therapy|A cognitive behavioral group prevention program An 8-session, cognitive behavioral group prevention program, featuring cultural appropriateness. One session per week, 3 hours for each session. The program contents include psychoeducation, cognitive skills training to identify and challenge maladaptive cognitions, and behavioral skills training. Each session contains mood check and homework. Participants' own examples are used in the group to demonstrate the CBT skills.
62497642|NCT04442854|NO_INTERVENTION|Wait-list control group|No immediate intervention No intervention was provided when the experimental group was receiving services, but the same cognitive behavioral group prevention program was delivered to the wait-list control group after that.
62497643|NCT05692154|EXPERIMENTAL|Arm A (active-active)|Two days of pre-treatment with Fexofenadine 180 mg each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.
62497644|NCT05692154|EXPERIMENTAL|Arm B (placebo-active)|Two days of pre-treatment with tablet of matching placebo each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.
62497645|NCT06476782|EXPERIMENTAL|Combined MRP and aerobic exercise|Group A received MRP treatment and aerobic exercise along with conventional therapy
62497646|NCT06476782|EXPERIMENTAL|MRP group|Group B received MRP treatment along with conventional therapy
62497647|NCT06679556|EXPERIMENTAL|Strength A Sublingual Minoxidil|
62497648|NCT06679556|EXPERIMENTAL|Strength B Sublingual Minoxidil|
62497649|NCT04712734|EXPERIMENTAL|Iloperidone|
61947457|NCT04810871|EXPERIMENTAL|Treatment (surgery)|Patients undergo surgery as indicated clinically when applicable.
62140348|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
62140349|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
61947458|NCT06232694|EXPERIMENTAL|Induction therapy and consolidation therapy after remission|Induction therapy:Venetoclax + idarubicin + cytarabine Consolidation therapy after remission:Venetoclax + cytarabineIf The patient meets the criteria for autologous hematopoietic stem cell transplantation (ASCT) during the treatment process, they can undergo ASCT.If the patient meets the criteria for transplantation and there is a suitable donor, they can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
61947459|NCT04298515|OTHER|Type 2 Diabetes group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
61947460|NCT04298515|OTHER|Insulin resistance group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
61947461|NCT04298515|OTHER|Obesity group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
61947462|NCT01951937|ACTIVE_COMPARATOR|Fish Meals|3 Fish meals per week for 4 months
61947463|NCT01951937|PLACEBO_COMPARATOR|Placebo|Habitual diet
61947464|NCT02848170|EXPERIMENTAL|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 12 weeks
61947465|NCT02848170|ACTIVE_COMPARATOR|olmesartan medoxomil|olmesartan medoxomil 10 to 20 mg, orally, once daily after breakfast for 12 weeks
61947466|NCT01393223|ACTIVE_COMPARATOR|LP-08 80mg|4 weekly intravesical administration of LP-08 80mg
61947467|NCT01393223|ACTIVE_COMPARATOR|LP-08 20mg|4 weekly intravesical administration of LP-08 20mg
61947468|NCT01393223|PLACEBO_COMPARATOR|Normal Saline|Four weekly normal saline intravesical administration
61947469|NCT01409434|OTHER|Follow-Up Arm|All patients are recruited for inclusion in the Follow-Up Arm, which is the sole arm of the study. The Follow-Up Arm includes a one time study visit in which study interventions are performed. The Follow-Up Arm involves patients from the parent study who were enrolled in the follow-up study. The intervention in the Follow-Up Arm is the Oral Glucose Tolerance Test.
62140350|NCT03220334|EXPERIMENTAL|Apply platelet rich plasma to the artificial gastric ulcer|
62140351|NCT03220334|PLACEBO_COMPARATOR|Apply normal saline to the artificial gastric ulcer|
62497650|NCT03496298|PLACEBO_COMPARATOR|Placebo|Participants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.
62497651|NCT03496298|EXPERIMENTAL|Efpeglenatide 4 mg|Participants received Efpeglenatide as SC injection 2 milligrams (mg) per week for 4 weeks then 4 mg per week up to end of treatment.
62497652|NCT03496298|EXPERIMENTAL|Efpeglenatide 6 mg|Participants received Efpeglenatide as SC injection 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 6 mg per week up to end of treatment.
62497653|NCT02361736|SHAM_COMPARATOR|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
62698407|NCT03815344|ACTIVE_COMPARATOR|Standard|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy.
61947470|NCT06556303|EXPERIMENTAL|Comparison of Some Characteristics of the Students with Sleep Quality Mean Score|The students in the intervention group were subjected to acupressure on the right and left sides of Shenmen (HT7) acupuncture point of the heart meridian, Sanyinjiao (SP6) acupuncture point of the spleen meridian, Neiguan (PC6) acupuncture point of the pericardium point, and Tian-Zhu (BL10) acupuncture point of the neck. The researcher having the certificate practised acupressure on each point for two minutes each, totalling 16 minutes, three days a week for four weeks.
61947471|NCT06556303|EXPERIMENTAL|Students and Their Sleep Quality Mean Score Before Acupressure Application|The students in the intervention group were subjected to acupressure on the right and left sides of Shenmen (HT7) acupuncture point of the heart meridian, Sanyinjiao (SP6) acupuncture point of the spleen meridian, Neiguan (PC6) acupuncture point of the pericardium point, and Tian-Zhu (BL10) acupuncture point of the neck. The researcher having the certificate practised acupressure on each point for two minutes each, totalling 16 minutes, three days a week for four weeks.
62140352|NCT00023920|EXPERIMENTAL|Treatment (bevacizumab, idarubicin, cytarabine)|Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62140353|NCT04661306|EXPERIMENTAL|SHUTi|
62140354|NCT01310140||Major Depressive Disorder|
62140355|NCT01310140||Major Depressive Disorder with Psychotic Features|
62140356|NCT01410409|ACTIVE_COMPARATOR|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
62140357|NCT01410409|ACTIVE_COMPARATOR|MEDIC + TKR|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
62140358|NCT01410409|ACTIVE_COMPARATOR|Observational Cohort|If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.
62140359|NCT01982994|EXPERIMENTAL|Education/Daily Planning|Physical Activity Education and Daily Planning Tool
62140360|NCT01982994|NO_INTERVENTION|No Education/Daily Planning|No Physical Activity Education/ Daily Planning Tool
62340953|NCT05372341||post-covid elective surgery patients|data of postcovid patients underwent elective surgery will be collected.
61947472|NCT06556303|EXPERIMENTAL|Comparison of Sleep Quality Total Scores and Subscale Mean Scores of Intervention and Control Groups|The students in the intervention group were subjected to acupressure on the right and left sides of Shenmen (HT7) acupuncture point of the heart meridian, Sanyinjiao (SP6) acupuncture point of the spleen meridian, Neiguan (PC6) acupuncture point of the pericardium point, and Tian-Zhu (BL10) acupuncture point of the neck. The researcher having the certificate practised acupressure on each point for two minutes each, totalling 16 minutes, three days a week for four weeks.
61947473|NCT01426438|EXPERIMENTAL|Arm A: Extended-release niacin with aspirin|
61947474|NCT01426438|EXPERIMENTAL|Arm B: Fenofibrate|
61947475|NCT02421471||Ingenol mebutate treatment cohort|Patients who are prescribed ingenol mebutate gel for the first time by investigator's medical judgment.
61947476|NCT04727073|EXPERIMENTAL|Arm A|Experimental: Spironolactone Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.
61947477|NCT04727073|PLACEBO_COMPARATOR|Arm B|Placebo Comparator: Placebo Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
61947478|NCT02646943||Cohort of patients with chronic chagas cardiomyopathy|"We have established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC) to evaluate if a clinical prediction rule based on electrocardiogram (ECG), Brain Natriuretic Peptide (BNP) levels and other biomarkers can be useful in clinical practice.~The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years. The baseline evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG."
61947479|NCT05602870|EXPERIMENTAL|Psychiatric patient|All patients having psychiatric disorders and hospitalised in a Psychiatry Unit of CHU Montpellier will have an non invasive evaluation of liver fibrosis after giving their consent
61947480|NCT03031132|EXPERIMENTAL|HP-Beverage Breakfast|For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
61947481|NCT03031132|EXPERIMENTAL|HP-Solid Breakfast|For 7 days, the participants will consume high protein solid breakfast meals each morning. These meals will consist of traditional solid breakfast meals and will include commonly consumed breakfast foods (e.g., burritos, waffles, etc.) and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35 g CHO, and 10 g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
61947482|NCT03031132|EXPERIMENTAL|Breakfast Skipping|For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until \~5h post habitual breakfast time on testing day 7.
61947483|NCT01961362||Pulmonary fibrosis patients|Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
61947484|NCT03617185|ACTIVE_COMPARATOR|Bariatric Surgery/HIIT|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
61947485|NCT03617185|ACTIVE_COMPARATOR|Bariatric Surgery/Routine Exercise|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
61947486|NCT03617185|ACTIVE_COMPARATOR|No Bariatric Surgery/HIIT|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
61947487|NCT03617185|ACTIVE_COMPARATOR|No Bariatric Surgery/Routine Exercise|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
61947488|NCT03120234|EXPERIMENTAL|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
62340954|NCT03531333|EXPERIMENTAL|Ultrasound|ultrasound navigation guided surgery.
62698408|NCT03815344|EXPERIMENTAL|Standard-Vaginal Misoprostol|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
62698409|NCT04063202||Non-cases|Secondary school students (seventh to tenth years of education) without probable depression at baseline interview.
62698410|NCT04998942|EXPERIMENTAL|Experimental|
62698411|NCT04998942|PLACEBO_COMPARATOR|Placebo comparator|
61947489|NCT03120234|EXPERIMENTAL|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
61947490|NCT05004077|ACTIVE_COMPARATOR|Conventional amiodarone dosing regimen (CDR)|Initial amiodarone bolus of 150 mg IV over 10 minutes then a 24-hour amiodarone loading infusion (1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours), followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.
62140361|NCT06593457|EXPERIMENTAL|Part 1: Sequence 1 (Treatment A, B, C)|Period 1: NX-5948 or placebo administered under fasted conditions Period 2: NX-5948 or placebo administered under fed conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4
62140362|NCT06593457|EXPERIMENTAL|Part 1: Sequence 2 (Treatment B, A, C)|Period 1: NX-5948 or placebo administered under fed conditions Period 2: NX-5948 or placebo administered under fasted conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4
62340955|NCT03531333|NO_INTERVENTION|Non-ultrasound|standard surgery without ultrasound guidance.
62698412|NCT04164719|EXPERIMENTAL|Treatment A|TNX-102 SL 2.8 mg, under fasting conditions
62698413|NCT04164719|EXPERIMENTAL|Treatment B|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fasting conditions
62698414|NCT04164719|EXPERIMENTAL|Treatment C|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fed conditions
62698415|NCT04641351|EXPERIMENTAL|corticosteroid|"Triamcinolone extended release (32 mg) administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.~* Knee injury and Osteoarthritis Outcome Score (KOOS) pain at 6 and 12 months~* T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months~* Morphologic grading of cartilage using the MOAKS score at 3 and 12 months~* 3D bone shape from MRI Osteoarthritis Knee Score (MOAKS) using statistical shape modeling at 3 and 12 months~* Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
62497654|NCT02361736|EXPERIMENTAL|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
62497655|NCT05608252|EXPERIMENTAL|Phase 1 Dose Escalation|"During 28 day/4 week study cycle, participants will receive:~* VS-6766 2x weekly for 3 out of the 4 week cycle~* Abemaciclib 2x daily~* Fulvestrant on day 1 of each study cycle (and day 15 of cycle 1 only)"
62497656|NCT05608252|EXPERIMENTAL|Phase 2 Dose Expansion|Participants will receive VS-6766 with abemaciclib and fulvestrant at the recommended phase II doses determined in the phase I portion of the study.
62497657|NCT04912206|EXPERIMENTAL|Intervention|Point-of-Care Ultrasound on top of diagnosis work-up
61947491|NCT05004077|ACTIVE_COMPARATOR|Repeated amiodarone bolus dosing regimen (RBDR)|Initial amiodarone bolus of 150 mg IV over 10 minutes, then 1.0 mg/min IV amiodarone infusion for 6 hours, then a 0.5 mg/min IV amiodarone infusion for 18 hours, followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. In addition, patients in the RBDR will receive an additional 150 mg IV amiodarone bolus whenever the patient develops tachycardia (Heart Rate (HR) = 110 beats per minute) lasting more than 10 minutes. This bolus may be repeated up to a total of 5 times (6 total boluses) over the first 24 hours. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.
61947492|NCT03133130|EXPERIMENTAL|BMT101|cp-lasiRNA
61947493|NCT03133130|PLACEBO_COMPARATOR|Placebo|Normal Saline
61947494|NCT00306189|ACTIVE_COMPARATOR|100 mg AMG 162|
61947495|NCT00306189|ACTIVE_COMPARATOR|60 mg AMG 162|
61947496|NCT00306189|PLACEBO_COMPARATOR|Placebo|
61947497|NCT00306189|ACTIVE_COMPARATOR|14 mg AMG 162|
61947498|NCT00581243|EXPERIMENTAL|1|2 mg SLV-313 SR (fixed dose)
61947499|NCT00581243|EXPERIMENTAL|2|5 mg SLV-313 SR (fixed dose)
61947500|NCT00581243|EXPERIMENTAL|3|10 mg SLV-313 SR (fixed dose)
61947501|NCT00581243|EXPERIMENTAL|4|xx mg SLV-313 SR (titration)
61947502|NCT05981339|SHAM_COMPARATOR|Control Group|In the control group, diaphragmatic breathing exercises will be performed together with the physiotherapist. Osteopathic manual therapy techniques will be applied as sham. The physiotherapist will not touch the appropriate anatomical points while performing the loosening.
62497658|NCT04912206|NO_INTERVENTION|Control|Usual diagnosis work-up without Point-of-Care Ultrasound
61947503|NCT05981339|EXPERIMENTAL|Study Group|In addition to breathing exercises, sacral release and bladder mobilization, which are osteopathic manual therapy techniques, will be applied to the patients in the study group.
61947504|NCT02047383||respiratory infection|Hospitalized patients with a respiratory infection
61947505|NCT04214171||group 2 years|The group underwent total hip arthroplasty at 2 years
62340956|NCT02893527|EXPERIMENTAL|"Group intervention"|Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
62497659|NCT05917262|EXPERIMENTAL|Mindfulness-based breathing|20-minute mindfulness-based breathing training
62497660|NCT05917262|EXPERIMENTAL|HRV biofeedback|20-minute HRV biofeedback
62497661|NCT05917262|ACTIVE_COMPARATOR|cognitive-behavioral pain psychoeducation|20-minute psychoeducation session
62497662|NCT05587023|EXPERIMENTAL|Test group|the test group was injected with 0.5% ropivacaine 6ml.
61947506|NCT04214171||group 5 years|The group underwent total hip arthroplasty at 5 years
61947507|NCT04214171||group 10 years|The group underwent total hip arthroplasty at 10 years
61947508|NCT04214171||group control|healthy patients
62340957|NCT02893527|NO_INTERVENTION|"Group standard"|conventional support
62340958|NCT00254293|PLACEBO_COMPARATOR|Group 1 (weight < 60 kg)|
61947509|NCT01574456||7 patients diagnosed with dementia of the Alzheimer's type|
61947510|NCT01574456||13 patients with mild cognitive impairment|
61947511|NCT01574456||19 healthy controls|
61947512|NCT05719376|EXPERIMENTAL|Experimental|
61947513|NCT05719376|OTHER|control|Follow the criteria for investigational product
61947514|NCT06098092|EXPERIMENTAL|Long-term Blood pressure and Heart rate monitoring with reference digital tonometer and smartwatch|Measurement of a non-invasive Blood pressure and Heart rate using a reference medical grade digital tonometer Omron and a smartwatch Samsung Galaxy Watch during 20-40 days every morning and evening.
61947515|NCT02633813|EXPERIMENTAL|Naftifine hydrochloride 2%|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
61947516|NCT02633813|ACTIVE_COMPARATOR|Naftin® 2% (Naftifine hydrochloride 2%)|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
61947517|NCT02633813|PLACEBO_COMPARATOR|Placebo vehicle cream.|A thin layer of sufficient quantity of vehicle cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
62340959|NCT00254293|PLACEBO_COMPARATOR|Group 2 (weight < 60 kg)|
62340960|NCT00254293|PLACEBO_COMPARATOR|Group 3 (weight 60-100 kg)|
62340961|NCT00254293|PLACEBO_COMPARATOR|Group 4 (weight > 100 kg)|
62340962|NCT00254293|PLACEBO_COMPARATOR|Group 5 (weight > 100 kg)|
62340963|NCT00254293|EXPERIMENTAL|Abatacept|Long Term
62340964|NCT00519493|ACTIVE_COMPARATOR|Suture|A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
62340965|NCT00519493|ACTIVE_COMPARATOR|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
62497663|NCT05587023|PLACEBO_COMPARATOR|Control group|The control group was injected with 6ml normal saline
62497664|NCT00701194|EXPERIMENTAL|1|EIFC/MTFC-P
62497665|NCT00701194|NO_INTERVENTION|2|Services as usual
62497666|NCT00701194|NO_INTERVENTION|Community Comparison|Non-maltreated community pre-schoolers from low-income biological families.
62497667|NCT05094596|EXPERIMENTAL|Standart treatment group|Standard treatment in accordance with our national COVID-19 diagnosis and treatment guide
62497668|NCT05094596|EXPERIMENTAL|Montelukast sodium 10 mg treatment|Received 10 mg/day oral montelukast in addition to standard treatment
62497669|NCT05094596|EXPERIMENTAL|Montelukast sodium 20 mg treatment|Received 10 mg/day oral montelukast in addition to standard treatment
62497670|NCT06679387|EXPERIMENTAL|Treatment arm|Forty patients who will receive memantine 20 mg once daily in addition to weekly 80 mg/m2 of paclitaxel for 12 weeks.
62497671|NCT06679387|PLACEBO_COMPARATOR|Control arm|Forty patients who will receive placebo once daily in addition to weekly 80 mg/m2 of paclitaxel for 12 weeks.
62497672|NCT02881359||LifeSeal® Kit|creation of a coloanal or colorectal anastomosis
62497673|NCT03184649|EXPERIMENTAL|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
62497674|NCT03184649|EXPERIMENTAL|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
62497675|NCT03184649|PLACEBO_COMPARATOR|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
61947518|NCT02995031|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62140363|NCT06593457|EXPERIMENTAL|Part 2: NX-5948 PK|Experimental: Part 2: NX-5948 PK NX-5948 or placebo administered 2 doses given 12 hours apart under fasted conditions
62140364|NCT06038942|EXPERIMENTAL|Formal mindfulness instruction|
62340966|NCT02474524|EXPERIMENTAL|Health intervention|+ treatment as usual
62340967|NCT02474524|ACTIVE_COMPARATOR|Social intervention|+ treatment as usual
62340968|NCT02765633|EXPERIMENTAL|Cangrelor|Cangrelor in up to four (4) dose cohorts consisting of a minimum of five participants in each cohort. One cohort of five participants will be enrolled at a time. Cohort 1 subjects will receive Cangrelor at 0.5 mcg/kg/min. Cohort 2 subjects will receive Cangrelor at 0.25 mcg/kg/min. Subsequent cohort dosing decisions are made at the completion of enrollment in each cohort.
62340969|NCT04777721|EXPERIMENTAL|Group 1: 1 x 10^4 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10\^4 cfu aerosol inhaled BCG. All Group 1 volunteers will have a bronchoscopy 14 days post challenge.
62340970|NCT04777721|EXPERIMENTAL|Group 2: 1 x 10^5 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10\^5 cfu aerosol inhaled BCG. All Group 2 volunteers will have a bronchoscopy 14 days post challenge.
62340971|NCT04777721|EXPERIMENTAL|Group 3: 1 x 10^6 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10\^6 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
62497676|NCT06581081|EXPERIMENTAL|Bridging to allo-HSCT|Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment. If the subject achieves bone marrow leukemia-free state (MLFS) and minimal residual disease (MRD) negative within 12 weeks after S1904 infusion, they will be randomly assigned to the bridging transplant group and the non-bridging transplant group at a ratio of 2:1.
62497677|NCT06581081|OTHER|No bridging to allo-HSCT|Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment. If the subject achieves bone marrow leukemia-free state (MLFS) and minimal residual disease (MRD) negative within 12 weeks after S1904 infusion, they will be randomly assigned to the bridging transplant group and the non-bridging transplant group at a ratio of 2:1.
62497678|NCT02217709|EXPERIMENTAL|Treatment (phenelzine sulfate)|Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade \< or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.
62698416|NCT04641351|PLACEBO_COMPARATOR|Placebo|"Normal saline of 5 mL administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.~* KOOS pain at 6 and 12 months~* T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months~* Morphologic grading of cartilage using the MOAKS score at 3 and 12 months~* 3D bone shape from MRI using statistical shape modeling at 3 and 12 months~* Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
62140365|NCT06038942|EXPERIMENTAL|Informal mindfulness instruction|
62140366|NCT06038942|NO_INTERVENTION|Inactive control|An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). Participants assigned to the inactive control condition will not complete any tasks during the four-week intervention period.
62340972|NCT04777721|EXPERIMENTAL|Group 4: 1 x 10^7 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
62340973|NCT06220630||Chinese|About 1,200 Chinese male breast cancer cases are anticipated to collected retrospectively. The clinicopathological characteristics, treatment and survival information are retrospectively collected.
62340974|NCT03810417|ACTIVE_COMPARATOR|Digifab|Digifab intravenous
62340975|NCT03810417|PLACEBO_COMPARATOR|Placebo|saline intravenous
62340976|NCT00846261|EXPERIMENTAL|Ilzarov|
62340977|NCT01530438|OTHER|ALS patients without cognitive disorders|Amyotrophic lateral sclerosis without cognitive disorders
62497679|NCT01098539|ACTIVE_COMPARATOR|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
62698417|NCT03870633||Observational (medical chart, interview)|Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
62698418|NCT05206370|PLACEBO_COMPARATOR|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
62140367|NCT04794972|EXPERIMENTAL|Study treatment|After the completion of the first cycle of treatment, if the patient has no intolerable toxic side effects during the first cycle of treatment, the investigator can communicate with the patient whether to continue the treatment during the 2-8 cycle.
62497680|NCT01098539|ACTIVE_COMPARATOR|sitagliptin|albiglutide matching placebo + sitagliptin
62497681|NCT06222606|NO_INTERVENTION|Control group|Patients randomized to the experimental group will have surgery performed in the exact same manner as in the control group.
61947519|NCT05661123|EXPERIMENTAL|will receive kinesio tape in addition to complete decongestive therapy for 6 successive weeks.|will receive Complete decongestive therapy in combination with kinesio tape
61947520|NCT05661123|OTHER|will receive complete decongestive therapy for 6 successive weeks.|"Complete Decongestive Therapy(traditional physical therapy) that includes:~1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises."
61947521|NCT04571320|EXPERIMENTAL|Summer STRIPES|Up to two weeks of daily high school orientation (four hours per day) immediately prior to the start of ninth grade, staffed by peer interventionists (2:1 ratio + extra interventionist in case of absences) and a school staff member. Two sessions of summer parent training. During the school year, ninth grade students will continue to meet weekly with their peer interventionists in a group setting under the supervision of the school staff sponsor. School year follow-up component of summer STRIPES will occur for 16 weeks and will include weekly 30 minute meetings between peer and target students. Parent components during the school year will include optional monthly group problem solving sessions with the school staff sponsor and school mental health liaison and a weekly phone call (up to five minutes) from the school staff sponsor to discuss home contingency management.
62340978|NCT01530438|OTHER|ALS patients with cognitive disorders|Amyotrophic lateral sclerosis with cognitive disorders
62340979|NCT01530438|OTHER|ALS patients + frontal-temporal dementia|Amyotrophic lateral sclerosis plus frontal-temporal dementia
62340980|NCT03984331|EXPERIMENTAL|Fish skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.
62340981|NCT03984331|ACTIVE_COMPARATOR|Cadaver skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.
62340982|NCT05316090|EXPERIMENTAL|study group|Children in study group treated using core stability exercises program in addition to traditional program
62340983|NCT05316090|ACTIVE_COMPARATOR|control group|Children in the control group treated using traditional physical therapy program.
62340984|NCT02472119|EXPERIMENTAL|rusks made with treated flour|Gluten-free diet adding rusks (100g / day) produced with commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester.
62340985|NCT02472119|ACTIVE_COMPARATOR|rusks made with not-treated flour|Gluten-free diet adding rusks (100g / day) produced with untreated wheat flour.
62340986|NCT05869552|EXPERIMENTAL|Suicidal Teens Accessing Treatment - Primary Care (STAT-PC)|This group will participate in a brief, suicide prevention intervention based on motivational interviewing that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management that has been adapted.
62340987|NCT05869552|EXPERIMENTAL|Youth-Nominated Support Team (YST-III)|This group will participate in a brief, suicide prevention intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation that has been adapted.
62340988|NCT03904641|EXPERIMENTAL|aPDT + ART group|In this group, both aPDT and ART will be performed.
62340989|NCT03904641|EXPERIMENTAL|ART group|In this group, only ART will be performed.
62340990|NCT01617187|EXPERIMENTAL|Asenapine 2.5 mg BID|
62340991|NCT01617187|EXPERIMENTAL|Asenapine 5 mg BID|
62340992|NCT01617187|ACTIVE_COMPARATOR|Olanzapine 15 mg QD|
62340993|NCT01617187|PLACEBO_COMPARATOR|Placebo BID|
62340994|NCT01095575|ACTIVE_COMPARATOR|group 1|NS preoperatively and MO postoperatively
62340995|NCT01095575|ACTIVE_COMPARATOR|group 2|MO preoperatively and NS postoperatively
62340996|NCT05515822|ACTIVE_COMPARATOR|Dezocine group|Dezocine (1ml: 5mg) was administered 30 minutes before the end of surgery (0.15mg/kg i.v.) and during patient controlled intravenous analgesia (Dezocine 30mg+ Tropisetron 10mg+Saline, total 200ml)
62340997|NCT05515822|EXPERIMENTAL|Oxycodone group|Oxycodone (1ml: 10mg) was administered 30 minutes before the end of surgery (0.15mg/kg i.v.) and during patient controlled intravenous analgesia (Oxycodone 30mg+ Tropisetron 10mg+Saline, total 200ml)
62340998|NCT05515822|EXPERIMENTAL|Esketamine+Oxycodone group|Esketamine (2ml: 50mg) was administered 5 minutes before incision (0.15mg/kg i.v.), while Oxycodone was administered 30 minutes before the end of surgery (0.15mg/kg i.v.) and during patient controlled intravenous analgesia (Oxycodone 30mg+ Tropisetron 10mg+Saline, total 200ml)
62340999|NCT01498081|EXPERIMENTAL|Single dose of AZD2115 25 µg|
62341000|NCT01498081|EXPERIMENTAL|Single dose of AZD2115 80 µg|
62341001|NCT01498081|EXPERIMENTAL|Single dose of AZD2115 240 µg|
62341002|NCT01498081|PLACEBO_COMPARATOR|Single doses of placebo|
62341003|NCT01498081|ACTIVE_COMPARATOR|Single dose of indacaterol 150 µg|
62698419|NCT05206370|EXPERIMENTAL|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
62698420|NCT05206370|EXPERIMENTAL|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
62698421|NCT03484104||Hypothermic circulatory arrest|Patients undergoing cardiac surgery with hypothermic circulatory arrest and selective antegrade cerebral perfusion
62341004|NCT01498081|ACTIVE_COMPARATOR|Single dose of indacaterol 150 µg + tiotropium 18 µg|
62341005|NCT00912899|EXPERIMENTAL|One|Noscapine HCl
62341006|NCT04119427|EXPERIMENTAL|Test Group|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
62341007|NCT04119427|PLACEBO_COMPARATOR|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
62341008|NCT04762407|EXPERIMENTAL|Sequence 1|Period 1 : Fasted state + HGP1910 + HGP1909, Period 2 : Fasted state + HCP1903
62698422|NCT00633958|EXPERIMENTAL|18F-FLT|All subjects will receive 18F-FLT prior to PET imaging.
62140368|NCT02628106|EXPERIMENTAL|Lipo-prostaglandin E1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days.
62140369|NCT03711084|PLACEBO_COMPARATOR|Water|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
62140370|NCT03711084|EXPERIMENTAL|Natural high potency sweetener from leaf extract|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
62497682|NCT06222606|EXPERIMENTAL|Surgery with EleVision IR camera system|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PGs during surgery. The surgeon will use AF at minimum two timepoints on each side of the neck: First, when the thyroid lobe is exposed and mobilized, and secondly after removal of the thyroid lobe. This is repeated in the contralateral side of the neck in case of TT. If a central neck dissection is performed, the specimen is also examined with AF following removal. Autotransplantation of inadvertently removed PGs may be performed after frozen section histology.
62497683|NCT05006833|EXPERIMENTAL|Bundled clinician training and bundled text messages|Clinicians will receive bundled approach training and parents will receive bundled text messages.
62497684|NCT05006833|EXPERIMENTAL|Bundled clinician training and benefits text messages|Clinicians will receive bundled approach training and parents will receive benefits text messages.
62497685|NCT05006833|EXPERIMENTAL|Bundled clinician training and no text messages|Clinicians will receive bundled approach training and parents will not receive any intervention text messages.
62497686|NCT05006833|EXPERIMENTAL|Benefits clinician training and bundled text messages|Clinicians will receive benefits approach training and parents will receive bundled text messages.
62497687|NCT05006833|EXPERIMENTAL|Benefits clinician training and benefits text messages|Clinicians will receive benefits approach training and parents will receive benefits text messages.
62497688|NCT05006833|EXPERIMENTAL|Benefits clinician training and no text messages|Clinicians will receive benefits approach training and parents will not receive any intervention text messages.
62497689|NCT05006833|EXPERIMENTAL|Deferred-clinician training and bundled text messages|Clinicians will receive training after the study and parents will receive bundled text messages.
62497690|NCT05006833|EXPERIMENTAL|Deferred-clinician training and benefits text messages|Clinicians will receive training after the study and parents will receive benefits text messages.
61947522|NCT04571320|ACTIVE_COMPARATOR|Enhanced School Services as Usual|Students who are assigned to the SSU plus group will be referred to their identified school counselor for referral to services available in the school setting. The counselor will be provided with a report from the student's intake assessment that summarizes the student's symptoms and presenting problems. The student will also receive new school supplies at the beginning of ninth grade. In our past trials, SSU plus students typically received subject-specific tutoring or after-school homework help. We will systematically track services received by students in the SSU plus condition.
61947523|NCT02587884|ACTIVE_COMPARATOR|Group TACE|Patients will treated with TACE after resection.
61947524|NCT02587884|NO_INTERVENTION|Group Control|Patients will treated without TACE after resection.
61947525|NCT01157923|EXPERIMENTAL|intervantion group|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor.
62140371|NCT03711084|EXPERIMENTAL|Glucose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
62140372|NCT03711084|EXPERIMENTAL|Sucrose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
62140373|NCT03711084|EXPERIMENTAL|Maltodextrin|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
62497691|NCT05006833|NO_INTERVENTION|Deferred-clinician training and no text messages|Clinicians will receive training after the study and parents will not receive intervention text messages.
62497692|NCT01085890|EXPERIMENTAL|Motivational interviewing group|The participants in this arm had 2 group seminars with information on hypertension and related lifestyle factors. They participated in 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
62497693|NCT01085890|NO_INTERVENTION|Treatment as usual|Participants in this group received treatment as usual for their high blood pressure, but no informational seminars and no extra visits with motivational interviewing and blood pressure measurement.
62497694|NCT03389763|EXPERIMENTAL|SPI-guided remifentanyl|remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI\>15, infusion speed of remifentanyl will be increased by 50%
62497695|NCT03389763|EXPERIMENTAL|PRD-guided remifentanyl|solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, PRD measurement every 15 minutes; when PRD\>5% infusion speed of remifentanyl will be increased by 50%
62698423|NCT04617860|EXPERIMENTAL|WVE-120102 (Dose A)|
61947526|NCT01157923|NO_INTERVENTION|control group|Regular treatment, No change will be made in the insulin pump setting during the study(unless there is a medical need or any safety concern).
62140374|NCT00822120|EXPERIMENTAL|HIV Positive, PET Positive: BEACOPP standard|Etoposide 100 mg/m2 IV Days 1, 2, 3 Dox 25 mg/m2 IV Day 1 Cyclo 650mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 Q 21 Days x 6 cycles
62140375|NCT00822120|EXPERIMENTAL|HIV Negative, PET Positive: BEACOPP escalated|Etoposide 200 mg/m2 IV Days 1, 2, 3 Dox 35 mg/m2 IV Day 1 Cyclo 1,250 mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles
62140376|NCT00822120|ACTIVE_COMPARATOR|HIV Positive, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
62140377|NCT00822120|ACTIVE_COMPARATOR|HIV Negative, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
62140378|NCT04088630|EXPERIMENTAL|Fingolimod Group|In addition to Standard of care treatment, those participants randomized to the fingolimod group will receive a single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset.
62698424|NCT04980157||All Participants|Patients born between 1945-1965 who have clinic visits at a partnering federally qualified health center.
62698425|NCT02568319|EXPERIMENTAL|LIPO-202|Experimental arm
62698426|NCT02568319|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62698427|NCT06037811|ACTIVE_COMPARATOR|Standard of care group|Prednisone 10 mg daily for 2 weeks, then taper by 2.5 mg every 2 weeks until stopped.
62698428|NCT06037811|ACTIVE_COMPARATOR|Adalimumab group|"Adalimumab 40 mg subcutaneous every 2 weeks for 6 doses (12 weeks)~+ Prednisone 10 mg daily for 2 weeks, tapering by 2.5 mg every 2 weeks until stopped."
61947527|NCT05251246|NO_INTERVENTION|Without recovery management program|
61947528|NCT05251246|EXPERIMENTAL|Trained in the recovery management program|Half of the included volunteered participants are randomized in the intervention group
61947529|NCT03354078|ACTIVE_COMPARATOR|interrupted sutures group|This group in which closure of the subcutaneous layer is closed by interrupted sutures
61947530|NCT03354078|ACTIVE_COMPARATOR|Continous sutures group|subcutanous tissue layer is closed by continous sutures in this group
61947531|NCT05992181|NO_INTERVENTION|control group|With the speech therapy already in place in the department.
61947532|NCT05992181|EXPERIMENTAL|experimental group|With the speech therapy already in place in the department, plus access to videos and the introduction of early orofacial stimulation.
62497696|NCT03389763|EXPERIMENTAL|BBS-guided remifentanyl|BBS assessment every 5 minutes, solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute; when BBS\>2, infusion speed of remifentanyl will be increased by 50%
62497697|NCT04478526|EXPERIMENTAL|e-CBT|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session were designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
62497698|NCT04478526|EXPERIMENTAL|Pharmacotherapy|Biweekly meeting with psychiatrist with GAD-7, DASS-42 and Q-LES-SF. Pharmacotherapy class decided according to protocol developed in accordance with Canada's best practice guidelines for GAD treatment. At second appointment, medication will be maintained and optimized, regardless of response. At third appointment, optimized if partial response or switched according to protocol if no response. Partial response is improvement of 20% or more in GAD-7. If switched, 6-week protocol will recommence with new medication. At fourth appointment, dosage optimized if responding well to medication and improvement greater than 50% within primary arm, or 20% if secondary arm, patient will remain on said medication for remainder of 12-week study. If not improving more than 20%, medication switched according to protocol and 6-week protocol will recommence. If primary arm and 20-50% improvement after six weeks on new medication, augmented with olanzapine, risperidone or benzodiazepines.
62497699|NCT04478526|EXPERIMENTAL|e-CBT + Pharmacotherapy|Participants will commence both treatments described above simultaneously.
62497700|NCT04403945||Group 1|healthy volunteers with normal fasting blood glucose and HbA1c, without hypertension, kidney diseases, or taking drugs that affects microcirculation
62497701|NCT04403945||Group 2|type 2 diabetic patients without microvascular complications like Diabetic nephropathy, diabetic retinopathy, diabetic foot or diabetic peripheral neuropathy
62497702|NCT04403945||Group 3|type 2 diabetic patients with diabetic nephropathy diagnosed by clinic or pathology.
61947533|NCT06556940|EXPERIMENTAL|Group 1|
61947534|NCT06556940|EXPERIMENTAL|Group 2|
61947535|NCT06556940|EXPERIMENTAL|Group 3|
61947536|NCT06556940|EXPERIMENTAL|Group 4|
61947537|NCT05815641|EXPERIMENTAL|food intake (breakfast)|the breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
61947538|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
62140379|NCT04088630|PLACEBO_COMPARATOR|Control Group|In addition to Standard of care treatment, those participants randomized to the control group will receive a single dose placebo pill within 24 hours of symptom onset
62698429|NCT00726583|EXPERIMENTAL|Investigational Drug|Dose Escalation
61947539|NCT05668884|EXPERIMENTAL|experimental group|Combination of Gemox, Donafenib and Tislelizumab
62140380|NCT03185936|EXPERIMENTAL|Optic disc pit maculopathy|pars plana vitrectomy with internal limiting membrane (ILM) peeling, endolaser
62140381|NCT00690131|EXPERIMENTAL|1|
62341009|NCT04762407|EXPERIMENTAL|Sequence 2|Period 1 :Fasted state + HCP1903, Period 2 : Fasted state + HGP1910 + HGP1909
62698430|NCT04980209||Ultrasonic and c-arm combination group|Ultrasound and c-arm were combined to evaluate intraoperatively conditions
61947540|NCT05367492|EXPERIMENTAL|Double Bline Varenicline|"Participants will...~* Receive the drug varenicline, in tablet form, up to 1 mg BID for 12 weeks.~* Attend QuitVaping behavioral support sessions, completed in-person or via video-conferencing, once per week for 12 weeks.~* Be encouraged to sign up for This Is Quitting (TIQ), a text message vaping cessation program for adolescents."
61947541|NCT05367492|PLACEBO_COMPARATOR|Double Blind Placebo|"Participants will...~* Receive placebo tablets, identical in appearance to varenicline, up to 1 mg BID for 12 weeks.~* Attend QuitVaping behavioral support sessions, completed in-person or via video-conferencing, once per week for 12 weeks.~* Be encouraged to sign up for This Is Quitting (TIQ), a text message vaping cessation program for adolescents."
61947542|NCT05367492|NO_INTERVENTION|Single Blind Monitoring only|"Participants will...~* Receive NO drug intervention.~* Attend NO behavioral support sessions.~* Will not be encouraged to sign up for text message vaping cessation support."
61947543|NCT01786148|ACTIVE_COMPARATOR|Educational music mobile app|A prerecorded program of songs on various topics in a mobile phone application (app). It is designed to provide education about non-health related topics and will be equivalent in length to the intervention app.
61947544|NCT01786148|EXPERIMENTAL|Live Network mobile phone App|The LN is a prerecorded mobile phone application (app). It employs a radio talk show format in which a Disc Jockey entertains HIV medication-, adherence-, and self-management-related questions and comments from callers and poses them to expert care providers, whose responses to these questions are augmented by songs that shed additional light on these issues.
62341010|NCT05852678||Patient registry|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
62341011|NCT00393913||Continuous Positive Airway Pressure (CPAP)|Participants will use a CPAP machine if they are found to have sleep apnea.
61947545|NCT05720260|EXPERIMENTAL|Arm A: goserelin/ fulvestrant/ durvalumab|Historical control arm (goserelin, fulvestrant) plus immunotherapy
61947546|NCT05720260|EXPERIMENTAL|Arm B: goserelin/ fulvestrant/ capivasertib/ durvalumab|Historical control arm (goserelin, fulvestrant) plus AKT inhibitor and immunotherapy
61947547|NCT05720260|EXPERIMENTAL|Arm C: goserelin/ fulvestrant/ capivasertib|Historical control arm (goserelin, fulvestrant) plus AKT inhibitor and immunotherapy
61947548|NCT05849701|ACTIVE_COMPARATOR|Shock wave therapy group|Patients in this group were managed by shock wave therapy, using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session, for six weeks
61947549|NCT05849701|ACTIVE_COMPARATOR|Vacuum-assisted closure group|the patients in this group were treated by vacuum-assisted closure using KCI's Vacuum Assisted Closure Device, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, The dressings were changed on the fourth day.
61947550|NCT00491764|EXPERIMENTAL|Posaconazole 100 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
61947551|NCT00491764|EXPERIMENTAL|Posaconazole 200 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
61947552|NCT00491764|EXPERIMENTAL|Posaconazole 400 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
61947553|NCT00491764|EXPERIMENTAL|Posaconazole 400 mg QD for 12 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
61947554|NCT00491764|ACTIVE_COMPARATOR|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
62341012|NCT01357915|EXPERIMENTAL|GSK149203A S- Group|Male subjects who received 3 doses of GSK Biologicals' candidate GSK149203A vaccine according to a 0-1-6 month schedule in the primary study 108890 (NCT00435396).
62497703|NCT04592653|EXPERIMENTAL|Cohort 1: Tumor Microenvironment (TME) Nemvaleukin and Pembrolizumab|Nemvaleukin will be administered via Intravenous (IV) infusion given daily for 5 consecutive days followed by an off-treatment period. Starting on Cycle 3, Day 1 of each cycle, Pembrolizumab will be administered via IV infusion followed by IV infusion of nemvaleukin
62140382|NCT00690131|NO_INTERVENTION|2|
62497704|NCT04592653|EXPERIMENTAL|Cohort 2 Part A: Less Frequent IV Dosing Nemvaleukin|
62497705|NCT04592653|EXPERIMENTAL|Cohort 2 Part B: Less Frequent IV Dosing Nemvaleukin and Pembrolizumab|This arm will not open for enrollment.
62497706|NCT04734704|EXPERIMENTAL|vitiligo patients|Adult patients diagnosed with Vitiligo according to usual criteria
62698431|NCT04980209||c-arm group|c-arm group was used to evaluate intraoperatively conditions
62698432|NCT02007343||Patients with gram-negative infections|"Sample (5/week/hospital) of all patients in a hospital that meet all of the following:~* meeting the criteria of at least one infection entity based on (modified) definitions of the Center for Disease Control and Infection Prevention (CDC; Am J Infect Control 2008;36:309-32) (restricted to infections that have septic potential);~* a culture with a gram-negative isolate (Enterobacteriaceae / Pseudomonas aeruginosa / Acinetobacter spp. / Stenotrophomonas maltophilia) with minimal inhibitory concentration (MIC) results from an automated system available that can be used to identify such an infection entity according to these criteria;~* receipt of antibiotics (oral, intravenous or intramuscular) for this infection, the choice of which is determined by the culture with the gram-negative (i.e. this isolate is seen as the causative pathogen);~* were admitted to the hospital during (part of) the infection episode.~Date of entry into cohort: date of index culture of infection episode"
61947555|NCT00491764|PLACEBO_COMPARATOR|Placebo|Placebo for 24 weeks.
61947556|NCT01331122|EXPERIMENTAL|droxidopa|Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
61947557|NCT01331122|PLACEBO_COMPARATOR|placebo|placebo
61947558|NCT02969564||prostate cancer patient, with up to five metastases|prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT.
61947559|NCT05331651|EXPERIMENTAL|Glycopyrronium in Combination With Tropisetron|
62341013|NCT01357915|OTHER|GSK149203A S+ Group|Male subjects who were assessed as being naturally infected with Cytomegalovirus (CMV) at the screening visit of the primary study 108890 (NCT00435396).
61947560|NCT05331651|PLACEBO_COMPARATOR|Normal Saline in Combination With Tropisetron|
61947561|NCT04368676|EXPERIMENTAL|Sudarshan Kroya Yoga (SKY)|Sudarshan Kriya Yoga (SKY) will be delivered using the Hospital approved Cisco WebEx platform. The online version of SKY will be delivered by at least one certified Canadian SKY teacher, with at least one back up teacher, under the supervision of Ms. Ronnie Newman, Director of Research and Health Promotion, Art of Living Foundation, USA. The online version of SKY for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered.
62140383|NCT05352308|EXPERIMENTAL|Common Sense Model Guided Narrative Video Group|The narrative videos is guided by the CSM and designed to provide a comprehensive resource for college students. The narrative video addresses illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers. The format of the narrative video includes (1) a direct testimonial of a college woman (in her dorm room) telling a story to her roommates about what motivated her to get vaccinated, and (2) a conversation among the roommates where information about the HPV vaccine is discussed.
62164448|NCT05667688|ACTIVE_COMPARATOR|Cohort 1: 5 mg, fasted|A single dose (5 mg) of tinlarebant will be administered to each study participant on study Day 1.
62164449|NCT05667688|ACTIVE_COMPARATOR|Cohort 2: 10 mg, fasted|A single dose (10 mg) of tinlarebant will be administered to each study participant on study Day 1.
62341014|NCT01162161||hydrostatic pulmonary edema|patients with a pulmonary edema caused by chronic heart failure
62341015|NCT01162161||toxic pulmonary edema|patients with a pulmonary edema preceded by pneumonia
62497707|NCT04734704|EXPERIMENTAL|metastatic melanoma patients under anti-PD-1 who did not develop cutaneous irAEs|metastatic melanoma patients under anti-PD-1 who did not develop Cutaneous Immune-Related Adverse Events (cutaneous irAEs).
62497708|NCT04734704|EXPERIMENTAL|Metastatic melanoma patients under anti-PD-1 who developed vitiligo lesions|patients with metastatic melanoma, under anti-PD-1 who developed vitiligo lesions
62497709|NCT04734704|EXPERIMENTAL|metastatic melanoma patients with vitiligo lesions under anti-PD-1 who discontinued|Metastatic melanoma who developed vitiligo lesions under anti-PD-1 who discontinued the treatment
62497710|NCT01483794||Genital warts treated|Patients that have had treatment on their genital warts
62497711|NCT01483794||Genital warts on treatment|Patients currently being treated for genital warts
62497712|NCT01566851||Patient|Patients with rheumatoid arthritis
62497713|NCT01068704|ACTIVE_COMPARATOR|BMS-690514 + Letrozole|
62497714|NCT01068704|ACTIVE_COMPARATOR|Lapatinib + Letrozole|
62497715|NCT04469400|NO_INTERVENTION|Group1|Researchers conduct health education on patients, including dietary guidance, physical activity guidance, psychological behavior counseling, etc.
62497716|NCT04469400|EXPERIMENTAL|Group2|In addition to education, the subjects will consume 2 composite protein solid drinks per day, in conjunction with the three-meal diet to increase satiety and intake of sufficient nutrients
62341016|NCT01162161||control group|not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)
62341017|NCT00647868|EXPERIMENTAL|Groups 1 and 2|Twice daily (7:00 am and 12:00 am or 7:00 am and 10:00 pm) dosing with intranasal testosterone for 14 days
62341018|NCT00647868|EXPERIMENTAL|Groups 3a and b|Single daily administration of testosterone (at 7:00 am or 10:00 pm) for 14 days
62341019|NCT00647868|NO_INTERVENTION|Group 4|24-h blood sampling in healthy eugonadal controls
62341020|NCT01585935|EXPERIMENTAL|Smoflipid|SMOFLIPID will be used for parenteral lipid supply
62341021|NCT01585935|ACTIVE_COMPARATOR|Intralipid|INTRALIPID will be used for parenteral lipid supply
62341022|NCT03169023|EXPERIMENTAL|Arm 1: ScaleDown (only first 16 patients)|"* Baseline quality of life and image surveys~* Weigh themselves every day on the provided Wi-Fi Scale~* Personalized feedback with text message comes as soon as participants step on the scale~* At the 6 month time period, quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~* At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~* Only 16 participants were in this arm because ScaleDown went out of business~* At 12 month follow-up weight will be abstracted from medical record"
62341023|NCT03169023|ACTIVE_COMPARATOR|Arm 2: Enhanced Usual Care|"* Baseline quality of life and image surveys~* Brief in-person counseling session by a research assistant using the Enhanced Usual Care Handouts from the American Cancer Society website which provides guidelines on healthy eating and exercise~* At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~* At 12 month follow-up weight will be abstracted from medical record"
62341024|NCT03169023|EXPERIMENTAL|Arm 3: iOTA|"* Baseline quality of life and image surveys~* Weigh themselves everyday using the provided Balance High Accuracy Digital Body Fat Scale~* Health coach will meet one-on-one with each participant (in-person or phone) to review health risk assessment and to choose 3 behavior goals related to healthy eating and physical activity at enrollment, 3 months, and 6 months~* Self-monitoring via SMS text messaging. Weekly check-ins by text providing data about weight and goals~* At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~* At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~* At 12 month follow-up weight will be abstracted from medical record"
62341025|NCT05722795|EXPERIMENTAL|Short term Imatinib|Imatinib 400 mg x 1 for 10 days before surgery.
62341026|NCT00358995|ACTIVE_COMPARATOR|1|Cognitive Behavior Therapy (CBT) may include keeping a diary of significant events and associated feelings, thoughts and behaviors; questioning and testing cognitions, assumptions, evaluations and beliefs that might be unhelpful and unrealistic; gradually facing activities which may have been avoided; and trying out new ways of behaving and reacting and using relaxation and distraction techniques.
62341027|NCT00358995|ACTIVE_COMPARATOR|2|Stress Management Therapy (SMT) includes relaxation, interaction, biofeedback, exercises, such as muscle stretching exercises, yoga, meditation, time management techniques, and many more.
62497717|NCT04469400|EXPERIMENTAL|Group3|In addition to education, the subjects will consume 2 nutrition bars daily to replace the staple food of daily lunch and dinner to help reduce carbohydrate intake and intake of sufficient nutrients
62497718|NCT01489930|EXPERIMENTAL|Endurance Exercise|Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise
62497719|NCT01489930|EXPERIMENTAL|Resistance Exercise|Participants will perform 8-weeks of whole-body resistance exercise training.
62497720|NCT01489930|EXPERIMENTAL|Control / Combined Training|Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.
62497721|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
62497722|NCT04568577|EXPERIMENTAL|tensioned tape|The tensioned tape group will apply weekly with gradual tension calculated by measuring the initial length of the tape. From the first week of application, there will be a 5% increase in tension up to the fifth week.
62497723|NCT04568577|ACTIVE_COMPARATOR|tape without tension|The tensionless tape group will receive the application of the tape weekly without tensioning during the five weeks.
62497724|NCT05736796|OTHER|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
62497725|NCT05736796|EXPERIMENTAL|Lumber Extension Excersie|Lumber Extension Excersie will be done to prevent the lumber straighten.
62497726|NCT00506012|EXPERIMENTAL|1|T2000
62736506|NCT01071499|ACTIVE_COMPARATOR|1|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
62341028|NCT02702518|ACTIVE_COMPARATOR|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
62341029|NCT02702518|PLACEBO_COMPARATOR|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
62341030|NCT01666678|EXPERIMENTAL|Arm 1|
62341031|NCT01666678|ACTIVE_COMPARATOR|Arm 2|
62497727|NCT01936012|EXPERIMENTAL|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
62698433|NCT02007343||Non-infected patients|"Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age.~Date of cohort entry: date of index culture of matched infected patient"
61947562|NCT04368676|ACTIVE_COMPARATOR|Health Enhancement Program (HEP)|The Health Enhancement Program (HEP) will be delivered using the Hospital approved Cisco WebEx platform. The online version of HEP for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered. HEP will be taught by Dr. Paris Lai, co-investigator and senior psychiatry resident.
61947563|NCT04137627|EXPERIMENTAL|Melatonin|The group received standard treatment with the oral administration of Melatonin
61947564|NCT04137627|PLACEBO_COMPARATOR|Placebo|The group received standard treatment with the oral administration of Placebo
61947565|NCT01193270|EXPERIMENTAL|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate (Aquasol E®) 50 IU/kg.
61947566|NCT01193270|PLACEBO_COMPARATOR|Placebo|Sterile water in volume equal to that of the comparator drug.
61947567|NCT01986946|EXPERIMENTAL|Intravenous opioids|This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.
61947568|NCT01986946|EXPERIMENTAL|Epidural Catheter|The intervention to be tested in this study against standard intravenous opioids is infusion of local anesthetic and dilaudid via epidural catheter for post-operative pain control in patients undergoing lumbar spine fusion surgery.
61947569|NCT01203631|EXPERIMENTAL|NNC 0142-0000-0002|
61947570|NCT01203631|PLACEBO_COMPARATOR|Placebo|
61947571|NCT05487352||hyperglycemia in the first trimester|The 75g oral glucose tolerance test was performed before 14 weeks of gestation, and any of the fasting, 1-hour and 2-hours blood glucose was ≥ 5.1, 10.0 and 8.5 mmol/L, respectively.
61947572|NCT05487352||euglycemia in the first trimester|The 75g oral glucose tolerance test was performed before 14 weeks of gestation, and the fasting, 1-hour and 2-hours blood glucose were all \< 5.1, 10.0 and 8.5 mmol/L, respectively.
61947573|NCT02738034|EXPERIMENTAL|Adaptive training group|The intervention group will be composed of hypertensive participants with cognitive decline that will be submitted to the training program (Cogmed) for approximately 10 weeks. Across training, task difficulty was adjusted as a function of individual performance.
61947574|NCT02738034|ACTIVE_COMPARATOR|Active control Group|In the control group, hypertensive patient will be submitted to a set of online games available on the internet and previously determined. In this way, the control group will receive the same motivation, as well as will be engaged in computerized activities, in the same way as the experimental group. The difference is that these varied games do not provide any type of intense and adaptive training, at the same time as they do not stimulate any specific cognitive function.
61947575|NCT00400764|EXPERIMENTAL|Phase Ib: Dulanermin 4 mg/kg|Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m\^2 weekly for up to eight doses.
61947576|NCT00400764|EXPERIMENTAL|Phase Ib: Dulanermin 8 mg/kg|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m\^2 weekly for up to eight doses.
61947577|NCT00400764|ACTIVE_COMPARATOR|Phase II: Rituximab|Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
61947578|NCT00400764|EXPERIMENTAL|Phase II: Combination Therapy|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m\^2 weekly for up to eight doses.
61947579|NCT00400764|EXPERIMENTAL|Phase II: Dulanermin|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
61947580|NCT00748735||A1|heart failure patients undergoing CRT implantation
61947581|NCT01952925|EXPERIMENTAL|Combined afib ablation and RA denervation|Patients with atrial fibrillation and resistant hypertension will be enrolled and undergo a single procedure consisting of pulmonary vein isolation and renal artery denervation.
61947582|NCT03383458|EXPERIMENTAL|Arm A|
61947583|NCT03383458|PLACEBO_COMPARATOR|Arm B|
61947584|NCT04710264||recombinant hFSH|Patient stimulated with recombinant hFSH
61947585|NCT04710264||recombinant hFSH : r-hLH|Patient stimulated with recombinant hFSH : r-hLH ratio 2:1
62341032|NCT01666678|ACTIVE_COMPARATOR|Arm 3|
62698434|NCT02239003|EXPERIMENTAL|DAOIB|250-1500 mg/day, oral, for 24 weeks
62698435|NCT02239003|PLACEBO_COMPARATOR|Placebo|placebo, oral, for 24 weeks
62698436|NCT03430999|EXPERIMENTAL|Group 1 (Japanese) Calmangafodipir|
61947586|NCT01338103|EXPERIMENTAL|Rituximab|
61947587|NCT01153074|EXPERIMENTAL|Occluder|The patients with bronchopleural fistulas treated with bronchoscopic deployment of the cardiac septal defects occluder.
61947588|NCT05244304|EXPERIMENTAL|Tinlarebant|5 mg tablet taken orally once a day
61947589|NCT05244304|PLACEBO_COMPARATOR|Placebo|Placebo tablets for tinlarebant 5 mg are prepared similarly but use microcrystalline cellulose, NF, in place of the active drug substance and will be identical in size and appearance.
61947590|NCT03775330||SRS|Stereotactic radiosurgery
61947591|NCT03775330||SRS plus WBRT|Stereotactic radiosurgery plus whole brain radiation
61947592|NCT04423276|PLACEBO_COMPARATOR|Control|
62341033|NCT01666678|EXPERIMENTAL|Arm 4|
62698437|NCT03430999|PLACEBO_COMPARATOR|Group 1 (Japanese) Placebo|
62698438|NCT03430999|EXPERIMENTAL|Group 2 (Caucasian) Calmangafodipir|
62698439|NCT03430999|PLACEBO_COMPARATOR|Group 2 (Caucasian) Placebo|
61947593|NCT04423276|EXPERIMENTAL|Donepezil|
61947594|NCT02494674|EXPERIMENTAL|Bite Counter tracking|Study participants will be asked to track their energy intake via a wearable device called the Bite Counter. Participants will attend weekly meetings to provide feedback on the Bite Counter.
61947595|NCT06270771||Transfusion Dependent|Patients who are currently receiving transfusions will be assigned to this cohort
61947596|NCT06270771||Transfusion Independent|Patients who are not currently receiving transfusions will be assigned to this cohort
61947597|NCT04785248|NO_INTERVENTION|Controlled group|the routine preoperative disinfection method
61947598|NCT04785248|EXPERIMENTAL|Three-step disinfection|new developed method of preoperative disinfection
61947599|NCT00354861|EXPERIMENTAL|A|IMP321
61947600|NCT00354861|PLACEBO_COMPARATOR|B|Saline
61947601|NCT00354861|ACTIVE_COMPARATOR|C|Engerix B
61947602|NCT01374841|EXPERIMENTAL|Stem Cell Transplant+Cyclophosphamide|patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide
61947603|NCT03175978|EXPERIMENTAL|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
61947604|NCT03652168|EXPERIMENTAL|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
61947605|NCT03652168|NO_INTERVENTION|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
61947606|NCT04049864|EXPERIMENTAL|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
61947607|NCT00091442|EXPERIMENTAL|DOXIL and docetaxel combination therapy|DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
62341034|NCT04507477|EXPERIMENTAL|Rituximab + Ex-vivo lung perfusion|Donor lungs deemed suitable for such patients will undergo ex vivo lung perfusion (EVLP) as per standard practice. In clinical practice almost all adult donor lungs are EBV seropositive. If in the rare case the donor lung is EBV seronegative, then the lung transplant candidate/recipient will no longer need to be part of the study. Therefore, for EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours. Lungs will then be transplanted as per standard procedure.
62341035|NCT03150108|EXPERIMENTAL|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
62341036|NCT03150108|EXPERIMENTAL|Participants of Japanese Descent|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
62341037|NCT00734734|EXPERIMENTAL|1|
62341038|NCT06288958||Children with Cerebral Palsy|Children aged 4 to 12 with CP diagnosis
62341039|NCT05071560|ACTIVE_COMPARATOR|Face-to-Face Group|This arm will have a 3 day per week face-to-face participant-tailored combined exercise program, with 2 supervised sessions and 1 non supervised aerobic session, for 8 weeks
61947608|NCT00091442|ACTIVE_COMPARATOR|Docetaxel monotherapy|Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
61947609|NCT02327689|EXPERIMENTAL|compensated HBV related cirrhosis patients|Chinese naive compensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
61947610|NCT02327689|EXPERIMENTAL|decompensated HBV related cirrhosis patients|Chinese naive decompensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
61947611|NCT03334591|EXPERIMENTAL|Apatinib 5 days' continuous use and 2 days' off|Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
61947612|NCT03334591|ACTIVE_COMPARATOR|Apatinib 500mg continuous use|Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
61947613|NCT04458207|EXPERIMENTAL|Experimental group (EG), the immediate rehabilitation group|The experimental group will begin with the rehabilitation immediately after the first measurement of cognitive tests (pre-test). Three months after complete rehabilitation the first post-test (post-test 1) will be conducted on all participants. Participants will be recalled after about a year for a long-term follow up (post-test 2). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at different time points (i.e., pre-test, post-test 1 and post-test 2).
61947614|NCT04458207|ACTIVE_COMPARATOR|Control group (CG), the test-retest group|The control group will be tested with the cognitive tests two times (pre-test + post-test 1) at an interval of about three months or more inbetween tests and before the onset of the prosthodontic rehabilitation. Three months after complete rehabilitation the post-test (post-test 2) will be conducted on all participants. Further, participants will be recalled after about a year for a long-term follow up (post-test 3). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at these time points (i.e., pre-test, post-test 1, post-test 2 and post-test 3).
61947615|NCT03137342|EXPERIMENTAL|Pepped on PrEP|"Using an efficient stepped care (adaptive) model, all participants will receive three sessions of PrEP-STEPS counseling for PrEP adherence delivered by a Masters-level or above therapist. Some individuals may require a more intensive approach. These participants will receive an additional seven counseling sessions of behavioral activation with integrated cognitive behavioral therapy (CBT) designed to reduce stimulant use and promote positive behaviors."
61947616|NCT03137342|NO_INTERVENTION|Standard of Care|PrEP adherence counseling from the Miriam Hospital PrEP Clinic.
61947617|NCT01597531|ACTIVE_COMPARATOR|Liraglutide only|
61947618|NCT01597531|ACTIVE_COMPARATOR|Orlistat only|
62698440|NCT04028258|OTHER|Group A: study+wash out+control|Study product (3 weeks) + wash out (2 weeks) + control product (3 weeks)
61947619|NCT01597531|ACTIVE_COMPARATOR|Liraglutide + Orlistat|
61947620|NCT00795145|PLACEBO_COMPARATOR|Cohort 1: Placebo|
61947621|NCT00795145|EXPERIMENTAL|Cohort 1: 900 mg linezolid|
61947622|NCT00795145|EXPERIMENTAL|Cohort 1: 1200 mg linezolid|
61947623|NCT00795145|PLACEBO_COMPARATOR|Cohort 2: Placebo|
62341040|NCT05071560|EXPERIMENTAL|Home-Based Group|This arm will have a 3 day per week home-based participant-tailored combined exercise program, with 2 remotely supervised sessions (online) and 1 non supervised aerobic session, for 8 weeks
62698441|NCT04028258|OTHER|Group B: control+wash out+study|Control product (3 weeks) + wash out (2 weeks) + study product (3 weeks)
62698442|NCT04319809|EXPERIMENTAL|Device feasibility|To investigate the utility of a device adaptation allowing Argus II users to detect the presence and location of desired objects. Performance of the unaided Argus II system will be compared with performance using the system augmented with object recognition.
62698443|NCT05014919|EXPERIMENTAL|Vortioxetine -open label treatment period|"Vortioxetine - 5, 10, 15, and 20 mg/day, film-coated tablets, orally once daily.~Patients will receive a targeted dose of 10 mg/day vortioxetine, however the investigator has the possibility to adjust the dose in case of unsatisfactory response or in case of dose-limiting adverse events."
62698444|NCT05014919|EXPERIMENTAL|Vortioxetine -double-blind relapse prevention period|"Vortioxetine - 5, 10, 15, and 20 mg/day, encapsulated film-coated tables, orally once daily.~In the double-blind period, the patients will continue on the same fixed dose as during the end of the open label period"
61947624|NCT00795145|EXPERIMENTAL|Cohort 2: 600 mg linezolid|
61947625|NCT00795145|EXPERIMENTAL|Cohort 2: 1200 mg linezolid|
61947626|NCT00795145|ACTIVE_COMPARATOR|Cohort 2: 400 mg Moxifloxacin|
62140384|NCT05352308|NO_INTERVENTION|Standard of Care Group|"Participants in the standard of care group will receive the Centers for Disease Control and Prevention's Vaccine Information Statement (VIS; https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv.pdf). The VIS contains information about HPV, the HPV vaccine, and the benefits and risks of the vaccine.~The VIS will be utilized because healthcare providers are required to distribute the VIS to patients before receiving each dose of the HPV vaccine, it is easy to understand, and it is publicly available information."
62698445|NCT05014919|PLACEBO_COMPARATOR|Placebo -double-blind relapse prevention period|Placebo - encapsulated tablets, orally once daily.
62140385|NCT05352308|NO_INTERVENTION|Time & Attention Group|Participants in the time and attention video group will receive a Centers for Disease Control and Prevention video on binge drinking (https://youtu.be/I9hdkDTaQWU; 4:22 minutes). The video contains information on the health risks of binge drinking including unintended pregnancy, sexually transmitted diseases, injury, car accidents, violence, and HIV/AIDS
62140386|NCT05889910|EXPERIMENTAL|Intervention Group|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
62164450|NCT02388399||OCT and Pressure wire pullback tracing|This study is pilot study evaluating the feasibility of invasive measurement and estimation of hemodynamic stress acting on plaque as well as co-registration of hemodynamic data with plaque geometric data, which is obtained by optical coherence tomography
62341041|NCT00587951||A|Candidates for epilepsy surgery, undergoing pre-surgical evaluation at Mayo Clinic, and in whom SISCOM was ordered by the treating physician as part of that evaluation
62698446|NCT04785638|EXPERIMENTAL|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
62698447|NCT06228937||Group A|patients affected by limb lymphedema with recurrent soft tissue infections
62698448|NCT06228937||Group B|patients affected by limb lymphedema without recurrent soft tissue infections
62698449|NCT04109300|EXPERIMENTAL|preemptive screening|prospective HLADQA1\*05A\>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
62698450|NCT04109300|ACTIVE_COMPARATOR|standard of care|administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1\*05A\>G genotyping will be performed retrospectively.
61947627|NCT02008318|EXPERIMENTAL|Phase (ph) 2: Galunisertib + BSC|Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
62341042|NCT01202721|EXPERIMENTAL|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg.
62341043|NCT01202721|EXPERIMENTAL|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg
61947628|NCT02008318|PLACEBO_COMPARATOR|Ph 3: Placebo + BSC|Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
61947629|NCT02008318|EXPERIMENTAL|Ph 3: Galunisertib + BSC|150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
61947630|NCT05545007|EXPERIMENTAL|HSRS pre-operative|"Patients undergo HSRS (hypofractionated Radiosurgery) on day 1, consisting in 27 Gray (gy) administered in 3 daily fractions.~Within 1 weeks, patients undergo surgical resection."
61947631|NCT05545007|ACTIVE_COMPARATOR|HSRS post-operative|Patients undergo surgical resection on day 1. Within 4-6 weeks, patients undergo HSRS (hypofractionated Radiosurgery), consisting in 27 Gray (gy) administered in 3 daily fractions.
61947632|NCT01950169|ACTIVE_COMPARATOR|Risedronate|35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)
61947633|NCT01950169|ACTIVE_COMPARATOR|Nutritional supplement|Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)
62497728|NCT01936012|ACTIVE_COMPARATOR|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
61947634|NCT01950169|ACTIVE_COMPARATOR|Calcium and vitamin D3|An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)
62140387|NCT05889910|ACTIVE_COMPARATOR|Control Group|"The control group intervention will be the usual clinical practice offered by the patient's nurse in the Primary Care setting during the duration of the study.~The usual clinical practice is based on attention to the user's demands, as well as the performance of interventions that can influence falls and/or the fear of falling. These activities or interventions are based on the Services of the Standardized Service Portfolio of the Community of Madrid (Updated as of January 28, 2022) in which these patients are included due to age or as a consequence of their chronic pathology."
62497729|NCT02464904|EXPERIMENTAL|Cryotherapy|Cryospray and biopsies
62497730|NCT02464904|OTHER|Control|Biopsies
62497731|NCT03724682|EXPERIMENTAL|Single arm|Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,
62497732|NCT05483608|EXPERIMENTAL|Vertical climbing ergometer exercise|8 weeks of 3 times per week (24 sessions in total) of 30 minutes of vertical climbing ergometer exercise using the CLMBR. Intensity will be prescribed at a level of 12 to 14 on the Borg Rate of Perceived Exertion Scale.
62497733|NCT05483608|ACTIVE_COMPARATOR|Recumbent cycling|8 weeks of 3 times per week (24 sessions in total) of 30 minutes of recumbent cycle ergometer exercise. Intensity will be prescribed at a level of 12 to 14 on the Borg Rate of Perceived Exertion Scale.
62497734|NCT00875082|ACTIVE_COMPARATOR|Montelukast|Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
62497735|NCT00875082|PLACEBO_COMPARATOR|placebo|placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed
62497736|NCT04303624||Community sample|Representative sample of the Singapore population
62497737|NCT05767762|EXPERIMENTAL|Idiopathic Clubfoot|
62497738|NCT06018064|EXPERIMENTAL|Interventional Arm|Subjects who are placed in the Prone Positioner for evaluation
62497739|NCT05414695|EXPERIMENTAL|Real acupuncture|The patient receives five sessions (weekly) of real acupuncture treatment in the acupuncture points LI4, S6, S7 and SI18. Each session lasts 30 minutes.
62497740|NCT05414695|PLACEBO_COMPARATOR|Placebo acupuncture|The patient receives five sessions (weekly) of placebo acupuncture in the same acupuncture points LI4, S6, S7 and SI18. Each session lasts 30 minutes. The placebo and real acupuncture devices have the same visual features but in the placebo device the needle does not even touch the skin.
62497741|NCT06245915|EXPERIMENTAL|AB-2100|Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-2100 intravenously on day 0.
62497742|NCT05193422|ACTIVE_COMPARATOR|Phase I: No mask|"Participants, without wearing a face mask, will undergo the following:~1. Measurement of peak nasal inspiratory flow~2. Cardiopulmonary exercise testing (CPET) with an ergometric bike at 30% of their predicted maximum workload (Wmax) for 4 minutes, 50% of Wmax for 2 minutes and 70% of Wmax for 1 minute, with continuous oxygen saturation (SpΟ2), heart rate (HR), end-tidal CO2 (EtCO2) and respiratory rate (RR) monitoring.~3. Spirometry and measurement of nPIF immediately after CPET.~4. Discomfort assessment using a special scale"
62497743|NCT05193422|EXPERIMENTAL|Phase II: Face mask|"Following nPIF measurement, participants will be asked to wear a standard surgical face mask. A temperature and humidity sensor will also be placed inside the mask. Will follow:~1. Resting phase, 6 minutes. SpO2, HR, EtCO2 and RR will be monitored.~2. CPET at 30% of Wmax for 4 minutes, 50% Wmax for 2 minutes and 70% Wmax for 1 minute. SpO2, HR, EtCO2 and RR will be continuously monitored.~3. Spirometry and measurement of nPIF immediately after CPET.~4. Discomfort assessment."
62497744|NCT03328390|EXPERIMENTAL|Quadratus lumborum block Group|ultrasound guided
62698451|NCT00113373|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62698452|NCT04440774|EXPERIMENTAL|CHIK low dose|Volunteers will receive a single dose of 5x10\^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698453|NCT04440774|EXPERIMENTAL|CHIK mid dose|Volunteers will receive a single dose of 2.5x10\^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
61947635|NCT03240354|EXPERIMENTAL|Saline|Use of saline to inflate cuff of endotracheal tube
61947636|NCT03240354|ACTIVE_COMPARATOR|Control|Use of air to inflate cuff of endotracheal tube
61947637|NCT02412995|EXPERIMENTAL|Meal sequence 1-2-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-2-3
61947638|NCT02412995|EXPERIMENTAL|Meal sequence 1-3-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-3-2
61947639|NCT02412995|EXPERIMENTAL|Meal sequence 2-3-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-3-1
61947640|NCT02412995|EXPERIMENTAL|Meal sequence 2-1-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-1-3
61947641|NCT02412995|EXPERIMENTAL|Meal sequence 3-1-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-1-2
62497745|NCT03328390|ACTIVE_COMPARATOR|Transversus abdominis plane block Group|ultrasound guided
61947642|NCT02412995|EXPERIMENTAL|Meal sequence 3-2-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-2-1
61947643|NCT00660699|EXPERIMENTAL|Arm 1 (gemcitabine, docetaxel, 5FU, radiation)|"Gemcitabine 1000 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~Docetaxel 35 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~5FU CIVI 225 mg/m2 per day throughout radiation (starts 3 weeks after start of cycle 2)~Radiation 5040 cGy or 5400 cGy for positive margins (starts 3 weeks after start of cycle 2). Daily dose of 1.8 Gy five days per week.~Gemcitabine 1000 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)~Docetaxel 35 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)"
61947644|NCT04752384|EXPERIMENTAL|Drug Treatment|The main objective of this study is to provide preliminary evidence that FDA approved dose of transdermal buprenorphine in conjunction with oral tramadol can provide adequate analgesia of radiation-induced mucositis pain during treatment and follow up period in head and neck cancer patients.
61947645|NCT01703325|ACTIVE_COMPARATOR|triamcinolone injection (10 mg/ml)|"Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection"
61947646|NCT01703325|ACTIVE_COMPARATOR|Topical 0.05% clobetasol ointment|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months
61947647|NCT01703325|NO_INTERVENTION|Controlled group|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group
62341044|NCT05656898|EXPERIMENTAL|Piezosurgery pulse Low-level laser therapy|Piezocision will be applied in this group of patients using a piezosurgery knife and after 6 weeks of initial retraction, low-level laser therapy will be applied in this group of patients using a diode laser device.
62698454|NCT04440774|EXPERIMENTAL|CHIK high dose|Volunteers will receive a single dose of 5x10\^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698455|NCT04440774|EXPERIMENTAL|ZIKA low dose|Volunteers will receive a single dose of 5x10\^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698456|NCT04440774|EXPERIMENTAL|ZIKA mid dose|Volunteers will receive a single dose of 2.5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698457|NCT04440774|EXPERIMENTAL|ZIKA high dose|Volunteers will receive a single dose of 5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698458|NCT04440774|EXPERIMENTAL|CHIK ZIKA low dose|Volunteers will receive a single dose of 5x10\^9 vp ChAdOx1 Chik and 5x10\^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698459|NCT04440774|EXPERIMENTAL|CHIK ZIKA mid dose|Volunteers will receive a single dose of 2.5x10\^10 vp ChAdOx1 Chik and 2.5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698460|NCT04440774|EXPERIMENTAL|CHIK ZIKA high dose|Volunteers will receive a single dose of 5x10\^10 vp ChAdOx1 Chik and 5x10\^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698461|NCT04440774|PLACEBO_COMPARATOR|Placebo|Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
62698462|NCT04139408|EXPERIMENTAL|Disposable Pulmonary Surgical Marker|Locate the pulmonary nodules with Disposable Pulmonary Surgical Marker before VATS.
62698463|NCT06040398||TAVR Patients|All outpatients undergoing TAVR and managed through the overnight-model pathway at the Hamilton General Hospital will be eligible for participation.
62698464|NCT05102370|EXPERIMENTAL|Participants with CCUS with mutations in IDH2|Participants will have CCUS with mutations in IDH2
62698465|NCT05918354||Allergy|Adults aged 18 years or above, consulting the outpatient clinic for an allergy diagnosis to aeroallergens with skin prick automated test device.
62698466|NCT03974061|EXPERIMENTAL|Brief Acceptance and Commitment Therapy|Participants randomized to the Acceptance and Commitment Therapy (ACT) arm will receive one, 1-hour intervention session followed by five weekly 30-45 minute intervention sessions delivered via telephone.
62341045|NCT05656898|EXPERIMENTAL|Piezosurgery|Piezocision will be applied in this group of patients using a piezosurgery knife.
62341046|NCT05656898|ACTIVE_COMPARATOR|Traditional treatment|En masse retraction in this group will be performed in a conventional method.
62341047|NCT01996748|EXPERIMENTAL|DF277|Two administrations daily for 7 days
62698467|NCT03974061|ACTIVE_COMPARATOR|Brief Alcohol Intervention|Participants randomized to the Brief Alcohol Intervention (BI) will receive the following telephone-based sessions over the duration of six weeks: a 30-45 minute session of a brief alcohol intervention, a 5-10 minute booster call, a reminder phone call for the next intervention session, a 30-45 minute intervention session, a 5-10 minute booster, and a reminder phone call for the post-treatment appointment.
61947648|NCT00265629|EXPERIMENTAL|1|RF ablation
62341048|NCT01996748|PLACEBO_COMPARATOR|Placebo|Two administrations daily for 7 days
62341049|NCT03767296|EXPERIMENTAL|Dose Bolus of E-P-E|Ephedrine Hydrochloride 3 MG/ML- Phenylephrine - Ephedrine Hydrochloride 3 MG/ML
62341050|NCT03767296|EXPERIMENTAL|Dose Bolus P-E-P|Phenylephrine- Ephedrine Hydrochloride 3 MG/ML - Phenylephrine
62341051|NCT03767296|EXPERIMENTAL|Dose Bolus E-E-E|Ephedrine Hydrochloride 3 MG/ML- Ephedrine Hydrochloride 3 MG/ML - Ephedrine Hydrochloride 3 MG/ML
62341052|NCT03767296|EXPERIMENTAL|Dose Bolus P-P-P|Phenylephrine-Phenylephrine-Phenylephrine
62497746|NCT03494686|EXPERIMENTAL|LLETZ under local anaesthesia|The LLETZ procedure will be performed under local anaesthesia
61947649|NCT02498132|EXPERIMENTAL|Behavioral Activation|Behavioral Activation will be administered via Moodivate will mirror the core BA components outlined above. Moodivate will also be modified for a mobile environment in key ways, with the most salient being: 1) Elimination of the need for a therapist: By eliminating the need for a therapist, we will be able to reach a broad patient/consumer base that may not utilize traditional therapy resources and will combat the primary barrier to PCPs recommending psychotherapy to their patients with elevated depressive symptoms and 2) Elimination of paper forms: By eliminating paper forms, we will increase the sensitivity of BA to motivational and organizational deficits frequently observed in patients with elevated depressive symptoms while also increasing treatment fidelity by prompting the patient to complete activities at scheduled times and giving the patient reinforcement for completing activities.
61947650|NCT02498132|ACTIVE_COMPARATOR|Cognitive Based Therapy|Moodkit will be used to administer cognitive based therapy which is commonly compared to behavioral activation.
61947651|NCT02498132|ACTIVE_COMPARATOR|Treatment as Usual|TAU will be provided to individuals. These subject will be provided with therapy but will not utilize a mobile application.
61947652|NCT03204201|EXPERIMENTAL|Urethral instillation of ICG|Urethral instillation of indocyanine green (ICG)
61947653|NCT03905408|EXPERIMENTAL|50 mL Dextrose|50 mL of 50% dextrose
62497747|NCT03494686|ACTIVE_COMPARATOR|LLETZ under general anaesthesia|The LLETZ procedure will be performed under general anaesthesia
61947654|NCT03905408|EXPERIMENTAL|100 mL Dextrose|100 mL of 50% dextrose
61947655|NCT03905408|EXPERIMENTAL|150 mL Dextrose|150 mL of 50% dextrose
61947656|NCT03905408|EXPERIMENTAL|200 mL Dextrose|200 mL of 50% dextrose
61947657|NCT05840380|ACTIVE_COMPARATOR|exercise+1ASTM group|"In addition to the exercises given to the exercise group to the IASTM group 8-10 repetitions with the device at a 45° angle twice a week for 4 weeks on erector spines, glutes maximus, gluteus medius and hamstrings Superficial and deep fascia will be applied. Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual.~cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied. They will perform the low back pain exercises shown. Pain intensity of all patients at the beginning and end of treatment Visual Analogue Scale and algometer, flexibility sit and lie test, position sense digital inclinometer, functional status Oswestry Disability Index and life Quality will be evaluated with Short Form-36 (SF-36)."
61947658|NCT05840380|ACTIVE_COMPARATOR|exercise group|The exercise group is; By physiotherapists 3 times a week for 4 weeks They will perform the low back pain exercises shown. Pain intensity of all patients at the beginning and end of treatment Visual Analogue Scale and algometer, flexibility sit and lie test, position sense digital inclinometer, functional status Oswestry Disability Index and life Quality will be evaluated with Short Form-36 (SF-36).
61947659|NCT01010373|EXPERIMENTAL|AS101 infusions|In addition to induction chemotherapy AS101 will be given intravenously. The patient will also receive AS101 infusions during the time break till the next chemotherapy course, as long as the patient does not achieve complete remission and the platelet count is \<20,000/μl; ANC \<1000. AS101 will be administered likewise up to two consolidation or equivalent chemotherapy courses (re-induction or salvage in the event that no CR is achieved following first induction chemotherapy), i.e., total of three chemotherapy courses.
61947660|NCT06314867|EXPERIMENTAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)|Batch number: Y202112011
61947661|NCT06314867|EXPERIMENTAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)|Batch number: Y202112012
61947662|NCT06314867|EXPERIMENTAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)|Batch number: Y202112013
61947663|NCT00261274|EXPERIMENTAL|Test Group A-ECO|
61947664|NCT00261274|PLACEBO_COMPARATOR|Control Group|
61947665|NCT06036823|ACTIVE_COMPARATOR|5 units of intravenous R insulin|"Will receive:~IV Insulin Regular 5 units with Dextrose 50 % 50 ml over 30 minutes. Salbutamol 10 mg Nebulization over 15 minutes."
61947666|NCT06036823|ACTIVE_COMPARATOR|10 units of intravenous R insulin|"Will Receive:~IV Insulin Regular 10 units with Dextrose 50 % 50 ml over 30 minutes. Salbutamol 10 mg nebulization over 15 minutes."
61947667|NCT03561116|EXPERIMENTAL|XAN|XAN (1 sachet of 12 mg/day)
61947668|NCT03561116|PLACEBO_COMPARATOR|Placebo|Placebo (1 sachet with excipient)
62140388|NCT06223633|EXPERIMENTAL|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
62140389|NCT02330588|EXPERIMENTAL|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
62497748|NCT05212038|EXPERIMENTAL|liopsoas plane block group|Arm Description: a iliopsoas plane block before surgery
62140390|NCT02330588|EXPERIMENTAL|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
62341053|NCT02765178||Patients with Tourette Syndrome|The primary caregiver will be asked to fill the Children's motivation Scale. Other measures will be collected including a clinician filled Yale Global Tic Severity Scale (YGTSS) - severity score, Center for Epidemiological Studies Depression Scale for Children (CES-DC) and Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL). Demographic data will also be collected for each study patient. Demographic data will also be collected for each study patient.
62497749|NCT05212038|SHAM_COMPARATOR|sham block group|sham block before surgery
62497750|NCT02421627|EXPERIMENTAL|Moxibustion group|Receiving moxibustion treatment
62497751|NCT02421627|SHAM_COMPARATOR|Sham moxibustion group|Receiving sham moxibustion.
62497752|NCT01041209|EXPERIMENTAL|BPS|BPS guidance
62497753|NCT01041209|ACTIVE_COMPARATOR|Guideline|Enforced guidelines
62497754|NCT05486923||KPS less than 70|"The patients in this group have Karnofsky performance Status less than 70，and the proportion of them is not less than 15%.~Patients need regular follow-up surveys within 2 years after the date of surgery."
62497755|NCT05486923||KPS more than 70|The patients in this group have Karnofsky performance Status more than 70. Patients need regular follow-up surveys within 2 years after the date of surgery.
61947669|NCT03402646|EXPERIMENTAL|Reminder module (SMS and Phone call)|"Intervention will consist of a Reminder module delivered via SMS and telephone calls by an automated, customized software application. This will include standardized SMS reminder 3 days prior to scheduled immunization clinic appointments, telephone call reminders a day prior to scheduled clinic appointment (4 to 6pm) (in addition to standard care - routine paper-based appointment scheduling and counselling by care providers) for routine immunization. Reminders will be provided consistently for all immunization clinic appointments until the child turns 12 months of age."
61947670|NCT03402646|EXPERIMENTAL|Photovoice|In two small groups of 15 participants each per state, purposively selected pregnant women in their third trimester and parents of infants aged 0-12 months in the community, as well as community leaders, service providers and policy makers will be exposed to photographs (taken from other sources) of debilitating consequences of non-immunization, which will form the basis of the group discussions, knowledge sharing and consensus-building sessions, each lasting about 45 minutes to 1 hour. Each community cluster will be linked to a PHC.
61947671|NCT03402646|NO_INTERVENTION|Control|Respondents in control clusters will receive standard care only - comprising routine paper-based appointment scheduling
61947672|NCT04664192||Lung transplant Recipients|Biobank registry for Lung transplant recipients
61947673|NCT04633577|EXPERIMENTAL|Group Lidocaine|20 eligible patients are received 1.5mg/kg 1%lidocaine intravenously over 30-60s. Then, 4mg/kg/h lidocaine infused intravenously until end of procedure.
61947674|NCT04633577|PLACEBO_COMPARATOR|Group Control|2020 eligible patients are received equal 0.9% normal saline.
62497756|NCT05360849|EXPERIMENTAL|Practice Facilitation|Practice Facilitation is an established evidence-based intervention to improve primary health care processes and outcomes, including the delivery of preventive services, through the creation of an ongoing, trusting relationship between an external Practice Facilitator (PF) and a clinical practice. In Practice Facilitation, a trained PF uses organization development, project management, quality improvement, and practice improvement approaches to build the internal capacity of a clinic to support it in reaching its goals for healthcare delivery, A PF's work includes relationship-building, helping to identify a clinic change champion, and facilitating change through logistical support, technical assistance, and external partnership building.
62497757|NCT05225467||Main group|All participants taking part in this study are subsequently categorized in this group
62698468|NCT04729439|EXPERIMENTAL|Organizational/behavioral intervention + digital health tool|Participants will receive sixteen 30-minute sessions of the organizational/behavioral skills intervention (i.e., Homework Organization and Planning Skills \[HOPS\]) plus the online digital health application during treatment
61947675|NCT04841538|EXPERIMENTAL|Cohort 1|ES101 is administered via intravenous infusion, 0.3mg/kg，once every 14 days, every 28 days as a treatment cycle.
61947676|NCT04841538|EXPERIMENTAL|Cohort 2|ES101 is administered via intravenous infusion, 1mg/kg，once every 14 days, every 28 days as a treatment cycle.
61947677|NCT04841538|EXPERIMENTAL|Cohort A1|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
61947678|NCT04841538|EXPERIMENTAL|Cohort A2|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
61947679|NCT04841538|EXPERIMENTAL|Cohort B|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
62698469|NCT04729439|ACTIVE_COMPARATOR|Organizational/behavioral intervention only|Participants will receive sixteen 30-minute sessions of the organizational/behavioral skills intervention (i.e., Homework Organization and Planning Skills \[HOPS\]) only, without the online digital health application during treatment
62736507|NCT01071499|ACTIVE_COMPARATOR|2|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
61947680|NCT04841538|EXPERIMENTAL|Cohort C|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
61947681|NCT03391089|EXPERIMENTAL|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
61947682|NCT03780543|ACTIVE_COMPARATOR|HBeAg-negative Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were standard of care (SOC) nucleos(t)ide (NrtI)-suppressed and HBeAg-negative will receive both ABI-H0731 + SOC NrtI for at least 52 weeks, after which time they will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up (FU) for up to 3 years.
61947683|NCT03780543|ACTIVE_COMPARATOR|HBeAg-positive Subjects from Parent Study ABI-H0731-201|"Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were SOC NrtI-suppressed and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~1. Subjects who meet the virologic response criteria will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up (FU) for up to 3 years.~2. Subjects with insufficient virologic response will discontinue ABI-H0731 only and continue on SOC NrtI alone and followed-up for 12 weeks."
61947684|NCT03780543|ACTIVE_COMPARATOR|Subjects from Parent Study ABI-H0731-202|"Subjects who on Day 1 of parent study ABI-H0731-202 (NCT03577171) were treatment-naive and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~1. Subjects who meet the virologic response criteria at Week 52 will continue to receive ABI-H0731 + SOC NrtI for an additional 96 weeks, after which time their viral response will be evaluated at Week 148.~   Subjects who meet the virologic response criteria at Week 148 will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up for up to 3 years. Subjects with insufficient virologic response at Week 148, will discontinue ABI-H0731 only and continue on SOC NrtI alone for up to 12 weeks.~2. Subjects with insufficient virologic response at Week 52 will discontinue from ABI-H0731only and continue on SOC NrtI alone and enter follow-up for up to 12 weeks."
61947685|NCT05188170|EXPERIMENTAL|Niclosamide 250 mg/m2 /day divided BID|
61947686|NCT05188170|EXPERIMENTAL|Niclosamide 500 mg/m2 /day divided BID|
61947687|NCT05188170|EXPERIMENTAL|Niclosamide 800 mg/m2 /day divided BID|
61947688|NCT05188170|EXPERIMENTAL|Niclosamide 1200 mg/m2 /day divided BID|
61947689|NCT05899088|NO_INTERVENTION|Control Arm|Patients follow-up as normal with physician. Recommended by physician to engage in physical activity 4x/w. No other intervention or follow-up.
61947690|NCT05899088|EXPERIMENTAL|Study Arm|Patients engage in weekly exercise program as recommended by the study. Researchers follow up weekly with patient to assess progress. Complete surveys at beginning and end.
61947691|NCT03428932|ACTIVE_COMPARATOR|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
61947692|NCT03428932|ACTIVE_COMPARATOR|Closed-Loop|Subjects will transition from their current treatment (insulin pump or injections) onto the Medtronic 670G insulin pump (intervention arm as a comparator) and will have close contact with the study team. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
61947693|NCT05253846|EXPERIMENTAL|SCRT--> FOLFOXIRI--> SURGERY|"SHORT-COURSE RT~FOLFOXIRI~* IRINOTECAN 165 mg/sqm iv over 60 minutes, day 1 followed by~* OXALIPLATIN 85 mg/sqm iv over 2 hours, day 1 in two-way with~* LEDERFOLIN 200 mg/sqm iv over 2 hours, day 1 followed by~* 5-FLUOROURACIL 3200 mg/sqm 48 h-continuous infusion, starting on day 1. The chemotherapy treatment will be repeated every 2 weeks up to 8 cycles.~Surgery with TME should be performed after 4 weeks after the last cycle of chemotherapy"
61947694|NCT06201364|EXPERIMENTAL|EOI group|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine 0.5% ,10ml saline) will be then injected, this procedure will be done bilaterally.
61947695|NCT06201364|ACTIVE_COMPARATOR|PVB group|we will be scanning the anatomy of the lateral paravertebral space using a high-frequency linear ultrasound transducer, after identification of the transverse process, internal intercostal membrane (IIM), and pleura at the T3 and T6 levels, an out-of-plane needle guidance technique would be used to perform the PVB with 20 ml volume (10 ml bupivacaine 0.5% ,10ml saline) will be then injected, this procedure will be done bilaterally.
61947696|NCT00404235|EXPERIMENTAL|paclitaxel + carboplatin|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.~After completion of study treatment, patients are followed periodically for up to 2 years."
62736508|NCT01071499|ACTIVE_COMPARATOR|3|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
61947697|NCT02793544|ACTIVE_COMPARATOR|Regimen A (RIC: Flu/Cy/TBI)|"1. Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~2. Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5~3. Total Body Irradiation (TBI) 200cGy on Day -1~4. Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
61947698|NCT02793544|ACTIVE_COMPARATOR|Regimen B 2a (FIC: Bu/Cy)|"1. Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~2. Cyclophosphamide 50mg/kg/day IV on Days -2,-1~3. Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
61947699|NCT02793544|ACTIVE_COMPARATOR|Regimen B 2b (FIC: Bu/Flu)|"1. Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~2. Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~3. Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
61947700|NCT02793544|ACTIVE_COMPARATOR|Regimen C (FIC: Cy/TBI)|"1. Cyclophosphamide 50mg/kg/day IV on Days -5,-4~2. Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1~3. Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
61947701|NCT05543967||Type 2 Diabetes Mellitus|These patients must have a definite diagnosis of type 2 diabetes mellitus (T2DM) according to the American Diabetes Association (ADA) standards. Some of these patients have symptoms of cognitive impairment, while others have normal cognition. All T2DM patients will undergo physical exam, cognitive and olfactory test as well as structural and brain functional MRI at baseline and follow-up time points.
61947702|NCT05543967||Healthy Control|These participants have normal glucose tolerance and normal cognition. All HC subjects will undergo physical exam, cognitive and olfactory test as well as structural and brain functional MRI at baseline and follow-up time points.
62341054|NCT02765178||Patients with Diabetes type 1|The primary caregiver will be asked to fill the Children's motivation Scale. Demographic data will also be collected for each study patient.
62341055|NCT03373552||non responder Group|"Platelet function assay:~High platelet reactivity: PRU\>208"
62341056|NCT03373552||responder Group|"Platelet function assay:~PRU\<208"
62341057|NCT05033548||Managed with AlloCare Monitoring|
62341058|NCT05033548||Managed with Standard of Care|
62341059|NCT04905199||Non-floating catheter|When using non-floating catheter.
62497758|NCT02377349|EXPERIMENTAL|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
62736509|NCT04407793||Diverticulitis Group|Patients with acute diverticulitis episode
62736510|NCT04407793||Diverticulosis group|Patients diagnosed with diverticulosis without any acute diverticulitis episode
62736511|NCT04407793||Non-diverticulosis|Patients without diverticulosis
62497759|NCT02377349|PLACEBO_COMPARATOR|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
62497760|NCT02190318|EXPERIMENTAL|Losartan|Losartan is taken orally 100mg/d
61947703|NCT01402765|ACTIVE_COMPARATOR|Group 1 (Summit first)|In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
61947704|NCT01402765|ACTIVE_COMPARATOR|Group 2 (Nimbus 3 first)|In Group 2 pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
61947705|NCT03459170|EXPERIMENTAL|BPX-501 T cells and rimiducid|"All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
61947706|NCT02198872|EXPERIMENTAL|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
61947707|NCT02198872|ACTIVE_COMPARATOR|Land Group|Patients of this group perform physical training on bicycle.
61947708|NCT02298530|EXPERIMENTAL|Combination of caffeine and theanine|250 mg caffeine + 200 mg theanine
61947709|NCT02298530|PLACEBO_COMPARATOR|Caffeine|250 mg caffeine
61947710|NCT02110238|ACTIVE_COMPARATOR|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
61947711|NCT02110238|EXPERIMENTAL|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
61947712|NCT06254651|EXPERIMENTAL|High resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
61947713|NCT06254651|ACTIVE_COMPARATOR|Low resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
61947714|NCT00821106|EXPERIMENTAL|Right transradial approach|Coronary diagnostic or interventional procedures performed through right radial approach
61947715|NCT00821106|EXPERIMENTAL|Left transradial approach|Diagnostic or interventional procedures performed through left radial approach
61947716|NCT04629807|ACTIVE_COMPARATOR|Demineralized Bone Matrix (DBM)|All enrolled subjects will undergo primary, contiguous 2-level ALIF without supplemental fixation. Study Implant (one-level) implanted with Demineralized Bone Matrix (DBM).
61947717|NCT04629807|ACTIVE_COMPARATOR|Cellular Bone Matrix (CBM)|All enrolled subjects will undergo primary, contiguous 2-level ALIF without supplemental fixation. Control Implant (one-level) implanted with Cellular Bone Matrix (CBM).
62497761|NCT02190318|EXPERIMENTAL|spirolactone|spirolactone is taken orally 20mg/d
62497762|NCT02190318|EXPERIMENTAL|losartan in combination with spirolactone|Losartan is taken orally 100mg/d and spirolactone is taken orally 20mg/d
61947718|NCT00831025|EXPERIMENTAL|1|Depigmented and polymerized allergen extract of Olea europaea pollen for subcutaneous injection.
61947719|NCT00831025|PLACEBO_COMPARATOR|2|Placebo for subcutaneous injection.
61947720|NCT06315959|ACTIVE_COMPARATOR|Group ESP|A bilateral ESP Block(60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
61947721|NCT06315959|OTHER|Group Control|IV morphine PCA
62497763|NCT02190318|SHAM_COMPARATOR|blank control|patients with antihypertensives besides ACEI/ARBs and spirolactone.
61947722|NCT03676192|EXPERIMENTAL|CT-P16|Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
61947723|NCT03676192|ACTIVE_COMPARATOR|Avastin|Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
61947724|NCT00553943|EXPERIMENTAL|Rituximab + Cytarabine|
61947725|NCT01442454||Chronic Pancreatitis|
61947726|NCT00386386|OTHER|1|Subject receives two infusions: One by EASI Access and one by IV access, at different sites
61947727|NCT02568774|EXPERIMENTAL|Traditional Acupuncture|Acupoints which are empirical for treating OAB in terms of Traditional Chinese medicine theory are used (in the sequence of scalp reproduction area and motor area of the unaffected side, RN3, bilateral BL32, BL33, BL28, BL39). And Ear point urinary bladder, and Ear point uterus will be treated after removal of needles. Needles will be left for 30 minutes and then removed. Subjects will be treated with acupuncture 2 times per week for the first 2 weeks and 1 per week for the 3rd and 4th week.
61947728|NCT02568774|OTHER|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
61947729|NCT05875701|EXPERIMENTAL|NVX CoV2373 (Ancestral strain)|1dose of NVX-COV2373 on Day 1
61947730|NCT05875701|EXPERIMENTAL|Updated COVID-19 Vaccine|1dose of updated COVID-19 vaccine on Day 1
61947731|NCT01590459|PLACEBO_COMPARATOR|Placebo Arm|
62497764|NCT04167696|EXPERIMENTAL|Dose Escalation Dose Level 1|"in case of no dose limiting toxicity (DLT) and no replacement of patients, 3 consecutive patients at the dose of 1x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
61947732|NCT01590459|EXPERIMENTAL|VX-509 100 mg qd Arm|
61947733|NCT01590459|EXPERIMENTAL|VX-509 150 mg qd Arm|
61947734|NCT01590459|EXPERIMENTAL|VX-509 100 mg bid Arm|
61947735|NCT01590459|EXPERIMENTAL|VX-509 200 mg qd Arm|
61947736|NCT04696055|EXPERIMENTAL|Regorafenib+Pembrolizumab|Participants with advanced hepatocellular carcinoma (HCC) progressed on 1L anti-PD-1/PD-L1 therapy.
62341060|NCT04905199||Floating catheter|When using floating catheter.
62736512|NCT03407469||Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
61947737|NCT01928173|ACTIVE_COMPARATOR|Abbreviated cognitive behavioral therapy|Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
61947738|NCT01928173|ACTIVE_COMPARATOR|Sleep education/sleep hygiene|Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).
61947739|NCT04057365|EXPERIMENTAL|DKN 01 and Nivolumab Safety Run in|"* DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle~* Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
62497765|NCT04167696|EXPERIMENTAL|Dose Escalation Dose Level 2|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 3x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
61947740|NCT04057365|EXPERIMENTAL|DKN 01 and Nivolumab|"* DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle~* Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
61947741|NCT02566447||Symptomatic|Subjects will be categorized by the clinician as symptomatic for Trichomonas vaginalis infection.
61947742|NCT00111501|EXPERIMENTAL|Targeted Internet Intervention|Web-based self help intervention developed to include specific cultural tailoring relevant to the LGBT community
61947743|NCT00111501|ACTIVE_COMPARATOR|Standard Intervention|Standard self-help internet-based intervention with no LGBT relevant information included
61947744|NCT04691271|EXPERIMENTAL|Intervention group|In addition to routine anesthesia management and surgical operations, a stellate ganglion block was performed before induction of anesthesia, and then receive standard care after operation. Related statistical indicators were collected prospectively.
62497766|NCT04167696|EXPERIMENTAL|Dose Escalation Dose Level 3|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 1x10e9 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
61947745|NCT04691271|NO_INTERVENTION|Blank control group|In this study, a blank control was used. Routine anesthesia management and surgical operation were used without any special interventions(only an camouflaging action), and then receive standard care after operation. Only relevant statistical indicators were collected prospectively.
61947746|NCT06203171||Group C|Patients with perioperative complications
61947747|NCT06203171||Group non-C|Patients with no perioperative complications
61947748|NCT05036590|ACTIVE_COMPARATOR|Control group|"The design is a stepped-wedge cluster randomized controlled trial. The study will be conducted in 9 centers (clusters) and will be conducted in 6 successive phases of 4 months each.~During the first period, groups will be in the control period, then sequentially and according to a randomly defined order, at each time, one group will go into the intervention period after a transition period of 4 months allowing the intervention to be deployed (training of three health professionals for each center and then implementation of the BREF program).~Thus, each cluster will belong successively to the control group and the intervention group. During the control period, caregivers will be supported according to the usual practices of each center. During the intervention period, the BREF program will be offered to all eligible caregivers."
62497767|NCT06334562|EXPERIMENTAL|Sugammadex Sodium group|The dose of Sugammadex Sodium is 2mg/kg
62497768|NCT06334562|ACTIVE_COMPARATOR|Neostigmine group|The dose of Neostigmine is 50 μg/kg
62497769|NCT03998592|EXPERIMENTAL|Low-dose vaccine|
62497770|NCT03998592|EXPERIMENTAL|Mid-dose vaccine|
62497771|NCT03998592|EXPERIMENTAL|High-dose vaccine|
62497772|NCT03998592|PLACEBO_COMPARATOR|Placebo|
61947749|NCT05036590|EXPERIMENTAL|intervention group|Thus, each cluster will belong successively to the control group and the intervention group. During the intervention period, the BREF program will be offered to all eligible caregivers.
61947750|NCT01202565||Adalimumab|Participants with moderate to severe plaque psoriasis received adalimumab (Humira®) therapy according to the local product label and prescription/reimbursement guidelines.
61947751|NCT01770496|NO_INTERVENTION|No reminder / recall notice|No childhood vaccination reminder / recall notification sent. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
61947752|NCT01770496|EXPERIMENTAL|mailed reminder / recall notice|Childhood vaccination reminder / recall notification sent by postal mail. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
62341061|NCT03754803||Treatment naïve subjects with HIV infection|Treatment naïve HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included
62341062|NCT03754803||Pre-treated subjects with HIV infection|Pre-treated HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included.
62497773|NCT01451996|OTHER|Claritin ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
62497774|NCT01451996|OTHER|Zyrtec ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
62497775|NCT05820789|EXPERIMENTAL|Experimental Group|When the patient comes intubated from the surgery to the cardiovascular surgery intensive care unit, when they meet the extubation criteria, the patients will be extubated by the healthcare professionals working in the intensive care unit in accordance with the service protocol.Patients in the experimental group will be provided with their relatives and support during weaning from the mechanical ventilator.
62497776|NCT05820789|NO_INTERVENTION|Control Group|Patient comes intubated from the surgery to the cardiovascular surgery intensive care unit, when they meet the extubation criteria, the patients will be extubated by the healthcare professionals working in the intensive care unit in accordance with the service protocol.
62736513|NCT04472481|OTHER|group II|50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) weekly for 3 months
62497777|NCT04943887|EXPERIMENTAL|PwMS eSupport Groups|12-weeks active treatment of eSupport Health's Weekly Group Sessions, a formal semi-structured program of psychoeducational support delivered in a small group format by licensed therapists who specialize in MS. The active treatment period will follow a 12-week waitlist period that will be used to enable a within-subject control design. Note that the very first group enrolled (N\~10) will not have a 12-week waitlist period but will instead enter directly into the 12-week treatment.
62497778|NCT04684511|EXPERIMENTAL|TRM-201 (Rofecoxib)|1 TRM-201 tablet taken orally once daily for 12 weeks in Part I and orally once daily for an additional 52 weeks in Part II
62497779|NCT04684511|PLACEBO_COMPARATOR|Placebo|1 placebo tablet (to match TRM-201) taken orally once daily for 12 weeks in Part I and then 1 TRM-201 tablet taken orally once daily for an additional 52 weeks in Part II
62497780|NCT02968550||Low shunt group|patients with shunt less than 30% in one-lung ventilation at ZEEP
61947753|NCT01932307|EXPERIMENTAL|PGY1 General Surgery Residents|All first year general surgery residents at the University of British Columbia
61947754|NCT01581710|ACTIVE_COMPARATOR|montelukast to placebo|14 days
61947755|NCT01581710|NO_INTERVENTION|Washout|14 days
61947756|NCT01581710|ACTIVE_COMPARATOR|Placebo to montelukast|14 days
61947757|NCT04478266|ACTIVE_COMPARATOR|Letrozole + Palbociclib|Participants received letrozole 2.5 milligrams (mg) capsule along with amcenestrant-matching placebo once daily, continuously and palbociclib 125 mg orally (PO), once daily (QD) from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death or study cut-off date, whichever comes first (maximum exposure: 112 weeks). Goserelin once every 4 weeks in pre/peri menopausal women and men.
61947758|NCT04478266|EXPERIMENTAL|Amcenestrant + Palbociclib|Participants received amcenestrant 200 mg tablet along with letrozole-matching placebo once daily, continuously and palbociclib 125 mg PO, QD from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death, or study cut-off date, whichever comes first (maximum exposure: 109 weeks). Goserelin once every 4 weeks in pre/peri menopausal women and men.
61947759|NCT03562910|EXPERIMENTAL|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
61947760|NCT03301805|EXPERIMENTAL|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
61947761|NCT01128842|EXPERIMENTAL|Neratinib + Capecitabine|Neratinib + Capecitabine
61947762|NCT06557096|EXPERIMENTAL|Sequential Treatment cohort|Participants receive osimertinib orally at a dose of 80mg daily for a 28-day treatment period. After the start of treatment, cerebrospinal fluid is collected every 12 weeks for circulating tumor cell (CTC) examination and routine cytopathological assessment. If the routine cytopathological test is positive, participants are sequentially treated with continued osimertinib at 80mg daily, in combination with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight, on the first day of each cycle, with medication given once every 3 weeks. A continuous treatment of 21 days constitutes one treatment cycle. After the initiation of treatment, cerebrospinal fluid is collected every 6 weeks for CTC testing and routine cytopathological examination.
61947763|NCT04521816|EXPERIMENTAL|Intervention--PACT Intensive Management|"The intervention is the PACT Intensive Management Program (PIM) provides a standardized menu of services, ranging from chart review assessment or in-home assessment, to a time limited intensive care management intervention. The following PIM features are standardized across the PIM demonstration sites:~A) Chart review assessment template in the EMR; B) Comprehensive assessment template of unmet needs and modifiable risk factors in EMR; C) Transitions in care process (eligibility criteria, clinical protocols); D) Diagnostic home visits process (eligibility criteria, clinical protocols); E) Core risk stratification/Triage process; F) Discharge criteria and note template in EMR; G) Standardized interdisciplinary team (IDT) meeting note procedure and template in EMR."
61947764|NCT04521816|NO_INTERVENTION|Usual care|High-Risk patients receiving care in PACT.
61947765|NCT06274320|EXPERIMENTAL|Group A: holistic approach|adult subjects having AK (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria including a Tolak® treatment planned before study start
61947766|NCT06274320|ACTIVE_COMPARATOR|Group B: Tolak® Standard of use|adult subjects having AK (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria including a Tolak® treatment planned before study start
62497781|NCT02968550||High shunt group|Patients with shunt equal or more than 30% in one-lung ventilation at ZEEP
62497782|NCT01436448|EXPERIMENTAL|Probiotics Lactobacillus Rhamnosus|dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
62497783|NCT01436448|NO_INTERVENTION|Placebo|Microcrystalline cellulose/d each, up till deliver
61947767|NCT04480008|EXPERIMENTAL|Resilient Living Program|All participants will be in the Resilient Living Program arm. Study participation involves participating in a 12-week stress management and resilience training program. This will involve four virtual sessions (video or phone) and answering questions about their health, well-being, and quality of life. There will also be online modules to watch and an accompanying journal (with prompts) to keep.
61947768|NCT04395404|EXPERIMENTAL|Single arm|
61947769|NCT02904889|EXPERIMENTAL|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
61947770|NCT02904889|ACTIVE_COMPARATOR|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
62497784|NCT04204590|OTHER|Participants|The aim of this study is to test the feasibility of this algorithm as an intervention to carry out deprescribing a targeted medication group, proton pump inhibitors (PPI's) and statins, among nursing home residents.
62497785|NCT03567460|EXPERIMENTAL|10,000 Steps/day for Pediatric Marfan Patients|Participants will be given a Garmin VivoFit and asked to take at least 10,000 steps per day. A study coordinator will reach out at least once per week to check in on progress made and help make weekly goals.
62736514|NCT05132179|ACTIVE_COMPARATOR|HOCl arm|Dakin´s Solution, with the active substance Hypochlorous Acid, HOCl was first invented 1915 for use on infected war wounds. The DFU will be cleaned with HOCl twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.
61947771|NCT03726307|EXPERIMENTAL|DCreg: 0.5 million cells/kg+SOC|"N=3 participants will receive 0.5 (± 0.1) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
62497786|NCT01142908|EXPERIMENTAL|Arm 1|The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
62497787|NCT01142908|NO_INTERVENTION|Arm 2|The education control group - these participants will receive educational material about CVD reduction.
62736515|NCT05132179|NO_INTERVENTION|PHMB arm|Prontosan, with the active substance PHMB, is recommended by 19 out of 21 regions in Sweden, for cleaning DFU. The DFU will be cleaned with PHMB twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.
62736516|NCT06658938|OTHER|Patients with B-ALL receiving allogeneic hematopoietic stem cell transplantation|
62140391|NCT02330588|EXPERIMENTAL|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
62140392|NCT02330588|EXPERIMENTAL|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
62140393|NCT02330588|PLACEBO_COMPARATOR|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
62140394|NCT01141075|EXPERIMENTAL|Ataluren|"Cycle 1: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 5 mg/kg (morning), 5 mg/kg (midday), and 10 mg/kg (evening); there will then be an interval of 21 up to 42 days without treatment.~Cycle 2: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening); there will then be an interval of 14 days without treatment."
62140395|NCT04773431|EXPERIMENTAL|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
62341063|NCT05425485|ACTIVE_COMPARATOR|EducAR strategy|"Healthcare personnel involved in the care of patients with RA in the selected centres will be provided with access to a website and instructed in its use in a videoconference. The website includes a training section for healthcare professionals and another for patients. The former includes explanatory videos on how to manage doctor-patient communication and to facilitate adherence and what not to do, tools to explain treatment options (shared decision aids) and links to key documents. The patient section includes information for patients (downloadable in leaflet format), medication calendars and disease diaries, videos explaining medication administration in RA and links to patient associations, among other tools.~Both access to the website and its materials and to the instruction session will be open to all those involved in the corresponding service, but will not be mandatory."
62341064|NCT05425485|NO_INTERVENTION|Standard of care|Physicians in the control group will not be instructed and will have no access to the materials included in the physician section of the webpage.
62341065|NCT00547638|EXPERIMENTAL|Dermabond Protape|DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
62341066|NCT00547638|ACTIVE_COMPARATOR|Dermabond HVD|DERMABOND HVD Topical Skin Adhesive
62341067|NCT00652067||1|Only one patient is being treated under a single patient IND.
62341068|NCT03667612||Patients with breast cancer|"* Patients clinical data collection~* Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres~* Realization of tumor samples series of cuts and paraffin shavings for:~  * Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~ * Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)~ * Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)~ * Characterization of lymphocyte populations~ * Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
62497788|NCT02473237|EXPERIMENTAL|indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once time on visit one, with dry powder inhaler device.
62140396|NCT00954668|EXPERIMENTAL|immediate angiography|Immediate invasive angiography \< 2 h after randomization
62140397|NCT00954668|ACTIVE_COMPARATOR|early invasive angiography|early invasive angiography 12-72 h after randomization
62497789|NCT02473237|ACTIVE_COMPARATOR|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once time a Day, with dry powder inhaler device.
62497790|NCT02443285|ACTIVE_COMPARATOR|Cefotaxime|cefotaxime 2gm every 12 hours daily for 5 days
62497791|NCT02443285|ACTIVE_COMPARATOR|Ceftriaxone|ceftriaxone 2 gm every 24 hours for 5 days.
62497792|NCT01833169|EXPERIMENTAL|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
62497793|NCT04438044|EXPERIMENTAL|ICP-022|150mg,QD
62497794|NCT06408402||Cases|Cases: SDHx mutation carriers diagnosed for a SDHx-related tumor
62497795|NCT06408402||Controls|Controls : SDHx mutation carriers with no SDHx-related tumor
62497796|NCT04199416|EXPERIMENTAL|mRehab app|Participants randomized to the intervention group will be given the mRehab app free of charge to perform self-management of their knees in their homes.
62736517|NCT01482806|EXPERIMENTAL|Computerized CBT + Internet Support Group|Guided patient access to Beating the Blues plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants (CCBT+ISG; N=300).
62497797|NCT04199416|SHAM_COMPARATOR|Sham app|Participants randomized to the control group will receive a sham app free of charge to perform self-management of their knees in their homes.
62698470|NCT03850067|EXPERIMENTAL|CC-90011 in combination with Cisplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
61947772|NCT03726307|EXPERIMENTAL|DCreg: 1.2 million cells/kg+SOC|"N=3 participants will receive 1.2 (± 0.2) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
61947773|NCT03726307|EXPERIMENTAL|DCreg:2.5 to 5.0 million cells/kg+SOC|"N=8 participants will receive 25 to 5.0 million cells /kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
61947774|NCT02431338|EXPERIMENTAL|Intervention group|Remote ischemic conditioning through intermittent arm ischemia with four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff performed in the ambulance during transport to primary percutaneous coronary intervention.
61947775|NCT02431338|NO_INTERVENTION|Control group|Standard treatment with primary percutaneous coronary intervention alone.
61947776|NCT00085709|EXPERIMENTAL|Post-consolidation GO|Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
61947777|NCT00085709|OTHER|Post-consolidation observation|Patients receive no additional therapy. Patients are observed at days 30 and 60 after randomization.
61947778|NCT00085709|ACTIVE_COMPARATOR|Induction 7+3|Standard induction regimen of 7 days of Ara-C (cytosine arabinoside) and 3 days of daunomycin
61947779|NCT00085709|ACTIVE_COMPARATOR|Induction 7+3+GO|Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C and 3 days of daunomycin
61947780|NCT03474861|EXPERIMENTAL|Combination therapy|The subjects will be given combination therapy which consists of an anticancer medication (A01) and immune cells (IC01).
61947781|NCT01259765|ACTIVE_COMPARATOR|VHH|"The active substance is VHH batch 203027."
61947782|NCT01259765|PLACEBO_COMPARATOR|Placebo|Placebo product
61947783|NCT02182739||Meloxicam|
62698471|NCT03850067|EXPERIMENTAL|CC-90011 in combination with Carboplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
62736518|NCT01482806|EXPERIMENTAL|Computerized CBT Alone|Guided patient access to Beating the Blues, a proven-effective, on-line 8-session CCBT program approved for use in the United Kingdom (CCBT-alone; N=300).
62736519|NCT01482806|NO_INTERVENTION|Usual Care|"Primary care physicians' usual care for mood and anxiety disorders (UC; N=100)."
61947784|NCT01987635|EXPERIMENTAL|MEMO 3D anuloplasty ring|MEMO 3D anuloplasty ring
61947785|NCT01987635|ACTIVE_COMPARATOR|rigid ring|rigid ring
61947786|NCT01821196|EXPERIMENTAL|biopsy|Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient.
61947787|NCT02418429|ACTIVE_COMPARATOR|waxy maize starch|pancake test meal - waxy maize starch
61947788|NCT02418429|ACTIVE_COMPARATOR|waxy maize starch and whey protein|pancake test meal - waxy maize starch and whey protein
61947789|NCT02418429|ACTIVE_COMPARATOR|resistant starch|pancake test meal - resistant starch
61947790|NCT02418429|ACTIVE_COMPARATOR|resistant starch and whey protein|pancake test meal - resistant starch and whey protein
62497798|NCT04970498||acute myelosuppression group|WBC \<4.0×10\^9 14 days after radiotherapy
61947791|NCT00935948|ACTIVE_COMPARATOR|Imescard ointment|
62497799|NCT04970498||chronic myelosuppression group|WBC \<4.0×10\^9 90 days after radiotherapy
62497800|NCT04970498||no myelosuppression group|WBC \>4.0×10\^9 during radiotherapy
62497801|NCT03366194|EXPERIMENTAL|Experimental|Each subject shall have a relatively homogenous section of the total scar divided into two relatively equal sides. One side shall be treated with SkinStylus Sterilock System and the other not treated. The side that is chosen for treatment remains constant. The side that is chosen is done so randomly and prior to meeting the subject via a coin flip randomization.
61947792|NCT00935948|PLACEBO_COMPARATOR|Placebo|
61947793|NCT05472753|EXPERIMENTAL|Group 1 (25 patients)|A product of the company DCOOP, with hydroxytyrosol extract
61947794|NCT05472753|EXPERIMENTAL|Group 2 (25 patients)|A product of the company Indukern, with extract of curcumin and selenium
61947795|NCT05472753|PLACEBO_COMPARATOR|Group 3 (25 patients)|Placebo
62698472|NCT03850067|EXPERIMENTAL|Nivolumab combination|"When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy.~A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each."
62698473|NCT05514288|OTHER|Endoscopic sleeve gastroplasty/Transoral outlet reduction|
62341069|NCT03667612||Patients with colorectal cancer|"* Patients clinical data collection~* Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments~* Realization of series of cuts and paraffin shavings of the tumor samples for:~  * Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~ * Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)~ * Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)~ * Characterization of lymphocyte populations~ * Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
62497802|NCT06667232|EXPERIMENTAL|Single-pulse stimulation|Single pulse electrical stimulation (SPES) is an investigational direct electrical stimulation (DES) pattern. Direct cortical stimulation applied at a frequency of ∼1Hz can probe cortico-cortical connections by averaging electrocorticogram time-lock to the stimuli.
62497803|NCT06667232|EXPERIMENTAL|Paired-pulse stimulation|Paired-pulse stimulation paradigm associates a conditioning and a test stimulation to induce intracortical inhibition or facilitation by modifying the response amplitude.
62497804|NCT06667232|EXPERIMENTAL|Stepwise frequency stimulation|Stepwise frequency stimulation is a DES protocol that incrementally increases the stimulation frequency, starting from a lower to higher.
62497805|NCT06667232|EXPERIMENTAL|Burst stimulation|"Burst stimulation is a DES patterned repetitive stimulation method; it represents a more precise and smarter electrical stimulation paradigm. Within a group, high-frequency pulses are emitted, and between groups, low-frequency pulses are delivered. This pattern of pulse delivery more closely mimics the physiological activity of neurons within the brain."
62497806|NCT03700398|EXPERIMENTAL|first OE|
62497807|NCT03700398|OTHER|First WLI|
62698474|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
62698475|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
62341070|NCT04350190|EXPERIMENTAL|Apatinib combined with PD-1|Eligible patients begin to use apatinib mesylate tablets and PD-1, apatinib mesylate tablets at the recommended dose of 250mg,oral, QD, continuous administration, 4 weeks (28 days) as an observation cycle. Until the disease progressed or unbearable adverse reactions appeared. If missed medication occurs during the medication period, it is confirmed that the next medication time is less than 12 hours, then there will be no replenishment. The recommended dose of PD-1 is 200mg/time, Q2W, intravenous injection, 4 weeks (28 days) as an observation cycle, until disease progression or intolerable toxicity.
62698476|NCT00363298|EXPERIMENTAL|d-amphetamine|dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
62698477|NCT00363298|SHAM_COMPARATOR|Sham comparison|caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
62698478|NCT04998513|ACTIVE_COMPARATOR|Medical Management Alone Arm|Antibiotics, steroids, fluids
62698479|NCT04998513|ACTIVE_COMPARATOR|Surgical Arm|Incision and drainage
61947796|NCT01672008|EXPERIMENTAL|NOX-100/Placebo|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
61947797|NCT01672008|EXPERIMENTAL|Placebo/NOX-100|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
61947798|NCT03628794|OTHER|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
62341071|NCT02143193|EXPERIMENTAL|Skin to Skin Contact|implement mother-baby Skin-to-Skin contact immediately after vaginal birth
62341072|NCT02143193|NO_INTERVENTION|Standard of Care|standard care for newborn and mother immediately after vaginal birth
62497808|NCT01952691|EXPERIMENTAL|kinesiotaping|all patients were implemented a kinesiotaping to align the hallux to correct position
62497809|NCT06021106|EXPERIMENTAL|Experimental group|Breathing exercises were applied to the experimental group with virtual reality glasses. Each application consists of 20 minutes. The exercises were performed 3 days a week for eight weeks, a total of 24 sessions.
62698480|NCT01073293|EXPERIMENTAL|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
62736520|NCT02952313|OTHER|Latera Implant|All participants have unilateral or bilateral placement of LATERA Nasal Implants.
61947799|NCT03628794|OTHER|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
61947800|NCT02504684|ACTIVE_COMPARATOR|1470-nm|Endovenous 1470-nm diode laser
61947801|NCT02504684|EXPERIMENTAL|1920-nm Group|Endovenous 1920-nm diode laser
61947802|NCT02646514|EXPERIMENTAL|RFA with RF catheter (ELRA®) with stenting|
61947803|NCT02646514|ACTIVE_COMPARATOR|stenting|
61947804|NCT05436093|EXPERIMENTAL|68Ga-ACN376|Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-ACN376 PET/CT scan.
61947805|NCT04763356|NO_INTERVENTION|Usual Care (UC)|The UC group (control) models the current standard of care model. The NTSS-6 will be completed daily by participants using the SCH system. The results will not be reported to their oncology team. Participants will be counseled at study entry to contact their treating care team to manage CIPN symptoms. They will also receive a reminder to do so at the end of each reporting session. UC participants will attend all regular visits with these providers and can receive any type of treatment for their CIPN symptoms. There are no limitations on the therapies that can be prescribed, or the means by which the clinical team communicates with the participant. Treating physicians will be provided with links to the current ASCP and NCCN guidelines but will not be provided with the algorithm as this group is meant to reflect current standard medical practice.
61947806|NCT04763356|EXPERIMENTAL|SCH with NP follow-up (SCH-NP)|Participants will report daily symptom as above. The SCH system will notify the study NP for any of the following symptoms measured by the NTSS6: aching, allodynia, burning, lancinating, numbness, and prickling that are concerning. Participants will receive a NP call back either the same day or the next day, depending on the time they reported their symptoms. The NP will follow a standardized script to elicit details about the CIPN symptoms and recommend and prescribe CIPN treatment per the treatment algorithm.
61947807|NCT05607615|EXPERIMENTAL|Experimental|Intravenous administration over at least 4 hours by IV infusion Trappsol Cyclo either 500 mg/kg or 1000 mg/kg every 4 weeks
61947808|NCT05607615|PLACEBO_COMPARATOR|Placebo|Intravenous administration of 0.5N saline over at least 4 hours every 4 weeks
61947809|NCT03151343|EXPERIMENTAL|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
61947810|NCT03151343|PLACEBO_COMPARATOR|Placebo|Placebo, coated tablets, once daily, for 13 weeks
61947811|NCT02272075|ACTIVE_COMPARATOR|active colposcope|Mobile OCT M3 scope
62698481|NCT01073293|EXPERIMENTAL|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
61947812|NCT02272075|NO_INTERVENTION|Standard of Care|Standard of Care
61947813|NCT01315964|ACTIVE_COMPARATOR|plant stanol ester|3 grams of plant stanol esters per day in a margarine product as part of daily diet for 6 months
61947814|NCT01315964|PLACEBO_COMPARATOR|Placebo|a margarine product as part of daily diet, which is not containing plant stanol esters
61947815|NCT01522248|ACTIVE_COMPARATOR|Cohort 1|receives vaccine in morning. Blood drawn at 3, 7, 24, and 48 hours and 14 days after vaccination.
61947816|NCT01522248|ACTIVE_COMPARATOR|Cohort 2|receives vaccine in evening, Blood drawn 16, 40 hours and 14 days after vaccination.
61947817|NCT05383521|EXPERIMENTAL|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
61947818|NCT05383521|EXPERIMENTAL|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
61947819|NCT01126970|PLACEBO_COMPARATOR|Placebos.|Velneperit Placebo q.d.+ Orlistat Placebo t.i.d.
61947820|NCT01126970|EXPERIMENTAL|Velneperit 400 mg|Velneperit 400 mg q.d.
61947821|NCT01126970|ACTIVE_COMPARATOR|Orlistat 120 mg|Orlistat 120 mg t.i.d.
61947822|NCT01126970|EXPERIMENTAL|Velneperit 400 mg + Orlistat 120 mg|Velneperit 400 mg q.d.and Orlistat 120 mg t.i.d
61947823|NCT04948528||Case group:|All suspected upper tract urothelial carcinoma participants will be assigned to case group.
61947824|NCT04948528||Control group|All suspected upper tract urothelial benign participants such as ureteral/renal calculi, ureteral stricture, upper urinary tract polyps, pyelonephritis, urinary tuberculosis will be assigned to control group.
61947825|NCT01827514||People with diagnosed cancer|People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
61947826|NCT01589978|EXPERIMENTAL|PROMUS Element|Subjects who receive the PROMUS Element everolimus-eluting coronary stent
62140398|NCT05407272|EXPERIMENTAL|Shared mode intervention group (experimental group)|Methods of collecting cases The subjects whose identity card numbers last in odd numbers are in the experimental group and even numbers are in the control group. They are randomly divided into two groups - the shared mode intervention group (experimental group) and the home care routine care group (control group). The experimental group was given a weekly sharing mode intervention for six weeks, 20-60 minutes per week; the control group was given the home health education manual in the third week.
62140399|NCT05407272|ACTIVE_COMPARATOR|home care routine care group (control group)|Methods of collecting cases The subjects whose identity card numbers last in odd numbers are in the experimental group and even numbers are in the control group. They are randomly divided into two groups - the shared mode intervention group (experimental group) and the home care routine care group (control group). The experimental group was given a weekly sharing mode intervention for six weeks, 20-60 minutes per week; the control group was given the home health education manual in the third week.
61947827|NCT01773252|EXPERIMENTAL|TEE|Within patient comparison of TEE, FDS and a TCD from select study sites
61947828|NCT05058820|EXPERIMENTAL|Post Facilitation stretch|Hot pack, TENS, Post Facilitation stretch, Deep friction massage
61947829|NCT05058820|ACTIVE_COMPARATOR|Active Isolated Stretching|Hot pack, TENS, Active Isolated Stretching, Deep friction massage
61947830|NCT01192659||Patients treated with saxagliptin or placebo|Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
61947831|NCT01192659||Patients currently or previously on treatment|Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.
62140400|NCT05095974||A (main group)|29 Consecutive patients with a singleton pregnancy complicated by severe PE will be included in the study at hospital admission. Assessment will be done by lung ultrasound , echocardiography and thoracic bioimpedence device
62698482|NCT06569979||1|Academicians who continued to teach amputee rehabilitation in different higher education institutions in Turkey were included in the study.
62736521|NCT01091714|ACTIVE_COMPARATOR|PRN Dry Eye Omega Benefits|4 capsules per day = 2240 mg Omega-3s
62736522|NCT01091714|ACTIVE_COMPARATOR|Nature's Made|2 capsules per day = 2400mg Omega-3s
61947832|NCT02433457|EXPERIMENTAL|CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)
62140401|NCT05095974||B (control group)|29 Consecutive healthy patients with a singleton pregnancy (control group) will be included in the study at hospital admission. Assessment will be done by lung ultrasound , echocardiography and thoracic bioimpedence device
62140402|NCT00694889|ACTIVE_COMPARATOR|1|Participants will use commercially available computer games.
62341073|NCT04054843||Gestational diabetes mellitus|First trimester pregnancies with gestational diabetes mellitus
62341074|NCT04054843||Control|First trimester healthy pregnancies
62341075|NCT06186635|EXPERIMENTAL|Traditional yoga group|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
62341076|NCT06186635|EXPERIMENTAL|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
62497810|NCT06021106|ACTIVE_COMPARATOR|Control group|In the control group, routine treatment and care continued and no additional intervention was made.
62497811|NCT03234608|EXPERIMENTAL|AASPIRE Healthcare Toolkit|Patients will use the AASPIRE Healthcare Toolkit and will share a copy of their Autism Healthcare Accommodations Report with their primary care provider.
62497812|NCT03234608|NO_INTERVENTION|Usual Care|Patients will receive usual care.
62497813|NCT03973788|EXPERIMENTAL|Intervention|repetitive transcranial magnetic stimulation
62497814|NCT06613334|EXPERIMENTAL|Schizophrenic patients treated with a primary treatment|"Study's interventions:~* 4 blood tests (inclusion visit, at follow-up visits at 2 and 4 months after inclusion, at the end-of-study visit at 6 months after inclusion) to measure the blood concentration of antipsychotic treatment (risperidone or paliperidone)~* completion of self-questionnaires and voice interviews of the application developed by CALLYOPE"
62497815|NCT01109849|ACTIVE_COMPARATOR|weight recovery treatment- monitoring|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the monitoring arm , participants will continue on their ER stimulant 7 days a week and have their weight, height and BMI checked monthly.
62698483|NCT04037215|OTHER|COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|In order to explore the cognitive treatment of patients with early onset anorexia nervosa in front of images of silhouettes and food, it is currently used in the child psychiatry department of the Robert Debré Hospital, the eye-tracking method. Eye tracking is a non-invasive and painless method of recording the path of vision on images presented on a computer screen. In order to understand the specificities of the eye path in sick patients, we will compare the data with those of controls without eating disorders.
62698484|NCT02587455|EXPERIMENTAL|Low Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
62140403|NCT00694889|EXPERIMENTAL|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
62140404|NCT00694889|ACTIVE_COMPARATOR|3|Healthy participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
62140405|NCT05758506||Pediatric PID patients (prospective)|Prospective, age-matched, healthy patients
62140406|NCT05758506||Pediatric PID patients (recontacted from registry)|
61947833|NCT02433457|EXPERIMENTAL|CC-292 SDD 300mg - Fed Condition|Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)
62140407|NCT05758506||Prospective, age-matched, healthy patients|
62140408|NCT05561231|ACTIVE_COMPARATOR|Group C|Group of patients intubated with C blade of CMAC videolaryngoscopes
62140409|NCT05561231|ACTIVE_COMPARATOR|Group D|Group of patients intubated with D blade of CMAC videolaryngoscope
62140410|NCT00223444||1|Genotype group Pro/Pro
62497816|NCT01109849|ACTIVE_COMPARATOR|behavior therapy|10 week basic parent training, advanced 8 week parent training course. monthly boosters, option for individual parent training sessions, school consultant assigned to each subject
61947834|NCT02433457|EXPERIMENTAL|375mg P22 - Fasted condition|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)
61947835|NCT02433457|EXPERIMENTAL|375mg P22 Fed Condition|Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)
61947836|NCT02433457|EXPERIMENTAL|CC-292 SDD 100 mg Fasted Condition|Single oral dose of 100 mg CC-292 SDD under fasted conditions
62140411|NCT00223444||2|Genotype group Pro/Ser
62140412|NCT02199626|EXPERIMENTAL|CCE-2|Second generation of Colon capsule endoscopy in pediatric Crohn's disease
62140413|NCT05909670|EXPERIMENTAL|Phase 1 intervention|Families will receive text and telephone support for child behavior and parenting stress issues.
62140414|NCT00345046|ACTIVE_COMPARATOR|Pred Forte 1%|Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
62140415|NCT00345046|ACTIVE_COMPARATOR|EconoPred Plus 1%|EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
62140416|NCT00345046|ACTIVE_COMPARATOR|Prednisolone Acetate 1%|Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
62140417|NCT05795088|EXPERIMENTAL|Patients with parkinson's disease|
62341077|NCT04922749|NO_INTERVENTION|TAU|Treatment as usual (TAU); consist mainly of pharmacological treatment and psychotherapy.
62341078|NCT04922749|EXPERIMENTAL|MULTI+|Lifestyle treatment
62341079|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
62341080|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
62341081|NCT05779579|EXPERIMENTAL|HS-10517 Dose 1|Dose level 1 of HS-10517 Tablets，Dose 1
62341082|NCT05779579|EXPERIMENTAL|HS-10517 Dose 2|Dose level 1 of HS-10517 Tablets，Dose 2
62341083|NCT05779579|EXPERIMENTAL|HS-10517 Dose 3|Dose level 1 of HS-10517 Tablets，Dose 3
62341084|NCT05779579|EXPERIMENTAL|HS-10517 Dose 4|Dose level 1 of HS-10517 Tablets，Dose 4
62341085|NCT05779579|EXPERIMENTAL|Placebo Comparator|Dose level A of placebo
62497817|NCT01109849|EXPERIMENTAL|ER stimulant|daily use of 12 hour extended release methylphenidate product
62698485|NCT02587455|EXPERIMENTAL|High Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
62698486|NCT05504434|EXPERIMENTAL|Adults patients treated with single use gastroscope|Patients will be treated with a single-use gastroscope instead of a reusable gastroscope. The procedure will be performed as normal, no additional actions will be performed.
62698487|NCT03242434|OTHER|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
61947837|NCT02433457|EXPERIMENTAL|SDD plus OMP (Oral Omeprazole)|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg
61947838|NCT02433457|EXPERIMENTAL|P22 plus OMP|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP
61947839|NCT04716907||Case : COVID-19 positive patients|patients hospitalized for COVID-19 infection
61947840|NCT04716907||Control : COVID-19 negative patients|patients hospitalized for other reasons
61947841|NCT00679666|SHAM_COMPARATOR|Sham treatment|Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit.
61947842|NCT00679666|ACTIVE_COMPARATOR|Treatment Arm|After randomization, the active arm will have the collagen crosslinking intervention.
61947843|NCT02663908|EXPERIMENTAL|Degarelix|
61947844|NCT02663908|ACTIVE_COMPARATOR|Leuprolide|
61947845|NCT05728021|EXPERIMENTAL|Recovery Record Aftercare|Intervention group (IG)
61947846|NCT05728021|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Control group (CG)
61947847|NCT04862455|EXPERIMENTAL|Treatment (NBTXR3, RT, pembrolizumab)|Patients receive hafnium oxide-containing nanoparticles NBTXR3 via injection intratumorally or intranodally on day 1. Beginning as early as day 3 and within 8 days of NBTXR3 injection, patients undergo SBRT QOD or hypofractionated RT QD over 1-2 weeks at the discretion of the treating radiation oncologist. Starting on the same day as radiation therapy, patients also receive pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
61947848|NCT00713856|ACTIVE_COMPARATOR|1|
61947849|NCT00713856|ACTIVE_COMPARATOR|2|
61947850|NCT04118504|EXPERIMENTAL|Intervention group|Lifestyle intervention on through mobile application
61947851|NCT04118504|NO_INTERVENTION|Control group|Usual care
61947852|NCT03713892|EXPERIMENTAL|CKD-504|investigational Drug
61947853|NCT03713892|PLACEBO_COMPARATOR|Placebo|investigational Drug
61947854|NCT01893203|OTHER|BF-200 ALA vs MAL|BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design
62140418|NCT06415994||Pregnant Mothers with Opioid Use Disorder|150 pregnant mothers with opioid use disorder who are on buprenorphine or methadone treatment
61947855|NCT05943028|EXPERIMENTAL|Control group|The preset EEG value of 36 in closed-loop target-controlled infusion is the baseline value of EEG closed-loop feedback guidance (obtained by the team's previous research results)
61947856|NCT05943028|EXPERIMENTAL|Experimental group|Due to the action of esketamine in closed-loop target-controlled infusion, the EEG preset value of 36+N is the baseline value of the new EEG closed-loop feedback guidance (pre-experiment and literature data, N value is 6-8)
62140419|NCT06415994||Pregnant Mothers|100 pregnant mother who to not have a history of opioid use disorder
62140420|NCT04040296|NO_INTERVENTION|Usual Care|Kidney Action Team Recommendations will not be delivered to the primary care teams of randomized patients.
62698488|NCT03242434|OTHER|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
62698489|NCT00725855|EXPERIMENTAL|1|1 mg dose
62698490|NCT00725855|EXPERIMENTAL|2|5 mg dose
61947857|NCT06257628||Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
61947858|NCT01719978|ACTIVE_COMPARATOR|Hyaluronidase|Lower Third Molar Extraction -- 3.6mL 2% Mepivacaine with 1:100,000 epinephrine + Hyaluronidase
61947859|NCT01719978|PLACEBO_COMPARATOR|Placebo|Lower Third Molar Extraction -- Anesthetic: 3.6 mL of the LA 2% HCl mepivacaine with 1:100,000 epinephrine + Placebo (0.9% saline)
61947860|NCT00866788|EXPERIMENTAL|Omalizumab 75 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
61947861|NCT00866788|EXPERIMENTAL|Omalizumab 300 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
61947862|NCT00866788|EXPERIMENTAL|Omalizumab 600 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
61947863|NCT00866788|PLACEBO_COMPARATOR|Placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
61947864|NCT04775069|ACTIVE_COMPARATOR|mRNA Group|The subjects will be vaccinated with the mRNA vaccine (Pfizer-Biontech).
61947865|NCT04775069|ACTIVE_COMPARATOR|Inactivated Virus Group|The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).
62140421|NCT04040296|EXPERIMENTAL|Kidney Action Team Recommendations|Recommendations made by the Kidney Action Team will be delivered to the patient's primary care team within 30 minutes of AKI development.
62698491|NCT00725855|EXPERIMENTAL|3|15 mg dose
62698492|NCT00725855|EXPERIMENTAL|4|50 mg dose
62698493|NCT00725855|PLACEBO_COMPARATOR|5|Placebo dose
62736523|NCT01091714|ACTIVE_COMPARATOR|Thera Tears|4 capsules per day = 2332mg Omega-3s
62497818|NCT01109849|EXPERIMENTAL|weight recovery treatment- caloric supplement|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the caloric supplement arm, participants will continue on their ER stimulant 7 days a week, have their weight, height and BMI checked monthly and be prescribed a 150 kcal caloric supplement to be consumed every evening.
62497819|NCT01109849|EXPERIMENTAL|weight recovery treatment- drug holiday|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the drug holiday arm, participants will only take their ER stimulant on school days a week and have their weight, height and BMI checked monthly.
62497820|NCT01118234|EXPERIMENTAL|Rituximab|Treatment with Rituximab 375 mg/m² every 3 months for 24 months
61947866|NCT04775069|ACTIVE_COMPARATOR|Adenovirus-vector Group|The subjects will be vaccinated with adenovirus-vector COVID-19 vaccine (Astrazeneca-Oxford).
61947867|NCT03572244|EXPERIMENTAL|Laser-Lok|A Laser-Lok microgrooved implant will be placed.
62140422|NCT05990933|EXPERIMENTAL|People with type 1 diabetes|The participants with type 1 diabetes will receive an intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour.
62140423|NCT05990933|ACTIVE_COMPARATOR|Healthy individuals|The participants without type 1 diabetes will receive an intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour.
61947868|NCT03572244|ACTIVE_COMPARATOR|Machine|A machined implant will be placed.
61947869|NCT04488796|EXPERIMENTAL|Assigned Strategies: Opt-in|"Participants in this group will be assigned two behavioural strategies under the theme of moving more and will be asked to Place a check in the box \[agree\] if you will breakup your sitting throughout your work hours by X this week. The strategy statement is followed up by; OR, click the next button at the bottom. Within the opt-in condition, the default is to not participate (by clicking next): participants are not required to explicitly state they do not want to do the strategy"
61947870|NCT04488796|EXPERIMENTAL|Assigned Strategies; Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Active choice condition, participants will be required to either, Place a check in one box: I will break up my sitting throughout my work hours by \[strategy\] this week or, I will not break up my sitting throughout my work hours by \[strategy\] this week."
62140424|NCT02776982|OTHER|Research procedures|Participants enrolled in study will have confocal endomicroscopy, research biopsies, mucosal impedance, and Bravo ambulatory pH capsule performed at the time of clinically indicated endoscopy.
62140425|NCT06698640|NO_INTERVENTION|Control|Participants will receive traditional passive outreach, which includes standard reminders and communications that do not utilize automated technologies.
62341086|NCT05189158|OTHER|HVS-|subjects with no complaint AND a Nijmegen questionnaire score of \< 23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS-)
62341087|NCT05189158|OTHER|HVS+|subjects with complaints AND a Nijmegen questionnaire score of ≥23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS+)
62341088|NCT01426399|EXPERIMENTAL|LC15-0444|LC15-0444 50mg qd
62341089|NCT01426399|EXPERIMENTAL|Metformin|Metformin 1000mg bid
62341090|NCT01426399|EXPERIMENTAL|LC15-0444+Metformin|LC15-0444 50mg qd +Metformin 1000mg bid
62341091|NCT01475864||Incomplete biliary stone extraction.|
62497821|NCT01118234|NO_INTERVENTION|Observation|Observation for 24 months
62497822|NCT00198536|EXPERIMENTAL|Ecabet 2.83%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
62497823|NCT00198536|EXPERIMENTAL|Ecabet 3.70%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
62497824|NCT00198536|PLACEBO_COMPARATOR|Vehicle|One drop of vehicle in study eye 4 times daily for 90 days.
61947871|NCT04488796|EXPERIMENTAL|Assigned Strategies; Enhanced Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Enhanced Active Choice condition, participants will to required to choose between two alternatives: I will break up my sitting throughout my work hours this week by \[strategy\] to reduce my risk of diabetes, mental health issues and other detrimental health outcomes and I want to win the eGiftcard or, I will not break up my sitting time during my work hours by \[strategy\] this week even if it means I increase my risk of developing diabetes, mental health issues and other detrimental health outcomes and I don't care about winning an eGiftcard"
62140426|NCT06698640|ACTIVE_COMPARATOR|Automated SMS|Participants will receive automated SMS messages reminding them of their Well-Child Visits. These messages will be standardized and sent at intervals designed to prompt appointment attendance.
62140427|NCT06698640|ACTIVE_COMPARATOR|Automated SMS + Scheduling Assistance|Participants will receive the same automated SMS messages as in Arm 2, but with the added component of proactive appointment scheduling assistance. This may include options for scheduling directly through the SMS platform or follow-up messages encouraging appointment setting.
62341092|NCT04049071||Case|Cases are patients that are prescribed tocilizumab as escalation therapy for relapsing/refractory GCA
62341093|NCT04049071||Control|Controls are those that are prescribed an alternative escalation therapy (not tocilizumab) for relapsing/refractory GCA.
62341094|NCT02317536|EXPERIMENTAL|Carnipure Product 1|Carnitine-based product 1, subjects will take one dose once daily for 56 days.
62497825|NCT02000115|EXPERIMENTAL|Randomized IDE Cohort, Portico Valve|"Portico transcatheter aortic valve and Portico delivery system.~Status: ACTIVE, NOT ENROLLING."
62497826|NCT02000115|ACTIVE_COMPARATOR|Randomized IDE Cohort, CAV|"Any FDA approved, commercially-available transcatheter aortic valve (CAV).~Status: ACTIVE, NOT ENROLLING."
62140428|NCT02250937|EXPERIMENTAL|Arm I (busulfan days -13 and -12 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
62341095|NCT02317536|EXPERIMENTAL|Carnipure Product 2|Carnitine-based product 2, subjects will take one dose once daily for 56 days.
62497827|NCT02000115|EXPERIMENTAL|Nested Valve-in-Valve Registry|"Subjects who have documented failed aortic surgical valve prosthesis and are deemed eligible to receive a transcatheter Portico valve~Status: ACTIVE, ENROLLING."
62497828|NCT02000115|EXPERIMENTAL|FlexNav Delivery System Study|"Portico transcatheter aortic valve and FlexNav delivery system~Status: ACTIVE, NOT ENROLLING"
62140429|NCT02250937|EXPERIMENTAL|Arm II (busulfan days -20 and -13 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
62140430|NCT06270862|EXPERIMENTAL|Active aging with resilience (AR)|"In the active aging with resilience (AR) condition, participants will complete physical, cognitive, and social engagement training modules, starting with a 15-min resilience-building module."
62140431|NCT06270862|ACTIVE_COMPARATOR|Active aging without resilience (AA)|"The traditional active aging (AA) training involves the same multi-domain active aging training without the initial resilience-building module, which will be replaced by watching 15 minutes of educational video on topics such as health, nature or travel."
62140432|NCT06270862|PLACEBO_COMPARATOR|Workshop training (WT)|"The workshop training (WT) control condition involves workshops following the same 4-week schedule on aging-related topics."
62698494|NCT03248752|ACTIVE_COMPARATOR|Group 1 - Self monitored|Fitbit use and reports details: Participants will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device and receive a Weekly Progress Report from Fitbit.
61947872|NCT04488796|EXPERIMENTAL|Choice of Assignment; Opt-in|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
62698495|NCT03248752|EXPERIMENTAL|Group 2 - Partner monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device. Participant will also engage with their partner through the Fitbit application. They will have access to their partner's daily progress and be able to communicate through the application. They will also receive their partner's Weekly Fitbit Reports and have a weekly discussion about the Weekly Fitbit Report.
62698496|NCT06564103||adjuvant FOLFOX plus lenvatinib therapy group|
61947873|NCT04488796|EXPERIMENTAL|Choice of Assignment; Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
61947874|NCT04488796|EXPERIMENTAL|Choice of Assignment; Enhanced Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
61947875|NCT02167425||Late Post-IMAT Cohort|Enrollment into the Late Post-IMAT Cohort will occur over a 9-month period in beginning in the second year of the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
61947876|NCT02167425||Early Post-IMAT Cohort|Enrollment into the Early Post-IMAT Cohort will occur over a 9-month period immediately following the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
61947877|NCT02167425||Late Pre-IMAT Cohort|Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
61947878|NCT02167425||Early Pre-IMAT Cohort|Enrollment into the Early Pre-IMAT Cohort will begin two years prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
61947879|NCT01163331|EXPERIMENTAL|Singing Therapy Group|Singing Therapy Group
61947880|NCT00167648|ACTIVE_COMPARATOR|A|Leuprolide 7.5 mg or Goserelin 3.6 mg
61947881|NCT00167648|EXPERIMENTAL|B|Transdermal estradiol 0.6 mg q 3 days
61947882|NCT00813020|EXPERIMENTAL|A|
61947883|NCT00813020|EXPERIMENTAL|B|
61947884|NCT00813020|EXPERIMENTAL|C|
62140433|NCT05995262||HbA1c|Minimum of one HbA1c reading within 90 days prior to first visit AND one HgbA1c reading within 90 days after the last clinic encounter
62140434|NCT06699862|NO_INTERVENTION|Control Group|During the 10-week intervention period, the control group will continue their regular physical education (PE) classes, taught by the schools' PE teachers following the standard curriculum.
62140435|NCT06699862|EXPERIMENTAL|Experimental condition 1: HIIT without competition (HIIT)|In the experimental group, Burn 2 Learn - Mallorca (B2L-M) HIIT sessions will be incorporated into regular PE classes twice a week, delivered by the schools' PE teachers. Each session will last 8-10 minutes at the start of class and include a brief warm-up with a mix of aerobic and bodyweight muscle-strengthening exercises. The sessions are designed to be both vigorous and enjoyable to maximize student engagement.
62698497|NCT06564103||non-adjuvant therapy group|
62698498|NCT06630767|EXPERIMENTAL|ERAS-LCBDE|Patients subjected to enhanced recovery after surgery care for laparoscopic common bile duct exploration
62698499|NCT06630767|ACTIVE_COMPARATOR|C-LCBDE|Patients subjected to conventional care for laparoscopic common bile duct exploration
61947885|NCT03429660||Cohort|"Data to be collected are :~- Medical information on Immune Thrombocytopenia treatment"
61947886|NCT01757522||ARDS group|Patients under mechanical ventilation since less than 24 hours at inclusion and presenting acute respiratory distress syndrome criteria.
61947887|NCT01757522||ALI group|Patients under mechanical ventilation and presenting acute lung injury criteria.
61947888|NCT01757522||Control Group|Patients under mechanical ventilation for a non-respiratory cause
62698500|NCT01833078|OTHER|7 day ghrelin dosing - all participants|All participants will receive an injection of ghrelin (7.5mcg/kg) dose subcutaneously once daily on Days 1, 2 and 7 in the research center and will self-administer the subcutaneous injection before breakfast on Days 2-6 at home.
62341096|NCT02317536|PLACEBO_COMPARATOR|Placebo|Placebo, subjects will take one dose once daily for 56 days.
61947889|NCT02051842|EXPERIMENTAL|Metadoxine|Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
61947890|NCT02051842|PLACEBO_COMPARATOR|Placebo tablet|Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
62341097|NCT05398419|EXPERIMENTAL|Music group|The participants will listen to music at bedtime and overnight for 7 consecutive nights. The music selected in our study will be pleasant instrumental slow tempo music in a major mode. It will also be low contrast (without periods of silence).
61947891|NCT05118243|ACTIVE_COMPARATOR|Control cracker|All participants eat control crackers, which contain high amounts of GOS (approx. 5g GOS/daily portion of crackers)
61947892|NCT05118243|ACTIVE_COMPARATOR|Enzyme-treated cracker|All participants eat enzyme-treated crackers, which contain minimal amounts of GOS (less than 1g GOS/daily portion of crackers)
61947893|NCT01020981||Group 1|Michigan State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
62341098|NCT05398419|ACTIVE_COMPARATOR|Non-musical sounds group|The participants will listen to non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be low-contrast nature sounds such as waves or rain. The investigators plan to use non-musical sounds that align with the frequency range of the musical stimuli.
62341099|NCT05398419|NO_INTERVENTION|Standard of care (Control)|The participants will have no change to their usual sleep routine on the Geriatric Assessment Unit.
62698501|NCT06637306|EXPERIMENTAL|Patients with locally advanced TNBC|Patients with advanced triple negative breast cancer (TNBC).
62698502|NCT00246103|EXPERIMENTAL|Dose Escalation and Possible Expansion|Escalating doses of Valproic acid and one dose escalation step of epirubicin. Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
62698503|NCT05072379|EXPERIMENTAL|Mobile health app group|routine care and mobile health app
62698504|NCT05072379|NO_INTERVENTION|control group|routine care
62698505|NCT00889330|EXPERIMENTAL|alcaftadine ophthalmic solution|active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
62698506|NCT00889330|PLACEBO_COMPARATOR|inactive ophthalmic solution vehicle|Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
62164451|NCT02896218||Pharmacist consulting group|When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation. Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines. Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement. For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen. Pharmacists will follow the patients until they discharge.
62164452|NCT02896218||Usual care group|Empirical use of vancomycin without pharmacists consultation.
62341100|NCT01674244|EXPERIMENTAL|Integrative Exercise|Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
62341101|NCT01674244|ACTIVE_COMPARATOR|Monitor Only Waitlist|Monitor Only Waitlist
62341102|NCT05499702|EXPERIMENTAL|Adults with type 2 diabetes|"20 subjects will be studied on one occasion, following 6 weeks of caloric restriction. They will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake. After this subjects will undergo a hyperglycemic clamp with 2 doses of glucagon infused."
62341103|NCT02000713|EXPERIMENTAL|Amyotrophic Lateral Sclerosis|All subjects will be interviewed and administered a brief questionnaire to determine current disease severity. A brief neurological examination will be given to determine reflexes. Subjects will also have magnetic resonance imaging(MRI)scans of the cervical spine (neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. The clinical examinations will take approximately 30 minutes to complete. Subject participation in this study will be complete following the MRI and clinical examinations.
62698507|NCT02602652|EXPERIMENTAL|a live attenuated chimeric JE vaccine|Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.
62698508|NCT04174586|EXPERIMENTAL|cord blood group|standard induction and consolidation chemotherapy with cord blood microtransplantation
62698509|NCT00556114||Optical Coherence Tomography|Optical Coherence Tomography
61947894|NCT01020981||Group 2|Indiana State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
61947895|NCT01553383|ACTIVE_COMPARATOR|Dental device|"Provent nasal peep valve vs dental device"
61947896|NCT01553383|ACTIVE_COMPARATOR|CPAP|"continuous positive airway pressure CPAP vs nasap peep valve Provent"
61947897|NCT03585062|EXPERIMENTAL|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40\~60mg bid, day 1\~14 (S-1: BSA \<1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
61947898|NCT03460275|OTHER|single group|Osimertinib Mesylate Tablets 80 mg, one time a day until disease progression
61947899|NCT03473483|EXPERIMENTAL|SREC only or cigarette only use|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; pharmacokinetic (PK) blood draws; ad libitum use of product; cardiovascular (CV) monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
62341104|NCT02000713|ACTIVE_COMPARATOR|Healthy controls (MRI)|Subjects will also have magnetic resonance imaging (MRI) scans of the cervical spine(neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. Subject participation in this study will be complete following the MRI.
62341105|NCT04191967|EXPERIMENTAL|Thermocoagulation|Thermal ablation of cervix for treatment of CIN2/3 among HIV-positive participants will be performed by a trained, non-physician clinician. Thermocoagulation will last approximately 20 seconds and will be performed using the Liger Thermocoagulator device
61947900|NCT03473483|EXPERIMENTAL|Alternate product from Arm 1|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
61947901|NCT03473483|EXPERIMENTAL|Standardized Dual Use|Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
62341106|NCT04995471|EXPERIMENTAL|In presence RRT - prototype software|10 biweekly in presence sessions of 45 minutes supervised by a trainer
62497829|NCT03518723|EXPERIMENTAL|Non-linear Periodized Resistance Training|"The objective of the Non-linear Periodized Resistance Training (NLPRT) program is to increase muscle strength as well as muscle endurance. The NLPRT program will over the 8 week intervention period target several different aspects of limb muscle function, by alternating the intensity and volume of the exercises.~Progression of exercise is symptom dependent and will be based on Borg CR-10 ratings (dyspnea, muscle fatigue and exertion).~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
62698510|NCT05770570|EXPERIMENTAL|ROADmAP schema|Participants will be randomly assigned to one of eight study groups which will be one or a combination of 4 conditions: (1) in person individualized diet and exercise counseling (2) diet and exercise text messages (3) weekly telephone support and (4) self-monitoring tools for diet and weight. For the first part of the study, Survey, approximately 64 drivers and 36 management staff will take pate in the feedback questionnaire. For the second part of the study, Interview, approximately 8 drivers and 12 management staff may be invited to take part in an interview via phone, in person, or teleconference (Zoom).
61947902|NCT04749706|ACTIVE_COMPARATOR|Normal weight|the normal weight women will receive the 12-week physical activity intervention and serve as a control group.
61947903|NCT04749706|EXPERIMENTAL|constitutionally lean women - Physical training only|women will receive the 12-week physical activity intervention
61947904|NCT04749706|EXPERIMENTAL|constitutionally lean women - Physical training + proteins|women will receive the 12-week physical activity intervention in addition to a protein supplementation
61947905|NCT01817530|PLACEBO_COMPARATOR|Cohort 1: Placebo|Placebo for elagolix and placebo for E2/NETA twice daily (BID)
61947906|NCT01817530|EXPERIMENTAL|Cohort 1: Elagolix 300 mg BID|Elagolix 300 mg BID alone
62164453|NCT06524960|EXPERIMENTAL|Denosumab|Denosumab 60 mg subcutaneous injection
61947907|NCT01817530|EXPERIMENTAL|Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD|Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)
61947908|NCT01817530|EXPERIMENTAL|Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD|Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD
61947909|NCT01817530|PLACEBO_COMPARATOR|Cohort 2: Placebo|Placebo for elagolix and E2/NETA QD
61947910|NCT01817530|EXPERIMENTAL|Cohort 2: Elagolix 600 mg QD|Elagolix 600 mg QD alone
61947911|NCT01817530|EXPERIMENTAL|Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD|Elagolix 600 mg QD plus LD E2/NETA QD
61947912|NCT01817530|EXPERIMENTAL|Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD|Elagolix 600 mg QD plus SD E2/NETA QD
62164454|NCT06524960|PLACEBO_COMPARATOR|Placebo|Normal Saline 1.0 ml subcutaneous injection
62341107|NCT04995471|EXPERIMENTAL|In presence RRT - online platform|10 biweekly in presence sessions of 45 minutes supervised by a trainer
62341108|NCT04995471|EXPERIMENTAL|Tele-RRT - prototype software|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
61947913|NCT01136148|EXPERIMENTAL|A Medical and Mental Health Unit|A specialist unit for cognitively impaired older patients admitted as a medical emergency to the acute hospital.
61947914|NCT01136148|ACTIVE_COMPARATOR|Standard care wards|The standard care provided by the acute hospital for cognitively impaired older patients admitted as a medical emergency.
61947915|NCT03974243|EXPERIMENTAL|treatment group|"In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.~Intervention: Drug: Chiauranib and Chidamide"
61947916|NCT01509365|NO_INTERVENTION|sensible|Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
61947917|NCT01509365|ACTIVE_COMPARATOR|simple dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
61947918|NCT01509365|EXPERIMENTAL|double dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
62164455|NCT03612999|EXPERIMENTAL|CGM and Activity Tracker|Subjects receive a continuous glucose monitor (CGM) and activity tracker and are instructed to record daily activities and psychological data.
62341109|NCT04995471|EXPERIMENTAL|Tele-RRT - online platform|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
62341110|NCT04995471|NO_INTERVENTION|No intervention|5 weeks no intervention period
62341111|NCT01234857|EXPERIMENTAL|Part A: ridaforolimus + dalotuzumab|Approximately 15 patients will be enrolled to the ridaforolimus-dalotuzumab combination treatment arm. Subsequent Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to exemestane single-therapy treatment.
62341112|NCT01234857|ACTIVE_COMPARATOR|Part A: exemestane|Exemestane 25 mg daily; single-agent therapy.
62497830|NCT03518723|ACTIVE_COMPARATOR|Resistance Training|"The primary objective of the Resistance training (RT) group is to increase muscular strength. The RT program will be performed in line with current guidelines that are recommended for increasing muscular strength in patients with COPD.~Progression of exercise is performance dependent and will be based on the previous 2 sessions.~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
62497831|NCT01967901|ACTIVE_COMPARATOR|Sequence: ABBA A=usual care, B=self-care|"The usual care consists of patients' follow up by their usual nephrologist and endocrinologist or general practitioner.~Self-care management consists of a the addition of a multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.~In this sequence, patients will receive the usual care for 3 months. Then, they will cross-over to receive a multidisciplinary self-management for the following 6 months and then cross-over to a 3 months of usual care."
62497832|NCT01967901|ACTIVE_COMPARATOR|Sequence BAAB|Patients will receive the multidisciplinary self-management program for 3 months. Then, they will cross-over to usual care for the following 6 months and then cross-over to 3 months of multidisciplinary self-management
62497833|NCT01967901|ACTIVE_COMPARATOR|Sequence AABB|Patients will receive the usual care for two periods of three months, then they will cross-over to a period of 6 months of a multidisciplinary self-management
62698511|NCT05770570|OTHER|Consumo de Opciones Mas Ideales De Alimento (COMIDA)|Participants will be placed in either individual or group interventions by convenience. Recruitment will be consecutive and participants will be placed in either intervention depending on what resource is available on a given day at the VDS, individual counselor or a group educator.
61947919|NCT05984472|ACTIVE_COMPARATOR|Edelweiss Prefabricated Veneers|Edelweiss veneers (device 1) were randomly applied to patients. The teeth were evaluated in terms of color and size matching in order to select the correct veneers. Edelweiss sizing guide was used for size selection. Prefabricated veneers were adapted to the teeth' surfaces. Then, the inner surfaces of the prefabricated veneers were roughened to obtain better mechanical retention. Then the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were rinsed and dried. An adhesive system was applied to the teeth. Prefabricated veneers' inner surfaces were cleaned with alcohol, and Veneer Bond dental adhesive was applied. Edelweiss nanohybrid resin composite was placed on the inner surfaces of the veneers and transferred to the teeth. These restorations were light-cured for 40 s Gingival borders were adapted with contouring and polishing discs (intervention 1).
61947920|NCT05984472|ACTIVE_COMPARATOR|Ceram-X Duo SphereTec with U-Veneer|Direct resin composite restorations were randomly applied to patients. Ceram-X Duo SphereTec resin composite (device 2) was used for color selection. Then U-Veneer transparent templates were tried to select their correct size. After the preparation, the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were then rinsed and dried. An adhesive system was applied to the teeth. Then Ceram-X Duo SphereTec nanohybrid resin composite with dentin shade was placed on labial surfaces of teeth and was light-cured. After that Ceram-X Duo SphereTec nanohybrid resin composite enamel shade was placed on the inner surface of the transparent template and was transferred to the tooth. After that, the resin composite veneer was light-cured for 20 s from each surface. The transparent template was removed. Gingival borders were adapted with contouring and polishing discs. Then proximal surfaces were polished using proximal sandpaper strips (intervention 2).
61947921|NCT01995110|EXPERIMENTAL|normal weight subjects|
61947922|NCT01995110|EXPERIMENTAL|obese subjects|
61947923|NCT02322346|PLACEBO_COMPARATOR|Group S|Preincisional bilateral peritonsillar infiltration of a total of 6 mL of saline
61947924|NCT02322346|ACTIVE_COMPARATOR|Group LL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.25% (3 mL to each tonsil).
61947925|NCT02322346|ACTIVE_COMPARATOR|Group HL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.5% (3 mL to each tonsil).
61947926|NCT02700113||ASD|There is only one group; minimally verbal individuals with Autism Spectrum Disorder aged 4 to 17 years.
61947927|NCT06556979||HNC patient who recieve RT|Reviewing medical record of all patiented who receive radiotherapy and focusing in ischemic cerebrovascular event and carotid artery stenosis. We categorized the patiented to 3 group : no carotid artery stenosis, seen carotid artery stenosis and seen significant carotid artery stenosis and find the risk factor of preexisting carotid artery stenosis before RT
61947928|NCT03851757|ACTIVE_COMPARATOR|waist-shaped interdental brush|waist-shaped interdental brush, use four times per interdental space
61947929|NCT03851757|ACTIVE_COMPARATOR|cylindric interdental brush|cylindric interdental brush, use four times per interdental space
61947930|NCT00809354|ACTIVE_COMPARATOR|IV Placebo + NSAID|Oral NSAID
61947931|NCT00809354|EXPERIMENTAL|Tanezumab 5 mg|IV tanezumab 5 mg every 8 weeks (through Week 48)
61947932|NCT00809354|EXPERIMENTAL|Tanezumab 10 mg|IV tanezumab 10 mg every 8 weeks (through Week 48)
62164456|NCT06687616|EXPERIMENTAL|SynerGI|The standardized CBT program (SynerGI) will be delivered through the Meta Quest 2 device and is self-administered and includes a network of environments arranged in a virtual clinic that participants experience at home though a protocolized, 8-week program. Depending on the module, experiences within the program last between 5-20 minutes. Participants will be prompted to regularly use the headset each week over the 8-week study period. The VR modules are reinforced with regularly scheduled messages and CBT exercises delivered by a webapp that is available on any smartphone or computer. The program progressively builds new skills and culminates in transitioning from using VR to applying the skills learned in VR to everyday life.
62341113|NCT01234857|EXPERIMENTAL|Part B: ridaforolimus + dalotuzumab|Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to one of two single-therapy treatments (ridaforolimus alone or dalotuzumab alone). With the implementation of Amendment 3, this study arm will not be opened.
62341114|NCT01234857|EXPERIMENTAL|Part B: ridaforolimus|Ridaforolimus; 40 mg daily five days a week, single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
62341115|NCT01234857|EXPERIMENTAL|Part B: dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg weekly; single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
62497834|NCT01967901|ACTIVE_COMPARATOR|Sequence BBAA|Patients will receive the multidisciplinary self-management for two periods of three months, then they will cross-over to a period of 6 months of usual care.
62497835|NCT02287220||Newborn Infants|0-12 months old Male or female Any ethnicity
62497836|NCT02919020|EXPERIMENTAL|Proprioceptive neuromuscular facilitation (PNF);|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
62497837|NCT02919020|EXPERIMENTAL|resistance exercise|Resistance exercise to strengthen lower limbs
61947933|NCT00809354|EXPERIMENTAL|Tanezumab 5 mg + NSAID|IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
62497838|NCT01819064|EXPERIMENTAL|Infants and children less than 15Kg.|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
62497839|NCT01361334|EXPERIMENTAL|Pazopanib|Pazopanib treatment
62736524|NCT04301934|ACTIVE_COMPARATOR|Vaginal Estrogen Therapy Group|Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
62497840|NCT01898598|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
62497841|NCT01898598|EXPERIMENTAL|Vismodegib|Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
62497842|NCT06127745|EXPERIMENTAL|Discure System|All participants enrolled in the study will be treated with the Discure system
62497843|NCT03803267|ACTIVE_COMPARATOR|Erector spinae plane block|Patients will receive bilateral ultrasound-guided erector spinae plane block as an adjuvant analgesic technique
62497844|NCT03803267|ACTIVE_COMPARATOR|Quadratus lumborum block|Patients will receive bilateral ultrasound-guided quadratus lumborum block as an adjuvant analgesic technique
62497845|NCT05192096||Intervention group|It includes two 1-hour health-related information sessions.
61947934|NCT00809354|EXPERIMENTAL|Tanezumab 10 mg + NSAID|IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
61947935|NCT03918148||SGLT-2i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a SGLT-2 inhibitor:~dapagliflozin 10 mg, oral, once daily or canagliflozin 100 mg, oral, daily or empagliflozin 10 mg, oral, daily"
61947936|NCT03918148||DPP-4i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a DPP-4 inhibitor:~sitagliptin 100 mg, oral once daily or vildagliptin 50 mg, oral, twice daily or saxaglitpin 5 mg, oral, once daily or linagliptin 5 mg, oral, once daily or alogliptin 25 mg, oral, once daily"
61947937|NCT03219541|ACTIVE_COMPARATOR|Interventional Automated mobile phone text|"Subjects will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention. During the intervention, participants will receive a text question at the end of every day asking you How many cigarettes have you smoked today?"
61947938|NCT03219541|PLACEBO_COMPARATOR|Control Texts|The intervention will consist of a 3-day pre-quit period and then a 4-week post-quit period. Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
62341116|NCT01354353|ACTIVE_COMPARATOR|Aripiprazole|Part A: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 21). Part B: Continue current prescribed dosing regimen (≤ 30 milligrams \[mg\]/day ) -- Study Day 1 to discharge (Study Day 23, 25 or 28 based on adaptive design)
62341117|NCT01354353|EXPERIMENTAL|Part A: 160 mg LY2140023|Administered orally, twice daily (BID) for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
62341118|NCT01354353|EXPERIMENTAL|Part A: 240 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
62497846|NCT06679738||Cirrhosis with GSD|Cirrhosis with GSD
62736525|NCT04301934|EXPERIMENTAL|Laser Therapy Group|Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.
61947939|NCT04965727|EXPERIMENTAL|Deep brain stimulation|"Participants will undergo a surgery for Deep Brain Stimulation (DBS). The neurostimulation system will be used for neuro-rehabilitation of the motor function.~Participants will follow a 3-month neuro-rehabilitation using DBS at a frequency of 3 times per week with physiotherapist."
61947940|NCT01804023||Healthy women|
61947941|NCT00885287|ACTIVE_COMPARATOR|HIV-positives on ARVs receiving AL for malaria|HIV-positive patients on first-line ARVs receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
61947942|NCT00885287|ACTIVE_COMPARATOR|HIV-positives receiving AL for malaria|HIV-positive patients not receiving antiretrovirals but receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
61947943|NCT00885287|ACTIVE_COMPARATOR|HIV-negatives receiving AL for malaria|HIV-negative patients receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
62341119|NCT01354353|EXPERIMENTAL|Part A: 320 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
62497847|NCT06679738||No cirrhosis with no GSD|No cirrhosis with no GSD
62497848|NCT06679738||Cirrhosis with no GSD|Cirrhosis with no GSD
62497849|NCT06679738||GSD with no cirrhosis|GSD with no cirrhosis
62497850|NCT06679738||Cirrhosis with history of cholecystectomy for GSD|Cirrhosis with history of cholecystectomy for GSD
62497851|NCT02171091||study arm|One tracheal sample will be obtained using sterile (5 ml) sterile saline solution using irrigation and wall suction from each patient every day for 72 hours, total sampling time is approximately 10 seconds per specimen. Lung samples or fiberoptic obtained samples will be collected at same time intervals as the tracheal samples when possible and if they are done as standard of care. Samples will not be collected for research only and the time for this procedure will not be extended to collect extra tissue. A blood sample (10ml) will be collected simultaneously with the airway samples and also will be used for baseline control measurements.
62736526|NCT02644096|NO_INTERVENTION|conventional treatment|After surgery, patients with total hip replacement are only seen once 3 months after surgery, and they have no further contact with the hospital.
62698512|NCT05770570|OTHER|SANOS|Conducting SANOS Focus Groups. We will conduct 3-5 focus groups (in Spanish) with 6-10 participants each, until saturation. Bilingual study staff will approach individuals visiting the VDS and VDS Mobile for potential participation. A brief screening questionnaire will be administered, and a BMI assessment conducted, to ascertain eligibility. Focus groups will be scheduled at the VDS Mobile unit at times convenient to participants. Participants will be verbally consented in Spanish, and will be apprised that their participation is purely voluntary and that their names will not be included in the final narrative. The 6-month follow-up and my plate dietary surveys can be done over phone. Study staff will access step counts (or obtain it through phone via the pedometer manual provided to the participant) and upload data onto the REDCap tracking tool. Staff may ask participants to report step counts captured by their personal devices (i.e., phone or smartwatch).
62698513|NCT00437073|EXPERIMENTAL|lapatinib plus capecitabine|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
62497852|NCT06679725|EXPERIMENTAL|Wild ginseng extract|The ginseng used in this study is a commercially manufactured standardized 140 ml liquid package and approved for safety. The drink contains 0.25% of wild ginseng extract and other ingredients while the placebo is manufactured to be identical in appearance (brown color, calorie (30.23 Kcal), taste, and content). The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% wild ginseng extract.
62497853|NCT06679725|PLACEBO_COMPARATOR|Placebo|The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% Korean wild Ginseng Extract. This was achieved by incor-porating 0.25% scented ginseng and 0.06% caramel coloring (Table 1).
62698514|NCT00437073|EXPERIMENTAL|lapatinib + topotecan|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
62698515|NCT01504360|EXPERIMENTAL|sarcoma group|patient suffering form radiation-induced sarcoma
61947944|NCT02269306|EXPERIMENTAL|clomiphen citrate(cc)|Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles.
62140436|NCT06699862|EXPERIMENTAL|Experimental condition 2: HIIT with competition (HIIT+C)|"A key challenge of HIIT is motivating students to maintain high-intensity effort (≥85% of maximum heart rate). To address this, the second experimental condition introduces a competitive element as a motivational strategy. Students will participate in a 10-week school competition to earn points for their class. During each HIIT session, heart rate data will be tracked to monitor exercise intensity and calculate competition points. Each class will earn points equal to the total minutes of vigorous exercise (≥85% of maximum heart rate) achieved collectively by its members.~The competition focuses exclusively on effort rather than physical fitness, ensuring that all participants can contribute equally regardless of their initial fitness levels. This approach emphasizes engagement and teamwork while encouraging students to give their best effort during the sessions."
62140437|NCT02186106|EXPERIMENTAL|Loading dose substitution|Substituted with a highdose of cholecalciferol at study start
62497854|NCT04909112|OTHER|group 1: patients with Sjogren's syndrome|Patients with Sjogren's syndrome
62497855|NCT04909112|OTHER|group 2: patients without sicca syndrome|Patients without sicca syndrome
62497856|NCT02682134|EXPERIMENTAL|"Xylocaine X"|Patients received xylocaine gel as lubricant on endotracheal tube
62497857|NCT02682134|EXPERIMENTAL|"Dexamethasone D"|Patients were given dexamethasone 8 mg intravenously
62497858|NCT02682134|EXPERIMENTAL|"xylocaine and dexamethasone XD"|Patients were given both xylocaine gel and dexamethasone 8 mg intravenously
62698516|NCT01504360|ACTIVE_COMPARATOR|free from sarcoma group|patient without sarcoma 5 years after radiation therapy
62698517|NCT04977232|EXPERIMENTAL|Escitalopram + game intervention|Escitalopram treatment and game intervention are given in combinations for 8 weeks.
62698518|NCT04977232|ACTIVE_COMPARATOR|Escitalopram|Escitalopram treatment for 8 weeks
62698519|NCT01836757|EXPERIMENTAL|MSM group|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
62698520|NCT01836757|PLACEBO_COMPARATOR|Placebo Group|Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
62698521|NCT04219020||Children with a CP diagnosis|"Children younger than 18 years with a CP diagnosis. Intervention will be determined later based on baseline results. Self- and/or proxy-reported survey and/or participation in interviews.~Parents of all participants will provide proxy report. Children with CP \> 8 years of age and cognitively able (approx. 50%) will provide self-report."
62341120|NCT01354353|EXPERIMENTAL|Part A: 400 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
62698522|NCT04219020||Controls|Siblings (12-17 years) of children with cerebral palsy. No intervention, self-reported survey.
62698523|NCT04219020||Health Care Professionals|Health Care Professionals identified as providers of pain care. No intervention, interview participants
62698524|NCT01942369||Deep Infiltrating Endometriosis (DIE)|
62698525|NCT02764138|EXPERIMENTAL|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.~These children also complete pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments."
62140438|NCT02186106|NO_INTERVENTION|Historic controls|Control subjects from journal archive
62140439|NCT02001805||Marathon runners|Very active runners that have been running \> 10 marathons, 2 within the last year, or an amount of 50 km/week for the last 5 years
62497859|NCT02914457|EXPERIMENTAL|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
62497860|NCT05109520||investigational group|Participants of the FUTURE study who switched during the study to Gla-300
62497861|NCT05109520||control group|Participants of the FUTURE study who did not switch to Insulin Gla-300
62497862|NCT04909645|EXPERIMENTAL|Clearsight (finger cuff)|
62497863|NCT05327712|EXPERIMENTAL|Control|The control group was assigned to receive no outreach beyond an initial eligibility determination notice
62497864|NCT05327712|EXPERIMENTAL|Email-only|An email-only group assigned to receive an initial eligibility determination plus email reminders about signing up for marketplace coverage
61947945|NCT03758443|EXPERIMENTAL|Active Treatment TD-1473 Dose A|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
61947946|NCT03758443|EXPERIMENTAL|Active Treatment TD-1473 Dose B|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
61947947|NCT03758443|EXPERIMENTAL|Active Treatment TD-1473 Dose C|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
61947948|NCT03758443|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive an oral daily dose of placebo. Participants who received Placebo (and were non-responders) may move to an extended induction. Subjects who are on placebo will be assigned to active TD-1473 for the extended induction (they will be blinded to dose).
61947949|NCT06356519||Sacituzumab Govitecan|Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
61947950|NCT05905900||Emergent IV Dye Preparation & Administration|The emergent IV dye drug trio is administered and followed immediately by Computed Tomography (CT) Angiography and/or CT Perfusion.
61947951|NCT02938312|ACTIVE_COMPARATOR|Weight Loss Only|24- month weight loss program (year 1: weekly in-person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
61947952|NCT02938312|EXPERIMENTAL|Weight Loss Plus|"Same intervention as Weight Loss Only but includes community-wide interventions to increase access to healthy affordable food and opportunities for safe and convenient physical activity"
61947953|NCT02462252|EXPERIMENTAL|BL-8040 plus hATG, methylprednisolone, cyclosporine|"BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.~Standard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)"
61947954|NCT03653338|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|"All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost.~Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy."
62140440|NCT02001805||Control subjects|Healthy normal weight control subjects, with a low activity level \< 1 hour phsyical activity pr. week. They are matched with runners on age, BMI and gender
62140441|NCT04587219|EXPERIMENTAL|Gam COVID Vac Vaccine|the test drug will be administered according to the prime-boost scheme: the introduction of component 1 (Ad26) will be carried out on the 1st day, and component 2(Ad5)- on the 21st day of the study.
62140442|NCT06182475|EXPERIMENTAL|EPPCom Provider Training|A highly engaging and interactive 60-minute, in-person communication skills training program will be developed as part of this project. Participating transplant providers will complete a brief online survey before (pre) and after (post) participating in the training.
62341121|NCT01354353|EXPERIMENTAL|Part A: 480 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
62341122|NCT01354353|EXPERIMENTAL|Part B: LY2140023|If doses up to or equal to 400 mg BID are not tolerated, Part B of the study may be started. The dose of LY2140023 will be titrated in the same participant from highest dose that was tolerated in Part A, with the intention to reach a dose of 480 mg LY2140023.
62341123|NCT02695524|ACTIVE_COMPARATOR|Scapula-focused exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
62341124|NCT02695524|EXPERIMENTAL|Motor control exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
62341125|NCT00574496|EXPERIMENTAL|High-Risk or Relapsed Hodgkin Lymphoma|This is a phase 2 intention-to-treat study of salvage chemotherapy followed by allogeneic HSC transplant for the treatment of primary refractory or relapsed HL. Patients who 1) do not progress on salvage chemotherapy, and 2) have both suitable HSC donors and 3) a satisfactory pre-allograft work-up will proceed to allograft. Patients who fail any of these 3 criteria will be off-study and considered treatment failures for the purposes of the intention-to-treat study.
62341126|NCT05080959|EXPERIMENTAL|CPL-01|CPL-01 200mg, 400mg, 600mg
62341127|NCT05080959|EXPERIMENTAL|Naropin|150mg
62341128|NCT05080959|EXPERIMENTAL|Placebo|30mL normal saline (0.9%)
62341129|NCT03700788|EXPERIMENTAL|Clorhexidine|2% Chlorhexidine
62341130|NCT03700788|ACTIVE_COMPARATOR|Calcium Hydroxide|Calcium Hydroxide
62341131|NCT01248910|EXPERIMENTAL|Alpine Skiing|
62341132|NCT01248910|NO_INTERVENTION|Control group|
62341133|NCT03069846|EXPERIMENTAL|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
62497865|NCT05327712|EXPERIMENTAL|Phone-only|A phone-only group assigned to receive an initial eligibility determination plus a phone call offering enrollment assistance from a service center representative (SCR);
62497866|NCT05327712|EXPERIMENTAL|Phone and email|A phone + email group assigned to receive an initial eligibility determination, email reminders about signing up for marketplace coverage and a phone call offering enrollment assistance.
62497867|NCT04083534|EXPERIMENTAL|REGN5459|Cohorts of multiple REGN5459 dose levels
62736527|NCT02644096|OTHER|Intervention|counselling and support after discharge from hospital
62736528|NCT00371215|EXPERIMENTAL|1|rThrombin
61947955|NCT03725137||Group A (young stroke)|Young stroke patients (≤ 55); Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), cognitive tests; structural MRI
61947956|NCT04105582|EXPERIMENTAL|Neo-antigen pulsed Dendritic cell|Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)
61947957|NCT04304742||Suspicion of hip fracture|Suspicion of hip fracture
61947958|NCT00369707|EXPERIMENTAL|Bortezomib and Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
61947959|NCT03069443|EXPERIMENTAL|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
61947960|NCT03069443|NO_INTERVENTION|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
61947961|NCT05343923||paroxistical AF|
61947962|NCT05343923||persistent AF|
61947963|NCT06557382||Primary school 1st grade students|Cognitive tests and reading-related evaluations will be administered to illiterate first-grade primary school students before and 6 months after they start education.
61947964|NCT04254861|EXPERIMENTAL|Simplified Papilla Preservation Flap (SPPF) and PRGF|
61947965|NCT04254861|ACTIVE_COMPARATOR|Simplified Papilla Preservation Flap (SPPF) and GTR|
61947966|NCT04002739|EXPERIMENTAL|Patients with Acute Coronary Syndrome (ACS)|Patients admitted to a Coronary Care Unit (CCU) with a new diagnosis of ST Elevation Myocardial Infarction (STEMI) or Non ST Elevation Myocardial Infarction (NSTEMI). Patients are eligible within 72 hours from the admission in CCU. All patients admitted to CCU are going to perform the following procedures/exams as standard clinical practice: coronary angiogram, blood samples, echocardiogram, 24-hour Holter EKG Monitoring. The experimental arm will also perform a polygraphy during CCU stay, a bioelectrical impedance and will complete baseline questionnaires assessing daytime sleepiness such as Epworth Sleepiness Scale (ESS), STOP-BANG and Mallampati score. After the discharge from CCU, patients that had a diagnosis of Obstructive Sleep Apnea Syndrome are going to complete a follow up visit in 90 days undergoing a new polygraphy, bioelectrical impedance, questionnaires (ESS, STOP-BANG and Mallampati Score), echocardiogram.
61947967|NCT05757596|ACTIVE_COMPARATOR|VSA001 injection|A single dose of active drug (VSA001, low or high dose) will be administered by subcutaneous injection on Day 1.
61947968|NCT05757596|PLACEBO_COMPARATOR|Placebo|The placebo is normal saline (0.9%) administered subcutaneously; volume matched to the corresponding VSA001 dose volume.
62497868|NCT03240120|EXPERIMENTAL|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
61947969|NCT01443208|EXPERIMENTAL|50 mg|
62140443|NCT03021512||Group 1 (BFG)|(Bifocal group). Subjects that underwent bifocal intraocular lenses implantation. (ie. Phaco with Restor intervention).
62140444|NCT03021512||Group 2 (TFG)|(Trifocal group). Subjects that underwent trifocal intraocular lenses implantation. (ie. Phaco with Panoptix intervention).
62341134|NCT02990897|NO_INTERVENTION|Control Group|Patients with Stage 3,4, or 5 CKD who are randomized to the control arm will receive standard care.
62497869|NCT01272024|ACTIVE_COMPARATOR|Information/Education Group|Assistance in using Symptom Management Toolkit
62497870|NCT01272024|EXPERIMENTAL|Nurse Intervention|Participants are given intensive nurse contacts to reduce uncertainty and maximize problem solving, and later, to transition to the treatment phase of their cancer.
61947970|NCT01443208|EXPERIMENTAL|100 mg|
61947971|NCT01443208|EXPERIMENTAL|200 mg|
61947972|NCT00575991|EXPERIMENTAL|A|
61947973|NCT00575991|PLACEBO_COMPARATOR|B|
61947974|NCT05727930|EXPERIMENTAL|High-intensity, task-specific (i.e., walking) interventions|30 1-hour (hr) sessions of walking training targeting higher cardiovascular intensities over approximately 2 months
61947975|NCT05727930|ACTIVE_COMPARATOR|High-intensity, non-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting higher cardiovascular intensities over approximately 2 months
61947976|NCT05727930|ACTIVE_COMPARATOR|Low-intensity, task-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting lower cardiovascular intensities over approximately 2 months
61947977|NCT05727930|ACTIVE_COMPARATOR|Low-intensity, non-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting lower cardiovascular intensities over approximately 2 months
62140445|NCT03989310|EXPERIMENTAL|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
62140446|NCT03989310|EXPERIMENTAL|anti-PD-1 antibody plus nPG chemotherapy|Subject received anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
62140447|NCT03568994|EXPERIMENTAL|ADE 10+3+5 plus Atovaquone (AQ)|Induction I ADE: cytarabine, daunorubicin, etoposide 10+3+5, atovaquone daily
62140448|NCT03568994|EXPERIMENTAL|DA 3+10 with GO plus AQ|Induction I DA: daunorubicin, cytarabine 3+10 with GO: gemtuzumab ozogamicin, atovaquone daily
62497871|NCT01268839|EXPERIMENTAL|001|Efavirenz 600mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 28 days
62698526|NCT02764138|NO_INTERVENTION|Comparison|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments. No intervention.
62140449|NCT00070317|EXPERIMENTAL|Diagnostic|Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.
62140450|NCT03065049|EXPERIMENTAL|Peer-PA+Fitbit|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
62341135|NCT02990897|EXPERIMENTAL|Intervention Group|Patients with Stage 3,4, or 5 CKD who are randomized to the intervention group will receive care from a physician who has been exposed to the intervention: a clinical decision support message. This clinical decision support message shows the patient's risk of kidney failure over the next 5 years.
62341136|NCT00624728|EXPERIMENTAL|A|
62698527|NCT01384487||Normal Eyes|Eyes without disease
62698528|NCT01384487||Eyes with Glaucoma|
62341137|NCT05585086|EXPERIMENTAL|Experimental|Peppermint oil will be applied by diluting 1/10 in wheat oil so that it does not cause skin irritation.
62341138|NCT05585086|NO_INTERVENTION|Control|Patients who underwent surgery will be monitored for the severity of nausea and vomiting after surgery. Follow-ups are 0-2, 2-6, 6-12, 12-24 and 24-48 postoperatively. hours and will be recorded without any application or intervention by the researcher.
62698529|NCT01384487||Eyes with Retinal Disease|
62698530|NCT01384487||Eyes with Corneal Disease|Including post keratorefractive surgery
62698531|NCT06172088|EXPERIMENTAL|Therapeutic fasting for the reduction of physical of limitations in physical well-being and qol|
62341139|NCT05415150|EXPERIMENTAL|Measurement of Platelet function|Patients with ischemic stroke may be given alteplase or other thrombolytic. Additionally, patients may be given IV platelet inhibitors and subjected to thrombectomy. Platelet functions are measured after intervention.
62341140|NCT01286506||Mechanically ventilated patients|
62341141|NCT01286506||Non-mechanically ventilated patients|
62341142|NCT00831441|ACTIVE_COMPARATOR|Apixaban|
62497872|NCT06618638|EXPERIMENTAL|SDM group|SDM group receives treatment using a shared decision-making model.
62497873|NCT06618638|OTHER|Conventional group|Conventional group receives treatment as usual.
62698532|NCT06416475|ACTIVE_COMPARATOR|Mankai supplementation group|Three times a day supplementation of postprandial Mankai duckweed drink (60mL crude plant Mankai beverage) right after breakfast, lunch, and dinner while maintaining the recommended Mediterranean diet lifestyle and medical treatment.
62698533|NCT06416475|PLACEBO_COMPARATOR|Water group|Three times a day consumption of postprandial water (60mL) right after breakfast, lunch, and dinner while maintaining the recommended Mediterranean diet lifestyle and medical treatment.
62698534|NCT05001737|EXPERIMENTAL|Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)|MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
62341143|NCT00831441|PLACEBO_COMPARATOR|Placebo|
62497874|NCT02208973|EXPERIMENTAL|PBF-680 (5 mg)|5 mg of PBF-680
62140451|NCT03065049|ACTIVE_COMPARATOR|Fitbit Only|Participants will be given a Fitbit activity tracker along with brief advice for increasing physical activity.
62140452|NCT03065049|NO_INTERVENTION|Usual Care|Participants do not receive any intervention but participate in the assessments only.
62140453|NCT04178421|EXPERIMENTAL|Experimental Group|A computerized eye -tracking program training the eye gaze fixation with the target to improve impulse control and sustained attention of children with special needs
62140454|NCT04178421|PLACEBO_COMPARATOR|Control Group|Computerized program
62341144|NCT02640352|ACTIVE_COMPARATOR|Probi Defendum|Dietary supplement (tablet) with probiotics
62341145|NCT02640352|PLACEBO_COMPARATOR|Placebo|Dietary supplement (tablet) without probiotics
62341146|NCT02139995|EXPERIMENTAL|Transfusion trigger based on WCTS-CP|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCTS-CP
62341147|NCT02139995|ACTIVE_COMPARATOR|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience
62497875|NCT02208973|EXPERIMENTAL|PBF-680 (10 mg)|10 mg of PBF-680
62497876|NCT02208973|EXPERIMENTAL|PBF-680 (20 mg)|20 mg of PBF-680
62497877|NCT02208973|EXPERIMENTAL|PBF-680 (40 mg)|40 mg of PBF-680
62698535|NCT04501822||Covid19 pneumonia patients|The study includes men and women ≥18 years old with documented COVID-19 pneumonia
62698536|NCT05294302|ACTIVE_COMPARATOR|eSCCIP/eSCCIP-SP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. A stakeholder-informed Spanish-language adaption of eSCCIP (eSCCIP-SP) has been developed and will be offered to Spanish-speaking PCCC. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
62698537|NCT05294302|ACTIVE_COMPARATOR|Coping Space|PCCC randomized to the patient education control condition will be given access to a website with information about psychosocial functioning, coping, and PTSS related to pediatric cancer. This website will be hosted on the same platform as the intervention, available in English and Spanish, and will consist of information modified from CopingSpace.org. CopingSpace.org is an evidence-informed website developed by Ryan's Case for Smiles, a national organization dedicated to supporting families impacted by pediatric cancer and other chronic diseases.
62698538|NCT06145646|EXPERIMENTAL|Muscle temperature|Heating the vastus lateralis of the right quadriceps using microwaves
62698539|NCT05389072|EXPERIMENTAL|Control Lens|
61947978|NCT05514483|PLACEBO_COMPARATOR|Placebo|All participants will receive a single injection of placebo, followed, three hours later, by a single injection of ondansetron.
61947979|NCT05514483|ACTIVE_COMPARATOR|Ondansetron|All participants will receive a single injection of placebo, followed, three hours later, by a single injection of ondansetron.
61947980|NCT06278519|EXPERIMENTAL|Blood and urinary collection, cardiac MRI|Blood and urinary collection, cardiac MRI at inclusion during acute phase of STEMI, and one year after inclusion visit.
61947981|NCT04456257|EXPERIMENTAL|Fractional Picosecond 1,064 nm laser|The subjects with abdominal striae alba were treated with a fractional picosecond 1,064 nm laser
61947982|NCT02652754|OTHER|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
61947983|NCT01696071|EXPERIMENTAL|Treatment A|2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
61947984|NCT01696071|EXPERIMENTAL|Treatment B|2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
61947985|NCT05192967|EXPERIMENTAL|Experimental 1|"The training program determined to the experimental group was applied with video. Training program content:~1. Knowledge, attitude, skills about COVID-19~2. Approach to the COVID-19 positive case~3. Communication skills~4. Psychological resilience"
61947986|NCT05192967|EXPERIMENTAL|Experimental 2|"The training program determined to the experimental group was applied with video.~Training program content:~1. Knowledge, attitude, skills about COVID-19~2. Approach to the COVID-19 positive case~3. Communication skills~4. Psychological resilience"
61947987|NCT05192967|OTHER|Control 1|"The training program determined to the control group was applied with classical method.~Training program content:~1. Knowledge, attitude, skills about COVID-19~2. Approach to the COVID-19 positive case~3. Communication skills~4. Psychological resilience"
61947988|NCT05192967|OTHER|Control 2|"The training program determined to the control group was applied with classical method.~Training program content:~1. Knowledge, attitude, skills about COVID-19~2. Approach to the COVID-19 positive case~3. Communication skills~4. Psychological resilience"
61947989|NCT02736838|EXPERIMENTAL|Phase I|Interventions: Different positions will be applied to subjects to measure preipheral tissue oxygenation, pressure, and changes in microvascular flow. Subjects will be placed up to 4 hours in each of the standard positions for the experiment: supine decubitus (SD) right lateral decubitus (RLD), left lateral decubitus (LLD). SD measurements will be made at 0, 30 and 45 degrees of inclination to bed. RLD and LLD positions will be evaluated with a body inclination of 30 and 90ª. The subjects will lie down on a memory foam mattress for an articulated bed, as are commonly used at home, residential or hospital care. Between the subject and the mattress will be inserted the pressure measuring surface. Measurements in each position will be made during intervals of 0-4 hours in the same position (SD-RLD-LLD) in each of the inclinations of the bed (0º, 30°, 45 °) or body (30º, 90º), respectively.
61947990|NCT01903174|EXPERIMENTAL|AeroForm Tissue Expansion|AeroForm Breast Tissue Expander placed after mastectomy
61947991|NCT04249531|EXPERIMENTAL|Amikacin|Patients will receive once amikacin i.v. 7,5 mg/kg in the first week
61947992|NCT06276673|EXPERIMENTAL|single chamber blood flow restriction cuff|Single Chamber BFR (Delfi, Vancouver, Canada) training devices will be used for exercise and testing sessions (see attachment). Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) in accordance with manufacturer specifications. The cuffs will maintain pressure during training and rest periods. The LOP will be decreased to 0% immediately after the set is completed.
61947993|NCT06276673|EXPERIMENTAL|Multiple chamber blood flow restriction cuff|Multiple chamber BFR (B-Strong, Park City, UT) training devices will be used for exercise and testing sessions (see attachment). Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) in accordance with manufacturer specifications. The cuffs will maintain pressure during training and rest periods. The LOP will be decreased to 0% immediately after the set is completed.
62140455|NCT00606333|EXPERIMENTAL|Investigational arm|Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
62497878|NCT02208973|EXPERIMENTAL|PBF-680 (60 mg)|60 mg of PBF-680
62698540|NCT03923868|EXPERIMENTAL|dose escalation in healthy subjects|
62698541|NCT03923868|EXPERIMENTAL|dose escalation in hyperuricemia patients|
61947994|NCT06276673|PLACEBO_COMPARATOR|No BFR cuff|No cuff will be worn during the training session.
62698542|NCT06019676||Patients with mHSPC and treatment decision for apalutamide by clinician|
62736529|NCT00141648|EXPERIMENTAL|1|Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
61947995|NCT00435864|OTHER|allogeneic donor from a file|
61947996|NCT00435864|OTHER|Registry geno-identical donor family|
62140456|NCT00606333|ACTIVE_COMPARATOR|Control Arm|Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
62341148|NCT04901741|EXPERIMENTAL|Arm 1: olaptesed pegol + pembrolizumab + nanoliposomal irinotecan + 5-FU + LV|
62341149|NCT04901741|EXPERIMENTAL|Arm 2: olaptesed pegol + pembrolizumab + gemcitabine + nab-paclitaxel|
62497879|NCT02208973|PLACEBO_COMPARATOR|Placebo|Comparator to the doses of 5, 10, 20, 40 and 60 mg. ( subjects for each dose level 6 are located to active treatment and two to placebo
62497880|NCT04590196|EXPERIMENTAL|treatment|
62497881|NCT04590196|PLACEBO_COMPARATOR|control|
62497882|NCT00474318||Adolescents with severe obesity|Adolescents and young adults with severe obesity
62497883|NCT05928234||Biventricular circulation|Research subjects with PA-IVS who have biventricular circulation
62736530|NCT03790813|EXPERIMENTAL|Eligible patients|
62736531|NCT01204905|EXPERIMENTAL|Open Label ART|Patients received raltegravir 400 mg PO BID and maraviroc 300 mg PO BID in combination for 48 weeks.
61947997|NCT00435864|OTHER|transplantation of HSCs derived from placental blood|
62698543|NCT06451146||OA Intervention|All consecutive patients with moderate/ severely calcified coronary lesions who underwent PCI facilitated by the Orbital Atherectomy The decision to perform orbital atherectomy was left to the operator's dissertation after the detection of a moderate/severely calcified lesion. Angiographic calcification was classified as moderate when it involved between 30% and 50% of the reference lesion diameter, and severe when it occupied over 50% of the reference diameter. When the initial assessment was based on IVUS finding lesion had to reach at least 2 points in the IVUS calcium score. There were no angiographic exclusion criteria regarding lesion anatomy such as the length, tortuosity, severity, or location. All procedural features(use additional lesion preparation technique; stent implantation parameters, periprocedural pharmacological therapy, use of intravascular imaging along with the left ventricular support device) were left to the discretion of the operator.
61947998|NCT04432025|ACTIVE_COMPARATOR|Control|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
61947999|NCT04432025|EXPERIMENTAL|Intervention|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
61948000|NCT04861909||AT LISA tri 839MP|Patients implanted with AT LISA tri 839MP
61948001|NCT03840928||Ankylosing Spondylitis|
61948002|NCT03840928||Fibromyalgia|
61948003|NCT03840928||Gout|
61948004|NCT03840928||Crohn's-related Arthritis|
61948005|NCT03840928||Juvenile Idiopathic Arthritis|
61948006|NCT03840928||Lupus|
61948007|NCT03840928||Myositis|
62140457|NCT04801823|ACTIVE_COMPARATOR|Home Introduction of Individual tree nuts|Current standard of care which is to advise families of infants diagnosed with peanut allergy to introduce tree nuts individually via a standardized, graded and cautious home introduction protocol. Day 1: smear of nut paste to the inside of lip; Day 2: 1/8 teaspoon; Day 3: 1/4 teaspoon; Day 4: 1/2 teaspoon; Day 5: 1 teaspoon. Repeat process with each individual tree nut.
62140458|NCT04801823|EXPERIMENTAL|In hospital multi-tree nut (almond, cashew hazelnut and walnut) oral food challenge (OFC)|Infant will be booked for a 4-nut butter (Almond, Hazelnut, Walnut, and Cashew) graded and supervised OFC in the allergy clinical trials unit at the Murdoch Children's Research Institute. The nut butter contains a 1g dose of each nut protein in a total weight of 20g. Doses will be administered every 15minutes (1. Smear to inside of lip, 2.1/8 teaspoon, 3.1/4 teaspoon, 4.1/2 teaspoon, 5.1 teaspoon, 6.remainder of 20g nut butter paste) If challenge negative, infants continue home introduction of tree nuts as per written instructions provided. If challenge positive, infants will have additional SPT (for full tree nut panel) and single tree nut OFC as per protocol to determine tolerance/allergic status (and +/- home introduction recommendation) for each tree nut.
62140459|NCT04682418|EXPERIMENTAL|xvision Spine|
62140460|NCT06225336|EXPERIMENTAL|AUR-201|AUR-201
62140461|NCT06596564|NO_INTERVENTION|Control|In this group, no nudge interventions were implemented, only data were collected.
62698544|NCT04638309|EXPERIMENTAL|Cohort 1|Dose level 1
61948008|NCT03840928||Osteoarthritis|
62140462|NCT06596564|EXPERIMENTAL|choice architecture (Sugar Content Information)|"Students are exposed to information about the sugar content of cola on the Questionnaire Star platform to nudge students towards healthier choices"
62140463|NCT06596564|EXPERIMENTAL|choice architecture (Sugar Harm Information)|"Students are exposed to information about the harms of cola on the Questionnaire Star platform to nudge students towards healthier choices"
62140464|NCT06596564|EXPERIMENTAL|choice architecture (Social Norm Information)|"Students are exposed to information about the most peers choose mineral water on the Questionnaire Star platform to nudge students towards healthier choices"
62140465|NCT04407975|EXPERIMENTAL|Betamethasone|Patients will receive 14 mg (2 ml) intramuscular betamethasone
62140466|NCT04407975|PLACEBO_COMPARATOR|Placebo|Patients will receive an equivalent volume of normal saline
62497884|NCT05928234||Univentricular circulation|Research subjects with PA-IVS who have univentricular circulation
62497885|NCT00926445||Preterm (BW < 1500 grams)|
62497886|NCT00926445||Critically ill term newborn|ventilation \> 48 hours
62497887|NCT00926445||Healthy term newborn|
62698545|NCT04638309|EXPERIMENTAL|Cohort 2|Dose level 2
62698546|NCT04638309|EXPERIMENTAL|Cohort 3|Dose level 3
62698547|NCT04541927||BCL11B|BCL11B intragenic pathogenic variant
62698548|NCT01771354|PLACEBO_COMPARATOR|Placebo|Placebo
62698549|NCT01771354|ACTIVE_COMPARATOR|Vaccine|Engerix B vaccine
61948009|NCT03840928||Osteoporosis|
61948010|NCT03840928||Psoriasis|
61948011|NCT03840928||Psoriatic Arthritis|
61948012|NCT03840928||Rheumatoid Arthritis|
61948013|NCT03840928||Scleroderma|
61948014|NCT03441269|ACTIVE_COMPARATOR|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
61948015|NCT03441269|ACTIVE_COMPARATOR|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
61948016|NCT03441269|ACTIVE_COMPARATOR|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
61948017|NCT02513342|EXPERIMENTAL|Endostar+Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.
61948018|NCT02513342|ACTIVE_COMPARATOR|Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.
61948019|NCT05933148|ACTIVE_COMPARATOR|Active Neurofeedback|Participants randomized to Active neurofeedback will receive real-time data depicting MOFC-precuneus brain activity while in the scanner.
61948020|NCT05933148|SHAM_COMPARATOR|Sham Neurofeedback|Participants randomized to the Sham neurofeedback control group will receive the feedback of a prior scanned participant's active MOFC-precuneus up-regulation and not their own brain activity. This condition will still visually resemble the active conditions.
61948021|NCT05285072||Vascular graft infection|Patients with confirmed vascular graft infection according to current syndromic criteria.
61948022|NCT05285072||Vascular graft without infection|Patients with no clinical evidence of infection and CRP less than 5.
61948023|NCT02339285|EXPERIMENTAL|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
61948024|NCT02339285|EXPERIMENTAL|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
61948025|NCT02339285|SHAM_COMPARATOR|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
61948026|NCT00985478|EXPERIMENTAL|A|SLV342 suspension or capsule
61948027|NCT00985478|PLACEBO_COMPARATOR|B|matching placebo
61948028|NCT05664607|NO_INTERVENTION|control group|no multimodal rehabilitation
61948029|NCT05664607|EXPERIMENTAL|multimodal rehabilitation group|include excise, nutrition consultant, nutrition supplement and psychologic intervention.
61948030|NCT02016001|EXPERIMENTAL|toothpaste 1|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
61948031|NCT02016001|EXPERIMENTAL|toothpaste 2|toothpaste 2 will be the intervention with 1000 ppm of fluoride, which will be used by control group. They will brush the teeth twice daily for 2 minutes
61948032|NCT00066729|EXPERIMENTAL|NY-ESO-1b peptide with Montanide® ISA-51|Patients received NY-ESO-1b peptide mixed with Montanide® ISA-51 by subcutaneous injections, once every 3 weeks (weeks 1, 4, 7, 10, and 13) for a total of 13 weeks.
61948033|NCT06040840|ACTIVE_COMPARATOR|BAX group|Axillary brachial plexus block + Tourniquet
61948034|NCT06040840|EXPERIMENTAL|WALANT group|Wide Awake Local Anesthesia No Tourniquet
61948035|NCT03128827|EXPERIMENTAL|Test Subjects|All test subjects were pediatric patients following general anesthesia who received the RAM sensor which measures respiration rate.
61948036|NCT04335032|EXPERIMENTAL|Eicosapentaenoic acid gastro-resistant capsules|"Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg gastro-resistant capsules 2g daily (two capsules twice daily).~One capsule of EPA-FFA gastro-resistant capsules contains 500mg EPA-FFA in a capsule containing gelatin, glycerol, sorbitol, titanium dioxide, FD\&C blue No. 1, hypromellose phthalate, dibutyl sebacate."
61948037|NCT04335032|PLACEBO_COMPARATOR|Placebo|Placebo capsules that cannot be visually differentiated from the active treatment
62140467|NCT04860505|EXPERIMENTAL|Doxycycline and Biktarvy|Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.
62698550|NCT04797884|EXPERIMENTAL|TheraBionic Arm - Active Arm|For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for \>200 one-hour treatment sessions.
61948038|NCT03663946||Patients taking combination therapy with Yervoy and Opdivo|Medical records will be reviewed for safety and treatments for specific ADR
61948039|NCT05449119||Non small eaters|Elderly subjects who are not malnourished
61948040|NCT05449119||Small eaters|Elderly subjects with loss of appetite
61948041|NCT01069016|EXPERIMENTAL|Sacral nerve modulation first|"Sacral nerve modulation is applied before the pudendal nerve stimulation. There is no wash-out period (pause) between the two treatments."
61948042|NCT01069016|EXPERIMENTAL|Pudendal nerve stimulation first|"Pudendal nerve stimulation is applied before the sacral nerve modulation. There is no wash-out period (pause) between the two treatments."
61948043|NCT03722069|OTHER|Low sodium diet|22 patients were randomized to receive 3 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
61948044|NCT03722069|OTHER|Normal sodium diet|22 patients were randomized to receive 7 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
61948045|NCT00137631|EXPERIMENTAL|Many Men, Many Voices (3MV) Intervention|Receive 6-session intervention immediately after baseline assessment and randomization
61948046|NCT00137631|NO_INTERVENTION|Wait list comparison|Receive intervention after 6-month delay (wait list control group)
62140468|NCT02894554|PLACEBO_COMPARATOR|lamivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy.
62140469|NCT02894554|ACTIVE_COMPARATOR|telbivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.
62140470|NCT05671510|EXPERIMENTAL|Arm 1: Gotistobart 6 mg/kg with 2 loading doses of 10 mg/kg, Q3W|Gotistobart will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
62140471|NCT05671510|EXPERIMENTAL|Arm 2: Gotistobart 3 mg/kg Q3W|Gotistobart will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
62698551|NCT04797884|PLACEBO_COMPARATOR|Placebo Arm|For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-specific modulation frequencies and will be activated for \>200 one-hour treatment sessions.
62698552|NCT06183021|EXPERIMENTAL|Total pulpotomy with cryotherapy|Total coronal amputation will be performed using vital pulp cryotherapy
62698553|NCT06183021|NO_INTERVENTION|Total pulpotomy|Total coronal amputation will be performed.
62698554|NCT06183021|EXPERIMENTAL|Root canal treatment with cryotherapy|Orthograde root canal treatment will be performed with intracanal cryotherapy.
62698555|NCT06183021|NO_INTERVENTION|Root canal treatment|Orthograde root canal treatment will be performed.
61948047|NCT04716465||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 (symptomatic and asymptomatic) will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
61948048|NCT04204343|ACTIVE_COMPARATOR|Caudal Block|US-guided caudal block with 0.7 ml/kg 0.25% Bupivacaine
61948049|NCT04204343|ACTIVE_COMPARATOR|Erector Spinae Plane Block|US-guided erector spinae plane block with 0.5 ml/kg 0.25% Bupivacaine
61948050|NCT01739309|EXPERIMENTAL|Abemaciclib|200 milligram (mg) abemaciclib administered orally every 12 hours on days 1 through 28 of a 28-day cycle
61948051|NCT05772429||Epidyolex|Participants will receive Epidyolex in accordance with their routine clinical practice as prescribed by their physician.
61948052|NCT02223312|EXPERIMENTAL|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
61948053|NCT03413345||subjects without a history of cardiac disease|
61948054|NCT03413345||subjects with a history of cardiac disease|
61948055|NCT03921073|EXPERIMENTAL|Intralesional injection of T-VEC|Participants will undergo intralesional injections of up to 4 cc of 10\^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10\^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.
61948056|NCT00354887|EXPERIMENTAL|Oxaliplatin + Capecitabine|Intravenous Oxaliplatin 130 mg/m\^2, Day 1 + Oral Capecitabine 750 mg/m\^2 twice daily Days 1-14.
61948057|NCT01722123|NO_INTERVENTION|DLST Only|Patients will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
61948058|NCT01722123|EXPERIMENTAL|Contemplate only|Patients will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
61948059|NCT01722123|EXPERIMENTAL|Decide with advice|Patients will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, patients will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
61948060|NCT01722123|EXPERIMENTAL|Decide without advice|Patients will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
61948061|NCT02718560|EXPERIMENTAL|Group 1 - Writing with 1 cm cue|This group uses to write space of 1 cm size
61948062|NCT02718560|EXPERIMENTAL|Group 2 - Writing with 1.5 cm cue|This group uses to write space of 1.5 cm size
61948063|NCT02718560|EXPERIMENTAL|Group 3 - Writing without cue|This group writes without using cues
61948064|NCT02718560|NO_INTERVENTION|Group 4 - no writing|This group do not write. Only wrist mobilization is performed.
61948065|NCT01788228|EXPERIMENTAL|Influenza A (H5N1) Virus monovalent vaccine 18-64 Years Group|Subjects 18-64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
61948066|NCT01788228|EXPERIMENTAL|Influenza A (H5N1) Virus monovalent vaccine > 64 Years Group|Subjects \>64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
62341150|NCT02660619||Low-risk patients|These will be patients with a prescription for opioids for chronic pain for at least 30 days, recruited from university-affiliated pain and rehabilitation medicine clinics that routinely employ precautions to avoid prescribing such medication to individuals seeking it for non-therapeutic reasons
62341151|NCT02660619||High-risk patients|These patients will be in treatment for addiction to opioids and have (or have had) a prescription of opioids to treat pain.
61948067|NCT05656508|EXPERIMENTAL|25 µg of antigen|Volunteers will receive 2 doses of ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2) of 25 µg of antigen, separated by 28 days
61948068|NCT05656508|EXPERIMENTAL|50 µg of antigen|Volunteers will receive 2 doses of ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2) of 50 µg of antigen, separated by 28 days
61948069|NCT03398044|EXPERIMENTAL|Dexamethasone|Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
61948070|NCT03398044|PLACEBO_COMPARATOR|Placebo|Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
61948071|NCT05115669|EXPERIMENTAL|Wortie freeze plus|"Cryogenic medical device (dimethylether-based product) + conductive gel + protective foam plasters.~Up to 3 applications one every 14 days"
61948072|NCT06203093||Charcot-Marie-Tooth Disease|Subjects in this group will have a diagnosis of Charcot-Marie-Tooth Disease.
61948073|NCT06203093||Healthy Control|Subjects in this group will serve as healthy controls.
61948074|NCT03643107|EXPERIMENTAL|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
61948075|NCT02923596||Patients with Ear Keloids|Records of Patients with Ear Keloids will be reviewed. Data and photographs will be analysed.
61948076|NCT02923596||Patients with Neck Keloids|Records of Patients with Neck area Keloids will be reviewed. Data and photographs will be analysed.
61948077|NCT02923596||Patients with Scalp Keloids|Records of Patients with Scalp Keloids will be reviewed. Data and photographs will be analysed.
62140472|NCT05671510|ACTIVE_COMPARATOR|Arm 3: Docetaxel 75 mg/m2, Q3W|Docetaxel will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
62140473|NCT05657210||KRAS wildtype|
62341152|NCT01586026||Group A|Maintenance flushes at days 1-28
62341153|NCT01586026||Group B|Maintenance flushes at days 29-56
62341154|NCT01586026||Group C|Maintenance flushes at days 57+
62341155|NCT01368159|ACTIVE_COMPARATOR|pressure centred at 25 mm Hg|
62341156|NCT01368159|ACTIVE_COMPARATOR|pressure between 20 and 36 mm Hg|
62341157|NCT01368159|PLACEBO_COMPARATOR|pressure between 10 and 15 mm Hg|
62341158|NCT06169930||high-risk|
62341159|NCT06169930||low-risk|
62341160|NCT04677530|EXPERIMENTAL|Part 1: JNJ-40411813 or Matching Placebo|Participants will receive a single oral dose of JNJ-40411813 or a matching placebo in Cohorts 1, 2, and 3.
62341161|NCT04677530|EXPERIMENTAL|Part 2: JNJ-40411813|Participants will receive a single oral dose of JNJ-40411813 in Cohort 4.
62698556|NCT05501899|EXPERIMENTAL|Treatment Arm (single arm)|
62698557|NCT04398225|EXPERIMENTAL|Cohort 1 (9-12 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
62140474|NCT05657210||KRAS codon 12 mutation|
62140475|NCT05657210||KRAS codon 13 mutation|
62497888|NCT06060522|ACTIVE_COMPARATOR|Multi-detector computed tomography (MDCT )|Multi-detector computed tomography (MDCT ) will be performed for 8 patients performed using CT scanner (SOMATOM Emotion6, Siemens, Germany). The protocol was 200 mAs, 120 kVp, 512 × 512 matrix, 1.172 pitch, 64 × 0.625 mm section collimation, 2 mm slice thickness, 0.6 mm section reconstruction
62497889|NCT06060522|ACTIVE_COMPARATOR|CBCT scans|CBCT will be performed for 8 patients with an exposure performed at 15 mA, 85 KV and at a field of view 7.5 cm x 14.5 cm x 14.5 cm.
62698558|NCT04398225|EXPERIMENTAL|Cohort 2 (9-12 y)|Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days
62140476|NCT05657210||KRAS codon 61 mutation|
62341162|NCT04677530|EXPERIMENTAL|Part 3: JNJ-40411813 or Matching Placebo|Participants will receive a multiple oral dose of JNJ-40411813 or a matching placebo in Cohort 5 and optional Cohort 6.
62497890|NCT05263713|EXPERIMENTAL|Running Horizontal Mattress|Half of the wound is repaired with running horizontal mattress sutures
62497891|NCT05263713|EXPERIMENTAL|Running Subcuticular Suture|Half of the wound is repaired with running subcuticular sutures
62497892|NCT02465684|EXPERIMENTAL|tourniquet|UKA surgery with tourniquet
62140477|NCT03739658|EXPERIMENTAL|Cognitive Based Neuromuscular Education|It will be applied for one hour. There are individual and partner parts. For example, in this training, the athlete will throw the tennis ball up and down on one foot.
62140478|NCT03739658|EXPERIMENTAL|Game Based Education|It will be applied for one hour. There are individual and partner parts. The active game will be played using the Xbox game console and the kinect sensor.
62140479|NCT03739658|NO_INTERVENTION|Control Group|You will not receive any training. Athletes who continue their training as athletes in the other group.
62341163|NCT01064193|EXPERIMENTAL|group 1 : IVF with biopsy|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF
62497893|NCT02465684|EXPERIMENTAL|no tourniquet|UKA without tourniquet
62497894|NCT06529133|EXPERIMENTAL|Control Group|Healthy children
61948078|NCT02460445|EXPERIMENTAL|Intervention|Premenopausal women with functional hyperandrogenism under combined oral contraceptive pill qd as usual clinical practice who will undergo a scheduled standard phlebotomy every 3 months from month 3 to 12 of follow-up.
61948079|NCT02460445|ACTIVE_COMPARATOR|Control|Premenopausal women with functional hyperandrogenism under standard combined oral contraceptive pill qd as usual clinical practice.
62140480|NCT01227421|ACTIVE_COMPARATOR|Nitazoxanide, Placebo|300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
62140481|NCT01227421|ACTIVE_COMPARATOR|Nitazoxanide, Nitazoxanide|Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
62140482|NCT01227421|PLACEBO_COMPARATOR|Placebo|2 placebo tablets twice daily for 5 days
62140483|NCT00312208|EXPERIMENTAL|1|Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -\> T)
62341164|NCT01064193|ACTIVE_COMPARATOR|group 2|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
62341165|NCT00082758|EXPERIMENTAL|Disease Measurable by Standard Criteria(hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute.~hu14.18-Interleukin-2 fusion protein : Given IV"
62497895|NCT06529133|EXPERIMENTAL|Study Group|Children with diagnosed epilepsy
62497896|NCT00743860|EXPERIMENTAL|Single dose|single oral dose
62497897|NCT00743860|EXPERIMENTAL|Repeat Dose|28 day repeat dose
62497898|NCT02381197||pregnant women|Women presenting for prenatal care will provide urine samples at each antenatal care visit. The sample will be used to perform a Congo Red Dot test.
62140484|NCT00312208|EXPERIMENTAL|2|Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
62140485|NCT01861015|EXPERIMENTAL|Epinephrine|In the epinephrine group, we used a dilute epinephrine, 0.5 mg of epinephrine (\[1/2\] vial of 1mg/mL) in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject.
62140486|NCT01861015|ACTIVE_COMPARATOR|Vasopressin|In the vasopressin group, a dilute vasopressin, 5 units in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject was injected.
62140487|NCT02254759|OTHER|IV Midazolam Alone|A single 1 milligram (mg) dose of IV Midazolam on Day 1.
62497899|NCT00851006|EXPERIMENTAL|Open-Label Creatine|Creatine Monohydrate 4 grams daily by mouth
62497900|NCT01398839|SHAM_COMPARATOR|Sham Control|
62497901|NCT01398839|EXPERIMENTAL|CXL Treatment|
62497902|NCT04265287||Pediatric patients with severe pneumonia|Pediatric patients admitted to PICU due to severe pneumonia
62497903|NCT04789187|ACTIVE_COMPARATOR|Arm A: Exercise intervention arm|
62497904|NCT04789187|PLACEBO_COMPARATOR|Arm B: Control arm|
62497905|NCT02105701|EXPERIMENTAL|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
62497906|NCT02105701|EXPERIMENTAL|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
62497907|NCT02105701|EXPERIMENTAL|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
62698559|NCT04398225|EXPERIMENTAL|Cohort 3 (9-12 y)|Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days
62698560|NCT04398225|EXPERIMENTAL|Cohort 4 (6-8 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
62698561|NCT04398225|EXPERIMENTAL|Cohort 5 (4-5 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
62698562|NCT02526290|EXPERIMENTAL|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
62497908|NCT02105701|EXPERIMENTAL|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
61948080|NCT01595607|ACTIVE_COMPARATOR|Typical American Diet|Participants will receive a typical American diet for 6 weeks.
61948081|NCT01595607|EXPERIMENTAL|Avocado Diet|Participants will receive a modified typical American diet in which avocado is substituted for foods that contain moderate and high amounts of saturated fat to allow the inclusion of avocado.
61948082|NCT04925661|EXPERIMENTAL|HEC53856|Drug: HEC53856 TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
61948083|NCT04925661|ACTIVE_COMPARATOR|Roxadustat|Drug: roxadustat TIW dosing There will be only one cohort: 70mg
61948084|NCT04925661|PLACEBO_COMPARATOR|Placebo|Drug: placebo TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
61948085|NCT01349088|EXPERIMENTAL|Motesanib|Eligible patients will be enrolled to receive ixabepilone, capecitabine, plus motesanib.
61948086|NCT05456165|EXPERIMENTAL|GRT-C901/GRT-R902 Vaccine arm|After surgical resection, patients who are circulating tumor DNA (ctDNA) positive will receive adjuvant chemotherapy for 12-24 weeks during which they will undergo neoantigen prediction, randomization, and vaccine manufacturing. After study treatment screening, patients who are still ctDNA positive with no evidence of residual or metastatic disease will receive a total of 6 doses of GRT-C901/ GRT-R902, 2 doses of ipilimumab, and 13 doses of atezolizumab. Study visits occur every 28 days.
61948087|NCT05456165|ACTIVE_COMPARATOR|Observation arm|After surgical resection, patients who are ctDNA positive will receive adjuvant chemotherapy for 12-24 weeks during which they will undergo neoantigen prediction and randomization. After study treatment screening, patients who are still ctDNA positive with no evidence of residual or metastatic disease will be observed via study visits occur every 12 weeks.
61948088|NCT04610970|EXPERIMENTAL|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
62341166|NCT00082758|EXPERIMENTAL|Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology.~hu14.18-Interleukin-2 fusion protein : Given IV"
62341167|NCT00082758|EXPERIMENTAL|Disease Identified by BM Immunohistochemistry Only|"Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (\>5 neuroblastoma cells per 1,000,000 nucleated marrow cells).~hu14.18-Interleukin-2 fusion protein : Given IV"
62341168|NCT02473003|EXPERIMENTAL|High intensity|high intensity exercise 80-90%
62341169|NCT02473003|EXPERIMENTAL|Low/Medium intensity|low/medium intensity exercise 40-50%
62341170|NCT02473003|EXPERIMENTAL|High Intensity with BM|high intensity exercise with Behavioral medicine strategies¨ 80-90%
62341171|NCT02473003|EXPERIMENTAL|Low/Medium intensity with BM|low/medium intensity exercise with Behavioral medicine strategies 40-50%
62341172|NCT03664284|ACTIVE_COMPARATOR|intervention group|
62341173|NCT03664284|NO_INTERVENTION|control group|
62341174|NCT04935047|EXPERIMENTAL|Experimental (Multilingual Support)|The treatment group will receive seven hours multilingual support weekly.
62341175|NCT04935047|NO_INTERVENTION|Control group|The control group will receive the same amount of support as the experimental group, but from a person without multilingual qualifications.
62341176|NCT00014378|EXPERIMENTAL|Chinese Herb Huanglian (Coptis chinesis)|
62497909|NCT05184803|EXPERIMENTAL|treatment|treatment arm(docetaxel, oxaliplatin, S-1)
62497910|NCT02712294|NO_INTERVENTION|Control Group (GC)|The GC received standard ambulatory care, including routine exams and drug therapy. All patients were reassessed after the 2 month protocol.
61948089|NCT05464810|EXPERIMENTAL|Arm I (letrozole, simvastatin)|Patients receive letrozole PO QD and simvastatin PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
61948090|NCT05464810|ACTIVE_COMPARATOR|Arm II (letrozole)|Patients receive letrozole PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
61948091|NCT05533177||Schizophrenia, schizotypal and delusional disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F20-F29 Schizophrenia、schizotypal and delusional disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
62341177|NCT02389712|ACTIVE_COMPARATOR|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
62341178|NCT02389712|ACTIVE_COMPARATOR|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
62140488|NCT02254759|OTHER|Oral Midazolam Alone|A single 5 mg oral dose of midazolam on Day 2.
62140489|NCT02254759|EXPERIMENTAL|RO5186582 Alone|RO5186582 240 mg oral tablet twice daily (BID) for 14 days from Days 3 to 16.
62341179|NCT05855317||Patients with pulmonary embolism|The presence of pulmonary embolism is determined from a CT scan realized between Day 5 and Day 28.
62341180|NCT05855317||Patients without pulmonary embolism|The absence of pulmonary embolism is determined from a CT scan realized between Day 5 and Day 28.
62341181|NCT02205606|ACTIVE_COMPARATOR|HGP0816 5mg|
62341182|NCT02205606|ACTIVE_COMPARATOR|HGP0816 10mg|
62341183|NCT02205606|ACTIVE_COMPARATOR|HGP0816 20mg|
62341184|NCT02205606|EXPERIMENTAL|HCP1306 5/10mg|
62341185|NCT02205606|EXPERIMENTAL|HCP1306 10/10mg|
62341186|NCT02205606|EXPERIMENTAL|HCP1306 20/10mg|
62341187|NCT01669811|EXPERIMENTAL|D961H 20mg twice daily|Double-blinded
62341188|NCT01669811|ACTIVE_COMPARATOR|D961H 20mg once daily|Double-blinded
62341189|NCT05644379|EXPERIMENTAL|Cadonilimab Injection in combination with Regorafenib|Cadonilimab Injection in combination with Regorafenib
62341190|NCT02093234|ACTIVE_COMPARATOR|Mobile health care application|Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
62341191|NCT02093234|ACTIVE_COMPARATOR|Community Health Worker (CHW)|CHWs assist study patients in managing there health care in various ways.
61948092|NCT05533177||Mood disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F30-F39 Mood disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
61948093|NCT05533177||Neurotic, stress-related and somatoform disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F40-F48 Neurotic、stress-related and somatoform disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
61948094|NCT02564796|PLACEBO_COMPARATOR|Control|Group II (non-treatment group): Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
61948095|NCT02564796|EXPERIMENTAL|Epoetin alfa and iron supplements|Group I (treatment group): Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
61948096|NCT00310167|EXPERIMENTAL|4 Gy|4 Gy in 2 fractions
61948097|NCT00310167|ACTIVE_COMPARATOR|24 Gy|24 Gy in 12 fractions
61948098|NCT05212922|EXPERIMENTAL|YH001 + Toripalimab|This study will include two cohorts of up to 40 subjects each treated with RP2D dose of YH001 in combination with 240 mg Toripalimab to assess the antitumor activity and safety/tolerability.
61948099|NCT05594056|EXPERIMENTAL|Preeclampsia|Patients with severe preeclampsia and gestational age between 34-40 weeks.
61948100|NCT05594056|ACTIVE_COMPARATOR|Control|Patients with normal gestations between 34-40 weeks.
61948101|NCT03969732|EXPERIMENTAL|amyloid PET、T807 PET|PET/CT
61948102|NCT02328300||FLT PET/MR|"All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.~All participants will receive a FLT PET/MR scan."
61948103|NCT01805440|ACTIVE_COMPARATOR|Uridine|Subjects randomized to this study arm will receive uridine 500 mg twice daily by mouth for 6 weeks.
61948104|NCT01805440|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm of the study will receive placebo 500 mg twice daily by mouth for 6 weeks.
62497911|NCT02712294|EXPERIMENTAL|NMES Group (GE)|Receiving the usual care and guidance on their illness, underwent 30 minute NMES sessions twice a week for two months using an electrostimulator. Specifically, 5 cm adhesive surface electrodes in four alternate channels on the Rectus Femoris (two channels the right and two on the left) were used to deliver two-phase symmetrical currents, with a rectangular pulse wave at a frequency of 35 Hz and pulse duration of 250 μ. The time of ascent and descent was one second, contraction time was four seconds and relaxation was eight seconds.
62497912|NCT05951751|EXPERIMENTAL|TRI-MOM|Women attending their first postnatal visit in one of the selected maternities (no maternal age limit) will be eligible to participate in the study
61948105|NCT01805440|NO_INTERVENTION|Healthy Comparison|Subjects are not randomized, and do not receive any treatment intervention.
62497913|NCT02581917||Ancillary-Correlative (metabolic changes)|Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
62497914|NCT01026649|EXPERIMENTAL|2 stage|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
62497915|NCT01026649|ACTIVE_COMPARATOR|1 stage|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
62341192|NCT02093234|EXPERIMENTAL|CHWs and mobile health care application|Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
62341193|NCT03198754|EXPERIMENTAL|PEI Experimental Light|Ambient light fixture installed in the patient's hospital room
62341194|NCT03198754|ACTIVE_COMPARATOR|Comparison Light|Ambient light fixture installed in the patient's hospital room
62341195|NCT01869166|EXPERIMENTAL|anti-tumor response of CART-EGFR|
62341196|NCT05320692|EXPERIMENTAL|Treatment group|TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib).
61948106|NCT06556498|ACTIVE_COMPARATOR|ProFlor group|patients underwent to laparoscopic hernia repair with the use of ProFlor mesh
61948107|NCT06556498|ACTIVE_COMPARATOR|Progrip group|patients underwent to laparoscopic hernia repair with the use of Progrip mesh
61948108|NCT01418287||Hospitalized|Subjects who are hospitalized due to influenza-like illness
61948109|NCT01418287||Non-hospitalized|Subjects who are not hospitalized
61948110|NCT05343442|EXPERIMENTAL|Patients assigned to percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
61948111|NCT03477136||First group: semen parameter showing normospermic|"* group will include 30 male~* Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~* blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
61948112|NCT03477136||second group: semen parameter asthenozoospermic|"* group will include 30 male~* Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~* blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
62341197|NCT05320692|ACTIVE_COMPARATOR|Control group|TACE Alone.
62698563|NCT01520441|EXPERIMENTAL|BOTOX Injection|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
61948113|NCT03477136||Third group: semen parameter oligozoospermic|"* group will include 30 male~* Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~* blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
62140490|NCT02254759|EXPERIMENTAL|RO5186582 Plus IV Midazolam|RO5186582 240 mg BID oral tablet in combination with a single 1 mg IV dose of midazolam on Day 17.
62497916|NCT06326424||Observational DELIRIUM cohort|We will follow up to 60 adults 65+ years old with dementia or suspected dementia who are likely to be in the emergency department, observation unit, or hospital for 48 hours. We will follow them for up to 48 hours while they wear an FDA approved biosensor watch and perform delirium checks.
62497917|NCT02269150|EXPERIMENTAL|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
62497918|NCT02269150|ACTIVE_COMPARATOR|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
62497919|NCT02248714|EXPERIMENTAL|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
62497920|NCT02248714|NO_INTERVENTION|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
62497921|NCT05754918|ACTIVE_COMPARATOR|TnoFS then TFS|Cochlear Implant with TnoFS first during 6 weeks then with TFS during 6 weeks
62497922|NCT05754918|ACTIVE_COMPARATOR|TFS then TnoFS|Cochlear Implant with TFS first during 6 weeks then with TnoFS during 6 weeks
62497923|NCT01578317|EXPERIMENTAL|AS03 adjuvanted|Adminsitered day 1, booster at Day 21
62497924|NCT01578317|EXPERIMENTAL|unadjuvanted|Administer day 1 and booster at Day 21
62497925|NCT02119052|EXPERIMENTAL|OCTEOTRIDE|octeotride 20 mg, intramuscular injection monthly for 3 years
62698564|NCT06528080|EXPERIMENTAL|LY-M001 Injection by Single Intravenous|This study preset 3 dose group levels, adaptive design method was adopted during the study, and about 6 to 9 adolescent subjects with type I Gaucher disease aged 12 years ≤ age \< 18 years were expected to be included.
62698565|NCT03770702|NO_INTERVENTION|Control group|No intervention
62698566|NCT03770702|ACTIVE_COMPARATOR|Angiotensin receptor blockers|ARB ( Angiotensin receptor blockers) + Traditional therpy.
61948114|NCT03477136||Forth groupsemen parameter: astheno-teratozoospermic,|"* group will include 30 male~* Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~* blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
61948115|NCT03477136||Fifth group semen parameter: oligo asthenoteratozoospermia|"* group will include 30 male~* Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~* blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
62341198|NCT02182141|EXPERIMENTAL|BIBF 1120|
62341199|NCT03719326|EXPERIMENTAL|Dose Escalation-Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
62341200|NCT03719326|EXPERIMENTAL|Dose Escalation-Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
62341201|NCT03719326|EXPERIMENTAL|Dose Escalation-Arm C|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
62497926|NCT02119052|PLACEBO_COMPARATOR|Placebo|Placebo (saline soluction), intramuscular injection monthly for 3 years
62140491|NCT02254759|EXPERIMENTAL|RO5186582 Plus Oral Midazolam|RO5186582 240 mg BID in combination with a single 5 mg oral dose of midazolam on Day 18.
62164457|NCT06687616|SHAM_COMPARATOR|Sham VR|Patients in the sham VR group will receive the same Meta Quest 2 device but will only have access to a distraction-based VR therapy program that includes 2D nature videos (e.g., relaxing on a beach, swimming with dolphins). Similar to the SynerGI arm, people in the sham VR group will be prompted to regularly use the headset each week for the 8-week treatment period.
62164458|NCT02494076|EXPERIMENTAL|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
62341202|NCT03719326|EXPERIMENTAL|Dose Expansion-TNBC-Arm 1|The dose given will be determined from the dose escalation part (Arm A).
62341203|NCT03719326|EXPERIMENTAL|Dose Expansion-Ovarian Cancer-Arm 2|The dose given will be determined from the dose escalation part (Arm A).
62341204|NCT03719326|EXPERIMENTAL|Dose Expansion-TNBC-Arm 3|The dose given will be determined from the dose escalation part (Arm B). .
62341205|NCT03719326|EXPERIMENTAL|Dose Expansion-TNBC-Arm 4|The dose expansion will be determined from the dose escalation part (Arm C).
62341206|NCT01945424||Pregnancy Cases|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
61948116|NCT05364190|EXPERIMENTAL|Group A(Intervention group)|patients will receive 100 mg canagliflozin initiated within 24 hours from patients hospital admission due to signs of hypervolemic state. All patients also will be prescribed the conventional diuretic therapy and other medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI) and mineralocorticoid receptor antagonists (MRAs). Canagliflozin will be continued for 90 days after hospital discharge
61948117|NCT05364190|ACTIVE_COMPARATOR|Group B|patients will receive 10 mg Empagliflozin initiated within 24 hours from patients hospital admission due to signs of a hypervolemic state.All patients also will be prescribed conventional diuretic therapy and other medications including ACEIs, ARBs, beta-blockers, ARNI, and MRAs.Empagliflozin will be continued for 90 days after hospital discharge
62341207|NCT03924141|EXPERIMENTAL|Third year nursing students - intervention|Third year nursing students will receive the intervention in de-escalation training
62341208|NCT03924141|NO_INTERVENTION|Third year nursing students - control|Third year nursing students will receive no training in de-escalation
62341209|NCT04237740|EXPERIMENTAL|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
62341210|NCT06357260|EXPERIMENTAL|Test group-1|Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need
62698567|NCT03770702|ACTIVE_COMPARATOR|Statins|Statin + Traditional therapy.
62698568|NCT04831346|EXPERIMENTAL|low level laser|"A low-level gallium arsenide diode (Biolase, USA) at a 940 nm wavelength with 0.2 W output power and 2 J energy. The device was calibrated, and the probe was disinfected prior to every treatment.~The Masseter and Temporalis muscles will be bilaterally assessed with constant pressure to define tenderness.~LLLT applied perpendicular to each tender point of the intended muscles for 10 seconds with an energy density of 2.5 J/cm2.~Sessions are scheduled 3 days a week (every other day)"
61948118|NCT00199875|EXPERIMENTAL|Cohort 1 (0.2 mCi/kg)|Patients initially received a nontherapeutic injection of \^111In-DOTA-cG250 (5 mCi \^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic \^90Y-DOTA-cG250 (0.2 mCi/kg \^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
62341211|NCT06357260|ACTIVE_COMPARATOR|Control group|Carbamazepine with dose of Carbamazepine being titrated as per patients's need
62341212|NCT01361919|EXPERIMENTAL|Feedback During CPR Training and Testing|"A feedback defibrillator (ZOLL R series) will be used at teaching, immediate testing and 12 week (retention) testing. A simulation manikin with an attached accelerometer pad on its sternum will be used to collect CPR performance data. Subjects will be told to perform compressions on top of the accelerometer pad and will be taught to use and follow the audio and visual feedback to optimize their CPR performance. After training, the raw data collected by the accelerometer will be used as a demonstration and training tool, to correct the subjects' performance by visually demonstrating the difference between ideal and suboptimal CPR performance. Testing will be carried out with the use of a feedback defibrillator."
62341213|NCT01361919|ACTIVE_COMPARATOR|Feedback during CPR Training Not Testing|"A feedback defibrillator will be used for teaching, with a standard no feedback defibrillator used at immediate and 12 week (retention) testing to assess if the techniques the students' learned during training are transferable to devices without feedback. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest."
62341214|NCT01361919|PLACEBO_COMPARATOR|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
62341215|NCT00987623|EXPERIMENTAL|nelfilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
62341216|NCT00987623|ACTIVE_COMPARATOR|narafilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
62341217|NCT03089216|EXPERIMENTAL|Combined Bleaching(2x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
62341218|NCT03089216|EXPERIMENTAL|Combined Bleaching(2x20) with arginine|Combined Bleaching(2x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
62341219|NCT03089216|EXPERIMENTAL|Combined Bleaching(1x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
62497927|NCT02738216|EXPERIMENTAL|Prenatal Yoga|A 9-week prenatal yoga program
62497928|NCT02738216|ACTIVE_COMPARATOR|Mother Baby Wellness Workshop|A 9-week workshop on mother and baby wellness in the first postpartum year
62497929|NCT06170034||TIA patients|
62497930|NCT02647515|EXPERIMENTAL|ranibizumab|
62497931|NCT03427801||Treatment Group|Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent
62497932|NCT03427801||Control Group|Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent
62698569|NCT04831346|EXPERIMENTAL|Occlusive splint therapy|"A soft occlusal splint (vacuum-formed ) made from a 2-mm-thick elastic rubber sheets will be used.~Splints were individually designed ( in the out patient clinic of the college of dentistry) for the upper arch of each patient. An alginate imprint of the maxillary arch will be taken to fabricate a master cast of the maxilla.~A vacuum pressure device was utilized for molding the rubber sheets (13 x 13 cm /2-mm thickness).~Sheets were removed after it has been appropriately adjusted to the mold in the vacuum former. Edges will be properly trimmed, and the palate part is detached to obtain the end shape.~Participants are instructed to wear the splint at all times except during mealtimes and oral hygiene."
62698570|NCT04831346|NO_INTERVENTION|Control|This group will be a wait list group recieving no intervention except for the regular analgesic prescribed by the reffering dentist
62698571|NCT06294990|ACTIVE_COMPARATOR|Testosterone|Testosterone gel applied to the skin
62698572|NCT06294990|PLACEBO_COMPARATOR|Placebo|Placebo gel applied to the skin
62698573|NCT01148771|EXPERIMENTAL|Ertapenem 1 gram intravenous (IV) 5 minute bolus|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 5 minute IV bolus.
61948119|NCT00199875|EXPERIMENTAL|Cohort 2 (0.3 mCi/kg)|Patients initially received a nontherapeutic injection of \^111In-DOTA-cG250 (5 mCi \^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic \^90Y-DOTA-cG250 (0.3 mCi/kg \^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
61948120|NCT00199875|EXPERIMENTAL|Cohort 3 (0.4 mCi/kg)|Patients initially received a nontherapeutic injection of \^111In-DOTA-cG250 (5 mCi \^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic \^90Y-DOTA-cG250 (0.4 mCi/kg \^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
61948121|NCT00199875|EXPERIMENTAL|Cohort 4 (0.45 mCi/kg)|Patients initially received a nontherapeutic injection of \^111In-DOTA-cG250 (5 mCi \^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic \^90Y-DOTA-cG250 (0.45 mCi/kg \^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
61948122|NCT00199875|EXPERIMENTAL|Cohort 5 (0.55 mCi/kg)|Patients initially received a nontherapeutic injection of \^111In-DOTA-cG250 (5 mCi \^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic \^90Y-DOTA-cG250 (0.55 mCi/kg \^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
62140492|NCT06106100|ACTIVE_COMPARATOR|Antireflux mucosal ablation|In patients fulfilling the inclusion criteria and being randomized for ARMA, retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
62341220|NCT03089216|EXPERIMENTAL|Combined Bleaching(1x20) with arginine|Combined Bleaching(1x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
62341221|NCT02634931|EXPERIMENTAL|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
61948123|NCT06467968|EXPERIMENTAL|Patients|Person for whom a 68Ga-DOTATOC PET/CT exam is requested as part of the diagnostic or pre-therapeutic assessment of a neuroendocrine tumor
62140493|NCT06106100|SHAM_COMPARATOR|Sham procedure|In patients fulfilling the inclusion criteria and being randomized for sham procedure, retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed
62140494|NCT02005159||Positive blood-culture to bacteremia by enterobacteria|Patients with positive blood-culture to bacteremia by enterobacteria
62341222|NCT05006521|EXPERIMENTAL|KN-002 for SAD (Part 1)|Up to 6 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
62341223|NCT05006521|PLACEBO_COMPARATOR|Placebo for SAD (Part 1)|Up to 6 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
62341224|NCT05006521|EXPERIMENTAL|KN-002 for MAD (Part 2)|Up to 4 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
62341225|NCT05006521|EXPERIMENTAL|Placebo for MAD (Part 2)|Up to 4 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
62341226|NCT05006521|EXPERIMENTAL|KN-002 for Part 3|Single cohort with up to 18 of 24 subjects randomised to active treatment
62698574|NCT01148771|ACTIVE_COMPARATOR|Ertapenem 1 gram IV 30 minute infusion|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 30 minute infusion (i.e., the standard dose).
62341227|NCT05006521|EXPERIMENTAL|Placebo for Part 3|Single cohort with up to 6 of 24 subjects randomised to placebo treatment
62341228|NCT05006521|EXPERIMENTAL|KN-002 for Part 4|Single cohort with up to 18 of 24 subjects randomised to active treatment
62341229|NCT05006521|EXPERIMENTAL|Placebo for Part 4|Single cohort with up to 6 of 24 subjects randomised to placebo treatment
62341230|NCT00539916|EXPERIMENTAL|Jus d'orange|
62341231|NCT00539916|PLACEBO_COMPARATOR|Boisson contrôle|
62341232|NCT04653818|ACTIVE_COMPARATOR|DAAs group|Those with complete HCC ablation who will start sofosbuvir / velpatasvir aiming to eradicate HCV.
62341233|NCT04653818|ACTIVE_COMPARATOR|Postponed DAAs group|Those who will not start DAAs within the 12 months follow up from HCC ablation procedure. Patients of this group will receive DAAs provided that there is no HCC recurrence after the end of 1 year.
62341234|NCT06518200|EXPERIMENTAL|Intervention Group|Individualised health recommendations + Individualised exercise intervention
62341235|NCT06518200|OTHER|Control Group|General health recommendations
62341236|NCT04215523||Dapagliflozin|Exposure group
62341237|NCT04215523||DPP-4 inhibitor|Reference group
62341238|NCT04815551|EXPERIMENTAL|AV-380 IV 4 mg/kg|IV infusion of AV-380 at dose level 4 mg/kg
62341239|NCT04815551|EXPERIMENTAL|AV-380 IV 8 mg/kg|IV infusion of AV-380 at dose level 8 mg/kg
62341240|NCT04815551|EXPERIMENTAL|AV-380 IV 13 mg/kg|IV infusion of AV-380 at dose level 13 mg/kg
62341241|NCT04815551|EXPERIMENTAL|AV-380 IV 20 mg/kg|IV infusion of AV-380 at dose level 20 mg/kg
62341242|NCT04815551|EXPERIMENTAL|AV-380 SC 4 mg/kg|Subcutaneous injection of AV-380 at dose level 4 mg/kg
62698575|NCT01245608|EXPERIMENTAL|Polypill|Single daily dose of PolyPill and 6-monthly visits
62698576|NCT01245608|NO_INTERVENTION|Control|Only 6-monthly visits
62698577|NCT04945837|OTHER|unique study arm|Initial socio-demographic questionnaire 5 timepoints psychologic and self-administered questionnaires
62698578|NCT01878448|EXPERIMENTAL|Anlotinib|
62698579|NCT01952977|ACTIVE_COMPARATOR|MCT|MCT oil (20 g) was included in the test breakfast
62698580|NCT01952977|PLACEBO_COMPARATOR|LCT|Corn oil (20 g) was included in the test breakfast
62497933|NCT05697757|EXPERIMENTAL|Placebo Condition followed by Dynamic Condition|Each lighting condition will last for three weeks (Weeks 2-4 or 5-7). The order of conditions will be randomized. Sleep data will be collected only on the last 7 days of each condition using actigraphy. Light spectrum and intensity will be tracked continuously throughout the waking hours (wearable light tracker). Moreover, caregivers will complete two questionnaires (CSDD and CMAI) every seven days to assess the short and long-term effects of each condition on mood and agitation of older adult participants.
62497934|NCT05697757|EXPERIMENTAL|Dynamic Condition followed by Placebo Condition|Each lighting condition will last for three weeks (Weeks 2-4 or 5-7). The order of conditions will be randomized. Sleep data will be collected only on the last 7 days of each condition using actigraphy. Light spectrum and intensity will be tracked continuously throughout the waking hours (wearable light tracker). Moreover, caregivers will complete two questionnaires (CSDD and CMAI) every seven days to assess the short and long-term effects of each condition on mood and agitation of older adult participants.
62497935|NCT05214144||evaluating sources of physical function (PF)|evaluate 4 distinct modalities of sources of PF (PRO, ClinRo, PerfO and wearable device data) on Hugo Health platform in breast cancer and lymphoma patients undergoing cytotoxic chemotherapy.
61948124|NCT06038214||core exercises grup|"Core Exercise Group Exercises The exercise program was planned as warm-up, core exercises and cool-down periods, 2 days a week, 30 minutes a day and 8 weeks.~In the warm-up and cool-down program, each exercise was planned as 3 sets of 10 seconds.~The first 2 weeks of exercises were planned as 6 repetitions, the next 2 weeks the exercises 10 repetitions and the last 4 weeks the exercises were planned as 12 repetitions."
61948125|NCT06038214||home exercises grup|"At the beginning of the study, it is planned to give a home exercise program for 30 minutes, 2 days a week for 8 weeks, with information and teaching home exercises at the beginning of the study. The content of the home exercise program will be therapeutic exercises, stretching and relaxation exercises.~Evaluations will be evaluated for each group at the same time of the day before the exercise program starts and 1 day after the last session after completing 2 sessions a week for 8 weeks."
61948126|NCT01435603|ACTIVE_COMPARATOR|Standard Lifestyle Advice|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
61948127|NCT01435603|EXPERIMENTAL|Advice Plus Lifestyle Intervention|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.
61948128|NCT02270008|ACTIVE_COMPARATOR|Pelvic floor training|The intervention group will undergo an in-person standardized training session by a trained nurse practitioner. The intervention is the pelvic floor training session. They will then be asked to continue muscle training at home at regular intervals and asked to log their exercises on a standardized exercise diary that is provided to them.
61948129|NCT02270008|NO_INTERVENTION|Literature-only group|The literature-only group will receive a pamphlet with instructions for pelvic floor muscle exercises; however, no in-person training will be administered.
61948130|NCT00939640|EXPERIMENTAL|Dietary intervention|Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
62341243|NCT04815551|EXPERIMENTAL|AV-380 SC 2 mg/kg|Subcutaneous injection of AV-380 at dose level 2 mg/kg
62341244|NCT04815551|EXPERIMENTAL|AV-380 SC 1 mg/kg|Subcutaneous injection of AV-380 at dose level 1 mg/kg
62341245|NCT04815551|PLACEBO_COMPARATOR|Placebo|
62341246|NCT00039195|EXPERIMENTAL|Induction R-CHOPac Therapy for patients with B-Cell Lymphoma|Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.
61948131|NCT03414320|EXPERIMENTAL|Study Arm|We will gather data from this group of patients.
61948132|NCT00963222|ACTIVE_COMPARATOR|with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
61948133|NCT00963222|PLACEBO_COMPARATOR|with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
62497936|NCT01456260|EXPERIMENTAL|TAK-438 10 mg QD|
62341247|NCT02987348||exenatide once weekly|type 2 diabetes patients who were first prescribed with exenatide once weekly in the index period identified from CPRD database of UK primary care
62341248|NCT02987348||basal insulin_1|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide once weekly group identified from CPRD database of UK primary care
62341249|NCT02987348||exenatide twice daily|type 2 diabetes patients who were first prescribed with exenatide twice daily in the index period identified from CPRD database of UK primary care
62497937|NCT01456260|EXPERIMENTAL|TAK-438 20 mg QD|
62497938|NCT01456260|ACTIVE_COMPARATOR|Lansoprazole 15 mg QD|
62497939|NCT03790137|EXPERIMENTAL|Treatment group|The treatment group will include approximately 20 pediatric and young adult patients (ages 4-25 years) seen by Elizabeth A. Thiele, M.D., Ph.D. at MGH's Pediatric Epilepsy Clinic. Subjects will be treated on an outpatient basis and will not require hospital admission. The treatment group will receive the investigational new drug, Fenfluramine Hydrochloride for approximately 4 months. Patients that benefit from this treatment will remain on medication through an extension phase of the study.
62497940|NCT05759156|ACTIVE_COMPARATOR|Tranexamic Acid|
62497941|NCT05759156|PLACEBO_COMPARATOR|Normal Saline|
62497942|NCT02088333|EXPERIMENTAL|mCRC intervention|intervention arm
62497943|NCT02088333|PLACEBO_COMPARATOR|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
62497944|NCT06232772||patients with clinically defined PD|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
62497945|NCT06232772||patients with clinically probable PD|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
62497946|NCT06232772||MSA group|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
62497947|NCT06232772||PSP group|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
62497948|NCT06232772||healthy subjects of equal age and sex without any risk or prodromal factor for PD|control group Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
62497949|NCT04229160|EXPERIMENTAL|patient with persistent atrial fibrillation|persistent atrial fibrillation is defined as lasting longer than 6 months documented by a 24h holter monitoring
62497950|NCT01470898|EXPERIMENTAL|anesthesia monitoring|Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.
62497951|NCT01470898|EXPERIMENTAL|no bispectral index monitoring|At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
62497952|NCT06172439|EXPERIMENTAL|experimental group|Women in the intervention group will receive acupressure for 12 minutes.
62497953|NCT06172439|NO_INTERVENTION|control group|Women in the control group will not receive acupressure and will continue with routine care.
62497954|NCT02463019|OTHER|Tenofovir|Tenofovir Disoproxil Fumarate 300mg daily for 3 years
62698581|NCT00003451|EXPERIMENTAL|Arm I|Cohorts of 3 patients receive interleukin-12 IV push on day 1, followed by escalating doses of interferon alfa by subcutaneous injection at 24, 48, 72, 96 and 120 hours. Courses repeat every 2 weeks for 6 months (12 courses total) in the absence of unacceptable toxicity and disease progression. Patients achieving partial response or stable disease at the completion of 6 months of therapy may receive additional courses of therapy for up to 24 months. Dose escalation of interferon alfa continues in subsequent cohorts in the absence of dose limiting toxicity (DLT). If 1 of 3 patients experiences DLT at a dose level, then 3 additional patients are entered at that dose level. If 2 of 6 patients experience DLT, then dose escalation stops. The maximum tolerated dose is defined as 1 level below that dose at which 2 or more of 6 patients experience DLT. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
61948134|NCT00963222|ACTIVE_COMPARATOR|without atherosclerosis/ vitamin A|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
61948135|NCT00963222|PLACEBO_COMPARATOR|without athrosclerosis/ placebo|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive placebo
61948136|NCT05702918|ACTIVE_COMPARATOR|Group A - ESWT + exercise|"Participants in group A will complete a 12-week ankle dorsiflexion resistance training protocol according to Silbernagel. It is a series of heel rise exercises with a gradual progression of load according to defined criteria, which the patient practices every day.~In addition, participants will receive a low-energy focused ESWT. In total, it will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal). The set values will not change throughout the research. These parameters were selected in accordance to ISMST guidelines."
61948137|NCT05702918|ACTIVE_COMPARATOR|Group B - exercise|Participants in group B will complete a 12-week ankle dorsiflexion resistance training protocol according to Silbernagel. It is a series of heel rise exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
61948138|NCT05852184||CMUH|Adult patients who receive maintenance hemodialysis through an arteriovenous (AV) fistula or AV graft access at CMUH.
61948139|NCT05852184||AUH|Adult patients who receive maintenance hemodialysis through an arteriovenous (AV) fistula or AV graft access at AUH.
62140495|NCT03725800||Aspirin|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using aspirin for mono-antiplatelet therapy.
62140496|NCT03725800||Clopidogrel|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using clopidogrel for mono-antiplatelet therapy.
62341250|NCT02987348||basal insulin_2|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide twice daily group identified from CPRD database of UK primary care
62341251|NCT06372067|EXPERIMENTAL|Intramedullary screw|Intramedullary (IM) screw fixation is a minimally invasive technique that provides rigid fixation of fractures, acting as an internal splint and load-sharing device. IM screw fixation may allow for early mobilization without the operative site morbidity of open reduction and its associated complications.
62341252|NCT06372067|ACTIVE_COMPARATOR|Kirschner wire|Kirschner wire (K-wire) fixation is a minimally invasive technique that provides non-rigid fixation of fractures. K-wires allow for fracture fixation with minimal soft tissue injury and preserved blood supply. However, patients require prolonged postoperative immobilization and are at risk of malunion and pin tract infection.
61948140|NCT05852184||SKC-Central|Adult patients who receive maintenance hemodialysis through an arteriovenous (AV) fistula or AV graft access at SKC-Central.
62341253|NCT02698618|EXPERIMENTAL|Ticagrelor|A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)
62341254|NCT02698618|ACTIVE_COMPARATOR|Clopidogrel|A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg
62341255|NCT03357146||CRA|Patients with chronic retinal artery occlusion
62497955|NCT00006467|EXPERIMENTAL|gemcitabine + ISIS 2503|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
61948141|NCT02846831|ACTIVE_COMPARATOR|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
62341256|NCT03357146||Control|Healthy
62497956|NCT05174754|EXPERIMENTAL|Inflammatory Bowel Disease Exercise Group|The exercise group will be randomized to a 20-week physician-prescribed exercise programme following the principles of Frequency, Intensity, Time, and Type (FITT) in addition to best medical therapy with the aim of increasing physical fitness levels, inflammatory response, quality of life/fatigue improvements and favorable body composition changes.
62497957|NCT05174754|OTHER|Inflammatory Bowel Disease Control Group|The IBD control group will be randomized to best medical therapy alone.
62497958|NCT05174754|NO_INTERVENTION|Healthy Control Group|A group of healthy controls without inflammatory bowel disease will be included in the study for comparison of inflammatory markers including cytokine analysis and body composition.
62497959|NCT01408888|EXPERIMENTAL|LY2189265, Sitagliptin + LY2189265|A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
62497960|NCT01408888|EXPERIMENTAL|Sitagliptin + LY2189265, LY2189265|100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
61948142|NCT02846831|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
61948143|NCT04710173||ARDS children|children with severe ARDS
61948144|NCT01812031|EXPERIMENTAL|Lung nodules|"Medical imaging intervention applied on patients included in the trial"
61948145|NCT01913678|ACTIVE_COMPARATOR|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
61948146|NCT01913678|ACTIVE_COMPARATOR|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
61948147|NCT01913678|PLACEBO_COMPARATOR|Complete diet|The participants will be given all dietary items in their diet.
61948148|NCT05577780||internal fixation|
61948149|NCT05577780||arthroplasty|
62698582|NCT05348122|EXPERIMENTAL|TG103, 15 mg,Q2W|TG103 (15 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
61948150|NCT01788488|NO_INTERVENTION|Standard Therapy|
61948151|NCT01788488|EXPERIMENTAL|Procalcitonin-guided therapy|Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
61948152|NCT06097169||Dex|patients using dexmedetomidine infusion
61948153|NCT06097169||Fen|patients using fentanyl for induction
61948154|NCT05578170||Pembro Neoadjuvant + SOC Adjuvant|
61948155|NCT00693849|ACTIVE_COMPARATOR|A|Escitalopram
61948156|NCT00693849|ACTIVE_COMPARATOR|B|Sertraline
62341257|NCT05311293||Patients with simple diarrhea-predominant irritable bowel syndrome|
62698583|NCT05348122|EXPERIMENTAL|TG103, 22.5 mg,Q2W|TG103 (22.5 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
61948157|NCT00693849|ACTIVE_COMPARATOR|C|Venlafaxine-XR
61948158|NCT00693849|NO_INTERVENTION|D|Healthy matched controls
61948159|NCT01554683|ACTIVE_COMPARATOR|High Dose Levetiracetam|Low Dose Levetiracetam administration via IV infusion over 20 min
61948160|NCT01554683|ACTIVE_COMPARATOR|Low Dose Levetiracetam|High Dose Levetiracetam administration via IV infusion over 20 min
62140497|NCT03725800||ASIDE|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using ASIDE for mono-antiplatelet therapy.
61948161|NCT01554683|PLACEBO_COMPARATOR|Placebo administration|Saline administration via IV infusion over 20 min
61948162|NCT00231842|EXPERIMENTAL|Ifosfamide with or without cisplatin|Participants with surgically staged carcinosarcoma (CS) with no gross residual disease were initially administered ifosfamide (1.2 g/m2/day for 5 days) with cisplatin (20 mg/m2/day for 5 days) every 3 weeks for 3 cycles followed by pelvic external beam RT and brachytherapy followed by 3 additional cycles of ifosfamide (1.0 g/m2/day) with cisplatin with cisplatin (20 mg/m2/day for 5 days) evrey 3 weeks. cisplatin added toxicity without additional efficacy, so mid-study, cisplatin was eliminated.
62341258|NCT05311293||Patients with irritable bowel syndrome accompanied by anxiety and depression|
62341259|NCT05311293||Healthy Volunteers|
62341260|NCT00190983|EXPERIMENTAL|Pemetrexed|
62341261|NCT03739476|EXPERIMENTAL|Interventional|Quetiapine 25 milligrams 1 hour after surgery and each 12 hours for 3 days
62341262|NCT03739476|PLACEBO_COMPARATOR|control|Placebo 1 hour after surgery and each 12 hours for 3 days
62341263|NCT05844956|EXPERIMENTAL|DZD8586|
62341264|NCT00853489|EXPERIMENTAL|recombinant bone morphogenetic protein 2|The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
62341265|NCT00853489|ACTIVE_COMPARATOR|Autogenous iliac crest bone graft|Bone will be harvested from the iliac crest and placed in the bone defect.
62497961|NCT02169336|EXPERIMENTAL|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
62497962|NCT02169336|EXPERIMENTAL|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
61948163|NCT02095223|EXPERIMENTAL|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
61948164|NCT02095223|ACTIVE_COMPARATOR|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
62341266|NCT05059548||Male Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
61948165|NCT04016064|OTHER|group 1;|Er:YAG laser
61948166|NCT04016064|OTHER|group 2|Nd:YAG laser
61948167|NCT04016064|OTHER|group 3|Electrosurgery
61948168|NCT01049100|EXPERIMENTAL|operative staging (A)|operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
62497963|NCT02169336|PLACEBO_COMPARATOR|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
62497964|NCT03316222|EXPERIMENTAL|Dose escalation|Dose escalation using 3+3 design with dose limiting toxicity (DLT) observation period of 28 days.
62497965|NCT03316222|EXPERIMENTAL|Dose Expansion|Additional patients will be enrolled into the recommended dose. These additional patients will undergo all of the same assessments as the patients enrolled in dose escalation with the exception of PK sampling.
62497966|NCT01176981|EXPERIMENTAL|HDMTX|This is a single arm study. All subjects enrolled in the study will be in this arm.
62497967|NCT02673086|ACTIVE_COMPARATOR|coracoid approach|Patients in this group will be randomized to receive an coracoid approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
62497968|NCT02673086|ACTIVE_COMPARATOR|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
61948169|NCT01049100|NO_INTERVENTION|Standard (B)|No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--\> CT controlled biopsy and histological analysis.
61948170|NCT04295772|EXPERIMENTAL|DOR/ISL|Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.
61948171|NCT04335097|ACTIVE_COMPARATOR|Control|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
61948172|NCT04335097|ACTIVE_COMPARATOR|Intervention|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service. I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
61948173|NCT04487106|EXPERIMENTAL|Treatment (azacitidine, venetoclax, trametinib)|"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
61948174|NCT04051281|NO_INTERVENTION|Just under target control|Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing; no letter sent.
61948175|NCT04051281|EXPERIMENTAL|Just under target letter|"Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing: receive a letter informing of this.~Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
61948176|NCT04051281|NO_INTERVENTION|Over target control|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; no letter sent~* Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)~* Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2)"
62341267|NCT05059548||Female Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
62497969|NCT01671657||Eeva Test Group|Day 3 embryo transfers that used Eeva with morphology grading (Test Group).
62497970|NCT01671657||Matched case control group|Day 3 embryo transfers using morphology grading only (from concurrent Control Group).
62341268|NCT00155454|EXPERIMENTAL|Study group|Group 1 had intravitreal long acting gas (10% C3F8) injection in the vitreous cavity at the end of surgery
62497971|NCT04937998|EXPERIMENTAL|Autologous PRP injection|This group of patients will be treated with single intra-articular injection of Autologous PRP.
62497972|NCT04937998|ACTIVE_COMPARATOR|HA injection|This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)
62497973|NCT05972564|ACTIVE_COMPARATOR|Empagliflozin Arm|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes. To ensure blinding, empagliflozin will be over-encapsulated in identical gelatin capsules as placebo.
62497974|NCT05972564|PLACEBO_COMPARATOR|Placebo Arm|Placebo consists of gelatin capsules.
62698584|NCT05348122|PLACEBO_COMPARATOR|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
61948177|NCT04051281|EXPERIMENTAL|Over target letter|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target (Letter B1)~Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
61948178|NCT04051281|EXPERIMENTAL|Over target letter with bar chart|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target, including a bar chart showing their prescribing compared to the target (Letter B1)~Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
61948179|NCT04051281|ACTIVE_COMPARATOR|Top 20% feedback letter control|"Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on--standard practice--(Letter C1)~Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
61948180|NCT04051281|EXPERIMENTAL|Top 20% above target letter|"Targeting practices that are currently in the top 20% of prescribers; letters informing them that their prescribing exceeds the new target (Letter C2)~Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
61948181|NCT04051281|EXPERIMENTAL|Top 20% feedback letter with specific example of patient harm|"Targeting practices that are currently in the top 20% of prescribers~• Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1) Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)~Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
61948182|NCT01907581|OTHER|Patients admitted to an ICU|
61948183|NCT01754870|EXPERIMENTAL|Bendamustine + Rituximab-->Rituximab and Lenalidomide|"Induction chemoimmunotherapy:~* Bendamustine 70 mg/m2 IV days 1 \& 2 every 28 days X 6 cycles~* Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)~Maintenance phase:~* Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.~* Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day."
61948184|NCT03904173||EMIT-1 - Multi-parameter tests|Patients with hormone sensitive HER2 negative primary breast cancer without lymph node metastasis. Treatment recommendations will be based on the Prosigna test result, in addition to conventional clinicopathological parameters.
62497975|NCT05885386|OTHER|Pheochromocytoma or Paraganglioma patients|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
62497976|NCT05857345||Lactating individuals|Lactating adults (age \>= 18) with children aged 2 weeks to 6 month
62497977|NCT00842309|ACTIVE_COMPARATOR|D-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
61948185|NCT02837289|OTHER|Treatment|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
61948186|NCT02837289|OTHER|Placebo|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
61948187|NCT02191137|EXPERIMENTAL|Riociguat 0.5mg to 2.5 mg|Single arm, open label
61948188|NCT06181578|EXPERIMENTAL|GP Ablation Group|Participants in this group will undergo a combined intervention, including standard ablation (pulmonary vein isolation and linear ablation) and additional ablation targeting the autonomic ganglionated plexus (GP).
62140498|NCT00118586||Muscle tension dysphonia|Increased phonatory muscle tension in the paralaryngeal and suprahyoid muscles onpalpation
62341269|NCT00155454|SHAM_COMPARATOR|Control group|Group 2 did not receive intravitreal long acting gas (10% C3F8)
62341270|NCT05299242|ACTIVE_COMPARATOR|Arm A|Participants will receive 2 injections of adalimumab. First injection: 160mg in 3.2ml Second injection approximately 2-3 weeks later 80mg in 1.6ml
62497978|NCT00842309|PLACEBO_COMPARATOR|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
62341271|NCT05299242|PLACEBO_COMPARATOR|Arm B|Participants will receive 2 injections of placebo First injection: 3.2ml Second injection approximately 2-3 weeks later 1.6ml
62341272|NCT02273557|EXPERIMENTAL|Asasantin ER (new formulation I - low)|
62341273|NCT02273557|EXPERIMENTAL|Asasantin ER (new formulation III - medium)|
62341274|NCT02273557|EXPERIMENTAL|Asasantin ER (new formulation II - high)|
62341275|NCT02273557|ACTIVE_COMPARATOR|Asasantin ER (present commercial formulation)|
62341276|NCT02152670|EXPERIMENTAL|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
62341277|NCT02152670|EXPERIMENTAL|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
62497979|NCT01715649|NO_INTERVENTION|Control-usual care|Nurse care coordination in a telephonic diabetes disease management program
62497980|NCT01715649|EXPERIMENTAL|Intervention paired testing and remote monitoring|Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
62497981|NCT01112462|EXPERIMENTAL|Tablet|Paracetamol 500 mg/Phenylephrine 5 mg tablet
62497982|NCT01112462|ACTIVE_COMPARATOR|Sachet|Paracetamol 1000 mg/Phenylephrine 10 mg sachet
62698585|NCT05348122|EXPERIMENTAL|TG103, 7.5 mg,QW|TG103 (7.5 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
62698586|NCT05348122|EXPERIMENTAL|TG103, 15 mg,QW|TG103 (15 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
62497983|NCT05540171|EXPERIMENTAL|Education intervention (Oral health education and instructions/training for self-oral care)|The intervention arm will be given a 45 minute oral health education which will include oral hygiene instructions and motivation/training for oral self-care (dietary counselling; snacking during and not mealtimes; post-meal rinsing; flossing; brushing frequency, time, and method; tongue cleaning; toothbrush type/care; toothpaste quantity/type; dental visits). Audio-visual aids and leaflets reinforcing the oral health education will also be provided.
62698587|NCT05348122|PLACEBO_COMPARATOR|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
62698588|NCT05348122|ACTIVE_COMPARATOR|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
61948189|NCT06181578|NO_INTERVENTION|Standard Ablation Group|Participants in this group will undergo standard ablation treatment, which includes pulmonary vein isolation (PVI) and linear ablation.
61948190|NCT01869439|EXPERIMENTAL|External wounds measured for length by width using a ruler|This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
61948191|NCT05166564|EXPERIMENTAL|PROMED (Experimental Intervention 1)|A Protein Enriched Mediterranean Diet (PROMED) intervention. Participants will receive individually tailored resources to encourage adoption of a protein-enriched Mediterranean diet pattern.
61948192|NCT05166564|EXPERIMENTAL|PROMED-EX (Experimental Intervention 2)|A Protein Enriched Mediterranean Diet \& Exercise (PROMED-EX) Intervention. Participants will receive the same PROMED diet resources (Experimental Intervention 1) and an individually tailored exercise intervention.
61948193|NCT05166564|NO_INTERVENTION|Control group|'Standard Care' - consisting of a general diet information sheet.
61948194|NCT01870284|EXPERIMENTAL|Ixekizumab Dosing Regimen 1|Administered by 80 milligram (mg) subcutaneous (SC) injection
61948195|NCT01870284|EXPERIMENTAL|Ixekizumab Dosing Regimen 2|Administered by 80 mg SC Injection
61948196|NCT01870284|PLACEBO_COMPARATOR|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection
61948197|NCT01870284|ACTIVE_COMPARATOR|Adalimumab|Administered by 40 mg SC injection
61948198|NCT04910945|EXPERIMENTAL|Micro-coring treatment|
61948199|NCT06030050|EXPERIMENTAL|Treatment group|Intervention: Animal-assisted intervention (therapy dog visit) Frequency: 2 dog visits per week Duration: each visit is approx 10 mins long, study lasts 20 weeks
61948200|NCT06030050|NO_INTERVENTION|Control group|Intervention: NONE - sit in waiting room like usual Frequency: 0 dog visits per week Duration: study lasts 20 weeks
61948201|NCT01999153|EXPERIMENTAL|DRUG : ROPIVACAINE|20 mL topically used during alginate dressing
62140499|NCT00118586||Normal Volunteers|Normal vocal function refers to normal voice quality with a negative history of voice orlaryngeal disorders
62341278|NCT02152670|EXPERIMENTAL|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
62341279|NCT02541474|OTHER|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
62341280|NCT02541474|NO_INTERVENTION|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
62341281|NCT00325286|EXPERIMENTAL|1|Treatment with lithium and extended release carbamazepine
61948202|NCT01999153|PLACEBO_COMPARATOR|PLACEBO : NaCl 0.9 %|20 mL topically used during alginate dressing
62341282|NCT00441441|EXPERIMENTAL|Fluticasone propionate/salmeterol 100/50 HFA|Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
62497984|NCT05540171|NO_INTERVENTION|No intervention (Control)|The control arm/group will receive no intervention (Oral health education) until right after the study is over.
61948203|NCT04131725||Cardiac Function Monitoring|Subjects will wear Cardiac Performance System (CPS) non-invasive device for brief periods during procedures including assessment by Pulmonary Artery Catheter (PAC) methods.
61948204|NCT06558045|EXPERIMENTAL|Test Rivaroxaban 20 mg PT Dexa Medica|Rivaroxaban 20 mg Film-coated Tablet, produced by PT Dexa Medica, Indonesia
61948205|NCT06558045|ACTIVE_COMPARATOR|Reference Xarelto 20 mg Bayer|Xarelto® 20 mg Film-Coated Tablet, manufactured by Bayer AG, Germany, imported by PT Bayer Indonesia, Indonesia
61948206|NCT00531934|EXPERIMENTAL|1|
61948207|NCT00531934|ACTIVE_COMPARATOR|2|
61948208|NCT04137029|EXPERIMENTAL|smoking|Healthy smoking volunteers
61948209|NCT04137029|EXPERIMENTAL|non-smoking|Healthy non-smoking volunteers
61948210|NCT00942448|EXPERIMENTAL|Diclofenac HPBCD s.c. 25mg/ml|
62140500|NCT00118586||Spasmodic dysphonia|A diagnosis of adductor or abductor SD will be based on voice testing and fiberoptic nasolaryngoscopy conducted during the initial interview
62140501|NCT00118586||Vocal Tremor|Vocal tremor during vocalization that primarily involves laryngeal structures
62140502|NCT01185041|PLACEBO_COMPARATOR|Maltodextrin|6g/day of placebo (maltodextrin)
62140503|NCT01185041|EXPERIMENTAL|Watermelon|(6g per day)containing L-citrulline/L-arginine (4/2 g)
61948211|NCT00942448|EXPERIMENTAL|Diclofenac HPBCD s.c. 50mg/ml|
61948212|NCT00942448|ACTIVE_COMPARATOR|Diclofenac HPBCD s.c. 75mg/ml|
61948213|NCT00942448|PLACEBO_COMPARATOR|Placebo s.c. (1ml)|
61948214|NCT00508755|EXPERIMENTAL|Arm 1|stroke
61948215|NCT02343237|EXPERIMENTAL|Osteopathy +|75 patients will make 6 osteopathic sessions
61948216|NCT02343237|ACTIVE_COMPARATOR|Osteopathy -|75 patients will make 6 factitious osteopathic sessions
61948217|NCT03602430|EXPERIMENTAL|Drug Group|twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period
61948218|NCT03602430|PLACEBO_COMPARATOR|Placebo Group|twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.
61948219|NCT00134030|ACTIVE_COMPARATOR|Maintenance therapy group 1 arm I|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 17, 22, and 26 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 17. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 16, 20, 21, 24, 25, 28, and 29.
61948220|NCT00134030|EXPERIMENTAL|Maintenance therapy group 1 arm II|Patients receive doxorubicin, cisplatin, and high-dose MTX as in arm I. Patients than receive PEG-interferon alfa-2b subcutaneously once daily on day 1 in weeks 30-104.
61948221|NCT00134030|ACTIVE_COMPARATOR|Maintenance therapy group 2 arm I|Patients receive doxorubicin, cisplatin, and high-dose MTX as in group 1 arm I.
61948222|NCT00134030|EXPERIMENTAL|Maintenance therapy group 2 arm II|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 20, 28, and 36 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 28. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 19, 23, 27, 31, 35, 39, and 40. Patients receive ifosfamide IV over 4 hours on days 1-5 in weeks 16, 24, and 32 and on days 1-3 in weeks 20 and 36 and etoposide IV over 1 hour on days 1-5 in weeks 16, 24, and 32.
61948223|NCT01504620|OTHER|Sugar infusion|Diagnostic assessment of blood glucose by means of different devices
61948224|NCT01504620|EXPERIMENTAL|insulin infusion|infusion of insulin to achieve low glucose levels
61948225|NCT04930991|EXPERIMENTAL|Arm A (High Dose)|Omeprazole, 80 mg, PO, BID for 2 weeks prior to surgical therapy of pancreatectomy. All 30 subjects in Arm A to be enrolled prior to Arm B cohort enrollment.
62140504|NCT04350619||Genetic study in retrospective and prospective groups|Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention
62341283|NCT00441441|EXPERIMENTAL|Fluticasone propionate 100mcg HFA|Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
62698589|NCT06195007|EXPERIMENTAL|Motivational Interview|Patients included in the study who are being treated by a resident in the MI intervention group will have a motivational interview during their initial hospitalization.
62698590|NCT06195007|NO_INTERVENTION|Control|Patients included in the study who are being treated by a resident in the Control group will not have a motivational interview during their hospitalization.
62698591|NCT04438824|EXPERIMENTAL|Palbociclib and INCMGA00012|"Initial design (safety lead-in and expansion): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib on Day 1 and INCMGA00012 on day 15 (+/- 7 days) of each cycle at the following dose schedule: INCMGA00012: 500 mg IV (flat dose) q28 days Palbociclib: 125 mg PO daily for 21 days, followed by 7 days off, q28 days Palbociclib will be taken on Day 1 of each cycle for 21 consecutive days followed by 7 days off (days 22-28 of each Cycle). INCMGA00012 will be administered on Day 15 of (+/- 7 days) each cycle and repeat every 28 days.(No longer using this)~Amended design (Expansion only): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib and INCMGA00012 on day 1 of each cycle: 500 mg IV (flat dose) of INCMGA00012 will be administered q28 days concurrently with palbociclib 125 mg PO daily for 21 days, followed by 7 days off, q28 days."
62698592|NCT05734066|EXPERIMENTAL|Phase 1 Part 1: Dose Selection|"Pediatric participants ≥ 2 to \< 18 years of age with previously treated solid tumors of any histology at 5 dose levels to determine the RP2D, followed by a safety expansion cohort.~Participants aged ≥ 6 to \< 18 years will be enrolled at the starting dose of 3.2 mg/m\^2 lurbinectedin. After the drug is deemed safe based safety and PK data from the older participants, participants aged ≥ 2 to \< 6 years are enrolled at the same starting dose. After this, the study opens to all participants (aged ≥ 2 to \< 18 years) for all dose levels.~Upon completion of the cohort at all dose levels, participants may be eligible to enroll in a safety expansion cohort."
62698593|NCT05734066|EXPERIMENTAL|Phase 1 Part 2: RP2D|Participants aged ≥ 2 to ≤ 30 years with recurrent/refractory Ewing sarcoma at the RP2D to assess safety and efficacy signals.
61948226|NCT04930991|PLACEBO_COMPARATOR|Arm B (Normal Dose)|Omeprazole, 20 mg, PO, QD for 2 weeks prior to surgical therapy of pancreatectomy.
61948227|NCT00586625|EXPERIMENTAL|Bepreve|bepotastine besilate ophthalmic solution 1.5%
61948228|NCT00586625|PLACEBO_COMPARATOR|Placebo|vehicle
61948229|NCT04652440|EXPERIMENTAL|Radiofrequency or microwave ablation combined with PD-1 monoclonal antibody|Patients who meet the inclusion criteria will receive 1 cycle of PD-1 antibody on the day before ablation, then 3 cycles of PD-1 antibody after primary radiofrequency or microwave ablation, on a schedule of per 3 weeks, then be followed until disease relapse or death.
61948230|NCT00252746|EXPERIMENTAL|ZD6474 100mg|Daily dose
61948231|NCT00252746|EXPERIMENTAL|ZD6474 200mg|daily dose
62698594|NCT05734066|EXPERIMENTAL|Phase 2|If a signal of efficacy is observed in Phase 1 Part 2, additional participants aged ≥ 2 to ≤ 30 years with recurrent/refractory Ewing sarcoma will be enrolled. Phase 2 will further assess the safety and efficacy of lurbinectedin monotherapy.
61948232|NCT00252746|EXPERIMENTAL|ZD6474 300mg|daily dose
61948233|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
61948234|NCT04784039|ACTIVE_COMPARATOR|TEE-group|
61948235|NCT04784039|ACTIVE_COMPARATOR|DD-group|
61948236|NCT05642767||Patients with pseudomonas aeruginosa infections|"All patients suffer from infections that can be caused by pseudomonas aeruginosa.~Clinical Data will be obtained as:~* Data about clinical manifestations including fever, expectoration, pus from wounds, urinary symptoms, symptoms of upper respiratory tract infections, and symptoms of otitis externa.~* Samples will be cultured on cetrimide agar.~* Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI.~* Molecular detection to efflux genes and some virulence genes by PCR."
62140505|NCT04574466|NO_INTERVENTION|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by a physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
62164459|NCT02494076|SHAM_COMPARATOR|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
62164460|NCT02978235|EXPERIMENTAL|TAS4464|
62497985|NCT03135340|EXPERIMENTAL|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
62497986|NCT03135340|ACTIVE_COMPARATOR|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
61948237|NCT05642767||Patients with infections other than pseudomonas aeruginosa|"* Data about clinical manifestations including fever, expectoration, pus from wounds, urinary symptoms, symptoms of upper respiratory tract infections, and symptoms of otitis externa.~* Samples will be cultured on different culture media and automated identification by Vitek system."
62341284|NCT06553430|EXPERIMENTAL|Intervention group|Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks and daily physical activity
62341285|NCT06553430|NO_INTERVENTION|Control group|daily physical activity
62341286|NCT06348407||Responder group|The improvement in ACT score ≥ 3,or pre-treatment ACT score \< 20 and a post-treatment ACT score ≥ 20；The GETE score was excellent or good.
62341287|NCT06348407||No-Responder group|The improvement in ACT score \< 3;The GETE score was moderate,poor and worse.
62341288|NCT06348407||Good adherence|The proportion of patients whose missed doses of omalizumab fewer than 10% of all doses over the1 year, we think these patients were good adherence.
62341289|NCT06348407||Poor adherence|the proportion of patients who missed at least 10% of all doses over the 1year,we think these patients were poor adherence.
62497987|NCT01956162|EXPERIMENTAL|"Group Orthèse Diabète"|"Using Orthèse Diabète, a new customized removable device with rocker sole for plantar off-loading"
62497988|NCT01956162|ACTIVE_COMPARATOR|Control Group|"Using Conventional devices, removable off-loading systems among the devices available in France"
61948238|NCT06442332||Cyclist injured|Persons injured while using a bike
61948239|NCT06442332||Controls|Matched controls not injured
62497989|NCT00913536|EXPERIMENTAL|Cone beam CT in Bladder Cancer|
62497990|NCT04113616|EXPERIMENTAL|Part A - Arm 1|"KRT-232+LDAC:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle."
61948240|NCT01803061|EXPERIMENTAL|WebCan|Provides computerized PRO to the treating physician at the point of care
61948241|NCT01803061|NO_INTERVENTION|Usual care|
61948242|NCT02297984||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
61948243|NCT03191422|EXPERIMENTAL|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
61948244|NCT01195246|EXPERIMENTAL|HEPLISAV|0.5 mL HEPLISAV
62698595|NCT02704884|EXPERIMENTAL|probiotic soy milk|consume a diet containing 200 ml/day probiotic soy milk in intervention group
61948245|NCT01195246|ACTIVE_COMPARATOR|Engerix-B|2.0 mL Engerix-B
61948246|NCT01195246|ACTIVE_COMPARATOR|Fendrix|0.5 mL Fendrix
61948247|NCT04382391|EXPERIMENTAL|gammaCore Sapphire® (nVNS) plus standard of care|Subjects will be administered study treatment with the nVNS device 3 times per day (prophylaxis) and also as needed for acute respiratory symptoms.
61948248|NCT04382391|ACTIVE_COMPARATOR|standard of care alone|Will receive standard of care therapies to treat CoViD-19 infection and symptoms
61948249|NCT04211181|EXPERIMENTAL|The multifaceted QI interventions|Hospitals randomized into experimental group will implement follow interventions including：the distribution of the guideline and pathway, a computer alert(computer-based clinical decision support system and computerized reminders),audit and feedback.
61948250|NCT04211181|ACTIVE_COMPARATOR|Routine VTE prophylaxis in local clinical practice|Patients in the routine VTE prophylaxis(control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices.
61948251|NCT06483178|EXPERIMENTAL|Attune|
61948252|NCT06483178|ACTIVE_COMPARATOR|Triathlon|
61948253|NCT03918161|EXPERIMENTAL|MRE exam|Magnetic Resonance Elastography (MRE) exam associated with standard T1-weighted and T2-weighted sequences
62164461|NCT03204045|ACTIVE_COMPARATOR|fentanyl|fentanyl 1 ㎍/kg
62341290|NCT03674203|EXPERIMENTAL|Application of platelet-rich plasma|The patients received three sessions of PRP application, at intervals of 15 days between each of them. It was applied by means of a 32G needle to introduce the PRP by means of superficial micro-injections via the mesotherapy technique (approximately 1.5-2.0 mm deep) and it was deposited in the papillary dermis of the rosotro.
62341291|NCT03916172|EXPERIMENTAL|APT Treatment|Participants in this arm will receive the Open Door Approach to Parenting Teenagers (APT). It offers 6 weekly 50-minute appointments with an optional 7th review session.
62341292|NCT03916172|NO_INTERVENTION|Waiting List|Participants in this group will be placed on a waiting list and will receive APT treatment after no longer than 25 weeks.
62341293|NCT00421603|ACTIVE_COMPARATOR|Adderall-XR and Topiramate|Adderall-XR (60 mg/day) and Topiramate (300mg/day)
62341294|NCT00421603|PLACEBO_COMPARATOR|Placebo|Placebo
62341295|NCT00052884|EXPERIMENTAL|Amifostine, Melphalan, and Stem Cell Reconstitution|Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2
62341296|NCT03569865|EXPERIMENTAL|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
62497991|NCT04113616|EXPERIMENTAL|Part A - Arm 2|"KRT-232(7-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
62497992|NCT04113616|EXPERIMENTAL|Part A - Arm 3|"KRT-232(14-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
62497993|NCT04113616|EXPERIMENTAL|Part B - Arm 1|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle
62698596|NCT02704884|ACTIVE_COMPARATOR|soy milk|200 ml/day soy milk in the control condition
61948254|NCT01315665|EXPERIMENTAL|Healthy volunteers|100 grams of raw broccoli sprouts once daily for 5 consecutive days
61948255|NCT01315665|EXPERIMENTAL|Subjects with cystic fibrosis|100 grams of raw broccoli sprouts once daily for 5 consecutive days
61948256|NCT02454725|EXPERIMENTAL|Social Network|Leaders of social networks will communicate messages endorsing regular HIV testing to network members.
61948257|NCT02454725|ACTIVE_COMPARATOR|Comparison|HIV counseling and testing
61948258|NCT00875264|EXPERIMENTAL|1|At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
61948259|NCT01868464|EXPERIMENTAL|BCG 16x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 16x10\^6 cfu
61948260|NCT01868464|EXPERIMENTAL|BCG 2x10^6 CFU|30 subjects, one dose of Tice Bacillus Calmette-Guerin vaccine (BCG) intradermally, 2x10\^6 colony forming units (cfu)
61948261|NCT01868464|EXPERIMENTAL|BCG 4x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 4x10\^6 cfu
61948262|NCT01868464|EXPERIMENTAL|BCG 8x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 8x10\^6 cfu
61948263|NCT02077283||Healthy people|This group contains healthy people only whose liver function and B ultrasound are normal.
61948264|NCT02077283||"group of liver depression and spleen deficiency pattern"|"In this group, patients are considered to be the pattern of liver depression and spleen deficiency. They mainly have the symptoms of loose stool, depression, fat tongue with white coating and teeth marks and soft or string pulse."
61948265|NCT02077283||"group of damp-heat in the interior pattern."|In this group ,NAFLD patients have symptoms with dry mouth, bitter mouth, heavy feeling in legs, yellow urine, reddish tongue with thick yellowish coating and slippery pulse.
61948266|NCT03835871|EXPERIMENTAL|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 12 weeks
61948267|NCT03835871|EXPERIMENTAL|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg per day Daily dose of Beclomethasone 200 µg 1 inhalation 100 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
62140506|NCT04574466|EXPERIMENTAL|Problem Management Plus|"The participants who are assigned to the intervention group will receive five sessions of PM+, a psychological intervention which has been developed by the WHO. PM+ is a new short, transdiagnostic (i.e., not specifically aimed at treating a certain mental disorder) program aiming to reduce common mental health symptoms and improve psychosocial functioning.~PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, and accessing social support. These elements have been recommended in recent WHO guidelines. PM+ has proven to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan."
62497994|NCT04113616|EXPERIMENTAL|Part B - Arm 2|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle in Cycle 1, followed by 240 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day cycle, in the subsequent cycles.
62497995|NCT04113616|EXPERIMENTAL|Part B - Arm 3|KRT-232 administered at 180 mg orally, once daily (QD) on Days 1-7 with 14 days off on a 21-day treatment cycle.
62497996|NCT05953506|EXPERIMENTAL|HS-10506|Healthy participants will be enrolled in dose escalation cohorts. Healthy participants will be receive either HS-10506 or matching placebo on Day 1.
62698597|NCT00561379|ACTIVE_COMPARATOR|1|
62698598|NCT00561379|ACTIVE_COMPARATOR|2|
62698599|NCT03801993||All Subjects|Subjects with a diagnosis of Cystic Fibrosis (CF) who meet all the inclusion and none of the exclusion criteria will be eligible for participation in this study.
62497997|NCT05953506|EXPERIMENTAL|HS-10506 Placebo|Healthy participants will be enrolled in dose escalation cohorts. Healthy participants will be receive either HS-10506 or matching placebo on Day 1.
62698600|NCT05617079||Medicine physicians|Anesthesiologists, intensive care specialists, heads of departments of anesthesiology and intensive care, deputy chief physicians for anesthesiology and intensive care (heads of centers), employees of the department of anesthesiology and intensive care, pulmonologists working in medical organizations that use nebulizer therapy.
62698601|NCT04458766|EXPERIMENTAL|Interventions|"All subjects in this trial will receive the following interventions:~1. Pre-Intervention (Days 0-14): Subjects given access to Wellth application reminders, no incentives provided. A virtual check in with the study team will occur at the end of the pre-intervention period (14 days).~2. Intervention (Days 15-74): Subjects will use Wellth app for 60 days, with incentives provided at the 30- and 60-day mark. At the end of the intervention period (Day 60), the subject will attend a clinic visit with the medical provider and a fasting lipid panel and MMAS will also be collected at this time.~3. Post-intervention (Days 74-134): Subjects will continue to use the Wellth app and receive reminders, but with no incentives provided, for 60 days. A clinic visit, fasting lipid profile, and MMAS will also be collected following the post-intervention period."
61948268|NCT03835871|EXPERIMENTAL|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg per day Daily dose of Beclomethasone 100 µg 1 inhalation 50 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
61948269|NCT03835871|PLACEBO_COMPARATOR|placebo|Intervention: Drug: placebo 2 inhalations 2 times a day for 12 weeks
61948270|NCT03308786|EXPERIMENTAL|IL2 treatment|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles, in addition to combination antiretroviral therapy.
61948271|NCT02479607|EXPERIMENTAL|Intervention group|Use of an application for a smartphone or tablet for daily reporting symptoms and access to self-care advice and health care professionals in real time in combination with standard care according to the clinic´s routines
61948272|NCT02479607|NO_INTERVENTION|Control group|Standard care according to the clinic's routines.
61948273|NCT02401022|ACTIVE_COMPARATOR|AZD8529 low dose|1.5 mg
61948274|NCT02401022|ACTIVE_COMPARATOR|AZD8529 high dose|40mg
61948275|NCT06556628||Fever|Elevated oral temperature of 37.5C or higher or elevated axillary temperature of 37.2C or higher.
61948276|NCT06556628||Healthy|Oral temperature between 36-37.4C Axillary temperature between 36-37.1C
61948277|NCT06556628||Cold|Oral or axillary temperatures below 36C
62698602|NCT06554587||Patients with suspected prostate cancer or on active surveillance|Diagnostic tests to measure three separate biomarkers in blood taken from patients pre-biopsy to assess the diagnostic performance of the biomarkers in detecting clinically significant prostate cancer (Gleason score ≥7)
62698603|NCT04830085|EXPERIMENTAL|Patients with adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was diagnosed with histopathological assessment.
61948278|NCT00938236|OTHER|Inhaled cyclosporine|Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
61948279|NCT03172169||Healthy control group|no intervention
61948280|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was \>48 hours and the first SBT failure
61948281|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
61948282|NCT00794703|EXPERIMENTAL|1. Micafungin|
61948283|NCT00794703|ACTIVE_COMPARATOR|2. Itraconazole|
61948284|NCT04076878|EXPERIMENTAL|Intervention in a Mechanism and a Clinical substudy|"Mechanism substudy: 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo). Patients and datacollectors were blinded in terms of the randomised order of the treatment at each of the 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo).~Clinical substudy: Use of the fitted and individually set body suit, Mollii, in the home setting for 6 weeks"
61948285|NCT00956969|EXPERIMENTAL|Anger awareness and expression|Training for anger awareness and expression
61948286|NCT00956969|ACTIVE_COMPARATOR|Relaxation Training|Teach patients relaxation training
61948287|NCT00956969|NO_INTERVENTION|No-treatment control|Assessment only control condition
61948288|NCT01000402|OTHER|Psychopharmacotherapy|No specific arms; Treatment decision based on available guidelines
61948289|NCT02957929|EXPERIMENTAL|Cohort 1a, Period A|single intravenous dose, crossover
61948290|NCT02957929|EXPERIMENTAL|Cohort 1a, Period B|single oral dose, crossover
61948291|NCT02957929|EXPERIMENTAL|Cohort 1a, Period C|single oral dose
61948292|NCT02957929|EXPERIMENTAL|Cohort 1a, Period D|single oral dose, crossover
61948293|NCT02957929|EXPERIMENTAL|Cohort 1b, Period E|Single oral dose under fasted conditions, crossover
61948294|NCT02957929|EXPERIMENTAL|Cohort 1b, Period F|Single oral dose under fed conditions, crossover
62140507|NCT06419296||CAZAVI + ATM|patients who received antibiotic therapy with a standard bacteremia treatment dose of Ceftazidima-Avibactam + Aztreonam (2.5 grams every 8 hours of ceftazidime-avibactam + 2 grams every 8 hours of aztreonam). Dosage adjustments for prolonged infusion or according to renal function will be considered.
62164462|NCT03204045|ACTIVE_COMPARATOR|oxycodone|oxycodone 0.08 mg/kg
62698604|NCT04830085|ACTIVE_COMPARATOR|Patients without adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was excluded with histopathological assessment.
62698605|NCT06639659|PLACEBO_COMPARATOR|Group C (control group) (n=23) patients will be operated under general anesthesia.|
62698606|NCT06639659|ACTIVE_COMPARATOR|Group SPGP (n=23) patients will receive ultrasound guided bilateral sphenopalatine block|
61948295|NCT02957929|EXPERIMENTAL|Cohort 2|Multiple oral doses
61948296|NCT02957929|EXPERIMENTAL|Cohort 3|Multiple oral doses
61948297|NCT02957929|EXPERIMENTAL|Cohort 4|Multiple oral doses in presence of CYP probe substrates
61948298|NCT00911547|EXPERIMENTAL|1|Montelukast + Beclomethasone
61948299|NCT00911547|EXPERIMENTAL|2|Montelukast + Placebo inhaler
61948300|NCT00911547|EXPERIMENTAL|3|Placebo tablet + Beclomethasone
61948301|NCT00911547|PLACEBO_COMPARATOR|4|Placebo tablet + Placebo inhaler
61948302|NCT01786655|EXPERIMENTAL|Neosaxitoxin in saline|Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
61948303|NCT01786655|EXPERIMENTAL|Neosaxitoxin + bupivacaine 0.2%|Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
61948304|NCT01786655|EXPERIMENTAL|Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml|Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
61948305|NCT01786655|PLACEBO_COMPARATOR|Saline placebo|Subjects receive one injection of saline on the back of one calf (test side).
61948306|NCT02659293|ACTIVE_COMPARATOR|Lenalidomide (Control)|Treatment with lenalidomide only
61948307|NCT02659293|EXPERIMENTAL|Experimental Combination Regimen|Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
61948308|NCT04622306|ACTIVE_COMPARATOR|Control Latex Condom C|Commercial Natural Rubber Latex Male Condom
61948309|NCT04622306|EXPERIMENTAL|Polyurethane Condom A|Polyurethane Condom A (002)
61948310|NCT04622306|EXPERIMENTAL|Polyurethane Condom B|Polyurethane Condom B (001)
61948311|NCT01869517|ACTIVE_COMPARATOR|Intrastromal corneal continuous ring (Myoring)|
61948312|NCT01869517|ACTIVE_COMPARATOR|Intrastromal corneal ring segments (Keraring)|
61948313|NCT00978978|ACTIVE_COMPARATOR|Propofol, endoscopies, liver diseases|Propofol, endoscopies, liver diseases
61948314|NCT00978978|ACTIVE_COMPARATOR|midazolam and fentanyl, endoscopies, liver diseases|Control: midazolam and fentanyl, endoscopies, liver diseases
61948315|NCT03846804|EXPERIMENTAL|Karius Test|Participants will have additional blood drawn for the purposes of analysis with the Karius test.
61948316|NCT02152800|EXPERIMENTAL|Vacyless® 1000 mg|one Vacyless® 1000 mg tablets, 3 times daily for 7days
61948317|NCT02152800|EXPERIMENTAL|Vacyless® 500mg|Two Vacyless® 500mg tablets, 3 times daily for 7 days
61948318|NCT02152800|ACTIVE_COMPARATOR|Valtrex® 500 mg|Two Valtrex® 500 mg tablets, 3 times daily for 7days
62164463|NCT03204045|PLACEBO_COMPARATOR|control|isotonic saline
62164464|NCT02952235|OTHER|SPF50+|SPF 50+ assigned to Left side of face SPF 100+ assigned to Right side of face
62164465|NCT02952235|OTHER|SPF100+|SPF 100+ assigned to Left side of face SPF 50+ assigned to Right side of face
61948319|NCT01599195||adults|adults audiodoc use to evaluate for carotid or femoral bruit
61948320|NCT05686031||Doctors|Anaesthesiologists
61948321|NCT05686031||Anaesthesia Nurses|
61948322|NCT06199778|EXPERIMENTAL|the observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
61948323|NCT06199778|ACTIVE_COMPARATOR|the control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
61948324|NCT03610282|EXPERIMENTAL|EEG Dynamics|EEG data will be collected on patients receiving propofol and IV methylphenidate together.
61948325|NCT03610282|PLACEBO_COMPARATOR|Propofol EEG Dynamics|EEG data will be collected on patients receiving propofol and a saline placebo.
61948326|NCT05170464|EXPERIMENTAL|Acute Exercise|20 minutes of moderate intensity acute exercise (treadmill speed to achieve ⅔ of maximum heart rate).
61948327|NCT05170464|ACTIVE_COMPARATOR|Caffeine Ingestion|1.2mg/kg of powdered caffeine (Caffeine powder, ReagentPlus® from Sigma-Aldrich) dissolved in 1 cup of water then sitting for 20 minutes.
61948328|NCT03488732||Patients undergonig transcatheter valvular interventions|
61948329|NCT02014571|EXPERIMENTAL|Cohort A|Eight subjects will be randomized to receive either 10 mg of GSK2878175 active treatment (4 HCV genotype 1a \[GT1a\] and 2 HCV genotype 1b \[GT1b\]) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
61948330|NCT02014571|EXPERIMENTAL|Cohort B|Eight subjects will be randomized to receive either 30 mg of GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
61948331|NCT02014571|EXPERIMENTAL|Cohort C|Eight subjects will be randomized to receive either GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
61948332|NCT02014571|EXPERIMENTAL|Cohort D|Twenty subjects will be randomized to receive either 60 mg of GSK2878175 active treatment (6 GT2, 6 GT3, 3 GT4) or matching placebo (2 GT2, 2 GT3, 1 GT4).
61948333|NCT06440902|EXPERIMENTAL|RAS mutated metastatic colorectal cancer|RAS mutated metastatic colorectal cancer were routinely treated after enrollment. When the disease progression was confirmed by imaging, peripheral blood ctDNA detection was performed to observe whether they were transformed into NeoRAS wild-type patients. If NeoRAS wild- type was detected, the anti-EGFR therapy may be considered as the following therapy for patients.
61948334|NCT00285233|EXPERIMENTAL|1|
61948335|NCT02033187|EXPERIMENTAL|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
61948336|NCT02033187|ACTIVE_COMPARATOR|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
61948337|NCT05938842|EXPERIMENTAL|Online DBT-Mindfulness intervention|"Experimental group Dialectical behavior therapy (DBT) is a type of cognitive behavioral intervention. The module of Mindfulness is directed to balance emotion with reasoning in order to achieve wise mind, to act with awareness and to decrease characteristic mood dependent."
61948338|NCT05938842|ACTIVE_COMPARATOR|Online psychoeducational intervention|Active control group,
61948339|NCT01604408|EXPERIMENTAL|LY2495655|Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
61948340|NCT01604408|PLACEBO_COMPARATOR|Placebo|Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
61948341|NCT03424408|OTHER|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
61948342|NCT02420340|OTHER|HOPES Group|Participants will participate in twice weekly sessions of the HOPES program until curriculum is completed (approximately 1 year) or discharge from Glencliff home
61948343|NCT02407795|ACTIVE_COMPARATOR|Arm 1|Conventional radiotherapy, 1x8Gy
61948344|NCT02407795|EXPERIMENTAL|Arm 2|Stereotactic radiotherapy, 1x20Gy
61948345|NCT05218135||Intervention|Breakthrough improvement collaborative
61948346|NCT02056639|EXPERIMENTAL|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
61948347|NCT02056639|NO_INTERVENTION|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
61948348|NCT04877483|EXPERIMENTAL|Group GB20|Group GB20 will received acupuncture at acupoint GB20 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
61948349|NCT04877483|EXPERIMENTAL|Group GB20 plus BL2|Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
61948350|NCT04877483|OTHER|Healthy control|Healthy control group will not received any treatment. And we could use the oral microbiota, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability to find the difference with the comparison between the dry eye syndrome and healthy control.
62497998|NCT01878513|EXPERIMENTAL|Low-dose-titration condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
61948351|NCT04877483|OTHER|Waiting list|Group Waiting list will not received any treatment. at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
61948352|NCT02898129|EXPERIMENTAL|Tube houses|Tube Houses. Group of 75-100 houses, with 4 inhabitants per house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
61948353|NCT02898129|EXPERIMENTAL|Apartment|Apartments. Group of 75-100 apartments, with 4 inhabitants per apartment. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
61948354|NCT02898129|EXPERIMENTAL|Rental Houses|Rental Houses. Group of 150-200 rental houses, with 2 inhabitants per rental house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
61948355|NCT02898129|EXPERIMENTAL|Rural houses|Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
61948356|NCT04299542|ACTIVE_COMPARATOR|conventional Multi-detector CT (MDCT)|Percutaneous lung biopsy using MDCT
61948357|NCT04299542|ACTIVE_COMPARATOR|cone-beam CT (CBCT)|Percutaneous lung biopsy using CBCT
62497999|NCT01878513|EXPERIMENTAL|Treatment-as-usual condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the treatment-as-usual condition, patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
62698607|NCT06639659|ACTIVE_COMPARATOR|Group DEX (n=23) patients will receive dexmedetomidine drug.|
61948358|NCT01848496|EXPERIMENTAL|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
61948359|NCT01848496|ACTIVE_COMPARATOR|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
61948360|NCT01201785|EXPERIMENTAL|Aspirin dose range|
61948361|NCT03489148|EXPERIMENTAL|Tamarkoz®|A Sufi method to focus, called Tamarkoz®. Participants had met in class twice a week for two and a half hours total for three months. One day of the week, they met for theoretical teachings of Sufism, and for the second day in the week they met with a Tamarkoz® instructor to learn meditation techniques.
61948362|NCT03489148|ACTIVE_COMPARATOR|Stress Management Resources|The self-care stress management group used the campus resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, and online reading materials for stress management as needed for themselves.
62698608|NCT01516476|EXPERIMENTAL|Liraglutide Arm|
61948363|NCT03489148|NO_INTERVENTION|Waitlist|The waitlist control group did not receive Tamarkoz® and did not use the stress management resources on campus for the duration of the study.
62140508|NCT06419296||Other Active Antibiotics treatment group|"Patients who received a combination or at least one of the following antibiotics, with doses adjusted according to renal function:~Colistin: 300 mg loading and 150 mg maintenance every 12 hours. Meropenem: 1000 or 2000 mg every 8 hours via infusion in 30 minutes or 3 hours. Fosfomycin: 12 to 24 grams per day, divided every 6 to 8 hours. Aminoglycoside (amikacin: 15 mg/kg/24 hours or gentamicin: 7 mg/kg/24 hours). Tigecycline: 100 or 200 mg loading and 50 or 100 mg maintenance every 12 hours."
62698609|NCT01516476|PLACEBO_COMPARATOR|Placebo Arm|
62140509|NCT05228184|EXPERIMENTAL|Treatment|Tirosint®-SOL (levothyroxine sodium) oral solution (IBSA Pharma Inc.) at the following strengths: 13, 25, 37.5, 44, 50, 62.5, 75, 88, 100 mcg.
62140510|NCT05228184|ACTIVE_COMPARATOR|Control|Crushed levothyroxine sodium tablets
62140511|NCT01988402|ACTIVE_COMPARATOR|Allopurinol|Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days
62140512|NCT01988402|PLACEBO_COMPARATOR|Sugar pill (Placebo)|Patients in this arm receive one placebo (sugar) pill per day for 14 days then 2 placebo pills for 14 days.
62140513|NCT05473663|ACTIVE_COMPARATOR|Radiofrequency Ablation|Patient undergoing genicular nerve radiofrequency ablation.
62140514|NCT05473663|SHAM_COMPARATOR|Sham|Patient undergoing sham.
62164466|NCT00574301|EXPERIMENTAL|1|
62164467|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
62698610|NCT01516476|EXPERIMENTAL|RO6807952 Arm 1|
62698611|NCT01516476|EXPERIMENTAL|RO6807952 Arm 2|
62698612|NCT03490565|ACTIVE_COMPARATOR|EX group|Exercise training
62698613|NCT03490565|NO_INTERVENTION|CON-group|Usual Care
62698614|NCT05913687||Parkinson's disease|Clinically diagnosed Parkinson's disease
62698615|NCT05913687||Multiple System Atrophy, Parkinsonian variant|Clinically diagnosed Multiple System Atrophy, Parkinsonian variant
62698616|NCT05913687||Progressive Supranuclear Palsy|Clinically diagnosed Progressive Supranuclear Palsy
62698617|NCT01230060|EXPERIMENTAL|enVista|enVista One-Piece Hydrophobic Acrylic Intraocular Lens
62698618|NCT04936555|EXPERIMENTAL|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
62698619|NCT04936555|NO_INTERVENTION|No Intervention|Control group Routine maintenance will be applied
62698620|NCT04694287||Volume flow group|The study will include consecutive patients undergoing standard fluoroscopically-guided percutaneous balloon angioplasty due to dysfunctional AVF. Intraprocedural volume flow measurements will be obtained just prior to the procedure and after final balloon dilation.
61948364|NCT04851457|EXPERIMENTAL|Intervention group|The participants in the experimental group will receive intravenous tirofiban combined with a standard MT protocol recommended by the current guidelines for the management of AIS
61948365|NCT04851457|NO_INTERVENTION|Control group|Patients are treated with MT therapy with no antiplatelet drugs (intravenous or intra-arterial) are administered. Besides, they will receive a standard pharmacological treatment as per current clinical guidelines.
61948366|NCT01072383|EXPERIMENTAL|BT061|receiving BT061 (active compound)
61948367|NCT01072383|PLACEBO_COMPARATOR|Placebo|receiving a placebo
62498000|NCT01878513|EXPERIMENTAL|Open-label treatment-as-usual condition|Extensive and ultrarapid CYP2D6 metabolizers will be treated open-label in the treatment-as-usual condition. Patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
61948368|NCT00886561|EXPERIMENTAL|HIV risk reduction intervention|Behavioral intervention designed to reduce HIV risk behaviors and enhance enhance HIV-preventive behaviors among female sex workers (FSWs) in Armenia
61948369|NCT00886561|ACTIVE_COMPARATOR|Wait list control|Will receive behavioral intervention after completion of study upon request.
61948370|NCT00875992|EXPERIMENTAL|ETN with ASLS|Angle stable locking of the Expert Tibial Nail using ASLS
61948371|NCT00875992|ACTIVE_COMPARATOR|ETN with conventional locking|Conventional locking of the Expert Tibial Nail using conventional locking bolts
61948372|NCT00983762||MIS knee arthroplasty|Persons scheduled for Minimally Invasive Surgery Mini-Incision (MIS) Total Knee Arthroplasty (TKA)
61948373|NCT00983762||Unicompartmental knee arthroplasty|Persons scheduled for Unicompartmental knee arthroplasty
61948374|NCT00983762||Standard knee arthroplasty|Persons scheduled for Standard Para-patellar surgery TKA
61948375|NCT00983762||Heathly knee subjects|Persons with healthy knees
61948376|NCT05932966||Patients with type 1 Diabetes equipped with control-IQ closed loop system|Patients with type 1 Diabetes equipped with control-IQ closed loop system
61948377|NCT05932966||Patients with type 1 diabetes equipped with Smart GUARD closed loop system|Patients with type 1 diabetes equipped with Smart GUARD closed loop system
61948378|NCT06410599|EXPERIMENTAL|Ketamine+TAU|"Combination of ketamine hydrochloride (Ketamin Inresa 2 ml) and TAU during week 4 to 6.~TAU (treatment as usual): standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements."
61948379|NCT06410599|PLACEBO_COMPARATOR|Placebo+CBASP|"Combination of placebo and CBASP during week 4 to 6.~CBASP: In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific."
61948380|NCT06410599|EXPERIMENTAL|Ketamine+CBASP|"Combination of ketamine hydrochloride (Ketamin Inresa 2 ml) and CBASP during week 4 to 6.~CBASP: In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific."
62140515|NCT01898299|EXPERIMENTAL|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
62498001|NCT02126150||Ethnicity|
62498002|NCT00464386|NO_INTERVENTION|POC Glucose Testing|Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
62498003|NCT00464386|EXPERIMENTAL|Continuous Glucose Monitoring|Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
62498004|NCT02141048|EXPERIMENTAL|Positive Parenting Skills Training|Participants assigned to the intervention group will receive the Positive Parenting Skills Training.
62698621|NCT05301127|ACTIVE_COMPARATOR|CSEGA group|Will be received combined spinal-epidural-general anesthesia.
61948381|NCT04208997|EXPERIMENTAL|Continuation of antiarrhythmic drugs|Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
61948382|NCT04208997|NO_INTERVENTION|Discontinuation of antiarrhythmic drugs|Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.
61948383|NCT03137420||Severely injured patients and their relatives|Severely injured patients (ISS \> 16) and their relatives. Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
61948384|NCT03137420||Monotrauma patients and theri relatives|Patients with isolated non-life threatening musculo-skeletal injuries and their relatives (control). Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
61948385|NCT02326051|ACTIVE_COMPARATOR|Early Enoxaparin initiation|Women will start Enoxaparin therapy once positive pregnancy test is established
61948386|NCT02326051|ACTIVE_COMPARATOR|Later Enoxaparin initiation|Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation
61948387|NCT06558461|EXPERIMENTAL|3% hypertonic saline|Children will receive standard medical care coordinating with nebulizing 3% hypertonic saline in the treatment of bronchiolitis. They received 4ml of 3% Sodium chloride, nebulized three times daily until discharge.
61948388|NCT06558461|ACTIVE_COMPARATOR|Control|Children will only receive standard medical care.
62140516|NCT01898299|SHAM_COMPARATOR|Sham tDCS|Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
62140517|NCT00692120|EXPERIMENTAL|1|
62140518|NCT00692120|EXPERIMENTAL|2|
62140519|NCT00692120|EXPERIMENTAL|3|
62498005|NCT02141048|NO_INTERVENTION|Wait-list control|Participants assigned to the wait-list control group will receive no intervention for the duration of this trial. Only after the one-year follow-up assessment has been completed will they receive the Positive Parenting Skills Training.
62698622|NCT05301127|NO_INTERVENTION|GA group|will be received general anesthesia only.
62698623|NCT05536115||Study population|Study patients are patients with post-extraction dry socket.
62698624|NCT04450550|ACTIVE_COMPARATOR|Active|
62698625|NCT04450550|SHAM_COMPARATOR|Sham|
62698626|NCT06253650|EXPERIMENTAL|Experimental|treatment with T-DXd (6.4 mg/kg intravenous every 3 weeks) plus capecitabine (1000 mg/sqm BID orally on days 1-14 every 3 weeks) or 5-fluorouracil (600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks) as per Investigator's choice for 6 cycles.
62140520|NCT00692120|EXPERIMENTAL|4|
62140521|NCT04233905||mute children|mute children and their mothers
62140522|NCT04233905||healthy children|healthy children control group
62140523|NCT04233905||mute adults|formerly mute adults
62140524|NCT04233905||healthy adults|healthy adults control group
61948389|NCT01058655|EXPERIMENTAL|Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
61948390|NCT01058655|EXPERIMENTAL|Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
61948391|NCT01058655|EXPERIMENTAL|Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
61948392|NCT01058655|EXPERIMENTAL|Phase II: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
61948393|NCT03784703|EXPERIMENTAL|Atrovastatin|atorvastatin (40 mg per day) for 6 months
61948394|NCT03784703|EXPERIMENTAL|Rosuvastatin|Rosuvastatin (10 mg per day) for 6 months
61948395|NCT06503913|EXPERIMENTAL|Treatment|Each participant will receive seven weekly sessions of Cognitive Muscular Therapy (CMT) + Breathing Visualisation at the University of Salford from an respiratory physiotherapist. This physiotherapist will have been trained to deliver the CMT intervention and will have at least three years' experience of working with patients with respiratory disorders. Each treatment session will last 45-60 mins. The CMT intervention comprises five components: Understanding long-COVID, general relaxation, postural deconstruction, contextual triggers and functional integration. Breathing Visualisation will be integrated into session 5, 6 and 7.
61948396|NCT02607930|EXPERIMENTAL|B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo administered without regard to food for at least 144 weeks.
61948397|NCT02607930|ACTIVE_COMPARATOR|ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo administered without regard to food for at least 144 weeks.
61948398|NCT02607930|EXPERIMENTAL|Open-label Phase B/F/TAF to B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
62140525|NCT06362291|EXPERIMENTAL|MRI-AI-guided cTB (AI-cTB) group|The trained AI algorithms were embedded into proprietary structured reporting software. Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. The prostate gland and suspicious lesions were annotated and highlighted by AI software. The urologists who were blinded to the picture archiving and communication system (PACS) and MRI reports read the AI findings at their discretion and then conducted 3-5 core TB at each suspicious lesion, followed by 12 core SB. If there was no suspicious lesion detected by the AI, only SB would be performed.
62140526|NCT06362291|EXPERIMENTAL|Routine cTB group|For patients in the cTB group, the MR images and reports were viewed by urologists preceding the biopsy. Then 3-5 core cTB were performed, followed by 12 core SB. In patients with negative MRI findings, only SB was performed. When urologists performed biopsies, ultrasound technicians and radiologists were present to provide necessary assistance.
62341297|NCT03569865|EXPERIMENTAL|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
62341298|NCT03569865|PLACEBO_COMPARATOR|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (\<1 Hz) frequency (outside of the entrainment range).
62341299|NCT04915924|EXPERIMENTAL|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
61948399|NCT02607930|EXPERIMENTAL|Open-label Phase ABC/DTG/3TC to B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
61948400|NCT05527197|OTHER|Patient reported function of daily ADL's post combined first MTP/TMT joint arthrodesis|Patients that meet the inclusion criteria will be contacted for participation in the study. If the patient agrees to participate in the study, informed consent will be obtained. The retrospective study will consist of a chart review and baseline radiographic analysis. The prospective follow-up will consist of the patient completing the Post-Operative Function and Satisfaction Survey via phone call with study staff. Radiographic images will be analyzed by a single central radiologist.
61948401|NCT06395129||Cohort study|"All participants in the cohort study will undergo surveys, HIV, and HCV testing at four possible timepoints (baseline, 6-months, 12-months, and if time permits 18-months).~They will also have access to the study sites usual services, and the introduced LDSS/N."
61948402|NCT01052571|ACTIVE_COMPARATOR|Without Steroids|Group I patients receiving lumbar transforaminal epidural injections with an injection of local anesthetic (lidocaine 1% or bupivacaine 0.25%
61948403|NCT01052571|ACTIVE_COMPARATOR|steroids|Group II patients will receive lumbar transforaminal epidural injections with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
61948404|NCT01691131|OTHER|Exercise training on land|High intensity exercise training on land.
62341300|NCT05945901|EXPERIMENTAL|HR070803|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
62341301|NCT05945901|PLACEBO_COMPARATOR|HR070803 simulator|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
62341302|NCT02144961||Ultrasound|Breast ultrasound in female patients who are post-mastectomy pursuing autologous tissue breast reconstruction surgery.
62341303|NCT01892319||All patients|
62341304|NCT01213368|EXPERIMENTAL|dronedarone 300 mg|Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
62341305|NCT01213368|EXPERIMENTAL|dronedarone 400 mg|Dronedarone, 400mg tablets twice daily, administered with food.
62341306|NCT01213368|EXPERIMENTAL|dronedarone 600 mg|Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
62498006|NCT05756465|EXPERIMENTAL|SVR group|Participant in the intervention arm will receive immersive virtual reality intervention in the form of VR box (Shinecon 6.0 VR Box Virtual Reality Glasses with headphones). SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) which attached to the head of cancer patient during chemotherapy, by displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical audio instruments (non-copyright).
62498007|NCT05756465|NO_INTERVENTION|Control group|In the control group, participants will be given standard care in the form of guided imagery leaflets. It is an information sheets in the form of leaflets about the meaning, benefits, and ways of doing guided imagery relaxation therapy for cancer patient during chemotherapy. RA will guide the participants to practice the guided imagery relaxation therapy listed on the leaflet for ± 10 minutes.
62498008|NCT05581134|EXPERIMENTAL|Virtual Reality Group|Patients will attend the in-person 5-day rehabilitation program (2 h/day) to re-establish normal movement patterns in a dynamic and challenging VR environment. During each session, the patients will be supervised by the physiotherapist. The immersive VR system will simultaneously deliver visual and auditory distractors during the exercises.
62498009|NCT05581134|ACTIVE_COMPARATOR|Control Group Treatment|Patients will attend the in-person 5-day rehabilitation program (2 h/day) to re-establish normal movement patterns within a multidisciplinary etiological framework according to a validated rehabilitation protocol for FMDs.The conventional group will undergo the same dose, frequency, and intensity of rehabilitation treatment as the VR group consisting of rehabilitation without VR exercises.
62698627|NCT06253650|ACTIVE_COMPARATOR|Control|treatment with post-operative FLOT for 4 cycles as per standard of care and using the doses previously adopted in the last cycle of the preoperative phase, i.e. 5-fluorouracil (2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks), leucovorin (200 mg/m2 intravenous infusion on day 1 every 2 weeks), oxaliplatin 85 mg/m2 (intravenous infusion on day 1 every 2 weeks) and docetaxel (50 mg/m2 intravenous infusion on day 1 every 2 weeks).
61948405|NCT01691131|OTHER|Exercise training on water|High intensity exercise training on water.
61948406|NCT02599896|EXPERIMENTAL|Group 1|5 mg/kg/IV on Day 0
61948407|NCT02599896|EXPERIMENTAL|Group 2|5 mg/kg SC on Day 0
61948408|NCT02599896|EXPERIMENTAL|Group 3|20 mg/kg IV on Day 0
61948409|NCT02599896|EXPERIMENTAL|Group 4|40 mg/kg IV on Day 0
61948410|NCT02599896|EXPERIMENTAL|Group 5|5 mg/kg SC on Day 0, Week 12 and Week 24
61948411|NCT02599896|EXPERIMENTAL|Group 6|20 mg/kg IV on Day 0, Week 12 and Week 24
61948412|NCT02599896|EXPERIMENTAL|Group 7|5 mg/kg SC on Day 0, Week 4
61948413|NCT02599896|EXPERIMENTAL|Group 8|20 mg/kg IV on Day 0, Week 4
62341307|NCT01213368|PLACEBO_COMPARATOR|placebo|Matching placebo tablets twice daily, administered with food.
62341308|NCT05145478||Shockwave Intravascular Lithotripsy (IVL)|Patients with calcified common-femoral artery disease, who are eligible to receive IVL per the FDA indications.
62341309|NCT01199250||Basic science (biomarker analysis)|Previously collected samples are analyzed for biomarker and other laboratory analyses.
62341310|NCT05775744|EXPERIMENTAL|Prospective interventional arm|The prospective cohort will identify patients in the postpartum period of their delivery hospitalization who are at risk of readmission for hypertensive disorders in the initial six weeks postpartum. Those at risk include patients with diagnosed with chronic hypertension or PIH. Chronic hypertension is defined as either taking antihypertensive medications or a blood pressure of greater than or equal to 140/90 mm Hg prior to 20 weeks of gestation. Pregnancy induced hypertension includes gestational hypertension, preeclampsia without severe features, preeclampsia with severe features and Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP). The minimum requirement to be diagnosed with this spectrum of disorders is having two blood pressures of greater than or equal to 140/90 mm Hg during the antepartum, intrapartum or postpartum periods.
62341311|NCT05775744|NO_INTERVENTION|Retrospective observational arm|The retrospective cohort will include all patients diagnosed with chronic hypertension or pregnancy-induced hypertensive (PIH) disorders at Robert Wood Johnson University Hospital and Cooperman Barnabas Medical Center in the past two years, including those presenting to the Emergency Department or readmitted for hypertensive disorders, during the immediate six weeks postpartum.
62341312|NCT05476185|EXPERIMENTAL|READY4Life Programming - classroom instruction|The intervention is an 16-hour classroom-based relationship education program taught by project staff. This instruction will strengthen and promote healthy marriages among young refugees and immigrants through education and comprehensive case management that will support an overall goal of helping youth build healthy relationship skills while supporting positive socio-emotional development and promoting successful transitions to young adulthood.
62498010|NCT03614455|EXPERIMENTAL|Milademetan alone (A)|During Period 1, participants receive a single 100 mg milademetan oral dose on Study Day 1, with PK sampling to 168 hours post-dose (during the following 7-day washout period)
62498011|NCT03614455|OTHER|Milademetan with itraconazole (AB)|During Period 2, participants receive itraconazole, 200 mg twice daily (BID) on Study day 8 and 200 mg once daily (QD) on Study Days 9 through 20, along with a single 100 mg milademetan dose on Day 14
61948414|NCT01199965|OTHER|IV DHE then MAP0004|Smokers and non-smokers received Intravenous Dihydroergotamine Mesylate (IV DHE) at Visit 2 followed by MAP0004 7-11 days later at Visit 3.
61948415|NCT01199965|OTHER|MAP0004 then IV DHE|Smokers and non-smokers received MAP0004 at Visit 2 followed by Intravenous Dihydroergotamine Mesylate (IV DHE) 7-11 days later at Visit 3.
61948416|NCT01971840|EXPERIMENTAL|MOVI-KIDS Program|Intervention group
61948417|NCT01971840|NO_INTERVENTION|Control|No intervention
61948418|NCT04674644|OTHER|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals|Dental professionals
61948419|NCT03720353|ACTIVE_COMPARATOR|Active H|Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.
61948420|NCT03720353|ACTIVE_COMPARATOR|Active L|Participants will take SAS2094AL and SAS2094BL for 10 days
61948421|NCT03720353|PLACEBO_COMPARATOR|Placebo|Participants will take placebo for 10 days.
62140527|NCT01356524|ACTIVE_COMPARATOR|Supplementary progesterone|Women with mid-luteal progesterone levels that are less than 15 ng/dl will receive higher doses of supplementary progesterone
62164468|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
62498012|NCT03614455|OTHER|Milademetan with posaconazole (AC)|During Period 2, participants receive 200 mg posaconazole three times daily (TID) on Study Days 8 through 20, along with a single 100 mg milademetan dose on Day 14
62498013|NCT02371837|EXPERIMENTAL|pilates group|Pilates based protocol for 6 weeks
62498014|NCT02371837|NO_INTERVENTION|control group|No treatment group
62498015|NCT01148069|EXPERIMENTAL|Surgery combined with IMRT-IGRT|
62498016|NCT05819437|NO_INTERVENTION|CONTROL|Standard of care for knee osteoarthritis
62498017|NCT05819437|EXPERIMENTAL|BALNEOTHERAPY PROGRAM|3-week balneotherapy program with Mineral Water of Saint Jean d'Angely in addition to standard of care for knee osteoarthritis
62498018|NCT06440278|EXPERIMENTAL|Behavioral Activation for Health and Depression|
62498019|NCT06440278|ACTIVE_COMPARATOR|Enhanced Usual Care|
62498020|NCT00178724||No Treatment Given|Any male or female 18 years or older admitted to a NACTN hospital, at the time of injury, with an initial (first time) spinal cord injury caused by trauma and has paralysis (muscle weakness) or loss of sensation (touch). The patient has not received medical or surgical care for this injury prior to admission to a NACTN hospital. Patient or family member must give consent to participate.
62498021|NCT06635200||Patients with a nociceptive pain phenotype|
62498022|NCT06635200||Patients with carpal tunnel syndrome with a neuropathic pain phenotype|
61948422|NCT01269411|EXPERIMENTAL|Treatment (RO4929097 and surgery)|"PART A: Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive oral RO4929097 once daily on days 1-7 and undergo surgery on day 8. Beginning 28 days later, patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
61948423|NCT00332280|EXPERIMENTAL|AMT2003|
61948424|NCT01824875|EXPERIMENTAL|Arm A (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
61948425|NCT01824875|EXPERIMENTAL|Arm B (temozolomide and capecitabine)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
61948426|NCT02171065|SHAM_COMPARATOR|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
61948427|NCT02171065|ACTIVE_COMPARATOR|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
61948428|NCT02932202|EXPERIMENTAL|Longitudinal Nutritional Counseling|The intervention group will be contacted every 2 weeks by medical students over the phone to provide nutrition counseling and complete a verbal survey. During the phone calls, participants will be asked a series of questions regarding their dietary intake over the course of the last 2 weeks. If any deficiencies are identified, participants will be counseled on those topics
62140528|NCT01356524|NO_INTERVENTION|No additional progesterone|No additional progesterone given to women with mid-luteal progesterone levels below 15 ng/dl
62140529|NCT03670121|EXPERIMENTAL|BTVA Treatment|All patients that will receive Bronchoscopic Thermal Vapor Ablation (BTVA) Treatment
62341313|NCT05476185|NO_INTERVENTION|No Intervention: Control|The control group does not receive any part of the classroom instruction that the intervention group receives. Like the intervention group, however, the control group does have access to case management.
62341314|NCT02235987|OTHER|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
62341315|NCT05454202||Non-communicating|Non-communicating (Glasgow ≤ 10) end-of-life patient hospitalized in palliative care (age ≥ 18 years old)
62341316|NCT04237324|EXPERIMENTAL|NAFL group|One side of the patient face has been therapied by 1565nm fiber nonablative fractional laser(Lumenis Co., Yokneam, Israel).
62341317|NCT04237324|ACTIVE_COMPARATOR|FMR group|Another side of the patient face has been therapied by FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
62341318|NCT05508672|EXPERIMENTAL|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI) group|The intervention group will receive Community-Centered eHealth Smoking Cessation Intervention(CCeSCI).
62341319|NCT05508672|ACTIVE_COMPARATOR|"Traditional smoking is harmful education group"|"The control group to receive the traditional smoking is harmful education."
62341320|NCT02438644||Study Population|Patients who are prescribed vismodegib in Argentina, according to standard of care and in line with the current SPC and local labeling, are eligible for observation. Dosing and treatment duration of vismodegib are at the discretion of the physician in accordance with local clinical practice and local labeling. Only patients with laBCC or mBCC will be considered in the effectiveness analysis.
62341321|NCT00231244|EXPERIMENTAL|1|CYPHER Sirolimus-Eluting Coronary Stent
62341322|NCT03136952||Pediatric children under 1 yrs old|Observation study of two measurement points of cerebral oxygenation
62341323|NCT04877314|EXPERIMENTAL|Intermittent fasting|
62341324|NCT02815176||Central serous chorioretinopathy|De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
62341325|NCT02815176||Polypoidal choroidal vasculopathy|De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
62498023|NCT06635200||Patients with carpal tunnel syndrome with a nosiplastic pain phenotype|
62498024|NCT03062176|EXPERIMENTAL|Active Treatment|Anakinra (Kineret)
62498025|NCT03727945|EXPERIMENTAL|abdominopelvic exercise and posture|N=21 received supervised physiotherapy abdominopelvic exercise previous postural correction.
62498026|NCT03727945|EXPERIMENTAL|abdominopelvic exercise|N=21 received supervised physiotherapy abdominopelvic exercise.
62498027|NCT02756858|EXPERIMENTAL|ANAVEX2-73 Oral as assigned in ANAVEX2-73-002|
62498028|NCT04556123|EXPERIMENTAL|Fluid overload: BIS-guided decongestion|
62498029|NCT04556123|ACTIVE_COMPARATOR|Fluid overload: Decongestion based on clinical judgement|
62498030|NCT04556123|NO_INTERVENTION|No fluid overload: standard of care|
62498031|NCT01634854|ACTIVE_COMPARATOR|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
62498032|NCT01634854|ACTIVE_COMPARATOR|Intravenous Oxytocin|"2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
62498033|NCT04320888|EXPERIMENTAL|Treatment (selpercatinib)|Patients receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
62498034|NCT04247841|NO_INTERVENTION|Phase I: Current Practice|This represents the first phase of the study in which a prospective cohort of patients will complete the survey to define baseline rates of recall of perioperative risk and level of patient satisfaction with risk discussion
62498035|NCT04247841|EXPERIMENTAL|Phase II Visual Aid & Scripted Risk Discussion|This will involve a group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
62498036|NCT04247841|ACTIVE_COMPARATOR|Phase II Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
62498037|NCT06035211|ACTIVE_COMPARATOR|Virtual 3D model group|exchange time with the virtual 3D model of the kidney to be operated on as information support
62498038|NCT06035211|ACTIVE_COMPARATOR|3D Printed Model Group|eexchange time with the printed three-dimensional model of the kidney to be operated on as information support
62498039|NCT06035211|NO_INTERVENTION|Control group|discussion time with the patient information sheet of the French Association of Urology (AFU) as information support
62498040|NCT06408636||We consecutively selected patients diagnosed with acute myocardial infarction from September 2019 th|
62498041|NCT02036749|ACTIVE_COMPARATOR|quadratus lumborum block (nerve block)|quadratus lumborum block with ropivacaine
62498042|NCT02036749|PLACEBO_COMPARATOR|sham block|QL block with saline
62698628|NCT05786326|EXPERIMENTAL|multiholes fully covered metaalic stents group|Insertion of multiholes fully covered self-expandable metallic stents in the biliary tree through Endoscopic retrogrades cholangiopancreatography (ERCP)patients with malignant biliary obstruction.
62698629|NCT05786326|ACTIVE_COMPARATOR|parially covered metallic stents group|Insertion of partially covered metallic stents in patients with malignant biliary obstruction.
62341326|NCT02815176||Epiretinal membrane|Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
62341327|NCT03414008|EXPERIMENTAL|Active Drug Group|Single dose
62341328|NCT03414008|PLACEBO_COMPARATOR|Placebo Group|
62341329|NCT03431324|EXPERIMENTAL|Mating-EFT Intervention Effectiveness|"Study 1: 90 participants will attend an initial session, at which point they will provide demographic information as well as their relationship status. They will then be randomly assigned to complete either the Episodic Future Thinking about Mating Opportunities intervention, a general-EFT intervention, or an unrelated questionnaire (yoked control condition).~All participants will submit daily reports of the number of cigarettes smoked for a period of one week. Participants will then complete a series of questionnaires measuring individual differences in fundamental social motives (including mate-seeking motives), self-efficacy, and nicotine dependence."
62341330|NCT03431324|EXPERIMENTAL|Message Tailoring for Smoking Cessation|Study 2: A quasi-experimental design will be employed in order to determine whether targeting individuals who are single and highly motivated to seek a mate with a Targeted Mating-EFT Intervention is a more effective means of reducing cigarette consumption than presenting all individuals with a general-EFT intervention. A total of 180 smokers who intend to quit or reduce smoking will be recruited as participants. These individuals will be selected from a larger pool of participants based upon responses to screening questions. The screening questions will measure relationship status and mate seeking motivation.
62341331|NCT00347763|NO_INTERVENTION|control|no active fly spray intervention
62341332|NCT00347763|ACTIVE_COMPARATOR|intervention|aerial spray of permethrin daily for two weeks and weekly as needed by assessment of fly density
62341333|NCT05480293|EXPERIMENTAL|SCT510A|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks
62341334|NCT05480293|ACTIVE_COMPARATOR|Ranibizumab|Ranibizumab(0.5mg), Vitreous injection, injection once every 4 weeks
62341335|NCT04859335|OTHER|Schwannomas patients needing gammaknife radiosurgery|"Patients will undergo balance and hearing questionnaires before and after gammaknife radiosurgery.~This is a before/after analysis needing only one arm: the before data will serve as control to the after data"
62341336|NCT03711006|EXPERIMENTAL|FMT treated patients|Seven patients with active Ulcerative Colitis treated with 25 multi-donor FMT Capsules daily.
62341337|NCT00745186|ACTIVE_COMPARATOR|1|Glucagen
62498043|NCT04025398|EXPERIMENTAL|REHABILITUS|Réhabilitus is a cognitive remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among adults with intellectual disabilities.
62498044|NCT04025398|ACTIVE_COMPARATOR|CONTROL GROUP|The control group involves manual activities and research computer information.
62498045|NCT00743145|PLACEBO_COMPARATOR|Placebo naltrexone + Inactive marijuana|Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
62498046|NCT00743145|PLACEBO_COMPARATOR|Placebo naltrexone + Active marijuana (5.5% THC)|Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
62498047|NCT00743145|PLACEBO_COMPARATOR|Placebo naltrexone + Active marijuana (6.2% THC)|Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
62498048|NCT00743145|EXPERIMENTAL|Naltrexone + Active marijuana (5.5% THC)|Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
62341338|NCT00745186|EXPERIMENTAL|2|Mayne Glucagon
62498049|NCT00743145|EXPERIMENTAL|Naltrexone + Active marijuana (6.2% THC)|Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
61948429|NCT02932202|PLACEBO_COMPARATOR|Standard Care Counseling|Participants in the control group will receive standard counseling, which includes weights at every visit, and counseling on weight gain goals as perceived necessary by the provider.
61948430|NCT04234022||Zn-DDC|samples to be exposed with Zn-DDC (Imuthiol) alone
61948431|NCT04234022||Lenalidomide with Zn-DDC|samples to be exposed with Lenalidomide in combination with Zn-DDC
62498050|NCT00743145|PLACEBO_COMPARATOR|Naltrexone + Inactive marijuana|Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
62498051|NCT02102919|EXPERIMENTAL|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 \& virtual games) - T2
61948432|NCT04234022||Pomalidomide with Zn-DDC|samples to be exposed with Pomalidomide in combination with Zn-DDC
61948433|NCT03500575|EXPERIMENTAL|photopheresis|
61948434|NCT03500575|NO_INTERVENTION|control|
61948435|NCT02176343|EXPERIMENTAL|ReSTOR Toric +2.5|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
61948436|NCT05615168|EXPERIMENTAL|AcumenIQ - HPI guided hemodynamic optimization|HPI guided hypotension prediction alarms... Interventions based on SVV (fluid), dp/dt (inotropes), EAdyn (pressors)
61948437|NCT05615168|ACTIVE_COMPARATOR|Flotrac - conventional GDT guided hemodynamic optimization|GDT guided hemodynamic optimization - MAP \> 65 mmHg, CI ≥ 2.4 l/min/m2, SVI ≥ 30 ml/beat/m2 and SVRI 1700-2400 dyn·s·cm-5/m2
61948438|NCT05541042||patients with glioblastoma|
61948439|NCT01871142|EXPERIMENTAL|Randomized crossover assignment|Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
61948440|NCT06260215|NO_INTERVENTION|Control|Participants in this arm will receive no intervention
62498052|NCT02102919|SHAM_COMPARATOR|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 \& Aktiv Tramp) - T2
62498053|NCT00753350|EXPERIMENTAL|1|Sensate™ anti-Obesity device
62698630|NCT05786326|ACTIVE_COMPARATOR|unocoered metaalic stents group|Insertion of uncovered metallic stents in patients with malignant biliary obstruction.
61948441|NCT06260215|EXPERIMENTAL|ST|Participants in this arm will participate in a soccer training (ST) session for 60 minutes. During the training the participans will execute the warm-up process, the part of soccer technical exercises and they will play a small-side-game.
61948442|NCT02692222||PPV|This study will track changes in PPV and CO before and after of volume expansion, which goal is to change the cardiac output.
61948443|NCT04961307||Women with breast cancer using trastuzumab|
61948444|NCT02364921|EXPERIMENTAL|Two-layer compression bandage|Two multilayer compression bandage: Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.Measure the ankle circumference and choose the correct kit accordingly (ankle size 18-25cm or 25-32cm). Apply one to seven days
61948445|NCT02364921|ACTIVE_COMPARATOR|crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
61948446|NCT03153527|PLACEBO_COMPARATOR|Placebo arm (intervention arm)|Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
62498054|NCT06678048|EXPERIMENTAL|Arsenous Acid plus Chemotherapy|Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine
62498055|NCT03109041|EXPERIMENTAL|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
62498056|NCT01995968||SGA stillbirths (Cases)|Stillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
62498057|NCT01995968||SGA livebirths (Controls)|Livebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
62498058|NCT01837186||EFP|Empyema following pneumonectomy
62498059|NCT01837186||nEFP|No empyema following pneumonectomy
61948447|NCT03153527|ACTIVE_COMPARATOR|Verum group (control/standard arm)|If patient is on \> 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
61948448|NCT04882384|EXPERIMENTAL|Peripheral Nerve Block (PENG)|Patients will receive the Pericapsular Nerve Group Block.
61948449|NCT05960552|EXPERIMENTAL|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. Within the given 120 seconds participants in the PreTEE group need to provide the leading cause with regard to difficult separation from cardiopulmonary bypass among high-risk cardiac surgical procedures.
61948450|NCT05960552|ACTIVE_COMPARATOR|The conventional TEE group|The routine intra-operative TEE examinations are performed within the given 120 seconds before patients are separated from the cardiopulmonary bypass.
61948451|NCT03802695|EXPERIMENTAL|Arm A|Recipients with HLA-identical or 1-allele mismatched (7/8 alleles) related or unrelated donor; with single-agent GVHD prophylaxis given
61948452|NCT03802695|EXPERIMENTAL|Arm B|Recipients with haploidentical-related donors; with single-agent GVHD prophylaxis given
61948453|NCT03802695|EXPERIMENTAL|Arm C|Recipients with an HLA-identical related or unrelated donor; no GVHD prophylaxis given
61948454|NCT02707107|ACTIVE_COMPARATOR|3 g of zidebactam (1 g q8h) and 6 g of cefepime (2 g q8h) or 6|administered as IV infusions every q8h, over a period of 60 minutes.
61948455|NCT02707107|PLACEBO_COMPARATOR|Placebo|administered as IV infusions every q8h, over a period of 60 minutes.
62498060|NCT05557656||HCC participants who received the treatment of Regorafenib|HCC participants who received the treatment of Regorafenib
61948456|NCT05747287|EXPERIMENTAL|Experimental group|
61948457|NCT03110094|OTHER|Rheumatoid arthritis - Adalimumab|
61948458|NCT03110094|OTHER|Healthy volunteer|
61948459|NCT06021197|EXPERIMENTAL|NMDAE|An NMDA enhancer
61948460|NCT06021197|PLACEBO_COMPARATOR|Placebo|Placebo
61948461|NCT03476278||regional, questionnaire|patients who underwent surgery under regional anesthesia.
61948462|NCT04747080|EXPERIMENTAL|TAC and HD-DXM|"Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).~Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks."
61948463|NCT04747080|ACTIVE_COMPARATOR|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14) .
61948464|NCT02964975|ACTIVE_COMPARATOR|Optimal medical therapy|conservative treatment
61948465|NCT02964975|ACTIVE_COMPARATOR|Percutaneous coronary intervention|Percutaneous coronary intervention of chronic total occlusion
61948466|NCT03155971|EXPERIMENTAL|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
61948467|NCT06101511|EXPERIMENTAL|Individualized high PEEP strategy with recruitment maneuvers|The intervention is intraoperative ventilation using the available ventilator with individualized high positive end-expiratory pressure (PEEP) titrated to the lowest driving pressure (ΔP) with recruitment maneuvers (RMs). After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial.
61948468|NCT06101511|NO_INTERVENTION|Standard low PEEP strategy without recruitment maneuvers|Patients randomized to the standard low PEEP group will receive 5 cm H2O PEEP for the complete duration of general anesthesia. They will neither receive one of the planned RMs nor a decremental PEEP trial.
62498061|NCT02285868||Arm, Shoulder and Hand injuries|Pre- and post-treatment outcomes of care as measured by the DASH (Disabilities of the Arm, Shoulder and Hand) via physical therapy
61948469|NCT01168583||Positive Fluid Balance of 2000ml|
61948470|NCT01168583||Negative Fluid Balance of 2000ml|
61948471|NCT02255903||Group 1(Control Group):|ultrasound and Doppler examination: of 100 pregnant females with gestational age 37-40 weeks.
61948472|NCT02255903||Group 2 (post date Group)|ultrasound and Doppler examination:will be done for 100 pregnant females with gestational age 41 weeks or more
61948473|NCT00310401|EXPERIMENTAL|Albuterol|Albuterol sulfate 5 mg dissolved in normal saline administered every 4 hours by nebulization
61948474|NCT00310401|PLACEBO_COMPARATOR|Saline|Saline administered every 4 hours by nebulization
62140530|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.\[NCT02221258\]
62498062|NCT02285868||Lumbar spine injuries|Pre- and post-treatment outcomes of care as measured by the Modified Oswestry (lumbar spine) via physical therapy
61948475|NCT02275858|EXPERIMENTAL|Stiffening wire first|This arm will use the stiffening wire first followed by the placebo wire
61948476|NCT02275858|PLACEBO_COMPARATOR|Placebo wire first|This arm will use the placebo wire first followed by the stiffening wire
61948477|NCT01058187||Control|Marketed cow milk-based infant formula containing DHA and ARA
61948478|NCT01058187||Investigational 1|Cow milk-based infant formula with differing level of ARA from Control formula
62140531|NCT02147093|OTHER|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
62140532|NCT02147093|OTHER|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
62140533|NCT00452452|EXPERIMENTAL|A|
62498063|NCT02285868||Knee injuries|Pre- and post-treatment outcomes of care as measured by the Knee Outcome Survey via physical therapy
62498064|NCT02285868||Foot and ankle injuries|Pre- and post-treatment outcomes of care as measured by the Foot \& Ankle Ability Measure via physical therapy
62498065|NCT02285868||Hip and lower extremity injuries|Pre- and post-treatment outcomes of care as measured by the Lower Extremity Functional Scale via physical therapy
62498066|NCT02285868||Neck injuries|Pre- and post-treatment outcomes of care as measured by the Neck Disability Index Questionnaire via physical therapy
62498067|NCT04792580|EXPERIMENTAL|Treatment|Subjects receive lifitegrast 5% ophthalmic solution twice a day for 4 weeks after a 2 week washout.
62498068|NCT04792580|PLACEBO_COMPARATOR|Placebo|Subjects receive the lifitegrast vehicle as placebo twice a day for 4 weeks after a 2 week washout.
62498069|NCT05963269|ACTIVE_COMPARATOR|Students receiving computer game support in intramuscular injection learning|After learning intramuscular injection with demonstration, a group of students reinforcing intramuscular injection training for 1 week with a computer-assisted game designed by the researcher.
62498070|NCT05963269|NO_INTERVENTION|Group of students learning intramuscular injection only by demonstration|Group of students learning intramuscular injection by demonstration method without computer-assisted games
61948479|NCT01058187||Investigational 2|Cow milk-based infant formula with a differing level of ARA from Control
62140534|NCT04802681|OTHER|Wirecath - PressureWire X|Patients will undergo simultaneous FFR measurements with the Wirecath and PressureWire X simultaneously.
62498071|NCT05456022|EXPERIMENTAL|Quercetin drug.|
62498072|NCT05456022|EXPERIMENTAL|Quercetin-encapsulated PLGA-PEG nanoparticles|
62498073|NCT05456022|ACTIVE_COMPARATOR|Doxorubicin chemotherapeutic drug|
62498074|NCT05216523||Cases|Admitted Covid-19 cases who developed Barotrauma
62498075|NCT05216523||Controls|Admitted Covid-19 cases who did not develop Barotrauma, matched with Cases with respect to age and sex.
62698631|NCT05921786|EXPERIMENTAL|Multiphoton microscopy|
62698632|NCT05921786|EXPERIMENTAL|Electrophysiological system|
62698633|NCT01568879|EXPERIMENTAL|Gout Chronic Disease Management Program|
62498076|NCT03368482|EXPERIMENTAL|Brain Gym Exercises|Brain Gym® (BG) is a movement-based program originally designed to improve learning capabilities through the performance of mind-body exercises. BG can be considered as an interesting field of research due to the need of identifying novel therapies which might be more pleasant for older adults who tend not to be prone to participating in conventional exercise programs and might have a positive effect on their cognitive function. In spite of this, scientific evidence regarding the effects of BG on people with cognitive impairment is scarce.
61948480|NCT06476327|ACTIVE_COMPARATOR|experimental 1 group|Robot-Assisted Gait with Self-Observation
61948481|NCT06476327|ACTIVE_COMPARATOR|experimental 2 group|Robot-Assisted Gait
61948482|NCT01931592|ACTIVE_COMPARATOR|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
61948483|NCT01931592|PLACEBO_COMPARATOR|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
61948484|NCT02254941||Active comparator: Chemotherapy|Metastatic colon cancer and first line treatment with conventional chemotherapy without monoclonal antibody.
61948485|NCT02254941||Experimental: Chemotherapy plus mAb|Metastatic colon cancer and first line treatment with conventional chemotherapy plus monoclonal antibody
61948486|NCT02585843|EXPERIMENTAL|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
61948487|NCT02585843|ACTIVE_COMPARATOR|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
61948488|NCT04418674|EXPERIMENTAL|Ketamine|Patient will be given Ketamine 0.3mg/kg intravenously before sitting positioning for subarachnoid block.
61948489|NCT04418674|ACTIVE_COMPARATOR|Fentanyl|Patient will be given Fentanyl 1.5mcg/kg intravenously before sitting position for subarachnoid block.
61948490|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
61948491|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
61948492|NCT06409715|EXPERIMENTAL|Experimental group|Progressive Muscle Relaxation Training (PMRT) involves a series of 11 steps, each involving muscle tension for 10 seconds, followed by 5 seconds of relaxation, with each step repeated twice. This method, provided by the Chinese Medical Association Audiovisual Publishing House, starts on the third postoperative day if there are no complications, with two 30-minute sessions daily. After PMRT, patients proceed with an Acupressure protocol. The session begins with 5-10 minutes of kneading around the knee and pinching the quadriceps, followed by lighter kneading around the patella and its periphery. Knee movements are made within pain limits. Acupressure targets points Zusanli(S36), Sanyinjiao (SP6), and Yanglingquan(GB34) with pressure held for 10 seconds when soreness or numbness is felt. Each point is treated in 3-5 cycles during the twice-daily, 5-minute sessions, concluding with palm percussion on the calf to relax muscles.
61948493|NCT06409715|EXPERIMENTAL|Control group|"Following recommended protocols from Arthroscopic Surgery and Sports Rehabilitation Nursing 26, post-meniscectomy patient care primarily involves vital sign monitoring, positional support, dietary management, pain control, psychological support, functional training, and educational initiatives on health matters."
62341339|NCT02961712|EXPERIMENTAL|cell therapy|NK cells and amniotic epithelial cells
62341340|NCT03936517|OTHER|Prednisolone first; hydrocortisone second|Participant will receive 4 months of prednisolone in the first study period and 4 months of hydrocortisone in the second study period.
62341341|NCT03936517|OTHER|Hydrocortisone first; prednisolone second|Participant will receive 4 months of hydrocortisone in the first study period and 4 months of prednisolone in the second study period.
62341342|NCT03943953|EXPERIMENTAL|Facial Palsy - Trial of ITG|In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
62341343|NCT01278017|EXPERIMENTAL|ceftriaxone|
62341344|NCT01956240|EXPERIMENTAL|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
62341345|NCT01956240|EXPERIMENTAL|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
62341346|NCT00379197|EXPERIMENTAL|Naltrexone|Naltrexone 50 mg will be taken orally once a day every day of a 28 day treatment course (cycle 1) and continue for another identical 28 day treatment (cycle 2) . PET scan will be performed after cycle 1 and cycle 2 complete.
62341347|NCT02343276|PLACEBO_COMPARATOR|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
62341348|NCT02343276|EXPERIMENTAL|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
62498077|NCT03368482|ACTIVE_COMPARATOR|Standard Exercises|A traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
62498078|NCT06492408|EXPERIMENTAL|Group 1: IT injection of double ICIs|Neoadjuvant therapy: intra-tumor injection of double ICIs only.
62498079|NCT06492408|EXPERIMENTAL|Group 2: IT injection of double ICIs and chemodrug|Neoadjuvant therapy: intra-tumor injection of double ICIs and chemodrug.
62498080|NCT06492408|EXPERIMENTAL|Group 3: IT injection of double ICIs and chemodrug plus bevacizumab|Neoadjuvant therapy: intra-tumor injection of double ICIs and chemodrug plus bevacizumab.
62698634|NCT01568879|ACTIVE_COMPARATOR|Usual Care|
61948494|NCT02368197|ACTIVE_COMPARATOR|Standard balloon angioplasty|Dilatation of stenosis with standard non drug eluting balloon catheter
61948495|NCT02368197|EXPERIMENTAL|Drug eluting balloon angioplasty|Dilatation of stenosis with paclitaxel eluting balloon catheter
61948496|NCT03738033||use of the educational platform|Before the hand-on practice and assessements, the participants use the platform for learning.
61948497|NCT03738033||without use of the educational platform|Before the hand-on practice and assessements, the participants did not use the platform for learning.
61948498|NCT05190367||No trauma|Patients suffering from chronic pain without traumatic life events
61948499|NCT05190367||Accidental trauma|Patients suffering from chronic pain who have experienced at least one accidental trauma
62698635|NCT00737789|EXPERIMENTAL|Mesalazine once/day|Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
62698636|NCT00737789|ACTIVE_COMPARATOR|Mesalazine twice/day|Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).
61948500|NCT05190367||Interpersonal trauma|Patients suffering from chronic pain who have experienced at least one interpersonal trauma
62341349|NCT02982538|OTHER|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
62498081|NCT04448041||Ghana|
62498082|NCT04448041||India|
62698637|NCT04608058|EXPERIMENTAL|Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, asynchronous Diabetes self-management training, using digital storytelling was made available to this group. Post-test data were collected 3 months after the pretest."
62698638|NCT04608058|EXPERIMENTAL|No Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, the control group received the clinics' routine training. Post-test data were collected 3 months after the pretest."
62698639|NCT04372953|ACTIVE_COMPARATOR|Static PEEP Group|Delivery of PEEP at 5-6 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). FiO2 and other aspects of respiratory care are then titrated using a standardised resuscitation algorithm.
62698640|NCT04372953|EXPERIMENTAL|Dynamic PEEP Group|"Dynamic delivery of PEEP at 8 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). PEEP levels increased step-wise to 10 and/or 12 cmH2O if FiO2/respiratory care needs to be escalated as per a standardised resuscitation algorithm.~If an infant shows evidence of respiratory improvement during resuscitative care, PEEP will be reduced in a stepwise method by 2 cmH2O each reduction, but to no lower than 8 cmH2O."
62698641|NCT03088033|EXPERIMENTAL|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
62698642|NCT03088033|SHAM_COMPARATOR|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
62698643|NCT00890760|EXPERIMENTAL|Group 1|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
62698644|NCT00890760|EXPERIMENTAL|Group 2|AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
62698645|NCT00890760|EXPERIMENTAL|Group 3|Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
61948501|NCT05190367||PTSD|Patients suffering from chronic pain and diagnosed with PTSD
61948502|NCT05232071|EXPERIMENTAL|Lanifibranor (IVA337) (800 mg/day)|2 Lanifibranor tablets 400 mg with food --\> once a day (quaque die, QD)
61948503|NCT05232071|PLACEBO_COMPARATOR|Matching placebo|2 Placebo to match tablets with food --\> once a day (quaque die, QD)
61948504|NCT05232071|EXPERIMENTAL|Lanifibranor (IVA337) (800 mg/day) plus Empagliflozin (10mg/day)|2 Lanifibranor tablets 400 mg plus 1 Empagliflozin tablet 10mg with food --\> once a day (quaque die, QD)
61948505|NCT00302185|ACTIVE_COMPARATOR|Nurse-led supportive care|Visit with a Palliative Care nurse once weekly for 4 weeks
61948506|NCT00302185|EXPERIMENTAL|Acupuncture|Patients received acupuncture once a week for 4 weeks.
61948507|NCT03738085||Previous abdominal surgery group|Previous abdominal surgery group underwent total laparoscopic hysterectomy
61948508|NCT03738085||No previous abdominal surgery group|No Previous abdominal surgery group underwent total laparoscopic hysterectomy
61948509|NCT03738085||Obese patients underwent TAH|BMI≥30 kg/m2
61948510|NCT03738085||Obese patients underwent TLH|BMI≥30 kg/m2
61948511|NCT02234388||Registry Participants|All patients who participate in the UCTD Registry will be put into this cohort and observed over approximately 3 years.
61948512|NCT01003392||Normal|Normal volunteers, with no diagnosed chronic disease.
62498083|NCT04448041||Philippines|
61948513|NCT01003392||Coronary artery disease|Group of patients with diagnosed coronary artery disease.
61948514|NCT01003392||Diabetes|Diabetic patients.
61948515|NCT06161870|EXPERIMENTAL|experimental group|The experimental group will be guided by the population pharmacokinetics (PK) model for individual dosing of vancomycin.
61948516|NCT06161870|OTHER|control group|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
61948517|NCT05327426|EXPERIMENTAL|fIPV-dmLT|Intradermal administration of fIPV with the addition of 0.47ug dmLT
62498084|NCT04448041||Zambia|
62498085|NCT01460030|EXPERIMENTAL|KRN1493|
62498086|NCT05150405|EXPERIMENTAL|QLF31907|single arm with QLF31907 treatment
62498087|NCT06361693||Patients|Adult patients benefiting from planned outpatient surgery under general anesthesia.
61948518|NCT05327426|ACTIVE_COMPARATOR|fIPV|Intradermal administration of fIPV alone.
61948519|NCT02898805|EXPERIMENTAL|LopiGLIK®|first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
61948520|NCT02898805|ACTIVE_COMPARATOR|Armolipid Plus|first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
61948521|NCT01694264|EXPERIMENTAL|Experimental Group|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
61948522|NCT01694264|PLACEBO_COMPARATOR|Control Group|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
61948523|NCT00319501|PLACEBO_COMPARATOR|Placebo|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
61948524|NCT00319501|EXPERIMENTAL|Diazepam|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
61948525|NCT06357858|EXPERIMENTAL|Oral Decitabine + Nivolumab|Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1) followed by Nivolumab on D8 with every 4 week cycle. The expected minimum treatment cycle is 2 and maximum treatment cycle of 6. However, treatment can be continued until disease progression.
61948526|NCT01095926|EXPERIMENTAL|Doxorubicin|
61948527|NCT05898685|EXPERIMENTAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
61948528|NCT05898685|SHAM_COMPARATOR|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
61948529|NCT01182142|EXPERIMENTAL|Capecitabine|All patients will receive capecitabine.
61948530|NCT03985059||Cases|Patients with ischemic stroke or transient ischemic attack who have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
61948531|NCT03985059||Controls|Patients with ischemic stroke or transient ischemic attack who do not have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
61948532|NCT01655797|EXPERIMENTAL|CBT|The treatment group received manualized CBT-I using a adapted version of a manual designed for use by primary care personnel. Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
61948533|NCT01655797|NO_INTERVENTION|Wait-list|A deferred treatment wait-list condition, with no restrictions placed on the usual care.
62698646|NCT00890760|EXPERIMENTAL|Group 4|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
62698647|NCT00890760|EXPERIMENTAL|Group 5|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
61948534|NCT00440414|EXPERIMENTAL|1|Alimta
62140535|NCT03849482||Parotid Gland Neoplasms|"Preoperative Assessment of Parotid Gland Neoplasms with:~* Clinical Evaluation;~* Fine Needle Aspiration Cytology;~* Multiparametric Magnetic Resonance Imaging.~Postoperative Collection of Final Histopathological Diagnosis"
61948535|NCT00440414|EXPERIMENTAL|2|Tarceva
61948536|NCT02447939|EXPERIMENTAL|Dabrafenib and Trametinib|Subject will be assigned in 2 cohorts, in cohort A, subjects will be administered dabrafenib (150 mg BID) monotherapy from Day1 to Day 21 (first part), followed by dabrafenib (150 mg BID) and trametinib (2mg QD) combination (second part, starting from day 22). After the last subject in cohort A has finished the last pharmacokinetic sampling(1st part ), another 10 subjects will be enrolled in cohort B with administration of dabrafenib (150 mg BID) in combination with oral trametinib (2mg QD).
61948537|NCT01297556|NO_INTERVENTION|Control group|Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
61948538|NCT01297556|EXPERIMENTAL|Treatment|Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
61948539|NCT04746339|ACTIVE_COMPARATOR|Apixaban Group|
62698648|NCT00890760|EXPERIMENTAL|Group 6|Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
62698649|NCT00890760|EXPERIMENTAL|Group 7|Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
62698650|NCT00890760|EXPERIMENTAL|Group 8|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
62698651|NCT00890760|EXPERIMENTAL|Group 9|2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
61948540|NCT04746339|PLACEBO_COMPARATOR|Placebo Group|
61948541|NCT03299465|EXPERIMENTAL|Yoga arm|A six-week restorative yoga intervention consisting of a weekly, 60-minute yoga group class led by a certified yoga instructor along with twice-weekly home practice using yoga DVD.
61948542|NCT01156259|EXPERIMENTAL|30 Gy|
61948543|NCT01156259|ACTIVE_COMPARATOR|40 Gy|
61948544|NCT05321108|EXPERIMENTAL|Group A (GA) (Aerobic exercise group):|the patient will receive aerobic exercise program: (graded treadmill machine walking and stepping exercises). The second part of the exercise program will be 10 minutes of stepping exercise at a speed of 96 beats per minute using a 20-cm-high bench, with rest after the first 5 minutes. Three sessions per week for 12 weeks.
62140536|NCT05279066||Patients scheduled to undergo an elective cardiac ultrasound|All cardiac patients undergoing an elective cardiac ultrasound as an outpatient at UCLA may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented prior to their scheduled ultrasound.
61948545|NCT05321108|EXPERIMENTAL|Group B (GB) (Whole-body vibration (WBV) group)|the patient will receive whole-body vibration with frequency 30-40Hz and 2 mm of amplitude will be used for the whole-body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum. The WBV group performed a training program 3 times a week with at least one day between each session for 12 weeks.
61948546|NCT02678273|EXPERIMENTAL|Intervention group|Intervention
61948547|NCT02678273|NO_INTERVENTION|Control group|Standard care when patient is in the hospital. At discharge, patients may be referred to community services as deemed necessary by the hospital team. This is not restricted.
61948548|NCT00028782|EXPERIMENTAL|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
61948549|NCT03144921|EXPERIMENTAL|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention, held via Zoom, designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend monthly booster sessions, held via Zoom, to reinforce the skills/lessons. Participants may voluntarily choose to continue attending booster sessions through 2024.
61948550|NCT03144921|ACTIVE_COMPARATOR|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention), held via Zoom, about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention, held via Zoom, immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend monthly booster sessions, held via Zoom, to reinforce the skills/lessons. Participants may voluntarily choose to continue attending booster sessions through 2024.
61948551|NCT03781843|ACTIVE_COMPARATOR|Genicular nerve block with lidocaine|The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 6 mL of a solution containing 6 mL of 2% lidocaine or 6 mL dextrose or 6 mL saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves Interventions: Drug: 6 mL 2% lidocaine Procedure: Genicular nerve block
61948552|NCT03781843|PLACEBO_COMPARATOR|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Saline Procedure: Genicular nerve block"
61948553|NCT03781843|PLACEBO_COMPARATOR|Genicular nerve block with dextrose|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a dextrose was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Dextrose Procedure: Genicular nerve block"
61948554|NCT00371826|EXPERIMENTAL|Calcineurin Inhibitor (CNI) Withdrawal|"Every randomized patient in this group received~Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone~Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough \>6 ng/mL, then MPA was stopped + prednisone 10-30mg/day~Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day"
61948555|NCT00371826|EXPERIMENTAL|Steroid Withdrawal|"Every randomized patient in this group received~Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day~Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough \>6 ng/mL, then MPA was stopped + prednisone 10-30mg per day~Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120.~Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol"
62698652|NCT00890760|EXPERIMENTAL|Group 10|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
61948556|NCT00371826|ACTIVE_COMPARATOR|CNI+MPA+ Steroid|"Patients randomized to this group received:~Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36."
61948557|NCT04569903|EXPERIMENTAL|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
61948558|NCT04742075|ACTIVE_COMPARATOR|(A) Olaparib|Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.
61948559|NCT04742075|EXPERIMENTAL|(B) Olaparib + durvalumab|"Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity."
61948560|NCT04742075|EXPERIMENTAL|(C) Olaparib + durvalumab + UV1|"Olaparib 300 mg tablets twice daily until disease progression or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity.~Eight UV1 vaccinations during the first 5 month: Four UV1 vaccinations 300 μg (+ 75 μg of sargramostim) during the first 10 days with a minimum of 2 days apart. From cycle 2-5 subjects will receive one UV1 (+ sargramostim) vaccination every 4th week."
61948561|NCT02426944|EXPERIMENTAL|LAAO group|Patients will be treated interventionally by left atrial appendage occlusion (LAAO). LAAO will be done using Amulet or Watchman device.
61948562|NCT02426944|EXPERIMENTAL|NOAC group|Patients will be treated by novel anticoagulants (NOAC).
61948563|NCT01742000|ACTIVE_COMPARATOR|Karinat|Karinat 500 mg tablet by mouth three times a day
61948564|NCT01742000|PLACEBO_COMPARATOR|Sugar pill|Placebo 500 mg tablet by mouth three times a day
61948565|NCT02486523|ACTIVE_COMPARATOR|Control group|"Outpatient management of children diagnosed with severe acute malnutrition.~Interventions allocated:~Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
62140537|NCT05279066||Patients with a pulmonary arterial catheterization scheduled or completed|All patients hospitalized in the cardiac ICU at UCLA with a pulmonary arterial catheterization scheduled or completed may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented during their hospital stay.
62698653|NCT04849897|ACTIVE_COMPARATOR|Active Comparator: Audio Only Guided Imagery Audio Recordings of Guided Imagery via tablet|Listen to narrative scripts based on traditional GI audio recordings. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the GI experience.
61948566|NCT02486523|EXPERIMENTAL|Intervention group|"Outpatient management of children diagnosed with severe acute malnutrition + household WASH package~Interventions allocated:~Behavioral: Hygiene promotion sessions Device: Household WASH package The content of the kit: soap and aquatab for 3 months, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.~Behavioral: Household visits during the OTP phase Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
61948567|NCT02566486|OTHER|Reciprocating system|Waveone root canal instrumentation file
62140538|NCT03197649|NO_INTERVENTION|Control|No laser phototherapy treatment
62140539|NCT03197649|EXPERIMENTAL|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
62140540|NCT01645046|ACTIVE_COMPARATOR|Coenzyme A 200mg|Coenzyme A 200mg per day.
62140541|NCT01645046|PLACEBO_COMPARATOR|Placebo|Capsule without coenzyme A.
61948568|NCT02566486|OTHER|Rotational system|ProTaper Next root canal instrumentation file
62140542|NCT01645046|ACTIVE_COMPARATOR|Coenzyme A 400mg|Coenzyme A 400mg per day.
62140543|NCT06395571|EXPERIMENTAL|Goat milk-based infant formula|Experimental group receives goat milk-based formula for 24 weeks
62140544|NCT06395571|ACTIVE_COMPARATOR|Cow's milk-based infant formula|Control group receives cow's milk-based formula for 24 weeks
62140545|NCT00893555|ACTIVE_COMPARATOR|control|Voriconazole dosing based on SPC
62140546|NCT00893555|EXPERIMENTAL|TDM|Voriconazole serum concentration based dosing
62140547|NCT06699888|EXPERIMENTAL|Cervicothoracic Manipulation group|the subject will receive cervicothoracic manipulation and Chin tuck, Strengthening Shoulder Retractors, Stretching SCM, Pectoralis Stretch
62140548|NCT06699888|ACTIVE_COMPARATOR|forward head correction exercises group|this group receive Chin tuck, Strengthening Shoulder Retractors, Stretching SCM, Pectoralis Stretch
62140549|NCT04546451|EXPERIMENTAL|Music practice|Patients will receive Music Practice interventions of 45 minutes twice a week over 6 months, provided by a professional musician
62140550|NCT04546451|EXPERIMENTAL|Psychomotor therapy|Patients will receive Psychomotor interventions of 45 minutes twice a week over 6 months, provided by a professional psychomotor therapist
62140551|NCT04546451|NO_INTERVENTION|Passive control group|Healthy passive controls will pass all measurements without any intervention. The control group participants must adhere to the same inclusion and exclusion criteria as the experimental groups, except for an MCI diagnosis. Control participants will be matched to the experimental groups for age, gender and education level.
62140552|NCT00273052|EXPERIMENTAL|Carvedilol Phosphate modified release formulation|
62140553|NCT00273052|ACTIVE_COMPARATOR|metoprolol succinate|
62140554|NCT05600114|EXPERIMENTAL|Cannabidiol (CBD) Oral Solution 300 mg/day|
62140555|NCT05600114|EXPERIMENTAL|Cannabidiol (CBD) Oral Solution 600 mg/day|
62140556|NCT05600114|PLACEBO_COMPARATOR|Placebo Oral Solution|
62140557|NCT05969899|OTHER|FOLFIRI+BEV|
62140558|NCT02376309|EXPERIMENTAL|Leu during inactivity|Leucine supplements
62140559|NCT02376309|EXPERIMENTAL|ND during inactivity|Nandrolone injection
62140560|NCT05980507|EXPERIMENTAL|ICI201|
62140561|NCT05995756||In pateint|
62140562|NCT05995756||Out pateint|
61948569|NCT03940287|EXPERIMENTAL|Muscle Energy Technique and Conventional Physiotherapy|Muscle Energy Technique will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks, where each session of Muscle Energy Technique will be repeated for 3-5 repetitions.
61948570|NCT03940287|EXPERIMENTAL|Kinesiotaping and Conventional Physiotherapy|Kinesiotape application will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks
62698654|NCT04849897|EXPERIMENTAL|Experimental: Virtual Reality Guided Imagery Platform and VR Headset|VR headset for guided imagery with audiovisual computer-generated VR content to accompany the GI narration. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the VR-GI experience.
61948571|NCT04184713|EXPERIMENTAL|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
61948572|NCT04184713|ACTIVE_COMPARATOR|Control group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
61948573|NCT00270335|ACTIVE_COMPARATOR|A|General anesthesia titrated according to a cerebral state monitor
61948574|NCT00270335|ACTIVE_COMPARATOR|B|General anesthesia titrated according to usual clinical criteria
61948575|NCT03464071|EXPERIMENTAL|Group HVM|When randomized to the Hyperinflation with mechanical ventilator (HVM) group, there will be an increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
62140563|NCT01681654|EXPERIMENTAL|Immediate Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
61948576|NCT03464071|EXPERIMENTAL|Group HM|When randomized to the Manual hyperinflation (HM) group, the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
61948577|NCT05065814|OTHER|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus patients who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
61948578|NCT05065814|OTHER|Systemic sclerosis group|Demographic information of systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
61948579|NCT05065814|OTHER|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
61948580|NCT05934578|EXPERIMENTAL|Fontan Group - Exercise Training|Online rehabilitation: 36 sessions of aerobic exercise training for two months
61948581|NCT05934578|NO_INTERVENTION|Fontan Control Group - No Exercise Training|Patients will not participate in the exercise program and will continue with their usual routine.
61948582|NCT02084693||COMPREHENSIVE|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
62140564|NCT01681654|EXPERIMENTAL|Immediate Lifestyle Intervention - No Maintenance Program|Patients will begin the 12-week lifestyle intervention during treatment. Patients will not receive a maintenance support following the 12-week intervention.
62140565|NCT01681654|EXPERIMENTAL|Delayed Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
61948583|NCT02418078||Geriatri|patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
61948584|NCT02418078||non-geriatri|patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
61948585|NCT05681663|EXPERIMENTAL|1.5 bar group|1. TENS, Parafin, exercise and In addition, 5 hertz 2000 pulses 1.5 bar ESWT will be applied to this group.
61948586|NCT05681663|EXPERIMENTAL|4 bar group|1. TENS, Parafin, exercise and In addition, 5 hertz 2000 pulses 4 bar ESWT will be applied to this group.
61948587|NCT00892047|EXPERIMENTAL|1: venlafaxine plus aripiprazole|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
61948588|NCT00892047|EXPERIMENTAL|2: Placebo Comparator|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
62140566|NCT01681654|EXPERIMENTAL|Delayed Lifestyle Intervention - No Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment completion (12 weeks following diagnosis). Patients will not receive maintenance support following the 12-week program.
61948589|NCT02000180|EXPERIMENTAL|Progressive Group|The progressive learning group will undertake 6 hours of interactive small-group didactic sessions, interlaced with up to 6 hours of self-directed instruction initially on the low-fidelity box simulator, with feedback provided one-on-one by an expert academic endoscopist. Participants in the progressive learning group can switch to the high-fidelity simulator at their discretion, but cannot return to the low-fidelity simulator. On the high fidelity VR simulator they can progress through six modules each in colonoscopy and endoscopic polypectomy in a self-directed fashion, with one-on-one feedback by an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback. The entirety of this will be delivered over two days.
62164469|NCT01825785|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 2 weeks (Q2W) or once every 4 weeks (Q4W) for 3 months.
62698655|NCT00105066|PLACEBO_COMPARATOR|Placebo|placebo
62698656|NCT00105066|EXPERIMENTAL|Metformin|Metformin 850 mg twice daily
62698657|NCT05935137||Pregnant women|It is a group of pregnant women after finished 37th week of gestation. We will take blood sample for a coagulation test on the device ClotPro.There is no more intervention.
62698658|NCT05935137||Non-pregnant women|It is a control group - non-pregnant women. We will take blood samples for blood count and coagulation status and a coagulation test on the device ClotPro.There is no more intervention.
62698659|NCT06095011|EXPERIMENTAL|normal conservative management + posture training|Participants will receive normal conservative management as well as posture training via the UpRight Go posture trainer. The device will be provided to participants with all supplies and instructions that come from the original manufacturer and will be walked through how to install and use the necessary smartphone application as well as wear the posture trainer. Participants will be asked to wear the device daily for six weeks with goals for the amount of time spent wearing the sensor each day provided by the smartphone app. Participants will return to clinic in six weeks to return the device and submit usage data, or will mail back the device. Devices will be cleaned with disinfectant wipes before use by future participants.
61948590|NCT02000180|NO_INTERVENTION|High-Fidelity Group|The high-fidelity group will undertake 6 hours of interactive small-group didactic and hands-on sessions on the theory of colonoscopy, led by an expert academic gastroenterologist. The sessions will be interlaced with up to six hours of self-directed instruction on the high-fidelity VR simulator. Six task-specific modules of increasing difficulty in colonoscopy and colonoscopic polypectomy will be taught solely on the VR simulator with one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback as necessary. The entirety of this will be delivered over two days.
61948591|NCT01514071|EXPERIMENTAL|Pop-up picture|
61948592|NCT01136473||congenital cataract or aphakic glaucoma|children with congenital cataract or aphakic glaucoma
61948593|NCT02173808|EXPERIMENTAL|Contraceptive|
61948594|NCT03960814||Cohort 1|New users of basal insulins glargine and detemir
61948595|NCT06183177|EXPERIMENTAL|Exercise + WBV Group|
61948596|NCT06183177|ACTIVE_COMPARATOR|Exercise Group|
61948597|NCT06183177|NO_INTERVENTION|Control Group|
61948598|NCT02328183|EXPERIMENTAL|Polymyxin B|Polymyxin B 1.5-2.5 mg/kg/day intravenous q 12 hrs duration 7-14 days
61948599|NCT02272426|EXPERIMENTAL|CARET + CTI|Combined Aerobic and Resistance Exercise Training (CARET) plus Cognitive Training Intervention (CTI)
61948600|NCT02272426|SHAM_COMPARATOR|Sham CARET + Sham CTI|Control group Sham Combined Aerobic and Resistance Exercise Training (CARET) plus Sham Cognitive Training Intervention (CTI)
61948601|NCT03998488|EXPERIMENTAL|Investigational FMT|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy.~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
61948602|NCT03998488|ACTIVE_COMPARATOR|Investigational FMT + psyllium fiber|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy. They will also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
61948603|NCT03998488|PLACEBO_COMPARATOR|Placebo FMT +/- psyllium fiber|"Participants will be blindly randomized to receive a single dose of placebo FMT during the week 0 colonoscopy. They may or may not also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.~Additionally, participants will blindly receive a single dose of investigational FMT during the week 8 by flexible sigmoidoscopy."
61948604|NCT01182610|EXPERIMENTAL|Treatment group|"Panitumumab 9mg/kg on Days 1, 22, and 43~Paclitaxel 200mg/m2 on Days 1 and 22~Carboplatin AUC=6 on Days 1 and 22~5FU 225mg/m2/day on Days 1-15 and 22-36"
61948605|NCT03673579|EXPERIMENTAL|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
61948606|NCT03673579|NO_INTERVENTION|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
61948607|NCT03673579|EXPERIMENTAL|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
61948608|NCT04824950|OTHER|Monitoring of Circulating Tumor DNA|
61948609|NCT04627246|EXPERIMENTAL|PEP-DC + Nivolumab + SOC|PEP-DC: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides Nivolumab SOC: Standard of Care Chemotherapy
61948610|NCT03727269|EXPERIMENTAL|Wii Fit Training Experimental Group|receiving Wii fit based abdomino-pelvic training
61948611|NCT03727269|ACTIVE_COMPARATOR|Conventional Training Control Group|receiving conventional pelvic floor exercises.
61948612|NCT03939026|EXPERIMENTAL|ALLO-647, ALLO-501|
61948613|NCT06103539||1|Patients with an indication for left heart catheterization or cardiac resynchornization therapy
62164470|NCT01825785|EXPERIMENTAL|Romosozumab|Participants were randomized to receive romosozumab administered by subcutaneous injection at doses of 1 mg/kg Q2W, 2 mg/kg Q4W, 2 mg/kg Q2W, or 3 mg/kg Q4W for 3 months.
61948614|NCT00576784|ACTIVE_COMPARATOR|A|pioglitazone/glimepiride
61948615|NCT05933616|EXPERIMENTAL|Study Arm|Participants in the study arm will undergo the study procedure which are different induced glycaemic states.
61948616|NCT01957774|EXPERIMENTAL|THR-18|
61948617|NCT01957774|PLACEBO_COMPARATOR|Placebo|matching placebo; look-alike with no active ingredients
62164471|NCT05971758|ACTIVE_COMPARATOR|Fimepinostat 60mg|two 30mg capsules once a day, 10 subjects
62698660|NCT06095011|NO_INTERVENTION|normal conservative management only (standard of care)|Participants will receive conservative management.only: standard of care for initial treatment of cubital tunnel syndrome
61948618|NCT02911857|EXPERIMENTAL|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
61948619|NCT04967378|EXPERIMENTAL|HEPPI program|
61948620|NCT04967378|NO_INTERVENTION|Waiting-list control group|Receives access to HEPPI program at the end of the study.
61948621|NCT05843045|NO_INTERVENTION|Pre-mitigation|Information will be collected from participants about their health status and asthma symptoms. Information about the air quality inside the participants' homes will also be collected.
61948622|NCT05843045|EXPERIMENTAL|Indoor Air Quality Mitigation|Indoor air quality mitigation strategies of a smart home thermostat, smart bath fan switch, and a high-quality furnace filter will be employed within the participants' homes. Information will continue to be collected about participants' health status and asthma symptoms as well as the air quality inside their homes.
61948623|NCT03417323|EXPERIMENTAL|Compressive garment|Groups wear compression garment after WB-EMS induced muscle soreness
61948624|NCT03417323|NO_INTERVENTION|No compression garment|Groups wear no compression garment after WB-EMS induced muscle soreness
61948625|NCT06436274|EXPERIMENTAL|Group 1|Will receive GARDASIL®9 vaccine at Day 0 and Menveo®/Menactra® vaccine at Month 18
61948626|NCT06436274|ACTIVE_COMPARATOR|Group 2|Will receive the Menveo®/Menactra® vaccine at Day 0 and GARDASIL®9 at Month 18
61948627|NCT01254097|PLACEBO_COMPARATOR|Probiotic|Participants are provided in double blinded fashion, probiotic given to take with antibiotics prescribed by their provider.
61948628|NCT01254097|PLACEBO_COMPARATOR|Placebo|Participants are provided in double blinded fashion, Look alike placebo given to take with antibiotics prescribed by their provider.
61948629|NCT02702219|EXPERIMENTAL|Dynamic streching|Mobility training of the hamstrings muscles to be performed every day
61948630|NCT02702219|ACTIVE_COMPARATOR|Static stretching|Static stretching of the hamstrings muscles to be performed every day
61948631|NCT05259358|ACTIVE_COMPARATOR|exercise|"In addition to routine treatment:~Postural evenness~Chin tuck exercise~Range of motion exercises for all angles of the cervical joint~Neck isometric exercises~Cervical stabilization exercises (with ball)~Stretching exercises of pectoralis, latissimus dorsi, trapezius upper part, levator scapula, rhomboid and scalene muscles"
61948632|NCT05259358|NO_INTERVENTION|routine|only routine treatment
61948633|NCT02489760|EXPERIMENTAL|Adalimumab switch to Etanercept|At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
61948634|NCT02489760|EXPERIMENTAL|Etanercept switch to Adalimumab|At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.
61948635|NCT06353854||Retrospective group|Registration of patients treated with pembrolizumab since February 2021. Collection of tumour sample archives will be associated
62736532|NCT02370823||Knee OA Treated with Regenexx SD|20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
61948636|NCT06353854||Prospective group|Recruitment of metastatic colorectal cancer patients with microsatellite instability prior to the first administration of pembrolizumab immunotherapy. Blood and tumour sampling will be combined.
61948637|NCT06441669||letermovir group|Patients will be given Letermovir with a recommended dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine or according to clinical instructions) from +1 day to +100 days after UCBT.
61948638|NCT01224964|ACTIVE_COMPARATOR|Montelukast|
61948639|NCT01224964|ACTIVE_COMPARATOR|long-acting beta2-mimetic|
61948640|NCT04842734|EXPERIMENTAL|Physical exercise and computerized cognitive stimulation|"Supervised Physical Exercise Program (SPEP) sessions will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed.~The Computerized Cognitive Stimulation Program (CCSP) (Beynex) will be planned for 12 weeks, 5 days a week, approximately 10 minutes, for a total of 40 sessions.~Fisrtly, the use of CCSP will be demonstrated to the patients. Then, it will be given as home program. While the patients play the games in CCSP via their smartphones, their caregivers will be informed in detail about accompanying the patients if they need it. The follow-up of cognitive stimulation will be made with the person accompanying the patient over the phone.~Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week)."
61948641|NCT04842734|EXPERIMENTAL|physical exercise|"SPEP sessions will be demonstrated to individuals by a 6-year-experienced physiotherapist via videoconference (Zoom Inc.) and the exercises will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed.~Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week)."
61948642|NCT04842734|NO_INTERVENTION|control|"The individuals included in this group will be informed that they should continue their normal daily life activities.~Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week)."
61948643|NCT03185988|EXPERIMENTAL|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|HER2 positive GI tumor beyond CRC, ESCC, BTC,GC\&GEJA
61948644|NCT03185988|EXPERIMENTAL|Esophageal squamous cell carcinoma|HER2 positive Esophageal squamous cell carcinoma
61948645|NCT03185988|EXPERIMENTAL|Biliary tract cancer|HER2 positive Biliary tract cancer
61948646|NCT03185988|EXPERIMENTAL|Colorectal cancer|HER2 positive and RAS/BRAF wild type colorectal cancer
61948647|NCT00492141|EXPERIMENTAL|L9-NC + Temozolomide|Liposomal 9-nitro-20(S)-camptothecin (L9-NC) alone, total 10 ml of 0.4 mg/ml in aerosol reservoir once a day for 5 days in row each 2 weeks, followed by 2 weeks off; then in combination with Temozolomide 100 mg/m\^2 oral/day for Cycle 2 Days 1-5.
62164472|NCT05971758|ACTIVE_COMPARATOR|Fimepinostat 30mg|single 30mg capsule daily in 10 subjects
62164473|NCT05958784|EXPERIMENTAL|Genetic Carriers and Non-Carriers of PKU|
62736533|NCT06422325|EXPERIMENTAL|Insulin Only Arm|Participants will use the closed loop system with insulin only for managing blood sugar during the 12.5 hour study. Insulin will be administered by an Omnipod. Sensor glucose will be measured by a Dexcom G6 CGM. Participants will eat two meals while in clinic.
61948648|NCT04206800|NO_INTERVENTION|Routine care|Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
61948649|NCT04206800|EXPERIMENTAL|Ejaculatory abstinence less than 24 hours|Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.
61948650|NCT05040048||Parkinson's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Motor and non motor assessments for Parkinson's disease group only.
61948651|NCT05040048||Alzheimer's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Brain MRI for Alzheimer's disease group only.
61948652|NCT01741090|EXPERIMENTAL|MSC injection|This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
61948653|NCT02106975|ACTIVE_COMPARATOR|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
61948654|NCT02106975|PLACEBO_COMPARATOR|5% Dextrose in Water|50ml every 6 hours for 96 hours
61948655|NCT04953754|EXPERIMENTAL|Melatonin Group|This group will get melatonin 5mg nightly
61948656|NCT04953754|ACTIVE_COMPARATOR|Control Group|This group will not get any treatment (melatonin)
61948657|NCT00066365|EXPERIMENTAL|Group 1 (unilateral recurrence) - Sargramostim and thoractomy|Patients receive initial inhalation therapy inhaled sargramostim (GM-CSF) twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure thoracotomy on day 22. Beginning on day 29, or as soon as possible thereafter, patients begin post-thoracotomy inhalation therapy for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
61948658|NCT00066365|EXPERIMENTAL|Group 2 (bilateral recurrence) - Sargramostim and thoractomy|Patients may be enrolled on study either before or after the first thoracotomy procedure. For the first thoracotomy, patients undergo surgical procedure unilateral thoracotomy. Patients receive initial inhalation therapy inhaled GM-CSF, as soon as possible after recovery from first thoracotomy, twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure contralateral thoracotomy on day 22. Beginning on day 29, or as soon as possible, patients begin post-thoracotomy inhalation therapy as above for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
62140567|NCT06207604|EXPERIMENTAL|Open sinus lifting without bone grafting and simultaneous implant placement|When adequate release of the membrane is achieved and deemed enough by the operator, an osteotomy is created in the edentulous area following the drilling sequence provided by the implant system used. the implant placement is done directly with the implant motor and the use of a hand driver if needed to adjust the implant platform relation to the crestal bone, followed by cover screw placement.
62140568|NCT06207604|ACTIVE_COMPARATOR|Open sinus lifting with bone grafting and simultaneous implant placement|When adequate release of the membrane is achieved and deemed enough by the operator, an osteotomy is created in the edentulous area following the drilling sequence provided by the implant system used. the palatal packing of bone is made before the implant placement, as the palatal aspect of the sinus will be inaccessible after placement of the implant, the implant placement is done directly with the implant motor and the use of a hand driver if needed to adjust the implant platform relation to the crestal bone, followed by cover screw placement.
62736534|NCT06422325|EXPERIMENTAL|Insulin and Pramlintide Arm|Participants will use the closed loop system with insulin and pramlintide for managing blood sugar during the 12.5 hour study. Insulin and pramlintide will be administered by two Omnipods. Sensor glucose will be measured by a Dexcom G6 CGM. Participants will eat two meals while in clinic.
61948659|NCT03463512|EXPERIMENTAL|Racecadotril plus standard treatment oral rehydration solution|
61948660|NCT03463512|ACTIVE_COMPARATOR|ORS (standard treatment)|
61948661|NCT03529812|EXPERIMENTAL|Early-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education during the first unit of their year-long residency.
61948662|NCT03529812|ACTIVE_COMPARATOR|Delayed-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education midway through their year-long residency.
61948663|NCT03812471|EXPERIMENTAL|Main study: 3D volumes acquisitions|3D volume acquisitions
61948664|NCT03812471|EXPERIMENTAL|Ancillary study: 2D and 3D acquisitions|2D standard measurements and 3D volumes acquisitions
61948665|NCT00772304|EXPERIMENTAL|1|Olopatadine 0.6% / Azelastine 137 mcg
61948666|NCT00561457|EXPERIMENTAL|Iliac Stenting|Stent placement in the iliac artery
61948667|NCT04515394|EXPERIMENTAL|Tepotinib + Cetuximab|
61948668|NCT04435587|EXPERIMENTAL|ivermectin|"Combination of~1. oral ivermectin 600 mcg/kg/day once daily for 3 days~2. Zinc sulfate (100mg/tab) 2 tab every 12 hours for 3 days"
61948669|NCT04435587|ACTIVE_COMPARATOR|ART/hydroxychloroquine|"Combination of~1. Day1 hydroxychloroquine 400mg bid, then 200mg bid on Day 2-5~2. Darunavir/ritonavir (400/100mg) every 12 hours for 5 days~3. Zinc sulfate (100/tab) 2 tab every 12 hours for 5 days"
61948670|NCT03208127|EXPERIMENTAL|Treatment with Direct Acting Antiviral (DAA) Fixed Dose Combination|12 weeks of HCV treatment with medically appropriate direct acting antiviral
61948671|NCT00815698|ACTIVE_COMPARATOR|no suture|self-adhesive mesh, i.e. no suture for mesh fixation
61948672|NCT00815698|EXPERIMENTAL|Suture|Suture for mesh fixation
61948673|NCT01554436|EXPERIMENTAL|patients in smoking cessation|patients in smoking cessation
61948674|NCT05469035|EXPERIMENTAL|Experimental|Nurses in the experimental group participated in mobile-based video learning.
61948675|NCT05469035|ACTIVE_COMPARATOR|Control|Nurses in the experimental group participated in face-to-face learning.
61948676|NCT00002854|EXPERIMENTAL|Sequential high dose chemotherapy|
62140569|NCT06179667|EXPERIMENTAL|Intervention Group|Caregivers will be encouraged to use the mobile application every day during the implementation period of the study (two months).
62140570|NCT06179667|NO_INTERVENTION|Control Group|No treatment will be performed on individuals in the control group.
62341350|NCT02982538|OTHER|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
62341351|NCT01593163|EXPERIMENTAL|EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
62341352|NCT01593163|OTHER|ST (standard treatment)|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
62341353|NCT01764529||The BVMC FCCM cohort|"Aim 1: To investigate the relationship between lesion burden and outcomes in familial CCM.~Aim 2: To investigate the role of the gut microbiome in familial CCM disease severity.~Aim 3: To establish blood markers predictive of disease severity and progression for medical treatment of CCM."
62341354|NCT01393171|ACTIVE_COMPARATOR|Polypropylene Mesh|Site-specific cystocele repair with polypropylene mesh augmentation
62341355|NCT01393171|PLACEBO_COMPARATOR|Anterior Colporrhaphy|Anterior vaginal prolapse repair with anterior colporrhaphy with no graft.
62341356|NCT01393171|ACTIVE_COMPARATOR|Porcine Dermis|Site-specific cystocele repair with porcine dermis augmentation
62341357|NCT05890313|EXPERIMENTAL|Group MoCA/MMSE (Interventional Group)|A training session about dementia management and standardized criteria for referral will be provided to participant PCCs, complemented with training in the administration of MMSE and MoCA, provided also to resident clinicians responsible for administration of the tests. MMSE will be administered if the patient has three to four years of schooling, and the MoCA will be used if the patient has more than four years of schooling. Patients with less than three years of education will be evaluated through regular clinical practice.
62341358|NCT05890313|EXPERIMENTAL|Group Brain on Track/MoCA/MMSE (Interventional Group)|The training sessions mentioned in group MoCA/MMSE will be similarly provided in this group. Brain on Track is a web-based platform, used to remotely monitor cognitive function. There will be a first assessment with the aim of training eligible patients to correctly use Brain on Track, and a second assessment, one week after the first session. Depending on the score obtained in the second assessment, patients will be immediately referred to a specialized consultation, will not be referred or will be followed up during a period of 12 months with remote self monitorization, every three months. According to the total score from the four self-assessments performed in the follow-up period, PCCs will decide whether to refer or not. Patients who are illiterate will be evaluated through regular clinical practice, or MMSE or MoCA tests, according to years of schooling, if they are literate, but do not gather the inclusion criteria for the administration of Brain on Track.
62341359|NCT05890313|NO_INTERVENTION|Control Group|Regular clinical practice complemented with the provision of standardized criteria for referring patients with a suspected diagnosis of MCI or early dementia to PCCs.
62341360|NCT02745132|OTHER|Cognitive evaluation in HCV patients|"Neuropsychological evaluation and Brain MRI~Intervention: The only intervention to be carried out along the study will consist of complete neuro-psychological tests and MRI studies performed at different times.~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied: A neuro-psychological battery of tests and brain MRI studies will be performed at different times before and after the end of the treatment. The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
62341361|NCT06396663|EXPERIMENTAL|Opioid de-escalation|An early opioid deprescribing intervention, delivered by clinical pharmacists, targeting surgical patients discharged from one-of-three East Kent University Foundation Trust hospitals, with opioids.
62341362|NCT05353101|EXPERIMENTAL|Cyclosporine 0.05% eye drops group|The patients with VKC will receive Cyclosporine 0.05% eye drops or Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% effect of Cyclosporine 0.05% eye drops would be evaluated during the follow-up visits.
62341363|NCT05355727|OTHER|Arm A: Visible to MDTM|Patients going through this arm have the decision support tool outcome visible to the MDTM
62498088|NCT05775120||Cohort 1|"Screening for H. pylori infection is planned in 5121 citizens living in different administrative districts of Moscow. The cohort will be formed based on age and sex structure of the Moscow population. The presence of H. pylori will be analyzed using 2 non-invasive methods - 13C-urease breath test and serological test (detection of IgG antibodies to H. pylori). An epidemiological questionnaire will be filled out for each respondent which will display basic information on the patient (gender, age, eating habits, bad habits, family history of cancer, etc.), as well as characterize the main symptoms, if any.~Based on pepsinogen (PG) I levels and PG II (serological markers of atrophy of the gastric mucosa), patients with a high risk of atrophic gastritis and precancerous lesions in the gastric mucosa will be identified and the age and sex structure of atrophic gastritis prevalence in Moscow will be constructed."
62498089|NCT05775120||Cohort 2|From 5121 respondents, 500 patients with confirmed H. pylori infection and serological markers of atrophic gastritis and a control group of infected with H. pylori without serological markers of gastric mucosa atrophy will be selected. They will undergo esophagogastroduodenoscopy with two gastric mucosa biopsies. The first will be conducted according to the OLGA system with a pathology assessment of the stage and degree of gastritis, while the second will be taken to determine the antimicrobial susceptibility of H. (polymerase chain reaction and culture). Correlations between serological and patholgy data on atrophy will be assessed in order to determine the reliability of serological screening for atrophy in the Moscow population.
62498090|NCT05775224||Sickle Cell Disease|
62498091|NCT05775224||Multiple Myeloma|
62498092|NCT01204125|EXPERIMENTAL|SAR240550 twice weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 5.6mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions twice weekly (day 1 and day 4; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
61948677|NCT00880542|EXPERIMENTAL|Sorafenib + Ifosfamide|"\* Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days\* for 3 courses.~NOTE: \*Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.~* Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.~* Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy."
62698661|NCT05177380|EXPERIMENTAL|Personalized rehabilitation program of facial involvement in systemic sclerosis|"3 sessions of 2 hours of facial rehabilitation in hospital over 2 weeks including:~* Physiotherapy with facial and endo-oral massages, self-massages, active and passive exercises of the face and mouth, tongue exercises~* Speech therapy with mobilization of the orofacial sphere applied to swallowing and speech difficulties~* Individual workshop on the theme of dry mouth, dry mouth, swallowing disorders, and oral care~* Individual therapeutic makeup workshop~* A motivational interview~* A patient notebook with a personalized protocol for self-rehabilitation of the face~* A video tutorial for self-rehabilitation of the face Facial self-rehabilitation sessions at home"
61948678|NCT02925117|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.
62698662|NCT05177380|OTHER|Routine care|Delivery of a standard prescription for facial rehabilitation
61948679|NCT02925117|EXPERIMENTAL|Upadacitinib 7.5 mg|Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.
61948680|NCT02925117|EXPERIMENTAL|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.
61948681|NCT02925117|EXPERIMENTAL|Upadacitinib 30 mg|Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.
62164474|NCT02137928|EXPERIMENTAL|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)
62498093|NCT01204125|EXPERIMENTAL|SAR240550 weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 11.2 mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions once weekly (day 1; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
62698663|NCT05617196|ACTIVE_COMPARATOR|Standard Care|
62698664|NCT05617196|EXPERIMENTAL|Virtual PREHAB|In addition to standard care, participants randomized to the The virtual PREHAB program will be delivered by the Hearts and Health in Motion cardiac rehabilitation CR health care team including a medical director nurse, dietician, and physiotherapist who routinely deliver CR postoperatively. The virtual PREHAB program will be up to 8-weeks in duration and deliver the core components of CR online or by telephone.
62698665|NCT00037882|EXPERIMENTAL|SCH 54031|Peg Interferon Alpha-2B/PEG-Intron
61948682|NCT03766074|EXPERIMENTAL|Intervention|vitamin D supplement every other week
61948683|NCT03766074|PLACEBO_COMPARATOR|control|Placebo every other week
61948684|NCT03469934|EXPERIMENTAL|Etokimab|Participants received a single dose of 300 milligrams (mg) etokimab administered on Day 1 by intravenous (IV) infusion over 1 hour. After completing the Day 1 assessments, all participants were followed up for 18 weeks.
61948685|NCT03469934|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo (0.9% sodium chloride) administered on Day 1 by IV infusion over 1 hour. After completing the Day 1 assessments, all participants were followed up for 18 weeks.
61948686|NCT06557707||Young individuals ACE (ages 18-30 years old)|Young individuals who experienced accumulative adverse childhood experiences
61948687|NCT06557707||Children ACE (ages 9-17 years old)|Children who experienced accumulative adverse childhood experiences .
62498094|NCT01204125|ACTIVE_COMPARATOR|Paclitaxel alone|Paclitaxel will be administered at the dose of 80mg/m2 as a 60-min IV infusion. Patients will receive weekly (day 1) paclitaxel infusions.
61948688|NCT06557707||Young individuals No ACE (ages 18-30 years old)|Young individuals who have not experienced accumulative adverse childhood experiences
61948689|NCT06557707||Children No ACE (ages 9-17 years old)|Children who have not experienced accumulative adverse childhood experiences.
61948690|NCT03483025|OTHER|Hair Cleansing product 1|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
61948691|NCT03483025|OTHER|Hair cleansing product 2|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
61948692|NCT03483025|OTHER|Hair cleansing product 3|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
62164475|NCT02137928|ACTIVE_COMPARATOR|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months
62164476|NCT03160859|OTHER|Control Method|One arm of the study will include unsedated colonoscopy with water exchange (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
62498095|NCT00514150|ACTIVE_COMPARATOR|1|1075 cc of 154 mEq/L solution of NaCl 0.9% , prepared by adding 75 cc of 154 mEq/L NaCl 0.9 % to 1000 cc of 154 mEq/L NaCl 0.9%
62498096|NCT00514150|ACTIVE_COMPARATOR|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate 8.4% to 1000 cc of 154 mEq/ L NaCl 0.9%.
62698666|NCT05595668|EXPERIMENTAL|Prism adaptation treatment|Prism Goggles with 15-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
62698667|NCT05595668|PLACEBO_COMPARATOR|Placebo control prism adaptation treatment|Prism goggles with 5-degree rightward deviating prism lenses will be used to maintain the double-blind methodology.
62698668|NCT02583841|ACTIVE_COMPARATOR|Scaling and Root Planing( SRP)|This was an interventional study in which scaling and root planing was done in systemically healthy patients with chronic periodontitis
61948693|NCT03483025|OTHER|Hair cleansing product 4|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
61948694|NCT03483025|OTHER|Hair cleansing product 5|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
62140571|NCT06691035|EXPERIMENTAL|Elacestrant + DC1|"Patients will undergo apheresis of peripheral blood to collect and create DC1 vaccines. DC1 will be pulsed with ESR1 native or mutated peptides. After DC1 vaccines have undergone safety testing and are ready to be used, patients will be injected in groin nodes (or accessible breast tumor if available) weekly with these pulsed DC1 for eight consecutive weeks. They will alternate between native ESR1 DC1s and mutated ESR1 DC1s.~Patients will receive combination of DC1 vaccinations and Elacestrant concurrently.~Elacestrant is a novel oral selective estrogen downregulator, administered during vaccination and continued after.~Elacestrant is considered standard of care for patients with ESR1 mutated HR+ HER2-metastatic breast cancer.~Pulsed DC1 will be administered after initial induction every four weeks x 3 doses."
62140572|NCT04950920|EXPERIMENTAL|Y-2 sublingual test group|Y-2 sublingual tablets: Edaravone 30mg and d-borneol 6mg.
62498097|NCT02214706|EXPERIMENTAL|sirolimus topical 40microgram/cm2|sirolimus topical 40microgram/cm2
62498098|NCT02214706|EXPERIMENTAL|Pulsed Dye Laser + Erbium yag + sirolimus|Pulsed Dye Laser + Erbium yag laser + topical sirolimus
62498099|NCT02214706|EXPERIMENTAL|Pulsed Dye Laser + topical sirolimus|Pulsed Dye Laser + topical sirolimus
62498100|NCT02214706|EXPERIMENTAL|Pulsed Dye Laser|Pulsed Dye Laser
61948695|NCT03483025|OTHER|Hair cleansing product 6|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
61948696|NCT03925597|EXPERIMENTAL|ARM 1: Arabinoxylan, Beta-Glucan, Resistant Starch, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Beta-Glucan 3- Resistant Starch 4- Inulin
61948697|NCT03925597|EXPERIMENTAL|ARM 2: Arabinoxylan, Beta-Glucan, Inulin, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Beta-Glucan 3- Inulin 4- Resistant Starch
61948698|NCT03925597|EXPERIMENTAL|ARM 3: Arabinoxylan, Resistant Starch, Beta-Glucan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Resistant Starch 3- Beta-Glucan 4- Inulin
61948699|NCT03925597|EXPERIMENTAL|ARM 4: Arabinoxylan, Resistant Starch, Inulin, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Resistant Starch 3- Inulin 4- Beta-Glucan
61948700|NCT03925597|EXPERIMENTAL|ARM 5: Arabinoxylan, Inulin, Beta-Glucan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Inulin 3- Beta-Glucan 4- Resistant Starch
61948701|NCT03925597|EXPERIMENTAL|ARM 6: Arabinoxylan, Inulin, Resistant Starch, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan, 2- Inulin, 3- Resistant Starch, 4- Beta-Glucan
62498101|NCT02842723|EXPERIMENTAL|Protontherapy|
62498102|NCT02583191|EXPERIMENTAL|Rivaroxaban|Arm A: Rivaroxaban
62498103|NCT02583191|ACTIVE_COMPARATOR|low-molecular heparine|Arm B: standard treatment with low-molecular heparine
62698669|NCT02583841|NO_INTERVENTION|Control Group|Scaling and root planing was not done , that is no intervention is carried out in the patients of this group.
61948702|NCT03925597|EXPERIMENTAL|ARM 7: Beta-Glucan, Arabinoxylan, Resistant Starch, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Arabinoxylan, 3- Resistant Starch, 4- Inulin
61948703|NCT03925597|EXPERIMENTAL|ARM 8: Beta-Glucan, Arabinoxylan, Inulin, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Arabinoxylan, 3- Inulin, 4- Resistant Starch
61948704|NCT03925597|EXPERIMENTAL|ARM 9: Beta-Glucan, Resistant Starch, Inulin, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Resistant Starch, 3- Inulin, 4- Arabinoxylan
61948705|NCT03925597|EXPERIMENTAL|ARM 10: Beta-Glucan, Resistant Starch, Arabinoxylan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Resistant Starch, 3- Arabinoxylan, 4- Inulin
61948706|NCT03925597|EXPERIMENTAL|ARM 11: Beta-Glucan, Inulin, Arabinoxylan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Inulin, 3- Arabinoxylan, 4- Resistant Starch
61948707|NCT03925597|EXPERIMENTAL|ARM 12: Beta-Glucan, Inulin, Resistant Starch, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Inulin, 3- Resistant Starch, 4- Arabinoxylan
61948708|NCT03925597|EXPERIMENTAL|ARM 13: Resistant Starch, Inulin, Beta-Glucan, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch 2- Inulin 3- Beta-Glucan 4- Arabinoxylan
62498104|NCT00090753|EXPERIMENTAL|Methoxy Polyethylene Glycol-Epoetin Beta|Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.
62498105|NCT00090753|ACTIVE_COMPARATOR|Comparator ESA|Patients received the same comparator ESA \[epoetin alfa, epoetin beta, or darbepoetin alfa\] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.
62140573|NCT04950920|SHAM_COMPARATOR|placebo group|60 μg d-borneol
62140574|NCT05738434|EXPERIMENTAL|Short-course Chemotherapy|
62698670|NCT06419881|EXPERIMENTAL|Tele-drama therapy intervention|This arm received a 12-week tele-drama therapy intervention, with each session lasting 75 minutes via the Uniper Care platform.
62698671|NCT06419881|OTHER|Usual Care|This usual care arm continued to receive routine activities provided by Uniper Care.
62698672|NCT00652834|OTHER|kidney recipients with GI symptoms|This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) on the equimola basis.
62698673|NCT02194179|EXPERIMENTAL|NVP XR 400 mg (KCR 25%) fasted|
62698674|NCT02194179|EXPERIMENTAL|NVP XR 400 mg (KCR 25%) fed|
62698675|NCT02194179|EXPERIMENTAL|NVP XR 400 mg (KCR 20%) fasted|
62698676|NCT02194179|EXPERIMENTAL|NVP XR 400 mg (KCR 20%) fed|
62698677|NCT02194179|EXPERIMENTAL|NVP XR 300 mg (KCR 25%) fasted|
62698678|NCT02194179|EXPERIMENTAL|NVP XR 300 mg (KCR 25%) fed|
61948709|NCT03925597|EXPERIMENTAL|ARM 14: Resistant Starch, Inulin, Arabinoxylan, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Inulin, 3- Arabinoxylan, 4- Beta-Glucan
61948710|NCT03925597|EXPERIMENTAL|ARM 15: Resistant Starch, Arabinoxylan, Inulin, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Arabinoxylan, 3- Inulin, 4- Beta-Glucan
61948711|NCT03925597|EXPERIMENTAL|ARM 16: Resistant Starch, Arabinoxylan, Beta-Glucan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Arabinoxylan, 3- Beta-Glucan, 4- Inulin
61948712|NCT03925597|EXPERIMENTAL|ARM 17: Resistant Starch, Beta-Glucan, Inulin, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Beta-Glucan, 3- Inulin, 4- Arabinoxylan
62140575|NCT05738434|ACTIVE_COMPARATOR|Chemotherapy|
62498106|NCT03680261|EXPERIMENTAL|Adjuvant chemoradiotherapy group|Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
62498107|NCT03680261|ACTIVE_COMPARATOR|Adjuvant chemotherapy group|Adjuvant chemotherapy (6 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
62698679|NCT02194179|EXPERIMENTAL|NVP XR 300 mg (KCR 20%) fasted|
62698680|NCT02194179|EXPERIMENTAL|NVP XR 300 mg (KCR 20%) fed|
62698681|NCT02194179|ACTIVE_COMPARATOR|NVP IR 200 mg (Viramune®)|
62698682|NCT04728425|ACTIVE_COMPARATOR|IVIG + SCIG|This group of MG patients will start with 2g/kg of IVIG on month 1, 1 g/kg of IVIG 4 and then 8 weeks later, and within 2 weeks switch to SCIG treatment
62698683|NCT04728425|ACTIVE_COMPARATOR|SCIG alone|This group of MG patients will start with SCIG alone
62698684|NCT02156947||Chronic cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
62698685|NCT02156947||Acute cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
62698686|NCT05106725||Neurological patients|This cohort will include patients having been diagnosed with a neurological condition.
62698687|NCT05106725||Control|This cohort will include patients who have not been diagnosed with a neurological disorder.
62698688|NCT04354233|EXPERIMENTAL|Physical activity intervention with connected devices|Women randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
62698689|NCT04354233|NO_INTERVENTION|Standard care|Women will receive stardard care and physical activity international recommendations, without further intervention
62698690|NCT05414045|EXPERIMENTAL|Patients|
62140576|NCT06132594|EXPERIMENTAL|Group I; Conventional arthrocentesis followed by I-PRF injection|Patients received arthrocentesis followed by I-PRF injection, employing the conventional TMJ injection technique aided by facial anatomical landmarks
62698691|NCT03289039|EXPERIMENTAL|Neratinib|"* Neratinib will be administered orally once daily~* Neratinib is dosed at 240mg (six 40mg tablets)"
62698692|NCT03289039|EXPERIMENTAL|Neratinib + Fulvestrant|"* Neratinib will be administered orally once daily~* Neratinib is dosed at 240mg (six 40mg tablets)~* Fulvestrant will be administered intramuscular as an injection (shot) on day 1 and 15 of cycle 1, day 1 of cycle 2, and then on day 1 of each subsequent cycle.~* Fulvestrant is dosed as 250 mg/5mL (x2) for a total of 500 mg via intramuscular injection (two injections)."
62698693|NCT04273061|EXPERIMENTAL|Breast Cohort|Cohort of participants whose primary tumour type is breast.
62698694|NCT04273061|EXPERIMENTAL|Lung Cohort|Cohort of participants whose primary tumour type is lung.
62698695|NCT04273061|EXPERIMENTAL|GI Cohort|Cohort of participants whose primary tumour type is gastrointestinal (including pancreas and hepatobiliary).
62140577|NCT06132594|EXPERIMENTAL|Group II; 3d surgical guided Arthrocentesis followed by I-PRF injection|Patients received arthrocentesis followed by I-PRF injection with the assistance of a CT-guided 3D printed surgical guide.
62341364|NCT05355727|OTHER|Arm B: Not-visible to MDTM|Patients going through this arm will not have the decision support tool outcome visible to the MDTM
62698696|NCT04273061|EXPERIMENTAL|GU Cohort|Cohort of participants whose primary tumour type is genitourinary.
62698697|NCT04273061|EXPERIMENTAL|Gyne Cohort|Cohort of participants whose primary tumour type is gynecological.
62698698|NCT04273061|EXPERIMENTAL|Sarcoma Cohort|Cohort of participants whose primary tumour type is sarcoma.
62698699|NCT04273061|EXPERIMENTAL|Primary Unknown Cohort|Cohort of participants whose primary tumour type is unknown.
62698700|NCT04273061|EXPERIMENTAL|Other Cohort|Cohort of participants whose primary tumour type is not classified as one of the other study arms. This cohort includes participants with cancers from the head and neck, skin, or rare cancers.
61948713|NCT03925597|EXPERIMENTAL|ARM 18: Resistant Starch, Beta-Glucan, Arabinoxylan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Beta-Glucan, 3- Arabinoxylan, 4- Inulin
61948714|NCT03925597|EXPERIMENTAL|ARM 19: Inulin, Resistant Starch, Arabinoxylan, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Resistant Starch, 3- Arabinoxylan, 4- Beta-Glucan
62698701|NCT04454333||Hospitalized caused by COVID-19|A total of 466 patients hospitalized with the diagnosis of SARS-COV-2 at the University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital were retrospectively screened. 212 of these patients did not answer the calls, 34 of them could not be reached because they gave the wrong phone number beforehand. 4 of the patients called by the phone had communication problems due to language problems and 10 people did not want to fill the questionnaire. 206 of them were contacted by the phone and their pain and myalgia in the head, neck-back, waist, shoulder and hip regions before, during and after SARS-COV-2, their anxiety and depression levels after SARS-COV-2, and their quality of life were questioned.
61948715|NCT03925597|EXPERIMENTAL|ARM 20: Inulin, Resistant Starch, Beta-Glucan, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Resistant Starch, 3- Beta-Glucan, 4- Arabinoxylan
61948716|NCT03925597|EXPERIMENTAL|ARM 21: Inulin, Beta-Glucan, Resistant Starch, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Beta-Glucan, 3- Resistant Starch, 4- Arabinoxylan
61948717|NCT03925597|EXPERIMENTAL|ARM 22: Inulin, Beta-Glucan, Arabinoxylan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Beta-Glucan, 3- Arabinoxylan, 4- Resistant Starch
61948718|NCT03925597|EXPERIMENTAL|ARM 23: Inulin, Arabinoxylan, Beta-Glucan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Arabinoxylan, 3- Beta-Glucan, 4- Resistant Starch
61948719|NCT03925597|EXPERIMENTAL|ARM 24: Inulin, Arabinoxylan, Resistant Starch, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Arabinoxylan, 3- Resistant Starch, 4- Beta-Glucan
61948720|NCT01170143|ACTIVE_COMPARATOR|Trastuzumab QW|Arm A: Trastuzumab 2mg/kg, d1; qw (loading dose 4mg/kg wk1) Paclitaxel 80mg/m2,. d1; qw Carboplatin AUC 2 d1, qw
61948721|NCT01170143|ACTIVE_COMPARATOR|Trastuzumab Q3W|Arm B: Trastuzumab 6mg/kg, d1(loading dose 8mg/kg wk1) Paclitaxel 175mg/m2,. d1, q3w; Carboplatin AUC 6 ,. d1,q3w
61948722|NCT01485575||Filter use during vitrectomy|
61948723|NCT06277557|OTHER|High fidelity Simulation|conventional teaching method
61948724|NCT06405451|ACTIVE_COMPARATOR|Conventional treatment|Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, six times a week.
61948725|NCT06405451|EXPERIMENTAL|Experimental treatment|Respiratory muscle training will be conducted using the Threshold IMT-Philips inspiratory training device and the Threshold PEP expiratory training device, both from Respironics®. Participants will be comfortably seated in a chair with their feet on the ground, without back support, and with the trunk at a 90° angle to the hips. A conventional nasal clip will be used to prevent air leaks. During forced expiratory training, participants will use the ThresholdPEP® with a customized mouthpiece and perform forced expiration through the resistance device. Inspiratory muscle training will follow the same procedure using the Threshold IMT®. Both inspiratory and expiratory training will be repeated 10-15 times, 5 sets for 20 minutes in one session, with a rest time of 30-60 seconds between each set.
62140578|NCT04713124|EXPERIMENTAL|R2C-M intervention|"R2C-M telephone intervention - Six approximately weekly sessions of R2C-M telephone-delivered intervention (50 minutes in duration), delivered by the same R2C-M Counsellor each session (a qualified clinical psychologist trained in the R2C protocol by the developer, Dr Kate Hall). Call duration will be recorded. Sessions will be digitally recorded, and an independent researcher will randomly select and rate fidelity of intervention sessions for 20% of participants.~R2C-M workbooks - Two workbooks to facilitate counsellor-delivered exercises within sessions, and between-session practice, will be mailed/emailed to participants.~Self-help booklet - (as in control group) R2C-M participants will also receive a booklet of information and self-help strategies for methamphetamine use problems."
62498108|NCT01987934||Normal or Control group|Those subjects with normal oral epithelium will be included in this group.
62498109|NCT01987934||Study Group|Those subjects with oral squamous cell carcinoma will be included in this group.
62498110|NCT05909241|EXPERIMENTAL|BA1202|BA1202 is a bispecific antibody targeting CEA and CD3.
62498111|NCT05473767|ACTIVE_COMPARATOR|Family Check Up Control|The Family Check-Up is a home visiting program that typically takes place over the course of 3-5 sessions - An initial interview, assessment, feedback session, and optional treatment sessions. The Family Check-Up is designed to support child development and improve parental well-being.
62498112|NCT05473767|EXPERIMENTAL|Family Check-Up Heart|Family Check-Up Heart combines the traditional Family Check-Up with a heart health component.
62698702|NCT02150629||SCI patients|
62698703|NCT02150629||Healthy subjects|
61948726|NCT02428270|EXPERIMENTAL|GSK2256098 and Trametinib|"GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles.~Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles."
61948727|NCT04765982|ACTIVE_COMPARATOR|patients with less than 80% time in range|Better control group
61948728|NCT04765982|PLACEBO_COMPARATOR|patients with more than 80% time in range|poor control group
61948729|NCT00458562||HIV+, <CIN2|HIV positive women without CIN2-3 or worse
61948730|NCT00458562||HIV-, no >=CIN3 biopsy, HR HPV+|HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
62498113|NCT04815460|EXPERIMENTAL|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
62498114|NCT04815460|EXPERIMENTAL|Ｍoderate intensity-continuous (MCT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
62498115|NCT04815460|NO_INTERVENTION|Control group|Without any exercise training
62498116|NCT05194709|EXPERIMENTAL|Anti-5T4 CAR-NK Cells|
62498117|NCT01346644|ACTIVE_COMPARATOR|No probiotics|Infant formula with no probiotics
61948731|NCT00458562||HIV-, <=CIN1, HPV- at screening|HIV negative women who are \<= CIN1 and HPV negative at screening
61948732|NCT05328063|EXPERIMENTAL|Control Group. Gluteus maximus strengthening specific program|
61948733|NCT05328063|EXPERIMENTAL|Intervention group. Specific manual therapy program for hip joint and Gluteus maximus strengthening|
61948734|NCT01313312|EXPERIMENTAL|Total Dysport®|A total of 254 subjects in the open label study received between 1 and 5 intramuscular (i.m) injections of Dysport® according to their individual needs, for a period of up to 12 months. All subjects were administered an appropriate dosage of Dysport® (1000 Units \[U\] or 500 U) on Day 1 of treatment Cycle 1. At each study visit from Week 12 onwards, subjects were assessed to determine whether a subsequent treatment cycle was required and treatment cycles were administered at intervals of a minimum of 12 weeks apart depending on the subject's safety and efficacy response. From Cycle 2 onwards, a total dose of 1500 U could be administered in subjects requiring treatment with Dysport® in their shoulder and other upper limb muscles. Subjects who showed improvement in their upper limb during the first two treatment cycles were able to receive concomitant injections of Dysport® 500 U into at least one calf muscle, from Cycle 3 onwards as long as the total dose did not exceed 1500 U.
62140579|NCT04713124|ACTIVE_COMPARATOR|Control|"Self-help booklet - Control participants will receive (by mail/email) a booklet of information and self-help strategies for methamphetamine use problems.~Telephone check-ins + information on further support - (to control for frequency of contact across treatment arms) Participants in this group will receive 6 telephone calls from the research team (lasting maximum 5 minutes, call duration will be recorded). During these calls, participants will be asked about their use of the booklet. Whenever required, the researcher will provide participants with information on further support (e.g. DirectLine or other state/territory AOD helpline for advice or referral)."
62498118|NCT01346644|EXPERIMENTAL|Probiotic|Infant formula supplemented with probiotic
62498119|NCT02571933||Grammar English|Patients who primarily speak Grammar English. Patients will answer the FPS-R in Grammar English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
62498120|NCT02571933||Pidgin English|Patients who primarily speak Pidgin English. Patients will answer the FPS-R in Pidgin English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
62498121|NCT02571933||French|Patients who primarily speak French. Patients will answer the FPS-R in French both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
62498122|NCT02974647|EXPERIMENTAL|rel/ref PTCLtumors are known to contain mutations associ|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
62498123|NCT02974647|EXPERIMENTAL|with rel/ref PTCL with functional evidence of JAK/STAT|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
62698704|NCT00508456|EXPERIMENTAL|Hominex®-2 + Temodar®|Dietary Methionine Restriction (Hominex®-2) Days 1-7 and 15-21 + Temodar® 150 mg/m\^2 orally Days 8-15
62698705|NCT00153231|EXPERIMENTAL|Infracoccygeal sacropexy|Intervention: IVS
62698706|NCT00153231|ACTIVE_COMPARATOR|Sacrospinofixation|Intervention: Sacrospinofixation
62698707|NCT03261804||Group I:internal vaginal douching users|
62698708|NCT03261804||Group II: none internal vaginal douching users|
62698709|NCT04881565|EXPERIMENTAL|Reactive balance training plus functional electrical stimulation|
62698710|NCT04881565|ACTIVE_COMPARATOR|Reactive balance training|
62698711|NCT02995200|EXPERIMENTAL|Group Post-Stroke|2 sessions of in-home accelerometer based feedback about paretic arm use
62698712|NCT02995200|NO_INTERVENTION|Healthy Control Group|
62698713|NCT05851547|EXPERIMENTAL|Prostate SBRT with Focal Boost and Androgen Deprivation Therapy|Stereotactic body radiotherapy to 27 Gy in 3 fractions to uninvolved regions of the prostate glad and up to 39 Gy in 3 fractions to mpMRI-defined intraprostatic lesions, with concurrent/adjuvant androgen deprivation therapy (6 months for intermediate risk, 24 months for high risk)
61948735|NCT00518687|EXPERIMENTAL|V710 60 µg|
61948736|NCT00518687|PLACEBO_COMPARATOR|Placebo|
62140580|NCT06027970|ACTIVE_COMPARATOR|Treatment|After successful Endoscopic variceal ligation (EVL) the treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days. Both the group will receive standard care of therapy.
62698714|NCT02136992|PLACEBO_COMPARATOR|Placebo (without active ingredient)|placebo will be taken two tablets 3 times a day during the whole study process.
61948737|NCT05717179|NO_INTERVENTION|Clinical decision strategy|All patients receive a TNF-alpha blocker while continuing background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use at week 12 is at the discretion of the investigator.
62698715|NCT02136992|EXPERIMENTAL|Pirfenidone（200mg）|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
62698716|NCT04144920|OTHER|Block 1|Participants in this arm performed the conditions in this order: CS, HFLD, LFHD
62698717|NCT04144920|OTHER|Block 2|Participants in this arm performed the conditions in this order: CS, LFHD, HFLD
62698718|NCT04144920|OTHER|Block 3|Participants in this arm performed the conditions in this order: HFLD, CS, LFHD
62698719|NCT04144920|OTHER|Block 4|Participants in this arm performed the conditions in this order: HFLD, LFHD, CS
62698720|NCT04144920|OTHER|Block 5|Participants in this arm performed the conditions in this order: LFHD, CS, HFLD
62698721|NCT04144920|OTHER|Block 6|Participants in this arm performed the conditions in this order: LFHD, HFLD, CS
62698722|NCT01706185||Cancer Group|
62698723|NCT00863590|EXPERIMENTAL|A|Panel A
62698724|NCT00863590|EXPERIMENTAL|B|Panel B
62698725|NCT00863590|EXPERIMENTAL|C|Panel C
62698726|NCT00863590|EXPERIMENTAL|D|Panel D
61948738|NCT05717179|EXPERIMENTAL|Clinical plus ultrasound-based decision strategy|All patients in this group will be evaluated by ultrasound at 44 joints. In case of clinically-verified plus ultrasound verified inflammation, patients will receive a TNF-alpha blocker while continuing background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are again evaluated by ultrasound at 44 joints. In case clinically-verified plus ultrasound-verified inflammation is present, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use is at the discretion of the investigator. In case clinically-verified plus ultrasound-verified inflammation is absent, patients receive step-up pain therapy while background csDMARD(s) will be continued.
61948739|NCT04821115|EXPERIMENTAL|Low intensity choc waves therapy (Experimental group)|The patients will use the device with a real applicator.
62698727|NCT01312298|EXPERIMENTAL|General Anesthesia|Patients allocated to this arm will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml in a Target Controlled Infusion (TCI)
62698728|NCT01312298|ACTIVE_COMPARATOR|Regional anesthesia|Patients will receive intrathecal anesthesia
61948740|NCT04821115|SHAM_COMPARATOR|Sham group|The patients will use the device with a sham applicator. Instead of a focusing lens, the applicator will have an internal foam piece that will dissipate the energy of the shockwave. Hence, the sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted
61948741|NCT06354062|OTHER|Group of assistant head nurses|First-line nurse managers received a talent management intervention program
61948742|NCT06354062|OTHER|Group of head nurses|First-line nurse managers received a talent management intervention program
61948743|NCT01551992|ACTIVE_COMPARATOR|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
62698729|NCT04637061||REC4T study patients|Rectal adenocarcinoma or polyp with indication for resection and primary colo-rectal mechanical anastomosis using a circular stapler with/or without protective ostomy undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery (see Inclusion/Exclusion Criteria)
62698730|NCT05029388|EXPERIMENTAL|Aerobic Exercise|This experimental group will receive aerobic exericse. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The aerobic exercise training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
62698731|NCT05029388|EXPERIMENTAL|High Intensity Interval Training|This experimental group will receive high intensity interval training. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The HIIT training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
61948744|NCT01551992|ACTIVE_COMPARATOR|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
61948745|NCT05862831|EXPERIMENTAL|PM1003|PM1003 0.02mg/kg-10mg/kg
61948746|NCT06221462|EXPERIMENTAL|treatment arm|
61948747|NCT03062007|EXPERIMENTAL|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
61948748|NCT03266731|EXPERIMENTAL|use of aspirin and clopidogrel|
61948749|NCT05893355|EXPERIMENTAL|Acupressure group|"* Participants in this group will be interviewed for the first time in the first week of postpartum and for the second time in the fourth week of postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS that will be applied to the participant to evaluate the back pain just before the application will be filled in by the participant.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed."
61948750|NCT05893355|NO_INTERVENTION|Control group|"* Participants in this group will be interviewed for the first time in the first week of postpartum and for the second time in the fourth week of postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* VAS to assess back pain will be filled in by the participant.~* No application will be made to this group."
61948751|NCT02040571|EXPERIMENTAL|Closed Loop|
61948752|NCT02040571|ACTIVE_COMPARATOR|Open Loop|
61948753|NCT03434574|PLACEBO_COMPARATOR|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
61948754|NCT03434574|ACTIVE_COMPARATOR|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
61948755|NCT05962931|EXPERIMENTAL|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Allogenic adipose-derived adult mesenchymal stem cells expanded on fibrinhyaluronic biological matrix
62698732|NCT05029388|NO_INTERVENTION|Control Group|This group will not take part in aerobic exercise and HIIT training programme. Participants will be given an exercise diary or logbook to keep track of their exercise habits (i.e., record the type of exercise/activity, hours, and intensity of exercise/activity every day) throughout the intervention periods.
62698733|NCT06563076|ACTIVE_COMPARATOR|Vestibular Rehabilitation Group|underwent vestibular rehabilitation program
62140581|NCT06027970|PLACEBO_COMPARATOR|Control|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days. Both the group will receive standard care of therapy.
62140582|NCT00192218|EXPERIMENTAL|1|FluMist
62140583|NCT01203293|EXPERIMENTAL|Cognitive Behavior Therapy|
62140584|NCT01203293|ACTIVE_COMPARATOR|Treatment as usual|
62698734|NCT06563076|ACTIVE_COMPARATOR|Vestibular Rehabilitation and Vestibular Electrical Stimulation Group|underwent vestibular electrical stimulation (VES) in addition to the supervised vestibular rehabilitation program.
61948756|NCT05962931|ACTIVE_COMPARATOR|Standard treatment (Control)|Standard treatment
61948757|NCT02693119|EXPERIMENTAL|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
61948758|NCT02693119|EXPERIMENTAL|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
61948759|NCT02693119|EXPERIMENTAL|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
61948760|NCT02693119|EXPERIMENTAL|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
61948761|NCT02997709||Radiation Therapy Group|Participants with prostate cancer diagnosis who are scheduled to undergo standard of care radiotherapy with or without the addition of Androgen Deprivation Therapy (ADT) will be evaluated
61948762|NCT02997709||Prostatectomy Group|Participants with prostate cancer diagnosis who are scheduled to undergo prostatectomy will be evaluated
61948763|NCT00562835|ACTIVE_COMPARATOR|1|Methylprednisolone
61948764|NCT00562835|PLACEBO_COMPARATOR|2|
61948765|NCT03973710|EXPERIMENTAL|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
61948766|NCT03973710|PLACEBO_COMPARATOR|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
61948767|NCT05435677|EXPERIMENTAL|Sequence 1|All participants will get each of the 3 medicines at 3 different timepoints IcoSema - insulin icodec - semaglutide, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
61948768|NCT05435677|EXPERIMENTAL|Sequence 2|All participants will get each of the 3 medicines at 3 different timepoints IcoSema- semaglutide . insulin icodec, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
61948769|NCT05435677|EXPERIMENTAL|Sequence 3|All participants will get each of the 3 medicines at 3 different timepoints insulin icodec- IcoSema- semaglutide, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
61948770|NCT05435677|EXPERIMENTAL|Sequence 4|All participants will get each of the 3 medicines at 3 different timepoints insulin icodec- semaglutide - IcoSema separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
61948771|NCT05435677|EXPERIMENTAL|Sequence 5|All participants will get each of the 3 medicines at 3 different timepoints semaglutide - IcoSema - insulin icodec, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
61948772|NCT05435677|EXPERIMENTAL|Sequence 6|All participants will get each of the 3 medicines at 3 different timepoints semaglutide - insulin icodec - IcoSema, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
61948773|NCT01284218||Aripiprazole cohort|
61948774|NCT01284218||Other atypical cohort|
62140585|NCT03891563||Sport specialists, MVPA|"AOSSM Criteria:~1. Participation in intensive training and/or competition in organized sports greater than 8 months per year (essentially year round)~2. Participation in 1 sport to the exclusion of participation in other sports (limited free play overall)~3. Involving prepubertal (seventh grade or roughly age 12 years) children.~AND~Activity Tracker Criteria:~Greater than 180 accumulated minutes of moderate-to-vigorous physical activity (MVPA) during participation in one sport type across one week of activity tracking~- Meets these criteria within either one or both years of follow-up"
62140586|NCT03891563||Non-sport specialist, any activity level|"AOSSM Criteria:~1. Participation in more than 1 sport at any physical activity level OR~2. Participation in none or low training and/or competition in organized sports for any period of time.~3. Involving prepubertal children.~AND~Activity Tracker Criteria:~Greater than or less than 180 accumulated minutes of MVPA across one week of activity tracking~- Meets these criteria during both years of follow-up"
62140587|NCT00734578|EXPERIMENTAL|SPD503-AM|SPD503 (Guanfacine Extended Release)
62140588|NCT00734578|EXPERIMENTAL|SPD503-PM|SPD503 (Guanfacine Extended Release)
61948775|NCT01284218||Other antidepressant cohort|
61948776|NCT01284218||Mood stabilizer cohort|
61948777|NCT01284218||Stimulant cohort|
61948778|NCT01232595|EXPERIMENTAL|LFF571 (POC)|
61948779|NCT01232595|ACTIVE_COMPARATOR|Vancomycin (POC)|
61948780|NCT01232595|EXPERIMENTAL|LFF571 Dose level 1 (cohort 2)|
61948781|NCT01232595|EXPERIMENTAL|LFF571 Dose level 2 (cohort 2)|
61948782|NCT01232595|EXPERIMENTAL|LFF571 Dose level 3 (cohort 2)|
61948783|NCT01232595|EXPERIMENTAL|LFF571 Dose level 4 (cohort 2)|
61948784|NCT05757687|EXPERIMENTAL|Omega procedure|
61948785|NCT05890144|EXPERIMENTAL|"Intensive Intervention (Big Canoe)"|"20 participants will be randomly assigned to Arm 1. Participants in Arm 1 (the Big Canoe) will complete an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. The curriculum in Arm 1 was developed by the San'yas Indigenous Cultural Safety Training Program in British Columbia with the support of the Ontario Indigenous Cultural Safety Training Program."
61948786|NCT05890144|ACTIVE_COMPARATOR|"Brief Intervention (Little Canoe)"|"20 participants will be randomly assigned to Arm 2. Participants in Arm 2 (the Little Canoe) will complete a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session. The intervention in Arm 2 is an Indigenous adaption of the Devine et al. (2012) anti-bias habit-breaking intervention."
61948787|NCT05890144|OTHER|Control|20 participants will be randomly assigned to Arm 3. Participants in Arm 3 (control) will complete a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
61948788|NCT04218695|EXPERIMENTAL|Treatment|1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization
61948789|NCT04218695|PLACEBO_COMPARATOR|Placebo|Normal saline (50cc) once daily for up to one week or until end of hospitalization
62140589|NCT00734578|PLACEBO_COMPARATOR|Placebo|
62698735|NCT03224884|ACTIVE_COMPARATOR|Interscalene block|Patients randomized to receive an interscalene block .
62498124|NCT02974647|EXPERIMENTAL|with rel/ref PTCL who do not meet criteria for cohort 1 or 2.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours).Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
62698736|NCT03224884|EXPERIMENTAL|Supraclavicular block|Patients randomized to receive a supraclavicular block.
61948790|NCT06534710|EXPERIMENTAL|experimental group|On the basis of the control group, an electronic moxibustion instrument was used every day (CreditEase Medical Device Technology, YXB-AJY-06) : The patient was placed in a comfortable lying position and the surgical incision area was fully exposed. The nurse placed the moxibustion tablets on the moxibustion head of the electronic moxibustion instrument, and the moxibustion head was connected to the electronic moxibustion treatment instrument through a wire. The moxibustion temperature should be slightly red on the skin and the patient should tolerate it. The total intervention time was 5 days, and the relevant study data at discharge were recorded if the patient was discharged early
62698737|NCT00104884|EXPERIMENTAL|Depsipeptide|Depsipeptide is administered as a 4-hour IV infusion weekly in doses of 13 mg/m\^2 for 3 weeks. Repeat cycle every 28 days until unacceptable toxicity or disease progression.
62698738|NCT03257657|EXPERIMENTAL|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC Registered Dietitian (RD) at the 12 week visit.
61948791|NCT06534710|NO_INTERVENTION|control group|The routine nursing plan was adopted. (1) Pain knowledge education, including understanding of pain and analgesic drugs, pain assessment methods, selection of analgesic drugs, etc. within 24 hours of admission and before and after surgery, to alleviate patients' fear and anxiety about pain; ② After surgery, choose the appropriate position, gently turn over, and try to avoid pain caused by the change of position and pressure on the affected side; ③ After the gauze or dressing was removed from the surgical incision, the nurse disinfected the surgical incision twice a day with iodophor cotton swabs, observed the healing of the wound at the surgical incision every day, and reported to the doctor in time if there was blood or fluid leakage.
61948792|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
61948793|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
61948794|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
61948795|NCT01890473|EXPERIMENTAL|Arm 1: Abatacept (autoinjector)|Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days
61948796|NCT01890473|EXPERIMENTAL|Arm 2: Abatacept (prefilled syringe)|Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days
61948797|NCT00142298|EXPERIMENTAL|telbivudine|telbivudine 600 mg p.o. daily for 104 weeks.
62698739|NCT03257657|EXPERIMENTAL|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
62698740|NCT06560190|EXPERIMENTAL|Postpartum Study Participant|Pragmatic Orthopaedic Physical Therapy
62698741|NCT04354857||RT-PCR SARS-CoV-2 positive|
62698742|NCT04354857||RT-PCR SARS-CoV-2 negative|
61948798|NCT01210469|EXPERIMENTAL|Strengthening Group|Performed balance training with lower limbs muscle strengthening.
62698743|NCT03317873|EXPERIMENTAL|wild type AA (CC)|All participants with the wild type genotype AA (CC) will be allocated to this group
62698744|NCT03317873|EXPERIMENTAL|mutation VV (TT)|All participants with the mutation genotype VV (TT) will be allocated to this group
62698745|NCT03092518|EXPERIMENTAL|1/Arm 1|HIPEC with gastrectomy
62698746|NCT02955290|EXPERIMENTAL|Phase I (CIMAvax, nivolumab)|"LOADING PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.~MAINTENANCE PHASE I: Patients who do not experience a DLT receive CIMAvax every 4 weeks and nivolumab every 2 weeks."
62498125|NCT02974647|EXPERIMENTAL|Rare sub-type expansion cohort: T-PLL and T-LGL & any T-Cell/NK Lymphoma with JAK fusion mutations.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
62498126|NCT02700971|EXPERIMENTAL|Cutaneous Biopsy for microarray analysis|To determine whether outcomes improve as a function of anti-tumor immunity which may enable the use of this technique as a predictive biomarker of treatment response.
62698747|NCT02955290|EXPERIMENTAL|Phase II Study A and B (CIMAvax, nivolumab)|PHASE II STUDY A and B: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for nivolumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients in Study A with antibody titer \>= 1:4000 at the end of the loading phase may receive CIMAvax IM every 8 or 12 weeks during the maintenance phase.
62698748|NCT02955290|EXPERIMENTAL|Phase II Study C, D & E (CIMAvax, pembrolizumab)|PHASE II STUDY C, D \& E: Patients with PD-L1 expression \>= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62698749|NCT02955290|EXPERIMENTAL|Phase II Study D (CIMAvax, pembrolizumab)|PHASE II STUDY D: Patients with PD-L1 expression \< 50% after 4 cycles of induction chemotherapy with pembrolizumab, receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62698750|NCT05035108|EXPERIMENTAL|extensive hepatectomy patient|hiHep bioartificial liver therapy
62698751|NCT05870072|EXPERIMENTAL|Dual task training (balance exercises combined with cognitive task) group|
62698752|NCT05870072|EXPERIMENTAL|Kinesthetic motor imagery training group|
62698753|NCT05870072|ACTIVE_COMPARATOR|Balance exercises (Control) group|
62698754|NCT03715907|NO_INTERVENTION|Control: W34|Members receiving the Control intervention for the W34 (3- to 6-year-old well visit) gap will not receive a mailer.
62698755|NCT03715907|EXPERIMENTAL|Information only: W34|Members receiving the Information Only intervention for the W34 care gap will receive a mailer informing them of that gap, but not of financial incentives for closing the care gap.
62698756|NCT03715907|EXPERIMENTAL|Incentives: W34|Informational W34 mailer and incentive to close gap
62698757|NCT03715907|NO_INTERVENTION|Control: LSC|Members receiving the Control intervention for the LSC (lead screening in children) gap will not receive a mailer.
62698758|NCT03715907|EXPERIMENTAL|Information only: LSC|Informational LSC mailer and incentive to close gap
62698759|NCT03715907|EXPERIMENTAL|Incentives: LSC|Members receiving the Incentives intervention for the LSC care gap will receive a mailer informing them of the gap and eligibility for a gift card if they close the gap.
62698760|NCT03715907|NO_INTERVENTION|Control: IMA|No mailer for IMA (immunizations) gap
62140590|NCT05845814|EXPERIMENTAL|Arm A: Coformulated favezelimab/pembrolizumab plus EV|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) as an intravenous (IV) infusion on Day 1 of every 3-week cycle for up to \~2 years (35 cycles) and EV at 1.25 mg/kg, administered as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.
62498127|NCT04346654|EXPERIMENTAL|Eltrombopag + Dexamethasone|Patients will be treated with eltrombopag in combination with a standard high-dose dexamethasone (1 cycle: 40 mg QD from day 1-4) to induce sustained response off treatment.
62698761|NCT03715907|EXPERIMENTAL|Information only: IMA|Informational IMA mailer
62698762|NCT03715907|EXPERIMENTAL|Incentives: IMA|Informational IMA mailer and incentive
62698763|NCT03715907|NO_INTERVENTION|Control: CDC|No mailer for CDC (clinical diabetes care) gap
62698764|NCT03715907|EXPERIMENTAL|Information only: CDC|Informational CDC mailer
62698765|NCT03715907|EXPERIMENTAL|Incentives: CDC|Informational CDC mailer and incentive
62698766|NCT03715907|NO_INTERVENTION|Control: CCS|No mailer for CCS (cervical cancer screening)
62698767|NCT03715907|EXPERIMENTAL|Information only: CCS|Informational CCS mailer
62698768|NCT03715907|EXPERIMENTAL|Incentives: CCS|Informational CCS mailer and incentive
62698769|NCT03715907|NO_INTERVENTION|Control: AWC|No mailer for AWC (adolescent well-care visit) gap
62698770|NCT03715907|EXPERIMENTAL|Information only: AWC|Informational AWC mailer
62698771|NCT03715907|EXPERIMENTAL|Incentives: AWC|Informational AWC mailer and incentive
62698772|NCT02758821|OTHER|CRP-Control|The health care provider will manage the patient using standard guidelines. No CRP will be measured onsite
62698773|NCT02758821|OTHER|CRP-A|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
62698774|NCT02758821|OTHER|CRP-B|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
62698775|NCT04576455|EXPERIMENTAL|Giredestrant|
62698776|NCT04576455|ACTIVE_COMPARATOR|Physician Choice of Endocrine Monotherapy|The physician choice of endocrine monotherapy will be limited to fulvestrant or an aromatase inhibitor.
62698777|NCT01481012||Group I: Cardiopulmonary Bypass + Heart Transplantation|CPB for orthotopic heart transplantation (excluding any patients with VADs)
62698778|NCT01481012||Group II: Cardiopulmonary Bypass + Pulsatile LVAD|CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
62140591|NCT05845814|EXPERIMENTAL|Arm B: Coformulated vibostolimab/pembrolizumab plus EV|Participants will receive coformulated vibostolimab/pembrolizumab (200 mg/200 mg) as an IV infusion on Day 1 of every 3-week cycle, for up to \~2 years (35 cycles) and EV at 1.25 mg/kg, administered as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.
62140592|NCT05845814|ACTIVE_COMPARATOR|Arm C: Pembrolizumab plus EV|Participants will receive 200 mg pembrolizumab as an IV infusion on Day 1 of every 3-week cycle for up to \~2 years (35 cycles) and EV at 1.25 mg/kg, administered as an IV infusion on Days 1 and 8 of every 3-week cycle, until disease progression, intolerable toxicity, or investigator decision.
62140593|NCT04565977||Retrospective Cohort|All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019
61948799|NCT01210469|EXPERIMENTAL|Stretching Group|Performed balance training with stretching
61948800|NCT01210469|NO_INTERVENTION|Control Group|
61948801|NCT02563171|PLACEBO_COMPARATOR|Healthy periodontium without obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
62698779|NCT01481012||Group III: Cardiopulmonary Bypass + Continuous Flow LVAD|CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
62698780|NCT01481012||Group IV: Cardiopulmonary Bypass + CABG Surgery|CPB for CABG surgery
62698781|NCT06597656|EXPERIMENTAL|Delandistrogene Moxeparvovec After Plasmapheresis Procedure|Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1 after plasmapheresis procedure if AAVrh74 antibodies are sufficiently low.
62698782|NCT01189851|OTHER|IORT|Treated with Intraoperative Radiation Therapy
62698783|NCT02343185|EXPERIMENTAL|diaphragmatic treatment|Subjects in this arm receive different manual techniques for the low back pain and diaphragmatic treatment.
62698784|NCT02343185|PLACEBO_COMPARATOR|Placebo|Subjects in this arm receive different manual techniques for the low back pain and a sham diaphragmatic treatment.
62698785|NCT06108947|ACTIVE_COMPARATOR|Aspirin|Aspirin 150 mg per day from pregnancy week 12 to 36 - according to current recommendations
61948802|NCT02563171|ACTIVE_COMPARATOR|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
61948803|NCT02563171|PLACEBO_COMPARATOR|Healthy periodontium with obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
61948804|NCT02563171|ACTIVE_COMPARATOR|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
61948805|NCT02404220|EXPERIMENTAL|ENTO 200 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): Entospletinib (ENTO) 200 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 200 mg twice daily continuously in combination with vincristine (VCR) 0.5 mg intravenously (IV) on Days 1, 8, 15, and 22 of each cycle; dexamethasone (DEX) 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and central nervous system (CNS) prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a complete remission (CR) received stem cell transplant (SCT) (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a partial response \[PR\]) after induction were offered maintenance therapy with ENTO 200 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
61948806|NCT02404220|EXPERIMENTAL|ENTO 400 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
61948807|NCT02404220|EXPERIMENTAL|ENTO 400 mg + VCR 1.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
62140594|NCT03676569|EXPERIMENTAL|Experimental group|Autologous ADRC transplantation in autoimmune refractory epilepsy
62140595|NCT01484925||With Barrett's Esophagus|Patients who have been diagnosed in the past with Barrett's Esophagus
62498128|NCT04346654|ACTIVE_COMPARATOR|Dexamethasone|Patients will be treated with a standard high-dose dexamethasone (1-3 cycles: 40 mg QD day 1-4 every 14-28 days) to induce sustained response off treatment
62498129|NCT01913054|ACTIVE_COMPARATOR|Fentanyl & Propofol|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.
62498130|NCT01913054|EXPERIMENTAL|fentanyl, propofol & etomidate|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.
62498131|NCT06632236|EXPERIMENTAL|Experimental: Phase 1b|The Phase 1b will evaluate the safety and tolerability of amivantamab and determine its preliminary antitumour activity when administered at the recommended Phase 2 dose (RP2D) in patients with molecularly defined malignant brain tumours.
62498132|NCT03590834|EXPERIMENTAL|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
62498133|NCT03590834|EXPERIMENTAL|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
62498134|NCT03590834|ACTIVE_COMPARATOR|Active Control|Active comparison group
62140596|NCT01484925||Without Barrett's Esophagus|Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
62140597|NCT02131922|PLACEBO_COMPARATOR|Hygenization Treatment|Basic oral hygiene instructions Supragingival plaque removal
62140598|NCT02131922|EXPERIMENTAL|Intensive Treatment|One-Stage Full-Mouth Disinfection. Scaling and root planing, four quadrants in one session. Extraction of radix relicta. Subgingival chlorhexidine (PerioKIN) (0.2%) in all pockets. Oral hygiene instructions.
62140599|NCT04690075|EXPERIMENTAL|Intervention|To receive routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
62140600|NCT04690075|PLACEBO_COMPARATOR|Control|To receive routine nutrition management for 12 weeks.
62140601|NCT02042703||exfoliation syndrome|patients with exfoliation syndrome
62140602|NCT02042703||POAG|patients with primary open angle glaucoma (POAG)
62140603|NCT02042703||cataracts|patients with cataracts
62140604|NCT03535272|ACTIVE_COMPARATOR|Intervention Group|Bismuth subsalicylate 4 tablets po bid (2.1 grams total of BSS)
62140605|NCT03535272|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet 4 bid
62341365|NCT04751903|EXPERIMENTAL|Oral motor stimulation|After the infants were assessed by a neonatologist, Oral motor stimulation was administered to the experimental group thrice a day (at 9:00, 12:00, 15:00 hours) for 15 minutes right before feeding, over a 14-day period.
62498135|NCT05594641|EXPERIMENTAL|T (Treatment)|Remote ischaemic preconditioning (RIPC) will be performed before the start of liver resection and the associated Pringle maneuver
62498136|NCT05594641|OTHER|C (Control)|RIPC will be not performed
61948808|NCT02404220|EXPERIMENTAL|ENTO 400 mg + VCR 2.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
61948809|NCT04750512|EXPERIMENTAL|real ESP, placebo TAP|US-guided ESP block + sham US-guided TAP block
61948810|NCT04750512|ACTIVE_COMPARATOR|real TAP, placebo ESP|sham US-guided ESP block + US-guided TAP block before laparoscopic hernia repair
61948811|NCT04099095|ACTIVE_COMPARATOR|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed
61948812|NCT04099095|ACTIVE_COMPARATOR|Delayed Appointment|Wait-list control group who receive Social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed
61948813|NCT05923034||had a computed tomography scan of the chest within 24 hours after stroke onset|
61948814|NCT05123170|ACTIVE_COMPARATOR|Group I|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) alone diluted with normal saline 0.9% to make the final volume 30 ml
61948815|NCT05123170|ACTIVE_COMPARATOR|Group II|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.25 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml.
61948816|NCT05123170|ACTIVE_COMPARATOR|Group III|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.5 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml
61948817|NCT05465460|ACTIVE_COMPARATOR|Banana blossom|Participants received banana blossom 225 mg tablet orally four time per day for 14 days.
61948818|NCT05465460|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablet orally four time per day for 14 days.
61948819|NCT04792320|EXPERIMENTAL|Active bamboo charcoal|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The participants will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
61948820|NCT04792320|EXPERIMENTAL|Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
61948821|NCT04792320|EXPERIMENTAL|Active bamboo charcoal+Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
61948822|NCT04792320|NO_INTERVENTION|No invervention|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
62140606|NCT02266654|EXPERIMENTAL|Prehospital-directed therapy arm|Patients who are hypotensive or whose lactate is ≥ 2.5, prehospital providers will provide a notification to the receiving hospital (Hospital Notification), establish an IV, and provide 1 liter normal saline (NS) bolus of IV fluids. An additional 1 liter normal saline bolus will be given for systolic blood pressure less than 100. Patients who have a history of end-stage renal disease or congestive heart failure would receive only 20 milliliters/kilogram of fluid. If the patient remains hypotensive, Emergency Medical Services will continue providing fluids as is standard of care.
62498137|NCT00545116|EXPERIMENTAL|a|Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)
62498138|NCT00545116|EXPERIMENTAL|b|Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving
62498139|NCT00545116|PLACEBO_COMPARATOR|c|Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin
62498140|NCT00545116|PLACEBO_COMPARATOR|d|Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin
62498141|NCT04680780|EXPERIMENTAL|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 month
62698786|NCT06108947|EXPERIMENTAL|Aspirin discontinuation|Discontinuation of Aspirin around 24-28 weeks in low risk women
62698787|NCT04704193|EXPERIMENTAL|Electronic Decision Aid|Participants in this arm will complete an electronic decision aid for genetic testing.
62698788|NCT06211296|EXPERIMENTAL|Shortcut|
62698789|NCT06061185||Testing populations|All patients with the possibility of acute hemorrhagic stroke and suitable for multimodal CT examination
62698790|NCT03728478|NO_INTERVENTION|Treatment arm 1: Step-up|JIA patients managed with a Treat-To-Target strategy (T2T)
62698791|NCT03728478|EXPERIMENTAL|Treatment arm 2: Step-down|JIA patients treated with an early combined therapy
62698792|NCT04781179|EXPERIMENTAL|CM-II Technique|
62498142|NCT04680780|EXPERIMENTAL|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months.
62498143|NCT04680780|PLACEBO_COMPARATOR|Control|Patients are allowed to eat ad libitum
62498144|NCT05456438|EXPERIMENTAL|COCONUT OİL|"* After feeding, wash hands and apply 2 drops of oil, COCONUT OİL in the 1st intervention group to the index finger and spread on the areola and nipple,~* Continue this application for 10 days"
62498145|NCT05456438|NO_INTERVENTION|Control group|They were told that no intervention would be performed, and that they should not use any application like herbal or chemical oils, creams, medications, etc. on the nipples during the first 10 days postpartum.
62498146|NCT05456438|EXPERIMENTAL|TEA TREE OİL|"* After feeding, wash hands and apply 2 drops of oil, TEA TREE OİL in the 2nd intervention group, to the index finger and spread on the areola and nipple,~* Continue this application for 10 days."
62698793|NCT04781179|PLACEBO_COMPARATOR|Psychoeducation|
61948823|NCT01582568||Certolizumab|Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
61948824|NCT03159221|EXPERIMENTAL|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
61948825|NCT03159221|NO_INTERVENTION|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
61948826|NCT05712967||PATIENTS WITH MM|patients fulfilling the International Myeloma Working Group (IMWG) diagnostic criteria for MM
61948827|NCT05712967||PATIENTS WITH sMM|patients fulfilling the International Myeloma Working Group (IMWG) diagnostic criteria for SMM
61948828|NCT05712967||Controls|healthy controls
61948829|NCT03828175|OTHER|cop variables|non invasive cop vsriables correlation to basic monitoring variables during prone position spinal anesthesia intervention pcnl operation at basic ,1hour and 2hours .
61948830|NCT06366932|OTHER|Cohort 1: patients who are about to initiate treatment|"Patients will receive the dose used in routine clinical practice.~Once the patient is included in the clinical trial their therapeutic management will be conducted according to standard clinical practice, but some additional procedures will be performed:~1. The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life.~2. Blood samples will be obtained for biochemical, pharmacogenetic and immunological biomarker analysis"
61948831|NCT06366932|OTHER|Cohort 2: patients who are already receiving second-line systemic treatment|If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
61948832|NCT02038881|EXPERIMENTAL|Group 1 (standard regimen)|One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
61948833|NCT02038881|EXPERIMENTAL|Group 2 (double dose regimen)|Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
61948834|NCT02038881|EXPERIMENTAL|Group 3 (booster regimen)|One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
61948835|NCT02890472||prenatal diagnosis of a fetal 22q11 deletion syndrome|
62140607|NCT02266654|EXPERIMENTAL|Control Arm|Prehospital providers will obtain a point of care lactate, establish an IV, and provide IV fluids as judged necessary.
62164477|NCT03160859|OTHER|Study Method|The other arm will include unsedated colonoscopy with water exchange (WE) and the addition of a simple commercially available accessory to the colonoscopy device: a cap (Disposable Distal Attachment, Olympus Medical Systems Corp., Tokyo, Japan) fitted to the colonoscope per manufacturer instruction. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
62498147|NCT01656798|EXPERIMENTAL|fasted condition|
62498148|NCT01656798|EXPERIMENTAL|fec condition|
62498149|NCT06163937|EXPERIMENTAL|Glucose as reference food|Ten healthy, normal-weight adults after 10-14 hours of fasting, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from orange juice and mixed fruit juice (consisted of apple, orange, grape, and pomegranate), each tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after beverage consumption. The first glucose sample was taken exactly 15min after the first sip of drink.
62698794|NCT05962775|NO_INTERVENTION|Control|In eligible patients allocated to control group, no interventions will be done before ART cycle.
61948836|NCT03873025|EXPERIMENTAL|Pembrolizumab and CXD101|"Initial dose ('dose level 0'):-~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 20mg twice daily PO (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity.~Reduced dose level ('Dose level -1'; if \>1 DLT observed at dose level 0):~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 given twice daily, 20mg in the morning and 10mg in the evening (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity."
61948837|NCT00851630|EXPERIMENTAL|Early|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 2 weeks after commencing antituberculous therapy
61948838|NCT00851630|EXPERIMENTAL|Delayed|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 8 weeks after commencing antituberculous therapy
62698795|NCT05962775|EXPERIMENTAL|Ethanol sclerotherapy|In eligible patients allocated to study group, endometrioma/s will be aspirated and treated with ethanol for 10 minutes 1-2 cycles before ART.
62698796|NCT06197581|OTHER|RT+capecitabine|Patients will receive concurrent radiotherapy and capecitabine.
62698797|NCT06197581|OTHER|RT+HER2 inhibitors|Patients will receive concurrent radiotherapy and any HER2 inhibitors ( eg. trastuzumab plus pertuzumab or TDM1)
62698798|NCT06197581|OTHER|RT+ CDK4/6 inhibitors|Patients will receive concurrent radiotherapy and any of the CDK4/6 inhibitors (abemaciclib，palbociclib ,ribociclib or other CDK4/6 inhibitors)
61948839|NCT03886480|EXPERIMENTAL|SaeboVR|Use of the SaeboVR for task specific upper extremity training
61948840|NCT04952675||low-risk group|Risk Index∈\[0,0.5)
61948841|NCT04952675||high-risk group|Risk Index∈\[0.5,1)
61948842|NCT04306848|EXPERIMENTAL|Pilot|Eligible subjects who have consented to the study, and have had the baseline data gathered as part of their participation in the Lifestyle Medicine Clinic, an intensive therapeutic lifestyle medicine program, will be given a CGMs device and supplies, and instructed in how to utilize these. They will set up the app on their smart phone to provide them with feedback on their glucose level to correlate with their lifestyle activities.
61948843|NCT00321308|ACTIVE_COMPARATOR|B|Standard of care chemotherapy
61948844|NCT00321308|EXPERIMENTAL|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
61948845|NCT01390688||Type 2 Diabetes|80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI \> 18.5 kg/m2 fatsing plasma glucose \< 12 mmol/l
61948846|NCT01390688||Impaired glucose tolerance|40 individuals with impaired glucose tolerance. age 40 -65 years, BMI \> 18. 5 kg/m2
61948847|NCT01390688||Normal glucose tolerance|80 Individuals without type 2 diabetes Age 40-65 years, BMI \>18.5 kg/m2.
61948848|NCT06454019|EXPERIMENTAL|Control Group without a phone call|Control Group was assigned to receive no phone outreach
61948849|NCT06454019|EXPERIMENTAL|Treatment Group with a phone call|Treatment group was assigned to receive a phone call from Covered California call center
61948850|NCT01674114|EXPERIMENTAL|TAP block|transversus abdominis plane block (TAP block). Ultrasound guided TAP-block at the end of surgery using 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml bilaterally by the anaesthesiologist, and 20 ml NaCl intracutaneously in the operating wound performed by the obstetrician
61948851|NCT01674114|ACTIVE_COMPARATOR|control|Ultrasound guided TAP block at the end of surgery with 20 ml NaCl bilaterally and 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml intracutaneously in the surgical wound(standard practice)
61948852|NCT01164800|EXPERIMENTAL|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
61948853|NCT01164800|ACTIVE_COMPARATOR|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
61948854|NCT05732246|NO_INTERVENTION|Conventional treatment group|"Hot pack and TENS at neck for 10minutes. Therapeutic ultrasound for 5 minutes Soft tissue techniques (gliding and kneading) was applied at a slow speed for 5 minutes over the neck muscles.~Gentle stretching and strengthening exercises"
61948855|NCT05732246|EXPERIMENTAL|First rib mobilization with balloon breathing exercises group|Patient was in supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner palpated 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depress the first rib as able during exhalation.
62140608|NCT01141972|ACTIVE_COMPARATOR|Supplement|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency
61948856|NCT00742378||C|Normal controls
61948857|NCT00742378||G|Glaucoma
61948858|NCT03757156|NO_INTERVENTION|Aspirin maintenance group|People who are taking aspirin continue to take aspirin.
61948859|NCT03757156|EXPERIMENTAL|Aspirin withdrawal group|People who are taking aspirin stop to taking aspirin.
61948860|NCT00255125|PLACEBO_COMPARATOR|Arm Placebo|Placebo
62341366|NCT04751903|NO_INTERVENTION|Control group|The preterm infant' the control group were only fed by the researcher thrice a day (at 9:00, 12:00, 15:00 hours) over a 14-day period.
62341367|NCT05630430|EXPERIMENTAL|Volar Carbon Plate Effects on Procedure Time|Carbon alloy plates, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line
61948861|NCT00255125|EXPERIMENTAL|Arm Soy Supplement|Soy Supplement
61948862|NCT05092646|PLACEBO_COMPARATOR|Control Group|Single dose, 2.0 mL of 0.9% normal saline, administered via intra-articular injection administered to the affected tibiotalar joint.
61948863|NCT05092646|EXPERIMENTAL|Investigational Group|"Biological/Vaccine: Axolotl Ambient~Axolotl Ambient is an allogeneic amniotic intraarticular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.~Other Names:~• CA20"
61948864|NCT02146664|EXPERIMENTAL|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 490 mg, one tablet three times daily, everyday for eight weeks of study period
61948865|NCT02146664|PLACEBO_COMPARATOR|Placebo|Placebo is administered one tablet three times daily, everyday for eight weeks of study period
62164478|NCT04917068||Bulimia Nervosa|Participants with diagnosed bulimia nervosa (BN) who will complete all tasks during Visits 1 and 2 in addition to ecological momentary assessment (EMA) procedures following Visit 2.
62341368|NCT05630430|ACTIVE_COMPARATOR|Titanium Alloy Plates Group|Titanium alloy plates are frequently used materials in our current orthopedic surgery practices. The main goal during surgical treatment is to obtain an accurate and acceptable bone alignment. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery.
62498150|NCT06163937|EXPERIMENTAL|Orange juice|Ten healthy, normal-weight adults after 10-14 hours of fasting, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from orange juice and mixed fruit juice (consisted of apple, orange, grape, and pomegranate), each tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after beverage consumption. The first glucose sample was taken exactly 15min after the first sip of drink.
61948866|NCT04521374|EXPERIMENTAL|Standard Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative \[IDSSI\] Level 7) will consist of meat, potatoes and peas: 333kcal, 16g protein.
61948867|NCT04521374|EXPERIMENTAL|Standard Protein Fortified Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative \[IDSSI\] Level 7) will consist of meat, potatoes and peas: 333kcal, 25g protein.
61948868|NCT04521374|EXPERIMENTAL|Texture Modified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative \[IDSSI\] Level 4) will consist of meat, potatoes and peas: 340kcal, 16g protein.
61948869|NCT04521374|EXPERIMENTAL|Texture Modified Protein Fortified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative \[IDSSI\] Level 4) will consist of meat, potatoes and peas: 350kcal, 25g protein.
61948870|NCT06385951|OTHER|Patients|Patients with mild cognitive impairment and mild Alzheimer's dementia
61948871|NCT06385951|OTHER|Healthy volunteers|Healthy volunteers
61948872|NCT02747290|EXPERIMENTAL|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
61948873|NCT05182190|ACTIVE_COMPARATOR|Control - White bread|Commercial white bread in a 50 gram available carbohydrate dose
61948874|NCT05182190|ACTIVE_COMPARATOR|Control - whole black beans|Whole boiled black beans (Zenith) in a 50 gram available carbohydrate dose
61948875|NCT05182190|EXPERIMENTAL|Knife Mill pasta|Heat treated black bean flour made with standard Knife Mill techniques
61948876|NCT05182190|EXPERIMENTAL|Combined pasta|Black bean flour with medium protein made with novel compression/decompression mill
61948877|NCT05182190|EXPERIMENTAL|Cyclone pasta|Black bean flour with lower protein made with novel compression/decompression mill
62698799|NCT06197581|OTHER|RT+PARP inhibitor.|Patients will receive concurrent radiotherapy and PARP inhibitor(Olaparib or other PARP inhibitors)
61948878|NCT05600803||DSOC group|Study subjects are patients who satisfied the inclusion/exclusion criteria and underwent single-operator cholangioscopy.
61948879|NCT00282100|EXPERIMENTAL|Gefitinib (Iressa)|Open label single arm study of Gefitinib (Iressa) 250mg daily as adjuvant therapy in patients with resectable Hepatocellular Carcinoma
61948880|NCT02845934|EXPERIMENTAL|Mucormycosis|blood sample
61948881|NCT05954702|ACTIVE_COMPARATOR|Conventional Esophagectomy group|Patients with malignant esophagus neoplasms randomized to Conventional Esophagectomy will undergo to an esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
61948882|NCT05954702|EXPERIMENTAL|Supercharged TRAM esophagectomy group|Patients with malignant esophagus neoplasms randomized to Supercharged TRAM esophagectomy will undergo to esophagectomy, immediately followed by supercharged esophagogastroplasty.
61948883|NCT03847246|ACTIVE_COMPARATOR|Baraclude® tablets，1.0 mg|
61948884|NCT03847246|EXPERIMENTAL|Entecavir tablets，1.0 mg|
61948885|NCT05585060|EXPERIMENTAL|PEEP titration for mechanical ventilated AECOPD patients|Pre- and post-self-controlled trials for invasive mechanical ventilated AECOPD patients during PEEP titration.
61948886|NCT02538081|ACTIVE_COMPARATOR|Risperidone plus placebo|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus placebo
62498151|NCT06163937|EXPERIMENTAL|Mixed fruit juice|Ten healthy, normal-weight adults after 10-14 hours of fasting, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from orange juice and mixed fruit juice (consisted of apple, orange, grape, and pomegranate), each tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after beverage consumption. The first glucose sample was taken exactly 15min after the first sip of drink.
62698800|NCT06197581|OTHER|RT+ICI|Patients will receive concurrent radiotherapy and immune checkpoint inhibitor (Pembrolizumab or other anti-PD1/PDL1 regimens).
61948887|NCT02538081|ACTIVE_COMPARATOR|Risperidone plus DMXB-A|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus DMXB-A
61948888|NCT03294759|EXPERIMENTAL|Bio-ACL (Amion)|Intervention: ACL Autograft Reconstruction with Amion Collagen Scaffold. Stem Cells isolated from bone marrow aspirate from distal femur will be injected inside the Amion Collagen Scaffold.
61948889|NCT03294759|ACTIVE_COMPARATOR|Control|Intervention: Normal ACL Autograft Reconstruction with either patella or hamstring autograft will be performed in the control group.
61948890|NCT03922126|EXPERIMENTAL|Listos peer intervention|Listos intervention (peer counseling, PrEP information, and HIV/STI testing kits)
62498152|NCT06535711||Acute CT|Those with an acute CT (within 24 h).
62498153|NCT06535711||Deferred CT|Those without an acute CT, instead a CT within 3-4 weeks.
62698801|NCT06183970|EXPERIMENTAL|AssistI patients|Patients will receive rehabilitation training using the AsistI software package in conjunction with standard upper limb rehabilitation interventions.
62698802|NCT06183970|ACTIVE_COMPARATOR|Habilect patients|Patients will receive rehabilitation training using the Habilect software and hardware complex, in addition to standard rehabilitation interventions for the upper limb.
62698803|NCT06183970|NO_INTERVENTION|Conventional therapy patients|Patients will undergo standard upper limb rehabilitation interventions without the utilization of additional methods.
62698804|NCT05198934|EXPERIMENTAL|Arm A: Sotorasib 960 mg QD + panitumumab|
62698805|NCT05198934|EXPERIMENTAL|Arm B: Sotorasib 240 mg QD + panitumumab|
62140609|NCT01141972|PLACEBO_COMPARATOR|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
62164479|NCT04917068||Healthy Control|Participants without diagnosed BN or other current or past eating disorders who will complete all tasks during Visits 1 and 2 and will not complete EMA procedures following Visit 2.
61948891|NCT03922126|ACTIVE_COMPARATOR|Peer only group|Peer only group (peer counseling, PrEP information)
61948892|NCT02248701|EXPERIMENTAL|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
61948893|NCT02248701|PLACEBO_COMPARATOR|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
61948894|NCT05622695||Catheterization Arm|Participants will be limited to adults older than 18 years of age, able to consent, planned for the cardiac catheterization lab for a right heart catheterization or in the cardiac care unit with an existing arterial line or Swan-Ganz catheter actively measuring the pulmonary artery pressure on a continuous basis.
61948895|NCT00550121|EXPERIMENTAL|1|
61948896|NCT00550121|PLACEBO_COMPARATOR|2|
61948897|NCT03258931|EXPERIMENTAL|Crenolanib|Crenolanib following salvage chemotherapy
61948898|NCT03258931|ACTIVE_COMPARATOR|Midostaurin|Midostaurin following salvage chemotherapy
61948899|NCT02041832|OTHER|Holter monitoring|Screening of patients with older age, arterial hypertension and diabetes for paroxysmal atrial fibrillation by using conventional Holter monitoring
62140610|NCT05703698|EXPERIMENTAL|Cognitive Behavioural Therapy for psychosis|CBTp will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
61948900|NCT02041832|OTHER|Implantable loop recorder|Screening of patients with older age, arterial hypertension and diabetes mellitus for paroxysmal atrial fibrillation by using an implantable loop recorder
61948901|NCT01275820||Nutralin|All 10 subjects in the study will consume the investigational food product.
61948902|NCT05568823|OTHER|"Patients responding to treatment after 8 weeks of treatment"|"Patients responding to treatment after 8 weeks of treatment: i.e. whose clinical evolution is beneficial."
62140611|NCT00587886||Cases|Cases will be women with newly diagnosed endometrial or ovarian cancer who are residents of six counties in New Jersey.
62140612|NCT00587886||Controls|Controls will be selected from the general population in those counties by use of random digit dialing for those under 65 years of age, from Centers for Medicare and Medicaid Services (CMS) lists for those aged 65 years and over, and from neighborhood sampling.
62140613|NCT00278135|ACTIVE_COMPARATOR|1|
62140614|NCT00278135|PLACEBO_COMPARATOR|2|
62498154|NCT05049772|EXPERIMENTAL|Telerehabilitation-based motor imagery group|Behavioral: Telerehabilitation-based motor imagery group Participants in the Telerehabilitation-based motor imagery group will imagine for the lumbar region exercises (e.g. bridges, knee-to-chest stretches, pelvic tilts) in the sessions in home using the study audio-video motor imagery script for 2 times per week; 30 min per day for 10 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week). In addition, the participants will be given stabilization exercises In addition, the participants will be given stabilization exercises for 10 weeks for 40 minutes, 2 days a week.
62498155|NCT05049772|ACTIVE_COMPARATOR|Stabilization Exercises group|Behavioral: Stabilization Exercises group An exercise program consisting of lumbar stabilization exercises for the participants will be planned for the pelvic ring muscles to develop the neutral lumbar spine. Co-contraction of the transversus abdominus muscle and the multifidus muscle will form the basis of the exercises. Stabilization exercises will be given for 10 weeks for 40 minutes, 2 days a week.
62498156|NCT05049772|NO_INTERVENTION|Healthy control group|no specific intervention
62498157|NCT02126657|OTHER|Single Arm|Single arm study - pre and post peel assessment
62698806|NCT05198934|ACTIVE_COMPARATOR|Arm C : Investigator's choice|Participants will be administered trifluridine and tipiracil, or regorafenib
62698807|NCT05962489|EXPERIMENTAL|OFF DBS followed by ON DBS|
62698808|NCT05962489|EXPERIMENTAL|ON DBS followed by OFF DBS|
62698809|NCT01274208||Gaucher Disease with Hepatitis C|
61948903|NCT05568823|OTHER|"Patients non-responding to treatment after 8 weeks of treatment"|"Patients non-responding to treatment after 8 weeks of treatment: i.e. whose clinical evolution is not satisfactory."
61948904|NCT03064750|EXPERIMENTAL|Pre-surgery exercise|pelvic floor exercises individually and in groups
61948905|NCT03064750|OTHER|Waiting list|wait as usual until surgery
61948906|NCT02173223|EXPERIMENTAL|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, \& Kopczynski, 2011). It is currently in phase II testing.
61948907|NCT02173223|EXPERIMENTAL|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, \& Kopczynski, 2011). It is currently in phase II testing.
61948908|NCT00406354|EXPERIMENTAL|Atomoxetine Fast Titration|0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
61948909|NCT00406354|EXPERIMENTAL|Atomoxetine Slow Titration|0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
61948910|NCT00406354|PLACEBO_COMPARATOR|Placebo|matching placebo daily dose taken orally
61948911|NCT00376064|EXPERIMENTAL|SMS995 + Carbegolin, Somavert + SMS995|
61948912|NCT00219739|EXPERIMENTAL|Imatinib mesylate 400 mg|
61948913|NCT00219739|EXPERIMENTAL|Imatinib mesylate 600 mg|
61948914|NCT00219739|EXPERIMENTAL|Imatinib mesylate 400 mg +Peg interferon|
61948915|NCT00219739|EXPERIMENTAL|Imatinib mesylate 400 mg +Cytarabine|
61948916|NCT02043080|NO_INTERVENTION|SOC: sputum smear and Chest x-ray|HIV-infected adult and pediatric TB suspects screened for TB according to current standard of care
61948917|NCT02043080|EXPERIMENTAL|Xpert MTB/RIF, sputum, chest xray &TB culture|HIV-infected adult and pediatric TB suspects screened for TB using the Xpert MTB/RIF Tuberculosis diagnostic tool (algorithm) which include chest x-ray, sputum TB culture
61948918|NCT01627483|EXPERIMENTAL|Medication review|Assessment of risks of falls and fractures, medication review
61948919|NCT01627483|NO_INTERVENTION|Controll|
61948920|NCT06679816|EXPERIMENTAL|Hormone supplementation therapy group|
61948921|NCT06679816|PLACEBO_COMPARATOR|Placebo therapy group|
61948922|NCT02653872|EXPERIMENTAL|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
61948923|NCT02653872|ACTIVE_COMPARATOR|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
61948924|NCT02653872|ACTIVE_COMPARATOR|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
61948925|NCT02653872|ACTIVE_COMPARATOR|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
61948926|NCT05802212|EXPERIMENTAL|Metformin intervention for 12 weeks|Metformin intervention for 12 weeks
62140615|NCT05325541|EXPERIMENTAL|Arms 1|Game-Based Rehabilitation received total 24 sessions, 45-50 minutes/session, 3 times/week for total 8 weeks.
62140616|NCT05325541|PLACEBO_COMPARATOR|Arms 2|Conventional Rehabilitation received total 24 sessions, 45-50 minutes/session, 3 times/week for total 8 weeks.
62498158|NCT01611506|EXPERIMENTAL|Cetuximab, capecitabine, cisplatin based chemoradiation|"Induction chemotherapy:~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.~Followed by:~Radio-chemo-immunotherapy:~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week~Surgery:~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy~Postoperative treatment:~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator."
62498159|NCT03372317||Non-demented elders|Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
62498160|NCT03211351|EXPERIMENTAL|Liposic|Liposic was applied to one eye of patients in this group
61948927|NCT04746248|NO_INTERVENTION|Baseline|The baseline arm includes participants from before the implementation of the outpatient regime. All participants are induced according to the standard inpatient protocol.
61948928|NCT04746248|ACTIVE_COMPARATOR|Women choosing to stay at the hospital|Include women who choose to stay at the hospital after implementing an outpatient alternative.
61948929|NCT04746248|EXPERIMENTAL|Women choosing to go home|Include women who choose the outpatient regime.
61948930|NCT05409248|EXPERIMENTAL|Experimental Group|Online games designed to target specific cognitive skills such as attention, perception, or inhibition). Activities' difficulty will be automatically adjusted accordingly to each participant's performance, always demanding a maximum cognitive effort.
61948931|NCT05409248|ACTIVE_COMPARATOR|Control Group|Online painting and artistic games designed not to target the specific cognitive skills at test. Activities' duration will match those of the experimental group, and its difficulty will be constant through the intervention.
61948932|NCT03113071|EXPERIMENTAL|Newly diagnosed AML/MDS|For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
61948933|NCT03113071|EXPERIMENTAL|Refractory or relapsed AML/MDS|or Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
62140617|NCT05157113|ACTIVE_COMPARATOR|Dropless Regimen|"* Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery~* Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~* No postoperative drops."
62140618|NCT05157113|ACTIVE_COMPARATOR|Standard Regimen|"* Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~* Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~* Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~* Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
62498161|NCT03211351|EXPERIMENTAL|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
62498162|NCT01616199|EXPERIMENTAL|Phase 1 Dose Escalation of PX-866 + vemurafenib|PX-866 given with vemurafenib
62498163|NCT01616199|EXPERIMENTAL|Phase 2 Combination PX-866 + vemurafenib|PX-866 given with vemurafenib
62498164|NCT01616199|ACTIVE_COMPARATOR|Phase 2 Single-agent vemurafenib|vemurafenib given as a single agent
62498165|NCT00762411|EXPERIMENTAL|LY450139|Participants received 60 milligrams (mg) LY450139 orally once daily for 2 weeks followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
62498166|NCT00762411|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, participants in the placebo arm received LY450139 titrated up to 140 mg orally once daily until Week 88.
62498167|NCT02183376|EXPERIMENTAL|BI 1356 - healthy subjects|
61948934|NCT03204578|EXPERIMENTAL|AB (Midazolam OD/Dormicum)|Subjects with sequence AB will first receive the Intervention OD formulation (Period A, 30 µg Midazolam) and at the second visit the oral solution (Period B, 30 µg Dormicum ).
61948935|NCT03204578|EXPERIMENTAL|BA (Dormicum/midazolam OD)|Subjects with sequence BA will first receive the Intervention oral solution (Period B, 30 µg Dormicum) and at the second visit the OD disintegrating formulation (Period A, 30 µg Midazolam).
61948936|NCT03376269|ACTIVE_COMPARATOR|Combined HBOT/psychotherapy|combined concurrent intervention of HBOT and creative art psychotherapy.
61948937|NCT03376269|OTHER|psychotherapy|single intervention with creative art psychotherapy
61948938|NCT02206542|EXPERIMENTAL|Robot-assisted group|Electroacupuncture, physical therapy and upper limb rehabilitation robot
61948939|NCT02206542|ACTIVE_COMPARATOR|Control group|Electroacupuncture and physical therapy
61948940|NCT05205525||Restrictive antibiotic strategy|
62498168|NCT02183376|EXPERIMENTAL|BI 1356 - mild liver impairment|
61948941|NCT05205525||Aggressive (immediate) antibiotic strategy|
61948942|NCT05695352|PLACEBO_COMPARATOR|Placebo Comparator in Normal Ovulatory Women|The two arm placebo comparator study will use each participant as her own control with a placebo arm in the first menstrual cycle consisting of two placebo tablets taken at the time of the ovarian follicle measuring 17 mm in diameter and a second dose of two tablets 48 hours later.
61948943|NCT05695352|ACTIVE_COMPARATOR|Active intervention in Normal Ovulatory Women|The second menstrual cycle for each participant is an active intervention arm. Levonorgestrel 1.5 mg plus meloxicam 15 mg will be taken when the ovarian follicle reaches 17 mm in largest diameter. The two medications will be repeated 48 hours later.
61948944|NCT01193530|EXPERIMENTAL|Bright Light Therapy|Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
61948945|NCT01193530|PLACEBO_COMPARATOR|Dim Red Light Therapy|Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.
61948946|NCT01118481||Pressure and flow velocity|
61948947|NCT01118481||Pressure only|
61948948|NCT01823302|OTHER|nutritional counseling|nutritional counseling
61948949|NCT01823302|OTHER|nutritional counseling and milk-based supplement|nutritional counseling plus oral milk-based nutrition supplement
61948950|NCT01907243|ACTIVE_COMPARATOR|spreader flap|Usage of spreader flap of upper lateral cartilage
62140619|NCT02094534|EXPERIMENTAL|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
62498169|NCT02183376|EXPERIMENTAL|BI 1356 - moderate liver impairment|
61948951|NCT01907243|NO_INTERVENTION|Control group|performing of rhinoplasty without spreader flap
61948952|NCT01446315|EXPERIMENTAL|Asthma APGAR|Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
61948953|NCT01446315|PLACEBO_COMPARATOR|Usual care|Usual asthma care as provided by the sites.
61948954|NCT04712383|EXPERIMENTAL|Fitbit Care intervention arm|The experimental arm will receive the full Fitbit Care product suite (Fitbit wrist-worn device, Fitbit connected weight scale, and Fitbit Premium + Health Coaching service). Participants in the experimental arm will also be offered support in improving health behaviors that are important to them, including activity, nutrition, sleep, stress management, and medication adherence.
61948955|NCT04712383|NO_INTERVENTION|Fitbit study control arm|Participants in the control arm will have access to standard healthcare benefits available to all employees, but will not have access to any of the Fitbit Care interventions
61948956|NCT01133873|EXPERIMENTAL|1|
62140620|NCT02094534|PLACEBO_COMPARATOR|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
62498170|NCT02183376|EXPERIMENTAL|BI 1356 - severe liver impairment|
62140621|NCT03274076|ACTIVE_COMPARATOR|Tofacitinib|5mg Tofacitinib twice a day
62140622|NCT03274076|PLACEBO_COMPARATOR|Placebo|5mg Placebo twice a day
62140623|NCT05443945|EXPERIMENTAL|Advanced Water -100 ionized nasal spray|3 sprays in each nostril, 3 times a day during 14 days
62498171|NCT01927991|EXPERIMENTAL|iCBT with therapeutic support|Participants work with the online self-help and receive additional therapeutic support on demand
61948957|NCT01133873|PLACEBO_COMPARATOR|2|
61948958|NCT05763095|EXPERIMENTAL|the MIED+TAU group|Intervention description: provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
61948959|NCT05763095|NO_INTERVENTION|the TAU-only group|
61948960|NCT02352129|EXPERIMENTAL|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
61948961|NCT02352129|ACTIVE_COMPARATOR|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
61948962|NCT03606512|EXPERIMENTAL|Group 1: RSV Seronegative Toddlers (Ad26.RSV.preF)|Respiratory syncytial virus (RSV) seronegative toddlers will receive intramuscular (IM) injection of 2.5\*10\^10 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F-protein on Days 1, 29, and 57.
61948963|NCT03606512|PLACEBO_COMPARATOR|Group 2: RSV Seronegative Toddlers (Placebo/Nimenrix)|RSV seronegative toddlers will receive IM injection of placebo on Days 1, 29 and 57. Placebo can be replaced with Nimenrix on Day 57 in countries where applicable.
62140624|NCT05443945|PLACEBO_COMPARATOR|Nasal spray with purified water|3 sprays in each nostril, 3 times a day during 14 days
62498172|NCT01927991|ACTIVE_COMPARATOR|iCBT without therapeutic support|Participants work with the online self-help on their own and do not receive additional therapeutic support
62498173|NCT04501536|EXPERIMENTAL|High Frequency|Participants will receive therapy 4 times a week for 10 weeks for 30 minutes per session.
61948964|NCT01594671|EXPERIMENTAL|Tranexamic acid|"Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin"
61948965|NCT01594671|ACTIVE_COMPARATOR|Habitual haemostasia|The surgical habitual haemostasia.
61948966|NCT01594671|EXPERIMENTAL|Topical Tranexamic acid|Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
61948967|NCT02385682||ST-segment elevation AMI|ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
61948968|NCT02385682||Non-ST-segment elevation AMI|Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
61948969|NCT04397601||A|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
61948970|NCT04397601||B|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
61948971|NCT03585231|EXPERIMENTAL|Experimental|This is the experimental arm of the study. This includes receiving immediate access to the novel/experimental smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
61948972|NCT03585231|ACTIVE_COMPARATOR|Control|This is the control arm of the study. This includes receiving receiving immediate access to the standard of care smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
61948973|NCT03585231|ACTIVE_COMPARATOR|Delayed Control|This is the second control arm of the study. This includes receiving the novel/experimental smoking cessation messaging program after completing the 3-month follow-up survey. Therapy description withheld to protect the integrity of the study.
61948974|NCT06069908|PLACEBO_COMPARATOR|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks.
61948975|NCT06069908|SHAM_COMPARATOR|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
61948976|NCT06069908|ACTIVE_COMPARATOR|Transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
61948977|NCT00762229|ACTIVE_COMPARATOR|Ezetimibe 10 mg|A whole ezetimibe 10 mg tablet
61948978|NCT00762229|EXPERIMENTAL|Ezetimibe 5 mg|"Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half"
61948979|NCT03116360|EXPERIMENTAL|Single Arm|All patients will undergo traditional xray screening as well as experimental screening with diagnostic ultrasound. All subjects will undergo confirmatory MRI.
61948980|NCT05602142|EXPERIMENTAL|[11C]CPPC|All participants will receive \[11C\]CPPC which is a radiotracer ligand that specifically binds to CSF1R.
61948981|NCT04262570|EXPERIMENTAL|SMA patients (therapy arm)|"* Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~* Magnetic Resonance Imaging (MRI) of lower leg~* Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
62498174|NCT04501536|EXPERIMENTAL|Low Frequency|Participants will receive therapy 1 time a week for 10 weeks for 2 hours per session.
62498175|NCT02189603|EXPERIMENTAL|Senior group(over 65 years old)-HE|Anti-HEV IgG seronegative participants over 65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
62698810|NCT06006286|EXPERIMENTAL|ADI-PEG20/ATEZO/BEV|Participants will first receive the study drug combination for up to 12 weeks. If participants have stable disease or a partial response to the study drug after 12 weeks, participants may continue to receive ADI-PEG 20 for up to 2 years of total dosing, and participants may continue to receive atezolizumab and bevacizumab indefinitely (no limit)
61948982|NCT04262570|ACTIVE_COMPARATOR|SMA patients (control arm)|"* Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~* Magnetic Resonance Imaging (MRI) of lower leg~* Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
61948983|NCT06558396|NO_INTERVENTION|Control phase|"After the first data collection session, participants spend 12 weeks and enter a control phase where they receive no intervention. At the end of the 12 weeks, participants will attend another data collection session."
61948984|NCT06558396|EXPERIMENTAL|ACE intervention|The ACE Program is a culturally inclusive, 4-H after school club where youth meet once a week for 12 weeks after school in person. They also receive groceries to make a meal 1 day every 2 weeks.
61948985|NCT04462770|EXPERIMENTAL|EPX-100 (clemizole HCl)|
61948986|NCT04462770|PLACEBO_COMPARATOR|Placebo arm|
61948987|NCT06428422|EXPERIMENTAL|Intervention group|"The intervention group will receive an oral dosage of 4 x 10\^9 cfu/g/day Bifidobacterium animalis subsp. lactis BL-04 strain (Danisco, USA) and 1 gram of maltodextrin (Danisco, USA) in conjunction with the conventional treatment, which consisted of systemic cancer immunotherapy with nivolumab at a dose of 3 mg/kg administered intravenously every two weeks. The immunotherapy with nivolumab will be completed in twelve weeks.~A probiotic strain is provided to the intervention group in the form of a sachet. Patients will be asked to pour the entire sachet into a glass of water (100 mL, room temperature), mix, and drink it every day for 12 weeks."
62140625|NCT00649272|EXPERIMENTAL|1|Oxybutynin Chloride Extended-Release Tablets, 15 mg
62498176|NCT02189603|ACTIVE_COMPARATOR|Younger groups(16-65 years old)|Participants aged 16-65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
62498177|NCT02189603|NO_INTERVENTION|Senior group(over 65 years old)-Cont|Anti-HEV IgG seropositive participants over 65 years old were enrolled. This is the safety control group, without any intervention.
61948988|NCT06428422|PLACEBO_COMPARATOR|Plasebo group|"The plasebo group will receive the conventional treatment, which consisted of systemic cancer immunotherapy with nivolumab at a dose of 3 mg/kg administered intravenously every two weeks. The immunotherapy with nivolumab will be completed in twelve weeks.~In addition to the traditional treatment (nivolumab), the plasebo group will be given 1 g/day maltodextrin (Danisco, USA) as placebo. Maltodextrin will be provided to the intervention group in the form of a sachet. Patients will be asked to pour the entire sachet into a glass of water (100 mL, room temperature), mix, and drink it every day for 12 weeks."
61948989|NCT05108285||MNV group|Eyes affected by MNV. The dark halo of MNV was evaluated by OCTA and ICGA
62698811|NCT05112640|ACTIVE_COMPARATOR|Suture wound closure|Absorbable sutures for closure of cesarean skin incision using Monocryl manufactured by Ethicon.
62698812|NCT05112640|EXPERIMENTAL|Absorbable staple wound closure|Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by Cooper Surgical.
62698813|NCT03321942|ACTIVE_COMPARATOR|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
61948990|NCT05964387|EXPERIMENTAL|SDF|38% SDF applied to hypomineralized permanent molar two weeks prior to restorative care of the tooth.
61948991|NCT05964387|PLACEBO_COMPARATOR|Placebo|Inert liquid (colored water) applied to hypomineralized permanent molar two weeks prior to restorative care of the tooth.
61948992|NCT05542160|PLACEBO_COMPARATOR|Placebo|Placebo capsule
61948993|NCT05542160|EXPERIMENTAL|Treatment|IRK-19 capsule
61948994|NCT01752985|EXPERIMENTAL|Arm A: BMS-813160 150 mg & Placebo matching with BMS-813160|BMS-813160 150 mg capsules by mouth in AM and Placebo matching with BMS-813160 in PM for 12 weeks
61948995|NCT01752985|EXPERIMENTAL|Arm B: BMS-813160 300 mg|BMS-813160 300 mg capsules by mouth twice daily for 12 weeks
61948996|NCT01752985|PLACEBO_COMPARATOR|Arm C: Placebo matching with BMS-813160|Placebo matching with BMS-813160 0 mg capsules by mouth twice daily for 12 weeks
61948997|NCT04926142||Patients planned for percutaneous PFO closure|Patients will undergo implantation of a Holter device (Reveal Linq Medtronic) 2 months prior to percutaneous PFO closure. Devices will be monitored by telemonitoring until the PFO closure procedure, and at 2, 12 and 24 months after the procedure.
61948998|NCT03146377|EXPERIMENTAL|Xeloxiri|
61948999|NCT01593085||patients in palliative cares|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
62698814|NCT03321942|PLACEBO_COMPARATOR|Control group|Treatment of chronic renal failure patients with conventional methods.
62698815|NCT01940055|EXPERIMENTAL|Experimental group|Dual Task Treadmill Walking Exercise Program
61949000|NCT03777488|EXPERIMENTAL|Tranexamic acid Group 1|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Intramuscular Third Dose: Oral"
61949001|NCT03777488|EXPERIMENTAL|Tranexamic acid Group 2|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Oral Third Dose: Intramuscular"
61949002|NCT03777488|EXPERIMENTAL|Tranexamic acid Group 3|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Intravenous Third Dose: Oral"
61949003|NCT03777488|EXPERIMENTAL|Tranexamic acid Group 4|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Oral Third Dose: Intravenous"
62698816|NCT01940055|ACTIVE_COMPARATOR|Control group|Dual task recumbent cycling exercise program
62698817|NCT04898179||Telecare group|"When discharged, patients will be followed at home by a telecare nursing and specialist teleconsultation program for 3 months. The key element of the program will be a structured nurse-managed telephone support and, when necessary, video consultations, to follow patients, for the first month. During these contacts, the nurse will conduct a standardized interview enquiring about the general clinical condition of the patient. In the case of any symptom or problem, the patient will be able to call the service. At the end of the third month, patients will contact again to check their clinical condition and to close the program. Patients will be provided with a pulse oximeter to measure O2 saturation.~At the start and end of the program, patients were administered the SF-12 quality of life questionnaire."
62698818|NCT04898179||Control group|The patients in the control group will be followed by their general practitioner and they will be contacted after three months to check their clinical condition.
61949004|NCT03777488|EXPERIMENTAL|Tranexamic acid Group 5|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intravenous Third Dose: Intramuscular"
61949005|NCT03777488|EXPERIMENTAL|Tranexamic acid Group 6|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intramuscular Third Dose: Intravenous"
61949006|NCT04835480|EXPERIMENTAL|OsrHSA Group|OsrHSA (10g or 20g), IV, qd
61949007|NCT04835480|ACTIVE_COMPARATOR|HSA Group1|HSA (10g or 20g), IV, qd
61949008|NCT06246929|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy With Walking (MBCT+w)|MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
62698819|NCT05643404||Isolated LBBB|Subjects with left bundle branch block in the absence of clinically detectable heart disease
62698820|NCT05643404||Matched controls without LBBB|Subjects without left bundle branch block and in the absence of clinically detectable heart disease
62698821|NCT05600517|NO_INTERVENTION|Standard prevention fluoride P4+|self-care prevention on diet, oral hygiene and fluoridated toothpaste 1450 ppm with checkup every second month with one occasion of fluoride varnish at the clinic.
62698822|NCT05600517|EXPERIMENTAL|Intensive prevention P4+|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
61949009|NCT06246929|ACTIVE_COMPARATOR|Active Living Every Day (ALED)|ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
61949010|NCT01223131|EXPERIMENTAL|Insulin glargine|injection once daily at bedtime
61949011|NCT01223131|ACTIVE_COMPARATOR|NPH insulin|injection once daily at bedtime or twice daily in the morning and at bedtime
61949012|NCT04321070|EXPERIMENTAL|Clindamycin Phosphate|Topical, once daily, for 84 days.
61949013|NCT04321070|ACTIVE_COMPARATOR|Clindamycin Phosphate RLD|Topical, once daily, for 84 days
61949014|NCT04321070|PLACEBO_COMPARATOR|Vehicle of the test product|Topical, once daily, for 84 days
61949015|NCT05929157|ACTIVE_COMPARATOR|Artesunate-pyronaridine intravenous|
61949016|NCT05929157|ACTIVE_COMPARATOR|Artesunate-pyronaridine intramuscular|
61949017|NCT02467075|ACTIVE_COMPARATOR|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
61949018|NCT02467075|PLACEBO_COMPARATOR|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
61949019|NCT05613361|EXPERIMENTAL|Group 1|patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours.
61949020|NCT05613361|ACTIVE_COMPARATOR|Group 2|patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours and curcumin will be administered as orally or through nasogastric tube at a dose of 2 capsules every 6 hours (1 gm/6 hour)
61949021|NCT04753528|EXPERIMENTAL|Group A|Personalized stimulation parameters and amplitude
61949022|NCT04753528|EXPERIMENTAL|Group B|Personalized stimulation amplitude
61949023|NCT04753528|ACTIVE_COMPARATOR|Group C|Non-personalized stimulation
61949024|NCT05106517|EXPERIMENTAL|denosumab|Denosumab 60mg/6 months subcutaneously + placebo intravenous
62498178|NCT01044134|EXPERIMENTAL|Diet + Water|"Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water)."
62698823|NCT05600517|NO_INTERVENTION|Standard prevention fluoride P4-|self-care prevention on diet, oral hygiene and fluoridated toothpaste 1450 ppm with checkup every second month with one occasion of fluoride varnish at the clinic.
61949025|NCT05106517|EXPERIMENTAL|zoledronic acid|intravenous zoledronic acid and placebo /6 months subcutaneously
61949026|NCT03889574||combination of aspirin, P2Y12 Inhibitor with a NOAC|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
61949027|NCT03889574||combination of aspirin, P2Y12 Inhibitor with warfarin|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
61949028|NCT01334346|ACTIVE_COMPARATOR|Neutral Shoe|Conventional, non-minimalist, footwear.
62140626|NCT00649272|ACTIVE_COMPARATOR|2|Ditropan XL® Extended-release tablets, 15 mg
62698824|NCT05600517|EXPERIMENTAL|Intensive prevention P4-|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
62698825|NCT01447784|PLACEBO_COMPARATOR|Placebo|
61949029|NCT01334346|EXPERIMENTAL|Partial minimalist shoe|
61949030|NCT01334346|EXPERIMENTAL|Full minimalist|
61949031|NCT02789995|EXPERIMENTAL|Patients with and without sepsis|"Patients with sepsis, Patients with inflammatory disease without sepsis, Patients without inflammatory disease without sepsis.~Human biological samples collected for research :~* Blood sample~* Muscle biopsy~* Bone marrow sample (mesenchymal stem cells)"
61949032|NCT03530969|EXPERIMENTAL|GI/GU/Lymphoma Oncologists|Doctors specializing in treating gastrointestinal cancer (cancer of the stomach, pancreas, colon, etc.), genitourinary cancer (cancer of the genitals and urinary tract), and lymphoma (cancer affecting the blood and lymph nodes)
61949033|NCT03530969|ACTIVE_COMPARATOR|Participants with GI/GU/Lymphoma Cancer|Patients of the physicians in group 1
61949034|NCT03530969|ACTIVE_COMPARATOR|Caregivers of Participants with GI/GU/Lymphoma Cancer|Family members or caregivers of the patients in group 2
61949035|NCT03614364|EXPERIMENTAL|nanoxel and herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
61949036|NCT05164796|EXPERIMENTAL|IVUS-guided|
61949037|NCT05289427|EXPERIMENTAL|TIPS Block|Group TIPS; patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
62140627|NCT06699069|EXPERIMENTAL|Group I (Control or Euthyroid) total number of rats=20|Fed on normal standard diet
62140628|NCT06699069|EXPERIMENTAL|Group II (Hypothyroid) total number of rats=20|Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
62140629|NCT06699069|EXPERIMENTAL|Group III (Hypothyroid received exercise) total number of rats=20|Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise.
62698826|NCT01447784|EXPERIMENTAL|ToleroMune HDM Dose 1|
62698827|NCT01447784|EXPERIMENTAL|ToleroMune HDM Dose 2|
61949038|NCT05289427|ACTIVE_COMPARATOR|FNB|Group FNB; patients will receive femoral nerve block (FNB) before surgical incision
61949039|NCT03892187|EXPERIMENTAL|Intervention Group|Participants are prescribed a walking prescription based on their baseline daily step count. During the interim between the day of consultation until the day of surgery, a study staff member will make weekly calls to each participant. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
61949040|NCT03892187|NO_INTERVENTION|Control Group|Participants receive usual care prior to surgery. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
61949041|NCT03892187|NO_INTERVENTION|Observation Group|Participants who are not frail will receive usual care prior to surgery and charts will be reviewed for outcomes following surgery.
61949042|NCT00806351|EXPERIMENTAL|Anidulafungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
61949043|NCT00806351|EXPERIMENTAL|Caspofungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
61949044|NCT06378580||Surufatinib combine immune checkpoint inhibitor|
61949045|NCT06378580||Chemotherapy|
62140630|NCT03280511|EXPERIMENTAL|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
61949046|NCT06326385||intracerebral hemorrhage|
61949047|NCT00018031|EXPERIMENTAL|1|Weekly Injection of peginterferon alfa-2b and weight based ribavirin (1-1.2g/day) for 48 weeks
61949048|NCT01348672||1. ARMD Study arm|"The ARMD study arm (n=150) consists of 3 groups. The groups are organised according to established risk criteria for clinical progression (AREDS, 2003).~Group 1A (n=50); Early stage ARMD with low risk of progression; several small drusen, or a few medium-sized drusen, in one or both eyes. One eye will be randomly selected for the study.~Group 2A (n=50); Intermediate ARMD with high risk of progression to advanced ARMD; many medium-sized drusen, or one or more large drusen, in one or both eyes. More severely affected eyewill be selected for the study.~Group 3A (n=50); In one eye only, either a break-down of light-sensitive cells and supporting tissue in the central retinal area (i.e. geographic atrophy), or abnormal and fragile blood vessels under the retina (i.e. choroidal neovascular membrane formation). The fellow eye is at high risk of progression to advanced ARMD. The fellow eye will be selected for the study."
61949049|NCT01348672||2. POAG study arm|"Patient groups are organised according to established risk criteria for clinical progression (EMGT, 2003).~Group 1P (n=36); Stable, early to moderate, treated patients with POAG. Early to moderate POAG is defined as having an untreated IOP prior to treatment of \>21mmHg and a repeatable visual field defect with a Mean Deviation of \<12dB and/or documented but stable ONH appearance, consistent with a diagnosis of glaucoma.~Group 2P (n=36); Early to moderate, treated patients with normal tension glaucoma (NTG). Normal Tension Glaucoma is defined using the same criteria as POAG but with an untreated IOP of \<21mmHg throughout the day. This group has NTG and is thought to be at increased risk of vascular dysfunction due to loss of ONH perfusion.~Group 3P (n=36); Early to moderate, treated patients with POAG or NTG with recurrent disc hemorrhage (indicative of progression)."
61949050|NCT01348672||3. DR study arm|"DR patient groups are organised according to established risk factors for the clinical progression of DR (increasing from Groups 1 A to 3 A, ETDRS, 1991). We will recruit 41 patients per group (Klein et al, 1984).~Group 1D (n=41); Type 2 diabetic patients with no, or minimal, clinically visible DR. These patients are at low risk of developing sight-threatening DR.~Group 2D (n=41); Type 2 diabetic patients with microaneurysms and / or hard exudates within 2 disc diameters of the fovea and no clinical evidence of retinal thickening. These patients are at increased risk of developing DME.~Group 3D (n=41); Type 2 diabetic patients with the typical features of moderate-to-severe DR i.e. venous beading, intra-retinal microvascular abnormalities (IRMA) and dark blot intra-retinal haemorrhages. These patients are at a much increased risk of developing proliferative DR and/or ischemic maculopathy."
61949051|NCT03722823|ACTIVE_COMPARATOR|Group 1: Healthy|Match-controlled healthy subjects with normal hepatic function
62140631|NCT05871385|EXPERIMENTAL|Group A (r TMS group)|"Twenty five randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.~Device: repetitive transcranial magnetic stimulation high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere."
62140632|NCT05871385|PLACEBO_COMPARATOR|Control (Group B) (placebo rTMS)|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
62698828|NCT01447784|EXPERIMENTAL|ToleroMune HDM Dose 3|
61949052|NCT03722823|EXPERIMENTAL|Group 2: Mild Hepatic Impairment|Subjects with Mild hepatic impairment (Child-Pugh Class A, score of 5 or 6)
61949053|NCT03722823|EXPERIMENTAL|Group 3: Moderate Hepatic Impairment|Subjects with Moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9)
61949054|NCT03722823|EXPERIMENTAL|Group 4: Severe Hepatic Impairment|Subjects with Severe hepatic impairment (Child-Pugh Class C, score of 10 to 14)
61949055|NCT00763711|EXPERIMENTAL|Injection with Needle Guide|
61949056|NCT00113503|ACTIVE_COMPARATOR|Azathioprine weight-based dose|
62140633|NCT06067347||Massachusetts General Hospital, Boston, USA|Participating investigators at various institutions will perform weekly review of their new patients with PTCL (newly diagnosed or relapsed/refractory) on the outpatient and inpatient clinical services with their clinical research teams to identify potential subjects for enrollment based on the above inclusion/exclusion criteria. Expected enrollment is anticipated to be up to 50 patients per site per year.
62140634|NCT03918252|EXPERIMENTAL|Arm A Nivolumab Only|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
62698829|NCT01088906|EXPERIMENTAL|1 ARM|pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
61949057|NCT00113503|EXPERIMENTAL|Azathioprine individualised dose|
61949058|NCT02055833|EXPERIMENTAL|Intensive nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks \[during radiotherapy\] and at 1 month and at 3 months since the end of radiotherapy) + n-3 polyunsaturated fatty acids-enriched oral nutritional supplements (1-2 bottles/day)
62341369|NCT04280419||Healty Subjects|Healthy Subjects Twenty-five healthy individuals will be included in the study. Physical properties of cases will be recorded. Respiratory functions and respiratory muscle strength will be evaluated. Physical activity will be assessed using the International Physical Activity Survey (IPAQ). Respiratory muscle endurance will be evaluated using an incremental workload test and fixed threshold load test. Tests will be repeated three times as motivational music, slow-paced music, and music. Heart rate, respiratory frequency, perceived exertion will be evaluated before and after the test.
62341370|NCT05207306|EXPERIMENTAL|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA) group|Patients receiving right M-TAPA.
62498179|NCT01044134|ACTIVE_COMPARATOR|Diet|Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.
62498180|NCT00498316|OTHER|Cord Blood Infusion|"Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.~Fludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.~Rituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.~Cyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
62498181|NCT06403137|PLACEBO_COMPARATOR|Maltodextrin|daily 2 x 20g maltodextrin ingestion
62498182|NCT06403137|EXPERIMENTAL|Milk protein|daily 2 x 20g milk protein ingestion
62498183|NCT06403137|EXPERIMENTAL|Plant protein blend|daily 2 x 20g plant protein blend ingestion
61949059|NCT02055833|ACTIVE_COMPARATOR|Nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks \[during radiotherapy\] and at 1 month and at 3 months since the end of radiotherapy)
61949060|NCT04905888|EXPERIMENTAL|Hyperbaric oxygen therapy|Treatment with hyperbaric oxygen
61949061|NCT04905888|NO_INTERVENTION|Control|Control, no treatment.
62498184|NCT00357955|EXPERIMENTAL|MEDIC|Multidisciplinary education and diabetes intervention for cardiac risk reduction
62498185|NCT00357955|NO_INTERVENTION|usual care|usual care
62498186|NCT02563249|OTHER|Dexterity, Coordination,Perception measurements|Dexterity, Hand-eye Coordination and Perception of Orientation and Distances
62498187|NCT03121079|EXPERIMENTAL|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
62498188|NCT04175860|EXPERIMENTAL|Intervention group|"Consists of a series of non-pharmacological preventive interventions that will focus on the - transition-discharge-hospital program including individualized non-pharmacological interventions such as dyad characterization, competency assessment, risk assessment, inherent program strategies, and monitoring.~The intervention or program  Hospital Discharge Plan to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes an educational session and weekly telephone follow-up according to the patient's risk characterization."
62498189|NCT04175860|NO_INTERVENTION|Control group|This group of patients-family caregivers will be carried out the discharge activities that are regularly developed in the second level institution and recorded in a check-sheet and field diary.
62498190|NCT05649150||Healthy group|For healthy group A.K.As adults without LBP are: (1) aged from 20 to 65 years old, (2) no specific low back pain in the past 6 months.
62498191|NCT05649150||LBP group|The inclusion criteria for adults with LBP are: (1) aged from 20 to 65 years old, (2) persistent LBP for more than 3 months.
62736535|NCT03772795|ACTIVE_COMPARATOR|Group 1- Alignment with fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Uniteks, 0.022 Roth prescription brackets.Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
61949062|NCT03385512|EXPERIMENTAL|OPEN High Touch|Participants in this arm will experience the OPEN High Touch intervention.
61949063|NCT03385512|EXPERIMENTAL|OPEN High Tech|Participants in this arm will experience the OPEN High Tech intervention.
62341371|NCT05207306|EXPERIMENTAL|Subcostal transversus abdominis plane block (subcostal TAPB) group|Patients receiving right subcostal TAPB.
62341372|NCT00642746|EXPERIMENTAL|FOLFOX with Erlotinib|Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
62341373|NCT00642746|EXPERIMENTAL|FOLFIRI with Erlotinib|Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
62341374|NCT04010890|EXPERIMENTAL|Culturally adapted CBT|Ca_CBT will be delivered to the experimental group using the newly developed manual . The intervention will be delivered over 8-12 sessions. The Control group will receive standard CBT
61949064|NCT03385512|EXPERIMENTAL|ASK Poster|Participants in this arm will experience the ASK intervention.
61949065|NCT01480089|PLACEBO_COMPARATOR|Atomized Intraperitoneal Saline (AIS)|Participants randomized to this arm will be given atomized intraperitoneal saline(AIS).
61949066|NCT01480089|ACTIVE_COMPARATOR|Intraperitoneal Ropivacaine(AIR)|Participants randomized to this arm will receive atomized intraperitoneal ropivacaine (AIR).
61949067|NCT02987556|ACTIVE_COMPARATOR|Usual System (open-loop)|In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
62698830|NCT06564597|EXPERIMENTAL|Verbal education and two brochure handouts|"The educational brochures are prepared to include clear, legible, realistic and up-to-date information. The context of the education includes the following topics:~* What is myocardial infarction?~* What are its clinical features?~* Risk factors~* Lifestyle changes~* What is cardiac rehabilitation?~* Stress and anxiety management~* Energy conservation techniques~* Progressive relaxation techniques"
61949068|NCT02987556|EXPERIMENTAL|DIABELOOP System (closed-loop)|In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
61949069|NCT01030536|EXPERIMENTAL|CAT-8015 20 microgram per kilogram (mcg/kg)|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
62698831|NCT06564597|EXPERIMENTAL|Verbal education, two brochure handouts and MET-based activity planning|"The educational brochures are prepared to include clear, legible, realistic and up-to-date information. The context of the education includes the following topics:~* What is myocardial infarction?~* What are its clinical features?~* Risk factors~* Lifestyle changes~* What is cardiac rehabilitation?~* Return to activity and activity-based prescription (based on MET)~* What are the abnormal responses that may occur in activities?~* Stress and anxiety management~* Energy conservation techniques~* Progressive relaxation techniques"
61949070|NCT01030536|EXPERIMENTAL|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
61949071|NCT01030536|EXPERIMENTAL|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
61949072|NCT01030536|EXPERIMENTAL|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
61949073|NCT01030536|EXPERIMENTAL|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
61949074|NCT00691301|EXPERIMENTAL|Pemetrexed and cisplatin|Pemtrexed plus cisplatin on day 1 every 21 days
61949075|NCT05274737|EXPERIMENTAL|Initial Immobilization with the novel sling|20 patients will be placed in the novel sling after surgery for the first two weeks. For the second two weeks (days 15-28) they will crossover and utilize the standard abduction sling. For the final two weeks (days 29-42) they will choose their preferred sling type and use it for the remainder of six week immobilization period.
61949076|NCT05274737|EXPERIMENTAL|Initial Postoperative Immobilization with the standard abduction sling|20 patients will be placed in the traditional abduction sling after surgery for the first two weeks. For the second two weeks (days 15-28) they will crossover and utilize the novel sling. For the final two weeks (days 29-42) they will choose their preferred sling type and use it for the remainder of six week immobilization period.
61949077|NCT02399371|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.
61949078|NCT00809393|ACTIVE_COMPARATOR|low dose|low dose tranexamic acid
61949079|NCT00809393|EXPERIMENTAL|high dose|
61949080|NCT01228643|EXPERIMENTAL|Norzyme®|
61949081|NCT01228643|ACTIVE_COMPARATOR|Creon®|
61949082|NCT00969696|ACTIVE_COMPARATOR|Galatamine|Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
61949083|NCT00969696|PLACEBO_COMPARATOR|Sugar Pill|Sugar Pill
61949084|NCT04367233|ACTIVE_COMPARATOR|Placebo group|General anesthesia with fentanyl, propofol and remifentanyl
61949085|NCT04367233|EXPERIMENTAL|Transverse block group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive transverse plan block, with ropivacaine 0,25% 0,2 ml/kg.
62140635|NCT03918252|EXPERIMENTAL|Arm B Nivolumab + Ipilimumab|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
62698832|NCT04388631||Exposed group|Male patient discharged with COVID-19
62698833|NCT04388631||Control group|Healthy male volunteers without COVID-19
62698834|NCT06421649|EXPERIMENTAL|Proton Beam Therapy|All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
61949086|NCT04367233|EXPERIMENTAL|Quadratus lumborum group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg.
61949087|NCT02004522|EXPERIMENTAL|Duvelisib|Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
61949088|NCT02004522|ACTIVE_COMPARATOR|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.
61949089|NCT05000281|EXPERIMENTAL|NSAID|Standard of care pain medication regimen with NSAIDs.
62140636|NCT05604755|EXPERIMENTAL|HQP1351 prophylactic therapy|HQP1351 prophylactic therapy after allo-hct on days 30 to 60
61949090|NCT05000281|NO_INTERVENTION|No NSAIDs|Standard of care pain medication regiment with no NSAIDs
61949091|NCT03056404|EXPERIMENTAL|control subject|additional blood sample and 15 control subjects will be seen in consultations in the service of pneumology. The visit will include an auscultation, a respiratory functional exploration and a blood test (2 tubes of 7 ml of total blood). A questionnaire of exhibition will be realized to collect the species of birds and the times of exhibition.
61949092|NCT01321307||Sorend|Group no. 1 shall receive Sorend following diagnosis of aphtostomatitis or mucositis.
61949093|NCT01321307||Sorend placebo|Group no. 2 shall receive Sorend placebo following diagnosis of aphtostomatitis or mucositis.
61949094|NCT01393301|EXPERIMENTAL|Behavioral Intervention Arm|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
61949095|NCT01393301|OTHER|Control Arm|Enhanced Treatment as Usual (ETAU); enhanced standard smoking cessation treatment and nicotine replacement therapy (NRT).
62140637|NCT04169542||Observational (questionnaire)|Patients complete up to 4 electronic questionnaires over 15 minutes before surgery and at 6, 12, and 24 months after surgery.
62140638|NCT05724966||Registration of side effects|patients are to registrer side effects prior to treatment with Bortezomib through an app.
62140639|NCT03565484|EXPERIMENTAL|Antimicrobial susceptibility testing guided therapy|14d bismuth quadruple therapy based on susceptibility test.
62341375|NCT04010890|ACTIVE_COMPARATOR|Standard CBT|Participants in this group will receive standard CBT
62341376|NCT01371487|EXPERIMENTAL|Treatment A|GSK1120212 Dose /Treatment 2.0 mg/Fasted
62341377|NCT01371487|EXPERIMENTAL|Treatment B|GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
62341378|NCT03773926|EXPERIMENTAL|Neuro-feedback therapy|"EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.~Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback."
62341379|NCT03248245|EXPERIMENTAL|LOG-model schools|Experimental schools implement the LOG-model
62341380|NCT03248245|ACTIVE_COMPARATOR|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
62341381|NCT02207595|EXPERIMENTAL|UCB5857 Cohort 1|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
62341382|NCT02207595|EXPERIMENTAL|UCB5857 Cohort 2|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
62498192|NCT01802216|NO_INTERVENTION|Control/Delayed Treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Rescue scaling and root planing only to sites of periodontal disease progression (since prior examination) of greater than 3mm. Subjects will be informed of their assignment to the delayed treatment group and provided referral list of local dentists should patient not feel comfortable waiting until end of study for full intensive periodontal disease treatment. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
62341383|NCT02207595|EXPERIMENTAL|UCB5857 Cohort 3|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
62341384|NCT02207595|EXPERIMENTAL|UCB5857 Cohort 4|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
62341385|NCT02207595|EXPERIMENTAL|UCB5857 Cohort 5|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
62341386|NCT02297542|ACTIVE_COMPARATOR|Flu Vaccine SD|Fluzone Standard Dose Influenza Vaccine
62341387|NCT02297542|ACTIVE_COMPARATOR|Flu Vaccine HD|Fluzone High Dose Influenza Vaccine
62341388|NCT05739877|EXPERIMENTAL|Sequence A(Before→ After)|
62341389|NCT05739877|EXPERIMENTAL|Sequence B(After→ Before)|
62698835|NCT01880463|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
62736536|NCT03772795|EXPERIMENTAL|Group 2- Alignment with clear aligners|Clear aligner orthodontic appliance (EON, Eon Dental NV, Belgium). Teeth alignment with clear aligners.
61949096|NCT01853423|EXPERIMENTAL|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
61949097|NCT02536560||Antibiotics|150 infants, (because of hospital protocol) treated with antibiotics because of a perinatal infection during the first week of life
61949098|NCT02536560||Controls|The control group comprises 300 healthy newborns, born in the hospital and needing clinical observation for 24-48 hours for several reasons like maternal comorbidity, low probability of neonatal infection, blood sugar monitoring, meconium containing amniotic fluid, or delivery by caesarean section
61949099|NCT03062982|EXPERIMENTAL|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
61949100|NCT03062982|EXPERIMENTAL|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
61949101|NCT03195764|EXPERIMENTAL|T-1101 (Tosylate)|
61949102|NCT05487846|EXPERIMENTAL|Arm I (peer navigation)|Patients receive assistance from a peer navigator during genetic evaluation processes. Peer navigators help patients schedule counseling appointments, discuss questions and concerns about testing, assist in sample collection, schedule a post-test disclosure visit, and do a results and recommendations debrief.
62140640|NCT03565484|EXPERIMENTAL|Personal medication history guided therapy|14d bismuth quadruple therapy based on previous medication history.
62140641|NCT03565484|OTHER|Salvage therapy for negative culture|14d bismuth quadruple therapy based on previous medication history.
62140642|NCT03565484|OTHER|Salvage therapy for failed eradication|14d bismuth quadruple therapy for salvage treatment.
62341390|NCT02675894|ACTIVE_COMPARATOR|RFA with cooled-wet electrode|RFA is performed using three cool-wet electrodes in switching bipolar mode under the fused US guidance.
62341391|NCT02675894|ACTIVE_COMPARATOR|RFA with separable clustered electrode|RFA using separable clustered electrode in switching monopolar mode under the fused US guidance
62341392|NCT00328965|OTHER|Lacidipine|All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.
62498193|NCT01802216|ACTIVE_COMPARATOR|Intensive periodontal disease treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Intensive periodontal disease treatment to include administration of local anesthetic to up to two quadrants for scaling and root planing with ultrasonic and hand instruments. Minocycline will be applied to any sites with probing depth \>=5mm. Hopeless teeth in scaled quadrants will be extracted. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
62498194|NCT04013750|EXPERIMENTAL|left hemiplegia|Patients in the left hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
62498195|NCT04013750|EXPERIMENTAL|right hemiplegia|Patients in the right hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
62498196|NCT04013750|NO_INTERVENTION|control|10 patients with right hemiplegia and 10 patients with left hemiplegia formed the control group and these patients were in line for inpatient rehabilitation programme.
62498197|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
62498198|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
62498199|NCT04155840|EXPERIMENTAL|Treatment (copanlisib, rituximab, bendamustine)|Patients receive copanlisib IV over 1 hour on days 1, 8 and 15 or days 1 and 15 (depending on dose level). Patients also receive rituximab IV on day 1 and bendamustine IV on days 1 and 2 of cycles 1-4. Patients who achieve at least a partial response (MRD-positive) continue on treatment for 2 additional cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 7, patients receive copanlisib IV over 1 hour on days 1 and 15 for an additional 6 cycles in the absence of disease progression or unacceptable toxicity.
62498200|NCT00695383|EXPERIMENTAL|1|
62140643|NCT06492148|ACTIVE_COMPARATOR|Myofascial Release Group|The technique known as myofascial release, also referred to as cross-hand release, will be applied to 7 regions. Among these regions are the lateral abdominal wall (right and left), the lower abdomen with the opposite side medial thigh (right and left crossed), the thoracolumbar fascia (bilateral), and the lumbosacral region. In the cross-hand technique, hands will be gently placed on the specified regions and directions. The release of the barriers of the tissue under the hands will be ensured, and the technique will be applied until a wave or oscillation is felt. A myofascial release technique with an optimal duration of 5 minutes will be applied to each region. The total treatment time will be 35 minutes.
62140644|NCT06492148|SHAM_COMPARATOR|Sham- Myofascial Release Group|The hands of the researcher applying the technique will be positioned on the same regions as the myofascial release technique, with only the palms lightly touching for the same duration. However, there will be no intervention aimed at applying pressure or opening tissue barriers. The total sham treatment time will be 35 minutes.
62140645|NCT00869934|ACTIVE_COMPARATOR|1. Cognitive-Behavior Therapy|
62140646|NCT00869934|EXPERIMENTAL|2. Behavior Therapy|
62140647|NCT00869934|EXPERIMENTAL|3. Cognitive Therapy|
62140648|NCT04316936|EXPERIMENTAL|Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg|Omidria (= ketorolac + phenylephrine) and intracanalicular dexamethasone insert (punctal plug)
62341393|NCT03306485||Patients with GERD symptoms refractory to PPI therapy|"Patients with proven GERD (gastro-esophageal reflux disease) off PPI (proton pump inhibitor) (Los Angeles grade B, C or D esophagitis and/or esophageal acid exposure \> 5% on pH monitoring performed off PPI).~These patients have persistent heartburn and/or regurgitation despite double dose proton pump inhibitor. Patients are referred for esophageal high resolution impedance manometry and ambulatory 24-h pH-impedance monitoring on proton pump inhibitor."
62341394|NCT01142609|EXPERIMENTAL|Internet (eGetgoing)|Subjects will assigned to use an accredited web-based platform (eGetgoingTM, CRC Health Group, Inc.) to deliver routine substance abuse counseling.
62341395|NCT01142609|NO_INTERVENTION|Routine on-site|Subjects will attend routine face-to-face individual counseling sessions.
62341396|NCT05582785|EXPERIMENTAL|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
62341397|NCT02488616|ACTIVE_COMPARATOR|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
62341398|NCT02488616|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
62498201|NCT00695383|ACTIVE_COMPARATOR|2|
62498202|NCT05008120||MDD + RBD|"1. Clinical diagnosis of lifetime major depressive disorder, based on the M.I.N.I.;~2. RBD diagnosis according to the International classification of sleep disorder (ICSD) 3rd edition, fulfilling both the clinical and video-polysomnography (vPSG) criteria;~3. Depressive symptoms onset before RBD onset"
62498203|NCT05008120||MDD|"1. Age-and sex-matched with MDD+RBD probands;~2. Lifetime diagnosis of MDD based on M.I.N.I.;~3. Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)~4. Free of RBD symptoms or other hallmark features of RBD (e.g. REM Sleep Without Atonia, RWSA) by vPSG"
62498204|NCT05008120||Health control|"1. Age-and sex-matched with MDD+RBD subjects;~2. Free of psychiatric disorders based on M.I.N.I.;~3. Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)~4. Free of RBD symptoms or RWSA by vPSG"
62140649|NCT04316936|EXPERIMENTAL|Omidria + Dexycu|Omidria (= ketorolac + phenylephrine) and intraocular dexamethasone suspension
62498205|NCT05717387|EXPERIMENTAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
62498206|NCT05717387|EXPERIMENTAL|the 5:2 diet|Participants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
62498207|NCT05717387|NO_INTERVENTION|Control|Participants in the control group will receive a general lifestyle counseling.
62498208|NCT00239824|EXPERIMENTAL|1|Strength training of the pelvic floor muscles with follow up instructions by a physiotherapist
62498209|NCT00239824|ACTIVE_COMPARATOR|2|Strength training of the pelvic floor muscles without follow up instructions
62498210|NCT04606017||Vitamain D|This group of patients were supplemented with 125IU/d Vitamin D
62140650|NCT04316936|ACTIVE_COMPARATOR|Omidria + Prednisolone Acetate 1%|Omidria (= ketorolac + phenylephrine) and topical prednisolone acetate ophthalmic drops
62140651|NCT06696521|OTHER|Telephonic and telemedicine evaluation|Patients will be randomized to telephonic or telemedicine evaluation during participation in the study
62140652|NCT01171638||Critical Controls|"Critically injured patients with NO severe traumatic lower extremity injuries to provide normative data for the critically injured physiological status upon arrival at study site"
62341399|NCT00567541|ACTIVE_COMPARATOR|Active BBPM stimulation|Therapeutic Stimulation is applied via the Battery Powered Microneuromodulator (BBPM) which is programmed to deliver set stimulation parameters with approximate frequency of 30 Hz, current 5mA for 200 microseconds for the first 12 weeks of the study. The BBPM is implanted near the axillary nerve within the quadrilateral space.
62341400|NCT00567541|PLACEBO_COMPARATOR|Sham BBPM stimulation|The Battery Powered Microneuromodulator is implanted near the axillary nerve within the quadrilateral space. The BBPM is programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, the device will be reprogrammed to deliver therapeutic stimulation over a 12 week period.
62341401|NCT02152592|NO_INTERVENTION|PCM/NAPR group|paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)
62341402|NCT02152592|ACTIVE_COMPARATOR|PCM/Oxy1 group|Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
62341403|NCT02152592|ACTIVE_COMPARATOR|PCM/Oxy2 group|CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
62341404|NCT06441851|ACTIVE_COMPARATOR|Videolaparoscopic Partial Nephrectomy (VPN)|Patients randomized to VPN group will be submitted to a videolaparoscopic partial nephrectomy in which lesion will be identified, renal artery will be selectively clamped and renal parenchyma will be section with scissors and cautery. Suture will be made in two planes with absorbable sutures.
62341405|NCT06441851|EXPERIMENTAL|Robot-assisted Partial Nephrectomy (RANP)|Patients randomized to RAN'P group will be submitted to a robot-assisted partial nephrectomy in which lesion will be identified, renal artery will be selectively clamped and renal parenchyma will be section with scissors and cautery. Suture will be made in two planes with absorbable sutures.
62341406|NCT01907984|EXPERIMENTAL|Diclofenac and Midazolam|Diclofenac 100 mg tablet and Midazolam 7.5 mg tablet were administered by mouth as premedication 30 minutes before surgical interventions.
62341407|NCT01907984|ACTIVE_COMPARATOR|Midazolam|Midazolam 7.5 g tablet was administered as premedication by mouth 30 minutes before surgical interventions.
62341408|NCT02704494|EXPERIMENTAL|Resveratrol|Resveratrol + Losartan
62341409|NCT02704494|PLACEBO_COMPARATOR|Placebo|Placebo + Losartan
62341410|NCT02598518|EXPERIMENTAL|Integrating Combined Therapies|Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).
62341411|NCT02598518|ACTIVE_COMPARATOR|Standard Care|Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
62341412|NCT04587453|EXPERIMENTAL|Tralokinumab+TCS|Week 0 to Week 16: Tralokinumab will be given as subcutaneous injections. Participants will receive tralokinumab loading dose on Day 0 followed by multiple tralokinumab injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
62341413|NCT04587453|PLACEBO_COMPARATOR|Placebo+TCS|Week 0 to Week 16: Placebo will be given as subcutaneous injections. Participants will receive placebo loading dose on Day 0 followed by multiple placebo injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
62341414|NCT01313806|ACTIVE_COMPARATOR|Resonator|Treatment with active Resonator device using low level magnetic fields
62341415|NCT01313806|PLACEBO_COMPARATOR|Placebo|
62341416|NCT05512208|EXPERIMENTAL|Avutometinib (VS-6766) + Defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week~Defactinib: will be administered at 200 mg orally twice a day (BID)."
62341417|NCT05606679||Patients undergoing ART with oocyte donation|Healthy patients with no history of RIF and RM which have undergone or are undergoing ART with oocyte donation and SET.
62498211|NCT04606017||Control|The other group did not receive the supplementation of 125IU/d Vitamin D
62498212|NCT02582554|EXPERIMENTAL|Intervention|Intervention: NutriSTEP The intervention will be the administration of NutriSTEP, a nutrition risk screening questionnaire for preschoolers along with a nutrition education brochure called How to Build a Healthy Preschooler
62498213|NCT02582554|NO_INTERVENTION|Control|Control: Wait-list control The wait-list control group will complete the NutriSTEP and receive the nutrition education information at the end of the 3 month study period
62498214|NCT04332211|EXPERIMENTAL|Pseudoephedrine Group|Patients randomized to pseudoephedrine prior to hyperbaric therapy
62498215|NCT04332211|PLACEBO_COMPARATOR|Placebo Group|Patients randomized to placebo prior to hyperbaric therapy
62140653|NCT01171638||Investigational cohort|"Soldiers with severe traumatic lower extremity injuries in stable or critical physiological status presenting to a participating study site within 12 hours of their injury, to provide data on the acute post-injury phase. This cohort will be made up of:~* Patients meeting inclusion criteria for investigational cohort, who have UNILATERAL severe lower extremity injuries~* Patients meeting inclusion criteria for investigational cohort, who have BILATERAL severe lower extremity injuries.~* Patients meeting inclusion criteria for investigational cohort, who have been clinically diagnosed by the treating provider using that treating providers standards for diagnosing ACS and the patient in addition to be diagnosed with ACS undergoes four-compartment leg fasciotomy."
62140654|NCT02520219|EXPERIMENTAL|GDP+Endostar|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum)chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma and Endostar."
62341418|NCT02128282|EXPERIMENTAL|Escalation CX-4945 plus Cis/Gem|"CX-4945 capsules at the combination MTD on Days 0, 1 and 2, and Days 7, 8 and 9.~PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle."
62341419|NCT02128282|ACTIVE_COMPARATOR|Cisplatin plus Gemcitabine|Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
62341420|NCT02128282|EXPERIMENTAL|10-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 10-day continuous dosing (Day 0 through Day 9). PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
62341421|NCT02128282|EXPERIMENTAL|21-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 21-day continuous dosing PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
62341422|NCT00734344|ACTIVE_COMPARATOR|Arm 1|Raltegravir plus Truvada
62341423|NCT00734344|ACTIVE_COMPARATOR|Arm 2|Efavirenz plus Truvada
62341424|NCT01876394|EXPERIMENTAL|Coconut oil|
62341425|NCT01876394|EXPERIMENTAL|Canola oil|
62341426|NCT01876394|EXPERIMENTAL|Grapeseed oil|
62341427|NCT01876394|EXPERIMENTAL|Chia oil|
62341428|NCT01876394|PLACEBO_COMPARATOR|Butter|
62341429|NCT02497157|EXPERIMENTAL|Treatment Arm|Patients receive FOLFOXIRI plus bevacizumab \[oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg\]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.
62341430|NCT01266434|EXPERIMENTAL|simvastatin|
62341431|NCT01266434|PLACEBO_COMPARATOR|B1-6-12|
62341432|NCT04407455||Children with cerebral palsy|Children who will be referred to pediatric dentistry above the age of 2 years.
62341433|NCT04407455||Children with typical development|Children who will be referred to pediatric dentistry above the age of 2 years.
62341434|NCT02695706|EXPERIMENTAL|Laboratoires Mercurochrome Reparador|A group of patients will be treated with a new restorative skin cream consists of hyperoxygenation essential fatty acids (60% linoleic acid) which does not contain preservatives (parabens) or known allergens.
62341435|NCT05656716|EXPERIMENTAL|Intervention group|Participants randomized to receive the multimodal intervention (nutrition and exercise)
62341436|NCT05656716|NO_INTERVENTION|Control group|Participants will not receive the multimodal intervention.
62341437|NCT03107676|ACTIVE_COMPARATOR|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
62341438|NCT03107676|ACTIVE_COMPARATOR|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
62341439|NCT03107676|ACTIVE_COMPARATOR|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
62341440|NCT03107676|NO_INTERVENTION|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
62341441|NCT02723110||rs78408340 heterozygous carriers|
62341442|NCT02723110||homozygous non-risk allele carriers|
62341443|NCT01864798|EXPERIMENTAL|Denosumab|
62341444|NCT02288065||responders|amelioration of dyspnea radiological amelioration after sterile talc pleurodesis
62341445|NCT02288065||failed intervention|unchanged symptoms and radiology after sterile talc pleurodesis
62498216|NCT00608634|PLACEBO_COMPARATOR|Placebo|Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
62341446|NCT02713191|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine + fentanyl before, and dexmedetomidine infusion during, procedure
62498217|NCT00608634|EXPERIMENTAL|Low Dose POH 0.30%|Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
62498218|NCT00608634|EXPERIMENTAL|High Dose POH 0.76%|Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
62498219|NCT03693833|EXPERIMENTAL|Intervention|10mg Cannabidiol (CBD) tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
62341447|NCT02713191|ACTIVE_COMPARATOR|Midazolam|Midazolam + fentanyl before, and matching saline infusion during, procedure
62341448|NCT02365584|EXPERIMENTAL|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
62498220|NCT03693833|PLACEBO_COMPARATOR|Placebo|10mg Placebo Oral tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
62498221|NCT00002633|ACTIVE_COMPARATOR|Total Androgen Blockade|
62698836|NCT01880463|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])"
62498222|NCT00002633|ACTIVE_COMPARATOR|Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation|
62498223|NCT02464670|EXPERIMENTAL|Group 1|INO-4201 IM + EP, 2 mg, 3 doses
62498224|NCT02464670|EXPERIMENTAL|Group 2|INO-4202 IM + EP, 2 mg, 3 doses
62498225|NCT02464670|EXPERIMENTAL|Group 3|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
62498226|NCT02464670|EXPERIMENTAL|Group 4|INO-4212 IM + EP, 4 mg, 3 doses
62498227|NCT02464670|EXPERIMENTAL|Group 5|INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses
62498228|NCT02464670|EXPERIMENTAL|Group 6|INO-4201 ID + EP 0.2A, 1 mg, 3 doses
62498229|NCT02464670|EXPERIMENTAL|Group 7|INO-4201 ID + EP 0.2A, 2 mg, 2 doses
62498230|NCT02464670|EXPERIMENTAL|Group 8|INO-4201 ID + EP 0.2A, 1 mg, 2 doses
62498231|NCT02464670|EXPERIMENTAL|Group 9|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses
62498232|NCT02464670|EXPERIMENTAL|Group 10|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses
62498233|NCT02464670|EXPERIMENTAL|Group 11|INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses
62498234|NCT02464670|EXPERIMENTAL|Part II: Group 3A|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
62498235|NCT02464670|EXPERIMENTAL|Part II: Group 3B|INO-4201 ID + EP 0.1A, 2 mg, 3 doses
62498236|NCT04145245|EXPERIMENTAL|Intervention or group a|Diabetic neuropathy patients with antidiabetic therapy in addition with l-carnitine supplementation
62698837|NCT01880463|PLACEBO_COMPARATOR|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
61949103|NCT05487846|ACTIVE_COMPARATOR|Arm II (best practice)|Patients receive standard care during genetic evaluation processes. Patients receive genetic counseling, undergo genetic testing, schedule a post-test disclosure visit, and receive their genetic test results and recommendations per standard care.
62140655|NCT02520219|ACTIVE_COMPARATOR|GDP|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum) chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma."
62140656|NCT02909205|OTHER|control|First phase : before training / sensitization / booklet delivery
62140657|NCT02909205|OTHER|post intervention|Second phase : after training / sensitization / booklet delivery
62140658|NCT02929420|EXPERIMENTAL|Xiaoru Sanjie capsules|a new recipe of traditional chinese medicine； Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.
62140659|NCT02929420|PLACEBO_COMPARATOR|Xiao Yao pills|"a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.~Xiaoyao pills,three pills every time,three time a day,PO,last three months."
62140660|NCT00916409|EXPERIMENTAL|NovoTTF-100A device in combination with Temozolomide|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
62140661|NCT00916409|ACTIVE_COMPARATOR|Temozolomide alone, as the best known standard of care|Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.
62140662|NCT01428206|OTHER|Liverpool care pathway|Liverpool care pathway for dying at nursing homes
62140663|NCT01428206|NO_INTERVENTION|control|Usual care is performed for the control group
62498237|NCT04145245|PLACEBO_COMPARATOR|Placebo or group b|Diabetic neuropathy patients with antidiabetic treatment in addition with placebo
61949104|NCT05023629|OTHER|Patients with a significant coronary artery lesion|Balloon inflation for 90s
62140664|NCT03863587|EXPERIMENTAL|HLX12 group|HLX12 are given intravenous infusion 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
62498238|NCT04525898|ACTIVE_COMPARATOR|Methadone Group|The methadone group will receive a dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
62498239|NCT04525898|PLACEBO_COMPARATOR|Control Group|The control group will be administered an equal volume of saline in an identical appearing syringe.
62498240|NCT05295524|EXPERIMENTAL|Patients with Cystic Fibrosis, with KAFTRIO® treatment prescription|Patients with Cystic Fibrosis, for whom treatment with KAFTRIO® is prescribed, regardless of previously prescribed CFTR modulator treatments.
62698838|NCT01880463|ACTIVE_COMPARATOR|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])"
62498241|NCT02409316|EXPERIMENTAL|FES PET/CT|All subjects will receive an \[18F\]FES PET/CT scan.
62498242|NCT02415933|EXPERIMENTAL|Trickle Up|Economic empowerment
62498243|NCT02415933|EXPERIMENTAL|Trickle Up Plus|Economic empowerment + child rights sensitization
62498244|NCT02415933|NO_INTERVENTION|Wait-list|Women in villages assigned to the control arm do not receive any intervention during the study period, but are placed on a wait-list to receive the intervention upon completion of the evaluation phase.
62498245|NCT03962868|EXPERIMENTAL|Endoscopic submucosal dissection (ESD)|
62498246|NCT03962868|ACTIVE_COMPARATOR|Endoscopic Mucosal Resection (WF-piece meal EMR)|
62498247|NCT01478516|EXPERIMENTAL|Plasmin|eyes with macular edema
62498248|NCT06383949||Prospective|All patients for whom the decision has been made to have the Synergy Disc system implanted and give informed consent will be enrolled in this study, following country-specific requirements.
62498249|NCT06383949||Retrospective|Patients who have previously received the Synergy Disc system in the last ten years are eligible for inclusion in the retrospective data collection; a waiver of consent, or an informed consent, for the retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations.
61949105|NCT02061774|ACTIVE_COMPARATOR|acetaminophen|1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
61949106|NCT02061774|PLACEBO_COMPARATOR|PlaceboComparator|Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
61949107|NCT06557941||A:successful extubation|mechanically ventilated PICU patients who pass spontaneous breathing trial and air leak test , extubated and not requiring to be re-intubated within 48 hours.
61949108|NCT06557941||B: failed extubation|mechanically ventilated PICU patients who don't pass spontaneous breathing trial and air leak test , extubated and requiring to be re-intubated within 48 hours.
61949109|NCT06081712|EXPERIMENTAL|Multiple Ascending Doses Cohort 1|TNP-2198 Capsules 200mg, BID, for 14days
61949110|NCT06081712|EXPERIMENTAL|Multiple Ascending Doses Cohort 2|TNP-2198 Capsules 400mg,BID, for 14days
61949111|NCT06081712|EXPERIMENTAL|Multiple Ascending Doses Cohort 3|TNP-2198 Capsules 600mg,BID, for 14days
61949112|NCT02654314|EXPERIMENTAL|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
61949113|NCT02654314|PLACEBO_COMPARATOR|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
61949114|NCT03317340||Patient Undergoing Urodynamics|
61949115|NCT00242216|ACTIVE_COMPARATOR|Atazanavir oral once daily|HIV treatment
62341449|NCT02365584|NO_INTERVENTION|Standard care|Standard care according to site clinical practice.
62498250|NCT06678867|OTHER|Patients with high grade brain tumours|This is a single-arm study with two cohorts
62498251|NCT01292668|EXPERIMENTAL|Group I|Patients apply methyl-5-aminolevulinate hydrochloride (MAL) cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo laser light treatment for 3-5 minutes.
62498252|NCT01292668|EXPERIMENTAL|Group II|Patients apply MAL cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo light emitting diode treatment for 5-10 minutes.
61949116|NCT00242216|ACTIVE_COMPARATOR|Fosamprenavir oral once daily|HIV treatment
61949117|NCT00154622|NO_INTERVENTION|pain/ disability survey|
61949118|NCT00293215|EXPERIMENTAL|Cohort 1 (1.0 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m\^2 on Day 1 of subsequent 21-day cycles.
61949119|NCT00293215|EXPERIMENTAL|Cohort 2 (2.6 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m\^2 on Day 1 of subsequent 21-day cycles.
61949120|NCT04966832|EXPERIMENTAL|XW10508|XW10508 capsules or tablets
62140665|NCT03863587|ACTIVE_COMPARATOR|Cyramza (Ramucirumab) group|Ramucirumab are given intravenous infusion of Cyramza 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
62164480|NCT01156922|EXPERIMENTAL|Rituximab|Rituximab induction two infusions (500 mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
62498253|NCT00919516|EXPERIMENTAL|Stem Cell Implantation|
61949121|NCT04966832|PLACEBO_COMPARATOR|Placebo|Placebo capsules or tablets
61949122|NCT00124228|NO_INTERVENTION|1|Antibiotic following hospital Protocols according the cause of the infection .
61949123|NCT00124228|ACTIVE_COMPARATOR|2|Antibiotic following hospital Protocols according the cause of infection plus albumin
61949124|NCT04883229|EXPERIMENTAL|tDCS +speech therapy followed by sham tDCS + speech therapy|
61949125|NCT04883229|ACTIVE_COMPARATOR|sham tDCS +speech therapy followed by tDCS + speech therapy|
61949126|NCT01005108|EXPERIMENTAL|placebo pill|
61949127|NCT01005108|EXPERIMENTAL|placebo accupuncture|
61949128|NCT01005108|EXPERIMENTAL|accupuncture|
61949129|NCT01005108|EXPERIMENTAL|gabapentin|
61949130|NCT02077478|EXPERIMENTAL|MCI|manually controlled infusion will be used
61949131|NCT02077478|EXPERIMENTAL|TCI|Target Controlled Infusion will be used
61949132|NCT00293033|PLACEBO_COMPARATOR|Placebo|Placebo
62341450|NCT03916471|EXPERIMENTAL|S (SOLYX)|The Solyx™SIS System is an innovative mid-urethral sling single incision system consisting of a 9 cm long polypropylene mesh, whose mid-urethral portion (4 cm) is detanged to potentially resist deformation and to reduce irritation to the urethral wall. Snap-fit to delivery device tip allows for advanced placement control and, therefore, the tensioning through the forward and reverse functions performed with this delivery device.
62498254|NCT04674228||Observational (medical record review)|Patients who participated in MAY2016-07-01 undergo review of medical records.
61949133|NCT00293033|EXPERIMENTAL|BEMA™ Fentanyl|BioErodible MucoAdhesive (BEMA) Fentanyl
61949134|NCT05921201|EXPERIMENTAL|Relax, Reflect, and Empower application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily brief check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
62498255|NCT04152356||PD-1|
62498256|NCT04152356||Sorafenib|
62498257|NCT03765190|EXPERIMENTAL|Radiation: Proton Therapy+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
62498258|NCT00954603|EXPERIMENTAL|quetiapine|atypical antipsychotic drug
62498259|NCT00954603|ACTIVE_COMPARATOR|haloperidol|typical antipsychotic drug
62498260|NCT03119662|EXPERIMENTAL|Visipaque™: Contrast-Enhanced Computed Tomography (CECT)|Participants received 1 intravenous injection of Visipaque™ 320 mg I/ml injection (100 mL iodixanol) and underwent computed tomography (CT) examination.
62498261|NCT03119662|PLACEBO_COMPARATOR|Saline: Non-Enhanced Computed Tomography (NECT)|Participants received 1 intravenous injection of saline placebo (matched to Visipaque™ 320 mg I/ml injection) and underwent computed tomography (CT) examination and supplemental non-contrast duplex ultrasonography imaging examination.
62498262|NCT00874549|ACTIVE_COMPARATOR|Group 1: Menomune Day 0|Participants received a single dose of Menomune® vaccine on Day 0.
62498263|NCT00874549|EXPERIMENTAL|Group 2: Menactra® Day 0 x 2|Participants received two single-dose injections of Menactra® vaccine on Day 0
62498264|NCT00874549|EXPERIMENTAL|Group 3: Menactra® Day 0 and 14|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14
62498265|NCT00874549|EXPERIMENTAL|Group 4: Menactra® Day 0 and 28|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.
62498266|NCT04305730|EXPERIMENTAL|Pedometer Group|This group will be given a pedometer following radical cystectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 1,000/day. POD 3-6: 2,000/day. POD 7-9: 3,000/day. POD 10-14: 4,000/day. POD 14-21: 5,000
62498267|NCT04305730|ACTIVE_COMPARATOR|Control group|This is the control group. Following radical cystectomy subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
62498268|NCT02876133|EXPERIMENTAL|Narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
62498269|NCT02876133|PLACEBO_COMPARATOR|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
61949135|NCT05921201|ACTIVE_COMPARATOR|Daily check-in text messages|Participants will receive a wellness check-in text message 5 days/week \[4 daily wellness check-in (2-3 minutes/day) +1 weekly wellness check-in (4-5 minutes/week)\] for 3 months.
61949136|NCT03359772|NO_INTERVENTION|Group 1|Exercise Only Group
61949137|NCT03359772|ACTIVE_COMPARATOR|Group 2|Kinesthetic Ability Trainer Group
61949138|NCT03816384|ACTIVE_COMPARATOR|Standard of Care|Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
61949139|NCT03816384|EXPERIMENTAL|Drain Line Clearance (DLC) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
61949140|NCT03816384|EXPERIMENTAL|Drain Line Clearance and Silver (DLCS) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
61949141|NCT00724932|EXPERIMENTAL|Sugammadex|4.0 mg.kg-1 sugammadex at 1-2 PTC
61949142|NCT00724932|EXPERIMENTAL|Neostigmine|50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2
61949143|NCT04450719||Group 1: Patients with lung cancer|Exercise capacity \[6-minute walk test (6-MWT)\], pulmonary functions \[spirometry\], respiratory \[maximal inspiratory and expiratory pressures (MIP-MEP), mouth pressure device\] and peripheral muscle strength \[dynamometer\], physical activity level \[metabolic holter\], dyspnea \[Modified Medical Research Council dyspnea scale (MMRC)\] and quality of life \[European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)\] were evaluated in patients with lung cancer. Vital signs, dyspnea and fatigue perception \[Modified Borg Scale\] were recorded as pre-post measurements of 6-MWT.
61949144|NCT04450719||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were performed in healthy individuals.
61949145|NCT06134752|ACTIVE_COMPARATOR|Radiofrequency ablation|Pulmonary vein and left atrial posterior wall isolation with point by point radiofrequency ablation.
62164481|NCT01686256|EXPERIMENTAL|Tc 99m EC20|A Phase 1, multi-center, open-label, single-treatment group, baseline-controlled (for safety) study designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation.
62164482|NCT04248049|EXPERIMENTAL|Experimental side|Roots covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
62498270|NCT01886534|EXPERIMENTAL|Enhanced Caregiver Support with Caregiver|"* Standardized Heart Failure Discharge Summary to Primary Care Physicians©~* Standardized education sessions~* Heart Failure Diuretic Decision Support Tool for Patient Self Management©~* Digital talking scale"
62498271|NCT01886534|OTHER|Usual Care with Caregiver|* Usual care
62498272|NCT01886534|EXPERIMENTAL|Enhanced Support without Caregiver|"* Standardized Heart Failure Discharge Summary to Primary Care Physicians©~* Standardized education sessions~* Heart Failure Diuretic Decision Support Tool for Patient Self Management©~* Digital talking scale"
62498273|NCT01886534|OTHER|Usual Care without Caregiver|* Usual Care
62498274|NCT06161701||Blood glucose management in patients with kidney disease after using glucocorticoids|Blood glucose monitoring for kidney disease patients after taking glucocorticoids
62498275|NCT06449391|EXPERIMENTAL|implanted group|This study is a single arm study, with only immediate implantation of root analogy implants
62736537|NCT05570656|ACTIVE_COMPARATOR|AS patients|Evaluation of kinematic parameters by wearing X-Sens sensors in different movements (flexion and extension of the spine, tying shoelaces, picking up an object on the ground, walking, etc.)
61949146|NCT06134752|EXPERIMENTAL|Pulse field ablation|Pulmonary vein and left atrial posterior wall isolation with point by point pulse field ablation.
61949147|NCT03665454|EXPERIMENTAL|PF-06412562|Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
61949148|NCT03665454|ACTIVE_COMPARATOR|Standard of Care carbidopa/levodopa|Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
61949149|NCT02917850|ACTIVE_COMPARATOR|Isokinetic|Patients who benefit from the hip flexors isokinetic strengthening rehabilitation program
61949150|NCT02917850|ACTIVE_COMPARATOR|Control|Patients who benefit from a conventional rehabilitation program
61949151|NCT00699764|EXPERIMENTAL|Group A|
61949152|NCT00699764|PLACEBO_COMPARATOR|Group B|
61949153|NCT05821400||Healthy controls without orthostatic hypotension|
62164483|NCT04248049|ACTIVE_COMPARATOR|Control side|Roots covered with coronally advanced flap (CAR)
62736538|NCT05570656|ACTIVE_COMPARATOR|healthy volunteers|Evaluation of kinematic parameters by wearing X-Sens sensors in different movements (flexion and extension of the spine, tying shoelaces, picking up an object on the ground, walking, etc.)
61949154|NCT06450353||Prospective evaluation|Participants are expected to be in this research study for up to 2 years after the participants bone marrow transplantation. However, your active participation will only last 1 day, when you sign the consent form and complete a questionnaire about your demographic information and ancestry (family ethnicity). For the rest of the study, information about the participants medical history, choice of bone marrow donor, and health outcomes will be collected from your medical record.
61949155|NCT05481606||Type I|1) the gestational sac is partially implanted in the uterine scar, partially or mostly located in the uterine cavity, and a few may even reach the uterine cavity at the bottom of the palace; 2) the gestational sac is significantly deformed, and elongated, and its the lower end presented a acute Angle; 3) The myometrium between the gestational sac and the bladder became thinner, with a thickness of \>3 mm; 4) Doppler flow image: trophoblast blood flow signal can be seen in the scar (low resistance blood flow)
61949156|NCT05481606||Type II|1) The gestating sac is partially implanted in the scar of the uterus, partially or mostly located in the uterine cavity, and a few may even reach the uterine cavity at the bottom of the uterus; 2)the gestational sac is significantly deformed, and elongated, and its the lower end presented a acute Angle; 3) The myometrium between the stretch and the bladder becomes thinner (3 mm in thickness); 4) color Doppler flow image: trophoblast blood flow signal (low resistance blood flow) can be seen in the scar.
61949157|NCT05481606||Type III|1) The gestating sac is completely implanted in the muscle layer of the scar of the uterus and protrudes outward toward the bladder; 2) Uterine cavity and cervical canal emptiness; 3) The myometrium between the gestational sac and the bladder was significantly thinner or absent, with a thickness of 3 mm; 4) color Doppler flow image: trophoblast blood flow signal (low resistance blood flow) can be seen in the scar. Among them, there is a special ultrasonic manifestation of cesarean scar pregnancy in type III, namely mass type, whose sonographic characteristics
61949158|NCT05781620|EXPERIMENTAL|Vitamin D group|
61949159|NCT05781620|PLACEBO_COMPARATOR|Placebo group|
61949160|NCT04680091|EXPERIMENTAL|Efavirenz 600 mg + Pyrotinib 400 mg|
61949161|NCT04680091|ACTIVE_COMPARATOR|Pyrotinib 400 mg|
61949162|NCT03619278|EXPERIMENTAL|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 dose of 10-1074 antibodies and 3 doses of romidepsin
61949163|NCT03619278|PLACEBO_COMPARATOR|Placebo|Participants will receive 5 doses of placebo, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
61949164|NCT05073601||control group|group of subjects with healthy cornea
61949165|NCT05073601||keratoconus group|group of keratoconus patients with no history of thyroid dysfunction
61949166|NCT02639767|EXPERIMENTAL|pemetrexed/cisplatin with pleural IMRT|This is a single institution phase I study of pemetrexed/cisplatin given concurrently with pleural intensity modulated radiation therapy (IMRT) in patients with unresectable malignant pleural mesothelioma (MPM). All patients will receive pleural intensity modulated radiation therapy (IMRT). Patients will be enrolled in cohorts of 3-6 at each dose level of pemetrexed/cisplatin, and dose escalation will proceed in a standard 3+3 fashion until the maximum tolerated dose (MTD) is identified.
61949167|NCT05922111|EXPERIMENTAL|cervical ripening balloon for 1 hour|Eligible women will undergo the usual procedure of CRB insertion using a double lumen Cook cervical ripening balloon (CCRB). The CRB will be removed approximately after an hour in the intervention group and thereafter, the women will proceed amniotomy or Pitocin use at the discretion of the labor and delivery physician
61949168|NCT05922111|ACTIVE_COMPARATOR|cervical ripening balloon for 12 hours|Eligible women will undergo the usual procedure of CRB insertion using a double lumen Cook cervical ripening balloon (CCRB). The CRB will be removed approximately after 12 hours in the control group and thereafter, the women will proceed amniotomy or Pitocin use at the discretion of the labor and delivery physician
61949169|NCT00570765|EXPERIMENTAL|DB OCA 10 mg|OCA 10 mg for 3 months during the DB phase.
61949170|NCT00570765|EXPERIMENTAL|DB OCA 50 mg|OCA 50 mg for 3 months during the DB phase.
62164484|NCT03999710|EXPERIMENTAL|Non-Small Cell Lung Cancer|All participants have locally-advanced non-small cell lung cancer, Stage II-III. Treatment will consist of durvalumab administered concurrently with thoracic radiation consisting of 60 Gy in 30 fractions. Patients will be monitored weekly during on-treatment visits. Durvalumab will then be continued up to 1 year as maintenance or until disease progression or unacceptable toxicity. Optional Research MRIs (Does not apply to the Alliance Sites. Research MRIs will only be done at MSKCC)
62164485|NCT05152706|EXPERIMENTAL|Intervention aerobic (IAER)|Patients assigned to the IAER participated in fourty-eigth aerobic exercise therapy sessions over the course of six months.
61949171|NCT00570765|PLACEBO_COMPARATOR|DB OCA Placebo|Matching placebo for 3 months during the DB phase.
61949172|NCT00570765|EXPERIMENTAL|LTSE OCA Total|After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.
61949173|NCT04528732|NO_INTERVENTION|Usual Care|Usual care consists of the traditional clinic intervention that focuses on testing services, ART treatment, and information about disease management.
61949174|NCT04528732|EXPERIMENTAL|Group-Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
61949175|NCT04528732|EXPERIMENTAL|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
61949176|NCT00434954|EXPERIMENTAL|Exenatide Twice Daily (BID)|
61949177|NCT00434954|ACTIVE_COMPARATOR|Premixed Insulin Aspart Twice Daily (BID)|
61949178|NCT03094429|ACTIVE_COMPARATOR|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
61949179|NCT03094429|ACTIVE_COMPARATOR|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
61949180|NCT03094429|PLACEBO_COMPARATOR|Placebo - 0 mg/day|The control treatment is placebo.
61949181|NCT04125888||AIT Cohort|Allergic rhinitis patients with and without asthma treated with AIT
61949182|NCT04125888||Control Cohort|Allergic rhinitis patients with and without asthma not treated with AIT
62498276|NCT03108820|EXPERIMENTAL|TMH Intervention|The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.
61949183|NCT03734575|EXPERIMENTAL|ClariCore System|Biopsy tissue, correlative spectral data, T2-weighted MR scans and ultrasound images acquired with the ClariCore System will be collected and recorded during standard practice transperineal biopsy.
61949184|NCT06535425|ACTIVE_COMPARATOR|Control|Initial Health Education for Participants Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
61949185|NCT06535425|EXPERIMENTAL|Platelet-Rich Plasma|The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
61949186|NCT06535425|EXPERIMENTAL|Isometric Contractions of Quadriceps|The IG and JG exercises followed the methods of our previous research, with participants undergoing an 16-week ICQ intervention five times per week. Each session consisted of isometric contractions and relaxations of the quadriceps muscle for 5 seconds each, in sets of 30 repetitions, for a total of 10 sets, with a 30-second rest between sets. During this period, researchers conducted weekly follow-up calls or face-to-face interviews with participants to understand their living conditions, ensuring that they did not change their original lifestyle habits and did not engage in any other form of regular fitness activities. Participants who did not comply were not included in the final data analysis.
61949187|NCT06535425|EXPERIMENTAL|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
61949188|NCT05490784|EXPERIMENTAL|Lee Silverman Voice Treatment big with conventional treatment|Lee Silverman Voice Treatment big with conventional treatment
61949189|NCT05490784|ACTIVE_COMPARATOR|control group|Patients assigned to control group received conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
61949190|NCT03485391|EXPERIMENTAL|PE+Exposure Workout Buddy|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to meet patients at exposure sites in the community to offer support during exposure.
61949191|NCT03485391|ACTIVE_COMPARATOR|PE+Peer General Support|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to call and talk to patients once per week, informally meet at patient appointments, encourage session attendance and check in about progress.
61949192|NCT00313300|ACTIVE_COMPARATOR|A1|
61949193|NCT00313300|EXPERIMENTAL|A2|
61949194|NCT00313300|PLACEBO_COMPARATOR|A3|
61949195|NCT00313300|EXPERIMENTAL|A4|
62164486|NCT05152706|EXPERIMENTAL|Intervention photobiomodulation (IPBM)|Patients assigned to the IPBM participated in fourty-eigth transcraneal photobiomodulation (PBM) theraphy sessions, using a therapeutic laser console, over the course of six months.
62164487|NCT05152706|EXPERIMENTAL|Intervention aerobic and photobiomodulation (IAER+PBM9|Patients assigned to the IAER+PBM participated in the aerobic exercise therapy and the PBM one at the same time, during six months.
62498277|NCT03108820|ACTIVE_COMPARATOR|Usual Care|Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.
62698839|NCT02648360|EXPERIMENTAL|Text Messaging Intervention Arm|Participants will be enrolled in either a dietary or physical activity text messaging program. The dietary program will include nutritional education, reading nutrition labels, portion control, making lifestyle changes, finding social support, and identifying triggers. The physical activity program will provide information on the benefits of physical activity, exercise tips, and encouragement to live more active lifestyles. The programs have limited interactive capability; patients will be asked to respond to specific questions, but questions asked by the participants will be answered with an automated message asking them to contact their health care provider.
62698840|NCT06341647|EXPERIMENTAL|Phase 1a Dose Escalation|"* Dose Escalation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression~* Interventions:~  * Drug: AB-201~ * Drug: Cyclophosphamide~ * Drug: Fludarabine"
62498278|NCT00591071|ACTIVE_COMPARATOR|B|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
62698841|NCT06341647|EXPERIMENTAL|Phase 1b Dose Expansion|"* Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression~* Interventions:~  * Drug: AB-201~ * Drug: Cyclophosphamide~ * Drug: Fludarabine"
62698842|NCT05718739|EXPERIMENTAL|FOG@Home|Patients with Parkinson's disease who agreed to be monitored using cameras and acceleration measurements during daily life.
62736539|NCT01635270|EXPERIMENTAL|midP arm|Patients treated with midP radiotherapy strategy.
62736540|NCT01635270|ACTIVE_COMPARATOR|ITV arm|Patient treated with radiotherapy ITV strategy
62498279|NCT00591071|EXPERIMENTAL|A|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
62498280|NCT06137807|EXPERIMENTAL|TricValve® Device (Device) Group|subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies, per physician discretion.
62498281|NCT00304434|OTHER|1|
62498282|NCT02531490|ACTIVE_COMPARATOR|randomized, interventiongroup|Women with a hyperdynamic vasodilated profile, characterized by a mean arterial pressure (MAP)/ Heart rate (Hr) ratio ≤ 1.1 are prescribed a beta-blocker. Women with a hypodynamic vasoconstrictive profile (MAP/Hr ratio ≥ 1.4) are prescribed nifedipine. Women with normodynamic profile (MAP/Hr ratio in between 1.1 and 1.4) are prescribed Methyldopa.
62498283|NCT02531490|NO_INTERVENTION|randomized, control-group|Women who give informed consent for randomization, and are randomized to the control group will not be medicinally treated for mild to moderate gestational hypertension.
62498284|NCT02531490|NO_INTERVENTION|not-randomized, control-group|Women who do not want to be randomized, but who give informed consent for follow-up on their data until discharge after delivery. They will receive standard care, i.e. no medication is prescribed for mild to moderate gestational hypertension.
62498285|NCT05347394|EXPERIMENTAL|Part A: VX-708|Participants will be randomized to receive a single dose of different dose levels of VX-708.
62498286|NCT05347394|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive placebo matched to VX-708.
62498287|NCT05347394|EXPERIMENTAL|Part B: VX-708|Participants will be randomized to receive multiple doses of different dose levels of VX-708. The dose levels will be determined based on the data from Part A.
61949196|NCT00908973||Good responders|Excess weight loss of \> 60% 1 year after gastric bypass surgery
61949197|NCT00908973||Poor responders|Excess weight loss of =\< 50% 1 year after gastric bypass surgery
61949198|NCT00908973||Lean controls|Non-gastric bypass operated lean individuals, matched for age and sex
61949199|NCT02866916|EXPERIMENTAL|Dose escalation|"The standard method 3+3 will be used for dose escalation: the first 3 patients will be treated at level 1; consecutive cohorts of 3 to 6 patients will be treated with increasing doses of SXL01.~Treatment will be administered until patient experiences unacceptable toxicity, PSA raising, progressive disease and/or treatment is discontinued at the discretion of the investigator or withdrawal of consent.~Additional patients will be included at the Recommended Phase II Dose (RP2D) in the expansion phase."
62140666|NCT06699212|EXPERIMENTAL|320 mg/m^2 ASP-1929 Photoimmunotherapy + pembrolizumab|"ASP-1929 320 mg/m\^2 IV infusion followed by illumination with 690 nm red light at accessible tumor sites using the investigational PIT690 Laser System (24 ± 4 hours after end of ASP-1929 infusion). Treatment with ASP-1929 PIT will be repeated every 4 to 6 weeks depending on clinical judgement of investigators.~Pembrolizumab: 200 mg every 3 weeks (Q3W) IV infusion over 30 minutes for the first 6 cycles. After the first 6 cycles, pembrolizumab dosing regimen can be converted from 200 mg Q3W to 400 mg every 6 weeks (Q6W) at the investigator's discretion.~Treatment in the experimental arm will start with the infusion of pembrolizumab on Cycle 1 Day 1 (C1D1) after which ASP-1929 Photoimmunotherapy will follow 7 days later, on Treatment 1 Day 1 (T1D1). Patients will be treated with ASP-1929 PIT and pembrolizumab for up to 24 months."
62164488|NCT05152706|NO_INTERVENTION|Control (CO)|Patients assigned to the control (CO) did not participated in any kind of therapy, they just followed their usual weekly routine during six months
62498288|NCT05347394|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive placebo matched to VX-708.
62498289|NCT00928057|EXPERIMENTAL|4 mm / 8 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 8mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
62498290|NCT00928057|EXPERIMENTAL|4 mm / 5 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 5mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
62736541|NCT04628702|EXPERIMENTAL|Intervention group|receives tablet-training
61949200|NCT01760720|NO_INTERVENTION|control|Standard care
61949201|NCT01760720|EXPERIMENTAL|intervention|The MMT CARE intervention has 3 session/modules: 1) MMT protocol and procedures, understanding stigma and its impact; 2) effective communication with clients, introducing motivational interviewing; 3) application of motivational interviewing, motivating clients for behavior change. The intervention contents reflect challenges faced by service providers working at MMT clinics and the impact of these challenges on their clients. Sessions will occur once a week for three weeks, with each session featuring a different set of themes and relevant activities. Each session will be 90-100 minutes long and will be conducted with a group of 5 to 7 providers.
62164489|NCT04623671|ACTIVE_COMPARATOR|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
62164490|NCT04623671|PLACEBO_COMPARATOR|Placebo|Matching placebo solution
61949202|NCT00191269|EXPERIMENTAL|A|Dose Level 1 - 1000 mg/m2
62164491|NCT06584747|EXPERIMENTAL|Experimental Arms|
62498291|NCT00534430|EXPERIMENTAL|Busulfan, FTBI and VP16|IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
62498292|NCT04534140|EXPERIMENTAL|HBKB Capsule|Experimental group participants will take one capsule of the HBKB botanical dietary supplement orally, once daily
62498293|NCT04534140|PLACEBO_COMPARATOR|HBKB Capsule Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
62498294|NCT02934633|EXPERIMENTAL|Keeping Baby Safe|Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
62736542|NCT04628702|NO_INTERVENTION|Control group|no training
62736543|NCT03989349|PLACEBO_COMPARATOR|Placebo|Placebo administered via subcutaneous injection
62498295|NCT02934633|ACTIVE_COMPARATOR|AAP TIPP Sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets that parents would typically receive from their pediatrician or general practitioner at well-baby visits.
62698843|NCT04925427|EXPERIMENTAL|Case Management and Peer Recovery|Participants in the CM/PRC + OEND arm will receive one year of service delivery. During the initial intake interview the CM will identify primary, secondary, and tertiary barriers to treatment initiation and completion, then create an action plan tailored to each client. PRCs with lived SUD or incarceration experience will address recovery barriers, while CMs will focus on service barriers. Where beneficial and desired by the clients, PRCs will accompany clients to provider and select service appointments to promote engagement and retention. CM/PRC teams will provide OEND upon community re-entry. The teams will provide follow-up phone calls and home visits to facilitate service linkages. Contact frequency will depend on clients' individual barriers (e.g., transportation, homelessness), but will include at least weekly in-person or telephone check-ins for first six months, reduced to monthly check-ins after that.
62698844|NCT04925427|PLACEBO_COMPARATOR|Naloxone-Only|Participants randomized to the Usual care + OEND condition will be trained on naloxone administration by research staff at the time of randomization. Upon community re-entry,they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
62698845|NCT06564909|EXPERIMENTAL|Control group|38 STEMI patients undergoing PCI who will receive the standard of care for 4 weeks and will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants and anti-ischemic measures (high intensity statin, ACEI or aldosterone) as per latest guidelines recommendations.
62698846|NCT06564909|EXPERIMENTAL|Test group|38 STEMI patients undergoing PCI who will receive the standard of care in addition to L-Carnitine 5 g intravenous administered as slow Iv push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) prior to PCI and then 2 g orally (Carnitol 500 mg®, Global Napi, Egypt) daily for 4 weeks after PCI
62698847|NCT04692506|ACTIVE_COMPARATOR|Low dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
62698848|NCT04692506|ACTIVE_COMPARATOR|High dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
61949203|NCT00191269|EXPERIMENTAL|B|Dose Level 2 - 1250 mg/m2
61949204|NCT02399553|EXPERIMENTAL|Soccer 2G|Soccer players who trained in second generation artificial turf
61949205|NCT02399553|EXPERIMENTAL|Soccer 3G|Soccer players who trained in third generation artificial turf
61949206|NCT02399553|EXPERIMENTAL|Soccer NG|Soccer players who trained in natural grass
61949207|NCT02399553|EXPERIMENTAL|Soccer NON-NG|Soccer players who trained in non-natural grass
61949208|NCT02399553|NO_INTERVENTION|Control group|
61949209|NCT01602120|EXPERIMENTAL|CFD4870g Sham|Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), will receive lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
61949210|NCT01602120|EXPERIMENTAL|CFD4870g Lampalizumab|Participants will receive lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
61949211|NCT01602120|EXPERIMENTAL|GX29455 Sham|Participants who were administered sham comparator in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
61949212|NCT01602120|EXPERIMENTAL|GX29455 Lampalizumab|Participants who were administered lampalizumab in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
62140667|NCT06699212|EXPERIMENTAL|640 mg/m^2 ASP-1929 Photoimmunotherapy + pembrolizumab|"ASP-1929 640 mg/m\^2 IV infusion followed by illumination with 690 nm red light at accessible tumor sites using the investigational PIT690 Laser System (24 ± 4 hours after end of ASP-1929 infusion). Treatment with ASP-1929 PIT will be repeated every 4 to 6 weeks depending on clinical judgement of investigators.~Pembrolizumab: 200 mg every 3 weeks (Q3W) IV infusion over 30 minutes for the first 6 cycles. After the first 6 cycles, pembrolizumab dosing regimen can be converted from 200 mg Q3W to 400 mg every 6 weeks (Q6W) at the investigator's discretion.~Treatment in the experimental arm will start with the infusion of pembrolizumab on Cycle 1 Day 1 (C1D1) after which ASP-1929 Photoimmunotherapy will follow 7 days later, on Treatment 1 Day 1 (T1D1). Patients will be treated with ASP-1929 PIT and pembrolizumab for up to 24 months."
62164492|NCT01874522|EXPERIMENTAL|TAS-102 tablets|
62164493|NCT01874522|EXPERIMENTAL|TAS-102 oral solution|
62164494|NCT03811483||Female gender|
62736544|NCT03989349|EXPERIMENTAL|Nemolizumab|Nemolizumab administered via subcutaneous injection
62164495|NCT03811483||Male gender|
61949213|NCT01460017|ACTIVE_COMPARATOR|DS arm|Deep sclerectomy surgery will be conduct in this arm
61949214|NCT01460017|ACTIVE_COMPARATOR|Trab arm|combined Trabeculectomy and Trabeculotomy surgery will be conducted in this arm
61949215|NCT03816488|EXPERIMENTAL|Metformin|Self-administered metformin (patient's usual dose) taken 2 hours prior to surgery
61949216|NCT03816488|EXPERIMENTAL|Salsalate|Self-administered salsalate taken 2 hours prior to surgery
61949217|NCT03816488|NO_INTERVENTION|Placebo|Self-administered placebo taken 2 hours prior to surgery
62164496|NCT00768716|EXPERIMENTAL|White subjects|2 x 500 mg acetaminophen by mouth once
62498296|NCT02208336||Observational (electronic medical record review)|Patients' electronic medical records are reviewed for adherence, severe myelosuppression, and patient morbidity retrospectively and prospectively.
62498297|NCT01021501|EXPERIMENTAL|nifedipine controlled release tablets|Prospective, open, non-randomized, non-controlled study to evaluate the effect and safety of nifedipine controlled release tablets in hypertensive patients on chronic maintenance hemodialysis and the influence of hemodialysis on the plasma concentration of nifedipine
62736545|NCT02540733||Diabetic stroke|
62736546|NCT02540733||Non-diabetic storke|
62698849|NCT04692506|PLACEBO_COMPARATOR|Placebo Sachet|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
61949218|NCT03878953|EXPERIMENTAL|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
62498298|NCT06134440|EXPERIMENTAL|Arm A (interventional arm)|a low-fiber dietary advice + oral nutritional supplement enriched with immune-nutrients for 5 pre-operative days and 5 post-operative days.
62498299|NCT06134440|NO_INTERVENTION|Arm B (control arm)|a low fiber dietary advice only
62498300|NCT06086314|EXPERIMENTAL|reactive exercise training|They will attend the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. After this program, they will receive reactive exercise training with ''FitPodz Light Trainer'' device.
61949219|NCT01688518|ACTIVE_COMPARATOR|Synera® for 30min & Lidoderm® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
61949220|NCT01688518|ACTIVE_COMPARATOR|Lidoderm® for 30min & Synera® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
61949221|NCT01360593|OTHER|Gem, Xeloda, SBRT|
61949222|NCT02840955|ACTIVE_COMPARATOR|Staphefekt SA.100|Staphefekt SA.100 cream, twice daily on (lesional) skin during 12 weeks
62341451|NCT03916471|EXPERIMENTAL|O (OBTRYX II)|The Obtryx II System (Halo) is a transobturator sling designed to allow inter-operative adjustability with minimal tissue disruption. It consists of two delivery devices (one patient right and one patient left) and one mesh assembly. The mesh assembly is comprised of a polypropylene knitted mesh with dilator legs and a center tab. At the distal ends of the dilator legs there are association loops designed to be placed in the needle slot of the distal end of the delivery device. The disposable delivery device consists of a handle with a stainless steel needle. The needle is designed to facilitate the passage of the mesh assembly through bodily tissues for placement through the obturator foramen.
62341452|NCT05674500|EXPERIMENTAL|Training Group|"Faculty participants will participate in educational training designed to teach them standardized coaching language for endoscopy instruction and strategies to promote effective communication during an endoscopy teaching. It will be comprised of:~1. A 15-minute-long training video demonstrating the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction)~2. The faculty will be given a small (10x10 cm) flash card with the recommended 14 standard terms which they can access during the second simulated encounter. To control for any potential effect of the presence of the card on the trainee during teaching, each faculty be given an identical card with 14 random words on it to hold during the first encounter"
62498301|NCT06086314|EXPERIMENTAL|reactive exercise training with co-contraction|They will attend the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. After this program, they will receive reactive exercise training aimed at creating co-contraction with ''FitPodz Light Trainer'' device.
62498302|NCT06086314|ACTIVE_COMPARATOR|functional reaching training|They will attend the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. After this program, they will receive functional reaching training without device.
62498303|NCT06111534|EXPERIMENTAL|MHC group|Each MHC group participant (n=30) was brought to the procedure room by its mother. The mother sat in a comfortable chair with back support. She held her baby close to her chest, with the baby's head in a crossed position so that it could see its mother. The same nurse collected the blood sample. The mother communicated with the baby verbally and made eye contact with it to calm it down during the procedure. She was holding the baby both during and after the procedure.
62698850|NCT02959346|SHAM_COMPARATOR|Sham Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture.
62698851|NCT02959346|EXPERIMENTAL|Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the acupuncture group, participants will receive acupuncture.
62698852|NCT02038036|EXPERIMENTAL|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
62736547|NCT04333979|EXPERIMENTAL|Drain replacement|Effects of drainage
61949223|NCT02840955|PLACEBO_COMPARATOR|Placebo|Placebo (Gladskin cream without the Staphefekt protein), twice daily on (lesional) skin during 12 weeks
61949224|NCT02581787|EXPERIMENTAL|(Phase 1) Fresolimumab 3 mg/kg|Patients receive fresolimumab 3 mg/kg IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12.
61949225|NCT02581787|EXPERIMENTAL|(Phase 1) Fresolimumab 1 mg/kg|Patients receive fresolimumab 1 mg/kg IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12.
61949226|NCT02581787|EXPERIMENTAL|(Phase 2) Fresolimumab|Fresolimumab will be administered IV at the dose selected in the preceding Phase 1 on Days 1, 15 and 36 and SABR will be administered in 4 fractions between Days 8 and 12.
61949227|NCT04259320|EXPERIMENTAL|Beeswax containing barrier|Beeswax containing barrier will be given to the breastfeeding mother within the first 24 hours. After breastfeeding, it can be placed on the breast after it is expected to dry a little.Outside of breastfeeding and bathing, it will be constantly attached to the breasts.
62164497|NCT00768716|EXPERIMENTAL|Black subjects|2 x 500 mg acetaminophen by mouth once
61949228|NCT04259320|EXPERIMENTAL|Breast milk|After breastfeeding, 2-3 drops of breast milk are applied to the nipple and areola. After the milk has dried, the breasts are closed. This application should be done at least 5 times a day.
62498304|NCT06111534|EXPERIMENTAL|PHC group|Each PHC group participant (n=30) was brought to the procedure room by its father. The father sat in a comfortable chair with back support. He held his baby close to his chest, with the baby's head in a crossed position so that it could see its father. The same nurse collected the blood sample. The father communicated with the baby verbally and made eye contact with it to calm it down during the procedure. He was holding the baby both during and after the procedure.
62498305|NCT06111534|NO_INTERVENTION|Control group|The control group participants (n=32) underwent the procedure according to the routine clinical practice. Either parent brought the baby into the procedure room and laid it on the procedure table in the supine position. The nurse collected the blood sample. The parent was present in the room and communicated with the baby only verbally during the procedure. The parent picked up the baby after the procedure.
62498306|NCT02244554|EXPERIMENTAL|enLighten Laser Picosecond Pulse|Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
62498307|NCT02244554|EXPERIMENTAL|enLighten Laser Nanosecond Pulse|Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
62498308|NCT03474393|NO_INTERVENTION|Normal diabetes care|Continue with their normal diabetes care. Come in for control visits
61949229|NCT04259320|NO_INTERVENTION|No treatment- control|It is a group that does not use any method to prevent nipple cracks. All follow-ups in the experimental groups are done.
61949230|NCT06125561||Diabetic|Diabetic patients with age ranges 18-60 years. Clinical Examination will be performed by CPTIN probe and questionnaire will be filled by participant's.
61949231|NCT06125561||Non diabetic|Non Diabetic patients with age ranges 18-60 years. Clinical Examination will be performed by CPTIN probe and questionnaire will be filled by participant's.
61949232|NCT00061347|EXPERIMENTAL|1|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
61949233|NCT03832777|ACTIVE_COMPARATOR|5 Hz Stimulation|This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.
61949234|NCT03832777|PLACEBO_COMPARATOR|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
61949235|NCT03803995|OTHER|Mapping and Pacing the His Bundle|All patients will be in this arm. Mapping and Pacing the His Bundle will be performed.
61949236|NCT06311825|EXPERIMENTAL|Horticultural Therapy Group (Experimental)|Horticultural therapy will be applied to experimental group.
61949237|NCT06311825|NO_INTERVENTION|Controls (Control Group)|No intervention will be applied to the control group.
61949238|NCT04621630|EXPERIMENTAL|Single Dose|Single dose administration
61949239|NCT04621630|EXPERIMENTAL|Multiple Dose|Multiple dose administration
61949240|NCT04621630|EXPERIMENTAL|Solid Dose Comparison|Solid dose administartion
61949241|NCT05886504|ACTIVE_COMPARATOR|Psychiatric intervention group|200 PWID diagnosed with either depression, psychosis or suicidal risk will be proposed to be included in the intervention arm Participants will receive free psychiatric consultation and medication on community-based organization (CBO) sites with full support from CBO members They will receive (together with the control group) linkage to care when needed (HIV, methadone treatment) and harm reduction services.
61949242|NCT05886504|NO_INTERVENTION|control group free from psychiatric disorder|"200 PWID living with HIV and 200 PWID non-infected with HIV, both free of a diagnosis of depression, psychosis or suicidal risk, will be recruited and proposed a one year follow-up.~They will receive (together with the intervention group) linkage to care when needed (HIV, methadone treatment) and harm reduction services."
61949243|NCT03875339|ACTIVE_COMPARATOR|Navigator Arm|Examination of adherence to follow-up with a navigator.
61949244|NCT03875339|NO_INTERVENTION|Non-Intervention Arm|Examination of adherence to follow-up without a navigator.
61949245|NCT00255112|NO_INTERVENTION|1|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel. The study consists of 40 participants (5-7 years old) with SAD and their families. Participants were randomly assigned to 12 weeks of SAD-specific family-based CBT treatment or to waitlist condition.
62341453|NCT05674500|ACTIVE_COMPARATOR|Control Group|"Faculty participants will take part in 'dummy' educational training comprised of:~1. A 15-minute-long 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices~2. This group will also be provided a small (10x10cm) flash card but with random words on it (identical to the first simulated colonoscopy teaching encounter)."
62498309|NCT03474393|EXPERIMENTAL|Systematic intensive therapy|Intensive Internet and telephone contact for 4 months and Control visits
62498310|NCT00734825|ACTIVE_COMPARATOR|1|IV contrast
62498311|NCT00734825|ACTIVE_COMPARATOR|2|IV contrast and oral contrast
61949246|NCT00255112|ACTIVE_COMPARATOR|2|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel in comparison to a global CBT treatment. The study consists of 60 participants (between 8 and 13 years old), randomly assigned to one of the two treatments.
61949247|NCT05397431||Lanadelumab|Participants will receive 300 milligram (mg) of Lanadelumab Subcutaneous (SC) injection once every 2 weeks.
61949248|NCT03605407|EXPERIMENTAL|Experimental group|Patient receiving one visit prior to hospital admission
61949249|NCT03605407|NO_INTERVENTION|Control group|Patient without receiving one visit prior to hospital admission
61949250|NCT03913988|ACTIVE_COMPARATOR|LUCID DREAMING, STRESS REDUCTION, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~* Psychoeducation regarding lucid dreaming, stress reduction, and sleep hygiene~* Practice of lucid dreaming induction techniques~* Guided visualization~* Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
62736548|NCT04333979|NO_INTERVENTION|Drain not placed|Effects of not using drain
62341454|NCT04834973|EXPERIMENTAL|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2 given every 28 days (+1 to 14days) in combination with three weekly 200 mg intravenous doses of pembrolizumab.
61949251|NCT03913988|ACTIVE_COMPARATOR|LUCID DREAMING, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~* Psychoeducation regarding lucid dreaming and sleep hygiene~* Practice of lucid dreaming induction techniques~* Guided visualization~* Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
62164498|NCT06407973|ACTIVE_COMPARATOR|Surgical (OMNI Surgical System (OSS))|Canaloplasty followed by Trabeculotomy using the OMNI Surgical System.
62498312|NCT03323411||Intervention and attention control|the Advance Care Treatment Plan experimental group received education on dementia cardiopulmonary resuscitation and tube feeding. The attention control group received education on exercise stress control diabetes and hypertension
62498313|NCT03733587|EXPERIMENTAL|Cyclophosphamide and GX-I7|Cyclophosphamide and determined dose of GX-I7 of each cycle
62498314|NCT01041196||perforated ulcer after gastric bypass|
62698853|NCT02038036|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
61949252|NCT03913988|ACTIVE_COMPARATOR|SLEEP HYGIENE|"This group will meet for 2 online group sessions and 4 email communications. The 2 online group sessions will each last 1 hour and occur in weeks 1 and 12. The 4 email communications will occur in weeks 3, 5, 7, and 9 and consist of individual communication between each participant and the PI or co-investigator. Each email communication will require 10 minutes of participants' time.~The control group will be asked to engage in Sleep Hygiene techniques in which they adhere to a recommended protocol and record their adherence in a Sleep Hygiene Tracking Log, requiring 5 minutes per day.~Through the 2 online sessions and the individual email with the investigators, participants will have the opportunity to discuss their experience with adherence to the sleep hygiene program and tracking log. Investigators will help participants trouble shoot problems adhering to the sleep hygiene protocol."
62164499|NCT06407973|ACTIVE_COMPARATOR|Standard Medical Care (SMC)|Standard Medical Care with Latanoprost and an adjunctive glaucoma medication at the discretion of the Principal Investigator
62164500|NCT03797417||Disease|patients with vitiligo
62164501|NCT03797417||Healthy Control|healthy control
62341455|NCT00423618|ACTIVE_COMPARATOR|Control arm|Radiotherapy Conventional treatment arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The first 50 Gy in 25 fractions will be given to CTV1 and subsequent 16 Gy in 8 fractions will be delivered to CTV2.
62341456|NCT00423618|EXPERIMENTAL|Research arm|Radiotherapy Research arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The 66Gy in 33 fractions will be delivered to CTV2 alone. No attempt will be made to include drain/biopsy sites or the surgical scar.
62341457|NCT05217992||Carriers or potential carriers of hemophilia A and B|All obligate and potential carriers among families of patient with hemophilia followed at the hemophilia treatment center of the Cliniques universitaires Saint-Luc, Brussels. Belgium
62341458|NCT04389398|EXPERIMENTAL|Pocket compression fixation belt|Pocket compression belt is used to compress the bleeding vessels and reduce bleeding after implantation.
62341459|NCT04389398|ACTIVE_COMPARATOR|Sand bag compression|Sand bag compression is used to compress the bleeding vessels and reduce bleeding after implantation.
62164502|NCT01876719|EXPERIMENTAL|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
62164503|NCT01876719|EXPERIMENTAL|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
62164504|NCT01876719|EXPERIMENTAL|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
62164505|NCT01876719|PLACEBO_COMPARATOR|Placebo|Placebo, QD for 7 weeks
62341460|NCT04858880|EXPERIMENTAL|Continued salvage radiotherapy + lymph node irradiation (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present) + the addition of lymph node irradiation (46 Gy/23 fractions) given in sequence. Total number of fractions: 35 + 8 = 43 with 15 of the lymph node irradiation fractions delivered concomitant with the prostate bed/local recurrence irradiation. These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
62498315|NCT05215054|EXPERIMENTAL|Gana V versus Sculptra|Participants will receive both Gana V and Sculptra: one in each nasolabial folds
62498316|NCT06678217|EXPERIMENTAL|CPT only|Participants go through the cold pressor test.
62498317|NCT06678217|EXPERIMENTAL|CPT and Stroop|Participants go through the Stroop task before the cold pressor test.
62498318|NCT04033484|ACTIVE_COMPARATOR|Biological Mesh|Using biological mesh to recnostruct the pelvic floor following ELAPE
62498319|NCT04033484|EXPERIMENTAL|Biological Mesh With Negative Pressure Wound Therapy|Using biological mesh compined with negative pressure wound therapy to recnostruct the pelvic floor following ELAPE
62498320|NCT03065231|ACTIVE_COMPARATOR|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
62498321|NCT03065231|ACTIVE_COMPARATOR|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
62498322|NCT02275754|EXPERIMENTAL|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
62498323|NCT02275754|ACTIVE_COMPARATOR|PN only|Patient Navigation ONLY. Participants assigned to this group will be assisted by the patient navigator with their health-related needs. Navigation will occur ONLY on contact with navigators initiated by the study participants.
62498324|NCT03179748||turoctocog alfa|Patients with haemophilia A
62698854|NCT03566732||Bereaved relatives|Bereaved relatives after cancer deaths in hospitals
62498325|NCT02287636|EXPERIMENTAL|Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)|Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
62736549|NCT04808726|OTHER|Control Group|standard breastfeeding education and counseling service to another group
61949253|NCT01216423||Incidence of recent stroke in patients with PFO|
62498326|NCT01816789|ACTIVE_COMPARATOR|"Group A: age"|Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.
62498327|NCT01816789|EXPERIMENTAL|"Group B: nomogram"|Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.
62498328|NCT05523960|EXPERIMENTAL|NBP group|Patients allocated to NBP were instructed to not prepare the bowel.
62498329|NCT05523960|OTHER|MBP group|Patients allocated to MBP were instructed by the study nurse to prepare their bowel mechanically by drinking 3\~4L of polyethylene glycol (Polyethylene Glycol Electrolytes Powder 68.56g; Shenzhen, China) with water before 6pm in the evening the day before the surgery.
62498330|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
62498331|NCT05960422|ACTIVE_COMPARATOR|Popliteal Sciatic Nerve Block|Patients are in the group undergoing popliteal sciatic block
62498332|NCT05960422|ACTIVE_COMPARATOR|Adductor Canal Block|Patients are in the group undergoing popliteal sciatic block + adductor canal block
62498333|NCT05421195|EXPERIMENTAL|Glucocorticoid therapy with olfactory training|olfactory training plus oral Glucocorticoid
62498334|NCT05421195|OTHER|Olfactory training|Olfactory training only
62498335|NCT01525680|ACTIVE_COMPARATOR|Prolonged Exposure therapy with Hydrocortisone|
62498336|NCT01525680|PLACEBO_COMPARATOR|Prolonged Exposure therapy with placebo|
62498337|NCT01909115|ACTIVE_COMPARATOR|1000 IU of Vitamin D Daily|Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
62498338|NCT01909115|EXPERIMENTAL|4000 IU of Vitamin D Daily|Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.
62498339|NCT03729557||Kidney Donors|
62498340|NCT03729557||Control group|
62498341|NCT05991362|EXPERIMENTAL|SAD:100mg|Participants received single PO dose of GFH312 100 mg.
62498342|NCT05991362|EXPERIMENTAL|SAD:200mg|Participants received single PO dose of GFH312 200 mg.
62498343|NCT05991362|EXPERIMENTAL|MAD:120mg|Participants received multiple PO doses of GFH312 120 mg for 14 days.
62498344|NCT05991362|PLACEBO_COMPARATOR|Placebo|Participants receiving placebo matching with the GFH312 dose groups
62498345|NCT02386761|EXPERIMENTAL|Single Ascending Dose (SAD)|"* Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg~* Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg~* Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.~In case the actual doses are modified, the number of inhalations will be adapted accordingly."
62498346|NCT02386761|EXPERIMENTAL|Multiple Ascending Dose (MAD)|"* Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo~* Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo~* Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo~Duration 14 days b.i.d."
62498347|NCT01660516||Tea|Black tea ingestion
62498348|NCT05636891|EXPERIMENTAL|Stimus|Treatment: Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
62736550|NCT02628600|EXPERIMENTAL|Prior LAI + Multidrug Regimen|Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR.
62164506|NCT02225340||Controls|
62164507|NCT02225340||Familial hypercholesterolemia|
62498349|NCT05636891|ACTIVE_COMPARATOR|Aranesp|Control: Amgen's Aranesp® 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
62498350|NCT02571309|OTHER|Smartphone app - Asthmatuner|"The app Asthmatuner contains four different modes;~1. Lung function testing with Bluetooth connection of external spirometry~2. Symptom evaluation~3. Actual treatment plan, based om lung function and symptoms~4. Trend views of lung function, symptoms and asthma control"
62498351|NCT02571309|OTHER|Conventional|Conventional treatment and Asthmatuner will be stratified and harmonized into categories of asthma management and current state-of-art at each health care centre. Each group harmonized group will include 43 subjects.
62736551|NCT02628600|EXPERIMENTAL|Prior Multidrug Regimen Alone|Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR.
61949254|NCT01216423||Incidence of recent stroke in patients without PFO|
62498352|NCT04417439||flame burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
62498353|NCT04417439||scald burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
62498354|NCT04417439||electrical burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
62498355|NCT02725164|PLACEBO_COMPARATOR|Uncuffed tracheal tubes|After tracheal intubation with an uncuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
62736552|NCT02148536||HPS-TIPS group|
62736553|NCT03909906|ACTIVE_COMPARATOR|Euphytose®|Euphytose® 2 tablets 3 times per day for 14 days
62498356|NCT02725164|ACTIVE_COMPARATOR|Cuffed tracheal tubes|After tracheal intubation with a cuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
62498357|NCT01928615|EXPERIMENTAL|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
62698855|NCT02853136|EXPERIMENTAL|3 mg BI 409306 [R1]/3 mg BI 409306 + 100 mg Fluvoxamine [T1]|"The subjects were administered 3 milligram \[mg\] BI 409306 Powder for Oral Solution \[PfOS\] single dose for one day in the pilot phase, taken as 6 mL of 0.5 mg/mL BI 409306 solved in 5 mg/mL \[milliLiter\] tartaric acid orally with 240 mL of water after an overnight fast of at least 10h, followed by 3 mg BI 409306 PfOS single dose for one day together with 100 mg Fluvoxamine \[Fevarin®\] film-coated tablet once daily orally with 240 mL of water after an overnight fast of at least 10h.~Prior to the combined treatment, Fluvoxamine was given for 3 days: 50 mg twice daily on Day -3, followed by 100 mg bid on Day -2 and Day -1.~There was a washout of at least 3 days after administration of BI 409306 in R1."
62736554|NCT03909906|PLACEBO_COMPARATOR|Placebo|Matched placebo 2 tablets, 3 times per day for 14 days
61949255|NCT01963273|EXPERIMENTAL|pilonidal sinuses|All consecutive patients with diagnosis of chronic sacrococcygeal pilonidal sinus will be screened for the enrollment in our study.
61949256|NCT01476956||Rheumatoid Arthritis|
61949257|NCT04147702|EXPERIMENTAL|Experimental Group: Balance analysis|fifty dancers will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
61949258|NCT04147702|ACTIVE_COMPARATOR|Control Group:Balance Analysis|fifty healthy subjects will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
61949259|NCT03484377|EXPERIMENTAL|Anodal tDCS|The anodal tDCS electrode will be placed over the area corresponding to the right DLPFC (F4 of the EEG10-20 international system). The anodal tDCS condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
61949260|NCT03484377|SHAM_COMPARATOR|Sham tDCS|The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
61949261|NCT00876057|ACTIVE_COMPARATOR|TH|Total hysterectomy
61949262|NCT00876057|ACTIVE_COMPARATOR|SH|Subtotal hysterectomy
61949263|NCT00395681|ACTIVE_COMPARATOR|propofol|propofol 200 mg versus 350 mg
61949264|NCT00395681|ACTIVE_COMPARATOR|Propofol|Propofol 350 mg versus 200 mg
61949265|NCT01586065|EXPERIMENTAL|CGM in adolescents with poorly-controlled T1D|Adolescents with poorly controlled type 1 diabetes on insulin pumps were admitted to the clinical research center (CRC) and a continuous glucose sensor was inserted. Sensor glucose (SG) values were compared to plasma glucose measured at least hourly using Yellow Springs Instrument's (YSI) glucose analyzer. SG rather than YSI was used for treatment decisions unless YSI was \<70 mg/dL or specific criteria indicating SG and YSI were very discordant were met.
61949266|NCT01761630||Severe Asthma|"We will classify subjects as having severe asthma using the following stages:~Stage 1: Subjects must have asthma which requires treatment with high-dose inhaled corticosteroids plus a 2nd controller, or systemic corticosteroids with or without a 2nd controller to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy~Stage 2: Assess for uncontrolled asthma by any one of the following criteria:~1. Poor symptom control evidenced by an Asthma Control Questionnaire score consistently \> 1.5 or an Asthma Control Test Score \< 20 or not well controlled by NAEPP or GINA asthma treatment guidelines~2. Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids (\> 3 days each) in the previous 12 months~3. Serious exacerbations reflected by at least one hospitalization, ICU stay or mechanical ventilation in the previous 12 months~4. Presence of airflow limitation evidenced by FEV1 \< 80% predicted (in the face of reduced FEV1/FVC)"
61949267|NCT01761630||Non-severe Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
62164508|NCT05148247|EXPERIMENTAL|PRPP Intervention|This baseline phase will be 3, 5 or 7 days, and intervention phase starts immediately after baseline with 45-60 minutes PRPP Intervention 3 times a week for 3 weeks.
61949268|NCT01761630||Healthy Control|"The purpose of the SARP Control Sub-study is to generate reference data for outcomes measured in biospecimens collected from asthmatic subjects enrolled in the SARP Longitudinal Protocol.~Seven healthy subjects between the ages of 18-65 will be enrolled."
61949269|NCT03820141|EXPERIMENTAL|Durvalumab + Trastuzumab + Pertuzumab|Durvalumab, trastuzumab, and pertuzumab will be administered on Day 1 every 3 weeks for 6 cycles. Trastuzumab will be administered as 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg IV. Pertuzumab will be administered as 840 mg IV loading dose, followed by 420 mg. Durvalumab will be administered at a fixed dose of 1120 mg IV.
62341461|NCT04858880|ACTIVE_COMPARATOR|Continued salvage radiotherapy (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
62341462|NCT04858880|NO_INTERVENTION|Continued salvage radiotherapy (responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as responders according to weekly PSA measurements during the first 4 weeks of radiotherapy, and are not followed according to the study protocol, follow up according to clinical practice.
62341463|NCT00301028|EXPERIMENTAL|Cetuximab + Carboplatin/Paclitaxel|Cetuximab beginning weekly dose 400 mg/m\^2 intravenous (IV), and 250 mg/m\^2 weeks 2-6; Weekly Carboplatin area under the curve (AUC) 2 and Paclitaxel 135 mg/m\^2 for 6 courses.
62341464|NCT02566252|EXPERIMENTAL|PUL-042|PUL-042 Inhalation Solution
61949270|NCT00678093|EXPERIMENTAL|SNAG|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
61949271|NCT05720208|EXPERIMENTAL|Therapeutic Arm|
62498358|NCT01928615|EXPERIMENTAL|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
62498359|NCT03895151|EXPERIMENTAL|Milk supplementation|"Children will receive 130 ml fresh milk, 6 days/week for 20 weeks (January-June 2019).~Milk will be provided and delivered by appointed supplier directly to school. Milk will be distributed with name of the student on the bottle - during break time.~Subjects must be consumed with supervision of the teacher at school during the break.~If they can not finish the milk at once, they can store it in the provided cool box. Student then can consume it again before they go home. Teacher have to record the remaining milk in each bottle that corresponds to every child name and record it in the provided form.~Prior to holiday, student will be given the milk according to school leave days.~Enumerators should collect the form every 3 days and make a recap in the provided form."
62498360|NCT03895151|EXPERIMENTAL|Food Based Recommendation (FBR) nutrition education|FBR group will received nutrition education delivered by trained teacher under the supervision of researcher/research assistant once a week. Those who received nutrition education is not only the recruited subjects but also includes their classmates.
62498361|NCT03895151|NO_INTERVENTION|Control|Control group will receive standard nutrition education
62498362|NCT06418243||Children planned to get an MRI or CT scan|Children with a pelvic or retroperitoneal tumor requiring an MRI or CT scan for a possible surgical intervention
61949272|NCT05720208|SHAM_COMPARATOR|Sham Arm|
61949273|NCT05468060|EXPERIMENTAL|PA1010 5mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 5 mg of PA1010 tablets or 5mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
61949274|NCT05468060|EXPERIMENTAL|PA1010 10mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 10mg of PA1010 tablets or 10mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
61949275|NCT05468060|EXPERIMENTAL|PA1010 20mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 20mg of PA1010 tablets or 20mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
61949276|NCT05468060|EXPERIMENTAL|PA1010 30mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 30mg of PA1010 tablets or 30mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
62498363|NCT05079841|EXPERIMENTAL|Intrapartum nipple stimulation|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or stimulate by hand (intervention) to induce labor.
62498364|NCT05079841|ACTIVE_COMPARATOR|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor.
62498365|NCT06678490||Drug Eluting SUPPORT C PTCA balloon catheter|The Drug Eluting SUPPORT C PTCA balloon catheter is indicated for use in patients with symptomatic ischaemic coronary heart disease due to discrete de novo lesions or restenosis of the coronary arteries as well as arterial or venous bypasses.
62498366|NCT05435833|EXPERIMENTAL|Group I (glossopharyngeal nerve block group)|bilateral ultrasound guided GPN block will be performed after induction of anesthesia and pre incisional by an experienced anesthesiologist
61949277|NCT05468060|EXPERIMENTAL|PA1010 45mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 45mg of PA1010 tablets or 45mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
61949278|NCT05468060|EXPERIMENTAL|PA1010 60mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 60mg of PA1010 tablets or 60mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
62498367|NCT05435833|NO_INTERVENTION|Group II(Control group)|general anesthesia alone (no block)
62698856|NCT02853136|EXPERIMENTAL|3 mg BI 409306 + 100 mg Fluvoxamine [T1]/3 mg BI 409306 [R1]|"The subjects were administered 3 mg BI 409306 PfOS single dose for one day in the pilot phase together with 100 mg Fluvoxamine \[Fevarin®\] film-coated tablet once daily orally with 240 mL of water after an overnight fast of at least 10h, followed by 3 mg BI 409306 PfOS single dose for one day orally with 240 mL of water after an overnight fast of at least 10h.~Prior to the combined treatment, Fluvoxamine was given for 3 days: 50 mg twice daily on Day -3, followed by 100 mg bid on Day -2 and Day -1.~There was a washout of at least 6 days after combined administration of BI 409306 and Fluvoxamine in T1."
62698857|NCT02853136|EXPERIMENTAL|10 mg BI 409306 [R2]/10 mg BI 409306 + 100 mg Fluvoxamine [T2]|"The subjects were administered 10 mg BI 409306 film-coated tablet single dose for one day in the main phase orally with 240 mL of water after an overnight fast of at least 10h, followed by 10 mg BI 409306 film-coated tablet single dose for one day together with 100 mg Fluvoxamine \[Fevarin®\] film-coated tablet once daily orally with 240 mL of water after an overnight fast of at least 10h.~Prior to the combined treatment, Fluvoxamine was given for 3 days: 50 mg twice daily on Day -3, followed by 100 mg bid on Day -2 and Day -1.~There was a washout of at least 3 days after administration of BI 409306 in R2."
62736555|NCT03267979|OTHER|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
61949279|NCT05468060|EXPERIMENTAL|PA1010 10mg before and after meals|Ten subjects will be administered 10mg PA1010 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA1010 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.
62498368|NCT02004691|PLACEBO_COMPARATOR|Placebo|Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
62498369|NCT02004691|EXPERIMENTAL|Olipudase alfa|Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
62498370|NCT03647917|EXPERIMENTAL|Platelet Rich Plasma, Left face and hands|"Subjects will receive PRP on left half of face and saline solution on right half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of left hand and saline solution on dorsal part of right hand through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
62498371|NCT03647917|EXPERIMENTAL|Platelet Rich Plasma, Right face and hands|"Subjects will receive PRP on right half of face and saline solution on left half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of right hand and saline solution on dorsal part of left hand, through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
62498372|NCT05740215|EXPERIMENTAL|F520 combined with lenvatinib|"F520:~F520 (200 mg) administered intravenously (IV) on Day 1 of each 21-day cycle in the phase Ib and II studies until progressive disease, unacceptable toxicity or ending treatment for other reasons. \[Time Frame: up to 2 years post infusion\]~Lenvatinib:~In the phase Ib study, three dose groups of 20 mg, 16 mg and 12 mg lenvatinib were designed. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT. The designated dose of lenvatinib administered orally once daily (QD) according to the assigned dose group.~In the phase II study, lenvatinib administered orally once daily (QD) according to recommended phase II dose (RP2D) obtained in phase Ib study."
62498373|NCT04776005||Patients with malignant disease undergoing chemotherapy|Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
62498374|NCT04776005||Patients with malignant disease undergoing chemotherapy + immunotherapy|Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
61949280|NCT05468060|EXPERIMENTAL|PA1010 10mg after and before meals|Ten subjects will be administered 10mg PA1010 within 30 minutes after the high-fat meal in the first cycle, and then will be administered 10mg PA1010 after overnight fasting 10 hours in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.
62698858|NCT02853136|EXPERIMENTAL|10 mg BI 409306 + 100 mg Fluvoxamine [T2]/10 mg BI 409306 [R2]|"The subjects were administered 10 mg BI 409306 film-coated tablet single dose for one day in the main phase together with 100 mg Fluvoxamine \[Fevarin®\] film-coated tablet once daily orally with 240 mL of water after an overnight fast of at least 10h, followed by 10 mg BI 409306 single dose film-coated tablet for one day orally with 240 mL of water after an overnight fast of at least 10h.~Prior to the combined treatment, Fluvoxamine was given for 3 days: 50 mg twice daily on Day -3, followed by 100 mg bid on Day -2 and Day -1.~There was a washout of at least 6 days after combined administration of BI 409306 and Fluvoxamine in T2."
61949281|NCT00696800|EXPERIMENTAL|150 µg Corifollitropin Alfa|Participants received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (org 36286) on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles \>= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
61949282|NCT00696800|ACTIVE_COMPARATOR|200 IU recFSH|Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles \>= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
61949283|NCT03685123|EXPERIMENTAL|PA-REC|After achieving clinically significant weight loss, participants will exercise at the minimum physical activity recommendations
61949284|NCT03685123|EXPERIMENTAL|WM-REC|After achieving clinically significant weight loss, participants will exercise at the weight maintenance recommendations
61949285|NCT03685123|EXPERIMENTAL|Weight Loss Phase|All participant prior to randomization will undergo a weight loss phase. This will include weight loss with Optifast and supervised aerobic exercise training (2-3 times per week). The goal of participants are to lose 7% of body weight. After the weight loss phase, participants will be randomized to the study arms (PA-REC, WM-REC)
61949286|NCT06175455||control|Healthy, age and sex matched controls
61949287|NCT06175455||Long Covid|patients who experienced persistent respiratory symptoms four weeks after contracting COVID-19
61949288|NCT02059408|NO_INTERVENTION|Usual Care|The patients in this arm will receive normal primary care.
61949289|NCT02059408|ACTIVE_COMPARATOR|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm recommends using creatinine, cystatin C and albuminuria for detection and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage.
62140668|NCT06699212|ACTIVE_COMPARATOR|Pembrolizumab or pembrolizumab + chemotherapy (Control)|"Patients in the control arm will receive physician's choice SOC. Patients randomized to SOC may only be treated with one of the following SOC options:~1. Pembrolizumab alone~2. Pembrolizumab + platinum (cisplatin or carboplatin) + 5-fluorouracil (5-FU) or taxane (paclitaxel or docetaxel)~Pembrolizumab: 200 mg Q3W IV infusion over 30 minutes for the first 6 cycles. After the first 6 cycles, pembrolizumab administration can be switched from 200 mg Q3W to 400 mg Q6W at the investigator's discretion.~Cisplatin or carboplatin: AUC 5 mg/mL/min or 100 mg/m\^2 IV infusion on Day 1 of each cycle, Q3W for up to 6 cycles~5-FU: 1000 mg/m\^2 IV infusion per day from Days 1-4 of each cycle, Q3W for up to 6 cycles~Paclitaxel: At investigator's choice, 100 mg/m\^2 IV infusion on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for up to 6 cycles~Docetaxel: 75 mg/m\^2 IV infusion on Day 1 of each cycle, Q3W for up to 6 cycles"
61949290|NCT02059408|ACTIVE_COMPARATOR|Screen-Educate and Intensify Treatment|Education and treatment program to improve blood pressure control among hypertensive non-diabetic persons. The Screen-Educate and Intensify Treatment adds a pharmacist-led CKD management program and attempts to improve BP management and patient-centered outcomes among persons with newly stratified higher risk CKD based on creatinine, cystatin c and albuminuria.
61949291|NCT00767962|OTHER|1|talc pleurodesis under medical thoracoscopy
61949292|NCT00767962|OTHER|2|pleurodesis under video-assisted thoracoscopy surgery
61949293|NCT03565978|EXPERIMENTAL|BAMA solution|This group will use BAMA solution. This is an digital solution used for cardiac post-discharge management. It is an application installed on a tablet. This arm will use this application and also have usual outpatient follow up.
61949294|NCT03565978|NO_INTERVENTION|Usual care|Not using the application installed on the tablet. Usual outpatient follow up.
61949295|NCT05919589||Parents and Carers|Parents and carers of children with special healthcare needs
61949296|NCT05919589||Staff and professionals|Staff and professionals involved (either directly or indirectly in healthcare and other services) with children with special healthcare needs
62498375|NCT04776005||Patients with malignant disease undergoing immunotherapy|Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
61949297|NCT03298906|EXPERIMENTAL|Esketamine + Ticlopidine|Participants will self-administer one 14 milligram (mg) spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg (Treatment A) in Treatment Period 1. After that participants will receive 250 mg of ticlopidine tablets orally twice daily on Day -9 through Day 1, and will self-administer one 14 mg spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later in the morning of Day 1, a total dose of 56 mg (Treatment B) in Treatment Period 2. A washout period of greater than or equal to (\>=)10 days will separate the esketamine self-administrations between 2 treatment periods.
61949298|NCT02980783|EXPERIMENTAL|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine was injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection was determined by the investigator. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine was injected on Day 14.
61949299|NCT03925857|EXPERIMENTAL|Allocetra-OTS|Standard of Care (SOC) Drug: One dose Allocetra-OTS 140 140x106 /kg
61949300|NCT03925857|EXPERIMENTAL|Allocetra-OTS Two doses|Standard of Care (SOC) Drug: Two doses Allocetra-OTS 140 140x106 /kg
61949301|NCT03267017||Patient scheduled for surgery under general anesthesia|
61949302|NCT06012474|EXPERIMENTAL|inspiratory muscle training group|30 patients will receive inspiratory muscle training by Power breath device once daily for 7 days.
62498376|NCT04776005||Patients with malignant disease treated with targeted therapies|Patients with malignant disease treated with targeted therapies within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
61949303|NCT06012474|ACTIVE_COMPARATOR|diaphragmatic breathing exercise group|20 patients will receive program of diaphragmatic breathing exercise by incentive spirometer once daily for 7 days.
61949304|NCT04437563|NO_INTERVENTION|Control|('Standard' care). No intervention offered.
61949305|NCT04437563|EXPERIMENTAL|Intervention|('Standard' care +) The 'Herlev Hospital Empowerment of Relatives through More and Earlier information Supply' (HERMES) intervention.
61949306|NCT00981370|OTHER|Single Arm study|Single Arm study, all subjects to receive study medication, deferasirox (Exjade).
61949307|NCT01577680|EXPERIMENTAL|Moderate Hepatic Impairment|Approximately 9 subjects will complete each of these treatment arms
61949308|NCT01577680|EXPERIMENTAL|Matched Healthy Volunteers|Matched to the moderate hepatic impairment subjects based on gender, ethnicity, body mass index (+/-15%) and age (+/-5 years) Approximately 9 subjects will complete each of these treatment arms
61949309|NCT04310046|OTHER|PCI before TAVI|PCI is performed within 1-45 days before TAVI.
61949310|NCT04310046|EXPERIMENTAL|PCI after TAVI|PCI is performed within 1-45 days after TAVI.
61949311|NCT00492531|EXPERIMENTAL|Sildenafil|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo.
61949312|NCT00492531|PLACEBO_COMPARATOR|Placebo|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo
61949313|NCT04721171|ACTIVE_COMPARATOR|Intervention group|The Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
61949314|NCT04721171|SHAM_COMPARATOR|Placebo Group|The sham is similar in appearance to the Bridge device but does not deliver any electrical stimulation and is a sham that is designed to look identical to the Bridge device. It is placed on the external ear at the beginning of the study and removed by the patient after 5 days.
61949315|NCT04232254|ACTIVE_COMPARATOR|Animal Protein - Skewed Distribution|Animal-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
61949316|NCT04232254|EXPERIMENTAL|Plant Protein - Skewed Distribution|Plant-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
61949317|NCT04232254|EXPERIMENTAL|Animal Protein - Balanced Distribution|Animal-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
62140669|NCT05989841|EXPERIMENTAL|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
62164509|NCT05855499|EXPERIMENTAL|Plasma (CAPT)|Conventional wound treatment according to S3 guideline, 3 visits weekly for 4 weeks, additive plasma treatment during each visit.
62341465|NCT02566252|EXPERIMENTAL|Cromolyn sodium|Pre-Treatment with cromolyn sodium followed by PUL-042 Inhalation Solution Administration
62341466|NCT02566252|EXPERIMENTAL|Albuterol sulfate|Pre-Treatment with albuterol sulfate followed by PUL-042 Inhalation Solution Administration
61949318|NCT04232254|EXPERIMENTAL|Plant Protein - Balanced Distribution|Plant-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
61949319|NCT01851460|EXPERIMENTAL|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
61949320|NCT02538029|EXPERIMENTAL|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
62341467|NCT00955292|EXPERIMENTAL|Quarfloxin|
62498377|NCT04776005||Patients with malignant disease undergoing radiotherapy|Patients with malignant disease undergoing radiotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
62498378|NCT01386125|EXPERIMENTAL|Mometasone Furoate Nasal Spray (MFNS)|Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
61949321|NCT02538029|ACTIVE_COMPARATOR|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
61949322|NCT04850820|EXPERIMENTAL|Novel essential amino acid supplementation (EAA+)|Arm will investigate the effect of a novel essential amino acid-based formula (essential amino acids enriched with active botanical compounds; EAA+) developed by Iovate Health Sciences International Inc. on post-exercise anabolism. The formulation was recently granted a Natural Product Number (NPN: 80087022) and approved by the Natural and Non-prescription Health Products Directorate of Health Canada.
62140670|NCT05989841|ACTIVE_COMPARATOR|Relaxation|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
62341468|NCT06091189|EXPERIMENTAL|Relevant Stressor Condition with No Ethanol|Participants complete the Relevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their sexuality has developed over time. Participants are then assigned to receive a placebo priming beverage (with no ethanol) to consume over 10 minutes. Participants will consume the initial placebo drink, which is intended as a priming cue. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional placebo cocktails, which do not contain ethanol.
62498379|NCT01386125|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo nasal spray BID for 16 weeks
62498380|NCT03974893||Vegetarian Diet|Includes children following a vegetarian diet.
62498381|NCT03974893||Non-Vegetarian Diet|Includes children following a non-vegetarian diet.
62498382|NCT06678113|EXPERIMENTAL|Active treatment|The patient will receive active treatment in a dose escalation manner increasing the dose every 3 days dependent on safety and efficacy
62498383|NCT03476681|EXPERIMENTAL|NEO-201 in combination with pembrolizumab|Subjects will receive 3 doses NEO-201 in combination with one dose of pembrolizumab in a 42 day cycle. This course will be repeated in the absence of disease progression or unacceptable toxicity.
62498384|NCT01065792||1|Patients with HIV-1 infection taking Stocrin
62698859|NCT03528733|EXPERIMENTAL|Multi-Energy Detector|Multi-Energy Digital Radiography Detector System
62698860|NCT03817229|ACTIVE_COMPARATOR|Control Group|mHealth education module and automated digital reminders
61949323|NCT04850820|ACTIVE_COMPARATOR|Branched-chain amino acid supplementation (BCAA)|Arm will used a branched-chain amino acid supplement developed by Iovate Health Sciences International Inc. to compare with the experimental arm after exercise.
61949324|NCT04850820|PLACEBO_COMPARATOR|Isocaloric carbohydrate supplementation|Carbohydrate supplement that is isocaloric to the EAA+ supplement and designed to function as a placebo to the experimental arm after exercise.
61949325|NCT04850820|OTHER|Rested control|Carbohydrate supplement that is isocaloric to the EAA+ supplement but consumed at rest to serve as the baseline control
61949326|NCT00384657|EXPERIMENTAL|Group I|iv iron sucrose
61949327|NCT00384657|NO_INTERVENTION|Group II|Patients will receive conventional treatment of Chronic Heart Failure.
61949328|NCT03011710|EXPERIMENTAL|E-cigarette with nicotine|Nicotine level: 6 mg/ml
61949329|NCT03011710|EXPERIMENTAL|E-cigarette without nicotine|Nicotine level: 0 mg/ml
61949330|NCT03011710|EXPERIMENTAL|Conventional cigarette|Nicotine content: 0,5mg
61949331|NCT03011710|PLACEBO_COMPARATOR|Cigarette tip|Placebo device
61949332|NCT05232045||Automated urinary output collection system group (tight monitoring of urine output)|
61949333|NCT05232045||Manual urinary output collection system group (routine monitoring of urine output)|
61949334|NCT06114160||pregnant women|Pregnant women between 20 and 41 weeks of amenorrhoea, primiparous.
62140671|NCT02290158|ACTIVE_COMPARATOR|Orthodontic finishing|Patients receiving a complete orthodontic finishing protocol according to the ABO-OGS
62140672|NCT02290158|NO_INTERVENTION|No orthodontic finishing|Patients receiving orthodontic treatment without the finishing protocol according to the ABO-OGS
62140673|NCT05685511|NO_INTERVENTION|Usual Care|
62498385|NCT03269955|EXPERIMENTAL|application of TachoSil®|Fibrinogen/thrombin-coated collagen patch (TachoSil®) and fibrin glue are applied to the pancreas anastomosis site in pancreatoduodenectomy
62498386|NCT03269955|NO_INTERVENTION|control|Only fibrin glue alone is applied to the pancreas anastomosis site in pancreaticoduodenectomy.
62498387|NCT01362296|EXPERIMENTAL|GSK1120212|Oral once daily
62498388|NCT01362296|ACTIVE_COMPARATOR|docetaxel|IV once every 3 weeks
62498389|NCT01647997|EXPERIMENTAL|study 1a|whole body lactate production after bacterial endotoxin challenge
62498390|NCT01647997|NO_INTERVENTION|study 1b|basal whole body lactate production
62498391|NCT01647997|EXPERIMENTAL|study 2a|muscle lactate concentration after bacterial endotoxin challenge
62498392|NCT01647997|NO_INTERVENTION|study 2b|basal muscle lactate concentrations
62498393|NCT02625337|ACTIVE_COMPARATOR|Pembrolizumab mono|Pembrolizumab monotherapy
62498394|NCT02625337|EXPERIMENTAL|Pembrolizumab with dabrafenib+trametinib short|Pembrolizumab combined with a short scheme of dabrafenib+trametinib
61949335|NCT05469581|EXPERIMENTAL|Intervention group|"Interventions to be administered:~A set of preventive interventions to improve adherence in vulnerable elderly people (We will not administer any medications in the research):~* reviewing the list of medications, delivery of an ordered list of medications and checking medication regimen understanding;~* delivering a leaflet on the correct/safe taking of medication, discussion, explanation, and verification of understanding of the content;~* a counseling about the importance of adherence;~* handing over the medication dispenser (if the elderly person does not have one yet),~* delivering of a personal medication card, which shows the timeline of taking prescribed medication."
62498395|NCT02625337|EXPERIMENTAL|Pembrolizumab with dabrafenib+trametinib intermediate|Pembrolizumab combined with an intermediate scheme of dabrafenib+trametinib
62498396|NCT02625337|EXPERIMENTAL|Pembrolizumab with dabrafenib+trametinib long|Pembrolizumab combined with a long scheme of dabrafenib+trametinib
62498397|NCT01499160|EXPERIMENTAL|HER2-positive or negative|Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.
61949336|NCT05469581|NO_INTERVENTION|Control group|"Interventions to be administered:~- review of the list of medication, delivery of an ordered list of medication, and counseling"
61949337|NCT01041326|EXPERIMENTAL|Leve 1 Radiation|Subjects in Group 1 will receive 39.6 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
62498398|NCT03245437|EXPERIMENTAL|Oxytocin with SCST|Oxytocin with SCST (active condition)
62498399|NCT03245437|SHAM_COMPARATOR|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
62498400|NCT03245437|PLACEBO_COMPARATOR|Placebo with SCST|Administration of Placebo with active psychosocial treatment
62498401|NCT03245437|PLACEBO_COMPARATOR|Placebo with HM|Administration of Placebo with control psychosocial treatment
62498402|NCT01475487|ACTIVE_COMPARATOR|Cricothyrotomy using Digital Palpation|Group-1 will perform Cricothyrotomy using conventional digital palpation technique
62498403|NCT01475487|EXPERIMENTAL|Ultrasound guided cricothyrotomy group|Group-2 Ultrasound guided cricothyrotomy
62140674|NCT05685511|EXPERIMENTAL|Intervention Bundle (Behavioral Activation + Medication Optimization)|"* Behavioral activation (BA) will span across 3 months postoperatively \& will begin pre-operatively, with sessions approximately every two weeks. After discharge, the behavioral intervention will continue for 10-12 sessions, or out to approximately 3 months postoperatively.~* Medications will be reviewed \& optimized by a team of interventionists including a psychiatrist, pharmacologist, \& pharmacists. While the participant is in-hospital, the interventionist's role will include coordinating with the hospital team to ensure that medication changes that were introduced preoperatively are maintained in-house \& that no new inappropriate medications are initiated. After discharge, \& up to approximately 3 months postoperatively, the interventionist will ensure that medication changes are reconciled during transitions of care. The interventionists will ensure the agreed-upon changes are implemented, or an alternative course of action is justified."
62140675|NCT00853255|EXPERIMENTAL|1|Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
62140676|NCT03615612|OTHER|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
62140677|NCT03615612|OTHER|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
62498404|NCT00640393|ACTIVE_COMPARATOR|Part 1 - Etanercept|All participants received etanercept 50 mg twice a week for 12 weeks.
62498405|NCT00640393|ACTIVE_COMPARATOR|Part 2 - Etanercept and nbUVB|Participants who did not reach a 90 percent reduction in psoriasis area and severity index (PASI-90) after 12 weeks and were randomized to the narrow band ultra violet B (nbUVB) group. They received nbUVB treatments three times a week and 50 mg Etanercept once per week.
62498406|NCT00640393|ACTIVE_COMPARATOR|Part 2 - Etanercept|Participants who did not reach PASI-90 after 12 weeks and were randomized to the Etanercept group. They received 50 mg Etanercept once per a week.
62498407|NCT01351363|EXPERIMENTAL|Electrical pain threshold measrement patients|
62498408|NCT01449409|NO_INTERVENTION|Usual care|
62498409|NCT01449409|EXPERIMENTAL|Real-time asthma care outreach|
62498410|NCT04080999|EXPERIMENTAL|r-TMS Group|"r-TMS Parameters International 10/20 system for the location of the target area (non-lesioned left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
62498411|NCT04080999|SHAM_COMPARATOR|Sham Group|Sham stimulation and Visual scanning training
62498412|NCT01526135|ACTIVE_COMPARATOR|Arm A GEMCITABINE|Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
62498413|NCT01526135|EXPERIMENTAL|Arm B mFOLFIRINOX|"Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
62498414|NCT01137734|EXPERIMENTAL|Valtech Cardinal Mitral Annuloplasty Ring|All subjects enrolled in the study are implanted with the Valtech Cardinal Mitral Annuloplasty ring.
62498415|NCT00344045|ACTIVE_COMPARATOR|A|
62498416|NCT00344045|PLACEBO_COMPARATOR|B|
62498417|NCT03426540|EXPERIMENTAL|Conbercept|intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery
62498418|NCT03426540|NO_INTERVENTION|control group|Pars plana vitrectomy alone
62736556|NCT04701853|EXPERIMENTAL|Specific abdominal muscle training|Specific abdominal muscle training which is introduced preoperatively and performed the first year after surgery
61949338|NCT01041326|EXPERIMENTAL|Level 2 Radiation|Subjects in Group 2 will receive 45 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
62736557|NCT04701853|ACTIVE_COMPARATOR|Usual care treatment|No specific abdominal muscle training
61949339|NCT01041326|EXPERIMENTAL|Level 3 Radiation|Subjects in Group 3 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 50.4 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
62498419|NCT06359275|EXPERIMENTAL|PD-1 Combined With chemotherapy + PULSAR.|"Toripalimab: 240 mg/time, intravenously infused over 30 minutes， administered once every three weeks until the treatment termination event specified in the protocol occurs.~Paclitaxel for injection (albumin-bound): 125 mg/m2 and infuse intravenously for at least 30 minutes: D1, 8 days of administration. Every 21 days is a cycle.~Gemcitabine hydrochloride for injection: 1000 mg/m2 for intravenous infusion over 30 minutes: D1, 8 days of administration. Every 21 days is a cycle.~PULSAR: Hypofractionated or stereotactic radiotherapy for the primary pancreatic tumor lesions and surrounding metastatic lymph nodes, 5-10 Gy/time, in conjunction with the chemotherapy cycle, completed once within each chemotherapy cycle, for a total of 5 times."
61949340|NCT01041326|EXPERIMENTAL|Level 4 Radiation|Subjects in Group 4 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 54 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
61949341|NCT00752180|EXPERIMENTAL|Wosulin R|Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
61949342|NCT00752180|ACTIVE_COMPARATOR|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
62736558|NCT00062855|EXPERIMENTAL|Gene Modified Neuroblastoma Cells|Gene modified neuroblastoma cells given as 4 subcutaneous injections over 5 weeks
61949343|NCT03569085|EXPERIMENTAL|Sevoflurane then isoflurane|
61949344|NCT00844181||0|white women
61949345|NCT00844181||1|Black women
61949346|NCT01435278|ACTIVE_COMPARATOR|Glucosanol|2 tablets 3 times a day
61949347|NCT01660061||APS patients|Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
61949348|NCT01660061||Controls|Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
62736559|NCT05007418|EXPERIMENTAL|STI-1492|Four dosing cohorts will be evaluated: Cohort 1 (1 × 10\^5 donor DAR-T cells/kg); Cohort 2 (5 × 10\^5 donor DAR-T cells/kg); Cohort 3 (1 × 10\^6 donor DAR-T cells/kg); Cohort 4 (3 × 10\^6 donor DAR-T cells/kg) where STI-1492 will be administered intravenously once.
61949349|NCT06306820|ACTIVE_COMPARATOR|Control group|Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O.
61949350|NCT06306820|EXPERIMENTAL|Ultrasound group|Patients will receive ultrasound -guided lung recruitment.
61949351|NCT06306820|EXPERIMENTAL|PEEP IND group|Patients will receive individualized positive end-expiratory pressure (PEEP).
61949352|NCT06275347|EXPERIMENTAL|Intervention Very low calorie ketogenic low-fat diet (VLCKLFD)|"Frank ketosis: between 650 and 730 kcal/day in 5 mealtimes. This stage in the nutritional intervention was done during the first 4 weeks.~Mixed Ketosis: in this stage, one intake of commercial preparations was replaced by proteins, which discreetly increased by 100 to 150 Kcal/day. This stage was done during the next 4 weeks."
61949353|NCT06275347|ACTIVE_COMPARATOR|Low-Calorie Diet (LCD)|The usual caloric intake of a balanced LCD is between 1,200 and 1,500 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
61949354|NCT03169543|EXPERIMENTAL|Sleep deprivation|36-hours of total sleep deprivation
61949355|NCT04312581|EXPERIMENTAL|First group (shock wave)|Extracorporeal shock wave therapy
61949356|NCT04312581|ACTIVE_COMPARATOR|Second group (conventional rehabilitation)|conventional rehabilitation
61949357|NCT02917733|EXPERIMENTAL|Radiolabelled LY3039478|Single dose of radiolabelled LY3039478 administered orally.
62140678|NCT01732120|EXPERIMENTAL|Off-clamp partial nephrectomy|Partial nephrectomy will be performed without clamping of the renal blood vessels.
61949358|NCT02234232|EXPERIMENTAL|Aerobic exercise|"Cycling-participants will exercise for 15 minutes at the initial session followed by a weekly increase of 2 min and 3 seconds over 12 weeks. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
61949359|NCT02234232|EXPERIMENTAL|Resistance|"Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
62140679|NCT01732120|NO_INTERVENTION|Traditional partial nephrectomy|Partial nephrectomy will be performed with clamping of the renal blood vessels.
62140680|NCT02377700|EXPERIMENTAL|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
62140681|NCT02520674|OTHER|Glaucoma and Ocular Hypertension|Patients to be examined with both smartphone ophthalmoscopy and slit-lamp biomicroscopy.
62736560|NCT03357029|ACTIVE_COMPARATOR|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
61949360|NCT02234232|EXPERIMENTAL|Combined aerobic and resistance|Participants will complete both the aerobic (cycling) and resistance (ankle weights) exercise prescriptions.
61949361|NCT02234232|ACTIVE_COMPARATOR|Flexibility|"A non-progressive flexibility regimen using a stretch band. Participants will perform 2 sets of the following exercises: seated pelvic tilt, seated calf stretch, supine hamstring stretch, and supine gluteal stretch. Participants will exercise 3 times per week and an intensity of very light (9 on the Borg scale). All exercises will be performed during hemodialysis."
61949362|NCT03421535|ACTIVE_COMPARATOR|Sleeper stretch group|A certified athletic trainer supervised and observed the athlete as he performed the sleeper stretch on his dominant shoulder.
61949363|NCT03421535|EXPERIMENTAL|Opposite SI joint Stretch|A certified athletic trainer supervised and observed the athlete as he performed the SI joint stretch opposite his dominant shoulder.
61949364|NCT02158130||Healthy Living|non exercise healthy living control group
62140682|NCT06052722|OTHER|Individuals with premenstrual syndrome|Level of relationship between premenstrual syndrome and temporomandibular disorders
62498420|NCT03562845||ARM 1-Bad vs Good Clinical Evolution|"This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:~* Patients who, over previous months, have had a bad clinical evolution, in which rejection mechanisms were involved~* Patients with a good and stable clinical evolution~IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences."
62498421|NCT03562845||ARM 2-Stable Renal Transplant Patients|This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
62498422|NCT04519879|EXPERIMENTAL|Arm IA (white mushroom extract)|Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
61949365|NCT02158130||General Health|Exercise Group (8 KKW) One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. We will recruit 1 year post study intervention.
61949366|NCT02158130||Weight Loss|Exercise Group (20 KKW) Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session. We will recruit 1 year post study intervention.
61949367|NCT02195336|EXPERIMENTAL|dMRT, Bevacizumab, Chemotherapy|"dMRT: Magnetic Resonance Tomograph, Baseline, day 8, day 28, day 92, progression/relapse.~Bevacizumab: 7.5mg/kg every 3 weeks for 3 cycles. Standard of care NSCLC first-line chemotherapy, doublets containing paclitaxel and carboplatin are preferred, every 3 weeks for 3 cycles.~Thereafter Bevacizumab 7.5mg/kg every 3 weeks until progression/relapse or unacceptable toxicity."
61949368|NCT01984788|ACTIVE_COMPARATOR|BCX4161|400 mg TID for 28 days
61949369|NCT01984788|PLACEBO_COMPARATOR|Placebo|TID for 28 days
61949370|NCT03424083||1 cohort|adult patients of both sexes (\>18 and \<80 years) with no previous diagnosis or follow up by a pulmonologist, send by a general practitioner to the lung function lab
61949371|NCT05595096|EXPERIMENTAL|spontaneous breathing anesthesia non-intubation group|In this group all the patients with spontaneous breathing anesthesia
61949372|NCT05595096|NO_INTERVENTION|general anesthesia with double-lumen endotracheal intubation group|In this group all the patients with tradition anesthesia with double-lumen endotracheal intubation
61949373|NCT02007993|ACTIVE_COMPARATOR|Group 1|Treatment with a tongue scraper
61949374|NCT02007993|EXPERIMENTAL|Group 2|PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
61949375|NCT02007993|EXPERIMENTAL|Group 4|Tongue scraper + PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
61949376|NCT02007993|EXPERIMENTAL|Group 3|PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
61949377|NCT02007993|EXPERIMENTAL|Group 5|Tongue scraper + PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
61949378|NCT04083196|EXPERIMENTAL|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
61949379|NCT04083196|PLACEBO_COMPARATOR|placebo group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
61949380|NCT02966769||Chemoradiation Group|Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (\>/= 60 Gy) plus Platinum-based Chemotherapy
61949381|NCT02966769||Neoadjuvant treatment plus Surgery Group|Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus \>/= 45Gy) followed by Surgery
61949382|NCT04068935|EXPERIMENTAL|Buddy taping|Buddy taping of the fractured finger to ist neighbouring uninjured finger.
61949383|NCT04068935|ACTIVE_COMPARATOR|splint immobilization|A forearm-based palmar Hand Splint in an intrinsic plus Position, enclosing all fingers without the thumb.
61949384|NCT02633605||First Sense Breast Exam|
61949385|NCT04376463|EXPERIMENTAL|Mood state and aminoacids supplementation|The aim of this study was to analyse the isolated and combined effects of BCAA supplementation and exercise on physical frailty status and mood states in pre-frail institutionalized older women.
61949386|NCT04376463|EXPERIMENTAL|Physical Tests|Through the combination of bcaa supplementation and physical exercise is able to improve the functional capacity of the elderly, through the SPPB test battery, short performance physical battery.
61949387|NCT04376463|EXPERIMENTAL|Psychometrics evaluated|Through the combination of bcaa supplementation and physical exercise, it is able to improve moods and cognition of the elderly.
62140683|NCT06052722|OTHER|Individuals with primary dysmenorrhea|Level of relationship between primary dysmenorrhea and temporomandibular disorders
62140684|NCT05600387|EXPERIMENTAL|Empagliflozin group|subjects in Empagliflozin group take 10mg Empagliflozin 10mg per day
61949388|NCT04376463|EXPERIMENTAL|Fried Scale Phenotype|Primary outcomes include Physical Frailty evaluated according to Fried's Frailty Phenotype2): Shrinking assessed by self-report of unintentional weight loss of four kilograms or more in the last six months; Self-reported exhaustion evaluated by concordance of two questions (7 and 20) of the Center for Epidemiology-Depression (CES-D) scale; Weakness analyzed using the handgrip strength test; Slowness measured by the 4.6 meters walking test; levels of Physical Activity assessed by the (IPAQ).
61949389|NCT00736424||1|Have received bilateral AN stimulation of the anterior nucleus (AN) of the thalamus for epilepsy or are receiving it at the time of enrollment
61949390|NCT03519620|EXPERIMENTAL|SWWSV|Spirometric Values: Forced Vital Capacity; Forced Expiratory Volume in 1 second; Peak Expiratory Flow
61949391|NCT02833363||patients with non-atrophic gastritis|
61949392|NCT02833363||Patients with gastritis|
61949393|NCT02833363||Patients with intestinal metaplasia|
61949394|NCT02833363||Patients with intrepithelial neoplasia|
61949395|NCT02833363||Patients with non-cardia gastric cancer|
61949396|NCT00392860|EXPERIMENTAL|PalmRim Experimental|Participants will have PalmRim installed on their wheelchair.
61949397|NCT00392860|EXPERIMENTAL|Natural-Fix Experiment|Participants will have a Natural-Fit installed on their wheelchair.
61949398|NCT00392860|PLACEBO_COMPARATOR|Handrim Control|Participants in this arm had a new standard handrim installed on their wheelchair as a control.
61949399|NCT01500889|ACTIVE_COMPARATOR|CLI sphincterotomy|Conventional Lateral internal sphincterotomy LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
61949400|NCT01500889|ACTIVE_COMPARATOR|GroupII: V-Y advancement flap|The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide. Figures 1, 2, 3 and 4 illustrate the procedure.
61949401|NCT01500889|ACTIVE_COMPARATOR|TLIS with VY anoplasty|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
61949402|NCT05439941|EXPERIMENTAL|Group 1 (1.6x10^11 total cells of EDP1815, 2 capsules once daily)|EDP1815-207 Cohort 1 participants will receive 1.6x10\^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 1)
62140685|NCT05600387|NO_INTERVENTION|Control group|subjects in Control group will not receive Empagliflozin or other sglt-2 inhibitors
62140686|NCT04826406|EXPERIMENTAL|Camrelizumab+Apatinib|
62140687|NCT02029469|EXPERIMENTAL|HRA Device|Patients who will be treated with Ascension HRA device.
62140688|NCT06263946|OTHER|Essilor® Stellest® spectacle lenses|patients will be asked to wear Essilor® Stellest® spectacle lenses for a full time wear (\>12 hours daily) for 24 months
62140689|NCT02300467|EXPERIMENTAL|NOV120401 (CKD-516 Tablet)|5 to 45 mg/day PO for 5 consecutive days and 2 days off
62140690|NCT02359448|EXPERIMENTAL|Melatonin|Patients will be prescribed and dispensed from pharmacy sustained -release Melatonin (Circadin) 2mg. This will be taken every night for twelve weeks.
62140691|NCT00177177|EXPERIMENTAL|1|L Carnosine
62140692|NCT00177177|PLACEBO_COMPARATOR|2|Placebo
62140693|NCT01972776|EXPERIMENTAL|QBM076 Part 1 Cohort 1|Participants received QBM076 25 mg twice daily (bid) for 14 days.
62140694|NCT01972776|EXPERIMENTAL|QBM076 Part 1 Cohort 2|Participants received QBM076 75 mg bid for 14 days.
62140695|NCT01972776|EXPERIMENTAL|QBM076 Part 1 Cohort 3|Participants received QBM076 150 mg bid for 14 days.
62140696|NCT01972776|PLACEBO_COMPARATOR|Placebo Part 1|Participants in each cohort received matching placebo for 14 days.
62140697|NCT01972776|EXPERIMENTAL|QBM076 Part 2|Participants received QBM076 150 mg bid for 8 weeks.
62140698|NCT01972776|PLACEBO_COMPARATOR|Placebo Part 2|Participants received matching placebo for 8 weeks.
62498423|NCT04519879|ACTIVE_COMPARATOR|Arm IB (clinical observation)|Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.
61949403|NCT05439941|EXPERIMENTAL|Group 2 (6.4x10^11 total cells of EDP1815, 2 capsules once daily)|EDP1815-207 Cohort 2 participants will receive 6.4x10\^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 2)
61949404|NCT05439941|EXPERIMENTAL|Group 3 (8.0x10^10 total cells of EDP1815, 1 capsule once daily)|EDP1815-207 Cohort 4 participants will receive 8.0x10\^10 total cells of EDP1815 in EDP1815-208 administered as 1 capsule once daily. (Group 3)
62140699|NCT00958321|EXPERIMENTAL|3-DCRT|Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT
62140700|NCT06454929|ACTIVE_COMPARATOR|operative group|fixation by k-wires or screws
62140701|NCT06454929|ACTIVE_COMPARATOR|non operative group|fixation by cast immobilisation
62140702|NCT03440086|EXPERIMENTAL|Abdominal Jackson-Pratt drain|Patients in this arm will undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
62140703|NCT03440086|NO_INTERVENTION|Controls|Patients in this arm will not undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
62140704|NCT03618758|EXPERIMENTAL|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
61949405|NCT05777746|EXPERIMENTAL|An online 12 week plant-based dietary program|
61949406|NCT05777746|OTHER|Usual Diet|
62140705|NCT04420078||CA BrS|Symptomatic BrS patients who underwent catheter ablation of the BrS/VF substrate
62140706|NCT05620979|ACTIVE_COMPARATOR|Active Navigation|Active navigation with the study-based financial navigator scheduling four check-in meetings throughout the study with the participant. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.
62140707|NCT05620979|ACTIVE_COMPARATOR|Ad Hoc Navigation|Ad hoc navigation in which participant is provided study-based financial navigator to contact as needed. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.
62140708|NCT05620979|ACTIVE_COMPARATOR|No study-based Navigation|No access to a study-based financial navigator, but access to a national hotline through the Leukemia \& Lymphoma Society. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.
62498424|NCT04519879|EXPERIMENTAL|Arm IIA (white mushroom extract)|Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
62698861|NCT03817229|EXPERIMENTAL|Treatment Group|mHealth education module, automated digital reminders, and individualized adherence feedback (stage 1 SMART). After three months of intervention, the treatment group will be evaluated for responsiveness (\> 95%) based on the 30-day adherence outcome (stage 2 SMART). If participants in the treatment group demonstrate adherence \> 95%, they will continue with the treatment arm of receiving automated digital reminders and individualized adherence feedback. If they are deemed to be non-responsive (adherence \< 95%), they will be re-randomized to either: 1) continued automated digital reminders and individualized adherence feedback or 2) a mHealth problem solving module with three therapist-guided problem-solving sessions.
62698862|NCT04946214|OTHER|Smart Water Bottle Intervention Arm|Patients will receive a smart water bottle, then instructed on bowel and bladder preparation for daily standard of care radiotherapy treatments for up to 10 weeks.
62698863|NCT02998307|EXPERIMENTAL|Monthly|Receive bedside CPR training monthly
61949407|NCT05333016|EXPERIMENTAL|Multimodal Exercise Intervention|12-week, twice weekly partner-based multimodal exercise program
62498425|NCT04519879|ACTIVE_COMPARATOR|Arm IIB (active surveillance)|Patients undergo active surveillance for 48 weeks.
62498426|NCT03843125|EXPERIMENTAL|2 mg Baricitinib|Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).
62498427|NCT03843125|EXPERIMENTAL|4 mg Baricitinib|Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.
62498428|NCT03843125|EXPERIMENTAL|Placebo to 2 mg Baricitinib|Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.
62498429|NCT03843125|EXPERIMENTAL|Placebo to 4 mg Baricitinib|Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.
62140709|NCT01143142|EXPERIMENTAL|Tailoring|Individuals assigned to the experimental group will receive a two-page brochure tailored based on their responses to the survey.
62140710|NCT01143142|ACTIVE_COMPARATOR|Untailored information|Individuals assigned to the control group will receive the CDC vaccine information sheet that is standardly provided.
62140711|NCT04473703||observation group|A total of 300 patients are expected to include in this group. And the cardiac adverse reactions related to immune checkpoint inhibitor will be observed.
62341469|NCT06091189|ACTIVE_COMPARATOR|Irrelevant Stressor Condition with No Ethanol|Participants complete the Irrelevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their gender identity has developed over time. Participants are then assigned to receive a placebo priming beverage (with no ethanol) to consume over 10 minutes. Participants will consume the initial placebo drink, which is intended as a priming cue. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional placebo cocktails, which do not contain ethanol.
62341470|NCT06091189|PLACEBO_COMPARATOR|Control Stressor Condition with No Ethanol|Participants complete the Control Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on a recent book participants read, or a recent movie participants saw. Participants are then assigned to receive a placebo priming beverage (with no ethanol) to consume over 10 minutes. Participants will consume the initial placebo drink, which is intended as a priming cue. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional placebo cocktails, which do not contain ethanol.
62498430|NCT02263768|OTHER|Group 1 - Recall Interval of 12 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
62498431|NCT02263768|OTHER|Group 2 - Recall Interval of 18 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
62498432|NCT03473067|EXPERIMENTAL|Social Norms Marketing|This arm includes a social norms marketing campaign tailored to the school.
62140712|NCT00547066|EXPERIMENTAL|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously.
62140713|NCT03908606|EXPERIMENTAL|Periodontitis patients with diabetes type 2|scaling and root planing was administered to all patients. Serum samples were collected before and after treatment to assess hs-CRP levels. Glycated hemoglobin was measured before and after treatment
62498433|NCT03473067|ACTIVE_COMPARATOR|Capacity Building|This arm includes a series of teacher training, and parent engagement meetings, with the goal of building capacity to address violence in the school.
62698864|NCT02998307|EXPERIMENTAL|3 months|Receive bedside CPR training every 3 months
62698865|NCT02998307|EXPERIMENTAL|6 months|Receive bedside CPR training every 6 months
62698866|NCT02998307|NO_INTERVENTION|Control|No additional training and only performance evaluation after 1 year
62698867|NCT05264454|PLACEBO_COMPARATOR|0 L|This will be the arm where the baseline IVC assessment size is conducted at
62498434|NCT01726257|EXPERIMENTAL|Nellix System|Nellix Endovascular Aneurysm Sealing System is the only arm for this study. This is a single arm study.
62498435|NCT04594720||Thyroid cancers|Enrolled study population have papillary thyroid cancers and benign thyroid tumors
62498436|NCT03922139|EXPERIMENTAL|Botox|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
61949408|NCT03473535|ACTIVE_COMPARATOR|PST Alone|Participants will receive six sessions of face-to-face PST.
61949409|NCT03473535|EXPERIMENTAL|Blended-Therapy|Participants with receive six sessions of face-to-face PST supplemented by the BEACON platform.
61949410|NCT00450255|EXPERIMENTAL|Arm I|Patients receive Aflibercept IV at 4 mg/kg over 1 hour on day 1. Treatment repeats every 14 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
61949411|NCT05101785|ACTIVE_COMPARATOR|Lidocaine|Lidocain hydrochloride 2 %with epinephrine 1:100000
61949412|NCT05101785|EXPERIMENTAL|Articaine|Articaine chloride 4% with epinephrine 1:100000
62498437|NCT06463119||Immunocompromised patients|"Priority will be given to patients with the following disease compromising their immune system:~* Solid organ recipients~* Hematopoietic stem cell transplant recipients~* HIV~* Dysimmune disorders~  * Inflammatory bowel disease~ * Rheumatologic disease~ * Neuro-immunological disease~ * Nephrotic syndrome~* Primary immunodeficiency disorder~* Pneumological disease requiring immunosuppression (e.g. bronchiolitis obliterans)~* Oncological disease"
62498438|NCT03043898||Part A(i) Healthy Volunteers|50 healthy volunteers. Intervention: Lung sound recording for part A(i) of the study.
62698868|NCT05264454|ACTIVE_COMPARATOR|30 L|The HFNC flow will be set at 30 L / min. The IVC size will then be assessed using a POCUS
62698869|NCT05264454|ACTIVE_COMPARATOR|60 L|The HFNC flow will be set at 60 L / min. The IVC size will then be assessed using a POCUS
61949413|NCT05890508|EXPERIMENTAL|Electro-acupuncture group|The electro-acupuncture intervention will be conducted for 2 session per week during 16-week treatment duration, and will be followed up for 8 weeks. In this study, 7 acupoints are chosen:GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). The puncture is made in accordance with the standards of traditional Chinese medicine, to a depth of 1 to 3 cm depending on the thickness of the local tissues. The acupoints are subjected to 2-5 Hz electroacupuncture from an electroacupuncture device at an intensity (5 to 10 mA) that can produce a muscle twitch acceptable to the participant.
62140714|NCT03908606|EXPERIMENTAL|Periodontitis patients|scaling and root planing will be done to periodontitis patients. Serum samples were collected before and after treatment to assess hs-CRP levels.
62341471|NCT06091189|EXPERIMENTAL|Relevant Stressor Condition with Ethanol|Participants complete the Relevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their sexuality has developed over time. Participants are then assigned to receive a priming beverage containing ethanol to consume over 10 minutes. Participants will consume the initial drink containing ethanol, which is intended as a priming dose. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional cocktails, which contain ethanol. The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol.
62341472|NCT06091189|ACTIVE_COMPARATOR|Irrelevant Stressor Condition with Ethanol|Participants complete the Irrelevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their gender identity has developed over time. Participants are then assigned to receive a priming beverage containing ethanol to consume over 10 minutes. Participants will consume the initial drink containing ethanol, which is intended as a priming dose. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional cocktails, which contain ethanol. The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol.
62341473|NCT06091189|PLACEBO_COMPARATOR|Control Stressor Condition with Ethanol|Participants complete the Control Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on a recent book participants read, or a recent movie participants saw. Participants are then assigned to receive a priming beverage containing ethanol to consume over 10 minutes. Participants will consume the initial drink containing ethanol, which is intended as a priming dose. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional cocktails, which contain ethanol. The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol.
62341474|NCT04674618|EXPERIMENTAL|US-assisted nusinersen administration|A paramedian sagittal oblique view will be used to identify with ultrasound specific lumbar interspaces. After local anesthesia the spinal needle will be used to identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
62341475|NCT04674618|NO_INTERVENTION|landmark based nusinersen administration|The desired intervertebral space will be first identified by manual palpation of surface landmarks and marked on the skin. After local anesthesia the spinal needle will be usedto identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
62341476|NCT01180114|EXPERIMENTAL|SUUBI-MAKA|Involves creating and broadening asset ownership opportunities and life options for children (ages 12 to 15 years) orphaned due to AIDS in Uganda.
62341477|NCT01180114|OTHER|Usual Care|No intervention for asset ownership, development of future planning skills, enhancement of mental health and reduction of risk taking behaviors for children orphaned due to AIDS in Uganda.
62341478|NCT02859493|ACTIVE_COMPARATOR|Saccharomyces cerevisiae|Inactivated whole yeast Saccharomyces cerevisiae presented in vaginal capsules. 1 capsule a day for 14 days.
62341479|NCT02859493|PLACEBO_COMPARATOR|Maize starch and magnesium stearate|Placebo presented in a vaginal capsule. 1 capsule a day for 14 days
62341480|NCT06399731|EXPERIMENTAL|Intervention arm 1: rTMS followed by tDCS|Participants in intervention arm 1 will undergo four phases in the following order: 1) a no-intervention baseline phase, 2) 12 sessions of 20-minute institute-based repetitive transcranial magnetic stimulation (rTMS) (10 Hz) targeting the left DLPFC, 3) a second no-intervention baseline phase, 4) 20 sessions of 20-minute at-home anodal high-definition transcranial direct current stimulation (tDCS) targeting the left DLPFC. All phases have a duration of 4 weeks.
62341481|NCT06399731|EXPERIMENTAL|Intervention arm 2: tDCS followed by rTMS|Participants in intervention arm 2 will undergo four phases in the following order: 1) a no-intervention baseline phase, 2) 20 sessions of 20-minute at-home anodal high-definition transcranial direct current stimulation (tDCS) targeting the left DLPFC, 3) a second no-intervention baseline phase, 4) 12 sessions of 20-minute institute-based repetitive transcranial magnetic stimulation (rTMS) (10 Hz) targeting the left DLPFC. All phases have a duration of 4 weeks.
62698870|NCT02649309|EXPERIMENTAL|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
62698871|NCT02649309|EXPERIMENTAL|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
62698872|NCT02649309|EXPERIMENTAL|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
62698873|NCT02649309|SHAM_COMPARATOR|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
62698874|NCT06563739|EXPERIMENTAL|Exposed group1|Patients who receive divergent low energy once a week
62140715|NCT03908606|NO_INTERVENTION|Healthy control group|We measured serum levels of hs-CRP in all healthy control subjects
62140716|NCT06699706|ACTIVE_COMPARATOR|active cTBS group|Dual-target active cTBS will be performed over 7 consecutive days
62140717|NCT06699706|SHAM_COMPARATOR|sham cTBS group|Sham stimulation of dual-target cTBS was performed for 7 consecutive days using a sham coil
61949414|NCT05890508|SHAM_COMPARATOR|Sham-acupuncture group|"For subjects assigned to the sham control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the corresponding non-acupoints, leave 0.5 cun from the corresponding acupoints, with the same stimulation modality. Addtionally, the stimulation will be a pseudo stimulation, which will be given by connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The credibility and validity of this system have been well demonstrated.~."
62341482|NCT06182813|EXPERIMENTAL|Group A- Experimental Group|"Group (A)/ Experimental group involves participants listening to the beta auditory beats for a duration of 25 min total.~Out of these 25 minutes, the first 20 min will be spent while listening to the beta beats stimulus and the remaining 5 minutes will be used to carry out 3 trials of 30 seconds each with a rest period of 1 minute between each trial. The average values are taken for each participant out of the three trials. The number of successful catches are noted down for this test."
62341483|NCT06182813|ACTIVE_COMPARATOR|Group B- Control Group|"Group (B)/ Control group involves participants listening to the white noise for a duration of 25 min total.~Out of these 25 minutes, the first 20 min will be spent while listening to the white noise stimulus and the remaining 5 minutes will be used to carry out 3 trials of 30 seconds each with a rest period of 1 minute between each trial. The average values are taken for each participant out of the three trials. The number of successful catches are noted down for this test."
62341484|NCT02370017|EXPERIMENTAL|ANKL combined with chemotherapy|combination of ANKL and doublet chemotherapy as 3rd and 4th course in patients who get stable response after initial x2 courses
62341485|NCT03951688|EXPERIMENTAL|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
62341486|NCT03951688|NO_INTERVENTION|Control Group|No intervention
61949415|NCT02672800|EXPERIMENTAL|Writing intervention|
61949416|NCT02672800|NO_INTERVENTION|Control|
61949417|NCT03374969|EXPERIMENTAL|Attachment and Biobehavioral Catch-Up|
61949418|NCT03374969|ACTIVE_COMPARATOR|Developmental Education for Families|
61949419|NCT04450173|EXPERIMENTAL|Treatment (obinutuzumab, venetoclax, ibrutinib)|Patients receive obinutuzumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, and 24. Patients also receive venetoclax PO QD on days 1-28 (days 4-28 of cycle 1) and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
61949420|NCT00573183|EXPERIMENTAL|STAGE-12|STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
61949421|NCT00573183|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
61949422|NCT01725711|EXPERIMENTAL|Implant System|
62341487|NCT05402436||Women attending Breast Cancer Screening in England with an atypia diagnosis|Women attending Breast Cancer Screening in England with an atypia diagnosis between 1st January 2003 and 30th June 2018
62341488|NCT01709136|EXPERIMENTAL|Sirolimus|
62341489|NCT01985633|EXPERIMENTAL|Mesenchymal stem cell, PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle
62698875|NCT06563739|EXPERIMENTAL|Exposed group2|Patients who receive divergent low energy twice a week
62698876|NCT06563739|EXPERIMENTAL|Exposed group3|Patients who recieve divergent medium and low energy once a week
62698877|NCT06563739|EXPERIMENTAL|Exposed group4|Patients who receive divergent medium and low energy twice a week
61949423|NCT05239975|EXPERIMENTAL|SCTV01C|Participants will be administrated one dose of SCTV01C on Day 0 and Day 180
61949424|NCT05239975|ACTIVE_COMPARATOR|Comirnaty|Participants will be administrated one dose of Comirnaty on Day 0 and Day 180
61949425|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
61949426|NCT02944032|EXPERIMENTAL|Cogmed|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
62140718|NCT05902936|EXPERIMENTAL|Control group|After control of bleeding in teeth allocated to the control group i-PRF is to be injected first. The i-PRF will be injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ) then a layer of premixed bioceramic putty is to be added for coronal sealing.
62140719|NCT05902936|ACTIVE_COMPARATOR|Intervention group|After control of bleeding in teeth allocated to the intervention group, i-PRF is to be mixed with Nano bioactive glass (Nano-BAG) powder to a putty consistency and injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ), then a layer of premixed bioceramic putty is to be added for coronal sealing.
62140720|NCT06411041|EXPERIMENTAL|Intervention group|The experimental group will receive regular care and a 12-week program of pelvic floor muscle training (PFMT) and yoga
62498439|NCT03043898||Part A(ii) Patients|100 patients with wheezing and/or crackles due to respiratory disease. Intervention: Lung sound recording for part A(ii) of the study.
62498440|NCT03043898||Part B(i) 'normal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having a 'normal' lung structure.~Intervention: Lung sound transmission measurement for part B(i) of the study."
61949427|NCT02944032|ACTIVE_COMPARATOR|MobyMax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
61949428|NCT05617950|EXPERIMENTAL|salicylic acid|30% salicylic acid
61949429|NCT05617950|ACTIVE_COMPARATOR|cryotherapy|liquid nitrogen
61949430|NCT05159284|EXPERIMENTAL|Intervention group|Softacort® Lephanet® Thealoz Duo® MGD Rx EyeBag®
61949431|NCT05159284|OTHER|Control group|Lephanet® Thealoz Duo® MGD Rx EyeBag®
61949432|NCT02530684||Knee osteoarthritis|Patients with knee osteoarthritis
61949433|NCT02530684||Control participants|Individuals without signs of knee osteoarthritis
61949434|NCT01857856|NO_INTERVENTION|No treatment|no medical treatment
61949435|NCT01857856|ACTIVE_COMPARATOR|Eplerenone|Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily
61949436|NCT00686283|OTHER|Exercise prescription|Each adolescents with type 1 or type 2 diabetes received individual fitness testing and a personalized exercise program prescription developed by an exercise physiologist. Pretest and posttest measures of glucose control and cardiorespiratory fitness, heart rate variability, metabolic control, lipid profile, body composition, and inflammatory markers, as well as psychological outcomes (i.e., diabetes quality of life) were completed.
61949437|NCT06044831||Expanded Population Health Access|Participants living in the neighborhood with access to expanded population health model.
61949438|NCT01881074||Triclosan containing toothpaste|Patients with type II diabetes will receive triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
61949439|NCT01881074||Non-triclosan containing toothpaste|Patients with type II diabetes will receive non-triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
62140721|NCT06411041|NO_INTERVENTION|Control group|The control group will receive regular care
62498441|NCT03043898||Part B(ii) 'abnormal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having an 'abnormal' lung structure.~Intervention: Lung sound transmission measurement for part B(ii) of the study."
62498442|NCT00138463||West Nile Virus (WNV) Neuroinvasive Disease Cohort|Fever (temperature \> 38 C) documented by a health care provider AND: at least one of the following, as documented by a health care provider and in the absence of a more likely clinical explanation: acutely altered mental status; other acute signs of central or peripheral neurologic dysfunction; or cerebrospinal fluid (CSF) pleocytosis associated with illness clinically compatible with meningitis.
61949440|NCT03105583||Pregnant women visiting the obstetrics department|
62140722|NCT03170050|EXPERIMENTAL|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
62140723|NCT03170050|ACTIVE_COMPARATOR|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
62498443|NCT00138463||West Nile Virus Fever Cohort|Temperature \> 38 C as documented by a health care provider.
62498444|NCT06369610|EXPERIMENTAL|Group I (radiation therapy)|Patients undergo radiation therapy to the prostate bed over 2 - 6 weeks. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study.
62498445|NCT06369610|EXPERIMENTAL|Group II (ADT, radiation therapy)|Patients receive ADT SC or IM for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to the prostate bed over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study.
62498446|NCT06369610|EXPERIMENTAL|Group III (ADT, radiation therapy, abiraterone acetate)|Patients receive ADT SC or IM with or without abiraterone acetate for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to identified areas over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study.
62498447|NCT04325516|EXPERIMENTAL|People with a lower limb amputation|"Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension"
62498448|NCT04325516|EXPERIMENTAL|Able bodied individuals|"Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension"
62698878|NCT06563739|EXPERIMENTAL|Exposed group 5|Patients who receive focused low energy once a week
62140724|NCT04878159||Emergency high-risk abdominal surgery|Patients undergoing emergency high-risk abdominal surgery, defined as immediate emergency laparoscopy or laparotomy, including intestinal obstruction, perforated viscus, intestinal ischemia and intraabdominal bleeding. Includes both primary surgery and re-operation after elective surgery.
62140725|NCT00686465|OTHER|PET/CT scan|PET/CT scan
62164510|NCT05855499|NO_INTERVENTION|Standard wound treatment (SWT)|conventional wound treatment according to S3 guideline, 3 visits weekly for 4 weeks
62164511|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
62698879|NCT06563739|EXPERIMENTAL|Exposed group6|Patients who receive divergent medium energy once a week
62698880|NCT06563739|EXPERIMENTAL|Exposed group 7|Patients who receive divergent medium energy twice a week
61949441|NCT02320539||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
62498449|NCT03563794|EXPERIMENTAL|CSII(insulin Lispro)+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
62498450|NCT03563794|ACTIVE_COMPARATOR|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
62498451|NCT02818296|EXPERIMENTAL|Active IU CBM-I|This paradigm was designed to train individuals to endorse benign interpretations of ambiguous information and reject negative/threatening interpretations of ambiguous information. Participant's baseline interpretation bias was measured at baseline. Participants then underwent two training phases in which their responses were either reinforced (i.e., they were told they were correct) or punished (i.e., they were told that they were incorrect). Interpretation bias was measured again at post-training.
62498452|NCT02818296|SHAM_COMPARATOR|Control CBM-I|This paradigm was identical to the active condition except that the word/sentence pairings used were not relevant to IU and/or anxiety.
62498453|NCT05061992|EXPERIMENTAL|Lactulose|
62498454|NCT05061992|NO_INTERVENTION|No treatment|Subjects will complete baseline and outcome assessments at 28 days and no intervention or placebo will be prescribed.
62498455|NCT01628549|EXPERIMENTAL|P005672-HCl approximately 0.75 mg/kg/day|One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
62498456|NCT01628549|EXPERIMENTAL|P005672-HCl approximately 1.5 mg/kg/day|Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
62498457|NCT01628549|EXPERIMENTAL|P005672-HCl approximately 3.0 mg/kg/day|Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
62498458|NCT01628549|PLACEBO_COMPARATOR|Placebo|Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks
62498459|NCT04030338||Prostate cancer|Participants with histologically confirmed prostate cancer, that is either newly diagnosed OR progressive as defined by standard PCWG3 criteria. Patients w ill remain on study until 30 days after their last PSMA imaging timepoint required by their companion therapeutic protocol.
62498460|NCT00570206|EXPERIMENTAL|1|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
61949442|NCT02320539||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
61949443|NCT02320539||SAH good grade|SAH without external ventricular drainage
61949444|NCT02320539||Healthy controls|Blood sample in healthy donors registered in the National Donor Registry.
61949445|NCT01484223|EXPERIMENTAL|Experimental Group|Intervention group: Structured nursing intervention
62498461|NCT00570206|NO_INTERVENTION|2|Probation officers who are interested in Motivational Interviewing, but have not yet been trained to use it while conducting meetings with probationers.
61949446|NCT01484223|NO_INTERVENTION|No intervention|Control group: conventional intervention or non_support
61949447|NCT03055156|EXPERIMENTAL|Low rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
61949448|NCT03055156|EXPERIMENTAL|High rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
61949449|NCT03320057|EXPERIMENTAL|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
61949450|NCT03320057|OTHER|Pharmacists|Pharmacists providing services at one of the study pharmacies during the study
61949451|NCT03629431|ACTIVE_COMPARATOR|postoperative standard care|Standard care after surgery in postoperative unit
61949452|NCT03629431|EXPERIMENTAL|Prophylactic non-invasive ventilation|Prophylactic noninvasive ventilation in postoperative and intensive care unit
61949453|NCT04396301|ACTIVE_COMPARATOR|Fydrane group|Fydrane is injected intracamerally at the beginning of cataract surgery after the first incision, at a dose of 0.2 ml of solution, in only one injection. Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). No preoperative topical eye drops are used.
61949454|NCT04396301|NO_INTERVENTION|Reference group:|not injected with intracameral Fydrane. Pupillary dilatation in this group is achieved using preoperative topical eye drops: cyclopentolate hydrochloride 1% and tropicamide 1 % one drop every 15 min for 1 hour preoperatively.
62498462|NCT00570206|NO_INTERVENTION|3|Treatment as usual. Regular probation officers conduct standard meetings with probationers.
62498463|NCT05530850|EXPERIMENTAL|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training
61949455|NCT04334057||Patients with haemophilia A|New patients who have not previously been exposed to Esperoct® (Turoctocog alfa pegol or N8-GP in clinical trials) are eligible for this study.
61949456|NCT00443092|EXPERIMENTAL|1|proprietary tart cherry juice blend (8 oz., BID)
62498464|NCT05530850|EXPERIMENTAL|Thoracic exercise program|Thoracic region focused exercise program
62498465|NCT05530850|NO_INTERVENTION|control group|Individuals in the control group were asked to continue their activities of daily living.
62498466|NCT01465568|ACTIVE_COMPARATOR|Denosumab|denosumab
62498467|NCT01465568|ACTIVE_COMPARATOR|bisphosphonates|continuation of bisphosphonates
62498468|NCT06474845|EXPERIMENTAL|Experimental arm (T-Control®)|Patients catheterized with a catheter with a control valve for intermittent drainage
62498469|NCT06474845|ACTIVE_COMPARATOR|Control arm (Foley)|Patients catheterized with a conventional urinary catheter with continuous drainage
61949457|NCT00443092|PLACEBO_COMPARATOR|2|control juice (color matched kool aid blend),(8 oz., BID)
61949458|NCT01670396||in-stent restenosis|
61949459|NCT01670396||non-in-stent restenosis|
62498470|NCT00999115|EXPERIMENTAL|Allogenic ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million in case of incomplete fistula closure following week 12 assessment.
62498471|NCT06615427||Infant treated with bubble CPAP and receiving blended air/oxygen|
62498472|NCT06062160|EXPERIMENTAL|Experimental|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
62498473|NCT06062160|NO_INTERVENTION|Control|There will be no intervention in the control group. Routine maintenance will be given.
62498474|NCT05077501|EXPERIMENTAL|ACD856|
62498475|NCT05077501|PLACEBO_COMPARATOR|Placebo|
62498476|NCT01611896|ACTIVE_COMPARATOR|Selenium|
62498477|NCT01611896|PLACEBO_COMPARATOR|Placebo|
62498478|NCT01134991|PLACEBO_COMPARATOR|Topical Minocycline Foam FXFM244 Placebo|Minocycline Foam FXFM244 Placebo
62498479|NCT01134991|EXPERIMENTAL|Topical Minocycline Foam FXFM244, 1%|Minocycline Foam FXFM244, 1%
62698881|NCT06563739|EXPERIMENTAL|Non-exposed group|Patients who receive rehabilitation assessment and training guidance
62698882|NCT06637566|ACTIVE_COMPARATOR|Experimental Group|They receive brandt daroff exercises with cawthorne cooksey exercises.
62698883|NCT06637566|OTHER|Control Group|They receive brandt daroff exercises only.
62698884|NCT01964261|EXPERIMENTAL|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
62698885|NCT01132885||Adults with WS or genetic abnormalities|Adults with Williams syndrome or genetic abnormalities in chromosome 7q11.23
61949460|NCT00894166|ACTIVE_COMPARATOR|Nicotine Replacement Therapy Responder|Nicotine Responders
62341490|NCT01985633|ACTIVE_COMPARATOR|platelet rich plasma|About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection.
61949461|NCT00894166|ACTIVE_COMPARATOR|Pre-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches
61949462|NCT00894166|ACTIVE_COMPARATOR|Pre-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline)
62341491|NCT06250517|EXPERIMENTAL|EVLP|
62341492|NCT06250517|ACTIVE_COMPARATOR|Cold preservation|
62341493|NCT00837005||1|Patients with suspected CAD
62341494|NCT00837005||2|Patients with known CAD and suspected ischemia.
62341495|NCT01364233|OTHER|MotifMesh|Condensed polytetrafluoroethylene (cPTFE, MotifMESH) mesh
62341496|NCT00703833|EXPERIMENTAL|1|Drug
62341497|NCT00703833|PLACEBO_COMPARATOR|2|Placebo
62341498|NCT01652755||AKI group|patients with AKI after cardiopulmonary bypass surgery
62341499|NCT01652755||non-AKI group|patients without AKI during study period
62341500|NCT02664532|EXPERIMENTAL|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
62341501|NCT02664532|OTHER|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
62341502|NCT05357326|ACTIVE_COMPARATOR|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years
62341503|NCT05357326|EXPERIMENTAL|0.04% atropine|use atropine sulfate 0.04% eye drop every night before sleep for two years
62341504|NCT05357326|EXPERIMENTAL|orthokeratology|wear orthokeratology lens every night for two years
62341505|NCT01274741|ACTIVE_COMPARATOR|Seeking Safety (SS)|17 sessions of present-focused therapy Seeking Safety
62341506|NCT01274741|EXPERIMENTAL|Creating Change (CC)|17 sessions of past-focused Creating Change
62341507|NCT00754728|EXPERIMENTAL|I|
61949463|NCT00894166|ACTIVE_COMPARATOR|Pre-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to continued use of nicotine patches
62341508|NCT02547116|NO_INTERVENTION|Standard anti-staphylococcal antibiotic|
62341509|NCT02547116|EXPERIMENTAL|Standard anti-staphylococcal antibiotic + Rifampin|Individuals with known, persistent small-colony variant MRSA, who are treated with standard anti-staphylococcal antibiotics, will be treated with their standard therapy in addition to Rifampin.
62498480|NCT01134991|EXPERIMENTAL|Topical Minocycline Foam FXFM244, 4%|Minocycline Foam FXFM244, 4%
62498481|NCT04584086|EXPERIMENTAL|MRI 3 Tesla|Patients will be followed by 3 Tesla MRIs during the study
62498482|NCT02506205|EXPERIMENTAL|LSVT LOUD|LSVT LOUD was developed based on concepts of neuroplasticity, motor learning, skill acquisition and motor speech. LSVT LOUD trains laryngeal and respiratory functions through loud and effortful phonatory tasks (Ramig, Sapir, Countryman, Pawlas, O'Brien, Hoehn, \& Thomson, 2001). It targets vocal intensity via stimulation of effortful speech productions with multiple repetitions and through encouraging self-calibrations of loud voice by patients. LSVT LOUD cues patients to speak loud (e.g., Fox et al., 2002; Ramig et al., 2001; Sapir et al., 2007). Having a single cue may increase treatment effects, as it reduces cognitive load in adults with PD because some of them develop cognitive deficits when PD progresses (Fox et al., 2002). Treatment is intensive, consisting of 4 individual sessions a week for 4 weeks, with 16 sessions in one month.
62698886|NCT01132885||Children with WS or genetic abnormalities|children ages 5-17 with Williams Syndrome or genetic abnormalities in chromosome 7q11.23
62698887|NCT01132885||Parents|Parents of children with 7q11.23 CNV will undergo blood draws
62498483|NCT01763658|EXPERIMENTAL|Antioxidant, drug therapy for ITP|interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
62498484|NCT01763658|ACTIVE_COMPARATOR|drug therapy for ITP|drug therapy for ITP according to ASH, 2011 guidelines.
62498485|NCT04543331||treatment naïve patients|Patients being the first time treated for nAMD or DME
62498486|NCT04543331||pre-treated patients|Patients already being treated for nAMD or DME
62498487|NCT03506087|EXPERIMENTAL|Coaching|Receives printed advance care planning (ACP) materials. Receives advance care planning coaching session. May receive followup coaching session, typically by telephone.
62698888|NCT01132885||Unaffected Siblings|Siblings of children with 7q11.23 CNV
61949464|NCT00894166|ACTIVE_COMPARATOR|Post-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Zyban (bupropion) in combination with nicotine patches
61949465|NCT00894166|ACTIVE_COMPARATOR|Post-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Chantix (varenicline)
62498488|NCT03506087|ACTIVE_COMPARATOR|Enhanced Control|Receives printed advance care planning materials only.
62498489|NCT01123291|ACTIVE_COMPARATOR|routine follow-up coronary angiography|routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
62498490|NCT01123291|ACTIVE_COMPARATOR|clinical follow-up|no routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
62498491|NCT03721887|EXPERIMENTAL|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
62498492|NCT03721887|SHAM_COMPARATOR|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
62498493|NCT04883333|EXPERIMENTAL|Cohort A1 LEO 153339|Single ascending dose (Part 1)
62498494|NCT04883333|EXPERIMENTAL|Cohort A2 LEO 153339|Single ascending dose (Part 1)
62498495|NCT04883333|EXPERIMENTAL|Cohort A3 LEO 153339|Single ascending dose (Part 1)
62498496|NCT04883333|EXPERIMENTAL|Cohort A4 LEO 153339|Single ascending dose (Part 1)
62498497|NCT04883333|EXPERIMENTAL|Cohort A5 LEO 153339|Single ascending dose (Part 1)
61949466|NCT00894166|ACTIVE_COMPARATOR|Post-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to continued use of nicotine patches
61949467|NCT05248867|PLACEBO_COMPARATOR|Placebo|Participants received 5 intramuscular injections of placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participants may have also received 1 open-label treatment of AGN-151586 on Day 43.
61949468|NCT05248867|EXPERIMENTAL|AGN-151586|Participants received 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, participants may also have received 1 open-label treatment of AGN-151586 on Day 43.
61949469|NCT03078972||Advanced Heart Failure|40 patients with advanced heart failure scheduled to undergo Left Ventricular Assist Device (LVAD) insertion will be recruited for testing. Test subjects will complete testing prior to, and following LVAD implantation.
61949470|NCT03078972||Healthy controls|10 age-matched healthy individuals will be recruited to establish normal/reference values.
62498498|NCT04883333|EXPERIMENTAL|Cohort A6 LEO 153339|Single ascending dose (Part 1)
62498499|NCT04883333|EXPERIMENTAL|Cohort A7 LEO 153339|Single ascending dose (Part 1)
62498500|NCT04883333|EXPERIMENTAL|Cohort B1 LEO 153339|Single ascending dose (Part 1)
62498501|NCT04883333|PLACEBO_COMPARATOR|All SAD cohorts placebo|Single ascending dose (Part 1), all participants receiving placebo in Cohorts A1-A7 and B1
62498502|NCT04883333|EXPERIMENTAL|Cohort C1 LEO 153339|Multiple ascending doses (Part 2)
62498503|NCT04883333|EXPERIMENTAL|Cohort C2 LEO 153339|Multiple ascending doses (Part 2)
62498504|NCT04883333|EXPERIMENTAL|Cohort C3 LEO 153339|Multiple ascending doses (Part 2)
62498505|NCT04883333|EXPERIMENTAL|Cohort C4 LEO 153339|Multiple ascending doses (Part 2)
62498506|NCT04883333|EXPERIMENTAL|Cohort C5 LEO 153339|Multiple ascending doses (Part 2)
62498507|NCT04883333|EXPERIMENTAL|Cohort C6 LEO 153339|Multiple ascending doses (Part 2)
61949471|NCT03078972||Mild Heart Failure|A second control group comprised of 10 age-matched individuals will be recruited to establish normal/reference values for individuals with mild, medically managed heart failure.
61949472|NCT05684705|EXPERIMENTAL|BV100|7 doses of BV100 (q12h)
62498508|NCT04883333|PLACEBO_COMPARATOR|All MAD cohorts placebo|Multiple ascending doses (Part 2, all participants receiving placebo in Cohorts C1-C6)
62498509|NCT04926701|EXPERIMENTAL|Single ascending dose|Single dose of inhaled ETD001/placebo on one occasion
61949473|NCT06224257|EXPERIMENTAL|Linperlisib|Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred.
62498510|NCT04926701|EXPERIMENTAL|Multiple ascending dose (7 days)|Daily doses of ETD001/placebo for 7 consecutive days
62498511|NCT04926701|EXPERIMENTAL|Multiple ascending dose (14 days)|Daily doses of ETD001/placebo for 14 consecutive days
62498512|NCT00912522|ACTIVE_COMPARATOR|LT PFC HIGH FREQ TMS|
62498513|NCT00912522|ACTIVE_COMPARATOR|LT PFC LOW FREQ TMS|
62698889|NCT01132885||Unrelated children|Typically developing children ages ages 5-17
62698890|NCT01446523|PLACEBO_COMPARATOR|Lactulose|Group L receives lactulose Group NL receives placebo
62698891|NCT01446523|PLACEBO_COMPARATOR|Placebo|Group NL receives placebo
62698892|NCT01190527|OTHER|FDG-PET|All subjects will have the same course of treatment, the study treatment.
62698893|NCT05729087|EXPERIMENTAL|Blended Intervention Group|A 10-week lifestyle intervention will be provided, addressing physical activity (PA) and healthy diet simultaneously. The program mode is a web- and center-based blended intervention. The web-based lifestyle behavior intervention will be developed based on the Health Action Process Approach.
62698894|NCT05729087|NO_INTERVENTION|Control Group|No treatment will be provided during the intervention period. Relevant intervention materials are accessible and available for all participants in the control group after the completion of data collection.
61949474|NCT05084014|EXPERIMENTAL|Deep Stripping|This group will receive deep stripping technique with conventional physical therapy.
62498514|NCT00912522|ACTIVE_COMPARATOR|RT PFC HIGH FREQ TMS|
62498515|NCT00912522|ACTIVE_COMPARATOR|RT PFC LOW FREQ TMS|
62498516|NCT00912522|SHAM_COMPARATOR|SHAM STIMULATION|
62498517|NCT00440622|EXPERIMENTAL|1|GHer
62498518|NCT00440622|EXPERIMENTAL|2|CapHer
62498519|NCT01931345|EXPERIMENTAL|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
62498520|NCT01931345|ACTIVE_COMPARATOR|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
62498521|NCT01387152||Very low dose stress test protocol|Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (\<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
62498522|NCT01151449|EXPERIMENTAL|Treatment (gamma-secretase/Notch signalling pathway inhibitor)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62498523|NCT00609154|EXPERIMENTAL|Diabetic Group|Participants with Type 2 diabetes
62498524|NCT00609154|ACTIVE_COMPARATOR|Non-diabetic Group|Participants who are non-diabetic will serve as control. treatment is matched to experimental group
62498525|NCT03161353|EXPERIMENTAL|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
62498526|NCT03161353|EXPERIMENTAL|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.~* PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.~* PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
62498527|NCT03161353|EXPERIMENTAL|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
62698895|NCT06645314|EXPERIMENTAL|BST06|intravenous infusion
62498528|NCT06030115||Cardiac Rehab Patients|All participants referred to the clinic meeting the inclusion and exclusion criteria who wanted to participate in the study.
62498529|NCT03605992|EXPERIMENTAL|Home-based Rehabilitation|Home-based cardiac rehabilitation that includes the components of education and physical exercises mainly unsupervised and oriented by telephone.
62498530|NCT03605992|ACTIVE_COMPARATOR|CentreRehabilitation|Traditional cardiac rehabilitation offered at the outpatient centre including components of education and physical exercises mainly supervised.
62698896|NCT05641116|EXPERIMENTAL|Lyme Borreliosis with physical activity program|Referral of the patient to the sport-health center of his department by the investigating physician (in connection with the attending physician for the prescription of Adaptive Physical Activity): for 24 sessions of APA for 3 months at a rate of 2 sessions/week at the sport and health center + 9 sessions of Therapeutic Patient Education in telecare
62698897|NCT05641116|OTHER|Lyme Borreliosis patients with physical activity at home|routine clinical practice : encouragement by the attending physician to modify lifestyle habits with advice on resuming regular physical activity independently and combating sedentariness. At home, in autonomy for 3 months.
61949475|NCT05084014|EXPERIMENTAL|Kneading|This group will receive deep kneading with conventional physical therapy.
61949476|NCT04676178|EXPERIMENTAL|SAD Cohorts 1-6 Experimental Arm|Subjects will receive single intravenous doses of PRA023 in a dose escalation format
61949477|NCT04676178|PLACEBO_COMPARATOR|SAD Cohorts 1-6 Placebo Arm|Subjects will receive intravenous doses of placebo
61949478|NCT04676178|EXPERIMENTAL|MAD Cohorts 1-5 Experimental Arm|Subjects will receive three intravenous doses of PRA023, one dose every 2 weeks, in a dose escalation format
62498531|NCT00022555|EXPERIMENTAL|Treatment (bryostatin 1, vincristine sulfate)|Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
62498532|NCT00970749||history of chlamydia infection|Women who self-reported a history of cervical infection with Chlamydia trachomatis
62498533|NCT00970749||no history of chlamydia infection|Women who self-reported no history of cervical infection with Chlamydia trachomatis
62498534|NCT02396927|PLACEBO_COMPARATOR|2D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
62698898|NCT01597700|EXPERIMENTAL|Acotral® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 day.
61949479|NCT04676178|PLACEBO_COMPARATOR|MAD Cohorts 1-5 Placebo Arm|Subjects will receive three intravenous doses of placebo, one dose every 2 weeks,
62498535|NCT02396927|ACTIVE_COMPARATOR|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
62498536|NCT02102269|ACTIVE_COMPARATOR|actimove sling|standard orthosis: actimove sling
62498537|NCT02102269|EXPERIMENTAL|shoulderlift|newly developed orthosis: shoulderlift
62498538|NCT02102269|NO_INTERVENTION|controle group|no orthosis
61949480|NCT02564497|OTHER|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
61949481|NCT02564497|OTHER|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
61949482|NCT05253638|EXPERIMENTAL|study group|"Patients will be recruited from the Rheumatology, Rehabilitation Department from The in patient and out patient clinic of Assiut University Hospitals with an informed consent will be obtained from all patients.~Adult SLE patients \>18 who fulfilled the 2012 systemic lupus international collaborating clinics (SLICC) criteria"
61949483|NCT00457301||Control|
61949484|NCT01146990||Infants Born to Mothers in the 17P-ES-003 Study|Infants Born to Mothers Who Participated in the 17P-ES-003 Study and whose mothers consented for them to be followed for this study.
61949485|NCT04707508|EXPERIMENTAL|Valsartan and metformin|
61949486|NCT04707508|ACTIVE_COMPARATOR|Metformin only|
61949487|NCT04774796|EXPERIMENTAL|Cognitive Behavioural Therapy|Participants in this group will take part in a group CBT workshop for parents of children with food allergy. They will also have access to a self-help booklet in order to reinforce the learning that has taken place during the workshop.
61949488|NCT04774796|NO_INTERVENTION|Treatment as usual|Participants in the control group will not take part in the group CBT workshop, but will have access to any treatment as usual relating to their child's food allergy. They will have access to the CBT self-help booklet after the all data collection has been finalised.
61949489|NCT03928158|EXPERIMENTAL|LCZ 696|Initial dose - 50 mg twice daily, up-titration to 200 mg twice daily. Patients will also receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
61949490|NCT03928158|ACTIVE_COMPARATOR|Valsatran|Initial dose - 40 mg twice daily, up-titration to 160 mg twice daily. Patients also will receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
61949491|NCT01597960|ACTIVE_COMPARATOR|Yoga 12 week programme|Usual care (standard cardiac rehabilitation programme) plus yoga intervention.
62498539|NCT06622486|EXPERIMENTAL|Monotherapy EGL-001 Dose Level 1|EGL-001 Dose Level 1
62498540|NCT06622486|EXPERIMENTAL|Monotherapy EGL-001 Dose Level 2|EGL-001 Dose Level 2
62498541|NCT06622486|EXPERIMENTAL|Monotherapy EGL-001 Dose Level 3|EGL-001 Dose Level 3
62498542|NCT06622486|EXPERIMENTAL|Monotherapy EGL-001 Dose Level 4|EGL-001 Dose Level 4
62498543|NCT06622486|EXPERIMENTAL|Monotherapy EGL-001 Dose Level 5|EGL-001 Dose Level 5
62498544|NCT06622486|EXPERIMENTAL|Monotherapy EGL-001 Dose Level 6|EGL-001 Dose Level 6
62498545|NCT06622486|EXPERIMENTAL|Monotherapy EGL-001 Dose Level 7|EGL-001 Dose Level 7
62498546|NCT06622486|EXPERIMENTAL|Combination therapy with EGL-001 dose Level x|EGL-001 Dose Level x in combination with anti-PDL1
62498547|NCT06622486|EXPERIMENTAL|Combination therapy with EGL-001 dose Level y|EGL-001 Dose Level y in combination with anti-PDL1
62498548|NCT06622486|EXPERIMENTAL|Combination therapy with EGL-001 dose Level z|EGL-001 Dose Level z in combination with anti-PDL1
61949492|NCT01597960|NO_INTERVENTION|Usual care|Usual care (standard cardiac rehabilitation programme) only.
61949493|NCT00352339|EXPERIMENTAL|Aripiprazole|switching group (from risperidone to aripiprazole)
61949494|NCT00352339|ACTIVE_COMPARATOR|Risperidone|Start with risperidone and keep it through the end of study
61949495|NCT00352339|ACTIVE_COMPARATOR|Abilify|Start with aripiprazole and keep it through the end of study
61949496|NCT01814384|OTHER|Control group|Control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
61949497|NCT01814384|OTHER|Matched patient|Treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
61949498|NCT06166589|EXPERIMENTAL|Zimberelimab in combination with SIROX chemotherapy|
61949499|NCT03356756||PET MRI exam|simultaneous combined 18F-FDG PET and cardiac MRI imaging (PET MRI) performed immediately after the PET CT exam.
61949500|NCT02962388|ACTIVE_COMPARATOR|Reference therapy arm|Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
61949501|NCT02962388|EXPERIMENTAL|Investigational therapy arm|"Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.~Maximum dose 25 mg BID."
61949502|NCT05210907|EXPERIMENTAL|CD19 CAR-T therapy|SNUH-CD19-CAR-T is administered as an intravenous infusion.
61949503|NCT02183896|EXPERIMENTAL|Platelet-rich plasma (PRP)|Intra-articular injections in the hip of autologous platelet-rich plasma (PRP) at week 1 and 2 post-operatively. Dose 5 mL. PRP is derived from the patient's own blood.
61949504|NCT02183896|PLACEBO_COMPARATOR|Saline|Intra-articular injections in the hip of saline, solution week 1 and 2 post-operatively. Dose: 5 mL at each injection.
62341510|NCT02855450|EXPERIMENTAL|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
62341511|NCT02855450|PLACEBO_COMPARATOR|Vehicle|Ophthalmic Placebo solution
62341512|NCT01635634|SHAM_COMPARATOR|Sham Cupping|Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
62341513|NCT01635634|EXPERIMENTAL|Cupping Therapy|Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
62341514|NCT01635634|NO_INTERVENTION|Wait list|Wait list control no specific intervention for 3 weeks study period
62341515|NCT05412472|EXPERIMENTAL|1) Healthy subjects with normal renal function|
62341516|NCT05412472|EXPERIMENTAL|2) Mild renal impairment|
62498549|NCT04439123|EXPERIMENTAL|Treatment (capivasertib)|Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62498550|NCT03815409|EXPERIMENTAL|BWSTT group|The sessions were conducted on a treadmill with partial weight unload.
62498551|NCT03815409|OTHER|Control group|The traditional PT rehabilitation treatment included passive, active and active-assisted exercises, according to the methods commonly used (Kabat, Bobath).
61949505|NCT04158752|EXPERIMENTAL|Open Label Galcanezumab|Participants will receive their 1st injectable dose during the Day 30 visit. Participants will then inject themselves at home on Day 60 and again on Day 90.
61949506|NCT03100097|EXPERIMENTAL|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
61949507|NCT03100097|NO_INTERVENTION|Medical Management|Normal medical management
61949508|NCT05142111|EXPERIMENTAL|Sexual therapy|In the sessions a series of questions will be proposed to the subject, who will be free to answer or not, being able to express questions in turn. The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions.
62698899|NCT01597700|ACTIVE_COMPARATOR|Zetia® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 days.
62698900|NCT05152823|EXPERIMENTAL|Single Intrathecal Delivery|
62698901|NCT06052553|NO_INTERVENTION|Control Group|Subjects will receive no intervention for the duration of the hockey season.
62698902|NCT06052553|EXPERIMENTAL|TopSpin360 Intervention Group|Subjects will use TopSpin360, twice- weekly and use for the duration of the hockey season.
61949509|NCT05142111|ACTIVE_COMPARATOR|Mindfulness|"During the mindfulness treatment the subjects will be subjected to sessions in which they will be invited to relax, to become aware of the present moment, of their body, through exercises that involve breathing, attention, and visualization of the body.~The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions."
61949510|NCT03881475||healthcare workers|Participants will participate in several sessions where they will complete the questionnaires. The questionnaires will be spaced: 0, 1 week, 6 months, 1 year and then at each occupational visit within 5 years.
61949511|NCT02206997||Passive Insulation standard treatment|no active warming before start of anesthesia and no active warming at PACU
61949512|NCT02206997||Active prewarming treatment|active warming before start of anesthesia and active warming at PACU following recommendations of S3-guideline
61949513|NCT06191640||HEMT Group|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the non-HEMT group of this study may enroll into the HEMT cohort if they become eligible for these CFTR modulator therapies and plan to start them.
62698903|NCT06288828|EXPERIMENTAL|Exercise group|Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
62698904|NCT06288828|OTHER|Control group|The control group will solely receive nutritional guidance and maintain their sedentary lifestyle. The researchers will compare outcomes between these two groups.
62698905|NCT00853684|EXPERIMENTAL|oxaliplatin, capecitabine plus endostar|
61949514|NCT06191640||Non-HEMT/Control Group|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
61949515|NCT05367427|EXPERIMENTAL|Heat treated postbiotic Bifidobacterium Longum|Consumption of 2 capsules/day of Bifidobacterium Longum CECT 7347 (Total daily equivalent of 2.5 x 10\^9 CFU)
61949516|NCT05367427|PLACEBO_COMPARATOR|Placebo|Consumption of 2 placebo capsules/day filled with maltodextrin
61949517|NCT00479193|OTHER|1|There is one arm to the study. The same subjects are their own control. One of the investigators will identify two sites that appear to be the same depth on each patient \[1 site Polymen and 1 site bacitracin/xeroform )\]. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale.The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
61949518|NCT01223430|EXPERIMENTAL|Si-Ni-Tang|
61949519|NCT01223430|PLACEBO_COMPARATOR|Placebo|
62341517|NCT05412472|EXPERIMENTAL|3) Moderate renal impairment|
62698906|NCT01336699|EXPERIMENTAL|Cohort A|WRSs2 vaccine 1x10\^3 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10\^3 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
62698907|NCT01336699|EXPERIMENTAL|Cohort B|WRSs2 vaccine 1x10\^4 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10\^4 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
62698908|NCT01336699|EXPERIMENTAL|Cohort C|WRSs2 vaccine 1x10\^5 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10\^5 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
62698909|NCT01336699|EXPERIMENTAL|Cohort D|WRSs2 vaccine 1x10\^6 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10\^6 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
62698910|NCT01336699|EXPERIMENTAL|Cohort E|WRSs2 vaccine 1x10\^7 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10\^7 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
62698911|NCT06198400|EXPERIMENTAL|All patients undergoing the pancreaticoduodenectomy|All consecutive patients undergoing the pancreaticoduodenectomy at our institution in the 1.5.2024-31.12.2026 period will be enrolled in this study.
62698912|NCT02367456|EXPERIMENTAL|Arm A|MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
62698913|NCT02367456|EXPERIMENTAL|Arm B|AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
62698914|NCT05036109|OTHER|Aspirin, Vitamin D|by mouth every day for up to 90 days
62698915|NCT03801590|EXPERIMENTAL|CXL on patients with infectious keratitis|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .
62698916|NCT04884802|EXPERIMENTAL|Tight pressure management|In patients assigned to tight blood pressure control, angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.
62341518|NCT05412472|EXPERIMENTAL|4) Severe renal impairment|
62698917|NCT04884802|OTHER|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
61949520|NCT05140785|EXPERIMENTAL|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional MRI sequences and biopsies in addition to the standard of care.
61949521|NCT05644769|ACTIVE_COMPARATOR|Determine the presence of the human sequence of Ang-(1-12) in plasma on no medications|Determine the presence of the human sequence of Ang-(1-2) in the plasma of ten normal male and female hypertensive patients at baseline on no medications.
61949522|NCT05644769|ACTIVE_COMPARATOR|Determine the presence of human sequence of Ang-(1-12) on Lisinopril 40 mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients at baseline and after four weeks on Lisinopril 40 mg every day
61949523|NCT05232175|EXPERIMENTAL|Part I (Allergy assessment) - ALT-BB4|
61949524|NCT05232175|PLACEBO_COMPARATOR|Part I (Allergy assessment) - 0.9%NaCl|
61949525|NCT05232175|EXPERIMENTAL|Part II-A (PK assessment)|
61949526|NCT05232175|EXPERIMENTAL|Part II-B (Safety assessment) - ALT-BB4|
61949527|NCT05232175|PLACEBO_COMPARATOR|Part II-B (Safety assessment) - 0.9% NaCl|
61949528|NCT04760821|NO_INTERVENTION|Usual Care|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2. Usual Care means the clinical protocol approved by the enrolling center.
61949529|NCT04760821|EXPERIMENTAL|Trimetazidine|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2 plus trimetazidine.Usual Care means the clinical protocol approved by the enrolling center.
61949530|NCT03593096|EXPERIMENTAL|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
61949531|NCT03593096|EXPERIMENTAL|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
61949532|NCT01956435|OTHER|Excimer Light Treatment Right Leg, Control Left Leg|Excimer light treatment will be performed on the right leg of every subject, no treatment on the left or control leg of the subject.
61949533|NCT01956435|OTHER|Excimer Light Treatment Left Leg, Control Right Leg|Excimer light treatment will be performed on the left leg of every subject, no treatment on the right or control leg of the subject.
61949534|NCT02264561|PLACEBO_COMPARATOR|Placebo|Mannitol administered at visit 1 and at visit 2
61949535|NCT02264561|ACTIVE_COMPARATOR|caffeine|caffeine administered at visit 1 and at visit 2
61949536|NCT05857059|ACTIVE_COMPARATOR|Misoprostol 25 mcg|Participants received misoprostol 25 mcg every 2 hours until the active stage of labour was attained or failed induction was diagnosed
61949537|NCT05857059|EXPERIMENTAL|Misoprostol 50 mcg|Participants received misoprostol 25 mcg matching misoprostol 50 mcg every 2 hours until the active stage of labour was attained or failed induction was diagnosed
61949538|NCT05020782|EXPERIMENTAL|Intervention Arm|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
62140726|NCT06085989|EXPERIMENTAL|Infant directed singing|The intervention group will receive standard breastfeeding support from health care staff combined with maternal infant-directed singing during breastfeeding. The starting point of the singing will be individually assessed and tailored to the dyads and will start approximately a few minutes before breastfeeding starts. An educational video about how to apply infant-directed singing will be shown to all mothers in the intervention group.
61949539|NCT02624752|NO_INTERVENTION|Standard of Care|"Standard of care could include liberalized diet consisting of 3 meals and snacks served daily or the standard oral nutrition supplementation (ONS) routinely used in the hospital, as prescribed by the medical team.These routine meals and snacks are the standard of care."
61949540|NCT02624752|EXPERIMENTAL|Ensure|Patients randomized to Enhanced Oral Nutritional Supplementation (ONS) will receive the standard of care hospital menu (3 meals and snacks per day) plus 2 cans of Ensure (or similar product) per day while in hospital and will continue 2 cans per day of Ensure when discharged home until they have been receiving the enhanced ONS for a total of 90 days.
61949541|NCT00619736|EXPERIMENTAL|NSA-789|
62698918|NCT05512338|EXPERIMENTAL|PACT treatment group|PACT treatment will include an initial physical assesment with feedback, identification of value-based goals, individualized physical exercise based on the DNS concept, manual therapy, addressing barriers and facilitators to self-management, and skills training to promote psychological flexibility.
61949542|NCT00619736|PLACEBO_COMPARATOR|Placebo|
61949543|NCT01044875|ACTIVE_COMPARATOR|green laser 532 nm conventional|Current type of laser used for treatment of proliferative diabetic retinopathy
61949544|NCT01044875|ACTIVE_COMPARATOR|Yellow 577 nm laser|new laser wavelength for treatment of PDR
61949545|NCT02096679|EXPERIMENTAL|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg \[14C\]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
61949546|NCT04216966|PLACEBO_COMPARATOR|Control group|This group did not undergo any instrumentation.
61949547|NCT04216966|EXPERIMENTAL|Gracey Curette group|Teeth under this group were subjected to debridement with Gracey curette .
61949548|NCT04216966|EXPERIMENTAL|After Five group|Teeth under this group were subjected to debridement with After 5 curette .
61949549|NCT04216966|EXPERIMENTAL|Mini Five group|Teeth under this group were subjected to debridement with Mini Five curette .
61949550|NCT02114671|EXPERIMENTAL|Faldaprevir QD high dose|capsules, oral administration with 240 ml water, fed conditions
61949551|NCT02114671|EXPERIMENTAL|Faldaprevir QD low dose|tablets/capsules, oral administration with 240 ml water, fed conditions
61949552|NCT02114671|PLACEBO_COMPARATOR|Placebo|capsules, oral administration with 240 ml water, fed conditions
61949553|NCT02114671|ACTIVE_COMPARATOR|Ciprofloxacin|tablets, oral administration with 240 ml water, fed conditions
61949554|NCT05176743|OTHER|Usual Care|"* Referral to services~* Nutrition pamphlets~* One-time payment of $300 paid 4 months after baseline"
62498552|NCT04543968|EXPERIMENTAL|hydroxytyrosol (HT) intake|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
62498553|NCT04543968|EXPERIMENTAL|hydroxytyrosol (HT) intake and withdraw|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
61949555|NCT05176743|EXPERIMENTAL|Unconditional Cash Transfer Intervention|"* Three monthly payments of $100~* Referral to services~* Nutrition pamphlets"
61949556|NCT02384161|EXPERIMENTAL|Total RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a total obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
61949557|NCT02384161|EXPERIMENTAL|Partial RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a partial obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
61949558|NCT02384161|PLACEBO_COMPARATOR|Free BR + Exercise Isometric|Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant limb with the free blood flow. A 'cuff' pressure on the member of the proximal region, but with a pressure that will not interfere with blood flow will be applied.
61949559|NCT03385200|ACTIVE_COMPARATOR|A|Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound
61949560|NCT03385200|NO_INTERVENTION|B|Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound
61949561|NCT04887844|ACTIVE_COMPARATOR|Group I|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per American College of Rheumatology (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
61949562|NCT04887844|ACTIVE_COMPARATOR|Group II|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
61949563|NCT04887844|OTHER|Group III|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
61949564|NCT00768950||Spondyloarthropathies|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset spondyloarthritis, and undifferentiated spondyloarthritis) as defined by the AMOR criteria
61949565|NCT06088108|EXPERIMENTAL|Single arm|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
62698919|NCT05512338|ACTIVE_COMPARATOR|Usual physiotherapy care group|UC will include an initial physical assesment with feedback, treatment considered suitable by their treating physiotherapist that will be based on exercises according to the DNS concept and manual therapy.
61949566|NCT00499499|EXPERIMENTAL|1|
61949567|NCT01102517|EXPERIMENTAL|VATS group|video-assisted thoracoscopic surgery
61949568|NCT01102517|OTHER|axillary thoracotomy|Control group
61949569|NCT04471142|EXPERIMENTAL|Group A|Intervention group with preventive application of compressive bandages in addition to suction drain (routine adopted at the institution).
61949570|NCT04471142|NO_INTERVENTION|Group B|Group control. The patient will follow the institution's routine with only the suction drain.
61949571|NCT01217801|EXPERIMENTAL|Ondansetron (ODFS)|single dose of Ondansetron Orally Dissolving Filmstrip 8 mg
62140727|NCT06085989|ACTIVE_COMPARATOR|Standard care|Mothers allocated to the control group will be offered standard breastfeeding support from health care staff, and data on secondary outcome measures will be collected during one breastfeeding session.
61949572|NCT01217801|ACTIVE_COMPARATOR|Zofran (ODT)|Single dose of Zofran (Ondansetron) ODT Orally Disintegrating Tablets 8 mg
62140728|NCT05099419|EXPERIMENTAL|High Frequency rTMS Protocol|High frequency with 10 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered in 10-second trains with a 50-second pause between the trains.
62140729|NCT05099419|EXPERIMENTAL|Low Frequency rTMS Protocol|Low frequency 1 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered continuously.
62698920|NCT03740113|EXPERIMENTAL|Kids SipSmartER|Kids SIPsmartER is a 12 session, 6-month program with an integrated two-way short service message (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes
62698921|NCT03740113|NO_INTERVENTION|Control|Control arm receives no intervention
62698922|NCT06283966|EXPERIMENTAL|BGF arm|BGF MDI 320/14.4/9.6 μg BID
62698923|NCT06283966|EXPERIMENTAL|GFF arm|GFF MDI 14.4/9.6 μg BID
62698924|NCT05539547|SHAM_COMPARATOR|Control Group|Patients shall receive the usual physiotherapy care, including chest and mobility physiotherapy on quadriceps strength and endurance during hospital admission on patients with severe acute exacerbation COPD.
62698925|NCT05539547|EXPERIMENTAL|Experimental Group|Patients shall receive the investigated modality, NMES on quadriceps strength and endurance as an adjunct to usual physiotherapy care (chest physiotherapy and mobility) during hospital admission in patients with severe acute exacerbation COPD.
62498554|NCT05553496|ACTIVE_COMPARATOR|RTX in Refractory Nephrotic syndrome patients on conventional treatment|Refratory Nephrotic syndrome participants will receive a 375 mg/m2 weekly rituximab for four doses, with retreatment every 2 months till 6 months regardless of proteinuria response in addition to triple optimized immunosuppression therapy including steroids ± Calcineurine inhibitors (CNI) (e.g: Tacrolimus), Mycophenloatemofetil (MMF) and Cyclophosphamide (CTX)
62498555|NCT05553496|ACTIVE_COMPARATOR|Refractory Nephrotic Syndrome patients on Conventional therapy|Nephrotic syndrome participants will receive conventional therapy treatment only including steroids ± Tacrolimus (TAC), Cyclosporine (CsA), Mycophenloatemofetil (MMF), and Cyclophosphamide (CTX) then if become refractory to conventional treatment will continue on the same treatment.
62498556|NCT06663475|ACTIVE_COMPARATOR|general health education videos|general health education videos about hazards of secondhand smoke exposure for expectant fathers in obstetric clinic
62498557|NCT06663475|EXPERIMENTAL|TTM-based health education about smoking cessation tailored for expectant fathers|health education videos based on transtheoretical model (TTM) to motivate quit attempt and maintain abstinence among smoking expectant fathers
62498558|NCT04763447|EXPERIMENTAL|OMA withdrawal attempt|Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA
62498559|NCT04763447|ACTIVE_COMPARATOR|OMA continuation|Patients will be prescribed the same dosage of Omalizumab than they received before randomization
62498560|NCT03278041|EXPERIMENTAL|surgical reconstruction with submental flap|surgical reconstruction with submental flap
62498561|NCT03278041|ACTIVE_COMPARATOR|maxillary obturator|maxillary obturator
62498562|NCT04688515|EXPERIMENTAL|Intervention group|Intervention group refers to mother-child dyads who will be participating in a nutrition program consisting of nutrition education and cooking sessions for 3 months.
62498563|NCT04688515|NO_INTERVENTION|Comparison group|The comparison group will not receive any intervention but will be provided with the developed educational materials used in the program after the program has been completed.
62498564|NCT04410705|EXPERIMENTAL|Tendinopathy patients|Patients with tendinopathy will be administered ESWT
62498565|NCT05505825|EXPERIMENTAL|AK104 once every 3 weeks and Chiauranib once a day|Subjects receive AK104 once every 3 weeks plus Chiauranib once a day until intolerable toxicity, no more clinical benefit as judged by the investigator, or completion of 24 months of treatment, or meeting other criteria for termination of treatment in the protocol, whichever occurs first.
62498566|NCT01924364|EXPERIMENTAL|Fat grafting with TGI|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
62498567|NCT01924364|SHAM_COMPARATOR|Fat grafting without TGI - Standard of care|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
61949573|NCT02737397|EXPERIMENTAL|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
61949574|NCT02737397|ACTIVE_COMPARATOR|pain medicine|SJP-304 and placebo
62698926|NCT04110145|EXPERIMENTAL|Cohort 1 (Linaclotide 18 μg)|Linaclotide 18 microgram (μg), capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
62698927|NCT04110145|EXPERIMENTAL|Cohort 2 (Linaclotide 36 μg)|Linaclotide 36 μg, capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
62140730|NCT06336590|NO_INTERVENTION|Normal Exercise|This arm has no intervention. Participants will continue to exercise at their normal evening time (6pm-11pm).
62698928|NCT04110145|EXPERIMENTAL|Cohort 3 (Linaclotide 72 μg)|Linaclotide 72 μg, capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
61949575|NCT02737397|ACTIVE_COMPARATOR|antihistamine|SJP-223 and placebo
61949576|NCT02737397|PLACEBO_COMPARATOR|placebo|placebo and placebo
61949577|NCT03823456|EXPERIMENTAL|True self-acupressure group|"True self-acupressure group \[Enhanced standard care + True self-acupressure intervention protocol\]:~Participants in this group will practice the four-week acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers."
62140731|NCT06336590|EXPERIMENTAL|Morning Exercise|Participants will change their exercise times to the morning (6am-11am).
62140732|NCT02994407|EXPERIMENTAL|N8-GP s.c.|
62140733|NCT03491540|EXPERIMENTAL|"1)  MBP and oral antibiotics  group"|Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
62140734|NCT03491540|PLACEBO_COMPARATOR|"2)  MBP alone  group"|Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
62140735|NCT02963571|EXPERIMENTAL|screw fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw internal fixation.
62498568|NCT05611723||Healthy older Adults|Healthy older Adults: older adults without disability indicators
62498569|NCT05611723||Disability Older Adults|Disability Older Adults: older adults with disability indicators
62498570|NCT05981716||Young Breast Cancer Survivors|The investigators will enroll approximately 384 female breast cancer patients. Only non-institutionalized, English literate, female breast cancer patients diagnosed within the previous ten years and younger than 50 years old at the time of diagnosis will be eligible.
62498571|NCT02684396|EXPERIMENTAL|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
61949578|NCT03823456|PLACEBO_COMPARATOR|Sham self-acupressure group|Patients in this group will practice the four weeks sham self-acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice sham acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers
61949579|NCT03823456|NO_INTERVENTION|Enhanced standard care group|The standard care for cancer patients undergoing chemotherapy includes health assessment, regular health advice regarding symptoms that patients report and nutrition advice during taking chemotherapy treatment. Apart from the standard care, we provide participants a leaflet with 10 recommendations which help participants manage insomnia, depression, and anxiety. By providing this leaflet, we slightly enhance the standard care but do not contaminate the effective of the intervention since these tips are basic and participants can easily read about them on the internet or newspaper. In addition, to minimize the bias caused by contacting between interventionist and participants, we also provide participants in the enhanced standard care group weekly follow up phone call in four weeks.
61949580|NCT02681783|ACTIVE_COMPARATOR|neovascular AMD group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
61949581|NCT02681783|EXPERIMENTAL|CSR group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
62498572|NCT02684396|EXPERIMENTAL|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
62498573|NCT02684396|EXPERIMENTAL|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
62498574|NCT02684396|EXPERIMENTAL|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
62498575|NCT02684396|EXPERIMENTAL|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
62498576|NCT02684396|PLACEBO_COMPARATOR|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
62498577|NCT03103828|ACTIVE_COMPARATOR|Computer-tailored intervention|
62498578|NCT03103828|ACTIVE_COMPARATOR|Motivational Interviewing|
62498579|NCT03103828|ACTIVE_COMPARATOR|Motivational Enhancement Therapy|
62498580|NCT03103828|NO_INTERVENTION|Control Group|
62498581|NCT04894630|OTHER|infective keratitis|150 patients with mean age 30 (range 12 to 85 years), 90 patients (60 %) were males and 60 (40%) were females, clinically diagnosed as infective corneal ulcer, attending the Ophthalmology Department - Faculty of Medicine. Minia University, Minia, Egypt. From 2018 to 2020.
61949582|NCT02681783|EXPERIMENTAL|iPCV group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
61949583|NCT02681783|NO_INTERVENTION|cataract patients|Patients diagnosed with cataracts requiring cataract surgery will serve as study controls. No intervention will be applied to these patients.
61949584|NCT00776204|ACTIVE_COMPARATOR|1|Drug Eluting Stent
61949585|NCT00776204|ACTIVE_COMPARATOR|2|Drug Eluting Stent
62140736|NCT06509646|EXPERIMENTAL|Goup A (Tia Chi Exercise)|"* Warm up 5 minutes~* Routine Physical Therapy 20 minutes (which may include exercises such as stretching, strengthening, and range-of- motion exercises)~* Rest Interval 5 minute~* Yang style 24-posture short-form (16) for 30 minute Intensity: low Frequency: 1-2 times/week. Duration: ≤30 min (minutes)(18)~* Cool down 5 mins."
62498582|NCT00159419|ACTIVE_COMPARATOR|Alendronate|1 mg/kg po qd rounded to nearest 10 or 20 mg dose
62498583|NCT00159419|ACTIVE_COMPARATOR|Pamidronate|3 mg/kg IV q4 months
62498584|NCT02527330||Control group|Age- and gender-matched healthy volunteers recruited as normal control group.
62498585|NCT02527330||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF\>=55%
62498586|NCT02527330||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF\<55%.
62498587|NCT04464603|EXPERIMENTAL|Arm A (InterFACE)|"Participants that will use the mHeath InterFACE tool during the simulation-based pediatric scenario.~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
62498588|NCT04464603|ACTIVE_COMPARATOR|Arm B (Conventional methods)|"Participants that will use conventional methods during the simulation-based pediatric scenario.~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
62498589|NCT01970917|OTHER|Healthy volunteers right eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
62498590|NCT01970917|OTHER|Healthy volunteers left eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
62498591|NCT06444165|EXPERIMENTAL|Lebrikizumab Pen|Injection of lebrikizumab pen into a practice pad.
62498592|NCT01620281|EXPERIMENTAL|Immediate treatment (IT)|Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
62498593|NCT01620281|OTHER|Waiting List Control (WLC)|The WLC group will go through the same evaluations at the same time intervals but will begin treatments 3 weeks later during which they will fill the diary daily but not use the device.
62498594|NCT05788432||Coronary Artery Disease (CAD)|
62698929|NCT04110145|EXPERIMENTAL|Final Cohort (Linaclotide 72 μg)|Linaclotide at the highest dose tested/determined to be safe (72 μg), capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
61949586|NCT00776204|ACTIVE_COMPARATOR|3|Drug Eluting Stent
61949587|NCT03050099||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
61949588|NCT03050099||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
61949589|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
61949590|NCT02416570|ACTIVE_COMPARATOR|Clarithromycin|Clarithromycin 250mg by mouth twice a day for 8 weeks
62341519|NCT04866303|EXPERIMENTAL|Active delivery|For the participants randomized to the active arm will have their home collection kit registered on their behalf by bilingual (Spanish and English) community health workers, who are trusted community members. Home testing kits augmented with study developed materials will direct participants to contact the study team for assistance.
62498595|NCT06678321|EXPERIMENTAL|İntervention group|Mobil Game
62498596|NCT06678321|NO_INTERVENTION|Control group|No game
62498597|NCT05363982|ACTIVE_COMPARATOR|Transcranial Photobiomodulation (tPBM) Treatment|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light is applied to forebrain.
62498598|NCT05363982|SHAM_COMPARATOR|Placebo/ Sham Treatment|The sham treatment will mimic the tPBM procedure, while delivering no light.
62498599|NCT02086916||Inpatients who test positive for CDI|Observational study, hence no intervention will be administered
62498600|NCT05147740|EXPERIMENTAL|B/F/TAF|B/F/TAF for 48 weeks
62498601|NCT03519490|PLACEBO_COMPARATOR|Single Vision Hybrid Contact Lens|Subjects will wear the Duette single vision hybrid contact lens.
62498602|NCT03519490|EXPERIMENTAL|Multifocal Hybrid Contact Lens|Subjects will wear the Duette hybrid multifocal contact lens with the near center design in one eye and the distance center design in the other eye with a crossover at every six months.
62498603|NCT04598607|EXPERIMENTAL|Hypidone Hydrochloride 60mg|30mg(10mg×3) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
62498604|NCT04598607|EXPERIMENTAL|Hypidone Hydrochloride 80mg|40mg(10mg×4) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
62498605|NCT04598607|EXPERIMENTAL|Hypidone Hydrochloride 100mg|50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
62498606|NCT04598607|PLACEBO_COMPARATOR|Placebo 60mg|3 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
61949591|NCT02416570|PLACEBO_COMPARATOR|Placebo|Placebo matched capsule one capsule by mouth twice a day for 8 weeks
61949592|NCT03188315|EXPERIMENTAL|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
61949593|NCT03188315|ACTIVE_COMPARATOR|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
61949594|NCT03342963|EXPERIMENTAL|ASC-01 in period 1, Aripiprazole and sertraline in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting."
61949595|NCT03342963|EXPERIMENTAL|Aripiprazole and sertraline in period 1, ASC-01 in period 2|"At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
62341520|NCT04866303|EXPERIMENTAL|Passive delivery|Participants randomized to the passive arm will receive a home test kit augmented with instructions on how to self-register their kit online, and will be directed to contact Everlywell for assistance, if needed.
62341521|NCT03956225|EXPERIMENTAL|iLux|Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes will be treated.
62341522|NCT03956225|ACTIVE_COMPARATOR|LipiFlow|Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes will be treated.
62498607|NCT04598607|PLACEBO_COMPARATOR|Placebo 80mg|4 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
62498608|NCT04598607|PLACEBO_COMPARATOR|Placebo 100mg|5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
62498609|NCT01129323|EXPERIMENTAL|Reduced-Intensity Preparative Regimen for Allogeneic SCT|Patient in this arm will receive maximally tolerated (reduced) doses of cytotoxic therapy with the goals of suppressing the immune system, and ablate host hematopoiesis to ensure engraftment of the donor's hematopoietic system.
62498610|NCT05219435|EXPERIMENTAL|Nivolumab plus Ipilimumab|Patients will receive maintenance therapy with 4 cycles of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg every three weeks (Q3W)(induction phase) followed by Nivolumab 480 mg every 4 weeks (Q4W)(consolidation phase) until unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
62498611|NCT03385954|EXPERIMENTAL|Intervention|distance education curse with 8 hours to be accomplished in 2 weeks,
62498612|NCT03385954|EXPERIMENTAL|Control|Wiil receive a lecture of 30 minutes
62498613|NCT00006124|EXPERIMENTAL|Arm I (celecoxib)|Patients receive oral celecoxib twice daily.
62498614|NCT00006124|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo twice daily.
62498615|NCT06289140|EXPERIMENTAL|Pterostilbene cocrystal - gelatin capsule|Participants consuming one gelatin capsule of Pterostilbene cocrystal (ccPT)
62498616|NCT06289140|EXPERIMENTAL|Pterostilbene cocrystal - gastro-resistant capsule|Participants consuming one gastro-resistant capsule of Pterostilbene cocrystal (ccPT)
62498617|NCT06289140|ACTIVE_COMPARATOR|Pterostilbene free form|Participants consuming one capsule with Pterostilbene free form (PT)
62498618|NCT01773239|EXPERIMENTAL|TARA computer-based exercises|"TARA is a computerized social cognitive (SC) remediation program consisting of a set of specific SC exercises. The program creates a game-like experience where the participant is encouraged to earn points and in-game rewards to further advance in each 'game'. Participants perform tens to hundred of trials over the course of their session, with each trial providing auditory and visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each trial, the difficulty of the next trial is updated to ensure that within each session, the participant gets \~85% of trials correct. Summary screens including game metrics (points, levels) and exercise metrics (usage, progress) are shown to the participant at the end of each session.~Participants in the TARA computer-based exercises arm will complete baseline- assessments, 24 hours of TARA computer based-exercises, and repeat post-assessments."
62698930|NCT04110145|PLACEBO_COMPARATOR|Placebo Pooled|Matching placebo, orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period pooled from Cohorts 1, 2, 3, and Final Cohort.
62698931|NCT06308315|EXPERIMENTAL|Group A (Rhythmic Training+ Routine Physical therapy)|"Rhythmic balance auditory vision training will be given thrice a week for 8 weeks. it is a 45 minute training program that consist of:~1. 5 minute warm up activities (arm swings).~2. Bal-A-Vis-X training thrice a week for 20 minutes.~3. 5-minute cool down activities.~Routine Physical therapy treatment for 15 minutes"
62698932|NCT06308315|EXPERIMENTAL|Group B (Strength Training+ Routine Physical Therapy)|"Strength training Program will be performed thrice a week for 8 weeks. session of 45 minute will be given to the patient. The expert managed sessions based on:~10-min warm-up activities, 25-min basic exercise 10- min cool-down activities."
62698933|NCT06256900|EXPERIMENTAL|Flow-controlled ventilation|Experimental intervention FCV (EVONE, Ventinova Medical): PEEP and Peak inspiratory pressure titration guided by dynamic compliance.
62698934|NCT06256900|ACTIVE_COMPARATOR|Pressure-controlled ventilation|Control intervention PCV (Dräger Medical, Atlan A350): lung-protective ventilation to current best practice. Settings determined by the attending anesthesiologist (based on the internal SOP: intraoperative ventilation in robot-assisted laparoscopic surgery).
62698935|NCT02326584|EXPERIMENTAL|Induction with SGN-CD33A|7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A
61949596|NCT03342963|EXPERIMENTAL|Fasting in period 1, After breakfast in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast."
61949597|NCT03342963|EXPERIMENTAL|After breakfast in period 1, Fasting in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
61949598|NCT06426810|EXPERIMENTAL|Electrosurgical bipolar systems group|Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
61949599|NCT06426810|NO_INTERVENTION|Conventional electrocautery group|Study participants using a conventional electrocautery will undergo sentinel lymph node biopsy using conventional bovie electrocautery during the surgery.
61949600|NCT03607487|EXPERIMENTAL|Cohort 1|INCB054707 at the Cohort 1 dose or placebo.
61949601|NCT03607487|EXPERIMENTAL|Cohort 2|INCB054707 at the Cohort 2 dose or placebo.
61949602|NCT03607487|EXPERIMENTAL|Cohort 3|INCB054707 at the Cohort 3 dose or placebo.
61949603|NCT03824730||Endovascular occlusions group|Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed
62698936|NCT02326584|EXPERIMENTAL|Consolidation with SGN-CD33A|High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)
62698937|NCT02326584|EXPERIMENTAL|SGN-CD33A Maintenance|SGN-CD33A Monotherapy (42-day cycles)
62698938|NCT02326584|EXPERIMENTAL|Induction and Consolidation with SGN-CD33A|7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A
62698939|NCT02474498|ACTIVE_COMPARATOR|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
62698940|NCT02474498|ACTIVE_COMPARATOR|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
62736561|NCT03357029|SHAM_COMPARATOR|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
61949604|NCT02836093||evaluations/assessments|
61949605|NCT01542320|EXPERIMENTAL|Probiotic|Lactobacillus reuteri DSM 17938
61949606|NCT01542320|PLACEBO_COMPARATOR|Placebo|Solution without the active probiotic Lactobacillus reuteri
61949607|NCT06217341||emergence agitation group|Patients in the emergence agitation group are patients who are observed to be agitated during recovery according to the Richmond agitation sedation scale after anesthesia.
61949608|NCT06217341||calm group|The calm group will consist of patients whose agitation scale is below +2 during recovery.
62341523|NCT03279302|EXPERIMENTAL|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
62341524|NCT03279302|EXPERIMENTAL|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
62341525|NCT03279302|EXPERIMENTAL|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
62341526|NCT03279302|EXPERIMENTAL|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
62341527|NCT03279302|EXPERIMENTAL|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
62341528|NCT01962155||chronic infected with hepatitis B virus|patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy
62341529|NCT00681538|EXPERIMENTAL|Sativex|"Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours"
62341530|NCT00681538|PLACEBO_COMPARATOR|Placebo|Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours.
62341531|NCT03326830|ACTIVE_COMPARATOR|Standard oxygen therapy|Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%
61949609|NCT00841919|ACTIVE_COMPARATOR|2|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
62140737|NCT06509646|ACTIVE_COMPARATOR|Group B (Frenkel's Exercise )|"* Warm up 5 minutes~* Routine Physical Therapy 20 minutes (which may include exercises such as stretching, strengthening, and range-of- motion exercises)~* Rest Interval 5 minute~* Frenkel's exercises 30 minutes (Through these exercises, the patients would learn how to stay balanced and prevent falls by using their visual, somatosensory, and vestibular systems) 4. Rest interval 5 minutes 5. Intensity: low 6. Frequency: 1-2 times/week. 7. Duration: ≤30 min (minutes) 8. Cool down 5 mins"
62140738|NCT02803749|EXPERIMENTAL|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
62140739|NCT02803749|PLACEBO_COMPARATOR|Placebo|Flexible dosage placebo for 12 weeks.
62498619|NCT00833625|EXPERIMENTAL|PET/CT Scan + Biomarkers Testing|"PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).~Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis."
62498620|NCT03755180|EXPERIMENTAL|Group 1|Exercise Group
62498621|NCT03755180|ACTIVE_COMPARATOR|Group 2|Compression Group
62498622|NCT01682187|EXPERIMENTAL|LY2157299 (Part A)|Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day.
62498623|NCT01682187|EXPERIMENTAL|LY2157299 + Lomustine (Part B)|"LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily.~Lomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter."
62498624|NCT01632449|EXPERIMENTAL|1|Test product
62498625|NCT01632449|EXPERIMENTAL|2|Reference product
62498626|NCT04678063|EXPERIMENTAL|Asthmatic subjects allergic to cat|Group A will be randomized into 2 subgroups of 10 subjects: group A1 and A2. Both subgroupes will be exposed to placebo on exposure 1 then Subgroup A1 will be exposed to dose A on exposure 2 and dose B on exposure 3. Subgroup A2 will be exposed to dose B on exposure 2 and dose A on exposure 3. Dose A and B correspond to different Allergen concentration in the EEC.
62498627|NCT04678063|ACTIVE_COMPARATOR|Asthmatic allergic subjects not sensitized to cat|Group B will be exposed to placebo at exposure 1, and then at exposure 2, the concentration of cat allergens corresponding to the dose that achieved the main objective (Dose A or B).
62698941|NCT02474498|ACTIVE_COMPARATOR|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
62140740|NCT05901532|EXPERIMENTAL|Chinese herbal medicine|The bilateral nasal cavity was irrigated with a bottle of NeilMed containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day.
62140741|NCT05901532|PLACEBO_COMPARATOR|Placebo|The bilateral nasal cavity was irrigated with a bottle of NeilMed containing edible caramel dissolved in 240 ml of warm normal saline once a day.
62140742|NCT06544499|EXPERIMENTAL|Efgartigimod IV|Participants receiving efgartigimod IV during the double-blinded treatment period and the open-label treatment period(s)
62498628|NCT01500005|EXPERIMENTAL|vitamin D|Baby D3 drops
62498629|NCT02077621|EXPERIMENTAL|PG2|"Treatment Group:~PG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
62498630|NCT02077621|PLACEBO_COMPARATOR|Placebo|"Control group:~Placebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
62498631|NCT05200364|EXPERIMENTAL|Experimental :STRO-002 treatment in combination with Bevacizumab|"Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg~Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg"
62498632|NCT03205501|EXPERIMENTAL|IV-tracer EMI-137|"* IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.~* Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
62698942|NCT03171948|EXPERIMENTAL|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
62698943|NCT03171948|EXPERIMENTAL|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
62140743|NCT06544499|EXPERIMENTAL|Placebo IV|Participants receiving placebo IV during the double-blinded treatment period and receiving efgartigimod IV during the open-label treatment period(s)
62140744|NCT04486820||Chordoma|Patients diagnosed with chordoma
62341532|NCT03326830|EXPERIMENTAL|High-flow nasal oxygen (HFNO)|Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.
62498633|NCT03693950|EXPERIMENTAL|BCD-066 1 µg/kg|Healthy volunteers will receive BCD-066 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
62498634|NCT03693950|ACTIVE_COMPARATOR|Aranesp 1 µg/kg|Healthy volunteers will receive Aranesp 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
62498635|NCT01618513|EXPERIMENTAL|SA monitored by GH|
62698944|NCT06639048||University students|Those with using social media
62498636|NCT01618513|EXPERIMENTAL|SA monitored by IGF-I|
62498637|NCT01618513|NO_INTERVENTION|Control|Control, patients who have achieved sufficient disease control by surgery alone.
62698945|NCT03531580|EXPERIMENTAL|Healthy volunteers|six healthy volunteers: 3 male (age 20-40; 40-60 and 60+) and 3 female (age 20-40; 40-60 and 60+)
61949610|NCT00841919|EXPERIMENTAL|1|"The study group will receive Insulin Glargine as basal insulin and bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff"
61949611|NCT00677131|ACTIVE_COMPARATOR|1|To read the package insert of the drug
61949612|NCT00677131|ACTIVE_COMPARATOR|2|To read the education information provided by the Pharmacy of NTUH
61949613|NCT00677131|ACTIVE_COMPARATOR|3|Oral education provided by the pharmacist
61949614|NCT03089320|NO_INTERVENTION|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
61949615|NCT03089320|EXPERIMENTAL|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth \> 8 ng/ml will continue on to Step 2."
61949616|NCT00487708|EXPERIMENTAL|1|ACZ885
61949617|NCT05227183|EXPERIMENTAL|Patients with suicidal recurrence during VigilanS monitoring (Reattempters)|Patients with at least a past experience of suicidal attempt (SA), included after their last SA in the 6 months VigilanS monitoring protocol and who have presented a recurrence of SA during this monitoring
61949618|NCT05227183|EXPERIMENTAL|Patients without suicidal recurrence during VigilanS monitoring (No reattempters)|Patients with at least a past experience of suicidal attempt (SA), included after their last SA in the 6 months VigilanS monitoring protocol and who have not presented a recurrence of SA during this monitoring
61949619|NCT05325060|EXPERIMENTAL|Electromagentically navigated Total knee arthroplasty|"Patients underwent total knee arthroplasty using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA). The system employs small reference frames attached to the femur and tibia which are incorporated within the primary surgical incision. A standard process of joint registration maps the surface anatomy of the joint. Alignment targets were similar in both groups with a neutral Hip-Knee-Ankle-Axis and the aim to implant both femur and tibial components perpendicular to this in the coronal plane.~All patients received a cemented posterior stabilized NexGen LPS Flex TKA (Zimmer, Warsaw, Indiana, USA)."
62140745|NCT06694441|EXPERIMENTAL|Intervention on Subjects with Insomnia|"The intervention in this study will involve 28 (+4) days of daily exposure to bright light (BL) for two 60-minute sessions (morning and afternoon).~For the intervention, we will use Re-Timer® light glasses emitting light with an intensity of 230μW/cm2 (\~500lux) with a green blue 500nm dominant wavelength (between 480-520nm). Light with these characteristics has been shown effective in suppressing melatonin levels supporting their potential to exert effects on other biological non-visual functions associated with exposure to light relevant for this study.~Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects."
62164512|NCT02250911|EXPERIMENTAL|This web-based CCC Workshop|The Care for the Cancer Caregivers (CCC) workshop is composed of six webcasts. The Introductory Webcast is based upon Sessions 1 and 2 of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) and provides participants with an introduction to the CCC Workshop, an overview of the different meaning-centered modules (i.e., legacy, choice, creativity, and connectedness), and a discussion about identity and how caregivers' identities have or have not changed since taking on this role.
62498638|NCT04000191|ACTIVE_COMPARATOR|Usual monitored anesthesia care (MAC)|Monitored anesthesia care (MAC) administered by anesthesiology and injection of local anesthesia by the operating surgeon.
62498639|NCT04000191|EXPERIMENTAL|MAC and perianal ice|Monitored anesthesia care (MAC) administered by anesthesiology, application of ice to the perianal area after it is prepared with betadine, and injection of local anesthesia by the operating surgeon.
62698946|NCT00836706|EXPERIMENTAL|Clarithromycin (test)|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
62698947|NCT00836706|ACTIVE_COMPARATOR|Biaxin®|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
62698948|NCT00693147|ACTIVE_COMPARATOR|A|mini Video Assisted Thyroidectomy (miVAT)
62698949|NCT00693147|ACTIVE_COMPARATOR|B|Classic Total Thyroidectomy
62698950|NCT00020683|EXPERIMENTAL|Arm I (low dose incyclinide)|"Patients receive low-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
62698951|NCT00020683|EXPERIMENTAL|Arm II (high dose incyclinide)|"Patients receive high-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
62698952|NCT03697447|EXPERIMENTAL|Endermotherapy treated scar|Endermotherapy massage treatment
62698953|NCT03697447|NO_INTERVENTION|Control scar|No intervention, standard of care
62341533|NCT06056349|EXPERIMENTAL|Orodispersable clonazepam|50 patients will receive oral orodispersable clonazepam.
62498640|NCT05568758|EXPERIMENTAL|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
62498641|NCT05568758|EXPERIMENTAL|exercises|Stretching exercises (hamstring stretch-lower back stretch) Strenghening exercises(abdominal curl up-supine bridging-trunk extension)
62498642|NCT02458391|EXPERIMENTAL|Treatment 2x/wk|Participants will receive standard of care complete decongestive therapy 2x/wk for 4 weeks.
62498643|NCT02458391|EXPERIMENTAL|Treatment 4x/wk|Participants will receive standard of care complete decongestive therapy 4x/wk for 4 weeks.
62498644|NCT06227754|ACTIVE_COMPARATOR|Angiography-guided PCI|The PCI procedure in this group will be performed as standard procedure.
62498645|NCT06227754|EXPERIMENTAL|Optical coherence tomography-guided PCI|Use of OCT will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT after stent implantation will be mandatory. In this group, the recommendations for selecting reference segment, selecting appropriate size of stent, and stent optimization are as follows. OPTIS imaging catheter (Abbott Vascular) will be used for the imaging arm according to MLD MAX algorithm.
62498646|NCT02985788||Video Instructions|Instructions on how to take a flexion/extension picture will be delivered in video format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
62498647|NCT02985788||Written instructions|Instructions on how to take a flexion/extension picture will be delivered in a written, on paper format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
62498648|NCT02860325|EXPERIMENTAL|NIV-NAVA|Patients allocated to non-invasive NAVA
62498649|NCT02860325|ACTIVE_COMPARATOR|Conventional|Patients allocated to nasal CPAP or non-synchronized nasal IPPV
62498650|NCT00131482|EXPERIMENTAL|10 micrograms|
62498651|NCT00131482|EXPERIMENTAL|30 micrograms|
62698954|NCT04154878||Pacemaker Optimization|Participants were referred for pacemaker optimization following implantation of a device. All had an intact atrial contraction either intrinsic or by device stimulation. A standard baseline echo was performed prior to programming changes with a final echo scan completed after all programming complete. Device programming consisted of adjusting atrial ventricular and right to left ventricular stimulation delays.
62698955|NCT04154878||Healthy|A brief cardiac history questionnaire and complete echocardiogram will be performed.
62736562|NCT02738541|ACTIVE_COMPARATOR|Group 1|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
62341534|NCT06056349|EXPERIMENTAL|Buccal midazolam|50 patients will receive buccal midazolam.
62341535|NCT06056349|ACTIVE_COMPARATOR|Conventional treatment|"50 patients will receive usual/ conventional treatment of seizure clusters"
62341536|NCT00707655|EXPERIMENTAL|Zalutumumab 4 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
62341537|NCT00707655|EXPERIMENTAL|Zalutumumab 8 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
62341538|NCT01165593||Patients with atrial fibrillation|Patients with atrial fibrillation who have received a cardiac CT scan as part of normal care prior to catheter-based treatment of atrial fibrillation.
62341539|NCT02230878|EXPERIMENTAL|JNJ-42847922, 5 milligram (mg) and Placebo|Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
62341540|NCT02230878|EXPERIMENTAL|JNJ-42847922, 10 mg and Placebo|Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
62498652|NCT00131482|PLACEBO_COMPARATOR|Placebo|
62498653|NCT00131482|EXPERIMENTAL|3 micrograms|
62498654|NCT00131482|EXPERIMENTAL|1 microgram|
62498655|NCT05196815|EXPERIMENTAL|The Royal Wolverhampton NHS Trust- New Cross Hospital|
62498656|NCT02153723|EXPERIMENTAL|Copaxone|"Dose escalation:~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection."
62498657|NCT04042402|EXPERIMENTAL|Open Label|Open label, monthly subcutaneous injection
62498658|NCT04313296|EXPERIMENTAL|Patients identified at PBMC with a documented diagnosis of AF|Patients identified at PBMC with a documented diagnosis of AF (at any point in time) and who have undergone any cardioversion.
62498659|NCT04316325||Women and girls seeking abortion.|
62498660|NCT01770834||Cohort|
62498661|NCT06086353||Patients with ATTR-CM in India|
62498662|NCT03485716|EXPERIMENTAL|running under hypoxia - first|running under hypoxia (first day) and normoxia (second day)
62498663|NCT03485716|ACTIVE_COMPARATOR|running under normoxia - first|running under normoxia (first day) and hypoxia (second day)
62498664|NCT01307943|EXPERIMENTAL|Mindfulness Based Stress Reduction|"Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat at the completion of the eight sessions to review and consolidate experience with the various mindfulness practices. The MBSR concepts and techniques will emphasize portability. Participants will be encouraged to find moments throughout their day in which to practice the techniques. The language used to describe mindfulness practices will be accessible to youth. Mindfulness concepts will be linked with tag phrases like breathing break, autopilot, and choice points. Homework will emphasize experiential, concrete tasks (notice five new things today; eat one meal mindfully this week)."
62140746|NCT06694441|ACTIVE_COMPARATOR|Dim Red Light|Participants randomized to the control group will wear for two 60-minute sessions (morning and afternoon) customized dim-red light (RL) control Re-Timer® light glasses (wavelength peak at 632nm, light intensity \< 3 lux). Participants will be instructed to wear the light glasses in habitual indoor environments, without engaging in strenuous activities. Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects.
62498665|NCT01307943|ACTIVE_COMPARATOR|Usual Care|The control group will be youth receiving therapies and programs already used at the site. The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
62498666|NCT00153257|OTHER|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
62498667|NCT00153257|NO_INTERVENTION|No device|standard anterior colporrhaphy
62498668|NCT06679712|EXPERIMENTAL|Transbronchial PDT|
62140747|NCT01640951|EXPERIMENTAL|AIN457 150 mg - Fixed Interval (FI)|1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
62140748|NCT01640951|EXPERIMENTAL|AIN457 150 mg - Start of relapse (SoR)|"Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
62140749|NCT01640951|EXPERIMENTAL|AIN457 300 mg - Fixed Interval (FI)|2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
62140750|NCT01640951|EXPERIMENTAL|AIN457 300 mg - Start of Relapse (SoR)|"Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
62140751|NCT01640951|EXPERIMENTAL|AIN457 300 mg - Open Label (OL)|Open Label - Secukinumab 300mg every 4 weeks
62140752|NCT05554549||UK Biobank|UK Biobank. There are no interventions in this observational cohort study.
62140753|NCT05930106|ACTIVE_COMPARATOR|Group Intraoperative fluid ratio|The intraoperative fluid ratio will determine fluid administration. This ratio is calculated by dividing the sum of subcutaneous infiltration and intravenous fluid by the total aspirate volume. Depending on the aspiration volume, it will be maintained at 1-1.4.
62140754|NCT05930106|EXPERIMENTAL|Group Carotid Artery Peak Velocity Variation|Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA.
62140755|NCT04492475|EXPERIMENTAL|Remdesivir plus Interferon Beta-1a|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 44 mcg of interferon beta-1a administered by a 0.5 mL subcutaneous injection on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
62140756|NCT04492475|PLACEBO_COMPARATOR|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and a 0.5 mL placebo injection administered subcutaneously on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
62140757|NCT02252822|EXPERIMENTAL|The Overcoming Bulimia Online Programme|This treatment incorporates a combination of cognitive-behavioral, motivational and education strategies. The program will be presented in 8 collaborative, multi-media, web based CBT sessions for BN.
62140758|NCT02646774|EXPERIMENTAL|Micafungin group|Injection
62140759|NCT05532501|ACTIVE_COMPARATOR|Oral Oxytocin|Administer oxytocin (24 IU) orally
62140760|NCT05532501|ACTIVE_COMPARATOR|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally
62341541|NCT02230878|EXPERIMENTAL|JNJ-42847922, 20 mg and Placebo|Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
62341542|NCT02230878|EXPERIMENTAL|JNJ-42847922, 40 mg and Placebo|Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
62341543|NCT03831802|EXPERIMENTAL|experimental group|The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary
62341544|NCT03831802|ACTIVE_COMPARATOR|Control group|The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance
62341545|NCT05166746|ACTIVE_COMPARATOR|Clindamycin + LACTIN-V (L.crispatus)|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
62341546|NCT05166746|ACTIVE_COMPARATOR|Clindamycin + placebo LACTIN-V|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V placebo (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
62341547|NCT05166746|PLACEBO_COMPARATOR|Placebo clindamycin + placebo LACTIN-V|Matching clindamycin placebo 2 times per day for 7 days followed by LACTIN-V placebo (Osel Inc.) until completion of the clinical pregnancy scan at week 7-9.
62341548|NCT01418053|EXPERIMENTAL|Hot Cataplasm with Caraway Oil|
62341549|NCT01418053|ACTIVE_COMPARATOR|Hot Cataplasm with Olive oil|
62341550|NCT01418053|ACTIVE_COMPARATOR|Cold cataplasm with Olive oil|
62498669|NCT00988468|EXPERIMENTAL|Manual Therapy|Subjects will receive oscillatory (grade 1 \& 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
62498670|NCT00988468|EXPERIMENTAL|Therapeutic Exercise|Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
62498671|NCT00988468|PLACEBO_COMPARATOR|Control|Subjects will watch a 15 minute instructional video on a health topic.
62498672|NCT01436643|EXPERIMENTAL|Fluoxetine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
62698956|NCT05467410|EXPERIMENTAL|COG-AM|30-minute morning session of a computerized cognitive training intervention (Lumosity), delivered between the hours of 09:00 AM - 12:00 PM, in addition to UC
61949620|NCT05325060|ACTIVE_COMPARATOR|Conventional mechanically alligned Total knee arthroplasty|"Participants randomized to the conventional group received a TKA implanted using standard instrumentation.~All patients received a cemented posterior stabilized NexGen LPS Flex TKA (Zimmer, Warsaw, Indiana, USA).~Alignment targets were similar in both groups with a neutral Hip-Knee-Ankle-Axis and the aim to implant both femur and tibial components perpendicular to this in the coronal plane."
61949621|NCT06086275|EXPERIMENTAL|8mg PO buprenorphine|After the open-label period, the participant will receive 8mg PO, then 16mg PO will be administered in the following visit.
61949622|NCT06086275|EXPERIMENTAL|16mg PO buprenorphine|After the open-label period, the participant will receive 16mg PO, then 8mg PO will be administered in the following visit.
61949623|NCT06086275|EXPERIMENTAL|0.15mg IV Dose|The first dose administered will be fixed to an open-label 0.15mg IV dose.
62498673|NCT01436643|EXPERIMENTAL|Venlafaxine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
62498674|NCT01436643|EXPERIMENTAL|Citalopram and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg
61949624|NCT06556862|EXPERIMENTAL|Dalpiciclib + Tucidinostat|Dalpiciclib + Tucidinostat + Endocrine therapy (doctor's choice)
61949625|NCT03353246|EXPERIMENTAL|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
62498675|NCT03224767|EXPERIMENTAL|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
61949626|NCT03754569|EXPERIMENTAL|Peritoneal biopsies|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
61949627|NCT00545766|EXPERIMENTAL|Interventional|
61949628|NCT04782661|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Participants will receive an oral solution of JNJ-70075200 or placebo in single ascending doses on Day 1 in cohorts 1, 2, 3, 4, 5a and 6 under fasted condition. Participants in cohort 5a will additionally receive the same study intervention under fed condition (Cohort 5b) after a washout period of at least 7 days.
61949629|NCT04782661|EXPERIMENTAL|Part 2: Multiple Ascending Dose (MAD)|After assessment of safety, tolerability and pharmacokinetics data in Part 1, participants will receive an oral solution of JNJ-70075200 or placebo twice daily in Cohorts 1 to 6 for 14 days under fasted/fed condition.
62341551|NCT05641038|ACTIVE_COMPARATOR|Group 1 Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session.
62698957|NCT05467410|EXPERIMENTAL|COG-PM|30-minute afternoon/evening session of a computerized cognitive training intervention (Lumosity), delivered between the hours of 15:00 PM - 18:00 PM, in addition to UC
61949630|NCT04782661|EXPERIMENTAL|Part 3: Single-dose Oral Solid Formulation (Optional)|Participants will receive oral dose of JNJ-70075200 on Day 1 in Cohort 1 under fasted condition. Part 3 will start after obtaining a formal regulatory/ethical approval.
61949631|NCT04682028|OTHER|experiment group|Nurses provide web-based continuous care to patients.
61949632|NCT04682028|OTHER|contral group|Nurses provide the routine care to patients.
61949633|NCT06557187|EXPERIMENTAL|Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost|HA-WBRT (30 Gy in 12 fractions, Dmax of the hippocampal volume ≤ 17 Gy, Dmean of the hippocampal volume ≤12 Gy) +SIB (48 Gy in 12 fractions)
61949634|NCT02027961|EXPERIMENTAL|Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib|Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
62341552|NCT05641038|ACTIVE_COMPARATOR|Group 2 Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session.
62341553|NCT06270355|EXPERIMENTAL|Experimental arm|Women randomised to the experimental arm / individualised screening will have their 2-year breast cancer risk assessed upfront. This is done via an AI (artificial intelligence) derived analyses of the mammograms. Women scored with the highest 2-year risk will be offered a contrast enhanced mammography and an additional mammography at 12 months.
62341554|NCT06270355|ACTIVE_COMPARATOR|No intervention arm|The 35,000 women randomised to the no intervention arm will continue in the Swedish National Breast Cancer Screening Program. This means that they are invited for the next mammography screening after 24 months.
62341555|NCT02476357|ACTIVE_COMPARATOR|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
62341556|NCT02476357|ACTIVE_COMPARATOR|Control|Monopolar scalpel and ligature
62341557|NCT01268423|EXPERIMENTAL|Early percutaneous tracheostomy|
62341558|NCT01268423|ACTIVE_COMPARATOR|Prolonged translaryngeal intubation|
62341559|NCT05363683|ACTIVE_COMPARATOR|Control|Standard care.
62341560|NCT05363683|EXPERIMENTAL|Experimental|Squat biofeedback intervention.
62341561|NCT02035982|ACTIVE_COMPARATOR|Cholinesterase Inhibitor|Participants randomized into the cholinesterase inhibitor arm will continue receiving their cholinesterase inhibitor at the same dosage.
62498676|NCT04011449|EXPERIMENTAL|Device Implantation|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
62498677|NCT06574191|EXPERIMENTAL|Diclofenac|All study participants receiving topical diclofenac gel 1%. Participants will be instructed to apply 4 grams of the gel to the index knee at least once per day, and up to 4 times per day, for 8 weeks.
62498678|NCT01160445|EXPERIMENTAL|HD IL-2 + Zanolimumab - Melanoma|"Patients with metastatic melanoma Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
62498679|NCT01160445|EXPERIMENTAL|HD IL-2 + Zanolimumab - Renal Cell|"Patients with metastatic renal cancer Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
62498680|NCT01579006||Cohort|
62341562|NCT02035982|PLACEBO_COMPARATOR|Placebo|Participants randomized into the placebo arm will be tapered off their cholinesterase inhibitor for the first 2 weeks. For the remaining 6 weeks of their study they will be receiving only placebo, and no cholinesterase inhibitor.
62341563|NCT04347226|EXPERIMENTAL|BMS-986253|BMS-986253 2400mg IV
62498681|NCT02795026|ACTIVE_COMPARATOR|Manual therapy|Intervention to be administered is manual therapy with myofascial release of trigger points for pelvic floor muscles, pelvis and abdominal musculature.
62498682|NCT02795026|ACTIVE_COMPARATOR|Dry needling & manual therapy|Intervention to be administered is Trans-perineal trigger point dry needling, done externally to target the trigger points in the pelvic floor muscles along with dry needling of the pelvis and abdominal musculature.Manual therapy will only be used in areas difficult to reach with the acupuncture needles.
62498683|NCT00556699|EXPERIMENTAL|1|
62498684|NCT02891213||LE (Lupus Erythematosus) group|"* Samples of the LE (Lupus Erythematosus) group from a specimen collection : Lupus BioBanque du Rhin Supérieur (LBBR UF 9882).~* It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank Lupus BioBanque du Rhin Supérieur (project : LBBR UF 9882)."
62498685|NCT05233787|EXPERIMENTAL|Arm A: Tailored use of defunctioning stoma after TME|"The tailored use of defunctioning stoma includes two steps:~* Firstly, the decision to use or not a defunctioning stoma will be based on the personalized risk of anastomotic leakage (according to AFOR score). This score is ranked from 0 to 6, and includes gender, Body Mass Index, smoking, diabetes, tumor size and preoperative radiotherapy.~* Patients with AFORS equal to 0 or 1 (risk of anastomotic leakage less than 10%) will not have defunctioning stoma;~* Patients with AFORS equal to or between 2 and 6 (risk of anastomotic leakage more than 20%) will have a defunctioning stoma.~* Secondly, in patients with a defunctioning stoma, an early closure will be performed day 8-12 after TME if:~* No fever postoperatively (≤ 38°C),~* CRP at day 2 lower than 115mg/L (+/- 10 mg/L), decreasing at day 4,~* CT-scan with colonic contrast retrograde enema showing no anastomotic leakage."
62498686|NCT05233787|ACTIVE_COMPARATOR|Arm B: Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 3 months after TME according to French national guidelines
62498687|NCT06016153|ACTIVE_COMPARATOR|Instructor feedback|BLS training participants will receive feedback from an experienced instructor certified by European Resuscitation Council on the depth and frequency of chest compressions, duty cycle, chest recoil and the quality of ventilation.
62341564|NCT04347226|NO_INTERVENTION|Standard of Care treatment|Usual treatment of COVID-19 per study physician discretion
62341565|NCT02289404|EXPERIMENTAL|NVP-1203(fed then fasting)|Subjects will receive a oral dose of NVP-1203 under fed conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fasting conditions in period 2
62341566|NCT02289404|EXPERIMENTAL|NVP-1203(fasting then fed)|Subjects will receive a oral dose of NVP-1203 under fasting conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fed conditions in period 2
62341567|NCT01755468|ACTIVE_COMPARATOR|Continuous metformin|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
62341568|NCT01755468|EXPERIMENTAL|Intermittent insulin therapy|After a 3-week course of intensive insulin therapy, participants will receive intermittent intensive insulin therapy for 2 weeks every 3 months. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months
62341569|NCT05868096|EXPERIMENTAL|Experimental group|During the 12 weeks of the internship, the experimental group took a pre-test after a case report-1 in weeks 4-5, which included completing the holistic thinking case analysis form and the personal learning self-efficacy questionnaire, followed by a 2-hour structured holistic thinking course. At the end of the session, subjects took the first post-test, revised the case analysis form completed in the pre-test based on the case report-1 observed in the pre-test, and completed the personal learning self-efficacy questionnaire and the satisfaction questionnaire again. During weeks 6-11 of the internship, participants continue to receive clinical practice training in assessment, intervention planning, and patient intervention skills. In weeks 11-12 of the internship, subjects took a second post-test after reading case report-2, which included completing the holistic thinking case analysis form and again completing the personal learning self-efficacy questionnaire.
62498688|NCT06016153|EXPERIMENTAL|Software feedback|BLS training participants will receive feedback based on a software (InnoMed CardioAid-1 Trainer AED, Innomed Inc., Budapest, Hungary) on the quality of chest compression (exact frequency, depth of chest compression, chest recoil and duty cycle) and tidal volume during ventilation.
62498689|NCT02203578|EXPERIMENTAL|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62498690|NCT03432273|EXPERIMENTAL|Nicotine 2 mg mint lozenges|
62498691|NCT03432273|ACTIVE_COMPARATOR|NiQuitin 2 mg mint lozenges|
62698958|NCT05467410|NO_INTERVENTION|UC|Standard post-ICU inpatient care/usual care, which includes physical/occupational therapy as ordered by treatment team
62698959|NCT04164901|EXPERIMENTAL|Vorasidenib|Vorasidenib 40 mg, continuous daily dosing.
62698960|NCT04164901|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo 40 mg, continuous daily dosing.
62698961|NCT04586257|EXPERIMENTAL|Group I|patients in this group will receive Erector spinae plane block after induction of general anesthesia.
62341570|NCT05868096|ACTIVE_COMPARATOR|Control group|During the 12 weeks of the internship, the control group had no structured holistic thinking course. During weeks 4-5 of the internship, after viewing case report-1, a pretest consisting of completing the holistic thinking case analysis form and the personal learning self-efficacy questionnaire was completed and a holistic thinking case analysis form - introductory version was given. Subjects will revise the holistic thinking case analysis form completed in the pretest and complete the personal learning self-efficacy questionnaire again. During weeks 6-11 of the internship, participants continue to receive clinical practice training in assessment, intervention planning, and patient intervention skills. In weeks 11-12 of the internship, subjects received the post-test, viewed the case report-2, and were given the holistic thinking case analysis form - introductory version and completed the holistic thinking case analysis form and the personal learning self-efficacy questionnaire.
62498692|NCT03113357|EXPERIMENTAL|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
62498693|NCT03113357|EXPERIMENTAL|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
61949635|NCT02027961|EXPERIMENTAL|Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib|Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
62140761|NCT05532501|PLACEBO_COMPARATOR|Oral placebo|Administer placebo orally (identical ingredients, except the active agent)
62341571|NCT05738902||Women affected by gynecological cancer.|Women affected by confirmed gynecological cancer treated with open access surgery and managed according to ERAS guidelines.
62341572|NCT00084929|EXPERIMENTAL|CT Colonography|CT colonography conducted during the same assessment as colonoscopy.
62341573|NCT01866878|EXPERIMENTAL|A group enjoying a corrective touch|"At first, the patient is asked to gradually define the different types of touch that is applied to the hyposensitive area (fixed or mobile touches) with different textures and then compare them with the healthy side. In a second step, the patient is asked to associate multiple items sensation shape and texture, shape and weight. In a third step is used everyday objects.~Desensitisation techniques find their interest mainly when symptoms or dysesthetic hyperesthésique. The objective is to increase the threshold of sensitivity to textures and particles eventually reduce dysaesthetic sensations.~The patient class in order of increasing tolerance 10 textures. Dysesthetic area is stimulated 5 to 10 minutes by the first texture to numb the area by saturation of the action potential. This helps promote functional work and recognition of objects. As soon as the texture causes more trouble we go to the next texture by applying the same job."
62341574|NCT01866878|EXPERIMENTAL|A group receiving TENS (TENS)|Well known in the management of neuropathic pain based on the gate control theory, the application of TENS in the rehabilitation of touch remains to be demonstrated. A recent study applied to the September highlighted the long-term interest of the transcutaneous electrical nerve stimulation (TENS) to improve sensitivity tact arguing possible action on brain plasticity.
62341575|NCT01866878|NO_INTERVENTION|A control group|
62341576|NCT02902913|EXPERIMENTAL|Oleocanthal-rich, D2i2|Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
62498694|NCT04063670|ACTIVE_COMPARATOR|Control|Routine, standard-of-care treatment
62498695|NCT04063670|EXPERIMENTAL|Video Intervention|Routine, standard-of-care PLUS peri-operative video series
62698962|NCT04586257|EXPERIMENTAL|Group II|patients in this group will receive thoracolumbar interfascial plane block after induction of general anesthesia
62698963|NCT06221449|PLACEBO_COMPARATOR|Group (I) Control group:(31 patients)|Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg Ideal body weight - fixed fio2 0.5% - fixed POSITIVE end expiratory pressure 6 cm. water - fixed respiratory rate10-14 Respiratory rate /min)
62140762|NCT05532501|PLACEBO_COMPARATOR|Intranasal placebo|Administer placebo intranasally (identical ingredients, except the active agent)
62698964|NCT06221449|ACTIVE_COMPARATOR|Group (II) Sustained inflation group (SI): (31 patients)|Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 centimetreswater, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg Ideal bogy weight - fixed fio2 0.5% - fixed positive end expiratory pressure 6 cmH2O - fixed respiratory rate 10-14 per minute.
62736563|NCT02738541|PLACEBO_COMPARATOR|Group 2|PLACEBO DENTRIFICE WITHOUT PYROPHOSPATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
62140763|NCT01733615||Mucopolysaccharidosis IVA|Patients with the condition.
62140764|NCT05139784||Type 1 diabetes|As defined by the presence of hyperglycemia and/or islet auto-antibodies.
62140765|NCT05139784||Other forms of diabetes or autoimmune endocrinopathy|Type 2 diabetes, ketosis-prone diabetes, familial diabetes, secondary diabetes, immunotherapy-induced diabetes; and/or autoimmune endocrinopathies.
62140766|NCT05139784||No diabetes|No diabetes or impaired glucose tolerance; no cancer, infectious or immune pathologies; no other condition related to autoimmune and metabolic alterations that may bias the variables under study.
61949636|NCT02027961|EXPERIMENTAL|Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent)|Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.
61949637|NCT02027961|EXPERIMENTAL|Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential)|Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.
61949638|NCT05139121|EXPERIMENTAL|MR-100A-01|MR-100A-01 is a transdermal delivery system designed to deliver daily hormone exposure of Norelgestromin and Ethinyl Estradiol
61949639|NCT01137396|EXPERIMENTAL|Modafinil|
61949640|NCT01137396|PLACEBO_COMPARATOR|Placebo|
61949641|NCT01439633|EXPERIMENTAL|MGH OFDI marking and imaging|OFDI imaging
61949642|NCT02632331|EXPERIMENTAL|Fasted dosing preceding group|
61949643|NCT02632331|EXPERIMENTAL|Fed dosing preceding group|
61949644|NCT02388919|EXPERIMENTAL|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
61949645|NCT02388919|PLACEBO_COMPARATOR|Placebo|Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
61949646|NCT05749965||Limit indications|Obèse (BMI\>30), ACL déficiency, HKA \> 10°, flessum \>10° \[HKA : hop knee angle\]
61949647|NCT05749965||Historical indications|Patient with a BMI between 18,5 and 30, HKA \<10°, functionnal ACL, no flessum or \<5°
61949648|NCT01965821|OTHER|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Mallinckrodt electronic device for 24h, followed by discontinuous control (every 8 hours) with a manual manometer for 24h.
61949649|NCT01965821|OTHER|Manual control of Pcuff followed by continuous control|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
61949650|NCT01696695||Metastatic Colorectal Carcinoma (mCRC) Participants|Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed. The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
61949651|NCT02834728||Frail elderly people|A group of elderly people hospitalised in medical wards via emergency department
61949652|NCT02198521||Bilateral Carpal Tunnel Syndrome (CTS)|
61949653|NCT01970657||HP802-247 in prior study|Observational safety follow up study, no treatment specified
61949654|NCT01970657||Vehicle Control in prior study|Observational safety follow up study, no treatment specified
61949655|NCT01275040|EXPERIMENTAL|Mobile screening team|The Primary Health Care clinics where the mobile screening team will visit and active screening for DM complications will take place.
61949656|NCT01275040|ACTIVE_COMPARATOR|No mobile screening team|No mobile team will visit clinics and active screening for DM complications will not be done. Patients and Health Workers will receive Education, same as intervention arm but no enhanced care.
61949657|NCT01560403|EXPERIMENTAL|Teduglutide|0.05 mg/kg/day
61949658|NCT02609204|EXPERIMENTAL|Healthy Controls|Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
61949659|NCT05944887|ACTIVE_COMPARATOR|Linisol|Patients will receive 1.5 mg/kg of intravenous linisol before propofol sedatation and gastroscope introduction
61949660|NCT05944887|PLACEBO_COMPARATOR|Sham|Patients will receive intravenous placebo (saline solution),before propofol sedation and gastroscope introduction
61949661|NCT04721730|EXPERIMENTAL|PLH-YC|"The Parents will receive the optimised version of the Parenting for Lifelong Health for Young Children from 2-9 y. (PLH-YC) identified in Phase 2.~The groups will be conducted with 12 parents per group (with 2 facilitators). If local restrictions due to COVID-19 restrictions do not allow-in person meetings of this size, we will reduce the sample size (6 parents per group, and facilitator) and or conduct the groups online (e.g., using an online video software).~For each session, parents will receive a snack (or food voucher of same amount), childcare, transportation support (if needed), and a certificate at the end. Also, parents participating in at least four out of five PLH sessions will get a small gift. If the groups need be conducted online because of the COVID-19 pandemic, the parents will receive pre-paid data or another voucher of the same amount."
61949662|NCT04721730|ACTIVE_COMPARATOR|Lecture|"Parents will receive a lecture called Raising Healthy Children.~The lecture will be conducted with 12 parents per group (with one facilitator). If local restrictions due to COVID-19 pandemic will not allow in-person meetings, the groups will be online (e.g., using a video meeting software).~During the lecture, parents will receive a snack (or a food voucher of the same amount), childcare, transportation support (if needed), and a certificate at the end. If the lecture needs be conducted online because of the COVID-19 pandemic and associated restrictions, the parents will receive pre-paid data or another voucher of the same amount (instead of childcare, transport voucher and the snack)."
61949663|NCT01846104|EXPERIMENTAL|50-μg booster dose RVEc|Subjects will be receive one 50-μg dose of RVEc
61949664|NCT04798755|ACTIVE_COMPARATOR|Adalimumab|
61949665|NCT04798755|ACTIVE_COMPARATOR|Methotrexate|
61949666|NCT04798755|EXPERIMENTAL|Adalimumab+Methotrexate|
61949667|NCT05154396|EXPERIMENTAL|Neratinib escalation 2 weeks（group A）|Neratinib: 120mg/ day for days 1-7, 160mg/ day for days 8-14, and then 240mg/ day to complete 1-year treatment, or to tumor recurrence and metastasis, new breast cancer, or unacceptable adverse reactions within 1 year.
62140767|NCT05139784||Lymphadenectomy planned at the occasion of an abdominal surgery|Patients undergoing a lymphadenectomy during surgery for the treatment of their underlying pathology.
62736564|NCT04753346||Mild Disease|Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.
62736565|NCT04753346||Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO2 ≥ 90% on room air
61949668|NCT05154396|EXPERIMENTAL|Neratinib escalation 4 weeks（group B）|Neratinib: 160mg/ day for days 1-14, 200mg/ day for days 15-28, and then 240mg/ day for 1 year, or to tumor recurrence and metastasis, new breast cancer, or unacceptable adverse reactions within 1 year.
61949669|NCT05154396|PLACEBO_COMPARATOR|Neratinib standard dose control （group C）|"Neratinib: 240mg/ day for 1 year, or to tumor recurrence and metastasis, new breast cancer or unacceptable adverse reactions within 1 year.~Loperamide prophylaxis: 4mg three times daily on days 1-14 and 4mg twice daily on days 15-56, followed by as needed, not exceeding 16mg/ day."
61949670|NCT01981980|EXPERIMENTAL|Carboxytherapy|It was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
61949671|NCT01981980|EXPERIMENTAL|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
61949672|NCT04496700|EXPERIMENTAL|Group 1 - Shooting test|All participants in this group were tested for shooting abilities before and after blood donation. No variation within the group.
61949673|NCT04496700|EXPERIMENTAL|Group 2 - VO2max|"All participants in this group were tested for physical abilities before and after blood donation. Method: Bruce protocol.~No variation of protocol within the group."
61949674|NCT04496700|EXPERIMENTAL|Group 3 - Feasability|"All participants in this group were tested for feasability before and after blood donation. Method: Hiking uphill with 20 kg backpack.~No variation of method within the group."
61949675|NCT01206075|OTHER|Mozobil + G-CSF - 001|Up to four patients (splenectomized and non-splenectomized) previously mobilized with G-CSF (previous study), who failed to yield by 2 leukaphereses sufficient CD34+ cells for a future gene therapy procedure, will receive the combination of G-CSF+Mozobil
61949676|NCT01206075|OTHER|Mozobil|Sixteen or more patients (non-splenectomized and splenectomized) who were not previously mobilized will receive Mozobil alone.
61949677|NCT01206075|OTHER|Mozobil + G-CSF - 002|Patients who, in this study, fail to mobilize sufficient yields of blood stem cells with Mozobil alone will be invited to be re-mobilized with the combination of Mozobil plus G-CSF.
61949678|NCT05808114|EXPERIMENTAL|Group cognitive behavioral therapy|Friends Program
61949679|NCT05808114|EXPERIMENTAL|Treatment as Usual|A TAU condition during which participants received routine care services tailored to each child individually.
61949680|NCT05766852|ACTIVE_COMPARATOR|Group A: Breath + Psychoeducation|Participants will be asked to participate in the 3 1.5-hour intervention classes. The pre-intervention and post-intervention assessments will require participants to complete a 20-25-minute online survey via Qualtrics and provide saliva samples.
61949681|NCT05766852|EXPERIMENTAL|Group B: Breath + Movement + Psychoeducation|Participants will be asked to participate in the 3 1.5-hour intervention classes. The pre-intervention and post-intervention assessments will require participants to complete a 20-25-minute online survey via Qualtrics and provide saliva samples.
61949682|NCT00889408|EXPERIMENTAL|Treatment|DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8
61949683|NCT01086761|EXPERIMENTAL|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
61949684|NCT01086761|EXPERIMENTAL|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
61949685|NCT01086761|EXPERIMENTAL|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
61949686|NCT01086761|EXPERIMENTAL|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
61949687|NCT01086761|EXPERIMENTAL|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
61949688|NCT01086761|EXPERIMENTAL|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
61949689|NCT01899261|EXPERIMENTAL|Treatment (SBRT)|Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
61949690|NCT01787331|EXPERIMENTAL|Treatment (itraconazole)|Patients receive twice/day 300mg itraconazole (oral)
61949691|NCT02364492|EXPERIMENTAL|MAG-Tn3 + AS15|"3 escalating doses of MAG-Tn3 in combination with a fixed dose of AS15 adjuvant.~For each dose patient will receive 6 injections at 3 interval weeks."
62140768|NCT02180724|EXPERIMENTAL|Previously Treated|Subjects previously treated with Waldenström Macroglobulinemia N=92
61949692|NCT06002607||Short course of antibiotics|Patients assigned to a 48-hour course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient
61949693|NCT06002607||Long course of antibiotics|Patients assigned to a 7 day course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient
61949694|NCT04050345||Part B TRACC Colon|Patients with diagnosis of large bowel cancer (in the colon) and no evidence of metastatic disease
61949695|NCT04050345||Part B TRACC Rectal|Patients who have a diagnosis of large bowel cancer (in the Rectum) and no evidence of metastatic disease
61949696|NCT04050345||Part C TRACC- Standard of Care Adjuvant Chemotherapy|Randomised to Arm A: Standard of Care Arm (Patients with fully resected high risk stage II or stage III colon or Rectal cancer with no evidence of metastatic disease. Patients with locally advanced rectal cancer who have previously undergone chemoradiotherapy are also eligible to enrol.
62140769|NCT02180724|EXPERIMENTAL|Treatment Naïve|Subjects with treatment-naïve Waldenström Macroglobulinemia. N=14
62140770|NCT01809275|EXPERIMENTAL|QBECO|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
62140771|NCT01809275|PLACEBO_COMPARATOR|Placebo|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
62140772|NCT00982072|ACTIVE_COMPARATOR|prednisolone|prednisolone tablets
62140773|NCT00982072|EXPERIMENTAL|tacrolimus|tacrolimus tablets
61949697|NCT04050345||Part C-ct DNA Guided Arm|"Patients with fully resected high risk stage II or stage III colon or rectal cancer with no evidence of metastatic disease. Patients with locally advanced rectal cancer who have previously undergone chemoradiotherapy are also eligible to enrol.~De-escalation of adjuvant chemotherapy in patients who have a post-operative ctDNA negative result"
61949698|NCT06372301|EXPERIMENTAL|Co-existing AS and ATTRwt|Symptomatic patients with co-existing wild-type transthyretin amyloid cardiomyopathy and low-flow low gradient AS.
61949699|NCT03896048||Successful extubation|
61949700|NCT03896048||Failed extubation|Failed extubation will be defined as a patient who in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy.
61949701|NCT02929914|EXPERIMENTAL|Control|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, dentin washed with sodium 0.9% saline, sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
61949702|NCT02929914|EXPERIMENTAL|PDT+CH|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, disinfect the remaining dentin with antimicrobial photodynamic therapy (DENFOTEX PADplus), sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
61949703|NCT01332370||Adults with Type 2 Diabetes|Subjects with a diagnosis (ICD-9 code) of diabetes
61949704|NCT01682954|EXPERIMENTAL|Lifestyle counseling|Diabetes Prevention Program lifestyle intervention
61949705|NCT01682954|NO_INTERVENTION|Usual Care|Usual care from primary care physician
61949706|NCT04142632||long term evaluation of hypospadias surgery|
61949707|NCT02430623|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Urinary Bladder Neoplasms
61949708|NCT02430623|NO_INTERVENTION|Control|The patients without treatment
61949709|NCT04167982|EXPERIMENTAL|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid(ALA) cream for 30min. A repeat treatment was administered once weekly for a maximum of 5 times. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and after treatment.
61949710|NCT04167982|ACTIVE_COMPARATOR|conventional-dose isotretinoin group|Patients in the conventional-dose isotretinoin group were given oral isotretinoin 0.5 mg/kg daily for 6 months, and the cumulative dose was 90 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
61949711|NCT04167982|ACTIVE_COMPARATOR|low-dose isotretinoin group|Patients in the low-dose isotretinoin group were given oral isotretinoin 0.2 mg/kg daily for 6 months, and the cumulative dose was 36 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
61949712|NCT04840004|OTHER|PVT-1|One arm study.
61949713|NCT04878497||Warfarin|New users of warfarin
61949714|NCT04878497||Dabigatran|New users of dabigatran
61949715|NCT04878497||Rivaroxaban|New users of rivaroxaban
61949716|NCT04878497||Apixaban|New users of apixaban
61949717|NCT04878497||Edoxaban|New users of edoxaban
61949718|NCT02371148|EXPERIMENTAL|Bortezomib-Rituximab-Bendamustine|Bortezomib-Rituximab-Bendamustine (BRB) combination in patients with relapsed/refractory lymphoplasmocytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia after one line of therapy.
61949719|NCT04447794|ACTIVE_COMPARATOR|Step Away App|Participants randomly assigned to this arm will access the Step Away smartphone-based mobile application immediately upon enrollment.
61949720|NCT04447794|EXPERIMENTAL|Step Away Chatbot|Participants randomly assigned to this arm will access the Step Away mobile, text-based, interactive AI chatbot immediately upon enrollment.
61949721|NCT04447794|NO_INTERVENTION|Step Away App Delay|Participants randomly assigned to this arm will be provided access to the Step Away smartphone-based mobile application three months after enrollment.
61949722|NCT04325178|EXPERIMENTAL|Animal|Participants receive the majority of their protein from animal-derived protein sources (1.8g.kg.day).
61949723|NCT04325178|EXPERIMENTAL|Non-animal|Participants receive all their protein from non-animal-derived protein sources (1.8g.kg.day).
61949724|NCT02768363|ACTIVE_COMPARATOR|CAN-2409|Patients randomized to the active arm will receive two courses of aglatimagene besadenovec (CAN-2409) + valacyclovir
61949725|NCT02768363|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir
61949726|NCT01431170|EXPERIMENTAL|Besivance Treatment Group|Besivance™ ophthalmic suspension, 0.6%
61949727|NCT01431170|ACTIVE_COMPARATOR|Polytrim Treatment Group|Polytrim ophthalmic solution
61949728|NCT03000569|EXPERIMENTAL|Part A: Antiparkinsonian Agent(s) Followed by SAGE-217|Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.
61949729|NCT03000569|EXPERIMENTAL|Part B: Antiparkinsonian Agent(s) + SAGE-217|Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.
61949730|NCT02885896||Experimental period (active platform)|During the experimental period, the eligible calls will be transferred to the platform by SAMU regulator doctors, and callers will be subject to health advice by specially trained nurses. The nurse conduct the call by holding the conversation guide, giving advice for a home care, answering questions from the circle (caller, family,..) and ensuring the proper understanding of these tips. An information leaflet for the theme of the call will be sent in the days following the call to the caller of the experimental group having given their consent.
61949731|NCT02885896||Control period (inactive platform)|During the control periods, the call center will not be active, eligible calls can not receive advice from nurses, but will be subject to the usual care: the regulator doctor will treat the call as its current practice.
61949732|NCT00546104|EXPERIMENTAL|Dasatinib|50- 100 mg PO BID
61949733|NCT04336293|EXPERIMENTAL|active|active sTMS
61949734|NCT04336293|SHAM_COMPARATOR|sham|sham sTMS
61949735|NCT04558944|NO_INTERVENTION|Control group|This group received pain and pruritus medication as needed, received the usual physical therapy as per the protocol of our burn unit, as well as compression garments, silicone sheets and gels and moisturizing cream twice a day. Additionally, the patients were advice on reducing sun exposure and applying +50SPF sunblock on a daily basis.
61949736|NCT04558944|EXPERIMENTAL|Extracorporeal Shock Wave Therapy group|This group received the same treatment as the control group plus Extracorporeal Shock Wave Therapy (The DermaPACE® System, SANUWAVE Health Inc., USA) with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
61949737|NCT04253262|EXPERIMENTAL|Dose Level -2|300 mg Rucaparib, 45 mg (day 1 \& 15) Copanlisib
61949738|NCT04253262|EXPERIMENTAL|Dose Level -1|400 mg Rucaparib, 45 mg (day 1 \& 15) Copanlisib
61949739|NCT04253262|EXPERIMENTAL|Dose Level 1|400 mg Rucaparib, 45 mg Copanlisib
61949740|NCT04253262|EXPERIMENTAL|Dose Level 2|500 mg Rucaparib, 45 mg Copanlisib
61949741|NCT04253262|EXPERIMENTAL|Dose Level 3|600 mg Rucaparib, 45 mg Copanlisib
61949742|NCT04253262|EXPERIMENTAL|Dose Level 4|600 mg Rucaparib, 60 mg Copanlisib
61949743|NCT00023946|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
61949744|NCT00957554|EXPERIMENTAL|irbesartan/amlodipine|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks
62698965|NCT06221449|ACTIVE_COMPARATOR|Group (III) Stepwise PEEP increasing: (31 patients)|Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in Positive end expiratory pressure 2 centimetres water every 5 respiratory cycle with maximum 10-12 centimetres water guided by hemodynamics \& airway pressure not exceeding 40 centimetres water With these parameters (fixed Tidal Volume 6-8ml/Kg Ideal body weight - fixed fio2 0.5% -fixed respiratory rate10-14 .
61949745|NCT00957554|ACTIVE_COMPARATOR|irbesartan|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks
61949746|NCT06068608|EXPERIMENTAL|TNM005 dose level 1/placebo|TNM005 on dose level 1 /placebo
61949747|NCT06068608|EXPERIMENTAL|TNM005 dose level 2/placebo|TNM005 on different dose level 2 /placebo
61949748|NCT06068608|EXPERIMENTAL|TNM005 level 3/placebo|TNM005 on dose level 3 /placebo
61949749|NCT06068608|EXPERIMENTAL|TNM005 dose level 4/placebo|TNM005 on dose level 4 /placebo
61949750|NCT06068608|EXPERIMENTAL|TNM005 dose level 5/placebo|TNM005 on dose level 5 /placebo
61949751|NCT06068608|ACTIVE_COMPARATOR|VARIZIG|VARIZIG 625 IU
61949752|NCT04261036|EXPERIMENTAL|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1g of vitamin C for 14 days.
61949753|NCT04261036|PLACEBO_COMPARATOR|Women on a placebo regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take placebo for 14 days
61949754|NCT01332643|ACTIVE_COMPARATOR|Test|The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
61949755|NCT01332643|NO_INTERVENTION|control|The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.
62498696|NCT04337229|EXPERIMENTAL|artificial intelligence techniques|Facial and body movements of newborns will be recorded by camera, and images will be processed in computer environment by using artificial intelligence techniques. As a result, it is planned to create a technology that determines the comfort level of the newborn quickly and simply and can be used by the mobile device.
62498697|NCT03993639|EXPERIMENTAL|KRN125|Single SC administration
62498698|NCT03578809|PLACEBO_COMPARATOR|Cohort A: Placebo|Participants will receive placebo matched to MEDI6012 on Day 1 prior to pPCI followed by a second inpatient dose on Day 3 by IV push.
61949756|NCT06128473|EXPERIMENTAL|Yung Sheng 38% color contact lens|
61949757|NCT02105883|NO_INTERVENTION|Scenario C (control)|no badge
61949758|NCT02105883|ACTIVE_COMPARATOR|Scenario B (badge)|Use of Identification badge during scenarios (roles and places)
61949759|NCT06341075|EXPERIMENTAL|Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|Novel, minimally invasive MRgLITT.
61949760|NCT06341075|NO_INTERVENTION|Open Surgery (OS)|Traditional OS, including ATL, SAH and so on.
61949761|NCT03158896|EXPERIMENTAL|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
61949762|NCT01786941|NO_INTERVENTION|Lean Group|Healthy Controls - no intervention
61949763|NCT01786941|OTHER|Pre-Diabetes Group|Pre-Diabetes Group will undergo a 6-mo Aerobic and Resistance combined exercise training intervention
62498699|NCT03578809|EXPERIMENTAL|Cohort A: MEDI6012|Participants will receive loading dose of MEDI6012 300 mg on Day 1 prior to pPCI followed by a second inpatient dose of MEDI6012 150 mg on Day 3 by IV push.
62498700|NCT03578809|PLACEBO_COMPARATOR|Cohort B: Placebo|Participants will receive placebo matched to MEDI6012 on Day 1 prior to pPCI followed by a second inpatient dose on Day 3, and outpatient maintenance doses on Days 10, 17, 24, and 31 by IV push.
62498701|NCT03578809|EXPERIMENTAL|Cohort B: MEDI6012|Participants will receive loading dose of MEDI6012 300 mg on Day 1 prior to pPCI followed by a second inpatient dose of MEDI6012 150 mg on Day 3, and outpatient maintenance doses of MEDI6012 100 mg on Days 10, 17, 24, and 31 by IV push.
62498702|NCT01702415|PLACEBO_COMPARATOR|Placebo|Placebo
62498703|NCT01702415|EXPERIMENTAL|Zoledronic acid|Active IMP
61949764|NCT01786941|OTHER|Gastric Bypass Group|Non-diabetic patients intending to undergo Gastric Bypass surgery
61949765|NCT01067664||Patients undergoing IVF with rFSH and GnRH antagonists|
61949766|NCT06176521|OTHER|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|
61949767|NCT01024075|PLACEBO_COMPARATOR|Saline|Sinufoam is mixed with saline and placed within the ethmoid cavity at the completion of sinus surgery
61949768|NCT01024075|ACTIVE_COMPARATOR|Dexamethasone|Sinufoam is mixed with dexamethasone and placed within the ethmoid cavity at the completion of sinus surgery
61949769|NCT02021227|NO_INTERVENTION|Standard group|
61949770|NCT02021227|OTHER|Chair sitting group|
62736566|NCT04753346||Severe Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea,fast breathing) plus one of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; or SpO2 \< 90% on room air.
61949771|NCT06424574|EXPERIMENTAL|Motivational interviewing|"I. Interview: -Research for parents information was given about. Pretest forms were applied.~Pre-test forms from filling;~1. st interview after 2 weeks (45 min)~2. nd interview after 2 weeks (45 min)~3. Interviews after 2 weeks (45 min)~4. th interview after 2 weeks (45 min)~5. th interview: Post-test data were obtained 2 weeks after the last interview they were."
61949772|NCT06424574|NO_INTERVENTION|Standard care|"I. Interview: -Research for parents information was given about. Pretest forms were applied.~II interview: Post-test data were obtained 2 weeks after the last interview they were.~Post-test data were obtained 10 weeks after the last interview (it was ensured that the same time period passed with the experimental group)"
61949773|NCT04479930|EXPERIMENTAL|HappyAir Group|The HappyAir app comprises two main parts: an educational program providing patients useful information and advice about their illness and data collection related to physical activity and disease.
61949774|NCT04479930|NO_INTERVENTION|Control group|The control group only underwent the scheduled check-ups
62140774|NCT06098118|EXPERIMENTAL|Decision Aid|Participants will receive the adapted MyMammogram decision aid that includes environmental risk information.
62140775|NCT06696508|EXPERIMENTAL|Insitu spatulation and pre-dismembering ureteropelvic angle suturing during laparoscopic pyeloplasty|"After proper dissection of the PUJ, the anterior wall of the renal pelvis was incised.~The incision continued downwards and laterally towards the PUJ and the lateral aspect of the ureter.~In cases where crossing vessels were present, the pelvis with the PUJ and the uppermost part of the ureter were properly dissected from these vessels. This gave a wide room for pulling the pelvis upwards and gentle retraction of the crossing vessels allowing incision of the anterior wall of the pelvis and starting the spatulation of the PUJ. Spatulation could then continue to the upper ureter behind the properly dissected and retracted vessels.~After complete spatulation and before dismembering the PUJ, we made benefit of splinting the ureter in place; a Maryland grasper opened the lumen of the ureter and the first stitch was precisely placed from outside inwards at the proper angle of the ureteric spatulation using 5/0 Vicryl sutures.~The posterior wall of the PUJ and the pelvis was then dismembered"
62498704|NCT03788876|ACTIVE_COMPARATOR|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
62498705|NCT03788876|SHAM_COMPARATOR|Conventional care|The protocol of physiotherapy by the physiotherapists of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
62498706|NCT02051660|EXPERIMENTAL|Manualized CALM Intervention|
62736567|NCT04753346||Critical Disease|Patients have one of the following: acute respiratory distress syndrome; sepsis; or septic shock.
62736568|NCT06369753|EXPERIMENTAL|Biofeedback|
61949775|NCT05400746|EXPERIMENTAL|Group 1 - low dose|8-10 volunteers receiving three doses of 10 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
61949776|NCT05400746|EXPERIMENTAL|Group 2 - standard dose|8-10 volunteers receiving three doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
61949777|NCT05400746|EXPERIMENTAL|Group 3 - fractional dose|8-10 volunteers receiving two doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0 and 28, followed by one dose of 10 µg Pfs48/45 in 50 µg Matrix-M on day 56 via intramuscular injection (IM) in the deltoid region of the arm
61949778|NCT01738542|EXPERIMENTAL|Antiaggregants & Statins & Antihypertensives & Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy
61949779|NCT01738542|ACTIVE_COMPARATOR|Antiaggregants & Statins & Antihypertensives|Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy
61949780|NCT06169046|EXPERIMENTAL|clenbuterole|45 patients will receive Clenbuterol at a final dosage of 0.04 mg/day, treated for a total of 48 weeks
62498707|NCT02051660|ACTIVE_COMPARATOR|Non-manualized supportive intervention|
62498708|NCT02937363|EXPERIMENTAL|Alpha-lipoic acid|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
62498709|NCT02937363|PLACEBO_COMPARATOR|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
62498710|NCT02123732|EXPERIMENTAL|DbXell|Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
62498711|NCT02123732|PLACEBO_COMPARATOR|Placebo|Drug: Placebo of DbXell Placebo of DbXell three times daily for 12 weeks and then switching to DbXell for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
62498712|NCT05798637||Group A|Elderly subjects diagnosed with coronary syndrome ascertained by coronary angiography
62498713|NCT05798637||Group B|Frail elderly
61949781|NCT06169046|PLACEBO_COMPARATOR|placebo|45 patients will receive placebo, treated for a total of 48 weeks
61949782|NCT02791997|EXPERIMENTAL|Brain-damaged patients|
62698966|NCT02305992|EXPERIMENTAL|Axillary Block with 0.5% Ropivicaine|Patients will receive an axillary block using an ultrasound-guided technique. After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the cephalic aspect of the transducer toward the posterior aspect of the axillary artery. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 20 mL solution of 0.5% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
62698967|NCT02305992|EXPERIMENTAL|Stellate Ganglion Block with 0.2% Ropivicaine|Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
61949783|NCT02791997|EXPERIMENTAL|Control participants|
61949784|NCT02791997|EXPERIMENTAL|Migraine patients|
61949785|NCT00855673|EXPERIMENTAL|Active|Active group receiving intermittent compression
61949786|NCT00855673|ACTIVE_COMPARATOR|Control|Standard Medical Treatment
61949787|NCT05759078|EXPERIMENTAL|Active|an i.v. 15-minute infusion of 20 mL Ferinject (containing 1000 mg of FCM) diluted in 50 mL of NaCl 0.9%
61949788|NCT05759078|PLACEBO_COMPARATOR|Placebo|70 mL of i.v. NaCl 0.9% infusion
61949789|NCT02362581|EXPERIMENTAL|On demand treatment, prophylaxis treatment|"On demand treatment arm:Patients received factorVIII concentrate(Hemofil M) when they had bleeding episodes.~Prophylaxis arm: patients received factorVIII concentrate (Hemofil M) 30-35 unit/kg once a week"
61949790|NCT04894448||PLWH|HIV positive
62498714|NCT05798637||Group C|Elderly subjects with type 2 diabetes mellitus
62698968|NCT02305992|ACTIVE_COMPARATOR|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
62698969|NCT06365749||Neonate with hearing loss|Neonates who failed in the neonatal hearing screening programs, including oto-acoustic emissions and automated auditory brain stem response.
62698970|NCT06641843||patients diagnosed with cardiovascular disease|Patients diagnosed with cardiovascular disease, including Kawasaki disease, anomalous origin of coronary artery, postoperative congenital heart diseases
62698971|NCT02495883|OTHER|Essential Tremor Group|Patients will be randomized to start in one of two treatment arms: 1) 50ml of 40% ethanol or 2) Propranolol SR 60-120mg. In patients who receive ethanol first, they will return for a second visit when they will receive Propranolol, and vice versa. Ethanol will be administered to participants diagnosed with Essential Tremor during the study visit, whereas patients receiving Propranolol SR will be administered daily over an estimated period of two weeks prior to the fMRI visit.
62698972|NCT02495883|NO_INTERVENTION|Health Volunteer Group|Healthy Volunteers will receive no interventions.
62736569|NCT06369753|PLACEBO_COMPARATOR|Placebo|
62736570|NCT06035406|EXPERIMENTAL|Treatment group A: Retagliptin Phosphate Tablet|
61949791|NCT04894448||Control|HIV negative
61949792|NCT01582204|EXPERIMENTAL|124IcG250|This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
61949793|NCT05455268|EXPERIMENTAL|eHOPE|Participants in the intervention group will receive access to e-Hematological Oncology Parent Education (eHOPE) and usual care. Participants will need to complete 4 self-paced activities over a period of 8 weeks. Each activity will be released at 2-weekly intervals.
61949794|NCT05455268|ACTIVE_COMPARATOR|Usual care|Participants in the waitlist-control group will receive verbal explanations and caregiver education based on clinician's needs assessment in the course of their child's treatment process. At the end of 8-weeks, they will also receive access to eHOPE.
61949795|NCT04600141|ACTIVE_COMPARATOR|Group 1 - Therapeutic anticoagulation|"* (I) intravenous UFH started at a dose of 18 IU/kg/h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value; OR~* (II) subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours."
61949796|NCT04600141|ACTIVE_COMPARATOR|Group 2 - Prophylactic anticoagulation|"* (I) subcutaneous UFH 5,000 IU every 8 hours; OR~* (II) subcutaneous LMWH - enoxaparin 40 mg daily."
61949797|NCT04600141|EXPERIMENTAL|Group 3 - Therapeutic anticoagulation with tocilizumab|"* (I) Intravenous UFH initiated at a dose of 18 IU / kg / h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value associated with 8 mg / kg / tocilizumab infusion / intravenous dose in a single dose; OR~* Subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours associated with an infusion of tocilizumab 8 mg / kg / dose in a single dose."
61949798|NCT04600141|EXPERIMENTAL|Group 4 - Prophylactic anticoagulation with tocilizumab|"* (I) subcutaneous UFH 5,000 IU every 8 hours associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose; OR~* (II) subcutaneous LMWH - enoxaparin 40 mg daily associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose."
61949799|NCT06169384|ACTIVE_COMPARATOR|Endoscopic total adenoidectomy|
61949800|NCT06169384|ACTIVE_COMPARATOR|Endoscopic partial adenoidectomy|
61949801|NCT05492214|EXPERIMENTAL|Delay 30s group|Cord clamping will be delayed at 30 seconds after delivery.
61949802|NCT05492214|EXPERIMENTAL|Delay 60s group|Cord clamping will be delayed at 60 seconds after delivery.
62498715|NCT05798637||Group D|Elderly subjects with alzheimer's disease
62498716|NCT05798637||Group E|Not frail elderly subjects
62498717|NCT02382822||HIV infected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
62498718|NCT02382822||HIV uninfected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling
61949803|NCT05492214|EXPERIMENTAL|Delay 90s group|Cord clamping will be delayed at 90 seconds after delivery.
61949804|NCT05492214|NO_INTERVENTION|Control group|Cord clamping will be immediate (within 15 seconds) after delivery, in accordance with the standard practice in the study sites
61949805|NCT05116878|EXPERIMENTAL|Omega-3 Group|Subjects will receive omega-3 supplementation (Nature's Bounty Fish Oil 1400 mg, containing 980 mg Omega-3 per capsule), to begin taking 3 days prior to surgical resection of their vestibular schwannoma. Subjects will continue to take the omega-3 supplementation for 6 weeks post-operatively.
61949806|NCT05116878|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive a placebo to begin taking 3 days prior to clinical care of surgical resection of vestibular schwannoma. Subjects will continue to take the placebo for 6 weeks post-operatively.
61949807|NCT05501275|EXPERIMENTAL|With Psychoeducation|interventional group will receive psychoeducation.
61949808|NCT05501275|NO_INTERVENTION|Basic Therapy Only|this group will receive only basic therapy
61949809|NCT00138372||Adult Repeat Cross-Sectional study (ARCS)|This group will be enrolled from the sub-location of Kanyawegi, Kisumu District, Nyanza Province.
61949810|NCT00138372||Prospective Infant Cohort study (PIC)|will be a clinic-based study recruiting infants attending Chulaimbo Rural Health Training Center (CRHTC), Maseno Division, Kisumu District, Nyanza Province for routine immunizations.
62698973|NCT05337566|EXPERIMENTAL|Azithromycin + Cefuroxime|"Changed with renewed study permissions:~These patients will receive Azithromycin 500 mg (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more) in the operating theatre before the incision.~The previous description:~These patients will receive Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision."
62698974|NCT05337566|ACTIVE_COMPARATOR|Placebo + Cefuroxime|"Changed with new study permissions:~These patients will receive placebo (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more)in the operating theatre before the incision.~The previous description:~These patients will receive placebo (2 tablets) per orally in the evening before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision."
62698975|NCT03639935|EXPERIMENTAL|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
62698976|NCT05416814|EXPERIMENTAL|Kefir administration in critically ill adults|Critically ill subjects will receive Kefir throughout the length of their ICU course in an ascending dosing regimen
62698977|NCT05645380|ACTIVE_COMPARATOR|High sTILs (≥30%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles.
62698978|NCT05645380|ACTIVE_COMPARATOR|Intermediate sTILs (5-29%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for six cycles.
62698979|NCT05645380|ACTIVE_COMPARATOR|Low sTILs (<5%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles followed by Doxorubicin (60 mg/m2) + Cyclophosphamide (600 mg/m2) + Pembrolizumab (200 mg) every 14 or 21 days for four cycles.
62698980|NCT06200948|ACTIVE_COMPARATOR|non-cycling group|patients will receive only complete decongestive treatment
62698981|NCT06200948|ACTIVE_COMPARATOR|cycling group|patients will receive complete decongestive treatment + cycling ergometry treatment
62698982|NCT05840913|EXPERIMENTAL|1.8 ml group|Participants in this group will be given 1 cartridge of articaine solution pre-operatively to endodontic treatment
61949811|NCT00138372||Normal volunteers|will be recruited from the CWRU/UHCMC area as well as general local community.
61949812|NCT03877549|PLACEBO_COMPARATOR|Placebo|10cc 0.0625% bupivacaine
62698983|NCT05840913|EXPERIMENTAL|3.6 ml group|Participants in this group will be given 2 cartridges of articaine solution pre-operatively to endodontic treatment
62698984|NCT01623947|PLACEBO_COMPARATOR|Placebo|
61949813|NCT03877549|EXPERIMENTAL|Low Dose|4mg Dexamethasone + 10cc 0.0625% bupivacaine
61949814|NCT03877549|EXPERIMENTAL|Higher Dose|8mg Dexamethasone + 10cc 0.0625% bupivacaine
61949815|NCT03771820|EXPERIMENTAL|NC-6004 +pembrolizumab|"NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.~In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion."
61949816|NCT03771820|ACTIVE_COMPARATOR|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
62698985|NCT01623947|ACTIVE_COMPARATOR|2.8 g Sustamine|
62698986|NCT01623947|ACTIVE_COMPARATOR|19.6 g Sustamine|
62698987|NCT02731560|OTHER|Single Arm|Treatment with Rituximab in RA patients showing inadequate response to standard DMARDs
62736571|NCT06035406|EXPERIMENTAL|Treatment group B: Retagliptin Phosphate Tablet|
61949817|NCT05159219|EXPERIMENTAL|Oral Colchicine, 0.5mg once daily|Active colchicine tablet
61949818|NCT05159219|PLACEBO_COMPARATOR|Oral matching placebo, once daily|Matching placebo tablet
61949819|NCT04526860|NO_INTERVENTION|Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
61949820|NCT04526860|OTHER|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
61949821|NCT03337295||Low-MGD|
61949822|NCT03337295||High-MGD|
61949823|NCT01443078|EXPERIMENTAL|pemetrexed plus cisplatin, vinorelbine and docetaxel|This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
61949824|NCT01706146|OTHER|Non-Coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
61949825|NCT01593657|EXPERIMENTAL|Mindful Movement and Breathing program|Mindful Movement and Breathing program implemented in a hospital room or clinic room three times by a yoga instructor: prior to surgery, one day and two days after surgery.
61949826|NCT00711139||1|AFFITOPE AD01
61949827|NCT00711139||2|AFFITOPE AD01 + Adjuvant
61949828|NCT00762060||Active|Surgical site continuous local anesthetic infusion with ONQ silver Soaker System
62341577|NCT02902913|EXPERIMENTAL|Oleacein-rich, D2i0.5|Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
62498719|NCT03417206|EXPERIMENTAL|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE between 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD\>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
62698988|NCT05889091|EXPERIMENTAL|Quality of life questionnaires|After the Fat Flap Reconstruction at 6 months post-operatively, all patients will be asked to complete the selected patient reported outcomes instruments and to complete clinical assessment with either the Head and Neck Surgery (HNS) or Plastic \& Reconstructing Surgery (PLA) care team. Range of Motion (ROM) measurements using a goniometer will be completed by a member of the HNS clinical team. At 12 months post-operatively, all patients will be asked to complete the selected patient reported outcomes instruments and to complete clinical assessment. Patients will be asked to complete inter-incisor distance measurement and barium swallow assessment, done by a member of the SLP team. Range of Motion (ROM) measurements using a goniometer will be completed by a member of the HNS clinical team.
62698989|NCT02128035|NO_INTERVENTION|Without Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~The LEAD SHIELD will not be used in this group.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
61949829|NCT00762060||Control|Hospital standard of care for pain management (Patient controlled analgesia or epidural)
62341578|NCT02902913|PLACEBO_COMPARATOR|Oleocanthal and Oleacein-low, D2i0|Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
62341579|NCT02902913|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen, 400 mg
62341580|NCT03932682|EXPERIMENTAL|Seqirus QIVc|Cell-derived Quadrivalent Influenza Vaccine
62341581|NCT03932682|ACTIVE_COMPARATOR|Comparator|Non-influenza Comparator (NesiVac-C)
62341582|NCT00775502|EXPERIMENTAL|BIW-8962, monoclonal antibody|
62341583|NCT04197544|EXPERIMENTAL|Intervention group|
62341584|NCT04197544|NO_INTERVENTION|Control group|
62341585|NCT02860845|EXPERIMENTAL|Boric acid and probiotics|Boric acid with L.gasseri and L.rhamnosus
61949830|NCT06341101|EXPERIMENTAL|Intervention group (Perindopril 2 mg)|Eligible subjects will be counselled and upon informed consent randomized for either medication or care as usual (i.e. no medication). After a complete cardiovascular assessment, medication will be initiated open-labeled (Perindopril 2 mg or no medication). In case of side effects Perindopril will be replaced by Valsartan 40 mg twice daily. A blood pressure below 120/80 mmHg is targeted. Blood pressure will be measured once per two weeks until the targeted blood pressure is achieved or until medication dosage has increased 4 times, corresponding Perindopril 10mg as maximum dosage or corresponding Valsartan 320mg (160 mg twice daily) as maximum dosage.
61949831|NCT06341101|NO_INTERVENTION|Standard care group (i.e. no medication)|Eligible subjects will be counselled and upon informed consent randomized for either medication or care as usual (i.e. no medication).
61949832|NCT01797731|ACTIVE_COMPARATOR|Conventional System|Conventional tibial extramedullary alignment system used by surgeon during surgery.
62341586|NCT02860845|ACTIVE_COMPARATOR|Antibiotic/Antifungal|Antibiotic: Clindamicine Antifungal: Clotrimazol
62341587|NCT01333696|EXPERIMENTAL|Pemetrexed|500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
61949833|NCT01797731|EXPERIMENTAL|KneeAlign System|Digital hand-held surgical navigation system for tibial component placement used by surgeon during surgery.
61949834|NCT05779969||Chest CT scan Patient|Identification of structural damage to the manubriosternal joint (MST) in a population of patients with radiographic axSpA
61949835|NCT05779969||Chest CT scan Control|Identification of structural damage to the manubriosternal joint (MST) in a control population free of chronic inflammatory rheumatism on chest CT.
62341588|NCT06082557|EXPERIMENTAL|All the subjects enrolled will receive the experimental intervention, T60c injection|
62341589|NCT02929849|EXPERIMENTAL|300mg SC|300 mg Salacia Chinensis (SC). This will be compared to placebo.
62341590|NCT02929849|ACTIVE_COMPARATOR|500mg SC|500 mg Salacia Chinensis (SC). This will be compared to placebo.
62341591|NCT02929849|PLACEBO_COMPARATOR|Placebo|The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
62341592|NCT01977079|OTHER|Premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
62341593|NCT01977079|OTHER|Not premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
62341594|NCT05982223|EXPERIMENTAL|Integrative oncology|All patients will be followed up by a haemato-oncologist. The frequency and type of visits and exams will be determined by National Comprehensive Cancer Network (NCCN) guidelines, patients' symptoms and physician's clinical judgement. Patients recruited to the intervention arm will receive, on top of the defined conventional medicine follow-up, integrative oncology intervention including emotional treatments (counseling, spiritual guidance), complementary medicine (acupuncture, herbal supplements, mind-body, touch and/or movement therapies) or both. The type and frequency of these interventions will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
62698990|NCT02128035|EXPERIMENTAL|With Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~In this group, a LEAD SHIELD will be used. The Pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
62698991|NCT01370551|EXPERIMENTAL|Gynoflor|Gynoflor vaginal tablets 1/day x 4 weeks, then 3/week for 8 weeks
62698992|NCT01606241|EXPERIMENTAL|Treatment (cyclophosphamide and vaccine therapy)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1. Within 3-5 days, patients receive multi-epitope folate receptor alpha peptide vaccine ID on day 1. Vaccine treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62698993|NCT02645799|ACTIVE_COMPARATOR|LABR-312|"LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -\> 0.01 mg LABR-312 Group 2: Intermediate dose-\> Up to 0.03 mg LABR-312 Group 3: High dose-\> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
62698994|NCT02645799|PLACEBO_COMPARATOR|saline|"Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -\> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-\> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-\> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
62698995|NCT01044069|EXPERIMENTAL|Pts with B Cell Acute Lymphoblastic Leukemia|This is a phase I study. Patients with CD19+ ALL (CR, relapsed, MRD, or refractory) are eligible for enrollment. B-ALL patients in first CR will be enrolled but only treated if they develop MRD or a frank relapse, while patients with MRD or with documented relapsed/refractory disease are eligible for immediate treatment. The T cell doses originally proposed in this study were based on doses administered safely in prior autologous T cell adoptive therapy trials but the dose has been modified based on the toxicities observed in patients with morphologic evidence of disease. Patients will be treated with different doses of T cells depending on the amount of disease at the time of T cell infusion. Patients in Cohort 1 (\<5% blasts in the BM) will continue to receive 10\^6 19-28z+ T cells/kg as previously. Patients in Cohort 2 (≥5% blasts in the BM) will receive the reduced dose of 1x106 19-28z+ T cells/kg).
62698996|NCT05995626|EXPERIMENTAL|Ablative CO2 laser, and intradermal hyaluronidase, via laser-assisted drug delivery|Uncover a safe, efficacious, and tolerable alternate treatment modality for patients with scleroderma-induced microstomia. Evaluate disease severity and patient quality of life before and after alternative treatment is administered
62698997|NCT02686775|EXPERIMENTAL|Patient coach|Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
62698998|NCT02686775|ACTIVE_COMPARATOR|Standard treatment|Standard care.
62698999|NCT03834740|EXPERIMENTAL|Cohort 1: last dose 1 to 3 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 1: last ribociclib+everolimus dose 1 to 3 hours prior to craniotomy for tumor resection"
62736572|NCT06035406|EXPERIMENTAL|Treatment group C: Retagliptin Phosphate Tablet|
62736573|NCT02667041|EXPERIMENTAL|rTMS treatment (Monophasic vs. biphasic)|Safety and efficacy
61949836|NCT02124525|PLACEBO_COMPARATOR|N-acetylcysteine|"Subjects receiving N-acetylcysteine (NAC): 6 pills/ day of N-acetylcysteine 500mg.~Duration: 12 weeks"
61949837|NCT02124525|PLACEBO_COMPARATOR|Placebo|Placebo will be taken for 12 weeks
61949838|NCT03505190|EXPERIMENTAL|RO7062931 0.3mg/kg|Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.
61949839|NCT03505190|EXPERIMENTAL|RO7062931 1.0mg/kg|Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.
62341595|NCT05982223|NO_INTERVENTION|Conventional medicine only|All patients will be followed up by a haemato-oncologist. The frequency and type of visits and exams will be determined by NCCN guidelines, patients' symptoms and physician's clinical judgement.
61949840|NCT03505190|EXPERIMENTAL|RO7062931 2.0mg/kg|Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.
61949841|NCT03505190|EXPERIMENTAL|RO7062931 4.0mg/kg|Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.
61949842|NCT03505190|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo.
61949843|NCT03410329|EXPERIMENTAL|High weekly training frequency|three sessions a week of resistance training
61949844|NCT03410329|EXPERIMENTAL|Low weekly training frequency|one workouts per week
61949845|NCT04314726|ACTIVE_COMPARATOR|amelogenins group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. Amelogenins effect was evaluated by applying them only in the test site and comparing healing results with those obtained on the contra-lateral site
62341596|NCT01204255|EXPERIMENTAL|Arm I|Patients apply lorazepam, diphenhydramine hydrochloride, and haloperidol gel topically over 2 minutes.
62736574|NCT02667041|ACTIVE_COMPARATOR|EEG/ERP biomarkers|Investigation of pre- and post-treatment cognitive biomarkers
61949846|NCT04314726|PLACEBO_COMPARATOR|placebo group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. In this group (control site) the conventional treatment was performed, and healing was ensured only by the simple blood clot
62498720|NCT03417206|EXPERIMENTAL|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD\>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
61949847|NCT04066647|EXPERIMENTAL|Dexamthesone|Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.
61949848|NCT03700593||Single Port Robotic Colorectal Surgery Patients|All patients who undergo a single port robot colorectal surgery.
61949849|NCT03829839|ACTIVE_COMPARATOR|Oxytocin or PLC|Single dose of intranasal oxytocin (24 international units) or PLC.
61949850|NCT03829839|ACTIVE_COMPARATOR|Lorazepam or PLC|Single dose of lorazepam (1mg) or PLC
61949851|NCT03000283|EXPERIMENTAL|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
61949852|NCT01773733||Obese|Patients 18-65 y.o.with alimentary obesity, BMI (Body Mass Index) ≥ 30 kg/m2)
61949853|NCT01773733||Overweight & risk factors|Patients 18-65 y.o., overweight, BMI ≥ 27 kg/m 2 plus T2DM ( type 2 diabetes mellitus) or dyslipidemia
61949854|NCT01644539|OTHER|Control|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion of 500 ml non caloric load consisting of water and thickening agent (guar gum), over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml non caloric load consisting of water and thickening agent (guar gum) in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
61949855|NCT01644539|OTHER|Oral ingestion|"Subjects participated in a 35 min fmri scan. Intervention: Oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk, over 5 min.~Time frame while scanning:~-5 - 0 min : baseline fmri scan 0 - 5 min: oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
61949856|NCT01644539|OTHER|Intra Gastric|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk, over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
61949857|NCT01033760|EXPERIMENTAL|arm 1|darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir
61949858|NCT01033760|ACTIVE_COMPARATOR|arm 2|darunavir, ritonavir, emtricitabine/tenofovir
62498721|NCT03417206|EXPERIMENTAL|TIVA USING PROPOROL|Infusion of propofol will be adjusted at target of SE 40,remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD\>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
62699000|NCT03834740|EXPERIMENTAL|Cohort 2: last dose 7 to 9 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 2: last ribociclib+everolimus dose 7 to 9 hours prior to craniotomy for tumor resection"
62736575|NCT02667041|ACTIVE_COMPARATOR|Blood biomarkers|Investigation of pre- and post-treatment protein biomarkers
61949859|NCT05143385|NO_INTERVENTION|Control|"The variables to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: Mississippi Aphasia Screening test, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfreiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16., Will be performed on all patients who are part of the trial.~Those patients where conventional rehabilitative treatment is performed will be:~* Physiotherapy sessions~* Speech therapy sessions~* Neuropsychology sessions~* Occupational therapy sessions"
61949860|NCT05143385|EXPERIMENTAL|Intervention Group|The variables are to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: MAST, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfeiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16.The beginning of the intervention will be once you have completed 15 calendar days from your admission.The intervention will be carried out once a week with a duration of 20 min with one of the games chosen by the patient together with the physiotherapist.The completion of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions carried out in order to participate in the study.A registration table will be executed where the number of sessions of each patient and the type of session are quantified like a control group.
61949861|NCT03855865|EXPERIMENTAL|Rapastinel|Rapastinel (450 mg prefilled syringe, weekly intravenous IV administration).
61949862|NCT03855865|ACTIVE_COMPARATOR|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
61949863|NCT03855865|PLACEBO_COMPARATOR|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
61949864|NCT01253473|ACTIVE_COMPARATOR|ipratropium/albuterol|1 puff 4 times daily
61949865|NCT01253473|EXPERIMENTAL|Budesonide|budesonide 180 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
61949866|NCT01253473|EXPERIMENTAL|budesonide/formoterol|budesonide/formoterol 160/4.5 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
62498722|NCT00662896|EXPERIMENTAL|naproxcinod 375 mg bid|
62498723|NCT00662896|ACTIVE_COMPARATOR|naproxen 250 mg bid|
62498724|NCT00662896|ACTIVE_COMPARATOR|ibuprofen 600 mg tid|
62498725|NCT00662896|EXPERIMENTAL|naproxcinod 750 mg bid|
62498726|NCT00662896|ACTIVE_COMPARATOR|naproxen 500 mg bid|
62736576|NCT03483779|EXPERIMENTAL|Experimental group:Ginkgo biloba pills|Five Ginkgo biloba pills a time and three times a day. One treatment period including 8 weeks.
62498727|NCT02250651|EXPERIMENTAL|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
61949867|NCT04284358|NO_INTERVENTION|Standard Instruction workshop|Standard instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and then attempt it themselves.
61949868|NCT04284358|EXPERIMENTAL|Technology Integrated Instruction workshop|Technology integrated instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application.
61949869|NCT01720056|ACTIVE_COMPARATOR|Verapamil|Verapamil 2.5 mg/mL injection sc intralesionally
61949870|NCT01720056|ACTIVE_COMPARATOR|Kenalog 10|Kenalog 10 mg/mL injection sc intralesionally
61949871|NCT03196856|EXPERIMENTAL|Yogurt Group|Group will be consuming 200g of Greek Yogurt (Plain, 0%) 3 times daily for 12 weeks
61949872|NCT03196856|PLACEBO_COMPARATOR|Study Designed Supplement Group|Group will consume an isoenergetic, protein void, maltodextrin-based placebo supplement during the same time points for 12 weeks as well. The Placebo contain maltodextrin and pudding powder to mimic the consistency of Greek yogurt.
61949873|NCT01186536|EXPERIMENTAL|Whey protein supplementation|Daily whey protein supplementation
61949874|NCT01186536|EXPERIMENTAL|Soy Protein supplementation|Daily soy protein supplementation
61949875|NCT01186536|EXPERIMENTAL|Placebo|Daily carbohydrate placebo supplementation
61949876|NCT05899985|OTHER|Single Arm|Eligible subjects will undergo their normal standard of care treatment pathway with the added interventions described below.
61949877|NCT02326792|EXPERIMENTAL|G1-Three sets of exercise|G1 group - the participants will perform three sets of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
61949878|NCT02326792|EXPERIMENTAL|G2-One set of exercise|G2 group - the participants will perform only one set of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
61949879|NCT02326792|NO_INTERVENTION|G3-Control|G3 group - the participants will be the control group, which not participating of exercise program in any time during the study.
61949880|NCT05406778|OTHER|TBD|
61949881|NCT04710602||Minimally invasive|Patients who underwent surgery with a muscle sparing, minimally invasive technique for unstable chest wall after trauma.
61949882|NCT04710602||Historical control|Patients who underwent surgery with large incisions and simultaneous thoracotomy for unstable chest wall after trauma.
61949883|NCT01934946|EXPERIMENTAL|comprehensive rehabilitation 10 days|comprehensive rehabilitation PT OT once per day for 10 times within 14 days hospitalization
61949884|NCT01934946|PLACEBO_COMPARATOR|home rehabilitation|home rehabilitation 6 times of PT home visit within 3 months after discharge
61949885|NCT00931879|PLACEBO_COMPARATOR|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
61949886|NCT00931879|ACTIVE_COMPARATOR|omega-3-ethyl esters 4g|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
61949887|NCT00900237|ACTIVE_COMPARATOR|Eslicarbazepine acetate|Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9
61949888|NCT00900237|ACTIVE_COMPARATOR|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9
61949889|NCT05464693||Patients with obstructive biliary disease|Patients admitted to hospital due to obstructive biliary disease secondary to benign and malign etiologies, undergoing ERCP, will be selected. Bile sample will be taken in ERCP procedure with sterile technique. Its macroscopic appearance will be assessed and biliary culture will be performed.
62341597|NCT02841319|EXPERIMENTAL|Intervention|Virtual reality exercises using Hand Tutor for 8 weeks
62341598|NCT02841319|NO_INTERVENTION|Control|Home exercises for 8 weeks
62341599|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration \> 8 g/dL.
62498728|NCT02250651|EXPERIMENTAL|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
62498729|NCT02250651|ACTIVE_COMPARATOR|Timolol 0.5%: Comparator|Both Eyes: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
62498730|NCT05349240|EXPERIMENTAL|Study Intervention|All subjects will receive treatment with the study device.
62498731|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
62498732|NCT04697316|EXPERIMENTAL|ADHD tDCS|
62498733|NCT04697316|SHAM_COMPARATOR|ADHD Sham|
62498734|NCT04697316|EXPERIMENTAL|Healthy control tDCS|
62498735|NCT04697316|SHAM_COMPARATOR|Healthy control Sham|
62699001|NCT03834740|EXPERIMENTAL|Cohort 3: last dose 23 to 25 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 3: last ribociclib+everolimus dose 23 to 25 hours prior to craniotomy for tumor resection"
62699002|NCT00663156|EXPERIMENTAL|subject|10 subjects receiving breast augmentation with fat grafting
61949890|NCT02741856|EXPERIMENTAL|Arm 1 (carboplatin/paclitaxel+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (50Gy/25 fractions)"
61949891|NCT02741856|EXPERIMENTAL|Arm 2 (cisplatin/capecitabine+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14~Cycles 3 and 4 are given concomitantly with radiotherapy (50Gy/25 fractions). Capecitabine stops on last day of RT."
61949892|NCT02741856|EXPERIMENTAL|Arm 3 (carboplatin/paclitaxel+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (60Gy/25 fractions)"
61949893|NCT02741856|EXPERIMENTAL|Arm 4 (Cisplatin+Capecitabine+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14 Cycles 3 and 4 are given concomitantly with radiotherapy (60Gy/25 fractions). Capecitabine stops on last day of RT."
61949894|NCT06192368|OTHER|Sequence of virtual reality followed by tablet game.|Over a period of two weeks (weeks 1 and 2), participants randomized to this sequence will be asked to use virtual reality for 15 minutes during four break periods. These two weeks of virtual reality will be followed by a week with no exposure (week 3). In the following two weeks, participants will be asked to play a game on a tablet for 15 minutes during four break periods (weeks 4 and 5).
61949895|NCT06192368|OTHER|Sequence of tablet game followed by virtual reality:|Over a two-week period (weeks 1 and 2), participants randomized to this sequence will be asked to play a game on a tablet for 15 minutes during four break periods. These two weeks of tablet gaming will be followed by a week with no exposure (week 3). In the following two weeks, participants will be asked to use virtual reality for 15 minutes during four break periods (weeks 4 and 5).
61949896|NCT04521660|EXPERIMENTAL|Intervention group|Patients in the intervention group will wear virtual reality glasses during coronary angiography.
61949897|NCT04521660|NO_INTERVENTION|Control group|Patients in the control group will not wear virtual reality glasses. They will be given standard care and treatment during the procedure.
61949898|NCT02336373|EXPERIMENTAL|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
61949899|NCT01622803|ACTIVE_COMPARATOR|parallel stent|parallel stent insertion group
61949900|NCT01622803|ACTIVE_COMPARATOR|Y-stent|Y-stent insertion group
61949901|NCT01673217|EXPERIMENTAL|Treatment (chemotherapy and vaccine therapy)|Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
61949902|NCT02706184|EXPERIMENTAL|Intervention|Patients receive E. coli Nissle suspension
61949903|NCT02706184|PLACEBO_COMPARATOR|Control|Patients receive placebo
61949904|NCT04974983||A|Treatment without bevacizumab
61949905|NCT04974983||B|Treatment with bevacizumab
61949906|NCT06198283|EXPERIMENTAL|Group A|This group will be treated by low level laser therapy with pressure garments
61949907|NCT06198283|ACTIVE_COMPARATOR|Group B|This group will receive low level LASER therapy without pressure garment
62699003|NCT00663156|OTHER|control|10 control will have breast augmentation using breast implants
61949908|NCT01684956|EXPERIMENTAL|Intradermal first|Intradermal injection experiment first, followed by subcutaneous injection experiment
61949909|NCT01684956|EXPERIMENTAL|Subcutaneous first|Subcutaneous injection experiment first, followed by intradermal injection experiment
61949910|NCT05706493|OTHER|Non-surgical periodontal treatment|assessment of different periodontal parameters and gingival crevicular fluid sampling will be done then non surgical periodontal treatment will be performed then after 3 months re assessment of the periodontal parameters and gingival crevicular fluid sampling will be done
61949911|NCT03605589|EXPERIMENTAL|Blinatumomab and Pembrolizumab|"Blinatumomab and Pembrolizumab will be given for 2 cycles (each cycle lasts 35 days).~Blinatumomab administered as a continuous IV infusion. Patient Weight Greater Than or Equal to 45 kg (Fixed dose) Patient Weight Less Than 45 kg (BSA-based dose)~Cycle 1 (Days 1-7):~Patient Weight Greater Than or Equal to 45 kg: 9 mcg/day Patient Weight Less Than 45 kg: 5 mcg/m2/day~Cycle 1(Days 8-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Cycle 2 (Days 1-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Pembrolizumab: 2 mg/kg (max dose 200 mg) administered as a 30 minute IV infusion on day 12 of cycle 1 and day 5 of cycle 2."
61949912|NCT00150709|EXPERIMENTAL|N159 PBO/LEV|Subjects had previously participated in study N159 in which they had received Placebo (PBO).
61949913|NCT00150709|EXPERIMENTAL|N159 LEV/LEV|Subjects had previously participated in study N159 in which they had received Levetiracetam (LEV).
62341600|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration \< 8 g/dL.
62498736|NCT04547036||Endothelial cell count measurment|
62736577|NCT03483779|PLACEBO_COMPARATOR|Control group:placebo pills|Five placebo pills a time and three times a day. One treatment period including 8 weeks.
62699004|NCT06141733||NIRS (Near-infrared spectroscopy) group of the COSGOD III trial|"A multi-center, multi-national randomized-controlled trial was performed in 11 centers in Europe and Canada. Preterm neonates less than 32 weeks gestation were randomly assigned to standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.~In the NIRS-group 252 (82.9%) out of 303 neonates (gestational-age, median (interquartile-range): 28.9 (26.9-30.6) weeks) survived without cerebral injury until term age or discharge. (primary outcome of the COSGOD III trial)"
62699005|NCT06141733||Control group of the COSGOD III trial|"A multi-center, multi-national randomized-controlled trial was performed in 11 centers in Europe and Canada. Preterm neonates less than 32 weeks gestation were randomly assigned to standard care (control-group) during immediate transition (first 15 minutes after birth) and resuscitation.~In the Control-group 238 (78.5%) out of 304 neonates (gestational-age, median (interquartile-range): 28.6 (26.6-30.6) weeks) survived without cerebral injury until term age or discharge. (primary outcome of the COSGOD III trial)"
62699006|NCT04434729|EXPERIMENTAL|Fetal embolization of vein of Galen malformation|This is a single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.
62699007|NCT06563648|EXPERIMENTAL|ShotBlocker group|A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.
61949914|NCT00150709|EXPERIMENTAL|N01010+N151 LEV/LEV|Subjects had previously participated in study N01010 or study N151 in which they had received Levetiracetam (LEV).
61949915|NCT00150709|EXPERIMENTAL|N01052 LEV/LEV|Subjects had previously participated in study N01052 in which they had received Levetiracetam (LEV).
61949916|NCT01065597|EXPERIMENTAL|Nonconvulsive electrotherapy|Open label single arm study of nonconvulsive electrotherapy
61949917|NCT00844675|EXPERIMENTAL|rabeprazole|rabeprazole
61949918|NCT00844675|EXPERIMENTAL|placebo|placebo
61949919|NCT01387789||Scheduled to start adalimumab therapy|Patients diagnosed with rheumatoid arthritis for at least 3 months that previously had not received prior anti-TNF agents.
61949920|NCT06558071|EXPERIMENTAL|Investigational Group|1 film-coated caplet (Galatonol 300 mg/Striatin 30 mg), twice daily, after morning and evening meals
61949921|NCT06558071|PLACEBO_COMPARATOR|Control Group|1 film-coated caplet of Placebo, twice daily, twice daily, after morning and evening meals
61949922|NCT00645385||MRS of the neural system|MRS to study epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism.
61949923|NCT05610683|EXPERIMENTAL|SHFVE-HD group|Hemodialysis sessions using the VieX™ (Polysulfone, surface area: 2.1 m², sterilization gamma, ultrafiltration coefficient: 104.3 ml/h/mmHg, Asahi Kasei Medical, Japan).
61949924|NCT05610683|EXPERIMENTAL|MCO-HD group|Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg).
61949925|NCT04773756|OTHER|Sofosbuvir / Daclatsvir|A drug used in the treatment of HCV infection, given in the same dose 400mg and 60 mg respectively once daily for 14 days
62699008|NCT06563648|EXPERIMENTAL|ShotBlocker placebo group|During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.
62699009|NCT06563648|EXPERIMENTAL|Local cold application group|Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack,and then the injection was performed.
62699010|NCT06563648|NO_INTERVENTION|control group|Patients in the control group were injected with a routine subcutaneous injection procedure.
61949926|NCT04118439|EXPERIMENTAL|Motor Imaginery|Patients allocated in this arm will recieve a training on the first day after recruitment on a motor imaginery task and will be asked to do the task every day during 30 days until they start the usual care. Then after the physical therapy treatment with a pragmatic perspective will be meassured just inthe last session, after 1 month an.d after 3 moths of the treatment for the follow up
61949927|NCT04118439|NO_INTERVENTION|Control Group|Patients allocated in this arm will be meassured at the start, again after 30 days and at the end of the physical therapy usual care with a pragmatic perspective. Then will be meassured again after 1 and 3 months.
61949928|NCT00850070|EXPERIMENTAL|sapropterin, 100 mg capsules|Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
61949929|NCT00850070|PLACEBO_COMPARATOR|Placebo, matching active drug|The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
61949930|NCT03185871|EXPERIMENTAL|Celecoxib|"The participants will be scheduled for the two quantitative breast MRI exams. Following the first MRI exam, participants will start taking celecoxib 200mg twice a day with food. Subjects will take a minimum of 26 doses and no more than 32 doses of celecoxib during the study.~Participants will intake 200mg of celecoxib two times a day (400mg/day total) for 2 weeks after biopsy. Histologic tissue samples will be obtained for evaluation at time of biopsy of the tumor and at time of surgery removal of the tumor."
61949931|NCT05791955|NO_INTERVENTION|Holdout Condition: No reminder|Eligible, randomized participants will receive no text message reminder.
61949932|NCT05791955|EXPERIMENTAL|Control Reminder|Eligible, randomized participants will receive a generic text message reminding them to close their outstanding health gap by clicking on the link to make an appointment.
62498737|NCT01652638|EXPERIMENTAL|Group A|"First periody: Test Drug (Heparin Blau Farmacêutica S/A)~Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals)"
62699011|NCT00455702|EXPERIMENTAL|D-cycloserine|50 mg d-cycloserine
62699012|NCT00455702|PLACEBO_COMPARATOR|Placebo|50 mg placebo
62699013|NCT03473587|EXPERIMENTAL|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
62699014|NCT03473587|ACTIVE_COMPARATOR|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
62498738|NCT01652638|EXPERIMENTAL|Group B|"First periody: Comparator Drug (Heparin APP Pharmaceuticals)~Secundy periody: Test Drug (heparin Blau Farmacêutica S/A)"
62498739|NCT06058364|EXPERIMENTAL|Intervention 1|Participants receiving triglyceride supplement
62498740|NCT06058364|PLACEBO_COMPARATOR|Intervention 2|Participants receiving placebo
62498741|NCT02961205|EXPERIMENTAL|Oral Nutritional Supplementation|Patients randomized to the interventional arm will receive Ensure Enlive (Abbott Nutrition), a high energy, high protein oral supplement.
62498742|NCT02961205|NO_INTERVENTION|Standard of care|Patients randomized to the control arm will continue their usual diet.
62498743|NCT05761743||PHPT and DM Patients, Parathyroidectomy|Patients with primary hyperparathyroidism with type 2 diabetes, that decided with their physician/surgeon to continue with a parathyroidectomy (independent of research).
62498744|NCT05761743||PHPT and DM Patients, NO Parathyroidectomy|Patients with primary hyperparathyroidism with type 2 diabetes, that have decided with their physician/surgeon to be managed medically with no parathyroidectomy.
62498745|NCT01463709|EXPERIMENTAL|nanopulse|Administer nano pulse to lesion for varying time intervals.
62498746|NCT01362192|OTHER|532 nm KTP Laser Treatment|
62498747|NCT01203917|OTHER|1|gefitinib 250mg tablet
62498748|NCT03755739|EXPERIMENTAL|Pembrolizumab via localized infusion|"This group dividied into two subgroups:~1. Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, plus chemotherapy, every 3 weeks.~2. Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a total dose of 150mg via intra-tumor fine needle injection in 5 min, plus doxorubicin, every 3 weeks."
62498749|NCT03755739|ACTIVE_COMPARATOR|Checkpoint inhibitor (CPI) Pembrolizumab plus chemotherapy via vein infusion|Checkpoint inhibitor (CPI) such as Pembrolizumab is administrated with a total dose of 2mg/kg via vein infusion (30 min), plus chemotherpy every 3 weeks.
62699015|NCT06109727|EXPERIMENTAL|Intervention|In the intervention group, the anodic stimulations will start after a ramp period of 30 s, followed by 20 min at 2 mili ampere and will end with a ramp of 30 s.
62699016|NCT06109727|PLACEBO_COMPARATOR|Placebo|In the simulated configuration, the ramp of 30 s will be immediately followed by the ramp of 30 s and without any current (Sham Group)
61949933|NCT05791955|EXPERIMENTAL|Personal Responsibility Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will ask them to click on the link to schedule an appointment, or to text back to acknowledge they are taking responsibility for closing the health gap on their own.
61949934|NCT05791955|EXPERIMENTAL|Planning prompt reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will prompt participants to either click on the link to schedule an appointment right away, or text back when they will do so
61949935|NCT01446107|EXPERIMENTAL|fissure sealant|single placement of resin fissure sealant on tooth surface
61949936|NCT01446107|EXPERIMENTAL|fluoride varnish|application of a 5% sodium fluoride varnish every 6 months
61949937|NCT01446107|EXPERIMENTAL|SDF solution|application of a 38% silver diamine fluoride solution onto tooth surface every year
61949938|NCT01446107|PLACEBO_COMPARATOR|control|application of water onto tooth surface every year
62699017|NCT03707392|ACTIVE_COMPARATOR|Control|Standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
61949939|NCT00412542|EXPERIMENTAL|Thalidomide + CPT-11|Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.
61949940|NCT04111575|EXPERIMENTAL|music therapy group 1|The mothers in the experimental group 1 received music therapy for 30 minutes a day.They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
61949941|NCT04111575|EXPERIMENTAL|music therapy group 2|The mothers in the experimental group 1 received music therapy for 30 minutes twice a day. They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
61949942|NCT04111575|NO_INTERVENTION|control group|the control group were made to rest in bed for 30 minutes a day for two consecutive days, considering the first day after the C-section as the beginning day.
61949943|NCT04512014||major liver surgery|Patients undergoing major liver surgery
62498750|NCT03538795|EXPERIMENTAL|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS\&eCIMT, and then receive post-treatment testing.
62699018|NCT03707392|EXPERIMENTAL|Treatment|Ostomy care educational video combined with standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
62699019|NCT02510586|EXPERIMENTAL|Sevo_postconditioning|Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
62699020|NCT02510586|NO_INTERVENTION|Non_postconditioning|Patients not receiving sevoflurane postconditioning after revascularization completed
61949944|NCT05771012|EXPERIMENTAL|group A|patients receive only medical treatment in the form of topical 0.05% cyclosporin (Restasis®, Allergan Inc) twice daily for 6 months.
61949945|NCT05771012|ACTIVE_COMPARATOR|group B|patients receive mini-Monoka stent insertion in the lower canaliculus for 6 months.
61949946|NCT02187744|EXPERIMENTAL|PF-05280014|
61949947|NCT02187744|ACTIVE_COMPARATOR|Herceptin®|
61949948|NCT05704062||Diagnostic (multi-parametric MRI)|Patients undergo an MRI exam that includes standard anatomic scans, DCE-MRI, and DW-MRI at baseline, after first treatment cycle, at mid-point of treatment course, and after completion of neoadjuvant chemotherapy.
62498751|NCT02845791|NO_INTERVENTION|Control|The control participants will not receive the educational intervention but will be provided with a detailed advice leaflet for themselves and their parents/guardians.
62498752|NCT02845791|OTHER|Intervention|The educational intervention participants will receive the eight 90 minute sessions of an interactive family based lifestyle programme.
62498753|NCT02780063|EXPERIMENTAL|Lenstar Biometry|Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time.
62498754|NCT03879486|EXPERIMENTAL|PVPI intervention|rectal cleansing and disinfection of the needle tip at transrectal ultrasound guided prostate biopsy
61949949|NCT05145595|EXPERIMENTAL|Psychophysical assessments of experimental pain|"At baseline, participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed and sex hormone levels will be analyzed. In addition, demographic, social, pubertal maturation, behavioral and psychological factors will be collected via questionnaires.~In the optional follow-up portion, participants can complete short surveys every 3 months and/or return for study visits after 6 months and/or after every year depending on the participant's availability. The study visits will include the same procedures as the baseline study visit. Additional surveys regarding new symptoms of pain will be completed. In some cases, participants will meet a pediatric physician who will determine if they meet the criteria for any pain syndrome (for research purposes only)."
62498755|NCT03879486|NO_INTERVENTION|Control arm|controls at transrectal ultrasound guided prostate biopsy
62498756|NCT04677686||Pre-implementation phase (October 2018 - September 2019)|"During this time period, 137 patients underwent colorectal surgery. Only basic measures for preventing SSI were performed:~1. Hair was removed in the operating field with a clipper instead of shaving hair.~2. Blood glucose was monitored only during the operation.~3. Antibiotic prophylaxis was applied 60 minutes before the operation.~4. The application of an antibiotic prophylaxis was repeated if the operation lasted longer than 4 hours.~5. Measures of warming were only applied during the operation and in the recovery room.~6. Instruments and gloves were changed after finishing the anastomosis."
62498757|NCT04677686||Implementation phase (October 2019 - September 2020)|"During this phase, additional measures have been introduced:~1. Implementation of wound protectors during colorectal surgery.~2. Colorectal operations were only performed with the support of an experienced consultant surgeon."
61949950|NCT02170194|EXPERIMENTAL|Resilience Enhancement Group|The resilience enhancement group will begin with a 90-minute session with the study psychologist, which will include a brief introduction to cognitive behavioral therapy (CBT), but focus primarily on psychoeducational, relaxation techniques and planning positive activities. The majority of the time will be focused on reviewing techniques that promote stress management. Emphasis will be placed on relaxation approaches such as controlled breathing, meditation and yoga. Focus will also be aimed at reviewing how engagement in positive activities may help prevent avoidance, promote social support and wellness. Over the subsequent 6 weeks, daily text messages to all participants will accentuate the positive, including providing recommendations on beneficial activities to engage in, encouraging such activities including in vivo exposure, and fostering behavioral changes.
61949951|NCT02170194|PLACEBO_COMPARATOR|Control Group|"The control group will be provided with an initial informational session providing them with details of where they can get help if they have worsened symptoms over time. In addition, the psychologist will briefly review the apps, but not provide the same pscyhoeducational detail given to the resilience enhancement group. They will receive daily texts with inspirational aphorisms (e.g., Early to bed and early to rise makes a man healthy, wealthy, and wise.) for 6 weeks."
61949952|NCT01776411|EXPERIMENTAL|Single Arm|Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
61949953|NCT06213246|EXPERIMENTAL|Sleep Hygiene Strategies (SHS)|In Week 3, the study participants will implement sleep hygiene strategies. Specifically, these sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the guidelines recommended by the National Sleep Foundation.
61949954|NCT00910026|EXPERIMENTAL|low tidal volume ventilation|6 ml/kg tidal volume ventilation
61949955|NCT00910026|EXPERIMENTAL|high tidal volume ventilation|12 ml/kg tidal volume ventilation
61949956|NCT03423082|EXPERIMENTAL|18F fluciclovine PET scan|Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.
61949957|NCT06129162|ACTIVE_COMPARATOR|Group I: Control Group|Use a conventional syringe to inject anesthetic solution by the inferior alveolar nerve block (IANB) technique. Also, use a conventional syringe to inject anesthetic solution by buccal infiltration (BI) technique.
61949958|NCT06129162|EXPERIMENTAL|Group II: STA group|Use STA Wand® (CCLA) to inject anesthetic solution by the inferior alveolar nerve block (IANB) technique. Also, use STA Wand® (CCLA) to inject anesthetic solution by buccal infiltration (BI) technique.
62341601|NCT03677817|ACTIVE_COMPARATOR|Lidocaine|perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
62699021|NCT01770704||Patients diagnosed with bipolar disorder I or II|
62699022|NCT05222711|ACTIVE_COMPARATOR|Monitor used|The device is applied and the GP provides usual care.
62699023|NCT05222711|NO_INTERVENTION|Usual care|Usual care is provided by the GP.
61949959|NCT06129162|EXPERIMENTAL|Group III: Star pen group|Use a Star Pen device to inject anesthetic solution by the inferior alveolar nerve block (IANB) technique. Also, use a Star Pen device to inject anesthetic solution by buccal infiltration (BI) technique.
61949960|NCT03689530|EXPERIMENTAL|Peer Support Arm.|Participants randomized to peer support will be matched with a peer supporter.
62341602|NCT03677817|PLACEBO_COMPARATOR|Placebo|perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure
62341603|NCT03768791|EXPERIMENTAL|SCS off|
62341604|NCT03768791|EXPERIMENTAL|SCS on|
62699024|NCT01377402||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
62699025|NCT02943473|EXPERIMENTAL|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
62699026|NCT02710032|EXPERIMENTAL|Intervention|Social Network-Based Adherence Intervention
62699027|NCT02710032|NO_INTERVENTION|Control|Control
62699028|NCT03408353||Observational (mammography, questionnaires, blood collection)|Participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. Participants also undergo standard of care mammography at baseline and then annually for 5 years.
61949961|NCT03689530|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants randomized to enhanced usual care will receive brief education and folder of information and resources.
61949962|NCT01622231|EXPERIMENTAL|GW685698X|GW685698X 55mcg/day
61949963|NCT02807519||Oncological patients|Children with confirmed haematological/oncological diagnosis who are admitted to the paediatric oncology ward at the Universitätsspital Beider Basel (UKBB), who will require radio- and/or chemotherapy . Collection of salivary cytokines will be performed in this group.
61949964|NCT02807519||Control group|Healthy children which are seen routinely at the Schulzahnklinik/Volkzahnklinik Basel. Collection of salivary cytokines will be performed in this group.
61949965|NCT00114530|EXPERIMENTAL|mHSCT|Myeloablative Hematopoietic Stem Cell Transplant (mHSCT) Participants will first have hematopoietic stem cells removed from their blood. They then will receive high doses of chemotherapy and radiation to eliminate their developed and presumably abnormal immune system, followed by autologous stem cell transplantation to reintroduce the purified stem cells to re-establish their immune system.
61949966|NCT00114530|EXPERIMENTAL|cyclophosphamide|"Cyclophosphamide (CY) Participants will receive high doses of intravenous cyclophosphamide. The dose being used in this study is about 50% higher than that commonly used by most physicians to treat many other autoimmune diseases.~Administration of 12 monthly pulses of high-dose intravenous cyclophosphamide (an initial dose of 500 mg/m\^2, followed by 11 doses of 750 mg/m\^2)."
62341605|NCT00798655|EXPERIMENTAL|Panitumumab, Cisplatin plus radiation|Standard radiation 60-66 Gy with 200 cGy daily fractions in 6-7 weeks Cisplatin\* 30 mg/m2 IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements) Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements)
62341606|NCT04402008|EXPERIMENTAL|Phase 1: Once Daily Dosing|Dose finding at 8 mg, 12 mg, or 16 mg of poziotinib once daily in 28-day treatment cycles.
62341607|NCT04402008|EXPERIMENTAL|Phase 1: Twice Daily Dosing|Dose finding at 4 mg, 6 mg, or 8 mg of poziotinib twice daily in 28-day treatment cycles.
62341608|NCT04402008|EXPERIMENTAL|Phase 2: Once Daily Dosing or Twice Daily Dosing|"Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.~Cohort 1: EGFR exon 20 insertion mutations~Cohort 2: HER2 exon 20 insertion mutations"
62498758|NCT04677686||Post-implementation phase (October 2020 - September 2021)|"During this phase, additional measures are implemented.~1. Close monitoring of blood glucose. During the stay in the recovery room and for 48 hours post-operative, blood glucose is monitored closely. Moreover, if blood glucose is higher than 9 mmol/l, the patient will be treated with insulin. This measure is applied to diabetic as well as to non-diabetic-patients.~2. The measures of warming will be intensified. First of all, during the operation and during the stay in the recovery room patients will be placed on warming mattresses. Moreover, a warming towel will be placed on the operating field directly after the operation.~3. The patients will be asked to take a shower the night before surgery. In case of an emergency operation, patients will be asked to wash the axilla, trunk, genitalia, groins and umbilicus"
62498759|NCT00460850|EXPERIMENTAL|1|
62498760|NCT05065541|EXPERIMENTAL|Part 1|
62498761|NCT05065541|EXPERIMENTAL|Part 2|
62498762|NCT05065541|EXPERIMENTAL|Part 3|
62498763|NCT05296941|EXPERIMENTAL|Brush biopsy|Brusch biopsy at baseline and at 3 or 6 months
62498764|NCT05296941|ACTIVE_COMPARATOR|Care as usual|Control at 3 or 6 month, surgical biopsy when needed
61949967|NCT00532558|EXPERIMENTAL|Lapaquistat Acetate 50 mg QD|
62341609|NCT04876703|EXPERIMENTAL|Excite group (Group A)|The experimental group (Group A) will receive standard motor retraining of the affected upper extremity in addition to functional electrical stimulation provided by means of Xcite system 4 days per week for 30 minutes for two weeks.
62341610|NCT04876703|ACTIVE_COMPARATOR|Standard motor training group (Group B)|The control group (Group B) will receive standard motor retraining of the upper extremity.
62498765|NCT03943134||Avive® Soft Tissue Membrane|Subjects with utilization of Avive® Soft Tissue Membrane on an impacted but intact nerve during a surgical procedure for one of the following targeted acute upper extremity traumas (selected injuries): Spaghetti Wrist, Distal Radius Fracture, Medial Epicondyle Fracture, Flexor Tenolysis at Wrist, and Ballistic Injuries in the Forearm and/or Hand.
62498766|NCT03943134||Standard Surgical Procedures - Control Arm|Subjects who have undergone surgical procedures for the same selected injuries, but without placement of a surgical implant on an impacted but intact nerve.
62498767|NCT05745636|EXPERIMENTAL|Broccoli, mustard, vitamin C|770 mg Broccoli Seed Extract (BSE) with 290 mg mustard seed powder (MSP) and 200 mg vitamin C
62498768|NCT05745636|PLACEBO_COMPARATOR|Placebo|inactive excipients including microcrystalline cellulose, rice hull, maltodextrin, ascorbyl palmitate and silicon dioxide
62498769|NCT06076941|EXPERIMENTAL|Education|Pregnant women in the experimental group were given oral and dental health education in groups of maximum five, and the forms were filled out before and one month after the education.
62498770|NCT06076941|NO_INTERVENTION|Control|No intervention was made to the pregnant women in the control group, and the forms were completed before and one month after the training.
61949968|NCT00532558|PLACEBO_COMPARATOR|Placebo QD|
61949969|NCT04516174|EXPERIMENTAL|Dex+TAPB group|Patients in Dex+TAPB group will receive the bilateral transversus abdominis plane block with 0.25% ropivacaine 20ml each side before anesthesia and combined with continuous infusion of dexmedetomidine during operation.
62498771|NCT06679673|EXPERIMENTAL|SHR-1701+BP102±SHR2554|The first 6 subjects will be treated with SHR-1701+BP102, and the subsequent subjects will be treated with SHR-1701+BP102+SHR2554
62498772|NCT06449027|EXPERIMENTAL|Leuprolide Injectable Emulsion|100 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks.
62498773|NCT06449027|ACTIVE_COMPARATOR|Leuprorelin Acetate Microspheres for Injection|100 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks.
62498774|NCT01644422|OTHER|Study arm A|Subjects will receive hair follicles transplants that are dipped in HPL before transplant
62498775|NCT01644422|OTHER|Study arm B|Subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection one week after transplant
62498776|NCT01644422|OTHER|Control arm C|Subject will receive Standard hair follicle transplant
62498777|NCT01861990|EXPERIMENTAL|Treatment arm|All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
61949970|NCT04516174|PLACEBO_COMPARATOR|Control group|Patients in control group will receive the bilateral transversus abdominis plane block with saline 20ml each side before anesthesia and don't receive the infusion of dexmedetomidine during operation.
61949971|NCT02699814|EXPERIMENTAL|H3 Parent/Child Dyads|A child is eligible for the H3 partnered evaluation if he or she is: 1) between the ages of 0.0-16.99 years; 2) speaks Spanish or English; 3) screens positive for a developmental delay or mental health problem. For children in the intervention groups, the additional eligibility criteria are: 1) referral to the H3 care program by a pediatrician based on clinical judgment; and 2) no prior history of receiving any H3 services in the past year.
62498778|NCT04489017|EXPERIMENTAL|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day for 24 weeks
62341611|NCT03978182|ACTIVE_COMPARATOR|active accelerated deep rTMS|Stimulation: We will use a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil, which includes a sham option. In analogy to our former accelerated rTMS studies (2, 3), all patients will receive 20 dTMS sessions (5 sessions per day; 4 consecutive days) with a stimulation intensity of 120% of the subject's resting MT, as reported by Levkovitz et al.(4). Furthermore, we selected these FDA approved dTMS parameters, so that for one session each dTMS repetition includes 2-sec pulse trains separated by 20-sec inter-train intervals. Patients will receive 55 trains in each treatment session, for a total of 1980 pulses per session. This makes 9900 pulses/day, and in total 39600 pulses per treatment.
62341612|NCT03978182|SHAM_COMPARATOR|sham|Built-in sham in the H1 Helmet (same device as active treatment)
62341613|NCT04179201||IBD with CDI|Inflammatory bowel disease with clostridium difficile infection
62341614|NCT04179201||IBD without CDI|Inflammatory bowel disease without clostridium difficile infection
62341615|NCT01370057|EXPERIMENTAL|Treatment Group|Treatment with bracing
62341616|NCT01370057|NO_INTERVENTION|Control Group|Watchful waiting without bracing
62341617|NCT01829802|EXPERIMENTAL|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
62498779|NCT04489017|PLACEBO_COMPARATOR|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day for 24 weeks
62498780|NCT01561924|EXPERIMENTAL|Ex vivo|
62498781|NCT05194202|EXPERIMENTAL|ED-HEART (Intervention Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive Emergency Department Healthcare Education Assessment and Response for Teen Relationships (ED HEART) by a trained health educator, complete an exit survey while in the ED, complete a 6-week check-in to confirm contact information and aid retention, and complete a 12-week follow up survey.
62498782|NCT05194202|NO_INTERVENTION|Enhanced Standard Care (Control Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive enhanced standard care (i.e., standard care + teen resource list), complete a 6-week check in to confirm contact information and aid retention, and complete a 12-week follow up survey.
62498783|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort A|Single dose of LEO 142397 or placebo.
62498784|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort B|Single dose of LEO 142397 or placebo.
62498785|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort C|2 single doses, separated by a washout of ≥7 days.
62498786|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort D|2 single doses, separated by a washout of ≥7 days.
62498787|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort E|Single dose of LEO 142397 or placebo.
62498788|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort F|Single dose of LEO 142397 or placebo.
62498789|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort G|Single dose of LEO 142397 or placebo.
62498790|NCT03995550|EXPERIMENTAL|Single ascending dose Cohort H|Single dose of LEO 142397 or placebo - tentative, female-only cohort (to be included only if the number of women recruited in the remaining cohorts is insufficient to assess the pharmacokinetics of LEO 142397 in women). Dose level ≥ that in Cohort C and ≤ that in Cohort D.
62498791|NCT03995550|EXPERIMENTAL|Multiple ascending dose Cohort K|Multiple doses of LEO 142397 or placebo.
62498792|NCT03995550|EXPERIMENTAL|Multiple ascending dose Cohort L|Multiple doses of LEO 142397 or placebo.
62498793|NCT03995550|EXPERIMENTAL|Multiple ascending dose Cohort M|Multiple doses of LEO 142397 or placebo.
62498794|NCT03995550|EXPERIMENTAL|Multiple ascending dose Cohort N|Multiple doses of LEO 142397 or placebo.
62498795|NCT03995550|EXPERIMENTAL|Multiple ascending dose Cohort O|Multiple doses of LEO 142397 or placebo.
62498796|NCT03995550|EXPERIMENTAL|Multiple ascending dose Cohort P|Multiple doses of LEO 142397 or placebo in Japanese-only subjects. Same dose level as for Cohort M.
62498797|NCT02594527|EXPERIMENTAL|Volunteer-led physical activity sessions|Patient will receive volunteer-led physical activity sessions twice a day during admission.
62498798|NCT06543446|NO_INTERVENTION|No-ICD implantation|No-ICD implantation despite current recommendation
62498799|NCT06543446|ACTIVE_COMPARATOR|ICD implantation|ICD implantation based on current guidelines
62498800|NCT01298609|ACTIVE_COMPARATOR|Suprathreshold Stimulation|Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
62498801|NCT01298609|SHAM_COMPARATOR|minimal stimulation|Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
62498802|NCT01298609|ACTIVE_COMPARATOR|Subthreshold Stimulation|Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
62498803|NCT01992874|EXPERIMENTAL|Pimasertib Capsule/Pimasertib Tablet|
62498804|NCT01992874|EXPERIMENTAL|Pimasertib Tablet/Pimasertib Capsule|
62498805|NCT04924751|EXPERIMENTAL|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area was performed. After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
62699029|NCT04770584|OTHER|PTSD group|After the initial screening / baseline assessment visit, Post Traumatic Stress Disorder participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
62498806|NCT04924751|ACTIVE_COMPARATOR|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
62699030|NCT04770584|OTHER|Trauma-Exposed Healthy Controls (TEHC)|After the initial screening / baseline assessment visit, trauma-exposed healthy participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
62498807|NCT06678100||Healthy community dwelling adults|Healthy adults ≥ 60 years old with no prior history of neurological or respiratory diseases, swallowing impairments, or history of head and neck surgery, cancer, or radiation to the head or neck will be enrolled in this study.
62498808|NCT06678100||Adults with Alzheimer's Disease and their caregivers|Adults with a diagnosis of Alzheimer's disease and their caregivers will be enrolled in this study.
62498809|NCT01958060|EXPERIMENTAL|BI 1034020 intravenous part|single rising doses
62498810|NCT01958060|EXPERIMENTAL|BI 1034020 subcutaneous part|single rising doses
62498811|NCT04221594||CAD detection/risk assessment|Patients with angina referred for the assessment of CAD will undergo imaging studies to develop tools to fuse coronary anatomic data obtained from CCTA with dPET data to non-invasively measure absolute MBF, MFR and RFR along vessels centerlines and across coronary lesions.
62498812|NCT04937738|ACTIVE_COMPARATOR|Perioperative XELOX chemotherapy|Oxaliplatin 130 mg/m2, d1 Capecitabine 1000 mg/m² two times per day (BID), d1-14, every 3 weeks (q3w) 4 cycles (12 weeks) pre-OP and 3 cycles (12 weeks) post-OP
62498813|NCT04937738|EXPERIMENTAL|Perioperative FLOT chemotherapy|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
62498814|NCT04458168|EXPERIMENTAL|Recently completed treatment|25 women who have just completed treatment
62498815|NCT04458168|EXPERIMENTAL|No recurrence of ovarian cancer for at least one year|25 women who have not experienced a recurrence of their ovarian cancer at least one year after their initial diagnosis
62498816|NCT04458168|EXPERIMENTAL|Recurrence of ovarian cancer|25 women who have experienced a recurrence of their ovarian cancer after primary treatment
62498817|NCT06624371|EXPERIMENTAL|Stratum 1:|"Newly diagnosed pHGG/DMG/DIPG patients.~New Diagnosis followed by 2 weeks (+/- 7 days) atovaquone followed by approx. 6 weeks Atovaquone + Radiotherapy"
62498818|NCT06624371|EXPERIMENTAL|Stratum 2|"Stratum 2 will be bifurcated into:~* Stratum 2a (patients with relapse or progression)~* Stratum 2b (patients without progression after radiation)~The same dosing regimen for atovaquone will be used for up to 6 months in the absence of toxicity, intolerance, or tumor progression. Patients will begin therapy between 2-4 weeks after documented relapse or progression of tumor or between 2-4 weeks after completion of standard RT for pHGG/DMG/DIPG patients who have completed standard Radiotherapy without previous atovaquone treatment."
62498819|NCT02912767||SLN cohort|Patients who underwent hysterectomy only or with SLN mapping alone.
62498820|NCT02912767||LND cohort|Patients who underwent hysterectomy with standard lymphadenectomy, with or without SLN mapping.
62498821|NCT02754492|EXPERIMENTAL|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
62498822|NCT02754492|EXPERIMENTAL|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
62699031|NCT05231980|EXPERIMENTAL|Pentoxifylline (PTX) group|30 patients
62699032|NCT05231980|EXPERIMENTAL|Alpha lipoic acid (ALA) group|30 patients
61949972|NCT04560036|OTHER|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
62498823|NCT02754492|EXPERIMENTAL|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections
62498824|NCT01264198|SHAM_COMPARATOR|Stretching Exercises|The patients will perform twice weekly home based static stretching workout.
62498825|NCT01264198|EXPERIMENTAL|Resistance Training|The patients will perform twice weekly supervised RT for 3 months
62498826|NCT05752552|EXPERIMENTAL|Cohort 1 (starting dose)|Oral administration, once a day for 28 days, in a 4-week cycle
62699033|NCT05231980|EXPERIMENTAL|Combined PTX and ALA group|30 patients
62699034|NCT05231980|ACTIVE_COMPARATOR|control group|clomiphene
62699035|NCT03769155|EXPERIMENTAL|A (VX15/2503, nivolumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and nivolumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
62699036|NCT03769155|EXPERIMENTAL|B (VX15/2503, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and ipilimumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
62699037|NCT03769155|EXPERIMENTAL|C (VX15/2503, nivolumab, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes, nivolumab IV over 30 minutes, and ipilimumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
61949973|NCT04185311|EXPERIMENTAL|Treatment (talimogene laherparepvec, nivolumab, ipilimumab)|Participants receive talimogene laherparepvec intratumorally on days 1, 22, and 36, nivolumab IV over 60 minutes on days 1, 15, 29, and 43, and ipilimumab IV over 90 minutes on days 1 and 43 in the absence of disease progression or unacceptable toxicity.
62498827|NCT05752552|EXPERIMENTAL|Cohort 2 (dose level 2)|Oral administration, once a day for 28 days, in a 4-week cycle
62498828|NCT05752552|EXPERIMENTAL|Cohort 3 (dose level 3)|Oral administration, once a day for 28 days, in a 4-week cycle
62498829|NCT05752552|EXPERIMENTAL|Cohort 4 (dose level 4)|Oral administration, once a day for 28 days, in a 4-week cycle
61949974|NCT06547099||Cognitively normal|Participants without symptoms of cognitive impairment will be followed up annually for potential cognitive changes, and will complete additional blood collections every two years.
61949975|NCT06547099||Cognitively impaired|For participants with symptoms of cognitive impairment, their medical providers will review the results of the research cognitive assessments and determine whether further testing (a clinical tau PET scan and choice of an amyloid PET, cerebrospinal fluid, or blood clinical test for amyloid plaques) is needed. Symptomatic participants will be followed up annually for research blood collections and cognitive assessments.
62498830|NCT05752552|EXPERIMENTAL|Cohort 5 (dose level 5)|Oral administration, once a day for 28 days, in a 4-week cycle
61949976|NCT03325127||Radium-223 concomitant with Abiraterone or Enzalutamide|Approximately 150 medical charts from mCRPC patients within the network will be collected
61949977|NCT05309408||ALS|Patients with Amyotrophic Lateral Sclerosis (ALS)
62498831|NCT05752552|EXPERIMENTAL|Cohort 6 (dose level 6)|Oral administration, once a day for 28 days, in a 4-week cycle
62498832|NCT05752552|EXPERIMENTAL|Cohort 7 (dose level 7)|Oral administration, once a day for 28 days, in a 4-week cycle
62498833|NCT05548920||Ultrasound guided Superior Vena Cava Collapsibility Index (SVC - CI)|Preoperative ultrasound guided Superior Vena Cava collapsibility Index will be measured with patient breathing spontaneously and on deep inspiration.
62498834|NCT05548920||Ultrasound Guided Inferior Vena Cava Collapsibility Index (IVC -CI)|Preoperative Ultrasound guided Inferior Vena Cava collapsibility Index will be measured with patient breathing spontaneously and on deep inspiration.
62498835|NCT03129776|ACTIVE_COMPARATOR|Hyperpolarized Pyruvate (13C) Injection|Participants will be injected with the study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43 ml/kg and will have their cervix imaged using MRI.
62498836|NCT03129776|ACTIVE_COMPARATOR|18F-FDG|Participants will be injected with the study drug 18F-FDG at a dose of 5 MBq/kg to a a maximum of 500 MBq (megabecquerel) and will have their cervix imaged using PET-CT imaging.
62498837|NCT03694938|EXPERIMENTAL|Magnetic resonance imaging|Annual MRI during 3 years
62498838|NCT04491734|OTHER|Tolerability Arm|Single arm study of active study product
62498839|NCT01845753||All colorectal cancer patients|
62498840|NCT00708682|EXPERIMENTAL|A|
62498841|NCT06641466|EXPERIMENTAL|Rimegepant 75 mg Orally Disintegrating Tablet (ODT) 7-Day Dosing|
62498842|NCT06641466|EXPERIMENTAL|Rimegepant 75 mg Orally Disintegrating Tablet (ODT) Acute Treatment Dosing|
62498843|NCT06641466|PLACEBO_COMPARATOR|Placebo|
62498844|NCT06641466|ACTIVE_COMPARATOR|Standard of Care|
62498845|NCT01712451|EXPERIMENTAL|LIPO-102, Low|
61949978|NCT05309408||Control|Participants who do not have chronic neuromuscular diseases or diseases that mimic ALS.
61949979|NCT00949260||Normal, Non-Pregnant|Normal, non-pregnant patients will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
61949980|NCT00949260||Normal, Pregnant|Normal, pregnant patients in their 3rd trimester will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
62498846|NCT01712451|EXPERIMENTAL|LIPO-102, Mid|
62498847|NCT01712451|EXPERIMENTAL|LIPO-102, High|
62498848|NCT01712451|EXPERIMENTAL|LIPO-102; Placebo|
62498849|NCT01712451|EXPERIMENTAL|salmeterol xinafoate|
62498850|NCT01006954|ACTIVE_COMPARATOR|Flare Up|Flare up protocol in poor responders for IVF/ICSI
62498851|NCT01006954|EXPERIMENTAL|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
62699038|NCT03769155|EXPERIMENTAL|D (nivolumab, surgery)|Participants receive nivolumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
62498852|NCT04884594|EXPERIMENTAL|AAV8-hCocH dose level 1: 2e12 vg/kg|Cohort 1: Participant receives one-time IV administration of low dose 2e12 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
62498853|NCT04884594|EXPERIMENTAL|AAV8-hCocH dose level 3: 6e12vg/kg|Cohort 3: Participant receives one-time IV administration of medium dose 6e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
62498854|NCT04884594|EXPERIMENTAL|AAV8-hCocH dose level 2: 4e12vg/kg|Cohort 2: Participant receives one-time IV administration of medium dose 4e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
62498855|NCT03864185|ACTIVE_COMPARATOR|Rituximab group (IgG4 autoantibody positive)|
62498856|NCT03864185|PLACEBO_COMPARATOR|Placebo group (IgG4 autoantibody positive)|
62498857|NCT03864185|ACTIVE_COMPARATOR|Rituximab group (IgG4 autoantibody negative)|
62498858|NCT06269861|OTHER|inward patients|The inward patients who will be weighed with bathroom scale and patient transfer scale
62498859|NCT06269861|OTHER|critically ill patients|The critically ill patients who will be weighed with patient transfer scale
62498860|NCT00564096|ACTIVE_COMPARATOR|Real TMS|10 patients will be given 20 minutes stimulation with real deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 20 consecutive working days.
62498861|NCT00564096|PLACEBO_COMPARATOR|Sham & real TMS|10 patients will be given 20 minutes stimulation with sham deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 10 consecutive working days, and thereafter 20 sessions of real TMS with the same parameters (=Left Tempor-oparietal Cortex in frequency of 1 Hz with 120% motor threshold).
62498862|NCT00196820|EXPERIMENTAL|A|Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study
62699039|NCT03769155|ACTIVE_COMPARATOR|E (surgery)|Participants undergo surgery.
62699040|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
61949981|NCT00949260||Pregnant, PIH|Pregnant patients in their 3rd trimester with pregnancy-induced hypertension that has not been treated will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
61949982|NCT05954975||Infants up to 6 months of age|Infants up to six months of age, presenting with systemic illness at the emergency GP post.
61949983|NCT03348137||Ancillary-Correlative (questionnaire)|Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation.
61949984|NCT04608487|EXPERIMENTAL|Fludarabine + Cyclophosphamide + Axicabtagene Ciloleucel|"Prior to receiving axi-cel, participants will undergo leukapheresis and the need for a Ommaya reservoir placement will be assessed and administered.~Day -5 to Day -3 of 28 day study cycle Fludarabine and cyclophosphamide; Day -1 admitted to hospital, receive axi-cel on day 0; Till at least cycle day 7 hospital monitoring; post treatment follow up will occur on day 14 and day 28 of cycle 1, monthly in cycles 2, 3, 6, 9,12,15,18,21,24, then yearly after cycle 24."
62699041|NCT01869673|ACTIVE_COMPARATOR|Face Mask|Patients will be ventilated with a face mask first and with a oral mask thereafter
61949985|NCT06377475||Wax registration|The jaw relation for the Michigan-splint will be performed with wax.
61949986|NCT06377475||JIG registration|The jaw relation for the Michigan-splint will be performed with JIG.
61949987|NCT03941405|NO_INTERVENTION|No treatment|No treatment.
61949988|NCT03941405|EXPERIMENTAL|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days.
61949989|NCT03622073|EXPERIMENTAL|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
61949990|NCT03622073|ACTIVE_COMPARATOR|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
61949991|NCT05009264||OMT Group|This group will receive OMT muscle energy as treatment for myofascial pain syndrome
61949992|NCT05009264||Injection Group|This group will receive lidocaine injections for myofascial pain syndrome
61949993|NCT03166007|EXPERIMENTAL|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
61949994|NCT03166007|ACTIVE_COMPARATOR|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
61949995|NCT00867893||DA group|RLS patients started treatment on dopamine agonists within the past year
61949996|NCT00867893||NonDA|RLS patients started treatment on medication other than dopamine agonists within the past year
61949997|NCT05426772|OTHER|Healthy sedentary people|Muscle oxygenation and vital signs will be measured before, during, and after of 20 minutes aerobic exercise in an environment where suitable conditions are provided. After 3 days, kinesio taping will be added to the same program and the measurements will be repeated.
61949998|NCT01784445|EXPERIMENTAL|Ceftazidime plus placebo|Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo
62341618|NCT01829802|ACTIVE_COMPARATOR|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
62498863|NCT06461442|EXPERIMENTAL|Cryotherapy and 5-Fluoruracil|Each actinic keratosis lesion, or treatment area, will be randomly assigned to receive either cryotherapy or 5-fluoruracil treatment.
62498864|NCT04667390|ACTIVE_COMPARATOR|total knee arthroplasty using the active robotic system|total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
62341619|NCT01841957|EXPERIMENTAL|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
62498865|NCT04667390|ACTIVE_COMPARATOR|total knee arthroplasty using computer navigation|Primary total knee arthroplasty using computer navigation and intraoperation control system
61949999|NCT01784445|ACTIVE_COMPARATOR|Diclophenac sodium plus placebo|Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo
62341620|NCT01841957|ACTIVE_COMPARATOR|DSBCS|Delayed Sequential Bilateral Cataract Surgery
61950000|NCT05757102|EXPERIMENTAL|Participants receiving FF/UMEC/VI|
61950001|NCT05757102|ACTIVE_COMPARATOR|Participants receiving FF/VI|
61950002|NCT01821638||Older adults with heart failure|Older adults with heart failure
62341621|NCT02670460|EXPERIMENTAL|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left subclavian vein.
62341622|NCT00000255|PLACEBO_COMPARATOR|0% Nitrous oxide|
61950003|NCT04850001||Patient Group|Asymptomatic intracranial stenosis patients who receive standard medical treatment without stenting
61950004|NCT04850001||Healthy Control|Healthy control are free from intracranial stenosis
61950005|NCT00645112|ACTIVE_COMPARATOR|1|
61950006|NCT00645112|ACTIVE_COMPARATOR|2|
61950007|NCT02168361|ACTIVE_COMPARATOR|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
61950008|NCT02168361|EXPERIMENTAL|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
62341623|NCT00000255|ACTIVE_COMPARATOR|10% nitrous oxide|
62341624|NCT00000255|ACTIVE_COMPARATOR|20% nitrous oxide|
62341625|NCT00000255|ACTIVE_COMPARATOR|30% nitrous oxide|
62341626|NCT00000255|ACTIVE_COMPARATOR|40% nitrous oxide|
62341627|NCT03038243|EXPERIMENTAL|Cohort 1|Group 1, 2.25 x 10\^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10\^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
62699042|NCT01869673|EXPERIMENTAL|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
62341628|NCT03038243|EXPERIMENTAL|Cohort 2|Group 1, 2.25 x 10\^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10\^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
62341629|NCT03038243|EXPERIMENTAL|Cohort 3|Group 1, 2.25 x 10\^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10\^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
62699043|NCT02507726|EXPERIMENTAL|Flexima Active Soft convexe|Flexima Active soft convexe (1 to 3 appliances per day)
62699044|NCT01971918|EXPERIMENTAL|early switch|"* early switch of monoclonal antibodies anti-TNF~* anti drug antibodies dosage"
61950009|NCT03697473|ACTIVE_COMPARATOR|Nordic Hamstring Exercise Group|Participants were required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they could no longer lower themselves as such, they were instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touched the ground they were instructed to immediately return to the starting position by pushing up with their hands.
61950010|NCT03697473|EXPERIMENTAL|Hip Extension Exercise Group|The participant lay on an exercise bench at a 45° angle with their hips held just over the top of the bench, their trunk erect and hips extended and their heel supported. Participants slowly flexed their hip until they reached 90° from the starting position and were then required to return to the starting position by extending through the hip while maintaining a neutral pelvic and trunk posture throughout. This exercise was then repeated on the opposite leg
62498866|NCT04667390|ACTIVE_COMPARATOR|total knee arthroplasty using the standard manual tekhnik|Primary total knee arthroplasty using the standard recommended set of instruments
62498867|NCT04733508|EXPERIMENTAL|111In-exendin-DTPA|Injection of 111In-exendin-DTPA for subsequent localization of the tracer in excised tissue using autoradiography
62498868|NCT04733508|EXPERIMENTAL|exendin-IRDye800CW|Injection of exendin-4-IRDye800CW for subsequent localization of the tracer in excised tissue using fluorescence microscopy
62498869|NCT06176560|EXPERIMENTAL|Mesalazine Experimental|Mesalazine oral formulation
62498870|NCT06176560|ACTIVE_COMPARATOR|Mesalazine Comparator|Mesalazine oral formulation
62498871|NCT03281096|EXPERIMENTAL|Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years
62498872|NCT03281096|PLACEBO_COMPARATOR|Placebo|identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years
62699045|NCT01971918|EXPERIMENTAL|therapeutic intensification|"* therapeutic intensification of monoclonal antibodies anti-TNF~* anti drug antibodies dosage"
61950011|NCT01214343|EXPERIMENTAL|Sorafenib with Low-dose FP|
61950012|NCT01214343|ACTIVE_COMPARATOR|Sorafenib|
61950013|NCT04941859|EXPERIMENTAL|experimental group|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
61950014|NCT04941859|NO_INTERVENTION|control group|The treatment plan of control group was carried out according to the diagnosis and treatment standard of acute poisoning.
61950015|NCT03557853||Golimumab injection|Patients with ankylosing spondylitis and coxitis being treated with Simponi (golimumab) according to local clinical practice and label.
62341630|NCT01904240||Parkinson's disease patients|Patients with Parkinson's disease
62341631|NCT01904240||Subjects without Parkinson's disease|Control subjects without Parkinson's disease
62341632|NCT01398072|ACTIVE_COMPARATOR|Moxifloxacin|
62341633|NCT01398072|ACTIVE_COMPARATOR|Azithromycin|
62498873|NCT03434145||patients with chronic kidney diseases|patients with end stage retinal disease undergoing hemodialysis underwent various ophthalmologic exams before and after hemodialysis.
62498874|NCT05491850|EXPERIMENTAL|Moderate Physical Activity Group|The Experimental Group gets moderate physical activity. Elliptical will be performed at least 5 days/per week. Moderate intensity, corresponding approximately to 40-60% of Vo2max (maximal aerobic capacity) 150 min/week of exercise undertaken at moderate intensity or greater. Warm-up and Dynamic stretching is given before and static stretching is given after moderate physical activity.
61950016|NCT04795960|EXPERIMENTAL|Low serine diet|
61950017|NCT04795960|EXPERIMENTAL|High serine diet|
62341634|NCT01398072|ACTIVE_COMPARATOR|Doxycycline|
62341635|NCT01398072|PLACEBO_COMPARATOR|Placebo|
62341636|NCT01831180||Premenopausal women 19-25 yrs|
62341637|NCT01831180||Postmenopausal 60 yrs +|
62341638|NCT05316337|EXPERIMENTAL|Atrial fibrillation|
62341639|NCT05316337|EXPERIMENTAL|Normal Sinus Rhythm|
62341640|NCT01147575|ACTIVE_COMPARATOR|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH respectively the groups were switched for another 6 months (period 2).
62498875|NCT05491850|NO_INTERVENTION|Non Specific Physical Activity Group|The Control group continues their regular medication for diabetic neuropathy.
62699046|NCT04433195|ACTIVE_COMPARATOR|Immediate NAA by clinician|Nucleic acid amplification test requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB
62699047|NCT04433195|EXPERIMENTAL|Immediate NAA as intervention|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, but Xpert MTB/RIF is performed as intervention in this study (intervention group)
62341641|NCT01147575|PLACEBO_COMPARATOR|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
62341642|NCT01757613|ACTIVE_COMPARATOR|AK 3012 a for topical use|
62341643|NCT01757613|ACTIVE_COMPARATOR|AK 3012 b for topical use|
62341644|NCT01757613|ACTIVE_COMPARATOR|AK 3012 c for topical use|
62341645|NCT05350566|EXPERIMENTAL|Sprint interval training group (SIT group)|The model of sprint interval training (SIT) consists of six 30 s all-out cycling bouts on a cycle ergometer, with 4 min rests between tests.
61950018|NCT02067130|OTHER|Fibroscan|Subjects enrolled will undergo Fibroscan. It is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Fibroscan reading will be collected at the Gastroenterologist's (Dr. Ko) outpatient clinic (Pacific Gastroenterology Associates) where a qualified research nurse/assistant will perform the scan under supervision of the physician. Anticipated timing of this procedure will be October to December 2013
61950019|NCT03763175|ACTIVE_COMPARATOR|SYN-010 21 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (21 mg PO QD). Study activities will be the same across all three arms.
61950020|NCT03763175|ACTIVE_COMPARATOR|SYN-010 42 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (42 mg PO QD). Study activities will be the same across all three arms.
61950021|NCT03763175|PLACEBO_COMPARATOR|Placebo|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of placebo. Study activities will be the same across all three arms.
61950022|NCT01007539|EXPERIMENTAL|CDP-choline|
61950023|NCT01007539|PLACEBO_COMPARATOR|Placebo (fructose)|
61950024|NCT00843856|ACTIVE_COMPARATOR|tacrolimus|Intervention type -drug tacrolimus therapy 2mg bd adjust to obtain levels of 5-12ng/L
61950025|NCT00843856|ACTIVE_COMPARATOR|tacrolimus and mycophenolate mofetil|tacrolimus 2mgs bd (adjusted to obtain levels 5-12mg/L and mycophenolate mofetil 500mg bd adjusted to obtain levels 1.5-3mg/L
61950026|NCT03884959|EXPERIMENTAL|HepaStem Infusion|A calculated dose based on patient's body weight will be administered via Permanent mesenteric Portal Access and Catheter for four times or a Transient Percutaneous Transhepatic Catheter for three times.
61950027|NCT00478231|EXPERIMENTAL|1|
62498876|NCT06361550|EXPERIMENTAL|Intervention group|Practical seminar, carried out in a market, on how to properly carry out the shopping cart. Afterwards, the participants will prepare a menu, consisting of three courses (starter, main and dessert). Finally, the tasting of the different preparations will take place.
62498877|NCT06361550|ACTIVE_COMPARATOR|Control|Group educational talk, lasting 2 hours, aimed at correct compliance with the Mediterranean Diet according to current recommendations.
62498878|NCT01094262|EXPERIMENTAL|JNJ-42160443 (lower dose)|
62498879|NCT01094262|EXPERIMENTAL|JNJ-42160443 (higher dose)|
62498880|NCT01094262|ACTIVE_COMPARATOR|Oxycodone CR (standard pain medication)|
62498881|NCT01094262|PLACEBO_COMPARATOR|Placebo|
62498882|NCT06641154|EXPERIMENTAL|GT-UGT1A1-AAV8-02|2 doses of the IMP assessed in the dose escalation, open-label, phase 1/2 study
62498883|NCT01652963|NO_INTERVENTION|Control task|The no-intervention control task consists of a presentation of the stimuli used in the training task. Participants will see situations and listen to the simultaneous voice recordings. Unlike in the training task participants will not receive instructions to link situations and emotions. There is no task requirement, just a presentation of the situation stimuli to assure that potential training effects are due to the training programme and not merely to the presentation of scenarios. The duration of the presentation of stimulus materials in the control group will range between fifteen and thirty minutes. The variable duration is necessary so the primary investigator cannot assume a participant's intervention group based on the duration of the intervention task.
61950028|NCT05340075||Staged percutaneous nephrolithotomy group 1|Those who underwent percutaneous nephrolithotomy 2-4 weeks after percutaneous nephrolithotomy for stones in the other kidney
62699048|NCT04433195|NO_INTERVENTION|No immediate NAA|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, and Xpert MTB/RIF is not performed as the initial diagnostic test in this study (control group). Nucleic acid amplification test may be ordered at a later point in time by clinicians as an add-on test after sputum smear microscopy
62699049|NCT05429411|EXPERIMENTAL|Gel treated scar|Gel treated scar
61950029|NCT05340075||Staged percutaneous nephrolithotomy group 2|Those who underwent percutaneous nephrolithotomy 4-6 weeks after percutaneous nephrolithotomy for stones in the other kidney
61950030|NCT01056029|EXPERIMENTAL|G-202|
61950031|NCT02241252|OTHER|iPhone ECG QT recording|iPhone ECG
61950032|NCT03218709|EXPERIMENTAL|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
61950033|NCT03218709|EXPERIMENTAL|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
61950034|NCT03218709|ACTIVE_COMPARATOR|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
61950035|NCT03218709|PLACEBO_COMPARATOR|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
61950036|NCT03698409|NO_INTERVENTION|Botox in preservative-free saline|OnabotulinumtoxinA (Botox) 200u will be reconstituted using 4 ml of preservative-free saline, as recommended by the manufacturer. 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites)
61950037|NCT03698409|ACTIVE_COMPARATOR|Botox in preserved saline|OnabotulinumtoxinA (Botox) 200u will be reconstituted using 4 ml of preservative saline (i.e. bacteriostatic saline). 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites).
62699050|NCT05429411|NO_INTERVENTION|Control scar|No intervention, standard of care
62699051|NCT00404248|ACTIVE_COMPARATOR|With Enzyme-inducing antiseizure drugs (+EIASD)|"subjects on the +EIASD treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
61950038|NCT06043726||Suspected PE|Patients with suspected pulmonary embolism
61950039|NCT00526370||A|Women with at least moderate dysplasia in biopsies from cervix uteri
61950040|NCT00526370||B|Women with only normal PAP-smears
61950041|NCT04222907||Women screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were screened for GBS during pregnancy
61950042|NCT04222907||Women not screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were not screened for GBS during pregnancy
61950043|NCT00539656|EXPERIMENTAL|Receive two cord blood units|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
61950044|NCT04767685||All patients|Consenting patients undergoing non-emergency surgery with anesthesia
62498884|NCT01652963|EXPERIMENTAL|Reed and Clements Training Task|The training task consists of 2 blocks of 6 items with items presented randomly within each block and blocks being counterbalanced between participants. Block 1 presents a situation and prompts participants to identify whether they would feel happy or sad in the given situation. Block 2 presents an emotion (happy or sad) and prompts the participant to identify which of two situations (positive or negative) most likely preceded this emotion. Within each block there will be at least one and maximum three training rounds. The second and third training rounds will only consist of the items to which the participant responded incorrect in the previous round. Each item in rounds 2 and 3 will be followed by feedback.
62498885|NCT05332691|EXPERIMENTAL|Hypertrophic Obstructive Cardiomyopathy|Transapical beating-heart septal myectomy for the patient with hypertrophic obstructive cardiomyopathy.
62498886|NCT02117505|EXPERIMENTAL|Group 1 (Formulation 2 Then Formulation 1)|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in first treatment period; followed by JNJ-54781532 formulation 1 as 150 mg orally (5\*30 mg tablet=150 mg) in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62498887|NCT02117505|EXPERIMENTAL|Group 2 (Formulation 1 Then Formulation 2)|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 mg oral tablet (5\*30 mg tablet=150 mg) in first treatment period; followed by JNJ-54781532 formulation 2 as 150 mg oral tablet in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
62498888|NCT03945058|EXPERIMENTAL|Experimental|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
62498889|NCT03945058|SHAM_COMPARATOR|CONTROL|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 4weeks.
62498890|NCT02176616|ACTIVE_COMPARATOR|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
61950045|NCT03949309||Eligible patients|All eligible patients discharged from hospital for Acute Myocardial Infarction (AMI) or acute decompensation of Chronic Heart Failure (CHF)
61950046|NCT03555032|EXPERIMENTAL|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
62498891|NCT02176616|EXPERIMENTAL|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
62498892|NCT02566096|PLACEBO_COMPARATOR|TAP with bupivicaine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
62498893|NCT02566096|ACTIVE_COMPARATOR|TAP with bupivicaine with morphine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
62498894|NCT03942211|EXPERIMENTAL|Selexipag 200 micro gram (μg)|Study intervention will be up-titrated to allow each participant to reach their individual maximum tolerated dose (iMTD), in the range of 200 μg to1600 μg (ie, 1 to 8 tablets) twice daily/once daily. Dosing frequency will be twice daily, except for participants with moderate hepatic impairment (Child-Pugh Class B) or who are concomitantly taking (a) moderate CYP2C8 inhibitor(s), who receive study intervention once daily. The dose will be up-titrated by the investigator/delegate in 200 μg twice daily/once daily increments at weekly intervals during scheduled TCs until reaching the iMTD. If the dose regimen is not well tolerated or symptoms cannot be fully managed with symptomatic treatment, the duration of the titration step can be prolonged to 2 weeks. If needed, the dose can be reduced by 200 μg twice daily/once daily.
62498895|NCT03942211|PLACEBO_COMPARATOR|Placebo|The comparator will be administered similarly to the experimental intervention.
62498896|NCT03200535|NO_INTERVENTION|Usual care|Usual care
61950047|NCT04450446||cerebral hemorrhage|
61950048|NCT04450446||thromboembolism|
61950049|NCT04450446||no thromboembolism and cerebral hemorrhage|
61950050|NCT02902900||Imnovid|Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice
61950051|NCT04608929|EXPERIMENTAL|Intervention|The arm where the Kegel exercise focused intervention is applied
61950052|NCT04608929|EXPERIMENTAL|Control|The arm where home follow-up and scale evaluations are made
61950053|NCT03047707|EXPERIMENTAL|S-Shearwave and TE|
61950054|NCT04053075|ACTIVE_COMPARATOR|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
62498897|NCT03200535|ACTIVE_COMPARATOR|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
62498898|NCT03200535|ACTIVE_COMPARATOR|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
62699052|NCT00404248|ACTIVE_COMPARATOR|With Non enzyme-inducing antiseizure drugs (-EIASD)|"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
62699053|NCT01051661|EXPERIMENTAL|Arepanrix 2D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children \<12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children \<12 months of age, in the right anterolateral thigh.
62699054|NCT01051661|EXPERIMENTAL|Arepanrix 2D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
62699055|NCT01051661|EXPERIMENTAL|Arepanrix 1D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children \<12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children \<12 months of age, in the right anterolateral thigh.
62699056|NCT01051661|EXPERIMENTAL|Arepanrix 1D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
61950055|NCT04053075|ACTIVE_COMPARATOR|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
61950056|NCT00850343|EXPERIMENTAL|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
61950057|NCT00850343|EXPERIMENTAL|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
61950058|NCT04690933||Multicentric NAViRe cohort with biocollection|"The National Reference Center (CNR) for cytomegalovirus with the French Society for Medullary Transplantation and Cell Therapy (SFGM-TC) has set up a surveillance cohort of allografted patients (NAViRe cohort) receiving, as prevention or treatment, Anti-Cytomegalovirus (Anti-CMV) molecules, new or less recent, thus allowing the development of a new observatory evaluating in real life the potentials of these drugs in terms of efficacy, emergence of resistance, tolerance and morbidity and mortality associated with CMV infection.This work is useful to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients and allows the emergence of an real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients."
61950059|NCT06066125|EXPERIMENTAL|AK111 regimen 1|
61950060|NCT06066125|EXPERIMENTAL|AK111 regimen 2|
61950061|NCT06066125|PLACEBO_COMPARATOR|Placebo|
61950062|NCT00001183||Group 1|Pulmonary Patients
61950063|NCT03137537|EXPERIMENTAL|Ivabradine|"* Ivabradine will be administered for a total of 6 weeks~* Ivabradine is taken orally twice daily~* Dosage will be adjusted according to physician determination"
61950064|NCT03137537|PLACEBO_COMPARATOR|Placebo Oral Tablet|"* Placebo will be administered for a total of 6 weeks~* Placebo is taken orally twice daily~* Dosage will be adjusted according to physician determination"
61950065|NCT05654935||Cohort A|Includes 26 healthy volunteers \>18 years of age without history of stroke or transient ischemic attack, coronary artery disease (prior myocardial infarction, typical angina, prior percutaneous coronary revascularization, and prior coronary bypass graft surgery), and peripheral arterial disease (claudication, peripheral arterial revascularization stenting of bypass surgery). Subjects will be recruited using advertisement flyers and emails.
61950066|NCT05654935||Cohort B|Includes 100 subjects ≥ 60 years of age without known carotid artery disease. These subjects will be recruited from patients scheduled to receive a clinically indicated cardiac stress test or echocardiogram in the noninvasive cardiac testing area at Rush University Medical Center (Chicago, IL).
61950067|NCT03683160|EXPERIMENTAL|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
62498899|NCT03200535|ACTIVE_COMPARATOR|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
62498900|NCT06336967|EXPERIMENTAL|GUIDE with incentives|Immediate access to the GUIDE App smartphone application for 4 weeks with the opportunity to earn additional compensation, up to $100 in total, based on app engagement.
62498901|NCT06336967|EXPERIMENTAL|GUIDE without incentives|Immediate access to the GUIDE App for 4 weeks without the opportunity to earn additional compensation.
62498902|NCT06336967|NO_INTERVENTION|Waitlist|Waitlisted with delayed access to the GUIDE App without the opportunity to earn additional compensation.
62498903|NCT03704974||Children of Parents Receiving IY|Children ages 3 to 6 years at start of group with behavior concerns whose parents are referred by their pediatricians for participation in a video-based parent training program from 2014 through 2018.
62498904|NCT05675995|EXPERIMENTAL|Immediate|Receives 6 sessions of qigong first.
62498905|NCT05675995|OTHER|Waitlist Control|Receives 6 sessions of qigong after the immediate group
62498906|NCT03526562|EXPERIMENTAL|Single arm phase I trial with 3 exercise dose-escalation arms|exercise dose-escalation: aerobic, resistance and flexibility training
62498907|NCT03405064|EXPERIMENTAL|levonadifloxacin|oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
62498908|NCT03405064|ACTIVE_COMPARATOR|linezolid|oral linezolid (600 mg BID) or IV linezolid (600 mg BID)
62498909|NCT01337596|EXPERIMENTAL|Single dose 1 milligram (mg) LY2951742|Administered single subcutaneous injection
61950068|NCT05867303|EXPERIMENTAL|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
61950069|NCT03352349|EXPERIMENTAL|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
61950070|NCT02422303|ACTIVE_COMPARATOR|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
61950071|NCT02422303|NO_INTERVENTION|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
61950072|NCT04715633|EXPERIMENTAL|PD-1 inhibitors plus VEGF inhibitors|Patients will be given 4 cycles of Camrelizumab (200mg iv every 3 weeks) plus Apatinib (250mg QD day1-14) before being evaluated for response.
61950073|NCT03434197|EXPERIMENTAL|SFPP (Esflurbiprofen plaster)|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
61950074|NCT03434197|ACTIVE_COMPARATOR|Diclofenac gel|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
61950075|NCT01816074|EXPERIMENTAL|Maternal Medication then meds|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
61950076|NCT01816074|EXPERIMENTAL|BPT then continued beh tx|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
61950077|NCT01816074|EXPERIMENTAL|Maternal Medication then BPT|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
62498910|NCT01337596|EXPERIMENTAL|Single dose 5 mg LY2951742|Administered single subcutaneous injection
62498911|NCT01337596|EXPERIMENTAL|Single dose 25 mg LY2951742|Administered single subcutaneous injection
62498912|NCT01337596|EXPERIMENTAL|Single dose 75 mg LY2951742|Administered single subcutaneous injection
61950078|NCT01816074|EXPERIMENTAL|BPT then maternal medication|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
61950079|NCT00963131|EXPERIMENTAL|antioxidant tablets|the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
61950080|NCT00963131|PLACEBO_COMPARATOR|placebo tablets|the control arm received placebo tablets for 3 months or until the resolution of the disease
62498913|NCT01337596|EXPERIMENTAL|Single dose 200 mg LY2951742|Administered single subcutaneous injection
62498914|NCT01337596|EXPERIMENTAL|Single dose 600 mg LY2951742|Administered single subcutaneous injection
62498915|NCT01337596|PLACEBO_COMPARATOR|Single dose placebo|Administered single subcutaneous injection
62498916|NCT01337596|PLACEBO_COMPARATOR|Multiple dose placebo|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
62498917|NCT01337596|EXPERIMENTAL|150 mg LY2951742|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
61950081|NCT02432482|ACTIVE_COMPARATOR|Standard care|Brief advice to quit (less than 5 minutes) Self-help brochure Offer of nicotine patches
61950082|NCT02432482|EXPERIMENTAL|mobile Positively Smoke Free (mPSF)|"mPSF: a targeted, intensive behavioral cessation intervention for PLWH smokers~* offer of nicotine patches"
62498918|NCT06094192|EXPERIMENTAL|active stimulation|Memory performance data is collected during active brain stimulation and reported 1 year later
61950083|NCT03145233|EXPERIMENTAL|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
62498919|NCT06094192|SHAM_COMPARATOR|sham stimulation|Memory performance data is collected during sham brain stimulation and reported 1 year later
62498920|NCT01618487|ACTIVE_COMPARATOR|Arthroscopic tenotomy|Patients who are in this group will have arthroscopic tenotomy. A scope is used to see the tendon and release it.
62498921|NCT01618487|ACTIVE_COMPARATOR|Open tenotomy|Patients in this group will undergo open tenotomy. This involves opening the skin to expose the muscle and tendon, and then the tendon is released.
62498922|NCT01618487|ACTIVE_COMPARATOR|Debridement and repair|The patients in this group will undergo an arthroscopic technique (scope and small incision) to go in and remove any tissue that is diseased/does not belong and repair the tear(s) in the tendon.
62498923|NCT06586411||PARDS|pediatric patients who were diagnosed with PARDS
62498924|NCT01964872|EXPERIMENTAL|JNJ-38877618|
62498925|NCT01964872|PLACEBO_COMPARATOR|Placebo|
62498926|NCT06581601|NO_INTERVENTION|Control group|1.Contorl group: healtyhy women.
62498927|NCT06581601|EXPERIMENTAL|Pre-menopausal group|2.Pre-menopasal group: experimental group - exercise's group
62498928|NCT06581601|EXPERIMENTAL|Post-menopausal group|3.Post-menopausal group: experimental group - exercise's group
62699057|NCT01051661|EXPERIMENTAL|GSK2340273A 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children \<12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children \<12 months of age, in the right anterolateral thigh.
62699058|NCT01051661|EXPERIMENTAL|GSK2340273A 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
61950084|NCT03145233|EXPERIMENTAL|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
61950085|NCT01827956||Blood sample|Blood sample for identifying the polymorphism
62498929|NCT02884258||Bariatric surgery group|Women undergoing IVF (IVF or ICSI) with a history of bariatric surgery (surgery procedures include sleeve gastrectomies and by-passes). No intervention is involved.
61950086|NCT06354309|EXPERIMENTAL|Pre and post control study|The subjects used the HMVR for 2 sessions of game training (30 minutes each, 10 minutes intervals).
61950087|NCT02439060|EXPERIMENTAL|Arm I (biologic mesh)|Patients undergo placement of biologic mesh during radical cystectomy and placement of the ileal conduit.
62341646|NCT05350566|EXPERIMENTAL|Moderate intensity continuous training (MICT group)|The moderate intensity continuous training (MICT) consists of 1h cycling on a cycle ergometer at 50% of the maximal aerobic power output
62341647|NCT00980980|NO_INTERVENTION|Arm 1: Usual Care-Active Surveillance|Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+
62498930|NCT02884258||Control Group|1. Women undergoing IVF with no history of bariatric surgery and matched to bariatric surgery patients for weight, parity and age. 2. non-operated severely obese women
62498931|NCT03941080||GIMICC|Adult patients with newly diagnosed metastasized or irresectable CRC with an indication for standard palliative systemic anti-tumor treatment.
62498932|NCT01259830|EXPERIMENTAL|Arcoxia® 120 mg|
62341648|NCT00980980|ACTIVE_COMPARATOR|Arm 2: Targeted Decolonization|Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
62341649|NCT00980980|ACTIVE_COMPARATOR|Arm 3: Universal Decolonization|Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
62341650|NCT05636371|EXPERIMENTAL|Written Communication|ICU care providers will initiate the process for providing written communication to families. Study investigators will facilitate the creation and distribution of written communication
62341651|NCT00613418|OTHER|single|Historical control
62341652|NCT05154266|EXPERIMENTAL|Mindfulness Programme|Participants randomized to the mindfulness programme were invited to complete a twelve-week programme called 'Taking it Further'.
62341653|NCT05154266|NO_INTERVENTION|Waitlist Control|Participants randomized to the waitlist control were asked to carry on as usual and were offered the Taking it Further course at a later time. No data was collected when the waitlist control group took part in the TiF programme.
62341654|NCT03529383|EXPERIMENTAL|Connected device|"Women randomized to the connected device arm will follow a 6-month exercise program using a connected device that includes an activity tracker and subscription to an exercise and physical activity management program through a smartphone application and a website. They will also receive international recommendations on physical activity."
62341655|NCT03529383|EXPERIMENTAL|Therapeutic education|"Women randomized to the therapeutic education arm will follow a 6-month program of therapeutic patient education. They will also receive international recommendations on physical activity."
62498933|NCT01259830|PLACEBO_COMPARATOR|Sugar pill|
62498934|NCT03117205|EXPERIMENTAL|Kinesio Taping® group|
62498935|NCT03117205|PLACEBO_COMPARATOR|placebo group|
62498936|NCT05135377||Children with Anaphylaxis|Patients under 18 years of age presenting to the Emergency Department (ED) with an allergic reaction that matches diagnostic criteria for anaphylaxis.
62498937|NCT06588673|OTHER|Art Therapy|psp patients enrolled into study.
62498938|NCT01953146||PCOS criteria|nfertile patients undergoing assisted reproduction were consecutively recruited at the Fertility Clinic, Arhus University Hospital from February 2011 to May 2013. Women aged \< 38 years without endometriosis where more than \> 8 oocytes were retrieved were eligible. Patients were categorized in PCOS and non-PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
62498939|NCT02926170|EXPERIMENTAL|rivaroxaban|Rivaroxaban 20 mg per day
62498940|NCT02926170|ACTIVE_COMPARATOR|acenocumarol|INR adjusted dose
62498941|NCT01599689|EXPERIMENTAL|Mirrors Intervention|Patients allocated to Mirrors will receive a structured, protocol-driven bedside mirrors intervention as part of their postsurgical ICU care. This intervention will commence as soon as all anaesthetic agents have been switched off and the patient is awake following surgery unless considered clinically inappropriate.
62498942|NCT01599689|NO_INTERVENTION|Standard Care|Patients allocated to Standard Care will receive the usual postsurgical ICU care that does not include the use of mirrors.
62498943|NCT04604210|EXPERIMENTAL|Dysphoric target|"The dysphoric target is a region in the dorsolateral prefrontal cortex. TMS targeted to this region has been shown to be more effective for depression than anxiety."
62498944|NCT04604210|EXPERIMENTAL|Anxiosomatic target|"The anxiosomatic target is a region in the dorsomedial prefrontal cortex. TMS targeted to this region has been shown to be more effective for anxiety than depression."
62498945|NCT06218511|EXPERIMENTAL|Single arm|single-arm open-label
62699059|NCT02395276|ACTIVE_COMPARATOR|Whole body hypothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for whole body hypothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Whole body hypothermia will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
62699060|NCT02395276|PLACEBO_COMPARATOR|Whole body normothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for normothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 36-37 °C . Treatment period will be 72 hrs.
62699061|NCT02395276|NO_INTERVENTION|Control|A group of children that underwent a cardiac surgery and was not suspected to have an hypoxic ischemic brain injury. This group will be undergo the similar biomarkers collection as arm 1 and 2. The information will be used to measure the change in biomarkers between surgeries with no HII to those in arm 1+2.
62699062|NCT00864357|EXPERIMENTAL|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
61950088|NCT02439060|NO_INTERVENTION|Arm II (no intervention)|Patients undergo standard of care radical cystectomy and placement of the ileal conduit.
61950089|NCT04803539|ACTIVE_COMPARATOR|Capecitabine|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year
62699063|NCT00864357|ACTIVE_COMPARATOR|B|COMBONOX® tablets, single dose
62699064|NCT02860403|EXPERIMENTAL|C6-C7 patients|C6-C7 patients able to recover tenodesis grasp.
62699065|NCT02860403|EXPERIMENTAL|C5-C6 patients|C5-C6 patients for whom surgery for rehabilitation of an upper limb is indicated with a upper limit of one year after trauma, and after complete clinical and functional evaluation
62699066|NCT02860403|NO_INTERVENTION|Control group|a control group (n=6) matched on age and sex to C6-C7 without medical history or neurological disorder
62699067|NCT01502527|EXPERIMENTAL|Treatment with Femarelle|An open labeled , twice daily treatment with Femarelle
62699068|NCT01467557||1-Day ACUVUE TruEye contact lens users|1-Day ACUVUE TruEye contact lens users
62699069|NCT01467557||1-Day ACUVUE MOIST contact lens users|1-Day ACUVUE MOIST contact lens users
61950090|NCT04803539|EXPERIMENTAL|Capecitabine + Apatinib + Camrelizumab|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year
61950091|NCT02050243|EXPERIMENTAL|5ALA|All included patients will receive 20mg/kg of 5ALA (oral suspension) about 3 hours prior to surgery
62341656|NCT03529383|EXPERIMENTAL|Combined|"Women will benefit from both the connected device intervention and the therapeutic education intervention and receive international recommendations on physical activity."
62699070|NCT04539288||Gestational diabetes mellitus|Women who were diagnosed GDM in 24-28 gestation weeks.
61950092|NCT06171295|OTHER|PK of Levobupivacain|Newborns who received epidural anesthesia with Levobupivacain
61950093|NCT02802943|EXPERIMENTAL|Peptide Vaccine MRD +|MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)
62699071|NCT05205837|PLACEBO_COMPARATOR|Active Comparator - placebo|Intervention: Intramuscular injection - placebo Intervention: Drug: placebo
62699072|NCT05205837|ACTIVE_COMPARATOR|Active comparator - treatment|Intervention: intramuscular injection - hCG Intervention: Drug: Letrozole
61950094|NCT02802943|EXPERIMENTAL|Peptide Vaccine MRD-|MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow \<10-4 6-10 weeks after the end of first line treatment)
62341657|NCT03529383|NO_INTERVENTION|Control|Women will receive standard care, i.e., international recommendations on physical activity, without further intervention.
62341658|NCT02999568||Experimental|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
62341659|NCT02999568||Control group|Women who practice low level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
62699073|NCT02639988||rheumatoid arthritis and type 2 diabetes|
62699074|NCT02639988||osteoarthritis and type 2 diabetes|
62699075|NCT06548048|PLACEBO_COMPARATOR|Placebo Treatment|
62699076|NCT06548048|ACTIVE_COMPARATOR|Active high dose of plant derived phenolics|
62699077|NCT01659294|EXPERIMENTAL|nurse case management|nurse case management of diabetic variables
62699078|NCT01659294|ACTIVE_COMPARATOR|standard diabetologist care|standard diabetologist care
61950095|NCT00178633||Bariatric Surgery|Procedures were not part of the trial. Patients already undergoing these clinical procedures agreed to analysis and follow-up for research purposes. All patients had one of two different types of procedures, but outcome analyses did not distinguish between the two procedures.
61950096|NCT03805399|EXPERIMENTAL|pyrotinib with capecitabine|If patients were LAR subtype with HER2 gene activated mutation
62699079|NCT04419519|EXPERIMENTAL|Venetoclax monotherapy|
61950097|NCT03805399|EXPERIMENTAL|AR inhibitor with CDK4/6 inhibitor|If patients were LAR subtype without HER2 gene activated mutation, but had PIK3CA mutation, enter into arm B1; If patients were LAR subtype without HER2 gene activated mutation or PIK3CA mutation, enter into arm B2;If B2 was closed, enter into B4;
62341660|NCT01757782|ACTIVE_COMPARATOR|Oral Sildenafil|In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
62699080|NCT04419519|EXPERIMENTAL|Venetoclax with anti-CD20 monoclonal antibody|
62699081|NCT05454514|OTHER|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
62699082|NCT02374255|EXPERIMENTAL|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
62699083|NCT02374255|NO_INTERVENTION|Usual Care|
62699084|NCT03490240|EXPERIMENTAL|BIPAMS|The behavioral intervention consists of two primary components, a dedicated Internet website and one-on-one video chats with a behavioral coach via Skype. The behavioral intervention focuses on the skills, techniques, resources, and strategies for becoming and staying physically active with MS, but it does not provide a prescription for exercise or physical activity itself.
62699085|NCT03490240|ACTIVE_COMPARATOR|WELLMS|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
61950098|NCT03805399|EXPERIMENTAL|anti PD-1 with nab-paclitaxel|If patients were IM subtype(CD8 positive T cell more than 20%)
61950099|NCT03805399|EXPERIMENTAL|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation
61950100|NCT03805399|EXPERIMENTAL|BLIS with anti-VEGFR included therapy|If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation
62341661|NCT01757782|PLACEBO_COMPARATOR|Distilled water|In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
62498946|NCT02828566|EXPERIMENTAL|IN ketamine and IV saline|Ketamine, single dose, 10 mg/kg (0.1 mL/kg) of 100 mg/mL solution delivered intranasally using an atomizer and divided to both nares to a maximum of 800 mg (8 mL) AND 0.9% normal saline (NS) 0.02 to 0.03 mL/kg delivered intravenously to a maximum of 2.4 mL
62498947|NCT02828566|ACTIVE_COMPARATOR|IV ketamine and IN saline|Ketamine, single dose, 1 to 1.5 mg/kg (0.02 to 0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 120 mg (2.4 mL) AND 0.9% normal saline (NS) 0.1 mL/kg delivered intranasally using an atomizer and divided to both nares, to a maximum of 8 mL
62498948|NCT01189682|ACTIVE_COMPARATOR|Tegaderm HP|
62498949|NCT01189682|PLACEBO_COMPARATOR|Tegaderm|
62498950|NCT01189682|ACTIVE_COMPARATOR|Tegaderm CHG|
62498951|NCT00448227|EXPERIMENTAL|Famciclovir|Famciclovir was administered orally as a suspension in OraSweet® on Day 1. Patients received a single, individualized dose between 25-200 mg based on body weight.
61950101|NCT03805399|EXPERIMENTAL|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation
62341662|NCT05838651|ACTIVE_COMPARATOR|Bone Graft Alone|Socket preservation sites with bone graft (MinerOss® X Plug) alone without complete flap closure (secondary intention healing) (n=10)
62341663|NCT05838651|EXPERIMENTAL|Bone Graft + Membrane|Socket preservation sites with bone graft (MinerOss® X Plug) and a non-crosslinked collagen membrane without complete flap closure (secondary intention healing) (n=10)
62341664|NCT04243356|EXPERIMENTAL|Nurse Encounter Group|Nurses that are assigned to this group will be asked to take surveys before and immediately following the post-ICU clinic encounter with a patient that they had cared for in the ICU during a follow-up care visit with the former ICU - patient.
62341665|NCT04243356|OTHER|Nurse Control Group|Nurses assigned to this group will only complete surveys and will not see a former patient in a post-ICU visit.
62341666|NCT01303380|EXPERIMENTAL|Canakinumab|
62341667|NCT01694550||Pacemaker mode programming|High grade AV-block
62341668|NCT02991937|ACTIVE_COMPARATOR|Medical Therapy|Subjects in the medical therapy arm will be treated with piperacillin/tazobactam for at least 24 hours. Ciprofloxacin/metronidazole will be used in penicillin-allergic patients. Subjects will be maintained on nothing by mouth with intravenous fluids for at least 12 hours. Subjects will be transitioned to oral antibiotics when their WBC is normal, they have a decrease in CRP by ≥ 15%, and they have been afebrile for 24 hours on IV antibiotics.
62498952|NCT05298254|EXPERIMENTAL|Non-adjuvanted HSV formulation 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 1 vaccine, one at Day 1 and one at Day 29.
62498953|NCT05298254|EXPERIMENTAL|Non-adjuvanted HSV formulation 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 2 vaccine, one at Day 1 and one at Day 29.
62498954|NCT05298254|EXPERIMENTAL|Non-adjuvanted HSV formulation 3 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 3 vaccine, one at Day 1 and one at Day 29.
62498955|NCT05298254|EXPERIMENTAL|HSV formulation 1 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
62498956|NCT05298254|EXPERIMENTAL|HSV formulation 2 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
62498957|NCT05298254|EXPERIMENTAL|HSV formulation 3 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
62498958|NCT05298254|EXPERIMENTAL|HSV formulation 1 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
62498959|NCT05298254|EXPERIMENTAL|HSV formulation 2 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
62498960|NCT05298254|EXPERIMENTAL|HSV formulation 3 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
62498961|NCT05298254|PLACEBO_COMPARATOR|Placebo - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
62498962|NCT05298254|EXPERIMENTAL|HSVTI formulation (F) 1 - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of the formulation of the HSVTI_F1 selected from Part I of the study, one at Day 1 and one at Day 29.
62498963|NCT05298254|EXPERIMENTAL|HSVTI_F2 - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of the HSVTI_F2 selected from Part I of the study, one at Day 1 and one at Day 29.
62498964|NCT05298254|PLACEBO_COMPARATOR|Placebo - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
62498965|NCT03846063|EXPERIMENTAL|Intervention: Home-based rehabilitation program|"A twelve-week home-based exercise strategy will be offered to patients after their discharge from the hospital. This home-based exercise strategy will be delivered by means of videos on a tablet-pc and consist of specified exercise instructions for improving muscle strength, balance and functional movements.~The intervention group will be compared with existing patientdata who received usual care in the Netherlands"
62498966|NCT06563583||Group 1|Group 1 will include patients aged 18-40 years.
62498967|NCT06563583||Group 2|Group 2 will include patients aged 40-64 years.
62498968|NCT06563583||Group 3|Group 3 will include patients aged 65-85 years.
61950102|NCT03805399|EXPERIMENTAL|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation
61950103|NCT01729182||Nexium|
61950104|NCT02877134|EXPERIMENTAL|Part I : Placebo|Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (\>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI \<150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22.
61950105|NCT02877134|EXPERIMENTAL|Part I : JNJ-64304500|Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22.
61950106|NCT02877134|EXPERIMENTAL|Part II : Placebo|"Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (\>=100-point reduction from baseline in CDAI or CDAI \<150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 150 mg SC at Week 12 and then JNJ-64304500 75 mg at Weeks 14, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive placebo up to 52 weeks (for a total of up to 72 weeks of placebo in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ- 64304500. Participants receiving placebo during the LTE will stop receiving placebo."
61950107|NCT02877134|EXPERIMENTAL|Part II : JNJ-64304500 High Dose|"JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 high dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
61950108|NCT02877134|EXPERIMENTAL|Part II : JNJ-64304500 Middle Dose|"JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 middle dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
62341669|NCT02991937|ACTIVE_COMPARATOR|Surgical Intervention|Subjects in the surgical treatment arm will receive intravenous antibiotics until the time of operation, and will be maintained on intravenous fluids and no oral intake until they undergo appendectomy as per standard of care. Appendectomy will occur within 24 hours of enrollment. Subjects in the surgical treatment arm will receive post-operative antibiotics as per standard of care.
62341670|NCT03032081|EXPERIMENTAL|High Intensity Group|3 set of 4 minutes of cycling intense exercise, 4 days per week, for 8 weeks at about 80% to 90% of heart rate reserve
62341671|NCT03032081|ACTIVE_COMPARATOR|Moderate Intensity Group|40 to 47 minutes of continuous cycling exercise at 50% to 60% of heart rate reserve, 4 days per week, for 8 weeks.
62341672|NCT04482868|PLACEBO_COMPARATOR|open reduction group|
62341673|NCT04482868|EXPERIMENTAL|percutaneous group|
62341674|NCT05582161|EXPERIMENTAL|DAOIB|
62498969|NCT05862987|EXPERIMENTAL|Hydrogen rich water|Hydrogen rich water supplied in 420 ml packages. Two days before testing - 2 packages (morning and evening), one day before testing - 3 packages (morning, afternoon, and evening), testing day - 4 packages (2 h before the run, 1 h before the run, immediately after the run, and 1 h after the run), 9 packages in total.
62498970|NCT05862987|PLACEBO_COMPARATOR|Placebo|Tap water supplied in 420 ml packages. Two days before testing - 2 packages (morning and evening), one day before testing - 3 packages (morning, afternoon, and evening), testing day - 4 packages (2 h before the run, 1 h before the run, immediately after the run, and 1 h after the run), 9 packages in total.
62498971|NCT03434691|EXPERIMENTAL|DEX group|continuous infusion of Dexmedetomidine at 0.4 μg/kg per hour and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
62498972|NCT03434691|ACTIVE_COMPARATOR|MDZ group|continuous infusion of a Midazolam at 0,1 mg/kg/h and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
62498973|NCT06503003||Laser Therapy Group|Participants will receive non-ablative dual-wavelength diode laser therapy for Genitourinary Syndrome of Menopause (GSM). The intervention includes three monthly sessions using the Leonardo® Diode laser (Biolitec®) with wavelengths of 980 nm and 1470 nm. Each session lasts about 20 minutes and involves 8 pulses per centimeter along the vaginal canal. Local lidocaine gel is used as an anesthetic. Evaluations occur at baseline, 3 months, and 6 months post-treatment.
62498974|NCT06389838|EXPERIMENTAL|Intervention|Intervention through a digital therapy program aimed at multimodal self-treatment for incontinence in addition to standard of care
62498975|NCT06389838|NO_INTERVENTION|Control|Participants will continue with their therapy treatment (standard of care) if they are on it for more that four weeks before inclusion. Beginning of new therapies during the study is not allowed.
62699086|NCT03255473|ACTIVE_COMPARATOR|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
62498976|NCT02480608|EXPERIMENTAL|combination Imatinib + Hydroxyurea|Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy.
62498977|NCT02480608|ACTIVE_COMPARATOR|monotherapy Imatinib|Imatinib monotherapy
62341675|NCT04465396|EXPERIMENTAL|Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)|Teduglutide, 3 mg, subcutaneous (SC) injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A1), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B1). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants with \>=40.0 kg to \<=75.0 kg of weight were included in Cohort 1.
62498978|NCT04427033||CHL & MHL (18 years and older)|CHL= conductive hearing loss, MHL= mixed hearing loss
62498979|NCT04427033||CHL & MHL (5 to 17 years)|
62498980|NCT04427033||SSD (5 years and older)|SSD= single sided deafness
62341676|NCT04465396|EXPERIMENTAL|Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)|Teduglutide, 3 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B1), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A1). A Washout Period of 7 days was maintained between the Treatment Periods 1 and 2. Participants with \>=40.0 kg to \<=75.0 kg of weight were included in Cohort 1.
62341677|NCT04465396|EXPERIMENTAL|Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)|Teduglutide, 4 mg, SC injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A2), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants \>75.0 kg to \<=120.0 kg of weight were included in Cohort 2.
62341678|NCT04465396|EXPERIMENTAL|Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)|Teduglutide, 4 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B2), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants \>75.0 kg to \<=120.0 kg of weight were included in Cohort 2.
62341679|NCT03252314||Subjects with ruptured aneurysms|
62341680|NCT00923234|EXPERIMENTAL|Azacitidine and Lenalidomide|Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
62341681|NCT00881855|EXPERIMENTAL|1|Cefprozil 500 mg Tablets (Sandoz, GmbH)
62341682|NCT00881855|ACTIVE_COMPARATOR|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
62341683|NCT04754165|EXPERIMENTAL|Immersive Virtual Reality plus the enhanced recovery after surgery protocol|"Patients in the immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones in the post anesthesia care unit (PACU) after surgery. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.~Patients in the VR group will also be treated according to the existing enhanced recovery after surgery protocol."
62341684|NCT04754165|NO_INTERVENTION|Enhanced recovery after surgery protocol|Subjects in the control group will only undergo standard enhanced recovery after surgery care.
62341685|NCT05524740|EXPERIMENTAL|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator)
62341686|NCT04482699|EXPERIMENTAL|Single agent RAPA-501 cells (dose level 1)|Dose level 1 is 40 x 10\^6
62341687|NCT04482699|EXPERIMENTAL|Single agent RAPA-501 cells (dose level 2)|Dose level 2 is 160 x 10\^6
62341688|NCT04482699|ACTIVE_COMPARATOR|RAPA-501 cells|RAPA-501 cells at either dose level 1 or dose level 2 (whichever has been deemed safe during phase 1)
62341689|NCT04482699|PLACEBO_COMPARATOR|Placebo-control Cohort|Placebo
62341690|NCT01414712||prostate cancer patients|
62341691|NCT04543955|EXPERIMENTAL|Arm 1: Low-Dose Telotristat|Participants in this group will receive 750mg Telotristat per day.
62341692|NCT04543955|EXPERIMENTAL|Arm 2: High-Dose Telotristat|Participants in this group will receive 1500mg Telotristat per day.
62341693|NCT05405036||Students|60 second-year students studying at the Department of Physiotherapy and Rehabilitation at University are planned to attend.
62341694|NCT01318772||Fluoroscopy and Angiography Procedure|Patient that have been scheduled for routine diagnostic fluoroscopy and angiography procedures by their physician.
62498981|NCT02937506|EXPERIMENTAL|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
62498982|NCT02937506|EXPERIMENTAL|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
62498983|NCT00681473|EXPERIMENTAL|Proton Radiation Therapy|Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.
62498984|NCT04212819|EXPERIMENTAL|Before erythrocyte suspension (ES) transfusion group|50 (Female/Male: 25/25) patients were included in this study. Total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients after diagnoses of anemia.
62498985|NCT04212819|EXPERIMENTAL|After erythrocyte suspension transfusion group|24 hours after ES transfusion, total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients.
62498986|NCT06512519|EXPERIMENTAL|intervention arm|second haploidentical stem cell transplantation
62498987|NCT04610580|EXPERIMENTAL|Crossover ALXN1840 Sequence 1|Participants will first receive a single dose of ALXN1840 test formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 reference formulation on Day 1 of Period 2.
62498988|NCT04610580|EXPERIMENTAL|Crossover ALXN1840 Sequence 2|Participants will first receive a single dose of ALXN1840 reference formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 test formulation on Day 1 of Period 2.
62498989|NCT04610580|EXPERIMENTAL|Parallel Dose-proportionality Extension: ALXN1840 Dose 1|Participants will receive a single dose of ALXN1840.
62498990|NCT04610580|EXPERIMENTAL|Parallel Dose-proportionality Extension: ALXN1840 Dose 2|Participants will receive a single dose of ALXN1840.
62498991|NCT04610580|EXPERIMENTAL|Parallel Dose-proportionality Extension: ALXN1840 Dose 3|Participants will receive a single dose of ALXN1840.
62699087|NCT03255473|ACTIVE_COMPARATOR|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
62699088|NCT04743011|PLACEBO_COMPARATOR|Placebo|Participants will receive inhalation with 5mL 0.9% saline solution (placebo), 4/4h, during the day period (5 doses).
62699089|NCT04743011|ACTIVE_COMPARATOR|Heparin sodium|Participants will receive inhalation with 5mL 0.9% saline solution + 2,5mg of high molecular weight heparin - enriched heparin, 4/4h, during the day period (5 doses).
62699090|NCT06571890|NO_INTERVENTION|Standard (STD)|Standard anaesthesia with Sevoflurane Inhalation anaesthesia, fentanyl and a laryngeal mask
62699091|NCT06571890|EXPERIMENTAL|Narcotrend (NCT)|Standard anaesthesia with Sevoflurane inhalation anaesthesia, fentanyl and a laryngeal mask. Sevoflurane concentration was titrated via a Narcotrend bispectral anaesthesia monitor.
62699092|NCT06571890|EXPERIMENTAL|Anaesthesia Nociception Index Monitor (ANI)|Standard anaesthesia with Sevoflurane inhalation anaesthesia, fentanyl and a laryngeal mask. Fentanyl dosage titrated with guidance from Mdoloris ANI monitor, a heart rate variability-based nociception monitor. When a threshold value is exceeded, additional fentanyl 1 mcg/kg is given
62699093|NCT01537432|PLACEBO_COMPARATOR|placebo|placebo
61950109|NCT02877134|EXPERIMENTAL|Part II : JNJ-64304500 Low Dose|"JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 low dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
62140776|NCT06696508|ACTIVE_COMPARATOR|the classic approach group|the PUJ was dismembered after proper dissection, the lateral aspect of the ureter was spatulated and the first stich was also placed in the spatulation angle from outside inwards. All these steps were done after the discontinuation of the ureter and the pelvis, losing the benefit of ureteric splinting and orientation
62341695|NCT01804322|ACTIVE_COMPARATOR|Usual care|usual care according to the practice of participating Epilepsy Centers
62341696|NCT01804322|EXPERIMENTAL|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug"
62341697|NCT06460142||PMR/ GCA|Patients diagnosed with GCA and/or PMR will be enrolled in this cohort. They will undergo a series of interventions including immunological profiling (cytokine profiling and immune cell phenotyping using flow cytometry, ELISA, 3'mRNA sequencing, high content analysis via a cell-based ex-vivo assay), and diagnostic imaging (MRI, OCTA including further ophthalmological assessment, vascular and transorbital ultrasound. Samples will be collected from patients at various stages of the disease (t=0, t=6, t=12, t=18 months, during flare-ups). Furthermore, TAB will be stained with a VAP-1 antibody to assess the expression and localization of VAP-1 in the arterial tissue.
62341698|NCT06460142||Control Group|Age- and gender-matched healthy subjects will serve as the control group to provide baseline data for comparative purposes. This group will not receive any treatment related to GCA or PMR but undergoes similar diagnostic procedures for baseline measurements, including imaging and immunological assessments.
62341699|NCT06020339|EXPERIMENTAL|Randomization group|"Pregnant women in the study group will be given a total of 4 modules, 3 modules during pregnancy and 1 module in the postpartum period;~* 1. module 20-28. During pregnancy weeks, trainings are in the form of face-to-face group training,~* 2. module 29-36. During pregnancy weeks, trainings are in the form of face-to-face group training,~* 3. module trainings 37-40. in the form of video-conference (zoom meeting) during pregnancy weeks,~* 4. module will be applied in 1 month postpartum with face-to-face interview technique).~Pregnancy 20-28. Pregnant women between weeks 29-36 should attend the 1st module education. 2nd module training in gestational weeks, 37-40. They will be trained in the 3rd module during the pregnancy weeks.~module training will be individualized during the mother's visit in the 1st month postpartum.~Version B (WDEQ) will be administered after the program is completed, and the Birth-Related Trauma Perception Scale will be administered after birth."
62498992|NCT04610580|EXPERIMENTAL|Parallel Dose-proportionality Extension: ALXN1840 Dose 4|Participants will receive a single dose of ALXN1840.
62699094|NCT01537432|EXPERIMENTAL|secukinumab|secukinumab
62699095|NCT00933478||Patients with Patulous Eustachian Tube Dysfunction|
62699096|NCT01387867|EXPERIMENTAL|Strength training|Strength training three times weekly, i.e.supervised strength training twice weekly and un-supervised strength training once weekly for 4 months.
62699097|NCT01387867|EXPERIMENTAL|Nordic Walking|Nordic walking three times weekly, i.e.Nordic walking twice weekly and un-supervised Nordic walking once weekly for 4 months.
62699098|NCT01387867|ACTIVE_COMPARATOR|Unsupervised home based exercise|The home based unsupervised exercise comprised exercises recommended by the Danish Arthritis Association.
62699099|NCT01929694|ACTIVE_COMPARATOR|Berocca Boost|Guarana and vitamin and mineral complex, one tablet dissolved in 250ml water taken once.
62699100|NCT01929694|PLACEBO_COMPARATOR|Placebo|Matched placebo tablet, one tablet dissolved in 250ml water taken once.
62699101|NCT02644304|ACTIVE_COMPARATOR|Clomiphene citrate plus cabergoline|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus cabergoline 0.25 mg from second day every 3 days (4 doses only)
62699102|NCT02644304|ACTIVE_COMPARATOR|Clomiphene citrate plus placebo|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus placebo tablets from second day every 3 days (4 doses only)
62699103|NCT02171728|EXPERIMENTAL|BIBW 2992|dose escalation
61950110|NCT02877134|EXPERIMENTAL|Part II : Ustekinumab|"Participants will receive tiered doses of Ustekinumab 260 mg (weight \<=55 kg), Ustekinumab 390 mg (weight \>55 kg and \<=85 kg), Ustekinumab 520 mg (weight \>85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive Ustekinumab up to 52 weeks (for a total of up to 72 weeks of Ustekinumab in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving Ustekinumab during the LTE will stop receiving study drug and will have a final safety follow-up visit after the last dose of study drug. However, participants receiving Ustekinumab in countries where Ustekinumab is not commercially available or approved for adult Crohn's disease were continued to receive Ustekinumab in the LTE."
62498993|NCT03546049|ACTIVE_COMPARATOR|US-guided percutaneous biliary drainage|The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
61950111|NCT03226860|EXPERIMENTAL|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
62140777|NCT06427590|EXPERIMENTAL|Part I-SAD in healthy subjects-Cohort 1|SAD cohort 1, dose 1
62140778|NCT06427590|EXPERIMENTAL|Part I-SAD in healthy subjects-Cohort 2|SAD Cohort 2, dose 2
62498994|NCT03546049|EXPERIMENTAL|EUS-guided biliary drainage|The initial transluminal puncture of the bile duct is performed by endoscopic ultrasound guidance (longitudinal echoendoscope) with an 19 G access needle. After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance. Then, a 0.035 inch guide wire is introduced into the bile duct. After dilatation of the transluminal access route with a balloon catheter, a self-expandable metal stent is introduced as an antegrade biliary drainage, a transhepatic biliary drainage or a choledochal biliary drainage. The placement of the metal stent is controlled by fluoroscopic and endoscopic luminal guidance.
62498995|NCT05857917|EXPERIMENTAL|VR group|Participants randomized into this group will be introduced to VR use and watch a VR video that introduces the operating room environment 1 day before surgery and play a soothing video through VR during the surgery.
62498996|NCT05857917|NO_INTERVENTION|Standard care group|The participants randomized to this group will receive the usual standard preoperative and intraoperative management.
62498997|NCT01309854|EXPERIMENTAL|pioglitazone|
62498998|NCT01309854|EXPERIMENTAL|pioglitazone and fostamatinib|
62498999|NCT05063539|EXPERIMENTAL|LY3372689 High Dose|LY3372689 given orally
62140779|NCT06427590|EXPERIMENTAL|Part I-SAD in healthy subjects-Cohort 3|SAD Cohort 3, dose 3
62140780|NCT06427590|EXPERIMENTAL|Part I-SAD in healthy subjects-Cohort 4|SAD Cohort 4, dose 4
62140781|NCT06427590|EXPERIMENTAL|Part I-SAD in healthy subjects-Cohort 5|SAD Cohort 5, doese 5
62140782|NCT06427590|EXPERIMENTAL|Part II-SAD in patients with obesity-Cohort 3A|SAD Cohort 3A, dose 3
62499000|NCT05063539|EXPERIMENTAL|LY3372689 Low Dose|LY3372689 given orally
62499001|NCT05063539|PLACEBO_COMPARATOR|Placebo|Placebo given orally
62499002|NCT05619796|EXPERIMENTAL|group 1: Kedo-S Square rotary files|Primary root canals(n=20) were instrumented using rotary P1 Kedo-S Square files (Reeganz Dental Care Pvt. Ltd. India) at 300 rpm and 2.2N cm torque. The rotary files were used with an Endo-Mate DT endodontic motor (NSK, Tokyo, Japan) and EDTA gel 17% (Meta Biomed Co. Ltd, Chungbuk, Korea) was used before instrumentation.
62499003|NCT05619796|EXPERIMENTAL|group II: Fanta AFTM-Baby rotary system|Primary root canals(n=20) were instrumented using Fanta AFTM-Baby rotary system (Shanghai Fanta Dental Materials, SUNGO Certification Company Limited, London, England) at 350 rpm and 2 N cm torque. Four files were used sequentially in the following order; open file #17/0.08, #20/0.04 yellow, #25/0.04 red and #30/0.04 blue. The rotary files were used with an Endo-Mate DT endodontic motor (NSK, Tokyo, Japan) and EDTA gel 17% (Meta Biomed Co. Ltd, Chungbuk, Korea) was used before instrumentation.
62499004|NCT05619796|ACTIVE_COMPARATOR|group III: manual K-files|Primary root canals(n=20) were instrumented using No.15 till 35 size manual K-files (Mani, Inc, Japan) using the quarter-turn-pull technique.
62499005|NCT04628481|EXPERIMENTAL|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
62499006|NCT04628481|PLACEBO_COMPARATOR|Placebo|matching placebo b.i.d. for 13 cycles of 14 days on/14 days off
62140783|NCT06427590|EXPERIMENTAL|Part II-SAD in patients with obesity-Cohort 4A|SAD Cohort 4A, dose 4
62140784|NCT06427590|EXPERIMENTAL|Part II-SAD in patients with obesity-Cohort 5A|SAD Cohort 5A, dose 5
62140785|NCT06238934|EXPERIMENTAL|Group A|Bone marrow aspirate matrix
62140786|NCT06238934|ACTIVE_COMPARATOR|Group B|Bone marrow aspirate
62140787|NCT06238934|ACTIVE_COMPARATOR|Group C|Hyaluronic acid
62140788|NCT06430021||patient|patients with proven MEN1, symptomatic or not
62140789|NCT03964740|EXPERIMENTAL|Intervention|Mobile App intervention group
62140790|NCT03964740|NO_INTERVENTION|Control Group|No intervention group
62140791|NCT02546531|EXPERIMENTAL|Dose escalation (defactinib, pembrolizumab, gemcitabine)|"* Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~* Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~* Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~* Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
62499007|NCT03038763||Mothers|Black or white mothers who have or have had hepatitis C and were born between 1945-1964. Participants must have at least one child over the age of 18.
62499008|NCT03038763||Adult Children|Adult children of Black or white mothers who have or have had hepatitis C and were born between 1945-1964. From speaking with these mothers, it must be possible that participants were exposed to hepatitis C virus while in the womb.
62499009|NCT04514133|EXPERIMENTAL|Action Civics program|Students in this arm will take part in an Action Civics (AC) program. AC delivers action civics programming to young people from diverse backgrounds nationwide. AC offers a school-based action civics curriculum in which classes collectively choose a local issue, learn strategies and skills for taking civic action, develop an action plan, and take action on their selected local issue. Students, as a class, tackle topics ranging from health-related (e.g., health of school lunches) to safety-related (e.g. lack of crosswalks) to community social issues (e.g., community-police relations).
62499010|NCT04514133|NO_INTERVENTION|No Action Civics program|Students in this arm will receive no intervention.
62499011|NCT00669435|ACTIVE_COMPARATOR|1|Amlodipine and Simvastatin
62699104|NCT05560113|EXPERIMENTAL|cTBS: Inhibitory Transcranial magnetic stimulation (TMS) to sensory Cortex|Participants will undergo a Functional magnetic resonance imaging (fMRI) scan while performing a fear conditioning/extinction task at the Center for Systems Imaging- Emory University Hospital (CSI-EUH) and then either stay at CSI-EUH or relocate to the Neural Plasticity Research Laboratory at Emory Rehabilitation Hospital. Participants will then be randomly assigned to either receive active or sham continuous theta burst stimulation (cTBS) to transiently disrupt neural activity in the targeted sensory cortex region specifically during the sensory memory consolidation window.
62499012|NCT00669435|EXPERIMENTAL|2|Losartan and Simvastatin
62499013|NCT05989945||Hidradenitis suppurativa patients|HS patients will be recruited prospectively from the Outpatient Clinic, Department of Dermato-Allergology, Herlev and Gentofte University Hospital, Denmark and the Outpatient Clinic, Department of Dermato-Allergology, Bispebjerg and Frederiksberg Hospital, Denmark. In order to approximate a random sample as accurate as possible including patients with mild HS, the project group will issue a general invitation to participate in the study through appropriate channels such as the Patientforeningen HS Danmark's newsletter and collaborating private dermatologists.
62499014|NCT05989945||Control group|The control group will consist of a retrospective random sample of around 1.000 patients from the general population examined in the 4th and 5th Copenhagen City Heart Study, 2001-2003 and 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
62499015|NCT06679335|EXPERIMENTAL|Neck Pain Patients|
62499016|NCT06679335|ACTIVE_COMPARATOR|Healty Controls|
62499017|NCT01376037|PLACEBO_COMPARATOR|inactive placebo laser device|The inactive placebo laser device looks identical to the active laser device, but does not emit any therapeutic light output.
62499018|NCT01376037|ACTIVE_COMPARATOR|Erchonia ML Scanner (MLS)|The Erchonia ML Scanner (MLS) is a low level laser light therapy device comprising 4 independent rotating diodes, each emitting 17mW 635nm of red laser light. The diodes are mounted in scanner devices positioned 120 degrees apart from each other, tilted at a 30 degree angle. The Erchonia® MLS is activated for 20 minutes per arm during which time the 4 rotating diodes create a spiraling circle pattern that is totally random and independent from the others. These patterns overlap each other to guarantee total coverage within the target area. The total laser energy the test subject is exposed to per treated arm is approximately 3.94 joules per square centimeter. Six procedures are administered evenly across 2 weeks.
62499019|NCT04286295|EXPERIMENTAL|Cytisine|Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
62699105|NCT05560113|PLACEBO_COMPARATOR|Sham cTBS|Participants will undergo a Functional magnetic resonance imaging (fMRI) scan while performing a fear conditioning/extinction task at CSI-EUH and then either stay at CSI-EUH or relocate to the Neural Plasticity Research Laboratory at Emory Rehabilitation Hospital. Participants will then be randomly assigned to either receive active or sham continuous theta burst stimulation (cTBS) to transiently disrupt neural activity in the targeted sensory cortex region specifically during the sensory memory consolidation window.
62140792|NCT02546531|EXPERIMENTAL|Dose expansion (defactinib, pembrolizumab, gemcitabine)|"* Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~* Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~* Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~* Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
62140793|NCT05657470|EXPERIMENTAL|TNK group|
62699106|NCT06549348|NO_INTERVENTION|Task navigation using fluoroscopy guidance|Standard of care treatment using
62699107|NCT06549348|ACTIVE_COMPARATOR|Task navigation using LumiGuide|Standard of care treatment using LumiGuide fluoroscopy guidance
62699108|NCT03761550||Stage 2|The Process Implementation Stage
62699109|NCT03359161|EXPERIMENTAL|In-Home Subcutaneous Furosemide Treatment ARm|Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.
62140794|NCT05657470|NO_INTERVENTION|control group|
62140795|NCT00900900|EXPERIMENTAL|Dehydroepiandrosterone (DHEA)|
62140796|NCT00900900|EXPERIMENTAL|Pregnenolone|
62140797|NCT00900900|PLACEBO_COMPARATOR|Placebo|
62699110|NCT01266980|EXPERIMENTAL|Severe Renal Imparement|Nine subjects with severe renal impairment (as defined by a Clcr\<30mL/min) will be recruited for this study. they will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
61950112|NCT03226860|ACTIVE_COMPARATOR|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
62699111|NCT01266980|EXPERIMENTAL|Matched healthy volunteers|For each of the 9 renally impaired subjects a healthy control subject (as defined by a Clcr\>80mL/min matched to the severe subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)) will be recuited. They will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
62699112|NCT03255395|EXPERIMENTAL|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
62699113|NCT01001689|EXPERIMENTAL|Nutritional counseling + exercise groups|Women in this arm will receive 2 telephone consultations on nutritional health during pregnancy, be invited to 2 evening meetings with nutritional topics and have access to a password protected internet site with topics related to nutrition and fitness in pregnancy. They will also be enrolled in an exercise group which will meet twice weekly, and be encouraged to exercise on their own 1-2 times each week.
62140798|NCT01310166|EXPERIMENTAL|Fingolimod|
62699114|NCT01001689|NO_INTERVENTION|control|Women in this arm of the study will receive routine pregnancy care.
62699115|NCT06140225|EXPERIMENTAL|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow the participant to plan his/her sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
62699116|NCT06140225|EXPERIMENTAL|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
62699117|NCT06140225|EXPERIMENTAL|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle
62699118|NCT06140225|EXPERIMENTAL|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
62699119|NCT06140225|EXPERIMENTAL|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
62699120|NCT06140225|EXPERIMENTAL|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
62699121|NCT06140225|EXPERIMENTAL|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
62699122|NCT06140225|NO_INTERVENTION|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
62699123|NCT00804232|EXPERIMENTAL|1|effects on child health of family-based home care compared to traditional hospital-based care,
62699124|NCT00804232|EXPERIMENTAL|2|effects on child health of family-based psychological treatment compared to traditional hospital-based treatment
62699125|NCT03256487|EXPERIMENTAL|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
62699126|NCT03256487|ACTIVE_COMPARATOR|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
62699127|NCT03308279||Asinthomatic|The only group evaluated
61950113|NCT05136352|ACTIVE_COMPARATOR|adductor canal block|loco-regional analgesia with adductor canal block (ACB) method (for anterior cruciate ligament reconstruction )
61950114|NCT05136352|EXPERIMENTAL|iPACK block|loco-regional analgesia with iPACK block (infiltration between the popliteal artery and the capsule of the posterior knee) ((for anterior cruciate ligament reconstruction )
61950115|NCT05257655|OTHER|Intervention|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius;
62140799|NCT05055063|EXPERIMENTAL|Belantamab mafodotin|belantamab mafodotin by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
62140800|NCT04346914|EXPERIMENTAL|Combined treatment group|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w
62699128|NCT05665283|ACTIVE_COMPARATOR|Reference Standard Group|"In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product.~In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes."
61950116|NCT06042504||Married students with no children|Submit Survey
61950117|NCT06042504||Married students with children|Submit Survey
61950118|NCT06042504||Unmarried Students with children|Submit Survey
61950119|NCT06042504||Familial caregiver|Submit Survey
61950120|NCT06042504||Unmarried without kids|Submit Survey
62140801|NCT02958696|ACTIVE_COMPARATOR|HTL0018318 low dose|low dose aqueous solution and/or equivalent low dose capsule
62140802|NCT02958696|ACTIVE_COMPARATOR|HTL0018318 mid dose|mid dose aqueous solution and/or equivalent mid dose capsule
62140803|NCT02958696|ACTIVE_COMPARATOR|HTL0018318 high dose|high dose aqueous solution and/or equivalent high dose capsule(s)
62699129|NCT05665283|ACTIVE_COMPARATOR|Test Standard Group|"In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product.~In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes."
62699130|NCT01436227|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 4 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may continue pazopanib hydrochloride in the absence of disease progression.
62699131|NCT02264366|EXPERIMENTAL|At Risk Group: ACCELERATION program|"This At Risk Group will include ;People at risk of cancer referred from UHN partners and community practices. Also included in this group are; First Nations population of BC, Asians and South Asian populations from Greater Vancouver and the working population of the City of Richmond employees. At the Montreal site users of the YMCA with risk factors for, or family history of, cancer and other chronic diseases will be targeted. And finally, in Nova Scotia the At Risk Group will be identified as being at risk of cancer and other chronic diseases referred from community practices and from the workplace population of the Capital District Health Authority (CDHA).~Intervention: Motivational Communication for Health Behavior management"
61950121|NCT04969874|OTHER|remote follow-up|patients with chronic disorders on sequelae of anti-cancer treatments after an intensive rehabilitation stay will undergo 5 months of remote follow-up with speech therapists including questionnaires and interview
61950122|NCT03719586|EXPERIMENTAL|A|Remdesivir plus optimized Standard of Care (oSOC)
61950123|NCT03719586|EXPERIMENTAL|B|MAb114 plus optimized Standard of Care (oSOC)
61950124|NCT03719586|EXPERIMENTAL|C|REGN-EB3 plus optimized Standard of Care (oSOC)
61950125|NCT03719586|EXPERIMENTAL|Control|Zmapp plus optimized Standard of Care (oSOC)
61950126|NCT05942560|EXPERIMENTAL|Cognitive behavioural therapy-based(CBT-based) intervention group|A specifically designed CBT-based intervention consisting of 8 weekly sessions will be conducted in a group format.
61950127|NCT05942560|ACTIVE_COMPARATOR|Control group|Participants will receive eight health education sessions simultaneously with the CBT-based intervention group.
61950128|NCT03095885|OTHER|Test Meal|controlled oxalate-rich test meal
61950129|NCT03966144|EXPERIMENTAL|RoboHear Device|Subjects will wear the Robo-Hear device and receive haptic stimuli. They will be tested on their ability to interpret these haptic sensations as sounds and words.
61950130|NCT00428792|EXPERIMENTAL|Very light breakfast (VLB) then standard breakfast (SB)|Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
61950131|NCT00428792|EXPERIMENTAL|Standard breakfast (SB) then very light breakfast (VLB)|Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
61950132|NCT05962437|EXPERIMENTAL|STANZA-Spain|Digital Acceptance and Commitment Terapy (ACT). It consists of 41 structured ACT lessons, incorporating mindfulness practices and daily activities to facilitate behavior change and promote gradual pacing of daily activities and exercise. The core content was designed to be completed within 8 weeks, with a 4-week maintenance period thereafter to strengthen skills.
61950133|NCT05962437|ACTIVE_COMPARATOR|FibroST-Spain|A digital active control intervention is implemented to control for study engagement, expectations, and healthcare provider interaction biases. Components of this active comparator include daily symptom and function tracking (Daily Symptom Tracker), symptom and function monitoring, and access to health education articles about fibromyalgia.
61950134|NCT05962437|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and rheumatologists through regular consultations. Clinicians prescribe medications and provide some counselling.
61950135|NCT05944289|EXPERIMENTAL|ACT|ACT Intervention Group
61950136|NCT05944289|OTHER|Support|Control Group - Caregiver support group
61950137|NCT03748784|EXPERIMENTAL|Dose 1|6E11 vg of ADVM-022
61950138|NCT03748784|EXPERIMENTAL|Dose 2|2E11 vg of ADVM-022
61950139|NCT05612711|EXPERIMENTAL|Dronabinol First|Participants will take Dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week. They will then undergo a 3-week washout period, followed by placebo capsules twice daily for 8 weeks.
62140804|NCT02867956|EXPERIMENTAL|Apatinib + Etoposide|"Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles."
62699132|NCT02264366|EXPERIMENTAL|Friends & Family -ACCELERATION Program|This group includes family and friends of cancer survivors and family and friends of cardiac \& COPD rehab patients. The intervention includes Motivational Communication for Health Behavior management
62699133|NCT03532347|EXPERIMENTAL|EUS tissue sampling|"Device: EUS-FNA needle (Beacon) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail~Device:EUS-FNB needle (Beacon Sharkcore) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail"
62140805|NCT05964907|OTHER|VL+UVA1|Participants will be treated with VL + UVA1 light source
61950140|NCT05612711|EXPERIMENTAL|Placebo First|Participants will take matching placebo capsules twice daily for 8 weeks, followed by a three week washout period. They will then begin taking dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week.
61950141|NCT02680717|ACTIVE_COMPARATOR|Treatment 1|Calcipotriene 0.005% ointment
61950142|NCT02680717|ACTIVE_COMPARATOR|Treatment 2|Clobetasol 0.05% ointment
61950143|NCT02680717|ACTIVE_COMPARATOR|Treatment 3|Tacrolimus 0.1% ointment
62499020|NCT04286295|ACTIVE_COMPARATOR|NRT+|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.
62499021|NCT01385423|EXPERIMENTAL|IL-15 Patients with AML|Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)
62699134|NCT03702309||LIBERATE|Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
62499022|NCT01026857|EXPERIMENTAL|PLC Colon release tablet 1 g|40 patients each arm
62499023|NCT01026857|EXPERIMENTAL|PLC colon release tablet 2 g|40 patients each arm
62499024|NCT01026857|PLACEBO_COMPARATOR|Placebo PLC colon release tablet 2 g|40 patients each arm
62699135|NCT00044174||Depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as exhibiting depressive symptoms
62341700|NCT06020339|NO_INTERVENTION|Control group|"Pregnant women who will be included in the control group will receive routine midwifery care. In the postpartum period (WDEQ), version B and the Birth Trauma Perception Scale will be used.~The pregnant women will inform the researcher by telephone after the birth (within the first 24 hours) and the mother will be visited by the researcher within the first month after the birth, and the trauma perceptions of the mothers will be evaluated with the Birth Trauma Perception Scale."
62699136|NCT00044174||Non-depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as not exhibiting depressive symptoms
62699137|NCT02735460|EXPERIMENTAL|Treatment arm|In this arm the Andago V2.0 is used.
62699138|NCT02798887|EXPERIMENTAL|Ridge preservation membrane|Positive control Patients will receive ridge preservation intrasocket allograft and overlay xenograft resorbable with membrane
62699139|NCT02798887|EXPERIMENTAL|Ridge preservation no membrane|test patients will receive ridge preservation intrasocket allograft and overlay xenograft with no membrane
62699140|NCT03129906|ACTIVE_COMPARATOR|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
62341701|NCT05887947|EXPERIMENTAL|1 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"1, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62341702|NCT05887947|EXPERIMENTAL|2 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"2, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62699141|NCT03129906|PLACEBO_COMPARATOR|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
62341703|NCT05887947|EXPERIMENTAL|3 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"3, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62499025|NCT04740424|EXPERIMENTAL|FS222 Q4W|The initial cohorts will enroll sequentially as single participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design. Additional participants will be recruited into the PK/PD expansion cohorts at dose levels deemed safe during dose escalation. Once a tolerated dose has been established participants will be recruited into tumour-specific expansion cohorts.
62499026|NCT02079233|EXPERIMENTAL|CLP 15 g QD|Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime
62499027|NCT02079233|EXPERIMENTAL|CLP 7.5 g BID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner
62499028|NCT02079233|EXPERIMENTAL|CLP 5 g TID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner
62699142|NCT04451798|EXPERIMENTAL|Intervention|Impella implantation and hemodynamic measurement
62699143|NCT03434730|EXPERIMENTAL|Adult Participants With High Risk Hematologic Malignancies|
62699144|NCT03961672|EXPERIMENTAL|Treatment (duvelisib)|"INDUCTION: Patients receive duvelisib PO BID on days 1-28. Cycles repeat every 28 days for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive duvelisib PO BID on days 1-2, 8-9, 15-16, and 22-23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62699145|NCT05212207||PBH|
62699146|NCT05812690||Children with molar incisor hypomineralisation|Children referred to the host centres with a clear diagnosis of MIH, as given by a specialist paediatric dentist
62699147|NCT05812690||Children without molar incisor hypomineralisation|Children referred to the host centres with no evidence of MIH
62499029|NCT02079233|EXPERIMENTAL|CLP 3.75 g QID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime
62499030|NCT06109805||Gastric cancer group|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
62499031|NCT06109805||Non-gastric cancer group|Patients diagnosed with benign gastric diseases or healthy controls
62499032|NCT03147833|EXPERIMENTAL|Sport beverages Protein|Intervention group ingesting PROTEIN
62499033|NCT03147833|ACTIVE_COMPARATOR|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
62699148|NCT02784587|EXPERIMENTAL|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
62341704|NCT05887947|EXPERIMENTAL|4 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"4, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62699149|NCT05196620||EAUS|Patients with EAUS pre and postpartum
62699150|NCT00770679|EXPERIMENTAL|High-Dose Statin|80 mg atorvastatin daily for 3 weeks
62341705|NCT05887947|EXPERIMENTAL|5 African American 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"5, African American, baseline smoking at enrollment is 11-30 cigarettes per day~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62341706|NCT05887947|EXPERIMENTAL|6 African American 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"6, African American, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62341707|NCT05887947|EXPERIMENTAL|7 African American 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"7, African American, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62499034|NCT06458751|OTHER|30 healthy subjects with no history of neuromuscular disease|30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination
62499035|NCT03433703|EXPERIMENTAL|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.
62499036|NCT03231345|EXPERIMENTAL|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
62499037|NCT04070079|OTHER|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Dosed orally, once daily with or without food.
62499038|NCT03845491||SR Classic|SR (Trevo®\]) + BGC (FlowGate2\] or Merci)
62499039|NCT03845491||SR Combination|"SR (Trevo) + Asp Cath (AXS Catalyst DAC, Vecta) ± Pump~+ LS (AXS Infinity LS, AXS Infinity LS Plus)~or~SR (Trevo) + Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2 or Merci)"
62499040|NCT03845491||Direct Aspiration|"Asp Cath (AXS Catalyst DAC, Vecta) ± Pump + LS (AXS Infinity LS, AXS Infinity LS Plus)~or~Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2, Merci)"
62499041|NCT03275857|OTHER|Cisplatin|
62499042|NCT00597428|PLACEBO_COMPARATOR|Placebo|0 mcg capsules twice daily (BID)
62499043|NCT00597428|EXPERIMENTAL|Lubiprostone|24 mcg capsules twice daily (BID)
62499044|NCT03312894|EXPERIMENTAL|Cohort 1 (Ketamine Responders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
62499045|NCT03312894|PLACEBO_COMPARATOR|Cohort 1 (Ketamine Responders): Placebo|TAK-653 placebo-matching tablets, orally, once daily up to Day 56
62699151|NCT03423979|EXPERIMENTAL|Optilume™ BPH Prostatic DCB Dilation Catheter|Optilume™ BPH Prostatic DCB treatment procedure
62699152|NCT05059275|EXPERIMENTAL|Modified operation group|Undergo the modified ostium obstruction surgery due to symptomatic TCs.
62699153|NCT02921867|EXPERIMENTAL|Intervention group|Simulation-based training in nine modules with optional training times and ending with an obligatory certification test before traditional training is started. Traditional training time unaltered: six weeks.
62699154|NCT02921867|NO_INTERVENTION|Traditional training|Six weeks focused stay at an ultrasound ward with day to day one-on-one supervision (current practise)
62699155|NCT00839501|EXPERIMENTAL|1|Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.
62699156|NCT03942744|NO_INTERVENTION|high-flux hemodialysis|high-flux hemodialysis cut-off membrane above 50
62499046|NCT03312894|EXPERIMENTAL|Cohort 2 (Ketamine Nonresponders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
62499047|NCT03312894|PLACEBO_COMPARATOR|Cohort 2 (Ketamine Nonresponders): Placebo|TAK-653 Placebo-matching tablets, orally, once daily up to Day 56
62699157|NCT03942744|ACTIVE_COMPARATOR|on-line hemodiafiltration|postdilutional on-line hemodiafiltration with a convective transport above 21 liters
62699158|NCT03027596|EXPERIMENTAL|Remote ischemic conditioning|Four cycles of 5 min occlusion and reperfusion in an extremity using a tourniquet.
62341708|NCT05887947|EXPERIMENTAL|8 African America 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"8, African American, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62699159|NCT03027596|NO_INTERVENTION|Control group|no intervention
62341709|NCT05887947|EXPERIMENTAL|9 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"9, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62341710|NCT05887947|EXPERIMENTAL|10 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"10, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62499048|NCT00587249|EXPERIMENTAL|3|50 mcg of ICC-1132 with alhydrogel adjuvant.
62499049|NCT00587249|EXPERIMENTAL|2|20 mcg of ICC-1132 with alhydrogel adjuvant.
62499050|NCT00587249|EXPERIMENTAL|1|10 mcg of ICC-1132 with alhydrogel adjuvant.
62499051|NCT01386034|EXPERIMENTAL|Citrulline/Placebo|
62499052|NCT01386034|EXPERIMENTAL|Placebo/Citrulline|
62499053|NCT04850287|PLACEBO_COMPARATOR|Control|
62499054|NCT04850287|EXPERIMENTAL|Intervention|
62499055|NCT04850287|EXPERIMENTAL|Optimal|
62499056|NCT02413424|EXPERIMENTAL|Drink Sucralose|Subjects will drink sucralose 10 min before drinking a glucose load
62499057|NCT02413424|PLACEBO_COMPARATOR|Drink Water|Subjects will drink water 10 min before drinking a glucose load
62499058|NCT02413424|EXPERIMENTAL|Taste and spit Sucralose|Subjects will taste and spit up sucralose 10 min before drinking a glucose load
62499059|NCT06677710|EXPERIMENTAL|Part 1 (dose escalation): IDP-023 in combination with IL-2 and ocrelizumab|MS patients treated with multiple doses of IDP-023 in combination with IL-2 and ocrelizumab
62499060|NCT06677710|EXPERIMENTAL|Part 2 (dose expansion): IDP-023 in combination with IL-2 and ocrelizumab|MS patients treated with the recommended dose of IDP-023 in combination with IL-2 and ocrelizumab
62499061|NCT01132417||Multidrug resistant (MDR)bacterial strains|
62499062|NCT00693589|ACTIVE_COMPARATOR|R|Rosuvastatin treatment for 6 weeks and after that combined treatment with rosuvastatin and vitamin supplementation for additional 6 weeks
62499063|NCT00693589|ACTIVE_COMPARATOR|V|Vitamin supplementation with folic acid, vitamin B12 and B6 for 6 weeks and after that combined treatment with vitamin supplementation and rosuvastatin
62499064|NCT04646694|EXPERIMENTAL|Study Group 1|Patient will receive Ketamine at a dose of 30 mg every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Ketamine for three days or nine doses total.
62699160|NCT04481841|EXPERIMENTAL|experimental group|"On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
62699161|NCT04481841|ACTIVE_COMPARATOR|control group|oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
62699162|NCT00057148|OTHER|Arm 1|
62499065|NCT04646694|PLACEBO_COMPARATOR|Study group 2|Patient will receive Placebo at a matching dose every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Placebo for three days or nine doses total.
62499066|NCT05124496||Comparison to Rt-PCR|
62499067|NCT03311945|EXPERIMENTAL|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
62499068|NCT02292550|EXPERIMENTAL|Ribociclib 100 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
62499069|NCT02292550|EXPERIMENTAL|Ribociclib 100 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
62499070|NCT02292550|EXPERIMENTAL|Ribociclib 200 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
62499071|NCT02292550|EXPERIMENTAL|Ribociclib 200 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
62499072|NCT02292550|EXPERIMENTAL|Ribociclib 300 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
62499073|NCT06614491||Ileostomy|Subjects with ileostomy
62499074|NCT06614491||Colostomy|Subjects with colostomy
62699163|NCT04110132|ACTIVE_COMPARATOR|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Patient will have hemorrhoidectomy."
62699164|NCT04110132|PLACEBO_COMPARATOR|Ganglion impar block with Saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Patient will have hemorrhoidectomy.
62699165|NCT02997202|EXPERIMENTAL|Gilteritinib|Participants received gilteritinib 120 milligrams (mg) (three tablets of 40 mg) orally, once daily (QD) for up to 2 years or until a protocol-defined discontinuation criterion was met.
62699166|NCT02997202|PLACEBO_COMPARATOR|Placebo|Participants received gilteritinib matching placebo orally, QD for up to 2 years or until a protocol-defined discontinuation criterion was met.
62699167|NCT04863404|EXPERIMENTAL|Bone-anchored maxillary protraction group|Face mask with hybrid-hyrax
62699168|NCT04863404|EXPERIMENTAL|Tooth-borne maxillary protraction group|Face mask with conventional bonded RME
61950144|NCT04497935||1LPEG|Patients receiving 1LPEG who had a colonoscopy in the morning were advised to follow a day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, they prepared the Dose 1 sachet in 500 mL of water and consumed it over a period of 30 minutes, followed by 500 mL of clear liquids. The second dose was then taken at 11:00 pm by mixing the two Dose 2 sachets in a single glass of 500 mL of water and consuming them over 30 minutes, followed by 500 mL of clear liquids. If the colonoscopy was scheduled for the afternoon, the same dosing instructions were given, but the first dose was taken at 7:00 am on the day of the procedure, and the second dose began at 10:00 am.
62341711|NCT05887947|EXPERIMENTAL|11 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"11, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
61950145|NCT04497935||2LPEG|Patients receiving 2LPEG who had a colonoscopy in the morning were asked to follow a similar day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, the first 1L dose was consumed over a 1-hour period, followed by the second dose at 11:00 pm. For 2LPEG patients with procedures in the afternoon, they took Dose 1 at 7:00 am and Dose 2 at 10:00 am. Any patient receiving 2LPEG was also told to consume 1L of clear liquids during the preparation procedure.
61950146|NCT02824575|EXPERIMENTAL|Arm A1-2: Paclitaxel plus Rebastinib.|"* Arm A1 (Dose Escalation Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~* Arm A2 (Expansion Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
62341712|NCT05887947|EXPERIMENTAL|12 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"12, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62341713|NCT05887947|EXPERIMENTAL|13 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"13, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62499075|NCT06614491||Urostomy|Subjects with urostomy
62499076|NCT02255487|EXPERIMENTAL|IrriSept System|IrriSept device used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen
62499077|NCT02255487|ACTIVE_COMPARATOR|Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
62499078|NCT00655317|ACTIVE_COMPARATOR|1|Treatment Acupuncture Group (Therapeutic Acupuncture Treatment): treatment with actual acupuncture needles
62699169|NCT04863404|NO_INTERVENTION|Control group|Control group consisting of 14 non-treated Class III malocclusion subjects
62699170|NCT06434493|EXPERIMENTAL|Proton Beam Therapy|All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy), and alongside concurrent oral capecitabine 625mg/m2 twice daily on radiation days.
62699171|NCT03741673|EXPERIMENTAL|Group I (pre-operative SRS)|Patients undergo SRS within 30 days of randomization followed by surgery within 30 days. Patients may undergo additional SRS if disease returns after treatment.
62699172|NCT03741673|ACTIVE_COMPARATOR|Group II (post-operative SRS)|Patients undergo surgery within 30 days of randomization followed by standard of care SRS within 30 days. Patients may undergo additional SRS if disease returns after treatment.
62699173|NCT01362179||unstimulated BM donors|Observational (non-interventional) study.
62699174|NCT01362179||filgrastim-mobilized PBSC donors|Observational (non-interventional) study.
62499079|NCT00655317|SHAM_COMPARATOR|2|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
62699175|NCT03797937|EXPERIMENTAL|Multiple sclerosis (MS) patients|Patients will undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
62699176|NCT03797937|NO_INTERVENTION|Healthy controls|Healthy controls will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
62699177|NCT03797937|NO_INTERVENTION|Multiple sclerosis (MS) patients undergoing a relapse|Multiple sclerosis (MS) patients undergoing a relapse will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
62699178|NCT03797937|NO_INTERVENTION|Multiple sclerosis (MS) patients from multiplex MS families|Multiple sclerosis (MS) patients from multiplex MS families will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
62699179|NCT01464606|EXPERIMENTAL|Type I PPB therapy|PPB Type I therapy: All patients will be treated with surgery. Chemotherapy after surgery is per the treating physician(s) discretion. If chemotherapy is used the Registry will suggest that it be combination chemotherapy with Vincristine, Dactinomycin, Cyclophosphamide (VAC).
62699180|NCT01464606|EXPERIMENTAL|Types II and III PPB therapy|"Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin (IVADo). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery."
62699181|NCT06482983|ACTIVE_COMPARATOR|ventilation mode during surgery|Volume control mode (VC) n: 40
62699182|NCT06482983|ACTIVE_COMPARATOR|Pressure-controlled volume guaranteed mode (PC-VG) ventilation|Pressure-controlled volume guaranteed mode (PC-VG) n:40
62699183|NCT06482983|ACTIVE_COMPARATOR|Pressure control mode (PC) ventilation|Pressure control mode (PC) n:40
62699184|NCT06570850|ACTIVE_COMPARATOR|Colistin group|Participants receive intravenous colistin (colistinmethate soidum) 5 mg/kg/day (dosage will be adjusted according to creatinine clearance) and colistin nebulization at 80 mg every 8 hours in case of pneumonia.
62699185|NCT06570850|ACTIVE_COMPARATOR|Colistin plus fosfomycin group|Participants receive intravenous colistin (colistinmethate soidum) (dosage regimen same as colistin group plus intravenous fosfomycin (dosage will be adjusted according to creatinine clearance and MIC).
62699186|NCT06042816|EXPERIMENTAL|Free-opioid anesthesia|49 patients were injected bolus doses of lidocaine 1 mg/kg and ketamine 0.5 mg/kg before induction. Then intravenous propofol 1% 2-2.5 mg/kg, rocuronium 0.6 mg/kg were utilized for induction. For anesthesia maintenance, patients received intraoperative multimodal analgesia, in which an epidural bolus of 3 - 5 ml of levobupivacaine 0.1% was followed by a continuous infusion of 3 - 5 ml/h epidurally; in addition, intravenous infusion of lidocaine 1 mg/kg/hour and ketamine 0.25 mg/kg/h were maintained until the end of surgery. Patients were given a bolus of 3-5 ml levobupivacaine 0.1% epidurally and ketamine 0.25 mg/kg intravenously if SPI \> 50, 40 \< SE \< 60, TOF = 0 and hemodynamics was stable. Postoperative pain management was implemented with patient-controlled epidural levobupivacaine 0.1% for 72 hours, and pain rescue with fentanyl 0.5 μg/kg.
62699187|NCT06042816|ACTIVE_COMPARATOR|Opioid anesthesia|49 patients received a bolus dose of fentanyl 2 µg/kg before induction of anesthesia. For anesthesia maintenance, in group OA, a bolus dose of fentanyl 3 µg/kg was given 5 minutes before skin incision, and then a continuous infusion of fentanyl 2 µg/kg/h was maintained for intraoperative pain management; fentanyl 0.5 μg/kg was bolused when SPI (Surgical Pleth Index) \> 50, 40 \< State Entropy (SE) \< 60, Train of four (TOF) = 0 and the patient was hemodynamically stable. Propofol and fentanyl were discontinued at the start of skin closure. Postoperative pain management was implemented with patient-controlled epidural levobupivacaine 0.1% for 72 hours, and pain rescue with fentanyl 0.5 μg/kg.
62699188|NCT00448513|EXPERIMENTAL|catechin|catechin capsule group
62699189|NCT01085214|EXPERIMENTAL|AZD6244 (Selumetinib) Treatment|Participants receive AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62699190|NCT03524066|EXPERIMENTAL|Inhaled + Bronchoscopy|One-time Inhalation of Salbutamol 200 µg, Salmeterol 50µg and Fluticasone 500µg. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and bronchoalveolar lavage (BAL) samples will be taken from each site.
62341714|NCT05887947|EXPERIMENTAL|14 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"14, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62341715|NCT05887947|EXPERIMENTAL|15 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"15, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62341716|NCT05887947|EXPERIMENTAL|16 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"16, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
62699191|NCT03524066|EXPERIMENTAL|Systemic + Bronchoscopy|One-time Salbutamol (8 mg) and Propranolol (40mg) administered orally. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples will be taken from each site.
62699192|NCT06456164|NO_INTERVENTION|Usual Care|Participants will receive mifepristone 200 mg by mouth 24 hours prior to induction of labor. Labor will be induced with use of vaginal misoprostol according to regimens endorsed by the American College of Obstetricians and Gynecologists and the Society of Family Planning.
62341717|NCT06290271||Passive Group|The cerebral blood flow pattern normalizes after the recanalization of the occluded artery
62341718|NCT06290271||Active Group|The overall major cerebral blood flow increases after the recanalization of the occluded artery
62341719|NCT05360420|EXPERIMENTAL|Immediate CEUS group|CEUS (SonoVue) was performed immediately after routine US screening of suspicious lesions. The lesions were classified according to CEUS examination by the diagnosing physician, including consideration of HCC, suspected HCC, and benign lesions. Further hepatobiliary-specific MRI (Modis/Primexian) was performed for lesions considered HCC or suspicious for HCC, and benign lesions were followed up. The diagnostic findings of hepatobiliary-specific MRI were classified by the diagnosing physician and included consideration of HCC, suspected HCC, and benign lesions. For hepatobiliary-specific MRI lesions considered HCC or suspicious for HCC, pathological examination was performed, and benign lesions were followed up.
62499080|NCT03545399|EXPERIMENTAL|Ulva Lactuca|The subject is given a capsule containing a concentrated fraction of freeze-dried and crushed hydrosoluble extract of seaweeds. The dose tested of extract of seaweeds is of 6.45mg per kg weight. The daily dose is 3 capsules per day for subjects weighing between 50 and 70kg, 4 capsules per day for subjects weighing between 70 and 90kg and 5 capsules per day for subjects weighing between 90 and 110kg. The duration of the treatment is 12 weeks.
62341720|NCT05360420|NO_INTERVENTION|Current clinical procedure group|After the suspicious lesions were screened by routine US, CECT, CEMRI and hepatobiliary-specific MRI (the first enhanced imaging examination) were independently selected by clinicians. According to the first examination results of the contrast-enhanced image, the diagnosis was classified by the diagnosing physician, including considering HCC, suspicious HCC, and benign lesions. Another contrast-enhanced imaging examination (CECT or CEMRI or hepatobiliary-specific MRI or CEUS) was performed again for lesions considered or suspected of HCC (second contrast-enhanced imaging study), and negative lesions were followed up. According to the examination results of the second enhanced imaging, the classification includes considering HCC, suspicious HCC, and benign. Pathological examination was performed for lesions considered HCC or suspicious for HCC on the second enhanced image, and benign lesions were followed up.
62341721|NCT03367065|EXPERIMENTAL|Dynamic contrast enhanced computerised tomography|
62699193|NCT06456164|EXPERIMENTAL|Usual care with mechanical dilation|"Participants will receive mifepristone 200 mg by mouth 24 hours prior to induction of labor. Participants will have their labor induced concomitantly with misoprostol (according to the regimen described in the Usual Care arm) and placement of the Cook Cervical Ripening Balloon."
62699194|NCT00789711||A|
62699195|NCT00789711||B|
62341722|NCT01566643|EXPERIMENTAL|Hybrid-10|RA3-RACM7: rabeprazole + amoxicillin x 3 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days.
62341723|NCT01566643|EXPERIMENTAL|Hybrid-12|RA5-RACM7: rabeprazole + amoxicillin x 5 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
62341724|NCT01566643|EXPERIMENTAL|Hybrid-14|RA7-RACM7: rabeprazole + amoxicillin x 7 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
62341725|NCT04311177|EXPERIMENTAL|Losartan|Participants in this arm will receive the study drug, Losartan.
62341726|NCT04311177|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo treatment.
62499081|NCT03545399|PLACEBO_COMPARATOR|Placebo|The subject is given a capsule looking alike that of the active product but containing no extract of seaweeds.The duration of the treatment is 12 weeks.
62499082|NCT04707846|EXPERIMENTAL|Bright Light Therapy|Individuals will receive bright blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Bright blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total). Bright blue light treatment has been previously identified as an efficacious treatment for fatigue. It has also been shown in a number of studies that the blue wavelength of light is a key component to the shift of fatigue measures in patient reported outcomes.
62499083|NCT04707846|ACTIVE_COMPARATOR|Dim Light Therapy|Individuals will receive dim blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Dim blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total).
62499084|NCT04707846|NO_INTERVENTION|Usual Care|During usual care periods, participants will be instructed to abstain from use of AYO light therapy devices, and instructed to treat their fatigue as they normally would. Usual care will be presented in 2 periods each 2 weeks in length (4 weeks total).
62499085|NCT05187325||myofascial trigger point and disc displacement with reduction|the participants have myofascial trigger points in master muscle and also temporomandibular joint disc displacement with reduction.
62499086|NCT05187325||disc displacement with reduction|the participants have only temporomandibular joint disc displacement with reduction.
62699196|NCT04683653|EXPERIMENTAL|Hypofractionated Radiation Treatment (Dose-Finding Arm)|All study participants in this arm will receive hypofractionated whole pelvic radiation treatment for a shortened time period of 3-5 weeks. The goal of this arm is to establish a safe and tolerable dose of shortened (hypofractionated) pelvic radiation treatment for study participants. Once a safe and tolerable dose is established for this shortened form of radiation treatment, participants who meet criteria for the second phase of this study will participate in an expansion cohort that will explore the efficacy (how effective shortened/hypofractionated radiation treatment is for treating endometrial cancer).
62499087|NCT05294367|EXPERIMENTAL|Cycle 1|Participants consume magnesium rich foods PO daily for 28 days.
62699197|NCT04683653|EXPERIMENTAL|Expansion Cohort (Efficacy Arm)|"Participants in this arm will test how effective hypofractionated/shortened whole radiation treatment is (efficacy) at the dose established in the first phase of this study by following up with their doctors to report their current health status and symptoms during clinical visits. Participants will return for routine clinical follow-up approximately 1 month following radiation, then at 3 months following radiation, then every 3 months for the next 2 years following treatment."
62699198|NCT00200239|EXPERIMENTAL|1|Behavioral: eating breakfast from portioned and unportioned foods
62699199|NCT00200239|EXPERIMENTAL|2|Behavioral: eating breakfast with portioned and unportioned foods
62699200|NCT06129955|EXPERIMENTAL|Pucotenlimab combined with Lenvatinib as neoadjuvant therapy|Pucotenlimab combined with Lenvatinib as neoadjuvant therapy
62699201|NCT06535373|EXPERIMENTAL|Blood flow restriction with low-weight resistance training (LWRT) group|a blood flow restriction with low-weight resistance training (LWRT) group
62699202|NCT06535373|NO_INTERVENTION|No Blood flow restriction group which just does LWRT|a non blood flow restriction group which just does low-weight resistance training
62699203|NCT05114174|NO_INTERVENTION|Usual care group|Pregnant women enrolled in the prenatal control program who receive routine medical care.
62699204|NCT05114174|EXPERIMENTAL|mami-educ group|Pregnant women enrolled in the prenatal care program who receive routine medical care and nutritional messages mom-educ.
62699205|NCT06268106|NO_INTERVENTION|Standard procedure informative|Patients in this group undergo procedure with standard explanation of the procedure itself, so they do not receive and visualize graphic novel.
62699206|NCT06268106|EXPERIMENTAL|Graphic novel visualization|Patients in this group do receive and visualize graphic novel in addition to standard explanation of the procedure.
62699207|NCT04527432|OTHER|All participants|Survey at 6 and 12 months time with optional antibody tests
62699208|NCT04853121|ACTIVE_COMPARATOR|tapered implant|
62699209|NCT04853121|PLACEBO_COMPARATOR|straight implant|
62699210|NCT03847584||Adults-low socioeconomic status|Survey completed by adults with low socioeconomic status
62699211|NCT03847584||Adults-middle/high socioeconomic status|Survey completed by adults with middle/high socioeconomic status
62699212|NCT02263547|OTHER|teriflunomide elimination with colestipol|
62699213|NCT06269315|EXPERIMENTAL|Exposure arm|Prepared test products, such as household cleaner, hand disinfectant, their ingredients, and control on patch testing tapes will be posted on the selected areas of forearm skin.
62699214|NCT06350110|EXPERIMENTAL|Experimental: Treatment (CD19/BCMA-CAR T cells, chemotherapy)|"Treatment (CD19/BCMA-CAR T cells, chemotherapy)~Patients will be administered fludarabine phosphate intravenously (IV) over a 30-minute period on days -4 to -2. Additionally, cyclophosphamide will be administered intravenously (IV) over 60 minutes on day -2. Subsequently, patients will receive CD19/BCMA-CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0. Patients who exhibit positive responses to the initial dose of CD19/BCMA-CAR T cells, do not experience unacceptable side effects, and have a sufficient quantity of cells available may be eligible to receive 2 or 3 additional doses of CD19/BCMA-CAR T cells."
62699215|NCT06642415|ACTIVE_COMPARATOR|Loupes group|Surgery performed under loupes
62699216|NCT06642415|EXPERIMENTAL|Microscope group|Surgery performed under microscope
62699217|NCT03412955|EXPERIMENTAL|Eribulin|Patients enrolled into the study will receive Eribulin 1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle till disease progression or non-tolerable toxicity.
62699218|NCT04957589|EXPERIMENTAL|VLCD & HIIT|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) High intensity interval training (3x sessions per week following intensity estimation using cardiorespiratory testing (VO2max), using an established training protocol within our department) No additional protein supplementation
62699219|NCT04957589|ACTIVE_COMPARATOR|VLCD only|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) No additional exercise or protein supplementation
62699220|NCT03594474|NO_INTERVENTION|control group|Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.
62341727|NCT05805670|EXPERIMENTAL|Children with surgical indication scoliosis follow the Yoga and Mindfulness protocol before surgery|Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to.
62499088|NCT05294367|EXPERIMENTAL|Cycle 2, Arm I|Participants continue consuming magnesium rich foods PO daily and apply Ancient Minerals Magnesium Lotion topically daily for 28 days.
62341728|NCT05675891|EXPERIMENTAL|Supplemental Feeding System Group|3 feeding between 08-16:00 are carried out with the supplemental feeding system. The remaining 5 feedings continue with the bottle.
62341729|NCT05675891|NO_INTERVENTION|Bottle Feeding Group (Control)|All feedings are made from a bottle.
62499089|NCT05294367|EXPERIMENTAL|Cycle 2, Arm II|Participants continue consuming magnesium rich foods PO daily for 28 days.
62699221|NCT03594474|EXPERIMENTAL|experimental group|"The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth.~The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group."
62699222|NCT05769062|EXPERIMENTAL|Single-digit pelvic exam|"* Patients will have a pelvic floor muscle exam performed by their gynecologic radiation oncologist prior to treatment, at treatment mid-point (after 3 weeks of treatment), at the end of treatment (after 6 weeks of treatment), and at a follow-up visit 6 months after the end of treatment. Patients will also complete the Pelvic Floor Impact Questionnaire 7 (PFIQ-7), Pelvic Floor Disability Index (PFDI-20), and the EORTC QLQ-CX24 at these time points.~* The patient will also undergo a standard of care MRI prior to starting treatment."
62341730|NCT05321485|EXPERIMENTAL|MedicijnWijs|All participants will undergo the same intervention of using MedicijnWijs, and they will serve as their own control.
62341731|NCT02737735|EXPERIMENTAL|Chemotherapy combined with compound herbal medicine|Standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks combined with compound Chinese herbal medicine for 2 years，which include 15 kinds of Chinese herbs:Thunberg fritillary bulb,antimutangenic ,cimicifuga foetida,astragalus,pinellia ,Radix Ophiopogonis ,Solanum nigrum,Hedyotis diffusa,Prunella vulgaris ,cordate houttuynia,Herba Patriniae,dried orange peel ,Codonopsis,Wolfiporia extensa,Coix seed,Rhizoma Alismatis.
62341732|NCT02737735|ACTIVE_COMPARATOR|Chemotherapy|The therapy of standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks
62341733|NCT03440255|EXPERIMENTAL|Transcutaneous Vagus Nerve Stimulation|TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs
62341734|NCT01348425|EXPERIMENTAL|Longer Stents|
62341735|NCT01348425|EXPERIMENTAL|Shorter Stents|
62499090|NCT05525702|EXPERIMENTAL|VR Stimulation|Patients wear head-mounted displays and experience high immersive virtual environments for treatment.
61950147|NCT02824575|EXPERIMENTAL|Arm B1-2: Eribulin plus Rebastinib.|"* Arm B1 (Dose Escalation Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 \& 8 q21 days plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~* Arm B2 (Expansion Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 \& 8 q21 days. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
62341736|NCT02072720|NO_INTERVENTION|on-treatment tumor biopsie|patients will undergo an pre-treatment and on-treatment tumor biopsy, to measure VEGF expression, and identify the time point of induction of VEGF expression.
62341737|NCT02072720|EXPERIMENTAL|bevacizumab|These patients will receive bevacizumab once a week during their chemoradiation, starting at the identified time point of enhanced VEGF expression. These patients will also undergo and pre-treatment tumor biopsy and 1 tumor biopsy 1 week after the start of bevacizumab treatment.
62341738|NCT01449552|EXPERIMENTAL|Group A|No clamp and placebo
62341739|NCT01449552|EXPERIMENTAL|Group B|Tranexamic acid
62341740|NCT01449552|EXPERIMENTAL|Group C|Drain clamping
62341741|NCT01449552|EXPERIMENTAL|Group D|Drain clamping and tranexamic acid
62341742|NCT03143868|EXPERIMENTAL|Aerobic Exercise|
62341743|NCT03143868|EXPERIMENTAL|Resistance Exercise|
62341744|NCT03143868|PLACEBO_COMPARATOR|No Exercise|
62341745|NCT05521217||Children with Spinal Muscular Atrophy|The patients were included if they were between 0 to 4 yeats, with a diagnosis of Spinal Muscular Atrophy.
62341746|NCT05521217||Healthy children|The healthy age-matched control group was included.
62341747|NCT00862316|EXPERIMENTAL|Computer Navigational Unit Assistance|Oxford Unicompartmental Knee arthroplasty will be performed with the assistance of a computer navigational unit.
62341748|NCT00862316|ACTIVE_COMPARATOR|Non- Computer Navigational Unit Assisted|Oxford Unicompartmental Knee arthroplasty will be performed traditionally (without the assistance of a computer navigational unit).
62341749|NCT05942157|NO_INTERVENTION|Control|The prescription of antibiotics will follow institution antibiotic prescribing guidelines or at the Infectious Disease (ID) clinician's discretion, based on culture and antibiotic susceptibilities results (whenever available). Empiric antibiotic treatment will be employed prior to the availability of culture or antibiotic susceptibilities results. Antibiotic level measurements, Minimum Inhibitory Concentrations (MIC) testing and Pharmacokinetics/Pharmacodynamics (PK/PD) target analysis will only be performed at Day 14 post enrolment, but the results will not be released to the ID clinician and the primary clinician.
62341750|NCT05942157|EXPERIMENTAL|Intervention|Once a positive GNB culture is known, antibiotic MIC testing will commence, and PK/PD target analysis will be performed using the antibiotic MIC. An every-other-day TDM-guided regimen will be chosen to rapidly adjust the antibiotic doses until the PK/PD target is achieved. In the event the antibiotic dose readjustment is unable to achieve the defined PK/PD target, blood sampling will continue every other day until Day 14 or the PK/PD target is achieved
62341751|NCT02671942|ACTIVE_COMPARATOR|roflumilast:250μg|Drug: Roflumilast Roflumilast tablets Roflumilast 250 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
62341752|NCT02671942|ACTIVE_COMPARATOR|roflumilast:375μg|Drug: Roflumilast Roflumilast tablets Roflumilast 375 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
62341753|NCT02671942|ACTIVE_COMPARATOR|roflumilast:500μg|Drug: Roflumilast Roflumilast tablets Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
62341754|NCT02671942|PLACEBO_COMPARATOR|placebo|Drug: placebo placebo tablets placebo tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
62341755|NCT05491694|EXPERIMENTAL|HIFU+Toripalimab+Chemotherapy|High Intensity Focused Ultrasoun， followed by Toripalimab 240 mg + epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 × 4 cycles → Toripalimab240 mg + carboplatin AUC 5 + nab-paclitaxel 260 mg/m2 IVD × 4 cycles every 3 weeks for 8 doses.
62499091|NCT05525702|NO_INTERVENTION|Standard ICU Care|Patients will be treated with standard ICU care and not receive VR stimulation.
62341756|NCT02791971|EXPERIMENTAL|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
62341757|NCT02791971|ACTIVE_COMPARATOR|Alcohol Control Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
62341758|NCT03580382|EXPERIMENTAL|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
62341759|NCT03580382|EXPERIMENTAL|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
62499092|NCT02376257|ACTIVE_COMPARATOR|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
61950148|NCT00437983|ACTIVE_COMPARATOR|PS-Omega3|Phosphatidylserine-Omega3, 300mg/day 15 wk
61950149|NCT00437983|PLACEBO_COMPARATOR|Placebo|Cellulose tainted with fishy odor, 3 capsules/day
61950150|NCT04015492|EXPERIMENTAL|BAY94-9027 / Adynovi|Treatment sequence A-B with washout before each treatment
61950151|NCT04015492|EXPERIMENTAL|Adynovi / BAY94-9027|Treatment sequence B-A with washout before each treatment
61950152|NCT03583697|EXPERIMENTAL|Active BMN111|Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN111 daily.
61950153|NCT03583697|PLACEBO_COMPARATOR|Placebo|Daily subcutaneous injection of placebo
61950154|NCT00193258|EXPERIMENTAL|Intervention|"In the phase I portion:~Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course~Erlotinib 150 mg orally daily~Imatinib 300 mg orally daily or 400 mg orally daily~In the phase II portion:~Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle~Erlotinib 150 mg orally daily~Imatinib 400 mg orally daily"
61950155|NCT03734042|EXPERIMENTAL|PRP group|These patients will receive platelet rich plasma intrauterine infusion at day 11
61950156|NCT03734042|PLACEBO_COMPARATOR|Control group|These patients will receive intrauterine normal saline infusion at day 11
62699223|NCT05169502||Patients with diabetes and newly diagnosed proliferative diabetic retinopathy, level 4. (n=10)|"Inclusion criteria: Type I or II diabetes, habile and age\>18 years. Exclusion criteria: Incapacitated or age\< 18 years.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.~A questionnaire describing the patients general health (gender, age, duration of diabetes, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
62699224|NCT05169502||Patients with diabetes and newly diagnosed diabetic maculopathy. (n=10)|"These patients will be matched 1:1 to the patients with proliferative diabetic retinopathy, regarding gender, age, duration of diabetes, smoking status, and blood pressure.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.A questionnaire describing the patients general health (gender, age, duration of diabetes, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
62699225|NCT05169502||Patients with diabetes without retinopathy, level 0. (n=10)|"These patients will be matched 1:1 to the patients with proliferative diabetic retinopathy, regarding gender, age, duration of diabetes, smoking status, and blood pressure.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.A questionnaire describing the patients general health (gender, age, duration of diabetes, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
61950157|NCT01447433|EXPERIMENTAL|Calcium+D|Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
61950158|NCT01447433|PLACEBO_COMPARATOR|Control|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
61950159|NCT01045525|EXPERIMENTAL|Phlebotomy + lifestyle and diet advices|
61950160|NCT01045525|ACTIVE_COMPARATOR|Lifestyle and diet advices|
62341760|NCT03752606|ACTIVE_COMPARATOR|TACHOSIL GROUP|Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
62341761|NCT03752606|NO_INTERVENTION|GROUP WITHOUT TACHOSIL|The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.
62341762|NCT04411212|ACTIVE_COMPARATOR|Granulocyte colony-stimulating factor and platelet-rich plasma|
62341763|NCT04411212|OTHER|Control group|
61950161|NCT06308367|EXPERIMENTAL|betaine|oral betaine
61950162|NCT06308367|PLACEBO_COMPARATOR|placebo|rice-flour as a placebo
62341764|NCT03489135|EXPERIMENTAL|Intervention using the ReVene Thrombectomy Catheter|Open label, prospective, non-randomised, multi-centre first-in-human evaluation of the Vetex ReVene Thrombectomy Catheter for treatment of acute iliofemoral deep vein thrombosis (DVT).
62341765|NCT02141802|ACTIVE_COMPARATOR|Control|Normal standing time
62341766|NCT02141802|EXPERIMENTAL|Doubling standing time|Doubled standing time calculated by doubling baseline standing time
62341767|NCT03218982|EXPERIMENTAL|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
62341768|NCT03218982|NO_INTERVENTION|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
62341769|NCT00123916|EXPERIMENTAL|Benznidazole|40 - 80 days (according to body weight) treatment with benznidazol
62341770|NCT00123916|PLACEBO_COMPARATOR|Placebo|40 - 80 days (according to body weight) treatment with matching placebo
62341771|NCT01881971|PLACEBO_COMPARATOR|Placebo|manufactured sugar pill to mimic rouvastatin once a day for 24 weeks
61950163|NCT02465515|EXPERIMENTAL|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
61950164|NCT02465515|PLACEBO_COMPARATOR|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
61950165|NCT03476993|EXPERIMENTAL|BCD-085|All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
61950166|NCT05532917||Gupta group|Cardiology consultation requested using Gupta score
61950167|NCT05532917||Non-Gupta group|Number of cardiology consultations requested without using Gupta score
61950168|NCT05579236||Patient Participants|Patient participants will have a diagnosis of mild cognitive impairment or prodromal / mild Alzheimer's Disease. Participants with a global CDR score of 0.5 and 1 will be recruited in a minimum of a 2:1 ratio respectively in the study.
61950169|NCT05579236||Study Companions|Study companions will have sufficient knowledge on the patient participant's condition to complete companion assessments of the patient, in the investigator's judgement, for example they may be carers of the patients.
61950170|NCT04033575|SHAM_COMPARATOR|Fluoride Control|Colgate Cavity Protection 0.76% as Na MFP Toothpaste
61950171|NCT04033575|ACTIVE_COMPARATOR|Colgate Total SF|Colgate Total Clean Mint White Paste 1100 ppm F Toothpaste
62341772|NCT01881971|EXPERIMENTAL|Rouvastatin calcium|Rouvastatin calcium once a day by mouth for 24 weeks.
62499093|NCT02376257|ACTIVE_COMPARATOR|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
61950172|NCT06298331|EXPERIMENTAL|Aerobic Exercise and Abdominal Massage|"Aerobic Exercise: Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down).~Abdominal Massage: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage."
61950173|NCT06298331|ACTIVE_COMPARATOR|Abdominal Massage|Abdominal Massage: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
62341773|NCT05662306|EXPERIMENTAL|Aripiprazole and Computerized Cognitive and Functional Skills Training Group|Participants in this arm will receive long-acting injectable aripiprazole every 2 months formulation for 12 consecutive months. Participants in this arm will also receive Computerized cognitive and functional skills training during the first 12 weeks of study participation.
62341774|NCT04321824||the innovative programm (PASS de ville)|specific care for precarious people
62341775|NCT04321824||the standard of care|
62341776|NCT03097796|EXPERIMENTAL|PUL-042|PUL-042 Inhalation Solution
61950174|NCT00722423|EXPERIMENTAL|Integrated Care Model|Integrated Care
61950175|NCT00722423|EXPERIMENTAL|Usual Care Model|Usual Care
61950176|NCT04548037||Patients with transient global amnesia|
62341777|NCT06134791||Cervicogenic headache with positive flexion-rotation test|Diagnosis of cervicogenic headache according to the ICHD-3 criteria. Age: 18+ years Headache for at least 1 day/week for at least 3 months Limited mobility of the neck Positive flexion-rotation test (\<32 degrees on the left/right side or a difference of 10 degrees or more between left and right side) NPRS \> 3/10
62341778|NCT06134791||Cervicogenic headache without positive flexion-rotation test|Diagnosis of cervicogenic headache according to the ICHD-3 criteria Age: 18+ years Headache for at least 1 day/week for at least 3 months Limited mobility of the neck Negative flexion-rotation test (\>32 degrees on the left/right side or a difference of less than 10 degrees between left and right side) NPRS \> 3/10
62341779|NCT01980706|PLACEBO_COMPARATOR|Placebo|Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
62341780|NCT01980706|ACTIVE_COMPARATOR|30 Mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
62341781|NCT01980706|ACTIVE_COMPARATOR|90 mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
62341782|NCT02911155||US Nuclear Medicine Technologist|radiologic technologists certified in nuclear medicine
61950177|NCT04548037||Healthy volunteers|
62341783|NCT03205826|OTHER|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
62499094|NCT02376257|PLACEBO_COMPARATOR|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
62499095|NCT04620941||ventilator-associated pneumonia|Ret-He values will be studied on the day (1st day), 4th and 7th days of VID diagnosis in patients receiving mechanical ventilation support in the intensive care unit. The hemogram, CRP, and NLR values that are routinely studied in the intensive care unit will be recorded. In addition, in case of infection, the routinely studied procalcitonin value will also be recorded. The patient's age, gender, APACHE II, SOFA scores will be recorded; respiratory system examination, fever, the mental status evaluation will be done daily.
62499096|NCT06053840|EXPERIMENTAL|Treatment|
62499097|NCT04645186||Calcium Phosphate Cement (CPC)|Evaluation of CPC in long bone \& extremities
62499098|NCT05626725||Observationnal cohort|Patients with type 1 diabetes and using an AID system.
62499099|NCT05696041|EXPERIMENTAL|The exercise group (WSE)|"Initial static strength training program for the wrist, which could progress to a higher weight in kilos alternatively to a dynamic strength training program~* Information about HSD/hEDS~* Daily exercise~* Training schedule~* 3-4 return visits to the OT"
62499100|NCT05696041|NO_INTERVENTION|Conventional intervention (HO)|"* Prescribed the wrist´s with plastic or metal orthoses~* Information about HSD/hEDS~* Use the orthosis in specific activities; carrying, vacuuming, doing laundry, driving, bicycling~* Training schedule~* 3-4 return visits to the OT"
62499101|NCT05318755||transgender men|People whose sex assigned at birth is female but whose self-identified gender is male.
61950178|NCT03532061|EXPERIMENTAL|FamCare Group|Family caregivers who receive 6 in-person problem-solving skills training sessions (FamCare Program).
61950179|NCT03532061|ACTIVE_COMPARATOR|Caregiver Support Group|Family caregivers who receive 6 in-person caregiver support group sessions.
61950180|NCT00509041|EXPERIMENTAL|Dasatinib|Use of dasatinib in treatment of pts with previously treated malignant mesothelioma
61950181|NCT00682422||Parent & Child Dyad|
61950182|NCT01457144|EXPERIMENTAL|RiBVD|Rituximab Bendamustine Velcade® Dexamethasone 6 cycles every 28 days
61950183|NCT06154187|EXPERIMENTAL|test 1|PBK_L2201
61950184|NCT06154187|PLACEBO_COMPARATOR|placebo|placebo
61950185|NCT00874107|EXPERIMENTAL|1|Imprime PGG + bevacizumab + paclitaxel/carboplatin
61950186|NCT00874107|OTHER|2|bevacizumab + paclitaxel/carboplatin
62499102|NCT05318755||transgender women|People whose sex assigned at birth is male but whose self-identified gender is female.
62499103|NCT05318755||Healthy cisgender people|People whose sex assigned at birth corresponds with their self-identified gender.
62499104|NCT06677905|EXPERIMENTAL|SCI&U self-management program|Following recruitment intervention participants will be scheduled for an orientation session to become better acquainted with the health coaching program and the associated platform's features. Participants will then be partnered with their peer health coach. In the first videoconference session, participants will identify priority issues related to their health and transitioning to home. They will work through goal-setting, problem solving and create action plans for behaviour change. Online coaching sessions are expected to cover a health-related topic and a self-management skill topic and will have an expected duration of 45 to 60 minutes. The selection of topics and the order will be determined jointly.
61950187|NCT04392752|EXPERIMENTAL|Participants|The participants are recruited via the University of Jyväskylä and Finnish Fitness Sports Association web page and social media channels. An online pre-study questionnaire are sent to randomly chosen athletes and control group candidates who claim to fulfill the inclusion criteria and volunteer for the study. The participants selected for the study filled an additional questionnaire which is subsequently reviewed by the physician of the study to confirm that they will meet inclusion criteria relating to health.
61950188|NCT04392752|NO_INTERVENTION|Control|The target is 15 male ja 15 female participants for both the control and intervention groups. To be included, participants need to be with two or more years of resistance training experience, similar to our previous study in females (Hulmi et al. 2017). If more than 15+15 control participants sign up for the study, the final group will be matched to the intervention group based on age, height, weight, and training experience reported on the pre-study questionnaire. The control group maintain their normal nutrition and training during the study.
61950189|NCT01956383|EXPERIMENTAL|PrePex™ device|Adult male circumcision by the PrePex™ device
61950190|NCT01580085||Pulmonary embolism|Patients who were diagnosed with pulmonary embolism
62499105|NCT06677905|ACTIVE_COMPARATOR|Wait list control|Control group will be offered the existing peer support program from the United Spinal Connecticut Chapter or SCI BC
62499106|NCT02677662|SHAM_COMPARATOR|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise or rest.
61950191|NCT01580085||control group|age and sex matched adults with osa and no thromboembolism
61950192|NCT04763668||Pregnant HIV positive women on ART|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV positive and have been on ARTs for at least four months before pregnancy. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
61950193|NCT04763668||Pregnant HIV negative women|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV negative. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
61950194|NCT04763668||Babies born to HIV positive mothers on ARTs|All babies born to pregnant HIV positive women on ARTs who were in the first arm of the study
62499107|NCT02677662|EXPERIMENTAL|Diesel exhaust exposure|2 hour exposure to dilute diesel exhaust (approximate PM10 (particulate matter\<10um) concentration 300 mcg/m3) during intermittent exercise or rest.
62699226|NCT05169502||Individuals without diabetes and known eye diseases (n=10)|"These patients will be matched 1:1 to the patients with proliferative diabetic retinopathy, regarding gender, age, smoking status, and blood pressure.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.A questionnaire describing the patients general health (gender, age, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
62699227|NCT04614532|OTHER|patients with alzheimer's disease|
61950195|NCT04763668||Babies born to HIV negative mothers|All babies born to pregnant HIV negative women who were in the first arm of the study.
61950196|NCT03147677|EXPERIMENTAL|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
61950197|NCT03147677|ACTIVE_COMPARATOR|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
62341784|NCT02358369|EXPERIMENTAL|13 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye (OU) for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops to each eye twice a day (BID) for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
62341785|NCT02358369|EXPERIMENTAL|2.2 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 2.2 mg Bimatoprost Ocular Insert in each eye for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops in each eye twice a day for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
62341786|NCT02358369|ACTIVE_COMPARATOR|Timolol 0.5%|"Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 0.5% timolol ophthalmic solution in each eye for 6 weeks. Note: participants simultaneously wore placebo ocular inserts for 12 weeks.~After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks."
62341787|NCT00580944|EXPERIMENTAL|Port Wien Stain Birthmark|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
62341788|NCT06027931|EXPERIMENTAL|Conservative Access Opening|Root canal treatment using Conservative Access Opening type.
62341789|NCT06027931|EXPERIMENTAL|Traditional Access Opening|Root canal treatment using Traditional Access Opening type.
62341790|NCT02740504||Subjects|All 20 subjects. Selected to have a range of ages (18 to less than 75) and BMI from 18.5 to 45
62341791|NCT02456181|EXPERIMENTAL|JumpMath|"The JUMP method focuses more on the mental activity involved in constructing mathematical knowledge. There is a strong emphasis on symbolic math (numbers, letters, mathematical symbols). Manipulatives are used prescriptively, in lessons carefully scaffolded to help students connect the objects (e.g., three buttons) to what they are intended to stand for (the magnitude 3)."
62341792|NCT00692510|EXPERIMENTAL|1|AZD3480 + cocktail
62341793|NCT00692510|PLACEBO_COMPARATOR|2|Placebo + cocktail
62499108|NCT03388008|ACTIVE_COMPARATOR|Standard of care|Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365
62499109|NCT03388008|EXPERIMENTAL|Belatacept-based immunosuppression|Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365
62699228|NCT04614532|OTHER|control subject|Matching by age (± 5 years), gender, and grade level
62499110|NCT01404962|OTHER|Group 1|
62699229|NCT06445777|EXPERIMENTAL|Intervention Group|Behavioural/ psychosocial intervention (i.e., mental health prevention and promotion programme) to boost emotional awareness, confidence, coping skills, and resilience.
62699230|NCT06445777|NO_INTERVENTION|Control Group|Participants in the control group will receive the intervention at a later stage.
62699231|NCT05713266||Severe COVID-19 survivors|Adult COVID-19 survivors who had 'severe COVID-19' during the acute phase and have at least one of the following pre-existing conditions: Hypertension, Asthma, COPD, Heart Failure, Chronic kidney disease and/or Diabetes. 'Severe COVID-19' is defined as requiring hospital or intensive level care for treatment of the infection and its complications.
61950198|NCT03147677|ACTIVE_COMPARATOR|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
61950199|NCT04710394|ACTIVE_COMPARATOR|Unimodal Olfactory Training with Conventional Odors|Participants will undergo smell training without a visual component, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
61950200|NCT04710394|EXPERIMENTAL|Unimodal Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training without a visual component, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
62341794|NCT00621452|EXPERIMENTAL|Treatment (autologous CD20 specific T-cells)|"CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.~IMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.~MAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.~Subjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse."
62341795|NCT05658185|NO_INTERVENTION|No Intervention: Control Group|All patients will be evaluated on 4 occasions: 1) T1: 1st pre-treatment measurement in control and experimental groups; 2) after 10 weeks, T2: 2nd pre-treatment measurement in control and experimental groups; 3) after 10 weeks, T3: 3rd pre-treatment measurement in control and experimental groups, and 1st post-treatment measurement in experimental groups. Between T2 and T3 the patients in the experimental group will receive for 10 weeks the 10 sessions of the psychological treatment protocol; 4) after that, in the following 10 weeks, the control group will receive the 10 sessions of psychological treatment, thus at T4: 1st post-treatment measurement in the control group, and 1st post-treatment follow-up session in the experimental group (during this time, the experimental group does not receive any more treatment sessions, but practices all the psychological management skills installed during the treatment protocol between T2 and T3).
62341796|NCT05658185|EXPERIMENTAL|Experimental Group|All patients will be evaluated on 4 occasions: 1) T1: 1st pre-treatment measurement in control and experimental groups; 2) after 10 weeks, T2: 2nd pre-treatment measurement in control and experimental groups; 3) after 10 weeks, T3: 3rd pre-treatment measurement in control and experimental groups, and 1st post-treatment measurement in experimental groups. Between T2 and T3 the patients in the experimental group will receive for 10 weeks the 10 sessions of the psychological treatment protocol; 4) after that, in the following 10 weeks, the control group will receive the 10 sessions of psychological treatment, thus at T4: 1st post-treatment measurement in the control group, and 1st post-treatment follow-up session in the experimental group (during this time, the experimental group does not receive any more treatment sessions, but practices all the psychological management skills installed during the treatment protocol between T2 and T3).
62499111|NCT06334016|EXPERIMENTAL|Arm A (placebo, THC, nicotine)|"Participants complete 3 vaping sessions separated by 7-14 days on study:~* VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.~* VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.~* VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.~All participants also undergo blood sample collection throughout the trial."
62140806|NCT03835559|ACTIVE_COMPARATOR|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure for treatment of incompetent Saphenous Veins is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
62699232|NCT02296125|EXPERIMENTAL|AZD9291+ placebo|AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
62699233|NCT02296125|ACTIVE_COMPARATOR|Standard of Care + placebo AZD9291|"Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
62699234|NCT01129206|EXPERIMENTAL|Arm I|Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62699235|NCT03828604|EXPERIMENTAL|Stress; Trier Social Stress Task|5 min challenging speech task, 5 min challenging math task; performed in front of evaluators
62341797|NCT06262893|ACTIVE_COMPARATOR|Interscalene block in shoulder arthroscopy|
62341798|NCT06262893|ACTIVE_COMPARATOR|Combined Supraclavicular block and suprascapular block in shoulder arthroscopy|
62341799|NCT05955209|EXPERIMENTAL|Disitamab Vedotin(RC48-ADC)|Disitamab Vedotin(RC48-ADC) :2.0mg/kg，Q2W
62499112|NCT06334016|EXPERIMENTAL|Arm B (placebo, THC, nicotine)|"Participants complete 3 vaping sessions separated by 7-14 days on study:~* VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.~* VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.~* VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.~All participants also undergo blood sample collection throughout the trial."
62499113|NCT06334016|EXPERIMENTAL|Arm C (placebo, THC, nicotine)|"Participants complete 3 vaping sessions separated by 7-14 days on study:~* VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.~* VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.~* VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.~All participants also undergo blood sample collection throughout the trial."
62499114|NCT05948033|EXPERIMENTAL|CD70-targeting CAR-T cells|"Enrolled participants will be given a preconditioning regimen consisted of fludarabine and cyclophosphamide before the infusion of CD70-CAR T cells.~Enrolled patients in this arm will be administered CD70-CAR T cells in 3+3 based escalation manner."
62499115|NCT02603549||Surgery or Blood Patch|
62499116|NCT05341856|ACTIVE_COMPARATOR|Uterine artery Doppler Changes After IMN In Patients with URPL|compare uterine artery blood flow before and after the administration of Isosorbide mononitrate as a nitric oxide donor during mid secretory phase of menstrual cycle for patients with unexplained recurrent pregnancy loss.
62499117|NCT05341856|PLACEBO_COMPARATOR|Uterine artery Doppler Changes After placebo In Patients with URPL|compare uterine artery blood flow before and after the administration of placebo during mid secretory phase of menstrual cycle for patients with unexplained recurrent pregnancy loss.
62499118|NCT01517867|EXPERIMENTAL|Intervention Chicago Parent Program arm|The Chicago Parent Program is a 12-session group-based parenting skills training program
62341800|NCT05203276|EXPERIMENTAL|Envafolimab+ Endostar Group|Envafolimab（300mg，SC，Q3W，d1） Endostar（210mg，CIV 72h，Q3W，d1-3）
62499119|NCT01517867|ACTIVE_COMPARATOR|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually tailored treatment for parents and children with behavior problems
62499120|NCT05009056|EXPERIMENTAL|postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
62499121|NCT05009056|ACTIVE_COMPARATOR|Presurgical computer guided functional appliance|Using the software, 3D digitized mandible will be virtually repositioned in ideal centric relation through accurate adjustment of the condyle in its glenoid fossa. Patients' dental casts will be scanned, and digitized into a virtual 3D model and superimposed to the CT cuts into the virtual plan software environment in order to produce preoperative CAD/CAM splint on the adjusted centric occlusion. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
62499122|NCT03517280||Children with Neuroblastoma|Children undergoing treatment for Neuroblastoma at ITACI in Sao Paolo in Brazil who are under the age of 18 years.
62499123|NCT05364606||50 Subjects|50 Subjects Receiving the Patient Specific Talus Spacer.
62499124|NCT02246348|EXPERIMENTAL|Doppler ultrasound|
62499125|NCT06064149|OTHER|Men With Prostate Cancer Planned for Receiving ADT|Men with prostate cancer \> 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of systemic androgen deprivation therapy (ADT).
62341801|NCT01487096|PLACEBO_COMPARATOR|Placebo|"Placebo (for teriflunomide),~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks."
62499126|NCT04226586|ACTIVE_COMPARATOR|Treatment Group|"* This is a double-blind study. Participants and the investigators will be blinded to the intervention.~* Children in the treatment (intervention) arm will receive essential amino acids (EAA) twice a day.~* Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~* Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~* EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
62699236|NCT03828604|ACTIVE_COMPARATOR|Placebo Trier Social Stress Task|5 min speech task, 5 min math task; performed alone
62699237|NCT01136720||patients injected with the Halifax produced 18-FDG|
62699238|NCT06069570|EXPERIMENTAL|KB-GDT-01 cells|Dose Level 1: 400 x10\^6, 800 x10\^6 or 1600 x10\^6 KB-GDT-01 cells + radiation (1.0 Gy/fraction)
62341802|NCT01487096|EXPERIMENTAL|Teriflunomide 7 mg|"Teriflunomide 7 mg:~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks."
62341803|NCT01487096|EXPERIMENTAL|Teriflunomide 14 mg|"Teriflunomide 14 mg:~* two tablets once daily for 1 week then,~* one tablet once daily for 35 weeks."
62341804|NCT01399528||Beaumont Hospital, Dublin, Ireland|
62341805|NCT01399528||St. James' Hospital, Dublin, Ireland|
62341806|NCT01399528||Hôpital Erasme, Brussels, Belgium|
62341807|NCT01399528||Duke Medical Centre, North Carolina, USA|
62341808|NCT01399528||The Institute of Neurology/University College London, UK|
62341809|NCT04224896||NBI PATIENT|
62341810|NCT04224896||LUGOL PATIENT|
62341811|NCT05630170|EXPERIMENTAL|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.The AI-ECG model will be used on all participants undergoing a 12-lead ECG.
62499127|NCT04226586|PLACEBO_COMPARATOR|Placebo|"* This is a double-blind study. Participants and the investigators will be blinded to the intervention.~* Children in the placebo arm will receive placebo twice a day. EAA and placebo supplements will look and taste alike. The same flavoring ingredients (stevia blend, citric acid, malic acid, natural flavors, tartaric acid, fruit and vegetable juice for color) will be used in both products at the same amount.~* Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~* Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~* EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
62499128|NCT06593405|EXPERIMENTAL|Receiving OT interventions|All participants will receive all OT interventions
62499129|NCT00526435|EXPERIMENTAL|Group WWE|Subjects will participate in a group-assisted 6 week WWE program.
62499130|NCT00526435|EXPERIMENTAL|Self-directed|Subjects will follow the self-directed WWE program.
62499131|NCT02005939|EXPERIMENTAL|Pomegranate extract capsule|All participants receive 1.1 g pomegranate extract capsule daily for 4 weeks
62341812|NCT02581111|EXPERIMENTAL|Naloxone|Naloxone 8-mg IV given once after baseline ABG
62341813|NCT02581111|SHAM_COMPARATOR|Placebo|Equivalent volume of saline given once
62341814|NCT02033772||Thoracoscopic surgery|Infants undergoing thoracoscopic surgery.
62341815|NCT01892618|ACTIVE_COMPARATOR|Pneumovax|Pneumovax, 1x 0.5 ml injection
62341816|NCT01892618|EXPERIMENTAL|Prevenar 13|Prevenar 13, 1x 0.5 ml injection
62341817|NCT01676402|EXPERIMENTAL|Group 1: HA DNA + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV ID at Week 14±2 wks
62341818|NCT01676402|EXPERIMENTAL|Group 2: HA DNA + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV IM at Week 14±2 wks
62341819|NCT01676402|EXPERIMENTAL|Group 3: TIV ID + TIV ID|licensed 2012/13 TIV ID at Day 0 and licensed 2013/14 TIV ID at Week 44±2 weeks
62341820|NCT01676402|EXPERIMENTAL|Group 4: TIV IM + TIV IM|2012/13 licensed TIV IM at Day 0 and licensed 2013/14 TIV IM at Week 44±2 weeks
62341821|NCT01676402|EXPERIMENTAL|Group 5: (HA DNA and TIV ID) + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV ID at Day 0 followed by licensed 2013/14 TIV ID at Week 44±2 weeks
62341822|NCT01676402|EXPERIMENTAL|Group 6: (HA DNA and TIV IM) + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV IM at Day 0 followed by licensed 2013/14 TIV IM at Week 44±2 weeks
62341823|NCT02830035|ACTIVE_COMPARATOR|Anatomical Landmark Technique|Traditional anatomical landmark technique based paramedian spinal anesthesia
62499132|NCT02005939|PLACEBO_COMPARATOR|Placebo capsule|All participants receive a 1.1g placebo capsule daily for 4 weeks
62499133|NCT06094894|EXPERIMENTAL|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
62499134|NCT06094894|PLACEBO_COMPARATOR|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
62499135|NCT03485001|SHAM_COMPARATOR|Sham of Argon Laser Treatment|Slit lamp light exposure
62499136|NCT03485001|EXPERIMENTAL|Argon Laser Treatment|Argon Laser Treatment
62499137|NCT02578290|EXPERIMENTAL|Treatment|Clinical Decision Support (CDS)
62499138|NCT02578290|NO_INTERVENTION|Control|Will not receive Clinical Decision Support (CDS)
62341824|NCT02830035|ACTIVE_COMPARATOR|Real-time Ultrasound-guided Technique|Ultrasound-guided paramedian spinal anesthesia Intervention: Ultrasound-guided Technique
62341825|NCT00750555|OTHER|1|
62341826|NCT03085147|EXPERIMENTAL|Fluorescent PARPi Binding Imaging Agent PARPi-FL|In the phase I of the study, increasing concentrations of PARPi-FL will be used in up to 12 patients with OSCC to determine concentration that results in the highest contrast between tumor and normal mucosa. Dose escalation will be performed in groups of three patients until image contrast decreases, side effects are noted or the concentration of PARPi-FL exceeds 1μM. Imaging will be performed in the Department of Surgery during a presurgical visit including clinical examination of the oral cavity. In the phase II part of the study the concentration of PARPi-FL determined in phase I will be used to image 18 patients with OSCC on the day of surgery. Imaging findings will be correlated with histopathologic findings in the surgically resected specimens.
62341827|NCT06046716|EXPERIMENTAL|Experimental mindful compassion group|Experimental randomised controlled waitlist study The experimental group (n=28) will receive mindful compassion intervention at week 1 and intervention terminates at week 4
62341828|NCT06046716|OTHER|Waitlist mindful compassion control group|Experimental randomised controlled waitlist study The delayed group (n=24) will receive mindful compassion intervention at week 4 and intervention terminates at week 8
62341829|NCT01070602|EXPERIMENTAL|anterior corneal incision|
62341830|NCT02603913||Normal pregnancy|Normal uncomplicated pregnancy
62499139|NCT02488109|ACTIVE_COMPARATOR|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
62499140|NCT02488109|ACTIVE_COMPARATOR|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
62499141|NCT04181164||HPP-Group|Adults with hypophosphatasia.
62499142|NCT04181164||Control-Group|Healthy control subjects.
62499143|NCT02611323|EXPERIMENTAL|Dose-Escalation Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and venetoclax when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
62499144|NCT02611323|EXPERIMENTAL|Dose-Escalation Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at escalating doses to identify the RP2D of venetoclax when combined with fixed doses of polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
62499145|NCT02611323|EXPERIMENTAL|Expansion Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
62499146|NCT02611323|EXPERIMENTAL|Expansion Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at the RP2D identified during the dose-escalation phase, in addition to polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
62499147|NCT06491979|EXPERIMENTAL|Vitamin A treatment|
62499148|NCT06491979|EXPERIMENTAL|Monounsaturated fatty acid mixture|
62499149|NCT06491979|EXPERIMENTAL|Polyunsaturated fatty acid mixture|
62499150|NCT06491979|EXPERIMENTAL|Fatty acid mixture|
62499151|NCT05795296|EXPERIMENTAL|Fruquintinib+Sintilimab|"Fruquintinib: 5mg po, d1-d14, q3w~Sintilimab: 200mg ivgtt, d1, q3w"
62341831|NCT02603913||Pre-eclampsia|"Hypertension (\>140 mmHg systolic or \>90 mmHg diastolic) developing after 20 weeks gestation and the coexistence of one or more of the following new onset conditions:~1. Proteinuria (\>300 mg/day)~2. Other maternal organ dysfunction~   * renal insufficiency (creatinine \>90 μmol/L)~  * liver involvement (elevated transaminases - and/or severe right upper quadrant or epigastric pain)~  * neurological complications (eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotomata)~  * hematological complications (thrombocytopenia, disseminated intravascular coagulation, hemolysis)~3. Uteroplacental dysfunction"
62341832|NCT02603913||Pregnancy induced hypertension|New onset of hypertension (\>140 mmHg systolic or \>90 mmHg diastolic) after 20 weeks gestation, without proteinuria, in a previously normotensive woman.
62499152|NCT02248116|EXPERIMENTAL|Alzheimer|
62499153|NCT06188780||victims of DFSA|Every patients presenting at the sexual assault care centre with a suspicion of drug-assisted sexual assault
62499154|NCT06001762|EXPERIMENTAL|Abemaciclib|"Study procedures will be conducted as follows:~* Cycles 1 - 24~  * Days 1 - 28 of 28-day cycle: Predetermined dose of Abemaciclib 2 x per day.~ * Endocrine therapy 1 x per day.~* In clinic visits with blood tests, questionnaires, and assessments:~  * Day 1 of Cycles 1, 2, and 3~ * Day 15 of Cycles 1 and 2~ * Every three cycles after Cycle 3 Day 1.~* End of treatment visit with blood tests, questionnaires, assessments, and stool sample collection."
62499155|NCT05554965|ACTIVE_COMPARATOR|propofol|The control group was sedated with propofol
62499156|NCT05554965|EXPERIMENTAL|Remimazolam besylate|The experimental group was given remazolam besylate for sedation
62499157|NCT01151891||Diabetics|Diabetics in the parish of St. James, Jamaica
62499158|NCT01744964|PLACEBO_COMPARATOR|Saline|Assessment of experimental pain models before and after treatment
62499159|NCT01744964|ACTIVE_COMPARATOR|Apomorphine|Assessment of experimental pain models before and after treatment
62499160|NCT06004934|EXPERIMENTAL|Group 1: Mild Hepatic Impairment|Participants with mild hepatic impairment (defined using Child-Pugh Classification of the Severity of Liver Disease \[C-P\] criteria \[C-P Class A, score of 5 to 6 points\]) will receive a single oral dose of 30 mg avacopan on Day 1 in the fasted state.
62499161|NCT06004934|EXPERIMENTAL|Group 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (defined using the C-P criteria \[C-P Class B, score of 7 to 9 points\]) will receive a single oral dose of 30 mg avacopan on Day 1 in the fasted state.
62499162|NCT06004934|ACTIVE_COMPARATOR|Group 3: Healthy Control Group|Participants with normal hepatic function (medically normal with no clinically significant illness or disease or abnormal physical examination findings, and with normal laboratory values at screening) will be demographically-matched to participants in Group 1 and Group 2, and will receive a single oral dose of 30 mg avacopan on Day 1 in the fasted state.
62499163|NCT06356987|EXPERIMENTAL|Group-A: Laparoscopic hernia repair|In group A (33 patients) laparoscopic assisted needle herniotomy was done
62499164|NCT06356987|ACTIVE_COMPARATOR|Group B open herniotomy|In group B(33 patients) open herniotomy was done
62499165|NCT04881513|OTHER|Structure /function of the taste buds and QoL|"The structure of the taste buds is measured by Narrow Band Imaging (NBI) technique prior to the operation, one month and six months after the surgery.~The tongue sensation is measured by two point discrimination before the operation, one month and six months after the operation.~The taste is tested by the taste strips prior to, on month and six month after the surgery.~The quality of life is measured by the SF36 questionnaire. The threshold change is measured by the stimulating electrode at the beginning and at the end of the surgery."
62499166|NCT06677762||IRE group|Patients who receive IRE ablation only
62341833|NCT02603913||Preterm birth|Babies born alive before 37 weeks of pregnancy are completed.
62499167|NCT06677762||IRE+anti-PD（L）1|Patients who receive IRE ablation combined with anti-PD（L）1
62499168|NCT04258709|EXPERIMENTAL|Antenatal Milk Expression (AME) Intervention Group|Weekly video interactions (weeks 37-40 of pregnancy) with International Board Certified Lactation Consultants (IBCLCs) to teach and reinforce antenatal milk expression. At-home practice of hand expression and collection of any expressed milk.
62499169|NCT04258709|ACTIVE_COMPARATOR|Video-based Infant Care Education Control Group|Weekly video education (weeks 37-40 of pregnancy) on various topics related to infant care (e.g., safe sleep, car seat safety, etc.).
62699239|NCT05611164|NO_INTERVENTION|Sperm selected by embryologist without software assistance|"For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups (no intervention and experimental arms), in a sibling oocyte study design. In the no intervention arm, the individual spermatozoa for injection are selected subjectively by the embryologist."
62699240|NCT05611164|EXPERIMENTAL|Sperm selected with AI assistant SiD|"For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups (no intervention and experimental arms), in a sibling oocyte study design. In the experimental arm, the spermatozoa selection for injection is performed based on the recommendation of the AI assistant SiD."
62699241|NCT05674955|EXPERIMENTAL|Circuit weight group|
62699242|NCT05674955|EXPERIMENTAL|Aerobic group|
62699243|NCT05674955|EXPERIMENTAL|Control Group|
62699244|NCT03504709||Patient (n=50)|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post injury.
62699245|NCT03504709||Healthy (n=25)|Healthy adults with no neurological, psychiatric, or medical disease.
62699246|NCT00567502||1|XAGRID® (anagrelide hydrochloride)
62699247|NCT00567502||2|Xagrid + Other cytoreductive
62699248|NCT00567502||3|Other cytoreductive
62341834|NCT02603913||Intra-uterine growth restriction|Moderate IUGR is an estimated fetal weight and / or abdominal circumference \< 10th percentile for its gestational age Severe IUGR is an EFW (estimated fetal weight) and/ or AC (abdominal circumference) \< 5th percentile for its gestational age
62341835|NCT04627142|EXPERIMENTAL|Expansion dose 1|Part C: Combination therapy expansion part
62341836|NCT04627142|EXPERIMENTAL|Expansion dose 2|Part C: Combination therapy expansion part
62341837|NCT02156960|EXPERIMENTAL|Denosumab and/or teriparatide treatment|Denosumab and/or teriparatide treatment in osteoporotic patients
62341838|NCT06179030||Group 1|switched from bevacizumab to ranibizumab 0.5
62341839|NCT06179030||Group 2|switched from bevacizumab to dexamethasone implant
62341840|NCT01604057|EXPERIMENTAL|Low Dose Nasal Spray|
62341841|NCT01604057|EXPERIMENTAL|Mid Dose Nasal Spray|
62341842|NCT01604057|EXPERIMENTAL|High Dose Nasal Spray|
62341843|NCT01604057|ACTIVE_COMPARATOR|Forteo|20ug subcutaneous injection daily
62341844|NCT01604057|PLACEBO_COMPARATOR|Placebo Nasal Spray|
62341845|NCT00413062|EXPERIMENTAL|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
62341846|NCT00413062|ACTIVE_COMPARATOR|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
62341847|NCT05430711|EXPERIMENTAL|Dinoprostone|Participants will receive dinoprostone 10 mg vaginal delivery system for up to 24 hours.
62341848|NCT05430711|NO_INTERVENTION|Expectant management|Participants will not receive drugs to induce labour, they will be managed expectantly for up to 24 hours.
62341849|NCT05679973|EXPERIMENTAL|Polybutester|Polybutester suture is a copolymer of polyglycol terephthalate and polybutylene terephthalate. It is a synthetic, non-resorbable, monofilament suture material. Polybutester is stronger than other monofilaments. Suture memory is poor and packaging does not retain its shape. Therefore, this suture is easier to work with and the knot security is higher. Polybutester suture adapts better to tensile strength than other synthetic sutures. This suture adapts to the increasing wound edema and returns to its original shape when the edema subsides. Also, this suture reduces the risk of hypertrophic scar formation due to its ability to adapt to the edema and changing configuration of a healing wound. It produces better cosmetic results.
62341850|NCT05679973|ACTIVE_COMPARATOR|Polypropylene|Polypropylene, used as suture material, is formed by bringing isotactic stereoisomers of a linear hydrocarbon crystalline polymer into sterile monofilament form. Polymer polypropylene is a non-resorbable, synthetic, monofilament suture. It has high compressive strength and low tissue reactivity. It is resistant to infection formation. In general, the ability to close and protect the wound is good. The suture memory is high, therefore it is difficult to use and the knot security is less than other sutures. Allergic reaction due to polypropylene sutures is very rare.
62341851|NCT04964492||responders to treatment|A patient will be defined as a responder to hydroxocobolamin infusion if there is an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
62341852|NCT04964492||non-responders to treatment|A patient will be defined as a non-responder to hydroxocobolamin infusion if there is not an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
62341853|NCT04793386|EXPERIMENTAL|Carotid ultrasound|When stopping chest compressions to check manual palpation every 2 minutes, an ultrasound scan of the carotid artery is performed. Whether or not return of spontaneous circulation is determined based on the compressibility and pulsatility of the carotid artery, and the time taken from the start of the ultrasound scan to the determination is recorded.
62341854|NCT04214730|EXPERIMENTAL|Combination of NK with chemotherapy group|Patients will receive NK treatments combined with Chemotherapy.
62699249|NCT05086380|EXPERIMENTAL|FND Patients Experimental|Group of patients with functional neurological disorders
62699250|NCT05086380|ACTIVE_COMPARATOR|Organic controls|Group of patients with organic neurological disorders
62699251|NCT05086380|ACTIVE_COMPARATOR|Healthy controls|Group of healthy controls
62341855|NCT04214730|ACTIVE_COMPARATOR|Chemotherapy group|Patients will only receive Chemotherapy.
62499170|NCT03346850|ACTIVE_COMPARATOR|nasogastric tube (NGT) feeding|
62699252|NCT05086380|ACTIVE_COMPARATOR|FND Patients Comparator|Group of patients with functional neurological disorders
62699253|NCT05129306||Patients|Patients with moderate to severe Allergic Rhinitis who have been prescribed RYALTRIS® nasal spray by their healthcare professional. Observational.
62699254|NCT05944692||Pediatric patients|pediatric patients with epilepsy
62699255|NCT05944692||Adult patients|Adult patients with epilepsy
62699256|NCT04129398|EXPERIMENTAL|Letermovir|Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 28 weeks, beginning up to 7 days post-transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A (CsA) and 480 mg once daily for participants not receiving CsA. IV infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
62699257|NCT01596270|EXPERIMENTAL|Once daily dosing|escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose
62699258|NCT01596270|EXPERIMENTAL|Twice daily dosing|escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose
62499171|NCT03346850|ACTIVE_COMPARATOR|nasoduodenal tube (NDT) feeding|
62699259|NCT00679614|EXPERIMENTAL|1|Group A oral tramacet 2 tablets preoperatively, 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. Naloxone infusion starting preop at 0.25ug/kg/hr and continuing during hospital stay (an equivalent of 400ug over 24 hours in a 70 kg man). The infusion will be discontinued 1 hour before patient discharge.
61950201|NCT04710394|EXPERIMENTAL|Bimodal Visual, Olfactory Training with Conventional Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
62341856|NCT06320938|ACTIVE_COMPARATOR|Neuroscience-Based Pain Education Combined with Home Exercise Program|Patients in this group will receive Neuroscience-Based Pain Education (NPE) treatment in addition to the home exercise program. Training sessions are planned once a week for an average of 35-45 minutes and 8 sessions. NPE will be performed by a physiotherapist who has an internationally recognized certificate in this regard. Training sessions will be organized as one-on-one conversation sessions focusing on the neurophysiology of pain, and patients will be reinforced through PowerPoint presentations and visual pictures, templates, and metaphors.
62499172|NCT05722249|EXPERIMENTAL|Arm A, Study Period 1 (Mindfulness and Sleep Hygiene):|"Immediately after the sleep hygiene content, the overview of the mindfulness intervention will be offered. All enrolled participants in Arm A, Study Period 1, will attend a 15 minute in-person Introduction to Mindfulness session after randomization."
62499173|NCT05722249|ACTIVE_COMPARATOR|Arm B, Study Period 1 (Physical Activity and Sleep Hygiene):|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods.
62499174|NCT06365320|EXPERIMENTAL|Pre-test and post-test measurements|Before and after a single collective training on the court. Collection of capillary blood and saliva samples; Completion of lifestyle questionnaires and sociodemographic and clinical factors; Anthropometric measurements.
62341857|NCT06320938|ACTIVE_COMPARATOR|Myofascial Induction Techniques Combined with Home Exercise Program|In addition to the home exercise program, Myofascial Induction Techniques (MIT) group patients will have MIT applied to the cervical and upper thoracic regions by a physiotherapist trained and experienced in myofascial treatments. The application will be once a week for 8 weeks, with an average duration of 35-45 minutes.
62341858|NCT06320938|ACTIVE_COMPARATOR|Home Exercise Program|Patients in this group will be taught an exercise program after undergoing general training. Exercises will include stretching and strengthening exercises for neck muscles and posture exercises. Patients are asked to take 35-45 minutes once a day, five days a week, for 8 weeks. They will be asked to do the given home exercises and fill out follow-up charts. The continuity of the exercises will be ensured by sending reminder messages to this group of patients once a week by the physiotherapist about doing their exercises.
62499175|NCT00223938|ACTIVE_COMPARATOR|1|Oral Iron
62499176|NCT00223938|EXPERIMENTAL|2|sodium ferric gluconate
61950202|NCT04710394|EXPERIMENTAL|Bimodal Visual, Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
61950203|NCT03221283|NO_INTERVENTION|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center.
62140807|NCT03835559|ACTIVE_COMPARATOR|Surgical stripping|For treatment of incompetent Saphenous Veins, surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries under all types of anesthesia (general, spinal, regional block, or local anesthesia). The saphenous vein is then removed using a stripper. Compression stocking is apply.
61950204|NCT03221283|EXPERIMENTAL|Music therapy group|Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
61950205|NCT00726375|EXPERIMENTAL|Etanercept|a maximum of 8 SQ doses of 'Etanercept (Enbrel) at 0.4mg/kg per dose up to a maximum of 25 mg per dose
61950206|NCT04105270|EXPERIMENTAL|Arm A (RMT)|
61950207|NCT04105270|EXPERIMENTAL|Arm B (Placebo)|
62341859|NCT05464862|EXPERIMENTAL|Group A|Popliteal Plexus Block given with 10 ml of Lidocaine Hydrochloride 10 mg/ml
62341860|NCT05464862|EXPERIMENTAL|Groups B|Popliteal Plexus Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
62341861|NCT05464862|EXPERIMENTAL|Group C|Popliteal Plexus Block given with 30 ml of Lidocaine Hydrochloride 10 mg/ml
62499177|NCT00223938|EXPERIMENTAL|3|sodium ferric gluconate
62499178|NCT02643927|EXPERIMENTAL|standard 8-weeks MBSR|8-week program
62499179|NCT02643927|EXPERIMENTAL|4-week shortened MBSR|Short 4 sessions intervention
62499180|NCT02643927|NO_INTERVENTION|Control Group|control group: No intervention
62499181|NCT01588548|ACTIVE_COMPARATOR|AZD1208|
62499182|NCT02864550|EXPERIMENTAL|Doxycycline arm|Participants in this intervention group will receive doxycycline 100mg orally daily, which is available as a 100mg capsule. This single daily dose was chosen to maximize adherence, given the common use of once-daily Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP), as well as its efficacy as once-daily prophylaxis against malaria and its utility as dosing as infrequent as once weekly for another spirochete infection, leptospirosis.
61950208|NCT04105270|EXPERIMENTAL|Safety Run-in|10 patients are enrolled in this safety run-in arm. Patients are directly assigned to RMT treatment arm. After safety- run-in period of 4 weeks after the first dose of RMT, in the 10 patients if no new safety signal are seen enrollment moves to randomization
62499183|NCT02864550|PLACEBO_COMPARATOR|Placebo arm|Participants in this control group will receive a placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group.
62499184|NCT04320576|EXPERIMENTAL|Bulk-fill resin composite|Bulk-fill resin composite will be places with bulk technique.
62499185|NCT04320576|ACTIVE_COMPARATOR|Nano-fill resin composite|Nano-fill resin composite will be placed with 2 mm thickness layering technique.
62499186|NCT00939523|EXPERIMENTAL|Lapatinib|All participants will be asked to take Lapatinib daily for a total of six months during the research study.
62499187|NCT06678477|EXPERIMENTAL|3D colonoscopy|Use 3D machine to generate the 3D image
62499188|NCT06678477|NO_INTERVENTION|2D colonoscopy|Traditional colonoscopy
62499189|NCT06616389|OTHER|Ascending dose|"Each subject will receive ODX treatment at 2-week intervals up to a maximum of 7 doses or until disease progression or unacceptable toxicity. The trial will consist of the following periods:~Screening period (V0) Treatment period (V1 to V9, which includes 2 telephone contacts) Follow-up period (V10)~The dose cohorts will be studied sequentially as follows:~Dose cohort 1: 3.0 mg/kg ODX Dose cohort 2: 6.0 mg/kg ODX Dose cohort 3: 9.0 mg/kg ODX~A dose escalation meeting will be called when data are available for Visit 4 of the 4th subject in a cohort. Based on the review of the safety data, the DMC will give recommendations regarding assessment of DLTs and dose escalation."
62499190|NCT01471951|EXPERIMENTAL|single embryo transfer|
62499191|NCT03660852||Before dedicated MRI|
62499192|NCT03660852||After dedicated MRI|
62499193|NCT03676790|EXPERIMENTAL|Group I|(in the first month, continuous ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
62140808|NCT02824198|EXPERIMENTAL|CYD Dengue Vaccine booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD63).
62341862|NCT05464862|ACTIVE_COMPARATOR|Group FNB|Femoral Nerve Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
62341863|NCT05464862|ACTIVE_COMPARATOR|Groups SNB|Sciatic Nerve Block given with 20 ml og Lidocaine Hydrochloride 10 mg/ml
62341864|NCT05798689|ACTIVE_COMPARATOR|PR|Fifty healthy volunteers were randomly allocated in the probiotic arm. To eliminate residual traces of gluten and similar proteins from the faecal material, both groups underwent a gluten-free diet (GFD) from day-1 to day-10. After 10 days, gluten administration started. The increasing administration plan was as follows: 50 mg/day for 4 days; 1 g/day for subsequent 4 days; 3 g/day for subsequent 4 days; and 10 g/day (in this case, reintroducing an equivalent amount of wheat-based bread - 4 slices) for subsequent 20 days. At this stage (10 + 4 + 4 + 4 + 10 days = total of 32 days), the administration of the probiotic preparation was interrupted, with a period of 10 days of wash-out.
62341865|NCT05798689|PLACEBO_COMPARATOR|PL|Twenty healthy volunteers were randomly allocated in the placebo.To eliminate residual traces of gluten and similar proteins from the faecal material, both groups underwent a gluten-free diet (GFD) from day-1 to day-10. After 10 days, gluten administration started. The increasing administration plan was as follows: 50 mg/day for 4 days; 1 g/day for subsequent 4 days; 3 g/day for subsequent 4 days; and 10 g/day (in this case, reintroducing an equivalent amount of wheat-based bread - 4 slices) for subsequent 20 days. At this stage (10 + 4 + 4 + 4 + 10 days = total of 32 days), the administration of placebo preparation was interrupted, with a period of 10 days of wash-out.
62341866|NCT05851586|EXPERIMENTAL|Supervised exercise + home exercise program|The intervention group (supervised exercise) which will receive supervised strengthening and stretching exercises by a licensed physical therapist in a group setting 2 times per month for 30 minutes each session as well as a home exercise program with general stretching and strengthening exercises for various body parts (focusing on neck, thoracic spine, lumbar spine, shoulder and hand/wrist) that will be identical to the home exercise program only group.
62341867|NCT05851586|ACTIVE_COMPARATOR|Home exercise program only|The home exercise program only group will be provided with a written home exercise program consisting of general stretching and strengthening exercises for various body parts (focusing on neck, thoracic spine, lumbar spine, shoulder and hand/wrist). The exercise programs will be identical for both the supervised exericse and the home exercise program only groups.
62341868|NCT04237402|OTHER|Intra individual|Before and after pregnancy, hair follicles will be analysed
62499194|NCT03676790|EXPERIMENTAL|Group II|(in the first month, pulsed ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
62140809|NCT02824198|PLACEBO_COMPARATOR|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received an injection of a placebo at Day 0 in this study (CYD63).
62341869|NCT02752568|ACTIVE_COMPARATOR|Endometrial scratch group|endometrial scratch controlled ovarian hyperstimulation
62341870|NCT02752568|ACTIVE_COMPARATOR|Assisted hatching group|assisted hatching controlled ovarian hyperstimulation
61950209|NCT04061265|ACTIVE_COMPARATOR|Lidocaine 2% group|lidocaine hydrochloride 2% and epinephrine 1:100000 (Lignospan® standard, 1.7ml, SEPTODONT Ltd)
61950210|NCT04061265|EXPERIMENTAL|Articaine 4%|articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)
62341871|NCT02752568|SHAM_COMPARATOR|ovarian stimulation only group|controlled ovarian hyperstimulation
62341872|NCT03408548|PLACEBO_COMPARATOR|Placebo|Scaling root planning + two lozenge per day not containing Bifidobacterium animalis lactis HN019 for 30 days.
62341873|NCT03408548|EXPERIMENTAL|Probiotic|Scaling root planning + two lozenge per day containing Bifidobacterium animalis lactis HN019 (10x9 colony-forming units) for 30 days.
62341874|NCT02763293|EXPERIMENTAL|Manual Therapy|Cranial therapy (CT). Neuro-lymphatic reflexes treatment (NL) Viscerosomatic reflexes (VR) Induction myofascial Visceral osteopathic therapy (VOT)
62499195|NCT03676790|EXPERIMENTAL|Group III|(in the first month, the continuous ultrasound was applied three times a week and in the second month, three times a week, the continuous ultrasound associated with exercises was applied)
62499196|NCT03676790|EXPERIMENTAL|Group IV|(in the first month, the pulsed ultrasound was applied three times a week and in the second month, three times a week, the pulsed ultrasound associated with exercises was applied)
61950211|NCT05840640|ACTIVE_COMPARATOR|Standard Medical therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
61950212|NCT05840640|EXPERIMENTAL|G-CSF|Standard Medical Therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
61950213|NCT05840640|EXPERIMENTAL|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
62699260|NCT00679614|ACTIVE_COMPARATOR|2|Group B will receive oral tramacet 2 tablets preoperatively and then 2 tablets every 6 hours for five days. ( or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). This group will also receive saline infusion at 4-6mls / hour for the duration of the hospital stay.
62341875|NCT02763293|NO_INTERVENTION|Control Group|Patients only came to make assessments, without receiving any treatment.
62499197|NCT03676790|EXPERIMENTAL|Group V|(patients received only exercise sessions three times a week for eight weeks)
62499198|NCT06290765|EXPERIMENTAL|Ropeginterferon alfa-2b group|Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), target optimal dose of 500 µg.
62499199|NCT06290765|OTHER|Control group|Patients will continuously receive the same therapy as s/he received for PV indication prior to screening.
62699261|NCT00679614|ACTIVE_COMPARATOR|3|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay.
62699262|NCT02144532|EXPERIMENTAL|Patients with EDS hypermobility type|Patients with EDS hypermobility type wearing compression garment then compression garment removal
61950214|NCT01686061||Blepharospasm Survey Group|
62140810|NCT04502381|EXPERIMENTAL|Intervention arm|The study participants in the intervention arm will receive nebulization with amphotericin B deoxycholate (10 mg twice a day every alternate day, as described below) along with intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
62140811|NCT04502381|ACTIVE_COMPARATOR|Conventional arm|Participants will receive treatment with only intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
62341876|NCT02499341|ACTIVE_COMPARATOR|Tramadol|Intraoperative administration of a bolus dose of tramadol and continuous intravenous infusion of tramadol for up to 48 h postoperatively.
62341877|NCT02499341|ACTIVE_COMPARATOR|Ketamine|Intraoperative administration of a bolus dose of ketamine and continuous intravenous infusion of ketamine for up to 48 h postoperatively.
62341878|NCT02909569|EXPERIMENTAL|INCB039110|INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
62341879|NCT04223700|EXPERIMENTAL|Group 1|Ultrasound scanning of the rhomboid muscle
61950215|NCT01095211|ACTIVE_COMPARATOR|B-Vitamins|folic acid, cobalamin, vitamin B6
61950216|NCT01095211|PLACEBO_COMPARATOR|placebo|none of the vitamins (99.5% mannitol)
61950217|NCT03805269|EXPERIMENTAL|TAP block|USG guided TAP block
62341880|NCT04045717|EXPERIMENTAL|Hypo-FLAME 2.0|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
62341881|NCT03447613||elderly participants with surgery|The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.
61950218|NCT03805269|ACTIVE_COMPARATOR|wound infiltration|local anesthetics infiltration at surgical incision site
61950219|NCT01543958|EXPERIMENTAL|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
61950220|NCT02244112|EXPERIMENTAL|Part I: Food Effect/QTc|"Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:~* Diet A: Fasted conditions~* Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat~* Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat"
61950221|NCT02244112|EXPERIMENTAL|Part II: Drug-Drug Interaction (DDI)|"* Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4~* Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2"
62140812|NCT04939909|OTHER|Patients treated with Botulinum toxin type A|Patients were treated with Botulinum toxin type A
62140813|NCT04633148|EXPERIMENTAL|UniCAR02-T-pPSMA|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the peptide TMpPSMA.
62341882|NCT03334864||I Retrospective cohort|Diagnosis of advanced non-small cell lung cancer from 2012-2016
62341883|NCT03334864||II Prospective cohort|Advanced non-small cell lung cancer with driver gene mutations
62341884|NCT03334864||III Prospective cohort|Non-small cell lung cancer in immuno-therapy;
62341885|NCT03334864||IV Prospective cohort|Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
62341886|NCT03334864||V Prospective cohort|Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
62341887|NCT00903747|EXPERIMENTAL|1|Prucalopride
62499200|NCT02414763|NO_INTERVENTION|Care as Usual|Participants will receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
62699263|NCT04258748|EXPERIMENTAL|Motivational Interviewing (MI)|
62699264|NCT04258748|EXPERIMENTAL|Gaming and MI|
62699265|NCT04258748|ACTIVE_COMPARATOR|Conventional dental health education|
62699266|NCT03410160||High frequency of adrenal crisis|Patients with a high frequency of adrenal crisis in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
62499201|NCT02414763|EXPERIMENTAL|Teachable Moment Brief Intervention|The brief intervention consists of engaging the patient in conversation regarding suicidal ambivalence (desire to live vs. desire to die), collaborative discovery of primary and secondary drivers of suicidality, functional analysis of the suicidal ideation and behaviors, and crisis response planning. Participants will also receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
62499202|NCT04083443||Patients with blood stream infections|Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment. There will be an additional blood sampling for these patients, which is the only intervention in the study.
62499203|NCT03303417|EXPERIMENTAL|Kiwifruit|Participants asked to consume 2 kiwifruit twice a day for 3 days before undergoing MRI Scan
62499204|NCT03303417|PLACEBO_COMPARATOR|Control|Participants asked to consume a calorie-matched sugar drink twice a day for 3 days before undergoing MRI Scan
62499205|NCT04323722|EXPERIMENTAL|Empty bladder|Planning CT scan and CBCTs with empty bladder after standard Planning CT scan and CBCTs with filling bladder
62140814|NCT04693741|OTHER|"Autogenous iliac bone graft group A"|The autogenous iliac bone graft will be used to fill the alveolar defect.
62499206|NCT04566549|PLACEBO_COMPARATOR|Placebo group|Shampoo base without probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance.
62699267|NCT03410160||Low frequency of adrenal crisis|Patients with no adrenal crisis or a low frequency of AC in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
62341888|NCT00903747|PLACEBO_COMPARATOR|2|Placebo/moxifloxacin
62341889|NCT04809389|EXPERIMENTAL|Test Product|DelNS1-nCoV-RBD LAIV at 1×107 EID50 and 1×107.7 EID50, 2 doses 4 weeks apart, intranasal administration
62699268|NCT03135860|EXPERIMENTAL|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
62140815|NCT04693741|OTHER|"Xenograft with PRF group B"|Xenograft with PRF will be used to fill the alveolar defect.
62140816|NCT03781349|ACTIVE_COMPARATOR|MENS|MENS are applied through placement of six electrodes (size of 4x4cm), of which four were placed exactly like the TENS electrodes and the other two, one in the palm and the other at the height of the asteroid ganglion. Duration of the intervention was 24 min for a total of 15 sessions. The frequency was 50 Hz and the intensity was 100 μA.
62140817|NCT03781349|ACTIVE_COMPARATOR|TENS|TENS are applied through the placement of four electrodes on either side of the deltoid muscle, on the front and back surfaces of the shoulder joint for 20 min and each patient received 15 sessions (five per week). A constant current of high frequency was used (100 HZ) and its intensity was initiated at 10mA and was then gradually increased to 15mA
62140818|NCT05657821|EXPERIMENTAL|pumpkin seed extract capsules|. In the intervention group, pregnant women received pumpkin seed extract capsules for 12 weeks
62140819|NCT05657821|PLACEBO_COMPARATOR|Iron tablets|the control group received iron tablets for 12 weeks
62140820|NCT02404441|OTHER|patients with solid tumors|Phase I Dose escalation cohorts
62140821|NCT02404441|OTHER|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
62341890|NCT04809389|PLACEBO_COMPARATOR|Reference Product|Matching placebo, 2 doses 4 weeks apart, intranasal administration
62341891|NCT04069741|OTHER|Usual care, no depression|Participants without symptoms of depression who have the opportunity to use a Decision Aid but otherwise receive Usual care
62341892|NCT04069741|OTHER|Usual care, depression|Participants with symptoms of depression who are randomized to receive Usual care (in addition to the Decision Aid)
62341893|NCT04069741|ACTIVE_COMPARATOR|Toolkit, depression|Participants with symptoms of depression who are randomized to receive the Toolkit intervention in addition to Usual care
62341894|NCT04212286|EXPERIMENTAL|Diagnostic CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions with Diameters ≤ 2cm will receive CEUS and EOB-MRI examinations.
62341895|NCT00650091|ACTIVE_COMPARATOR|1|Participants will receive N-acetylcysteine (NAC) for 60 weeks.
62341896|NCT00650091|PLACEBO_COMPARATOR|2|Participants will receive placebo for 60 weeks.
62699269|NCT04365855|OTHER|Subjects at risk for NAFLD|Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.
62699270|NCT06518928||AI Asssited Sperm Selection|SiD software to select sperm for ICSI
62699271|NCT06518928||Manual Sperm Selection|Human visualization of sperm for ICSI selection
62699272|NCT04026802|EXPERIMENTAL|In--Bed Resistance Training Device|The present invention provides full body resistance training devices that attach to a planar edge, such as a footboard, headboard, or sideboard of a bed. The devices employ resistance bands for resistance training in both the incursion (force applying) and excursion (force releasing) phase of exercise.
62699273|NCT04026802|ACTIVE_COMPARATOR|Standard of Care|No resistance training device
62699274|NCT05993884|EXPERIMENTAL|Treatment (clinical standard treatment, iEPCs)|Patients receive clinical standard treatment and iEPCs IV with a single dose
62699275|NCT05993884|PLACEBO_COMPARATOR|Placebo (clinical standard treatment, Placebo)|Patients receive clinical standard treatment and placebo IV 150 mL with a single dose
62699276|NCT00209131|EXPERIMENTAL|Flomax|Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
62341897|NCT05836519||Individuals with a pes planus|Navicular drop test, International Physical Activity Questionnaire (IPAQ), Digital dynamometer measurement, SF-36 quality of life Questionnaire, 6 Minutes Walk test, Foot Function Index, borg value, heart rate, blood pressure, oxyhemoglobin values will be measured for individuals with pes planus.
62341898|NCT05836519||Individuals Without Giving Up Planus|Navicular drop test, International Physical Activity Questionnaire (IPAQ), Digital dynamometer measurement, SF-36 quality of life Questionnaire, 6 Minutes Walk test, Foot Function Index, borg value, heart rate, blood pressure, oxyhemoglobin values will be measured for individuals with pes planus.
62341899|NCT03810209|ACTIVE_COMPARATOR|magnesium sulphate group|The investigator injected 28.5 mL of bupivacaine 0.5% and 1.5 ml MgSo4 (150 mg), a total volume of 30 ml, it was confirmed visually by the ultrasound.
62499207|NCT04566549|ACTIVE_COMPARATOR|Test group|Shampoo base with probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance、Heat-killed Lactobacillus paracasei powders (5x10\^8 cells/ g-shampoo).
62499208|NCT01917084|EXPERIMENTAL|Passive range of motion (ROM) exercise|A 10 - 15 minute passive range of motion (ROM) exercise program will be administered daily during hospitalization for up to 21 days or until discharge (whichever comes first).
61950222|NCT02244112|EXPERIMENTAL|Extension|After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.
61950223|NCT05562414|EXPERIMENTAL|High-intensity Interval Training (HIIT)|Participants will complete one heart-rate-controlled HIIT bout within their 3-week inpatient stay.
61950224|NCT05562414|ACTIVE_COMPARATOR|Moderate Continuous Training (MCT)|MCT represents the standard treatment at Valens rehabilitation clinic. Participants will complete one heart-rate-controlled MCT bout within their 3-week inpatient stay.
62140822|NCT01837602|EXPERIMENTAL|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
62140823|NCT03042741|EXPERIMENTAL|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
62140824|NCT03042741|PLACEBO_COMPARATOR|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
62341900|NCT03810209|PLACEBO_COMPARATOR|control group|The investigator injected 28.5 mL of Bupivacaine 0.5% and 1.5 mL of normal saline, a total volume of 30 ml, it was confirmed visually by the ultrasound.
62341901|NCT02556593|EXPERIMENTAL|IMRT & erlotinib|Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
62699277|NCT00209131|PLACEBO_COMPARATOR|Sugar pill|Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.
62699278|NCT06220084|EXPERIMENTAL|Live DfPD®|Eight weeks intervention of two 60min live dance classes per week plus their usual care
62699279|NCT06220084|EXPERIMENTAL|Remote DfPD®|Eight weeks intervention of two 60min online-via zoom platform dance classes per week plus their usual care
62699280|NCT06220084|NO_INTERVENTION|Control|Non-interventional group in which participants receive their usual care only
62699281|NCT06387953|ACTIVE_COMPARATOR|Bridge Therapy|Subjects receive the Bridge therapy
62341902|NCT02556593|ACTIVE_COMPARATOR|whole-brain radiotherapy|Patients in this group receive WBRT at 30Gy in 10 fractions
62341903|NCT02853006|OTHER|Group 1 lung cancer in stage 1-2|Group 1 : patient with lung cancer in stage 1-2, lung cancer of all histology kind eligible for surgery
62699282|NCT06387953|PLACEBO_COMPARATOR|Placebo|Subjects receive a placebo or sham therapy
62699283|NCT05147142|EXPERIMENTAL|Target Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the target region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
62699284|NCT05147142|ACTIVE_COMPARATOR|Control Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the control region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
61950225|NCT00628485|EXPERIMENTAL|Low Stimulation|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation."
62699285|NCT06447103|EXPERIMENTAL|Diagnostic (89Zr-DFO-GmAb PET/CT)|Patients receive 89Zr-DFO-GmAb IV over 3 minutes on day 0 then undergo whole body PET/CT and SOC diagnostic contrast-enhanced CT scan on day 7. Patients also blood sample collection on study. In addition, patients may undergo bone scan and CT or MRI of the brain on study as clinically indicated.
61950226|NCT00628485|EXPERIMENTAL|High Stimulation|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions."
61950227|NCT00628485|PLACEBO_COMPARATOR|Control Group|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises.
62140825|NCT02660294|EXPERIMENTAL|Platlet rich plasma|For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity
62341904|NCT02853006|OTHER|Group 2 lung cancer in stage 3-4|Group 2 : patient with lung cancer in stage 3-4 (no adenocarcinoma or squamous) receiving classical or targeted chemotherapy on genetic anomalies.
62341905|NCT02853006|OTHER|Group 3 : control patients|Group 3 control patients : carriers of non-cancerous radiological anomalies : benign nodules, cicatricial lesions, infectious or inflammatory, paired with the two other groups by age, sex or tobacco.
62341906|NCT04903964|EXPERIMENTAL|oral nutrition only group that received nutrition education|This group consists of children who are fed orally according to their chronological age. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the hospitalized child after the operation will be determined and the measurements will be checked.
62499209|NCT02109835||Asymptomatic type 2 diabetes|Patients without previous history of coronary artery disease
62499210|NCT01480895|NO_INTERVENTION|Post GDM follow-up group.|
62499211|NCT01480895|EXPERIMENTAL|lifestyle intervention group.|The women in this group had participated in lifestyle intervention by diet instructions and physical exercise program.
62499212|NCT03414034|EXPERIMENTAL|Arm A: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m\^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone. This arm was discontinued.
62499213|NCT03414034|EXPERIMENTAL|Arm B: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m\^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
62499214|NCT03414034|EXPERIMENTAL|Arm C: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m\^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
62699286|NCT06477770|EXPERIMENTAL|Intervention|The surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap, then 75 g of sucrose will be administered to the surgical wound at 8:00 am every day, once a day, and then it will be covered with sterile gauze.
62699287|NCT06477770|SHAM_COMPARATOR|Control|The surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap, once a day, and then covered with sterile gauze.
61950228|NCT00334321|EXPERIMENTAL|IMRT with chemotherapy|"IMRT (upper third of vagina \& para-vaginal tissue and the common, external and internal iliac nodal regions) 160-180 cGy daily fractions for a total dose of 4500-5120 cGy. Once a day treatment four to five days a week for approximately 6 weeks.~Intracavitary vaginal brachytherapy - some patients will be given this and it will be decided by the treating physician.~Carboplatin - AUC 6, IV over 30-60 minutes following completion of paclitaxel, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles~Paclitaxel - 175 mg/m2, 3 hour continuous IV infusion, administered prior to carboplatin, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles"
61950229|NCT02675985|EXPERIMENTAL|Intervention arm|Early intensive physical therapy will be the intervention arm. There is not a control group.
62341907|NCT04903964|EXPERIMENTAL|group that received nutrition education and fed with nutritional support|This group consists of children who receive nutritional support provided by oral food supplements, oral food supplements, enteral tube feeding and / or parenteral nutrition. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the child hospitalized after the operation will be determined and the measurements will be checked.
62341908|NCT04903964|NO_INTERVENTION|control group|While collecting research data on the specified dates; Comparison group (KG) will be selected as many as the number of volunteers who want to participate in the research. No nutritional attempt will be made to the child included in this group. The parameters used in the evaluation of growth (height, head and chest circumference measurement) and the Ankara Development Screening Inventory (AGTE) will be applied to children aged 0-3 who are followed up due to congenital heart disease.
62499215|NCT02971813|EXPERIMENTAL|Facebook group|The Facebook group will receive peer support, education and provider support via social media.
62499216|NCT02971813|ACTIVE_COMPARATOR|Comparison group|The comparison group will receive the same educational materials as the Facebook™ group but will receive it in handout form, or via email if the patient misses cardiac rehabilitation on a particular week.
62699288|NCT00642044|EXPERIMENTAL|A|The eye with the worst visual acuity receives the treatment. (the other eye serve as control).
62699289|NCT00642044|NO_INTERVENTION|B|The eye with the best visual acuity do not receive the treatment.
61950230|NCT05622331||RSV cohort|Children (\<5 years of age at diagnosis) with a diagnosis of RSV (ICD-10 code) in hospital care between July 1st 2006 and June 30th 2021
62499217|NCT03825744|EXPERIMENTAL|Hetrombopag Olamine+Standard Therapy|
62499218|NCT03825744|PLACEBO_COMPARATOR|Placebo+Standard Therapy|
62499219|NCT03837171|ACTIVE_COMPARATOR|Liberal strategy|Maintain a hemoglobin level \> 9 g/dL during the first 48 hours of resuscitation of septic shock
62499220|NCT03837171|EXPERIMENTAL|Restrictive strategy|Maintain a hemoglobin level \> 7 g/dL during the resuscitation of septic shock
62499221|NCT05965986|NO_INTERVENTION|Standard of Care Group|A group consisting of the current standard of care at HULC, which is a WebEx pre-operative education class lead by a physiotherapist and occupational therapist.
62499222|NCT05965986|EXPERIMENTAL|Online only|a group consisting of an online pre-rehabilitation program 6 weeks before surgery
62499223|NCT05965986|EXPERIMENTAL|Online and PT|a group consisting of an online pre-rehabilitation program 6 weeks before surgery + therapist
62499224|NCT05397301|ACTIVE_COMPARATOR|sedoanalgesia(SA group)|Sedoanalgesia was applied to the SA group
62699290|NCT00912886||1: Case|Patients with early and moderate AD
62699291|NCT00912886||2: Controls|AD free volunteer-controls matched for gender and age
62699292|NCT06135090|EXPERIMENTAL|Trauma Recovery Program (official title TBD)|The trauma recovery program (TRP) is a seven-session, peer-led, group program for family members/significant others of people with borderline personality disorder (BPD) and emotion dysregulation. It draws on principles of cognitive processing therapy for PTSD and cognitive behavioural conjoint therapy for PTSD to target PTSD symptoms in these individuals that are related to having a loved one with BPD or emotion dysregulation. As a peer-support model, it is not a psychotherapy. The TRP involves learning about common reactions to trauma and learning methods of challenging trauma-related beliefs that inhibit trauma recovery. Group members are asked to practice exercises outside of sessions that focus on challenging beliefs that fall into several key trauma-related themes.
62341909|NCT06191887|EXPERIMENTAL|Treatment (BARRF based chimeric antigen receptor T-cells)|Patients undergo leukapheresis. Patients then receive cyclophosphamide IV, over 60 minutes and fludarabine IV over 30 minutes on day -5 to -3 or bendamustine IV over 10 minutes on days -4 and -3. Patients receive BAFFR based chimeric antigen receptor T-cells IV on day 0. Patients undergo echocardiography and MRI at screening, CT scan, PET scan, bone marrow biopsy/aspirate and blood sample collection throughout the study and tumor biopsy at progression.
62499225|NCT05397301|ACTIVE_COMPARATOR|general anaesthesia (GA group)|General anaesthesia was applied to the GA group
62499226|NCT02033317|EXPERIMENTAL|patiromer|
62499227|NCT02274662|EXPERIMENTAL|Cultured thymus tissue implantation (CTTI)|Cultured thymus tissue for the treatment of immunodeficiency and autoimmune disorders
62499228|NCT04771767|EXPERIMENTAL|Ketamine + eCBT|Over 12 weeks, participants receive weekly sessions of asynchronous online cognitive-behavioural therapy as well as 6 sub-anesthetic infusions of Ketamine
62499229|NCT04771767|NO_INTERVENTION|Control|Participants are in a control condition receiving treatment as usual, during which time they will not receive the experimental treatment and will have no change in their treatment regimen.
62499230|NCT00108550|EXPERIMENTAL|1|Gabapentin 300 mg orally three times daily up to a maximum of 1200 mg orally three times daily for 12 weeks
62499231|NCT00108550|SHAM_COMPARATOR|2|Inert placebo capsules identical in size and shape to the experimental capsules, one to three capsules taken orally three times daily for 12 weeks
62499232|NCT02340624|NO_INTERVENTION|Control group|No intervention(control group)
62499233|NCT02340624|EXPERIMENTAL|condition 2|Intervention:Smokefreemoms texting
62499234|NCT02340624|EXPERIMENTAL|condition 3|Intervention: Quitline referral
62499235|NCT02340624|EXPERIMENTAL|condition 4|Intervention:Smokefreemoms texting and quitline referral
62499236|NCT02340624|EXPERIMENTAL|condition 5|Intervention: Brief intervention
62499237|NCT02340624|EXPERIMENTAL|condition 6|Intervention:Smokefreemoms texting and Brief intervention
62699293|NCT05385822|NO_INTERVENTION|Control|The control group will not recieve any training in the trial period but will have to answer the same questionnaires on erectile function (IIEF-EF) and international prostate symptom score (IPSS).
62699294|NCT05385822|EXPERIMENTAL|Pelvic Floor Muscle Training|Participants who are randomized to pelvic floor training will then undergo instruction in the anatomy, function and training of the pelvic floor muscles.
62699295|NCT03999476|EXPERIMENTAL|ambu scope|intubation of cancer tongue patients with ambu scope device
61950231|NCT05622331||Regional primary care RSV cohort|Children (\<5 year of age) with a diagnosis of RSV (ICD-10 code) in primary care identified in regional databases (Region Skåne, Region Halland and VGR) between July 1st 2006 and June 30th 2021
62341910|NCT01714752|EXPERIMENTAL|exercise|Patients perform exercise and pression measure is performed
61950232|NCT05622331||Regional laboratory RSV cohort|Children (\<5 years of age) with a positive laboratory RSV test result (multiplex/rapid PCR, antigen, immunofluorescence or immunochromatography rapid test) in primary or hospital care, identified in regional laboratory databases (Region Skåne and Region Halland) between July 1st 2006 and June 30th 2021
61950233|NCT05622331||Acute Respiratory Infections (ARI) cohort|Children (\<5 of age) with a diagnosis of ARI (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
61950234|NCT05622331||Regional ARI cohort|Children (\<5 years of age) with a diagnosis of RSV (ICD-10 code, see Table 1) in primary care, identified in regional databases (Region Skåne, Region Halland and VGR)
62341911|NCT03220711|EXPERIMENTAL|Subjects with abnormal colon tissue|The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
62341912|NCT03508765|EXPERIMENTAL|rsfMRI + Neurocognitive Tests|Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
61950235|NCT05622331||Rhinovirus cohort|Children (\<5 of age) with a diagnosis of rhinovirus (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
62341913|NCT03338114|EXPERIMENTAL|FLX-787-ODT (orally disintigrating tablet)|FLX-787-ODT (orally disintigrating tablet)
62341914|NCT02439944|EXPERIMENTAL|Experimental Arm|Escalating nicotine patch dose to satiety over 6 weeks with dosage depending on the number of cigarettes smoked per day and the occurrence of adverse effects
61950236|NCT05622331||Human Metapneumovirus (HMPV) cohort|Children (\<5 of age) with a diagnosis of HMPV (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
61950237|NCT05622331||Parainfluenza cohort|Children (\<5 of age) with a diagnosis of parainfluenza (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
61950238|NCT05622331||Parent cohort|Parents to all children will be linked to the study population, which is possible through linkage between children and parents by their personal identifiers
62341915|NCT02439944|ACTIVE_COMPARATOR|Positive Control Arm|Nicotine patch dose of 21mg coupled with nicotine mouthspray which is to be used as needed.
62341916|NCT00854178|EXPERIMENTAL|2|
62499238|NCT02340624|EXPERIMENTAL|condition 7|Intervention: Quitline referral and Brief intervention
62499239|NCT02340624|EXPERIMENTAL|condition 8|Intervention:Smokefreemoms texting, Quitline referral and Brief intervention
62499240|NCT03744286|EXPERIMENTAL|Balance Slip|"* Perform standard clinical balance assessments~* Determine the optimal slip distance by 10 passes each with plank movement of 2, 4, 6 and 8 on visit 1"
62499241|NCT03008538|EXPERIMENTAL|Mineralized Plasmatic Matrix|MPM(Mineralized plasmatic matrix) insertion in extraction sockets for socket preservation for later implant placement and histomorphometric analysis.
62499242|NCT03008538|ACTIVE_COMPARATOR|Autogenous Bone Graft (Gold Standards).|Socket preservation using Autogenous bone graft for later implant placement and histomorphometric analysis.
62699296|NCT03999476|ACTIVE_COMPARATOR|fiberoptic|intubation of cancer tongue patients with fiberoptic device
62699297|NCT00552045||subject|individuals with epilepsy
62699298|NCT00863304|EXPERIMENTAL|1|
62699299|NCT00863304|EXPERIMENTAL|2|
62699300|NCT00863304|ACTIVE_COMPARATOR|3|
62140826|NCT02660294|NO_INTERVENTION|Hormone replacement therapy|Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity
62140827|NCT00463229|EXPERIMENTAL|Interprofessional Team Approach|Participants in the experimental group will receive home care services from a team of professional service providers \[Community Care Access Centre (CCAC) Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist\] and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
62499243|NCT04776304|OTHER|qEEG Art Therapy|Participants will receive art therapy while a noninvasive, mobile qEEG measures brain activity. There is no comparison as this is an exploratory pilot study.
62499244|NCT06398834|EXPERIMENTAL|Group BK|Group BK received esketamine infusion at a rate of 0.3 mg/kg/h during surgery. Patients were provided with patient-controlled intravenous analgesia (PCIA) containing esketamine (1.5 mg/kg), butorphanol (0.15 mg/kg), and azasetron (20 mg) in a total volume of 100 ml within 48 hours after surgery.
62341917|NCT01419704|EXPERIMENTAL|Hemoglobinopathies diagnosed patients|Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
62341918|NCT02612441|EXPERIMENTAL|1 real Acupuncture group-intervention|real Acupuncture Needles
62341919|NCT02612441|SHAM_COMPARATOR|2 sham Acupuncture group|sham Acupuncture Needles
62341920|NCT02395497|EXPERIMENTAL|Treatment: Transplantation|Penile transplantation with an immunomodulatory protocol consisting of monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
62341921|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
62341922|NCT06498752|NO_INTERVENTION|MRD negative|Intervention name: regular review of MRD monitoring; Intervention description: thoracic and abdominal CT, Esophagography and MRD monitoring every 3 months for 2 years after completion of radiotherapy
62341923|NCT06498752|EXPERIMENTAL|MRD positive|Intervention name: PD-1 monoclonal antibody consolidation therapy;
62341924|NCT04550611|EXPERIMENTAL|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|will receive blood group -specific MP-IVIG in a regimen of 2 g/kg bodyweight, usually as 0.4 g/kg bodyweight per day for five consecutive days within two weak of onset of symptoms.
62341925|NCT04550611|EXPERIMENTAL|plasmapheresis|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
62341926|NCT04103398|EXPERIMENTAL|Transarterial chemoembolization combined with sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
62341927|NCT04103398|ACTIVE_COMPARATOR|Transarterial chemoembolization alone|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
62341928|NCT01993862|NO_INTERVENTION|Next Day Discharge|The patient will have a 23 hour standard of care observational stay in the hospital after an implantable cardioverter defibrillator implant procedure.
62499245|NCT06398834|PLACEBO_COMPARATOR|Group B|Group B received an equivalent volume of saline during surgery. Patients were provided with patient-controlled intravenous analgesia (PCIA) containing butorphanol (0.15 mg/kg), and azasetron (20 mg) in a total volume of 100 ml within 48 hours after surgery.
62499246|NCT04933357|EXPERIMENTAL|Dose escalation|
62140828|NCT00463229|NO_INTERVENTION|Usual Home Care Services|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessment and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessment with clients.
62140829|NCT01064999|EXPERIMENTAL|High intensity group|(RT 55Gy + CapOx) + a cycle of Xelox + Surgery
62140830|NCT01064999|ACTIVE_COMPARATOR|Low instensity group|(RT 50Gy + CapOx) + Surgery
62140831|NCT06699108|EXPERIMENTAL|interventional group|
62341929|NCT01993862|ACTIVE_COMPARATOR|Same Day Discharge|The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
62341930|NCT01006863|ACTIVE_COMPARATOR|Ephedrine 0.15 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1.5 mg/kg of ephedrine
62499247|NCT04933357|ACTIVE_COMPARATOR|Standard dose|
62140832|NCT06699108|NO_INTERVENTION|Control group|
62140833|NCT00418652|NO_INTERVENTION|No TMS stimulation|The patients performed 2 tasks: a study and a control assignments with no TMS stimulation.
62499248|NCT05482425|OTHER|Autologous facial fat graft injection- washed fat|Washed fat injected into both the left and right sides of the face.
62499249|NCT05482425|OTHER|Autologous facial fat graft injection-unwashed fat|Unwashed fat injected into both the left and right sides of the face.
62499250|NCT00052520|EXPERIMENTAL|Treatment|See Detailed Description
62499251|NCT00057967|EXPERIMENTAL|Treatment arm|alemtuzumab
62699301|NCT00863304|PLACEBO_COMPARATOR|4|
62699302|NCT05356715|EXPERIMENTAL|Group A|● Group A (n=110): will receive Ultrasound guided bilateral ESBP.
62699303|NCT05356715|ACTIVE_COMPARATOR|Group B|● Group B (n=110): will receive fentanyl IV infusion 2mic/kg/hr
61950239|NCT05622331||Non-RSV control cohort|A non-RSV control population consisting of children (\<5 years of age) will be extracted to estimate the burden compared to the general population
61950240|NCT02678975|ACTIVE_COMPARATOR|Control|Alkylating chemotherapy
62341931|NCT01006863|ACTIVE_COMPARATOR|Ephedrine 0.1 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1 mg/kg of ephedrine
62341932|NCT01006863|ACTIVE_COMPARATOR|Ephedrine 0.07 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 0.7 mg/kg of ephedrine
62341933|NCT01006863|PLACEBO_COMPARATOR|Placebo|received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
62341934|NCT01006863|ACTIVE_COMPARATOR|Phenylephrine|received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/kg of phenylephrine
62341935|NCT02025491|EXPERIMENTAL|Liposomal Amphotericin|Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.
62341936|NCT04222933|EXPERIMENTAL|Motorized cryotherapy|Application of motorized cryotherapy after ACL reconstruction for 6 postoperative days
62341937|NCT04222933|ACTIVE_COMPARATOR|Classical cryotherapy|Application of ice bags for 6 postoperative days
62341938|NCT05566652|EXPERIMENTAL|NPS|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing Neural Pressure Support Ventilation.
62499252|NCT04318431|OTHER|Data collection and rhinopharyngeal swab|"After information, the collection of consent will be carried out. A clinical information sheet will be completed by the investigator in order to collect socio-demographic data, history, clinical symptoms and signs, and complementary examinations performed.~During the same consultation, a rhinopharyngeal swab will be taken for the detection of SARS -Cov2 and other respiratory pathogens by PCR."
62499253|NCT02135991|EXPERIMENTAL|Project CHOICE + Getting To Outcomes|Boys and Girls Club sites will receive a) training and materials for Project CHOICE and b) training, ongoing technical assistance for two years, and materials for Getting To Outcomes
62499254|NCT02135991|ACTIVE_COMPARATOR|Project CHOICE only|Boys and Girls Club sites will receive a) training and materials for Project CHOICE
62499255|NCT01731236|ACTIVE_COMPARATOR|Carnitine (No antibiotics, No aspirin)|L-Carnitine 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
62499256|NCT01731236|ACTIVE_COMPARATOR|Choline (No Antibiotics, No aspirin)|Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
62699304|NCT06638905|EXPERIMENTAL|Babor Products|Enrolled subjects will all receive Babor Ultimate ECM Repair Serum and Babor Cure Cream to be applied to their entire face.
61950241|NCT02678975|EXPERIMENTAL|Experimental|Alkylating chemotherapy + disulfiram + copper
61950242|NCT01276405||Cohort|
61950243|NCT03824288|ACTIVE_COMPARATOR|The landmark technique|PTA a needle aspiration attempted according to the landmark technique is conducted. If the initial aspiration is unsuccessful, two additional attempts are made in the middle and lower pole of the tonsil.
62341939|NCT05566652|SHAM_COMPARATOR|PSV|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing Pressure Support Ventilation.
62341940|NCT00446485|ACTIVE_COMPARATOR|1|Ginkgo Biloba standardized extract 24/6
62341941|NCT00446485|PLACEBO_COMPARATOR|3|placebo
62341942|NCT03280342|ACTIVE_COMPARATOR|IR-TPM (Topamax)|IR-TPM (Topamax)
62341943|NCT03280342|ACTIVE_COMPARATOR|XR-TPM (Trokendi XR)|
62341944|NCT03201952|ACTIVE_COMPARATOR|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
62341945|NCT03201952|ACTIVE_COMPARATOR|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
62341946|NCT04547894|EXPERIMENTAL|ASC09F|ASC09F one tablet at a time, once per day, up to 7 days.
62341947|NCT02077855||Toddlers fractures|
62341948|NCT01727050|ACTIVE_COMPARATOR|Mechanical stapling|
62341949|NCT01727050|ACTIVE_COMPARATOR|Fibrin sealant spray|
62341950|NCT02176291|EXPERIMENTAL|Buprenorphine|Buprenorphine
62341951|NCT02176291|PLACEBO_COMPARATOR|Placebo|Placebo
62341952|NCT04717193|EXPERIMENTAL|Rectus Sheath Block|Participants randomized to the experimental arm will receive a bilateral rectus sheath block which is additional to the standard of care (infiltration of 5mg (2mL) 0.25% bupivacaine with epinephrine around port site incisions). For rectus sheath block, use the formula Volume (ml) = 2mg/kg x weight (kg) divided by 2.5mg/ml - 6ml to a maximum of 14ml. Maximum total dose is 2mg/kg. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
62341953|NCT04717193|ACTIVE_COMPARATOR|Local Anesthetic|Participants in the control arm will receive the standard care which is infiltration of 5mg (2mL) of 0.25% bupivacaine with epinephrine around port site incisions. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
62341954|NCT02683694|OTHER|study arm|iOCT is performed
62341955|NCT03766724|EXPERIMENTAL|Group A|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
62341956|NCT03766724|EXPERIMENTAL|Group B|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
62341957|NCT03766724|EXPERIMENTAL|Group C|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
61950244|NCT03824288|EXPERIMENTAL|Ultrasound-guided aspiration|An intraoral ultrasound is conducted with a Burr-Hole N11C5s transducer (BK Ultrasound) and if an abscess cavity is suspected, an ultrasound-guided aspiration is performed with an in-plane needle guide attached to guide the needle.
61950245|NCT02202187|EXPERIMENTAL|GSK2140944|Dose range 100mg to 3000mg single dose
61950246|NCT02202187|PLACEBO_COMPARATOR|Matching Placebo|Placebo
61950247|NCT00034541|EXPERIMENTAL|1|An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
62499257|NCT01731236|ACTIVE_COMPARATOR|Antibiotics|"Antibiotics (Ciprofloxacin, Vancomycin, Metronidazole and Neomycin) Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)~Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)~Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)~Drug: Neomycin 1 gram, po, four times daily for 7 days (Other Names: Aminoglycoside)"
61950248|NCT04525846|EXPERIMENTAL|PFMT group|Researcher was trained and test pelvic floor muscle strength by urogynecologist with Brink scores, participants PFMT group were educated by VDO and recieved program of PFMT after consented form 4 weeks reassess Brink score for check compliance of PFMT and followed up by telephone weekly about compliance of PFMT, general symptom, notice self recording book total 12 weeks and evaluate urinary incontinence by UDI-6 questionaires at third trimester
62499258|NCT01731236|ACTIVE_COMPARATOR|Choline and Aspirin|"Choline supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
62499259|NCT01731236|ACTIVE_COMPARATOR|Carnitine and Aspirin|"Carnitine supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Carnitine supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
61950249|NCT04525846|EXPERIMENTAL|non PFMT|Randomized to non PFMT group watchful waiting until 36-38 week gestation follow up and evaluate UI by UDI6 questionaires at third trimester sames as intervention group
61950250|NCT04534582|EXPERIMENTAL|Part I: HLX14 group|Part I: HLX14 are given subcutaneous injection at a single dose of 60 mg.
61950251|NCT04534582|ACTIVE_COMPARATOR|Part I: EU-Prolia® group|Part I: EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
61950252|NCT04534582|EXPERIMENTAL|Part II: HLX14 group|Part II: HLX14 are given subcutaneous injection at a single dose of 60 mg.
61950253|NCT04534582|ACTIVE_COMPARATOR|Part II: EU-Prolia® group|Part II: EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
62341958|NCT03766724|EXPERIMENTAL|Group D|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
62341959|NCT00644254||Resected DPAC|145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.
62499260|NCT05091632||Observational (EEG, questionnaires)|Patients undergo EEG over 30 minutes daily until death or discharge and complete questionnaires over 30 minutes daily until death or discharge to check level of consciousness, thought, and ability to communicate.
62499261|NCT03028155|ACTIVE_COMPARATOR|Oxaliplatin: BSA-based HIPEC|Intervention: oxaliplatin: BSA-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution during 30 minutes. Volume of the carrier solution: depended on the capacity of the abdominal cavity of the patient.
62499262|NCT03028155|ACTIVE_COMPARATOR|Oxaliplatin: Concentration-based HIPEC|Intervention: oxaliplatin: concentration-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution at 2L/m2, which equals a concentration of 230 mg/L during 30 minutes.
62499263|NCT04957615|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61950254|NCT04534582|ACTIVE_COMPARATOR|Part II: US-Prolia® group|Part II: US-Prolia® are given subcutaneous injection at a single dose of 60 mg.
61950255|NCT04534582|ACTIVE_COMPARATOR|Part II: CN-Prolia® group|Part II: CN-Prolia® are given subcutaneous injection at a single dose of 60 mg.
61950256|NCT05123196|EXPERIMENTAL|MT-8554|MT-8554 will be started from a low dose, and gradually increase the dose in order.
61950257|NCT05123196|PLACEBO_COMPARATOR|Placebo|
62140834|NCT00418652|EXPERIMENTAL|TMS over the dorsal stream|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the dorsal stream area (PO3 EEG site).
62341960|NCT02326207|EXPERIMENTAL|Weekly ventilator circuit change|Ventilator circuit change every 7 days until extubation
62341961|NCT02326207|ACTIVE_COMPARATOR|No routine ventilator circuit change|No routine ventilator circuit change until soiling or malfunction or extubation
62341962|NCT05014048|ACTIVE_COMPARATOR|vitamin D3|20 mikrog vitamin D3 daily, 3 months
62341963|NCT05014048|PLACEBO_COMPARATOR|Placebo|Placebo
62341964|NCT04436809|OTHER|SNB only|"cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have disease-free sentinel nodes (pN0) after primary chemotherapy, are directed to SNB only: i.e. no further treatment to the axilla."
62140835|NCT00418652|SHAM_COMPARATOR|TMS over the vertex|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the vertex area.
62341965|NCT04436809|OTHER|SNB + AD|cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have metastatic sentinel nodes (pN1) on sentinel node biopsy (SNB) will undergo axillary dissection (AD) i.e. surgical removal of most axillary lymph nodes.
62341966|NCT05259267|EXPERIMENTAL|Online Group Therapy for PTG|It consists of eight sessions that occur during app. 90 minutes. A group therapist and a cotherapist will lead the therapy sessions. There will be one session per a week.
61950258|NCT06209931||RIRS|Patients were performed under general anesthesia in the oblique supine lithotomy position. Initially, preliminary ureteroscopy was performed with a semirigid 8/9.8 Fr ureteroscope guided by zebra guide wire. Next, the patented tip flexible pressure-controlling ureteral access sheath (UAS,12/14 Fr) was inserted along the guidewire without the fluoroscopic guidance. The fully automatic mode was chosen to operate the platform.The pressure sensory and suctioning channels of UAS were connected to the irrigation and suctioning platform. After water injection, zero calibration was performed at platform. Perfusion flow rate was then set at 100-150 ml/min, the renal pelvic pressure (RPP) control value was set at -15\~5 mmHg, the RPP warning value was set at 20 mmHg, and the RPP maximum value was set at 30 mmHg. Intraoperatively, a holmium laser was used to crush the stone at 1.5-2.0 J/pulse with a frequency of 20-30 pulses/s ( (CHUNHUI, CHINA, 276µm).
62341967|NCT05259267|ACTIVE_COMPARATOR|Online Support Group|It consists of eight sessions that occur during app. 90 minutes. A group therapist and a cotherapist will lead the therapy sessions without using any psychological methods. There will be one session per a week.
62341968|NCT05259267|NO_INTERVENTION|Wait-list|We used a wait-list as a control group. After each participants in both online PTG group therapy and online support group completed the interventions, wait-list will be randomly assigned to one of these two interventions.
62341969|NCT03419052|EXPERIMENTAL|MINDSpeed Intervention|Consumption of foods high in polyphenols (i.e., MIND foods) AND speed of processing training
62341970|NCT03419052|ACTIVE_COMPARATOR|MIND food and training control|Consumption of foods high in polyphenols (i.e., MIND foods) AND online (inert) games
62341971|NCT03419052|ACTIVE_COMPARATOR|Control foods and speed of processing training|Consumption of low polyphenol foods AND speed of processing training
62341972|NCT03419052|SHAM_COMPARATOR|Double Control|Consumption of low polyphenol foods AND online (inert) games
62341973|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
62341974|NCT00467025|EXPERIMENTAL|Arm A|
62341975|NCT00467025|EXPERIMENTAL|Arm B|
62341976|NCT00467025|ACTIVE_COMPARATOR|Arm C|
62341977|NCT00574119|EXPERIMENTAL|Results with spironolactone|patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.
62341978|NCT01814683|EXPERIMENTAL|Primaquine 7 day|Standard blood schizontocidal therapy plus 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
62341979|NCT01814683|PLACEBO_COMPARATOR|Placebo controlled arm|Standard blood schizontocidal therapy plus 14 days placebo.
62341980|NCT01814683|ACTIVE_COMPARATOR|Primaquine 14 day|Standard blood schizontocidal therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
62341981|NCT01717703|EXPERIMENTAL|Water Control|Water Control
62341982|NCT01717703|EXPERIMENTAL|Fruit drink|Fruit drink
62341983|NCT01717703|EXPERIMENTAL|Cola|Cola
62341984|NCT01717703|EXPERIMENTAL|1% chocolate milk|1% chocolate milk
62341985|NCT03716986|OTHER|SatO2|
62341986|NCT06552858|EXPERIMENTAL|Fluzoparib with Dalpiciclib|Oral administration of Fluzoparib with Dalpiciclib until disease progression or toxicity intolerance.
62341987|NCT05890118|ACTIVE_COMPARATOR|SC Group|In up to 15 volunteers, 0.5mg of Stelara will be administered subcutaneously and serial blood samples will be collected for PK analysis.
62341988|NCT05890118|EXPERIMENTAL|RT-111 Group 1|In up to 20 volunteers, a RaniPill capsule containing 0.5mg of ustekinumab will be administered and serial blood samples will be collected for PK analysis.
62341989|NCT05890118|EXPERIMENTAL|RT-111 Group 2|In up to 20 volunteers, a RaniPill capsule containing 0.75mg of ustekinumab will be administered and serial blood samples will be collected for PK analysis.
62341990|NCT02140905||Patients undergoing hemodialysis.|Subjects participating in the study
62341991|NCT02432040|EXPERIMENTAL|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
62341992|NCT02432040|PLACEBO_COMPARATOR|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
62341993|NCT03309267||Intercostal block|Anesthesia induction was performed to all patients .At the end of the operation some patients were performed with intercostal block by the chest surgeon. For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
62341994|NCT03309267||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation some patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
62341995|NCT05277688|EXPERIMENTAL|experimental group|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; pelvic radiotherapy: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
62341996|NCT05277688|ACTIVE_COMPARATOR|controlled group|pelvic radiotherapy alone: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
62341997|NCT05122195||Group A, compression therapy group|Elastic compression therapy with a thigh length stockings of 23-32 mmHg, at least 8 hours a day.
62341998|NCT05122195||Group B, control group|No compression therapy prescribed in the follow-up period.
62341999|NCT03000387|EXPERIMENTAL|Experimental Condition|Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day
62342000|NCT03000387|PLACEBO_COMPARATOR|Placebo Condition|Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximum daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.
61950259|NCT06209931||MPCNL|Patients were performed under general anesthesia. The patient was first placed in a lithotomy position. A 5 Fr ureteral catheter was then inserted retrogradely into the renal pelvis through cystoscopy or ureteroscopy , and saline was continuously infused to produce artificial hydronephrosis. The patient was then placed in the prone position. Ultrasound-guided percutaneous punctures were made with an 18-gauge coaxial needle into the targeted calix. The puncture point was in the 12th rib infracostal margin, between the posterior axillary line and scapula line. A Zebra guidewire was inserted and fixed. The puncture needle was then removed. After a 0.5-0.7 cm skin incision was made, the percutaneous tract was dilated serially over the guidewire with a fascial dilator to 18Fr. Holmium laser lithotripsy at 1.5-2.0 J/pulse with a frequency of 20-30 pulses/s (CHUNHUI, CHINA, 550µm) was performed with a 18 Fr peel-away sheath.
61950260|NCT04489797|EXPERIMENTAL|Arm A|Participants will receive single oral dose of acalabrutinib capsule with 100 mL of water.
61950261|NCT04489797|EXPERIMENTAL|Arm B|Participants will receive single oral dose of acalabrutinib capsule taken with 100 mL of COCA-COLA along with 20 mg rabeprazole.
61950262|NCT03641339|EXPERIMENTAL|Cohort A: One vector feeding and three biopsies|Undergo one vector feeding and three biopsies on Day 0
61950263|NCT03641339|EXPERIMENTAL|Cohort B: Four vector feedings and three biopsies|Undergo 4 vector feedings over 8 weeks and 3 biopsy procedures after the 4th and final feeding
61950264|NCT06365112|ACTIVE_COMPARATOR|Endoscopic assisted acetabulum fractrure treatment|
61950265|NCT06365112|ACTIVE_COMPARATOR|Open reduction|
61950266|NCT00944671|ACTIVE_COMPARATOR|A|Famotidine/antacid combination tablet with water
61950267|NCT00944671|EXPERIMENTAL|B|Famotidine/Antacid EZ Chew tablet without water
61950268|NCT00944671|EXPERIMENTAL|C|Famotidine/Antacid EZ Chew tablet with water
61950269|NCT01390649|EXPERIMENTAL|IgPro10|
61950270|NCT00936156|EXPERIMENTAL|Chemotherapy|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
61950271|NCT02721160|EXPERIMENTAL|Nutrition PBF|45 health centres are assigned to this group. The intervention consists in a performance based financing scheme applied to nutrition services.
61950272|NCT02721160|NO_INTERVENTION|Control|45 health centres are in the control group. Health centres in this group are not incentivized, but they receive an equivalent funding to the one received by the intervention group. The main difference is that this payment is not based on their own performance.
61950273|NCT03031197|EXPERIMENTAL|Tailored realtime triggered reminder pkg|The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
61950274|NCT03031197|NO_INTERVENTION|Control|Comparison subjects will receive usual care and an offer of counseling at monthly clinic visits.
62140836|NCT05869734|EXPERIMENTAL|Intervention group A|The intervention group A receives conservative management with sleep hygiene related adjustments, pelvic floor muscle training, and urologic health promotion.
62140837|NCT05869734|EXPERIMENTAL|Intervention group B|The intervention group B receives conservative management with brief behavioral treatment for insomnia (BBTI), pelvic floor muscle training, and urologic health promotion.
61950275|NCT05560360|EXPERIMENTAL|healthy subjects|
61950276|NCT03095612|EXPERIMENTAL|Selinexor Monotherapy and in Combination with Docetaxel|"For the selinexor monotherapy cohort, 6 patients each will be treated in two dosing cohorts (weekly and biweekly). Selinexor once weekly oral (40mg, 60mg, 80mg) OR Selinexor twice weekly oral (60mg, 40mg, 60mg weekly).~Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks."
61950277|NCT00769210|EXPERIMENTAL|A|
61950278|NCT00001880|EXPERIMENTAL|Stem Cell Transplantation in Patients With Progressive and Incurable Metastatic Solid Tumors|Cyclosporin beginning day -4 then stem cells given on Day 0 followed by intravenous Methotrexate on days +1, +3, and +6.
61950279|NCT02534714||Retrospective (Part 1) Group|This is a retrospective pilot study in patients diagnosed with any form of spinal disease who underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from November 1, 2012 to October 31, 2014. Only spinal fusion patients with a serum Vitamin D level prior to or at time of surgery and after surgery are included in this review. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The charts reviewed will belong to subjects who were closely followed at the OSF/INI clinic.
62140838|NCT05869734|SHAM_COMPARATOR|Comparison group|The comparison group receives information related to pelvic floor muscle training and urologic health promotion.
62140839|NCT00714207|EXPERIMENTAL|NOT Intervention|Students in this arm of the study were randomized to receive the reformatted NOT program
62342001|NCT03000387|ACTIVE_COMPARATOR|Quit condition|Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.
62342002|NCT01260935|ACTIVE_COMPARATOR|Arm A|Laparoscopic Hill
62342003|NCT01260935|ACTIVE_COMPARATOR|Arm B|Laparoscopic Nissen
61950280|NCT02534714||Prospective (Part 2) Group|"This is a prospective pilot study in subjects diagnosed with any form of spinal disease that underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016.~(Screening period July 1, 2015-June 30, 2016)~Only spinal fusion patients with a serum Vitamin D level, and Bone Marrow Density prior to or at time of surgery are included in this study. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The subjects were closely followed at the OSF/INI clinic post-operatively at 3, 6, and 12 months. Pre-op Vitamin D level and Bone Marrow Density will be measured at the baseline, and again at 3, 6, and 12 months."
61950281|NCT01686828|EXPERIMENTAL|Acyline & placebo gel & placebo pill|Acyline (300mcg/kg) + placebo transdermal gel + placebo pill daily
61950282|NCT01686828|EXPERIMENTAL|Acyline & Testosterone 1.25g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (1.25g) daily + placebo pill daily
61950283|NCT01686828|EXPERIMENTAL|Acyline & Testosterone 5g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (5g) daily + placebo pill daily
61950284|NCT01686828|EXPERIMENTAL|Acyline & Testosterone & Letrozole|Acyline (300mcg/kg) + Testosterone gel (5g) daily + letrozole (5mg) daily
61950285|NCT02978898||LN Lymph nodes|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
62140840|NCT00714207|ACTIVE_COMPARATOR|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
62499264|NCT03833427|EXPERIMENTAL|Selumetinib at Dose Level 1 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; every three weeks \[Q3W\]) in combination with selumetinib at dose level 1 (dosed orally; twice daily \[BID\]) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
62499265|NCT03833427|EXPERIMENTAL|Selumetinib at Dose Level 2 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 2 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
62499266|NCT03833427|EXPERIMENTAL|Selumetinib at Dose Level 3 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 3 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
62499267|NCT03833427|EXPERIMENTAL|Selumetinib at Dose Level 4 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 4 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
62499268|NCT03833427|EXPERIMENTAL|Selumetinib at Dose Level 5 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 5 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
62499269|NCT03833427|EXPERIMENTAL|Selumetinib at Dose Level 6 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 6 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
62499270|NCT03833427|EXPERIMENTAL|Selumetinib at Dose Level 7 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 7 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
62499271|NCT03493035||MCA aneurysm group|All patients with unruptured MCA aneurysm diagnosed on three-dimensional computed tomography angiography (3D CTA) and transcranial color-coded sonography (TCCS) .
62499272|NCT03493035||non-MCA aneurysm group|All patients with no evidence of intracranial pathologies on 3D CTA and diagnosed on transcranial color-coded sonography (TCCS).
62499273|NCT03022890|EXPERIMENTAL|Hatha yoga|12 weeks of hatha yoga classes, once per week
62499274|NCT03022890|PLACEBO_COMPARATOR|Health education|12 weeks of health education classes, once per week
62499275|NCT03004508|EXPERIMENTAL|Gingko biloba Extract|
62499276|NCT03004508|PLACEBO_COMPARATOR|Placebo|
61950286|NCT02978898||PB peripheral blood|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
61950287|NCT02774954|EXPERIMENTAL|Change the cycle|CTC uses the Information-Motivation-Behavioral skills (IMB) model to achieve changes among active PWID through seven short modules. Information and motivational domains are addressed in guided conversations about (1) their own first injection episode and consequences, (2) past experiences initiating injection-naive people and consequences, (3) health, legal, and social risks related to injection drugs, (4) health, legal, social risks of initiating people, and (5) identifying their own behaviors that might promote injection among others. The behavioral skills domain is addressed through a (6) skill-building discussion and rehearsal of responses to possible initiation scenarios, and (7) safer injection education.
62140841|NCT00714207|EXPERIMENTAL|KB intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
62140842|NCT00714207|ACTIVE_COMPARATOR|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
62140843|NCT04334317|EXPERIMENTAL|Placebo + TAK-071 (PD Participants)|TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2.
62140844|NCT04334317|EXPERIMENTAL|TAK-071 + Placebo (PD Participants)|TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2.
62140845|NCT04334317|EXPERIMENTAL|Sentinel Cohort: Placebo (Healthy Participants)|A single dose of TAK-071 placebo-matching mg, tablet, orally, on Day 1.
61950288|NCT02774954|ACTIVE_COMPARATOR|Nutrition|The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
61950289|NCT02323243|EXPERIMENTAL|Allium BUS|Temporary urethral stent
61950290|NCT02847975|EXPERIMENTAL|Sodium nitrate|Sodium nitrate will be administered orally and functional sympatholysis assessed before and after treatment
61950291|NCT03219138|NO_INTERVENTION|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
61950292|NCT03219138|EXPERIMENTAL|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
61950293|NCT00354744|EXPERIMENTAL|High Risk Rhabdomyosarcoma|Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
61950294|NCT00398918|EXPERIMENTAL|Zonisamide|
61950295|NCT00398918|PLACEBO_COMPARATOR|Placebo|
61950296|NCT04344548|EXPERIMENTAL|Treatment group|Adult patients with COVID-19 infection with NEWS 2 score \>4
61950297|NCT01984411|EXPERIMENTAL|Radial Technical|Radial technical is the procedure for catheterization
61950298|NCT01984411|ACTIVE_COMPARATOR|Femoral Technical|Vascular Access for cardiac catheterization
61950299|NCT06050005|EXPERIMENTAL|Experimental - rehabilitation activity|All participants will be included in this arm.
62342004|NCT01153191|EXPERIMENTAL|Pressurized irrigation|first group-After closure of patients abdominal wall fascia, Hydrostatic irrigation with 3 liters of normal saline with Simpulse Solo irrigation system (Davol) at less than 15PSI will be applied to subcutaneous tissues prior to closure
62342005|NCT01153191|EXPERIMENTAL|Sub Q Antibiotic|second group of patients will receive 2mg/lg of gentamicin in 20 ml of sterile saline injected into the superficial tissues above the ABD wall fascia prior to initial incision
62342006|NCT01345344|EXPERIMENTAL|Cognitive-Behavioral Therapy|8 individual weekly visits with a psychologist for pain-related CBT.
62342007|NCT01345344|ACTIVE_COMPARATOR|Disease Education|8 individual weekly visits with a psychologist for fibromyalgia education (this is an active comparator arm, matched for provider contact).
62342008|NCT01345344|NO_INTERVENTION|Healthy Controls|No intervention.
62342009|NCT03522350|ACTIVE_COMPARATOR|EmbryoScope|Standard of care embryo incubator.
62342010|NCT03522350|EXPERIMENTAL|EmbryoScope+|New experimental embryo incubator.
62342011|NCT03408652|EXPERIMENTAL|Arm A|bone targeted treatment (denosumab or zoledronic acid)
62342012|NCT03408652|NO_INTERVENTION|Arm B|no specific treatment
62342013|NCT02280941|EXPERIMENTAL|Single photon emission computed tomography|Myocardial blood flow (MBF) measurement will be analyzed using attenuation and scatter corrected dynamic single photon emission computed tomography (SPECT) imaging data. The data will be compared to MBF obtained from positron emission tomography (PET) imaging.
62342014|NCT04511026|EXPERIMENTAL|Lymphoseek/SPECT-CT/Indocyanine|The subject will receive f 0.5 mL each Lymphoseek into the uterine cervix prior to surgery and subsequent SPECT/CT imaging preoperatively. Intraoperatively, following anesthesia induction, Indocyanine Green (0.5 mL) will be injected into the uterine cervix. Using near-infrared imaging, efferent lymphatic vessels and lymph nodes will be visualized and confirmed by detected radioactivity using a laparoscopic gamma counter. The preoperatively obtained SPECT/CT images will help guide the surgery.
62342015|NCT00315705|EXPERIMENTAL|clofarabine, etoposide, cyclophosphamide|"Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m\^2, etoposide dosage from 75-100 mg/m\^2, cyclophosphamide dosage from 340-440 mg/m\^2.~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 delivered intravenously"
62342016|NCT02570763|EXPERIMENTAL|Active Stimulation|Active tDCS administration during the first 20 minutes of each of the six therapy sessions.
62499277|NCT01213407|EXPERIMENTAL|Standard therapy plus Trivax|Standard therapy with Surgery, Temozolomide, and Radiotherapy; plus Trivax, 5x10e6 autologous interleukine-12 secreting dendritic cells charged with autologous tumour lysate.
61950300|NCT03412760|EXPERIMENTAL|Exome sequencing|There is only one arm of this study. All enrolled participants with unexplained NIHF or other birth defect will be offered exome sequencing for the affected fetus or neonate. Please refer to the Study Design section for further details.
61950301|NCT01506258|NO_INTERVENTION|Patients not infused with stem cells|Historic Controls
61950302|NCT01506258|EXPERIMENTAL|Patients infused with stem cells|
61950303|NCT02921542||Homogenous Lesions|
61950304|NCT02921542||Heterogenous Lesions|
61950305|NCT02921542||Calcific Lesions|
61950306|NCT02921542||Restenotic Lesions|
61950307|NCT04226872|EXPERIMENTAL|Intervention|"The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet."
61950308|NCT04226872|NO_INTERVENTION|Control|"The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet. Data collection for outcome variables will be the same as participants in the intervention group."
62140846|NCT04334317|EXPERIMENTAL|Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants)|A single dose of TAK-071 ≤ 7.5 milligrams (mg), tablet, orally, on Day 1.
62342017|NCT02570763|SHAM_COMPARATOR|Sham Stimulation|Sham tDCS administration during the first 20 minutes of each of six therapy sessions.
62499278|NCT01213407|ACTIVE_COMPARATOR|Standard therapy|Surgery, Temozolomide, Radiotherapy
61950309|NCT04085393|ACTIVE_COMPARATOR|GERSC for patients receiving highly emetogenic chemotherapy|Participants will receive GERSC, and two other standard antiemetics prior to chemotherapy
61950310|NCT04085393|ACTIVE_COMPARATOR|GERSC on patients receiving moderately emetogenic chemotherapy|Participants will receive GERSC and one other standard antiemetic prior to chemotherapy
61950311|NCT05521620|ACTIVE_COMPARATOR|Father-friendly NICU|"* Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker"
61950312|NCT05521620|NO_INTERVENTION|No Father-friendly NICU (baseline)|Baseline - before implementation of the intervention
61950313|NCT06273462|EXPERIMENTAL|Palmitoylethanolamide|Participants randomized to the experimental arm will receive the supplement Palmitoylethanolamide (PEA) at a dose of 600mg twice a day
61950314|NCT06273462|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo arm will receive a visually identical placebo capsule
61950315|NCT01237821|ACTIVE_COMPARATOR|BenzaClin|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with \> or equal to 15 inflammatory lesions, \> or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
61950316|NCT01237821|ACTIVE_COMPARATOR|effaclar|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with \> or equal to 15 inflammatory lesions, \> or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
61950317|NCT05629078|ACTIVE_COMPARATOR|Toric Intraocular lens|Toric intraocular lens- AT TORBI® 709M, to be implanted bilaterally in the cataract surgery to correct astigmatism at the same time.
61950318|NCT05629078|ACTIVE_COMPARATOR|Monofocal intraocular lens|Standard monofocals IOLs- Zeiss CT ASPHINA 409/509M, to be implanted bilaterally in the standard NHS cataract surgery without correcting the astigmatism.
61950319|NCT02233114|EXPERIMENTAL|Yogic exercises|Yogic exercises for lung disorders
61950320|NCT02233114|ACTIVE_COMPARATOR|physiotherapy|Physiotherapy during the yogic exercises
61950321|NCT05979259|EXPERIMENTAL|Experimental (Foodbot Factory) Group|
61950322|NCT05979259|ACTIVE_COMPARATOR|Control Group|
62342018|NCT06126874|EXPERIMENTAL|Patient education, Pelvic floor muscle training, Aerobic and Resistance exercise trainings|"Patient Education: Individuals in both study groups will be provided with patient education through verbal and visual presentations.~Pelvic Floor Muscle Training (PFMT): In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program.~Aerobic Exercise Training: Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).~Resistance Exercise Training: Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training."
61950323|NCT03039452|EXPERIMENTAL|High intensity interval training|
62342019|NCT06126874|ACTIVE_COMPARATOR|Patient education and Pelvic floor muscle training|"Patient Education: Individuals in both study groups will be provided with patient education through verbal and visual presentations.~Pelvic Floor Muscle Training (PFMT): In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program."
62499279|NCT00707187|EXPERIMENTAL|1|35 doses of study medication, IC 351 (20 mg) -- crossover to placebo
62499280|NCT00707187|EXPERIMENTAL|2|35 placebo pills followed with 35 study medication (20 mg)
62499281|NCT04217538||EBH|
62499282|NCT05974358|EXPERIMENTAL|Kono-S group|Kono-S group, in which ileocolonic anastomosis will be performed following the technique described by Kono et al.
62499283|NCT05974358|OTHER|Control group|Conventional side-to-side ileocolonic anastomosis
62499284|NCT03837405|ACTIVE_COMPARATOR|Diet Education|All participants will receive instruction in the Carbohydrate-Restricted (CR) diet and basic behavioral strategies in weekly, in-person, group sessions for 3 months. The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat.
62499285|NCT03837405|EXPERIMENTAL|Diet Education + Mindfulness|In addition to the diet components described above, participants randomized to the Education + Mindfulness (Ed+MBI) group will receive MBI components using the Eat Right Now (ERN) platform. This will consist of two integrated components: 1) use of the ERN app at home, during the week, to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based discussions of how the mindful eating practices are going, trouble-shooting obstacles/pain points, and doing group exercises and reflecting on them.
62499286|NCT02310841|EXPERIMENTAL|unilateral transfemoral amputees|
61950324|NCT03386318||day surgery patients|20 patients female 30-60 years of age
61950325|NCT06000332|EXPERIMENTAL|InogenOne Rove 6 Portable Oxygen Concentrator|InogenOne Rove 6 Portable Oxygen Concentrator
61950326|NCT06026709|EXPERIMENTAL|usual care + EmoEase group|EmoEase, the digital intervention, will be delivered through a WeChat Mini Program. It will integrate two main pieces of training for anxiety and depression. We will develop the training mainly based on CBT.
62499287|NCT02403973|OTHER|Patient hotel group|
62499288|NCT02403973|OTHER|Ward group|
62499289|NCT05761587||cancer patients|Questionnaires
62499290|NCT02539368||CT-P13|biosimilar infliximab
61950327|NCT06026709|NO_INTERVENTION|usual care|"We will distribute informational pamphlets to participants in both the intervention and control groups, which will include guidance on the following aspects of self-management of COPD:23~1. Concise overview of COPD, encompassing its definition, prevalent risk factors, commonly observed symptoms, and disease progression;~2. Minimizing exposure to high-risk factors, such as tobacco/smoke exposure, air pollutants, household cooking emissions, and respiratory infections; .......~(10) Receiving vaccinations for influenza and streptococcus pneumoniae."
61950328|NCT03890406|EXPERIMENTAL|Group D|Deep neuromuscular blockade
61950329|NCT03890406|ACTIVE_COMPARATOR|Group M|Moderate neuromuscular blockade
61950330|NCT03857399|EXPERIMENTAL|Arm-1|Patients will be assigned to receive intravenous local caspofungin (70 mg on day 1 and 50 mg once daily),If the study therapy was well tolerated but fever persisted for four or more days and the patient's clinical condition deteriorated, the dosage could be increased to 70 mg once daily.For patients who have no evidence of baseline or breakthrough fungal infection, study therapy was administered until the absolute neutrophil count was at least 500 per cubic millimeter and for up to 72 hours thereafter. The onsite investigator determined the duration of therapy for patients with baseline or breakthrough fungal infections; however,it was recommended that treatment be given for at least 14 days and for at least 7 days after neutropenia and symptoms resolved.
61950331|NCT03857399|ACTIVE_COMPARATOR|Arm-2|Patients will be assigned to receive intravenous original caspofungin (70 mg on day 1 and 50 mg once daily),the therapeutical duration is 4 Days.
61950332|NCT01741974|ACTIVE_COMPARATOR|Karinat|Karinat 500 mg tablet by mouth three times a day
61950333|NCT01741974|PLACEBO_COMPARATOR|Sugar pill|Placebo tablet 500 mg by mouth three times a day
61950334|NCT04289142|ACTIVE_COMPARATOR|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1.2 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.3 μg/kg/h for up to 12 hours or until patient is ready for discharge from CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
61950335|NCT04289142|NO_INTERVENTION|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
61950336|NCT03609879|NO_INTERVENTION|without cervical collar|baseline - without cervical collar
61950337|NCT03609879|EXPERIMENTAL|with cervical collar|scenarios with cervical collars
61950338|NCT02369016|EXPERIMENTAL|Copanlisib (BAY 80-6946)|patients with rituximab-refractory iNHL
61950339|NCT02236442|NO_INTERVENTION|Usual care|First arm : Passive recording head pain, linked symptoms, treatment used and diagnosis.
61950340|NCT02236442|EXPERIMENTAL|After protocol recommendation care|Recording head pain, linked symptoms, treatment used and diagnosis after intervention that is recommendation to use global headache treatment protocol
61950341|NCT03095339|ACTIVE_COMPARATOR|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
61950342|NCT03095339|NO_INTERVENTION|Control|The control group did not receive any intervention
62499291|NCT02539368||Remicade|infliximab
61950343|NCT01728350|EXPERIMENTAL|Treatment|Participants in this arm will participate in a novel structured volunteering intervention called HOPE - Helping Others through Purpose and Engagement. This intervention involves orientation, training, volunteer placement assistance, and problem solving and support.
61950344|NCT01728350|NO_INTERVENTION|Control|Participants who are randomized to the control arm will be offered the HOPE intervention at the conclusion of study.
61950345|NCT04391361|EXPERIMENTAL|trial group|
62499292|NCT05455606|ACTIVE_COMPARATOR|Arm 1 (usual care)|Participants receive usual care. This consists of physicians ordering GTT for patients and reviewing the results without the GTB being involved.
61950346|NCT04391361|PLACEBO_COMPARATOR|control group|
61950347|NCT06489925|EXPERIMENTAL|Cerebrolysin group|Patients with acute basilar artery occlusion who meet the eligibility criteria will receive Cerebrolysin in a single-day dosage of 30 ml, diluted with 250 ml of 0.9% saline intravenously in the first 24 hours after the stroke. Cerebrolysin will be further administered in the same dosage once daily in the morning for 14 consecutive days.
61950348|NCT06132295|EXPERIMENTAL|Nursing care|Investigators used in-house-designed radiotherapy red and green light markers to distinguish individual measures after the provision of the initial nursing care to participants, added a homemade health education leaflet to collect data via actual observation, and counted the disappearance or fading of participants' body markers
61950349|NCT04781023|EXPERIMENTAL|Intervention (Colpofix)|intravaginal gel with carboxymtheyl beta-glucan and polycabophil
61950350|NCT04781023|NO_INTERVENTION|Control|No intervention (standard of care)
61950351|NCT03403088|EXPERIMENTAL|Group LA|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
61950352|NCT03403088|PLACEBO_COMPARATOR|Group LA-P|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
61950353|NCT03403088|EXPERIMENTAL|Group DE|INTERVENTION: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
61950354|NCT03403088|PLACEBO_COMPARATOR|Group DE-P|INTERVENTION: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
61950355|NCT03403088|EXPERIMENTAL|Group RGI|INTERVENTION: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
61950356|NCT03403088|EXPERIMENTAL|Group RX|INTERVENTION: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity
62499293|NCT05455606|EXPERIMENTAL|Arm 2 (EGTB)|Patients and physicians receive the EGTB intervention. This is comprised of 2 components: the structured GTB and the supporting education. Physicians submit cases for discussion to the GTB within 2 weeks of GTT results. The GTB sessions are held weekly and conducted virtually over a video-conferencing platform. Each case presentation is 10 to 15 minutes long, and 4 to 6 cases are discussed during each 60 minute GTB session. GTT results and clinical data are presented and expert interpretation of genomic test results is provided to help prioritize potential treatment options and provide a framework for interpretation. Supporting education materials are also available online to participants to support GTT decision making.
62499294|NCT03552367|EXPERIMENTAL|Personalized structured exercise|"This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and personalized structured exercise prescription that will be offered on-site and online and monitored through the use of heart rate monitoring devices. The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters.~Intervention: Non-personalized non-structured exercise"
62499295|NCT03552367|ACTIVE_COMPARATOR|Non-personalized non-structured exercise|This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and non-personalized non-structured exercise prescription Intervention: Non-personalized non-structured exercise
62499296|NCT03602027|EXPERIMENTAL|Anlotinib Plus Gefitinib|"This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day and Gefitinib. middle-dose groups: Anlotinib 10mg per day and Gefitinib. high-dose groups: Anlotinib 12mg per day and Gefitinib.~A dose limiting toxicity (DLT) event is defined as any of the following events:~1. CTCAE Grade 4 event (ANC\<1000/ul, body temperature≥38.5°C);~2. Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any dose group, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any dose group, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
61950357|NCT03859778||pharmacy students|
61950358|NCT03659734|EXPERIMENTAL|Motivational Interviewing and Guided Opioid Tapering Support|
61950359|NCT03659734|EXPERIMENTAL|Enhanced Usual Care|
61950360|NCT03361163|EXPERIMENTAL|GAS oropharyngeal challenge|"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)~Direct oropharyngeal application using a sterile-tipped Dacron swab after immersion for 10 seconds in a 1mL vial containing 1-3x10\^4 to 1-3x10\^8 colony forming units (CFU) of the challenge strain (depending on dose group allocation)."
61950361|NCT04207021|EXPERIMENTAL|intervention|"the study involves the intake of two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks of a nutritional supplement~INTERVENTION CAPSULE COMPOSITION active substances for 2 capsules Bio Curcumin 400 mg Polydatin 00 mg Beta-Caryophyllene 48 mg"
61950362|NCT04207021|PLACEBO_COMPARATOR|placebo|particpants included in the placebo group will take two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
61950363|NCT02358837||Conventional Sonography|Conventional Sonography to detect breast lesion
62499297|NCT06286670|OTHER|Single Implant Fixation|Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
61950364|NCT02358837||Ductosonography Technique|Ductosonography Technique to detect breast lesion
61950365|NCT06180720|EXPERIMENTAL|Test (T)-Reference (R)|In this trial, 36 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group A: Test (T)-Reference (R), The washout period (dosing interval) between doses will be at least 2 days. After fasting for at least 10 hours.
61950366|NCT06180720|EXPERIMENTAL|Reference (R)-Test (T)|In this trial, 36 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group B: Reference (R)-Test (T), The washout period (dosing interval) between doses will be at least 2 days. After fasting for at least 10 hours.
61950367|NCT04259567|ACTIVE_COMPARATOR|Filter|Patients with CytoSorb absorber
61950368|NCT04259567|NO_INTERVENTION|Control|Patients without CytoSorb absorber
61950369|NCT04260308||residents|"1. Voluntary residents~2. Can use mobile phone or computer"
62499298|NCT06286670|OTHER|Dual Implant Fixation|Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
62499299|NCT06293352|ACTIVE_COMPARATOR|All-cement articulating spacer|An articulating spacer with a tibial and femoral component made of cement using molds, that are cemented in place; use of highdose antibiotic cement (at least 2g/batch, including vancomycin and tobramycin); use of dowels at discretion of surgeon; 6 weeks IV antibiotics; intent to reimplant definitive prosthesis if infection eradicated.
61950370|NCT04260308||medical staff|"1. Voluntary residents~2. Can use mobile phone or computer"
61950371|NCT02972671|EXPERIMENTAL|MiStent (MT005) Coronary Artery Stent|A balloon expandable crystalline sirolimus eluting stent with an absorbable polymer coating will be implanted.
61950372|NCT02972671|ACTIVE_COMPARATOR|Xience Coronary Artery Stent|Balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating will be implanted
61950373|NCT04111198||coronary artery disease in diabetic and non diabetic patients|
61950374|NCT02272660|EXPERIMENTAL|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision.
61950375|NCT02272660|PLACEBO_COMPARATOR|Normal saline injection|The control group received 2 mL normal saline injection at the same time point.
61950376|NCT06324812|EXPERIMENTAL|611|subcutaneous injection, 611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
61950377|NCT05250778|EXPERIMENTAL|Nudge Group|Encounters in this group will be nudged
61950378|NCT05250778|NO_INTERVENTION|Control Group|Encounters in this group will not receive a nudge.
61950379|NCT06057831|EXPERIMENTAL|Single Arm|All patients receive total neo-adjuvant therapy (TNT), depending on institutional policy
61950380|NCT00515489||001|Risperidone as prescribed
61950381|NCT02982668|ACTIVE_COMPARATOR|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
61950382|NCT02982668|EXPERIMENTAL|Modified full enteral feeding|Consistent with full enteral feeding plan, preventively add metoclopramide or mosapride everyday to improve gastrointestinal (GI) motility.
61950383|NCT02982668|EXPERIMENTAL|Permissive underfeeding|The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
61950384|NCT04759573|EXPERIMENTAL|Early Vocal Contact|"The EVC will take place in the hospital room while infants are in their individual incubators or open cribs. In the intervention group, mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.~Early Vocal Contact will be performed by mothers three times a week for 2 weeks, more than one hour after afternoon feeding. It will begin when the newborns are in an active sleep state, in calm awake state or in active awake state, but not in deep sleep or crying. Preterm infants will be enrolled from 25+0 to 32+6 weeks of GA, following the established inclusion criteria."
61950385|NCT04759573|ACTIVE_COMPARATOR|Behavioral observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
62140847|NCT03567616|EXPERIMENTAL|Part 1: Dose Escalation|Venetoclax (400 mg oral \[PO\], once daily \[QD\]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly \[qw\]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
62140848|NCT03567616|EXPERIMENTAL|Part 2: Dose Expansion, t(11;14) positive|Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])
62140849|NCT03567616|EXPERIMENTAL|Part 2: Dose Expansion, t(11;14) negative|Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])
62140850|NCT03039296||One side endoscopic rhizotomy|Endoscopic rhizotomy will be provided only on one back side according pain
62499300|NCT06293352|ACTIVE_COMPARATOR|Durable, real-component articulating spacer|Uses metal (or ceramicized metal) on plastic for bearing surface; use of high-dose antibiotic cement (at least 2g/batch, including vancomycin and tobramycin); no cones/sleeves, no pressurized cement in canal; use of stems/dowels/augments and level of constraint at discretion of surgeon; 6 weeks IV antibiotics; intent to leave in situ indefinitely/until clinical failure.
62499301|NCT06293352|OTHER|Observation|Patients who do not wish to be randomized or who meet the randomization-specific exclusion criteria will be offered enrolment into the non-randomized, prospective observational arm of the study. The participant and their surgeon will collaboratively decide which of the 2 treatments the participant will receive.
62499302|NCT01691586|EXPERIMENTAL|Remote patient management|Remote patient management system + yearly in-clinic follow-up
62499303|NCT01691586|OTHER|In-Clinic follow-up|In-clinic follow-up according to standard practice (every 3-6 months)
62499304|NCT06520683|EXPERIMENTAL|Tislelizumab Arm|Two cycles of Tislelizumab 200mg intravenously, on day 1 and day 22, with or without adjuvant chemotherapy
62140851|NCT03039296||Both sides endoscopic rhizotomy|Endoscopic rhizotomy will be provided on both back sides according pain
62499305|NCT06520683|ACTIVE_COMPARATOR|Control Arm|Receiving standard of Care (either with adjuvant chemotherapy or surveillance alone).
62499306|NCT05659238||1|those who exposed early to TV (before 1 year age)with long time of exposure/day (6hours\\day or more)
62499307|NCT05659238||2|those who exposed later to TV (after 2 years of age) with short time of exposure/day.(2 hours \\day or less)
62499308|NCT05603858||Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
62499309|NCT03644043||Early stage of MCI symptoms|Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results.
62499310|NCT03547830|EXPERIMENTAL|Plerixafor/G-CSF|Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients
62499311|NCT02702986|EXPERIMENTAL|imILT of pancreatic cancer|10 patients suffering from LAPC will be submitted to immunostimulating interstitial laser thermotherapy (imILT) in a single-arm setting
62499312|NCT05741502|EXPERIMENTAL|Clozapine Arm|Patients will be on Clozapine for at least 6 months
62499313|NCT05741502|ACTIVE_COMPARATOR|Non-Clozapine arm|Patients will be on non-Clozapine antipsychotic for at least 6 months
62499314|NCT02651064|EXPERIMENTAL|HIP|Received a 30% rebate on targeted fruits and vegetables (TFV) purchased using SNAP benefits in participating retailers. TFV earning the rebate included fresh, canned, frozen, and dried fruits and vegetables without added sugars, fats, oils, or salt, excluding white potatoes, mature legumes (dried beans and peas), and 100% juice.
62140852|NCT04471441|EXPERIMENTAL|CertiroBell Tablet|De novo liver transplant recipients will be randomized after liver transplant operation.
62140853|NCT04471441|ACTIVE_COMPARATOR|Mycophenolate mofetil Tablet/Capsule|De novo liver transplant recipients will be randomized after liver transplant operation.
62140854|NCT02301806|EXPERIMENTAL|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
62140855|NCT02301806|ACTIVE_COMPARATOR|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
62140856|NCT01476241||EarNoseThroatGroup|a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery
62140857|NCT01476241||SurgeryGroup|a historic cohort group of patients with the PEG tube placed in the Department of Surgery from September 2005 until September 2009
62140858|NCT01948024|ACTIVE_COMPARATOR|Reference Arm - SAPHRIS|10 mg BID sublingual tablet
62140859|NCT01948024|EXPERIMENTAL|Test Arm - Asenapine|10 mg BID sublingual tablet
62499315|NCT02651064|NO_INTERVENTION|Non-HIP|Received SNAP benefits as usual.
61950386|NCT05570292|ACTIVE_COMPARATOR|Domperidone|
62342020|NCT02780765|EXPERIMENTAL|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
62499316|NCT01272076||Dry AMD and geographic atrophy|Patients diagnosed with dry AMD and geographic atrophy
62499317|NCT06676618|EXPERIMENTAL|Multimodal Exercise Training Group|Participants in the multimodal exercise training group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 12 weeks, 3 days a week for 1 hour.
62499318|NCT06676618|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 12 weeks.
62499319|NCT02185963|EXPERIMENTAL|Rosuvastatin|Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors
62499320|NCT00084864|EXPERIMENTAL|Stage 1, Arm I|Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
62499321|NCT00084864|EXPERIMENTAL|Stage 1, Arm II|No study drugs before surgery.
62499322|NCT00084864|EXPERIMENTAL|Stage 1 Arm 3|Patients receive oral dexamethasone once daily on days 1-4.
62699305|NCT06558604|EXPERIMENTAL|Cohort A - POD24|"* Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2~* Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min)~* Zanubrutinib PO 320 mg total daily dose (QD) From C1D2 continuously until end C35~* Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35"
61950387|NCT05570292|PLACEBO_COMPARATOR|Folic acid|
61950388|NCT06282510|ACTIVE_COMPARATOR|Intranasal Povidone Iodine|Nasal iodophor applied twice daily for five days.
61950389|NCT06282510|NO_INTERVENTION|Control|Routine care.
61950390|NCT06016920|EXPERIMENTAL|Phase1: Dose Escalation: 3 mg VB10.16 + Pembrolizumab|"3 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
61950391|NCT06016920|EXPERIMENTAL|Phase 1: Dose Escalation: 6 mg VB10.16 + Pembrolizumab|"6 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles and quadriceps or gluteus muscles~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
61950392|NCT06016920|EXPERIMENTAL|Phase 1: Dose Escalation: 9 mg VB10.16 + Pembrolizumab|"9 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles and quadriceps and/or gluteus muscle~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
61950393|NCT06016920|EXPERIMENTAL|Phase 2: Dose Expansion: High dose of VB10.16 + Pembrolizumab|"The highest dose of VB10.16 to be safety-cleared in the escalation phase will be given via i.m. needle-free injections in the deltoid muscles and quadriceps and/or gluteus muscle~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
61950394|NCT06016920|EXPERIMENTAL|Phase 2: Dose Expansion: 3 mg VB10.16 + Pembrolizumab|"3 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
62499323|NCT00084864|EXPERIMENTAL|Stage 1, Arm 4|Patients receive oral calcitriol once daily on days 2-4.
62499324|NCT06678880|EXPERIMENTAL|Experimental Group|Participants assigned to the experimental condition.
62499325|NCT06678880|ACTIVE_COMPARATOR|Active Comparator Group|Participants assigned to the active comparator condition.
62499326|NCT03996616|NO_INTERVENTION|Control Group|"During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.~The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor."
62499327|NCT03996616|ACTIVE_COMPARATOR|Assigned Intervention|During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
62499328|NCT04784637|EXPERIMENTAL|Group 1|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) for 6 weeks
62499329|NCT04784637|EXPERIMENTAL|Group 2|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) +Behavioral Adaptation Module (BAM) for 6 weeks
62499330|NCT03447444|OTHER|music and physical activity|An intervention consisting of physical activity, music and walking, was systematically implemented for eight weeks
62499331|NCT04736394|ACTIVE_COMPARATOR|Epirubicin hydrochloride group|intravesical instillation of Epirubicin hydrochloride
62499332|NCT04736394|EXPERIMENTAL|APL-1202 group|receive APL-1202 single-agent oral treatment
62499333|NCT05678530||Healthy|Healthy Subjects who undergo the CPET
62499334|NCT05678530||Standard of Care|Standard of Care subjects who undergo the CPET as part of routine Standard of Care
62699306|NCT06558604|EXPERIMENTAL|Cohort B - BTKI failure|"* Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2~* Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min)~* Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35"
62342021|NCT02780765|ACTIVE_COMPARATOR|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
61950395|NCT00917371||atomoxetine group|
61950396|NCT00917371||methylphenidate group|
61950397|NCT00917371||psychological counseling group|
62499335|NCT03782662|EXPERIMENTAL|RV521 plus Itraconazole|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive
61950398|NCT04672395|EXPERIMENTAL|Group 1|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
61950399|NCT04672395|PLACEBO_COMPARATOR|Group 2|Placebo Comparator: 0.9% Saline
61950400|NCT04672395|EXPERIMENTAL|Booster dose of SCB-2019|Adult SCB-2019 recipients will receive 1 dose of SCB-2019 at least 4 months after the second dose
61950401|NCT04672395|PLACEBO_COMPARATOR|Vaccination of placebo recipients with SCB-2019|Placebo participants will be offered two doses of SCB-2019 vaccine
61950402|NCT01313858||Participants with Rheumatoid Arthritis|Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.
61950403|NCT01313858||Participants with Psoriatic Arthritis|Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.
61950404|NCT01313858||Participants with Ankylosing Spondylitis|Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.
61950405|NCT05476406|EXPERIMENTAL|äKwä Group|participants use äKwä products daily as instructed for 30 days
61950406|NCT05476406|ACTIVE_COMPARATOR|Control Group|participants use a competitor products daily as instructed for 30 days
61950407|NCT02002091||Complications,no specific treatment|After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.
61950408|NCT01705730||Tocilizumab|Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.
62499336|NCT03782662|EXPERIMENTAL|RV521 plus Verapamil|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive
61950409|NCT02657538|ACTIVE_COMPARATOR|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
61950410|NCT02657538|ACTIVE_COMPARATOR|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
61950411|NCT04281303||Endoscopic vertical gastroplasty|Proof-of-concept study that will prospectively include a number of patients undergoing endoscopic vertical gastroplasty + lifestyle modifications to evaluate the effect of this technique in an adult population with obesity and NASH cirrhosis
62499337|NCT03782662|EXPERIMENTAL|RV521 plus Rifampicin|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive
61950412|NCT04261868|EXPERIMENTAL|Virtual Reality|Dichoptic playing games with fine stimulation will present to the amblyopic eye.
61950413|NCT04261868|ACTIVE_COMPARATOR|Patching|Non- amblyopic eye will be recommended to patch.
61950414|NCT03191188|EXPERIMENTAL|Levothyroxine|
61950415|NCT03191188|PLACEBO_COMPARATOR|Placebo|
61950416|NCT01924000|EXPERIMENTAL|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
62342022|NCT01228942|OTHER|Platinum Sensitive|Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
62499338|NCT03782662|EXPERIMENTAL|RV521 plus Midazolam|RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
62499339|NCT03782662|PLACEBO_COMPARATOR|Placebo plus Midazolam|Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
61950417|NCT01924000|PLACEBO_COMPARATOR|Placebo|Placebo is applied twice daily to the other eyebrow.
61950418|NCT04694781|EXPERIMENTAL|Monotherapy Dose Escalation|LVGN6051 monotherapy dose escalation
61950419|NCT04694781|EXPERIMENTAL|Monotherapy Dose Expansion|LVGN6051 dose expansion cohorts
61950420|NCT04694781|EXPERIMENTAL|Combination therapy dose escalation|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose escalation
61950421|NCT04694781|EXPERIMENTAL|Combination therapy dose expansion|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose expansion cohorts
61950422|NCT03186495|EXPERIMENTAL|Normal renal function|Subjects with normal renal function
61950423|NCT03186495|EXPERIMENTAL|Mild renal impairment|Subjects with mild renal impairment
61950424|NCT03186495|EXPERIMENTAL|Moderate renal impairment|Subjects with moderate renal impairment
61950425|NCT03186495|EXPERIMENTAL|Severe renal impairment|Subjects with severe renal impairment
61950426|NCT03186495|EXPERIMENTAL|Requiring haemodialysis treatment|Subjects requiring haemodialysis treatment
61950427|NCT05123820|EXPERIMENTAL|ACT-1014-6470, Midazolam and Omeprazole|"Treatment Period A (Day 1 to Day 2) The plan is that all participants will receive treatment A and then treatment B.~* A single oral dose of midazolam 2 mg and a single oral dose of omeprazole 20 mg on Day 1.~Treatment Period B (Day 8 to Day 11)~* A single oral dose of 100 mg ACT-1014-6470, a single oral dose of 20 mg omeprazole, and a single oral dose of 2 mg midazolam on Day 8."
61950428|NCT06178289|EXPERIMENTAL|3M Cavilon Advanced Skin Protectant|3M Cavilon Advanced Skin Protectant (2,7ml) is a cyanoacrylate based film and will be administered every third day for a study period of 21 days.
62342023|NCT01228942|OTHER|Platinum resistent|single agent based on Coxen prediction model
61950429|NCT06178289|ACTIVE_COMPARATOR|Standard hospital wound treatment protocol|Usual wound treatment care provided in the hospital will be administered.
61950430|NCT03884491|EXPERIMENTAL|Vortioxetine|
61950431|NCT01086722|EXPERIMENTAL|"karolinska cocktail"|The karolinska cocktail contains dextromethorphan, caffeine, losartan and omeprazol
61950432|NCT02787382|EXPERIMENTAL|Pregnant women with CMV infection|"An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography)."
61950433|NCT02787382|EXPERIMENTAL|Pregnant women with suspected CMV infection|"The healthy women from the group will serve as controls. An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography). As the control group-Newborns found to be negative for CMV will serve as control group."
61950434|NCT06271213||Respiratory Disease|Children with respiratory complications receiving general anaesthesia undergoing bronchoscopy
61950435|NCT06271213||Gastrointestinal Disease|Children with G.I. complications receiving general anaesthesia undergoing endoscopy
61950436|NCT06271213||Orthopaedic controls|Children with orthopaedic issue receiving general anaesthesia undergoing orthopaedic correction
62140860|NCT06511908|EXPERIMENTAL|1|Individuals in Arm 1 will receive double-blinded (2R,6R)-HNK infusions four times over two weeks during Test Session 1 and daily double-blinded placebo infusions four times over two weeks during Test Session 2. The starting dose will be 0.25 mg/kg and the treatment target for all participants will be 2.0 mg/kg. If response criteria is not met by the morning of the next infusion, the dose may be increased. Doses will be decreased if tolerability issues arise.
62140861|NCT06511908|EXPERIMENTAL|2|Individuals in Arm 2 will receive double-blinded placebo infusions four times over two weeks during Test Session 2 and double-blinded (2R,6R)-HNK infusions four times over two weeks during Test Session 1. The starting dose will be 0.25 mg/kg and the treatment target for all participants will be 2.0 mg/kg. If response criteria is not met by the morning of the next infusion, the dose may be increased. Doses will be decreased if tolerability issues arise.
62140862|NCT05323032|EXPERIMENTAL|Normal subjects|Normal subjects at banha university that are seeking regular ophthalmic check-up.
62140863|NCT01223274|EXPERIMENTAL|CPAP/PEEP Intervention|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
62699307|NCT06558604|EXPERIMENTAL|Cohort C - first Line|"* Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2~* Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min)~* Zanubrutinib PO 320 mg total daily dose (QD) From C1D2 continuously until end C35~* Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35"
62699308|NCT06301373|EXPERIMENTAL|Methotrexate Combined With Tofacitinib|Methotrexate 10-15mg orally once a week, tofacitinib 5mg orally twice a day
62699309|NCT06301373|ACTIVE_COMPARATOR|Methotrexate|Methotrexate 10-15mg orally once a week
62699310|NCT03391882|EXPERIMENTAL|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
62699311|NCT03391882|ACTIVE_COMPARATOR|subcutaneous apomorphine|subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
62699312|NCT03254784|EXPERIMENTAL|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
62699313|NCT03254784|EXPERIMENTAL|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
62699314|NCT03254784|EXPERIMENTAL|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
62699315|NCT03254784|EXPERIMENTAL|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
62699316|NCT03254784|EXPERIMENTAL|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
62699317|NCT03254784|EXPERIMENTAL|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
61950437|NCT06271213||Asthma Control|Children with Asthma/wheeze not indicated for biologics therapy
61950438|NCT06271213||Asthma Treatment|Children with Asthma/wheeze indicated for biologics therapy
61950439|NCT00431769|EXPERIMENTAL|Bortezomib|
61950440|NCT00825682|EXPERIMENTAL|1|20 breast cancer patients scheduled for adjunctive radiation treatment will be recruited for this study to receive reflexology treatment initiated at the beginning of radiation therapy, once a week, for 10 weeks.
61950441|NCT00825682|NO_INTERVENTION|2|20 breast cancer patients, scheduled for adjunctive radiation treatment, matched by age to the intervention group will receive treatment as usual, and will be evaluated by the same measures as the intervention group.
61950442|NCT04021771|OTHER|Group A (Intervention Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
62140864|NCT01223274|ACTIVE_COMPARATOR|Control|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
62140865|NCT01137916|EXPERIMENTAL|drug|Imatinib 800 mg
61950443|NCT04021771|OTHER|Group B (Control Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP; following this session, participants in Group B will be introduced to the intervention. Group B will return for a third visit (T3) to provide information on how the curriculum impacts their score.
61950444|NCT02850601|EXPERIMENTAL|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
62499340|NCT03696043|ACTIVE_COMPARATOR|EVD placement|Catheter placement is most commonly performed via a freehand approach using external anatomical landmarks to help identify the location of the lateral ventricle within the brain without the aid of imaging. Proper identification of the ventricles on pre-procedure imaging, surgeon skill, and estimation of pathologic perturbations to the normal location of the ventricles all factor into the success of catheter placement. Multiple passes are often required. The accuracy rate from the freehand technique has been reported to range from 40 to 98 percent.
62499341|NCT03696043|EXPERIMENTAL|Axium Stealth Image Guidance|The novelty of this study is to investigate whether using image guidance technology can improve EVD catheter placement. Image guidance is used very commonly for EVD and shunt placement in the operating room with excellent accuracy and precision. We hypothesize that using this same workflow at the bedside will improve accuracy; decrease the number of passes needed for a successful placement, decrease the number of post-placement hemorrhagic events, and help improve the effectiveness of the catheter as well as patient outcomes.
62499342|NCT06048887|EXPERIMENTAL|Single Ascending Dose (Part 1)|
62499343|NCT06048887|EXPERIMENTAL|Multiple Ascending Dose (Part 2)|
62699318|NCT05946044|NO_INTERVENTION|Attention Control|This comparison group provides attention, social interaction, and healthy lifestyle classes. There will be 4, 1-hour face-to-face group meetings per year featuring community health professionals, quarterly newsletters, and quarterly text messages.
62699319|NCT05946044|EXPERIMENTAL|Diet and Exercise|The dietary component of the weight loss intervention is characterized by the frequency of contacts, methods to induce dietary restriction, and behavioral therapy strategies. The first 6 months of the diet program is an energy-restricted diet with the option of using partial meal replacements and nutritious snacks (Rapid Nutrition, PLC). The weight loss goal for the diet and exercise group is a minimum of 10% of baseline body weight by the end of year 1. The weight loss phase is followed by 3 years of a weight-loss maintenance program, with the goal of sustaining the achieved weight loss. The exercise component includes 60-minute sessions 2 days per week for 48 months.
62699320|NCT00895505|ACTIVE_COMPARATOR|oral anticoagulants|Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.
62699321|NCT00895505|NO_INTERVENTION|2|Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.
62699322|NCT02570438||Older surgical patients|older patients (≥ 65 years of age) presenting to Massachusetts General Hospital (MGH) or Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery requiring hospital admission
62499344|NCT06160388||Patients that underwent mastoidectomy + mastoid obliteration using bioactive glass|This is the intervention group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy followed by obliteration of the mastoid cavity using S53P4 bioactive glass for any indication
62699323|NCT06639087|ACTIVE_COMPARATOR|AZD5462 + dapagliflozin|Participants will receive AZD5462 on top of dapagliflozin once daily.
62699324|NCT06639087|PLACEBO_COMPARATOR|Placebo + dapagliflozin|Participants will receive placebo on top of dapagliflozin once daily.
62699325|NCT06545552|ACTIVE_COMPARATOR|Active product|Hard shell capsule containing 280 mg of active compound.
62699326|NCT06545552|PLACEBO_COMPARATOR|Placebo|Hard shell capsule containing maltodextrine
62699327|NCT04523025||Low NLR-ratio|Patients with low NLR ratio (NLR\<3)
61950445|NCT02850601|ACTIVE_COMPARATOR|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
61950446|NCT04200950|EXPERIMENTAL|Intervention|Previse alert arm
61950447|NCT04200950|NO_INTERVENTION|Control|No alert
61950448|NCT02652832|ACTIVE_COMPARATOR|Depression Electroconvulsive therapy|40 patients with major depression receiving a mean of 12 sessions of Electroconvulsive therapy
61950449|NCT02652832|ACTIVE_COMPARATOR|Depression active repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
61950450|NCT02652832|SHAM_COMPARATOR|Depression sham repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of sham 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
61950451|NCT02652832|ACTIVE_COMPARATOR|Schizophrenia active transcranial magnetic stimulati|40 patients with schizophrenia and predominant negative symptoms receiving 20 sessions of intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
62342024|NCT03386578|EXPERIMENTAL|Pharmacokinetics Component: Group 1|Participants will be enrolled during singleton pregnancy at 14-24 weeks' gestation. Participants will receive a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) once daily under direct observation from Day 0 through Week 12.
62499345|NCT06160388||Patients that underwent mastoidectomy alone|This is the control group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy without mastoid obliteration for any indication
62499346|NCT02262741|EXPERIMENTAL|MEDI4736 + tremelimumab|
62699328|NCT04523025||High NLR-ratio|Patients with high NLR ratio (NLR≥3)
62699329|NCT06460376|EXPERIMENTAL|Wurn technique|The principle intent of the Wurn Technique is to decrease pain and increase mobility and function of abdominopelvic and reproductive organs by diminishing adhesions. The protocol focuses on deforming the adhesive collagen cross-links comprising adhesions that appear to contribute to the underlying causes of endometriosis.
62699330|NCT06460376|ACTIVE_COMPARATOR|Mercier therapy|The principal intent of mercier therapy is visceral pelvic manipulation that addresses scar tissue, adhesions, and the misalignment of pelvic organs. It increases blood flow and circulation to the pelvis.
61950452|NCT02652832|SHAM_COMPARATOR|Schizophrenia sham transcranial magnetic stimulation|patients with schizophrenia and predominant negative symptoms receiving 20 sessions of sham intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
61950453|NCT02652832|ACTIVE_COMPARATOR|Schizophrenia active transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
61950454|NCT02652832|SHAM_COMPARATOR|Schizophrenia sham transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of sham transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
62699331|NCT05577741|EXPERIMENTAL|Interventional Group|"Patients complete a measurement session at inclusion visit (Day 1). These measures include an assessment of explicit and implicit craving, a measure of mindfulness skills and a measure of the perceived richness (in stimuli) of daily environment. After inclusion visit, patients randomized in the interventional group will have 6 sessions of enriched environment (from Day 2 to Day 9).~The enriched environment includes:~* the multisensory virtual reality pod offers sessions of 20 minutes of mindfulness in immersive situations. Some immersive situations are relaxing and others trigger cues in order to improve craving management;~* the cognitive bike offers training sessions of 20 minutes. The patient pedals while using a touch pad with cognitive training games. This simultaneously stimulate motor skills and cognition by means of bicycle-game coupling.~A second measurement session takes place at Day 10. Alcoholic relapse is then evaluated at two weeks, one month and 3 months."
62699332|NCT05577741|ACTIVE_COMPARATOR|Control Group|"Patients complete a similar measurement session to the intervention arm, that include psychological tasks and questionnaires at inclusion visit (Day 1). After inclusion visit, patients randomized in the control group wil received the standard of care.~A second measurement session takes place at Day 10. Alcoholic relapse is then evaluated at two weeks, one month and 3 months."
61950455|NCT02652832|NO_INTERVENTION|Healthy volunteers|80 healthy volunteers receiving no stimulation
62699333|NCT03790189|EXPERIMENTAL|Bone Marrow Concentrate|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
61950456|NCT06088875|EXPERIMENTAL|Group N (Nebulization group)|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg nebulization + saline 10 ml via spray-as-you-go technique.
61950457|NCT06088875|EXPERIMENTAL|Group S (Spray-as-you-go)|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization.
61950458|NCT04797078|ACTIVE_COMPARATOR|Transrectal fusion biopsies of the prostate|"1. Transrectal approach, patient in left lateral position, local anestesia 10ml lidocaine 1% at prostate base laterally and apex if indicated.~2. MRI-ultrasound fusion-guided biopsies with 4 biopsy cores per lesion, where clinically indicated. 18G biopsy needle.~3. Standard 12-core template for systematic biopsies. 18G biopsy needle.~4. Antibiotic prophylaxis with 750mg ciprofloxaicin, single dose p.o."
61950459|NCT04797078|EXPERIMENTAL|Transperineal free hand fusion biopsies of the prostate|"Men randomized to the experimental arm undergoes free-hand targeted transperineal fusion biopsies as defined below.~1. Patient is placed supine in the lithotomy-position. The perineal area is prepared with chlorhexidine 0,5ml/ml.~2. Ropivacain 7,5mg/ml is used as an anesthetic agent. Up to 40ml's (equivalent to 300mg) can be used to anestitize the skin, caudal and cranial part of the urogenital diaphragm and periprostatic tissue.~3. Free-hand MRI-ultrasound fusion-guided biopsies with at least 4 biopsy cores per lesion. Coaxial technique with 18G biopsy needle.~4. 10-12 Systematic biopsies according to the modified Barzell 12-core template.~5. No antibiotic profylaxis unless warranted by immunosuppression, previous sepsis or urinary tract infection."
61950460|NCT04969575||day 3 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.~Media refreshment: Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3). Embryo grading will not be done day2-5. Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator. Embryo grading should be done prior to media refreshment. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
61950461|NCT04969575||day 5 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.~Media refreshment and embryo grading timings: Zygote scoring on day 1 (18-20hpi). Embryo grading and culture media refreshment will be done 114-118 hours post insemination (Day5).~Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops. Dishes will be equilibrated overnight in a CO2 incubator.~Embryo grading and media refreshment is done prior to blastocyst biopsy. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
61950462|NCT01790854|EXPERIMENTAL|Prasugrel dose 5 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
61950463|NCT01790854|ACTIVE_COMPARATOR|Prasugrel dose 10 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months
61950464|NCT05866406|EXPERIMENTAL|TRE group|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
61950465|NCT05866406|ACTIVE_COMPARATOR|Control group|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
62699334|NCT03459222|EXPERIMENTAL|Arm A|Relatlimab + Nivolumab + BMS-986205
62499347|NCT05586724|ACTIVE_COMPARATOR|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
61950466|NCT00003970|EXPERIMENTAL|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 90 minutes once every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.
61950467|NCT05820945|EXPERIMENTAL|Medication review group|Pharmacist-led medication review at patient level, and change proposals at physician level.
61950468|NCT05820945|NO_INTERVENTION|Control group|Usual pharmacotherapy management.
61950469|NCT04094129|PLACEBO_COMPARATOR|Placebo|Subjects received two placebo sachets per day
61950470|NCT04094129|EXPERIMENTAL|Probiotic|Subjects received two Wismemo sachets with 1x10\^10 cfu/day
62140866|NCT06232681|EXPERIMENTAL|Progressive relaxation exercise application|Progressive relaxation exercise practice Those who agree to participate in the study will be asked to fill in the Patient and Patient Relative Form, Cheltanhams Patient Classification Scale, Caregiving Burden Scale and Meaning and Purpose of Life Scale, which include personal information and information about the patient. Relaxation exercises will be explained and demonstrated by the researcher (Funda AKTÜRK) once a day for 1 month starting from the hospitalisation to the clinic and will be played on the computer. You will be asked to perform these exercises after listening to the video (CD). Relaxation exercises are exercises based on stretching and relaxing your muscles. Before the application, in the middle of the application (15th day) and at the end of the application, all forms except the introduction form will be filled in again.
62342025|NCT03386578|EXPERIMENTAL|Pharmacokinetics Component: Group 2|Participants will be enrolled postpartum within 6-12 weeks after delivery. Participants will receive a fixed-dose combination of FTC/TDF once daily under direct observation from Day 0 through Week 12.
62342026|NCT03386578|EXPERIMENTAL|PrEP Comparison Component: Cohort 1|Participants will receive daily oral PrEP (FTC/TDF) from Day 0 through Week 26. Participants will also receive behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
62342027|NCT03386578|ACTIVE_COMPARATOR|PrEP Comparison Component: Cohort 2|Participants will receive a behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
62342028|NCT04863924||Advanced NSCLC|Patients with radiologic evidence of advanced (unresectable stage III or IV) non-small cell lung cancer
62342029|NCT01642836|EXPERIMENTAL|multi-component, multi-level, multi-setting (MMM)|"1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions."
62342030|NCT01642836|ACTIVE_COMPARATOR|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
62499348|NCT05586724|ACTIVE_COMPARATOR|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan.
62140867|NCT06232681|NO_INTERVENTION|Control group|The participants in the control group also filled in the data collection tools without undergoing any intervention.
62140868|NCT04747418||Study Group: Women with low segment uterine scar following cesarean delivery|Women with low segment uterine scar following cesarean delivery, with no other abnormalities observed during diagnostic hysteroscopy
62140869|NCT04747418||Cohort Group: Women with no uterine scar|Women with no uterine scar, with no other abnormalities observed during diagnostic hysteroscopy
62140870|NCT06207617|EXPERIMENTAL|Immediate implant placement + customized healing abutment|After atraumatic extraction, flapless immediate implant of a suitable size will be placed using sequential drills of the Straumann implant system for osteotomy preparation. According to the prosthetically driven planned position, implant will be placed. Primary stability of the implant will be measured by rotational insertion torque, to be more than or equal 30 Ncm. All patients will receive an immediate anatomical customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
62499349|NCT06239844|EXPERIMENTAL|Nav-Team|Participants in this arm will receive additional assistance related to asthma, and will participate in encounters over the subsequent 9 months
62499350|NCT06239844|NO_INTERVENTION|Non-Nav-Team|Participants in this arm will participate in surveys but will receive no navigation assistance.
62342031|NCT03425942|EXPERIMENTAL|Internet CBT for insomnia|The intervention consists of Internet-based Cognitive Behavioral Therapy for insomnia (ICBT-i) (the main components are sleep restriction and stimulus control) for five consecutive weeks.
61950471|NCT04007926|NO_INTERVENTION|Control Group|Participants assigned to the control arm of the study will be asked to maintain their normal dietary and exercise habits.
61950472|NCT04007926|EXPERIMENTAL|Aerobic exercise group|Participants randomised to the aerobic exercise intervention will undertake a 12-week aerobic exercise training programme.
61950473|NCT04007926|EXPERIMENTAL|Resistance exercise group|Participants randomised to the resistance exercise intervention will undertake a 12-week aerobic exercise training programme.
61950474|NCT06311786|EXPERIMENTAL|[14C]-BIIB091|Participants will receive a single oral dose of \[14C\]-BIIB091 on Day 1.
61950475|NCT06051370|EXPERIMENTAL|Glenohumeral injection|Ultrasound-guided posterior approach of glenohumeral space injection for impingement syndrome with mild stiffness of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline.
62342032|NCT03425942|ACTIVE_COMPARATOR|Internet ART for insomnia|The intervention consists of internet-based applied relaxation exercises/techniques (ART) (different and commonly used) for five consecutive weeks.The acronyme for this intervention is (IART-i).
62499351|NCT02813382||B-group|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
62499352|NCT02813382||C-group|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
62140871|NCT06207617|ACTIVE_COMPARATOR|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|After atraumatic extraction, immediate implant will be placed as mentioned-above, then particulate xenogeneic bone graft will be packed into the gap between the implant and the buccal plate mesially and distally. bone grafting will be up to the level of the buccal bone crest, followed by screwing the customized healing abutment.
62140872|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
62140873|NCT04865718||neurovascular surgery group|Subjects undergoing neurovascular surgery including aneurysm clipping
62342033|NCT03033238||Early or mild knee symptoms|"Existing Cohort study participants (3,026) were enrolled in 2003-2005, Surviving participants without endstage knee osteoarthritis will be asked to participate in the 144-, 152-, 160- and 168-month follow-up contacts \[2,660 were enrolled\].~New Cohort study participants (1,500) will be recruited and enrolled in 2016-2018 \[1,525 were enrolled\]."
62499353|NCT02813382||P-group|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
62499354|NCT06074640|EXPERIMENTAL|interventional group 1(MET PIR with Dry needling)|Participants of this group will be treated with a MET protocol, and a dry needling session for Calf muscles MTrPs. Home regimen of self stretches for Calf muscles and plantar fascia will be given to patients
62499355|NCT06074640|EXPERIMENTAL|interventional group II (MET PIR without dry needling)|participants will follow the same MET PIR exercises but without adjunct dry needling for Calf muscles. Home regimen of self stretches for Calf muscles and plantar fascia will be given to patients
62499356|NCT02277951||Participants|The Bonfils Intubation Fibrescope the Video Rigid Flexing Laryngoscope the C-MAC® S Video Laryngoscope the Macintosh Laryngoscope
62499357|NCT06024382|EXPERIMENTAL|twin block|group treated with twin block only
62499358|NCT06024382|EXPERIMENTAL|twin block combined with low level laser|group treated with twin block combined with low level laser therapy
62499359|NCT04307849|EXPERIMENTAL|Adolescent Health Club|A systematic approach for the adaptation of sexual health/HIV-related evidence-based interventions
62499360|NCT04307849|PLACEBO_COMPARATOR|Wait-list Control|
62499361|NCT06677671||Healthy|Healthy Individuals
62499362|NCT06677671||COPD|Chronic Obstructive Pulmonary Disease Patients
62342034|NCT02010437|ACTIVE_COMPARATOR|Foam Sclerotherapy Group|"The axial vein will be cannulated under local anaesthesia and ultrasound guidance with the patient reclined in a supine position for GSV or ASV treatment, prone position if SSV or GV treatment.~The foam is then prepared by the Tessari technique by the surgeon. Two 2-ml syringes will be connected via a three way stop-cock tap and a 5 micron filter in series (Braun Medical, Sheffield, UK). The syringes will contain 1 part Sodium Tetradecyl Sulphate 3% and 3 parts air. In practice 0.5ml of 3% STS will be drawn up against 2 ml of air. The foam will be produced by at least 20 passages from syringe to syringe through the filter.~Up to 2ml of foam will be injected into each cannula under ultrasound control to observe venous spasm, followed by gentle massaging of the skin to propagate the foam through the segment of vein treated."
62499363|NCT00799708|PLACEBO_COMPARATOR|1|Placebo
62499364|NCT00799708|ACTIVE_COMPARATOR|2|Estrace 0.5 mg
62499365|NCT00799708|ACTIVE_COMPARATOR|3|Estrace 2 mg
62499366|NCT03460899|EXPERIMENTAL|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
62499367|NCT04315779|ACTIVE_COMPARATOR|Conventional laparoscopy|In this arm, patients will be treated via conventional laparoscopy
62699335|NCT03459222|EXPERIMENTAL|Arm B|Relatlimab + Nivolumab + Ipilimumab
62499368|NCT04315779|ACTIVE_COMPARATOR|Transvaginal natural orifice transluminal endoscopic surgery|In this arm, patients will be treated via transvaginal natural orifice transluminal endoscopic surgery
61950476|NCT06051370|ACTIVE_COMPARATOR|Subacromial injection|Ultrasound-guided anterolateral approach of subacromial space injection for impingement syndrome with mild stiffness of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline.
62140874|NCT02945059|EXPERIMENTAL|1|Patients will undergo reversible PVE before major hepatic resection.
62140875|NCT01256242|EXPERIMENTAL|Group 1|Standard Suture Repair + Augment Rotator Cuff
62140876|NCT01256242|ACTIVE_COMPARATOR|Group 2|Standard Suture Repair
62140877|NCT03408028||Cognitive impairment|Geriatric patients with a cognitive impairment
62140878|NCT05523869|EXPERIMENTAL|Intravitreal topotecan with pars plana vitrectomy with or without scleral buckle|
62140879|NCT05523869|ACTIVE_COMPARATOR|Pars plana vitrectomy with or without scleral buckle|
62499369|NCT04436133|EXPERIMENTAL|vaccine group|
62499370|NCT04436133|ACTIVE_COMPARATOR|Positive control group|
62499371|NCT02296957|EXPERIMENTAL|Intervention|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
62499372|NCT02296957|NO_INTERVENTION|Control|Usual Care
62499373|NCT00147914|ACTIVE_COMPARATOR|1|cefdinir
62499374|NCT00147914|ACTIVE_COMPARATOR|2|amoxicillin/clavulanate
62499375|NCT03267654|EXPERIMENTAL|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
62499376|NCT03267654|EXPERIMENTAL|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
62499377|NCT03267654|ACTIVE_COMPARATOR|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
62499378|NCT05998291||Refractory dermatitis herpetiformis patients|Dermatitis herpetiformis rash not controlled by strict glute-free diet
62499379|NCT05998291||Dermatitis herpetiformis patients with good response to gluten-free diet|Dermatitis herpetiformis rash controlled by strict glute-free diet
62499380|NCT01148225|OTHER|Adalimumab|Participants received open label (OL) adalimumab 40 mg by subcutaneous (SC) injection every other week (eow) until the final visit.
62699336|NCT04722354|ACTIVE_COMPARATOR|ABA group|95 ug 2x/day for 14 days
62699337|NCT04722354|PLACEBO_COMPARATOR|Placebo group|Corn Starch 300 mg for 14 days
61950477|NCT00006111|EXPERIMENTAL|resectable disease|
61950478|NCT00006111|EXPERIMENTAL|unresectable disease|
62699338|NCT04661488||Children and adolescence|
61950479|NCT04996108||Participants with recurrent pericarditis (RP)|Patients aged 16 or over with (1) RP, diagnosed by a clinician, meeting the European Society of Cardiology (ESC) diagnostic criteria, and (2) where the aetiology of the RP is defined as idiopathic (i.e. there is no other aetiology identified, such as infective, malignant, post cardiac injury, as part of an autoimmune condition, as part of another known auto-inflammatory disease).
62342035|NCT02010437|ACTIVE_COMPARATOR|Catheter Directed Foam Sclerotherapy (CDS) Group|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and a guide-wire inserted to facilitate the placement of the catheter system.The appropriate Unifuse® catheter will be selected and deployed through the introducer sheath and advanced to within 2cm of the junction or perforator at the upper limit of incompetence or the top of the incompetent segment in the case of segmental reflux. A 1:3 foam of 3% STD will be produced as described for FS. At this point the patient will be repositioned into a Trendelenburg position (head up)
61950480|NCT04996108||Participants with systemic auto-inflammatory diseases (disease controls)|Patients aged 16 or over with a systemic auto-inflammatory disease, diagnosed by a trained specialist.
61950481|NCT04996108||Healthy volunteers (healthy controls)|Sex, ethnicity and aged matched healthy individuals who do not have a personal history of pericarditis or systemic auto-inflammatory disease.
62499381|NCT06580561|EXPERIMENTAL|Move and Snooze program|This includes the personalized exercise program plus Cognitive Behavioral Therapy for Insomnia (CBT-I).
62699339|NCT02227355||PD Patients < 70 years of age|Patients with Parkinson's Disease (PD) \<70 years of age.
62699340|NCT02227355||PD Patients ≥ 70 years of age|Patients with Parkinson's Disease (PD) ≥ 70 years of age.
62699341|NCT04349969|EXPERIMENTAL|Treatment|"Parts A and B: AK117 monotherapy intravenous (IV) infusion- weekly doses in a 28-day cycle.~Parts A2: AK117 (QW) + AK104 (Q3W) combination therapy intravenous (IV) infusion in a 21-day cycle."
62699342|NCT06274957|EXPERIMENTAL|control|Conventional training was applied to the patients
62699343|NCT06274957|EXPERIMENTAL|Positive Expiratory Pressure|We applied PEP (positive expiratory pressure) therapy in adddition to the conventional exercises
62699344|NCT06274957|EXPERIMENTAL|High Frequency Chest Wall Oscillation|We applied HFCWO (High Frequency Chest Wall Oscillation) in addition to the conventional exercises
62699345|NCT03068000|EXPERIMENTAL|Judo training|Judo intervention will take place twice a week, lasting 50 minutes per session, for 3 months, divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
62699346|NCT03068000|ACTIVE_COMPARATOR|Ball games|The Ball Games will take place twice a week, with a duration of 50 minutes per session, for 3 months, divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
62699347|NCT05246566||Subjects covered for suspected or SE diagnosis|"Patients covered for suspected or SE diagnosis defined by one of the following:~* a prolonged generalized tonic-clonic crisis lasting more than 5 minutes and accompanied by impaired consciousness or at least 2 generalized tonic-clonic crisis without return to normal consciousness between crisis.~* a focal convulsive crisis (motor or not) with disturbances of consciousness which lasts beyond 10 minutes or crisis which are repeated (≥ 2) at short intervals without recovery of interictal consciousness.~* a focal convulsive crisis (motor or not) without alteration of consciousness that lasts beyond 10 to 15 minutes.~* an absence-type crisis that lasts longer than 10 to 15 minutes.~* a myoclonic, clonic and tonic crisis that lasts longer than 10 to 15 minutes.~* a coma with an epileptic cause diagnosed on an EEG."
61950482|NCT04996108||Relatives of individuals with recurrent pericarditis (familial controls)|First degree relatives of participants meeting the criteria for, and included in the study as, RP cases, who are aged 16 or over.
61950483|NCT00684099|EXPERIMENTAL|1|
62140880|NCT05088421|EXPERIMENTAL|BWC0977|"SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hours. Planned doses to be studied are 120, 240, 480, 720, and 1050mg.~MAD Cohorts: Subjects will receive multiple doses of 240mg TID 7 days, 350mg TID 7 days BWC0977 via IV infusion over 2 hours in the first 2 cohorts. The dose for the B3 cohort will be determined based on safety and tolerability data from the previous two cohorts Up to three dose groups will be studied."
62140881|NCT05088421|PLACEBO_COMPARATOR|Placebo|"Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hour.~MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hour for 10 consecutive days. Frequency of infusions will be determined based on safety, tolerability and PK data obtained for BWC0977 in SAD Cohorts."
62140882|NCT04089930||Vaccine|Those SLE patients who had been given herpes zoster vaccine in our original RCT
62699348|NCT04993196|EXPERIMENTAL|T1rho MRI|
62699349|NCT00492544|EXPERIMENTAL|Cervarix|Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
62699350|NCT06569719|EXPERIMENTAL|Intervention|Patients who have recieved lymphovenous anastomosis in the past 12 months and participates in complex decongestive therapy (CDT), including all its techniques, consisting of a total of 10 therapy sessions and a follow-up at 3 months
61950484|NCT02304718|EXPERIMENTAL|exercise intervention group|Pregnant women randomised to the exercise intervention group will complete three supervised, exercise sessions each week, exercise sessions completed on alternate days, and lasts until they give birth by using a stational bike. And also they will have regular prenatal care.
61950485|NCT02304718|NO_INTERVENTION|control group|Pregnant women randomised to the control group only have regular prenatal care.
61950486|NCT03659500||Four-week routine bloodwork|Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014
61950487|NCT03659500||Six-week routine bloodwork|Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015
61950488|NCT03328767|EXPERIMENTAL|Early activity and Mobilisation intervention|Patients will be randomised within 48 hrs of commencing ECMO. Patients unable to initially receive active physical training will receive passive physical training for a minimum of 20 minutes and a maximum of one hour per day to maintain joint and muscle activity until active physical training is commenced. The intervention involves a progression of exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 minutes) at each session, based on our published ICU mobility scale now used internationally in ICU trials. This is performed with or without IMV (including both endotracheal tubes or tracheostomies).
61950489|NCT03328767|NO_INTERVENTION|Standard Care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
61950490|NCT00915122|EXPERIMENTAL|IMRT in prostate cancer|
62699351|NCT06569719|NO_INTERVENTION|Control|Patients received lymphovenous anastomosis and they are provided with compression garments as part of the treatment withot recieving CDT . This group will have an initial assessment and follow-up at 3 months
62699352|NCT03375242||crizotinib|
62342036|NCT02010437|ACTIVE_COMPARATOR|ClariVein Group (CV) Treatment|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and the ClariVein device 4-F micro sheath will be introduced up the vein via a guide wire as per manufacturer's instructions. Concentration of STD will depend on axial vein to be treated; if treating GSV or ASV 1.5% STD liquid will be used, if SSV or GV 1.0% STD liquid will be used. Volume of STD to be prepared for the CV treatment will be calculated using a dosage chart provided by the manufacturer
62342037|NCT03038659||Penile Duplex|Measuring intima media thickness
62342038|NCT06536764|EXPERIMENTAL|Interventional group|This group will receive Conventional therapy (hot pack, TENS, patient education) \& Progressive muscle Relaxation exercises on low back 2 sessions per week for 6 weeks.
62342039|NCT06536764|ACTIVE_COMPARATOR|Control Group|This group will receive Conventional therapy 2 sessions per week for 6 weeks. Conventional therapy involves hot pack, TENS and patient education.
62699353|NCT06645184|OTHER|ONS with fibre with added nutrients|
62699354|NCT06645184|OTHER|ONS without fiber with added nutrients|
61950491|NCT04779346||Outpatient cancer patients|Cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)
61950492|NCT00828412|ACTIVE_COMPARATOR|1|EpiCeram Skin Barrier Emulsion
62699355|NCT06645184|OTHER|ONS with fibre without added nutrients|
62342040|NCT05997017|EXPERIMENTAL|Endometrioid Endometrial Cancer|Patients with advanced or recurrent endometrioid endometrial carcinoma
62342041|NCT01057069|EXPERIMENTAL|HRD; 1x ddAC, 2x tCTC|HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
62342042|NCT01057069|ACTIVE_COMPARATOR|HRD; 3x CP|HRD tumors; any response to 3x ddAC; 3 courses of CP
62342043|NCT01057069|ACTIVE_COMPARATOR|non-HRD;3x CP|non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
62342044|NCT01057069|ACTIVE_COMPARATOR|non-HRD; response; 3x ddAC|non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC
62342045|NCT01057069|ACTIVE_COMPARATOR|non-HRD; response; 3x CP|non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
62699356|NCT06645184|OTHER|ONS without fibre without added nutrients|
62699357|NCT02766855|EXPERIMENTAL|cysteamine eye drops|Patients used cysteamine eye drops every 2 hours while awake to both eyes.
62699358|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 1)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 1 administered with a DPI.
62699359|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 2)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 2 administered with a DPI.
62699360|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI(Dose 3)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 3 administered with a DPI.
62699361|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 4)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 4 administered with a DPI.
62699362|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 5)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 5 administered with a DPI.
62699363|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 6)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 6 administered with a DPI.
61950493|NCT00828412|ACTIVE_COMPARATOR|2|Desonide Cream 0.05%
61950494|NCT00675948|EXPERIMENTAL|Sativex|Active treatment
61950495|NCT00675948|EXPERIMENTAL|GW-2000-02|Active treatment
61950496|NCT03175757|EXPERIMENTAL|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
61950497|NCT03175757|PLACEBO_COMPARATOR|Placebo|Placebo
62140883|NCT04089930||Placebo|Those SLE patients who had been given placebo vaccination in our original RCT
62140884|NCT05430555|EXPERIMENTAL|MAGE-A1 - directed TCR transduced autologous T-cells|Single-dose, intravenous infusion
62342046|NCT06188195|EXPERIMENTAL|the experimental group|For pregnant women with a probability greater than 80% in the prediction model of NARDS, those who agreed to ACS intervention were included in the experimental group
62342047|NCT06188195|NO_INTERVENTION|the control group|For pregnant women with a probability greater than 80% in the prediction model of NARDS, those who did not agree with ACS intervention were included in the control group
62342048|NCT02054143|EXPERIMENTAL|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) after the intubation occured until the patient was extubated.
62499382|NCT06580561|EXPERIMENTAL|Personalized exercise program|
62499383|NCT01041235|EXPERIMENTAL|ATI-1123|
62342049|NCT06082648|SHAM_COMPARATOR|Sham Stimultion Group|Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
61950498|NCT05430152|EXPERIMENTAL|Low-Dose Naltrexone|The Low-Dose Naltrexone (LDN) will be provided as a compounded capsule starting at a strength of 1mg/day of naltrexone and increasing up to a maximum of 4.5 mg/day. The compounding pharmacy will compound the needed doses in Capsugel® empty gelatin based capsules using Naltrexone Hydrochloride Tablets and CELLULOSE.
61950499|NCT05430152|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule will be created by compounding pharmacy to look exactly like the LDN doses. The compounding pharmacy will compound the placebo in Capsugel® empty gelatin based capsules using CELLULOSE.
62499384|NCT02131935||ISR Group|Patients Group Experienced In-Stent Restenosis (ISR)
61950500|NCT01685034|EXPERIMENTAL|Allergy Immunotherapy Group|There is only one active experimental group as this is a pilot study comparing clinical/histologic/endoscopic changes before and after treatment.
61950501|NCT06349330|EXPERIMENTAL|3D intra-oral scanner|Subjects will undergo 3D scanning and the 3D rendered image will be used to facilitate oral hygiene instructions.
61950502|NCT06349330|ACTIVE_COMPARATOR|Standard oral hygiene|Subjects will receive standard oral hygiene instructions with hand mirror.
61950503|NCT03532841|EXPERIMENTAL|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
61950504|NCT03532841|PLACEBO_COMPARATOR|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
62140885|NCT06700096|NO_INTERVENTION|Lead-in|All subjects will be enrolled in the Lead-in period in order to collect information on individual bleeding rate anf FIX concentrates consumption
62499385|NCT02131935||Non-ISR|Patients Group Without in-stent restenosis (ISR)
62499386|NCT06678074|EXPERIMENTAL|Experimental drug intervention|monoclonal antibody against CD14
62499387|NCT06678074|PLACEBO_COMPARATOR|Placebo|Identical-appearing normal saline for injection, intravenous, once
62499388|NCT02658019|EXPERIMENTAL|Pembrolizumab in Advanced HCC|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.
62499389|NCT03114345|OTHER|Single arm|Measurement of interface pressure and Measurement of micro-vascularization related parameters
62499390|NCT02441322|EXPERIMENTAL|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
61950505|NCT00094172|EXPERIMENTAL|Atorvastatin|80 mg/day
61950506|NCT00094172|PLACEBO_COMPARATOR|Placebo|Once daily.
61950507|NCT04512417|EXPERIMENTAL|Combined radiotherapy group|
62499391|NCT06678399|EXPERIMENTAL|Low dose|
61950508|NCT04512417|EXPERIMENTAL|Immunotherapy alone group|
61950509|NCT01161459|EXPERIMENTAL|Tripterygium wilfordii|120mg/d for 6 months,then decrease to 60mg/d by 30mg/d every month for 12 months
62140886|NCT06700096|EXPERIMENTAL|ANB-002|After completion of lead-in period subjects will enter the main period which starts with ANB-002 infusion.
62499392|NCT06678399|EXPERIMENTAL|High dose|
61950510|NCT01161459|ACTIVE_COMPARATOR|FK506|
61950511|NCT03904732||Cohort 1|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for primary prevention
62140887|NCT05986994||Group A|15 healthy newborns with umbilical cord arterial pH between 7.26 and 7.35
62499393|NCT06678399|NO_INTERVENTION|Historical matched-control group|
61950512|NCT03904732||Cohort 2|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for secondary prevention
61950513|NCT03904732||Cohort 3|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for primary prevention
61950514|NCT03904732||Cohort 4|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for secondary prevention
62342050|NCT06082648|ACTIVE_COMPARATOR|Pre-ileostomy-closure Stimultion Group|Patients on the Pre-ileostomy-closure group will be interfered with stimulation 3 weeks before the procedure of ileostomy closure.
62342051|NCT06082648|ACTIVE_COMPARATOR|Post-ileostomy-closure Stimultion Group|Patients on the Post-ileostomy-closure group will be interfered with stimulation 3 weeks after the procedure of ileostomy closure.
62499394|NCT06678399|EXPERIMENTAL|Best dose|
62499395|NCT06678399|PLACEBO_COMPARATOR|Placebo|
62499396|NCT03473002|PLACEBO_COMPARATOR|Placebo|One dose of placebo (0.9% Sodium Chloride) intranasally, n=4
62499397|NCT03473002|EXPERIMENTAL|SeVRSV|1 x 10\^7 EID50 (one dose) of SeVRSV vaccine intranasally, n=16
61950515|NCT03904732||Cohort 5|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for primary prevention
61950516|NCT03904732||Cohort 6|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for secondary prevention
61950517|NCT03904732||Cohort 7|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for primary prevention
61950518|NCT03904732||Cohort 8|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for secondary prevention
61950519|NCT01355003||All Participants|Participants who were vaccinated with GARDASIL™ by their physician
62499398|NCT06043713|EXPERIMENTAL|Treatment (FHA11KRASG12V-TCR)|Patients undergo leukapheresis prior to treatment and receive lymphodepletion chemotherapy with either cyclophosphamide IV and fludarabine IV on days -6, -5, and -4, or bendamustine IV on days -4 and -3 at the discretion of the treating clinician and/or PI. Patients then receive FHA11KRASG12V-TCR IV on day 0. Patients may receive an additional FHA11KRASG12V-TCR IV infusion as soon as 28 days or up to 1 year after the first infusion. Patients undergo ECHO or MUGA during screening. Patients also undergo CT, PET or MRI as well as blood sample collection and a tissue biopsy at baseline and throughout the trial.
62499399|NCT06220526|OTHER|Menghini-type needle|the standard needle type
62499400|NCT06220526|ACTIVE_COMPARATOR|Franseen-type needles|the active comparator arm
61950520|NCT02144623|EXPERIMENTAL|Valproate|
61950521|NCT01372592||Degenerative|Patients being treated for degenerative spine conditions.
61950522|NCT01372592||Deformity|Patients being treated for a deformity spine condition.
62342052|NCT01362218|EXPERIMENTAL|Fixed Dose Combination Pill|A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
62499401|NCT02979041|ACTIVE_COMPARATOR|control|Patients in the control group will receive standard physiotherapy and medical care, as provided to all patients with neck pain in the aviation medicine clinic. This will reflect the standard care that has been provided to all patients.
62499402|NCT02979041|EXPERIMENTAL|intervention|Standard care (as provided to controls) with the addition of virtual reality training (a self-exercise program) using a VR system to address the fast, accurate head control required in flying tasks.
62499403|NCT02613286|EXPERIMENTAL|Extrafascial Hysterectomy|Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
62499404|NCT02613286|ACTIVE_COMPARATOR|Modified radical hysterectomy|Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
62499405|NCT06073847||Participants with myelofibrosis receiving fedratinib|
62499406|NCT02973269|EXPERIMENTAL|DAXI 240 U|DaxibotulinumtoxinA for injection for the treatment of plantar fasciitis (PF) with 240 U
62499407|NCT02973269|PLACEBO_COMPARATOR|Placebo|Placebo Intramuscular injection
62499408|NCT06432140|EXPERIMENTAL|VGN-R09b injection|Different levels of VGN-R09b will be injected into bilateral putamen by stereotactic surgery
62499409|NCT03638596|EXPERIMENTAL|Contingency Management|Incentive delivery contingent upon maintaining transdermal alcohol concentration below cut-off
62499410|NCT03638596|PLACEBO_COMPARATOR|Control|Incentive delivery not contingent on transdermal alcohol concentration
62499411|NCT01591915|EXPERIMENTAL|MBSR self care program including weekly sessions|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week. Participants will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 hours.
62499412|NCT01591915|EXPERIMENTAL|MBSR self care program|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week.
61950523|NCT01372592||Trauma|Patients being treated for a trauma related spine condition.
62499413|NCT01591915|NO_INTERVENTION|Standard care|
62499414|NCT03508154|ACTIVE_COMPARATOR|Control Meal 1|Control carbohydrate solution
62499415|NCT03508154|ACTIVE_COMPARATOR|Control Meal 2|Control carbohydrate solution
61950524|NCT02281201|EXPERIMENTAL|BE1116|Single intravenous (I.V.) infusion, dosage depending on baseline INR and body weight
61950525|NCT06049953||Antipsychotic medication|Pregnant women with severe mental illness (diagnosis of bipolar disorder, primary psychotic disorder, or any history of psychiatric hospitalization) who are treated with any of the following medications during pregnancy: Quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, lurasidone, haloperidol, or any other medication in the first- or second-generation antipsychotic class. All orally administered, with dosages titrated to clinical effect by the participant's primary psychiatrist.
61950526|NCT06049953||Non-antipsychotic medication|Pregnant women with severe mental illness (diagnosis of bipolar disorder, primary psychotic disorder, or any history of psychiatric hospitalization) who are treated with any psychotropic medications during pregnancy other than those listed.
61950527|NCT06049953||No medication|Pregnant women with severe mental illness (diagnosis of bipolar disorder, primary psychotic disorder, or any history of psychiatric hospitalization) who are not treated with any psychotropic medications during pregnancy.
61950528|NCT04767763||Patients with Acute Kidney Injury|Patients with acute kidney injury and indications for initiation of continuous renal replacement therapy (CRRT) were included to this study irrespective of their gender, race and age.
62342053|NCT01362218|ACTIVE_COMPARATOR|Simvastatin|Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
62342054|NCT03364673|EXPERIMENTAL|Fitness Tracker + Social Incentive Intervention|Participants will enroll with a teammate (i.e. family or friend) and collaborate together. Teams will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive a social incentive intervention.
62342055|NCT04638712|OTHER|Group 1 without trastuzumab|
62699364|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 7)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 7 administered with a DPI.
62699365|NCT04769869|EXPERIMENTAL|Part 1a (SAD): AZD4604 for inhalation via DPI|An additional cohort of healthy volunteers will receive a single inhaled dose of AZD4604 administered with a DPI.
62699366|NCT04769869|PLACEBO_COMPARATOR|Part 1a (SAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
61950529|NCT00968201|EXPERIMENTAL|1|Montelukast
62140888|NCT05986994||Group B|15 newborns with metabolic acidosis at birth with umbilical cord arterial pH at birth \< 7.12 and who do not practice therapeutic hypothermia due to lack of enrollment criteria
62342056|NCT04638712|OTHER|Group 2 with trastuzumab|
62342057|NCT05487716||Heart failure patients (HF)|"Subjects in HF were subgrouped according to their baseline left ventricular ejection fraction obtained by 2-D echocardiography as HFrEF (LVEF\<40%), HFmrEF (LVEF\>=40% and \<50%), and HFpEF (LVEF\>50%)~Subjects underwent an additional 36 sessions of high-intensity interval training (alternating 80% and 40% peak oxygen consumption) were considered HIIT participants in each subgroup (HFrEF, HFmrEF, HFpEF). Others without exercise intervention were considered multidisciplinary disease management program (MDP) participants."
62499416|NCT03508154|EXPERIMENTAL|Experimental Nutritional Product|Study nutritional formulation
62499417|NCT06113913|EXPERIMENTAL|Interventional (SC infliximab, weekly)|Participants will switch from an optimized dose of intravenous infliximab to an optimized dose of subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every week.
62699367|NCT04769869|EXPERIMENTAL|Part 1b: AZD4604 for intravenous administration|Healthy volunteers will receive a single IV dose of AZD4604 administered as a 20 minute infusion.
62699368|NCT04769869|EXPERIMENTAL|Part 1b: AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604.
62499418|NCT06113913|EXPERIMENTAL|Interventional comparator (SC infliximab, bi-weekly)|Participants will switch from an optimized dose of intravenous infliximab to subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every other week.
61950530|NCT00968201|PLACEBO_COMPARATOR|2|Placebo
61950531|NCT02649270|EXPERIMENTAL|Group1|10 Psoriasis patients,T1h 0.2mg/kg,only single dose administration at week 1.
61950532|NCT02649270|EXPERIMENTAL|Group2|10 Psoriasis patients,T1h 0.4mg/kg ,first administration at week 1 and continous administration from fifth week for 9 weeks.
61950533|NCT02649270|EXPERIMENTAL|Group3|10 Psoriasis patients,T1h 0.8mg/kg,first administration at week 1 and continous administration from fifth week for 9 weeks.
61950534|NCT02649270|EXPERIMENTAL|Group4|"10 Psoriasis patients,T1h 1.6mg/kg,first administration at week 1 and biweekly from fifth week for 9 weeks.~."
61950535|NCT00593502|ACTIVE_COMPARATOR|1|Oseltamivir
61950536|NCT00593502|PLACEBO_COMPARATOR|2|Placebo
61950537|NCT03006107|EXPERIMENTAL|intraligamentary injection of piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
61950538|NCT03006107|ACTIVE_COMPARATOR|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
61950539|NCT00638482|EXPERIMENTAL|1|Hydrochlorothiazide
61950540|NCT06240871||Pulmonary artery pressure measurements|The investigators will compare noninvasive right sided pressure measurements with invasive right heart catheterization performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
62342058|NCT02612961|EXPERIMENTAL|Saline Instillation|3mL normal saline from pink sodium chloride bullet instilled into tracheostomy immediately prior to suctioning.
62342059|NCT02612961|SHAM_COMPARATOR|Placebo|Pretend to instill 3mL of normal saline using empty pink sodium chloride bullet immediately prior to suctioning.
62342060|NCT04799236|ACTIVE_COMPARATOR|Group 1: Oral Miltefosine|Miltefosine will be administered per os at 150 mg/day \[50 mg tid\] for 28 days. This is the standard regimen of miltefosine for persons \>45 kg.
62499419|NCT06113913|ACTIVE_COMPARATOR|Intravenous comparator (IV infliximab, optimized dosing schedule)|Participants not willing to switch will continue treatment with intravenous infliximab at the same dosing schedule as before.
62699369|NCT04769869|EXPERIMENTAL|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 8)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
62699370|NCT04769869|EXPERIMENTAL|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 9)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
61950541|NCT03625622|PLACEBO_COMPARATOR|Placebo|Placebo, orally administered once daily for 26 weeks.
61950542|NCT03625622|ACTIVE_COMPARATOR|AR1001 - 10 mg|Active, AR1001 - 10 mg, orally administered once daily for 26 weeks.
61950543|NCT03625622|ACTIVE_COMPARATOR|AR1001 - 30 mg|Active, AR1001 - 30 mg, orally administered once daily for 26 weeks.
62140889|NCT05986994||Group C|15 newborns with metabolic acidosis at birth with umbilical cord arterial pH at birth \< 7.12 and practicing therapeutic hypothermia in accordance with current guidelines
62140890|NCT06678243|EXPERIMENTAL|Smiling instead of Smoking|"Participants will be onboarded to the smartphone app Smiling instead of Smoking (SiS4) and will be asked to use it for 7 weeks while they quit smoking."
62140891|NCT06678243|ACTIVE_COMPARATOR|QuitGuide|"Participants will be onboarded to the smartphone app QuitGuide (QG) which will be 're-branded', so that the name Smiling instead of Smoking will appear in the banner of the app instead of QuitGuide, and will be asked to use it for 7 weeks while they quit smoking."
62140892|NCT03406169|ACTIVE_COMPARATOR|Sildenafil 25mg Oral Tablet|25mg sildenafil citrate twice daily
62140893|NCT03406169|ACTIVE_COMPARATOR|Pentoxifylline|400mg pentoxifylline twice daily
62140894|NCT03406169|PLACEBO_COMPARATOR|Placebo|placebo twice daily
62140895|NCT03438409|EXPERIMENTAL|Single Arm Study|This study has a single arm with repeated baseline measures. This arm will complete the robotic gait training.
62140896|NCT01100151|EXPERIMENTAL|RDC-1036 (ALKS 37)|Capsules for oral administration
62140897|NCT01100151|PLACEBO_COMPARATOR|Placebo|Capsules for oral administration
62342061|NCT04799236|ACTIVE_COMPARATOR|Group 2: Intravenous pentavalent antimony|IV pentavalent antimony (meglumine antimoniate) will be administrated at 20 mg x kg x d during 20 consecutive days. Antimony will be diluted in 10 times its volume in 5%Dextrose in destilled water and injected IV in 20 minutes
62342062|NCT04799236|EXPERIMENTAL|Group 3: Intravenous liposomal amphotericin B|LAMB will be administered IV at 3 ampules \[150 mg\] on each of days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Three ampules is the individual dose suggested by Aronson et al \[2016\] and equals 2.5 mg/kg/dose for a 60 kg person. 15 doses of 3 ampules (total of 2250 mg) equals 37.5 mg/kg for a 60 kg person.
62342063|NCT02051894||HIE Group|
62342064|NCT05378516||obstetric antiphospholipid syndrome|obstetric antiphospholipid syndrome 20 cases and normal pregnant women 20 cases
62499420|NCT04309994||Experimental|bypass surgery with blood cardioplegia by means of MPS
62499421|NCT04309994||Active Comparator|bypass surgery with blood cardioplegia by means of Cardioplexol ®
62499422|NCT06003309|ACTIVE_COMPARATOR|The fully individualized form of iTBS (BOTH the frequency and E-field targeting approaches)|In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modeling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
62499423|NCT06003309|ACTIVE_COMPARATOR|iTBS individualized using E-field targeting only (targeted-iTBS)|In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modeling and coordinate-based cortical targeting.
62699371|NCT04769869|EXPERIMENTAL|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 10)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
61950544|NCT05424302|EXPERIMENTAL|Virtual Reality Group|Patients have baseline data collected two weeks pre-intervention by assessing patient symptomatology using the dizziness handicap inventory, activities specific balance confidence questionnaires and a simulator sickness questionnaire remotely. Next, an interview will be conducted to collect information including age, sex, ethnicity, physical activity level and VR experience. Lastly, VR headset will be mailed to patients home address. A date for VR device tutorial will be discussed during this interview. Next patients will undergo 4 or 8 weeks of vestibular rehabilitation if diagnosed with unilateral or bilateral vestibular hypofunction respectively. This involves weekly 40-45 minute in-person sessions with a physiotherapist and three 20 minute sessions a day of at-home independent exercises. In addition, they will undergo an at home VR vestibular rehabilitation protocol that involves playing a video game projected on an android or apple device in a VR headset for 20 minutes daily.
61950545|NCT05424302|ACTIVE_COMPARATOR|Control Group|Patients have baseline data collected two weeks pre-intervention by assessing patient symptomatology using the dizziness handicap inventory, activities specific balance confidence questionnaires and a simulator sickness questionnaire remotely. Next, an interview will be conducted to collect information including age, sex, ethnicity, physical activity level and VR experience. Next patients will undergo 4 or 8 weeks of vestibular rehabilitation if diagnosed with unilateral or bilateral vestibular hypofunction respectively. This involves weekly 40-45 minute in-person sessions with a physiotherapist and three 20 minute sessions a day of at-home independent exercises. In addition, they will undergo an at-home regime that consists of auditory stimulation while wearing a VR headset for 20 minutes daily.
61950546|NCT04996017|EXPERIMENTAL|Arm A|atezolizumab 1200mg every 21 days
61950547|NCT04996017|PLACEBO_COMPARATOR|Arm B|Placebo will be supplied by the sponsor and will be identical in appearance to atezolizumab and will comprise the same excipients but without atezolizumab every 21 days
61950548|NCT04689009|ACTIVE_COMPARATOR|SOC Group|SOC Group (or control group) will follow the standard therapy with visits twice a week. More specifically, the treatment consists of: dressing change, cleansing and eventual debridement of the lesion, the topic treatment and compression bandage.
62342065|NCT01714817|EXPERIMENTAL|BMS-188667 + Mycophenolate mofetil + Prednisone|BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
62342066|NCT01714817|PLACEBO_COMPARATOR|Placebo + Mycophenolate mofetil + Prednisone|Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
62342067|NCT02495740|EXPERIMENTAL|E-bike intervention|Intervention is active commuting to work by an electric assisted bike to work for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
62342068|NCT02495740|ACTIVE_COMPARATOR|Bike intervention|Intervention is active commuting to work by classic bike for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
62342069|NCT05129995|EXPERIMENTAL|Passive heat treatment|Infrared sauna bathing
62342070|NCT04721041|EXPERIMENTAL|Washed Microbiota Transplantation (WMT)|Patients undergo once WMT a day for three consecutive days.
62499424|NCT06003309|ACTIVE_COMPARATOR|Standard iTBS treatment (i.e., typical iTBS localized to the DLPFC using the Beam F3 method)|The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA-approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
62699372|NCT04769869|PLACEBO_COMPARATOR|Part 2 (MAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
62699373|NCT04769869|EXPERIMENTAL|Part 3 (MAD): AZD4604 for inhalation via DPI (Dose 9)|Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
62699374|NCT04769869|EXPERIMENTAL|Part 3 (MAD): AZD4604 for inhalation via DPI (Dose 10)|Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
62342071|NCT00514202|PLACEBO_COMPARATOR|1|Placebo plus cognitive behavioral therapy
62699375|NCT04769869|PLACEBO_COMPARATOR|Part 3 (MAD): Placebo for AZD4604 for inhalation via DPI|Patients will receive placebo administered with a DPI.
62342072|NCT00514202|EXPERIMENTAL|2|Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy
62342073|NCT01670409|EXPERIMENTAL|SMART combined with PF chemotherpay|SMART-base IMRT with concurrent and adjuvant chemotherapy(cisplatin and 5-fluorouracil)
62342074|NCT03308981|EXPERIMENTAL|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
62342075|NCT03308981|ACTIVE_COMPARATOR|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
62342076|NCT03308981|NO_INTERVENTION|Wait-list|Participants will not receive any intervention.
62342077|NCT00973921||Stent deployment evaluation|The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.
62699376|NCT04769869|EXPERIMENTAL|Part 3 (PoM): AZD4604 for inhalation via DPI (Dose 9 or Dose 10)|Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
62699377|NCT02458014|EXPERIMENTAL|Treatment (blinatumomab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
62699378|NCT04331275|EXPERIMENTAL|Viral Specific T-cells (VSTs)|
62499425|NCT02998606|EXPERIMENTAL|Study Group|MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily
62499426|NCT02998606|PLACEBO_COMPARATOR|Control Group|Placebo Oral Capsule 25 mg, daily
62699379|NCT04395547|PLACEBO_COMPARATOR|Placebo|
62699380|NCT04395547|EXPERIMENTAL|JointAlive™|
62699381|NCT04237584|OTHER|Enzalutamide during Lead-in Period|Randomized, open-label lead-in ARB (enzalutamide tablets, 160 mg PO QD) for 12 weeks.
62699382|NCT04237584|ACTIVE_COMPARATOR|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|Randomized, open-label lead-in ARB (enzalutamide) for 12 weeks followed by randomized, double-blind Radium-223 IV at 55 kBq/kg IV up to 6 cycles (at 4 week intervals) with continued randomized open-label enzalutamide.
62699383|NCT04237584|PLACEBO_COMPARATOR|Lead-in Enzalutamide followed by Placebo/Enzalutamide|Randomized, open-label lead-in ARB (enzalutamide) for 12 weeks followed by randomized, double-blind normal saline placebo IV up to 6 cycles (at 4 week intervals) with continued randomized open-label enzalutamide.
62699384|NCT04237584|OTHER|Darolutamide during Lead-in Period|Randomized, open-label lead-in ARB (darolutamide tablets, 300 mg PO BID) for 12 weeks.
62699385|NCT04237584|ACTIVE_COMPARATOR|Lead-in Darolutamide followed by Radium-223/Darolutamide|Randomized, open-label lead-in ARB (darolutamide) for 12 weeks followed by randomized, double-blind Radium-223 IV at 55 kBq/kg IV up to 6 cycles (at 4 week intervals) with continued randomized open-label darolutamide.
62699386|NCT04237584|PLACEBO_COMPARATOR|Lead-in Darolutamide followed by Placebo/Darolutamide|Randomized, open-label lead-in ARB (darolutamide) for 12 weeks followed by randomized, double-blind normal saline placebo IV up to 6 cycles (at 4 week intervals) with continued randomized open-label darolutamide.
62699387|NCT05073588|ACTIVE_COMPARATOR|Indo Mediterranean diet|Indian version of Mediterranean diet will be given to NAFLD children
61950549|NCT04689009|EXPERIMENTAL|EmoLED Group|EmoLED Group will be visited once a week. Therapy in this case includes, in addition to the standard therapy, a treatment with EmoLED device; it consists in irradiating each 5 cm diameter area of the lesion for 60 seconds, with the blue light emitted by the device. For lesions larger than 5 cm, several applications will be applied on adjacent areas, until the whole lesion is covered.
61950550|NCT06361433|EXPERIMENTAL|Cell product transplantation|Autologous MSC with scaffold containing approximately 5 x 10\^7 MSC cells.
61950551|NCT03070028|EXPERIMENTAL|Phenol|crystallised phenol application
61950552|NCT03070028|EXPERIMENTAL|platelet rich plasma|PRP application
61950553|NCT04775407||Screening|Serological SARS-CoV-2 test
61950554|NCT04067700|OTHER|Coronary perfusion PET/CT patients|
61950555|NCT01481597|EXPERIMENTAL|deuteporfin 1mg/kg|
61950556|NCT01481597|ACTIVE_COMPARATOR|deuteporfin 2.5mg/kg|
61950557|NCT01481597|ACTIVE_COMPARATOR|deuteporfin 5mg/kg|
61950558|NCT01481597|ACTIVE_COMPARATOR|deuteporfin 7.5mg/kg|
62699388|NCT05073588|ACTIVE_COMPARATOR|Calorie restricted Diet|Diet restricted in calories will be given to NAFLD children
62699389|NCT05126303|EXPERIMENTAL|RMC-035|"RMC-035 is a concentrate (6.0 mg/mL) for solution for infusion for IV administration.~Dosing will be based on renal function at Day -1: Subjects with eGFR ≥60 mL/min/1.73m2 will receive 1.3 mg/kg (per dose) for the first and second dose, followed by 0.65 mg/kg (per dose) for the third, fourth and fifth dose, while subjects with eGFR \>30 and \<60 mL/min/1.73m2 will receive 0.65 mg/kg (per dose) for all five doses Dosing occurs at time 0 and then after 6, 12, 24 and 48 hours."
61950559|NCT01481597|PLACEBO_COMPARATOR|placebo|
61950560|NCT04131426|EXPERIMENTAL|Remune dosed twice daily|A nutritional supplement taken twice per day each day and standard care for your cancer as prescribed by your oncologist
61950561|NCT04131426|EXPERIMENTAL|Remune dosed twice daily and daily exercise with EXCAP|A nutritional supplement taken twice by day each day and a home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
61950562|NCT04131426|NO_INTERVENTION|Usual Care|Usual standard care as prescribed by your oncologist
62140898|NCT06699186|EXPERIMENTAL|Sleep Group|The sleep group was instructed to engage in a minimum of six hours of sleep over the course of the 24-hour observation period. Individuals who slept for a duration of less than six hours were excluded from the study.
62699390|NCT05126303|PLACEBO_COMPARATOR|Placebo|Identical to RMC-035 arm except that the placebo contains no active ingredient.
62699391|NCT02106806|EXPERIMENTAL|Zinc chemotherapy|Patients in colorectal chemotherapy supplemented with zinc
61950563|NCT00385710|EXPERIMENTAL|valproic acid|Depakine
61950564|NCT00385710|PLACEBO_COMPARATOR|Placebo|Placebo
61950565|NCT02432495||Anterior screw fixation|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
62140899|NCT06699186|ACTIVE_COMPARATOR|Non-sleep group|The participants were permitted to sleep for a maximum of four hours in total over the course of the 24-hour period in non-sleep group.
62140900|NCT01462799|EXPERIMENTAL|PBL- patient education|Patients will be randomised to PBL in patient education (experiment group)
62699392|NCT02106806|PLACEBO_COMPARATOR|Placebo chemotherapy|Patients in colorectal chemotherapy with placebo
62140901|NCT01462799|EXPERIMENTAL|Mailed patient information|Patients will be randomised to controlgroup receiving mailed patient information during the year
62699393|NCT02106806|OTHER|Zinc Control|Healthy volunteers supplemented with zinc
61950566|NCT02432495||Halo immobilization|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone of halo immobilization of type II odontoid fractures
61950567|NCT06343740|EXPERIMENTAL|COMET-Y|All participants receive COMET-Y.
61950568|NCT04722887|EXPERIMENTAL|Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)|Participants will receive Alpha-1 15% 72 mg/kg, single weekly subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.
61950569|NCT04722887|EXPERIMENTAL|Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)|Following treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation phase, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
61950570|NCT04722887|EXPERIMENTAL|Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)|Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.
61950571|NCT04722887|EXPERIMENTAL|Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)|Participants will receive Alpha-1 15% 180 mg/kg, single weekly SC infusion in treatment-period 1 (Single-Dose) at Week 1.
62699394|NCT02106806|OTHER|Placebo Control|Volunteers received placebo
61950572|NCT04722887|EXPERIMENTAL|Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)|Following treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation phase. During the single-dose data evaluation phase, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
61950573|NCT04722887|EXPERIMENTAL|Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)|Following treatment period 1 and single-dose data evaluation phase, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 180 mg/kg, for 8 weekly SC infusions.
61950574|NCT04121923|EXPERIMENTAL|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG) will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. There will be no separate arm to test a different device.
61950575|NCT04903275|EXPERIMENTAL|Fluoride and Laser|In the split-mouth design, the left maxillary anterior teeth receive topical fluoride application and carbon dioxide (CO2) laser irradiation.
61950576|NCT04903275|ACTIVE_COMPARATOR|Fluoride|In the split-mouth design, this arm - the contralateral teeth (right maxillary incisors), will receive topical fluoride application.
61950577|NCT00474760|EXPERIMENTAL|1|
61950578|NCT01484678||Age Matched Controls|"Age matched non-affected (non-DMD) boys \* This arm is full~Age matched non-affected men, matched for men with Becker MD \*Recruiting"
61950579|NCT01484678||Boys/Men with DMD|This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. \*Recruiting
61950580|NCT01484678||Adults with Becker MD|This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. \* Recruiting
61950581|NCT02420522|EXPERIMENTAL|Active-first|Participants randomly assigned to this arm will receive one week of active Repetitive Transcranial Magnetic Stimulation prior to one week of Sham Transcranial Magnetic Stimulation, separated by at least one week.
61950582|NCT02420522|EXPERIMENTAL|Sham-first|Participants randomly assigned to this arm will receive one week of Sham Transcranial Magnetic Stimulation prior to one week of active Repetitive Transcranial Magnetic Stimulation, separated by at least one week.
62342078|NCT04171648|EXPERIMENTAL|Roasted Peanut Group 1|Arm 1 is the arm of participants that will receive the roasted peanut treatment first and then will crossover to the boiled peanut treatment.
62342079|NCT04171648|EXPERIMENTAL|Boiled Peanut Group 1|Arm 2 is the arm of participants that will receive the boiled peanut treatment first then will crossover to the roasted peanut treatment.
62342080|NCT01469663||Healthy Control|Healthy participants without borderline personality or depression
62342081|NCT01469663||Major Depression, No Borderline Personality Disorder|With major depression and no borderline personality
62342082|NCT01469663||Major Depression + Borderline Personality Disorder|With major depression and borderline personality disorder
62342083|NCT01469663||No Major Depression, Borderline Personality Disorder|With no major depression, but with borderline personality disorder
62342084|NCT03435263||hospital admission group B|Women presented with premature rupture of membranes will be admitted at hospital.
62342085|NCT03435263||home management group A|home management
62699395|NCT02457065|EXPERIMENTAL|Receive Plaque|"Treatment~Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators gave the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors."
61950583|NCT02420522|ACTIVE_COMPARATOR|Full-course Active|Participants in this arm will receive three weeks (30 session, twice-daily) of active Repetitive Transcranial Magnetic Stimulation. This arm will not involve random assignment.
61950584|NCT00808990|EXPERIMENTAL|OSA and NAFLD patients using CPAP|OSA and NAFLD patients using CPAP being followed for 6 months.
61950585|NCT00808990|NO_INTERVENTION|control|OSA and NAFLD patients not using CPAP being followed for 6 months.
61950586|NCT00669656|EXPERIMENTAL|Prostate Health Cocktail|
62140902|NCT05174520|ACTIVE_COMPARATOR|Routine Physical Therapy group|"Routine physical therapy group includes thermotherapy for 10 mins, transcutaneous electrical nerve stimulations for 10 mins. Exercises such as: Pelvic tilts, bridging exercise, William flexion exercises and stretching will be performed for 7-10 repetitions.~Treatment duration will be 25 minutes."
62342086|NCT03518814||Multimetastatic melanoma in remission|Questionnaires
62342087|NCT00384826|EXPERIMENTAL|1|
62342088|NCT00384826|EXPERIMENTAL|2|
62342089|NCT05004142|EXPERIMENTAL|FCN-437c with Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
62342090|NCT05004142|EXPERIMENTAL|FCN-437c in combination with Letrozole + Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
62342091|NCT02889978||Cancer arm|Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
62342092|NCT02889978||Non-cancer arm|Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.
62342093|NCT04379219|ACTIVE_COMPARATOR|surgery|"* Valid consent~* Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )~* Laparotomy transverse incision (pfannenstiel incision)~* Exploration of the abdominal cavity~* Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.~* Surgical repair of the uterine incision, and the abdomen"
62342094|NCT04379219|ACTIVE_COMPARATOR|methotrexate before surgery|"Valid consent~* patient will receive 50 mgm /m2 of methtrexate after full investigation ( CBC, serum creatinie, AlT, AST), 1 week before surgery.~* Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )~* Laparotomy transverse incision (pfannenstiel incision)~* Exploration of the abdominal cavity~* Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.~* Surgical repair of the uterine incision, and the abdomen"
62499427|NCT02710240|EXPERIMENTAL|ICG Arm|Subjects undergo indocyanine green injection within 72 hours prior to surgery. Permitting infusion time within 72 hours of operation is believed to be adequate for tissue glow/surgical visualization. Alternately, patients may receive 25 mg of indocyanine green during induction. Dose and time of administration will be determined by the neurosurgeon during surgical planning. This 25 mg dose of indocyanine green is similar to dosing for other intraoperative vascular visualization.
62499428|NCT03609333|EXPERIMENTAL|Internal arm|
62499429|NCT00003387|EXPERIMENTAL|Chemo + radiation|
62499430|NCT00003387|EXPERIMENTAL|Induction chemo + chemo & radiation|
62699396|NCT02457065|NO_INTERVENTION|Do Not Receive Plaque|"Control~No Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators did not give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors or any other intervention."
62342095|NCT04753814|OTHER|Identyfication of prognostic factors in HFrEF|Selected prognostic factors will be analyzed in patients with LVEF ≤40%
62699397|NCT02908217|EXPERIMENTAL|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
62499431|NCT05863845|EXPERIMENTAL|V-BEAM|"Patients in this arm will receive Venetoclax Combined With BEAM (Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT.~Participants receive Venetoclax PO QD on days -10 to -1, Carmustine IV on day -7, Etoposide IV BID on days -6 to -3, Cytarabine IV BID on days -6 to -3, and Melphalan IV on day -2. Participants then undergo hematopoietic cell transplantation on day 0."
62499432|NCT05863845|SHAM_COMPARATOR|BEAM|"Patients in this arm will receive BEAM (Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT.~Participants receive Venetoclax PO QD on days -10 to -1, Carmustine IV on day -7, Etoposide IV BID on days -6 to -3, Cytarabine IV BID on days -6 to -3, and Melphalan IV on day -2. Participants then undergo hematopoietic cell transplantation on day 0."
62499433|NCT01958229||CHB patients without cirrhosis|
62499434|NCT05578794|EXPERIMENTAL|Valsalva Straining (Control Group)|The straining techniques for the groups were explained by the researcher in line with the process steps in the latent phase. Valsalva straining is supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
62699398|NCT02908217|PLACEBO_COMPARATOR|Placebo|6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks
62699399|NCT03602508||mirabegron|Patients on mirabegron as prescribed by a physician in routine clinical practice.
62140903|NCT05174520|EXPERIMENTAL|Experimental group|"Experimental group includes 6-7 repetitions of Muscle energy technique on Quadratus Lumborum muscle and Routine physical therapy, i.e Thermotherapy, transcutaneous electrical nerve stimulations, Pelvic tilts, bridging exercise, William flexion exercises and stretching will be performed for 7-10 repetitions.~Treatment duration will be 40 minutes."
62140904|NCT02628626|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo for 4 weeks.
62342096|NCT04753814|OTHER|Identyfication of prognostic factors in HFmrEF|Selected prognostic factors will be analyzed in patients with LVEF 41-49%
62499435|NCT05578794|EXPERIMENTAL|Spontaneous Straining|The straining techniques for the groups were explained by the researcher in line with the process steps in the latent phase. Spontaneous straining is supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
62499436|NCT05578794|EXPERIMENTAL|Natural Straining|The straining techniques for the groups were explained by the researcher in line with the process steps in the latent phase. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
62499437|NCT06051409|EXPERIMENTAL|Olverembatinib|Olverembatinib in combination with chemotherapy
62499438|NCT06051409|ACTIVE_COMPARATOR|Imatinib|Imatinib in combination with chemotherapy
62499439|NCT02773433|EXPERIMENTAL|PAV group|Using Proportional Assist Ventilation after failed Spontaneous Breathing Trial
62499440|NCT02773433|NO_INTERVENTION|Control group|Using Volume Assist Control mode after failed SBT
62499441|NCT01658358|EXPERIMENTAL|Phase I part :Systemic Therapy|"* Drug: Lapatinib~* Drug: Lipo-Dox"
62499442|NCT01658358|EXPERIMENTAL|Phase II part|"* Drug: Lapatinib~* Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
62499443|NCT04515420||Group A|"Group A for patients that will need an infusion of NA solution to meet the desired CPP.~Group A will be further divided into three sub-groups: A1 for patients that will receive NA in the dose of 0.06-0.12 μg/kg/min, A2 for patients that will receive a dose of 0.13-0.2 μg/kg/min, and A3 for patients that will receive a dose of NA \> 0.2 μg/kg/min."
62499444|NCT04515420||Group B|Group B for patients that will not receive NA infusion.
62699400|NCT03602508||antimuscarinics|Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.
62699401|NCT01927913|EXPERIMENTAL|SPD602|
62699402|NCT01927913|ACTIVE_COMPARATOR|Deferasirox|
62140905|NCT02628626|ACTIVE_COMPARATOR|Colesevelam and Clonidine|Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks.
62342097|NCT04753814|OTHER|Identyfication of prognostic factors in HFpEF|Selected prognostic factors will be analyzed in patients with LVEF ≥50%
62342098|NCT04406051|ACTIVE_COMPARATOR|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive colloid preloading (5 mL/kg)
62342099|NCT04406051|ACTIVE_COMPARATOR|norepinephrine infusion and crystalloid co-loading (NOR-CRYS)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive crystalloid co-loading (10 mL/kg)
62342100|NCT00797797|EXPERIMENTAL|Milnacipran Added|
62342101|NCT00797797|EXPERIMENTAL|No Treatment Added|
62499445|NCT01500616|EXPERIMENTAL|open label telaprevir|Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.
62499446|NCT04791371|EXPERIMENTAL|Type 2 Diabetes|Participants aged 30-55 with type 2 diabetes
62499447|NCT04791371|EXPERIMENTAL|Healthy overweight control|Participants aged 30-55 with BMI 25-40 without type 2 diabetes
62499448|NCT01360216|EXPERIMENTAL|LARC education and training|Clinicians and contraceptive educators practicing in clinics assigned to this arm receive a special half-day Continuing Medical Education (CME/CEU) accredited LARC education and training session.
62499449|NCT01360216|NO_INTERVENTION|Standard practice- control|Clinicians and contraceptive educators practicing in clinics assigned to this arm do not receive special LARC training and education session. Standard practice will be followed at clinics assigned to the control arm.
62499450|NCT05253430||D1 lymph node dissection (LND)|Patients with gastric cancer that underwent curative surgery with gastrectomy and D1 lymph node dissection
62499451|NCT05253430||D2 lymph node dissection (LND)|Patients with gastric cancer that underwent curative surgery with gastrectomy and D2 lymph node dissection
62499452|NCT04523480|EXPERIMENTAL|Testopel 75mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 10 x 75 mg pellets of Testopel for a total of 750 mg Testopel.
62499453|NCT04523480|ACTIVE_COMPARATOR|Compounded testosterone pellets 100mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 8 x 100 mg compounded testosterone for a total of 800 mg compounded testosterone.
62140906|NCT01999036||Resuscitation of OHCA|Resuscitation of out-of-hospital cardiac arrest
62140907|NCT05381519|EXPERIMENTAL|DXP604|1800mg，IVgtt
62140908|NCT05381519|PLACEBO_COMPARATOR|placebo|IVgtt
62140909|NCT06267300|EXPERIMENTAL|Hyperbaric Oxygen therapy|40 sessions of HBOT at 2.4 ATM
62140910|NCT06267300|NO_INTERVENTION|Standard care|
62140911|NCT06698432||CMD|Microvascular function was assessed using caIMR, CMD was identified with caIMR\>25U, in line with prior research.
62140912|NCT06698432||non-CMD|Microvascular function was assessed using caIMR, non-CMD was identified with caIMR≤25U, in line with prior research.
62140913|NCT04788524|EXPERIMENTAL|Computer Task Manipulation|Participants will complete computer tasks while undergoing an fMRI brain scan
62140914|NCT01286636|EXPERIMENTAL|artificial neural network|
62140915|NCT01286636|ACTIVE_COMPARATOR|Polysomnogram|
62140916|NCT01617369|EXPERIMENTAL|Acute Hypertonic Saline Effect|2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
62140917|NCT01617369|ACTIVE_COMPARATOR|Sustained Hypertonic Saline Effect|2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
62140918|NCT05357820|EXPERIMENTAL|Itraconazole cohort|
62140919|NCT05357820|EXPERIMENTAL|Rifampicin cohort|
62342102|NCT00004929|EXPERIMENTAL|Vaccine|Patients receive vaccination with glycosylated MUC-2 antigen with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, 15, and 27 for a total of 6 vaccinations. Patients are followed every 3 months for 1 year or until disease progression.
62342103|NCT01379495|NO_INTERVENTION|Usual Care|Burns victims will receive information according to the service routine
62342104|NCT01379495|EXPERIMENTAL|educational program+telephone follow up|Burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
62342105|NCT01766817|EXPERIMENTAL|Arm 1: BMS 986020, 600 mg. once daily|BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
62342106|NCT01766817|EXPERIMENTAL|Arm 2: BMS-986020, 600 mg twice daily|BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
62342107|NCT01766817|PLACEBO_COMPARATOR|Arm 3: Placebo matching with BMS-986020|Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
62342108|NCT05605041|NO_INTERVENTION|Did Not Use Headspace|Those that did not use headspace during the time the study is conducted
62342109|NCT05605041|EXPERIMENTAL|Did Use Headspace|Those that were randomized into the group and used Headspace at least once during the study period
62342110|NCT02298478|EXPERIMENTAL|Group without support by the therapist|"Intervention group that do the NO-FEAR Airlines program and does not receive support by the therapist."
62342111|NCT02298478|EXPERIMENTAL|Group with support by the therapist|"Intervention group that do the NO-FEAR Airlines program and receives support by the therapist (a brief weekly five-minutes call)."
62342112|NCT02298478|OTHER|Waiting list control group|"Control group that could access the NO-FEAR Airlines program after waiting for 6 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
62342113|NCT05331430|EXPERIMENTAL|Experimental group 1: Dry needling on cervical trigger point|Dry needling of the trigger point of the upper fibres of the trapezius muscle. Using the Hong technique.
62342114|NCT05331430|EXPERIMENTAL|Experimental group 2: Trapezius muscle stretch|Manual passive stretching of the upper trapezius muscle fibres.
62342115|NCT05331430|NO_INTERVENTION|Control group: Informative talks|Informative talks on breathing techniques, relaxation techniques and posture hygiene.
62342116|NCT01984879||Inflammatory bowel diseases|Patients who have inflammatory bowel diseases and who give consent to participate in the survey
62342117|NCT06219434|EXPERIMENTAL|Supportive care (mindfulness program)|Patients participate in a mindfulness program composed of topics that include mindfulness of breathing and the body scan, mindful eating, mindful activity, mindfulness in daily life, expanding the field of awareness, and maintaining a flexible mindfulness practice weekly over 2.5 hours for 8 weeks. Patients also undergo blood sample collection and fMRI on the study.
62342118|NCT04000555|EXPERIMENTAL|Study drug|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
62342119|NCT04000555|PLACEBO_COMPARATOR|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
62342120|NCT03266666|OTHER|Intervention Arm - WellnessRX|This is a longitudinal outcome study. All participants will receive the class and grocery credit intervention.
62342121|NCT02208024|EXPERIMENTAL|Stereotactic Body Radiation Therapy|5 fractions of 6.6 Gy delivered twice weekly with each fraction separated by greater than 48 hours over 15 days
62342122|NCT02692170|EXPERIMENTAL|CVI-HBV-001 (5 μg)|"* HBV surface antigen 5 μg/dose~* Intramuscular injection at 0, 1, 6th month"
62499454|NCT04523480|ACTIVE_COMPARATOR|Compounded Testosterone pellets 200mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 4 x 200 mg compounded testosterone for a total of 800 mg compounded testosterone.
62499455|NCT01679431||Patients with aortic stenosis|"Patients have every year: 1) an assessment of cardiometabolic risk profile with measure of body mass index, waist circumference and fasting blood sample and 2) a comprehensive Doppler-echocardiography exam.~Computed tomography and magnetic resonance imaging are performed every 2 years."
62499456|NCT02077881|EXPERIMENTAL|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.~Phase 2 portion:~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
62499457|NCT04346862|EXPERIMENTAL|Acetyl-L-carnitine hydrochloride|
62499458|NCT04346862|PLACEBO_COMPARATOR|Placebo|
62499459|NCT01961245|ACTIVE_COMPARATOR|nocturnal non-invasive ventilation|patients will undergo 12 nights of non-invasive ventilation during pulmonary rehabilitation
62499460|NCT01961245|NO_INTERVENTION|no nocturnal non-invasive ventilation|patients will undergo pulmonary rehabilitation without nocturnal non-invasive ventilation
62499461|NCT00499824|EXPERIMENTAL|1|Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
62499462|NCT00499824|NO_INTERVENTION|2|Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
62499463|NCT06579417||ART-Pro-1|
62499464|NCT02833831|EXPERIMENTAL|Part 1: Group 1|Participants will receive Treatment A (a single dose of ALS-008176 1,500 mg) or Treatment B (a single dose of placebo) under fasted conditions.
62499465|NCT02833831|EXPERIMENTAL|Part 1: Group 2|Participants will receive Treatment C (a single dose of ALS-008176 2,500 mg) or Treatment D (a single dose of placebo) under fasted conditions.
62499466|NCT02833831|EXPERIMENTAL|Part 1: Group 3|Participants will receive Treatment E (a single dose of ALS-008176 3,000 mg) or Treatment F (a single dose of placebo) under fasted conditions.
62499467|NCT02833831|EXPERIMENTAL|Part 2: Sequence GHI|Participants will receive Treatment G (a single dose of ALS-008176 3,000 mg + a single dose of moxifloxacin placebo under fasted conditions) then Treatment H (a single dose of ALS-008176 placebo + a single dose of moxifloxacin 400 mg under fasted conditions) then Treatment I (a single dose of ALS-008176 placebo + a single dose of moxifloxacin placebo under fasted conditions). There will be a washout period of at least 14 days between subsequent treatments.
62499468|NCT02833831|EXPERIMENTAL|Part 2: Sequence HIG|Participants will receive Treatment H then Treatment I and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
62499469|NCT02833831|EXPERIMENTAL|Part 2: Sequence IGH|Participants will receive Treatment I then Treatment G and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
62499470|NCT02833831|EXPERIMENTAL|Part 2: Sequence IHG|Participants will receive Treatment I then Treatment H and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
62499471|NCT02833831|EXPERIMENTAL|Part 2: Sequence HGI|Participants will receive Treatment H then Treatment G and then Treatment I. There will be a washout period of at least 14 days between subsequent treatments.
62499472|NCT02833831|EXPERIMENTAL|Part 2: Sequence GIH|Participants will receive Treatment G then Treatment I and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
62499473|NCT06440863|ACTIVE_COMPARATOR|Total Knee Arthroplasty|Patients indicated for total knee arthroplasty.
62499474|NCT06440863|ACTIVE_COMPARATOR|Total Hip Arthroplasty|Patients indicated for total hip arthroplasty.
62499475|NCT01861249|EXPERIMENTAL|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
62499476|NCT05122858|EXPERIMENTAL|EUS guided biliary drainage|
62499477|NCT05122858|ACTIVE_COMPARATOR|ERCP (Endoscopic Retrograde Cholangiopancreatography|
62499478|NCT04437277|EXPERIMENTAL|Patients consenting|
62499479|NCT03776929|NO_INTERVENTION|Standard Care|No intervention - Standard care only. Group of 32 subjects
62499480|NCT03776929|EXPERIMENTAL|Dialectical Behavioral Therapy|Dialectical Behavioral Therapy in addition to standard care. Four hour and a half group sessions (or one-on-one sessions, if not enough for a group session) commencing after surgery while still inpatient. Each session is designed to stand-alone, allowing for enrolling patients on a rolling basis.
62499481|NCT00943280||1 EGD|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to EGD.
62499482|NCT00943280||2 Transnasal|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to Transnasal endoscopy.
62342123|NCT02692170|EXPERIMENTAL|CVI-HBV-001 (10 μg)|"* HBV surface antigen 10 μg/dose~* Intramuscular injection at 0, 1, 6th month"
62342124|NCT02692170|EXPERIMENTAL|CVI-HBV-001 (20 μg)|"* HBV surface antigen 20 μg/dose~* Intramuscular injection at 0, 1, 6th month"
62342125|NCT02692170|EXPERIMENTAL|CVI-HBV-001 (40 μg)|"* HBV surface antigen 40 μg/dose~* Intramuscular injection at 0, 1, 6th month"
62342126|NCT02692170|ACTIVE_COMPARATOR|Conventional Hepatitis B vaccine (20 μg)|"* HBV surface antigen 20 μg/dose~* Intramuscular injection at 0, 1, 6th month"
62499483|NCT00943280||3 PillCam|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to PillCam.
62499484|NCT05824949|EXPERIMENTAL|Osseodensification (test) group|installation of 40 implants using the osseodensification protocol + measurement of implant stability (ISQ)
62499485|NCT05824949|ACTIVE_COMPARATOR|Conventional (control) group|installation of 40 implants using the conventional drilling protocol + measurement of implant stability (ISQ)
62499486|NCT05361343|OTHER|Arm 1|"1. Nutrition: intermittent fasting;~2. Physical activity: medium-intensity or high-intensity physical activity;~3. Hypoxic training (at least three per visit to the center);~4. correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~5. Individual motivational counseling."
62499487|NCT04540692|ACTIVE_COMPARATOR|Start with Cyclophosphamide + Doxorrubicin|Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.
62499488|NCT04540692|EXPERIMENTAL|Start with Docetaxel or Paclitaxel|Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.
62499489|NCT05522634|EXPERIMENTAL|TJAOA101|Once enrolled, participants will be administrated TJAOA101 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
62499490|NCT05005637|EXPERIMENTAL|Anti Tuberculosis Therapy|"Dosage form: ATT fixed-dose combination (FDC). FDC intensive phase containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), while FDC continuation phase containing rifampicin-isoniazid.~Dosage: according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets.~Frequency: Intensive phase: once daily. Continuation phase: 3 times/week. Duration: 6 months (2 months of FDC intensive phase + 4 months of FDC continuation phase)"
62499491|NCT05005637|ACTIVE_COMPARATOR|Oral Steroid|Dosage form: Oral prednisone Dosage: 1 mg/kgBW/day (max 60 mg/day) Duration: until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
62499492|NCT03264664|EXPERIMENTAL|E7386 BID|E7386 will be administered as a single agent orally, initially twice daily (BID) continuously in 28 days treatment cycle. The dose will be escalated in cohorts of participants subject to safety data and the absence of DLTs. Based on the emerging data after completion of Dose Escalation Part, identifying MTD or RP2D, or after a decision is made to evaluate more than one potential RP2D level, a Dose Expansion Part will be initiated. Participants will continue to receive study treatment in extension phase until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study program.
62499493|NCT05517174|EXPERIMENTAL|High-Dose Quadrivalent Influenza Vaccine|QIV-HD single injection at Day 0
62499494|NCT05517174|ACTIVE_COMPARATOR|Standard-Dose Quadrivalent Influenza Vaccine|QIV-SD single injection at Day 0
62499495|NCT00806962|EXPERIMENTAL|Vaccine Arm 1|50 µg Norwalk VLP Vaccine + Adjuvant/Excipients
62499496|NCT00806962|EXPERIMENTAL|Vaccine Arm 2|100 µg Norwalk VLP Vaccine + Adjuvant/Excipients
62499497|NCT00806962|ACTIVE_COMPARATOR|Adjuvant/Excipients (MPL)|14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL
62499498|NCT00806962|SHAM_COMPARATOR|Empty device|Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.
62499499|NCT05271227||Cardiogenic Shock Patients|"Cardiac output and Carotid Blood flow is measured before \& after PLR test, then percent change is calculated were increase in cardiac output with 10 % or more is considered volume responder.~Measurements can be repeated as needed, and fluid resuscitation continues until no further response to passive leg raising is noted."
62499500|NCT04162197|EXPERIMENTAL|Experimental 1: Gait Group (GG)|Gait Group (GG) will perform, in addition to conventional therapy, gait training using only an end effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 12 sessions/month. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/ h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
62499501|NCT04162197|EXPERIMENTAL|Experimental 2: Balance Group (GHG)|Balance Group (GHG) will receive, in addition to conventional therapy, a combined robotic treatment program with the same end-effector robotic system and a robotic proprioceptive platform, 3 times/week for 12 sessions/month. The time of the single session (45 minutes) is dived in gait training and balance training. The balance training will consist in static and dynamic exercises during sitting and standing position, dual-task exercises and exercises aimed to improve trunk control.
62499502|NCT05970614|NO_INTERVENTION|Control group|No application will be made to the participants. Participants will receive routine care.
62499503|NCT05970614|OTHER|intervention group|In addition to routine care, participants will be given eye masks and ear plugs for 3 days.
62736787|NCT01715688|ACTIVE_COMPARATOR|Alkalinized lidocaine|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
62499504|NCT01869556|ACTIVE_COMPARATOR|Oxytocin only|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
62499505|NCT01869556|ACTIVE_COMPARATOR|Oxytocin + Ergot|Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
62499506|NCT01869556|ACTIVE_COMPARATOR|Oxytocin + Carboprost|Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
62499507|NCT01559558||cystocele|
62499508|NCT06569758|EXPERIMENTAL|GenSci098|
62499509|NCT06569758|PLACEBO_COMPARATOR|GenSci098 Placebo|
62499510|NCT01546727|EXPERIMENTAL|Family Behavioral Treatment|This intervention will provide nutritional counseling for a health diet, parent training in effective child behavioral management strategies, and stimulus control of the home environment delivered via group based clinic visits and individual home visits on alternate weeks
62499511|NCT01546727|ACTIVE_COMPARATOR|Motivational Interviewing|This intervention will shared information with parents about their child's weight and use motivational interviewing to elicit changes parents would like to make to their child diet and activity patterns.
62499512|NCT01546727|NO_INTERVENTION|Standard of Care|Participants in this arm will be followed over time and be assessed on the primary and secondary outcomes at the same time points as the two treatment arms
62499513|NCT06660121||Performed electrochemotherapy|Patients diagnosed with desmoid fibromatosis unable to perform or failed other treatments who are treated with electrochemotherapy
62499514|NCT03092388|EXPERIMENTAL|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
62499515|NCT03092388|EXPERIMENTAL|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.~Additionally, during daytime a special test with random parts of the study group basic is performed:~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
62499516|NCT04834895|ACTIVE_COMPARATOR|mhealth exercise group|home exercise program is given to patients via mobile application
62499517|NCT04834895|EXPERIMENTAL|brochure exercise group|home exercise program is given to patients via brochure
62499518|NCT00516087|EXPERIMENTAL|Patients|Patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies.
62499519|NCT01571817|EXPERIMENTAL|Study intervention|endoscopically-guided intestinal submucosal transplantation of Isolated Human Pancreatic Islets in a type 1 diabetic patient
62499520|NCT05306600||Breast cancer|745 patients with HER2-positive and triple-negative breast cancer who underwent neoadjuvant therapy followed by breast surgery.
62499521|NCT05306600||Prostate cancer|137 patients with metastatic prostate cancer
62499522|NCT04233216|EXPERIMENTAL|ISL + ART|HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL fixed dose combination (FDC) QD + OBT from Day 8 to Week 97.
62499523|NCT04233216|EXPERIMENTAL|DOR + ART|HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
62499524|NCT04233216|EXPERIMENTAL|DOR/ISL + ART|HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
62499525|NCT04233216|PLACEBO_COMPARATOR|Placebo + ART|HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
62499526|NCT06468722||Post-Covid-19 Syndrome Patients|
62499527|NCT04262739|EXPERIMENTAL|NYH817G|
62499528|NCT04262739|EXPERIMENTAL|NYH100P|
62499529|NCT04262739|EXPERIMENTAL|NYH817G and NYH100P|
62499530|NCT02254109|EXPERIMENTAL|BEA 2180 BR - rising dose|
62499531|NCT02254109|PLACEBO_COMPARATOR|Placebo|
62499532|NCT00562120|PLACEBO_COMPARATOR|Placebo|
62499533|NCT00562120|ACTIVE_COMPARATOR|Allegra|
62499534|NCT00562120|ACTIVE_COMPARATOR|Allegra-D|
62499535|NCT00562120|EXPERIMENTAL|PF-03654746|
62499536|NCT01115933|EXPERIMENTAL|XIENCE PRIME SV EECSS|XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
62499537|NCT04374422||1|study group pre-pandemic time interval
62499538|NCT04374422||2|same population during pandemic
62499539|NCT06239428|EXPERIMENTAL|i-TREAT|The intervention in the experimental group is an internet-based therapist-guided self-help program, called i-TREAT. The program consists of 12 online treatment sessions. It is mainly based on Cognitive Behavior Therapy while inspired by Acceptance and Commitment Therapy. Participants are instructed to complete session-related tasks and receive written feedback from their therapist throughout the treatment. Furthermore, the intervention is also supported by text, illustrations, videos, and a chat function, allowing asynchronous text messaging with the therapist. The treatment courses are expected to run for 12 weeks.
62499540|NCT06239428|ACTIVE_COMPARATOR|Waitlist-control|Participants randomized to the active waitlist-control group gains access to online mindfulness material for 12 weeks, however, using the material is non-mandatory. After completing the waitlist, participants are offered the i-TREAT intervention. The active waitlist was implemented to prevent potential adverse effects of being on a passive waitlist (which currently comes closest to treatment as usual since no other treatment modalities exist for the target group in the Danish psychiatry).
62499541|NCT03710707|EXPERIMENTAL|DNL201 low dose|
62499542|NCT03710707|EXPERIMENTAL|DNL201 high dose|
62499543|NCT03710707|PLACEBO_COMPARATOR|Placebo|
62499544|NCT01535911|EXPERIMENTAL|Obsrvational study adding ketogenic diet to standard initial treatment of glioblastom multiforme|Add ketogenic diet to standard tx of glioblastoma multiforme. After patients have recovered from surgical intervention patients are given a ketogenic diet along with standard of care, radiation and temozolomide treatments. The ketogenic diet is modified by dietitians based on twice daily measurements of blood ketone levels.
62499545|NCT04834336|EXPERIMENTAL|Physical training plus inspiratory muscle training|"Inspiratory Muscle Training (IMT) will be implemented by using the Power Breathe® device. IMT training will begin with mild to moderate intensity of maximal inspiratory pressure. It will be performed 6 to 10 breaths, 4 sets, and twice daily during the hospitalization when as soon as hemodynamic stability is provided.~Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided."
62499546|NCT04834336|ACTIVE_COMPARATOR|Physical training|Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided.
62499547|NCT03911180|EXPERIMENTAL|PFN straight parallel blade|All patients with pertrochanteric fracture that is eligible will undergo PFNA with straight parallel blade.
62499548|NCT02874950|EXPERIMENTAL|Office exercise training|A package of exercise raining was defined by the researcher and one of the intervention group did it for 6 months.
62499549|NCT02874950|EXPERIMENTAL|Ergonomic modification|The ergonomic group, followed 6 months ergonomic modification.
62499550|NCT02874950|EXPERIMENTAL|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months ergonomic modification.
62342127|NCT06131125|EXPERIMENTAL|Plyometric Training|Group A will perform plyometric training that includes squats, burpees, box jumps, tuck jumps, skaters hop, single-leg deadlift to jump. 10 reps of 3 sets with three sessions per week for 6 weeks.
62342128|NCT06131125|EXPERIMENTAL|Explosive Strength Training|Group B will perform explosive strength training that includes dumbbell push presses, sprint running, sled pushes, shuttle runs. 10 reps of 3 sets with three sessions per week for 6 weeks.
62342129|NCT01333852|ACTIVE_COMPARATOR|Paclitaxel, placebo|Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
62342130|NCT01333852|EXPERIMENTAL|Paclitaxel plus metformin|Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
62342131|NCT02399592|EXPERIMENTAL|Bevacizumab and Tocotrienol|
62342132|NCT01423773|OTHER|Lotrafilcon A test/lotrafilcon A control|Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
62342133|NCT01423773|OTHER|Lotrafilcon A control/lotrafilcon A test|Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
62342134|NCT01357304|EXPERIMENTAL|Group treatment and PAR|
62342135|NCT01357304|NO_INTERVENTION|Usual care|
62342136|NCT04793763|PLACEBO_COMPARATOR|group A|"placebo Comparator Group A~: twenty patients were received traditional Physical Therapy agents"
62342137|NCT04793763|EXPERIMENTAL|group B|experimental Group B Group B: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and deep neck flexors exercises;
62342138|NCT04793763|EXPERIMENTAL|group C|"Experimental Group C~Group C: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and Mckenzie technique."
62342139|NCT05429554||group 1|patients will be treated with DPP4 inhibitor + metformin
62342140|NCT05429554||control|patients will be treated with metformin without DPP4 inhibitor.
62342141|NCT06243341|EXPERIMENTAL|MACA (MC)|Daily MACA supplementation for two weeks.
62342142|NCT06243341|PLACEBO_COMPARATOR|placebo|Daily placebo supplementation for two weeks.
62342143|NCT04377061||NCWS retrospective and prospective patients|"The clinical charts of NCWS patients, diagnosed by DBPC gluten/wheat challenge, between January 2001 and December 2019, attending the Department of Internal Medicine at the University Hospital of Palermo, the Department of Internal Medicine of the Hospital of Sciacca, and the Department of Medical and Surgical Sciences of the University of Bologna, will be reviewed retrospectively. The investigators prospectively will also survey patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS by DBPC gluten/wheat challenge. The patients will be recruited between January 2019 and January 2022 at the same centers, and at the Internal Medicine Division of the Cervello-Villa Sofia Hospital of Palermo, Palermo."
62342144|NCT04377061||CD retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of a control group of CD patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of CD patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
62342145|NCT04377061||IBS retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of another control group of IBS patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of IBS patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
62342146|NCT01836211|EXPERIMENTAL|Fast strategy|High sensitivity cardiac troponin T followed by computed coronary tomography angiography
62342147|NCT01836211|ACTIVE_COMPARATOR|Standard of care strategy|Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
62342148|NCT04438018||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D \< 22, PAID \< 40)
62342149|NCT04438018||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D \< 22, PAID ≥ 40)
62499551|NCT02874950|EXPERIMENTAL|Control|Control group did not do any exercise and did not follow any ergonomic modification.
62499552|NCT05795439|EXPERIMENTAL|Intervention Group|The Intervention group arm of participants will be asked to attend weekly online classes on nutrition and health and to follow a low-fat, vegan diet for 16 weeks.
62499553|NCT05795439|NO_INTERVENTION|Control Group|The Control group arm of participants will be asked to maintain their regular, pre-study diet.
62499554|NCT03316976|EXPERIMENTAL|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
62499555|NCT03316976|EXPERIMENTAL|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
62499556|NCT03127306||CAM-ICU (+) Delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
62499557|NCT03127306||CAM-ICU (-) Non-delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
62499558|NCT01733576|SHAM_COMPARATOR|Sham HD-tDCS|
62499559|NCT01733576|ACTIVE_COMPARATOR|Active HD-tDCS 1|
62499560|NCT01733576|ACTIVE_COMPARATOR|Active HD-tDCS 2|
62499561|NCT01733576|ACTIVE_COMPARATOR|Active HD-tDCS 3|
62499562|NCT04636541|EXPERIMENTAL|Goal Management Training|GMT modules were adapted for French-speaking patients with PD-MCI. Each session was reduced from nine 90-120-minute sessions (original GMT) to five 60-90-minute sessions, one session per week, in order to avoid fatigue. As for original GMT, participants were given exercises between sessions (mindfulness exercises and metacognitive reflections). In original-GMT, some information is repeated several times, but not in Adapted-GMT. Exercises demanding motor dexterity, such as card distribution, were removed. Adapted-GMT included information on PD-MCI and executive dysfunction (some psychoeducation). In addition, Adapted-GMT modules were administered individually with an iPad, as opposed to a power-point group presentation in original-GMT. A workbook was handed to participants, as in previous studies.
61950587|NCT03181035|EXPERIMENTAL|FAZA and pimonidazole|(18)F-Fluoroazomycin arabinoside (FAZA) will be administered via intravenous injection at a dose of 5.2 MBq/kg with a minimum dose of 200 Megabecquerel (MBq) (5.4 Millicurie (mCi)) and a maximum dose of 600 MBq (16.2 mCi) prior to positron emission tomography (PET) imaging. A single dose of oral pimonidazole capsules at a dose of 0.5 g/m2, will be taken by participants 16-20 hours prior to tumor resection surgery.
62499563|NCT04636541|ACTIVE_COMPARATOR|Psychoeducation sessions coupled mindfulness exercises|Five modules were designed as a discussion with patients and caregivers about various PD symptoms: module I-brain and motor symptoms; module II-autonomic symptoms; module III- psychological symptoms; module IV-brain and cognition; and module V-cognitive impairments in PD. Patients were handed the information book about the five modules at the beginning of the study. The objective was to improve their understanding of their condition and to discuss other components that could affect their cognitive abilities. After the 40-60-minute informative part, mindfulness exercises were offered for 20-30 minutes per session. Participants were not invited to practice exercises between sessions, but 3/6 participants reported they did.
62499564|NCT05099133|EXPERIMENTAL|LEO 138559 Dose 1|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
62499565|NCT05099133|EXPERIMENTAL|LEO 138559 Dose 2|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
62499566|NCT05099133|EXPERIMENTAL|LEO 138559 Dose 3|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
62499567|NCT05099133|PLACEBO_COMPARATOR|Placebo|LEO 138559 placebo will be administered subcutaneously up to 3 injections per dosing
62499568|NCT01785615|EXPERIMENTAL|Atorvastatin|44 women randomized to 80 mg atorvastatin for 6weeks
62499569|NCT01785615|PLACEBO_COMPARATOR|sugar pill|44 women randomized to placebo for 6 weeks
62499570|NCT04832776|EXPERIMENTAL|FOLFOXIRI+C225|
62499571|NCT04832776|ACTIVE_COMPARATOR|FOLFOXIRI+BEV|
62499572|NCT01422486|EXPERIMENTAL|ezatiostat hydrochloride (Telintra®)|Patients received ezatiostat at a starting dose of 2000 mg total daily dose in divided doses (1000 mg PO b.i.d.) for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles.
62499573|NCT05413733|EXPERIMENTAL|Digital care pathway|Intervention group goes through a web-based neuropsychological intervention program. The program includes eight structured sessions regarding general neuropsychological symptoms after ABI - problems with fatigue, attention, executive functions and memory. A new session opens after the previous one is completed, and after a minimum of 3 days between the sessions. The intervention takes approximately 2 months depending on the progression pace of a patient. The eight sessions consist of psychoeducation, self-assessments, cognitive strategy training and feedback (automatic or given by a monitoring neuropsychologist). A neuropsychologist from HUS monitors patients' progression and provides personal feedback when needed. Participants can also be in contact with a monitoring neuropsychologist via message feature of the program.
62499574|NCT05413733|ACTIVE_COMPARATOR|Care as usual|Control group attends the standard care of patients with ABI in HUS including all necessary outpatient rehabilitation visits. When available, neuropsychological rehabilitation typically takes 1-2 months among the study target group.
62499575|NCT03525249|EXPERIMENTAL|Comparator Membraflex 500mg|experimental product one dose
62499576|NCT03525249|EXPERIMENTAL|Comparator Membraflex 300mg|experimental product two doses
62499577|NCT03525249|PLACEBO_COMPARATOR|Placebo Comparator|placebo product
62699403|NCT01817400|EXPERIMENTAL|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
61950588|NCT06044454||Service deployment|Intervention Chest X-ray received - care team (standard of care) CT scan - care team (standard of care)
61950589|NCT00389597|EXPERIMENTAL|1 Level|Cervical artificial disc (investigational device) at 1 level compared with control procedure (ACDF) at one level
62499578|NCT06125002|EXPERIMENTAL|Intervention (placebo, corn starch tablets)|Treatment will occur by oral route, and everyone will ingest identical opaque capsules (750 mg). The treatment protocol will be applied before the start (pre-treatment) of the intense dynamic exercise sessions, once a day, during the two days before, and on the day (immediately before) the execution of the exercise protocol.
62499579|NCT06125002|EXPERIMENTAL|Intervention (diosmin)|Treatment will occur by oral route, and everyone will ingest identical opaque capsules (750 mg). The treatment protocol will be applied before the start (pre-treatment) of the intense dynamic exercise sessions, once a day, during the two days before, and on the day (immediately before) the execution of the exercise protocol.
62499580|NCT03617120|EXPERIMENTAL|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
62499581|NCT06361472|ACTIVE_COMPARATOR|Standard Care (SC)|Treatment will be carried out based on the mechanical neck pain clinical practice guideline. Physiotherapists treating this group of patients will avoid enhancing the contextual factors mentioned in the intervention group.
62499582|NCT06361472|EXPERIMENTAL|Contextual Factors-Enriched Standard Care (CFs+SC)|Treatment will be carried out based on the mechanical neck pain clinical practice guideline. Additionally, Contextual Factors, which include physical, psychological, and social elements involved in the clinical encounter between the patient and the physiotherapist, will be deliberately enhanced in this group.
62699404|NCT01817400|EXPERIMENTAL|Anti-inflammatory treatment|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
61950590|NCT00389597|EXPERIMENTAL|2 Level|Cervical artificial disc (investigational device) at 2 levels compared with control procedure (ACDF) at two levels
61950591|NCT01286233||Group 1: Metformin|850 mg orally twice a day for 5 years
61950592|NCT01286233||Group 2: Placebo|One caplet orally twice a day for 5 years
61950593|NCT05715697|EXPERIMENTAL|Renal denervation and maintenance of heart failure medications|Renal denervation in patients with HFpEF and uncontrolled hypertension
62140920|NCT03647358|EXPERIMENTAL|Lesion Dosimetry With Iodine-124|Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In order to perform a dual exponential fit, 4 scans are needed to obtain the necessary amount of data points required. Lesion dosimetry shall be performed based on the 124I PET scan data through tumor uptake and clearance pharmacokinetics. 10 patients, who sign consent for the sub-study, will be administered an additional tracer diagnostic activity of 124I (4 to 7 mCi). These patients will then undergo additional (up to a maximum of 4) PET scanning during radioiodine therapy at time points matched, if possible, to the days of the pre-therapy 124I dosimetry study.
62342150|NCT04438018||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID \< 40)
61950594|NCT05715697|SHAM_COMPARATOR|Sham intervention, maintenance of heart failure medications|Sham Treatment. After 1 year, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
61950595|NCT05085730|EXPERIMENTAL|Treatment|All subjects will receive 4 separate treatments with the InMode Morpheus8 System.
61950596|NCT04034628||Laparoscopic insertion|Individuals who undergo laparoscopic PD catheter insertion
62342151|NCT04438018||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
62342152|NCT03377244|EXPERIMENTAL|HBHS|Participants in the Healthy Bodies Healthy Souls (HBHS) arm received the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) with the addition of church-level policy changes to support the individual behavioral intervention of the WORD DPP. The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
62342153|NCT03377244|ACTIVE_COMPARATOR|HBHS Policy|Participants in the HBHS Policy arm included members of churches enrolled in the HBHS study who did not receive the WORD DPP intervention (ie, these participants were exposed to only the church-level policy changes). Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
61950597|NCT04034628||Percutaneous insertion|Individuals who undergo percutaneous PD catheter insertion by either a nephrologist or radiologist.
61950598|NCT06166485|ACTIVE_COMPARATOR|1st group babies where the head is washed first and then the whole body|The effects of washing the head first and then the whole body on the physiological parameters (oxygen level, pulse, body temperature, calming time, stress level) of the first group babies will be examined.
62140921|NCT01767467|EXPERIMENTAL|Vaccine Group|Subjects will receive the candidate HZ vaccine (GSK 1437173A).
61950599|NCT06166485|ACTIVE_COMPARATOR|2nd group babies, where the whole body is washed first and the head is washed last.|The effects on the physiological parameters (oxygen level, pulse, body temperature, calming time, stress level) of the second group of babies, where the whole body is washed first and the head last, will be examined.
61950600|NCT02856035|EXPERIMENTAL|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional sessions up to 60 total; Phase IV: follow-up testing at 3 months after-treatment ends"
61950601|NCT05822661|EXPERIMENTAL|Black Seed Oil|900 mg (as two separate soft gels) twice daily for 8 weeks
61950602|NCT05822661|PLACEBO_COMPARATOR|Placebo|matched placebo capsules
61950603|NCT03840798||Pretest/Baseline period|
61950604|NCT03840798||Posttest/go-live period|
61950605|NCT05159544||Multi-omics model developing and training arm|Blood samples and individual health information from 50,000 participants in community, who got 3-year follow-up are selected.
61950606|NCT05159544||Multi-omics model validating arm|10,000 participants in routine annual physicals from hospitals will be selected, and they will be followed up for 2 years.
61950607|NCT05159544||Multi-omics model evaluating arm|Participants in Taizhou cohort will be selected.
61950608|NCT02004483|EXPERIMENTAL|Percutaneous Coronary Intervention|Each patient will get elective percutaneous coronary angioplasty with balloon inflation(PCI). During and after PCI 2D-echography (strain) will be performed.
61950609|NCT00761904|EXPERIMENTAL|receipt of free generic samples|
62699405|NCT01817400|EXPERIMENTAL|Insulin-lowering therapy|We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
62699406|NCT01900184|EXPERIMENTAL|500 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
61950610|NCT00761904|NO_INTERVENTION|usual prescribing|
62140922|NCT01767467|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive the placebo vaccine.
62342154|NCT03377244|OTHER|WORD DPP|Participants in the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) arm included participants enrolled in a separate DPP study without the church-level policy changes (ie, these participants received only the WORD DPP intervention). The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP-LI includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length.
62342155|NCT03269656||AGES-Reykjavik participants|Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.
62342156|NCT00718289|EXPERIMENTAL|Citrate|Citrate dialysate for haemodialysis
62699407|NCT01900184|EXPERIMENTAL|750 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
61950611|NCT01233258|EXPERIMENTAL|Arm 1: rFVIII on demand first CS/EP then CS/ADJ|Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
61950612|NCT01233258|EXPERIMENTAL|Arm 2: rFVIII on demand first CS/ADJ then CS/EP|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
61950613|NCT01233258|EXPERIMENTAL|Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
61950614|NCT01233258|EXPERIMENTAL|Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
61950615|NCT01233258|EXPERIMENTAL|Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
61950616|NCT01233258|EXPERIMENTAL|Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
61950617|NCT02434978|ACTIVE_COMPARATOR|Supplementary doppler-guided endoscopic therapy|
61950618|NCT02434978|PLACEBO_COMPARATOR|control group|
61950619|NCT01771744||Morbidly obese patients|48 morbidly obese patients with revisional gastric bypass
62140923|NCT02449785|EXPERIMENTAL|Cystic fibrosis adults|
62140924|NCT05299034||Stroke patients 6-24h receiving non-contrast CT + CTA|Stroke patients 6-24h undergoing non-contrast CT + CTA to decide stroke therapy
62140925|NCT05299034||Stroke patients 6-24h receiving multimodal imaging|Stroke patients 6-24h undergoing NCCT+CTA+CTP or MRI with DWI and PWI imaging to decide stroke therapy
62342157|NCT00718289|ACTIVE_COMPARATOR|Acetate|Acetate dialysate
62699408|NCT01900184|EXPERIMENTAL|1,000 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
62699409|NCT01900184|PLACEBO_COMPARATOR|Placebo|The placebo will be administered in solution with 200 mL of purified water.
62499583|NCT06338423|EXPERIMENTAL|Vacuum Mattress Arm|"Patients will be operated in a beach chair position. The patient will ley on vacuum mattresses during the surgery.~Patients' demographics, and perioperative data including age, gender, body mass index (BMI), smoking, ASA score, incidence of co-morbidities, compliance with ERABS protocol, amount of intraoperative blood loss, intraoperative complications, and surgery duration will be collected. Blood samples will be collected on first postoperative day to measure RML markers (myoglobin, creatine kinase, creatinine). Symptoms of RML, AKI and other complications were monitored for 30 days after surgery."
62499584|NCT06338423|OTHER|Standard Mattress arm|"Patients will be operated in a beach chair position. The patient will ley on standard mattresses during the surgery.~Patients' demographics, and perioperative data including age, gender, body mass index (BMI), smoking, ASA score, incidence of co-morbidities, compliance with ERABS protocol, amount of intraoperative blood loss, intraoperative complications, and surgery duration will be collected. Blood samples will be collected on first postoperative day to measure RML markers (myoglobin, creatine kinase, creatinine). Symptoms of RML, AKI and other complications were monitored for 30 days after surgery."
62140926|NCT02470169|ACTIVE_COMPARATOR|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
61950620|NCT01771744||48 morbidly obese patients|with primary gastric bypass
62499585|NCT02720549|EXPERIMENTAL|post-ischemic conditioning group|
61950621|NCT02221687|EXPERIMENTAL|Synbiotic formula|"Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.~Route : oral, ad libitum~Duration of product intake:~* Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)~* Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)"
61950622|NCT02221687|PLACEBO_COMPARATOR|Control formula|"Control formula : standard formula without pre and probiotic~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.~Route: oral, ad libitum~Duration of product intake:~* Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)~* Control FoF : 6 months of consumption (from 6 to 12 months of age)"
61950623|NCT02221687|NO_INTERVENTION|Breast-fed group|"- Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.~Dose:~* Breast milk : on demand~Route : oral, ad libitum~Duration of product intake:~* Breast milk : at least 4 month (from birth until at least 4 months of age)"
61950624|NCT04794309|EXPERIMENTAL|Experimental Group|The participants will receive circuit training exercise and dietary intervention.
61950625|NCT04794309|ACTIVE_COMPARATOR|Control group|The participants will be only involved in dietary intervention.
62499586|NCT02720549|PLACEBO_COMPARATOR|valvular surgery with bypass group|
61950626|NCT06469593|EXPERIMENTAL|Adults with type 1 diabetes (intervention)|
61950627|NCT06469593|NO_INTERVENTION|Adults with type 1 diabetes (control)|
61950628|NCT06469593|EXPERIMENTAL|Children with type 1 diabetes (intervention)|Pediatric population of 7-17 years, stratified 1:1 to two groups of 7-11 and ≥12 years accordingly
61950629|NCT06469593|NO_INTERVENTION|Children with type 1 diabetes (control)|Pediatric population of 7-17 years, stratified 1:1 to two groups of 7-11 and ≥12 years accordingly
61950630|NCT04326673||diurnal variation assessment|Assessment of diurnal variation in salivary testosterone adjusted for prandial state
61950631|NCT04326673||Glucose load measurements|Measurement of salivary and serum testosterone and related biomarkers before and after a standard 75g oral glucose load
61950632|NCT06378931||Quality of life change in patients Undergoing Parathyroidectomy with end-stage renal failure|Quality of Life Progression in Patients Undergoing Parathyroidectomy With Secondary Hyperparathyroidism Due to End-stage Renal Failure
61950633|NCT00992290|EXPERIMENTAL|Lactobacillus GG|
61950634|NCT00992290|PLACEBO_COMPARATOR|Placebo|
61950635|NCT05427708|EXPERIMENTAL|Interoceptive Exposure (IE)|Participants assigned to the interoceptive exposure condition will receive twice-weekly 90-minute in-person treatment sessions for four weeks. This treatment will include education about anxiety and factors that maintain anxiety symptoms. In addition, participants will be asked to perform exercises designed to activate potentially distressing - but harmless - bodily sensations that are commonly associated with stress and anxiety. Participants will also be encouraged to practice these exercises daily at home.
61950636|NCT05427708|EXPERIMENTAL|Capnometry-Guided Respiratory Intervention (CGRI)|If assigned to this condition, participants will be expected to complete twice-daily 17-minute tablet-assisted breathing exercises at home for four weeks. They will also receive brief phone check-ins with their study therapist weekly to review progress and troubleshoot any problems they may be experiencing. Last, these participants will have access to a paced-breathing app that provides audio recordings to maintain specified breathing rates for up to 10 minutes.
61950637|NCT05427708|ACTIVE_COMPARATOR|Psycho-Education (PsyEd)|If assigned to the psycho-education condition, participants will undergo once-weekly 20-minute video conferencing session with a therapist for four weeks. During these sessions, they will be provided information about the nature and causes of anxiety-related disorders and learn tips for coping with anxiety symptoms when they arise. At the end of their sessions with the therapist, they will receive handouts that will help reinforce what they've learned.
61950638|NCT02074930|OTHER|Single Arm|
62499587|NCT01280227|EXPERIMENTAL|1|Patients uses the symptom assessment tool SiSom. A summary of their reported symptoms are printed out and given to the pediatrician and nurse before the consultation. The consultation is videotaped.
62499588|NCT01280227|NO_INTERVENTION|2|"The control group do not use the symptom assessment tool SiSom before the consultation. The control group receives usual care and the consultation is videoptaped."
62499589|NCT02650973|EXPERIMENTAL|Sequence A|3 doses of CHS-1701 or Neulasta, random order
62499590|NCT02650973|EXPERIMENTAL|Sequence B|3 doses of CHS-1701 or Neulasta, random order
62499591|NCT02650973|EXPERIMENTAL|Sequence C|3 doses of CHS-1701 or Neulasta, random order
62499592|NCT01545206||acute STEMI, Primpary PCI|
62499593|NCT02569541|EXPERIMENTAL|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:~* 6 months of treatment; or~* 24 months of treatment (if continued on chronic suppressive therapy)"
62499594|NCT00128141|NO_INTERVENTION|1|
62499595|NCT00128141|EXPERIMENTAL|2|tactile stimulus
62499596|NCT00683592|EXPERIMENTAL|1|vilazodone
62499597|NCT00683592|PLACEBO_COMPARATOR|2|
62499598|NCT05907148|ACTIVE_COMPARATOR|Routine Physical therapy along with Coordination exercises|The Control group training will consist of active joint mobilization, muscle stretching, motor coordination exercises and additionally will receive 30-minute general balance training. Active joint mobilization will be carried out with the patient in the supine, prone (if possible), or sitting positions. Muscle stretching will be carried out mainly in the supine, prone (if possible), and standing positions. Motor coordination exercises will be carried out in a supine position, sitting and standing positions.
62499599|NCT05907148|EXPERIMENTAL|sensory Integration training group along with Routine physical therapy|experimental group training will consist of active joint mobilization, muscle stretching, motor coordination exercises and additionally 30 minutes of sensory integration therapy.
62499600|NCT04716829|EXPERIMENTAL|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG for 12 weeks.
62499601|NCT04716829|NO_INTERVENTION|Control|The control group will receive its rehabilitation care.
62699410|NCT05707260|ACTIVE_COMPARATOR|CKD SMS intervention|CKD SMS (Chronic Kidney Disease Self-Management Support) intervention (6,27), guided by the Social Cognitive Theory, through the manipulation of self-efficacy, is educational for the adult with CKD in early stages where a primer will be used which contains a primer that explains the functions of the kidneys, the first signs and symptoms of CKD and the strategies to control or delay the progression of CKD, such as the benefits of maintaining a healthy lifestyle and adherence to treatment. Also, a diary for participants to record side effects of medications, monitor their clinical data, treatment plan and questions for medical appointments.
61950639|NCT04960631||Clinical diagnosis of suspected malignant tumor by dual site CT guided needle biopsy|
61950640|NCT05351502|EXPERIMENTAL|Cohort 1|Subjects will receive 25,000 ppm NO
61950641|NCT05351502|EXPERIMENTAL|Cohort 2|Subjects will receive 50,000 ppm NO
61950642|NCT05351502|EXPERIMENTAL|Cohort 3|Subjects will receive 100,000 ppm NO
61950643|NCT05351502|EXPERIMENTAL|RP2D Expansion|Subjects will receive the RP2D dose of NO
62342158|NCT03236428|EXPERIMENTAL|Daratumumab|Daratumumab will be administered by IV infusion weekly during cycles 1 and 2 Daratumumab will be administered by IV infusion every other week during cycles 3 through 6 Daratumumab will be administered by IV infusion monthly during cycles 7 through 20
62342159|NCT01479959|ACTIVE_COMPARATOR|No PEEP level|protocol conducted while no PEEP is applied
61950644|NCT06287008||OKT|"patients who underwent open kidney transplantation"
61950645|NCT06287008||RAKT|"patients who underwent robot-assisted kidney transplantation"
62140927|NCT02470169|ACTIVE_COMPARATOR|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
62342160|NCT01479959|ACTIVE_COMPARATOR|effective PEEP level (PEEPeff)|PEEP level allowing the entire expiratory volume to go through the upper airways during quiet breathing
62342161|NCT01479959|ACTIVE_COMPARATOR|intermediate PEEP level (PEEP50)|50% of PEEPeff
62342162|NCT01063816|EXPERIMENTAL|Arm 1|
62342163|NCT00764478|EXPERIMENTAL|Asenapine 5 mg BID|Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
62342164|NCT00764478|EXPERIMENTAL|Asenapine 10 mg BID|Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
62342165|NCT00764478|PLACEBO_COMPARATOR|Placebo BID|Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days
62342166|NCT05127070||Behavioural science and implementation research|"The investigators will recruit adult health care professionals, senior hospital managers and parents/carers of neonates. Approximate sample sizes in each country are as follows:~Zimbabwe: \~80 Healthcare Professionals ; \~20 Carers/ parents of newborn babies and \~10 Hospital administrators/ managers.~Malawi: \~40 Healthcare Professionals (\~10 HCPs per focus group discussion); \~10 Carers/ parents of newborn babies and \~10 Hospital administrators/ managers.~Total participants for new data collection: 180 (this number is likely to be much lower if there is limited staff turnover at neonatal units and if HCPs agree to participate in multiple research activities)."
62342167|NCT05127070||Cost data|A time-use survey will be conducted with a small sample of Healthcare professionals at all 3 hospitals where the Neotree is implemented (sample size \~30) to measure time spent for different activities/procedures carried out on or for a patient.
62342168|NCT05127070||Neonatal admissions at Hospital sites where Neotree is implemented in Zimbabwe and Malawi|"The investigators will record routine clinical admission, discharge and microbiological data for all newborns admitted to the newborn care units using the NeoTree as a replacement to paper-based forms. Individual-level patient data will be collected on all neonates admitted for care at Sally Mugabe Central (Oct 2019 to April 2022) and Chinhoyi Provincial Hospitals (Oct 2020 to April 2022) Zimbabwe, and Kamuzu Central Hospital (Oct 2019 to April 2022), Malawi. Given typical admission rates, this equates to a sample size \~12,000 babies in Zimbabwe and \~ 4000 babies in Malawi.~Data will be collected from February 2019 to the end of the study, to explore trends over time and also include measures of quality newborn care."
62499602|NCT01135264|ACTIVE_COMPARATOR|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
62499603|NCT01135264|EXPERIMENTAL|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
62140928|NCT02470169|ACTIVE_COMPARATOR|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
62140929|NCT01745965|EXPERIMENTAL|T-DM1|single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)
62140930|NCT01745965|EXPERIMENTAL|T-DM1 + endocrine therapy|Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage).
62140931|NCT01745965|ACTIVE_COMPARATOR|Trastuzumab + endocrine therapy|The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage).
62342169|NCT05127070||Comparative case-fatality rates in units using NeoTree and representative control sites|The investigators will collect outcome data from neonatal clinical records at two additional representative hospital sites in Zimbabwe over a 6 month period (sample size \~1200), to inform our sample size calculation for a full evaluation at scale in the future. Individual level data will be collected retrospectively from Bindura Provincial Hospital and Parirenyatwa Hospital (1/4/2021 to 01/10/2021 or beyond depending on sample size).
62342170|NCT05127070||Clinical validation sub-study|The sample size for our diagnostic sub-study has been calculated using sepsis as the index diagnosis. Assuming sensitivity and specificity of 92% (lower 95% CI: 84%) \>222 babies would need to be diagnosed with sepsis over five months, during which \~\>2000 babies will be admitted with sepsis across sites (Sally Mugabe Central Hospital, Zimbabwe and Kamuzu Central Hospital, Malawi). If necessary, the investigators will continue to collect data throughout the duration of the study until our sample size is achieved. These data will be collected as part of the routine Neotree data collection.
62342171|NCT03314181|EXPERIMENTAL|Arm A, Part 1a: VenDd Dose Escalation|Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous \[IV\]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
62342172|NCT03314181|EXPERIMENTAL|Arm B, Part 1b: VenDd Dose Expansion|Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
62342173|NCT03314181|EXPERIMENTAL|Arm D, Part 2a: VenDVd Dose Escalation|Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection \[preferred\] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
62342174|NCT03314181|EXPERIMENTAL|Arm E, Part 2b: VenDVd Dose Expansion|Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
62342175|NCT03314181|EXPERIMENTAL|Arm F: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
62342176|NCT03314181|EXPERIMENTAL|Arm G: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
62499604|NCT00781079|EXPERIMENTAL|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
62499605|NCT00781079|NO_INTERVENTION|Care as Usual|Care as usual
62499606|NCT03407222|ACTIVE_COMPARATOR|Intervention group|Intervention group receives weekly text messages which encourage the increment of daily step count
62499607|NCT03407222|NO_INTERVENTION|Control group|Control group does not receive text message
62140932|NCT05198674|EXPERIMENTAL|Main Cohort: Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
62140933|NCT02568215|EXPERIMENTAL|Group 1: Low-Dose VRC01|Participants will receive an IV infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
62140934|NCT02568215|EXPERIMENTAL|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
62140935|NCT02568215|PLACEBO_COMPARATOR|Group 3: Placebo for VRC01|Participants will receive an IV infusion of placebo for VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
62140936|NCT02966249|OTHER|Levobupivacaine intrathecally|3 ml Levobupivacaine 0,5% (15mg) given intrathecally once for anesthesia in total knee arthroplasty
62499608|NCT02346149|OTHER|Patient with impaired glucose tolerance|Bold-MRI before and after glucose injection
62499609|NCT02026362|OTHER|The foundation treatment after radical operation or RFA|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
62499610|NCT02026362|EXPERIMENTAL|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens
62499611|NCT04224948|EXPERIMENTAL|PET-MR arm|Every eligible patient will be scanned by PET-MR at baseline and following 1 cycle of chemotherapy. PET-CT at baseline will also be obtained as it is the current standard of care and will be used to determine trial eligibility (no evidence metastasis at baseline).
62342177|NCT03314181|ACTIVE_COMPARATOR|Arm H: DVd Dose|Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1
62499612|NCT04573309|EXPERIMENTAL|ALXN1840|Participants will be administered ALXN1840 at a dose of 15 milligrams (mg)/day on Day 1 through Day 28 and then increased to 30 mg/day on Day 29 through Day 39
62699411|NCT05707260|NO_INTERVENTION|Conventional intervention|The conventional intervention corresponds to the protocol established in the program of the renal unit for the management of people with CKD in early stages.
62699412|NCT02371356||Depressed, Medication only|Screen positive for depression and use only antidepressants during pregnancy
62140937|NCT02966249|ACTIVE_COMPARATOR|Dexmetomidine intrathecally|5 μgr Dexmetomidine given intrathecally once for anesthesia in total knee arthroplasty
62342178|NCT02927340|EXPERIMENTAL|Lorlatinib|Lorlatinib will be administered orally once daily on a 21 day cycle Blood will be collected for biomarker studies
62342179|NCT05562024|EXPERIMENTAL|T cell injection targeting TAA06 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 2.0 × 10\^6, 4.0 × 10\^6 and 8.0 × 10\^6 CAR-T/kg groups in order of sequence.
62342180|NCT01456845||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
62342181|NCT03448224|EXPERIMENTAL|Group I (web-based Indoor Tanning intervention)|Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
62342182|NCT03448224|ACTIVE_COMPARATOR|Group II (wait-list)|Participants are placed on wait-list and may receive full intervention after follow-up.
62342183|NCT04381429|ACTIVE_COMPARATOR|Group 1: A-F-A-F|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid).~Each treatment period will last 3 months."
62342184|NCT04381429|ACTIVE_COMPARATOR|Groupe 2: F-A-F-A|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP)."
62342185|NCT05010629|EXPERIMENTAL|9-ING-41 + carboplatin|"Participants will be divided into 2 cohorts: Salivary Gland Cancer with adenoid cystic carcinoma (ACC) and Salivary Gland Cancer without adenoid cystic carcinoma (ACC) and receive:~* 9-ING-41 2x every 21 day study cycle on Day 1 and Day 4 up to 1 year with option to continue beyond if participant is showing benefit~* Carboplatin 1x every 21 day study cycle on Day 1 up to 1 year"
62342186|NCT01734980|EXPERIMENTAL|Endobronchial Ultrasound|EBUS-TBNA is a procedure that allows accurate sampling of mediastinal lymph nodes and peribronchial lesions
62342187|NCT00280241|EXPERIMENTAL|FLUDARABINE, CYCLOSPHOSPHAMIDE AND RITUXIMAB|
62342188|NCT04741334||patients not in therapy with anticoagulants or antiplatelets drugs|Patients presenting in ED with mild head trauma and not in therapy with antiplatelets and/or anticoagulants
62342189|NCT04741334||patients in therapy with direct anticoagulant|Patients presenting in ED with mild head trauma and in therapy with direct anticoagulants
62342190|NCT04741334||patients in therapy with oral anticoagulant (dicumarolics)|Patients presenting in ED with mild head trauma and in therapy with oral anticoagulants (dicumarols)
62342191|NCT04741334||patients in therapy with antiplatelet drugs|Patients presenting in ED with mild head trauma and in therapy with antiplatelets
62499613|NCT02470182||At-Home|Overnight sleep at home (30 subjects)
62699413|NCT02371356||Depressed, Psychotherapy only|Screen positive for depression and receive psychotherapy only.
62699414|NCT02371356||Depressed, Medication & Psychotherapy|Screen positive for depression and receive both antidepressants and psychotherapy.
62699415|NCT02371356||Depressed, untreated|Screen positive for depression and receive no treatment.
62699416|NCT02371356||Not depressed|Screen negative for depression and receive no treatment.
62342192|NCT00574431|OTHER|Observation|Observation
62342193|NCT00574431|ACTIVE_COMPARATOR|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
62342194|NCT03416686|EXPERIMENTAL|Radiofrequency|
62342195|NCT06155916|EXPERIMENTAL|High ISI|Patients that have clinically significant insomnia according to ISI questionnaire (score 15 or more) at baseline.
62342196|NCT06155916|EXPERIMENTAL|Low ISI|Patients with no clinically significant insomnia according to ISI questionnaire (score 14 or less) at baseline.
62342197|NCT05242445|EXPERIMENTAL|Cohort 1: Cetrelimab or Placebo (Dose 1)|Participants will receive cetrelimab Dose 1 or placebo via subcutaneous (SC) injection on Day 1.
62499614|NCT02470182||Sleep Lab|Overnight sleep at the OHSU sleep lab during routine polysomnography (30 subjects)
62699417|NCT02811887|ACTIVE_COMPARATOR|Usual care|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic
62699418|NCT02811887|EXPERIMENTAL|SMS-messages|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic + regular text messages via SMS over a 12-week period
62499615|NCT02470182||Sleep Lab + At-Home|Overnight sleep at the OHSU sleep lab during routine polysomnography, followed by overnight sleep at home (30 subjects)
61950646|NCT06202430|ACTIVE_COMPARATOR|Ultrasound Guided High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. Subsequently, an ultrasound (US)-guided aseptic technique, with a high-frequency linear probe enveloped in a sterile sheath containing a thin film of US gel, was used to locate the transverse process of T2. After LA skin infiltration, a 22-G block was inserted in a cephalocaudal direction until the space between the fascia of the erector spinae and the transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
61950647|NCT06202430|ACTIVE_COMPARATOR|Ultrasound Guided Shoulder Block|Shoulder Block Suprascapular nerve block (SSNB) approach: A high-frequency linear probe was utilized across the supra-spinous fossa parallel to the spine of the scapula after skin cleaning with an antiseptic solution, if a deep block is required, a low frequency probe was required. A hyperechoic line was identified, followed by an acoustic shadow that corresponds to the floor of the supra-spinous fossa. The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle. Along with Axillary nerve block technique.
61950648|NCT05679323||Early discharge|Patients who will be discharged 24 hours after cesarean section
61950649|NCT05679323||Traditional discharge|Patients who will be discharged 48 hours after cesarean section
61950650|NCT01817829|ACTIVE_COMPARATOR|paracetamol|paracetamol 2 tablets1000mg PO.
61950651|NCT01817829|PLACEBO_COMPARATOR|placebo|placebo 2 tablets containing Starch PO
61950652|NCT02204956|EXPERIMENTAL|Sustained Care|A 40-minute, in-hospital motivational counseling session about smoking cessation, 8 Interactive Voice Response (IVR) phone calls and/or texts over 90 days, including the possibility of a warm transfer to a telephone tobacco quit line and up to 8-weeks of free transdermal nicotine patches.
61950653|NCT02204956|ACTIVE_COMPARATOR|Usual Care|A brief 5-10 minute tobacco education session that all hospitalized smokers will receive, delivered by a hospital nurse. During this session, they will be provided with written handouts describing the stages of readiness for change in quitting, self-monitoring of smoking, self-management of smoking situations, relapse prevention, managing stress, other quitting tips and use of nicotine replacement therapy.
61950654|NCT06227260|ACTIVE_COMPARATOR|Study 1: Thai massage|Participants were randomized to receive an arm. In this arm, participants received Thai massage without any oil for 1 hour/day, 1 day/week for 12 weeks. Massage was performed at Burapha University by an expert.
61950655|NCT06227260|ACTIVE_COMPARATOR|Study 1: Thai massage with pure coconut oil|Participants were randomized to receive an arm. In this arm, participants received Thai massage with pure coconut oil which is a popular oil used in spa for 1 hour/day, 1 day/week for 12 weeks. Massage was performed at Burapha University by an expert.
61950656|NCT06227260|EXPERIMENTAL|Study 1: Thai massage with oil mixed with Snake fruit extract|Participants were randomized to receive an arm. In this arm, participants received Thai massage with oil mixed with Snake fruit extract for 1 hour/day, 1 day/week for 12 weeks. Massage was performed at Burapha University by an expert.
61950657|NCT06227260|EXPERIMENTAL|Study 2: Facial mask with Snake fruit extract|Participants were randomized to receive an arm. In this arm, participants received home-based program facial mask with Snake fruit extract for 30 min/day, 2 days/week for 12 weeks.
61950658|NCT06227260|ACTIVE_COMPARATOR|Study 3: Control jelly|Participants were randomized to receive an arm. In this arm, participants consumed with control jelly at 3.5 g/kg body weight. Consumption was taken at Burapha University.
62499616|NCT06679647|EXPERIMENTAL|ChatGPT group|Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
62699419|NCT05041504|EXPERIMENTAL|Intervention|Participants assigned to the intervention arm will receive the True North Peer Navigation intervention.
62699420|NCT05041504|OTHER|Active Waitlist Control|Participants assigned to the control arm will receive usual care and access to an online health resource library. After completion of the study, they will receive the True North Peer Navigation intervention.
62699421|NCT06455904|EXPERIMENTAL|Training group|This group of patients will perform concentric cycling training program during the chemotherapy treatment.
62699422|NCT06455904|NO_INTERVENTION|Control group|This group of patients will benefit from standard care without additional training program.
62699423|NCT02160431|EXPERIMENTAL|CBT for pediatric OCD|Participants complete standard CBT for OCD
61950659|NCT06227260|EXPERIMENTAL|Study 3: Jelly with Snake fruit juice|Participants were randomized to receive an arm. In this arm, participants consumed with jelly with Snake fruit juice at 3.5 g/kg body weight. Consumption was taken at Burapha University.
61950660|NCT01109238||Process Feasibility|
61950661|NCT06069323|ACTIVE_COMPARATOR|Active ASD group|The rTMS will be administered 18 times, twice per week, with the following stimulation parameters: 1.0 Hz frequency, 90% MT, 180 pulses per session with 9 trains of 20 pulses each with 20-30s intervals between the trains.
61950662|NCT06069323|SHAM_COMPARATOR|Sham ASD group|18 rTMS sessions will be administered, placing the coil perpendicular to the scalp of the stimulation site, to avoid stimulation.
62499617|NCT04694703||Covid-19 group|Patients diagnosed with COVID-19 will be enrolled in this group.
62499618|NCT05388474||Cohort 1 (No ibalizumab or Pre-ibalizumab treatment):|This cohort will be comprised of Heavily treatment-experienced (HTE) patients with Multi Drug Resistant (MDR) HIV who are not receiving ibalizumab. These patients will roll-over into cohort 2 if a change to their ARV regimen is made to include ibalizumab.
62699424|NCT05177536|EXPERIMENTAL|Iberdomide|Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle
62699425|NCT04168125|EXPERIMENTAL|Tilapia skin|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a tilapia skin as an occlusive biological dressing for palatal wound healing.~Device: Tilapia skin. A xenogeneic collagen dressing will be placed over palate wound and stabilized with sutures during the healing process."
61950663|NCT06069323|ACTIVE_COMPARATOR|Active ADHD group|The rTMS will be administered 18 times, twice per week, with the following parameters: 5-10 Hz frequency, 90% MT, 180 pulses per session with 9 trains of 20 pulses each with 20-30 s intervals between the trains.
62499619|NCT05388474||Cohort 2 (On ibalizumab treatment):|This cohort will be comprised of Heavily Treatment-Experienced patients (HTE) with Multi Drug Resistant (MDR) HIV who are starting treatment with an ARV regimen that includes ibalizumab. Patients already receiving ibalizumab prior to study entry may also be included in Cohort 2 if baseline viral load (VL) and cluster of differentiation 4 (CD4) count data are available prior to ibalizumab treatment. Recruited patients will be required to consent to provide their full retrospective ARV treatment and drug resistance history, as well as retrospective historical data from their medical records from 01 May 2018 to enrollment.
62499620|NCT05034185||Patients with one or more polyps detected|"During colonoscopy, the Clinician inspect for the presence of polyps as per routine clinical practice with the CAD EYE function turned off. When a polyp is encountered, the Clinician will make a prediction on the histology based on the white light and BLI features of the polyp with and without optical magnification, as per routine clinical practice. Following this, the CAD EYE function will be switched on and the Clinician will take note of the CADx prediction for the same polyp, which will be either neoplastic or hyperplastic.~In addition, other polyp features such as the size and location will be recorded, which is similar to what is performed in routine clinical practice. The polyp will be resected and sent for pathological examination, which will form the gold standard for the diagnosis of polyp histology."
62499621|NCT01688882|EXPERIMENTAL|QGE031|QGE031 240 mg Q2W s.c.
62499622|NCT01688882|PLACEBO_COMPARATOR|Placebo|Placebo to Match Q2W s.c.
62499623|NCT01688882|EXPERIMENTAL|Open Label QGE031|Open Label QGE031 Q2W s.c.
62499624|NCT03852524|EXPERIMENTAL|Study Arm|The study arm will receive subcutaneous methylnaltrexone (0.15mg/kg rounded to 8 or 12 mg) before surgery and then daily, for the following three days after surgery (four doses).
62499625|NCT03852524|PLACEBO_COMPARATOR|Placebo Arm|The placebo arm will receive subcutaneous placebo before surgery and then daily, for the following three days after surgery (four doses).
62140938|NCT02966249|ACTIVE_COMPARATOR|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously starting 10 min before spinal anesthesia in total knee arthroplasty
62140939|NCT02966249|PLACEBO_COMPARATOR|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
62342198|NCT05242445|EXPERIMENTAL|Cohort 2 (Optional): Cetrelimab or Placebo (Dose 2)|Participants will receive cetrelimab Dose 2 or placebo administered via an Intravenous (IV) infusion on Day 1 based on the data review of previous cohort(s) (safety and tolerability data through at least 6 weeks postdose as well as pharmacokinetic (PK) and receptor occupancy (RO) data through at least day 4 postdose).
62342199|NCT05242445|EXPERIMENTAL|Cohort 3 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on the data review of previous cohort(s) (safety and tolerability data through at least 6 weeks postdose as well as PK and RO data through at least day 4 postdose).
62499626|NCT02058160|EXPERIMENTAL|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
62499627|NCT02058160|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
62699426|NCT04168125|ACTIVE_COMPARATOR|Surgical Wound Dressing|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a surgical wound dressing as a mechanical protection during palatal wound healing.~Device: Surgical wound dressing A surgical wound dressing will be placed over palate wound during the healing process to provide mechanical protection."
62699427|NCT05844618|ACTIVE_COMPARATOR|Triamcinolone Acetonide (Aristocort® C)|
61950664|NCT06069323|SHAM_COMPARATOR|Sham ADHD group|18 rTMS sessions will be administered, placing the coil perpendicular to the scalp of the stimulation site, to avoid stimulation.
62342200|NCT05242445|EXPERIMENTAL|Cohort 4 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on the data review of previous cohorts (safety and tolerability data through at least 6 weeks postdose as well as PK and RO data through at least day 4 postdose).
62342201|NCT06390189||Lean and metabolically healthy|
62342202|NCT06390189||Lean and metabolically unhealthy|
62140940|NCT02966249|OTHER|Normal Saline added intrathecally|Normal Saline added intrathecally up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
62140941|NCT02966249|OTHER|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously for total knee arthroplasty will start 10 minutes before spinal anesthesia to the end of the operation
62140942|NCT06671353|NO_INTERVENTION|control|
62499628|NCT05413512|EXPERIMENTAL|Acute psychological stress|Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
62499629|NCT06678425|EXPERIMENTAL|real rPMS|Real rPMS was applied to supraspinatus and posterior deltoid muscles for 20 Hz total 2,400 pulses.
62499630|NCT06678425|SHAM_COMPARATOR|sham rPMS|sham rPMS was applied to supraspinatus and posterior deltoid muscles with the same coil as real rPMS, but in a position perpendicular to the skin, using intensity for 5% of the maximum output.
62499631|NCT03544840|EXPERIMENTAL|Dynamic Standing Device|Home program using the Upsee
62499632|NCT04802213|ACTIVE_COMPARATOR|Rehabilitation exercise|1.perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)
62140943|NCT06671353|ACTIVE_COMPARATOR|with video decision aid|video decision aid
62699428|NCT05844618|PLACEBO_COMPARATOR|Vehicle|
62699429|NCT02749916||Patients with acute or recent (within 3months) stroke|
62342203|NCT06390189||Overweight and metabolically healthy|
62342204|NCT06390189||Overweight and metabolically unhealthy|
62699430|NCT05547984|EXPERIMENTAL|Dual Mobility Cup|dual mobility articulation
62699431|NCT05547984|ACTIVE_COMPARATOR|Standard Acetabular component|standard articulation with polyethylene + vitamin E inlay and metal head
62342205|NCT06390189||Obese and metabolically healthy|
62342206|NCT06390189||Obese and metabolically unhealthy|
62499633|NCT04802213|EXPERIMENTAL|Rehabilitation exercise + joint mobilization device treatment|"1. perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~2. perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)"
62499634|NCT04802213|EXPERIMENTAL|Rehabilitation exercise +joint mobilization device treatment + laser acupuncture device treatment|"1. perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~2. perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)~3. perform laser acupuncture device treatment for patients with frozen shoulders ( three sessions per week for 8 consecutive weeks. patients in each treatment session received laser at a dosage of 4 joules/cm2 for the eight chosen position. )"
62499635|NCT00199901|ACTIVE_COMPARATOR|Vaccine|NY-ESO-1 ISCOMATRIX® vaccine
62499636|NCT00199901|PLACEBO_COMPARATOR|Adjuvant Alone|ISCOMATRIX® adjuvant alone
62499637|NCT01186562|ACTIVE_COMPARATOR|Sitagliptin|
62499638|NCT01186562|PLACEBO_COMPARATOR|Placebo|
62499639|NCT06401941|EXPERIMENTAL|Patients|Hyperbaric oxygen (HBO) therapy.
62342207|NCT02746523||Case / Retired NHL Players|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
62499640|NCT06401941|NO_INTERVENTION|Controls|Healthy individuals that never treated with HBO therapy.
62499641|NCT05911919||Patients|Patients with ABCD1 pathogenic variant
62342208|NCT02746523||Age Matched Controls|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
62342209|NCT02961686||Patients with prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach that comprise exclusive radiotherapy, psychological and andrologic evaluation.
62342210|NCT00838916|EXPERIMENTAL|albiglutide weekly injection|albiglutide weekly subcutaneous injection
62342211|NCT00838916|ACTIVE_COMPARATOR|insulin glargine|insulin glargine daily injection
62342212|NCT04093258|EXPERIMENTAL|Test/Control|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
62342213|NCT04093258|EXPERIMENTAL|Control/Test|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
62499642|NCT05911919||Healthy volunteers|Healthy volunteers inclusion in order to calibrate the MRI machine used and its settings.
62499643|NCT02681588|EXPERIMENTAL|Obese group|
62499644|NCT02681588|ACTIVE_COMPARATOR|Normal Weight group|
62499645|NCT00298987|EXPERIMENTAL|A1|
62499646|NCT03701126|ACTIVE_COMPARATOR|group A|Transversus Abdominis Plane block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
62699432|NCT06230198|EXPERIMENTAL|Retrograde autologous priming|sites implement retrograde autologous priming (RAP) during cardiac surgery
62699433|NCT06230198|EXPERIMENTAL|Crystalloid priming|sites implement crystalloid priming use during cardiac surgery
62499647|NCT03701126|ACTIVE_COMPARATOR|group B|Caudal block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
62499648|NCT06471179||group A Patients|Schizophrenic patients according to diagnostic criteria
62499649|NCT06471179||group B Control|healthy subjects not suffering from any Psychiatric illness
62499650|NCT06462118|EXPERIMENTAL|Treatment A|Participants will receive one subcutaneous (SC) dose in the abdomen.
62499651|NCT06462118|EXPERIMENTAL|Treatment B|Participants will receive one subcutaneous (SC) dose in the thigh.
62499652|NCT06462118|EXPERIMENTAL|Treatment C|Participants will receive one subcutaneous (SC) dose in the upper arm.
62499653|NCT02502968|EXPERIMENTAL|Cytarabine & BL8040|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle~Subjects \<60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle"
62499654|NCT02502968|ACTIVE_COMPARATOR|Cytarabine & Placebo|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle~Subjects \<60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle"
62499655|NCT03095950|ACTIVE_COMPARATOR|News with Spin|News items reporting results of RCTs with spin
62499656|NCT03095950|EXPERIMENTAL|News without spin|News items reporting results of RCTs without spin
62699434|NCT06644742||Prospective Cohort|
62736788|NCT01715688|PLACEBO_COMPARATOR|Saline|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
61950665|NCT03396185|EXPERIMENTAL|Icotinib|Patients with EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
62499657|NCT04592419|EXPERIMENTAL|KSI-301 (Arm A)|"Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 to Week 44.~In the Extension Phase, participants randomized to KSI-301 (5 mg) in the Primary Study will continue to receive KSI-301 (5 mg) based on protocol-defined disease activity criteria."
62699435|NCT03301584|ACTIVE_COMPARATOR|Enhanced collaboration|"Enhanced OT and PT collaboration to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
62699436|NCT03301584|ACTIVE_COMPARATOR|Usual Care Treatment|Standard rehabilitation
61950666|NCT05100459|EXPERIMENTAL|Pasture-raised whey protein|whey protein from strictly grass fed cows
61950667|NCT05100459|EXPERIMENTAL|Conventional whey protein|whey protein from conventional animal feeding operation
61950668|NCT05100459|PLACEBO_COMPARATOR|Placebo|Maltodextrin given in iso-caloric amounts to protein
62342214|NCT04195100|ACTIVE_COMPARATOR|Low dose pilocarpine|low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day
62342215|NCT04195100|ACTIVE_COMPARATOR|High dose pilocarpine|high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
62342216|NCT03013205|EXPERIMENTAL|PT+IA+CHL|"1. Intraarticular triamcinolone injection~2. Intraarticular Xylocaine injection~3. Coracohumeral ligament triamcinolone injection~4. Physiotherapy"
62342217|NCT03013205|ACTIVE_COMPARATOR|PT+IA|"1. Intraarticular triamcinolone injection~2. Intraarticular Xylocaine injection~3. Physiotherapy"
62342218|NCT00800865|OTHER|Biomarker Evaluation Group I|Biomarker evaluation before and after dosing with cytotoxic agent(s)
62342219|NCT00800865|OTHER|Biomarker Evaluation Group II|Biomarker evaluation before and after dosing with cytotoxic agent(s)
62342220|NCT00505232|EXPERIMENTAL|Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin|Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)
62342221|NCT00694694|EXPERIMENTAL|1AZ+AQ|Azithromycin + artesunate
62699437|NCT02001792|SHAM_COMPARATOR|Controll group|Patients lying in a supine position during colonoscopy
62699438|NCT02001792|ACTIVE_COMPARATOR|Intervention|Patients lying in a left lateral position during colonoscopy
62699439|NCT06571539|EXPERIMENTAL|AR-assisted EVD placement|External ventricular drain (EVD) placement using a standalone augmented reality (AR) headset equipped with high-accuracy inside-out infrared tracking and software addressing EVD placement.
62699440|NCT01149694|OTHER|Cohort 1|
62699441|NCT01149694|OTHER|Cohort 2|
61950669|NCT04793867||CF and Non-CF Bronchiectasis|In the first arm (Aims 1 \& 2) Up to 50 subjects will be recruited-approximately 25 with normal FEV1 (\>85% predicted) and 25 with mild to moderate disease. All subjects will be asked to undergo longitudinal (i.e., approximately annually) 129Xe and UTE MRI, spirometry, and lung clearance index (LCI) measurement.
61950670|NCT04793867||Healthy Subjects|Up to 50 age and sex matched control subjects (i.e., subjects with no known cardiopulmonary disorders) may also be recruited to provide a reference data set from healthy subjects for comparison.
61950671|NCT05276037||Study group|Milan-out, up-to-7-in, PET negative (≤1.15) HCC patients
61950672|NCT05276037||Control group|Milan-in HCC patients
62140944|NCT05999682|EXPERIMENTAL|apigenin|Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
62140945|NCT05999682|PLACEBO_COMPARATOR|sterilized water|Gastric tube injection of 5 ml of sterilized water for injection + conventional standardized treatment, for 4 consecutive days.
62140946|NCT00894257||HCV/HIV infected pregnant women|
62342222|NCT00694694|ACTIVE_COMPARATOR|2AL|Artemether-lumefantrine
62342223|NCT06093217||Prospective Cohort: 'Live' Introduction of AI technology|Consecutive CTPAs, for patients with suspected acute PE, which have their imaging interpreted 'live' by AI technology. The radiologist will have ultimate responsibility for the report generated.
62342224|NCT06093217||Comparator Cohort: Standard Radiology reporting|"Retrospective CTPAs, for patients with suspected acute PE, which have been reported by a human radiologist only.~These CTPAs will not be interpreted by AI technology 'live' BUT undergo analysis to help assess the sensitivity, specificity, false negative, false positive rates of AI technology."
62342225|NCT04274140||Obese Pregnant Women|obese, BMI 30-50
62342226|NCT04274140||Normal weight pregnant women|normal weight, BMI 18.5-25
62342227|NCT04380974|EXPERIMENTAL|OCTA plus OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization, OCTA and OCT in the extension treatment period.
62342228|NCT04380974|ACTIVE_COMPARATOR|OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization and OCT in the extension treatment period.
62342229|NCT02209311|EXPERIMENTAL|Tissue engineered construction implantation|
62342230|NCT06025123|EXPERIMENTAL|Early transnasal evaporative cooling with the RhinoChill device|Early transnasal evaporative cooling initiated during ACLS at the scene of the cardiac arrest within 20 minutes from EMS arrival and subsequent hypothermia at 33ºC for 24 hours and fever control for 72 hours at the ICU
62342231|NCT06025123|NO_INTERVENTION|Standard of care|Standard advanced cardiac life support, subsequent fever control (Normothermia) for 72 hours at ICU
62342232|NCT01030458|EXPERIMENTAL|amlodipine plus valsartan|In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.
62699442|NCT01149694|OTHER|Cohort 3|
62699443|NCT01149694|OTHER|Cohort 4|
62699444|NCT05576649|ACTIVE_COMPARATOR|Control Group 1|In this group, the number of flashes per row and column during the P300 speller training will be adapted based on the participants' previous performance according to the approach used by Arvaneh et al. (2019).
62699445|NCT05576649|SHAM_COMPARATOR|Control Group 2|In this group, the number of flashes per row and column during the P300 speller training will be chosen randomly. It is independent of the participants' performance.
62699446|NCT05576649|EXPERIMENTAL|Experimental Group|In this group, the number of flashes per row and column during the P300 speller training will be adapted according to an iterative learning control law that was developed by the principal investigator of this study. The control law uses the previous number of flashes, as well as the participants' previous performance.
62699447|NCT06644807|EXPERIMENTAL|Peripheral nerve stimulation|
62699448|NCT06644807|EXPERIMENTAL|Spinal cord stimulation|
62699449|NCT06644807|EXPERIMENTAL|Motor Cortex Stimulation|
62699450|NCT06644807|EXPERIMENTAL|Dorsal Root Ganglion Stimulation|
62699451|NCT04827914|EXPERIMENTAL|Enhanced Care Condition|
61950673|NCT05705388|ACTIVE_COMPARATOR|POSE2.0 Procedure|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
62699452|NCT04827914|ACTIVE_COMPARATOR|Basic Care Condition|
62699453|NCT04433182|EXPERIMENTAL|Single arm Copa-RB|Induction phase with Copanlisib, Rituximab and Bendamustina. Maintenance phase (for patients who reach at least SD after induction) with Copanlisib in monotherapy.
62699454|NCT02699307|EXPERIMENTAL|Intervention|OT-led counseling based on home activity pattern
62699455|NCT02499926|EXPERIMENTAL|Dietary supplement: Arginine|Graded arginine excess intake
62699456|NCT03282266|EXPERIMENTAL|PADN + 5-phosphodiesterase|A total of 64 patients are assigned to PADN + 5-phosphodiesterase group after randomization schedule.
62699457|NCT03282266|SHAM_COMPARATOR|Sham operation + 5-phosphodiesterase|A total of 64 patients are assigned to sham operation + 5-phosphodiesterase group after randomization schedule.
62699458|NCT04696003|NO_INTERVENTION|control|The patients with classic PPROM between 22/0-26/0 weeks' gestation with oligo/anhydramnion with standard conservative treatment (7 days Amoxicillin/Clarithromycin therapy or 7 days Amoxicillin and once Azithromycin 1 g per os, and corticosteroids like Celestan®, Essex Pharma, Munich, Germany) as RDS prophylaxis will represent the control group (DGGG Guideline AWMF 015-025, February 2019, Version 1.0). The diagnosis of the PPROM must be not early than 20/0 weeks' gestation.
62699459|NCT04696003|ACTIVE_COMPARATOR|Amnion Flush group (continuous amnioinfusion)|"In the Amnion Flush group additionally to the standard treatment the amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intra-amniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. Amnion Flush Solution (CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h (2400 ml/d) under periodic ultrasound using the standard i.v. pump. The deepest pool of amniotic ﬂuid should be stabilized by about 4 cm. The ultrasound control will be performed daily. Induction of the labour or c-section at 34/0 week of gestation or earlier if indicated."
62699460|NCT06557161|EXPERIMENTAL|TMLI conditioning group|Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI) plus Cyclophosphamide
61950674|NCT05705388|ACTIVE_COMPARATOR|Liraglutide|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
61950675|NCT01468883|ACTIVE_COMPARATOR|M|Modified radical mastectomy
62342233|NCT01030458|ACTIVE_COMPARATOR|hydrochlorothiazide plus bisoprolol|In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol
62342234|NCT01760993|EXPERIMENTAL|SPD489|
62699461|NCT06557161|ACTIVE_COMPARATOR|TBI conditioning group|Total Body Irradiation (TBI) plus Cyclophosphamide
62342235|NCT02097758|EXPERIMENTAL|transcatheter device closure|Choosing device size using three dimensional image and the formula without sizing balloon
62699462|NCT03413800|EXPERIMENTAL|Lenalidomide-Dexamethasone-DLI|"1. Patients will receive Len (10 mg in the presence of ≤ grade I acute GVHD or absence of chronic GVHD; 5 mg in presence of controlled mild or moderate chronic GVHD) daily x 21 days with Dex 40 mg once weekly for a total of 6 cycles of 28 days each~   1. For grade ≥III non hematologic or grade IV hematologic toxicity, Len can be reduced to 5 mg~  2. In absence of these toxicities, acute GVHD (using Glucksberg modified criteria) or severe chronic GVHD (using NIH criteria), Len dose can be increased by 5 mg per cycle to a maximum of 25 mg~2. If eligibility is confirmed, sibling and unrelated donor transplant recipients will both receive 3 donor lymphocyte infusions (DLIs) at the following doses: 5 x 106 CD3+/kg; 1 x 107 CD3+/kg; 5 x 107 CD3+/kg~3. Patient will be followed for 5 years post relapse."
62699463|NCT00297791|OTHER|1|surgery (open or laparoscopic) and observation
62699464|NCT06641011|ACTIVE_COMPARATOR|Resin based fissure sealant restoration one week after silver fluoride (AgF) application|Resin-based fissure sealant restoration one week after silver fluoride (AgF) application
62699465|NCT06641011|ACTIVE_COMPARATOR|Immediate resin based fissure sealant after blot drying silver fluoride (AgF) application|Immediate resin based fissure sealant after blot drying silver fluoride (AgF) application
62699466|NCT06641011|ACTIVE_COMPARATOR|Immediate GI-based fissure sealant after rinsing silver fluoride application|Immediate GI-based fissure sealant after rinsing silver fluoride application
62699467|NCT06641011|ACTIVE_COMPARATOR|Immediate GI-based fissure sealant after blot-drying of silver fluoride application|Immediate GI-based fissure sealant after blot-drying of silver fluoride application
61950676|NCT01468883|EXPERIMENTAL|X|Excisional biopsy plus radiation
61950677|NCT03431870|OTHER|Aorta dilated|Patients with aorta of 40mm or more who undergo a cardiac surgery. The intervention include: Trans-Esophageal Echocardiography
61950678|NCT00781274|EXPERIMENTAL|MP-424|
61950679|NCT01480752|ACTIVE_COMPARATOR|Lornoxicam|
61950680|NCT01480752|PLACEBO_COMPARATOR|normal saline|
61950681|NCT01480752|PLACEBO_COMPARATOR|no injection|
61950682|NCT00822042||1|Patients with corticotherapy lasting more than 3 months
61950683|NCT04333550|EXPERIMENTAL|Experimental: Desferal addition to standard treatment|
61950684|NCT04333550|EXPERIMENTAL|Experimental: standard treatment|
61950685|NCT03750955|EXPERIMENTAL|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where plaque induced gingivitis results from a cessation of oral hygiene in a sextant using a stent-induced biofilm overgrowth model.
61950686|NCT03750955|ACTIVE_COMPARATOR|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene (tooth brushing with fluoride toothpaste and flossing twice daily) is maintained.
61950687|NCT03566784||Electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, with the use of electrocoagulation.
61950688|NCT03566784||No electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, without the use of electrocoagulation.
61950689|NCT02554695|PLACEBO_COMPARATOR|placebo|single subcutaneous injection of placebo (normal saline)
61950690|NCT02554695|ACTIVE_COMPARATOR|Denosumab|single subcutaneous injection of denosumab 60 mg
62499658|NCT04592419|ACTIVE_COMPARATOR|Aflibercept (Arm B)|"Intravitreal injection of aflibercept (2 mg) once every 4 through Week 20 followed by an individualized dosing regimen of Intravitreal injection of Aflibercept (2 mg) once every 4 weeks from Week 24 to Week 44.~In the Extension Phase, participants randomized to aflibercept in the Primary Study will cross over to treatment with KSI-301 (5 mg). They will receive their first dose of KSI-301 (5 mg) at Week 48 and will receive additional treatment with KSI-301 (5 mg) based on protocol-defined disease activity criteria."
62499659|NCT00758758|EXPERIMENTAL|Experimental Arm 1|Hedrocel 1 level - No plate
61950691|NCT02554695|NO_INTERVENTION|young normal premenopausal women|no intervention
61950692|NCT02418650|EXPERIMENTAL|Part 1|A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C
61950693|NCT02418650|EXPERIMENTAL|Part 2|A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C
62140947|NCT02432066|ACTIVE_COMPARATOR|GTS-21|Participants in the GTS-21 arm will receive 150 mg/BID GTS-21 over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
61950694|NCT02886832|EXPERIMENTAL|Prostate Health formulation|Prostate Health formulation
62140948|NCT02432066|PLACEBO_COMPARATOR|Placebo|Participants in the Placebo arm will receive placebo compound twice daily over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
62140949|NCT05964023|EXPERIMENTAL|pBFS rTMS|3 sessions of active rTMS would be delivered to the pBFS-guided left DLPFC daily, with a session of 1800 pulse.
62140950|NCT05964023|ACTIVE_COMPARATOR|5-cm rTMS|"3 sessions of active rTMS would be delivered to the 5-cm rule guided left DLPFC daily, with a session of 1800 pulse."
62699468|NCT06641011|ACTIVE_COMPARATOR|Immediate resin-based fissure sealant after rinsing of silver fluoride application|Immediate resin-based fissure sealant after rinsing of silver fluoride application
61950695|NCT05740124|EXPERIMENTAL|Slip recovery training|Once weekly sessions of slip recovery training for 3 or 6 weeks. Each session will be 20 minutes of training. Training will involve volitional and reactive stepping movements that mimic the movements necessary to recover balance after slipping while walking.
61950696|NCT05740124|ACTIVE_COMPARATOR|Alternative balance training|Once weekly sessions of balance training for 3 or 6 weeks. Each session will be 20 minutes of training. Training will involve standing balance under varied sensory conditions, and tandem walking forward and backward under varied sensory conditions.
61950697|NCT03668275|EXPERIMENTAL|Intervention|(partial) oncological home-hospitalization
61950698|NCT03668275|NO_INTERVENTION|Control|standard oncological ambulatory hospital care
61950699|NCT03838952|EXPERIMENTAL|Chinese herbal medicine group|drug for the subjects
61950700|NCT00734175|EXPERIMENTAL|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
61950701|NCT01272674|ACTIVE_COMPARATOR|exercise training|4 weeks of supervised physical exercise training
61950702|NCT01272674|NO_INTERVENTION|control|sedentary lifestyle
61950703|NCT01272674|NO_INTERVENTION|healthy control|
61950704|NCT02137265|ACTIVE_COMPARATOR|Clomiphene citrate|Clomiphene citrate 50 mg daily during 4-6 months
61950705|NCT02137265|PLACEBO_COMPARATOR|Placebo|Placebo (1 pill daily) during 4-6 months
62342236|NCT03579524|ACTIVE_COMPARATOR|ESPB group|Erector Spinae Plane Block administered group
61950706|NCT03407625|EXPERIMENTAL|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
61950707|NCT03407625|ACTIVE_COMPARATOR|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
61950708|NCT05047770|ACTIVE_COMPARATOR|HZ/suSeq Group|Participants randomized to HZ/suSeq Group received one mRNA-1273 booster dose administered at Day 1, followed by the first dose of HZ/su vaccine administered at Week 2 and the second dose of HZ/su vaccine administered at Week 10.
61950709|NCT05047770|EXPERIMENTAL|HZ/suCoAd Group|Participants randomized to HZ/suCoAd Group received one mRNA-1273 booster dose co-administered with the first dose of HZ/su vaccine at Day 1, followed by the second dose of HZ/su vaccine administered at Week 8.
61950710|NCT05047770|ACTIVE_COMPARATOR|FluD-QIVSeq Group|Participants randomized to FluD-QIVSeq Group received one mRNA-1273 booster dose at Day 1, followed by one dose of Flu D-QIV vaccine at Week 2.
61950711|NCT05047770|EXPERIMENTAL|FluD-QIVCoAd Group|Participants randomized to FluD-QIVCoAd Group received one mRNA-1273 booster dose co-administered with one dose of Flu D-QIV vaccine at Day 1.
62499660|NCT00758758|EXPERIMENTAL|Experimental Arm 2|Hedrocel 1 level with plate
62499661|NCT00758758|EXPERIMENTAL|Experimental Arm 3|Hedrocel 2 levels with plate
62499662|NCT00758758|ACTIVE_COMPARATOR|Control Arm 1|Autograft alone - Illiac crest
62499663|NCT00758758|ACTIVE_COMPARATOR|Control Arm 2|Autograft 1 level with plate
62499664|NCT00758758|ACTIVE_COMPARATOR|Control Arm 3|Allograft 1 level with plate
61950712|NCT06150625|ACTIVE_COMPARATOR|Orthopedic Manual Therapy|"Participants randomized to this arm will receive clinician-selected orthopedic manual therapy targeting the joints of the low back. Selected techniques can involve joint mobilizations or spinal manipulation. The dosage parameters will be determined by the clinician.~Patient Education Patients will receive education regarding their low back pain, advice to stay active, proper performance of their home exercise program.~Home exercise program The program will consist of 10 exercises which the clinician will select 5 they feel would be most beneficial to the patient. These can include aerobic, general strengthening, directional preference, or neural self-mobilizations."
61950713|NCT06150625|ACTIVE_COMPARATOR|Dry Needling|"Participants randomized to this arm will receive dry needling to the low back and lower extremity while being applied based on clinician-selected areas of symptomatic soft tissue. The dosage parameters will be determined by the clinician.~Patient Education Patients will receive education regarding their low back pain, advice to stay active, proper performance of their home exercise program.~Home exercise program The program will consist of 10 exercises which the clinician will select 5 they feel would be most beneficial to the patient. These can include aerobic, general strengthening, directional preference, or neural self-mobilizations."
61950714|NCT06150625|EXPERIMENTAL|Orthopedic Manual Therapy and Dry needling|"Participants randomized to this arm will receive dry needling to the lumbar spine and lower extremity based on clinician-selected areas of symptomatic soft-tissue and or orthopedic manual therapy targeting the joints of the low back.~Patient Education Patients will receive education regarding their low back pain, advice to stay active, proper performance of their home exercise program.~Home exercise program The program will consist of 10 exercises which the clinician will select 5 they feel would be most beneficial to the patient. These can include aerobic, general strengthening, directional preference, or neural self-mobilizations."
61950715|NCT05723302|EXPERIMENTAL|Maximal Inspiratory Pressure|MIP Maximal Inspiratory Pressure
61950716|NCT05723302|EXPERIMENTAL|Maximal Expiratory Pressure|MEP Maximal Expiratory Pressure
61950717|NCT05705518|EXPERIMENTAL|Systane Complete PF (Treatment)|Masked subjects assigned to Arm 1 will use Systane Complete PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
62140951|NCT00449774|EXPERIMENTAL|Subjects in Treatment regimen C|Subjects in treatment regimen C will receive 200 milligram (mg) orally disintegrating tablets (ODT) of lamotrigine disintegrate in mouth without water in fasting condition.
61950718|NCT05705518|PLACEBO_COMPARATOR|Refresh Relieva PF (Control)|Masked subjects assigned to Arm 2 will use Refresh Relieva PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
62140952|NCT00449774|EXPERIMENTAL|Subjects in Treatment regimen D|Subjects in treatment regimen D will receive 200 mg Immediate Release (IR) tablets of lamotrigine with water in fasting condition.
62342237|NCT03579524|ACTIVE_COMPARATOR|SAPB group|Serratus Anterior Plane Block administered group
62342238|NCT02662985|ACTIVE_COMPARATOR|Group 1|"In Treatment Period-1:~Patients in this group were administered secukinumab with 12 weeks of treatment from baseline.~In Treatment Period-2:~Patients continued to receive the same active dose of secukinumab every 4 weeks until Week 24~In Treatment Period 3 (extension period):~the extension period allowed responder patients the possibility to continue open-label secukinumab treatment up to Week 52"
62342239|NCT02662985|PLACEBO_COMPARATOR|Group 2|"In Treatment Period-1:~Patients received placebo at baseline and same time points as secukinumab until Week 8.~In Treatment Period-2:~Patients commenced open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12~In Treatment Period-3:~Open-label secukinumab continued to be assigned to patients"
62342240|NCT02019524|EXPERIMENTAL|E39 peptide vaccine|Patients receive 6 monthly injections of E39 peptide + GM-CSF. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
62499665|NCT00758758|ACTIVE_COMPARATOR|Control Arm 4|Autograft 2 levels with plate
62499666|NCT00758758|ACTIVE_COMPARATOR|Control Arm 5|Allograft 2 levels with plate
62499667|NCT04952467|EXPERIMENTAL|Drug: (14C)-XEN1101|Subjects will receive oral 14C-XEN1101 under fed conditions.
62499668|NCT05891119|EXPERIMENTAL|Rocatinlimab and CYP450 Substrates|"A single oral dose of a CYP450 substrates cocktail which will include caffeine, metoprolol, midazolam, warfarin (with vitamin K), and omeprazole will be administered on Day 1.~A single dose of rocatinlimab will then be administered on Days 8, 22, 36, 64, and 92.~A single oral dose of CYP450 substrates cocktail in combination with a single dose of rocatinlimab will then be administered on Day 120."
62499669|NCT05916716|ACTIVE_COMPARATOR|PR+CAF|Partial restoration will be performed, and its apical margin will be placed 1 mm beyond the estimated position of the cementoenamel junction. Patients enrolled in this group will receive a coronally advanced flap (CAF). Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
62699469|NCT06641011|ACTIVE_COMPARATOR|GI-based fissure sealant restoration one week after silver fluoride (AgF) application|GI-based fissure sealant restoration one week after silver fluoride (AgF) application
62699470|NCT03527667|EXPERIMENTAL|Short term incentives|usual quit smoking treatment (counseling + medication) plus 6-weeks of payments for proof of smoking abstinence
62699471|NCT03527667|EXPERIMENTAL|Long term incentives|usual quit smoking treatment (counseling + medication) plus 12-weeks of payments for proof of smoking abstinence
61950719|NCT05705518|ACTIVE_COMPARATOR|Refresh Optive Mega-3 PF (Active Comparator 1)|Masked subjects assigned to Arm 3 will use Refresh Optive Mega-3 PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
61950720|NCT05705518|ACTIVE_COMPARATOR|CVS Health Lubricant Eye Drop (PG 0.6%) (Active Comparator 2)|Masked subjects assigned to Arm 4 will use CVS Health Lubricant Eye Drop (PG 0.6%) artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
62342241|NCT02019524|EXPERIMENTAL|E39 vaccine then J65 vaccine|Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
62342242|NCT02019524|EXPERIMENTAL|J65 vaccine then E39 vaccine|Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
62342243|NCT03938441|EXPERIMENTAL|Intermittent Fasting|Modified 5:2 intermittent fasting
62499670|NCT05916716|EXPERIMENTAL|PR + CAF + VCMX|Partial restoration will be performed, and its apical margin will be placed 1 mm beyond the estimated position of the cementoenamel junction. Patients enrolled in this group will receive a coronally advanced flap (CAF) associated with a volume-stable collagen matrix (VCMX). Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. In sequence, VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction level and stabilized in the adjacent surgery papillae by interrupted sutures. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
62499671|NCT06679296||Observation group|Establish a screening and long-term tracking cohort study related to healthy aging and the development of cognitive impairments to understand changes in physiological, psychological, mental, and daily living abilities across different age groups in humans. Analyze genetic factors, environmental influences, lifestyle, and their impacts on the occurrence and development of healthy aging, cognitive impairments, and other age-related diseases.
62499672|NCT00458159|EXPERIMENTAL|1|
62499673|NCT01889550|ACTIVE_COMPARATOR|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
62499674|NCT01889550|PLACEBO_COMPARATOR|Access to the website www.ouh.dk|Access to the usual information from the hospital website
62499675|NCT01863355|EXPERIMENTAL|B0|(basal rate 0cc/hr, bolus 3cc, lockout time 10min)
62499676|NCT01863355|ACTIVE_COMPARATOR|BL|(basal rate 1cc/hr, bolus 2cc, lockout time 10min)
62499677|NCT01863355|ACTIVE_COMPARATOR|BH|(basal rate 2cc/hr, bolus 1cc, lockout time 10min)
61950721|NCT02727673||healthy volunteers|matched group
62342244|NCT01983410||BRCAmut carrier relatives of a BRCAmut PDAC patient|Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
62342245|NCT01983410||BRCAmut carrier relatives of a BRCA mutation PDAC|Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
62342246|NCT01983410||BRCAmut carriers|who are not related to a BRCAmut PDAC patient
62499678|NCT00842816|EXPERIMENTAL|1|10 mg ST101
62499679|NCT00842816|EXPERIMENTAL|2|60 mg ST101
62499680|NCT00842816|EXPERIMENTAL|3|120 mg ST101
61950722|NCT02727673||hepatitis cirrhosis|negative group
61950723|NCT02727673||hepatocellular carcinoma|patients with primary HCC
61950724|NCT01887665|EXPERIMENTAL|Incentives|Prize-based financial incentives, informed by contingency management principles, are offered to patients who attend treatment visits.
61950725|NCT02592252|EXPERIMENTAL|Microfinance + gender training|Microfinance + 10 sessions of participatory gender training
61950726|NCT02592252|EXPERIMENTAL|Microfinance only|Receive microfinance only
61950727|NCT02592252|EXPERIMENTAL|Gender training only|10 sessions of participatory gender training for women and their male partners
62499681|NCT00842816|PLACEBO_COMPARATOR|4|Placebo
62499682|NCT04139941||Individuals with known or unknown HCV status|
62499683|NCT05959486|ACTIVE_COMPARATOR|BR6002A+BR6002B|
62499684|NCT05959486|EXPERIMENTAL|BR6002|
62499685|NCT01022255|EXPERIMENTAL|Arm 1|
62499686|NCT01424098|EXPERIMENTAL|Balance Training|The treatment group will complete a specific balance training program in addition to conventional pulmonary rehabilitation.
62499687|NCT01424098|NO_INTERVENTION|Usual care|The control group will undergo the usual pulmonary rehabilitation program offered at our centre with no additional balance training classes.
61950728|NCT02592252|NO_INTERVENTION|No intervention|No microfinance or participatory gender training
61950729|NCT01441180|EXPERIMENTAL|Phase 1|Participants (N =10) will receive GS-7977 QD in combination with RBV for a total of 24 weeks. The study team will perform an interim evaluation of data and safety at the end of 12 weeks of treatment.
61950730|NCT01441180|ACTIVE_COMPARATOR|Phase 2 Arm A|(N =25) 24 weeks of GS-7977 QD in combination with weight based RBV (1000 mg for participants weighing \<75 kg and 1200 mg for participants weighing ≥75kg)
61950731|NCT01441180|ACTIVE_COMPARATOR|Phase 2 Arm B|(N = 25): 24 weeks of GS-7977 QD with low dose RBV (600mg).
62342247|NCT01983410||AJ PDAC patients|who are proven non-BRCAmut carriers.
62499688|NCT05491512|EXPERIMENTAL|Cohort A|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC)
61950732|NCT02850107|OTHER|Non-randomized|"Directional Atherectomy + Drug Coated Balloon: DA followed by DCB will be performed in all enrolled subjects.~DA includes the use of Intervention 'Medtronic HawkOne® or TurboHawk™.~Medtronic Spider™ Distal Protection Device (DPD) is recommended for use according to IFU.~Medtronic IN.PACT® Admiral® DCB will be used after DA.~Volcano Visions® PV .014 IVUS catheter required to assess lesion in each procedure.~Nitinol Stent Placement: Only FDA approved nitinol stents can be used if provisional stenting is required."
61950733|NCT03519178|EXPERIMENTAL|Dose Escalation|Single Agent Dose Escalation
61950734|NCT03519178|EXPERIMENTAL|Dose Finding Endocrine Therapy 1 Combination|Part 1B PF-06873600 plus Endocrine Therapy 1
62342248|NCT01983410||AJ first or second degree relatives of an AJ PDAC patient from a multiplex family|A family with at least two first or second degree relatives w ho have had PDAC.
62342249|NCT01861938|EXPERIMENTAL|Melanoma vaccine|
61950735|NCT03519178|EXPERIMENTAL|Dose Finding Endocrine Therapy 2 Combination|Part 1B PF-06873600 plus Endocrine Therapy 2
61950736|NCT03519178|EXPERIMENTAL|Dose Expansion Arm A|PF-06873600 as a Single Agent
61950737|NCT03519178|EXPERIMENTAL|Dose Expansion Arm B|PF-06873600 as a Single Agent in Various Tumor Types
61950738|NCT03519178|EXPERIMENTAL|Dose Expansion Arm C|PF-06873600 in Combination with Endocrine Therapy 1
61950739|NCT03519178|EXPERIMENTAL|Dose Expansion Arm D|PF-06873600 in Combination with Endocrine Therapy 1
62140953|NCT00449774|EXPERIMENTAL|Subjects in Treatment regimen E|Subjects in treatment regimen E will receive 200 mg ODT disintegrate of lamotrigine in mouth without water in fed state.
62140954|NCT00449774|EXPERIMENTAL|Subjects in Treatment regimen F|Subjects in treatment regimen F will receive 200 mg ODT of lamotrigine, that subjects will swallow with water in fasting condition.
62140955|NCT03212638|EXPERIMENTAL|Baricitinib T1 (Part A)|4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)
62140956|NCT03212638|EXPERIMENTAL|Baricitinib T2 (Part A)|4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)
62140957|NCT03212638|EXPERIMENTAL|Baricitinib R (Part A)|4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)
62140958|NCT03212638|EXPERIMENTAL|Baricitinib TF Fasted (Part B)|4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)
62140959|NCT03212638|EXPERIMENTAL|Baricitinib TF Fed (Part B)|4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)
62140960|NCT06698861|EXPERIMENTAL|Cohort 1: PEG-MetHuG-CSF 2 mg|To evaluate the safety and tolerability of P2203. In Cohort 1, the first two subjects will be the sentinel subjects treated with staggered dosing. The 1st sentinel subject of Cohort 1 will be dosed at least 96 hours prior to the 2nd sentinel subject. The 2nd sentinel subject will receive P2203 when the Criteria for Dosing Suspension or Termination in a Given Dose Cohort is not met at least during the first 96 hours following administration of P2203 of the 1st sentinel subject. The remaining subject in Cohort 1 will receive P2203 when the Criteria for Dosing Suspension or Termination in a Given Dose Cohort is not met at least during the first 96 hours following administration of P2203 of the 2nd sentinel subject.
62140961|NCT06698861|ACTIVE_COMPARATOR|Cohort 2b: Neulasta 6 mg|In Cohort 2, subjects will be randomized in a 1:1 ratio to receive a single dose of 6 mg P2203 (Cohort 2a, 12 subjects) or a single dose of 6 mg pegfilgrastim (Cohort 2b, 12 subjects).
62140962|NCT06698861|EXPERIMENTAL|Cohort 2a: PEG-MetHuG-CSF 6 mg|In Cohort 2, subjects will be randomized in a 1:1 ratio to receive a single dose of 6 mg P2203 (Cohort 2a, 12 subjects) or a single dose of 6 mg pegfilgrastim (Cohort 2b, 12 subjects).
62342250|NCT04039191|PLACEBO_COMPARATOR|SMS survey|Subject to receive SMS survey.
62342251|NCT04039191|ACTIVE_COMPARATOR|SMS survey with education|Subject to receive SMS survey with education.
62699472|NCT03527667|NO_INTERVENTION|No incentives|usual quit smoking treatment (counseling + medication)
61950740|NCT03519178|EXPERIMENTAL|Dose Expansion Arm E|PF-06873600 in Combination with Endocrine Therapy 2
61950741|NCT01090492|EXPERIMENTAL|Secondary Raynaud 4 mg dose (period 1)|
61950742|NCT01090492|EXPERIMENTAL|Secondary Raynaud 4 mg dose (period 2)|
61950743|NCT01090492|EXPERIMENTAL|Secondary Raynaud 20 mg dose (period 1)|
62140963|NCT06550401|ACTIVE_COMPARATOR|Control group|Participants in the control group will receive the usual feedback from questionnaires completed before and after routine surgery by discussing it with their surgeon
62140964|NCT06550401|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive feedback using the BREAST-Q REACT tool from questionnaires completed before and after routine surgery, in addition to the usual way by discussing it with their surgeon.
62140965|NCT02595346|EXPERIMENTAL|hydroxychlorquine|hydroxychloroquine 200 mg twice a day for 6 months
62140966|NCT02595346|PLACEBO_COMPARATOR|control|placebo 2 pills a day for 6 months
62342252|NCT01534234|EXPERIMENTAL|SonR group|SonR CRT Optimization
62342253|NCT01534234|ACTIVE_COMPARATOR|ECHO group|Echocardiographic Optimization
62342254|NCT02822534|EXPERIMENTAL|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
62342255|NCT02822534|EXPERIMENTAL|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
62699473|NCT05507242|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection
62699474|NCT05507242|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injection
62699475|NCT06464991|EXPERIMENTAL|Experimental group|Drug:Equecabtagene Autoleucel Injection
62699476|NCT06464991|ACTIVE_COMPARATOR|Control group|"Drug:~Daratumumab, Bortezomib, Dexamethasone, Pomalidomide, DPd group: Daratumumab, Pomalidomide, Dexamethasone PVd group: Bortezomib, Dexamethasone, Pomalidomide"
62699477|NCT04192708|EXPERIMENTAL|DV-ICNB group|intercostal nerve block under direct vision
62499689|NCT05491512|EXPERIMENTAL|Cohort B|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). Participants in Cohort B will receive 1 cycle of carboplatin and Paclitaxol the same week of the start of radiation. Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel). Paclitaxel can be substituted with Abraxane and the dose will be 50mg/m\^2. For Cohort B, patients over 70yrs will be able to enroll regardless of Cisplatin or carboplatin/5-fluorouracil (FU) eligibility.
62499690|NCT05491512|EXPERIMENTAL|Cohort C|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). For participants in Cohort C where induction chemotherapy is used, additional pre-treatment 18F-FMISO PET and post induction pre radiation FMISO PET Scans will be obtained. These patients will start with induction chemotherapy of carboplatin, paclitaxel with or without cetuximab for 6 weeks and follow the same precision chemoradiation algorithm as Cohort A. A window of +/- 2 days is acceptable during the induction phase Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel). For patients who cannot tolerate paclitaxel, Abraxane and the dose will be at 100mg/m\^2.
62499691|NCT05491512|EXPERIMENTAL|Cohort D|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). Cohort D will just have T1- T2N0 participants. Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel). Will follow the guidelines for Cohort A and Cohort B for chemotherapy options.
62499692|NCT00652002|EXPERIMENTAL|1|
62499693|NCT00652002|ACTIVE_COMPARATOR|2|budesonide
62499694|NCT00652002|ACTIVE_COMPARATOR|3|formoterol
62499695|NCT04536506|EXPERIMENTAL|Treatment group|Bobath group received 45 min of sessions three times weekly for 12 weeks.
61950744|NCT01090492|EXPERIMENTAL|Secondary Raynaud 20 mg dose (period 2)|
61950745|NCT01090492|EXPERIMENTAL|Primary Raynaud 4 mg dose (period 1)|
61950746|NCT01090492|EXPERIMENTAL|Primary Raynaud 4 mg dose (period 2)|
62140967|NCT01448941|ACTIVE_COMPARATOR|Primary arthrodesis TMT 1|Arthrodesis TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
62342256|NCT02822534|EXPERIMENTAL|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
62342257|NCT05784337|EXPERIMENTAL|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system
62342258|NCT01884857|ACTIVE_COMPARATOR|'TOPROL-XL®' ER Tablets 50 mg|'TOPROL-XL®' ER Tablets 50 mg of Astrazeneca LP, USA
62342259|NCT01884857|EXPERIMENTAL|Metoprolol Succinate ER Tablets 50 mg|Metoprolol Succinate ER Tablets 50 mg of Ipca Laboratories Limited, India
62342260|NCT03741296|ACTIVE_COMPARATOR|single stage revision|One surgery where the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided and washed out before a new artificial hip joint (prosthesis) is implanted. All the procedures will be done in a single surgery.
62342261|NCT03741296|ACTIVE_COMPARATOR|two-stage revision|"Patients will undergo 2 separated surgeries. In the first operation, the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided, washed out and a spacer will be placed in the hip (temporarily replace prosthesis).~A secondary surgery to re-implant the hip will be performed with an interval period of 4-10 weeks when the infection is cleared.~The site will be debrided and irrigated, and any component/spacer will be removed. A new artificial joint will then be implanted."
62342262|NCT02158702|EXPERIMENTAL|Pomalidomide and Dexamethasone|"PO pomalidomide 4mg from D1-21 and PO dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~PO or IV cyclophosphamide 300mg/m2 on D1, 8 and 15 can be added at the discretion of the treating physician to induce added response under the following circumstances: 1) If there is less than a MR after 3 cycles in the absence of disease progression, or 2) If there is disease progression within the first 3 cycles of Pomalidomide and Dexamethasone treatment.~Patients will be assessed every 28 days (+/-10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
62342263|NCT01929655|EXPERIMENTAL|Radium-223 dichloride|
62342264|NCT04922619|ACTIVE_COMPARATOR|Cochlear Implant (CI) with default fitting then tonotopy based fitting|Cochlear Implant with default fitting first during 6 weeks then with tonotopy based fitting during 6 weeks
62342265|NCT04922619|ACTIVE_COMPARATOR|Cochlear Implant (CI) with tonotopy based fitting then default fitting|Cochlear Implant with tonotopy based fitting during 6 weeks then with default fitting during 6 weeks
62499696|NCT04536506|ACTIVE_COMPARATOR|Control group|Vojta group received the following three times weekly for 12 weeks.
62499697|NCT03343639|EXPERIMENTAL|5 mg Serlopitant Tablets|Serlopitant Tablets
62499698|NCT03343639|PLACEBO_COMPARATOR|Matching Placebo Tablets|Placebo Tablets
62499699|NCT00571480|EXPERIMENTAL|1 true acupuncture|acupuncture needles are inserted into three preselected ear acupuncture points which are thought to be specific for low back pain
62499700|NCT00571480|SHAM_COMPARATOR|2|three acupuncture needles are inserted to three ear acupuncture points which are not specific for low back pain during pregnancy
62499701|NCT00571480|OTHER|3|standard of care
62499702|NCT01263561|ACTIVE_COMPARATOR|trabeculectomy|trabeculectomy filtering surgery
62499703|NCT01263561|EXPERIMENTAL|ExPRESS|ExPRESS miniature glaucoma drainage device
62699478|NCT04192708|EXPERIMENTAL|UG-ICNB group|intercostal nerve block under ultrasound guidance
61950747|NCT01090492|EXPERIMENTAL|Primary Raynaud 20 mg dose (period 1)|
61950748|NCT01090492|EXPERIMENTAL|Primary Raynaud 20 mg dose (period 2)|
61950749|NCT02343679|EXPERIMENTAL|Ceritinib for ALK + patients|all ALK + hematologic malignancies patients will receive ceritinib
61950750|NCT01126801|EXPERIMENTAL|Estradiol|
62140968|NCT01448941|EXPERIMENTAL|Temporary extraarticular plate fixation|Temporary extraarticular plate fixation of TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
62140969|NCT03592797|EXPERIMENTAL|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
62499704|NCT01256060|EXPERIMENTAL|Intanasal Oxytocin|A modified dose finding method will be used to determine safety among four dose levels for Intranasal Oxytocin. Half the dose (0.2 IU/kg /dose) is the minimum dose and two intermediate doses will also be evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations will be done in groups of three patients.Three patients will be studied at the first dose level. If none of these patients experience dose limiting toxicity, the dose will be escalated. If one experiences dose limiting toxicity, up to three more will be accrued at the same level. If none of these experience dose limiting toxicity, the dose will be escalated. If one or more of these experience dose-limiting toxicity, entry at that dose level will be stopped. Up to three more patients will be treated at the next lower dose. If zero out of these experience dose limiting toxicity, an additional three patients will be treated at that dose.
61950751|NCT01126801|PLACEBO_COMPARATOR|Placebo control|
61950752|NCT02041078|PLACEBO_COMPARATOR|Extrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA.
62499705|NCT02311517|EXPERIMENTAL|ropivacaine group|45 patients will be randomly allocated into ropivacaine group with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia.
62699479|NCT04192708|EXPERIMENTAL|PV group|thoracic paravertebral block under ultrasound guidance
61950753|NCT02041078|EXPERIMENTAL|Intrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA and intrahepatic division of the right hepatic vein.
61950754|NCT03057678|EXPERIMENTAL|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
61950755|NCT02128802|EXPERIMENTAL|Surgical Gastric Bypass|Patients will undergo surgical gastric bypass according to standard institutional protocols
61950756|NCT02128802|EXPERIMENTAL|Medical Weight Loss Management|Patients will receive best practices medical management for weight loss under current institutional protocols
61950757|NCT00991718|EXPERIMENTAL|A|On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.
61950758|NCT00991718|EXPERIMENTAL|B|On Day 1, subjects received a single oral dose of 14C-GDC-0449.
61950759|NCT00991718|EXPERIMENTAL|C|On Days 1-7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.
61950760|NCT00991718|EXPERIMENTAL|D|On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
61950761|NCT06013904|ACTIVE_COMPARATOR|Usual difficult PIV placement personnel|Patients randomized to this arm will follow the usual protocol for difficult IV placement (ultrasound-trained nurses) in the pediatric ED.
61950762|NCT06013904|EXPERIMENTAL|US-trained PEM Fellows|Patients randomized to this arm will have a trained PEM fellow place the difficult PIV in the pediatric ED.
61950763|NCT04164355||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months
61950764|NCT04164355||Control Group|Healthy controls without previous surgery of radical prostatectomy.
61950765|NCT04076397|OTHER|lipofilling group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~* Make EVA (evaluation of the pain),~* Complete DASH questionnaire~* Complete DN4 questionnaire~Patients in the lipofilling group will also have:~* the repair of the last dressing during the consultation at J15~* Ablation of any threads~* Control of the digital and abdominal scar~* Making a photo of their finger at V1 and M6"
61950766|NCT04076397|OTHER|desensitization group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~* Make EVA (evaluation of the pain),~* Complete DASH questionnaire~* Complete DN4 questionnaire"
62342266|NCT03488251|EXPERIMENTAL|Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX|In original protocol and amendment 2, participants will be administered intravenous (IV) MT-3724 10 micrograms per kilograms (mcg/kg) over 1 hour on Days 1, 3, 5, 8, 10 and 12 in Cycles 1 and 2 (each 28-day cycle) and on Days 1, 8, 15, and 22 in Cycles 3 and 4 (each 28-day cycle). Participants will also be administered Gemcitabine 1000 milligrams per meter square (mg/m\^2) as 30-minute IV infusion and Oxaliplatin 100 mg/m\^2 as 2-hour IV infusion on Days 2 and 16 in Cycles 1, 2, 3 and 4 (each 28-day cycle). Per amendment 2, participants will be administered MT-3724 10 mcg/kg on Days 1, 3, 5, 8, 10, 12, 15, 22, 29, and 36 in Cycle 1 (42-day cycle). In Cycles 2, 3 and 4, MT-3724 10 mcg/kg will be administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle. Gemcitabine and oxaliplatin will be administered on Days 16 and 30 of Cycle 1 and on Days 2 and 16 in Cycles 2, 3 and 4 (42-day cycle for Cycle 1 and 28-day cycle for Cycle 2, Cycle 3 and Cycle 4).
61950767|NCT05809882|EXPERIMENTAL|the study group|
61950768|NCT05809882|ACTIVE_COMPARATOR|the control group|
61950769|NCT03207477|EXPERIMENTAL|Prematurely born infants|Visual acuity measurement in prematurely born infants included in PREMAVISION study
61950770|NCT03207477|ACTIVE_COMPARATOR|Term born infants|Visual acuity measurement in term born control infants
62140970|NCT03592797|SHAM_COMPARATOR|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
62140971|NCT06207578|EXPERIMENTAL|Implant placement using crestal sinus approach|Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
62140972|NCT06207578|ACTIVE_COMPARATOR|Implant placement using osseodensification|Using Densah bur kit foe osteotomy preparation followed by implant placement
61950771|NCT01064596||blood sample|Patient with 4 blood samples to measure anti-Xa activity
61950772|NCT04972292|EXPERIMENTAL|Group 1: FDC of codeine 30 mg/dipyrone 500 mg from Eurofarma Laboratórios SA|Subjects randomized to this group will receive one (1) experimental drug tablet + one (1) Tylex® placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
62140973|NCT02738307|EXPERIMENTAL|altitude exposure|Altitude Exposure Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
61950773|NCT04972292|ACTIVE_COMPARATOR|Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg)|Subjects randomized to this group will receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
62699480|NCT05215145|ACTIVE_COMPARATOR|Baby Navigator Bundle|Parent and child measures, including a home observation video, will be collected at baseline, after which study staff will use Motivational Interviewing techniques to engage families to access resources and support (Baby Navigator Bundle) when parents first learn their child has social communication/language delay. Families may use the Baby Navigator Bundle as little or as much as desired. The Baby Navigator Bundle includes: Social Communication Growth Charts and the Baby Navigator webinar series.
62499706|NCT02311517|PLACEBO_COMPARATOR|saline group|40 patients are randomly allocated into saline group with 0.4 ml/kg saline after induction of anesthesia.
61950774|NCT02530359|ACTIVE_COMPARATOR|Group 1|Pirfenidone extended release 600mg per mouth every 12 hours for 7 days.
61950775|NCT02530359|ACTIVE_COMPARATOR|Group 2|Pirfenidone extended release 600mg per mouth in the morning and placebo by night (each treatment every 12 hrs) for 7 days.
62499707|NCT01889797|ACTIVE_COMPARATOR|Arm A: Rituximab|Rituximab 375 mg/m² IV weekly for 4 weeks.
62499708|NCT01889797|EXPERIMENTAL|Arm B: GA101|GA101 1,000 mg IV weekly for 4 weeks.
62499709|NCT02875028|EXPERIMENTAL|Vorapaxar|subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
62499710|NCT02875028|PLACEBO_COMPARATOR|Placebo|subjects will be treated with 4 empty lactose-starch capsules
61950776|NCT02530359|PLACEBO_COMPARATOR|Group 3|Placebo equivalent per mouth every 12 hrs for 7 days.
61950777|NCT06220773|EXPERIMENTAL|BR1019A + BR1019B + BR1019C-1|
61950778|NCT06220773|ACTIVE_COMPARATOR|BR1019A + BR1019B-1 + BR1019C-1|
61950779|NCT06220773|ACTIVE_COMPARATOR|BR1019A-1 + BR1019B + BR1019C-1|
61950780|NCT06220773|OTHER|BR1019A-1 + BR1019B + BR1019C|
61950781|NCT05763693|ACTIVE_COMPARATOR|Azithro-Azithro|A single oral dose of azithromycin (20 mg/kg) at baseline and a single oral dose of azithromycin (20 mg/kg) at the day 21 follow-up
61950782|NCT05763693|ACTIVE_COMPARATOR|Azithro-Placebo|A single oral dose of azithromycin (20 mg/kg) at baseline and a single oral dose of matching placebo at the day 21 follow-up
61950783|NCT05763693|ACTIVE_COMPARATOR|Placebo-Azithro|A single oral dose of placebo at baseline and a single oral dose of azithromycin (20 mg/kg) at the day 21 follow-up
61950784|NCT05763693|PLACEBO_COMPARATOR|Placebo-Placebo|A single oral dose of placebo at baseline and a single oral dose of matching placebo at the day 21 follow-up
61950785|NCT03334630|EXPERIMENTAL|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter
62342267|NCT03488251|EXPERIMENTAL|Part 1: Cohort 2: MT-3724 25 mcg/kg/ GEM/ OX|In original protocol and amendment 2, participants will be planned to administer IV MT-3724 25 mcg/kg over 1 hour on Days 1, 3, 5, 8, 10 and 12 in Cycles 1 and 2 (each 28-day cycle) and on Days 1, 8, 15, and 22 in Cycles 3 and 4 (each 28-day cycle). Participants will also be planned to administer Gemcitabine 1000 mg/m\^2 as 30-minute IV infusion and Oxaliplatin 100 mg/m\^2 as 2-hour IV infusion on Days 2 and 16 in Cycles 1, 2, 3 and 4 (each 28-day cycle). Per amendment 2, participants will be planned to administer MT-3724 25 mcg/kg on Days 1, 3, 5, 8, 10, 12, 15, 22, 29, and 36 in Cycle 1 (42-day cycle). In Cycles 2, 3 and 4, MT-3724 25 mcg/kg will be planned to administer weekly on Days 1, 8, 15, and 22 of each 28-day cycle. Gemcitabine and oxaliplatin will be planned to administer on Days 16 and 30 of Cycle 1 and on Days 2 and 16 in Cycles 2, 3 and 4 (42-day cycle for Cycle 1 and 28-day cycle for Cycle 2, Cycle 3 and Cycle 4).
62499711|NCT00963430|EXPERIMENTAL|Group 2: 30 mcg H1N1 vaccine|60 subjects to receive 30 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
62499712|NCT00963430|EXPERIMENTAL|Group 1: 15 mcg H1N1 vaccine|60 subjects to receive 15 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
62499713|NCT04502706|EXPERIMENTAL|GS-0189 (Monotherapy Dose Escalation, MDE)|Relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) participants will receive GS-0189 doses of 10, 30, or 100 mg every 2 weeks.
62736789|NCT02472587||Pap test|Women attending our institute in order to do Pap test
61950786|NCT03334630|ACTIVE_COMPARATOR|TactiCath Quartz Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter
61950787|NCT06193317|EXPERIMENTAL|Active taVNS|TaVNS will be administered by an earset, with conductive eartips placed on the auricular concha of the ears, connected to a stimulator, and during active stimulation, we stimulate both the cymba conchae and external auditory canal of both left and right ears with the following parameters: 30Hertz (Hz), 200-250 us, and with adjustable intensity for 60 min for 16 sessions.
61950788|NCT06193317|SHAM_COMPARATOR|Sham taVNS|Sham condition will have the same device, with an earset, and conductive eartips placed in the same location of the active stimulation; however during 60 min for 16 sessions there will be no current and the device will be turned off.
61950789|NCT01848860|SHAM_COMPARATOR|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
61950790|NCT01848860|EXPERIMENTAL|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
61950791|NCT04862117|ACTIVE_COMPARATOR|Active stimulation QD|
61950792|NCT04862117|ACTIVE_COMPARATOR|Active stimulation QID|
61950793|NCT01344785||Patients with a intertrochanteric fracture|Patients with a intertrochanteric fracture, n=100
61950794|NCT00252915|EXPERIMENTAL|Verum|GM-CSF therapy
61950795|NCT06157359|NO_INTERVENTION|control group|Patients in the control group will receive general anesthesia without the nerve blocks.
61950796|NCT06157359|EXPERIMENTAL|SNB group|Participants randomized to the SNB group will receive general anesthesia combined with SNB using 0.75% ropivacaine, which will be performed by the same attending anesthesiologist.
62499714|NCT04502706|EXPERIMENTAL|GS-0189 + Rituximab (Combination Dose Escalation, CDE)|R/R NHL participants will receive GS-0189 doses of 100, 300, 1000, 2000, and 3000 mg in combination with rituximab at 375 mg/m\^2.
62499715|NCT04502706|EXPERIMENTAL|GS-0189 + Rituximab (Pharmacokinetic (PK) Evaluation)|R/R NHL participants will receive GS-0189 dose of up to 30 mg followed by the highest designated safe dose from the Combination Dose Escalation cohort (CDE) in combination with rituximab at 375 mg/m\^2.
62499716|NCT04502706|EXPERIMENTAL|GS-0189 + Rituximab (Alternate Schedule Evaluation, ASE)|R/R NHL participants will receive GS-0189 every 4 weeks in combination with rituximab 375 mg/m\^2. The GS-0189 dose will be determined based on the totality of safety, PK, and pharmacodynamic (PD) data from the preceding cohorts.
62499717|NCT04502706|EXPERIMENTAL|GS-0189 + Rituximab (DLBCL Expansion)|Diffuse large B-cell lymphoma (DLBCL) participants will receive GS-0189 in combination with rituximab 375 mg/m\^2. The GS-0189 dose will be determined based on the totality of safety, PK, and PD data from the preceding cohorts.
62499718|NCT02411149|PLACEBO_COMPARATOR|Local Inflitration Only|"This group will receive LIA and saline solution (placebo) in the adductor canal block with NO morphine in the spinal anesthesia:~* 30 ml normal saline~* 3ml 0.5% preservative-free bupivacaine"
62499719|NCT02411149|ACTIVE_COMPARATOR|Adductor Canal Block|"This group will receive LIA and the standard local anesthetic in the ACB with NO morphine in the spinal anesthetic:~* ropivacaine 0.5% with 1:400,000 epinephrine~* 3ml 0.5% preservative-free bupivacaine"
62499720|NCT02411149|ACTIVE_COMPARATOR|Adductor Canal Block with Morphine|"This group will receive LIA with local anesthetic in the ACB and morphine in the spinal anesthetic:~* ropivacaine 0.5% with 1:400,000 epinephrine~* 3ml 0.5% preservative-free bupivacaine with 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)"
62499721|NCT02953925||primary health care users|Subjects with high risk of cardiovascular diseases who lived in the catchment areas of the participating PHC institutions.
62499722|NCT03941795|EXPERIMENTAL|JS001(Toripalimab Injection) Combined With Axitinib|
62499723|NCT03941795|EXPERIMENTAL|JS001 alone|
62499724|NCT03941795|ACTIVE_COMPARATOR|Axitinib alone|
62499725|NCT04552522|EXPERIMENTAL|Shrimp allergy with Intend to eat shrimp|Case shrimp Immunoglobulin E mediated allergy and intend to eat shrimp and start oral immunotherapy for shrimp
62499726|NCT04552522|NO_INTERVENTION|Shrimp allergy with avoid shrimp|Case shrimp allergy with avoid shrimp
62499727|NCT05486338|OTHER|Gastric mucosal ablation|Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid Argon Plasma Coagulation (HAPC)
62499728|NCT05488119|EXPERIMENTAL|Pilot Intervention|The design for this phase is a prospective pilot study. The intervention modules (co-developed with the stakeholder advisory board in Phase 1 of this aim) will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment.
62499729|NCT04967651||Patients with pulmonary complications following cardiac surgery|
62499730|NCT04967651||Patients without pulmonary complications following cardiac surgery|
62342268|NCT03488251|EXPERIMENTAL|Part 1: Cohort 3: MT-3724 50 mcg/kg/ GEM/ OX|In original protocol and amendment 2, participants will be planned to administer IV MT-3724 50 mcg/kg over 1 hour on Days 1, 3, 5, 8, 10 and 12 in Cycles 1 and 2 (each 28-day cycle) and on Days 1, 8, 15, and 22 in Cycles 3 and 4 (each 28-day cycle). Participants will also be planned to administer Gemcitabine 1000 mg/m\^2 as 30-minute IV infusion and Oxaliplatin 100 mg/m\^2 as 2-hour IV infusion on Days 2 and 16 in Cycles 1, 2, 3 and 4 (each 28-day cycle). Per amendment 2, participants will be planned to administer MT-3724 50 mcg/kg on Days 1, 3, 5, 8, 10, 12, 15, 22, 29, and 36 in Cycle 1 (42-day cycle). In Cycles 2, 3 and 4, MT-3724 50 mcg/kg will be planned to administer weekly on Days 1, 8, 15, and 22 of each 28-day cycle. Gemcitabine and oxaliplatin will be planned to administer on Days 16 and 30 of Cycle 1 and on Days 2 and 16 in Cycles 2, 3 and 4 (42-day cycle for Cycle 1 and 28-day cycle for Cycle 2, Cycle 3 and Cycle 4).
62499731|NCT01489605|EXPERIMENTAL|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
62499732|NCT01489605|ACTIVE_COMPARATOR|Control: Standard GlideScope|Control: Patients will be intubated using standard practice, a standard GlideScope (Verathon)
62342269|NCT03488251|EXPERIMENTAL|Part 2: MT-3724/ GEM/ OX|Participants will be planned to administer Maximum tolerated dose (MTD) of MT-3724 in combination with Gemcitabine and Oxaliplatin (GEMOX).
62342270|NCT05986032||no bronchopulmonary dysplasia|Group of patients who do not receive the diagnosis of bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-mentrual age
62499733|NCT02079363||Patients with pancreatic adenocarcinoma|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
62342271|NCT05986032||bronchopulmonary dysplasia|Group of patients developing bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-menstrual age.
62499734|NCT02079363||Patients with chronic pancreatitis|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
62499735|NCT02079363||Patients with acute pancreatitis|"Exclusion criteria:~No prior cancer."
62499736|NCT02079363||Patients screened for but not having upper GI cancer|"Exclusion criteria:~No prior cancer."
62499737|NCT01515150||Out-patients in diverticulitis|All patient with acute uncomplicated diverticulitis how accept participation in the study will be enrolled in the study.
62499738|NCT01990105||Patients with AF in the ER|All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
62499739|NCT02971787|EXPERIMENTAL|Probiotics and salt|Lactobacillus enrichment and salt increase
62499740|NCT00007787|EXPERIMENTAL|Antibody plus delayed cyclosporine therapy|Anti-human thymocyte globulin (rabbit) (Thymoglobulin®) is admistred at the time of transplant followed delayed clyclosporine A therapy post tranplant.
62499741|NCT00007787|ACTIVE_COMPARATOR|Standard cyclosporine A therapy|Cyclosporine A therapy (either Cyclosporine or Tacrolimus) will be initiated pre-transplantations
62499742|NCT06678139|EXPERIMENTAL|Study Group|Exercise group
62499743|NCT03045822|EXPERIMENTAL|Patients with cardiac implantable electronic devices|
62499744|NCT05126212||Patients|Patients admitted to the Hospi'Senior room
62499745|NCT05126212||Informal caregivers|Informal caregivers of patients admitted to the Hospi'Senior room
62499746|NCT05126212||Caregivers|Caregivers who have worked in the Hospi'Senior room
62140974|NCT05605613|EXPERIMENTAL|PD-1 Antibody in Addition to Bronchial Arterial Chemoembolization|Treated with BACE and PD-1 antibody as induction therapy during which BACE was performed on the first day and PD-1 antibody was given 3-5 days later, then PD-1 antibody was administered at 200mg Q3W as maintenance therapy.
62140975|NCT05605613|ACTIVE_COMPARATOR|Bronchial Arterial Chemoembolization|Bronchial artery chemoembolization (BACE) is a technique of drug delivery and embolization performed via injecting anti-tumor drugs with drug carriers and implanting the embolization agents into the tumor feeding artery
62140976|NCT04480385|EXPERIMENTAL|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last 7 days through post-operative monitoring room (continuous comparison with reference monitor), general ward (comparison with spot-check monitoring) and patient's home
62499747|NCT05610007|EXPERIMENTAL|Prilocaine|50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume)
62499748|NCT05610007|ACTIVE_COMPARATOR|bupivacaine|12.5, 5 mg hyperbaric 0.5% bupivacaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume)
62499749|NCT03722108|EXPERIMENTAL|Regorafenib and Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.
62499750|NCT03722108|ACTIVE_COMPARATOR|Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle administered until progression of disease or unacceptable toxicity
61950797|NCT02564237|EXPERIMENTAL|Group 1: StreptAnova™|Three (3) 0.6 mL doses (600 µg protein) of StreptAnova™ (Group A streptococcal (GAS) vaccine) will be will be administered on days 0, 30 and 180.
61950798|NCT02564237|ACTIVE_COMPARATOR|Group 2: Comparator|Three (3) 0.5 mL doses of comparator (Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine) will be administered on days 0, 30 and 180.
62140977|NCT00779194|EXPERIMENTAL|SLE subjects|SLE subjects receiving the study drug, Rapamune.
62140978|NCT06513507|EXPERIMENTAL|CBG Treatment|Participants will receive 0.5 milliliters of purified cannabigerol (CBG) in sesame oil once daily in the evening for a duration of eight weeks.
62140979|NCT02280031|ACTIVE_COMPARATOR|Experimental|Acetylsalicylic Acid 80mg administered daily at bedtime
62140980|NCT02280031|PLACEBO_COMPARATOR|Control|Identical placebo administered daily at bedtime
62342272|NCT01972009||Subjects without pulmonary hypertension|Patients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
62342273|NCT01972009||Subjects with pulmonary hypertension|Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
62164513|NCT02250911|ACTIVE_COMPARATOR|Waitlist Control|"Participants randomized to the waitlist control arm will be offered what is considered usual care at the ACS: the provision of the ACS Telephone Hotline number (1-800- 227-2345) and direction to the ACS website (www.cancer.org) where participants can find many resources for caregivers, including links to the ACS Caregiver ToolKit. They will complete assessments at time points that correspond with the completion of assessments in the CCC Workshop arm: after consent as soon as they are able (T1), about 2 months (± 4 weeks) after T1 (T2), and about 2-3 months after T2 (T3). Upon completion of all study assessments the waitlist control arm participants will be offered the opportunity to complete the CCC Workshop."
62342274|NCT01129180|EXPERIMENTAL|Arm I|Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
62342275|NCT02730442|EXPERIMENTAL|Single dose F901318 with fluconazole|AUC0-t for F901318 will be assessed before and after 5 days of treatment with fluconazole oral
62342276|NCT00992784|EXPERIMENTAL|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
62342277|NCT00992784|ACTIVE_COMPARATOR|Fluarix elderly Group|Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
62342278|NCT00992784|ACTIVE_COMPARATOR|Fluarix young Group|Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine
62499751|NCT02760355|EXPERIMENTAL|Active treatment|Ledipasvir 90 mg/Sofosbuvir 400 mg, one tablet once a day + b.w. dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks
61950799|NCT02694965||Stage IV/Unresectable Stage III Melanoma|Observational - Eligible patients with stage IV/unresectable stage III melanoma selected to undergo treatment with an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or a combination of an anti-CTLA-4 antibody/anti-PD-1 antibody will be asked to participate in the study by the Principal Investigator, co-Investigators, or clinical staff.
62342279|NCT01519284|PLACEBO_COMPARATOR|Group 1|Placebo at all the dosing times
62342280|NCT01519284|EXPERIMENTAL|Group 2|"Day 1 to 7:~BIA 9-1067 5 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 5 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
62342281|NCT01519284|EXPERIMENTAL|Group 3|"Day 1 to 7:~BIA 9-1067 15 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 15 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
62342282|NCT01519284|EXPERIMENTAL|Group 4|"Day 1 to 7:~BIA 9-1067 30 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 30 mg: 7 AM dose Placebo + levodopa/carbidopa 100/25 mg: 8 AM dose"
62499752|NCT03712202|EXPERIMENTAL|Group I Arm A (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62342283|NCT01519284|EXPERIMENTAL|Group 5|"Day 1 to 7:~Placebo: 7 AM dose; Entacapone 200 mg: 8 AM; 4 PM; 12 PM dose~Day 8:~Placebo: 7 AM dose Entacapone 200 mg + levodopa/carbidopa 100/25 mg: 8 AM dose"
62499753|NCT03712202|EXPERIMENTAL|Group I Arm B (ABVD, nivolumab)|Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62499754|NCT03712202|EXPERIMENTAL|Group II (AVD, brentuximab vedotin, nivolumab)|Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62499755|NCT05426954|ACTIVE_COMPARATOR|BFR deflate|BFR cuff will be deflated at the end of each of the 4 BFR exercises, BFR cuff is inflated prior to start next BFR exercise.
62499756|NCT05426954|ACTIVE_COMPARATOR|BFR do not deflate|BFR cuff will not be deflated at the end of each of the 4 BFR exercises. Cuff remains inflated start exercise 1 thru completion exercise 4.
62499757|NCT01157598|ACTIVE_COMPARATOR|BIS group|
62499758|NCT01157598|PLACEBO_COMPARATOR|non BIS group|
62499759|NCT04971863||Clareon Monofocal IOL|Patients bilaterally implanted with the Clareon monofocal IOL
62499760|NCT04971863||Asqelio Monofocal IOL|Patients bilaterally implanted with the Asqelio monofocal IOL
62140981|NCT04478487|EXPERIMENTAL|Study Participants|all preterm infants ≤ 32 weeks and 0 days gestational age (GA) with a birth weight 700 g to 1500 g at the hospital, who are enterally fed human milk in the neonatal intensive care unit (NICU) for at least 7 days. Various blending ratios of the fortifier with either the mother's expressed milk or donor milk will be used to deliver macro and micronutrients based on established guidelines to be adjusted according to the infant's tolerance for volume and calories. The estimated time for each subject's participation is approximately from 1 week through 8 weeks, depending on the weight and age at enrollment. Historic control cases treated by another human milk based human milk fortifier will be obtained from medical records, matched on birth weight and gender, with sample size twice (n=80) that of the study population.
62342284|NCT00723411|ACTIVE_COMPARATOR|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
62342285|NCT00723411|ACTIVE_COMPARATOR|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
62342286|NCT00723411|PLACEBO_COMPARATOR|C|This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.
62342287|NCT01970930||PV or ET|subject who has polycythemia vera or essential thrombocythemia
62342288|NCT06402812||Regulators|Regulators
62342289|NCT06402812||Proefssionals|Professionals
62342290|NCT05109819|NO_INTERVENTION|Arm A: standard radiotherapy treatment|Patients in arm A will receive standard radiotherapy treatment for metastatic spinal cord compression.
62342291|NCT05109819|EXPERIMENTAL|Arm B: esophagus sparring radiotherapy treatment|Patients in arm B will receive esophagus sparring radiotherapy treatment.
62342292|NCT01889654||patient|
62499761|NCT05730452|NO_INTERVENTION|Phase 1: Observational, children 0-59 months of age|Phase 1: Observational only
62499762|NCT05730452|EXPERIMENTAL|Phase 2: Interventional, children 0-59 months of age|Phase 2: Intervention
61950800|NCT02694965||Stage III/IV Adjuvant Melanoma|Observational - 1) Patients either undergoing resection of stage III or stage IV melanoma or have previously undergone resection and who are considered candidates for adjuvant anti-PD-1 antibody immunotherapy. 2) Patients who previously underwent resection of stage III or stage IV melanoma and received prior adjuvant anti-PD-1 antibody immunotherapy and have subsequently developed recurrent melanoma.
61950801|NCT01142752||Control|Control group of women with uneventful pregnancy
62140982|NCT04636138|EXPERIMENTAL|Single arm|
62140983|NCT06161987|ACTIVE_COMPARATOR|Rehabilitation Intervention Group|Comprehensive rehabilitation plan containing 18 sessions of a structured exercise and inspiratory muscle training program over 6 weeks (3 times per week).
62342293|NCT01889654||healthy volunteers|
62342294|NCT05553678|EXPERIMENTAL|treatment group|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
62342295|NCT05553678|PLACEBO_COMPARATOR|Control group|Normal saline (0.03 ml/kg/30 min) will administered during UIA clipping through microscope.
62342296|NCT02381496|EXPERIMENTAL|Part A: Cohort A1: ACT-453859 1 mg|"ACT-453859 1 mg or placebo, single dose, administered orally in the fasted state~* Six male subjects will receive ACT-453859~* Two male subjects will receive matching placebo"
62342297|NCT02381496|EXPERIMENTAL|Part A: Cohort A2: ACT-453859 3 mg|"ACT-453859 3 mg or placebo, single dose, administered orally in the fasted state~* Six male subjects will receive ACT-453859~* Two male subjects will receive matching placebo"
62499763|NCT05934539|EXPERIMENTAL|ALG.APV-527|"Part 1 Dose Escalation using ALG.APV-527 doses with a starting dose of 0.1 mg/kg and projected 6 dose cohorts will be explored to determine the MTD and/or the RP2D. Part 1 consists of a 3 + 3 dose-escalation examination of ALG.APV-527 single agent therapy in adult patients with RECIST Version1.1-measurable advanced solid tumors.~Part 2 Dose Expansion with ALG.APV-527 based on RP2D determined during Dose Escalation."
62342298|NCT02381496|EXPERIMENTAL|Part A: Cohort A3: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, single dose, administered orally in the fasted state~* Six male subjects will receive ACT-453859~* Two male subjects will receive matching placebo"
62342299|NCT02381496|EXPERIMENTAL|Part A: Cohort A4: ACT-453859 30 mg|"ACT-453859 30 mg or placebo, single dose, administered orally in the fasted state~* Six male subjects will receive ACT-453859~* Two male subjects will receive matching placebo"
62342300|NCT02381496|EXPERIMENTAL|Part A: Cohort A5: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, single dose, administered orally in the fasted state~* Six male subjects will receive ACT-453859~* Two male subjects will receive matching placebo~After a washout period of 10-20 days subjects will return for a second study period to receive the same treatment received in the first session but under fed conditions"
62342301|NCT02381496|EXPERIMENTAL|Part A: Cohort A6: ACT-453859 300 mg|"ACT-453859 300 mg or placebo, single dose, administered orally in the fasted state~* Six male subjects will receive ACT-453859~* Two male subjects will receive matching placebo"
62342302|NCT02381496|EXPERIMENTAL|Part A: Cohort A7: ACT-453859 800 mg|"ACT-453859 800 mg or placebo, single dose, administered orally in the fasted state~* Six male subjects will receive ACT-453859~* Two male subjects will receive matching placebo"
62499764|NCT04795869|EXPERIMENTAL|Treatment (brentuximab vedotin, pembrolizumab)|Patients receive brentuximab vedotin IV over 30 minutes on day 1, and pembrolizumab IV over 30 minutes on day 3 of cycle 1, day 1 of subsequent cycles. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles of treatment, patients may discontinue treatment if they experience disease progression, are eligible for stem cell transplant, or if they elect to not undergo SCT.
62699481|NCT05215145|ACTIVE_COMPARATOR|Baby Navigator Bundle + Individual-ESI|At 18-21months of age, slow responders (communication delay still below the 10th percentile) will be randomized to continue the Baby Navigator Bundle with or without Individual-ESI, and responders (communication above the 10th percentile) will continue with Baby Navigator Bundle. For Individual ESI, trained coaches or family navigators will coach families using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. Family navigators will also engage the family in the How-to Guide for Families online course. The family navigator will use zoom or other telehealth platform to meet with parents 1 time per week for 30-60 minutes per session for 6 months.
62699482|NCT05750407|EXPERIMENTAL|Evidence based home visiting with lifestyle modules|Three lifestyle change modules will be discussed with clients: healthy eating, activity, and tracking diet and weight
61950802|NCT01142752||Population at risk with preterm birth|Women medically considered at risk for PTB and actually delivering preterm
61950803|NCT01142752||Population at risk without preterm birth|Women medically considered at risk for PTB but with uneventful pregnancy
61950804|NCT05213481|EXPERIMENTAL|Tepotinib then Carbamazepine|Participants received a single oral dose of Tepotinib 500 milligrams (mg) on Day 1 and Day 26 in the morning under fed state followed by Carbamazepine 100, 200 or 300mg oral dose under fed state twice daily at the same time each day in the morning and evening from Days 8 to Day 32
61950805|NCT02552875|ACTIVE_COMPARATOR|Tetanic Stimulation|50 Hz tetanic stimulation for 5 seconds before TOF-twitch stabilization at the one arm
61950806|NCT02552875|ACTIVE_COMPARATOR|Staircase Stimulation|TOF-twitch stabilisation without 50 Hz tetanic stimulation at the contralateral arm
61950807|NCT01944696|ACTIVE_COMPARATOR|continuous (uninterrupted) phototherapy|standard phototherapy
61950808|NCT01944696|EXPERIMENTAL|15 minute per hour cycled phototherapy|15 minute per hour cycled phototherapy
62342303|NCT02381496|EXPERIMENTAL|Part B: Cohort B1: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, once a day for 7 days, administered orally in the fasted state~* Three male subjects will receive ACT-453859~* Three female subjects will receive ACT-453859~* One male subject will receive matching placebo~* One female subject will receive matching placebo"
61950809|NCT01577108|EXPERIMENTAL|Probiotics, GBS Test|Treated with 2 oral probiotics once daily before sleeping for 14 days
61950810|NCT01577108|PLACEBO_COMPARATOR|Non-probiotics, GBS test|Treated with 2 placebo capsules once daily before sleeping for 14 days
62342304|NCT02381496|EXPERIMENTAL|Part B: Cohort B2: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, once a day for 7 days, administered orally in the fasted state~* Three male subjects will receive ACT-453859~* Three female subjects will receive ACT-453859~* One male subject will receive matching placebo~* One female subject will receive matching placebo"
62342305|NCT02381496|EXPERIMENTAL|Part B: Cohort B3: ACT-453859 800 mg|"ACT-453859 800 mg, once a day for 7 days, administered orally in the fasted state~* Three male subjects will receive ACT-453859~* Three female subjects will receive ACT-453859~* One male subject will receive matching placebo~* One female subject will receive matching placebo"
62342306|NCT02381496|EXPERIMENTAL|Part C: Treatment Periods I & II: Setipiprant|"Setipiprant 500 mg, twice daily for 7 days, administered orally in Treatment Period I (TPI) and setipiprant 1000 mg, twice daily for 7 days, administered orally in Treatment Period II (TPII)~* Four male subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~* Four female subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~There will be a washout period of 10 days between TPI and TPII"
62342307|NCT03263936|OTHER|Other|decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
62342308|NCT03986775|ACTIVE_COMPARATOR|citrus drink with isomaltulose|
62342309|NCT03986775|PLACEBO_COMPARATOR|citrus drink with sucrose|
61950811|NCT01796509|EXPERIMENTAL|multidisciplinary follow-up|
61950812|NCT01796509|NO_INTERVENTION|no follow-up|
61950813|NCT03556774|EXPERIMENTAL|With smoking cessation training|Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
62140984|NCT06161987|NO_INTERVENTION|Attention Control|Conventional care with bi-weekly contact from study personnel.
62140985|NCT06381700|EXPERIMENTAL|Intervention Group|Participants in this group will get the School Dental Service and MySmile App.
62342310|NCT03337152|OTHER|1A: primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
62699483|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 50 mg twice-weekly|Eligible subjects will receive GSK2816126 with a starting dose of 50 milligrams (mg) twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
62140986|NCT06381700|ACTIVE_COMPARATOR|Control Group|Participants in this group will get the School Dental Service only
62140987|NCT03855293|OTHER|Study group|rhexis protection shield
62140988|NCT03855293|NO_INTERVENTION|Control group|regular surgery
62140989|NCT00012259|EXPERIMENTAL|troxacitabine|
61950814|NCT03556774|NO_INTERVENTION|Without smoking cessation training|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
62699484|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 100 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
62699485|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
61950815|NCT00002734|EXPERIMENTAL|Arm I|Patients receive interferon alfa subcutaneously on days 1, 3, 5, and 7; paclitaxel intraperitoneally (IP) on day 4 or topotecan IP on day 6; and 177Lu-CC49 IP on day 6. Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity. Once the MTD of paclitaxel is determined, the dose of 177Lu-CC49 is escalated. Once the MTD of 177Lu-CC49 is determined, 90Y-CC49 is substituted. The MTD of 90Y-CC49 is then determined when administered with paclitaxel. Topotecan is then substituted for paclitaxel (administered with the MTD of 177Lu-CC49 and interferon alfa only) and escalated until the MTD is determined.
61950816|NCT04158492|ACTIVE_COMPARATOR|Standard diagnostic tests|Patients who will undergo only the standard diagnostic procedures
61950817|NCT04158492|EXPERIMENTAL|Experimental + standard diagnostic tests|Patients will undergo described standard diagnostic procedures and in addition, real-time multiplex Protein Chain Reaction (PCR, FilmArray Pneumonia panel Plus ™, Biofire, BioMérieux).
61950818|NCT00106197|EXPERIMENTAL|1|Participants will receive bupropion in the sleep study
61950819|NCT06256965||patients with present reduced left ventricular ejection fraction|patients with preoperatively shows in echocardiographic parameters LVEF lower 40%.
62140990|NCT01162772||Female Diabetics|female, 25-75 years old, no pregnancy, with/out Hormone replacement therapy T2DM, HbA1c \> 7% with metformin mono-therapy
62699486|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
62140991|NCT01162772||Male diabetics|25-75 years, T2DM, HbA1c \> 7% with metformin mono-therapy
62140992|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
62140993|NCT06239532|EXPERIMENTAL|TAE+HAIC+Tislelizumab+Surufatinib|Patients will receive hepatic arterial infusion chemotherapy (HAIC) sequential transcatheter arterial embolization(TAE) combined with Tislelizumab and Surufatinib
62140994|NCT01532999|EXPERIMENTAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
62140995|NCT01532999|SHAM_COMPARATOR|Present Centered Group Therapy|Present Centered Group Therapy (PCGT) serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
62140996|NCT01719874|EXPERIMENTAL|TCN-032|single-dose, administered intravenously
62140997|NCT01719874|PLACEBO_COMPARATOR|Placebo (saline)|single-dose, administered intravenously
62140998|NCT05184062|EXPERIMENTAL|AZD7442|co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion.
62140999|NCT05184062|PLACEBO_COMPARATOR|Placebo|co-administration of a single dose of 600mg placebo by intravenous (IV) infusion.
62141000|NCT06226155|EXPERIMENTAL|TENDAI4PrEP|TENDAI4PrEP problem-solving intervention will likely entail 4-5 sessions, inclusive of the dyadic session with a partner, with an optional postpartum booster session. The intervention will involve PrEP education and psychoeducation, Nzira Itsva (a culturally adapted Life Steps intervention), and problem-solving therapy.
62141001|NCT06226155|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (ETAU)|Participants randomized to ETAU will receive care as usual, which is monthly visits to the ANC, plus a pamphlet of information that describes PrEP efficacy, safety during pregnancy/postpartum, and PrEP availability at the ANC. Antenatal treatment as usual will also be enhanced at the clinic level through the provider-level training, which will be offered to all clinic staff in a nonrandomized design. ETAU participants will also be referred for psychological services at the hospital.
62699487|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
62699488|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 1200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
62699489|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 1800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
62141002|NCT02358005|EXPERIMENTAL|60mJ ESWT|ESWT (0.04 mJ/mm2, 1500 shock + sham stimulation 2500) / total dose per treatment : 60mJ
62141003|NCT02358005|EXPERIMENTAL|120mJ ESWT|ESWT (0.04 mJ/mm2, 4000 shock) / total dose per treatment : 160mJ
62141004|NCT02358005|PLACEBO_COMPARATOR|sham ESWT stimulation|ESWT (0 mJ/mm2, sham stimulation 4000) / total dose per treatment : 0mJ
62699490|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 2400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
62699491|NCT02082977|EXPERIMENTAL|Part 1:GSK2816126 3000 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
61950820|NCT06256965||patients with present preserved left ventricular ejection fraction|patients with preoperatively shows in echocardiographic parameters LVEF higher 40%.
61950821|NCT00610766||1|
61950822|NCT04821648|EXPERIMENTAL|Dosage group A|"Dosage group A will consist of 6 subjects, 1:1:1 (A1:A2:A3 below):~A1: 0.04 mg/injection; A2: 0.075 mg/injection; A3: 0.15 mg/injection Two subjects will be dosed in the area scheduled for resection with 5 injections of the lowest of the 3 RJV001 test article strengths (i.e., 0.04 mg/injection); the two subjects will also be dosed with a single injection of vehicle in the area scheduled for resection for a total of 6 injections. At the conclusion of a given test article dose group, if tolerated, enrollment will continue to the next higher dose after approval to advance based upon an interim safety review. This same process will be repeated for the 0.075 mg/injection dose with 2 additional subjects. Assuming the interim safety review for the mid dose (i.e., 0.075 mg/injection) is deemed acceptable, the 2 final subjects will be treated with the high dose (0.15 mg/injection)."
61950823|NCT04821648|EXPERIMENTAL|Dosage group B|"Dosage group B will consist of 3 subjects (if only 1 dose from Dosage group A is well tolerated) or 6 subjects (if 2 doses from Dosage group A are well tolerated), randomized 1:1 (B1:B2 below).~B1: RJV001 Solution for Injection, Dose 1 B2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Dosage group A, referred to as Dose 1 and Dose 2). Up to 13 injections (12 active and 1 vehicle) will be administered in an open label manner in the area scheduled for resection. If tolerated, enrollment will continue to Dosage group C after approval to advance based upon an interim safety review."
61950824|NCT04821648|EXPERIMENTAL|Dosage group C|"Dosage group C will consist of 3 subjects (if only 1 dose from dosage group B is well tolerated) or 6 subjects (if 2 doses from Dosage group B are well tolerated), randomized 1:1 (C1:C2 below).~* C1: RJV001 Solution for Injection, Dose 1~* C2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Cohort B, referred to as Dose 1 and Dose 2). Up to 31 injections (30 active and 1 vehicle) will be administered in an open-label manner in the area scheduled for resection."
61950825|NCT01355757|EXPERIMENTAL|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
62499765|NCT02725060|EXPERIMENTAL|Autonomic and Antibody Assessments|"On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case:~* Posture study with blood samples for autoantibody testing~* 24-hour heart rhythm and blood pressure monitoring~* autonomic function tests~* Quantitative Axonal Sudomotor Reflex Testing~* Total blood volume assessment~* Pharmacologic testing with phenylephrine~* Pharmacologic testing with isoproterenol~* Cardiac output with rebreathing~* Assessment of splanchnic capacitance~* Microneurography"
62499766|NCT05753982|EXPERIMENTAL|kinesiotape|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
62499767|NCT05753982|PLACEBO_COMPARATOR|control|No kinesiotape, standard of care
61950826|NCT01355757|ACTIVE_COMPARATOR|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
61950827|NCT01040975|EXPERIMENTAL|Motivational Interviewing intervention|Web-based intervention targeting MD communication and Summary Report
61950828|NCT01040975|NO_INTERVENTION|Control|MD receives Summary Report only
61950829|NCT01610661|OTHER|Unrefined-carbohydrate|unrefined carbohydrate diet
62499768|NCT02684331||T2DM|
62499769|NCT02725411|ACTIVE_COMPARATOR|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
62342311|NCT03337152|OTHER|1B: chloroquine + primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
62499770|NCT02725411|EXPERIMENTAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
61950830|NCT01610661|OTHER|Refined-carbohydrate|refined carbohydrate diet
61950831|NCT01610661|OTHER|Simple-carbohydrate|simple carbohydrate diet
62342312|NCT01721031|EXPERIMENTAL|DPNB|Patients receive DPNB 30min before extubation at the end of operation.
62342313|NCT01721031|ACTIVE_COMPARATOR|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
61950832|NCT02776865|EXPERIMENTAL|physical therapy and suprascapular nerve block|patient received ultrasound-guided suprascapular nerve block as well as physical therapy.
62342314|NCT01758965|EXPERIMENTAL|combination therapy of H2RA and surgicel|H2RA and surgicel
62342315|NCT01758965|EXPERIMENTAL|Monotherapy of PPI|PPI
62499771|NCT02725411|EXPERIMENTAL|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
62499772|NCT04038606|ACTIVE_COMPARATOR|acceptance of mastectomy|Assess the determinants of acceptance of mastectomy based on personal background,Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
62499773|NCT04038606|EXPERIMENTAL|rejection of mastectomy|Assess the determinants of rejection of mastectomy based on personal background, Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
62499774|NCT01966809|EXPERIMENTAL|Photofrin photodynamic therapy.|Photofrin photodynamic therapy. Drug - 2.5 mg/kg, light - 240 mJ/cm2.
62499775|NCT05513469|OTHER|Peptide receptor radionuclide therapy|PRRT 4x7.4GBq
62499776|NCT00769587|EXPERIMENTAL|Thalidomide|Use of thalidomide
62499777|NCT04480307|EXPERIMENTAL|temelimab 18 mg/kg|Monthly IV repeated dose
62499778|NCT04480307|EXPERIMENTAL|temelimab 36 mg/kg|Monthly IV repeated dose
62499779|NCT04480307|EXPERIMENTAL|temelimab 54 mg/kg|Monthly IV repeated dose
62499780|NCT04480307|PLACEBO_COMPARATOR|Placebo|Monthly IV repeated dose
62499781|NCT05314062|ACTIVE_COMPARATOR|Ferrous sulfate (FeSO4)|FeSO4 supplements containing 54 mg elemental iron
61950833|NCT02776865|ACTIVE_COMPARATOR|physical therapy only|patient received physical therapy only.
62141005|NCT00885313|EXPERIMENTAL|DHA250|DHA 250 mg/kg/d plus lifestyle intervention \[hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
62342316|NCT04625894|EXPERIMENTAL|Treatment Arm|Patients with oligometastatic gastrointestinal cancer will receive multisite SABR, followed by Camrelizumab within one week from completion of radiation. Camrelizumab for injection at 200 mg, d1, q2w, 14-day cycle will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
62342317|NCT03001843|ACTIVE_COMPARATOR|Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
62499782|NCT05314062|EXPERIMENTAL|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|Ao iron supplements containing 54 mg elemental iron
62499783|NCT06080698|ACTIVE_COMPARATOR|Intravenous Antibiotics|IV antibiotics from the time of randomization to the completion of antibiotic treatment. Includes antibiotics such as ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem.
62499784|NCT06080698|ACTIVE_COMPARATOR|Oral Antibiotics|Oral antibiotics from the time of randomization to the completion of antibiotic treatment, Includes antibiotics such as amoxicillin, cephalexin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
62699492|NCT02082977|EXPERIMENTAL|Part 2: All subjects|Subjects with Germinal Center B-cell-like Diffuse Large B-cell Lymphoma (GCB-DLBCL)-mutant and wild type, Transformed Follicular Lymphoma (TFL)-mutant and wild type as well as with multiple myeloma (MM) will be enrolled in Part 2 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D).
62699493|NCT05005533||Mild and Moderate Severe Group|Individuals with Chronic Obstructive Pulmonary Disease with a Forced Expiratory Volume greater than 50% of the expected value
62699494|NCT05005533||Severe and Very Severe Group|Individuals with Chronic Obstructive Pulmonary Disease whose Forced Expiratory Volume is less than 50% of the expected value
62699495|NCT00284128|EXPERIMENTAL|ilepatril (2.5 mg ) once daily|AVE7688 oral administration
62699496|NCT00284128|EXPERIMENTAL|ilepatril (10 mg) once daily|AVE7688 oral administration
62699497|NCT00284128|EXPERIMENTAL|ilepatril (35 mg) once daily|AVE7688 oral administration
62699498|NCT00284128|EXPERIMENTAL|ilepatril (50 mg) once daily|AVE7688 oral administration
61950834|NCT02671305|EXPERIMENTAL|placental circulation intact|preterm newborns assisted bedside with placental circulation intact
61950835|NCT02671305|ACTIVE_COMPARATOR|cord milking|preterm newborns who receive cord milking before assistance performed in a routine setting
62342318|NCT03001843|ACTIVE_COMPARATOR|Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
62342319|NCT03889600|EXPERIMENTAL|REDD-CAT Recipient|The nurse care manager will incorporate the administration of the REDD-CAT to the patient as part of the standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
62342320|NCT05446025||pregnant women with a diagnosis of hyperemesis gravidarum( n:50)|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be examined in patients with hyperemesis gravidarum.
62342321|NCT05446025||Control group pregnants (n:50)|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be examined in the patients of the control group .
62499785|NCT01839838|EXPERIMENTAL|APBI with protons Phase 1|Feasibility phase 1
62499786|NCT01839838|EXPERIMENTAL|APBI with protons Phase 2|Study phase 2
62499787|NCT06407999|EXPERIMENTAL|APAP w/ EPR On|The patient will use their normal CPAP device and equipment in the normal operating mode but we will set EPR on if they do not already use it that way.
62141006|NCT00885313|EXPERIMENTAL|DHA500|DHA 250 mg/kg/d plus lifestyle intervention \[hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
62499788|NCT06407999|PLACEBO_COMPARATOR|APAP w/ EPR Off|The patient will use their normal CPAP device and equipment in the normal operating mode but we will set EPR off if they do not already use it that way.
62499789|NCT00680524|EXPERIMENTAL|Phone Based Outreach Intervention Group|Open pilot trial
62699499|NCT00284128|OTHER|Losartan-potassium (100 mg) once daily|oral administration
62699500|NCT03519880|EXPERIMENTAL|Custom Mask Interface|Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
62699501|NCT06047470|ACTIVE_COMPARATOR|Kangaroo Care Arm (KC)|Lactating parents will be asked to arrive at the NICU 2 hours after they have fully expressed their breasts at home and to provide their infants with kangaroo care for 1 hour. Following KC and while still at the infant's bedside, lactating parents will be asked to pump from both of their breasts using a hospital grade pump available in the NICU. Study personnel will weigh the collected milk to determine the total volume of milk expressed by mass. The milk collected from both breasts will be gently swirled six times or more until the fat layer is incorporated in the bottle and will be combined into one bottle. Study personnel will take one 6 mL aliquot from the collected milk for compositional analysis. The remainder of the milk will be saved in the NICU per routine so that it can be fed to the infant later.
62141007|NCT00885313|PLACEBO_COMPARATOR|PLA|placebo and lifestyle intervention \[hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
62342322|NCT03714282|EXPERIMENTAL|Noninvasive Spinal Stimulation with Gait Training|May receive up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
62499790|NCT02199379|EXPERIMENTAL|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
61950836|NCT01414660||islet|type 1 diabetic patients undergoing islet transplantation
61950837|NCT01414660||liver|non diabetic patients undergoing a liver transplantation
61950838|NCT01414660||kidney|non diabetic patients undergoing a kidney transplantation
61950839|NCT04486911|EXPERIMENTAL|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
61950840|NCT02657915|PLACEBO_COMPARATOR|Placebo|This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.
61950841|NCT02657915|EXPERIMENTAL|BIIB033 100mg/Kg|This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.
61950842|NCT05618366|EXPERIMENTAL|Tazemetostat and Venetoclax|All participants will receive a combination of oral 800 mg tazemetostat BID and oral venetoclax. Since this is a phase 1 trial, the dose of venetoclax will be determined by the investigators per a sequential dose escalation (3+3). Participants will be provided study drug in the form of pills to take at home. Study participants will need to regularly come to the clinic for blood work, imaging, and to monitor and side effects. Participants may receive study drug until their cancer progresses or for up to 24 months.
61950843|NCT06197971|OTHER|Instrument Assisted Soft Tissue Mobilization|The therapist will assess the hamstrings to identify areas of restriction or dysfunction. They will use the Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied. The duration of the IASTM treatment will be 15-30 minutes.
61950844|NCT06197971|OTHER|Therapeutic Cupping Technique|After thorough assessment of the Hamstring area, a thin layer of lubricant will be applied on the area about to be cupped. Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings. For cupping the hamstrings, cups with a diameter of around 1.5 to 2.5 inches (3.8 to 6.4 cm) will be suitable considering the large area of treatment
61950845|NCT00560105|ACTIVE_COMPARATOR|Acapella|The Active Comparator is the Acapella, a OPEP device
61950846|NCT00560105|EXPERIMENTAL|Lung Flute|The Active Comparator is the Lung Flute, a new indication of this device
61950847|NCT05608759|EXPERIMENTAL|single arm|4 weeks of multimodal pre-rehabilitation
61950848|NCT06556992|EXPERIMENTAL|FIT Teens|Fitness Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
62342323|NCT03714282|ACTIVE_COMPARATOR|Conventional Gait Training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
62342324|NCT03714282|OTHER|Healthy Control Group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
62499791|NCT01000688|EXPERIMENTAL|vildagliptin treatment first, acarbose treatment second|
62499792|NCT01000688|EXPERIMENTAL|acarbose treatment first, vildagliptin treatment second|
62499793|NCT03976934|ACTIVE_COMPARATOR|Tamsulosin group|administration of 0,4mg of tamsulosin 24 hours before surgery and 0,4mg 6 hours before surgery
62499794|NCT03976934|PLACEBO_COMPARATOR|Placebo group|administration of placebo 24 and 6 hours before surgery
62499795|NCT06039774|EXPERIMENTAL|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Subjects will receive α-Mangostin Hydrogel Film With Chitosan Alginate Base in the form of a patch. Subjects will apply the patch once a day after breakfast or at night before sleep, subjects will be told to avoid drinking or eating for 1 hour after using the hydrogel film because these activities can remove the hydrogel film. Ulcer size and VAS score will recorded on the first day (baseline), the 3rd day, the 5th day, and the 7th day
62499796|NCT06039774|PLACEBO_COMPARATOR|Placebo|Subjects will receive Hydrogel Film With Chitosan Alginate Base without an active compound in the form of a patch. Subjects will apply the patch once a day after breakfast or at night before sleep and will be told to avoid drinking or eating for 1 hour after using the hydrogel film because these activities can remove the hydrogel film. Ulcer size and VAS score will recorded on the first day (baseline), the 3rd day, the 5th day, and the 7th day
62499797|NCT01948401|EXPERIMENTAL|Controlled asthma|
61950849|NCT01060813|ACTIVE_COMPARATOR|Exercise + Leucine|Patients will receive leucine 10 g/d po + exercise for 3 months
61950850|NCT01060813|ACTIVE_COMPARATOR|Leucine without exercise|patients will receive leucine 10 g/d po
61950851|NCT00622284|EXPERIMENTAL|BI 1356 5mg, once daily|patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
61950852|NCT00622284|ACTIVE_COMPARATOR|Glimepiride|patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
61950853|NCT03836248|OTHER|1-Current practice Medication treatment|Medication treatment according to current practice.
61950854|NCT03836248|SHAM_COMPARATOR|2- Sham osteopathic treatment|Medication treatment according to current practice + sham osteopathic treatment.
62342325|NCT00772382|EXPERIMENTAL|MCI-196|
62342326|NCT03886142|ACTIVE_COMPARATOR|radiofrequency|genicular nerves pulsed radiofrequency
62499798|NCT01948401|EXPERIMENTAL|Uncontrolled asthma with additional OCS|
62499799|NCT01948401|EXPERIMENTAL|Uncontrolled asthma without additional OCS|
62499800|NCT03480022|EXPERIMENTAL|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
61950855|NCT03836248|EXPERIMENTAL|3- Osteopathic treatment|Medication treatment according to current practice + osteopathic treatment.
61950856|NCT03875365||POPE Patients|Patients who underwent POPE for end-stage achalasia, a sigmoid esophagus, or a redundant conduit that has been used to replace the esophagus.
61950857|NCT00958100|EXPERIMENTAL|Tenofovir Emtricitabine Raltegravir|Patients switching to raltegravir with tenofovir+emtricitabine as backbone
61950858|NCT00958100|EXPERIMENTAL|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
61950859|NCT00958100|EXPERIMENTAL|Abacavir free|Patients switched to raltegravir whose backbone therapy should not be randomized in order to avoid the use of abacavir (HLA-B\*5701 positive patients,Framingham score 20% or higher)
61950860|NCT03392467|EXPERIMENTAL|PNEUMOSTEM|human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
61950861|NCT03392467|PLACEBO_COMPARATOR|Placebo|normal saline
61950862|NCT01418170|EXPERIMENTAL|Two rcSMT group|A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
61950863|NCT01418170|SHAM_COMPARATOR|One scSMT + One rcSMT Group|A scSMT will be performed with the contact hand of the clinician resting lightly on the paraspinal area of the neck of the subject. The subject's head will be rotated to 45 degrees and supported by the clinician's forearm, lying on headpiece. A inferior drop thrust will be applied to the drop piece. After the first scSMT maneuver the subject will turn over on the chiropractic table to lie in the prone position for a post-scSMT PPT measurement. PPT measurements will be taken at 5-minute intervals for 30 minutes. A rcSMT will be performed 30 minutes after the first scSMT. The subject will turn over to the prone position for repeat PPT measurements in 5-minute intervals for 30 minutes post-rcSMT. Once the subject has left the treatment area the clinician will mark on the treatment card weather the scSMT was performed adequately without cavitation and whether a cavitation occurred with the rcSMT.
61950864|NCT02902432|PLACEBO_COMPARATOR|SCCHN|patients with advanced squamous cell carcinoma of the head and neck.IMRT.
61950865|NCT02902432|EXPERIMENTAL|SCCHN-Endostar|patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.
61950866|NCT06289569|EXPERIMENTAL|Tele Rehabilitation|Telerehabilitation therapy Occupational therapist prescribed hand/arm exercises will continue for 90 minutes per day with adequate rest periods for 4 weeks, followed by telerehabilitation with the application for 4 weeks, when subjects will perform the tasks at home with the guidance of the treatment app. Detailed records of each subject's motor tasks, number of repetition and level of performance will be kept. Treatment will be performed Monday-Friday for approximately 4 weeks. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
61950867|NCT01099137|EXPERIMENTAL|Vildagliptin|Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
62342327|NCT03886142|ACTIVE_COMPARATOR|intra-articular platelet rich plasma|injection of platelet rich plasma in the affected joint
62342328|NCT03809832||Patients with COPD|Patients established on home non-invasive ventilation for COPD admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
62342329|NCT03809832||Patients with OHS|Patients established on home non-invasive ventilation for obesity hypoventilation syndrome admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
62342330|NCT03079349|ACTIVE_COMPARATOR|Traditional Classroom|Medical Education
62342331|NCT03079349|EXPERIMENTAL|Online Synchronous Classroom|Medical Education
62342332|NCT06081673|EXPERIMENTAL|Penpulimab combined with cisplatin and albumin-paclitaxel neoadjuvant therapy|"Penpulimab injection combined with cis-platinum and albumin-bound paclitaxel before surgery, 21 days as a treatment cycle.~Adjuvant therapy was started within 6 weeks after surgery：Patients who achieved MPR after surgery were randomized 1:1 with standard adjuvant therapy(RT alone or combined with cisplatin) and Alternative adjuvant therapy(RT alone or combined with Penpulimab).~Non-MPR patients receive standard adjuvant therapy"
62342333|NCT01270243||Control|No tonsilar or adenoid problems
62342334|NCT01270243||Adenotonsillectomy (recurrent)|Recurrent adenotonsillitis
62342335|NCT01270243||Adenotonsillectomy (obstruction)|Upper airway obstruction
62342336|NCT05469477|OTHER|Control|Participants are asked to buckle up and not engage in handheld phone use while driving. No further messaging will be provided about their behavior, and participants will not receive financial incentives for avoiding risky driving behavior.
62342337|NCT05469477|EXPERIMENTAL|Behavioral Engagement|Participants will receive a multicomponent safer driving intervention based on behavioral science. This will include persuasive education, WOOP (mental contrasting with implementation intentions) and customized habit tips.
62499801|NCT03480022|PLACEBO_COMPARATOR|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
62499802|NCT04747184||Asthmatic patients|Asthmatic patients aged 14-year-old, and more were included in the study. Knowing that patient with the age of 14-year is treated as adults at Al Bashir Hospital. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
62342338|NCT05469477|EXPERIMENTAL|Raffle incentive + behavioral engagement|Participants will receive the entire multicomponent safer driving behavioral intervention from arm 2. Participants will also be eligible for the Raffle Financial incentive, where participants can earn prize money for seat belt adherence and/or no phone use while driving.
62342339|NCT05469477|EXPERIMENTAL|Shared pot incentive + behavioral engagement|Participants will receive the entire multicomponent safer driving behavioral intervention from arm 2. This arm will be identical to Arm 3, except there will be a shared pot financial incentive instead of a raffle. Participants that abstain from phone use while driving and seat belt adherence earn an equal share of prize money allocated for the entire group.
62499803|NCT04747184||Healthy subjects|Healthy subjects aged 14-year-old, and more were included in the study. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
62499804|NCT03826394|EXPERIMENTAL|Exercise Intervention|Exercise intervention with the aim of incrementally increasing physical activity to meet the national recommendation of 150 minutes a week of moderate-vigorous physical activity, reducing BMI and improving overall health.
62499805|NCT03826394|EXPERIMENTAL|Dietary Intervention|Staged dietary intervention with the aim of improving eating behaviours, reducing BMI and improving overall health.
62499806|NCT05924880|EXPERIMENTAL|durvalumab in combination with gemcitabine-based chemotherapy|single-arm
61950868|NCT01099137|ACTIVE_COMPARATOR|Sulphonylurea dose-up|Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin
61950869|NCT05251766|ACTIVE_COMPARATOR|Arm1: epirubicin + cyclophosphamide followed by docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 4 cycles, Follow Docetaxel :75 mg/m2, D1, q3W, 4 cycles
61950870|NCT05251766|EXPERIMENTAL|Arm2: epirubicin + cyclophosphamide followed by nab-paclitaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 4 cycles, Follow Nab-paclitaxel :260 mg/m2, d1, q3W; 4 cycles
62499807|NCT03581162||Patients|Patients with diagnosis of Juvenile Mixed Connective Tissue Disease
62499808|NCT03581162||Controls|Healthy, age-and sex-matched controls
62499809|NCT04208490|OTHER|HN-STAR|
62499810|NCT04208490|NO_INTERVENTION|Usual Care|
62499811|NCT05104502|EXPERIMENTAL|Fasting|Dietary fasting.
62499812|NCT06464874||conventional ESD|Submucosal injection of methylene blue solution at various sites was performed, followed by periphery incision using a dual knife. The submucosal injection was administered multiple times, followed by the utilization of an IT knife for submucosal separation and gradual excision of the lesion. In cases of significant bleeding at the wound site, electrocoagulation hemostatic forceps were employed for hemostasis.
62499813|NCT06464874||hybrid ESD|The submucosal injection and circumferential incision of the Hybrid ESD were performed as described above. Subsequently, snaring was conducted post submucosal dissection utilizing a polypectomy snare for complete lesion removal. Careful attention was paid during excision to avoid muscle layer penetration and to control cutting speed in order to mitigate the potential for hemorrhage and perforation. The subsequent steps of the procedure closely followed the conventional ESD methodology outlined previously.
62499814|NCT01475786|ACTIVE_COMPARATOR|Low Dose 16mg Engensis (VM202) and Placebo|intramuscular injections in each calf for a total of 16mg Engensis (VM202): Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
62499815|NCT01475786|ACTIVE_COMPARATOR|High Dose 32mg Engensis (VM202)|Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202
62499816|NCT01475786|PLACEBO_COMPARATOR|Control - Placebo (normal saline)|32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14
62499817|NCT05511441|EXPERIMENTAL|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
62499818|NCT04906096|EXPERIMENTAL|PAXALISIB|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.~* Paxalisib (GDC-0084)~* Each study treatment cycle lasts 28 days, up to 24 months."
62499819|NCT00610506|EXPERIMENTAL|A|Lexapro
62499820|NCT06677944|EXPERIMENTAL|Preoperative PBI|PBI before surgery
61950871|NCT05251766|EXPERIMENTAL|Arm3: nab-paclitaxel combined with epirubicin + cyclophosphamide|Nab-paclitaxel :260 mg/m2, D1, q3W; Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 6 cycles
61950872|NCT05170984|EXPERIMENTAL|CACIPLIQ20®|Treatment of the target wound with CACIPLIQ20® in addition to optimal local care
61950873|NCT02028793||Pharmacists provide pharmaceutical care|The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach.
61950874|NCT04849754|OTHER|Patients with transthyretin related cardiac amyloidosis|Bone scintigraphy
61950875|NCT01006174|EXPERIMENTAL|A|Subjects will be assigned to consume 3 grams soybean oil, 8 grams canola oil, and 20 grams butter that is added to a salad.
61950876|NCT01006174|EXPERIMENTAL|B|Subjects will be assigned to consume 8 grams soybean oil, 20 grams canola oil, and 3 grams butter that is added to a salad.
61950877|NCT01006174|EXPERIMENTAL|C|Subjects will be assigned to consume 20 grams soybean oil, 3 grams canola oil, and 8 grams butter that is added to a salad.
62342340|NCT02258867|PLACEBO_COMPARATOR|Placebo|
62499821|NCT03407729||Post-hypoxic former preterm|Born in the years 2005-2009 with birth gestational age between 23-28 weeks and birth weight appropriate for gestational age (AGA). Part of a research cohort with available oxygen saturation level data recorded continuously from the first day of life to 8 weeks postnatal age (n=11).Children will undergo Magnetic Resonance Imaging and Cognitive Performance Testing.
62499822|NCT03407729||Healthy term-born children|Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging and Cognitive Performance Testing.
62499823|NCT01266603|EXPERIMENTAL|HDIL-2 + recMAGE-A3 + AS15|HDIL-2 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle. recMAGE-A3 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
62499824|NCT01570231|EXPERIMENTAL|bilateral limb ischemic preconditioning (BLIPC)|5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
62499825|NCT01570231|NO_INTERVENTION|Control group|underwent equivalent medical treatments only
62499826|NCT06361355|EXPERIMENTAL|Post-change CMAB807|60 mg Subcutaneous injection around belly button
62499827|NCT06361355|ACTIVE_COMPARATOR|Prolia|60 mg Subcutaneous injection around belly button
62499828|NCT02833636||Successful CTO-PCI group|low ACEF score \<1.215 (n = 79), intermediate ACEF score from 1.215 to 1.493 (n=70), and high ACEF score≥1.493 (n=72)
62499829|NCT02833636||Failed/non-attempted CTO-PCI group|low ACEF score\<1.215 (n=45), intermediate ACEF score from 1.215 to 1.493 (n=57), and high ACEF score≥1.493 (n=54).
61950878|NCT05236400|EXPERIMENTAL|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|After participating in a clinical trial and receiving unmanned electric airway aspiration, the efficacy and safety are checked on Day 3 and on Day 7 and Day 14 of the follow-up period.
62342341|NCT02258867|EXPERIMENTAL|Gevokizumab|
62699502|NCT06047470|PLACEBO_COMPARATOR|Control Arm (CON)|Lactating parents will be asked to arrive at the NICU 3 hours after they have fully expressed their breasts at home. Lactating parents will be taken to a private room where they will be asked to pump from both of their breasts using a hospital grade pump available in the NICU. Study personnel will weigh the collected milk to determine the total volume of milk expressed by mass. The milk collected from both breasts will be gently swirled six times or more until the fat layer is incorporated in the bottle and will be combined into one bottle. Study personnel will take one 6 mL aliquot from the collected milk for compositional analysis. The remainder of the milk will be saved in the NICU per routine so that it can be fed to the infant later. Lactating parents will then provide their infants with kangaroo care for 1 hour.
62699503|NCT06640101|SHAM_COMPARATOR|sham IMT|conventional treatment + sham IMT
62342342|NCT03056976|EXPERIMENTAL|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
62342343|NCT03056976|EXPERIMENTAL|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
62342344|NCT03056976|EXPERIMENTAL|Fixed mandibular denture|A fixed four-implant mandibular denture
62342345|NCT06129396|EXPERIMENTAL|Aerobic exercise group|The aerobic exercise consists of: (1) 5 min warm-up exercise, (2) 20 min aerobic exercise with heart rate (HR) at target zone (one research assistant will be onsite to monitor whether the HR is around the range of moderate intensity), and (3) 5 min cool-down exercise.
62342346|NCT06129396|ACTIVE_COMPARATOR|Video-watching group|The video-watching group will be asked to watch a nature documentary for 30 mins
62342347|NCT02849964||First time renal replacement therapy|Patients beginning renal replacement therapy by renal dialysis or preemptive kidney transplant.
62342348|NCT03170479|EXPERIMENTAL|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
62499830|NCT01921335|ACTIVE_COMPARATOR|ARRY-380 Twice Daily Dosage|ARRY-380 will be 450mg orally twice-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg.ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
62499831|NCT01921335|ACTIVE_COMPARATOR|ARRY-380 Once Daily|ARRY-380 will be 750mg orally once-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg. ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
62499832|NCT04256707|EXPERIMENTAL|Monotherapy: Normal Hepatic Function (Selinexor)|"(Closed for Enrollment)~Cohort 1:~* Week 1: selinexor 5 x 20-mg tablet daily;~* Week 2: selinexor 1 x 100-mg tablet daily~Cohort 2:~* Week 1: selinexor 1 x 100-mg tablet daily;~* Week 2: selinexor 5 x 20-mg tablet daily."
62499833|NCT04256707|EXPERIMENTAL|Monotherapy: Impaired Hepatic Function (Selinexor)|"Cohort 3:~Patients with Moderate Hepatic Impairment with any Solid Tumors;~- Selinexor 2 x 20-mg tablet once weekly (QW).~Cohort 4:~Patients with Severe Hepatic Impairment with any Solid Tumors;~- Selinexor 2 x 20-mg tablet QW."
62499834|NCT04256707|EXPERIMENTAL|Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)|"(Closed for Enrollment)~Selinexor 60 mg oral dose QW and docetaxel 75 mg/m\^2 intravenously (IV) once every 3 weeks (Non-small cell lung cancer \[NSCLC\] patients)."
62499835|NCT04256707|EXPERIMENTAL|Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)|"(Closed for Enrollment)~Selinexor 80 mg oral does QW and pembrolizumab 200 mg IV every 3 weeks (Colorectal cancer \[CRC\] Patients)."
62699504|NCT06640101|EXPERIMENTAL|Target IMT (sitting on the chair)|conventional treatment + target IMT while sitting on the chair
62699505|NCT06640101|EXPERIMENTAL|Target IMT (sitting on an unstable surface)|conventional treatment + target IMT while sitting on an unstable surface
62699506|NCT00867139|EXPERIMENTAL|TCAD-Randomized Arm|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
62699507|NCT00867139|ACTIVE_COMPARATOR|Neuraminidase Monotherapy Arm|Zanamivir or Oseltamivir
62699508|NCT00867139|OTHER|TCAD Open Label Arm|TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir
62699509|NCT06373679|EXPERIMENTAL|Choice of Medication|This arm includes participants randomly assigned to the Meds Group. Participants will choose between 1) combo NRT and 2) varenicline. The NRT will consist of transdermal NRT and nicotine lozenge. Participants will receive study product for 11 weeks.
62699510|NCT06373679|EXPERIMENTAL|Choice of E-Cigarette|This arm includes participants randomly assigned to the E-Cigarette Group. Participants will choose between two different brands of e-cigarettes and choose up to two different flavors. Participants will receive study product for 11 weeks.
61950879|NCT05236400|ACTIVE_COMPARATOR|Manual phlegm suction system|After participating in a clinical trial and applying manual airway aspiration, the efficacy and safety are checked on Day 3 and on Day 7 and Day 14 of the follow-up period.
61950880|NCT03093220||community-acquired pneumonia|all adult patients (aged \> 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
61950881|NCT03063242|EXPERIMENTAL|Project I: Healthy participants|5 healthy participants will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Blood samples will be drawn and analyzed for mDC levels.
61950882|NCT03063242|EXPERIMENTAL|Project II: Patients with CKD stage IV/V|5 Patients with CKD stage IV/V who are cytomegalovirus (CMV) seropositive with mean blood mDC levels \<1.0x104/mL will receive sargramostim treatment once all 5 healthy participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
61950883|NCT03063242|EXPERIMENTAL|Project III: kidney transplant patients|5 Kidney transplant recipients who are CMV seropositive with neutropenia (defined as absolute neutrophil count \<1.0 x103/mm3) and/or CMV viremia will receive sargramostim treatment once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
61950884|NCT00493025|EXPERIMENTAL|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
61950885|NCT02623023|EXPERIMENTAL|Combigan group|Combigan will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
61950886|NCT02623023|PLACEBO_COMPARATOR|Refresh tears|Refresh tears will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
61950887|NCT05879679||Binge Eating Disorder|Participants with a binge eating disorder (DSM-5 criteria)
61950888|NCT05879679||Bulimia Nervosa|Participants with a bulimia nervosa (DSM-5 criteria)
62342349|NCT03170479|PLACEBO_COMPARATOR|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
62342350|NCT00479557|ACTIVE_COMPARATOR|1|arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
62699511|NCT06167148|EXPERIMENTAL|940nm wavelength Diode laser|
62699512|NCT06167148|ACTIVE_COMPARATOR|980nm wavelength Diode laser|
62699513|NCT04847882||Cystic fibrosis, children from 6 to 17.|This group is made up of children with cystic fibrosis followed at the Strasbourg pediatrics CRCM, aged from 6 to 17 years old, not hospitalized at the time of inclusion, without any other criterion prejudging the seriousness of the pathology.
62141008|NCT02788994|EXPERIMENTAL|Endovis BA2 Nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~* stable fracture synthesis for fast rehabilitation and early mobilization~* an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)~This is a one off surgical fixation."
62141009|NCT02788994|ACTIVE_COMPARATOR|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
62141010|NCT05765331|EXPERIMENTAL|Chatbot-aid intervention|Chatbot-aid intervention group
62342351|NCT00479557|ACTIVE_COMPARATOR|2|arm 2: ACC-001
62699514|NCT04847882||Control group, children from 6 to 17.|"This group is the control group. It is made up of children consulting in pediatric surgical emergencies, aged 6 to 17 years. Surgical emergencies were chosen because it is a point of consultation, rather accidental, where sleep has often not been impacted in the previous months and where the frequency of chronic pathology is not higher than the general population.~An other criteria is that these children are accompanied by at least one of their parents and that they can read and understand French well."
62699515|NCT04124757|NO_INTERVENTION|Standard neuromuscular blockade|Subjects will receive regular rocuronium induction dose, followed by bolus foses of 10 mg in case of insufficient conditions
62141011|NCT05765331|NO_INTERVENTION|Control group|Written routine nursing health education guidance intervention.
62141012|NCT01478594|EXPERIMENTAL|Tivozanib + mFOLFOX6|Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
62141013|NCT01478594|ACTIVE_COMPARATOR|Bevacizumab + mFOLFOX6|Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
62342352|NCT00479557|PLACEBO_COMPARATOR|3|arm 3: QS-21
62342353|NCT00479557|PLACEBO_COMPARATOR|4|Drug: Phosphate Buffered Saline (PBS)
62499836|NCT04256707|EXPERIMENTAL|Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)|"(Closed for Enrollment)~Cohort 1:~Selinexor 40 mg oral dose Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5- fluorouracil (5-FU) 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).~Cohort 2:~Selinexor 80 mg oral dose Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5-FU 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients)."
61950889|NCT01285154||Traditional Steel Triple Osteotomy|Traditional technique
62342354|NCT00835107|EXPERIMENTAL|Ziprasidone|
62342355|NCT00835107|PLACEBO_COMPARATOR|Sugar pill|
61950890|NCT01285154||Modified Triple Osteotomy|Modified technique
62499837|NCT02327325|EXPERIMENTAL|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
62499838|NCT02327325|EXPERIMENTAL|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
61950891|NCT04997083|EXPERIMENTAL|cleft lip and palate patients|Cleft patients with transverse maxillary constriction and anteroposterior deficiency
61950892|NCT05781854|ACTIVE_COMPARATOR|Group P (PIEB-group)|After the initial epidural loading dose of 10 ml, 30 patients will receive programmed intermittent epidural boluses (5 ml every 45 min with the first bolus 30 minutes after epidural initiation) + patient controlled epidural analgesia (PCEA) as 5 ml boluses with a 20-minute lockout period).
61950893|NCT05781854|ACTIVE_COMPARATOR|Group C (CEI-group)|After the initial epidural loading dose of 10 ml, 30 patients will receive continuous epidural infusion (5 ml/h starting immediately after the loading dose) + patient controlled epidural analgesia (PCEA) as 5 ml boluses with a 20-minute lockout period).
61950894|NCT01216761|ACTIVE_COMPARATOR|CHG then PI then IT|"Skin antisepsis prior to any peripheral blood culture collection on Floor A was performed with CHG for 3 months, followed by PI for 3 months, followed by IT for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT"
62342356|NCT00792233|EXPERIMENTAL|1|Participants taking anti-TNF medications will be monitored for signs of their disease for 6 months. If, after 6 months, their disease has become inactive, they will stop taking anti-TNF medications for up to 8 months. If participants who are no longer taking anti-TNF medications have a disease flare-up, they will begin treatment again.
62342357|NCT04466501|EXPERIMENTAL|ACR LAB for Professional User|
62342358|NCT05626517||National Heart Centre Singapore|At NHCS, patients who have undergone either CTCA or CT CAC scan within past 6 months will be identified. All the consented participants will have a one-off retinal imaging performed at the respective institution by the trained study team member, which should take approximately 15-20 minutes to complete. 3 to 4 questionnaires will also be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire), depending patient's gender and literacy. Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function questionnaire. Participants have the option to not complete sthe whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
62342359|NCT05626517||Singapore Eye Research Institute|At SERI, patients who are found to be at high risk for vision threatening diabetic retinopathy will be identified. All the consented participants will have a one-off retinal imaging performed at the respective institution by the trained study team member, which should take approximately 15-20 minutes to complete. 3 to 4 questionnaires will also be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire), depending patient's gender and literacy. Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function questionnaire. Participants have the option to not complete sthe whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
62342360|NCT02476591||Charge transparency|Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
62342361|NCT02476591||Without charge transparency|Providers without access to patient specific charge data
62499839|NCT02327325|NO_INTERVENTION|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
62699516|NCT04124757|EXPERIMENTAL|Deep neuromuscular block|Subjects will receive high dose rocuronium induction dose followed by continuous rocuronium administration, to achieve a depth of neuromuscular block of 1-2 twitches post tetanic count
62699517|NCT04003038|ACTIVE_COMPARATOR|Group I (wound care with a standard dressing)|Patients receive wound care with a standard dressing (bandage) after surgery for 7 days.
62141014|NCT02508441|EXPERIMENTAL|Andes-1537 for Injection|Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.
62141015|NCT00001349||1|Donors first admitted to another approved clinical research protocol of the NIAID before having the apheresis procedures described in this protocol.
62141016|NCT03944694||Delirious|Patients were delirious if CAM-ICU was positive within 24 hours from admission due to acute ischemic stroke.
62342362|NCT01471704|EXPERIMENTAL|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
62342363|NCT01471704|ACTIVE_COMPARATOR|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
62499840|NCT01705483|EXPERIMENTAL|Part 1: ASP9853 with docetaxel|2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
62499841|NCT01705483|EXPERIMENTAL|Part 2: ASP9853 with paclitaxel|Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
62499842|NCT03391050|EXPERIMENTAL|APR-246 + Dabrafenib|
62699518|NCT04003038|EXPERIMENTAL|Group II (NPWT)|Patients receive NPWT after surgery for 7 days.
62342364|NCT01471704|ACTIVE_COMPARATOR|INX-08189 50 mg & verapamil HCLER 240 mg|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
61950895|NCT01216761|ACTIVE_COMPARATOR|IT then CHG then PI|"Skin antisepsis prior to any peripheral blood culture collection on Floor B was performed with iodine tincture for 3 months, followed by Chlorhexidine gluconate for 3 months, followed by povidone iodine for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI"
61950896|NCT01216761|ACTIVE_COMPARATOR|PI then IT then CHG|"Skin antisepsis prior to any peripheral blood culture collection on Floor C was performed with povidone iodine for 3 months, followed by iodine tincture for 3 months, followed by chlorhexidine gluconate for 3 months. Each 3 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG"
61950897|NCT06557200|EXPERIMENTAL|Intervention group|A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
61950898|NCT06557200|NO_INTERVENTION|Control|No intervention will be provided except usual care
61950899|NCT04482257|EXPERIMENTAL|T-R|Subjects will receive Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV
61950900|NCT04482257|EXPERIMENTAL|R-T|Subjects will receive Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV
62699519|NCT06154590||Method(s)1/PIF Used to Evaluate|"Competency Areas- Surgical care to patients with complex or recurrent neoplasms, including diagnosis and management of rare or unusual tumors.~Determining disease stage/treatment options for individual cancer patients at time of diagnosis and throughout the disease course.~Provide surgical care to patients with complex or recurrent neoplasms, including selecting for surgical therapy in combination with other forms of cancer treatment.~Performing palliative surgical.~Intervention(s): Use Attribution, assign category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use list of Adverse Events.~Dose Units -1 mg, anastrozole. 20 mgs NOLVADEX administer to patient. Tamoxifen citrate was added to melphalan (Lphenylalanine mustard (P) and fluorouracil (F))."
61950901|NCT03836599|EXPERIMENTAL|24 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.
61950902|NCT03836599|EXPERIMENTAL|12 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol once daily from Day -7 to Day -1. During Treatment Period, participants will receive a single dose of 12 mg verinurad and 300 mg allopurinol on Day 1. No dosing will be done on Day 2. Participants will continue dosing on Day 3 and will be dosed once daily until Day 9.
61950903|NCT03836599|PLACEBO_COMPARATOR|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
61950904|NCT06127615|EXPERIMENTAL|ClearFit Longeviti Implant|Patients with chronic subdural hematomas that qualify for study and agree to participate will receive the ClearFit implant to cover the craniectomy site and have ultrasound imaging for their post-operative follow-up rather than CT/MRI, with exception of first initial post-op CT scan, and crossover to CT/MRI if clinically indicated or required for diagnostic purposes/patient safety
61950905|NCT02051686|ACTIVE_COMPARATOR|Tranexamic Acid|Group I will receive 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
61950906|NCT02051686|PLACEBO_COMPARATOR|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
61950907|NCT04886128||Aim 1/Outcome 1|Secondary analysis of frozen plasma samples from the existing STRATIFY cohort of patients with and without acute heart failure presenting to emergency departments. n= \~900
61950908|NCT04886128||Aim2/Outcome 2|Secondary analysis of frozen plasma samples from the existing EMROC cohort of patients with and without acute heart failure presenting to emergency departments. n= \~900
61950909|NCT04886128||Aim 3/Outcome 3|Prospective recruitment of approximately 1000 patients with and w/o acute heart failure presenting to emergency departments.
61950910|NCT00187200|ACTIVE_COMPARATOR|Simultaneous VV Pacing|Programmed to simultaneous biventricular pacing
61950911|NCT00187200|ACTIVE_COMPARATOR|Sequential VV Pacing|Programmed to sequential biventricular pacing
62499843|NCT06459960|EXPERIMENTAL|Hydrotherapy|"Patients practised the rehabilitation exercises in a heated pool (32°C). Exercises included: 1) Knee mobilization exercises, 2) Muscle stretching exercises, 3) Muscle strengthening exercises, such as wall slide, leg press with life ring, and lunges, 4) Balance and functional training - Single-leg standing, tandem walking, heel walking and tip-toe walking, and 5) Balance functional training - Cycling in water, fast walking and running (for patients in Hydrotherapy group only).~Patients practised once a week for a total of four weeks, complimentary to conventional physiotherapy rehabilitation (8 weeks). Total number of weeks is 8+4 weeks = 12 weeks."
62499844|NCT06459960|ACTIVE_COMPARATOR|Convention|"The conventional physiotherapy rehabilitation programme included: 1) knee mobilization exercises, such as static bike and heel sliding board, 2) Muscle stretching exercises of hamstrings and calf, 3) Muscle strengthening exercises, such as adding cuff weights for quadriceps strengthening and wall slide with gym ball, and 4) Balance and functional training, such as stepping or single-leg standing on soft foam, stepping exercises on various heights of steps.~Patients practised twice a week for a total of 8 weeks."
62499845|NCT04666597||Adapted-CCI single-intervention group in children|The single-group intervention will be the adapted-CCI 4D-cycle caries care, with non-AGP and reduced in-office appointments' time. A trained examiner per centre will conduct examinations at baseline, at 5-5.5 months (three months after basic management), 8.5 and 12 months, assessing the child's CCI caries risk and oral-health behaviour, visually staging and assessing caries-lesions severity and activity without air-drying (ICDAS-merged Epi); fillings/sealants; missing/dental-sepsis teeth, and tooth symptoms, synthetizing together with parent and external-trained dental practitioner (DP) the patient- and tooth-surface level diagnoses and personalised care plan. DP will deliver the adapted-CCI caries care. Parents' and dentists' process acceptability will be assessed via Treatment-Evaluation-Inventory questionnaires, and costs in terms of number of appointments and activities. Twenty-one centres in 13 countries will participate.
62699520|NCT06154590||Method(s)2/PIF Used to Evaluate|"Competency Areas- Biologic, pharmacologic, and physiologic rationale for each form of therapy, indications, risks, and benefits of regional and systemic therapy in adjuvant and advanced disease settings.~Nonsurgical cancer treatment modalities, including radiotherapy, chemotherapy, immunotherapy, and endocrine therapy.~Nonsurgical palliative treatments.~Rehabilitative services, including reconstructive surgery and physical rehabilitation.~Tumor biology, carcinogenesis, epidemiology, tumor markers, and tumor pathology.~Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use list of Adverse Events.~Dose Units- adjuvant cytotoxic chemotherapy, added to lequo, low-dose cyclophosphamide methotrexate and fluoruracil"
62699521|NCT04434755||health care professionals in palliative care|health care professionals in palliative care
62699522|NCT04434755||health care professionals in neurorehabiliation|health care professionals in neurorehabiliation
62699523|NCT04947189|EXPERIMENTAL|Seviteronel, dexamethasone and docetaxel|"Part 1: Seviteronel will be administered orally beginning with 450 mg (3 x 150 mg tablets) once daily along with 0.5 mg dexamethasone, continuously in 28-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly.~Part 2: The recommended phase 2 dose for seviteronel (established in Part 1) once daily along with 0.5 mg dexamethasone, continuously in 21-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly."
62699524|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
62699525|NCT00581100|ACTIVE_COMPARATOR|1|etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
62699526|NCT00581100|ACTIVE_COMPARATOR|2|etanercept 50 mg SC once weekly for the complete 24 week treatment period
62699527|NCT04039464|ACTIVE_COMPARATOR|Monotherapy with Sildenafil Group|mono-therapy: first-line monotherapy (sildenafil alone) - in pediatric subjects with PAH.
62499846|NCT03025776||stroke|individuals chronic (\> 6 months) post-stroke
62699528|NCT04039464|ACTIVE_COMPARATOR|Duo Therapy with Sildenafil + Bosentan Group|duo-therapy: compare two treatment strategies - first-line combination therapy (sildenafil and bosentan)
62699529|NCT02221726|EXPERIMENTAL|JNJ-35684-AAA-023: 5.5 cm^2 Patch|
62699530|NCT02221726|EXPERIMENTAL|JNJ-35684-AAA-023: 44 cm^2 Patch|
62699531|NCT06332157|EXPERIMENTAL|Remimazolam group|Anesthesia was induced by pump injection of remimazolam besylate at a rate of 6mg/min. Anesthesia was maintained with 1.0-2.0mg/min remimazolam besylate by continuous pump.
62699532|NCT06332157|ACTIVE_COMPARATOR|Propofol group|Anesthesia was induced with propofol injection 2mg/kg intravenously. Anesthesia was maintained by continuous pumping of 6-8mg/kg/h propofol injection.
62699533|NCT03463655||solid cancer in a palliative situation with ascites|Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.
61950912|NCT05026411|OTHER|Orthodontic patients|Magnetic resonance images will be taken from 20 individuals with eating disorders before fixed orthodontic treatment, 12 months of orthodontic treatment and 6 months after orthodontic treatment finished
62699534|NCT03896763|EXPERIMENTAL|Supine / CMV|Supine positioning and conventional mechanical ventilation
62699535|NCT03896763|EXPERIMENTAL|Prone / CMV|Prone positioning and conventional mechanical ventilation
62699536|NCT03896763|EXPERIMENTAL|Supine / HVOF|Supine positioning and high-frequency oscillatory ventilation
62699537|NCT03896763|EXPERIMENTAL|Prone / HFOV|Prone positioning and high-frequency oscillatory ventilation
61950913|NCT01866774|EXPERIMENTAL|Fecal calprotectin level|Fecal calprotectin level
62699538|NCT03132142|EXPERIMENTAL|Capsaicin|Capsacin (8%) patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
62699539|NCT03132142|EXPERIMENTAL|Trans-cinnamaldehyde|Trans-cinnamaldehyde (10%, dissolved in 90% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
62699540|NCT03132142|EXPERIMENTAL|L-menthol|L-menthol (40%, dissolved in 96% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
62699541|NCT03132142|PLACEBO_COMPARATOR|Vehicle patch|Inert vehicle patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
62699542|NCT06122948|ACTIVE_COMPARATOR|(Group M)|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
62699543|NCT06122948|EXPERIMENTAL|(Group MK)|Midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
61950914|NCT01866774|NO_INTERVENTION|Symptom questionnaire|
62499847|NCT03025776||age matched health controls|age matched (double sample size anticipated) healthy controls
62499848|NCT05995379||Derivation cohort|
61950915|NCT03306563|EXPERIMENTAL|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
61950916|NCT03306563|ACTIVE_COMPARATOR|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
61950917|NCT03306563|SHAM_COMPARATOR|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
61950918|NCT02980497|ACTIVE_COMPARATOR|Listerine Zero Mouthwash (without alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Zero Mouthwash (without alcohol) for 30 seconds.
61950919|NCT02980497|ACTIVE_COMPARATOR|Listerine Antiseptic Mouthwash (with alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Antiseptic Mouthwash (with alcohol) for 30 seconds.
61950920|NCT02980497|NO_INTERVENTION|Brush only|Brush only twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush.
61950921|NCT02717520|EXPERIMENTAL|All study participants|One permanent molar with an approximal and occlusal carious lesion restored with EQUIA Forte, and one permanent molar with an approximal and occlusal carious lesion restored with Tetric EvoCeram
61950922|NCT06505174||Use of hydroxypropyl Guar-based artificial tears four times per day|Use of hydroxypropyl Guar-based artificial tears four times per day
61950923|NCT06129175|EXPERIMENTAL|Neuroncell-EX|Umbilical cord-derived mesenchymal stem cells
61950924|NCT06129175|PLACEBO_COMPARATOR|Control|Normal saline
61950925|NCT03190590|ACTIVE_COMPARATOR|Transcranial direct current stimulator (tDCS)|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
61950926|NCT03190590|ACTIVE_COMPARATOR|Transcranial magnetic stimulation (TMS)|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry \[this is not repetitive TMS and so does NOT modulate brain excitability.\]
61950927|NCT03190590|PLACEBO_COMPARATOR|Sham-tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
61950928|NCT03360604|EXPERIMENTAL|Low GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a low glycaemic index. This is the Low Glycaemic Diet intervention.
61950929|NCT03360604|EXPERIMENTAL|High GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a high glycaemic index. This is the High Glycaemic Diet intervention.
61950930|NCT01176383|NO_INTERVENTION|Control group|The control group will have a standard NHS cessation clinic experience
62342365|NCT03814590|EXPERIMENTAL|Group Low Dose_PLAIN_A|Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342366|NCT03814590|EXPERIMENTAL|Group Medium Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342367|NCT03814590|EXPERIMENTAL|Group High Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62499849|NCT05995379||Validation cohort|
62499850|NCT01685216|EXPERIMENTAL|velaglucerase alfa|IV infusion, 60 U/kg, every other week for 1 year
62499851|NCT01427881|EXPERIMENTAL|Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126."
61950931|NCT01176383|EXPERIMENTAL|Respiragene test and risk score|Subjects will have a buccal swab taken at first attendance for a 12 gene test of SNP variants associated with risk of lung cancer. From the genetic data and clinical data (any history of COPD, family history of lung cancer in a first degree relative and age) a risk score is calculated from which a lifetime risk of lung cancer if the subject continues to smoke can be calculated. This is expected to be a powerful motivator to encourage smoking cessation.
61950932|NCT01004965||Group 1|"Samples are obtained: 1) pretreatment, 2) at the time of documentation of refractory disease in acute myeloid leukemia (AML) patients who do not achieve complete response (CR) after induction therapy, and 3) at the time of first relapse in patients who achieve CR.~Marrow cells are preferentially used for all samples, but peripheral blood is acceptable if marrow is not available and the blood contains 20% or more blasts."
61950933|NCT01628133||blood transfusion group|
61950934|NCT06192784|EXPERIMENTAL|DEB-TACE-len-puco|Patients with advanced intrahepatic cholangiocarcinoma who was initially evaluated unsuitable for the radical therapy and received combined DEB-TACE plus lenvatinib (Len) and pucotenlimab as conversion therapy for downstaging.
62141017|NCT03944694||Non-delirious|Patients were delirious if CAM-ICU was negative within 24 hours from admission due to acute ischemic stroke.
62499852|NCT00099580|EXPERIMENTAL|1|
62499853|NCT00099580|PLACEBO_COMPARATOR|2|
62499854|NCT05721469|NO_INTERVENTION|kontrol group|Pretest and posttest application
62499855|NCT05721469|EXPERIMENTAL|experimental group|Art therapy application to the experimental group
62499856|NCT05721469|NO_INTERVENTION|Posttest phase|Applying posttest to the experimental and control groups
62499857|NCT02729207|ACTIVE_COMPARATOR|Esflurbiprofen 1.5% Hydrogel Patch|One patch per 24hr for 7 days
61950935|NCT06313489||Patients with ruptures of Extensor pollicis longus tendon after distal radial fracture|Patients planned for intervention according to the clinical practice. We planned to include all patients that would be treated in out department.
61950936|NCT05246683||cohort|Observational evaluation during the hospital stage on diagnosis, treatment and evolution of patients with cardiogenic shock.
61950937|NCT04843020|EXPERIMENTAL|Drug subcutaneous injection|Monthly injection of ION 682884, administered subcutaneously at a dose of 45 mg.
61950938|NCT02732756|EXPERIMENTAL|Sleep Restriction|The Sleep Restriction condition will allow 6.5 hours in bed, which in previous research results in an average of 6.1-6.3 hours of nightly sleep. This condition reflects a realistic dose of sleep restriction (similar to the school-night sleep of 15-20% of healthy adolescents) that has been shown to be feasible and to induce daytime sleepiness, inattention, and irritability/moodiness in typically developing adolescents.
61950939|NCT02732756|EXPERIMENTAL|Sleep Extension|The Sleep Extension condition will allow adolescents to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep), which (a) is how long adolescents sleep during controlled trials of sleep satiation and naturally on non-school nights, (b) has been shown to result in a well-rested state, and (c) matches clinical recommendations for adolescents.
62699544|NCT06608589|EXPERIMENTAL|Local Services Network (LSN) Alphonse-Desjardins|The local services network (LSN) Alphonse-Desjardins is set in a urban region with the most important community hospital of the greater region of Chaudière-Appalaches. The CoMPAS+ TNCM workshops (intervention) in the LSN Alphonse-Desjardins will be conducted with health professionals and caregiver partners from the FMG of Lévis (GMF-U de Lévis), the home support services team, and the emergency department of the Hotel-Dieu de Lévis. The population that will be recruited to evaluate the impact of the intervention will have either 1) received home care services within the last 6 months before the intervention; 2) visited the emergency department of Hotel-Dieu de Lévis within the last 6 months before the intervention; or 3) consulted with their primary health care team within the last 6 months before the intervention.
61950940|NCT03475823|PLACEBO_COMPARATOR|Placebo control|Inert comparator indistinguishable from active interventions
61950941|NCT03475823|ACTIVE_COMPARATOR|Active control|240 mg ginkgo biloba
61950942|NCT03475823|EXPERIMENTAL|Low dose sideritis scardica|475 mg sideritis scardica
61950943|NCT03475823|EXPERIMENTAL|High dose sideritis scardica|950 mg sideritis scardica
61950944|NCT02021032|EXPERIMENTAL|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
61950945|NCT03989700|EXPERIMENTAL|Low dose|Low dose of thiamin supplementation
61950946|NCT03989700|EXPERIMENTAL|High dose|High dose of thiamin supplementation
61950947|NCT03989700|PLACEBO_COMPARATOR|Placebo|placebo supplementation
62342368|NCT03814590|PLACEBO_COMPARATOR|Group Placebo_A|Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
61950948|NCT02095977|OTHER|participants|all subjects meeting inclusion and none of exclusion criteria
61950949|NCT02579837|NO_INTERVENTION|Usual Screening|Participants randomized to the Usual Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care).
61950950|NCT02579837|EXPERIMENTAL|On-Site Screening|"Participants randomized to the On-Site Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care). However, they will also undergo non-mydriatic ultra-widefield (UWF) retinal imaging (both 100 and 200 degrees) using the Optos 200Tx UWF retinal imaging device in the Ophthalmology Department on the same day as their Diabetes Clinic visit.~Half of this group will by random allocation undergo optical coherence tomography (OCT) using the Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding availability of OCT at the hospital)."
61950951|NCT05693948|EXPERIMENTAL|Serum X|Participants will used serum X twice daily for 12 weeks
61950952|NCT03717246|EXPERIMENTAL|Sleep Smart Latino|Sleep Smart Latino is a sleep hygiene intervention culturally tailored to be consistent with the beliefs, behaviors and needs of urban Latino middle school children and families. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting, and 2 60-minute long home based sessions that involve the student and their caregiver. The intervention focuses on sleep education, including effective sleep hygiene practices, use of electronics and caffeine and their impact on sleep.
61950953|NCT03717246|ACTIVE_COMPARATOR|Basic Sleep Education and Child Health|The basic sleep education and child health condition includes education regarding sleep hygiene , and the effects of sleep on child functioning integrated with additional child health topics such as nutrition, physical activity and safety. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting
61950954|NCT03717246|NO_INTERVENTION|No treatment control|Students randomly assigned to this arm, will receive standard of care , which is no treatment and will not participate in any group sessions.
61950955|NCT05964101|EXPERIMENTAL|Nivolumab|Neoadjuvant treatment stage: Nivolumab 360mg, Carboplatin AUC5+ paclitaxel 100 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with primary tracheal squamous cell carcinoma received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.
61950956|NCT05210673|EXPERIMENTAL|group A|non ERAS pathway
61950957|NCT05210673|ACTIVE_COMPARATOR|group B|ERAS pathway
61950958|NCT05303181|EXPERIMENTAL|Group1|training used Russian Current carrier frequency at 2500-Hz alternating current.
61950959|NCT05303181|EXPERIMENTAL|Group2|training used Russian Current carrier frequency at 3750-Hz alternating current.
62499858|NCT02729207|PLACEBO_COMPARATOR|Placebo comparator|Placebo One patch per 24hr for 7 days
62499859|NCT02400463|EXPERIMENTAL|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
62499860|NCT02751892|EXPERIMENTAL|Active Lifestyle Programme|Supervised exercises for 3 months and motivational interviewing to facilitate physical activity behaviour change. Supervised exercise sessions took place twice per week for the first four weeks. This was tapered off to once per week for the second four weeks. During the last month of the intervention participants continued with the exercise at home and were encouraged to achieve 150min of moderate to vigorous PA per week.
62499861|NCT02751892|NO_INTERVENTION|Standard Care|Received usual care. Was offered the intervention after the completion of the study.
62499862|NCT01040273|EXPERIMENTAL|Experiment|Anesthetics intraarticular injection
62499863|NCT01040273|PLACEBO_COMPARATOR|Placebo|saline intraarticular injection
62499864|NCT01406249|ACTIVE_COMPARATOR|S-1,Cisplatin|
62499865|NCT01406249|EXPERIMENTAL|Capecitabine, Cisplatin|
62499866|NCT04608682|EXPERIMENTAL|Sugammadex group|
62499867|NCT04608682|SHAM_COMPARATOR|control group|
62499868|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:~* Heart Failure~* COPD~* Cancer"
62499869|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:~* Heart Failure~* COPD~* Cancer"
62499870|NCT02335372|EXPERIMENTAL|Multi-Modal Optical Imaging of Cervix|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes before application of 3-6% acetic acid. The clinician will identify all sites required for biopsy according to clinical impression, marking each location on the recorded unpolarized white light image. Topical application of 0.01% proflavine solution will then be applied for 1 minute, after which wide-field imaging in fluorescence mode will be performed. The clinician will then select up to 2 additional sites for biopsy based on the appearance of this wide-field fluorescence image, recording the location of each. The high-resolution microendoscope will then be used to acquire images at all sites selected for biopsy, followed by collection of biopsy specimens.
62499871|NCT04693221|SHAM_COMPARATOR|Control|VNS therapy with randomly-set combination of parameters (similar to current practice)
62499872|NCT04693221|EXPERIMENTAL|Experimental|VNS therapy with set combination of parameters chosen based on the lowest phase lag index
62499873|NCT01611415|EXPERIMENTAL|ipragliflozin|
62499874|NCT01611415|EXPERIMENTAL|furosemide|
62499875|NCT01611415|EXPERIMENTAL|ipragliflozin & furosemide|
62699545|NCT06608589|EXPERIMENTAL|Local Services Network (LSN) Bellechasse|The local services network (LSN) of Bellechasse is set in a rural area. The population requiring urgent medical care are lead to Hotel-Dieu de Lévis (45 km, Alphonse-Desjardins) or Hopital de Montgagny (30 km, Montmagny-L'Islet). The CoMPAS+ TNCM workshops (intervention) in the LSN of Bellechasse will be conducted with health professionals and caregiver partners from the FMG Rive de l'Etchemin (GMF Rive de l'Etchemin) which comprises the organisational merging of 2 medical clinics. Will also participate in the workshops members the home care team. The population that will be recruited to evaluate the impact of the intervention will have either 1) received home care services within the last 6 months before the intervention; 2) visited one of the 2 emergency departments (Hotel-Dieu de Lévis or Hopital de Montmagny) within the last 6 months before the intervention; or 3) consulted with their primary care team within the last 6 months before the intervention.
62499876|NCT03632694|EXPERIMENTAL|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
62499877|NCT03632694|ACTIVE_COMPARATOR|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
62499878|NCT03632694|NO_INTERVENTION|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
62499879|NCT06309784|EXPERIMENTAL|Drill Guidance System|Using a camera based system attached to a standard surgical drill the operating surgeon will use the DGS to drill with the aim of making the drilling more accurate.
62499880|NCT00605150||Patients enrolled|Total number of patients enrolled
62499881|NCT05869916|EXPERIMENTAL|experimental group|"In this study, the Psychological First Aid: A Guide for Field Workers program published by the World Health Organization in 2011 was adapted to the needs and culture of the region/people where the research will be conducted. Psychological First Aid training was given by the psychiatric nurse participating in the study after a two-day training organized by the Psychiatric Nursing Association."
62499882|NCT05869916|NO_INTERVENTION|control group|No interference
62499883|NCT02075840|EXPERIMENTAL|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
62499884|NCT02075840|ACTIVE_COMPARATOR|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
62499885|NCT04171401||Participants post stroke|Severly affected patients in the subacute phase post stroke that are unable to walk without the help of one or two therapists to assist for balance and weight-carrying. Participants were able to sit independently for two minutes. Participants post stroke performed limits of stability testing in sitting, and tests for trunk control and functional balance.
62499886|NCT04171401||Healthy controls|Healthy control subjects who matched patients post stroke for age and gender, and had no limitations to perform measurements. Healthy controls performed limits of stability measurements and a clinical measurements for balance.
62499887|NCT05922709|EXPERIMENTAL|CS12192 Cohort 1|Subjects receive a single dose of 50 mg CS12192 or matching placebo.
62499888|NCT05922709|EXPERIMENTAL|CS12192 Cohort 2|Subjects receive a single dose of 150 mg CS12192 or matching placebo.
62499889|NCT05922709|EXPERIMENTAL|CS12192 Cohort 3|Subjects receive a single dose of 200 mg CS12192 or matching placebo.
62499890|NCT05922709|EXPERIMENTAL|CS12192 Cohort 4|Subjects receive a single dose of 300 mg CS12192 or matching placebo.
61950960|NCT05303181|EXPERIMENTAL|Group3|training used Russian Current carrier frequency at 5000-Hz alternating current.
61950961|NCT05303181|EXPERIMENTAL|Group4|training used Russian Current at different mode.
61950962|NCT03466567|EXPERIMENTAL|Oral semaglutide, ciclosporin, probenecid|Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3.
61950963|NCT03466567|EXPERIMENTAL|Probenecid, oral semaglutide, ciclosporin|Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3.
61950964|NCT03466567|EXPERIMENTAL|Ciclosporin, probenecid, oral semaglutide|Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
61950965|NCT02996578|ACTIVE_COMPARATOR|Solid Matrix - Intervention|"Dietary Supplement: polyphenol rich chocolate bar~17.5g of commercially available dark chocolate will be consumed daily for 8 weeks"
61950966|NCT02996578|ACTIVE_COMPARATOR|Powder Matrix - Intervention|"Dietary Supplement: polyphenol rich cocoa powder~6g of commercially available cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
61950967|NCT02996578|PLACEBO_COMPARATOR|Solid Matrix Intervention - Placebo|"Dietary Supplement: low polyphenol chocolate~17.5g of commercially available, nutritionally similar, dark chocolate will be consumed daily for 8 weeks"
61950968|NCT02996578|PLACEBO_COMPARATOR|Powder Matrix - Placebo|"Dietary Supplement: nutritionally similar low polyphenol cocoa powder~6g of commercially available, nutritionally similar, cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
61950969|NCT04899154|EXPERIMENTAL|Patients with spondyloarthritis (Spa)|
62342369|NCT03814590|EXPERIMENTAL|Group Low Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
61950970|NCT04899154|EXPERIMENTAL|Healthy subjects|
62499891|NCT05922709|EXPERIMENTAL|CS12192 Cohort 5|Subjects receive a single dose of 400 mg CS12192 or matching placebo.
61950971|NCT01173575||Bacterial Infection|All Patients with bacterial infection receiving fosfomycin may be included
62499892|NCT05922709|EXPERIMENTAL|CS12192 Cohort 6|Subjects receive 200 mg CS12192 or matching placebo for 7 days, twice daily (every 12 h) from Day 1 to Day 6, and once on Day 7.
62499893|NCT05922709|EXPERIMENTAL|CS12192 Cohort 7|Subjects receive 300 mg CS12192 or matching placebo, twice daily (every 12 h) from Day 1 to Day 6, and once on Day 7.
62499894|NCT05922709|EXPERIMENTAL|CS12192 Cohort 8|Subjects receive 400 mg CS12192 or matching placebo for 7 days, twice daily (every 12 h) from Day 1 to Day 6, and once on Day 7.
62499895|NCT05922709|EXPERIMENTAL|CS12192 Cohort 9|Subjects receive a single dose 400 mg CS12192 in either the fasted or fed state for two periods.
62499896|NCT05922709|EXPERIMENTAL|CS12192 Cohort 10|Subjects receive a single dose of 600 mg CS12192 or matching placebo.
62499897|NCT00501332|ACTIVE_COMPARATOR|2|
62499898|NCT01601938|EXPERIMENTAL|Selenium|500 mcg of selenium (10mL) daily for 7 days
62499899|NCT01601938|PLACEBO_COMPARATOR|Placebo|Placebo 10 mL (delivered from biosyn) for 7 days
61950972|NCT00515411|ACTIVE_COMPARATOR|Arm A, - Modified DCF|"Drug Dose (mg/m2) Schedule~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments)."
61950973|NCT00515411|ACTIVE_COMPARATOR|ARM B - Parent DCF with G-CSF|"Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg"
61950974|NCT00515411|ACTIVE_COMPARATOR|Arm C - Modifid DCF + Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
61950975|NCT05840783|EXPERIMENTAL|Group A - Open-ended needle|Open ended needle group. Irrigation in this group shall be done using a conventional open-ended needle during root canal therapy
62342370|NCT03814590|EXPERIMENTAL|Group Low Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342371|NCT03814590|EXPERIMENTAL|Group Low Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342372|NCT03814590|EXPERIMENTAL|Group Medium Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62499900|NCT05171660|EXPERIMENTAL|Sintilimab + XELOX + Bevacizumab|Sintilimab + XELOX + Bevacizumab
62499901|NCT05171660|ACTIVE_COMPARATOR|XELOX + Bevacizumab|XELOX + Bevacizumab
62499902|NCT06559774|EXPERIMENTAL|Hastiin Bidziil (Strong Man) intervention|CETA intervention adapted for AI men ages 18-26. Adaptation will take place leading up to implementation of the randomized controlled trial
62499903|NCT06559774|PLACEBO_COMPARATOR|Active Control Group - Vehicle Maintenance|Control condition was selected by the Community Research Council and includes five sessions on basic vehicle maintenance.
62499904|NCT00712244|ACTIVE_COMPARATOR|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.
62499905|NCT00712244|ACTIVE_COMPARATOR|DuoVisc|Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.
62499906|NCT00712244|ACTIVE_COMPARATOR|Healon5|Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.
62499907|NCT00712244|ACTIVE_COMPARATOR|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.
62499908|NCT00348153|EXPERIMENTAL|Adalimumab + corticosteroids + immunosuppressive treatments|Adalimumab 40 mg eow, stable immunosuppression, corticosteroids in 1 mg/kg/Bodyweight (max. 80 mg) and taper
62499909|NCT00348153|ACTIVE_COMPARATOR|immunosuppressive treatment + corticosteroids|corticosteroids upped to 1mg/kg/Bodyweight and taper, stable immunosuppressive treatment
61950976|NCT05840783|EXPERIMENTAL|Group B- side-vented needle|Side vented needle group. Irrigation in this group shall be done using a 30G side-vented needle during root canal therapy
61950977|NCT05840783|EXPERIMENTAL|Group C- Endoactivator|Sonic activation group. In this group, final irrigation during endodontic therapy shall be done using a sonic activation device (Endoactivator)
62342373|NCT03814590|EXPERIMENTAL|Group Medium Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342374|NCT03814590|EXPERIMENTAL|Group Medium Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342375|NCT03814590|EXPERIMENTAL|Group High Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342376|NCT03814590|EXPERIMENTAL|Group High Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342377|NCT03814590|EXPERIMENTAL|Group High Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342378|NCT03814590|PLACEBO_COMPARATOR|Group Placebo_B|Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
62342379|NCT00797069|ACTIVE_COMPARATOR|standard nutritional product|Standard nutritional product not specific for diabetes
62342380|NCT00797069|ACTIVE_COMPARATOR|diabetes specific product|Diabetes specific nutritional product
62342381|NCT00797069|EXPERIMENTAL|Experimental diabetes specific product|Diabetes specific experimental nutritional product
61950978|NCT01406743||EOS™ Acquisition|
62342382|NCT00389103|PLACEBO_COMPARATOR|placebo|
62342383|NCT06258135|ACTIVE_COMPARATOR|Treatment|
62342384|NCT06258135|PLACEBO_COMPARATOR|Placebo|
62342385|NCT05400473|ACTIVE_COMPARATOR|Therapeutic exercise group|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
62342386|NCT05400473|EXPERIMENTAL|Therapeutic exercise group + photobiomodulation|This group will consist of 30 participants. Initially, photobiomodulation will be applied on the cervical region. A low-power infrared laser therapy unit (Therapy XT - ANVISA RDC Standard 185/2001 - DMC, São Paulo, SP, Brazil) will be used to carry out the photobiomodulation protocol. The infrared laser therapy unit to be used has the characteristics: continuous optical output of 100 mW, with a wavelength of 808 nm, beam size area of 0.028 cm2, power density 1.78 W/cm2, with 7 Joules per point, with a duration of 70 seconds of application for each point.For application, the individual will be seated. With the cervical region bare, the therapist will position the tip of the laser therapy unit perpendicularly on each of the 12 predefined points along the cervical region (6 points laterally to the right and 6 points laterally to the left).
62499910|NCT05013723||Intervention|Patients who received casirivimab-imdevimab antibody infusion
62499911|NCT05013723||Control|Matched control group who did not receive MAb, matched on diagnosis date, age, gender and Utah COVID-19 Risk Score
62342387|NCT03119844|EXPERIMENTAL|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
62342388|NCT03119844|EXPERIMENTAL|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
62499912|NCT00499473|EXPERIMENTAL|Stratum 1 (kinase inhibitor therapy)|Non-EIAC patients receive oral sunitinib malate once daily for 4 consecutive weeks followed by 2 weeks of rest.
61950979|NCT03953820|EXPERIMENTAL|Diazepam Buccal Film, Then Diastat Rectal Gel|Participants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
62499913|NCT00499473|EXPERIMENTAL|Stratum 2 (kinase inhibitor therapy)|EIAC \& OSU patients receive oral sunitinib malate as in stratum 1. Patients receive escalating doses of oral sunitinib malate until the maximum tolerated dose (MTD) is determined.
62499914|NCT01298245||Case: diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those with known positive results of diabetic retinopathy
61950980|NCT03953820|EXPERIMENTAL|Diastat Rectal Gel, Then Diazepam Buccal Film|Participants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
62141018|NCT01808352|OTHER|Daily PrEP + coordination of client centered svs|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
62499915|NCT01298245||Control: no diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those without known positive results of diabetic retinopathy
61950981|NCT03953820|EXPERIMENTAL|Diazepam Buccal Film following a High-Fat Meal|Participants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.
61950982|NCT01488370|ACTIVE_COMPARATOR|Glidescope|A device for endotracheal intubation.
61950983|NCT01488370|ACTIVE_COMPARATOR|Storz|A device for endotracheal intubation.
62342389|NCT00243100|EXPERIMENTAL|Arm I|"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and gemcitabine IV over 1-2 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD"
62342390|NCT04839354|EXPERIMENTAL|Arginine Hydrochloride|Arginine is a nutritional supplement in parenteral form
62342391|NCT04839354|PLACEBO_COMPARATOR|Placebo|Normal saline
62342392|NCT03217773|EXPERIMENTAL|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
62342393|NCT03217773|ACTIVE_COMPARATOR|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
62342394|NCT02029352|EXPERIMENTAL|Sinecatechins 10%|Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
62342395|NCT02029352|PLACEBO_COMPARATOR|Placebo|Patients are instructed to apply a thin layer of the placebo ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
62499916|NCT01738217|EXPERIMENTAL|Fluobeam|
62499917|NCT02957578|EXPERIMENTAL|Solo TTD|Placement of tympanostomy tube with Solo TTD
62499918|NCT04228627|ACTIVE_COMPARATOR|Treatment|Intravenous Iron to correct Iron deficiency without anaemia
62499919|NCT04228627|NO_INTERVENTION|Prophylaxis|Usual antenatal care
62499920|NCT06650124|ACTIVE_COMPARATOR|Azathioprine + Prednisolone Arm|Azathioprine + Prednisolone Arm Participants will receive azathioprine (AZA) in combination with prednisolone as part of their treatment regimen.
61950984|NCT01488370|ACTIVE_COMPARATOR|Standard Laryngoscope|A device for endotracheal intubation
61950985|NCT00967603|NO_INTERVENTION|observation|no therapy until progression
61950986|NCT00967603|EXPERIMENTAL|sunitinib|sunitinib until progression or for a maximum of 6 months
62141019|NCT04366024||Observed group|COVID-19 disease patients who were detected by RT-PCR and CT imaging.
62342396|NCT03311399|EXPERIMENTAL|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
62342397|NCT03311399|EXPERIMENTAL|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
62342398|NCT03311399|NO_INTERVENTION|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
62342399|NCT02165033|EXPERIMENTAL|Budesonide/Procaterol 180/10 X 4 puffs|Multiple dose of SYN006 HFA MDI (Budesonide 180ug + Procaterol 10ug/puff), 4 puffs each day for consecutive 7 days
62342400|NCT03863067|EXPERIMENTAL|Lumbar spinal stenosis patients|Epiduroscopy in patients with lumbar spinal stenosis
62342401|NCT01349686|EXPERIMENTAL|Oral intake of fluids|Intake of oral fluids during labour.
62342402|NCT01349686|PLACEBO_COMPARATOR|Fasting|No intake of oral fluids during labour.
62342403|NCT02558556|EXPERIMENTAL|NIRF-LC|"This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.~Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video."
62499921|NCT06650124|ACTIVE_COMPARATOR|Mycophenolate Mofetil + Prednisolone Arm|Mycophenolate Mofetil + Prednisolone Arm Participants will receive mycophenolate mofetil (MMF) in combination with prednisolone as part of their treatment regimen.
62499922|NCT03506841|ACTIVE_COMPARATOR|Cerbrolysin|Preterm infants with gestational age less than 32 weeks at birth will receive once weekly Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections) starting at the corrected postnatal age of 5 months.
62499923|NCT03506841|NO_INTERVENTION|Control|Preterm infants with gestational age less than 32 weeks at birth will receive routine care.
62499924|NCT04995354|EXPERIMENTAL|EGF loaded Hydrogel (Gp I)|30 patients will receive EGF loaded Hydrogel (Intervention 1) to be applied three times a day for 1weeks.
62499925|NCT04995354|ACTIVE_COMPARATOR|Hydrogel alone ( Gp II)|30 patients will receive Hydrogel alone (Intervention 2) to be applied three times a day for 2 weeks.
62499926|NCT04995354|NO_INTERVENTION|Control (Gp III)|30 patients will receive the standard of care treatment (Control) which includes benzydamine mouthwash, increased hydration, topical analgesics and antifungals.
62499927|NCT03971734|EXPERIMENTAL|Arm 1 regadenoson 0.05mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose.~Regadenoson 0.05mg"
62499928|NCT03971734|EXPERIMENTAL|Arm 2 regadenoson 0.1mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
62499929|NCT03971734|EXPERIMENTAL|Arm 3 regadenoson 0.2mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
62499930|NCT03971734|EXPERIMENTAL|Arm 4 regadenoson 0.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
61950987|NCT04337801|EXPERIMENTAL|Acupressure|The acupressure was carried out as two sessions, postpartum second (the first session of intervention) and fourth hours (the second session of intervention). The intervention was applied bilaterally and clockwise (left Pericardium 6, left Large Intestine 4, right Large Intestine 4 and right Pericardium 6) in this study. The acupressure was applied for three minutes in average, one minute for massage and two minutes for pressure per point; with an average of 12 minutes for the whole application. In addition, the pain score of the women was assessed by themselves through the VAS before the intervention (Time 1) and 15 minutes (Time 2) after the intervention at postpartum second hour. Also, it was assessed before the intervention (Time 3) and 15 minutes (Time 4) after the intervention at postpartum forth hour. Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
61950988|NCT04337801|PLACEBO_COMPARATOR|Placebo|The Pericardium 6 and Large Intestine 4 points were slightly touched without pressure to women in the placebo group. Touches were applied to each acupressure point for three minutes similar to the acupressure group, each session of placebo lasted approximately 15 minutes. Similar to the acupressure group, In parallel with the acupressure, the pain score of the women was recorded at the postpartum second hour (Time 1) before intervention and 15 minutes later after intervention (Time 2), and at the fourth hour (Time 3) before intervention and 15 minutes later after intervention (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the researcher.
61950989|NCT04337801|NO_INTERVENTION|Control Group|No intervention was applied to the control group except for the routine nursing care. The data collection process in the control group was conducted in parallel with the acupressure and placebo groups. Pain score of women was recorded prior to intervention in the acupressure and placebo groups. The duration of intervention in the acupressure and placebo groups was 12 minutes and the measurements were repeated 15 minutes after the intervention. The average duration between the first and the second measurements is 30 minutes in the acupressure and placebo groups. In parallel with the acupressure and placebo groups, the current pain score of the women was recorded at the postpartum second hour (Time 1) and 30 minutes later (Time 2), and at the fourth hour (Time 3) and 30 minutes later (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
61950990|NCT01458236|EXPERIMENTAL|BPS-314d-MR|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration.
61950991|NCT01458236|EXPERIMENTAL|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group.
62499931|NCT03971734|EXPERIMENTAL|Arm 5 regadenoson 0.7mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
62714793|NCT05659849|EXPERIMENTAL|Conventional physical therapy with Neuromuscular training|"Physical therapists use a variety of transcutaneous electrical nerve stimulation (TENS) applications to reduce or alleviate pain for individuals with Knee OA. TENS (symmetrical biphasic waveform, frequency 32-50 Hz, pulse width 80 microseconds) for the same amount of time and the same number of days. The TENS electrodes were applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care was taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg.~Neuromuscular training (NEMEX-TJR training program):~(2 times per week for 6 weeks) The neuromuscular training program consists of 3 parts: warming up, a circuit program, and cooling down. The program is performed twice a week for 6 weeks, with each session lasts for 60 minutes."
62499932|NCT03971734|EXPERIMENTAL|Arm 6 regadenoson 1.0mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
62499933|NCT03971734|EXPERIMENTAL|Arm 7 regadenoson 1.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
62499934|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
62499935|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
62499936|NCT04019054|EXPERIMENTAL|Active iTBS, Ventromedial Prefrontal Cortex (vmPFC)|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vmPFC, as determined by position Fpz of the international 10-20 EEG electrode system."
62499937|NCT04019054|PLACEBO_COMPARATOR|Control iTBS, vertex|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vertex, as determined by position Cz of the international 10-20 EEG electrode system."
62499938|NCT04091763|EXPERIMENTAL|Polidocanol foam sclerotherapy|"1. Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the microbubbles of the foam did not disintegrate);~2. Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;~3. Patients treated in a maximum of 3 sessions at 3 weeks intervals;~4. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;~5. In each session more than one hemorrhoid cushion could be treated."
62499939|NCT04091763|EXPERIMENTAL|Rubber band ligation|"1. Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;~2. A maximum of 3 sessions of ligation at 3-week intervals were performed;~3. More than 1 band per session could be applied."
62499940|NCT05714241||Ischemia with non-obstructive coronary artery disease|Patients with INOCA will be defined as those presenting with either stable, chronic symptoms (stable angina or angina equivalent) and/or signs of ischemia on noninvasive testing (i.e.: exercise stress test, stress echocardiography or nuclear imaging) undergoing elective diagnostic CAG and without obstructive coronary artery disease (defined as \<50% diameter stenosis and/or fractional flow reserve \[FFR\]\>0.80 in any major epicardial vessel).
62499941|NCT04664881|NO_INTERVENTION|Control (standard treatment) Group|Participants will receive routine cardiac treatment
62499942|NCT04664881|EXPERIMENTAL|SmartHeart Device Group|In addition to routine cardiac treatment, participants will wear the SmartHeart device
62499943|NCT04509050||Part A|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
62499944|NCT04509050||Part B|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.
62499945|NCT04487964|ACTIVE_COMPARATOR|the conventional therapy according to the MOH protocol.|Patients who are receiving conventional therapy according to the MOH protocol.
62499946|NCT04487964|ACTIVE_COMPARATOR|conventional therapy +Liquorice cap and Boswellia Serrata gum|Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy
62499947|NCT05771935|EXPERIMENTAL|(Group R)|receive radial artery cannulation using ultrasound
62499948|NCT05771935|ACTIVE_COMPARATOR|(Group U)|receive ulnar artery cannulation using ultrasound
62499949|NCT00684944|ACTIVE_COMPARATOR|1|30mg tid TRx0014
62699546|NCT06608589|EXPERIMENTAL|Local Services Network (LSN) Montmagny-L Islet|The local services network (LSN) Montmagny-L'Islet is set in a semi-urban region with a small community hospital. The CoMPAS+ TNCM workshops (intervention) in the LSN Montmagny-L'Islet will be conducted with health professionals and careviver partners from the FMG of Montmagny (GMF de Montmagny) which comprises the organisational merging of 5 different medical clinics in the region. Will also participate in the workshops are healthcare professionals from the home care services team, and from the emergency department of the Hopital de Montmagny. The population that will be recruited to evaluate the impact of the intervention will have either 1) received home care services within the last 6 months before the intervention; 2) visited the emergency department of Hopital de Montmagny within the last 6 months before the intervention; or 3) consulted with their family doctor within the last 6 months before the intervention.
61950992|NCT06474702||study arm|"the investigator will utilize Fitbit-Charge 4 a wearable 'smart-watch' in order to collect patients' physiological measurements, including continuous heart rate, heart-rate variability and breathing rate, as well as behavioral measurements such as movements and sleep pattern in order to predict aggression and violence outburst in children under 12 years old admitted at an inpatient psychiatric ward and characterization of those physiological measures in the prediction of aggression and violence outbursts."
62499950|NCT00684944|ACTIVE_COMPARATOR|2|60mg tid TRx0014
62499951|NCT00093730|EXPERIMENTAL|BMS-59926|
62499952|NCT04815434||Adults with disabilities and complex health conditions|Interviews, experience of the mouth and oral health and function
61950993|NCT04993820|EXPERIMENTAL|Physical Activity (PA)|Combination of aerobic exercise and muscle strengthening exercise.
61950994|NCT04993820|ACTIVE_COMPARATOR|Education Control (CON)|No exercise group.
61950995|NCT01681472|ACTIVE_COMPARATOR|Levoleucovorin 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
61950996|NCT01681472|ACTIVE_COMPARATOR|Levoleucovorin 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
61950997|NCT01681472|EXPERIMENTAL|6R-MTHF 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
61950998|NCT01681472|EXPERIMENTAL|6R-MTHF 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
61950999|NCT04282642|EXPERIMENTAL|Cognitive Training|Computerized Cognitive Training
61951000|NCT04282642|EXPERIMENTAL|WLC|Waitlist Control
61951001|NCT00736944|EXPERIMENTAL|1|"Induction chemotherapy followed by Radiation therapy plus Cisplatin~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42."
61951002|NCT00736944|EXPERIMENTAL|2|"Induction chemotherapy followed by Radiation therapy plus Cetuximab~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB"
61951003|NCT03479970|EXPERIMENTAL|GNPT + Social Cognition|"Experimental Group: will undertake a rehabilitation treatment integrated by a set of tasks aimed at working attention, memory and executive functions together with a computerized treatment for the rehabilitation of the Social Cognition. The treatment will be carried out through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT).~The treatment will consist of the carrying out of 24 treatment sessions"
61951004|NCT03479970|ACTIVE_COMPARATOR|GNPT (only N-SC measures)|Control Group: will only conduct a cognitive rehabilitation treatment through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT) focused on attention, memory and executive functions.
61951005|NCT06013397|EXPERIMENTAL|self pre-and post-control|It is a self pre- and post-control, which compares the outcomes of the ketogenic diet with the status that did not receive ketogenic treatment
61951006|NCT04328766|EXPERIMENTAL|DWP14012 Cohort A|
61951007|NCT04328766|EXPERIMENTAL|DWP14012 Cohort B|
62499953|NCT06458244||HSCT-group|The participants receive HSCT after two-cycle of consolidation treatment.
62499954|NCT06458244||Chemo-group|The participants receive chemotherapy after two-cycle of consolidation treatment.
62499955|NCT01091766|ACTIVE_COMPARATOR|bupivacaine|test solution consists of bupivacaine 0.125%
62499956|NCT01091766|ACTIVE_COMPARATOR|bupivacaine+epinephrine|test solution consists of bupivacaine 0.125% with epinephrine 1:200000
62499957|NCT01091766|ACTIVE_COMPARATOR|epinephrine|test solution consists of epinephrine 1:200000
62499958|NCT04200911|EXPERIMENTAL|RAPA intervention|Sirolimus 1mg orally once a day for 8 weeks
62499959|NCT06222229|EXPERIMENTAL|No-bandaging group|Only general measures will be recommended without the use of external support devices.
62499960|NCT06222229|ACTIVE_COMPARATOR|Bandaging group|functional bandage for 5 days and general measure.
61951008|NCT04328766|EXPERIMENTAL|DWP14012 Cohort C|
61951009|NCT05158465|EXPERIMENTAL|Motivational Interviewing and Assessments|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo. Three one-on-one, half hour educational and skill-building MI sessions will address: proper oral hygiene technique, bacteria and dental caries process, and nutrition. Intervention group adolescents will also receive three calls over one month reinforcing their hygiene behavior goals.
61951010|NCT05158465|NO_INTERVENTION|Assessments Only|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo.
61951011|NCT05116215|EXPERIMENTAL|Hydrogen inhalation|Participants in the gas group will then undergo exposure to 2% H2 in medical air via a high flow nasal cannula for either 1 (n=3), 2 (n=3) or 4 (n=3) hours every day for one month.
61951012|NCT05116215|EXPERIMENTAL|Hydrogen capsules|Participants in capsule group will receive either 1 (n=3), 3 (n=3) or 6 (n=3) capsules every day for one month.
61951013|NCT05116215|EXPERIMENTAL|Hydrogen water|Participants in the water group will be suggested to drink 1 L hydrogen-rich water every day for one month.
61951014|NCT01196507|EXPERIMENTAL|Carvedilol|Tablet Carvedilol 12.5 mg BD or maximum tolerated dose
61951015|NCT01196507|PLACEBO_COMPARATOR|Placebo|Placebo tablets 2 to 4 BD
61951016|NCT00699569|EXPERIMENTAL|1|Patients receiving active investigational product
61951017|NCT00699569|PLACEBO_COMPARATOR|2|Patients receiving Placebo
62499961|NCT04381013|EXPERIMENTAL|Phase 1: Routine surgery|As part of routine cardio-thoracic surgery, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 1 minute.
62499962|NCT04381013|EXPERIMENTAL|Phase 2: ECHO treatment|During care with Extracorporeal Membrane Oxygenation (ECMO) for non-SARS-CoV-2, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 24 hours.
62499963|NCT04381013|EXPERIMENTAL|Phase 3: COVID-19 treatment|Endotracheal tubes split from ventilator delivering oxygen independently to two patients with COVID-19 disease for up to 1 hour.
62499964|NCT02922582|EXPERIMENTAL|DepoTXA 400mg|400mg Intracapsular at the end of surgery one time
62499965|NCT02922582|EXPERIMENTAL|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
62499966|NCT02922582|EXPERIMENTAL|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
62499967|NCT02922582|ACTIVE_COMPARATOR|IV Tranexamic acid (TXA)|1 g of IV TXA at the end of surgery
62499968|NCT02463487|ACTIVE_COMPARATOR|Cardinal Pro + Irrigation (NPWTi)|Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation
62499969|NCT02463487|ACTIVE_COMPARATOR|Cardinal Pro (NPWT) Therapy|Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation
62499970|NCT02476305|EXPERIMENTAL|cryoablation|patients undergo cryoablation procedure for desmoid tumor
62499971|NCT04912986|PLACEBO_COMPARATOR|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
62499972|NCT04912986|EXPERIMENTAL|Experimental group|The intervention was implemented in accordance with the Early Lung Rehabilitation Training Programme for Adult Double Lung Transplant Patients
62499973|NCT02474654|EXPERIMENTAL|Arm 1: PI+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
62499974|NCT02474654|EXPERIMENTAL|Arm 2:NS+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml
62499975|NCT02474654|EXPERIMENTAL|Arm 3: PI+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
62499976|NCT02474654|EXPERIMENTAL|Arm 4: PI+FNB+NS|Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
62499977|NCT02474654|ACTIVE_COMPARATOR|Arm 5:NS+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml
62499978|NCT04621045|EXPERIMENTAL|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
62499979|NCT04621045|ACTIVE_COMPARATOR|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
62499980|NCT03012893|EXPERIMENTAL|Ultrasound transverse scan|Transvers scan by identifying the C7 transvers process using vertebral artery and absence of anterior tubercle as a landmark and then scan back following articular process, lamina and then find out the spinous process of C7
62499981|NCT03012893|EXPERIMENTAL|Ultrasound sagittal scan|Sagittal scan by identifying the first and second ribs and scan medially to depict the C7 transvers process.
62499982|NCT03012893|ACTIVE_COMPARATOR|Floroscopic technique|Fluoroscopy image will do on lateral view including all cervical spines and upper thoracic spines. C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
62499983|NCT04993417|EXPERIMENTAL|Mime Therapy along with EMS|MT Group: Mime Therapy along with EMS
62499984|NCT04993417|EXPERIMENTAL|Motor imagery technique along with EMS|MIT Group: Motor imagery technique along with EMS
62499985|NCT03182751|ACTIVE_COMPARATOR|Tranexamic Acid Arm (TXA)|Subjects will be treated with early administration of TXA in the Emergency Department
62499986|NCT03182751|PLACEBO_COMPARATOR|Control Arm|Subjects will be treated with a placebo in the Emergency Department
62499987|NCT04245293|EXPERIMENTAL|Ainara|Experimental: Ainara Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
62699547|NCT03204812|EXPERIMENTAL|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles for tremelimumab and up to 13 cycles for durvalumab in the absence of disease progression or unacceptable toxicity.
62699548|NCT01150032||Osteopenic women|Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)
62699549|NCT06565247|EXPERIMENTAL|Pre-surgical imaging of high-risk prostate cancer using [18F]PSMA-PET/mpMRI or mpMRI|One-time pre-surgical imaging using \[18F\]PSMA-PET/mpMRI (at Umea University Hosptial) or mpMRI (at Skåne University Hospital)
62699550|NCT05166902|EXPERIMENTAL|Lens A, Then Lens B|Participants will wear lens A for one month and then cross over to wear lens B for one month.
62499988|NCT04245293|ACTIVE_COMPARATOR|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
62499989|NCT05307562|ACTIVE_COMPARATOR|Training program|Global intervallic exercise using cyclometer and analytical strength exercises
62499990|NCT05307562|EXPERIMENTAL|Training program + Inspiratory muscle traioning (IMT)|Global intervallic exercise using cyclometer and analytical strength exercises + inspiratory muscles training
62499991|NCT01705717||cohort|
62499992|NCT00856622|EXPERIMENTAL|Fixed combination of latanoprost 0.005% and timolol 0.5%|
62499993|NCT00856622|ACTIVE_COMPARATOR|timolol 0.5% ophthalmic solution|one drop in the morning and evening
62699551|NCT05166902|EXPERIMENTAL|Lens B, Then Lens A|Participants will wear lens B for one month and then cross over to wear lens A for one month.
62699552|NCT00973128|EXPERIMENTAL|Group 1|Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)
62699553|NCT00973128|ACTIVE_COMPARATOR|Group 2|Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.
62714794|NCT05716451|EXPERIMENTAL|Intervention Group|Mobilization incl. support by the Liana. In the intervention group, Liana is used to train trunk stability in a sitting position. If this is successful, the patient is trained to stand. Mobilization to higher levels is performed according to clinical standards.
62499994|NCT00856622|ACTIVE_COMPARATOR|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
62499995|NCT02767947|EXPERIMENTAL|Luliconazole Cream 1%|Luliconazole cream 1% will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
61951018|NCT06558409|EXPERIMENTAL|Safer Still Intervention|First, we will present parents with suggested alternatives for restricting lethal means, particularly firearms and medications with high toxicity in overdose. We will present multiple options for restricting access as opposed to just one alternative that may be deemed unreasonable by a family. We will generate these options based upon the expertise of our lethal means consultant. Second, our mobile technology platform will provide weekly prompts about means restriction. Parents who have not restricted access to lethal means will be asked to document their reasons for inaction-a justification for not following safe storage practices. Third, our mobile technology platform will provide descriptive normative data (peer comparisons) regarding means restriction to those who have not secured these items. For example, parents will be given information that most other families of adolescents with significant emotional concerns do not have firearms or have utilized gun safety precautions.
61951019|NCT06558409|PLACEBO_COMPARATOR|Enhanced Usual Care (EUC)|Families randomly assigned to the control condition will receive a psychological placebo that will feature an education only website developed by NCH's web design team. This website will cover warning signs for suicide, the leading methods of suicide - so that both conditions have content that features information about firearms - and locating professional help. Like the intervention Safer Still web-based program, the control website will be branded with a Nationwide Children's Hospital affiliation, as opposed to an outside organization that will be less familiar to our central Ohio sample. The control website will NOT feature these three behavioral economic strategies--namely (a) multiple suggested alternatives for means restriction, (b) requests to justify inaction regarding means restriction, and (c) normative feedback about means restriction.
61951020|NCT02615314||BPPV without migraine|Two hundred and sixty-three patients with BPPV (2009-2014), confirmed by videonystagmography (VNG), were enrolled in the study. Patients' charts were reviewed. They were grouped as those with or without migraine. Distribution of gender, age, duration of symptoms and affected side were reviewed. Two hundred and thirty-one patients with no migraine were identified.
62342404|NCT02558556|NO_INTERVENTION|CLC|"This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video.~Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated."
62699554|NCT06564714|EXPERIMENTAL|Early Baclofen treatment group|"Oral baclofen will be started as soon as any sign of acute spasticity consisting of spasms, velocity-dependent hypertonia and/or clonus is observed. Oral baclofen will be initiated the same day as when signs of spasticity are first observed.~Dosage : oral administration of baclofen is started initially at 5 mg three times a day. The dose is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response,"
62342405|NCT06160869|EXPERIMENTAL|ACT Group|Received 90-minutes weekly group sessions of acceptence and commitment therapy plus treatment as usual.
62342406|NCT06160869|ACTIVE_COMPARATOR|Treatment as usual (TAU) group|Will receive the TAU alone
62342407|NCT02843581|EXPERIMENTAL|Cryosurgery and NK immunotherapy|We use comprehensive cryosurgery to destroy big tumors, and use multiple (more than 6 times) NK immunotherapy to destroy small tumors
62342408|NCT02843581|ACTIVE_COMPARATOR|Cryosurgery|We use comprehensive cryosurgery to destroy big tumors
62342409|NCT06468501|EXPERIMENTAL|Price reduction on healthier foods|"* Price reduction of 10% for healthier dishes (based on a score of less than 4 on the UK Nutrient Profile Model (NPM))~* Existing price structure for less healthy dishes (based on a score of 4 or higher on the UK NPM)"
62342410|NCT06468501|EXPERIMENTAL|Price increase to less healthy foods|"* Price increase of 10% for less healthy dishes (based on a score of less than 4 on the UK NPM)~* Existing price structure for healthier dishes (based on a score of 4 or higher on the UK NPM)"
62342411|NCT06468501|EXPERIMENTAL|Combination of price reduction to healthier foods and price increase to less healthy foods|"* Price reduction of 10% for healthier dishes (based on a score of less than 4 on the UK NPM)~* Price increase of 10% for less healthy dishes (based on a score of 4 or higher on the UK NPM)"
62499996|NCT02767947|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream (containing no active ingredient) will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
62499997|NCT03542734||Individuals with SVDs|Individuals with at least one following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
62342412|NCT06468501|PLACEBO_COMPARATOR|Existing price structure (control)|- No changes in prices
62342413|NCT05027516|ACTIVE_COMPARATOR|Rocephine®|ceftriaxone 1g + lidocaine 35mg; intramuscular injection
62499998|NCT03542734||Individuals without SVDs|Individuals without any following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
62499999|NCT05884255|EXPERIMENTAL|Treatment group A|
62500000|NCT05884255|ACTIVE_COMPARATOR|Treatment group B|
62500001|NCT02128516|ACTIVE_COMPARATOR|whey protein|whey protein
62500002|NCT02128516|PLACEBO_COMPARATOR|placebo|placebo
62500003|NCT02128516|EXPERIMENTAL|pea protein|pea protein
62500004|NCT02288351|OTHER|RYGB with mucosal abnormality on EGD|Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
62500005|NCT04522245|PLACEBO_COMPARATOR|Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
62500006|NCT04522245|EXPERIMENTAL|Noom Health Weight Program|
62500007|NCT02440555||patients included|fulfill the self-administered questionnaire.
62500008|NCT04841967|EXPERIMENTAL|TELL Tool Group|Parents in the TELL Tool group will complete a decision support aid that has four interactive, multimedia and multicomponent modules that will be administered digitally. It will take parents about 60 minutes to complete the TELL Tool.
62699555|NCT06564714|OTHER|Control group|"The control group will receive the usual routine care as per which baclofen is prescribed only when acute spasticity becomes severe and problematic.~In the presence of problematic spasticity, oral administration of baclofen is started initially at 5 mg three times a day. The dose is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response."
62699556|NCT06511401|EXPERIMENTAL|PGx Arm|PGX information is provided to clinicals to inform opioid dosing and selection.
62342414|NCT05027516|ACTIVE_COMPARATOR|Rocephine® + Azithromycin|ceftriaxone 1g + lidocaine 35mg intramuscular injection + azithromycin 2g orally
62342415|NCT01170117|PLACEBO_COMPARATOR|Placebo|Control group receiving placebo
62342416|NCT01170117|EXPERIMENTAL|Olanzapine|Group receiving olanzapine
62342417|NCT01895452|EXPERIMENTAL|ALKS 9072, Low Dose|
62342418|NCT01895452|EXPERIMENTAL|ALKS 9072, High Dose|
62342419|NCT05912920|EXPERIMENTAL|gastric band|to do gastric banding use either round ligament or omental flap
62342420|NCT05912920|ACTIVE_COMPARATOR|sleeve gastrectomy|to do sleeve gastrectomy as standard
62342421|NCT04235530||VAS and DVAS|To measure the pain score of patients after surgery
62342422|NCT04224428|PLACEBO_COMPARATOR|Control group|
62342423|NCT04224428|ACTIVE_COMPARATOR|Fexofenadine group|
62342424|NCT06358937|EXPERIMENTAL|Laser Assisted New Attachment Procedure using ND:YAG laser|
62342425|NCT06358937|EXPERIMENTAL|Laser Assisted New Attachment Procedure using diode laser|
62342426|NCT06358937|ACTIVE_COMPARATOR|Scaling and Root Planing using ultrasonic and curettes|
62342427|NCT06345755|EXPERIMENTAL|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-407.
62342428|NCT06345755|PLACEBO_COMPARATOR|Part A: Placebo|Participants will be randomized to receive placebo matched to VX-407.
62342429|NCT06345755|EXPERIMENTAL|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-407. The dose levels will be determined based on the data from Part A.
62342430|NCT06345755|PLACEBO_COMPARATOR|Part B: Placebo|Participants will be randomized to receive multiple doses of placebo matched to VX-407.
62342431|NCT06345755|EXPERIMENTAL|Part C (Optional): Drug-Drug Interaction|Participants will be administered Midazolam (MDZ) in the presence or absence of VX-407. The dose levels will be determined based on the data from Part B.
61951021|NCT02615314||BPPV with migraine|Thirty-two patients (11.4%) with migraine were identified. Diagnosis and classification of migraine and its differentiation from other type of headaches was based on third edition of International classification of headache disorders (ICHD-III beta) by international headache society (IHS). All patients with migraine had migrainous headache with or without aura and they all were diagnosed in our institution and followed by our neurology staff.
61951022|NCT04649320||cancer patients|adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms
61951023|NCT00566995|EXPERIMENTAL|Vandetanib in Participants with Kidney Cancer|300 mg/day (starting dose) oral dose of vandetanib once a day for 28 days
62342432|NCT00934427|ACTIVE_COMPARATOR|Vascana|
62342433|NCT00934427|PLACEBO_COMPARATOR|Vehicle|
62342434|NCT03386331|OTHER|Diet and Exercise|
61951024|NCT03499977|EXPERIMENTAL|Sitting|The participant will be asked to sit for 10 min (not increasing their heart rate) then do the anti-saccade task
61951025|NCT03499977|EXPERIMENTAL|Low-Intensity Cycling|Participant will be asked to cycle for 10 min (\<40% VO2R) and then perform the anti-saccade task
62342435|NCT06483165|EXPERIMENTAL|BE FAST Group|The experimental BE FAST acronym education messaging, including 5 stroke warning signs and a call-to-action to call 911, will be shown to the participants using a brief video.
61951026|NCT03499977|EXPERIMENTAL|Moderate-Intensity Cycling|The participant will be asked to do 10 min of cycling (40-59% VO2R) followed but the anti-saccade task
61951027|NCT03499977|EXPERIMENTAL|High-Intensity Cycling|The participant will be asked to do 10 min of cycling (60%-84% VO2R) followed but the anti-saccade task
61951028|NCT04613050|ACTIVE_COMPARATOR|Group A (Respiratory Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive respiratory training for 6 weeks.
62342436|NCT06483165|ACTIVE_COMPARATOR|F.A.S.T. Group|The comparator F.A.S.T. acronym education messaging, including 3 stroke warning signs and a call-to-action to call 911, will be shown to the participants using a brief video.
62342437|NCT04787588||Hospitalized patients|100 patients hospitalized with Covid-19, and 100 hospitalized controls without Covid-19
62342438|NCT04787588||Mild/Moderate asthma and health controls|20 asthmatic patients, 10 patients with asthma and allergic rhinitis, and 5 healthy controls.
62342439|NCT03137121|EXPERIMENTAL|Olanzapine|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
62342440|NCT03137121|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo orally for 1 to 7 days daily.
62342441|NCT06409091||Medium weight PP mesh|Patients receiving medium weight PP mesh in clean-contaminated and contaminated settings
62342442|NCT06409091||Heavy Weight PP Mesh|Patients receiving heavy weight PP mesh in clean-contaminated and contaminated settings
62342443|NCT04717141|EXPERIMENTAL|Biomecanical evaluation of the selective nerve block effects|"D0 :~* Information, collection of consent, inclusion,~* Clinical and instrumental evaluation,~* Realization of the selective nerve block,~* Post-selective nerve block clinical and instrumental re-evaluation,~* Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
62342444|NCT03444818|EXPERIMENTAL|[14C]-E6007|Participants will receive a single oral dose of 60 milligrams (mg) of \[14C\]-E6007.
62342445|NCT00607958|EXPERIMENTAL|1|dose reduction
62342446|NCT02522832|EXPERIMENTAL|Titre 1|Low infectious titre of innoculum
62342447|NCT02522832|EXPERIMENTAL|Titre 2|Medium infectious titre of innoculum
62342448|NCT02522832|EXPERIMENTAL|Titre 3|High infectious titre of innoculum
62342449|NCT00004418|EXPERIMENTAL|Glyceryl trierucate/glyceryl trioleate|Treatment of all enrolled participants. Dosage form is a liquid oil taken orally. Dose is to provide 20% of daily calories. Daily for duration of trial
62342450|NCT05093257||Group I|age and sex matched healthy control individuals.
62342451|NCT05093257||Group II|available number of ITP patients.
62500009|NCT04841967|ACTIVE_COMPARATOR|eBook Attention-Control|Parents in the eBook attention-control group will complete one interactive, multimedia and multicomponent program that contains information about good parenting principles and is administered digitally. It will take parents about 60 minutes to complete the eBook attention control.
62500010|NCT01132261|ACTIVE_COMPARATOR|1|brain preservation diet
62500011|NCT01132261|NO_INTERVENTION|2|
62500012|NCT06678126|ACTIVE_COMPARATOR|Arm 1i|Adaptive RT \& Standard Bladder Filling Instructions
62342452|NCT03630484|ACTIVE_COMPARATOR|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
62342453|NCT03630484|ACTIVE_COMPARATOR|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
62342454|NCT02786940|EXPERIMENTAL|Live Remote Cardiac Monitoring|Patients in this arm will receive the Cardiophone device, a live remote cardiac monitoring with transmission of cardiac rhythm (device-triggered: if rhythm abnormalities detected by device algorithm; or patient-triggered by pressing the transmit button because of symptoms) for 15 days.
62342455|NCT02786940|ACTIVE_COMPARATOR|Usual Care|Patients in this arm will receive the Mobile Cardiac Telemetry device for 48-hour Holter monitoring as part of usual care. This device combines holter, event monitoring and mobile cardiac telemetry (continuous cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring will be compared to the 15-day live monitoring.
62342456|NCT05343806|ACTIVE_COMPARATOR|Nifedipine|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
62342457|NCT05343806|ACTIVE_COMPARATOR|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
62342458|NCT01951690|EXPERIMENTAL|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
62342459|NCT04253834|ACTIVE_COMPARATOR|Incentive Spirometer Control Arm|Participants assigned to use the incentive spirometer after surgery.
62342460|NCT04253834|EXPERIMENTAL|GO2 Mouthpiece|Participants assigned to use the Bidirectional Oxygenation Valve (GO2 Mouthpiece) after surgery.
62342461|NCT06552715|EXPERIMENTAL|Treatment with hydroxyapatite-based composite|Patients with partially edentulous and atrophic jaws, requiring implant-prosthetic rehabilitation (from 1 to 3 implants), classified as Seibert Class II or III, and needing a GBR bone regeneration intervention with defects not exceeding 7 mm in height. Patients must be 18 years or older and must provide informed consent.
62342462|NCT04012944|EXPERIMENTAL|Cordella™ Pulmonary Artery Sensor System|The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management
62342463|NCT05693090|EXPERIMENTAL|Escalation Cohort|Adult participants with EGFR-mutated Non-Small Cell Lung Cancer
62342464|NCT05693090|EXPERIMENTAL|Expansion Cohort|Adult participants with EGFR-mutated Non-Small Cell Lung Cancer
62342465|NCT02042339|EXPERIMENTAL|Hyperbaric oxygen|Problem-wound schedule: 2.4 atmospheres, 100% oxygen for 90 minutes, two 10 - minute breaks (patients breathing pressurized air from the chamber atmosphere)
62342466|NCT02042339|PLACEBO_COMPARATOR|Sham Hyperbaric oxygen|The patients will be transferred into the chamber like the treatment group. Instead of 100% oxygen they will breathe normal air through the tight fitting masks, at an ambient pressure of 1.1 bar. During the two 10 - minute breaks patients will breathe pressurized air from the chamber atmosphere.
62500013|NCT06678126|ACTIVE_COMPARATOR|Arm 1ii|Adaptive RT and Custom Bladder Filling Instructions
62500014|NCT06678126|ACTIVE_COMPARATOR|Arm 2i|Non Adaptive RT and Standard Bladder Filling Instructions
62500015|NCT06678126|ACTIVE_COMPARATOR|Arm 2ii|Non Adaptive RT and Custom Bladder Filling Instructions
62500016|NCT03866928|EXPERIMENTAL|Stiripentol|
62500017|NCT03394716||Patient brain tumor treated with fractionated radiotherapy|
62500018|NCT06678295|EXPERIMENTAL|Cognitive behavioral therapy|Twelve weekly sessions of individual cognitive behavioral therapy
62500019|NCT01104948|EXPERIMENTAL|DA-8031|
62500020|NCT01104948|PLACEBO_COMPARATOR|Placebo|
62500021|NCT04149535|EXPERIMENTAL|TAVR with Sentinel|Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.
62500022|NCT04149535|NO_INTERVENTION|TAVR without Sentinel|Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.
61951029|NCT04613050|ACTIVE_COMPARATOR|Group B : (Aerobic Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive aerobic training for 6 weeks
62500023|NCT02171897|EXPERIMENTAL|Patients treated with osteosynthesis|
62500024|NCT02171897|EXPERIMENTAL|Patients treated with total hip replacement|
62500025|NCT03501420||Physicians|A sample of 230 to 325 rheumatologists actively involved in management and treatment decisions of pSS subjects in France, Italy, Spain, Germany and the United States will be included in the survey.
62500026|NCT03501420||Subjects with pSS|Subjects with a confirmed diagnosis of pSS under consultation of the rheumatologists enrolled in the study will be included.
62500027|NCT03334045||Stress patients|Patients diagnosed with work-related Adjustment disorder
62500028|NCT03334045||Controls|Healthy controls
62500029|NCT02874196|EXPERIMENTAL|Patients with painful prosthesis|
62500030|NCT02128009||osteoporosis,non-osteoporosis|
62500031|NCT05619822|OTHER|TAU + waiting list|Treatment as usual
61951030|NCT04613050|NO_INTERVENTION|Group C : (control group)|It will include 20 patients of both sexes, recovered from COVID-19 infection on medical drugs only will receive no exercise as control group.
61951031|NCT01330030|EXPERIMENTAL|Drug Selegiline|6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
61951032|NCT01330030|PLACEBO_COMPARATOR|Matching placebo|matching placebo worn 24 hours for 8 weeks
62342467|NCT04944888|EXPERIMENTAL|Experimental Dose 1|"Eliglustat 84mg will be administered once daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs), in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be daily administered every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
62342468|NCT04944888|EXPERIMENTAL|Experimental Dose 2|"Eliglustat 84mg will be administered twice daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), or intermediate metabolizers (IMs), or in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
62342469|NCT02494739|EXPERIMENTAL|Yogurt enriched with polyphenols|Two yogurts (400g) enriched with polyphenols (10mg/100g yogurt) per day, for two weeks.
62342470|NCT02494739|PLACEBO_COMPARATOR|Yogurt not enriched with polyphenols|Two yogurts (400g) not enriched with polyphenols per day, for two weeks.
62342471|NCT05594108|EXPERIMENTAL|Experimental Group|Ultrasound guided IUD insertion
62342472|NCT05594108|NO_INTERVENTION|Control Group|Non ultrasound guided IUD insertion
62342473|NCT03060083|EXPERIMENTAL|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
62342474|NCT03060083|EXPERIMENTAL|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
62342475|NCT02357797|ACTIVE_COMPARATOR|Vortioxetine|Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
62342476|NCT02357797|PLACEBO_COMPARATOR|Placebo|Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.
62342477|NCT05579912||Esophagogastric Surgery Patients|Patients who underwent esophageal and gastric resections requiring an anastomosis from January 2001 to March 2019
62342478|NCT05140395|EXPERIMENTAL|Pre transfusion control|Pre control transfusion with the referent reagent and the in study reagent
62699557|NCT06511401|NO_INTERVENTION|Control Arm|No PGX information provided opioid dosing and selection is according to standard of care.
62342479|NCT00286130|ACTIVE_COMPARATOR|FOLFOX 6|"FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
61951033|NCT01945281|EXPERIMENTAL|Caspofungin|Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
62342480|NCT00286130|ACTIVE_COMPARATOR|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
62342481|NCT02935699|EXPERIMENTAL|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
62342482|NCT02935699|ACTIVE_COMPARATOR|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
62342483|NCT02207478|EXPERIMENTAL|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
62342484|NCT02207478|ACTIVE_COMPARATOR|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
62714795|NCT05716451|NO_INTERVENTION|Control Group|Standard of Care without the use of the Liana. In the control group the therapy is carried out according to the ward standard without using the Liana.
61951034|NCT01945281|ACTIVE_COMPARATOR|Amphotericin B Deoxycholate|Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
61951035|NCT02740556|PLACEBO_COMPARATOR|AdhereTech Passive Monitoring|Patients not using the HepCure patient app while AdhereTech passively monitors adherence (no chimes or reminders).
61951036|NCT02740556|EXPERIMENTAL|HepCure Toolkit|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard with AdhereTech passively monitoring adherence (no chimes or reminders).
61951037|NCT02740556|EXPERIMENTAL|HepCure Toolkit and AdhereTech Active Features|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard and with AdhereTech actively monitoring adherence (chimes and reminders enabled).
61951038|NCT06318429|EXPERIMENTAL|stretching exercise group|stretching exercise group
61951039|NCT06318429|NO_INTERVENTION|control group|control group
61951040|NCT02012283|EXPERIMENTAL|Vegetable Intake with Spices Added|Subjects consuming vegetables with mixed-spices added.
61951041|NCT02012283|ACTIVE_COMPARATOR|Vegetable Intake without Spices Added|Subjects consuming vegetables without spice.
62500032|NCT05619822|EXPERIMENTAL|TAU + A comprehensive third-generation intervention|he protocol will bedeveloped following the three stages of recovery from trauma (Herman, 2015): first, focusing on establishing the therapeutic alliance and safety; second, focusing on recounting and re-processing the traumatic event; and third, focusing on reconnecting with others and with life despite the trauma experienced. The therapy will be administered in 11 90-minute individual sessions per week, combining strategically ACT, Mindfulness, EMDR as well as Positive Psychology interventions.
62500033|NCT02277964||RRMS with treatment change|"All patients with treatment change from natalizumab 300mg iv monthly to fingolimod 0.5mg orally/daily.~16 patients were switched with an interval of 8 weeks until october 2013. After an interims analysis the interval has been changed to 4 weeks (after october 2013)."
62500034|NCT01234324|EXPERIMENTAL|Arm 1: ECX + Panitumumab|
61951042|NCT04639167|EXPERIMENTAL|Paths to everyday life (PEER)|The Paths to everyday life (PEER) intervention added to service as usual (SAU) consists of a 10-week group course and an opportunity of individual companionship to persons with mental vulnerability and mental health difficulties. The 10 week group sessions is facilitated by two volunteer peers with their own lived experiences with mental vulnerability.
61951043|NCT04639167|NO_INTERVENTION|Service as usual (SAU)|Participants who will be allocated to the control group of the trial will receive service as usual (SAU) by their social security officer, or no specific service if the participant has been referred to the trial by self-referral. Participants who are referred to the trial via §82 in the municipality, can receive other §82 offers depending on the individual municipality.
62342485|NCT03901807|EXPERIMENTAL|PMX Treatment|Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)
62342486|NCT03901807|NO_INTERVENTION|Control|Standard medical care alone
62342487|NCT01597037|ACTIVE_COMPARATOR|High complexity, high feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
62342488|NCT01597037|ACTIVE_COMPARATOR|High complexity, low feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
62342489|NCT01597037|ACTIVE_COMPARATOR|Low complexity, high feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
62342490|NCT01597037|ACTIVE_COMPARATOR|Low complexity, low feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
62342491|NCT02278640|OTHER|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
62342492|NCT06020027|EXPERIMENTAL|Intervention Arm|Water is K'é is a family-based intervention aimed at improving health and wellness of family members and of the family as a whole. The multi-level intervention targets change at environmental, community and family levels through three core activities: a lesson plan, social media campaign and water access plan. ECE staff will receive a brief training on the curriculum and its relation to the Navajo Wellness Model before delivering the lessons and posting messages. Four interactive lesson plans will be delivered by ECE staff. Caregiver and family sessions will be delivered at the Head Start / FACE facility or in the home, depending on staff preference.
62342493|NCT06020027|NO_INTERVENTION|Control Arm|"Participants attending an ECE site randomly assigned to waitlist will receive usual programs and services at the site."
62342494|NCT03521193|EXPERIMENTAL|Migraine evaluation in PFO patients|Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Patients will undergo evaluation of platelet reactivity, serotonin and cytokines before PFO closure with a dedicated device and at 6 months follow-up and these results compared to those of a control, group of healthy subjects treated with aspirin alone
62342495|NCT03521193|NO_INTERVENTION|healthy subjects on aspirin treatment|12 healthy subjects on 100 mg aspirin daily will be compared to PFO patients in terms of platelet reactivity, serotonin and cytokines
62342496|NCT04307836|EXPERIMENTAL|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
62342497|NCT04307836|NO_INTERVENTION|Control group|Subjects are not treated with the renal denervation, not sham, after randomization and maintained baseline anti-hypertensive medications
62342498|NCT05811767||The Esbjerg Cohort|This is a cross-sectional study and therefore there is no intervention to describe. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
62342499|NCT06045559||S(Sevoflurane)|Anesthesia induction for all patients will be performed with 2 mg/kg propofol and 2 µg/kg fentanyl. Following loss of eyelash reflex, 1.2 mg/kg rocuronium will be administered intravenously to all patients. Anesthesia will be maintained with sevoflurane, with a BIS value between 40-50 and a minimal alveolar concentration (MAC) value between 1-1.5.
62500035|NCT01234324|ACTIVE_COMPARATOR|Arm 2: EXC alone|
62500036|NCT03844230|OTHER|Inhibition Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
61951044|NCT05510440|EXPERIMENTAL|Effect of citrulline supplementation combined with long distance running on systemic inflammation|14-day protocol of supplementation with 6 g of citrulline.
62699558|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
62699559|NCT03741270|EXPERIMENTAL|Vaccine|
62699560|NCT04102566|NO_INTERVENTION|Standard of care arm|"The standard of care group will group will receive the following regimen while inpatient:~* 2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~* Acetaminophen 1000mg every 8 hours standing~* Oxycodone 5mg PO every 4 hours as needed pain~* Phenazopyridine 100mg TID as needed for urinary burning~* Senna 1 tab every 12 hours~* Miralax 17g powder once daily as needed for constipation~The standard of care group will get the following prescriptions on discharge:~* Oxycodone 5mg every 4 hours as needed pain - 15 tabs~* Acetaminophen 1000mg every 8 hours standing for two days then as needed~* Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~* Senna 1 tab every 12 hours - 10 tabs"
62699561|NCT04102566|EXPERIMENTAL|Multi-modal group|"The multi-modal group will receive the following regimen while inpatient:~* 2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~* Acetaminophen 1000mg every 8 hours standing~* Ibuprofen 600mg every 6 hours standing~* Oxycodone 5mg PO every 4 hours as needed pain~* Phenazopyridine 100mg TID as needed for urinary burning~* Senna 1 tab every 12 hours~* Miralax 17g powder once daily as needed for constipation~* Patient Education (Figures 2 \& 3)~The multi-modal group will receive the following prescriptions on discharge:~* Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs~* Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs~* Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~* Senna 1 tab every 12 hours - 10 tabs"
61951045|NCT05510440|PLACEBO_COMPARATOR|Effect of placebo supplementation combined with long distance running on systemic inflammation|14-day protocol of supplementation with 6 g of placebo.
61951046|NCT02715180|OTHER|Chest computed tomography|Low dose chest computed tomography during expiration and inspiration
62342500|NCT06045559||D(Desflurane)|Anesthesia induction for all patients will be performed with 2 mg/kg propofol and 2 µg/kg fentanyl. Following loss of eyelash reflex, 1.2 mg/kg rocuronium will be administered intravenously to all patients. Anesthesia will be maintained with desflurane, with a BIS value between 40-50 and a MAC value between 1-1.5.
62342501|NCT06045559||P(Propofol)|Anesthesia induction for all patients will be performed with 2 mg/kg propofol and 2 µg/kg fentanyl. Following loss of eyelash reflex, 1.2 mg/kg rocuronium will be administered intravenously to all patients. Propofol was administered intravenously at a rate of 6-12 mg/kg/min to maintain anesthesia, keeping the BIS value between 40-50.
62342502|NCT01259973|EXPERIMENTAL|Risperidone|
62342503|NCT01259973|PLACEBO_COMPARATOR|Placebo|
62342504|NCT01259973|EXPERIMENTAL|Haloperidol|
62342505|NCT04044092|ACTIVE_COMPARATOR|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization, Cervical Spine strengthening exercises
62342506|NCT04044092|EXPERIMENTAL|ELDOA stretching exercise|ELDOA stretching exercise protocol along with Conservative physical therapy
62342507|NCT01969799|EXPERIMENTAL|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.
62342508|NCT01969799|PLACEBO_COMPARATOR|Aerosolized placebo|Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System
62342509|NCT01760824|EXPERIMENTAL|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
62342510|NCT01760824|ACTIVE_COMPARATOR|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days
62342511|NCT04966884|EXPERIMENTAL|A single-arm open-label pilot observational study|Patients were received a glucocorticoids (0.8mg-1mg/kg/day) and a combination with tofacitinib (at a dose of 5 mg twice daily).
62342512|NCT00305253|NO_INTERVENTION|Pre-Intervention|The Pre-Intervention Phase served as the Control / Baseline group.
62699562|NCT06625437|EXPERIMENTAL|Acceptance and commitment therapy|Trial of acceptance and commitment therapy for hiv-positive men who have sex with men
61951047|NCT04075760|EXPERIMENTAL|EUS-guided combined therapy|Patients with endoscopic and EUS documented GOV II and IGV I will be included. Procedure will be performed under general anesthesia using a linear array therapeuthic echoendoscope, coils and cyanoacrylate will be injected within the feeder vessel under EUS and fluroscopic guidance.
62342513|NCT00305253|EXPERIMENTAL|Post-Intervention|Intervention used in this phase and outcomes compared to the Pre-Intervention phase.
62342514|NCT05732844|EXPERIMENTAL|Intervention group with Enna pelvic ball|This group will receive instructions on how to carry out PFMT daily at home, and indications for the placement of Enna pelvic ball vaginal spheres daily.
62342515|NCT05732844|ACTIVE_COMPARATOR|Control group|This group will receive instructions on how to carry out PFMT daily at home.
62342516|NCT04026854||Psychiatric nurses|Nurse with a degree in the state or psychiatric sector. Work in a psychiatric ward that offers full hospitalization, a day hospital (HdJ) or a medico-psychological center (CMP).
62342517|NCT01887587|EXPERIMENTAL|(modified VXLD) plus MLN9708|"Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22~Dexamethasone- 10 mg/m2 orally or IV on days 1-14~Doxorubicin- 60 mg/m2 on day 1 by IV bolus.~MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.~For patients without central nervous system (CNS) involvement:~* Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)~* Methotrexate 12 mg administered intrathecally on day 8~For patients with CNS involvement:~-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day))."
62342518|NCT00511342|EXPERIMENTAL|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC
62342519|NCT00511342|ACTIVE_COMPARATOR|LNG-EE|Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC
62342520|NCT05759845|ACTIVE_COMPARATOR|topiramate group|50 patients will take topiramate
62342521|NCT05759845|ACTIVE_COMPARATOR|amitriptyline group|50 patients will take amitriptyline
62342522|NCT05759845|ACTIVE_COMPARATOR|combination group|50 patients will take topiramate plus amitriptyline
62342523|NCT01114373|ACTIVE_COMPARATOR|Melatonin|Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
61951048|NCT04075760|PLACEBO_COMPARATOR|Beta Blocker (Propranolol)|o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose will be increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication will be attempted if cessation of the medication did not result in improvement of the reported side-effect.
62342524|NCT01114373|PLACEBO_COMPARATOR|Placebo|Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.
62342525|NCT01451034|ACTIVE_COMPARATOR|WHYX cancer group|WHYX cancer diagnosed by pathologic report
62342526|NCT01451034|PLACEBO_COMPARATOR|non-WHYX cancer group|all cancer except WHYX cancer diagnosed by pathologic report
62342527|NCT02590523|EXPERIMENTAL|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
62342528|NCT02590523|EXPERIMENTAL|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
62342529|NCT02590523|PLACEBO_COMPARATOR|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
62342530|NCT04061252|EXPERIMENTAL|KHK4827 210mg Q2W SC|
62342531|NCT04061252|PLACEBO_COMPARATOR|Placebo Q2W SC|
62342532|NCT00907582|EXPERIMENTAL|ASCT in relapsed APL|autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission
62342533|NCT01393756|EXPERIMENTAL|Lenalidomide dose 25 mg|
62342534|NCT01954472|EXPERIMENTAL|Enhanced Portfolio plus structured exercise|Diet: The dietary portfolio advice: to limit saturated fat to \<7% of total calories and cholesterol to \<200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
62342535|NCT01954472|ACTIVE_COMPARATOR|High fiber diet plus routine exercise|A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
62342536|NCT03117062|EXPERIMENTAL|Occlusal Reduction|performing occlusal reduction on functional cusps until abscence of contact was confirmed
62342537|NCT03117062|NO_INTERVENTION|non-occlusal reduction|occlusal surface left intact
61951049|NCT00990405|EXPERIMENTAL|Lansoprazole+Clarithromycin+Amoxycillin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
61951050|NCT02040493|EXPERIMENTAL|Intra-operative radiation therapy (IORT)|IORT
61951051|NCT03928496|EXPERIMENTAL|Abobotulinumtoxina|300 units of abobotulinumtoxinA was reconstituted with 2.4 ml of 0.9% preservative free sterile saline so that each 0.1 ml contained 12.5 units of Abobotulinumtoxina 0.1 ml were injected into 31 sites of the head and neck
62164514|NCT02879669|EXPERIMENTAL|ONCOS-102+cyclophosphamide+pemetrexed/cisplatin (carboplatin)|ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
62342538|NCT04869904||Patients with Alzheimer's disease|
62342539|NCT04869904||patients without Alzheimer's disease|
62342540|NCT00987012|EXPERIMENTAL|Pomegranate juice|
62342541|NCT00987012|PLACEBO_COMPARATOR|Placebo drink|
62342542|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
62342543|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
62342544|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
62342545|NCT06386809|EXPERIMENTAL|TAVNS group|
62342546|NCT06386809|OTHER|Exercise group|
62342547|NCT04853043|EXPERIMENTAL|Cetuximab|
62342548|NCT03930641|EXPERIMENTAL|RTH258|brolucizumab 6 mg in a prefilled syringe
62342549|NCT03520816|EXPERIMENTAL|Burn Physiotherapy Protocol Group|Patients in the treatment group have been received to the physiotherapy programme from the first day of their stay in the hospital.
62342550|NCT03520816|NO_INTERVENTION|Control Group|The control group consisted of patients who could not receive physiotherapy due to various reasons.
62342551|NCT01124448|EXPERIMENTAL|Lactobacillus salivarius PS2|Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
62342552|NCT01124448|ACTIVE_COMPARATOR|Lactobacillus salivarius PS2B|Lactating women without mastitis (n=15)
62342553|NCT03765255|EXPERIMENTAL|In the Know (ITK): sexual health education|Cohorts/participants in the experimental (treatment) arm receive an intervention that combines 6 hours of in-person sexual health and adolescent development education with an app that includes a resource locator, text message reminders (for one month), goal setting, and other resources.
62342554|NCT03765255|NO_INTERVENTION|Control: do not receive ITK intervention|Cohorts/participants in the no intervention arm do not receive either the in-person education or the app. However, after completing the 10 month survey, they will have access to the app and will be invited to participate in the in-person program after the study implementation phase is completed (years 4 and 5).
62342555|NCT01011452|ACTIVE_COMPARATOR|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
62342556|NCT01011452|PLACEBO_COMPARATOR|Placebo|
62342557|NCT02430428|EXPERIMENTAL|VisuMax lenticule removal|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
62342558|NCT02836860|OTHER|Healthy Controls|Effects of tactile stimulation on lumbar multifidus activation in healthy adults without LBP.
62500037|NCT03844230|OTHER|Stimulation Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Stimulation, Experimental I- Stimulation, Experimental II -Stimulation). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
62500038|NCT01067794||pemetrexed + platinum|Patients with pemetrexed + platinum doublet, with or without additional targeted agents
62500039|NCT01067794||gemcitabine + platinum|Patients with gemcitabine + platinum doublet, with or without additional targeted agents
62500040|NCT01067794||taxanes + platinum|Patients with taxanes + platinum doublet, with or without additional targeted agents
62500041|NCT01067794||vinorelbine + platinum|Patients with vinorelbine + platinum doublet, with or without additional targeted agents
62500042|NCT01067794||others + platinum|Patients with other platinum-based doublet, with or without additional targeted agents
62500043|NCT02299687|EXPERIMENTAL|CYP2C19 EM|CYP2C19 EM
62500044|NCT02299687|EXPERIMENTAL|CYP2C19 IM|CYP2C19 IM
62500045|NCT02299687|EXPERIMENTAL|CYP2C19 PM|CYP2C19 PM
62500046|NCT03904836|EXPERIMENTAL|Tobramycin|Subjects with end-stage renal disease who have been involved in an intermittent hemodialysis program and who have suspected or diagnosed Gram-negative rod-type infection
62500047|NCT03111667|EXPERIMENTAL|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
62500048|NCT03111667|OTHER|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
62500049|NCT03111667|EXPERIMENTAL|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
62500050|NCT03111667|ACTIVE_COMPARATOR|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
62141020|NCT04065399|EXPERIMENTAL|Revumenib|"Phase 1: Oral revumenib; sequential cohorts of escalating dose levels of revumenib to identify the MTD and RP2D. Participants will be enrolled in 1 of 6 dose-escalation arms:~* Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole~* Arm B: Participants receiving any strong CYP3A4 inhibitors for antifungal prophylaxis~* Arm C: Participants receiving revumenib and cobicistat~* Arm D: Participants receiving fluconazole for antifungal prophylaxis~* Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers~* Arm F: Participants receiving isavuconazole for antifungal prophylaxis~Phase 2: Oral revumenib; Following the determination of the RP2D in Phase 1, 3 indication-specific expansion cohorts will be enrolled as follows:~* Cohort 2A: Participants with KMT2Ar ALL/MPAL~* Cohort 2B: Participants with KMT2Ar AML~* Cohort 2C: Participants with NPM1m AML"
62141021|NCT02944123|OTHER|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.
62500051|NCT03111667|NO_INTERVENTION|Administrator Participants: Environment|School Administrators will provide data about the school environment.
62500052|NCT03111667|NO_INTERVENTION|School Staff Participants: Environment|Staff will provide data about the school environment
62500053|NCT03772756|EXPERIMENTAL|EUS-RFA group|Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy
62500054|NCT03772756|ACTIVE_COMPARATOR|control group|the control group will receive chemoradiotherapy only
62500055|NCT04590339|ACTIVE_COMPARATOR|Repositioning the bone window|Computer guided inferior alveolar nerve lateralization and implant placement with subsequent repositioning of the osteotomized bone window.
62500056|NCT04590339|ACTIVE_COMPARATOR|Augmentation using sticky bone|Computer guided inferior alveolar nerve lateralization and implant placement with grafting around the implant using sticky bone
62699563|NCT06641713||TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then conventional TACE or drug-eluting TACE was used.
62699564|NCT06641713||HAIC|HIAC was conducted with hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin every 3-4 weeks.
62141022|NCT02944123|EXPERIMENTAL|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
62141023|NCT02944123|EXPERIMENTAL|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
62500057|NCT04547179|EXPERIMENTAL|BLAfit® usage|In this arm, subjects will used the fixed orthotic device called BLAfit® for one minute of facial exercise a day for three months.
62500058|NCT04547179|EXPERIMENTAL|fremanezumab-vfrm|Subjects in this arm will receive three Ajovy® (fremanezumab-vfrm) injections at the start of month 2. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
62500059|NCT04547179|PLACEBO_COMPARATOR|Saline injection|This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
62500060|NCT05402917||Thoracic Epidural Analgesia (TEA)|For patients undergoing TEA is done under general anesthesia after surgery procedure.Once the catheter is secured, a bolus dose of 15 ml of 0.25% bupivacaine will be administered as an epidural injection through the catheter, followed by a continuous infusion of 0.125% bupivacaine at a rate of 0.1 mL/kg/h for the postoperative 24-hour period.
62500061|NCT05402917||Erector Spina Plan Block (ESPB)|For patients undergoing ESPB is done under general anesthesia after surgery procedure.A bolus dose of 15 mL of 0.25% bupivacaine will be administered from the inserted catheter. Subsequently, 0.125% bupivacaine will be given continuously at a rate of 0.1 mL/kg/h for up to 24 hours post-operatively.
62500062|NCT01353716|EXPERIMENTAL|Cohort 1|Healthy subjects matched to the renal impaired subjects by gender, age and body mass index to the renal impaired subjects. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
62500063|NCT01353716|EXPERIMENTAL|Cohort 2|Subjects with severe renal impairment. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
62500064|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
62141024|NCT01439906||Adult degenerative scoliosis|Patients aged 40-75 years affected by lumbar or thoraco-lumbar degenerative kyphoscoliosis presenting chronic low back pain from six months at least and/or neurological deficits who underwent a surgical correction of the deformity
62141025|NCT02432898||Normal Healthy Eyes|Normal healthy eyes with no known ocular diseases
62141026|NCT03510052|OTHER|Diet Modification Pilot Program|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
62342559|NCT02836860|OTHER|Low Back Pain|Effects of tactile stimulation on lumbar multifidus activation in adults with LBP.
62342560|NCT05471245|EXPERIMENTAL|angiographic evaluation|QCA at 9 months
62342561|NCT06101524|EXPERIMENTAL|Free Gingival greft Group|"Patients who are found to have keratinized mucosa insufficiency as a result of the examination, undergo free gingival graft to increase the keratinized mucosa. procedures will be done and you will be called for a check-up after 6 months.~The keratinized tissue volume formed after the procedure will be evaluated."
62342562|NCT06101524|EXPERIMENTAL|Gingival Unit Greft Group|"Patients who are found to have keratinized mucosa insufficiency as a result of the examination, undergo gingival unit graft to increase the keratinized mucosa. procedures will be done and you will be called for a check-up after 6 months.~The keratinized tissue volume formed after the procedure will be evaluated."
62342563|NCT04597281|EXPERIMENTAL|Mediterranean lifestyle|Mediterranean lifestyle, including dietary advice and physical activity advice. In addition, families receive extra-virgin olive oil and fish and two sessions of physical activity per week, for free.
62342564|NCT04597281|NO_INTERVENTION|Usual care|General care by their pediatricians.
62342565|NCT01981278|EXPERIMENTAL|Treatment A|Tapentadol ER 250-mg tamper-resistant formulation (TRF) tablet will be administered as a single oral dose under fasted condition.
62342566|NCT01981278|EXPERIMENTAL|Treatment B|Tapentadol ER 250-mg prolonged-release formulation 2 (PR2) tablet will be administered as a single oral dose under fasted condition.
62342567|NCT04903184|EXPERIMENTAL|Group RUTI|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
62342568|NCT04903184|PLACEBO_COMPARATOR|Group Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
62342569|NCT01999855|ACTIVE_COMPARATOR|control group|"* the Phonatory Maximum Time~* Vocal Handicap Index~* Scale GRBAS of Hirano~* Videolaryngoscopy"
62342570|NCT01999855|EXPERIMENTAL|Asthmatic patients|"* The Phonatory Maximum Time~* Vocal Handicap Index~* Scale GRBAS of Hirano~* Videolaryngoscopy"
62342571|NCT02899117|EXPERIMENTAL|Yoga intervention|Patients in the yoga intervention group will have 4 yoga sessions with a certified yoga instructor while they are in the cancer clinic or on the inpatient floor.
62342572|NCT05534204|ACTIVE_COMPARATOR|Silk suture|Silk suture is a multifilament suture, used for surgical sides closure.
62342573|NCT05534204|ACTIVE_COMPARATOR|Polyester suture|Polyester suture is a monofilament suture, used for surgical sides closure.
62342574|NCT03312712||Participants with sarcoidosis|"* Bronchoscopy, BAL collection, and PFTs\* \[SoC\] \*if required~* Screening, research and safety bloods~* Dynamic 18F-FDG PET/CT scan"
62342575|NCT03312712||Healthy volunteers|"Part A:~* PFTs~* Screening, research and safety bloods~* Dynamic 18F-FDG PET/CT scan~Part B:~* PFTs~* Screening, research and safety bloods~* Baseline and post challenge Dynamic 18F-FDG PET/CT scans~* LPS/saline challenge"
62342576|NCT04704895|ACTIVE_COMPARATOR|Arm A: Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
62342577|NCT04704895|EXPERIMENTAL|Arm B: Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
62342578|NCT04627116|EXPERIMENTAL|Tecarfarin 10mg|
62500065|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
62500066|NCT00050076|EXPERIMENTAL|MCC-135 50 mg BID|
62342579|NCT04627116|EXPERIMENTAL|Tecarfarin 20mg|
62342580|NCT04627116|EXPERIMENTAL|Tecarfarin 30mg|
62342581|NCT04627116|EXPERIMENTAL|Tecarfarin 40mg|
62342582|NCT01885078|EXPERIMENTAL|4 milligram (mg) Baricitinib|"4 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
62342583|NCT01885078|EXPERIMENTAL|2 mg Baricitinib|"2 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
62500067|NCT00050076|EXPERIMENTAL|MCC-135 100 mg QD|
62500068|NCT00050076|EXPERIMENTAL|MCC-135 200 mg QD|
62500069|NCT00050076|PLACEBO_COMPARATOR|Placebo|
62500070|NCT04791956|EXPERIMENTAL|Prebiotic|Inulin-type fructans
62500071|NCT04791956|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62500072|NCT06662617|ACTIVE_COMPARATOR|Group M-TAPA|Patients had bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
62500073|NCT06662617|ACTIVE_COMPARATOR|Group TAP|Patients had bilateral TAP block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
62500074|NCT01705002|EXPERIMENTAL|Cohort A: Promitil 0.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62500075|NCT01705002|EXPERIMENTAL|Cohort B: Promitil 1.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62500076|NCT01705002|EXPERIMENTAL|Cohort C: Promitil 1.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62500077|NCT01705002|EXPERIMENTAL|Cohort D: Promitil 2.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62500078|NCT01705002|EXPERIMENTAL|Cohort E: Promitil 2.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62500079|NCT01705002|EXPERIMENTAL|Cohort F: Promitil 3.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62342584|NCT01885078|EXPERIMENTAL|2 mg Baricitinib Step-down|"2 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
62342585|NCT01885078|EXPERIMENTAL|4 mg Baricitinib Step-down|"4 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
61951052|NCT03928496|PLACEBO_COMPARATOR|Placebo|0.9% preservative free sterile saline. 0.1 ml were injected into 31 sites of the head and neck
61951053|NCT05814289|OTHER|Healthy young adults group|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
61951054|NCT04944420|EXPERIMENTAL|Intervention|"Intervention group will have access to Health enSuite Caregivers, an e-health program designed to meet some of the most common needs of caregivers of persons with dementia, including information about dementia and dementia care, caregivers' emotional health, formal or informal help received from others. It also recommends specific strategies to promote well-being and provides tools to help caregivers implement these strategies in their everyday lives.~Health enSuite Caregivers is designed to offer advice to caregivers of persons with dementia based on an assessment of their specific needs. Topics are divided into five main content areas, which are recommended based on an assessment of the caregivers current challenges and sources of stress."
62342586|NCT01220934||Cohort|
62342587|NCT06382337|EXPERIMENTAL|Group A :immediate dental Implants cases with ice-cream cone technique in type 2 socket|immediately placed implants in which the socket defect will be treated utilizing ice cream cone technique by Dennis Tarnow using collagen membrane , allograft bone graft and custom healing abutments
62342588|NCT06382337|EXPERIMENTAL|Group B : immediate dental Implants cases with the vestibular socket therapy in type 2 socket|8 immediately placed implants in which the socket defect will be treated utilizing vestibular socket therapy technique using cortical lamina , allograft , bone tacks for fixation and custom healing abutment
62342589|NCT04883658|EXPERIMENTAL|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(2) - A single oral dose of 1 tablet under fasting condition"
62342590|NCT04883658|EXPERIMENTAL|Sequence 2|"Period 1: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
61951055|NCT04944420|NO_INTERVENTION|Waitlist Control|Participants in the control group will be wait-listed and receive only treatment as usual from their healthcare providers during the study. After their participation is the study has ended, participants in the control group will be given access to the full Health enSuite Caregivers program.
61951056|NCT04511546|EXPERIMENTAL|BPET Scan|
61951057|NCT02060123|EXPERIMENTAL|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
61951058|NCT02060123|OTHER|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
61951059|NCT03345914|EXPERIMENTAL|Group 1|Participants will receive dupilumab, dosing regimen 1
61951060|NCT03345914|EXPERIMENTAL|Group 2|Participants will receive dupilumab, dosing regimen 2
61951061|NCT03345914|EXPERIMENTAL|Group 3|Participants will receive matching placebo
61951062|NCT01289080|ACTIVE_COMPARATOR|Group 1|subjects with normal renal function
62342591|NCT01252342|EXPERIMENTAL|Intramyometrial oxytocin|
62342592|NCT01252342|PLACEBO_COMPARATOR|Intramyometrial Saline|
61951063|NCT01289080|ACTIVE_COMPARATOR|Group 2|severely renally impaired subjects
61951064|NCT03916991|EXPERIMENTAL|Neuromuscular Exercise|Neuromuscular Exercise
61951065|NCT03916991|NO_INTERVENTION|Control|No intervention
62500080|NCT01705002|EXPERIMENTAL|Cohort G: Promitil 3.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62500081|NCT01705002|EXPERIMENTAL|Cohort H: Promitil 4.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
62500082|NCT01705002|EXPERIMENTAL|Expanded Cohort|"Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.~Only for mCRC patients."
62500083|NCT01705002|EXPERIMENTAL|Combination Cohort|"Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.~Only for mCRC patients."
62500084|NCT01705002|EXPERIMENTAL|Triple combination Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.~Only for mCRC patients."
62699565|NCT00509288|EXPERIMENTAL|anti-MART-1 F5 TCR PBL + HD IL-2|Patients treated with peripheral blood lymphocytes (PBL)
62699566|NCT00509288|EXPERIMENTAL|anti-MART-1 F5 TCR TIL + HD IL-2|Patients treated with TIL (tumor infiltrating lymphocytes).
62699567|NCT06565286|ACTIVE_COMPARATOR|inner preputial graft|managemet of proximal penile hypospadias in 2stage using inner preputial graft in the first stage
62699568|NCT06565286|ACTIVE_COMPARATOR|transverse preputial island flap|managemet of proximal penile hypospadias in 2stage using transverse preputial island flap in the first stage
62342593|NCT01578057|EXPERIMENTAL|tasimelteon + placebo ethanol|
61951066|NCT03916991|SHAM_COMPARATOR|Sham Exercise|Sham Exercise
61951067|NCT05451225|EXPERIMENTAL|Targeted Educational Campaign (TEC) for Correction Officers|The investigators will implement a Targeted Educational Campaign (TEC) within 3 jails. The TEC is designed to lead to referrals of detainees (previously not detected as having potential mental health concerns) to Correctional Health Services (CHS) by Correction Officers.
61951068|NCT01404858||Patients undergoing IVF|
61951069|NCT05013489|EXPERIMENTAL|Mindfulness, compassion and intercare based Intervention|An Eight week mindfulness and intercare group online program.
62141027|NCT03629171|EXPERIMENTAL|Treatment (CPX-351, venetoclax)|"INDUCTION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and on days 1 and 3 of cycle 2. Participants also receive venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
61951070|NCT05013489|NO_INTERVENTION|Waiting list|Psychological support if needed. No other intervention.
61951071|NCT02985372|EXPERIMENTAL|Acute myeloid leukemia|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
61951072|NCT03081533|EXPERIMENTAL|Circle Dance Program (CircleCare)|Caregivers (n=20) allocated to the experimental group will participate in 12-week CircleCare twice a week (24 sessions), for 60 min each session. The planning and conduction of the intervention will be the responsibility of the researcher, a Fitness Professional with training in Circle Dance, called focalizer.
62342594|NCT01578057|EXPERIMENTAL|ethanol + placebo tasimelteon|
62342595|NCT01578057|EXPERIMENTAL|tasimelteon + ethanol|
62342596|NCT01578057|EXPERIMENTAL|placebo tasimelteon + placebo ethanol|
62342597|NCT00432094|EXPERIMENTAL|2 Transplants/1 Transplant (Overall)|"2 Transplants: Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.~1 Transplants:Patients with Germ cell tumors who receive one transplant only."
62342598|NCT04600050|ACTIVE_COMPARATOR|Control group: stroke patients with education|
62342599|NCT04600050|EXPERIMENTAL|Experimental: stroke patients with exercise|
62342600|NCT03093961|EXPERIMENTAL|Intervention|IASD Implantation
62342601|NCT03011580|EXPERIMENTAL|Immediate supplementation arm|"Fultium-D3 (oral cholecalciferol or vitamin D3) will be given at a dose of 9,600 IU/day for 8 weeks (three capsules once daily as each Fulitium D-3 capsules contains 3,200 IU vitamin D3). Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it.~All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study."
62342602|NCT03011580|PLACEBO_COMPARATOR|Delayed supplementation arm|Oral placebo will be given for 8 weeks at a dose of three capsules once daily. Fultium-D3 and placebo will be identical in appearance and taste. Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it. All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study.
62141028|NCT04276506|EXPERIMENTAL|information booklet group|information session before the coronary angiography
62141029|NCT04276506|EXPERIMENTAL|music group|music session before the coronary angiography
62342603|NCT06400316|NO_INTERVENTION|Standard Care|This 'control' group will receive standard care following a flare of rheumatoid arthritis.
62342604|NCT06400316|EXPERIMENTAL|Nutritional Supplementation|This 'intervention' group will receive a 4-week intervention involving twice daily consumption of amino acid supplements.
62342605|NCT03786237|EXPERIMENTAL|Treatment Oral Capsules / Intravenous|
62342606|NCT01814488|EXPERIMENTAL|allogenic transplant|The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias. Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.
62500085|NCT01705002|EXPERIMENTAL|3 Weekly Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.~Only for mCRC patients."
62500086|NCT01495715|EXPERIMENTAL|Idebenone|
62500087|NCT01495715|PLACEBO_COMPARATOR|Placebo|
62699569|NCT03924895|EXPERIMENTAL|Arm A: Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.
62699570|NCT03924895|ACTIVE_COMPARATOR|Arm B: Surgery alone|Participants receive standard of care surgery alone.
62699571|NCT03924895|EXPERIMENTAL|Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.
62699572|NCT04345614|EXPERIMENTAL|Auxora|Patients will be randomized 1:1 to receive either Auxora or placebo
62699573|NCT04345614|PLACEBO_COMPARATOR|Placebo|Patients will be randomized 1:1 to receive either Auxora or placebo
62699574|NCT05280054|EXPERIMENTAL|AV-101|AV-101 360 mg oral capsules single dose
62699575|NCT05280054|EXPERIMENTAL|AV-101 + Probenecid|AV-101 360 mg oral capsules + 1000 mg Probenecid
62699576|NCT02040909|EXPERIMENTAL|Propofol|A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg
61951073|NCT03081533|NO_INTERVENTION|Control group|Caregivers (n=20) of this group will not receive the intervention, participating only in the assessment protocol. They will be instructed not to initiate any regular exercise program during the study period. At the end of the study, the same CircleCare applied to the experimental group will be offered to the interested of the control group.
61951074|NCT00489138|EXPERIMENTAL|1|Noradrenalin infusion
61951075|NCT00489138|NO_INTERVENTION|2|No adrenalin infusion
61951076|NCT04446000|EXPERIMENTAL|CSL730 (dose 1 with premedication)|administered as a single dose by subcutaneous (SC) injection or by SC infusion
61951077|NCT04446000|EXPERIMENTAL|CSL730 (dose 2 with premedication)|administered as a single dose by SC injection or by SC infusion
61951078|NCT04446000|EXPERIMENTAL|CSL730 (dose 3 with premedication)|administered as a single dose by SC injection or by SC infusion
61951079|NCT04446000|EXPERIMENTAL|CSL730 (dose 1 without premedication)|administered as a single dose by SC injection or by SC infusion
61951080|NCT04446000|EXPERIMENTAL|CSL730 (dose 2 without premedication)|administered as a single dose by SC injection or by SC infusion
61951081|NCT04446000|EXPERIMENTAL|CSL730 (dose 3 without premedication)|administered as a single dose by SC injection or by SC infusion
61951082|NCT04446000|EXPERIMENTAL|CSL730 (dose 4 without premedication)|administered as a single dose by SC injection or by SC infusion
61951083|NCT04446000|EXPERIMENTAL|CSL730 (dose 5 without premedication)|administered as a single dose by SC injection or by SC infusion
61951084|NCT04446000|EXPERIMENTAL|CSL730 (dose 6 without premedication)|administered as a single dose by SC injection or by SC infusion
61951085|NCT04446000|EXPERIMENTAL|CSL730 (dose 7 without premedication)|administered as a single dose by SC injection or by SC infusion
61951086|NCT04446000|PLACEBO_COMPARATOR|Placebo|A solution matching the excipient profile of CSL730 without the active substance administered as a single dose by SC injection or by SC infusion
61951087|NCT03751696|EXPERIMENTAL|Group coaching|There will be a total of 4 sessions of group coaching intervention within 8 weeks. Each session is in a group of 5-6 women and lasts for approximately 1-1.5 hours. The sessions will be conducted by experienced social workers online.
61951088|NCT03751696|ACTIVE_COMPARATOR|SMS Self-help tips|The participants in the control group will receive four self-help tips on mental well-being on the same schedule as the group coaching group.
61951089|NCT04669652|NO_INTERVENTION|ICSI|Traditional microinjection (ICSI) is performed on oocytes.
61951090|NCT04669652|EXPERIMENTAL|Piezo-ICSI|Microinjection (ICSI) is performed using the Piezo-ICSI technique.
61951091|NCT04087265|OTHER|Study Population (All Participants)|Patients who are referring for scheduled screening colonoscopy
61951092|NCT02010710|EXPERIMENTAL|Decison support|"Decision-support - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time."
61951093|NCT02010710|NO_INTERVENTION|No Decision Support|"No decision-support - CTGs with no additional interpretation (UK standard care),"
61951094|NCT04779814||Cohort 1|Demipulse®/Aspire HC® (30 adult subjects)
61951095|NCT04779814||Cohort 2|Demipulse®/Aspire HC® (30 pediatric subjects)
61951096|NCT04779814||Cohort 3|Aspire SR® (30 adult subjects)
61951097|NCT04779814||Cohort 4|Aspire SR® (30 pediatric subjects)
61951098|NCT04779814||Cohort 5|SenTiva® (30 adult subjects)
61951099|NCT04779814||Cohort 6|SenTiva® (30 pediatric subjects)
61951100|NCT03841812|EXPERIMENTAL|Propofol|5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.
62141030|NCT04276506|NO_INTERVENTION|control group|No information or music session before the coronary angiography
62500088|NCT04499482|EXPERIMENTAL|Foods containing 10 g soy flour|Participants will receive foods containing 10 g of soy flour to be consumed everyday for one week. If they tolerate the dose, they will receive the next dose without any wash-out period.
62500089|NCT04499482|EXPERIMENTAL|Foods containing 20 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week. If they tolerate the dose, they will receive the next dose without any wash-out period.
62500090|NCT04499482|EXPERIMENTAL|Foods containing 30 g soy flour|Participants will receive foods containing 30 g of soy flour to be consumed everyday for one week.
61951101|NCT03841812|EXPERIMENTAL|Propofol & Sevoflurane|2mg/kg/h Propofol \& 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia
61951102|NCT06177522|EXPERIMENTAL|Adebrelimab combined with chemotherapy administration group|Adebrelimab is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Pharmaceutical. It can block the PD-1/PD-L1 pathway leading to tumor immune tolerance through specific binding of PD-L1 molecules, and reactivate the anti-tumor activity of the immune system, so as to achieve the purpose of tumor treatment.
61951103|NCT01769807|EXPERIMENTAL|CPAP treatment|67 consecutive male patients with OSA were recruited: 36 with mild-moderate OSA and 31 with severe OSA. Data were collected in all subjects at baseline and after 1 month of CPAP.
61951104|NCT01577368|EXPERIMENTAL|Piperacillin continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours
61951105|NCT01577368|ACTIVE_COMPARATOR|Piperacillin intermittent infusion|Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours
61951106|NCT03461978|OTHER|10 patients with meibomian gland dysfunction|
61951107|NCT03461978|OTHER|10 patients with cataract|
61951108|NCT03461978|OTHER|10 patients after minimally invasive glaucoma surgery (MIGS)|
61951109|NCT03461978|OTHER|10 patients after partial corneal transplantation|
61951110|NCT03461978|OTHER|5 patients with demodicosis|
61951111|NCT03461978|OTHER|5 patients with conjunctival pathologies|
61951112|NCT03461978|OTHER|5 patients with Acanthamoeba keratitis|
61951113|NCT03461978|OTHER|5 patients with aniridia|
61951114|NCT04286399|OTHER|Intensive Treatment Group|High dose of RAASi and beta-blockers (unless contraindicated) as well as preferential use of SGLT2i as per local drug label guidelines on top of standard therapy.
62141031|NCT02561195|EXPERIMENTAL|Low-dose C. difficile Vaccine (accelerated schedule)|
62141032|NCT02561195|EXPERIMENTAL|High-dose C. difficile Vaccine (accelerated schedule)|
62141033|NCT02561195|PLACEBO_COMPARATOR|Placebo (accelerated schedule)|
62500091|NCT04068987||Healthy Volunteers|"Healthy volunteers~1. Recruited from the public~2. Patients who have scheduled imaging scans for non-cardiac reasons and without a prior history or suspected history of cardiac disease"
62500092|NCT04068987||Children undergoing clinically indicated cardiac MRI|Patients who are scheduled to have a clinically indicated cardiac MRI
62500093|NCT05740553|EXPERIMENTAL|Training First|
62500094|NCT05740553|EXPERIMENTAL|Training Second|
62500095|NCT01158807||HHT- Brain Arteriovenous Malformation|"1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and~2. Presence of Brain Arteriovenous Malformation"
62500096|NCT01158807||HHT -NO BAVM|1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
62500097|NCT03079427|ACTIVE_COMPARATOR|Capecitabine|Adjuvant Capecitabine
62500098|NCT03079427|EXPERIMENTAL|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
62500099|NCT06574139|EXPERIMENTAL|Unstained|
62500100|NCT06574139|SHAM_COMPARATOR|Like|
62500101|NCT03561987||Obese patients and bariatric surgery|"The investigators include men and women, over 18 years old, with morbid obesity and candidates for bariatric surgery, under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
62699577|NCT06455033|ACTIVE_COMPARATOR|Study Group|30 patients with chronic obstructive pulmonary disease
62699578|NCT06455033|ACTIVE_COMPARATOR|Control group|30 patients with chronic obstructive pulmonary disease
62699579|NCT04961593||Treatment group|Children treated with caspofungin in the pediatric intensive care unit
62699580|NCT05537376|EXPERIMENTAL|SUPPORT|Veterans receiving SUPPORT will be offered all modules of the intervention via weekly, 50-minute sessions with a Peer Specialist. Following the completion of a mental health evaluation by a licensed professional, the Peer Specialist leads the Veteran who is at risk for suicide through recovery planning that is tailored to the Veteran's suicidal experiences with cognitive learning strategies to enhance recall of the Veteran's safety plan and improve recovery.
62141034|NCT02561195|EXPERIMENTAL|Low-dose C. difficile Vaccine (non-accelerated schedule)|
62342607|NCT04284020|EXPERIMENTAL|Educational program & pelvic floor muscle training|"The educational strategy will consist of explaining a healthy lifestyle guide with videos, mobile apps and activities about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, high impact sports, constipation, smoking, or drinking too much caffeine and alcohol. They will also instruct in toilet habits.~The pelvic floor muscle training (PFMT) protocol will be applied. Participants will perform exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
62500102|NCT03561987||No obese patients and abdominal surgery|"The investigators include men and women, over 18 years old, without obesity and candidates for abdominal surgery (hernioplasty, cholecystectomy, fundoplication), under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
62500103|NCT03375749|EXPERIMENTAL|Standing Desk Intervention|Each participant allocated to the experimental group will receive a low-cost, cardboard, fixed-height standing desk converter (https://oristand.co/) that will be placed in their regular office environment, along with their usual sitting desk. The participants will be instructed on how to use the fixed-height standing desk converter (herein referred to as standing desk) as a way to break up sitting time every 30 minutes. In addition, each participant will be provided with information about the health benefits of breaking up sitting time.
62500104|NCT03375749|OTHER|Waitlist Control|Control group participants will not encounter any changes to their regular office environment. They will be provided with the standing desk and behaviour change strategies 6-months post-intervention.
62500105|NCT06214637|PLACEBO_COMPARATOR|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
62500106|NCT06214637|EXPERIMENTAL|Melissa officinalis 6 CH|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. This concentration that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
62500107|NCT06214637|EXPERIMENTAL|Melissa officinalis 9 CH|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. This concentration that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
62699581|NCT05537376|NO_INTERVENTION|ESC|The enhanced standard care (ESC) condition contains the elements of standard practice suicide prevention delivered at VHA, which include: 1) suicide risk assessment, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, and 4) Suicide Prevention Coordinator follow-up contacts. It is enhanced due to the contact with the research study.
62699582|NCT01441492|EXPERIMENTAL|No Drains|Patients who will not receive intraperitoneal drainage following pancreas resection.
62699583|NCT01441492|EXPERIMENTAL|Drains|Patients who will receive drains, the standard of care treatment, following pancreas resection.
62141035|NCT02561195|EXPERIMENTAL|High-Dose C. difficile Vaccine (non-accelerated schedule)|
62141036|NCT02561195|PLACEBO_COMPARATOR|Placebo (non-accelerated schedule)|
62500108|NCT06214637|EXPERIMENTAL|Melissa officinalis 12 CH|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. This concentration that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
62500109|NCT03768817||Patients treated with triheptanoin|Patients with LC-FAOD treated with triheptanoin before 01 September 2018 under eIND
62500110|NCT04164758|EXPERIMENTAL|Drug - pimavanserin|Pimavanserin 34 mg provided as 2 x 17 mg encapsulated tablets
62500111|NCT04164758|PLACEBO_COMPARATOR|Placebo|Placebo encapsulated tablet
62500112|NCT04164758|ACTIVE_COMPARATOR|Quetiapine|Immediate release Quetiapine encapsulated tablets
62500113|NCT03869294||LAPC or MPC patients with GS first-line chemotherapy|
62500114|NCT01350596|ACTIVE_COMPARATOR|Reference Drug|
62500115|NCT01350596|ACTIVE_COMPARATOR|Test Drug|
62500116|NCT04309162|EXPERIMENTAL|soft tissue therapy|Soft tissue therapy includes various techniques which is usually done by manipulating the soft tissues. The techques like stroking, petrissage, percussing maniulations are proved helpful in managing various painful conditions. The main effect of the soft tissue therapy is enhanced blood circulation to the area. When the techniques of soft tissue therapy are applied they will results in stretching and rubbing the muscular tissue which results in increased venous flow to heart and removal of the lactic acid accumulation occurs as the fresh supply of blood to the area will increased. Endorphins the natural pain relievers are released as there is improved oxygenation and perfusion of oxygen in tissues.
62500117|NCT01663467|ACTIVE_COMPARATOR|Ginkgo biloba only|control group Ginexin-F 80mg tablet will be given twice a day for 6 months.
62500118|NCT01663467|EXPERIMENTAL|Ginkgo biloba + modified TRT|"experimental group modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
62500119|NCT03749915|ACTIVE_COMPARATOR|Comparator: Ametop only|Ametop Gel applied as sole topical anesthetic.
62500120|NCT03749915|EXPERIMENTAL|Intervention: Pain Ease Cold Spray|Pain Ease Cold spray applied immediately before IV insertion, as an adjunct to Ametop Gel.
61951115|NCT04286399|NO_INTERVENTION|Control Group|Standard therapy where the use of SGLT2i at randomization is not encouraged but RAASi and beta-blockers (except for maximal dosage) are allowed. Prescription or up-titration of the study drugs listed under Intensive Treatment is not encouraged. If investigators/treating physicians feel that further prescription or up-titration is required, a thorough justification is mandatory. Unless there is clinically irrefutable reason, every attempt should be made to use other blood pressure lowering drugs than RAASi or beta-blockers, as well as glucose lowering drugs than SGLT2i, in the control group.
61951116|NCT05234996|ACTIVE_COMPARATOR|virtual reality|In The VRE arm, patients will use Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics. During the entire experience, an operator dedicated to patient care will be present to allow the most possible comfortable experience.
61951117|NCT05234996|ACTIVE_COMPARATOR|control arm|In control arm, patients will entertain themselves with conventional means such as listening to music, watching a mobile program, reading newspapers, books, magazines or also doing nothing, according to the patient's preferences
61951118|NCT00158574|PLACEBO_COMPARATOR|Placebo|IPTi placebo
61951119|NCT00158574|EXPERIMENTAL|Sulphadoxine-pyrimethamine|IPTi SP
61951120|NCT00158574|EXPERIMENTAL|Mefloquine|
61951121|NCT00158574|EXPERIMENTAL|Chlorproguanil dapsone|
61951122|NCT02560909|EXPERIMENTAL|Experimental|The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.
62500121|NCT01858922|EXPERIMENTAL|Rapid Early Responders|All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients with rapid early response (RER) determined by FDG-PET/CT scan after two cycles of ABVE-PC will receive two more cycles of ABVE-PC. If subsequent PET/CT scan indicates a complete response (CR), therapy will stop and regular follow-up will begin. If the subsequent PET/CT for RER patients indicates a partial response, those patients will undergo IFRT.
62500122|NCT01858922|EXPERIMENTAL|Slow Early Responders|"All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients determined to have a slow early response (SER) determined by PET/CT scan after two cycles of ABVE-PC will receive 2 courses of DECA. If after PET/CT, the patient has a partial or complete response, then 2 additional courses of ABVE-PC will be given. If subsequent PET/CT scan indicates PR or CR, those patients will then undergo IFRT.~If stable or progressive disease is found at either PET/CT scan, the patient will be taken off-study and follow up will begin."
62500123|NCT01236495|EXPERIMENTAL|spinal morphine 0.2 mg|spinal morphine 0.2 mg
62500124|NCT01236495|ACTIVE_COMPARATOR|spinal morphine 0.3 mg|spinal morphine 0.3 mg
62500125|NCT03874026|EXPERIMENTAL|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
62500126|NCT02266940|EXPERIMENTAL|200mg DS-1971a oral suspension fasted|200 mg DS 1971a given as oral suspension in fasted condition
62500127|NCT02266940|EXPERIMENTAL|200 mg DS-1971a tablet fasted|single 200 mg DS 1971a oral tablet in fasted condition
61951123|NCT02560909|ACTIVE_COMPARATOR|Control|The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.
61951124|NCT00747656||1|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and not eligible for bypass based on transport time
61951125|NCT00747656||2|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and eligible for bypass based on transport time, if 12 lead PHECG was possible
61951126|NCT00747656||3|12 lead ECG subjects with prehospital notification transported to nearest receiving ED adn not eligible for bypass to PCI center based on transport time
61951127|NCT00747656||4|12 lead PHECG subjects with prehospital notification bypassed past the nearest receiving ED to the PCI center.
61951128|NCT05956691|EXPERIMENTAL|Investigation|"Dosing Instructions~1. Brush teeth with water (no toothpaste).~2. Scrub tongue with warm, wet, washcloth from the back to the front until most of the white/yellow biofilm on the tongue is gone.~3. Gargle and swish hot (optimal 120°F) water for 10-20 seconds. Spit out and repeat gargling over the next 5 minutes. The tongue should be red and without any biofilm. If it is not, repeat Step 2, and gargle once more.~4. Self-administer one lozenge. Let the lozenge slowly melt in the mouth. Do not chew or swallow whole. This may take up to 60 minutes. Discard if it is not fully dissolved after 60 minutes.~5. Wash the washcloth to be ready before next use."
61951129|NCT05956691|ACTIVE_COMPARATOR|Control|"Dosing Instructions~1. Microwave: heat the product in 5 second increments until soft. (Caution: more than 10 seconds of microwaving the product may cause it to burn).~2. Cut: cut the product into smaller pieces~3. Swallow: swallow without chewing the pieces with warm water while they are still warm. It can be swallowed over time or at once."
61951130|NCT05817643|ACTIVE_COMPARATOR|Dose Under Fed Condition|Investigational Drug is administered with a meal
62699584|NCT03514576|EXPERIMENTAL|Pasireotide75|75 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
61951131|NCT05817643|ACTIVE_COMPARATOR|Dose Under Fasted Condition|Investigational Drug is administered after fasting
61951132|NCT02933723|EXPERIMENTAL|Blood draw- adjuvanted TIV|individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw
61951133|NCT02933723|ACTIVE_COMPARATOR|Blood draw - nonadjuvanted TIV|individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw
61951134|NCT02021773|EXPERIMENTAL|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
61951135|NCT02021773|EXPERIMENTAL|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
61951136|NCT02021773|PLACEBO_COMPARATOR|Placebo|Subcutaneous Placebo Administered Monthly x 3
61951137|NCT02939430|ACTIVE_COMPARATOR|Control|Reversal of neuromuscular blockade will be performed using classic drugs (neostigmine 80 mic/kg and atropine 40 mic/kg)
61951138|NCT02939430|EXPERIMENTAL|Sugammadex group|Reversal of neuromuscular blockade will be performed using Sugammadex 2mg/kg
61951139|NCT04562688|EXPERIMENTAL|Arm A|Participants assigned to Arm A will engage in CICADAS app only for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period. Participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician.
61951140|NCT04562688|EXPERIMENTAL|Arm B|Participants assigned to Arm B will engage in PEERS + CICADAS for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
61951141|NCT04562688|EXPERIMENTAL|Arm C|Participants assigned to Arm C will engage in PEERS + Active Comparator for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
61951142|NCT06085378|EXPERIMENTAL|Urinary Kallidinogenase for injection|Patients in this arm will be given urinary kallidinogenase for injection, 0.15 peptide nucleic acids(PNA), once a day for 10 days
61951143|NCT06085378|PLACEBO_COMPARATOR|Placebo|An inactive substance identical in appearance to the urinary kallidinogenase for injection, once a day for 10 days
61951144|NCT03300284||Thyroid cancer|This study does not involve any intervention, but rather data collection on patient and physician preferences and beliefs, communication, and patient psychological outcomes.
61951145|NCT02321410|OTHER|Imaging of carotid plaque|Patient undergo contrast enhanced ultrasound of the carotid plaque and dynamic contrast-enhanced carotid plaque MRI
61951146|NCT00633750|EXPERIMENTAL|Tarceva|
61951147|NCT02423759|ACTIVE_COMPARATOR|ciprofloxacin|standard chemoprophylaxis \[500mg ciprofloxacin twice daily for 3 days\]
62699585|NCT03514576|EXPERIMENTAL|Pasireotide150|150 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
61951148|NCT02423759|EXPERIMENTAL|ciprofloxacin and gentamycine|Augmented Chemoprophylaxis \[standard chemoprophylaxis plus 160mg\]
62500128|NCT02266940|EXPERIMENTAL|200 mg DS-1971a tablet fed|single 200 mg DS 1971a oral tablet given in fed condition
62699586|NCT06034340|EXPERIMENTAL|Lidocaine-epinephrine-tetracaine (LET) Gel After and Without STAR Particle Application|Children, adolescents, and young adults will receive local anesthesia with lidocaine-epinephrine-tetracaine (LET) gel via different methods on different arms. One arm will have STAR particles used prior to LET gel and the other arm will have aloe gel applied prior to LET gel.
61951149|NCT02423759|EXPERIMENTAL|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
61951150|NCT01544283|EXPERIMENTAL|Patch|Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
62699587|NCT05558579|NO_INTERVENTION|Patients Using Sling|Patients will continue using shoulder sling per standard of care
62699588|NCT05558579|EXPERIMENTAL|Patients Without Sling|Patients will not use shoulder sling postoperatively.
61951151|NCT01544283|ACTIVE_COMPARATOR|Subacromial Injection|A single injection will be administered into the subacromial space utilizing triamcinolone acetonide at the baseline visit.
61951152|NCT02527161|OTHER|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
61951153|NCT00727636|EXPERIMENTAL|Gardasil vaccine - Prospective Study|Prospective study participants received the Gardasil vaccine during the study
62500129|NCT05502055||LGBTQ+_PD|Individuals who identify as LGBTQ+ and are diagnosed with PD
61951154|NCT00727636|NO_INTERVENTION|Retrospective Study|Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider
62699589|NCT06633393|EXPERIMENTAL|Experimental Arm|At baseline and six months, feedback on ophthalmic examination results and future high myopia risk at 18 years of age using the myopia prediction system
62699590|NCT06633393|ACTIVE_COMPARATOR|Control Arm|At baseline and six months, feedback on ophthalmic examination results.
62699591|NCT06641635|EXPERIMENTAL|Experimental group|Radiotherapy +Concurrent Chemotherapy or Immunotherapy Experimental
62699592|NCT06641635|ACTIVE_COMPARATOR|Control group|Radiotherapy +Concurrent Chemotherapy or Immunotherapy Standard of Care
62699593|NCT01353729|EXPERIMENTAL|Treatment A|Treatment A will include combination of zanamivir 600 mg IV plus placebo for moxifloxacin
62699594|NCT01353729|EXPERIMENTAL|Treatment B|Treatment A will include combination of zanamivir 1200 mg IV plus placebo for moxifloxacin
61951155|NCT05499715|EXPERIMENTAL|ScTIL injection|In the dose escalation of the study, starting with the dose of injection of 5x10\^9. If there is no DLT, followed by the second dose of 1.0x10\^10 until the third dose of 2.0x10\^10.
61951156|NCT02662829|EXPERIMENTAL|Community-based intervention (CBI)|"1. Nurse training and mentorship in TB prevention using clinical algorithm based on national guidelines.~2. Health education using a treatment literacy curriculum for parents and guardians.~3. Community outreach by trained village health workers."
62699595|NCT01353729|EXPERIMENTAL|Treatment C|Treatment C will include zanamivir placebo plus placebo for moxifloxacin
62699596|NCT01353729|EXPERIMENTAL|Treatment D|Treatment D will include moxifloxacin plus zanamivir placebo
62699597|NCT06327425|EXPERIMENTAL|Patients with atrial tachycardia|Patients with atrial tachycardia will receive dynamic ECG, MCG and cardiac electrophysiologic examinations.
62699598|NCT06327425|EXPERIMENTAL|Patients with atrial flutter|Patients with atrial flutter will receive dynamic ECG, MCG and cardiac electrophysiologic examinations.
62699599|NCT01532739|EXPERIMENTAL|Cognitive training|
62699600|NCT01532739|NO_INTERVENTION|No cognitive training|
62699601|NCT03601026|EXPERIMENTAL|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
62699602|NCT03601026|NO_INTERVENTION|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
62699603|NCT05206929|EXPERIMENTAL|Arm 1|Arm 1 will receive instruction to use pain and discomfort as the safe limits for their upper limb use during daily activities at post operative discharge.
61951157|NCT02662829|ACTIVE_COMPARATOR|Standard of Care (SOC)|At SOC clinics, patients will receive usual care for management of contact tracing, screening, and IPT provision. Childhood TB in Lesotho is managed by nurses in health centers. Per national guidelines, TB patients are asked to bring in child contacts, who are screened using a simple symptom questionnaire. Children who screen negative are assessed for IPT eligibility. Absent contra-indications (eg, active hepatitis, regular alcohol consumption, peripheral neuropathy), nurses counsel children and guardians on IPT benefits, potential side effects, and importance of adherence. Children requiring chest x-rays or gastric lavage and HIV-infected children under age 1 are referred to the hospital. After initiation, patients and guardians return to the clinic monthly for monitoring for side effects, TB symptoms, adherence, and 30-day supply of isoniazid. If adherence problems are noted, the nurse counsels patient and guardian as appropriate.
61951158|NCT02692274||Primary Health care clinics|A survey of 100 primary Health care clinics was carried out
62342608|NCT04284020|ACTIVE_COMPARATOR|PFMT group|"They will receive a basic behavioral educational strategy in the first session including pelvic anatomy and physiology, recommendations to avoid risk factors and toilet habits.~The PFMT protocol will be applied. Participants will perform PFMT exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
62342609|NCT01257919|EXPERIMENTAL|Azelaic Acid Foam 15%|Dermal application of Azelaic Acid Foam 15%
62342610|NCT01257919|ACTIVE_COMPARATOR|Azelaic Acid Gel 15%|Dermal application of Azelaic Acid Gel 15%
62342611|NCT01963208|EXPERIMENTAL|Double Blind - Cohort 1 - Ganaxolone|1200 mg/day and 1800 mg/day + AED
62699604|NCT05206929|ACTIVE_COMPARATOR|Arm 2|Arm 2 will receive the standard sternal precautions at time of post operative discharge.
62342612|NCT01963208|PLACEBO_COMPARATOR|Double Blind - Cohort 1 - Placebo|Placebo + AED
62342613|NCT01963208|EXPERIMENTAL|Open Label - Ganaxolone in Double-blind phase|1800 mg/day + AED
62342614|NCT01963208|EXPERIMENTAL|Double Blind - Cohort 2 - Ganaxolone|1800 mg/day + AED
62342615|NCT01963208|PLACEBO_COMPARATOR|Double Blind - Cohort 2 - Placebo|Placebo +AED
62342616|NCT01963208|EXPERIMENTAL|Open Label - Placebo in Double-blind phase|1800 mg/day + AED
62699605|NCT01580787|EXPERIMENTAL|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
62699606|NCT01580787|ACTIVE_COMPARATOR|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
62342617|NCT00883220|EXPERIMENTAL|Self-management of urinary catheter|Intervention: Self-management group--teaching behavioral approaches(awareness, self-monitoring, and self-management) to prevent or minimize urinary catheter complications.
62342618|NCT00883220|NO_INTERVENTION|Usual care 2|Usual care for urinary catheter. Home care and/or clinic care is the usual care for people with long-term urinary catheters.
62342619|NCT04981574|EXPERIMENTAL|A group: neck pain|
61951159|NCT02692274||Pregnant and breast feeding women|208 patients were recruited from nine clinics that participated in the survey for evaluation of the accuracy of results produced by the HIV rapid test.
61951160|NCT06558305||Patients on cDMARDS|
61951161|NCT06558305||Patients on janus kinase (JAK) inhibitors|
61951162|NCT06558305||Control|
61951163|NCT00797771|EXPERIMENTAL|A|"Adi insulin pump users"
62342620|NCT04981574|EXPERIMENTAL|B group: low back pain|
62342621|NCT05783193|EXPERIMENTAL|TGIR (Traditional Gastrointestinal Remedy)|TGIR (500mg/capsule), 1.0g (2 capsules)
62342622|NCT05783193|PLACEBO_COMPARATOR|Control (Microcrystalline cellulose)|Placebo control (2 capsules)
62342623|NCT04881240|EXPERIMENTAL|Group A|Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.
62342624|NCT04881240|EXPERIMENTAL|Group B|Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.
62342625|NCT03498287|EXPERIMENTAL|Study Device|Small, non-invasive, stiff patch for the wrist
62342626|NCT03498287|SHAM_COMPARATOR|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
62342627|NCT05543460|EXPERIMENTAL|Corticopuncture-facilitated MARPE|Patients will be treated using Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) with corticopunctures .along the mid-palatal suture
62342628|NCT05543460|ACTIVE_COMPARATOR|Conventional MARPE|Patients will be treated using Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) without corticopunctures.
62342629|NCT04427436||Patients|Mild Cognitive Impairment (clinical determination)
62342630|NCT04427436||Control|Healthy Elderly
62342631|NCT00777231|EXPERIMENTAL|Sickle Cell Disease|Recipients treated with an enriched hematopoetic stem cell infusion
62342632|NCT00777231|EXPERIMENTAL|Non-Malignant Disorders|Recipients treated with an enriched hematopoetic stem cell infusion
62500130|NCT05502055||Non-LGBTQ_PD|Individuals who identify as non-LGBTQ+ and are diagnosed with PD
62342633|NCT00777231|EXPERIMENTAL|Aplastic Anemia|Recipients treated with an enriched hematopoetic stem cell infusion
62342634|NCT00777231|EXPERIMENTAL|Sickle Cell Disease : Extended Protocol|Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning
62342635|NCT04626193|EXPERIMENTAL|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline,Levofloxacien,tinadizole
62342636|NCT04626193|ACTIVE_COMPARATOR|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole,amoxicilline
62342637|NCT00005060|ACTIVE_COMPARATOR|Taxotere-Cisplatin-5FU preoperatively|TCF preoperatively
62500131|NCT05502055||Care Partner|Individuals who are Care Partners of individuals with PD
62500132|NCT05502055||Health Care Provider|Health Care Providers who provide service to people with PD
62342638|NCT00005060|ACTIVE_COMPARATOR|Immediate surgery followed by TCF|Surgery followed by Taxotere-Cisplatin-5FU
61951164|NCT02067897||Vandenbos procedure (skinfold excision)|Participants in this cohort will undergo with Vandenbos procedure (skinfold excision) for one or more ingrown toenails. This surgery will be formed as an day procedure under general anesthetic.
61951165|NCT00915278|EXPERIMENTAL|PF-04605412|
61951166|NCT06044610|EXPERIMENTAL|GENPOP passive dehydration|24-hour data collection using a parallel design comparison of TOI blood flow patterns vs. reference methods of hydration status in 10 PEP employees.
61951167|NCT06044610|EXPERIMENTAL|EXERCISE without fluid replacement|Randomized cross-over design in 15 moderately active non-employee participants. 90 minutes of standard cycling exercise trial in heat chamber. TOI signals will obtain blood flow patterns from the face to compare against reference methods of dehydration including body mass, urine specific gravity, urine color, and thirst.
61951168|NCT06044610|OTHER|GENPOP ad lib fluid intake|24-hour data collection using a parallel design comparison of TOI blood flow patterns vs. reference methods of hydration status in 10 PEP employees.
62342639|NCT00926913||Group 1|
62342640|NCT05040789|EXPERIMENTAL|Group 1|CoVLP Lot 1
62342641|NCT05040789|EXPERIMENTAL|Group 2|CoVLP Lot 2
62342642|NCT05040789|EXPERIMENTAL|Group 3|CoVLP Lot 3
62342643|NCT04004078||Group A|Non-gene directed group：Voriconazole was intravenously administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 4mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 400mg or 200mg（weight\>40Kg or \<40Kg）at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight\>40Kg or \<40Kg）. Voriconazole was sequential therapy administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight\>40Kg or \<40Kg）.
62342644|NCT04004078||Group B|Gene directed group（UMs and EMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with UMs，EMs.
62342645|NCT04004078||Group C|Gene directed group（IMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with IMs.
62342646|NCT04004078||Group D|Gene directed group（PMs）： Voriconazole was intravenously administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 3mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 200mg or 100mg（weight\>40Kg or \<40Kg）at 12h intervals , followed by maintenance dosing 100mg . Voriconazole was sequential therapy administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 100mg.
62500133|NCT05499416|EXPERIMENTAL|Bimekizumab 320 mg SC injections|Bimekizumab 320 mg solution administered via SC injections every 4 weeks for 16 weeks.
62500134|NCT06233851||mTBI patient|Children \<16 years-old who suffered a head trauma in the last 24 hours with signs of mild traumatic brain injury
62500135|NCT06233851||control|Children \<16 years-old who have a scheduled blood test for any reason
62500136|NCT04079452|EXPERIMENTAL|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) coformulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 4 weeks
62500137|NCT05188417|EXPERIMENTAL|Tirofiban 0.25μg/kg/min(0.005ml/kg/min) group|The tirofiban hydrochloride sodium chloride injection is pumped intravenously at a constant rate of 0.25μg/kg/min (0.005 ml/kg/min) for 30 minutes, and then pumped intravenously at a constant rate of 0.1 μg/kg/min (0.002 ml/kg/min) for 24 hours.
62500138|NCT05188417|EXPERIMENTAL|Tirofiban 0.4μg/kg/min(0.008ml/kg/min) group|The tirofiban hydrochloride sodium chloride injection is pumped intravenously at a constant rate of 0.4 μg/kg/min (0.008 ml/kg/min) for 30 minutes, and then pumped intravenously at a constant rate of 0.1 μg/kg/min (0.002 ml/kg/min) for 24 hours.
61951169|NCT06044610|OTHER|EXERCISE with fluid replacement|Randomized cross-over design in 15 moderately active non-employee participants. 90 minutes of standard cycling exercise trial in heat chamber. TOI signals will obtain blood flow patterns from the face to compare against reference methods of dehydration including body mass, urine specific gravity, urine color, and thirst.
61951170|NCT03233607||Antepartum Patients|Includes antepartum patients receiving prenatal care at the Broadway Practice who plan to deliver at Allen Hospital in New York City (NYC). On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
61951171|NCT03596008|EXPERIMENTAL|Active1|freeze-dried strawberry powder (25 g) in active drink
62342647|NCT05600647|EXPERIMENTAL|Electromagnetic Field therapy with an exercise program|The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. Every patient is lying on the mattress in a supine position. In addition to exercise training program included postural correction strengthening exercises, stretching, proprioception and balance training
62342648|NCT05600647|ACTIVE_COMPARATOR|exercise program|Every patients will practice the exercise training program alone. the program included postural correction, strengthening exercises, stretching, proprioception and balance training
62342649|NCT00165841|PLACEBO_COMPARATOR|Placebo|
62342650|NCT00165841|EXPERIMENTAL|Rabeprazole 20 mg|
62342651|NCT05785390|EXPERIMENTAL|Active Drug Treatment|Phase IIa - Dose escalation. 3g cohort and 4.8g cohort run simultaneously, followed by a 6 g cohort. Administered in 600 g capsules of NP-101 for a total daily dose of 3g, 4.8g and 6g adminstered BID. Administered for 14 days.Establish MTDD Phase IIB - Continue study with MTDD as established above.
62342652|NCT05785390|PLACEBO_COMPARATOR|Placebo|As above, except dosed with matching placebo capsules.
62342653|NCT03503214||Septic patients|Patients with sepsis or septic shock according to the SEPSIS-III (Singer M Jama 2016) admitted to the general Intensive Care Unit
61951172|NCT03596008|PLACEBO_COMPARATOR|Placebo|Placebo drink
62342654|NCT03503214||Healthy volunteers|Subjects without known respiratory, cardiovascular, hepatic, renal or hematologic diseases.
62342655|NCT04039633|EXPERIMENTAL|Burst spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
62342656|NCT04039633|SHAM_COMPARATOR|sham spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
62342657|NCT04901533|EXPERIMENTAL|cervical manipulation|The objective of this technique is to restore joint mobility between the joints of the occipital, first (atlas) and second cervical vertebra (axis). It is a technique performed in rotation on a vertical axis that passes through the odontoid process of the axis, without placing flexion or extension, and with very slight sidebending; it is done bilaterally.
62342658|NCT04901533|ACTIVE_COMPARATOR|Cranial Listening|Cranial palpation maneuver
62342659|NCT05293652|EXPERIMENTAL|Iontophosresis group|
62500139|NCT05188417|PLACEBO_COMPARATOR|0.9% sodium chloride solution|The placebo is pumped intravenously at a constant rate of 0.008 ml/kg/min for 30 minutes, and then pumped intravenously at a constant rate of 0.002 ml/kg/min for 24 hours.
62500140|NCT06386601|EXPERIMENTAL|Intervention group|This group will receive directed feedback and guided practice regarding their ergonomic positioning while performing basic surgical skills exercises on a trainer
62500141|NCT06386601|OTHER|Control|This group will not receive directed feedback or guided practice regarding their ergonomic positioning while performing basic surgical skills exercises on a trainer during the study. After the study is completed they will receive this feedback, but it will not be included as a part of the study data.
61951173|NCT02606448|ACTIVE_COMPARATOR|Femoral Nerve Block|Patients in this group received preoperative ultrasound guided femoral nerve blocks by senior anesthesiologist using ropivicaine.
61951174|NCT02606448|EXPERIMENTAL|Liposomal Bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
61951175|NCT05076487||African American Women with Food Security|30 African American women with obesity who are food secure
61951176|NCT05076487||African American Women with Food Insecurity|30 African American women with obesity who are food insecure
62141037|NCT02195232|EXPERIMENTAL|Cohort A - Isoquercetin|"-- Cohort A: 500 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
62342660|NCT05293652|EXPERIMENTAL|Phonophoresis group|
62342661|NCT05293652|EXPERIMENTAL|Traditional group|
62342662|NCT03440853|EXPERIMENTAL|TASCCI|Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
62342663|NCT03440853|OTHER|Technology Delivered Health Education|Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
62342664|NCT02351843|EXPERIMENTAL|500 mA ECT|Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude
62342665|NCT02351843|ACTIVE_COMPARATOR|800 mA ECT|Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude
62342666|NCT00794651||OA|moderate to severe osteoarthritis of the knee
62500142|NCT06474598|ACTIVE_COMPARATOR|100 mg QD|Participants will be assigned to receive 3 months oral tablet administration of MTX228 at the 100mg QD dose
62500143|NCT06474598|ACTIVE_COMPARATOR|100 mg BID|Participants will be assigned to receive 3 months oral tablet administration of MTX228 at the 100mg BID dose
62699607|NCT03247101|EXPERIMENTAL|Probiotics group|Miyarisan-BM (Clostridium Butyricum Miyairi) 40 mg po tid x 6 months
62500144|NCT06474598|ACTIVE_COMPARATOR|200 mg QD|Participants will be assigned to receive 3 months oral tablet administration of MTX228 at the 200mg BID dose
62699608|NCT03247101|ACTIVE_COMPARATOR|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
62699609|NCT03247101|ACTIVE_COMPARATOR|Biotase group|Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
62699610|NCT04210960||Patients group|50 multiple sclerosis patients
61951177|NCT06403228|EXPERIMENTAL|Experimental Group|The intervention group participated in a mindfulness-based structured nursing interventions program planned for a total of eight days, 60 minutes each day, led by Elçin Alaçam, who has a Mindfulness Institute-approved certificate. The mindfulness-based structured nursing interventions program was structured for 8 days, taking into account the literature and the characteristics of high-risk pregnant women such as length of hospitalization.
61951178|NCT06403228|NO_INTERVENTION|Control Group|No intervention was applied to the control group. Data were collected from the control group simultaneously with the study group.
61951179|NCT02368015|OTHER|Patients with a large hepatic cyst|"During this study all subjects undergo aspiration sclerotherapy and receive antibiotic prophylaxis with a single dose of cefazolin (intravenous infusion 1000mg) following standard care.~In order to secure patient safety and allow accurate measurement of cefazolin concentrations, an additional peripheral intravenous cannula (IVC) will be placed to allow blood withdrawal at three timepoints."
62699611|NCT04210960||Control group|30 normal healthy control
62699612|NCT05328648|EXPERIMENTAL|Community Score Card|In the Community Score Card approach, community members come together to document challenges they encounter when seeking services and develop a corresponding set of indicators that can be used to produce a validated facility score. The score is shared with the community and a collaborative process between key community members and facility staff takes place to develop feasible solutions and a strategic action plan.
61951180|NCT02187497|EXPERIMENTAL|Low dose of BIBR 277|
62500145|NCT01762228|ACTIVE_COMPARATOR|Transcutaneus electrical stimulation|Sensorial transcutaneous electrical stimulation to the pharynx and larynx will be used 1 hour/day during 5 days/week for 2 weeks.
62500146|NCT01762228|ACTIVE_COMPARATOR|TRPV1 agonist|Sensorial stimulation of TRPV1 receptors into the oropharynx of patients will be used 3 times/day (before meals) during 5 days/week for 2 weeks.
62699613|NCT05328648|EXPERIMENTAL|Citizen Report Card|In the Citizen Report Card approach, individual-level feedback is collected from actual clients of target facilities, via a structured questionnaire, to assess facility performance and generate a public record of service quality. In addition to sharing the final report card with communities, engaged policymakers are invited to use the citizen feedback to improve service delivery.
62699614|NCT05328648|NO_INTERVENTION|Control|Communities in the control arm will not receive an intervention.
61951181|NCT02187497|EXPERIMENTAL|Medium dose of BIBR 277|
62342667|NCT03741920|EXPERIMENTAL|Personal KinetiGraph™ (PKG™) +|For subjects in the PKG+ Group, the study MDS will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment. PKG results will be recorded in the PKG Reporting case report form (CRF). The study MDS will complete the MDS-Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures along with the PKG information.
61951182|NCT02187497|EXPERIMENTAL|High dose of BIBR 277|
61951183|NCT03033485|EXPERIMENTAL|Melanoma patients|Melanoma patients enrolled for the clinical diagnosis study are performed with both 18F-P3BZA PET/CT and18F-FDG PET/CT scans before surgery.
61951184|NCT02398396|EXPERIMENTAL|Open Label: 4CMenB (Bexsero®)|
62699615|NCT04846998|EXPERIMENTAL|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 1: A-B-C"
61951185|NCT05509270|NO_INTERVENTION|Control|No additional pro-vaccination intervention - some patients are currently targeted for flu vaccination messages due to a non-machine learning-based assessment that they are at high risk for complications, but are not told that they are at high risk or that they have been targeted
61951186|NCT05509270|EXPERIMENTAL|Letter only|This group will receive a letter telling them they are at high risk for flu and complications
62699616|NCT04846998|EXPERIMENTAL|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 2: A-C-B"
62699617|NCT04846998|EXPERIMENTAL|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 3: B-A-C"
62699618|NCT04846998|EXPERIMENTAL|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 4: B-C-A"
62699619|NCT04846998|EXPERIMENTAL|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 5: C-A-B"
62699620|NCT04846998|EXPERIMENTAL|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~\*sequence 6: C-B-A"
61951187|NCT05509270|EXPERIMENTAL|Patient portal only|This group will receive a patient portal message telling them they are at high risk for flu and complications
61951188|NCT05509270|EXPERIMENTAL|SMS only|This group will receive an SMS telling them they are at high risk for flu and complications
61951189|NCT05509270|EXPERIMENTAL|Patient portal + SMS|This group will receive a patient portal message and an SMS telling them they are at high risk for flu and complications
62699621|NCT03622606|EXPERIMENTAL|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
62699622|NCT05633927||Non-immunological responder|Patients who start ART with \<350 CD4+ T cells, maintaining undetectable viral load, and increasing \<200 CD4+ T cell count after 18 months of follow-up.
62500147|NCT04271306|EXPERIMENTAL|Groups 1A & 1B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
61951190|NCT05509270|EXPERIMENTAL|Letter + Patient portal + SMS|This group will receive a letter, a patient portal message, and an SMS telling them they are at high risk for flu and complications
62342668|NCT03741920|ACTIVE_COMPARATOR|Personal KinetiGraph™ (PKG™) -|For subjects in the PKG- Group (control group), the study Movement Disorder Specialist (MDS) will complete the MDS - Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures. The study Movement Disorder Specialist will be blinded to the PKG information until the second part of the 90-day follow-up visit.
62500148|NCT04271306|EXPERIMENTAL|Groups 2A & 2B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
62500149|NCT04271306|EXPERIMENTAL|Groups 3A & 3B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
62500150|NCT04271306|EXPERIMENTAL|Group 3C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
62500151|NCT04271306|EXPERIMENTAL|Groups 4A & 4B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
62500152|NCT04271306|EXPERIMENTAL|Group 4C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0 and 1 and a dose of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at month 6.5
62500153|NCT05260008|EXPERIMENTAL|ATX-101 Dose A|ATX-101 Dose A
62500154|NCT05260008|EXPERIMENTAL|ATX-101 Dose B|ATX-101 Dose B
62500155|NCT05260008|ACTIVE_COMPARATOR|bupivacaine hydrochloride|bupivacaine hydrochloride without epinephrine via local infiltration and/or nerve block
62500156|NCT06461845|EXPERIMENTAL|whole body vibration group|The wBV program comprises various positions such as the child stands in an erect position, sitting, and in kneeling position on vibrating platform. This platform vibrates horizontally at a frequency ranged from 10 to 25 Hz. The participants had to carry out each position for 2 min in the first month, and then it was increased to 3 min in the second month. The rest period between each position was 1 min in the first month, then it became half a minute in the second month. The duration of the vibration exposure was 10 min.
62342669|NCT04117178|ACTIVE_COMPARATOR|Standard of care|Participants allocated to this arm follow the usual routines of the out patient dementia clinic but are requested to have the serum level of the prescribed drug measured after 12 month. Also, CYP2D6, BcHE K and APOe4 status will be determined after 12 months.
62342670|NCT04117178|EXPERIMENTAL|Intervention arm|Participants allocated to this arm follow are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention arm not experiencing side effects will have their treatment adjusted after 6 months based upon serum level of the drug in question.
62699623|NCT05633927||Immunological responder|Patients with \>350 CD4+ T cells
62699624|NCT05145010|EXPERIMENTAL|Arm 1: Rollover subjects|Children who have completed QED-sponsored interventional study with infigratinib (Phase 2 or Phase 3)
62699625|NCT05145010|EXPERIMENTAL|Arm 2: Treatment naïve subjects|Children naïve to infigratinib
62699626|NCT06402487|ACTIVE_COMPARATOR|Propionic acid 1000 mg|
62699627|NCT06402487|PLACEBO_COMPARATOR|Placebo|
62699628|NCT06477601|ACTIVE_COMPARATOR|Continued menthol smoking|Current menthol smokers will be assigned to smoke study provided menthol cigarettes.
62699629|NCT06477601|EXPERIMENTAL|Synthetic cooling agent cigarette smoking|Current menthol smokers will be assigned to smoke study provided synthetic cooling agent cigarettes.
61951191|NCT05405868|EXPERIMENTAL|Nicotinamide|Participants will receive Nicotinamide for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
61951192|NCT05405868|PLACEBO_COMPARATOR|Matching Placebo|Participants will receive matching placebo for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
62342671|NCT00199134|OTHER|Letrozole|Letrozole 2.5 mg per day
62500157|NCT06461845|ACTIVE_COMPARATOR|conventional therapy group|This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexors.
62500158|NCT04356807|EXPERIMENTAL|Reflex Locomotion Therapy|during 15 minutes once a day five days a week
62500159|NCT04356807|EXPERIMENTAL|Passive Joint Mobilizations|during 15 minutes once a day five days a week
62500160|NCT04356807|PLACEBO_COMPARATOR|Massage|during 15 minutes once a day five days a week
62500161|NCT00000317|PLACEBO_COMPARATOR|PLacebo|Placebo plus relapse prevention counseling
62500162|NCT00000317|EXPERIMENTAL|Risperidone|Risperidone (4mg/day) plus relapse prevention counseling
62500163|NCT06678152||Group 1:|smokers
62500164|NCT06678152||Group 2:|nonsmokers
62500165|NCT03293719||Ceramic|Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
62500166|NCT03293719||CoCr|Patients receiving BPK-S Integration UC implant made from CoCr (metal)
62500167|NCT01207141||rATG induction|Liver transplant recipients who receive induction with rATG prior to transplantation.
62500168|NCT01207141||no rATG induction|Liver transplant recipients who do not receive rATG induction therapy prior to transplantation.
62699630|NCT06477601|EXPERIMENTAL|Traditional non-menthol cigarette smoking|Current menthol smokers will be assigned to smoke study provided traditional non-menthol cigarettes.
62699631|NCT01771497||Women undergoing neoadjuvant therapy|
62699632|NCT06640738|EXPERIMENTAL|arm 1|"During uterine fibroid ablation, the arm1 participant received Remifentanil \[ ALVOGEN® (2 mg/vial)\] 1.0 ng/mL via syringe infusion pump \[Perfusor® Space \| B. Braun\] as a pain treatment."
61951193|NCT04094883|EXPERIMENTAL|4CMenB Vaccine|Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.
62699633|NCT06640738|ACTIVE_COMPARATOR|arm 2|"During uterine fibroid ablation, the arm2 participant received Remifentanil \[ ALVOGEN® (2 mg/vial)\] 2.0 ng/mL via syringe infusion pump \[Perfusor® Space \| B. Braun\] as a pain treatment."
61951194|NCT03349697|EXPERIMENTAL|Active Product then Placebo|
61951195|NCT03349697|EXPERIMENTAL|Placebo then Active Product|
61951196|NCT03959553|PLACEBO_COMPARATOR|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
62699634|NCT05044897|EXPERIMENTAL|Study treatment|"SI-B001 is a bispecific antibody targeting EGFR and HER3, which is administered weekly by intravenous infusion（QW）.~The 4-week cycle was maintained until disease progression or cessation due to intolerable toxicity or other reasons (e.g., withdrawal of informed consent or death). From C1D1, efficacy was evaluated every 8 weeks ±7 days in the first year and every 12 weeks ±7 days in the second year."
62342672|NCT05388591|EXPERIMENTAL|Musicotherapy|
62342673|NCT05388591|NO_INTERVENTION|Standard care|
62342674|NCT03901261|EXPERIMENTAL|Down syndrome patients|
62699635|NCT06572293|EXPERIMENTAL|Intervention|Nurse-led follow-up
62699636|NCT06572293|NO_INTERVENTION|Control|Physician-led follow-up
61951197|NCT03959553|EXPERIMENTAL|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
61951198|NCT03959553|EXPERIMENTAL|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
61951199|NCT01194466|ACTIVE_COMPARATOR|Active TENS|Active high frequency TENS will be use for Active TENS.
62141038|NCT02195232|EXPERIMENTAL|Cohort B - Isoquercetin|"--Cohort B: 1000 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
62141039|NCT01534546|ACTIVE_COMPARATOR|arm A postoperative Oxaliplatin/capecitabine（XELOX）|"postoperative Oxaliplatin/capecitabine（XELOX） patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.~capecitabine：1000 mg/m2 ，bid, d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
62342675|NCT02880397|ACTIVE_COMPARATOR|Garcinia Mangostana|The constituents of mangostana containing gel were prepared under the following proportions: Mangostana powder - 4gm, Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml.
62342676|NCT02880397|PLACEBO_COMPARATOR|Placebo gel|The placebo gel was prepared with Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml excluding the active ingredient mangostana powder - 4 mg and maintaining same physical properties such as color and taste.
62699637|NCT03589833|PLACEBO_COMPARATOR|MTX|Treated with oral methotrexate and two placebos.
62699638|NCT03589833|PLACEBO_COMPARATOR|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
62699639|NCT03589833|ACTIVE_COMPARATOR|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
62699640|NCT03589833|EXPERIMENTAL|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
61951200|NCT01194466|EXPERIMENTAL|Placebo (low intensity) TENS|Placebo TENS will be applied for one arm of the study
61951201|NCT01194466|SHAM_COMPARATOR|No Treatment|TENS unit in place but not turned on
61951202|NCT04470323||COVID19 patients|Patients admitted to Assiut university Hospitals diagnosed as COVID19 positive patients by PCR.
62699641|NCT06239558||South Asian Service Users|Service users who identify themselves as South Asian will be invited to participant in a semi-structured interview and/or a focus group. The interview will be used to identify lived experiences of the barriers and enablers to cardiac rehabilitation, relating to uptake, adherence or completion. The focus group will be used to collaboratively generate adaptations to CR services which could be implemented to overcome the barriers, and enhance the enablers, identified during the interviews.
61951203|NCT04470323||healthy volunteer|as negative control for each sample
61951204|NCT01854658|EXPERIMENTAL|FF MDI (PT005)|FF MDI administered as two puffs BID
61951205|NCT01854658|EXPERIMENTAL|GP MDI (PT001)|GP MDI administered as two puffs BID
61951206|NCT01854658|EXPERIMENTAL|GFF MDI (PT003)|GFF MDI administered as two puffs BID
61951207|NCT01854658|PLACEBO_COMPARATOR|Placebo MDI|Inhaled placebo administered as two puffs BID
61951208|NCT03864978|EXPERIMENTAL|Rifaximin-EIR 800 mg BID for 10 days|2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
61951209|NCT03864978|EXPERIMENTAL|Rifaximin-EIR 400 mg BID for 30 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
61951210|NCT03864978|EXPERIMENTAL|Rifaximin-EIR 400 mg BID for 10 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
62141040|NCT01534546|EXPERIMENTAL|arm B: postoperative Oxaliplatin/S-1（SOX）|"postoperative Oxaliplatin/S-1（SOX） patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.~S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
62141041|NCT01534546|EXPERIMENTAL|Arm C：postoperative Oxaliplatin /S-1（SOX）|"Postoperative Oxaliplatin /S-1（SOX） patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.~Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)"
62141042|NCT04125641||Elxaban group|AF patients taking Elxaban
61951211|NCT03864978|PLACEBO_COMPARATOR|Two placebo tablets BID for 30 days|2 x placebo tablets twice a day for 30 days
62342677|NCT01759498|EXPERIMENTAL|HYDRO 2|Subjects in the second experimental group will follow the procedures of first experimental group with additional administration of hydrogen-rick packs 6 times per day for 20 minutes throughout the study.
62699642|NCT06239558||Cardiac Rehabilitation Healthcare Professionals|The rehabilitation healthcare professionals will be invited to participant in a semi-structured interview and/or a focus group. The interviews will be used to explore their the perceptions of barriers and enablers and knowledge around the cultural requirements of South Asian service users.
62699643|NCT06239558||Key stakeholders|Key stakeholders relating to cardiac rehabilitation, University Hospitals of Leicester (UHL) NHS Trust, and/or South Asian communities will be invited to participate in the focus group, helping to generate adaptations to CR services.
62699644|NCT06070376|ACTIVE_COMPARATOR|Group A|placement of the esophageal prostheses fully covered in the palliative treatment of malignant esophageal obstructions.
62699645|NCT06070376|ACTIVE_COMPARATOR|Group B|placement of the partially covered esophageal prostheses in the palliative treatment of malignant esophageal obstructions.
62699646|NCT03699865|EXPERIMENTAL|Purple|Participants will receive cigarettes with intermediate or very low nicotine content in purple packaging
61951212|NCT05722197|EXPERIMENTAL|Crisis Response Plan and Lethal Means Counseling|All participants will complete a narrative suicide risk assessment, collaboratively develop a Crisis Response Plan, and receive lethal means counseling. The Crisis Response Plan will include the following sections: (1) identifying personal warning signs for suicide; (2) identifying self-regulation strategies for reducing emotional distress; (3) identifying reasons for living; (4) identifying sources of social support; and (5) accessing professional crisis services. Participants will handwrite the plan on an index card, sheet of paper, or another similar medium. After completing the Crisis Response Planning, researchers will conduct lethal means counseling to develop a plan for restricting or limiting access to potentially lethal methods of suicide.
61951213|NCT05868395|EXPERIMENTAL|Polatuzumab, bendamustine and rituximab|Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle, bendamustine 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle and rituximab 375 mg/m2 i.v. on day 1 of each cycle every 3 weeks.
61951214|NCT01519232||Liver Irradiation|patients already scheduled to undergo liver irradiation
61951215|NCT05993819|EXPERIMENTAL|pilates based core stability training and congnitive therapy|the patients will receive pilates and cognitive therapy three times a week for eight weeks
61951216|NCT05993819|ACTIVE_COMPARATOR|Pilates based core stability training|the patients will receive pilates three times a week for eight weeks
61951217|NCT02903355|PLACEBO_COMPARATOR|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
61951218|NCT02903355|EXPERIMENTAL|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
61951219|NCT01112553||Treximet|All migraine subjects will receive Treximet during a migraine episode at Visit 2.
61951220|NCT00072566|EXPERIMENTAL|Treatment (bevacizumab, cyclophosphamide)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61951221|NCT03817879|EXPERIMENTAL|VivaSight double-lumen tube|
61951222|NCT03817879|ACTIVE_COMPARATOR|Conventional double-lumen tube|
61951223|NCT02930330|EXPERIMENTAL|Interval|"2x / week INT~2x / week CONT"
61951224|NCT02930330|ACTIVE_COMPARATOR|Continuous|4x / week CONT
61951225|NCT00325273|EXPERIMENTAL|probiotics & allergy|"1. To understand the preventive effect of probiotics in neonatal peroid~2. To investate the possible mechanism"
62342678|NCT01759498|ACTIVE_COMPARATOR|ACTIVE|During the period of 2 weeks subjects will receive traditional treatment protocol after the soft-tissue injury, consisting of RICE protocol during the first 48 h (e.g. rest, ice packs for 20 minutes every 2 hours, compression with elastic bandage, elevation of the injured area above the level of the heart at all possible times) and sub-acute protocol thereafter (e.g. passive stretching 3 times per day for 90 sec, isometric strength exercise with 3 sets with 15 repetitions, 30 min of pain-free weight-bearing exercise).
62699647|NCT03699865|EXPERIMENTAL|White|Participants will receive cigarettes with intermediate or very low nicotine content in white packaging
61951226|NCT01390129|EXPERIMENTAL|Control|
62699648|NCT03699865|EXPERIMENTAL|Black|Participants will receive cigarettes with intermediate or very low nicotine content in black packaging
62699649|NCT03286699|ACTIVE_COMPARATOR|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
62699650|NCT03286699|ACTIVE_COMPARATOR|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
61951227|NCT01390129|ACTIVE_COMPARATOR|Remote ischemic preconditioning|
62699651|NCT03073577|EXPERIMENTAL|Treatment Group|PKX-001 will be supplemented to islet preservation CMRL-1066 medium at final concentration of 3 mg/mL during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays. Islets are maintained for minimal 6 hours up to 72 hours in supplemented CMRL1066-based media containing PKX-001 until the time of transplant. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally.
61951228|NCT01197560|EXPERIMENTAL|Lenalidomide|Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
61951229|NCT01197560|ACTIVE_COMPARATOR|Investigators Choice|"One of the following:~Gemcitabine, Oxaliplatin, Rituximab, or Etoposide"
61951230|NCT01189604|PLACEBO_COMPARATOR|Arm1 - Placebo|
61951231|NCT01189604|ACTIVE_COMPARATOR|Arm 2 - ICI35,868 (propofol)|
62699652|NCT04602845|EXPERIMENTAL|Remimazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 3 mg/2ml remimazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Remimazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
62699653|NCT04602845|ACTIVE_COMPARATOR|Midazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 2.5 mg/2ml midazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Midazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
62699654|NCT00141011|EXPERIMENTAL|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
62342679|NCT01759498|EXPERIMENTAL|HYDRO|Subjects in the first experimental group will follow the PLA procedures with additional administration of oral hydrogen-rich capsules (4 capsules three times per day) throughout the study.
62500169|NCT03082651|ACTIVE_COMPARATOR|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
62500170|NCT03082651|EXPERIMENTAL|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
62500171|NCT03082651|EXPERIMENTAL|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
62500172|NCT03082651|EXPERIMENTAL|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
62699655|NCT00141011|PLACEBO_COMPARATOR|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
62699656|NCT04282915|ACTIVE_COMPARATOR|Implementation as Usual|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme adapted by the Nepal Ministry of Health.
62342680|NCT03839017|EXPERIMENTAL|Digital cognitive aid|The leader uses a digital cognitive aid designed as a smartphone app during advanced combat casualty care. Intervention: Device: SIMMAXMARCHERYAN2 Digital cognitive aid during the management of simulated war wounded.
62500173|NCT05476133|EXPERIMENTAL|study group|single group who had intervention and comparison of pre and post intervention assessment
62500174|NCT03680716|EXPERIMENTAL|IPACK block|Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
62500175|NCT03680716|ACTIVE_COMPARATOR|Local infiltration analgesia|Periarticular infiltration by surgeon
62500176|NCT05395767|EXPERIMENTAL|endoscopic ACL reconstruction with parent allograft tendon|
62500177|NCT02010034|OTHER|Compassionate use|This lipid preparation is only being used for compassionate use.
62500178|NCT06631729|EXPERIMENTAL|Group 1|randomized to HRV bio
62500179|NCT06631729|EXPERIMENTAL|Group 2|Randomized to ED-JITAI treatment
62500180|NCT01030484||NAFLD|adult patients with non-alcoholic fatty liver disease (NAFLD).
62500181|NCT02569281|EXPERIMENTAL|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, they will receive one session of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
62699657|NCT04282915|EXPERIMENTAL|RESHAPE|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme, plus they will have co-facilitation by mental health service users providing recovery testimonials as well as aspirational figures presenting testimonies and conducting myth-busting sessions.
62699658|NCT04183686|EXPERIMENTAL|Part A (SAD): Dose A1|Single dose A1 of ACT-1014-6470; soft capsule for oral use.
62699659|NCT04183686|EXPERIMENTAL|Part A (SAD): Dose A2|Single dose A2 of ACT-1014-6470; soft capsule for oral use.
62699660|NCT04183686|EXPERIMENTAL|Part A (SAD): Dose A3|Single dose A3 of ACT-1014-6470 under fasted and fed conditions, separated by at least 18 days; soft capsule for oral use.
62699661|NCT04183686|EXPERIMENTAL|Part A (SAD): Dose A4|Single dose A4 of ACT-1014-6470; soft capsule for oral use.
62141043|NCT06117891||Treatment|Patients with a diagnosis of uHCC treated with first-line AB or another approved 1L-IO combo and in whom a decision to treat with a second-line of systemic therapy has been made by the treating physician at the time of study enrollment
62342681|NCT03839017|EXPERIMENTAL|Without digital cognitive aid|The leader practices advanced combat casualty care without the digital cognitive aid designed as a smartphone app. Intervention: Device: SIMMAXMARCHERYAN2 Without digital cognitive aid during the management of simulated war wounded.
62500182|NCT02569281|ACTIVE_COMPARATOR|Eccentric exercise|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
62699662|NCT04183686|EXPERIMENTAL|Part A (SAD): Dose A5|Single dose A5 of ACT-1014-6470; soft capsule for oral use.
62699663|NCT04183686|EXPERIMENTAL|Part A (SAD): Dose A6|Single dose A6 of ACT-1014-6470; soft capsule for oral use.
62699664|NCT04183686|EXPERIMENTAL|Part B (MAD): Dose B1|Multiple doses B1 of ACT-1014-6470; soft capsules for oral use.
61951232|NCT01189604|ACTIVE_COMPARATOR|Arm 3 - ICI35,868 (propofol)|
61951233|NCT01189604|ACTIVE_COMPARATOR|Arm 4 - ICI35,868 (propofol)|
61951234|NCT01189604|ACTIVE_COMPARATOR|Arm 5 - ICI35,868 (propofol)|
62342682|NCT02472691|EXPERIMENTAL|Lenalidomide + Aza + DLI|Patients will be included at the time of relapse after first allo-SCT. As standard of care all patients will receive Azacitidine 75 mg/m2/d for 7 days every 28 days for up to 8 cycles and DLIs given after cycle 4, 6 and 8 at a dose of 0.5-1x106CD3/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI). As intervention (investigational drug), Lenalidomide will be also started on day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
62342683|NCT02750904|EXPERIMENTAL|Experimental therapy|
62342684|NCT02750904|ACTIVE_COMPARATOR|Control Therapy|
62342685|NCT00259740|EXPERIMENTAL|Denosumab|
62342686|NCT02646267|EXPERIMENTAL|standard intensity warfarin group|standard intensity warfarin group， target international normalised ratio(INR) was 2.1-3.0, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(2.1-3.0)
62342687|NCT02646267|EXPERIMENTAL|low intensity warfarin group|low intensity warfarin group， target international normalised ratio(INR) was 1.7-2.2, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(1.7-2.2)
62342688|NCT02646267|ACTIVE_COMPARATOR|dabigatran etexilate group|110mg dabigatran etexilate was administrated twice a day
62342689|NCT05624775|EXPERIMENTAL|Virtual Culinary Medicine|
62342690|NCT02199301|EXPERIMENTAL|BMTKT|Transplantation Conditioning for bone marrow transplantation (BMT) Kidney transplantation and BMT (BMTKT)
62342691|NCT05254314|EXPERIMENTAL|Study Drug (Semaglutide)|Semaglutide 2.4mg once weekly
62342692|NCT05254314|PLACEBO_COMPARATOR|Placebo|Placebo 2.4mg once weekly
62342693|NCT03060330|EXPERIMENTAL|LVMR|Modified Laparoscopic Ventral Mesh Rectopexy
62342694|NCT03060330|EXPERIMENTAL|LVMR with STARR|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
62342695|NCT03309592|OTHER|Combination Therapy|Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
62699665|NCT04183686|EXPERIMENTAL|Part B (MAD): Dose B2|Multiple doses B2 of ACT-1014-6470; soft capsules for oral use.
62699666|NCT04183686|EXPERIMENTAL|Part B (MAD): Dose B3|Multiple doses B3 of ACT-1014-6470; soft capsules for oral use.
62699667|NCT04183686|EXPERIMENTAL|Part B (MAD): Dose B4|Multiple doses B4 of ACT-1014-6470; soft capsules for oral use.
62699668|NCT05295472|EXPERIMENTAL|Grapholearn group|Children with DLD who attend a special school for children with DLD. This group will play the computer game GL in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
62699669|NCT05295472|ACTIVE_COMPARATOR|Math game group|Children with DLD who attend a special school for children with DLD. This group will play a computer game focusing on math in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
62342696|NCT01919905|ACTIVE_COMPARATOR|High dose|High dose vitamin D group receiving Mozzarella cheese/pizza with 28000 IU vitD/serving once a week
62342697|NCT01919905|PLACEBO_COMPARATOR|Low dose|Low dose vitamin D group receiving Mozzarella cheese/pizza with 200 IU vitD/serving once a week
61951235|NCT01189604|ACTIVE_COMPARATOR|Arm 6 - ICI35,868 (propofol)|
61951236|NCT01189604|ACTIVE_COMPARATOR|Arm 7 - ICI35,868 (propofol)|
61951237|NCT03748693||POP Group|Women with POP undergoing surgery in our OB/GYN department.
61951238|NCT03748693||Non-POP Group|Women undergoing hysterectomy for other indications.
61951239|NCT01296217|EXPERIMENTAL|lymph nod detection|
61951240|NCT04467606|EXPERIMENTAL|Experimental|The experimental group will receive a discharge planning which use the strategy of motivational interviewing.
61951241|NCT04467606|NO_INTERVENTION|Control|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
62342698|NCT03589885|PLACEBO_COMPARATOR|Placebo 2 mL auto-injector|Placebo to secukinumab s.c., provided in 2 mL auto-injector form
62342699|NCT03589885|PLACEBO_COMPARATOR|Placebo 1 mL prefilled syringe|Placebo to secukinumab s.c., provided in 2 \* 1 ml prefilled syringe form
62342700|NCT03589885|EXPERIMENTAL|Secukinumab 2 mL auto-injector|Secukinumab 300 mg provided in 2 mL auto-injector form
62342701|NCT03589885|ACTIVE_COMPARATOR|Secukinumab 1 mL prefilled syringe|Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
62342702|NCT05102149|EXPERIMENTAL|Test arm|PB-201: 100 mg each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;
62342703|NCT05102149|ACTIVE_COMPARATOR|Vildagliptin arm|Vildagliptin: 50 mg each time, orally in the morning and evening respectively; PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
62342704|NCT05102149|PLACEBO_COMPARATOR|Placebo arm|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;
62500183|NCT05765617|PLACEBO_COMPARATOR|Control|Placebo 2x1 per day
62500184|NCT05765617|EXPERIMENTAL|Calcitriol|the treatment group received calcitriol 2x400 iu per day for 5 day
62699670|NCT05295472|ACTIVE_COMPARATOR|Usual schooling|Children with DLD who attend a special school for children with DLD. This children will have normal schooling as usual without playing any of the above computer games.
62699671|NCT05951101|EXPERIMENTAL|Zenith LAA Occlusion System|Zenith LAA Occlusion System Implantation
61951242|NCT01524107||Urgent Caesarian Section|
61951243|NCT01524107||Elective Caesarian Section|
61951244|NCT02445508|PLACEBO_COMPARATOR|Placebo+Placebo|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.
61951245|NCT02445508|ACTIVE_COMPARATOR|Placebo+Cholecystokinin|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.
61951246|NCT02445508|ACTIVE_COMPARATOR|Sevelamer+Placebo|Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.
61951247|NCT02445508|ACTIVE_COMPARATOR|Sevelamer+Cholecystokinin|Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.
61951248|NCT03949036|EXPERIMENTAL|target of Stroke Volume Variation ≤ 6%|The rate of intraoperative fluid administration will be adjusted to achieve the target of Stroke Volume Variation ≤ 6%. A crystalloid bolus of 200 ml will be repeatedly administered every 20 min until the target was achieved. The basal rate of fluid administration will be 3 ml/kg/hr.
61951249|NCT03949036|ACTIVE_COMPARATOR|target of Stroke Volume Variation ≤ 12%|The rate of intraoperative fluid administration will be adjusted to achieve the target of Stroke Volume Variation ≤ 12%. A crystalloid bolus of 200 ml will be repeatedly administered every 20 min until the target was achieved. The basal rate of fluid administration will be 3 ml/kg/hr.
61951250|NCT01059591|EXPERIMENTAL|Active|GSK424887 once daily
61951251|NCT01059591|PLACEBO_COMPARATOR|Placebo|Placebo once daily
61951252|NCT03515278|EXPERIMENTAL|suprascapular nerve block (SCNB) group|"SCNB with physiotherapy. Suprascapular nerve block: Ultrasound-guided SCNB by 3 c.c. 1% lidocaine with 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
62699672|NCT06271915|EXPERIMENTAL|lateral epicondilitis with SNAG's|The intervention group, will receive mulligan's technique on C4-C7 cervical region and eccentric exercises to the affected forearm interventions done 2 times per week, 45 minutes each session for 4 weeks
62699673|NCT06271915|ACTIVE_COMPARATOR|lateral epicondylitis|"control group will receives only localized treatment as eccentric exercise, stretching of forearm extensors, cross-friction massage and ultrasound with frequency 3 MHz and intensity 2 W/cm2, 100% duty cycle on the affected forearm.~interventions done 2 times per week, 45 minutes each session for 4 weeks"
61951253|NCT03515278|ACTIVE_COMPARATOR|intra-articular corticosteroid injection (IACI) group|"IACI with physiotherapy. Intra-articular steroid Injections: Receive intra-articular corticosteroid injection.Ultrasound-guided IACI with 3c.c. 1% lidocaine and 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
62699674|NCT01322152|EXPERIMENTAL|wXELIRI regimen|
62699675|NCT01969929|ACTIVE_COMPARATOR|20G|20G vitrectomy with scleral and conjunctival sutures for closure
61951254|NCT01365052|EXPERIMENTAL|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|
61951255|NCT01365052|PLACEBO_COMPARATOR|Placebo|
62500185|NCT04755621|EXPERIMENTAL|Core stability Group|
62500186|NCT04755621|ACTIVE_COMPARATOR|Control Group|
62500187|NCT01872715|EXPERIMENTAL|Oracea|"Oracea (doxycycline USP, 40mg\[30mg immediate release/ 10mg delayed release beads\] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.~Oral dose for 12 weeks"
62500188|NCT05167617|EXPERIMENTAL|Vitamin Deficiency|
62500189|NCT03394833|EXPERIMENTAL|Preoperative fluids|40 individuals receiving preoperative colloid fluid bolus at 6 ml/kg LBW, (Gelofusine™, Fresenius Kabi AB, Sweden) before anesthesia induction by TCI (n = 20) or RSI (n =20).
62500190|NCT03394833|NO_INTERVENTION|No preoperative fluids|40 individuals anesthetized by TCI (n = 20) or RSI (n =20) without preoperative fluids.
62699676|NCT01969929|ACTIVE_COMPARATOR|23G|23G transconjunctival sutureless vitrectomy
62699677|NCT01076699|ACTIVE_COMPARATOR|Group taking 0.075 mg RVX-100|This group is taking 0.075 mg RVX-100
62699678|NCT01076699|ACTIVE_COMPARATOR|Group taking 0.125 mg RVX-100|This group is taking 0.125 mg RVX-100
62699679|NCT01076699|ACTIVE_COMPARATOR|0.250 mg RVX-100|This group is taking 0.250 mg RVX-100
62699680|NCT01076699|PLACEBO_COMPARATOR|placebo|This group is taking a placebo
61951256|NCT04925583|EXPERIMENTAL|Level 0|Total dose 50 Gy, (10 x 5 Gy single dose)
61951257|NCT04925583|EXPERIMENTAL|Level 1|Total dose 55 Gy, (10 x 5.5 Gy single dose)
61951258|NCT04925583|EXPERIMENTAL|Level 2|Total dose 60 Gy, (10 x 6 Gy single dose)
61951259|NCT04925583|EXPERIMENTAL|Level 3|Total dose 65 Gy, (10 x 6.5 Gy single dose)
61951260|NCT05764421|EXPERIMENTAL|intervention groups|"The experimental group received a uniform exercise - cognitive intervention at a community health centre or a geriatric activity station. The intervention lasted for a total of 12 weeks at a frequency of once every fortnight, with each intervention lasting 60-90 minutes. At the end of the intervention, the participants were followed up by the researchers for a total of 12 weeks, at a frequency of once every fortnight.~The intervention consisted of physical-motor activities as well as integrated cognitive training."
62500191|NCT01069614|EXPERIMENTAL|Skin stretching device|Skin stretching device
62500192|NCT03092414|EXPERIMENTAL|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
62500193|NCT03092414|EXPERIMENTAL|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
62500194|NCT02806609|OTHER|Group 1|Cold water immersion, with 10 degrees, for 10 minutes
62500195|NCT02806609|OTHER|Group 2|immersion in water at room temperature
62500196|NCT02806609|OTHER|Group 3|active recovery - running
62500197|NCT02806609|OTHER|Group 4|rest in the chair
62500198|NCT03793296|EXPERIMENTAL|Paravalvular leak|After transcatheter- or surgical valve replacement
62500199|NCT03737916|EXPERIMENTAL|dextrose group|"Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation"
62699681|NCT04512690|EXPERIMENTAL|Epidural electrical stimulation of the cervical spinal cord|Individuals with prior subcortical stroke and hemiparesis of the upper extremity.
62699682|NCT00894881||1 group|patients before colonoscopy
62342705|NCT03970395|EXPERIMENTAL|Osteopathic manipulative therapy|"Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits."
62342706|NCT03970395|SHAM_COMPARATOR|Light Touch Therapy|"Repositioning Therapy plus Light Touch Therapy (LTT)~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group."
62342707|NCT05585892|OTHER|Intervention items 1-15|Students in this arm were exposed to intervention and control items in the 10 weekly e-seminars. Assignment of item types was the exact opposite of that in group B.
62342708|NCT05585892|OTHER|Intervention items 16-30|Students in this arm were exposed to intervention and control items in the 10 weekly e-seminars. Assignment of item types was the exact opposite of that in group A.
62699683|NCT02330003|EXPERIMENTAL|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
61951261|NCT05764421|NO_INTERVENTION|control group|Participants in the control group did not undergo any intervention and kept their old lifestyle unchanged. The control group was asked to avoid cognitive training and exercise training beyond the routine throughout the investigation.
61951262|NCT04079946|ACTIVE_COMPARATOR|patients for whom Complete mesocolic excision will be done|
61951263|NCT04079946|ACTIVE_COMPARATOR|patients had conventional surgery before|
62699684|NCT02330003|ACTIVE_COMPARATOR|TIV PFS|Fluarix Prefilled Syringe
61951264|NCT03988088|EXPERIMENTAL|Lasmiditan|Participants with lower body weight (15 to ≤40 kilograms (kg)) received single oral dose of 100 milligrams (mg) Lasmiditan in Cohort 1 and higher body weight (\>40 to ≤55 kg) participants received single oral dose of 200 mg Lasmiditan in Cohort 2.
62699685|NCT05193708|ACTIVE_COMPARATOR|Digital Indirect bonding|An indirect bonding tray will be fabricated from a 3D printed model
61951265|NCT06451003|NO_INTERVENTION|Control|"For each surgeon cluster this will be the time period prior to initiation of the intervention during which time we will assess contemporary baseline rate of guideline concordant utilization of extended pharmacologic venous thromboembolism prophylaxis.~For patients, this will include survey responses prior to use of dedicated discharge education on venous thromboembolism and prophylaxis strategies."
61951266|NCT06451003|EXPERIMENTAL|Intervention|"For each cluster this will be the time period after initiation of the intervention during which time we will assess the rate of guideline concordant utilization of extended pharmacologic venous thromboembolism prophylaxis with dedicated education and the use of an electronic medical record based clinical decision support system.~For patients, this will include survey responses after use of dedicated discharge education on venous thromboembolism and prophylaxis strategies."
61951267|NCT06402071||Group A (Cases)|Cirrhotic ascitic patients with spontaneous bacterial peritonitis
61951268|NCT06402071||Group B (Controls)|Cirrhotic ascitic patients without spontaneous bacterial peritonitis
62342709|NCT03296293|OTHER|Group I:IVPD≤3mmHg|Effect of PEEP at 5cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 10cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 15cmH2O on ICP in Group I:IVPD≤3mmHg
62342710|NCT03296293|OTHER|Group II:3mmHg<IVPD≤6mmHg|Effect of PEEP at 5cmH2O on ICP in Group II:3mmHg\<IVPD≤6mmHg Effect of PEEP at 10cmH2O on ICP in Group II:3mmHg\<IVPD≤6mmHg Effect of PEEP at 15cmH2O on ICP in Group II:3mmHg\<IVPD≤6mmHg
62342711|NCT03296293|OTHER|Group III:IVPD>6mmHg|Effect of PEEP at 5cmH2O on ICP in Group III:IVPD\>6mmHg Effect of PEEP at 10cmH2O on ICP in Group III:IVPD\>6mmHg Effect of PEEP at 15cmH2O on ICP in Group III:IVPD\>6mmHg
62342712|NCT06362499|EXPERIMENTAL|Experimental Group (GE)|TMI with 30% of Pimax. with a weekly load increase of 10% of the Pimax value initial. The sessions will consist of 30 repetitions, 4 times a day, 2 sets in the morning and two sets in the afternoon, with a one-minute break between sets, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds, in each maneuver, and will have the possibility to rest after every 3 repetitions of the IMT, for 30 seconds, to avoid muscle fatigue or any other complications.
62699686|NCT05193708|EXPERIMENTAL|Windowed Bonding technique|3D printed guide with windows for positioning the bracket
62699687|NCT00633685|EXPERIMENTAL|Fluoxetine|Receives Fluoxetine at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
62699688|NCT00633685|PLACEBO_COMPARATOR|Placebo|
62699689|NCT02946697|NO_INTERVENTION|Enhanced care and wait-list control group|Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.
62699690|NCT02946697|EXPERIMENTAL|Social support intervention group|The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
62699691|NCT02464748|EXPERIMENTAL|Intervention|Patients and their primary carer will use a weekly telehealth system. This involves a series of questions on a tablet computer that is transmitted to their regional MND care centre for review and action.
61951269|NCT01086085|EXPERIMENTAL|A|
61951270|NCT01086085|EXPERIMENTAL|B|
61951271|NCT01086085|EXPERIMENTAL|C|
61951272|NCT01086085|EXPERIMENTAL|D|
61951273|NCT03119233|EXPERIMENTAL|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
61951274|NCT05132673||Participants|Those who meet the Eligibility Criteria will be asked to complete online questionnaires and wear a device on your wrist for two weeks that measures your heart rate, physical activity, and sleep. A WHOOP® wrist monitor and charging equipment will be used.
61951275|NCT03217357|ACTIVE_COMPARATOR|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
61951276|NCT03217357|PLACEBO_COMPARATOR|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
61951277|NCT04302896|EXPERIMENTAL|dolutegravir + emtricitabine/tenofovir alafenamide|Tivicay® (dolutegravir 50 mg tablet) + Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg combination tablet), one tablet of each taken by mouth once daily for 15 days
62699692|NCT02464748|NO_INTERVENTION|Control|Usual care
62699693|NCT05266495||Brolucizumab|patients who received their first injection of Brolucizumab either during the active recruitment period (1 year prospective) or during the 6 months pre-start of the recruitment (6 months retrospective)
61951278|NCT04302896|EXPERIMENTAL|dolutegravir + tenofovir disoproxil fumarate + lamivudine|Tivicay® (dolutegravir 50 mg tablet) + Viread® (tenofovir disoproxil fumarate 300 mg tablet) + lamivudine 300 mg tablet, one tablet of each taken by mouth once daily for 15 days
62500200|NCT03737916|PLACEBO_COMPARATOR|control group|"Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: Normal Saline Normal saline is safe for perineural injection."
62342713|NCT06362499|PLACEBO_COMPARATOR|Sham Group (SG)|: Individuals will use a TMI device without any charge and will receive the same instructions as in G1. At the end of the research, the control group will be entitled to experimental treatment with the IMT protocol, if it proves to be effective.
62342714|NCT00064350|EXPERIMENTAL|Induction then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease."
61951279|NCT02221830|PLACEBO_COMPARATOR|Placebo|Normal Saline (standard of care)
62342715|NCT00064350|PLACEBO_COMPARATOR|Induction then Placebo then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm."
62699694|NCT04261985|ACTIVE_COMPARATOR|Mobile Phone Obesity Intervention|Approximately 30 caregiver-child dyads will be randomized into the intervention arm. Every week for 4 weeks, caregivers will receive 4 interactive multi-media phone prompts to support the intervention's targeted topics. Each mobile phone prompt starts with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share their goal/s, perceived barriers, questions, tips and strategies that may be helpful to other participants. Each week, caregivers will also receive strategies, and individual and group feedback on changing unhealthy behaviors.
62699695|NCT04261985|NO_INTERVENTION|Control|Approximately 30 caregiver-child dyads will be randomized into the control (no intervention) arm. Every week for 4 weeks, these caregivers will receive 4 interactive multi-media phone prompts around managing common illness in young children (i.e. fever, vomiting, constipation, etc.) Each mobile phone prompt will start with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share questions and strategies that may be helpful to other participants. Each week, caregivers will also receive tips and group feedback based on group questions.
62342716|NCT00064350|OTHER|Induction, not randomized|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.~Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study."
62342717|NCT04070170|EXPERIMENTAL|Low-level laser therapy and no orthodontic force|No orthodontic force. Laser is applied on the first day and the premolars is extracted after 24 hours
62500201|NCT00719589||1|Patient who have had implantation of an interstim.
62500202|NCT01207492|EXPERIMENTAL|Nilotinib|Nilotinib 200 mg taken as 400 mg twice daily, continuously
61951280|NCT02221830|EXPERIMENTAL|Treatment|normal saline + oxytocin
61951281|NCT05913258|EXPERIMENTAL|Er:YAG Laser Caries Removal group|Complete isolation was performed using a rubber dam and saliva ejector. Patients received topical anesthesia before the clamp was placed. Dental caries was excavated using the Er:YAG laser with a wavelength of 2940nm according to the manufacturer's instructions until visual inspection showed that the carious lesions have been thoroughly removed. If the patient experienced pain and requested local anaesthesia, the procedure was stopped, local anaesthesia has been applied, and then the procedure has resumed. Cavities were restored using the Clearfil Universal Bond Quick system in total each mode; 37% phosphoric acid was used, then the Clearfil Universal Bond system was applied, light cured for 90 seconds, after which composite resin was applied (3M Filtek TM Z350 XT Universal Restorative Composite (3M ESPE) according to the manufacturer's instructions.
61951282|NCT05913258|ACTIVE_COMPARATOR|Conventional Caries Removal Group|Complete isolation was performed using a rubber dam and saliva ejector. Patients received topical anesthesia before the clamp was placed. Dental caries was excavated using the Mastertorque high/low-speed air rotor handpiece until visual inspection showed that the carious lesions have been thoroughly removed. If the patient experienced pain and requested LA, the procedure was stopped, LA was applied, and then the procedure resumed. According to the manufacturer's instructions, cavities were restored using the Clearfil Universal Bond Quick system and composite resin (3M Filtek TM Z350 XT Universal Restorative Composite (3M ESPE).
61951283|NCT05624593|OTHER|Optical Coherence Tomography (OCT)|
61951284|NCT03638609|NO_INTERVENTION|Control|Group of patients not receiving IABP
61951285|NCT03638609|EXPERIMENTAL|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
62699696|NCT05366751|EXPERIMENTAL|SAGE-324 60 mg|Participants will receive SAGE-324 oral tablets from Day 1 to the End of Treatment (EOT) Period at a starting dose of 15 milligrams (mg). The dose will be up titrated in 15 mg increments to 60 mg. In case of intolerable adverse events, the dose will be down titrated in 15 mg decrements.
62699697|NCT06411938|EXPERIMENTAL|All women and girls eligible for the study|"All women and girls eligible for the study.~There is no control arm."
61951286|NCT00662246|EXPERIMENTAL|1|"Primary objectives :~* to determine the recommended dose (i.e., the safest and most effective dose) by evaluating frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to proton beam radiotherapy for HCC."
61951287|NCT00816296||Controls|Obese (BMI\>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
62699698|NCT03815552|EXPERIMENTAL|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with type 1 Diabetes.The System will be set to provide realtime glucose information, including alarms and alerts in the home settings für 180 days.
62699699|NCT04824911|EXPERIMENTAL|Intervention group|"This group will receive dual antiplatelet and high-intensity statin treatment.~* Dual antiplatelet treatment: loading of clopidogrel 300mg plus aspirin 300mg, followed by clopidogrel 75 mg/day and aspirin 100 mg/d from day 2 to day 21, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.~* High-intensity statin treatment: Atorvastatin 40-80mg/day or Rosuvastatin 20 mg/day for 90 days."
61951288|NCT00816296||Liver Disease|Obese (BMI\>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
61951289|NCT05457426||robotic right hemicolectomy with CME|The robot was set to come and dock from the right shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook/scissors for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R2), and Cadiere's fenestrated forceps in the right lower quadrant port (R3) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transverse mesocolon with the grasp in R3, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R2. All procedures were performed keeping the principle of complete mesocolic excision.
61951290|NCT05457426||laparoscopic right hemicolectomy with CME|In the aparoscopic group, five trocars were used: a periumbilical incision and left upper quadrant for 12-mm trocars, both lower quadrants for 5-mm trocars, and the right quadrant for one more 5-mm trocar. A 30 degrees laparoscope was inserted through the periumbilical trocar site. After insertion of the trocars, the patient was placed in the Trendelenburg position with a 15 degrees rightward tilt. An ultrasonic device was used for dissection. All procedures were performed keeping the principle of complete mesocolic excision.
61951291|NCT03656432|EXPERIMENTAL|CPP-ACP paste|MI Paste represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
61951292|NCT03656432|EXPERIMENTAL|CPP-ACP containing fluoride|MI paste plus contains fluoride 0.2% (900 ppm) that is very similar to the amount of fluoride in the toothpaste binds to the tooth surfaces and plaque and provides biocompatible calcium, phosphate and fluoride in a localized way. So, it provides all the ions needed to build fluorapatite crystals that are more resistant to the acid attack compared to hydroxyapatite
61951293|NCT03656432|ACTIVE_COMPARATOR|toothpaste contains fluoride|Fluoridated Toothpaste are the most significant and worldwide spread forms of caries control used globally as the greater acceptability of toothpaste makes its regular use more likely, thereby improving effectiveness
61951294|NCT02937675|EXPERIMENTAL|Tomivosertib (eFT-508) Escalation Cohort|This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
62342718|NCT04070170|EXPERIMENTAL|Low-level laser therapy and application of orthodontic force|Orthodontic force and Laser is applied on the first day and the premolars is extracted after 24 hours
62699700|NCT04824911|ACTIVE_COMPARATOR|Historical control|A historical control group of patients receiving single antiplatelet therapy but no high-intensity statin treatment will be drawn from previous prospective observation studies. Antiplatelet therapy includes aspirin(100-300mg/day) or Clopidopgrel (75mg/day).
61951295|NCT02937675|EXPERIMENTAL|Tomivosertib (eFT-508) Expansion Cohort|This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas
61951296|NCT05107674|EXPERIMENTAL|Phase 1a Dose Escalation of NX-1607 (monotherapy)|Multiple dose levels and dosing regimen of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose.
61951297|NCT05107674|EXPERIMENTAL|Phase 1a Food Effect|Impact of food on NX-1607 bioavailability and tolerability to be evaluated
61951298|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in platinum-resistant EOC|Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma
61951299|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in advanced gastric/GEJ cancer|Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma
61951300|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in HNSCC|Patients with recurrent, locally advanced, or metastatic HNSCC
61951301|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in recurrent melanoma|Patients with recurrent and either metastatic or unresectable Melanoma
61951302|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in advanced NSCLC|Patients with Stage IV adenocarcinoma NSCLC
62342719|NCT04070170|ACTIVE_COMPARATOR|Orthodontic force only|Orthodontic force is applied and the premolars is extracted after 24 hours, with no laser therapy
62342720|NCT04070170|EXPERIMENTAL|Low-level laser therapy and orthodontic force|Orthodontic force and Laser is applied and the orthodontic tooth movement is evaluated
61951303|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in mCRPC|Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA or radiographic progression
61951304|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in mixed solid tumor cohort|Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or DLBCL/DLBCL-RT
61951305|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in DLBCL including DLBCL-RT|Patients with DLBCL or DLBCL-RT, previously treated with standard, systemic chemotherapy, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options.
61951306|NCT05107674|EXPERIMENTAL|Phase 1a Dose Escalation of NX-1607 in combination with Paclitaxel|Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer. HSNCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer and cervical cancer.
61951307|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion of NX-1607 in combination with Paclitaxel|Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer, HSNCC, NSCLC, TNBC, and locally advanced or metastatic urothelial cancer
61951308|NCT05107674|EXPERIMENTAL|Phase 1b Dose Expansion in MSS CRC|Patients with histologically confirmed MSS CRC, known KRAS WT, and must have been previously treated with \> 2 lines of systemic therapy including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if known Ras wild type)
62342721|NCT04070170|ACTIVE_COMPARATOR|Orthodontic force with no laser therapy|Orthodontic force is applied and the orthodontic tooth movement is evaluated, with no laser therapy
62342722|NCT04427917|EXPERIMENTAL|PF-06835919|
62342723|NCT04427917|PLACEBO_COMPARATOR|Placebo|
62342724|NCT01273389|EXPERIMENTAL|CNTO 136|CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.
62500203|NCT01007409|ACTIVE_COMPARATOR|Group B|Period 1: fed control → Period 2: fasted control
62500204|NCT01007409|ACTIVE_COMPARATOR|Group A|Period 1: fasted control → Period 2: fed control
62500205|NCT01591824|EXPERIMENTAL|POLD TREATMENT|Patients who applies the treatment of resonant oscillation according to the Pold Concept
62500206|NCT01591824|ACTIVE_COMPARATOR|CONVENCIONAL: column exercise group|Patients who applied the conventional treatment of hospital
61951309|NCT00372762|ACTIVE_COMPARATOR|Furosemide|Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
61951310|NCT00372762|ACTIVE_COMPARATOR|Bumetanide|Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
61951311|NCT05039073|EXPERIMENTAL|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response or partial response at any time after 4 cycles may discontinue study therapy to proceed to autologous or allogeneic stem cell transplant.
61951312|NCT00962910|EXPERIMENTAL|Pathway|A care pathway will be implemented in this experimental group.
61951313|NCT00962910|NO_INTERVENTION|Usual Care|Usual Care will be provided.
61951314|NCT05711784|EXPERIMENTAL|Phaseolean (White Kidney Bean Standardized Extract)1500 mg Capsules|Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
61951315|NCT05711784|EXPERIMENTAL|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
61951316|NCT05711784|PLACEBO_COMPARATOR|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
61951317|NCT01642979|EXPERIMENTAL|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
61951318|NCT01642979|ACTIVE_COMPARATOR|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
61951319|NCT01642979|ACTIVE_COMPARATOR|Glucocorticoids|Glucocorticoids
61951320|NCT03273270|EXPERIMENTAL|Active TMS|1 Hz repetitive transcranial magnetic stimulation
62342725|NCT01273389|PLACEBO_COMPARATOR|Placebo|
62342726|NCT02288624|PLACEBO_COMPARATOR|Control|Water control (240 ml)
62342727|NCT02288624|EXPERIMENTAL|Orange Juice|Orange juice, 240 ml. Commercial orange juice
62342728|NCT02288624|EXPERIMENTAL|Whole orange|Whole orange, 240 ml. Whole orange, blended to include all edible orange material.
62342729|NCT02288624|EXPERIMENTAL|processed orange juice|Processed orange juice, 240 ml. Experimental orange juice processing
62342730|NCT00789958|EXPERIMENTAL|Adjuvant Chemo+ Chemoradiotherapy|"Adjuvant Chemotherapy~* Capecitabine, 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~* Gemcitabine hydrochloride, 1000 mg/m\^2, IV, Days 1 \& 8 of each cycle~Chemoradiotherapy~-Capecitabine, 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT~Radiation (RT):~3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.~intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions."
62500207|NCT00496262|EXPERIMENTAL|Human Fibrinogen Concentrate|
62500208|NCT04511611|EXPERIMENTAL|Test A: 10 mg ODT with water, then 10 mg film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
62500209|NCT04511611|EXPERIMENTAL|Test A: 10 mg film-coated tablet, then 10 mg ODT with water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
62699701|NCT05054101|EXPERIMENTAL|VieCovid2020 smartphone application|The VieCovid2020 smartphone application in add-on to usual psychiatric intervention
62342731|NCT04675359|ACTIVE_COMPARATOR|Enzymatic digestion group|A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue
61951321|NCT03273270|PLACEBO_COMPARATOR|Sham TMS|No active stimulation
61951322|NCT00113022|EXPERIMENTAL|Org 24448|Blinded, active experimental compound
61951323|NCT00113022|PLACEBO_COMPARATOR|Placebo|Blinded placebo
61951324|NCT00317512|ACTIVE_COMPARATOR|1|Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
61951325|NCT00317512|ACTIVE_COMPARATOR|2|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
61951326|NCT00317512|EXPERIMENTAL|3|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by HBOC-201 at 7.7 ml/min over 15 minutes
62342732|NCT04675359|ACTIVE_COMPARATOR|Mechanical fragmentation group|A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint
62342733|NCT04550221|EXPERIMENTAL|Intervention|The Shauriana intervention is aimed at promoting sexual health and preventing HIV through a comprehensive prevention toolbox including PrEP. Components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions.
62342734|NCT04550221|ACTIVE_COMPARATOR|Standard care|Standard care includes clinic-based HIV counseling and testing, screening for symptoms of sexually transmitted infections (STI), and individual counseling about HIV prevention methods. Standard of care counseling for HIV prevention in Kenya includes general information about HIV transmission and discussions of risk reduction including condom use. PrEP counseling sessions focus on PrEP knowledge, adherence tips, and strategies to address adherence barriers.
62342735|NCT06472388|EXPERIMENTAL|Everolimus 5|oral everolimus 5 mg/daily continuously until progression or intolerance or consent withdrawal. dose reduction for toxicity is allowed.
62342736|NCT06472388|ACTIVE_COMPARATOR|Everolimus 10|oral everolimus 10 mg/daily continuously until progression or intolerance or consent withdrawal. dose reduction for toxicity is allowed.
62342737|NCT01258530|EXPERIMENTAL|Treatment A|Over-encapsulated oseltamivir 75 mg (1 capsule)
62342738|NCT01258530|EXPERIMENTAL|Treatment B|oseltamivir 75 mg (1 capsule)
62342739|NCT01690169|EXPERIMENTAL|NNC0113-0987|
62342740|NCT01690169|PLACEBO_COMPARATOR|Placebo|
62500210|NCT04511611|EXPERIMENTAL|Test B: 10 mg ODT without water, then 10 film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
62500211|NCT04511611|EXPERIMENTAL|Test B: 10 mg film-coated tablet, then 10 mg ODT without water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
61951327|NCT04267822|EXPERIMENTAL|RV521 Capsules|RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
62500212|NCT05352438|EXPERIMENTAL|Manual Therapy Group|Manual Therapy combined with education and home exercises
62500213|NCT05352438|EXPERIMENTAL|Splint Therapy Group|Splint Therapy combined with education and home exercises
62500214|NCT01806311|ACTIVE_COMPARATOR|PartA: Candesartan, Candesartan + Amolodipine|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
61951328|NCT04267822|PLACEBO_COMPARATOR|RV521 Placebo Capsules|RV521 placebo capsules will contain mannitol and microcrystalline cellulose only. They are a white, opaque capsule and administered orally.
62500215|NCT01806311|ACTIVE_COMPARATOR|PartB: Amlodipine, Amlodipine+Candesartan|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
62500216|NCT01910831|EXPERIMENTAL|DerMend Moisturizing Bruise Formula|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Applied twice daily for 12 weeks. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
62699702|NCT05054101|PLACEBO_COMPARATOR|Usual psychiatric intervention|Usual psychiatric intervention alone
62699703|NCT03468998|ACTIVE_COMPARATOR|Ridge Preservation with Small Particle Allograft|
61951329|NCT02028754|EXPERIMENTAL|Sodium Carboxymethylcellulose and Conventional Therapy|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
61951330|NCT02028754|ACTIVE_COMPARATOR|Conventional Therapy|Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
61951331|NCT00289133|ACTIVE_COMPARATOR|GVF|Gamma Vacuum Foil polyethylene tibial insert
61951332|NCT00289133|ACTIVE_COMPARATOR|P.F.C.|Cross-linked polyethylene tibial insert
61951333|NCT01977742|ACTIVE_COMPARATOR|Initiate with SEP but without RTTE|Initiate supervised exercise (SEP) program but without rest-exercise transition training (RTTE)to improve cardiac vagal tone at same time; will stop RTTE after 8 weeks.
61951334|NCT01977742|ACTIVE_COMPARATOR|Initiate with RETT and SEP|"Supervised exercise program (aerobic, strength and flexibility exercises) and a specific sudden rest-exercise training protocol, three times a week. After 8 weeks, the sudden rest-exercise training protocol will be discontinued.~The cardiac vagal index will be measured at every 8 weeks."
61951335|NCT01162460|ACTIVE_COMPARATOR|Carbamazepine controlled release|
61951336|NCT01162460|EXPERIMENTAL|Eslicarbazepine acetate|
61951337|NCT05875428|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|The eligible patients will receive mitoxantrone hydrochloride liposome injection (20 mg/m\^2) once every 4 weeks for a maximum of 8 cycles.
61951338|NCT01146665|EXPERIMENTAL|Computer-based PAF|Standard medical care followed by computer-based personalized assessment feedback (PAF).
61951339|NCT01146665|SHAM_COMPARATOR|Computer-based sham|Standard medical care followed by a computer-based sham.
62500217|NCT01910831|PLACEBO_COMPARATOR|Non-active placebo control|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
61951340|NCT01215565|EXPERIMENTAL|patient treated|patient who receive sunitinib
62500218|NCT05489796|EXPERIMENTAL|Dual group|The two drugs are administered separately.
62500219|NCT05489796|ACTIVE_COMPARATOR|Single group|One drug is administered alone.
62699704|NCT03468998|ACTIVE_COMPARATOR|Ridge Preservation with Large Particle Allograft|
61951341|NCT01122771|ACTIVE_COMPARATOR|Ambisome|15mg Ambisome on days 1,3 and 5
61951342|NCT01122771|EXPERIMENTAL|Ambisome + Miltefosine|Ambisome 5mg + miltefosine 10 days
61951343|NCT01122771|EXPERIMENTAL|Ambisome +paromomycin|AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
61951344|NCT01122771|EXPERIMENTAL|Miltefosine + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
61951345|NCT06071208||cases of study|Patients is diabetes whether recently discovered or long standing diabetes
61951346|NCT06071208||controls of study|prediabetics ,or patients with clinical manifestations of insulin resistance eg acanthosis negricans
61951347|NCT03329508|EXPERIMENTAL|P2B001 0.6/0.75 mg|Fixed dose combination once daily capsule of pramipexole 0.6mg and rasagiline 0.75mg, + matching placebo tablet
61951348|NCT03329508|EXPERIMENTAL|rasagiline 0.75mg|Rasagiline 0.75mg Once daily capsule, component of P2B001, + matching placebo tablet
61951349|NCT03329508|EXPERIMENTAL|Pramipexole 0.6mg|Pramipexole 0.6mg once daily capsule, component of P2B001 + matching placebo tablet
61951350|NCT03329508|ACTIVE_COMPARATOR|Pramipexole Extended Release|Marketed pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg + matching placebo capsule
61951351|NCT02539446|OTHER|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
61951352|NCT02539446|OTHER|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
61951353|NCT04449601||Group 1 (with hypertension )|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
61951354|NCT04449601||Group 2( without hypertension)|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
61951355|NCT05882942|EXPERIMENTAL|Placebo|Participants will be supplemented with a placebo.
61951356|NCT05882942|EXPERIMENTAL|Matcha green tea|Participants will be supplemented with Matcha green tea.
61951357|NCT02605070|EXPERIMENTAL|Infertility group|Patients referred will be evaluated to participate in the study and then asked to take part.In this visit,the normal protocol for infertility patients will be followed and at least 2 spermiograms and a blood test analyzing the following parameters:FSH, LH,Estradiol,Total testosterone,SHBG, Albumin,Calculation of bioavailable testosterone,Prolactin.If these tests have not been performed,a second baseline visit will be scheduled.Should the patient meet all the inclusion criteria and after the patient has signed an informed consent form agreeing to participate in the study,the physician will prescribe the medication and schedule visits.Before initiating the treatment, they will provide a semen sample.This sample will be sent to the Center for Reproductive Biology,where the sample will be subjected to epigenetic analysis.The patient will be given samples of Bravelle.It is administered subcutaneously.The dose will be 150 IU 3times a week for 3months
62342741|NCT06079775|EXPERIMENTAL|Single Dose Drug-Drug-Interaction Crossover & Multiple Dose Cohorts|"During the DDI crossover part of the study, 24 subjects will be enrolled into 3 cohorts of 8 subjects each, Cohorts 1, 2, \& 3 respectively.~All subjects in Cohorts 1, 2, and 3 will receive a single dose of xeruborbactam oral prodrug on Day 1. On Day 6, they will receive a single dose of ceftibuten. On Day 9 they will receive a single combined dose of xeruborbactam oral prodrug and ceftibuten.~During the MAD part of the study, 48 subjects will be enrolled into 3 cohorts of 16 subjects each, Cohorts 4, 5, \& 6 respectively.~All subjects in Cohorts 4, 5, and 6 will receive either a combined dose of xeruborbactam oral prodrug and ceftibuten, active ceftibuten, or active xeruborbactam oral prodrug.~Cohort 4 \& 5 will be dosed BID on Days 1 through 9, with last and final dose on the morning of Day 10.~Cohort 6 will be dosed BID on Day 1, and then QD on Days 2 through 10 with last dose on the morning of Day 10.~All subjects will be followed for safety and PK data collection."
62342742|NCT06079775|PLACEBO_COMPARATOR|Placebo Comparator to maintain the blind|During the multiple-dose portion of the study, Xeruborbactam Oral Prodrug Placebo and Ceftibuten placebo will be used to maintain the blind. In Cohorts 4, 5, and 6, ten (10) subjects in each cohort will receive a combined dose of xeruborbactam oral prodrug and ceftibuten. Three (3) subjects in each cohort will receive active ceftibuten capsules with xeruborbactam oral prodrug placebo capsules. Three (3) subjects in each cohort will receive active xeruborbactam oral prodrug capsules with ceftibuten placebo capsules.
62342743|NCT00965783|EXPERIMENTAL|1|Sleep time restriction
62342744|NCT00965783|EXPERIMENTAL|2|Sleep time extension
62342745|NCT05194046|EXPERIMENTAL|Sequence A|"T1→Washout period(D6\~14)→ T3→Washout period(D20\~28)→ T2~* T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days~* T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~* T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
62342746|NCT05194046|EXPERIMENTAL|Sequence B|"T1 →Washout period(D6\~14)→ T2→Washout period(D20\~28) → T3~* T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~* T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~* T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
62500220|NCT04712643|EXPERIMENTAL|Arm A: atezolizumab + bevacizumab + TACE|Participants will receive atezolizumab plus bevacizumab on Day 1 of a 21-Day cycle, after every on-demand transarterial chemoembolization procedure.
62699705|NCT03468998|ACTIVE_COMPARATOR|Ridge Augmentation with Small Particle Allograft|
62699706|NCT03468998|ACTIVE_COMPARATOR|Ridge Augmentation with Large Particle Allograft|
61951358|NCT02605070|NO_INTERVENTION|Fertily group|"Patients who volunteer will be informed of the nature of the study and asked to sign the informed consent form. At least two spermiograms will be performed along with a blood test analyzing the following parameters:FSH,LH,Estradiol,Total testosterone,SHBG,Albumin,Estimation of bioavailable testosterone,Prolactin.~A second baseline visit will be scheduled to evaluate the test results and to check whether these subjects meet all the inclusion criteria for the control group. Those subjects will provide a semen sample which will be stored at -20º C.~Outpatient visit: week twelve: a physical exam will be carried out to identify any adverse reactions. A blood test and a semen sample will also be obtained."
61951359|NCT00481143|EXPERIMENTAL|deferasirox|
61951360|NCT05259514|EXPERIMENTAL|CytoSorb|Phase 2: 40 (20 each in treatment and control group). The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
61951361|NCT05259514|NO_INTERVENTION|Standard of Care|Only routine treatment
61951362|NCT00725374|ACTIVE_COMPARATOR|Arm 1|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with tibolone
61951363|NCT00725374|PLACEBO_COMPARATOR|Arm 2|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with placebo
61951364|NCT02349529|EXPERIMENTAL|Psychosocial group intervention|
61951365|NCT02349529|OTHER|Waiting List control|Participants in the waiting list control will continue in TAU but will then start the intervention once the first group of participants have completed the 3 month follow up in the psychosocial group intervention arm.
62342747|NCT05194046|EXPERIMENTAL|Sequence C|"T2 →Washout period(D6\~14)→ T3→Washout period(D20\~28) → T1~* T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days~* T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~* T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
62500221|NCT04712643|ACTIVE_COMPARATOR|Arm B: TACE alone|Participants will receive on-demand transarterial chemoembolization.
62500222|NCT02625376|EXPERIMENTAL|Trans-Resveratrol|capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
62500223|NCT02625376|ACTIVE_COMPARATOR|Resvega|"capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.~two capsules daily : one in the morning and evening for 24 months"
62500224|NCT02625376|PLACEBO_COMPARATOR|Placebo|capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
62500225|NCT06183320|ACTIVE_COMPARATOR|Incremental Composite in Proximal Wall|38 teeth will receive class II restorations using flowable bulk fill composite to fill the cavities, leaving the proximal wall and the occlusal surface to be restored with traditional incremental composite.
61951366|NCT05216783|EXPERIMENTAL|Experimental|The Personal Information Form, the Traumatic Childbirth Perception Scale (TCPS), and the short-form Childbirth Self-Efficacy Inventory (CBSEI-32) were utilized for the collection of research data. First of all, the TCPS was applied to the pregnant women, and the pregnant women who obtained a score above 53 points (moderate-level traumatic childbirth perception) from the TCPS were invited to the research. Next, the Personal Information Form and the CBSEI-32 were applied to the pregnant women who agreed to participate in the research. The motivational interviews were held with the pregnant women in the experimental group once a week for four weeks. No initiative was applied to the pregnant women in the control group. The TCPS and CBSEI-32 were applied to all participant pregnant women after four weeks following the first application. The application of the measurement tools took 10-15 minutes.
61951367|NCT05216783|NO_INTERVENTION|Control|The researchers applied no initiative to the control group, and the pregnant women in the control group solely had the routine checks performed at the city hospital. At the end of the study, the questions of pregnant women in the cotrol group about childbirth were answered. Before applying the initiative to the experimental group, the researcher (SB) had had training about motivational interview techniques.
62164515|NCT02879669|ACTIVE_COMPARATOR|Pemetrexed/cisplatin (carboplatin)|Patients will be treated with pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy. Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
62164516|NCT02025023|ACTIVE_COMPARATOR|Incision and Curettage|A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.
62164517|NCT02025023|ACTIVE_COMPARATOR|Injection of Triamcinolone Acetonide|0.1 ml of triamcinolone is injected directly in the chalazion.
62164518|NCT02025023|ACTIVE_COMPARATOR|Injection of 5-fluorouracil|0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.
62164519|NCT02025023|ACTIVE_COMPARATOR|Injection of triamcinolone/5FU mixture|0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.
62164520|NCT02660047|ACTIVE_COMPARATOR|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
62164521|NCT02660047|PLACEBO_COMPARATOR|Liraglutide - Placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dose: same as Liraglutide~Duration: 26 weeks"
62164522|NCT00767585||A:|70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
62164523|NCT00767585||B|70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
62164524|NCT00767585||C|70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
62164525|NCT00767585||D|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
61951368|NCT02095093|EXPERIMENTAL|Intellijoint HIP|Patient's will have their leg length and hip offset determined intraoperatively using Intellijoint HIP.
62500226|NCT06183320|EXPERIMENTAL|Bulk Fill Composite in Proximal Wall|38 teeth will receive class II restorations using flowable bulk fill composite to fill the cavities, leaving the occlusal surface to be restored with traditional incremental composite.
61951369|NCT02095093|ACTIVE_COMPARATOR|Outrigger|Control patients will have their leg length and hip offset determined intra-operatively using the standard at Mount Sinai Hospital, which is a pin and outrigger system.
61951370|NCT02179866|EXPERIMENTAL|[14C]-labeled RO5285119|Single oral dose - drinking solution
61951371|NCT00653120|EXPERIMENTAL|A|Subjects received Par Products under fasting conditions
61951372|NCT00653120|ACTIVE_COMPARATOR|B|Subjects received Wyeth Pharmaceuticals product under fasting conditions
62500227|NCT05868824|EXPERIMENTAL|Main Cohort|
62500228|NCT04193579|EXPERIMENTAL|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
61951373|NCT06556589||Collaborative Care offered|Implement collaborative care in at least 2 clinic locations for patients with depression and/or anxiety using population-based outreach using electronic health record tools and provider referral, and tracking outcomes in the medical record.
62342748|NCT05194046|EXPERIMENTAL|Sequence D|"T2 →Washout period(D6\~14)→ T1→Washout period(D20\~28) → T3~* T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~* T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~* T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
62342749|NCT05194046|EXPERIMENTAL|Sequence E|"T3 →Washout period(D6\~14)→ T1→Washout period(D20\~28) → T2~* T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~* T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~* T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
62342750|NCT05194046|EXPERIMENTAL|Sequence F|"T3 →Washout period(D6\~14)→ T2→Washout period(D20\~28) → T1~* T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~* T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~* T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
62500229|NCT04193579|SHAM_COMPARATOR|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
62500230|NCT01745094|EXPERIMENTAL|Concomitant Group|concomitant administration of mirabegron to solifenacin treated patients
62500231|NCT03880149|EXPERIMENTAL|Omega-3 supplementation|Omega-3 fatty supplementation and vitamin E. Each 1 g omega-3 capsule contain 600 mg omega-3 including 400 mg EPA + 200 mg DHA. Individual omega-3 dose will be determined according to the athlete's body mass, 1 g omega-3 / 15 kg body mass per day and vitamin E: 1 capsule of vitamin E (400 IU) for every five omega-3 capsules
62500232|NCT03880149|PLACEBO_COMPARATOR|Placebo|Medium-chain triglyceride (MCT) and vitamin E. Each MCT capsule contain 1 g, the dose will be 115 mg per kg body mass per day, and vitamin E: 1 capsule of vitamin E (400 IU) for every five MCT capsules
62500233|NCT03206151|EXPERIMENTAL|CMAB009 + FOLFIRI|"Drug: CMAB009(recombinant chimeric anti-EGFR monoclonal antibody injection), will be administered every 7 days at an initial dose of 400mg/m\^2 and 250mg/m\^2 for subsequent infusions until progression of disease , withdrawal of consent, or unacceptable toxicity.~Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m\^2 on Day 1. Drug: Folinic Acid infusion 400mg/m\^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-48 h continuous infusion of 2400mg/m\^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
61951374|NCT06556589||No Collaborative Care offered|Provide care as usual for patients with depression and/or anxiety at all other KPCO clinics.
61951375|NCT01423370|EXPERIMENTAL|Group A|
61951376|NCT01423370|EXPERIMENTAL|Group B|
61951377|NCT01423370|EXPERIMENTAL|Group C|
61951378|NCT01423370|ACTIVE_COMPARATOR|Group D|
61951379|NCT01423370|PLACEBO_COMPARATOR|Group E|
61951380|NCT01902199|ACTIVE_COMPARATOR|TRAA|participants will be given the active TRAA intervention where landscape images are linked with a push motion, and portrait images linked with a pull motion. Pictures will exclusively be related to smoking.
61951381|NCT01902199|PLACEBO_COMPARATOR|Control|participants will be given a mix of landscape and portrait pictures, equally divided into push or pull. the images will be a mix of smoking related pictures and non smoking pictures.
61951382|NCT06027294|EXPERIMENTAL|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive six sessions of ischemic conditioning over the course of two weeks.
61951383|NCT06027294|SHAM_COMPARATOR|Ischemic Conditioning Sham|There will also be an IC Sham group which is identical to the IC intervention, except the cuff will only be inflated to 10 mmHg, which is not a high enough pressure to occlude arterial blood flow.
61951384|NCT05664490|NO_INTERVENTION|Standard-of-Care Mental Health Services|Participants randomized to this group will receive standard-of-care mental health services as specified in the South African Department of Health Adult Primary Care Guidelines.
61951385|NCT05664490|EXPERIMENTAL|Youth Friendship Bench SA + Standard-of-Care|Participants randomized to this group will receive the Youth Friendship Bench SA intervention in addition to standard-of-care mental health services as specified in the South African Department of Health Adult Primary Care Guidelines.
61951386|NCT04939116|EXPERIMENTAL|200 mg QD|200 mg of ANG-3070 will be taken once daily for 12 weeks.
62500234|NCT03206151|ACTIVE_COMPARATOR|FOLFIRI|"FOLFIRI Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m\^2 on Day 1. Drug: Folinic Acid infusion 400mg/m\^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-48 h continuous infusion of 2400mg/m\^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
62500235|NCT01355328|EXPERIMENTAL|laser|
62500236|NCT01355328|NO_INTERVENTION|control|
62500237|NCT02177552|EXPERIMENTAL|Experimental chemotherapy|Intravenous carboplatin (C) AUC5 day 1 plus intravenous docetaxel (T) 60 mg/m2 day 1 plus oral capecitabine (X) 1000 mg/m2 twice daily from day 1-14, every 4 weeks.
62500238|NCT02177552|OTHER|Standard chemotherapy|Intravenous epirubicin (E) 50 mg/m2 day 1 plus intravenous oxaliplatin (O) 130 mg/m2 day 1 plus oral capecitabine (X) 625 mg/m2 twice daily continuously, every 3 weeks
62500239|NCT02795676|EXPERIMENTAL|PRX-102 (pegunigalsidase alfa)|PRX-102 infusion every 2 weeks
62500240|NCT02795676|ACTIVE_COMPARATOR|agalsidase beta|agalsidase beta infusion every 2 weeks
62342751|NCT00235690|OTHER|blood draws|all patients enrolled will have PK blood samples obtained around a colistin dosing
62342752|NCT03751592|EXPERIMENTAL|Chlorogenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
62342753|NCT02604927|PLACEBO_COMPARATOR|Placebo|800 mg of dextrose, four times per day, during 28 days.
62500241|NCT03900884|EXPERIMENTAL|Letrozole + Palbociclib + Venetoclax|"The Letrozole dose is 2.5 mg (D1-28) for all dose levels.~Starting dose Level 1: Palbociclib 100 mg (D1-21) and Venetoclax 100 mg (D1-21) daily."
61951387|NCT04939116|EXPERIMENTAL|400 mg QD|400 mg of ANG-3070 will be taken once daily for 12 weeks
62342754|NCT02604927|EXPERIMENTAL|Beta-alanine|800 mg of beta-alanine, four times per day, during 28 days.
62342755|NCT04408118|EXPERIMENTAL|Atezolizumab + Paclitaxel + Bevacizumab (Avastin®)|"All eligible patients will be treated with atezolizumab (840 mg) intravenously on days 1 and 15, Paclitaxel (90 mg/m2) on days 1, 8 and 15 via IV infusion and Bevacizumab (Avastin® 10mg/kg) intravenously on days 1 and 15.~Treatment cycles and patient visits are organized in scheduled cycles of 28 days."
62342756|NCT02807064|ACTIVE_COMPARATOR|Bifidobacteria mixture 0.5 ml|Bifidobacteria 0.5 ml per os all days for 2 months
62342757|NCT02807064|PLACEBO_COMPARATOR|placebo|Placebo 0.5 ml per os all days for 2 months
62342758|NCT01098461|ACTIVE_COMPARATOR|albiglutide 15mg weekly|once weekly subcutaneous injection of albiglutide 15mg
62342759|NCT01098461|ACTIVE_COMPARATOR|albiglutide 30mg weekly|once weekly subcutaneous injection of albiglutide 30mg
62342760|NCT01098461|ACTIVE_COMPARATOR|albiglutide 30mg every other week|subcutaneous injection of 30mg albiglutide every other week
62342761|NCT01098461|PLACEBO_COMPARATOR|placebo|once weekly subcutaneous injection of placebo to match albiglutide
62342762|NCT03046940|NO_INTERVENTION|Control group|No communication with a doctor
62342763|NCT03046940|EXPERIMENTAL|Patient-centered|Participants communicate with a doctor that uses a patient-centered style of communication
62500242|NCT05454085|OTHER|pregnancies with neural tube defects|patients with pre-diagnosis of neural tube defects (47 patients).
62500243|NCT05454085|OTHER|pregnancies without neural tube defects|patients with abnormal maternal serum screening test or prenatal diagnosis test, patients with abnormal ultrasonography findings (45 patients)
62500244|NCT02431624|EXPERIMENTAL|Test treatment|BTDS 40 milligram
62500245|NCT02431624|ACTIVE_COMPARATOR|Reference treatment|BTDS 20 milligram
62500246|NCT04245358|OTHER|Ainara|Ainara is a class II medical device, already marketed in several EU countries. Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
62500247|NCT06358963|EXPERIMENTAL|CoQ10|Group A will receive 30 mg of CoQ10 daily, after teh two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
61951388|NCT04939116|EXPERIMENTAL|300 mg BID|300 mg of ANG-3070 will be taken twice a day for 12 weeks.
62342764|NCT03046940|EXPERIMENTAL|Doctor-centered|Participants communicate with a doctor that uses a doctor-centered style of communication
62500248|NCT06358963|EXPERIMENTAL|Omega-3|Group B will be given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare the total antioxidant capacity in saliva before and after the intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at the beginning and end of the study for analysis using UV-spectrophotometric methods, furthermore, the following criteria determined the selection of eligible participants for dis study.
61951389|NCT04939116|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be taken once or twice daily for 12 weeks.
61951390|NCT01431989|ACTIVE_COMPARATOR|Test formulation|Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.
62342765|NCT04316663|EXPERIMENTAL|Well-Being and Sleep Hygiene|Participants in the experimental group will receive an intervention focused on both principles of psychological well-being and sleep hygiene education.
62342766|NCT04316663|ACTIVE_COMPARATOR|Sleep Hygiene (Control)|Participants in the control group will receive sleep hygiene education alone.
62342767|NCT01916993|EXPERIMENTAL|Healthy Volunteers|single dose of NBI-98854 50 mg capsule
62342768|NCT01916993|EXPERIMENTAL|Mild Hepatic Impairment|single dose of NBI-98854 50 mg capsule
62342769|NCT01916993|EXPERIMENTAL|Moderate Hepatic Impairment|single dose of NBI-98854 50 mg capsule
62342770|NCT01916993|EXPERIMENTAL|Severe Hepatic Impairment|single dose of NBI-98854 50 mg capsule
62342771|NCT03522272|EXPERIMENTAL|Ultrasonic cleaning with cetylpyridinium chloride|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with 0.07% cetylpyridinium chloride mouthrinse
62500249|NCT06358963|ACTIVE_COMPARATOR|No-medication;|Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare the total antioxidant capacity in saliva before and after the intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at the beginning and end of the study for analysis using UV-spectrophotometric methods, furthermore, the following criteria determined the selection of eligible participants for this study.
62699707|NCT01445275||Ancillary-Correlative (Health Services Research)|Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
62699708|NCT00392574|EXPERIMENTAL|1|Prulifloxacin
62699709|NCT00392574|PLACEBO_COMPARATOR|2|Placebo
62500250|NCT06608030|EXPERIMENTAL|Esketamine group|Patients who undergo general anesthesia using esketamine.
62500251|NCT06608030|PLACEBO_COMPARATOR|Control group|Patients who undergo general anesthesia without esketamine
61951391|NCT01431989|ACTIVE_COMPARATOR|Reference formulation|Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2
61951392|NCT00972582|EXPERIMENTAL|Leucine|
61951393|NCT04148352|EXPERIMENTAL|Dupilumab|24-week treatment period, which includes a 4-week run-in period with dupilumab followed by 12 weeks of treatment with dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no dupilumab
61951394|NCT04148352|PLACEBO_COMPARATOR|Placebo|24-week treatment period, which includes a 4-week run-in period with placebo for dupilumab followed by 12 weeks of treatment with placebo for dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no placebo
62500252|NCT05958381|EXPERIMENTAL|Transcranial direct current stimulation|"Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.~Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10"
62500253|NCT05958381|SHAM_COMPARATOR|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
62500254|NCT00258856|EXPERIMENTAL|Menactra® Group 1|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination.
62500255|NCT00258856|EXPERIMENTAL|Menactra® Group 2|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination.
62500256|NCT00258856|EXPERIMENTAL|Meningococcal Vaccine-naïve Group 3|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination.
62699710|NCT04838288|EXPERIMENTAL|Change from Prograf to Envarsus|All participants will be switched from Prograf to Envarsus
61951395|NCT01918384|EXPERIMENTAL|NPC-14|Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
61951396|NCT01918384|PLACEBO_COMPARATOR|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
61951397|NCT05832801|OTHER|Group ( Traditional dietary advice)|Each patient will follow traditional dietary advice only for 2 months.
61951398|NCT05832801|EXPERIMENTAL|Group (Pilates and traditional dietary advice )|Patients in this group will participate in 2 months Pilates exercise program, 2 times per week for 16 sessions, and will follow traditional dietary advice. Warming up and cooling down stretches for 5 minutes will be done before and after exercise .
62699711|NCT00663078|EXPERIMENTAL|A|Group A: Women from GP practices and area of Knowle West, Bristol
62699712|NCT00663078|EXPERIMENTAL|B|Group B: Women from Wellspring, GP practice or geographical area of Barton Hill Bristol.
62342772|NCT03522272|ACTIVE_COMPARATOR|Ultrasonic cleaning with water|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with distilled water
62342773|NCT03522272|ACTIVE_COMPARATOR|Conventional denture hygiene|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent (Control group)
62342774|NCT02077387|EXPERIMENTAL|CHild Inhibitory Control Play (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
62699713|NCT05632393|EXPERIMENTAL|Daridorexant 50 mg|Daridorexant 50 mg will be administered once in the morning of Day 1.
62699714|NCT03058874|PLACEBO_COMPARATOR|Control arm|Standard protocol of fluid management in hemodialysis
62699715|NCT03058874|EXPERIMENTAL|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
61951399|NCT03643796|ACTIVE_COMPARATOR|Remifentanil Group|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
61951400|NCT03643796|ACTIVE_COMPARATOR|Ketamine and Dexmedetomidine group|"dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.~Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation."
61951401|NCT04239859|EXPERIMENTAL|Secukinumab|"Participants will be offered secukinumab as first-line systemic treatment for moderate to severe PsO. The indication for secukinumab will be equivalent to current registered indications. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months.~secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care."
62500257|NCT00258856|EXPERIMENTAL|Meningococcal Vaccine-naïve Group 4|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination.
62500258|NCT06347809||Observational|"PHASE I: Participants undergo urine sample collection on study.~PHASE II: Participants undergo standard prostate massage and collection of prostatic fluid and urine samples on study.~All participants complete a questionnaire and have their medical records reviewed on study."
61951402|NCT04239859|ACTIVE_COMPARATOR|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
61951403|NCT05091359|EXPERIMENTAL|Study group|Participants in which absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste at the time of the placement of the hip implant to prevent loosening of it's unstable trans-trochanteric fractures of the proximal femur, were applied.
61951404|NCT05091359|NO_INTERVENTION|Control Group|Participants without application of graft during hip implant.
61951405|NCT03295084|EXPERIMENTAL|Irinotecan|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily for 14 days within 3 week treatment cycle
61951406|NCT03295084|EXPERIMENTAL|Irinotecan with Capecitabine|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily in combination with Capecitabine tablet taken twice daily for 14 days within 3 week treatment cycle
61951407|NCT04431180|EXPERIMENTAL|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors'life saving donation during 2019-nCoV epidemic.
62342775|NCT02077387|ACTIVE_COMPARATOR|Attention control|Children will receive information regarding other healthy behaviors: brushing teeth, sunscreen use, being physically active
62342776|NCT00729313|EXPERIMENTAL|1|"Drug: Lanreotide 30 mg microparticle formulation~One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h~For non-responders patients lanreotide will be stopped."
62342777|NCT00729313|PLACEBO_COMPARATOR|2|"One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment."
62342778|NCT05140954|EXPERIMENTAL|Perfect Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC once daily (7 doses per week).
62500259|NCT03927495|EXPERIMENTAL|Concurrent chemoradiotherapy and KN046|Participants in the Arm I will receive chemoradiotherapy and concurrent KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
62500260|NCT03927495|EXPERIMENTAL|chemoradiotherapy and sequential KN046|Participants in the Arm II will receive chemoradiotherapy and sequential KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
62500261|NCT05494632|EXPERIMENTAL|Single arm|CI speech processor programming
61951408|NCT04431180|EXPERIMENTAL|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
61951409|NCT04431180|EXPERIMENTAL|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
61951410|NCT04431180|PLACEBO_COMPARATOR|SMS with blood donor day greeting|SMS content in this group will be about SMS with blood donor day greeting.
61951411|NCT05703516||Capmatinib|Participants will be treated with capmatinib as per locally approved label
61951412|NCT01205204|ACTIVE_COMPARATOR|BF25 (Control)|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
61951413|NCT01205204|EXPERIMENTAL|BC15(Study 1)|GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
61951414|NCT01205204|EXPERIMENTAL|BC30(Study 2)|GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
61951415|NCT01205204|EXPERIMENTAL|BC60 (Study 3)|GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
62342779|NCT05140954|EXPERIMENTAL|Moderate Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC 4 times per week
62500262|NCT04883788||Pandemic group|Patients undergone hip and knee replacement during pandemic period (June-december 2020)
62500263|NCT04883788||Pre-pandemic group|Patients undergone hip and knee replacement during the pre-pandemic period (january-march 2020)
62141044|NCT06038747|EXPERIMENTAL|Individual Psychotherapy + Self-Monitoring|Participants in the intervention group will continue their regular individual psychotherapy sessions. Additionally, after each session, they will complete a brief postsession battery consisting of two scales on the affective reactions of the participants towards their therapist during session and read general feedback encouraging them to discuss their feelings and reflections with their therapist. This questionnaire aims to prompt reflection on the own experience of the therapeutic relationship.
62342780|NCT05140954|EXPERIMENTAL|Poor Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC twice per week
61951416|NCT01112358|EXPERIMENTAL|r-FSH + r-hLH|Lutropin alfa (r-hLH) will be administered at a daily dose of 150 International Units (IU) from the presence of at least one follicle greater than (\>) 14 millimeter (mm) to complete ovarian stimulation. Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 milligrams (mg) of recombinant Human Chorionic Gonadotropin (r-hCG) will be administered subcutaneously at 12 hours after the last injection of lutropin alfa and/or follitropin alfa and analogous GnRH antagonist.
61951417|NCT01112358|ACTIVE_COMPARATOR|r-FSH|Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 mg of r-hCG will be administered subcutaneously at 12 hours after the last injection of follitropin alfa and analogous GnRH antagonist.
61951418|NCT02703831|ACTIVE_COMPARATOR|Dual attending|Two attending spine surgeons during the critical portions of the surgery
61951419|NCT02703831|PLACEBO_COMPARATOR|Single attending|One spine attending and an assistant during the critical portions of the surgery, The assistant can be a spine fellow, a resident or a physician's assistant.
61951420|NCT06350396|EXPERIMENTAL|active rTMS treatment|3 sessions of active rTMS would be delivered to the left DMPFC daily, with 1800 pulse/session.
61951421|NCT06350396|SHAM_COMPARATOR|sham control|The identical treatment parameters will be administered akin to the active rTMS treatment, albeit devoid of actual stimulation.
61951422|NCT03651544|EXPERIMENTAL|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
61951423|NCT03651544|EXPERIMENTAL|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
61951424|NCT03651544|EXPERIMENTAL|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
61951425|NCT03922997|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
61951426|NCT04315883||Standard Treatment|"Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
61951427|NCT02025322|NO_INTERVENTION|Standard of Care|Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
61951428|NCT02025322|EXPERIMENTAL|Peer Mentoring|Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
62699716|NCT05438121||Patients with multivessel CAD undergoing DCB PCI|"I. Patients with significant multi-vessel coronary artery disease will be screened.~II. If the patient is found to have at least one lipid-rich plaque (LRP, LCBI\>250) requiring revascularization (DS\>70%) will undergo multi-vessel IVUS-NIRS imaging.~III. If multi-vessel NIRS screening revealed another LRP (LCBI\>250) with DS\<70%, the patient will be enrolled.~IV. The stenotic LRP lesion (DS\>70%) will be subjected to DCB angioplasty while non-stenotic LRP lesion (DS\<70%) will be left unintervened and treated medically.~V. Comparative lesions:~1. DCB-treated LRP (DS\>70%, maxLCBI\>250)~2. Unintervened, medically-treated LRP (DS\<70%, maxLCBI\>250)"
62699717|NCT06029647|EXPERIMENTAL|Mango|The participants will consume one cup of fresh mango (100 kcal) per day for sixteen weeks.
61951429|NCT01814631||Aloka|image quality and resolution
62500264|NCT01680367|EXPERIMENTAL|Arm I (control)|Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery.
62500265|NCT01680367|EXPERIMENTAL|Arm II (native collagen wound dressing)|Patients receive native collagen wound dressing after surgery.
62500266|NCT04846439|EXPERIMENTAL|CAR-T infusion|CD19 and BCMA CAR-T cells were infused into complete remission acute leukemia patients with PTR sequentially, with（1.0-2.0）×10e7/kg respectively. Each patient was followed up for 1 years.
62500267|NCT04287608||Patients with qualifying conjunctivitis events|
62500268|NCT04287608||Patients with no clinical signs of eye inflammation|
61951430|NCT02537106|EXPERIMENTAL|1.5% NaCl|After standardized induction to general anesthesia group A patients will be given the infusion of hyperosmotic 1.5% NaCl 5 ml/kg/BW during 15 min.
61951431|NCT02537106|EXPERIMENTAL|3% NaCl|After standardized induction to general anesthesia group B patients will be given the infusion of hyperosmotic 3% NaCl 5 ml/kg/BW during 15 min.
61951432|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
61951433|NCT04650022||TPCIV-ABAO|TPCIV-ABAO
62500269|NCT03857724|EXPERIMENTAL|prolapse surgery|
62500270|NCT05996770||Patients with COVID-19 packaged with Paxlovid|Treatment of patients with COVID-19 with Paxlovid
62500271|NCT05996770||Patients with COVID-19 packaged with Azvudine|Treatment of patients with COVID-19 with Azvudine
61951434|NCT05378178|EXPERIMENTAL|Phase I：Dose escalation|HS-10381 given orally QD of various dose strengths administered in 21 day dosing cycles.
61951435|NCT02933606|EXPERIMENTAL|BNC210 600 mg b.i.d.|Suspension administered orally for 12 weeks.
61951436|NCT02933606|EXPERIMENTAL|BNC210 300 mg b.i.d.|Suspension administered orally for 12 weeks.
61951437|NCT02933606|EXPERIMENTAL|BNC210 150 mg b.i.d.|Suspension administered orally for 12 weeks.
61951438|NCT02933606|PLACEBO_COMPARATOR|Placebo b.i.d.|Suspension administered orally for 12 weeks.
61951439|NCT03120000|OTHER|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
61951440|NCT03005145|ACTIVE_COMPARATOR|Short duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
61951441|NCT03005145|ACTIVE_COMPARATOR|Long duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
61951442|NCT04930965|EXPERIMENTAL|Intervention|
61951443|NCT04930965|NO_INTERVENTION|Usual care|
61951444|NCT01613300|EXPERIMENTAL|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
61951445|NCT02856178|EXPERIMENTAL|F901318 + Caspofungin|"Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:~* Day 1: 4.0 mg/kg i.v. b.i.d.~* Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.~* Day after last i.v. application: 2.0 mg/kg oral q.d.~Concomitant medication:~For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:~* Chemo day 4: Caspofungin 70 mg i.v. q.d.~* Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.~All patients will undergo chemotherapy for acute leukaemia according to local clinical standard."
61951446|NCT02646657|OTHER|Early UC|Patients with 'early UC' defined as disease duration \< 4 years and no other treatments than aminosalicylates and/or corticosteroids
61951447|NCT02646657|OTHER|Late UC|Patients with 'late UC' defined as active disease despite treatment with immunosuppressives (IS) and/or anti-TNF. Patients wih intolerance to IS AND anti-TNF will also be allowed in the latter group.
61951448|NCT02308605||Suspected stroke patients and subset|"Blood samples taken on admission and at 24 hours, MRI scan between 24 and 48 hours~Subset: Blood samples repeated once per hour for six hours"
61951449|NCT02308605||Control participants (relatives)|To donate blood on two occasions, 24 hours apart, to draw comparison with stroke patients
61951450|NCT02308605||Feeding control participants|To donate a baseline blood sample, eat a simple purine rich meal (meat sandwich), then donate 4 more blood samples at 10, 30, 60 and 120 minutes following the meal
62500272|NCT05996770||Patients with COVID-19 packaged with Paxlovid and Azvudine|Treatment of patients with COVID-19 with Paxlovid and Azvudine
62699718|NCT06029647|PLACEBO_COMPARATOR|Wafer|The participants will consume vanilla wafers (100 kcal) per day for sixteen weeks.
61951451|NCT03507803|EXPERIMENTAL|Gait Biofeedback|This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
61951452|NCT03507803|NO_INTERVENTION|Control|This arm will not receive any audiovisual feedback about the position of their foot during walking.
61951453|NCT03475914||Psoriasis vulgaris|Pathological conditions stable for at least 1 month before collection. One punch biopsy from each patient, was taken from a big reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
61951454|NCT03475914||Psoriasis guttate|One punch biopsy from each patient, was taken from a small reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
61951455|NCT03475914||Healthy skin of psoriasis vulgaris|Healthy skin area of 2mm2 belonging to the left gluteus from patients affected by psoriasis vulgaris
61951456|NCT03475914||Healthy skin of psoriasis guttate|Healthy skin area of 2mm2 belonging to the left gluteus rom patients affected by psoriasis guttate
61951457|NCT04790929|EXPERIMENTAL|Regular Muse Meditation System - No Coaching|Participants will join a 1.5-hour virtual onboarding session where they will complete their first Muse session. Participants will then be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks. If they wish to use the system more frequently within the 6 weeks, they will be encouraged to do so and will be able to choose between all the styles of meditation available in the Muse Meditation System (Mind, Heart, Breath, Body, Guided or Sleep Journeys). For any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
61951458|NCT04790929|EXPERIMENTAL|Regular Muse Meditation System - Additional Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 8 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
61951459|NCT04790929|NO_INTERVENTION|Controls|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery, plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness, anxiety and depression and sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
61951460|NCT05768217|EXPERIMENTAL|Community Resiliency Collective Efficacy Intervention (CRCEI)|Community Resiliency Collective Efficacy Intervention (CRCEI) to engage community members in dialogue on thriving, community leadership, and organizing for social change (9 sessions).
62500273|NCT01279109|EXPERIMENTAL|Social network building intervention|Healthy lifestyle intervention focused on building healthy lifestyle skills and reciprocal social ties between the intervention group members
61951461|NCT05768217|ACTIVE_COMPARATOR|Health Education Sessions|Comparison neighborhoods will receive health education sessions as a control intervention. (9 sessions)
61951462|NCT05912244|EXPERIMENTAL|IO102/IO103, Nivolumab, and Relatlimab|All patients will be treated with nivolumab-relatlimab FDC on Day 1 of every 28-day cycle for up to two years. Patients will be treated with IO102/IO103 on Days 1 and 15 of the first two 28-day cycles, then on Day 1 of subsequent cycles for up to two total years of treatment.
61951463|NCT01477593|EXPERIMENTAL|Group I|
61951464|NCT01477593|ACTIVE_COMPARATOR|Group II|
62699719|NCT02644070|EXPERIMENTAL|alveolar bone preservation with mp3|Extraction sockets grafted with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy) with graft particle size between 600 and 1000 µm and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
62342781|NCT05990036|EXPERIMENTAL|Sports vision participants|Women softball team participating in a sports vision training program
62342782|NCT00976950||Patients with HIV-1 infection|
62342783|NCT01284270|OTHER|All Patients|All patients undergo the same study procedures
62342784|NCT01819311|EXPERIMENTAL|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program
62342785|NCT01819311|PLACEBO_COMPARATOR|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
62342786|NCT02068131|EXPERIMENTAL|Novaferon+ xeloda|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week."
62342787|NCT04863417|EXPERIMENTAL|Cohort 1 (2000 cm2 Body Surface Area)|
62342788|NCT04863417|EXPERIMENTAL|Cohort 2 (4000 cm2 Body Surface Area)|
62342789|NCT06164145||patients with hemiplegia|The intervention program will be based on usual care physiotherapy treatment in a hospital setting. It will be given 3 times per day, 5 days per week for 4 weeks duration.
62342790|NCT05038748||ASD group|80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
62342791|NCT05038748||Sibling group|30 unaffected siblings of ASD youths
62699720|NCT02644070|EXPERIMENTAL|alveolar bone preservation with apatos|Extraction sockets grafted with cortical porcine bone with particle size between 600 and 1000 µm (Apatos, Osteobiol, Coazze, Italy ) and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
61951465|NCT01477593|ACTIVE_COMPARATOR|Group III|
61951466|NCT04614597||Three-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 2, 3, and 4 months of age, collected two blood samples and laboratory test results were available.
61951467|NCT04614597||Two-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 4 and 8-11 months of age, collected two blood samples and laboratory test results were available.
61951468|NCT06557668||Cancer treatment with immunomodulator|CRC patients had previously received cancer therapies along with immunomodulator
61951469|NCT06557668||Cancer treatment without immunomodulator|CRC patients had previously received cancer therapies without immunomodulator
62342792|NCT05038748||TD group|40 healthy typical developing(TD) control from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007
62342793|NCT04696458|EXPERIMENTAL|EXPERIMENTAL PROBIOTIC|1 Multistrain Probiotic Capsule
62342794|NCT04696458|PLACEBO_COMPARATOR|Placebo|1 Identical Placebo Capsule
62342795|NCT02723292|EXPERIMENTAL|Experimental group services|This study will replicate the evidence-based TOP™ in after-school sessions held during RC hours. The primary components of TOP™ include: Comprehensive age-appropriate sexuality education; 90-minute sessions, once a week after-school, during the school year for nine months, using the Changing Scenes© curriculum, and at least twenty hours of youth-led service learning, which involves youth in planning, implementing and reflecting on, community service and leadership.
62699721|NCT02644070|NO_INTERVENTION|NO_graft|extraction sockets with spontaneous healing
61951470|NCT05350410|EXPERIMENTAL|HALT-AD|HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
61951471|NCT03740633|EXPERIMENTAL|Study group|Patients in the study group accept functional training and regular care.
61951472|NCT03740633|ACTIVE_COMPARATOR|Control group|Patients in the control group only accept regular care.
61951473|NCT01752270|EXPERIMENTAL|diane-35|Diane-35 pretreatment from the third day of menstrual cycle
61951474|NCT01752270|NO_INTERVENTION|blank control|
61951475|NCT01236482|ACTIVE_COMPARATOR|Oxytocin|
61951476|NCT01236482|EXPERIMENTAL|Oxytocin - ergometrine|
62342796|NCT02723292|ACTIVE_COMPARATOR|Control group services|Youth in the control arm will receive a work readiness training curriculum focused on competencies to secure employment. This will include such topics as building customer service skills, clear and direct communication, and creating a work portfolio.
62342797|NCT03771612|ACTIVE_COMPARATOR|Naproxen|
62342798|NCT03771612|PLACEBO_COMPARATOR|Placebo|
62342799|NCT06155760|EXPERIMENTAL|Extended Steroid Therapy|10mg of prednisolone plus standard medical therapy for 60 days. SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision
61951477|NCT05892120||control group|The control group only received usual care, the PANSS and MMSE were used to assess psychiatric symptoms and cognitive functions before (week 0) and after 8 weeks.
61951478|NCT05892120||experimental group|The experimental group use the MedAdhere app for eight weeks, the PANSS and MMSE were used to assess psychiatric symptoms and cognitive functions before (week 0) and after (week 8) intervention.
62342800|NCT06155760|ACTIVE_COMPARATOR|Placebo group|"Standard treatment plus placebo that the patient would receive included in the trial.~SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision"
62342801|NCT03746223|EXPERIMENTAL|R2-R/IV-MTX（methotrexate）|experimental arm will be treated rituximab plus lenalidomide (R2) regimen for 6 cycles and followed by lenalidomide maintenance for 2 years, meanwhile intravitreal methotrexate will be given as protocol
62342802|NCT00479024||observation|patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
62699722|NCT04053387|EXPERIMENTAL|Tapinarof (DMVT-505) Cream Group|"Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study.~Subjects entering with a PGA ≥ 1 received treatment with tapinarof cream, 1% until they achieve a PGA = 0, at which time treatment was discontinued and subjects were monitored for durability of response (remittive response). If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~This treatment and re treatment pattern of use was continued until the end of the study"
62699723|NCT05694494|EXPERIMENTAL|iLiFE|receiving Lifestyle-integrated Functional Exercise training and home safety assessment
62699724|NCT05694494|PLACEBO_COMPARATOR|attention control|upper limb exercise training
62500274|NCT01279109|ACTIVE_COMPARATOR|Home visit|Home visits focused on preventable infant injuries
62699725|NCT05819528||Patients enrolled|Patients with a diagnosis primary cardiac lymphoma. The study includes patients with PCL diagnosed from 01/01/2000 to 31/12/2020.
61951479|NCT06504706|ACTIVE_COMPARATOR|Green Tea|Green tea contains a significant amount of catechins, which are subgroup of flavonoids and play a vital role in maintaining health having strong bactericidal as well as antibacterial activity
62699726|NCT00950521|ACTIVE_COMPARATOR|PBSC Treatment|Patients in PBSC treatment will receive brain implant of autologous peripheral blood stem cell(CD34+) plus convention stroke treatment that include rehabilitation and antiplatelet medication
61951480|NCT06504706|EXPERIMENTAL|Matcha Tea|Matcha, powder of specially cultivated tea leaves, is gaining popularity in functional food and other food markets all over the world. Various studies have reported the difference in bioactive compounds in matcha as compared to green tea and other tea formulations
62699727|NCT00950521|ACTIVE_COMPARATOR|Control|Control group receive conventional stroke treatment that include rehabilitation and antiplatelet medication
62699728|NCT04634435|EXPERIMENTAL|BHV-1100 Combination Treatment|
62699729|NCT02259595|EXPERIMENTAL|HPN-07 500 mg / Placebo|Single dose of 500mg HPN-07 plus placebo in oral capsules.
62699730|NCT02259595|EXPERIMENTAL|HPN-07 1000 mg / Placebo|Single dose of 1,000mg HPN-07 plus placebo in oral capsules
61951481|NCT00567307|EXPERIMENTAL|The Red Heart Pill 2b (Polypill) (A)|The Polypill is composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
61951482|NCT00567307|ACTIVE_COMPARATOR|Standard Practice Group (B)|Standard Practice
61951483|NCT03538002|NO_INTERVENTION|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
61951484|NCT03538002|EXPERIMENTAL|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
61951485|NCT01634334|EXPERIMENTAL|Real-time Intervention|
61951486|NCT01634334|ACTIVE_COMPARATOR|Usual Education|Participants will receive usual education about secondhand and thirdhand smoke.
61951487|NCT02138500|EXPERIMENTAL|Cohort 1: PF-06372865 10 mg|
61951488|NCT02138500|EXPERIMENTAL|Cohort 2: PF-06372865 TBD dose|
61951489|NCT02138500|EXPERIMENTAL|Cohort 3: PF-06372865 TBD dose|
61951490|NCT06263920||Case (Late-onset epilepsy)|"Observational study - no intervention. Participants with first seizure or new diagnosis of epilepsy, in adulthood.~Inclusion criteria for cases includes:~* diagnosis of LOE or first seizure after the age of 18.~* diagnosis confirmed or established at a tertiary neurology centre.~* sequential cases will be used; in the unlikely event that eligible cases outstrip capacity, an annual cap of the first 150 patients per year per cohort will be used.~Exclusion criteria for cases includes:~* another 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma, vascular or congenital abnormality of likely aetiological significance.~* people with migraine or headache syndrome can be included in case group - the presence or absence of a seizure syndrome is mutually exclusive between case and control groups, not the presence or absence of migraine."
61951491|NCT06263920||Control (migraine)|"Inclusion criteria for controls includes:~* established diagnosis of migraine.~* with or without therapeutic medications with antiepileptic properties.~Exclusion criteria for controls includes:~* diagnosis of epilepsy or confirmed seizure.~* 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma.~However, in both cases and controls, people with dementia, alcohol excess, recreational drug use or pre-existing small vessel disease will be included, as excluding these conditions would bias against the inclusion of the population who may benefit from this research and against the inclusion of patients with high risk of small vessel disease."
62342803|NCT04259385|ACTIVE_COMPARATOR|Calorie/Control Label Condition|Beverages at the concession stand and in the parent survey in this arm will display solely a calorie label.
62500275|NCT02670785|EXPERIMENTAL|Estradiol Vaginal Capsule 0.003 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
62500276|NCT02670785|EXPERIMENTAL|Estradiol Vaginal Capsule 0.01 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
62699731|NCT02259595|EXPERIMENTAL|HPN-07 1500 mg / Placebo|Single dose of 1,500mg HPN-07 plus placebo in oral capsules
62699732|NCT02259595|EXPERIMENTAL|HPN-07 MTD plus NAC 1200mg|Single dose of maximum tolerated dose of HPN-07 plus 1,200 mg NAC in oral capsules. Dose selection will be determined from safety data of previous cohorts by Data Assessment Committee (DAC).
62500277|NCT02670785|EXPERIMENTAL|Estradiol Vaginal Capsule 0.02 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
62699733|NCT02311504||DiabCheck ophta OCTplus|persons with diabetes undergoing OCT examination
62699734|NCT04323046|EXPERIMENTAL|Neoadjuvant nivolumab and adjuvant nivolumab|"NEOADJUVANT: Patients receive nivolumab IV over 30 minutes 14 days before undergoing standard of care surgical resection.~ADJUVANT MAINTENANCE: After completion of neoadjuvant infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62699735|NCT03510689||Group 1|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
62500278|NCT02670785|PLACEBO_COMPARATOR|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
62500279|NCT01792453|EXPERIMENTAL|240 mL water drink|Volunteers will be asked to drink 240 mL water drink
62500280|NCT04194606|ACTIVE_COMPARATOR|Forearm radial access|Patients who undergo coronary angiography or intervention by forearm radial artery access
62500281|NCT04194606|EXPERIMENTAL|Distal radial access|Patients who undergo coronary angiography or intervention by accessing the distal radial artery in the area of the anatomical snuff-box
61951492|NCT02056938|EXPERIMENTAL|ATG|"The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery)."
61951493|NCT02056938|ACTIVE_COMPARATOR|Basiliximab|The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).
62500282|NCT02865148|EXPERIMENTAL|Cognitive behavioral therapy (CBT) group|Participants will receive 4 sessions that lasts approximately 50 mins. The sessions will teach patients to manage their symptoms.
62500283|NCT02865148|NO_INTERVENTION|Waitlist control (WLC) group|The WLC group receives standard usual care before being offered the same CBT protocol and assessment thereafter.
62500284|NCT01566994|EXPERIMENTAL|TTM Tailored|
62500285|NCT01566994|EXPERIMENTAL|Motivational Enhancement Therapy|
62699736|NCT03510689||Group 2|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer does not include anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
61951494|NCT00673504|EXPERIMENTAL|A|Gemcitabine + Sunitinib
61951495|NCT00673504|OTHER|B|Gemcitabine
61951496|NCT04275531||regional anesthesia|surgical procedures which will be performed under intrathecal anesthesia without sedation
61951497|NCT04275531||sevoflurane|surgical procedures which will be performed under general anesthesia and sevoflurane will be used for maintenance of anesthesia
61951498|NCT04275531||isoflurane|surgical procedures which will be performed under general anesthesia and isoflurane will be used for maintenance of anesthesia
61951499|NCT04275531||propofol|surgical procedures which will be performed under general anesthesia and propofol infusion will be used for maintenance of anesthesia
61951500|NCT03523130||HIV-infected|
61951501|NCT03523130||non-HIV-infected|
62141045|NCT06038747|ACTIVE_COMPARATOR|Individual Psychotherapy|Participants in the control group will receive only treatment as usual (i.e., individual psychotherapy) sand and will not complete post-session questionnaires. Additionally, they will not receive any feedback at all encouraging them to discuss their emotional responses with their therapist during the session.
61951502|NCT06201520|EXPERIMENTAL|MA group (manual acupuncture group)|Acupunctue Needle: 1 inch- 32 gauge（0.3x25 mm）for 20 min after De-qi Acupoints selection: PC4\[Ximen\], PC6\[Neiguan\], PC7\[Daling\], PC8\[Laogong\], HT2\[Qingling\], HT7\[Shenmen\], HT8\[Shaofu\], LU9\[Taiyuan\], LI11\[Quchi\]
61951503|NCT06201520|EXPERIMENTAL|LA group (laser acupuncture group)|laser acupuncture gruoup with LaserPen, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; Nogier C frequency for 4 J each points The acupoints selection is the same as the MA group.
61951504|NCT06201520|SHAM_COMPARATOR|SLA group (sham laser acupuncture group)|sham laser acupuncture group is designed with the same acupoints selection and no energy output
61951505|NCT03782961|EXPERIMENTAL|Stand up|After application of the product (sodium lactate and combination of polymers) will remain standing for 30 minutes
62141046|NCT03214172||Cancer-associated thrombosis|Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
62141047|NCT00739934|EXPERIMENTAL|Children aged 2 to <12 years|Immunocompromised children aged 2 to \<12 years who are at high risk for systemic fungal infection.
62342804|NCT04259385|EXPERIMENTAL|Text Warning Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display both a text warning and a calorie label.
62342805|NCT04259385|EXPERIMENTAL|Sugar Graphic Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display a sugar graphic warning label depicting the amount of sugar in the product, the same text warning, and a calorie label.
62342806|NCT05824637|OTHER|Skin Prick Test|Study participants will receive a skin prick test by the skin prick automated test device on the right arm and manually by a health care provider on the left arm.
62342807|NCT02693795|EXPERIMENTAL|Baduanjin exercise group|"The participants randomized to Baduanjin exercise will collectively practice at cardiac rehabilitation centre in Guangdong Provincial Hospital of Chinese Medicine. A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
62500286|NCT01566994|EXPERIMENTAL|Integrated Treatment|
62500287|NCT02964390|EXPERIMENTAL|Balloon Pulmonary Angioplasty|This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
62699737|NCT03510689||Group 3|Subjects with genetic testing confirming no mutation in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
61951506|NCT03782961|EXPERIMENTAL|Lying down|After application of the product (sodium lactate and combination of polymers) remained lying down with the legs stretched for 30 minutes;
61951507|NCT05363631|EXPERIMENTAL|Seleno-L Methionine (SLM) in Combination with Axitinib and Pembrolizumab|SLM only will be taken by mouth during a two-week run in period. Then patients will receive SLM and Axitinib drugs by mouth, and Pembrolizumab intravenously (IV), at the start of each 21 day cycle.
61951508|NCT02831452||non-pregnant nulliparous|nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
61951509|NCT02831452||primigravid on 1º trimester|"nulliparous women on her first pregnancy and gestational age until 13 weeks and 6 days.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
61951510|NCT02831452||primigravid on 2º trimester|"nulliparous women on her first pregnancy and gestational age between 14 weeks and 27 weeks.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
61951511|NCT02831452||primigravid on 3º trimester|nulliparous women on her first pregnancy and gestational age above 28 weeks. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
61951512|NCT01721993|EXPERIMENTAL|T121E01F|
61951513|NCT01721993|ACTIVE_COMPARATOR|zoledronic acid IV|
61951514|NCT05222737|ACTIVE_COMPARATOR|test group|intra pocket diode laser application
61951515|NCT05222737|ACTIVE_COMPARATOR|control group|antibiotic adminstration
61951516|NCT02206074|ACTIVE_COMPARATOR|T2DM|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
61951517|NCT02206074|PLACEBO_COMPARATOR|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
61951518|NCT04210596|ACTIVE_COMPARATOR|Control group|Connective tissue graft harvested from the palate
61951519|NCT04210596|EXPERIMENTAL|Collagen matrix|Pig-derived collagen matrix (Fibro-Gide, Geistlich Biomaterials, Wolhusen, Switserland)
61951520|NCT01629030||Coronary Artery Bypass Graft Group|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung Medical Center during the period of January 2008 and December 2011.
61951521|NCT03068455|EXPERIMENTAL|nivolumab + ipilimumab|Specified Dose on Specified Days
62342808|NCT02693795|ACTIVE_COMPARATOR|usual exercise control group|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
62342809|NCT06463548|EXPERIMENTAL|Irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib|Patients will receive irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib therapy in a 2-week treatment cycle.
62500288|NCT04162587||1)Patients with significant carotid stenosis only|Patients with significant carotid stenosis without intracranial stenosis.
62500289|NCT04162587||2) Patients with carotid and intracranial stenosis.|Patients with carotid and intracranial stenosis.
61951522|NCT03068455|EXPERIMENTAL|nivolumab|Specified Dose on Specified Days
61951523|NCT06039397|EXPERIMENTAL|"Semi-fowler 30 Right Lateral"|
61951524|NCT06039397|ACTIVE_COMPARATOR|Conventional care|
61951525|NCT01171430|EXPERIMENTAL|MRI WHOLE BODY|
61951526|NCT05456269|EXPERIMENTAL|Stratum 1|"Bisantrene infused daily for 7 days of induction cycle 1; followed by bisantrene infusion on Days 1 and 2 and cytarabine arabinoside continuous infusion on Days 1 to 5 of each consolidation cycle for up to 3 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
62500290|NCT04162587||3) Patients with lone intracranial stenosis.|Patients with lone intracranial stenosis.
61951527|NCT05456269|EXPERIMENTAL|Stratum 2|"Decitabine/cedazuridine daily on Days 1-5, Bisantrene infusion on Days 3 and 5 in 28 day cycle. Treatment repeats every 28 days up to 12 cycles in the absence of disease progression or unacceptable toxicity.~Each has potential to expand to 42 days to allow for full hematologic recovery."
61951528|NCT01070498|EXPERIMENTAL|Trichuris suis ova (TSO)|
62500291|NCT04162587||4) Patients with no significant stenosis|Patients with no significant carotid or intracranial stenosis.
62500292|NCT05855824|PLACEBO_COMPARATOR|Placebo - 0 mg carotenoids / d|"The placebo 0 mg/d group consumes 1-90 g pouch of applesauce providing 0 mg carotenoids/d (Unsweetened Applesauce Pouches) daily for 4 weeks."
62500293|NCT05855824|EXPERIMENTAL|Low - 2.5 mg carotenoids / d|"The low 2.5 mg/d group will consume alternating pouches of the applesauce (0 mg carotenoids/90 g pouch) and a 120 g pouch of fruit-vegetable puree blend providing 5 mg mixed carotenoids (Carrot, Banana, Mango, \& Sweet Potato pouch) daily for 4 weeks."
61951529|NCT03460938|EXPERIMENTAL|RIPC|
61951530|NCT03460938|NO_INTERVENTION|Control|
61951531|NCT05749107||Atrial secondary tricuspid regurgitation|Patients with persistent/permanent atrial fibrillation and any degree of isolated tricuspid regurgitation
61951532|NCT06405230|EXPERIMENTAL|Pembrolizumab ± Platinum-based chemotherapy doublet (PBCD)|Participants will receive pembrolizumab with or without PBCD.
61951533|NCT06405230|EXPERIMENTAL|Dostarlimab ± PBCD|Participants will receive dostarlimab with or without PBCD.
61951534|NCT02329392||SPP|Patients undergoing cardiac surgery with perioperative monitoring of Skin Perfusion Pressure
61951535|NCT03651505||Prior Burosumab Clinical Trial Participants|Patients who participated in burosumab clinical trials and continue to receive burosumab via prescription from their physician.
61951536|NCT03651505||Not from Prior Burosumab Clinical Trial|Patients may take other treatments for XLH and may start burosumab treatment at any time as prescribed by a physician.
62164526|NCT00767585||E|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
62164527|NCT00767585||F|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
62500294|NCT05855824|EXPERIMENTAL|High - 5 mg carotenoids / d|"The high dose 5 mg/d group will be provided one 120 g pouch/day of the fruit-vegetable puree blend (Carrot, Banana, Mango, \& Sweet Potato pouch) daily for 4 weeks."
62500295|NCT05756738|EXPERIMENTAL|Alternative sentences to prison|Persons with alternative sentences to prison will be informed of the study and, according to the randomization code, will be: a) given an envelope with all the necessary material to carry out the test at home and send it to the hospital for processing or, b) be tested on site at the the Social Insertion Center premises, who will also send it to the hospital for processing by the Central Laboratory of the University Hospital of the Canary Islands.
62500296|NCT05756738|EXPERIMENTAL|Open system|They will be offered to take the diagnostic test in situ at the the Social Insertion Center premises.
62500297|NCT03935737||Full dose Chest X-Ray|Subjects will receive a full (standard) dose chest X-ray at Day 1.
62500298|NCT03935737||Low dose Chest X-Ray|Subjects will receive a follow up X-ray at at a lower dose within 3 months after the first dose.
62500299|NCT03803254|EXPERIMENTAL|HAIC plus lenvatinib and PD-1 antibody|Hepatic arterial infusion chemotherapy plus lenvatinib and programmed cell death protein-1 antibody
62500300|NCT03803254|ACTIVE_COMPARATOR|HAIC plus lenvatinib|Hepatic arterial infusion chemotherapy plus lenvatinib
62500301|NCT02298387|EXPERIMENTAL|OMP-305B83|The dose levels of OMP-305B83 will be 0.5, 1.0, 2.5, 5 and 10 mg/kg administered IV once every 3 weeks.
62500302|NCT02104258|ACTIVE_COMPARATOR|Physiotherapy ASPETAR|"The patients will follow the ASPETAR Hamstring Rehabilitation Protocol, which is a standardised physiotherapy protocol, including range of motion exercises, progressive strengthening exercises, core stability training and agility exercises \[10\].~The ASPETAR protocol consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
62500303|NCT02104258|ACTIVE_COMPARATOR|Physiotherapy ASPETAR+|"The patients will follow the ASPETAR+ Hamstring Rehabilitation Protocol. ASPETAR+ is similar to ASPETAR, but consists of additional lengthening exercises which will be initiated early in the rehabilitation phase.~ASPETAR+ consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
61951537|NCT04443010|EXPERIMENTAL|Phase 1 part: Dose Finding|Patients will be treated in cohorts according to a 3+3 study design with standard treatment (consisting of radiotherapy of 60 Gy/30 fractions for 6 weeks plus 75 mg/m2 TMZ (temozolomide) daily (chemoradiotherapy), followed by 4 weeks of treatment break, followed by maintenance treatment with 6 maintenance cycles of TMZ 150-200 mg/m2 on Days 1 to 5 q28) combined with L19TNF at different dose levels on Day 1, 3, 5, 22, 24 and 26 of chemoradiotherapy and on Day 1, 3 and 5 of each 28-day chemotherapy maintenance cycle.
62500304|NCT02756949|EXPERIMENTAL|Smartphone-enabled app for linkage to care|Participants in this arm are randomised to receive the smartphone application which provides direct access to HIV-related laboratory test results.
62500305|NCT02756949|NO_INTERVENTION|Standard of care|Participants in this arm are randomised to receive standard of care services.
62500306|NCT03266055|EXPERIMENTAL|Blueberry powder|
62699738|NCT05840263||Metastatic Colorectal Cancer Patients|We anticipate enrolling up to a total of 18 patients who have been diagnosed with metastatic colorectal cancer; 12 patients will participate in the qualitative interview, and 6 patients will participate in the cognitive interview.
62699739|NCT05840263||Metastatic Colorectal Cancer Patients Partners|We anticipate enrolling up to a total of 18 partners of patients who have been diagnosed with metastatic colorectal cancer; 12 partners will participate in the qualitative interview, and 6 paartners will participate in the cognitive interview.
61951538|NCT04443010|EXPERIMENTAL|Phase 2 part: Signal Seeking|32 patients will receive standard chemoradiotherapy and L19TNF at RD and with the administration scheme established in phase I part of the study.
62164528|NCT00767585||G|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
62164529|NCT00767585||H|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
62500307|NCT03266055|PLACEBO_COMPARATOR|Blueberry placebo powder|
62500308|NCT04936594|EXPERIMENTAL|People Living with HIV/AIDS Who Smoke|Participants will be people living with HIV/AIDS who smoke. They will receive two interventions: iTBS and a sham comparator (TMS).
62500309|NCT06299709|EXPERIMENTAL|Part A: Sequence 1|Participants will receive VNZ/TEZ/D-IVA reference fixed dose combination (FDC) tablet in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 2, and finally VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
62500310|NCT06299709|EXPERIMENTAL|Part A: Sequence 2|Participants will receive VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 2, and finally VNZ/TEZ/D-IVA reference FDC tablet in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
62500311|NCT06299709|EXPERIMENTAL|Part A: Sequence 3|Participants will receive VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 1, then VNZ/TEZ/D-IVA reference FDC tablet in dosing period 2, and finally VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
62500312|NCT06299709|EXPERIMENTAL|Part B: Sequence 1|Participants will receive VNZ/TEZ/D-IVA test FDC granules under fasted condition in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules under fed state in dosing period 2. A washout period of 18 days will be maintained between 2 dosing periods.
62500313|NCT06299709|EXPERIMENTAL|Part B: Sequence 2|Participants will receive VNZ/TEZ/D-IVA test FDC granules under fed state in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules under fasted condition in dosing period 2. A washout period of 18 days will be maintained between 2 dosing periods.
62500314|NCT05179161|EXPERIMENTAL|Prone crawl position|Patients are placed in the prone crawl position for whole breast irradiation and are treated with 15 x 2,67 Gy (± boost treatment if required as per international guidelines)
62500315|NCT06593067|EXPERIMENTAL|Healthy Adults Arm|Healthy Subject will rest in an environmental chamber that is no hotter than 47°C (117 °F). While in the chamber, the study team will periodically use a water spray to wet subject's skin and turn on an electric fan. During this time, the temperature of skin on arm using a temperature probe placed on the surface of skin and another temperature probe placed within skin (intradermal) will be monitored.
62500316|NCT05695417|ACTIVE_COMPARATOR|OTX-TKI|
62500317|NCT05695417|SHAM_COMPARATOR|Sham|
62141048|NCT04896736|EXPERIMENTAL|Multisite tissue oxygenation monitoring-guided care|"Details are as follows. • Monitoring: SctO2 monitored using two probes placed on left and right forehead. SstO2 monitored using one probe placed over the forearm brachioradialis muscle on the arm not used for non-invasive blood pressure monitoring.~• Baseline: The first baseline is measured 12-48 hours before surgery, with the patient supine, awake, calm, eyes closed, and breathing room air or oxygen that is equivalent to the home oxygen rate for patients using home oxygen.~* Goals: Maintain both SctO2 and SstO2 within 90-110% of the baseline level.~* Trigger of intervention: SctO2/SstO2 outside of the 90-110% baseline range.~* Diagnosis:~* Care team: The caregivers providing SctO2/SstO2-guided care will be trained and given the opportunity to use the intervention protocol in at least 20 patients before the formal study.~* Treatments: Refer to the algorithm to restore SctO2/SstO2 within 90-110% baseline range."
62342810|NCT02587624||RMN AF ablation|Consecutive patients with class I or class IIa indication for catheter ablation for symptomatic atrial fibrillation according to the current guidelines.
62500318|NCT01006967|ACTIVE_COMPARATOR|ActiveStep|Subjects will use the ActiveStep treadmill as part of their physical therapy program for balance
62699740|NCT05840263||Clinicians|We anticipate enrolling 12 clinicians (including physicians, nurse practitioners, physician assistants, mental health providers, other advanced practice clinicians) who treat patients with colorectal cancer at the University of Colorado to participate in qualitative interviews. We seek to enroll a variety of clinicians from advanced practiced clinical roles (physicians, nurse practitioners, and mental health providers) to capture diverse perspectives.
62699741|NCT05586776|ACTIVE_COMPARATOR|Decolonization|Participants randomized into this arm will perform decolonization using topical antiseptic soap (chlorhexidine body wash) and an antibiotic ointment (nasal mupirocin).
62699742|NCT05586776|PLACEBO_COMPARATOR|Routine Care|Participants randomized into this arm will perform routine care using soap without antiseptic properties (placebo) and placebo nasal ointment.
62699743|NCT03298893|EXPERIMENTAL|Nivolumab + radiochemotherapy|5 weeks of radiochemotherapy + nivolumab followed by 5 months of nivolumab alone
62699744|NCT05620940|ACTIVE_COMPARATOR|Part A Group 1 (Vivitrol Injection)|Vivitrol, Single Dose, IM injection
62699745|NCT05620940|EXPERIMENTAL|Part A Group 2 (IVL3004 A mg)|IM, Single Dose
62699746|NCT05620940|EXPERIMENTAL|Part A Group 3 IVL3004 B mg)|IM, Single Dose
62699747|NCT05620940|EXPERIMENTAL|Part B Group 1 (IVL4002 Cmg)|SC, Single Dose
62699748|NCT02947048|EXPERIMENTAL|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
62699749|NCT02947048|EXPERIMENTAL|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
62699750|NCT02947048|EXPERIMENTAL|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
62699751|NCT02947048|EXPERIMENTAL|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
62699752|NCT02947048|PLACEBO_COMPARATOR|Placebo|placebo t.i.d.
62699753|NCT04931017|EXPERIMENTAL|Cohort A (metformin ER)|Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.
62342811|NCT04994444|EXPERIMENTAL|Preloading|Participants will be started on nicotine patch 3 weeks prior to quit date. At quit date they will use patch and lozenge or gum for 8 weeks.
62342812|NCT04994444|ACTIVE_COMPARATOR|Standard treatment|Participants will start combination nicotine replacement therapy (patch/gum or patch/lozenge) on their assigned quit date. NRT will be provided for 8 weeks.
62342813|NCT01013896|ACTIVE_COMPARATOR|Cystic Fibrosis Education|This intervention is designed to increase knowledge and enhance the skills needed to optimize CF-management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem-solving training to overcome barriers.
62342814|NCT01013896|EXPERIMENTAL|Motivational Interviewing|The Counselor's overarching goal for the intervention is to motivate and assist the participant to improve his/her adherence to the CF pulmonary medications. The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic-level figures showing the association between adherence and health outcomes.
62342815|NCT06409702||DKRd|All patients will be treated with VRD induction for first-cycle,and then DKRD induction and consolidation therapy for following 5\~7 cycles, then maintenance therapy.
62342816|NCT05263128||Boston carpal tunnel syndrome questionnaire|
62342817|NCT05263128||Hand-20 questionnaire|
62699754|NCT04931017|ACTIVE_COMPARATOR|Cohort B (metformin ER with waiting period)|Participants receive no intervention for 26 weeks, then cross-over to Cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.
62699755|NCT04482127|EXPERIMENTAL|SubEpithelial connective graft|"SCTG harvested from palatal tissue by single line incision technique, blade will be oriented perpendicular to the palatal tissue surface. A single incision will be made down to the bone in a horizontal direction approximately 2 to 3 mm apical to the gingival margin of the maxillary teeth. A partial thickness dissection will then be made within the single incision, leaving an adequate thickness of the palatal flap intact to minimize the chance of sloughing of the overlying tissue. Careful manipulation of the graft with tissue forceps will be required and care must be taken to prevent compression or tearing of the graft.~The fatty tissue (yellow in color) will be eliminated and some contouring of the graft will be done to fit the prepared envelope. The harvested SCTG will be placed at the extraction sites in a supra-periosteal partial dissection (pouch II technique) prepared at the buccal aspect without using vertical incisions and without flap elevation."
62699756|NCT04482127|NO_INTERVENTION|Atraumatic extraction|Extraction with Periotomes and Luxators keeping the buccal plate of bone intact
61951539|NCT04443010|ACTIVE_COMPARATOR|Phase 2b part: Activity Evaluation_control arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).~- Arm 2: Patients will receive radiotherapy and TMZ (temozolomide)."
62342818|NCT05590767||shoulder rotators repair|Patients scheduled to undergo shoulder rotators repair surgery
62342819|NCT00946881|EXPERIMENTAL|WST11 (TOOKAD® Soluble)|WST11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses
62342820|NCT04622969|EXPERIMENTAL|Intervention|Provide the 15-week Healthy Child Development Program intervention
62342821|NCT04622969|NO_INTERVENTION|Wait list control|
62342822|NCT02247674|PLACEBO_COMPARATOR|Education & training consultation|Education and training consultations were provided for subjects in control group during study period.
62342823|NCT02247674|EXPERIMENTAL|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
62342824|NCT01575197|ACTIVE_COMPARATOR|Rotavirus Vaccine at age 6 & 10 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6 \& 10 weeks of age.
62342825|NCT01575197|EXPERIMENTAL|Rotavirus vaccine at age 10 & 14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 10 \& 14 weeks of age.
62342826|NCT01575197|EXPERIMENTAL|Rotavirus vaccine at age 6,10,&14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6, 10, \& 14 weeks of age.
62342827|NCT05600166||Experimental group|Participants were treated with artificial dermal repair materials in combination with growth factors.
62342828|NCT05600166||Control group|Cases treated with a double layer of artificial dermal repair material
62342829|NCT04585295|EXPERIMENTAL|Betaine|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
62342830|NCT04585295|EXPERIMENTAL|Placebo|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
62342831|NCT04585295|EXPERIMENTAL|NOW Foods Big 6|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
62342832|NCT04561245|EXPERIMENTAL|ALT-801 (Part 1)|Escalating doses of ALT-801 administered once
62342833|NCT04561245|PLACEBO_COMPARATOR|Placebo (Part 1)|Placebo administered once
62342834|NCT04561245|EXPERIMENTAL|ALT-801 (Part 2)|Escalating doses of ALT-801 administered once weekly for 12 weeks
62342835|NCT04561245|PLACEBO_COMPARATOR|Placebo (Part 2)|Placebo administered once weekly for 12 weeks
62342836|NCT05124340|EXPERIMENTAL|Vaccine|1 dose of BCG vial vaccine injected in right deltoid armintradermally
62342837|NCT05124340|ACTIVE_COMPARATOR|Active Comparator|1 dose of BCG ampoule vaccine injected in right deltoid arm intradermally
62342838|NCT01236313||TEE report|Cardiac surgery patients requiring TEE
62342839|NCT01763021|EXPERIMENTAL|PCI-32765 + Rifampin|Participants will recieve a single oral dose of PCI-32765 560 mg on Day 1 and Day 11 along with rifampin; and rifampin 600 mg from Day 4 to Day 13.
62699757|NCT05371379|EXPERIMENTAL|CM338 75 mg, subcutaneous injection|Qquaque week
61951540|NCT04443010|EXPERIMENTAL|Phase IIb part: Activity Evaluation_treatment arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).~- Arm 1: Patients will receive radiotherapy, TMZ (temozolomide) and L19TNF."
61951541|NCT03046758|EXPERIMENTAL|Participants|
62342840|NCT04848454|EXPERIMENTAL|Experimental group|"Drug:~Vinorelbine i.v. 25 mg/m2, d1, d8 or p.o. 60-80 mg/m2 d1, d8; q3w; for 6 cycles.~Cisplatin i.v. 75 mg/m2，d1, d2; q3w; for 6 cycles. Camrelizumab i.v. 200mg, q3w; for 17cycles (1 year)."
62342841|NCT03816410|EXPERIMENTAL|LAA amputation group|
62342842|NCT03816410|NO_INTERVENTION|No LAA amputation group|
62342843|NCT00668200|OTHER|zoledronic acid|5 mg of Reclast (ZOL446, zoledronic acid) injection in 100 mL ready to infuse solution administered intravenously via a vented line. The infusion time was to be not less than 15 minutes given over a constant infusion rate.
62699758|NCT05371379|EXPERIMENTAL|CM338 150 mg, subcutaneous injection|Qquaque week
62699759|NCT05371379|EXPERIMENTAL|CM338 300 mg, subcutaneous injection|Qquaque week
62699760|NCT05371379|EXPERIMENTAL|CM338 300 mg, intravenous infusion|Qquaque week
62699761|NCT05371379|PLACEBO_COMPARATOR|Placebo|placebo
61951542|NCT02772107|EXPERIMENTAL|BSC group|Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. Radiotherapy was allowed. Follow-up until disease progression.
62500319|NCT01006967|ACTIVE_COMPARATOR|Standard physical therapy|Subjects will receive a standard physical therapy program for gait and balance.
62500320|NCT04387617|EXPERIMENTAL|CBD Oil Group|
62500321|NCT04387617|PLACEBO_COMPARATOR|Control Group|
62699762|NCT05627921|EXPERIMENTAL|botulinum toxin group|
62699763|NCT05627921|EXPERIMENTAL|botilinum toxin and ESWT group|
62500322|NCT03297151|SHAM_COMPARATOR|CONTROL|"Intervention: Dietary Supplement: Non-essential amino acids A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g non-essential amino acids dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry.~Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
62500323|NCT03297151|ACTIVE_COMPARATOR|PROTEIN|"Intervention: Dietary Supplement: Whey Protein Concentrate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Concentrate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
62500324|NCT03297151|ACTIVE_COMPARATOR|HYDROLYSATE|"Intervention: Dietary Supplement: Whey Protein Hydrolysate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Hydrolysate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
62500325|NCT06608355|EXPERIMENTAL|NouvNeu001|
62500326|NCT05327439|EXPERIMENTAL|Electronic Cigarette|Participants in this experimental condition will be provided with a 4th generation electronic cigarette device and disposable cartridges.
62500327|NCT05327439|EXPERIMENTAL|Nicotine Pouch|Participants in this experimental condition will be provided with nicotine pouches.
62500328|NCT05327439|NO_INTERVENTION|Smoking As Usual|Participants in this assessment-only condition will continue smoking as usual.
62500329|NCT05119049|EXPERIMENTAL|Aquatic exercise plan in the pool.|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department.
62500330|NCT05119049|ACTIVE_COMPARATOR|Exercises in a rehabilitation room.|The control group did the same exercises and sessions in one of the rooms in the rehabilitation department.
62141049|NCT04896736|ACTIVE_COMPARATOR|Usual care|Patients in the control group will be managed by clinical staff according to usual care. Patients in this group will be monitored using the same tissue oximeter used in the intervention group; however, the screen will be covered by an opaque cloth to prohibit the care givers seeing the monitoring data. The same baseline measurements will be performed in patients allocated to the usual care group.
62500331|NCT02930876|EXPERIMENTAL|Resistance training at home|Participants will undergo training sessions at their own homes. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
62500332|NCT02930876|EXPERIMENTAL|Resistance training at the hospital|Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
62342844|NCT02935686|EXPERIMENTAL|Group 1: Ad26.Mos4.HIV + Clade C gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12, followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
62342845|NCT02935686|EXPERIMENTAL|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + combination of 125 mcg Mosaic gp140 and 125 mcg Clade C gp140 mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
62342846|NCT02935686|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive a single placebo injection at Weeks 0 and 12, followed by two placebo injections at Weeks 24 and 48.
62500333|NCT02930876|NO_INTERVENTION|Controls|Participants will be given an information leaflet with the exercise recommendations of the Portuguese national ministry of health.
62500334|NCT01953289||Appendicitis|Free fluid in perforated or non-perforated appendicitis
62500335|NCT04989569|NO_INTERVENTION|control|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the control group will not be given to the dietitians for adjusting the diet formula according to the patient's body composition.
62500336|NCT04989569|EXPERIMENTAL|nutritional intervention|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the intervention group will be given to the dietitians for adjusting the diet formula according to the patient's body composition.
62500337|NCT04520061|EXPERIMENTAL|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
62500338|NCT04520061|NO_INTERVENTION|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
62500339|NCT06679426|ACTIVE_COMPARATOR|Investigational product|Human recombinant C1-INH, also known as conestat alfa (Ruconest™), has been purified from the breast milk of genetically modified rabbits. Conestat alfa targets activated C1s, kallikrein, factor XIIa, and factor XIa. Inhibition kinetics are comparable to plasma-derived human C1-INH. The elimination half-life is approximately 2.5 hours.37 One vial consists of 2100 units, which corresponds to 2100 units per 14 mL after reconstitution, resulting in a concentration of 150 units/mL. One unit of activity corresponds to C1 esterase inhibiting activity in 1 mL of normal plasma. Each vial also contains 19.5 mg of sodium.41 In order to administer 4200 IU of conestat alfa, 2 reconstituted vials are needed
62699764|NCT00750399|EXPERIMENTAL|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab on a monthly basis depending on response to treatment
62699765|NCT04860466|EXPERIMENTAL|Administration of CC-96673|CC-96673 will be administered on a once weekly (Q1W) or once every 2 weeks (Q2W) schedule
62141050|NCT06687148|EXPERIMENTAL|Manipulative therapy|Experimental group, subject to manipulation performed by the same Physiotherapist, using the techniques described by Shadmehr, A. et al (2018).
62342847|NCT02935686|EXPERIMENTAL|Group 1b: Ad26.Mos4.HIV + gp140 HIV Bivalent Vaccine|Participants enrolled in the LTE phase will receive late boost vaccination Ad26.Mos4.HIV and bivalent gp140 within 4 weeks prior to Week 192 until 4 months after Week 192 (that is, approximately 3 years after the 4th vaccination of the primary vaccination series).
62342848|NCT02935686|PLACEBO_COMPARATOR|Group 2b: Placebo|Participants will receive placebo injection at Week 192 -4 weeks/+4 months, that is, approximately 3 years after the 4th vaccination of the primary vaccination series.
62342849|NCT05545579|EXPERIMENTAL|circuit training|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes.
62342850|NCT05545579|EXPERIMENTAL|Trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
62342851|NCT00150670|EXPERIMENTAL|1|TS-1 and cisplatin
62342852|NCT00150670|ACTIVE_COMPARATOR|2|TS-1
62342853|NCT05510778|EXPERIMENTAL|Charcocaps|2 capsules 15 minutes before meal and 2 additional capsules 2 hours after meal
62342854|NCT05510778|PLACEBO_COMPARATOR|Placebo|2 capsules 15 minutes before meal and 2 additional capsules 2 hours after meal
62342855|NCT05678192|OTHER|Transdermal MHT|The group includes women 45-59 years old, with menopausal symptoms. The choice of transdermal MHT was based on personal history (chronic diseases of the gastrointestinal tract, high blood pressure, etc.), family history (stroke, thromboembolism in relatives, etc.), and patient preferences. Used estradiol hemihydrate 0.6 mg 2 protective pumps. The progesterone component of MHT includes micronized progesterone 100 mg or 200 mg, depending on the MHT regimen (continuous or cyclic). Blood sampling to determine the immune status is carried out before the start of therapy after 3 months.
62342856|NCT05678192|OTHER|Oral MHT|"The group includes women 45-59 years old, with menopausal symptoms. Examination before the appointment of MHT can be carried out according to clinical recommendations. The choice of transdermal MHT was based on the history (chronic diseases of the gastrointestinal tract, high blood pressure, etc.), family history (stroke, thromboembolism in relatives, etc.), the patient's preferences.Drugs used in this group include:~Dydrogesterone 5 mg + Estradiol 1 mg or Dydrogesterone 10 mg + Estradiol 1 mg, depending on the MHT regimen. Blood sampling to determine the immune status is performed before the start of therapy and after 3 months"
62342857|NCT04193852|EXPERIMENTAL|Dienogest and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
62342858|NCT04193852|ACTIVE_COMPARATOR|Dienogest and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
62141051|NCT06687148|SHAM_COMPARATOR|Participants will be submitted to a simulated manipulation.|Sham group, subjected only to a simulation of manipulation, using the same gestures, but without manipulating, used as a placebo group.
62141052|NCT06687148|NO_INTERVENTION|Group will not be subject to any intervention.|Control group, which will not be subject to any intervention.
62141053|NCT04456413|EXPERIMENTAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
62141054|NCT04456413|ACTIVE_COMPARATOR|Best Supportive Care|Patients will receive best supportive care. Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease.
62699766|NCT03923088|EXPERIMENTAL|jacobson's progressive muscle relaxation technique|
62699767|NCT03923088|EXPERIMENTAL|audiovisual distraction technique|
62699768|NCT03923088|NO_INTERVENTION|conventional|
62714796|NCT06328127|EXPERIMENTAL|Positive Affect in the Transplantation of Hematopoietic Stem Cells (PATH)|"Participants recruited from the Dana-Farber Cancer Institute, Duke Cancer Institute, and Moffitt Cancer Center who are randomized to the intervention/experimental arm will receive the PATH intervention, which is focused on gratitude, strengths, and meaning, as well as focused exercises on goal-setting and tracking daily physical activity.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol."
62141055|NCT05078775|EXPERIMENTAL|Nonessential Amino Acid Restriction (NEAAR) Medical Food|This is a single arm study in which all subjects will receive NEAAR medical food.
62141056|NCT03658109|ACTIVE_COMPARATOR|Lidocaine Bolus Infusion|"Patients will also undergo a loading dose of lidocaine, followed by continuous lidocaine infusion in the lidocaine group.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block."
62141057|NCT03658109|ACTIVE_COMPARATOR|QL Block & Saline Bolus Infusion|"Patients will undergo a posterior QL block.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will receive a saline bolus infusion."
62141058|NCT03658109|NO_INTERVENTION|Intrathecal Morphine Alone|"Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block.~Patients will receive a saline bolus infusion."
62141059|NCT06637358|ACTIVE_COMPARATOR|Extended Scheduled Gradual Reduction (SGR)|Extended scheduled gradual reduction. Participants are asked to gradually reduce smokeless tobacco usage.
62141060|NCT06637358|EXPERIMENTAL|Quit Coach and Extended Scheduled Gradual Reduction (SGR)|Extended scheduled gradual reduction given with the extra support of a live text-based coach. Participants are asked to gradually reduce smokeless tobacco usage and engage in weekly check-ins with their assigned quit coach.
62141061|NCT01214759|OTHER|Truvada and Raltegravir|Single arm
62141062|NCT00765544|EXPERIMENTAL|Arm 1|Anklebot
62141063|NCT00765544|EXPERIMENTAL|Arm 2|Body-weight supported treadmill training
62141064|NCT00765544|EXPERIMENTAL|Arm 3|Combination therapy (Anklebot and BWSTT)
62699769|NCT03285360|EXPERIMENTAL|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.~Steps:~1. Isolation: D.M. will make proper isolation for the teeth using cotton rolls.~2. Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.~3. Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.~4. Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
62699770|NCT03285360|ACTIVE_COMPARATOR|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.~Steps:~1. Preparation: The tooth will be properly cleaned, and the surface will be air-dried.~2. Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.~3. Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
62699771|NCT03405350|ACTIVE_COMPARATOR|Study Group|The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
62699772|NCT03405350|NO_INTERVENTION|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
62141065|NCT01082900|EXPERIMENTAL|Prophylactic CPAP intervention|Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
62342859|NCT06461546|EXPERIMENTAL|Imlifidase treatment|"Single arm pilot study~All highly sensitized patients included in the study will receive the immunosuppressive standard of care therapy at Hospital Clínic de Barcelona and in addition the study drug:~* Imlifidase (POD0, pre-transplantation), imlifidase, 0.25 mg/kg over a period of 15 minutes, prior to transplantation.~* Dose Adjustment Criteria~FC-XM screening and single antigen will be performed after 6 hours of imlifidase infusion, It will take 3 hours to obtain the results, respectively:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - 2nd Imlifidase infusion will be required (imlifidase dose: 0.25mg/Kg).~FC-XM screening and single antigen will be performed after 2 hours of the 2nd Imlifidase infusion:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - The scheduled kidney transplant will be canceled."
62342860|NCT05152017|EXPERIMENTAL|Flu-M Quadro with preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine with a preservative
62342861|NCT05152017|EXPERIMENTAL|Flu-M Quadro without preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine without a preservative
62342862|NCT05152017|PLACEBO_COMPARATOR|Placebo|25 volunteers were vaccinated with a Placebo
62342863|NCT00258206|EXPERIMENTAL|rituximab + cyclophosphamide|Rituximab 375 mg/m\^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m\^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m\^2 once each during months 3, 6, 9, and 12
62342864|NCT04045236||Non metastatic rectal cancer|Patients receiving the diagnosis of non metastatic rectal cancer and the indication for a curative treatment will be enrolled in the registry. The study population will consist of all the patients enrolled in the participating centres from the start of the rectal cancer registry on.
62342865|NCT03258047|EXPERIMENTAL|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
62342866|NCT02974387|ACTIVE_COMPARATOR|Fluorometholone(FMl)|Patients will be randomized to the eye and will receive FML in one eye.
62342867|NCT02974387|ACTIVE_COMPARATOR|Loteprednol (Lotemax)|Patients will be randomized to the eye and will receive Lotemax in contralateral eye.
62342868|NCT02626845|ACTIVE_COMPARATOR|Rituximab Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional rituximab infusions at week 16 and week 32.
62342869|NCT02626845|PLACEBO_COMPARATOR|Placebo Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional placebo infusions at week 16 and week 32.
62342870|NCT01800123||Acute poisoning|Consecutive acute drug self poisoned patients admitted in the ED.
62141066|NCT01082900|ACTIVE_COMPARATOR|No Intervention|Provision of standard care in the Delivery Room
62141067|NCT00326196|ACTIVE_COMPARATOR|PCI|Percutaneous coronary intervention
62141068|NCT00326196|ACTIVE_COMPARATOR|CABG|Coronary artery bypass graft (CABG)
62141069|NCT02659124|OTHER|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
62342871|NCT00643487||1|observation of the behavior of the infrapatellar plica
62342872|NCT04597619|NO_INTERVENTION|Pre-Implementation Cohort|Cohort undergoing PCNL prior to implementation of the novel nonopioid pathway
62342873|NCT04597619|EXPERIMENTAL|Implementation Cohort|Cohort undergoing PCNL with implementation of the novel nonopioid pathway
62342874|NCT05910541|EXPERIMENTAL|Intervention|Patients will receive standard care plus daily sessions of 30-minute mindful breathing for four consecutive days
62342875|NCT05910541|SHAM_COMPARATOR|Control|Patients will only receive standard care.
61951543|NCT02772107|EXPERIMENTAL|TMZ group|"Patients will receive platinum-based first-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cyclesfor the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study, radiotherapy was allowed."
61951544|NCT02974283|EXPERIMENTAL|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.
61951545|NCT02974283|NO_INTERVENTION|Control group|The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
61951546|NCT02501226|OTHER|Control group|Treatment as usual
61951547|NCT02501226|EXPERIMENTAL|Interventional group|ENVIE psychoeducational program
61951548|NCT05864755|EXPERIMENTAL|HAIC+Durvalumab+Tremelimumab+Bevacizumab|
61951549|NCT01469754||Lymphoma Survivors|
61951550|NCT02419105|ACTIVE_COMPARATOR|Testosterone + Vitamin D|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
61951551|NCT02419105|ACTIVE_COMPARATOR|Testosterone + Placebo|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
61951552|NCT02419105|ACTIVE_COMPARATOR|Placebo + Vitamin D|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
62342876|NCT04252612|EXPERIMENTAL|Cohort 1: Pramlintide 60 mcg twice daily|Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.
62342877|NCT04252612|EXPERIMENTAL|Cohort 2: Pramlintide 60 mcg three times daily|Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.
62500340|NCT06679426|PLACEBO_COMPARATOR|Placebo|The comparator in the study will be a placebo, an isotonic sterile solution (pH 5.5 ± 0.3) for IV injection. The solution does not contain any preservatives. The placebo is formulated to match the study drug (conestat alfa) and is supplied in an identical single-dose IV bag. To maintain the blinding of the study, the IV bag containing the placebo will be indistinguishable from that containing conestat alfa, in addition to the labeling
61951553|NCT02419105|PLACEBO_COMPARATOR|Control|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
61951554|NCT04614558|EXPERIMENTAL|Isatuximab for MGRS|Subjects will receive Isatuximab for 6 months and will be followed for an additional one year post therapy for outcome follow-up.
62699773|NCT05462704|EXPERIMENTAL|IV Iron|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes and daily placebo tablets until delivery.
61951555|NCT04203797|EXPERIMENTAL|dupilumab|A loading dose at the start of the treatment followed by once every two weeks (Q2W).
61951556|NCT04203797|EXPERIMENTAL|Matching placebo|Matching dupilumab
61951557|NCT02746146|EXPERIMENTAL|Chronic dialysis patients|"The study population consists of patients over 70 (≥) and under 85 years (\<) of age with stage 5 chronic renal disease and initiating a first session of chronic dialysis in the Languedoc-Roussillon and Midi-Pyrénées regions. Eligible patients must have a 3 year prognostic mortality score less than (\<) 7 points (Dusseux et al. 2015).~Intervention: Systematic use of a prognostic score"
61951558|NCT04067674||Septic shock patients|Patients included in this cohort will have blood sampling for measurement of immune related biomarkers (immunophenotyping, functional tests, messenger ribonucleic acid (mRNA), circulating markers) in circulating blood and their associations with relevant clinical outcomes
61951559|NCT05401357|EXPERIMENTAL|Bimatoprost 0.01% Ophthalmic Solution|Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
62500341|NCT06031337||Oral Cancer Group|23 patients with oral cancer
62500342|NCT06031337||Control Group|23 age-and-sex-matched healthy individuals, as normal controls
62500343|NCT06120660|EXPERIMENTAL|Case Group|Music
61951560|NCT05401357|ACTIVE_COMPARATOR|LUMIGAN® 0.01% Ophthalmic Solution|Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
62141070|NCT06699537|EXPERIMENTAL|Probiotic group|Participants in the probiotic group received 1 sachet probiotic product per day.
62342878|NCT04252612|EXPERIMENTAL|Cohort 3: Pramlintide 120 mcg three times daily|Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.
62342879|NCT02542917||All patients|IBDoc home test for faecal calprotectin
62342880|NCT06372821|EXPERIMENTAL|NIO752|Intrathecal administration.
62342881|NCT06372821|PLACEBO_COMPARATOR|Saline|10mL of saline (placebo) is administered intrathecally.
62342882|NCT02753829|EXPERIMENTAL|Experimental group 1|Cardiovascular rehabilitation program using Kinect of Xbox, in home care context,virtual format
62500344|NCT06120660|NO_INTERVENTION|Control Group|
62500345|NCT00593827|ACTIVE_COMPARATOR|Arm 1|ixabepilone 16 mg/m\^2 weekly for 3 weeks followed by 1 week rest
62500346|NCT00593827|ACTIVE_COMPARATOR|Arm 2|ixabepilone 40 mg/m\^2 every 3 weeks
62500347|NCT03041532|EXPERIMENTAL|proximal retroflexion|Procedure: The endoscopy explore right colon with frontal view and a second look with proximal retroflexion
62500348|NCT03041532|ACTIVE_COMPARATOR|frontal view of right colon|Procedure: The endoscopy explore right colon with frontal view and frontal view
62500349|NCT05766787|OTHER|LID022821, then AOHP|Serafilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.
62699774|NCT05462704|ACTIVE_COMPARATOR|Oral Iron|Participants assigned to the oral iron group will receive a single 250 mL IV normal saline infusion given over 20 minutes and 325mg tablets of ferrous sulfate (65 mg of elemental iron) to be taken until delivery.
61951561|NCT04211883|EXPERIMENTAL|Active intervention|Participants will come to the Project Active clinic and be asked questions about their health history, assist in their health goals, medications will be adjusted, lab work and screening tests will be ordered. At end of each visit, current health recommendations and goals as well as previous health changes will be given after each visit.
61951562|NCT04211883|NO_INTERVENTION|Standard Clinical Treatment|Participants will continue with their usual clinic care.
61951563|NCT01796483|ACTIVE_COMPARATOR|healthy Volunteers|
61951564|NCT01796483|EXPERIMENTAL|Patients|
61951565|NCT02046681||Acetam, acetam + codeine, Ibuprofen, Oxycodone|monitoring side effects of pain medication prescribed in patients over 65 acetaminophen 1000 mg tabs po q6h acetaminophen + codeine 500 mg tabs po q6h ibuprofen 200 mg tabs po q8h oxycodone 5 mg tabs po bid
62699775|NCT06632080|EXPERIMENTAL|Substance P|Substance P will be administered by intravenous infusion.
61951566|NCT05599191|EXPERIMENTAL|BLU-5937 25 mg|BLU-5937 oral dose 25 mg twice a day.
61951567|NCT05599191|EXPERIMENTAL|BLU-5937 50 mg|BLU-5937 oral dose 50 mg twice a day.
61951568|NCT05599191|PLACEBO_COMPARATOR|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
61951569|NCT04340180|EXPERIMENTAL|Subjects with enhancing breast lesions|
61951570|NCT00771069||1|Type II Diabetes Mellitus patients with Complication and Hypertension
61951571|NCT01802801||1|
62141071|NCT06699537|PLACEBO_COMPARATOR|Placebo group|Participants in the placebo group received 3g of maltodextrin per day.
62342883|NCT02753829|EXPERIMENTAL|Experimental group 2|Cardiovascular rehabilitation program using paper manual, in home care context, conventional format
62342884|NCT02753829|OTHER|Control Group|Educational component
62342885|NCT02217150||Metastatic Lesions to the spine|Patients over the age of 18 receiving treatment using the DFINE Inc. STAR tumor ablation system for palliation of painful metastases of the spine.
62342886|NCT04703322|EXPERIMENTAL|Pexidartinib|Participants with TGCT who will receive oral pexidartinib 800 mg (400 mg twice daily \[BID\]).
62699776|NCT06632080|PLACEBO_COMPARATOR|Placebo|Placebo (isotonic saline) will be administered by intravenous infusion.
62699777|NCT04468360|EXPERIMENTAL|IV Allopregnanolone (Allo) for Extinction Retention (Expt. 1)|Arm 1 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after completion of extinction training.
62342887|NCT00448760|EXPERIMENTAL|Neoadjuvant + Adjuvant Chemotherapy|
62342888|NCT06466928||Standard Total pancreatectomy|Total pancreatectomy without vascular or adjacent organ resection. In cases with concomitant liver resection, only an excisional biopsy or wedge resection was to be performed
62699778|NCT04468360|PLACEBO_COMPARATOR|IV Placebo for Extinction Retention (Expt. 1)|Arm 2 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after completion of extinction training.
62699779|NCT04468360|EXPERIMENTAL|IV Allo for Reconsolidation Blockade (Expt. 2)|Arm 1 of Expt. 2 will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
62699780|NCT04468360|PLACEBO_COMPARATOR|IV Placebo for Reconsolidation Blockade (Expt. 2)|Arm 2 of Expt. 2 will include will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
62699781|NCT03346837|EXPERIMENTAL|Inhibition (Cohort 1)|Single oral dose BMS-986205
61951572|NCT04924907||Dysbiosis microbiota|microbiota with proinflammatory pattern or dysbiosis
62342889|NCT06466928||Total pancreatectomy with venous resection|Total pancreatectomy with portal vein and/or superior mesenteric vein resection
61951573|NCT04924907||Normal microbiota|microbiota with antiinflammatory pattern or normal
61951574|NCT01209611|EXPERIMENTAL|Autologous bone marrow mononuclear cells|Patients received autologous MNC transplantation. Bone marrow aspirates are harvested from the anterior iliac crest of the patients under general or local anesthesia. MNCs are isolated by density gradient centrifugation. The cell suspension was adjusted to a final volume of 6-20 ml with saline. The cell suspension was injected into expanded skin intradermally via a 27-gauge needle (approximately 0.5-1×10\^6 cells/cm2).
61951575|NCT01209611|PLACEBO_COMPARATOR|Saline|Patient has intradermally and subcutaneously injection of saline.
61951576|NCT02015754|EXPERIMENTAL|DEBIRI|
61951577|NCT05111925||Pilot Cohort|Active duty Service members with no recent history of musculoskeletal injury, no history of musculoskeletal related surgery, and no restrictions on physical activity participation.
62141072|NCT05590559|ACTIVE_COMPARATOR|paravertebral block|
62141073|NCT05590559|EXPERIMENTAL|Ultrasound-guided erector spinae plane block|
62141074|NCT01943305|EXPERIMENTAL|Test arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
62342890|NCT06466928||Total pancreatectomy with multivisceral resection|Total pancreatectomy with additional adjacent organ resection. The procedure extended beyond pylorus preserving, pylous resecting, and procedures with antrectomy and included the partial or total resection of additional organs with the exception of partial or total splenectomy. Procedures with liver resections, that required a larger atypical, segmental, bisegmental or major (hemihepatectomy) resection.
62342891|NCT06466928||Total pancreatectomy with arterial resection|Total pancreatectomy with arterial resection: superior mesenteric artery resections, hepatic artery resections, aortic resections, or resections of the celiac axis
62699782|NCT03346837|EXPERIMENTAL|Inhibition (Cohort 2)|Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
62699783|NCT03346837|EXPERIMENTAL|Induction (Cohort 3)|Single oral dose BMS-986205
62699784|NCT03346837|EXPERIMENTAL|Induction (Cohort 4)|Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8
62500350|NCT05766787|OTHER|AOHP, then LID022821|Senofilcon A contact lenses worn first, with serafilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.
61951578|NCT05111925||Uninjured Cohort - Initial Assessment|Active duty Service members who are not currently receiving healthcare for a musculoskeletal injury and who have no physical activity participation restrictions.
61951579|NCT05111925||Injured Cohort - Initial Assessment|Active duty Service members who are receiving conservative treatment for a musculoskeletal injury of the low back or lower extremity.
61951580|NCT05111925||Uninjured Cohort - Optimized Assessment|Active duty Service members who are not currently receiving healthcare for a musculoskeletal injury and who have no physical activity participation restrictions.
61951581|NCT05111925||Injured Cohort - Optimized Assessment|Active duty Service members who are receiving conservative treatment for a musculoskeletal injury of the low back or lower extremity.
62141075|NCT01943305|EXPERIMENTAL|Control arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 25 subjects in the control arm will not receive Japanese Encephalitis vaccine but will receive 1 dose of Yellow Fever vaccine.
62342892|NCT02049801|EXPERIMENTAL|Treatment (MEK inhibitor, MEK162, idarubicin, cytarabine)|"INDUCTION THERAPY: Patients receive MEK inhibitor MEK162 PO BID on days -4 to -1 and days 5-18, cytarabine IV continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. Patients may receive a second course of induction at the discretion of the principal investigator.~POST-REMISSION THERAPY: Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62342893|NCT01132339||Enhanced MR (case group)|those with an exposure to gadolinium-based contrast agent
62342894|NCT01132339||Unenhanced MR (control group)|those without an exposure to gadolinium-based contrast agent
62342895|NCT01132339||Unenhanced CT (control group)|those without an exposure to iodine-containing contrast agent
62342896|NCT01132339||Enhanced CT (case group)|those with an exposure to iodine-containing contrast agent
62342897|NCT00709358|ACTIVE_COMPARATOR|2|Detection by blood culture
62342898|NCT00709358|EXPERIMENTAL|1|Test LightCycler SeptiFast® (Roche)
62500351|NCT05215938||Study I: Multi-organ sodium imaging with B1 field correction|"The scan will be performed in four area of interests (AOFs) to acquire sodium level signal form the thigh, heart, kidneys, and brain. Between each AOF the sodium receive coil will be moved to cover the specific organ. Determination of the sodium imaging method robustness is performed with a series of MRI sequences.~The scans at the four AOFs are repeated to evaluate repeatability. The scan time with repositioning of coils is approximately 15 min per station (total scan time 2 hours).~If needed the participants are able to have a break between scan stations."
62699785|NCT06114368||Endoscopic Flexor Hallucis Longus transfer / Group 1|Patients with acute Achilles tendon rupture managed with Endoscopic Flexor Hallucis Longus transfer by one surgeon (A.E.) in one hospital (General Hospital of Naoussa, Naoussa, Greece), all of which followed the same rehabilitation protocol.
62699786|NCT06114368||Minimally Invasive Primary repair / Group 2|Patients with acute Achilles tendon rupture managed with Minimally Invasive Primary repair by one surgeon (P.S.) in one hospital (St. Luke's Hospital, Thessaloniki, Greece), all of which followed the same rehabilitation protocol.
61951582|NCT02552992|EXPERIMENTAL|Yoga Classes|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
62141076|NCT02720432|EXPERIMENTAL|CIMT|"A soft splint or restraint will be posed to best functioning hand of the infant only during the therapy session. Parents will be educated to perform the therapy, which consists of stimulation of reaching and grasping with the hemiplegic arm.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform CIMTfor 30 minutes, 6 days a week."
62141077|NCT02720432|EXPERIMENTAL|HABIT|"No restraint will be implemented and instead of promoting unilateral grasping, bimanual grasping will be stimulated. Toys will be precisely selected to stimulate progressed bimanual grasping. The approach of the therapist and parents remain equal.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform HABIT for 30 minutes, 6 days a week."
62141078|NCT02720432|SHAM_COMPARATOR|Baby-massage|3 sessions of baby-massage will be given by a qualified instructor
62342899|NCT02357641||Patients with thoracal disorder|"300 patients with thoracal disorder, cardiac or non- cardiac, are enrolled prospectively to undergo routinely examinations such as clinical and hemodynamic chemistry as well as echocardiography for strain analysis refering to myocardial deformation.~Especially analysis of strain data (circumferential and radial), regional and global left and right ventricular wall movement data and diastolic parameters will be analysed retrospectively to investigate a probable cut off value corresponding to acute coronary disease or non cardiac disorder (Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome)."
62342900|NCT04044209|EXPERIMENTAL|Patients receiving nivolumab and ivosidenib|"Patients who meet eligibility criteria will initiate therapy with the IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.~On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle. Patient will be treated until progression, transplant or unacceptable toxicity. The patient will be continually monitored on therapy and will undergo scheduled response assessments to evaluate response."
62342901|NCT00418964|EXPERIMENTAL|Single bundle hamstring|
62342902|NCT00418964|EXPERIMENTAL|Double bundle hamstring|
62342903|NCT00418964|ACTIVE_COMPARATOR|Bone patellar tendon bone|
61951583|NCT02552992|ACTIVE_COMPARATOR|Self-Directed Mind-Body Program|Study Participants will receive: The Back Pain Helpbook, a mind-body self-care program for better living.
61951584|NCT03941392||Healthy children between 1 and 9 years old|A sample of 1500 apparently healthy children between 1 to 9 years old from urban areas from different regions of Spain.
61951585|NCT02586129|EXPERIMENTAL|YH14755|PO, Once Daily, 16 weeks
61951586|NCT02586129|ACTIVE_COMPARATOR|Metformin|PO, Once Daily, 16 weeks
62699787|NCT06252415||parent-to-be|Pregnant women and the biological father
62699788|NCT05249270||Safe and Sound Protocol Participants|Parents of children receiving the Safe and Sound Protocol (a clinical auditory therapy provided outside of the study) will complete questionnaires to assess sensory behaviors prior to therapy initiation (baseline), 1 week after therapy conclusion, and 4 weeks after therapy conclusion. The SSP typically consists of 1 hour of listening per day, for 5 consecutive days. If modifications of the typical dosage are implemented due to client needs, they will be documented by parents in the 1 week post therapy questionnaire.
62699789|NCT01854450|EXPERIMENTAL|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
61951587|NCT02586129|ACTIVE_COMPARATOR|Rosuvastatin|PO, Once Daily, 16 weeks
62342904|NCT05760820|EXPERIMENTAL|Intervention Group|Access to the digital intervention post-baseline questionnaire and randomization.
62342905|NCT05760820|NO_INTERVENTION|Control Group|Control group will gain access to the digital intervention after the 3-month follow-up.
62342906|NCT02638896|EXPERIMENTAL|Dose reduction arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
62342907|NCT02638896|ACTIVE_COMPARATOR|Dose maintenance arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
62342908|NCT02638896|OTHER|Etanercept discontinuation arm|AS patients who achieved remission will take sulfasalazine (2g/d) till week24. Celecoxib will be the background therapy.
62500352|NCT05215938||Study II: Circadian sodium level variation in the kidney measured with MRI|"Participation requires one full day at the MR Centre. MRI scans will be performed three times at the same day within the following time periods: 6.30-8.00 am. (before breakfast), 12.30-14-00 pm. (after lunch) and 21.00-22.00 pm. (after dinner). The scan time is expected to be 30-40 min at each scan (three scans are performed on one examination day), which requires a total scan time \~1½ hours.~Participants are not allowed to perform excessive physical exercise the day before and during the study day. Lighter physical exercise as walking, biking etc. is accepted. Alcohol consuming is not allowed the day before and during the study day. The participants can drink and eat as usual, but all fluid intake and urinations shall be documented in a liquid urination schedule. Blood pressure will be measured at each scan session and urine samples are collected just after each scan session to assess the osmolarity."
62500353|NCT01279915|EXPERIMENTAL|ASP group|ASP0456 receiving group
62500354|NCT01279915|PLACEBO_COMPARATOR|Placebo group|Placebo treatment
62500355|NCT04282694||High risk (former) smokers|"Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.~Inclusion criteria~* Age between 50 and 75 years~* Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years~* Status of current smoker or ex-smoker for \<10 years.~Exclusion criteria~• Personal history of cancer within the prior 5 years"
62500356|NCT00818220|EXPERIMENTAL|1-Delayed Cord Clamping (DCC)|Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
62500357|NCT00818220|ACTIVE_COMPARATOR|2-Immediate Cord Clamping (ICC)|Routine care which is immediate cord clamping
62500358|NCT03826901|EXPERIMENTAL|Part 1: adults and adolescents (12 years and above)|Delgocitinib cream (dosage: A mg/g).
62500359|NCT03826901|EXPERIMENTAL|Part 2: children (2-11 years)|Delgocitinib cream (dosage: B mg/g).
62500360|NCT03559127|EXPERIMENTAL|Group A. Cold Protocol with 6 oC|"Use of 20 mL cold (6 oC) sterile saline solution.~After the clinical procedure cryotherapy was applied. 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
62500361|NCT03559127|EXPERIMENTAL|Group B. Cold Protocol with 2.5 oC|"Use of 20 mL cold (2.5 oC) sterile saline solution~After the procedure cryotherapy was applied. 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
62500362|NCT03559127|EXPERIMENTAL|CG. Room temperature Protocol|"Use of 20 mL (at room temperature) sterile saline solution~The group will receive irrigant at room temperature. 5mL of 17% EDTA and 20 mL of sterile saline usingmetallic micro-cannula included in the Endo Vac System for five minutes."
62500363|NCT00355524|EXPERIMENTAL|Group A with >= 20 kg to < 30 kg body weight|300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter \[mL\]) of ritonavir liquid (80 milligram/milliliter \[mg/ml\]) will be administered orally twice daily.
62500364|NCT00355524|EXPERIMENTAL|Group A with >= 30 kg to < 40 kg body weight|300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter \[mL\]) of ritonavir liquid (80 milligram/milliliter \[mg/ml\]) will be administered orally twice daily.
62500365|NCT00355524|EXPERIMENTAL|Group A with >= 40 kg to < 50 kg body weight|450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
62699790|NCT01854450|OTHER|control|usual obstetrical care
62141079|NCT06699485|EXPERIMENTAL|Group 1|Children and adolescents aged 10 - 18 years, diagnosed with T1DM for at least 1 year
62141080|NCT01915914|EXPERIMENTAL|fluticasone propionate|To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis
62342909|NCT03544554|EXPERIMENTAL|Intervention group and control group|This research is planned with semi experimental design
62342910|NCT04706429|ACTIVE_COMPARATOR|Trientine|Trientine dihydrochloride 1200 mg per day. This shall be taken orally as two Cufence 200mg hard capsules two times per day. The IMP will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
62699791|NCT06565117|EXPERIMENTAL|A:Emollient for systemic application|Emollient for systemic application
62699792|NCT06565117|EXPERIMENTAL|B:Emollient was applied locally|Apply skin lotion in locally affected skin areas or in areas previously affected by AD
62699793|NCT06565117|NO_INTERVENTION|C:No moisturizer|No moisturize
62699794|NCT05994846|EXPERIMENTAL|Experimental Treatment Arm|Participants will receive closed-loop transcutaneous spinal cord stimulation via the RISES-T System while completing repetitive task practice
62699795|NCT01924819|EXPERIMENTAL|Preoperative chemoradiotherapy|"2 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 3 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~5 weeks preoperative chemoradiotherapy.~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
61951588|NCT06557226||patient with oral hypofunction with 3 impaired oral functional parameters|patient's will receive an oral examination comprising the evaluation of 7 parameters: the oral hygiene, the oral dryness, the occlusal force, the tongue-lip motor function, the tongue pressure, the chewing function and the swallowing function. Oral hypofunction is defined as a state when 3 or more signs were present.
61951589|NCT03917238|OTHER|Patients with T1D|gallium-68-exendin followed by a PET/CT scan (twice)
61951590|NCT04873115|ACTIVE_COMPARATOR|Sialanar|Sialanar administered as per the SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
61951591|NCT04873115|PLACEBO_COMPARATOR|Placebo|Placebo administered as per the Sialanar SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
61951592|NCT03681665||Abscess|Patients group with abdominal abscess
61951593|NCT02126917|EXPERIMENTAL|HC-ER + 40% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.
61951594|NCT02126917|EXPERIMENTAL|HC-ER + 20% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.
61951595|NCT02126917|EXPERIMENTAL|HC-ER + 0% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.
61951596|NCT05010057|EXPERIMENTAL|New Zealand blackcurrants (NZBC)|1 NZBC capsule (containing 300 mg active cassis containing 105 mg of anthocyanins, i.e. 35-50 % delphinidin-3-rutinoside, 5-20 % delphinidin-3-glucoside, 30-45 % cyanidin-3-rutinoside, 3-10 % cyanidin-3-glucoside), consumed in the morning, for 12 days.
61951597|NCT05010057|PLACEBO_COMPARATOR|Placebo (PLA)|1 placebo capsule (containing 300 mg microcrystalline cellulose M102), consumed in the morning, for 12 days.
62714797|NCT06328127|NO_INTERVENTION|Usual Care|"Participants recruited from the Dana-Farber Cancer Institute, Duke Cancer Institute, and Moffitt Cancer Center who are randomized to the usual care arm will receive their usual support from the HSCT team, including all routine supportive care resources (e.g., support from social work) offered by the HSCT team.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol."
61951598|NCT03373292|EXPERIMENTAL|Venous stenting (Group-1)|Patients in this group will undergo venous stenting treatment at once after enrollment.
61951599|NCT03373292|EXPERIMENTAL|Stenting one-month after routine medical treatment (Group-2)|Patients in this group will undergo routine medical treatment for one month, followed by venous stenting intervention.
61951600|NCT00049192|EXPERIMENTAL|Treatment (oblimersen sodium, imatinib mesylate)|"Patients receive oblimersen IV continuously on days 1-10 and oral imatinib mesylate once or twice daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without a hematologic response after 2 courses go off study. Patients with complete or partial response after 4 courses may continue to receive oral imatinib mesylate daily.~Patients in cohort 2 receive an escalated dose of oblimersen; if well tolerated, subsequent cohorts receive oblimersen at the higher dose with the original dose of imatinib mesylate. If oblimersen is not well tolerated in cohort 2, subsequent cohorts receive the original dose of oblimersen with an escalated dose of imatinib mesylate. The first 6 patients accrued continue to receive the original dose (dose taken prior to study) of imatinib mesylate throughout the study."
61951601|NCT01164930|EXPERIMENTAL|Acceptance and Commitment Therapy group|8-week ACT group
61951602|NCT01164930|NO_INTERVENTION|Wait-list control group|Participants will be offered treatment following wait-list data collection
61951603|NCT06557564||Liver Transplant patient will be undergoing liver graft biopsy.|Liver transplant patients will be undergoing liver graft biopsy (for any reason), or have had a liver biopsy within 48 hours of consent.
61951604|NCT01274078|NO_INTERVENTION|conventional food|Regular eating habits during exercise period
61951605|NCT01274078|ACTIVE_COMPARATOR|Blueberries|Intervention: Addition of blueberries (150g/day) to regular food during the exercise period on days with exercise
61951606|NCT06544889|EXPERIMENTAL|Sunscreen|Eligible study participants will visit the Site for an initial evaluation of skin condition and receive the Sunscreen to be used at home. Next, participants will use the Sunscreen in normal conditions at home for 28 +/- 2 days, returning to the Site after 7 days of product use, then make the last study visit to complete the final analysis.
61951607|NCT05230420|EXPERIMENTAL|Clamping|This arm will undergo chest drain clamping after a certain criteria has been met. Four hours post clamping a chest x-ray will be made, and the presence of pneumothorax will be assessed. The chest drain will be removed only in the absence of pneumothorax, if pneumothorax persists patients will stay attached to the underwater seal
61951608|NCT05230420|ACTIVE_COMPARATOR|Urine bag|The second arm will be attached to a urine bag, and bag inflation will be measured after a certain criteria has been met. bag inflation will be assessed four hours after its attachment. Bag inflation indicates the persistence of an air leak, thus the absence of bag inflation indicates the removal of the chest drain
62141081|NCT01915914|ACTIVE_COMPARATOR|physiogel|To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis
62141082|NCT00753545|EXPERIMENTAL|1|AZD2281
62141083|NCT00753545|PLACEBO_COMPARATOR|2|matching placebo
62500366|NCT00355524|EXPERIMENTAL|Group B with >= 20 kg to < 30 kg body weight|375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
60806836|NCT05848726||A Group|Group of patient who underwent laparoscopic cholecystectomy using Airseal
60806837|NCT05848726||S Group|Group of patient who underwent laparoscopic cholecystectomy using a standard insufflation
62500367|NCT00355524|EXPERIMENTAL|Group B with >= 30 kg to < 40 kg body weight|450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
62500368|NCT00355524|EXPERIMENTAL|Group B with >= 40 kg to < 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
62500369|NCT00355524|EXPERIMENTAL|Participants with >= 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
62500370|NCT02578745|EXPERIMENTAL|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
62500371|NCT02578745|ACTIVE_COMPARATOR|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
62699796|NCT01924819|ACTIVE_COMPARATOR|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine) OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
62699797|NCT04695665|ACTIVE_COMPARATOR|Cervical pain|Only patients with positive Cervical pain syndrome.
61951609|NCT04822324|EXPERIMENTAL|Spencer Muscle energy technique with conventional Physiotherapy|"1. shoulder extension with elbow flexion.~2. shoulder flexion with elbow extension.~3. circumduction with compression~4. circumduction with distraction~5. shoulder abduction and internal rotation with elbow flexion.~6. shoulder adduction and external rotation with elbow flexion~7. stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
62342911|NCT04706429|PLACEBO_COMPARATOR|Placebo|The placebo shall be taken orally as two capsules two times per day. This will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
62342912|NCT04300491||Beneficiaries of suspension walking|
62342913|NCT04300491||Non-Beneficiaries of suspension walking|
62342914|NCT01546389|EXPERIMENTAL|Cohort 3, Group E|Cohort 3 (High Dose, Low Aliquot), Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose); 5 subjects
62342915|NCT01546389|EXPERIMENTAL|Cohort 1, Group A|Cohort 1 (Medium Dose, Medium Aliquot), Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose); 5 subjects.
62342916|NCT01546389|EXPERIMENTAL|Cohort 1, Group B|Cohort 1 (Medium Dose, Medium Aliquot), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose); 5 subjects
62342917|NCT01546389|EXPERIMENTAL|Cohort 3, Group F|Cohort 3 (High Dose, Low Aliquot), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose); 5 subjects
62342918|NCT01546389|EXPERIMENTAL|Cohort 2, Group D|Cohort 2 (Medium Dose, Low Aliquot), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose); 5 subjects
62342919|NCT01546389|EXPERIMENTAL|Cohort 2, Group C|Cohort 2 (Medium Dose, Low Aliquot), Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose); 5 subjects
62342920|NCT00455793||1|HIV
62342921|NCT00455793||2|Non-HIV infected controls
62342922|NCT02709473|ACTIVE_COMPARATOR|propofol|Propofol arm includes patients that induction of general anesthesia started with propofol and followed by remifentanil and rocuronium administration
62699798|NCT04695665|ACTIVE_COMPARATOR|Thoracic pain|Only patients with positive Thoracic pain syndrome.
62342923|NCT02709473|ACTIVE_COMPARATOR|remifentanil|Remifentanil arm include patients that induction of general anesthesia started with remifentanil and followed by propofol and rocuronium administration
62342924|NCT06359743|EXPERIMENTAL|Group QL:|patients will receive Ultrasound Guided bilateral QL lumborum block (Anterior Approch) by anesthesiologist (20 ml of 0.25% bupivacaine hydrochloride at each side).
62342925|NCT06359743|EXPERIMENTAL|Group SH:|will receive laparoscopic Superior Hypogastric block by gynecologist (30 ml of 0.25% bupivacaine hydrochloride ).
62342926|NCT00805545|EXPERIMENTAL|A|Group of patients that will receive antibiotics 30-60 minutes prior to incision
62342927|NCT00805545|ACTIVE_COMPARATOR|B|Group of patients that will receive antibiotics immediately after clamping the umbilical cord
62342928|NCT00383422|EXPERIMENTAL|1|
62342929|NCT00383422|ACTIVE_COMPARATOR|2|
62342930|NCT05038033|EXPERIMENTAL|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy program adapted for the prevention of excessive weight gain. Involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
62342931|NCT05038033|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy (CBT)|The CBT program will match the delivery format and dose of the IPT program. There will be one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
62342932|NCT05668468|PLACEBO_COMPARATOR|Control Group|Daily cellulose capsule
62342933|NCT05668468|EXPERIMENTAL|Experimental Group|Daily Bifidobacterium adolescentis IVS-1,capsule
62342934|NCT03657667|OTHER|Ureteroscopy (URS) (standard treatment)|Endoscopic procedure used to remove kidney stones
62342935|NCT00255086|EXPERIMENTAL|Memantine|10mg Memantine
62342936|NCT00255086|PLACEBO_COMPARATOR|Control|10 mg Placebo pill
62342937|NCT02935114|EXPERIMENTAL|37% Carbamide Peroxide|"* no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
62342938|NCT02935114|ACTIVE_COMPARATOR|35% Hydrogen Peroxide|"* Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
62500372|NCT05653362|OTHER|Coconut Oil followed by Commercial Ultrasound Gel|"After the patient is consented and all questions are answered, the patient's information will be entered into a RedCap and they will be randomized to either starting the scan by first obtaining the required study images with coconut oil and then proceeding to the standard ultrasound using commercial ultrasound gel (Arm 1) or to starting with the scheduled ultrasound using the commercial ultrasound gel and ending by obtaining the required study images using coconut oil (Arm 2).~Whether assigned to Arm 1 or Arm 2, prior to the collection of the study images using coconut oil, the participant will be handed a small plastic cup with a pre-measured amount of coconut oil and they will be asked to warm it in their hand for at least 2 minutes. They will then apply the coconut oil to their own abdomen with their hands prior to the ultrasound technician obtaining the required images.~The ultrasound technician will collect 3 extra images for study purposes only using the coconut oil."
62699799|NCT04695665|ACTIVE_COMPARATOR|Lumbar pain|Only patients with positive Lumbar pain syndrome.
62699800|NCT05270863|EXPERIMENTAL|BRIMOCHOL™ PF|A single drop in each eye at a visit.
62699801|NCT05270863|ACTIVE_COMPARATOR|Carbachol PF|A single drop in each eye at a visit.
62699802|NCT05270863|ACTIVE_COMPARATOR|Brimonidine tartrate|A single drop in each eye at a visit.
62699803|NCT03190876|NO_INTERVENTION|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
62342939|NCT01740388|EXPERIMENTAL|Besifloxacin|besifloxacin ophthalmic suspension 0.6% administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
62342940|NCT01740388|PLACEBO_COMPARATOR|Vehicle|vehicle of besifloxacin ophthalmic suspension administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
62342941|NCT03420326||Atria fibrillation (AF) group|"1. Detection of AF during 30 seconds ECG assessment~2. Once diagnosed with atrial fibrillation before~3. Undergo the frailty status assessment"
62342942|NCT03420326||Non-AF group|"1. No detection of AF during 30 seconds ECG assessment~2. Undergo the frailty status assessment"
62342943|NCT06432556|OTHER|patients with isolated cutaneous mastocytosis with associated skin involvement - RNAseq|
62342944|NCT06432556|OTHER|patients with mastocytosis indolent systemic with associated skin involvement|
62342945|NCT06432556|OTHER|patients with isolated cutaneous mastocytosis with associated skin involvement|
62342946|NCT06432556|OTHER|patients with mastocytosis indolent systemic with associated skin involvement - RNAseq|
62342947|NCT00523406|ACTIVE_COMPARATOR|A|standard fluence photodynamic therapy and intravitreal triamcinolone combination
62342948|NCT00523406|ACTIVE_COMPARATOR|B|reduced fluence photodynamic therapy and intravitreal triamcinolone combination
62342949|NCT05246007|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
62342950|NCT05246007|PLACEBO_COMPARATOR|Placebo group|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
62342951|NCT00960128||A|Adult cohort
62342952|NCT00960128||B|Paediatric cohort
62342953|NCT00553137|ACTIVE_COMPARATOR|1|single dose fluconazole (750 mg) and placebos 150 mg tablets once daily for 14 days
62342954|NCT00553137|ACTIVE_COMPARATOR|2|150 mg fluconazole once daily for 14 days and placebos (5 placebos tablets) 750 mg once
62342955|NCT05360355||patients undergone total face reconstruction and intraoperative indocyanine green angiography|This clinical study enrolled 10 patients treated with total face reconstruction and intraoperative indocyanine green angiography from Jun 2018 to Jun 2021.
62342956|NCT03616327|OTHER|MATRx in-lab or MATRx plus test|Participants will undergo the MATRx in-lab or MATRx plus home test to determine adequacy for mandibular repositioning oral appliance therapy. The tests only differ in their setting (i.e., in the sleep lab or at home). All participants will receive the same treatment protocol preceding and following the MATRx/MATRx plus test.
62699804|NCT03190876|ACTIVE_COMPARATOR|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
62342957|NCT04940442|EXPERIMENTAL|Active choice|FIT or colonoscopy
62342958|NCT04940442|EXPERIMENTAL|Sequential choice|FIT offered first, then colonoscopy offered to those still unscreened
62699805|NCT03190876|ACTIVE_COMPARATOR|No drain|Conventional body contouring procedure, no application of drains
62699806|NCT05595239|EXPERIMENTAL|standard treatment+CVVH|
62699807|NCT05595239|EXPERIMENTAL|standard treatment+TPE+CVVH|
62342959|NCT05576155|EXPERIMENTAL|Local losartan perfusion|\~1 hour of losartan is perfused through an intradermal microdialysis fiber
62342960|NCT05576155|OTHER|Local lactated Ringer's (control) perfusion|\~1 hour of lactated Ringer's is perfused through an intradermal microdialysis fiber
62342961|NCT04050501|ACTIVE_COMPARATOR|non-invasive Vagus Nerve Stimulation|non-invasive Vagus Nerve Stimulation on top of best medical practice
62342962|NCT04050501|NO_INTERVENTION|Standard Care|Best medical practice alone
62699808|NCT05595239|EXPERIMENTAL|standard treatment+HP+CVVH|
62699809|NCT04305210|EXPERIMENTAL|F-18-PMPBB3|F-18-PMPBB3 imaging
62699810|NCT04305210|EXPERIMENTAL|18F-florbetapir|18F-florbetapir (AV45) imaging
62699811|NCT06564883|EXPERIMENTAL|Experimental Arm|Hyaluronic Acid will applied under recommended conditions during the period of T22 ±2 days.
62699812|NCT04956887|EXPERIMENTAL|Intervention|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
62699813|NCT04956887|PLACEBO_COMPARATOR|Placebo|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning.
62699814|NCT01344356|OTHER|Benign Tumors|Benign head and neck tumors will be treated with SBRT
62500373|NCT05653362|OTHER|Commercial Ultrasound Gel followed by Coconut Oil|"After the patient is consented and all questions are answered, the patient's information will be entered into a RedCap and they will be randomized to either starting the scan by first obtaining the required study images with coconut oil and then proceeding to the standard ultrasound using commercial ultrasound gel (Arm 1) or to starting with the scheduled ultrasound using the commercial ultrasound gel and ending by obtaining the required study images using coconut oil (Arm 2).~Whether assigned to Arm 1 or Arm 2, prior to the collection of the study images using coconut oil, the participant will be handed a small plastic cup with a pre-measured amount of coconut oil and they will be asked to warm it in their hand for at least 2 minutes. They will then apply the coconut oil to their own abdomen with their hands prior to the ultrasound technician obtaining the required images.~The ultrasound technician will collect 3 extra images for study purposes only using the coconut oil."
62500374|NCT06069544|EXPERIMENTAL|BNT165e|Escalating dose levels
62500375|NCT06069544|PLACEBO_COMPARATOR|Placebo|
62500376|NCT06331130||Retrospective cohort|Patients affected by High Grade Seruous Ovarian Cancer with mesenteric infiltration confirmed by diagnostic laparoscopy, from January 2021 to December 2023
62500377|NCT06331130||Prospective cohort|Patients affected by High Grade Seruous Ovarian Cancer with mesenteric infiltration confirmed by diagnostic laparoscopy
62500378|NCT00055809|EXPERIMENTAL|Arm I (bevacizumab)|Patients receive bevacizumab IV on day 1.
62500379|NCT00055809|EXPERIMENTAL|Arm II (PEG-interferon alfa-2b)|Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
61951610|NCT04822324|ACTIVE_COMPARATOR|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
62500380|NCT02497235|EXPERIMENTAL|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of \[18F\]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
62500381|NCT02683291|ACTIVE_COMPARATOR|Tacrolimus + Mycophenolate|"The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
62500382|NCT02683291|EXPERIMENTAL|Tacrolimus + Sirolimus|"The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
62500383|NCT01294449||MADIT-CRT ICD|
62500384|NCT01294449||MADIT-CRT CRT-D|
61951611|NCT03566160|EXPERIMENTAL|Cryobiopsy probe as a tool for biopsy|Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
62500385|NCT03865225|SHAM_COMPARATOR|Control group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes sham-biofeedback over a period of three days
62500386|NCT03865225|ACTIVE_COMPARATOR|Treatment group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes biofeedback sessions over period of three days
62500387|NCT06678607|EXPERIMENTAL|Experimental group 1|60 participants will be randomized to receive Reinovax PCV24 formulation 1. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
62500388|NCT06678607|EXPERIMENTAL|Experimental group 2|60 participants will be randomized to receive Reinovax PCV24 formulation 2. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
62500389|NCT06678607|ACTIVE_COMPARATOR|Active control group|60 participants will be randomized to receive PPSV23. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
62500390|NCT06678607|PLACEBO_COMPARATOR|Placebo group|60 participants will be randomized to receive placebo. The route of administration is intramuscular injection at the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
62500391|NCT00802373|EXPERIMENTAL|I|Solifenacin succinate 5/10mg
62500392|NCT00802373|EXPERIMENTAL|II|Tolterodine 4mg
62500393|NCT04911205|EXPERIMENTAL|Intervention Group|Patients who were randomly allocated to intervention group (N=44) completed a 6-week preoperative training program, 5 days per week prior to surgery
62500394|NCT04911205|NO_INTERVENTION|Control Group|Patients who were randomly allocated to control group (N=44), they continued to live as usual, prior to surgery
62500395|NCT02129517|EXPERIMENTAL|Arm I (IMPACT Intervention)|Oncology nurses watch tailored, web-based informational video clips addressing knowledge, attitudes, subjective norms, and perceived behavioral control (barriers of discussing clinical trials with patients). They also watch role-play video clips to help improve perceived behavioral control and address attitudinal barriers.
62500396|NCT02129517|ACTIVE_COMPARATOR|Arm II (online educational materials)|Oncology nurses view online clinical trials educational materials developed based upon NCI clinical trials educational materials for health care providers. The educational materials contain text and tables as presented on the NCI Website.
62500397|NCT03690089|EXPERIMENTAL|Intervention Group (Atropine 0.01%)|The intervention group will receive 0.01% atropine sulfate eye drops, administered once daily for two years.
62500398|NCT03690089|PLACEBO_COMPARATOR|Placebo Group|The control group will receive placebo eye drops, administered once daily for two years.
62500399|NCT00671567|EXPERIMENTAL|Ramelteon 8 mg QD|
62500400|NCT00671567|EXPERIMENTAL|Ramelteon 16 mg QD|
62500401|NCT00671567|PLACEBO_COMPARATOR|Placebo|
61951612|NCT05791188||1- Prediabetics|"Prediabetics who will be diagnosed by:~Glycated hemoglobin (HbA1C) test 5.7 - 6.4% % on two separate tests~Fasting blood sugar test 110-125 mg/dL (6.1 - 6.9 mmol/L) on two separate tests.~Glucose tolerance test 140 - 179 mg/dL (7.8 - 9.9 mmol/L)"
62500402|NCT03787017|EXPERIMENTAL|Sequence Group A|"1. 1st period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted~2. 2nd period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted"
62500403|NCT03787017|EXPERIMENTAL|Sequence Group B|"1. 1st period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted~2. 2nd period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted"
62500404|NCT00464113|EXPERIMENTAL|1|once-weekly dosing
62500405|NCT00464113|EXPERIMENTAL|2|twice-weekly dosing
62500406|NCT02894827||EMS|
62500407|NCT02894827||Control|
62500408|NCT01066130|EXPERIMENTAL|Intensive treatment arm|Every second person with psychosocial problems was randomized into this arm. The intervention consisted of personalized, intensive psychosocial treatment provided by a medical social worker on the basis of the patient's problems for up to 2 years after inclusion.
62500409|NCT01066130|EXPERIMENTAL|Minimal treatment arm|Every second patient with psychosocial problems was assigned to this arm. Patients in this arm received minimal social support by a medical social worker.
62500410|NCT01066130|NO_INTERVENTION|No need for psychosocial treatment|This arm consisted of individuals who did not need psychosocial treatment or measures. The need for such treatment and measures was determined at baseline for all persons included in the study.
62500411|NCT01023061|EXPERIMENTAL|Treatment (antihormone therapy and radiation therapy)|Patients receive abiraterone acetate and prednisone daily for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62500412|NCT01513044|EXPERIMENTAL|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
62500413|NCT01513044|ACTIVE_COMPARATOR|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
62500414|NCT06210685|EXPERIMENTAL|ACES Device|Implantation of the ACES device for treatment of aseptic pleural effusion
62500415|NCT02725645|EXPERIMENTAL|Healthy school children|elementary school children will be presented with different backpack loading conditions
62699815|NCT01344356|OTHER|Malignant Tumors|Malignant Head and Neck Tumors will be treated with SBRT.
62500416|NCT01808248|EXPERIMENTAL|SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
62500417|NCT06044727|EXPERIMENTAL|Test group|After phase 1 therapy, management of RT1 cases will be done with Minimally invasive non surgical periodontal therapy.
62500418|NCT06044727|ACTIVE_COMPARATOR|Control Group|After phase 1 therapy, management of RT1 cases will be done with Conventional subgingival instrumentation.
62699816|NCT02354573|ACTIVE_COMPARATOR|Active arm|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
62699817|NCT02354573|PLACEBO_COMPARATOR|Placebo arm|All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
62699818|NCT04055012|EXPERIMENTAL|High Dose Metformin|High Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1,000mg) for the first week then increase to 3 tabs per day (1,500mg) for the remaining 6 months.
61951613|NCT05791188||2- Diabetic patients without complications|"Patients with Type 2 diabetes who will be diagnosed by:~Glycated hemoglobin (HbA1C) test ≥ 6.5% on two separate tests~Fasting blood sugar test ≥ 126 mg/dL (7 mmol/L) on two separate tests~Glucose tolerance test ≥ 200 mg/dL (11.1 mmol/L) Random blood sugar test ≥ 200 mg/dL (11.1 mmol/L)"
61951614|NCT05791188||3- Diabetic patients with complications|Diabetic patients with complications (nephropathy, neuropathy, cardiovascular, retinopathy, metabolic disorders, diabetic ketoacidosis)
61951615|NCT05791188||4- Controls|apparently normal subjects who have matched age and sex with patients groups
61951616|NCT04555343|EXPERIMENTAL|Intervention- TXA|"Drug: one-time intravesical administration of 1gm of TXA instilled via urinary catheter, instilled for 15min before continuous bladder irrigation treatment beings.~1gm of TXA will be mixed with 100cc NS"
62500419|NCT01367938||OMNI Apex Ultracongruent Knee Device|
62500420|NCT05531617|ACTIVE_COMPARATOR|M group|Group Intubated with Macintosh laryngoscope is labelled as M group
62500421|NCT05531617|ACTIVE_COMPARATOR|V group|Group Intubated with C-Mac video laryngoscope is labelled as V group
62500422|NCT01397266|ACTIVE_COMPARATOR|Active TMS|active rTMS delivered to the left dorsolateral prefrontal cortex
62500423|NCT01397266|PLACEBO_COMPARATOR|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
62500424|NCT06630611|ACTIVE_COMPARATOR|Control Arm (Arm A)|Patients will receive standard high dose of IL2 (HD-IL-2) after receiving standard lymphodepleting chemotherapy and TIL product. In the control arm, the first i.v. dose of HD-IL2 will be administered within 3-24 hours after TIL infusion, and thereafter every 8 hours to tolerance up to a maximum of 6 doses.
62500425|NCT06630611|EXPERIMENTAL|Experimental Arm (Arm B)|Patients will receive IL2 analog (ANV419) after receiving standard lymphodepleting chemotherapy and TIL product. In the experimental arm, ANV419 (one dose) will be administered within 3-24 hours after TIL infusion.
62500426|NCT01536249|EXPERIMENTAL|Dexpramipexole single dose & 12 Doses Cimetidine|300 mg Dexpramipexole Oral Dose (to be taken in conjunction with multiple doses of Cimetidine at 400 mg per dose)
62500427|NCT01536249|EXPERIMENTAL|Dexpramipexole single Dose|300 mg Dexpramipexole Oral Dose
62699819|NCT04055012|EXPERIMENTAL|Low Dose Metformin|Low Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 1 tab per day (1 metformin tab (500mg) for 6 months.
62699820|NCT04055012|PLACEBO_COMPARATOR|Placebo|Placebo Group (n=100). Subjects will receive placebo and will be instructed to take either 2 tabs per day for the first week then increase to 3 tabs per day for the remaining 6 months OR take 1 placebo tab for 6 months.
62699821|NCT04055012|OTHER|Wait-List Control|"Control Group (n=100). Subjects will be told that they are in the wait-list control group. They will have a 3 month waiting period before they will be randomized again to a treatment group. They will be randomized to one of the previous groups."
62699822|NCT06601179|EXPERIMENTAL|HIFU|
62500428|NCT04134637|EXPERIMENTAL|PIFB group|"For carrying out PIFB bilaterally the skin on either side of the sternum will be prepared with povidone iodine solution. Then a linear ultrasound probe will be placed on the right and left sides at 2 cm from the sternal body.~A 22 gauge, 4 inch needle will be advanced until contacting the 4th costal cartilage following the lower edge of US probe, directing the tip from the bottom of the sternum and positioning the needle tip between the pectoralis major and the external intercostal muscles. Group A will receive twenty milliliters of a solution of 0.25% bupivacaine plus epinephrine (5 mcg/ml). Boluses of 5 ml are introduced to perform hydrodissection of the interfascial plane."
62500429|NCT04134637|NO_INTERVENTION|control group|the block will not be given
62500430|NCT06266754|EXPERIMENTAL|Oral polio vaccine|Oral polio vaccine, 2 drops on a sugar lump
62699823|NCT00823797|EXPERIMENTAL|Treatment (bendamustine hydrochloride)|Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
62699824|NCT03130049|EXPERIMENTAL|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS \>3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
61951617|NCT06558266||menstrual cycle monitoring group|Female students between 18-25 with regular menstrual cycles
61951618|NCT05399654|EXPERIMENTAL|TAC-001 Single-Agent Dose-Escalation Cohorts|
61951619|NCT02000583|EXPERIMENTAL|Aerobic Exercise Group|Exercise 150 minutes per week (over 3 to 5 days) for 52 weeks
61951620|NCT02000583|OTHER|Control Group|Standard of Care exercise recommendations
61951621|NCT03197454|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
61951622|NCT03197454|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
61951623|NCT02292121|EXPERIMENTAL|obese group|40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
61951624|NCT02292121|ACTIVE_COMPARATOR|non-obese control group (T1)|30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
61951625|NCT02292121|NO_INTERVENTION|non obese control group undergoing a surgery (T2)|40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
61951626|NCT03424200|OTHER|Coaching plus Routine Care|Participants will receive coaching plus routine care
61951627|NCT03424200|OTHER|Routine Care|Participants will receive the routine care
61951628|NCT02236403|EXPERIMENTAL|Ivermectin 0.1% Metronidazole 1%|30 patients will receive the treatment and at 15 days a second visit will be done and changes in mite counts will be determinated and correlated with symtoms and signs.
61951629|NCT02236403|PLACEBO_COMPARATOR|Control|30 volunters with no signs of blepharitis and with eyelashes with no demodex .None intervention. Symptoms and signs will be compared with experimental group
61951630|NCT03719612|EXPERIMENTAL|DEFINITY®|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
61951631|NCT03994107|EXPERIMENTAL|PLD/albumin-bound paclitaxel/Trastuzumab|"First phase~PLD: Level 1：30mg/m2； Level 2：35mg/m2； Level 3：40mg/m2； IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion , Subsequent infusions 6mg/kg. d1, q21d×6.~Second phase~PLD: maximum tolerated dose (MTD). IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion ,Subsequent infusions 6mg/kg. d1, q21d×6."
62342963|NCT05133193|EXPERIMENTAL|14d concomitant therapy|The eligible patients received 14-day concomitant therapy, including vonoprazan and three kinds of antibiotics according to the previous eradication regimens and antibiotic use. Antibiotics are selected from Amoxicillin, Tetracycline, Furazolidone, Levofloxacin, Clarithromycin, Tinidazole, Metronidazole.
62342964|NCT04124692|NO_INTERVENTION|Control Group: No-treatment|Participants will receive no treatment during the study.
62500431|NCT06266754|PLACEBO_COMPARATOR|Placebo|Saline, 2 drops on a sugar lump
62500432|NCT00297141|EXPERIMENTAL|single arm (radiochemotherapy)|single arm study (capecitabine, oxaliplatin)
61951632|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
62500433|NCT02159287|EXPERIMENTAL|Low molecular-weight heparin|these patients will receive 1 mg of enoxaparin (clexane) per kilogram of body weight subcutaneous every 12 hour with warfarin 5mg QD and both drugs will be continued until the target INR level (2.5) is reached then clexane will be discontinued.
62500434|NCT02159287|ACTIVE_COMPARATOR|unfractionated heparin|This group will receive continuous intravenous unfractionated heparin sodium infusion 1000 unit per hour initially and then the dose will be adjusted to maintain a therapeutic aPTT level (two times to baseline) then warfarin will be started (5 mg QD).
62699825|NCT03130049|NO_INTERVENTION|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
61951633|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
61951634|NCT05274880|EXPERIMENTAL|Sequence 1|Period 1: CKD-393 administration after a high-fat meal/ Period 2: CKD-393 administration at fasting state
61951635|NCT05274880|EXPERIMENTAL|Sequence 2|Period 1: CKD-393 administration at fasting state/ Period 2: CKD-393 administration after a high-fat meal
62699826|NCT05452668|EXPERIMENTAL|Group I|Seventeen patients will receive treatment using the red wavelength (660 nm) to provide biostimulation. Plus the current protocol (antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file.
62699827|NCT05452668|EXPERIMENTAL|Group II|Seventeen patients will receive treatment using the infrared wavelength (970 nm) to provide biosstimulation. plus the current protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file.
62699828|NCT05452668|SHAM_COMPARATOR|Group III|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
61951636|NCT00846235|EXPERIMENTAL|Moisturising cream|
62500435|NCT03854409|EXPERIMENTAL|Part A - Deltoid Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
62500436|NCT03854409|EXPERIMENTAL|Part A - Gluteal Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
62500437|NCT03854409|EXPERIMENTAL|Part A - Deltoid Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
62500438|NCT03854409|EXPERIMENTAL|Part A - Gluteal Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
62500439|NCT03854409|EXPERIMENTAL|Part B - Gluteal Site: Group 1 (X)|Participants will receive a single dose of aripiprazole LAI.
62500440|NCT03854409|EXPERIMENTAL|Part B - Gluteal Site: Group 1 (Y)|Participants will receive a single dose of aripiprazole LAI.
62342965|NCT04124692|EXPERIMENTAL|Treatment Group: Sculptra Aesthetic|Participants will be injected with Sculptra Aesthetic by Treating Investigator at Day 1 until optimal correction achieved (up to 4 total treatment sessions)
62342966|NCT04678011||Personalized surveillance and intervention protocol|
62500441|NCT03854409|EXPERIMENTAL|Part B - Gluteal Site: Group 2|Participants will receive a single dose of aripiprazole LAI.
62500442|NCT06409858|EXPERIMENTAL|Intervention group|All participants will receive twice weekly Pilates classes for 8 weeks
62500443|NCT02867085||Group 1 (MDS group)|
62500444|NCT02867085||Group 2 (control group)|
62500445|NCT06150599|EXPERIMENTAL|SNM for the treatment of CPP|Patients will be enrolled based on study eligibility criteria. Eligible patients will be scheduled for a Interstim X implant in the operating room. The procedure is completed under anesthesia, either conscious sedation with intubation or breathing assistance. Under fluoroscopic guidance a standard lead will be introduced. Each electrode on the lead will be tested by confirming motor response on at least 3 of 4 leads. Next the implantable pulse generator will be placed in a subcutaneous pocket and secured. Impedance will be tested, 4 standard programs will be set, and then the device will be shut off. The device settings will be adjusted per protocol and the device will be turned on and off during visits 2-7.
62500446|NCT04212728|EXPERIMENTAL|AMSCs plus PRP group|Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
62500447|NCT04212728|ACTIVE_COMPARATOR|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
62342967|NCT02168894|EXPERIMENTAL|Group 1 - Acupuncture With Electrical Stimulation|Participants in Group 1 have acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
62500448|NCT03017014||Pediatric participants receiving adalimumab|Pediatric participants receiving adalimumab for CD in real-life conditions.
62500449|NCT04956445||Population 1|Once a positive diagnosis of COVID-19 has been made in the clinical setting, the clinical team caring for the patient will ask the patient / family whether they would be willing to be contacted by the study team about the study. If so, a trained member of the study team will describe the study in person or by telephone. Community members who see the study flyer will also be able to reach out to the study team to learn more about the study and to find out if they meet eligibility criteria. If the eligible patient / legally authorized representative / legal guardian would like to participate. The verbal informed consent / verbal HIPAA, assent, and/or parental permission (as appropriate) will then be obtained in person.
62500450|NCT04956445||Population 2|Persons with a history of past (\>14 days ago) diagnosis of COVID-19 infection will be invited to participate in this study. In addition, persons who have had significant exposure to a patient with COVID-19 (contact at a distance of less than 6 feet without personal protective equipment) and have remained asymptomatic for 14 days following exposure will be recruited. Candidates will be identified through initial enrollment in Population 1, or by clinicians who have been informed of the study but are not part of the study team. Then, the clinical care team will ask the patient if he/she is willing to be contacted by the study team. Community members who see the study flyer or are otherwise informed of the study will also be able to reach out to the study team. Additionally, individuals with no defined past COVID-19 infection, but the potential to have been exposed to, and mounted antibodies against, COVID-19 will also be enrolled in Population 2 for this study.
62500451|NCT06675227|NO_INTERVENTION|Drinking Water Group|This group will apply the ordinary drinking water as the solvents for 2L PEG to dissolve.
62500452|NCT06675227|EXPERIMENTAL|Electrolyte Beverages Group|This group will apply the electrolyte beverages(Alienergy) instead of ordinary drinking water as the solvents for 2L PEG to dissolve.
62500453|NCT02230176|EXPERIMENTAL|177Lu-DOTA0-Tyr3-Octreotate or OCLU|7.4 GBq per injection (max: 4 injections)
62500454|NCT02230176|ACTIVE_COMPARATOR|Sunitinib|37.5 mg/day
62500455|NCT02406287|EXPERIMENTAL|Active|Netarsudil (AR-13324) Ophthalmic Solution
62500456|NCT02406287|PLACEBO_COMPARATOR|Placebo|Netarsudil (AR-13324) Ophthalmic Solution Placebo
62500457|NCT06677840|EXPERIMENTAL|GKB7|
62500458|NCT06677840|PLACEBO_COMPARATOR|Placebo|
62342968|NCT02168894|EXPERIMENTAL|Group 2 - Acupuncture Sessions Without Electrical Stimulation|Participants in Group 2 have acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
62699829|NCT00499447|EXPERIMENTAL|Radiofrequency Ablation with External Beam Radiation|Radiofrequency Ablation (RFA)under computerized tomography guidance followed 3-4 weeks later with External Beam Radiation Therapy
62500459|NCT05999734|NO_INTERVENTION|Patients undergoing pediatric thoracotomy will receive general anesthesia alone.|the patients will receive general anesthesia alone. Anesthesia will be induced by inhalation of sevoflurane at 8% concentration which will decreased gradually down to 2% concentration carried by 100% oxygen, with loss of consciousness; a peripheral intra venous cannula with suitable size will be inserted, then the neuromuscular blockade will be facilitated by cisatracurium 0.15 mg/ kg to allow tracheal intubation with appropriate sized endotracheal tube. Fentanyl 1μg/ kg will be given and anesthesia will be maintained with air and O2 (50:50) and along with 2% end tidal concentration of sevoflurane to control the depth of anesthesia. At the end of surgery residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes.
62500460|NCT05999734|ACTIVE_COMPARATOR|general anesthesia and ultrasound guided MTP block|midpoint between the transverse process and the pleura 0.5mL/kg 0.25% bupivacaine will be injected.
62500461|NCT02314494||Infants at risk|Infants identified as at risk of obesity using the ProAsk intervention
62500462|NCT02314494||Infants not at risk|Infants identified as not at risk of obesity using the ProAsk intervention.
62699830|NCT03463187|EXPERIMENTAL|80mg SHR-1314-Part A|SHR-1314 80mg, subcutaneously
62699831|NCT03463187|EXPERIMENTAL|160mg SHR-1314-Part A|SHR-1314 160mg, subcutaneously
62699832|NCT03463187|EXPERIMENTAL|240mg SHR-1314-Part A|SHR-1314 240mg, subcutaneously
62342969|NCT02168894|ACTIVE_COMPARATOR|Group 3 - Waitlist Group|Participants in Group 3 have acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
62342970|NCT06214351|EXPERIMENTAL|Experimental Group|"A mobile application will be installed on the smartphones of the pregnant women in the experimental group.~The mobile application will be installed on the phones of the pregnant women in the experimental group. (The mobile application will be downloaded from the Play Store for Android users and from the App Store for iOS users). Information about the application will be provided and any questions from the pregnant women will be answered. Pregnant women will be free to access the application at any time during the study."
62342971|NCT06214351|NO_INTERVENTION|Control Group:|Pregnant women in the control group will receive routine antenatal care. Routine antenatal care will be provided to pregnant women in the control group.
62342972|NCT01185249|EXPERIMENTAL|Body weight taken in a standing position|Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.
62342973|NCT05048706|EXPERIMENTAL|Super Pulse Thulium fiber Laser|
62342974|NCT05048706|ACTIVE_COMPARATOR|Holmium: Yttrium-Aluminium-Garnet Laser|
62699833|NCT03463187|EXPERIMENTAL|40mg SHR-1314 (Part B)|SHR-1314 40mg, subcutaneously
62699834|NCT03463187|EXPERIMENTAL|80mg SHR-1314 (Part B)|SHR-1314 80mg, subcutaneously
62699835|NCT03463187|EXPERIMENTAL|160mg SHR-1314 (Part B)|SHR-1314 160mg, subcutaneously
62342975|NCT04697433||Myotonometry|The evaluation of myotonometry will be carried out by two independent evaluators. The first evaluator will perform the test bilaterally on the middle deltoid, upper trapezius, pectoralis major, biceps brachii, rectus femoris, anterior tibialis, triceps brachii, lumbar multifidus, biceps femoris and soleus previously marked. Immediately after, the second appraiser will perform the same measurements in the same order (Inter-rater reliability). After a 15-minute interval, the retest (intra-rater reliability) will be performed following the same procedure and order as the test step.
62342976|NCT01022567|ACTIVE_COMPARATOR|Operative treatment|Regular open appendicectomy
62342977|NCT01022567|ACTIVE_COMPARATOR|Antibiotic treatment|Ertapenem 1 g i.v. x 1 three days
62699836|NCT03463187|EXPERIMENTAL|240mg SHR-1314 (Part B)|SHR-1314 240mg, subcutaneously
62699837|NCT03463187|EXPERIMENTAL|SHR-1314 Placebo (Part B)|SHR-1314 Placebo, subcutaneously
62699838|NCT06567392|EXPERIMENTAL|[14C] HRS-5965|
62699839|NCT02096354|EXPERIMENTAL|RRx-001 followed by irinotecan|Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
62699840|NCT02096354|ACTIVE_COMPARATOR|Regorafenib followed by irinotecan|Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
62699841|NCT04870515|EXPERIMENTAL|Group I (diet, physical activity)|Patients attend 10 in-person or virtual sessions with a registered dietician over 6 months to receive diet instructions. Patients also attend 2 one-on-one sessions with an exercise psychologist to receive instruction to complete aerobic physical activity and strength/resistance training. Patients may also complete up to 21 additional supervised exercise sessions.
62699842|NCT04870515|ACTIVE_COMPARATOR|Group II (standard lifestyle recommendations)|Patients receive standard lifestyle recommendations and attend an individual session with a dietitian over 20-30 minutes including US dietary guidelines, activity goal of 30 minutes of physical activity 5 days/week; and discussion of the health benefits of weight loss along with general behavior change suggestions for weight loss.
62699843|NCT02798757|EXPERIMENTAL|Dapagliflozin|All patients will take dapagliflozin, the intervention does not refer to a drug or device but to the specific 1HNMR test spectroscopy
62699844|NCT05196776|EXPERIMENTAL|Portable, Handheld Device|Patients will receive a point-of-care ultrasound using a handheld, portable ultrasound device.
62699845|NCT05196776|ACTIVE_COMPARATOR|Traditional, Cart-based Ultrasound|Patients will receive a point-of-care ultrasound using a traditional, cart-based ultrasound machine.
62699846|NCT04430738|EXPERIMENTAL|Cohort 1A|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
62699847|NCT04430738|EXPERIMENTAL|Cohort 1B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
62699848|NCT04430738|EXPERIMENTAL|Cohort 1C|Tucatinib + trastuzumab + CAPOX given in 21-day cycles
62699849|NCT04430738|EXPERIMENTAL|Cohort 1D|Tucatinib + trastuzumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles and trastuzumab given every 21 days
62714798|NCT02552797|EXPERIMENTAL|Using Power Up|Participants will use 'Power Up' to help them make shared decisions about their treatment or care
62500463|NCT03388099||patients with FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
62500464|NCT03388099||patients without FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
62699850|NCT04430738|EXPERIMENTAL|Cohort 1E|Tucatinib + trastuzumab + pembrolizumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles, trastuzumab given in 21-day cycles, and pembrolizumab given in 42-day cycles
62699851|NCT04430738|EXPERIMENTAL|Cohort 1F|Tucatinib + trastuzumab + pembrolizumab + CAPOX. Tucatinib, trastuzumab, and CAPOX given in 21-day cycles and pembrolizumab given in 42-day cycles.
61951637|NCT03854201|EXPERIMENTAL|Personalized Exercise Counseling (PEC)|The Personalized Exercise Counselling intervention includes 3 face-face counseling sessions and 4-6 phone calls during six months. In addition, the participants are provided with the ExSed® interactive accelerometer to record their physical activity 24/7 from which they will receive personal daily feedback on their smart phone, which is provided to each person not having a suitable one of their own to be used during the 6-month intervention period.
62699852|NCT04430738|EXPERIMENTAL|Cohort 1G|Tucatinib + trastuzumab + pembrolizumab. Tucatinib and trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
62699853|NCT04430738|EXPERIMENTAL|Cohort 2A|Tucatinib + trastuzumab + pembrolizumab + (FOLFOX or CAPOX). Either (1) tucatinib and FOLFOX given in 14-day cycles or (2) tucatinib and CAPOX given in 21-day cycles. Trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
61951638|NCT03854201|NO_INTERVENTION|Control-arm|The participants only take part in the study measurements at baseline and the three follow-up time points. They will be provided personal written information by the UKK Institute on their blood sugar and lipid profiles, objectively measured physical activity (light, moderate, vigorous), standing, sedentary behaviour and sleep, and the three fitness tests measuring flexibility, muscular strength and cardiorespiratory fitness.
61951639|NCT04489628|ACTIVE_COMPARATOR|Vitamin D|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
62342978|NCT04687605|EXPERIMENTAL|Optimum duration of hypercapnia|Daily serial measurement of 2 hours under target hypercapnia of pCO2 50 - 55 mmHg by changes of respirator settings once per day
62342979|NCT03641547|EXPERIMENTAL|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 \& A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.~Stage A1: M6620 \& palliative radiotherapy Stage A2: M6620 \& palliative chemotherapy (Cisplatin \& Capecitabine) Stage B: M6620 \& definitive chemoradiotherapy"
62342980|NCT03740412|EXPERIMENTAL|Sedentary behaviour reduction (behaviour change techniques)|Intervention group attending visits 1, 2, 3, 4, 5
62342981|NCT03740412|NO_INTERVENTION|Usual care|Will receive usual orthopaedic care, attending visits 1, 4, 5
62342982|NCT02429258|EXPERIMENTAL|Farxiga with metformin or insulin|Farxiga with metformin (\>/=1500mg/day) or insulin (\>/=30 units/day) and up to 2 OAD medications
62342983|NCT02429258|PLACEBO_COMPARATOR|Placebo with metformin or insulin|Placebo with metformin (\>/=1500mg/day) or insulin (\>/=30 units/day) and up to 2 OAD medications
62342984|NCT03017365|ACTIVE_COMPARATOR|M-SRT|Machine-based stable resistance training. Exercising 'traditional' machine-based resistance training.
62342985|NCT03017365|EXPERIMENTAL|F-URT|Free weight unstable resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
62342986|NCT03017365|EXPERIMENTAL|M-ART|Machine-based adductor/abductor resistance training. Exercising with 'traditional' adductor/abductor machines.
62342987|NCT04619264|EXPERIMENTAL|Papacarie-Duo|
62342988|NCT04619264|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment|
62342989|NCT03900806|EXPERIMENTAL|Basic Cognitive Rehabilitation|The basic arm will consist of a brief cognitive training programme without individual guidance throughout the intervention, involving three to five sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks.
62342990|NCT03900806|EXPERIMENTAL|Extensive Cognitive Rehabilitation|The extensive arm will consist of a comprehensive training program, involving five to eight sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks. After the first session, each further session in the extensive group involves tailored therapy guidance . Cognitive strategy modules will be assigned by the therapist depending on the participants' cognitive profile and personal treatment goals.
62342991|NCT03900806|NO_INTERVENTION|Waitlist control group|Participants in the waiting list control group will be offered the opportunity to follow the basic cognitive rehabilitation program after completion of the 26-week follow-up measurement.
62500465|NCT03468296|EXPERIMENTAL|Continued Q2 Week Treatment|Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
62500466|NCT03468296|ACTIVE_COMPARATOR|Treat-And-Extend Treatment|Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
62500467|NCT01487499|EXPERIMENTAL|patients with limited stage SCLC|Subjects with limited stage SCLC treated sequentially with cisplatin.
62500468|NCT01487499|NO_INTERVENTION|Historical Controls|No intervention
62500469|NCT05955937|EXPERIMENTAL|Step 1. Core HF intervention period|All sites will be trained in an evidence-based clinical care bundle for HF, to ensure standardized basic HF care across the participating RRHs in the study. For this service bundle which will augment self-care (Core-HF), the investigators will train providers in an evidence-based HF clinical care service bundle including a care protocol (treatment algorithm for HF), self-care training for patients and providers, and medication stock management prior to introducing the digital health intervention (Medly Uganda, described in Arm 2).
62699854|NCT04430738|EXPERIMENTAL|Cohort 2B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles.
62342992|NCT00377910|ACTIVE_COMPARATOR|1, drug|Injections of polidocanol
62342993|NCT00377910|PLACEBO_COMPARATOR|2 drug|injections of lidocaine
61951640|NCT04489628|PLACEBO_COMPARATOR|Placebo|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
61951641|NCT01872364||Dominican Republic patients at NPO Outpatient Surgery Center|
61951642|NCT00242320|ACTIVE_COMPARATOR|1|Roflumilast 500 µg
62699855|NCT06305429|EXPERIMENTAL|Feasibility testing of an education program promoting effective parenting habit|Parents will receive a series of 6 short videos via Whatsapp
62699856|NCT01714674|PLACEBO_COMPARATOR|Placebo beverage|the impact of placebo (no active substance) on exercise-induced cTnT release
62699857|NCT01714674|ACTIVE_COMPARATOR|Dietary nitrate beverage|The impact of dietary nitrate (active substance) on exercise-induced cTnT release
61951643|NCT00242320|PLACEBO_COMPARATOR|2|Placebo
62699858|NCT06014983|ACTIVE_COMPARATOR|Ferrous fumarate|24 mg elemental iron/day
61951644|NCT02761785||Celiacs with oat-related symptoms|Celiac patients who have self-reported gastrointestinal symptoms after ingestion of gluten-free oats
61951645|NCT02761785||Celiacs without oat-related symptoms|Celiac patients who include gluten-free oats in their diet and have no symptoms related to oats
61951646|NCT02761785||Healthy controls|Healthy controls (without celiac disease) who include oats in their diet
61951647|NCT02761785||Non-celiac gluten sensitive subjects|Subjects with manifestations precipitated by ingestion of gluten in whom celiac disease and wheat allergy are excluded.
61951648|NCT02747875|ACTIVE_COMPARATOR|Control - Fentanyl|Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
61951649|NCT02747875|ACTIVE_COMPARATOR|Treatment - Methadone|Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
61951650|NCT01421914|OTHER|Bupivacaine 0,5%|Single arm study
61951651|NCT04203654|OTHER|Cognitive-behavior group therapy group|
61951652|NCT04567498|EXPERIMENTAL|Presumptive TB patients and residents of area with high risk of TB|Presumptive TB patients consists of 395 participants - adult and children, while Residents of area with high risk of TB consists of 1383 participants - adult and children)
61951653|NCT03837860|ACTIVE_COMPARATOR|Oxycodone/Placebo|Each study participant will receive all three study interventions in random order.In this arm, the participant receives oxycodone or placebo
61951654|NCT03837860|ACTIVE_COMPARATOR|Oxycodone/Risperidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or risperidone
62141084|NCT03177941|EXPERIMENTAL|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
62141085|NCT03177941|ACTIVE_COMPARATOR|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.~Assigned Interventions~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
62342994|NCT00946569|EXPERIMENTAL|Treatment A (JNJ39758979)|Participants will receive JNJ39758979 300mg once daily for 12 weeks.
62699859|NCT06014983|EXPERIMENTAL|Ferrous bisglycinate|24 mg elemental iron/day
62699860|NCT06602817||Surgery in prone position|Patients undergoing elective surgery in prone position with i-gel Plus used for airway management
62699861|NCT06602817||Surgery in supine position|Existing prospective control cohort with patients undergoing elective surgery in supine position with i-gel Plus used for airway management
62699862|NCT02779231|EXPERIMENTAL|Texting group|This group will be enrolled in bi-directional texting to send back blood pressure.
62699863|NCT02779231|NO_INTERVENTION|Standard of care group|
62699864|NCT05116280||TJA|"patients with primary osteoarthritis of the knee and hip who underwent elective primary total hip and total knee arthroplasty.~MACE and pulmonary embolism were recorded"
61951655|NCT03837860|ACTIVE_COMPARATOR|Oxycodone/Ziprasidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or ziprasidone
61951656|NCT06533917|EXPERIMENTAL|Main|All participants will undergo a single-stage SCS implantation procedure with 2 leads inserted in the posterior epidural space according to standard clinical practice. For ventral column stimulation SCS electrodes will be placed ventrally at T9/10 for upper abdominal pain and at T10/11 to T11/12 for lower abdominal pain.
61951657|NCT06004362|EXPERIMENTAL|Complementary and Integrative Medicine online intervention, routine care and book|
61951658|NCT06004362|ACTIVE_COMPARATOR|Routine care and book|
61951659|NCT02164214|EXPERIMENTAL|patients PSORIATIC ARTHRITIS|etanercept Treatment
61951660|NCT02164214|ACTIVE_COMPARATOR|patients RHEUMATOID ARTHRITIS|etanercept Treatment
61951661|NCT00853775||African American Families|Families with 2 parents and 2 children - no intervention, observational study
61951662|NCT00853775||Caucasian Families|Families with 2 parents and 2 children - no intervention, observational study
62141086|NCT04300764|NO_INTERVENTION|Control|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Control participants' steps will be passively monitored. Data will continue to be collected for 30 days after discharge.
62699865|NCT02720458|EXPERIMENTAL|Standardized hypnotic taper and self-help program|
62699866|NCT02720458|ACTIVE_COMPARATOR|Standardized hypnotic taper only|
62699867|NCT06399224|ACTIVE_COMPARATOR|Planter vibrator with otago exercise|This group will receive15 minutes of plantar vibration with frequency of 80 Hz, with 10 seconds of vibration and 5 seconds of rest with total time 15 min before the 50 minutes Otago exercise. The frequency of the exercise will be 3 times a week for 12 weeks.
62699868|NCT06399224|ACTIVE_COMPARATOR|Otago exercise|This group will receive 50 minutes Otago exercise only. The frequency of the exercise will be 3 times a week for 12 weeks.
62699869|NCT06634875|EXPERIMENTAL|combination immunotherapy|
62699870|NCT04233892|EXPERIMENTAL|CBD-bFGF|
61951663|NCT06453278||The study group will comprise of consenting adults aged 40 years and above.|"A) INTERVIEW Demographic data, family history of type 2 diabetes mellitus and periodontal treatment history is obtained.~BODY MASS INDEX (BMI) CALCULATION C) ORAL EXAMINATION-POCKET PROBING DEPTH (PPD) MEASUREMENT PPD Measurement of PPD will be done using a periodontal probe and mouth mirror. Measurement will be done on all teeth present in the mouth (except third molars) at six sites per tooth: mesio-buccal, mid-buccal, distobuccal, mesio-lingual, mid-lingual and distolingual.~The number of sites with ≥5-mm probing pocket depth will be recorded on the DDS proforma. The total DDS point score will be obtained by adding all individual variable scores, ranging from 0 to 22.~BIOCHEMICAL MEASUREMENT ( HbA1c levels in blood):~All participants will be asked for providing blood sample for evaluation of HbA1c levels."
61951664|NCT03534414||Intervention|A Portfolio Dietary Pattern involving a combination of 4 cholesterol lowering foods, namely: plant sterols, viscous fibre, plant protein, and nuts.
61951665|NCT03534414||Control|A National Cholesterol Education Program (NCEP) based diet, a diet low in saturated fat and cholesterol.
61951666|NCT06250777|EXPERIMENTAL|Trastuzumab Deruxtecan|
61951667|NCT03506789|ACTIVE_COMPARATOR|Treatment A:|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
62699871|NCT04233892|EXPERIMENTAL|Collagen/BMMNCs|
62699872|NCT04233892|EXPERIMENTAL|Estrogen|
61951668|NCT03506789|ACTIVE_COMPARATOR|Treatment B:|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
61951669|NCT03506789|PLACEBO_COMPARATOR|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
61951670|NCT04502433|NO_INTERVENTION|Control|Patients treated with standard-of-care (SoC), as control cohort
61951671|NCT04502433|EXPERIMENTAL|Poractant alfa|Patients treated with CUROSURF® (poractant alfa), as an add-on to standard-of-care (SoC)
61951672|NCT03791138|EXPERIMENTAL|intervention group|Care as usual and an online patient decision aid
61951673|NCT03791138|NO_INTERVENTION|control group|Care as usual with a standard information leaflet
62342995|NCT00946569|PLACEBO_COMPARATOR|Treatment B (Placebo)|Participants will receive matching placebo once daily for 12 weeks.
62342996|NCT02389140|EXPERIMENTAL|Trigger point treatment|Trigger point release
62699873|NCT06044571|ACTIVE_COMPARATOR|Prescriptive|A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals- Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs) will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs) will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapy: 40 min).
61951674|NCT04747509|EXPERIMENTAL|Blackburn exercises|Blackburn exercises and hot pack
61951675|NCT04747509|ACTIVE_COMPARATOR|Conventional physical therapy|Conventional physical therapy and hot pack
61951676|NCT01743352||Hypertension patients|Local common carotid artery pulse wave velocity is compared in patients with hypertension and healthy volunteers.
61951677|NCT01743352||Healthy Volunteers|Local common carotid artery pulse wave velocity is compared in hypertension patients and healthy volunteers
61951678|NCT04128085|EXPERIMENTAL|TQB3804|TQB3804 tablet administered orally , once daily in 28-day cycle.
62141087|NCT04300764|EXPERIMENTAL|Gamification Intervention|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Intervention patients will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Data will continue to be collected for 30 days after discharge.
62141088|NCT05909449|EXPERIMENTAL|research group|provide primary care services to individuals with physical disabilities
62342997|NCT02389140|SHAM_COMPARATOR|Ultrasound|Sham US at Trigger point
62342998|NCT01172834|EXPERIMENTAL|Lifestyle counseling|
62699874|NCT06044571|ACTIVE_COMPARATOR|Behavioral|"Health coaches have a bachelor's degree and take a 6-8-week certification program. Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.~Conceptual model targets include:~1. barrier identification: problem-solving to identify and address barriers to meet goals~2. self-regulation: a focus on self-monitoring and behavior goals with feedback~3. autonomous motivation: self-selecting goals, motivational interviewing use, and creating plans; and (d) self-efficacy: learning from group experiences, verbal persuasion, and encouraging pursuit of goals in the face of setbacks."
62699875|NCT06044571|EXPERIMENTAL|Responders to Prescriptive- Continue Prescriptive|The prescriptive strategy will continue among participants who responded to this intervention well initially, meaning that participants who lost greater than or equal to 2.5 percent (%) of their body weight using the prescriptive intervention. Participants will continue their diet and exercise programs that were initially tailored to them.
62714799|NCT02552797|NO_INTERVENTION|Not using Power Up|Participants will continue treatment as usual
62342999|NCT05271422|EXPERIMENTAL|Experimental Group|Dry eye disease patients (n=12)
62343000|NCT05271422|SHAM_COMPARATOR|Control Group|Dry eye disease patients (n=12)
62141089|NCT06698497|EXPERIMENTAL|Communications Intervention Group|
62699876|NCT06044571|EXPERIMENTAL|Non-responders to Prescriptive- Switch to Behavioral|Participants who lost less than 2.5 percent (%) of their body weight initially will be randomized to a different type of intervention. One possibility could be that participants switch first-line treatment from a prescriptive strategy to the alternative (behavioral) as participants may need motivation or problem-solving.
61951679|NCT06298825||sarcopenia|Acute decompensated heart failure with sarcopenia. Sarcopenia will be defined using the Asian Working Group for Sarcopenia (AWGS) criteria in the study. According to the guidelines, we can define participants as having sarcopenia when low muscle strength or physical performance coexisted with low skeletal muscle mass. We will define low muscle strength as handgrip strength \<26kg for men and \<18 kg for women, low physical performance as a walk speed of \<1.0m/s for both sexes. We can use bioelectrical impedance analysis to measure the appendicular skeletal muscle mass. The appendicular skeletal muscle mass index (ASMI) is calculated as the sum of muscle mass in the extremities divided by the height squared (kg/m2). The cut-off values of \<7.00 kg/m2 for men and \<5.70 kg/m2 for women will be used.
61951680|NCT06298825||Non-sarcopenia|Acute decompensated heart failure without sarcopenia
61951681|NCT05546502|EXPERIMENTAL|COVID-19 Protein Subunit Recombinant Vaccine|2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
61951682|NCT05546502|ACTIVE_COMPARATOR|Active Comparator|2 doses of Covovax® - administered with 28 days interval (0.5 mL per dose)
62343001|NCT03755284|EXPERIMENTAL|sacral Massage Group|"The massage was applied only to the pregnant women in the intervention group at every phase of labour. There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~For the pregnant women included in the experimental group:~In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour."
62343002|NCT03755284|NO_INTERVENTION|Control Group|"There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~One-on-one interviews were conducted with the pregnant women, and the voluntary disclosure forms, which explained the purpose of the study, were completed.~The prepared questionnaire form was applied. Routine nursing/midwifery care was applied. The state-trait anxiety inventory (STAI FORM TX-I) was applied and evaluated in the active (5-7 cm) phase.~The Visual Analogue Scale (VAS) was evaluated once in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases.~Birth action follow-up form and postpartum interview forms were applied"
62343003|NCT01632735|EXPERIMENTAL|Mobile Continuing Care|Behavioral: 12-week Structured Texting intervention focused on recovery monitoring, feedback for self-management, social support and education
62343004|NCT01632735|NO_INTERVENTION|Standard Continuing Care as Usual|Continuing care as usual to 12-step facilitation (Anonymous group)
62343005|NCT00630812|EXPERIMENTAL|A|active treatment
62343006|NCT00630812|PLACEBO_COMPARATOR|B|
62343007|NCT05415852|ACTIVE_COMPARATOR|fractional CO2 laser|Laser
62343008|NCT05415852|ACTIVE_COMPARATOR|Pulsed dye laser|Laser
62343009|NCT05415852|ACTIVE_COMPARATOR|Nd Yag|Laser
62343010|NCT05415852|ACTIVE_COMPARATOR|Q switched Nd Yag|Laser
62343011|NCT04144075|EXPERIMENTAL|Mindful Self-Compassion|Protocolized training program in mindfulness and self-compassion skills.
61951683|NCT05190237|EXPERIMENTAL|TMD21-16 group|"Effective Microorganisms high content soybean paste powder group~- 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day)"
61951684|NCT05190237|EXPERIMENTAL|TCD21-55 group|"Effective Microorganisms low content soybean paste powder group~- 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day)"
61951685|NCT05190237|PLACEBO_COMPARATOR|TFD21-1 group|"Commercial soybean paste powder group~- 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day)"
61951686|NCT00983437|EXPERIMENTAL|Armodafinil|Armodafinil tablets 150 mg or 250 mg administered orally, once daily in the morning.
61951687|NCT01896050||AI therapy|Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
62714800|NCT01361984|EXPERIMENTAL|Brovana (nebulized arformoterol)|Brovana (nebulized arformoterol) treatment for 2 weeks
61951688|NCT01896050||Tamoxifen|Subjects who started treatment with tamoxifen
61951689|NCT03127410|EXPERIMENTAL|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
61951690|NCT03597880|OTHER|obese patient|BMI\>30 kg/m2 and underwent bariatric surgery
61951691|NCT01523535|PLACEBO_COMPARATOR|normal sleep|Subjects have 8 hours of sleep opportunity per night
61951692|NCT01523535|EXPERIMENTAL|cycles of sleep restriction|subjects are exposed to bouts of reduced sleep duration. The sleep loss is the intervention (experimental challenge).
61951693|NCT03441711||Group 1|elevated sFlt-1/PlGF ratio
61951694|NCT03441711||Group 2|normal sFlt-1/PlGF ratio
62343012|NCT04144075|ACTIVE_COMPARATOR|Cognitive Behaviour Therapy Group|A control intervention designed to develop a control group suitable for comparison with experimental groups receiving interventions based on mindfulness and compassion.
62343013|NCT04144075|PLACEBO_COMPARATOR|Treatment as Usual|Es variable según las características clínicas y personales del paciente.
62343014|NCT00638924||Exercise Capacity|Individuals from the female gender; age range of 20 to 30 years old; considered healthy (i.e. with no diagnosed health condition; considered sedentary (i.e. performing less than 150 minutes of moderate intensity physical activity per week); will be asked to volunteer in the research and perform a exercise capacity test.
62343015|NCT03659370|ACTIVE_COMPARATOR|Fumigation Full|Full Fumigation after acupuncture, 2 times per week, for 4 weeks.
62343016|NCT03659370|ACTIVE_COMPARATOR|Fumigation 1/16|1/16 Fumigation after acupuncture, 2 times per week, for 4 weeks.
62343017|NCT03659370|ACTIVE_COMPARATOR|Acupuncture|Acupuncture only, 2 times per week, for 4 weeks.
62343018|NCT04609085||Participants with Rare Diseases|Participants with history of rare disease
61951695|NCT05428046|EXPERIMENTAL|MHL intervention|Mental health literacy intervention for eating disorder
61951696|NCT05428046|OTHER|Waiting list|The waiting list group received MHL intervention at the end of 12 weeks follow-up assessment.
61951697|NCT06212154|EXPERIMENTAL|ThisCART19A|ThisCART19A comprises of allogeneic T-cells, which are genetically engineered to express chimeric antigen receptor (CAR) and targets cells expressing CD19.
61951698|NCT03873974||Negative trial arm|"Venous blood samples will be taken for central laboratory analysis with:~* DualDur dark-field microscopic test~* DualDur dark-field automatic microscopic test~* Western blot IgM and IgG~* Bózsik Western blot IgM and IgG~* Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~* DualDur Polymerase chain reaction"
61951699|NCT03873974||Positive trial arm|"Venous blood samples will be taken for central laboratory analysis with:~* DualDur dark-field microscopic test~* DualDur dark-field automatic microscopic test~* Western blot IgM and IgG~* Bózsik Western blot IgM and IgG~* Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~* DualDur Polymerase chain reaction"
61951700|NCT02130297|ACTIVE_COMPARATOR|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
61951701|NCT02130297|ACTIVE_COMPARATOR|Group 2 - day 14|Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.
62343019|NCT05074719||Cohort A|Cohort A comprises individuals that enroll within two weeks of diagnosis of SARS-CoV-2 infection. These individuals will be asked to provide a baseline mid-turbinate nasal swab for SARS-CoV-2 testing and complete questionnaires at baseline and on Days 7 and 14. Through these questionnaires, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines). Enrolled Cohort A index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
62699877|NCT06044571|EXPERIMENTAL|Non-responders to Prescriptive- Combination of Prescriptive and Behavioral|Participants who lost less than 2.5 percent (%) of their body weight early on will be re-randomized to a different type of intervention. One possibility could be that participants will have a combined prescriptive and behavioral intervention- three guideline-advised strategies that may be synergistic in a subset of participants requiring knowledge, and needing goal setting and problem-solving skills. This approach is available in multispecialty, tertiary care obesity clinics.
61951702|NCT02130297|ACTIVE_COMPARATOR|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
61951703|NCT01523262|ACTIVE_COMPARATOR|Preconditioning and normal treatment|
61951704|NCT01523262|PLACEBO_COMPARATOR|normal treatment|Standard treatment
61951705|NCT00583973||1|Chronic hemodialysis patients
61951706|NCT03889106||Lassa fever|
61951707|NCT05306977|OTHER|Pilot arm|Aims 1 and 2 of this project will be tested using a within-subjects design where anxiety patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right IPS.
61951708|NCT01213329|EXPERIMENTAL|Phase I: Alemtuzumab|During Phase I Portion: Each kidney transplant recipient received one 30mg dose (IV push)of Alemtuzmab in the operating room per Standard of Care.
62343020|NCT05074719||Cohort B|Cohort B comprises individuals that enroll more than two weeks after diagnosis of SARS-CoV-2 infection. These individuals will be asked to provide a mid-turbinate nasal swab for SARS-CoV-2 testing and to complete a questionnaire reporting retrospectively on their COVID-19 illness and household environment. Through this questionnaire, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines). These individuals will also complete a questionnaire reporting on the persistence and/or delayed onset of symptoms and complications that they associate with their COVID-19 illness. Enrolled Cohort B index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
62343021|NCT00424528|ACTIVE_COMPARATOR|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
62343022|NCT00424528|ACTIVE_COMPARATOR|Tiotropium 18 mcg once daily|Tiotropium 18 mcg once daily/Placebo Inhalation Solution
62699878|NCT06044571|EXPERIMENTAL|Responders to Behavioral- Continue Behavioral|The behavioral strategy will continue among participants who responded to this intervention well initially, meaning that participants who lost greater than or equal to 2.5 percent (%) of their body weight using the behavioral intervention.
61951709|NCT04811885||child with ASD of school going age|Questionnaire complete by parent with children with ASD semi structure interview complete by parent with children
61951710|NCT05282329|EXPERIMENTAL|tACS group|Participants receive tACS 20-min sessions in a 5-day sequence for four consecutive weeks,combined with original and stable medication. Active group participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
61951711|NCT05282329|SHAM_COMPARATOR|Sham group|Controls received sham stimulation with the same protocol.
61951712|NCT04286750|EXPERIMENTAL|ACT-1004-1239 Dose level 1 (30 mg) to 5|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
61951713|NCT04286750|PLACEBO_COMPARATOR|Placebo|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
61951714|NCT03109249|EXPERIMENTAL|SPARC1613|Intravenous administration of SPARC1613
61951715|NCT03109249|ACTIVE_COMPARATOR|Reference 1613|Intravenous administration of Reference1613
61951716|NCT00719108|EXPERIMENTAL|Wosulin R|Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
61951717|NCT00719108|ACTIVE_COMPARATOR|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
61951718|NCT05499858|OTHER|Vegetables|Vegetables will be provided to volunteers as part of a heat and serve meal kit.
61951719|NCT05236296|EXPERIMENTAL|EASE-CG Intervention|"Participants will be offered one EASE-CG therapy session every week for up to 12 weeks. Each session will last for approximately 30-60 minutes, delivered by a trained therapist at our center. Frequency and/or length of sessions may vary to accommodate the needs and availability of each participant.~Outcomes will be assessed at baseline, 1, 3, 6, 9, and 12 months. Participants may be invited to brief, semi-structured interviews."
61951720|NCT04907903|EXPERIMENTAL|RinasciMENTE|Participants will receive the internet-based intervention.
61951721|NCT04907903|NO_INTERVENTION|Waiting-list|Participants will no receive the internet-based intervention.
61951722|NCT00760123|EXPERIMENTAL|1|Early Physical Therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
61951723|NCT00760123|OTHER|2|Educational Strategy: instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
61951724|NCT01362569||predialytic renal insufficiency|Patents without renal replacement therapy
61951725|NCT01362569||hemodialysis/hemofiltration patients|patients undergoing regular hemodialysis/hemofiltration
61951726|NCT01362569||peritoneal dialysis patients|patients undergoing peritoneal dialysis
61951727|NCT01362569||acute renal failure|patients with acute renal failure
61951728|NCT01362569||post renal transplantation|patients after renal transplantation
61951729|NCT01362569||healthy controls|control group
61951730|NCT02758990|EXPERIMENTAL|Predictions: BMI vs. Broccoli|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951731|NCT02758990|EXPERIMENTAL|Predictions: BMI vs. Caffeine|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951732|NCT02758990|EXPERIMENTAL|Predictions: BMI vs. Coffee|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951733|NCT02758990|EXPERIMENTAL|Predictions: BMI vs. Spinach|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951734|NCT02758990|EXPERIMENTAL|Predictions: BMI vs. Vitamin A|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951735|NCT02758990|EXPERIMENTAL|Predictions: BMI vs. Vitamin C|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951736|NCT02758990|EXPERIMENTAL|Predictions: Headache vs. Vitamin B6|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951737|NCT02758990|EXPERIMENTAL|Predictions: Headache vs. Vitamin C|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951738|NCT02758990|EXPERIMENTAL|Predictions: Headache vs. Nicotinamide|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951739|NCT02758990|EXPERIMENTAL|Predictions: Headache vs. Axon Eyewear|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
62343023|NCT00424528|EXPERIMENTAL|Arformoterol /Tiotropium|Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
62343024|NCT00239837|EXPERIMENTAL|Middle School Success Intervention (MSS)|Middle School Success Intervention (MSS): Participants receive the preventative intervention
62343025|NCT00239837|NO_INTERVENTION|Foster Care Services as Usual|Foster Care Services as Usual: Participants continue with usual foster care
62343026|NCT06127706|ACTIVE_COMPARATOR|Formal lecture and training|exposure to single test of skills
61951740|NCT02758990|EXPERIMENTAL|Predictions: Rhinitis vs Broccoli|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
62343027|NCT06127706|ACTIVE_COMPARATOR|Digital learning only|exposure to single test of skill
62343028|NCT00738374|EXPERIMENTAL|1|
61951741|NCT02758990|EXPERIMENTAL|Predictions: Rhinitis vs Caffeine|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
62141090|NCT06698497|NO_INTERVENTION|Control|
62343029|NCT02654574|EXPERIMENTAL|Face-to-face collection followed by collection by phone|Reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, followed by the collection of IADL by phone, one month later.
62343030|NCT02654574|EXPERIMENTAL|Collection by phone followed by face-to-face collection|Collection of IADL by phone, followed by the collection of the IADL questionnaire using the reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, one month later.
62343031|NCT00765440|PLACEBO_COMPARATOR|Arm I|Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.
62343032|NCT00765440|EXPERIMENTAL|Arm II|Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.
62343033|NCT00765440|EXPERIMENTAL|Arm III|Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.
62343034|NCT00877669|ACTIVE_COMPARATOR|Transurethral resection of the prostate|TURP group
62343035|NCT00877669|EXPERIMENTAL|Holmium Laser Enucleation of Prostate|HoLEP group
62343036|NCT03832153||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
62699879|NCT06044571|EXPERIMENTAL|Non-responders to Behavioral- Switch to Prescriptive|Participants who lost less than 2.5 percent (%) of their body weight early on will be re-randomized to a different type of intervention. One possibility could be that participants switch first-line treatment strategy to the alternative (prescriptive) as participants may need knowledge to support adherence.
61951742|NCT02758990|EXPERIMENTAL|Predictions: Rhinitis vs Chocolate|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951743|NCT02758990|EXPERIMENTAL|Predictions: Rhinitis vs Coffee|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951744|NCT02758990|EXPERIMENTAL|Predictions: Rhinitis vs Vitamin A|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951745|NCT02758990|EXPERIMENTAL|Predictions: Insomnia vs Axon Eyewear|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951746|NCT02758990|EXPERIMENTAL|Predictions: Insomnia vs Vitamin A|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951747|NCT02758990|EXPERIMENTAL|Predictions: Insomnia vs Vitamin E|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951748|NCT02758990|EXPERIMENTAL|Predictions: Insomnia vs Nicotinamide|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951749|NCT02758990|EXPERIMENTAL|Predictions: Insomnia vs Vitamin D3|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951750|NCT02758990|EXPERIMENTAL|Predictions: Joint pain vs Broccoli|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951751|NCT02758990|EXPERIMENTAL|Predictions: Joint pain vs Caffeine|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951752|NCT02758990|EXPERIMENTAL|Predictions: Joint pain vs Coffee|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951753|NCT02758990|EXPERIMENTAL|Predictions: Joint pain vs Spinach|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
61951754|NCT00392015|EXPERIMENTAL|Dose-escalation|NMRC-M3V-Ad-PfCA
62343037|NCT03832153||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
62343038|NCT01021813|EXPERIMENTAL|Suvorexant|After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to \<65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
62714801|NCT01361984|EXPERIMENTAL|Serevent (Salmeterol dry powder inhaler)|Serevent (Salmeterol dry powder inhaler) treatment for 2 weeks
62343039|NCT01021813|PLACEBO_COMPARATOR|Placebo|After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.
62343040|NCT01594138||Suicidal Subjects|Suicidal Subjects
62343041|NCT01594138||Non-Suicidal Control Subjects|Non-Suicidal Control Subjects
62714802|NCT05170412||Patients|outpatient adults with the diagnosis of Sickle Cell Disease
62714803|NCT05246514|EXPERIMENTAL|T-DXd arm|Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.
61951755|NCT00392015|EXPERIMENTAL|Regimen-comparison|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
61951756|NCT03844932|EXPERIMENTAL|ST-0529 18.75 mg*|"ST-0529: 18.75 mg orally twice daily (BID)~\*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
61951757|NCT03844932|EXPERIMENTAL|ST-0529 37.5 mg*|"ST-0529: 37.5 mg orally twice daily (BID)~\*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
61951758|NCT03844932|EXPERIMENTAL|ST-0529 75 mg|ST-0529: 75 mg orally twice daily (BID)
62343042|NCT06269289|EXPERIMENTAL|intervention group|It will be determined using a table of random numbers. The group has been diagnosed for at least 1 year, It will consist of people (25) between the ages of 18-65, who can read and write in Turkish, who volunteer to participate in the study and who have not received any training before. After meeting the individuals and obtaining their verbal and written consent, they will be asked to fill out the Patient Information Form, Patient Empowerment Scale and Asthma Control Test obtained through Google Forms. Post-tests will be applied to individuals who complete all 5 modules of training.
62343043|NCT06269289|ACTIVE_COMPARATOR|Control group|The participants will be individuals who apply to the Allergy and Immunology Clinic of Istanbul Sureyyapasa Chest Diseases and Surgery Training and Research Hospital, have been diagnosed with asthma for at least one year and agree to participate in the study. It will consist of people who are between the ages of 18-65, understand Turkish, know how to read and write. Twenty five people selected by the randomization table method will be in the control group. They will be given the Ministry of Health's asthma education brochure. As in the intervention group, pre-test and post-test will be conducted.
62500470|NCT05955937|EXPERIMENTAL|Step 2. Core-HF plus Medly Uganda digital health intervention|Medly Uganda will utilize a patient-facing mobile health application designed to improve self-care among patients with HF. Its principal components are: 1) a patient-facing mobile application that processes patient-reported symptoms and generates algorithm-driven messages to guide self-care and symptom management and 2) a clinician- facing internet dashboard that monitors symptom reports and facilitates nurse-guided management recommendations and physician backup support. The project will support an integrated, digital interface at participating hospitals to monitor and intervene with patients who are using the mobile health application.
62500471|NCT06190886|EXPERIMENTAL|PTX-912|Single or multiple ascending dose of PTX-912
62500472|NCT01029509|EXPERIMENTAL|OPB-31121|OPB-31121 200 mg twice daily for 21 days followed by 7 days of rest
62500473|NCT03377972||WHO diagnostic standard|
62500474|NCT03377972||Japan diagnostic standard|
62500475|NCT02129062|EXPERIMENTAL|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62500476|NCT02846233|ACTIVE_COMPARATOR|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
62500477|NCT02846233|NO_INTERVENTION|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
62500478|NCT05732350||Group 1|Patients in group 1 already receive a DOAC and will start treatement with an SMI. Blood samples will be drawn before start of the SMI and during concomittant use with the SMI.
62500479|NCT05732350||Group 2|Patients in group 2 already use a potentially relevant DOAC-SMI combination or already use an SMI and start with a DOAC. In this group, blood samples are taken after the start of concomittant use of the DOAC-SMI combination.
62699880|NCT06044571|EXPERIMENTAL|Non-responders to Behavioral- Combination of Prescriptive and Behavioral|Participants who lost less than 2.5 percent (%) of their body weight early on will be re-randomized to a different type of intervention. One possibility could be that participants will have a combined prescriptive and behavioral intervention - three guideline-advised strategies that may be synergistic in a subset of participants requiring knowledge, and needing goal setting and problem-solving skills. This approach is available in multispecialty, tertiary care obesity clinics.
62500480|NCT01545739||CRT pacemaker implantation|
62500481|NCT01720849||Fampyra group|
61951759|NCT03844932|PLACEBO_COMPARATOR|Matching Placebo|Placebo: matching placebo orally twice daily (BID)
61951760|NCT01459081|EXPERIMENTAL|Zanamivir|
61951761|NCT01459081|PLACEBO_COMPARATOR|Placebo|
61951762|NCT02846714|EXPERIMENTAL|FLARE intervention|All FLARE participants enrolled will receive the intervention
62500482|NCT04037982|EXPERIMENTAL|LPD|In this group, patients will undergo laparoscopic pancreaticoduodenectomy.
62500483|NCT04037982|ACTIVE_COMPARATOR|OPD|In this group, patients will undergo open pancreaticoduodenectomy.
62500484|NCT03310086|EXPERIMENTAL|Traditional fixed appliance|"Fixed orthodontic appliances will be applied for aligning and leveling of lower anterior teeth up to 19\*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
62500485|NCT03310086|EXPERIMENTAL|Fixed appliance and corticision|"Fixed orthodontic appliances with corticison will be applied for aligning and leveling of lower anterior teeth up to 19\*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
61951763|NCT00860483|NO_INTERVENTION|observational|This is an observational study. no intervention occurs in subjects. their performance in a laparoscopic trainer is observed and correlated with brain activity
61951764|NCT04624646|ACTIVE_COMPARATOR|Conventional Holter Monitoring Group|Holter monitoring is performed for 24 hours each at 1, 3, and 12 months after the diagnosis of stroke, and if atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
61951765|NCT04624646|EXPERIMENTAL|Discontinuous Monitoring Group|Discontinuous ECG monitoring by finger contact is performed 3 times every day for 12 months after a stroke diagnosis. If atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
61951766|NCT04624646|EXPERIMENTAL|Single-lead Continuous Patch Group|Continuous 72 hours of ECG monitoring by a single-lead patch is performed at a week and 1, 3, 6, 12 months after a stroke diagnosis. If atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
61951767|NCT00540774|OTHER|Oral tissue|Imaging of oral structures and pathologies
62500486|NCT05505760|EXPERIMENTAL|Appointment Reminder Model|This is the current MomConnect WhatsApp model (control). Mothers receive weekly conversation starter messages reminding them about their upcoming clinic appointments, providing more comprehensive and relevant maternal health information only after mothers respond to the appointment reminder.
62500487|NCT05505760|EXPERIMENTAL|Relevant Content Model (WhatsApp)|"Mothers receive weekly conversation starter messages on WhatsApp, which carry both clinic appointment reminders along with some maternal and infant health information relevant to their pregnancy/postpartum stage. In addition, a list of frequently asked questions (FAQs) relevant to the week of pregnancy the mother is in are provided so that mothers can engage further with maternal health information topics relevant to them."
62714804|NCT05701917|ACTIVE_COMPARATOR|Interventional|Interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm).
61951768|NCT04863040|NO_INTERVENTION|Usual classroom teaching methodology|Students in the CG will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT materials once the interventions are completed.
61951769|NCT04863040|EXPERIMENTAL|Usual classroom teaching methodology + MOVI-HIIT intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of one school year and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
61951770|NCT05046899|EXPERIMENTAL|BIOpH+ Psoriasis Medical Bath|BIOpH+ Psoriasis Medical Bath is bath. Each bath will take 20 minutes and number of bath during the entire study period is approximately 35 baths.
62714805|NCT05701917|ACTIVE_COMPARATOR|Conservative Medical Management|Conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm).
61951771|NCT05046899|ACTIVE_COMPARATOR|Comparative device|Comparative device is Cetaphil Moisturizing Lotion. The lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
61951772|NCT06464796|EXPERIMENTAL|Motor Imagery Techniques|"1. Motor imagery Techniques~2. Conventional Therapy"
61951773|NCT06464796|ACTIVE_COMPARATOR|Conventional Exercise Therapy|"1. Exercises~2. Conventional Therapy"
61951774|NCT03214146|EXPERIMENTAL|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.~\*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
61951775|NCT01267045|EXPERIMENTAL|Arm 1|Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction course
61951776|NCT01267045|NO_INTERVENTION|Arm 2|Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
61951777|NCT05133232|EXPERIMENTAL|SynPhNe physio-neuro platform|Subjects will receive 15 to18 sessions of training at 60 minutes each on the use of the SynPhNe physio-neuro platform, for over the course of 4 weeks, outside of their conventional occupational therapy in accordance to a study protocol.
62343044|NCT00503880|EXPERIMENTAL|Treatment|G-CSF 300 μg subcutaneously to begin one day prior to treatment and continued until ANC greater than 1.0 or recovers back to the patients baseline ANC for 3 days in a row subsequent to completion of chemotherapy (SOC) Low-dose Cytarabine 10 mg/m2 subcutaneously daily starting on day 1 for the first 5 consecutive days of the treatment course 2-4 hours following the end of the clofarabine infusion. (SOC) Clofarabine starting at dose level 0. Dose-10 mg/m2 IV over 1 hour daily starting on day 1 for the first 5 consecutive days of the treatment course The G-CSF and cytarabine doses are fixed. The dose of clofarabine is initially fixed. For the subsequent cohort, the dose of clofarabine will be advanced to the next dose level.
62343045|NCT02489006|EXPERIMENTAL|Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery|"Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery.~Platinum-based chemotherapy chosen by the study doctor and per standard of care after surgery.~Olaparib, orally, at 300 mg twice per day, continuously, after chemotherapy."
62343046|NCT02489006|EXPERIMENTAL|Olaparib Prior to Surgery and Post Surgery|Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery and after surgery.
62343047|NCT04900480|NO_INTERVENTION|Public subsidy to physiotherapy continue as usual|This control arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, where the access and public subsidy to physiotherapy continue as usual.
62343048|NCT04900480|EXPERIMENTAL|Direct access to publicly subsidized physiotherapy|This intervention arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, introducing temporary exemption on the legal required general practitioner referral for public subsidy for treatment in general physiotherapy.
62343049|NCT01536119|EXPERIMENTAL|Coparenting Breastfeeding Support Intervention|The intervention group will receive a in-hospital discussion, a video, a workbook,a breastfeeding booklet, access to a secure study website, two follow-up emails, and one telephone call.
62343050|NCT01536119|NO_INTERVENTION|Usual Care Group|The usual care group will receive standard postpartum care in the hospital and in the community
62343051|NCT04613102|EXPERIMENTAL|interventional arm, phase 2|"All participant of phase 2 will receive CBD cream for their chronic wound treatment.~This is an open-label part of the study."
61951778|NCT05133232|NO_INTERVENTION|Conventional occupational therapy|Subjects will receive conventional occupational therapy (OT) only.
61951779|NCT03844880|EXPERIMENTAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
61951780|NCT03844880|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
62699881|NCT02373657|EXPERIMENTAL|WASH Intervention|"In these seven communities we built a well in a central location for all state team residents. We plan on providing tippy-taps (water and soap dispensers), instruction in soap-making, and hygiene education to these communities. We will also put fly traps in the communities to see if wells reduce flies. We plan on performing monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density."
62699882|NCT02373657|NO_INTERVENTION|Control|In these seven communities, we plan to perform monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density.
61951781|NCT01768286|EXPERIMENTAL|LDV/SOF 12 Weeks|Participants will receive LDV/SOF FDC for 12 weeks.
61951782|NCT01768286|EXPERIMENTAL|LDV/SOF+RBV 12 Weeks|Participants will receive LDV/SOF FDC plus RBV for 12 weeks.
61951783|NCT01768286|EXPERIMENTAL|LDV/SOF 24 Weeks|Participants will receive LDV/SOF FDC for 24 weeks.
61951784|NCT01768286|EXPERIMENTAL|LDV/SOF+RBV 24 Weeks|Participants will receive LDV/SOF FDC plus RBV for 24 weeks.
61951785|NCT06371443|EXPERIMENTAL|experimental group|41 premature infants in the experimental group
61951786|NCT06371443|NO_INTERVENTION|control group|41 premature infants in the control group
61951787|NCT01206348|EXPERIMENTAL|Open Label Combination|Solodyn, Ziana, Triaz FC
61951788|NCT02152722||Total Body Irradiation Subjects|Subjects undergoing total body irradiation prior to chemotherapy. It is expected that all of these subjects will be receiving ablative radiation prior to bone marrow transplant. Breath will be collected before and after the first radiation exposure on each day of total body irradiation.
61951789|NCT01337700|EXPERIMENTAL|Milnacipran|
61951790|NCT01337700|PLACEBO_COMPARATOR|Placebo|
61951791|NCT06442280|EXPERIMENTAL|Dapa-Tonic|This group will undergo a 15-minute intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily, severe water restriction (\< 500 mL), and SGLT2 inhibitors (Dapagliflozin).
62343052|NCT04613102|EXPERIMENTAL|Interventional arm, phase 3|"Each participants of the phase 3 will receive the active study medication (AVCN583601) during the entire study treatment period on the one of his body sides, and placebo cream - on the other body side simultaneously (left/right). So, each participant will be his own control.~The research support pharmacy will randomize, which side of the body participant should apply CBD cream on, and provide two jars with the study medications, labeled accordingly ( Left /Right)."
62343053|NCT06330285|EXPERIMENTAL|Group 1|e-learning
62343054|NCT06330285|ACTIVE_COMPARATOR|Group 2|face to face learning
62343055|NCT06414538|EXPERIMENTAL|Digital Mind Map Technique|"Students determined as a result of randomization will be given a pre-test before entering the Family Planningcourse planned according to the academic calendar. The planned topics will be explained using the prepared digital mind maps technique."
62343056|NCT06414538|ACTIVE_COMPARATOR|Classic Method Group|The determined topics will be explained to the students in the control group using the classical method. Students' knowledge level will be measured with knowledge tests.
62343057|NCT02017236|EXPERIMENTAL|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
62343058|NCT02017236|EXPERIMENTAL|Volitinib,after general diet|B:single oral Volitinib, after general diet
61951792|NCT06442280|PLACEBO_COMPARATOR|Tonic-Placebo|This group will undergo a 15-minute intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily along with severe water restriction (\< 500 mL).
61951793|NCT06442280|PLACEBO_COMPARATOR|Furosemide-Placebo|This group will undergo intravenous furosemide twice daily and severe water restriction (\< 500 mL) without hypertonic saline solutions.
61951794|NCT06442280|ACTIVE_COMPARATOR|Dapa-Furo|This group will undergo intravenous furosemide without hypertonic saline solutions twice daily, severe water restriction (\< 500 mL), and SGLT2 inhibitors (Dapagliflozin).
62343059|NCT03379012|EXPERIMENTAL|Testosterone and Targeted therapy|Testosterone undecanoate (Nebido®) and Targeted therapy (sunitinib or pazopanib)
62343060|NCT03379012|ACTIVE_COMPARATOR|Control|Targeted therapy (sunitinib or pazopanib) only
62343061|NCT01322646|ACTIVE_COMPARATOR|Driver Training|Driver Education Program Practice driving on a driving simulator Provision of the CarChipPro to the family
62343062|NCT01322646|EXPERIMENTAL|STEER Program|Driver Education STEER Program
62343063|NCT05432674|EXPERIMENTAL|Digital Fall Prevention|Subjects will participate in Digital Fall Prevention intervention for 12 weeks
61951795|NCT01813188|EXPERIMENTAL|ABM seeded onto a porous TCP and DBM|ABM seeded onto a porous TCP and DBM
61951796|NCT01813188|ACTIVE_COMPARATOR|autologous bone graft|autologous bone graft
62343064|NCT01378936|EXPERIMENTAL|MI plus IOC group intervention|
61951797|NCT03572972||Patients prescribed apixaban|
61951798|NCT03572972||Patients prescribed dabigatran|
61951799|NCT03572972||Patients prescribed rivaroxaban|
61951800|NCT03572972||Patients prescribed warfarin|
61951801|NCT03572972||Patients prescribed antiplatelet|
61951802|NCT03203616|EXPERIMENTAL|Kadcyla (T-DM1)|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
61951803|NCT01253408|EXPERIMENTAL|Dronabinol 2.5 mg bid|Dronabinol 2.5 mg will be taken orally with water twice per day for two days.
61951804|NCT01253408|EXPERIMENTAL|Dronabinol 5 mg bid|Dronabinol 5 mg will be taken orally with water twice per day for two days.
62343065|NCT01378936|EXPERIMENTAL|Motivational Interview only|
62343066|NCT04274660|EXPERIMENTAL|DWELL Intervention|People with type 2 diabetes participating in the 12-week DWELL (Diabetes and WELLbeing) Programme
61951805|NCT01253408|PLACEBO_COMPARATOR|Placebo|Placebo will be taken orally with water twice per day for two days.
61951806|NCT03840174|EXPERIMENTAL|V160|Participants will receive V160 vaccination by IM injection on Day 1, Month 2, and Month 6.
61951807|NCT03840174|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo by IM injection on Day 1, Month 2, and Month 6.
61951808|NCT02339935|EXPERIMENTAL|ABA Treatment Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
61951809|NCT02339935|OTHER|Control Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
61951810|NCT05167929|EXPERIMENTAL|Intervention Group|
61951811|NCT05167929|EXPERIMENTAL|Intervention PLUS Group|
61951812|NCT05167929|ACTIVE_COMPARATOR|Comparison Group|
61951813|NCT01397890|OTHER|1|Add-on treatment
61951814|NCT01397890|OTHER|2|Add-on treatment
61951815|NCT03228433|EXPERIMENTAL|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
61951816|NCT03228433|EXPERIMENTAL|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
61951817|NCT03228433|EXPERIMENTAL|Cohort 3: TAK-418 30 mg Fasted + TAK-418 30 mg Fed|TAK-418 30 mg, capsule, in fasted state, orally, once on Day 1, followed by a 28-day washout period, further followed by TAK-418 30 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
61951818|NCT03228433|EXPERIMENTAL|Cohort 4: TAK-418 40 mg|TAK-418 40 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
62343067|NCT04274660|NO_INTERVENTION|DWELL non-intervention/Control|People with type 2 diabetes who are receiving routine care from their GP and healthcare team. People with type 2 diabetes will continue to receive routine standard care. Routine care in this respect constitutes usual health and social care or any other nationally or locally commissioned education programmes
62500488|NCT05505760|EXPERIMENTAL|Relevant Content Model (SMS)|Mothers receive twice weekly conversation starter messages of 160 characters each per SMS, which carry both clinic appointment reminders as well as maternal and infant health information, relevant to their stage of pregnancy or the age of their baby. Mothers can access the list of frequently asked questions relevant to their week of pregnancy via USSD.
61951819|NCT03228433|EXPERIMENTAL|Cohort 5: TAK-418 60 mg|TAK-418 60 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
62343068|NCT04786132|EXPERIMENTAL|Dual Task (proprioception, balance and cognitive) training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
62500489|NCT05505760|EXPERIMENTAL|Relevant Content + Browsable Content Model|This is a combination of the Relevant Content and Browsable Content Models on WhatsApp (RCM+BCM), including appointment reminders, clinical information, a browsable menu and prompts to relevant stage-based topics. Mothers receive weekly conversation starter messages.
62500490|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
62500491|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
62500492|NCT01520987|EXPERIMENTAL|Caucasian 5 mg OPC|OPC, opicapone, BIA 9-1067
62500493|NCT01520987|EXPERIMENTAL|Caucasian 25 mg OPC|OPC, opicapone, BIA 9-1067
62500494|NCT01520987|EXPERIMENTAL|Caucasian 50 mg OPC|OPC, opicapone, BIA 9-1067
62500495|NCT01520987|PLACEBO_COMPARATOR|Caucasian Placebo|Placebo, PLC
62500496|NCT01520987|EXPERIMENTAL|Japanese 5 mg OPC|OPC, opicapone, BIA 9-1067
62500497|NCT01520987|EXPERIMENTAL|Japanese 25 mg OPC|OPC, opicapone, BIA 9-1067
61951820|NCT03228433|PLACEBO_COMPARATOR|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
61951821|NCT02846584|EXPERIMENTAL|CD19 or CD20 CAR T cells briging HSCT|lentiviral transfection and transfuse anti-CD19 or anti-CD20 CAR T cells into patients. Six months later, select appropriate patients to transplant hemopoietic stem cells.
61951822|NCT03416725||Patients with chronic suppurative otitis media.|patients of the age group 18-60 years with Chronic suppurative otitis media (CSOM) planned for tympanoplasty.
61951823|NCT04271527|EXPERIMENTAL|cognitive targeted biopsy|a cognitive fusion targeted biopsy combined with a systematic biopsy
61951824|NCT04271527|ACTIVE_COMPARATOR|software targeted biopsy|software-based fusion targeted biopsy combined with a systematic biopsy
61951825|NCT02408627|ACTIVE_COMPARATOR|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
61951826|NCT02408627|ACTIVE_COMPARATOR|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
61951827|NCT02408627|EXPERIMENTAL|EEG-registration with dry electrodes|EEG-registration with dry electrodes
61951828|NCT03433157|EXPERIMENTAL|Hall technique|SSCs placed on primary teeth using Hall technique
61951829|NCT03433157|ACTIVE_COMPARATOR|Traditional technique|SSCs placed on primary teeth using Traditional technique
61951830|NCT01373242|EXPERIMENTAL|Peanut ( liquid peanut extract) SLIT|All subjects will receive peanut SLIT upon enrollment for at least the first 48 months. After the desensitization DBPCFC after at least 48 months of treatment, subjects will be randomized off treatment from 1 to 17 weeks. Subjects will then undergo another DBPCFC.
62141091|NCT02397707|EXPERIMENTAL|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
62500498|NCT01520987|EXPERIMENTAL|Japanese 50 mg OPC|OPC, opicapone, BIA 9-1067
62500499|NCT01520987|PLACEBO_COMPARATOR|Japanese Placebo|Placebo, PLC
62343069|NCT04786132|ACTIVE_COMPARATOR|Proprioception and balance training|"The control group training protocol is the same as the experimental group, whit the same duration and the same sessions, the unique difference is that there was no music included in the sessions, and therefore cognitive ability was not worked.~The sessions were carried out by the main researcher who controlled the technique of the exercises and motivated the participant."
62343070|NCT01833104|EXPERIMENTAL|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
62343071|NCT01833104|EXPERIMENTAL|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
62500500|NCT04197258|EXPERIMENTAL|intervention group|"For 6 months after discharge, patients in the intervention group will benefit from peer support by a trained patient (number and frequency of contacts defined according to the patient's needs).~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon discharge at home, including identifying and seeking for the necessary health or social resources"
61951831|NCT03076320|EXPERIMENTAL|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency an duration: topically applied every 12 hours for 6 months."
61951832|NCT03076320|ACTIVE_COMPARATOR|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 month"
61951833|NCT02283619||Patients with LBBB being evaluated for ACS|Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description.
61951834|NCT04987398||Intubation for respiratory reasons|All patients who were intubated for respiratory reasons (i.e. acute respiratory distress syndrome, pneumonias, pleural effusions for example)
61951835|NCT04987398||Intubation for neurological reasons|All patients who were intubated for neurological reasons (i.e. stroke, intracranial bleeding, cervical fracture with tetraparesia for example)
61951836|NCT04987398||Intubation for other reasons|All patients who were intubated for other reasons than respiratory or neurological (i.e. intubation before surgery, cardiac arrest, hemodynamic instability and polytraumatism without respiratory distress or neurological pathology necessitating intubation)
61951837|NCT01139489|ACTIVE_COMPARATOR|procalcitonin-guidance|A daily advise to continue or stop antibiotics based on the measurement of the biomarker procalcitonin
61951838|NCT01139489|NO_INTERVENTION|standard-of-care|standard-of-care treatment of ICU infections based upon consensus guidelines and expert opinion
61951839|NCT02086383||Patients with COPD|This is an observational study of patients with chronic obstructive pulmonary disease (COPD) who attend pulmonary rehabilitation, which is the routine standard of care in Guy's and St. Thomas' Hospital, London. It lasts for 14 sessions, twice a week and primarily consists of a supervised exercise program and educational sessions.
61951840|NCT03998930|EXPERIMENTAL|brain injuried patients|"* Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R),~* 15-minute break between the two evaluations.~* Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task (imagine moving the right or left wrist)."
61951841|NCT02624609|PLACEBO_COMPARATOR|Control without pomegranate juice|Control meal will be white bread and a glass of water containing the same amounts of sugars naturally present in the pomegranate juice.
61951842|NCT02624609|EXPERIMENTAL|Test with pomegranate juice|Test meal will be white bread with a glass of pomegranate juice
61951843|NCT04549857|EXPERIMENTAL|intervention group|The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.
62141092|NCT02397707|EXPERIMENTAL|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
62343072|NCT01833104|NO_INTERVENTION|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
62343073|NCT01833104|ACTIVE_COMPARATOR|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
61951844|NCT04549857|PLACEBO_COMPARATOR|Placebo group|The placebo group only used base oil (sweet almond oil).
61951845|NCT04549857|NO_INTERVENTION|Control group|No intervention
61951846|NCT05737589||Observation group|This is an observational study, no interventions will be applied to patients in the observation group, and only blood and cerebrospinal fluid ctDNA and TCR data of patients with brain metastases from non-small cell lung cancer treated with radiotherapy will be recorded to predict patient prognosis. Peripheral blood and CSF samples were collected at baseline, 24 h (T0), and 28 days (T28) after completion of radiotherapy and underwent deep sequencing of ctDNA and TCR. The 6-month response rates of brain metastases and systemic lesions were evaluated based on Response Evaluation Criteria in Solid Tumors version 1.1 for further study.
61951847|NCT05472831|EXPERIMENTAL|BAILAMOS dance program plus MIND diet|BAILAMOS dance program plus MIND diet: Includes a 6-month, twice a week x 60 minutes/session, virtually delivered Latin dance program plus a 60 minute MIND diet session per week.
62141093|NCT04358107||1|Medical records of subjects enrolled on various ACC studies conducted by CCR
62141094|NCT01913093||Leukemia survivors with neurocognitive deficit|"Leukemia survivors with neuro-cognitive deficit phenotype. Based on DIVERGET and other phenotyping tools, we will identify those with the deficit phenotype. This will be treated as case."
62141095|NCT01913093||Leukemia survivors without neurocognitive deficit|Leukemia survivors who did not show impaired neurocognitive function, compared to the Control group defined above.
62141096|NCT02992652|ACTIVE_COMPARATOR|Study Group|Received 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
62141097|NCT02992652|NO_INTERVENTION|Control Group|Underwent ERCP without allopurinol prophylaxis
62141098|NCT05141513|OTHER|Intra Operative Radiation Therapy (IORT) Group|The IORT group is the single arm of this study. Enrolled patients who undergo standard of care treatment will also receive a study treatment of High Dose Rate (HDR) Intra Operative Radiation Therapy.
62141099|NCT04784585|EXPERIMENTAL|Enhanced Education|Theory-driven intervention focused on providing information about dietary quality and goals
62343074|NCT01833104|NO_INTERVENTION|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
62343075|NCT02075749|ACTIVE_COMPARATOR|triamcinolone acetonide mucoadhesive|30 patients received triamcinolone acetonide mucoadhesive films
62343076|NCT02075749|EXPERIMENTAL|Licorice|30 patients received licorice mucoadhesive films
62343077|NCT02075749|PLACEBO_COMPARATOR|Mucoadhesive film|30 patients received mucoadhesive films without any drug ingredients
62343078|NCT03522701|EXPERIMENTAL|Group CBTI|Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I) The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
62343079|NCT03522701|ACTIVE_COMPARATOR|Email-delivered CBTI|The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
62343080|NCT03522701|NO_INTERVENTION|Waiting-list control|Participants will not receive any active treatment.
62343081|NCT02483403|OTHER|Healthy Volunteers|Healthy elderly volunteers will undergo pulmonary function tests, hyperpolarized Helium-3 MRI at each visit.
62343082|NCT00546039|ACTIVE_COMPARATOR|1|
62343083|NCT00546039|PLACEBO_COMPARATOR|2|
62343084|NCT02006264|ACTIVE_COMPARATOR|TDF Intravaginal Ring|Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
62343085|NCT02006264|PLACEBO_COMPARATOR|Placebo Intravaginal Ring|The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
62343086|NCT01446601|EXPERIMENTAL|Treatment|The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
62343087|NCT01446601|OTHER|Control|The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
62343088|NCT00609219|EXPERIMENTAL|EBV specific CTL|autologous EBV specific CTLs
62343089|NCT05877651|EXPERIMENTAL|MASCT-I injection|MASCT-I injection
62699883|NCT02247921|EXPERIMENTAL|Rehabilitation|nurse-led caregiver-delivered rehabilitation
62141100|NCT04784585|EXPERIMENTAL|Self-efficacy|Theory-driven intervention focused on providing skills to increase self-efficacy for following dietary goals
62343090|NCT00781248|EXPERIMENTAL|1|starting with active NG Shield
62343091|NCT00781248|EXPERIMENTAL|2|Starting with inactive NG Shield
62343092|NCT00084812|EXPERIMENTAL|Safingol and Cisplatin|"Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days\* in the absence of disease progression or unacceptable toxicity.~NOTE: \*Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.~Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level."
62343093|NCT05197673|EXPERIMENTAL|Intervention group|This arm will receive TPB intervention to build positive attitudes towards COVID-19 related preventive behaviour (e.g., good compliance with infection control measures, encouraging uptake of testing and vaccination), subjective norms (tackling strategies for perceived social pressure from others or normative beliefs), and improve perceived behavioural control towards risks of outbreaks in workplace.
62343094|NCT05197673|NO_INTERVENTION|Control group|Control group will receive only general health information.
62343095|NCT02492685|EXPERIMENTAL|Contrast enhanced EUS group|Contrast enhanced EUS with quantitative analysis
62343096|NCT05807178|EXPERIMENTAL|LSA-1|Light Scheduling Algorithm-1 (LSA-1): High circadian effective irradiances
62699884|NCT02247921|NO_INTERVENTION|Usual care|The patients in the control arm will receive conventional care in terms of access to rehabilitation in hospital, timeliness of discharge and follow-up, without any explicit provision of caregiver training or accelerated discharge.
62699885|NCT01189565||Joint Replacement Patients|
62141101|NCT04784585|EXPERIMENTAL|Motivation|Theory-driven intervention focused on providing skills to increase motivation for following dietary goals
62343097|NCT05807178|ACTIVE_COMPARATOR|LSA-2|Light Scheduling Algorithm-2 (LSA-2): Irradiance levels comparable to conventional hospital lighting (control group).
62343098|NCT03482141|OTHER|Whole Exome Sequencing|Whole exome sequencing (WES) will take place for prenatal patients (pregnancies with fetal structural defects). All patients will get exome sequencing and will follow the same procedures.
62500501|NCT04197258|NO_INTERVENTION|control group|Patients included in the control group before intervention will receive the usual practices. As part of the study, they will be contacted for data collection 6 months after the transition to home by a clinical research associate.
62500502|NCT06188585|EXPERIMENTAL|Test Group|UI-EWD
62500503|NCT06188585|ACTIVE_COMPARATOR|Control Group|Conventional endoscopic therapy
62141102|NCT04784585|EXPERIMENTAL|Self-regulation|Theory-driven intervention focused on providing skills to increase self-regulation
62141103|NCT04784585|ACTIVE_COMPARATOR|Generic Risk Alert|A notification to alert participant of lapse risk, no additional intervention provided
62699886|NCT06565676|EXPERIMENTAL|White Bread|Participants will have their fasting blood glucose measured immediately before the meal containing the white flour test bread and will then be asked to consume the entire test bread with their breakfast meal within 15 minutes.
61951848|NCT05472831|EXPERIMENTAL|BAILAMOS dance program plus Health Education|BAILAMOS dance program plus Health Education: Includes a 6-month, twice a week x 60 minutes/session, virtually delivered Latin dance program plus a 60 minute health education session per week.
61951849|NCT00259610|ACTIVE_COMPARATOR|1|methotrexate (MTX) + etanercept
61951850|NCT00259610|ACTIVE_COMPARATOR|2|methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
61951851|NCT00259610|ACTIVE_COMPARATOR|3|methotrexate (MTX) or MTX + Etanercept
62343099|NCT04413643|EXPERIMENTAL|Noninvasive Ventilation|Subjects will be introduced to NIV and educated on sleep disordered breathing. NIV will be initiated during hospitalization following resolution of acute respiratory failure. NIV settings will be based on inspiratory and expiratory positive airway pressures (IPAP, EPAP), rates, and tidal volumes tolerated during the acute phase of treatment. Initial settings will be set with goals of tolerance and acceptance of therapy. Minimum pressure difference between IPAP and EPAP settings will be 5cmH20. Volume assured pressure support mode with a target tidal volume (Vt) of 8ml/kg ideal body weight will be used. Final device settings and patient parameters will be documented after 10 minutes of acclimation to the device. Data from the device will be reviewed the following day. Tolerance, mask comfort, and acceptance of therapy will be assessed. Changes to settings, mask interface, or other comfort features will be performed at this initial reassessment period.
62699887|NCT06565676|EXPERIMENTAL|White Bread with Whey Powder|Participants will have their fasting blood glucose measured immediately before the meal containing the white flour with added whey powder test bread and will then be asked to consume the entire test bread with their breakfast meal within 15 minutes.
62343100|NCT01235286|EXPERIMENTAL|remote ischemic preconditioning|
62343101|NCT01088438|EXPERIMENTAL|Contextualization workshop|A four-hour course on contextualization.
62343102|NCT01088438|NO_INTERVENTION|Control|No intervention
62343103|NCT01490762|ACTIVE_COMPARATOR|Regular Human Insulin|Subcutaneous injection
62343104|NCT01490762|EXPERIMENTAL|TI and Regular Human Insulin|All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
62343105|NCT04496947|EXPERIMENTAL|Stress Reduction|8 week stress reduction course
62343106|NCT04496947|NO_INTERVENTION|Control|No intervention
62343107|NCT04450056||Mother-infant pairs|Mothers with a term-born (\>37 weeks gestation) infant whom they are exclusively or predominantly breastfeeding at 1 month postpartum. Mothers must be enrolled in the MaPPS Trial (ClinicalTrials.gov Identifier: NCT03287882).
62343108|NCT06011291|EXPERIMENTAL|Arm A: SYH2051 monotherapy dose escalation in advanced solid tumors (Phase Ia)|
62343109|NCT06011291|EXPERIMENTAL|Arm B: SYH2051+RT dose escalation in locally advanced head and neck cancer (Phase Ib)|
62343110|NCT06011291|EXPERIMENTAL|Arm C: SYH2051+RT dose expansion in locally advanced head and neck cancer (Phase Ic)|
62343111|NCT03215082|EXPERIMENTAL|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
62343112|NCT03215082|ACTIVE_COMPARATOR|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
62343113|NCT02645383|ACTIVE_COMPARATOR|PASCAL group|Patients undergone PASCAL laser photocoagulation
62343114|NCT02645383|ACTIVE_COMPARATOR|Conventional group|Patients undergone conventional laser photocoagulation
62343115|NCT03623282|EXPERIMENTAL|Synatura® 15 mL|Synatura syrup single arm
62699888|NCT06565676|EXPERIMENTAL|Wheat Bread|Participants will have their fasting blood glucose measured immediately before the meal containing the wheat flour test bread will then be asked to consume the entire test bread with their breakfast meal within 15 minutes.
61951852|NCT00259610|ACTIVE_COMPARATOR|4|methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
61951853|NCT06270810|EXPERIMENTAL|Aerobic Exercise (AeroEx) Group|Participants in this group will do moderate-intensity aerobic training for 4 days a week for 8 weeks.
61951854|NCT06270810|EXPERIMENTAL|Aerobic Exercise+non-Exercise (nE) Physical Activity (AeroEx+nE PA) Group|Participants in this group will increase their non-exercise physical activities and do moderate-intensity aerobic training for four days a week for 8 weeks.
61951855|NCT04530526|OTHER|Regenerative Peripheral Nerve Interface (RPNI)|Using evaluative ultrasound measurements and a standard panel of patient-reported outcome measures (PROMs) to measure pain experience, anxiety and depression, patients will be evaluated at baseline (T1=0months), pre-operatively following 3 months of standard neuropathic pain management therapy (T2=3months) and at three months (T3=6months) and nine months (T4=12months) post RPNI surgery.
61951856|NCT04299074|OTHER|Addiction|problematic addiction
62343116|NCT00944255||RA with drug|
62343117|NCT00944255||RA without drug|
62343118|NCT06348810|EXPERIMENTAL|Dual-task training|Participants in the experimental group will receive dual-task training, which consists of cognitive and motor task carried out at the same time. The length of therapy is 12 weeks; sessions are 3 times per week, each session lasts 45 minutes, and total sessions are 36.
62343119|NCT06348810|EXPERIMENTAL|Cognitive training|Participants in this group receive cognitive training only. The length of therapy is 12 weeks; sessions are 3 times per week, each session lasts 45 minutes, and total sessions are 36.
62343120|NCT06348810|EXPERIMENTAL|Motor training|Participants in this group receive motor training only. The length of therapy is 12 weeks; sessions are 3 times per week, each session lasts 45 minutes, and total sessions are 36.
61951857|NCT05190588|NO_INTERVENTION|Exercise|Quadriceps Strength 10 repetition in three-set, 5 times a week
62141104|NCT04784585|SHAM_COMPARATOR|No Intervention|No notification or intervention is delivered to the participant during lapse risk
61951858|NCT05190588|ACTIVE_COMPARATOR|Mesotherapy|Group 2: Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used. One time a week for a total of 3 times.
61951859|NCT02077816||Central venous catheter|Inpatients with CVC for medical care.
61951860|NCT01466153|ACTIVE_COMPARATOR|Rituximab + Bendamustine|Rituximab was administered by IV infusion as 375 mg/m\^2 on Day 2 of Cycle 1 and then 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
61951861|NCT01466153|EXPERIMENTAL|MEDI-551 2 mg/kg + Bendamustine|MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
61951862|NCT01466153|EXPERIMENTAL|MEDI-551 4 mg/kg + Bendamustine|MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
61951863|NCT02821169|PLACEBO_COMPARATOR|saline solution 0.9%|injection of saline solution in the sphenopalatine area in both nasal fossa
61951864|NCT02821169|ACTIVE_COMPARATOR|ropivacaine (2mg/ml)|injection of ropivacaine in the sphenopalatine area in both nasal fossa
61951865|NCT05903170|ACTIVE_COMPARATOR|360J LifePak Monitor/Defibrillator|"The standardised cardioversion protocol below performed with a 360J shock from a Lifepak Monitor/Defibrillator.~1. First shock with anteroposterior pad configuration~2. In event of failure of the above, a second shock with anterolateral pad configuration~3. In event of failure of the above, a third shock with anteroposterior pad configuration + manual pad pressure"
61951866|NCT05903170|ACTIVE_COMPARATOR|200J Philips HeartStart MRx Monitor/Defibrillator|"The standardised cardioversion protocol below performed with a 200J shock from a Philips HeartStart MRx Monitor/Defibrillator.~1. First shock with anteroposterior pad configuration~2. In event of failure of the above, a second shock with anterolateral pad configuration~3. In event of failure of the above, a third shock with anteroposterior pad configuration + manual pad pressure~4. The addition of a fourth 'rescue' shock at 360J using the LifePak Monitor/Defibrillator with pads in the anteroposterior configuration in the event of the first three steps failing to cardiovert to sinus rhythm"
61951867|NCT05086926|EXPERIMENTAL|Exercises and CSI|A corticosteroid injection in the lateral hip prior to performing an 8-week home exercise program
61951868|NCT01235689|EXPERIMENTAL|Tight Control Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI \< 150, hs-CRP, \< 5 mg/L, fecal calprotectin \< 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI \< 150, hs-CRP \< 5 mg/L, fecal calprotectin \< 250 μg/g, and absence of prednisone during the preceding week."
61951869|NCT01235689|ACTIVE_COMPARATOR|Clinically Driven Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine.~Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified failure criteria using less stringent criteria:~At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI \< 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI \< 200, and absence of prednisone during the preceding week."
61951870|NCT02403986|EXPERIMENTAL|R. Vital Skinboosters Lidocaine (three)|Treatment with three initial sessions
61951871|NCT02403986|EXPERIMENTAL|R. Vital Skinboosters Lidocaine (two)|Treatment with two initial sessions
61951872|NCT02118883|OTHER|Essentia Water|Essentia Water, electrolyzed high-pH water
61951873|NCT02118883|OTHER|Bottled Water|Purified bottle water
62141105|NCT04250636|EXPERIMENTAL|Study Participants|HIV-infected individuals, off ART, and with plasma HIV-1 RNA levels between 500 and 100,000 copies/ml by standard assays. Study participants will receive a single intravenous infusion of 3BNC117-LS and a single infusion of 10-1074-LS. The antibodies will be administered sequentially and dosed at 30 mg/kg.
62141106|NCT05106842|ACTIVE_COMPARATOR|Hydrotherapy after Rotator Cuff Repair|The participants will start with passive mobilization right after surgery for 4 weeks. Intervention in hydrotherapy will follow after that.
62141107|NCT05106842|ACTIVE_COMPARATOR|Classical Land Based Rehabilitation after Rotator Cuff Repair|The participants will start with passive mobilization right after surgery for 4 weeks. Intervention in classic dry land based rehabilitation will follow after that.
62141108|NCT03946956|ACTIVE_COMPARATOR|Prebooking|Participants randomised to this arm receives a prebooked appointment to screening
62141109|NCT03946956|PLACEBO_COMPARATOR|Web based booking|Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
62343121|NCT06348810|ACTIVE_COMPARATOR|Usual|Participants in this group receive usual care provided by the nursing home staff, which typically includes assistance with activities of daily living, medication management, and social activities. They do not receive the structured physical exercise program.
62343122|NCT04907591|EXPERIMENTAL|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band for 12 months.
62343123|NCT04907591|NO_INTERVENTION|Education brochure|Control group is provided general education through the hospital brochure.
62699889|NCT06565676|EXPERIMENTAL|Wheat Bread with Whey Powder|Participants will have their fasting blood glucose measured immediately before the meal containing the wheat flour with added whey powder test bread and will then be asked to consume the entire test bread with their breakfast meal within 15 minutes.
62699890|NCT02957240|ACTIVE_COMPARATOR|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
61951874|NCT02459301|EXPERIMENTAL|IPH2201|"Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks.~Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1"
61951875|NCT03059758|EXPERIMENTAL|Brain activity during reasoning and measure of math skill|Brain activity during reasoning and measure of math skill
61951876|NCT05834374|EXPERIMENTAL|Contextual variation|The contextual variation group alternate between six affordance conditions where the surface of the model i either half covered combined with no guide, a partial guide or a complete guide.
61951877|NCT05834374|EXPERIMENTAL|Maximum affordances|The maximum affordances group has half the surface model covered and a complete guide throughout the session.
61951878|NCT05834374|NO_INTERVENTION|Minimum affordances|The control group has the whole surface uncovered and no guide throughout the session.
61951879|NCT00547495|PLACEBO_COMPARATOR|1|Placebo tablet
61951880|NCT00547495|ACTIVE_COMPARATOR|2|5 mg tadalafil
61951881|NCT00547495|ACTIVE_COMPARATOR|3|10 mg tadalafil
61951882|NCT00547495|ACTIVE_COMPARATOR|4|20 mg tadalafil
61951883|NCT02911220|OTHER|blood sample for genetic evaluation|a blood sample is collected once for genetic analysis
61951884|NCT00968214||Single group|DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
61951885|NCT00570570|OTHER|group 1|Muscular Strengthening for paretic knee flexor and extensor
61951886|NCT00570570|ACTIVE_COMPARATOR|group 2|conventional physiotherapy
61951887|NCT02916589|PLACEBO_COMPARATOR|Baseline|The subjects will start with one week eating their normal diet.
61951888|NCT02916589|ACTIVE_COMPARATOR|Igelosa Diet|After one week the subjects will be provided the Igelosa Diet.
62500504|NCT06638398|EXPERIMENTAL|Arm I (Radiomic Prediction Score)|Patients undergo SOC CT evaluation and receive a Virtual Nodule Clinic radiomic prediction score on study. Patients then receive SOC lung nodule management on study.
61951889|NCT00411528|EXPERIMENTAL|1: 8 mg/m2 study drug + prednisone|Patupilone 8 mg/m2 + prednisone 5 mg bid daily
61951890|NCT00411528|EXPERIMENTAL|2: study drug + prednisone days 1 -8|Patupilone 10 mg/m2 + prednisone days 1 -8 at 25 mg bid, day 9 at 20 mg bid, day 10 at 15 mg bid, day 11 at 10 mg bid, day 12 - 21 at 5 mg bid
61951891|NCT00411528|EXPERIMENTAL|3: Study drug + prednisone days 1 - 4|Patupilone 10 mg/m2 + prednisone days 1 - 4 at 5 mg bid, days 5 -12 at 25 mg bid, day 13 at 20 mg bid, day 14 at 15 mg bid, day 15 at 10 mg bid, day 16 - 21 at 5 mg bid
61951892|NCT00411528|ACTIVE_COMPARATOR|4: Docetaxel 75 mg/m2 + prednisone 5 mg bid daily|Docetaxel 75 mg/m2 once every 3 weeks + prednisone 5 mg bid daily
61951893|NCT01760629|EXPERIMENTAL|Cooling arm|Whole body cooling to 33 to 34 C rectal temperature
61951894|NCT06144281|EXPERIMENTAL|Intervention|The inpatient care team, including the attending/ordering and covering providers, for participants in this group will receive a message from the research team identifying their patient as appropriate for home palliative care and will be asked to refer their patient for these services.
61951895|NCT06144281|NO_INTERVENTION|Usual Care|Participants in this group will receive usual care upon discharge from the hospital. Their clinical team will not be notified that they are appropriate for home palliative care services, but they may still be referred for those services if their clinicians feel their patient will benefit.
61951896|NCT06383936|EXPERIMENTAL|TKA patients|
62500505|NCT06638398|ACTIVE_COMPARATOR|Arm II (Usual Care)|Patients undergo SOC CT evaluation on study. Patients then receive SOC lung nodule management on study.
62500506|NCT00337558|EXPERIMENTAL|1|Solifenacin succinate
62500507|NCT00337558|EXPERIMENTAL|2|Solifenacin succinate and simplified bladder training
62500508|NCT01376544|ACTIVE_COMPARATOR|Assist control ventilation|Assist control ventilation
62699891|NCT02957240|EXPERIMENTAL|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
61951897|NCT04099628|EXPERIMENTAL|Diagnostic tests|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
61951898|NCT02178735|EXPERIMENTAL|Anterior compartment prolapse|Woman with cystocele who underwent anterior vaginal tailored mesh surgery
61951899|NCT02178735|EXPERIMENTAL|Posterior compartment prolapse|Woman with rectocele, enterocele, uterine prolapse, vaginal stump prolpase who underwent posterior vaginal tailored mesh surgery
61951900|NCT02178735|EXPERIMENTAL|anterior and posterior prolapse|Woman with cystocele and rectocele/uterine prolapse/vaginal vault prolapse/enterocele who underwent anterior and posterior vaginal tailored mesh surgery
61951901|NCT03386448|PLACEBO_COMPARATOR|control|Participants will receive placebo medication
61951902|NCT03386448|EXPERIMENTAL|Active|participants will receive active medications scopolamine and naltrexone
61951903|NCT04728399|EXPERIMENTAL|Experimental group|2g Soybean peptide, 3g CLA and ng protein.
61951904|NCT04728399|PLACEBO_COMPARATOR|Control group|2g+N protein and 3g Soybean oil.
61951905|NCT01826188|ACTIVE_COMPARATOR|THC 5 mg/ml and CBD 50 mg/ml.|olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
61951906|NCT01826188|PLACEBO_COMPARATOR|Placebo|olive oil but without any active ingredients.
61951907|NCT02990689|ACTIVE_COMPARATOR|809M|bifocal intraocular lens (IOL)
61951908|NCT02990689|ACTIVE_COMPARATOR|839MP|trifocal intraocular lens (IOL)
62500509|NCT01376544|ACTIVE_COMPARATOR|Pressure support ventilation|
62500510|NCT03023189|ACTIVE_COMPARATOR|Tranexamic acid|At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
62500511|NCT03023189|PLACEBO_COMPARATOR|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
62141110|NCT03946956|ACTIVE_COMPARATOR|Pictured invitation|Participants randomised to this arm receives a pictured invitation to screening
62500512|NCT03869424|EXPERIMENTAL|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.
62500513|NCT03869424|NO_INTERVENTION|No-treatment control group|Participants do not receive the nasal spray.
62500514|NCT06462144|EXPERIMENTAL|Intervention|IMPT-514
61951909|NCT02990689|ACTIVE_COMPARATOR|SN6AD1|bifocal intraocular lens (IOL)
61951910|NCT00509444|ACTIVE_COMPARATOR|Educational materials|
61951911|NCT00509444|EXPERIMENTAL|Educational materials, plus patient navigation|
61951912|NCT00667407|EXPERIMENTAL|1|Levalbuterol 1.25 mg
61951913|NCT00667407|ACTIVE_COMPARATOR|2|Racemic Albuterol 2.5 mg
61951914|NCT05953311||ICU survivors|Cohort of patients who survive an ICU stay of at least 7 days
61951915|NCT00791570|EXPERIMENTAL|A|
61951916|NCT00765557|ACTIVE_COMPARATOR|MiraLAX|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to MiraLAX versus placebo.
61951917|NCT00765557|PLACEBO_COMPARATOR|Placebos|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to placebo versus MiraLAX.
61951918|NCT00303901|EXPERIMENTAL|cryosurgery|cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
61951919|NCT06487585|OTHER|Study Drug Arm - Angiotensin II arm|Angiotensin II
61951920|NCT04937231|EXPERIMENTAL|Aerobic exercises|Treadmill and Cycle ergometer
62500515|NCT03157869|EXPERIMENTAL|Transcranial Direct Current Stimulation|"* Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~* Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
62500516|NCT03157869|SHAM_COMPARATOR|Control|"* Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~* Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
62500517|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
62500518|NCT01396694||all|All patients requiring arthroscopy or arthroplasty
61951921|NCT04937231|EXPERIMENTAL|Resistance exercises|unilateral leg press, Bilateral leg press, unilateral arm curls
61951922|NCT04937231|EXPERIMENTAL|Combined training|Treadmill and Cycle ergometer along with resistive Training
61951923|NCT05871775|EXPERIMENTAL|Personalized exercise|
61951924|NCT05871775|ACTIVE_COMPARATOR|Stabilization exercise|
61951925|NCT05871775|ACTIVE_COMPARATOR|General exercise|
61951926|NCT03857893|ACTIVE_COMPARATOR|Control Group : pH-Cream|Control Group will be only treated with a fixed amount (1g) of pH-cream (Cetomacrogol cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days and if deem necessary, additional doses can be applied and notified in the calendar provided).
61951927|NCT03857893|EXPERIMENTAL|Dynamic Quadripolar Radio-Frequency treatment|"Experimental Group will be treated with Dynamic Quadripolar Radio-Frequency (DQRF) (with Eva™ Device) for 8 weeks (+ 4 weeks). The Dynamic Quadripolar Radio-frequency sessions will involve -5 sessions (one every 14-21 days), if necessary External treatment (vulvar - will be applied before internal treatment for more comfort) : 10 minutes (5 minutes left side, 5 minutes right side), and Internal treatment (VVA, Vaginal Laxity, Mild-Stress Urinary Incontinence (SUI)): 20 minutes.~In parallel, patients can also apply pH-cream (Cetomacrogol cream) (one dose of 1g) if they judge necessary but they are not allowed to use it during the seven days before radiofrequency session. If they use pH-cream, they must notify it in the calendar provided."
61951928|NCT06188338|ACTIVE_COMPARATOR|Formulation containing MLYAAT-1002® Composition|After the 1064nm fractional picosecond laser treatment, daily use of the formulation for 56 days: apply one pump of the formulation to the treated side of the face in the morning and evening, respectively.
62141111|NCT03946956|PLACEBO_COMPARATOR|Texted invitation|Participants randomised to this arm receives a classical texted invitation to screening
62141112|NCT05144659|ACTIVE_COMPARATOR|Double faced transverse preputial onlay island flap (group A)|Thirty-four patients undergo double faced transverse preputial onlay island flap are categorized as (group A)
62141113|NCT05144659|ACTIVE_COMPARATOR|transverse inner preputial onlay island flap (control group) (group B)|Another thirty-four patients undergo transverse inner preputial onlay island flap are categorized as the control group = (group B)
62500519|NCT05127135|EXPERIMENTAL|ThisCART7 cells injections|In this study, allogeneic anti-CD7 CAR T Cells(ThisCART7 cells) is used to treat patients with refractory or relapsed CD7 positive T cell malignancies.
62500520|NCT03230123|EXPERIMENTAL|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
62500521|NCT03230123|PLACEBO_COMPARATOR|Diet alone|The control group will receive diet counseling during six months.
62500522|NCT06594588|EXPERIMENTAL|Aerobic exercise group|Aerobic exercise intervention combined with conventional drug treatment
62500523|NCT06594588|NO_INTERVENTION|Waiting control group|Antidepressants were routinely used and aerobic exercise interventions were performed at the end of the 8-week follow-up
62500524|NCT01043250||Risperidone|Receiving risperidone treatment
62500525|NCT01043250||Olanzapine|Receiving olanzapine treatment
62500526|NCT01043250||Aripiprazole|Receiving aripiprazole
62500527|NCT00260273|ACTIVE_COMPARATOR|1|cognitive Behavioural Therapy
62500528|NCT00260273|NO_INTERVENTION|2|supportive therapy
62500529|NCT03045133|ACTIVE_COMPARATOR|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
61951929|NCT06188338|PLACEBO_COMPARATOR|Blank formulation without MLYAAT-1002® Composition|After the 1064nm fractional picosecond laser treatment, daily use of the blank formulation for 56 days: apply one pump of the blank formulation to the control side of the face in the morning and evening, respectively.
61951930|NCT05593588|EXPERIMENTAL|Fisetin Group|Subjects will receive the supplement, Fisetin, for 2 cycles of 2 consecutive days (first on days 0 \& 1 and then repeated on days 28 \& 29)
61951931|NCT05593588|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo for 2 cycles of 2 consecutive days (first on days 0 \& 1 and then repeated on days 28 \& 29)
61951932|NCT06506682|ACTIVE_COMPARATOR|CIMT|Both groups will participate in 60 hours of intensive therapy over 10 days at SRC (6 hours per day Monday-Friday) following the established 'Pirate Camp' CIMT protocol. The full protocol can be found at: https://twu.edu/occupational-therapy/Camp-Based-Augmented-CIMT-Guide/. Both groups will participate in child friendly outdoor and indoor activities that promote the use of the involved side for example; parachute games, sock toss, penny pick up.
61951933|NCT06506682|EXPERIMENTAL|CIMT+VR|The CIMT+VR group will use the VR technology to work on upper limb motor skills for approximately two hours per day (4 of the activities described under Key Information at the beginning of this form) while the CIMT-only group will participate in traditional motor-based task-specific activities. Both the VR games and traditional intervention will target the improvement of the same upper limb domains.
61951934|NCT01142271|EXPERIMENTAL|Billroth-I|Patients in this group should be underwent gastroduodenostomy as reconstruction procedure after standard distal subtotal gastrectomy with lymph node dissection.
61951935|NCT01142271|EXPERIMENTAL|Roux en Y|Patients in this group should be underwent jejunojejunostomy and gastrojejunostomy as reconstruction procedure after standard distal gastrectomy.
61951936|NCT01895062|EXPERIMENTAL|active cNEP @ -45cmw|cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
61951937|NCT01895062|NO_INTERVENTION|no intervention|Routine care is administered without the application of cNEP.
62699892|NCT04016714|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, and 4 (approximately 3, 5, and 12 months of age). As part of the study design, participants will also receive other pediatric vaccines, including Vaxelis™ (0.5 mL single dose at Visits 1, 2, and 4); M-M-R™II (0.5 mL single dose at Visit 4); and VARIVAX™ (0.5 mL single dose at Visit 4, except participants in Norway and Denmark, who will receive a second dose of VARIVAX™ at Visit 5, according to local vaccination requirements).
61951938|NCT00940160|ACTIVE_COMPARATOR|QAX576 1 mg/kg|
61951939|NCT00940160|ACTIVE_COMPARATOR|QAX576 3 mg/kg|
61951940|NCT00940160|ACTIVE_COMPARATOR|QAX576 10 mg/kg|
61951941|NCT00940160|PLACEBO_COMPARATOR|Placebo|
62141114|NCT04842253|EXPERIMENTAL|High flow nasal cannula|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen during deep sedation.
62141115|NCT04842253|NO_INTERVENTION|Low flow nasal cannula|Participants in the current standard of care will receive low flow nasal cannula during deep sedation.
62141116|NCT06699966|EXPERIMENTAL|Celecoxib Arm|Participants will take 400mg (two 200mg tablets) of celecoxib daily with a meal for 8 weeks.
62141117|NCT06699966|EXPERIMENTAL|Minocycline|Participants will take minocyline for 8 weeks. Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
62141118|NCT03769415|EXPERIMENTAL|Intrinsic subtyping of Primary Breast Cancer|Intrinsic subtype of primary breast tissue from metastatic breast cancer subject will be determined
62141119|NCT01439685||Biliary Stent plus Photodynamic therapy|Biliary Stent plus Photodynamic therapy
62141120|NCT01439685||Biliary Stent group|Biliary Stent group
61951942|NCT01533077|EXPERIMENTAL|Group 1|Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
61951943|NCT01533077|EXPERIMENTAL|Group 2|Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
62141121|NCT06357299|EXPERIMENTAL|Standard, Clear|This group will receive standard-sized clear bottles
62141122|NCT06357299|EXPERIMENTAL|Standard, Opaque|This group will receive standard-sized opaque bottles
62141123|NCT06357299|EXPERIMENTAL|Small, Clear|This group will receive small-sized clear bottles
62141124|NCT06357299|EXPERIMENTAL|Small, Opaque|This group will receive small-sized opaque bottles
62714806|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
61951944|NCT01533077|EXPERIMENTAL|Group 3|Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
61951945|NCT01533077|EXPERIMENTAL|Group 4|Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
61951946|NCT01064310|EXPERIMENTAL|pazopanib followed by sunitinib|800mg pazopanib orally for 10 weeks followed by 50mg sunitinib orally for 10 weeks
61951947|NCT01064310|EXPERIMENTAL|sunitinib followed by pazopanib|50mg sunitinib orally for 10 weeks followed by 800mg pazopanib orally for 10 weeks
61951948|NCT03974191||131 participants with chronic low back pain|All the participants (n=131) with chronic low back pain (CLBP) from the cross-sectional study in 2006 are invited to participate in the present 13-year follow-up. The same examination battery used in the cross-sectional study plus a supplementary Chair Stand Test will be used.
61951949|NCT01705990|EXPERIMENTAL|Group A: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10\^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10\^10 vp at Month 4. (Vaccine/Placebo = 12/4)
61951950|NCT01705990|EXPERIMENTAL|Group B: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10\^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10\^10 vp at Month 4. (Vaccine/Placebo = 12/4)
61951951|NCT01705990|EXPERIMENTAL|Group C: Ad35-GRIN followed by SeV-G(NP)|Ad35-GRIN (IM) at 1x10\^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10\^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
61951952|NCT01705990|EXPERIMENTAL|Group D: SeV-G(NP) only|SeV-G(NP) (IN) at 2x10\^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)
61951953|NCT06533722|EXPERIMENTAL|Treatment arm|Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
61951954|NCT01785264|ACTIVE_COMPARATOR|Open surgery|Treatment is divided into three arms, and patients between 18 and 60 years of age sustaining first time achilles tendon ruptures will be invited to participate. All three groups will have identical rehabilitation protocol. Open surgical repair is done through a 10 cm longitudinal incision, through the fascia curries and the paratenon. After necessary revision of the injure site, the tendons ends is sutured with a double layer, three knot, Krakow whip suture technique. 5 to 10 degrees of overcorrection compared to the uninjured side is endeavored. The paratenon is sewn as much as possible back over the injure site and suture material. The fascia is sutured and then continuous lying mattress skin suture.
62343124|NCT01836744|ACTIVE_COMPARATOR|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
62343125|NCT01836744|ACTIVE_COMPARATOR|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
61951955|NCT01785264|ACTIVE_COMPARATOR|Non-operative treatment|Non-operative treatment starts with casting the ankle in equinus position. The rest of the treatment from there on will be identical to the two other arms: Minimal invasive and open surgery. Casting lasts for 2 weeks for all three arms.
61951956|NCT01785264|ACTIVE_COMPARATOR|Mini-invasive surgery|Patients allocated to mini-invasive treatment will (as patients treated with open surgery) be operated within 7 days from injury with the technique developed by Dr Amlang and Prof Zwipp in Dresden. Patients in all three arms will have an active, early weight bearing rehabilitation protocol.
61951957|NCT04258163||MCT Group|People who received chemotherapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
61951958|NCT04258163||MET Group|People who received endocrine therapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
61951959|NCT04258163||Observation Group|People who didn't receive any maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks.
61951960|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
61951961|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
61951962|NCT03098121|EXPERIMENTAL|Genotype 1 HCV and HIV co-infection|Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.
61951963|NCT01128556|EXPERIMENTAL|Bepreve|topical ocular treatment as indicated
61951964|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
61951965|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
61951966|NCT00639431|EXPERIMENTAL|1|Direct observation of a sequence of right foot movements performed by the experimenter while visualizing moving the amputated or phantom right foot.
61951967|NCT00639431|EXPERIMENTAL|2|Direct observation of a sequence of left foot movements performed by the experimenter while visualizing moving the amputated or phantom left foot.
61951968|NCT00639431|EXPERIMENTAL|3|Direct observation of a sequence of left and right foot movements performed by the experimenter while visualizing moving the amputated or phantom left and right feet.
61951969|NCT00639431|EXPERIMENTAL|4|Mental visualization with closed eyes of a sequence movements performed with the right amputated or phantom foot.
61951970|NCT00639431|EXPERIMENTAL|5|Mental visualization with closed eyes of a sequence movements performed with the left amputated or phantom foot.
61951971|NCT00639431|EXPERIMENTAL|6|Mental visualization with closed eyes of a sequence movements performed with the left and right amputated or phantom feet.
62343126|NCT02713763|EXPERIMENTAL|Sunitinib|Sunitinib 37.5 mg/day
62343127|NCT00171314|EXPERIMENTAL|Upfront Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
61951972|NCT01972100|ACTIVE_COMPARATOR|Low-level laser therapy (LLLT)|Use of low-level laser therapy (LLLT) to induce a muscle fatigue resistance in intense exercises
61951973|NCT01972100|ACTIVE_COMPARATOR|Placebo low-level laser therapy (Placebo)|Use of low-level laser therapy (LLLT) placebo to induce a muscle fatigue resistance
61951974|NCT05847855||pNETs|Patients with pancreatic neuroendocrine tumors (pNETs).
61951975|NCT05847855||Healthy|Healthy volunteers.
61951976|NCT03405584|EXPERIMENTAL|Bismuth Plus Dual Therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.
62343128|NCT00171314|EXPERIMENTAL|Delayed Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
62343129|NCT01403701|EXPERIMENTAL|Physical therapy|Standardized pelvic floor physical therapy
61951977|NCT03405584|ACTIVE_COMPARATOR|Dual Therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.
61951978|NCT02834039|ACTIVE_COMPARATOR|Tidal volume 6 ml/kgBW|Tidal volume 6 ml/kgBW was given to patients after endotracheal tube was inserted properly
61951979|NCT02834039|ACTIVE_COMPARATOR|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to patients after endotracheal tube was inserted properly.
61951980|NCT05902520|EXPERIMENTAL|DP CD8 TIL|Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 an CD103 and expanded in vitro. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion.
61951981|NCT05902520|EXPERIMENTAL|DP CD8 TIL KD|Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 and CD103 and expanded in vitro in the presence of PH-762, a silencing RNA that reduces the expression of the checkpoint inhibitor PD-1. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion.
61951982|NCT04352569|ACTIVE_COMPARATOR|transcranial direct current stimulation|The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the LTP, le cathode over L DLPFG.
61951983|NCT04352569|SHAM_COMPARATOR|transcranial direct current stimulation sham|tDCS device allows sham stimulation. This technic give the same impression that active stimulation and allows optimum placebo stimulation.
61951984|NCT03326544|EXPERIMENTAL|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
61951985|NCT03326544|EXPERIMENTAL|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
61951986|NCT01884480||500 Stable renal transplant recipients|cohort of 500 stable RTRS. A subset of this group who required dose adjustment after conversion will be compared to a matched cohort not requiring dose adjustment. Genotyping for Cyp3A5 will be done for both cohorts
61951987|NCT01884480||500 renal transplant recipients|500 Stable renal transplant recipients converted from prograf to advagraf
61951988|NCT00816920||1|Outpatients with suspected leg DVT after exclusion of proximal DVT
61951989|NCT06358820|OTHER|Self Control|Compare the nutritional and safety indicators of the subjects before treatment and during the third and sixth months of treatment.
61951990|NCT06251752|ACTIVE_COMPARATOR|Lateral closing wedge high tibial osteotomy|
61951991|NCT06251752|ACTIVE_COMPARATOR|Medial opening wedge high tibial osteotomy|
61951992|NCT05108662|ACTIVE_COMPARATOR|HOLEP|Patients with a prostate volume greater than 80 g
61951993|NCT05108662|ACTIVE_COMPARATOR|TURP|Patients with a prostate volume less than 80 g
62343130|NCT01403701|NO_INTERVENTION|routine care|Standard postoperative visits
62343131|NCT05738694|EXPERIMENTAL|Neoadjuvant group|Neoadjuvant group will be given the neoadjuvant combination of axitinib plus Toripalimab + nephrectomy
62343132|NCT05738694|ACTIVE_COMPARATOR|Control group|The control group will be given nephrectomy alone.
61951994|NCT01146834|EXPERIMENTAL|Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
61951995|NCT01146834|EXPERIMENTAL|Arm B: VELCADE & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection
61951996|NCT01146834|EXPERIMENTAL|Arm C: CYCLOPHOSPHAMIDE & G-CSF|High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
61951997|NCT01146834|EXPERIMENTAL|Arm D: PLERIXAFOR & G-CSF|G-CSF is given for ten (+/- two) consecutive days starting on day 1 at a dose of 10 micrograms/kg/day. Plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5. Both G-CSF and plerixafor are continued daily until collection is complete. Pheresis will commence for everyone on Day 5 regardless of ANC status.
62141125|NCT05150873||Patients ttreatted for AAA|Patients affected by AAA and treated att our institution with EVAR and/or Open Repair between 2010 and 2020
62343133|NCT00212303|EXPERIMENTAL|Exercise training|Exercise training, 3 times per week, for 6 months.
62343134|NCT00212303|NO_INTERVENTION|Control|Usual care no active exercise intervention
62343135|NCT05487313|ACTIVE_COMPARATOR|10 ml ESP group|ESP group using 10 ml mixture of local anesthetics and contrast medium
62343136|NCT05487313|ACTIVE_COMPARATOR|20 ml ESP group|ESP group using 20 ml mixture of local anesthetics and contrast medium
62343137|NCT05250830|EXPERIMENTAL|TrueRelief device|Patients receive an experimental procedure using a TrueRelief device.
62343138|NCT05250830|SHAM_COMPARATOR|Sham TrueRelief device|Patients receive a placebo procedure using a sham TrueRelief device that looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
62343139|NCT02287701|EXPERIMENTAL|PET/MRI|Patient receives MRI
62343140|NCT05436886|EXPERIMENTAL|Test Group (Neurogabin-M 400 mg) Capsules|A single dose consisting of one capsule of Test Drug (Neurogabin 400 mg capsule) will be administered to each of the subjects in both Periods in fasting conditions with 240 mL ambient temperature water.
62343141|NCT05436886|ACTIVE_COMPARATOR|Reference Group (Parketin 400 mg) Capsules|A single dose consisting of one capsule of Reference Drug (Parketin 400 mg capsule) will be administered to each of the subjects in both Periods under fasting conditions with 240 mL ambient temperature water.
62343142|NCT06308640|EXPERIMENTAL|Fast Back Rapid Distalizer|Group 1: Consisted of 10 patients, their upper molar will be distalized with bone suppored Fast Back (Fast Back Rapid Distalizer, leone, s.p.a, Italy).
62343143|NCT06308640|EXPERIMENTAL|Modified Leaf Spring Self-Activated Expander|Group 2: Consisted of 10 patients, their upper molar will be distalized with bone supported modified Leaf Spring Self-Activated Expander. (Leaf Self Expander, leone, s.p.a, Italy).
62343144|NCT04777214|ACTIVE_COMPARATOR|Active TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS are delivered to a previously determined optimal response site in right frontal lobe.
62500530|NCT03045133|ACTIVE_COMPARATOR|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
62699893|NCT04016714|ACTIVE_COMPARATOR|Prevenar 13™|Participants will receive a single 0.5 mL IM injection of Prevenar 13™ at Visit 1, 2, and 4 (approximately 3, 5, and 12 months of age). As part of the study design, participants will also receive other pediatric vaccines, including Vaxelis™ (0.5 mL single dose at Visits 1, 2, and 4); M-M-R™II (0.5 mL single dose at Visit 4); and VARIVAX™ (0.5 mL single dose at Visit 4, except participants in Norway and Denmark, who will receive a second dose of VARIVAX™ at Visit 5, according to local vaccination requirements).
61951998|NCT01146834|EXPERIMENTAL|Arm E: PLERIXAFOR, VELCADE, & G-CSF|"Bortezomib at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- wo) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day.~Plerixafor is given on day 12, approximately 11 hours prior to stem cell collection attempt and is continued daily until collection is complete. Pheresis will commence for everyone on Day 13 regardless of ANC status."
61951999|NCT00985023|ACTIVE_COMPARATOR|Steel screw fixation|
61952000|NCT00985023|EXPERIMENTAL|Bioabsorbable screw fixation|
61952001|NCT05043909|EXPERIMENTAL|Experimental Group (EG)|The students in EG received VR-based training for elderly oral health care at 2-week (Time 2), 4-week (Time 3), and 6-week (Time 4) follow-ups. The learning module was divided into three sessions according to the physical condition (1) Mild disability, (2) Semi-disability, (3) Total disability and oral condition, (1) wearing dentures, (2) missing teeth of the elderly. Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
61952002|NCT05043909|NO_INTERVENTION|Control Group (CG)|The students in CG do not receive any of the interventions. However, the same VR-based curriculum of oral health care on dependency elderly were provided at the end of the study.
61952003|NCT02938104|EXPERIMENTAL|Prehabilitation|"Immediately after randomization, until surgery and to be continued for 8 weeks after surgery, patients in this arm will:~1. Receive a personalized physical exercise program~2. Receive nutritional counselling with whey protein isolate powder~3. Receive relaxation techniques"
61952004|NCT02938104|ACTIVE_COMPARATOR|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patient in the other arm but to be started after surgery.
61952005|NCT06323057|EXPERIMENTAL|Single-pulse Peak Phase TMS|Participants will receive a single active TMS pulse during the peak phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target . For the second TMS session, participants will receive single pulse Sham TMS during the peak phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target. Total number of TMS pulse for each session is 520 pulses
61952006|NCT06323057|EXPERIMENTAL|Single-pulse Trough Phase TMS|Participants will receive a single active TMS pulse during the trough phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target . For the second TMS session, participants will receive single pulse Sham TMS during the peak phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target. Total number of TMS pulse for each session is 520 pulses
61952007|NCT03809676||heaart transplant recipients|
61952008|NCT03809676||healthy controls|
62141126|NCT06014372|EXPERIMENTAL|Envafolimab Group|Patients diagnosed with colon cancer, with T stage determined as 3-4 based on enhanced MR imaging, or with any T stage accompanied by imaging findings suggestive of lymph node metastasis, and excluding patients with distant metastasis, who are confirmed to have microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colon cancer, will be enrolled in Group A
62343145|NCT04777214|SHAM_COMPARATOR|Sham TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz TMS are delivered, however, the coil will be rotated 90 degrees during stimulation.
62343146|NCT00747617|ACTIVE_COMPARATOR|PCOS group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
62343147|NCT00747617|ACTIVE_COMPARATOR|Control group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
62343148|NCT04163406|ACTIVE_COMPARATOR|ferrous fumarate|Maize-based porridge fortified with iron (5mg) as ferrous fumarate
62343149|NCT04163406|ACTIVE_COMPARATOR|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) as ferrous fumarate + GOS (3g)
62343150|NCT04163406|ACTIVE_COMPARATOR|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) as ferrous fumarate + HMOs (2'-FL (2g) + LNnT (1g))
62343151|NCT05912309|EXPERIMENTAL|Time Restricted Eating (TRE)|
62343152|NCT05912309|EXPERIMENTAL|Time Restricted Eating (TRE) + Exercise|
62343153|NCT05912309|ACTIVE_COMPARATOR|Caloric restriction (CR) + Exercise|
62500531|NCT04601350|EXPERIMENTAL|Remimazolam 1|
62500532|NCT04601350|OTHER|Control|
62500533|NCT05659758|OTHER|control|patients will be preoxygenated in supine position
62500534|NCT05659758|EXPERIMENTAL|20 degree|patients will be preoxygenated in 20 degrees head up position
62500535|NCT05659758|EXPERIMENTAL|30 degree|patients will be preoxygenated in 30 degrees head up position
62500536|NCT06033313|EXPERIMENTAL|Positively framed text messages|Positively framed text messages
62500537|NCT06033313|EXPERIMENTAL|Negatively frame text messages|Negatively framed text messages
62500538|NCT00676650|EXPERIMENTAL|A|Treatment Arm A - sunitinib + prednisone
62500539|NCT00676650|PLACEBO_COMPARATOR|B|Treatment Arm B - placebo + prednisone
62500540|NCT06227520|EXPERIMENTAL|Dermgen|Application of Dermgen
62699894|NCT06216288|ACTIVE_COMPARATOR|repeated back extension exercise (McKenzie)|Repeated back extension exercise as described by McKenzie in prone position was performed of three sets of ten repetitions with one minute rest between the sets. The patient was asked to reach the maximum extension possible in all attempts and maintain this position for one second. The intervention was done 3 times per week for 6 weeks.
62500541|NCT04139460|ACTIVE_COMPARATOR|CRT-D|Implantation of cardiac resynchronization therapy with a defibrillator (CRT-D)
62500542|NCT04139460|ACTIVE_COMPARATOR|CRT-P|Implantation of cardiac resynchronization therapy pacemaker (CRT-P)
61952009|NCT04979468|OTHER|ARM A|Participants in Arm A will be randomized to switch to DTG/3TC 50/300 mg QD until week 48 (early switch).
61952010|NCT04979468|OTHER|ARM B|Participants in Arm B will continue the INSTI-based ART regimen until week 48, and then will be switched to DTG/3TC through week 96 (delayed switch).
61952011|NCT01942343|ACTIVE_COMPARATOR|Arm 1 : Droperidol 1,25 mg|
61952012|NCT01942343|ACTIVE_COMPARATOR|Arm 2 : Droperidol 0,625 mg|
61952013|NCT01942343|ACTIVE_COMPARATOR|Arm 3 : Odansetron 4 mg|
61952014|NCT04383483||CoVID patients admitted to ICU|Patients admitted to the intensive care unit with the diagnosis of COVID
61952015|NCT05325788|OTHER|Single daily message followed by location-based messaging|Participants in this condition receive a single daily message through the intervention app for two weeks (14 days) followed by location-based messaging for two weeks (14 days).
61952016|NCT05325788|OTHER|Location-based messaging followed by single daily message|Participants in this condition receive location-based messaging through the intervention app for two weeks (14 days) followed by a single daily message for two weeks (14 days) .
61952017|NCT03636984||rheumatoid arthritis patients|subjects with rheumatoid arthritis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
61952018|NCT03636984||ankylosing spondylitis patients|subjects with ankylosing spondylitis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
62141127|NCT06014372|ACTIVE_COMPARATOR|Envafolimab+CAPEOX Group|Patients diagnosed with colon adenocarcinoma, with T stage determined as 3-4 based on enhanced MR imaging, or with any T stage accompanied by imaging findings suggestive of lymph node metastasis, and excluding patients with distant metastasis, who are confirmed to have microsatellite stable (MSS)/proficient mismatch repair (pMMR) colon cancer, will be enrolled in Group B.
62343154|NCT01965236|EXPERIMENTAL|Group 1|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
62343155|NCT01965236|EXPERIMENTAL|Group 2|Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.
62500543|NCT05578469||posterior chamber intraocular lens(IOL) implantation with a Cionni capsular tension ring (CTR)|
62500544|NCT05578469||sutured scleral fixation of posterior chamber IOL/ posterior chamber IOL and CTR|
62500545|NCT06448637|ACTIVE_COMPARATOR|Drug Coated Balloon (DCB)|Drug Coated Balloon (DCB)
62500546|NCT06448637|EXPERIMENTAL|Drug Eluting Stent (DES)|Drug Eluting Stent (DES)
61952019|NCT01264757|ACTIVE_COMPARATOR|Education|Educational brochure about physical activity provided.
61952020|NCT01264757|EXPERIMENTAL|Pedometer|A pedometer was provided in addition to educational materials.
61952021|NCT03209531|EXPERIMENTAL|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
61952022|NCT03209531|EXPERIMENTAL|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
61952023|NCT04799977||COVID19 infection with olfaction disorder|Patients, ≥18 ans, who suffered from an olfaction disorder while going through a COVID19 infection
62343156|NCT03586245|ACTIVE_COMPARATOR|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.~* 57FePP (95.8%) 3.49 mg~* Aspergillus oryzae (unenriched) 0.025 mg~* FePP natural abundance 0.685 mg.~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
62343157|NCT03586245|EXPERIMENTAL|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.~* ASP-p (8% Fe; natural abundance) 3.516 mg~* 58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg~* 4.2 total mg of Fe"
62500547|NCT02664987||Patients receiving cancer pain treatment|
62500548|NCT04902911||Antigen testing in those who have history of COVID-19|Individuals must have had history of COVID-19. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
62500549|NCT04902911||Antigen testing in those who do not have history of COVID-19 and COVID immunization|Individuals may not have history of COVID-19 and COVID immunizations in order to be eligible. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
62500550|NCT00096122|EXPERIMENTAL|Arm I|See Detailed Description
61952024|NCT04799977||COVID19 infection without olfaction disorder|Patients, ≥18 ans, who suffered from a COVID19 infection without any olfaction disorders
61952025|NCT04815681|EXPERIMENTAL|Common Elements Toolbox (COMET)|
61952026|NCT04815681|ACTIVE_COMPARATOR|Active Control Condition|
61952027|NCT02548416|ACTIVE_COMPARATOR|PEEP group|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using positive end-expiratory pressure.
61952028|NCT02548416|ACTIVE_COMPARATOR|Control group zero PEEP|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using zero end-expiratory pressure.
62343158|NCT03586245|OTHER|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .~* Aspergillus oryzae (unenriched) 0.027 mg~* 57FeSO4 (95.4%) 3.18 mg~* 4.2 total mg of Fe"
62343159|NCT00396149|PLACEBO_COMPARATOR|Placebo|Placebo group
62343160|NCT00396149|EXPERIMENTAL|Active group|rBet v 1 tablets
62343161|NCT02540096|EXPERIMENTAL|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
62343162|NCT02540096|PLACEBO_COMPARATOR|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
61952029|NCT04010695|OTHER|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor point-of-care G6PD test and the point-of-care HemoCue Hb test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
62343163|NCT05671601||TLI+AI Assessment Group|
62343164|NCT05671601||Morphological Assessment Group|
62343165|NCT05084794|NO_INTERVENTION|Non-fixated|Posterior malleolus fractures won't be fixated.
62343166|NCT05084794|EXPERIMENTAL|Fixated|Posterior malleolus fractures will be fixated with either plate or screws.
62343167|NCT03987919|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62343168|NCT03987919|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62343169|NCT03987919|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62343170|NCT03987919|ACTIVE_COMPARATOR|1 mg Semaglutide|1 mg semaglutide administered SC once a week.
62343171|NCT06394401|ACTIVE_COMPARATOR|Energy Balance: Glucose|Following 48 hours of consuming an energy balance diet, volunteers complete 80 min of steady-state (60 ± 5% V̇O2peak) exercise on a cycle ergometer while consuming 80 g of glucose
62343172|NCT06394401|EXPERIMENTAL|Energy Balance: Glucose plus Fructose|Following 48 hours of consuming an energy balance diet, volunteers complete 80 min of steady-state (60 ± 5% V̇O2peak) exercise on a cycle ergometer while consuming 53 g of glucose and 27 g of fructose.
61952030|NCT04099147||ETHON|Subjects from the general population identified in the ETHON
61952031|NCT04099147||HEPAmet|Subjects belonging to the Spanish registry of NAFLD (HEPAmet)
61952032|NCT04879628|EXPERIMENTAL|Intravenous (IV) SAR441344|SAR441344 IV
62343173|NCT06394401|ACTIVE_COMPARATOR|Energy Deficit: Glucose|Following 48 hours of consuming an energy deficit diet, volunteers complete 80 min of steady-state (60 ± 5% V̇O2peak) exercise on a cycle ergometer while consuming 80 g of glucose
62343174|NCT06394401|EXPERIMENTAL|Energy Deficit: Glucose plus Fructose|Following 48 hours of consuming an energy deficit diet, volunteers complete 80 min of steady-state (60 ± 5% V̇O2peak) exercise on a cycle ergometer while consuming 53 g of glucose and 27 g of fructose.
62343175|NCT03348241|EXPERIMENTAL|Gum Arabic group|Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed addition to verbal instructions pertaining to the optimal nutrition and daily routine for oral hygiene.
62500551|NCT03760874||Non Vitamin K Oral Anticoagulant|Dabigatran, Rivaroxaban, Apixaban, Edoxaban
61952033|NCT04879628|PLACEBO_COMPARATOR|IV Placebo|Placebo IV
61952034|NCT04879628|EXPERIMENTAL|Subcutaneous (SC) SAR441344|SAR441344 SC
61952035|NCT04879628|PLACEBO_COMPARATOR|SC Placebo|Placebo SC
61952036|NCT03366038||Modified Pancreaticojejunostomy|Shark Mouth Modified Pancreaticojejunostomy is performed following pancreaticoduodenectomy.
61952037|NCT00329004|EXPERIMENTAL|1|
61952038|NCT02543710|EXPERIMENTAL|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
61952039|NCT02543710|EXPERIMENTAL|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
62141128|NCT03069391|ACTIVE_COMPARATOR|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
62343176|NCT03348241|OTHER|Control group|Patients of control group was received only chemotherapy regimen and verbal counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
62343177|NCT06098209|EXPERIMENTAL|Group D (Dexmedetomidine)|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h. Patients will be randomized to receive dexmedetomidine intravenously at rates of 0.2-1.4 μg/kg/h and 0.3-4 mg/kg/h for 2 days, respectively, to maintain the Richmond Agitation-Sedation Scale (RASS) within the range of +1 to -2.
62343178|NCT06098209|EXPERIMENTAL|Group P (Propofol)|Patient will receive propofol 0.3-4 mg/kg/h. Patients will be randomized to receive propofol intravenously at rates of 0.2-1.4 μg/kg/h and 0.3-4 mg/kg/h for 2 days, respectively, to maintain the Richmond Agitation-Sedation Scale (RASS) within the range of +1 to -2.
62343179|NCT02077985|NO_INTERVENTION|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
62343180|NCT02077985|EXPERIMENTAL|Sensory Adapted Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
62343181|NCT01159626|EXPERIMENTAL|Single dose|
62500552|NCT03760874||Vitamin K Oral Anticoagulant|Warfarin, Acenocoumarol.
62500553|NCT02101073|EXPERIMENTAL|ALX-0061 low dose i.v.|
61952040|NCT05637866||Soy Milk|Soy milk beverage
61952041|NCT01352104|EXPERIMENTAL|waiting-intervention-course|
62343182|NCT01159626|EXPERIMENTAL|Multiple dose|
62343183|NCT04338516|ACTIVE_COMPARATOR|Bio-Oss® Collagen,|subjects treated with Bio-Oss® Collagen, (Geistlich, Inc.)
62343184|NCT04338516|EXPERIMENTAL|Ossix™ Bone|subjects treated with Ossix™ Bone (Datum Dental Ltd)
62343185|NCT05963048|EXPERIMENTAL|Rituxmab|1000 mg Rituxmab IV infusion at 1st day then after 15 weeks then after 6 months for 1 year
62343186|NCT05963048|EXPERIMENTAL|IL-6 inhibitor|6 mg/kg IV infusion every month not exceed 600 mg for 1 year
62343187|NCT05711199|EXPERIMENTAL|normal weight|"Treatment phase~1. administration of glyceroltrinitrate (Nitroderm TTS) for 15 days.~2. measurement of energy expenditure before and after cold exposure~3. performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~4. measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test.~Control phase:~1. measurement of energy expenditure before and after cold exposure~2. performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~3. measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test."
62343188|NCT05711199|EXPERIMENTAL|overweight|"Treatment phase~1. administration of glyceroltrinitrate (Nitroderm TTS) for 15 days.~2. measurement of energy expenditure before and after cold exposure~3. performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~4. measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test.~Control phase:~1. measurement of energy expenditure before and after cold exposure~2. performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~3. measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test."
62343189|NCT05385497|EXPERIMENTAL|Combined Aerobic Exercise (AE) and Virtual Reality (VR)-based program|Individuals diagnosed with PD will participate in AE and VR.
62343190|NCT01185587||healthy patients with a normal heart|
62343191|NCT01185587||patients with HF without an lCD|
62343192|NCT01185587||patients with HF and an ICD without shock|
62343193|NCT01185587||patients with HF and an ICD with shock|
62343194|NCT03695640|ACTIVE_COMPARATOR|Group L|continuous femoral nerve block with levobupivacaine
62343195|NCT03695640|EXPERIMENTAL|Group LM|continuous femoral nerve block with levobupivacaine and magnesium sulfate
62500554|NCT02101073|EXPERIMENTAL|ALX-0061 high dose i.v.|
61952042|NCT02509481|ACTIVE_COMPARATOR|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
61952043|NCT02509481|EXPERIMENTAL|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
61952044|NCT00330746|EXPERIMENTAL|A|cetuximab and gemcitabine combination
61952045|NCT00330746|EXPERIMENTAL|B|gemcitabine followed by cetuximab (sequential)
61952046|NCT00316719|EXPERIMENTAL|Adefovir Dipivoxil (ADV)|
62343196|NCT01532713|EXPERIMENTAL|non-block side|
62343197|NCT02266758|OTHER|GDM Screening Method 1|GDM Screening Methods
62343198|NCT02266758|OTHER|GDM Screening Method 2|GDM Screening Methods
62343199|NCT01182389|ACTIVE_COMPARATOR|robotic VT Ablation|Robotic VT ablation by substrate elimination
62343200|NCT01182389|ACTIVE_COMPARATOR|Conventional therapy|review of ICD programming to ensure that detection and therapy will occur appropriately.
62343201|NCT03558555|ACTIVE_COMPARATOR|Oral Acetaminophen|Patients who are randomized to have oral acetaminophen will take oral acetaminophen preoperatively and receive saline intraoperatively.
62343202|NCT03558555|ACTIVE_COMPARATOR|Acetaminophen IV Soln|Patients randomized to IV acetaminophen will receive IV acetaminophen after induction of general anesthesia and will take placebo pills preoperatively.
62343203|NCT03183830|EXPERIMENTAL|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing \~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
62343204|NCT03183830|PLACEBO_COMPARATOR|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
62343205|NCT06394518|EXPERIMENTAL|200 mg single dose group (low-dose group)|Participants in the single-dose groups (200 mg in the low-dose group) were enrolled and received a single intravenous infusion of TNP-2092 for injection(Day 1) over 60 min (± 1 0 min).
62500555|NCT02101073|EXPERIMENTAL|ALX-0061 low dose s.c.|
62500556|NCT02101073|EXPERIMENTAL|ALX-0061 middle dose s.c.|
62500557|NCT02101073|EXPERIMENTAL|ALX-0061 high dose s.c.|
61952047|NCT00316719|ACTIVE_COMPARATOR|Lamivudine (LAM)|
61952048|NCT05097274||DNA repair gene mutation carriers|"* Newly diagnosed with prostate cancer (any Gleason score, any stage, any PSA)~* Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy~* Patients on active surveillance, with a PSA doubling time of 6 months or less"
61952049|NCT03397537|OTHER|the postmenopausal|2.5 mg letrozole every day for six months
61952050|NCT03397537|EXPERIMENTAL|the premenopausal|2.5 mg letrozole daily along with a GnRH analogue for ovarian suppression, which was administered as an intramuscular injection of 3.75 mg triptorelin every 28 days for 6 months.
62500558|NCT06062550|ACTIVE_COMPARATOR|Low-dose group|Patient-controlled analgesia is established with esketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
62500559|NCT06062550|EXPERIMENTAL|Medium-dose group|Patient-controlled analgesia is established with esketamine 100 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
62500560|NCT06062550|EXPERIMENTAL|High-dose group|Patient-controlled analgesia is established with esketamine 150 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
62500561|NCT01960608||low sodium group|24_hours_urine_sodium \< 100 mEq/L
62500562|NCT01960608||mid sodium group|24_hours_urine_sodium \>= 100 mEq/L and \< 200 mEq/L
62500563|NCT01960608||high sodium group|24_hours_urine_sodium \>= 200 mEq/L
62500564|NCT01960608||low income group|the income 25% below the quartile
62500565|NCT01960608||low mid income group|the income 25% - 50% below the quartile
62500566|NCT01960608||mid income group|the income 50% - 75% below the quartile
62500567|NCT01960608||high income group|the income 75% over the quartile
62500568|NCT04386408|EXPERIMENTAL|Combination of plant extracts (BSL_EP027)|Volunteers will dissolve in water a sachet per day with the Combination of plant extracts (BSL_EP027), and maltodextrin.
62500569|NCT04386408|PLACEBO_COMPARATOR|Placebo|Volunteers will dissolve in water a sachet per day with maltodextrin.
62343206|NCT06394518|EXPERIMENTAL|300 mg single and multiple dose continuous dose group (medium-dose group)|Participants in the single-dose, multiple-dose continuous dosing group (300 mg in the medium-dose group) received a single intravenous infusion of TNP-2092 for injection on Day 1 of the study. Subsequently, TNP-2092 for injection or placebo was administered as an intravenous infusion every 12 hours (q12 h, ± 10 min) daily on Study Days 4 to 10, and the last dose of TNP-2092 for injection was administered on the morning of Study Day 11.
62699895|NCT06216288|EXPERIMENTAL|Combined mechanical lumbar traction and repeated back extension exercise (McKenzie)|Participants allocated to mechanical lumbar traction received the McKenzie approach described above in combination with mechanical lumbar traction. The traction was applied using a 3D ActiveTrac table which is a motorized split table. Participants were placed in prone position and static traction was applied for 15 minutes at an intensity of 40% to 60% of the participant's body weight. At the end of traction intervention, participants continued with the McKenzie repeated back extension exercise intervention. The intervention was done 3 times per week for 6 weeks.
62343207|NCT06394518|EXPERIMENTAL|400 mg single dose group (high-dose group)|Participants in the single-dose groups (400 mg in the high-dose group) were enrolled and received a single intravenous infusion of TNP-2092 for injection over 60 min (± 1 0 min)
62343208|NCT06394518|PLACEBO_COMPARATOR|Placebo|
62500570|NCT02855840||systemic lupus erythematous|
62500571|NCT02855840||systemic sclerosis|
62500572|NCT02855840||inflammatory myopathy|
62500573|NCT06678763||CRS-HIPEC|The patient received open laparotomy cytoreduction surgery in the same principle as epithelial ovarian cancer surgery, and received intraperitoneal hyperthermic chemotherapy with docetaxel (75 mg/m²) and gemcitabine (1000 mg/m²) within 24 hours after surgery.
62500574|NCT05983627|EXPERIMENTAL|Human Umbilical Cord Mesenchymal Stem Cells|The trial was divided into three dose groups： Low-dose group: 1000000 cells/kg Medium-dose group: 2000000 cells/kg High-does group: 4000000 cells/kg
62500575|NCT00681018|EXPERIMENTAL|1|Liquid human milk fortifier
62500576|NCT00681018|ACTIVE_COMPARATOR|2|Powder human milk fortifier
62141129|NCT03069391|ACTIVE_COMPARATOR|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
62141130|NCT04539015||Group-I|Patients randomized to the Group-I will receive PREVENA Plus, which is currently being used at our institution (Prevena, KCI) and it is FDA-approved device. Dressings will be applied under sterile conditions at the end of the surgery while still in the operating room and will continuously apply for 5 days.
62343209|NCT04745286|EXPERIMENTAL|S-ketamine group|
62343210|NCT04745286|PLACEBO_COMPARATOR|saline group|
62500577|NCT05227677|EXPERIMENTAL|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals and the anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
62500578|NCT05227677|ACTIVE_COMPARATOR|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals，but investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
62500579|NCT00962494|EXPERIMENTAL|online workshop|
62500580|NCT04863157|EXPERIMENTAL|Survivor-SHIP|Parents/guardians will take part in 3 education sessions over a one month period. During the sessions, they will learn more about common sleep problems following cancer treatment and ways to understand their child's unique patterns. They will then be educated about behavioral changes they can make to improve their child's sleep.
62500581|NCT05926635||Exoskeleton group|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their of their routine rehabilitation
62500582|NCT05926635||Control group|The children included in the control group will continue receiving their usual conventional therapy
62500583|NCT03969641|EXPERIMENTAL|RIV4|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
62500584|NCT03969641|ACTIVE_COMPARATOR|IIV4|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
62500585|NCT02695927|EXPERIMENTAL|Chronic|Crossover study on the benefits of computer rehabilitation glasses on chronic sufferers of hemispatial neglect
62500586|NCT02695927|EXPERIMENTAL|Acute|Randomized, controlled study on the benefits of computer rehabilitation glasses on acute sufferers of hemispatial neglect
62500587|NCT02695927|EXPERIMENTAL|Optimization|Study to identify optimal operating parameters of computer rehabilitation glasses
62500588|NCT02695927|ACTIVE_COMPARATOR|Duration|Study to determine duration of effect of computer rehabilitation glasses
62500589|NCT04302337|ACTIVE_COMPARATOR|Conventional Curettage Adenoidectomy|Adenoidectomy with Beckmann Adenoid Curette
62500590|NCT04302337|EXPERIMENTAL|Curettage Adenoidectomy With Transoral Endoscopic Ablation|Transoral endoscopic adenoidectomy with Coblator 2 system
62500591|NCT03674138|ACTIVE_COMPARATOR|DNA-guided choice of therapy|DNA-guided choice of antidepressant therapy
62500592|NCT03674138|ACTIVE_COMPARATOR|Clinical management|Clinical management
62500593|NCT04106817|EXPERIMENTAL|Cohort 1|1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 10\^6TCID50/dose)
62500594|NCT04106817|EXPERIMENTAL|Cohort 2|1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 10\^6TCID50/dose)
62500595|NCT04106817|EXPERIMENTAL|Cohort 3|1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 10\^6TCID50/dose)
62500596|NCT01031992|EXPERIMENTAL|Group I|First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
62500597|NCT01031992|EXPERIMENTAL|Group II|First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).
62500598|NCT03038568||Cohort 1|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
62500599|NCT03038568||Cohort 2|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
62500600|NCT03038568||Cohort 3|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
62500601|NCT03038568||Cohort 4|-10 second time gap between routine abdominal CT and add on CT, Noise index 12
62500602|NCT03038568||Cohort 5|-10 second time gap between routine abdominal CT and add on CT, Noise index 14
62500603|NCT03038568||Cohort 6|-10 second time gap between routine abdominal CT and add on CT, Noise index 16
62500604|NCT03038568||Cohort 7|- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
62500605|NCT03038568||Cohort 8|- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
62500606|NCT03038568||Cohort 9|- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
62500607|NCT03038568||Cohort 10|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
62141131|NCT04539015||Group-II|"Subjects randomized to SOC surgical incision dressing arm will receive SOC dressing for 4 days immediately following surgery. The closed incision will be covered with materials which may include sterile gauze pieces, surgical tape and tegaderm.~Any material used for the SOC dressing will be documented."
62500608|NCT03038568||Cohort 11|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
62500609|NCT03038568||Cohort 12|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
62500610|NCT03038568||Cohort 13|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
62500611|NCT03038568||Cohort 14|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
62500612|NCT03038568||Cohort 15|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
62500613|NCT03038568||Cohort 16|+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
62500614|NCT03038568||Cohort 17|+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
62500615|NCT03038568||Cohort 18|+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
62500616|NCT03716323|EXPERIMENTAL|immediate premolar implant with xenograft and allograft|Immediate Implant Placement in Maxillary Premolar zone with grafting the jumping gap using xenograft and allograft
62500617|NCT01781312|EXPERIMENTAL|ProTectis|
62699896|NCT02114034||Non-severe asthma|"* Children Controlled without treatment or with low doses of inhaled corticosteroids (\<500 mg / day beclometasone equivalent) asthma~* and Children with normal EFR~* and Children who did not have more severe exacerbation (assessed taking oral corticosteroids) in the previous year~* and Children not admitted in the previous year for asthma"
62141132|NCT03451422|EXPERIMENTAL|Efavaleukin Alfa|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
62500618|NCT01781312|EXPERIMENTAL|Gastrus|
62500619|NCT05001009|ACTIVE_COMPARATOR|No then high patient engagement|"First stage: No patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): High patient engagement and high intensity clinician training."
62500620|NCT05001009|ACTIVE_COMPARATOR|No then low patient engagement|"First stage: No patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): Low intensity patient engagement and high intensity clinician training."
62500621|NCT05001009|ACTIVE_COMPARATOR|Low then high patient engagement|"First stage: Low intensity patient engagement. Low intensity clinician training.~Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): High patient engagement and high intensity clinician training."
62500622|NCT05001009|ACTIVE_COMPARATOR|Low then low patient engagement|"First stage: Low patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): Low intensity patient engagement and high intensity clinician training."
62500623|NCT00590694|ACTIVE_COMPARATOR|Group1|Will receive ranibizumab treatments until resolution of macular edema only and as macular edema recurs.
62500624|NCT00590694|ACTIVE_COMPARATOR|Group 2|Will receive ranibizumab treatments until resolution of both macular edema and PED, and as macular edema or PED recur.
62500625|NCT01610024|ACTIVE_COMPARATOR|Beetroot|
62500626|NCT00198354|EXPERIMENTAL|A: pre-operative chemotherapy|pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
62500627|NCT00198354|EXPERIMENTAL|B: pre-operative chemotherapy|pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
62500628|NCT00198354|EXPERIMENTAL|C: peri-operative chemotherapy|peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
62500629|NCT00198354|EXPERIMENTAL|D: peri-operative chemotherapy|peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
62500630|NCT00915109||vascular|People with a unilateral below-knee amputations due to a vascular reason
62500631|NCT00915109||nonvascular|People with a below-knee amputation due to nonvascular reasons
62500632|NCT00915109||Control|People with no gait impairments.
62714807|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
62714808|NCT04351594|EXPERIMENTAL|Topical analgesia (+Menthol)|Biofreeze Topical Gel with active ingredient (Menthol 4%)
62714809|NCT04351594|PLACEBO_COMPARATOR|Topical analgesia (-Menthol)|Biofreeze Topical Gel with no active ingredient (Menthol 0%)
61952051|NCT03948672|ACTIVE_COMPARATOR|Control-then-Intervention|In each intensive care unit assigned to the Control-then-Intervention arm, all participants who regularly access the ICUs will wear the wristband while at work for 5 months. The functionality of the wristband will not be disclosed to the healthcare providers. Handwashing compliance data will be automatically collected, but data will not be shared with the healthcare providers or hospital management teams. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from the sensor system. Then, all healthcare providers will be educated on the functionalities of the CleanHands system with real time reminders now turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection reduction. This phase will last for 5 months.
61952052|NCT03948672|ACTIVE_COMPARATOR|Intervention-then-Control|In each intensive care unit assigned to the Intervention-then-Control arm, all participants who regularly access to the ICUs will be educated on the functionalities of the CleanHands system with real time reminders turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection control. This phase will last for 5 months. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from sensor system installation and implementation. Then, the real-time reminder functionality of the wristband will be turned off and no more education will be provided. Handwashing compliance data will be automatically collected but will not be shared with the healthcare providers. This process will last for 5 months.
61952053|NCT06271122|EXPERIMENTAL|Voluntary activation assessed by magnetic stimulation group|The inclusion visit (V0) will be conducted at the beginning of the stay. On Day 1 (D+1), the patients will undergo the first visit (V1), during which specific evaluations (maximal quadriceps force test, transcranial and femoral magnetic stimulation) will be performed. Subsequently, the patients will follow the standard 4-week PR program. On Day 28 (D+28), patients will undergo the second visit (V2), during which they will undergo the same evaluations as those performed in V1.
61952054|NCT00438308||1|Subjects who begin therapy immediately after fracture.
61952055|NCT00438308||2|Subjects delay therapy for 3 weeks after injury.
61952056|NCT02327065|ACTIVE_COMPARATOR|EUS-FNA Group|FNA,Fine needle aspiration
61952057|NCT02327065|ACTIVE_COMPARATOR|EUS-FNB Group|FNB,Fine needle biopsy
61952058|NCT01723345|ACTIVE_COMPARATOR|omega 3|receive omega 3 in addition to standard treatment
62343211|NCT04740099|EXPERIMENTAL|SOONER Training (Intervention)|Arm receives video training and kit designed by SOONER team.
62343212|NCT04740099|OTHER|Standard of care training (control)|Participant referred to standard of care (community based Naloxone training)
61952059|NCT01723345|NO_INTERVENTION|control|just receive standard treatment
61952060|NCT04573712|EXPERIMENTAL|Fatigue Severity Scale scores assessment|Fatigue Severity Scale scores assessment
61952061|NCT03868046||Patients treated with ICIs.|All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
62343213|NCT02813759|EXPERIMENTAL|Sucralose|14 mg sucralose (Zero K sucralose powder, IANSA®) an 200 mL of water
62343214|NCT02813759|PLACEBO_COMPARATOR|Water|200 mL of water
62343215|NCT04586244|EXPERIMENTAL|Treatment Group A|epacadostat will be administered in combination with retifanlimab.
62343216|NCT04586244|EXPERIMENTAL|Treatment Group B|retifanlimab will be administered as monotherapy.
62343217|NCT04586244|EXPERIMENTAL|Treatment Group C|epacadostat will be administered as monotherapy.
62343218|NCT04586244|EXPERIMENTAL|Treatment Group D|retifanlimab will be administered in combination with INCAGN02385.
62343219|NCT04586244|EXPERIMENTAL|Treatment Group E|retifanlimab will be administered in combination with INCAGN02385 and INCAGN02390.
62343220|NCT01523561|NO_INTERVENTION|usual care|The participants in the no intervention group were informed that they should continue living as usual
62500633|NCT00511927||GHD|Patients with Growth Hormone Deficiency
62500634|NCT00511927||non-GHD|Patients with CHF, without coexisting growth hormone deficiency
61952062|NCT00508365|EXPERIMENTAL|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
61952063|NCT00508365|EXPERIMENTAL|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
62141133|NCT03451422|PLACEBO_COMPARATOR|Placebo|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
62500635|NCT01138345||Treatment w/Surgery|Breast Cancer survivors treated with surgery with or without radiation.
62500636|NCT01138345||Treatment w/endocrine therapy|Breast Cancer survivors treated with surgery with or without radiation plus endocrine therapy.
62500637|NCT01138345||Treatment w/ chemotherapy|Breast Cancer survivors treated with surgery with or without radiation and chemotherapy with or without endocrine therapy.
61952064|NCT05514418|EXPERIMENTAL|Intervention Arm|"This group will receive three monthly sessions of intensive adherence counselling (IAC) and psychosocial support, using the 5 A's principles for chronic care (which include; Assess, Advise, Agree, Assist and Arrange). Each monthly IAC session will be offered by the research assistants for about one hour, and adherence will also be assessed by pill counts. Colour-coded IAC forms will be developed and used to differentiate the study from routine IAC services for the non-suppressed patients; and the study will be conducted on different days, from those on which the routine clinic occurs.~Following the three months of the study, all the study participants both in the control and intervention groups will be reviewed at the health facility and a repeat viral load (VL) test done for each of the participants, to determine whether they have achieved a non-detectable VL or not."
62699897|NCT02114034||Severe asthma|"Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene (inhaler technique and compliance verified) presents one of the 3 criteria following:~* Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months~* exacerbations in the previous year:~  * at least one care unit admission or continued resuscitation~ * at least two hospitalizations for acute severe asthma requiring IV therapy~ * at least 2 courses of oral corticosteroids for exacerbations~* post BD FEV \<80% or UARS post BD\> 150% predicted"
61952065|NCT05514418|NO_INTERVENTION|Control Arm|This group will comprise of participants who will receive the routine standard of care. These participants will receive the normal patient education and encouragement to continue with their antiretroviral therapy (ART) at the start of the study. They will not be reviewed monthly or offered any counselling for the entire three months. These participants will be given an appointment after three months for repeat viral load (VL) testing.
61952066|NCT03274596|ACTIVE_COMPARATOR|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
61952067|NCT03274596|PLACEBO_COMPARATOR|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
61952068|NCT03576612|EXPERIMENTAL|Cohort 1: MGMT Unmethylated Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
61952069|NCT03576612|EXPERIMENTAL|Cohort 2: MGMT Methylated & undetermined Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
61952070|NCT03556735|OTHER|PEMF treatment|No sham group (placebo) was chosen. Treatment consisted of one active group in a multicenter study.
61952071|NCT02544360|EXPERIMENTAL|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
61952072|NCT02544360|NO_INTERVENTION|Control|The control group consists of schools participating in the survey but not receiving the intervention.
61952073|NCT01399814|ACTIVE_COMPARATOR|standard fluid regimen group|perioperative fluid treatment
62141134|NCT01507675||Military Veterans|Participants will be recruited from the Denver VA Medical Center (DVAMC), regardless of clinic.
61952074|NCT01399814|EXPERIMENTAL|restricted fluid regimen group|perioperative fluid treatment
62141135|NCT02079649|EXPERIMENTAL|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
62699898|NCT03091855||PLUG Dementia Trial|Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
62699899|NCT03091855||MRI PLUG Dementia Sub-Study|20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.
62500638|NCT04505735||Normal Control|Adults with no history of memory complaints, diagnosis of MCI, or dementia from a physician
62699900|NCT05670184|EXPERIMENTAL|LSD condition|60 participants will receive LSD.
62699901|NCT05670184|PLACEBO_COMPARATOR|Ethanol condition|60 participants will receive placebo.
62699902|NCT00853853|ACTIVE_COMPARATOR|1. EnSeal Device|The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
61952075|NCT05344365|EXPERIMENTAL|Iloperidone (Cohort 1)|
61952076|NCT05344365|EXPERIMENTAL|Iloperidone (Cohort 2)|
62141136|NCT02079649|EXPERIMENTAL|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
62141137|NCT02079649|ACTIVE_COMPARATOR|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
62141138|NCT02079649|PLACEBO_COMPARATOR|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
62141139|NCT01203943|EXPERIMENTAL|Cohort 1|• Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
62141140|NCT01203943|EXPERIMENTAL|Cohort 2|• Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
62500639|NCT04505735||Adults with Mild Cognitive Impairment|Adults with cognitive decline verified by a study partner or cognitive impairment verified by the study physician. The cognitive decline has had limited impact on functional activities; general cognition and functional performance are sufficiently preserved such that a diagnosis of dementia cannot be made by the enrolling physician
62500640|NCT05713227|ACTIVE_COMPARATOR|Gellan gum|White rice test meal boiled in 356 g water containing 5.5g of gellan to each 185g of uncooked rice (50 g of available carbohydrate). Consumed on Day 1 at the study site, then consumed at home once daily for 7 days, then consumed again once at test site at Day 8
61952077|NCT04022850|ACTIVE_COMPARATOR|Non-reflective decision assistance strategy|The decision support tools integrated in the electronic health record (EHR) for the non-reflective decision assistance strategy will be applied to all FPs from the 13 Integrated Healthcare Organizations (IHOs) of Osakidetza- Basque Health Service
61952078|NCT04022850|EXPERIMENTAL|Reflective and non-reflective decision information strategy in addition to the previous arm|At least 58 FPs from two IHOs (Barakaldo-Sestao and Ezkerraldea-Enkarterri-Cruces) will be randomly assigned to this experimental arm (decision assistance strategy + decision information strategy)
61952079|NCT04022850|EXPERIMENTAL|A reflective decision structure strategy in addition to the previous arm|At least other 58 FPs from two IHOs (Barakaldo-Sestao and Ezkerraldea-Enkarterri-Cruces) will be randomly assigned to this experimental arm (decision assistance strategy + decision information strategy + decision structure strategy)
61952080|NCT04361318|EXPERIMENTAL|Hydroxychloroquine plus Nitazoxanide|200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days
62343221|NCT01523561|EXPERIMENTAL|dance intervention|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
62343222|NCT03632252|EXPERIMENTAL|Powered ankle prosthesis|We will use data from various sensors to optimize the amount of power provided by custom ankle ankle prosthesis. This is a single session study lasting about 4 hours.
62343223|NCT06019936|EXPERIMENTAL|MT2004 Capsule|The MT2004 Capsule will be orally used twice daily after meal for 12 weeks.
62343224|NCT06019936|PLACEBO_COMPARATOR|MT2004 Capsule Placebo|The MT2004 Capsule Placebo will be orally used twice daily after meal for 12 weeks.
62343225|NCT04042675||parkinson group|parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage.
62343226|NCT04042675||Control group|healthy individuals between the ages of 40-75 and without any neurological disorders.
62500641|NCT05713227|PLACEBO_COMPARATOR|Control|White rice test meal boiled in 356 g water without gellan gum (50 g of available carbohydrate). Consumed on Day 1 at the study site, then consumed at home once daily for 7 days, then consumed again once at test site at Day 8
61952081|NCT04361318|ACTIVE_COMPARATOR|Standard care|Standard care delivered in the COVID-19 isolation hospitals.
62343227|NCT01833325|EXPERIMENTAL|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
62500642|NCT04802551|EXPERIMENTAL|Intervention group|
62500643|NCT04802551|NO_INTERVENTION|Control group|
62714810|NCT03487094|ACTIVE_COMPARATOR|Growth, Tolerance of Infants-Exp|Infant Formula
62714811|NCT03487094|ACTIVE_COMPARATOR|Growth,Tolerance of Infants-Com|Infant Formula
61952082|NCT00628056|ACTIVE_COMPARATOR|1|
61952083|NCT00628056|PLACEBO_COMPARATOR|2|
61952084|NCT05984095|ACTIVE_COMPARATOR|SELF|All the participants in the SELF group were asked to participate in 10 sessions of 45 minutes of pelvic floor training and exercises, once every 5 days. The exercises were available in pre-recorded videos and the participants were allowed to access it when and where they preferred, respecting the requested frequency. No supervision was provided during the trainings.
61952085|NCT05984095|EXPERIMENTAL|REMOTE|All the participants in the REMOTE group were asked to participate in 10 sessions of 45 minutes of pelvic floor training and exercises, once every 5 days. The exercises were shown and monitored remotely during a one-to-one videocall with a physiotherapist.
61952086|NCT00282412|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA
61952087|NCT04792008|EXPERIMENTAL|YQ23 Single dose|Two-third of randomized patients will receive YQ23 as active treatment
61952088|NCT04792008|PLACEBO_COMPARATOR|Placebo Single dose|One-third of randomized patients will receive matching placebo
61952089|NCT06295302|EXPERIMENTAL|HWH486|
62343228|NCT02568124|EXPERIMENTAL|Tranexamic acid|Tranexamic acid 750 mg daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
62343229|NCT02568124|PLACEBO_COMPARATOR|Placebo|Placebo tablet daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
62343230|NCT02298712||Observation|Patients with Hurler disease or high-grade suspicion for Hurler disease
62343231|NCT00218426|ACTIVE_COMPARATOR|ONP + DNI|Oral naltrexone placebo (ONP) + Depot Naltrexone Implant (DNI) 1000 mg
62500644|NCT05045612|EXPERIMENTAL|Intervention|Stop antibiotic therapy as instituted by admitting physician
62500645|NCT05045612|NO_INTERVENTION|Control|Continue antibiotic therapy at the discretion of the treating physician (no change in ongoing treatment)
62500646|NCT01174667|EXPERIMENTAL|Fascial massage|A specific type of fascial massage to release restricted lumbodorsal fascia.
62500647|NCT01174667|NO_INTERVENTION|No treatment control|Patient will rest quietly without receiving any instruction.
62500648|NCT05550662|EXPERIMENTAL|Single arm|Participants will inhale hyperpolarized 129Xe gas.
62500649|NCT02166801|ACTIVE_COMPARATOR|Early intervention for infants|A 30w intensive intervention according to the small step program, with daily practice sections conducted by parents at home, with weekly support by therapists.
62500650|NCT02166801|ACTIVE_COMPARATOR|Usual care|Usual care means that the Children in this arm of the study participate in the established follow up program that is established at the Astrid Lindgrens Children's Hospital and offered to all Children that displays a delayed early gross and fine motor development.
62500651|NCT02636673||Robotic-assisted sigmoid resection|Patient that have undergone robotic-assisted sigmoid resection for benign or malignant disease between 2010 and 2015
61952090|NCT06295302|PLACEBO_COMPARATOR|Placebo|
61952091|NCT00002946|EXPERIMENTAL|Arm I|atients enrolled on the bioavailability portion of this study receive one dose of IV penclomedine over 1 hour followed by 2 weeks of rest. At the end of two weeks, they receive oral penclomedine for 5 days every 28 days. The starting dose is determined by a single primary patient who has been administered oral penclomedine and observed for dose limiting toxicity (DLT). \[Bioavailability portion completed as of 3/98.\] Those not on the bioavailability portion of study start on a standard design dose escalating schedule in which patients enroll in cohorts of 3. Patients are administered oral penclomedine daily for 5 days. This treatment repeats every 4 weeks. The MTD is defined as the dose immediately below that at which 2 patients experience DLT. Treatment repeats for 6 courses or until severe toxicity or tumor progression is observed.
61952092|NCT05399732|EXPERIMENTAL|efficiency and safety in luspatercept plus ciclosporin|luspatercept is at a dose of 1.0 mg per kilogram of body weight, administered subcutaneously every 3 weeks，and ciclosporin is at a dose of 3\~5mg/kg /day for at least 6 months.
61952093|NCT05399732|ACTIVE_COMPARATOR|controll group in ciclosporin alone|ciclosporin is at a dose of 3\~5mg/kg /day for at least 6 months.
61952094|NCT06557746|EXPERIMENTAL|Cola group|100 ml cola every 30 minutes during the operation
61952095|NCT06557746|EXPERIMENTAL|Oxygen group|Continuous supply of oxygen (2 L/min) during the operation
61952096|NCT03681431|EXPERIMENTAL|Ceftriaxone 4g/ 24h|Single intravenous dose of Ceftriaxone 4g/ 24h
61952097|NCT03681431|ACTIVE_COMPARATOR|Ceftriaxone 2g/ 12h|Two intravenous doses of Ceftriaxone 2g/ 12h
61952098|NCT05747430|EXPERIMENTAL|IRX-101|Subjects randomized to IRX-101 will receive the investigational product, IRX-101.
61952099|NCT05747430|ACTIVE_COMPARATOR|5% Povidone-iodine|Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.
61952100|NCT02656732|EXPERIMENTAL|coronally advanced flap with amnion chorion membrane|coronally advanced flap was reflected and amnion chorion allograft membrane was placed under the flap as a guided tissue regeneration barrier.
62141141|NCT01203943|EXPERIMENTAL|Cohort 3|• Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
62343232|NCT00218426|ACTIVE_COMPARATOR|ON + DNIP|Oral naltrexone (ON) 50 mg + Depot Naltrexone placebo Implant (DNIP)
61952101|NCT02656732|ACTIVE_COMPARATOR|subepithelial connective tissue graft|coronally advanced flap was reflected and subepithelial connective tissue graft was harvested from the palate and placed under the flap.
62343233|NCT00218426|PLACEBO_COMPARATOR|ONP + DNIP|Oral placebo naltrexone + placebo naltrexone implant
62343234|NCT02927873|EXPERIMENTAL|RSV LD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV low dose (LD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
61952102|NCT01358045|ACTIVE_COMPARATOR|Solaraze|
61952103|NCT01358045|ACTIVE_COMPARATOR|Solaraze + Silkis|
61952104|NCT01358045|ACTIVE_COMPARATOR|Silkis|
61952105|NCT01358045|NO_INTERVENTION|No treatment|
61952106|NCT04242329|EXPERIMENTAL|PD1-inhibitor + surgery|Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
62343235|NCT02927873|EXPERIMENTAL|RSV MD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of the RSV middle dose (MD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
62343236|NCT02927873|EXPERIMENTAL|RSV HD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV high dose (HD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
61952107|NCT04242329|ACTIVE_COMPARATOR|PD1-inhibitor|Patients randomized to control study arm, receiving continued immunotherapy only. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
61952108|NCT00533897|EXPERIMENTAL|Abatacept|
61952109|NCT00533897|PLACEBO_COMPARATOR|Placebo|
61952110|NCT01479478|ACTIVE_COMPARATOR|Probiotic dietary supplement|Probiotic dietary supplement one capsule once per day until delivery.
61952111|NCT01479478|PLACEBO_COMPARATOR|Placebo|Placebo capsule, one daily until delivery.
62343237|NCT02927873|PLACEBO_COMPARATOR|Placebo LD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
62343238|NCT02927873|PLACEBO_COMPARATOR|Placebo MD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
62343239|NCT02927873|PLACEBO_COMPARATOR|Placebo HD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
62343240|NCT00501046|PLACEBO_COMPARATOR|Placebo|
62343241|NCT00501046|EXPERIMENTAL|AST-120|
62343242|NCT00701155||A|
62141142|NCT01203943|PLACEBO_COMPARATOR|Placebo|Placebo
62141143|NCT06698718|EXPERIMENTAL|Treatment group|
62343243|NCT05239559||bubble CPAP arm|"Oxygen will be delivered by Bubble CPAP device, which will have three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit: short nasal prongs are generally used to deliver nasal CPAP. They must be carefully fitted to minimize leakage of air (otherwise, CPAP will not be achieved) .~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure: in bubble CPAP, the positive pressure is maintained by placing the far end of the expiratory tubing in water. The pressure is adjusted by altering the depth of the tube under the surface of the water."
62343244|NCT03937193||Non-SMAS group|subjects in this group are not clinically diagnosed as superior mesenteric artery syndrome(SMAS).
62343245|NCT03937193||SMAS group|subjects in this group are clinically diagnosed as superior mesenteric artery syndrome(SMAS).
62500652|NCT02636673||Laparoscopic sigmoid resection|Patient that have undergone laparoscopic sigmoid resection for benign or malignant disease between 2010 and 2015
62500653|NCT03525340|NO_INTERVENTION|Standard of Care|Participants in the standard of care arm will receive no navigation assistance to remain in care. They will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation, but no additional services to remain engaged in care other than what is provided as standard by the clinic.
61952112|NCT01147523|EXPERIMENTAL|Vitamin E|Vitamin E, capsules 400 mg daily, for 52 weeks
61952113|NCT01708161|EXPERIMENTAL|BYL719 + AMG 479|For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
61952114|NCT05720221||Adalimumab group|"Patients receive adalimumab (Humira) at an induction dose of 160/80 mg (week 0 and 2) and at a maintenance dose of 40 mg every other week.~The efficacy of the drug will be assessed."
61952115|NCT05720221||Ustekinumab group|"Patients receive ustekinumab (Stelara) through intravenous infusion with a weight based dose for treatment induction, followed by a subcutaneous dose injection with a fixed dose (90 mg) for maintenance every 8 weeks.~The efficacy of the drug will be assessed."
61952116|NCT00143182|EXPERIMENTAL|1|Asenapine
62699903|NCT00853853|ACTIVE_COMPARATOR|2. Ferguson Hemorrhoidectomy|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced.
62141144|NCT06698809|EXPERIMENTAL|Participants with Moderate-to-Severe OSA|Participants will receive tPBM treatment for approximately 12 minutes and complete assessments. Participants have the choice to participate in an optional follow-up 1 week post-initial visit, in which they will receive tPBM treatment for approximately 11-12 minutes and complete assessments at a different time of day.
62343246|NCT02129335||stress|patient with glioblastoma diagnosis and partners
62343247|NCT00999219|EXPERIMENTAL|FK199B-first group|
62343248|NCT00999219|EXPERIMENTAL|Zolpidem-first group|
62343249|NCT03405493|EXPERIMENTAL|Wake and Light Therapy|This consists of (a) Total Sleep Deprivation with group support on days one and two; (b) Phase Advance of Sleep over 5 days and daily Light Therapy. (c) Light Therapy is given daily
62343250|NCT03405493|ACTIVE_COMPARATOR|Sleep and Light Therapy|Participants will be given information on sleep hygiene and getting a good night's sleep. They are then given Light Therapy daily for 1 week.
62343251|NCT00473837|ACTIVE_COMPARATOR|Treatment|Subjects initially treated with Co-arthemeter, and then continued on weekly chloroquine till day 90
62699904|NCT00195728|EXPERIMENTAL|hydrocodone/acetaminophen extended release|
62699905|NCT01844596|NO_INTERVENTION|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
61952117|NCT00143182|ACTIVE_COMPARATOR|2|Olanzapine
61952118|NCT02573168|EXPERIMENTAL|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
61952119|NCT02573168|EXPERIMENTAL|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
61952120|NCT02573168|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
62141145|NCT05808205||Open Non-comparative|In this study, it is planned to include about 70 patients each year, assuming two treatments per patient. Due to the post-market nature of the study, this sample size is not based on a formal statistical sample size calculation, but the size is considered appropriate for the study purposes and considering the enrollment rate estimated at the center.
62141146|NCT01084941|EXPERIMENTAL|Lifestyle intervention|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
62343252|NCT00473837|PLACEBO_COMPARATOR|Control|Subjects initially treated with Co-arthemeter, and then continued on weekly placebo till day 90
62343253|NCT06313177|ACTIVE_COMPARATOR|group A|group(A) cases with ankle in neutral position during syndesmosis fixation
62343254|NCT06313177|ACTIVE_COMPARATOR|group B|group(B) cases with ankle in dorsiflexion position during syndesmosis fixation
62343255|NCT00188266|EXPERIMENTAL|5-Fluorouracil (5FU) and Cisplatin with Radiation|
62343256|NCT05138874|EXPERIMENTAL|Trending Feedback + Private Commitment|Clinicians receive both Trending Feedback + Private Commitment interventions.
62500654|NCT03525340|EXPERIMENTAL|Peer Navigation|Participants in the peer navigation arm will meet with a peer navigator at least once per month for nine months in-person, and have at least one other navigator contact per month. Like the standard of care arm, they will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation.
62500655|NCT00859040|EXPERIMENTAL|SOM230C|Monthly SOM230C (pasireotide LAR) - 60 mg intramuscularly (Single-Arm Trial)
61952121|NCT02122172|EXPERIMENTAL|Treatment (afatinib)|Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
61952122|NCT02518074|OTHER|HEARING AND VESTIBULAR INTERACTIONS|Hearing and Vestibular Interactions during two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
61952123|NCT01262911|ACTIVE_COMPARATOR|1.0 g SRT2379|Single dose of 1.0g of SRT2379
61952124|NCT01262911|PLACEBO_COMPARATOR|1.0 g Placebo|Single dose of 1.0g of placebo
62699906|NCT01844596|EXPERIMENTAL|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
62699907|NCT01844596|EXPERIMENTAL|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
61952125|NCT00659997|ACTIVE_COMPARATOR|1|1 Individuals treated with Albendazole
61952126|NCT00659997|ACTIVE_COMPARATOR|2|Individuals treated with Levamisole
61952127|NCT02989545|NO_INTERVENTION|Off treatment|2 week period without intervention
61952128|NCT02989545|EXPERIMENTAL|Treatment period|2 week period with intervention
61952129|NCT02509273|EXPERIMENTAL|CLONIDINE HYDROCHLORIDE|solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
61952130|NCT02509273|ACTIVE_COMPARATOR|MIDAZOLAM|solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)
61952131|NCT02296320|ACTIVE_COMPARATOR|MEDI4893 5000 mg|Participants will receive a single intravenous (IV) dose of MEDI4893 5000 milligrams (mg) on Day 1 of the study.
61952132|NCT02296320|PLACEBO_COMPARATOR|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
61952133|NCT02296320|ACTIVE_COMPARATOR|MEDI4893 2000 mg|Participants will receive a single IV dose of MEDI4893 2000 mg on Day 1 of the study.
61952134|NCT06557980|ACTIVE_COMPARATOR|Toothpaste containing calcium silicate nanoparticles|patients with hypersensitive areas will use the calcium silicate based toothpaste
61952135|NCT06557980|ACTIVE_COMPARATOR|Toothpaste containing sodium fluoride nanoparticles|patients with hypersensitive areas will use the sodium fluoride based toothpaste
62699908|NCT02500108||Treated with domperidone|Patients who received a new prescription for domperidone (ATC A03FA03) in the year prior to the index date.
62699909|NCT02500108||Unexposed (reference) group|Patients with no prescription for domperidone in the year prior to the index date.
62699910|NCT04150445|EXPERIMENTAL|Internet treatment for overweight and obese patients|The intervention is a treatment of overweight and obesity based on cognitive behavioural therapy provided via the Internet. The treatment lasts for six months and comprises 12 treatment modules. The patient works with each module for two weeks. The modules conclude with one or more exercise tasks to be performed before the next module is activated. The patient has written contact with the therapist via the Internet platform.
61952136|NCT04312880|NO_INTERVENTION|Control|Patient will receive no transexemic acid of any kind
61952137|NCT04312880|EXPERIMENTAL|IV-transexemic acid|weight adjusted standard dose of TXA will be administered to these subset of patients prior to incision in IV-form
62343257|NCT05138874|EXPERIMENTAL|Trending Feedback + Public Commitment|Clinicians receive both Trending Feedback + Public Commitment interventions.
62699911|NCT05053685||Obstructive Sleep Apnoea (OSA)|Subjects with OSA
62699912|NCT05053685||Elevated Urine Metanephrines|Subjects with elevated metanephrines
62699913|NCT05696119|EXPERIMENTAL|I-PROTECT|I-PROTECT includes physical and psychological injury prevention information and training (i.e., the intervention) and tailored support to implement it specifically developed for Swedish community youth handball.
62699914|NCT05696119|ACTIVE_COMPARATOR|Control group|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
61952138|NCT04312880|EXPERIMENTAL|Topical-transexemic acid|the wound site after the surgery is completed will be bathed in TXA for a standardized period of time prior to skin closure
61952139|NCT00094705|EXPERIMENTAL|1|One subcutaneous vaccination with a 10\^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
61952140|NCT00094705|EXPERIMENTAL|2|One subcutaneous vaccination with a 10\^5 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
61952141|NCT00094705|PLACEBO_COMPARATOR|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm.
62343258|NCT05138874|EXPERIMENTAL|Trending Feedback + Commitment Control|Clinicians receive Trending Feedback intervention + Commitment Control.
62343259|NCT05138874|EXPERIMENTAL|Benchmark Peer Comparison Feedback + Private Commitment|Clinicians receive both Benchmark Peer Comparison Feedback + Private Commitment interventions.
62343260|NCT05138874|EXPERIMENTAL|Benchmark Peer Comparison Feedback + Public Commitment|Clinicians receive both Benchmark Peer Comparison Feedback + Public Commitment interventions.
62699915|NCT02410187|ACTIVE_COMPARATOR|Arm 1|systemic therapy+palliative RT
61952142|NCT01999114|EXPERIMENTAL|BTDS|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr
61952143|NCT01999114|EXPERIMENTAL|BTDS with naltrexone|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
61952144|NCT01999114|ACTIVE_COMPARATOR|Naltrexone|Naltrexone 50 mg tablets
61952145|NCT01999114|PLACEBO_COMPARATOR|Placebo|Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
61952146|NCT01999114|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin 400-mg tablets
61952147|NCT03883711||Patients with acute coronary syndrome or myocardial injury|Incident consecutive patients presenting with acute coronary syndrome or myocardial injury
61952148|NCT04617171|EXPERIMENTAL|Benralizumab|Benralizumab 30 mg given in the form of subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
62699916|NCT02410187|EXPERIMENTAL|Arm 2|systemic therapy+SBRT
62714812|NCT03495401|EXPERIMENTAL|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
62343261|NCT05138874|EXPERIMENTAL|Benchmark Peer Comparison Feedback + Commitment Control|Clinicians receive Benchmark Peer Comparison Feedback intervention + Commitment Control.
62500656|NCT06678087|NO_INTERVENTION|Group A control group|This is the group that receives routine antenatal care.
62500657|NCT06678087|OTHER|Group B Pregnancy School|This is a group of pregnant women who receive birth preparation training at the hospital's pregnancy school in addition to routine antenatal care.
62500658|NCT06678087|EXPERIMENTAL|group c experimental group|In addition to routine antenatal care and childbirth preparation training at the hospital's pregnancy school, this group will receive childbirth and motherhood preparation meditation training prepared with the thetahealing meditation method simultaneously with the childbirth preparation training.
62500659|NCT00462839|EXPERIMENTAL|Calibrated drapes viewed first|Caregivers were shown calibrated drape demonstrating level of blood and asked to estimate amount of blood in collection bag. These same individuals were then crossed over and shown non-calibrated drapes and asked to estimate the amount of blood they contained.
62500660|NCT00462839|ACTIVE_COMPARATOR|Non-calibrated drapes viewed first|Standard vaginal delivery drape (non-calibrated) was shown to caregiver who was asked to estimate amount of blood. These same individuals were then crossed over and shown calibrated delivery drapes and asked to estimate the amount of blood they contained.
62500661|NCT04042649|NO_INTERVENTION|pre-intervention|Critically ill patients didn't provide environmental intervention (help sleep cycle, provide comfortable environment)
62500662|NCT04042649|EXPERIMENTAL|post-intervention|After providing environmental intervention for critically ill patients
62500663|NCT01325038|ACTIVE_COMPARATOR|extra protein supplement|isometric training with addition of extra protein
62500664|NCT01325038|ACTIVE_COMPARATOR|extra food supplement|isometric exercise with addition of extra food and calories: one fast food meal/day
62500665|NCT06179563|NO_INTERVENTION|Standard telemonitoring|Patients will be monitored according to a fixed telemonitoring schedule at their treating hospitals, based on the patient's medication type and in adherence to national and international guidelines.
61952149|NCT04617171|PLACEBO_COMPARATOR|Placebo|Normal Saline given subcutaneously every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
61952150|NCT06246175|EXPERIMENTAL|A group (Healthy Control)|
61952151|NCT06246175|EXPERIMENTAL|B group (Mild Renal Impairment)|
61952152|NCT06246175|EXPERIMENTAL|C group (Moderate Renal Impairment)|
61952153|NCT06246175|EXPERIMENTAL|D group (Severe Renal Impairment)|
61952154|NCT04617587|EXPERIMENTAL|Early Intervention|All the enrolled preterm infants are assigned to receive the early neurodevelopmental intervention during the NICU stay.
61952155|NCT00521326||A|Patients with an acute coronary syndrome that are candidates for coronary angiography. Doppler results will be compared to angiographic findings.
62343262|NCT05138874|EXPERIMENTAL|Public Commitment + Feedback Control|Clinicians receive Public Commitment intervention + Feedback Control.
62343263|NCT05138874|EXPERIMENTAL|Private Commitment + Feedback Control|Clinicians receive Private Commitment intervention + Feedback Control.
62343264|NCT05138874|NO_INTERVENTION|Commitment Control + Feedback Control|Clinicians receive no intervention.
62343265|NCT06552338||Class of 2028|
62343266|NCT06552338||Class of 2029|
62343267|NCT06552338||Class of 2030|
62343268|NCT06552338||Class of 2031|
62500666|NCT06179563|EXPERIMENTAL|On-Demand Telemonitoring|Patients will have the flexibility to use the telemonitoring application at their own discretion
62500667|NCT02633241|OTHER|Dexmedetomidine (bolus and high infusion)-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg bolus, Dexmedetomidine 1 mcg/kg/hour infusion, and Propofol 100mcg/kg/minute to accomplish an MRI examination.
62500668|NCT02633241|OTHER|Dexmedetomidine (bolus and low infusion)-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg bolus, Dexmedetomidine 0.5 mcg/kg/hour infusion, and Propofol 100mcg/kg/minute to accomplish an MRI examination.
62500669|NCT02633241|OTHER|Dexmedetomidine (bolus only)-Propofol arm|Patients in this cohort will receive dexmedetomidine 1mcg/kg over 5 minutes and then propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion to accomplish MRI
62500670|NCT01115062|EXPERIMENTAL|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg)
61952156|NCT00880997|EXPERIMENTAL|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both groups were tapered off doxazosin or placebo over study weeks 14-17."
61952157|NCT00880997|PLACEBO_COMPARATOR|placebo|A sugar pill to mimic the experiment drug, doxazosin, will be administered in the same manner as the experimental drug through the study duration.
61952158|NCT02398578|EXPERIMENTAL|Amphora OAB Device|Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
61952159|NCT06450821|NO_INTERVENTION|Control Arm|Control Arm: NHS standard care pathway delivered.
61952160|NCT06450821|EXPERIMENTAL|Intervention Arm|Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \[Proactive Intensive Oral Review \& Treatment\] prior to chemotherapy.
61952161|NCT06095804|EXPERIMENTAL|Percutaneous Ultrasound Jejunostomy|Placement of a longterm jejunostomy tube using the PUMA-J System
62343269|NCT04639401|EXPERIMENTAL|persons with Multiple Sclerosis|
62343270|NCT04639401|PLACEBO_COMPARATOR|Healthy controls|
62500671|NCT01115062|EXPERIMENTAL|LMX-4 Cream|LMX-4 (liposomal lidocaine 4%) cream
62500672|NCT01115062|PLACEBO_COMPARATOR|Placebo Patch|Placebo Patch
62500673|NCT02412722|EXPERIMENTAL|Single-Agent QD Arm: Sapanisertib 3 mg|Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
62500674|NCT02412722|EXPERIMENTAL|Single-Agent QD Arm: Sapanisertib 4 mg|Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
62500675|NCT02412722|EXPERIMENTAL|Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2|Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m\^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
62699917|NCT05323344|ACTIVE_COMPARATOR|Neuro-physiotherapy|In intervention group I, patients will receive a one hour session of special Neuro-physiotherapy (NPT) twice per week with a total of 20 sessions over 10 weeks. In addition, patients will be instructed to a home-based training, so that they continue their training in between sessions and after completion of the 10 weeks intervention. NPT is designed to target the abnormal movements. It is based on previously established consensus recommendations and feasibility for a short (5 days) intervention was already tested. Adapted from Nielsen et al., each of our NPT sessions will include patient education, movement retraining and development of a self-management plan.
62699918|NCT05323344|ACTIVE_COMPARATOR|Combination of metacognitive therapy and Neuro-physiotherapy|In intervention group II, patients will be treated for 10 weeks by a combination of Metacognitive behavioral therapy (MCT) and Neuro-physiotherapy (NPT) (1 hour MCT and 1 hour NPT per week with a total of 20 treatment sessions over 10 weeks). The key feature during MCT sessions will be based on an attention training technique (ATT), which prevents or interrupts self-focused attention and reduces the overall level of preoccupation with the FMD. Patients will receive at least three competing sounds. Patients will be asked to practice the training with their eyes open and focused on a visual fixation point. Patients' self-reliance will be strengthened by an individualized cognitive self-training explained and practiced with the MCT therapist including an audio tape of the ATT training. This should be continued daily at home in between sessions and after completion of the 10 weeks intervention. Self-training will be documented in a daily training diary.
61952162|NCT01158157|OTHER|Vaccination|This study was a single arm study. All eligible subjects received ACAM2000.
61952163|NCT02273232|ACTIVE_COMPARATOR|Supervised Exercise Group|All PVD patients will get the standard advice regarding exercises but this group will have a constructed exercise program under supervision of Dr. Micheál Newell who is qualified Sports and Exercise Scientist with a Doctorate degree in Integrated Biology. This include six minute walk test, Chair Stand Test and symptoms free distance.
61952164|NCT02273232|ACTIVE_COMPARATOR|RIPC and supervised Exercise Group|This group will have structured intermitting periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be applied for 5 minutes alternatively with 5 minutes rest to the total of 4 cycles, which needs 40 minutes per day. The RIPC group will receive an exercise program identical to the first group. The total number of days for each participant will be 28 days.
61952165|NCT02273232|ACTIVE_COMPARATOR|RIPC with Standard Care Group|The patients in this group will receive standard care advice regarding exercise in addition to RIPC as in the 2nd group.
62141147|NCT01084941|ACTIVE_COMPARATOR|Standard of care group|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
62141148|NCT00729209|EXPERIMENTAL|ARRY-371797 (Schedule 1)|
61952166|NCT02273232|SHAM_COMPARATOR|Control Group (Standard Care)|This group will get the standard advice regarding exercise for PVD patients and all the information available in Out patients clinic settings.
61952167|NCT03975036|EXPERIMENTAL|Anlotinib&pd-1 antibody|Anlotinib 10mg/d,q.d.,p.o.\&pd-1 antibody 200mg/d.q.3w.d.l.v
61952168|NCT01766596|OTHER|3C cohort|
62141149|NCT00729209|EXPERIMENTAL|ARRY-371797 (Schedule 2)|
62141150|NCT00729209|PLACEBO_COMPARATOR|Placebo|
62141151|NCT02897206|EXPERIMENTAL|Imipenem group|Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)
62343271|NCT03878524|EXPERIMENTAL|Treatment (biospecimen collection, 2 drug combination)|"TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.~SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health \& Science University (OHSU).~Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity."
62500676|NCT02412722|EXPERIMENTAL|Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2|Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m\^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
61952169|NCT00552565|PLACEBO_COMPARATOR|1|
61952170|NCT00552565|EXPERIMENTAL|2|
61952171|NCT00552565|EXPERIMENTAL|Rezular 37.5mg|
61952172|NCT00552565|EXPERIMENTAL|Rezular - 75mg|
61952173|NCT05042154|NO_INTERVENTION|Standard of Care Cohort for COPD|Standard care patients will receive routine clinical management as per their treating physicians based on the GOLD Criteria.
62141152|NCT02897206|PLACEBO_COMPARATOR|Placebo group|Identical placebo administered in identical dosage, timing and duration.
62141153|NCT02669173|EXPERIMENTAL|Treatment: Capecitabine + Bevacizumab|Capecitabine, PO dose to be determined by phase 1 dose escalation, cycle length 28 days. Treated with Bevacizumab, IV, 10 mg/kg days 1, 15 every 28 days, until progression.
62141154|NCT03875313|EXPERIMENTAL|600 mg CB-839 + 1 mg Talazoparib|600 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with advanced or metastatic solid tumors.
62141155|NCT03875313|EXPERIMENTAL|800 mg CB-839 + 1 mg Talazoparib: ccRCC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received ≥ 2 prior systemic regimens including ≥ 1 vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy.
62141156|NCT03875313|EXPERIMENTAL|800 mg CB-839 + 1 mg Talazoparib: TNBC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic triple-negative breast cancer (TNBC) estrogen receptor (ER)-, progesterone receptor (PR)-, and human epidermal growth factor receptor 2 (HER2)-negative who received ≥ 1 prior line of cytotoxic chemotherapy with no prior poly adenosine diphosphate ribose polymerase (PARP) inhibitor therapy for TNBC or platinum-based chemotherapy for metastatic TNBC.
62500677|NCT02412722|EXPERIMENTAL|Single-Agent QW Arm: Sapanisertib 20 mg|Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
62500678|NCT02412722|EXPERIMENTAL|Single-Agent QW Arm: Sapanisertib 30 mg|Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
62500679|NCT03253744|EXPERIMENTAL|Cohort 1, Level 1, Arm 1: Tumor Irradiation|"Arm 1: Tumor irradiation.~Cohort 1, Level 1, Arm 1 - 40 gray (Gy) to Tumor planning target volume (PTV)~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.~External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment."
62500680|NCT03253744|EXPERIMENTAL|Cohort 1, Level 2, Arm 1 - Tumor Irradiation|"Arm 1: Tumor irradiation.~Cohort 1, Level 2, Arm 1 - 42.5 gray (Gy) to Tumor planning target volume (PTV)~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.~External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment."
62500681|NCT03253744|EXPERIMENTAL|Cohort 2, Level 1, Arm 2 - Prostate and Tumor Irradiation|"Arm 2: Prostate and tumor irradiation~Cohort 2, Level 1, Arm 2 - 30 gray (Gy) PTV to Prostate and 40 Gy to Tumor planning target volume (PTV)~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.~Brachytherapy: Participants with locally recurrent prostate cancer after treatment with brachytherapy +/- external beam radiation therapy (EBRT). These participants must have had brachytherapy as part of their treatment."
62500682|NCT03253744|EXPERIMENTAL|Cohort 2, Level 2, Arm 2 - Prostate and Tumor Irradiation|"Arm 2: Prostate and tumor irradiation~Arm 2 - 30 gray (Gy) planning target volume (PTV) to Prostate and 42.5 Gy to Tumor PTV~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.~Brachytherapy: Participants with locally recurrent prostate cancer after treatment with brachytherapy +/- external beam radiation therapy (EBRT). These participants must have had brachytherapy as part of their treatment."
62500683|NCT06182085|PLACEBO_COMPARATOR|Placebo|Daily oral administration of 3 capsules in the morning and evening.
62500684|NCT06182085|EXPERIMENTAL|PRI-002, dosage arm 1|Daily oral administration of 3 capsules in the morning and evening, lower dose.
62500685|NCT06182085|EXPERIMENTAL|PRI-002, dosage arm 2|Daily oral administration of 3 capsules in the morning and evening, higher dose.
62500686|NCT05634707|EXPERIMENTAL|Fluoxetine pre-surgery|Patients randomized to the experimental arm will receive fluoxetine at 20 mg/day for 5 days (initiation dose) followed by a maintenance dose of 40 mg/day starting on Day 6 (dose level 1) or 60 mg/day starting on Day 6 (dose level 2).
62500687|NCT05634707|ACTIVE_COMPARATOR|Temozolomide pre-surgery|Temozolomide pre-surgery (control) arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
62500688|NCT03066934||NIV Failure Group|NIV Failure Group consisted of children who failed their noninvasive ventilation session and required intubation or re-intubation
62500689|NCT03066934||NIV success group|Children who successfully managed their noninvasive ventilation therapy
62500690|NCT03255044|ACTIVE_COMPARATOR|Lipophilic statin|Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
62500691|NCT03255044|ACTIVE_COMPARATOR|Hydrophilic statin|Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
62500692|NCT06321471|OTHER|AeviceMD|This is a single site, single arm, open label medical device (AeviceMD) pilot where only intervention groups will be recruited.
62500693|NCT02427399|NO_INTERVENTION|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
62500694|NCT02427399|EXPERIMENTAL|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
62500695|NCT02427399|EXPERIMENTAL|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
61952174|NCT05042154|ACTIVE_COMPARATOR|WatchPAT Cohort|Consented patients will undergo group randomization to either standard AECOPD care or to the WatchPAT One cohort (WPC). The WPC will undergo a single night of in-hospital sleep apnea testing from 2200 to 0600 using the WatchPAT One, a portable and disposable home sleep apnea testing device (Itamar Medical, Israel \[WPAT\]).
61952175|NCT04028778|EXPERIMENTAL|Gefitinib + Anlotinib|Patients will be treated with Gefitinib 250mg, p.o., qd and anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle.
62500696|NCT02427399|EXPERIMENTAL|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
62500697|NCT02427399|EXPERIMENTAL|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
62500698|NCT01691430|ACTIVE_COMPARATOR|2 cranberry capsules|Experimental: 2 cranberry capsules
62699919|NCT01955863|ACTIVE_COMPARATOR|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
62699920|NCT01955863|EXPERIMENTAL|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
61952176|NCT04028778|PLACEBO_COMPARATOR|Gefitinib + Placebo|Patients will be treated with Gefitinib 250mg, p.o., qd and placebo to simulate anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle
61952177|NCT01468363|ACTIVE_COMPARATOR|Group 1|"Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight as needed before a dialysis session.~1. If OH is positive value, we will try to reach dry weight by ultrafiltration without regard to the level of blood pressure.~2. If OH is negative value , we will not change dry weight."
62343272|NCT03720821|EXPERIMENTAL|Cognitive Training + fMRI|"Participants will complete Trail Making Test (TMT) A \& B (both electronic and paper-pencil), the paper-pencil Color-Word Matching Stroop Test (CWMST), and its electronic version called Color Match, and a computer-based subset of NCPT (Neurocognitive Performance Test). In addition, participants will also complete Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and the Resilience Scale questionnaires at baseline.~Participants will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.~Participants will be asked to undergo 2 functional magnetic resonance imaging (fMRI) sessions. One prior to, and one after the 5-week cognitive training period."
62343273|NCT02247284|EXPERIMENTAL|group 1|patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
62343274|NCT04989504|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients receive standard of care skin management during radiation therapy for up to 6 weeks.
62343275|NCT04989504|EXPERIMENTAL|Arm II (Mepitel Film)|Patients receive Mepitel Film applied to breast or chest wall every week before radiation therapy for up to 6 weeks.
62343276|NCT02680405||Atopic Dermatitis|Subjects with Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
62343277|NCT02680405||Non Atopic Dermatitis|Subjects with no Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
62343278|NCT02346500|EXPERIMENTAL|Transrectal ultrasound|TRUS and TRUS-Robot will be used during PVP
62343279|NCT01948141|EXPERIMENTAL|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62343280|NCT05511831|EXPERIMENTAL|ketotifen|Ketotifen was added to the standard treatment within 24 hours after the completion of primary PCI for 3 months, taking 1 mg each time, 1-2 times a day according to the patient's tolerance.
62343281|NCT05511831|SHAM_COMPARATOR|Control group|Standard treatment according to guidelines
62343282|NCT04895605|EXPERIMENTAL|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
62343283|NCT04895605|PLACEBO_COMPARATOR|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
62343284|NCT03555188|EXPERIMENTAL|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
62343285|NCT03555188|PLACEBO_COMPARATOR|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
62343286|NCT00762372|EXPERIMENTAL|desflurane|
62343287|NCT00762372|EXPERIMENTAL|desflurane/N2O|
62343288|NCT00762372|ACTIVE_COMPARATOR|sevoflurane/N2O|
62343289|NCT02705508|EXPERIMENTAL|PEG group|Treatment PEG dosages were as follows: days 1 and 8,30min intravenous infusion of 1000mg/m2 gemcitabine;day1,4h intravenous infusion of 100mg/m2 etoposide,day1-3,deep intramuscular injection of 2500U/m2 Pegaspargase at three different sites.The regimen was repeated every 3 weeks.Stage IE/IIE patients underwent four cycles induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved-field radiation (IFRT) dose was 50-56 Gy.Stage IIIE/IVE patients were given for a maximum of six cycles.
62343290|NCT03000374|EXPERIMENTAL|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
62343291|NCT03886831|EXPERIMENTAL|PRT543|PRT543 will be administered orally
62343292|NCT01628094|EXPERIMENTAL|A: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin \[Copegus\] and RO5024048
62500699|NCT01691430|PLACEBO_COMPARATOR|2 placebo capsules|Experimental: 2 placebo capsules qd
61952178|NCT01468363|NO_INTERVENTION|Group 2|BCM results obtained at the beginning and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
62500700|NCT05632796|EXPERIMENTAL|tailored pfannenstiel incision according to the fetal head OFD|Pfannenstiel incision performed according to the occipitofrontal diameter of the fetal head
62500701|NCT06384287||Fluid challenge|Impact of fluid challenge on peripheral tissue perfusion on sepsis patients
62500702|NCT06384287||Vasopressors|Impact of vasopressors on peripheral tissue perfusion on sepsis patients
62500703|NCT06384287||Inotrope|Impact of dobutamine on peripheral tissue perfusion on patients with septic or cardiogenic shock
62500704|NCT02631252|EXPERIMENTAL|Open-label, Single-arm|"Hydroxychloroquine + Mitoxantrone + Etoposide~Hydroxychloroquine is given up to 21 days, started concurrently with both Mitoxantrone, administered by IVPB over 15 minutes each day for 5 days and Etoposide, administered intravenously over 2 hours each day for 5 days"
61952179|NCT02004119|PLACEBO_COMPARATOR|Placebo|
61952180|NCT02004119|EXPERIMENTAL|KHK4577|
61952181|NCT01303393||Surgery for colorectal cancer|Patients that had surgery for colorectal cancer without receiving a stoma, and their next of kin.
61952182|NCT00871533|EXPERIMENTAL|1|"REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at MAINTENANCE dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study."
61952183|NCT00871533|EXPERIMENTAL|2|No intervention / no injection control.
61952184|NCT00871533|EXPERIMENTAL|3|"PEG IFN INDUCTION: System PEG IFN-a2b given subcutaneously at INDUCTION dose level"
61952185|NCT00871533|EXPERIMENTAL|4|"REGIONAL HDI MAINTENANCE: Regional HDI given subcutaneously at MAINTENANCE dose level per standard HDI regimen"
61952186|NCT00871533|NO_INTERVENTION|5|"HDI Induction: Systemic HDI given intravenously at INDUCTION dose level per the standard HDI regimen."
61952187|NCT03478657|EXPERIMENTAL|Subjects using placebo ELLIPTA DPI|Subjects in stratum 1 and stratum 2 will be of age group from 5 to 7 years and 8 to 11 years respectively. Subjects will take placebo ELLIPTA DPI once daily. During Visit 2 (Day 28) subjects will be randomized to receive questionnaire on ELLIPTA DPI usage either version A or B.
61952188|NCT01513343|EXPERIMENTAL|Parent and child classes (prevention group)|Parent and child groups focused on self-regulation of eating
61952189|NCT01513343|NO_INTERVENTION|Treatment as usual (control group)|Treatment as usual
62343293|NCT01628094|EXPERIMENTAL|B: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin \[Copegus\] and RO5024048
62343294|NCT01628094|EXPERIMENTAL|C: GT1a 2DAA|including RO5466731, RO5190591, ritonavir and ribavirin \[Copegus\]
62343295|NCT01628094|EXPERIMENTAL|D: GT1b 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin \[Copegus\] and RO5024048
62343296|NCT01628094|EXPERIMENTAL|E: GT1b 2DAA|including RO54664731, RO5190591, ritonavir and ribavirin \[Copegus\]
62343297|NCT01628094|EXPERIMENTAL|Part II|
62500705|NCT02389595||HIV positive subjects|This group will provide a blood sample.
62500706|NCT02389595||Non-infected control subjects|This group consist of de-identified blood samples from a commercial source.
62500707|NCT06286241||HEPA-filtered room|multiple myeloma patients who received autologous stem cell transplantation were admitted in HEPA-filtered room
62500708|NCT06286241||non-HEPA-filtered room|multiple myeloma patients who received autologous stem cell transplantation were admitted in non-HEPA-filtered room
61952190|NCT00844129||Neurofibromatosis Type 1|Children with Neurofibromatosis Type 1
61952191|NCT04258865|EXPERIMENTAL|Sequence 1|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
62343298|NCT01504386|EXPERIMENTAL|TAP block|TAP block with ropivacaine
62343299|NCT01504386|PLACEBO_COMPARATOR|Placebo TAP block|Sham block with saline
62343300|NCT00878215|EXPERIMENTAL|Phase 1:Localize Anatomical Points on Liver Surface|-The surgeon will use image-guided surgery equipment to create the mapping with 3-D pictures of the participants liver. Laser range scanning will also be used to take 3-D pictures of the liver surface. The participant will then have planned standard surgery.
62500709|NCT06270095||Exposed|Aircrew exposed to a fume event
62500710|NCT06270095||Non-exposed|Aircrew not exposed to a fume event but present on a control flight
62500711|NCT02026479|EXPERIMENTAL|regular treatment comparator|Ginaton
61952192|NCT04258865|EXPERIMENTAL|Sequence 2|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
61952193|NCT04258865|EXPERIMENTAL|Sequence 3|"Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
61952194|NCT04258865|EXPERIMENTAL|Sequence 4|Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
62500712|NCT02026479|EXPERIMENTAL|Dexamethasone Phosphate low dose|5mg
62500713|NCT02026479|EXPERIMENTAL|Dexamethasone Phosphate high dose|10mg
62500714|NCT01097551||Patients with type 1 diabetes|Diabetes duration \>= 5 years, age \>= 18 and \<= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension
62500715|NCT01097551||Healthy subjects|Sex and age-matched control healthy subjects
62500716|NCT05239182|EXPERIMENTAL|9-ING-41 plus Retifanlimab plus Gem/Abraxane|"* intravenous (IV) infusion of nab-paclitaxel at a dose of 125 mg per square meter, followed by an infusion of gemcitabine according to the gemcitabine label at a dose of 1000 mg per square meter, on days 1, 8, 15 of a 28-day cycle.~* Retifanlimab 500 mg IV on day 1 of a 28-day cycle. (Retifanlimab will be administered following gemcitabine/nab-paclitaxel.)~* 9-ING-41 administered at a dose of 9.3 mg/kg by IV infusion twice weekly on Days 1 and 4 of each week of a 28-day cycle. (9-ING-41 will be administered following retifanlimab.)"
62500717|NCT05393323|EXPERIMENTAL|Distraction technique|conventional physical therapy with distraction technique
62699921|NCT01955863|EXPERIMENTAL|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
62699922|NCT03309202|EXPERIMENTAL|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
62699923|NCT03309202|EXPERIMENTAL|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
62699924|NCT03309202|EXPERIMENTAL|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
62699925|NCT03309202|EXPERIMENTAL|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
62343301|NCT00878215|EXPERIMENTAL|Phase 2: Ceramic bead|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. During the surgery, a ceramic bead will be placed in a pre-operatively determined target location within the tumor using image-guided surgery. Standard surgical procedures will then be used to remove the tumors. Magnetic resonance (MR) images of the resected liver will confirm targeting accuracy.
62343302|NCT00878215|EXPERIMENTAL|Phase 3: Ablative therapy|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. The liver tumors will be ablated using image-guided surgery. Standard surgical procedures will then be used to remove the portion of the liver that has the ablated tumors. The accuracy of the ablation will be confirmed via pathology sectioning.
62343303|NCT00878215|EXPERIMENTAL|Phase 4: Ablative therapy (not liver resection candidates)|-This phase is for patients who otherwise do not qualify to have a portion of their liver to be surgically removed. The surgeon will use image-guidance to create the mapping with 3-D pictures of the liver. The tumors will be ablated using image-guided therapy.
62343304|NCT05668312|EXPERIMENTAL|TELE-pre group|Subjects in the TELE-prehabilitation group receive remote prehabilitation using advanced technologies.
62343305|NCT05668312|ACTIVE_COMPARATOR|Control group|"The control group is composed by the Con-O (Control Older) group and the Con-Y (Control Young) group. In the Con-O group (n=24) subjects receive home-based prehabilitation using a printed booklet; in the Con-Y group (n=20) subjects do not receive any prehabilitation program.~Subjects in the Con-Y group will be recruited from patients waiting for anterior cruciate ligament reconstruction, thus they will be only assessed with muscular biopsy and blood sampling."
62343306|NCT02785952|EXPERIMENTAL|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62343307|NCT02785952|ACTIVE_COMPARATOR|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62343308|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 1|Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg
62343309|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 2|Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg
62343310|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 3|Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg
62343311|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 4|Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo
62343312|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 5|Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg
62343313|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 6|Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg
62343314|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 7|Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg
62500718|NCT05393323|EXPERIMENTAL|Traction technique|conventional physical therapy with traction technique
62699926|NCT04900298|EXPERIMENTAL|Intervention Arm|Use of SafeHaven hand hygiene system in the operating room
62699927|NCT04900298|NO_INTERVENTION|Control Arm|Standard of care hand hygiene
62699928|NCT02845414|EXPERIMENTAL|Intravenous Infusion of dCD133KDEL|
62699929|NCT05299580|EXPERIMENTAL|single arm|Patients will be treated with Dabrafenib 150 mg bid and Trametinib 2mg qd. Each cycle is 28 days and the treatment will be continued until documented disease progression, unacceptable toxicity, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons.
62699930|NCT06569355|EXPERIMENTAL|80mg dose group|Participants will receive VCT220 or placebo tables in 2 weeks dose titration period and take the maintanance dose 80 mg from week 3 to week 16.
62699931|NCT06569355|EXPERIMENTAL|120mg dose group|Participants will receive VCT220 or placebo tables in 4 weeks dose titration period and take the maintanance dose 120 mg from week 5 to week 16.
62699932|NCT06569355|EXPERIMENTAL|160mg dose group fast titration|Participants will receive VCT220 or placebo tables in 4 weeks dose titration period and take the maintanance dose 160 mg from week 5 to week 16.
62699933|NCT06569355|EXPERIMENTAL|160mg dose group slow titration|Participants will receive VCT220 or placebo tables in 6 weeks dose titration period and take the maintanance dose 160 mg from week 7 to week 16.
62699934|NCT06460532|EXPERIMENTAL|Group A: Diaphragm Manual Therapy|Group A were receiving diaphragm Manual therapy by Leon Chaitow. Subsequently, in order to indirectly stretch and mobilize the fibres of the diaphragm, diaphragmatic manual therapy was used, which should result in improved muscle contraction and reduced tension. The doming diaphragmatic technique and the manual diaphragmatic release technique, both as described by Leon Chaitow, will be among the experimental methods employed. For 10 min, both manoeuvres were performed in 2 sets of 10 repetitions each, separated by 1 min.
62714813|NCT03495401|PLACEBO_COMPARATOR|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
62699935|NCT06460532|ACTIVE_COMPARATOR|Group B: Sustained Natural Apophyseal Glide (SNAGs)|Group B has received the Sustained natural apophyseal glide (SNAGS). Treatment procedure for SNAGs was sustained natural apophyseal glides whereby the patient attempts to actively move a painful or stiff joint through its ROM while the therapist overlays an accessory glide parallel with the treatment plane. SNAG mobilization was given to a patient (as defined by Mulligan) sitting on a chair. At the same time, the treating physiotherapist stood behind by placing the medial border of the distal phalanx of the thumb on the spine of one vertebra above the affected region. The glides were given with the tip of the thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. In the session, glides were repeated six times, and three sets were given at C3-C7 cervical levels.
62699936|NCT04118101|ACTIVE_COMPARATOR|ESPB group|A total of 25 ml bupivacaine 0.5% willbe injected into the ESP.
62699937|NCT04118101|PLACEBO_COMPARATOR|Control group|The ESPB will not be performed.
62699938|NCT00737360|EXPERIMENTAL|1|
62699939|NCT04897568|NO_INTERVENTION|Control|The control group will consist of each participant and clinic before the intervention (baseline, first 2 months).
62699940|NCT04897568|ACTIVE_COMPARATOR|Patient decision aid|The intervention group will consist of each participant and clinic once they move to the intervention phase (after the first 2 months).
62699941|NCT03638375|EXPERIMENTAL|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.~* Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~* TILs are given at a dose ranging between 2.5-7.5x10\^8 T cells i.v. once every three weeks, three times per cycle."
62699942|NCT03638375|EXPERIMENTAL|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.~* IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion~* Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~* TILs are given at a dose ranging between 2.5-7.5x10\^8 T cells i.v. once every three weeks, three times per cycle."
62699943|NCT06254833|NO_INTERVENTION|regular dose ICG|
62699944|NCT06254833|ACTIVE_COMPARATOR|micro dose icg|
62343315|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 8|Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo
62343316|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 9|"Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:~Phentermine 45 mg"
62343317|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 10|Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg
62343318|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 11|Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg
62343319|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 12|Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg
62343320|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 13|Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg
62343321|NCT01500018|EXPERIMENTAL|Crossover Treatment Sequence 14|Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg
62343322|NCT03064958|ACTIVE_COMPARATOR|Control|Consumption of a high fat meal (1000kcal, 45g fat)
62343323|NCT03064958|EXPERIMENTAL|Spice 2g|Consumption of a high fat meal (1000kcal, 45g fat) with 2g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
62343324|NCT03064958|EXPERIMENTAL|Spice 6g|Consumption of a high fat meal (1000kcal, 45g fat) with 6g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
62343325|NCT03431701|EXPERIMENTAL|Group chlorhexidine|Patients will receive chlorhexidine abdominal and vaginal scrubbing
62343326|NCT03431701|ACTIVE_COMPARATOR|Group iodine|Patients will receive iodine abdominal and vaginal scrubbing
62343327|NCT00144755|ACTIVE_COMPARATOR|R-CHOP21|8 cycles of R-CHOP21
62343328|NCT00144755|EXPERIMENTAL|R-CHOP21, Darbepoetin alfa|8 cycles of R-CHOP21 + prophylactic darbepoetin alfa
62343329|NCT00144755|EXPERIMENTAL|R-CHOP14|8 cycles of R-CHOP14
62343330|NCT00144755|EXPERIMENTAL|R-CHOP14, Darbepoetin alfa|8 cycles of R-CHOP14 + prophylactic darbepoetin alfa
62343331|NCT00156299|EXPERIMENTAL|Dexamethasone plus Choline Magnesium Trisalicylate|Dexamethasone plus Choline Magnesium Trisalicylate
62343332|NCT00156299|EXPERIMENTAL|Choline Magnesium Trisalicylate|Choline Magnesium Trisalicylate
62343333|NCT02568345|EXPERIMENTAL|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
62343334|NCT05217953|EXPERIMENTAL|Test Group|"The CGM will be integrated with the users mobile handset and all relevant measures taken will be entered. Participant will be provided with a smart watch and this will also be integrated with the users smartphone.~The user will then download and install the LovedBy mobile app. Once installed the user will set up an account and the account number will be recorded by the clinical research team to track the participant throughout the trial. The final step is to review the permissions of the mobile application and allow the mobile application to connect to the users handset"
62343335|NCT05217953|NO_INTERVENTION|Control-Group|The same measurements will be taken as with the test group but here no app will be provided to the participants in this group.
62343336|NCT00145249|ACTIVE_COMPARATOR|Standard Therapy|Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
61952195|NCT04258865|EXPERIMENTAL|Sequence 5|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
61952196|NCT04258865|EXPERIMENTAL|Sequence 6|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions"
62141157|NCT03875313|EXPERIMENTAL|800 mg CB-839 + 1 mg Talazoparib: CRC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with with incurable/locally advanced or metastatic colorectal cancer (CRC) who received appropriate oxaliplatin or irinotecan- and fluorouracil (5-FU)-based chemotherapy with or without bevacizumab.
62141158|NCT03875313|EXPERIMENTAL|800 mg CB-839 + 1 mg Talazoparib: Other Histology|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with other tumor types (prostate, urinary bladder, pancreas, and stomach).
62343337|NCT00145249|EXPERIMENTAL|Fluconazole Low Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
62343338|NCT00145249|EXPERIMENTAL|Fluconazole High Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
62343339|NCT01319110|EXPERIMENTAL|CoenzymeQ10|Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
62343340|NCT01319110|PLACEBO_COMPARATOR|Placebo|Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). Placebo will be given through pre-existing NG or OG tube.
62343341|NCT05160558|EXPERIMENTAL|Cohort 1: BIIB132 Dose 1 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 1 or matching placebo, intrathecally (IT), every 4 weeks (Q4W), up to Day 85.
62343342|NCT05160558|EXPERIMENTAL|Cohort 2: BIIB132 Dose 2 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 2 or matching placebo, IT, Q4W, up to Day 85.
62343343|NCT05160558|EXPERIMENTAL|Cohort 3: BIIB132 Dose 3 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 3 or matching placebo, IT, Q4W, up to Day 85.
62343344|NCT05160558|EXPERIMENTAL|Cohort 4: BIIB132 Dose 4 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 4 or matching placebo, IT, Q4W, up to Day 85.
62343345|NCT05160558|EXPERIMENTAL|Cohort 5: BIIB132 Dose 5 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 5 or matching placebo, IT, either Q4W or every 12 weeks (Q12W), up to Day 85 or every 8 weeks (Q8W) up to Day 57.
62343346|NCT00839878||A|
62343347|NCT03675438|EXPERIMENTAL|Sub-epitheilal TCA Inlay|Implantation of a sub-epithelial presbyopia corrective inlay using TCA technology
62343348|NCT05108519||Observational (medical records review)|Patients' medical records are reviewed.
61952197|NCT04273204|EXPERIMENTAL|UCP Group|
62343349|NCT02232087|EXPERIMENTAL|test product A|salmeterol and fluticasone propionate, 2 puffs
61952198|NCT04273204|OTHER|Control Group|
62343350|NCT02232087|ACTIVE_COMPARATOR|reference product D|salmeterol and fluticasone propionate, 2 puffs
62343351|NCT02232087|EXPERIMENTAL|test product B|salmeterol and fluticasone propionate, 6 puffs
62343352|NCT02232087|ACTIVE_COMPARATOR|reference product E|salmeterol and fluticasone propionate, 6 puffs
62699945|NCT04602260||Prospective Cohort|The prospective cohort will assess patients upon admission to general internal medicine, at hospital discharge, and at 3, 6, 9, and 12-month follow-up.
62699946|NCT04602260||Retrospective Cohort|The retrospective cohort will assess patients at 3, 6, 9, and 12-months after being discharged from the hospital.
61952199|NCT04427371||survivors|Improve or under treatment
61952200|NCT04427371||nonsurvivors|all-cause 28-day mortality
61952201|NCT05116475|EXPERIMENTAL|Arm A|Arm A: ADT + Intensity-Modulated Image-Guided Radiation Therapy + Darolutamide ADT will be associated with LHRH agonists or antagonists for 24 months4. Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
62343353|NCT02232087|EXPERIMENTAL|test product C|salmeterol and fluticasone propionate, 12 puffs
62343354|NCT02232087|ACTIVE_COMPARATOR|reference product F|salmeterol and fluticasone propionate, 12 puffs
62343355|NCT03941236|EXPERIMENTAL|Dasiglucagon open-label|Dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
62343356|NCT01093001|ACTIVE_COMPARATOR|Lead size|The pacemaker lead will be \< or = to 7Fr. The ICD lead will be 9 Fr.
62343357|NCT01093001|ACTIVE_COMPARATOR|RV Lead position|50 patients will be randomized to RV apex lead placement.
62343358|NCT01093001|ACTIVE_COMPARATOR|Mid-Septum Lead position|50 patients will be randomized to RV mid-septum lead placement.
62343359|NCT01093001|ACTIVE_COMPARATOR|CS lead position|50 patients will have lead placed in the CS
62343360|NCT05902819|EXPERIMENTAL|PTSD intervention group|30 individuals with PTSD will receive imagery with minocycline.
62343361|NCT05902819|PLACEBO_COMPARATOR|PTSD control group|30 individuals with PTSD will receive imagery with placebo.
62343362|NCT05902819|EXPERIMENTAL|CUD intervention group|30 individuals with CUD will receive imagery with minocycline.
62343363|NCT05902819|PLACEBO_COMPARATOR|CUD control group|30 individuals with CUD will receive imagery with placebo.
62343364|NCT05902819|NO_INTERVENTION|Healthy control group|30 healthy individuals who will not receive any intervention.
62343365|NCT05902819|NO_INTERVENTION|Clinical control group|30 individuals with both PTSD and CUD who will not receive any intervention
62343366|NCT02559206|EXPERIMENTAL|30 μg linaclotide DR1 and placebo|
62343367|NCT02559206|EXPERIMENTAL|100 μg linaclotide DR1 and placebo|
61952202|NCT05116475|PLACEBO_COMPARATOR|Arm B|"Arm B: ADT + Intensity-Modulated Image-Guided Radiation Therapy + Placebo of Darolutamide~ADT will be associated with LHRH agonists or antagonists for 24 months4. Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months."
62500719|NCT04095624|EXPERIMENTAL|Opioid Taper Group|Patients randomized to the taper group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive a scheduled tapering protocol, with a goal of 10-15% reduction in their weekly opioid use, along with weekly phone calls from a study coordinator assessing their ability to taper and pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
62343368|NCT02559206|EXPERIMENTAL|300 μg linaclotide DR1 and placebo|
62343369|NCT02559206|EXPERIMENTAL|30 μg linaclotide DR2 and placebo|
62699947|NCT05849207|EXPERIMENTAL|Open Arm|All patients will receive cyclophosphamide on Day +3 and Day +4 following transplant.
62699948|NCT03616340|EXPERIMENTAL|Ketorolac|
61952203|NCT01645345|OTHER|RF Pixel handpiece treatment|There is only one arm, and that is a treatment arm. For patients with wrinkles and acne scars, they are being treated with the RF Pixel handpiece to decrease the appearance of these cosmetic deficiencies. The improvement is documented in before and after photographs.
61952204|NCT03026660|EXPERIMENTAL|Moringa treatment|Moringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
61952205|NCT03026660|PLACEBO_COMPARATOR|Placebo|The placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
61952206|NCT01234285|EXPERIMENTAL|intravenous heparin aPTT 40-50 seconds|Patients 11-15: IV heparin, target aPTT range 40-50 seconds
61952207|NCT01234285|EXPERIMENTAL|intravenous heparin|Patients 26-40: IV heparin, target range aPTT 50-60 seconds
61952208|NCT01234285|EXPERIMENTAL|Intravenous heparin|Patients 41-55 IV heparin, target aPTT range 60-70 seconds
61952209|NCT01234285|ACTIVE_COMPARATOR|sq heparin three times a day|Patients 1-10 will receive subcutaneous heparin three times a day
62343370|NCT02559206|EXPERIMENTAL|100 μg linaclotide DR2 and placebo|
62343371|NCT02559206|EXPERIMENTAL|300 μg linaclotide DR2 and placebo|
62343372|NCT02559206|EXPERIMENTAL|290 μg linaclotide IR and placebo|
62343373|NCT02559206|PLACEBO_COMPARATOR|Placebo|
62343374|NCT05176496||Cohort 1|Women with a continuous observation of 365 days after January 1st, 2000 and before December 31, 2020.
62343375|NCT05176496||Cohort 2|Women diagnosed with HMB.
62343376|NCT02126943||Opsumit (macitentan)|10 mg tablets
62343377|NCT04573205|EXPERIMENTAL|> 50 years|"Healthy individuals \> 50 years of age divided into age groups 50-59 years, 60-69 years and \>70 years, approximately 20 participants in each group.~Vaccinated with 4 doses FSME immune Adult intramuscular injection according to the recommended primary vaccine Schedule in Sweden for individuals \> 50 years of age, at time 0, 1, 2 and 7 months."
62343378|NCT04573205|ACTIVE_COMPARATOR|< 40 years|Healthy individuals \< 40 years of age. Vaccinated with 3 doses FSME immune Adult intramuscular injection according to the standard recommended primary vaccine at time 0, 1, and 7 months.
62343379|NCT04198103|EXPERIMENTAL|SoracteLite|Transperineal Focal Laser Ablation (TPLA)
62343380|NCT05113173||Type I Achalasia|Severe loss of ganglion cells,loss of ICCs.
62699949|NCT03616340|EXPERIMENTAL|Kenalog|
62699950|NCT06251310|EXPERIMENTAL|Phase 1 Dose Escalation Cohorts Ranging in Dose|Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort.
61952210|NCT02672826|EXPERIMENTAL|adipose tissue surgery|The adipose tissue surgery (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated.
61952211|NCT05540457|EXPERIMENTAL|Non-Invasive Blood Pressure (NIPB)Monitors|"NIPB Tablo Brachial Cuff (Intermittent): Will be placed contralateral to the access arm. Blood pressure measurements will be collected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~VitalStream Monitor (Continuous):A cuff will be applied to the middlefinger ipsilateral to the accessarm. Blood pressuremeasurements will be collectedpre-dialysis, continuously duringdialysis, and post-dialysis."
61952212|NCT04798963|OTHER|On-clamp partial nephrectomy|Patients who are assigned to on-clamp partial nephrectomy.
61952213|NCT04798963|OTHER|Off-clamp partial nephrectomy|Patients who are assigned to off-clamp partial nephrectomy.
61952214|NCT06230432||healthy control|
62343381|NCT05113173||Type II Achalasia|Loss of ICCs, mild loss of ganglion cells.
62343382|NCT05113173||Type III Achalasia|Preserved ICCs, less loss of ganglion.
62343383|NCT02778633||Sepsis|Patients diagnosed with septic shock, admitted to the intensive care unit, with a good left ventricular ejection fraction without significant co-morbidity are highly eligible for this study. Patients must be equipped with a pulse-contour cardiac output (PICCO)-system with a central venous catheter which will be applied by the intensivist on admission.Patients will be subsequently connected to the hemodynamic monitoring device Navigator™. In those patients with clinical signs of inadequate tissue perfusion, passive leg raising and standardized fluid challenge will be performed.
62343384|NCT06388330|EXPERIMENTAL|low FODMAP diet|
62343385|NCT01011985||AVF|Initial access is an AVF
62343386|NCT01011985||AVG|Initial vascular access is an AVG
62343387|NCT01011985||TC|Initial vascular access is a tunneled catheter, with or without a maturing AVF or AVG
62343388|NCT00296660||1|Proven acute HIV-1 infection
62343389|NCT00296660||1A|Sexual partners of members of Group 1
62343390|NCT00296660||2|Established HIV-infection
62343391|NCT00296660||3|HIV-1 uninfected
62343392|NCT06390254|EXPERIMENTAL|resilience-building nursing intervention.|Participants receiving the resilience-building nursing intervention.
62343393|NCT06390254|NO_INTERVENTION|Control|Participants receiving standard care or placebo, depending on the design of your study.
62699951|NCT06251310|EXPERIMENTAL|Part 2 Dose Expansion Cohort 1|Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.
61952215|NCT06230432||mild acute pancreatitis|
61952216|NCT06230432||moderately severe acute pancreatitis|
61952217|NCT06230432||severe acute pancreatitis|
62699952|NCT06251310|EXPERIMENTAL|Part 2 Dose Expansion Cohort 2|Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.
62699953|NCT06251310|EXPERIMENTAL|Part 2 Dose Expansion Cohort 3|Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.
62699954|NCT06251310|EXPERIMENTAL|Part 2 Dose Expansion Cohort 4|Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data.
62699955|NCT06344416|EXPERIMENTAL|Control Study Group|"The control group of the study is designed to capture baseline data especially regarding ribo therapy duration of patients prescribed with ribociclib. Data will be collected by reviewing historical patient records as captured within the electronic medical record (chart review) by recording demographics, International Classification of Diseases (ICD-10) codes, prescription fill rates and Current Procedural Terminology (CPT) codes. De-identified data of patients treated with ribociclib for HR+/HER2 negative metastatic Breast Cancer (mBC) during June 2022 to April 2024 and collated in a de-identified database by Dosentrx will be retrospectively analyzed. The results of the treatment duration for these participants will be used as a baseline for the ReX study group.~A minimum of 50 and a maximum of 200 patient charts are expected to be reviewed for the control study group."
62699956|NCT06344416|EXPERIMENTAL|ReX Platform Study Group|The ReX platform study group will utilize data, collected from the same study sites that were chosen for control study group. A database consisting of at least fifty (50) female and male participants who initiated ribociclib for metastatic breast cancer and signed IRB research consent will be used for ReX study group. This group will include participants who started the recommended ribo dose of 600 mg QD and additional doses, delivered by the ReX technology platform. Physical examinations and laboratory tests will be performed in accordance with routine clinical practice; however, these parameters will not be collected for the study.
62699957|NCT03690245|ACTIVE_COMPARATOR|Control|Infants will have immediate cord clamping and respiratory support afterwards
61952218|NCT01015209|ACTIVE_COMPARATOR|Cohort 1: 18 healthy subjects|18 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3% (6 subjects per group)
61952219|NCT01015209|ACTIVE_COMPARATOR|Cohort 2: 12 healthy patients|12 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3%
61952220|NCT02354495|EXPERIMENTAL|Diet intervention arm|Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
61952221|NCT06556732|EXPERIMENTAL|Study arm|Were given Eplereone 25 mg daily
61952222|NCT06556732|PLACEBO_COMPARATOR|Control arm|Were given nothing
62141159|NCT00864006|EXPERIMENTAL|1|Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
62141160|NCT00864006|ACTIVE_COMPARATOR|2|Depakote 125 MG DR Tablets Abbott Laboratories USA
62141161|NCT05362942|EXPERIMENTAL|venetoclax + Hypomethylation agent + low-dose cytarabine treatment group|patients treated with venetoclax combined with decitabine/azacytidine and low-dose cytarabine
62141162|NCT06550804|EXPERIMENTAL|A-TEAM|This arm receives the A-TEAM approach where the men, their social support (if they have one), and their case manager participate. If the adherence device identifies non-opening of the device, the men are alerted by text or email the same day. If the device identifies non-opening of the device two days in a row, the social support (or case manager) is notified, and if 7 days of non-opening is detected, the case manager is notified.
62141163|NCT06550804|NO_INTERVENTION|Control|The men are monitored with the adherence device but there is no intervention on their adherence - they otherwise experience routine care and they don't receive alerts if they the device detects non-openings.
62141164|NCT05599815|EXPERIMENTAL|ADX-629|
62141165|NCT01617707|ACTIVE_COMPARATOR|conventional sedation group|midazolam
62141166|NCT01617707|EXPERIMENTAL|BPS group|midazolam plus propofol
62141167|NCT02025504|EXPERIMENTAL|ColoWrap Intervention Group|Patients randomized to ColoWrap Intervention Group will have the ColoWrap abdominal binder secured firmly around their lower abdomen just prior to colonoscopy.
62141168|NCT02025504|SHAM_COMPARATOR|Sham Group|Sham Group will also have a ColoWrap binder placed around their lower abdomen, but it will be placed loosely so no appreciable lower abdominal pressure is generated by the device.
62141169|NCT01566890|EXPERIMENTAL|Regadenoson ARM|Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
62141170|NCT01566890|OTHER|Sickle Cell Controls ARM|Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
62141171|NCT01566890|OTHER|Sickle Cell CEU ARM|Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
62141172|NCT01566890|OTHER|Healthy Control ARM|Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound
62141173|NCT01566890|OTHER|Technique Optimization Controls|Healthy volunteers will undergo contrast-enhanced ultrasound.
62699958|NCT03690245|EXPERIMENTAL|Initiation of Resuscitation While Attached to the Cord|Infants will receive respiratory support for 120 seconds while attached to the cord.
62699959|NCT06153264|EXPERIMENTAL|Control Group|Upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
61952223|NCT05595941|EXPERIMENTAL|TELEYOG'AVC Group|The subjects of the experimental group will be invited to participate in 60-minute tele-yoga sessions, twice a week, for 12 weeks. The sessions will take place via the Zoom videoconference software, in small groups (maximum 5 people) in order to adapt the practice to the possibilities of each subject. In addition, an additional weekly session, independently at home, will be recommended to participants, accompanied by a pre-recorded video support hosted on YouTube.
61952224|NCT05595941|NO_INTERVENTION|Wainting list Group|The subjects in the control group will be asked not to change their habits during the entire experimental phase (T0-T1). They will be able to benefit in turn from the tele-yoga program (free of charge), if they wish, once the evaluations in T1 are completed.
62141174|NCT06685809|EXPERIMENTAL|FZ008-145 solution- Part A|All participants will receive single dose of oral FZ008-145 solution or placebo.
62500720|NCT04095624|ACTIVE_COMPARATOR|Control Group|Patients randomized to the control group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive no recommendation or guidance in their preoperative opioid pain medication use, but will received weekly phone calls from a study coordinator assessing their preoperative pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
61952225|NCT03307967|EXPERIMENTAL|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
61952226|NCT02294955|ACTIVE_COMPARATOR|Catheterablation|Pulmonary vein isolation with Cryo-energy using a Arctic Front™ Cardiac CryoAblation Catheter or an irrigated radiofrequency ablation catheter, with an optional roof line.
61952227|NCT02294955|ACTIVE_COMPARATOR|Antiarrhythmic drug Class IC or III.|Serial testing of oral antiarrhythmic drugs; amiodarone 600 mg once daily 7-10 days, then 100-200 mg once daily; sotalol: 80-160 mg twice daily; flecainide 100 to 150 mg twice daily or entire dose as slow-release formula once daily; propafenone 300 mg twice daily; disopyramide 250-375mg twice daily, or dronedarone 400 mg twice Daily.
61952228|NCT02092831|EXPERIMENTAL|Crossover sequence 1|
61952229|NCT02092831|EXPERIMENTAL|Crossover sequence 2|
61952230|NCT02092831|EXPERIMENTAL|Crossover sequence 3|
61952231|NCT02092831|EXPERIMENTAL|Crossover sequence 4|
61952232|NCT05853185|EXPERIMENTAL|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
61952233|NCT05853185|ACTIVE_COMPARATOR|EBRRM®|Patients in this group will receive the pulpotomy with Endosequence Bioceramic Root Repair Material (EBRRM)®.
61952234|NCT05281679|EXPERIMENTAL|Low-intensity resistance exercise with blood flow restriction group (L-BFR).|All the participants in the low-intensity resistance exercise with blood flow restriction group (L-BFR) will receive 3 sessions of low-intensity resistance training with blood flow restriction for a total of 5 weeks.
61952235|NCT05281679|ACTIVE_COMPARATOR|High-intensity resistance exercise without blood flow restriction group (H-BFR).|All the participants in the high-intensity resistance exercise without blood flow restriction group (H-BFR) will receive 3 sessions of high-intensity resistance training without blood flow restriction for a total of 5 weeks.
61952236|NCT00977860|OTHER|SBRT|
61952237|NCT01972568|EXPERIMENTAL|Atacicept 75 mg|
61952238|NCT01972568|EXPERIMENTAL|Atacicept 150 mg|
61952239|NCT01972568|PLACEBO_COMPARATOR|Placebo|
61952240|NCT02562534|OTHER|Patients with conductive troubles|Patients with conductive troubles
62141175|NCT06685809|EXPERIMENTAL|FZ008-145 tablet- Part B|All participants will receive single dose of oral FZ008-145 tablet or placebo.
62343394|NCT02237976|EXPERIMENTAL|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
62343395|NCT02237976|ACTIVE_COMPARATOR|Routine practice|No specific intervention
62343396|NCT06112002|EXPERIMENTAL|Health Services Research (educational session and materials)|Participants attend an educational session with CHEs and receive educational materials on study.
62343397|NCT01467648|EXPERIMENTAL|0.5 g by 4 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 4 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
62343398|NCT01467648|EXPERIMENTAL|0.5 g by 1 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 1 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
62343399|NCT01938690|SHAM_COMPARATOR|Sham stimulation|Sham stimulation on the scalp of unaffected brain
62343400|NCT01938690|EXPERIMENTAL|transcranial magnetic stimulation|transcranial magnetic stimulation on unaffected brain
62343401|NCT02300896|EXPERIMENTAL|Intervention|Group-based exercise training during hospitalization Procedure: Exercise training. Individual program training 5 days a week during hospitalization
62343402|NCT02300896|NO_INTERVENTION|Control|Usual care including rehabilitation when necessary
62343403|NCT03337555|ACTIVE_COMPARATOR|Macintosh|intubation using Macintosh direct laryngoscope
62343404|NCT03337555|EXPERIMENTAL|McGrath|intubation using McGrath MAC®
61952241|NCT02562534|OTHER|Patients with rhythm troubles|Patients with rhythm troubles
61952242|NCT02562534|OTHER|Volunteers|Volunteers with normal ECG
61952243|NCT00677729|ACTIVE_COMPARATOR|1|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline (NaCl)
62343405|NCT03337555|EXPERIMENTAL|Pentax|intubation using Pentax-airway scope®
62343406|NCT05800106|EXPERIMENTAL|Sunitinib malate capsules generic product|Single dose of Sunitinib malate capsule under fed condition on Day 1 and Day 29, respectively.
62343407|NCT05800106|ACTIVE_COMPARATOR|Sunitinib malate capsules reference product|Single dose of Sunitinib malate capsule under fed condition on Day 1 and Day 29, respectively.
62343408|NCT02136199|OTHER|Active Implementation of Share EBM Toolkit|Investigators led implementation of tailored activities and tactics (Shared EBM Toolkit) designed to promote the use of the decision aids in clinical encounters (i.e. journal clubs, value map streaming).
62500721|NCT06055309|EXPERIMENTAL|Cannabis (up to three doses)|Brownies containing a dose of cannabis
62500722|NCT06679140|EXPERIMENTAL|ibuzatrelvir|Ibuzatrelvir administered orally every 12 hours (twice daily) for a total of 5 days.
62500723|NCT06679140|PLACEBO_COMPARATOR|placebo|placebo administered orally every 12 hours (twice daily) for 5 days.
62343409|NCT02136199|OTHER|Passive Implementation of Share EBM Toolkit|Locally supported dissemination of Shared EBM Toolkit designed to promote the use of the decision aids in clinical encounters.
62500724|NCT01493596|OTHER|CPP-115 Dose 1|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
62500725|NCT01493596|OTHER|CPP-115 Dose 2|2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
62500726|NCT01493596|OTHER|CPP-115 Dose 3|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
62500727|NCT01493596|OTHER|CPP-115 Dose 4|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
62500728|NCT01493596|OTHER|CPP-115 Dose 5|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
62500729|NCT01493596|OTHER|CPP-115 Dose 6|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
62500730|NCT02497079|EXPERIMENTAL|Nested PCR for formalin-fixed tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with formalin-fixed paraffin-embedded specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
62500731|NCT02497079|EXPERIMENTAL|Nested PCR for fresh tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
62500732|NCT02497079|EXPERIMENTAL|Real-time PCR for fresh tissues|In all patients, real-time polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
62500733|NCT02987634|EXPERIMENTAL|PeriActive mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive
62500734|NCT02987634|ACTIVE_COMPARATOR|chlorhexidine 0.12% mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive
62343410|NCT03579550|ACTIVE_COMPARATOR|Intervention arm: Hysterocopy group|Office hyteroscopic metroplasty will be performed. After oparetion 9 months spontaneous conception Intervention arm for hysteroscopy group
62343411|NCT03579550|NO_INTERVENTION|Spontaneous cycles plus COH/IUI|Six months spontaneous coitus cycles plus 3 cycles of Clomiphene citrate and intrauterine insemination (COH/IUI)
62343412|NCT05091229||Cohort A|Blood specimen collection. Study samples must be collected prior to any treatment.
62500735|NCT01165476|ACTIVE_COMPARATOR|manufacturer #1|treprostinil diethanolamine from manufacturer #1
62500736|NCT01165476|EXPERIMENTAL|manufacturer #2|treprostinil diethanolamine from manufacturer #2
62500737|NCT06490770|OTHER|group 1|
62699960|NCT06153264|EXPERIMENTAL|Study Group|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
61952244|NCT00677729|PLACEBO_COMPARATOR|2|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl)
61952245|NCT00025363|EXPERIMENTAL|Arm I|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
61952246|NCT00025363|EXPERIMENTAL|Arm II|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
61952247|NCT02225561|EXPERIMENTAL|Intervention arm|Pharmaco- mechanical optimization
61952248|NCT02225561|ACTIVE_COMPARATOR|Mechanical optimization only|Mechanical optimization only
62343413|NCT05091229||Cohort B|Blood specimen collection. Study samples must be collected prior to any treatment.
62343414|NCT05091229||Cohort C|Blood specimen collection. Study samples must be collected prior to any treatment.
62343415|NCT00510224|EXPERIMENTAL|1|
62343416|NCT02178293|ACTIVE_COMPARATOR|Benzidamine hydrochloride|
62343417|NCT02178293|EXPERIMENTAL|Ketoprofen lysine salt|
62343418|NCT05463042|EXPERIMENTAL|Intermittent Hypoxia|Participants will receive intermittent hypoxia and perform balance and gait assessments before and after the intermittent hypoxia session.
62343419|NCT05463042|SHAM_COMPARATOR|Normoxia (sham)|Participants will receive normoxia and perform balance and gait assessments before and after the normoxia session.
62343420|NCT04148599|ACTIVE_COMPARATOR|dexmedetomidine|dexmedetomidine ( precedex) infusion will be administered preoperatively and continued intraoperatively
62343421|NCT04148599|ACTIVE_COMPARATOR|lidocaine|Lidocaine (Xylocaine) infusion will be administered preoperatively and continued intraoperatively
62343422|NCT04148599|PLACEBO_COMPARATOR|placebo|saline infusion will be administered preoperatively and continued intraoperatively
62343423|NCT04202653|ACTIVE_COMPARATOR|Naive:ETV|Entecavir 0.5 mg po daily for 24 weeks in naive patients
62343424|NCT04202653|EXPERIMENTAL|Naive:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in naive patients
62343425|NCT04202653|EXPERIMENTAL|Naive:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus inhibitor of TQ-B2450 for 24 weeks in naive patients
62343426|NCT04202653|ACTIVE_COMPARATOR|Experienced:ETV|Entecavir 0.5 mg po daily for 24 weeks in treatment experienced patients
62343427|NCT04202653|EXPERIMENTAL|Experienced:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in treatment experienced patients
62500738|NCT05956756|EXPERIMENTAL|Intervention|Occupational therapy students will engage in health and resiliency programming as part of their course work over their three year program.
62500739|NCT04873245|ACTIVE_COMPARATOR|Intensive Behavioral Program Arm|"Participants randomized to this arm of the study will receive intensive behavioral therapy.~Participants will receive 52 weekly sessions (50% in person and 50% virtual)."
62500740|NCT04873245|ACTIVE_COMPARATOR|Medication Arm|Participants randomized to this arm of the study will receive semaglutide and will receive behavioral therapy. Behavioral therapy will consist of 12 monthly sessions (50% in person and 50% virtual).
61952249|NCT06447740|EXPERIMENTAL|Stenting plus OMT with FFR <0.80|
61952250|NCT06447740|PLACEBO_COMPARATOR|OMT alone with FFR < 0.80|
61952251|NCT06447740|OTHER|OMT alone with FFR ≥0.80|
61952252|NCT05739188|EXPERIMENTAL|Anti-GPRC5D CAR-T|Subjects who meet the enrollment conditions will receive intravenous infusion of anti--GPRC5D CAR-T Cells after lymphodepleting therapy.
61952253|NCT03694587|ACTIVE_COMPARATOR|Test IMP|
61952254|NCT03694587|ACTIVE_COMPARATOR|Reference IMP|
61952255|NCT01988688|EXPERIMENTAL|Bilateral DBS placement in area LC|Bilateral DBS placement in area LC. Devices include Medtronic Activa DBS model 3387 and 3389; Medtronic DBS extension; Medtronic Activa PC or Activa RC neurostimulator; Medtronic Patient Programmer; Medtronic Test Stimulator; Medtronic N/Vision Clinician Programmer
61952256|NCT05638178||Adult|18+
61952257|NCT05638178||Pediatric|Under 18
61952258|NCT02008760|PLACEBO_COMPARATOR|vegetable oil with betacarotene|4 capsules vegetable oil with betacarotene
61952259|NCT02008760|ACTIVE_COMPARATOR|krill and vitamin D3|krill and vitamin D3. (72 mg), four capsules daily
61952260|NCT01626430|EXPERIMENTAL|200 mg gd-TRF|
61952261|NCT01626430|EXPERIMENTAL|400 mg gd-TRF|
61952262|NCT01626430|EXPERIMENTAL|Placebo|
61952263|NCT04279457|ACTIVE_COMPARATOR|Standardized Hydration protocol|These cases will follow Charleston Area Medical Centers standard Hydration protocol
62500741|NCT02999698||Psoriasis Group|Patients with psoriasis complete the questionnaires for psychological impact.
62699961|NCT05077384|EXPERIMENTAL|Surufatinib|Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
62699962|NCT03477422|EXPERIMENTAL|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|"CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was an Experimental drug in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. It was administered twelve hourly through intravenous route as infusion over 30 minutes. The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the Principal Investigator (PI).~Interventions:~* Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)~* Drug: Matching Placebo"
61952264|NCT04279457|ACTIVE_COMPARATOR|Hydration + Device|These cases will follow Charleston Area Medical Centers standard hydration protocol plus use the DyeVert Plus System
61952265|NCT04253223|EXPERIMENTAL|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses
61952266|NCT06435676|EXPERIMENTAL|SAD Stage: HRS9531|Administered po once
61952267|NCT06435676|PLACEBO_COMPARATOR|SAD Stage: placebo|Administered po once
61952268|NCT06435676|EXPERIMENTAL|MAD Stage: HRS9531|Administered po for multiple dose
61952269|NCT06435676|PLACEBO_COMPARATOR|MAD Stage: placebo|Administered po for multiple dose
62500742|NCT02999698||Hidradenitis Suppurativa Group|Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
62699963|NCT03477422|ACTIVE_COMPARATOR|Meropenem|"Meropenem was the active comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg. It was administered eight hourly through intravenous route as infusion over 30 minutes.The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the PI.~Interventions:~* Drug: Meropenem~* Drug: Matching Placebo"
62699964|NCT06317987|EXPERIMENTAL|Care Navigation (pilot)|Mental health care coordinators are able to offer and refer patients to a care navigator in addition to offering substance use resources and treatment options as usual.
62699965|NCT06317987|NO_INTERVENTION|Services as Usual (pilot)|Mental health care coordinators will continue offering substance use resources and treatment options to patients as usual
62714814|NCT00342927||Volunteers|Volunteers for a genetic study of diabetes and nephropathy
61952270|NCT00705289||RA Subjects/ Infliximab 3 mg/kg|Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics \[SPC\] of Remicade®).
61952271|NCT02554500|EXPERIMENTAL|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
61952272|NCT02554500|EXPERIMENTAL|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
62714815|NCT01595477|EXPERIMENTAL|Mind-Body Skills Groups|
61952273|NCT02554500|EXPERIMENTAL|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
61952274|NCT02554500|EXPERIMENTAL|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
61952275|NCT02554500|EXPERIMENTAL|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
61952276|NCT05961579|EXPERIMENTAL|Barrier Renew Cleanser, Barrier Renew PM Moisturizer, and mineral sunscreen.|Enrolled subjects will all receive Barrier Renew Cleanser, Barrier Renew PM Moisturizer, and mineral sunscreen. Cleanser and Barrier Renew PM moisturizer will be used twice daily. Mineral sunscreen will be used every morning and throughout the day as indicated.
61952277|NCT00568997||1|Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus
62500743|NCT00557245|ACTIVE_COMPARATOR|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
61952278|NCT03573739|EXPERIMENTAL|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
61952279|NCT03573739|ACTIVE_COMPARATOR|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
61952280|NCT02711592|OTHER|Genetic Panel for Analgesics|Genetic testing for analgesics prior to surgery will be conducted. The subject will receive postoperative analgesia based on test results.
61952281|NCT01234441|SHAM_COMPARATOR|Control|This group of patients will receive a non-nutritive beverage, and no exercise.
61952282|NCT01234441|ACTIVE_COMPARATOR|Protein|This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session
61952283|NCT01234441|ACTIVE_COMPARATOR|Protein + Exercise|This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment
61952284|NCT02300246|EXPERIMENTAL|Test Group|Alveolar socket post-extraction covered with PRF
61952285|NCT02300246|NO_INTERVENTION|Control Group|Only clot (spontaneous healing)
62343428|NCT04202653|EXPERIMENTAL|Experienced:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus TQ-B2450 for 24 weeks in treatment experienced patients
62343429|NCT04923919|EXPERIMENTAL|Single arm|CLL-1 targeting CAR-T treatment
62343430|NCT05739812|EXPERIMENTAL|Urological disease group|Patients with urological diseases (renal cell carcinoma, nonfunctioning kidney and adrenal tumor, renal pelvis carcinoma, ureteral tumor, bladder cancer, prostate cancer, pelvic tumor) will be treated by telesurgery.
62343431|NCT04504370|EXPERIMENTAL|PB-119 once-weekly-subcutaneous injection|PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150μg once-weekly subcutaneously to patients in active drug group for 24 weeks.
62343432|NCT04504370|PLACEBO_COMPARATOR|Placebo once-weekly-subcutaneous injection|PB-119 150μg matched placebo which will be used in placebo group for 24 weeks.
62343433|NCT06504329|EXPERIMENTAL|MCAT + subepithelial connective tissue graft|In this group, participants will undergo the modified coronally advanced tunnel (MCAT) technique, and a subepithelial connective tissue graft will be placed.
62343434|NCT06504329|EXPERIMENTAL|MCAT + enamel matrix derivative|In this group, participants will undergo the modified coronally advanced tunnel (MCAT) technique, and Emdogain (0.15 ml gel form) will be applied. Emdogain will be used as an enamel matrix derivative.
62343435|NCT06504329|EXPERIMENTAL|MCAT + subepithelial connective tissue graft + enamel matrix derivative|In this group, participants will undergo the modified coronally advanced tunnel (MCAT) technique, a subepithelial connective tissue graft will be placed, and an enamel matrix derivative(Emdogain -0.15 ml gel form) will be applied.
62343436|NCT01094730|OTHER|galyfilcon A prototype/marketed galyfilcon A|The galyfilcon A prototype lens worn daily for 12-16 days during the first period then the marketed galyfilcon A lens worn daily for 12-16 days during the second period.
62343437|NCT01094730|OTHER|marketed galyfilcon A/galyfilcon A prototype|The marketed galyfilcon A lens worn daily for 12-16 days during the first period then the galyfilcon A prototype lens worn daily for 12-16 days during the second period; during each period.
62343438|NCT05913141||Patients with PDO/PDO-TIL/PDOTS|Patients whose tumors were established into patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture systems, or patient-derived organotypic tissue spheroids, and screened for drug-sensitive.
62343439|NCT00656734|EXPERIMENTAL|MDX 1411|Dose Escalation Cohorts
62343440|NCT06335823|EXPERIMENTAL|Active TENS unit|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients in this arm will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
62343441|NCT06335823|PLACEBO_COMPARATOR|Non-active TENS unit|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will not have the TENS unit turned on.
62699966|NCT02927964|EXPERIMENTAL|Phase 1b -SD-101 3mg|Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also receive ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity.
61952286|NCT05191342||Rheumatoid arthritis|Patients with rheumatoid arthritis (n=25).
61952287|NCT05191342||Rheumatoid arthritis complicated atrial fibrillation|Patients with rheumatoid arthritis complicated atrial fibrillation (n=25).
61952288|NCT05191342||healthy volunteers|Healthy volunteers (n=25).
62343442|NCT01794247|EXPERIMENTAL|Intrathecal magnesium|Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
61952289|NCT03385564|EXPERIMENTAL|BI 655064 120 mg|120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
61952290|NCT03385564|PLACEBO_COMPARATOR|Placebo|Matching placebo were administered as solution for subcutaneous injection in a prefilled syringe once every week over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
62343443|NCT01794247|ACTIVE_COMPARATOR|Intrathecal fentanyl|Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant
62343444|NCT03882346|NO_INTERVENTION|Control Group|Patients in Control Group will receive best supportive care for the disease.
62343445|NCT03882346|EXPERIMENTAL|Experimental Group|Patients in Experimental Group will receive LifeLiver treatment in addition to best supportive care for the disease.
62343446|NCT00423085|PLACEBO_COMPARATOR|Placebo|Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
62699967|NCT05393492|EXPERIMENTAL|GREMO patients|"1. 5 months of baseline : usual care of in a medico-social service (medical, social, neuropsychological and psychological),~2. 5 months of dialectical behavior therapy (DBT)~   -DBT skills training group : during 19 weeks~3. 5 months of follow-up : usual care of + monthly reminders of DBT intervention skills"
62714816|NCT01595477|NO_INTERVENTION|Control Group|
62500744|NCT00557245|ACTIVE_COMPARATOR|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
62500745|NCT00557245|PLACEBO_COMPARATOR|Placebo|Placebo TDF + Placebo FTC/TDF orally, once daily.
62500746|NCT00201136|NO_INTERVENTION|MD-C/PT-C|Physician and patient control group.
62500747|NCT00201136|EXPERIMENTAL|MD-I/PT-C|MD CQI-type intervention; Patient control
62500748|NCT00201136|EXPERIMENTAL|MD-C/Pt-I|MD control; patient behavioral intervention
62500749|NCT00201136|EXPERIMENTAL|MD-I/Pt-I|MD CQI-type intervention; Patient behavioral intervention
62500750|NCT02707887|PLACEBO_COMPARATOR|Treatment as Usual|Patients are offered substance use group therapy including relapse prevention. They are also provided medical consultation on an ongoing basis as needed.
62500751|NCT02707887|ACTIVE_COMPARATOR|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT) involves the discussion of the treatment rationale, identification of values and goals in various life areas and activities in line with chosen life areas, and training for patients to identify their cycle of negative mood and behavior using forms to track their daily goals.
62500752|NCT02707887|ACTIVE_COMPARATOR|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
62500753|NCT05892172||HFrEF group|HFrEF was defined as Left ventricular ejection fraction ≤40%
62500754|NCT05892172||HFmrEF group|HFmrEF was defined as Left ventricular ejection fraction 41%\~49%
62500755|NCT05892172||HFpEF group|HFpEF was defined as Left ventricular ejection fraction ≥50%
62500756|NCT06604481|EXPERIMENTAL|eCoaching Group I|Online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills. All content will be covered.
62500757|NCT06604481|EXPERIMENTAL|eCoaching Group II|Online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills. Content will be covered specified to the carer's specific needs.
62500758|NCT06604481|ACTIVE_COMPARATOR|Control Group|Online sessions focused on education about lifestyle and communication.
62500759|NCT03458364|EXPERIMENTAL|High flow nasal cannula|High flow nasal cannula (HFNC) is a type of oxygen device, which provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation.
62500760|NCT03458364|ACTIVE_COMPARATOR|Noninvasive ventilation|Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the patient's upper airway using a mask. This technique is distinguished from those which bypass the upper airway with a tracheal tube, laryngeal mask, or tracheostomy and are therefore considered invasive.
62500761|NCT00422045|NO_INTERVENTION|2|No Laser done. All outcome measures are the same.
62500762|NCT00422045|EXPERIMENTAL|1|Low Level Laser Therapy
62500763|NCT02351167|ACTIVE_COMPARATOR|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
62500764|NCT02351167|ACTIVE_COMPARATOR|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
62699968|NCT05393492|NO_INTERVENTION|Controls without brain injury|People without brain injury used as controls for linguistic markers of emotional expression regulation and free will.
62699969|NCT05393492|NO_INTERVENTION|GREMO patients' family|GREMO patients' relatives, without brain injury, living with the GREMO patient and ready to complete every day and adapted self-observational diary card similar to the one of the GREMO patient
62141176|NCT06685809|EXPERIMENTAL|FZ008-145 tablet- Part C|"Subjects in Cohort C1 will receive a single oral dose of FZ008-145 tablet in fasted state in Sequence 1 followed by at least 10-day washout period and same drug after a high-fat meal in sequence 2.~Subjects in Cohort C2 will receive a single oral dose of FZ008-145 tablet after a high-fat meal in Sequence 1 followed by at least 10-day washout period and same drug in the fasted state in Sequence 2."
62500765|NCT02351167|PLACEBO_COMPARATOR|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
62699970|NCT05393492|NO_INTERVENTION|Qualitative research ABI patients and families|Patients and relatives followed by the same medico-social service but not meeting GREMO patients eligibility criteria, participating only in the qualitative research on free will and spirituality
62500766|NCT00774241|EXPERIMENTAL|1|
62500767|NCT01177891||Subject index|Population of familial cases of POF : 20 families with at least two subjects with POF nonsyndromic
62500768|NCT01177891||Population Index Related topics|Women, healthy women, men are potential carriers
62500769|NCT01177891||Population control|100 Caucasian women with normal cycles until at least the age of 40 years and a proven fertility
62500770|NCT00570128|ACTIVE_COMPARATOR|Donepezil HCl|
62500771|NCT00570128|PLACEBO_COMPARATOR|Placebo|
62500772|NCT02482558|EXPERIMENTAL|High GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day high glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
62500773|NCT02482558|EXPERIMENTAL|Low GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day low glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
62500774|NCT04086160|EXPERIMENTAL|schizophrenia- tDCS|
62699971|NCT04132297|EXPERIMENTAL|Virtual Asthma Academy Training + Telehealth Visit Group|Participants will receive the Asthma Academy Training virtually. One week after the virtual training, participants will be scheduled to complete a Telehealth visit via zoom through their smart phones or computers.
62699972|NCT04132297|EXPERIMENTAL|Virtual Asthma Academy Training|Participants will receive the virtual Asthma Academy Training via zoom through their smart phones or computers.
62699973|NCT04721717||People with SCI|People with paraplegia and quadriplegia People with multiple sclerosis People with transverse myelitis Caregivers of people with amyotrophic lateral sclerosis (ALS)
61952291|NCT03385564|EXPERIMENTAL|BI 655064 180 mg|180 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
62500775|NCT04086160|SHAM_COMPARATOR|schizophrenia- sham|
62500776|NCT04086160|EXPERIMENTAL|at risk- tDCS|
62500777|NCT04086160|SHAM_COMPARATOR|at risk- sham|
61952292|NCT03385564|EXPERIMENTAL|BI 655064 240 mg|120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every week (240 mg every 2 weeks) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
61952293|NCT01149226|PLACEBO_COMPARATOR|placebo control|
62500778|NCT04086160|EXPERIMENTAL|healthy controls for schizophrenia- tDCS|
62500779|NCT04086160|SHAM_COMPARATOR|healthy controls for schizophrenia- sham|
62500780|NCT04086160|EXPERIMENTAL|healthy controls for at risk- tDCS|
61952294|NCT01149226|EXPERIMENTAL|oral medication chloral hydrate|
61952295|NCT00926484||Tooth Mousse|
61952296|NCT00926484||fluoride varnish|
61952297|NCT00926484||Tooth Mousse + fluoride varnish|
61952298|NCT06455176|ACTIVE_COMPARATOR|Symphyseal bone group|
61952299|NCT06455176|ACTIVE_COMPARATOR|iliac cancellous bone group|
62343447|NCT00423085|EXPERIMENTAL|rivastigmine 5 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm\^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm\^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
62343448|NCT00423085|EXPERIMENTAL|Rivastigmine 10 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm\^2 patch for the first 4 weeks, rivastigmine 5 cm\^2 patch for the next 4 weeks, rivastigmine 7.5 cm\^2 patch for the next 4 weeks and then rivastigmine 10 cm\^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
62343449|NCT00671580|EXPERIMENTAL|A|PZ-601
62343450|NCT00671580|EXPERIMENTAL|B|PZ-601
62500781|NCT04086160|SHAM_COMPARATOR|healthy controls for at risk- sham|
62500782|NCT00779441|EXPERIMENTAL|1|Zolpidem 10mg tablets of ranbaxy
62500783|NCT00779441|ACTIVE_COMPARATOR|2|AmbienÂ® 10mg tablets
62500784|NCT02288260||Part A|PATIENTS RECEIVED THE STANDARD MEDICAL CARE AS DETERMINED BY THE TREATING CARDIOLOGIST
62500785|NCT02288260||Part B|Patients on ticagrelor at the time of discharge from hospital
62500786|NCT06595004|EXPERIMENTAL|Experimental 1|Take HCP1004 twice daily for 12 weeks orally.
62500787|NCT06595004|ACTIVE_COMPARATOR|Active Comparator|Take RLD2401 twice daily for 12 weeks orally.
62500788|NCT02413528|SHAM_COMPARATOR|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: Inhaler sensor"
62500789|NCT02413528|EXPERIMENTAL|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.~Interventions: Inhaler sensor and mobile application for asthma adherence"
62500790|NCT01396655|EXPERIMENTAL|docetaxel + doxorubicin|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks.
61952300|NCT01457469|ACTIVE_COMPARATOR|Arm I (usual care plus) (closed to accrual as of 3/6/2012)|"Patients receive a personalized letter from their physician with advice to quit smoking and a copy of the National Cancer Institute's Cleaning the Air smoking cessation booklet."
61952301|NCT01457469|EXPERIMENTAL|Arm II (enhanced quitline)|Patients receive a personalized letter and a smoking cessation booklet. Patients also receive an 8-week supply of nicotine replacement patches and undergo a counseling session over 30-45 minutes with a trained nurse or midlevel provider that focuses on the benefits of quitting smoking for cancer patients and addresses cancer-specific concerns about smoking cessation. Patients also undergo a quitline-based smoking cessation intervention comprising 5 individual 25- to 30-minute telephone counseling sessions and unlimited inbound phone-based access to Quit Coaches over 8-11 weeks, mailed written materials, and an interactive online program.
61952302|NCT00713960||1|Patients in secondary prevention of cardiovascular disease in primary care
61952303|NCT05374733|OTHER|Single arm|Coronary physiology measurements both pre- and post- transcatheter left-sided valvular intervention.
62343451|NCT00671580|ACTIVE_COMPARATOR|C|Standard of Care
62343452|NCT00003225|EXPERIMENTAL|Ethyol plus Irinotecan|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
62343453|NCT00325650|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily
62343454|NCT00325650|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily.
62500791|NCT01715155||Female patients diagnosed with metastatic breast cancer|Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
62500792|NCT02449616|EXPERIMENTAL|Study Drug|MST-188
62500793|NCT03985046|EXPERIMENTAL|Sintilimab plus chemotherapy|
62500794|NCT02872051|NO_INTERVENTION|Control|Standard treatment and standard vocational rehabilitation
62500795|NCT02872051|EXPERIMENTAL|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
61952304|NCT02019693|EXPERIMENTAL|Capmatinib (INC280)|INC280 400 mg twice every day by mouth, continuously
61952305|NCT06199596|EXPERIMENTAL|ACH (Aalpha-s1 casein hydrolysate)|Each participant will take Prelactium capsules (alpha-s2 casein hydrolysate supplement; 150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.
62500796|NCT02872051|EXPERIMENTAL|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
62500797|NCT05625269|EXPERIMENTAL|Education and follow-up group|Patients in the intervention group will be given training on the procedure and home care process on the first day of hospitalization and the day before discharge. Afterwards, patients will be followed up by phone at intervals of two weeks. The purpose of telephone monitoring is to question adherence to treatment, to identify and change barriers, to apply counseling and to control symptoms.
62699974|NCT04031508|EXPERIMENTAL|Omega 3|The experimental group will receive a parenteral emulsion containing soy oil, MCT, olive oil and n-3 LCPUFA in fish oil
62699975|NCT04031508|SHAM_COMPARATOR|Control group|The Control group will receive a parenteral emulsion containing soy oil and MCT
61952306|NCT06199596|PLACEBO_COMPARATOR|Placebo (Maltodextrin)|Each participant will take Maltodextrin capsules (150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.
61952307|NCT05075902|EXPERIMENTAL|Multimorbidity Group (MULTI)|Multimorbidity group is composed of post menopausal women with two or more chronic diseases cardiometabolic (Hypertension, diabetes, dislipidemias, obesity).
62500798|NCT05625269|NO_INTERVENTION|Control group|The control group will be given the standard care applied in the clinic, and the patients of this group will be given training after the research is completed.
62500799|NCT01954901|EXPERIMENTAL|Standard treatment plus Hyperbaric Oxygen|The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
62500800|NCT01954901|PLACEBO_COMPARATOR|Standard treatment with Hyperbaric Room Air|The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.
62500801|NCT06073886|EXPERIMENTAL|Active continuous theta-burst stimulation (cTBS) plus exposure|10 days of active, continuous theta-burst stimulation (cTBS) will be delivered to a personalized region of the ventromedial prefrontal cortex (vmPFC) based on baseline brain circuit mapping for each individual participant.
62500802|NCT06073886|SHAM_COMPARATOR|Inactive/Sham continuous theta-burst stimulation (cTBS) plus exposure|10 days of inactive, or sham, continuous theta-burst stimulation (cTBS) will be delivered to a personalized region of the ventromedial prefrontal cortex (vmPFC) based on baseline brain circuit mapping for each individual participant.
62500803|NCT06073886|ACTIVE_COMPARATOR|Active Comparator continuous theta-burst stimulation (cTBS) plus exposure|10 days of active, continuous theta-burst stimulation (cTBS) will be delivered to a personalized region of the ventromedial prefrontal cortex (vmPFC) based on baseline brain circuit mapping for each individual participant.
62500804|NCT03297541|EXPERIMENTAL|m-health approach|All dyads will receive the m-health approach.
62699976|NCT04203576|EXPERIMENTAL|FIRE1 System|FIRE1 System
62699977|NCT06298734|EXPERIMENTAL|Group A: High-Intensity Exercise (EX)|"10 participants will complete:~* In-office baseline visit.~* Virtual exercise sessions 3x weekly.~* Post-intervention in-office visit."
62699978|NCT06298734|EXPERIMENTAL|Group B: High-Fiber Diet (DT)|"10 participants will complete:~* In-office baseline visit.~* 1x weekly appointment with research staff to review to review diet adherence.~* Post-intervention in-office visit."
62699979|NCT06298734|EXPERIMENTAL|Group C: Combined High-Intensity Exercise and High-fiber Diet (COMB)|"10 participants will complete:~* In-office baseline visit.~* Virtual exercise sessions 3x weekly.~* 1x weekly appointment with research staff via Zoom platform to review to review diet adherence. Diet appointment may be combined with exercise session appointment.~* Post-intervention in-office visit."
62699980|NCT06298734|NO_INTERVENTION|Group D: Attention Control (AC)|"10 participants will complete:~* In-office baseline visit.~* Participants will receive a general healthy lifestyle guidebook.~* Pot-intervention in-office visit."
62699981|NCT00689884|EXPERIMENTAL|Group A|All eligible patients will receive chemotherapy and one dose of Pegfilgrastim
61952308|NCT05075902|EXPERIMENTAL|Morbidity Group (MORB)|Morbidity group is composed of postmenopausal women with one or no chronic cardiometabolic disease (Hypertension, diabetes, dislipidemias, obesity)
61952309|NCT00036270|EXPERIMENTAL|exemestane|
62343455|NCT04251689|EXPERIMENTAL|intervention|mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
61952310|NCT00036270|EXPERIMENTAL|tamoxifen + exemestane|
61952311|NCT01950975|OTHER|Parents|2 parents of child
61952312|NCT01950975|OTHER|infant|
61952313|NCT01686308|ACTIVE_COMPARATOR|Conventional Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
61952314|NCT01686308|EXPERIMENTAL|Yellow Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
61952315|NCT06143813|ACTIVE_COMPARATOR|Block|This group will receive standard of care + a selective nerve root block as part of the diagnostic work up.
61952316|NCT06143813|NO_INTERVENTION|No-block|This group will receive standard of care.
61952317|NCT01842321|EXPERIMENTAL|Abiraterone Acetate|
61952318|NCT05852015|ACTIVE_COMPARATOR|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy
62343456|NCT04251689|PLACEBO_COMPARATOR|placebo|0.9% normal saline 100 ml one hour after cisplatin
62343457|NCT03448978|EXPERIMENTAL|Descartes-08 plus fludarabine/cyclophosphamide pretreat|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
62343458|NCT04711876||Test group with enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV +
62343459|NCT04711876||Control group with no enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV -
62343460|NCT06102642|EXPERIMENTAL|Combining Free Gingival Graft with frenotomy procedure|evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
62699982|NCT06638658||Orthopedic surgery patients from high-altitude regions|high altitude patients Undergoing orthopedic surgery
62699983|NCT02085720|EXPERIMENTAL|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
62699984|NCT00734032|PLACEBO_COMPARATOR|Placebo Group|Matched Placebo
62343461|NCT03120481||Normal control|
62699985|NCT00734032|EXPERIMENTAL|SB480848 40mg Group|SB480848 40mg/day
62699986|NCT00734032|EXPERIMENTAL|SB480848 80mg Group|SB480848 80mg/day
62343462|NCT03141372|ACTIVE_COMPARATOR|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR \> 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
61952319|NCT05852015|EXPERIMENTAL|TAU Plus Digital Mindfulness-Based Treatment|TAU consists of weekly outpatient-based group therapy. The digital mindfulness-based treatment is multimedia app-based program teaching mindfulness skills.
62343463|NCT03141372|ACTIVE_COMPARATOR|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR \> 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
62343464|NCT01182337|EXPERIMENTAL|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
62343465|NCT01182337|PLACEBO_COMPARATOR|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
62343466|NCT03785795||Uncertain diagnosis of true labor|Patients who cannot be accurately classified as experiencing true labor or false labor based on standard clinical assessments.
62343467|NCT01987388|EXPERIMENTAL|High Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
62343468|NCT01987388|EXPERIMENTAL|High Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
62343469|NCT01987388|EXPERIMENTAL|Low Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
62343470|NCT01987388|EXPERIMENTAL|Low Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
62343471|NCT02932332|ACTIVE_COMPARATOR|High-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
62343472|NCT02932332|ACTIVE_COMPARATOR|Low-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
62343473|NCT02932332|SHAM_COMPARATOR|High-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
62343474|NCT02932332|SHAM_COMPARATOR|Low-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
62343475|NCT03090373|SHAM_COMPARATOR|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
62343476|NCT03090373|ACTIVE_COMPARATOR|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
62343477|NCT03472235|ACTIVE_COMPARATOR|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
62343478|NCT03472235|ACTIVE_COMPARATOR|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
62699987|NCT00734032|EXPERIMENTAL|SB480848 160mg Group|SB480848 160mg/day
62343479|NCT05807386|EXPERIMENTAL|Exercise Intervention|Participants will undertake a 12 week, online delivered, home-based exercise programme.
62343480|NCT05807386|NO_INTERVENTION|Waitlist Control|Participants assigned to the waitlist control will adhere to their usual routine.
62343481|NCT03284255|EXPERIMENTAL|study group|in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
62699988|NCT03931330|EXPERIMENTAL|Percutaneous neurostimulation|Subjects will have 4 weeks of active therapy.
62699989|NCT04823026||Group 1|"70 young infants with proven bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
62714817|NCT00685061|EXPERIMENTAL|A|Thymoglobulin Induction
62714818|NCT00685061|EXPERIMENTAL|B|Campath-1H Induction
61952320|NCT04992598|EXPERIMENTAL|Hypnosis group|
61952321|NCT04992598|PLACEBO_COMPARATOR|Control group|
61952322|NCT05582473|NO_INTERVENTION|Wait-List Control Group|Randomized subjects will wait for a 3 month period before being assigned to the LST-LC education. This group of subjects will act as the control group.
62343482|NCT03284255|ACTIVE_COMPARATOR|control group|in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
62343483|NCT03991884|EXPERIMENTAL|Dose -1 (0.3 mg/m^2)|Patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on day 8. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
61952323|NCT05582473|OTHER|Learning Skills Together-Latino Caregivers (LST-LC)|The study team convened a team of health care professionals, including nursing, occupational therapy, speech-language pathology, gerontology, nutrition, and dental hygiene, to develop a community-based education program for family caregivers.
61952324|NCT03004742|EXPERIMENTAL|Flavonoid|Flavonoid supplement
62343484|NCT03991884|EXPERIMENTAL|Dose 1 (0.3 mg/m^2)|Dose 1 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
61952325|NCT03004742|PLACEBO_COMPARATOR|Placebo|Placebo
61952326|NCT00811707||1: volunteers|non-pregnant female
61952327|NCT00811707||2: parturients|parturients was scheduled to receive lumbar epidurals for elective cesaeran delivery labor analgesia
61952328|NCT01998776|ACTIVE_COMPARATOR|Misoprostol|ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
61952329|NCT01998776|PLACEBO_COMPARATOR|Placebo misoprostol|ASA 100 mg daily + placebo misoprostol four times daily (placebo group)
62343485|NCT03991884|EXPERIMENTAL|Dose 2 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 2 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62699990|NCT04823026||Group 2|"70 young infants with non-bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
62714819|NCT00685061|EXPERIMENTAL|C|Daclizumab Induction
61952330|NCT05018975|EXPERIMENTAL|Tazemetostat|Subjects will receive tazemetostat 800mg BID for 15 days in addition to standard of care treatment. The duration of the interventional part of the study will last 15 days.
61952331|NCT05018975|NO_INTERVENTION|Control|Subjects receiving standard of care treatment
61952332|NCT02027207|EXPERIMENTAL|Shanchol|
61952333|NCT02027207|PLACEBO_COMPARATOR|Placebo|
61952334|NCT06159985|ACTIVE_COMPARATOR|Pericardiostomy|The patients who were created with left posterior pericardiotomy during the operation
61952335|NCT06159985|NO_INTERVENTION|No pericardiostomy|The patients who were not created with left posterior pericardiotomy during the operation
61952336|NCT05412303||With ECMO-VA|postcardiotomy cardiogenic shosck supported by ECMO-VA
61952337|NCT05412303||Without ECMO-VA|Post cardiotomy cardiogenic shock medically treated (inotrope and vasopressor)
61952338|NCT04103983|ACTIVE_COMPARATOR|Sensory Retraining Interactive Device|The interactive device is a sensory retraining device. A pad consisting of twelve equally spaced electrodes is placed over the residual limb. This pad is connected to a handheld device which delivers an electrical current to the electrodes. The type of electrical current is similar to a TENS device. The device stimulates the skin via one of the electrodes, with either a single, or a rapid burst of pulse(s). The device touch screen then presents the questions, Which electrode (location) was stimulated? Was a single continuous or a rapid burst of pulses given (stimulation type)? The user responds via the screen and is told if they are correct. If correct, a new stimulus is delivered (different location and type) and the process repeated. If incorrect, the user is informed of the correct response, the same stimulation (location and type) is repeated once before moving onto to a new stimulus.
61952339|NCT04103983|PLACEBO_COMPARATOR|Placebo Sensory Retraining Interactive Device|The placebo device is visually identical to the active device
61952340|NCT04103983|ACTIVE_COMPARATOR|Sensory Retraining Non-Interactive Device|The non-interactive device is physically visually identical to the interactive device. This device delivers the stimulation using microcurrents that the participants may or may not feel. There is no interaction required with this device i.e. there is no Q\&A element, feedback nor response dependent progression.
61952341|NCT04103983|PLACEBO_COMPARATOR|Placebo Sensory Retraining Non-Interactive Device|The placebo device is visually identical to the active device
61952342|NCT02236975|EXPERIMENTAL|BuMA Supreme Biodegradable drug coating coronary stent system|Implant BuMA Supreme stent only
61952343|NCT02236975|ACTIVE_COMPARATOR|Resolute Integrity durable polymer stent system|Implant Resolute stent
62714820|NCT02268643||group 1|ultrasound plus clinical breast examination
61952344|NCT04312750|EXPERIMENTAL|Lidocaine Patch|All subjects received one lidocaine topical system, which was applied to a predetermined fixed area on subject's left side of the back or right side of the back (lower/mid back) according to randomization schedule and worn for 12 hours.
61952345|NCT03801343|EXPERIMENTAL|Nutrakos®|12 female subjects aged 35-70, have taken during a meal, for the 1 month ,2 stick packs/die of the food supplement
62141177|NCT01883193|EXPERIMENTAL|Arm 1: Preconception|Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI \<20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
62141178|NCT01883193|EXPERIMENTAL|Arm 2: Pregnancy|Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
61952346|NCT03070366|ACTIVE_COMPARATOR|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:~* PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)~* PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
62343486|NCT03991884|EXPERIMENTAL|Dose 3 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 3 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62343487|NCT05936034|ACTIVE_COMPARATOR|Patients suffering from chemotherapy-induced ototoxicity|Arm 1: Patients with chemotherapy-induced ototoxicity who continue their usual care.
62500805|NCT04155073|EXPERIMENTAL|COPD/smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking, quitting smoking, and respiratory symptoms, 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit, and if needed, 3) a home spirometry test with instructions on how to video themselves completing a lung functioning test via the device within an additional e-visit.
62500806|NCT04155073|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
61952347|NCT03070366|EXPERIMENTAL|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
61952348|NCT03566888||Single Group|85 eligible study participants
61952349|NCT04343469|ACTIVE_COMPARATOR|Bariatric surgery|The effect of bariatric surgery (RYGB or LSG) on central inflammation
61952350|NCT04343469|NO_INTERVENTION|No intervention|Healthy lean volunteers
61952351|NCT02698046|EXPERIMENTAL|Ferrous sulfate|
61952352|NCT02698046|PLACEBO_COMPARATOR|Placebo|
61952353|NCT02656537|EXPERIMENTAL|EnSite™ HD Grid Catheter AF/AT Mapping|
61952354|NCT02179489|NO_INTERVENTION|Control|surgery alone
61952355|NCT02179489|EXPERIMENTAL|Hipec|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
62141179|NCT01883193|NO_INTERVENTION|Arm 3: Control|Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
62141180|NCT04157894||Standard LLIN|This group receives Interceptor ITNs during the mass distribution campaign.
62141181|NCT04157894||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
62343488|NCT05936034|EXPERIMENTAL|Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids|Arm 2: Experimental group patients with chemotherapy-induced ototoxicity wearing a hearing aid to evaluate quality of life.
62343489|NCT04859478|OTHER|All eligible patients|All patients undergo the same CT protocol in addition to standard care.
62343490|NCT05254613|EXPERIMENTAL|Cohort 1|Participants will receive a single SC dose of ALXN1830 or placebo (750 mg).
62343491|NCT05254613|EXPERIMENTAL|Cohort 2|Participants will receive a single SC dose of ALXN1830 or placebo (1500 mg).
62343492|NCT05254613|EXPERIMENTAL|Cohort 3|Participants will receive a single SC dose of ALXN1830 or placebo (2250 mg).
62500807|NCT00630903|ACTIVE_COMPARATOR|A|8-MOP + UVA x 24 weeks
62500808|NCT00630903|ACTIVE_COMPARATOR|B|IFN alone, 2 weeks, 8-MOP + UVA irradiation + IFN, 22 weeks
61952356|NCT02055417|EXPERIMENTAL|Personal Approaches to Treatment Choices for HIV|PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART.
61952357|NCT02055417|ACTIVE_COMPARATOR|Stress Reduction Skills Program|SRSP includes training in stress reduction skills such as relaxation, problem solving, and expressing negative feelings.
62500809|NCT06308263|EXPERIMENTAL|Period 1: Mass Balance: M1774 + [14C]M1774 microtracer|
62500810|NCT06308263|EXPERIMENTAL|Period 2: M1774|
62141182|NCT04157894||Piperonyl butoxide LLIN|This group receives PBO ITNs during the mass distribution campaign.
62141183|NCT02491489|EXPERIMENTAL|Painful shoulders|Subjects with shoulder pain undergoing glenohumeral mobilization
62141184|NCT02491489|ACTIVE_COMPARATOR|Normal shoulders|Subjects without shoulder pain undergoing glenohumeral mobilization
62141185|NCT02663804|ACTIVE_COMPARATOR|Implant design 1|Journey II, BCS, Smith\&Nephew
62141186|NCT02663804|ACTIVE_COMPARATOR|Implant design 2|Persona, Zimmer
62141187|NCT02663804|ACTIVE_COMPARATOR|Implant design 3|Unity, Corin
62141188|NCT04839809|EXPERIMENTAL|CC-92480-02 (Formulation A) with Placebo|CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.
62141189|NCT04839809|EXPERIMENTAL|CC-92480 (Formulation B)- fasted condition|A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.
62500811|NCT01784237|EXPERIMENTAL|Anterior meatuscopy|All patients in the study group receive anterior meatoscopy whereas patients in the control group perform a sniff test to select the most patent nostril for nasal anesthesia and transnasal endoscopic insertion.
62141190|NCT04839809|EXPERIMENTAL|CC-92480-02 (Formulation A) - fasted condition|A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.
61952358|NCT06395545|EXPERIMENTAL|Participants ( control and test group )|At room temperature, 1% lidocaine combined with 1:100,000 epinephrine was used as a local anesthesia. The electronic constant-speed injector, i-JECT® (MediHub Inc., Gyeonggi-do, Korea) (Figure 1) was used, and the injection speed of the injector was set at level 1 (0.25 mL/s) or level 2 (0.4 mL/s). The injection site in a patient was divided into two sides (left and right). The method of local infiltration (manual or using the electronic injector) was randomly assigned to each side of the surgical field, and 2.5 cc (0.5 cc at five separate areas) of local anesthetic was injected individually using a 5 cc syringe with a 31-gauge needle. All injections were administered by a single surgeon (Sung Joo Tommy Hwang) to reduce inter-operator variation.
61952359|NCT01581775|EXPERIMENTAL|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
61952360|NCT01581775|ACTIVE_COMPARATOR|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
62141191|NCT04839809|EXPERIMENTAL|CC-92480 (Formulation B) - Low-fat meal|A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).
62141192|NCT04839809|EXPERIMENTAL|CC-92480-02 (Formulation A) - high-fat meal|A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).
62141193|NCT01500200|EXPERIMENTAL|ALKS 5461|
62141194|NCT01500200|PLACEBO_COMPARATOR|Placebo|
62141195|NCT06533865|EXPERIMENTAL|Romosozumab|Participants with functional hypothalamic amenorrhea randomized to romosozumab.
61952361|NCT01536470|EXPERIMENTAL|Noradrenaline|Continuous infusion of noradrenaline to maintain arterial blood pressure management in high-risk surgical patients
61952362|NCT01536470|EXPERIMENTAL|Ephedrine chorhydrate|Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline)using intravenous bolus of Ephedrine chorhydrate
61952363|NCT00318123|EXPERIMENTAL|A|Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD
61952364|NCT00318123|EXPERIMENTAL|B|Abacavir 600mg + lamivudine 300mg in ine tablet QD \* lopinavir/ritonavir 400/100 mg BID
61952365|NCT01492985|PLACEBO_COMPARATOR|Vaccine placebos|Vaccine placebos corresponding to the dilutant of these vaccines
61952366|NCT01492985|EXPERIMENTAL|Vaccine arm|
61952367|NCT05141591||ENT surgical patients|ASA physical status I-IV adult subjects, ≥ 18 years of age, scheduled for elective ENT surgeries in the Department of ENT at the Medical University of Vienna. On the day before elective ENT- surgery patients will be asked to complete self-administered questionnaires (STOA, APAIS, PCS) concerning their emotional and anxiety state. These questionnaires will be re-tested on the day of surgery and opioid consumption during the stay in the recovery room documented.
61952368|NCT04242719|ACTIVE_COMPARATOR|Only electromagnetic stimulation|Only rEMS was preferred as the initial step
61952369|NCT04242719|ACTIVE_COMPARATOR|Combined with electromagnetic stimulation and PRP|Order to augment the effect of the rEMS, sub-tenon aPRP injection was added.
61952370|NCT04242719|NO_INTERVENTION|Natural course|Served as control group, and existing systemic disorder(s) were consulted and treated accordingly.
61952371|NCT04121975|EXPERIMENTAL|Chemoradiotherapy|"Radiation:~Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.~Drug: Endostar 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.~Drug: Cisplatin 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29."
61952372|NCT01781975|EXPERIMENTAL|Imatinib Mesylate|400 mg imatinib given once daily basis.
61952373|NCT01781975|PLACEBO_COMPARATOR|Placebo|Placebo given once daily basis.
61952374|NCT00371280|ACTIVE_COMPARATOR|1|Pegged unpegged hydroxyapatite orbital implantation
61952375|NCT00371280|ACTIVE_COMPARATOR|2|Unpegged hydroxyapatite orbital implantation
61952376|NCT01999868|EXPERIMENTAL|UST, ABA/UST Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing \<=100 kg at study entry or 90 mg for those weighing \>100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of abatacept (ABA) (125 mg) subcutaneous injections weekly from Week 12 to 39, in addition to ustekinumab placebo subcutaneous injections at Weeks 16 and 28.
61952377|NCT01999868|ACTIVE_COMPARATOR|UST, UST/ABA Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing \<=100 kg at study entry or 90 mg for those weighing \>100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of ustekinumab (45 mg if \<=100 kg or 90 mg if \>100 kg at study entry) subcutaneous injections at Weeks 16 and 28, in addition to abatacept (ABA) placebo subcutaneous injections weekly from Week 12 to 39.
62141196|NCT06533865|PLACEBO_COMPARATOR|Placebo|Participants with functional hypothalamic amenorrhea randomized to placebo.
62141197|NCT06533865|NO_INTERVENTION|Healthy Controls|Healthy controls (girls and women with regular menstrual periods) will be followed without intervention.
62343493|NCT05254613|EXPERIMENTAL|Cohort 4|Participants will receive multiple SC doses of ALXN1830 or placebo (300 mg twice weekly; 8 doses total).
62343494|NCT05254613|EXPERIMENTAL|Cohort 5|Participants will receive multiple SC doses of ALXN1830 or placebo (750 mg once weekly; 12 doses total).
62343495|NCT05254613|EXPERIMENTAL|Cohort 6|Participants will receive multiple SC doses of ALXN1830 or placebo (1500 mg once weekly; 4 doses total).
62141198|NCT05717140|EXPERIMENTAL|Treatment (aerosolized sargramostim, nivolumab)|Patients receive aerosolized sargramostim via inhalation using the Aerogen Solo nebulization device and receive nivolumab IV on study. Patients also undergo collection of blood samples on study and undergo CT or MRI at screening and on study.
62141199|NCT02310581|EXPERIMENTAL|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
62141200|NCT02310581|EXPERIMENTAL|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
62141201|NCT02310581|EXPERIMENTAL|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
62343496|NCT05254613|EXPERIMENTAL|Cohort 7|Participants will receive multiple SC doses of ALXN1830 or placebo (2250 mg once weekly; 4 doses total).
62343497|NCT01518244|EXPERIMENTAL|AZARGA®|Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks
62343498|NCT04109872||Mantle cell lymphoma treated with lenalidomide cohort|Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.
62500812|NCT01784237|ACTIVE_COMPARATOR|Nasal sniff test|A sniff test for nasal patency is a common method before ultrathin transnasal esophago-gastro-duodenoscopy (UT-EGD) to select the right or left nostril for insertion.
62500813|NCT03201263|ACTIVE_COMPARATOR|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
62699991|NCT04823026||Group 3|"30 young infants without infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
62699992|NCT02075060|EXPERIMENTAL|IPOI|One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),
62699993|NCT02075060|ACTIVE_COMPARATOR|IPOP|One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).
61952378|NCT01034631|ACTIVE_COMPARATOR|Combination Arm A: Everolimus + BNC105P|Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
62141202|NCT02310581|PLACEBO_COMPARATOR|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
62343499|NCT03671382|EXPERIMENTAL|Intervention Arm|Communication Training Program and Patient Prompt Sheet
62699994|NCT02836249|EXPERIMENTAL|Double-Blind TAF|Tenofovir alafenamide (Vemlidy®; TAF) 25 mg tablet + tenofovir disoproxil fumarate (Viread®; TDF) placebo tablet once daily for up to 144 weeks (per amendment 3.1).
62699995|NCT02836249|ACTIVE_COMPARATOR|Double-Blind TDF|TDF 300 mg tablet + TAF placebo tablet once daily for up to 144 weeks (per amendment 3.1).
62343500|NCT03671382|NO_INTERVENTION|Control Arm|Oncologists will not receive the communication skills training program and their patients will not receive the Patient Prompt Sheet
62343501|NCT02745236|EXPERIMENTAL|Nurse Practitioner Led-Care|"Nurse Practitioner (NP) Intervention Initial Visit and Interventions: An experienced nurse practitioner with extra atrial fibrillation (AF) management training will complete the initial assessment to determine a treatment plan based on current AF Guidelines. The NP will provide patient education on AF management.~Follow-up: Follow-up will occur at 3 and 6 months from baseline to evaluate the patient's response to treatment and will be modified as required based on AF symptoms, testing results and physical assessment.~A physician will be consulted for advanced specialty AF management or if a patient requires admission to hospital."
62343502|NCT02745236|ACTIVE_COMPARATOR|Cardiologist Led-Care|"Standard Care Initial Visit and Intervention: A general cardiologist will manage patients as per their usual practice.~Follow-up: As per the cardiologist's usual practice. The patient's care will remain with the family physician if no follow-up is required.~Follow-up: Follow-up will be determined as per the cardiologist's usual practice. If a follow-up appointment is required it will done in the cardiologist's own independent clinic. The patient's care will be referred back to the family physician if no follow-up is required."
62343503|NCT04527601||ELGAN admissions during peak three months of COVID-19 pandemic|
62343504|NCT04527601||ELGAN admissions in the three corresponding months of 2019|
62699996|NCT02836249|EXPERIMENTAL|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
62699997|NCT04029779|EXPERIMENTAL|Immediate implant placement coated with I-PRF|The test group received implants coated with injectable platelet-rich fibrin and also the sockets were injected with injectable- platelet rich fibrin
62699998|NCT04029779|NO_INTERVENTION|immediate implant only|The control group received immediate dental implants only after extraction of the teeth without any local coating.
62699999|NCT06634524|EXPERIMENTAL|Dexmeditomidine group|Patients who will receive IV infusion of (0.2 µg/kg/hr dexmeditomidine).
62700000|NCT06634524|PLACEBO_COMPARATOR|Control group|Patients who will receive IV infusion of normal saline, at the same rate of dexmedetomidine infusion
62700001|NCT06132464|EXPERIMENTAL|Expanding Communication and Language Generated in Conversation Treatment|Participants will complete 20 one-hour therapy sessions over 10 weeks with an experienced, trained, and licensed speech-language pathologist delivering Expanding Communication and Language Generated in Conversation Therapy, following the therapy protocol. Sessions will take place through casual conversational interactions, with incremental problem-solving and communication support by the speech-language pathologist.
62700002|NCT06151483|ACTIVE_COMPARATOR|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
61952379|NCT01034631|ACTIVE_COMPARATOR|Sequential Arm B:Everolimus followed by BNC105P Monotherapy|"Sequential Arm B: Everolimus 10 mg, 21 day cycle~Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy."
61952380|NCT03289858|EXPERIMENTAL|Exparel (Liposomal Bupivacaine)|"Exparel (liposomal bupivacaine) is FDA approved, with a labeled indication of single-dose infiltration into the surgical site to produce postsurgical analgesia."
61952381|NCT03289858|PLACEBO_COMPARATOR|Saline Control|Saline Solution (Sodium Chloride)
61952382|NCT00045968|ACTIVE_COMPARATOR|treatment cohort|
61952383|NCT00045968|PLACEBO_COMPARATOR|Placebo Chohort|Autologous PBMC
61952384|NCT01880502|EXPERIMENTAL|Belviq 10mg|
61952385|NCT01880502|EXPERIMENTAL|Belviq 20mg|
61952386|NCT01880502|PLACEBO_COMPARATOR|Placebo|
62141203|NCT04130932|NO_INTERVENTION|Normal flooring|standard office flooring
62141204|NCT04130932|EXPERIMENTAL|Ergonomic flooring|Ergonomically designed flooring
62141205|NCT03435367|EXPERIMENTAL|Intervention Group (VR)|The patient will be allowed to 'try-out' the VR system (including all auditory and visual features) for \~5 minutes prior to the start of the procedure. In addition to usual care, consisting of child-life presence and topical analgesics if ordered by the treating medical team, children in the experimental condition will wear the VR HMD plus headphones and hold the VR controller.
62700003|NCT06151483|EXPERIMENTAL|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62700004|NCT02686944|EXPERIMENTAL|Intuvax (ilixadencel)|"Intuvax (ilixadencel) will be administered 2 or 3 times. First injection Day 1 (pat 1-12), second injection 14 days after the first vaccination (pat 1-12), third injection 28 days after the second vaccination (only pat 7-12).~Max 10 000 000 allogeneic dendritic cells/ml per injection."
62700005|NCT06549231|EXPERIMENTAL|Rituximab|
62700006|NCT06549231|PLACEBO_COMPARATOR|Placebo|
61952387|NCT04764279|EXPERIMENTAL|OPTIFAST Arm|Participants in the intervention group will be given OPTIFAST® meal replacement shakes, 4 per day to achieve 900kcal/day, for the first 12 weeks of the study. The second phase will consist of partial meal replacement and food reintroduction over a 4 week period. When the intervention group begins to reintroduce foods, all study participants will be provided a workbook, created for the study, to explain optimal lifestyle changes for DMII management. The third phase will be a 8-month follow-up of participants on continued healthy lifestyle as described in the workbook.
61952388|NCT04764279|NO_INTERVENTION|Control/Usual Care Arm|Usual Care : A gift card will be offered to participants in the control group to stabilize the incentive of the intervention. Participants in the control group will receive usual diabetes care based on the current Canadian Diabetes Association guidelines by their family physician. Participants in the control group will receive the same workbook as the intervention group at 16 weeks into the study.
61952389|NCT01403181||Chronic hepatitis C|"* 10 naïve genotype 1 chronic hepatitis C patients treated with PEG plus RBV (control arm)~* 20 naïve genotype 1 chronic hepatitis C patients treated with a response guided therapy consisting of Boceprevir in combination with PEG plus RBV (experimental arm)"
62141206|NCT03435367|ACTIVE_COMPARATOR|Control Group (Standard Care - Video)|The patient will be allowed to watch an age-appropriate video on a tablet device. The patient will be offered to wear the same headphones as in the experimental condition. The patient will have the tablet and headphones for \~5 minutes prior to the start of the procedure. In addition, the patient will receive standard care consisting of a child life specialist and topical analgesics (if ordered by the treating medical team).
62141207|NCT02620449|EXPERIMENTAL|single arm study|
62141208|NCT03725020|EXPERIMENTAL|Fluoride varnish|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply the test varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The NFV test varnish has mint flavour and the active ingredient is ammonium fluoride dissolved in ethanol, water and an acrylate polymer.
62343505|NCT00169117|EXPERIMENTAL|1|Behavioural intervention: Songs/posters aimed at behaviour change to increase repair and maintenance of mosquito nets
62700007|NCT03003663|EXPERIMENTAL|SensableCare System|Device:The interrupted time series design will alternate between the following on a monthly basis: (1) standard medical care and (2) standard medical care and the SensableCare System.
62700008|NCT04089358|ACTIVE_COMPARATOR|Control Group (educational materials, Fitbit)|Participants receive educational materials about physical activity and wear a Fitbit daily for 48 weeks.
62700009|NCT04089358|EXPERIMENTAL|Intervention group (educational materials, goal set, Fitbit)|See outline
62700010|NCT05230277|PLACEBO_COMPARATOR|The experimental group is defined by the sham osteopathic treatment (SOT)|Patients will receive 3 SOT of 30 minutes each for 2 weeks in a private practice by an experienced osteopath who will receive prior training to optimize the quality of the SOT. The positions of the patient and the practitioner will be the same as in the AOT group
62700011|NCT05230277|EXPERIMENTAL|The experimental group is defined by the active osteopathic treatment (AOT)|Patients will receive 3 AOT of 30 minutes each for 2 weeks in a private practice by an experienced osteopath who will receive prior training to optimize the quality of the AOT.
62700012|NCT06055231|EXPERIMENTAL|Arm 1 (Vape followed by Joint)|Patients receive a vape device with THC containing liquid and consume the provided amount in up to 10 minutes. 7 to 14 days later patients receive a cannabis joint and smoke the provided joint in up to 10 minutes. Patients also undergo blood sample collection throughout the study.
61952390|NCT04470141|EXPERIMENTAL|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
61952391|NCT02318251|EXPERIMENTAL|Involuntary muscle contractions|Standard physiotherapy program (focus on involuntary reflexive pelvic floor muscle contractions)
61952392|NCT02318251|ACTIVE_COMPARATOR|Voluntary muscle contractions|Physiotherapy program (focus on voluntary pelvic floor muscle contractions)
62141209|NCT03725020|PLACEBO_COMPARATOR|Varnish without Fluoride|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply either the placebo varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The placebo varnish has an identical composition as the test varnish except for the ammonium fluoride. Thus, taste, colour and handling properties are the same.
62141210|NCT05376982|EXPERIMENTAL|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
62141211|NCT05376982|EXPERIMENTAL|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
62141212|NCT06648785|EXPERIMENTAL|Modified administration schedule of capecitabine with oxaliplatin|"* Oxaliplatin (85mg/m2), will be administered IV every 2 weeks~* Capecitabine (1000mg/m2) will be given twice daily, administered orally (PO) for 7 days, followed by 7 days with no capecitabine Cycles will repeat every 14 days."
62141213|NCT04516226|EXPERIMENTAL|Vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to undergo vaginal cleansing with chlorhexidine gluconate within 24 hours of PPROM diagnosis.
62141214|NCT04516226|NO_INTERVENTION|No vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to not undergo vaginal cleansing.
62141215|NCT01428869||statin+ASA+dutasteride|
62141216|NCT01428869||statin+ASA|
62141217|NCT01428869||dutasteride+statin|
62141218|NCT01428869||dutasteride+ASA|
61952393|NCT01655771|EXPERIMENTAL|Elderly|TD-1211 Dose 1
61952394|NCT01655771|EXPERIMENTAL|Younger|TD-1211 Dose 2
61952395|NCT00868608|EXPERIMENTAL|inotuzumab ozogamicin|inotuzumab ozogamicin
61952396|NCT04824352|EXPERIMENTAL|apatinib+IE|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
61952397|NCT02438020|EXPERIMENTAL|Metformin|500 mg metformin oral intake before main meal
61952398|NCT02438020|PLACEBO_COMPARATOR|Placebo|Placebo tablet before main meal.
61952399|NCT04923256|EXPERIMENTAL|Experimental: Approach Bias Modification|Participants will complete 2 x 5-7 min training sessions of approach bias modification for the period of four weeks
61952400|NCT04923256|ACTIVE_COMPARATOR|Control: Minimal intervention|Participants will complete a standardised alcohol approach-avoidance training task (AAT) on a weekly basis for four weeks.
61952401|NCT01841788|EXPERIMENTAL|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
61952402|NCT01841788|ACTIVE_COMPARATOR|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
61952403|NCT01841788|PLACEBO_COMPARATOR|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
61952404|NCT03531697|EXPERIMENTAL|Generic Loteprednol Etabonate - RLD|Period 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)
61952405|NCT03531697|ACTIVE_COMPARATOR|RLD - Generic Loteprednol Etabonate|Period 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate
61952406|NCT02218749|EXPERIMENTAL|Initially triaged to physiotherapist|Initially triaged to physiotherapist
61952407|NCT02218749|ACTIVE_COMPARATOR|Initially triaged to physician|Initially triaged to physician
61952408|NCT01849783|EXPERIMENTAL|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
61952409|NCT06557083|SHAM_COMPARATOR|Control, Controlling Stress|No intervention will be administered. The control participants will watch a video emphasizing the importance of stress management
62500814|NCT03201263|EXPERIMENTAL|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
62700013|NCT06055231|EXPERIMENTAL|Arm II (Joint followed by Vape)|Patients receive a cannabis joint and smoke the provided joint in up to 10 minutes. 7 to 14 days later patients receive a vape device with THC containing liquid and consume the provided amount in up to 10 minutes. Patients also undergo blood sample collection throughout the study.
62700014|NCT05745922|NO_INTERVENTION|Control|Resting in seated position
61952410|NCT06557083|EXPERIMENTAL|Breathing Exercises|The participants in the intervention group will receive a home exercise program (HEP) of Polyvagal breathing exercises. They are instructed to complete these exercises for at least five minutes per day. They are allowed to choose between the three exercises we provide.
61952411|NCT04712994|EXPERIMENTAL|PrEP Optimization Strategies|Four facilities will be assigned to the intervention group. The intervention group will receive a pre-identified package of interventions (PrEP video counselling, HIV Self-Testing, and optimized delivery and prescription processes).
61952412|NCT04712994|NO_INTERVENTION|Comparator|Four facilities will be assigned to the comparator group.
61952413|NCT02500420|OTHER|Diagnosis examens|"* Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~* Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
61952414|NCT03893370|ACTIVE_COMPARATOR|Treatment|RJA MCS
61952415|NCT03893370|SHAM_COMPARATOR|Sham Control|Sham
61952416|NCT00622401|EXPERIMENTAL|Group 1|Dendritic Cell/Tumor Fusion Vaccine Only
61952417|NCT00622401|EXPERIMENTAL|Group 2|Dendritic Cell/tumor fusion vaccine and low dose IL-12
62500815|NCT02241798|EXPERIMENTAL|Pre-oxygenation first|"1. st, 3rd, 5th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated~2. nd, 4th, 6th, etc seizure: Standard practice (O2 only in post-ictal period)."
62700015|NCT05745922|EXPERIMENTAL|Moderate intensity exercise|Moderate intensity endurance exercise, treadmill walking/running at 70% of heart rate maximum for 40 minutes
61952418|NCT00622401|EXPERIMENTAL|Group 3|Dendritic Cell/tumor fusion vaccine and higher dose IL-12
61952419|NCT02918201|EXPERIMENTAL|topical tranexamic acid|tranexamic acid solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
61952420|NCT02918201|PLACEBO_COMPARATOR|placebo control|Saline solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
61952421|NCT03857048|ACTIVE_COMPARATOR|Control|Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
62700016|NCT05745922|EXPERIMENTAL|High intensity exercise|High intensity interval training: treadmill walking/running. 10 minutes warm-up at 70% of heart rate maximum, followed by four 4-minutes bouts at 90-95% of heart rate maximum, separated by 3-minutes active recovery (at 70% of heart rate maximum)
61952422|NCT03857048|EXPERIMENTAL|Reduced obese + diet + exercise|Persons with obesity randomized to a weight loss program consisting of caloric restriction, behavioral support, and supervised endurance exercise training. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
61952423|NCT03857048|ACTIVE_COMPARATOR|Reduced obese + diet group|Persons with obesity randomized to a weight loss program consisting of caloric restriction and behavioral support. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
61952424|NCT03307681|EXPERIMENTAL|White bread|Matched for energy content and available carbohydrate content of potato treatments
61952425|NCT03307681|EXPERIMENTAL|Baked potato with skin|Baked russet potato
61952426|NCT03307681|EXPERIMENTAL|Mashed potato served hot|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
61952427|NCT03307681|EXPERIMENTAL|Fried French fries|Matched for available carbohydrate content of baked potato
61952428|NCT03307681|EXPERIMENTAL|Meal skipping|No food given
61952429|NCT01906632|OTHER|gene expression profile|
61952430|NCT04872582|EXPERIMENTAL|PD-1 immune checkpoint inhibitor combined with bevacizumab|
61952431|NCT05550285|EXPERIMENTAL|Orbital Volume After Using Guided Calvarial Graft in Floor Recontsruction|
61952432|NCT05550285|EXPERIMENTAL|Orbital Volume After Using 3D Printed Titanium mesh in Floor Recontsruction|
61952433|NCT05276518||o Group (1): 30 cases who will undergo Two Layer Uterine Closure|o After the delivery the first group will undergo Two Layer Uterine Closure: Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.
62141219|NCT03407144|EXPERIMENTAL|Pembrolizumab + AVD (Group 1)|After receiving two 4-week cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) induction therapy, SER participants in Group 1 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) on Day 1 of each 3-week cycle (Q3W) in combination with two cycles of AVD chemotherapy (doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2 and dacarbazine 375 mg/m\^2 on Days 1 and 15; cycle frequency every 4 weeks \[Q4W\]). All SERs in Group 1 will receive radiotherapy (RT) after completing AVD chemotherapy.
62141220|NCT03407144|EXPERIMENTAL|Pembrolizumab + COPDAC-28 (Group 2)|After receiving two 4-week cycles of OEPA (vincristine, etoposide/etopophos, prednisone/prednisolone and doxorubicin) induction therapy, SER participants in Group 2 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) Q3W, in combination with 4 cycles of COPDAC-28 chemotherapy (cyclophosphamide 500 mg/m\^2 on Days 1 and 8, vincristine 1.5 mg/m\^2 with maximum single dose 2 mg on Days 1 and 8, prednisone/prednisolone 40 mg/m\^2/day divided in 3 doses on Days 1 to 15, dacarbazine 250 mg/m\^2 on Days 1 to 3; cycle frequency Q4W). SERs in Group 2 will receive RT if they have a positive Positron Emission Tomography (PET) response after completing COPDAC-28 chemotherapy.
62141221|NCT04698382||Non-COVID-19-related sepsis|"Non-COVID-19 sepsis patients will be identified with sepsis or septic shock without a COVID-19 diagnosis code or a positive COVID-19 laboratory test.~Sepsis patients will be defined as patients with concurrent infection and organ dysfunction. Presumed concurrent infection will be defined as a blood culture order and ≥ 3 days of antibiotics administration, including at least 24h of intravenous antibiotics, or death while on antibiotics within 3 days of admission. Organ dysfunction will be defined by ICD-10-modified acute organ failure score. Sensitivity analyses will use ICD-10 explicit sepsis codes to define non-COVID-19 sepsis instead.~COVID-19 will be identified based on receiving a diagnosis code for COVID-19 (U07.1) or legacy coding (prior to the implementation of a specific COVID-19 code) present-on-admission and/or a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test on admission"
62141222|NCT04698382||Non-COVID-19, Non-Sepsis Control Population|"This will be defined as patients identified with emergency conditions of interest without a diagnosis code of sepsis, COVID19 or a positive COVID-19 laboratory test.~These include~1. Acute Gastrointestinal Bleeding (GIB): Patients with at least one GIB ICD-10 code and one relevant CPT intervention codes.~2. Myocardial Infarction (MI): Patients with at least one MI ICD-10 code and one relevant CPT intervention codes"
62141223|NCT01801800||Aneurysmal subarachnoid haemorrhage|Speckle-tracking images in Echocardiography
62141224|NCT06133530|PLACEBO_COMPARATOR|Maltose|The placebo contains maltose powder applied orally.
62141225|NCT06133530|EXPERIMENTAL|Human milk oligosaccahride|The experimental group HMO powder applied orally.
62164530|NCT04761614|EXPERIMENTAL|Treatment (riluzole, mFOLFOX6, bevacizumab)|Patients receive riluzole PO BID on days 1-14. Patients also receive oxaliplatin via IVPB over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via IV push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62164531|NCT00355771|EXPERIMENTAL|Treatment Group 1|
62164532|NCT00355771|PLACEBO_COMPARATOR|Treatment Group 2|
62700017|NCT05078112|EXPERIMENTAL|Sleep Device intervention|Infants will utilize the sleep device during sleep for 20 days
62700018|NCT05677971|EXPERIMENTAL|Fazirsiran|Participants will receive fazirsiran 200 milligram per milliliter (mg/ml) subcutaneous (SC) injection on Day 1, at Week 4, and then every 12 weeks (Q12 W) thereafter up to Week 196.
62700019|NCT05677971|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
62700020|NCT03039868||Normal Pap smears|This is the control group.
62700021|NCT03039868||Abnormal Pap smears|This is the case group.
61952434|NCT05276518||o Group (2): 30 cases who will undergo single layer uterine closure.|The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa
61952435|NCT05382663|EXPERIMENTAL|ESKD Subjects|Non-invasive device worn over vasculature.
61952436|NCT00913172||Intervention group|Directly Observed Treatment under Health Extension Workers
62500816|NCT02241798|EXPERIMENTAL|Standard practice first|"1. st, 3rd, 5th, etc seizure: Standard practice (O2 only in post-ictal period).~2. nd, 4th, 6th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated"
62343506|NCT05960461|EXPERIMENTAL|FMF (Families Moving Forward) Connect Pro with ECHO implementation|Mental health providers are trained in FMF Connect Pro with ECHO (Extension of Community Healthcare Outcomes) tele-mentoring. FMF Connect Pro teaches mental health providers how to do routine screening of prenatal alcohol exposure, diagnose fetal alcohol spectrum disorders (FASD), and support caregivers in using the FMF Connect app. The FMF Connect Pro Dashboard organizes intervention content for providers and includes tools for client progress monitoring. In this arm, providers receive training in FMF Connect Pro through 13 bi-weekly ECHO tele-mentoring sessions. Each ECHO session involves brief didactic presentations by Hub Team members on FASD-informed care principles and FMF Connect content and case-based discussions and recommendations by Spoke Sites.
62500817|NCT03084458|NO_INTERVENTION|Control|Once consented, recruited ICD patients will complete the baseline psychosocial and quality of life measures. At the first and final visit, a 6-minute walk test will be administered. Participants will be sent text messages to encourage physical activity. Participants will be re-assessed with psychosocial and quality of life measures at 30 and 90 days post enrollment. At the final (90 day) visit participants ICD will be interrogated to obtain accelerometer activity data.
62500818|NCT03084458|EXPERIMENTAL|Fitbit|Same as control condition. In addition, participants in the experimental group will receive a Fitbit device with full instructions and troubleshooting. These participants will be given daily step goals, which will be increased during the course of the study, and be able to monitor their progress using the Fitbit app.
62500819|NCT02118025||Off-pump coronary artery bypass graft|Patients operated on with off-pump coronary artery bypass graft, beating heart surgery.
62500820|NCT02118025||Mini extracorporeal circulation bypass|Patients operated on with mini extracorporeal circulation bypass. A modified extracorporeal system.
62500821|NCT01514513|EXPERIMENTAL|Licefreee Spray|
62500822|NCT01514513|ACTIVE_COMPARATOR|Nix Creme Rinse, 1% Permethrin|
62500823|NCT02105909|EXPERIMENTAL|obese subjects|DNA analysis
62500824|NCT02105909|PLACEBO_COMPARATOR|lean subjects|DNA analysis
62500825|NCT03749733|EXPERIMENTAL|Test Product|"Participants will receive a single film-coated tablet of the test formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
62700022|NCT06645431|EXPERIMENTAL|High water intake|For six days, participants will consume the NAM's recommended total water intake of 2.7 liters per day for women and 3.7 liters per day for men
61952437|NCT00913172||Control group|Directly observed treatment under general health workers
61952438|NCT04994600||EFA_1st_phase|Exploratory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of Charite intensive care units
62500826|NCT03749733|ACTIVE_COMPARATOR|Reference Product|"Participants will receive a single film-coated tablet of the marketed reference formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
62500827|NCT01103596||HIV-infected patients, 1st wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
62500828|NCT01103596||HIV-infected patients, 2nd wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
62700023|NCT06645431|ACTIVE_COMPARATOR|Low water intake|For six days, participants will consume 0.7 liters per day for women and 1 liter per day for men.
61952439|NCT04994600||CFA_2nd_phase|Confirmatory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of collaborating intensive care units.
61952440|NCT03986398|EXPERIMENTAL|Prophylactic efficacy of Urell®|Prophylactic efficacy of Urell® on urinary tract infections in patients with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty
61952441|NCT03475368|EXPERIMENTAL|Vegetarian diet|People randomized to interventional groups will take a vegetarian diet (i.e. without animal products, except milk and eggs)
61952442|NCT03475368|EXPERIMENTAL|Low carbs|People randomized to interventional groups will take a low carbs diet (i.e. with a limited amount of carbohydrates).
61952443|NCT03475368|ACTIVE_COMPARATOR|Mediterranean diet|People randomized to interventional groups will take a mediterranean diet (i.e. with low glycemic index carbohydrates and vegetables).
62500829|NCT05642533||Without a history of Type 2 diabetes|Adults with obesity
62500830|NCT05642533||With a history of Type 2 diabetes|Adults with obesity
62500831|NCT03422224||Good transplant function|Kidney transplant recipients without histological signs of rejection.
62500832|NCT03422224||Transplant Rejection|Kidney transplant recipinets experiencing a T cell mediated rejection episode.
62500833|NCT04976023|ACTIVE_COMPARATOR|Active Arm|14.55g of Yupingfeng Powder granules twice daily for 8 weeks
62500834|NCT04976023|PLACEBO_COMPARATOR|Placebo Arm|14.55g of placebo granules twice daily for 8 weeks
62500835|NCT03604549|PLACEBO_COMPARATOR|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
62500836|NCT03604549|EXPERIMENTAL|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
62700024|NCT06630156|ACTIVE_COMPARATOR|Bio-MTA revascularization|
62700025|NCT06630156|ACTIVE_COMPARATOR|Total Fill biocearmic root repair material revascularization|
62700026|NCT05826665||STAR Apollo Mapping System Group|Patients who have been referred for persistent AF catheter ablation, who have already had AF recurrence post Pulmonary Vein Isolation (PVI), will be considered for this study.
62700027|NCT05145569|EXPERIMENTAL|Carboplatin/paclitaxel + HCW9218|HCW9218 in combination with chemotherapy including carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
62700028|NCT05145569|ACTIVE_COMPARATOR|Carboplatin/paclitaxel|Carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
62700029|NCT01421420||Alzheimer's Disease|
61952444|NCT01251939||Treatment with ibuprofen|Gestational age \<32 weeks and \<1500 g, postnatal age older than 48 hours and echocardiographic evidence of hemodynamically significant PDA
61952445|NCT01251939||Controls|Gestational age \<32 weeks and \<1500 g, postnatal age older than 48 hours and without significant PDA
61952446|NCT00003487|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
61952447|NCT03539328|OTHER|Standard treatment|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion
61952448|NCT03539328|EXPERIMENTAL|Pembrolizumab|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion plus Pembrolizumab 200 mg d1 q 21 iv infusion in 30 minutes
62700030|NCT01421420||Mild Cognitive Impairment|
61952449|NCT01655914|ACTIVE_COMPARATOR|Arm A|"Sequence of Exposure:~Sequence A (N=5) Week 1: S/L 1.1 mg Week 2: S/L 2.2 mg Week 3: IV 0.2 mg Week 4: S/L 2.2 mg with 240 ml water"
61952450|NCT01655914|ACTIVE_COMPARATOR|Arm B|Sequence B (N=5) Week 1: IV 0.2 mg Week 2: S/L 2.2 mg Week 3: S/L 1.1 mg Week 4: S/L 2.2 mg with high fat diet
61952451|NCT00480883|ACTIVE_COMPARATOR|1|injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
61952452|NCT00480883|EXPERIMENTAL|2|injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
61952453|NCT03041077|EXPERIMENTAL|Instaflex Advanced|Dietary supplement: Joint function
62141226|NCT01644032|EXPERIMENTAL|Device_ Teleconsultation|"Six ambulances from five different Emergency Medical Service (EMS) districts are equipped with a portable telemedicine system. In cases of emergencies, where intravenous analgesia is necessary, if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team and can delegate the application of morphine and other analgesics. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The safety, efficacy and the quality of analgesia should be compared with regular EMS."
62141227|NCT01644032|NO_INTERVENTION|Historical Control Period|After completion of the study arm, matched pairs from a historical phase (without the ability of teleconsultation) were searched. Local cases were always matched with comparable controls from the same location.
62141228|NCT00937287||youth and caregivers|
62141229|NCT00653172|EXPERIMENTAL|1|NXL103
62141230|NCT00653172|ACTIVE_COMPARATOR|3|
62141231|NCT00653172|EXPERIMENTAL|2|NXL103
62141232|NCT03356236||Observation group 1|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe receive Huaier Granule are as observation group 1
62141233|NCT03356236||Observation group 2|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe not receive Huaier Granule are as observation group 2
62141234|NCT02198300|ACTIVE_COMPARATOR|rDES Group|regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
62141235|NCT02198300|EXPERIMENTAL|BiOSS LIM Group|BiOSS LIM® stent implantation into coronary lesion within bifurcation.
62141236|NCT06509607|EXPERIMENTAL|Group A|32 participants will be in experimental group A and will perform concentric lower limb training program including squats, lunges and leg extension exercises.
62141237|NCT06509607|EXPERIMENTAL|Group B|32 participants will be in experimental group B and will perform eccentric lower limb training program including wall sit, sitting straddle single leg and full squat exercises.
62141238|NCT05803109|EXPERIMENTAL|virgin cold-pressed coconut oil with Peppermint essential oil|Patients will be instructed to use one packet of the coco pull healthy blend of organic oil (virgin cold pressed coconut oil with Peppermint essential oil)and swish the oil in the mouth and pull it between teeth for 5 minutes then spit out the oil and brush their teeth with the oil for 2 minutes; such a regimen will be repeated twice daily for three months.
62141239|NCT05803109|ACTIVE_COMPARATOR|The fluoride toothpaste (Colgate Total,|Patients will be instructed to brush their teeth with the fluoride toothpaste (Colgat Total, 1450 ppm) for 2 minutes; such a regimen will be repeated two times daily for three months and use 10 ml of 0.12% chlorhexidine rinse for 1 min/day, 30 min after tooth brushing before going to bed.
62141240|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:~* Complete a diagnostic screening interview at baseline.~* Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.~* Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.~* Complete 9 follow-up phone calls to assess for relapse."
62141241|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:~* Complete a diagnostic screening interview at baseline.~* Complete questionnaires and computer tasks at baseline and 2 month time points.~* Complete MRI brain imaging data collection at the baseline and 2 month time points."
62141242|NCT02842957|EXPERIMENTAL|Lifestyle intervention|Behavioral: The Lifestyle arm is the experimental group that will be exposed to an intensive, individualized approach aimed at assisting these CKD patients to adhere to lifestyle changes that are expected to be beneficial to their health and wellbeing. Patients will receive direction to implement a plant based diet, along with more physical activity in their lives. They will be assisted with the optimal use of their prescribed medications by pharmacy professionals and they will receive behavioral counseling by experts in that area.
62141243|NCT02842957|NO_INTERVENTION|Usual Care|The Usual Care arm will continue to receive the current standard of care involving all the services provided at a contemporary nephrology practice in Western Massachusetts
62141244|NCT01782105|ACTIVE_COMPARATOR|Control group|In addition to the usual monitoring of pregnancy, this group will receive information about the recommended weight gain during pregnancy and an evaluation about of their nutritional and physical activity habits.
62700031|NCT01421420||Other forms of Dementia, not AD|
62700032|NCT01421420||Normal Elderly Individuals|
62700033|NCT02875418|EXPERIMENTAL|EUM and tocodynamometry|Pregnant women with gestational age 24+0/7 to 33+6/7 weeks of gestation and contractions, cramping, pelvic pressure or backache.
61952454|NCT03041077|PLACEBO_COMPARATOR|Placebo|Dietary supplement: Placebo
61952455|NCT04737382|OTHER|Biopsy and blood|A histological core biopsy of a tumor lesion and a blood sample for ctDNA analysis will be collected
61952456|NCT03265639|NO_INTERVENTION|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
61952457|NCT03265639|EXPERIMENTAL|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
62141245|NCT01782105|EXPERIMENTAL|Intervention group|"This group will receive a regular monitoring by health professionals (nutritionist and kinesiologist) who will ensure nutritional changes and physical activity necessary to secure the adoption of a healthy lifestyle and could participate to a physical activity group session once a week until week 36 of gestation.~The intervention include:~A nutritional counseling every 2 weeks by a nutritionist until week 36 of gestation; a physical activity group session once a week lead by a kinesiologist until week 36 of gestation; 2 sessions of physical activity counseling (weeks 12 and 24)."
62141246|NCT00738400|EXPERIMENTAL|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
62343507|NCT05960461|EXPERIMENTAL|FMF (Families Moving Forward) Connect Pro with Self-directed materials|Mental health providers are trained in FMF Connect Pro with self-directed materials. FMF Connect Pro teaches mental health providers how to do routine screening of prenatal alcohol exposure, diagnose fetal alcohol spectrum disorders (FASD), and support caregivers in using the FMF Connect app. The FMF Connect Pro Dashboard organizes intervention content for providers and includes tools for client progress monitoring. In this arm, mental health providers will access similar didactic content as ECHO participants, but in an asynchronous format on the FMF Connect Pro Dashboard. This will include pre-recorded videos, activities, and additional resources for further learning.
62500837|NCT04957719|EXPERIMENTAL|Selatogrel|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
62500838|NCT04957719|PLACEBO_COMPARATOR|Placebo|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
62500839|NCT04087863||Atopic Dermatitis|
62500840|NCT06679257||Lung transplanted patients|All eligible patients were transplanted and followed up within the catchment area of the participating centre.
62500841|NCT03853096|EXPERIMENTAL|Subcutaneous cefazolin arm|"A patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison.~Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route."
62500842|NCT04201795|EXPERIMENTAL|pressure and traction|pressure and traction durin 5 minutes will be applied in plantar fascia
62500843|NCT04201795|SHAM_COMPARATOR|Laser|Applied during 5 minutes each plantar fascia of sham laser
62500844|NCT00006034|EXPERIMENTAL|Arm I|Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.
62700034|NCT03113344||Children with the usage of anti-infective drugs|
62700035|NCT05724030|ACTIVE_COMPARATOR|integrated pulmonary index hypoxia -capnogarph|integrated pulmonary index montorization apliied
62343508|NCT05960461|NO_INTERVENTION|Waitlist Comparison Group|The waitlist comparison group will receive FMF Connect Pro via Self-directed materials after completing assessments at the 6-month timepoint.
62700036|NCT05724030|EXPERIMENTAL|saturation - apnea|saturation apllied
61952458|NCT03265639|NO_INTERVENTION|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
62343509|NCT00353496|EXPERIMENTAL|lanreotide (Autogel formulation)|
62343510|NCT00353496|PLACEBO_COMPARATOR|Placebo|
62500845|NCT00006034|ACTIVE_COMPARATOR|Arm II|Patients receive doxorubicin IV once weekly in weeks 1-6.
62700037|NCT03466151|EXPERIMENTAL|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
62700038|NCT03466151|ACTIVE_COMPARATOR|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
62700039|NCT03645460|EXPERIMENTAL|Direct intravenous injection of ivlv-ADA lentiviral vector|Direct intravenous injection of ivlv-ADA lentiviral vector
62700040|NCT06644053||Chronic Non-Specific Low Back Pain participants|Participants must have pain located between the thoracolumbar hinge and the lower gluteal fold, with or without pain in either leg, present for more than 12 weeks, on a daily or almost daily basis (at least 4 days out of 7).
61952459|NCT05678569||High Risk Group|Group identified by machine learning model as being at high risk of developing osteoporosis.
61952460|NCT04424888|EXPERIMENTAL|WB-011|3 capsules administered twice daily with morning and evening meal for 2 weeks
61952461|NCT04424888|PLACEBO_COMPARATOR|Placebo|3 capsules administered twice daily with morning and evening meal for 2 weeks
61952462|NCT05561569|ACTIVE_COMPARATOR|Air tamponade group|Cases with primary upper retinal detachment that will be treated with air tamponade.
61952463|NCT05561569|ACTIVE_COMPARATOR|Non expansile gas tamponade group|Cases with primary upper retinal detachment that will be treated with sulfur-hexafluoride 6 (SF-6) gas tamponade.
61952464|NCT03865914||Type 2 diabetic nephropathy|The cohort will be followed for at least 10 years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
62500846|NCT06678334||chronic rhinitis|In this study, no additional intervention was performed on the patients. Only nasal secretions and blood samples were collected from patients with chronic rhinitis in our hospital.
61952465|NCT00783237|EXPERIMENTAL|Mometasone Furoate Nasal Spray|
61952466|NCT00783237|PLACEBO_COMPARATOR|Placebo Nasal Spray|
61952467|NCT06001645||Acute Respiratory Distress Syndrome|Patients with ARDS requiring or not requiring invasive ventilation
61952468|NCT00731627|PLACEBO_COMPARATOR|1|placebo
61952469|NCT00731627|ACTIVE_COMPARATOR|11|simvastatin
61952470|NCT03142178|EXPERIMENTAL|Experimental 3VM1001 2g X 3 daily|3VM1001 active cream administered 2g cream three times daily for seven days
61952471|NCT03142178|PLACEBO_COMPARATOR|Placebo; 3VM1001 vehicle 2g X 3 daily|3VM1001 placebo vehicle administered 2g cream three times daily for seven days
61952472|NCT03142178|EXPERIMENTAL|Experimental 3VM1001 3g X 3 daily|3VM1001 active cream administered 3g cream three times daily for seven days
61952473|NCT03142178|PLACEBO_COMPARATOR|Placebo; 3VM1001 vehicle 3g X3 daily|3VM1001 placebo vehicle administered 3g cream three times daily for seven day
61952474|NCT03142178|EXPERIMENTAL|Experimental 3VM1001 3g x 4 daily|3VM1001 active cream administered 3g cream four times daily for seven days
61952475|NCT03142178|PLACEBO_COMPARATOR|Placebo; 3VM1001 vehicle 3g X 4 daily|3VM1001 placebo vehicle administered 3g cream four times daily for seven days
61952476|NCT04755790|NO_INTERVENTION|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
62141247|NCT00738400|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks
62343511|NCT01881841|NO_INTERVENTION|Treatment As Usual|Those randomized to Treatment as Usual (TAU) will not complete cMET but will receive standard treatment from the doctor.
62343512|NCT01881841|EXPERIMENTAL|cMET|Those randomized to cMET will complete a 2-session computerized Motivational Enhancement Therapy (cMET) intervention.
62343513|NCT01962519|EXPERIMENTAL|Early oral feeding|Early oral feeding starting with liquids on postoperative day (POD) 1, followed by a soft diet on POD 2, and solid foods on day 3
62343514|NCT01962519|NO_INTERVENTION|Delayed oral feeding|Delayed oral feeding starting with liquids on postoperative day (POD) 4, followed by a soft diet on POD 5, and solid foods on day 6
61952477|NCT04755790|EXPERIMENTAL|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, \~30 days post-fitting, and \~60 days post-fitting
61952478|NCT00769392|OTHER|All Participants|All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
61952479|NCT06127654|EXPERIMENTAL|Intervention|Lung sparing treatment plan
61952480|NCT06127654|NO_INTERVENTION|Control|Standard treatment plan
61952481|NCT00469274|ACTIVE_COMPARATOR|Antibiotic PEP|Subjects who did receive PEP following pertussis exposure
61952482|NCT00469274|NO_INTERVENTION|No PEP|Subjects who did not receive PEP following pertussis exposure
61952483|NCT04152655|ACTIVE_COMPARATOR|Group 1: idebenone|Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
62164533|NCT02419040|EXPERIMENTAL|Barbotage|Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
62164534|NCT02419040|ACTIVE_COMPARATOR|Corticosteroid injection|Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
62164535|NCT02419040|SHAM_COMPARATOR|Lidocain injection (sham)|Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
62164536|NCT06009770|EXPERIMENTAL|Telerehabilitation|"The TR intervention for people with PD, MS, and people post-stroke will be focused on addressing impairments and functional limitations that affect activities and participation in everyday life.~1. Frequency: 5 weeks (4 sessions/week) of TR intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous, in-clinic session/week);~2. Intensity: customized according to the patient's functional abilities (system's feedback);~3. Time: 50 minutes/session;~4. Type: according to the disease, TR protocols with a digital system (for MS and PD) or robotic tool (for post-stroke)."
62164537|NCT06009770|ACTIVE_COMPARATOR|Usual Care|Conventional rehabilitation exercises at home, customized according to the disease.
62164538|NCT02261519|EXPERIMENTAL|NaBen®|NaBen® is a oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
62164539|NCT02261519|PLACEBO_COMPARATOR|Placebo|The control treatment is placebo.
62164540|NCT05306613|EXPERIMENTAL|Prolonged sitting|Participants sat on a chair during the trial.
62164541|NCT05306613|EXPERIMENTAL|Breaking sitting|Participants walked regularly during the trial.
62164542|NCT04367948|EXPERIMENTAL|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
62164543|NCT04367948|EXPERIMENTAL|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
62164544|NCT01039116|EXPERIMENTAL|Level of intervention intensity|"High Intensity: Behavioral Experimental:Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.~Active Comparator: Low-intensity Participants were provided with educational materials 4 times yearly."
62164545|NCT00525642|EXPERIMENTAL|A|six cycles of adjuvant TAC
62164546|NCT00525642|EXPERIMENTAL|B|four cycles of T followed by 4 cycles of AC
62164547|NCT05763121|EXPERIMENTAL|150 mg BID|Dexpramipexole 150 mg oral tablet taken twice a day
62500847|NCT02518607|EXPERIMENTAL|Group 1, Session 1, Active|"Lowest dose of SAD:~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
62500848|NCT02518607|EXPERIMENTAL|Group 1, Session 2, Active|"Dose Escalation SAD:~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
62700041|NCT06644053||Control group|Participant with no current or past chronic pain
61952484|NCT04152655|PLACEBO_COMPARATOR|Group 2: placebo|Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
61952485|NCT02011971|ACTIVE_COMPARATOR|Low dose|Vinpocetine 10 mg Healthy subjects
61952486|NCT02011971|ACTIVE_COMPARATOR|Mid-dose 1|Vinpocetine 20mg Healthy subjects
61952487|NCT02011971|PLACEBO_COMPARATOR|Placebo|0 dose of vinpocetine Healthy and Epilepsy subjects
61952488|NCT02011971|ACTIVE_COMPARATOR|High Dose|Vinpocetine 60 mg single dose Healthy Subjects \& 20mg tid Epilepsy Subjects
61952489|NCT02696460|ACTIVE_COMPARATOR|N2O/O2 analgesia|Wound debridement under analgesia with N2O/O2 premix.
61952490|NCT02696460|ACTIVE_COMPARATOR|Lidocaine/Prilocaine analgesia|Wound debridement under analgesia with eutectic mixture of 5% lidocaine/prilocaine.
61952491|NCT04425512|ACTIVE_COMPARATOR|Thyroid Malignancy|Thyroidectomy
61952492|NCT04425512|SHAM_COMPARATOR|Benign Thyroidal Goitor|Thyroidectomy
61952493|NCT04425512|OTHER|Control Group|Selective lichtenstein procedure for inguinal hernia
61952494|NCT05997160||hospital name + infection type + number|There is no intervention.
61952495|NCT00259337|EXPERIMENTAL|1|
61952496|NCT06134622|EXPERIMENTAL|Intravenous thrombolysis plus tirofiban administration|Patients will receive Intravenous thrombolysis and tirofiban administration
61952497|NCT06134622|ACTIVE_COMPARATOR|Intravenous thrombolysis plus placebo administration|Patients will receive Intravenous thrombolysis and placebo (saline) administration
61952498|NCT01552694|EXPERIMENTAL|Sitagliptin|100 mg sitagliptin/day for 2 months
61952499|NCT01552694|PLACEBO_COMPARATOR|Placebo|Matching placebo daily for 2 months
61952500|NCT02946528|EXPERIMENTAL|urgent-start peritoneal dialysis|All patients in urgent-start peritoneal dialysis arm initiate peritoneal dialysis as urgent-start dialysis modality.
61952501|NCT02946528|ACTIVE_COMPARATOR|urgent-start hemodialysis|All patients in urgent-start hemodialysis arm initiate hemodialysis as urgent-start dialysis modality.
61952502|NCT00550524|EXPERIMENTAL|A|Knee osteoarthritis
61952503|NCT03033004|ACTIVE_COMPARATOR|Conventional Cryolipolysis|Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
61952504|NCT03033004|ACTIVE_COMPARATOR|Contrast Cryolipolysis|Subjects will receive one treatment session of contrast cryolipolisys. Subcutaneous fat tissue will be heated for 10 minutes, cooled for 60 minutes, and heated again for 10 minutes with the cryolipolitic device. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
62700042|NCT06261255|EXPERIMENTAL|ATT + EMD|There is only 1 arm, autotransplantation (ATT) + adjunctive EMD
62700043|NCT01630109|ACTIVE_COMPARATOR|Metoclopramide 5 mg|Pro-motility agent
62700044|NCT01630109|ACTIVE_COMPARATOR|Metoclopramide 10 mg|Pro-motility agent
62700045|NCT01630109|PLACEBO_COMPARATOR|Placebo control|Placebo to be used as the control group
62700046|NCT01859013|EXPERIMENTAL|Topiramate|Four (4) weeks of meal replacement therapy, followed by 28-weeks of topiramate therapy. Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks.
62700047|NCT01859013|PLACEBO_COMPARATOR|Sugar Pill|Four (4) weeks of meal replacement therapy, followed by 28-weeks of placebo (sugar pill) therapy.
62700048|NCT00936936|EXPERIMENTAL|Cycle # 1|"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC"
61952505|NCT03033004|ACTIVE_COMPARATOR|Reperfusion Cryolipolysis|Subjects will receive one treatment session of Reperfusion Cryolipolysis. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes and heated for 10 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
61952506|NCT00762385|ACTIVE_COMPARATOR|galyfilcon A/comfilcon A|galyfilcon A first, comfilcon A second
61952507|NCT00762385|ACTIVE_COMPARATOR|comfilcon A/galyfilcon A|comfilcon A first, galyfilcon A second
61952508|NCT01898637|ACTIVE_COMPARATOR|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
61952509|NCT01898637|OTHER|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
61952510|NCT02599714|EXPERIMENTAL|Triplet Combination (Dose Finding)|Phase 1 triplet dose finding phase in 3-6 patients per cohort - approximately 30 patients depending on emerging data to determine the maximum tolerated dose (MTD) of the triplet.
61952511|NCT02599714|EXPERIMENTAL|Triplet Combination (Dose Expansion)|Additional patients will be enrolled at the dose determined in Part A.
61952512|NCT05248061|ACTIVE_COMPARATOR|Group A|home exercise program
61952513|NCT05248061|EXPERIMENTAL|Group B|PRP+home exercise program
61952514|NCT01685892|EXPERIMENTAL|Dose-Finding: Schedule A: Relapsed/Refractory CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
61952515|NCT01685892|EXPERIMENTAL|Dose-Finding: Schedule B: Relapsed/Refractory CLL|In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
62164548|NCT05763121|EXPERIMENTAL|75 mg BID|Dexpramipexole 75 mg oral tablet taken twice a day
62164549|NCT05763121|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet taken twice a day
62500849|NCT02518607|EXPERIMENTAL|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
62500850|NCT02518607|EXPERIMENTAL|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
62500851|NCT02518607|EXPERIMENTAL|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
62500852|NCT02518607|EXPERIMENTAL|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
62500853|NCT02518607|EXPERIMENTAL|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
62500854|NCT02518607|EXPERIMENTAL|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
62500855|NCT02518607|EXPERIMENTAL|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
61952516|NCT01685892|EXPERIMENTAL|Dose-Finding: Schedule A: Previously Untreated CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
61952517|NCT01685892|EXPERIMENTAL|Dose-Finding: Schedule B: Previously Untreated CLL|In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
62343515|NCT02462941|EXPERIMENTAL|Adenosine|After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.
62343516|NCT04151355|EXPERIMENTAL|Atorvastatin group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) in addittion to atorvastatin (20 mg once daily)
62343517|NCT04151355|NO_INTERVENTION|Control group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks)
62700049|NCT00936936|EXPERIMENTAL|Cycle #2|"Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC"
62343518|NCT03441893|ACTIVE_COMPARATOR|Patients with ulcerative colitis|Patients with ulcerative colitis in this group will take nitazoxanide per os
62500856|NCT02518607|PLACEBO_COMPARATOR|Group 1, Session 1, Placebo|"Lowest dose of SAD:~Placebo, 1 liquid filled enterically coated capsule, single dose"
62500857|NCT02518607|PLACEBO_COMPARATOR|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
62500858|NCT02518607|PLACEBO_COMPARATOR|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
62500859|NCT02518607|PLACEBO_COMPARATOR|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
62500860|NCT02518607|PLACEBO_COMPARATOR|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
62500861|NCT02518607|PLACEBO_COMPARATOR|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
62500862|NCT02518607|PLACEBO_COMPARATOR|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
62500863|NCT02518607|PLACEBO_COMPARATOR|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
62700050|NCT03730350|EXPERIMENTAL|Hypnosis|Prior to surgery, a member of the pain psychology team will guide patients through a clinical hypnosis session aimed at preparing for surgery by reducing anxiety and introducing relaxation and self-soothing strategies that can be used after surgery for adaptive coping. They will also be provided with a recording of this hypnosis script to use at home, and it will be recommended that they listen to the recording on the two days prior to surgery. Following surgery, a clinician from the pain psychology team will visit the patient in hospital on post-operative day one or whenever they are able to be seen prior to hospital discharge, in order to guide them through a clinical hypnosis session targeted at increasing comfort and pain relief.
61952518|NCT01685892|EXPERIMENTAL|Safety Expansion: Relapsed/Refractory CLL|In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
61952519|NCT01685892|EXPERIMENTAL|Safety Expansion: Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
61952520|NCT01702961|OTHER|BEAM+R: Autologous Stem Cell Transplant|Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
61952521|NCT04996043|PLACEBO_COMPARATOR|Placebo drink|
61952522|NCT04996043|EXPERIMENTAL|Collagen Peptide Drink|
62500864|NCT02518607|PLACEBO_COMPARATOR|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
62500865|NCT02963064|EXPERIMENTAL|Blood Stem Cell Transplant w/ anti-CD117 conditioning|The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID. The study plans to assess JSP191 in different dose cohorts. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
62500866|NCT05700136||MOMENT cohort|The cohort will be recruited at third trimester of pregnancy and required to fill up questionnaires and complete saliva collection. We will then follow up with the cohort at 3 months after birth to collect follow up data of the mother and infant. Lastly, we will collect growth outcomes of the infant at 6 months.
61952523|NCT01675791|PLACEBO_COMPARATOR|ALK tree AIT Placebo|1 AIT administered sublingually every day
62500867|NCT02261220|EXPERIMENTAL|MEDI4736 + Tremelimumab|Subjects with multiple tumor types.
62500868|NCT00930592||Children with Psoriasis|Children and adolescents from 10-17 years of age with moderate to severe psoriasis.
62500869|NCT00930592||Control: children with warts|Children and adolescents from 10-17 years of age with warts.
62500870|NCT01352364|EXPERIMENTAL|deaf children|
62500871|NCT00846898|EXPERIMENTAL|cinnamon|Subjects in this group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
62500872|NCT00846898|PLACEBO_COMPARATOR|Control|Subjects in this group will receive placebo capsules (starch flour) for 12 weeks period. The 2 g dose of starch capsules will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
61952524|NCT01675791|EXPERIMENTAL|ALK tree AIT 0.5 DU|1 AIT administered sublingually every day
61952525|NCT01675791|EXPERIMENTAL|ALK tree AIT 1 DU|1 AIT administered sublingually every day
61952526|NCT01675791|EXPERIMENTAL|ALK tree AIT 2 DU|1 AIT administered sublingually every day
61952527|NCT01675791|EXPERIMENTAL|ALK tree AIT 4 DU|1 AIT administered sublingually every day
61952528|NCT01675791|EXPERIMENTAL|ALK tree AIT 7 DU|1 AIT administered sublingually every day
61952529|NCT01675791|EXPERIMENTAL|ALK tree AIT 12 DU|1 AIT administered sublingually every day
61952530|NCT04999488|PLACEBO_COMPARATOR|Older adults with sarcopenia (placebo)|
61952531|NCT04999488|ACTIVE_COMPARATOR|Older adults with sarcopenia (drug)|
61952532|NCT02072083|ACTIVE_COMPARATOR|dexmedetomidine|intranasal 1mcg/kg
61952533|NCT02072083|ACTIVE_COMPARATOR|ketamine|intranasal 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
61952534|NCT03764696|NO_INTERVENTION|air, the first and second stage of labor|"Patients randomized to the group will receive room air.~The therapy will continue until after delivery"
62500873|NCT01191606|ACTIVE_COMPARATOR|Group A|the exchange of ventilatory mode from volume controlled ventilation to pressure controlled ventilation
62700051|NCT03730350|NO_INTERVENTION|Standard Care|This control group will receive standard care pre- and post-surgery. After the completion of their one-month trial, control participants will be offered access to the hypnosis recordings, as well as an in-person hypnosis session.
62700052|NCT05888064||Prospective non-invasive MRI acquisitions are planned to be performed|Prospective non-invasive MRI acquisitions are planned to be performed
61952535|NCT03764696|EXPERIMENTAL|oxygen, the first and second stage of labor|"Patients randomized to the group will receive oxygen administered by high flow facemask oxygen at 10 L/min oxygen.~The therapy will continue until after delivery"
61952536|NCT00917995|EXPERIMENTAL|Colostomy with a prophylactic mesh|
61952537|NCT00917995|NO_INTERVENTION|Colostomy without a prophylactic mesh|
62500874|NCT01191606|ACTIVE_COMPARATOR|Group B|the exchange of ventilatory mode from pressure controlled ventilation to volume controlled ventilation
62500875|NCT00831987|EXPERIMENTAL|Fluzone® Vaccine Group - Age 18-59 Years|Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
62700053|NCT05888064||retrospective group|patients treated for skull base chordoma with particle therapy
61952538|NCT00668707|EXPERIMENTAL|Melatonin|To receive 20 mg of melatonin nightly for 1 year post-surgery
61952539|NCT00668707|PLACEBO_COMPARATOR|Placebo|To receive 20 mg placebo nightly for 1 year post-surgery
61952540|NCT02487667|ACTIVE_COMPARATOR|Intervention Group|Therapeutic exercise
61952541|NCT02487667|NO_INTERVENTION|Control Group|No treatment
61952542|NCT05066854|EXPERIMENTAL|Integron research|"Empirical antibiotic treatment chosen based on the results of the integron search:~* when PCR is negative, patients will receive SXT (30 mg/kg/j of sulfamethoxazole and 6 mg/kg/j of trimethoprim)~* when PCR is positive or uninterpretable for integrons, patients will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
61952543|NCT05066854|OTHER|Usual practice|Empirical antibiotic treatment based on the usual practice of each center according to the GPIG guidelines.
61952544|NCT01739452||erythropoiesis-stimulating agents|Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents.
61952545|NCT01739452||Transfusion support|A control group of patients who received only transfusional support.
61952546|NCT02128971|ACTIVE_COMPARATOR|Ferrochel® 90 mg|Ferrochel® capsule 90 mg OD for 30 days
61952547|NCT02128971|ACTIVE_COMPARATOR|Sumalate® 90 mg|Sumalate® capsule 90 mg OD for 30 days
61952548|NCT02128971|ACTIVE_COMPARATOR|Ferrous Fumarate 90 mg|Ferrous Fumarate capsule 90 mg OD for 30 days
61952549|NCT02128971|ACTIVE_COMPARATOR|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg OD for 30 days
61952550|NCT02128971|ACTIVE_COMPARATOR|Ferric glycinate 90 mg|Ferric glycinate capsule 90 mg OD for 30 days
61952551|NCT02128971|ACTIVE_COMPARATOR|Placebo|Placebo capsule OD for 30 days
61952552|NCT00544518|EXPERIMENTAL|2|
61952553|NCT00544518|ACTIVE_COMPARATOR|1|
61952554|NCT00753571|ACTIVE_COMPARATOR|1|1,CTG,po
61952555|NCT00753571|PLACEBO_COMPARATOR|2|
62500876|NCT00831987|EXPERIMENTAL|Fluzone® Vaccine Group - Age ≥ 60 Years|Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
62500877|NCT01734694|ACTIVE_COMPARATOR|Vancomycin|
61952556|NCT05663567|EXPERIMENTAL|experimental group 1|Implementing a solution-focused approach to support breastfeeding ONE TO ONE STUDY
62343519|NCT03441893|NO_INTERVENTION|Participants (control group)|only parasitological diagnostics will be performed in this group to compare the prevalence of some representatives of the microbiota
62700054|NCT04855890|ACTIVE_COMPARATOR|Cryo-Ablation|Cryo-Balloon (Arctic Front Advance ProTM, Medtronic, Minneapolis, MN, USA) will be advanced to the LA and navigated to the PV's using an inner-lumen circular mapping catheter (Achieve AdvanceTM, Medtronic, Minneapolis, MN, USA). After confirming complete PV sealing by the CB using occlusion angiograms cryothermal energy will be applied for min 120 seconds aiming at PV isolation of all PV's according to the clinical standard.
61952557|NCT05663567|EXPERIMENTAL|experimental group 2|Implementing a solution-focused approach to support breastfeeding GROUP STUDY
62141248|NCT03454256|EXPERIMENTAL|Virtual Reality Group (VRG)|The Virtual Reality Group (VRG) will perform the rehabilitation trough the Virtual Reality Rehabilitation system (VRRS, Khymeia,Italy). The patient standing upright on a balance board will practice exercises of vertical position control with a visual biofeedback received from the VRRS and interacting with the serious video-games. The difficulty level of the exercises will increase gradually session by session. Every session will last 45 minutes with a frequency of at least 5 times a week.
62141249|NCT03454256|NO_INTERVENTION|Control Group (CG)|The Control Group (CG) will perform the traditional treatment consisting of the exercises of rehabilitation of gait and postural passages, exercises for postural control, and proprioceptive exercises in a vertical position according to the method chosen by the physiotherapist. Every session will last 45 minutes with a frequency of at least 5 times a week.
62141250|NCT02912247|EXPERIMENTAL|monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once
62141251|NCT02912247|ACTIVE_COMPARATOR|adalimumab|adalimumab 40mg administered subcutaneously once
62141252|NCT06475521|EXPERIMENTAL|Arm 1|Infant formula test group; Group that receives the test product.
62141253|NCT06475521|ACTIVE_COMPARATOR|Arm 2|Infant formula control group; Group that receives a comparative control product.
62141254|NCT00759798|EXPERIMENTAL|Fludarabine, Cyclophosphamide, Rituximab|"Fludarabine 25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
62141255|NCT03646266|EXPERIMENTAL|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
62141256|NCT03646266|NO_INTERVENTION|Control|Standard of care
62141257|NCT03601715|ACTIVE_COMPARATOR|Coplanar|Electrode placed side by side on the same aspect of the right tight.
62500878|NCT01734694|ACTIVE_COMPARATOR|Comparator|
62500879|NCT04086524|EXPERIMENTAL|Binocular cartoon treatment at home|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL at home. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
62500880|NCT04086524|ACTIVE_COMPARATOR|Control group|"Participants will patch for 2 hours every day at home. After 2 weeks, they will be given the option to crossover to the teratment group for an additional 2 weeks (total of 4 weeks). Patching is a common treatment for amblyopia, often considered the golden standard. It is the most common comparison as a control group in amblyopia and vision therapy literature."
62500881|NCT04086524|EXPERIMENTAL|Binocular cartoon treatment in office|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL in office. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
62500882|NCT03296735|EXPERIMENTAL|Ipsilateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
62500883|NCT03296735|NO_INTERVENTION|Supine|Measuring the cross-sectional area of right subclavian vein in supine position.
61952558|NCT05663567|NO_INTERVENTION|No Intervention|ROUTINE MAINTENANCE WILL BE DONE SOLUTION-FOCUSED APPROACH WILL NOT BE APPLIED.
61952559|NCT03947801|EXPERIMENTAL|Greek Yogurt condition|3x 160g of 0% Plain Greek yogurt (\~115 kcals, 17 g protein, \~11.5 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
61952560|NCT03947801|PLACEBO_COMPARATOR|Isoenergetic condition - Carbohydrate|3x 30g of isoenergetic CHO supplement (\~115 kcal, 0.04 g protein, \~28.6 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
61952561|NCT03147560|EXPERIMENTAL|Group 1|The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
61952562|NCT03147560|EXPERIMENTAL|Group 2|The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
61952563|NCT03147560|EXPERIMENTAL|Group 3|The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.
62141258|NCT03601715|ACTIVE_COMPARATOR|Contraplanar|Electrode placed over opposite aspects of the right tight.
62141259|NCT03601715|ACTIVE_COMPARATOR|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
62141260|NCT03398798|ACTIVE_COMPARATOR|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
62141261|NCT03398798|ACTIVE_COMPARATOR|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
62343520|NCT03441893|ACTIVE_COMPARATOR|UC patients (cohort 1)|Patients with ulcerative colitis in this group will take standart therapy (mesalazin)
61952564|NCT00986830|EXPERIMENTAL|Balloon Dilation|Balloon dilation of the maxillary sinuses using the FinESS Sinus Treatment device.
61952565|NCT03144960|OTHER|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
61952566|NCT05212571|EXPERIMENTAL|Outpatient|The experimental intervention group visits the outpatient clinic to receive intravenous esketamine in day-care setting every 2 weeks for 3 months.
62500884|NCT03296735|ACTIVE_COMPARATOR|Contralateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
62700055|NCT04855890|ACTIVE_COMPARATOR|High Power Short Duration-Ablation|"A detailed electroanatomical map of the left atrium during sinus rhythm will be acquired using Ensite (Abbott, St. Paul, MN, USA).~Upon completion of the LA map, a second transseptal puncture will be performed in order to insert an ablation catheter. To achieve antral PVI irrigated radiofrequency current ablation will be performed using a power of 70W and a flush rate of 8-30ml/min with a duration of 5 seconds for the anterior and 7 seconds for the posterior LA. Ablation catheters used will contain Flexibilty (Abbott, St. Paul, MN, USA) and TactiFlex (Abbott, St. Paul, MN, USA)."
62700056|NCT05543317|EXPERIMENTAL|68Ga-FAPI-RGD|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAPI-RGD, and undergo PET/CT imaging within the specified time.
61952567|NCT05212571|ACTIVE_COMPARATOR|Inpatient|The standard treatment group receives intravenous esketamine for 6 consecutive days in hospital.
62141262|NCT03398798|ACTIVE_COMPARATOR|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
62141263|NCT03398798|ACTIVE_COMPARATOR|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
62141264|NCT02170259|EXPERIMENTAL|suboccipital technique|The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region.
62141265|NCT02170259|EXPERIMENTAL|The articulatory technique|- The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases.
62343521|NCT03441893|PLACEBO_COMPARATOR|UC patients (cohort 2)|Patients with ulcerative colitis in this group will take placebo tabletes
62343522|NCT03441893|ACTIVE_COMPARATOR|UC patients (cohort 3)|Patients with ulcerative colitis in this group will take combination standart therapy with nitazoxanide
62700057|NCT05136560|NO_INTERVENTION|Placebo|normal saline
62700058|NCT05136560|EXPERIMENTAL|low dose dexamethasone|0.1 mg/kg dexamethasone iv once per day, for 1 or 2 days
62343523|NCT01056341|EXPERIMENTAL|Propranolol oral solution|
62343524|NCT01056341|PLACEBO_COMPARATOR|Placebo|
62343525|NCT00755846|EXPERIMENTAL|Alogliptin 6.25 mg QD|
62700059|NCT05136560|EXPERIMENTAL|high dose dexamethasone|0.2 mg/kg dexamethasone iv once per day, for 1 or 2 days
62700060|NCT05943678||Healthy controls|negative controls
62700061|NCT05943678||Pompe Disease patients|
62700062|NCT05943678||McArdle Disease patients|positiv controls
62700063|NCT02919618|EXPERIMENTAL|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to a region of the heart determined by EP-guidance, using noninvasive electrical mapping combined with anatomic imaging.
62700064|NCT05525390|ACTIVE_COMPARATOR|Traditional Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life. Participants will complete the PHQ-9 and their activity monitoring and scheduling on separate worksheets.
61952568|NCT00384566|EXPERIMENTAL|1|
61952569|NCT00384566|ACTIVE_COMPARATOR|2|
61952570|NCT00727428|EXPERIMENTAL|Group A|
61952571|NCT05947383|EXPERIMENTAL|Psilocybin|
61952572|NCT05947383|PLACEBO_COMPARATOR|Placebo|
61952573|NCT05541120|NO_INTERVENTION|Living Well with Diabetes|Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program, PCP evaluation and management, including medication adjustment or interventions, and other types of interventions depending on clinical judgement. This may include eConsults between the provider and a pharmacist, in-person visits between the provider and the patient, synchronous telemedicine visits between the provider and the patient, and synchronous telemedicine visits between the pharmacist and the patient.
61952574|NCT05541120|EXPERIMENTAL|Living Well with Diabetes + Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
62343526|NCT00755846|EXPERIMENTAL|Alogliptin 12.5 mg QD|
61952575|NCT04020380|EXPERIMENTAL|Azithromycin 250 mg|Azithromycin, 250 mg capsules once a day for a total of 3 months
61952576|NCT02164942||Single Arm|Specimen Collection
61952577|NCT05620771|EXPERIMENTAL|Y90 + Atezolizumab and Bevacizumab|
61952578|NCT05620771|EXPERIMENTAL|Y90 + TKI|
61952579|NCT05723978||Selective extended dissection (SED) group|
61952580|NCT05723978||Standard dissection (SD) group|
61952581|NCT02107170|EXPERIMENTAL|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
62500885|NCT02319057|EXPERIMENTAL|Panel 1|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
62500886|NCT02319057|EXPERIMENTAL|Panel 2|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
62500887|NCT02319057|EXPERIMENTAL|Panel 3|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
62500888|NCT02319057|EXPERIMENTAL|Panel 4|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
62500889|NCT02319057|EXPERIMENTAL|Panel 5|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
62500890|NCT02319057|EXPERIMENTAL|Panel 6|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
62700065|NCT05525390|EXPERIMENTAL|XR-Enhanced Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in extended reality (XR). Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick at least four pleasurable activities to enjoy in extended reality. Participants will complete their post-XR surveys and add and schedule activities on separate worksheets.
62700066|NCT05932498|EXPERIMENTAL|PENG group|Participants with PENG block
62700067|NCT05932498|ACTIVE_COMPARATOR|QL group|Participants with QL block
62141266|NCT02170259|EXPERIMENTAL|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT.
62500891|NCT06215196|EXPERIMENTAL|Semaglutide with Active Fiber Supplement Group|
62500892|NCT06215196|PLACEBO_COMPARATOR|Placebo group|
62500893|NCT04347330|EXPERIMENTAL|Intensive BP Control|Participants randomized into the Intensive BP Control arm will have a goal of home SBP \<120mmHg. For most participants in the Intensive Group, a two- or three-drug regimen should be initiated at randomization. Following the randomization visit, addition of another drug or medication dose titration is indicated if home SBP is ≥120 mmHg. Monthly visits will continue in the Intensive Group until home SBP \<120 mmHg or no more titration planned. If the home SBP is not \<120 mmHg at the every 6-month visit, then an antihypertensive drug from a class different from what is being taken should be added, rather than up-titration the dosage of previous drugs, unless there are compelling reasons against this practice.
62500894|NCT04347330|ACTIVE_COMPARATOR|Standard BP Control|Participants randomized into the Standard BP Control arm will have a goal of home SBP \<135mmHg. The Standard BP protocol is designed to achieve a home SBP of 130-134 mmHg in as many participants as possible. Following the randomization visit, medication dose titration or addition of another drug is indicated if home SBP ≥135 mmHg. Monthly visits will continue in the Standard Group when home SBP ≥155 mmHg. Down titration (a reduction of the dose or number of antihypertensive drugs) should be carried out if the home SBP is \<125 mmHg.
62500895|NCT04439331|EXPERIMENTAL|Treatment (defactinib)|Patients receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62500896|NCT02857387|EXPERIMENTAL|acute coronary syndrome|
62500897|NCT06679231|EXPERIMENTAL|Stress Ball|After the initial measurements of the participants assigned to the experimental group, the students involved in the project will accompany the patient and prepare the patient for the gynecological examination. To make the patient feel more comfortable during the gynecological examination, she will be given two stress balls. The patient will be asked to count each time she squeezes the stress ball during the examination. During the gynecological procedure, the participant will be administered the first EC-3. The stress ball intervention will help to reduce the participant's anxiety level and make the examination process more tolerable.
62500898|NCT06679231|NO_INTERVENTION|Control|After the initial measurements of the participants assigned to the control group, the student involved in the project will prepare the patient for a gynecological examination. Patients in the control group will be provided with only a relaxing environment, without a stress ball during the examination.
62500899|NCT05624762|ACTIVE_COMPARATOR|LIFU group|receive LIFU therapy
62141267|NCT02170259|NO_INTERVENTION|Control group|Control group. The control group was not applied a treatment technique
62343527|NCT00755846|EXPERIMENTAL|Alogliptin 25 mg QD|
62141268|NCT04018222||Lupus Cases|This cohort of patients will involve individuals with a confirmed medical history of Systemic Lupus Erythematosus. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
62141269|NCT04018222||Healthy Controls|This cohort of patients will involve individuals whom do not have a diagnosis of Systemic Lupus Erythematosus or any other rheumatological or auto-immune diseases. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
62141270|NCT02762201|EXPERIMENTAL|PASI|PASI dental prosthesis delivery
62141271|NCT02762201|ACTIVE_COMPARATOR|PAC|PAC dental prosthesis delivery
62500900|NCT05624762|SHAM_COMPARATOR|Control group|receive sham LIFU therapy
62141272|NCT01809457|EXPERIMENTAL|educational poster|poster display for 2 weeks in classrooms,
62500901|NCT06424691|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive comprehensive support to improve their infant's gut health over six months.
62500902|NCT06424691|NO_INTERVENTION|Control|Participants in the control arm will serve as a comparison group and will not receive the intervention during the study period.
62500903|NCT01105182||Radiofrequency Ablation|
62700068|NCT05548114|ACTIVE_COMPARATOR|EUS-guided gastrojejunostomy|EUS-guided gastrojejunostomy is performed using a lumen-apposing metal stent
62700069|NCT05548114|ACTIVE_COMPARATOR|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic or open technique, as clinically appropriate.
62700070|NCT06067698|PLACEBO_COMPARATOR|Group (Placebo)|(Placepo group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo once daily
62700071|NCT06067698|ACTIVE_COMPARATOR|Group (Alpha lipoic acid)|(Alpha-lipoic acid group; n=30) which will receive mesalamine 1000 mg three times daily plus alpha-lipoic acid 600 mg
62343528|NCT00755846|EXPERIMENTAL|Alogliptin 50 mg QD|
62500904|NCT05465096|EXPERIMENTAL|MF-AT injection|Patients will be treated with an intra-articular-ultrasound-guided injection of Micro-fragmented adipose tissue containing mesenchymal stromal cells.
62500905|NCT02332005|ACTIVE_COMPARATOR|Group 1 150 mg|150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo
62500906|NCT02332005|ACTIVE_COMPARATOR|Group 2 300 mg|300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline
62343529|NCT00755846|EXPERIMENTAL|Alogliptin 100 mg QD|
62500907|NCT02332005|PLACEBO_COMPARATOR|Group 3|Tablet administered twice daily morning and evening containing placebo
61952582|NCT02107170|ACTIVE_COMPARATOR|propofol & remifentanil|propofol (50 - 150 µg/kg/min) plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
62343530|NCT00755846|PLACEBO_COMPARATOR|Placebo QD|
61952583|NCT00807170|EXPERIMENTAL|ZACTIMA TM|
61952584|NCT05938517|EXPERIMENTAL|Betahistine-dihydrochloride|Subjects received single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally for pharmacokinetic serum draw with at least two days between the different dosages.
61952585|NCT05938517|EXPERIMENTAL|Betahistine-dihydrochloride and Selegiline-hydrochloride|Subjects were pre-treated with Selegiline (5 mg/day) orally for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally with at least two days between the different dosages.
61952586|NCT02655796|EXPERIMENTAL|Moderate/High Risk|Participants assessed as moderate/high risk of falling according to the CDC Algorithm for Fall Risk Assessment
61952587|NCT02655796|EXPERIMENTAL|Low Risk|Participants assessed as low risk of falling according to the CDC Algorithm for Fall Risk Assessment
61952588|NCT05820672||Patients on SKYTROFA Treatment|Patients on SKYTROFA Treatment managed in USA with appropriate written Informed Consent
61952589|NCT02492269|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
61952590|NCT02492269|PLACEBO_COMPARATOR|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
61952591|NCT04709107||Elective|Patients undergoing elective revascularisation (endovascular or surgical) for PAD.
61952592|NCT04709107||Emergent|Patients undergoing emergent revascularisation (endovascular or surgical) for PAD.
61952593|NCT01848691|EXPERIMENTAL|Sickle Cell|This arm will include 20 children with sickle cell anemia
61952594|NCT01848691|ACTIVE_COMPARATOR|Control|This arm will include 20 children without sickle cell anemia
61952595|NCT03533296|EXPERIMENTAL|Children|Children who receive elective surgery under general anesthesia and are supported by mechanical ventilation
61952596|NCT04092400||Micro-Invasive Glaucoma Surgical devices|Patients implanted With Micro-invasive Glaucoma Surgical (MIGS) devices at the National University Hospital, Singapore
61952597|NCT03562533||pegylated liposomal doxorubicin + carboplatin|carboplatin area under the curve \[AUC\] 5 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 every 4 weeks
61952598|NCT03562533||paclitaxel + carboplatin|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks
61952599|NCT04263077|PLACEBO_COMPARATOR|PLACEBO|IN THE PLACEBO GROUP, THE ENDS OF THE TAPES WILL BE APPLIED NO TENSION WITHOUT OVERLAPPING EACH OTHER.
61952600|NCT04263077|OTHER|50% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 50% TENSION.
61952601|NCT04263077|OTHER|75% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 75% TENSION.
61952602|NCT04263077|OTHER|100% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 100% TENSION.
62141273|NCT01809457|NO_INTERVENTION|control|no intervention, waiting for two weeks
62141274|NCT05023434||Awake Craniotomy|
62141275|NCT05023434||Healthy Volunteers - No Longer Enrolling|
62343531|NCT05735509|ACTIVE_COMPARATOR|Before rubber dam|Impression taken before rubber dam placement is used for crown manufacturing
62500908|NCT01849458||BioFiber|Subjects implanted with BioFiber Scaffold or BioFiber-CM Scaffold
62500909|NCT02479477|EXPERIMENTAL|kinesio therapy|"The intervention is one protocol of labour kinesiotherapy that will be realized tree times per week, eatch intervention with fiveteen minutes, during eitgh weeks.~To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase."
62500910|NCT02479477|NO_INTERVENTION|control|the control group will continue their daily tasks uring eitgh weeks. To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase.
62500911|NCT00569777|EXPERIMENTAL|K-lens|etafilcon A contact lens with ketotifen.
61952603|NCT06061536|EXPERIMENTAL|Group A：Lipovirtide 10mg+3TC+TDF|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）
61952604|NCT06061536|EXPERIMENTAL|Group B：Lipovirtide 40mg+3TC+TDF|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）
61952605|NCT06061536|EXPERIMENTAL|Group C：Lipovirtide 60mg+3TC+TDF|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）
61952606|NCT06061536|EXPERIMENTAL|Group D：DTG +3TC + TDF|DTG +3TC + TDF（once daily）
61952607|NCT05620927||Type 1 diabetes|Type 1 diabetes \> 10 years duration of diabetes
61952608|NCT01862900|EXPERIMENTAL|15 Gy|Patients receive a radiation dose of 15 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
61952609|NCT01862900|EXPERIMENTAL|20 Gy|Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
61952610|NCT01862900|EXPERIMENTAL|25 Gy|Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
61952611|NCT05004103|EXPERIMENTAL|Skin microbiome evaluation|Female healthy volunteers applied cosmetic products (cleanser and moisturizer cream), the diversity of skin microbiome will be examined before and after using the products
61952612|NCT03714971|EXPERIMENTAL|Receiving WhatsApp messages|Among patients applying to the smoking cessation outpatient clinic between March and October 2017, \>18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
62141276|NCT06699628|EXPERIMENTAL|IRL757|IRL757, single dose
62141277|NCT02328144|ACTIVE_COMPARATOR|Metronidazole|22 patients received oral metronidazole 500mg 3 times for day for 7 days
62343532|NCT05735509|EXPERIMENTAL|After rubber dam|Impression taken after rubber dam placement is used for crown manufacturing
62500912|NCT00569777|PLACEBO_COMPARATOR|Placebo|etafilcon A contact lens without ketotifen
62500913|NCT06679569|ACTIVE_COMPARATOR|moderate neuromuscular blockade|
62500914|NCT06679569|EXPERIMENTAL|deep neuromuscular blockade|
62500915|NCT03052855|OTHER|Participants|All the participants of the 3 groups (depressed patients with suicide attempt, depressed patients without suicide attempt, healthy volunteers) will have to realize a MRI and biological samples.
62500916|NCT02686762|ACTIVE_COMPARATOR|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
62500917|NCT02686762|ACTIVE_COMPARATOR|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
62500918|NCT02686762|PLACEBO_COMPARATOR|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
62500919|NCT04335188||In-patients with SARS-CoV-2 infection|"In-patients fulfilling the following criteria:~SARS-CoV-2 infection In-patient treatment Written informed consent for participation in observational study No explicit medical exclusion criteria are stated to avoid selection bias."
62500920|NCT00721916|EXPERIMENTAL|1|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
62500921|NCT00721916|ACTIVE_COMPARATOR|2|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
62500922|NCT04482933|EXPERIMENTAL|Experimental: HSV G207|All subjects will receive G207 at 1 x 10\^8 plaque-forming units (pfu), intratumorally via controlled rate infusion through up to 4 silastic catheters over a 6 hour period. The subject will then receive a single 5 Gy dose of radiation to the tumor within 24 hours of virus inoculation.
62500923|NCT02698930|EXPERIMENTAL|dexmedetomidine group|
62500924|NCT02698930|PLACEBO_COMPARATOR|Control group|
62500925|NCT06578091||Executive Function Deficit Group|
62500926|NCT06578091||Control Group|
62500927|NCT00800618|EXPERIMENTAL|PF-02413873|PF-2413873 active treatment
62500928|NCT00800618|PLACEBO_COMPARATOR|Placebo|Placebo
62141278|NCT02328144|PLACEBO_COMPARATOR|Placebo|22 patients received oral placebo 500mg 3 times for day for 7 days
62500929|NCT04379284||Pregnant women - positive COVID19 test|Pregnant women of any gestational age 8 weeks through delivery with a positive COVID19 test, with or without physical symptoms
62700072|NCT06267846|EXPERIMENTAL|NBI-1070770: Low Dose|Participants will receive low-dose NBI-1070770.
62141279|NCT00776009|EXPERIMENTAL|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
62500930|NCT04379284||Pregnant women - negative or unknown COVID19 test|Pregnant women experiencing any respiratory or other physical symptoms of COVID19 at onset of labor, with negative or uncertain COVID19 test results
62500931|NCT04614714|EXPERIMENTAL|NR First|Mothers will receive NR during the first 7 days of intervention, then placebo for the 7 days following washout.
62700073|NCT06267846|EXPERIMENTAL|NBI-1070770: Medium Dose|Participants will receive medium-dose NBI-1070770.
62700074|NCT06267846|EXPERIMENTAL|NBI-1070770: High Dose|Participants will receive high-dose NBI-1070770.
62141280|NCT00776009|ACTIVE_COMPARATOR|Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
62141281|NCT00776009|PLACEBO_COMPARATOR|Placebo|Two Capsules taken orally once a day for 7 days
62141282|NCT02824926|EXPERIMENTAL|Dapaconazole|(cream; 2%; topical)
62343533|NCT01222572|EXPERIMENTAL|Stereotactic Boost to Chemoradiotherapy (Dose Level 1)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 54 Gy; Stereotactic Boost to Primary: 10 Gy; Total Dose to Primary: 64 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
62500932|NCT04614714|EXPERIMENTAL|Placebo First|Mothers will receive placebo during the first 7 days of intervention, then NR for the 7 days following washout.
62141283|NCT02824926|ACTIVE_COMPARATOR|Ketoconazole|(cream; 2%; topical)
62500933|NCT02824640|ACTIVE_COMPARATOR|Patient Navigation|"The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.~Health Promotion Sessions: PNs will deliver 4 standardized health promotion sessions to all patients either individually or within a group.~Optional Weekly Support Groups: Subjects randomized to the PN arm will be offered weekly support groups led by Peers."
62500934|NCT02824640|ACTIVE_COMPARATOR|modified Directly Observed Therapy|"OAT clinic setting: Observation of HCV medications will be linked to methadone visits among patients receiving methadone. Patients will be receiving methadone as part of routine clinical care for opioid addiction and not as an intervention related to this study. The schedule of five days per week will be considered modified DOT (mDOT). Subjects will initiate HCV treatment on Mondays if feasible. Take home medications will be packed in a weekly electronic blister pack.~Community health clinic setting: This intervention is considered modified DOT (mDOT) since between 3-5 weekly doses will be directly observed. A minimum of one dose will be observed in person by clinic/study staff. For the remaining observed doses, the research staff and provider will present the participant with a menu of options and determine what will work best for that participant."
62700075|NCT06267846|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo.
62700076|NCT06201845|EXPERIMENTAL|Exercise awareness training|
62700077|NCT06201845|ACTIVE_COMPARATOR|physical activity awareness training|physical activity awareness training,
62700078|NCT05750368||women undergoing epigastric hernia repair|all women who have undergone epigastric hernia repair open or laparoscopic in Denmark during af 4-year period from January 1st, 2018, to Dec 31st, 2021.
62700079|NCT01585025|EXPERIMENTAL|Primary BAD|Defined as SeHCAT \<10% without other causes such as Crohn's disease and/or ileal resection
62700080|NCT01585025|EXPERIMENTAL|Secondary BAD|With Crohn's disease or ileal resection
61952613|NCT03714971|NO_INTERVENTION|Not receiving WhatsApp messages|"In not receiving WhatsApp messages group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group."
61952614|NCT00991731|ACTIVE_COMPARATOR|Faith-based|Faith-based interventions incorporate tenets of the faith-based organization (e.g., religious beliefs, scriptural references) and involve the faith-based organization in the planning of the intervention from beginning to end
61952615|NCT00991731|ACTIVE_COMPARATOR|Non-faith-based|A curriculum designed for delivery without biblical references. In the traditional teachings of how to increase physical activity.
62141284|NCT01561300|PLACEBO_COMPARATOR|Control|Nutrition intervention study with a control
62141285|NCT01561300|EXPERIMENTAL|Tea extract|Nutrition intervention study with a black tea extract
62141286|NCT02711332||Degree of Haemolysis|Each subject will have four capillary blood sampling on different fingers. A reference venous blood sampling will be conducted.
62343534|NCT01222572|EXPERIMENTAL|Stereotactic Boost to Chemoradiotherapy (Dose Level 2)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 50 Gy; Stereotactic Boost to Primary: 15 Gy; Total Dose to Primary: 65 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
62343535|NCT01222572|EXPERIMENTAL|Stereotactic Boost to Chemoradiotherapy (Dose Level 3)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 46 Gy; Stereotactic Boost to Primary: 20 Gy; Total Dose to Primary: 66 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
62343536|NCT01757756|EXPERIMENTAL|Arm Label Pf-05175157, placebo, midazolam|
62343537|NCT05847491||Healthcare workers|"Clinical evaluation, chest x-ray and Interferon-γ release assay (IGRA). Immunocompromised patients will be submitted to a tuberculin skin test.~The patients will be evaluated in two or more separate appointments. In the first appointment, patients will be submitted to clinical evaluation and exam request. In the second appointment the results will be evaluated."
62343538|NCT01908517|EXPERIMENTAL|HPV Vaccine Electronic Reminders|Parents in the intervention group will receive 1 electronic message per month in addition to the baseline and final assessments which equates to 8 contacts over a 7 month period. Specifically, intervention group participants will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey.
62500935|NCT05798338||Early Breast Cancer patients|"* Diagnosis of early breast cancer;~* Indication for surgery after multidisciplinary discussion."
62500936|NCT05798338||Metastatic Breast Cancer patients|"* First diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;~* Indication to chemotherapy."
62500937|NCT05798338||Healthy patients|- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.
62700081|NCT01585025|EXPERIMENTAL|Idiopathic Diarrhoea Controls|Chronic diarrhoea with SeHCAT \>15% and no Crohn's or ileal resection
62141287|NCT03878966|EXPERIMENTAL|Invasive Strategy group|* Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .
62141288|NCT04415775|EXPERIMENTAL|Dual-task walking Intervention|
62141289|NCT04415775|ACTIVE_COMPARATOR|Conventional Gait Rehabilitation|
62141290|NCT04415775|NO_INTERVENTION|Healthy Controls|
62141291|NCT00567073||Pregnant women with confirmed diagnosis of Pompe Disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Pompe disease that are participating in the Pompe Registry (NCT00231400) and consented to participate in the Pompe Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglusidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated.
62141292|NCT00567073||Pregnant women receiving no treatment for Pompe disease|Pregnant women with Pompe disease enrolled in the Pompe disease registry (NCT00231400) who are not receiving treatment
62141293|NCT00567073||Infants born to mothers receiving treatment for Pompe disease|The infants of mothers with Pompe disease enrolled in the Pompe disease registry (NCT00231400) where the mothers are receiving treatment of alglucosidase alfa (Myozyme/Lumizyme) or avalglucosidase alfa (Nexviadyme/Nexviazyme)
62141294|NCT00567073||Infants born to mothers receiving no treatment for Pompe disease|The infants of mothers with Pompe disease enrolled in the Pompe Disease Registry (NCT00231400) where the mothers are not receiving Treatment
62141295|NCT05106049||cases|non-alcoholic fatty liver patients
62141296|NCT05106049||control|healthy persons
62141297|NCT01553526||Orsiro DES|
61952616|NCT00991731|NO_INTERVENTION|Control|"This group will receive a printed pamphlet Energize Yourself! Stay Physically Active, published by the National Heart Lung and Blood Institute, that encourages participation in at least 30 minutes of daily physical activity all at once or in bouts lasting 10 minutes at a time."
62343539|NCT02820883|EXPERIMENTAL|High dosage vaccine|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
62500938|NCT03635697|EXPERIMENTAL|Mindfulness Intervention Group|Participants in this group will listen to a short mindfulness audio clip during 6 of their NST appointments.
62343540|NCT02820883|EXPERIMENTAL|Middle dosage vaccine|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
62343541|NCT02820883|EXPERIMENTAL|Low dosage vaccine|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
62500939|NCT03635697|NO_INTERVENTION|Control Group|Participants in this group will have the regular standard of care for their NST appointments.
62500940|NCT03033134|EXPERIMENTAL|BSJ003W|BSJ003W implant group
62500941|NCT01015417|ACTIVE_COMPARATOR|Amoxicillin clavulanic acid|Postoperative administration of 2g of Augmentin, 3 times daily for 5 days.
62500942|NCT01015417|OTHER|No medication|no postoperative antibiotics
62500943|NCT02976051|EXPERIMENTAL|Treatment with HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole
62500944|NCT02476331|EXPERIMENTAL|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
62500945|NCT02476331|NO_INTERVENTION|Control|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, participants will complete post-testing assessments.
62500946|NCT06678659|EXPERIMENTAL|Phase 1a|Dose Escalation
62500947|NCT06678659|EXPERIMENTAL|Phase 1b Dose #1|Dose Confirmation
62500948|NCT06678659|EXPERIMENTAL|Phase 1b Dose #2|Dose #2 TBD
62500949|NCT00091286|EXPERIMENTAL|Peptide Vaccine + Montanide + GM-CSF|Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant
62500950|NCT00808262|EXPERIMENTAL|TNFa Kinoid dose 1|
62500951|NCT00808262|EXPERIMENTAL|TNFa Kinoid dose 2|
62500952|NCT00808262|EXPERIMENTAL|TNFa Kinoid dose 3|
62500953|NCT05064267||CKD stage 3|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 3 from a non-inflammatory etiology.
61952617|NCT01610570|EXPERIMENTAL|Phase I Dose Level -1|Dose Escalation Phase 9.0 mcg/kg.dose
61952618|NCT01610570|EXPERIMENTAL|Phase I Dose Level 1|Dose Escalation Phase 13.0 mcg/kg.dose
61952619|NCT01610570|EXPERIMENTAL|Phase I Dose Level 2|Dose Escalation Phase 17.5 mcg/kg.dose
62343542|NCT05550818|EXPERIMENTAL|High Ultra Processed Food Diet|Participants will consume a diet containing 81% total energy from UPF for 2 weeks.
62500954|NCT05064267||CKD stage 4|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 4 from a non-inflammatory etiology.
62700082|NCT00867035|ACTIVE_COMPARATOR|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions from investigator: twice a day a tongue scraper was used with 4 or more strokes, followed by 20ml of 0.12% chlorhexidine gluconate mouthwash used for 30 sec, for one week.
62700083|NCT00867035|EXPERIMENTAL|Chlorine dioxide and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.1% stabilized chlor8ine dioxide rinse for 30sec, for one week.
61952620|NCT01610570|EXPERIMENTAL|Phase II - Expansion Phase|Expansion phase 17.5 mcg/kg.dose
61952621|NCT04076475|EXPERIMENTAL|electrical stimulation|receive daily NMES for 30 min/session for 10 days.
61952622|NCT04076475|SHAM_COMPARATOR|Control|receive similar electrical stimulation (ES) procedure as those in the intervention group but with ES machine power off.
62343543|NCT05550818|EXPERIMENTAL|No Ultra Processed Food Diet|Participants will consume a diet containing 0% total energy from UPF for 2 weeks.
62343544|NCT02299141|EXPERIMENTAL|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle. Starting with cycle 64, cycles will last 12 weeks.
62343545|NCT00680290|EXPERIMENTAL|1|Exercise group
62343546|NCT01000779|ACTIVE_COMPARATOR|Endoscopic Variceal Ligation|endoscopic therapy to obliterate varices
62343547|NCT01000779|ACTIVE_COMPARATOR|Propranolol|drugs to decrease portal pressure
62500955|NCT05064267||CKD stage 5|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 5 from a non-inflammatory etiology.
62500956|NCT03293771||Stage 1 Focus Groups|The focus groups will involve transgender women who have completed gender confirmation surgery who volunteer to discuss their postoperative experience regarding bladder function, genital complaints, and sexual function.
62500957|NCT03293771||Stage 2 Questionnaire Groups|Stage 2 participants will be asked to complete a questionnaire packet after surgery followed by a second questionnaire completion 2 weeks later. Participants' operative notes and postoperative visit records will be reviewed.
62500958|NCT02301533|EXPERIMENTAL|Shikamana Intervention|The Shikamana Intervention consists of provider support (modified Next Step Counseling) and peer support (trained peer navigator) to promote adherence to antiretroviral therapy
62500959|NCT02301533|OTHER|Standard Care|The standard care arm will receive adherence counseling per standard Kenyan Ministry of Health guidelines, along with the recommendation to disclose to a family member or friend in order to obtain support
62500960|NCT02993419|EXPERIMENTAL|Bacillus licheniformis Intervention|The intervention is use Bacillus licheniformis particles，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
61952623|NCT01478880|EXPERIMENTAL|cTBS|
62700084|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in the respective country.
62700085|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in the respective country.
62700086|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in the respective country.
62700087|NCT02314195|ACTIVE_COMPARATOR|Standard treatment + music therapy|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
61952624|NCT01478880|SHAM_COMPARATOR|Sham cTBS|
61952625|NCT05344170|EXPERIMENTAL|30 mg Cannabinol (CBN)|Single fixed dose administered 2 hours prior to habitual sleep onset.
61952626|NCT05344170|EXPERIMENTAL|300 mg Cannabinol (CBN)|Single fixed dose administered 2 hours prior to habitual sleep onset.
61952627|NCT05344170|PLACEBO_COMPARATOR|Placebo|Single fixed dose administered 2 hours prior to habitual sleep onset.
61952628|NCT03737942||control group|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
61952629|NCT03737942||T2DM without neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
62141298|NCT05400161|ACTIVE_COMPARATOR|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
62141299|NCT05400161|EXPERIMENTAL|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
62141300|NCT04809376|EXPERIMENTAL|PPS Twice Weekly|Pentosan Polysulfate Sodium (PPS) twice weekly for 6 weeks
62343548|NCT04567446||Patients with bladder cancer who will start cancer treatment|"Collection of biological samples (stool and blood) and data from patients included in the study will be performed:~1. By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).~2. Collection of biological resources (all samples will be collected in fresh): stool and blood~3. Collection of clinical data corresponding to each patient included in the study by a clinical research assistant"
61952630|NCT03737942||T2DM with neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
62700088|NCT02314195|ACTIVE_COMPARATOR|Standard treatment only|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
62700089|NCT04199026|EXPERIMENTAL|Device Feasibility (microdevice, surgery)|Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.
61952631|NCT04984330|EXPERIMENTAL|selinexor/ dexamethasone (Sd)|"Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity~Dexamethasone~• 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23"
61952632|NCT02657369|EXPERIMENTAL|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
61952633|NCT01790880|ACTIVE_COMPARATOR|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system, for 90 minutes per day, 6 days per week for 6 weeks.
61952634|NCT01790880|EXPERIMENTAL|ORLA + Writing|"Practice on ORLA + writing computer program, 90 minutes per day, 6 days per week, for 6 weeks."
61952635|NCT00726869|EXPERIMENTAL|Cohort 1|2.5 mg/kg
61952636|NCT00726869|EXPERIMENTAL|Cohort 2|5.0 mg/kg
61952637|NCT00726869|EXPERIMENTAL|Cohort 3|10.0 mg/kg
61952638|NCT00726869|EXPERIMENTAL|Cohort 4|20.0 mg/kg
61952639|NCT02796469||Pentoxifylline + Corticosteroid|Association of treatment by pentoxifylline and corticosterone during 28 days
61952640|NCT02796469||Corticosteroid|treatment by corticosteroid during 28 days
61952641|NCT02796469||Pentoxifylline|treatment by pentoxifylline during 28 days
62141301|NCT04809376|EXPERIMENTAL|PPS Once Weekly|Pentosan Polysulfate Sodium (PPS) + placebo once weekly for 6 weeks
62700090|NCT01508767|EXPERIMENTAL|Study group 1|Early removal of urethral catheter 48 hours post-operatively.
62700091|NCT01508767|OTHER|Study group 2|Removal of urethral catheter once epidural analgesia has been withdrawn.
62700092|NCT02771301|OTHER|dendritic cell|Patients will receive autolgous IDH1R132H dendritic cells and cytotoxic lymphocytes treatment.
62700093|NCT05585320|EXPERIMENTAL|IMM-1-104 monotherapy (Treatment Group A)|IMM-1-104 monotherapy for first/second line pancreatic adenocarcinoma; first/second/third line melanoma; or second/third line non small cell lung cancer
61952642|NCT02796469||Placebo|
61952643|NCT00133913||Cohort|Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy.
61952644|NCT05178771|EXPERIMENTAL|test site|The test site will receive ScRp in addition to PRF
62141302|NCT04809376|EXPERIMENTAL|PPS Fixed Dose Once Weekly|Pentosan Polysulfate Sodium (PPS) Fixed dose (100mg,150mg, or 180mg) once weekly + placebo once weekly for 6 weeks
62141303|NCT04809376|PLACEBO_COMPARATOR|Placebo|Placebo twice weekly for 6 weeks
62141304|NCT00562094||Pantoprazole|
62141305|NCT01143935||Live patients|All patients undergoing CT scans of the abdomen for non hepatobiliary conditions
61952645|NCT05178771|NO_INTERVENTION|control sites|The control site will be treated by ScRp only
61952646|NCT00785694|EXPERIMENTAL|B|One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
61952647|NCT00785694|NO_INTERVENTION|A|Multiple instillations of mitomycin C after transurethral resection in white light alone.
61952648|NCT00579150||Exenatide|Exposure to any form of exenatide during pregnancy for treatment of type 2 diabetes. Patients also taking Insulin may be included, though only as part of a combination treatment.
61952649|NCT00579150||Non-exenatide group|Exposure to non-insulin antidiabetic medication not including exenatide for treatment of pre-existing type 2 diabetes during pregnancy. Patients also taking Insulin may be included, though only as part of a combination treatment.
61952650|NCT01062659||chronic Hepatitis C|Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
61952651|NCT04868175|ACTIVE_COMPARATOR|Group 1|control (hypromellose), then Timolol, then Travatan
61952652|NCT04868175|ACTIVE_COMPARATOR|Group 2|Timolol, then Travatan, Hypromellose
62141306|NCT01143935||Autopsy cases|All autopsy cases with no liver disease or trauma.
62343549|NCT04567446||Patients with Non-Small-Cell Lung cancer who will start cancer treatment|"Collection of biological samples (stool and blood) and data from patients included in the study will be performed:~1. By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).~2. Collection of biological resources (all samples will be collected in fresh): stool and blood~3. Collection of clinical data corresponding to each patient included in the study by a clinical research assistant"
62500961|NCT02993419|PLACEBO_COMPARATOR|placebo Intervention|The intervention is use placebo，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
62500962|NCT04905693|EXPERIMENTAL|Inhaled Treprostinil|Treprostinil inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated to a target of 15 breaths QID or until the subject reaches their maximum clinically tolerated dose.
62500963|NCT02564016|ACTIVE_COMPARATOR|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
62500964|NCT02564016|EXPERIMENTAL|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
62500965|NCT03184012|EXPERIMENTAL|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
62500966|NCT03184012|EXPERIMENTAL|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
62700094|NCT05585320|EXPERIMENTAL|IMM-1-104 in combination with mGnP (Treatment Group B)|IMM-1-104 in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first line pancreatic adenocarcinoma
62700095|NCT05585320|EXPERIMENTAL|IMM-1-104 in combination with mFFX (Treatment Group C)|IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first line pancreatic adenocarcinoma
62700096|NCT04636073|EXPERIMENTAL|Leaflex™ Performer|
62700097|NCT03868696|SHAM_COMPARATOR|MUA with sham ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with sham ultrasound (screen concealed from participants)
61952653|NCT04868175|ACTIVE_COMPARATOR|Group 3|Travatan, then Hypromellose, Timolol
61952654|NCT02481583|EXPERIMENTAL|part 1|12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
61952655|NCT02481583|EXPERIMENTAL|part 2|30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
61952656|NCT04495270||Clinical observation|All study patients were examined by 1 endodontist clinically and radiographically at baseline and after follow up of endodontic treatment.
61952657|NCT04843137||Individuals with cervical spinal cord injury|Cohort of individuals who have experiences a chronic spinal cord injury at the cervical level (specifically C5-C7).
61952658|NCT03772925|EXPERIMENTAL|Treatment (belinostat, pevonedistat)|Patients receive belinostat IV QD over 30 minutes on days 1-5 and pevonedistat IV QD over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61952659|NCT03985904|EXPERIMENTAL|Art Therapy|Participants will attend art therapy group sessions for three months in a designated museum.
62141307|NCT06432257||Using the head mounted magnifying glass|This study was divided into an experimental group and a control group based on whether a head mounted magnifying glass was used, with the main calculation indicator being changes in PTH levels before and after surgery.
62141308|NCT06522061|EXPERIMENTAL|Intervention Arm|"Stream™ Platform will be attached to the abdominal/pelvic drains of the patients enrolled in this group. The platform will conduct continuous pH and electrical conductivity measurements of the abdominal drain fluid.~All subjects recruited will take part in the evaluation of Stream™ Platform in a simulated home-use environment."
62141309|NCT06699394|OTHER|Group 1|Teclistamab monotherapy
62500967|NCT00566657|EXPERIMENTAL|Riferminogene pecaplasmid|4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals
62500968|NCT00566657|PLACEBO_COMPARATOR|Placebo|4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals
62500969|NCT02725996|EXPERIMENTAL|curative therapy+NK infusion|Adjuvant adoptive immune therapy using NK cell 4 times after curative therapy
62500970|NCT02725996|OTHER|curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation\[RFA\]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
62500971|NCT02629016|EXPERIMENTAL|Mindfulness|Education and experiential exercises for mindfulness including movement, thoughts and meditation
62500972|NCT02629016|ACTIVE_COMPARATOR|Wellness|Education and experiential exercises for general wellness including sleep hygiene, goal setting and power poses.
62500973|NCT02629016|NO_INTERVENTION|Waitlist|Students receive regular health class instruction without intervention.
62500974|NCT06227091|EXPERIMENTAL|Beetroot juice|beetroot juice with high concentration of nitrates ( 800mg)
62700098|NCT03868696|EXPERIMENTAL|MUA with active ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with active ultrasound (screen concealed from participants)
62700099|NCT06581237|EXPERIMENTAL|Eat2Win App|Participants will be provided a sport-specific nutrition program on the Eat2Win app.
62700100|NCT02089269||Cohort 1|2,200 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
62700101|NCT02089269||Cohort 2|125 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention
62700102|NCT06627049||Rehabilitation professionals|Pediatric rehabilitation professionals
62700103|NCT06627049||Decision makers|healthcare managers or directors
62700104|NCT06627049||Children|Children in paediatric rehabilitation services
62700105|NCT00661856|ACTIVE_COMPARATOR|1|Soy Protein group 25g of Soy protein with no Isoflavones
62700106|NCT00661856|EXPERIMENTAL|2|Soy Isoflavone group 25g of Soy Protein with 90mg of Isoflavones
62700107|NCT00661856|PLACEBO_COMPARATOR|3|25g of Milk protein
62700108|NCT06010979||conventional group|Conventional instrument-assisted knee arthroplasty
61952660|NCT00300274|EXPERIMENTAL|everolimus 1.5 mg|Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
61952661|NCT00300274|EXPERIMENTAL|everolimus 3.0 mg|"Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.~Randomization of new patients in this arm was prematurely stopped as of 27 March 2008 due to high mortality rate, as per Data Monitoring Committee."
62141310|NCT02029443|EXPERIMENTAL|Relapsed/Refractory Cohort|Phase 1 (dose-escalation) and Phase 2 (dose-expansion) will be conducted for participants with relapsed/refractory CLL or SLL. In Phase 1, participants will receive oral once daily (QD) acalabrutinib at Dose 1 (Cohort 1), Dose 2 (Cohort 2a), Dose 3 (Cohort 3), and Dose 4 (Cohort 4a), and twice daily (BID) acalabrutinib at Dose 1 (Cohort 2b) and Dose 5 (Cohort 4b) for 28 days (1 cycle). In Phase 2, participants will receive oral acalabrutinib at Dose 1 BID (Cohort 2b) or Dose 5 QD (Cohort 2c, later will be switched to Dose 1 BID per protocol amendment 6) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest. Participants from Phase 1 will be continued to receive Dose 1 BID until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
62141311|NCT02029443|EXPERIMENTAL|Treatment-naive Cohort|Treatment-naïve participants with confirmed CLL or SLL, will receive oral acalabrutinib Dose 5 QD (Cohort 7, later will be switched to Dose 1 BID per protocol amendment 6) or Dose 1 BID (Cohort 11) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
62141312|NCT02029443|EXPERIMENTAL|Ibrutinib-intolerant Cohort|Participants with confirmed CLL or SLL and were not tolerating ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 8a, later switched to Dose 1 BID per protocol amendment 4) or Dose 1 BID (Cohort 8b) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
62343550|NCT04567446||Patients with kidney cancer who will start cancer treatment|"Collection of biological samples (stool and blood) and data from patients included in the study will be performed:~1. By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).~2. Collection of biological resources (all samples will be collected in fresh): stool and blood~3. Collection of clinical data corresponding to each patient included in the study by a clinical research assistant"
62700109|NCT06010979||CAS group|computer navigation assisted knee arthroplasty
61952662|NCT00300274|ACTIVE_COMPARATOR|mycophenolate mofetil|Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.
62500975|NCT06227091|PLACEBO_COMPARATOR|Depleted beetroot Juice|beetroot juice with low concentration of nitrates
62700110|NCT06010979||RAS group|robotic system assisted knee arthroplasty
62700111|NCT06010979||PSI group|patient-spercific instrumentation assisted knee arthroplasty
62700112|NCT05627037|EXPERIMENTAL|Loading in 30 days|Implant allocated to the study arm will be restored with a temporary restoration after 30 days of implant placement, that will be replaced with definitive restoration after 90 days of implant placement.
62700113|NCT05627037|ACTIVE_COMPARATOR|Loading in 90 days|Implant allocated to the study arm will be restored directly with the definitive restoration after 90 days of implant placement.
62700114|NCT02439957|ACTIVE_COMPARATOR|Treatment 1|100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
62700115|NCT02439957|ACTIVE_COMPARATOR|Treatment 2|900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
62700116|NCT05651711|EXPERIMENTAL|Rocatinlimab|Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
61952663|NCT01323283|ACTIVE_COMPARATOR|Omega-3 supplementation|50 % of all included children will be randomized to this arm and administered capsules containing an omega-3 fatty acid composition.
61952664|NCT01323283|PLACEBO_COMPARATOR|Placebo|50 % of included children will be randomized to this arm and will be administered placebo capsules for the 15 week intervention.
62700117|NCT05651711|PLACEBO_COMPARATOR|Placebo|Placebo Q4W for 24 weeks with a loading dose at Week 2.
62700118|NCT01172782|PLACEBO_COMPARATOR|control group|control group (CG) received 6 mg of hyperbaric bupivacaine and 0.05 mL of saline.
62700119|NCT01172782|ACTIVE_COMPARATOR|2.5 ug hydromorphone recieved group|the 2.5 μg hydromorphone group (2.5HG) received 1.2 (6 mg) mL of 0.5% hyperbaric bupivacaine and 2.5 μg of hydromorphone in 0.05 mL of saline
61952665|NCT04447651||Patients with SF3B1, U2AF1 or SRSF2 mutation|Metastatic solid tumor patients that have a SF3B1, U2AF1 or SRSF2 mutation
61952666|NCT01602354||Gram-negative Septic shock|Patients affected by Gram-negative septic shock
61952667|NCT02628470|EXPERIMENTAL|group cervical manipulation|The patient is supine without a pillow and physiotherapist standing in the ipsilateral corner of the hand of the thrust.
62500976|NCT05787392||Completed Chamas program|women who participated in Chamas throughout the pandemic
62500977|NCT05787392||Did not complete Chamas program|women who left Chamas during the pandemic
62500978|NCT05787392||Did not participate in Chamas program|women whose communities were randomized to not receive the Chamas intervention
62500979|NCT04952168|EXPERIMENTAL|Almonertinib group|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
62700120|NCT01172782|ACTIVE_COMPARATOR|5 μg hydromorphone group|5 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 5 μg of hydromorphone in 0.05 mL of saline
61952668|NCT02628470|PLACEBO_COMPARATOR|Placebo group|Participants will receive a protocol of domiciliary cervical control exercises.
61952669|NCT02628470|ACTIVE_COMPARATOR|Group cervical mobilization|Oscillatory mobilization technique. With the patient in prone, the investigator applies an oscillatory motion in the most painful cervical segment for three minutes
61952670|NCT01471808|ACTIVE_COMPARATOR|CSII|continuous subcutaneous insulin infusion
61952671|NCT01471808|ACTIVE_COMPARATOR|Metformin & Pioglitazone|CSII combined with metformin and pioglitazone
61952672|NCT01471808|ACTIVE_COMPARATOR|Sitagliptin|CSII combined with sitagliptin 100mg/d
61952673|NCT01317654||Survivors of TBM trial 2001-2005|
62141313|NCT02029443|EXPERIMENTAL|Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort|Participants with diffuse large B-cell lymphoma (DLBCL) Richter's transformation (RS) or prolymphocytic leukemia (PLL) transformation, will receive oral acalabrutinib Dose 5 BID (Cohort 9) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
62343551|NCT01478399|EXPERIMENTAL|Impaired Renal Function|Subjects have impaired renal function matched to subjects with normal renal function by age and weight.
62343552|NCT01478399|EXPERIMENTAL|Normal Renal Function|Subjects have normal renal function matched to subjects with impaired renal function by age and weight.
62343553|NCT06082752|EXPERIMENTAL|Massage group|In the intervention group measures will be taken twice: before and after the 5-minute massage session.
62343554|NCT06082752|NO_INTERVENTION|Non-massage group|In the control group measures will be taken twice: at the beginning of the meeting and again after 5 minutes.
62343555|NCT02943512|EXPERIMENTAL|Discharge day of Procedure|Subjects in this arm will be discharged the same day of their cardiac device implant if deemed safe by treating physician.
62343556|NCT02943512|NO_INTERVENTION|Control|Subjects in this arm will remain in the hospital overnight per standard of care and will be discharged the next day if deemed safe by treating physician.
62343557|NCT00844064|EXPERIMENTAL|AP 12009|
62343558|NCT02598466||Abatacept|
62343559|NCT06194175||Patients undergoing bariatric surgery|"350 adults (1) suffering from obesity, with a body mass index (BMI) greater than or equal to 40, or a BMI greater than or equal to 35 with at least one obesity-related comorbidity; (2) and whose candidacy for bariatric surgery has been accepted (i.e. who have obtained an operation date).~Participants are recruited from four hospitals practicing bariatric surgery in Belgium."
62343560|NCT04803968|EXPERIMENTAL|control group|"After the evaluations are completed, the participants will be randomly divided into two groups using a computer-assisted randomization program.~The cardiac rehabilitation program will be a total of 30 sessions, 5 days a week x 6 weeks. All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training"
62700121|NCT01172782|ACTIVE_COMPARATOR|the 10 μg hydromorpnone group|the 10 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 10 μg of hydromorphone in 0.05 mL of saline.
62700122|NCT04429919|EXPERIMENTAL|AP-325|25 mg capsule for oral use, 4 capsules (100 mg) once daily in the morning before meals
62700123|NCT04429919|PLACEBO_COMPARATOR|Placebo|4 capsules once daily in the morning before meals
61952674|NCT03296098|EXPERIMENTAL|ulipristal acetate|Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
61952675|NCT04311502|EXPERIMENTAL|Arm 1: Experimental 3-month, with CFZ loading dose|Participants will receive rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks.
61952676|NCT04311502|ACTIVE_COMPARATOR|Arm 2: Standard of care for drug-susceptible (DS) TB|Participants will receive rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks.
61952677|NCT04311502|EXPERIMENTAL|Arm C: PK only subgroup|Participants will receive PHZE + CFZ 100 mg once daily for 4 weeks; then on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks).
61952678|NCT03092921|EXPERIMENTAL|F&P Mask Seal|Participants to use trial seal in-home for 1 week
62343561|NCT04803968|EXPERIMENTAL|intervention group|The combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.
62343562|NCT02749877|EXPERIMENTAL|Cognitive Training|"This group will undergo a working memory training program (Training A). The children will receive individual memory training based on the computer program Cogmed RM and will be supervised by trained neuropsychologists. Its efficacy in the use with children with cancer has been recently published. The children will undergo 25 training sessions online; each session takes about 45 minutes and consists of a selection of various tasks that target the different aspects of working memory."
62700124|NCT03758846|EXPERIMENTAL|Cognitive-motor Exergaming|A total of 6 Wii-fit games: Bubble balance, Table Tilt, Tightrope walking, Soccer head, Basic Run and Basic Step. A total of 6 cognitive tasks namely Digit recall, repeated letter, word list generation (category and alphabets), mental arithmetic, analogies. Each session was divided into 3 sub-sessions. Every Wii-fit game was played with any 3 cognitive tasks. The combination of games with cognitive tasks was randomized in such a manner that all the cognitive tasks were played with the Wii-fit games in that session. Breaks were provided after each sub-session or when the participant demanded one or when the research personnel noticed any discomfort of the participant.
62700125|NCT03758846|ACTIVE_COMPARATOR|Conventional balance Training for people with Chronic stroke|The sessions were divided into 10 minutes of warm-up that involved active movements of the body (arm movements, trunk twists, lunges). Next 15 minutes consisted of functional strengthening exercises like high stepping, lunges, squats, resistance training using therabands and weights. Following 35 minutes included balance training exercises like one leg standing, tandem standing, sit to stand exercises, reach outs and step-ups. Last 10-15 minutes were spent treadmill walking. Breaks were provided in between the exercise training as and when needed by the participant.
61952679|NCT03092921|EXPERIMENTAL|F&P Mask|Participants to use trial mask in-home for 2 weeks
62343563|NCT02749877|EXPERIMENTAL|Physical Training|This group will receive a physical training that can be executed at home (Training B). The training will be based on xbox Kinect games and comprise games and activities such as jump'n'run games, physical training, and dance activities. One training session will last approximately 45 minutes and will be performed 3 days a week over a period of 8 weeks (in total 25 sessions).
62343564|NCT02749877|ACTIVE_COMPARATOR|Waiting Control Group|This group will serve as a waiting control group and will receive either the physical or the working memory training program after completion of the Neuropsychological Assessment II
62343565|NCT01589055|ACTIVE_COMPARATOR|Male Smokers|
62343566|NCT01589055|ACTIVE_COMPARATOR|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
62343567|NCT01589055|ACTIVE_COMPARATOR|Female Smokers (Early Follicular Phase; cycle days 4-8)|
62343568|NCT05570045|NO_INTERVENTION|Usual Diet|(n=300): Children eat usual dietary (not using nutrient products) for 3 months. After that, they will use the products
62343569|NCT05570045|EXPERIMENTAL|Colos Gain Dietary Supplement|(n=300): Children eat usual dietary, but with 2 glasses of the nutrient product as the side meals. The product provides GOS(Galactooligosaccharides), Calcium, Probiotics, HMO, DHA, and Taurine within 3 months of use.
62343570|NCT04810299|EXPERIMENTAL|Aromatherapy Massage Group|According to this Tisserand Institute guide chart, for a 2% dilution process, dilution will be provided with a total of 12 drops by adding 4:4:4 drops of lavender, Roman chamomile and ginger essential oils in 20 ml of sweet almond oil. Expert opinion was obtained from a phytotherapy and aromatherapy specialist physician that the oils and dilution rates used were appropriate. Foot massage will be applied on the 1st, 2nd and 3rd postoperative days. State Anxiety Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and after the application.Richard-Campbell Sleep Quality Scale will be applied before application Foot massage will be applied for 20 minutes.
62343571|NCT04810299|EXPERIMENTAL|Classical Foot Massage Group|Baby oil will be applied as massage oil to patients who are assigned to the classical foot massage group before the surgery. Foot massage will be applied for 20 minutes on the 1st,2nd and 3rd days. State Anxiety Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and after the application.Richard-Campbell Sleep Quality Scale will be applied before application
62343572|NCT04810299|NO_INTERVENTION|Control Group|Except for routine care practices, no attempt will be made to the patients assigned to the pre-operative control group. State Anxiety Scale, Richard-Campbell Sleep Quality Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied on postoperative 1st, 2nd and 3rd days. The same scales will be re-evaluated 60 minutes after the first measurement. Richard-Campbell Sleep Quality Scale will be applied once
62500980|NCT04539808|EXPERIMENTAL|Treatment (mFOLFIRINOX, chemotherapy)|"mFOLFIRINOX REGIMEN: Oxaliplatin intravenously (IV) over 2 hrs, leucovorin calcium IV over 2 hrs, and irinotecan hydrochloride IV over 90 minutes on day 1. Also receive fluorouracil IV over 46 hrs starting on day 1. Repeats every 14 days for up to 4 cycles. Those with response and no disease progression may receive an additional 2 months.~GA REGIMEN: Those with disease progression or toxicity to mFOLFIRINOX switch to GA regimen comprising gemcitabine hydrochloride IV over 30-60 mins and nab-paclitaxel IV over 30-40 mins on days 1, 8, and 15. Repeats every 28 days for 2 cycles.~LOSARTAN: Cycle 1 day 1, start losartan potassium orally once daily until end of RT.~RT/SURGERY: Short-course RT for 10 fractions over 5 days weekly or long-course RT with 15-25 fractions over 5 days weekly along with oral capecitabine twice daily on Monday-Friday or fluorouracil IV over 5-7 days weekly until completion of RT. Patients then undergo surgery 1-4 weeks following RT"
62500981|NCT00948337|EXPERIMENTAL|Photonovella of Secondary Cancer Screening|
62500982|NCT00948337|ACTIVE_COMPARATOR|Photonovella of Dietary Suppelment of Cancer survivor|
62500983|NCT04709224|EXPERIMENTAL|Cohort 1: LAI Lumateperone 50 mg SC in the abdomen|
61952680|NCT00951548|EXPERIMENTAL|VSL#3|Probiotic preparation VSL#3
62500984|NCT04709224|EXPERIMENTAL|Cohort 2: LAI Lumateperone 100 mg SC in the abdomen|
62500985|NCT04709224|EXPERIMENTAL|Cohort 3: LAI Lumateperone 200 mg SC in the abdomen|
61952681|NCT00951548|PLACEBO_COMPARATOR|placebo|Corn Starch
61952682|NCT05911529|EXPERIMENTAL|Motivational Interviewing Group|Patients will receive four sessions of Motivational Interviewing within two weeks.
61952683|NCT05911529|ACTIVE_COMPARATOR|Control Group|Patients in the control group receive four sessions of supportive conversations within two weeks.
61952684|NCT06129838||Healthy participants|Healthy participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
62700126|NCT03758846|EXPERIMENTAL|Dance Therapy for Stroke|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
62700127|NCT03758846|EXPERIMENTAL|Dance Therapy for Older Adults|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
62700128|NCT03758846|ACTIVE_COMPARATOR|Conventional therapy - Home education for Older adults|Participants received a one-hour education on conventional physical exercises and fall prevention.
62700129|NCT04087642|EXPERIMENTAL|Intraoperative Crede manoeuver|"Method 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak.~In this group, the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly."
62700130|NCT04087642|ACTIVE_COMPARATOR|Preoperative prolapse reduction cough stress test|"An examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak.~In this group, the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly."
62141314|NCT02029443|EXPERIMENTAL|Ibrutinib Relapsed/Refractory Cohort|Participants with confirmed CLL/SLL and had relapsed/refractory to ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 10) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
62700131|NCT02278003|EXPERIMENTAL|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.~measure the amnesic effects of propofol."
62700132|NCT02278003|ACTIVE_COMPARATOR|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
62700133|NCT01821755|EXPERIMENTAL|Behavioral: Foster parent intervention|Foster parents receive a foster parent intervention consisting of 10 individual home visits and three group sessions. Duration of the intervention is four months
62700134|NCT01821755|NO_INTERVENTION|Control|waiting-list control group who receive care-as-usual
62700135|NCT05018481|PLACEBO_COMPARATOR|HA35 Placebo Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a placebo to take once a day with breakfast.
62700136|NCT05018481|ACTIVE_COMPARATOR|HA35 Treatment Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a HA35 to take once a day with breakfast.
62700137|NCT05720104|EXPERIMENTAL|Study group|Use of Lumoral Treatment device. Standard oral hygiene instructions.
62141315|NCT00349206|EXPERIMENTAL|Arm 1|Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
62141316|NCT06523478|EXPERIMENTAL|Intratonsillar Immunotherapy (ITIT) group|"The intervention of ITIT will be a series of 3 injections of a commercially-available standardized dust mite allergen extracts (Novo Helisen-Depot, Allergopharma, Merck, Germany) given every four weeks into tonsil through guidance using a 1-mL hypodermic syringe with a 25-gauge or smaller needle. The specific doses are 5 TU (0.1 ml, the first injection), 50 TU (0.1 ml, the second injection), and 50 TU (0.1 ml, the third injection).~Before each injection, patients will take one tablet of antihistamine."
62141317|NCT06523478|ACTIVE_COMPARATOR|Subcutaneous Immunotherapy (SCIT) group|The same drugs will be used in active comparator. SCIT consists of two stages: the accumulation stage and the maintenance stage. During the initial 14 weeks, patients will receive sequential subcutaneous injections as follows: (1) 1st vial: 0.1 mL, 0.2 mL, 0.4 mL, and 0.8 mL; (2) 2nd vial: 0.1 mL, 0.2 mL, 0.4 mL, and 0.8 mL; (3) 3rd vial: 0.1 mL, 0.2 mL, 0.4 mL, 0.6 mL, 0.8 mL, and 1.0 mL of allergen, achieving a maintenance dose of 5000 TU. Subsequently, maintenance therapy involves subcutaneous injections of 5000 TU (1.0 mL, 3rd vial) every 4-6 weeks. The intervention process before and after each injection is similar to that of the ITIT group.
62500986|NCT04709224|EXPERIMENTAL|Cohort 4: LAI Lumateperone 100 or 200 mg SC in the outer area of the upper arm|
62700138|NCT05720104|OTHER|Control group|Standard oral hygiene instructions.
62700139|NCT00184392|EXPERIMENTAL|debridement or saline irrigation|1 arm undergo debridement of the nose 1 week and 2 weeks after surgery the other arm rinse their nose with saline irrigation
62500987|NCT00250705|OTHER|Adolescent Conduct Disorder Males|All subjects were male and had a diagnosis of conduct disorder. All subjects were offered treatment with aripiprazole.
62700140|NCT04701242|ACTIVE_COMPARATOR|Atorvastatin-Ezetimibe combination|Eligible patients randomized to this arm will receive combination of Atorvastatin 80mg plus Ezetimibe 10mg
62500988|NCT03157349|EXPERIMENTAL|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
62500989|NCT03157349|SHAM_COMPARATOR|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
61952685|NCT06129838||Participants with cognitive impairment (Alzheimer's disease)|Participants with cognitive impairment will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
62500990|NCT06679244|EXPERIMENTAL|Performing Hao's esophagogastrostomy by fissure technique|
62500991|NCT06679244|ACTIVE_COMPARATOR|Performing double-tract reconstruction|
62500992|NCT00566722|EXPERIMENTAL|Open Label|
62500993|NCT04496037||Standard of care (SOC)|See NCT03994783
62500994|NCT04496037||Rituximab + SOC (SOCR)|See NCT03994783
62500995|NCT05585489|EXPERIMENTAL|Persons with moderate idiopathic Parkinson's disease|
62500996|NCT05357287|EXPERIMENTAL|Prevena|
62500997|NCT04832334||Stroke Participants|Stroke patients with hemiplegia or chronic hemiparesis
62500998|NCT04832334||Healthy Participants|The healthy control group was matched with stroke participants in terms of age, gender, dominant side and education level.
62500999|NCT02995564|EXPERIMENTAL|Social Skills Intervention|The intervention is a 16-week social skills therapy program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the peer generalization portion. During the group therapy session young adults will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with typically developing peer volunteers.
62501000|NCT03705871|EXPERIMENTAL|Differential Expansion Group|The experimental group will be comprised 24 patients treated with a rapid maxillary expansion using the expander with differential opening. The expander is composed by two screws, one posteriorly and the other anteriorly positioned on the palate.
61952686|NCT00882063|EXPERIMENTAL|P276-00|Starting dose level of P276-00 is 50 mg/m2/day. The drug will be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min. Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.
61952687|NCT02718157|EXPERIMENTAL|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
61952688|NCT04336540|EXPERIMENTAL|Energy labelling|Energy labelling provided on restaurant menus
61952689|NCT04336540|NO_INTERVENTION|No energy labelling|No energy labelling provided on restaurant menus
61952690|NCT04336540|EXPERIMENTAL|Increased availability of lower energy meals|Higher proportion of meals are 600kcals or less
61952691|NCT04336540|NO_INTERVENTION|Baseline availability of lower energy meals|Proportion of meals that are 600kcals or less at baseline level
61952692|NCT01352546|EXPERIMENTAL|BOTOX|intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.
61952693|NCT04216238||Cardiovascular surgical patients|Patients who received cardiovascular surgery and was released from the hospital due to meeting and exceeding a certain walking distance.
61952694|NCT05866783||No HCC recurrence|Patients receiving a liver transplantation that do NOT develop HCC recurrence after liver transplantation.
61952695|NCT05866783||HCC recurrence|Patients receiving a liver transplantation that develop HCC recurrence after liver transplantation.
61952696|NCT03217812|ACTIVE_COMPARATOR|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m\^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2 (if serum creatine is greater than \[\>\]2 milligram per deciliter \[mg/dL\] at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2) orally, once daily (on Days 1 to 4) and prednisone 60 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
62343573|NCT04624035|ACTIVE_COMPARATOR|Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.|Implantation of ICL (V4c with central hole) for treatment of myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
62501001|NCT03705871|ACTIVE_COMPARATOR|Fan-Fype Expander Group|The active comparator group will be comprised by 24 patients treated with rapid maxillary expansion using the the fan-type expander. The expander is composed by one screw anteriorly positioned on the palate.
62501002|NCT02045355|EXPERIMENTAL|Fish intervention|The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
62501003|NCT02045355|NO_INTERVENTION|Meat control group|The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).
62164550|NCT06646068|OTHER|Philips 66 Brainstorming Technique Group (Intervention Group)|Participants in this group will engage in the Philips 66 Brainstorming Technique as part of their case-based learning sessions. This structured method involves dividing participants into smaller groups of 6, with each group discussing a topic for 6 minutes, aimed at enhancing critical thinking and clinical judgment skills in nursing students.
62501004|NCT03856034|EXPERIMENTAL|Fetoscopic repair|
62501005|NCT01966939||Surgery|Craniotomy or Craniectomy
62501006|NCT01966939||Control|age, gender and teeth condition matched
62501007|NCT03144479|EXPERIMENTAL|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
62501008|NCT03144479|EXPERIMENTAL|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
62501009|NCT00003350|EXPERIMENTAL|Arm I (paclitaxel)|"Patients receive paclitaxel over 3 hours by intravenous infusion. Treatment course repeats every 2 weeks. Patients are evaluated every third course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
62700141|NCT04701242|NO_INTERVENTION|Atorvastatin monotherapy|Eligible patients randomized to this arm will receive Atorvastatin 80mg as monotherapy for LDL-C reduction. They can be upgraded to combination (adding Ezetimibe 10mg) if found in follow-up that they had not achieve recommended LDL-C targets.
62700142|NCT04707209|EXPERIMENTAL|Intravitreal Sirolimus|
62700143|NCT00619866|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablets once a day for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) QD for 12 weeks.
62700144|NCT00619866|EXPERIMENTAL|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg QD for an additional 12 weeks.
62700145|NCT00619866|EXPERIMENTAL|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
62141318|NCT00003593|EXPERIMENTAL|Arm A: TMD patients only|Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
62700146|NCT03966547|EXPERIMENTAL|Local anesthetic|
62700147|NCT03966547|PLACEBO_COMPARATOR|Isotonic NaCl|
62700148|NCT06634719|EXPERIMENTAL|Juveena Hydrogel System|One time instillation of the Juveena Hydrogel into the uterine cavity.
62141319|NCT00003593|EXPERIMENTAL|Arm B: AML/MDS patients only|(closed to accrual as of 6/24/04 except for patients first enrolled in group I): Patients receive induction therapy comprising cytarabine IV continuously, daunorubicin hydrochloride IV continuously, and oral thioguanine twice daily on days 0-3. Treatment repeats every 28 days for 4 courses. Patients with no CNS disease at diagnosis receive cytarabine intrathecally (IT) on day 0. Patients with CNS disease at diagnosis receive cytarabine IT on days 0, 5, and 7. If CNS disease persists on day 7, patients receive up to 6 courses of cytarabine IT, therapeutic hydrocortisone IT, and methotrexate IT, twice weekly beginning on day 10. Asparaginase during Intensification 1 day 1 hour 18.
62700149|NCT06081920|EXPERIMENTAL|IBI363|
62700150|NCT06333561||HAIC+Len+PD-1 inhibitor group|HAIC combined with Lenatinib and PD-1 inhibitor group
62700151|NCT06333561||Len group|Lenvatinib alone
62700152|NCT02693639||liver transplantation grafts|
62141320|NCT04108403|EXPERIMENTAL|Pain Inducing Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
62700153|NCT06296680|EXPERIMENTAL|Reiki|In the intervention group, patients received an energy therapy called Reiki. Reiki was administered to cancer patients for four consecutive days at specified times. During this procedure, while the patient was in the supine position, the researcher's hands were placed approximately two to three centimeters above the chakra regions of the patient, covering the seven chakra areas as well as the areas experiencing pain. The application lasted a total of 25-30 minutes. Silence was maintained in the patient's room during the intervention.
62700154|NCT06296680|SHAM_COMPARATOR|Sham Reiki|In the placebo group, patients received Sham Reiki. Sham Reiki was administered to cancer patients for four consecutive days at specified times. During this procedure, while the patient was in the supine position, Sham Reiki practitioner's hands were placed approximately two to three centimeters above the chakra regions of the patient, covering the seven chakra areas as well as the areas experiencing pain. The application lasted a total of 25-30 minutes. Silence was maintained in the patient's room during the intervention.
62700155|NCT06296680|ACTIVE_COMPARATOR|Progressive Relaxation Exercise|Silence was maintained in the patient's room during the intervention. At the beginning of the session, the patient is asked to assume the most comfortable seated or supine position. Then, they are instructed to close their eyes, take deep breaths, direct their thoughts to their own body and the muscle groups being treated, notice the tension and relaxation in the muscle groups during the exercise, and continue to breathe regularly. This practice was conducted in four parts of the body: hands and arms; face and shoulders; chest, abdomen, hips; legs and feet.
62700156|NCT06000683|EXPERIMENTAL|Empower LCS|Patient will be given education material(addressing knowledge barriers); patients' referral to financial navigation resources (addressing health-related social risks); and patients' reminder to discuss LCS during PCP visit. Providers will also be notified of eligibility of their patients to receive LCS.
62700157|NCT04835259|ACTIVE_COMPARATOR|Group 1(treatment group)|"Topical application of a cream of a combination of antioxidants once daily at night for 6 months Name: Selenium ACE cream (Interpharma UK company, Egypt)~Ingredients:~Selenium (Selenium amino acid chelate) 0.5% Vitamin C (Sodium ascorbyl phosphate - stay C) %1 Vitamin E (Tocopheryl acetate) % 0.5 Vitamin A (Retinyl palmitate) %1 Emulsifiers ( Ceteareth 20 , Glycerol monostearate , Cetyl alcohol) Emollient(Caprylic capric triglycerides)"
62700158|NCT04835259|ACTIVE_COMPARATOR|Group 2 (positive control)|Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)
62700159|NCT04835259|PLACEBO_COMPARATOR|Group 3 (Negative control)|Topical application of a panthenol cream once daily at night for 6 months (panthenol 2% cream, El Nile company, Egypt)
62700160|NCT03199079||Group 1: Non-pregnant women|Non-pregnant women with normal pelvic floor
62700161|NCT03199079||Group 2: Pregnant women|Pregnant women; 22-29 weeks of pregnancy
62700162|NCT03238573||optical enhancment endoscopy|
62700163|NCT02445911|EXPERIMENTAL|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
62700164|NCT02445911|EXPERIMENTAL|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
62700165|NCT02445911|EXPERIMENTAL|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
62700166|NCT02445911|PLACEBO_COMPARATOR|Placebo|Multiple ascending doses matching KQ-791 dose
61952697|NCT03217812|EXPERIMENTAL|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m\^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion or daratumumab Subcutaneously (SC) at the discretion of the investigator, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
61952698|NCT04800744|EXPERIMENTAL|Lavender Peppermint Elequil Aromatab|Participants will have a lavender peppermint elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new treatment elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
61952699|NCT04800744|ACTIVE_COMPARATOR|Sweet Almond Oil Elequil Aromatab|Participants will have a sweet almond oil active comparator elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new active comparator elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
61952700|NCT00932100|EXPERIMENTAL|REG1-a|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
61952701|NCT00932100|EXPERIMENTAL|REG1-b|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
61952702|NCT00932100|EXPERIMENTAL|REG1-c|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
61952703|NCT00932100|EXPERIMENTAL|REG1-d|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
61952704|NCT00932100|ACTIVE_COMPARATOR|Heparin|Heparin per standard of care at the local institution
61952705|NCT03795454|EXPERIMENTAL|Singing Kangaroo|The parent is singing during the skin-to -skin sessions Musical therapeutist gives the instructions
61952706|NCT03795454|NO_INTERVENTION|Silent Kangaroo|The parent is silent during the skin-to -skin sessions Musical therapeutist gives the instructions
61952707|NCT01801878|EXPERIMENTAL|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
61952708|NCT01801878|ACTIVE_COMPARATOR|Normal saline|Normal saline inject to the half of irradiated breast
61952709|NCT04916821|EXPERIMENTAL|water extract of propolis|Patients given 2 ml of aqueous propolis extract (50mg / ml) orally 3 times a day for 1 week
61952710|NCT04916821|EXPERIMENTAL|olive oil extract of propolis including perga|Patients given 1 ml oily propolis extract (64 mg / ml) + 1 ml oily perga extract (120 mg / ml) orally 3 times a day for 1 week
62141321|NCT04108403|ACTIVE_COMPARATOR|Pain Inducing Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
62164551|NCT03534141|EXPERIMENTAL|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
62501010|NCT00003350|EXPERIMENTAL|Arm II (pegylated liposomal doxorubicin hydrochloride)|"Patients receive doxorubicin HCL liposome over 30-60 minutes by intravenous infusion. Treatment course is repeated every 3 weeks. Patients are evaluated before every odd course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
62501011|NCT02749591|EXPERIMENTAL|Robot-assisted therapy (RT)|After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.
61952711|NCT04916821|NO_INTERVENTION|control|control group (patients not given any investigational product)
61952712|NCT03428724|ACTIVE_COMPARATOR|standard group|standard polyethylene glycol preparation for colonoscopy
61952713|NCT03428724|EXPERIMENTAL|individualized group|either a low or a high volume bowel preparation according to patient characteristics
61952714|NCT04794842|ACTIVE_COMPARATOR|Tetracaine|Patients will be positioned in supine position at this time 0.5% tetracaine drops will be used to fill the ear canal. Tetracaine will then be allowed to stay in place for approximately 10 to 15 minutes with the patient's head positioned with affected ear up. After this, using an operative microscope the drops will be removed from the ear canal with suction.
61952715|NCT04794842|ACTIVE_COMPARATOR|Phenol|Patients will be positioned in supine position and tympanic membrane visualized with operative microscope. Phenol applicator will be used to topically apply 90% phenol to the injection site (posterior/Inferior aspect of tympanic membrane).
61952716|NCT02237131|EXPERIMENTAL|Oral contraceptives cyclic|Oral contraceptives containing 0.03 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for 21 days followed by 7 days pill free. The regimen will be repeated for the duration of the trial.
61952717|NCT02237131|ACTIVE_COMPARATOR|Oral contraceptives continuous|Oral contraceptives containing 0.030 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for the duration of the trial.
61952718|NCT01029834|EXPERIMENTAL|Intervention- Lifestyle family based|Behavioral family based
61952719|NCT01029834|ACTIVE_COMPARATOR|Information control|Child intervention only
61952720|NCT05343598|ACTIVE_COMPARATOR|Active cerebellum rTMS|Cerebellar targeted iTBS, twice daily, one week.
61952721|NCT05343598|SHAM_COMPARATOR|Sham cerebellum rTMS|Cerebellar targeted sham iTBS, twice daily, one week.
61952722|NCT04497831|EXPERIMENTAL|Study Drug|Morphine hydrochloride
61952723|NCT04497831|PLACEBO_COMPARATOR|Placebo|Placebo
61952724|NCT02094183|EXPERIMENTAL|GLP-1|GLP-1 and low calorie diet
61952725|NCT02094183|EXPERIMENTAL|Control|low calorie diet
61952726|NCT03951233||K-RAS and EGFR mutated|
61952727|NCT03951233||Wild type|
61952728|NCT02911714|EXPERIMENTAL|CEUS and Delayed Graft Function|On the first post-operative day after kidney transplantation, recipients enrolled in the study will undergo CEUS using Lumason to quantify microvascular perfusion within the cortical and medullary zones of the kidney allograft for comparison to the concentration of neutrophil gelatinase-associated lipocalin (NGAL, an early biomarker of acute kidney injury) measured from recipient urine simultaneously collected on the first post-operative day.
61952729|NCT02911714|EXPERIMENTAL|CEUS and Biopsy-Proven Acute Rejection|We will identify and enroll kidney transplant recipients in need of clinically-indicated duplex ultrasounds and possible biopsy to evaluate allograft dysfunction during hospital admissions and outpatient follow-up. Immediately after the duplex ultrasound, we will perform CEUS using Lumason for allograft perfusion measurements to determine its potential association with biopsy-proven acute rejection according to the most recent Banff criteria.
61952730|NCT02370134|EXPERIMENTAL|Parkinson's glove|Parkinson's glove 14 days use with 4 times follow-up
61952731|NCT02370134|PLACEBO_COMPARATOR|sham glove|sham glove (with light and sound)14 days use with 4 times follow-up
61952732|NCT05845736||control group|absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive
61952733|NCT05845736||mild neurocognitive disorder|MMSE from 21 to 26 inclusive
61952734|NCT05845736||moderate neurocognitive disorder|MMSE from 11 to 20 inclusive
62141322|NCT04108403|ACTIVE_COMPARATOR|Pain Free Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
62141323|NCT04108403|ACTIVE_COMPARATOR|Pain Free Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
62700167|NCT06565351||Spinal Cord Injury Individuals|248 individuals with spinal cord injury and neurogenic bladder dysfunction, coming to routine controls of the renal function. Glomerular filtration rate (GFR) was measured by 99mTc-DTPA clearance and estimated by eGFR from creatinine and Cystatine C
62141324|NCT04390724||Patient Group 1: Y90 Standard-of-Care|The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care
62141325|NCT04390724||Patient Group 2: Y90 Dose determined by results from Group 1|The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1
62141326|NCT02813954||Study Group|Neonates with respiratory distress
62141327|NCT02813954||Control Group|Healthy Infants
62141328|NCT02115659|PLACEBO_COMPARATOR|Placebo|Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
62141329|NCT02115659|EXPERIMENTAL|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring.
62141330|NCT03986359|EXPERIMENTAL|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
62141331|NCT03986359|SHAM_COMPARATOR|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
62141332|NCT00745875|EXPERIMENTAL|1|ZD4054 + Pemetrexed
62700168|NCT04942145|ACTIVE_COMPARATOR|Virtual Reality Group|With virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
62700169|NCT04942145|EXPERIMENTAL|Control Grooup|Without virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
61952735|NCT05845736||severe neurocognitive disorder|MMSE less than or equal to 10
61952736|NCT01822795|EXPERIMENTAL|Lung volume reduction coïl treatment|Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention
61952737|NCT01822795|OTHER|Regular Medical Treatment|No intervention, just a follow up under usual medical treatment
61952738|NCT01596478|ACTIVE_COMPARATOR|Treatment As Usual|The standard treatment usually provided at the clinic.
61952739|NCT01596478|ACTIVE_COMPARATOR|Cognitive Motivational Behavior Therapy|An approach that addresses motivation to change gambling and behavioral patterns related to gambling.
61952740|NCT01596478|ACTIVE_COMPARATOR|12-week wait list|Participant will start treatment 12 weeks from day of consent.
61952741|NCT04612673|EXPERIMENTAL|Treatment|Participants received Sintilimab, 200mg, iv, d1, Q3W,and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
61952742|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has undergone spine fusion (SF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
61952743|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
62141333|NCT00745875|PLACEBO_COMPARATOR|2|ZD4054 matched placebo + pemetrexed
62141334|NCT03530631|EXPERIMENTAL|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
62141335|NCT03530631|PLACEBO_COMPARATOR|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
62141336|NCT03530631|EXPERIMENTAL|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
62700170|NCT06547320|EXPERIMENTAL|Just-in-time Adaptive Intervention|A sensor device called an Automatic Ingestion Monitor (AIM) will be worn on eyeglasses to monitor eating. Information from the device will be used to send messages to a smartphone to change eating behavior.
62700171|NCT01809431|EXPERIMENTAL|intervention|Breastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
62700172|NCT01809431|NO_INTERVENTION|Wait-listed control group|Wait-listed control group receive usual care delivered by their health care provider and after completion of their time in the study they are offered the intervention
62700173|NCT02427932||Pregnant/Ampicillin|pregnant participants who will receive Ampicillin for conditions such as Group B Streptococcus
62700174|NCT02427932||Non-pregnant/Ampicillin|non-pregnant participants who will receive Ampicillin for a qualifying hospital admission
62700175|NCT02427932||Pregnant and Non-pregnant/Ampicillin and Gentamicin|pregnant participants who will receive Ampicillin and Gentamicin for conditions such as chorioamnionitis; non-pregnant participants who will receive Ampicillin and Gentamicin for a qualifying hospital admission
62700176|NCT02427932||Non-Pregnant/Gentamicin|non-pregnant participants who will receive Gentamicin for a qualifying hospital admission
62700177|NCT01269775|EXPERIMENTAL|Face to face lecture|The lecturer allocated 1.5 hours for delivering the lecture by using provided slides about the topic and 0.5 hours for question and answer.
62700178|NCT01269775|EXPERIMENTAL|Internet based teaching|For providing materials for interactive internet-based group the professor's lecture was converted to an interactive electronic content. This content started with a case introduction followed with asking questions and then based on each student's answer a learning pathway would be assigned to his/her.
62700179|NCT01269775|EXPERIMENTAL|Computer based teaching|For providing material for computer-based group the lecture of the same professor was recorded in studio environment and was synchronized with the slides that were similar to those for lecture-based group. Then the lecture and the slides were converted to a CD as a multimedia CD.
61952744|NCT03240484||Spine Fusion Only Group|Any patient who has had spine fusion only (no hip replacement surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
61952745|NCT04888468|EXPERIMENTAL|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
61952746|NCT01160315|EXPERIMENTAL|Arm A (GnRha arm)|IM injection of Triptorelin -Decapeptyl PR 11.25mg- (every 3 months) and Norethisterone acetate- Primolut-Nor 5 mg- per os continuously until the end of the chemotherapy
61952747|NCT01160315|ACTIVE_COMPARATOR|Arm B (control Arm)|Norethisterone acetate alone, 5mg par day, (ARM B) until the end of the chemotherapy.
61952748|NCT03736733|EXPERIMENTAL|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
61952749|NCT03736733|OTHER|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
61952750|NCT03372096|EXPERIMENTAL|All patients|Patients will receive the Prostatic Artery Embolization procedure.
61952751|NCT01130454|ACTIVE_COMPARATOR|SCIO Test Group|
61952752|NCT01130454|PLACEBO_COMPARATOR|SCIO Placebo Group|
61952753|NCT04574011|EXPERIMENTAL|Fluid challenge responder|If the ratio of the stroke volume change after passive leg raising is the same or larger than 10%, the patient is assigned to RESPONDER group.
62700180|NCT03859011|EXPERIMENTAL|Acupuncture|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks), then no acupuncture between 10 weeks and 6 months. After treatment is completed, final measurement instruments are applied at 6 months. Questionnaires will be readministered at 2.5 and 6 months.
62700181|NCT03859011|PLACEBO_COMPARATOR|"Usual care"|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments) for 6 months. Questionnaires will be readministered at 2.5 and 6 months. After the control phase the participants will continue usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks, 8.5 months), then no acupuncture between 8.5 months and 12 months.
62700182|NCT06048458||Cohort 1|Stable patients with gastrointestinal malignancies will be recruited to this 3 timepoint study prior to initiation of fluoropyrimidine chemotherapy. All investigations will be performed at baseline, at the end of cycle 1 and 4-6 weeks post completion of treatment.
62700183|NCT06048458||Cohort 2|Patients with gastrointestinal malignancies presenting to hospital with acute symptoms of fluoropyrimidine cardiotoxicity. All investigations will be performed during the acute presentation and the second visit will be performed 4-6 weeks post completion of treatment.
61952754|NCT04574011|EXPERIMENTAL|Fluid challenge non-responder|If the ratio of the stroke volume change after passive leg raising is less than 10%, the patient is assigned to RESPONDER group.
61952755|NCT04981548||raised intracranial pressure|more than 200 mmH2O
61952756|NCT04981548||the normal intracranial pressure group|more than 80 mmH2O and no more than 200 mmH2O
61952757|NCT01268969|ACTIVE_COMPARATOR|excision and krydakis reconstruction|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
61952758|NCT01268969|ACTIVE_COMPARATOR|surgical excision and limberg closure|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia . The fasciocutaneous flap was transposed medially so that the defect would be covered without any tension.
61952759|NCT02967731|EXPERIMENTAL|480 Mometasone Furoate Sinus Drug Depot|480 Mometasone Furoate Sinus Drug Depot
61952760|NCT05252455|OTHER|exercise group|pelvic and abdominal mechanics exercise
61952761|NCT05252455|NO_INTERVENTION|control group|Normal prenatal examination
61952762|NCT01527799||Subjects with Sickle Cell Anemia|Subjects with Sickle Cell Anemia, 10-21 years of age
61952763|NCT01527799||Healthy controls|Healthy controls, 10 to 21 years of age
62501012|NCT02749591|EXPERIMENTAL|Mirror therapy (MT)|After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
62501013|NCT02749591|ACTIVE_COMPARATOR|Control Intervention (CI)|After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
62501014|NCT02938013|EXPERIMENTAL|Group A|Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
62501015|NCT02938013|ACTIVE_COMPARATOR|Group B|Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
62501016|NCT02938013|ACTIVE_COMPARATOR|Group C|HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
62501017|NCT05696704|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) combines the ideas of cognitive therapy with meditative practices and attitudes based on the cultivation of mindfulness. The heart of this work lies in becoming acquainted with the modes of mind that often characterize mood disorders while simultaneously learning to develop a new relationship to them.
62501018|NCT05696704|EXPERIMENTAL|Behavior Activation|BA Increase reinforcing behaviors in order to influence emotions and cognitions.
62501019|NCT05028634|EXPERIMENTAL|Cohort 1 - Ozanimod|"Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine~-Enrollment is closed for this cohort"
62501020|NCT05028634|EXPERIMENTAL|Cohort 1 - non-pegylated interferon-β or no disease modifying therapy|"Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), Pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine~-Enrollment is closed for this cohort"
61952764|NCT04153942|EXPERIMENTAL|12-Hour Bed Rest|Subjects will be mobilized 12 hours after receiving IV thrombolysis therapy per usual care
61952765|NCT04153942|ACTIVE_COMPARATOR|24-Hour Bed Rest|Subjects will be mobilized 24 hours after receiving IV thrombolysis therapy per usual care
61952766|NCT01270516|PLACEBO_COMPARATOR|Control, to be given saline solution|Intervention: This group will be given saline (30 ml every 12 hours) for 10 days
61952767|NCT01270516|EXPERIMENTAL|EPA, eicosapentaenoic acid|This group will be given 1000 mg EPA every 12 hours for 10 days
62501021|NCT05028634|EXPERIMENTAL|Cohort 2 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), and pneumococcal polysaccharide vaccine (PPSV23).
62501022|NCT05028634|EXPERIMENTAL|Cohort 2 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap) and Pneumococcal polysaccharide vaccine (PPSV23).
62501023|NCT02879773||Lung cancer|Patients undergoing thoracic surgery for suspected or confirmed lung cancer; including wedge resection, segmentectomy, lobectomy, bilobectomy or pneumonectomy. CTPVe will be modelled to predict postoperative lung function.
62501024|NCT02879773||Emphysema|Patients undergoing assessment of emphysema/chronic obstructive pulmonary disease (COPD) for potential surgical intervention; including lung volume reduction surgery, endobronchial valve insertion or endobronchial coil insertion. CTPVe will be modelled to predict postoperative lung function.
62501025|NCT02879773||Interstitial lung disease|Patients undergoing assessment or treatment of suspected or confirmed interstitial lung disease. CTPVe will be modelled to aid diagnosis of the subtype of interstitial lung disease confirmed by histological diagnosis.
62501026|NCT04633616|EXPERIMENTAL|Tailored Delivery of Education|Communication will be tailored as the mode of weblink delivery will be customized to patient preference.
61952768|NCT01270516|EXPERIMENTAL|HMB, hydroxymethylbutyrate|This arm will be given HMB (1500 mg) every 12 hours for 10 days.
61952769|NCT01270516|EXPERIMENTAL|EPA and HMB|Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.
61952770|NCT03128411|EXPERIMENTAL|Bosutinib|Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
61952771|NCT02605824|EXPERIMENTAL|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
61952772|NCT02605824|PLACEBO_COMPARATOR|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
61952773|NCT02710474|ACTIVE_COMPARATOR|Standard Care|Preterm infants will receive current Standard Care (SC) in the NICU.
61952774|NCT02710474|EXPERIMENTAL|Intervention|Preterm infants will receive Family Nurture Intervention (FNI) in addition to current Standard Care (SC) in the NICU. Specifically, staff will support the parents and facilitate contact between mother and infant during the NICU stay.
61952775|NCT02710474|ACTIVE_COMPARATOR|Term Controls|Full term infants will receive current Standard Care (SC) in the NICU. Term Controls (TC)
61952776|NCT02710474|ACTIVE_COMPARATOR|Chart Review|Chart review will be conducted to acquire a comparison group to determine if our study participants differ from the non-study population.
61952777|NCT04808544|PLACEBO_COMPARATOR|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
61952778|NCT04808544|ACTIVE_COMPARATOR|Naldebain group|Patients assigned to Naldebain group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
61952779|NCT01112865|OTHER|Mark VII/Current pen|Subject will use Mark VII pen for 2 months followed by Current pen for 2 months
61952780|NCT01112865|OTHER|Current pen/Mark VII|Subject will use current Genotropin pen for 2 months followed by Mark VII pen for 2 months
61952781|NCT04693988|EXPERIMENTAL|Case management|Patient receives case management while in hospital.
62141337|NCT03530631|EXPERIMENTAL|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
62141338|NCT01660659|EXPERIMENTAL|cooking with Biomass Briquettes and Rocket Stove|cooking with Biomass Briquettes and Rocket Stove
62141339|NCT01660659|NO_INTERVENTION|standard cooking|standard way of cooking
62141340|NCT05230966|NO_INTERVENTION|Group 1- angina pectoris|Patients with acute coronary syndrome; angina pectoris (chest pain with negative troponin T with or without changes in electrocardiographic findings);
62501027|NCT04633616|PLACEBO_COMPARATOR|Non-tailored Delivery of Education|Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy.
62141341|NCT05230966|NO_INTERVENTION|Group 2 - angina pectoris + STEMI+ PCI|Patients with acute myocardial infarction with ST-segment elevation, \< 6 hours from the onset of chest pain and preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
62141342|NCT05230966|ACTIVE_COMPARATOR|Group 3 - without angina pectoris + STEMi + RIC + PCI|Patients with acute myocardial infarction with ST-segment elevation, \< 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention during which it's carried out remote ischemic conditioning (RIC)
62141343|NCT05230966|NO_INTERVENTION|Group 4 - without angina pectoris + STEMI + PCI|Patients with acute myocardial infarction with ST-segment elevation, \< 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
62141344|NCT05230966|ACTIVE_COMPARATOR|Group 5 - healthy + RIC|healthy volunteers of the same age and sex, whose samples will be taken after the RIC procedure
62501028|NCT05191745|EXPERIMENTAL|Intervention group|Patients will receive bilateral parasternal blocks at the end of cardiac surgery.
62501029|NCT05191745|PLACEBO_COMPARATOR|Control group|Patients will receive all standard care as per the hospital protocols.
62501030|NCT03086135|EXPERIMENTAL|Bone-conduction hearing device|The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
62501031|NCT03934060|EXPERIMENTAL|Intervention|Supervised exercise training including specific strength training tools and general exercise contents (standard care), 2-3 times per week, 30 minutes per session
62501032|NCT03934060|NO_INTERVENTION|Control|Supervised exercise training regarding general exercise contents (standard care), 2-3 times per week, 30 min per session
62501033|NCT02642523|PLACEBO_COMPARATOR|Saline Infusion|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
62501034|NCT02642523|EXPERIMENTAL|Insulin Clamp|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
62501035|NCT02642523|EXPERIMENTAL|BNP Infusion (Nesiritide)|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
62700184|NCT01621100|EXPERIMENTAL|OROS hydromorphone|Once-Daily OROS (Osmotic release oral system \[a controlled release oral drug delivery system in the form of a tablet\]) hydromorphone
61952782|NCT04693988|NO_INTERVENTION|Usual Care|This control condition does not receive intervention of case management
61952783|NCT05161767||Recovered group|This will group will consists of people who have a remission of their symptoms at 6-months follow-up after whiplash injury.
61952784|NCT05161767||non-recovered group|This will group will consists of people who develop persistent symptoms at 6-months follow-up after whiplash injury.
61952785|NCT00672646|EXPERIMENTAL|AZD1386|
61952786|NCT00672646|ACTIVE_COMPARATOR|Naproxen|
61952787|NCT00672646|PLACEBO_COMPARATOR|Placebo|Placebo matching AZD1386
61952788|NCT01397162|EXPERIMENTAL|BI 54903 - low dose|BI 54903 low dose 2 puffs twice daily (b.i.d.) via Respimat inhaler plus hydrofluoralkane (HFA) metered dose inhaler (MDI) matching placebo 2 puffs b.i.d.
61952789|NCT01397162|EXPERIMENTAL|BI 54903 - medium dose|BI 54903 medium dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
61952790|NCT01397162|EXPERIMENTAL|BI 54903 - high dose|BI 54903 high dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
62141345|NCT00555503||1|Patients who have risk-reduction mastectomy of any type, per protocol inclusion and exclusion criteria.
62141346|NCT00949117|EXPERIMENTAL|Arm I- cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
62141347|NCT00949117|EXPERIMENTAL|cyproheptadine HCl & PediaSure or Ensure|Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
62141348|NCT02816398|EXPERIMENTAL|Treatment|Interventional use of experimental Ellipsys catheter system for percutaneous creation of an arteriovenous fistula
62501036|NCT04374188|ACTIVE_COMPARATOR|ciprofloxacin|ciprofloxacin tablets
62501037|NCT04374188|ACTIVE_COMPARATOR|levofloxacin|levofloxacin tablets
62700185|NCT04910867|NO_INTERVENTION|Control Arm|No intervention will be administered. Usual care will be administered.
61952791|NCT01397162|ACTIVE_COMPARATOR|Fluticasone propionate|Fluticasone propionate 2 puffs twice b.i.d via HFA MDI plus placebo BI 54903 via Respimat inhaler 2 puffs b.i.d.
61952792|NCT01397162|PLACEBO_COMPARATOR|Placebo|Placebo Respimat inhaler 2 puffs b.i.d. and placebo HFA MDI, 2 puffs b.i.d.
61952793|NCT00229593|ACTIVE_COMPARATOR|1|100 mg Testosterone gel daily for 3 weeks
61952794|NCT00229593|ACTIVE_COMPARATOR|2|2 mg Nestorone gel daily for 3 weeks
61952795|NCT00229593|ACTIVE_COMPARATOR|3|4 mg Nestorone gel daily for 3 weeks
62501038|NCT01974362||Monolithic Zirconia with Buccal Veneer (MZ)|Patients that have a full-mouth (maxilla and/or mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial with buccal veneers
62501039|NCT01974362||Monolithic Zirconia full-contour (FCMZ)|Patients that have a full-mouth (maxilla and/or mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial full contour (without veneer)
62501040|NCT01974362||Zirconia-Feldspathic (PVZ)|Patients that have a full-mouth (maxilla and/or mandible) implant supported rehabilitation restored with zirconia substructure and feldspathic veneered biomaterial
62501041|NCT05829239|EXPERIMENTAL|ADI-PEG20|ADI-PEG20 (ADI-PEG20 is arginine deiminase (ADI) conjugated to polyethylene glycol (PEG) of 20,000 molecular weight) will be weekly intramuscularly at a dose of 18 mg/m2 body surface area/week for 8-week.
62501042|NCT05829239|PLACEBO_COMPARATOR|Placebo|Will be weekly intramuscularly for 8-week
62501043|NCT04396444|EXPERIMENTAL|Lavender Aromastick Group|The aromastick is a plastic tube, similar in size to a lipstick. A study team member will prepare the aromastick by infusing ten drops of lavender essential oil onto a blank cotton wick inside the tube and sealing the cap.
62501044|NCT04396444|PLACEBO_COMPARATOR|Blank Aromastick Group|A study team member will prepare the blank aromastick by placing a blank cotton wick inside the aromastick tube and sealing the cap.
62501045|NCT05884970|ACTIVE_COMPARATOR|FEV1 >90%|Children with lung function FEV1 \> 90%
62501046|NCT05884970|ACTIVE_COMPARATOR|FEV1 80-90%|Children with lung function FEV1 80-90%
62501047|NCT05884970|ACTIVE_COMPARATOR|FEV1 70-80%|Children with lung function FEV1 70-80%
61952796|NCT00229593|ACTIVE_COMPARATOR|4|100 mg Testosterone gel + 2 mg Nestorone gel
61952797|NCT00229593|ACTIVE_COMPARATOR|5|100 mg Testosterone gel + 4 mg Nestorone gel
61952798|NCT00229593|ACTIVE_COMPARATOR|6|100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
61952799|NCT00229593|ACTIVE_COMPARATOR|7|100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
61952800|NCT03129178|EXPERIMENTAL|Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
61952801|NCT03129178|EXPERIMENTAL|Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
61952802|NCT03712956|EXPERIMENTAL|Caelyx® for 8 courses|Caelyx® administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.
62141349|NCT04864782|EXPERIMENTAL|QL1604+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m\^2 plus cisplatin 70 mg/m\^2 or paclitaxel 175 mg/m\^2 plus carboplatin Area Under the Curve (AUC) 6)
62501048|NCT05884970|ACTIVE_COMPARATOR|FEV1 60-70%|Children with lung function FEV1 60-70%
62501049|NCT05884970|ACTIVE_COMPARATOR|FEV1 < 60%|Children with lung function FEV1 \< 60%
62501050|NCT06003127|EXPERIMENTAL|TMS-EEG Arm|This arm will undergo TMS-EEG during the study.
62501051|NCT06003127|NO_INTERVENTION|Non-TMS-EEG Arm|This arm will not undergo TMS-EEG during the study.
62501052|NCT02103101|OTHER|Study cohort|"Measurement of Plasma Concentrations of NOACs Identification of ABCB1 polymorphisms coding for P-gp~All patients aged over 18 and less than 80 years admitted for a serious adverse event (bleeding or thrombo-embolic complication) while under treatment with any of the following oral anticoagulant agents: dabigatran, rivaroxaban or apixaban. Blood samples will be drawn to measure plasma concentrations of the oral anticoagulant agent at the time of the adverse event, and presence of polymorphisms of ABCB1 will be investigated."
62501053|NCT00924963|EXPERIMENTAL|Jet injection lidocaine|J-Tip jet injection of 1% buffered lidocaine
62700186|NCT04910867|EXPERIMENTAL|Intervention Arm|APOL1 testing program
62700187|NCT06250673|EXPERIMENTAL|Mediterranean Diet Group|Patients taking medication will be given a diet in accordance with the basic Mediterranean diet rules.
61952803|NCT00777114|EXPERIMENTAL|All patients|
61952804|NCT05057182|EXPERIMENTAL|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
61952805|NCT02329912|EXPERIMENTAL|Patients after abdominal surgery|SmartPill application after abdominal surgery
61952806|NCT02329912|SHAM_COMPARATOR|Patients after extraabdominal surgery|SmartPill after extraabdominal surgery
61952807|NCT01460004|NO_INTERVENTION|patella knee strap|infra patella knee strap- cotton, applied in straight leg
62501054|NCT00924963|PLACEBO_COMPARATOR|Jet injection saline|J-Tip jet injection of sterile saline
62700188|NCT06250673|EXPERIMENTAL|Low Cholesterol Group|Patients taking medication will be given a diet containing \<200 mg of cholesterol per day, based on personal wishes.
61952808|NCT02066142|ACTIVE_COMPARATOR|Tomosynthesis|Tomosynthesis will be compared to Ultrasound
61952809|NCT02066142|OTHER|Ultrasound|Ultrasound (sensitivity and specificity) will be compared to Tomosynthesis
61952810|NCT06006741|EXPERIMENTAL|Universal CART cells to treat MM|
62501055|NCT00924963|ACTIVE_COMPARATOR|Lidocaine cream|Lidocaine 4%cream applied for 30 minutes prior to IV insertion or venipuncture
62501056|NCT03129061|EXPERIMENTAL|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline \[18F\]F-AraG PET/CT scan and another \[18F\]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
62141350|NCT03163563||Easywarm|Self warming blanket to prevent perioperative hypothermia
62501057|NCT03129061|EXPERIMENTAL|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline \[18F\]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second \[18F\]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
62501058|NCT02237547|EXPERIMENTAL|IV and IT UC-MSC and BMMC|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
62501059|NCT01520545|EXPERIMENTAL|Gablofen 3 mg/mL (baclofen Injection)|3 mg/mL Gablofen (baclofen Injection)
62501060|NCT02259348|EXPERIMENTAL|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
62501061|NCT06030544|EXPERIMENTAL|OA-enriched functional olive oil|Functional olive oil elaborated enriching the control olive oil with high purity (\> 95 %) Oleanolic acid from olive leaf up to 600 mg OA/kg oil.
62501062|NCT06030544|ACTIVE_COMPARATOR|Control olive oil|Commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
62501063|NCT05709782|EXPERIMENTAL|Group 1 (Therapeutic Cohort)|Participants in Group 1 will receive spine radiosurgery on the MR LINAC machine, along with imaging scans using the same machine.
62501064|NCT05709782|EXPERIMENTAL|Group 2 (Imaging-only Cohort)|Participants in Group 2 will receive spine radiosurgery using a standard radiation therapy machine and have the opportunity to get imaging on the MR LINAC.
62501065|NCT02502331|EXPERIMENTAL|study group|Test Oral Cholera Vaccine
62501066|NCT02502331|ACTIVE_COMPARATOR|comparator group|Euvichol®
62501067|NCT04912856|EXPERIMENTAL|Stage 1: Blinded Dose Transition/Titration|"24-day blinded transition/titration period. Subjects who received XEN496 in the preceding study will continue to receive XEN496 at the same dose, in a blinded manner, without any further titration. Subjects, who were allocated to placebo in the preceding study, will be titrated to a tolerated dose up to a maximum dose of 21 mg/kg/day, with a maximum daily dose of 672 mg/day. To maintain the blinded aspect of the study, placebo will be dispensed to all subjects during the transition/titration period to ensure the total number of capsules are consistent across all subjects.~Subjects who discontinue will be required to taper off study drug over a period of up to 15 days"
62501068|NCT04912856|EXPERIMENTAL|Stage 2: Open-Label Treatment|"Optimally-tolerated dose level established during the transition/titration period will be maintained throughout the duration of open-label period unless dose adjustment is required.~Subjects who discontinue or complete the study treatment will be required to taper off study drug over a period of up to 15 days."
62501069|NCT04205162|EXPERIMENTAL|Verofilcon A / Etafilcon A|The participant will wear Verofilcon A in their right eye and Etafilcon A in their left eye.
62501070|NCT04205162|EXPERIMENTAL|Etafilcon A / Verofilcon A|The participant will wear Etafilcon A in their right eye and Verafilcon A in their left eye.
62501071|NCT05735028|EXPERIMENTAL|CM group|CM+PD-1/PD-L1 inhibitor
62501072|NCT05735028|ACTIVE_COMPARATOR|Control group|PD-1/PD-L1 inhibitor
62501073|NCT01689155||Study Group|Participants must have received Menactra Vaccine according to routine clinical practice.
62501074|NCT02371096|EXPERIMENTAL|RGB-03|
62501075|NCT02371096|ACTIVE_COMPARATOR|MabThera (rituximab)|
62501076|NCT02816424|EXPERIMENTAL|Brief Motivational Interviewing|Principles and skills of motivational interviewing will be used with participants assigned to brief intervention. These participants will receive feedback that they are at risk for unintended pregnancy. They will receive information on the likelihood of pregnancy given their self-reported frequency of unprotected sex. They will be given information regarding negative consequences associated with teen pregnancy. They will be provided with information on the chances of pregnancy with abstinence, condom use, oral contraceptives, and Long Acting Reversible Contraceptives (LARC). Following information exchange, participants who are high in readiness to change will engage in action planning, whereby a specific plan for reducing risk for unintended pregnancy will be collaboratively developed with the interventionist. Patients who are low in readiness to change will complete a motivational interviewing-based roadmap activity that is designed to strategically evoke motivational speech.
62501077|NCT02816424|NO_INTERVENTION|Control|
62501078|NCT01128868|ACTIVE_COMPARATOR|Proximal femur locking plate|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc)
62141351|NCT03163563||BairHugger|Forced-air warming blanket to prevent perioperative hypothermia
62501079|NCT01128868|OTHER|Trochanteric nail|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
62501080|NCT03752450||ICU patients|All patients admitted to ICU \>48 hours will be included. Eventually, a number of these patients will develop hypernatremia and form the cases. The patients who will not develop hypernatremia will be assigned as the controls.
62501081|NCT03656263||High risk cardiac surgery patients|"Defined as either:~* Multiple surgical procedures planned and/or,~* EuroSCORE ≥ 5% and/or,~* Known pulmonary hypertension (mPAP\>25 mmHg or sPAP \> 40 mmHg)"
62501082|NCT00493792|ACTIVE_COMPARATOR|Control|Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
62501083|NCT00493792|EXPERIMENTAL|Treatment|Stryker Orthopaedics X3 Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
62700189|NCT06250673|NO_INTERVENTION|Control Group|They will not take a diet, and take only the medication.
61952811|NCT00828932|EXPERIMENTAL|Lorcaserin 10mg|
62164552|NCT03534141|ACTIVE_COMPARATOR|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
62164553|NCT06646146|EXPERIMENTAL|Fat Graft Combined with Hair Transplantation Group|
62164554|NCT06646146|ACTIVE_COMPARATOR|Hair Transplantation Group|
61952812|NCT04138238||Supraflex Cruz Sirolimus-eluting Stent|
62700190|NCT03549325|EXPERIMENTAL|Group 1|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner.~Follow up visits occur on Days 5, 14 and 32."
62700191|NCT03549325|EXPERIMENTAL|Group 2|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner.~Follow up visits occur on Days 15, 24 and 42."
61952813|NCT03434093|ACTIVE_COMPARATOR|PPC-DLPFC|In this arm, the TMS paired-pulses will be first delivered over the posterior parietal cortex (PPC) and then over the dorsolateral prefrontal cortex (DLPFC)
61952814|NCT03434093|ACTIVE_COMPARATOR|DLPFC-PPC|Arm Description: In this arm, the TMS paired-pulses will be first delivered over the over the dorsolateral prefrontal cortex (DLPFC) and then posterior parietal cortex (PPC)
61952815|NCT02649595|OTHER|Red Cross respite care|A 2 week free stay at a Red Cross respite center after hospitalization.
61952816|NCT02649595|NO_INTERVENTION|Streets/communal programmes|Homeless being discharged from hospital to the streets and communal programmes.
61952817|NCT05593926|EXPERIMENTAL|Intervention|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
61952818|NCT05593926|NO_INTERVENTION|Placebo|Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks. Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks.
61952819|NCT04312204|EXPERIMENTAL|Sintilimab+Gemcitabine+Carboplatin|
61952820|NCT00000371|EXPERIMENTAL|D-Cycloserine|Subjects were given 50 mg/day of D-Cycloserine for 24 weeks
62501084|NCT03460990|ACTIVE_COMPARATOR|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
62501085|NCT03460990|EXPERIMENTAL|VX-659/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
62501086|NCT05167149|EXPERIMENTAL|Carbon nanoparticles group|
62501087|NCT05167149|ACTIVE_COMPARATOR|Indocyanine green group|
62501088|NCT03285919|EXPERIMENTAL|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
62501089|NCT03285919|ACTIVE_COMPARATOR|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
62501090|NCT02845011|EXPERIMENTAL|Audiovisual compression feedback|Cardiopulmonary resuscitation according to international guidelines with chest compressions performed with real-time audiovisual feedback using the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) device.
62141352|NCT04125901|EXPERIMENTAL|Pain Neuroscience Education and Exercise|Participants will received an 8-week intervention consisting of exercise and pain neuroscience education. Pain neuroscience education will be conducted in line with international guidelines and will address the following topics: pain neurophysiology, nociception and nociceptive pathways, inhibition and spinal cord stimulation, peripheral and central sensitization, nervous system plasticity and the impact of variables such as stress, anxiety, sleep and exercise on pain behavior. Exercise will be performed in accordance with international guidelines for chronic NP. Motor control, endurance and strengthening exercises will be performed for the neck and scapulo-thoracic region.
62501091|NCT02845011|ACTIVE_COMPARATOR|Standard chest compression|Cardiopulmonary resuscitation according to international guidelines with standard manual chest compression
62700192|NCT03033784|EXPERIMENTAL|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
62700193|NCT03033784|PLACEBO_COMPARATOR|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
62141353|NCT04125901|OTHER|Exercise|Participants will received an 8-week intervention consisting of exercise. The exercise performed in this group will be the same as in the intervention group and will follow the same international guidelines for chronic NP.
62141354|NCT02937493||Migration Background|Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
62700194|NCT03931551|EXPERIMENTAL|Interventional Arm|Olaparib tablet 300mg bd po + Herceptin (IV 4 mg/kg body followed by weekly doses of 2 mg/kg, or SC 600 mg every 3 weeks) until progression or unacceptable toxicity.
62700195|NCT01537328|EXPERIMENTAL|Progressive Treatment|Progressive intervention will involve the early initiation of intensive rehabilitation using progressive exercise and faster progression to functional strengthening exercises.
62700196|NCT01537328|ACTIVE_COMPARATOR|Traditional treatment|Traditional intervention represents the synthesis of previously published total knee arthroplasty rehabilitation programs.
62700197|NCT05532800|EXPERIMENTAL|JS002|Cobort 1:150 mg/1mL Q2W PFS,Cobort 2:150 mg/1mL Q2W AI
62700198|NCT05532800|PLACEBO_COMPARATOR|Placebo|Cobort 1:/1mL Q2W PFS,Cobort 2:1mL Q2W AI
61952821|NCT00000371|PLACEBO_COMPARATOR|Placebo|Participants were given 50 mg/day of Placebo for 24 weeks.
62501092|NCT01529593|EXPERIMENTAL|Temsirolimus + Metformin|Starting dose of Temsirolimus 25 mg by vein weekly. Metformin titrated over 3 weeks at 500 mg by mouth daily. Four weeks of treatment constitute 1 cycle. Cycle one (1) however, will be 6 weeks long to allow for metformin titration.
62700199|NCT05593289|EXPERIMENTAL|Telerehabilitation group|Participants assigned to the telerehabilitation program will complete a 3 month intervention consisting of 5 weekly sessions of 30 minutes of pre-recorded video, with a frequency of 2-3 times a day.
62700200|NCT05593289|NO_INTERVENTION|Control group|The usual care group will be instructed to follow their physicians' orders during the 3-month intervention period. Baseline measurements will be made for each group, at 2 weeks, 6 weeks and 3rd month.
62700201|NCT06570304||iCount Device|A novel external device which can count the swabs and surgical tampons used during childbirth in an objective and validated manner.
62700202|NCT06570304||User Feedback Survey|"Anonymised feedback data will be collected from 20 staff users about the user experience and usability of the device. This will be conducted with an online survey questionnaire designed with advice from ergonomics experts after an extensive literature review of human factors-ergonomics principles and MHRA guidance about conducting medical device usability~5 staff users will be randomly selected from the consent forms to have semi-structured interviews developed in accordance with qualitative research methodology for medical device usability testing and user experience."
62700203|NCT05628571|PLACEBO_COMPARATOR|Fluoride toothpaste|Participants will brush their teeth with a commercially available Fluoride toothpaste (1450 ppm F) and a commercially available adult soft bristle toothbrush
62700204|NCT05628571|EXPERIMENTAL|Zinc toothpaste|Participants will brush their teeth with a toothpaste containing amine base, zinc lactate and fluoride (1400 ppm F) and a commercially available adult soft bristle toothbrush
62700205|NCT01296204|EXPERIMENTAL|BB4 antibody-Iodine 131|
62700206|NCT01224314|ACTIVE_COMPARATOR|dialysis fluid potassium high|potassium concentration in the dialysis fluid 1 mmol/L higher than usual
61952822|NCT04838483|EXPERIMENTAL|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
61952823|NCT03555916|EXPERIMENTAL|Drug|BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment
61952824|NCT03555916|PLACEBO_COMPARATOR|Placebo|2 mL of saline solution (0.9% NaCl) treatment
61952825|NCT03454542|EXPERIMENTAL|Menicon DSRB Redesign|Menicon DSRB Modified Lens Design is a single use contact lens with revised thickness specifications worn for 6 hours or more.
61952826|NCT03454542|ACTIVE_COMPARATOR|Menicon DSRB Original Design|Menicon DSRB Initial Lens Design is a single use contact lens with the original thickness specifications worn for 6 hours or more.
61952827|NCT04971343||Unselected blood donors|
61952828|NCT04971343||Hospitalized patients|
62141355|NCT02937493||Non Migration Background|If the following criteria is not fulfilled: Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
62141356|NCT01218659|EXPERIMENTAL|Migalastat|Participants received 150 mg migalastat orally QOD during the 18-month randomized treatment period and the optional 12-month OLE period. Participants received an inactive reminder capsule on alternate days during both treatment periods.
61952829|NCT04971343||Known HIV-1 Ab positive|
61952830|NCT04971343||Known HIV-2 Ab positive|
61952831|NCT04971343||Known Acute HIV-1 p24 Ag positive|
61952832|NCT02829554||Respondents|US residents recruited to an on-line questionnaire through Amazon mTurk.
61952833|NCT04676074|NO_INTERVENTION|control group|the participant will not do any exercise program but just they will take the routine medication.
62141357|NCT01218659|ACTIVE_COMPARATOR|ERT|Participants received ERT (either agalsidase alfa or agalsidase beta) as prescribed by the participant's treating physician and administered in accordance with the approved prescribing information during the 18-month randomized treatment period. Participants were required to be given \>80% of the currently labeled dose and regimen during the 18-month randomized treatment period. During the optional 12-month OLE period, participants received 150 mg migalastat orally QOD. Participants received an inactive reminder capsule on alternate days during the OLE.
62141358|NCT03520036|EXPERIMENTAL|MT-7117 low dose|
62141359|NCT03520036|EXPERIMENTAL|MT-7117 high dose|
62141360|NCT03520036|PLACEBO_COMPARATOR|Placebo|
62141361|NCT01182649|EXPERIMENTAL|EES Group|Patients who received an everolimus eluting stent
62141362|NCT01182649|ACTIVE_COMPARATOR|SES Gruop|Patients who received a sirolimus eluting stent
62501093|NCT04809662||Main cohort|This is a split-body study, with patients acting as their own controls between lesional and nonlesional skin. All patients will apply imiquimod.
62501094|NCT04288128||SCA early-manifest and premanifest patients|This cohort is defined by individuals with a SARA score between 0 and 15 (both values included).
62700207|NCT01224314|ACTIVE_COMPARATOR|dialysis fluid potassium low|potassium concentration in the dialysis fluid 1 mmol/L lower than usual
62700208|NCT05213741|EXPERIMENTAL|Magnetic-assisted colonoscopy group|Participants in this group will recieve magnetic-assisted colonoscopic examination
62700209|NCT03225404|EXPERIMENTAL|Experimental group|EPTE + EXER Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
62700210|NCT03225404|EXPERIMENTAL|Control group|
62700211|NCT06040788|EXPERIMENTAL|immediate implant placement with customized healing abutment|
62501095|NCT04288128||Control participants|This cohort is defined by individuals with a SARA score less than 5 and no significant neurological symptoms.
62501096|NCT00071539|EXPERIMENTAL|TP38 50 ng/mL|
62501097|NCT00071539|EXPERIMENTAL|TP38 100 ng/mL|
62501098|NCT06401954|EXPERIMENTAL|HIFEM with foot core training|High-intensity focused electromagnetic therapy is used to stimulate intrinsic foot muscles, and foot core training is performed with intrinsic foot muscle isometric contraction exercise.
62501099|NCT06401954|ACTIVE_COMPARATOR|HIFEM|High-intensity focused electromagnetic therapy is used to stimulate intrinsic foot muscles
62501100|NCT06401954|SHAM_COMPARATOR|Sham HIFEM with foot core training|Sham high-intensity focused electromagnetic therapy is applied on intrinsic foot muscles, and foot core training is performed with intrinsic foot muscle isometric contraction exercise.
62501101|NCT00576186||1|Patients being referred for the routine Equilibrium Radionuclide Angiocardiography (ERNA) for assessment of their left ventricular function will be asked to participate in the study. All patients will be asked to sign the consent form. Patients will be given a choice to participate in either or both studies (i.e. ERNA plus ACGBS or ERNA plus ACGBS and 3 DE).
61952834|NCT04676074|EXPERIMENTAL|study group|will receive normal routine medication with the treatment program of moderate intensity upper limb ergometer for 15 minute with frequency three times per week for four weeks.
61952835|NCT04049357|EXPERIMENTAL|The intervention group|"If the FIT test is returned and positive the individual can choose either Camera Capsule Endoscopy (CCE) or Optical colonoscopy (OC) as the primary bowel investigation. If OC is chosen, it is performed as standard and the participant outcomes remains analyzed in the intervention group as intention to treat.~If CCE is chosen an out-clinic CCE will be done at one of four regional sites. Overall and segmental bowel preparation grade (Leighton-Rex 1-4) and all pathological findings are reported. If the anal verge is identified without video blackout in the colon the transit is considered complete. Any incomplete CCE investigation will be followed by standard optical endoscopy to the extent needed to investigate the proportion of the colon not visualized by the capsule and remove any detected polyps. If the CCE is complete with complete transit and adequate preparation, individuals with more than two polyps or one polyp over 9 mm will be referred for colonoscopy."
62141363|NCT03948295|EXPERIMENTAL|Lipid Challenge Intervention|Participants of all weights will receive the lipid challenge intervention.
62501102|NCT00120315|NO_INTERVENTION|esomeprazole|Long-term users continue antisecretory medication
62501103|NCT00120315|PLACEBO_COMPARATOR|placebo drug|Long-term users are treated with placebo
62501104|NCT05740748|EXPERIMENTAL|Tezepelumab|tezepelumab 210 mg sc q4wks 20 weeks treatment
62501105|NCT05740748|PLACEBO_COMPARATOR|Placebo|placebo sc q4wks 20 weeks treatment
62501106|NCT04660032|EXPERIMENTAL|Nudge|Obstetric care providers will receive electronic prompts (nudge) for participants in this arm
62501107|NCT04660032|NO_INTERVENTION|Usual care|Usual postpartum follow-up with visit at 4-12 weeks postpartum
62501108|NCT01459757||Data generated from the past sunitinib A6181036 GIST study|
62501109|NCT01530906|EXPERIMENTAL|rTMS|"patients included in this arm will receive 10 sessions of transcranial magnetic stimulation (10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC).~Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)"
62501110|NCT01530906|PLACEBO_COMPARATOR|rTMS SHAM|Transcranial magnetic stimulation SHAM Intervention: Repetitive transcranial Magnetic Stimulation SHAM Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol
62501111|NCT01853371|EXPERIMENTAL|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions, with 4 weeks interval between each session and the other.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
62501112|NCT01853371|ACTIVE_COMPARATOR|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department.
62501113|NCT02940522|EXPERIMENTAL|Treatment A|Subcutaneous (SQ) injection using an autoinjector
62501114|NCT02940522|ACTIVE_COMPARATOR|Treatment B|Intramuscular injection (IM) using syringe and needle
62501115|NCT00265785|EXPERIMENTAL|Pemetrexed|pemetrexed
62141364|NCT03363945|ACTIVE_COMPARATOR|MDR-101|A single dose will be administered via IV infusion post-kidney transplant.
62501116|NCT02101879||Breast cancer Her2 positive|Trastuzumab \& Pertuzumab \& Taxanes
62501117|NCT01812473||Patients admitted to the Intensive Care Unit|All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study.
62501118|NCT02959840|NO_INTERVENTION|Control|No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
62501119|NCT02959840|ACTIVE_COMPARATOR|Metoclopramide, Ondansetron|10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
62501120|NCT02959840|EXPERIMENTAL|Acupressure Point P6 stimulator|Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
62501121|NCT05570630|EXPERIMENTAL|VAX-MOM COVID-19 Intervention|
62501122|NCT05570630|ACTIVE_COMPARATOR|Standard of Care|
62501123|NCT04735887|EXPERIMENTAL|SADL-eM & conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive a copy of the SADL-eM in addition to conventional therapy.
62501124|NCT04735887|NO_INTERVENTION|Conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive conventional therapy.
62501125|NCT04117893|EXPERIMENTAL|Duloxetine combined with intra-articular injection|
62501126|NCT04117893|ACTIVE_COMPARATOR|Intra-articular injection|
62501127|NCT01745081|EXPERIMENTAL|Mannitol|Bolus mannitol 20% at skin incision
62501128|NCT01745081|EXPERIMENTAL|Hypertonic saline|Hypertonic saline 3% at skin incision
62501129|NCT06678672|EXPERIMENTAL|Contingency Management (CM)|A VA CM Protocol will be established after gathering feedbacks from focus groups with Veterans and advice from the experts in 1) surgical care, 2) CM, and 3) VA policy. The CM intervention group will follow the established VA CM Protocol to deliver treatment over 5 weeks. The participants in the CM group will also be offered a 5-week supply of medication for Tobacco Use Disorder (TUD).
62501130|NCT06678672|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants assigned to TAU will receive usual care at San Francisco VA Health Care System (referral to Tobacco Cessation Clinic and the VA Telequit Quitline) over the 5 weeks. They will also be offered a 5-week supply of medication for Tobacco Use Disorder (TUD).
61952836|NCT04049357|NO_INTERVENTION|The control group|The control group will be invited to screening as usual. The intervention group will be informed that if the fecal test is returned and positive they can either choose to have an initial colon capsule endoscopy, and only colonoscopy if significant findings are made or an initial colonoscopy as usual.
61952837|NCT05305820|EXPERIMENTAL|Intervention|"Exercise: The exercise training program was designed to improve physical fitness prior to surgery and for a 6-week period after surgery once deemed fit.~Nutrition: The nutritional arm consists of nutritional intervention tailored to the outcome of the nutritional screening.Participants will be asked to take part in a dietary food recall system called Foodbook24, and based on their dietary needs will be supported in nutritional optimisation."
61952838|NCT05305820|NO_INTERVENTION|Control|This group will receive standard oncological care and will receive no formal education of exercise or nutritional intervention.
61952839|NCT04636229|EXPERIMENTAL|ASA|Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)
61952840|NCT04636229|PLACEBO_COMPARATOR|Placebo|Participants receive a single IA injection of 4 mL of normal saline
61952841|NCT01259596|ACTIVE_COMPARATOR|Cognitive behavioral therapy|Cognitive-behavioral therapy consists of psychoeducation, relaxation techniques, cognitive therapy, problem-solving, thought stopping, behavioral activation, exposure, coping with pain, sleep, and relapse prevention
61952842|NCT01259596|ACTIVE_COMPARATOR|Nondirective supportive therapy|Nondirective supportive therapy consists of providing a warm and accepting environment in which a person can reflect on their experiences, thoughts, and feelings
61952843|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
62141365|NCT03363945|NO_INTERVENTION|Control Arm|Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.
62141366|NCT03704519|EXPERIMENTAL|Men_EPD|Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.
62141367|NCT03704519|EXPERIMENTAL|Men_DEP|Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.
62141368|NCT03704519|EXPERIMENTAL|Men_PDE|Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.
62141369|NCT03704519|EXPERIMENTAL|Men_DPE|Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.
62141370|NCT03704519|EXPERIMENTAL|Men_EDP|Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.
62141371|NCT03704519|EXPERIMENTAL|Men_PED|Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.
62141372|NCT01748864|EXPERIMENTAL|Single Arm - Healthy Volunteers|Etarfolatide (EC20)
62141373|NCT06452173||high risk|Patients with cerebrovascular events within six months, including i. cerebral infarction in the middle cerebral artery territory on the side of carotid stenosis; ii. transient ischemic attack symptoms (including motor and sensory) in the hemisphere on the side of stenosis; and iii. transient amaurosis on the side of stenosis. This indicates an unstable condition and such patients are defined as high-risk carotid stenosis patients.
62141374|NCT06452173||low risk|Patients without cerebrovascular events within six months are defined as low-risk carotid stenosis patients.
62501131|NCT01175473|EXPERIMENTAL|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD for up to Week 4.
62501132|NCT01175473|ACTIVE_COMPARATOR|Liraglutide|2-step initiation regimen of liraglutide: 0.6 milligram (mg) QD subcutaneously for 1 week, followed by 1.2 mg QD for 1 week, then 1.8 mg QD up to Week 4.
62501133|NCT03045627|ACTIVE_COMPARATOR|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
62501134|NCT03045627|ACTIVE_COMPARATOR|Active comparator|"Ara-C, Aclarubicin Combined G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .~One course includes 28 days."
62501135|NCT03864458|EXPERIMENTAL|KHK7791 A|Patients take KHK7791 low dose BID.
62501136|NCT03864458|EXPERIMENTAL|KHK7791 B|Patients take KHK7791 middle dose BID.
62501137|NCT03864458|EXPERIMENTAL|KHK7791 C|Patients take KHK7791 high dose BID.
62501138|NCT03864458|EXPERIMENTAL|KHK7791 D|Patients start at KHK7791 high dose and can down titrate weekly ,based on a GI tolerability question.
62501139|NCT03864458|PLACEBO_COMPARATOR|Placebo|Patients take Placebo BID.
62501140|NCT02206009|EXPERIMENTAL|Collagen membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
62501141|NCT00263627|PLACEBO_COMPARATOR|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
62501142|NCT00263627|EXPERIMENTAL|Specific Immunotherapy|Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
62501143|NCT01085669||VEPTR patients|Children treated with VEPTR Implants for severe spinal or thoracic deformities
62501144|NCT05525676|EXPERIMENTAL|Brief Relationship Checkup (BRC)|Couples in the experimental condition will participate in three joint sessions of the Brief Relationship Checkup (BRC; Cordova 2014; Cigrang et al., 2016). This program has been tested in Air Force Primary Care but has not been explored in Veterans with ongoing mental health issues and has not been compared to an active treatment.
62501145|NCT05525676|ACTIVE_COMPARATOR|Co-Located Collaborative Care (CCC)|The comparison condition will be three sessions of Co-Located Collaborative Care (CCC) offered to the Screened Veteran only. This reflects the current standard of care in VA Primary Care Mental Health.
62501146|NCT03437330|EXPERIMENTAL|Empagliflozin (Jardiance®)|Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral
62501147|NCT03437330|ACTIVE_COMPARATOR|Insulin Glargine (Lantus®)|"Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU FBG 7-8 mmol/L: +3 IU FBG \> 8 mmol/L: +5 IU"
62501148|NCT05831579|EXPERIMENTAL|Cohort A: Reirradiation of Treatment Fields|Radiotherapy will consist of 20 Gy proton GRID radiotherapy x 3 fractions.
62501149|NCT05831579|EXPERIMENTAL|Cohort B: De Novo Radiation Treatment Fields|Radiotherapy will consist of 20 Gy proton GRID radiotherapy x 3 fractions.
62501150|NCT02907073|EXPERIMENTAL|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion \[18F\]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
62501151|NCT02907073|EXPERIMENTAL|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo \[18F\]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of \[18F\]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of \[18F\]BF4 in up to three myeloma patients when the site is accessible for biopsy.
62501152|NCT02907073|EXPERIMENTAL|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo \[18F\]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of \[18F\]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of \[18F\]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
62700212|NCT06142591|ACTIVE_COMPARATOR|Group A (10mg oxycodone)|The burn wound was covered with a three-layer sterile dressing. The first layer was a dressing soaked in Octanisept (a solution of octenidine dihydrochloride and phenoxyethanol) with 10mg Oxycodone, the second dressing with paraffin, and the third dry dressing. Octenisept (Schulke\&Mayer Poland, 1000ml) is a disinfectant liquid. The 1 gram of Octenisept contains 1 mg of octenidine dihydrochloride and 20 mg of Phenoxyethanol.
62700213|NCT06142591|ACTIVE_COMPARATOR|Group B (20mg oxycodone)|The burn wound was covered with a three-layer sterile dressing. The first layer was a dressing soaked in Octanisept (a solution of octenidine dihydrochloride and phenoxyethanol) with 20mg Oxycodone, the second dressing with paraffin, and the third dry dressing. Octenisept (Schulke\&Mayer Poland, 1000ml) is a disinfectant liquid. The 1 gram of Octenisept contains 1 mg of octenidine dihydrochloride and 20 mg of Phenoxyethanol.
62141375|NCT04969666|EXPERIMENTAL|IPED2015_dose 1|Active treatment
61952844|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
62141376|NCT04969666|EXPERIMENTAL|IPED2015_dose 2|Active treatment
62141377|NCT04969666|PLACEBO_COMPARATOR|Placebo|Placebo treatment
62141378|NCT05049941||group1|Group (1): veno-arterial carbon dioxide tension / arteriovenous oxygen content P(v-a)CO2/C(a-v)O2 ratio group.
62501153|NCT05338853|EXPERIMENTAL|Gongs Mmobilization|to deal adhesive capsulitis
62501154|NCT05338853|EXPERIMENTAL|scapular mobilization|to deal adhesive capsulitis
62501155|NCT04536792|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once on Day 1. AG-946 will be given under fasted or fed conditions.
61952845|NCT02085122|EXPERIMENTAL|noninvasive ventilation|
62141379|NCT05049941||group 2|Group (2): Lactate clearance (LC) group; Lactate level was measured then LC rate was calculated by the equation \[(lactate(T0)- lactate(T8))/lactate(T0)\] × 100%.
62141380|NCT05049941||group 3|"Group (3):~veno-arterial carbon dioxide tension group; P(v-a)co2 difference"
62141381|NCT05319041|EXPERIMENTAL|Active herbal capsules|"Wei's Qi Ju Gan Lu Formula is a herbal formulation initiated by the senior TCM collaborator, Prof Wei QP. This TCM formulation is prescribed to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
62141382|NCT05319041|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsule which contains 0.5g maltodextrin without any herbs medicine.
62141383|NCT01160887||Patients with diabetic peripheral neuropathy|
62141384|NCT01160887||Healthy matched controls|
62141385|NCT00973999|EXPERIMENTAL|Injection into salivary gland|
62141386|NCT05842265|EXPERIMENTAL|Experimental:|Self acupressure
62501156|NCT04536792|EXPERIMENTAL|Part 2: Multiple Ascending Dose (MAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once daily (QD) for 14 days or using an alternative dosing regimen for up to 28 days under fasted conditions.
62501157|NCT04536792|EXPERIMENTAL|Part 3: Sickle Cell Disease (SCD) Phase|Participants will receive a range of selected ascending doses of AG-946, orally, QD or using an alternative dosing regimen for 28 days.
62501158|NCT06677684|NO_INTERVENTION|a control group|the control group received standard antibiotic therapy
61952846|NCT02085122|NO_INTERVENTION|Control Group|
62141387|NCT05842265|NO_INTERVENTION|Control|Routine maintenance will be applied.
62141388|NCT00123409|EXPERIMENTAL|Telephone Disease Management|Telephone based disease management or counseling used to promote a reducution in alcohol misuse
62141389|NCT00123409|PLACEBO_COMPARATOR|Usual Care|Usual Care
62343574|NCT04624035|ACTIVE_COMPARATOR|Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults|Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
62343575|NCT02992158|EXPERIMENTAL|behavioral activation|The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client's important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
62343576|NCT02992158|OTHER|treatment-as-usual|Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.
62343577|NCT05765695|EXPERIMENTAL|Treated group|
62343578|NCT06512948||Logistics regression model|This article is a retrospective study, which mainly incorporates patients' preoperative and postoperative imaging parameters and demographic data into Logistics regression analysis to analyze factors that may affect the surgical effect. No interventions such as medication are involved.
62501159|NCT06677684|EXPERIMENTAL|the intervention group received standard antibiotics plus adjunctive vitamin A supplementation|the intervention group received standard antibiotics plus adjunctive vitamin A supplementation (25,000 IU daily for two days)
62501160|NCT00574769|EXPERIMENTAL|1|
62501161|NCT05078827|ACTIVE_COMPARATOR|Comparator Arm|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
62501162|NCT05078827|EXPERIMENTAL|Arms and Interventions|Test Product (A): Fluorouracil Cream, 5% of Encube Ethicals Pvt. Ltd., India
62501163|NCT05078827|PLACEBO_COMPARATOR|Placebo Arm|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
62501164|NCT01459198|EXPERIMENTAL|Adults: Vaccine (Group 1)|Adult participants will receive one dose of the 10\^6 RSV MEDI ΔM2-2 vaccine intranasally.
62501165|NCT01459198|EXPERIMENTAL|Seropositive Children: Vaccine (Group 2)|Seropositive children will receive one dose of the 10\^6 RSV MEDI ΔM2-2 vaccine intranasally.
62501166|NCT01459198|PLACEBO_COMPARATOR|Seropositive Children: Placebo Vaccine (Group 2)|Seropositive children will receive one dose of the placebo vaccine intranasally.
62501167|NCT01459198|EXPERIMENTAL|Seronegative Infants and Children: Vaccine (Group 3)|Seronegative infants and children will receive one dose of the 10\^5 RSV MEDI ΔM2-2 vaccine intranasally.
62141390|NCT04596488|EXPERIMENTAL|Efavirenz 400mg+TDF+3TC|Combined antiretroviral therapy(cART) consisting of three regimens such as efavirenz, tenofovir and lamivudine is an effective measure for the treatment of HIV-1 infection.Efavirenz 600mg daily was approved by the US Food and Drug Administration in 1998. In this single-arm research, patients were treated with a reduced 400mg dose of efavirenz combined with tenofovir 300mg and lamivudine 300mg once a day. This treatment had to be maintained indefinitely due to the existence of HIV reservoir.
62141391|NCT03958773|EXPERIMENTAL|Cardiovalve treatment|Patients that implanted with the Cardiovalve device
62141392|NCT04825379|EXPERIMENTAL|bioactive composite|Cention N, Ivoclar Vivadent, Schaan, Liechtenstein (CN)
62141393|NCT04825379|EXPERIMENTAL|posterior resin composite|G-ænial Posterior (GC, Tokyo, Japan) (GP)
62501168|NCT01459198|PLACEBO_COMPARATOR|Seronegative Infants and Children: Placebo Vaccine (Group 3)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
62501169|NCT01459198|EXPERIMENTAL|Seronegative Infants and Children: Vaccine (Group 4)|Seronegative infants and children will receive one dose of the 10\^6 RSV MEDI ΔM2-2 vaccine intranasally.
62501170|NCT01459198|PLACEBO_COMPARATOR|Seronegative Infants and Children: Placebo Vaccine (Group 4)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
62501171|NCT04973800|EXPERIMENTAL|Experimental arm: Simvastatin|Simvastatin 20mg ON PO for 28-30 days
62501172|NCT04973800|PLACEBO_COMPARATOR|Control arm: Placebo|Sucrose placebo ON PO for 28-30 days
62501173|NCT02930135|EXPERIMENTAL|Antibacterial Bond|"Indirect pulp capping using antibacterial bond and x-tra fil composite~1. Local anesthesia administration~2. Isolation of tooth with rubber dam~3. Opening of the cavity and the removal of undermined enamel~4. Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~5. Partial removal of carious dentin on the pulp wall.~6. Washing the cavity and dryness~7. Apply antibacterial light-cure, self-etching bonding agent (Clearfil SE Protect, Kuraray America, Inc.)~8. Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
61952847|NCT04758104|EXPERIMENTAL|Yttrium90|Intracystic application of yttrium90
62501174|NCT02930135|ACTIVE_COMPARATOR|Conventional Bond|"Indirect pulp capping using conventional bond and x-tra fil composite~1. Local anesthesia administration~2. Isolation of tooth with rubber dam~3. Opening of the cavity and the removal of undermined enamel~4. Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~5. Partial removal of carious dentin on the pulp wall.~6. Washing the cavity and dryness~7. Apply conventional light-cure, self-etching bonding agent (Clearfil SE Bond, Kuraray America, Inc.)~8. Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
62501175|NCT01669824||Group 1|
62501176|NCT03211455|PLACEBO_COMPARATOR|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
62501177|NCT03211455|EXPERIMENTAL|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
62700214|NCT03045952|EXPERIMENTAL|microwave ablation|Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
62141394|NCT00949364|EXPERIMENTAL|Pomalidomide|Every patient will remain on treatment until disease progression for at least 12 cycles, withdrawal of patient's informed consent or the occurrence of unacceptable toxicity. If a patient may benefit from treatment with pomalidomide the investigator together with the principle investigator will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision. This additional treatment will be performed within the follow-up period of the study, data will be collected and duration will be maximally 12 cycles.
62343579|NCT05835245|EXPERIMENTAL|Cryoablation combined with Sintilimab and Lenvatinib|Cryoablation treatment starts at day 0. Sintilimab and Lenvatinib will be initiated on day 1 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62501178|NCT06646016|EXPERIMENTAL|UVADEX in conjunction with extracorporeal photopheresis|Participants will receive UVADEX, in conjunction with ECP procedure twice weekly for four weeks and then every other week for 8 weeks during the 12-week treatment period according to the treatment schedule.
62501179|NCT06646016|ACTIVE_COMPARATOR|Best available therapy (BAT)|Participants will receive either infliximab or vedolizumab as per the investigator's choice during the 12-week treatment period.
62501180|NCT00691756|EXPERIMENTAL|1|Cold blood renal perfusion
62343580|NCT05045469|ACTIVE_COMPARATOR|group A (dian dao san group)|Herbal medicine (dian dao san) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
62343581|NCT05045469|PLACEBO_COMPARATOR|group B( topical medicine without therapeutic effects)|Placebo (topical medicine without therapeutic effects) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
62501181|NCT00691756|ACTIVE_COMPARATOR|2|Cold crystalloid renal perfusion
62501182|NCT03675893|EXPERIMENTAL|Cohort 1|"* Abemaciclib is administered by mouth twice daily~* LY3023414 is administered by mouth twice daily~* Letrozole is administered by mouth once daily"
62501183|NCT03675893|EXPERIMENTAL|Cohort 2|"* Abemaciclib is administered by mouth twice daily~* LY3023414 is administered by mouth twice daily"
62501184|NCT03675893|EXPERIMENTAL|Cohort 1A|"* Abemaciclib is administered by mouth twice daily~* Letrozole is administered by mouth once daily"
62501185|NCT03675893|EXPERIMENTAL|Cohort 3|"* Abemaciclib is administered by mouth twice daily~* Letrozole is administered by mouth once daily~* Metformin is administered by mouth once daily"
62501186|NCT03675893|EXPERIMENTAL|Cohort 4|"* Abemaciclib is administered by mouth twice daily~* Letrozole is administered by mouth once daily~* Zotatifin is administered intravenously on days 1 and 8 of a 21-day cycle"
62343582|NCT04158986|NO_INTERVENTION|Standard treatment|Receives standard post-discharge care with planned follow-up in the clinic for liver failure or ambulatory.
62343583|NCT04158986|EXPERIMENTAL|Nurse-driven post-discharge intervention|Participates in a nurse-driven post-discharge intervention program.
62343584|NCT02482441|EXPERIMENTAL|OMP-131R10 intravenous (in the vein) infusions|OMP-131R10 will be administered IV on the first day of each 14-day cycle.
62700215|NCT01784484||patients with abnormal liver enzymnes|
62700216|NCT00427037|PLACEBO_COMPARATOR|Placebo|Placebo
62700217|NCT00427037|ACTIVE_COMPARATOR|Cholecalciferol|D3
62343585|NCT02482441|EXPERIMENTAL|FOLFIRI (5-FU, irinotecan, leucovorin).|dosing continues up to the 20 mg/kg dose level
62343586|NCT00905723|EXPERIMENTAL|Estrogen|Women randomized to this group will receive daily pills containing 1 mg of estradiol
62343587|NCT00905723|EXPERIMENTAL|Isoflavone|Women randomized to this group will receive daily pills of 150 mg isoflavone
62343588|NCT00905723|PLACEBO_COMPARATOR|Placebo|Women randomized to this group will be administered daily placebo pills
62700218|NCT00924274|EXPERIMENTAL|Lifestyle counseling|
62343589|NCT05553626|EXPERIMENTAL|LBBP Treatment|Patients were performed left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device
62343590|NCT05553626|ACTIVE_COMPARATOR|BVP Treatment|Patients were performed bi-ventricular pacing by a CRT/CRTD device
62700219|NCT00924274|ACTIVE_COMPARATOR|sunflower oil|
62141395|NCT02470806|EXPERIMENTAL|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
62501187|NCT03675893|EXPERIMENTAL|Cohort 5|"* Abemaciclib is administered by mouth twice daily~* Letrozole is administered by mouth once daily~* Zotatifin is administered intravenously on days 1 and 8 of a 21-day cycle"
62501188|NCT01098851||Obstructive Sleep Apnea|Surgery patients at high risk for Obstructive Sleep Apnea
62501189|NCT01098851||Surgery Patients|Surgery patients at low risk for Obstructive Sleep Apnea
62501190|NCT06260891|EXPERIMENTAL|Dose 1: Zinc 25 mg/day|25 mg of zinc as zinc gluconate taken orally once a day
62141396|NCT02470806|ACTIVE_COMPARATOR|tNPWT System|Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
62141397|NCT04696900|OTHER|Exercise training|14 participants will absolve a prescribed exercise training for 12 months.
62141398|NCT02741505|EXPERIMENTAL|Sleep Deprivation followed by Normal Sleep|Subjects will be sleep deprived at the sleep laboratory.
62141399|NCT03643224|EXPERIMENTAL|Experimental|Radiofrequency Ablation. Catheter ablation to treat persistent atrial fibrillation using temperature-controlled ablation catheter
62141400|NCT03142490|EXPERIMENTAL|Treatment|In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
62343591|NCT01318512||Chronic Kidney Disease|Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.
62343592|NCT05651893|EXPERIMENTAL|Second forward view examination group|After successful intubation of the cecum, the colonoscope is withdrawn to the splenic curvature with the colonic mucosa carefully inspected. Then the left colon, including the splenic curvature to the anus, is examined twice in the forward view.
62343593|NCT05651893|EXPERIMENTAL|Extended withdrawal time group|After successful intubation of the cecum, the colonoscope is withdrawn to the splenic curvature with the colonic mucosa carefully inspected. The colonoscope was withdrawn to the anus directly with withdrawal time extended to the double routine withdrawal time of the left colon.
62343594|NCT05228106||Patients eligible for [68Ga]-PSMA-617-PET|All cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with a \[68Ga\]-PSMA-617 dose calculated depending on the characteristics of the PET tomograph and patient weight (maximum 370 MBq). 60-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.
62343595|NCT01194804|EXPERIMENTAL|Eculizumab|Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
62343596|NCT05405595|EXPERIMENTAL|ADG126 in combination with Pembrolizumab (Trade name KEYTRUDA®)|An IV infusion of ADG126 over 60-90 minutes will be administered 30-60 minutes after administration of pembrolizumab (KEYTRUDA®) infusion. A treatment cycle will consist of 21 days.
62343597|NCT00115765|ACTIVE_COMPARATOR|Oxaliplatin and bevacizumab without panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.
62343598|NCT00115765|EXPERIMENTAL|Irinotecan and bevacizumab plus panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
62343599|NCT00115765|ACTIVE_COMPARATOR|Irinotecan and bevacizumab without panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W alone
62501191|NCT06260891|EXPERIMENTAL|Dose 2: Zinc 40 mg/day|40 mg of zinc as zinc gluconate taken orally once a day
62141401|NCT03142490|ACTIVE_COMPARATOR|Control|In vitro fertilization patients not submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
62343600|NCT00115765|EXPERIMENTAL|Oxaliplatin and bevacizumab plus panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
62501192|NCT03431896||Primary|"1.) To evaluate the relative amount of misfolded ATTR oligomers in asymptomatic ATTR amyloid genetic carriers and correlate their levels with clinical symptoms and outcomes.~1. Determine if misfolded ATTR oligomers are elevated compared to healthy control data obtained by Scripps during probe development~2. Describe the levels longitudinally~3. Determine if treatment with ATTR-specific medications (examples: diflunisal, doxycycline, ursodiol, tauroursodeoxycholic acid (TUDCA), green tea extract, curcumin, tafamidis, inotersen, patisiran) lead to reduction in the probe levels in those with elevated levels at baseline"
62501193|NCT04648007||Control|10 patients with no personal or family problems with gambling as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
62501194|NCT04648007||Moderate Gamblers|10 patients with moderate gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
62501195|NCT04648007||Severe Gamblers|10 patients with severe gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
61952848|NCT01282632|EXPERIMENTAL|Risperidone|Commence at 0.5 mg once daily Increase, blindly, to 1 mg and then by 1 mg at discretion of clinicians through weeks 1-4 to a maximum of 3 mg.
62164555|NCT02211508|ACTIVE_COMPARATOR|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
62343601|NCT04104906|EXPERIMENTAL|motor control training|8-week exercise program, twice a week, with motor control training
62343602|NCT04104906|ACTIVE_COMPARATOR|exercises|8-week exercise program, twice a week.
62343603|NCT01928485|ACTIVE_COMPARATOR|Arm A (active surveillance)|Patients undergo active surveillance for 52 weeks.
62343604|NCT01928485|EXPERIMENTAL|Arm B (Sunphenon)|Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
62343605|NCT05053997|EXPERIMENTAL|NAVIGATE intervention arm|Nurse navigation
62343606|NCT05053997|NO_INTERVENTION|Navigate control arm|Standard treatment and care
62501196|NCT05626387|ACTIVE_COMPARATOR|Prednisolone alone|Oral prednisolone will be administered over 52 weeks, according to following schedule 0.75 mg/kg x 2 weeks 0.5 mg/kg x 2 weeks 20 mg/day x 4 weeks 15 mg/day x 4 weeks 10 mg/day x 4 weeks 5 mg/day x 10 weeks 5 mg on alternate days x 26 weeks
62700220|NCT06564571||Patients undergoing endoscopic ultrasound procedures|Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
62700221|NCT04826302|EXPERIMENTAL|Myofascial treatment|4 sessions of myofascial intervention, 40 minutes per session, 1 session per week
62700222|NCT04826302|SHAM_COMPARATOR|Sham myofascial treatment|4 sessions of sham myofascial intervention, 40 minutes per session, 1 session per week
62700223|NCT02843633|EXPERIMENTAL|BioFreedom™ Drug Coated Stent|
62700224|NCT06349213||Young healthy volunteers|Healthy young adults (20-35 years) will undergo the first two visits detailed above.
62700225|NCT06349213||Older healthy volunteers|Healthy older adults (60-85 years) will undergo each visit detailed above (five visits in total).
62700226|NCT03901430|EXPERIMENTAL|Class|Group navigation model
62700227|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
61952849|NCT01282632|EXPERIMENTAL|Olanzapine|Commence at 2.5 mg once daily Increase to 5.0 mg, blindly, and then by 5 mg at the discretion of the clinician through weeks 1 - 4 to a maximum of 15 mg
62343607|NCT03154151|EXPERIMENTAL|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders and survivors process any traumatic experiences they lived through during their WTC recovery work and exposure.
62700228|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
62700229|NCT04759287|ACTIVE_COMPARATOR|VS group|include patients undergoing awake intubation using the C-MAC VS
62700230|NCT04759287|PLACEBO_COMPARATOR|FOB group|will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
62343608|NCT03154151|ACTIVE_COMPARATOR|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders and survivors work through any life problems they might currently be experiencing.
62700231|NCT03577457|EXPERIMENTAL|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
62700232|NCT03577457|EXPERIMENTAL|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
62700233|NCT03577457|EXPERIMENTAL|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
62700234|NCT03577457|PLACEBO_COMPARATOR|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
62700235|NCT03223675|EXPERIMENTAL|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
61952850|NCT06445296|EXPERIMENTAL|Meal Consumption with Beyond Meat|During the Beyond Meat arm, participants will consume a high-fat meal containing Beyond Meat (rather than beef). Meals will be otherwise identical.
61952851|NCT06445296|ACTIVE_COMPARATOR|Meal Consumption with Beef|During the Beef arm, participants will consume a high-fat meal containing beef (rather than Beyond Meat). Meals will be otherwise identical.
61952852|NCT01061411|EXPERIMENTAL|Treatment (sunitinib malate, dalteparin)|Patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in week 6 during course 1. In all subsequent courses, patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in weeks 1-6. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
61952853|NCT04827381|NO_INTERVENTION|Usual care|Patients visiting their clinician will receive the normal, written after-visit-summary (available on paper or via the patient portal).
62343609|NCT04191291|EXPERIMENTAL|Shortened lunch period|The amount of seated lunch time will be 10 minutes.
62343610|NCT04191291|EXPERIMENTAL|Longer lunch period|The amount of seated lunch time will be 20 minutes.
62343611|NCT02940717|EXPERIMENTAL|Vita suprinity|Vita Suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10 % by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (ZLS).
62343612|NCT02940717|ACTIVE_COMPARATOR|Emax cad|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for laminate venners
62343613|NCT02262234|EXPERIMENTAL|Education Program Type 1|
62343614|NCT02262234|EXPERIMENTAL|Education Program Type 2|
62501197|NCT05626387|EXPERIMENTAL|Mycophenolate mofetil plus prednisolone|Oral prednisolone will be administered according to the schedule in the prednisolone alone arm. Mycophenolate mofetil will be administered starting from 2 weeks after randomization. It will be initiated at a dose of 500 mg twice daily and will be escalated to 1000 mg twice daily after two weeks.
62700236|NCT05188014|EXPERIMENTAL|All participants|All participants will be in a single study arm.
62700237|NCT02009267||Patient controlled analgesia|Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
62700238|NCT02009267||Continuous thoracic epidural infusion|Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
62700239|NCT02009267||Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
62700240|NCT00741377|EXPERIMENTAL|BHQ880 + zoledronic acid|BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle.
62700241|NCT04835129|EXPERIMENTAL|Safety Run-in|Six subjects will be enrolled. Isatuximab (10 mg/kg) intravenous (IV) on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) by mouth (PO) days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
61952854|NCT04827381|EXPERIMENTAL|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
61952855|NCT04827381|EXPERIMENTAL|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
62141402|NCT02349516|EXPERIMENTAL|Squalamine Solution BID 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
62141403|NCT02349516|PLACEBO_COMPARATOR|Vehicle Solution 0.2% BID|Vehicle Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
62700242|NCT04835129|EXPERIMENTAL|Expansion|"Forty-seven subjects with relapsed and/or refractory multiple myeloma will be enrolled.~Isatuximab (10 mg/kg) IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) PO days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle."
62700243|NCT02946203|ACTIVE_COMPARATOR|Flavored Beverage Oral Contrast-Breeza|Pediatric patients that are undergoing awake CT and MR enterography at the Cincinnati Children's Hospital Medical Center (CCHMC) base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
62700244|NCT02946203|ACTIVE_COMPARATOR|Barium Sulfate Oral Contrast-VoLumen|Pediatric patients that are undergoing awake CT and MR enterography at the CCHMC base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
62700245|NCT03322566|EXPERIMENTAL|Pembrolizumab + Chemotherapy + Epacadostat|Participant received pembrolizumab 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, twice daily (BID) in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m\^2 IV infusion, Q3W + cisplatin 75 mg/m\^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m\^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
61952856|NCT04650490|EXPERIMENTAL|Immediate SRS followed by IO|Participants will receive SRS followed by physician's choice of standard of care immunotherapy, given at the FDA-approved dose within 14 days of SRS.
61952857|NCT04650490|EXPERIMENTAL|Immediate IO followed by SRS|Participants will receive physician's choice of immunotherapy, given at the FDA-approved dose followed by SRS, if deemed appropriate, at the time of intracranial progression.
61952858|NCT05875363||ADHD|ADHD is among the most commonly diagnosed neurodevelopmental disorders, and the worldwide prevalence.
61952859|NCT05875363||ASD|Autistic spectrum disorder (ASD), characterized by overriding obsessions and difficulties in social cognition, might render the affected individuals vulnerable for becoming an offender or a victim of crime.
62141404|NCT02349516|EXPERIMENTAL|Squalamine Solution 0.2% QID|Squalamine Lactate Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
62141405|NCT02349516|PLACEBO_COMPARATOR|Vehicle Solution 0.2% QID|Vehicle Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
62141406|NCT00367653|EXPERIMENTAL|1|
62343615|NCT03095521|EXPERIMENTAL|Arm A|Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
62141407|NCT00367653|EXPERIMENTAL|2|
62141408|NCT02334215|EXPERIMENTAL|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
62141409|NCT02334215|EXPERIMENTAL|Methadone|Participants will begin methadone during detention.
62141410|NCT02334215|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
62141411|NCT01307800|EXPERIMENTAL|80 milligrams (mg) LY2140023, BID|An 80-mg LY2140023 tablet administered orally, twice daily (BID) for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time placebo tablets identical to LY2140023 are administered orally, BID.
62141412|NCT01307800|EXPERIMENTAL|40 mg LY2140023, BID|A 40-mg LY2140023 tablet administered orally, BID for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time, placebo tablets identical to LY2140023 are administered orally, BID.
62164556|NCT02211508|SHAM_COMPARATOR|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
62164557|NCT06247761|ACTIVE_COMPARATOR|Vicryl rapide suture for Skin closure|Skin closure at end of hand trauma surgery
62164558|NCT06247761|ACTIVE_COMPARATOR|Nylon suture for Skin closure|Skin closure at end of hand trauma surgery
62164559|NCT06720194|EXPERIMENTAL|Experimental group|This arm receives the virtual therapy plus the usual treatment
62164560|NCT06720194|OTHER|Control Group|This arm receives the usual treatment at the same dose and time than experimental group
61952860|NCT05875363||Other disorders in youth: CD or substance use disorder|Conduct disorder (CD), characterized by antisocial and aggressive behavior, affects 2-2.5% of children and adolescents. CD is a risk factor for antisocial personality disorder, and despite the fact that a CD diagnosis completely relies on behavioral symptoms, research has identified neurocognitive impairments.
61952861|NCT05890885|EXPERIMENTAL|Real - Sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
61952862|NCT05890885|EXPERIMENTAL|Sham - Real|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
61952863|NCT05707975||Adolescents hospitalized in the service|Adolescents between 12 and 16 years old Intervention: filling of three scales (CAS, C-SSRS, HAD)
61952864|NCT00925041|EXPERIMENTAL|Kxl Vedera|
61952865|NCT02727361|EXPERIMENTAL|Cholinergic striatal imaging|Cholinergic striatal imaging (IRM and TEP) to compare the intensity of the binding of cholinergic tracer
61952866|NCT00871897||Cardiac Rehabilitation|People with heart failure who elect to participate in cardiac rehabilitation.
62700246|NCT03322566|EXPERIMENTAL|Pembrolizumab + Chemotherapy + Placebo|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat matching placebo tablets, orally, BID in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m\^2 IV infusion, Q3W + cisplatin 75 mg/m\^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m\^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
61952867|NCT00871897||No Cardiac Rehabiliation|People with heart failure who elect NOT to participate in cardiac rehabilitation.
61952868|NCT05717946|EXPERIMENTAL|"Group I PRO-D"|50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
61952869|NCT05717946|PLACEBO_COMPARATOR|"Group II PLC-D"|50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a placebo.
61952870|NCT00951223||Patients with Chronic Hepatitis C|HCV positive patients who have failed previous HCV therapy This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patientadministered therapy with Infergen® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV. The primary endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends. Safety will be assessed by monitoring AEs, reduction/discontinuation of therapy because of AEs, routine laboratory results and by other means determined by the Investigator
61952871|NCT05509036||Critically ill patients|Critically ill adults \> 50 admitted to the ICU and receiving a life support intervention
61952872|NCT05950256|EXPERIMENTAL|N95 mask group|Continuously wearing N95 mask for 4 hours
61952873|NCT05950256|ACTIVE_COMPARATOR|Surgical mask group|Continuously wearing surgical mask for 4 hours
61952874|NCT02138682||l-123 Ioflupane|Study group includes those clinically diagnosed with Parkinson disease who are aged 75 and older who have agreed to donate brain tissue at time of death and are able to participate in the imaging scan process.
61952875|NCT04808999|EXPERIMENTAL|Pembrolizumab|Neoadjuvant Phase: 200 mg IV infusion, every 3 weeks (Day 1 of each 3-week cycle, 2 cycles) Adjuvant Phase: Day 1 of each 3-week cycle, 15 cycles
61952876|NCT01797744|EXPERIMENTAL|Vestibular rehabiliation|Vestibular rehabiliation
62141413|NCT01307800|EXPERIMENTAL|10 mg LY2140023, BID|A 10-mg LY2140023 tablet administered orally, BID for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time, placebo tablets identical to LY2140023 are administered orally, BID.
62141414|NCT01307800|PLACEBO_COMPARATOR|Placebo|A placebo tablet administered orally, BID for 7 weeks.
62141415|NCT03937765|EXPERIMENTAL|PRP|Intervention group will receive PRP instead of the standard of care for skin grafts. PRP Group-will remove surgical dressing post operative day 5. Donor site will be cleaned with soap and water daily and dressed with gauze daily until drainage stops.
61952877|NCT01797744|NO_INTERVENTION|Control group|Usual rehabilitation whitout additional vestibular exercises
62141416|NCT03937765|NO_INTERVENTION|Control|Control group receiving the standard of care for skin grafts. Control Group-will remove gauze dressing post operative day 2 but leave adeptic. Donor site will be cleaned daily with soap and water. Gauze applied daily as needed for drainage and will be stopped when drainage stops. The adeptic, which forms a biologic dressing, will be removed by the patient over time as it lifts from the wound.
62141417|NCT05705323|EXPERIMENTAL|Internet-delivered cognitive behavioral therapy for tinnitus|An 8-week modular cognitive behavioral therapy
62343616|NCT03095521|ACTIVE_COMPARATOR|Arm B|ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.
61952878|NCT03372044|EXPERIMENTAL|PF-06865571|Treatment
62141418|NCT05705323|EXPERIMENTAL|Internet-delivered mindfulness-based therapy for tinnitus|An 8-week mindfulness-based stress reduction.
61952879|NCT03045185|EXPERIMENTAL|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
61952880|NCT00951444|EXPERIMENTAL|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
61952881|NCT00951444|ACTIVE_COMPARATOR|Arm II|Patients receive gemcitabine hydrochloride and carboplatin as in arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients may crossover to arm upon disease progression.
62141419|NCT05705323|NO_INTERVENTION|Waiting-list control|The waiting list for 8 weeks.
62164561|NCT00977340|EXPERIMENTAL|Imagery Rehearsal Treatment|Imagery Rehearsal Treatment; 1 session on-site and 4 weeks of individual daily training; following principles Krakow and Zadra (2006)
62164562|NCT00977340|EXPERIMENTAL|Confrontation|Confrontation with nightmare content, until fear reaction habituates; 1 session on-site and 4 weeks of individual daily training
61952882|NCT00087607|EXPERIMENTAL|Peginterferon Alfa-2a + Ribavirin|Participants received Peginterferon alfa-2a (40 kD) \[Pegasys\] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin \[Copegus\] 1000 or 1200 milligram (mg)/day), orally, \[according to body weight, lesser than or greater than/equal to (\< or \>/=) 75 kilogram (kg), respectively\] twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (\< or \>/=75 kg body weight, respectively twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
61952883|NCT00087607|ACTIVE_COMPARATOR|Peginterferon Alfa-2b + Ribavirin|Participants received Peginterferon alfa-2b (12 kD) \[PEG-Intron\] at a dosage of 1.5 μg/kg SC once weekly plus Ribavirin \[Rebetol\] 1000 or 1200 mg/day orally (\< or \>/=75 kg body weight, respectively) twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (\< or \>/=75 kg body weight, respectively) twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
61952884|NCT04084431|ACTIVE_COMPARATOR|WBRT (10 x 2 Gy) + OSC|Whole brain radiotherapy will be applied with a total dose of 20 Gy in 10 fractions (single dose of 2 Gy). OSC as needed.
61952885|NCT04084431|EXPERIMENTAL|Optimal Supportive Care (OSC) alone|Symptomatic treatment including steroids, pain medication, nutritional support, etc
61952886|NCT01745406||Doctor and nurse|
61952887|NCT01745406||Doctor without nurse|
61952888|NCT04336306|EXPERIMENTAL|Evaluation of chronic hemodynamic and autonomic repercussions|Participants in a cardiovascular rehabilitation program will be randomly allocated to CR + VRBT interventions. This group will hold 3 weekly sessions (one for VRBT and two for CR) for 12 weeks. In the first, sixth and last week, chronic hemodynamic data and autonomic data will be evaluated.Furthermore,at the end of 12 weeks, a focus group with therapists and a focus group with patients will be held to identify qualitative aspects in relation to the insertion of VRBT. And in all eligible patients of CR wiil be applied the Questionnaire of barriers identification in frequenters of Cardiovascular Rehabilitation.
61952889|NCT02925923|ACTIVE_COMPARATOR|Ticagrelor|crushed ticagrelor (180 mg); (n=50 patients)
61952890|NCT02925923|ACTIVE_COMPARATOR|Eptifibatide bolus+clopidogrel|Eptifibatide bolus (180 mcg/kg x 2 boluses) + clopidogrel 600 mg and heparin low-dose (n=50 patients)
61952891|NCT00528463|EXPERIMENTAL|sciatic block|One arm, all patient studied received a block
62141420|NCT04239768|EXPERIMENTAL|MonoDermà HA gel combined to a low level laser|"Monodermà HA Bio-revitalizing gel is a sterile, biodegradable, isotonic intradermal filler produced by Innate S.r.l. (Italy) and distributed by Giuliani S.p.A. (Italy) in non-pyrogenic pre-filled syringe of 2 ml containing 2% (20mg/ml) of medium chain (1.0-1.5 x 106 Dalton) hyaluronic acid (HA), obtained from bacterial fermentation, in a physiologic buffer (see Appendix 1) and used as a filler for the correction of deep skin sagging and roughness."
62141421|NCT06566339|EXPERIMENTAL|Experimental: Imaging patients|Participants eyes will be imaged with a Robotically aligned eye imaging system to help eye care through the emergency department
62343617|NCT03415763|NO_INTERVENTION|Observation|Observation for patients with pathological complete response or yp stage I(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil)
62343618|NCT03415763|EXPERIMENTAL|5-fluorouracil|Capecitabine for patients with pathological complete response or yp stage I Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil )
62700247|NCT03322566|EXPERIMENTAL|Pembrolizumab + Epacadostat|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, BID in each 21 day cycle for up to 35 cycles.
61952892|NCT01238510|ACTIVE_COMPARATOR|Provisional fKBT|Stent technique that final kissing balloon technique(fKBT) is performed if side branch flow was aggravated to TIMI0-2 after stent deployment
61952893|NCT01238510|ACTIVE_COMPARATOR|Routine fKBT|Stent technique that fKBT was mandatory irrespective of side branch flow after stenting.
61952894|NCT02644642|EXPERIMENTAL|DLT(Double Lumen Tube) group|disconnection technique will be applied
61952895|NCT02644642|EXPERIMENTAL|BB(Bronchial Blocker) group|disconnection technique will be applied
61952896|NCT05076292|EXPERIMENTAL|150 ug glucagon before exercise|150 ug glucagon will be administered subcutaneously just before exercise and placebo will be administered after exercise.
61952897|NCT05076292|EXPERIMENTAL|2*75 ug glucagon before exercise and after exercise|75 ug glucagon will be administered subcutaneously just before exercise and another 75 ug of glucagon will be administered immediately after exercise.
61952898|NCT05076292|ACTIVE_COMPARATOR|Saline as placebo|Saline as placebo will be administered in the same amount as glucagon before and after exercise.
61952899|NCT06303908|EXPERIMENTAL|The Simple Gymnastics Training group|The observation group is the only group.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Simple Gymnastics Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 30 minutes. Each training session will be conducted approximately at 9.00 a.m. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
61952900|NCT01348165|EXPERIMENTAL|BI 137882 Dose 1|Powder for oral solution
61952901|NCT01348165|EXPERIMENTAL|BI 137882 Dose 2|Powder for oral solution
61952902|NCT01348165|EXPERIMENTAL|BI 137882 Dose 3|Powder for oral solution
61952903|NCT01348165|EXPERIMENTAL|BI 137882 Dose 4|Powder for oral solution
61952904|NCT01348165|EXPERIMENTAL|BI 137882 Dose 5|Powder for oral solution
61952905|NCT01348165|EXPERIMENTAL|BI 137882 Dose 6|Powder for oral solution
61952906|NCT01348165|EXPERIMENTAL|BI 137882 Dose 7|Powder for oral solution
62700248|NCT03439488|EXPERIMENTAL|Part 1 (Healthy Participants): Single Ascending Dose (SAD)|Participants in Cohorts 1 to 5 and 3 optional cohorts (Cohorts 6, 7 and 10) will receive a single dose of JNJ-440/placebo on Day 1. Two cohorts will receive a second dose of JNJ-440/placebo in a fed state (participants from Cohort 3 will also participate in Cohort 8) or as an alternative JNJ-440 formulation (participants from Cohort 2 will also participate in optional Cohort 9) after a washout window of at least 10 days. In Cohorts 1 to 4, study drug will be administered under fasted conditions; in the remaining cohorts, study drug will be administered under fasted/fed conditions depending on the results of the food effect evaluation.
61952907|NCT01348165|EXPERIMENTAL|BI 137882 Dose 8|Powder for oral solution
61952908|NCT01348165|EXPERIMENTAL|BI 137882 Dose 9|Powder for oral solution
61952909|NCT01348165|PLACEBO_COMPARATOR|Placebo|Powder for oral solution
61952910|NCT04926428|EXPERIMENTAL|experimental arm|In situ thrombolysis with tPA
61952911|NCT01109797|EXPERIMENTAL|Transition Social Behavioral Intervention|
61952912|NCT01109797|EXPERIMENTAL|Diabetes Transition Clinic|
61952913|NCT01837108|PLACEBO_COMPARATOR|Placebo|fully mimicking placebo 50 mg bid during 8 days
61952914|NCT01837108|EXPERIMENTAL|eplerenone|eplerenone 50 mg bid during 8 days
61952915|NCT04638257|EXPERIMENTAL|Lactobacilli|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14 Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
61952916|NCT04638257|PLACEBO_COMPARATOR|Placebo|Receives placebo
62700249|NCT03439488|EXPERIMENTAL|Part 2 (Healthy Participants): Multiple Ascending Dose (MAD)|Participants in Cohorts 1 and 2 will receive a once daily dose of JNJ-440/placebo for the duration of 7 days under fasted or fed conditions. Participants in an optional cohort (Cohort 3) may receive a once daily or twice daily dose of JNJ-440/placebo for the duration of 7 or 14 days under fasted or fed conditions. The starting dose for Cohort 1 in Part 2 will be determined by the Sponsor in consultation with the Principal Investigator based on the data from Part 1. Dose escalation will be performed only after review of safety and pharmacokinetic (PK) data after a minimum of 7 days of study drug administration.
61952917|NCT04042896|EXPERIMENTAL|exergame group|"The exergame group performed exercise using the Exer Heart device (D\&J Humancare, Seoul, South Korea), which consisted of a running/jumping board and a screen connected to the board. The exercise program Alchemist's Treasure, a running-based exergame, moves the avatar according to the user's motions and was used for the exercise session. Alchemist's Treasure is a game in which the user listens to stimulating music, runs with the avatar, avoiding obstacles, and wins items using the front, back, left, and right sensors on the exercise board. The subject can control the speed of the avatar movement by adjusting the walking or running speed on the board.~This study did not enforce exercise intensity in order to allow patients to enjoy the exergame. Thus, during the training period, the patients exercised at a self-selected pace for 40 minutes per day."
61952918|NCT04042896|ACTIVE_COMPARATOR|treadmill group|The treadmill group consisted of 40 minutes of walking or jogging at 60-80% of the heart rate (HR) reserve. The exercise intensity was determined using the Karvonen method target HR = \[Exercise Intensity × (HRmax - resting HR)\] + resting HR. The HR was recorded during each session using an HR monitor (Polar RS400sd; Madison Height, Michigan, USA). The control group was asked to maintain their regular physical activity level for 12 weeks.
61952919|NCT04042896|NO_INTERVENTION|control group|The control group was asked to maintain their regular physical activity level for 12 weeks.
61952920|NCT02793921|EXPERIMENTAL|Moderate-intensity aerobic exercise|Participants engage in a supervised 6-month moderate-intensity aerobic exercise intervention.
62141422|NCT06566339|NO_INTERVENTION|Standard of care exam|ED providers' standard of care exam
62141423|NCT03041961|PLACEBO_COMPARATOR|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
62141424|NCT03041961|ACTIVE_COMPARATOR|Aronia full spectrum|Formulation of an aronia full spectrum ingredient in a 1-hard capsule regimen (500 mg)
62141425|NCT03041961|ACTIVE_COMPARATOR|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
62141426|NCT02892019|ACTIVE_COMPARATOR|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
62343619|NCT03415763|EXPERIMENTAL|5-fluorouracil alone|5-fluorouracil alone for patients with yp stage II or III Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
62501198|NCT00935623|EXPERIMENTAL|Cohort 1|The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (\>10 sporozoites in salivary gland).
61952921|NCT02793921|NO_INTERVENTION|Usual Care|Physical activity neither limited nor withheld. Participants engage in activity in the same manner as if they were not part of an active intervention.
61952922|NCT02000479|EXPERIMENTAL|training|12 weeks (2 x 6 weeks) of combined exercise training programme (supervised)
61952923|NCT02000479|NO_INTERVENTION|Control|Continued usual care, habitual lifestyle
61952924|NCT01890369|EXPERIMENTAL|Early leucine refeed|15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
61952925|NCT01890369|EXPERIMENTAL|Early EAA refeed|15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
61952926|NCT01890369|EXPERIMENTAL|Mid latency EAA refeed|15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
61952927|NCT01890369|EXPERIMENTAL|Late latency EAA refeed|15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
62141427|NCT02892019|ACTIVE_COMPARATOR|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
62141428|NCT01588054||adults, cervical deformity, surgical treatment|Adults 18years or older at time of enrollment, cervical deformity to include kyphosis (C2-7 greater than 10 degrees) or scoliosis (coronal cobb greater than 10 degrees), plans for surgical treatment of cervical deformity
62141429|NCT01201837|PLACEBO_COMPARATOR|Placebo|
62141430|NCT01201837|EXPERIMENTAL|Low Dose|CER-001 Low Dose
62501199|NCT00935623|EXPERIMENTAL|Cohort 2|If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.
61952928|NCT05021601|EXPERIMENTAL|Bi-atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with bi-atrial ablation procedure.
61952929|NCT05021601|ACTIVE_COMPARATOR|Left atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with left atrial ablation procedure.
61952930|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
61952931|NCT01188421|ACTIVE_COMPARATOR|buprenorphine|Sublingual buprenorphine/naloxone tablets (or placebo)
61952932|NCT01188421|ACTIVE_COMPARATOR|clonidine|Oral clonidine tablets (or placebo)
61952933|NCT01188421|EXPERIMENTAL|tramadol ER|Oral tramadol tablets (or placebo)
61952934|NCT01131611|EXPERIMENTAL|CBPT intervention|Standard PT treatment + CBPT
62700250|NCT03439488|EXPERIMENTAL|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD|Participants in Cohorts 1 and 2 and 3 optional cohorts (Cohorts 3, 4, and 5) will receive multiple ascending doses of JNJ-440/placebo once daily or twice daily for 28 days under fed or fasted conditions. The starting dose and formulation for Cohort 1 will be determined based on the review of available data in healthy participants from Part 1 (SAD) and Part 2 (MAD). Dose escalation will be performed only after review of safety, tolerability, and PK data after a minimum of 14 days of study drug administration from at least 8 CHB participants.
62501200|NCT04117945|EXPERIMENTAL|Arm A (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
62700251|NCT04450953|ACTIVE_COMPARATOR|Eplerenone group A (cross over design)|Patient will receive eplerenone 50mg/day taken orally for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period without eplerenone, until the end of the study.
62700252|NCT04450953|ACTIVE_COMPARATOR|Eplerenone group B (cross over design)|Eplerenone-free for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period in which patients will receive eplerenone 50 mg/day as a single dose taken orally.
62700253|NCT03277599|ACTIVE_COMPARATOR|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
62700254|NCT03277599|ACTIVE_COMPARATOR|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
62700255|NCT04890509|EXPERIMENTAL|Standard of Care + Bemcentinib|Bemcentinib will be administered for up to 15 days, or until discharge from hospital, whichever comes sooner. SoC will be administered based on local guidelines.
62700256|NCT04890509|ACTIVE_COMPARATOR|Standard of Care|The SoC will be administered based on local guidelines in place at the time of treatment during the study.
61952935|NCT01131611|PLACEBO_COMPARATOR|Control-Attention|Standard PT treatment + weekly phone calls
62700257|NCT04997850|EXPERIMENTAL|TACE + lenvastinib + sindilimab/carrelizumab|The patients with body weight ≥ 60kg were treated with oral lenvastinib within 3 days (the initial dose was 12mg QD for patients with body weight \< 60kg, the initial dose was 8mg QD for patients with body weight \< 60kg). After 1-2 weeks of treatment, the patients received the first TACE treatment (3 days before TACE), and continued to take oral lunvastinib 3 days after TACE. Within one week after TACE treatment, 200 mg of sindilimab was given intravenously once every three weeks (every 21 days as a cycle) or 200 mg of carrelizumab was given intravenously once every three weeks (every 21 days as a cycle).
62700258|NCT04997850|ACTIVE_COMPARATOR|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
61952936|NCT03928353|EXPERIMENTAL|1: 18 g PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
61952937|NCT03928353|EXPERIMENTAL|2: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
61952938|NCT03928353|EXPERIMENTAL|3: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
61952939|NCT03928353|EXPERIMENTAL|4: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
61952940|NCT03928353|EXPERIMENTAL|5: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
61952941|NCT00751933|EXPERIMENTAL|2|Vaccination with Vivotif and Dukoral
61952942|NCT00751933|EXPERIMENTAL|3|Dietary supplement with oats
61952943|NCT00751933|PLACEBO_COMPARATOR|4|Placebo instead of vaccines No dietary supplement
61952944|NCT00751933|EXPERIMENTAL|1|Vaccination with Vivotif and Dukoral + dietary supplement with oats.
61952945|NCT00891592|EXPERIMENTAL|Dose Escalation Arm|Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.
61952946|NCT00891592|ACTIVE_COMPARATOR|Observation Arm|Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.
61952947|NCT04601415||GP Referrals|Patients with HF referred by GP to echo department
61952948|NCT04601415||Echo patients|Non-selected patients attending echo department in hospital
61952949|NCT00074204|EXPERIMENTAL|Immediate Docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
61952950|NCT00074204|ACTIVE_COMPARATOR|Delayed Docetaxel|Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
61952951|NCT02021578|EXPERIMENTAL|Family Cognitive Behavioral Prevention|A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.
61952952|NCT02021578|ACTIVE_COMPARATOR|Written Information|Families receive written materials about depression and the effects of parental depression on children.
62141431|NCT01201837|EXPERIMENTAL|Mid Dose|CER-001 Mid Dose
62141432|NCT01201837|EXPERIMENTAL|High Dose|CER-001 High Dose
62501201|NCT04117945|EXPERIMENTAL|Arm B (cetuximab, panitumumab, irinotecan)|Patients receive cetuximab or panitumumab IV over 30-90 minutes on days 1 and 15. Patients may also receive irinotecan IV on days 1 and 15 as determined by the study doctor. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
62501202|NCT03786354|EXPERIMENTAL|Arm A (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy over 5 weeks.
62700259|NCT02615288|ACTIVE_COMPARATOR|High Dose Vitamin D3 (10,000 IU daily)|
62700260|NCT02615288|PLACEBO_COMPARATOR|Low Dose Vitamin D3 (1000 IU daily)|
62700261|NCT02978495|EXPERIMENTAL|A- BRCA Mutation|"1. Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~2. Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
61952953|NCT06484738||patients with histologically confirmed CD|patients with histologically confirmed CD undergoing intestinal resection
62501203|NCT03786354|EXPERIMENTAL|Arm B (3DCRT)|Patients undergo 3-Dimensional Conformal Radiation Therapy over 5 weeks.
62501204|NCT05281172|EXPERIMENTAL|Guided Self-Change therapy|
62501205|NCT05281172|ACTIVE_COMPARATOR|Psychoeducation program about healthy habits|
62501206|NCT04961567|EXPERIMENTAL|Litifilimab High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of litifilimab, subcutaneously (SC), every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
62700262|NCT02978495|ACTIVE_COMPARATOR|B- BRCA Mutation|"1. Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~2. Paclitaxel 80 mg/m2 once a week, for 12 weeks."
62700263|NCT02978495|EXPERIMENTAL|C- BRCA wild-type|"1. Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~2. Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
62700264|NCT02978495|ACTIVE_COMPARATOR|D- BRCA wild-type|"1. Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~2. Paclitaxel 80 mg/m2 once a week, for 12 weeks."
62700265|NCT03765931|ACTIVE_COMPARATOR|subjects treated with doxycycline|The participants treated by doxycycline 100 mg will have one dose but followed 5 days
62700266|NCT03765931|PLACEBO_COMPARATOR|subjects treated with amoxycilline|The participants treated with amoxycilline 500 mg will have 2 doses per days during 5 days treatement and follwed during these 5 days
62700267|NCT03014089|EXPERIMENTAL|mRNA-1325|
62700268|NCT03014089|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride
61952954|NCT06484738||patients with histologically confirmed UC|patients with histologically confirmed UC undergoing intestinal resection
61952955|NCT04420442|ACTIVE_COMPARATOR|Intervention Group|In addition to the comparison between arm 1 and 2, there will be an intraindividual comparison within arm 1.
61952956|NCT04420442|NO_INTERVENTION|Control Group|No Intervention.
62141433|NCT01413659|EXPERIMENTAL|Symbiotic|Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host
62141434|NCT05624138|PLACEBO_COMPARATOR|placebo|"Group I Placebo group n=32 Patients will receive 12 cycles of modified FOLFOX-6 regiment plus placebo tablets 2mg daily throughout the twelve chemotherapy cycles. The chemotherapy cycles will be received every 2 weeks and will be as follows:~Day 1 and Day 15: Oxaliplatin 85 mg/m2 intravenous infusion in 250-500 mL 5% dextrose solution and leucovorin 400 mg/m2 intravenous infusion in 5% dextrose solution both were given over 120 minutes at the same time in separate bags using a Y-line access, followed by 5-fluorouracil 400 mg/m2 intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenous infusion in 500 mL 5% dextrose solution as a 46-hour infusion."
62141435|NCT05624138|ACTIVE_COMPARATOR|ketotifen oral tablets|"Group II ketotifen group n=32 Patients will receive 12 cycles of modified FOLFOX-6 regiment plus ketotifen tablets 2mg daily throughout the twelve chemotherapy cycles. The chemotherapy cycles will be received every 2 weeks and will be as follows:~Day 1 and Day 15 : Oxaliplatin 85 mg/m2 intravenous infusion in 250-500 mL 5% dextrose solution and leucovorin 400 mg/m2 intravenous infusion in 5% dextrose solution both were given over 120 minutes at the same time in separate bags using a Y-line access, followed by 5-fluorouracil 400 mg/m2 intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenous infusion in 500 mL 5% dextrose solution as a 46-hour infusion"
62501207|NCT04961567|EXPERIMENTAL|Litifilimab Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of litifilimab, SC Q4W, up to Week 48 with an additional dose at Week 2.
62501208|NCT04961567|PLACEBO_COMPARATOR|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive litifilimab-matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
62501209|NCT02272309|EXPERIMENTAL|Healthy volunteers|Healthy volunteers
62501210|NCT02272309|EXPERIMENTAL|Patients with LUTS|Patients with LUTS
62501211|NCT02272309|EXPERIMENTAL|Patients with LUTS and treatment|Patients with LUTS and treatment
61952957|NCT03208712|EXPERIMENTAL|Radium-223 and Atezolizumab|"Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses~Atezolizumab 1200 mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity, or 17 doses"
61952958|NCT03087643|EXPERIMENTAL|Passive mobilization - PM|Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
61952959|NCT03087643|NO_INTERVENTION|Control group - ctrl|Participants will receive ther standard therapies.
61952960|NCT02500160|EXPERIMENTAL|patient specific instrumentation (MRI)|MRI based patient-specific instrumentation
62501212|NCT03514355|EXPERIMENTAL|Intervention|Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.
61952961|NCT02500160|ACTIVE_COMPARATOR|patient specific instrumentation (CT)|CT based patient-specific instrumentation
61952962|NCT03277664|EXPERIMENTAL|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
61952963|NCT03277664|NO_INTERVENTION|control group|"All the device-monitored adherence data were downloaded from the background database and calculated weekly. However, feedback and reminders were not given to the caregivers. Caregivers were also asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
62700269|NCT01691911|EXPERIMENTAL|Remote preconditioning|Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
62700270|NCT01691911|NO_INTERVENTION|Remote preconditioning control|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
62700271|NCT02259803|EXPERIMENTAL|Telmisartan/amlodipine fixed-dose combination|
62700272|NCT02259803|ACTIVE_COMPARATOR|Telmisartan and amlodipine mono-components|
62700273|NCT04778566||Cologuard Study Group|Within 60 days of their already scheduled screening colonoscopy, participants will provide a stool sample to be tested by a Cologuard screening test kit. Participants will also complete surveys prior to their colonoscopy as well as post colonoscopy.
62700274|NCT06563882|EXPERIMENTAL|Home-based exercise program|Intervention Group: Hyperkyphotic participants will participate in a home exercise program designed to improve thoracic spine and shoulder mobility and flexibility, while also strengthening spine extensor muscles, alongside a cardiac rehabilitation exercise program. The home-based program will include six exercises to be performed three times a week over a period of 12 weeks.
62700275|NCT06563882|OTHER|Cardiac rehabilitation exercise program - Hyperkyphosis|Control Group: Hyperkyphotic participants will participate in a 12-week cardiac rehabilitation exercise program, consisting of two one-hour sessions per week at the cardiac rehabilitation center. These sessions will include aerobic activity along with a variety of resistance, flexibility, and balance exercises.
62700276|NCT06563882|OTHER|cardiac rehabilitation exercise program - without hyperkyphosis|Control Group: Participants without hyperkyphosis will participate in a 12-week cardiac rehabilitation exercise program, consisting of two one-hour sessions per week at the cardiac rehabilitation center. These sessions will include aerobic activity along with a variety of resistance, flexibility, and balance exercises.
62501213|NCT03514355|NO_INTERVENTION|Control|The control group will receive usual care, with no treatment restrictions. Treating physicians will be informed of CES-D results. Patients will be asked to fulfill the same clinical assessment and questionnaires, and to provide the same biosamples than those patients in the intervention.
62501214|NCT05715307|EXPERIMENTAL|Intensive training group|Endocrinologists will receive a 1-week intensive training in T2DM health care at Ruijin Hospital. This training includes a 1-week hospitalization experience, health examinations, results interpretation, and integrated courses for T2DM management.
62700277|NCT04943679||Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b|Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years; Anti-PD-1/PD-L1 Antibodies: given by intravenous injection at indicated dose for up to 2 years
62700278|NCT02247128|ACTIVE_COMPARATOR|Aspirin + Clopicogrel (Cohort A)|Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
61952964|NCT01402011|EXPERIMENTAL|25% dextrose in shoulder entheses|25% dextrose and .1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
61952965|NCT01402011|ACTIVE_COMPARATOR|.1% lidocaine in shoulder entheses|.1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
61952966|NCT01402011|PLACEBO_COMPARATOR|.1% lidocaine subcu. above shouldr enth.|.1% lidocaine injected subcutaneously above the shoulder entheses (ligament and tendon insertions on the periosteum).
61952967|NCT01652209|NO_INTERVENTION|Control|"After implementing PCI, contemporary drug treatment is conducted.~\*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, β-blocker, CCB, Diuretics, Statin, etc.)"
61952968|NCT01652209|EXPERIMENTAL|Single dose of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10\^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted.
62141436|NCT02191670||METALYSE®|
62141437|NCT03712150||Healthy|"Healthy adults~- Participants will receive single session of tdcs after application"
62700279|NCT02247128|ACTIVE_COMPARATOR|Aspirin monotherapy (Cohort A)|Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
61952969|NCT03892096||Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer|A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled. It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
62700280|NCT02247128|ACTIVE_COMPARATOR|OAC + Clopicogrel (Cohort B)|Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
62700281|NCT02247128|ACTIVE_COMPARATOR|OAC monotherapy (Cohort B)|Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
61952970|NCT03619317||Cancer esophagus and gastroesophageal junction|EGEJ cancer patients referred to combined therapy of chemoRT and surgery can be included.
61952971|NCT00702195||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)
62700282|NCT00478257|ACTIVE_COMPARATOR|1 Active Bright White Light Treatment|Intervention: Bright white light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
62700283|NCT00478257|ACTIVE_COMPARATOR|2 Comparator Red Light Treatment|Intervention: Dim red light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
61952972|NCT00702195||Experimental Group 2|Placebo
61952973|NCT00702195||Experimental Group 3|all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)
62700284|NCT06240676|EXPERIMENTAL|experimental group|After the 3rd month postpartum, mothers who are given classical breastfeeding training by the researcher will then be given a breastfeeding training based on mindfulness therapy methods. After the classical breastfeeding training, a pre-test will be applied and then mindfulness-based training will be started. The effectiveness of the training will also be determined within the group with the post-test to be applied after the training. A sleep diary will be applied to the newborn. After breastfeeding, how many hours of sleep and body temperature will be noted.
61952974|NCT00702195||Experimental Group 4|150 IU Puregon®
61952975|NCT05165836|PLACEBO_COMPARATOR|Erector Spinae Plane block without Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL saline
61952976|NCT05165836|EXPERIMENTAL|Erector Spinae Plane block with Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg
62501215|NCT05715307|ACTIVE_COMPARATOR|Control group|Endocrinologists will receive regular training from MMC under the guidance of T2DM management.
62700285|NCT06240676|NO_INTERVENTION|control group|From mothers whose information was collected during pregnancy, only breast milk will be taken for 1 week without any intervention in the 3rd month after birth.
62700286|NCT03781063|EXPERIMENTAL|Lasofoxifene|5 mg/d of oral lasofoxifene
62700287|NCT03781063|ACTIVE_COMPARATOR|Fulvestrant|500 mg fulvestrant intramuscular (IM)
62700288|NCT04430998|EXPERIMENTAL|Zinc L-Carnosine mouth rinse|Using undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 60 seconds, 3 times daily
62700289|NCT04430998|ACTIVE_COMPARATOR|Chlorhexidine|Using undiluted 10 ml of Chlorhexidine mouth rinse, retain for 60 seconds, 3 times daily
61952977|NCT01218243|EXPERIMENTAL|acupoint|Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
61952978|NCT01218243|SHAM_COMPARATOR|non-acupoint|Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
61952979|NCT01597401|EXPERIMENTAL|Aes-103 300 mg to 1000 mg (Group A)|Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
61952980|NCT01597401|EXPERIMENTAL|Aes-103 2000 mg to 4000 mg (Group B)|Group B will consist of six subjects receiving an initial dose of either Aes 103 (2,000 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (4,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
62141438|NCT05018156|EXPERIMENTAL|Default Genetics Referral Process|
62141439|NCT03347396|EXPERIMENTAL|BIVV009|Participants with primary CAD who had a recent history of transfusion (defined as at least 1 transfusion during the last 6 months prior to screening) received an intravenous (IV) infusion of BIVV009 6.5 grams (g) (if body weight was less than \[\<\] 75 kilograms \[kg\]) or BIVV009 7.5 g (if body weight was greater than or equal to \[\>=\] 75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) could continue to receive BIVV009 in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks. All participants who completed Part A elected to continue in Part B.
62700290|NCT04430998|PLACEBO_COMPARATOR|Water|Mouth rinsing with 10 ml of water, retain for 60 seconds, 3 times daily
62700291|NCT01542892|EXPERIMENTAL|Supplement|
61952981|NCT01597401|EXPERIMENTAL|Top Dose Expansion (Group C)|Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
61952982|NCT03756077||Primary diagnosis and staging|Patients suspected of or diagnosed with prostate cancer who want a differential diagnosis and staging by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT before treatment
61952983|NCT03756077||Evaluation of recurrence|Patients with a history of prostate cancer and elevated PSA level after treatment, who need to determining whether or not there are recurrences/metastatic lesions and its locations by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
61952984|NCT05412615|EXPERIMENTAL|Meniscal Allograft with PRC|These patients will receive a tissue allograft with their wrist reconstruction procedure.
61952985|NCT05412615|PLACEBO_COMPARATOR|PRC only|These patients will receive the standard proximal row carpectomy procedure.
61952986|NCT05399641|EXPERIMENTAL|Group A|"Subjects without underlying medical conditions and have isolates other than C glabrata, C krusei, C auris.~Single day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day."
61952987|NCT05399641|EXPERIMENTAL|Group B (3 Day dosing)|"Subjects with underlying medical conditions: DM, immunocompromised conditions (e.g. HIV), debilitation, immunosuppressive therapy (e.g. corticosteroids), recurrent VVC (≥3 episodes/year) and/or known to have C glabrata, C krusei or C auris isolates.~Three day dosing, 300 mg Ibrexafungerp BID for a total of 600mg a day."
61952988|NCT05399641|EXPERIMENTAL|Group B (7 Day dosing)|"Subjects with underlying medical conditions: DM, immunocompromised conditions (e.g. HIV), debilitation, immunosuppressive therapy (e.g. corticosteroids), recurrent VVC (≥3 episodes/year) and/or known to have C glabrata, C krusei or C auris isolates.~Seven day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day"
61952989|NCT05134675||Consumption|Patients consuming homemade beer
62501216|NCT06043375|EXPERIMENTAL|Licorice Root Powder Capsule|PCOS diagnosed patients in this group will receive licorice root powder capsules, once per day for 12 weeks.
62700292|NCT01542892|SHAM_COMPARATOR|Placebo|
62700293|NCT01542892|EXPERIMENTAL|Exercise|
62700294|NCT04194827|EXPERIMENTAL|Concentration guided dose reducion|Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.
62700295|NCT04194827|ACTIVE_COMPARATOR|Disease activity quided dose reduction|Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab
62700296|NCT04408612||Dyspnea in stable coronary artery disease|Stable patients with dyspnea and coronary artery disease
62700297|NCT04236076|EXPERIMENTAL|PulseHaler™|Patients will receive PulseHaler for home treatment
62700298|NCT04236076|SHAM_COMPARATOR|Sham PulseHaler - CONTROL group|Patients will receive Sham device for home treatment
62700299|NCT06588582|EXPERIMENTAL|Cold Water|
62700300|NCT06588582|PLACEBO_COMPARATOR|Warm Water|
62141440|NCT03477214||Normal|No UI, no OAB conditions. Transvaginal biomechanical and electromyography mapping will be completed.
62700301|NCT01910454|EXPERIMENTAL|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|
62700302|NCT01910454|ACTIVE_COMPARATOR|Task Specific Training (TST)|
62700303|NCT00834574|EXPERIMENTAL|1|
62501217|NCT06043375|NO_INTERVENTION|Control Group|PCOS diagnosed patients in this group will not receive licorice root powder capsules or any treatment for 12 weeks.
62501218|NCT02064140|EXPERIMENTAL|Neuromuscular blocking agent|
62501219|NCT02069262|EXPERIMENTAL|angiography combination laparoscopy|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence. Those who developed rebleeding during the observation would be crossed over to the other investigation modality. Patients with negative findings on the initial assigned investigation but who developed rebleeding would undergo further investigation to localize the site of bleeding.
62700304|NCT00834574|ACTIVE_COMPARATOR|2|
62700305|NCT03049644|ACTIVE_COMPARATOR|Mechanical Diagnosis and Therapy|Mechanical diagnosis refers to the classification based on examination of posture and range of motion of the spine, associated with the assessment of subjective symptomatic responses.
62700306|NCT03049644|ACTIVE_COMPARATOR|Manual Therapy|Manual therapy (MT) is a broad term encompassing many techniques which attempt to affect possible pain contributors such as joints, tendons, ligaments, and muscles, typically using the therapist's hands but may also utilize a tool or instrument in the case of some soft tissue mobilization therapies as well as low force instrument assisted spinal manipulation therapy.
62700307|NCT01930500|EXPERIMENTAL|Individual neuropsychological rehabilitation|12 times 90 minutes, once per week or once per two weeks, during 5 months
62700308|NCT01930500|EXPERIMENTAL|Group based neuropsychological rehabilitation|12 times 120 minutes + a brake, once per week or once per two weeks, during 5 months
62700309|NCT01930500|NO_INTERVENTION|Control group|Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
62700310|NCT04507204|EXPERIMENTAL|Adhansia XR|Adhansia XR capsules taken orally once daily with or without food.
62700311|NCT04507204|ACTIVE_COMPARATOR|Concerta|Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.
62700312|NCT04765397|ACTIVE_COMPARATOR|Group M|Patients are in this group with monopolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
62700313|NCT04765397|ACTIVE_COMPARATOR|Group B|Patients are in this group with bipolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
62700314|NCT05095922|EXPERIMENTAL|Heart-Protecting Musk Pill group|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)+Valsartan Capsules(capsule, 80mg, once a day, 3 months）+Calcium Dobesilate Capsules (capsule, 500mg, three times a day, 3 months)
61952990|NCT05134675||Not consumption|Patients are not consuming homemade beer
61952991|NCT04665700|EXPERIMENTAL|BI 764198 Single dose part|
61952992|NCT04665700|EXPERIMENTAL|BI 764198 Multiple dose low|
61952993|NCT04665700|PLACEBO_COMPARATOR|Placebo|
61952994|NCT04665700|EXPERIMENTAL|BI 764198 Multiple dose medium|
61952995|NCT04665700|EXPERIMENTAL|BI 764198 Multiple dose high|
61952996|NCT05200832||COVID+|Participants who have experienced COVID-19
61952997|NCT05200832||COVID-|Participants who have not experienced COVID-19
61952998|NCT03724032|ACTIVE_COMPARATOR|TMD Patients Active Group: Active Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS\*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
61952999|NCT03724032|SHAM_COMPARATOR|TMD Patients Sham Group: Sham Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS\*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
62343620|NCT03415763|EXPERIMENTAL|mFOLFOX6 or CAPOX|Oxaliplatin combined with 5-fluorouracil for patients with yp stage II or III mFOLFOX6 (leucovorin 400 mg/m2 as a 2-hour infusion, and the concurrent administration of oxaliplatin 85 mg/m2 as a 2-hour infusion, followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks), three cycles or CAPOX (oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1, followed by capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks), three cycles( According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
62343621|NCT04785079|EXPERIMENTAL|Graston effect medial arch, plantar fascia, and trapezius|Pre and post Graston change in blood flow at the medial arch foot, plantar fascia, and the trapezius region
62343622|NCT02603185|EXPERIMENTAL|Hemay007|"Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.~Part 3: Multiple doses group Hemay007 tablets will be taken orally once daily in low, medium, high doses"
62343623|NCT02603185|PLACEBO_COMPARATOR|Placebo|"Part 1: Single ascending dose Group Placebo tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 3: Multiple doses group Placebo tablets will be taken orally once daily in low, medium, high doses"
62343624|NCT00643591||Observational|Patients with a primary glioblastoma
62343625|NCT02918409|ACTIVE_COMPARATOR|Standard colistin arm|Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule.
61953000|NCT03724032|NO_INTERVENTION|Healthy Control Group|"20 Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n \</= 10) may be used from a prior study (NIDCR-R56-DE022637 project \[IRBMED #HUM00080911; Dr. Alexandre DaSilva, Principal Investigator\]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
61953001|NCT00787384|EXPERIMENTAL|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
61953002|NCT05900271|EXPERIMENTAL|intermittent theta burst transcranial magnetic stimulation (iTBS)|5-day multi daily neuronavigated intermittent theta burst sessions (developed by Stanford University) and coined, SNT, i.e., Stanford NeuromdulaTion protocol
61953003|NCT05900271|ACTIVE_COMPARATOR|10 Hz repetitive-transcranial-magnetic-stimulation (rTMS)|6-weeks standard 10 Hz rTMS
61953004|NCT01151007||Patients with colorectal carcinoma|Patient with colorectal carcinoma operated in Martinique between January 1st, 2007 and December 31st, 2009
61953005|NCT03493399|EXPERIMENTAL|Problem Gamblers|Interference
61953006|NCT01133522|EXPERIMENTAL|Evolocumab|Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
61953007|NCT01133522|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
61953008|NCT00705484||Remicade Group|Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
61953009|NCT00705484||Standard Therapy Group|Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
61953010|NCT02188108|EXPERIMENTAL|Survey|Wisconsin Stone-QOL survey. Patients with kidney stones or a history thereof will complete a kidney stone-specific health-related survey at enrollment and post-enrollment at 3 months, 12 months, 24 months, and 36 months.
61953011|NCT02292875||TG002 Subjects|Subjects previously randomised in study TG002
62343626|NCT02918409|ACTIVE_COMPARATOR|Modified colistin arm|Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion).
61953012|NCT04532970|PLACEBO_COMPARATOR|Standard|"Eligible patients will be randomized to one of the treatment arms, which will involve 5 phone-delivered counseling sessions over a 9 week treatment phase. SC will be based on the 2008 PHS Clinical Practice Guideline (Fiore et al., 2008) and on SC in our ongoing two-site trials (R01DA025078; R01CA165001) This intervention arm will begin with a pre-quit session designed to help participants prepare for their Target Quit Day (TDQ). The TQD session will occur at week 1. The SC arm will focus on self-monitoring, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, relapse prevention, and homework. The pre-quit session prepares participants for their TQD by reviewing their experience with quitting, beliefs about smoking/quitting, perceived barriers to cessation, and creating a quit plan to identify smoking triggers and implement alternative strategies to manage those triggers without smoking."
61953013|NCT04532970|EXPERIMENTAL|BAPS|Key components of BAPS include activity monitoring and rewarding activity scheduling, assessment of personal goals and values, assessment and altering of avoidance behavior and other maladaptive coping strategies, and contingency management. BAPS focuses on reducing stress pile-up and loss of pleasure that accompanies the cessation process and on identifying and establishing environmental/social changes to promote abstinence. BAPS addresses smoking as a behavior that prevents and restricts opportunities for contact with healthy rewarding behaviors. These changes are achieved through altering daily routines previously associated with smoking in ways that increase pleasure and mastery across life domains, reducing rumination, and increasing behavioral skills to prevent return to smoking as a means of avoiding stressors.
61953014|NCT01646762|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
61953015|NCT00687960|EXPERIMENTAL|1|Resistant Starch Type 4-Raw
61953016|NCT00687960|EXPERIMENTAL|2|Resistant Starch Type 4-cooked
61953017|NCT00687960|ACTIVE_COMPARATOR|3|Puffed wheat
61953018|NCT00687960|PLACEBO_COMPARATOR|4|Dextrose
61953019|NCT06199817|EXPERIMENTAL|Intervention Group|The intervention group was informed about the research. The intervention group consists of patients diagnosed with schizophrenic disorder. Music, sports and garden-soil activities were applied to the intervention group.
61953020|NCT06199817|NO_INTERVENTION|Control Group|The control group was informed about the research.
61953021|NCT00129428|EXPERIMENTAL|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
61953022|NCT01607242||patients|patients undergoing total thyroidectomy
61953023|NCT00651352|EXPERIMENTAL|2 mg nicotine prototype|2 mg nicotine prototype
61953024|NCT00651352|ACTIVE_COMPARATOR|2 mg nicotine lozenge|marketed formulation
62141441|NCT03477214||Urinary incontinence|Urinary incontinence conditions. Transvaginal biomechanical and electromyography mapping will be completed.
62141442|NCT03477214||Overactive bladder|Overactive bladder conditions
62141443|NCT00887224|EXPERIMENTAL|Desvenlafaxine succinate sustained release 50 mg|
62141444|NCT00887224|PLACEBO_COMPARATOR|Placebo|
62141445|NCT05153681||Peloid Therapy|Peloidotherapy is a special balneotherapy method made with natural mud. In both domestic and international scientific studies on peloid treatment, it has been shown that pain in patients decreases, physical functions improve, quality of life increases, and the amount of painkillers use decreases.
62343627|NCT02918409|ACTIVE_COMPARATOR|Standard tobramycin arm|Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes
62343628|NCT06051981|EXPERIMENTAL|Fluoride Varnish (control)|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. In group I, FV EnamelastTM will be applied to all teeth using compressed air and cotton rolls, leaving them to dry for one minute. Patients will be advised to avoid eating, drinking, or brushing for 3-4 hours after application.
62343629|NCT06051981|EXPERIMENTAL|Intensive Fluoride Varnish|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Patients in group II Intensive FV will be applied three times a week for a week (every two days).
61953025|NCT00651352|EXPERIMENTAL|4 mg nicotine prototype|4 mg
61953026|NCT00651352|ACTIVE_COMPARATOR|4 mg nicotine lozenge|4 mg
61953027|NCT06506656|EXPERIMENTAL|Patients with coxarthrosis|Three intra-articular infiltrations (1/week) with 2 ml Hyaluronic Acid and Adelmidrol
61953028|NCT06506656|EXPERIMENTAL|Patients with rhizoarthrosis|Three intra-articular infiltrations (1/week) with 1 ml Hyaluronic Acid and Adelmidrol
62141446|NCT05153681||Kinesio Tape|Kinesio tapes, which have been used in the conservative treatment of plantar fasciitis in recent years, are elastic tapes similar to the structural properties and flexibility of human skin, without limiting joint movements.
62141447|NCT05153681||Home exercise|In addition to the cold application, gastrocnemius and plantar fascia stretching and strengthening exercises were applied to patients with plantar fasciitis.
62141448|NCT02507869|EXPERIMENTAL|Affect-Guided Prescription|Intervention: Participants in the affect-guided condition are instructed to exercise while monitoring how they feel, and to adjust the intensity of their exercise to maintain a pleasant affective response.
62141449|NCT02507869|ACTIVE_COMPARATOR|Heart Rate-Guided Prescription|Intervention: Participants in the heart rate-guided condition are instructed to exercise while monitoring their heart rate, and to adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
62164563|NCT00977340|PLACEBO_COMPARATOR|Imagination|Imagination of a safe and pleasant site; 1 session on-site and 4 weeks of individual daily training
62700315|NCT05095922|PLACEBO_COMPARATOR|Control group|Valsartan Capsules(capsule, 80mg, once a day, 3 months), Calcium Dobesilate Capsules (capsule, 500mg, three times a day, 3 months)
62700316|NCT00754572|EXPERIMENTAL|1|
62141450|NCT05343494|EXPERIMENTAL|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
62501220|NCT02069262|PLACEBO_COMPARATOR|angiography alone|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence.
62700317|NCT06539481|EXPERIMENTAL|ILUVIEN® 190μg|
62700318|NCT01188967|EXPERIMENTAL|GSK598809|Active medication
62700319|NCT01188967|PLACEBO_COMPARATOR|Placebo|Placebo
62700320|NCT02209987|EXPERIMENTAL|GS-5745 SC|Participants will receive a single dose of GS-5745 by SC injection.
62700321|NCT02209987|EXPERIMENTAL|GS-5745 IV|Participants will receive a single dose of GS-5745 by IV infusion.
62700322|NCT04214509||PD + LRRK2|Patients with LRRK2-associated Parkinson's syndrome
62700323|NCT04214509||no PD + LRRK2|Participants with LRRK2-mutations but without Parkinson's symptoms
62700324|NCT04214509||no PD + no LRRK2|Participants without mutations and without Parkinson's symptoms
62700325|NCT04214509||PD+ other than LRRK2|Parkinson patients with mutations in other genes than LRRK2
62700326|NCT04214509||PD+ no LRRK2|Patients with idiopathic Parkinson's disease
62700327|NCT03539679|EXPERIMENTAL|Encouraging physical activity|Encouraging physical activity by using motion sensor and feedback.
62700328|NCT03539679|NO_INTERVENTION|CONTROL GROUP|No intervention.
62700329|NCT00645658|EXPERIMENTAL|Chronic kidney disease|Patients with chronic kidney disease between the ages of 55 and 75 years.
62700330|NCT00645658|NO_INTERVENTION|Control|Control participants with baseline data collection only (for baseline comparator).
62700331|NCT06562829|NO_INTERVENTION|Group A|Catheters were implanted according to PICC routine procedures:Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter
62700332|NCT06562829|EXPERIMENTAL|Group B|The virtual reality device used was PICO NE2, with accessories including helmet equipment , (with a field of view of about 98°, built-in Android 8.1 system, Qualcomm Snapdragon processor), and an infrared sensor (handle)and the VR headset was worn in the optimal state 5 minutes before catheterization.After preparing the vr device,Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter
62700333|NCT06562829|EXPERIMENTAL|Group C|The virtual reality device used was PICO NE2, with accessories including helmet equipment , (with a field of view of about 98°, built-in Android 8.1 system, Qualcomm Snapdragon processor), and an infrared sensor (handle)and the VR headset was worn in the optimal state 5 minutes before catheterization.After preparing the vr devicea and disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length
62700334|NCT04306926|EXPERIMENTAL|TQB2450+SBRT|SBRT three days before TQB2450.
62700335|NCT00651287|ACTIVE_COMPARATOR|quinapril 20 mg|
62141451|NCT05728996||Group 1|"standard: only routine diagnostic procedures are performed"
62141452|NCT05728996||Group 2A|"less invasive: in addition to routine monitoring, patients also undergo semen sampling"
62141453|NCT05728996||Group 2B|"less invasive: in addition to routine monitoring, patients undergo semen sampling and/or leukapheresis."
62343630|NCT06051981|EXPERIMENTAL|Casein Phosphopeptide-Amorphous Calcium Phosphate|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Group III (CPP-ACP) uses Tooth Mousse® for 12 weeks, will be applied after daily brushing with traditional toothpaste, left intact for 180 seconds, and rinsed with distilled water.
62501221|NCT04623528||Pericarditis patients with constrictive physiology|Patients with pericarditis and signs of constrictive physiology (increased ventricular coupling)
62700336|NCT00651287|ACTIVE_COMPARATOR|quinapril 20 mg+hydrochlorothiazide 12.5 mg|
62700337|NCT00651287|ACTIVE_COMPARATOR|quinapril 40 mg|
62700338|NCT02003313|EXPERIMENTAL|Group T|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
62700339|NCT02003313|ACTIVE_COMPARATOR|Group C|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
62700340|NCT06642649|ACTIVE_COMPARATOR|study intervention with morphine and no fentanyl|Every patient will receive, before induction of general anesthesia as in control group, a spinal anesthesia composed by hyperbaric bupivacaine 5 mg 0,5% and morphine sulfate 100 mcg.
62700341|NCT06642649|ACTIVE_COMPARATOR|study intervention with morphine and 20 mcg fentanyl|every patient will receive, before induction of general anesthesia as in the control group, a spinal anesthesia composed by hyperbaric bupivacaine 5 mg 0,5%, morphine sulfate 100 mcg and fentanyl 20 mcg.
62700342|NCT06642649|ACTIVE_COMPARATOR|study intervention NO spinal|Every patient will receive a general anesthesia induced with propofol (1.5-2.5 mg/kg, individually adjusted), rocuronium (0.6 mg/kg) for muscle relaxation and a continuous infusion of remifentanil (0.05-0.3 mcg/kg/min, depending on the clinical characteristics of the patient). General anesthesia was maintained with a continuous infusion of propofol (4-8 mg/kg/h), and the infusion of remifentanil which was started with the induction. Fractionated doses of rocuronium were administered based on TOF monitoring (train of four) to maintain muscle relaxation.
61953029|NCT03481075|EXPERIMENTAL|Rigid and Elastic registration softwares|
61953030|NCT02664259|EXPERIMENTAL|UTB-VBN-EBUS group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
61953031|NCT02664259|ACTIVE_COMPARATOR|UTB-VBN-EBUS-X-ray group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
61953032|NCT06557629|EXPERIMENTAL|Ultrasound group|Assessment of gastric residual volume via US
61953033|NCT06557629|NO_INTERVENTION|Aspiration group|assessment of gastric residual volume via aspiration of gastric content
61953034|NCT04372082|PLACEBO_COMPARATOR|standard of care (SOC)|
61953035|NCT04372082|EXPERIMENTAL|SOC + Hydroxychloroquine|
61953036|NCT04372082|EXPERIMENTAL|SOC + Diltiazem-Niclosamide|
61953037|NCT00084383|EXPERIMENTAL|GVAX pancreatic cancer vaccine|"5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination"
61953038|NCT02222740|EXPERIMENTAL|Group 1|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice per day (BID) for 7 days, followed by 20 mg BID for 7 days, followed by 30 mg BID for 7 days
61953039|NCT02222740|EXPERIMENTAL|Group 2|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice Per Day (BID) for 7 days, followed by 30 mg BID for 7 days, followed by 40 mg BID for 7 days
61953040|NCT04493073|ACTIVE_COMPARATOR|Trabectulectomy with mitomycin|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India) 10 mg vial 2 mg/ml concentration
61953041|NCT04493073|ACTIVE_COMPARATOR|Trabectulectomy with Ologen implants|Ologen Collagen Implant (Aeon Astron Europe, Netherlands) - three-dimensional collagen- GAG implant \>90% lyophilized porcine atelocollagen and \<10% lyophilized porcine GAG 12 mm in diameter with 1 mm of thickness and 6 mm in diameter with 2 mm of thickness
61953042|NCT04789135|EXPERIMENTAL|Ozone Therapy|Administration of intravesical ozone gas in patients with Interstitial cystitis/bladder pain sydrome
61953043|NCT04571879|EXPERIMENTAL|Arm 1|"Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr.~Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg)."
61953044|NCT04571879|EXPERIMENTAL|Arm 2|"Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg).~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
61953045|NCT04571879|PLACEBO_COMPARATOR|Arm 3|"Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
61953046|NCT06328101||AIP_mlg|Autoimmune pancreatitis patients with cancer
62141454|NCT05728996||Group 3|"extended: patients undergo (in addition to routine sampling) semen sampling, invasive tissue sampling (GALT and/or lumbar puncture) and leukapheresis."
62343631|NCT06051981|EXPERIMENTAL|Resin Infiltration|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Group IV uses ICON® resin infiltration, applying a 15% hydrochloric acid solution, rinsing with water, drying, and applying ICON-Dry. Excess resin is removed, and a light curing process is performed. The roughened enamel surface is polished using composite resin polish discs and cups.
62343632|NCT01895491|EXPERIMENTAL|CohortⅠ|VM206DNA 6mg and VM206Ad 3\*10\^9VP injected into the brachial muscle
62343633|NCT01895491|EXPERIMENTAL|CohortⅡ|VM206DNA 12mg and VM206Ad 3\*10\^9VP injected into the brachial muscle
61953047|NCT06328101||AIP_nomlg|Autoimmune pancreatiits patients without cancer
61953048|NCT06328101||general population|"Cancer Incidence in Five Continents Volume XI (CI5XI) registry patients used to determine expected cancer incidence and calculate SIR"
61953049|NCT04589455|EXPERIMENTAL|hennep extract|A hennep extract administered in soft gel capsules in a fasted state
61953050|NCT04589455|EXPERIMENTAL|hennep extract + high fat meal|A hennep extract administered in soft gel capsules in a fed state
61953051|NCT05898360|EXPERIMENTAL|daily time-restricted eating (TRE) for 2 weeks|Subjects will be instructed to consume all calories needed for a stable weight (based on their resting energy expenditure) in either one meal per day (TRE; between 10:00-11:00; a protein snack at 13 h) or in three meals per day (control; breakfast, lunch and dinner). Prior to the intervention, a dietician will instruct subjects on nutritional intake based on their caloric need measured by indirect calorimetry (see indirect calorimetry). During the intervention, subjects will fill in online or written dietary diary (e.g. eetmeter) and a physical activity diary. Halfway the intervention, a telephone consult with a dietician will take place
61953052|NCT05898360|PLACEBO_COMPARATOR|control protocol for each two weeks|Subjects will be instructed to consume normal diet/calories. Prior to the intervention, a dietician will instruct subjects on nutritional intake based on their caloric need measured by indirect calorimetry (see indirect calorimetry). During the intervention, subjects will fill in online or written dietary diary (e.g. eetmeter) and a physical activity diary. Halfway the intervention, a telephone consult with a dietician will take place
61953053|NCT05780580||patients with a prescription for triptan reimbursed by health insurance|
61953054|NCT05780580||patients without a prescription for triptan reimbursed by health insurance|
61953055|NCT03167905|EXPERIMENTAL|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
61953056|NCT03167905|ACTIVE_COMPARATOR|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
61953057|NCT03471520|EXPERIMENTAL|Earplugs and eye masks|
61953058|NCT04341077|EXPERIMENTAL|SHR3162|A single dose of fluzoparib was administered orally
62141455|NCT01779050|ACTIVE_COMPARATOR|Arm I (definitive therapy)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~* doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~* docetaxel plus cyclophosphamide~* single-agent paclitaxel~* docetaxel plus carboplatin~* fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
62343634|NCT01895491|EXPERIMENTAL|CohortⅢ|VM206DNA 24mg and VM206Ad 3\*10\^9VP injected into the brachial muscle
62501222|NCT04623528||Pericarditis patients without constrictive physiology|Patients with pericarditis but without signs of constrictive physiology (normal ventricular coupling)
62501223|NCT04623528||Dilated cardiomyopathy patients with biventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular and right ventricular ejection fraction less than 35%
62501224|NCT04623528||Dilated cardiomyopathy patients with preserved right ventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular ejection fraction less than 35%, and right ventricular function \>45%
62501225|NCT04623528||Patients with pulmonary arterial hypertension|Cohort of patients with pulmonary hypertension, either idiopathic or secondary to pulmonary emboli
62501226|NCT04623528||Control group|Cohort of subjects with no evidence of pericarditis, pulmonary hypertension, dilated cardiomyopathy and normal findings at cardiovascular magnetic resonance imaging
62501227|NCT02330016|EXPERIMENTAL|Voluma XC|Injections of Voluma will be accomplished using a serial puncture and fanning technique with the needle inserted to the periosteal plane as well as in the subcutaneous plane. The treatment area will include the medial and lateral chin as defined: lateral chin landmark is the depressor anguli oris.
62501228|NCT06326645|EXPERIMENTAL|Crofelemer Group|
62501229|NCT05155527|EXPERIMENTAL|Favipiravir plus Ivermectin|Ivermectin 600 mcg/kg once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW \> 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
62501230|NCT05155527|PLACEBO_COMPARATOR|Favipiravir plus Placebo|Matching placebo once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW \> 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
62700343|NCT03773484|EXPERIMENTAL|Clinical Decision Support|"Clinical decision support nudges within the electronic health record to discourage unnecessary opioid prescribing through the application of behavioral insights-empirically-tested social and psychological interventions that affect choice. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart."
62700344|NCT01370044|EXPERIMENTAL|Verum|Verum arm receiving Carbogen
62700345|NCT01370044|PLACEBO_COMPARATOR|Placebo|Placebo arm receiving oxygen
62700346|NCT05128747|ACTIVE_COMPARATOR|group of intervention will receive nutritional program|group of type 2 diabetes on diabetic diet undergo nutritional program (low fat contents) to control the lipid profile (lowering cholesterol profile) in duration of 3 months.
62700347|NCT05128747|NO_INTERVENTION|group of control will not receive nutritional program|group of type 2 diabetes on diabetic drugs without nutritional program to compare their lipid profile with the diabetic patients on nutritional program.
62700348|NCT02009787|EXPERIMENTAL|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.
62700349|NCT02009787|PLACEBO_COMPARATOR|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.
62700350|NCT04089696|EXPERIMENTAL|ExSpiron|10 patients with ALS
62700351|NCT01040247|EXPERIMENTAL|Day 0 Embryo Transfer|Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
62501231|NCT01107028||Rehab|Subjects randomized to the Rehab group will have data collected at baseline and then within one week enroll in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
62501232|NCT01107028||Wait|Subjects randomized to the Wait group will have data collected at baseline and wait eight weeks before enrolling in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
62700352|NCT01040247|ACTIVE_COMPARATOR|Day 2,3 Embryo Transfer|Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization
62700353|NCT01734044|EXPERIMENTAL|combination treatment group|100 enrolled patients are randomly picked up to take rhTPO in combination with dexamethasone at the indicated dose.
62700354|NCT01734044|ACTIVE_COMPARATOR|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
62700355|NCT03802019|EXPERIMENTAL|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will complete a 30-day experimental period when they will continue to receive their own preferred brand of cigarettes (i.e., control group).
62700356|NCT03802019|EXPERIMENTAL|LNC Cigarettes + Gray Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in standard investigational packaging (gray).
62700357|NCT03802019|EXPERIMENTAL|LNC Cigarettes + Red Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in red packaging.
62700358|NCT03802019|EXPERIMENTAL|LNC Cigarettes + Blue Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in blue packaging.
61953059|NCT06409923|ACTIVE_COMPARATOR|Invisalign MA- group (mandibular advancement)|Patients treated by MA aligner system of invisalign
62343635|NCT00530530|EXPERIMENTAL|1|Dose 1
62343636|NCT00530530|EXPERIMENTAL|2|Dose 2
62343637|NCT00530530|EXPERIMENTAL|3|Dose 3
62343638|NCT00530530|PLACEBO_COMPARATOR|4|
62343639|NCT05024877|EXPERIMENTAL|Hetrombopag treatment group|stanozolol 2mg tid + Hetrombopag (started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
62343640|NCT03298152|ACTIVE_COMPARATOR|Emax CAD Endocrowns|Using lithium disilicate e.max restorations is documented in literature as a successful restoration. Two different ceramic crowns systems were investigated clinically for three-years and howed that patient was satisfied with the final restoration
62700359|NCT03802019|EXPERIMENTAL|LNC Cigarettes + Plain Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in plain packaging.
62700360|NCT05856396|ACTIVE_COMPARATOR|Pregnant women|Pregnant women will receive one dose of Pertussis-containing vaccine during pregnancy.
62700361|NCT05856396|ACTIVE_COMPARATOR|Non pregnant women|Non-Pregnant women will receive one dose of Pertussis-containing vaccine.
62700362|NCT05856396|ACTIVE_COMPARATOR|Infants born to Tdap-vaccinated mothers|Infants whose mothers have been immunized during pregnancy with Tdap vaccine. Infants will receive three doses of Pertussis-containing vaccine (with 28 days interval starting at two months of age).
62700363|NCT05856396|ACTIVE_COMPARATOR|Infants born to non Tdap-vaccinated mothers|"Infants whose mothers have not been immunized during pregnancy with Tdap vaccine.~Infants will receive three doses of Pertussis-containing vaccine (with 28 days interval starting at two months of age)."
62700364|NCT05642338||cohort 1 dysplastic cohort|208 BE patients referred for work up after diagnosis of LGD, HGD or earlystage cancer in the last 18 months.
62700365|NCT05642338||Cohort 2: non-dysplastic cohort|208 patients under standard BE surveillance without a diagnosis of dysplasia in last 18 months.
62700366|NCT00244985|EXPERIMENTAL|Arm 1: Rituximab and Doxorubicin HCI Liposome|Patients receive rituximab IV over 3-8 hours on day 1 and doxorubicin HCl liposome IV over 1-3 hours on day 3
62700367|NCT01395082||Entire registry group|Participants with potential myopericarditis cases referred to the Registry
62700368|NCT03231553|EXPERIMENTAL|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.~Receive MiQuit text message cessation programme."
62700369|NCT03231553|NO_INTERVENTION|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
62700370|NCT05759767|ACTIVE_COMPARATOR|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
62700371|NCT05759767|PLACEBO_COMPARATOR|Placebo|Children in this group will receive Placebo for 3 weeks after ESWL session.
61953060|NCT06409923|ACTIVE_COMPARATOR|Herbst group|Patient treated with the herbst appliance
61953061|NCT02963792|EXPERIMENTAL|Structured group intervention|"Experimental: Structured group intervention a 'structured' intervention, leaning mostly on tools designed to prevent burnout and promote resilience, including predetermined exercises and topics as discussion goals in each meeting.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
62343641|NCT03298152|EXPERIMENTAL|Cerasmart Endocrowns|A new material CERASMART (Force Absorbing Flexible nano ceramic CAD/CAM block) with high density of ultrafine glass particles with 71 wt% filled nano-composite. It combines high strength and unique aesthetics. full homogeneous and even distribution nano ceramic network lead to unique physical properties for cerasmart . Uniform scuttle (very short inter-particle distance) of silanated and bonded particles is key to delivering CERASMART's™ with exceptional strength, retention, acceptable level of marginal adaptation
62343642|NCT05837052|EXPERIMENTAL|Serplulimab plus chemotherapy|Patients with unresectable NSCLC will receive 3-4 cycles of serplulimab plus chemotherapy as the conversion treatment (serplulimab 300mg d1 q3w; carboplatin (AUC 5) on day 1, and pemetrexed (500 mg/m2 for adenocar- cinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma) d1 q3w), and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions. Maintenance treatment with PD-1 antibody q3w will continue up to 12 months or disease progression after surgery.
62700372|NCT02878785|EXPERIMENTAL|Phase 1: Decitabine and Talazoparib Combo|"Phase 1:~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28.~The 'outer layer' of this nested dose escalation trial will escalate the dose of the two drugs by sequentially going through dose levels 1-6 in the table found in the protocol. The standard algorithm of the 3+3 design will be applied."
62700373|NCT02878785|EXPERIMENTAL|Phase 2: Decitabine and Talazoparib Combo|"Phase 2:~Recommended Phase 2 Dose (RP2D) The MTD of the combination of decitabine with a dose of talazoparib of at least 0.25 mg is defined as the maximal tolerated dose of decitabine studied - and for that dose level, combined with the maximum dose of talazoparib for which the incidence of DLT was less than 33% in 6 participants treated and this will be chosen as the recommended Phase 2 dose (RP2D). Among potential combined dose levels at MTD, available pharmacodynamic data (PARP trapping) will also be considered in the choice of RP2D, as will any significant indications of differences in clinical efficacy"
62700374|NCT02878785|ACTIVE_COMPARATOR|Phase 2 Arm A|Adult patients with AML who are thought not to be likely to tolerate or respond to standard chemotherapy
62700375|NCT02878785|ACTIVE_COMPARATOR|Phase 2 Arm B|Adult patients with AML that has not responded to previous treatment or has come back after responding to previous treatment
62700376|NCT02878785|ACTIVE_COMPARATOR|Phase 2 Arm C|Adult patients previously treated with a DNA methyltransferase inhibitor (decitabine, azacitidine or guadecitabine)
62700377|NCT02647502|ACTIVE_COMPARATOR|Continuous calorie restriction|Participants will be provided with a diet that includes approximately 78% of calories each day that would be needed to maintain current BMI.
62700378|NCT02647502|EXPERIMENTAL|Intermittent calorie restriction|Participants will be provided a diet that with a daily calorie intake required to maintain current BMI, except only 25% of this calorie intake will be provided for 2 days a week.
62343643|NCT05181540|EXPERIMENTAL|AB-205 plus standard-of-care preventive and supportive therapies.|
62343644|NCT05181540|PLACEBO_COMPARATOR|Placebo plus standard-of-care preventive and supportive therapies.|
62343645|NCT01621672|EXPERIMENTAL|Revlimid|Revlimid dosing will be in the morning at the same time each day
62343646|NCT01621672|NO_INTERVENTION|No further treatment|No treatment control.
62700379|NCT02647502|PLACEBO_COMPARATOR|Control calorie intake|Participants will be assigned to consume enough calories each day required to maintain current BMI
62700380|NCT05977296|EXPERIMENTAL|OSA patients|The experimental group in this study consisted of individuals who were assigned to the CPAP (Continuous Positive Airway Pressure) intervention. Participants in the experimental group were instructed to wear a CPAP device during their sleep.
62700381|NCT05977296|NO_INTERVENTION|Usual group|In the control group, participants received standard or routine nursing care without any specific interventions(CPAP) or modifications. The standard nursing care provided to the participants followed established protocols and guidelines commonly practiced in general healthcare settings.
62700382|NCT04610515||Symptomatic Individuals with infection with SARS-COV2 (ie exposed cohort)|Symptomatic Individuals test positive for SARS-COV2. Participants will be enrolled soon after infection and followed to assess for long term outcomes.
62700383|NCT04610515||Symptomatic Individuals without infection with SARS-COV2 (ie unexposed cohort)|Symptomatic Individuals test negative for SARS-COV2. Participants will be enrolled soon after testing and followed to assess for long term outcomes.
62700384|NCT03903783|ACTIVE_COMPARATOR|Cefotaxime|
62700385|NCT03903783|ACTIVE_COMPARATOR|Ceftriaxone|
62700386|NCT05994287|ACTIVE_COMPARATOR|Drug: celecoxib|The patients received celecoxib in a dose of 400 mg orally daily. The drug was prescribed from the second day of the operation for 5 days.
61953062|NCT02963792|EXPERIMENTAL|Semi-Structured group intervention|"Experimental: Semi-Structured group intervention a 'semi-structured' intervention, based on tools for developing an emotional discourse, building a supporting team and self reflection.~The 'semi-structured' intervention offers predetermined contents that are discussed through the stories and needs presented by group members.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
61953063|NCT05002452||Locally Advanced HCC Patients|Patients which are diagnosed with locally advanced hepatocellular carcinoma (HCC) will receive standard HAIC treatment.
61953064|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization.
61953065|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on CEM) during hospitalization.
61953066|NCT05327257|EXPERIMENTAL|iTBS rTMS Left Dorsolateral Prefrontal Cortex (DLPFC) then Vertex|Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.
61953067|NCT05327257|EXPERIMENTAL|iTBS rTMS Lateral Parietal Cortex (LPC) then Vertex|Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the LPC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.
61953068|NCT05327257|EXPERIMENTAL|iTBS rTMS Vertex then Left Dorsolateral Prefrontal Cortex (DLPFC)|Subjects will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days in the first treatment period, complete a washout period of 4 weeks then receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC.
61953069|NCT05327257|EXPERIMENTAL|iTBS rTMS Vertex then Lateral Parietal Cortex (LPC)|Subjects will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days in the first treatment period, complete a washout period of 4 weeks then receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the LPC.
61953070|NCT05327257|SHAM_COMPARATOR|iTBS rTMS Vertex only|Cognitively normal and healthy controls will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days. The vertex serves as a control as there are no functional improvements in cognition with stimulation of the vertex region.
61953071|NCT02675283|OTHER|coeliac disease point of care test|Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
61953072|NCT00565045|EXPERIMENTAL|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~* Stimulation to finger and thumb extensors and flexors only in response to and with an intensity proportional to opening and closing of the contralateral unimpaired hand~* A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity~* Therapy sessions are done with the subject being assisted by the CCFES system."
62343647|NCT04246593|EXPERIMENTAL|Intervention - Market|"Partner sites that are randomized to the Intervention - Market will plan and start (or expand) a Mobile Market and run the Market weekly for at least 10 months (non necessarily nonconsecutive). The Mobile Market will follow the Veggie Van Model which includes a share model, price reductions (incentives), and an educational component."
62501233|NCT02721550|EXPERIMENTAL|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 \~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4"
62700387|NCT05994287|EXPERIMENTAL|Drug: aspirin with ketorolac|The patients received aspirin in a dose of 100 mg and ketorolac 90 mg orally daily. The drugs were prescribed from the second day of the operation for 5 days.
62501234|NCT05367037|ACTIVE_COMPARATOR|PhysioVP group|Physiological ventricular pacing
62700388|NCT05994287|EXPERIMENTAL|Drug: ketorolac and celecoxib|The patients received ketorolac in a dose of 90 mg and celecoxib 400 mg orally daily. The drugs were prescribed from the second day of the operation for 5 days.
62700389|NCT05994287|ACTIVE_COMPARATOR|Drug: aspirin, ketorolac and celecoxib|The patients received aspirin in a dose of 200 mg, ketorolac 90 mg, and celecoxib 400 mg orally daily. The drugs were prescribed from the second day of the operation for 5 days.
62700390|NCT02987387||TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
62700391|NCT02020226|EXPERIMENTAL|TH-302|480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
62700392|NCT06150430|EXPERIMENTAL|Training with APO|All participants are assigned to the training group with the APO
62700393|NCT05098821||Dupilumab treated Patients|Patients with atopic dermatitis with indication for dupilumab treatments will be observed
62501235|NCT05367037|ACTIVE_COMPARATOR|DDD-VPA group|Dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance
62501236|NCT01758406|EXPERIMENTAL|cardiac stem cell transplantation|The patients with heart failure that underwent cardiac stem cell transplantation.
62501237|NCT01758406|PLACEBO_COMPARATOR|Placebo|The patients with heart failure that underwent placebo injection.
62501238|NCT02919189|EXPERIMENTAL|Visible light exposure Red 30 lux|The participants will be exposed to red fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62501239|NCT02919189|EXPERIMENTAL|Visible light exposure Red 120 lux|The participants will be exposed to red fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62501240|NCT02919189|EXPERIMENTAL|Visible light exposure Blue 30 lux|The participants will be exposed to blue fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62501241|NCT02919189|EXPERIMENTAL|Visible light exposure Blue 120 lux|The participants will be exposed to blue fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62501242|NCT02919189|EXPERIMENTAL|Visible light exposure Green 30 lux|The participants will be exposed to green fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62501243|NCT02919189|EXPERIMENTAL|Visible light exposure Green 120 lux|The participants will be exposed to green fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62343648|NCT04246593|NO_INTERVENTION|Control - Planning|At Control - Planning (comparison) sites, engagement will focus on involving community members in food access program planning and research. It is anticipated that each organization will create one or more community advisory committees to oversee their food access work. At comparison sites, engagement efforts will be more generally centered on food access and understanding what types of programs would be most acceptable. Examples of community engagement activities include community forums and listening sessions, informational tables at community events, and establishment of text, e-mail or social media sites for ongoing communication and feedback around food access issues. As part of this community engagement work, partners will collect contact information from community members that will assist in the data collection process.
62343649|NCT02336412|EXPERIMENTAL|SMS reminder|Daily SMS medication reminder
62343650|NCT02336412|NO_INTERVENTION|No SMS reminder|No daily SMS medication reminder
62343651|NCT06243822|ACTIVE_COMPARATOR|Ketamine group|
62343652|NCT06243822|ACTIVE_COMPARATOR|propofol group|
62343653|NCT05764278|EXPERIMENTAL|effectiveness of earlier rehabilitation intervention after IA thrombectomy(experimental)|The effectiveness of early rehabilitation interventions within 24 hours compared with the control group
62343654|NCT05764278|ACTIVE_COMPARATOR|effectiveness of earlier rehabilitation intervention after IA thrombectomy(control)|The effectiveness of early rehabilitation interventions compared with the experimental group
62501244|NCT02919189|EXPERIMENTAL|Visible light exposure White 30 lux|The participants will be exposed to white fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62501245|NCT02919189|EXPERIMENTAL|Visible light exposure White 120 lux|The participants will be exposed to white fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62501246|NCT01937117|EXPERIMENTAL|Trastuzumab and Pertuzumab|Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET)
62501247|NCT03359720||guyane|
62501248|NCT03359720||martinique|
62501249|NCT03359720||guadeloupe|
62501250|NCT03310619|EXPERIMENTAL|Arm A: JCAR017 in combination with Durvalumab|JCAR017 will be administered at a single flat dose of 50 x 10\^6 CAR+T cells or 100 x 10\^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules
62501251|NCT03310619|EXPERIMENTAL|Arm B: JCAR017 in combination with CC-122|This arm will test JCAR017 in combination with the CC-122. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10\^6 CAR+T cells. The combination agent will be administered at different doses
62343655|NCT02240537|EXPERIMENTAL|Open Label Treatment Arm|BB-MPI-03 peptides plus montanide plus sargramostim
62343656|NCT03398122|EXPERIMENTAL|Apatinib combined with TACE|patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
62501252|NCT03310619|EXPERIMENTAL|Arm C: JCAR017 in combination with CC-220|This arm will test JCAR017 in combination with CC-220. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10\^6 CAR+T cells. The combination agent will be administered at different doses
62501253|NCT03310619|EXPERIMENTAL|Arm D: JCAR017 in combination with Ibrutinib|This arm will test JCAR017 in combination with ibrutinib. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10\^6 CAR+T cells. The combination agent will be administered at a fixed dose of 420 mg daily
62501254|NCT03310619|EXPERIMENTAL|Arm E: JCAR017 in combination with relatlimab and/or nivolumab|This arm will test JCAR017 in combination with relatlimab and/or nivolumab in adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10\^6 CAR+T cells. The combination agent will be administered at different doses and/or schedules
62501255|NCT03310619|EXPERIMENTAL|Arm F: JCAR017 in combination with CC-99282|This arm will test JCAR017 in combination with CC-99282 in adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10\^6 CAR+T cells. The combination agent will be administered at different doses and/or schedules.
62501256|NCT05099510|ACTIVE_COMPARATOR|NatrunixTM|Each participant will receive one single subcutaneous injection of 200 mg (Cohort 1), 400 mg (Cohort 2), or 800 mg (Cohort 3) of NatrunixTM.
62501257|NCT05099510|PLACEBO_COMPARATOR|Placebo|Each participant will receive one single subcutaneous injection of placebo.
62501258|NCT06325124|ACTIVE_COMPARATOR|Muscle Energy Technique of Calf and hamstrings|Muscle Energy Technique of Calf and hamstrings (soft tissue technique)
62501259|NCT06325124|OTHER|Conventional PT|Cervical isometric exercises Hot pack
61953073|NCT00565045|ACTIVE_COMPARATOR|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation.~* Preprogrammed cycles of finger and thumb flexor and extensor stimulation repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~* Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~* Therapy sessions are done without the stimulation system"
62164564|NCT00003588|EXPERIMENTAL|Arm I|Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.
62164565|NCT05774418||vaccinated|Healthcare workers (aged ≥18 years) working at hospital sites who could provide written informed consent and who will complete the immunization program with the administration of the second dose after approximately 21 days from the first dose at the FPG
62501260|NCT04485507|EXPERIMENTAL|Nature-VR|Viewing 3D pictures of natural environments
62501261|NCT04485507|ACTIVE_COMPARATOR|Urban-VR|Viewing 3D pictures of urban environments
62501262|NCT02272894||Group A|D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
62501263|NCT02272894||Group B|D2 Radical Gastrectomy
62501264|NCT06415864||Cladribine (Mavenclad, Merck Serono Ltd)|In the summary of product characteristics the recommended cumulative dose is 3.5 mg/kg body weight over 2 years, taken as 1 treatment course of 1.75 mg/kg per year. Each treatment course consists of 2 treatment weeks, 1 at the beginning of the first month and 1 at the beginning of the second month of the respective treatment year. Each treatment week consists of 4 or 5 days on which a patient takes 10 mg or 20 mg (1 or 2 tablets) as a single daily dose, depending on body weight
62343657|NCT03398122|PLACEBO_COMPARATOR|chemoemtranscatherer arterial bolization|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
62343658|NCT03083509|OTHER|Group1 (Resistance trained individuals)|Resistance trained individuals (\>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
62343659|NCT03083509|OTHER|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of \<25 minutes and a training history of ≥5 hours per week for ≥2 years)
62343660|NCT03083509|OTHER|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
62343661|NCT04488224|EXPERIMENTAL|Patients receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.~Participants in this arm undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. These participants do not require an additional conventional CBCT as the SOC conventional CBCT images are used to benchmark the experimental Nano-X CBCT scans for evaluation of the primary outcome measure."
62343662|NCT04488224|EXPERIMENTAL|Patients not receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.~Participants in this arm do not undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. As such these participants will receive an additional conventional CBCT scan on standard equipment which used to benchmark the experimental NAno-X CBCT scans for evaluation of the primary outcome measure."
62343663|NCT00176241|EXPERIMENTAL|1|
62343664|NCT03799926|EXPERIMENTAL|Stratum 1: 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to \< 6.0 mEq/L range at baseline
62343665|NCT03799926|EXPERIMENTAL|Stratum 1: 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to \< 6.0 mEq/L range at baseline
62343666|NCT03799926|EXPERIMENTAL|Stratum 1: placebo of 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to \< 6.0 mEq/L range at baseline
62501265|NCT04541680|EXPERIMENTAL|Nintedanib|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
62501266|NCT04541680|PLACEBO_COMPARATOR|Placebo|Control group will receive Placebo BID for 12 months in addition to SoC. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient. Standard of care may include pulmonary rehabilitation.
62343667|NCT03799926|EXPERIMENTAL|Stratum 1: placebo of 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to \< 6.0 mEq/L range at baseline
62343668|NCT03799926|EXPERIMENTAL|Stratum 2: 8.4 g patiromer|Non-dialysis subjects with serum potassium 6.0 to \< 6.5 mEq/L range at baseline
62501267|NCT05380050|EXPERIMENTAL|Inpatient GMT plus Attention Training|Goal Management Training is a group metacognitive intervention to improve ability to complete complex task more effectively. 2-hour session are conducted in-person weekly over 10-weeks. A second weekly session includes Attention training which is conducted one-on-one with the therapist in the clinic. Participant completed 5-6 hours of homework between sessions.
62700394|NCT02662751|ACTIVE_COMPARATOR|Routine Imaging|"Patients randomized to this arm will have routine post-stroke/TIA imaging assessments.~Intervention: Routine Imaging Assessment"
62164566|NCT05774418||unvaccinated|unvaccinated health workers
62501268|NCT05380050|EXPERIMENTAL|Telehealth GMT plus Attention Training|Goal Management Training is a group metacognitive intervention to improve ability to complete complex task more effectively. 2-hour session are conducted over the VA VideoConnect weekly over 10-weeks. A second weekly session includes Attention training which is conducted one-on-one with the therapist via VA VideoConnect. Participant completed 5-6 hours of homework between sessions
62501269|NCT05380050|PLACEBO_COMPARATOR|Brain Health Workshop|Brain Health Workshop includes educational information about the brain to control for GMT and National Geographic Movies is used as a control to equate time with therapist in Attention Training. Each session occurs weekly for 2-hours over 10-weeks.
62501270|NCT00519103|EXPERIMENTAL|1|Active resistive excercise for 7 weeks
62501271|NCT06240065|EXPERIMENTAL|Short Bowel Syndrome Arm|Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
62501272|NCT06240065|ACTIVE_COMPARATOR|Control Arm|Patients without SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
62501273|NCT04761445|EXPERIMENTAL|Straumann Standard Plus (SP)|Patients receiving Straumann SP implants of 4.1 mm in diameter and length of 10 mm.
62501274|NCT04761445|EXPERIMENTAL|JDental care Octa (JD Octa)|Patients receiving JD Octa implants of 4.3 mm in diameter and 10 mm in length.
62501275|NCT03756701|EXPERIMENTAL|Group 1|Initial participants in the 10 mind body sessions
62501276|NCT03756701|ACTIVE_COMPARATOR|Group 2|10 week no intervention groups - receives the mind body interventions after group 1 has completed.
62700395|NCT02662751|EXPERIMENTAL|LDWBA first|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~Intervention: LDWBA first followed by Routine Imaging Assessment if required."
62343669|NCT03799926|EXPERIMENTAL|Stratum 2: 16.8 g patiromer|Non-dialysis subjects with serum potassium 6.0 to \< 6.5 mEq/L range at baseline
62164567|NCT03435939|EXPERIMENTAL|losartan|a daily dose of 50 mg losartan for 7 days (for tolerability). Then, the losartan dose will be increased to 100 mg daily for 12 weeks.
62343670|NCT03799926|EXPERIMENTAL|Stratum 3: 8.4 g patiromer|Dialysis subjects with serum potassium 5.5 to \< 6.5 mEq/L range at baseline
62343671|NCT03799926|EXPERIMENTAL|Stratum 3: 16.8 g patiromer|Dialysis subjects with serum potassium 5.5 to \< 6.5 mEq/L range at baseline
62343672|NCT01940510|EXPERIMENTAL|Healthy subjects|
62343673|NCT05856825||Sun Yat-sen Memorial Hospital|
62164568|NCT05704465|OTHER|Reiki Therapy|Reiki is a biofield therapy technique based on energy healing.
62343674|NCT05856825||Renji Hospital, Shanghai Jiaotong University School of Medicine|
62343675|NCT05856825||The Third Medical Centre of Chinese PLA General Hospital|
62343676|NCT05856825||The First Affiliated Hospital of Zhengzhou University|
62343677|NCT05856825||Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College|
62164569|NCT05704465|OTHER|Qi-gong Therapy|Qigong technique is a type of mind-body meditative exercise developed in traditional Chinese medicine more than 5000 years ago.
62164570|NCT02326740|EXPERIMENTAL|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
62164571|NCT02326740|PLACEBO_COMPARATOR|Placebo|Solution for subcutaneous injection (Part 1, Group A)
62164572|NCT02326740|EXPERIMENTAL|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
62164573|NCT01604499|EXPERIMENTAL|Feedback only|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
62164574|NCT01604499|EXPERIMENTAL|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
62164575|NCT01604499|NO_INTERVENTION|Control group|
62164576|NCT04711018||Group DL (+)|Grade III or IV laryngeal view according to Cormack-Lehane classification
62164577|NCT04711018||Group DL (-)|Grade I or II laryngeal view according to Cormack-Lehane classification
62164578|NCT00896389|OTHER|Salt-loading and thiazide diuretic (HCTZ)|Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week
62164579|NCT05966545|ACTIVE_COMPARATOR|intraocular foreign body extraction via the limbus|pars plana vitrectomy and intraocular foreign body removal via the limbus, after complete removal of adhesions around intraocular foreign body, then the foreign body will be grasped using basket forceps, and it will be brought to anterior chamber and then removed through limbal incision. The external earth magnet will be applied close to the limbus to prevent its slippage from the forceps if needed.
62164580|NCT05966545|ACTIVE_COMPARATOR|intraocular foreign body extraction via the pars plana route|pars plana vitrectomy and intraocular foreign body removal via pars plana route, after complete removal of adhesions around intraocular foreign body, then IOFB will be grasped using basket forceps, and while the IOFB removed through the sclerotomy an external earth magnet will be applied close to the sclerotomy after enlargement the sclerotomy to prevent its slippage from the forceps and falling down onto the posterior pole if needed.
62343678|NCT05856825||Southwest Hospital, Third Military Medical Hospital (Army Medical University)|
62343679|NCT05856825||Tongji Hospital Affiliated to Tongji Medical College Hust|
62343680|NCT05856825||The First Affiliated Hospital of Xi'an Jiaotong University|
62343681|NCT05856825||The First Affiliated Hospital of Navy Medical University|
62343682|NCT05856825||The First Affiliated Hospital of Nanchang University|
62343683|NCT05856825||Zhongda Hospital Southeast University|
62343684|NCT05856825||The Second Xiangya Hospital, Central South University|
62343685|NCT05856825||The First Affiliated Hospital of Nanjing Medical University|
62343686|NCT05856825||Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital|
62343687|NCT05856825||Gansu Provincial Hospital|
62343688|NCT05856825||The Affiliated Yantai Yuhuangding Hospital of Qingdao University|
62501277|NCT03916562|EXPERIMENTAL|Healthy Participants|The investigators will determine how asymmetric walking constraints influence spatiotemporal coordination, energetic cost, and dynamic balance in healthy individuals. The investigators will manipulate spatiotemporal coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
62501278|NCT03916562|EXPERIMENTAL|Post-stroke Participants|The investigators will determine how different patterns of coordination during walking influence energetic cost and dynamic balance in people post-stroke. The investigators will manipulate coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
62501279|NCT03711396|EXPERIMENTAL|Advance Care Planning Group Visits - amnestic Mild Cognitive Impairment|Participants with amnestic Mild Cognitive Impairment will attend group visits to discuss advance care planning with their study partners. Group visits will last up to two hours and be help up to twice.
62501280|NCT03711396|EXPERIMENTAL|Advance Care Planning Group Visits - Care Partners|Care partners of persons with amnestic Mild Cognitive Impairment will attend group visits, with the person with Mild Cognitive Impairment, to discuss advance care planning. Group visits will last up to two hours and be help up to twice.
62343689|NCT05856825||West China Hospital, Sichuan University|
62501281|NCT02394288||Adults without cardiac disease|Extremity orthopedic or trauma surgery
62501282|NCT02978651|EXPERIMENTAL|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
62700396|NCT06571058|EXPERIMENTAL|Clinicians (B3 Buddy)|Clinicians receive a short instructional session, secure the urinary drainage bag to the patient using the B3 Buddy device. Clinicians also assist patient with walking and then remove the device and return urinary drainage bag to the standard position on study.
62700397|NCT06571058|EXPERIMENTAL|Patients (B3 Buddy)|Patients receive a short instructional session, wear the B3 Buddy device to secure urinary drainage bag and walk approximately 90 feet before urinary drainage bag is returned to the standard position on study.
62343690|NCT05856825||The First Hospital of China Medical University|
62501283|NCT02978651|PLACEBO_COMPARATOR|Placebo|Placebo
62501284|NCT03677843||cerebral palsy|They are included in GMFCS level 3, 4, 5. and they have diplegia or quadriplegia
62501285|NCT06677632||Alzheimer's disease patients|TO DETERMINE THE EXPRESSION OF zDHHC ENZYMES AND CHANGES OF PROTEIN S- PALMITOYLATION IN THE hiPSC-DERIVED NEURONS AND BRAIN ORGANOIDS OBTAINED FROM AD PATIENTS
62501286|NCT02369354|NO_INTERVENTION|Usual Care|Usual medical care at the Duke Kidney Transplant Clinic
62501287|NCT02369354|OTHER|TALKS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings
62501288|NCT02369354|OTHER|TALKS PLUS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings plus live donor financial assistance intervention
62501289|NCT02102932|EXPERIMENTAL|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
62343691|NCT05856825||The Third Xiangya Hospital of Central South University|
62501290|NCT02102932|EXPERIMENTAL|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
62700398|NCT05444387|EXPERIMENTAL|Upper Limb Loading Group|Partial body weight support treadmill training with upper limb external weights in addition to conventional treatment: balance, gait training, facilitation for normal development
62700399|NCT05444387|NO_INTERVENTION|Control Group|Partial body weight support treadmill training without upper limb external weights in addition to conventional treatment: balance, gait training, facilitation for normal development
62700400|NCT04932148|EXPERIMENTAL|Incremental HD|Participants randomised to incremental HD will commence HD twice weekly and continue until an indication for an increase to three sessions/week (trigger point) is reached.
62700401|NCT04932148|OTHER|Conventional HD|Participants randomised to conventional HD will commence HD thrice weekly from the first HD session.
62700402|NCT05704387|ACTIVE_COMPARATOR|restrictive fluid therapy group|Patients in this group will have a restrictive fluid therapy (1 ml/kh/h) from anesthesia induction until end of liver resection.
62700403|NCT05704387|EXPERIMENTAL|individualized GDFT group|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommendation of the AFM software in order to optimize patient's stroke volume (SV)
61953074|NCT04858633|ACTIVE_COMPARATOR|PEP group|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg)
61953075|NCT04858633|PLACEBO_COMPARATOR|Control group|Placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
62343692|NCT05856825||General Hospital of Central Theater Command|
62343693|NCT05856825||Kunming First People's Hospital|
62343694|NCT05856825||The East Campus of Qingdao Municipal Hospital|
62343695|NCT05856825||The second Affiliated Hospital of Kunming Medical University|
62343696|NCT05856825||Second Hospital of Dalian Medical University|
62343697|NCT05856825||The Second Affiliated Hospital of Xi'an Jiaotong University|
62343698|NCT05856825||The First Hospital of Jilin University|
62343699|NCT05856825||Zhejiang Cancer Hospital|
62343700|NCT05856825||Peking University Third Hospital|
62343701|NCT05856825||Changzheng Hospital, Naval Medical University|
62343702|NCT05856825||Peking Union Medical College Hospital|
62343703|NCT05856825||The First Affiliated Hospital of Chongqing Medical University|
62343704|NCT05856825||Beijing United Family Hospital and Clinics|
62343705|NCT01140854||Hypertension (case)|Elderly patients 60 years old or older undergoing simple lumbar spine surgery under general anesthesia will receive neurologic/neuropsychometric examinations.
62700404|NCT05765721|EXPERIMENTAL|intervention group|Patients in this group will receive a 8-week family-based frailty self-management program including: (1) one 20-30 minute individual consultation (teaching how to join the family-based frailty self-management program by using poster); (2) provided self-management booklet; (3) provided family-based frailty self-management program video through Line group meeting, once per two weeks ; (4) individual consultation through telephone follow-up once per week for 8 weeks
62700405|NCT05765721|NO_INTERVENTION|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
62141456|NCT01779050|EXPERIMENTAL|Arm II (definitive therapy, trastuzumab)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~* doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~* docetaxel plus cyclophosphamide~* single-agent paclitaxel~* docetaxel plus carboplatin~* fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
62141457|NCT06223373|EXPERIMENTAL|Blood Flow Restriction (BFR)|Blood Flow Restriction (BFR) pressurized per standard protocols in addition to our institutional rehabilitation protocol
62141458|NCT06223373|SHAM_COMPARATOR|"sham Blood Flow Restriction (BFR)"|"rehabilitation using sham BFR as well as our institutional rehabilitation protocol"
62141459|NCT03624283|EXPERIMENTAL|Group A|Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;
62141460|NCT03624283|EXPERIMENTAL|Group B|Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;
62141461|NCT03624283|EXPERIMENTAL|Group C|Group C will receive an combination of Exercise-based VR plus Betahistine.
62141462|NCT01354782|EXPERIMENTAL|Roflumilast|(This is a pharmacokinetic study)
62141463|NCT04786275||Tetanic stimulation|Single arm study
62141464|NCT04071106|ACTIVE_COMPARATOR|Turmeric Extract group|10 psoriasis patients receiving turmeric based ointment levigated in glycerin twice daily and assessed for response and side effects weekly for 12 weeks
62141465|NCT04071106|ACTIVE_COMPARATOR|Turmeric extract + olive oil group|10 psoriasis patients receiving turmeric extract levigated in olive oil instead of glycerin. The ointment will be applied twice daily for 12 weeks \& will be assessed weekly
62141466|NCT04071106|PLACEBO_COMPARATOR|Petrolatum group|10 Psoriasis patients will receive the base of the therapeutic ointment which is the petrolatum. Patients will apply it twice daily and will be assessed weekly clinically and dermoscopically for 12 weeks
62141467|NCT04071106|ACTIVE_COMPARATOR|NBUVB group|10 Psoriasis patients will receive two sessions of NBUVB weekly for 12 weeks and will be assessed weekly clinically and with dermoscope.
62141468|NCT04071106|ACTIVE_COMPARATOR|Established ttt group|10 Psoriasis patients will receive topical betamethasone dipropionate or calcipotriol cream twice daily for 12 weeks and will be assessed on weekly basis clinically and by dermoscope
62141469|NCT04671875|EXPERIMENTAL|MIL93|
62141470|NCT00452114|ACTIVE_COMPARATOR|Assignment to In-Exsufflator Cough Assist Device|In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
62141471|NCT00452114|ACTIVE_COMPARATOR|Assignment to flutter valve device|flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily
62141472|NCT05953805||Patients With iPads|Patients who have been assigned an iPad to complete their PPI sessions remotely
62141473|NCT05953805||Patients Without iPads|Patients who will continue to attend the classic face to face PPI meetings
62141474|NCT05953805||Staff|Staff who will give their opinions on the use of iPads against normal PPI methods
62141475|NCT00198419|EXPERIMENTAL|Vitrase|a single intradermal dose of 3 USP Units of Vitrase (ovine hyaluronidase) at one site and the same volume of saline at a distant site for comparative control
62141476|NCT03528213|SHAM_COMPARATOR|Normal saline|at physician discretion
62501291|NCT02102932|EXPERIMENTAL|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
62700406|NCT06564935|ACTIVE_COMPARATOR|Heptaminol hydrochloride group|
62700407|NCT06564935|PLACEBO_COMPARATOR|Placebo group|
62141477|NCT03528213|EXPERIMENTAL|Sodium lactate light dose|bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
62141478|NCT03528213|EXPERIMENTAL|Sodium lactate high dose|bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
62141479|NCT05137600|EXPERIMENTAL|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
62141480|NCT05137600|EXPERIMENTAL|Midazolam|Midazolam is a sensitive CYP3A index substrate
62141481|NCT05137600|EXPERIMENTAL|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites
62141482|NCT00621673|OTHER|Arm 1|
62141483|NCT01830049||Group I|Older males with ED
62700408|NCT02227745||Dorzolamide hydrochloride (2%)|dorzolamide: diabetic patients with clinical significally macular edema with treatment photocoagulation dorzolamide (2%) application 1 drop every 8 hours for 4 weeks
62700409|NCT02227745||Placebo Sodium hyaluronate4mg|placebo: diabetic patients with clinically significant macular edema(focal), with photocoagulation sodium hyaluronate (0.5%) application 1 drop every 8 hours for 4 weeks
62700410|NCT04611243||COVID survivors|
62141484|NCT01830049||Group II|Older males with normal erectile function
62141485|NCT01830049||Gourp III|Young males with normal rectile function
62141486|NCT02325349|EXPERIMENTAL|radiopharmaceutical|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
62700411|NCT04611243||Vaccination with CoronaVac vaccine|
62700412|NCT04611243||Vaccination with BionTech vaccine|
62700413|NCT04611243||third dose vaccination with CoronaVac vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
62700414|NCT04611243||third dose vaccination with BionTech vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
62700415|NCT03110562|EXPERIMENTAL|SVd Arm: Selinexor + Bortezomib + Dexamethasone|Participants received a fixed oral dose of 100 milligrams (mg) selinexor tablets (5 tablets of 20 mg each) once weekly (QW) on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with subcutaneous (SC) injection of 1.3 milligrams per square meter (mg/m\^2) bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone twice weekly (BIW) on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.
62700416|NCT03110562|EXPERIMENTAL|Vd Arm: Bortezomib + Dexamethasone|Participants received SC injection of 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by greater than or equal to (\>=) 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles \>= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.
62700417|NCT03110562|EXPERIMENTAL|SVdX Arm: Selinexor + Bortezomib + Dexamethasone|Participants in the VD arm who had IRC-confirmed PD and were able to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m\^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.
62343706|NCT01140854||Normotension (control)|Middle-aged patients (40-60 years) undergoing simple lumbar spine surgery under general anesthesia as controls to compare their performance to those patients \>60 years - will also receive neurologic/neuropsychometric examinations.
62343707|NCT06373172|EXPERIMENTAL|Enhancing Clinical Reasoning Competency for Undergraduate Nursing Students|Enhancing Clinical Reasoning Competency for Undergraduate Nursing Students Using Virtual Simulation-based Education based on the Rasch model
62343708|NCT01362946|EXPERIMENTAL|Reward-Emphasized treatment|This treatment consisted of behavior therapy modified to match the unique learning styles of children with CPCU. This was accomplished by emphasizing rewards and de-emphasizing punishments. This treatment was administered using a summer treatment program.
62700418|NCT03110562|EXPERIMENTAL|SdX Arm: Selinexor + Dexamethasone|Participants in the VD arm who had IRC-confirmed PD and were unable to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.
62700419|NCT05007704||Anesthesiologists for preliminary survey|Anesthesiologists who have completed their training within the last three years to identify preliminary competencies for Delphi round one survey.
62700420|NCT05007704||Global Experts in Anesthesiology and Critical Care Medicine|Anesthesiologist (a medical graduate who has completed a nationally recognized Anesthesiology training programme) involved in the management of critically ill patients in ICU and have more than ten years of experience in teaching and training in Critical Care. They will be involved in the Delphi process to generate expert consensus on the additional competencies (mandatory desirable and optional) required for Anesthesiologists to practice Critical Care in the Intensive Care Unit (ICU).
62700421|NCT05603676|EXPERIMENTAL|Hypertensive IHHC|Hypertensive participants who performed IHHC
62700422|NCT05603676|PLACEBO_COMPARATOR|Hypertensive placebo|Hypertensive participants who performed placebo intervention
62700423|NCT05603676|ACTIVE_COMPARATOR|Healthy IHHC|Healthy participants who performed IHHC
62700424|NCT05603676|SHAM_COMPARATOR|Healthy Placebo|Healthy participants who performed placebo intervention
62141487|NCT00195403||1|
62141488|NCT01600482|EXPERIMENTAL|CELT ACD device|The CELT ACD device is a vascular closure device.
62141489|NCT01600482|NO_INTERVENTION|Manual Compression|Manual Compression
62141490|NCT01961466||Diabetic patients|
62343709|NCT01362946|ACTIVE_COMPARATOR|Standard treatment|This treatment consisted of standard behavior therapy, in which reward and punishment components were used in a balanced manner, as is typically done in outpatient settings. This treatment was administered using a summer treatment program.
62141491|NCT05519852|EXPERIMENTAL|Pilates group|this pilates group (20 patients) will be trained 30 minutes of pilates (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
62141492|NCT05519852|NO_INTERVENTION|control group|The patients will not receive training (20 patients)
62343710|NCT03903744|EXPERIMENTAL|Treatment arm|Patients treated with cardioneuroablation.
62700425|NCT05478876|EXPERIMENTAL|carbon ion radiotherapy|Patients affected by pelvic recurrence of gynecological cancer, who had not undergone to previous pelvic irradiation, will be enrolled on this study. After enrollment, patients undergo baseline exams, simulation CT and MRI and then carbon ion radiation therapy treatment will be performed, according to trial indications.
61953076|NCT02834260|EXPERIMENTAL|ozurdex group|Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.
61953077|NCT04802317||Control|Health people without any respiratory diseases
61953078|NCT04802317||Bronchial asthma|Patients with asthma
61953079|NCT04802317||COPD|Patients with chronic obstructive pulmonary disease
62141493|NCT05850793|EXPERIMENTAL|Sensorimotor Exercise Training|Sensorimotor exercise content has been prepared based on previous sensorimotor, balance and proprioceptive studies in the literature. It is organized as a structured traditional exercise program + SM training content.
62141494|NCT05850793|EXPERIMENTAL|Progressive Motor Imagery Training|In order to sequentially activate the cortical motor networks and improve cortical organization, a literature-supported program including the components of AMI training (first stage laterality training, second stage motor imagery and third stage mirror therapy) was prepared and a six-week structured exercise program suitable for knee joint treatment + AMI training was prepared.
62141495|NCT05850793|ACTIVE_COMPARATOR|Conventional Exercise Training|A 6-week program was prepared from traditional treatment exercises based on previous studies in knee osteoarthritis. It consists of progressive muscle strengthening of Quadriceps, Hamstrings and gluteals and also stretching exercises.
62141496|NCT00399685|ACTIVE_COMPARATOR|A|
62501292|NCT02102932|EXPERIMENTAL|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
62700426|NCT01442610|EXPERIMENTAL|Rasagiline|Effect of Rasagiline on sleep parameters in PD Patients
62141497|NCT00399685|ACTIVE_COMPARATOR|B|
62141498|NCT00399685|ACTIVE_COMPARATOR|C|
62141499|NCT00399685|ACTIVE_COMPARATOR|D|
62141500|NCT06466616|EXPERIMENTAL|Real Stretching|This group is going to realize 3 sessions of ESWT plus an 8 weeks stretching program.
62141501|NCT06466616|PLACEBO_COMPARATOR|Placebo Stretching|This group is going to realize 3 sessions of ESWT plus an 8 weeks placebo stretching program.
62141502|NCT02873533|OTHER|A-Elderly patients with cancer|geriatric care and longitudinal follow up
62141503|NCT01488656|PLACEBO_COMPARATOR|Placebo dietary supplements|Visually identical inactive dietary supplement pack
62141504|NCT01488656|EXPERIMENTAL|Active dietary supplements|Combination of antioxidants, minerals, fish oil, proflavanol and vitamin D
62141505|NCT03473717|ACTIVE_COMPARATOR|classic method group|IUD/IUS insertion will be done using the conventional method
62141506|NCT03473717|ACTIVE_COMPARATOR|direct method group|IUD/IUS insertion will be done using the direct method
62700427|NCT01442610|PLACEBO_COMPARATOR|Placebo|Effect of placebo on sleep parameters in PD Patients
62141507|NCT02821299|EXPERIMENTAL|Laryngeal transplantation|Laryngeal transplantation
62141508|NCT01565187||hand transplant candidates|Participants enrolled will be asked to complete behavioral questionnaires.
62700428|NCT05781451|EXPERIMENTAL|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
61953080|NCT04044378|EXPERIMENTAL|Arm A: famitinib and camrelizumab|"In the dose-defining phase I portion, camrelizumab was given at a fixed dose of 200mg Q2W, while the de-escalated 3+3 design was used to detect the recommended dose of famitinib from an initial level of 15mg orally taken daily. Recommended phase 2 dose (RP2D) was defined as the highest dose at which no more than 30% patients experience a DLT in the first two courses.~In the phase II portion, famitinib will be orally taken daily with RP2D together with camrelizumab intravenous infusion at a dose of 200 mg over 30 minutes, once every two weeks (Q2W), 4 weeks (28 days) as one treatment cycle."
61953081|NCT04044378|ACTIVE_COMPARATOR|Arm B: famitinib alone|Only phase II portion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle.
61953082|NCT04044378|EXPERIMENTAL|Arm C: Famitinib and Ifofamide|Only phase II protion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle together with ifofamide 1800 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 and 15-17 of each 28-day cycle for a total of 5 cycles.
62141509|NCT06352905|EXPERIMENTAL|WBV Intervention|Participants will complete testing on the 3 meter backward test (3MBWT) for 3 trials (pretest). Participants will perform mid-squats on a whole body vibration (WBV) platform. The participant will complete the WBV with the platform next to a wall so they can use the wall for balance if needed. Additionally, supervision or hand held assist will be provided if needed for balance by a licensed physical therapist. After the completion of the WBV session, the participant will complete testing 3MBWT for 3 trials (posttest). All participants will have a gait belt donned the entire time and be closely guarded during every test by a licensed physical therapist. At any point the participant appears unsafe to continue, the protocol will stop immediately. Participants will be given the option to stop and rest when needed.
62343711|NCT03903744|ACTIVE_COMPARATOR|Control arm|Patients treated with standard non-pharmacological methods.
62343712|NCT00383214|ACTIVE_COMPARATOR|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
62343713|NCT00383214|PLACEBO_COMPARATOR|Placebo|Intravenous
62343714|NCT02907320|EXPERIMENTAL|CYCLO 3 ® FORT and placebo MPFF|MPFF = Micronized Purified Flavonoid Fraction
62343715|NCT02907320|ACTIVE_COMPARATOR|MPFF and placebo CYCLO 3 ® FORT|MPFF = Micronized Purified Flavonoid Fraction
62700429|NCT03416894|EXPERIMENTAL|Deep Brain Stimulation|
62700430|NCT05923723|EXPERIMENTAL|Dietary intervention|
62700431|NCT05923723|PLACEBO_COMPARATOR|Placebo|
61953083|NCT04394117|ACTIVE_COMPARATOR|Standard Care + Angiotensin Receptor Blocker (ARB)|Participants will receive an Angiotensin Receptor Blocker on top of the standard care provided by their institution.
62700432|NCT02006511|EXPERIMENTAL|Incisional Neg Pressure Wound Therapy|Incisional negative pressure wound therapy dressings applied to the surgical site
61953084|NCT04394117|PLACEBO_COMPARATOR|Standard Care + Placebo|Participants will receive a placebo on top of the standard care provided by their institution.
61953085|NCT03540173||Training Cohort|In the training cohort, we evaluated the impact of patient-related factors on the pain during the colonoscopy. In univariatelogistic regression analysis, All factors associated with the pain during colonoscopy (p\<0.1) were included in multivariate analysis.
62501293|NCT05275049|EXPERIMENTAL|PT+ Device|PT plus translingual stimulation device PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
61953086|NCT03540173||Validation group|The validation cohort was used to verify the intubation discomfort score.
62141510|NCT06352905|ACTIVE_COMPARATOR|Control group|Participants will complete testing on the 3 meter backward test (3MBWT) for 3 trials (pretest). Participants will perform 5 sets of 60 seconds of mid-squats on level ground. There will be a 1 minute rest in between each set. The participant will complete the mid-squats next to a wall so they can use the wall for balance if needed. Additionally, supervision or hand held assist will be provided if needed for balance by a licensed physical therapist. After the completion of the the mid-squats, the participant will complete testing 3MBWT for 3 trials (posttest). All participants will have a gait belt donned the entire time and be closely guarded during every test by a licensed physical therapist. At any point the participant appears unsafe to continue, the protocol will stop immediately. Participants will be given the option to stop and rest when needed.
62141511|NCT05866536|EXPERIMENTAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
62141512|NCT05866536|PLACEBO_COMPARATOR|Saline Injection|2 placebo injections spaced 4 weeks apart at the beginning of the trial
62141513|NCT00989742|ACTIVE_COMPARATOR|Doxycycline|
62141514|NCT00989742|PLACEBO_COMPARATOR|Placebo|
62141515|NCT05671484|ACTIVE_COMPARATOR|Transversalis Fascial Plane Block Group|Patients will receive ultrasound-guided transversalis fascial plane block
62141516|NCT05671484|ACTIVE_COMPARATOR|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block
62141517|NCT00794300||Acute myocardial infarction patients|
62141518|NCT02605174|EXPERIMENTAL|Lasmiditan 50 milligram (mg)|Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
62141519|NCT02605174|EXPERIMENTAL|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
62141520|NCT02605174|EXPERIMENTAL|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
62141521|NCT02605174|PLACEBO_COMPARATOR|Placebo|Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
62141522|NCT02061124|ACTIVE_COMPARATOR|T2DM, sevelamer|Patients with type 2 diabetes treated with sevelamer
62141523|NCT02061124|PLACEBO_COMPARATOR|T2DM, placebo|Patients with type 2 diabetes treated with placebo
62141524|NCT02061124|ACTIVE_COMPARATOR|Healthy subjects, sevelamer|Healthy subjects treated with sevelamer
62141525|NCT02061124|PLACEBO_COMPARATOR|Healthy subjects, placebo|Healthy subjects treated with placebo
62141526|NCT04535999|EXPERIMENTAL|Open Label|Secukinumab
62141527|NCT00385606|ACTIVE_COMPARATOR|cisplatino plus gemcitabine|Gemcitabina 1200 mg/m2 infusion of 30 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks for 6 cycles.
61953087|NCT01939808|OTHER|Wrist splinted in extended position|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
61953088|NCT01939808|OTHER|Wrist Splinted in the Neutral postion|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
61953089|NCT05210335|NO_INTERVENTION|Observational part|This part covers the list for comprehensive medication use at admission, medication reconciliation and medication review at preoperative surgical ward, postoperative intensive care, postoperative surgical ward and discharge made by clinical pharmacist. The identification and classification of drug related problems was made at each ward according to PCNE classification system. The expert panel (2 surgeon, 2 nurse, 1 pharmacist) scored all the drug related problems as a part of the risk analysis model development. Patients quality of life, nutritional status, cognitive functions and frailty status also recorder at admission, discharge and 1 month after surgery.
62141528|NCT00385606|EXPERIMENTAL|cisplatino plus gemcitabine plus rofecoxib|Gemcitabina 1200 mg/m2 infusion of 30 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks + rofecoxib 50 mg/die per os until progression of disease.
62141529|NCT00385606|EXPERIMENTAL|cisplatino plus gemcitabine 10 mg/m2/min|Gemcitabina 1200 mg/m2 infusion of 120 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks for 6 cycles.
62141530|NCT00385606|EXPERIMENTAL|cisplatino plus gemcitabine 10 mg/m2/min plus rofecoxib|Gemcitabina 1200 mg/m2 infusion of 120 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks + rofecoxib 50 mg/die per os until progression of disease.
62343716|NCT02907320|PLACEBO_COMPARATOR|placebo|MPFF = Micronized Purified Flavonoid Fraction
62343717|NCT05334719||Cohort 1|Participants with previously untreated advanced/recurrent gastric cancer (GC)
62343718|NCT04470492|EXPERIMENTAL|Experiment|
62343719|NCT04470492|OTHER|Control|
62343720|NCT00736866|EXPERIMENTAL|Acetylcysteine|
62343721|NCT00736866|PLACEBO_COMPARATOR|Control|
62343722|NCT00743457||VPS Patients|Children 6 months-18 years with VPS and symptoms of possible shunt failure
62501294|NCT05275049|ACTIVE_COMPARATOR|PT + Control Device|PT plus translingual stimulation control device Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
62700433|NCT02006511|ACTIVE_COMPARATOR|Standard of care wound dressing|Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site
62501295|NCT01922960|OTHER|micro-imaging|"Sublingual or subconjunctival micro-imaging of the microcirculation taken for 3 minute intervals at certain timepoints.~Timepoints for burn/trauma subjects: Day0, Day1,Day2,Day6 \& Day7 Timepoints for general surgery population: post-induction, prior to resection, after resection,\& closing of surgical wound."
62501296|NCT01619956|EXPERIMENTAL|OSFE with grafting|OSFE with grafting (autogenous bone chips+xenograft material with a ratio of 1:4)
61953090|NCT05210335|EXPERIMENTAL|Interventional part|This part covers the list for comprehensive medication use at admission, medication reconciliation and medication review at preoperative surgical ward, postoperative intensive care, postoperative surgical ward and discharge made by clinical pharmacist. Clinical pharmacist made recommendation about drug related problems regarding solutions, record intervention type and problem status differently from observational part. As a component of the risk analysis model the affect of clinical pharmacist was shown clearly. Patients quality of life, nutritional status, cognitive functions and frailty status also recorder at admission, discharge and 1 month after surgery.
61953091|NCT03680560|EXPERIMENTAL|ACTR T cell product in combination with trastuzumab|
61953092|NCT01509092|NO_INTERVENTION|obervation|patients in this arm received 6-months observation alone after injury
61953093|NCT01509092|ACTIVE_COMPARATOR|Surgical intervention|patients in this arm received vitrectomy surgery as soon as possible after injury
61953094|NCT01697488||Cohort|Overall sample
62501297|NCT01619956|ACTIVE_COMPARATOR|OSFE without grafting|OSFE without grafting. No grafting materials or autogenous bone chips were used.
61953095|NCT01697488||Subgroup|Patients aged \>/= 70 years
62501298|NCT01592552||Neurological Condition|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
62501299|NCT01592552||Control|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
62501300|NCT04439760|NO_INTERVENTION|control study.|No intervention
62501301|NCT04439760|ACTIVE_COMPARATOR|superior cervical block.|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
62501302|NCT04178382|EXPERIMENTAL|experiment group|Combined detection of PCR and CRISPR/Cas12a in alveolar lavage fluid to guide early target adjustment of antibiotics
62501303|NCT04178382|NO_INTERVENTION|control group|Guide the target adjustment of antibiotics according to traditional microbiological detection methods
62501304|NCT05058768||control group|Healthy people served as the control group
61953096|NCT00702923|EXPERIMENTAL|1|Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
61953097|NCT05086848|EXPERIMENTAL|Treatment group:|Irinotecan liposome plus 5-fluorouracil, Leucovorin
61953098|NCT03795623|SHAM_COMPARATOR|Conventional arm|Muted audio recordings of the patients relatives.
61953099|NCT03795623|EXPERIMENTAL|Voice-Weaning arm|Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
62501305|NCT05058768||experimental group|Patients with acute lung injury were treated as the experimental group.
62501306|NCT02870439|EXPERIMENTAL|patients with at least 20% of wounded burns body|
62501307|NCT02870439|EXPERIMENTAL|patients with at least 5% of wounded burns body|
62501308|NCT02870439|EXPERIMENTAL|patients with post-surgical wounds with skin resection|
62501309|NCT00243152|ACTIVE_COMPARATOR|Lamotrigine to Placebo Crossover|The drug lamotrigine will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
62700434|NCT00520338|PLACEBO_COMPARATOR|2|"1. placebo~2. celecoxib"
62700435|NCT00520338|NO_INTERVENTION|1|1 placebo
62700436|NCT03172767||Preterm Preschoolers|Preterm children who haven't attend school.
61953100|NCT03616626|ACTIVE_COMPARATOR|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
61953101|NCT03616626|EXPERIMENTAL|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
61953102|NCT03616626|EXPERIMENTAL|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
61953103|NCT04532047|EXPERIMENTAL|Experimental: in utero enzyme replacement therapy|ERT will be delivered in utero. Typically, the target of the procedure to administer in utero ERT will be the umbilical vein near the insertion of the umbilical cord into the placenta. The dose of the ERT will be dependent on the specific disease process and enzyme being replaced, and the estimated weight of the fetus. The dosage will be the same as the recommended weight-based postnatal dosing, adjusted for estimated fetal weight. IUERT will be repeated every 2-4 weeks, which is an interval consistent with the standard of care for IUTs (every 2-4 weeks) to avoid excessive access through the umbilical vein. This interval is also consistent with the half-life of each relevant enzyme.
62700437|NCT03172767||Term Preschoolers|Term children who haven't attend school.
61953104|NCT03892070|EXPERIMENTAL|HMB GROUP|HMB Supplementation with 1.5 g of HMB taken twice daily. Supplementation will be provided for 12 weeks
62700438|NCT04389060|ACTIVE_COMPARATOR|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing
61953105|NCT03892070|PLACEBO_COMPARATOR|PLACEBO GROUP|Mannitol 1.5 g twice daily. Supplementation will be provided for 12 weeks
61953106|NCT02476383|ACTIVE_COMPARATOR|augmented spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner interacting in a warm and friendly way who is free to respond to participant conversation. Participants in this group will receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
61953107|NCT02476383|ACTIVE_COMPARATOR|neutral spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner engaging in minimal interaction. Participants in this group will not receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
61953108|NCT00549081|EXPERIMENTAL|1|IVF patients who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
61953109|NCT00549081|NO_INTERVENTION|2|IVF patient who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
61953110|NCT03609905|EXPERIMENTAL|Intervention group|interventions: The MSCs of 5×10\*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week，a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
61953111|NCT03609905|OTHER|Control group|interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
61953112|NCT06043531|EXPERIMENTAL|EVOO supplementation|50g/day, dietary supplementation Extra Virgin Olive Oil (EVOO)
61953113|NCT06043531|NO_INTERVENTION|Standard of Care|Standard of care control
61953114|NCT00524862|OTHER|1|
61953115|NCT00524862|OTHER|2|
61953116|NCT05140915|EXPERIMENTAL|Intervention|Students in school randomized to the intervention will receive: (1) peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit; (2) peer coaching, facilitated by texting; and (3) gamification, designed to motivate participation.
61953117|NCT05140915|ACTIVE_COMPARATOR|Control|Students in schools randomized to the control condition will be provided written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
61953118|NCT01918436|EXPERIMENTAL|TEAMS intervention|"Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program.~The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups.~In the child group, the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development."
61953119|NCT01918436|ACTIVE_COMPARATOR|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
62141531|NCT05461235|EXPERIMENTAL|Anti-PD-1 antibody combined with autologous DC and NK cells|"Anti-PD-1 antibodies (one of six options)~1. Pembrolizumab: 2 mg/kg or 200 mg by intravenous infusion every 3 weeks~2. Nivolumab:3 mg/kg or 240 mg by intravenous infusion every 2 weeks~3. Sintilimab: 200 mg by intravenous infusion every 3 weeks~4. Toripalimab: 3 mg/kg or 240 mg by intravenous infusion every 2 weeks~5. Camrelizumab: 200 mg by intravenous infusion every 2 or 3 weeks, or 3 mg/kg by intravenous infusion every 3 weeks~6. Tislelilzumab: 200mg by intravenous infusion every 3 weeks. DC, NK cells. 50ml of peripheral blood is collected 1 day before the dosing cycle for in vitro isolation and expansion of DC and NK cells; the first infusion of DC and NK cells (not less than 1x10\^6 cells/Kg) is completed on day 14."
62141532|NCT03842605|EXPERIMENTAL|Strength training|
62141533|NCT03989388|EXPERIMENTAL|Intervention Group|Occupational Self-Analysis Programme
62141534|NCT03989388|ACTIVE_COMPARATOR|Control group|Vocational guidance or usual rehabilitation (in the case of ABI participants)
62141535|NCT06322121||Dementia patients|Patients with a dementia diagnosis; probable Alzheimer or mixed-type dementia
62141536|NCT06322121||MCI patients|Patients with a MCI diagnosis; patients demonstrating cognitive deficits on neuropsychological testing but not fulfilling the criteria for dementia.
62141537|NCT06322121||SCI patients|Patients not demonstrating cognitive deficits on neuropsychological testing are classified as SCI
62141538|NCT06322121||Controls|Control subject without cognitive complaints
62700439|NCT04389060|PLACEBO_COMPARATOR|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 2 hours prior to testing
62141539|NCT05464498|EXPERIMENTAL|MD-Tissue Medical Device|Group A which, alongside physiotherapy (eccentric strengthening protocol) will receive MD-Tissue Collagen Medical Device.
62141540|NCT05464498|OTHER|Eccentric strengthening protocol|Group B who will only perform physiotherapy (eccentric strengthening protocol).
62141541|NCT01074242||Rotateq|Korean Infants vaccinated with Rotateq in usual practice. The Rotateq vaccination series consists of 3 ready-to-use liquid (oral) doses with the first dose to be administered at age 6-12 weeks and subsequent doses to be administered at 4 to 10-week intervals.
62700440|NCT00916916||Lanreotide|Patients taking lanreotide for the treatment of acromegaly.
62700441|NCT00571714|ACTIVE_COMPARATOR|1 Standard Peginterferon alpha-2a plus Rivavirin Therapy|Peginterferon alpha-2a once a week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
62700442|NCT00571714|ACTIVE_COMPARATOR|2 Peginterferon alpha-2a plus Rivavirin Therapy with Betaine for First 12 Weeks|Peginterferon alpha-2a once a week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
62700443|NCT03723473||PAOD patients statin (+)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) and statin treatment.~They will have Magnetic Resonance Imaging (MRI; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
61953120|NCT05792709|EXPERIMENTAL|Oral Motor Therapy|These are exercises designed to increase the range of movement in tongue, lips, and jaw, which helped in speech and/or swallow functioning. It is important to move the designated area as far as can in each direction until feel the muscles stretch. Stop if feel any pain, and mention it to speech therapist or doctor. Practice these exercises, once through, 10 times a day.
61953121|NCT05792709|OTHER|Traditional Therapy|weeks traditional Speech Therapy was provided. Pre-language skills (vocalizations) manual sign languages, gestures, picture communication boards, voice output communication devices were used. Playing and talking, using pictures, books, objects, or ongoing events to help language development. Use of repetition exercises to build speech and language skills.
61953122|NCT02053051|EXPERIMENTAL|Phase 4: Intervention (ABC4D)|Advanced Bolus Calculator for Type Diabetes (ABC4D)
61953123|NCT02053051|ACTIVE_COMPARATOR|Phase 4 Control: Standard bolus calculator|Standard bolus calculator
62501310|NCT00243152|ACTIVE_COMPARATOR|Placebo to Lamotrigine Crossover|The placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, the drug lamotrigine (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
62501311|NCT03247699|OTHER|"Basel phenotyping cocktail capsule"|
62343723|NCT01608724|EXPERIMENTAL|Open label|Saxagliptin, oral 5mg once a day(Q. D.)
62343724|NCT01415856|PLACEBO_COMPARATOR|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
62501312|NCT03247699|OTHER|"Basel phenotyping cocktail individual components"|
62501313|NCT00776568|ACTIVE_COMPARATOR|2|
62501314|NCT00776568|EXPERIMENTAL|1|
61953124|NCT04257734||optic neuritis|Aquaporin 4 antibody seropositive optic neuritis patients, Myelin oligodendrocyte glycoprotein antibody seropositive optic neuritis patients, and double antibodies seronegative optic neuritis patients
61953125|NCT06057844|OTHER|Non applicable|
61953126|NCT02352974|EXPERIMENTAL|GAD-Alum+Vitamin D|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
61953127|NCT02044393|EXPERIMENTAL|Reference|single dose BI 691751
61953128|NCT02044393|EXPERIMENTAL|Test|multiple doses of itraconazole + single dose BI 691751
62141542|NCT04011930|ACTIVE_COMPARATOR|Experimental study|"vitamin D Generic name -cholecalciferol (40,000IU)Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks.~Drug cholecalciferol- ingredients -cholecalciferol (40,000 IU) Microcrystalline cellulose(58.1 gm),hydroxy toluene (.2mg),magnesium stearate(3mg0,gelatin capsule shell(1mg)~other name D-rise"
62501315|NCT01309724|NO_INTERVENTION|Control|No measurements are made on the control group.
62501316|NCT01309724|EXPERIMENTAL|USCOM|Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
62501317|NCT04445701|EXPERIMENTAL|AO-176 Dose Escalation Monotherapy|The dose escalation monotherapy cohorts will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
62501318|NCT04445701|EXPERIMENTAL|AO-176 + DEX Expansion Cohort|Once the monotherapy RP2D has been established, an expansion cohort of AO-176 + dexamethasone will be enrolled.
62501319|NCT04445701|EXPERIMENTAL|AO-176 + DEX + BORT Dose Escalation|Following evaluation of AO-176 + dexamethasone, dose escalation cohorts of AO-176 + dexamethasone + bortezomib will be enrolled. Each dose escalation cohort will initially recruit 3 patients in a standard 3+3 design; cohorts will be expanded in the event of a DLT. The Phase 2 portion of the study will further evaluate the RP2D of AO-176 + DEX + BORT.
62343725|NCT01415856|ACTIVE_COMPARATOR|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
62343726|NCT02130258|OTHER|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
62343727|NCT02130258|OTHER|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
62343728|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
62343729|NCT02252692|ACTIVE_COMPARATOR|Enalapril|Renitec® 2 x 5 mg tablets administered at once, to be entirely swallowed with 240 ml water
62343730|NCT02252692|EXPERIMENTAL|Enalapril ODMT|10 x 1mg of Enalapril ODMT, swallowed entirely with 240ml of water
62501320|NCT05568173|EXPERIMENTAL|Boxing Training|In the Boxing Training Group (BG) boxing training will be given. Additionally, stretching exercises and postural training will be applied.
62501321|NCT05568173|EXPERIMENTAL|Scapular Stabilization|In the Scapular Stabilization Group (SSG) scapular stabilization training will be given. Additionally, stretching exercises and postural training will be applied.
62501322|NCT05568173|NO_INTERVENTION|Control|Individuals in this group will not receive any treatment. Evaluations will be made before treatment and after 8 weeks of treatment.
62501323|NCT06186219|EXPERIMENTAL|Rituximab|Rituximab 1000 mg will be administered at week -6 and week -4 via intravenous infusion over the duration of 5 hours prior to the Pegloticase (Standard-of-Care) treatment.
61953129|NCT02450591|EXPERIMENTAL|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression \[partial response (PR) or stable disease (SD)\] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
61953130|NCT04342884||Clients of Wake Forest Baptist Health (WFBH)|
61953131|NCT04342884||Health care workers of Wake Forest Baptist Health (WFBH)|
62700444|NCT03723473||PAOD patients statin (-)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) without statin treatment .~They will have Magnetic Resonance Imaging (MRI ; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
61953132|NCT01041833|EXPERIMENTAL|atRA group|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
61953133|NCT01041833|PLACEBO_COMPARATOR|Placebo Group|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
61953134|NCT06342752||Preterm infants|all included infants will undergo a breath test and two throat swabs, in case the infant is intubated also endotracheal aspirates will be collected
61953135|NCT06342752||Mothers of preterm infants|placental biopsies, a placental swab and a vaginal swab will be taken after birth
61953136|NCT01890941|EXPERIMENTAL|KCT-0809 Lower Dose|
62343731|NCT02252692|EXPERIMENTAL|Enalapril ODMT dispersed|10 x 1mg of Enalapril ODMT, dispersed on tongue
62343732|NCT02363270|ACTIVE_COMPARATOR|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
62343733|NCT02363270|ACTIVE_COMPARATOR|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
62343734|NCT01551134|ACTIVE_COMPARATOR|Open fundoplication|Fundoplication performed with open surgery
62343735|NCT01551134|EXPERIMENTAL|Lap fundoplication|Primary fundoplication performed by laparoscopic surgery
62343736|NCT03974113|EXPERIMENTAL|Fitusiran|Participants will receive a selected dose of fitusiran at regular intervals, as per study protocol
62343737|NCT03963934|EXPERIMENTAL|Women with uncontrolled hypertension|Women with uncontrolled hypertension and unsatisfactory medication adherence
62343738|NCT02024191|EXPERIMENTAL|Glutamine|The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
62343739|NCT02024191|NO_INTERVENTION|Observation|The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
61953137|NCT01890941|EXPERIMENTAL|KCT-0809 Higher Dose|
62343740|NCT04621006||UC group|Patients with active ulcerative colitis
62343741|NCT01724983|EXPERIMENTAL|ketamine|patients will receive ketamine at induction
62700445|NCT05586295|PLACEBO_COMPARATOR|Placebo|
61953138|NCT01890941|PLACEBO_COMPARATOR|Placebo|
61953139|NCT01823978|EXPERIMENTAL|BPX-201|BPX-201 vaccine plus AP1903
61953140|NCT05536583|EXPERIMENTAL|PCOS group|Obese Patients with PCOS underwent LSG
61953141|NCT05536583|ACTIVE_COMPARATOR|Control group|Sample obese patients without PCOS underwent LSG
61953142|NCT06284031|EXPERIMENTAL|3 fractions|
61953143|NCT01878279||HIV negative|
61953144|NCT01878279||HIV positive|HIV positive children in care
61953145|NCT00679432|EXPERIMENTAL|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
61953146|NCT00679432|EXPERIMENTAL|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
61953147|NCT00679432|PLACEBO_COMPARATOR|3: Placebo|Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
62700446|NCT05586295|EXPERIMENTAL|EX plus|
62343742|NCT01724983|ACTIVE_COMPARATOR|fentanyl|patients will receive fentanyl at induction
62343743|NCT01549743|EXPERIMENTAL|Celecoxib|
62343744|NCT01549743|EXPERIMENTAL|Rebamipide|
62700447|NCT05770973|ACTIVE_COMPARATOR|Compression dressing|Randomized, eyes were patched with a compression dressing after surgery.
62343745|NCT01549743|EXPERIMENTAL|Celecoxib plus Rebamipide|
62343746|NCT02051725|EXPERIMENTAL|Active life-style intervention|"The active life-style intervention is designed as 12-week structured and progressive heavy-resistance power training combined with recommended everyday physical activity."
62343747|NCT02051725|NO_INTERVENTION|Control|The control group is offered to enroll in the same active life-style intervention after the end of the 12-week control period. During the control period this group is asked to maintain the habitual life style.
62501324|NCT02666417|ACTIVE_COMPARATOR|MNP+iron and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as FeFum and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
62700448|NCT05770973|NO_INTERVENTION|No Compression dressing|Randomized, eyes were not patched with a dressing.
61953148|NCT00679432|ACTIVE_COMPARATOR|4: Asacol® 400 mg|Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
61953149|NCT01940601|EXPERIMENTAL|Balugrastim 300 ug/kg|Balugrastim 300 μg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
61953150|NCT01940601|EXPERIMENTAL|Balugrastim 670 μg/kg|Balugrastim 670 μg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
61953151|NCT01940601|ACTIVE_COMPARATOR|Filgrastim 5 μg/kg|Filgrastim will be administered at a dose of 5 μg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to ≥2\*10\^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle.
61953152|NCT03857958|EXPERIMENTAL|FCSEMS|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In FCSEMS group, patients are inserted with Fully covered self-expandable metal stent (FCSEMS) bilaterally for malignant hilar biliary stricture via endoscopic retrograde cholangio-pancreatography.
61953153|NCT03857958|ACTIVE_COMPARATOR|Plastic stent|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In plastic stent group, patients are inserted with plastic stents bilaterally for malignant hilar biliary stricture.
61953154|NCT03493607|EXPERIMENTAL|AMO-01|Intravenous Infusion
62700449|NCT01358734|EXPERIMENTAL|Lenalidomide in combination with azacitidine|Repeated cycles of azacitidine 75 mg/m\^2/day subcutaneous (SC) on Days 1-7 and lenalidomide 50 mg/day by mouth (PO) on Days 8-28 followed by a 14-day break plus best supportive care
62700450|NCT01358734|EXPERIMENTAL|Lenalidomide - single agent|Lenalidomide 50 mg PO daily for 28 days for the first 2 cycles and lenalidomide 25 mg daily for 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg daily PO plus best supportive care
61953155|NCT04431453|EXPERIMENTAL|Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg|Participants will receive RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion, daily, up to 10 days.
61953156|NCT04431453|EXPERIMENTAL|RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
61953157|NCT04431453|EXPERIMENTAL|RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
61953158|NCT04431453|EXPERIMENTAL|RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
61953159|NCT04431453|EXPERIMENTAL|RDV, Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
61953160|NCT04431453|EXPERIMENTAL|RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg|Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.
61953161|NCT04431453|EXPERIMENTAL|RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg|Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.
62141543|NCT04011930|PLACEBO_COMPARATOR|Experimental control|"Placebo oral capsule Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks~placebo oral capsule-ingredients-microcrystalline cellulose,butylated hydroxy toluene~,magnesium stearate~other name D-rise"
62141544|NCT03068988|EXPERIMENTAL|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
62343748|NCT02586987|EXPERIMENTAL|Dose escalation: Selumetinib+MEDI4736|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).~The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort."
62343749|NCT02586987|EXPERIMENTAL|Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736|One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type will be determined from emerging data.
62141545|NCT03068988|PLACEBO_COMPARATOR|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
62141546|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
62343750|NCT02586987|EXPERIMENTAL|Dose escalation: Selumetinib+MEDI4736+tremelimumab|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab.~For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging data from dose escalation cohorts of double combination treatment."
62343751|NCT02586987|EXPERIMENTAL|Mandatory paired biopsy expansion cohort: triple combination|One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type will be determined from emerging data.
62700451|NCT01358734|EXPERIMENTAL|Azacitidine-single agent|Repeated cycles of azacitidine 75mg/m\^2/day subcutaneous on Days 1-7 followed by a 21-day break plus best supportive care
62343752|NCT02769806||GBM patients undergoing MRI|GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.
62141547|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
62501325|NCT02666417|ACTIVE_COMPARATOR|MNP+iron+GOS and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
62501326|NCT04631380|NO_INTERVENTION|CONTROL|THIS GROUP WILL RECEIVE THE PROTCOLL TREATMENT GIVEN TO PATIENTS COVID -POSITIVE TESTED.
62501327|NCT04631380|EXPERIMENTAL|PRAYER|THIS GROUP WILL RECEIVE THE SAME TREATMENT GIVEN TO THE CONTROL GROUP, PLUS PRAYERS BY THEOLOGIANS WHOSE PRAYERS INTERCEDE IN FAVOR OF THEIR PROMPT RECOVERY
62501328|NCT05157035|EXPERIMENTAL|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
62501329|NCT05157035|NO_INTERVENTION|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
62501330|NCT02992457|ACTIVE_COMPARATOR|Sof-Riba|Sofosbuvir ribavirin 6 months.
62501331|NCT02992457|ACTIVE_COMPARATOR|Sof- Riba- Pegylated interferon|Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months
62501332|NCT02992457|ACTIVE_COMPARATOR|Sof- Olysio|Sofosbuvir and simeprevir for 3 months.
62501333|NCT02992457|ACTIVE_COMPARATOR|Sof- Dacla|Sofosbuvir and Daclatasvir for 3 months.
62501334|NCT02992457|ACTIVE_COMPARATOR|Harvony|Sofosbuvir and ledipasvir for 3 months
62501335|NCT02992457|ACTIVE_COMPARATOR|Ritaprevir, paritaprevir, ombetasvir|Querevo for 3 months
62501336|NCT02992457|ACTIVE_COMPARATOR|Salvage therapy|sofosbuvir, daclatasvir, simeprevir,ribavirin or sofosbuvir and querevo
62343753|NCT03162497|EXPERIMENTAL|Azithromycin|Preservative-free azithromycin 15mg/g (Azyter® Augentropfen im Einzeldosisbehältnis, Thea, Clermont-Ferrand, France) one drop twice daily for two days then once daily for 26 days
62343754|NCT03162497|ACTIVE_COMPARATOR|Doxycycline|"Doxycycline 100mg (Doxycycline Genericon, Genericon Pharma GmbH, Graz, Austria) twice daily for 6 weeks"
62501337|NCT01273480|EXPERIMENTAL|002|Sequence 2 Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
62501338|NCT01273480|EXPERIMENTAL|001|Sequence 1 Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
62501339|NCT04347096|EXPERIMENTAL|mHealth Intervention|The mHealth intervention group will have access to the Internet for using a newly developed Simple health web app and receive an activity tracker. The web app users are required to: (1) wear an activity tracker every day; (2) set goals of daily stand-up, physical activity, and healthy eating bi-weekly; (3) record stand-up, physical activity, and healthy eating behaviors daily; (4) set reminders to stand-up and record health behaviors; and (5) read educational and motivational tools. After completing the behavioral record, the personal advice will automatically provide to encourage, motivate and support the user. Moreover, the user will be able to look at his/her personal and team health ranking.
62501340|NCT04347096|OTHER|Control Intervention|The control intervention group will only receive educational tools (usual care).
62501341|NCT06148662|EXPERIMENTAL|No intervention (negative control)|Negative control
62501342|NCT06148662|EXPERIMENTAL|Water (positive control)|Tap water
62343755|NCT06342323||Fiducial marker group|all patient is observed for SBRT treatment error after fiducial marker implantation.
62343756|NCT00796094||Evaluation of tissue elasticity|Evaluate the potential importance of tissue elasticity in the assessment soft tissue structures.
62343757|NCT02862223|EXPERIMENTAL|Neoprinol|
62343758|NCT03850782|EXPERIMENTAL|Bimatoprost SR - Dose A|"Study Eye: Participants will receive 1 - 2 Cycles of Bimatoprost SR administrations of Dose A~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
62501343|NCT06148662|EXPERIMENTAL|"Dental foam Biorepair PERIBIOMA"|"Ingredients:~Aqua, Sorbitol, Xylitol, Zinc Hydroxyapatite, Aroma, Pistacia Lentiscus (Mastic) Gum Oil, Lactobacillus, Bifidobacterium, Sodium Hyaluronate, Ascorbic Acid, Hamamelis Virginiana Leaf Extract, Spirulina Platensis Extract, Calendula Officinalis Flower Extract, Tocopheryl Acetate, Retinyl Palmitate, Eucalyptus Globulus Leaf Oil, PEG-40 Hydrogenated Castor Oil, Phenoxyethanol, Sodium Benzoate, Cocamidopropyl Betaine, Glycerin, Maltodextrin, Sodium Saccharin, Helianthus Annuus Seed Oil, Potassium Sorbate, BHT, Limonene, CI 16255."
61953162|NCT04431453|EXPERIMENTAL|RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg|Participants will receive RDV 200 mg, IV infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.
62343759|NCT03850782|EXPERIMENTAL|Bimatoprost SR - Dose B|"Study Eye: Participants received 1 - 3 Cycles of Bimatoprost SR administrations of Dose B~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
62343760|NCT03268694|EXPERIMENTAL|Cognitive and Emotion Processing Tasks|As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task
62343761|NCT01310816|ACTIVE_COMPARATOR|IPI-926|IPI-926
62343762|NCT01310816|PLACEBO_COMPARATOR|Sugar Pill|Placebo Arm, sugar pill
62343763|NCT04654091|EXPERIMENTAL|Cryoteraphy with liquid nitrogen|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
62343764|NCT04654091|EXPERIMENTAL|Nitric-zinc complex|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
62343765|NCT02170649|EXPERIMENTAL|Single Group|the volunteers received a single 800 mg BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period
62343766|NCT00623467|EXPERIMENTAL|Gadobutrol (Gadavist, BAY86-4875)|Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.
62343767|NCT04876599|EXPERIMENTAL|Intervention (IN FOCUS)|Participants will be randomly assigned and participate in eight weekly virtual group sessions to learn mind-body, cognitive behavioral, and positive psychology skills.
62343768|NCT04876599|ACTIVE_COMPARATOR|Usual Care|Participants will be randomly assigned and receive usual care, which is a referral for virtual group supportive services for cancer survivors provided in the community.
62343769|NCT02763072|EXPERIMENTAL|Enlighten Laser|12 subjects will receive treatment the Enlighten laser.
62343770|NCT02763072|ACTIVE_COMPARATOR|Excel V Laser|12 subjects will receive treatment with the Excel V laser.
62343771|NCT03882255|EXPERIMENTAL|Treatment Period 1: Ponesimod (2 mg)|Participants will receive a single dose ponesimod 2 milligram (mg) oral tablet under fed conditions on Day 1. Participants not fulfilling discontinuation criteria can continue to Treatment Period 2 after a washout period of at least 7 days and a maximum of 14 days.
62343772|NCT03882255|EXPERIMENTAL|Treatment Period 2:Ponesimod, Propranolol, Placebo Propranolol|Participants who do not fulfill any of discontinuation criteria will be randomized to 1 of 2 Treatments (Treatment A or B) on Day 1. Treatment A: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus placebo propranolol once daily from Day 1 to Day 19; Treatment B: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus 80 mg propranolol once daily from Day 1 to Day 19.
62343773|NCT03102359|EXPERIMENTAL|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
62343774|NCT03102359|EXPERIMENTAL|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
62343775|NCT03102359|EXPERIMENTAL|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
62343776|NCT03102359|NO_INTERVENTION|Control|No intervention in this group
62343777|NCT01217190|EXPERIMENTAL|Ondansetron ODFS then Zofran ODT|Single dose of Ondansetron Orally Dissolving Film Strip 8 mg followed by single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg with 7 days washout between the 2 periods
62343778|NCT01217190|EXPERIMENTAL|Zofran ODT then Ondansetron ODFS|Single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg followed by single dose of Ondansetron Orally Dissolving Film Strip 8 mg with 7 days washout between the 2 periods
62343779|NCT06377345|ACTIVE_COMPARATOR|Control group|The control group will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
62343780|NCT06377345|EXPERIMENTAL|Intervention group|The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
62343781|NCT03720730|EXPERIMENTAL|Study participants|Patients with a recent history of suicidal crisis (within the last 7 days) will use a smartphone application to evaluate sleep, appetite and social parameters.
62343782|NCT02417467|EXPERIMENTAL|Nicotine E-Cigarette and Counseling|"As with standard nicotine replacement therapies, participants are expected to self-regulate administration of nicotine e-cigarettes according to their withdrawal symptoms. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
62343783|NCT02417467|OTHER|Non-Nicotine E-Cigarette and Counseling|"Participants are expected to self-regulate administration of e-cigarettes. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
62501344|NCT06148662|EXPERIMENTAL|"Dental foam WATER:DENT"|Aqua, Xylitol, PVP, PEG-40 Hydrogenated Castor Oil, Hippophae Rhamnoides Extract, Chamomilla Recutita Extract, Sodium Benzoate, Sodium Lauryl Sulfate, Aroma, Propylene Glycol, Olaflur, Potassium Sorbate, Sodium Phosphate, Disodium Phosphate, Menthol, Bisabolol, Menthyl Lactate, PPG-26 Buteth-26, Sodium Saccharin, Sodium Methylparaben, Citric Acid, Limonene.
62501345|NCT06148662|EXPERIMENTAL|"Spray BUCCOTHERM"|Aqua (Castéra-Verduzan Thermal Spring water), Alcohol, Xylitol, Glycerin, Camellia sinensis leaf water, Mentha piperita leaf water, Hydrogenated starch hydrolysate, Aqua, Aroma, Limonene, Benzyl alcohol, Dehydroacetic acid.
62141548|NCT05886972||Patients aware about propofol injection induced pain|Patients who will be informed about the possibility of incidence of propofol injection pain
62141549|NCT05886972||Patients not aware about propofol injection induced pain|Patients will not be informed about the possibility of incidence of propofol injection pain
62141550|NCT01105975|EXPERIMENTAL|30 milligram (mg) LY2484595 monotherapy|
62343784|NCT02417467|OTHER|Counseling|Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development.
62343785|NCT01875367|EXPERIMENTAL|Arm A: T-IV + T-SC vial + T-SC device|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
62343786|NCT01875367|EXPERIMENTAL|Arm B: T-IV + T-SC device + T-SC vial|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
62343787|NCT01611129|ACTIVE_COMPARATOR|reading about hearing loss and its management|General self-reading reading about hearing loss and its management This would run for 30 days and the participants have to manage their own time.
62343788|NCT01611129|EXPERIMENTAL|Internet-based counseling|This would involve 4 stages of designated internet sessions and additional tasks which the patients can complete in their own time. This programme should be completed within 30 days.
62343789|NCT05819736||Rivaroxaban|Cancer patients treated with rivaroxaban
62343790|NCT05819736||Apixaban|Cancer patients treated with apixaban
62343791|NCT01797965|EXPERIMENTAL|BIIB019|BIIB019 150 mg subcutaneous (SC) every 4 weeks
62343792|NCT00823940|PLACEBO_COMPARATOR|Cohort A1|Dose escalation: 5 - 100mg and placebo in 4 planned doses
62343793|NCT00823940|PLACEBO_COMPARATOR|Cohort A2|Dose escalation: 100-600mg and placebo in 4 planned doses
62343794|NCT00823940|OTHER|Cohort B1|Glucagon challenge test
62343795|NCT00823940|ACTIVE_COMPARATOR|Cohort B3|Glucagon challenge test + selected dose of GSK1362885
62343796|NCT05915234|EXPERIMENTAL|Order number 1: Ice-Peas-Control|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: crushed ice - frozen peas - control.
62343797|NCT05915234|EXPERIMENTAL|Order number 2: Ice-Control-Peas|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: crushed ice - control - frozen peas.
62343798|NCT05915234|EXPERIMENTAL|Order number 3: Peas-Ice-Control|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: frozen peas - crushed ice - control.
62343799|NCT05915234|EXPERIMENTAL|Order number 4: Peas-Control-Ice|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: frozen peas - control - crushed ice.
62343800|NCT05915234|EXPERIMENTAL|Order number 5: Control-Ice-Peas|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: control - crushed ice - frozen peas.
62343801|NCT05915234|EXPERIMENTAL|Order number 6: Control-Peas-Ice|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: control - frozen peas - crushed ice.
61953163|NCT01216631|ACTIVE_COMPARATOR|IA steroid|Intra-articular injection of steroid (80mg depomedrone)
61953164|NCT01216631|EXPERIMENTAL|IA infliximab|intra-articular injection of 100mg infliximab
61953165|NCT01216631|EXPERIMENTAL|IV infliximab|intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
62141551|NCT01105975|EXPERIMENTAL|100 mg LY2484595 monotherapy|
62141552|NCT01105975|EXPERIMENTAL|500 mg LY2484595 monotherapy|
62141553|NCT01105975|PLACEBO_COMPARATOR|Placebo|
62141554|NCT01105975|ACTIVE_COMPARATOR|20 mg Atorvastatin monotherapy|
62141555|NCT01105975|EXPERIMENTAL|100 mg LY2484595 + 20 mg Atorvastatin|
62141556|NCT01105975|ACTIVE_COMPARATOR|40 mg Simvastatin monotherapy|
62343802|NCT03136133|ACTIVE_COMPARATOR|Active protein drink|Active protein drink
62343803|NCT03136133|PLACEBO_COMPARATOR|Placebo drink|Placebo drink
62343804|NCT02137759|ACTIVE_COMPARATOR|Std RT/TMZ (Cohort 1)|"* Standard radiation therapy~* Standard temozolomide"
62343805|NCT02137759|EXPERIMENTAL|Std RT/TMZ + belinostat (Cohorts 2a, 2b)|"* Standard radiation therapy~* Standard temozolomide~* Belinostat"
62343806|NCT03714906|EXPERIMENTAL|Treatment|Patients randomized to the Treatment arm will be assigned to receive a stellate ganglion block. While in the hospital after surgery, patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
62343807|NCT03714906|NO_INTERVENTION|Control|Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
62501346|NCT05303948|EXPERIMENTAL|Direct laryngoscopy in the ice-pick position|"In this arm, participants are assigned to intubations attempts in weightlessness on a manikin.~The insertion of a 7.0 mm cuffed oro-tracheal tube was performed by using a direct laryngoscope with a Macintosh non-angulated size 3 blade, in a face-to-face or ice-pick position."
62501347|NCT05303948|EXPERIMENTAL|Video-laryngoscopy in free-floating position|"In this arm, participants are assigned to intubations attempts in weightlessness on a manikin.~The insertion of a 7.0 mm cuffed oro-tracheal tube was performed by using a video laryngoscopy in a semi-free-floating position (McGrath model, Covidien™, Medtronic™)."
62501348|NCT01740791|EXPERIMENTAL|Velpatasvir 5 mg (GT 1a)|Participants with genotype (GT) 1a HCV infection will receive velpatasvir 5 mg or placebo once daily for 3 days under fasted conditions.
62501349|NCT01740791|EXPERIMENTAL|Velpatasvir 25 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
62141557|NCT01105975|EXPERIMENTAL|100 mg LY2484595 + 40 mg Simvastatin|
62501350|NCT01740791|EXPERIMENTAL|Velpatasvir 50 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
62501351|NCT01740791|EXPERIMENTAL|Velpatasvir 100 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 100 mg or placebo once daily for 3 days under fasted conditions.
62501352|NCT01740791|EXPERIMENTAL|Velpatasvir 150 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
62501353|NCT01740791|EXPERIMENTAL|Velpatasvir 150 mg (GT 1b)|Participants with GT 1b HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
62501354|NCT01740791|EXPERIMENTAL|Velpatasvir 150 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
62501355|NCT01740791|EXPERIMENTAL|Velpatasvir 25 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
62501356|NCT01740791|EXPERIMENTAL|Velpatasvir 50 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
62501357|NCT01740791|EXPERIMENTAL|Velpatasvir 150 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
62501358|NCT01740791|EXPERIMENTAL|Velpatasvir 150 mg (GT 4)|Participants with GT 4 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
62501359|NCT01740791|EXPERIMENTAL|Velpatasvir up to 400 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir up to 400 mg or placebo once daily for 3 days under fasted conditions.
62501360|NCT00973310|EXPERIMENTAL|Combined Treatment arm|All the patients received oral erlotinib and concurrent radiation therapy
62501361|NCT01122589|EXPERIMENTAL|Motivation Interviewing/CBT|
62501362|NCT01122589|ACTIVE_COMPARATOR|Control|Receive a smoking cessation pamphlet and watch a series of six weekly 30-45 minutes general wellness videos.
62700452|NCT01911260|ACTIVE_COMPARATOR|Growth Deficit+zinc amino acid chelate|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
62141558|NCT01105975|ACTIVE_COMPARATOR|10 mg Rosuvastatin monotherapy|
62343808|NCT02723136|EXPERIMENTAL|Smartphone application|Participants allocated to this arm will receive a smartphone application developed to assist and guide the study of internal medicine and its subspecialties. The application will provide feedback to participants regarding their overall performance in terms of correct answers and the overall time required to solve a clinical vignette.
62343809|NCT02723136|NO_INTERVENTION|Usual care|Students allocated to this arm will not receive any further assistance in studying for this trial's tests.
62700453|NCT01911260|PLACEBO_COMPARATOR|Growth Deficit receiving placebo|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
62141559|NCT01105975|EXPERIMENTAL|100 mg LY2484595 + 10 mg Rosuvastatin|
62141560|NCT05435859|EXPERIMENTAL|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 25-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
62501363|NCT00438659|EXPERIMENTAL|Mometasone|Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.
62343810|NCT05247619|EXPERIMENTAL|Intervention|Tislelizumab + Bevacizumab + Paclitaxel + Cisplatin/Carboplatin
62343811|NCT02513784|EXPERIMENTAL|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
62343812|NCT02513784|NO_INTERVENTION|No intervention|Subjects will be randomized to no intervention for 21 days.
62343813|NCT01062620|EXPERIMENTAL|AXL1717|
62501364|NCT00438659|PLACEBO_COMPARATOR|Placebo|Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm I.
62501365|NCT05289557|ACTIVE_COMPARATOR|Bonjesta|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score \>3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
62501366|NCT05289557|PLACEBO_COMPARATOR|Placebo|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score \>3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
62501367|NCT04381481|EXPERIMENTAL|Control beverage, text snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
62501368|NCT04381481|EXPERIMENTAL|Control beverage, control snack|The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a barcode label (control label) (task 2).
62501369|NCT04381481|EXPERIMENTAL|Control beverage, graphic snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
62501370|NCT04381481|EXPERIMENTAL|Claim 1 beverage, text snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
62501371|NCT04381481|EXPERIMENTAL|Claim 1 beverage, control snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a barcode label (control label) (task 2)."
62501372|NCT04381481|EXPERIMENTAL|Claim 1 beverage, graphic snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
62501373|NCT04381481|EXPERIMENTAL|Claim 2 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
62501374|NCT04381481|EXPERIMENTAL|Claim 2 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a barcode label (control label) (task 2)."
62501375|NCT04381481|EXPERIMENTAL|Claim 2 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
62501376|NCT04381481|EXPERIMENTAL|Claim 3 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
62501377|NCT04381481|EXPERIMENTAL|Claim 3 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a barcode label (control label) (task 2)."
62501378|NCT04381481|EXPERIMENTAL|Claim 3 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
62501379|NCT01872624|ACTIVE_COMPARATOR|Valves plus cells|Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.
62501380|NCT01872624|PLACEBO_COMPARATOR|Valves plus saline|Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.
62700454|NCT01911260|PLACEBO_COMPARATOR|Normal Height receiving placebo|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
62700455|NCT01911260|ACTIVE_COMPARATOR|Normal Height+zinc amino acid chelate|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
62700456|NCT02323048|EXPERIMENTAL|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
62343814|NCT01844622|OTHER|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
62343815|NCT03925961|NO_INTERVENTION|control arm|All subjects in the control arm will receive the current preoperative and post operative instructions.
61953166|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 1|Oral Nutritional Supplement 1
62343816|NCT03925961|EXPERIMENTAL|'education booklet' arm|All subjects in the 'education booklet' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery
62501381|NCT01594034||no treatment|
62501382|NCT04315272|ACTIVE_COMPARATOR|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
62501383|NCT04315272|PLACEBO_COMPARATOR|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
62700457|NCT02323048|EXPERIMENTAL|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
62700458|NCT02323048|EXPERIMENTAL|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
62501384|NCT02773940|EXPERIMENTAL|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during the patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
62141561|NCT04399772|EXPERIMENTAL|Cognitive Functional Therapy+ pathway|Treatment is performed by a CFT trained physiotherapists and a psychologist in the Pain Center. Patients receive max 10 consultations over 3 months. The first two sessions is combined with the physiotherapist and psychologist who investigates potential maintaining factors for pain and disability in the patient's everyday life. Remaining sessions are run by the physiotherapist, and the treatment is individually tailored to the needs of the individual patient, aiming to provide the patient with skills in dealing with his / her own situation via information, reflection, change of movement and training of functions and physical level. The psychologist provide extra support for 2-3 sessions to reinforce the physiotherapist work.The ethical committee made blinding conditional on a possibility of usual care after CFT+ if: the patient does not feel ready to stop treatment AND analgesic treatment is inappropriate OR the social situation is problematic OR significant psychological distress.
62501385|NCT06531850||Benign nodule|"* Pulmonary nodules were detected by imaging and surgically resected.~  * Age 15-75 years old.~    * Surgery or puncture is to be performed for pathological diagnosis. ④ Adequate hematological function and liver and kidney function reserve. ⑤ The sample has no hemolysis, sufficient margin, and the source record is clear and can be checked."
61953167|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 2|Oral Nutritional Supplement 2
61953168|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 3|Oral Nutritional Supplement 3
61953169|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 4|Oral Nutritional Supplement 4
62141562|NCT04399772|ACTIVE_COMPARATOR|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Treatment can be diverse, but based on an individual assessment it consists of a combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects) AND (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs. On average patients in the pain center receives 9-10 sessions."
62141563|NCT01581216|EXPERIMENTAL|10 minute walk|10-minute walk and exercises for the upper limbs with 1 lb-dumbbells
62141564|NCT01581216|EXPERIMENTAL|20 minute walk|20-minute walk and exercises for the upper limbs with 1 lb-dumbbells
62141565|NCT01581216|EXPERIMENTAL|30 minute walk|30-minute walk and exercises for the upper limbs with 1 lb-dumbbells
62141566|NCT05040828|EXPERIMENTAL|Early interventional treatment group|The patients in this group:oral drug therapy from onset of the low pollen stage (August 1st, 2020) to the end of the pollen stage (September 30, 2020). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
62141567|NCT05040828|ACTIVE_COMPARATOR|Post-onset treatment group|The patients in this group: oral drug therapy after the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020.). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
62141568|NCT05040828|ACTIVE_COMPARATOR|Control group|The patients in this group:Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
62141569|NCT01753011||Stress Urinary Incontinence|Stress Urinary Incontinence
62141570|NCT02813525||IUGR group|estimated fetal weight \<10th percentile associated with an abnormal umbilical artery Doppler with IP\>95th percentile or a confirmation of placental vascular disease by histological examination
62141571|NCT02813525||CONTROL group|non IUGR fetuses for gestational age (normal for weight, Doppler, and structural analyse)
62141572|NCT02765594|EXPERIMENTAL|valsartan only:control group|valsartan (160mg/d)
62141573|NCT02765594|EXPERIMENTAL|hydroxychloroquine with valsartan:study group|valsartan (160mg/d) and Hydroxychloroquine Sulfate ( 400mg/d, twice daily)
62501386|NCT06531850||Tumor|"* Pulmonary nodules were detected by imaging and surgically resected.~  * Age 15-75 years old.~    * Surgery or puncture is to be performed for pathological diagnosis. ④ Adequate hematological function and liver and kidney function reserve. ⑤ The sample has no hemolysis, sufficient margin, and the source record is clear and can be checked."
62501387|NCT04241341|EXPERIMENTAL|axillary lymph node dissection with ILR|
62501388|NCT04241341|ACTIVE_COMPARATOR|axillary lymph node dissection (ALND) without ILR|
62501389|NCT06678633|EXPERIMENTAL|T-Control®|Patients will be catheterized for intravesical therapy with a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end.
62501390|NCT06678633|ACTIVE_COMPARATOR|Folysil®|Patients will be catheterized for intravesical therapy with Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.
62501391|NCT00760786|ACTIVE_COMPARATOR|1|Intensive lipid lowering plus Omega3-fatty acid
62501392|NCT00760786|ACTIVE_COMPARATOR|2|Moderate lipid lowering plus Omega3-fatty acid
62501393|NCT00760786|ACTIVE_COMPARATOR|3|Intensive lipid lowering plus placebo
62501394|NCT00760786|ACTIVE_COMPARATOR|4|Moderate lipid lowering plus placebo
61953170|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 5|Oral Nutritional Supplement 5
61953171|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 6|Oral Nutritional Supplement 6
61953172|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 7|Oral Nutritional Supplement 7
61953173|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 8|Oral Nutritional Supplement 8
61953174|NCT06358716|EXPERIMENTAL|Oral Nutritional Supplement 9|Oral Nutritional Supplement 9
61953175|NCT06358716|ACTIVE_COMPARATOR|Glucose|Glucose solution
61953176|NCT04623112|OTHER|FC Deactivated|Frequency Compression feature on hearing aids is deactivated for 4 weeks
61953177|NCT04623112|EXPERIMENTAL|FC activated & set to default|Frequency compression feature activated on hearing aids and set to default software settings for 4 weeks.
61953178|NCT04623112|EXPERIMENTAL|FC activated and set to hearing loss|Frequency Compression feature activated on hearing aids and set to hearing loss cut-off for 4 weeks
61953179|NCT02106260|EXPERIMENTAL|CLS003|
61953180|NCT06120296|NO_INTERVENTION|control group|In the blinded HPI group (the control group) the arterial waveform and pressure will be presented on a Philips patient monitor (the standard monitor), while the display of the hemosphere monitor shall be covered and the alarms will be silenced.
62141574|NCT04780074|ACTIVE_COMPARATOR|Standard product (SP): USP CoQ10 powder, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
61953181|NCT06120296|EXPERIMENTAL|intervention group|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
61953182|NCT00078793||Methotrexate group|Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
61953183|NCT06004336|EXPERIMENTAL|Radiation therapy (Control Arm)|Participants will be asked to receive radiation therapy and be randomly assigned to receive pembrolizumab or not after that.
61953184|NCT06004336|EXPERIMENTAL|Radiation Therapy and Pembrolizumab|Participants will be asked to receive radiation therapy and be randomly assigned to receive pembrolizumab or not after that.
61953185|NCT05827731|NO_INTERVENTION|Natural delivery group|The patients in this group were treated with natural delivery
61953186|NCT05827731|EXPERIMENTAL|Cesarean section group|The patients in this group were delivered by cesarean section
61953187|NCT04465110|EXPERIMENTAL|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 7 days
61953188|NCT04465110|PLACEBO_COMPARATOR|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 7 days
61953189|NCT05801965|EXPERIMENTAL|Digital intervention group|"Participants will be instructed to download Sidekick Health app and receive a code to access the 14-week digital intervention in addition to standard of care, as is defined for the control arm.~Beyond this, all participants in the interventional arm will also receive standard of care as defined for the control arm."
62141575|NCT04780074|EXPERIMENTAL|Investigational product 1 (IP1): CoQ10 in soybean oil, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
62141576|NCT04780074|EXPERIMENTAL|Investigational product 2 (IP2): Q-Gel hydrosoluble/bioenhanced CoQ10, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
62141577|NCT04780074|EXPERIMENTAL|Investigational product 3 (IP3): Qunol Mega Ubiquinol, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
62141578|NCT04780074|EXPERIMENTAL|Investigational product 4 (IP4): HydroQsorb Coenzyme Q10, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
62141579|NCT03777566||group A|35 patients with an indication for hysterectomy without gross uterine pathology
62141580|NCT03777566||group B|150 infertile patients in the childbearing age without gross uterine pathology
62141581|NCT00309751|EXPERIMENTAL|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
62141582|NCT00309751|ACTIVE_COMPARATOR|Atorvastatin 20 mg QD|Atorvastatin 20 mg once daily
62141583|NCT03088800|ACTIVE_COMPARATOR|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
62141584|NCT03088800|ACTIVE_COMPARATOR|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
62141585|NCT03088800|ACTIVE_COMPARATOR|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
62141586|NCT04566172|EXPERIMENTAL|Prehabilitation program|Patient undergoing thoracic or upper abdominal surgery as part of their regular medical care will be approached. Participants will receive a prehabilitation program that includes an inspiratory muscle training that they will do leading up to the day of their surgery.
62141587|NCT04784390|ACTIVE_COMPARATOR|Patching|Patching of the sound eye (fellow eye) - patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
62141588|NCT04784390|EXPERIMENTAL|Binocular video games|Binocular video games - patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
62141589|NCT03865004|PLACEBO_COMPARATOR|Placebo|
62141590|NCT03865004|ACTIVE_COMPARATOR|Paracetamol|
62141591|NCT03865004|ACTIVE_COMPARATOR|Dexketoprofene|
62141592|NCT02746107|EXPERIMENTAL|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
62141593|NCT02746107|ACTIVE_COMPARATOR|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
62141594|NCT02746107|ACTIVE_COMPARATOR|1year risk estimate|risk of stroke presented over a timeframe of 1 year
62141595|NCT02746107|EXPERIMENTAL|5year risk estimate|risk of stroke presented over a timeframe of 5 years
62141596|NCT02746107|OTHER|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
62141597|NCT02746107|OTHER|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
62141598|NCT02746107|OTHER|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
62141599|NCT02746107|OTHER|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
62141600|NCT02746107|OTHER|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
62141601|NCT02746107|ACTIVE_COMPARATOR|prescription to virtual patient|prescription is done for a virtual patient
62141602|NCT02746107|EXPERIMENTAL|prescription to physician himself|prescription is done to physician himself
61953190|NCT05801965|ACTIVE_COMPARATOR|Standard of care - control group|Participants in the control arm will receive standard of care treatment. Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
61953191|NCT02449252|EXPERIMENTAL|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
61953192|NCT02449252|ACTIVE_COMPARATOR|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
61953193|NCT00144391|EXPERIMENTAL|Transdermal Testosterone Gel|Transdermal Testosterone Gel (2 mg per pump), 2 pumps per day for 6 months
61953194|NCT00144391|PLACEBO_COMPARATOR|Placebo|Placebo 2 pumps per day for 6 months
61953195|NCT02323867|EXPERIMENTAL|Alpha Beta Total Body Irradiation - total body irradiation (TBI) first|"Alpha Beta Total Body Irradiation - TBI first Day Treatment~* 11 Anti-thymocyte globulin (ATG)~* 10 ATG~* 9 ATG~* 8 TBI~* 7 TBI~* 6 TBI~* 5 Thiotepa~* 4 Thiotepa~* 3 Cyclophosphamide~* 2 Cyclophosphamide~* 1 Rest 0 Transplant with alpha beta T cell depleted stem cells"
61953196|NCT02323867|EXPERIMENTAL|Alpha Beta Total Body Irradiation - TBI last|"Alpha Beta Total Body Irradiation - TBI last Day Treatment~* 9 ATG~* 8 ATG~* 7 Thiotepa + ATG~* 6 Thiotepa~* 5 Cyclophosphamide~* 4 Cyclophosphamide~* 3 TBI~* 2 TBI~* 1 TBI 0 Transplant with alpha beta T cell depleted stem cells"
61953197|NCT02323867|EXPERIMENTAL|Alpha Beta Non-irradiation regimen|"Alpha Beta Non-irradiation regimen Day Treatment~* 9 Busulfan + ATG~* 8 Busulfan + ATG~* 7 Busulfan +ATG~* 6 Busulfan~* 5 Thiotepa~* 4 Thiotepa~* 3 Cyclophosphamide~* 2 Cyclophosphamide~* 1 0 Transplant with alpha beta T cell depleted stem cells"
62501395|NCT01056926|EXPERIMENTAL|Nicotine Patch + Denic Smoking|Subjects will wear a nicotine patch and smoke denic cigarettes for 24 hours prior to scan
62501396|NCT01056926|EXPERIMENTAL|Placebo Patch + Denic Smoking|Subjects will wear a placebo patch and smoke denic cigarettes 24 hours prior to scan
61953198|NCT04731181|EXPERIMENTAL|mobile application (little lovely dentist).|intervention mobile application simulating the dental procedure that will be done to the child
61953199|NCT04731181|NO_INTERVENTION|Tell-Show-Do technique.|control behavior technique where ''tell'' is to tell the child about the procedure in non-threatening words, ''show'' is to demonstrate the procedure to the child, and ''do'' is the execution of the procedure
61953200|NCT04599140|EXPERIMENTAL|Treatment (SX-682, nivolumab)|"MONOTHERAPY STAGE: Patients receive SX-682 orally PO BID on days 1-21 in the absence of disease progression or unacceptable toxicity.~COMBINATION STAGE: Patients receive SX-682 PO BID on days 1-56 and nivolumab IV over 30 minutes on days 1 and 29. Treatment repeat every 56 days weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
61953201|NCT01778972|EXPERIMENTAL|Otago home training programme|"Otago home exercise programme was designed specifically to prevent fall. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
61953202|NCT01778972|EXPERIMENTAL|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
61953203|NCT01778972|NO_INTERVENTION|Control grop|Participants are instructed to live their ordinary lives.
61953204|NCT04977193|EXPERIMENTAL|Treatment group|
61953205|NCT02572401|EXPERIMENTAL|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
61953206|NCT02572401|NO_INTERVENTION|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
62141603|NCT01641900|EXPERIMENTAL|Schizophrenia|"Outpatients with a Structural Clinical Interview confirmed DSM-IV diagnosis of schizophrenia.~All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week."
62501397|NCT01056926|EXPERIMENTAL|Nicotine Patch + No Smoking|Subjects will wear a nicotine patch and not smoke for 24 hours prior to scan
62501398|NCT01056926|EXPERIMENTAL|Placebo Patch + No Smoking|Subjects will wear a placebo patch and not smoke for 24 hours prior to scan
61953207|NCT02572401|EXPERIMENTAL|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
62141604|NCT01641900|EXPERIMENTAL|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use. All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week.
62141605|NCT02132520|NO_INTERVENTION|Control|Subjects receiving standard-of-care physical therapy only.
62141606|NCT02132520|SHAM_COMPARATOR|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
62141607|NCT02132520|ACTIVE_COMPARATOR|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
62141608|NCT01575015|ACTIVE_COMPARATOR|Standard intraoperative support (no CRRT)|
62141609|NCT01575015|EXPERIMENTAL|Intraoperative renal support (CRRT)|
62141610|NCT03113409|EXPERIMENTAL|Procedure 1|Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
62141611|NCT03113409|EXPERIMENTAL|Procedure 2|Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
62501399|NCT01149434|EXPERIMENTAL|Pharmacokinetic Arm|Patients going on Pharmacokinetic arm will receive JI-101 \& Everolimus (4 patients only)
61953208|NCT02572401|EXPERIMENTAL|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
61953209|NCT00845858|ACTIVE_COMPARATOR|Metoclopramide Nasal Spray 10 mg|
61953210|NCT00845858|ACTIVE_COMPARATOR|Metoclopramide Nasal Spray 14 mg|
61953211|NCT00845858|PLACEBO_COMPARATOR|Placebo Nasal Spray|
61953212|NCT00758537||Patients with chronic kidney disease stage 3|
61953213|NCT00758537||patients with chronic kidney disease stage 4|
61953214|NCT00758537||patients with chronic kidney disease stage 5 (ESRD)|
61953215|NCT00758537||Controls (no kidney disease)|
61953216|NCT03243071|EXPERIMENTAL|Intervention Group|The intervention group will have access to culturally tailored website.
61953217|NCT03243071|ACTIVE_COMPARATOR|Control Group|Participants in the control group will have access to NYU 's standard trial participation website.
61953218|NCT05095597|OTHER|Umbilical cord PRP donors|"Women who are going to give birth to a healthy live newborn at the Hospital Universitario y Politécnico La Fe.~Donors will donate their umbilical cord blood to obtain the hUC-PRP. A total of 30±15 donors will be recruited."
62141612|NCT03113409|EXPERIMENTAL|Procedure 3|Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.
62501400|NCT01149434|EXPERIMENTAL|Pharmacodynamic arm|Patients going on the Pharmacodynamic study will receive JI-101 only.
62700459|NCT02323048|EXPERIMENTAL|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
61953219|NCT05095597|EXPERIMENTAL|Group B- Asherman with PRP treatment and estrogen therapy|Women with thin endometrium/endometrial atrophy and/or Asherman's syndrome with fertility problems and reproductive desires, desires that could be achieved by their participation in the present study. A total of 15 patients will be included; all of them will receive the investigational treatment as well as estrogen therapy.
61953220|NCT05095597|OTHER|Group A1- POI with PRP treatment and estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the investigational treatment as well as estrogen therapy.
62141613|NCT06696690|EXPERIMENTAL|MNS treatment group|Bundle treatment after cardiac arrest. Meanwhile, use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
62141614|NCT06696690|PLACEBO_COMPARATOR|Sham stimulation treatment group|Bundle treatment after cardiac arrest. The control group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
61953221|NCT05095597|OTHER|Group A2- POI with estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the estrogen therapy.
61953222|NCT05095597|OTHER|Group A3- POI without PRP treatment nor estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. None of them will receive either the investigational treatment nor estrogen therapy.
61953223|NCT03959943||Innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction with additional sensory nerve coaptation.
61953224|NCT03959943||Non-innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction without sensory nerve coaptation.
61953225|NCT05962957|ACTIVE_COMPARATOR|control group|control group ( levo-dopa group, n =25 ) who will receive levo-dopa/carbidopa (125/12.5) mg three times daily for 6 months.
61953226|NCT05962957|ACTIVE_COMPARATOR|PTX group|(Pentoxyifylline group, n= 25) will receive levo-dopa/carbidopa (125/12.5) mg three times daily plus pentoxifylline 400 mg two times daily for 6 months.
61953227|NCT05962957|ACTIVE_COMPARATOR|Celecoxib group|will receive levo-dopa/carbidopa (125/12.5) mg three times daily plus celecoxib 200 mg once daily for 6 months.
61953228|NCT04247880|EXPERIMENTAL|Mentees|This arm consists of apprentice-level, female-identifying construction workers who will receive active mentorship (the intervention) for two years from trained journey-level mentors.
61953229|NCT04247880|NO_INTERVENTION|Control Apprentices|This arm consists of apprentice-level, female-identifying construction workers who will not receive mentorship.
61953230|NCT03726411|EXPERIMENTAL|periodontitis group|in this group, prolactin in GCF will be assessed at baseline and after 3 months of receiving non-surgical periodontal treatment
61953231|NCT03726411|NO_INTERVENTION|control group|in this group of systemically and periodontally healthy participants, prolactin in GCF will be assessed at baseline only
61953232|NCT02435446|EXPERIMENTAL|Eligible patients for cone-beam|A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.
61953233|NCT01839123|ACTIVE_COMPARATOR|Non-Vacuum Socket|Prosthetic suction or pin socket
61953234|NCT01839123|EXPERIMENTAL|Vacuum Socket|Prosthetic LimbLogic vacuum socket
62141615|NCT04477707||Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO or FIGARO.
62501401|NCT00826345|EXPERIMENTAL|Acupuncture/Moxibustion|Diagnostic Acupuncturists assessments will inform acupuncture/moxibustion treatment prescriptions for persons with HIV/AIDS experiencing distal peripheral neuropathy. This protocol is tailored specifically for the subject's unique diagnosis according to the symptoms being reported at each diagnostic acupuncture (DA) session.
62501402|NCT00826345|PLACEBO_COMPARATOR|Placebo Acupuncture / Moxibustion|Sham/placebo Arm: Points will be administered away from the classic/traditional true point location.
62501403|NCT05690035|EXPERIMENTAL|patients with mCRC|Tislelizumab 200mg ivdrip every 3 weeks; Fruquintinib 5mg qd day 1-14, every 3 weeks
62700460|NCT02323048|EXPERIMENTAL|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
61953235|NCT06050148|EXPERIMENTAL|Feacal microbial transplantation (FMT)|
62343817|NCT03925961|EXPERIMENTAL|'education booklet and preoperative' arm|All subjects in the 'education booklet and preoperative' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery. Those subjects randomized to the 'education booklet and preoperative' arm will receive a pre-operative phone call by the research study's lead nurse, Catherine Davidson, approximately 1 week after participants enroll in the study. She will review pre-operative and post-operative guidelines pertinent to participants' operative as outlined in the patient information booklet. The amount of time (in minutes) that this phone call takes will be recorded in an excel file sheet.
62343818|NCT04357990|EXPERIMENTAL|Viruxal Oral and Nasal Spray|The Device will be administered to the oral and nasal passages, three times per day.
62343819|NCT04357990|PLACEBO_COMPARATOR|Placebo|The placebo will be administered to the oral and nasal passages, three times per day.
61953236|NCT06050148|PLACEBO_COMPARATOR|Placebo transplantation (PT), transplantation with coloured 0,9% NaCl-solution|
62343820|NCT05319080|EXPERIMENTAL|Individualized magnetic resonance imaging (MRI) guided rTMS|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive a 20-min once-daily rTMS sessions over a period of 2 weeks (weekends off), and therefore accrue a total of 10 rTMS stimulation sessions. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
62343821|NCT06319001|EXPERIMENTAL|Positive stress education (PSE)|This intervention will consist of standardized information about the relationships between expectations and the stress response. Using the CATS as a theoretical framework, the participants will be explained that when people face stressors, i.e., pain, heat, and cold water, the expectations about handling the situation will influence both the experience (e.g., pain) and the physiological stress response.
62343822|NCT06319001|SHAM_COMPARATOR|Neutral control|To control for the PSE intervention, the participants will receive 15 min of neutral information about the effects of physical exercise on cardiovascular fitness.
62343823|NCT04959253|EXPERIMENTAL|Psilocybin 25mg PO|
62343824|NCT04959253|PLACEBO_COMPARATOR|Placebo PO|
62343825|NCT06552806|EXPERIMENTAL|Probiotic group|SLAB51 will be administered orally each day during the four days at high altitude. Each dose of SLAB51 consists of one six-gram sachet dissolved in 100 mL of water, containing approximately 800 billion bacteria. Participants will receive, in one of their trips, one dose of SLAB51 after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
61953237|NCT00727220||Insulin Pump Therapy|Children starting insulin pump therapy
62343826|NCT06552806|PLACEBO_COMPARATOR|Placebo group|Placebo will be administered in the other trip, following the same schedule as SLAB51 as described above.
62343827|NCT03921138||Benign laparoscopic hysterectomy|Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy
62343828|NCT02124707|EXPERIMENTAL|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
62343829|NCT01230736|EXPERIMENTAL|DuoTrav|One drop in study eye(s) once daily for 8 weeks
62343830|NCT05015205|EXPERIMENTAL|MET Group|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The exercises were performed 3 times per week for 4 weeks.
62343831|NCT05015205|EXPERIMENTAL|Control Group|Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. The exercises were performed 3 times per week for 4 weeks.
62343832|NCT04574063|NO_INTERVENTION|Breast cancer risk leaflet only|
62343833|NCT04574063|NO_INTERVENTION|Breast cancer risk leaflet PLUS SNPs|
62343834|NCT04574063|EXPERIMENTAL|Lifestyle website only|
62343835|NCT04574063|EXPERIMENTAL|Lifestyle website PLUS SNPs|
62343836|NCT04574063|EXPERIMENTAL|Lifestyle website PLUS group coaching|
61953238|NCT00727220||Insulin Injections|Children remaining on insulin injections.
61953239|NCT03173313|OTHER|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
62343837|NCT04574063|EXPERIMENTAL|Lifestyle website PLUS group coaching PLUS SNPs|
62343838|NCT00261170|ACTIVE_COMPARATOR|1|bupropion and behavioral counseling
62343839|NCT00261170|PLACEBO_COMPARATOR|2|placebo medication
62700461|NCT01285102|EXPERIMENTAL|Arm I|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for up to 3 (unilobar disease) or 4 (bi-lobar disease) courses in the absence of disease progression or unacceptable toxicity.
62700462|NCT05288192|ACTIVE_COMPARATOR|Suprachoroidal triamcinolone injection|Eyes treated with suprachoroidal injection of triamcinolone acetonide.
62700463|NCT05288192|NO_INTERVENTION|Non-treated eyes|Eyes that are receiving no interventions during the study period.
61953240|NCT03173313|OTHER|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
61953241|NCT01667484|PLACEBO_COMPARATOR|Placebo|treatment group #1
61953242|NCT01667484|ACTIVE_COMPARATOR|Adderall XR 5mg|treatment group #2
61953243|NCT01667484|ACTIVE_COMPARATOR|Adderal XR 10mg|treatment group #3
62700464|NCT04717466|EXPERIMENTAL|Psoriasis Group|Psoriasis participants will be given Secukinumab for a total of 4 months. This is a 300mg subcutaneous injection that will occur at weeks 0, 1, 2, 3, 4, 8, and 12.
62700465|NCT04717466|NO_INTERVENTION|Healthy Group|Healthy participants will not receive any intervention.
62700466|NCT01640080|EXPERIMENTAL|Esketamine (Group 1)|
61953244|NCT01809106|ACTIVE_COMPARATOR|Morphine|
61953245|NCT01809106|EXPERIMENTAL|Oxycodone|
61953246|NCT01809106|EXPERIMENTAL|Buprenorphine|
61953247|NCT01809106|EXPERIMENTAL|Fentanyl|
62141616|NCT04477707||Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO or FIGARO.
62141617|NCT03473041|ACTIVE_COMPARATOR|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
62141618|NCT03473041|ACTIVE_COMPARATOR|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
62141619|NCT03418610|OTHER|Open Label Single Arm|Azelaic Acid Foam 15% applied twice daily
62141620|NCT04955951||polarized light group|group A (20 patients) will receive Polarized light therapy
62141621|NCT04955951||topical corticosteroid group|group B (20 patients) will receive topical corticosteroid therapy
62141622|NCT06407804|EXPERIMENTAL|Thrower's Ten Exercise Program|"1. D2 PNF flexion~2. D2 PNF extension~3. Internal rotation~4. External rotation~5. Push ups~6. Press ups"
62141623|NCT06407804|SHAM_COMPARATOR|Routine physical therapy|"1. Unilateral bench press~2. Bi lateral shoulder retraction~3. Extension in prone position~4. Neck retraction. Then isometrics will be performed which includes~1. Isometric shoulder internal and external rotation 2. Side lying shoulder external rotation 3. Scapular scaption exercise"
62141624|NCT01028287|ACTIVE_COMPARATOR|ACTH-16 units|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
62141625|NCT01028287|ACTIVE_COMPARATOR|ACTH-32 units|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
62141626|NCT02961634|EXPERIMENTAL|Nailner 2 in 1 + Ciclopirox 8%|"Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail.~They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun."
62141627|NCT02961634|ACTIVE_COMPARATOR|Ciclopirox 8%|Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
62141628|NCT02163148||Public Speaking Anxiety|Intervention to be administered: One speech exposure session.
62141629|NCT02987218|ACTIVE_COMPARATOR|PROPOFOL|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP(Intracranial pressure) Better cognitive Function preservation
62141630|NCT02987218|ACTIVE_COMPARATOR|DESFLURANE|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
62141631|NCT04048746||ASTHMA|"The patient presents to the emergency department for an aggravation of his asthma. The patient later sees an emergency investigator for medical care for his aggravation of asthma. When the patient's condition is stabilized, the investigator checks his eligibility for study and offers to participate. If the patient agrees, the investigator gives him the questionnaire and possibly helps to fill it out.~When the investigator returns to see the patient for a reassessment of his condition, he retrieves the completed questionnaire. He verifies that the patient has completed the questionnaire. Prescriptions and action plans are retrieved by the principal investigator either in digitized format from the patient's computerized medical record or in paper format. Each medication prescription and each action plan are read by the principal investigator and evaluated according to the grids."
62141632|NCT04198467|EXPERIMENTAL|PRP (100billion platelets)|platelet rich plasma having 100 billion platelets in 10 ml plasma prepared from 60 ml blood
62141633|NCT04198467|PLACEBO_COMPARATOR|hyaluronic acid|Four ml of high-molecular-weight hyaluronic acid (HMWHA) with a concentration of 22mg/ml
62141634|NCT04842916||Gastric cancer patients|gastric cancer patients with histologically confirmed, potentially resectable adenocarcinoma of the stomach or the gastroesophageal junction receiving the standard of medical care in Europe
62141635|NCT01722409|NO_INTERVENTION|sevoflurane and saline infusion|After induction of general anesthesia, Group S received a placebo infusion of normal saline.
62141636|NCT01722409|EXPERIMENTAL|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
62141637|NCT01722409|EXPERIMENTAL|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
62141638|NCT01419808|ACTIVE_COMPARATOR|Vascularized Bone Graft|Patients randomized to a vascularized bone graft will undergo a 1, 2-ICRSA vascularized bone graft based upon the 1,2 supra-retinacular vessels as described by Zaidemberg . (9. Zaidemberg C, Siebert JW, Angrigiani C. A new vascularized bone graft for scaphoid nonunion. J Hand Surg. 1991; 16A: 474-478.)
62141639|NCT01419808|ACTIVE_COMPARATOR|Non-Vascularized Bone Graft|Patients randomized to the non-vascularized group will undergo trapezoidal bone grafting from the iliac crest as described by Fernandez . (10. Fernandez DL. A technique for anterior wedge-shaped grafts for scaphoid nonunions with carpal instability. J Hand Surg \[Am\]. 1984 Sep;9(5):733-7.)
62700467|NCT01640080|EXPERIMENTAL|Esketamine (Group 2)|
62700468|NCT01640080|PLACEBO_COMPARATOR|Placebo|
62700469|NCT04093453|PLACEBO_COMPARATOR|Placebo + Fasting|Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
61953248|NCT01273597||End-stage kidney disease with secondary hyperparathyroidism|Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
61953249|NCT05211362|EXPERIMENTAL|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
61953250|NCT05211362|ACTIVE_COMPARATOR|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
61953251|NCT02499822|EXPERIMENTAL|Nifedipine GITS 30 mg slow release|Nifedipine GITS 30 mg slow release in tablets.
61953252|NCT02499822|EXPERIMENTAL|Ramipril 10 mg|Ramipril 10 mg in tablets.
62700470|NCT04093453|PLACEBO_COMPARATOR|Placebo + Exercise|Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.
62700471|NCT04093453|PLACEBO_COMPARATOR|Placebo + Post-prandial|Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.
62700472|NCT04093453|EXPERIMENTAL|Propionate and Fasting|Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
62700473|NCT04093453|EXPERIMENTAL|Propionate and Exercise|Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.
62141640|NCT04521907||Group 1|Group 1 includes patients who underwent cataract surgery with primary IOL implantation
62700474|NCT04093453|EXPERIMENTAL|Propionate and Post-prandial|Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.
62700475|NCT03048682|EXPERIMENTAL|Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #2, 3, or 4"
62700476|NCT03048682|ACTIVE_COMPARATOR|Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #7 or after. This is our current practice."
62700477|NCT06639646|EXPERIMENTAL|Dietary group|"A Dietary intervention group receiving health education message about healthy diet and probiotics supplements ( spores of poly antibiotic resistant Lactobacilli 5 billion in form of capsules registrated by the Egyption drug auyjority EDA and sold in Egyption markets under brand name Lactèol Forte ® capsules by Rameda® company.~The probiotic supplement is recommended to be given twice daily for 12 wks duration."
62700478|NCT06639646|ACTIVE_COMPARATOR|Control group|A Control group receiving health education about healthy diet. At the end of the 12 wk. period, the same measurements are repeated.
62700479|NCT05424588||Healthy male amateur Caucasian cyclists|Healthy male amateur Caucasian cyclists who attended the NC4000 4th edition underwent clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection.
62700480|NCT03864848|EXPERIMENTAL|Treatment|Treatment with the Mitral Touch Implant for Epicardial Annuloplasty.
62700481|NCT01524744|ACTIVE_COMPARATOR|Pimecrolimus ointment 0.1 %|This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
61953253|NCT00654017|PLACEBO_COMPARATOR|placebo|
61953254|NCT00654017|ACTIVE_COMPARATOR|sildenafil|
62141641|NCT04521907||Group 2|Group 2 includes patients who underwent cataract surgery with secondly IOL implantation
62141642|NCT04521907||Group 3|Group 3 includes patients who underwent cataract surgery without IOL implantation.
62141643|NCT01835639|EXPERIMENTAL|Vitamin D Supplementation|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
62141644|NCT00091988|EXPERIMENTAL|Lifestyle & Behavioral Change Program|
62141645|NCT00091988|ACTIVE_COMPARATOR|Structured Education Program|
62141646|NCT01766206|EXPERIMENTAL|MenACWY-CRM Group|Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.
62700482|NCT01524744|ACTIVE_COMPARATOR|Adcortyle|Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
62700483|NCT04827030|ACTIVE_COMPARATOR|Ropivacaine hydrochloride injected by Erector Spinae block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
61953255|NCT01372696|OTHER|Tissue sample|Patients who consent to participate in this study will have a small sample of their polyp and normal tissue sent for molecular testing.
61953256|NCT05627323|EXPERIMENTAL|Treatment (CAR T cell therapy) 1|"Arm 1 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle.~Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations.~After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain."
62141647|NCT05085418|EXPERIMENTAL|Treatment of Immune Nephritis|Administration of CD19/BCMA CAR T-cells A dose levels of 1-4\*10E6/kg are administrated for each subject.
62141648|NCT06380309|EXPERIMENTAL|1E9 PFU of oncolytic virus|Intravenous injection of 1E9 PFU oncolytic virus
62141649|NCT06380309|EXPERIMENTAL|3E9 PFU of oncolytic virus|Intravenous injection of 3E9 PFU oncolytic virus
62700484|NCT04827030|ACTIVE_COMPARATOR|Ropivacaine hydrochloride injected by Paravertebral block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
61953257|NCT05627323|EXPERIMENTAL|Treatment (CAR T cell therapy) 2|"Arm 2 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle.~Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations.~After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain."
61953258|NCT04922970|EXPERIMENTAL|Strength training|"In this arm participants will go through the Strength training intervention."
61953259|NCT03019783|PLACEBO_COMPARATOR|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
61953260|NCT03019783|ACTIVE_COMPARATOR|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
61953261|NCT05858242||Early and mid-stage breast cancer patients awaiting radical surgery|To explore the predictive effect of plasma ctDNA methylation on postoperative prognosis of breast cancer and the application value of monitoring postoperative recurrence risk through regular postoperative follow-up of stage I-III breast cancer patients undergoing radical surgery.
61953262|NCT05247775|EXPERIMENTAL|Patients with prostate cancer|We performed urethral pressure profilometry prior to open retropubic radical prostatectomy (ORRP). Patients were interviewed about the urinary incontinence by the usage of pads and International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) prior to ORRP and at 2, 8, 16 and 24 weeks after ORRP.
62501404|NCT01235442|EXPERIMENTAL|etanercept and clobetasol|Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
61953263|NCT01643356|ACTIVE_COMPARATOR|Fiber Cereal|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided high fiber cereal to manage hunger.
61953264|NCT01643356|NO_INTERVENTION|Control Group|Women assigned to this arm of the study will receive routine clinical care and no additional interventions.
61953265|NCT01643356|ACTIVE_COMPARATOR|Resistant Starch|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided resistant starch to control hunger
62141650|NCT06380309|EXPERIMENTAL|1E10 PFU of oncolytic virus|Intravenous injection of 1E10 PFU oncolytic virus
62141651|NCT06380309|EXPERIMENTAL|3E10 PFU of oncolytic virus|Intravenous injection of 3E10 PFU oncolytic virus
62141652|NCT03941106|EXPERIMENTAL|Left aTMS|
62141653|NCT03941106|EXPERIMENTAL|Right aTMS|
62141654|NCT01462175|EXPERIMENTAL|Schedule A: RO5503781 QW|Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.
62141655|NCT01462175|EXPERIMENTAL|Schedule B: RO5503781 QD|Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.
62141656|NCT03506945|EXPERIMENTAL|mPEP|Behavioral Activation Therapy - Increase engagement in pleasant activities as a mechanism for reducing distress and improving overall well-being. Participants will use an online web tool to select and schedule activities they deem will be rewarding and fulfilling. They will then track their engagement in these activities on a weekly basis.
62141657|NCT03506945|ACTIVE_COMPARATOR|Bibliotherapy|Bibliotherapy - Develop improved coping and problem-solving skills. Participants will receive bibliotherapy handouts describing various means of managing their distress and solving caregiving-related problems.
62141658|NCT02725697||TCM treatment|TCM treatment (e.g. acupuncture, Tuina massage, Chinese herbal medicine, moxibustion, electroacupuncture, ear acupuncture)
62141659|NCT02481856|EXPERIMENTAL|12 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
62141660|NCT02481856|EXPERIMENTAL|7 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
62141661|NCT02481856|EXPERIMENTAL|2 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
61953266|NCT06063278|EXPERIMENTAL|BN Group|Patients will take part of a Therapeutic BN Group
62141662|NCT02481856|PLACEBO_COMPARATOR|Placebo|No active ingredient, Oral lyophilisate
62141663|NCT00609869|EXPERIMENTAL|Lenalidomide and Rituximab|"28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.~Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.~Rituximab: at 375 mg/m\^2 on a weekly basis for the first cycle starting on day 15."
62141664|NCT02563119|ACTIVE_COMPARATOR|Gastric Bypass Group|Twenty morbidly obese patients undergoing gastric bypass surgery
62141665|NCT02563119|ACTIVE_COMPARATOR|Sleeve Group|Twenty morbidly obese patients undergoing sleeve gastrectomy
62141666|NCT02563119|NO_INTERVENTION|Healthy controls|Thirty healthy, lean controls
62141667|NCT00663819|ACTIVE_COMPARATOR|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
62141668|NCT00663819|OTHER|Procedure/Surgery|Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
62141669|NCT02440438|EXPERIMENTAL|Clostridium difficile infection|
62141670|NCT03991416|EXPERIMENTAL|Understanding Your Baby|Understanding Your Baby plus postnatal care as usual
62141671|NCT03991416|ACTIVE_COMPARATOR|Care As Usual|Postnatal care as usual
62141672|NCT04574206|EXPERIMENTAL|Elaborative Reminiscence (ER)|ER is a communication strategy used between a caregiver and child to support children's cognitive and emotional development. ER involves a caregiver and child jointly reminiscing about a past event that they personally experienced, to co-create a coherent narrative that describes the event from both their perspectives. ER consists of two crucial elements, the use of elaborative language (e.g. open ended questions, contributing new information to the conversation) and specific talk focused on recollections of the past as opposed to observations of the present.
62343840|NCT01648452|EXPERIMENTAL|NT-501 CNTF-releasing implant|Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline
62343841|NCT00310388|EXPERIMENTAL|Retigabine (INN), Ezogabine (USAN)|Retigabine (Ezogabine): all subjects
62501405|NCT01235442|EXPERIMENTAL|etanercept|Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks
62501406|NCT01598545|EXPERIMENTAL|Hydromorphone|Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
62700485|NCT06122168|EXPERIMENTAL|Intervention Group|"Standard induction handling plus mandala delivery. The standard management involves, upon admission, a verbal interview with the doctor and midwife regarding the labor induction procedure (Time 1) Time 1 will end with the signing of the consent to participate in the study. Time 2, shortly before the induction, there is a time dedicated to written informed consent relating to the induction, with explanations of possible complications.~Time 3: once the induction is complete, the patient will be invited to return to the hospital room and where the time for the intervention will start, with the delivery of the mandala and colours. During the phases preceding the start of labour, except for the time dedicated to coloring the mandala, the patient will be subjected to standard care management, as required by the ward induction protocol."
61953267|NCT06063278|NO_INTERVENTION|Waiting List|Participants will be in the waiting list.
61953268|NCT00536679|EXPERIMENTAL|Sequence ABC|Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
61953269|NCT00536679|EXPERIMENTAL|Sequence ACB|Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
61953270|NCT00536679|EXPERIMENTAL|Sequence BAC|Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
62141673|NCT04574206|SHAM_COMPARATOR|Present Tense Talk (PTT)|PTT is an active control intervention, designed to ensure that caregivers/ guardians in this group spend a similar amount of time engaging in conversation with their children but do not use elaborative reminiscing language. The focus will be on describing activities as they are happening in real time; PTT caregivers will be asked to avoid reference future or past events .
62141674|NCT04243200||Analyses of repeat ambulance calls and costs|For our analyses of repeat ambulance calls and costs we will use routine anonymised data from routine call-and-dispatch and clinical records data from EMAS for 12 months before the intervention was first introduced (September 2017) to at least 6 months after the final step of the introduction in April 2019, i.e. October 2019. This is likely to involve the analysis of an estimated 11916 cases so that we can implement a stepped wedge (non-randomised control)design .
61953271|NCT00536679|EXPERIMENTAL|Sequence BCA|Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
61953272|NCT00536679|EXPERIMENTAL|Sequence CAB|Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
62141675|NCT04243200||Survey of patients receiving intervention|We will survey about 447 patients who received the intervention in order to obtain data from a sample of n=96
62141676|NCT04243200||Survey of ambulance staff|We will send out surveys/questionnaires to all front-line ambulance staff (n=approximately 600)
62141677|NCT04243200||Qualitative interviews of staff|We will sample 10-15 staff for qualitative interviews.
62141678|NCT04243200||Qualitative interviews of patients|We will sample 10-15 patients for qualitative interviews
62141679|NCT03528603|EXPERIMENTAL|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
62141680|NCT03528603|PLACEBO_COMPARATOR|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
62141681|NCT00750477|EXPERIMENTAL|NEM Treatment|NEM, 500 mg, once daily, orally for 8 weeks
62141682|NCT00750477|PLACEBO_COMPARATOR|Placebo|Placebo, 500 mg, once daily, orally for 8 weeks
62141683|NCT01438034|EXPERIMENTAL|Kisspeptin, GnRH|Intravenous (IV) administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg
62141684|NCT06625684||Adults with Glioblastoma|This group consists of adults diagnosed with glioblastoma, a type of aggressive brain tumor. Participants are observed to identify factors influencing their outcomes, including genetic, immunologic, and personal medical history factors. The study aims to explore how these factors impact survival rates and quality of life in this patient population. There are no specific interventions. Instead, the focus is on analyzing survey data and biological samples to understand risk factors and disease progression.
62141685|NCT02766296|EXPERIMENTAL|Active Emotional Working Memory Training|Each participant will receive 15 sessions (each lasting 20 minutes) over a 5 week. This will be Internet-based cognitive training based on the adaptive dual n-back paradigm.
62141686|NCT02766296|PLACEBO_COMPARATOR|Control Working Memory Training|Participants in this condition will receive 15 sessions (each lasting 20 minutes) over a 5-week period. This will also be home-based training over the Internet. This training will be based on a fixed 1-back training program.
62141687|NCT02617693|OTHER|Standard of care|
62141688|NCT02617693|EXPERIMENTAL|Life style intervention|
62141689|NCT01752699|EXPERIMENTAL|Methadone|in this arm patients will take methadone 5mg.
62141690|NCT01752699|EXPERIMENTAL|Placebo|in this arm patients will take placebo pills.
62141691|NCT01534091|ACTIVE_COMPARATOR|Pedometer with supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
62141692|NCT01534091|ACTIVE_COMPARATOR|Pedometer without supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
62141693|NCT01534091|NO_INTERVENTION|Control group|Overweight \& obese children not participating in an intervention.
62700486|NCT06122168|ACTIVE_COMPARATOR|Control Group|Will follow all the standard management of hospitalization, informed consent and post-induction (time 1, 2 and 3) foreseen for the intervention group, but will not receive the mandala.
62141694|NCT01453959|OTHER|Diet cycles|The patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days). After 4 weeks without any intervention, the patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days.
62141695|NCT01453959|OTHER|Fludrocortisone|The patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days. After 4 weeks without any intervention, the patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days).
62141696|NCT02447666|EXPERIMENTAL|Azacitidine Myelodysplastic Syndrome (MDS)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
62343842|NCT02312076|ACTIVE_COMPARATOR|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
62343843|NCT02312076|NO_INTERVENTION|Control group|No GnRHa administration in luteal phase
62141697|NCT02447666|EXPERIMENTAL|Azacitidine Juvenile Myelomonocytic Leukemia (JMML)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
62141698|NCT05836103|EXPERIMENTAL|Micro-randomized trial group|The micro-randomized trial will determine if CBT and Mindfulness/ACT messages are superior to control messages in reducing the primary outcome momentary smoking urges. Based on participants' training data collected in the initial 14 days of EMA monitoring, intervention messages will be delivered during time-periods and at high-risk locations for smoking. In the intervention phase, participants will be prompted to complete 3 geofence-triggered EMAs per day for a total of 30 days. Each EMA will be followed by an intervention message and the type of message (CBT, Mindfulness/ACT, control) will be randomly selected at each time point (within-subject randomization).
62343844|NCT05364983|EXPERIMENTAL|Investigational IOL|Juvene® IOL
62343845|NCT05364983|ACTIVE_COMPARATOR|Control IOL|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)
62343846|NCT01391819|OTHER|Study cohort|Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.
62343847|NCT04641819|EXPERIMENTAL|Yangzheng Compound Mixture plus conventional treatment|"Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least.~Conventional treatment:~Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
62343848|NCT04641819|OTHER|conventional treatment only|"Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
62343849|NCT06071299|EXPERIMENTAL|FCC model|Participants will receive family-focused care.
62343850|NCT06071299|ACTIVE_COMPARATOR|CCC model|Participants will receive the usual child-focused care.
62343851|NCT04512469|NO_INTERVENTION|Control Group|The control group will undergo standard running fascial closure with PDS .
62343852|NCT04512469|EXPERIMENTAL|Treatment Group - Mesh|The treatment group will undergo standard running fascial closure with PDS plus a low molecular weight mesh extending 3 cm from the fascial incision.
62343853|NCT00213252|EXPERIMENTAL|1|
62343854|NCT00213252|ACTIVE_COMPARATOR|2|
62343855|NCT00804739|EXPERIMENTAL|MITT|Mothers will be assigned to the Mother-Infant Treatment Team (MITT)and will receive either psychotherapy or sertraline or both as well as outreach.
62343856|NCT00679068|EXPERIMENTAL|1|treatment with Bosentan
62343857|NCT06003257|ACTIVE_COMPARATOR|primary molars will be restored by stainless steel crowns|
62343858|NCT06003257|ACTIVE_COMPARATOR|primary molars will be restored by zirconia crowns|
62343859|NCT06003257|ACTIVE_COMPARATOR|primary molars will be restored by fiberglass crowns.|
62343860|NCT00781599|ACTIVE_COMPARATOR|1|Chantix for 3 months and Standard Counseling
62343861|NCT00781599|EXPERIMENTAL|2|Chantix for 3 months and Adherence Counseling
62343862|NCT01961843|EXPERIMENTAL|Abiraterone acetate with Prednisone|1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
62343863|NCT01434641|OTHER|low-dose stress MPI SPECT|Patients will receive a low-dose stress/high-dose rest protocol. Subject results are compared to archived patients undergoing a standard protocol./
62343864|NCT01561560|OTHER|DAILIES TOTAL1, then TRUEYE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
62343865|NCT01561560|OTHER|TRUEYE, then DAILIES TOTAL1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
62343866|NCT00523341|EXPERIMENTAL|Denosumab|Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.
62343867|NCT04260659|ACTIVE_COMPARATOR|Opioid liberal group|
62343868|NCT04260659|EXPERIMENTAL|Opioid free group|
62343869|NCT03832439|ACTIVE_COMPARATOR|Probiotic|This arm will be receiving probiotic supplements.
62343870|NCT03832439|PLACEBO_COMPARATOR|Placebo|This arm will be receiving placebo containing microcrystalline cellulose.
62343871|NCT03948308|EXPERIMENTAL|Interventional arm|blood sample before, during and after treatment for infection
62700487|NCT06317844|EXPERIMENTAL|Gratitude Writing|In the gratitude writing condition, participants will write continuously for 5 minutes about someone they are grateful for.
62343872|NCT06043141||Patients with carpal tunnel syndrome|Patients with carpal tunnel syndrome
62343873|NCT01999166||Osteoarthritis|
62700488|NCT06317844|PLACEBO_COMPARATOR|Neutral Writing|Participants in the neutral writing condition will write continuously for 5 minutes about how they got to the research laboratory.
61953273|NCT00536679|EXPERIMENTAL|Sequence CBA|Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
61953274|NCT04219657|EXPERIMENTAL|skin grafting only|All the cases in this group are managed with skin grafting only. Every odd case are kept in skin grafting only group.
61953275|NCT04219657|EXPERIMENTAL|skin grafting and stem cell group|All the cases in this group are managed with skin grafting and application of stem cells. every even cases are kept in skin grafting and stem cells group.
61953276|NCT03351933|EXPERIMENTAL|Immune Globulin (Human) GamaSTAN|The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
61953277|NCT04920552|PLACEBO_COMPARATOR|Placebo binder first|"Participants in this arm will wear the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
61953278|NCT04920552|ACTIVE_COMPARATOR|Elastic abdominal binder first|"Participants in this arm will wear the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
61953279|NCT05561738|EXPERIMENTAL|Daily oral therapy with Nicotinamide Riboside Chloride (Niagen) + Standard Therapy|"Nicotinamide Riboside Chloride (Niagen) 75mg or 250mg capsules provided by ChromaDex, Inc. Dosing is recommended at 12.5mg/kg/day.~The dosing plan is as follows (in mg po qD):~20-25 kg 250mg; 25-30 kg 325mg; 30-35 kg 400mg; 35-40 kg 475mg; 40-45 kg 500mg; 45-50 kg 575mg; 50-55 kg 650mg; 55-60 kg 725mg; 60-65 kg 750mg; 65-70 kg 825mg; \>70 kg 900mg (max dosing)."
61953280|NCT05561738|EXPERIMENTAL|Daily oral therapy with placebo + Standard Therapy|"Placebo 75mg or 250mg capsules provided by ChromaDex, Inc. Dosing is recommended at 12.5mg/kg/day.~The dosing plan is as follows (in mg po qD):~20-25 kg 250mg; 25-30 kg 325mg; 30-35 kg 400mg; 35-40 kg 475mg; 40-45 kg 500mg; 45-50 kg 575mg; 50-55 kg 650mg; 55-60 kg 725mg; 60-65 kg 750mg; 65-70 kg 825mg; \>70 kg 900mg (max dosing)."
61953281|NCT06210971|EXPERIMENTAL|Liposomal irinotecan-based TNT therapy|Concurrent Chemoradiotherapy (Radiation 50.4Gy/28 fractions + Capecitabine 625mg/m\^2 bid + Liposomal irinotecan 50mg/m\^2) followed by Chemotherapy (Capecitabine 1000mg/m\^2 bid d1-7 + Liposomal irinotecan 70mg/m\^2 or 50mg/m\^2, d1, Q2W) before surgery.
61953282|NCT04812899|EXPERIMENTAL|Parents who have a child/adolescent with an eating disorder on waitlist|"Each participant will receive a series of pre-recorded videos and book -(10 videos of about 10 minutes each, along with the book Help Your Teenager Beat an Eating Disorder). This will include content on empowering parents to renourish their child and interrupt binge/purge behaviors."
61953283|NCT02339584|EXPERIMENTAL|Brinz/Brim|Vehicle solution, 1 drop, followed by Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) twice daily (BID) for 3 months
61953284|NCT02339584|ACTIVE_COMPARATOR|Brinz+Brim|Brimonidine 2 mg/mL eye drops, solution, 1 drop, followed by Brinzolamide 10 mg/mL eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) BID for 3 months
61953285|NCT00818480|EXPERIMENTAL|1. YM155|
61953286|NCT01786668|EXPERIMENTAL|Tofacitinib 2 mg|
61953287|NCT01786668|EXPERIMENTAL|Tofacitinib 5 mg|
61953288|NCT01786668|EXPERIMENTAL|Tofacitinib 10 mg|
61953289|NCT01786668|PLACEBO_COMPARATOR|Placebo|
61953290|NCT04305418|EXPERIMENTAL|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
61953291|NCT04305418|NO_INTERVENTION|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
61953292|NCT04208633|OTHER|Horizontal placement of the intraocular lens|The eyes randomised to have horizontal placement of intraocular lenses
62501407|NCT00942812|EXPERIMENTAL|Intervention|A diarrhea Pack comprising of low osmolality ORS, Zinc, water purification sachets and pictorial chart.
61953293|NCT04208633|OTHER|Vertical placement of the intraocular lens|Fellow eye receiving vertical placement of intraocular lens.
62141699|NCT05836103|NO_INTERVENTION|EMA-only control group|A total of N=80 participants will be randomized into an EMA-only control group, parallel to the micro-randomized trial intervention group. This group will conduct 14-day EMA only training phase just like the micro-randomized trial group, but will not be switched over to the intervention phase after these initial 14 days. Instead, participants will continue the EMA-only data collection procedure for an additional 30-days (analogous to the 30-day intervention phase of the micro-randomized trial). During these 30 days, the EMA-only control group will continue to receive 3 randomly prompted EMA surveys per day and an additional 3 EMA surveys triggered by smoking reports.
62700489|NCT05336695|EXPERIMENTAL|Cognitively Normal Subjects and ADRD subjects|Cognitively Normal Subjects and ADRD subjects
62501408|NCT00942812|OTHER|Control|Standard Care through National LHW (Lady Health Workers)program
62700490|NCT04466839||parkinsonian patients|Cohort of parkinsonian patients followed by doctors from the Parkinson Expert Centers in teaching hospitals.
61953294|NCT04119544|ACTIVE_COMPARATOR|Conventional Rehabilitation|at least 4 sessions/week for 6 weeks, from 1 hour of conventional upper limb rehabilitation by an occupational therapist.
61953295|NCT04119544|EXPERIMENTAL|Intensive Visual Simulation|at least 4 sessions/week for 6 weeks, of 1 hour of upper limb rehabilitation including 45 minutes of conventional rehabilitation (occupational therapy) and 15 minutes of work with a medical device allowing intensive visual digital simulation.
62501409|NCT05305950||Healthcare administrators|Healthcare administrators at MD Anderson Cancer Center and the sister institutions
62501410|NCT05305950||Physicians/referring providers|Physicians/referring providers and the occupational therapy (OT) and physical therapy (PT) therapists at MD Anderson Cancer Center and the sister institutions
62501411|NCT02247076|PLACEBO_COMPARATOR|Grazing|"Participants will eat meals spread over the course of the day (grazing)."
61953296|NCT03241875|PLACEBO_COMPARATOR|placebo|Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
62501412|NCT02247076|EXPERIMENTAL|Time-restricted feeding (early eating)|Participants will eat meals only in the early part of the day (early lunch and very early dinner).
62501413|NCT00277043|EXPERIMENTAL|1 Test Dose|
62501414|NCT00277043|ACTIVE_COMPARATOR|2) Non test dose arm|
62501415|NCT05120817|NO_INTERVENTION|Control Group|Participants do not undergo any intervention. Pre-and post data collection only.
61953297|NCT03241875|EXPERIMENTAL|pregabalin|patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
61953298|NCT03241875|EXPERIMENTAL|gabapentin|patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.
61953299|NCT03338010|EXPERIMENTAL|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre \[mmol/L\]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
61953300|NCT03338010|ACTIVE_COMPARATOR|Lantus®|Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.
61953301|NCT03658239|EXPERIMENTAL|Experimental|"Subjects will undergo 4-5 visits total over the course of 6 months. There will be 3-4 visits that will be done at the Flaum Eye Institute. During these sessions the subject will be measured with a stationary topographer (GALILEI G4), with a rotatable topography measurement (Oculus Topographer) and a Tonometer. The subject's heart rate and blood pressure will also be measured (using a commercially available blood pressure and heart rate meter).~The GALILEI measurement will only be done once. The rest of the measurements will be done up to 4 times. Once at the start of the study session then, after the subject has been inverted using a commercially available inversion table to first 135 degrees, then 150 degrees and finally to 165 degrees.~The blood pressure and heart rate will be monitored to ensure subject safety.~There will also be one visit at the Massachusetts General Hospital. The visit will be 2 hours and will involve a Brillouin Microscopy measurement."
61953302|NCT05840510|EXPERIMENTAL|Dose Escalation and Clinical Efficacy|Dose escalation of adagrasib and nab-Sirolimus to determine maximum tolerated dose in combination and evaluate the clinical efficacy of adagrasib in combination with nab-sirolimus in patients with solid tumors (Phase 1) and NSCLC (Phase 2) harboring a KRAS G12C mutation
61953303|NCT03942666|EXPERIMENTAL|Treatment A|Single administration of CHF 6532 Dose #1
61953304|NCT03942666|EXPERIMENTAL|Treatment B|Single administration of CHF 6532 Dose #2
61953305|NCT03942666|EXPERIMENTAL|Treatment C|Single administration of CHF 6532 Dose #3
61953306|NCT03942666|EXPERIMENTAL|Treatment D|Single administration of CHF 6532 Dose #4
62141700|NCT02224469|EXPERIMENTAL|ECoG (electrocorticography) sensing|Use ECoG-based Brain Computer interface to control assistive technology
62141701|NCT01072045|ACTIVE_COMPARATOR|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
62141702|NCT01072045|ACTIVE_COMPARATOR|Prednisone|Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
62141703|NCT01238874|NO_INTERVENTION|No intervention|Mostly observational study with 1 patient global assessment.
62141704|NCT01006538|EXPERIMENTAL|Arm A (treatment)|Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.
62501416|NCT05120817|EXPERIMENTAL|Personal|Participants are exposed to the message about the personal benefits (and costs) of vaccination which refers to their own safety, their freedoms, their worries about the well-being of their significant others.
62501417|NCT05120817|EXPERIMENTAL|Social|Participants are exposed to the message about the social benefits (and costs) of vaccination which refers to public safety, the well-being of others in their community, the vulnerable groups, etc.
62501418|NCT05120817|EXPERIMENTAL|Personal + Social|Participants are exposed to the message about both personal and social benefits (and costs) of vaccination. The message alludes to personal safety as well as public safety and the strain on the healthcare system associated with the uncontrollable spread of the virus.
61953307|NCT03942666|PLACEBO_COMPARATOR|Treatment E|Single administration of CHF 6532 Placebo
61953308|NCT03942666|OTHER|Treatment F|Part II: Administration of tablet of CHF 6532 b.i.d. for 10 days at one dose.
61953309|NCT03136354|ACTIVE_COMPARATOR|ESD Group|Endoscopic Submucosal Dissection
61953310|NCT03136354|ACTIVE_COMPARATOR|LAG Group|Laparoscopic Assisted Gastrectomy
61953311|NCT05085873|EXPERIMENTAL|Sodium oxybate|
61953312|NCT05085873|ACTIVE_COMPARATOR|Midazolam|
62141705|NCT01006538|ACTIVE_COMPARATOR|Arm B (control):|Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.
62141706|NCT02540031|EXPERIMENTAL|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
62141707|NCT02540031|ACTIVE_COMPARATOR|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
62141708|NCT03784469|EXPERIMENTAL|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
62501419|NCT03623893|OTHER|Intervention group|Unilateral inguinal hernia repair with contralateral exploration.
62501420|NCT03623893|NO_INTERVENTION|Control group|Unilateral inguinal hernia repair.
62501421|NCT04276012|EXPERIMENTAL|Intervention group|The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)
62501422|NCT04276012|NO_INTERVENTION|Control group|Usual clinical care
62700491|NCT05432167|EXPERIMENTAL|Low dose CIN-107|Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.
62343874|NCT01887392|EXPERIMENTAL|Wave A|LTC Homes randomized into Wave A will receive the intervention first. The intervention includes Knowledge Translation Education Sessions.
61953313|NCT04751565|EXPERIMENTAL|Tissue level implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients with tissue level implant~Primary outcome~The primary outcome will be based on probing depth (PD)"
62343875|NCT01887392|EXPERIMENTAL|Wave B|LTC Homes randomized into Wave B will receive the intervention after Wave A. The intervention includes Knowledge Translation Education Sessions.
61953314|NCT04751565|EXPERIMENTAL|Bone level implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients with bone level implant~Primary outcome~The primary outcome will be the change in Bleeding on Probing (BOP) (Lang, Joss, Orsanic, Gusberti, Siegrist, 1986)."
61953315|NCT04360668|EXPERIMENTAL|Muscle Energy Technique combined with Trigger Point Therapy|For this group of participants, combined therapy (Muscle Energy Technique with Trigger Point Therapy) will be used
61953316|NCT04360668|ACTIVE_COMPARATOR|Muscle Energy Technique|For this group of participants, a single method (Muscle Energy Technique) will be used
61953317|NCT04360668|ACTIVE_COMPARATOR|Trigger Point Therapy|For this group of participants, a single method (Trigger Point Therapy) will be used
61953318|NCT02425020|EXPERIMENTAL|Meat protein|Post workout (training days) or breakfast (non training days) 20g of meat protein mixed with 250ml of orange juice and water
61953319|NCT02425020|EXPERIMENTAL|Whey Protein|Post workout (training days) or breakfast (non training days) 20g of whey protein isolate mixed with 250ml of orange juice and water
61953320|NCT02425020|ACTIVE_COMPARATOR|Carbohydrate|Post workout (training days) or breakfast (non training days) maltodextrin mixed with 250ml orange juice and water
62141709|NCT03784469|NO_INTERVENTION|Control group|No changing body position in bed,remaining supine position in complete bed rest and immobilized for four hours.
62141710|NCT00512252|EXPERIMENTAL|Phase I Dose Escalation|"* AMD3100 SQ on days 0-5~* Mitoxantrone on days 1-5~* Etoposide on days 1-5~* Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d"
62141711|NCT00512252|EXPERIMENTAL|Phase II Dose Treatment|"* AMD 3100 SQ on days 0-5~* Mitoxantrone on days 1-5~* Etoposide on days 1-5~* Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)"
62141712|NCT01235520|EXPERIMENTAL|1|
62141713|NCT01235520|EXPERIMENTAL|2|
62501423|NCT03278158|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
62501424|NCT03278158|EXPERIMENTAL|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
62501425|NCT03278158|EXPERIMENTAL|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)
62501426|NCT03278158|EXPERIMENTAL|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
62141714|NCT01235520|PLACEBO_COMPARATOR|3|
61953321|NCT03375606|EXPERIMENTAL|CSL730|
62141715|NCT04546776||Faecal and saliva sampling|A minimum of 4 and a maximum of 8 sample sets will be asked for over the study period
62141716|NCT06308406|EXPERIMENTAL|HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer|
62141717|NCT01499849|EXPERIMENTAL|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
62141718|NCT01499849|PLACEBO_COMPARATOR|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
62141719|NCT00689455||1|Primary care population
62501427|NCT03278158|EXPERIMENTAL|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
62700492|NCT05432167|EXPERIMENTAL|High dose CIN-107|Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.
61953322|NCT03375606|PLACEBO_COMPARATOR|Placebo|
61953323|NCT05946928||Ozased group|50 patients premedicated with OZALIN® / OZASED®
61953324|NCT05946928||Control group|50 patients who did not receive any premedication
62141720|NCT00698867||Discovery™ Elbow|Discovery™ Elbow minimally constrained
62141721|NCT05811273|EXPERIMENTAL|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
62141722|NCT05811273|ACTIVE_COMPARATOR|control group|general routine exercises
62343876|NCT00494871|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
62343877|NCT00494871|ACTIVE_COMPARATOR|Warfarin|Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
62501428|NCT00564187|ACTIVE_COMPARATOR|1|"Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
62700493|NCT05432167|PLACEBO_COMPARATOR|Placebo|Patients will take oral tablets of Placebo for 26 weeks. The dose strength may be titrated within 6 weeks.
62700494|NCT06089603|EXPERIMENTAL|CPAP treatment|Diet and conventional pharmacological treatment plus continuous positive airway pressure (CPAP)
62700495|NCT06089603|ACTIVE_COMPARATOR|Control treatment|Diet and conventional pharmacological treatment
62700496|NCT01890031|NO_INTERVENTION|Low Risk, No ICAT|Low risk, not randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
62700497|NCT01890031|OTHER|Low risk, ICAT|Low risk, randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
62700498|NCT01890031|OTHER|Low risk, ICAT, and study physician|Low risk, assigned to use the Interactive Cholesterol Advisory Tool, and study physician visits.
62700499|NCT01890031|OTHER|Moderate risk, no ICAT|Moderate risk, study physician visits, and not randomized to use the Interactive Cholesterol Advisory Tool
62700500|NCT01890031|OTHER|Moderate risk, ICAT|Moderate risk, study physician visits, and randomized to use the Interactive Cholesterol Advisory Tool
62700501|NCT06308237|EXPERIMENTAL|GROUP A (RESISTED EXERCISES)|Group A will receive a session of resisted exercises for 30 minutes. Treatment session will be given for 3 days per week for 12 weeks. This resisted training exercise program consist of three phases: Warm-up phase (5 minutes, after Warm-Up phase 20 minutes resisted exercise training then cooling phase (5 minutes).
62700502|NCT06308237|EXPERIMENTAL|GROUP B (BALANCE EXERCISES)|Group B will receive a session of Balance exercises for 30 minutes. Treatment session will be given for 3 days per week for 12 weeks. This balance exercise program consist of three phases:Warm-up phase (5 minutes), after Warm-Up phase, 20 minutes balance exercise training then cooling phase (5 minutes).
62700503|NCT05379530|EXPERIMENTAL|TEG Arm|"All patients enrolled in the study will have up to four 0.5cc blood samples obtained specifically for TEG analysis at the following defined points (for a total of up to 2cc of blood) when other routine labs are drawn (via an existing intravenous line or arterial line placed for clinical care) :~* Once at the beginning of the case~* Once at the end of the case~* Up to two times at the same time as arterial blood gas (ABG) samples (if drawn)~The research team will collect the following information from the electronic medical record and input it into the Internal REDCap database:~* De-identified demographic data, including age, height, weight, and diagnosis~* Preoperative, intraoperative, and postoperative laboratory values( including PT, PTT, INR and fibrinogen and platelets), as dictated by standard clinical practice~* Time of TEG results printed and time delivered to anesthesiologist~* Complications/Adverse events within the first 48 hours postoperatively"
62700504|NCT05540483|EXPERIMENTAL|Experimental arm|Disitamab Vedotin combined with Zimberelizumab
62700505|NCT04406454||Heathy volunteers|Patients has healthy skin at 5 anatomical locations including face, back, dorsal forearm, volar forearm, calf and at least a nevus without superficial scales and crusting.
62700506|NCT01616147|EXPERIMENTAL|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
62700507|NCT01616147|ACTIVE_COMPARATOR|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
61953325|NCT05087108|EXPERIMENTAL|Study arm|In this single arm study all enrolled subjects will the intervention by the investigational device, and both reference devices. Ultrasound will be used to measure the blood flow in the subject during the use of all three devices.
61953326|NCT00115739|EXPERIMENTAL|Imatinib|Patients will be treated with Imatinib (Gleevec) 400 mg two times a day for eight weeks after which radiologic imaging will be obtained to assess response. Patients who attained a complete response will be treated with four additional weeks of Imatinib. Patients who attain a partial response or stable disease will be treated until a complete response is attained, or until disease progression. All patients with progression of disease will be taken off the study. Patients continuing on the study, will undergo radiologic imaging every eight weeks following their initial response assessment. All patients will be followed until death.
61953327|NCT02858960|EXPERIMENTAL|High Flow Nasal Cannula Oxygen|"1. Incremental Load Treadmill Test (ILTT) using HFNCO~2. Constant Treadmill Load Test (CTLT) using HFNCO"
61953328|NCT02858960|ACTIVE_COMPARATOR|The Venturi Mask|"1. Incremental Load Treadmill Test (ILTT) using venturi mask~2. Constant Treadmill Load Test (CTLT) using venturi mask"
61953329|NCT01122654||Control|
61953330|NCT01122654||Experimental 1|
62343878|NCT01669941|EXPERIMENTAL|IPTp-DP|At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
62700508|NCT03766672||Intervention Arm|Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .
62700509|NCT01107886|EXPERIMENTAL|Saxagliptin|
62700510|NCT01107886|PLACEBO_COMPARATOR|Placebo|Placebo
62700511|NCT05534126|ACTIVE_COMPARATOR|Stellate Ganglion Block|
62700512|NCT05534126|PLACEBO_COMPARATOR|Placebo|
62700513|NCT04922216|EXPERIMENTAL|Condition 1|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + No Choice
62700514|NCT04922216|EXPERIMENTAL|Condition 2|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + Choice
62700515|NCT04922216|EXPERIMENTAL|Condition 3|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + No Choice
62700516|NCT04922216|EXPERIMENTAL|Condition 4|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
62700517|NCT04922216|EXPERIMENTAL|Condition 5|Core+Standard Diet Monitoring+Daily Activity Goal+Adaptive Timing+Standard Content+No Choice
62700518|NCT04922216|EXPERIMENTAL|Condition 6|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Standard Content + Choice
62700519|NCT04922216|EXPERIMENTAL|Condition 7|Core+ Standard Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
61953331|NCT01122654||Experimental 2|
61953332|NCT03781869|EXPERIMENTAL|Anlotinib + Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, and Anlotinib 12mg/d on day 1 to day 14 , repeated every 21 days, a total of 4-6 cycles, and then continue to take Anlotinib 12mg/d on day 1 to day 14, repeated every 21 days until progressive Disease(PD).
61953333|NCT03781869|PLACEBO_COMPARATOR|Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, repeated every 21 days, a total of 4-6 cycles, and then follow up observation until PD.
62501429|NCT00564187|ACTIVE_COMPARATOR|2|• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
61953334|NCT06558292|EXPERIMENTAL|Virtual Reality Group|"Students will experience the operating room environment with virtual reality glasses before clinical practice.~Anxiety and stress will be evaluated in clinical practice"
62700520|NCT04922216|EXPERIMENTAL|Condition 8|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Adaptive Content + Choice
62700521|NCT04922216|EXPERIMENTAL|Condition 9|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + No Choice
62700522|NCT04922216|EXPERIMENTAL|Condition 10|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
62700523|NCT04922216|EXPERIMENTAL|Condition 11|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + No Choice
62700524|NCT04922216|EXPERIMENTAL|Condition 12|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
62700525|NCT04922216|EXPERIMENTAL|Condition 13|Core+Standard Diet Monitoring+Weekly Activity Goal+Adaptive Timing+Standard Content+No Choice
61953335|NCT06558292|NO_INTERVENTION|Control Group|Anxiety and stress will be evaluated in clinical practice
61953336|NCT03224715|EXPERIMENTAL|Actinic Cheilitis patients|
61953337|NCT00007683|ACTIVE_COMPARATOR|1|Warfarin Titrated to an INR of 2.5-3.0
61953338|NCT00007683|ACTIVE_COMPARATOR|2|Aspirin 182 mg
62141723|NCT03779672|ACTIVE_COMPARATOR|Memantine Hydrochloride 10 mg Placebo|"Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.~Dose regimen:~Memantine Hydrochloride~* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~Washout (Weeks #7-8)~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps"
62141724|NCT03779672|PLACEBO_COMPARATOR|Placebo Memantine Hydrochloride 10 mg|"Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~Washout (Weeks #7-8) Memantine Hydrochloride~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps"
62141725|NCT01388413|EXPERIMENTAL|Weekly Oral Cyclic Antibiotic programme|
62141726|NCT01388413|NO_INTERVENTION|Classic care|
62141727|NCT00836498|EXPERIMENTAL|Part I, RotaTeq|3 doses of RotaTeq
62700526|NCT04922216|EXPERIMENTAL|Condition 14|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Standard Content + Choice
62700527|NCT04922216|EXPERIMENTAL|Condition 15|Core + Standard Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
62700528|NCT04922216|EXPERIMENTAL|Condition 16|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content + Choice
62700529|NCT04922216|EXPERIMENTAL|Condition 17|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ No Choice
62700530|NCT04922216|EXPERIMENTAL|Condition 18|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ Choice
61953339|NCT00007683|ACTIVE_COMPARATOR|3|Clopidogrel 75 mg
61953340|NCT04749277||Endoscopist characterization on WLI and BLI modes|Optical characterization of an identified polyp, first in WLI and then in BLI mode, with CAD EYE® OFF. This evaluation should be systematically performed by two independent endoscopists in the exam room, preferably (but not necessarily) an experienced endoscopist and a trainee. The presence of at least one experienced endoscopist is mandatory. An independent evaluation is guaranteed. First step - The 1st endoscopist (who performing colonoscopy) request the polyp evaluation and record written by the 2nd endoscopist (who not performing the colonoscopy) - blinded evaluation since 1st endoscopist doesn't verbalize his evaluation); 2nd step - when the 2nd endoscopist signals that he completed his record, the 1st endoscopist verbally explicit his classification, which is recorded by the 2nd endoscopist. This evaluation should include polyp histological type (hyperplastic, adenoma, sessile serrated lesion or other type) and the level of confidence of the evaluation performed (high or low).
62141728|NCT00836498|PLACEBO_COMPARATOR|Part I, placebo|3 doses of placebo
62141729|NCT00836498|EXPERIMENTAL|Part II, RotaTeq|3 doses of RotaTeq
62141730|NCT00836498|EXPERIMENTAL|Part II, RotaTeq and placebo|1 dose of RotaTeq and 2 doses of placebo
62141731|NCT00836498|PLACEBO_COMPARATOR|Part II, placebo|3 doses of placebo
62141732|NCT04022421|EXPERIMENTAL|hydroxychloroquine arm|
62141733|NCT00086359|EXPERIMENTAL|A|One pill of abacavir/lamivudine/zidovudine twice daily
62141734|NCT00086359|EXPERIMENTAL|B|One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.
62501430|NCT05772286|EXPERIMENTAL|763SIP8/MPLA-5 vaccine|Intramuscular injection of 100 μg of 763SIP8 protein adjuvanted with 500 μg MPLA liposomes will be administrated 4 times (day 0, week 8, week 24 and week 48).
62700531|NCT04922216|EXPERIMENTAL|Condition 19|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
62700532|NCT04922216|EXPERIMENTAL|Condition 20|Core + Simplified Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
62700533|NCT04922216|EXPERIMENTAL|Condition 21|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
62700534|NCT04922216|EXPERIMENTAL|Condition 22|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ Choice
62700535|NCT04922216|EXPERIMENTAL|Condition 23|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
62700536|NCT04922216|EXPERIMENTAL|Condition 24|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ Choice
62700537|NCT04922216|EXPERIMENTAL|Condition 25|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Standard Content+ No Choice
62700538|NCT04922216|EXPERIMENTAL|Condition 26|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
62700539|NCT04922216|EXPERIMENTAL|Condition 27|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
62700540|NCT04922216|EXPERIMENTAL|Condition 28|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
62700541|NCT04922216|EXPERIMENTAL|Condition 29|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
62700542|NCT04922216|EXPERIMENTAL|Condition 30|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ Choice
61953341|NCT04749277||CAD EYE® characterization on BLI mode|Optical characterization mode of CAD EYE® (CAD EYE® ON) in BLI mode should be activated for the evaluation of CAD EYE® optical characterization, in hyperplastic or neoplastic polyps, as well as the level of characterization (graduated from 1 to 3). The evaluation of the CAD EYE® should also be recorded by the endoscopist in the exam room who is not performing the colonoscopy, on its own record sheet. The iconographic record of evaluated polyps in WLI and BLI modes and the evaluation video using CAD EYE® in BLI characterization mode should be done.
61953342|NCT05530759||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood and buccal samples before or after SOC biopsy or tumor resection. Patients undergo collection of tumor tissue at time of SOC biopsy or tumor resection. Patients' medical records are also reviewed. Patients' archived tissue or blood samples may also be collected.
61953343|NCT00000308|EXPERIMENTAL|1|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
62501431|NCT02289820|EXPERIMENTAL|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram \[mcg\] respiratory syncytial virus \[RSV\] soluble fusion protein \[sF\] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
62501432|NCT02289820|EXPERIMENTAL|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
62501433|NCT02289820|EXPERIMENTAL|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
61953344|NCT00000308|EXPERIMENTAL|2|30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
61953345|NCT00000308|EXPERIMENTAL|3|placebo
61953346|NCT03460730|EXPERIMENTAL|Immunised children|Single 0.5 ml sub-cutaneous dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax)
62141735|NCT06017700|EXPERIMENTAL|IPT-G|Participants in the intervention arm will receive group interpersonal therapy in schools facilitated by trained laypersons. Groups are gender specific and comprise 6-8 adolescents. There are ten group sessions (approximately 90 min each, delivered weekly): in the first session the facilitator will focus on encouraging participants to review and share their interpersonal problems and instilling hope for recovery. In the middle sessions (2-9) participants will learn and practice interpersonal skills and offer and receive support from group members to resolve their problems. In the last session, they will review and celebrate progress and make plans to tackle future problems.
62343879|NCT01669941|EXPERIMENTAL|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
62343880|NCT01669941|ACTIVE_COMPARATOR|IPTp-SP|Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.
62343881|NCT02681055|EXPERIMENTAL|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
62343882|NCT04325776|EXPERIMENTAL|AL2846+An analog of zoledronic acid injection|AL2846 capsules 150 mg given orally, once daily in 28-day cycle, an analog of zoledronic acid injection (5ml:0mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
62343883|NCT04325776|ACTIVE_COMPARATOR|An analog of AL2846+ zoledronic acid injection|An analog of AL2846 capsules 0 mg given orally, once daily in 28-day cycle, zoledronic acid injection (5ml:4mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
62343884|NCT02491502|EXPERIMENTAL|Echopulse|Echopulse HIFU
62501434|NCT02289820|EXPERIMENTAL|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
62501435|NCT02289820|ACTIVE_COMPARATOR|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
62501436|NCT01226524|EXPERIMENTAL|Traditional Chinese Medicine|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
62501437|NCT02906813|EXPERIMENTAL|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
62501438|NCT02906813|EXPERIMENTAL|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fat meal on Day 1 of Intervention Period 3.
62501439|NCT02906813|EXPERIMENTAL|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
62501440|NCT01843309|EXPERIMENTAL|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
62501441|NCT01843309|PLACEBO_COMPARATOR|Placebo|Placebo twice a day orally
62501442|NCT01843309|EXPERIMENTAL|Spironolactone 100mg|Spironolactone 100mg once a day
61953347|NCT04733404|EXPERIMENTAL|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
62700543|NCT04922216|EXPERIMENTAL|Condition 31|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
62700544|NCT04922216|EXPERIMENTAL|Condition 32|Core + Simplified Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content+Choice
61953348|NCT00538291|EXPERIMENTAL|Arm 1|Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.
61953349|NCT02824614|NO_INTERVENTION|Control|20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.
61953350|NCT02824614|ACTIVE_COMPARATOR|E967-Xylitol|20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.
62700545|NCT06559332|EXPERIMENTAL|Risk-based management strategy without invasive coronary angiography|Patients will not undergo routine coronary angiography prior to TAVI. For patients without known atherosclerotic cardiovascular disease, a calcium score will be derived from the available routine computed tomography (CT) and in case of a score \>100, statin treatment of at least moderate intensity is recommended.
61953351|NCT02824614|ACTIVE_COMPARATOR|E968-Erythritol|20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.
61953352|NCT05898113|EXPERIMENTAL|EXTRA VIRGIN (intervention / control)|After a 3-day run in period avoiding EVOO consumption, participants will consume a daily amount of 0.7 g EVOO / kg body weight in addition to their usual diet for 1 months. They will then have 4 weeks with their usual diet and another 3-day run in period before starting the control intervention, which consists of following their usual diet plus 0.7 g olive oil low of polyphenol (OOLP)/ kg body weight daily for one month.
61953353|NCT05898113|EXPERIMENTAL|LOW POLYPHENOL (control/intervention)|After a 3-day run-in period avoiding EVOO consumption, participants will consume a daily amount of 0.7 g of OOLP/ kg body weight in addition to their usual diet for 1 month. Then, they will have 4 weeks with their usual diet and another run in period of 3 days before starting the intervention which consists of following their usual diet plus 0.7 g of EVOO / kg body weight daily for one month.
62343885|NCT00438399|ACTIVE_COMPARATOR|C. propionate-Wash out-Corticosteroid 1|"Clobetasol propionate Shampoo:~* Dose or Concentration: Clobetasol propionate 0.05% shampoo~* Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~* Duration of Treatment: 4 weeks as a maximum~Wash-out up to 8 weeks~Corticosteroid 1:~* Dose or Concentration: Corticosteroid 1 Foam~* Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~* Duration of Treatment: 4 weeks as a maximum"
62343886|NCT00438399|ACTIVE_COMPARATOR|C. propionate-Wash out-Corticosteroid 2|"Clobetasol propionate Shampoo:~* Dose or Concentration: Clobetasol propionate 0.05% shampoo~* Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~* Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~* Dose or Concentration: Corticosteroid 2 Lotion~* Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~* Duration of Treatment: 4 weeks as a maximum"
62343887|NCT00438399|ACTIVE_COMPARATOR|C. propionate-Wash out-Corticosteroid 3|"Clobetasol propionate Shampoo:~* Dose or Concentration: Clobetasol propionate 0.05% shampoo~* Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~* Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~* Dose or Concentration: Corticosteroid 3 Scalp application~* Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~* Duration of Treatment: 4 weeks as a maximum"
62501443|NCT00731991|ACTIVE_COMPARATOR|ART|ART to the levator scapulae.
62700546|NCT06559332|OTHER|Routine invasive coronary angiography|Routine invasive coronary angiography prior to TAVI. Percutaneous coronary intervention (PCI) recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
62700547|NCT05904483|EXPERIMENTAL|Pinwheel Group|In the pinwheel group, a windmill made of colored cardboard is introduced to the children, and then they are asked to blow on the pinwheel during the blood sampling procedure.The blood sampling is terminated at the same time by blowing the pinwheel.
62700548|NCT05904483|EXPERIMENTAL|Finger Puppet Group|In the finger puppet group, a finger puppet made of felt is introduced to the children, and they are told a story (Brave Little Rabbit) by the same researcher using the finger puppet.The blood sampling is terminated at the same time by reading story with finger puppet.
62501444|NCT00731991|ACTIVE_COMPARATOR|PNF|PNF to the levator scapulae.
62700549|NCT05904483|EXPERIMENTAL|Abeslang Puzzle Group|In the abeslang puzzle group, a puzzle made of colorful abeslang pieces with animal images (sheep, duck) is introduced to the children, and then they are asked to complete the puzzle using their non-dominant hand during the blood sampling procedure.The blood sampling is terminated at the same time by completing abeslang puzzle.
62700550|NCT05904483|NO_INTERVENTION|Control|Children in the control group are monitored during the blood sampling procedure if their informed consent is obtained by the researcher. They have the routine blood draw procedure, and do not receive any distraction techniques and other pharmacological interventions.
62501445|NCT00731991|PLACEBO_COMPARATOR|Control|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
62700551|NCT01927614||Cohort 1|20 patients 1-year post heart transplant will undergo standard of care invasive cardiac catheterization but will also have intravascular ultrasound performed to measure the maximal intimal thickness of the proximal left anterior descending artery. Patients will be dichotomized into those with MIT \<0.5mm (10 patients) and those with MIT \>0.5mm (10 patients). All 20 patients will undergo both cardiac CT and cardiac MRI with perfusion imaging.
62700552|NCT01927614||Cohort 2|10 patients 1 year post heart transplant classified as CAV grade 0 by standard cardiac catheterization will undergo both cardiac CT and cardiac MRI with perfusion imaging.
61953354|NCT01530360|EXPERIMENTAL|cerebral oximetry + treatment guideline|Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline
62141736|NCT06017700|ACTIVE_COMPARATOR|Enhanced Usual Care|Participants in the control arm will receive enhanced usual care. In intervention and control arms we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package. Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Participants in the control cluster reporting a current suicide plan or a suicide attempt in the past three months at baseline or in subsequent surveys will be assessed by a psychosocial counsellor employed through the project and offered one to one counselling as needed.
62501446|NCT04229290|EXPERIMENTAL|Dolutegravir|Participants in this arm will have a switch from a protease inhibitor based second line regimen to Dolutegravir maintaining the same NRTI backbone
62501447|NCT04229290|ACTIVE_COMPARATOR|Protease Inhibitor|Participants in this arm will be maintained on their protease inhibitor based second line regimen
62501448|NCT04544852|PLACEBO_COMPARATOR|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge."
62501449|NCT04544852|ACTIVE_COMPARATOR|Targeted intervention programme|"Intervention B involves a targeted intervention programme tackling issues relating to a lack of education, inconvenience and cost would improve screening rates amongst the spouses."
62700553|NCT01927614||Cohort 3|10 patients with a diagnosis of CAV grade 1 as assessed by routine coronary angiogram at any time point post heart transplantation, will undergo cardiac CT and cardiac MRI with perfusion imaging
62501450|NCT01995331|OTHER|moderate-dose cyclophosphomide|
62501451|NCT01897987|EXPERIMENTAL|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10\^7 cells/kg)
62700554|NCT04382092|EXPERIMENTAL|Intervention COVID-19|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
62141737|NCT03813472||Atopic Dermatitis|Evaluate sensor performance for hydration sensing.
62501452|NCT01897987|PLACEBO_COMPARATOR|normal saline|A single intratracheal administration of normal saline
62501453|NCT04405739|EXPERIMENTAL|EIDD-2801 twice daily (BID) for 5 days|EIDD-2801 orally twice daily (BID) for 5 days at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
62501454|NCT04405739|PLACEBO_COMPARATOR|placebo (PBO) twice daily (BID) for 5 days|Placebo (PBO) orally twice daily (BID) for 5 days matched for size and appearance to active IP
62501455|NCT01543867||Users of somatropin|
62501456|NCT06112054|EXPERIMENTAL|Treatment Arm|One arm only - in all eligible study patients, the study device will be used.
62501457|NCT00890279|EXPERIMENTAL|Cilnidipine|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
62501458|NCT00890279|ACTIVE_COMPARATOR|Imidapril|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
62501459|NCT01333917|EXPERIMENTAL|Curcumin|4g Curcumin C3 tablet daily
62501460|NCT01857206|EXPERIMENTAL|TIVc|Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
62700555|NCT01772654|EXPERIMENTAL|Left Temporal Lobe Epilepsy Subjects|Arterial Spin Labeled (ASL) MRI sequence
62501461|NCT01857206|ACTIVE_COMPARATOR|TIVf|Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
62501462|NCT04692584|EXPERIMENTAL|The Lullaby Group|In this group, their mothers sang a lullaby during the vaccination process. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure.
62501463|NCT04692584|NO_INTERVENTION|Control Group|"In this group, their mothers did not sing a lullaby during the vaccination process.~Mothers touched their infant's hands and body and talk to their infants during and after vaccination. Mothers hugged their infant after the procedure."
62700556|NCT01772654|ACTIVE_COMPARATOR|Control Subjects|Arterial Spin Labeled (ASL) MRI sequence
62700557|NCT03487133|EXPERIMENTAL|bortezomib/dexamethasone|Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
62700558|NCT05613231|EXPERIMENTAL|Aerobic plus Muscle-Strengthening Activity Intervention|Participants will receive access to a web-based, individually tailored, theory-driven aerobic moderate-to-vigorous physical activity (MVPA) intervention that was enhanced with content on muscle-strengthening activity.
61953355|NCT06535542|EXPERIMENTAL|WGS + Digital Twin Group|20 participants who are randomized to have whole-genome sequencing performed on their sample and given access to Predictiv™ Digital Twin. These participants will meet with a genetic counselor for results disclosure and training to access the Predictiv™ Digital Twin platform.
62141738|NCT03813472||Healthy aged matched controls|Evaluate sensor performance for hydration sensing.
62141739|NCT01299194|ACTIVE_COMPARATOR|ATORVASTATIN|Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
62501464|NCT04542915||U.S. licensed dental hygienists|Dental hygienists licensed in the United States. No intervention will be administered.
62501465|NCT05507996|EXPERIMENTAL|A single-arm study of recombinant adeno-associated virus|An open, single-arm study of recombinant adeno-associated virus
62501466|NCT04306172||Readmitted inpatients/Cases|"Outcome 1: Patients who were readmitted within 18 days of index hospitalization discharge date to the same hospital, with a diagnosis leading to the same Major Diagnostic Group as the index stay (definition according to Swiss Diagnosis Related Groups system, case merger)~Outcome 2: Patients with an unplanned readmission within 30 days of index hospitalization discharge date to the same hospital. An unplanned readmission was defined as a readmission through the emergency department."
62700559|NCT05613231|ACTIVE_COMPARATOR|Original Physical Activity Intervention|Participants will receive access to a web-based, individually tailored, theory-driven aerobic moderate-to-vigorous physical activity (MVPA) intervention
62700560|NCT04958603||Traditional surgery group|Traditionally loosen the lateral support belt proximally
61953356|NCT06535542|NO_INTERVENTION|Standard of Care Group|20 participants who are randomized to not have whole-genome sequencing performed on their sample. These participants will have standard-of-care familial hypercholesterolemia (FH) evaluation using medical history and family history only. They will not receive genetic results or Predictiv™ Digital Twin results as part of this study.
61953357|NCT06089499|EXPERIMENTAL|Get Palliative Care: four educational learning module videos|Get Palliative Care educational learning module videos available online in the public domain. A Webinar: How to Manage Shortness of Breath and Improve Your Quality of Life (2019) presented by Tara Liberman, DO reviews how to live with COPD, where and when palliative care can be implemented, what alternatives to treatment may look like, and final provides a summary of the benefits of palliative care. Each learning module is approximately five to seven minutes in length. The four learning modules are accessible at https://youtu.be/__phRXS4jZs?si=TivFch6cFE6roXDZ. After completing the weekly learning module, the participant will log their viewing in REDCap via a link provided to the participant by the email provided at the time of enrollment.
61953358|NCT06089499|NO_INTERVENTION|Usual Care|Usual care for COPD includes oxygen therapy, steroid therapy, chest radiography, nebulized bronchodilators, and antimicrobial therapy.
62700561|NCT04958603||New surgery group|"Laterally loosen the outer support belt, that is, L-shaped loosen"
62700562|NCT04017858|EXPERIMENTAL|Experimental|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
62700563|NCT04017858|ACTIVE_COMPARATOR|Control|Patients will be submitted to total knee replacement.
62700564|NCT05857241|EXPERIMENTAL|Fasting mimicking diet (FMD)|patients aged 65 and over, institutionalized in Long Term Care Units (USLD) or Establishments for the elderly (EHPAD).
62700565|NCT01229566|ACTIVE_COMPARATOR|Active Comparator|Active comparator
62700566|NCT01229566|PLACEBO_COMPARATOR|Placebo|Placebo control
62700567|NCT01229566|EXPERIMENTAL|AKR-963|Investigational drug
61953359|NCT01752361||Ulcerative Colitis|
61953360|NCT04597723|EXPERIMENTAL|80% oxygen|80% oxygen given group
61953361|NCT04597723|EXPERIMENTAL|60% oxygen|60% oxygen given group
61953362|NCT04597723|NO_INTERVENTION|routine hospital care|The patients in this group received routine hospital care.
61953363|NCT01908283|EXPERIMENTAL|Patient non immunosuppressed|Group 1 : patient without immunosuppressive treatment
61953364|NCT01908283|EXPERIMENTAL|Patient immunosuppressed|Group 2 : patient with immunosuppressive treatment
61953365|NCT06507787|EXPERIMENTAL|With EDIT-B test result|The investigator will have the EDIT-B® test result to guide the treatment strategy.
61953366|NCT06507787|PLACEBO_COMPARATOR|Without EDIT-B test result|The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study.
62501467|NCT04306172||Non-Readmitted inpatients/Controls|Outcome 1 \& 2: Patients who were not readmitted within 30 days of index hospitalization discharge date.
61953367|NCT00791856|ACTIVE_COMPARATOR|1|28 cm2 testosterone patch
61953368|NCT00791856|EXPERIMENTAL|2|14 cm2 testosterone patch
61953369|NCT01954992|EXPERIMENTAL|glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle
61953370|NCT01954992|ACTIVE_COMPARATOR|5-FU|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
61953371|NCT02114801|EXPERIMENTAL|manual brushing|manual brushing; Oral-B®, Stages 4, Rio de Janeiro, Rio de Janeiro;
61953372|NCT02114801|EXPERIMENTAL|electric toothbrush linked|electric toothbrush linked; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
61953373|NCT02114801|EXPERIMENTAL|off electric toothbrush|off electric toothbrush; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
62141740|NCT01299194|PLACEBO_COMPARATOR|PLACEBO|Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily
62141741|NCT02103166|EXPERIMENTAL|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
62700568|NCT01656122|EXPERIMENTAL|PK|PK of abacavir and lamivudine
62700569|NCT04282785||Cohort of patients with severe infections|Patients with severe infections admitted to the Uppsala University Hospital and gets treated with either Piperacillin-Tazobactam, Meropenem or Cefotaxim
62700570|NCT01194037|EXPERIMENTAL|Hanferon (low dose) sc weekly + RBV oral daily|
62700571|NCT01194037|EXPERIMENTAL|Hanferon (high dose) sc weekly + RBV oral daily|
62700572|NCT01194037|ACTIVE_COMPARATOR|Pegasys 180 ug sc weekly + RBV oral daily|
62700573|NCT00601731|EXPERIMENTAL|Adjuvanted MenACWY vaccine group|Blood test
62700574|NCT00601731|ACTIVE_COMPARATOR|Non-adjuvanted MenACWY vaccine group|Blood test
62700575|NCT02935036|EXPERIMENTAL|ADPS topical product|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
62700576|NCT02935036|PLACEBO_COMPARATOR|Placebo Control|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
62700577|NCT02329808||Mycophenolic acid|Patients treated for their regular patient care with mycophenolic acid.
62700578|NCT02329808||Cyclosporin|Patients treated for their regular patient care with cyclosporin.
62700579|NCT02329808||Tacrolimus|Patients treated for their regular patient care with tacrolimus.
62700580|NCT02329808||Sirolimus|Patients treated for their regular patient care with sirolimus.
61953374|NCT01242462|ACTIVE_COMPARATOR|AB|2 hours of treatment with conventional ventilation strategy, then crossover to 2 hours of treatment with mid-frequency ventilation strategy
61953375|NCT01242462|ACTIVE_COMPARATOR|BA|2 hours of treatment with mid-frequency ventilation strategy, then crossover to 2 hours of treatment with conventional ventilation strategy
61953376|NCT01934023|ACTIVE_COMPARATOR|Varenicline|FDA approved smoking cessation medication
62141742|NCT02103166|PLACEBO_COMPARATOR|Physiological serum|100 ml of physiological serum (0.9% NaCl).
62141743|NCT02108704|ACTIVE_COMPARATOR|Helicobacter pylori eradication therapy|Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD
62141744|NCT02108704|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62700581|NCT02329808||Everolimus|Patients treated for their regular patient care with everolimus.
62700582|NCT02329808||Voriconazole|Patients treated for their regular patient care with voriconazole.
62700583|NCT02329808||Posaconazole|Patients treated for their regular patient care with posaconazole.
62700584|NCT02329808||Itraconazole+metabolite|Patients treated for their regular patient care with itraconazole.
62700585|NCT02329808||Fluconazole|Patients treated for their regular patient care with fluconazole.
61953377|NCT01934023|PLACEBO_COMPARATOR|Placebo Sugar Pill|sugar pill
61953378|NCT05780372|EXPERIMENTAL|Reduced CTVn2|Patients will receive the reduced neck prophylactic irradiation, only the level of positive lymph nodes and its next level.
61953379|NCT05780372|ACTIVE_COMPARATOR|Conventional CTVn2|Patients will receive the conventional neck prophylactic irradiation, as suggested by the international guideline.
61953380|NCT02087735|EXPERIMENTAL|cranberry extract 1|One capsule with a proanthocyanidin standardized cranberry extract of 36 mg and one capsule of placebo cranberry extract.
61953381|NCT02087735|EXPERIMENTAL|cranberry extract 2.|Two capsules with a proanthocyanidin standardized cranberry extract of 36 mg.
61953382|NCT02087735|PLACEBO_COMPARATOR|cranberry extract 3.|Two capsules with a proanthocyanidin standardized cranberry extract of 2 mg.
61953383|NCT03209661|ACTIVE_COMPARATOR|E-Cigarette 5.4% NBV|Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.
61953384|NCT03209661|PLACEBO_COMPARATOR|E-Cigarette 0% NBV|Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.
61953385|NCT03209661|PLACEBO_COMPARATOR|Menthol Inhaler|Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.
61953386|NCT06421792||Standard|10 patients receiving standard reversal with 1:1 protamine / heparin ratio
61953387|NCT06421792||PRODOSE Algorithm|10 patients who had heparin reversed using the PRODOSE algorithm anticipated (average protamine / heparin ratio 0.6:1).
61953388|NCT03342183|EXPERIMENTAL|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation). To be administered on a monthly basis from the baseline visit to the year 1 visit.
62141745|NCT02108574|PLACEBO_COMPARATOR|Placebo Filter|Placebo device
62141746|NCT02108574|ACTIVE_COMPARATOR|Rhinix Nasal Filter|Actual Rhinix Nasal Filter
62141747|NCT00057499|EXPERIMENTAL|IBC-VS01 vaccine|IBC-VS01 vaccine is administered twice.
62141748|NCT00057499|PLACEBO_COMPARATOR|Control Group|IBC-VS01 placebo is administered twice
62501468|NCT04393623|EXPERIMENTAL|Cognitive Reappraisal Microintervention|"The CR microintervention (session 1) is drawn from Barlow \& colleagues empirically supported treatment for emotional disorders (the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders). The microintervention consist of four sections: (1) Introduction to cognitive appraisal; (2) Introducing the idea of thinking traps that prevent reappraisal and maintain negative emotion; (3) Describing cognitive reappraisal as a strategy that can help the participant get out of such thinking traps; (4) Providing an example of this process (situation\> negative appraisal \> negative emotion \> thinking trap \> opportunity for cognitive reappraisal) and have participants provide a personalized example."
62501469|NCT04393623|ACTIVE_COMPARATOR|Psychoeducation (Control)|The manualized psychoeducational control module, serving as an attentional control, is derived from two sources: 1. The first session of the Women's Health Education Manual, which provides psychoeducation about the basic body systems and their function, with focus on components of the immune system and 2. Fact sheets published by the American College of Obstetricians and Gynecologists(ACOG), providing female-specific facts about cancer and heart health. None of this psychoeducation discusses potential relevancy of alcohol use, nor will any behavior changes be suggested during the control microintervention.
62141749|NCT02599025|NO_INTERVENTION|Supine position|Children tested while lying down
62141750|NCT02599025|NO_INTERVENTION|Standing position|Children tested while standing
62343888|NCT00438399|ACTIVE_COMPARATOR|Corticosteroid 1-Wash out-C. propionate|"Clobetasol propionate Shampoo:~* Dose or Concentration: Clobetasol propionate 0.05% shampoo~* Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~* Duration of Treatment: 4 weeks as a maximum~Corticosteroid 1:~* Dose or Concentration: Corticosteroid 1 Foam~* Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~* Duration of Treatment: 4 weeks as a maximum"
62343889|NCT00438399|ACTIVE_COMPARATOR|Corticosteroid 2-Wash out-C. propionate|"Clobetasol propionate Shampoo:~* Dose or Concentration: Clobetasol propionate 0.05% shampoo~* Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~* Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~* Dose or Concentration: Corticosteroid 2 Lotion~* Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~* Duration of Treatment: 4 weeks as a maximum"
62343890|NCT00438399|ACTIVE_COMPARATOR|Corticosteroid 3-Wash out-C. propionate|"Clobetasol propionate Shampoo:~* Dose or Concentration: Clobetasol propionate 0.05% shampoo~* Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~* Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~* Dose or Concentration: Corticosteroid 3 Scalp application~* Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~* Duration of Treatment: 4 weeks as a maximum"
62501470|NCT04202458|EXPERIMENTAL|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA
62501471|NCT00860600|EXPERIMENTAL|1. PG2 Treatment: 5 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
62501472|NCT00860600|EXPERIMENTAL|2. PG2 Treatment: 3 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
62700586|NCT04337970|EXPERIMENTAL|Phase Ib, Dose Level 1|3-6 participants
62700587|NCT04337970|EXPERIMENTAL|Phase Ib, Dose Level 2|3-6 participants
62700588|NCT04337970|EXPERIMENTAL|Phase Ib, Dose Level 3|3-6 participants
62700589|NCT04337970|EXPERIMENTAL|Phase II, Dose Expansion|Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)
62141751|NCT02599025|EXPERIMENTAL|Cycling supine postion|Children lying down with APT cycling system
62700590|NCT01312831|EXPERIMENTAL|Oral Eligen® B12|Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.
62700591|NCT01312831|ACTIVE_COMPARATOR|IM B12|Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.
62700592|NCT03935347|EXPERIMENTAL|Treatment (cyclophosphamide, fludarabine, pembrolizumab)|Patients receive cyclophosphamide IV over 2 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -2, and pembrolizumab IV over 30 minutes on day -1. At least 24 hours later, patients receive autologous tumor infiltrating lymphocytes LN-145 IV on day 0, and receive aldesleukin IV over 30 minutes for up to 6 doses on days 1-4. Patients then continue receiving pembrolizumab IV over 30 minutes beginning on day 21. Cycles of pembrolizumab repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity.
62700593|NCT02101463|OTHER|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
62700594|NCT05371327||Public Deliberants|Minors and adults recruited through a community outreach process.
62700595|NCT06501898|ACTIVE_COMPARATOR|CoreBiome|Participants will be given tributyrin (as CoreBiome)
62700596|NCT06501898|PLACEBO_COMPARATOR|Placebo|Participants will be given a taste-, color-, and odor-matched placebo
62700597|NCT01715116|EXPERIMENTAL|Enhanced ICD programming|
62700598|NCT01495013|ACTIVE_COMPARATOR|Glimepiride Atorvastatin fixed dose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
62700599|NCT01495013|ACTIVE_COMPARATOR|Glimepiride +Atrovastatin loose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.
62700600|NCT05607472|OTHER|All patient with Dengue prognostic purpose|blood samples for bio collection clinical exam : Fitzpatrick phototype classification , Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation)
62700601|NCT02642757|EXPERIMENTAL|Brief intervention|AUDIT brief intervention
62700602|NCT02642757|SHAM_COMPARATOR|Control group|Pamphlet on alcohol use
62700603|NCT02294864|EXPERIMENTAL|Pulsed Radiofrequency|Pulsed Radiofrequency This group will receive one dose of intra-articular PRF in the affected knee using previous literature standards. This includes standard blood pressure monitoring, sterile preparation, and needle insertion of the PRF probe directed at the site of maximal pain. The RFG-3C Plus radiofrequency generator will be activated at 42C, pulse width 10ms, and 2Hz frequency for 15 min.
62700604|NCT02294864|ACTIVE_COMPARATOR|Physical Therapy|This group will receive standard of care outpatient physical therapy weekly for 3-4 weeks with therapist instructions to reduce knee pain.
62700605|NCT03572283|EXPERIMENTAL|Bethanechol|Patients with pancreatic adenocarcinoma will receive bethanechol prior to pancreatic surgery
61953389|NCT03342183|SHAM_COMPARATOR|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
62700606|NCT05727332|EXPERIMENTAL|Intervention|The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks.
62700607|NCT05727332|NO_INTERVENTION|Time-Matched Control|The control group will be asked to maintain pre-intervention habits/behavior over 4 weeks.
62700608|NCT04734392||Cohort A|Historical cohort 2019 + 2020
62700609|NCT04734392||Cohort B|Prospective study cohort 2020 + 2021 (TAVR implantation according new IFU)
62700610|NCT03682744|EXPERIMENTAL|anti-CEA CAR-T cells|One intraperitoneal infusion of gene-modified anti-CEA T cells are administered to patients with CEA-expressing peritoneal metastases or malignant ascites
62700611|NCT05626712|EXPERIMENTAL|CELZ-201 Treatment Group|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care of care for Type 1 Diabetes treatment.
62700612|NCT05626712|PLACEBO_COMPARATOR|Control Group|Participants in this group will receive standard of care for Type 1 Diabetes only.
62700613|NCT02659241|EXPERIMENTAL|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5. Patients then undergo standard of care laparoscopy. Patients may also receive adavosertib PO QD on days 8-12, 15-19, and 22-26 for up to 28 days based on surgery schedule.
61953390|NCT00397345|EXPERIMENTAL|Trovax|
61953391|NCT00397345|PLACEBO_COMPARATOR|Placebo|
62141752|NCT02599025|EXPERIMENTAL|Cycling standing postion|Children standing with Innowalk cycling system
61953392|NCT03741062|EXPERIMENTAL|J. Morita AdvErl Evo Er:YAG laser|Immediately following completion of the surgical procedure, this group will receive photobiomodulation treatment of the palatal tissue donor site with Er:YAG laser according to the parameters recommended by experts in this field and which have shown to induce maximal proliferation of human gingival fibroblasts (Energy Setting: 80 mJ, Pulse Rate: 25 Hz, Duration: 30 s).
62141753|NCT01971112|EXPERIMENTAL|Multivitamins and minerals|Experimental: X: Multivitamins and minerals (MVM) Arm X: 1X US-RDA of vitamins A, D,E,B6,B12, folate, copper and iron plus 500 mg vitamin C, and 14 mg of Zinc
62141754|NCT01971112|PLACEBO_COMPARATOR|Placebo|
62700614|NCT01561469||Linezolid observational cohort|
62700615|NCT01561469||Vancomycin observational cohort|
62700616|NCT01007955||Severely Obese|Severely obese individuals scheduled to undergo gastric bypass surgery
62700617|NCT05121350|EXPERIMENTAL|Arotinib hydrochloride capsule + Epirubicin|Arotinib hydrochloride capsule combined with epirubicin, 21 days as a treatment cycle
62700618|NCT05121350|ACTIVE_COMPARATOR|Placebo + Epirubicin|Placebo combined with epirubicin, 21 days as a treatment cycle
62700619|NCT02553096|EXPERIMENTAL|ACCESS|ACCESS is used when participants experience more COPD symptoms.
62700620|NCT02553096|NO_INTERVENTION|paper plan|Paper exacerbation action plan is used when participants experience more COPD symptoms.
61953393|NCT03741062|SHAM_COMPARATOR|Control|This group will receive sham treatment of the palatal tissue donor site. The laser unit will be turned off. The clinician will simulate usage of the Er:YAG laser in a manner that is indistinguishable to the patient from the experimental group.
61953394|NCT01065259|EXPERIMENTAL|OROS MPH|the group treated by OROS MPH
61953395|NCT01065259|ACTIVE_COMPARATOR|atomoxetine|the group treated by atomoxetine
61953396|NCT01065259|NO_INTERVENTION|control|the normal control with no intervention
62501473|NCT01358253|ACTIVE_COMPARATOR|HyperCVAD|"Consolidation:~HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9."
61953397|NCT05254886|NO_INTERVENTION|Routine practice|Patients who benefit from the classic management of CD (i.e. clinical + biological ± radiological ± endoscopic follow-up ± therapeutic education program).
61953398|NCT05254886|EXPERIMENTAL|Routine practice + nurse-led program|Patients who receive, in addition to routine practice, a single nursing consultation dedicated to the identification and management of comorbidities and EIMs in CD at the inclusion visit.
61953399|NCT03225885|ACTIVE_COMPARATOR|Printed Handout|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as a printed gestational age specific handout about prematurity.
62501474|NCT01358253|EXPERIMENTAL|R-HyperCVAD|"Consolidation:~R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12."
62501475|NCT01181531|ACTIVE_COMPARATOR|Traditional Vitamin D Therapy|
62501476|NCT01181531|EXPERIMENTAL|Cinacalcet|
62501477|NCT02853916|ACTIVE_COMPARATOR|500 mg InSea2®|
61953400|NCT03225885|EXPERIMENTAL|Multimedia Information|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as have bedside access to iPad multimedia information regarding prematurity.
61953401|NCT05795075|EXPERIMENTAL|Computerized Modified Paramedian Approach Technique|The L3-4 inter-laminar space will be selected as the target for puncture, and in the longitudinal direction, 1.0-1.5cm will be opened beside the upper edge of the spinous process (tip) of the lower vertebra as the entry point. The lumbar puncture needle will be inserted vertically along the axis of the anesthesia needle. The puncture path will be maintained completely perpendicular to the skin until the needle reached the PLTLF (posterior layer of the thoracolumbar fascia), where some resistance will be felt. The puncture direction is adjusted as needed. The tip of the needle will be tilted 20±10° in the sagittal direction and 15±5° inward such that the tip will point at the midpoint of the spinal canal. After the needle reaches the PLTLF, it will be further inserted 3-7 cm.
62501478|NCT02853916|ACTIVE_COMPARATOR|250 mg InSea2®|
62501479|NCT02853916|PLACEBO_COMPARATOR|Placebo|
61953402|NCT05795075|EXPERIMENTAL|Conventional Midline Approach Technique|Puncture will be performed on the posterior median line near the midpoint of the L3-4 Space of spinous process. The lumbar puncture needle will be inserted vertically along the axis of the anesthesia needle, or the tip of the needle will be tilted 15° in the sagittal direction toward the head, so that the needle path is parallel to the space of spinous process.
61953403|NCT02433405||Group 1|Chronic Periodontitis-serum amyloid A, Fetuin-A
62501480|NCT04429867|EXPERIMENTAL|Hydroxychloroquine|
61953404|NCT02433405||Group 2|Plaque induced Gingivitis-serum amyloid A, Fetuin-A
62501481|NCT04429867|PLACEBO_COMPARATOR|Placebo|
62501482|NCT00754052|ACTIVE_COMPARATOR|1|
62501483|NCT00754052|ACTIVE_COMPARATOR|2|
62501484|NCT00754052|PLACEBO_COMPARATOR|3|
62501485|NCT04229914|OTHER|stroke patients|Assessment
62501486|NCT05940259|EXPERIMENTAL|[68Ga]P3|Subjects with suspected or confirmed Prostate will receive an intravenous injection of 68Ga-P3 followed by PET imaging.
62501487|NCT06276296||PFA group|Patients undergoing pulsed field ablation
62501488|NCT06276296||RFA group|Patients undergoing radiofrequency ablation
62501489|NCT04413968|EXPERIMENTAL|Interventional|nasopharyngeal and blood sample
62501490|NCT04810533|EXPERIMENTAL|[14C] SH-1028|Volunteers will receive 200 mg \[14C\] SH-1028 containing a nominal 88 μCi activity, administered by mouth, as a solution.
62501491|NCT06679764|ACTIVE_COMPARATOR|Anterior quadratus lumborum block technique (AQLB)|"AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process.~A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane."
62501492|NCT06679764|ACTIVE_COMPARATOR|Pericapsular Nerve Group (PENG) block|With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.
62501493|NCT06679764|ACTIVE_COMPARATOR|Control Group|Pataints received opioid analgesia with GA
62501494|NCT00037752|ACTIVE_COMPARATOR|1|Sibutramine plus a behavioral smoking cessation program
62501495|NCT00037752|ACTIVE_COMPARATOR|2|Placebo sibutramine plus a behavioral smoking cessation program
61953405|NCT02433405||Group 3|Control Group-serum amyloid A, Fetuin-A
61953406|NCT02363842|EXPERIMENTAL|Skin IQ™ MCM Coverlet|Skin IQ™ MCM coverlet used over a commercially available pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
61953407|NCT02363842|ACTIVE_COMPARATOR|Pressure redistribution surface|Commercially available pressure redistribution surface already in use at participating study sites (SOC) to manage patients at risk for tissue breakdown
62700621|NCT06327438|EXPERIMENTAL|Group (A)|(n=20) received complex decongestive therapy only
61953408|NCT03584178|EXPERIMENTAL|Mucosal Atomization Device|Budesonide via MAD Device
61953409|NCT03584178|EXPERIMENTAL|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
61953410|NCT00690105|EXPERIMENTAL|A|
61953411|NCT00690105|ACTIVE_COMPARATOR|B|
61953412|NCT03963596|ACTIVE_COMPARATOR|Ranibizumab|Arm 1
61953413|NCT03963596|ACTIVE_COMPARATOR|Aflibercept|Arm 2
61953414|NCT02753114|EXPERIMENTAL|Intranasal Ketamine|Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
61953415|NCT02753114|PLACEBO_COMPARATOR|Placebo|"Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered."
61953416|NCT01390805||Subjects with recurrent genital herpes|
61953417|NCT03574831||Stretta|Radio Frequency Ablation (RFA) using a Stretta device.
61953418|NCT05490810|EXPERIMENTAL|Trunk stabilization|Trunk stabilization exercises were given three times a week for two weeks.
61953419|NCT05490810|EXPERIMENTAL|Activation exercises|Activation exercises exercises performed twice for 5s, with 2 min rest between them for three times a week for two weeks.
61953420|NCT01723488|EXPERIMENTAL|Tau diagnostic|Experimental: Tau diagnostic \[F18\] T808
62141755|NCT03440645|EXPERIMENTAL|Family or Household Members|
62141756|NCT04639999||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
62141757|NCT01823224|EXPERIMENTAL|Group 1|"Group 1 will receive IV acetaminophen 1000mg plus 2 oral capsules sugar pills 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses of acetaminophen totaling or equaling 2000mg"
61953421|NCT02012101|EXPERIMENTAL|niv plus oxygen therapy|oxygen therapy is given during the whole experimental process, niv is given at peak exercise until the borg scale reaches it's baseline point
62141758|NCT01823224|EXPERIMENTAL|Group 2|"Group 2 will receive an IV salt water infusion plus 2 capsules of oral acetaminophen 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses totaling or equaling 2000mg."
62141759|NCT02722434|EXPERIMENTAL|Arm I (MC5-A scrambler therapy)|Patients undergo MC5-A scrambler therapy over 30 minutes for 10 consecutive weekdays.
61953422|NCT02012101|ACTIVE_COMPARATOR|oxygen therapy|oxygen therapy is given during the whole experimental process
61953423|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
62141760|NCT02722434|ACTIVE_COMPARATOR|Arm II (TENS therapy)|Patients undergo TENS therapy over 30 minutes daily for 14 days.
62141761|NCT06502132|NO_INTERVENTION|Control Group|Control group patients will receive routine care and no other intervention will be made within the scope of the study.
62343891|NCT04206527|EXPERIMENTAL|Intervention - Women|Women who receive enhanced FP counseling from an ASHA
61953424|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
61953425|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
61953426|NCT02147470|OTHER|prerenal AKi, acute tubular necrosis and hepatorenal syndrome|All subjects will undergo CEUS with the use of Definity to measure renal blood flow. At the same time clinical tools (urine output, response to volume expansion, urine sodium, urine output, fractional excretion of sodium and urea and urine microscopy) will be used to differentiate between prerenal AKI, ATN and HRS. the quantity and patterns of RBF measured by CEUS will be compared between these three groups.
61953427|NCT05477693|EXPERIMENTAL|Experimental Group|1200 participants(including 600 subjects aged 2\~17 years,240 subjects aged 18\~59 years and 360 subjects aged 60 years and above)received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd
62141762|NCT06502132|ACTIVE_COMPARATOR|Patient Education Group|The patient education group will be informed about the waiting process that occurs as a result of surgery postponement through an education booklet prepared by the researcher in line with the literature.
62141763|NCT06502132|ACTIVE_COMPARATOR|Therapeutic Touch Group|During the waiting period, patients will receive therapeutic touch by a certified researcher.
62141764|NCT03492021|EXPERIMENTAL|Adequate Protein_Carbohydrate Post Therapy|Diet Intervention - Adequate Protein (1.0 g/kg/d) - Carbohydrate Post Therapy \[AP-CPT\]
62343892|NCT04206527|NO_INTERVENTION|Control - Women|Women who receive standard FP counseling from an ASHA
62700622|NCT06327438|EXPERIMENTAL|Group (B)|(n=20) received cryotherapy and complex decongestive therapy
62700623|NCT06327438|EXPERIMENTAL|Group (C)|(n=20) received kinesio taping and complex decongestive therapy
62501496|NCT00959439|EXPERIMENTAL|1|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
62141765|NCT03492021|EXPERIMENTAL|Optimal Protein_Protein Post Therapy|Diet Intervention - Optimal Protein (2.0 g/kg/d) - Protein Post Therapy \[OP-PPT\]
62501497|NCT00959439|ACTIVE_COMPARATOR|2|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
62501498|NCT01642563|EXPERIMENTAL|Pathogen reduced platelets|Transfusion
62501499|NCT01642563|ACTIVE_COMPARATOR|Standard platelets|Transfusion
62501500|NCT05830682|EXPERIMENTAL|Intervention Group|Participants in this study group asked to walk with using a walking aid during the first three mobilizations in the intensive care unit on the first postoperative day.
62700624|NCT05400564|EXPERIMENTAL|FCU Online + Coach|Parents in this arm will receive access to the FCU app and telehealth coaching/ support provided by a trained mental health provider. The FCU app includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include videos, animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching sessions will focus on Healthy Behaviors, Positive Parenting, Rules and Consequences, School Support, and Communication.
62700625|NCT05400564|NO_INTERVENTION|Control|Parents in this arm will receive school support as usual.
62700626|NCT00659425|EXPERIMENTAL|5 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62700627|NCT00659425|EXPERIMENTAL|10 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62700628|NCT00659425|EXPERIMENTAL|20 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62700629|NCT00659425|EXPERIMENTAL|20 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62700630|NCT00659425|EXPERIMENTAL|30 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62700631|NCT00659425|EXPERIMENTAL|30 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62141766|NCT01212913|EXPERIMENTAL|group 1: Basal plus|Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
62343893|NCT04206527|EXPERIMENTAL|Intervention - ASHA|ASHA who receive enhanced FP counseling training
62343894|NCT04206527|NO_INTERVENTION|Control ASHA|ASHA who receive standard FP training
62501501|NCT05830682|NO_INTERVENTION|Control Group|Participants in this study group asked to walk with the help of 2 nurses during the first three mobilizations in the intensive care unit on the first postoperative day.
62700632|NCT00659425|EXPERIMENTAL|40 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62700633|NCT00659425|EXPERIMENTAL|32 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
62141767|NCT01212913|ACTIVE_COMPARATOR|group 2: Biphasic insulin|Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL \< Pre-meal blood glucose (dinner and breakfast).
62141768|NCT06699355|EXPERIMENTAL|Atorvastatin|Participants receive a single oral dose of atorvastatin (Treatment A) on Day 1.
62343895|NCT01005511|EXPERIMENTAL|Grindcare|24 patients receiving active treatment
62343896|NCT01005511|PLACEBO_COMPARATOR|Placebo treatment|24 patients receive a placebo treatment
62501502|NCT01321437|EXPERIMENTAL|Axitinib|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 14-21 days after completion of treatment. Beginning 28-56 days after surgery, patients receive axitinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
62501503|NCT00889252|EXPERIMENTAL|K-Lens|Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug
62501504|NCT00889252|PLACEBO_COMPARATOR|Placebo Lens|Placebo lens
62501505|NCT04232527||Professional Footballers|About 110 players (out of about 400 competing in the Premier League of Bosnia and Herzegovina) would be included in the research.
62501506|NCT05425368|EXPERIMENTAL|silver diamine fluoride group|partial caries removal will be carried out then Silver Diamine Fluoride will be applied as indirect pulp capping agent and rubbed for 1 minute followed by Glass ionomer filling
62501507|NCT05425368|ACTIVE_COMPARATOR|mineral trioxide aggregate group|partial caries removal will be carried out then mineral trioxide aggregate will be placed as indirect pulp capping agent followed by glass ionomer filling
62501508|NCT06359340|ACTIVE_COMPARATOR|MAT- OBOT|Those randomized to MAT standard of care will continue to receive standard office-based buprenorphine treatment.
62700634|NCT00659425|EXPERIMENTAL|50 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
62700635|NCT00659425|EXPERIMENTAL|50 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
62700636|NCT03088683|ACTIVE_COMPARATOR|Nathanson Retractor|Nathanson retractor will be used
62700637|NCT03088683|ACTIVE_COMPARATOR|Reveel Retractor|Reveel retractor will be used
62700638|NCT04429763|EXPERIMENTAL|Experimental|Usual tratment for COVID-19 plus MSC
62700639|NCT04429763|PLACEBO_COMPARATOR|Control|Usual treatment for COVID-19
62700640|NCT03236545|EXPERIMENTAL|No to Low Endogenous Estrogen|PMW and young women (YW) will receive medical study clearance after a detailed physical examination. YW will self-administer subcutaneous injections of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix acetate (Antagon, 0.25 mg/day in 0.5 ml of normal saline, Organon, Inc., West Orange, New Jersey,) daily to suppress endogenous ovarian hormone production (16, 17, 18). This will begin following a separate medical screening at Reproductive Associates of Delaware 48 hours prior to initiating the hormone intervention to rule out other contraindications prior to beginning the treatment. YW will begin using the antagonist on days 26-28 of their menstrual cycle, and continue daily for 10-12 days. The experimental protocol will be conducted in YW after 3-4 days of using the GnRH antagonist. PMW will complete the experimental protocol prior to use of the 17β-estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch).
62700641|NCT03236545|EXPERIMENTAL|Estrogen Add-Back|Estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch) will be administered for 7 days to both young and PMW. Young women will use the E2 over the last 7 days of Antagon administration.
61953428|NCT05477693|ACTIVE_COMPARATOR|Control Group|600 participants(including 300 subjects aged 2\~17 years,120 subjects aged 18\~59 years and 180 subjects aged 60 years and above)received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Merck Sharp \& Dohme.
62141769|NCT06699355|EXPERIMENTAL|Enlicitide Decanoate + Atorvastatin|Participants receive a single oral dose of enlicitide decanoate plus a single oral dose of atorvastatin (Treatment B) on Day 1.
62343897|NCT03553602|EXPERIMENTAL|HDR Brachytherapy + EBRT + STAD|"Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions.~6 months hormonal therapy(LHRH agonist and antiandrogen \[until the end of radiotherapy\])"
62343898|NCT03550287|EXPERIMENTAL|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
62700642|NCT05341843|EXPERIMENTAL|sertraline|they will receive sertraline at the intended dose of 50 mg twice daily for 8 weeks.
62700643|NCT05341843|PLACEBO_COMPARATOR|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 8 weeks
62700644|NCT01512576|EXPERIMENTAL|acupuncture|All patients were treated at the basic points bilaterally situated in the local region (neck), distal region (low back, arms and legs) and ear. In addition, acupuncture treatment was performed according to the rules of traditional Chinese medicine and was semi-standardized. This means that the therapist was allowed to choose from a list of the following acupuncture points: GV14, Huatuojiaji C1-C7, GB20, SI11, GB21, TE15, SI14, BL17, MT10, SI3, BL64, TE5, GB41, Zero point, Jerome point, C0. The combination of acupuncture points were chosen individually, according to the patients' self-reported symptoms. In order to obtain the required information, patients had to fill out a Margolis pain diagram, and the acupuncturist questioned the patient and performed a tongue- and pulse diagnosis.
62700645|NCT01512576|ACTIVE_COMPARATOR|relaxation|For the relaxation treatment the method of guided imagery is applied. Guided imagery is a system of visualization. During guided imagery relaxation, the patient's state of consciousness is similar to one which occurs in meditative status. Patients are instructed to listen to a CD with relaxation music (Arcade TV-CD Ad Vissesr's Brainsessions, track 3). Patients will sit in an identical position like during the acupuncture treatment (i.e. on a relaxation chair) and listened to the audio CD by headphone.
62700646|NCT03446690|EXPERIMENTAL|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
62700647|NCT03446690|OTHER|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
62700648|NCT00271245|EXPERIMENTAL|1|200 µg selenium as selenate
62343899|NCT03550287|PLACEBO_COMPARATOR|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
62501509|NCT06359340|ACTIVE_COMPARATOR|MAT+ office-based CBT|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT.
62501510|NCT06359340|ACTIVE_COMPARATOR|MAT+ CRS/Peer Support Specialist|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with a CRS.
61953429|NCT00000409|ACTIVE_COMPARATOR|Surgery|Decompressive Laminectomy Fusion-Instrumented Fusion-Non-instrumented
61953430|NCT00000409|ACTIVE_COMPARATOR|Non-surgical intervention|Other. Non-surgical treatments
61953431|NCT04734938|NO_INTERVENTION|Habitual Diet|All volunteers will participate in this arm, continuing this habitual diet for 1 week
61953432|NCT04734938|EXPERIMENTAL|100% Huel|All volunteers will participate in this arm of the study and consumer 100% Huel as their food for 4 weeks
62141770|NCT06699355|EXPERIMENTAL|Enlicitide Decanoate|Participants receive a single oral dose of enlicitide decanoate (Treatment C) on Day 1.
62141771|NCT03773549||Body dysmorphic disorder|Meet DSM-5 criteria for principal body dysmorphic disorder, assessed via the Structured Clinical Interview for the DSM-V Axis I Disorders (SCID)
62343900|NCT01756066|ACTIVE_COMPARATOR|A|Participant has 50% subsidy, i.e. gets a 50% discount off regular price of the program
62343901|NCT01756066|EXPERIMENTAL|B|Participant has 100% subsidy, i.e. program attendance is free
62343902|NCT01756066|EXPERIMENTAL|C|Participant has 80% subsidy; i.e. gets 80% discount off regular price of the program
62501511|NCT06359340|ACTIVE_COMPARATOR|MAT+ both CBT and CRS/Peer Support Specialist|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
62700649|NCT00271245|EXPERIMENTAL|2|400 µg selenium as selenate
62700650|NCT00271245|EXPERIMENTAL|3|200 µg selenium as selenomethionine
62700651|NCT00271245|PLACEBO_COMPARATOR|4|placebo
62700652|NCT01704157|OTHER|Open Treatment|Treatment with Cryo-Touch III Device
62343903|NCT01756066|EXPERIMENTAL|D|Participant has 50% subsidy up front (i.e. pays 50%), with possibility for 100% subsidy based on attaining monthly participation goals
62343904|NCT00817206|EXPERIMENTAL|LCP-Tacro|LCP-Tacro tablets™, once daily (LifeCycle Pharma A/S, Hoersholm DK)
62343905|NCT00817206|ACTIVE_COMPARATOR|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
62700653|NCT02692027|ACTIVE_COMPARATOR|Standard of care|Standard of care in Lesotho. ART-initiation after at least two clinic visits for pre-ART counseling and monthly follow-up visits at the clinic thereafter.
62700654|NCT02692027|EXPERIMENTAL|Same-day ART initiation with less frequent follow-up visits|Proposition of same-day ART initiation with less frequent follow-up visits thereafter.
62700655|NCT06126159|EXPERIMENTAL|multiparametric and fat-detection magnetic resonance imaging (MRI)|detecting the small amount of fat with the use of fat-detecting pulse sequences on MRI
62700656|NCT06569823|EXPERIMENTAL|Z-1018 A1|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.
62700657|NCT06569823|EXPERIMENTAL|Z-1018 A2|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.
62700658|NCT06569823|EXPERIMENTAL|Z-1018 B1(a)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.
62700659|NCT06569823|EXPERIMENTAL|Z-1018 B2(a)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.
62700660|NCT06569823|EXPERIMENTAL|Z-1018 B1(b)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85
61953433|NCT02201485|ACTIVE_COMPARATOR|PTA in combination with stent-placement|In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
61953434|NCT02201485|ACTIVE_COMPARATOR|PTA alone|In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.
62141772|NCT03773549||Healthy control|Individuals who do not have a current psychiatric diagnosis, assessed via the Mini-International Neuropsychiatric Interview (MINI)
62141773|NCT05743426||Single Arm|Subjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.
62141774|NCT03580551|EXPERIMENTAL|Intervention Group|Ten participants from each racial group (Black/White) will be assigned to the Intervention, which will receive the home-based DVD Chair Exercise Program. This is the group that will receive the chair exercise intervention upon enrollment.
62343906|NCT03662633||Breast cancer group|Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
61953435|NCT02129114|EXPERIMENTAL|ReDura Onlay|The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
62343907|NCT03662633||Benign breast tumor group|Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
62343908|NCT02580994|EXPERIMENTAL|Pembrolizumab + chemotherapy|Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease
62343909|NCT02580994|ACTIVE_COMPARATOR|Chemotherapy|4 cycles of cis/carboplatin and etoposide
62343910|NCT02085213|EXPERIMENTAL|Glyceryl Trinitrate|"Nitrolingual Pump Spray \[Coro-Nitro\] A liquid within non-pressurised, red plastic-coated glass bottle fitted with a pump capable of delivering a metered dose containing 400μg of glyceryl trinitrate.~Excipients: The formulation contains fractionated coconut oil, absolute ethanol, medium chain partial glycerides and peppermint oil.~The treatment will be self administered (2 puffs) as a single intervention. No second intervention will be given."
62343911|NCT02085213|PLACEBO_COMPARATOR|Placebo|Matched placebo formulation (except for active ingredient of Glyceryl Trinitrate) with matched packaging and labelling.
62343912|NCT05138549|PLACEBO_COMPARATOR|Control: Placebo Group|Patients will receive a 6 week daily oral supply of placebo, identical in appearance to the astaxanthin supplement.
62343913|NCT05138549|ACTIVE_COMPARATOR|Experimental: Astaxanthin Supplementation Group|Patients will receive a 6 week daily oral supply of 12 mg astaxanthin supplement.
62343914|NCT02545842|EXPERIMENTAL|Group 1|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of \<=5.6 mmol/L
62343915|NCT02545842|EXPERIMENTAL|Group 2|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of \<=6.1 mmol/L
62700661|NCT06569823|EXPERIMENTAL|Z-1018 B2(b)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85
62700662|NCT06569823|EXPERIMENTAL|Z-1018 Formulation C1(a)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.
62700663|NCT06569823|EXPERIMENTAL|Z-1018 Formulation C2(a)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.
62700664|NCT06569823|EXPERIMENTAL|Z-1018 Formulation C1(b)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.
61953436|NCT02129114|ACTIVE_COMPARATOR|DuraGen|Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.
62141775|NCT03580551|ACTIVE_COMPARATOR|Waitlist Control Group|Ten participants from each racial group (Black/White) will be assigned to the Waitlist Control Group, which will receive the home-based DVD Chair Exercise Program at the end of 8 weeks.
62141776|NCT00210275|NO_INTERVENTION|Control|Usual practice; no additional information provided.
62141777|NCT00210275|EXPERIMENTAL|Printed Educational Message #1|Information about Angiotensin-converting enzyme inhibitors, hypertension treatment, and cholesterol lowering agents for diabetes
62141778|NCT00210275|EXPERIMENTAL|Printed Educational Message #2|Retinal screening for diabetes
62700665|NCT06569823|EXPERIMENTAL|Z-1018 Formulation C2(b)|Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.
62700666|NCT06569823|EXPERIMENTAL|Shingrix|Participants will receive a dose of Shingrix by intramuscular (IM) injection on Day 1 and Day 57, or Day 1 and Day 85.
62700667|NCT04631692|NO_INTERVENTION|Usual care|Usual care in participating primary care practices.
61953437|NCT03308201|EXPERIMENTAL|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
61953438|NCT03308201|EXPERIMENTAL|Hemay022 and Letrozole|Part two: Hemay022 in combination with letrozole will be taken in OTR dose until disease progression, intolerable toxicity or death.
62141779|NCT00210275|EXPERIMENTAL|Printed Educational Message #3|Diuretics for hypertension
62141780|NCT04724265|EXPERIMENTAL|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation
62501512|NCT05629923||Kidney and Liver Transplant|All Kidney and Liver Transplant recipients who are at follow-up in our institution will be enrolled. anti-COVID-19 title was obtained by ECLIA Test(Elyx, Roche). In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca). At three months, a follow-up was performed to assess any COVID-19 infection.
62501513|NCT00153205|PLACEBO_COMPARATOR|Introduction of A Clinical Pharmacist|
62501514|NCT00153205|EXPERIMENTAL|Technological|
62501515|NCT02169791|EXPERIMENTAL|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
62501516|NCT02939261|ACTIVE_COMPARATOR|Control|Families randomized to control will receive monthly emails containing publicly available handouts on general child health.
62501517|NCT02939261|EXPERIMENTAL|Intervention - 4 Home Visits|Families randomized to the intervention will receive: a) 4 home visits from a health educator, b) weekly e-mails, and c) monthly mailed behavioural supports.
62141781|NCT06195306|EXPERIMENTAL|Group 1 (tamoxifen)|Participants receive tamoxifen PO QD for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.
62141782|NCT06195306|EXPERIMENTAL|Group 2 (tamoxifen, omega-3 fatty acids)|Participants receive tamoxifen PO QD and omega-3 fatty acids PO BID for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD and omega-3 fatty acids PO BID for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.
62141783|NCT04359069|EXPERIMENTAL|Urinary catheter removal on postoperative day 1|
62141784|NCT04359069|ACTIVE_COMPARATOR|Urinary catheter removal on postoperative day 3|
62141785|NCT00518206|EXPERIMENTAL|Cohort 1|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
62501518|NCT02798328||Reference Range|Healthy Subjects
62501519|NCT02798328||DOAC Pivotal|DOAC Eligible Subjects
62501520|NCT01347320|NO_INTERVENTION|No preoperative MRI|control arm of the study
62501521|NCT01347320|ACTIVE_COMPARATOR|MRI group|preoperative MRI
62501522|NCT04674150|SHAM_COMPARATOR|Non-AR Group|Patients allocated to the control group will be able to interact with the iPad and visualize objects and decals in the walls but not able to initiate the AR technology. In other terms, patients in this group will be provided with the same iPad to the AR group patients with the only exception that the AR technology will be off and will only see objects through the device camera in normal reality.
62501523|NCT04674150|ACTIVE_COMPARATOR|AR Group|Patients randomized to the AR group will be able to use the iPad and SpellBound app to initiate the AR experiences in the game.
62501524|NCT03509285|PLACEBO_COMPARATOR|Qualification Y|Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
62501525|NCT03509285|ACTIVE_COMPARATOR|Qualification Z|Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated
62501526|NCT03509285|PLACEBO_COMPARATOR|Treatment A|Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
62501527|NCT03509285|ACTIVE_COMPARATOR|Treatment B|Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
62501528|NCT03509285|ACTIVE_COMPARATOR|Treatment C|Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
62501529|NCT03509285|EXPERIMENTAL|Treatment D|Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
62501530|NCT03509285|EXPERIMENTAL|Treatment E|Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
62501531|NCT01658995|ACTIVE_COMPARATOR|Post ESI implant - Doxycycline|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received Doxycycline 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
62501532|NCT01658995|PLACEBO_COMPARATOR|Post ESI implant - Placebo|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received placebo 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
62501533|NCT02418624|EXPERIMENTAL|Dose escalation|carboplatin, olaparib
62501534|NCT06678841|EXPERIMENTAL|Personalized Pacing Therapy (Treatment Group)|The treatment group will receive a qualifying Medtronic dual chamber pacemaker limited to Astra XT or Azure XT and programmed to provide dual chamber pacing at a personalized elevated cardiac pacing rate determined by patient height and baseline LVEF percentage.
62501535|NCT06678841|NO_INTERVENTION|Control Group|The control group will receive a qualifying Medtronic dual chamber pacemaker limited to Astra XT or Azure XT and programmed to provide ventricular pacing at a lower rate of 30 bpm. This is considered limited or backup pacing.
62501536|NCT01873339|EXPERIMENTAL|Darapladib|The subjects will receive a single oral dose of midazolam 5 mg on Day 1. The subjects will receive darapladib 160 mg once daily on Days 3-14. The subjects will also receive a single dose of midazolam 5 mg on Day3 and 14.
62700668|NCT04631692|ACTIVE_COMPARATOR|Health literacy intervention|Health literacy intervention combining health literacy and colorectal cancer screening training for general practitioners with a short brochure and video targeting eligible patients.
62343916|NCT02545842|EXPERIMENTAL|Group 3|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of \<=7.0 mmol/L
62343917|NCT02632500|EXPERIMENTAL|30 compressions and 2 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 30 compressions and 2 seconds of pause protocol (30 chest compressions followed by 2 seconds of pause) on a manikin connected to the Personal Computer."
62501537|NCT06228248||medical worker|Medical workers working in clinical settings, including nurses, doctors, and Health care worker.
62501538|NCT06228248||health population|Healthy individuals who do not engage in medical work
61953439|NCT03308201|EXPERIMENTAL|Hemay022 and Fulvestrant|Part two: Hemay022 in combination with fulvestrant will be taken in OTR dose until disease progression, intolerable toxicity or death.
62343918|NCT02632500|EXPERIMENTAL|50 compressions and 5 seconds of pauses|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 50 compressions and 5 seconds of pause protocol (50 chest compressions followed by 5 seconds of pause) on a manikin connected to the Personal Computer."
62343919|NCT02632500|EXPERIMENTAL|100 compressions and 10 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 100 compressions and 10 seconds of pause protocol (100 chest compressions followed by 10 seconds of pause) on a manikin connected to the Personal Computer."
62343920|NCT02632500|EXPERIMENTAL|hands-only|"After the randomization the participant will be asked to perform 8 minutes of CPR following the hands-only protocol (continuous chest compressions without any pauses) on a manikin connected to the Personal Computer."
62343921|NCT04540302|EXPERIMENTAL|AVF Peripheral study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
62343922|NCT04540302|OTHER|AVF Peripheral control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
62501539|NCT04187703|EXPERIMENTAL|5AZA-alt-DEC|"Participants will be treated for a minimum of 24 weeks in the absence of clear evidence of progressive disease. Patients who have any response will be permitted to continue treatment until relapse or progression of disease that is not sensitive to protocol defined dose escalation.~Treatments will include:~5-azacytidine (50mg/m\^2) Day 1 every week~Decitabine (5mg/m\^2) Day 4 every week~Weeks 1-8 will be an induction phase, and weeks 9+ will be a long-term treatment phase"
62501540|NCT00843089|NO_INTERVENTION|1|Standard care
62501541|NCT00843089|EXPERIMENTAL|2|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
62501542|NCT01978691|ACTIVE_COMPARATOR|Probiotic|Bifidobacterium animalis ssp. lactis 420 (10\^10 colony-forming units (CFU)/day in 12 g of microcrystalline cellulose), once per day for six months in a sachet mixed into a smoothie drink
62501543|NCT01978691|ACTIVE_COMPARATOR|Prebiotic|Polydextrose, 12 g once per day for six months in a sachet mixed into a smoothie drink
62501544|NCT01978691|ACTIVE_COMPARATOR|Synbiotic|B. lactis 420 (10\^10 CFU/day) in 12 g of polydextrose, once per day for six months in a sachet to be mixed into a smoothie drink
62501545|NCT01978691|PLACEBO_COMPARATOR|Control|12 g of microcrystalline cellulose once per day for six months in a sachet to be mixed into a smoothie drink
62501546|NCT06400238|EXPERIMENTAL|Treatment (copanlisib)|Patients receive copanlisib IV over 60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients undergo biopsies and blood sample collection on study.
62501547|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
62501548|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
62141786|NCT00518206|EXPERIMENTAL|Cohort 2|Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
62501549|NCT05995990|EXPERIMENTAL|Colorectal liver metatases|Liver tissue containing colorectal liver metastases
62501550|NCT00345033|EXPERIMENTAL|1|Participants will take aripiprazole 15mg/day for 8 weeks.
62501551|NCT00345033|PLACEBO_COMPARATOR|2|Participants will take placebo for 8 weeks.
62501552|NCT05542849|EXPERIMENTAL|Arm A|
62501553|NCT05542849|EXPERIMENTAL|Arm B|
62141787|NCT00040105|EXPERIMENTAL|Zarnestra + Gleevec|
62343923|NCT04540302|EXPERIMENTAL|AVG Anastomosis|All subjects in this single arm cohort will receive treatment with the WRAPSODY Endovascular Stent Graft
62343924|NCT02781454|ACTIVE_COMPARATOR|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 4 weeks.
62501554|NCT05874648||Cancer arm|
62343925|NCT02781454|ACTIVE_COMPARATOR|Mexiletine, 600 milligrams|Mexiletine, 600 milligrams by mouth per day for 4 weeks.
62343926|NCT02781454|PLACEBO_COMPARATOR|Placebo|Placebo, by mouth per day for 4 weeks.
62501555|NCT05874648||Non-cancer arm|
62501556|NCT05203146|EXPERIMENTAL|Arm A (PIMPmyHospital)|Participants that will use the mobile heath PIMPmyHospital tool during the semi-simulation-based scenario.
62501557|NCT05203146|ACTIVE_COMPARATOR|Arm B (Conventional methods)|Participants that will use conventional methods (i.e., without mobile app support) during the semi-simulation-based scenario.
62501558|NCT01647360||Women with Heavy Menstrual Bleeding (HMB)|
62501559|NCT01630616|EXPERIMENTAL|Adolescents Odanacatib 10 mg|Study drug (single oral dose of odanacatib 10 mg) was administered following at least an 8-hour fast to adolescents.
62141788|NCT06086067|EXPERIMENTAL|Aerobic session in luteal phase|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 40 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test. This session will be held on day 21 of menstruation.
62343927|NCT05725421|EXPERIMENTAL|cT1a Radical Nephrectomy + Donor Kidney Transplantation|Radical nephrectomy will be used to remove a cT1a renal mass in an altruistic kidney donor. The kidney obtained from the radical nephrectomy participant with the cT1a mass removed will be transplanted to the recipient using an allograft.
62501560|NCT01630616|EXPERIMENTAL|Adolescents Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to adolescents.
62501561|NCT01630616|PLACEBO_COMPARATOR|Adolescents Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to adolescents.
62501562|NCT01630616|EXPERIMENTAL|Young Adults Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to young adults.
62343928|NCT04101487|NO_INTERVENTION|Control|Participants in this arm will receive routine monthly visits along with survey administration and the regular package of health services provided at the facility level and at home by community health assistants
62343929|NCT04101487|EXPERIMENTAL|Cash Transfers|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants and unconditional cash transfers every month
62343930|NCT04101487|EXPERIMENTAL|Cash Transfers and Nutrition Education|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants, unconditional cash transfers every month, and structured nutrition education provided at household level by community health assistants based on a structured nutrition education handbook.
62343931|NCT05175209|OTHER|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
62343932|NCT03388996||Benign ovarian disease|The group consists of patients of benign ovarian diseases and health conditions (eg infertility), who would accept the tests of pelvic microbiomes.
62343933|NCT03388996||Malignant ovarian disease|The group consists of patients of high grade serous carcinoma, who would accept the tests of pelvic microbiomes.
62343934|NCT00684125|EXPERIMENTAL|1|mediastinal drainage will be accomplished using a 28F or 32F chest tube in the anterior mediastinum and a 19F Blake drain located in the posterior pericardial cavity.
62343935|NCT00684125|ACTIVE_COMPARATOR|2|mediastinal drainage will be accomplished using two 28F or 32F chest tubes located in the anterior mediastinum.
62343936|NCT03085355|ACTIVE_COMPARATOR|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
62343937|NCT03085355|EXPERIMENTAL|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
62343938|NCT04985331|EXPERIMENTAL|W-GenZD|W-GenZD is powered by natural language processing and machine learning techniques, the brief, self-guided intervention draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT-A) and some elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile medical application is designed to be targeted, relevant, tailored, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.
62343939|NCT04985331|NO_INTERVENTION|Psychoeducation Control|The control for this study is the scheduled delivery of digital psychoeducational files (PDFs). The PDFs were selected to provide information on depression, anxiety and stress, as well as outline common coping skills.
62343940|NCT01498237|EXPERIMENTAL|Photoacoustic endoscopy|This is a one-arm, feasibility study to determine how well the experimental procedure photoacoustic endoscopy will evaluate the human endometrial cavity in vivo.
62343941|NCT01380444|ACTIVE_COMPARATOR|1|Gamma3 Intramedullary Nails
62343942|NCT01380444|ACTIVE_COMPARATOR|2|Sliding Hip Screws
62343943|NCT00483158|PLACEBO_COMPARATOR|A|Rising Single Dose
62343944|NCT00483158|PLACEBO_COMPARATOR|B|Rising Multiple Dose
62343945|NCT00483158|EXPERIMENTAL|C|Open Label H. pylori cohort
62343946|NCT03701217|EXPERIMENTAL|Eltrombopag treatment|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
62343947|NCT03701217|ACTIVE_COMPARATOR|Eltrombopag free|Eltrombopag treatment is not performed in this group. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
62343948|NCT02995330|EXPERIMENTAL|Bone marrow transplantation|"Bone marrow transplantation followed by Cytoxan and testosterone~Day -6 to -1: Subjects will be treated with a standard non-myeloablative conditioning regimen~Day 0: subjects will be infused with non-T-cell depleted bone marrow from a related female donor.~Subjects will receive GVHD prophylaxis consisting of:~Day +3 and +4: Cytoxan (Cy) 50mg/kg IV Day +5 through Day +180: tacrolimus (IV or PO) beginning \[dose adjusted to maintain trough level of 5-15 ng/mL\] Day +5 through Day +35: Mycophenolate mofetil (MMF) 15 mg/kg PO TID, with a maximum dose of 1g TID.~Day +5: filgrastim (G-CSF) 5 mcg/kg/day, continued until ANC ≥ 1500/mm3.~Day +60, +90, and +120: testosterone cypionate 400 mg IM every 30 days x 3 doses~Subjects will be maintained on continuous LHRH agonist/antagonist therapy (if not previously surgically castrated). Subjects who achieve biochemical CR will stop LHRH agonist/antagonist treatmentat day 180."
62700669|NCT06563908|EXPERIMENTAL|Lipiodol® uterine treatment prior to IVF/ICSI|"For those who are randomized to Lipiodol®, treatment will be performed by a HSG technique with X-ray screening on day 3 or day 5 after oocyte retrieval. The contrast medium will be Lipiodol Ultra Fluide® (Guerbet, France), an iodized poppy seed oil obtained by substitution of ethyl esters for the glyceryl esters of Lipiodol®. After that the procedure to assess study participants' pain perception.~Endometrial preparation for frozen embryo transfer will perform on the subsequence cycle"
62700670|NCT06563908|NO_INTERVENTION|No Lipiodol® uterine treatment prior to IVF/ICSI|"For those who are randomized to no intervention arm (control group), there will be no HSG performed.~Endometrial preparation for frozen embryo transfer will perform on the subsequence cycle"
62700671|NCT02593630|EXPERIMENTAL|Unicirc circumcision|Unicirc circumcision under topical anaesthetic, wound sealing with cyanoacrylate tissue adhesive
62501563|NCT01630616|PLACEBO_COMPARATOR|Young Adults Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to young adults.
62501564|NCT02224053|EXPERIMENTAL|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
62700672|NCT05031832||HIV-negative|
62700673|NCT05031832||HIV-positive|
62700674|NCT00160563|EXPERIMENTAL|LCTZ-LCTZ|Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
62141789|NCT06086067|EXPERIMENTAL|Aerobic session in follicular phase|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 40 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test. This session will be held on day 3 of menstruation.
62141790|NCT02631668|EXPERIMENTAL|ferrous succinate and vitamin C|In this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
62141791|NCT02631668|ACTIVE_COMPARATOR|ferrous succinate with normal dosage|In this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
62141792|NCT02631668|ACTIVE_COMPARATOR|ferrous succinate with double dosage|In this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
62141793|NCT03075683|EXPERIMENTAL|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
62343949|NCT00000113|EXPERIMENTAL|Progressive Addition Lenses (PALs)|
62343950|NCT00000113|ACTIVE_COMPARATOR|Single Vision Lenses|
62343951|NCT02066194|ACTIVE_COMPARATOR|Electroacupuncture|Patients randomized to the experimental group will receive EA at acupoints relevant to the treatment of abdominal pain and anxiety. Selection of these acupoints is based on a consensus between the acupuncturist of the study (Leung WW) and several professors of the Diploma Course of Clinical Acupuncture of the School of Professional and Continuing Education, University of Hong Kong.
62501565|NCT04133675|ACTIVE_COMPARATOR|Emsella Chair Active Treatment|Active treatment subjects will be asked to sit on the center of the Emsella chair. The height of the chair will be adjusted until the participant's feet are on the floor. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
62700675|NCT00160563|PLACEBO_COMPARATOR|LCTZ-PLC|Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
62700676|NCT00160563|PLACEBO_COMPARATOR|PLC-PLC|Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)
62700677|NCT02145884|EXPERIMENTAL|timolol maleate 0.5% gel|timolol gel 1 to 2 drops twice a day to lesions for 4 months
62700678|NCT04023045|ACTIVE_COMPARATOR|Habitual Prosthesis|Participant's prescribed prosthesis
62700679|NCT04023045|EXPERIMENTAL|Assist-Knee|Experimental knee prosthesis
62700680|NCT00203606|EXPERIMENTAL|Active Treatment|Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin
62141794|NCT03075683|ACTIVE_COMPARATOR|Applied relaxation|Internet-based applied relaxation
62343952|NCT02066194|PLACEBO_COMPARATOR|Sham Acupuncture|Patients randomized to the control group will receive Sham acupuncture with sterile blunt-tip needles
62343953|NCT06066203|EXPERIMENTAL|Study treatment|Participants receive GNC-035 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62343954|NCT01780909|EXPERIMENTAL|Paromomycin Sulfate Fasted State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
62501566|NCT04133675|SHAM_COMPARATOR|Emsella Sham Treatment|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).
62700681|NCT00203606|NO_INTERVENTION|Observation|Observation with no active treatment for Hepatitis C. Observation period is based on standard treatment duration based on genotype of Hepatitis C. Active treatment offered to participants at conclusion of observation. (Protocol Amendment #1, October 30, 2001. Ethics approval Jan 19, 2004).
62700682|NCT05119582|EXPERIMENTAL|TOOsonix System ONE-M|Cutaneous neurofibromas will be treated by high intensity focused ultrasound.
62700683|NCT05020457|EXPERIMENTAL|SI-B001 combined with AP or TP_A|SI-B001 combined with Platinum-based chemotherapy(AP or TP). Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant after first-line treatment with anti-PD-1 /L1 mab alone.
62700684|NCT05020457|EXPERIMENTAL|SI-B001 combined with Docetaxel_B|Patients with EGFRwt/ALKwt non-small cell lung cancer were included and progressed or were intolerant after first-line treatment with platinum-based two-drug chemotherapy plus anti-PD-1 /L1 mab.
62700685|NCT05020457|EXPERIMENTAL|SI-B001 combined with Docetaxel_C|Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant to treatment with anti-PD-1 /PD-L1 monoclonal antibody after first-line or above chemotherapy.
62700686|NCT03424343||cancer survivor, parents, sibling|study samples adolescent and young adult survivors of pediatric cancer, their parents, and one sibling; they are assessed using self-report questionnaires, so no intervention takes place
62700687|NCT01622478||Clinically node-positive patients before NAC|"Patients with clinically positive lymph node receiving neoadjuvant chemotherapy~1. Clinically negative-node after NAC~2. Clinically positive-node after NAC"
62700688|NCT00567554|EXPERIMENTAL|1|EC-T
62700689|NCT00567554|EXPERIMENTAL|2|EC-T +/- B
62700690|NCT00567554|EXPERIMENTAL|3|Pw
62700691|NCT00567554|EXPERIMENTAL|4|Pw + RAD001
62700692|NCT00567554|EXPERIMENTAL|5|EC-T + H
62700693|NCT00567554|EXPERIMENTAL|6|EC-T + L
62700694|NCT03505060|EXPERIMENTAL|Group 1: DNA CON-S env + IHV01|Participants will receive 4 mg of DNA CON-S env at Months 0 and 1. They will receive 4 mg of DNA CON-S env and 150 mcg of IHV01 at Months 3 and 6.
62700695|NCT03505060|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive placebo at Months 0, 1, 3, and 6.
62700696|NCT01413009||ICU patients|Adult patients admitted to the University of Nebraska Medical Center or the Nebraska Medical Center trauma critical care service.
62700697|NCT05176067|NO_INTERVENTION|drug therapy group|targeted therapy, immune, chemotherapy
62700698|NCT05176067|EXPERIMENTAL|drug therapy concurrent radiotherapy|drug therapy(targeted therapy, immune, chemotherapy ) combined with thoracic tumor concurrent radiotherapy
62700699|NCT03367104||Normal healthy controls|
62700700|NCT03367104||Heart failure patients|
62700701|NCT04843592||Type II diabetes|using mobile app
62700702|NCT04669795|PLACEBO_COMPARATOR|Group 1|Placebo was given to ten patients during consolidation period ( 2 capsule daily for 6 months during consolidation period)
62700703|NCT04669795|EXPERIMENTAL|Group 2|Cissus quadrangularis in form of capsules given to ten patients ( 2 capsule daily for 6 months during consolidation period)
62700704|NCT04194242|EXPERIMENTAL|HEC96719 tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240 mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
62700705|NCT04194242|PLACEBO_COMPARATOR|placebo tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
62700706|NCT04597801|EXPERIMENTAL|Fluorescein sodium|A single dose of fluorescein sodium is applied before brain tumor resection. 20-40 minutes prior to the planned tumor resection, a bolus of 5 mg per kg body weight is administered intravenously, staining tumor tissue with fluorescent dye to visualize tumor cells.
61953440|NCT00080470|EXPERIMENTAL|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
61953441|NCT00080470|SHAM_COMPARATOR|2|No Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
61953442|NCT02556554|NO_INTERVENTION|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
62700707|NCT01798602|EXPERIMENTAL|Rosuvastatin|"Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug~Both are crushed for administration"
61953443|NCT02556554|ACTIVE_COMPARATOR|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
62700708|NCT01798602|PLACEBO_COMPARATOR|Placebo|Identical drug vehicle with no active agent
62700709|NCT02115529|ACTIVE_COMPARATOR|Cesamet (nabilone)|0.5 mg capsule containing Cesamet (single dose) given preoperatively
62700710|NCT02115529|PLACEBO_COMPARATOR|Placebo|identical capsule containing placebo (single dose) given preoperatively
62700711|NCT02106429||Platelet Hyperactivity|Subjects with platelet hyperactivity undergoing non emergent lower extremity revascularization.
62700712|NCT02106429||No Platelet Hyperactivity|Subjects with no platelet hyperactivity undergoing non emergent lower extremity revascularization.
62700713|NCT03205267|EXPERIMENTAL|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
62700714|NCT04033640|OTHER|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as finger-stick capillary blood samples.~At the clinic site, study staff performed the SD Biosensor STANDARD G6PD test and the POC HemoCue hemoglobin test on finger stick blood samples.~At the reference laboratories, G6PD activity was measured from whole blood samples using the SD Biosensor STANDARD G6PD test and the Pointe Scientific G6PD reference assay and hemoglobin was measured using the HemoCue hemoglobin test and by a complete blood count (CBC) using an automated hematology analyzer (Manaus site only)."
62700715|NCT04033640|NO_INTERVENTION|Health Workers|Participants were trained on use of the SD Biosensor STANDARD G6PD test by members of the study team with extensive experience with G6PD diagnostics and the STANDARD G6PD test. Health worker participants were surveyed to assess label and packing comprehension as well as results interpretation.
62700716|NCT02652247|EXPERIMENTAL|ventilated trauma patients with pneumonia|ventilated trauma patients with pneumonia
62700717|NCT02652247|EXPERIMENTAL|ventilated trauma patients without pneumonia|ventilated trauma patients without pneumonia
62700718|NCT02652247|EXPERIMENTAL|ventilated surgical ICU patients with pneumonia|ventilated surgical ICU patients with pneumonia
62700719|NCT02652247|EXPERIMENTAL|ventilated surgical ICU patients without pneumonia|ventilated surgical ICU patients without pneumonia
62700720|NCT02769104|EXPERIMENTAL|AI+Chemo|aromatase inhibitors (Letrozole 2.5mg po. QD for 5 years) starts at the beginning of neoadjuvant treatment combined with chemotherapy (AC\*4-T\*4) in patients with postmenopausal hormone receptor-positive breast cancer
62141795|NCT01841671|EXPERIMENTAL|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
62501567|NCT04949386|EXPERIMENTAL|Treatment with S-1226 (8%)|Subjects randomized to this treatment arm will receive S-1226(8%) twice daily for 7 consecutive days. S-1226 will be administered by inhalation for 3-4 minutes.
61953444|NCT02556554|ACTIVE_COMPARATOR|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
62343955|NCT01780909|EXPERIMENTAL|Paromomycin Sulfate Fed State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state. Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed. 20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
61953445|NCT02283385|EXPERIMENTAL|PROTECT Intervention|Participants will receive a brief psychotherapy that builds on Problem Solving Therapy (PST)
62343956|NCT01780909|EXPERIMENTAL|Paromomycin Sulfate w/ Domperidone|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
62343957|NCT01780909|EXPERIMENTAL|Paromomycin Sulfate w/ Loperamide HCl|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
62343958|NCT06087042||Group I|patients suffering from oral squamous cell carcinoma
62343959|NCT06087042||Group II|patients diagnosed with potentially malignant lesions such as leukoplakia, and dysplastic erosive or atrophic oral lichen planus
62343960|NCT06087042||Group III|individuals with no oral mucosal lesions
62343961|NCT02640144|ACTIVE_COMPARATOR|Treatment group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of Sodium Hyaluronate 1% - ARTHREASE TM
62141796|NCT01841671|ACTIVE_COMPARATOR|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
62141797|NCT01841671|ACTIVE_COMPARATOR|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
62141798|NCT01051271|ACTIVE_COMPARATOR|diphenhydramine|
62343962|NCT02640144|PLACEBO_COMPARATOR|Control group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of BPS - Buffer Phosphate Solution - as a placebo
62343963|NCT02494388||Serous cystadenoma|Serous cystadenoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
62501568|NCT04949386|PLACEBO_COMPARATOR|Placebo|Subjects randomized to receive placebo will be administered with medical grade air with 3ml saline (0.9% NaCl) using the Circulaire II hybrid system. Placebo will be administered by inhalation for 3-4 minutes.
62501569|NCT01186016|EXPERIMENTAL|Genetic Education Session (GES)|The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
62501570|NCT01186016|ACTIVE_COMPARATOR|Nutrition Education Session (NES)|The objective is to provide a control group that will received comparable attention as the experimental group by providing USDA approved nutritional information (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
62501571|NCT06015672|ACTIVE_COMPARATOR|TMS to premotor cortex|Participants receive TMS at premotor cortex
62501572|NCT06015672|ACTIVE_COMPARATOR|TMS to primary somatosensory cortex|Participants received TMS sessions at primary somatosensory cortex
62501573|NCT06015672|SHAM_COMPARATOR|TMS at low amplitude to primary somatosensory cortex|Participants receive TMS at a cortical target at smaller amplitude
62501574|NCT02522780|EXPERIMENTAL|Mesalamine|Mesalamine 2 g extended release granules (sachet), administered orally once daily (QD) for 6 months.
62501575|NCT02522780|PLACEBO_COMPARATOR|Placebo|Placebo matched to mesalamine extended release granules (sachet), administered orally QD for 6 months.
62501576|NCT03354208||Group 1|patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy
62700721|NCT02769104|ACTIVE_COMPARATOR|Chemo|chemotherapy (AC\*4-T\*4) as neoadjuvant treatment without aromatase inhibitors in patients with postmenopausal hormone receptor-positive breast cancer
62700722|NCT03185026|ACTIVE_COMPARATOR|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
62700723|NCT03185026|EXPERIMENTAL|Psychoeducational group|The patients will experiment the last innovating psychological skills in order to acquire the ability to engage in behaviors to manage their disease.
62700724|NCT00822094|EXPERIMENTAL|CPX-351 (Arm A)|First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
62700725|NCT00822094|ACTIVE_COMPARATOR|Salvage Therapy (Arm B)|First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
62700726|NCT04763109|EXPERIMENTAL|Whole-Body Magnetic Resonance Imaging|
62700727|NCT03639402|EXPERIMENTAL|Health education classes|"Intervention consist of 2 rounds. Round 1: Locally selected mothers who have children 1-9 years old are trained by research team (peer mothers). Peer mothers conduct 4 education classes each for approximately 10 eligible mothers in their neighbourhood (fellow mothers).~Round 2: After one month gap one meeting for recapitulation and feedback is conducted by research team for peer mothers. Similarly, peer mothers conduct one meeting with fellow mothers."
62700728|NCT03639402|NO_INTERVENTION|No health education classes|Community is exposed to health-related information, which is provided by the regular health system of Nepal
62700729|NCT00422487|EXPERIMENTAL|MBX-2044 1.5 mg|
62700730|NCT00422487|EXPERIMENTAL|MBX-2044 4.5 mg|
62700731|NCT00422487|EXPERIMENTAL|MBX-2044 15 mg|
62700732|NCT00422487|EXPERIMENTAL|MBX-2044 30 mg|
62700733|NCT00422487|EXPERIMENTAL|MBX-2044 60 mg|
62700734|NCT00422487|EXPERIMENTAL|MBX-2044 90 mg|
62700735|NCT00422487|PLACEBO_COMPARATOR|Placebo|
62700736|NCT06234514|EXPERIMENTAL|Combination Therapy Group|"During the initial month, the patient consumed Jueling Mingmu decoction daily for one month.~Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria."
62700737|NCT06234514|ACTIVE_COMPARATOR|Intravitreal Ranibizumab Group|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
62700738|NCT02480049|EXPERIMENTAL|A Test|test drug (Asmakast)1 tablet contains 10 mg Montelukast
62700739|NCT02480049|ACTIVE_COMPARATOR|B Reference|reference drug (Singulair) 1 tablet contains 10 mg Montelukast
62141799|NCT01051271|PLACEBO_COMPARATOR|saline|
62700740|NCT00425555|EXPERIMENTAL|Previously treated with oral bexarotene|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
62700741|NCT00425555|EXPERIMENTAL|No prior oral bexarotene treatment|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
62700742|NCT02576626|OTHER|A|Participants start with Ultibro (indacaterol/glycopyrronium 110/50) + placebo nebulization , then after a new washout period of 7 days they will receive ipratropium/salbutamol nebulization and placebo Breezhaler Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation
62700743|NCT02576626|OTHER|B|"Participants start with ipratropium/salbutamol nebulization and placebo Breezhaler , then after a new washout period of 7 days they will receive Ultibro(indacaterol/glycopyrronium 110/50) + placebo nebulization.~Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation"
62700744|NCT05589025|ACTIVE_COMPARATOR|treatment group|pulpotomy: amputation of coronal pulp
62700745|NCT05589025|ACTIVE_COMPARATOR|control group|Pulpectomy: complete removal of the pulp tissues from the canals
62700746|NCT03220009|ACTIVE_COMPARATOR|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients undergo active surveillance for 1 year."
62141800|NCT00605306|EXPERIMENTAL|indacaterol maleate/mometasone furoate|Participants received 2 inhalations of indacaterol maleate / mometasone furoate 250/400 μg once daily in the evening (full dose 500/800 μg) delivered via the Twisthaler device for 14 days.
62141801|NCT00605306|PLACEBO_COMPARATOR|Placebo|Participants received 2 inhalations of placebo to indacaterol maleate / mometasone furoate once daily in the evening delivered via the Twisthaler device for 14 days.
62141802|NCT04874259|EXPERIMENTAL|Colorectal cancer liver metastasis|Liver transplantation for the treatment of unresectable colorectal cancer liver metastasis
62343964|NCT02494388||Mucinous cystic neoplasms|Mucinous cystic neoplasms patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
62501577|NCT03354208||Group 2|patients with suspected HIE, non-confirmed
62700747|NCT03220009|EXPERIMENTAL|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
61953446|NCT02875054|ACTIVE_COMPARATOR|Continued Casting|Participants with 24 hour cast wear (continued casting) for the entire duration of the constraint portion of camp (2 initial weeks).
61953447|NCT02875054|ACTIVE_COMPARATOR|Intermittent Casting|Participants who wear a univalve cast for 3 hours of constraint camp with home exercise program of 2 hours cast wear on the weekends (intermittent casting).
62700748|NCT06389032|EXPERIMENTAL|Caregiver Mentees|Less experienced LBD family caregivers (\<3 years since care recipient's cognitive impairment and/or hallucinations began) will receive PDF and website versions of the PERSEVERE modular curriculum, covering key areas of knowledge in LBD symptom and progression, caregiver strain and self-care, and links to pre-existing additional resources available on the web through various patient-facing foundations (e.g., Lewy Body Dementia Association, Parkinson's Foundation). These mentees will be matched with a trained peer mentor and will complete weekly phone or videoconference calls with each other, using the PDF and/or web-based curriculum (identical in content) as a guide for practical discussions for 12 weeks. They will complete biweekly online surveys regarding frequency, duration, and content of mentoring calls, and any falls or acute healthcare utilization of their care recipient. After the 12 weeks of mentoring, they will complete biweekly surveys for six months of follow-up.
62700749|NCT06389032|ACTIVE_COMPARATOR|Education Group|Less experienced LBD family caregivers (\<3 years since care recipient's cognitive impairment and/or hallucinations began) randomized (1:1) to the education group arm will receive weekly emails from the study team delineating key topics in LBD symptom and progression, caregiver strain and self-care, and links to pre-existing additional resources available on the web through various patient-facing foundations (e.g., Lewy Body Dementia Association, Parkinson's Foundation). They will complete biweekly online surveys regarding frequency, duration, and content of mentoring calls, and any falls or acute healthcare utilization of their care recipient. After the 12 weeks of emails, they will complete biweekly surveys for six months of follow-up.
61953448|NCT02320669|EXPERIMENTAL|Triostat|Active Medication - Synthetic Thyroid Hormone
62343965|NCT02494388||Intraductal papillary mucinous neoplasms (IPMN)|IPMN patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
62343966|NCT02494388||Mucinous cystdenocarcinoma|Mucinous cystadenocarcinoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
62343967|NCT02494388||Other cystic lesions|Other cystic lesions patients (cystic neuroendocrine tumors, solid pseudopapillary neoplasms, cystic lymphangioma, etc.) Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients..
62343968|NCT01309438|EXPERIMENTAL|Normal renal function|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
62343969|NCT01309438|EXPERIMENTAL|Mild renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
62700750|NCT06389032|OTHER|Peer mentors|Experienced LBD caregivers with \>3 years' caregiving experience OR caregivers whose loved one with LBD is deceased will be recruited and trained through asynchronous and synchronous online peer mentor training to serve as mentors to less experienced LBD caregivers in the experimental arm.
62700751|NCT06022640|EXPERIMENTAL|Group 1|The study included 75 patients in the intervention group who received an educational and supportive program designed by a clinical pharmacist. The intervention group received support through five visits: at admission, monitoring medication, monitoring ovulation, monitoring harmful effects, providing emotional support, and following up after egg retrieval during embryo transfer.
62700752|NCT06022640|NO_INTERVENTION|Group 2|The control group included 75 infertile married ladies attending the hospital for the same purpose and managed in the traditional protocol followed by the hospital system. The study assessed the fertility quality of life and depression status of the patients at the beginning and end of the IVF cycle. All patients received frozen embryo transfers (fertilized eggs), not fresh embryos.
61953449|NCT02320669|PLACEBO_COMPARATOR|Placebo|Placebo Control
61953450|NCT05406141|EXPERIMENTAL|children with food protein allergy|
61953451|NCT00742430||Resistant|patients who are resistant to standard antithrombotic drugs
61953452|NCT00742430||Nonresistant|patients who are not resistant to standard dual antithrombotic drugs
61953453|NCT05334966|NO_INTERVENTION|Historical LHH Controls|Previous women with a dx of fetal LHH and whose care was continued at Texas Children's Hospital.
62501578|NCT03354208||Group 3|healthy, retrospectively classified as such
61953454|NCT05334966|PLACEBO_COMPARATOR|Healthy Fetal Controls|Healthy mothers with healthy fetuses that will come in monthly for fetal echcos starting at 20 wks.
61953455|NCT05334966|EXPERIMENTAL|Chonic Maternal Hyperoxygenation w/ LHH|Mothers who have a fetus diagnosed with LHH and elect daily maternal hyperoxygenation therapy.
62501579|NCT01370239|EXPERIMENTAL|Hu3S193|Single arm
61953456|NCT05334966|EXPERIMENTAL|Acute Maternal Hyperoxygenation with LHH|Mothers who have a fetus diagnosed with LHH and elect acute maternal hyperoxygenation challenge testing.
61953457|NCT02144415|EXPERIMENTAL|EB-1020 400 mg|EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules
61953458|NCT02144415|EXPERIMENTAL|EB-1020 800 mg|EB-1020 800 mg, administered as eight 100-mg IR capsules
61953459|NCT02144415|ACTIVE_COMPARATOR|lisdexamfetamine 150 mg|lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules
61953460|NCT02144415|ACTIVE_COMPARATOR|d-amphetamine 40 mg|d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules
61953461|NCT02144415|PLACEBO_COMPARATOR|Placebo|Placebo, administered as 8 matching placebo capsules
61953462|NCT03350581|ACTIVE_COMPARATOR|FAM-CT 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM with CT or MRI.
61953463|NCT03350581|EXPERIMENTAL|FAM 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM alone.
61953464|NCT05762198|ACTIVE_COMPARATOR|Rezūm|
61953465|NCT05762198|ACTIVE_COMPARATOR|TURP|
61953466|NCT03674671|EXPERIMENTAL|Intravenous Ketamine|
61953467|NCT03674671|ACTIVE_COMPARATOR|Electroconvulsive Therapy|
61953468|NCT05995483|EXPERIMENTAL|Have access to web based BSE training and notifications|Have the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
62343970|NCT01309438|EXPERIMENTAL|Moderate renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
62501580|NCT01671592|EXPERIMENTAL|Day 1 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
62501581|NCT01671592|EXPERIMENTAL|Day 3 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
62501582|NCT01671592|EXPERIMENTAL|Day 1 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
62343971|NCT03424889|EXPERIMENTAL|Xylometazoline|Patients receiving topical xylometazoline nasally during bronchoscopy
62343972|NCT03424889|PLACEBO_COMPARATOR|Saline placebo|Patients receiving topical saline nasally during bronchoscopy
62501583|NCT01671592|EXPERIMENTAL|Day 3 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
62501584|NCT03788356|EXPERIMENTAL|Diaphragmatic breathing|Diaphragmatic breathing exercise for 15 minutes.
62501585|NCT03788356|EXPERIMENTAL|10% inspiratory muscle training|Inspiratory muscle training at 10% intensity of maximal inspiratory pressure for 15 minutes
62700753|NCT06495606||GERD-Group|Patients with confirmed gastroesophageal reflux in diagnostics
61953469|NCT05995483|NO_INTERVENTION|Has no intervention during the study|Only has an powerpoint training og BSE, not knowing about the web base system
61953470|NCT06194630|EXPERIMENTAL|68Ga-A3|Within 1 week, each participant underwent PET/CT scan after intravenous administration of 68Ga-A3
61953471|NCT01313793|EXPERIMENTAL|Sequence 1|Subjects will receive clinical formulation (treatment A) followed by commercializable formulation (treatment B).
61953472|NCT01313793|EXPERIMENTAL|Sequence 2|Subjects will receive commercializable formulation (treatment B) followed by clinical formulation (treatment A).
61953473|NCT01259128|EXPERIMENTAL|SER120 500 ng/day|SER120 Level 1 (500 ng/day)
62343973|NCT00118729|EXPERIMENTAL|Arm 1|
62343974|NCT00073814|EXPERIMENTAL|1|levalbuterol MDI 90 mcg QID
62343975|NCT00073814|ACTIVE_COMPARATOR|2|racemic albuterol MDI 190 mcg QID
62343976|NCT00073814|PLACEBO_COMPARATOR|3|Placebo MDI QID
62501586|NCT03788356|EXPERIMENTAL|30% inspiratory muscle training|Inspiratory muscle training at 30% intensity of maximal inspiratory pressure for 15 minutes
62501587|NCT03788356|EXPERIMENTAL|60% inspiratory muscle training|Inspiratory muscle training at 60% intensity of maximal inspiratory pressure for 15 minutes
62501588|NCT03180255|EXPERIMENTAL|EGP-437|40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
62501589|NCT03180255|PLACEBO_COMPARATOR|Placebo|100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
62501590|NCT04161573||TBI group|15 people in this group. Each should be post TBI for 6 months.
62501591|NCT04161573||Control group to TBI|15 people in this group. Their gender and age accord with TBI group.
62501592|NCT04161573||Aging group 1- 20 to 39|Normal people whose age range from 20 to 39.
62501593|NCT04161573||Aging group 2- 40 to 59|Normal people whose age range from 40 to 59.
62501594|NCT04161573||Aging group 3- above 60|Normal people whose age are above 60.
62501595|NCT05475431||The Charlson scores >= 2|Patients who are \>= 20 years and diagnosed with H. pylori infection either by rapid urease test or by histology from January 1, 2012 to December 31, 2019 are reviewed retrospectively. Patients are excluded if they ever received H. pylori eradication before. Patient characteristics, including age, sex, and the parameters of the Charlson scores, are recorded and analyzed. Moreover, the tablet number and varieties of medications patients took for underlying diseases are also recorded. If the patients' Charlson scores \>= 2, they are divided into the Charlson scores \>= 2 group.
62501596|NCT05475431||The Charlson scores < 2|Patients who are \>= 20 years and diagnosed with H. pylori infection either by rapid urease test or by histology from January 1, 2012 to December 31, 2019 are reviewed retrospectively. Patients are excluded if they ever received H. pylori eradication before. Patient characteristics, including age, sex, and the parameters of the Charlson scores, are recorded and analyzed. Moreover, the tablet number and varieties of medications patients took for underlying diseases are also recorded. If the patients' Charlson scores \< 2, they are divided into the Charlson scores \< 2 group.
62501597|NCT05484609|EXPERIMENTAL|OUD scenario|
62501598|NCT05484609|ACTIVE_COMPARATOR|Diabetes scenario|
61953474|NCT01259128|EXPERIMENTAL|SER120 750 ng/day|SER120 Level 2 (750 ng/day)
61953475|NCT04066023|EXPERIMENTAL|C213 1.9 mg|C213, 1.9 mg administered as one 1.9 mg patch and one placebo patch
61953476|NCT04066023|EXPERIMENTAL|C213 3.8mg|C213 3.8 mg administered as two 1.9 mg patches
61953477|NCT04066023|PLACEBO_COMPARATOR|Placebo|Placebo microneedle system administered as two placebo patches
62141803|NCT03360032||All participants|All patients will be asked to undertake an incremental shuttle walk test and a cardiopulmonary exercise test and the results will be compared.
62141804|NCT06510608||Healthy|
62501599|NCT00133679|EXPERIMENTAL|1|Sildenafil x 45 days
62501600|NCT00133679|PLACEBO_COMPARATOR|2|Placebo x 45 d
62501601|NCT04560517||Anorexia Nervosa|
62501602|NCT04560517||Healthy Control Subjects|
62501603|NCT00899535||Group 1|This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
62343977|NCT00592553|EXPERIMENTAL|High-Dose Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.
62501604|NCT00804245|EXPERIMENTAL|radiolabeled choline tracer scans|PET-CT scans supplemented with Choline 11 tracer
62501605|NCT02682108|OTHER|Diffusion-weighted imaging|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
62501606|NCT05652309||spinal anesthesia|spinal block will be performed to patients after monitoring
62501607|NCT05652309||spinal anesthesia and obturator nerve block|spinal block will be performed to patients after monitoring, and then the patients in the ONB block group will be given the appropriate position, with a USG-assisted distal approach, 5 cc %2 prilocain into the anterior and 5cc %2 prilocain into the posterior branch of the obturator nerve.
62700754|NCT06495606||Non-GERD-Group|Patients with confirmed absence of gastroesophageal reflux in diagnostics
62700755|NCT01524406|EXPERIMENTAL|HPP593|
61953478|NCT04990557|EXPERIMENTAL|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10\^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
61953479|NCT04990557|EXPERIMENTAL|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10\^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.~A total of 2 x 10\^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
61953480|NCT04990557|EXPERIMENTAL|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 4 x 10\^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
61953481|NCT01783431|EXPERIMENTAL|Leukapheresis and Poly-ICLC|Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
62343978|NCT00592553|EXPERIMENTAL|Low-Dose Ataluren|Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
62343979|NCT00592553|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.
62343980|NCT01773096|EXPERIMENTAL|Study group|Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
62343981|NCT01773096|ACTIVE_COMPARATOR|Institutional bowel protocol|Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
62343982|NCT00118508|PLACEBO_COMPARATOR|A|Group A will receive active study drug
62343983|NCT02729948|EXPERIMENTAL|Screening (TCE)|Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
62343984|NCT06398106|NO_INTERVENTION|Standard dosing of biologics|"Patients will receive biological therapy according to standard clinical practice. Secukinumab, ixekizumab and guselkumab will be administered according to standard dosing regimen. Adjustments in doses and intervals, or biological switch according to clinical parameters or at the physicians' discretion are considered as standard clinical practice.~Investigators will not have access to information on levels of the drug or antidrug antibodies and no decision tree will be provided to guide treatment adjustments."
62700756|NCT01524406|PLACEBO_COMPARATOR|Placebo|
62700757|NCT03719131|ACTIVE_COMPARATOR|Arm A (standard of care)|This is standard of care arm: induction with 4 cycles (21 days each) of Ipilimumab and nivolumab followed by continuation with nivolumab alone every month X1 year (13 doses).
61953482|NCT01500577|EXPERIMENTAL|Nimesulide|Nimesulide 100 mg (capsules), 100mg/die every day for 1 year. Oral administration
61953483|NCT01500577|EXPERIMENTAL|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
62141805|NCT06510608||Gingivitis|
62501608|NCT04334096|EXPERIMENTAL|QoL diagnosis and therapy|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
62501609|NCT04720287|ACTIVE_COMPARATOR|Group 1(QL group)|
62501610|NCT04720287|ACTIVE_COMPARATOR|Group 2 (CB group)|
62501611|NCT04196348|ACTIVE_COMPARATOR|Short BPL RYGB in glucose-tolerant participants|Procedure: short biliopancreatic limb (BPL) Roux en Y Gastric Bypass (RYGB) Obese patients without type 2 diabetes mellitus (T2DM) to be submitted to short BPL (n=10)
62501612|NCT04196348|ACTIVE_COMPARATOR|Long BPL RYGB in glucose-tolerant participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome without T2DM to be submitted to long BPL (n=10)
62501613|NCT04196348|ACTIVE_COMPARATOR|Long BPL RYGB in diabetic participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome and T2DM to be submitted to long BPL (n=10)
62501614|NCT01959802|OTHER|Vitrectomy|Vitrectomy for macular pseudo hole
62501615|NCT02136836||gastric adenocarcinoma|
62501616|NCT03930069|ACTIVE_COMPARATOR|misoprostol group|20 cases received 400 microgram prostaglandin E1 analogue, misoprostol, (Misotac®, 200 microgram, by SIGMA pharmaceutical industries, Alexandria, Egypt), intra-vaginally, 2 hr before operation.
62501617|NCT03930069|ACTIVE_COMPARATOR|vasopressin group|20 patients who had hysteroscopic guided intralesional vasopressin injection before hysteroscopic myomectomy
62501618|NCT05072821|EXPERIMENTAL|Botulinum Toxin type A injection side|The Botulinum Toxin type A will be injected into the dermal layer before skin closure in keloid excision surgery. The concentration of Botulinum Toxin type A is 100 units in 2 mL and dosage is 8 units/cm. The maximal dose is 100 units for each participant.
62501619|NCT05072821|PLACEBO_COMPARATOR|0.9% saline injection side|The 0.9% saline will be injected into the dermal layer before skin closure in keloid excision surgery. The dosage is 0.16 mL/cm.
62501620|NCT04535193|OTHER|Low likelihood of coronary heart disease|Thorax and total body imaging for quantification of normal biodistribution and myocardial sympathetic innervation. PET imaging to 210 minutes post-administration.
62501621|NCT04535193|OTHER|Heart Failure + left ventricular function (LVEF ≤ 35%)|Thorax and total body imaging for quantification of myocardial sympathetic innervation. PET imaging to 100 minutes post-administration
62501622|NCT04950894|ACTIVE_COMPARATOR|Active|HGN therapy activation at Month 1 - compared at Month 7 to Control group, continued stimulation through Month 13
62343985|NCT06398106|EXPERIMENTAL|Proactive TDM based dosing|"Stepwise treatment modifications based on drug levels: if the drug level is below/above the target the dose of the biologic will be increased/decreased by stepwise interval shortening/lengthening - first modified by 33% and then 50% increase or decrease. If the target is still not reached at the next study visit, the dosing interval will be shortened or prolonged with one additional week at each additional visit until the target is reached.~In case the dosing regimen shifts from dose increase to dose decrease or vice versa, the dosing interval will be shortened or prolonged with one additional week at each additional visit until the target is reached."
62343986|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
62501623|NCT04950894|OTHER|Control|HGN therapy NOT activated at Month 1 - compared at Month 7 to Active group, stimulation will start at Month 7 + 1 Day and continue through Month 13
62501624|NCT00636324|EXPERIMENTAL|1|Nasal CPAP, level of 7 to 9 cmH2O
62501625|NCT00636324|ACTIVE_COMPARATOR|2|Nasal CPAP, level 4 to 6 cmH2O
61953484|NCT01500577|PLACEBO_COMPARATOR|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
61953485|NCT01805804|PLACEBO_COMPARATOR|Placebo|Placebo pills to match valsartan tablets administered once daily
62343987|NCT00693680|ACTIVE_COMPARATOR|1|zinc + imipramine
61953486|NCT01805804|EXPERIMENTAL|valsartan 80mg daily|Valsartan 80mg tablet once daily
62343988|NCT00693680|PLACEBO_COMPARATOR|2|placebo + imipramine
62501626|NCT05822674||Sitagliptin/metformin|Patients with T2D treated with sitagliptin/metformin (50/500mg) once daily for 10 weeks
62501627|NCT05822674||Empagliflozin/metformin|Patients with T2D treated with empagliflozin/metformin (10/500mg) once daily for 10 weeks
62501628|NCT00526162|EXPERIMENTAL|Implantation of Consulta CRT-D|Patients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator
62501629|NCT05999240|EXPERIMENTAL|Pimavanserin tartrate|Pimavanserin 34 mg white to off-white capsules.
62501630|NCT05999240|PLACEBO_COMPARATOR|Placebo|Placebo to Pimavanserin tartrate
62501631|NCT00162682|ACTIVE_COMPARATOR|1|\* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
62501632|NCT00162682|EXPERIMENTAL|2|CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
62501633|NCT03467282|EXPERIMENTAL|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
62501634|NCT03467282|PLACEBO_COMPARATOR|Placebo|1g polydextrose/maltodextrin - twice day
62501635|NCT00264381|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 800mg tid X 7 days + additional 7 days determined by protocol
62141806|NCT06510608||Periodontitis|
62501636|NCT04869137|EXPERIMENTAL|Lenvatinib plus Pembrolizumab|Participants with Merkel cell carcinoma amenable to complete resection will receive two cycles (6 weeks) of therapy with the combination of lenvatinib plus pembrolizumab and then proceed to planned resection within 2-4 weeks following completion of cycle 2. Following surgical recovery and completion of adjuvant radiation therapy (if indicated), treatment will resume with pembrolizumab monotherapy with intent to complete 17 cycles total of pembrolizumab.
62501637|NCT01830309|EXPERIMENTAL|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
62501638|NCT01830309|EXPERIMENTAL|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
62501639|NCT03066895|EXPERIMENTAL|Experimental|BabyGentleStick
62501640|NCT03066895|ACTIVE_COMPARATOR|Standard of Care|HMC Standard Lancing Device
62501641|NCT03133728||Pre-Intervention Group|The Investigators will visit each of the selected 3 clusters (i.e. 6 primary health clinics) to construct a retrospective cohort of high-risk HIV-infected women who entered the national PMTCT program and received the SOC between June 1, 2017 and May 31, 2018. Using existing data through the electronic health record information (SmartCare and LIMS), the investigators will gather individual-level retrospective data on high-risk Mother-Infant Pairs (MIPs) from PMTCT enrolment through the child's ART enrolment, initiation, and retention rate at 3 months.
62501642|NCT03133728||Post-Intervention Group|Study Research Assistants (RA) will review routine patient files and registers, augmented by existing electronic health record information, to identify a new cohort of high-risk Mother-Infant Pairs (MIPs) at each study site between the dates of June 1, 2019 and May 31, 2020. The outreach team will include, at a minimum, the study RA, a study peer, and an HIV counselor from the health facility, who will carry the Alere™ q HIV-1/2 Detect with them. When the outreach team contacts a high-risk MIP at community level, the team will approach the MIP for study screening, consent, and enrolment procedures. Study staff will ask the parent/guardian if the parent/guardian would like the IYC to be tested at their home, at a community health post, or other private space in the community. The IYC will be tested using both the Alere™ q HIV-1/2 Detect platform and a reflex DBS PCR test to evaluate performance of the POC platform in a mobile setting against the gold standard.
62501643|NCT03113435|NO_INTERVENTION|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
61953487|NCT01805804|EXPERIMENTAL|valsartan 160mg daily|Valsartan 160mg tablet once daily
61953488|NCT01945528|EXPERIMENTAL|US-guided tenotomy with PRP|ultrasound guided percutaneous tenotomy with PRP injection each alternate week for a total of two interventions
61953489|NCT01945528|ACTIVE_COMPARATOR|US-guided tenotomy with lidocaine|ultrasound-guided percutaneous needle tenotomy with lidocaine injection each alternate week for a total of two interventions
61953490|NCT06062134|EXPERIMENTAL|Pericapsular nerve group block group|All subjects enrolled in the study received a pericapsular nerve group block using a local anesthetic mixed with a contrast agent. After injection, subjects were transferred to the CT scan to obtain a 3D reconstruction to determine the spread of the injectate.
61953491|NCT03711461|ACTIVE_COMPARATOR|nonintubated|patients received nonintubated during thoracoscopy
62501644|NCT03113435|ACTIVE_COMPARATOR|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
62501645|NCT03113435|EXPERIMENTAL|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
62501646|NCT04753853|EXPERIMENTAL|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
62501647|NCT00368082|EXPERIMENTAL|TGFbeta resistant LMP-specific CTLs|"CTLs be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~If patients with active disease have stable disease or a partial response at their 6 week or subsequent evaluations they will be eligible to receive up to 6 additional doses of CTLs at 1-2 monthly intervals-each of which will consist of the same cell number as their second injection."
62501648|NCT01321177|EXPERIMENTAL|Integrated Treatment|Integrated program of treatments and services delivered by a coordinated team of providers.
62501649|NCT01321177|ACTIVE_COMPARATOR|Community Care|Standard mental health treatments and services offered at the local agency.
61953492|NCT03711461|EXPERIMENTAL|intubated|patients receiving intubated during thoracoscopy
61953493|NCT02518256|OTHER|(Suspected) Ovarian Epithelial Cancer|Lavage of the Cavum uteri and proximal fallopian tubes
61953494|NCT04851080||Schoolchildren|Schoolchildren of Vladikavkaz secondary schools aged 13-16 years
61953495|NCT04851080||Students|Students of North-Ossetian State Medical Academy at the age of 19-22 years
61953496|NCT04851080||Volunteers|Scientists of the North Caucasian Research Institute of Mountain and Foothill Agriculture at the age of 30-56 years
61953497|NCT00767130||1|receiving atorvastatin
61953498|NCT00767130||2|receiving simvastatin
61953499|NCT00767130||3|receiving rosuvastatin
61953500|NCT00378378|EXPERIMENTAL|MFNS 100 mcg QD for subjects 6 to less than 12 years|Mometasone Furoate nasal Spray (MFNS) 100 mcg once per day (QD) for subjects 6 to less than 12 years of age
61953501|NCT00378378|PLACEBO_COMPARATOR|Placebo QD for subjects 6 to less than 12 years|
61953502|NCT00378378|EXPERIMENTAL|MFNS 200 mcg QD for subjects 12 to less than 18 years|
61953503|NCT00378378|EXPERIMENTAL|MFNS 200 mcg BID for subjects 12 to less than 18 years|
61953504|NCT00378378|PLACEBO_COMPARATOR|Placebo QD for subjects 12 to less than 18 years|
61953505|NCT00378378|EXPERIMENTAL|MFNS 100 mcg BID for subjects 6 to less than 12 years|
61953506|NCT00378378|PLACEBO_COMPARATOR|Placebo BID for subjects 6 to less than 12 years|
61953507|NCT00378378|PLACEBO_COMPARATOR|Placebo BID for subjects 12 to less than 18 years|
61953508|NCT00453063|EXPERIMENTAL|MFNS 200 mcg QD|
61953509|NCT00453063|PLACEBO_COMPARATOR|Placebo|
62343989|NCT01382836||Black inner city children with persistent asthma|
61953510|NCT04882618|EXPERIMENTAL|ICG group|ICG injection before LRRP via cystoscopy
61953511|NCT04383262|EXPERIMENTAL|Oral Fosamprenavir-Sodium Alginate (FOS-SA)|FOS- SA: 1,400 mg fosamprenavir calcium and 24.5 mg sodium alginate, b.i.d. (AM/PM) for 12 weeks
62700758|NCT03719131|EXPERIMENTAL|Arm B (rituximab, hyaluronidase human)|This includes induction with 4 cycles of ipilimumab and nivolumab X 4 cycles followed by continuation with nivolumab alone every month for 1 year as in standard of care arm. Each induction cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. In addition, patients will receive 4 weekly doses of Rituxan (first dose intravenously and then 3 weekly doses subcutaneously). First dose of Rituxan will be administered one week following the start of cycle 1 of ipilimumab and nivolumab. All treatments will have a +/-3 business day window for administration.
61953512|NCT04383262|PLACEBO_COMPARATOR|Placebo|Sodium Alginate: 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate b.i.d (AM/PM) for 12 weeks.
61953513|NCT02785120|EXPERIMENTAL|High dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 \[50 patients\] and placebo \[25 patients\]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
61953514|NCT02785120|EXPERIMENTAL|Middle dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 \[50 patients\] and placebo \[25 patients\]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
62501650|NCT01053091|EXPERIMENTAL|Exercise|exercise
61953515|NCT02785120|EXPERIMENTAL|Low dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 \[50 patients\] and placebo \[25 patients\]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
61953516|NCT05801133|EXPERIMENTAL|Pirfenidone combined with radiotherapy|"Pirfenidone: synchronized with RT, 200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months~Radiotherapy: no limitation, TD≥50Gy (BED/ α/β： 10）"
61953517|NCT00003997|EXPERIMENTAL|Arm I|Patients receive 6-hydroxymethylacylfulvene (HMAF) IV over 5 minutes on days 1-5. Treatment repeats every 3-4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of HMAF. The maximum tolerated dose is defined as the dose at which dose limiting toxicity occurs in at least 40% of patients.
61953518|NCT06060743|NO_INTERVENTION|control group|Data collection tools were applied to individuals in the control group on day 0 (Z0), day 14 (Z1) and day 28 (Z2) of follow-up. Data collection tools applied to the control group are as follows: Patient Introduction Form, Insulin Treatment Appraisal Scale,, Insulin Therapy Self-Management Scale, Insulin Information Form, Insulin Injection Skill Observation Form and Metabolic Control Variables Form.
62343990|NCT01382836||Black inner city non-atopic healthy children|
61953519|NCT06060743|EXPERIMENTAL|application group|Individuals in the application group will be given individual training on how to use the application through the application demo. Data collection forms will be applied to individuals in the application group on day 0 (Z0), day 14 (Z1) and day 28 (Z2). The forms to be used are: Patient Introduction Form, Insulin Treatment Appraisal Scale, Insulin Therapy Self-Management Scale, Insulin Information Form, Metabolic Control Variables Form, Insulin Injection Skill Observation Form and Digital Literacy Scale.
62343991|NCT05153798||PerioMonitor Testing|117 Subject to be tested for Oral Inflammatory Load (OIL) with PerioMonitor. Same subjects to be tested for Oral Inflammation with the BOP method.
62343992|NCT01023438|EXPERIMENTAL|Assisted uptitration|Uptitration of recommended drugs by primary care physician with specialist support
62343993|NCT01023438|ACTIVE_COMPARATOR|Usual care|Usual communication strategy from cardiologist to primary care physician
62501651|NCT01053091|NO_INTERVENTION|Control|control
62501652|NCT04281524|EXPERIMENTAL|CSL312 Cohort 1 (Dose 1)|CSL312 administered as IV infusion
62501653|NCT04281524|EXPERIMENTAL|CSL312 Cohort 2 (Dose 2)|CSL312 administered as IV infusion
62501654|NCT04281524|EXPERIMENTAL|CSL312 Cohort 3 (Dose 3)|CSL312 administered as IV infusion
62501655|NCT04281524|EXPERIMENTAL|CSL312 Cohort 4 (Dose 4)|CSL312 administered as IV infusion
62501656|NCT04281524|PLACEBO_COMPARATOR|Placebo|Placebo administered as IV infusion
62501657|NCT02721368|EXPERIMENTAL|Investigational medical device|Neuramis® Volume Lidocaine
62343994|NCT03497429|EXPERIMENTAL|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
62343995|NCT03497429|EXPERIMENTAL|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
62343996|NCT03335618|EXPERIMENTAL|Active Coaching and Monitoring|
62343997|NCT03335618|SHAM_COMPARATOR|Passive Monitoring|
62343998|NCT03805581|EXPERIMENTAL|Interventional|Defibrotide 6.25 mg/kg IV q6h
62501658|NCT02721368|ACTIVE_COMPARATOR|Comparator medical device|Juvederm® Voluma® with Lidocaine
62501659|NCT01673841||Relative + absolute cerebral oxygen saturation.|
62343999|NCT03691753|EXPERIMENTAL|Experimental arm|Patients will be treated with Fitaya Vena Cava Filter System.
62344000|NCT03691753|ACTIVE_COMPARATOR|Control arm|Patients will be treated with Aegisy Vena Cava Filter.
62344001|NCT04721067|EXPERIMENTAL|CBT-I|This arm will receive internet CBT-I using SHUTi, a validated and proven therapy provided via internet in the general population.
62344002|NCT04721067|ACTIVE_COMPARATOR|Sleep Education/Hygiene|This arm will receive best practices education on sleep hygiene.
62344003|NCT02685891|ACTIVE_COMPARATOR|playing tones|During slow-wave sleep short tones (50ms, 50dB) will be played
62344004|NCT02685891|SHAM_COMPARATOR|Playing no tones|During slow-wave sleep no tones will be played
62501660|NCT01374945|NO_INTERVENTION|SOC preparation and colonoscopy|
62501661|NCT01374945|EXPERIMENTAL|Miniprep and Clearpath|
62501662|NCT04083391||CAI group|assessment had been done to this group that include patients with ankle sprain injury from more than one year and complain with repetitive injuries, giving way and instability feelings
62501663|NCT04083391||non injured ankle group|assessment had been done to this group that include control participants had not injured their ankle before and matched with CAI in age, gender, dominant side
62700759|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
62700760|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
62700761|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
62700762|NCT03100279|EXPERIMENTAL|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
62700763|NCT06343623|ACTIVE_COMPARATOR|superiorly based flap|superiorly bases pharyngeal flap
62700764|NCT06343623|EXPERIMENTAL|myomucosal resection and direct closure|myomucosal resection and direct closure
62700765|NCT06217263|EXPERIMENTAL|Vibration|After coronary artery bypass graft surgery, patients will receive routine monitoring, pharmacological treatment and nursing care in the unit where the research is conducted. The vibration device will be placed in the upper quadrant proximal to the patient's drain tube entrance. Care will be taken to ensure that the point where the vibration device is placed is the same as the vibration device placement point in the vibration and cold application group. 10 minutes after the application, the patient's skin temperature will be measured and the vibration device will be pulled above the chest tube insertion area.
62700766|NCT06217263|EXPERIMENTAL|Vibration & Cold application|After coronary artery bypass graft surgery, patients will receive routine monitoring, pharmacological treatment and nursing care in the unit where the research is conducted. Cold gel pack will be placed around the patient's chest tube insertion area. In order to optimize the effect of cold, the cold application will not exceed 20 minutes and the temperature of the skin will not fall below 12 ℃. At the 10th minute of cold application, the vibration device will be placed proximal to the chest tube, over the upper area of the cold gel pack. At the 20th minute of the application, the patient's skin temperature will be measured and the cold applied vibration device will be pulled above the chest tube insertion area.
62700767|NCT06217263|NO_INTERVENTION|Control|After coronary artery bypass graft surgery, patients will receive routine monitoring, pharmacological treatment and nursing care in the unit where the research is conducted. In the control group, the processes and monitoring in the application groups will be continued in the same period without the application.
62700768|NCT03419819|EXPERIMENTAL|PKU Sphere|"Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis.~Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis."
62700769|NCT05287373|ACTIVE_COMPARATOR|PNS Therapy plus Conventional Medical Management|peripheral nerve stimulator plus conventional medical management
62700770|NCT05287373|OTHER|Conventional Medical Management|Control arm conventional medical management only
62700771|NCT05956483||Rapid Mood Screener (RMS)|Participants with Unipolar Major Depressive Disorder and Bipolar 1 Depression will be evaluated with RMS questionnaire and MINI interview.
62700772|NCT05534867|EXPERIMENTAL|Mandala coloring group|Mandala painting will be applied to pregnant women who have anxiety related to pregnancy.
62700773|NCT05534867|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms.
62700774|NCT06114745|EXPERIMENTAL|Dose level 1 SHR-1707|SHR-1707 is administered intravenously.
62700775|NCT06114745|PLACEBO_COMPARATOR|Dose level 1 Placebo|Placebo is administered intravenously.
62700776|NCT06315998||Training and testing cohort|
62700777|NCT06315998||External validation cohort|
62700778|NCT06256055|EXPERIMENTAL|UCMYM802 Injection|Active ingredient：Anti-MSLN CAR+ T cell
62700779|NCT03316430||Patients|Patients coming before 16 weeks of gestation at their first planned prenatal visit at the Hôpital Femme Mère Enfant, who planned to deliver at the Hôpital Femme Mère Enfant
62700780|NCT02665377|ACTIVE_COMPARATOR|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
62700781|NCT02665377|PLACEBO_COMPARATOR|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
62700782|NCT00710619||A|
62700783|NCT05595005||Stroke|Stroke patients (ischemic or hemorrhagic) in the chronic phase (\> 6 months)
62700784|NCT05595005||Healthy controls|Healthy adult controls
62700785|NCT01186757|ACTIVE_COMPARATOR|PF-03715455 1.6mg BID|
61953520|NCT05344911|ACTIVE_COMPARATOR|remifentanil|Anesthesia maintenance：target-controlled infusion of propofol combined with remifentanil）
61953521|NCT05344911|EXPERIMENTAL|alfentanil|Anesthesia maintenance：target-controlled infusion of propofol combined with afentanil
62344005|NCT01827930|EXPERIMENTAL|Imatinib 600 (Randomized trial)|Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po
62344006|NCT01827930|ACTIVE_COMPARATOR|Imatinib 400 (Randomized trial)|Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
62344007|NCT01827930|OTHER|Imatinib400 (Cohort)|Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
62700786|NCT01186757|ACTIVE_COMPARATOR|PF-03715455 4 mg BID|
62700787|NCT01186757|ACTIVE_COMPARATOR|PF-03715455 10 mg BID|
62700788|NCT01186757|PLACEBO_COMPARATOR|Placebo|
62700789|NCT01688804|EXPERIMENTAL|Behavioral intervention|Behavioral intervention to reduce sedentary time delivered via mobile smartphone
62501664|NCT04012931|EXPERIMENTAL|Rilpivirine (RPV) (25 mg or adjusted weight-based dose)|Participants will receive rilpivirine (RPV 25 milligram \[mg\], adjusted weight-based dose) orally once daily in combination with an investigator selected background regimen (that is investigator-selected antiretrovirals \[ARVs\] such as nucleoside/nucleotide reverse transcriptase inhibitor \[N{t}RTIs\] and integrase inhibitors) for 48 weeks.
62700790|NCT01061788|EXPERIMENTAL|Everolimus, AMG 479, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
61953522|NCT06247514|EXPERIMENTAL|The BEET Diabetes Program|The BEET Diabetes program consists of 6 sessions that follow a sequence: the first 3-sessions weekly and the last 3-sessions every other week. These sessions help participants learn strategies and health behavior change through a self-monitoring form. Supporters (in this study, the BHPs) guide individuals through the program, maintain motivation, and facilitate appropriate goal-setting. The BEET Diabetes Program emphasizes treating disorder eating behaviors (DEBs) in the context of diabetes (i.e., psychoeducation on DEBs in diabetes, optimal daily glucose management, benefits of physical activity, and fruit and vegetable intake).
61953523|NCT06247514|ACTIVE_COMPARATOR|Cognitive behavioral Therapy Guided Self-help|"The Cognitive Behavioral Therapy Guided Self-help consists of 6 sessions that follow a sequence: the first 3-sessions weekly and the last 3-sessions every other week. These sessions help participants learn strategies and health behavior change through a self-monitoring form. The CBTgsh program is delivered through the self-help book: Overcoming Binge Eating by Christopher G. Fairburn. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or DEBs, as the book acts as the expert."
61953524|NCT04526431||Tacrolimus once-daily|Patients receiving tacrolimus as a once-daily formulation (Envarsus)
61953525|NCT04526431||Tacrolimus bid|Patients receiving tacrolimus as a twice-a-day formulation.
61953526|NCT00530309|EXPERIMENTAL|Subjects receiving GSK716155 + placebo|Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
61953527|NCT01646307|PLACEBO_COMPARATOR|standard care group|patients receive atorvastatin 20 mg/d
62501665|NCT01863433|EXPERIMENTAL|Trivalent Influenza Vaccine|The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
62501666|NCT03195452|EXPERIMENTAL|Raltegravir|antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
61953528|NCT01646307|ACTIVE_COMPARATOR|intensive rosuvastatin|administrated with rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI
61953529|NCT01646307|ACTIVE_COMPARATOR|intensive atorvastatin|patients will be administrated with atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI;
61953530|NCT03747588|EXPERIMENTAL|Minimally-invasive Pancreaticoduodenectomy|MIPD
61953531|NCT03747588|PLACEBO_COMPARATOR|Open Pancreaticoduodenectomy|OPD
61953532|NCT03953196|EXPERIMENTAL|Cohort 1: Vaccine Challenge Imvanex|Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
62700791|NCT04120467|EXPERIMENTAL|Dance|Dance Standard rehabilitation post-stroke
62700792|NCT04120467|ACTIVE_COMPARATOR|Control|Standard rehabilitation post-stroke
61953533|NCT03953196|EXPERIMENTAL|Cohort 2: Vaccine Challenge Shingrix|Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
62700793|NCT01690273|NO_INTERVENTION|ankylosing spondylitis control|control group
62700794|NCT01690273|EXPERIMENTAL|mobility exercise|mobility exercises
62700795|NCT01690273|EXPERIMENTAL|mobility and elastic resistance exercise|AS patients was submitted to a program mobility exercise plus elastic resistance exercises
62700796|NCT06539182|EXPERIMENTAL|Daily dose of DZD8586 at 25 mg|
61953534|NCT03953196|EXPERIMENTAL|Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)|Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
61953535|NCT03953196|EXPERIMENTAL|Cohort 4: Antigen Challenge Candin|Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
61953536|NCT03953196|EXPERIMENTAL|Cohort 5: Skin Wounding Challenge|3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.
61953537|NCT01077570||Repaglinide|
61953538|NCT01389388|EXPERIMENTAL|Rosuvastatin intervention|Patients \> 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient \<70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
62700797|NCT06539182|EXPERIMENTAL|Daily dose of DZD8586 at 50 mg|
62700798|NCT06539182|EXPERIMENTAL|Daily dose of DZD8586 at 75 mg|
61953539|NCT01559467|OTHER|Routine clinical care plus early CMR|
61953540|NCT01559467|NO_INTERVENTION|Routine clinical care|
61953541|NCT01559467|OTHER|Routine clinical care plus early CTA|
61953542|NCT02192359|EXPERIMENTAL|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61953543|NCT02569658|EXPERIMENTAL|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
61953544|NCT02569658|PLACEBO_COMPARATOR|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
62700799|NCT02014376|EXPERIMENTAL|SD-101 Dermal Cream (6%)|SD-101 dermal cream (6%) applied topically once daily over the entire body for 90 days.
62700800|NCT02014376|EXPERIMENTAL|SD-101 Dermal Cream (3%)|SD-101 dermal cream (3%) applied topically once daily over the entire body for 90 days.
61953545|NCT00390065|EXPERIMENTAL|Study group|Hypoxemic Respiratory Failure treated by Nitric Oxide;
61953546|NCT00390065|PLACEBO_COMPARATOR|Control|Hypoxemic Respiratory Failure control (Placebo);
61953547|NCT00390065|NO_INTERVENTION|Reference|Reference (Non hypoxemic respiratory failure)
61953548|NCT03363958|EXPERIMENTAL|RIC Group|Three cycles of remote ischemic conditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation); First three cycles the patient will receive 24 hours preoperatively, second three cycles the patient will receive after the induction of general anesthesia but before skin incision shortly before CABG. Remote ischemic postconditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation) will be administered to the patient within 60 minutes after the completion of all coronary artery bypass grafts and the restoration of coronary blood flow.
62141807|NCT00677209|ACTIVE_COMPARATOR|A|house dust mite allergics will undergo autovaccine immunization
62344008|NCT05938777|EXPERIMENTAL|Non-Stage-Matched Intervention|The proposed arm would be non-Stage-matched that involves using different Processes of Change as strategies to enhance engaging in regular physical exercise.
62344009|NCT01757405|EXPERIMENTAL|≤ 3 doses of 90 µg/kg rFVIIa BI|
62700801|NCT02014376|PLACEBO_COMPARATOR|Vehicle (0%)|Vehicle dermal cream (SD-101 0%) applied topically once daily over the entire body for 90 days.
61953549|NCT03363958|SHAM_COMPARATOR|Control Group|Control group will receive sham procedure near identical to intervention. That will be afforded by inflation of pressure cuff on artificial leg hidden under the draping by an assistant who is not included in the research team and does not have any connection to study design and data analysis.
62344010|NCT01757405|EXPERIMENTAL|One dose of 270 µg/kg rFVIIa BI|
61953550|NCT04436367||SAA patients with Monosomy 7|Severe Aplastic Anemia Patients who Developed High Risk Clonal Evolution with Chromosome 7 Abnormalities after Immunosuppressive Therapy
61953551|NCT01550731|EXPERIMENTAL|PREPARE|The intervention group will review the PREPARE advance care planning website and PREPARE materials plus receive an advance directive. The control group will only receive an advance directive.
61953552|NCT01550731|ACTIVE_COMPARATOR|CONTROL|The control group will only receive an advance directive.
61953553|NCT03115086||Existing User|Patients who have been using Cholbam for at least 30 days
61953554|NCT03115086||New User|First-time initiators of Cholbam
61953555|NCT02655640||Lupus|Characteristics of patients with Systemic Lupus Erythematosus. No interventions will be administered. Patients will be asked to complete questionnaires.
61953556|NCT02655640||Scleroderma|Characteristics of patients with Systemic Sclerosis. No interventions will be administered. Patients will be asked to complete questionnaires.
61953557|NCT03652597|ACTIVE_COMPARATOR|Left|Subjects are ascribed to left hemispheric stimulation
61953558|NCT03652597|ACTIVE_COMPARATOR|Right|Subjects are ascribed to right hemispheric stimulation
61953559|NCT04301037|ACTIVE_COMPARATOR|Tension band wiring|This group was treated by k-wires fixation and tension band wiring
61953560|NCT04301037|ACTIVE_COMPARATOR|Cannulated screws|This group was treated by 2 cannulated screws
62344011|NCT06403891||Control|The control group was planned to consist of patients who received a 6-week conventional rehabilitation program that was prepared to meet the requirements of their clinical conditions, including neurophysiological exercises, balance-coordination and posture exercises.
62344012|NCT06403891||Case|The case group was planned to consist of patients who received a comprehensive rehabilitation program using high-tech devices including functional electrical stimulation (FES) and robotic rehabilitation applications in addition to the conventional rehabilitation program that was prepared to meet the requirements of their clinical conditions, including neurophysiological exercises, balance-coordination and posture exercises.
62344013|NCT02242227|EXPERIMENTAL|Salmeterol xinafoate|25 μg Salmeterol inhalation powder administered via HandiHaler®
62344014|NCT02242227|ACTIVE_COMPARATOR|Serevent® Diskus®|50 μg Salmeterol (dry powder inhaler) administered via Diskus®
62344015|NCT02242227|PLACEBO_COMPARATOR|Placebo|
62344016|NCT01146249||1: healthy subject|
62344017|NCT01146249||3: post stroke patients|
62700802|NCT03352947|ACTIVE_COMPARATOR|Continuous (Standard)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-28 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-28 of a 28 day cycle
62700803|NCT03352947|EXPERIMENTAL|Intermittent (experimental)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-21 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-14 of a 28 day cycle
62700804|NCT04442009|ACTIVE_COMPARATOR|Group S = SCPB group|"US-guided SCPB will be performed at the end of the surgery before extubation, with patients in the supine position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the high frequency linear probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath and a 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used.~Sternocleidomastoid (SCM) muscle will be visualized. The 22 G needle will be inserted between the SCM and the prevertebral fascia by using in plane technique horizontally. The needle tip will be corrected with injecting 2 ml of normal saline. Then a 20 mL dose of 0.25% bupivacaine will be injected here. The same procedure will be performed for the opposite site (totally 40 mL dose of 0.25% bupivacaine)."
62700805|NCT04442009|NO_INTERVENTION|Group C = Control group|Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
62700806|NCT02538796|EXPERIMENTAL|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
62700807|NCT02538796|EXPERIMENTAL|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
62700808|NCT02538796|EXPERIMENTAL|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
62700809|NCT02538796|EXPERIMENTAL|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
62700810|NCT02538796|ACTIVE_COMPARATOR|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
62700811|NCT02538796|ACTIVE_COMPARATOR|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
62700812|NCT02538796|ACTIVE_COMPARATOR|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
62700813|NCT02538796|ACTIVE_COMPARATOR|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
62141808|NCT04425980|EXPERIMENTAL|Modified Constraint-Induced Movement Therapy (test treatments)|A list of fine and motor activities consisted of the functional tasks or play activities such as school-education and sports activities, manipulative games, arts, and crafts, etc. to elicit the maximum capacity of the more affected upper limb was created according to the procedure of modified constraint-induced movement therapy (Gordon et al., 2005) and Bimanual training. In addition, specific activities were also chosen in terms of deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request. In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook a role as a dominant hand
61953561|NCT06257797||Allergic patients to fenugreek|
61953562|NCT06257797||Non allergic patients to fenugreek|
62141809|NCT04425980|ACTIVE_COMPARATOR|Bimanual training|For the Bimanual training, skilled, repetitive, and structured bimanual activities (part or whole task practice) were used to promote bimanual hand use and improve movement deficits determined before the intervention. All targeted deficits of interest were addressed within the context of the selected activity. Specifically, symmetrical bilateral movements were utilized to augment neural input from both sides. Also, meaningful activities such as buttoning and zipping-up trousers, etc. were used to ensure a transition from structured setting to real-life activities
62344018|NCT01146249||2: vestibular patients|Vestibular patients with a unique history of peripheric vestibular disorder
62344019|NCT01146249||4: ataxic patients|Patient with proprioception disorder related to peripheral neuropathy
62344020|NCT01146249||5: Old fallers|Old subjects with a history of falls (one or more during the last year)
62344021|NCT04900038|EXPERIMENTAL|GSK3640254 100 mg + Dolutegravir (DTG) 50 mg|Participants with human immunodeficiency virus type 1 (HIV-1) orally received low dose (100 mg) GSK3640254 tablet blinded and 50 mg DTG unblinded. Each participant received one tablet per day of each intervention up to Week 24.
62700814|NCT00208338|EXPERIMENTAL|1|Rotator cuff repair with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
62700815|NCT00208338|ACTIVE_COMPARATOR|2|Standard rotator cuff repair
62344022|NCT04900038|EXPERIMENTAL|GSK3640254 150 mg + DTG 50 mg|Participants with HIV-1 orally received medium dose (150 mg) GSK3640254 tablet blinded and 50 mg DTG unblinded. Each participant received one tablet per day of each intervention up to Week 24.
62700816|NCT04998630|EXPERIMENTAL|A (4Hz)|ESWT frequency 4Hz washout period: 1 week
62700817|NCT04998630|EXPERIMENTAL|B (8Hz)|ESWT frequency 8Hz washout period: 1 week
62700818|NCT02191618|OTHER|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
62700819|NCT05930639|EXPERIMENTAL|Surgical Site Infection (SSI) prevention package; Identification of risk factors|"Risk factors of the individual created in line with the literature; Advanced age, history of skin or soft tissue infection, DM, alcohol addiction, smoking, preoperative albumin \<3.5 mg/dl, total bilirubin\>1.0 mg/dl, immunosuppression, long postoperative stay, long preoperative stay, high BMI,ASA score \> II,preoperative low Hgb level.~Risk factors associated with the surgical procedure; Presence of drain, prolongation of surgery time, preoperative skin preparation, blood transfusion, non-sterile equipment, insufficient ventilation, heavy operating room traffic, insufficient hemostasis.~Participants will be evaluated in terms of these risks."
62700820|NCT05930639|EXPERIMENTAL|Surgical Site Infection (SSI) prevention package; Antibiotic prophylaxis|determined antibiotic (active ingredient: imipenem cilastatin sodium)
62700821|NCT05930639|EXPERIMENTAL|Surgical Site Infection (SSI) prevention package;achieving and maintaining normothermia|Body temperature will be recorded with an infrared thermometer. The patient will be warmed with various passive heating techniques before and after the operation. To prevent hypothermia, the operating room ambient temperature will be kept in the range of 23-26°C.
62700822|NCT05930639|EXPERIMENTAL|Surgical Site Infection (SSI) prevention package; maintenance of normoglycemia|In the 2017 guidelines, perioperative glycemic control with a blood glucose level of \<200 mg/dL is recommended for patients with and without DM. Ideal blood glucose control should provide good glycemic control with a minimal incidence of hypoglycemia.
61953563|NCT01771952|EXPERIMENTAL|Synvisc-One™|Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.
62141810|NCT00859300||1|500 patients with ventricular fibrillation at the acute phase of myocardial infarct
62141811|NCT00859300||2|500 patients without ventricular fibrillation at the acute phase of myocardial infarct.
62141812|NCT03126604||vaginal delivery|Women underwent non complicated non instumental normal vaginal delivery
62141813|NCT03126604||Cesarean section|Women underwent elective Cesarean section
62344023|NCT04900038|EXPERIMENTAL|GSK3640254 200 mg + DTG 50 mg|Participants with HIV-1 orally received high dose (200 mg) GSK3640254 tablet blinded and 50 mg DTG unblinded. Each participant received one tablet per day of each intervention up to Week 24.
62344024|NCT04900038|ACTIVE_COMPARATOR|DTG 50 mg + Lamivudine (3TC) 300 mg|Participants with HIV-1 orally received unblinded 50 mg DTG one tablet and blinded 300 mg 3TC. Each participant received one capsule per day of each intervention up to Week 24.
61953564|NCT01771952|SHAM_COMPARATOR|Sham Treatment|Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.
61953565|NCT03104543|EXPERIMENTAL|Education|Educational materials
61953566|NCT03104543|ACTIVE_COMPARATOR|Test results|Test results only; with delayed access to the experimental materials
61953567|NCT02467400|PLACEBO_COMPARATOR|placebo|Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
61953568|NCT02467400|ACTIVE_COMPARATOR|Atenolol|Atenolol 50 mg 1/day for 20 weeks
61953569|NCT02467400|ACTIVE_COMPARATOR|Nebivolol|Nebivolol 5 mg/day for 20 weeks
61953570|NCT02467400|ACTIVE_COMPARATOR|Propranolol 40 mg|Propranolol 20 mg bid for 20 weeks
61953571|NCT02467400|ACTIVE_COMPARATOR|Propranolol 80 mg|Propranolol 40 mg bid for 20 weeks
61953572|NCT04378556|OTHER|Nutrition|All participants received diet coaching, nutrition education and a per-meal protein prescription.
61953573|NCT03150017|EXPERIMENTAL|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
61953574|NCT03150017|NO_INTERVENTION|Usual Care|Continue to manage pain using usual care.
61953575|NCT06306781|EXPERIMENTAL|HCL001 cell injection (homologous allogeneic hepatocytes)|low/middle/high dose group
61953576|NCT02577549|EXPERIMENTAL|Diet & Exercise|Participants will attend an exercise class 3 days/week for 18 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant's minimum weight loss goal will be 10% of baseline body weight.
61953577|NCT02577549|ACTIVE_COMPARATOR|Attention Control|The attention control intervention will cover an 18-month period. There will be five total face to face group meetings over the 18 months, with one meeting each at months 1, 3, 6, 9, and 15; and during the other months (months 2-5, 7-11, 13-17) participants will receive a combination of informational packets, webinars, phone sessions, and/or emails based on continued monitoring of participant needs and delivered via their preferred mode of contact.
61953578|NCT02867462|OTHER|A-Standard Care|standard care
61953579|NCT02867462|EXPERIMENTAL|B-manipulator consultation radiotherapy added to standard care|manipulator consultation radiotherapy added to standard care
61953580|NCT03236025|EXPERIMENTAL|Experimental group|Video+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. The videos which presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy, will be sent in sequence through the smart phone to the participants in the experimental group.
61953581|NCT03236025|ACTIVE_COMPARATOR|Conditional control group|Text-message+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. Text-message contains the same content with videos and will be sent in the same frequency with the videos through the smart phone to the participants in the Conditional control group.
61953582|NCT03236025|PLACEBO_COMPARATOR|Placebo control group|Participants in the control group will be given a one-sentence smoking cessation advice during the baseline assessment. A leaflet showed the information related to the smoking cessation will be allocated to them at the same time.
61953583|NCT05509114|EXPERIMENTAL|Virtual Reality Glasses|The intervention introductory information formula was face-to-face by researchers from the State-Trait Anxiety Inventory (STAI-I, STAI-II), the Scale of Patient Perception of Hospital Experience with Nursing Care (PPHEN) and Visual Analog Scale for Pain (VAS) Before starting the research, a preliminary application plan is determined with 10 virtual virtual applications. It is not included in the applications made in the pre-application. Before watching the video, patients are informed about how to train, how to do it, and detailed information about the video. When the patient is removed from the service and in the left lateral position, 2 minutes before the assistant physician, the virtual is about to take place. The video was watched after about 10-15 minutes until the process was finished. After the procedure, STAI-I, STAI-II, PPHEN and VAS were reapplied by the researchers.
61953584|NCT00717093|EXPERIMENTAL|Active|
61953585|NCT00717093|PLACEBO_COMPARATOR|Placebo|
61953586|NCT01419691|EXPERIMENTAL|Phase 2 Dose|Auranofin 6 mg orally in the morning / 6 mg orally in the evening
61953587|NCT03268993|OTHER|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
62141814|NCT04197037||People with schizophrenia treated with clozapine|People more than 18 with diagnosis of schizophrenia and treated with clozapine in a stable dose and stable status of the disease (at least 2-3 weeks).
62501667|NCT05647291|EXPERIMENTAL|extracorporeal Shock wave therapy (ESWT)|ESWT was performed by the same physician. The applicator was placed at the point of maximum sensitivity. Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week for two weeks, adding up to a total of 4 sessions. Local or regional anesthesia was not administered to any patient during ESWT.
62700823|NCT05930639|EXPERIMENTAL|Surgical Site Infection (SSI) prevention package;patient education|SSI definition, SSI signs and symptoms, Hand hygiene, smoking, hair removal in the operation area, shower and bath before surgery. Conditions that require hospitalization, factors affecting wound healing, wound care, control time and who should be contacted will be discussed.
62501668|NCT05647291|ACTIVE_COMPARATOR|Kinesiotaping|Kinesio tape (KinesioTex, KinesioTaping, US) was applied to the relevant extremity of the patient by the physical therapy and rehabilitation physician once a week, three times in total. During KT, the patient was positioned with the knee and ankle joints in the neutral position. The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends.
62501669|NCT05647291|ACTIVE_COMPARATOR|Corticosteroid injection|In the CI group, 40mg/1ml methylprednisolone was applied from the inferior-medial side of the heel to the most sensitive area of the calcaneus medial tubercle of the plantar fascia. The same physician performed a total of two sessions once a week.
61953588|NCT00911560|EXPERIMENTAL|vaccine group one|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a inimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to in Group 1 will receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
62141815|NCT05467943|EXPERIMENTAL|Cohort 1 based on the EZH2 mutations|MT patients with R/R FL; planned enrollment number: 19;
62501670|NCT03114358|EXPERIMENTAL|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
62501671|NCT03114358|NO_INTERVENTION|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
62501672|NCT03512249|EXPERIMENTAL|H56:IC31|"The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.~H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique."
62501673|NCT03512249|PLACEBO_COMPARATOR|Placebo|Sterile saline for injection
62501674|NCT06679634|EXPERIMENTAL|Chemoplaque|Chemoplaque (also referred to as Episcleral Topotecan) treatment will involve single application of the Episcleral Topotecan 1.2 mg dose that delivers sustained delivery for 8 weeks.
62501675|NCT04674826|EXPERIMENTAL|TR (Test-Reference)|Treatment period 1: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T) Treatment period 2: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R)
62501676|NCT04674826|EXPERIMENTAL|RT (Reference-Test)|Treatment period 1: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R) Treatment period 2: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T)
62501677|NCT04560426|EXPERIMENTAL|Naked eyes & Instrument assistance|Identify the parathyroid glands through the experience of surgeons and assistance of instrument.
62501678|NCT04560426|NO_INTERVENTION|Naked eyes only|Identify the parathyroid glands only through the experience of surgeons.
62501679|NCT06677749|EXPERIMENTAL|Eccentric Exercise|300 repetitions of isokinetic dynamometer eccentric knee extensions.
62501680|NCT03200145||Control|The control group is made by persons living in nursing homes under usual care
62501681|NCT02140424||youth with type 1 diabetes|
62501682|NCT02140424||healthy controls|
62501683|NCT00142116|EXPERIMENTAL|Thalidomide and Rituximab|"Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later."
62501684|NCT04526080|EXPERIMENTAL|TheraBionic Arm|Self-administered from the device that delivers low levels of radiofrequency electromagnetic fields into the body with a spoon-shaped antenna placed in the mouth.
62501685|NCT04526080|PLACEBO_COMPARATOR|Placebo Arm|Placebo device that looks and sounds like the active device.
62501686|NCT01080586|ACTIVE_COMPARATOR|NEORAL® Capsule 100 mg|
62501687|NCT01080586|EXPERIMENTAL|Cyclosporine 100 mg Capsule|
62501688|NCT02245698|EXPERIMENTAL|Stem Cell|Bone marrow mononuclear cells
62501689|NCT02798419|EXPERIMENTAL|DFD05 Cream|DFD05 Cream
62501690|NCT02798419|ACTIVE_COMPARATOR|Active01 Cream|Active01 Cream
62501691|NCT02655224|EXPERIMENTAL|Relugolix 40 mg|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix 40 mg, tablet, orally once daily before breakfast for 12 weeks.
62700824|NCT05930639|NO_INTERVENTION|control group|"Antibiotic prophylaxis is applied to both groups. In the clinic where the study will be conducted, the blood glucose level of patients with a diagnosis of DM is controlled (5 measurements per day). All patients are fasted after 21.00 in the evening. The blood glucose levels of patients without a diagnosis of DM are not routinely checked. The body temperature of the patients is not monitored intraoperatively. No extra intervention is applied to maintain normothermia in the clinic and operating room.~There is no training on prevention of infection. There is no intervention in the control group."
62141816|NCT05467943|EXPERIMENTAL|Cohort 2 based on the EZH2 mutations,|WT patients with R/R FL; planned enrollment number: 20;
62141817|NCT00557284|EXPERIMENTAL|1|Montelukast
62141818|NCT00557284|PLACEBO_COMPARATOR|2|
62141819|NCT03710252|EXPERIMENTAL|Single|Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)
62141820|NCT00861003||Schizophrenia, antipsychotics|Stable outpatient status of schizophrenia or schizoaffective disorder currently taking a single oral antipsychotic
62141821|NCT02958566|ACTIVE_COMPARATOR|Narcotic|"Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.~Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN"
62501692|NCT02655224|PLACEBO_COMPARATOR|Placebo|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix placebo-matching tablet, orally once daily before breakfast for 12 weeks.
61953589|NCT00911560|EXPERIMENTAL|vaccine group two|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to Group 2 will receive oral β glucan (40 mg/kg/day) starting week 1 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
61953590|NCT00911560|EXPERIMENTAL|vaccine group three|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Group 3 will include patients who have previously received vaccine and oral β glucanglucan. Patients in this group will not be randomized using the MSK CRDB system. They will be treated as patients in Group 1 and receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination . They will not be eligible for primary endpoint.
62344025|NCT04786548|EXPERIMENTAL|Celecoxib Treatment|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment
62344026|NCT01573013|ACTIVE_COMPARATOR|NaFeEDTA treatment, biscuit|Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
62344027|NCT01573013|ACTIVE_COMPARATOR|EDTA treatment, biscuit|Group receives Na2EDTA enriched biscuit
62344028|NCT01573013|ACTIVE_COMPARATOR|FeSO4 treatment, biscuit|Group receives 10 mg of iron as FeSo4 per day for 8 months
62344029|NCT01573013|PLACEBO_COMPARATOR|control treatment, biscuit|group receives a biscuit without additional iron
62344030|NCT00012012|EXPERIMENTAL|Radiation therapy plus cisplatin|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin.
62344031|NCT00012012|EXPERIMENTAL|Radiation therapy plus cisplatin and amifostine|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin and amifostine trihydrate.
61953591|NCT01676571|EXPERIMENTAL|Lu AA21004|
62344032|NCT04580030||hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure \<90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
62344033|NCT04580030||no hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure \<90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
62501693|NCT00943865|ACTIVE_COMPARATOR|hypocaloric diet + exercise advice|Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
62700825|NCT02895555|ACTIVE_COMPARATOR|Allograft group, standard treatment|Control group, standard treatment. Approx 50 g pr level fused.
62700826|NCT02895555|EXPERIMENTAL|i-FACTOR|i-FACTOR putty in the operation site. Fda approved. Approx 5 ml pr level fused.
62700827|NCT00654355|EXPERIMENTAL|Active Drug|tacrolimus ointment
62700828|NCT03148002|ACTIVE_COMPARATOR|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
61953592|NCT00578708|EXPERIMENTAL|1|
62141822|NCT02958566|EXPERIMENTAL|Non-Narcotic|Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.
61953593|NCT03708016|EXPERIMENTAL|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
61953594|NCT03708016|ACTIVE_COMPARATOR|Robot gait training without brain stimulation|Lokomat robot training and sham tDCS on the leg motor areas
61953595|NCT01100541|EXPERIMENTAL|Polymeric plate characteristics|Evaluation, in the volunteers viewpoint, of the polymeric plate characteristics.
61953596|NCT03470870||Patients discharged before 2 days after surgery|patients discharged before 2 days of hospitalization following surgery
61953597|NCT03470870||Patients discharged after 2 days after surgery|patients discharging after 2 days of hospitalization following surgery
62141823|NCT01507506|ACTIVE_COMPARATOR|Conventional arm|3-dimensional conformal radiotherapy + Temozolomide
62141824|NCT01507506|EXPERIMENTAL|Experimental arm|simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
62141825|NCT03738384|EXPERIMENTAL|TKR Patients|Any patient 3-6 weeks post-op from a TKR
62141826|NCT01012063|EXPERIMENTAL|group IE|The group IE received iron sucrose and erythropoietin-β (Epo-β) during the operation
61953598|NCT03999177|EXPERIMENTAL|Kinect-TOLF prototype|
62501694|NCT00943865|EXPERIMENTAL|pragmatic diet+ pedometer 10000 steps|Group 2 (pragmatic diet + step counter) - Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control. Subjects were provided with pedometers and were instructed to perform at least 10.000 steps daily, diary recorded.
62344034|NCT03051724|EXPERIMENTAL|Intervention group|"These OSA patient's are not familiarized with the use of internet and mobile technologies and with CPAP prescription. They follow the intervetion follow up that consists in an adaptation session where the tecnitian delivers them an automatic CPAP machine. Patient's are titrated with this automatic device in 5-7 days and are treated with the automatic device during 3 months.~The other part of the follow up consists on a voicemail where the patient can contact us 24h a day and on an , with an internet-connected tablet with a special app where the patient's answer a questionnaire once two weeks."
62700829|NCT03148002|ACTIVE_COMPARATOR|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
61953599|NCT02369432|EXPERIMENTAL|Group of healthy volunteers and group of patients|"* Healthy volunteers: Microparticles will be applied to the skin of the forearm and then a skin biopsy of this area will be performed~* Patients suffering from atopic dermatitis: Microparticles will be applied to the skin of the forearm both to an area affected by dermatitis and to an area deprived from the disease. A skin biopsy of these two areas will be performed"
61953600|NCT04369287||IDH1-mutated AML|Patients affected with AML and carryng IDH1 mutations
61953601|NCT04369287||IDH2-mutated AML|Patients affected with AML and carryng IDH2 mutations
61953602|NCT04369287||IDH1/2 unmutated AML|Patients affected with AML without IDH1/2 mutations
61953603|NCT05219175|EXPERIMENTAL|Co-occurring PTSD and OUD prior and after treatment with MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)"
62141827|NCT01012063|PLACEBO_COMPARATOR|group C|The group C received saline as same method.
62344035|NCT03051724|NO_INTERVENTION|Control group|These patient's are patient's that follow the process that all patient's take during CPAP treatment. During the three months of study, the follow up will be the usual.
62344036|NCT06006312||Elderly population|The elderly population is defined as those over 60 years of age and residing in retirement home. Excluding people with critical conditions, mental disorders that prevent them from cooperating with the study, and those who are unable to defecate due to intestinal obstruction or other illnesses.
62344037|NCT06006312||Community population|This group is the resident population of the community. Excluding people with critical conditions, mental disorders that prevent them from cooperating with the study, and those who are unable to defecate due to intestinal obstruction or other illnesses.
62344038|NCT06006312||Chronic pancreatitis|Patients with chronic pancreatitis are considered as study subjects. If a CP patient has diabetes mellitus (exclude type 1 diabetes mellitus), a blood test will be performed to assess glycemic control.
62344039|NCT06006312||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus are considered as study subjects.
62344040|NCT04265170|EXPERIMENTAL|Single-arm|Eligible patients are treated with BlastX and VAC. The subjects return to the center three times per week for dressing changes and application of BlastX. The duration of the trial is four weeks and 8 weeks for larger wounds (2 subjects only). Subjects undergo study procedures (biopsy for quantitative tissue culture, photography, fluorescence imaging and swabbing for protease testing) on a weekly basis. The standard of care for pressure ulcers will be continued including debridement, off-loading, and nutritional supplementation when appropriate.
62344041|NCT06483763|OTHER|The group using the SmokerFace App from the Education Against Tobacco (EAT) program|Trained medical students will deliver the intervention and will be conducted in the specific classrooms of enrolled schools. The school students will be taught how to use the SmokerFace App from the Education Against Tobacco (EAT) program (26) with parental supervision at home. Medical Students will send the links to download the app from the App Store (iOS) and Play Store (Android), along with an explanation of how to install and use the app.
62344042|NCT06483763|OTHER|The group receiving of standardized school-based educational module|The control arm will receive a standardized school-based educational module that aligns with the tobacco health hazards awareness educational toolkit provided by the World Health Organization.
62700830|NCT05910346|EXPERIMENTAL|Experimental Group|At the beginning of the study, the pregnant women who applied to the obstetrics clinics and met the sample selection criteria will be divided into the experimental and control groups by randomization method by filling out the Personal Information Form. Motherhood Theory-Based Education Program will be applied to the pregnant women who are allocated to the experimental group.
61953604|NCT01262131|ACTIVE_COMPARATOR|Resonator Protocol A|
61953605|NCT01262131|ACTIVE_COMPARATOR|Resonator Protocol B|Application of magnetic fields using the Resonator device Protocol B
61953606|NCT01262131|PLACEBO_COMPARATOR|Inactive Resonator|
62344043|NCT05797454|EXPERIMENTAL|Untreated patients-combined localization|In untreated non-palpable breast cancer patients, positioning focus use wire and marker clip at 1day before operation
62141828|NCT05919680|EXPERIMENTAL|Part A-800 mg NST-6179|up to 12 subjects
62141829|NCT05919680|EXPERIMENTAL|Part A matched NST-6179 placebo|up to 6 subjects
62141830|NCT05919680|EXPERIMENTAL|Part B- 1200mg NST-6179|up to 12 subjects
62501695|NCT00943865|EXPERIMENTAL|pragmatic diet + fitness|Group 3 (pragmatic diet + fitness) - They received the same diet intervention (low carbohydrates, high protein and vegetables style diet and favoring daily brazilian cook habits colored handbook) and hand sized portion control instructions of group 2. They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions.
62501696|NCT03528096|EXPERIMENTAL|Intervention night|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat B rocking bed. Stimulation is provided for the first 60 minutes of the night and for 10 minutes upon detection of symptoms. The stimulation frequency is in the range of 0.25-2 Hz.
62141831|NCT05919680|EXPERIMENTAL|Part B matched NST-6179 placebo|up to 6 subjects
62344044|NCT05797454|ACTIVE_COMPARATOR|Untreated patients-single localization|In untreated non-palpable breast cancer patients, positioning focus use wire at 1day before operation
62344045|NCT03550638|EXPERIMENTAL|group A|Coil system(Ton-bridgeMT)
62344046|NCT03550638|ACTIVE_COMPARATOR|group B|Axium Detachable Coil(Medtronic)
62344047|NCT01706549||Posthysterectomy pain|Observational study on posthysterectomy pain
62344048|NCT01479166||affected patients with small airway disease (SAD)|20 patients suffering from mild cystic fibrosis and involvement of small airways
62344049|NCT01479166||affected patients without small airway disease (SAD)|20 patients suffering from mild cystic fibrosis without SAD
62344050|NCT01479166||non-affected patients|20 matched controls not suffering from cystic fibrosis
62344051|NCT05165979||Hospitalized COVID-19 patients|Hospitalized COVID-19 patients
62344052|NCT01519063|EXPERIMENTAL|Naltrexone and memantine|Treatment with Naltrexone and memantine first
62344053|NCT01519063|PLACEBO_COMPARATOR|Naltrexone and Placebo|Treatment with naltrexone and placebo first
62344054|NCT05685576|EXPERIMENTAL|Ridge splitting and osseodensification with simultaneous implant placement|
62344055|NCT06419517|EXPERIMENTAL|Supervised Pelvic Floor Muscle Training + EMG-triggered ES|"Group A (supervised PFMT + EMG-triggered ES) Supervised Pelvic Floor Muscle Training Twenty sessions will be applied, 2 per week for ten weeks~Stimulation parameters:~Duration: 15 min Electrode placement: vaginal probe Frequency: 50 Hz. - Pulse width 250 microseconds Intensity: to motor response (activation of PFM) Number of sessions: 20 Ramp up/down: 1 sec."
62344056|NCT06419517|ACTIVE_COMPARATOR|Supervised PFMT + sham EMG-triggered ES)|"Group B: Supervised PFMT + sham EMG-triggered ES) Supervised Pelvic Floor Muscle Training Twenty sessions will be applied, 2 per week for ten weeks~Stimulation parameters:~Duration: 15 min Electrode placement: vaginal probe model xx Frequency: 2 Hz. - Pulse width 10 microseconds Intensity: to sensory response Number of sessions: 20 Ramp up/down: 1 sec."
62344057|NCT03863236|ACTIVE_COMPARATOR|regular diet|The control group (group 1) will continue their regular diet.
62501697|NCT03528096|SHAM_COMPARATOR|Baseline night|The sound of the moving bed is played back to the participant at the right sound intensity level.
61953607|NCT02365831||Prospective|Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
62344058|NCT03863236|ACTIVE_COMPARATOR|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support two weeks before the operation and the nutritional support will continue 10 days after the operation.
62501698|NCT04659486|EXPERIMENTAL|Exercise training|A 12 weeks parallel-group randomized controlled trial will be performed, in which covid-19 survivors adolescents will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength and aerobic exercises
61953608|NCT02365831||Retrospective|Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
62344059|NCT03596658|EXPERIMENTAL|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
62344060|NCT02453009|EXPERIMENTAL|Arm A|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks
62344061|NCT02453009|ACTIVE_COMPARATOR|Arm B|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks
62344062|NCT04350229|EXPERIMENTAL|EXPERIMENTAL GROUP|"In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.~Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg."
62344063|NCT04350229|ACTIVE_COMPARATOR|CONTROL GROUP|Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg and dexamethasone 10mg.
62344064|NCT01733901|ACTIVE_COMPARATOR|RSD+PCI+Medicine|We will recruit 300 randomised CHD patients who meet the inclusion criteria. First undergo percutaneous coronary intervention, and then perform the renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. After renal sympathetic denervation traditional secondary prevention of coronary heart disease is recommend. Finally we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
62344065|NCT01733901|PLACEBO_COMPARATOR|PCI+Medicine|We aslo will recruit 300 randomised CHD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will perform percutaneous coronary intervention firstly, then give traditional secondary prevention of coronary heart disease just like the RSD+PCI+Medicine group. Third we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
62344066|NCT02156232|ACTIVE_COMPARATOR|TIPS, SPSS Emboliaztion|The covered stents wil be used for TIPS The SPSS will be embolized during the procedure of TIPS
62501699|NCT04659486|NO_INTERVENTION|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
62700831|NCT05910346|NO_INTERVENTION|Control Group|"First stage: Pregnant women in the control group will receive routine care. Second stage: Data Collection Form for the follow-up and Birth Process and Results will be filled within the first 24 hours after the birth.~Third stage: Follow-up will be done by phone within 4 weeks after birth. Maternal Attachment Scale (MBI), Barkin Maternal Function Inventory will be applied.~Fourth stage: At the end of the fourth month postpartum, follow-up counseling will be made by telephone and the Maternal Attachment Scale and the Barkin Maternal Function scale will be filled.~Fifth stage: When the study is completed, a training booklet will be given to the mothers in the control group."
61953609|NCT02901405|EXPERIMENTAL|Negative Pressure Wound Therapy|120 hours of negative pressure wound therapy (ActiVAC, KCI) applied to a primarily closed ('acute') wound.
61953610|NCT02901405|ACTIVE_COMPARATOR|Standard dressings|Absorbant dressings applied in a standard fashion, i.e. only changed as necessary
61953611|NCT03342677|OTHER|Single Arm|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver MRI with Primovist before hepatic transplantation.
61953612|NCT05500157|ACTIVE_COMPARATOR|Aspiration sclerotherapy|Aspiration sclerotherapy is a percutaneous procedure that evacuates fluid from the liver cyst and subsequently exposes cyst lining to a sclerosing agent (e.g. ethanol, minocycline) for a limited period of time.
61953613|NCT05500157|ACTIVE_COMPARATOR|Laparoscopic Fenestration|Laparoscopic fenestration exposes the liver through laparoscopic surgery. During this procedure the cyst is punctured and drained followed by resection of the extra-hepatic cyst wall
61953614|NCT04988139|ACTIVE_COMPARATOR|Intervention group|traditional rehabilitation programs with additional individualized educational training
61953615|NCT04988139|NO_INTERVENTION|Control group|traditional rehabilitation programs without additional individualized educational training
61953616|NCT03022136|EXPERIMENTAL|Epidural Block|Epidural block for patients undergoing urological surgery
62344067|NCT02156232|ACTIVE_COMPARATOR|TIPS alone|The covered stents will be used for TIPS No embolization of SPSS will be performed during TIPS
62501700|NCT03928236|EXPERIMENTAL|Limited Benzodiazepine Policy|Policy of no routine use of any intraoperative benzodiazepines.
62501701|NCT03928236|ACTIVE_COMPARATOR|Liberal Benzodiazepine Policy|Policy for the administration of benzodiazepine as per clinical guidelines but no lower than 0.03 mg/kg (ideal body weight midazolam equivalent) to all patients undergoing cardiac surgery. Any benzodiazepine may be used.
62700832|NCT03802916|EXPERIMENTAL|Low dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
61953617|NCT05947175|EXPERIMENTAL|Experimental group - vertebral bone marrow (vBMA) clot|Bone allograft chips will be obtained from Istituto Ortopedico Rizzoli while vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot associated with bone allograft chips will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot associated to bone allograft chips will be applied on each side of the vertebra according to the number of segments to be fused.
62501702|NCT00374166|EXPERIMENTAL|SSR149415 - 250 mg|SSR149415 250 mg, twice daily for a maximum of 8 weeks
62501703|NCT00374166|EXPERIMENTAL|SSR149415 - 100 mg|SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
61953618|NCT05947175|ACTIVE_COMPARATOR|Control - bone allograft chips|Bone allograft chips will be obtained from Istituto Ortopedico Rizzoli. In detail, conventional posterior approach for lumbar SF will be performed. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. Bone allograft chips alone will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary.
61953619|NCT05499000|EXPERIMENTAL|Experimental group|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS pre-tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the second session, post-test data will be obtained with SUE, PMSS."
61953620|NCT05499000|NO_INTERVENTION|Control group|KBF, SUE and PMSS pre-tests will be applied to the participants, SUE, PMSS and post-test data will be obtained simultaneously with the experimental group.
62501704|NCT00374166|ACTIVE_COMPARATOR|Paroxetine|Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
61953621|NCT05146895|EXPERIMENTAL|Local Hyperthermia at 44℃ for falt warts|Local hyperthermia at 44℃ for 30 mins on one lesion region, at days of 1,2,3, 15, 16, 21 and 28.
61953622|NCT05146895|ACTIVE_COMPARATOR|Imiquimod for Flat Warts|Miquimod treatment: 3 times a week for 1 month
61953623|NCT04790773|NO_INTERVENTION|Standard of care|Patient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
61953624|NCT04790773|ACTIVE_COMPARATOR|Alexa Education|Patient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.
61953625|NCT04816266||Myopic patients|
61953626|NCT04816266||Hypermetropic patients|
61953627|NCT04816266||Emmetropic people|
62501705|NCT00374166|PLACEBO_COMPARATOR|Placebo|Placebo for a maximum of 9 weeks
62501706|NCT03887598||breast nodule|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of breast surgery or breast biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
62700833|NCT03802916|EXPERIMENTAL|High dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
62501707|NCT05412121|EXPERIMENTAL|Acupressure|The self-acupressure intervention will be delivered using the modified MeTime Acupressure mobile application (App) in addition to in-person or virtual instruction via study staff.
62700834|NCT03749239|EXPERIMENTAL|Effects of collagen protein.|Non-hydrolized collagen protein
62700835|NCT00855101|EXPERIMENTAL|voriconazole|
62700836|NCT00542178|EXPERIMENTAL|Intensive glycemia control|A strategy of intensive glycemia treatment to HbA1c less than 6%
62700837|NCT00542178|ACTIVE_COMPARATOR|Standard glycemia control|A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
61953628|NCT01631773||subjects w/ Nasal polyps & AERD disease|subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
62700838|NCT00542178|EXPERIMENTAL|Intensive BP control|A strategy of BP treatment for SBP less than 120 mm Hg
62700839|NCT00542178|ACTIVE_COMPARATOR|Standard BP control|A strategy of BP treatment for SBP less than 140 mm Hg
61953629|NCT01631773||subjects w/ nasal polyps without AERD|subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
61953630|NCT03725852|EXPERIMENTAL|GLPG1205 100 mg|Participants will receive GLPG1205 100 milligrams (mg) (2 capsules x 50 mg), orally once daily for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
61953631|NCT03725852|PLACEBO_COMPARATOR|Placebo|Participants will receive GLPG1205 matching placebo, orally once daily (as 2 capsules) for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
61953632|NCT02184481|EXPERIMENTAL|Working memory training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level adapted to the working memory capacity of the participant.
61953633|NCT02184481|PLACEBO_COMPARATOR|Placebo training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level in the placebo condition was easy and did not adapt to the working memory capacity of the participant.
61953634|NCT01647646|ACTIVE_COMPARATOR|Symbicort|"We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period.~Intervention drug: Seretide fixed doses therapy"
61953635|NCT01647646|EXPERIMENTAL|Seretide|In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year
61953636|NCT03854695||Cohort 1|Cohort 1: clinically uninfected (1A and 1C) ulcers.
61953637|NCT03854695||Cohort 2|Cohort 2: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) with no recent antibiotic therapy (within 28 days)
61953638|NCT03854695||Cohort 3|Cohort 3: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) on antibiotic therapy
61953639|NCT00716703|EXPERIMENTAL|1|cohort = pediatric patients in the ED (3-18 yo) with abdominal pain suspicious for appendicitis that are to undergo CT scan
62141832|NCT02423005|EXPERIMENTAL|Neurotech Vital Compact|The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
62141833|NCT02423005|ACTIVE_COMPARATOR|itouch Sure Pelvic Floor Exerciser|The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
62501708|NCT05958056|EXPERIMENTAL|Low load resistance exercises with Practical blood flow restriction (PBFR)|Participants in the experimental group performed one session of 30% 1RM with Practical blood flow restriction training. The number of repetitions in every set was 15 times with PBFR.19 Participants in the experimental group used the elite band (occlusion training bands) for both thighs during the training session. The width of the thigh band was 5cm, which would produce a pressure between 160-240 mmHg. This pressure range is appropriate for most of the individuals who used PBFR.27 The perceived pressure scale (PPS) was used to estimate the appropriate pressure (7 out of 10) in training before performing the exercises.28,29 The blood flow restriction bands booklet was used30 along with previous studies to design the training session. Participants removed the BFR band immediately after the end of the training session.
62501709|NCT05958056|ACTIVE_COMPARATOR|High resistance exercises|Participants in the control group performed one session of 80% 1RM without PBFR. The number of repetitions in every set was 10 times.
62700840|NCT00542178|EXPERIMENTAL|Fibrate|Blinded fenofibrate + simvastatin 20-40 mg/d
62700841|NCT00542178|PLACEBO_COMPARATOR|Fibrate Placebo|Blinded placebo + simvastatin 20-40 mg/d
62700842|NCT06377501|EXPERIMENTAL|Intervention Group|Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.
61953640|NCT00332163|EXPERIMENTAL|Pre-emptive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy.
62700843|NCT06564428||Mutation carriers|Patients presented to our hospital with a definite pathological diagnosis of epithelial ovarian cancer, who carry suspective gene mutations or have family history of cancer.
62700844|NCT06564428||Control group|Patients presented to our hospital with a definite pathological diagnosis of epithelial ovarian cancer, who don't carry any suspective gene mutations and have no family history of any type of cancer.
62700845|NCT00867334|EXPERIMENTAL|Imatinib mesylate and panitumumab|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 1. Each participant assigned to Arm 1 will receive imatinib mesylate for 28 days, followed by a combination of imatinib mesylate and panitumumab.
62700846|NCT00867334|ACTIVE_COMPARATOR|Panitumumab (standard-of-care)|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 2. Participants in Arm 2 will receive standard-of-care treatment with panitumumab.
62700847|NCT03436667||Orthopedic surgery|Pediatric patients presenting for ambulatory orthopedic procedures
62700848|NCT02129972|EXPERIMENTAL|video capsule endoscopy|
62700849|NCT00877656|EXPERIMENTAL|CD4|Open label treatment arm
61953641|NCT00332163|EXPERIMENTAL|Reactive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required.
61953642|NCT01750983|EXPERIMENTAL|Ipilimumab + Lenalidomide|"Dose Escalation Group Ipilimumab Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Escalation Group Lenalidomide Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab and Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Groups."
61953643|NCT03196726|EXPERIMENTAL|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
61953644|NCT03196726|PLACEBO_COMPARATOR|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
61953645|NCT03703622|EXPERIMENTAL|Video-debriefing with standard HBB training|Health workers are given standard HBB training according to American Association of Pediatrics (AAP) plus video-debriefing. Filming of the simulated case scenarios will be done and after which the films will be used for debriefing or feedback. Participants will be encouraged to give feedback with the guidance of master trainer and the PI. Teams of three participants(birth attendant, mother and helper) will perform the HBB simulation or scenarios. After each scenario, debriefing is done until all participants have had the opportunity to participate in the simulation exercise. All the participants in this arm will undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick newborn baby who needs resuscitation care. Pre and post-tests will be done to assess performance of all participants.
61953646|NCT03703622|ACTIVE_COMPARATOR|Standard HBB training only|Health workers are given standard HBB training according to AAP without video-debriefing. All the participants in this arm, like in intervention arm, will also undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick new-born baby who needs resuscitation care only. Pre-and post-tests will be done to assess performance of all participants.
61953647|NCT02346552|EXPERIMENTAL|Group 1|Procedures will be performed with the AutoLpap system used for holding and controlling the movement of the laparoscope.
61953648|NCT02346552|NO_INTERVENTION|Group 2|Procedures will be performed with the assistance of human camera holder.
61953649|NCT01300650|EXPERIMENTAL|Anakinra|
61953650|NCT03021941|OTHER|Elelyso 60 units/kg|All patients receive 60 units/kg of Elelyso.
62700850|NCT05218707||Group A|An appropriate size oropharyngeal airway (GUEDEL) will be inserted immediately after removal of LMA and time will be noted. (Size will be chosen by placing the flange at the corner of the mouth and tip at the angle of the jaw).
61953651|NCT06040931|ACTIVE_COMPARATOR|Infrequent exacerbators (IFE) group|"15 patients with infrequent exacerbation (IFE) ≤1 exacerbation per year in the preceding 12 months before enrolment."
61953652|NCT06040931|ACTIVE_COMPARATOR|Frequent exacerbators (FE) group|"15 patients with frequent exacerbation(FE) ≥ 2 per year in the preceding 12 months before enrolment"
61953653|NCT02211079|EXPERIMENTAL|JNJ-54861911 + Caffeine + Midazolam +Tolbutamide|JNJ-54861911, 50 milligram (mg) (2\*25 mg tablets) orally once daily from Day 2 to Day 9 along with caffeine 100 mg (2\*50 mg tablets), midazolam 2 mg (1 milliliter \[mL\], 2 mg/mL solution), and tolbutamide 500 mg tablet, orally on Day 1, 2, and 9.
61953654|NCT03919331|EXPERIMENTAL|Experimental|Every adult patient admitted to the medical intensive care unit for de novo acute hypoxemic respiratory failure, and placed under hign flow nasal canula (HFNC). Inclusion and exclusion criterion are listed elsewhere.
61953655|NCT04929574||beta thalassemia patients|
61953656|NCT03680690||Group A|women with normal uterus,detected by hysteroscopy.
61953657|NCT03680690||Group B|Women with detected or corrected uterine cavitary lesions by hysteroscopy.
61953658|NCT00183677|EXPERIMENTAL|Escitalopram|Participants will receive open treatment with escitalopram.
61953659|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
61953660|NCT05600452|ACTIVE_COMPARATOR|Traditional heat acclimation|The traditional heat acclimation programme will consist of daily 75-minute heat exposures for eight consecutive days
61953661|NCT05600452|EXPERIMENTAL|Condensed heat acclimation|The condensed heat acclimation programme will consist of two consecutive days with four, 75-minute heat exposures undertaken on each day
62700851|NCT05218707||Group B|In Group B No oropharyngeal airway (GUEDEL) will be inserted.
62700852|NCT06536426|EXPERIMENTAL|Knee Isometric Program (KIP) - Intervention|This group will incorporate the KIP protocol, which is a modified physical therapy regimen that is less time-intensive than the gold standard counterpart. Typical structured/skilled physical therapy occurs over the course of 4-8 weeks with 1-2 visits per week to establish improved lower extremity muscle strength, education, and improve gross function. Home exercise programs (HEP) are utilized in tandem with physical therapy visits so that patients are completing interventions 4-5 days per week. Long-term maintenance is generally provided via a refined comprehensive HEP on completion and discharge from formal physical therapy.
62700853|NCT06536426|NO_INTERVENTION|Patellofemoral Clinical Practice Guideline (CPG) - Control|This group will incorporate the standard of care physical therapy regimen which includes a specific and structured combination of quadriceps and gluteal strengthening as defined in the patellofemoral pain clinical practice guideline. Typical structured/skilled physical therapy occurs over the course of 4-8 weeks with 1-2 visits per week to establish improved lower extremity muscle strength, education, and improve gross function. Home exercise programs (HEP) are utilized in tandem with physical therapy visits so that patients are completing interventions 4-5 days per week. Long-term maintenance is generally provided via a refined comprehensive HEP on completion and discharge from formal physical therapy.
62501710|NCT02103582|PLACEBO_COMPARATOR|control|Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
62700854|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Standard/Nested 1|This is a triple cross-over with a sham control condition; the standard tACS administered first, then Nested, then sham.
61953662|NCT03158025|EXPERIMENTAL|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant \[LEM\] tablets; 3 × placebo zolpidem \[ZOL\] tablets; 2 × placebo suvorexant \[SUV\], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
62700855|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Older Adults Active 1|This is a double cross-over with a sham control condition; the tACS administered first, then the sham
62700856|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- MCI Active 1|This is a cross-over with a sham control condition; the standard tACS administered first, then sham.
62700857|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Standard/Nested 2|This is a triple cross-over with a sham control condition; the standard tACS administered first, then sham, then nested tACS.
62700858|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Standard/Nested 3|This is a triple cross-over with a sham control condition; the sham tACS administered first, then nested tACS, then standard tACS.
61953663|NCT03158025|EXPERIMENTAL|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
61953664|NCT03158025|EXPERIMENTAL|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
62700859|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Older Adults Active 2|This is a double cross-over with a sham control condition; the sham administered first, then the tACS.
62700860|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- MCI Active 2|This is a cross-over with a sham control condition; the sham administered first, then standard tACS.
62700861|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Standard/Nested 4|This is a triple cross-over with a sham control condition; the sham tACS administered first, then standard tACS, then nested tACS.
62700862|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Standard/Nested 5|This is a triple cross-over with a sham control condition; the nested tACS administered first, then sham, then standard tACS.
62700863|NCT03112902|ACTIVE_COMPARATOR|Effects of tACS during SWS- Standard/Nested 6|This is a triple cross-over with a sham control condition; the nested tACS administered first, then standard tACS, then sham.
62700864|NCT04770896|EXPERIMENTAL|Atezolizumab + Lenvatinib or Sorafenib|Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62700865|NCT04770896|ACTIVE_COMPARATOR|Lenvatinib or Sorafenib|Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
62700866|NCT06465238|EXPERIMENTAL|Treatment group 1|SHR-A2009
62700867|NCT06465238|EXPERIMENTAL|Treatment group 2|SHR-A1921
62700868|NCT05338307|EXPERIMENTAL|BHB supplementation|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol, for a total of 4 weeks.
62700869|NCT02899403|EXPERIMENTAL|healthy subjects|
62700870|NCT05367947|EXPERIMENTAL|In-phase bilateral RRMS Participants A-E|The study follows a concurrent multiple baseline design across subjects, which involves five people with RRMS as five different case studies.
62501711|NCT02103582|EXPERIMENTAL|intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
62700871|NCT04992273|EXPERIMENTAL|≥20 kg to <40 kg|SC administration
61953665|NCT03158025|EXPERIMENTAL|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
61953666|NCT03158025|EXPERIMENTAL|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
61953667|NCT03158025|EXPERIMENTAL|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
61953668|NCT04188847|EXPERIMENTAL|Study group|The patients would accept the regimen of apatinib combined with cisplatin and paclitaxel
61953669|NCT01011777|EXPERIMENTAL|Autologous Muscle Derived Cells|Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
61953670|NCT00808860|PLACEBO_COMPARATOR|Placebo group|Gliclazide + Placebo tea
61953671|NCT00808860|ACTIVE_COMPARATOR|GP group|Gliclazide + Gynostemma pentaphyllum tea
61953672|NCT03477097|NO_INTERVENTION|Control group w/o social network intervention|Subjects did not receive any intervention of nutrition, physical activity and social network.
62141834|NCT00787709|EXPERIMENTAL|1|Receives Pathways universal school-based health promotion curriculum from 4th-6th grade
61953673|NCT03477097|EXPERIMENTAL|Control group w/ social network intervention|Subjects only received the intervention of social network.
61953674|NCT03477097|EXPERIMENTAL|Nutrition group 1 w/o social network intervention|Subjects only received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder).
61953675|NCT03477097|EXPERIMENTAL|Nutrition group 1 w/ social network intervention|Subjects received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder) and social network intervention as well.
61953676|NCT03477097|EXPERIMENTAL|Nutrition group 2 w/o social network intervention|Subjects only received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil).
61953677|NCT03477097|EXPERIMENTAL|Nutrition group 2 w/ social network intervention|Subjects received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and social network intervention as well.
61953678|NCT03477097|EXPERIMENTAL|Physical activity group w/o social network intervention|Subjects only received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training.
61953679|NCT03477097|EXPERIMENTAL|Physical activity group w/ social network intervention|Subjects received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training, and social network intervention as well.
62141835|NCT00787709|NO_INTERVENTION|2|Control group of students who do not receive the intervention
62141836|NCT03476772|NO_INTERVENTION|A|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % via caudal route to achieve post operative analgesia
62141837|NCT03476772|ACTIVE_COMPARATOR|B|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % plus 0.1 mg nalbuphine via caudal route to achieve post operative analgesia
62501712|NCT01617551|EXPERIMENTAL|Renal denervation|Patient group randomized to renal denervation
62501713|NCT01617551|SHAM_COMPARATOR|Sham|Patients randomized to sham procedure
62501714|NCT00324896|EXPERIMENTAL|eszopiclone|eszopiclone. Those under 65yo received 3mg of eszoplicone ( or randomized to matching placebo)and those 65yo or older received 2mg of eszoplicone ( or randomized to matching placebo)taken each night at bedtime
62501715|NCT00324896|PLACEBO_COMPARATOR|placebo|Those randomly assigned to matching placebo, took their dose each night at bedtime
62700872|NCT04992273|EXPERIMENTAL|≥10 kg to <20 kg|SC administration
62700873|NCT04992273|EXPERIMENTAL|≥5 kg to <10 kg|SC administration
62700874|NCT04992273|EXPERIMENTAL|≥3 kg to <5 kg|SC administration
62501716|NCT05359783|EXPERIMENTAL|Sentinel node detection with 0.1mL SPIO|An intradermal injection of SPIO (MagTrace®), according to the pre-specified dose of 0.1mL, will be performed 7 days, up to the day of surgery. The injection should be in the skin over the tumour, or at the border of the areola
62501717|NCT05260203|EXPERIMENTAL|App RITA|The interventional study group will use the Device Rita, an application that allow the oncological and onco-hematological patients to receive and communicate information about the quality of life and about the treatment related adverse events, providing a support in the therapy management. The access to the app functionalities is granted when the physician habilitates the personal profile. The app can be also used from people designated from the patient as caregiver, who can view the data inserted by the patient and, if enabled, they can insert the data for the patient.
62501718|NCT05260203|NO_INTERVENTION|Retrospective Historical|This clinical trial has no control intervention; on the other hand, the clinical outcomes of this treatment will be compared with the retrospective clinical data obtained from a historical group of comparison. The historic control used in this clinical trial is specifically selected to reflect the endpoints. According to a feasibility phase of this study, the information on the date of start and end of treatments is routinely collected in the medical records of patients, and for this reason, these data are potentially already available for the historical control group.
62501719|NCT04153786|EXPERIMENTAL|Cohort|Pacemakers will be programmed to BiV pacing, left ventricular (LV) pacing, right ventricular (RV) pacing and no pacing for five minutes each. LVAD flow will be recorded every thirty seconds for five minutes with each setting. Once the interventions have been completed, all pacemakers will be returned to their original setting.
62501720|NCT05796518|EXPERIMENTAL|PREVENT - Cardiovascular Health Assessment Tool|An adapted version of the PREVENT tool for endometrial cancer survivors will be used collect data during routine follow-up care for endometrial cancer that will yield a cardiovascular health score based on the Simple 7 risk factors (current smoking habits, body mass index, physical activity, diet, cholesterol, blood pressure and fasting plasma glucose).
62501721|NCT02776527|EXPERIMENTAL|A group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox,and taking Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses.
62501722|NCT02776527|NO_INTERVENTION|B group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox
62501723|NCT01875887||treat bilateral maxillofacial deformties|treatment of bilateral maxillofacial post-traumatic deformities
62501724|NCT02966340|EXPERIMENTAL|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
62501725|NCT02966340|EXPERIMENTAL|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
62501726|NCT01288924|ACTIVE_COMPARATOR|Parecoxib|Parecoxib 2 ml intravenous
62501727|NCT01288924|PLACEBO_COMPARATOR|Control|0.9% sodium chloride 2 ml intravenous
62501728|NCT01462578|EXPERIMENTAL|Azacytidine|Azacytidine injection: 75 mg/m²/d, subcutaneous
62501729|NCT04726852||Patients|Patients having elective cardiac surgery
61953680|NCT03477097|EXPERIMENTAL|Nutrition 1 + physical activity group w/o social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder) and exercise (e.g., personalized homed-based exercise plan) intervention.
62141838|NCT04990388|EXPERIMENTAL|UX053 Dose Level 1S ->OL-1R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
62501730|NCT02701608|EXPERIMENTAL|Oral switch treatment|Oral switch to the combination of levofloxacin and rifampicin
62501731|NCT02701608|ACTIVE_COMPARATOR|Conventional IV treatment according to european guidelines|Conventional IV treatment of staphylococci IE (European guidelines 2015)
62501732|NCT04201028|EXPERIMENTAL|Video Conferencing Health Coaching with devices|The DEV group participants will meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) to discuss exercise and diet goals. Participants in this group were provided with a blood pressure and body weight scale which connected to the CoachCare App®.
62501733|NCT04201028|EXPERIMENTAL|Video Conferencing Health Coaching with no devices|The NODEV group participants meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) for health coaching to discuss exercise and diet goals. Participants in this group did not receive devices.
62501734|NCT06594367||Patients|10 patients from di 7 families living in 3 villages of the Bergamo province i.e., Torre de Roveri, Albano S. Alessandro and Scanzorosciate who during genetic tests for ADPKD have revealed the presence of a new heterozygous deletion in the PKD2 gene will be included in this study.
62501735|NCT05396950|EXPERIMENTAL|CPAP Planned|Radiotherapy planning with CPAP in addition to standard plans
62501736|NCT00605176|ACTIVE_COMPARATOR|3.75% imiquimod cream|
62501737|NCT00605176|ACTIVE_COMPARATOR|2.5% imiquimod cream|
61953681|NCT03477097|EXPERIMENTAL|Nutrition 1 + physical activity group w/ social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
61953682|NCT03477097|EXPERIMENTAL|Nutrition 2 + physical activity group w/o social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and exercise (e.g., personalized homed-based exercise plan) intervention.
62501738|NCT00605176|PLACEBO_COMPARATOR|Placebo cream|
61953683|NCT03477097|EXPERIMENTAL|Nutrition 2 + physical activity group w/ social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
61953684|NCT01507012|EXPERIMENTAL|Powdered berryfruit extract|Powdered berry extract containing 500mg of polyphenols
62501739|NCT05862844|EXPERIMENTAL|The single-arm trial with a pre- and post-test design|The Intervention Arm in the Promise Women Project evaluates a specific educational intervention program for Muslim women to promote cervical cancer prevention. It involves a one-time, 90-minute culturally and religiously tailored educational session with 20 participants. The session covers perceived risks of Human Papilloma Virus (HPV) infection, cervical cancer, and benefits of early screening and vaccination. Pre- and post-intervention surveys measure changes in participants' knowledge. This experimental arm assesses the intervention's effects on knowledge and acceptance of cervical cancer prevention.
62501740|NCT03996837|EXPERIMENTAL|Fresh embryo transfer with intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
62501741|NCT03996837|NO_INTERVENTION|Fresh embryo transfer without intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
62501742|NCT03996837|EXPERIMENTAL|Freeze embryo transfer with intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
62700875|NCT04503369||EMS crews|Crews of Emergency Medical Services
61953685|NCT01507012|PLACEBO_COMPARATOR|Placebo|
61953686|NCT01507012|EXPERIMENTAL|Berryfruit juice|Berryfruit juice containing 500mg polyphenols
62141839|NCT04990388|EXPERIMENTAL|UX053 Dose Level 2S->OL-2R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
62141840|NCT04990388|EXPERIMENTAL|UX053 Dose Level 3S->OL-3R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
62141841|NCT04990388|EXPERIMENTAL|UX053 or Placebo Dose Level DB-1R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
62141842|NCT04990388|EXPERIMENTAL|UX053 Dose Level DB-2R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
62700876|NCT05156528|EXPERIMENTAL|Experimental group|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine, 0.5ml/dose, 2 doses with an interval of 30 days.
62141843|NCT04990388|EXPERIMENTAL|UX053 Dose Level DB-3R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
62700877|NCT05156528|PLACEBO_COMPARATOR|Placebo group|Aluminium phosphate adjuvant, 0.5ml/dose, 2 doses with an interval of 30 days.
62700878|NCT06560788||Case group 1: Children with Open Spina Bifida and Chiari II Malformation|CSF will be collected during postnatal surgical repair at Great Ormond Street Hospital (GOSH)
62700879|NCT06560788||Control group 1: Newborns with hydrocephalus undergoing shunt surgery, unrelated to spina bifida|CSF will be collected during suregry at GOSH
62700880|NCT06560788||Control group 1bis: Infants undergoing spinal surgery for conditions other than SB|CSF will be collected during surgery at GOSH.
62700881|NCT06560788||Case group 2: Fetuses Undergoing Prenatal Surgery for Spina Bifida|CSF will be collected during prenatal surgery at University College London Hospitals (UCLH).
61953687|NCT04252781|OTHER|Exhaustive exploration|Exhaustive exploration of newly diagnosed COPD patients (pulmonary pathology and associated comorbidities)
61953688|NCT04862819|ACTIVE_COMPARATOR|scaling root planning|patients in this group will have a scaling root planing procedure only
61953689|NCT04862819|EXPERIMENTAL|scaling root planning with new local drug delivery|patients in this group will have a scaling root planing procedure and a drug administered
61953690|NCT02261896|EXPERIMENTAL|Placebo|1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
61953691|NCT02261896|ACTIVE_COMPARATOR|Antibiotic|Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)
61953692|NCT05207046||Patients with spinal cord injury|Patients treated with mechanical ventilation after a traumatic spine lesion with spinal cord injury
62501743|NCT03996837|NO_INTERVENTION|Freeze embryo transfer without intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
62344068|NCT03899532|EXPERIMENTAL|Remote Ischemic Conditioning|"Remote ischemic conditioning will be performed using a standard manual blood pressure cuff. The pressure in the blood pressure cuff will be maintained at 30 mm of Hg higher than the patient's systolic blood pressure. 4 cycles of ischemic conditioning will be performed each day for a period of 7 days. Each cycle consists of 5 min of controlled upper limb ischemia (cuff up) followed by 5 min of reperfusion (cuff down). The total duration of the treatment cycle will be 40 min. The study protocol is based on our published literature in traumatic brain injury.~Blood samples will be collected at 0 hours (before randomization). Then the first 4 cycles of RIC (done consecutively) will be performed, blood samples will be taken at 6 hours post randomization and then at 24 hours post randomization. RIC cycles will then be performed on a daily basis followed by taking a blood sample once daily during the patients' length of stay up to a maximum of 7 days"
62344069|NCT03899532|PLACEBO_COMPARATOR|No Remote Ischemic Conditioning|Blood samples will be collected at 0 hours (before randomization). Blood samples will then be collected at 6 hours post randomization and 24 hours post randomization. These patients will not receive daily RIC therapy but will only have their blood drawn once daily during the patients' length of stay up to a maximum of 7 days.
62700882|NCT06560788||Control group 2: Aborted fetuses within the gestational age range of 22-24 weeks,|CSF will be collected from fetuses provided by the Human Developmental Biology Resource (HDBR).
61953693|NCT05207046||Patients with NO spinal cord injury|Patients treated with mechanical ventilation after a traumatic spine lesion with NO spinal cord injury
61953694|NCT05618197|EXPERIMENTAL|Passive heating intervention|\~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C) sessions over a period of 6 weeks.
61953695|NCT05618197|NO_INTERVENTION|Control|6 weeks of no hot water immersion
62141844|NCT02401932||Hemophagocytosis|The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites.
62344070|NCT04089813||Metformin|Patients use metformin to control blood sugar
62344071|NCT04089813||Insulin|Patients use Insulin to control blood sugar
62501744|NCT00826137|EXPERIMENTAL|A|Treated with prebiotics.
62501745|NCT00826137|PLACEBO_COMPARATOR|B|Placebo treated.
62501746|NCT01616316|EXPERIMENTAL|subfascial flap|
62501747|NCT01616316|EXPERIMENTAL|Subplatysmal flap|
62501748|NCT04487288|EXPERIMENTAL|CEUS with fusion|Control group: The historic cohort is used to compare the results of the biopsy using fusion only technique from 2013 to 2019.
62501749|NCT04433494|EXPERIMENTAL|TY-302 ; TY-302 combine with Tamoxifen|"1. TY-302~   * Find the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D) of TY-302, given orally.~  * Increased dose cohorts from low dose to MTD, starting at 25mg daily.~2. TY-302 combine withTamoxifen in dose-escalation stage~   * TY-302: RP2D-1to RP2D daily for 28 days of each 28 day cycle.~  * Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle.~3. TY-302 combine withTamoxifen in dose-expansion stage~   * TY-302: RP2D daily for 28 days of each 28 day cycle.~  * Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle."
62501750|NCT03930251|NO_INTERVENTION|Treatment as Usual|This is the standard coordinated specialty care treatment (without cognitive remediation) that is provided to OnTrackNY clients. This treatment involves psychiatric treatment, employment and educational support, substance abuse treatment, family education and support, CBT-informed individual psychotherapy, and cognitive health support services as needed.
62501751|NCT03930251|EXPERIMENTAL|Clinic-Based Cognitive Remediation|Clinic-based cognitive remediation consists of twice weekly group-based and clinician-led sessions.
62141845|NCT02983266|EXPERIMENTAL|Group 1: Low Hertz|"Participants will receive 10 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
62141846|NCT02983266|EXPERIMENTAL|Group 1: High Hertz|"Participants will receive 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
62700883|NCT06560788||Case group 3: mouse model of spina bifida (Cdx2Cre x Pax3flox)|CSF will be collected
62700884|NCT06560788||Control group 3: normal (wild-type) mice|CSF will be collected
61953696|NCT05988008|EXPERIMENTAL|Cohort A: Single Oral Dosing of CCX168 in Japanese Adult Males|Healthy Japanese adult males will receive 1 of 3 single oral doses of CCX168 (10 mg, 30 mg or 100 mg) or placebo. Each dose level will be administered under fasted conditions. Single doses of CCX168 30 mg will be administered under fasted and fed conditions.
61953697|NCT05988008|EXPERIMENTAL|Cohort B: Multiple Oral Dosing of CCX168 in Japanese Adult Males|Healthy Japanese adult males will receive 1 of 2 oral doses of CCX168 (30 mg or 50 mg) or placebo twice-daily for 7 days under fed conditions.
62141847|NCT02983266|SHAM_COMPARATOR|Group 1: Control|"Participants will receive 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
62501752|NCT03930251|EXPERIMENTAL|Partial-Remote Cognitive Remediation|Partial-Remote cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
62501753|NCT05478928|EXPERIMENTAL|Dynamic dry needling|Dynamic dry needling will be done in the upper trapezius trigger point.
62501754|NCT05478928|EXPERIMENTAL|Fixed dose dynamic MEP|Dynamic low intensity percutaneous electrolysis will be applied in the upper trapezius trigger point with a fixed dose.
61953698|NCT05988008|EXPERIMENTAL|Cohort C: Single Oral Dosing of CCX168 in Caucasian Adult Males|Healthy Caucasian adult males will receive 1 of 2 single oral doses of CCX168 (10 mg or 30 mg) or placebo under fasted conditions.
62141848|NCT02983266|EXPERIMENTAL|Group 2: Pre-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
62501755|NCT05478928|EXPERIMENTAL|Static dry needling:|Static dry needling will be done in the upper trapezius trigger point.
62700885|NCT01953250||Infiltrating endometriosis|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011.
62700886|NCT03453216|EXPERIMENTAL|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
62700887|NCT03757494|EXPERIMENTAL|Use of Alpha Stim|Use of Alpha Stim Device
62700888|NCT01380665|OTHER|There is one group of 100 patients|50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;
62700889|NCT05205863|EXPERIMENTAL|Cofact Dose 1|
62700890|NCT05205863|EXPERIMENTAL|Cofact Dose 2|
62700891|NCT05205863|PLACEBO_COMPARATOR|Placebo|
62700892|NCT02181920|EXPERIMENTAL|Metamizole - Diclofenac|metamizole followed by diclofenac
62700893|NCT02181920|EXPERIMENTAL|Diclofenac - Metamizole|diclofenac followed by metamizole
62700894|NCT02181920|EXPERIMENTAL|Metamizole - Placebo|metamizole followed by placebo
62700895|NCT02181920|EXPERIMENTAL|Placebo - Metamizole|placebo followed by metamizole
62700896|NCT01705392|EXPERIMENTAL|Bevacizumab plus propranolol|Bevacizumab 10mg/kg q2w plus propranolol 80 mg x 1
62700897|NCT01705392|EXPERIMENTAL|Bevacizumab plus enalapril|Bevacizumab 10mg/kg q2w plus enalapril 5 mg x 1
61953699|NCT05988008|EXPERIMENTAL|Cohort D: Multiple Oral Dosing of CCX168 in Caucasian Adult Males|Healthy Caucasian adult males will receive an oral dose of CCX168 30 mg or placebo twice-daily for 7 days under fed conditions.
61953700|NCT02631759|EXPERIMENTAL|Lévétiracetam|52 patients will be recruited over 2 years in the experimental group
61953701|NCT02631759|PLACEBO_COMPARATOR|Placebo|52 patients will be recruited over 2 years in the control group
61953702|NCT02994992|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61953703|NCT00129272|ACTIVE_COMPARATOR|Bupropion (Wellbutrin-SR)|Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
62141849|NCT02983266|EXPERIMENTAL|Group 2: Post-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session after experimental sympathetic induction.~Device: InTENsity MicroCombo"
62141850|NCT02983266|PLACEBO_COMPARATOR|Group 2: Control|"Participants will receive 10 or 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
62141851|NCT02983266|EXPERIMENTAL|Group 3: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
62700898|NCT01705392|ACTIVE_COMPARATOR|Dacarbazine|Dacarbazine 1000mg/m2 q3w
62700899|NCT01534559|EXPERIMENTAL|Outpatient Medicine Management Clinic|Consented patients will attend two outpatient clinic appointments to receive help with any (potential) medicine-related problems
62700900|NCT01534559|NO_INTERVENTION|Control|Patients will receive the normal care provided by the hospital
62700901|NCT06168344|EXPERIMENTAL|Intervention Group|Mothers were assigned to groups by simple randomization method. The website was designed, mothers were given their usernames and passwords and their memberships were created. Pretests (Parent-Baby Introductory Information Form, Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were administered via the website. Mothers completed the modules in the web-based training program within four weeks. Four weeks later, posttests (Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were administered via the website.
62700902|NCT06168344|NO_INTERVENTION|Control Group|Mothers' usernames and passwords were created and website memberships were made. Pretests (Parent-Baby Introductory Information Form, Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were applied. Website use by mothers in the control group was restricted and access to web-based educational content was closed to all mothers in this group. The mothers in the control group were applied the hospital outpatient clinic routine without any intervention. Four weeks later, posttests (Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were administered via the website. Pre-test and post-tests of mothers in the control group were collected via the website. After the research data was collected, a web-based training program was opened to the mothers in the control group and they were allowed to benefit from the training content.
62141852|NCT02983266|EXPERIMENTAL|Group 4: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session. Participants will also receive stimulation on a subsequent session prior to urodynamic testing.~Device: InTENsity MicroCombo"
62141853|NCT02983266|EXPERIMENTAL|Group 1: Response|"Participants will receive 10-30 hertz stimulation to the left auricular branch of the vagus nerve, delivered over the course of 1 hour.~Device: InTENsity MicroCombo"
62344072|NCT00972829|EXPERIMENTAL|Crestor|Crestor 10 or 20 milligrams
62700903|NCT03344484|EXPERIMENTAL|Midline Approach|A midline surgical approach will be used for the exposure required to complete the lumbar fusion.
62700904|NCT03344484|EXPERIMENTAL|Paramedian Approach|A paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
62700905|NCT03270995|EXPERIMENTAL|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
61953704|NCT00129272|PLACEBO_COMPARATOR|Matching Placebo|Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
61953705|NCT02367443|EXPERIMENTAL|one group|Radiation: Hypofractionated accelerated Radiotherapy with concomitant full dose Chemotherapy
62141854|NCT03697603|EXPERIMENTAL|Brexpiprazole 1mg|Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
62141855|NCT03697603|EXPERIMENTAL|Brexpiprazole 2mg|Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
62141856|NCT03697603|PLACEBO_COMPARATOR|Placebo|Tablets, Oral, once daily, 14 weeks
62344073|NCT00972829|ACTIVE_COMPARATOR|Ezetimibe|Ezetimibe 5 or 10 milligrams
62501756|NCT05478928|EXPERIMENTAL|Fixed dose static MEP|Static low intensity percutaneous electrolysis will be applied in the upper trapezius trigger point with a fixed dose.
62501757|NCT05478928|EXPERIMENTAL|Algorithm-based dose static MEP|Low intensity percutaneous electrolysis will be applied in the upper trapezius trigger point with an algorithm-based dose.
62501758|NCT05478928|PLACEBO_COMPARATOR|Placebo|An acupuncture needle will be slightly introduced into the upper trapezius trigger point.
62700906|NCT03270995|ACTIVE_COMPARATOR|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
62700907|NCT05494086|EXPERIMENTAL|DPLDG arm|Dual-port laparoscopic distal gastrectomy
62700908|NCT05494086|ACTIVE_COMPARATOR|LDG arm|Laparoscopic distal gastrectomy
62700909|NCT04928547||U.S.|
62700910|NCT04928547||MRI|
61953706|NCT02579187|PLACEBO_COMPARATOR|control group|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). A biodegradable sponge (type I bovine collagen) to stabilize the blood clot will be placed.The site will be stabilized with a simple external, cross mattress suture. Blood , wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
61953707|NCT02579187|ACTIVE_COMPARATOR|Experimental group 1|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
61953708|NCT02579187|ACTIVE_COMPARATOR|Experimental group 2|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
61953709|NCT02579187|ACTIVE_COMPARATOR|Experimental group 3|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
61953710|NCT03454711|EXPERIMENTAL|Patient with food addcitions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
61953711|NCT03454711|EXPERIMENTAL|Patients without food addictions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
61953712|NCT04473391|EXPERIMENTAL|Robot-assisted Rehabilitation|Participants will receive Functional Electrical Stimulation (FES) training with a lower extremity cycle-ergometer (MOTOmed Viva 2, Reck GmbH., Germany) and a 6-channel FES Device (TrainFES, Biomedical Devices SpA, Chile). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 3 sessions per week for 8 weeks, each lasting about 45 minutes.
62344074|NCT04198324|ACTIVE_COMPARATOR|Entire fold uterine closure|The uterus will be sewn with full fold locked sutures that pass through myometrium and endometrium.
62501759|NCT01609582|EXPERIMENTAL|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 6 years.
62501760|NCT01609582|PLACEBO_COMPARATOR|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 6 years.
62501761|NCT02714296|ACTIVE_COMPARATOR|Group Nutridrink 200ml|50 patients: two days before the investigation is assigned to a diet with the use of specialized clinical nutrition Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
62700911|NCT04838067|EXPERIMENTAL|Cefaly Intervention|Cefaly
62700912|NCT03777228||Control|Individuals without traumatic brain injury
62700913|NCT03777228||Mild TBI|Individuals with mild traumatic brain injury
62700914|NCT03777228||Moderate to Severe TBI|Individual with moderate to severe traumatic brain injury
62700915|NCT03748550|NO_INTERVENTION|Control|Participants will receive standard of care treatment for their breast cancer.
62700916|NCT03748550|EXPERIMENTAL|Exercise|Participants will receive standard of care treatment for their breast cancer plus be given a 12-week home based aerobic exercise program.
62700917|NCT04647760|OTHER|Active treatment|Participants will start the intervention immediately upon study enrollment.
62700918|NCT04647760|OTHER|Delayed treatment|Participants will start the intervention 4-months post enrollment.
62714821|NCT02649764|EXPERIMENTAL|Treatment (fludarabine phosphate, cytarabine, prexasertib)|Patients =/\< 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Patients \> 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3, cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
62501762|NCT02714296|ACTIVE_COMPARATOR|Group Nutridrink compact protein|two days before the study is assigned diet with the addition of specialized clinical nutrition Nutridrinc compact protein 125 ml 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
62501763|NCT02714296|NO_INTERVENTION|Group control|only diet without receiving specialized nutrition
62501764|NCT05419817|EXPERIMENTAL|Pembrolizumab + Sitravatinib|Standard of care pembrolizumab 200 mg IV combined with oral sitravatinib 100 mg oral QD every 21 days until disease progression, unacceptable toxicities or complete response.
62501765|NCT03455036|EXPERIMENTAL|Whole body vibration training|Healthy female subjects complete whole body vibration training (10 x 1 min exposure)
62501766|NCT00785876|NO_INTERVENTION|1|Control Sites
62501767|NCT00785876|EXPERIMENTAL|2|Intervention Sites
62501768|NCT02757339||Women with History of Childhood Abuse|The study will enroll up to 140 female patients with either DID or PTSD ages 18-89
62501769|NCT02757339||Healthy Control Group|We will recruit up to 60 control subjects matched for demographics (age, race, gender).
62501770|NCT02150356|EXPERIMENTAL|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
62501771|NCT02150356|PLACEBO_COMPARATOR|Control|Diet based on refined cereal products for a period of 8 weeks.
62501772|NCT01723917|EXPERIMENTAL|PhytoSERM 50 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
61953713|NCT00934089|EXPERIMENTAL|PF-04217329 + placebo|Active study drug + latanoprost vehicle
62501773|NCT01723917|EXPERIMENTAL|PhytoSERM 100 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
62141857|NCT02555306|EXPERIMENTAL|Low Dose DE-122|Single intravitreal injection of DE-122 Low Dose Injectable Solution
62141858|NCT02555306|EXPERIMENTAL|Medium-Low Dose DE-122|Single intravitreal injection of DE-122 Medium-Low Dose Injectable Solution
62141859|NCT02555306|EXPERIMENTAL|Medium-High Dose DE-122|Single intravitreal injection of DE-122 Medium-High Dose Injectable Solution
62501774|NCT01723917|PLACEBO_COMPARATOR|Placebo tablet|Dietary supplement: placebo tablet to be taken once per day for 12 weeks
62501775|NCT02329431|EXPERIMENTAL|activation curriculum|Psycho-social curriculum teaching activation skills
62501776|NCT02329431|ACTIVE_COMPARATOR|support group|Parent-directed support group
62501777|NCT03171324|EXPERIMENTAL|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
62501778|NCT03171324|EXPERIMENTAL|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
62700919|NCT02753972|EXPERIMENTAL|Mindful Eating and Living|The goal of the Mindful Eating and Living (MEAL) intervention was to apply mindfulness to apply mindfulness to eating behavior. The content for the MEAL sessions included group discussion, mindfulness meditation, and group eating exercises. The course, based on the work of Kristeller, Baer, \& Quillian-Wolever (31), emphasized brief daily meditation and pairing meditation with eating, but was more streamlined in terms of didactic content and course length. Participants examined hunger and satiety cues, the qualities of foods they crave, and emotional and cognitive states associated with eating. Each session included an eating exercise with a variety of foods. The monthly refresher sessions included a brief meditation, a brief eating exercise, and group discussion. (The MEAL curriculum is available from the authors.)
61953714|NCT00934089|EXPERIMENTAL|PF-04217329 + latanoprost|Active study drug + latanoprost
62141860|NCT02555306|EXPERIMENTAL|High Dose DE-122|Single intravitreal injection of DE-122 High Dose Injectable Solution
62501779|NCT03171324|EXPERIMENTAL|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
62501780|NCT03171324|EXPERIMENTAL|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
62141861|NCT05298371||Patients with adolescent idiopathic scoliosis|"Patients with AIS applying to Bandırma Onyedi Eylül University Physiotherapy and Rehabilitation Department will be included in this study.~Individuals diagnosed with AIS, whose Cobb angle is between 20º -50º, who do not have any chronic disease requiring neurological or psychiatric medication, and who volunteered to participate in the study will be included. Individuals with any contraindications for exercise, previous spinal surgery, 6 or more curvature of the thoracic apex, mental problems, non-idiopathic scoliosis but with different causes will be excluded from the study."
62141862|NCT01267617||chronic hemodialysis outpatients|
62141863|NCT01433185|EXPERIMENTAL|Text message (SMS)|Text messages sent to women before and after delivery
62141864|NCT01433185|NO_INTERVENTION|Usual care (current standard of care)|Current standard of care for women enrolled in PMTCT programs
62141865|NCT02432300|EXPERIMENTAL|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
62501781|NCT04874363||smoker|active smokers
62501782|NCT04874363||non-smoker|Patients who have never smoked
62501783|NCT06531915|EXPERIMENTAL|Ciprofol group|
62501784|NCT06531915|ACTIVE_COMPARATOR|Remimazolam group|
62141866|NCT03950206|OTHER|Women with endometriosis|Women undergoing laparoscopic surgery for endometriosis
62344075|NCT04198324|EXPERIMENTAL|Non-endometrial uterine closure|The uterus will be sewn with locked sutures that pass through myometrium without endometrium.
62344076|NCT00917306|EXPERIMENTAL|PEP005 gel|PEP005 gel, 0.05% administered once daily for 2 consecutive days
62501785|NCT01463891||Eribulin Mesylate|
62501786|NCT06096350||patients with stroke|Inpatients admitted to the investigators' rehabilitation facility
62501787|NCT00924586|PLACEBO_COMPARATOR|P|
62501788|NCT00924586|EXPERIMENTAL|E|
62501789|NCT03848858|EXPERIMENTAL|EMDR plus TAU|20 individual weekly sessions of 60 minutes each of Eye Movement Desensitization and Reprocessing Therapy (EMDR), plus Treatment as Usual (TAU), applying first the standard EMDR protocol (Shapiro, 2005), and then a specific protocol for the sequelae of somatic illness and medical trauma (Hase, 2018).
62501790|NCT03848858|NO_INTERVENTION|TAU only|The patients in this condition are newly diagnosed and will be introduced to the study in their first appointment with the Infectious Diseases Unit, in which analyses of HIV-related biological markers are taken. In a follow up appointment between 1 and 2 weeks later, antiretroviral treatment is initiated. There is a further check-up 1-2 months after initiating antiretroviral treatment, and then 6-monthly check-ups. In these checkups, measures of CD4 and the CD4/CD8 ratio are taken and treatment adherence is reviewed. The patients receiving EMDR therapy will also participate in these activities.
62501791|NCT06571487||Women with a history of gestational diabetes mellitus|
62501792|NCT06571487||Women without a history of gestational diabetes mellitus|
61953715|NCT03918785|EXPERIMENTAL|Rice Germ|"The Rice Germ was supplied in vacuum jars of a weight of 130 grams. These jars once opened, were stored in the refrigerator (-3-4°C). Together with cans, small containers were provided to act as dosers and served to determine the correct dose to be taken (25 grams, twice a day). The rice germ or placebo were continually taken every day twice a day (25 grams in the morning with breakfast and 25 grams in the afternoon as snacks) for 5 weeks. The rice germ was supplied by the company Acquerello (TenutaColombara, Livorno Ferraris, Vercelli, Italy)."
61953716|NCT03918785|ACTIVE_COMPARATOR|Control group|Active comparator, which consisted of an isocaloric wheat germ-based supplement. Characteristics of supplementation are the same of experimental group.
61953717|NCT01594983|EXPERIMENTAL|LCQ908 1|LCQ908 (Diacylglycerol acyltransferase inhibitor)once daily for 12 weeks
61953718|NCT01594983|EXPERIMENTAL|LCQ908 2|LCQ908 once daily for 12 weeks
61953719|NCT01594983|EXPERIMENTAL|LCQ908 3|LCQ908 once daily for 12 weeks
61953720|NCT01594983|ACTIVE_COMPARATOR|Fenofibrate|Intervention Type: Drug Intervention Name: Fenofibrate
61953721|NCT01594983|ACTIVE_COMPARATOR|Fish Oil|Fish oil once daily for 12 weeks
61953722|NCT01594983|PLACEBO_COMPARATOR|Arm Label: Placebo|Intervention Type: other Intervention Name: other
61953723|NCT03308032|EXPERIMENTAL|Intervention|Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course. Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons. For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both
61953724|NCT03308032|ACTIVE_COMPARATOR|Control|"Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course.~Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons (see below). For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both"
61953725|NCT03789474|NO_INTERVENTION|Group A|No intervention was done ,served as a control group.
61953726|NCT03789474|EXPERIMENTAL|Group B|Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.
62501793|NCT03098186|ACTIVE_COMPARATOR|Intervention SMS|"1. SMS aimed to improved adherence to medications used in secondary prevention of cardiovascular disease.~2. Control SMS: SMS to thanks for participation in the trial and reminders of trial appointments."
62501794|NCT03098186|PLACEBO_COMPARATOR|Control SMS|SMS to thanks for participation in the trial and reminders of trial appointments.
62501795|NCT05222360||female high school athletes|Athletes who identify as female at a local high school who are in an athletic program. There was no control group as the school wanted everyone to have the 3 educational sessions. The athletes underwent 3 educational sessions. No medication was used. Education was the intervention
62501796|NCT05484791|EXPERIMENTAL|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization technique during two sessions per week
62501797|NCT01708655|OTHER|Sweat Evaporimeter measurement|"1. 0.1 ml Carbachol, intraocular solution - diluted to 0.1 µg/ml in normal saline- dose 0.01 µg~2. 0.2 ml Atropine sulphate, injection solution - diluted to 44 µg/ml in normal saline - dose 8.8 µg.~3. 0.2 ml of the Beta cocktail injection solution diluted to 44 µg/ml atropine, 22 µg/ml isoproterenol and 4.6 mg/ml aminophylline in normal saline - dose:~   * 4.4 µg Isoproterenol hydrochloride, injection solution~  * 0.93 mg Aminophylline injection solution~  * 8.8 µg Atropine, injection solution"
62501798|NCT06590350||Cohort who received clinical nutrition counseling <72 hours|Patients at risk of malnutrition who received clinical nutrition counseling within 72 hours.
62501799|NCT06590350||Cohort who did NOT received clinical nutrition counseling <72 hours|Patients at risk of malnutrition who did NOT receive clinical nutrition counseling within 72 hours.
62501800|NCT06679192|EXPERIMENTAL|Thickness-Varied soft surface insole|Each participant will be measured with this insole. The order between the three insoles is randomized.
62501801|NCT06679192|EXPERIMENTAL|3mm soft surface insole|Each participant will be measured with this insole. The order between the three insoles is randomized.
62714822|NCT06072183|EXPERIMENTAL|Arm 1- Ritlecitinib 100 milligrams (mg)|Randomized to Ritlecitinib 100 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
61953727|NCT05306275|EXPERIMENTAL|CSL312 AI Abdomen|CSL312 administered subcutaneously (SC) in the abdomen via a prefilled syringe assembled to an autoinjector (AI)
61953728|NCT05306275|EXPERIMENTAL|CSL312 AI Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to an AI
61953729|NCT05306275|EXPERIMENTAL|CSL312 AI Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to an AI
61953730|NCT05306275|EXPERIMENTAL|CSL312 NSD Abdomen|CSL312 administered SC in the abdomen via a prefilled syringe assembled to a needle safety device (NSD)
62501802|NCT06679192|EXPERIMENTAL|No soft surface insole|Each participant will be measured with this insole. The order between the three insoles is randomized.
61953731|NCT05306275|EXPERIMENTAL|CSL312 NSD Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to a NSD
61953732|NCT05306275|EXPERIMENTAL|CSL312 NSD Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to a NSD
61953733|NCT06273085|ACTIVE_COMPARATOR|Intervention|Intervention arm will receive initial face to face education during hospital admission and also an educational flier about GDMT. They will get 3 more sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
61953734|NCT06273085|NO_INTERVENTION|Control|Control arm will receive initial face to face education during hospital admission and also an educational flier about GDMT.
61953735|NCT02324257|EXPERIMENTAL|Part I: RO6958688|Participants will receive single dose of RO6958688 starting from a dose of 0.05, 0.15, 0.45, 1.3, and 2.5 mg in Part I of the study.
61953736|NCT02324257|EXPERIMENTAL|Part II: RO6958688 With/Without Obinutuzumab Pretreatment|Participants will receive RO6958688 with or without obinutuzumab pretreatment QW, Q3W, or according to a combined QW/Q3W step up dosing schedule. Doses will start at 40mg and increase with each administration up to the MTD or 1200mg, whichever is lower.
61953737|NCT04754152|EXPERIMENTAL|TBS Group|On the basis of drug treatment, a course of TBS treatment is performed every three months and 4 courses of treatment a year.
61953738|NCT04754152|PLACEBO_COMPARATOR|Drug Group|Stable doses of cholinesterase inhibitors for the treatment and primary care guidance.Once every 3 months follow-up.
61953739|NCT00622817|ACTIVE_COMPARATOR|1|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
61953740|NCT00622817|EXPERIMENTAL|2|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
61953741|NCT04253444|ACTIVE_COMPARATOR|slow deep breathing|Patients are instructed to do deep breathing at full inspiratory capacity for 4 seconds followed by forced expiration in 6 seconds (forced vital capacity) for 10 minutes.
61953742|NCT04253444|SHAM_COMPARATOR|sham breathing|Patients are instructed to count 10 breaths and tick a box every time they count ten breaths. The counting distracts the patient reducing the effect of focussing of breathing on their autonomic nervous system.
61953743|NCT03912168|EXPERIMENTAL|Question Prompt List|
61953744|NCT03912168|ACTIVE_COMPARATOR|3 questions list|
61953745|NCT06192277|EXPERIMENTAL|Low risk|Low risk patients will participate in the DOC challenge
62141867|NCT03926624|EXPERIMENTAL|Experimental|DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to 4 mg/m²/day x 14 days for subsequent treatment cycles
62141868|NCT03926624|ACTIVE_COMPARATOR|Control|"Non-Intensive:~* LoDAC: 20 mg SC BID 10 days~* Azacitidine: 75 mg/m²/day SC 7 days(or 5+2)~* Decitabine: CIV 20 mg/m²x5 days~* Venetoclax + LoDAC/Azacitidine/Decitabine:LoDAC-Venetoclax ramp-up to 600 mgxday. Cytarabine SC 20 mg/m²xday D1-10. Azacitidine or Decitabine-Venetoclax ramp-up to 400 mgxday. Azacitidine IV or SC 75 mg/m² D1-7. Decitabine IV 20 mg/m² on D1-5 or 1-10.~Intensive:~* High DAC: cytarabine 1-2 g/m² up to 5 days, max total dose 10 g/m²~* FLAG: D1-5: fludarabine 30 mg/m² IV for 30min, D1-5: cytarabine 1-2 g/m² for 4hr daily x 5 \& G-CSF 5 mcg/kg or 300 mcg/m² until PMN recovery, with or without idarubicin D1-3 8 mg/m² IV dailyx3 (FLAG-Ida)~* MEC: D1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV 1hr \& cytarabine 1g/m² IV 6hr.~* CLAG/M or Ida = cladribine 5 mg/m² D1-5, cytarabine 2 g/m² D1-5, G-CSF 300 μg D0-5, mitoxantrone 10 mg/m² D1-3 or Idarubicin 10 mg/m² D1-3.~* Intermediate DAC: cytarabine 20 mg/m² IV dailyx5"
62501803|NCT02726386|EXPERIMENTAL|24-hour dosing regimen|"Continuous SC infusion over 24 hours: fixed day rate of up to 0.64 mL/h for 18 hours, followed by a night rate of 0.08 mL/h for 6 hours to deliver a total daily dose of up to 720/90 mg of levodopa/carbidopa.~All patients who had been previously assigned to the 24-hour group in the prior study continued on this dosing regimen; patients who had previously been assigned to the 14-hour daytime regimen were switched to the 24-hour regimen."
62501804|NCT02726386|EXPERIMENTAL|16-hour dosing regimen|"Continuous SC infusion for over 16 hours: fixed rate of 0.75 mL/h to deliver a total infusion dose of 720/90 mg of levodopa/carbidopa over 16 hours.~The device is removed at night and patients in this group also receive a morning oral dose of levodopa/carbidopa upon awakening."
62501805|NCT00866645|EXPERIMENTAL|1|Intramuscular Levosulpiride
62700920|NCT02753972|ACTIVE_COMPARATOR|Active Control|The Active Control (CONT) group matched the MEAL group regarding schedule. The agenda for the CONT sessions involved giving each participant the opportunity to discuss issues such as food choices, activity levels, and caloric goals. The sessions began by having the participants check-in about their experiences with eating. Next, the clinical psychology graduate student led the participants in goal setting and finally there was a question and answer period when the registered dietician answered questions about food selection. The monthly refresher sessions had the same agenda as the initial weekly sessions.
61953746|NCT06192277|NO_INTERVENTION|High risk|Any participant defined as more than low risk will not receive the DOC
61953747|NCT02385942|OTHER|Tele-consultation system|compare the Live assessed wound size with the transmitted Smart phone-based wound size through Tele-consultation system
61953748|NCT00691314|EXPERIMENTAL|1|
61953749|NCT00691314|ACTIVE_COMPARATOR|2|
62141869|NCT03795688||Basic, non-imaging group|"Pregnant women who will deliver by planned caesarian. Participants enrolled in the study that are not eligible for the imaging subgroup.~All participants start in the basic program. Includes collection of blood, cerebrospinal fluid, saliva, hair, placenta tissues, umbilical cord blood and psychometrics."
62141870|NCT03795688||Extended, imaging group|A subgroup of 70 pregnant women who will deliver by planned caesarian selected towards either high (N=35) or low (N=35) risk for perinatal depression will undergo brain imaging in addition to the elements of the basic program. The extended imaging program includes functional and structural magnetic resonance imaging, positron emission tomography (PET) and a semistructured interview for depression symptoms (HAM-D17).
62501806|NCT00866645|ACTIVE_COMPARATOR|2|Intramuscular Haloperidol
62501807|NCT05560451|EXPERIMENTAL|Peer health coach intervention|Participants will receive 20 virtual visits with a trained Veteran peer health coach over 12 months. Coaches will provide participants with brief health education, assist with goal setting and problem solving, enhance social support, and link participants to VA and community resources.
62501808|NCT05560451|NO_INTERVENTION|Control group/no intervention|Participants will continue to receive their regular, usual primary care.
61953750|NCT03039140|EXPERIMENTAL|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
61953751|NCT03245684|EXPERIMENTAL|Pressure Support Ventilation|"after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.~assessment of inflammatory response during PSV"
62700921|NCT03325231||Bladder Cancer Patients|Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years. No form of payment will be offered for participation, but participants will be reimbursed for travel expenses. There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
61953752|NCT03245684|ACTIVE_COMPARATOR|Controlled Mechanical Ventilation|patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol
61953753|NCT06376292|EXPERIMENTAL|Interventional arm|Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa twice a week for a total of 4 weeks.
61953754|NCT00978198|EXPERIMENTAL|Part 1|single administration
61953755|NCT00978198|EXPERIMENTAL|Part 2|multiple administration
61953756|NCT02208479||cardiac surgery|
61953757|NCT03348150|EXPERIMENTAL|Gastrecomy + Cytoreductive surgery + HIPEC|Gastrectomy combined with cytoreductive surgery and HIPEC (experimental treatment)
62700922|NCT05032586|NO_INTERVENTION|control groups: without wearing virtual reality headsets|"Before dressing, the child was given paracetamol, which is routinely used to prevent pain. The child was reminded that they would be with their family during the procedure, and either the mother or father was taken to the dressing room during dressing. After the standard burn dressing was applied to the patient by the healthcare personnel in the burn center treatment room, oxygen saturation and heart rate measurements were made again after the procedure and recorded in the Application Registration Form. Before and after the procedure, the patients were asked about the pain and anxiety levels felt during dressing and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
62141871|NCT00843050|EXPERIMENTAL|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
62700923|NCT05032586|EXPERIMENTAL|experimental groups|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
62141872|NCT05333367|OTHER|Patients undergoing extracorporeal photochemotherapy|
62700924|NCT06090552|OTHER|Letter, AD, PREPARE|Letter about ACP, PREPARE advanced directive (AD), PREPARE website
62700925|NCT06090552|OTHER|Letter, AD, PREPARE, reminders|Letter, AD, PREPARE plus reminder text/phone messages
62700926|NCT06090552|OTHER|Letter, AD, PREPARE, reminders, healthcare navigator|Letter, AD, PREPARE website plus reminders plus a healthcare navigator on ACP documentation (discussions and care-plans, primary outcome)
62714823|NCT06072183|EXPERIMENTAL|Arm 2- Ritlecitinib 50mg|Randomized to Ritlecitinib 50 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
62714824|NCT06072183|PLACEBO_COMPARATOR|Arm 3- Placebo|Randomized to Placebo QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
62141873|NCT00960206|EXPERIMENTAL|Trident®System|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
62141874|NCT00960206|EXPERIMENTAL|ABC System|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
62141875|NCT00960206|ACTIVE_COMPARATOR|Control|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
62141876|NCT02909959|ACTIVE_COMPARATOR|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.~The weight-based dosing schedule is as follows:~3 tablets (approx. 46.5 µmol SF) if \<100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
62141877|NCT02909959|PLACEBO_COMPARATOR|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
62344077|NCT03744130|EXPERIMENTAL|patients with UC|"Patients with endoscopically proven UC with various extents of disease activity.~Diagnostic Test: Contrast-enhanced Ultrasound"
61953758|NCT03348150|NO_INTERVENTION|palliative systemic chemotherapy|Palliative systemic chemotherapy only (standard treatment)
62344078|NCT03744130|EXPERIMENTAL|patients with CD|Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound
62501809|NCT02970045||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood during a regular care visit or not up to 4 times a year. Extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. During bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. Patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. Patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data.
62344079|NCT01583452|EXPERIMENTAL|Chewing Gum Group|Group of patients given chewing gum as part of the treatment for prevention of post-operative ileus right after surgery, besides the standard pharmacologic treatment and post-operative care.
62344080|NCT01583452|NO_INTERVENTION|No intervention|By observing the clinical evolution of the participants not given chewing gum as a prevention for post-operative ileus, and just given the standard pharmacologic treatment and post-operative care.
62501810|NCT02310503||Mohs surgery|Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
62714825|NCT06072183|EXPERIMENTAL|Arm 4- Ritlecitinib 100mg|Non-randomized open-label Ritlecitinib 100mg QD for 52 weeks.
61953759|NCT05540756||SCS|Patients undergoing a spinal cord stimulator trial who is planning to have intraoperative neuromonitoring performed during the procedure
62344081|NCT04248192|EXPERIMENTAL|Donor Derived HIV-Specific T-cells (DD HST-NEETs)|Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
62344082|NCT04065373|EXPERIMENTAL|Non-Infiltrated Tissue|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored a common peripheral IV site over a 24 hour observation period.
62344083|NCT03317574|EXPERIMENTAL|MEDITOXIN|
62344084|NCT03317574|ACTIVE_COMPARATOR|BOTOX|
62501811|NCT02055092||YOD-FTD|Young onset dementia - frontotemporal dementia, 38 persons with their respective family members.
62501812|NCT02055092||YOD-AD|Young onset dementia - Alzheimer's disease, 50 persons with their respective family members.
62501813|NCT02055092||LOD|Late onset dementia \>= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
61953760|NCT00191139|EXPERIMENTAL|Gemcitabine|
61953761|NCT00191139|EXPERIMENTAL|Gemcitabine plus Docetaxel|
61953762|NCT02050997||B|Unresectable or metastatic PDAC patients who will receive standard treatment of CT +/- radiotherapy
61953763|NCT02050997||A|Resectable PDAC patients who will receive standard treatment of CT +/- radiotherapy
62141878|NCT01579318|EXPERIMENTAL|Treatment|Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
62344085|NCT03016026|EXPERIMENTAL|ERAS|Preoperative education,breathing training and atomizing during the time of preoperative preparation.Shorten fasting time and carbohydrate load.The intravenous fluid therapy is restricted.Drainage and nasogastric tube are not placed (except the concerns of surgical safety).All patients undergo laparoscopic distal gastrectomy.An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia.Early oral take and move.
62344086|NCT03524105|ACTIVE_COMPARATOR|Thrive Professional Learning plus ParentCorps|
62344087|NCT03524105|ACTIVE_COMPARATOR|Thrive Professional Learning track|
62344088|NCT06090383||Adolescents with CP and typically developed adolescents.|
62501814|NCT06494826||crohn disease patients|Candidates for a medically-indicated, diagnostic colonoscopy due to suspected new-onset CD.
62501815|NCT06494826||healthy controls|healthy participants admitted for non-specific GI complaints (such as changes in bowel movements, bloating, abdominal pain) or routine screening for colorectal cancer as part of primary
62501816|NCT05887687|EXPERIMENTAL|[68Ga]P3|Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-P3 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
62501817|NCT03267927|EXPERIMENTAL|Patient with OSA|
62501818|NCT05385900|EXPERIMENTAL|Penpulimab in combination with anlotinib and chemotherapy|After receiving the corresponding neoadjuvant therapy for 3 cycles according to the established treatment plan, surgery should be performed within 3-6 weeks after drug withdrawal.
62714826|NCT03347630|OTHER|oesophagus cancer MRI|Diagnostic test
62714827|NCT04593121|EXPERIMENTAL|Cohort 1A|Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.
61953764|NCT04944251|EXPERIMENTAL|aerobic exercise group|the patients in the aerobic group started to exercise at a heart rate corresponding to 60% of the maximal VO2, by adjusting the pedal resistance of the exercise bike, consistent with the Karvonen formula. This was followed by exercise cycling at a heart rate corresponding to 70% of maximal VO2 in the second month, and 80% of maximal VO2 in the third month, for 30 minutes, 3 days a week
61953765|NCT04944251|EXPERIMENTAL|strength exercise group|The patients included in the strength exercise group performed weight training exercises involving 10 large muscle groups (leg press, chest press, leg curl, lateral pull down, leg extension, dumbbell lateral raise, calf press, upright row, sit up, quadruped arm opposite leg raise), 3 days a week; including 1 set of 12-15 repetitions in the first month, 2 sets of 12-15 repetitions in the second month, and 3 sets of 12-15 repetitions in the third month (Figure 1). Participants' working weights were set as 60% of the maximum weight they could lift.
61953766|NCT04944251|NO_INTERVENTION|control group|The patients who didn't want to exercise were included in the control group.
62344089|NCT03215524|EXPERIMENTAL|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
62344090|NCT03215524|EXPERIMENTAL|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
62344091|NCT06341179|EXPERIMENTAL|Sleep extension|The sleep extension group (n=150) will receive a behavioral intervention focusing on parents putting their children to bed earlier by 60-90 minutes. Parents will be instructed only to alter their children's daily sleeping routine, and not to directly alter their diet and physical activity habits. The intervention will be delivered via 2 in-person (weeks 1 and 2) and 4 virtual meetings (weeks 4, 6, 8, and 10).
62714828|NCT04593121|EXPERIMENTAL|Cohort 2A|Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1.
61953767|NCT01525563||Subjects with irregular Menstrual cycle|Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled.
62714829|NCT04593121|EXPERIMENTAL|Cohort 3A|Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1.
61953768|NCT00873015|EXPERIMENTAL|Nitrite|Continuous intravenous infusion of Sodium Nitrite
61953769|NCT00873015|PLACEBO_COMPARATOR|Vehicle control|Continuous intravenous infusion of saline
61953770|NCT00192569|EXPERIMENTAL|Treated|Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)
61953771|NCT00192569|NO_INTERVENTION|Untreated|Subjects will be followed for natural history of newly acquired HCV
61953772|NCT06429436|EXPERIMENTAL|VENDY|Each participating site will install at least 1 machine (vending or kiosks) in the respective community for naloxone distribution.
61953773|NCT03747458|ACTIVE_COMPARATOR|OPN-375 186 μg BID|"Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks"
61953774|NCT03747458|PLACEBO_COMPARATOR|Placebo|Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
61953775|NCT02609009|EXPERIMENTAL|Spinal Manipulation Therapy|Active chiropractic care for this RCT will consist of diversified technique prone, side posture and supine manipulations with soft-tissue therapy
61953776|NCT02609009|OTHER|Usual Medical Care|Control group patients will follow the usual medical visit scheduled according to their attending orthopaedists. Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises.
61953777|NCT03980041|EXPERIMENTAL|IPI-549 + Nivolumab|Participants receive IPI-549 orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
61953778|NCT03980041|ACTIVE_COMPARATOR|Placebo + Nivolumab|Participants receive placebo orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
61953779|NCT00536185|EXPERIMENTAL|1|
61953780|NCT00536185|PLACEBO_COMPARATOR|2|
61953781|NCT05496400||Group I|(anemic group)
61953782|NCT05496400||Group II|(non-anemic group)
61953783|NCT03389620|ACTIVE_COMPARATOR|Transforaminal Cervical Epidural Corticosteroid Injections|
61953784|NCT03389620|EXPERIMENTAL|Lateralized Interlaminar Epidural Corticosteroid Injections|
62714830|NCT04593121|EXPERIMENTAL|Cohort 4A|Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1.
61953785|NCT03247751|EXPERIMENTAL|one group|one group receiving NIDEK intraocular lens
61953786|NCT02849431|EXPERIMENTAL|Mindfulness-based intervention|
61953787|NCT05626855|EXPERIMENTAL|Treatment Period|Patients who are ≥2 years of age with Type 2 and Type 3 SMA will receive apitegromab 20 mg/kg every 4 weeks by intravenous (IV) infusion during the 104-week Treatment Period
61953788|NCT03842514|EXPERIMENTAL|High-emulsifier to Low-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days high-emulsifier (soya lecithin) low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate"
61953789|NCT03842514|EXPERIMENTAL|Low-emulsifier to High-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days high-emulsifier( soya lecithin) low-calorie diet at 100% resting metabolic rate"
61953790|NCT04396340|EXPERIMENTAL|Dose Escalation|XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.
61953791|NCT04396340|EXPERIMENTAL|Confirmation of Dose|New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose
61953792|NCT01466647|OTHER|AXL1717 in combination with Gemcitabine HCL and Carboplatin|AXL1717 in combination with Gemcitabine HCL and Carboplatin
61953793|NCT02761252|EXPERIMENTAL|Bilastine+montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
61953794|NCT02761252|ACTIVE_COMPARATOR|Bilastine+placebo montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
61953795|NCT02761252|ACTIVE_COMPARATOR|Montelukast+placebo bilastine|Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
61953796|NCT01388738|ACTIVE_COMPARATOR|cerebrolysin|IV
61953797|NCT01388738|ACTIVE_COMPARATOR|L-Alpha glycerylphosphorylcholine|IV
61953798|NCT01388738|ACTIVE_COMPARATOR|citicoline|IV and per os
61953799|NCT05146167|EXPERIMENTAL|Bodhi AIM|Participants randomized to the intervention group will receive the Bodhi AIM app
62700927|NCT02157610|EXPERIMENTAL|Standard Treatment (ST)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
61953800|NCT05146167|ACTIVE_COMPARATOR|HIB|Participants randomized to the health promotion control group will receive the HIB app
62344092|NCT06341179|NO_INTERVENTION|Control|The control group (n=150) will follow their habitual sleeping schedule. Parents will be instructed not to alter their children's daily sleeping routine, or their diet and physical activity habits. The same number and frequency of meetings (in-person or virtual) and methods of registration of bedtime/wake-up times will be used as in the sleep extension group. All sessions for the control group will be educational in nature and will focus on the appropriate use of devices to monitor sleep, and preparation for the assessments.
62501819|NCT03065699|NO_INTERVENTION|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
62501820|NCT03065699|ACTIVE_COMPARATOR|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
62700928|NCT02157610|EXPERIMENTAL|Motivation + Problem Solving (MAPS)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline.Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months. 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
62700929|NCT02834364|EXPERIMENTAL|single arm|Encorafenib 450 mg. p.o.once daily and Binimetinib 45 mg p.o. twice daily until disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as 28 days.
62700930|NCT03815188||Heart Valve Surgery|Pre-operative patients undergoing heart valve surgery will be selected and data recorded from each patient on the day of their surgery. This patient cohort is required in order to be able to accurately measure their JVP upon physical examination. Patients must have a central line inserted as part of their ongoing clinical management.
62700931|NCT01082939|EXPERIMENTAL|CFAR|CFAR: Cyclophosphamide 250 mg/m\^2/day intravenous (IV) Days 3-5, Fludarabine 25 mg/m\^2/day IV Days 3-5, Alemtuzumab 30 mg IV Days 1, 3 and 5 over 2-4 hours, repeated every four weeks for a total of 6 planned cycles, and Rituximab Cycle 1 (Week 1): 375 mg/m\^2/day IV Day 2 over 4- 6 hours, Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV Day 2 over 4- 6 hours.
62700932|NCT04587492||Children with SMA|All children with SMA are eligible for the study
62700933|NCT03898427||Individuals with atopic dermatitis|Sensor technology and digital measures will be used to evaluate scratch and sleep in individuals with atopic dermatitis receiving standard of care treatments (SOC) who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
62700934|NCT00226356|EXPERIMENTAL|Supplements of L-methionine, betaine and folate|
61953801|NCT02167399||smart phone inclinometer|For the smart phone analysis we will be using the tilt meter application which is a digital inclinometer application available on the I phone. The phone will be placed in the vertical position utilizing the bubble level feature of the application. The application will be set to display measurements to the closest tenth of the degree, set to log measurements every 0.2 seconds. The subject will stand with knee extended to 0 degrees and quadriceps muscle activated and upper extremity support on opposite side of stance limb. The phone will be placed in the vertical position on the anterior portion of the middle third of the subject's thigh attached using double sided adhesive tape. Being placed as close as possible to level when attached to the anterior thigh with subject in single limb stance with a reading of less than 1 deg as minimum for correct set-up prior to testing. Immediately prior to testing recording will be initiated logging measurements for later assessment.
62141879|NCT03693807|EXPERIMENTAL|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
62141880|NCT05314049|EXPERIMENTAL|Experimental Group|
62141881|NCT05314049|ACTIVE_COMPARATOR|Active Comparator Group|
62141882|NCT05064631|EXPERIMENTAL|Active intervention|Oral Broncho-Vaxom (3.5mg) administered daily for 10 days per month for 24 months
62141883|NCT05064631|PLACEBO_COMPARATOR|Placebo control|Matched placebo administered daily for 10 days per month for 24 months
62344093|NCT06509724|ACTIVE_COMPARATOR|Conventional Fractionation Group|"The conventional fractionation group will receive 1.8-2.0G per session for a total of 25-28 sessions, amounting to 40-50.4Gy of radiation therapy. Chemotherapy will be administered once a week for a total of 5-6 sessions.~This group are allowed to receive brachytherapy."
62700935|NCT05616442|EXPERIMENTAL|Group 1 as Vitamine E group|Vitamin E as standard therapy
62141884|NCT02201888|EXPERIMENTAL|Computer-assisted cognitive training|Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention (4 minutes), attention/perception (5 minutes), working memory (8 minutes), auditory and visual memory (8 minutes), executive function (10 minutes), language (6 minutes), and games (4 minutes).
62141885|NCT02201888|ACTIVE_COMPARATOR|Computerized active condition|Patients allocated to this condition completed the same number of sessions as the cognitive training group but followed a computerized typing program (www.rapidtyping.com). This had similar design characteristics to the CRT condition, in that it was hierarchically organized with exercise level of difficulty being adjusted to the individual's level of performance and feedback being given at the end of each exercise. Additionally, patients in this condition played computerized games requiring typing (crosswords, word puzzles, etc) and were taught basic internet navigation by a supervisor. Exposure to the computer was of equivalent duration to the CRT condition.
62700936|NCT05616442|EXPERIMENTAL|Group two as Ketotifen group|Ketotifen as interventional
62344094|NCT06509724|EXPERIMENTAL|Hypofractionation Group|"The hypofractionation group will receive 2.5Gy per session for a total of 16 sessions, amounting to 40 Gy of radiation therapy. Chemotherapy will be administered once a week for a total of 3 sessions.~This group are allowed to receive brachytherapy."
62344095|NCT01413841|ACTIVE_COMPARATOR|Nasal oxygen|3 liter per minute
62344096|NCT01413841|PLACEBO_COMPARATOR|Nasal Air|3 l regular nasal air
62344097|NCT02997384||General practitioner|
62344098|NCT02997384||gynecologist|
62344099|NCT02997384||radiologist|
62344100|NCT04309669|EXPERIMENTAL|Tot'hema|three ampoules per day during 12 weeks daily dose: 150mg of iron per day.
62344101|NCT03102216|NO_INTERVENTION|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
62344102|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
62700937|NCT04839887||Validation study|Three hundred patients with ischemic stroke (18-65 years) will be enrolled for the validation of the Czech version of the the Stroke Impact Scale 3.0. The reliability and validity study will have a cross-sectional design.
61953802|NCT02167399||2-D video analysis|two dimensional video analysis by first placing markers on the subject at the midpoint of the femoral condyles, midpoint of the ankle malleoli, and the proximal thigh along a line from the anterior superior iliac spine (ASIS) to the knee marker. Testing will take place in front of a digital video camera with tape on the floor to give a reference point for the subject being tested. Participants will be tested twice on day 1 and then again 5-9 days later. Subjects will be allowed 2-3 practice trials prior to each test in order to allow the subject to feel comfortable with each test. Following the practice trials the subject will perform 3 trials of each test on bilateral lower extremities. This set up was consistent with the set up by Munro et al.
61953803|NCT03525171|ACTIVE_COMPARATOR|GHD children|23 prepubertal children with isolated GHD consecutively admitted to the Section of Endocrinology of the University of Palermo during treated with GH for at least 12 months underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
62141886|NCT02201888|PLACEBO_COMPARATOR|Treatment as usual|Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities
62141887|NCT05851014|EXPERIMENTAL|GB491 combined with Letrozole|
62141888|NCT05851014|PLACEBO_COMPARATOR|Placebo combined with Letrozole|
62141889|NCT00738959|EXPERIMENTAL|1|
62141890|NCT04140643|EXPERIMENTAL|Ozone therapy|Oral hygiene instructions given by dental hygienist and home daily use of ozonated water delivering system.
62141891|NCT04140643|ACTIVE_COMPARATOR|Only oral hygiene instructions|Oral hygiene instructions given by dental hygienist.
62141892|NCT06699563|EXPERIMENTAL|Experimental: Experimental (with Card)|In this procedure, patients used a pedometer and mobilization motivation card during their mobilization on the first postoperative day.
62344103|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
62344104|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
62344105|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
62344106|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
62344107|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
62344108|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
62344109|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
62344110|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
62344111|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
62344112|NCT03102216|EXPERIMENTAL|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
62344113|NCT06084338|EXPERIMENTAL|Arm 1|Metastasis directed therapy with stereotactic ablative radiotherapy to all detectable sites of disease plus PSMA radiopharmaceutical therapy and discontinuation of castration
62344114|NCT06084338|EXPERIMENTAL|Arm 2|Metastasis directed therapy with stereotactic ablative radiotherapy to all detectable sites of disease plus PSMA radiopharmaceutical therapy and discontinuation of castration, followed by restoration of physiologic testosterone
62714831|NCT04593121|EXPERIMENTAL|Cohort 7A|Participants will receive Dose 5 of BIIB107 or placebo SC on Day 1.
62344115|NCT05078073|EXPERIMENTAL|aGVHD-HBOT|Patients after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
62344116|NCT05078073|NO_INTERVENTION|aGVHD-HBOT free|Patients after allo-HSCT will NOT receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
62501821|NCT04669457|EXPERIMENTAL|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
61953804|NCT03525171|PLACEBO_COMPARATOR|controls|12 prepubertal healthy subjects with short stature recruited among children referred for assessment of short stature as a control group at baseline underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
61953805|NCT04661904|EXPERIMENTAL|cTBS group|Patients randomly assigned to cTBS group will receive 12 sessions cTBS for total four days after surgery.
62141893|NCT06699563|NO_INTERVENTION|No Intervention: Standard (No Card)|In this procedure, patients used a pedometer during their mobilization on the first postoperative day. They did not use a mobilization motivation card.
61953806|NCT04661904|SHAM_COMPARATOR|sham group|Patients randomly assigned to sham group will receive 12 sessions sham stimulation for total four days after surgery.
61953807|NCT06082492|EXPERIMENTAL|Intervention group|"The intervention group (n = 345) consists of usual care until 3 years of follow-up (see comparator) with additional whole-body 18F FDG PET/CT scans (from the skull to, at least, the midfemoral region) during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up. After the 36-month follow-up period, patients will receive follow-up usual care (i.e. CT-scans).~The scanning protocol of Boellaard et al (2015) is the basis of all center-specific protocols and therefore will be followed approximately (PET low dose CT 60 minutes post injection with scan trajectory from skull to (at least the) thighs followed by a CT scan)."
61953808|NCT06082492|ACTIVE_COMPARATOR|Control group (care as usual)|"The control group (n = 345) consists of regular follow-up visits with physical check-ups and CT-scans at least every 6 months for the first 2 years and then at least yearly CT-scans until 3 years of follow-up. In case of suspected recurrence/metastasis or inconclusive results of a CT-scan (eg, after radiotherapy), 18F FDG PET/CT should be considered.~The standard protocol for a diagnostic CT of the thoracic region during IV contrast administration according to the lung tumor protocol will be followed"
61953809|NCT02230800|EXPERIMENTAL|Tocovid SupraBio plus pentoxifylline (PTX)|Tocovid SupraBio\* 200mg po bd plus pentoxifylline (PTX) 400mg po bd for 12 months.
61953810|NCT02230800|PLACEBO_COMPARATOR|Matching placebos|Matching placebos bd for 12 months.
61953811|NCT06037070|EXPERIMENTAL|group with PRF|PRF placed inside the hole that prepared to place dental implant
62141894|NCT06698757|EXPERIMENTAL|8 cycles of neoadjuvant treatment with Sintilimab|A total of 48 subjects were enrolled and received Sintilimab at a dose of 200 mg, administered via intravenous infusion on the first day of each cycle, with each cycle lasting 3 weeks (Q3W), for a total of 8 treatment cycles.
62344117|NCT02379754|EXPERIMENTAL|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board."
62344118|NCT02379754|NO_INTERVENTION|Non-gentamicin|Rehabilitation exercises before and after surgery. Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board.
62344119|NCT02512744|NO_INTERVENTION|Capping trial protocol|"Decannulation protocol based on tolerance to 24 hours capping trial to decide when to decannulate.~Decapping during the capping trial for aspiration of respiratory secretions is considered a failure criteria of the trial.~High flow conditioned oxygen therapy through tracheal cannula will be applied during periods out of capping trials."
62344120|NCT02512744|EXPERIMENTAL|Suctioning frequency protocol|"Decannulation protocol based on suctioning frequency to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).~Intervention: suctioning frequency of respiratory secretions will be recorded untill fulfill decannulation criteria. Capping trials will not be allowed in this group.~High flow conditioned oxygen therapy will be applied through tracheal cannula during all the study period."
62344121|NCT02748941|EXPERIMENTAL|symptomatic and asymptomatic patients|
62344122|NCT03379506|EXPERIMENTAL|EBR/GZR|Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.
62700938|NCT04839887||Prospective quantitative study|Two hundred enrolled IS patients (100 young IS patients \< 50 years and 100 IS patients of 50-65 years) will undergo a serial of structured and standardized questionnaires during scheduled outpatients' controls three, six and 12 months after IS. In all enrolled patients, the functional outcome, neuropsychological status and quality of life will be assessed using standardized scales and tools.
62700939|NCT04839887||In-depth interview qualitative study|twenty young IS patients \< 50 years will undergo an in-depth, semi-structured interview with explanatory questions that will allow a detailed understanding of the patient's experience. Interpretative phenomenological analysis (IPA) study design will be used.
62700940|NCT06530459|EXPERIMENTAL|Exercise|"Curated exercises designed to address specific muscle groups and joints that are painful and problematic.~Exercises would focus on upper and lower body strength generally. It is anticipated that participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training."
61953812|NCT06037070|NO_INTERVENTION|control group|with out and additive
61953813|NCT03894800|ACTIVE_COMPARATOR|Methoxyflurane (M)|"A session starts with a CPT - cold pressor test (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale metoxyflurane through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
62141895|NCT06698757|ACTIVE_COMPARATOR|4 cycles of neoadjuvant treatment with Sintilimab|A total of 48 subjects were enrolled and received Sintilimab at a dose of 200 mg, administered via intravenous infusion on the first day of each cycle, with each cycle lasting 3 weeks (Q3W), for a total of 4 treatment cycles.
62141896|NCT01738698|EXPERIMENTAL|SPD489 40mg|
62141897|NCT01738698|EXPERIMENTAL|SPD489 100mg|
62141898|NCT01738698|EXPERIMENTAL|SPD489 160mg|
62344123|NCT04212858|EXPERIMENTAL|case|myeloma patients
62344124|NCT04212858|EXPERIMENTAL|control|healthy control
62700941|NCT06530459|EXPERIMENTAL|Menopausal hormone therapy|Menopausal hormone therapy comprising: 17beta-estradiol topical gel (1.25-2.5 gms) applied daily, and micronized Progesterone 200mg daily for 12 days each month.
62700942|NCT06530459|EXPERIMENTAL|Combination of exercise and menopausal hormone therapy|"1. Curated exercises designed to address specific muscle groups and joints that are painful and problematic.~   Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training.~2. Menopausal hormone therapy comprising: 17beta-estradiol topical gel (1.25-2.5 gms) applied daily, and micronized Progesterone 200mg daily for 12 days each month."
62700943|NCT06530459|NO_INTERVENTION|Standard care|Standard care will be provided.
62700944|NCT05293717|EXPERIMENTAL|All Participants|You are being asked to apply topical medication called Ruxolitinib cream to your skin at home twice daily.
62700945|NCT03884673||DTG+3TC|These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).
62700946|NCT00569179|EXPERIMENTAL|Alloreactive NK cell infusion|Escalating doses of alloreactive NK cells.
62700947|NCT05423613|EXPERIMENTAL|Microneedling treated scar|Microneedling
62141899|NCT01738698|PLACEBO_COMPARATOR|Placebo|
62141900|NCT05290090|EXPERIMENTAL|Rituximab, lenalidomide, zanubrutinib and RCHOP|"Rituximab, lenalidomide, zanubrutinib for 2 cycles: rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~RCHOP for 4 cycles: rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
62344125|NCT04528797|EXPERIMENTAL|Levothyroxine|Levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
62501822|NCT04669457|ACTIVE_COMPARATOR|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
62501823|NCT03933267|EXPERIMENTAL|Group I|This group of participant will receive Cervical sensorimotor control training exercises. In addition to it conventional physical therapy protocol will be given.
62344126|NCT04528797|EXPERIMENTAL|Methylprednisolone|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later.
62344127|NCT04528797|EXPERIMENTAL|Combination|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later plus levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
62344128|NCT04528797|NO_INTERVENTION|Control|No levothyroxine or methylprednisolone administered.
62344129|NCT06041295|EXPERIMENTAL|the cardiovascular surgery ICU nurse staff|on-the-job training of lung expansion therapy
62344130|NCT02106988|EXPERIMENTAL|Chemotherapy + Radiation Therapy|"Radiation therapy delivered for a total dose of 50.4 to 54 Gy over 28 to 30 treatments. Within seven days of starting radiotherapy, the first cycle of chemotherapy started and repeated every 3 weeks for a total of 3 cycles.~DeVIC on day 1 of every cycle. Dexamethasone 40 mg by vein Days 1-3, Etoposide 67 mg/m2 by vein on Days 1-3, Ifosfamide 1 g/m2 by vein on Days 1-3, Mesna 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, Mesna 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump, Carboplatin 200 mg/m2 by vein on Day 1. Cycles repeated every 21 days."
62344131|NCT03712345|EXPERIMENTAL|IFX-1 low dose|Will receive IFX-1 low dose regimen diluted in sodium chloride solution
62344132|NCT03712345|EXPERIMENTAL|IFX-1 high dose|Will receive IFX-1 high dose regimen diluted in sodium chloride solution
62344133|NCT03712345|PLACEBO_COMPARATOR|Placebo|Will receive placebo
62344134|NCT06390917|EXPERIMENTAL|With PVAs group|With the assistance of PVA function, researchers identify the patient-ventilator asynchronies and take actions to reduce the asynchronies.
62700948|NCT05423613|NO_INTERVENTION|Control scar|No intervention, standard of care
62700949|NCT00497497|EXPERIMENTAL|1|
62700950|NCT00497497|EXPERIMENTAL|2|
62700951|NCT04619602|EXPERIMENTAL|GSNO therapy|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
62700952|NCT02306252|EXPERIMENTAL|CARE Intervention|This group will be contacted to make an appointment for outpatient Occupational and Physical therapy. The therapist will determine the type, frequency and length of treatment. Follow up phone calls will be made to ensure appointments are made, kept and rescheduled as needed.
62700953|NCT02306252|NO_INTERVENTION|CARE Control|Patients randomized to this arm will receive contact information and a brochure outlining the services available within the supportive care program. The study coordinator will provide the information based on their results and assist the patient with contacting the program if desired.
62141901|NCT06249165|EXPERIMENTAL|Inclisiran|Inclisiran + Usual Care
62344135|NCT06390917|NO_INTERVENTION|Without PVAs group|PVA function is not utilized in this arm, researchers identify the patient-ventilator asynchronies by their own and take actions to reduce the asynchronies.
62344136|NCT04020094|EXPERIMENTAL|Treatment: all patients|
62501824|NCT03933267|ACTIVE_COMPARATOR|Group II Control|this group of participant will receive Conventional physical therapy protocol.
62501825|NCT02608476|EXPERIMENTAL|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
62501826|NCT02608476|PLACEBO_COMPARATOR|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
62501827|NCT01622660|EXPERIMENTAL|Gemcitabine and Pazopanib|This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.
62501828|NCT01660477|EXPERIMENTAL|Arm 1: isavuconazole only|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13
62700954|NCT03868501|EXPERIMENTAL|High Working memory load: n-back task|During the intervention, each participant of this group will finish the 3-back task.
62700955|NCT03868501|EXPERIMENTAL|Low Working memory load: n-back task|During the intervention, each participant of this group will finish the 1-back task.
62141902|NCT06249165|NO_INTERVENTION|Usual Care|Usual Care
62344137|NCT02222389|EXPERIMENTAL|CM for alcohol|CM for alcohol
62700956|NCT04540367|NO_INTERVENTION|No Intervention: Control|Participants in this group performed the exercises without the blood flow restriction therapy cuff
62700957|NCT04540367|EXPERIMENTAL|Experimental: BFR|Participants in this group performed the exercises with the blood flow restriction therapy cuff
62700958|NCT02011412||Intermountain Risk Score known|
61953814|NCT03894800|ACTIVE_COMPARATOR|Fentanyl (F1)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.025 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs.Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
61953815|NCT03894800|ACTIVE_COMPARATOR|Fentanyl (F2)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.05 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
61953816|NCT03894800|PLACEBO_COMPARATOR|NaCl (C)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
61953817|NCT03206775||Healthy controls (Phase 1)|Participants will participate in Cognitive Assessments (Phase 1) developed by Posit Science
61953818|NCT03206775||Healthy Controls, Battery A (Phase 2)|Participants will complete the Cognitive Battery A (Phase 2) developed by Posit Science while at the Minnesota State Fair.
61953819|NCT03206775||Healthy Controls, Battery B (Phase 2)|Participants will complete the Cognitive Battery B (Phase 2) developed by Posit Science while at the Minnesota State Fair.
61953820|NCT03206775||Healthy Controls, Battery C (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
61953821|NCT03206775||Healthy Controls (Phase 3)|Participants will complete the full Posit Science cognitive assessment battery and self-report questionnaires for credit in the Research Experience Program at the University of Minnesota.
61953822|NCT03206775||Healthy Controls, Battery D (Phase 2)|Participants will complete the Cognitive Battery E (Phase 2) developed by Posit Science while at the Minnesota State Fair.
61953823|NCT03206775||Healthy Controls, Battery E (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
62141903|NCT03776760||Fingerstick Point of Care GeneXpert HCV Test|Participants will have HCV testing using the finger-stick point of care GeneXpert quantitative HCV RNA assay.
62141904|NCT03776760||Treat - SOF/VEL|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - sofosbuvir/velpatesvir
62141905|NCT03776760||Treat - G/P|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - glecaprevir/pibrentasvir
62501829|NCT01660477|EXPERIMENTAL|Arm 2 : LPV/RTV only|Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13
62700959|NCT02011412||Intermountain Risk Score Unknown|
62700960|NCT04217317|EXPERIMENTAL|CPI-613 in Combination with Bendamustine|CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.
62700961|NCT03586921|EXPERIMENTAL|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
62344138|NCT02222389|EXPERIMENTAL|CM for drugs|CM for drugs
62344139|NCT02222389|EXPERIMENTAL|CM for both substances|CM for both substances
62344140|NCT02222389|OTHER|Non-Contingent group|No CM for either substance, the Non-Contingent (NC) group
62344141|NCT04186468|EXPERIMENTAL|ICU follow-up clinic|Participants will be invited to visit the ICU follow-up clinic.
62344142|NCT04186468|NO_INTERVENTION|Usual care|Participants will solely receive usual care.
62501830|NCT01660477|EXPERIMENTAL|Arm 3: isavuconazole and LPV/RTV|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir twice daily (BID) on Days 1-13
62501831|NCT04556734|EXPERIMENTAL|Etrasimod 2 mg|
62501832|NCT04556734|EXPERIMENTAL|Etrasimod 3 mg|
62501833|NCT04556734|PLACEBO_COMPARATOR|Placebo|
62714832|NCT04593121|EXPERIMENTAL|Cohort 5A|Participants will receive Dose 5 of BIIB107 or placebo intravenous (IV) on Day 1.
62344143|NCT05766228|EXPERIMENTAL|Experimental|Web-Based Intercultural Midwifery Training
62344144|NCT05766228|NO_INTERVENTION|Control|without any intervention
62714833|NCT04593121|EXPERIMENTAL|Cohort 8A|Participants will receive Dose 6 of BIIB107 or placebo SC on Day 1.
62714834|NCT04593121|EXPERIMENTAL|Cohort 1B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
61953824|NCT03206775||Adolescents with anxiety diagnosis (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
61953825|NCT03206775||Adolescents, healthy controls (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
61953826|NCT04375371|ACTIVE_COMPARATOR|Obese patients who have received a bariatric surgery|Obese patients who have undergone a bariaric surgery as part of routine clinical management within the indication of this intervention.
61953827|NCT04375371|NO_INTERVENTION|Obese patients without a bariatric surgery|Obese patients who have not undergone bariaric surgery.
61953828|NCT05958667|EXPERIMENTAL|Quitxt bilingual text messaging and chat|"Culturally and linguistically tailored, bilingual text messaging or chat mobile app.~Our text messaging or chat intervention will include messaging options in which users can text or message a code when they are craving a cigarette or at risk of relapse and immediately receive text or social media messages to help them avoid smoking. The social media content also will include opportunities for users to repeatedly visit key content pages and receive immediate support when experiencing cravings, stress, bad mood, or when feeling at risk of smoking."
61953829|NCT05958667|OTHER|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit (www.yesquit.org) available to smokers seeking help quitting. The abbreviated text messaging will include general information on smoking harms and benefits of cessation, and baseline data collection and follow-up assessments.
61953830|NCT01517074|EXPERIMENTAL|Sirolimus|Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).
61953831|NCT03651869|EXPERIMENTAL|Condition 1|
61953832|NCT03651869|EXPERIMENTAL|Condition 2|
61953833|NCT03651869|EXPERIMENTAL|Condition 3|
61953834|NCT03651869|EXPERIMENTAL|Condition 4|
61953835|NCT02226146|EXPERIMENTAL|Bertilimumab|Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)
61953836|NCT02240732||Total knee replacement patients|"Patients who are due to have a total knee replacement will be studied to look for the presence of Emboli.~Observational with imaging."
61953837|NCT02050841|EXPERIMENTAL|Octaplas|Qualified patients will receive Octaplas as per protocol.
61953838|NCT02334358||YVOIRE Classic s|Treatment with YVOIRE Classic s
61953839|NCT02545556|EXPERIMENTAL|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
62141906|NCT02821936|EXPERIMENTAL|Parametric Imaging|"one parametric PET at the inclusion and one at 42 Gray after the beginning of radiotherapy.~Two PET scans at 3 months and one year after inclusion"
62141907|NCT04300244|EXPERIMENTAL|Arm A|Ipilimumab and nivolumab + UV1
62141908|NCT04300244|ACTIVE_COMPARATOR|Arm B|Ipilimumab and nivolumab
61953840|NCT02545556|PLACEBO_COMPARATOR|control|liver cancer patients received traditional therapy
61953841|NCT03398785|EXPERIMENTAL|Intevention|Adrenal Artery Ablation
61953842|NCT03398785|NO_INTERVENTION|Control|No intervention, but treated with standard anti-hypertensive drigs
61953843|NCT02260544|EXPERIMENTAL|Test Product - T|"doxorubicin hydrochloride liposome ( Dr. Reddy's Lab )~Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks."
61953844|NCT02260544|ACTIVE_COMPARATOR|Reference Product - R|"doxorubicin hydrochloride liposome ( Sun Pharma )~Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks."
61953845|NCT01489397|EXPERIMENTAL|Gastric intestinal metaplasia|
62141909|NCT01193205|EXPERIMENTAL|20 weeks skills group|Participants receive 20 weeks of Dialectical Behaviour Therapy Skills training, covering 5 modules: mindfulness, interpersonal effectiveness, emotional regulation, distress tolerance, dialectics.
62501834|NCT04300998||older lymphoma patients|This is a prospective observational cohort where 18 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory high-grade B-cell lymphoma will undergo serial comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
62714835|NCT04593121|EXPERIMENTAL|Cohort 2B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
62714836|NCT05672914|EXPERIMENTAL|Tablet-based Sustained Care|Intervention to support sustained smoking cessation.
62714837|NCT05672914|NO_INTERVENTION|Usual Care|Standard hospital care: : A brief (5-10 min.) tobacco education session from a hospital nurse, along with educational materials about quitting and a quitline brochure.
61953846|NCT01489397|PLACEBO_COMPARATOR|Normal|
61953847|NCT00818597|EXPERIMENTAL|EISS-treatment|In this arm patients receive additional treatment with the EISS-bioreactor
61953848|NCT01317485|EXPERIMENTAL|Purulent peritonitis|"Patients with purulent peritonitis are randomised at a 2:1:1 ratio between~1. Laparoscopic lavage and drainage~2. Sigmoidectomy with primary anastomosis~3. Sigmoidectomy with end-colostomy"
62141910|NCT01193205|NO_INTERVENTION|Waitlist|Participants on the waitlist condition will be assessed at baseline and symptoms monitored at 10 weeks, 20 weeks and 8 months following baseline assessment. They will then be offered the active treatment.
62141911|NCT03232398|ACTIVE_COMPARATOR|Apixaban|Apixaban Oral Tablet \[Eliquis\]
62141912|NCT03232398|ACTIVE_COMPARATOR|Warfarin|Warfarin - Vitamin K antagonist
62700962|NCT03586921|ACTIVE_COMPARATOR|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
62700963|NCT01784302|ACTIVE_COMPARATOR|Maalox Plus extra|Subjects will receive doses of raltegravir 400 mg and maalox plus extra
62700964|NCT01784302|ACTIVE_COMPARATOR|Multivitamin|Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet
62700965|NCT01784302|ACTIVE_COMPARATOR|Sodium bicarbonate|Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate
61953849|NCT01317485|EXPERIMENTAL|Fecal peritonitis or overt perforation|"Patients with fecal peritonitis or an overt perforation are randomised between~1. Sigmoidectomy with primary anastomosis~2. Sigmoidectomy with end-colostomy"
61953850|NCT02151110|PLACEBO_COMPARATOR|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
61953851|NCT02151110|EXPERIMENTAL|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
61953852|NCT02151110|EXPERIMENTAL|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
61953853|NCT02151110|EXPERIMENTAL|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
61953854|NCT02151110|EXPERIMENTAL|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
61953855|NCT02151110|EXPERIMENTAL|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
61953856|NCT02151110|EXPERIMENTAL|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
61953857|NCT02151110|EXPERIMENTAL|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
61953858|NCT03745131||Pre-exposure prophylaxis recipients|40 healthcare workers who provide specialist medical care to patients with monkeypox and who received vaccine as pre-exposure prophylaxis.
61953859|NCT03745131||Post-exposure prophylaxis recipients|40 healthcare workers who received vaccine as post-exposure prophylaxis following monkeypox-exposure risk assessments.
61953860|NCT03745131||Control Group 1|20 healthcare workers who provided specialist medical care to patients with monkeypox but declined the offer of vaccine as pre-exposure prophylaxis.
61953861|NCT03745131||Control Group 2|Healthcare workers not involved in the care of, and have not had known exposure to, patients with monkeypox and, therefore, were not offered vaccine.
61953862|NCT02015572|EXPERIMENTAL|Occupational intervention|Early coordinated occupational intervention. Supervision in physically activities by a physiotherapist.
61953863|NCT02015572|ACTIVE_COMPARATOR|Usual care|Intervention from the patient's general physician.
61953864|NCT01546805|PLACEBO_COMPARATOR|Placebo|
61953865|NCT01546805|EXPERIMENTAL|Zinc Group|
61953866|NCT04584151|NO_INTERVENTION|standard of care|Peri operative analgesia by opioid
61953867|NCT04584151|EXPERIMENTAL|Continuous regiona analgesia|Peri operative algesia by continuous bilateral ESP catheters
61953868|NCT02383498|EXPERIMENTAL|GI-6301 Vaccine|Radiation + GI-6301 Vaccine + Actigraph
61953869|NCT02383498|PLACEBO_COMPARATOR|Placebo|Radiation + Placebo + Actigraph
61953870|NCT03254875|EXPERIMENTAL|Intervention|Individually tailored nurse navigation
61953871|NCT03254875|NO_INTERVENTION|Control|Usual care
61953872|NCT01867788||Parkinson's disease subjects|
61953873|NCT01867788||Healthy Control subjects|
61953874|NCT00989560|ACTIVE_COMPARATOR|Active arm|
61953875|NCT00989560|NO_INTERVENTION|Standard care arm|
61953876|NCT05647460|ACTIVE_COMPARATOR|computer guided plates|computer guided screw holes locating guide and custom-made plates in management of parasymphseal mandibular fracture
61953877|NCT05647460|ACTIVE_COMPARATOR|conventional plates|conventional plate osteosynthesis in management of parasymphseal mandibular fracture
61953878|NCT06210607|EXPERIMENTAL|HS-10511 Tablets|Subjects will be assigned to one of 5\~6 planned dose cohorts in (single ascending dose)SAD and one of 4 planned dose cohorts in (multiple ascending dose)MAD.
61953879|NCT06210607|PLACEBO_COMPARATOR|HS-10511 Tablets Placebo|Subjects will be assigned to one of 5\~6 planned dose cohorts in SAD and one of 4 planned dose cohorts in MAD.
61953880|NCT05178888|EXPERIMENTAL|Dose Escalation|Dose escalation of MRTX849 and palbociclib to determine maximum tolerated dose in combination.
61953881|NCT05178888|EXPERIMENTAL|Dose Expansion|Expansion cohorts may be implemented to ensure sufficient safety experience, pharmacokinetic data and early evidence of clinical activity of MRTX in combination with palbociclib.
61953882|NCT01374997|OTHER|patients with Fabry disease|detection of this disease in end-stage renal failure patients, transplant or hemodialysis
61953883|NCT04345042|NO_INTERVENTION|First Group|In the first group; the investigators applied the TP such as hot pack, ultrasound, exercise and TENS.
61953884|NCT04345042|EXPERIMENTAL|Second Group|In the second group; the investigators applied the classic massage (Swedish Technique) together with TP.
61953885|NCT01423318|EXPERIMENTAL|A|
61953886|NCT01423318|PLACEBO_COMPARATOR|B|
61953887|NCT01943500||Cancer or no prior history of cancer|Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
62344145|NCT04846166||Control|
62700966|NCT04426474|EXPERIMENTAL|LY3502970|LY3502970 administered orally.
62700967|NCT04426474|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62700968|NCT05425121|ACTIVE_COMPARATOR|Core stability protocol|Participants in this group will undergo core stability exercise program . Each exercise plan will be progressively increased.
62700969|NCT05425121|EXPERIMENTAL|Core Stability with surface electromyography biofeedback|Participants in this group will undergo core stability exercise program with surface electromyography biofeedback. Each exercise plan will be progressively increased with application of surface electromyography biofeedback.
62501835|NCT04300998||older patients with lymphoma and other lymphoid malignancies|This is a prospective observational cohort where 80 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory lymphoma and lymphoid malignancies will undergo comprehensive geriatric assessment, aging biomarker analysis, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
62501836|NCT04300998||older patients with myeloma and other plasma cell disorders|This is a prospective observational cohort where 40 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory plasma cell disorders will undergo
62501837|NCT05740696||ALF|acute liver failure
62501838|NCT05740696||SALF|subacute liver failure
62501839|NCT05740696||ACLF|acute-on-chronic liver failure
61953888|NCT04218630|EXPERIMENTAL|Reformer pilates group|All participants were informed about the reformer machine and the treatment program by the physiotherapist in reformer pilates group. Reformer pilates exercises were applied in the form of general muscle strengthening and flexibility exercises under the supervision of physiotherapist. Exercises were performed in 2 times a week for 6 weeks. The duration of one session was 60 minutes.
61953889|NCT04218630|ACTIVE_COMPARATOR|Home mat pilates group|In home mat pilates group, clinical pilates exercises were applied as a home program. Brochures and exercise follow-up forms, which illustrated and written all the exercises in this program, which consisted of clinical pilates-based general muscle strength and flexibility exercises, were given to all participants in this group. Exercises were performed in 2 times a week for 6 weeks at home. Participants marked the follow-up form when they performed exercises. Attendance of participants to exercise was checked by phone calls.
62700970|NCT03037749|EXPERIMENTAL|Distressed violent|Distressed violent partners participated in a within-subjects placebo-controlled alcohol administration arm with an emotion-regulation task.
61953890|NCT02771431|NO_INTERVENTION|Standard|Group 1 will consist of patients receiving in-person attending-patient encounters while inpatients.
62700971|NCT03037749|EXPERIMENTAL|Distressed nonviolent|Distressed nonviolent partners participated in a within-subjects placebo-controlled alcohol administration arm with an emotion-regulation task.
62700972|NCT02363166||Acute Abscess Group|Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
62700973|NCT04881058|EXPERIMENTAL|PicoSure Device|The PicoSure device will be used on the face for the treatment of pigmentation and mild to moderate wrinkles.
62700974|NCT03251989||1/Patient with a rare CNS diagnosis|A diagnosis of rare CNS Tumors
62700975|NCT03464773|OTHER|Pathway|The PIUO Pathway is implemented by clinicians (MD and RN) with expertise in treating pain in children. Each participant proceeds through the PIUO Pathway as long as their pain persists, but will exit the PIUO Pathway at any stage in case their pain is resolved. The Pathway has two steps: Step 1 is a thorough history and patient evaluation, including directed testing. Step 2 is a series of screening tests to further explore any potential underlying disease or injury not apparent based on history and physical examination.
62700976|NCT03464773|NO_INTERVENTION|Waitlist|Participants randomized to the Waitlist will cross over to the Pathway after 8 weeks.
62700977|NCT05870631|EXPERIMENTAL|Group A|Group with DTap vaccination produced by Chendu Institute of Biological Products Co., Ltd
62141913|NCT03293238|ACTIVE_COMPARATOR|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
62700978|NCT05870631|EXPERIMENTAL|Group B|Group with DT vaccination
62700979|NCT05963126||Patients with hypertension, resistant hypertension, and secondary hypertension|Patients with arterial hypertension, resistant arterial hypertension, and secondary hypertension.
61953891|NCT02771431|EXPERIMENTAL|Tele-rounding|Group 2 will consist of patients receiving video-conference attending-patient encounters. The intervention is being seen via ipad
61953892|NCT04005911||Post-Surgical|Patients who underwent surgery and were admitted to the PACU
61953893|NCT01976338|EXPERIMENTAL|Ranibizumab 0.5 mg|PRN Intravitreal injection
61953894|NCT01976338|SHAM_COMPARATOR|Sham injection|As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
62141914|NCT03293238|SHAM_COMPARATOR|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
62141915|NCT03293238|ACTIVE_COMPARATOR|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
62344146|NCT04846166||Periodontitis|
62344147|NCT06007339|EXPERIMENTAL|Investigational Device Arm (PerQseal Elite- Venous)|Large hole percutaneous venous closure device - PerQseal Elite
62344148|NCT06187623||Home based Group|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
62344149|NCT06187623||Clinic based Group|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
62344150|NCT05231174|EXPERIMENTAL|A self-evlaution tool based on Large Language Model|The self-evlaution tool, powered by a large language model, processes user queries through a comprehensive generation, decision, action, and safety framework to deliver optimal responses. The system's key features include retrieval-augmented in-context learning, which enhances the responses generated by sourcing information from reliable websites. It also incorporates a Guardrail module to mitigate potential harmful content in the responses by validating the content before delivery. Additionally, the system features a Self-checking memory module that maintains essential clinical characteristics across multi-turn dialogues, ensuring consistent and continuous interactions with users.
62700980|NCT02371889|EXPERIMENTAL|Topiramate + Medical Management|Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit
61953895|NCT02743169||Standard Practice|This group will consist of ambulance calls under the standard practice of Aman Foundation for ambulance placement.
61953896|NCT02743169||Post-Intervention|This group will consist of ambulance calls after the spatially-optimized placement of ambulances.
61953897|NCT05518019|EXPERIMENTAL|"Prima CBD The Daily Supplement"|Participants are provided with the dietary supplement (1 capsule per day). Participants are to take the supplement at the same time every day Participants will take a weekly well-being survey Participants are to complete the well-being questionnaire after the 4th week
61953898|NCT01667029|EXPERIMENTAL|sulfasalazine|1 g oral twice daily for 2 weeks
61953899|NCT01667029|PLACEBO_COMPARATOR|placebo|oral placebo pill twice daily for two weeks.
61953900|NCT05476471|EXPERIMENTAL|intervention arm|The intervention consisted of one 60-minutes group exercise session once a week in first 8 weeks, and self-management in next 8 weeks
61953901|NCT05476471|NO_INTERVENTION|control arm|The control arm received an education leaflet.
61953902|NCT00828997|OTHER|Prevenar vaccine|all participants are immunized with a dose of pneumococcal conjugate vaccine
61953903|NCT06467448||Adductor Pollicis EMG|The Train of Four Ratio will be recorded at 90% as a time and as a reference point
61953904|NCT06467448||Adductor Digiti Minimi|The Train of Four Ratio will be recorded when the adductor pollicis ratio reads 90%
61953905|NCT02416401|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
61953906|NCT02416401|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
62501840|NCT04423445|EXPERIMENTAL|Laser acupuncture combined with acupressure (LAA)|A 4-week LAA intervention included low-level laser acupuncture and auricular acupressure. Six acupuncture points were selected, and three auricular points. Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. After five days, the seed was removed, and a new seed was taped on the other ear.
61953907|NCT01091974|EXPERIMENTAL|1 - CBT-I + placebo|CBT-I and placebo
62501841|NCT04423445|NO_INTERVENTION|Control group|Control participants received a similar intervention, but without laser energy output or acupressure.
62501842|NCT04249622|EXPERIMENTAL|Arm I (rifaximin, pertuzumab-based chemotherapy)|Patients that experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy receive rifaximin PO BID on days 1-5 and standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
62501843|NCT04249622|ACTIVE_COMPARATOR|Arm II (pertuzumab-based chemotherapy)|Patients that do not experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy continue receiving standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
62700981|NCT02371889|PLACEBO_COMPARATOR|Placebo Pill + Medical Management|Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
61953908|NCT01091974|EXPERIMENTAL|2 - CBT-I + Armodafinil|CBT-I + Armodafinil
61953909|NCT01091974|PLACEBO_COMPARATOR|3 - Placebo only|Placebo only
61953910|NCT01091974|EXPERIMENTAL|4 - Armodafinil only|Armodafinil only
61953911|NCT02920385|EXPERIMENTAL|Levothyroxine/SNAC/Placebo/Semaglutide|
61953912|NCT01614080||High sc-tPA/tc-tPA ratio group|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The High sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio higher than the median
61953913|NCT01614080||Low sc-tPA/tc-tPA ratio|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The Low sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio lower than the median
61953914|NCT05719662|EXPERIMENTAL|Weight bearing exercises|weight bearing exercises (I.e standing on preferred foot, standing with close eyes, walking forward on a line using normal stride and heel to toe gait, stepping over response speed stick on balance beam).
61953915|NCT05719662|EXPERIMENTAL|Jaffrey's core stability exercises|Jaffrey's core stability exercises (I.e contracting muscles, sitting on Swiss ball, Bridging, Squatting side lying bridge etc).
61953916|NCT01921387|EXPERIMENTAL|Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)|Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.
61953917|NCT03859193|NO_INTERVENTION|Standard care|Participants will receive standard nutrition counseling
61953918|NCT03859193|EXPERIMENTAL|Video|Participants will watch an Nutritional video at their first high risk visit. Participants will also receive standard nutrition counseling
61953919|NCT01376284||Subjects prescribed dutasteride capsules|Subjects with BPH prescribed dutasteride capsules during study period
61953920|NCT06187584|ACTIVE_COMPARATOR|Control Group (opioid group)|Hydrocodone/acetaminophen 0.15mg/kg PO q6 hours PRN with ibuprofen 10mg/kg PO q6 hours PRN
61953921|NCT06187584|EXPERIMENTAL|Experimental Group (nonopioid group):|Acetaminophen 15mg/kg PO q6 hours with ibuprofen 10mg/kg PO q6 hours
61953922|NCT01471171|EXPERIMENTAL|Aclidinium bromide|3-week treatment periods
61953923|NCT01471171|EXPERIMENTAL|Placebo|3-week treatment periods
61953924|NCT05279339|NO_INTERVENTION|Control|Participants will not perform any exercise
62700982|NCT00967499|ACTIVE_COMPARATOR|1|
62700983|NCT00967499|ACTIVE_COMPARATOR|2|
62700984|NCT05575102|EXPERIMENTAL|Walking Football|Walking football intervention for 6-weeks (2-hour per week) at a local sports hall, supervised by a walking football coach with assistance from CB.
61953925|NCT05279339|EXPERIMENTAL|Exercise|Participants will perform an exercise recommended for preventing neck and shoulder pain
62700985|NCT06571682||Total Intravenous Anesthesia Group|"Patients will undergo anesthesia induction as routine after premedication. Once the target BIS level is reached (40-60) and muscle relaxation is achieved, the airway will be secured with an appropriately sized endotracheal tube or laryngeal mask (LMA).~The effect zone target concentration of propofol will be adjusted to 3 mcg/ml with the HKI device.~Patients will receive controlled ventilation with 50% oxygen/air, and mechanical ventilation parameters will be adjusted so that the end tidal carbon dioxide level (EtCO2) is 35-45 mmHg."
62700986|NCT06571682||Inhalation Anesthesia Group|Patients will undergo anesthesia induction as routine after premedication. The level of sevoflurane, an inhalation gas, will be adjusted so that BIS values are between 40-60. Patients will receive controlled ventilation with 50% oxygen/air, and mechanical ventilation parameters will be adjusted so that the end tidal carbon dioxide level (EtCO2) is 35-45 mmHg.
62700987|NCT05443321|NO_INTERVENTION|Baseline|The baseline arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year pre-intervention phase. They will not receive any intervention, but rather usual care
61953926|NCT05827380|EXPERIMENTAL|Training group|Patients assigned to the training group will receive a training targeting on gait adaptability using the C-mill. Subjects are asked to stop any other physical therapy program targeting gait, balance or leg function during the training period. Assessments will take place pre- and post-intervention
61953927|NCT05827380|NO_INTERVENTION|Waitlist control group|Patients assigned to the waitlist control group will receive standard care for 5 weeks whereafter they will receive the same training as the training group. Assessments will take place pre-intervention, post-waiting period and post-intervention.
61953928|NCT06260852||Premium presbyopia surgery|Participants that underwent uncomplicated pseudophakic presbyopia correction with bilateral premium intraocular lenses (IOL) implantation
61953929|NCT01218113|EXPERIMENTAL|3D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
61953930|NCT01218113|EXPERIMENTAL|2D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm.
62501844|NCT06246734|EXPERIMENTAL|Treatment, Immediate Robot Pet Companion|Participants will receive a Hasbro Joy for All robotic pet. These are low cost (\< $150), life-like cats and dogs that respond to human interaction by making sounds or turning their head for eye contact. The robot companion pets are designed as supports for older people with cognitive impairment. In this trial, the older person can treat it like a pet or ignore it. Family caregivers will report on engagement with the pet and effects on mood.
62501845|NCT06246734|NO_INTERVENTION|Control, Delayed Robot Pet Companion|During the 6-8 week trial, this group will not receive the robot pet companion but will complete baseline and follow-up assessments on teh same schedule as the treatment arm. Participants in this arm will receive the robot pet after the trial.
62501846|NCT02972515|EXPERIMENTAL|See Me Smoke-Free|"Participants received access to the See Me Smoke-Free mobile application (app) delivered via smart phone, and were asked to use the app most days for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques."
62501847|NCT06038318|EXPERIMENTAL|PRISM Program Mobile App|"Participants will be randomized to app-only group and will complete:~* Baseline questionnaire.~* mPRISM App self guided modules~* 3 month questionnaire.~* mPRISM App self guided modules until final survey at 6 months and end of participation."
62501848|NCT06038318|ACTIVE_COMPARATOR|PRISM Program Video Coach|"Participants will be randomized to video group and will complete:~* Baseline questionnaire.~* PRISM sessions.~* 3 month questionnaire with re-randomization to either app-only or text groups or referral to specialty psychosocial support.~* After re-randomization, participants will complete PRISM sessions until final survey at 6 months and end of participation."
62501849|NCT06038318|ACTIVE_COMPARATOR|PRISM Program Text Coach|"Participants will be randomized to text group and will complete:~* Baseline questionnaire.~* PRISM sessions.~* 3 month questionnaire with re-randomization to app-only, text, or video groups.~* After re-randomization, participants will complete PRISM sessions until final survey at 6 months and end of participation."
62501850|NCT02425501||Aflibercept (Eylea,BAY86-5321)|Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert
62501851|NCT03799822|ACTIVE_COMPARATOR|Control|Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
62501852|NCT03799822|EXPERIMENTAL|rivaroxaban|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
61953931|NCT01218113|PLACEBO_COMPARATOR|Control Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
61953932|NCT03131921||Colorectal cancer|No intervention. Patients with newly diagnosed stage II-IV colorectal cancer will be enrolled.
61953933|NCT05638581|ACTIVE_COMPARATOR|LTOWB|Participants randomized to receive (Low Titer O Whole Blood \[LTOWB\])
61953934|NCT05638581|ACTIVE_COMPARATOR|Components|Participants randomized to receive the component blood products.
61953935|NCT00133497|EXPERIMENTAL|20 mcg CMV gB + MF59|200 subjects will receive vaccine CMV gB + MF59.
61953936|NCT00133497|PLACEBO_COMPARATOR|Saline|200 subjects will receive saline placebo.
61953937|NCT00103883||HIV Infected Teens -ATN Clinical Sites|HIV infected teens who are referred to or engaged in care at any of the 15 ATN clinical sites during the course of the study.
61953938|NCT00103883||HIV Positive - ATN Clinical Sites|Youth who test HIV positive at ATN-managed or ATN-affiliated HIV Counseling and Testing Sites (CTS) during the course of the study.
62700988|NCT05443321|EXPERIMENTAL|Intervention|The intervention arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year intervention phase. They will receive the intervention, which will include utilization of the developed health information exchange platform to transfer clinical information between transferring and accepting hospital. The intervention will not interact directly with the patient, but rather their clinical data.
61953939|NCT00103883||HIV Positive - BCHD STD Clinic|Youth who test HIV positive at the BCHD STD Clinic during the course of the study.
61953940|NCT02043171|PLACEBO_COMPARATOR|Placebo Exercise|Placebo supplementation group with 3 days per week of exercise
61953941|NCT02043171|PLACEBO_COMPARATOR|Placebo Non-exercise|Placebo supplementation group without exercise
61953942|NCT02043171|ACTIVE_COMPARATOR|HMB plus Vitamin D Exercise|HMB plus Vitamin D supplementation group with 3 days per week of exercise
62141916|NCT03293238|SHAM_COMPARATOR|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch without ultrasound guidance.
62700989|NCT06015009|EXPERIMENTAL|Intervention group|Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.
62700990|NCT00889005|EXPERIMENTAL|Cognitive Behavioral Therapy|Five sessions of trauma-focused, telephone based cognitive behavioral therapy, followed by assessment and referral to clinical treatment if needed.
62700991|NCT00889005|NO_INTERVENTION|Waitlist control group|Five weeks without active intervention, followed by assessment and referral to clinical treatment if needed.
62700992|NCT06397092||TA-BSM|The hypertrophic cardiomyopathy patients received TA-BSM
62700993|NCT03643237|EXPERIMENTAL|Video game-based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 45 minutes long that will be administered at a rate of 1 per week with between-session homework.
62700994|NCT03643237|ACTIVE_COMPARATOR|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
62700995|NCT00654732|EXPERIMENTAL|Arm A (rituximab, combination chemotherapy)|Participants receive rituximab intravenously IV over 7 hours on days 1, 8, 15, and 22 of course 1 and on days 1 and 8 of course 2. Participants also receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine IV over 1 hour on days 1 and 15. Treatment with ABVD repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62700996|NCT00654732|ACTIVE_COMPARATOR|Arm B (combination chemotherapy)|Participants receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine as in Arm A.
61953943|NCT02043171|ACTIVE_COMPARATOR|HMB plus Vitamin D Non-exercise|HMB plus Vitamin D supplementation group without exercise
61953944|NCT04174846|ACTIVE_COMPARATOR|Treatment of SAM children with RUTF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with standard ready-to-use therapeutic food (RUTF)
61953945|NCT04174846|EXPERIMENTAL|Treatment of SAM children with RUSF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with ready-to-use-supplementary food (RUSF)
61953946|NCT02829528|EXPERIMENTAL|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a New York based organization dedicated to making the tools of yoga and mindfulness available to all children and teens. Their Teacher Training Program focuses on the physical, mental emotional, and social wellbeing of students. Teachers are trained to use the five elements format (connect, breathe, move, focus, relax). Implementation of the Little Flower Yoga for Kids curriculum will be manualized prior to the start of the study with Ms. Love, and will be presented as a series of activities (e.g., poses) throughout the school year. The emphasis in these yoga and mindfulness activities is exploration not competition, which allows the child to learn and develop at her own pace with the support of Ms. Love. The children participate in the Little Flower Yoga for Kids intervention at school for 40 minutes per class, 3 to 5 times per week, for the entire academic school year (9 months).
62141917|NCT03314324|EXPERIMENTAL|ODM-201|
62141918|NCT03314324|ACTIVE_COMPARATOR|Enzalutamide|
62501853|NCT03799822|EXPERIMENTAL|rivaroxaban + K2|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements
61953947|NCT03302234|EXPERIMENTAL|Pembrolizumab + Ipilimumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
61953948|NCT03302234|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
61953949|NCT05675176||Group 1|Patients with non muscle invasive bladder cancer undergoing intravesical instillation with the use of self lubricated silicon tiemann 10 fr urinary catheter.
61953950|NCT05675176||Group 2|Patients with non muscle invasive bladder cancer undergoing intravesical instillation with the use of straight tipped latex foley 14 fr urinary catheter
62141919|NCT03551600||Preterm, no PDA|"Babies \</= 32 weeks gestation at birth with no symptoms of a patent ductus arteriosus (PDA) or echocardiogram confirmation of no PDA~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded"
62501854|NCT01057173|EXPERIMENTAL|Transcatheter Aortic Valve Implantation|
62700997|NCT03924414|ACTIVE_COMPARATOR|Zoledronic acid (ZA)|A single intravenous infusion of Zoledronic acid (5 mg) infused over 45 minutes
62700998|NCT03924414|PLACEBO_COMPARATOR|Placebo|A single intravenous infusion of placebo infused over 45 minutes
61953951|NCT01727999||TPO responder|Patients with therapeutic response to TPO
61953952|NCT01727999||TPO non-responder|Patients not responding to TPO agonists
62141920|NCT03551600||Preterm, moderate to large PDA|Babies \</= 32 weeks gestation at birth with confirmed moderate to large PDA on echocardiogram Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded
62700999|NCT03032484|EXPERIMENTAL|Bevacizumab and TVB-2640|Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
62701000|NCT03032484|EXPERIMENTAL|Bevacizumab for Cycle 1, then Bevacizumab and TVB-2640|Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle, and then receive both Bevacizumab and TVB-2640 for the remainder of their participation in this study.
62701001|NCT03290521|EXPERIMENTAL|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
62701002|NCT03290521|EXPERIMENTAL|B- No Washing (NL)|No washing was performed before the end of surgery
62701003|NCT06638827|ACTIVE_COMPARATOR|Patients complaining of primary focal hyperhidrosis|This is a prospective clinical study that includes all patients with Primary Focal Hyperhidrosis, who will be operated on with Bilateral Thoracoscopic Sympathectomy.
62701004|NCT03341936|EXPERIMENTAL|Nivolumab+Lirilumab|"* The drugs will be administered intravenously. A single dose of Nivolumab and Lirilumab will be administered prior Salvage surgical resection.~* In Cycle 1-3: Nivolumab will be administered on Days 1 and 15 and lirilumab will be administered on Day 1 of each 28 day long cycle~* In Cycle 4-6 and beyond: Nivolumab and lirilumab will be administered on Day 1 of each 28 day long cycle."
62701005|NCT01146002|OTHER|Guanfacine treated.|Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
62701006|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Level 1|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 1
62701007|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Level 2|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 2
62701008|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Level 3|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 3
62701009|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Level 4|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 4
62701010|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Level 5|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 5
62701011|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Level 6|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 6
62701012|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Level 7|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 7
62701013|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 in combination with pembrolizumab|Enrolled subjects will receive DB-1305/BNT325 in combination with pembrolizumab
62701014|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 1|subjects with Non-Small Cell Lung Cancer (NSCLC) with actionable genetic alterations (AGAs) who will receive DB-1305/BNT325 on either dose level 1 or dose level 2
62701015|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 2|Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on either dose level 1 or dose level 2
62701016|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 3|Enrolled subjects with OC who will receive DB-1305/BNT325 on either dose level 1 or dose level 2
62701017|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 4|Enrolled subjects with BC who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62501855|NCT01057173|ACTIVE_COMPARATOR|Surgical Aortic Valve Replacement|
62701018|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 5|Enrolled subjects with Triple-Negative Breast Cancer (TNBC) who have progressed on or after standard systemic treatments and without prior treatment of sacituzumab govitecan who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701019|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 6|Enrolled subjects with TNBC with treatment failure on sacituzumab govitecan who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701020|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 7|Enrolled subjects with EC who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701021|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 8|Enrolled subjects with malignant mesothelioma will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701022|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 9|Enrolled subjects with Cervical Cancer (CC) who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701023|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 Dose Expansion 10|Enrolled subjects with pancreatic cancer who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701024|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 11|Enrolled subjects with Castration-Resistant Prostate Cancer (CRPC) who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701025|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion PB1|Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with pembrolizumab
62701026|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 Dose Level 8|Enrolled subjects will receive DB-1305/BNT325 at Dose Level 8
62701027|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 in combination with BNT327|Enrolled subjects will receive DB-1305/BNT325 in combination with BNT327
62701028|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 Dose Expansion PM1|Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327
62701029|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 Dose Expansion PM2|Enrolled subjects with NSCLC with AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327
62701030|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 Dose Expansion PM3|Enrolled subjects with CC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327
62701031|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 Dose Expansion PM4|Enrolled subjects with OC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327
62701032|NCT05438329|EXPERIMENTAL|Experimental: DB-1305/BNT325 Dose Expansion PM5|Enrolled subjects with TNBC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327
62701033|NCT05438329|EXPERIMENTAL|DB-1305/BNT325 Dose Expansion 12|Enrolled subjects with head and neck cancer who will receive DB-1305/BNT325 on a selected dose level (RP2D)
62701034|NCT04923672|NO_INTERVENTION|Control group|Participants will be asked to wear an Apple watch through about 30 days after surgery and will be asked to maintain their current activity level.
62701035|NCT04923672|ACTIVE_COMPARATOR|Moderate continuous training group|"Apple watch and a smartphone application~Increase activity to 5 days a week, 40 minutes a day of continuous moderate intensity exercise prior to surgery."
62701036|NCT04923672|ACTIVE_COMPARATOR|High intensity interval training group|"Apple watch and a smartphone application~Increase activity to 5 days a week, 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery."
62701037|NCT02754297|EXPERIMENTAL|Personalized PRRT (P-PRRT)|"177Lu-Octreotate (LuTate) P-PRRT will be administered as follows:~* Renal absorbed radiation dose will be prescribed for the 4-cycle induction course (23 Gy) and for each subsequent cycle (6 Gy), with a reduction in cases of impaired renal or bone marrow function, or significant toxicity from prior cycles.~* The personalized activity to be administered at each cycle will be derived from renal dose per unit of injected activity that is predicted by patient characteristics or renal dose delivered during prior cycle(s).~* Participants responding to the induction course of P-PRRT will be eligible to receive additional consolidation and/or maintenance cycles.~* Participants with prior PRRT exposure outside the trial may receive less induction cycles, or only consolidation/maintenance cycle(s)."
62701038|NCT06563518|EXPERIMENTAL|Group 1|Toothpaste
62701039|NCT06563518|ACTIVE_COMPARATOR|Group II|Toothpaste
62701040|NCT03038087|EXPERIMENTAL|SENSE Device Monitoring in ICH Patients|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit that contains:~   1. The driving electronics for the array;~  2. A spectrum analyzer coupled with a computer; and,~  3. The operating software that controls the device function and data acquisition, processing and archiving.~For this study, the research personnel will place the headset over the subject's head. The headset will be sized to fit snuggly. Each headset is marked with a unique headset identification number. The patient-contacting components of the molded plastic form are made from a medical grade (USP Class VI), biocompatible plastic and foam."
62701041|NCT03637348|OTHER|TrueTear|Use of TrueTear device to stimulate tear production
62701042|NCT06336304||Pediatric|
61953953|NCT02579239|EXPERIMENTAL|Group A - FSHD|Participants with FSHD will receive single dose of placebo intravenous (IV) infusion followed by ATYR1940 IV infusion at doses of 0.3 up to 1.0 milligrams/kilograms (mg/kg) once weekly for 8 weeks and then twice weekly for 4 weeks using intraparticipant dose escalation for up to 12 weeks.
61953954|NCT02579239|EXPERIMENTAL|Group B - LGMD2B and FSHD|Participants with LGMD2B and FSHD will receive single dose of placebo IV infusion followed by ATYR1940 IV infusion at doses of 0.3 up to 1.0 and 3.0 mg/kg once weekly for 8 weeks and then twice weekly for 4 weeks using intraparticipant dose escalation for up to 12 weeks.
61953955|NCT02560532|EXPERIMENTAL|Clazosentan|Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days
61953956|NCT05679583|EXPERIMENTAL|Preoperative SBRT arm|Patients with resectable pancreatic cancer will receive preoperative SBRT 2 to 4 weeks before surgery. And 4 weeks after surgery, adjuvant CTx will be administered for 6 months.
61953957|NCT05198999|EXPERIMENTAL|Aqua-PLYO group|Participants in this group received the Aqua-PLYO training program
62701043|NCT06336304||Male Adult Obstructive|
62701044|NCT06336304||Male adult incontinence and/or urgency|
61953958|NCT05198999|ACTIVE_COMPARATOR|Control group|Participants in this group received the standard physical rehabilitation program
61953959|NCT03834441|OTHER|Oral screening|
61953960|NCT03834441|OTHER|Written screening|
61953961|NCT01184391|EXPERIMENTAL|Test: Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
61953962|NCT01184391|ACTIVE_COMPARATOR|Reference: Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
61953963|NCT05405374|ACTIVE_COMPARATOR|OSTEOAMP|OSTEOAMP SELECT Fibers as an autograft substitute in lumbar interbody fusion procedures
61953964|NCT05405374|ACTIVE_COMPARATOR|Infuse|The Infuse Bone Graft as an autograft substitute in lumbar interbody fusion procedures
61953965|NCT03641859|NO_INTERVENTION|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 1 (usual care): the procedure of care will be the same as usual."
61953966|NCT03641859|EXPERIMENTAL|local anesthesia + virtual reality|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 2 (intervention): local anesthesia + virtual reality"
62141921|NCT03551600||>/= 34 wk infants, no CHD|"Babies \>/= to 34 weeks gestation at birth with no evidence of ductal dependent congenital heart disease (CHD)~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
62701045|NCT06336304||Female adult obstructive|
62701046|NCT06336304||Female adult incontinence and/or urgency|
62701047|NCT06336304||Adults with neurological co-morbidities|
62701048|NCT02845882|OTHER|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
61953967|NCT01699360|EXPERIMENTAL|Cyclosporine A, Tacrolimus, Sirolimus|"Cyclosporine A：soft capsule,2-6mg/kg/d, the same twice daily dose at least five days.~Tacrolimus:capsule,0.15-0.3mg/kg/d, the same twice daily dose at least five days.~Sirolimus:tablet,2mg/d, once a day."
61953968|NCT05947045|ACTIVE_COMPARATOR|IPad Cogmed Training|The investigator will be randomizing participants to complete Cogmed training on an iPad.
61953969|NCT05947045|EXPERIMENTAL|Virtual Reality Cogmed Training|The investigator will be randomizing participants to complete Cogmed training in Virtual Reality.
62501856|NCT06551129||Mavacamten|Adult participants with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten
62501857|NCT01117844|EXPERIMENTAL|Proton radiation|
62501858|NCT06677983|EXPERIMENTAL|Bioflex|
62501859|NCT06677983|ACTIVE_COMPARATOR|SSC|
62501860|NCT00600873|EXPERIMENTAL|1|patients with early ALS
62501861|NCT06616441|ACTIVE_COMPARATOR|Grouo A|Patients that will receive intraoperative instillation of bupivacaine.
62501862|NCT06616441|NO_INTERVENTION|Group B|(Control group) that will not receive the medication.
61953970|NCT01086033||Humira|Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.
61953971|NCT00745329||2|"1. patients~2. healthy volunteers"
61953972|NCT06055101|OTHER|DEXMEDETOMIDINE|Group 1 ( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (10 μg) DXM and 0.1 ml normal saline.
61953973|NCT06055101|OTHER|Neostigmine|Group 2( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (50 μg) neostigmine and 0.1 ml normal saline.
61953974|NCT06055101|OTHER|Bupivacaine|Group 3 ( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.2 ml normal saline as control.
61953975|NCT01837433|EXPERIMENTAL|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
61953976|NCT01837433|ACTIVE_COMPARATOR|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
61953977|NCT01964833|SHAM_COMPARATOR|Periodontal treatment|Conventional periodontal treatment with hygiene orientation, calculus removal and root scaling and planing. Sham PDT.
61953978|NCT01964833|EXPERIMENTAL|Periodontal Treatment and PDT|Conventional periodontal treatment with hygiene orientation, calculus removal, root scaling and planing. Active PDT with diode laser and methylene blue photosensitizer
61953979|NCT04173559|NO_INTERVENTION|Usual care|Women randomized to this group will receive no guidance regarding exercise / activity / sleep during pregnancy.
61953980|NCT04173559|EXPERIMENTAL|Activity Intervention|Women randomized to this group will receive detailed information and reminders about physical activity and sleep in pregnancy. .
61953981|NCT05241912|NO_INTERVENTION|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
61953982|NCT05241912|EXPERIMENTAL|Goal-directed fluid group|"Intervention: administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
61953983|NCT05231057|EXPERIMENTAL|experimental group|Patients in the study group received Pilates exercises plus conventional physical therapy program
61953984|NCT05231057|EXPERIMENTAL|control group|Patients in the control group received conventional physical therapy
61953985|NCT03236285|EXPERIMENTAL|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
62501863|NCT01432028|ACTIVE_COMPARATOR|Non-oral hormone therapy|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
61953986|NCT03236285|EXPERIMENTAL|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
61953987|NCT03236285|EXPERIMENTAL|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
61953988|NCT03236285|EXPERIMENTAL|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
61953989|NCT03661671|EXPERIMENTAL|LCI+white light|Using white light firstly to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
61953990|NCT03661671|NO_INTERVENTION|White light|Using white light only.
61953991|NCT04388878|EXPERIMENTAL|PF-07054894|Participants will receive single or multiple ascending doses of oral PF-07054894
61953992|NCT04388878|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo
61953993|NCT05806073|EXPERIMENTAL|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
61953994|NCT05806073|EXPERIMENTAL|Therapeutic neck dissection|Patient underwent therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
62141922|NCT03551600||>/= 34 week infants, CHD|"Babies \>/= to 34 weeks gestation at birth with ductal dependent CHD~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
62501864|NCT01432028|ACTIVE_COMPARATOR|oral homone therapy|estradiol 1mg and drospirenone 2 mg/day
61953995|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
61953996|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
61953997|NCT02915016|EXPERIMENTAL|Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.
62141923|NCT02708394|EXPERIMENTAL|olanzapine|Atypical antipsychotic
62501865|NCT06677190|EXPERIMENTAL|Belzutifan|"15 participants will be enrolled for Stage 1 and will complete:~* Baseline in-clinic visit~* Imaging every 2 cycles~* ECG on Day 1 of each cycle~* Cycle 1 through End of Treatment:~  * Day 1 through 28 of 28 day cycle: Predetermined dose of Belzutifan 1x daily.~ * Day 15 of 28 day cycle: in-clinic visit~* Cycle 2 Day 15 of 28 day cycle: in-clinic visit~* End of treatment visit with ECG, blood tests, and imaging.~* 30 Day post-treatment visit~* Long-term follow up: every 6 months for 3 years~* If 3 or more participants have objective response OR 2 or more participants are progression-free at 6 months, the study will enroll an additional 14 participants for Stage 2. Otherwise, enrollment will stop if there are less than 3 participants with objective response AND less than 2 participants are progression-free at 6 months."
62501866|NCT06381687|EXPERIMENTAL|Experimental intervention: characteristics of the movement and music programme|A multi-component, multi-level programme (MoviMusi) will be designed and implemented in each city by the 12 ECEC centres in the intervention group. The intervention programme will start after baseline measurements and it will be implemented during 12 months. Accompanied by members of the intervention team, the educational community will be empowered to identify areas for improvement and make the necessary changes in their centres. In addition, the intervention programme will aim to address the main barriers and facilitators identified during the first year (baseline assessment) in relation to movement and music curricular practices.
62501867|NCT06381687|NO_INTERVENTION|Control group|In the three cities, 12 ECEC institutions will participate in the control group. The centres will follow their usual curricular programme and will be visited to identify the curricular movement and music practices they are implementing, to assess the quality of the school environment and to measure PA, gross and fine motor skills, and music skills at baseline and at the end of the study.
62501868|NCT03091868|EXPERIMENTAL|Group 1 (BIA 6-512 25 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
62501869|NCT03091868|EXPERIMENTAL|Group 2 (BIA 6-512 50 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
62501870|NCT03091868|EXPERIMENTAL|Group 3 (BIA 6-512 100 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
62501871|NCT03091868|EXPERIMENTAL|Group 4 (BIA 6-512 200 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
62501872|NCT01257191|EXPERIMENTAL|Carbon Black|
62501873|NCT01257191|EXPERIMENTAL|Diesel Exhaust Particles|
62501874|NCT01257191|EXPERIMENTAL|Fine Concentrated Ambient Particles|
62501875|NCT01257191|EXPERIMENTAL|Ultrafine Concentrated Ambient Particles|
62501876|NCT01257191|PLACEBO_COMPARATOR|Placebo|
62501877|NCT04641403|NO_INTERVENTION|Group 1 (Standard IV analgesia group (SA), n=40):|In this group, the block will be administered with normal saline (NS) and all port sites will be infiltrated with NS.
62501878|NCT04641403|ACTIVE_COMPARATOR|Group 2 (Local analgesia group (LA), n=40):|In this group, the block wiil be administered with NS and local anesthetic will be administered to the port sites.
62501879|NCT04641403|EXPERIMENTAL|Group 3 (two qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, right sided two-quadrant block will be performed using bupivacaine.
62501880|NCT04641403|EXPERIMENTAL|roup 4 (Four qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, bilateral four-quadrant block will be performed using bupivacaine.
62701049|NCT02845882|OTHER|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
62701050|NCT02845882|OTHER|High risk group|Failure to qualify a PR, or \>5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
61953998|NCT02915016|EXPERIMENTAL|Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
61953999|NCT02915016|EXPERIMENTAL|Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
61954000|NCT02915016|EXPERIMENTAL|Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
61954001|NCT02915016|EXPERIMENTAL|Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
62141924|NCT02708394|PLACEBO_COMPARATOR|placebo|Placebo comparator
62501881|NCT06678022|EXPERIMENTAL|Intervention Arm|Delivery of ART by fixed wing drones to landing sites
62501882|NCT06678022|ACTIVE_COMPARATOR|Control arm|Usual ART delivery to landing sites
62501883|NCT06130969|EXPERIMENTAL|Group A|Cervical Retraction exercise without diaphragmatic breathing along with baseline treatment
62501884|NCT06130969|EXPERIMENTAL|Group B|Cervical Retraction exercise with diaphragmatic breathing along with baseline treatment
62141925|NCT03881046||lung cancer|
62141926|NCT03881046||healthy control group|
62501885|NCT05747560|PLACEBO_COMPARATOR|Placebo|Participants in the Placebo will consume buckwheat at a dose of 500 mg, twice a day (morning and evening) for 6 months.
62501886|NCT05747560|ACTIVE_COMPARATOR|Astragalus extract|Participants in the Astragalus extract will take dietary supplement with astragalus extract at a dose of 450 mg, twice a day for the same duration.
62701051|NCT03615638|EXPERIMENTAL|Fall prevention group|Fall prevention program
62701052|NCT03615638|NO_INTERVENTION|Usual care group|Usual postoperative care
61954002|NCT02915016|EXPERIMENTAL|Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
62501887|NCT05747560|EXPERIMENTAL|Wolfiporia extract|Participants in the Wolfiporia extract will take dietary supplement with wolfiporia extract at a dose of 15 g, twice a day for the same duration.
62501888|NCT00877994|ACTIVE_COMPARATOR|Immediate|This group will receive the nurture group therapy immediately after enrolling in the study.
62501889|NCT00877994|ACTIVE_COMPARATOR|Delayed|This group will receive the nurture group therapy 16 weeks after enrolling in the study.
62501890|NCT02034448||Acute Kidney Injury|CRRT intervention with adult patients with Acute Kidney Injury
62501891|NCT00804999|PLACEBO_COMPARATOR|Placebo 1|Subjects that have never worn contacts with no ocular problems were selected. A baseline HRT was performed. Trial contact lenses were soaked in clear care solution for 10 hours. After 10 hours of the lenses soaking in clear care the subject returned. The contacts lenses that were soaked in clear care were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contact lenses were removed. An HRT was performed immediately after removing the contact lenses. The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
62501892|NCT00804999|ACTIVE_COMPARATOR|Renu|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in ReNu contact solution for 10 hours. After 10 hours of the lenses soaking in ReNu the subject returned. The contacts were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contacts lenses were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
62501893|NCT00804999|ACTIVE_COMPARATOR|Optifree|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
62501894|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated \~ 9 months after surgery.
62701053|NCT03615638|NO_INTERVENTION|Asymptomatic control|No intervention
62701054|NCT02116023|EXPERIMENTAL|Orange flavored beverage - Test1|240ml processed whole orange low dose
62701055|NCT02116023|EXPERIMENTAL|Orange flavored beverage - Test2|240ml processed whole orange high dose
62701056|NCT02116023|PLACEBO_COMPARATOR|Orange flavored beverage - Placebo|240ml orange beverage
62701057|NCT05880524|ACTIVE_COMPARATOR|Pulmozyme|Dornase alfa; intravenous administration; 500 µg/kg
61954003|NCT02915016|EXPERIMENTAL|Group 7: Placebo + Protein/AS01B|Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
62501895|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated \~ 9 months after surgery.
62701058|NCT05880524|PLACEBO_COMPARATOR|Isotonic Saline Solution|NaCl 0,9 %; intravenous administration; 0,5 ml/kg
62701059|NCT02755350|EXPERIMENTAL|Truvada|Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.
62701060|NCT06379100|EXPERIMENTAL|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for four weeks
62701061|NCT06379100|SHAM_COMPARATOR|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for four weeks
62701062|NCT05194995|EXPERIMENTAL|Phase 1b Dose Escalation|Dose escalation of JAB-21822 to determine maximum tolerated dose of JAB-21822 in combination with cetuximab.
62701063|NCT05194995|EXPERIMENTAL|Phase 2 Dose Expansion, Cohort 1|Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
62701064|NCT05194995|EXPERIMENTAL|Phase 2 Dose Expansion, Cohort 2|Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced small intestinal cancer and advanced appendiceal cancer.
62701065|NCT01142570|ACTIVE_COMPARATOR|Group 1|Patients will be receive caloric support as dictated by Hariss-Benedict Formula (Group 1)
62701066|NCT01142570|ACTIVE_COMPARATOR|Group 2|Patients will be receive caloric support as dictated by Indirect Calorimetry (Group 2)
61954004|NCT02915016|PLACEBO_COMPARATOR|Group 8: Placebo|Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.
61954005|NCT04159571|EXPERIMENTAL|Real TBS to the vmPFC|Ten sessions of real Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC)
61954006|NCT04159571|SHAM_COMPARATOR|Sham TBS to the vmPFC|Ten sessions of sham Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC)
62701067|NCT01142570|ACTIVE_COMPARATOR|Group 1A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the first(Group 1A)group will receive caloric support calculated by the HARISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight."
61954007|NCT02384486|EXPERIMENTAL|intervention group|"intervention group will receive the Training to Reduce Stress in Mothers of Children with (ASD)"
62701068|NCT01142570|ACTIVE_COMPARATOR|Group 2A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight."
61954008|NCT02384486|OTHER|control group|control group will receive nothing but for ethical purposes will receive the same intervention after the end of the trial for the intervention group
61954009|NCT05528185|EXPERIMENTAL|Intervention|The intervention consists of family participation in morning interdisciplinary team rounds in the cardiac ICU. Family participation will consist of orientation, engagement, summary, questions, and communication follow-up by the care team.
61954010|NCT05528185|NO_INTERVENTION|Usual care|Usual care consists of interdisciplinary team rounds that occur outside the patient's room each morning without a family member present.
61954011|NCT05846204|EXPERIMENTAL|PMR Group|"The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks. PMR exercises and training on the application of these exercises were given to the patients individually by face-to-face interview method. During the training process, Muscle Relaxation Exercises Practice Guide and Relaxation Exercises Audio Recordings, which were prepared by the researcher and included relaxation exercises, were used. Voice recordings were uploaded to each patient's mobile phone so that they could continue the application at home. The steps of the relaxation exercises were explained to the patient by the researcher and he was shown exactly how to do the exercises."
61954012|NCT05846204|EXPERIMENTAL|Deep Breath Group|WB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught. Informing and application training took an average of 20-25 minutes for each patient. The patients were told to do the 10-minute application at home 3 times a day for 8 weeks. They were called once a week and asked whether they continued the practice and whether they had any difficulties during the exercises.
62141927|NCT03667833|EXPERIMENTAL|shoulder brace with comfortable tension|"Self-comfortable tension of strap will be adjusted by subject's feedback with comfortable feeling as please feel postural correction by shoulder brace without tight pressure."
62141928|NCT03667833|EXPERIMENTAL|shoulder brace with forced tension|Forced tension, the self-comfortable tension of strap will be increased till forced tension of strap using buckles.
62701069|NCT01142570|ACTIVE_COMPARATOR|Group 3A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the third group will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight."
62501896|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
62501897|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
62501898|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated \~ 9 months after surgery.
62701070|NCT06563778|EXPERIMENTAL|Chidamide+Decitabine+ Anti-PD-1 Antibody|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance. Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Immune checkpoint inhibitors have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
62701071|NCT06563778|ACTIVE_COMPARATOR|Brentuximab Vedotin+ Bendamustine+anti-PD-1 antibody|
62701072|NCT05801887|EXPERIMENTAL|Shockwave treated group|The osteoblast like cells are treated with shockwaves
62701073|NCT05801887|PLACEBO_COMPARATOR|No shockwave group|The osteoblast like cells are not exposed to shockwaves
62701074|NCT02992730||Women Diagnosed with Breast Cancer|Observational - Usual Care
62701075|NCT00982280|EXPERIMENTAL|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
61954013|NCT05846204|NO_INTERVENTION|Control|No intervention will be applied to the control group.
61954014|NCT06271382|EXPERIMENTAL|Acupressure Group|In the research, acupressure will be applied to the patients in the acupressure group on LR 3 Taichung(LR 3), Tai Xi (KI 3), San Yin Jiao(SP 6), Xue Hai (SP 10), Zusanli(ST 36 ) points.
61954015|NCT06271382|SHAM_COMPARATOR|Sham Acupressure Group|"The same process will continue with the acupressure group by applying pressure to different points in the group where acupressure is applied to the sham points.~Pressure will be applied on the bone area where the meridians do not pass, parallel to the points where acupressure is applied to the sham points (approximately 1-1.5 cm away)."
62141929|NCT02168309|OTHER|Labetalol|Labetalol 200mg PO BID starting dose
62141930|NCT02168309|OTHER|Nifedipine|Nifedpine XL starting at dose 30mg PO daily
62141931|NCT00668798||A|mother CMV positive
62141932|NCT00668798||B|mother CMV negative
62701076|NCT01480830|NO_INTERVENTION|Standard colonoscopy|
62701077|NCT01480830|EXPERIMENTAL|Magnetic endoscopic imaging colonoscopy|
62701078|NCT04910620|PLACEBO_COMPARATOR|Placebo|Placebo without TCI378 and TCI507
62701079|NCT04910620|EXPERIMENTAL|TCI378|probiotics TCI378 (Lactobacillus plantarum TCI378)
62701080|NCT04910620|EXPERIMENTAL|TCI507|TCI507 (Lactobacillus plantarum TCI507)
62141933|NCT02767674|EXPERIMENTAL|R-GemOx|Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)
62344151|NCT02822911|OTHER|Alcohol Used Disorders Identification Test (AUDIT C)|Submission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
62344152|NCT02387619|EXPERIMENTAL|Group 1 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T during the period 1 and Rosuvastatin 20mg 1T and Telmisartan/Amlodipine 40/5mg 2T during the period 2
62344153|NCT02387619|EXPERIMENTAL|Group 2 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T during the period 2
62501899|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
62701081|NCT00149357||1, 2 ,3|Group 1 Women with unprovoked VTE and No Known Thrombophilia Group 2 Women who are investigated for VTE and are negative (Control) Group 3 Women with unprovoked VTE who have Thrombophilia
61954016|NCT06271382|EXPERIMENTAL|Foot Ankle Exercise Group|"The foot and ankle exercise complex includes the following exercises.~1. Pulling the foot towards itself from the ankle up~2. Bending the foot downwards from the ankle~3. Opening the feet like a fan, moving the toes inward and outward, left and right~4. Circling exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under your feet (The water in the bottle will be warm tap water)"
61954017|NCT03226483|EXPERIMENTAL|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
61954018|NCT04273711||Obese patients|
61954019|NCT04273711||Non-obese patients|
62344154|NCT02387619|EXPERIMENTAL|Group 1 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 2
62344155|NCT02387619|EXPERIMENTAL|Group 2 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Telmisartan/Amlodipine 40/5mg 2T during the period 2
62344156|NCT00220766|EXPERIMENTAL|Group 1|Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
62344157|NCT00220766|EXPERIMENTAL|Group 2|Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
62344158|NCT05562284|EXPERIMENTAL|IAT combined with conservative therapies|IAT (Drug: 50 mg Alteplase)+conservative treatments
62344159|NCT05562284|OTHER|Conservative therapies|conservative treatments including traditional ones and hyperbaric oxygen therapy
62344160|NCT05318105|EXPERIMENTAL|Aquadex ultrafiltration therapy|
62344161|NCT05318105|ACTIVE_COMPARATOR|IV loop diuretics|
62344162|NCT02303171|ACTIVE_COMPARATOR|Enoxaparin group|Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy
62344163|NCT02303171|ACTIVE_COMPARATOR|Warfarin group|Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester
62344164|NCT01924052|ACTIVE_COMPARATOR|Migraine patients with high genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
62344165|NCT01924052|ACTIVE_COMPARATOR|Migraine patients with low genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
62344166|NCT00835419|EXPERIMENTAL|1|P276-00 investigational product (small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor)
61954020|NCT06184386||Prospective NIDCAPARENTALIM|A group of prospectively assigned preterm newborns that will be included in NIDCAP strengthened with a practice focalized on feeding, named PARENTALIM.
61954021|NCT06184386||Retrospective SOFS|A group of retrospectively assigned preterm newborns that had standardized orofacial stimulations named SOFS.
61954022|NCT03068260|ACTIVE_COMPARATOR|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml ropivacaine 0,375% single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
61954023|NCT03068260|PLACEBO_COMPARATOR|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml saline single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
62344167|NCT02231294||Idiopathic Parkinson's Disease Patients|
62344168|NCT04674839|EXPERIMENTAL|MS-20|8 ml/day for 8 weeks
62344169|NCT04674839|OTHER|Placebo|8 ml/day for 8 weeks
62344170|NCT00253318|EXPERIMENTAL|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m\^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
62344171|NCT02930603||Control|Control: Healthy child
62344172|NCT02930603||Experimental|Patients with Developmental Disabilities
62501900|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
62501901|NCT00559026|ACTIVE_COMPARATOR|1|
62501902|NCT00559026|EXPERIMENTAL|2|
62501903|NCT01024777|ACTIVE_COMPARATOR|High dose cholecalciferol|Patients in the high dose arm will receive 10,000 international units of cholecalciferol daily.
61954024|NCT05876975|ACTIVE_COMPARATOR|procedure: laparoscopic pectopexy|MRI evaluation will be conducted on eleven participants who underwent laparoscopic pectopexy surgery after one month.
62501904|NCT01024777|ACTIVE_COMPARATOR|Low dose cholecalciferol|Patients enrolled in the low dose arm will receive up to 1000 international units of cholecalciferol daily.
62501905|NCT01898234|EXPERIMENTAL|Revaclear|
62501906|NCT01898234|EXPERIMENTAL|Helixone high flux|
62501907|NCT01898234|EXPERIMENTAL|Xevonta|
62501908|NCT01898234|EXPERIMENTAL|Helixone low flux|
62501909|NCT05132439|EXPERIMENTAL|Metformin ER 1000mg|daily by mouth
62501910|NCT05132439|PLACEBO_COMPARATOR|Matching placebo|daily by mouth
61954025|NCT05876975|NO_INTERVENTION|Nulliparous women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI
61954026|NCT03940222|EXPERIMENTAL|I-BiT group|Amblyopic patients will play I-BiT games without patching.
61954027|NCT03940222|PLACEBO_COMPARATOR|Placebo group|Amblyopic patients will patch their dominant eye and they will play placebo I-BiT games.
61954028|NCT03813069|OTHER|Laboratory study|
61954029|NCT03813069|OTHER|Field study: IR3535|
61954030|NCT03813069|OTHER|Field study: Permethrin lower dose|
62344173|NCT05657782|EXPERIMENTAL|Fixed Dose-Ranging|"The first, fixed dose-ranging module utilizes a classical 3+3 design. The name is derived from the typical cohort size at a given dose \[3\], and the typical expansion size at that dose \[3\] if 1 dose-limiting side effect is observed. This module will address the uncertainty regarding the relationship between dose and adverse events (AEs). A set of pre-specified doses (log10 values 6, 7, 8, 9, and 10) will be employed, based on animal experiments and other live OCV trials. Three participants will be administered each dose (15 participants total)."
62344174|NCT05657782|EXPERIMENTAL|Adaptive Dose-finding/Optimization|A modified continual reassessment method (CRM) adaptive design will guide the dose optimization module. CRM cohorts comprise 3 participants treated concurrently at each dose. All three subjects in each cohort will receive a single dose based on the CRM model fit to all the available dose-response data.
62344175|NCT05657782|ACTIVE_COMPARATOR|Expansion module - active product|The purpose of the expansion cohort is to gather additional clinical experience at the optimal dose of PanChol and increase the precision with which the rate of AEs is estimated. The expansion module will be randomized, double blind and placebo-controlled (20 receiving active product, 6 receiving placebo, 26 participants total).
62344176|NCT05657782|PLACEBO_COMPARATOR|Expansion module - placebo|The purpose of the expansion cohort is to gather additional clinical experience at the optimal dose of PanChol and increase the precision with which the rate of AEs is estimated. The expansion module will be randomized, double blind and placebo-controlled (20 receiving active product, 6 receiving placebo, 26 participants total).
62344177|NCT01769261|EXPERIMENTAL|Internet, eligible patients|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
62344178|NCT01769261|ACTIVE_COMPARATOR|Telephone, eligible patients|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
62344179|NCT01769261|OTHER|" Non eligible patients"|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
62344180|NCT04314596|PLACEBO_COMPARATOR|Placebo Group|Participants will engage in a one day, whole-body, cross-training course while consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
62344181|NCT04314596|EXPERIMENTAL|Experimental Group|Participants will engage in a one day, whole-body, cross-training course while consuming the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
62501911|NCT06539676|EXPERIMENTAL|Nighttime Aligners|Nighttime Aligners worn 10-12 hours per day or night
62501912|NCT06539676|ACTIVE_COMPARATOR|Daytime Aligners|Daytime aligners worn 20-22 hours day and night
62501913|NCT00623558|ACTIVE_COMPARATOR|1|Docetaxel+CDDP
62501914|NCT00623558|EXPERIMENTAL|2|Docetaxel+CDDP+Cetuximab
62501915|NCT05424380|EXPERIMENTAL|Part 1: Dose escalation|Part 1 will evaluate a dosing schedule for a total of 28 days in each cycle. The starting dose for Cycle 1 will be escalated in the next dose escalation cohort until MTD is reached.
62501916|NCT05424380|EXPERIMENTAL|Part 2: Dose expansion|Part 2 will evaluate efficacy after an induction phase. The induction phase consists of a treatment regimen at RP2D determined in Part 1.
62501917|NCT06679322|EXPERIMENTAL|Intervention Group (high-dose group)|Androtriol injection (300 mg BID)
62501918|NCT06679322|EXPERIMENTAL|Intervention Group (low-dose group)|Androtriol injection (100 mg BID)
62501919|NCT06679322|PLACEBO_COMPARATOR|Placebo|Hydroxypropyl-β-cyclodextrin injection
62501920|NCT05845372||Stress Ulcer Prophylaxis|Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.
62501921|NCT05845372||Control Group|Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.
61954031|NCT03813069|OTHER|Field study: Permethrin higher dose|
61954032|NCT03813069|NO_INTERVENTION|Field study: control arm|
61954033|NCT00799383|EXPERIMENTAL|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
61954034|NCT00799383|PLACEBO_COMPARATOR|Placebo|Placebo
61954035|NCT00334958|PLACEBO_COMPARATOR|Placebo|For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily.
61954036|NCT00334958|ACTIVE_COMPARATOR|Rufinamide|For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
61954037|NCT00356291|EXPERIMENTAL|1|Participants will receive Skill-Building and Motivational Interviewing.
61954038|NCT00356291|ACTIVE_COMPARATOR|2|Participants will receive Skill-Building.
61954039|NCT06255964|OTHER|Phase Ia study|Phase Ia study: for adults with BCG treatment failure or intolerance to BCG, high-risk non muscle invasive bladder cancerPatient, evaluate the safety and tolerability of IAP0971 monotherapy bladder infusion, and determine dose limiting toxicity and/or phase II recommended dose.
61954040|NCT06255964|EXPERIMENTAL|Phase Ib study|Phase Ib study:To evaluate the safety and tolerability of intravesical IAP0971 in combination with BCG in patients with BCG unresponsive high risk non-muscle invasive bladder cancer, and to determine the DLT and RP2D.
61954041|NCT06255964|EXPERIMENTAL|Phase II study|Phase II study:To evaluate the efficacy of intravesical IAP0971 in combination with BCG in patients with BCG unresponsive high risk NMIBC using RP2D as determined in the phase I study.
61954042|NCT02425371|EXPERIMENTAL|Intervention|screening and treatment of comorbidities
61954043|NCT02425371|PLACEBO_COMPARATOR|Control|No screening of comorbidity
61954044|NCT00674362|EXPERIMENTAL|Certolizumab pegol 200 mg (CDP870)|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
61954045|NCT00674362|PLACEBO_COMPARATOR|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
61954046|NCT04401423|EXPERIMENTAL|TXA127|Participants will receive one 3-hour dosage (0.5 mg/kg per day), intravenously, for 10 days consecutively (or until discharge if less than 10 days).
61954047|NCT04401423|PLACEBO_COMPARATOR|Placebo|Participants will receive one 3-hour dosage (0.5 mg/kg per day), intravenously, for 10 days consecutively (or until discharge if less than 10 days).
62141934|NCT02767674|ACTIVE_COMPARATOR|R-miniCHOP|Rituximab, 375 mg/m2 IV d0 Cyclophosphamide 400 mg/m2 IV d1 Epirubicin 35 mg/m2 IV d1 vindesine 2 mg IVP d1 Prednisone 40mg/m2 PO d1-5(every 21 days a cycle)
62141935|NCT02794363|OTHER|Autologous platelet rich plasma|Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms
62141936|NCT06698991|EXPERIMENTAL|Daily plasma exchange + SMT|(Maximum 3+1 sessions during a period of 7 days)
62141937|NCT06698991|ACTIVE_COMPARATOR|Alternate day therapeutic plasma exchange + SMT|Alternate day therapeutic plasma exchange + SMT
61954048|NCT01575587|EXPERIMENTAL|Treatment A|
61954049|NCT01575587|EXPERIMENTAL|Treatment B|
61954050|NCT01575587|EXPERIMENTAL|Treatment C|
61954051|NCT01575587|EXPERIMENTAL|Treatment D|
62344182|NCT05097248|EXPERIMENTAL|Camrelizumab, Liposomal doxorubicin and Losartan|Participants receive intravenous camrelizumab (200 mg, Q3W) and liposomal doxorubicin (40 mg, Q3W for 6 weeks) plus oral losartan (50 mg loading dose followed by 100 mg QD, Q3W, until discontinuation of liposomal doxorubicin).
62344183|NCT02421744|EXPERIMENTAL|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
62344184|NCT02421744|ACTIVE_COMPARATOR|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
61954052|NCT00917397|EXPERIMENTAL|psychotherapy|Trauma-focused cognitive behavioral therapy
61954053|NCT00917397|EXPERIMENTAL|Drug|drug treatment and psychoeducation
61954054|NCT00917397|NO_INTERVENTION|Waiting list|subjects randomized to waiting list
61954055|NCT00917397|EXPERIMENTAL|Combination|Both drug and psychotherapy
61954056|NCT04912193||antithrombin III < 50 %|preoperative antithrombin III levels \<50%
61954057|NCT04912193||Antithrombin III ≥ 50 %|preoperative antithrombin III levels ≥ 50 %
61954058|NCT06032468|EXPERIMENTAL|Rehabilitation with ARC Intellicare Device|rehabilitation exercise for 8 weeks using wearable devices
61954059|NCT06032468|ACTIVE_COMPARATOR|Rehabilitation with exercise sheet|rehabilitation exercise for 8 weeks using rehabilitation exercise sheets
61954060|NCT06438068|EXPERIMENTAL|Modern Colon Hydrotherapy plus probiotic product intake|Colonic cleansing through 3 interventions of Modern Colon Hydrotherapy. In addition, a daily intake of a product with prebiotic and prebiotic properties for 30 days.
61954061|NCT06438068|ACTIVE_COMPARATOR|Modern Colon Hydrotherapy plus placebo intake|Colonic cleansing through 3 interventions of Modern Colon Hydrotherapy. In addition, a daily intake of a placebo for 30 days.
62141938|NCT00824408|EXPERIMENTAL|BI 6727 +pemetrexed|BI 6727 plus 500 mg/\^m2 pemetrexed i.v. on day 1 of 21 day cycle
62141939|NCT00824408|ACTIVE_COMPARATOR|pemetrexed|500 mg/m\^2 i.v. on day 1 of a 21 day cycle
62141940|NCT06509165||Modified coronally advanced flap technique|Patients using a modified coronally placed flap technique to cover gingival recession
62141941|NCT06509165||Tunnel technique|Patients using the tunnel technique to cover gingival recession
61954062|NCT02981264|ACTIVE_COMPARATOR|Transcricoid|Lignocaine delivery using transcricoid injection
61954063|NCT02981264|ACTIVE_COMPARATOR|Spray as You go|Lignocaine delivery using spray as you go method
62701082|NCT05828108|EXPERIMENTAL|Experimental -Bitopertin|Bitopertin, up to a maximum dose of 60 mg (5 mg, 10mg, 20mg, 40mg, 60mg)
62701083|NCT06472856|EXPERIMENTAL|Acupuncture|
61954064|NCT00145522|EXPERIMENTAL|1|
61954065|NCT00145522|ACTIVE_COMPARATOR|2|
62701084|NCT03134209|EXPERIMENTAL|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
62701085|NCT03134209|ACTIVE_COMPARATOR|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
62701086|NCT03134209|ACTIVE_COMPARATOR|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
62701087|NCT06564545|EXPERIMENTAL|TMLI conditioning group|Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI) plus Cyclophosphamide
62701088|NCT06564545|ACTIVE_COMPARATOR|TBI conditioning group|Total Body Irradiation (TBI) plus Cyclophosphamide
62701089|NCT05903235|EXPERIMENTAL|Virtual Reality-based Mirror Therapy (VR+MT)|In each therapy session, the patients will execute 2 upper-limb functional tasks, starting with easy then more complex tasks.
61954066|NCT01332903|EXPERIMENTAL|1|\[14C\] AZD5069
61954067|NCT05087459||patients with primary hepatocellular carcinoma undergoing elective hepatectomy|The baseline platelet count before enrollment was \< 75×10\^9/L and \> 30×10\^9/L.The primary clinical diagnosis of hepatocellular carcinoma was confirmed, and the CNLC stages were Ia and Ib.An elective hepatectomy, including laparotomy or laparoscopic hepatectomy, except hepatectomy combined with splenectomy or radiofrequency ablation.
61954068|NCT05856071|EXPERIMENTAL|clamshells exercises|
61954069|NCT05856071|ACTIVE_COMPARATOR|traditional physical therapy|
61954070|NCT04937764||Study population|Population who underwent a surgical arthrodesis procedure for arthritic or inflammatory involvement of the Lisfranc tarsometatarsal joint
61954071|NCT02023606|EXPERIMENTAL|SPN-810M|Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) \[14C\] SPN-810M.
61954072|NCT06241508|EXPERIMENTAL|Low-intensity priming intermittent theta burst stimulation|"Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability.~In the present study, real stimulation will be delivered in an intensity of 55% (low-intensity) or 70% (conventional intensity) individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% (ineffective) individual resting motor threshold.~Low-intensity priming intermittent theta burst stimulation will use a session of 55% RMT cTBS followed by a session of 70% RMT iTBS. Both sessions will be applied to the ipsilesional primary motor cortex."
61954073|NCT06241508|EXPERIMENTAL|Conventional intensity priming intermittent theta burst stimulation|"Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability.~In the present study, real stimulation will be delivered in an intensity of 55% (low-intensity) or 70% (conventional intensity) individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% (ineffective) individual resting motor threshold.~Conventional intensity priming intermittent theta burst stimulation will use a session of 70% RMT cTBS followed by a session of 70% RMT iTBS. Both sessions will be applied to the ipsilesional primary motor cortex."
62344185|NCT04831515|EXPERIMENTAL|Lens A|"daily disposable soft contact lens - test lens~Subjects will be randomized to wear test lenses for one week and then cross-over to control lenses for one week."
62344186|NCT04831515|ACTIVE_COMPARATOR|Lens B|"daily disposable soft contact lens - control lens~Subjects will be randomized to wear control lenses for one week and then cross-over to test lenses for one week."
62501922|NCT03039036|EXPERIMENTAL|Early Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy within 1 hour of Foley catheter removal.
62701090|NCT05903235|EXPERIMENTAL|Mixed Reality-based Mirror Therapy (MR+MT)|The patients will execute 2 upper-limb functional tasks in each session.
62701091|NCT05903235|ACTIVE_COMPARATOR|Traditional Mirror Therapy (MT)|The patients will execute 2 to 3 categories of activities per training session: (1) active range of motion exercises, (2) reaching movement or object manipulation, and (3) upper-limb functional tasks.
62701092|NCT01965847|ACTIVE_COMPARATOR|AM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to MORNING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
62701093|NCT01965847|EXPERIMENTAL|PM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to EVENING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
62701094|NCT03544463|EXPERIMENTAL|Treated|iNAP® Sleep Therapy System Treatment Intervention
62701095|NCT03544463|NO_INTERVENTION|Baseline/Control|Self-controlled, pre-treatment baseline condition
62701096|NCT06251115|EXPERIMENTAL|QY-1-T|"Each patient will undergo a core study of approximately 1 year after enrollment: including screening period, apheresis, first treatment cycle (induction phase), observation period, second treatment cycle (maintenance phase), and routine follow-up period.~The first treatment cycle (induction period): It is planned to use 4 induction doses of 1×10\^4 cells/Kg, 1×10\^5 cells/Kg, 1×10\^6 cells/Kg, 5×10\^6 cells/Kg or 10×10\^6 cells/Kg respectively on day 1 ( C1D1), day 8 (C1D8), day 15 (C1D15) and day 22 (C1D22) received stepped dosing of QY-1-T. A 30-day medical observation will be conducted after the first treatment cycle, followed by the second treatment cycle.~Second treatment cycle: The dose is 5×10\^6 cells/Kg or 10×10\^6 cells/Kg. TCR-T was infused once a week, that is, QY-1-T administration was performed on day 1 (C2D1), day 8 (C2D8), day 15 (C2D15), and day 22 (C2D22)."
62701097|NCT04411992|EXPERIMENTAL|Allocated to Vibration intervention (1) A|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
61954074|NCT06241508|ACTIVE_COMPARATOR|Standard, nonpriming intermittent theta burst stimulation|"Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability.~In the present study, real stimulation will be delivered in an intensity of 55% (low-intensity) or 70% (conventional intensity) individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% (ineffective) individual resting motor threshold.~Nonpriming priming intermittent theta burst stimulation will use a session of 20% RMT cTBS followed by a session of 70% RMT iTBS. Both sessions will be applied to the ipsilesional primary motor cortex."
61954075|NCT03802760||TAVI patients|Patients undergoing transfemoral TAVI
61954076|NCT03802760||MitraClip patients|Patients undergoing MitraClip implantation
61954077|NCT03802760||TricuspidalClip|Patients undergoing TricuspidalClip implantation
62701098|NCT04411992|NO_INTERVENTION|Allocated to Control intervention (1) B|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
62701099|NCT04411992|EXPERIMENTAL|Allocated to Vibration intervention (2) B|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
62701100|NCT04411992|NO_INTERVENTION|Allocated to Control intervention (1) A|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
62701101|NCT04862780|EXPERIMENTAL|Part 1A: BLU-945 as monotherapy|Phase 1 dose escalation of BLU-945 as monotherapy at various dose levels
62701102|NCT04862780|EXPERIMENTAL|Part 1B: BLU-945 with osimertinib|Phase 1 dose escalation of BLU-945 in combination with osimertinib 80 mg tablets for oral administration
62701103|NCT04862780|EXPERIMENTAL|Phase 2, Group 1: BLU-945 as monotherapy|Phase 2 expansion group for BLU-945 as monotherapy at a dose determined during Part 1A in patients with EGFR T790M and C797S mutations
62701104|NCT04862780|EXPERIMENTAL|Phase 2, Group 2: BLU-945 as monotherapy|Phase 2 expansion group for BLU-945 as monotherapy at a dose determined during Part 1A in patients with EGFR T790M mutations
62701105|NCT04862780|EXPERIMENTAL|Phase 2, Group 3: BLU-945 as monotherapy|Phase 2 expansion group for BLU-945 as monotherapy at a dose determined during Part 1A in patients with EGFR C797S mutations
62701106|NCT04862780|EXPERIMENTAL|Phase 2, Group 4: BLU-945 with osimertinib|Phase 2 expansion group for BLU-945 with osimertinib at a dose determined during Part 1B in patients
62701107|NCT00103844|EXPERIMENTAL|1|Active Comparator
62701108|NCT00103844|EXPERIMENTAL|2|Active Comparator
62701109|NCT04339062|EXPERIMENTAL|Cohort 1 Cemiplimab|"Participants who received allogeneic hematopoietic stem cell transplant~-- Cemiplimab: via IV, flat predetermined dosage every 21 days"
62701110|NCT04339062|EXPERIMENTAL|Cohort 2 Cemiplimab + Everolimus/Sirolimus + Prednisone|"Participants who received a kidney transplant will receive~* Cemiplimab via IV, flat predetermined dosage every 21 days~* Everolimus or Sirolimus-least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab~* Prednisone 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapering doses while receiving Cemiplimab"
62701111|NCT02248571|EXPERIMENTAL|Arm A|"Bevacizumab plus Capecitabine (1st treatment phase) followed by Everolimus plus Exemestane (2nd treatment phase)~Dosing (treatment cycle: 21days):~1. Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~2. Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
61954078|NCT01066208||WG classification|Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
61954079|NCT01066208||MPA classification|Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
61954080|NCT01066208||CSS classification|Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
61954081|NCT01066208||PAN classification|Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
62701112|NCT02248571|EXPERIMENTAL|Arm B|"Everolimus plus Exemestane (1st treatment phase) followed by Bevacizumab plus Capecitabine (2nd treatment phase)~Dosing (treatment cycle: 21days):~1. Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~2. Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
62701113|NCT06418282|EXPERIMENTAL|Dayspring, Non-Pneumatic Active Compression Device (NPCD)|The Dayspring, an Non-Pneumatic Active Compression Device (NPCD) Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
62701114|NCT00552136|ACTIVE_COMPARATOR|Ankle Arthroplasty|
62701115|NCT00552136|ACTIVE_COMPARATOR|Ankle Artrodeses|
62501923|NCT03039036|ACTIVE_COMPARATOR|Delayed Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy no sooner than 4 hours following removal of Foley catheter.
62501924|NCT03446599|EXPERIMENTAL|Hydroxocobalamin|Participants in this arm will receive one intravenous 5-gram dose of hydroxocobalamin reconstituted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
62701116|NCT06186310|ACTIVE_COMPARATOR|Aquatic Therapy Group|in addition to the home programme exercises, aquatic exercises will be performed with a physiotherapist
61954082|NCT01066208||Control Classification|For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
61954083|NCT01066208||WG diagnostic|Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
61954084|NCT01066208||MPA diagnostic|Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
62701117|NCT06186310|ACTIVE_COMPARATOR|Conventional Physical Therapy Group|Personalized exercises in the form of a home program will be demonstrated by the physiotherapist
62701118|NCT03318094|PLACEBO_COMPARATOR|Intact Day|Saline
62701119|NCT03318094|EXPERIMENTAL|Blocked Day|Phentolamine
62701120|NCT03318094|ACTIVE_COMPARATOR|Vasodilator Comparison|Sodium Nitroprusside
62701121|NCT02656056|EXPERIMENTAL|Lean Adults|Adults with a BMI between 21-25 will consume 8 oz of the fermented soybean beverage, twice daily.
62701122|NCT02656056|EXPERIMENTAL|Obese Adults|Adults with a BMI between 32-37 will consume 8 oz of the fermented soybean beverage, twice daily.
62701123|NCT04431063|EXPERIMENTAL|Sutured Stump|The group consist of subject with distal stump suturing of perobeus longus agains peroneus brevis in ACL Reconstruction Case
62701124|NCT04431063|NO_INTERVENTION|Unsutured Stump|The group consist of subject without distal stump suturing of peroneus longus agains peroneus brevis in ACL Reconstruction Case
62701125|NCT03132467|EXPERIMENTAL|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.
62701126|NCT01427673|ACTIVE_COMPARATOR|CPAP Procedure control group|Overlap patients randomly assigned to the CPAP titrated per AASM guidelines.
61954085|NCT01066208||CSS diagnostic|Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
62501925|NCT03446599|EXPERIMENTAL|Methyelene blue|Participants in this arm will receive one intravenous 2mg/kg dose of methylene blue diluted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
62701127|NCT01427673|EXPERIMENTAL|Bipap procedure group|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
61954086|NCT01066208||PAN diagnostic|Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
61954087|NCT01066208||Control diagnostic|Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
61954088|NCT01066208||GCA classification|Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
62501926|NCT03446599|PLACEBO_COMPARATOR|Normal saline|Participants in this arm will receive an intravenous administration of 200ml normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
62501927|NCT06676449|EXPERIMENTAL|Immunotherapy plus TDLN-sparing RT and Chemotherapy|"PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.~Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.~TDLN-sparing radiotherapy 50.4Gy/28Fx."
62701128|NCT00741728||general population|Observational study of 10000 adult men and women from the general population who benefited from a free extensive health check up in Paris, France
62701129|NCT02169596|OTHER|Coronary Artery Disease|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
61954089|NCT01066208||TAK classification|Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
61954090|NCT01066208||GCA diagnostic|Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
62701130|NCT02169596|OTHER|Healthy Normals|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
62701131|NCT06291779||Pancreatic cancer group|scheduled for curative surgery for pancreatic cancer
62701132|NCT06291779||Control group|group included healthy individuals as well as patients with benign diseases
62701133|NCT01992757||Cardiac surgery with cardiopulmary bypass|
62701134|NCT02567903|ACTIVE_COMPARATOR|No Tourniquet|Knee arthroscopy without the use of a thigh tourniquet.
62701135|NCT02567903|EXPERIMENTAL|Tourniquet|Knee arthroscopy with the use of a thigh tourniquet.
62701136|NCT03518151|EXPERIMENTAL|Intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section at store entrance; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
62701137|NCT03518151|SHAM_COMPARATOR|Control|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
61954091|NCT01066208||TAK diagnostic|Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
61954092|NCT01780077|EXPERIMENTAL|RXI-109|
61954093|NCT01780077|PLACEBO_COMPARATOR|Placebo|
61954094|NCT01815801|EXPERIMENTAL|Ventilated group|Lungs were mechanically ventilated during subclavian vein catheterization.
61954095|NCT01815801|ACTIVE_COMPARATOR|Control group|Lungs were not mechanically ventilated during subclavian vein catheterization.
61954096|NCT02805010|EXPERIMENTAL|Subcutaneous(SC) Abatacept|
61954097|NCT02805010|PLACEBO_COMPARATOR|Placebo|
62501928|NCT06676449|ACTIVE_COMPARATOR|TDLN-sparing RT and Chemotherapy|"Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.~TDLN-sparing radiotherapy 50.4Gy/28Fx."
62701138|NCT00573768|ACTIVE_COMPARATOR|1|
62701139|NCT00573768|PLACEBO_COMPARATOR|2|
62701140|NCT00573768|ACTIVE_COMPARATOR|3|
62701141|NCT05840302|EXPERIMENTAL|Pain Neuroscience Education|The Pain Neuroscience Education program takes place over ten days consisting of providing knowledge about the neurophysiology and central processes of pain (nociceptive pathways, inhibitory circuits, peripheral and central sensitization, nervous system plasticity) as well as psychosocial factors and beliefs contributing to chronic pain. Workshops will use experimental data from neuroscience, but also analogies, brainstorming or games. Questions are proposed to the patient at the end of each theme.
61954098|NCT03758066|OTHER|PlusCare|Patients and case managers who work with them will be given access to a web-/mobile-based application, PlusCare, to support various case management activities for one year.
61954099|NCT01669226|EXPERIMENTAL|Regimen B, PEip and TCiv therapy|Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
61954100|NCT01669226|ACTIVE_COMPARATOR|Regimen A: Standard TCiv therapy|IV paclitaxel plus carboplatin or docetaxel plus carboplatin
61954101|NCT04152473|EXPERIMENTAL|Proglumide|Open labelled proglumide treated
61954102|NCT00548223|EXPERIMENTAL|Dengzhan Shengmai capsule|Dengzhan Shengmai capsule 0.18g by mouth twice a day for 1year
61954103|NCT00548223|PLACEBO_COMPARATOR|Placebo|Placebo 0.18g by mouth twice a day for 1year
61954104|NCT05269823|ACTIVE_COMPARATOR|Ice-therapy|Ice therapy will be provided prior to the provision of the intravitreal injection
61954105|NCT05269823|PLACEBO_COMPARATOR|No Ice-therapy|No ice therapy will be provided prior to the provision of the intravitreal injection
61954106|NCT05274061|EXPERIMENTAL|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy (AIM-CBCT for PTSD)|This is a single-arm study in which each couple will receive AIM-CBCT. The intervention is described in the section below.
61954107|NCT00785265|EXPERIMENTAL|Group Based|60-minute group session involving other study patients who have been assigned to this condition and their guests.
61954108|NCT00785265|ACTIVE_COMPARATOR|Home-Based|60-minute educational intervention in their home, which will be delivered by an African American health educator.
61954109|NCT00785265|NO_INTERVENTION|Standard Care|60-minute individual session with an African American health educator.
62501929|NCT05805813|EXPERIMENTAL|Group A|group A carry on continuous ambulatory peritoneal dialysis (the original dialysis method) for 1 month, and then changed to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month
62701142|NCT05840302|ACTIVE_COMPARATOR|Back School|The Back School program takes place over ten days. It begins with a presentation of spinal economy, which consists of promoting the protection of the back. Then, the anatomy and biomechanics of the spine as well as the most common spinal pathologies are presented. On this biomechanical basis, the other sessions consist in indicating the gestures and postures to adopt, always according to the protection policy, in different situations. These different sessions alternate between theory and practical exercises.
62701143|NCT01538199|EXPERIMENTAL|TLT Treatment Group 1|The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
62701144|NCT01538199|SHAM_COMPARATOR|TLT Treatment Group 2|The sham group will receive 2 treatments of the sham device per week for 8 weeks
62701145|NCT02010502|ACTIVE_COMPARATOR|Concentrated Beet Root Juice|500ml per day for 6 days
62701146|NCT02010502|ACTIVE_COMPARATOR|Beet root powder|500ml per day for 6 days
62701147|NCT02010502|PLACEBO_COMPARATOR|Placebo juice|Negligible nitrate
61954110|NCT03690531||Take Pause Virtual Reality Head Set|The mbVR intervention arm will be a Take-Pause virtual reality simulation will be for 5 minutes shown through a virtual reality goggle, headset and iPhone.
62701148|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
62701149|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
62701150|NCT05132491|EXPERIMENTAL|Online Training Program|An online intervention for people with disabilities intended to increase social skills and interest in coding careers.
62701151|NCT01930448||gastric bypass|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
62701152|NCT01930448||gastric banding|surgical group of obese patients with type 2 diabetes undergoing gastric banding
61954111|NCT03690531||Passive Distraction Group_IPAD|The Passive Distraction group will utilize the standard or passive distraction technique of using an IPAD lasting 5 minutes.
61954112|NCT06293222||Participants with personal experience of sickle cell disorder.|Participants with personal experience of sickle cell disorder (parents, affected children or siblings).
62344187|NCT01315847|EXPERIMENTAL|Healthy Participants (Part I)|Baseline PET imaging of the brain using \[11C\]MK-4232 tracer (\~300 megabecquerel \[MBq\]) was performed in healthy participants; this PET data served as the baseline for both Period 1 and 2 of Part I. Subsequently in study Part I, Period 1 the healthy participants received a single 1120 mg dose of telcagepant followed by PET imaging of brain with \[11C\]MK-4232 tracer (\~300 MBq) beginning \~3 hours post telcagepant dose. In Part I, Period 2 the healthy participants received a single 140 mg dose of telcagepant followed by PET imaging of brain with \[11C\]MK-4232 tracer (\~300 MBq) beginning \~2 hours post telcagepant dose. Interval between Part I Period 1 and 2 was to be at least 1 week.
62501930|NCT05805813|EXPERIMENTAL|Group B|Group B carry on intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month, and then change to continuous ambulatory peritoneal dialysis (original dialysis method) for 1 month.
62344188|NCT01315847|EXPERIMENTAL|Participants with Migraine (Part III)|In study Part III, Period 1 baseline PET imaging of the brain using \[11C\]MK-4232 tracer (\~300 MBq) was performed in participants with migraine during a migraine attack (ictal phase). Later in Part III, Period 1 the participants with an ongoing migraine attack (ictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with \[11C\]MK-4232 tracer (\~300 MBq) beginning \~2 hours post telcagepant dose. In Part III, Period 2 baseline PET imaging of the brain using \[11C\]MK-4232 tracer (\~300 MBq) was performed in participants with migraine, however, without a migraine attack ongoing (interictal phase). Later in Part III, Period 2 participants with migraine without a migraine attack ongoing (interictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with \[11C\]MK-4232 tracer (\~300 MBq) beginning \~2 hours post telcagepant dose. Interval between Part III Period 1 and 2 was to be at least 1 week.
62344189|NCT03077763|ACTIVE_COMPARATOR|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
62344190|NCT03077763|ACTIVE_COMPARATOR|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
62344191|NCT01277562||Breast Cancer|Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
62344192|NCT01277562||Prostate Cancer|Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
62344193|NCT00868452|EXPERIMENTAL|Lurasidone|
62344194|NCT00868452|PLACEBO_COMPARATOR|Placebo|
62344195|NCT01295580|ACTIVE_COMPARATOR|ARTZ sodium hyaluronate|The comparator product, ARTZ, is manufactured by Seikagaku Corporation, Japan. Subjects randomized to the ARTZ group were administered five weekly intra-articular injections (2.5 ml, NASHA 25 mg). ARTZ is a sterile, viscoelastic nonpyrogenic solution of purified, high molecular weight (620,000-1,170,000 daltons) sodium hyaluronate having a pH of 6.8-7.8. The sodium hyaluronate is extracted from chicken combs.
62344196|NCT01295580|ACTIVE_COMPARATOR|DUROLANE hyaluronic acid|The investigational product was provided in pre-filled syringes containing stabilized non-animal hyaluronic acid (20 mg/mL). Only one injection was given for those subjects randomized to the DUROLANE group, followed by 4 sham injections. DUROLANE is free from products of animal origin and is manufactured by Q-Med AB Corporation.The sham injection procedure was same as the active injection, except that they were subcutaneous and an empty syringe was used.
61954113|NCT06293222||Researchers|Researchers working with children with life limiting or life changing conditions
62344197|NCT04694105|ACTIVE_COMPARATOR|dexmedetomidine|Bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
62344198|NCT04694105|ACTIVE_COMPARATOR|dexamethasone|Bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml)
61954114|NCT06293222||Members of a patient advocacy organisation|Members of a patient advocacy organisation (Sickle Cell Society)
61954115|NCT02027883|ACTIVE_COMPARATOR|Nominal Parameter|Nominal T shock setting
61954116|NCT02027883|EXPERIMENTAL|Experimental Parameter|Educated T shock setting
61954117|NCT02326532|EXPERIMENTAL|PRO data utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm and provided to the treating physicians.
61954118|NCT02326532|SHAM_COMPARATOR|PRO data not utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm but will not be provided to the treating physicians.
61954119|NCT03705520||Cross-Sectional|This cohort is composed of only medicated PD subjects and their spouse or 1st degree relative.
61954120|NCT03705520||Logitundinal|This cohort is composed of only non-medicated PD subjects and their spouse or first degree relative.
61954121|NCT05667844|EXPERIMENTAL|mind-body intervention|
61954122|NCT01926236|ACTIVE_COMPARATOR|Arm A: Active symptom control (ASC)|Active Symptom Control
62344199|NCT04694105|PLACEBO_COMPARATOR|control group|Bupivacaine 30 ml 0.25% was combined with 2 ml normal saline
62501931|NCT05597839|EXPERIMENTAL|Monotherapy DF9001 Dose Escalation|Dose escalation cohorts of DF9001 in sequential ascending order.
62501932|NCT05597839|EXPERIMENTAL|Monotherapy DF9001 Expansion in Head and Neck Squamous Cell Carcinoma|Monotherapy expansion cohort enrolling up to 20-40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 1b dose (REED) identified in the Monotherapy Dose Escalation arm.
61954123|NCT01926236|EXPERIMENTAL|Arm B: ASC with OxMdG chemotherapy|Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid \& 5FU)
61954124|NCT05738603|NO_INTERVENTION|Standard Therapy Group|The standard therapy group patients will have invasive blood pressure monitoring + standard medical therapy. The therapeutic decision regarding treatment of hypotension, the use of fluids and vasopressors will be determined by the anaesthesia team. The decisions will be based on the information from the standard invasive blood pressure monitoring.
61954125|NCT05738603|EXPERIMENTAL|Hypotension Prediction Index Group|The HPI-group will have the HPI based monitoring with the Acumen IQ sensor (Edwards Lifesciences) and the HPI algorithm connected also to the HemoSphere platform (Edwards Lifesciences). The hemodynamic management will be based on the HPI indications and the specific algorithm, which considers hypovolemia, impaired contractility and vasodilatation. An alert pops up on the monitor screen when the HPI values exceeds 85 and then the clinician needs to make therapeutic decision in order to avoid the hypotensive episode.
62501933|NCT05597839|EXPERIMENTAL|Monotherapy DF9001 Expansion in Non-small Cell Lung Cancer|Monotherapy expansion cohort enrolling up to 20-40 patients with Non-small cell lung cancer (NSCLC) using the recommended phase 1b dose (REED) identified in the Monotherapy Dose Escalation arm.
62501934|NCT05597839|EXPERIMENTAL|Combination Expansion of DF9001 and pembrolizumab in Head and Neck Squamous Cell Carcinoma|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling 20-40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 1b dose (REED) identified in the Monotherapy Dose Escalation arm.
62501935|NCT05597839|EXPERIMENTAL|Combination Expansion of DF9001 and pembrolizumab in Renal Cell Carcinoma|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling 20-40 patients with renal cell carcinoma (RCC) using the recommended phase 1b dose (REED) identified in the Monotherapy Dose Escalation arm.
62501936|NCT05597839|EXPERIMENTAL|Monotherapy DF9001 Expansion in Renal Cell Carcinoma|Monotherapy expansion cohort enrolling up to 20-40 patients with renal cell carcinoma (RCC) using the recommended phase 1b dose (REED) identified in the Monotherapy Dose Escalation arm.
61954126|NCT06492967|EXPERIMENTAL|Systematic Lifestyle Intervention|Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.
61954127|NCT06492967|EXPERIMENTAL|Flexible Lifestyle Intervention|Lifestyle modification program that is developed by the participant to meet his/her specific needs.
61954128|NCT00816595|EXPERIMENTAL|Arm A: Pentostatin, Cyclophosphamide, Rituximab, and Avastin|Patients receive 15 mg/kg bevacizumab IV over 30-90 minutes on day 1 of courses 1-5 and on days 1, 22, and 43 of course 6; 375 mg/m\^2 rituximab IV over 2-4 hours on days 2 and 3 of course 1 and on day 1 of courses 2-6; and 2 mg/m\^3 pentostatin IV over 30 minutes and 600 mg/m\^2 cyclophosphamide IV over 30 minutes on day 2 of course 1 and on day 1 of courses 2-6. Patients also receive 6 mg pegfilgrastim subcutaneously (SC) on day 3 of course 1 and on day 2 of courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62501937|NCT02923063|EXPERIMENTAL|Combined Aerobic and Resistance Exercise|Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Each session will start at 30 minutes in duration and include either high-intensity interval targeting a relative perceived exertion (RPE) of greater than 14 (on a scale of 6-20) or strength training (RPE 12-14) or power walking (RPE 12-14). Each 1 week of supervised sessions will alternate with 1 week of self-directed sessions with mid-week trainer check-in.
62501938|NCT02923063|NO_INTERVENTION|Usual Care|"The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a Go4Life Workout to go sample exercise routing created by the national institutes on aging (NIA)."
62344200|NCT01028833|EXPERIMENTAL|Power mobility|Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
62344201|NCT01028833|NO_INTERVENTION|Control|Children in the control group will not receive any additional intervention, but will continue to receive the early intervention or other services they were receiving prior to enrollment in this study.
62344202|NCT01404442|ACTIVE_COMPARATOR|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
62344203|NCT01404442|ACTIVE_COMPARATOR|midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
62344204|NCT01404442|PLACEBO_COMPARATOR|placebo|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
62344205|NCT02345824|EXPERIMENTAL|Ribociclib (LEE011) Treatment|Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
62344206|NCT04260828|ACTIVE_COMPARATOR|Aspirin|
62344207|NCT04260828|PLACEBO_COMPARATOR|Placebo (sugar pill)|
62344208|NCT03448861|EXPERIMENTAL|Polso Wearable watch|Polso Wearable watch for the purpose of NEWS measurement
62344209|NCT04417504|EXPERIMENTAL|MobFood breakfast kit|
62501939|NCT01077258||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
62501940|NCT01504711|EXPERIMENTAL|Treatment (nausea and vomiting prophylaxis)|Receive fosaprepitant dimeglumine IV 30 mins. prior to FOLFIRINOX chemotherapy.
62344210|NCT04417504|EXPERIMENTAL|Control isocaloric breakfast|
62344211|NCT03539861|OTHER|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:~Treatment 1 will be standard hemodialysis (no device).~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
62501941|NCT03537911|EXPERIMENTAL|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
62501942|NCT00793234|EXPERIMENTAL|1|0.3 mg/kg TB-402
61954129|NCT00816595|EXPERIMENTAL|Arm B: Pentostatin, Cyclophosphamide, and Rituximab|Patients receive 100 mg rituximab IV over 2-4 hours on day 1 and 375 mg/m\^2 on day 2 of course 1 and 375 mg/m\^2 on day 1 of courses 2-6. They receive 2 mg/m\^2 pentostatin IV over 30 minutes and 600 mg/m\^2 cyclophosphamide IV over 30 minutes on day 1. Patients also receive 6 mg pegfilgrastim SC on day 2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62141942|NCT04789759|EXPERIMENTAL|Socket Preservation Alloplastic Material|"10 Consecutive Patients with hopeless teeth and 1/3 or more buccal bone resorption will be placed in a therapy go bone regeneration called socket preservation technique.~The surgery will include placement of 2/3 biphasic calcium sulfate cement matrix's with hydroxyapatite (HA granules) to fill the alveolar defects, and place a resorbable membrane sutured to adjacent tissue, to avoid material leakage.~No flap retraction. 3 Month later an implant will be placed, and a bone biopsy of the healed socket harvested. 2 Month later a final Zirconia ceramic crown screw retained to the osseointegrated implant.~Primary (T0) and Secondary (T1) stability measured with ISQ values.~Intraoral Scanner and an STL File will be taken at T0 , T1 and T2 for volumetric alteration evaluation."
62344212|NCT01999946|EXPERIMENTAL|Extended-Release Naltrexone (XR-NTX)|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
62344213|NCT01999946|NO_INTERVENTION|Enhanced Treatment As Usual (ETAU)|Enhanced Treatment As Usual arm will not receive any study medication, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment, including agonist maintenance (methadone and buprenorphine programs), drug-free outpatient and 12-step resources, and residential treatment including supportive housing programs will be provided. These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards.
62344214|NCT01999946|NO_INTERVENTION|Methadone Treatment Program (MTP)|Quasi-Experimental cohort, will be participants recruited from NYC Rikers Island jail's Key Extended Entry Program (KEEP)'s jail methadone maintenance program, they will not receive any intervention from study, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment.These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards. MTP participants are new KEEP methadone participants not enrolled in community methadone at the time of arrest.
62344215|NCT05072717|EXPERIMENTAL|Patients with a meniscal tear requiring surgery|Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an arthroscopic imaging system.
62344216|NCT02445599|EXPERIMENTAL|Diclofenac group|"Diclofenac 100 mg tablet were administered orally and Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication, 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
62344217|NCT02445599|EXPERIMENTAL|Control group|"Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
62344218|NCT04865250|EXPERIMENTAL|treatment|ATEZOLIZUMAB; Carboplatin; Nab-Paclitaxel
62344219|NCT01286948|ACTIVE_COMPARATOR|Levonorgestrel (LNG) gel (Levogel)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
62501943|NCT00793234|EXPERIMENTAL|2|0.6 mg/kg TB-402
62501944|NCT00793234|EXPERIMENTAL|3|1.2 mg/kg TB-402
62501945|NCT00793234|ACTIVE_COMPARATOR|4|
62501946|NCT00152516|EXPERIMENTAL|Levetiracetam|
62501947|NCT06679049|EXPERIMENTAL|Micromotion Cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal tibial interlocking screw
62501948|NCT06679049|EXPERIMENTAL|Standard Cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal interlocking screw
62701153|NCT06565312|EXPERIMENTAL|Flora Power Probiotic Vaginal Suppository|Participants will use the Flora Power suppository once daily at bedtime for 5 consecutive days when they feel they are experiencing any of the common signs of vaginal imbalance like vaginal malodor, vaginal irritation, and/or vaginal itching.
61954130|NCT05923983|EXPERIMENTAL|Intervention Group|
62501949|NCT00527917|EXPERIMENTAL|Uracyst|Sodium chondroitin sulfate
62501950|NCT00527917|PLACEBO_COMPARATOR|Placebo|placebo
62501951|NCT03011879||1.STEMI patients with symptom onset within 30 days|First round enrollment of STEMI patients with symptom onset within 30 days
62501952|NCT03011879||2.STEMI patients with symptom onset within 30 days|Second round enrollment of STEMI patients with symptom onset within 30 days
62501953|NCT03011879||3.STEMI patients with symptom onset within 30 days|Third round enrollment of STEMI patients with symptom onset within 30 days
62501954|NCT00024258|EXPERIMENTAL|Arsenic Trioxide|"Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2-3 months for 1 year and then annually thereafter."
62501955|NCT04983524|EXPERIMENTAL|Propolis|intervention intracanal medicament
61954131|NCT05923983|OTHER|Control Group|
62501956|NCT04983524|ACTIVE_COMPARATOR|Calcium Hudroxide|Gold standard intracanal medicament
62501957|NCT06120530|ACTIVE_COMPARATOR|Intraperitoneal bupivacaine|30 mL of bupivacaine without epinephrine 0.25%
62501958|NCT06120530|PLACEBO_COMPARATOR|placebo|Saline
62501959|NCT02221817|ACTIVE_COMPARATOR|Blind|Trochanter injection
61954132|NCT03981770||Group good sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are more than four hours.
61954133|NCT03981770||Group poor sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are less than four hours.
62501960|NCT02221817|EXPERIMENTAL|Ultrasound|Trochanter injection
62501961|NCT02964650|NO_INTERVENTION|Standard rate-response settings|Patients allocated to standard rate-response settings.
62701154|NCT05699109||Aranesp group|Aranesp group: patients received darbepoetin alpha prefilled syringe subcutaneously once weekly or biweekly
62701155|NCT05699109||Eprex group|Eprex group: patients received epoetin alpha prefilled syringe subcutaneously one to three times per week
62501962|NCT02964650|EXPERIMENTAL|Personalised rate-response settings|Patients allocated to optimised rate-response settings.
62141943|NCT04789759|ACTIVE_COMPARATOR|Extraction Socket Spontaneous Healing|10 Consecutive patients with a tooth extraction without the aim of placing a future implant and without Biomaterial filler placed in the socket. Spontaneous healing
62501963|NCT06678893|EXPERIMENTAL|Auricular Acupunture|Participants randomized to this arm will undergo treatment with the 5 Needle Protocol of Auricular Acupuncture
62501964|NCT06678893|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will undergo treatment with small adhesives without needles placed in the same configuration as the 5 Needle Protocol
62501965|NCT02941588||non-cardiac surgery after DES|The patients who underwent non-cardiac surgery after percutaneous coronary intervention with drug-eluting stent
62501966|NCT06106152|EXPERIMENTAL|Fixed-dose in patients with advanced lung cancer|WTX212A injection Fixed-dose in advanced lung cancer patients
62701156|NCT01678742|EXPERIMENTAL|High-protein diet|
62701157|NCT01678742|ACTIVE_COMPARATOR|Standard diet|
62501967|NCT06106152|EXPERIMENTAL|Combined Study in patients with advanced lung cancer|Fixed-dose WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer
62501968|NCT06276621|EXPERIMENTAL|Family Bridge Program|
62501969|NCT06276621|ACTIVE_COMPARATOR|Care as Usual- Resources Only|
62701158|NCT05068583||Osteosarcoma|
62701159|NCT05068583||Ewing Sarcoma|
62701160|NCT05068583||Rhabdomyosarcoma|
62501970|NCT04931160|ACTIVE_COMPARATOR|Sjögren patients|patients diagnosed Sjögren
62501971|NCT04931160|OTHER|Non-Sjögren witnesses|patients diagnosed no Sjögren
62501972|NCT04469725|EXPERIMENTAL|Thymic carcinoma|enrolled subjects will receive KN046 every 2 weeks.
61954134|NCT04655378||Acute Rheumatoid Purpura|
61954135|NCT04655378||Rheumatoid Purpura in Remission|
61954136|NCT04655378||Controls|Without infection, inflammatory or auto-immune pathology
61954137|NCT00358852||Patients with Schizophrenia|
61954138|NCT02527135|EXPERIMENTAL|Behavioural|Intervention arm receiving weekly HIV sensitization text messages
61954139|NCT02527135|NO_INTERVENTION|Control|No weekly messages were sent to this group
61954140|NCT03044678|EXPERIMENTAL|Experimental: REACH for Success|Experimental: Exposure-based, cognitive and behavioral, social skills training intervention 6-weeks - 6 session -20-30 min each
61954141|NCT03044678|ACTIVE_COMPARATOR|Active Comparator: Self-study|"Active Comparator: Books What to do when you are scared and worried?How to do homework without throwing-up? How to get organized without losing it? Reading at home"
61954142|NCT06192134|EXPERIMENTAL|CPM group|group receiving CPM therapy
61954143|NCT02477150|ACTIVE_COMPARATOR|SLE (vaccine)|Zostavax SC injection (0.65ml)
62501973|NCT02260635|EXPERIMENTAL|Evacetrapib|130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
62501974|NCT02260635|PLACEBO_COMPARATOR|Placebo|Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.
62501975|NCT04752319|EXPERIMENTAL|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
62501976|NCT04752319|EXPERIMENTAL|EStim|EStim is transcutaneous electrical nerve stimulation.
62501977|NCT00360490|EXPERIMENTAL|Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
62501978|NCT00360490|ACTIVE_COMPARATOR|Medroxyprogesterone acetate (MPA)|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
62501979|NCT02408120|ACTIVE_COMPARATOR|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels \>140 mg/dL.
62701161|NCT05068583||Synovial Sarcoma|
62701162|NCT05068583||Non-Rhabdomyosarcoma Soft Tissue Sarcoma|
62701163|NCT05068583||Hepatic Tumors|
62701164|NCT05068583||Renal Tumors|
62701165|NCT05068583||Thyroid Tumors|
62701166|NCT05068583||Germ Cell Tumors|
62701167|NCT05068583||Healthy Volunteers|
62701168|NCT05954884|EXPERIMENTAL|Intervention|This is a single-arm pilot study and all participants will receive the intervention. Participants will be diagnosed and treated for hypertension at Community Clinic (CC) by a Community Health Care Provider (CHCP) under telemedicine supervision from a Medical Officer at the Upazila Health Complex (UHC).
62701169|NCT02115087|EXPERIMENTAL|ultrasound guided rectus sheath block|Ultrasound guided rectus sheath block
62701170|NCT02115087|ACTIVE_COMPARATOR|iv morphine|0.1 mg.kg-1 loading dose of morphine by intravenous route in intraoperative period
61954144|NCT02477150|PLACEBO_COMPARATOR|SLE (placebo)|Placebo SC injection (normal saline 0.65ml)
61954145|NCT04457635|EXPERIMENTAL|Brief psychotherapy (brief PsT)|The focus was on normalizing, accepting and coping with their present mental health complaints and their hindrance for work participation. Primarily, there was no intention to process previous pathogenic experiences. The standard duration was set on six sessions.
62141944|NCT02551224|EXPERIMENTAL|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
62141945|NCT02551224|EXPERIMENTAL|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
62141946|NCT03071354|EXPERIMENTAL|HMB Protein Supplementation Group|"Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
62701171|NCT05817110||Computed tomography Cohort|In case of any nodule detection by qXR, it will be classified either as low-risk LNMS(lung nodule malignancy score ) or high-risk LNMS confirmed by radiologist. The patient will be requested to get a CT scan after enrolment in the study.
61954146|NCT04457635|ACTIVE_COMPARATOR|Short psychotherapy (short-PsT)|With more extended focus, there was besides coping of mental health and challenges concerning WP, an emphasis on both an extensive anamnesis and possibility to establish a so-called central theme based on previous or current challenging issues such as trauma, difficult childhood conditions, and personality-related issues. Additional aims of the intervention could include reducing symptoms and problematic behaviour and an improvement of home situation, with deeper focus on cognitive maladaptive coping strategies or dynamic repetitions. The number of sessions was aimed to be 20 on average
61954147|NCT00149162|ACTIVE_COMPARATOR|1|Patients treated by Proleukin
61954148|NCT00149162|NO_INTERVENTION|2|Without Proleukin
61954149|NCT06469424||Cohort 1 (Tofacitinib cohort):|Initiation of tofacitinib (i.e., first ever prescription) from 01 July 2018 through to 31 March 2025
61954150|NCT06469424||Cohort 2 (Biologics cohort):|"* Initiation (i.e., first ever prescription) of a specific biologic agent (any TNFi or non-TNFi agent) from 01 July 2018 through to 31 March 2025~* No prior use of specific biologic agent prior to index date using all available data"
62141947|NCT03071354|ACTIVE_COMPARATOR|Control Group|"Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
62141948|NCT05508854|EXPERIMENTAL|Experimental (counselling) group|Experimental (counseling) group Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb for diseases, the tests that can be done for the diagnosis of the disease, test results and presentation.A data collection form will be applied to all pregnant women between the ages of 18-49 who applied to the medical genetics polyclinic between September and November 2022 and wished to participate in the study. Prenatal genetic counseling will then be given. When it comes to obtaining genetic results, an individual interview will be made with the pregnant woman and the data collection form will be applied again. In the study, routine clinical information will be given to the pregnant women in the control group by the physician. Before the clinical information and when they come to get genetic results, the data collection form will be applied again by making an individual interview with the pregnant woman.
62501980|NCT02408120|ACTIVE_COMPARATOR|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels \>260 mg/dL.
61954151|NCT06469424||Cohort 3 (Immunosuppressants cohort):|"* Initiation (i.e., first ever prescription) of a specific immunosuppressant agent (without concurrent biologic therapy) from 01 July 2018 through to 31 March 2025~* No prior use of specific immunosuppressant prior to index date using all available data"
62501981|NCT01392001||Cohort|
62501982|NCT03878264|EXPERIMENTAL|Part 1|On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
62501983|NCT03878264|EXPERIMENTAL|Part 2|On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
62501984|NCT01745068|NO_INTERVENTION|Control group|
62501985|NCT01745068|EXPERIMENTAL|Integrated program|Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
61954152|NCT06469424||Cohort 4 (Naïve cohort):|"* Patients diagnosed with UC since 01 July 2018 through to 31 March 2025~* Patients with no history of surgery for UC (surgery suggests more severe disease, and such patients would not be representative of patients with generally mild disease in Cohort 4)"
61954153|NCT05746793||Subfertile polycystic ovarian syndrome (PCOS) patients undergoing ART treatment|Peripheral blood collection. MOCK frozen embryo preparative cycle. Endometrial pipelle biopsy. Collection of menstrual blood. Questionnaire. Nutritional/metabolic evaluation. Cardiac work-up. Preconceptional and prenatal ultrasound. Blood pressure measurements. Urine analysis.
61954154|NCT05746793||Oocyte acceptors|Peripheral blood collection. MOCK frozen embryo preparative cycle. Endometrial pipelle biopsy. Collection of menstrual blood. Questionnaire. Nutritional/metabolic evaluation. Cardiac work-up. Preconceptional and prenatal ultrasound. Blood pressure measurements. Urine analysis.
61954155|NCT01960400|ACTIVE_COMPARATOR|GMI + tDCS|Graded motor imagery (GMI) + tDCS
61954156|NCT01960400|PLACEBO_COMPARATOR|GMI + sham TDCS|Graded motor imagery (GMI) + sham tDCS
62701172|NCT03403686||Controls|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
62701173|NCT03403686||Diabetic no retinopathy|Patients with diabetes but with no evidence of diabetic retinopathy
62701174|NCT03403686||Diabetic with mild retinopathy|Diabetics with mild non proliferative diabetic retinopathy (NPDR).
62701175|NCT03403686||Diabetic with moderate retinopathy|Diabetics with moderate NPDR
62701176|NCT03403686||Diabetics with severe retinopathy|Diabetic with severe NPDR.
62701177|NCT03403686||Diabetics with proliferative diabetic retinopathy (PDR)|Diabetics with proliferative diabetic retinopathy (PDR)
62701178|NCT00514189|EXPERIMENTAL|Autologous Dendritic Cells|
62701179|NCT00339352||1|Cases
61954157|NCT01724918|OTHER|100 mg IV|100 mg IV lacosamide infused over 30 minutes
62141949|NCT05508854|NO_INTERVENTION|Control group|In the study, routine clinical information will be given to the pregnant women in the control group by the physician. Before the clinical information and when they come to get genetic results, the data collection form will be applied again by making an individual interview with the pregnant woman.
62701180|NCT00339352||2|Controls
62701181|NCT00339352||3|first-degree relatives of cases/controls
62701182|NCT01483560|EXPERIMENTAL|Metformin|Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
62701183|NCT01483560|PLACEBO_COMPARATOR|Placebo|
62701184|NCT05853965|EXPERIMENTAL|Cohort 1|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 400mg QD
62701185|NCT05853965|EXPERIMENTAL|Cohort 2|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 800mg QD
62701186|NCT05853965|EXPERIMENTAL|Cohort 3|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 400mg QD Dexamethasone 40mg Q1W (20mg for subjects ≥ 75 years)
62701187|NCT05853965|EXPERIMENTAL|Cohort 4|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 800mg QD Dexamethasone 40mg Q1W (20mg for subjects ≥ 75 years)
62701188|NCT05210543||Anaphylactic reaction (observational)|Patients who experienced an anaphylactic reaction will be observed
62701189|NCT03514134|EXPERIMENTAL|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
62701190|NCT03514134|ACTIVE_COMPARATOR|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
62701191|NCT05790876|EXPERIMENTAL|SSO2 therapy|After successful PCI of a proximal or middle LAD lesion, the patient will be informed and emergency consent will be obtained. SSO2 therapy will then be performed. Overoxygenated blood will be delivered to the origin of the LAD for 60 minutes. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
62701192|NCT02898688|OTHER|Control Site + Control Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
62701193|NCT02898688|EXPERIMENTAL|Control Site + Intervention Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
62701194|NCT02898688|EXPERIMENTAL|Intervention Site + Control Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
62701195|NCT02898688|EXPERIMENTAL|Intervention Site + Intervention Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
62701196|NCT01779960||Londrina|20 patients with moderate-severe COPD from State University of Londrina, Brazi
62701197|NCT01779960||Leuven|20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium
61954158|NCT01724918|OTHER|200 mg IV|200 mg IV lacosamide infused over 30 minutes
61954159|NCT01724918|OTHER|400 mg IV|400 mg IV lacosamide infused over 30 minutes
61954160|NCT03223142|EXPERIMENTAL|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received cryoablation immediately followed by radiofrequency ablation
61954161|NCT03870074||Responders|Patients with improvement of at least one NYHA class after one year from CRT.
61954162|NCT03870074||Non-responders|Patients with no improvement of at least one NYHA class after one year from CRT.
61954163|NCT01529502|EXPERIMENTAL|Fresh blood|
61954164|NCT01529502|EXPERIMENTAL|Old blood|
61954165|NCT01529502|EXPERIMENTAL|Old blood + inhaled Nitric Oxide|
61954166|NCT04269252|PLACEBO_COMPARATOR|CHI-804 at 6 mL|Standard 6 mL dose of placebo oil.
61954167|NCT04269252|ACTIVE_COMPARATOR|CHI-907 at 1.5 mL|Subjects are assigned to receive one dose of CHI-907.
61954168|NCT04269252|ACTIVE_COMPARATOR|CHI-907 at 3 mL|Subjects are assigned to receive one dose of CHI-907.
62701198|NCT00760760|EXPERIMENTAL|n-3 PUFA|
62701199|NCT00760760|PLACEBO_COMPARATOR|Control|
62701200|NCT05077969|EXPERIMENTAL|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
62701201|NCT05077969|PLACEBO_COMPARATOR|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.
62701202|NCT02077608||Hyaluronan enriched transfer media|Embryos are incubated at least 10 minutes in hyaluronan enriched embryo transfer media before transfer
62701203|NCT02077608||Control group|Embryos are incubated in embryo transfer media containing low concentration of hyaluronan for at least 10 minutes before transfer
62701204|NCT04023487|EXPERIMENTAL|Lifestyle Intervention|Resilient, Empowered, Active Living-Telehealth (REAL-T)
62701205|NCT04023487|NO_INTERVENTION|Usual Care|Participants will continue to have access to routine diabetes care from the provider of their choosing; they will not receive any study-related intervention.
62701206|NCT04066959|EXPERIMENTAL|Question Prompt List (QPL)|A QPL is a simple, inexpensive communication tool that is comprised of list of questions related to the physical and psychosocial aspects of an illness and treatment components about which patients may want to ask their diabetes care team during a routine diabetes clinic visit.
62501986|NCT00464139||1|"The electronic files of all patients who consulted the LUFC since 2003 were searched to select women with at least 1 year of infertility, a regular cycle (variation 21 - 35 days), whose partner had normal sperm according to World Health Organization (WHO) criteria (n = 304).~After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of endometriosis before referral to our centre, 221 (72,7%) infertile women were included in our study."
62501987|NCT03486938|PLACEBO_COMPARATOR|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
61954169|NCT04269252|ACTIVE_COMPARATOR|CHI-907 at 6 mL|Subjects are assigned to receive one dose of CHI-907.
61954170|NCT00695877|EXPERIMENTAL|1|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10\^9 virus particles (VP) given at Days 0, 28, and 168
62501988|NCT03486938|EXPERIMENTAL|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
62501989|NCT03936894|EXPERIMENTAL|Treatment|Canakinumab treatment
61954171|NCT00695877|EXPERIMENTAL|2|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10\^10 virus particles (VP) given at Days 0, 28, and 168
61954172|NCT00695877|EXPERIMENTAL|3|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10\^11 virus particles (VP) given at Days 0, 28, and 168
61954173|NCT00695877|EXPERIMENTAL|4|1 injection of rAd5.ENVA.48 HIV-1 vaccine or placebo at a dose determined by the safety data from Arms 1, 2 and 3 given at Day 0.
61954174|NCT02627521|EXPERIMENTAL|PRU Guided CABG|Timing of CABG surgery within 24 hours of reaching a normalized platelet function (NPF). NPF defined as a PRU value \>235 or a PRU value between \>170 and \<235 for two consecutive days as documented by VerifyNow assay.
61954175|NCT02627521|ACTIVE_COMPARATOR|CABG per standard of care|Timing of CABG per standard of care
61954176|NCT01016197|ACTIVE_COMPARATOR|Conservative|Four weeks of splinting followed by mobilisation.
62501990|NCT02476188|EXPERIMENTAL|Patients|Samples of blood at H0, H+6, H+24 and H+72
62501991|NCT02476188|EXPERIMENTAL|Patients control|Samples of blood at H0
61954177|NCT01016197|EXPERIMENTAL|Surgery|Surgical repair of the tendon with a bone anchor followed by four weeks of splinting and then mobilisation.
61954178|NCT03503175|EXPERIMENTAL|Novel urinary access system|Participants randomized to this arm will receive the novel urinary access system (CystoSureTM).
61954179|NCT03503175|ACTIVE_COMPARATOR|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and rigid cystoscopy.
61954180|NCT04546815||Gram-positive cocci infection|No intervention. The clinical data of patients (including demographic information, details of anti-infective therapy, imaging and laboratory testings) will be collected and analyzed.
61954181|NCT06506721|ACTIVE_COMPARATOR|Double balloon device|In this group of patients, the labour will be induced using the Cook double balloon device
61954182|NCT06506721|ACTIVE_COMPARATOR|Hygroscopic cervix dilators|In this group of patients, the labour will be induced using the hygroscopic cervix dilators Dilapan-S
61954183|NCT03159624|EXPERIMENTAL|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
62501992|NCT02476188|ACTIVE_COMPARATOR|Control (healthy person)|Samples of blood at H0
62501993|NCT02520453|EXPERIMENTAL|Durvalumab|Durvalumab 20 mg/Kg IV Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
62501994|NCT02520453|PLACEBO_COMPARATOR|Placebo|Placebo Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
62501995|NCT04203433|EXPERIMENTAL|DLX105-DMP Multi-Dose Twice Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion twice weekly
62501996|NCT04203433|EXPERIMENTAL|DLX105-DMP Multi-Dose Once Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion once weekly
62501997|NCT06629142|ACTIVE_COMPARATOR|Standardized Usual Care|Active control group, where moderately high-risk patients (e.g., with a 1-year mortality risk between 60% and 94%) will receive usual care. A specialist PC consult is ordered by default for the highest-risk patients (i.e., 1-year mortality risk ≥ 95%), unless clinicians cancel the order.
62714838|NCT06718634|EXPERIMENTAL|BL-M08D1|Participants receive BL-M08D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62714839|NCT06562842|EXPERIMENTAL|NGT - Exercise|Regular exercise for 12 weeks and detraining for 4 weeks
61954184|NCT03159624|ACTIVE_COMPARATOR|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
61954185|NCT05452031|EXPERIMENTAL|In-Person Care2Sleep|In-person, manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
61954186|NCT05452031|ACTIVE_COMPARATOR|Telehealth Care2Sleep|Telehealth, manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
61954187|NCT05452031|PLACEBO_COMPARATOR|Sleep Education only|In-person, education on sleep, aging, and dementia but without specific or individualized recommendations
61954188|NCT01275885|ACTIVE_COMPARATOR|Vitamin D3 10µg|
61954189|NCT01275885|ACTIVE_COMPARATOR|Vitamin D3 30µg|
61954190|NCT01275885|ACTIVE_COMPARATOR|Vitamin D3 40µg|
61954191|NCT03677921|EXPERIMENTAL|Investigational Group- Bio-Germanium|"* Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Duration of use: 8 weeks"
61954192|NCT03677921|PLACEBO_COMPARATOR|Control Group - Placebo Product|"* Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Duration of use: 8 weeks"
62501998|NCT06629142|EXPERIMENTAL|Trained Generalist Palliative Care|Generalist clinicians trained in PC domains receive an EHR-based alert to document whether or not they have addressed PC domains for moderately high-risk patients ('accountable justification intervention'). A specialist PC consult is ordered by default for the highest-risk patients unless clinicians cancel the order.
62501999|NCT06629142|EXPERIMENTAL|Specialist Palliative Care|A specialist PC consult is ordered by default for all patients with a ≥ 60% 1-year mortality risk ('default order intervention'), unless clinicians cancel the order.
62502000|NCT02814708|EXPERIMENTAL|Dose Group 1|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 1
62502001|NCT02814708|EXPERIMENTAL|Dose Group 2|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 2
61954193|NCT06556342|EXPERIMENTAL|Diagnostic cohort|This trial will adopt a self-controlled design, where each participant will first undergo gray-scale/power Doppler ultrasound imaging, followed by FRD001 injection-enhanced ultrasound imaging. At least 198 subjects will be needed, which includes 79 participants with malignant tumors (N1) and 119 with benign conditions (N2). All screening assessments for each participant will be conducted within 7 days prior to the administration of the investigational medicinal product (IMP), including the day of administration. Safety observations will continue for 72 ± 24 hours post-IMP administration. Pathological results for the target lesions will be collected within 30 days following the IMP imaging examination.
61954194|NCT02601391|OTHER|STEPPS within forensic services.|"Forensic inpatients attend the STEPPS-HI group. Consent will be obtained. Pre and post group psychometric questionnaires will be completed as well as each service user attending a short semi-structured interview following the conclusion of the group .~Primary nurse will fill in pre and post group questionnaires. Facilitators will complete short feedback forms each session and attend a focus group upon completion.~Psychology Assistants/Interns will collect records of self harm and violence/aggressive incidents for each service user as well as records of nursing observation level and leave status taken."
62502002|NCT02814708|EXPERIMENTAL|Dose Group 3|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 3
62701207|NCT04066959|EXPERIMENTAL|Motivation Enhancement System (MES)|MES is a brief, 2-session computer-delivered intervention to enhance intrinsic motivation for behavior change. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. Session 1 begins with psychoeducation describing optimal diabetes self-management, then youth motivation for diabetes self-management is assessed and followed by exercises designed to increase or reinforce his/her current motivational state (e.g., decisional balance) and build self-efficacy, (e.g., building on strengths and past success). Session 1 concludes with goal setting to promote autonomous diabetes self-management. Session 2 begins with an assessment of progress toward the behavioral goal and proceeds to build motivation and self-efficacy with exercises consistent with the youth's current motivational state. Session 2 concludes with goal setting to promote autonomous diabetes self-management.
61954195|NCT04742959|EXPERIMENTAL|Monotherapy Cohorts|TT-00420 tablets will be administered once daily in 28-day cycles.
62714840|NCT06562842|ACTIVE_COMPARATOR|NGT - Control comparator|Sedentary behavior for 16 weeks
61954196|NCT04742959|EXPERIMENTAL|Dose Escalation Cohorts (Combination Therapy)|TT-00420 tablets will be administered once daily in 28-day cycles. Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Day 1, 8, and 15 of each 28-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
61954197|NCT04742959|EXPERIMENTAL|PK Run-in Cohorts|TT-00420 tablets will be administered once or twice daily in 28-day cycles according to assigned cohort.
61954198|NCT01941667|EXPERIMENTAL|Daily Messages, virtual home visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
61954199|NCT01941667|PLACEBO_COMPARATOR|Usual Care|Infants will have usual care as defined by cardiology.
61954200|NCT02736760|EXPERIMENTAL|Daylight photodynamic therapy (PDT)|"One intervention in the daylight photodynamic therapy arm:~Daylight photodynamic therapy using Methylaminolevulinate (MAL) will be performed five times within 18 months (visits 1-5). In the PDT group the patients will apply a chemical sunscreen (SPF 50+) to the whole face and other light-exposed, unprotected areas of the skin. After at least 15 minutes a lesion preparation of AKs (removal of crusts) will be performed and methylaminolevulinate (MAL) will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours."
61954201|NCT02736760|ACTIVE_COMPARATOR|Cryosurgery|In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. In the control group, cryosurgery will be performed using liquid nitrogen spray in each AK lesion; this will be done at visit 1 and, if necessary, also at visits 2-5. At visits 2-6, the efficacy of the treatment will be evaluated by the observer by documenting all existing and newly appearing AKs in the face.
61954202|NCT02257008|EXPERIMENTAL|Single rising dose of BILR 355 BS with grapefruit juice|
61954203|NCT02257008|EXPERIMENTAL|Single rising dose of BILR 355 BS with nelfinavir|
61954204|NCT02257008|EXPERIMENTAL|Single dose of BILR 355 BS with atazanavir|
61954205|NCT02257008|EXPERIMENTAL|Single dose of BILR 355 BS with atazanavir, ritonavir|
61954206|NCT00544830|EXPERIMENTAL|Treatment (androgen therapy, radiation therapy)|"ADT: Patients not currently on ADT receive goserelin acetate SC or leuprolide acetate via injection once every 4 or 12 weeks and bicalutamide PO QD. Treatment repeats every 12 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients already receiving ADT at the time of enrollment continue treatment until they have received 36 weeks of therapy.~RADIATION THERAPY: Patients achieving PSA normalization after initiation of androgen deprivation therapy undergo intensity-modulated radiation therapy daily for 2-7 weeks during or after completion of androgen deprivation therapy."
61954207|NCT04456946|EXPERIMENTAL|Group of Low Level Laser Therapy|
62141950|NCT03908164|EXPERIMENTAL|Vaccination at <23+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy before 23+6 gestational weeks (GW). Although the time period for study group 1 is ≤23+6 no pertussis vaccine will be given in this study at less than 16 GW.
62502003|NCT02814708|EXPERIMENTAL|Dose Group 4|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 1
62502004|NCT02814708|EXPERIMENTAL|Dose Group 5|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 2
62502005|NCT02814708|EXPERIMENTAL|Dose Group 6|rTSST-1 Variant Candidate Vaccine 100 µg Number of Immunizations: 3
61954208|NCT04456946|EXPERIMENTAL|Group of Occlusal Splint Treatment|
61954209|NCT01989897|EXPERIMENTAL|diluents|Negative control = diluent, saline with HSA--phenol Positive control = saline with 1mg/ml Histamine base
62502006|NCT02814708|PLACEBO_COMPARATOR|Dose Group 7|Al(OH)3 Adjuvant, 1mg Number of Immunizations: 3
62502007|NCT02324231|OTHER|39.0°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature \>=39.0°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
61954210|NCT04923061|EXPERIMENTAL|Acupressure group|The experimental group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
62701208|NCT04066959|EXPERIMENTAL|Text Message Reminders (TXT)|Participants will receive 30 days of one-way text messages targeting one of three key daily diabetes care behaviors: monitoring blood glucose, insulin administration, or carbohydrate counting. Participants will set a reminder schedule, i.e., frequency and timing of text message reminders.
61954211|NCT04923061|SHAM_COMPARATOR|Sham acupressure group|The sham group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
61954212|NCT01220050|EXPERIMENTAL|Paricalcitol|
61954213|NCT01220050|ACTIVE_COMPARATOR|Standard therapy|
61954214|NCT02639065|EXPERIMENTAL|Investigational Treatment|Durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
61954215|NCT04224480|EXPERIMENTAL|Treatment|Neoadjuvant treatment will consist of one dose of IV pembrolizumab. Tumor resection will be performed approximately 4 weeks after neoadjuvant pembrolizumab. Adjuvant treatment with pembrolizumab will be administered 4 weeks after the surgery.
61954216|NCT04199910||Liver cirrhosis with spironolactone|
61954217|NCT04199910||Liver cirrhosis with rifaximin|
61954218|NCT04199910||Liver cirrhosis without spironolactone or rifaximin|
62502008|NCT02324231|OTHER|38.5°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature \>=38.5°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
62502009|NCT02118987|EXPERIMENTAL|Omalizumab|300mg of omalizumab under the skin every four weeks at three separate visits representing a treatment period of 12 weeks. During this treatment period, patients will continue receiving their regularly scheduled chemotherapy desensitizations per the prescribed treatment schedule from the patient's oncologist.
62502010|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
62502011|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
62502012|NCT05083754|EXPERIMENTAL|Arm A- Retifanlimab and Radiation Therapy|Participants will receive Retifanlimab and Radiation Therapy.
62502013|NCT05083754|EXPERIMENTAL|Arm B- Retifanlimab, Radiation Therapy and Temozolomide|Participants will receive Retifanlimab, Radiation Therapy and Temozolomide.
62502014|NCT05083754|OTHER|Arm C- Radiation Therapy and Temozolomide|Participants will receive Radiation Therapy and Temozolomide which is the Standard of Care.
62502015|NCT06450925|ACTIVE_COMPARATOR|Vitamin A|"Route of administration: Oral. Frequency: Once. Timing: Pre-transplant Dose of Vit A: 1.2 mg/kg, max dose 75 mg Formulation of Vit A: 2.5 mg liquid filled oral capsules.~Vitamin A level assessment: Vitamin A levels will be measured pre-transplant and again at day +30 (± 10 days)"
62502016|NCT06450925|PLACEBO_COMPARATOR|Placebo|Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.
62701209|NCT04066959|EXPERIMENTAL|QPL & MES|Participants will receive the QPL and MES interventions as described above.
62701210|NCT04066959|EXPERIMENTAL|QPL & TXT|Participants will receive the QPL and TXT interventions as described above.
62701211|NCT04066959|EXPERIMENTAL|MES & TXT|Participants will receive the MES and TXT interventions as described above.
62701212|NCT04066959|EXPERIMENTAL|MES, QPL & TXT|Participants will receive the MES, QPL, and TXT interventions as described above.
61954219|NCT04199910||Pneumonia|
61954220|NCT04199910||Crohn's disease|
61954221|NCT04199910||Ulcerative colitis|
61954222|NCT03340688|ACTIVE_COMPARATOR|Cervical cerclage + vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤15mm and Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
61954223|NCT03340688|NO_INTERVENTION|Vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
61954224|NCT06304428|ACTIVE_COMPARATOR|Deprescribing Care Model|In this pragmatic, cluster randomized crossover trial 42 Skilled Nursing Facilities (SNF) will each receive 6 months of each care model in random sequence. All patients with OP fracture admitted to the SNF within the intervention time period will receive the full designated care model, even if their stay in the SNF extends into the next intervention period.
61954225|NCT06304428|ACTIVE_COMPARATOR|Bone Heath Service Model|In this pragmatic, cluster randomized crossover trial 42 Skilled Nursing Facilities (SNF) will each receive 6 months of each care model in random sequence. All patients with OP fracture admitted to the SNF within the intervention time period will receive the full designated care model, even if their stay in the SNF extends into the next intervention period.
61954226|NCT06304428|ACTIVE_COMPARATOR|Injury Prevention Service Model|In this pragmatic, cluster randomized crossover trial 42 Skilled Nursing Facilities (SNF) will each receive 6 months of each care model in random sequence. All patients with OP fracture admitted to the SNF within the intervention time period will receive the full designated care model, even if their stay in the SNF extends into the next intervention period.
62141951|NCT03908164|EXPERIMENTAL|Vaccination at 24-27+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 24 and 27+6 gestational weeks.
62141952|NCT03908164|EXPERIMENTAL|Vaccination at 28-31+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 28 and 31+6 gestational weeks.
62141953|NCT01911559||constipated quadriplegic CP children|In this study we included children with CP, in the manifestation of severe diplegia or quadriplegia, who do not currently use the standing-frame.
62141954|NCT05758584|EXPERIMENTAL|Group 1|Vibrating tourniquet group
62502017|NCT05152615|EXPERIMENTAL|New Onset Rheumatoid Arthritis (NORA) Patient|NORA patients receiving methotraxate as first line therapy (standard of care) will take additional oral SCFA supplementation for the purposes of the study.
62714841|NCT06562842|EXPERIMENTAL|Pre-D - Exercise|Regular exercise for 12 weeks and detraining for 4 weeks
62714842|NCT06562842|ACTIVE_COMPARATOR|Pre-D - Control comparator|Sedentary behavior for 16 weeks
62714843|NCT06562842|EXPERIMENTAL|T2D - Exercise|Regular exercise for 12 weeks and detraining for 4 weeks
62502018|NCT05841524||AAA patients, without intraluminal thrombus|patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and without intraluminal thrombus.
62344220|NCT01286948|ACTIVE_COMPARATOR|oral LNG (1.5mg)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
62344221|NCT01650818|EXPERIMENTAL|Aerobic exercise training|
62344222|NCT01650818|ACTIVE_COMPARATOR|Standard physical therapy|
62344223|NCT04258046|EXPERIMENTAL|Oral Trametinib|Patients will receive oral trametinib once daily
62344224|NCT03097224|EXPERIMENTAL|Prehabilitation group|Tele-supervised prehabilitation
62344225|NCT03097224|NO_INTERVENTION|Control group|Usual care
62344226|NCT03861195||Da Vinci Robotic Surgical System|
62344227|NCT03861195||conventional laparoscopic surgery|
62344228|NCT02383680||Patients under low dose methotrexate therapy|Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination
62344229|NCT02383680||Healthy controls|Healthy travelers who have an indication for yellow fever vaccination
62502019|NCT05841524||AAA patients, with intraluminal thrombus|patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and with intraluminal thrombus.
62502020|NCT04743817|EXPERIMENTAL|OtoSet - Ear Cleaning Sytem|
62701213|NCT04066959|NO_INTERVENTION|Standard Medical Care|Participants will receive standard medical care at one of two participating clinical sites. Clinical practices at these sites are consistent with the standards of T1D care recommended by the American Diabetes Association and will include diabetes clinic visits every 3-4 months for routine diabetes medical care provided by an endocrinologist and/or nurse practitioner.
62701214|NCT06644820||Primary spontaneous pneumothorax|Primary spontaneous pneumothorax (PSP) occur in the absence of underlying lung disease. Primary spontaneous pneumothorax is more common in men and in younger patients and associated with smoking.
62344230|NCT02418533|EXPERIMENTAL|Mono-menotropin protocol|Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
62502021|NCT01445860|EXPERIMENTAL|Treatment|
62502022|NCT05190276||The hematoma group|with symptomatic epidural hematoma after surgery
62701215|NCT06644820||Secondary spontaneous pneumothorax|Secondary spontaneous pneumothorax (SSP) occur in the presence of underlying lung disease, most commonly chronic obstructive pulmonary disease, cystic fibrosis, pneumocystis pneumonia, lung cancer, and interstitial lung diseases (ILDs) in older adults.
62701216|NCT03127930|EXPERIMENTAL|Intervention|Intervention: Participants receive both usual care including a standard brochure on patient management provided by the Alzheimer's Association plus a tailored problem-solving intervention to improve caregiver's management of medications for their family or friend care recipient who has memory deficit.
62502023|NCT05190276||The control group|without symptomatic epidural hematoma after surgery
62701217|NCT03127930|NO_INTERVENTION|Usual Care|No Intervention: Participants do not receive the problem solving intervention and are followed as a Usual Care condition including receiving a standard brochure on patient management provided by the Alzheimer's Association. .
62701218|NCT03360344|EXPERIMENTAL|Kinesio Tape|"Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.~A tape removal form will be provided should the participants want to remove it prior to the next visit."
62344231|NCT02418533|EXPERIMENTAL|rFSH protocol|Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
62344232|NCT04574921|EXPERIMENTAL|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
62344233|NCT04574921|SHAM_COMPARATOR|Sham|Exposure to LTS device set to continues color matched white light for 1 hour a day for consecutive days
62344234|NCT04170777||Arm A|The CBCT imaging involved for Arm A is considered part of the study treatment. Pre and post treatment images will be acquired of the patient treated on Perfexion Gamma Knife using the 'Leksell Coordinate Frame'.
62344235|NCT04170777||Arm B|Arm B will be undergoing standard treatment on Gamma Knife Perfexion for Stereotactic Radiosurgery using the 'relocatable mask'. Patients with lesions that are \>3 cm at the largest diameter will be treated with the relocatable mask for which a hypo fractionated approach may be beneficial.
62502024|NCT02212106|EXPERIMENTAL|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
62502025|NCT02212106|ACTIVE_COMPARATOR|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
62502026|NCT06519747||Study Cohort|Participants will receive up to 14 days of continuous cardiac monitoring
62502027|NCT04837833|EXPERIMENTAL|research ultrasound (rUS1)|Participants will undergo research ultrasound (rUS1) within three days of their routine contrast enhanced CT scan (CECT). A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT.
62701219|NCT03360344|SHAM_COMPARATOR|Control group|Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
62701220|NCT03360344|ACTIVE_COMPARATOR|Standard of Care|Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
62701221|NCT03331887|ACTIVE_COMPARATOR|E-max CAD crowns retained with Fiber Reinforced Composite Post|"The modulus of elasticity of FRC post is (18-22 GPa) resembling that of dentin. Ideally the remaining tooth, the fiber post and the composite cement create a monoblock in which the loads are uniformly dissipated, ensuring a behavior similar to healthy teeth with a lower risk of root fracture. Using lithium disilicate e.max restorations is documented in literature as a successful restoration."
62701222|NCT03331887|EXPERIMENTAL|E-max CAD Endocrowns|Endocrowns have several advantages over conventional crowns like adequate function and esthetic with less chair time reduced number of interfaces in the restorative system. Stress concentration is less because of the reduction in the nonhomogenous material present. The preparation design is conservative compared to the traditional crown. Supragingival margin prevents interferences with periodontal tissues so involvement of the biological width is minimal. The application and polymerization of resins is also better controlled. Emax ceramic material have a high mechanical strength and are capable of being acid etched, with the adhesive capacity of adhesive systems and resinous cements, made it possible to restore endodontically treated teeth, without cores and intraradicular posts.
62701223|NCT03575598|EXPERIMENTAL|Sitravatinib and Nivolumab|"Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.~Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study."
62701224|NCT06278324|EXPERIMENTAL|Nasal spray Humer Stop Virus (HSV)|Patients treated with the nasal spray Humer Stop Virus (HSV) . Analgesics and antipyretics are authorized. Any other nasal spray, nasal cleansing (saline, water or other), and inhalation are prohibited
62701225|NCT06278324|NO_INTERVENTION|Control|Analgesics and antipyretics are authorized. Any nasal spray, nasal cleansing (saline, water or other), and inhalation are prohibited
62701226|NCT06293781|EXPERIMENTAL|ACT|Web-based ACT with treatment as usual
62701227|NCT06293781|ACTIVE_COMPARATOR|Controls|Waitlist being on the treatment as usual
62701228|NCT02741050|EXPERIMENTAL|Tailored Physical Activity Intervention|Intervention group will receive Spanish-language physical activity print intervention based on SCT and Transtheoretical Model, (TTM) that emphasizes behavioral strategies for increasing activity levels.
62701229|NCT02741050|ACTIVE_COMPARATOR|Standard of Care Control Group|Control group will receive standard of care through the Family Medicine clinic as well as monthly questionnaires on topics other than physical activity (e.g. diet) to complete.
62701230|NCT04198649|EXPERIMENTAL|Azithromycin|62 patients Non-surgical periodontal treatment and two 250mg azithromycin tablets one time daily for 3 days
62701231|NCT04198649|PLACEBO_COMPARATOR|Placebo|62 patients Non-surgical periodontal treatment and two 250mg starch tablets one time daily for 3 days
62701232|NCT01379690||Control|Controls were selected from patients with diabetes on consultation during the year 2005-2010 in specialist clinic, without a previous hip fracture. There was no followup period for these patients. Instead the A1C value upon the point of consultation was used to reflect glycaemic control at the point of consultation
62701233|NCT01379690||Case|All patients with treated diabetes admitted with primary diagnosis hip fractures from 2005-2010 to Changi General Hospital was included in the study. The A1C at the point of admission was used to reflect the glycaemic control at that point in time. This was a retrospective study and there was no subsequent follow up on patients after the point of admission
62701234|NCT03874559||Arm A|All patients enrolled will be placed in Arm A. Serum blood draw samples will be collected as well as additional data from medical records will be collected. This data includes demographic data, clinical information from notes, radiology images and reports, diagnostic test results, and procedure and pathology reports.
62701235|NCT04565730|ACTIVE_COMPARATOR|Grup I= General anesthesia group|After applying standard ASA monitoring; 2-2,5 mg/kg propofol, and 0,6 mg/kg rocuronium IV will be performed for general anesthesia induction, and then orotracheal intubation will be performed. The patients will be placed in the supine position. General anesthesia will be maintained with sevoflurane in the mixture of oxygen-fresh air. Controlled mechanical ventilation will be initiated with a tidal volume of 8-10 ml/kg at 12 breaths per minute (I:E ratio 1:2), a fresh gas flow rate of 2 L per min, end tidal CO2 value at 30-35 mmHg, and peak airway pressure of maximally 30 cm H2O. All patients will undergo cesarean delivery surgery with the same technique by the same surgical team.
62701236|NCT04565730|ACTIVE_COMPARATOR|Grup II= Spinal anesthesia group|A standardized spinal anesthesia will administrated to the patients. After skin disinfection, 25G needle will used for puncture at the level of L2-L3 or L3-L4. After observing the cerebrospinal fluid, 15 mg bupivacaine (marcain spinal heavy) will be administered into the subarachnoid space. The level of anesthesia below T6 will be controlled.
62701237|NCT05380700|EXPERIMENTAL|Virtual Reality Stimulation|All participants will be receiving the standard care and additionally the VR stimulation during their stay in the intermediate care unit.
62701238|NCT06564558|EXPERIMENTAL|Real Postural Correction Group|The experimental group will receive real thoracic spine hyperkyphosis treatment. This treatment is focused around impairments that are linked with spinal kyphosis such as spinal extensor muscle weakness, anterior muscle chain tightness, and thoracic spine hypomobility. The participants will undergo spinal strengthening exercises, thoracic spine tight musculature stretching, and finally thoracic spine mobility exercises. All exercises will follow a 3 set parameter rule with patient tolerance kept in mind.
62701239|NCT06564558|SHAM_COMPARATOR|Sham Postural Correction Group|The control group will receive sham thoracic kyphosis treatment comprised an hour of social interaction with similar participants where a blinded therapist will provide educational tips for dealing with kyphosis along with educational reading material for each participant.
62701240|NCT03361449|ACTIVE_COMPARATOR|Group 1|training with kinesthetic ability trainer.
62502028|NCT04771247|EXPERIMENTAL|CLEAR|Patients with GERD post LSG will undergo CLEAR (cardia band ligation).
62502029|NCT06077929||Rhinosinusitis|Patients with rhinosinusitis
62502030|NCT03399006||preeclampsia|women who developed preeclampsia. Preeclampsia was defined as a blood pressure 140/90 mmHg and proteinuria of 300 mg in 24 hours, or two readings of at least 2+ on dipstick analysis of midstream urine specimens if no 24-hour urine collection was available in absence of urinary tract infection
62701241|NCT03361449|ACTIVE_COMPARATOR|Group 2|Flamingo exercise
62701242|NCT03361449|ACTIVE_COMPARATOR|Group 3|training with kinesthetic ability trainer and Flamingo exercise
62701243|NCT06045078|EXPERIMENTAL|Lavender-Peppermint Aromatherapy Group|This is the interventional group. Participants in this group will receive aromatherapy tabs in the scent of lavender-peppermint. Tabs will be worn on a badge for a total of 72 hours, and participants will replace the aroma tabs every 12 hours.
62701244|NCT06045078|PLACEBO_COMPARATOR|Almond-oil Aromatherapy Group|This is the placebo group. Participants in this group will receive aromatherapy tabs in the scent of almond oil. Tabs will worn on a badge for a total of 72 hours, and participants will replace the aroma tabs every 12 hours.
62701245|NCT00574015|ACTIVE_COMPARATOR|oral|administration of oral analgesia
62701246|NCT00574015|EXPERIMENTAL|Dental Block|Administration of supraperiosteal nerve block to effected tooth
62701247|NCT01257750|EXPERIMENTAL|Pazopanib|This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.
62701248|NCT04557423|ACTIVE_COMPARATOR|Evidence-Based Intervention|Culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided.
62141955|NCT05758584|EXPERIMENTAL|Group 2|Distraction cards group
62344236|NCT06048406|EXPERIMENTAL|Intervention|The intervention group will receive a monthly health education intervention focused on influenza vaccination literacy for 5 months.
62344237|NCT06048406|NO_INTERVENTION|Control|The control group will continue with their routine school health education for 5 months.
62344238|NCT05267912|EXPERIMENTAL|ORGANOTREAT 01|"To assess the feasibility of timely generating chemograms from PDOs in advanced CRC.~To assess the proportion of patients treated according to the chemogram tumor board (CTB)'s recommendations on the basis of their personalized chemogram.~To assess the efficacy and safety of chemogram-driven treatment in advanced CRC."
62344239|NCT05267912|EXPERIMENTAL|ORGANOTREAT 02A|is a single-arm, Phase II study to evaluate the efficacy of chemogram-driven treatment in patients with advanced, pretreated solid cancers of low-to-intermediate incidence and/or with a PDO take-on rate \<50%. The primary endpoint is the Growth Modulation Index (GMI), defined as PFSn/PFSn-1, where PFSn is the -progression-free survival (PFS) time on study treatment and PFSn-1 the PFS time within the previous treatment line.
62344240|NCT05267912|EXPERIMENTAL|ORGANOTREAT 02B|is a randomized Phase II study to compare the efficacy of chemogram-driven treatment vs SoC in patients with advanced, pretreated solid cancers with a PDO take-on rate ≥50%. A cross-over will allow patients enrolled in the control arm to benefit from chemogram-based treatment. Patients for whom no chemogram can be obtained will not be randomized and they will be treated according to SoC. The primary endpoint will be PFS. The study will include multiple strata, each for a different tumor type (e.g., stratum 1, pancreatic ductal adenocarcinoma (PDAC); stratum 2, CRC; etc.). Each stratum will be conducted and analyzed independently from the other strata.
62344241|NCT01824173|EXPERIMENTAL|Amino Acid Infusion in Lean|Amino Acid Infusion in Lean
62344242|NCT01824173|EXPERIMENTAL|Amino acid Infusion in Obese|Amino acid Infusion in Obese
62344243|NCT01824173|EXPERIMENTAL|Exercise in lean|Exercise in lean
62344244|NCT01824173|EXPERIMENTAL|Exercise in Obese|Exercise in Obese
62344245|NCT00304317|EXPERIMENTAL|I|Celecoxib
62344246|NCT00304317|PLACEBO_COMPARATOR|II|Placebo
62344247|NCT00970957|EXPERIMENTAL|Central RVO - Macular edema - Avastin|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
62502031|NCT03399006||Normal pregnancy|women with normal blood presure
62502032|NCT05111990||Maternal pre-gestational BMI 18.5<25|
62502033|NCT05111990||Maternal pre-gestational BMI 25<30|
62502034|NCT05111990||Maternal pre-gestational BMI >30|
62502035|NCT03442192|OTHER|PrEP Care Anywhere Services|The PrEP Care Anywhere intervention adapts peer PrEP case management for virtual delivery and provides clinical services through a tele-health program, delivered by the same clinic providers. After an initial face-to-face intake clinical evaluation within the clinic, will then receive the remaining PrEP clinical evaluations via telemedicine using the HIPPA compliant polycom platform. Case management interventions will be conducted virtually via the PrEPme application, telephone consultation, text, or email.
62502036|NCT02300987|ACTIVE_COMPARATOR|LEE011|600 mg daily dosing days 1-21 of a 28 day cycle
62502037|NCT02300987|PLACEBO_COMPARATOR|Placebo Arm|600 mg daily dosing days 1-21 of a 28 day cycle
62502038|NCT06024031|EXPERIMENTAL|NAC group|Low, intermediate risk AML patients were enrolled, and NAC (400mg tid) was administered orally from day1 to day 28 (D1-D28) after the end of induction chemotherapy.
62502039|NCT04736758|EXPERIMENTAL|GP681 tablet 40mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 40mg orally once with 240mL water.
62701249|NCT04557423|EXPERIMENTAL|HPV Self-Sampling|Previously tested evidence-based intervention (i.e. culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided). Participants will also receive a self-sampling kit.
62701250|NCT01081392|EXPERIMENTAL|LPS sequence 1|Nebulizers A then B then C
62701251|NCT01081392|EXPERIMENTAL|LPS sequence 2|Nebulizers B then C then A
62701252|NCT01081392|EXPERIMENTAL|LPS sequence 3|Nebulizers C then A then B
62701253|NCT01081392|EXPERIMENTAL|LPS sequence 4|Nebulizers A then C then B
62701254|NCT01081392|EXPERIMENTAL|LPS sequence 5|Nebulizers C then B then A
62701255|NCT01081392|EXPERIMENTAL|LPS sequence 6|Nebulizers B then A then C
62714844|NCT06562842|ACTIVE_COMPARATOR|T2D - Control comparator|Sedentary behavior for 16 weeks
61954227|NCT06263556|EXPERIMENTAL|Pelvic floor exercises and Transcutaneous tibial nerve stimulation|"Patients in this group will receive pelvic floor exercise program as described before and transcutaneous tibial nerve stimulation (TTNS).~The intervention will comprise 12 session of transcutaneous tibial nerve stimulation (Twice a week, for 6 continuous weeks). Each session will last 30 minutes. Two self adhesive surface electrodes will be positioned according to the protocol used by Booth et al and Sonmez et al, with the negative electrode 2 cm behind the medial malleolus, and positive electrode 10 cm proximal to it. Correct positioning will be determined by noting a hallux reaction (plantar flexion of great toe). Stimulation will be delivered at fixed frequency of 20 Hz and pulse width of 200 ms. The intensity level of the stimulation current (range 0-50 mA) will be determined once hallux reaction is observed, according to patient's tolerance."
61954228|NCT06263556|SHAM_COMPARATOR|Pelvic floor exercises and Sham Stimulation|"Patients in this group will receive pelvic floor exercise program as described before and Sham stimulation.~The intervention will comprise 12 session of sham stimulation. (Twice a week, for 6 continuous weeks) Each session will last 30 minutes. Two self adhesive surface electrodes will be positioned According to the protocol used by Booth et al, with the negative electrode 2 cm behind the lateral malleolus, and positive electrode 10 cm proximal to it, therefore avoiding the posterior tibial nerve. The stimulation current will be reduced to 2 mA once the tingling sensation is obtained and patients will be informed that they may not feel electrical sensation during the session. Stimulation will be delivered at fixed frequency of 20 Hz and pulse width of 200 ms.~If willing, patients in this group will receive TTNS treatment after the study is completed."
61954229|NCT00945893|EXPERIMENTAL|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.
62714845|NCT03704493|NO_INTERVENTION|Image Group|The patients were looking at a static image of a lavender flower while exercising on the treadmill.
62714846|NCT03704493|EXPERIMENTAL|Video Group|The patients were watching a video of a group of amateur runners while exercising on the treadmill.
61954230|NCT00945893|PLACEBO_COMPARATOR|Placebo|Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
61954231|NCT05846971|NO_INTERVENTION|Control Group|The control group will receive standard-of-care clinical data for their virtual patient cases. No educational material on the methylation assay will be provided.
61954232|NCT05846971|EXPERIMENTAL|Intervention Group|The intervention group will receive standard-of-care clinical data for their virtual cases along with educational materials about the methylation assay. This group will then be provided with methylation assay data to be used in addition to clinical data.
61954233|NCT05473910|EXPERIMENTAL|TSC-100 Treatment Arm|HA-1 positive patients
61954234|NCT05473910|EXPERIMENTAL|TSC 101 Treatment Arm|HA-1 negative and HA-2 positive patients
61954235|NCT05473910|ACTIVE_COMPARATOR|Standard of Care or Control arm|
61954236|NCT03507231|ACTIVE_COMPARATOR|Control|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination.
61954237|NCT03507231|EXPERIMENTAL|Direct Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for Vaccination ($5 Amazon Gift Card).
61954238|NCT03507231|EXPERIMENTAL|Indirect Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for completing a short survey ($5 Amazon Gift Card).
61954239|NCT03692468|EXPERIMENTAL|Intervention Group|Participants will engage in a 5 session psychotherapy intervention focused on improving pain and mood.
61954240|NCT03692468|NO_INTERVENTION|Control Group|Patients will receive treatment as usual from their care providers.
61954241|NCT02966431|EXPERIMENTAL|Counseling|Receive counseling for 8-wks
61954242|NCT02966431|PLACEBO_COMPARATOR|Control|Does not receive counseling for 8-wks
62141956|NCT05758584|NO_INTERVENTION|Group 3|Control group
62141957|NCT05095740|ACTIVE_COMPARATOR|repetitive transcranial magnetic stimulation (rTMS)|5 consecutive days of rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
61954243|NCT05199181|EXPERIMENTAL|Full pulpotomy|All patients were treated in one visit (with Full Pulpotomy); the previously trained General Practice Dentist performed all the clinical procedures
62344248|NCT00970957|SHAM_COMPARATOR|Central RVO - Macular edema - Sham|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
62502040|NCT04736758|EXPERIMENTAL|GP681 tablet 20mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 20mg orally once with 240mL water.
61954244|NCT01951274|EXPERIMENTAL|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
61954245|NCT01951274|EXPERIMENTAL|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
62141958|NCT05095740|SHAM_COMPARATOR|Sham rTMS|5 consecutive days of sham rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
62141959|NCT02179359|EXPERIMENTAL|Reduced Toxicity Ablative Regimen|For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are \<12 years and/or have mild/moderate iron exposure.
62714847|NCT04102007|OTHER|Risankizumab|Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab
61954246|NCT01951274|EXPERIMENTAL|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
61954247|NCT01951274|PLACEBO_COMPARATOR|Placebo|placebo tablets to be taken daily by mouth for 42 days
61954248|NCT00180544|OTHER|1|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
61954249|NCT04847856|EXPERIMENTAL|List of health centers that randomly allocated to receive the intervention|The intervention was structured Diabetes self-care information, education, and communication (IEC) delivered to the participants at the selected primary health care center level. The Information, education, and communication intervention were delivered by relevant and trained health animators working in chronic care clinics. The intervention was composed of sessions and the participants were planned to attend five structured sessions on diabetes self-care at months: 1, 2, 3,4,5\&6. Besides, the participants were provided with a single-page checklist with a to-do list of activities and simple advice that covering the various aspects of diabetes self-care.
61954250|NCT04847856|NO_INTERVENTION|List of health centers that randomly allocated to receive routine care|The comparators were type II diabetic patients of both genders attending the selected primary health care centres that receiving routinely provided diabetic care including advice from the health care providers. Participants were interviewed at the start of the trial to collect the baseline data about self-care with measurements of blood glucose level, serum cholesterol level, blood pressure, BMI, and waist circumference. At the end of the trial, the sam participants were interviewed to collect end-line data and similar measurements.
61954251|NCT06276283|EXPERIMENTAL|DZD9008 plus Bevacizumab|This single-arm study includes two parts (dose escalation \[Part A\] and dose expansion \[Part B\]).
61954252|NCT02598804|EXPERIMENTAL|Intervention group|"No single group but 2 groups :~* Intervention group (5 educational workshop in addition to spa therapy)~* Control group (Written information booklet in addition to spa therapy)"
61954253|NCT02598804|OTHER|control group|"No single group but 2 groups :~* Intervention group (5 educational workshop in addition to spa therapy)~* Control group (Written information booklet in addition to spa therapy)"
62344249|NCT00970957|EXPERIMENTAL|Branch RVO - Macular edema - Avastin|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
62502041|NCT04736758|PLACEBO_COMPARATOR|Placebo group|Patients in the Placebo group is treated with GP681 Simulant orally once with 240mL water.
62701256|NCT06558773|EXPERIMENTAL|Arm A:Eliglustat+Immune checkpoint inhibitor+Regorafenib|"Eliglustat 84mg will be administered twice daily in patients who are CYP2D6 extensive metabolizers (EMs), or intermediate metabolizers (IMs), in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks.~Regorafenib orally 80mg daily for 21 days (3 weeks on, 1 week off, 4 weeks as a cycle).Dose escalation to 120mg daily was allowed if well tolerated. until:unacceptable toxicity occurred or disease progression."
62701257|NCT06558773|EXPERIMENTAL|Arm B:Eliglustat+Immune checkpoint inhibitor|"Eliglustat 84mg will be administered twice daily in patients who are CYP2D6 extensive metabolizers (EMs), or intermediate metabolizers (IMs), in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
61954254|NCT03138278|NO_INTERVENTION|Usual care|ICU with ordinary care for elderly ICU survivors and their care-givers
62502042|NCT05264831|ACTIVE_COMPARATOR|PVI procedure alone|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 1: PVI procedure alone in accordance with ESC recommendations"
61954255|NCT03138278|ACTIVE_COMPARATOR|Telephone support|ICU with day-time telephone support to care-givers
61954256|NCT00976040|EXPERIMENTAL|Early antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy within 7 days of enrollment.
61954257|NCT00976040|NO_INTERVENTION|Standard antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy approximately 4 weeks after enrollment.
61954258|NCT02347280|EXPERIMENTAL|Loop ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
61954259|NCT02347280|ACTIVE_COMPARATOR|Total abdominal colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
61954260|NCT02189460||Healthy adults|20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more.
62344250|NCT00970957|SHAM_COMPARATOR|Branch RVO - Macular edema - Sham|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
62344251|NCT01148316|ACTIVE_COMPARATOR|Fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
62502043|NCT05264831|EXPERIMENTAL|PVI procedure combined with substrate modulation|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 2: PVI procedure associated with substrate modulation"
62502044|NCT02274558|EXPERIMENTAL|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
62502045|NCT02274558|EXPERIMENTAL|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
62502046|NCT02274558|EXPERIMENTAL|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
61954261|NCT05310838|EXPERIMENTAL|Behavioral Activation for First Episode Psychosis|Patients will receive BA for FEP in individual session format provided by the PI based on a manual adapted for this study.
61954262|NCT05310838|ACTIVE_COMPARATOR|Treatment at Usual|Patients randomized to TAU will receive typical clinic care offered beyond psychiatric services.
62344252|NCT01148316|ACTIVE_COMPARATOR|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
62344253|NCT02496481|EXPERIMENTAL|Group1 Baseline+MI+tailored brochure|"Participants randomized to Group 1 will receive the motivational interviewing intervention in the ED and will be mailed a tailored educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
62344254|NCT02496481|EXPERIMENTAL|Group2 Baseline+MI+general info|"Participants randomized to Group 2 will receive the motivational interviewing intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
62502047|NCT01504087||patinet with deep venous thrombosis|patient with deep venous thrombosis by ultrasonography as case; patient with no deep venous thrombosis by ultrasonography as control
62344255|NCT02496481|EXPERIMENTAL|Group3 Baseline+tailored brochure|"Participants randomized to Group 3 will receive no intervention in the ED and will be mailed a tailored educational brochure about child passenger safety~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
62344256|NCT02496481|NO_INTERVENTION|Group4 Baseline+general info|"Control Group. Participants randomized to this arm will receive no intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
62502048|NCT01504087||patient without deep venous thrombosis|
62502049|NCT00604916|EXPERIMENTAL|E|received a 7 day standardized oral care protocol
61954263|NCT03026322|ACTIVE_COMPARATOR|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
62344257|NCT03709524|ACTIVE_COMPARATOR|insertion time|1 minute Airtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
62344258|NCT03709524|ACTIVE_COMPARATOR|intubation time|2 minutesAirtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
62344259|NCT03946826|EXPERIMENTAL|PDL+ Halometasone Cream group|PDL+ Halometasone Cream Halometasone Cream, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
62344260|NCT03946826|EXPERIMENTAL|PDL+Vaseline group|PDL+Vaseline Vaseline, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
62344261|NCT03946826|ACTIVE_COMPARATOR|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
62344262|NCT03946826|PLACEBO_COMPARATOR|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
62344263|NCT02807363|EXPERIMENTAL|Treatment A: Leuprolide Oral Tablet, 4 mg QD|Leuprolide Oral Tablet QD: 4 mg for 28 consecutive days.
62344264|NCT02807363|EXPERIMENTAL|Treatment B: Leuprolide Oral Tablet, 4 mg BID|Leuprolide Oral Tablet BID: 4 mg, 12 hours apart for 28 consecutive days.
62502050|NCT00604916|PLACEBO_COMPARATOR|C|received a 7 day mimic protocol
62502051|NCT04983602|NO_INTERVENTION|Usual care Control group|The usual care control group receives conventional care in the Emergency Department (ED) or Acute Medical Assessment Unit (AMAU)The comparison group will receive routine care as would be usual in the ED or AMAU. Currently there is no dedicated team to perform CGA in the ED and AMAU at UHL with ad hoc allied health assessment available only at the discretion of the referring ED doctor or medical team. This process will be continued during the study and will be documented. The participants in this group will under baseline data collection prior to randomisation and follow up.
62502052|NCT04983602|EXPERIMENTAL|Comprehensive Geriatric assessment arm|The intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team (consisting of a geriatric specialist registrar, specialist geriatric nurse, senior pharmacist, senior physiotherapist, senior occupational therapist, and senior medical social worker) in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED.
62701258|NCT06558773|ACTIVE_COMPARATOR|Arm C:Regorafenib+Immune checkpoint inhibitor|"Regorafenib orally 80mg daily for 21 days (3 weeks on, 1 week off, 4 weeks as a cycle).Dose escalation to 120mg daily was allowed if well tolerated. until:unacceptable toxicity occurred or disease progression.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
62701259|NCT00189137|ACTIVE_COMPARATOR|doxorubicin and ifosfamide|
62141960|NCT02179359|EXPERIMENTAL|Reduced Intensity Preparative Regimen|For use in patients with unrelated donor bone marrow and for DBA patients who are \>12 years and/or have significant iron exposure.
62141961|NCT02179359|EXPERIMENTAL|Myeloablative Preparative Regimen|For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.
62344265|NCT02807363|ACTIVE_COMPARATOR|Treatment C: Leuprolide 1 month depot|Leuprolide Depot : intramuscular (IM) 3.75 mg depot injection administered for one month of therapy
62344266|NCT02807363|EXPERIMENTAL|Treatment D: Leuprolide Oral Tablet, 10 mg BID|Leuprolide Oral Tablet BID: 10 mg, 12 hours apart for 28 consecutive days
62344267|NCT00756886|ACTIVE_COMPARATOR|Atorvastatin|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
62701260|NCT00189137|EXPERIMENTAL|gemcitabine and docetaxel|
61954264|NCT03026322|ACTIVE_COMPARATOR|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
62701261|NCT05197764||Children with spastic cerebral palsy|Children between 6 months and 9 years old.
62701262|NCT05197764||Typically developing children|Children between 6 months and 9 years old.
62701263|NCT05197764||Children with an acquired brain injury|Children between 1,5 years and 9 years.
62701264|NCT00183248|EXPERIMENTAL|DBMCs|Kidney transplantation, followed by immunotherapy given along with kidney donor Donor bone Bone marrow Marrow stem cell Cells (DBMCs) infusions
62701265|NCT00183248|ACTIVE_COMPARATOR|Control Group|Kidney transplantation, followed by immunotherapy
62701266|NCT02970565|EXPERIMENTAL|Nutrition and Play Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
62701267|NCT02970565|EXPERIMENTAL|Family Nurture Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
61954265|NCT02973061||GH treated patients|All participants family member and teacher will fill questionnaires regarding signs of ateention deficit prior to GH treatment and after 6 and 12 months
62701268|NCT01748656|ACTIVE_COMPARATOR|AVAPS|AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night
62701269|NCT01748656|ACTIVE_COMPARATOR|IVAPS|IVAPS mode(STELAR 150-RESMED)1 night
62701270|NCT02076711|ACTIVE_COMPARATOR|Active|Metoprololsuccinate
62701271|NCT02076711|PLACEBO_COMPARATOR|Placebo|Placebo
62701272|NCT02478541|ACTIVE_COMPARATOR|Sugar Study_low fructose|Consumption of a single test meal that contains fat and a sugary drink made with a low amount of fructose and high amount of glucose
62701273|NCT02478541|ACTIVE_COMPARATOR|Sugar Study_high fructose|Consumption of a single test meal that contains fat and a sugary drink made with a high amount of fructose and low amount of glucose
62701274|NCT04952714||Dynamic Cohort|"Initially, participants who meet the inclusion criteria will be recruited to assemble a cohort of patients with sepsis and those who develop sepsis-induced acute kidney injury will be observed.~Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device (Baxter), at a dose of 25 mL / Kg of PrismaSate dialysis solution (Baxter) and the removal filter oXiris® cytokines (Baxter) vs. the standard filter, for patients who require it, in the presence of a confirmed diagnosis of acute renal failure.~Hemodynamic and ventilatory parameters will be monitored every 24 hours, and inflammatory parameters every 48 hours. A follow-up will be done at 28 days to establish mortality."
62701275|NCT01613651|EXPERIMENTAL|Arm I (RALP)|Patients undergo RALP.
62701276|NCT01613651|EXPERIMENTAL|Arm II (RALP and placement of pelvic drain)|Patients undergo RALP and placement of pelvic drain.
62701277|NCT05588167||Affected|Patients with Niemann-Pick Disease, type C
62701278|NCT04890184|ACTIVE_COMPARATOR|grape juice|100 g of grape juice daily
62701279|NCT04890184|PLACEBO_COMPARATOR|control|no dietary intervention
62701280|NCT02228928|EXPERIMENTAL|CAPNP, 50 ug/cm2 capsaicin patch|50 ug/cm2 capsaicin patch, 49cm2, 1patch/4days
62701281|NCT02228928|EXPERIMENTAL|CAPNP, 100 ug/cm2 capsaicin patch|100ug/cm2 capsaicin patch, 49cm2, 1patch/4days
62701282|NCT02228928|ACTIVE_COMPARATOR|0.075% capsaicin cream|capsaicin cream qc/day
62701283|NCT02228928|PLACEBO_COMPARATOR|Placebo patch|
62701284|NCT04417530|EXPERIMENTAL|Cohort 1 AU-011 & Laser|Low dose of AU-011 + 1 laser application
62701285|NCT04417530|EXPERIMENTAL|Cohort 2 AU-011 & Laser|Medium dose of AU-011 + 1 laser application
62701286|NCT04417530|EXPERIMENTAL|Cohort 3 AU-011 & Laser|Medium dose of AU-011 + 2 laser applications
62701287|NCT04417530|EXPERIMENTAL|Cohort 4 AU-011 & Laser|Highest tolerated dose of AU-011/laser applications from Cohorts 1 to 3 administered weekly for 2 treatments
62701288|NCT04417530|EXPERIMENTAL|Cohort 5 AU-011 & Laser|AU-011/laser applications from Cohorts 1 to 3 administered weekly for 3 treatments. Up to 2 cycles of this regimen may be administered and subjects have the option of receiving a third cycle of treatment.
62701289|NCT04417530|EXPERIMENTAL|Cohort 6 AU-011 & Laser|High dose of AU-011/laser applications administered weekly for 3 treatments and up to 3 cycles of treatment.
62701290|NCT04992130|EXPERIMENTAL|Intervention cohort|Pre-season supplementary neurologic training program
62701291|NCT04992130|NO_INTERVENTION|Control cohort|Usual pre-season training program
62701292|NCT00347269|EXPERIMENTAL|CALM Intervention|"Participant choice of:~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization"
62701293|NCT00347269|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants assigned to TAU with their primary care provider (PCP)
62701294|NCT03889379|EXPERIMENTAL|Effects of Albuterol on Immune Cell Composition|This is a single subject repeated measure experimental design with each participant acting as his/her own control.
62701295|NCT05348421|EXPERIMENTAL|the ultrasound-guided fascia transversalis plane block|The TFPB will be performed while the participant is in the supine position. a high-frequency linear ultrasound probe (5-13 MHz) will be placed transversely in the midaxillary line between the iliac crest and the costal margin. After the external oblique, internal oblique, transversus abdominis muscle, and quadratus lumborum (QL) muscle will be identified.
62701296|NCT05348421|EXPERIMENTAL|The ultrasound guided Pericapsular Nerve Group block|while the participant is in the supine position, a linear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees; In this view, the ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed.
62701297|NCT02465008|EXPERIMENTAL|levobupivaciane group|Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
62701298|NCT02465008|PLACEBO_COMPARATOR|Placebo Comparator (saline solution)|Placebo group (saline solution) 60 ml (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
62701299|NCT05852327||COPD|Subjects with COPD exacerbation
62701300|NCT02383784|EXPERIMENTAL|Low-GI diet|Low glycemic index diet
62701301|NCT02383784|EXPERIMENTAL|High-GI diet|High glycemic index diet
62701302|NCT01799902||Male subjects with LUT predominant storage symptoms (OAB)|male subjects with Overactive Bladder Syndrome (OAB) being treated with solifenacin in monotherapy or combination
62701303|NCT02485886|EXPERIMENTAL|68Ga-BMV101 injection and PET/CT scan|The patients were intravenously injected with 68Ga-BMV101 and underwent PET/CT scan 1 h and 2.5 h after that.
62701304|NCT05807594|EXPERIMENTAL|HMZ 2.0 Intervention Group|HMZ 2.0 will be delivered by a registered dietitian in weekly didactic, one-on-one discussions in remote synchronous format (e.g., Zoom). If a subject has internet connectivity issues, she will be able to participate in the remote sessions from an onsite location (e.g., laboratory space on the Penn State University Park campus, clinical space at Hershey campus or Geisinger). All intervention women will receive the baseline intervention delivered as a maximum of 24 weekly modules (depending on gestational age at enrollment) which includes: Education and Counseling (GWG/PA/EI/sedentary behaviors/sleep behaviors/stress management, etc.), Goal-Setting and Action Plans (guided and self-selected PA/EI goals including recipe and workout booklet use), Self-Monitoring (wearing/using mHealth tools to monitor GWG/PA/EI/sleep), and Featured Evidence and Fetal Growth Facts (evidence-based studies and baby growth fun facts shared with women about how mom's health impacts her baby).
62701305|NCT05807594|ACTIVE_COMPARATOR|Attention Control Group|All women will receive prenatal care offered by recruitment sites with routine provider visits, prenatal counseling, brief discussions on healthy prenatal behaviors, and clinical oversight of health (e.g., monitor glucose levels if diagnosed with gestational diabetes during the study period). Women randomized to the attention control group will complete the same measurement procedures as the intervention group. To match the HMZ intervention group, women will receive weekly, remote-delivered education content (60 min/session) on preparing for labor/delivery and benefits of behavioral pain management strategies (e.g., mindfulness-based relaxation, imagery, music, massage, deep-breathing) to regulate pain after childbirth with non-pharmacological approaches. Content is drawn from evidence-based guidelines and materials designed by Dr. Downs and her team for a Patient-Provider Toolbox to reduce opioid-related pain management use after childbirth.
62701306|NCT05509348|EXPERIMENTAL|Phase 1: ADAPT Workshop|2 - day long in-person workshops (7 hours each day). Workshops are 2 weeks apart.
62701307|NCT05509348|EXPERIMENTAL|Phase 1: ADAPT Online|3 weeks are given to complete 12 online modules using a secure website. Online modules include skill video, practice video, summary sheets, mindfulness audio and exercise video, printable handouts and motivation questionnaire.
62701308|NCT05509348|EXPERIMENTAL|Phase 2: ADAPT Group|3 - 2 hour long in-person group sessions. Group sessions are consecutive weeks.
62701309|NCT05509348|EXPERIMENTAL|Phase 2: ADAPT Individual|3 - 1 1/2 hour in-person individual sessions. Sessions are consecutive weeks.
62701310|NCT00829244|EXPERIMENTAL|CONSORT Dosing|GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
62141962|NCT03130894||Healthy control|A FPG concentration \< 6.1 mmol/l, and a 2-h oral glucose tolerance test (OGTT) plasma glucose concentration \< 7.8 mmol/l was considered normal glucose tolerance.
62141963|NCT03130894||Type 2 diabetes|Type 2 diabetes was diagnosed when fasting plasma glucose (FPG) ≥ 7.0 mmol/l, and/or 2-h post-glucose load ≥ 11.1 mmol/l.
62344268|NCT00756886|PLACEBO_COMPARATOR|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
62502053|NCT04983602|EXPERIMENTAL|EDPLUS arm|The ED PLUS intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED. Additionally the participants in this arm will undergo a 6 week physiotherapy led intervention in the community involving 3 home visits and weekly telephone support. The intervention will involved assessment of the patients function in terms of strength, balance and mobility. Following assessment the intervention will be aimed at addressing deficits in the function of the participants, review of their medical management by a geriatrician trainee and focusing on self management of their own program.
62701311|NCT00829244|ACTIVE_COMPARATOR|Standard Dosing|GONAL-f® at a standard dose of 150 IU per day
62701312|NCT00797303|EXPERIMENTAL|1|A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
62701313|NCT02640300|EXPERIMENTAL|Immediate discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules at week 3. All capsules contained placebo (i.e., the antipsychotic drugs were abruptly discontinued). Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
62701314|NCT02640300|EXPERIMENTAL|Gradual discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules (i.e., the antipsychotic drugs were discontinued) at week 3. Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
62141964|NCT06135220||PE confirmed|Patients admitted with confirmed pulmonary embolism.
62502054|NCT04618484|EXPERIMENTAL|Biomodulation|6-weeks post-operative cryo-, photo- and electro-biomodulation protocol after repair
62502055|NCT04618484|NO_INTERVENTION|Control|standard rehabilitation after repair
62502056|NCT04767087|ACTIVE_COMPARATOR|Honey and Nigella sativa Arm|0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds
62141965|NCT06135220||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
62141966|NCT06135220||Controls|Healthy controls - same gender and age (within af range of 10 years) as PE patients.
62141967|NCT04082507||Non_adherent plcenta|placenta separated within 15 minutes after delivery of fetus
62502057|NCT04767087|PLACEBO_COMPARATOR|Placebo Arm|empty capsule with sugar water
62502058|NCT04781322|EXPERIMENTAL|Intervention|Heavy drinking healthy volunteers
62502059|NCT04781322|PLACEBO_COMPARATOR|Placebo|Heavy drinking healthy volunteers
62502060|NCT05455164|OTHER|Without supplementation, followed by Supplementation with Dietary Fibre|"For the first two weeks, subjects were given eucaloric prepared meals typical of Indonesian diet, which has low protein and low DF contents (contain less than 15 g/d of DF and protein content less than 15% of total macronutrient distribution range).~After two weeks of washing periods, all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range). At the end of interventions, waist circumference, body weight, body composition, fasting plasma glucose, uric acid, and total cholesterol were measured again. Half of DF content in food came from natural occurring fiber from fruit, vegetables and whole grains, the other half (50%) come from IMO-based fiber supplement (FibercremeⓇ, PT. Lautan Natural Krimerindo, Mojokerto, Indonesia"
62502061|NCT04035954|ACTIVE_COMPARATOR|Interventional|The control group will continue the routine physiotherapy program based on NDT: Neurodevelopmental Therapy twice a week, 2 days / 1 hour / day during 8 weeks.
62502062|NCT04035954|EXPERIMENTAL|Experimental|The treatment group will participate in clinical pilates exercises 2 days / 1 hour / day during 8 weeks.They will also continue their weekly routine physiotherapy programs.
62502063|NCT05768178|EXPERIMENTAL|Treatment Arm 05- Vemurafenib and Cobimetinib|This vemurafenib and cobimetinib appendix is for BRAF V600 mutation-positive malignancies occurring in adults.
62502064|NCT04602585|EXPERIMENTAL|Experimental|After discharge, the program manager will link the participants with a VHT nearest to them. The participants (randomized to the intervention arm) will be informed during the consent procedure that they will undergo 6 psycho-education sessions (1 per month) together with a family member at the participant's residence. The VHTs and participants will meet and schedule appointments for the next engagements. This shall be done on a case by case basis. Some psycho-education sessions could take place in the patient's residence, others in the nearest public space (school or church or mosque compounds). The investigators will document where the majority of these sessions happen. This will help the investigators document feasibility. The PI and RAs will sit in some of the sessions during the pilot phase of data collection to ensure fidelity to the manual.
62502065|NCT04602585|PLACEBO_COMPARATOR|Usual care arm|Participants will receive usual care
62502066|NCT05795231||Gender Based|Male patients will be compared to female patients with regards to incidence of complications
62502067|NCT05795231||Age Based|Various age groups will be evaluated to determine vulnerable age groups
62502068|NCT03605979||diabetes group|Patient with hypoglycemia unawareness
62502069|NCT06467851|NO_INTERVENTION|Healthy subject group|Healthy subjects completed questionnaires and underwent saliva collection
62502070|NCT06467851|EXPERIMENTAL|Chronic insomnia patients group|Questionnaire completion and saliva collection in patients with chronic insomnia before and after Chinese herbal medicine treatment, respectively
62502071|NCT02771028|EXPERIMENTAL|Intervention group|Patients assigned to intervention group receive an 8-week EFT-program
62502072|NCT02771028|NO_INTERVENTION|Control group|Patients assigned to control group are placed on a waitlist for a period of 8 weeks
62502073|NCT04219358|ACTIVE_COMPARATOR|Placebo & Standard Treatment|
62502074|NCT04219358|EXPERIMENTAL|Imiquimod 5% & Standard Treatment|
62502075|NCT04219358|EXPERIMENTAL|Imiquimod 0.05% & Standard Treatment|
62502076|NCT04219358|EXPERIMENTAL|Imiquimod nanoencapsulated 0.05% & Standard Treatment|
62502077|NCT06237348|EXPERIMENTAL|Simeox|Airway clearance device
62502078|NCT06237348|ACTIVE_COMPARATOR|Control|Usual chest physiotherapy (manual, breathing exercise, PEP/oPEP)
62502079|NCT06077617||Diagnostic group|Adult ICU patients submitted to feeding tube placement according to institutional standard operating procedure
62502080|NCT04580420|EXPERIMENTAL|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
62502081|NCT01613794|NO_INTERVENTION|No intervention|
62502082|NCT01613794|EXPERIMENTAL|Rosuvastatin|
62502083|NCT00292591|ACTIVE_COMPARATOR|cholecalciferol-400 IU|Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
62502084|NCT00292591|EXPERIMENTAL|cholecalciferol 2000 IU|Experimental group receiving 2000 IU total vitamin D3/day.
62502085|NCT00292591|EXPERIMENTAL|cholecalciferol 4000 IU|Experimental group receiving 4000 IU/day cholecalciferol
62502086|NCT00917735|EXPERIMENTAL|Green tea extract|Green tea extract capsules containing 80.7 % total catechins (51.7 % EGCG)
62502087|NCT00917735|PLACEBO_COMPARATOR|Sugar pill|Placebo capsules containing 50% maltodextrin, 49.5 % cellulose, and 0.5 % magnesium stearate
62502088|NCT05541640|PLACEBO_COMPARATOR|control group|
62502089|NCT05541640|ACTIVE_COMPARATOR|lidocaine group|
62502090|NCT01891058|ACTIVE_COMPARATOR|drug-shock vs shock only|For ED patients with RAFF, Investigators will compare conversion to normal sinus rhythm between the two strategies of i) attempted pharmacological cardioversion with intravenous procainamide followed by DC cardioversion if necessary (Drug-Shock), and ii) DC cardioversion alone (Shock Only).
62502091|NCT01891058|NO_INTERVENTION|pad positions|For ED RAFF patients undergoing DC cardioversion, Investigators will compare conversion to normal sinus rhythm between the i) antero-posterior and ii) antero-lateral pad positions.
62502092|NCT06628609|OTHER|Control|Passive recovery for 30 minutes
62502093|NCT06628609|EXPERIMENTAL|PBMT-sMF|Photobiomodulation therapy combined with static magnetic field, with a total treatment duration lasting for around 30 minutes.
62502094|NCT06628609|ACTIVE_COMPARATOR|Shock wave|Shock wave therapy applied for 30 minutes.
62502095|NCT06628609|ACTIVE_COMPARATOR|Pneumatic compression|Pneumatic compression applied for 30 minutes.
62502096|NCT01120899|EXPERIMENTAL|Minocycline|
62502097|NCT01487629|EXPERIMENTAL|Bevacizumab|Treatment of macular edema with intravitreal Bevacizumab
62502098|NCT01487629|EXPERIMENTAL|Ranibizumab|Treatment of macular edema with intravitreal Ranibizumab
62502099|NCT05226741|EXPERIMENTAL|Head protection|Participants are given a form of head protection
62714848|NCT01041261|NO_INTERVENTION|Control arm|Subjects will be issued control study product (Carnation Instant Breakfast, no sugar added)
62714849|NCT01041261|EXPERIMENTAL|Treatment arm|Medical food
62502100|NCT04561336|EXPERIMENTAL|avelumab plus cetuximab|avelumab at a dose of 10 mg/kg once every 2 weeks plus cetuximab at a starting dose of 400 mg/m2 by i.v.infusion over 120 minutes at first dose and at the dose of 250 mg/ m2 by i.v.infusion over 60 minutes for subsequent infusions every week.
62502101|NCT03863041|OTHER|Additional MRI SCAN sequence|Additional sequence performed during MRI scan
62502102|NCT00645151|EXPERIMENTAL|High Risk|
62502103|NCT00645151|EXPERIMENTAL|Low Risk|
62502104|NCT00645151|EXPERIMENTAL|Medium Risk|
62502105|NCT06378788||Fibromyalgia|Patients meeting the diagnostic criteria of 2016 American College of Rheumatology (ACR) guide for fibromyalgia
62502106|NCT06378788||Control|healthy participants
62502107|NCT04362332|ACTIVE_COMPARATOR|chloroquine|1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
62502108|NCT04362332|ACTIVE_COMPARATOR|hydroxychloroquine|2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
62502109|NCT04362332|NO_INTERVENTION|Supportive care only|3. Supportive care only.
62502110|NCT05898763|EXPERIMENTAL|Treatment arm|Patients will be vaccinated with the TEIPP24 vaccine in Montanide ISA 51 every three weeks for a total of three rounds of vaccination. The total treatment duration is 9 weeks for each patient. The three dose levels tested are 20, 40 and 100 µg of peptide. Dose 1: 20 µg of peptide in Montanide ISA 51; Dose 2: 40 µg of peptide in Montanide ISA 51; Dose 3: 100 µg of peptide in Montanide ISA 51. Patients in the extension cohort will receive the highest safest dose of peptide in combination with pembrolizumab.
62502111|NCT03078257|EXPERIMENTAL|dual antiplatelet therapy|clopidogrel +aspirin
62502112|NCT03078257|EXPERIMENTAL|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
62502113|NCT03078257|EXPERIMENTAL|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
62502114|NCT03078257|EXPERIMENTAL|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
62502115|NCT03078257|PLACEBO_COMPARATOR|placebo|clopidogrel +aspirin +placebo
62502116|NCT05155293|EXPERIMENTAL|AVT06 (proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of AVT06 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
62502117|NCT05155293|EXPERIMENTAL|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
62502118|NCT01754376|EXPERIMENTAL|Treatment Arm|"Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression."
62502119|NCT05940233|EXPERIMENTAL|Letrozole plus Misoprostol|We give the Letrozole 10 mg PO daily at day 1-3 prior to Misoprostol 800 mcg SL in day 4.
62502120|NCT05940233|ACTIVE_COMPARATOR|Misoprostol|We give only Misoprostol 800 mcg SL.
62701315|NCT06564090|EXPERIMENTAL|robot assisted gait training|Morning Walk® is a new end-effector type robot developed by Hyundai Heavy Industries and Taeha Mechatronics for lower limb rehabilitation in the patients with gait disturbance.The RAGT group received RAGT with robot training for 30 minutes and conventional physiotherapy for 30 minutes per session
62502121|NCT05517096|EXPERIMENTAL|E-Health and monitoring|eHealth care and explorative observational home-monitoring
62502122|NCT05517096|NO_INTERVENTION|regular care and monitoring|only explorative observational home-monitoring during regular care
62502123|NCT02123524|EXPERIMENTAL|Rivaroxaban|Rivaroxaban 10mg tablet daily for 45 days
62502124|NCT02123524|PLACEBO_COMPARATOR|Control|Placebo tablet daily for 45 days
62502125|NCT03929809||Adult Single-sided deafness|Adult subjects with unilateral single-sided deafness at least 6 months (to ensure stability of hearing loss), but no greater than 10 years will be implanted with a MED-EL Synchrony Cochlear Implant.
62502126|NCT04108962|EXPERIMENTAL|Treatment|Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment
62502127|NCT04491916|EXPERIMENTAL|Iron Treatment|Treatment with iron sucrose with orginal guideline from ferritin\>500ng/ml, or TSAT\>20% to ferritin\>800ng/ml, or TSAT\>50%.
62701316|NCT06564090|ACTIVE_COMPARATOR|conventioanl gait training|The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
62701317|NCT02643485||Study group|Patients undergoing forefoot reconstruction of hallux valgus or hallux rigidus
62701318|NCT02643485||Control group|Healthy volunteers (Students)
62701319|NCT00659022|ACTIVE_COMPARATOR|A|immediate surgery of the primary colorectal tumor, no neoadjuvant therapy
62701320|NCT00659022|EXPERIMENTAL|B|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
62701321|NCT00659022|EXPERIMENTAL|C|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
62701322|NCT00659022|EXPERIMENTAL|D|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
62502128|NCT04315324|EXPERIMENTAL|Treatment (AKR1C3-activated prodrug OBI-3424)|Patients receive AKR1C3-activated prodrug OBI-3424 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
62502129|NCT05793632|EXPERIMENTAL|Quetiapine|The patients with multiple risks for delirium will receive 25 mg/day PO
62502130|NCT05793632|NO_INTERVENTION|Non pharmacological preventive bundle|The patients will only be monitored with application of delirium preventive bundle without pharmacological agent
62502131|NCT04712916|EXPERIMENTAL|Intervention group|Individualized education on medication use, appropriate diet and physical activity was given to the participants in intervention group.
62502132|NCT04712916|NO_INTERVENTION|Control group|Participant received usual care in the clinic. No individualized education on medication use, appropriate diet and physical activity was given to the participants.
62502133|NCT06531876|EXPERIMENTAL|Suspected Hypersomnia Arm [Arm A]|Subjects being evaluated for a hypersomnia condition at participating sleep clinics will be recruited to Arm A. These subjects will not yet have a diagnosis and not yet be on treatment. These subjects will undergo 1 week of at-home ambulatory monitoring with the Dreem Headband, followed by formal in-lab evaluation with gold-standard polysomnography/multiple sleep latency testing while also using the Dreem Headband.
62344269|NCT04693689|EXPERIMENTAL|Conventional vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 0%."
62502134|NCT06531876|EXPERIMENTAL|Known Narcolepsy Type 1 Arm [Arm B]|Subjects with known Narcolepsy Type 1, under treatment at participating sleep clinics, will be recruited to Arm B. These subjects will be asked to withdraw from their Narcolepsy related medication therapy starting on day -7, undergo 1 week of at-home ambulatory monitoring with the Dreem Headband on days 1-7, and then undergo two consecutive nights of in-lab PSG followed by MSLT while synchronously using the Dreem headband.
62502135|NCT00508898|EXPERIMENTAL|treatment group|Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
62502136|NCT00508898|ACTIVE_COMPARATOR|control group|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
62502137|NCT06581120||GLP-1|Individuals currently taking glucagon like peptide receptors who have a surgery scheduled with Cincinnati Children's Hospital same day surgery endocrinology clinic and will receive a point of care gastric ultrasound.
62502138|NCT06581120||Control|Individuals not taking GLP-1 who have a surgery scheduled with Cincinnati Children's Hospital same day surgery or endocrinology clinic and will receive a point of care gastric ultrasound.
62502139|NCT01784016|EXPERIMENTAL|Healthy Smokers|Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.
62502140|NCT01784016|EXPERIMENTAL|Healthy Nonsmokers|Healthy nonsmoking controls aged 18-50 reporting consumption of \<100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of \< 9 ppm at screening.
62502141|NCT02672969|EXPERIMENTAL|Smoke evacuation uses|Smoke evacuation uses means using RapidVac Smoke Evacuator with electrosurgical unit during coagulation and cutting surgery. (Experimental group)
62502142|NCT02672969|NO_INTERVENTION|no smoke evacuation uses|No smoke evacuation uses means using only the regular electrosurgical unit during coagulation and cutting surgery. (Control group)
62502143|NCT04830982|EXPERIMENTAL|Diazoxide|IV Diazoxide as additive to hypothermic hyperkalemic cardioplegia.
62502144|NCT04830982|PLACEBO_COMPARATOR|Placebo|Placebo as additive to hypothermic hyperkalemic cardioplegia.
62502145|NCT02569307|ACTIVE_COMPARATOR|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
62502146|NCT02569307|ACTIVE_COMPARATOR|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose
62502147|NCT02569307|ACTIVE_COMPARATOR|Placebo|Placebo added to TAU
62502148|NCT02569307|ACTIVE_COMPARATOR|Minocycline Plus Omega-3 fatty acids|Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose
62502149|NCT06467201|EXPERIMENTAL|KSHN001126 150mg|Low Dose
62502150|NCT06467201|EXPERIMENTAL|KSHN001126 300mg|Mid Dose
62502151|NCT06467201|EXPERIMENTAL|KSHN001126 600mg|High Dose
62701323|NCT04372485|OTHER|mHealth|Adolescents enrolled in this arm will receive treatment-related text messages.
62701324|NCT04372485|NO_INTERVENTION|Usual care|Adolescents in this arm will receive usual care.
62502152|NCT03423667|EXPERIMENTAL|N-acetylcysteine|
62701325|NCT05093621|ACTIVE_COMPARATOR|Furosemide|"Furosemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide"
61954266|NCT02973061||Healthy control|All participants family member and teacher will fill questionnaires regarding signs of atention deficit at baseline and after 6 and 12 months
62502153|NCT03423667|PLACEBO_COMPARATOR|Lactose powder|
62502154|NCT06401434|ACTIVE_COMPARATOR|On-site radiologist|On-site radiologist reads/interprets all CXR images
62502155|NCT06401434|EXPERIMENTAL|CAD-based triage (with INSIGHT CXR software)|CAD software processes all CXR images and the on-site radiologist only reads/interprets the subset not deemed totally to be clear/normal by the CAD software
62502156|NCT02657005|EXPERIMENTAL|TK216 treatment|Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
62502157|NCT03225352|EXPERIMENTAL|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
62701326|NCT05093621|ACTIVE_COMPARATOR|Torsemide|"Torsemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide"
62701327|NCT02449187|EXPERIMENTAL|JLP-1310, Fasted followed by fed|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
62502158|NCT03225352|EXPERIMENTAL|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
62502159|NCT03225352|EXPERIMENTAL|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
62502160|NCT03225352|EXPERIMENTAL|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
62701328|NCT02449187|EXPERIMENTAL|JLP-1310, Fed followed by fasted|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
62701329|NCT02055508|EXPERIMENTAL|Exercise Intervention Program (EIP)|"Inpatient periods: The combined resistance and endurance program consist of free weight and rubber band training for major upper and lower body muscle groups respectively of cycling/walking on an ergometer/treadmill 3x/week.~Outpatient periods (3x/week at least two/one supervised training sessions): Supervised training sessions in the local outpatient training center will comprise of resistance exercise on machines and endurance training on an ergometer/treadmill. For non-supervised training session during the outpatient period participants will receive an exercise manual for individualized home-based exercising.~In weekly phone calls, the advanced practice nurse will review adherence to the intervention and identify problems. Furthermore, the patients will also be asked the same questions as in the CMPC group."
62701330|NCT02055508|ACTIVE_COMPARATOR|Care-Management-Phone-Calls (CMPC)|"Patients in this arm will receive a weekly care-management-phone-call (CMPC), performed by an advanced practice nurse (APN). The CMPCs are based on a structured questionnaire, reflecting pain, shortness of breath, disturbed sleep, exhaustion and distress and potentially treatment related side effects (e.g. infections, polyneuropathy, etc.). In case of demanding management of symptoms or complaints (e.g. uncontrolled pain or breathlessness) the treating physician is contacted by the APN to facilitate improvement."
62344270|NCT04693689|EXPERIMENTAL|Conventional vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 20%."
62344271|NCT04693689|EXPERIMENTAL|Conventional vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 40%."
61954267|NCT06429748|EXPERIMENTAL|Open Label|Single Group
61954268|NCT03460860|EXPERIMENTAL|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|
61954269|NCT03460860|PLACEBO_COMPARATOR|Placebo|
61954270|NCT03758001|EXPERIMENTAL|IBI101|IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.
61954271|NCT03758001|EXPERIMENTAL|IBI101 in combination with Sintilimab|"IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.~Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each."
61954272|NCT02156986||9 month old infant|
61954273|NCT02156986||12 month old infant|
61954274|NCT02156986||18 month old toddler|
62344272|NCT04693689|EXPERIMENTAL|Conventional vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 60%."
62344273|NCT04693689|EXPERIMENTAL|Conventional vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 80%."
62344274|NCT04693689|EXPERIMENTAL|RNA vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 0%."
62701331|NCT00636779||1|Up to five hundred eligible patients seen at each of the nine participating Integrative Medicine Centers will be approached (by mail, phone, at the time of their visit, etc.) and invited to consent to the paper and pencil study.
62701332|NCT06407011|SHAM_COMPARATOR|Control|The CON group did not have any intervention but usual care.
61954275|NCT02156986||24 month old toddler|
61954276|NCT02156986||36 month old toddler|
61954277|NCT01446978|ACTIVE_COMPARATOR|initial single dose of hep A vaccine|The participants will receive a single dose of hepatitis A vaccine at 0+1+6 months
61954278|NCT01446978|ACTIVE_COMPARATOR|initial double dose|Participants will receive one dose of hepatitis A vaccine in each M. deltoids and an additional dose at 6 months later
61954279|NCT06180772|NO_INTERVENTION|Control|Continue normal activities
61954280|NCT06180772|EXPERIMENTAL|3/wk|Use FIT FIRST 3 times pr. week
61954281|NCT06180772|EXPERIMENTAL|1.5/wk|Use FIT FIRST 1.5 times pr. week
61954282|NCT02200432|NO_INTERVENTION|Control|The study's current rule-based CTHC system is embedded within the Decide2Quit.org web service. Control smokers will receive the current Decide2Quit.org system, including informational web pages, an interactive quit plan, plus pushed email messages. The messages will be selected using the current rule-based CTHC system. The CTHC selects messages based on decision rules (e.g: readiness to quit, gender) using information from a smoker's baseline profile. Participants will receive one message per day for 30 days
62141968|NCT04082507||Adherent placenta|placenta dosenot separated within 15 minutes after delivery of fetus
62141969|NCT00834379|EXPERIMENTAL|Pravastatin|Pravastatin 40 mg Tablet (test) dosed in first period followed by Pravachol® 40 mg Tablet (reference) dosed in second period
61954283|NCT02200432|EXPERIMENTAL|Intervention|The PERSPeCT intervention smokers will receive all components of the Decide2Quit.org web service, but persuasive email messages will be selected by the PERSPeCT recommender system developed in Aim 2. PERSPeCT will use data (see Figure 1) to predict messages that would be most influential to the participant. Intervention smokers will receive one PERSPeCT-generated message per day for 30 days. With each message rating, the PERSPeCT system will further adapt to patient preferences.
62344275|NCT04693689|EXPERIMENTAL|RNA vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 20%."
62344276|NCT04693689|EXPERIMENTAL|RNA vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 40%."
62344277|NCT04693689|EXPERIMENTAL|RNA vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 60%."
62344278|NCT04693689|EXPERIMENTAL|RNA vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 80%."
62344279|NCT03383978|EXPERIMENTAL|NK-92/5.28.z + Ezabenlimab|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8; intravenous infusion of Ezabenlimab 240mg q 3 weeks
61954284|NCT02738060|EXPERIMENTAL|Case group|The patients in case group will be received baked milk daily in the form of muffin for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.
61954285|NCT02202980|EXPERIMENTAL|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
61954286|NCT02202980|EXPERIMENTAL|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
61954287|NCT02202980|EXPERIMENTAL|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
61954288|NCT02202980|EXPERIMENTAL|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
61954289|NCT02202980|EXPERIMENTAL|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
61954290|NCT02202980|EXPERIMENTAL|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
61954291|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
61954292|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
61954293|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
61954294|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
62344280|NCT02867449|EXPERIMENTAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
62344281|NCT02867449|EXPERIMENTAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
62344282|NCT04557254||silver-triclosan graft implantation (SynG group)|
62344283|NCT04557254||standard Dacron graft implantation (DacrG group)|
61954295|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
61954296|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
61954297|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
62141970|NCT00834379|ACTIVE_COMPARATOR|Pravachol®|Pravachol® 40 mg Tablet (reference) dosed in first period followed by Pravastatin 40 mg Tablet (test) dosed in second period
62141971|NCT01536093|EXPERIMENTAL|Colostrum|oropharyngeal administration of own mother's colostrum
62141972|NCT01536093|PLACEBO_COMPARATOR|Placebo|oropharyngeal administration of sterile water
61954298|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
61954299|NCT02202980|EXPERIMENTAL|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
61954300|NCT01048177|EXPERIMENTAL|Treatment|
61954301|NCT02032225||CADASIL|patients with CADASIL
61954302|NCT04536701|EXPERIMENTAL|Dementia/Caregiver Dyad|All dementia/caregiver dyads will have in-home acoustic monitoring to classify mood and will be provided mindfulness-based stress reduction recommendations via a smart phone.
61954303|NCT01528475|ACTIVE_COMPARATOR|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs, initiation of an intravenous infusion of cold saline, and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
61954304|NCT01528475|NO_INTERVENTION|Usual pre-hospital care|Patients in this arm will receive usual post-resuscitation care by paramedics. Usual post-resuscitation care does not include initiation of cooling in the pre-hospital setting.
61954305|NCT01926015|EXPERIMENTAL|Concomitant RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (\>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
61954306|NCT01926015|ACTIVE_COMPARATOR|Staggered RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (\>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
61954307|NCT04157491|EXPERIMENTAL|anlotinib and anti PD-1 antibody|
61954308|NCT03569618|ACTIVE_COMPARATOR|Game 1|Tablet-based Game 1.
61954309|NCT03569618|PLACEBO_COMPARATOR|Game 2|Tablet-based Game 2.
61954310|NCT00896246|ACTIVE_COMPARATOR|Klean-Prep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
61954311|NCT00896246|EXPERIMENTAL|Moviprep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
61954312|NCT02726152|EXPERIMENTAL|Polymer clips|Patients will be randomised to polymer clips for closure of the appendiceal stump
61954313|NCT02726152|ACTIVE_COMPARATOR|Endoloops|Patients will be randomised to endoloops for closure of the appendiceal stump
61954314|NCT01216748|EXPERIMENTAL|health life-time non smokers|health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation
61954315|NCT04289662|EXPERIMENTAL|K-924 LD|K-924 LD once daily
61954316|NCT04289662|EXPERIMENTAL|K-924 HD|K-924 HD once daily
61954317|NCT02056977|EXPERIMENTAL|Titration|Individualized PEEP titration by EIT
61954318|NCT02056977|ACTIVE_COMPARATOR|Control|PEEP stablished according to the routines at the institution (PEEP table according to the P/F ratio)
61954319|NCT02685410|EXPERIMENTAL|One Night Stan Pilot Testing Group|The pilot testing of the One Nigh Stan prototype intervention will utilize 20 young black women aged 18-24 as participants.
61954320|NCT04138810|EXPERIMENTAL|post-op VCE|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The VCE group will conduct their encounter via the videoconference section of the MyChart mobile applications. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
61954321|NCT04138810|ACTIVE_COMPARATOR|Office post-operative visits|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
61954322|NCT01593098||Exposed siblings|Siblings (age \>40 and \<70) of individuals diagnosed with advanced neoplasm on screening colonoscopy. Advanced neoplasm is defined as adenomas≥10mm size, \>25% villous features, severe dysplasia or carcinoma-in-situ
61954323|NCT01593098||unexposed siblings|Siblings (age \>40 and \<70) of individuals diagnosed with no polyp on screening colonoscopy who is age and sex matched to case.
61954324|NCT06107400|EXPERIMENTAL|RM-004|RM-004 (ex vivo gene-edited CD34+ autologous hematopoietic stem cells) will be administered as a single intravenous infusion
61954325|NCT06373796|EXPERIMENTAL|FAT PLUS|
61954326|NCT05587803|EXPERIMENTAL|study group|This arm consists of all the patients that fulfill the inclusion and exclusion-criteria and are therefore suitable for the study. The Neurowave brain monitor is attached on the patients forehead and the study starts. At that moment the included patients are monitored by the Masimo/Sedline en the Neurosense/Neurowave monitor.
61954327|NCT05229406|EXPERIMENTAL|5-minute app usage|Participants will be asked to use the HMP app for 5-minutes per day.
61954328|NCT05229406|EXPERIMENTAL|15-minute app usage|Participants will be asked to use the HMP app for 15-minutes per day.
61954329|NCT02767843|EXPERIMENTAL|treatment|continuous negative external pressure (cNEP) at various negative pressures
61954330|NCT03562832|EXPERIMENTAL|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
61954331|NCT06504914|EXPERIMENTAL|Arms|Food is Medicine approach Groups of 10 will attend a 12 week intervention that includes cooking classes, grocery delivery and nutrition education.
62141973|NCT01075750||Normal Saline|Patients receiving Normal Saline during and after the renal transplantation.
62344284|NCT05596903|EXPERIMENTAL|EMDR 2.0|EMDR 2.0 Online Group protocol will be administered.
62344285|NCT05596903|ACTIVE_COMPARATOR|Control|Mental Health Gap Action Programme (mhGAP) will be administered.
62344286|NCT01452555|ACTIVE_COMPARATOR|In Person Counseling|Participants will receive an in person HIV and HIV testing counseling session
61954332|NCT05062356|EXPERIMENTAL|Suprainguinal fascia iliaca compartment block (FICB)|Suprainguinal fascia iliaca compartment block (FICB) is a technique that involves injection of local anesthetics underneath the fascia of the iliacus muscle to block the femoral nerve, the lateral femoral cutaneous nerve and, possibly, the obturator nerve.
61954333|NCT05062356|ACTIVE_COMPARATOR|Pericapsular nerve group block (PENG)|The pericapsular nerve group block (PENG) is a technique that involves injection of local anesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus.
61954334|NCT05062356|SHAM_COMPARATOR|Local analgesia infiltration (LAI)|local anesthetic infiltration (LAI) into the anterior pericapsular tissues
61954335|NCT05062356|SHAM_COMPARATOR|No adjunct: spinal anaesthesia (control)|Standard spinal anesthesia technique
61954336|NCT01936805|ACTIVE_COMPARATOR|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
61954337|NCT01936805|PLACEBO_COMPARATOR|Control|A loading dose of placebo was administrated 24 h before the PCI.
61954338|NCT00903396|EXPERIMENTAL|Arm I|Patients receive palonosetron hydrochloride IV on day 1.
61954339|NCT00903396|EXPERIMENTAL|Arm II|Patients receive palonosetron hydrochloride IV on days 1 and 4.
61954340|NCT00903396|PLACEBO_COMPARATOR|Arm III|Patients receive placebo IV on day 1.
61954341|NCT00903396|PLACEBO_COMPARATOR|Arm IV|Patients receive placebo IV on days 1 and 4.
61954342|NCT01306396|OTHER|Intervention group|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
61954343|NCT01306396|NO_INTERVENTION|Control group|"Families participating in the control group are given only one dietary counseling based on the references of the DGE at the beginning of the study if they wish."
62344287|NCT01452555|EXPERIMENTAL|Video Presentation|Participants will watch an HIV and HIV testing video
62701333|NCT06407011|EXPERIMENTAL|Swedish massage prior circuit breathing training group (SBT)|Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
62701334|NCT06407011|EXPERIMENTAL|Circuit breathing training group (CBT)|Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
61954344|NCT05500105|EXPERIMENTAL|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
61954345|NCT03097172||Group 1|"Stable elective patients Stenotic coronary artery 10 x LAD 10 x RCA 10 x Cx~30 patients total"
61954346|NCT03097172||Group 2|"Stable elective patients Chronic total occlusion of one artery~10 x LAD 10 x RCA~20 patients total"
61954347|NCT00459225|ACTIVE_COMPARATOR|1|The parent/guardian will be educated on the iron study and provided the opportunity to ask questions. If the parent/guardian chooses to participate in the study, the parent/guardian will give informed consent for the patient to be placed in either Group I or Group II, based upon guardian/parents' choice for participation in the iron arm of the study. Group I will be randomized in a 1:1 ratio in this open label trial to either receive or not receive iron. Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
62701335|NCT01432444|EXPERIMENTAL|OPC-14597|Aripiprazole IM depot injection 300 mg or 400 mg.
61954348|NCT00459225|NO_INTERVENTION|2|Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
61954349|NCT01120145||Therapeutic efficacy study|Asymptomatic parasitemic pregnant women at 16-26 weeks of gestation will be enrolled into the study and followed weekly for 42 days after the receipt of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy to assess the clearance of parasitemia.
61954350|NCT01120145||Birth outcomes study|Women presenting for delivery will be enrolled and assessed for a history of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy and evidence of malaria infection by placental histology, maternal peripheral parasitemia, maternal anemia and infant cord blood parasitemia.
61954351|NCT01120145||Characterizing molecular markers of SP resistance|Parasitemic outpatients attending the health facility will be tested for parasite molecular markers of sulphadoxine-pyrimethamine resistance.
61954352|NCT04177667|ACTIVE_COMPARATOR|Proxeed arm|Subjects received 2 packets per day for 6 months of supplement (1000 mg of L-carnitine, 725 mg of fumarate, 500 mg of acetyl-L-carnitine, 1000 mg of fructose, 50 mg of citric acid, 50 µg of selenium, 20 mg of coenzyme Q10, 90 mg of vitamin C, 10 mg of zinc, 200 µg of folic acid and 1.5 µg of vitamin B12)
61954353|NCT04177667|PLACEBO_COMPARATOR|Placebo arm|Subjects received 2 packets per day for 6 months of placebo
62701336|NCT00913822|EXPERIMENTAL|1|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
61954354|NCT04795011|ACTIVE_COMPARATOR|control group|Standard rehabilitation protocol will be administered to the control group. In the standard rehabilitation protocol for the first three days after surgery, 3 sets of exercises will be applied as 10 repetitions. The treatment will be initiated for the patients with tolerable coughing and deep breathing exercises. Active dorsi-plantar flexion of the ankle, isometric contraction for the quadriceps, hamstrings and gluteus maximus, for the knee in the supine position on the bed; active heel shift exercises, straight leg raising and standing knee and hip flexion, active hamstring curling, and self-hamstring stretching will be performed. After the exercise, the morning treatment protocol will be completed with a walker at a tolerable distance. The patient will be given assignment in the form of walking and repetition of morning exercises at a tolerable level at least twice during the day.
62141974|NCT01075750||Elomel Isoton|Patients receiving Elomel Isoton during and after renal transplantation
62344288|NCT01080937||Patient with acute heart failure|Hospitalized patient, whatever the mode of initial admission with acute heart failure
62344289|NCT00913133|EXPERIMENTAL|Desirudin|desirudin 15 mg twice daily for a minimum of 5 days
61954355|NCT04795011|EXPERIMENTAL|manual lymphatic drainage group|manual lymphatic drainage (MLD) will be applied to the second group (MLD group) in addition to the standard rehabilitation protocol
61954356|NCT05373745|EXPERIMENTAL|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
61954357|NCT05373745|PLACEBO_COMPARATOR|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
61954358|NCT00424983|EXPERIMENTAL|Zometa q 4 weeks|
61954359|NCT00424983|ACTIVE_COMPARATOR|Zometa q 12 weeks|
61954360|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
61954361|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
61954362|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
62344290|NCT05511675|NO_INTERVENTION|control group|Patients who are in the control group will receive standard clinical care and pain level and hematoma condition will be recorded. In addition usage time of the TR band will be in accordance with the manufacturer's guidelines and will be recorded with the help of a chronometer.
62502161|NCT02191124|EXPERIMENTAL|measurement-based care|MBC allows psychiatrists to individualize treatment decisions for each patient based on the change of psychopathology and tolerance toward antidepressants. Treatment decisions were made by treating psychiatrists according to ratings of self-report scales obtained at each treatment visit. Paroxetine was started at 20mg/day and then raised to 30mg/day by week 4, 40mg/day by week 6, 50mg/day by week 8 and 60mg/day by week 10. Mirtazapine was started at 15mg/day and raised to 30mg/day by week 1 and 45mg/day by week 4. Dose adjustments were dependent on how long a patient had received a particular dose, symptom changes and side effects.
62502162|NCT02191124|ACTIVE_COMPARATOR|Standard treatment|Patients in the ST group are treated by their psychiatrists according to their clinical needs as judged at each outpatient visit, receiving either open-label paroxetine (20-60mg/day) or mirtazapine (15-45mg/day) within the therapeutic dose range.
62502163|NCT00890942|EXPERIMENTAL|naloxone|
62502164|NCT00890942|PLACEBO_COMPARATOR|normal saline|
62502165|NCT04640012|EXPERIMENTAL|DC371739 100mg|Single dose of 100 mg tablet orally administered
62502166|NCT04640012|PLACEBO_COMPARATOR|Placebo|Placebo orally administered
62701337|NCT00913822|ACTIVE_COMPARATOR|2|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
61954363|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
61954364|NCT04674410||Empiric Antibiotic|All patients with COVID19 diagnosed on admission who received empiric antibiotics within 48 hours of admission without another site of infection identified or suspected septic shock.
61954365|NCT04674410||Control group|All patients admitted with COVID19 who did not receive empiric antibiotics in the first 48 hours of admission
61954366|NCT05370534||Study Population|"The investigators anticipate validating two specific actions: a box jump and walking gait. Both will be captured in two planes, coronal and sagittal. Healthy patients without musculoskeletal complaints will be voluntarily enrolled to undergo motion capture with both methods, completed during the same visit to the UAMS Human Biomechanics Laboratory.~Each patient will perform a box jump and walking gait using each of the two modalities. We anticipate 4 hrs will be required for each patient: 1 hr for setup before the patient arrives, 1 hr for testing, and 2 hrs for data cleaning and initial processing. This work will be performed at the UAMS Human Biomechanics Laboratory (off campus on Aldersgate Road), which is equipped for this type of analysis."
61954367|NCT02155790|EXPERIMENTAL|Renal Denervation by Neurolysis|Infusion of 0.3 ml of dehydrated alcohol (96%-98%) into the peri-adventitial space of the renal artery, to achieve renal denervation by Neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
62344291|NCT05511675|EXPERIMENTAL|experimental group I|Study group I patients will have cold application twice for a twenty minute period each time. For study group I extremity pain and hematoma will be followed and the TR band will be removed after one and a half hours.
62502167|NCT04560439|EXPERIMENTAL|Treatment (METFIT program)|Patients undergo METFIT program for 16 sessions over 6 months.
62344292|NCT05511675|EXPERIMENTAL|experimental group II|Study group II patients will have cold application twice for a twenty minute period each time and extremity pain and hematoma will be followed but the TR band will be removed in accordance with manufacturer's guidelines as in the control group.
62502168|NCT06467097|NO_INTERVENTION|A group|Only standard treatment is administered. The standard treatment includes targeted cancer therapy, immunotherapy, or monotherapy with each therapeutic agent.
62701338|NCT02476227|EXPERIMENTAL|Visitag group|Ablation using CARTO system. Visitag module: automated algorithm to collect RF ablation points using Visitag module. Criteria of ablation point: catheter stability range of motion ≤2.5mm, catheter stability time \>15sec, contact force \>5g over \>50% of time. Optimal contact force suggested: 10-40g.
62701339|NCT02476227|ACTIVE_COMPARATOR|Control group|Ablation using CARTO system. Manual collection of RF ablation points by operator or by assistant. Optimal contact force suggested: 10-40g.
61954368|NCT06199154|ACTIVE_COMPARATOR|Control - 25 mcg vaginal misoprostol|Participants will receive 25 mcg vaginal misoprostol every 4 hours.
61954369|NCT06199154|EXPERIMENTAL|Intervention - 50 mcg vaginal misoprostol|Participants will receive 50 mcg vaginal misoprostol every 4 hours.
62502169|NCT06467097|EXPERIMENTAL|B group|This group receives concurrent partial nephrectomy radiotherapy for all metastatic lesions in addition to standard treatment.
61954370|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
61954371|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
61954372|NCT05694767|EXPERIMENTAL|Intervention (CM313)|20 enrolled subjects: once a week x 8 doses
61954373|NCT06362577||high-intensity focused ultrasound.|Medical records and questionnaire data will be collected from patients with localized prostate cancer treated with Sonablate® high intensity focused ultrasound (HIFU) and robot-assisted laparoscopic radical prostatectomy (RALP) at Renji Hospital, Shanghai Jiao Tong University School of Medicine from 2021 to 2023 for local ablation or resection. And make a summary analysis.Patients with localized prostate cancer treated by high-intensity focused ultrasound.This Group Have No intervention.These do not require medication。EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG Diagnostic Tests were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after patients with localized prostate cancer treated with Sonablate® high intensity focused ultrasound (HIFU) .
61954374|NCT06362577||robot-assisted laparoscopic radical prostatectomy|Medical records and questionnaire data will be collected from patients with localized prostate cancer treated with Sonablate® high intensity focused ultrasound (HIFU) and robot-assisted laparoscopic radical prostatectomy (RALP) at Renji Hospital, Shanghai Jiao Tong University School of Medicine from 2021 to 2023 for local ablation or resection. And make a summary analysis.Patients with localized prostate cancer treated by robot-assisted laparoscopic radical prostatectomy (RALP)。This Group Have No intervention.These do not require medication。EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG Diagnostic Tests were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after patients with localized prostate cancer treated with robot-assisted laparoscopic radical prostatectomy (RALP) .
62701340|NCT05876520|OTHER|Total pulpotomy with I-PRF only|Total pulpotomy is done in mature permanent molars followed by I-prf application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
62701341|NCT04098588|EXPERIMENTAL|BEAST|There are 3 parts to BEAST. Part 1 involves the Behavioral Nudge technique using previously collected injunctive and descriptive norms from a National Guard sample. Soldiers will be given a customized feedback form that shows norms relevant to the target behavior they selected. The soldier will be given a chance to ask any follow-up questions. Part 2 of the intervention focuses on the principle of targeting others, considering how a change would impact those closest to them. Part 3 will utilize the Reciprocal Concessions procedure combined with the Reducing Barriers technique.
62344293|NCT05225220|EXPERIMENTAL|Transcutaneous Vagus Nerve Stimulation (t-VNS)|Participants will receive 60 minutes of t-VNS stimulation every day for 10 consecutive days while wearing a fitness tracker.
62344294|NCT05091892|EXPERIMENTAL|Water Group|Neurodevelopmental treatment
62344295|NCT05091892|EXPERIMENTAL|Land Group|Lonqitudinal, transversal and compined rotation in a hydrotherapy programm
62502170|NCT06046326|EXPERIMENTAL|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
62502171|NCT06046326|NO_INTERVENTION|control group|The control group will receive individual, content-focused education through a web platform that will cover the same topics as the VCoP but will be self-administered and without social interaction within theplatform.
62344296|NCT03446651|EXPERIMENTAL|Lysine Chloride|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
61954375|NCT02616081||Clean Intermittent Catheterization|Participants performing intermittent catheterization of their bladder, having not had augmentation cystoplasty or creation of a catheterizable channel
61954376|NCT02616081||Indwelling Catheter|Participants utilizing an Foley catheter or a suprapubic tube (cystostomy)
61954377|NCT02616081||Surgery|Undergoing any of the following surgeries: augmentation cystoplasty with or without a catheterizable channel, creation of catheterizable channel alone, urinary diversion (conduit or continent catheterizable pouch)
61954378|NCT02616081||Voiding|Participants with volitional control, voiding into diapers or a condom catheter via crede, valsalva, or spontaneous leakage
62141975|NCT00926159||ICD eligible|Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.
62344297|NCT03446651|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Placebo group will receive placebo.
62344298|NCT01850862|EXPERIMENTAL|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
62344299|NCT01850862|ACTIVE_COMPARATOR|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
62502172|NCT02797379|OTHER|Immediate start|This group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later.
62714850|NCT05459298|ACTIVE_COMPARATOR|Usual care plus placebo|Infants will receive placebo (normal saline) in the first 28 days after birth. Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
62344300|NCT02764983|ACTIVE_COMPARATOR|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Driving safety professional, three x 1 hour sessions to discuss traffic safety, rules of the road, defensive driving, driving under influence, driver attitudes and safety. Additionally, the study will obtain real world driving data from the Department of Motor Vehicles (public records) which will include citations, violations, and recorded collisions/ crashes.
62502173|NCT02797379|OTHER|Delayed start|This group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8.
62502174|NCT04415047|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Trilogy Heart Valve System Intervention Device: JenaValve Trilogy Heart Valve System
61954379|NCT05745571|OTHER|Patients with acute coronary syndrome|30 patients admitted to our hospital with the diagnosis of STEMI-type ACS and ejection fraction ≤ 35% on echocardiographic evaluation
61954380|NCT05745571|OTHER|Patients with non-ischaemic dilated cardiomyopathy|30 patients with non-ischaemic dilated cardiomyopathy and ejection fraction ≤35% on echocardiographic evaluation
61954381|NCT05745571|OTHER|Patients diagnosed with STEMI-type ACS|Patients diagnosed with STEMI-type ACS and ejection fraction \> 50% on echocardiographic evaluation
61954382|NCT05745571|OTHER|Controls|Controls with normal left ventricular contractile function
61954383|NCT03021070|EXPERIMENTAL|Cash transfer arm|The intervention is a conditional cash transfer payment for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
62502175|NCT00542360|EXPERIMENTAL|Social marketing program|Behavioral: Social marketing program to motivate exercise class participation
62502176|NCT00542360|NO_INTERVENTION|Control|Control: No intervention
62701342|NCT04098588|ACTIVE_COMPARATOR|Descriptive Feedback|This condition will involve a presentation of descriptive data based on the soldiers' tests scores and an opportunity to ask any follow-up questions. This process is a component of some behavioral change interventions (e.g., motivational interviewing); therefore this should be a more useful control condition (mirroring parts 1 and 2 of the active condition) versus a more passive or waitlist control condition. Participants in the control condition will also be given standard referral information to the USM Psychology Clinic (mirroring part 3 of the active condition).
61954384|NCT03021070|NO_INTERVENTION|Non-cash transfer arm|The control is a mobile phone airtime transfer value of 50 Ksh. transferred through the electronic system for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
61954385|NCT05371431|EXPERIMENTAL|non-BFR groups|Traditional rehabilitation training is designed according to postoperative orthopaedic rehabilitation guidelines. Traditional rehabilitation trainings include grip and pinch, wrist flexion with forearm pronated, wrist extension with forearm pronated, wrist flexion with forearm supinated, wrist extension with forearm supinated, prayer sign (wrist flexion), prayer sign (wrist extension), forearm pronation, forearm supination. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks.
61954386|NCT05371431|EXPERIMENTAL|BFR groups|Patients in the BFR group underwent the same traditional rehabilitation training protocol with non-BFR utilizing a medical grade tourniquet system (ATS 4000 TS，Zimmer Surgical, Inc. Dover). The ATS 4000 tourniquet system tailors the individualized tourniquet pressure to each patient following determination of the limb occlusion pressure (LOP), and studies have shown that 50% LOP is safe and effective in the rehabilitation of DRF. When the tourniquet system was used, LOPs were reassessed for every session before training, and pressures were continually monitored. Participants were to perform the entirety of each training (including intra-set rest periods) under 50% LOP with the tourniquets released during the 2-minute rest periods between sets. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks.
61954387|NCT00923156|EXPERIMENTAL|Aliskiren|In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received aliskiren (150 mg once daily) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site and matching placebo of ramipril capsules.
62502177|NCT03405857|EXPERIMENTAL|Group 1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
61954388|NCT00923156|EXPERIMENTAL|Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (Period 2), patients received ramipril 10 mg capsule o.d and matching placebo of aliskiren tablet."
61954389|NCT00923156|EXPERIMENTAL|Aliskiren plus Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (period 2), patients received ramipril (10 mg once daily capsule) and aliskiren (150 mg once daily tablet) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site"
61954390|NCT06005480|EXPERIMENTAL|Block upper extremity (arm)|Upper extremity with a nerve block
61954391|NCT06005480|NO_INTERVENTION|Control upper extremity (arm)|Upper extremity without a nerve block
61954392|NCT01970397|EXPERIMENTAL|JUVEDERM® Ultra XC|Perioral lines treated with JUVEDERM® Ultra XC
61954393|NCT01970397|EXPERIMENTAL|Belotero Balance®|Perioral Lines treated with Belotero Balance®
62502178|NCT03405857|NO_INTERVENTION|Group 2|No intervention will be administered
62502179|NCT04511572|NO_INTERVENTION|Standard Care: burr hole surgery|Patients who have had burr hole evacuation for symptomatic chronic subdural hematomas will be followed in the outpatient clinic after hospital discharge at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
62502180|NCT04511572|ACTIVE_COMPARATOR|embolisation middle meningeal artery|Besides standard treatment those patient who are allotted to the intervention group will receive embolization of the middle meningeal artery until 72 hours after burr hole evacuation. After hospital discharge follow-up is at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
62502181|NCT05091086|ACTIVE_COMPARATOR|Persistent treatment of Denosumab:|persistent denosumab for 7 years
62701343|NCT05605249|EXPERIMENTAL|Cue X|"All participants will train with Cue X gamified AR gait-and-balance-exercises in their home environment for 6 weeks. Participants are invited to use Cue X minimally 5 times a week for 30 minutes total, but preferably on a daily basis. The exact exercises, exercise duration and difficulty level will be prescribed by a movement expert and will be evaluated and adjusted every week in telephone calls or during one of the laboratory assessment.~Half of the participants will train with HoloLens 2 and the other half with Magic Leap 2."
62701344|NCT05634005|EXPERIMENTAL|Ordering Providers Assigned to Visible Clinical Decision Support Alerts|Clinical decision support alert will fire and become visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.
62701345|NCT05634005|NO_INTERVENTION|Ordering Providers Assigned to No Visible Clinical Decision Support Alerts|Clinical decision support alert will not be visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.
61954394|NCT05512767|EXPERIMENTAL|Group I (pneumatic therapy, lymphedema management)|Patients undergo 32 minute treatments twice daily for 12 weeks using the FlexiTouch Plus System and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
61954395|NCT05512767|ACTIVE_COMPARATOR|Group II (standard of care, lymphedema management)|Patients undergo standard of care self-manual lymphatic drainage (technique instructions provided) twice daily for 12 weeks and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
61954396|NCT04923438|EXPERIMENTAL|telerehabilitation|The exercises will be applied twice a week for a total of 12 weeks, and each program will last roughly 30 minutes.
61954397|NCT04923438|ACTIVE_COMPARATOR|control|The same exercise program will be prepared and given as a printout and they will be asked to do their exercises at home. This group will also be included in the study as a control group.
61954398|NCT00804284||Pentacel Group|Infants initiated on PENTACEL® vaccine
61954399|NCT00804284||Other DTap vaccines Group|Infants initiated on other DTaP vaccines
61954400|NCT04002661|ACTIVE_COMPARATOR|Arm 1 - Active|Participants will take flibanserin 100mg orally every night for approximately 3 months.
61954401|NCT04002661|PLACEBO_COMPARATOR|Arm 2 - Placebo|Participants will take a placebo orally every night for approximately 3 months.
61954402|NCT03949530|EXPERIMENTAL|IDL-2965 Oral Capsule|IDL-2965 oral capsule, single and multiple doses
61954403|NCT03949530|PLACEBO_COMPARATOR|Placebo Oral Capsule|Placebo oral capsule, single and multiple doses
61954404|NCT03312478|OTHER|Case|Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases
61954405|NCT03312478|OTHER|Control|Age-matched non-diabetic controls as described in the inclusion criteria for controls
61954406|NCT05626803|EXPERIMENTAL|Open Label Sentinel|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (sentinel n=10)
62344301|NCT02764983|EXPERIMENTAL|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors, and driving simulator with feedback. The study will also obtain real world driving data from the Department of Motor Vehicles (public records) which includes citations, violations, and recorded collisions/crashes.
62344302|NCT02764983|ACTIVE_COMPARATOR|Caregiver Control Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
62344303|NCT02764983|ACTIVE_COMPARATOR|Caregiver Experimental Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
62714851|NCT05459298|EXPERIMENTAL|Usual care plus vitamin D supplementation|Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day (when feedings reach about 120 -160 mL/kg/day). At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
62714852|NCT06717958|EXPERIMENTAL|Ivosidenib|
62714853|NCT03407768|OTHER|Individualized interventions|Exercise, Yoga, massage therapy, acupuncture, and others
61954407|NCT05626803|EXPERIMENTAL|Medium Dose Arm|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets total dose is 1×10 to the power 11 IU/dose (N=50)
61954408|NCT05626803|EXPERIMENTAL|High Dose Arm|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (N=50)
61954409|NCT05626803|PLACEBO_COMPARATOR|Placebo Arm|Placebo tablets (N= 25)
61954410|NCT00221403|ACTIVE_COMPARATOR|Valproate (VPA)|VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to achieve a blood level of 80-100 lg/mL. An independent, unblinded study psychiatrist adjusted VPA doses to achieve a therapeutic level
61954411|NCT00221403|ACTIVE_COMPARATOR|Risperidone|Risperidone was administered in liquid form matched for taste and color to the placebo. Medications were administered in a double-blinded manner on a twice-daily basis.
61954412|NCT00221403|PLACEBO_COMPARATOR|Placebo|The placebo was administered in liquid form, matched for taste and color with the active comparator.
61954413|NCT02590003|EXPERIMENTAL|Platinum-based doublet chemotherapy|"* Carboplatin AUC 5 30 minute infusion IV on day 1~* Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
61954414|NCT02590003|ACTIVE_COMPARATOR|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
61954415|NCT01180985|OTHER|galyfilcon A prototype/comfilcon A|The galyfilcon A prototype lenses are worn during first period and comfilcon A lenses worn during second period. Each period consists of daily lens wear for one week.
61954416|NCT01180985|OTHER|comfilcon A/galyfilcon A prototype|The comfilcon A lenses are worn during first period and galyfilcon A prototype lenses worn during second period. Each period consists of daily lens wear for one week.
61954417|NCT02349061|EXPERIMENTAL|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
61954418|NCT02349061|EXPERIMENTAL|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
61954419|NCT02577978|OTHER|Medacta Sphere|Ball-and-socket
61954420|NCT02577978|OTHER|Medacta PS|Cam-and-post
61954421|NCT05799586|EXPERIMENTAL|traditional Chinese medicine health preservation group|"The participants in the traditional Chinese medicine health preservation group will attend six traditional Chinese medicine health preservation courses (2h each per one, for 6 weeks) to learn and experience traditional Chinese medicine health preservation from a registered traditional Chinese medicine practitioner in a classroom at the School Nursing, the Hong Kong Polytechnic University.~Each class will be conducted in a small group of 4 to 6 participants to enhance interaction and ensure the quality of teaching. Participants will then practice traditional Chinese medicine health preservation at home for 6 weeks."
61954422|NCT05799586|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will receive usual care during the 6-week waitlist period of intervention, and 6-week waitlist period of follow-up. After the follow-up assessment, they will be provided an equivalent traditional Chinese medicine health preservation for depression.
61954423|NCT02851095|EXPERIMENTAL|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with two Extended Release (XR) tablet of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D of (1 XR fixed dose combination \[FDC\] tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and 1 metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with 2 metformin (XR) tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
61954424|NCT02851095|EXPERIMENTAL|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62502182|NCT05091086|EXPERIMENTAL|Alternating treatment of Denosumab and Zoledronic acid|alternating treatment of Denosumab and Zoledronic acid for 7 years
62502183|NCT01117987|EXPERIMENTAL|Core imatinib|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
62701346|NCT02296099|EXPERIMENTAL|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
61954425|NCT02851095|EXPERIMENTAL|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
62344304|NCT02764983|OTHER|Focus Group Discussion Interview Guide|This group will comprise of a subset of the control and experimental groups. A focus group with 8 participants (4 with Traumatic Brain Injury/Post Traumatic Stress Disorder and 4 with orthopedic conditions). The focus group will meet once for a discussion which will be guided with a semi-structured interview that will explore the driving behavior prior to war, during war and post-deployment. Responses will be outlined in an intervention matrix.
62344305|NCT05484180|EXPERIMENTAL|experimental group|As a nursing initiative to the experimental group in the research; Training and consultancy supported guided imagery application based on the health promotion model was applied.
62502184|NCT01117987|EXPERIMENTAL|Core placebo|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
62502185|NCT01680016|EXPERIMENTAL|Zagreb(≥6 to ≤17 Years)|
62502186|NCT01680016|EXPERIMENTAL|Zagreb(≥51 Years)|
62502187|NCT01680016|ACTIVE_COMPARATOR|Essen(≥6 to ≤17 Years)|
62502188|NCT01680016|ACTIVE_COMPARATOR|Essen(≥51 Years)|
61954426|NCT02851095|EXPERIMENTAL|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
61954427|NCT04171440|EXPERIMENTAL|Minimally Invasive Pancreaticoduodenectomy|Patients that undergo pancreaticoduodenectomy through small incisions with state-of-the-art robotic-assisted technology.
62502189|NCT00891098|ACTIVE_COMPARATOR|Imaginal exposure|
62502190|NCT00891098|EXPERIMENTAL|Imagery rescripting|
62502191|NCT05681819|EXPERIMENTAL|SHR-1707|Up to4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 injection
62502192|NCT05681819|PLACEBO_COMPARATOR|SHR-1707 placebo|Up to 4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 placebo injection
62502193|NCT03222037|EXPERIMENTAL|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
62502194|NCT03222037|EXPERIMENTAL|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
62502195|NCT04888533||All Patients evaluated by PESP during the trial period.|EHSSA tool applied to every patient in cohort.
62502196|NCT02681406|NO_INTERVENTION|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
62502197|NCT02681406|EXPERIMENTAL|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
62502198|NCT02681406|EXPERIMENTAL|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
62701347|NCT02296099|PLACEBO_COMPARATOR|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
61954428|NCT04998110|EXPERIMENTAL|Supportive Care Intervention|The supportive care intervention arm will receive their usual ambulatory longitudinal nephrology care integrated with ambulatory supportive care through monthly supportive care visits over six months.
61954429|NCT04998110|NO_INTERVENTION|Usual Care Control|The usual care control arm will be seen at the discretion of their nephrologist, or receive their usual dialysis if on dialysis.
62344306|NCT05484180|NO_INTERVENTION|control group|No attempt will be made on individuals in the control group during the research process. After the research process is over; After the training booklet, Mp3 player loaded with directed imagery recording and exercise materials are delivered, guided imagery application based on the Health Promotion Model will be supported by training and counseling.
62344307|NCT01555905|EXPERIMENTAL|Exercise|Threshold PEP or IMT device Phillips-Respironics
62344308|NCT01911013|ACTIVE_COMPARATOR|Cage and Plate|anterior cervical discectomy and fusion surgery at one segment is performed using cervical cage and plate system
62344309|NCT01911013|EXPERIMENTAL|Cage alone|anterior cervical discectomy and fusion surgery at one segment is performed using only cervical cage without plate
62344310|NCT01568424|OTHER|Treatment Group|Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.
62344311|NCT04377334|EXPERIMENTAL|MSC Treatment|
62344312|NCT04377334|NO_INTERVENTION|control|
62344313|NCT01448915||Persons with HIV and HCV coinfection|Persons with HIV and HCV coinfection who receive medical care for HIV infection at Johns Hopkins Hospital
62344314|NCT06159348||Healthy adults|Participants will be adults aged 18-70, male or female
62344315|NCT00914758||MS patients on Campath®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Campath® treatment arm of the Care-MS II trial, for which this study is a sub-study
62344316|NCT00914758||MS patients on Rebif®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Rebif® treatment arm of the Care-MS II trial, for which this study is a sub-study
62344317|NCT00914758||Control group|This group is comprised of non-MS, non-CNS compromised control participants matched in age, education level, and socioeconomic status to the participants in the 2 MS treatment groups
62344318|NCT05646446|EXPERIMENTAL|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to experiences of harm among bisexual women.
62701348|NCT01137084|ACTIVE_COMPARATOR|a steroid immunosuppression protocol|
62701349|NCT01137084|ACTIVE_COMPARATOR|a steroid-free immunosuppression protocol|without steroid
62701350|NCT01558167|EXPERIMENTAL|Bendamustine, Rituximab,Lenalidomide|Dose modification treatment plan of lenalidomide
62701351|NCT05192278|ACTIVE_COMPARATOR|Group 20 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 10 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 7 ml saline 0.9% (total 20 ml with bupivacaine 0.25%).
62701352|NCT05192278|ACTIVE_COMPARATOR|Group 30 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 15 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 12 ml saline 0.9% (total 30 ml with bupivacaine 0.25%).
62344319|NCT05646446|NO_INTERVENTION|Wait List Control Group|The Wait List Control Group will have the opportunity to complete the REACH program after completing study assessments at the 4-month follow-up.
62502199|NCT02681406|EXPERIMENTAL|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
62502200|NCT06677931|PLACEBO_COMPARATOR|1565 non-ablative fractional laser combined with normal Saline|1565 non-ablative fractional laser combined with normal Saline
62502201|NCT06677931|EXPERIMENTAL|1565 non-ablative fractional laser combined with umbilical cord mesenchymal stem cell exosomes|1565 non-ablative fractional laser combined with umbilical cord mesenchymal stem cell exosomes
61954430|NCT01949831|NO_INTERVENTION|Control|Usual care
61954431|NCT01949831|EXPERIMENTAL|Functional assessment|Assessment of functional ability in combination with follow-up at home
61954432|NCT06101758|EXPERIMENTAL|Muscular ultrasound assessment|Adult patients aged 18-69 years with a diagnosis of either liver cirrhosis, non-alcoholic fatty liver disease or hepatocellular carcinoma
61954433|NCT02021331|ACTIVE_COMPARATOR|immediate implant placement without provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will have no temporary crown on the implant.
61954434|NCT02021331|EXPERIMENTAL|immediate implant placement with immediate provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will get a temporary crown on the implant.
61954435|NCT01651910||Controlled Pain|Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
61954436|NCT01651910||Uncontrolled Pain|Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
61954437|NCT01651910||Breakthrough pain|Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.
61954438|NCT02782728|ACTIVE_COMPARATOR|TIPS-Basic|Providers receive tailored scripts based on the patient's responses to the questions administered via tablet.
61954439|NCT02782728|EXPERIMENTAL|TIPS-Plus|Patients receive tailored messages in addition to the scripts given to providers.
61954440|NCT03879278|OTHER|Treatment 2 mg/kg|Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
61954441|NCT03879278|OTHER|Treatment 5 mg/kg|Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
61954442|NCT03879278|OTHER|Treatment 12.5 mg/kg|Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
61954443|NCT04523220|EXPERIMENTAL|BAY1213790 low dose|Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
61954444|NCT04523220|PLACEBO_COMPARATOR|Placebo low dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
61954445|NCT04523220|EXPERIMENTAL|BAY1213790 high dose|Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
61954446|NCT04523220|EXPERIMENTAL|Placebo high dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
61954447|NCT05000463|ACTIVE_COMPARATOR|ozone group|Ozone injection under ultrasound guidance in addition to the medical treatment
61954448|NCT05000463|OTHER|control group|receive the medical treatment only. The medical treatment includes optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin
61954449|NCT03018769||chronic SCAD|
61954450|NCT00905411|NO_INTERVENTION|Attention Control / Usual Care|
61954451|NCT00905411|EXPERIMENTAL|Intervention|
61954452|NCT05909644|EXPERIMENTAL|Omaveloxolone only (Period 1), Then Omaveloxolone and efavirenz (Period 2)|Period 1 (Day 1 - 15): Omaveloxolone Capsules, 150 mg, administered orally in a single dose on Day 1 Period 2 (Day 15 - 43): Efavirenz Tablet, 600 mg, administered orally once daily from Day 15 - Day 42 and Omaveloxolone Capsules, 150 mg, administered orally in a single dose on Day 29
61954453|NCT04312048|EXPERIMENTAL|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
61954454|NCT04312048|PLACEBO_COMPARATOR|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
61954455|NCT04811781||Cancer Patients with SARS-COV-2 infection.|
62344320|NCT05174130|EXPERIMENTAL|Patients undergoing mechanical ventilation in stable phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
62701353|NCT00398814|EXPERIMENTAL|Perifosine + Sorafenib|
61954456|NCT00150748|EXPERIMENTAL|Levetiracetam|Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
61954457|NCT04453722||Monitor only mode|Randomization will be to Oxalert in monitor-only mode
61954458|NCT04453722||Monitor in normal mode|Randomization will be to Oxalert in monitor normal mode which provides progressive audible and tactile alerts for hypoxemia.
61954459|NCT06209177|EXPERIMENTAL|ARO-CFB (Healthy Volunteers)|1 or 2 doses of ARO-CFB by subcutaneous (sc) injection
61954460|NCT06209177|EXPERIMENTAL|Placebo (Healthy Volunteers)|placebo calculated volume to match active treatment by sc injection
61954461|NCT06209177|EXPERIMENTAL|ARO-CFB (Adult Patients with IgAN)|3 doses of ARO-CFB by sc injection
61954462|NCT02267083|EXPERIMENTAL|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
61954463|NCT04524897|OTHER|The use of Triamcinolone Injection|Triamcinolone acetate (40 mg/mL)
61954464|NCT05005793|EXPERIMENTAL|Sodium bicarbonate|Oral sodium bicarbonate at a dose of 0.5 mEq/kg-lean body weight/day
61954465|NCT05005793|PLACEBO_COMPARATOR|Placebo|Oral placebo at a dose of 0.5 mEq/kg-lean body weight/day
61954466|NCT05915078||Tula Tympanostomy|Patients undergoing in-office tympanostomy using the Tula® System
61954467|NCT00261807|OTHER|Single ARM Study|It was a single arm study with higher dose of daptomycin used for patients with severe skin and soft tissue infections.
62141976|NCT05570617|EXPERIMENTAL|Transition Coach Intervention|Half (53) of the participants will be randomly allocated to the Transition Coach Intervention arm of the study. Individuals in the Transition Coach Intervention group will receive the current standard of care (receiving the Youth Transition Roadmap) and meet with the transition coach six times and with a clinical psychologist two times over the course of six months. The meetings between the participant and TC/psychologist will occur over the phone or using the Ontario Telemedicine Network or EPIC.
62701354|NCT06482385||Transgender men|"TM in this study were defined as individuals who were compatible with Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).~TM who had never used testosterone therapy before the enrollment."
62701355|NCT05980702|EXPERIMENTAL|4 courses arm|Drug:Pembrolizumab , Carboplatin,albumin-bound paclitaxel Patients receive Pembrolizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Then surgery.
62701356|NCT05980702|ACTIVE_COMPARATOR|2 courses arm|Drug:Pembrolizumab , Carboplatin,albumin-bound paclitaxel Patients receive Pembrolizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Then surgery.
61954468|NCT01334164|EXPERIMENTAL|Recovery Management Checkup (RMC)|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
61954469|NCT01334164|ACTIVE_COMPARATOR|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own.
61954470|NCT00363883|EXPERIMENTAL|Treatment (vorinostat)|Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62141977|NCT05570617|ACTIVE_COMPARATOR|Standard of Care|The other half of participants will only receive the current standard of care is the Youth Transition Roadmap which has been developed by Hamilton Health Sciences and provides patients information about 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation.
62344321|NCT05174130|EXPERIMENTAL|Patients undergoing mechanical ventilation in weaning phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
62344322|NCT01313520|EXPERIMENTAL|Infliximab|3 mg/kg of Infliximab intravenous infusion
62344323|NCT01313520|PLACEBO_COMPARATOR|Placebo|saline via intravenous infusion
62344324|NCT00478725|EXPERIMENTAL|Part A|Absorption, Distribution, Metabolism and Elimination of a Single Oral \[14C\] Labeled Dose of GW786034
62344325|NCT00478725|EXPERIMENTAL|Part B|characterize the pharmacokinetics of a single IV dose of GW786034
62344326|NCT04315480|EXPERIMENTAL|tocilizumab|
62344327|NCT00238303|EXPERIMENTAL|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62344328|NCT00238303|EXPERIMENTAL|Stratum 2 (undergoing surgery)|Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses. Patients then undergo surgery to remove the tumor. Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62344329|NCT05005988|EXPERIMENTAL|Empowerment educational intervention|Three 30-minute sessions will be conducted with each mother in the intervention group, the first during the first week after admission, the second session within 7 days after the second session, and the third 3 to 2 days before discharge. An induction to the out-of-hospital kangaroo program will also take place on the day of admission to the program. Mothers will receive a booklet with general care contents and empowerment information.
62344330|NCT05005988|NO_INTERVENTION|Usual intervention|Mothers receive information for home infant care, no theoretical perspective and no empowerment approach is considered
62344331|NCT00607568|EXPERIMENTAL|1|atomoxetine 40mg per day
62344332|NCT00607568|PLACEBO_COMPARATOR|2|second arm is placebo, sugar pill
62344333|NCT01650792|ACTIVE_COMPARATOR|Aspirin|Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
62344334|NCT01650792|NO_INTERVENTION|Best medical treatment|Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
62344335|NCT04905875||Critically ill patients with COVID-19|n centres that obtained IRB approval for this prospective study, all critically ill adult patients (\>18yrs) undergoing PP - that are homogeneous in terms of both clinical and treatment characteristics - will be prospectively observed.
62344336|NCT02225574|EXPERIMENTAL|Advanced CML + Philadelphia positive Acute Leukemia-Group 1|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle."
62701357|NCT03919162|EXPERIMENTAL|600 mg|First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID
62701358|NCT03919162|EXPERIMENTAL|300 mg|First 4 weeks 150 mg BID, week 5-24 300 mg BID
62701359|NCT03919162|EXPERIMENTAL|150 mg|24 weeks on 150 mg BID
62701360|NCT03919162|PLACEBO_COMPARATOR|Placebo|
62701361|NCT00759395|EXPERIMENTAL|AZD2327|AZD2327 3mg BID
62701362|NCT00759395|PLACEBO_COMPARATOR|Placebo|Placebo BID
62701363|NCT04311307|EXPERIMENTAL|Patients|GSDIa patients
62141978|NCT03392194|EXPERIMENTAL|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
61954471|NCT03642457|ACTIVE_COMPARATOR|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
61954472|NCT03642457|PLACEBO_COMPARATOR|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
61954473|NCT03974425|OTHER|Diabetic macular edema resistant to Bevacizumab|Patients resistant to 6 monthly Bevacizumab injection were switched to Aflibercept.
61954474|NCT01710969|EXPERIMENTAL|Individual Intervention|behavioral - children receive the Coping Power program in an individual, face-to-face format
61954475|NCT01710969|EXPERIMENTAL|Group Intervention|behavioral - children receive the Coping Power program in a small group format (5-6 children per group)
61954476|NCT01036893|NO_INTERVENTION|oral contraceptives without prucalopride|
61954477|NCT01036893|ACTIVE_COMPARATOR|oral contraceptives with prucalopride|prucalopride
61954478|NCT00060008|EXPERIMENTAL|18FDG-PET scan and MR perfusion|Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.
61954479|NCT05045131|EXPERIMENTAL|PVI+PWI, 6 months reassessment procedure, 3 year continued rhythm monitoring|Single arm experimental, observational study: All participants receive a single-procedure combined PVI + posterior wall isolation (PVI+PWI), loop recorder implantation, esophagoscopy, a mandated interventional reassessment /reablation procedure at six months and continuous rhythm monitoring for three years
61954480|NCT04911881|EXPERIMENTAL|Phase Ia Dose-Escalation Stage: IBI321|
61954481|NCT02386735|EXPERIMENTAL|Investigational treatment|Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
61954482|NCT02386735|ACTIVE_COMPARATOR|Standard treatment|Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
61954483|NCT01136603|EXPERIMENTAL|TIGR Mesh|Experimental - TIGR Mesh
61954484|NCT01136603|ACTIVE_COMPARATOR|Control|Control group - Non absorbable Polypropylene mesh
61954485|NCT04970355|EXPERIMENTAL|Erenumab|Double-Blind Treatment Phase: Participants receive erenumab 280 mg subcutaneous (SC) injections (loading dose, week 0) followed by erenumab 140 mg s.c. in week 4.
62502202|NCT03547817|EXPERIMENTAL|Optimal negative pulse pressure regime|The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber of the intermittent negative pressure device. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels. The order of the different negative pressure levels will be randomized to avoid causal interference.
62502203|NCT05133726|EXPERIMENTAL|Text Message cluster|This arm will receive only daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together)
62701364|NCT04311307|ACTIVE_COMPARATOR|Controls|Healthy volunteers
61954486|NCT04970355|PLACEBO_COMPARATOR|Placebo|Double-Blind Treatment Phase: Participants receive placebo subcutaneous (SC) injections in week 0 and week 4.
62701365|NCT02399228|EXPERIMENTAL|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
62701366|NCT02880319|EXPERIMENTAL|Oligometastatic Disease|"Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine~* Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~* Dosage will be determined by physician"
61954487|NCT00941005|EXPERIMENTAL|Electroacustimulation|Received electroacustimulation at the wrist using a small, battery-powered electroacustimulation device.
61954488|NCT00941005|SHAM_COMPARATOR|Control|Received a device that was not turned on.
61954489|NCT04568733|NO_INTERVENTION|Resting|
62701367|NCT02880319|EXPERIMENTAL|Re-irradiation to Metastatic Disease|"Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine~* Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~* Dosage will be determined by physician"
62701368|NCT01160185||cisplatin|
61954490|NCT04568733|EXPERIMENTAL|Pilates exercise session|
61954491|NCT04568733|ACTIVE_COMPARATOR|Treadmill walking at 3.2 kph|
61954492|NCT04568733|ACTIVE_COMPARATOR|Treadmill walking at 4.8 kph|
61954493|NCT01261910|NO_INTERVENTION|Usual education (standard care)|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant.
61954494|NCT01261910|EXPERIMENTAL|Intensive initial education|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant. In addition, participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
61954495|NCT05431192|EXPERIMENTAL|Mindful Training + Enhanced Usual Care|Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks.
61954496|NCT05431192|OTHER|Enhanced Usual Care alone|Usual care.
61954497|NCT03750617|EXPERIMENTAL|pre-endoscopic screening risk assessment|
61954498|NCT03750617|NO_INTERVENTION|routine screening|
62141979|NCT03392194|ACTIVE_COMPARATOR|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
61954499|NCT02496585|EXPERIMENTAL|Nintedanib + Prednisone|The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
62701369|NCT01160185||cisplatin + topotecan|
62701370|NCT01160185||cisplatin + paclitaxel|
62701371|NCT01896973|EXPERIMENTAL|Vortx Rx - Histotripsy BPH Device|The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
62701372|NCT06481631|OTHER|PEN-3 Assessment Model|Application of a sociocultural model to assess patient-clinical linkages that support positive maternal health outcomes
62701373|NCT06384963|EXPERIMENTAL|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|"The experimental arm is atrial pacing with additional respiratory sinus arrhythmia (RSA) modulation following coronary artery bypass graft (CABG) surgery. Pacing impulses will be grouped together during inspiration, such that heart rate (HR) will increase by approximately 6 bpm above median during inspiration, and decrease by around 6 bpm below median during expiration. Five pacing rates will be used to accommodate a range of patients' intrinsic HR.~Pacing will be initiated after randomisation, after the patient is removed from ventilator support (Pacing Day 1, PD1). This is usually the day after surgery. Pacing will continue until the patient is ready for discharge or there is a clinical decision to stop pacing and remove the leads (whichever is soonest).~Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) modulated to respiratory phase by a Ceryx device (intervention)"
62701374|NCT06384963|ACTIVE_COMPARATOR|Monotonic atrial pacing|"The control arm is standard monotonic right atrial pacing at the relevant median rate following coronary artery bypass graft (CABG) surgery. Pacing will be initiated after randomisation, after the patient is removed from ventilator support (Pacing Day 1, PD1). This is usually the day after surgery. Pacing will continue until the patient is ready for discharge or there is a clinical decision to stop pacing and remove the leads (whichever is soonest).~Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing."
61954500|NCT02496585|EXPERIMENTAL|Placebo + Prednisone|Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
61954501|NCT02975336|PLACEBO_COMPARATOR|Double-Blind Placebo-Controlled (DBPC) Period: Placebo|
61954502|NCT02975336|EXPERIMENTAL|DBPC Period: M2951 25 mg QD|
62701375|NCT03014804|EXPERIMENTAL|Group I (DCVax-L)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.
62701376|NCT03014804|EXPERIMENTAL|Group II (DCVax-L, nivolumab)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.
61954503|NCT02975336|EXPERIMENTAL|DBPC Period: M2951 75 mg QD|
61954504|NCT02975336|EXPERIMENTAL|DBPC Period: M2951 50 mg BID|
62141980|NCT05538572|EXPERIMENTAL|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
62141981|NCT06466083||postoperative delirium(POD) and postoperative neurocognitive disorder(pNCD)|Delirium (CAM scale ) was assessed 7 days after surgery and divided into POD and non-POD groups; one of the above scenarios indicated postoperative delirium;The patients in the POD group were evaluated for cognitive function at 1 month and 12 months after surgery to determine whether pNCD occurred. The patients in the POD group were further divided into pNCD subgroup and non-PNCD subgroup, and fMRI scanning were performed
62714854|NCT05456048||VAH group|Patients assigned to this group received one to two cycles of VAH regimen as salvage therapy of RR-AML.
62714855|NCT05456048||VEN+HMA group|Patients assigned to this group received one to two cycles of venetoclax plus HMA regimen as salvage therapy of RR-AML.
62714856|NCT01889992|ACTIVE_COMPARATOR|Cardiac biopsy C4D stain|A procedure that removes a very small sample of your heart muscle so that it can be evaluated in the lab. This procedure may be done to determine the cause of cardiac myopathy (a weakened heart muscle) or to check for rejection after a heart transplant.
61954505|NCT02975336|EXPERIMENTAL|Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID|
61954506|NCT02975336|EXPERIMENTAL|LTE Period: M2951 25 mg QD/ M2951 50 mg BID|
61954507|NCT02975336|EXPERIMENTAL|LTE Period: M2951 75 mg QD/ M2951 50 mg BID|
61954508|NCT02975336|EXPERIMENTAL|LTE Period: M2951 50 mg BID/ M2951 50 mg BID|
61954509|NCT04172142||Control group|Healthy individuals of similar age and sex who meet the inclusion criteria
61954510|NCT04172142||Pectus Excavatum|Individuals with pectus excavatum that meet the inclusion criteria
61954511|NCT04172142||Pectus Carinatum|Individuals with pectus excavatum that meet the inclusion criteria
61954512|NCT03005600||Asian Indian|"Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF).~As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies.~3400 pregnant women in early pregnancy will be studied in this cohort."
61954513|NCT03005600||African|"Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal.~4000 pregnant women in early pregnancy will be studied in this cohort."
61954514|NCT03445208|EXPERIMENTAL|Cohort 1|BMI 18.0 to ≤ 25.0
61954515|NCT03445208|EXPERIMENTAL|Cohort 2|BMI \>25.0 to ≤ 30.0
62141982|NCT03830151|EXPERIMENTAL|Diagnostic (carbon C 13 pyruvate, MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
62141983|NCT06511089|EXPERIMENTAL|Carotid artery stenting during endovascular thrombectomy|In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal)
62141984|NCT06511089|ACTIVE_COMPARATOR|No immediate carotid artery stenting during endovascular thrombectomy|The control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke)
62141985|NCT05150093|EXPERIMENTAL|Electrophysiological signal data collection|Patients diagnosed with dystonia or tremor who are recommended for DBS surgery. Electrophysiological data will be collected at the time of DBS surgery.
62701377|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
62502204|NCT05133726|EXPERIMENTAL|Text message with or without peer support|All individuals in this cluster will receive daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together) with some selected members also receiving peer support for six months
62502205|NCT05133726|NO_INTERVENTION|Control group|This group will only receive usual care plus weekly text message over 6 weeks (six information text messages all together) with provides information about community services
62502206|NCT03217526|ACTIVE_COMPARATOR|Ex Group|"EX: Standard exercise program (EX) (active range-of otion exercises, balance and mobility exercises) and walking training on the overground.~This rehabilitation program physiotherapist will be applied to participants for five days a week. Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be instructed to walk with verbal commands and encourage them to continue their walk at constant speed.The duration of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale."
62502207|NCT03217526|EXPERIMENTAL|Ex +WT Group|Ex: A standard exercise (SE) (active range-of otion exercises, balance and mobility exercises) WT: walking training on the treadmill (WT). This rehabilitation program physiotherapist will be applied to participants for five days a week.Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be trained on the treadmill.The duration of walking training and the speed of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale.
62502208|NCT02223286||ASGES (Treatment Group)|Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
62502209|NCT02223286||Non-ASGES (Control Group)|Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
62502210|NCT03561558|EXPERIMENTAL|Ibuprofen D, oral suspension|Ibuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
62502211|NCT03561558|ACTIVE_COMPARATOR|Nurofen® for Children, oral suspension|Nurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.
62502212|NCT05105919|EXPERIMENTAL|Aspirin therapy|All participants will be assigned to aspirin therapy. Participants will receive 80 mg of enteric coated aspirin per day for a 7 day period.
62502213|NCT02197208|ACTIVE_COMPARATOR|Spontaneous NC|Timing by the onset of LH surge as shown daily blood monitoring of serum estradiol and LH levels
62502214|NCT02197208|EXPERIMENTAL|hCG induced NC|Timing by giving hCG when the dominant follicle reaches \>=17mm in diameter on ultrasound monitoring
62502215|NCT00481026|SHAM_COMPARATOR|Placebo|Placebo tDCS
62701378|NCT06039696||patients received mNGS test|After enrolment, patients will receive mNGS test.
62701379|NCT01514357|OTHER|Nesiritide (BNP)|Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.
62141986|NCT06470386|EXPERIMENTAL|Alverine Group|Compound Alverine Citrate Capsules (Lejiansu; specification: each capsule contains 60 mg of Alverine Citrate and 300 mg of Simethicone; manufactured by the French company UCB Pharma), 180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks.
62701380|NCT01514357|PLACEBO_COMPARATOR|Placebo|Subjects will receive SQ placebo bid for seven consecutive days.
62701381|NCT04746898|EXPERIMENTAL|Virtual Reality Training Group (VR group)|The students in the first group received basic life support practice training with virtual reality applications.
62502216|NCT00481026|ACTIVE_COMPARATOR|active tDCS|active tDCS
62502217|NCT02889302|EXPERIMENTAL|KPS-0373|
62502218|NCT02889302|PLACEBO_COMPARATOR|Placebo|
62502219|NCT06229158||Patients' group|Patients diagnosed with advanced solid or hematological cancers, whether or not undergoing specific treatment for the ongoing oncological condition and having a cancer diagnosis for more than 3 months (baseline diagnosis consultation).
62502220|NCT06229158||Partners' of life group|Partners' of life group of patients' diagnosed with advanced solid or hematological cancers, whether or not undergoing specific treatment for the ongoing oncological condition and having a cancer diagnosis for more than 3 months (baseline diagnosis consultation).
62502221|NCT06285006|EXPERIMENTAL|Desmopressin|Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
62502222|NCT06024343|EXPERIMENTAL|MPD Manipulation|During laparoscopic or robotic pancreatic tumor enucleation, tumors located near or surrounding the main pancreatic duct (MPD) can result in the exposure, injury, or transection of the MPD, requiring MPD repair and reconstruction.
62701382|NCT04746898|EXPERIMENTAL|High Fidelity Simulation Training Group (HFS group)|The students in the second group received basic life support practice training with high fidelity simulators.
62701383|NCT04746898|EXPERIMENTAL|Low Fidelity Simulation Training Group (LFS group)|The students in the third group received basic life support practice training with the classical method, low-reality mannequin.
62701384|NCT02511288||Cohort 1|Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
62701385|NCT02511288||Cohort 2|Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
62701386|NCT02511288||Cohort 3|Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
62502223|NCT06024343|NO_INTERVENTION|MPD not exposed|In laparoscopic or robotic pancreatic tumor enucleation procedures where the MPD remains unexposed, there is no need for MPD repair and reconstruction.
62502224|NCT04691700|ACTIVE_COMPARATOR|Goreisan|Goreisan (TJ-17) will be added at a dose of 7.5g per day to standard treatment
62502225|NCT04691700|ACTIVE_COMPARATOR|No Goreisan|Standard treatment without Goreisan (TJ-17)
62701387|NCT06500507|EXPERIMENTAL|QLS4131|Dose escalation and does expansion of QLS4131 injection will be evaluated.
62701388|NCT00212004|ACTIVE_COMPARATOR|Pioglitazone|Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
62701389|NCT00212004|ACTIVE_COMPARATOR|Control|Participants assigned to Control group were treated with diet and exercise therapy or sulfonylurea (SU) or other additional drugs than pioglitazone.
62701390|NCT02035657|EXPERIMENTAL|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
62701391|NCT06301113|EXPERIMENTAL|300 Nano mg CBD Candy|
62701392|NCT06301113|PLACEBO_COMPARATOR|Sugar free raspberry flavor candy|
62701393|NCT06029790|EXPERIMENTAL|gum chewing|"All participants will receive standard postoperative care, 2 L/min of oxygen delivered via nasal cannula if oxygen saturation is below 95%. In addition, participants will be encouraged to use the incentive spirometer 10 times per hour to prevent respiratory complications such as pneumonia. In the postoperative period, all participants will be removed from bed and mobilized as soon as possible.~For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence."
62141987|NCT06470386|ACTIVE_COMPARATOR|Carvedilol Group|Jinluo (Carvedilol Tablets; specification: 6.25 mg; manufactured by Qilu Pharmaceutical Co., Ltd.), taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.
62141988|NCT06009666||Patient Group|Both Extremities of Patients With Breast Cancer Related Lymphedema
62141989|NCT06009666||Control Group|Both Extremities of Healthy People With No History of Breast Cancer
62141990|NCT05610566|EXPERIMENTAL|A single set of test|The HighLife Trans-Septal TMVR System comprises a 28mm Transcatheter Mitral Valve, a loop placement catheter, a sub-annular implant and its delivery systems.
62141991|NCT01229904|EXPERIMENTAL|Arm 1|patients with PTSD are randomized to either entering immediately a 6 week treatment with music therapy, or being in the delay group that enters the treatment arm after 6 weeks. This is a delayed entry RCT.
62141992|NCT02132676||Active treatment|All those scheduled for a Shared Medical Appointment (SMA), regardless of whether the Peer to Peer (P2P) program was offered.
62141993|NCT02132676||Usual Care|The randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
62141994|NCT02134171|EXPERIMENTAL|Biological investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
62141995|NCT00447837|EXPERIMENTAL|1|
62141996|NCT00447837|EXPERIMENTAL|2|
62141997|NCT00447837|PLACEBO_COMPARATOR|3|
62141998|NCT05077475|EXPERIMENTAL|Sequence A|Period 1: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
62141999|NCT05077475|EXPERIMENTAL|Sequence B|Period 1: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
62142000|NCT01220115||No treatment|Patients aged 2 to less than 12
62142001|NCT01220115||No treatment patients aged 12 to less than 18|Patients aged 12 to less than 18
62142002|NCT01220115||No treatment Patients greater than 18 years|patients greater than 18 years
62502226|NCT04629339|EXPERIMENTAL|INCB086550|INCB086550 will be administered orally twice a day.
62502227|NCT04766216|EXPERIMENTAL|Warfarin Patient Self-Management|Patients managing decisions relating to warfarin dose and next INR test based on the results of current INR test
62502228|NCT04766216|ACTIVE_COMPARATOR|Historical Control|Patients managed by anticoagulation providers prior to transitioning to warfarin patient self-management
62502229|NCT05768789|EXPERIMENTAL|Buoy Electrolyte Drops|The goal is to give 600mg of Na+ over 4 hours while measuring urine output over 6 hours. The recommended Buoy dosage is ⅓ tsp in 237 ml of water (50mg Na+) multiple times a day (Table 1). Therefore, to safely achieve a total dose 600mg Na+ (6-fold increase from single dose) we will use 4 tsps (18 ml) of Buoy diluted in 1 L of water.
62502230|NCT05768789|EXPERIMENTAL|Nuun Electrolyte Tablet|The goal is to give a one-time dose of Nuun (600mg Na+) at the start of the trial, diluted in 1L water to be consumed within 30 min (similar to prior published data, Pence 2020).
62502231|NCT05768789|PLACEBO_COMPARATOR|Water|Participants will ingest the same quantity of water (1 L) at a rate of 6.25% of the calculated amount of water every 15 min for 4 hours.
62502232|NCT00646503|EXPERIMENTAL|1|600 mg/day, oral telbivudine for 52 weeks
62701394|NCT06029790|NO_INTERVENTION|control group|"All participants will receive standard postoperative care, 2 L/min of oxygen delivered via nasal cannula if oxygen saturation is below 95%. In addition, participants will be encouraged to use the incentive spirometer 10 times per hour to prevent respiratory complications such as pneumonia. In the postoperative period, all participants will be removed from bed and mobilized as soon as possible.~The control group will receive only standard care."
62701395|NCT00829868|EXPERIMENTAL|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
62701396|NCT00829868|ACTIVE_COMPARATOR|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
62701397|NCT06564233|EXPERIMENTAL|care.coach Avatar™|care.coach Avatar™ with usual supportive care. The avatar program includes companionship, HCT educational modules, relaxation and mindfulness exercises, simple (seated) physical exercises, nightly check ins, and symptom self-management as needed.
61954516|NCT03445208|EXPERIMENTAL|Cohort 3|BMI \>30.0 ≤ 40.0
62142003|NCT00741650|EXPERIMENTAL|1|Information and peer advisor
62502233|NCT03495206|EXPERIMENTAL|Y-2(Edaravone And Borneol) sublingual tablet|
62502234|NCT05426616|ACTIVE_COMPARATOR|Control group: Collagen membrane|(Xenoprotect, Nobel Biocare, Göteborg, Sweden)
62701398|NCT06564233|NO_INTERVENTION|Usual Supportive Care|Traditional supportive care comprising of a binder with HCT educational materials and regular meetings with a transplant nurse.
62701399|NCT06288893|ACTIVE_COMPARATOR|SHEN211 Tablets|A total of 20 subjects were randomized to the test group
62701400|NCT06288893|PLACEBO_COMPARATOR|Placebo for SHEN211 Tablets|10 subjects randomized to placebo
61954517|NCT04274413|EXPERIMENTAL|Interventional Arm|All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
61954518|NCT04745130|EXPERIMENTAL|Intervention arm 1|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
62142004|NCT00741650|EXPERIMENTAL|2|Information, peer advisor and referral to further treatment
62142005|NCT00741650|NO_INTERVENTION|3|Treatment as usual
62142006|NCT05372224|EXPERIMENTAL|Vitamin D 4000 IU|4000 IU of vitamin D were administrated once a day orally and calcium carbonate 1.2 g a day in a single dose.
62142007|NCT04805736|EXPERIMENTAL|Microwave Ablation alone|Microwave Ablation+ Breast Surgery
62142008|NCT04805736|EXPERIMENTAL|Camrelizumab alone|Camrelizumab+ Breast Surgery
62142009|NCT04805736|EXPERIMENTAL|Microwave Ablation & Camrelizumab|Microwave Ablation + Camrelizumab + Breast Surgery
62142010|NCT05716425|EXPERIMENTAL|Arm A|"* STI-1558~* n=600"
62142011|NCT05716425|PLACEBO_COMPARATOR|Arm B|"* Placebo~* n=600"
62142012|NCT00306475|ACTIVE_COMPARATOR|1|
62142013|NCT00306475|PLACEBO_COMPARATOR|2|
62142014|NCT04999007|NO_INTERVENTION|Control|Whether the patients in the control arm will receive a temporary ileostomy depends on surgeons' experience.
62142015|NCT04999007|EXPERIMENTAL|Intervention|Whether the patients in the intervention arm will receive a temporary ileostomy depends on the risk of anastomotic leakage calculated by the artificial intelligence algorithm.
62142016|NCT06296407|EXPERIMENTAL|Respiratory exercises|Males and females with obesity on standard metabolic integrated rehabilitation protocol + respiratory exercises
62142017|NCT06296407|ACTIVE_COMPARATOR|Control|Males and females with obesity on standard metabolic integrated rehabilitation protocol
62142018|NCT00592891|EXPERIMENTAL|Hyperbaric oxygen therapy|Patients undergoing low pressure HBOT for chronic brain injury
62142019|NCT06030817|EXPERIMENTAL|99mTc-CNDG SPECT/CT|Inject 99mTc-CNDG and then perform SPECT/CT scan.
62142020|NCT02227706|EXPERIMENTAL|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
62142021|NCT02227706|ACTIVE_COMPARATOR|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
62142022|NCT00229970|EXPERIMENTAL|1|Placebo
62142023|NCT00229970|EXPERIMENTAL|2|MK0476 7 mg injection
62142024|NCT00229970|EXPERIMENTAL|3|MK0476 14 mg injection
62142025|NCT01878305||MARS|Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
62142026|NCT02808234|OTHER|Nucel treatment group|One or two level lumbar interbody fusion surgery with Nucel
62142027|NCT01827839|EXPERIMENTAL|HZ Group|Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
62142028|NCT05670821||Patients with generalized pustular psoriasis (GPP)|
62142029|NCT03537326|EXPERIMENTAL|Budesonide|Healthy women, aged between 18 and 45 years old, with weigh between 50 and 75 kg and with IMC included between 19 and 27 kg/m². Patients will be given, on an empty stomach since 10 hours minimum, a single dose of 3 mg of Budesonide, in the form of Entocord ® tablets. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
62142030|NCT03479918|ACTIVE_COMPARATOR|R-DA-EPOCH-21|The protocol involves 4-6 cycles. Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.
62142031|NCT03479918|ACTIVE_COMPARATOR|R-BL-M-04|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 50 mg/m2/day IV day 3, Vincristine 2 mg IV 1 day, Cytarabine 150 mg/m2/day IV 1 h 4, 5 days.~Course C:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Vinblastine 5 mg/m2 IV day 1, Cytarabine 2000 mg/m2/day IV 3 h 2, 3 days, Etoposide 150 mg/m2/day IV 3-5 days.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
62502235|NCT05426616|EXPERIMENTAL|Test group: titanium reinforced d-PTFE membrane|(Creos Syntoprotect,Nobel Biocare AB, Göteborg, Sweden)
62502236|NCT04194554|EXPERIMENTAL|Niraparid Dose Escalation|"Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT~Dose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT~Dose Level 3: 200 mg PO daily of Niraparib without breaks during SBRT until completion of 6 cycles."
62502237|NCT04066257|ACTIVE_COMPARATOR|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg twice daily for 7 days
62701401|NCT01716702|EXPERIMENTAL|Couples Prostate Cancer Support Group|"The participants in the support group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
62701402|NCT01716702|NO_INTERVENTION|Wait-List Control|Participants will be asked to complete questionnaires at three time points: 1)week 1 2) week 7, and 3) week 13.
61954519|NCT04745130|EXPERIMENTAL|Intervention arm 2|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
61954520|NCT02367937|EXPERIMENTAL|PRC-4016 (Icosabutate)|
61954521|NCT05197556|EXPERIMENTAL|HSG4112 200 mg Multiple Dose|Multiple oral dosing of HSG4112 200 mg for 12 weeks
61954522|NCT05197556|EXPERIMENTAL|HSG4112 400 mg Multiple Dose|Multiple oral dosing of HSG4112 400 mg for 12 weeks
62502238|NCT04066257|ACTIVE_COMPARATOR|Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg \& Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
62502239|NCT04066257|ACTIVE_COMPARATOR|MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg \& Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
62502240|NCT04355572|EXPERIMENTAL|Vitamin D Supplement|Patients will take vitamin D tablet with 4,000IU daily for 6 months.
62502241|NCT04355572|PLACEBO_COMPARATOR|Placebo|Patients will take placebo for 6 months
62502242|NCT03209024|OTHER|Control|Participants complete a 3-week home blood pressure monitoring regimen using a handwritten logbook to record all blood pressure readings.
61954523|NCT05197556|EXPERIMENTAL|HSG4112 600 mg Multiple Dose|Multiple oral dosing of HSG4112 600 mg for 12 weeks
61954524|NCT05197556|PLACEBO_COMPARATOR|Placebo|Multiple oral dosing of placebo
61954525|NCT05251987||High PD1+ T Cell Expression|high PD1+ T cell expression in peripheral blood
61954526|NCT05251987||Low PD1+ T Cell Expression|low PD1+ T cell expression in peripheral blood
61954527|NCT00672932|EXPERIMENTAL|raltegravir group|The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
61954528|NCT00672932|NO_INTERVENTION|No augmented treatment|Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.
61954529|NCT01382095|EXPERIMENTAL|Group A|
61954530|NCT01382095|EXPERIMENTAL|Group B-1|
61954531|NCT01382095|EXPERIMENTAL|Group B-2|
61954532|NCT01382095|EXPERIMENTAL|Group C|
61954533|NCT05289791|EXPERIMENTAL|ultrasonic activation of bioceramic sealer|ultrasonic activation of bioceramic sealer for 20 seconds
61954534|NCT05289791|ACTIVE_COMPARATOR|bioceramic sealer|bioceramic sealer
61954535|NCT01959074|ACTIVE_COMPARATOR|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
61954536|NCT01959074|PLACEBO_COMPARATOR|Control groups with only analgesics|Control groups will receive only analgesics
61954537|NCT01696084|EXPERIMENTAL|Arm A (CPX-351)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
61954538|NCT01696084|ACTIVE_COMPARATOR|Arm B (7+3)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
61954539|NCT03794271|EXPERIMENTAL|Pupilometer group|In this group, intraoperative analgesia is performed using pupilometer guided anesthesia.
61954540|NCT03794271|ACTIVE_COMPARATOR|SPI group|In this group, intraoperative analgesia is performed using SPI guided anesthesia
62142032|NCT03479918|ACTIVE_COMPARATOR|R-DA-EPOCH-21 + auto-SCT|"The protocol involves 4-6 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
62142033|NCT03479918|ACTIVE_COMPARATOR|R-BL-M-04 + auto-SCT|"The protocol involves 4 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
61954541|NCT01987297|EXPERIMENTAL|ATRA+Arsenic|All low- and intermediate-risk patients receive retinoic acid and arsenic trioxide based consolidation. High-risk patients receive ATRA+Arsenic+Anthracycline consolidation.
62142034|NCT02168998|NO_INTERVENTION|No clown|Routine venipuncture without distraction
62142035|NCT02168998|ACTIVE_COMPARATOR|Clown|A medical clown is present in the procedure room during venipuncture
62142036|NCT00146172|EXPERIMENTAL|Neratinib 40 mg|
62142037|NCT00146172|EXPERIMENTAL|Neratinib 80 mg|
62142038|NCT00146172|EXPERIMENTAL|Neratinib 120 mg|
62142039|NCT00146172|EXPERIMENTAL|Neratinib 180 mg|
62142040|NCT00146172|EXPERIMENTAL|Neratinib 240 mg|
62142041|NCT00146172|EXPERIMENTAL|Neratinib 320 mg|
62142042|NCT00146172|EXPERIMENTAL|Neratinib 400 mg|
62142043|NCT00146172|EXPERIMENTAL|Neratinib 320 mg MTD|
62142044|NCT06699784|EXPERIMENTAL|Progressive lenses intervention group|Progressive lenses intervention group will receive 1-month progressive lens correction in daily life.
62142045|NCT06699784|PLACEBO_COMPARATOR|Single-vision lenses intervention group|Single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month.
62142046|NCT04181099|OTHER|Zirconia structure|The participants will carry an orthodontic device containing 4 discs of differently structured zirconia and titanium to test the biofilm formation in order to determine the ideal structure for the neck area of zirconia dental implants.
62142047|NCT05561491|EXPERIMENTAL|ONCOS-102|ONCOS-102 will be administered by intratumoral (IT) injection at 1.0×10\^12 VP/dose with the potential to de-escalate dosing to 3.0×10\^11 VP/dose.
62502243|NCT03209024|EXPERIMENTAL|Intervention|Participants complete a 3-week home blood pressure monitoring regimen using a smartphone app and Bluetooth® technology to wirelessly record all blood pressure readings.
62502244|NCT04478240|EXPERIMENTAL|Intervention (access to PeerLearning.net)|Teachers and students in intervention schools will be given access to PeerLearning.net software for the purposes of instruction for the 2021-2022 school year.
62502245|NCT04478240|NO_INTERVENTION|Passive Control (no intervention)|Teachers and students in control schools will conduct instruction as usual without PeerLearning.net.
62502246|NCT06212674|EXPERIMENTAL|A|80 patients
62502247|NCT06212674|EXPERIMENTAL|B|80 patients
62502248|NCT06212674|ACTIVE_COMPARATOR|C|80 patients
62502249|NCT04409587|NO_INTERVENTION|NovoLog®-only|In the aspart-Only group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
62502250|NCT04409587|ACTIVE_COMPARATOR|Novolog® and Tresiba® Group|This study population will have an expertise in diabetes self-management with their insulin pump and Dexcom CGM. In the Novolog® and Tresiba® group, the subject will still take aspart via their pump for meals and correction boluses, but they will reduce the slow trickle (basal insulin) programmed in their pump to almost zero. Instead of receiving their normal basal insulin via CSII, the subject will injected degludec once or twice daily from an insulin pen for your basal insulin.
62502251|NCT00137202|ACTIVE_COMPARATOR|2|
62502252|NCT02962089|PLACEBO_COMPARATOR|Placebo|Isocaloric isonitrogenous placebo for 4 months (7g, twice daily)
62701403|NCT01120353||Cancer survivors|Survivors of cancer, diagnosed under 21 years of age, between 1970 and 1999 This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
62701404|NCT01120353||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine consistency of findings between data sources.
61954542|NCT01987297|ACTIVE_COMPARATOR|ATRA+chemo|All low-risk and intermediate-risk patients receive retinoic acid and chemotherapy with idarubicin or daunorubicin as consolidation. High-risk patients receive ATRA+anthracycline and cytarabine as consolidation.
61954543|NCT02207244|EXPERIMENTAL|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
62344337|NCT02225574|EXPERIMENTAL|Chronic Phase CML - Group 2|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
62344338|NCT04970316||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
62344339|NCT04970316||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
62344340|NCT03298191|EXPERIMENTAL|Magnesium sulphate|
62344341|NCT03298191|EXPERIMENTAL|Ritodrine|
62344342|NCT03298191|EXPERIMENTAL|Calcium channel blocker|
62344343|NCT01935362|PLACEBO_COMPARATOR|placebo|Placebo administered to participant
62344344|NCT01935362|ACTIVE_COMPARATOR|Citrus supplement|Citrus supplement administered to participant
62344345|NCT02210104|EXPERIMENTAL|Ipilimumab + Cyclophosphamide + CD4+T Cells|Starting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10\^10 cells/m\^2.
62344346|NCT05429177|EXPERIMENTAL|SAD Cohort 1(0.1% QY101 ointment or vehicle apply to 5%BSA)|3 subjects use 0.1% QY101 ointment，1 subject uses vehicle topical applied to 5% Body Surface Area，assessed until 72 hours postdose
62344347|NCT05429177|EXPERIMENTAL|SAD Cohort 2(0.1% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.1% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
62502253|NCT02962089|ACTIVE_COMPARATOR|Branched chain amino acids (BCAA)|BCAA mixture for 4 months (7g, twice daily)
62502254|NCT01874977|EXPERIMENTAL|Pedometer only|This group will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer. Participants will be shown how to wear the pedometer, and instructed to wear it from the time they get out of bed in the morning until they go to bed at night, except while showering or bathing. (If any subjects begin a swimming- or cycling-based activity program, we will ask them to remove the pedometer at that time but track the time they are in the water. Step counts will be adjusted to account for this time by adding 150 steps for every minute engaged in swimming and/or cycling.)
62701405|NCT00809822|ACTIVE_COMPARATOR|1|Intravenous immunoglobulin
62701406|NCT00809822|PLACEBO_COMPARATOR|2|Physiological saline
62344348|NCT05429177|EXPERIMENTAL|SAD Cohort 3(0.3% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.3% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
62701407|NCT04649099|EXPERIMENTAL|Leaflex™ Performer|
62701408|NCT03060889|ACTIVE_COMPARATOR|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
62701409|NCT03060889|NO_INTERVENTION|Controls|Control group will not receive Tranexamic acid
62701410|NCT01490021|EXPERIMENTAL|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
61954544|NCT02207244|PLACEBO_COMPARATOR|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
62701411|NCT01490021|PLACEBO_COMPARATOR|rTMS/Placebo TBS|rTMS/Placebo TBS
61954545|NCT02207244|ACTIVE_COMPARATOR|Group III|Participants will receive adalimumab 80 mg (two 40 mg \[0.8 mL\] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
61954546|NCT01100697||thoracal lesion|spinal lesion at thoracal level detected at prenatal ultrasound exam
61954547|NCT01100697||lumbar lesion|spinal lesion at lumbar level detected at prenatal ultrasound exam
61954548|NCT01100697||sacral lesion|spinal lesion at sacral level detected at prenatal ultrasound exam
61954549|NCT03568734|EXPERIMENTAL|Transplant arm|Fecal transplant sample given to child at delivery
61954550|NCT04454294|EXPERIMENTAL|Control|The first method; There is no application in maintaining the drain opening, but if there are necessary medical indications such as clot formation, blood accumulation in the drainage connections, lack of drainage, this group is intervened by milking method. In our study, this group will be taken as a control group, there will be a situation that requires intervention in the first 6 hours, and if the milking method is used, it will be excluded from the sample.
61954551|NCT04454294|EXPERIMENTAL|Experimental Group (Absorption Group)|The second method used to maintain the drain opening is the suction method. In this study, this group will be taken as the first experimental group. The suction method is a continuous use until the patient's drainage requirement and the physician's request is terminated by ensuring that the pressure is between 5 and 15 kPa (kilopascals) or 10-20 cm H20 after the appropriate negative pressure tracking system of the patient, who is accepted with intensive care under water drainage system, is established. system.
62142048|NCT05561491|EXPERIMENTAL|ONCOS-102 and balstilimab|ONCOS-102 will be administered by IT injection at 3.0×10\^11 VP/dose with planned dose escalation to 1.0×10\^12 VP/dose. Balsitilmab will be administered at a fixed dose of 300 mg by intravenous (IV) injection.
62344349|NCT05429177|EXPERIMENTAL|SAD Cohort 4(0.5% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.5% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
62344350|NCT05429177|EXPERIMENTAL|SAD Cohort 5(1.0% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
62344351|NCT05429177|EXPERIMENTAL|SAD Cohort 6(1.0% QY101 ointment or vehicle apply to 40%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 40% Body Surface Area，assessed until 72 hours postdose
62344352|NCT05429177|EXPERIMENTAL|MAD Cohort 7(0.3% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.3% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
62344353|NCT05429177|EXPERIMENTAL|MAD Cohort 8(0.5% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.5% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
62701412|NCT01362790|EXPERIMENTAL|Mesothelioma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg days 10, 12, and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
62142049|NCT00372476|EXPERIMENTAL|Imatinib + Vinorelbine|
62344354|NCT05429177|EXPERIMENTAL|MAD Cohort 9(1.0% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
62701413|NCT01362790|EXPERIMENTAL|Mesothelioma Pilot Phase Regimen B|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle Regimen B: Cycle 1: 4 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen B: Cycle 1: 35mcg/kg days 18, 20, and 22. Cycles 2-4: (Days 6, 8, and 10), for a maximum of six treatment cycles."
62714857|NCT01889992|EXPERIMENTAL|Genetic Mechanism of M-TOR|"To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.~Sirolimus dosage is based on blood levels."
62142050|NCT02377193|EXPERIMENTAL|Simulect|Simulect IV 40 mg D0 and D4
62142051|NCT02377193|ACTIVE_COMPARATOR|ATG Fresenius|ATG IV min dose 3 mg/ kg/ day D0, D1, D3, D5
62142052|NCT06699407|EXPERIMENTAL|Qishenyiqi|
62142053|NCT06699407|PLACEBO_COMPARATOR|Placebo|
62142054|NCT01894399|EXPERIMENTAL|Cohort 1|100 mg HM61713 single dose in Korean
62142055|NCT01894399|EXPERIMENTAL|Cohort 2|200 mg HM61713 single dose in Korean
62142056|NCT01894399|EXPERIMENTAL|Cohort 3|300 mg HM61713 single dose in Korean
62701414|NCT01362790|EXPERIMENTAL|Phase 2 Peritoneal Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5 and 9 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on day 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen B: Cycle 1: 35 mcg/kg or 25 mcg/kg days 18, 20 and 22. Cycles 2-4: Days 6, 8, and 10, for a maximum of six treatment cycles."
62701415|NCT01362790|EXPERIMENTAL|Phase 2 Pleural Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
62701416|NCT01362790|EXPERIMENTAL|Mesothelioma Positive Ca Dose De-escalation Pilot Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
62701417|NCT01362790|EXPERIMENTAL|Phase 2 Pancreatic Adenocarcinoma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
62701418|NCT01362790|EXPERIMENTAL|Phase 2 Lung Adenocarcinoma Pilot Expansion Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
62502255|NCT01874977|EXPERIMENTAL|Pedometer + step count goals|Pedometer + step goals. This group will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
62701419|NCT03226691|EXPERIMENTAL|Single Cohort - Plerixafor|Plerixafor at a single dose of 240 microgram/kg
62701420|NCT04409444||Data (main study)|This study group is for any individual that attends and has a lung health check. The data collected for this study group is to evaluate the uptake and performance of a community-based lung health check / lung screening programme.
62701421|NCT04409444||Biomarker (sub-study)|This sub-study is for participants that are determined to require a CT scan through their lung health check and have also signed up to the data part of the study. This part of the study is to evaluate the potential for biomarkers to improve the early detection of lung cancer.
62701422|NCT05185622|EXPERIMENTAL|Treatment Group 1|Patients in Treatment Group 1 must be ages 2-\<4 years and will receive Vamorolone at 2.0 mg/kg/day for the duration of the study. Treatment Group 1 will be enrolled prior to Treatment Group 2.
62142057|NCT01894399|EXPERIMENTAL|Cohort 4|200 mg HM61713 single dose in Japanese
62142058|NCT01894399|EXPERIMENTAL|Cohort 5|300 mg HM61713 single dose in Japanese
62142059|NCT01894399|EXPERIMENTAL|Cohort 6|200 mg HM61713 single dose in Caucasian
62142060|NCT01894399|EXPERIMENTAL|Cohort 7|300 mg HM61713 single dose in Caucasian
62142061|NCT03827200|EXPERIMENTAL|Ambrisentan|Ambrisentan
62142062|NCT01937494|EXPERIMENTAL|asthma patients|patients who show a positive response at the first dos of histamine challenge test will be enrolled
62142063|NCT05302882|EXPERIMENTAL|Experimental Group|Myofascial release was applied to the experimental group
62142064|NCT05302882|ACTIVE_COMPARATOR|Control Group|Classical massage was applied to the control group
62701423|NCT05185622|EXPERIMENTAL|Treatment Group 2|Patients in Treatment Group 2 must be ages 2-\<4 years and will receive Vamorolone at 6.0 mg/kg/day for the duration of the study. Treatment Group 2 will be enrolled after Treatment Group 1.
62142065|NCT04301206|EXPERIMENTAL|Intervention: Receiving video material|The parents who accepts to participate and receives videos and action cards by sms
62142066|NCT04301206|NO_INTERVENTION|Control group|The parents who accepts to participate, but proceed to 1813 and do not receive videos and action cards
62142067|NCT04604652|EXPERIMENTAL|Open-label|HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.
62142068|NCT02734355|ACTIVE_COMPARATOR|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
62142069|NCT02734355|PLACEBO_COMPARATOR|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
62142070|NCT04045652||Kenyan women|Kenyan women, some HIV-infected and some HIV-uninfected, VIA negative at enrollment.
62142071|NCT03408041||Alzheimer Disease|Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
62142072|NCT01662388|EXPERIMENTAL|automatrix band, Separation ring|The prepared teeth received Automatrix band (similar to the control group, product code# 62422513). The Automatrix was burnished against the adjacent tooth gently. Anatomical wedges were applied in the proximal area and then the separation ring (BiTine® round ring by Palodent systems, Dentsply International, DE, USA product # 659040) placed with the help of retainer forceps.
62142073|NCT01662388|ACTIVE_COMPARATOR|automatrix band|Teeth received Automatrix band alone (Wide-Regular type, dimensions 7.9 mm height and 0.05mm thickness, product code # 62422513). It was secured on the prepared tooth and burnished against the adjacent tooth gently. Anatomical wedges were placed in the inter-proximal area gingival to the cavity preparation.
62142074|NCT04390516|OTHER|COViage|Machine learning intervention
62142075|NCT00365885|EXPERIMENTAL|1|electronic mail notifications to care managers about sentinel health events
62142076|NCT00365885|EXPERIMENTAL|2|feedback reports with notifications to clinic managers about sentinel health events
62142077|NCT00365885|EXPERIMENTAL|3|letters to patients with notifications about sentinel health events
62502256|NCT01874977|OTHER|Education materials|"Educational materials. This group will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment. They will receive follow-up contact at the same time points as the intervention groups, although the Week 0 and Week 1 contacts will be by phone instead of in-person and the content of contacts will be different."
62502257|NCT03017352|EXPERIMENTAL|Intervention|Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.
62701424|NCT05185622|EXPERIMENTAL|Treatment Group 3|Patients in Treatment Group 3 must be ages 7-\<18 years and must be steroid untreated at entry. Treatment Group 3 will receive Vamorolone at 2.0 mg/kg/day for the duration of the study.
62701425|NCT05185622|EXPERIMENTAL|Treatment Group 4|Patients in Treatment Group 4 must be ages 7-\<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 4 will receive Vamorolone at 2.0 mg/kg/day for the duration of the study.
61954552|NCT04454294|EXPERIMENTAL|Experimental Group (Milking Group)|The third method is milking. In our study, this group will be taken as the 2nd experimental group. In the milking method, the process starts from the area close to the drain entry point. The latex tube is folded into 12 cm long pieces and gripped with two hands. The nurse repeats the process 3 times by compressing the parts gripped by the hand. This process is then used at intervals every hour to repeat the distal part.
62142078|NCT00365885|NO_INTERVENTION|4|electronic mail notifications to care managers about sentinel health events -- generated but withheld
62142079|NCT00365885|NO_INTERVENTION|5|feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
62344355|NCT05429177|EXPERIMENTAL|MAD Cohort 10(1.0% QY101 ointment or vehicle apply to 40%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 40% Body Surface Area，twice daily for 7 days and once in the morning on D8
62344356|NCT06278558|EXPERIMENTAL|Interviews with a psychologist/psychiatrist|Implementation of an interview with a psychologist or psychiatrist following a telephone conversation with patients with no psychological follow-up and a high HADS score (≥11), at all stages of the study (start of chemotherapy T1, end of chemotherapy T2, 6 months after the end of chemotherapy).
62344357|NCT02719236|ACTIVE_COMPARATOR|Direct anterior approach|Primary total hip arthroplasty using a direct anterior approach
62344358|NCT02719236|ACTIVE_COMPARATOR|Direct lateral approach|Primary total hip arthroplasty using a direct lateral approach
62344359|NCT03896880||blood culture positive|hematological malignancy patients with positive blood culture
62344360|NCT05978856||A|real photoes (after treatment)
62502258|NCT03017352|PLACEBO_COMPARATOR|Placebo|Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.
62701426|NCT05185622|EXPERIMENTAL|Treatment Group 5|Patients in Treatment Group 5 must be ages 7-\<18 years and must be steroid untreated at entry. Treatment Group 5 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.
62701427|NCT05185622|EXPERIMENTAL|Treatment Group 6|Patients in Treatment Group 6 must be ages 7-\<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 6 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.
62701428|NCT05185622|EXPERIMENTAL|Treatment Group 7|Patients in Treatment Group 7 must be ages 12-\<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 7 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.
62344361|NCT05978856||B|simulated photoes
62344362|NCT05625854|EXPERIMENTAL|Blow a fan to the face combine aromatherapy|
62344363|NCT05625854|EXPERIMENTAL|Blow a fan to the face|
62344364|NCT05625854|PLACEBO_COMPARATOR|Blow a fan to the feet|
62344365|NCT03544268|EXPERIMENTAL|Acoustic Angiography|All clinical patients will be included in the experimental group.
62502259|NCT01109017||Norditropin®|
62344366|NCT03544268|EXPERIMENTAL|Image Optimization|In addition to clinical patients, 30 participants will be recruited to aid in optimizing the imaging parameters.
62701429|NCT06628986|EXPERIMENTAL|Mindfulness-based stress reduction program|MBSR; Mindfulness-based stress reduction program. 8 weeks of practice once a week for 20 minutes each. Mindfulness-based stress reduction practices will be carried out online. Mothers will actively participate.
62701430|NCT06628986|EXPERIMENTAL|Neurolinguistic programming|NLP; Neurolinguistic programming 8 weeks of practice once a week for 20 minutes each. Neurolinguistic programming will be carried out online. Mothers will actively participate.
61954553|NCT01591759|EXPERIMENTAL|Citicoline|8-week treatment of 2,000mg/day of citicoline
61954554|NCT01591759|PLACEBO_COMPARATOR|Placebo|
61954555|NCT00837057|OTHER|early crrt, late crrt|
61954556|NCT01964430|EXPERIMENTAL|nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2|Participants received nab-Paclitaxel 125 mg/m\^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m\^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
61954557|NCT01964430|ACTIVE_COMPARATOR|Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m\^2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
62502260|NCT05317195|EXPERIMENTAL|NP-1|Nicotine Pouch 1.0 (variant NP-1)
62502261|NCT05317195|EXPERIMENTAL|NP-2|Nicotine Pouch 1.0 (variant NP-2)
62502262|NCT05317195|EXPERIMENTAL|NP-3|Nicotine Pouch 1.0 (variant NP-3)
62502263|NCT05317195|EXPERIMENTAL|NP-4|Nicotine Pouch 1.0 (variant NP-4)
62502264|NCT05317195|ACTIVE_COMPARATOR|Velo-NP|Velo® Ice Cool
62502265|NCT05317195|ACTIVE_COMPARATOR|Zyn-NP|Zyn® Cool Mint Mini Dry
62142080|NCT00365885|NO_INTERVENTION|6|letters to patients with notifications about sentinel health events -- generated but withheld
62344367|NCT00945074|EXPERIMENTAL|Condition 1|"Condition 1:~Subjects receive Standard Acu/Moxa (fixed protocol)"
62502266|NCT01857973|EXPERIMENTAL|Hybrid Closed Loop|In-clinic evaluation of the HCL System under various conditions.
62502267|NCT02990078||Acute TBI|Subjects will be recruited from the neurointensive care unit within 72 hours of their injury. At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index). This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
62502268|NCT02990078||Sub-acute/Chronic TBI|Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist. In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
62502269|NCT02990078||Healthy Controls|"The investigators will also enroll healthy peer controls. These control subjects will be family members and friends of TBI subjects. These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR. These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging. These subjects will be tested in the same way as both TBI groups, but will only have one visit."
62502270|NCT00497588|ACTIVE_COMPARATOR|radiotherapy|patients receive radiotherapy
62502271|NCT00497588|EXPERIMENTAL|surgery|Patients undergo surgery
62502272|NCT01093196|ACTIVE_COMPARATOR|Rd|Induction treatment with oral Lenalidomide and low dose dexamethasone followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
62502273|NCT01093196|EXPERIMENTAL|MPR|Induction treatment with oral Lenalidomide, Prednisone and Melphalan followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
62502274|NCT01093196|EXPERIMENTAL|CPR|Induction treatment with oral Lenalidomide, Cyclophosphamide and Prednisone for followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone.
62142081|NCT02499601|EXPERIMENTAL|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
62344368|NCT00945074|EXPERIMENTAL|Condition 2: Individualized Acupuncture/Moxibustion|"Condition 2:~Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis)."
62344369|NCT00945074|SHAM_COMPARATOR|Condition 3: Control|"Condition 3:~Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)"
62344370|NCT01557218|EXPERIMENTAL|Cucumber|
62344371|NCT01557218|EXPERIMENTAL|Pepper|
62502275|NCT03816436||Follow- up (FU) assessment on clavicular non- union|clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting
62502276|NCT05390398|EXPERIMENTAL|Intervention group|The intervention group follows a six-month personalized lifestyle program to increase adherence to the World Cancer Research Fund cancer prevention guidelines on healthy nutrition, physical activity and healthy weight.
62701431|NCT06628986|EXPERIMENTAL|control|control; MBSR and NLP applications will not be performed. Mothers will be monitored online every week.
62701432|NCT05039281|EXPERIMENTAL|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62701433|NCT00123630|PLACEBO_COMPARATOR|placebo|placebo group
61954558|NCT06024460|EXPERIMENTAL|Non-pharmacological treatment strategy|"Interventions: Non-pharmacological treatment include acupuncture, electroacupuncture, spinal manual therapy, and motion style acupuncture treatment.~Frequency: Not specified (Twice a week recommended) Duration: Eight weeks."
61954559|NCT06024460|ACTIVE_COMPARATOR|Pharmacological treatment strategy|"Interventions: Active pharmacological treatment involving prescription medication, injection therapy, or other pharmacological interventions.~Frequency: Not specified (Twice a week recommended) Duration: Eight weeks."
62701434|NCT00123630|EXPERIMENTAL|omalizumab|Xolair group
62701435|NCT00337168|EXPERIMENTAL|Induc, ReInduc, Consol, clofarabine, cytarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
62701436|NCT04872439||Antibody isolation, DNA isolation|Patients with GI dysmotility
62701437|NCT00331721|ACTIVE_COMPARATOR|1|Enecadin
62701438|NCT00331721|PLACEBO_COMPARATOR|2|Placebo
62142082|NCT00990600|EXPERIMENTAL|Simplified one pill regimen|Fixed dose combination of tenofovir + emtricitabine + efavirenz
62142083|NCT05622097|EXPERIMENTAL|Warmed saline|0.9% Saline will be warmed to 37 degrees Celsius
62142084|NCT05622097|EXPERIMENTAL|Room temperature saline|0.9% Saline will be warmed to 24 degrees Celsius
62142085|NCT05566444|EXPERIMENTAL|Experimental heat pain|For each participant, we will collect TMS-EEG responses in 4 conditions: 1) Baseline, 2) Heat pain; 3) warm sensation; 4) post-pain.
62344372|NCT01557218|EXPERIMENTAL|Tomato|
62344373|NCT01557218|EXPERIMENTAL|Vegetable variety|
62344374|NCT01557218|EXPERIMENTAL|Apple|
62344375|NCT01557218|EXPERIMENTAL|Peach|
62344376|NCT01557218|EXPERIMENTAL|Pineapple|
62344377|NCT01557218|EXPERIMENTAL|Fruit variety|
62344378|NCT02910544||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
62344379|NCT06079957|EXPERIMENTAL|Exercise and ergonomic intervention group|"Patients will be explained about the procedure and informed consent will be taken.~1. Individuals will be given a copy of ergonomic guidelines to follow which includes:~   * Organize workstation according to the primary , secondary and tertiary zones.~  * Place frequently used items within the reach of an arm.~  * Don't move head while reading documents instead raise or lower the eyes to read.~  * Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~  * Keep reference material upright at desk.~  * Avoid slouched postural habits, sit upright.~  * Adjust chair height in such a way that it shouldn't compress the thigh.~  * Arm rest should be at elbow flexion of 90 degrees.~  * Phone must be cradled between neck and shoulder to avoid forward head posture.~2. Neck exercises will be given"
62701439|NCT05657847||Rheumatoid arthritis|Rheumatoid arthritis patients. (American College of Rheumatology (ACR) 1987, ACR/European League Against Rheumatism (EULAR) \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis (including RF, ACPA)
62701440|NCT05657847||Psoriatic arthritis|Psoriatic arthritis patients. (CASPAR Criteria) \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
61954560|NCT03692247|OTHER|Quantitative Sensory Testing|After answering brief questionnaires assessing psychosocial factors related to anxiety, catastrophizing, and pain, participants will undergo quantitative sensory tests where they will use a simple numeric rating scale (0-10) to rate pain and anxiety at several points during two QST sessions. During the second QST session, participants will use Unwind, a smartphone-based music intervention.
61954561|NCT04563702|EXPERIMENTAL|Low Dose VXA-CoV2-1|Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1. A subset will also receive a second dose at Day 29
61954562|NCT04563702|EXPERIMENTAL|High Dose|High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1
61954563|NCT03255798|OTHER|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
61954564|NCT04176666|EXPERIMENTAL|Intervention group receiving NettOpp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
61954565|NCT04176666|NO_INTERVENTION|Control group|The control group will receive the intervention after study completion.
61954566|NCT01755221||Adult patients with Reflux Symptom Index scores (RSI) greater than or equal to 13 off PPI therapy|"1. Restech pH probe placement at initial clinic visit; subject returns 24 hrs later for probe removal.~2. Proton pump inhibitor (PPI) therapy; subject starts PPI medication (omeprazole 40mg once daily) and returns for follow-up visit 8-12 weeks later.~3. Optional second pH probe placement at follow up visit; Subject returns 24 hours later for probe removal; Subject continues PPI medication for 2 more weeks"
61954567|NCT04719286|EXPERIMENTAL|Intervention group|The intervention is the use of the MinSafeStart mobile application. The app utilizes the Pregnancy-Unique-Quantification-of-Emesis-24 (PUQE-24) scale to categorize the women's NVP severity (e.g. mild, moderate, or severe) on a daily basis, and visualizes the fluctuations over time in a graph. Each woman will have their own personal graph based on the information they put in. They will also be able to see how their symptoms are compared to an average graph. The women will get treatment advice based on their PUQE-24 scale, e.g. dietary and lifestyle advice for mild symptoms and referral to see the doctor for moderate and severe symptoms.
61954568|NCT04719286|NO_INTERVENTION|Control group|Standard care.
61954569|NCT00225069|EXPERIMENTAL|1|T2 sympathectomy
61954570|NCT00225069|EXPERIMENTAL|2|T2-T3 sympathectomy
62142086|NCT01584466|EXPERIMENTAL|Paliperidone|
62142087|NCT01543893|EXPERIMENTAL|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
62344380|NCT06079957|ACTIVE_COMPARATOR|Group B(Ergonomic intervention group)|"Patients will be explained about the procedure and informed consent will be taken.~Individuals will be given a copy of ergonomic guidelines to follow which includes:~* Organize workstation according to the primary , secondary and tertiary zones.~* Place frequently used items within the reach of an arm.~* Don't move head while reading documents instead raise or lower the eyes to read.~* Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~* Keep reference material upright at desk.~* Avoid slouched postural habits, sit upright.~* Adjust chair height in such a way that it shouldn't compress the thigh.~* Arm rest should be at elbow flexion of 90 degrees.~* Phone must be cradled between neck and shoulder to avoid forward head posture."
61954571|NCT02687633|EXPERIMENTAL|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
62344381|NCT01750632|EXPERIMENTAL|Orchiectomy|The patients undergo subcapsular orchiectomy
62344382|NCT01262612|ACTIVE_COMPARATOR|immediate treatment with cediranib|8 patients with ascites and 8 patients with pleural effusion will start immediate treatment with cediranib
61954572|NCT02687633|ACTIVE_COMPARATOR|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
62344383|NCT01262612|ACTIVE_COMPARATOR|start cediranib after 28 days BSC|patients in group B will start with cediranib after one month best supportive care.
62344384|NCT00847938|ACTIVE_COMPARATOR|1|neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
61954573|NCT05269498|EXPERIMENTAL|CORTEXPLORER MED|Mixed-reality assisted planning of aneurysm clipping with the optical navigation system CORTEXPLORER MED.
61954574|NCT01223794||Experimental Group|Fall in higher risk
62344385|NCT00847938|ACTIVE_COMPARATOR|2|neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
62344386|NCT00847938|ACTIVE_COMPARATOR|3|neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
62701441|NCT05657847||Crystal arthropathies|Crystal arthropathies patients. \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
62701442|NCT04763343|EXPERIMENTAL|Ketamine Treatment + CAMS Therapy|
62701443|NCT04763343|PLACEBO_COMPARATOR|Saline Placebo Treatment + CAMS Therapy|
62701444|NCT00540631|NO_INTERVENTION|P|subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals
61954575|NCT01223794||Control Group|Fall in lower risk
61954576|NCT03830424||Control group|Healthy term newborns without pain relief during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
61954577|NCT03830424||Sucrose group|Healthy term newborns with oral application of sucrose during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
62701445|NCT00540631|EXPERIMENTAL|A|Active treatment with house dust mite extract
61954578|NCT03830424||Mother milk group|Healthy term newborns with oral application of mother milk during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
61954579|NCT05473598|ACTIVE_COMPARATOR|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
62701446|NCT02124408|EXPERIMENTAL|Intervention group|Personalized Behavioral Intervention
62701447|NCT02124408|NO_INTERVENTION|Control group|
62701448|NCT02987738|EXPERIMENTAL|dapagliflozin|two administrations of 10 mg dapagliflozin as tablet
61954580|NCT05473598|EXPERIMENTAL|UC + Stand Down app (app only)|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
62701449|NCT02987738|PLACEBO_COMPARATOR|Placebo Oral Tablets|two administrations identical to the experimental drug
61954581|NCT05473598|EXPERIMENTAL|UC + Peer-Supported Stand Down (PS-Stand Down)|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approximately 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
61954582|NCT03792191|EXPERIMENTAL|Ultrasonography|Preprocedural lumbar spinal ultrasonography and skin marking. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
61954583|NCT03792191|ACTIVE_COMPARATOR|Palpation|Sham ultrasound procedure. Conventional landmark palpation and skin marking.Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
61954584|NCT00939770|EXPERIMENTAL|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
61954585|NCT02983825|EXPERIMENTAL|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
62344387|NCT00847938|NO_INTERVENTION|4|no injection of neostigmine
62344388|NCT01552824|EXPERIMENTAL|Vesico-amniotic shunt|In this arm, patients will be randomly selected to undergo vesico-amniotic shunting.
62344389|NCT01552824|EXPERIMENTAL|CYSTO|In this arm, all patients will be randomly selected for fetal cystoscopy.
62344390|NCT01549223|ACTIVE_COMPARATOR|Standard Care Group|"Standard Care Group (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion oxytocin. If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
62344391|NCT01549223|ACTIVE_COMPARATOR|Protocol Group|"Protocol Group will receive 3 mL syringes marked study solution-oxytocin which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).~If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked study solution-9 min, containing methylergonovine maleate (methergine) 0.2mg, will be given IM.~If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked study solution-12 min, containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
62344392|NCT01206478|EXPERIMENTAL|Amitriptyline plus Megestrol|Amitriptyline once daily at bedtime plus megestrol starting at visit 2
62344393|NCT01206478|ACTIVE_COMPARATOR|Placebo plus Megestrol|Matching placebo once daily at bedtime plus megestrol starting at visit 2
62344394|NCT01479374|EXPERIMENTAL|AL-4943A|AL-4943A ophthalmic solution, 1 drop to each eye, 3 nonconsecutive days
62344395|NCT01479374|PLACEBO_COMPARATOR|Vehicle|AL-4943A vehicle, 1 drop to each eye, 3 nonconsecutive days
62344396|NCT01479374|ACTIVE_COMPARATOR|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop to each eye, 3 nonconsecutive days
62701450|NCT01316666||Neurogenic Hypotension|Patients with neurogenic hypotension, which includes those with Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA) and Parkinson Disease (PD)
62701451|NCT04908228|EXPERIMENTAL|Ibrutinib + obinutuzumab|Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1).
62701452|NCT02784340|ACTIVE_COMPARATOR|IV dexamethasone|40 women received 16 mg Dexamethasone IV drip.
62701453|NCT02784340|ACTIVE_COMPARATOR|Local dexamethasone|40 women received 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
62701454|NCT02784340|PLACEBO_COMPARATOR|placebo|Placebo in the form of IV fluids 500 cc saline infusion
62701455|NCT04505800|EXPERIMENTAL|Tryptophan supplement|"* Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
62701456|NCT04505800|PLACEBO_COMPARATOR|Maltose|"* Placebo is maltose powder capsule (500mg/capsule)~* 3g maltose powder per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
62701457|NCT04227587|EXPERIMENTAL|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx.
61954586|NCT03038932||Discovery Cohort|"A minimum of 50 recurrent Atopic Dermatitis with a history of Eczema Herpeticum(ADEH+), 500 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-), and 237 Non-Atopic (NA) European American participants from the Atopic Dermatitis Research Network (ADRN) DNA Repository.~The study will learn from this cohort:~1. All Single Nucleotide Variants (SNVs) in ADEH+~2. ADEH+ specific deleterious SNVs~The study will determine the function of:~4. ADEH+ risk variants"
61954587|NCT03038932||Independent populations of participants|"Two independent populations of participants:~1. Children, aged 3-17 years and~2. Adults 18-64 years of age.~A minimum of 12 recurrent Atopic Dermatitis with a history of Eczema Herpeticum (ADEH+) with ≥3 Eczema Herpeticum (EH) episodes, 12 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-) and 12 Non-Atopic (NA) participants will be enrolled in each of the two populations."
61954588|NCT03249675||ARM 1|ARM 1: Retrospective Arm: Subjects tested with BNA in the past and have been diagnosed by their physician as having Post Concussive Syndrome. Study staff will contact the subjects and obtain Informed Consent. Study physicians will then review both BNA data and Clinical data. All relevant clinical data and all available BNA data will be shared with ElMindA. Subjects may be invited for an additional BNA follow up as part of the study.
61954589|NCT03249675||ARM 2|"ARM 2: Subjects will be prospectively enrolled in the study at the following time points when available:~* Acute: within 2 weeks of injury~* PCS: Subjects which sustained a concussion in the past 3 months or more, and are still experiencing symptoms related to the injury"
61954590|NCT04315909|EXPERIMENTAL|Intervention group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus vitamin supplements (E (200 IU/ 2day) and C (250 mg/ 2day) ) for 8 weeks.
62701458|NCT04227587|ACTIVE_COMPARATOR|Sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse. Each subject will receive a handout and a sleep hygiene log.Subjects will be told to record their daily compliance with sleep hygiene instructions using yes/no questions in the sleep hygiene log.
61954591|NCT04315909|EXPERIMENTAL|Control group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus placebo for 8 weeks.
62142088|NCT01543893|ACTIVE_COMPARATOR|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
62142089|NCT05120336|EXPERIMENTAL|Non-depressed control participants: sham first, active taVNS second|Non-depressed control participants receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).
62344397|NCT05663840|EXPERIMENTAL|Progressive resistance exercise (exercise group)|Subjects will receive physical therapy that will predominantly include progressive resistance exercise training program along with continuation of standard of care (exercise group)
62344398|NCT05663840|ACTIVE_COMPARATOR|Standard of care (non-exercise group).|Subjects will receive continuation of standard of care (non-exercise group).
62344399|NCT01006720||Sgx 0.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
62344400|NCT01006720||Sgx 0.5|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
62344401|NCT01006720||Sgx 0.75|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
62344402|NCT01006720||Sgx 1.0|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
62344403|NCT01006720||Sgx 1.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
62701459|NCT02644551|EXPERIMENTAL|CELEXT07|suspension that is applied topically to the infected nail(s) daily.
62701460|NCT02644551|PLACEBO_COMPARATOR|placebo|placebo is a suspension that simulates the physical properties of the experimental agent CELEXT07. It is applied topically to the infected nail(s) daily.
62701461|NCT02644551|ACTIVE_COMPARATOR|Penlac|Is a standard of care for the condition and is applied topically to the infected nail(s) daily.
62344404|NCT01006720||Neo 10|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
62701462|NCT06398184|EXPERIMENTAL|Exercise + motor imagery and action observation|
62701463|NCT06398184|ACTIVE_COMPARATOR|Exercise|
62344405|NCT01006720||Neo 25|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
62344406|NCT01006720||Neo 40|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
62344407|NCT01006720||Neo 55|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
62344408|NCT01006720||Neo 70|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
62701464|NCT00189475|ACTIVE_COMPARATOR|Montelukast|Treated for 4 months with montelukast 4 mg per day
62701465|NCT00189475|PLACEBO_COMPARATOR|Placebo|Treated for 4 months with placebo
62701466|NCT05818462||Patients who received EBRT to the pelvis.|Childhood cancer survivors who were treated with chemotherapy and radiation therapy to the pelvis, with or without surgical intervention. This group will consist of both primary pelvic sarcomas as well as patients who received whole abdominal radiation that included bladder exposure.
62701467|NCT05818462||Control cohort.|Childhood cancer survivors who have been treated for a sarcoma who did not receive pelvic radiation, and were treated with chemotherapy, with or without surgical intervention or radiation therapy (outside of the pelvis). These patients will be matched as closely as possible to Group 1 to match chemotherapy regimens, and sex.
62701468|NCT00899301||Patients with Breast Cancer|
62701469|NCT00899301||Patients without breast cancer|
62701470|NCT01139515|EXPERIMENTAL|Treatment A|1 X 20 mg eletriptan
62344409|NCT01006720||Saline|Saline group: Saline as placebo
62344410|NCT04448262||G1 Asthma|Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
62701471|NCT01139515|EXPERIMENTAL|Treatment B|1 X 40 mg eletriptan
62701472|NCT01139515|EXPERIMENTAL|Treatment C|2 X 40 mg eletriptan
62701473|NCT01139515|EXPERIMENTAL|Treatment D|1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose
62701474|NCT04321655|EXPERIMENTAL|High Intensity LASER Therapy group (HILT)|Forty patients with chronic KOA in HILT group will received Class IV LASER therapy. A Class IV LASER emits power more than 500 milliwatt (mW) .
61954592|NCT00170495||observation|male and female adults age 65 and older with acute respiratory illness (common colds, flu, bronchitis, pneumonia)
62701475|NCT04321655|EXPERIMENTAL|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in ibuprofen gel phonophoresis (IGP) group will administered with continuous ultrasound set at a frequency of 1 megahertz (MHz) and an intensity of 1 W/cm2 was applied on a circular basis.
62701476|NCT04321655|EXPERIMENTAL|Transcranial direct current stimulation (tDCS) group|Fourty patients with chronic KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
62701477|NCT04321655|ACTIVE_COMPARATOR|Conventional physiotherapy group (CPT)|Individual with chronic KOA will be educated on how to do the set of exercises correctly at their home during the first session. All the groups will receive the same, standardized exercise protocol for KOA which consisted of nine exercises including muscle strengthening and flexibility training.
62701478|NCT06400082|ACTIVE_COMPARATOR|Povidone iodine 10%|
62701479|NCT06400082|EXPERIMENTAL|Topical insulin|
61954593|NCT01292811|EXPERIMENTAL|Functional electrical Stimulation|The functional electrical stimulation for the treatment group will begin by designing a stimulation protocol that can generate the palmar and/or the lateral grasp on demand. In other words, the stimulation sequence (protocol) will be developed for each patient individually using either Compex Motion or HEWHS stimulator; this will allow the patient, who otherwise cannot grasp, to do so with the system. Both stimulators will be used to deliver the same FES therapy. Stimulation parameters are: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from 250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
61954594|NCT01292811|OTHER|Control Group|"The Control group will receive conventional occupational therapy pertaining to hand function \[15\].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
62344411|NCT04448262||G2 Diabetes|Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c \< 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
62344412|NCT04448262||G3 Asthma plus diabetes|Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c \< 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
62344413|NCT06553846|EXPERIMENTAL|treatment group|Lutetium \[177Lu\]-FAP-75 accumulates at the tumor site, and beta rays act on surrounding tumor cells, causing tumor cell apoptosis.
62701480|NCT05450211|ACTIVE_COMPARATOR|Group SFI (Suprainguinal fascia iliaca block)|"In the patient lying in the supine position, a high-frequency linear probe is inserted under sterile conditions, using an in-plane technique, 1 cm cephalad of the inguinal ligament with an 85 mm needle. Using hydro-dissection, the fascia iliaca is separated from the iliac muscle and a space is created where the needle can be advanced cranially, and the procedure will be completed by injecting local anesthetic into this space.~When the patient whose block procedure is successful, is taken to the recovery room, controlled analgesia will be applied to the patient and he will be transferred to the ward. Tramadol HCL will be used for postoperative pain control for PCA."
62701481|NCT05450211|ACTIVE_COMPARATOR|Group PCA (patient controlled analgesia)|No block attempt will be made to the patients in this group, and when the patient is taken to the recovery room after surgery, controlled analgesia will be administered and transferred to the ward. Tramadol HCL will be used for postoperative pain control for PCA.
62701482|NCT02008643|EXPERIMENTAL|children with food allergy|Chidren aged 8-18 year with food allergy
62701483|NCT02008643|ACTIVE_COMPARATOR|children with chronic diseases|
62701484|NCT02008643|ACTIVE_COMPARATOR|witnesses|"Inclusion criteria Age between 8-18 year old Children attending schools of Nice City Signed informed consent of the two parents Signed informed consent of the child Health insurance recipient~Non inclusion criteria Association with another medical or psychiatric chronic disease No signed consent"
62701485|NCT00779909|PLACEBO_COMPARATOR|1- Placebo|placebo capsule once per day
61954595|NCT03693300|EXPERIMENTAL|WHO/ECOG PS 0 to 1 Cohort|100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
62344414|NCT02260466|OTHER|elderly patients with Aortic steNosis valvular replacement|
62344415|NCT06152419|EXPERIMENTAL|Interrogated patients|Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information. Patients will be recruited at the first consultation at the radiotherapy department or at one of the first radiotherapy sessions. In addition, focus groups will be organised to assess whether this video meets the patients' needs.
62701486|NCT00779909|EXPERIMENTAL|2- Vitamin D3, 500 IU|vitamin D3, 500 IU capsule once per day
62701487|NCT00779909|EXPERIMENTAL|3- Vitamin D3, 2500 IU|vitamin D3, 2500 IU capsule once per day
62701488|NCT00779909|EXPERIMENTAL|4- Vitamin D3, 5000 IU|vitamin D3, 5000 IU capsule once per day
61954596|NCT03693300|EXPERIMENTAL|WHO/ECOG PS 2 Cohort|up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
61954597|NCT01099553|OTHER|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Boston Medical Center
61954598|NCT01099553|EXPERIMENTAL|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions asking them to watch an educational video on the Center for Digestive Disorders website
62701489|NCT05593939|EXPERIMENTAL|Exercise arm|12 week aerobic exercise will be performed in agreement with current guidelines for exercise in older adults from the American College of Sports Medicine. A frequency of 5 days/week, totaling 150-300 min/week, performed at both moderate and vigorous intensities is chosen. This dose has a high level of evidence supporting positive effects on health- and life-span.
62701490|NCT05593939|EXPERIMENTAL|Time restricted feeding|A 12 week fasting/feeding regiment of 16 hours fasting /8 hours feeding each day is chosen. This ratio has been shown to be tolerable in older individuals.
62701491|NCT05593939|EXPERIMENTAL|Nicotinamide riboside|Previous clinical trials have shown that an nicotinamide riboside dose up to 2 g/day is well tolerated with no treatment-emergent adverse events reported so far and with efficacy on our primary outcome measurement. A dose of 2 g/day NR is therefore chosen and will be split in two: 1 g in the morning and 1 g in the evening.
61954599|NCT00282984|PLACEBO_COMPARATOR|placebo|
61954600|NCT00282984|EXPERIMENTAL|varenicline|
62344416|NCT02849314|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62344417|NCT02849314|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62142090|NCT05120336|EXPERIMENTAL|Patients with major depressive disorders: sham first, active taVNS second|participants with depression receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).
62142091|NCT05120336|EXPERIMENTAL|Patients with major depressive disorders: active taVNS first, sham second|participants with depression receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).
62142092|NCT05120336|EXPERIMENTAL|Non-depressed control participants: active taVNS first, sham second|Non-depressed control participants receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).
61954601|NCT01844440|EXPERIMENTAL|HRM|
61954602|NCT01897844|EXPERIMENTAL|ITF2984/Placebo 2000 mcg sc bid|ITF2984/Placebo 2000mcg s.c. b.i.d. for 14 days
61954603|NCT01897844|EXPERIMENTAL|ITF2984/Placebo 3000 mcg sc bid|ITF2984/Placebo 3000mcg s.c. b.i.d. for 14 days
61954604|NCT01897844|EXPERIMENTAL|ITF2984/Placebo 100 mcg sc bid|ITF2984/Placebo 100mcg s.c. b.i.d. for 14 days
61954605|NCT06446011|EXPERIMENTAL|Chronic kidney disease group|Root canal treatment will be performed in teeth with apical periodontitis in chronic kidney disease patients and change in PAI score, eGFR and systemic markers will be checked.
61954606|NCT06446011|ACTIVE_COMPARATOR|Healthy group|Root canal treatment will be performed in teeth with apical periodontitis in healthy patients and change in PAI score and systemic markers will be checked
61954607|NCT01410422||COPD|COPD
61954608|NCT01410422||Bronchiectasis|Bronchiectasis
62344418|NCT05052541|EXPERIMENTAL|Analgesia Arm: THC (tetrahydrocannabinol), then THC/CBD (cannabidiol), then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
62344419|NCT05052541|EXPERIMENTAL|Analgesia Arm: THC, then Placebo, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
62701492|NCT05593939|NO_INTERVENTION|Control|A control group with no intervention.
62701493|NCT05751304|ACTIVE_COMPARATOR|Group D|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg dexametomidine.
62701494|NCT05751304|ACTIVE_COMPARATOR|Group K|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
62701495|NCT02796651|EXPERIMENTAL|Formoterol 6 μg|Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
61954609|NCT02400333|EXPERIMENTAL|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
61954610|NCT02400333|EXPERIMENTAL|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
61954611|NCT02400333|EXPERIMENTAL|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
61954612|NCT02400333|EXPERIMENTAL|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
62344420|NCT05052541|EXPERIMENTAL|Analgesia Arm: THC/CBD, then THC, then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
62701496|NCT02796651|EXPERIMENTAL|Formoterol 12 μg|Participants received formoterol fumarate 12 μg administered via Pressair BID.
62701497|NCT02796651|EXPERIMENTAL|Formoterol 24 μg|Participants received formoterol fumarate 24 μg administered via Pressair BID.
62701498|NCT02796651|PLACEBO_COMPARATOR|Placebo|Participants received placebo to formoterol fumarate administered via Pressair BID.
62344421|NCT05052541|EXPERIMENTAL|Analgesia Arm: THC/CBD, then Placebo, then THC|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
62701499|NCT02796651|EXPERIMENTAL|Formoterol 20 μg|Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
62142093|NCT03281603|EXPERIMENTAL|CAD/CAM complete denture|"First intervention: Constructing complete denture by CAD/CAM technology utilizing milling technique.~Second intervention:Constructing complete denture CAD/CAM technology utilizing 3D printing technique"
62142094|NCT03281603|ACTIVE_COMPARATOR|Conventional complete denture|Constructing complete denture by conventional technique of denture processing
62142095|NCT06031116|EXPERIMENTAL|ceramic soft tissue bur|Eight dental arches were treated by ceramic soft tissue bur
62344422|NCT05052541|EXPERIMENTAL|Analgesia Arm: Placebo, then THC, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
62344423|NCT05052541|EXPERIMENTAL|Analgesia Arm: Placebo, then THC/CBD, then THC|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
62344424|NCT05052541|EXPERIMENTAL|Reduction Arm: THC/CBD|Subjects in this parallel arm will be assigned to 13 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
62344425|NCT05052541|PLACEBO_COMPARATOR|Reduction Arm: Placebo|Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
62344426|NCT01457001|EXPERIMENTAL|25-OH-D vitamin|
62344427|NCT01457001|NO_INTERVENTION|control|
62344428|NCT00543907||Pre programmatic development|Patients who have undergone mastectomy for breast cancer prior to implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
62344429|NCT00543907||Post programmatic development|Patients who have undergone mastectomy for breast cancer after implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
62344430|NCT04569916|EXPERIMENTAL|treatment group|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
62344431|NCT06490198|EXPERIMENTAL|Globo-H|OBI-833, 30 μg/ OBI-821 100 μg, Subcutaneous injection at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56, 64, 72, and 80 weeks
62344432|NCT05931744|ACTIVE_COMPARATOR|Oral steroid|patients given prednisone 1 mg/kg for 3 days then tapered by 5mg daily for two weeks
62344433|NCT05931744|EXPERIMENTAL|Budesonide Intrapolyp injection|patients given budesonide 0.5 mg/2ml intrapolyp injection once weekly for 5 consecutive weeks
62701500|NCT02796651|EXPERIMENTAL|Formoterol 40 μg|Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
62701501|NCT05539677||Melanoma|
62701502|NCT05539677||Soft tissue sarcoma|
62701503|NCT05539677||Kidney cancer|
62701504|NCT05539677||Primary brain tumors|
61954613|NCT01084083|EXPERIMENTAL|Group 1|After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
62344434|NCT05931744|PLACEBO_COMPARATOR|Saline intrapolyp injection|patients given 2ml normal saline intrapolyp injection once weekly for 5 consecutive weeks
62344435|NCT02573376|OTHER|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
62344436|NCT02573376|OTHER|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
62344437|NCT04205578|ACTIVE_COMPARATOR|Butylphthalide (NBP)|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
62344438|NCT04205578|PLACEBO_COMPARATOR|Normal saline|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
62344439|NCT05059951||Cohort A|Extansive Stage Small Cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
62344440|NCT05059951||Cohort B|Limit Stage Small Celll Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
62344441|NCT05059951||Cohort C|Small Celll Lung Cancer who progressed from first line treatment and received subsequential Chemotherapy with or without Checkpoint Inhibitors.
62344442|NCT05059951||Cohort D|Metastastic Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
62344443|NCT05059951||Cohort E|Metastastic Non-small cell Lung Cancer who progressed from first line treatment and received subsequential Chemotherapy with or without Checkpoint Inhibitors.
62344444|NCT05059951||Cohort F|Resectable Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
62344445|NCT05059951||Cohort G|Unresectable Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
62344446|NCT05059951||Cohort H|Non-small cell Lung Cancer received neoadjuvent or adjuvent Chemotherapy with or without Checkpoint Inhibitors.
62701505|NCT05539677||Malignant neoplasms|
62701506|NCT05539677||Prostate cancer|
62701507|NCT05539677||Colorectal cancer|
62701508|NCT01332916|EXPERIMENTAL|patients aged 45 and over group|patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
62701509|NCT01332916|ACTIVE_COMPARATOR|healthy volunteers (controls) aged 45 and over|healthy volunteers (controls) aged 45 and over
62701510|NCT01019941|OTHER|1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.|
62701511|NCT01019941|OTHER|1st cycle:Taxotere inj.-> 2nd cycle:CKD-810|
62701512|NCT06375148||Zhejiang Quality Control Center|
62701513|NCT06375148||Sichuan Provincial Center for quality control of TCM critical care medicine|
61954614|NCT01084083|EXPERIMENTAL|Group 2|After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.
61954615|NCT03415334|OTHER|behavioral change|two approaches for behavior changes : social marketing and behavioral development
61954616|NCT02045810|ACTIVE_COMPARATOR|Treatment|Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.
62142096|NCT06031116|ACTIVE_COMPARATOR|scalpel|Eight dental arches were treated by conventional scalpel technique
62142097|NCT02265354|EXPERIMENTAL|Collective-Intelligence computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a collective intelligence recommender systems algorithm for up to 6 months
62142098|NCT02265354|ACTIVE_COMPARATOR|Rule-based computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a rule-based algorithm for up to 6 months
62701514|NCT06375148||Severe nutrition group / nursing group of Zhejiang nutrition branch|
62142099|NCT00552253|EXPERIMENTAL|1|under eltroxin
62142100|NCT05161000|EXPERIMENTAL|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
62344447|NCT05059951||Cohort I|Cohort I, Non-small cell Lung Cancer with EGFR, ALK and ROS1 sensitive mutation who received Chemotherapy with or without Checkpoint Inhibitors.
62344448|NCT05059951||Cohort J|Non-small cell Lung Cancer with other oncogenic mutation including RET, BRAF etc who received Chemotherapy with or without Checkpoint Inhibitors.
62344449|NCT05059951||Cohort K|Non-small cell Lung Cancer received Chemotherapy plus bevacizumab with or without Checkpoint Inhibitors.
62344450|NCT05059951||Cohort L|Non-small cell Lung Cancer who enrolled in clinical trials.
62344451|NCT00634114|EXPERIMENTAL|1|Esomeprazole and Omeprazole
62344452|NCT00634114|EXPERIMENTAL|2|Esomeprazole
62344453|NCT04119817|EXPERIMENTAL|Mucosave® capsules|60 healthy volunteers taking 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day after dinner before going to bed.
62701515|NCT06375148||Critical care medicine of China Research Hospital Association|
62701516|NCT05849558|EXPERIMENTAL|Ursoplus® capsules (UDCA 250mg & Silymarin 140mg)|"Ursoplus® capsules: UDCA 250mg \& Silymarin 140mg~2 Capsules every 12 hours"
62701517|NCT05849558|ACTIVE_COMPARATOR|UDCA 250mg|"UDCA capsules: UDCA 250mg~2 Capsules every 12 hours"
62701518|NCT05849558|PLACEBO_COMPARATOR|Placebo|"Placebo alone~2 Capsules every 12 hours"
62344454|NCT04119817|PLACEBO_COMPARATOR|Placebo|40 healthy volunteers taking capsules of placebo for a period of 8 weeks, once a day after dinner before going to bed.
62344455|NCT02979301|EXPERIMENTAL|Tamoxifen 5 mg/day|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
62344456|NCT02979301|EXPERIMENTAL|Tamoxifen 10 mg/day|Women with high background uptake on MBI take 10 mg tam per day for 30 days.
62701519|NCT01399853|EXPERIMENTAL|160U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
62142101|NCT05161000|OTHER|Control Group|dietary counseling
62142102|NCT03744026|EXPERIMENTAL|SonoCloud-9 Ultrasound + Carboplatin|SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)
62142103|NCT05866575|OTHER|escitalopram strategy|The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist.
62142104|NCT05866575|OTHER|vortioxetine strategy|The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist.
62142105|NCT01683188|OTHER|Cohort 1|Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
62344457|NCT03885089||Infliximab [infliximab biosimilar 3]|Patients with Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis treated by Infliximab BS
62344458|NCT02489565|NO_INTERVENTION|Tertiary care|Outpatient from tertiary care with discharge criteria who remains in the tertiary care.
62701520|NCT01399853|EXPERIMENTAL|320U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
62701521|NCT01399853|EXPERIMENTAL|640U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
62701522|NCT01399853|EXPERIMENTAL|(without adjuvant) 640U /0.5ml in children (12-36months)|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
62701523|NCT01399853|EXPERIMENTAL|160U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
62701524|NCT01399853|EXPERIMENTAL|320U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
62701525|NCT01399853|EXPERIMENTAL|640U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
62701526|NCT01399853|EXPERIMENTAL|(without adjuvant) 640U /0.5ml in infants (from 6 to 11 months|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
62701527|NCT01399853|PLACEBO_COMPARATOR|0/0.5ml placebo in children (from 12 to 36 months old)|0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
62701528|NCT01399853|PLACEBO_COMPARATOR|0/0.5ml placebo in infants (from 6 to 11 months old)|0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28
62701529|NCT04656561|EXPERIMENTAL|ANX007 Group 1|ANX007 administered every month
62701530|NCT04656561|EXPERIMENTAL|ANX007 Group 2|ANX007 administered every other month
62701531|NCT04656561|SHAM_COMPARATOR|Sham Group 3|Sham injection administered every month
62701532|NCT04656561|SHAM_COMPARATOR|Sham Group 4|Sham injection administered every other month
61954617|NCT02045810|PLACEBO_COMPARATOR|Control group|Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.
61954618|NCT00594659|ACTIVE_COMPARATOR|1|Therapist delivered cognitive behavioral treatment
61954619|NCT00594659|EXPERIMENTAL|2|Computerized Cognitive Behavioral treatment
61954620|NCT00594659|ACTIVE_COMPARATOR|3|Motivational enhancement therapy
61954621|NCT02654834||Pediatric Operating Room (OR) Staff|OR Staff exposed to nitrous oxide, and other volatile anesthetics
62344459|NCT02489565|EXPERIMENTAL|Primary care|Outpatient discharge from tertiary care to a primary care near the patient's home with the support of telemedicine.
62344460|NCT01599546||Full Term children|born \>36 weeks, currently age 6 +/- 6 months
62344461|NCT01599546||Preterm children|born \<35 weeks, age 6 +/- 6 months at the beginning of the study.
62344462|NCT05067686||Mental Health Professionals|
62344463|NCT05067686||Non Mental Health Professionals|
62344464|NCT00676936|EXPERIMENTAL|Methylprednisolone|Methylprednisolone 16 mg twice daily
62502277|NCT05390398|NO_INTERVENTION|Wait-list usual care group|The wait-list usual care group follows usual care and usual activities. Participants receive a lifestyle program after the intervention period of six months: this includes two personalized behavioural coaching sessions and any material that the intervention group also received.
61954622|NCT02654834||Pediatric Intensive Care Unit (ICU) Staff|ICU Staff unexposed to any volatile anesthetics
61954623|NCT02091492|ACTIVE_COMPARATOR|Teriparatide|Teriparatide 20µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
61954624|NCT02091492|PLACEBO_COMPARATOR|Placebo-Teriparatide|Placebo-Teriparatide 20 µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
61954625|NCT03584360|EXPERIMENTAL|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
61954626|NCT03584360|EXPERIMENTAL|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
61954627|NCT03584360|EXPERIMENTAL|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
62142106|NCT01683188|OTHER|Cohort 2|Patients who have receive \>7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2
62142107|NCT03385759|ACTIVE_COMPARATOR|UKA|Medial unicompartmental knee arthroplasty
62142108|NCT03385759|ACTIVE_COMPARATOR|TKA|Total knee arthroplasty
62142109|NCT04810390|EXPERIMENTAL|Bilastine|Daily instillation of one drop in each eye of Bilastine ophthalmic solution 0.6% for 8 weeks.
62142110|NCT04810390|PLACEBO_COMPARATOR|Placebo|Daily instillation of one drop in each eye of placebo for 8 weeks.
62344465|NCT00676936|PLACEBO_COMPARATOR|Placebo|Placebo capsules twice daily
62344466|NCT03830814||Cases|Patients with heart failure with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines
62344467|NCT04180800||Folic acid deficiency|Those with a folic acid defiency
62344468|NCT04180800||No deficiency|Those with no folic acid deficiency
62344469|NCT01604876|EXPERIMENTAL|light condition 1 + day night structure|exposure to 10.000 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
62344470|NCT01604876|ACTIVE_COMPARATOR|light condition 2 + day night structure|exposure to 200 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
62701533|NCT06281457|EXPERIMENTAL|Manipulations of task demands (Expt 2.1)|Participants will view a single stimulus containing dots moving in one of two directions (clock-wise or counterclockwise) and drawn in one of two colors (orange and cyan). To complete the correct task for a trial, a cue at fixation will be manipulated.
61954628|NCT06066164|PLACEBO_COMPARATOR|Control group|
61954629|NCT06066164|ACTIVE_COMPARATOR|Polysubstance use disorder patients|
61954630|NCT06066164|ACTIVE_COMPARATOR|Monosubstance use disorder patients|
61954631|NCT00970970||Von Hippel Lindau|Adult patients with Von Hippel-Lindau disease
62142111|NCT00779805|EXPERIMENTAL|1|Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
62142112|NCT00779805|ACTIVE_COMPARATOR|2|Sudafed 120 mg ER tablets
62142113|NCT04872296|ACTIVE_COMPARATOR|Early weight bearing|Participants treated for an ankle fracture will be allowed to weight bear early after surgery starting at 2 weeks post operatively
62142114|NCT04872296|ACTIVE_COMPARATOR|Postponed weight bearing|Participants treated for an ankle fracture will be treated with standard protocol of non-weight bearing for 6 weeks post operatively.
62142115|NCT05829109|EXPERIMENTAL|Fecal Microbiota Transplant (FMT)|Single arm of 16-18 subjects, all of whom will receive the interventional FMT.
62344471|NCT02056834||chronOS Inject|Closed proximal tibial fractures of type Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
62344472|NCT03583372|EXPERIMENTAL|Vibegron + Placebo to match Tolterodine|
62344473|NCT03583372|ACTIVE_COMPARATOR|Tolterodine + Placebo to match vibegron|
62344474|NCT01743599||Diabetic men|
62344475|NCT01743599||Non-diabetic men|
62344476|NCT03648307||Trauma splenectomized|Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
62344477|NCT03648307||Bowel resection|Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
62344478|NCT00615251|EXPERIMENTAL|1|
62344479|NCT00615251|ACTIVE_COMPARATOR|2|
62344480|NCT01488942|EXPERIMENTAL|monetary reinforcer|Subjects randomized to this arm will receive an escalating reinforcer initially for attendance at each clinic visit (until month 6 after starting HAART) and subsequently (until month 12 after starting HAART) will receive an escalating variable reinforcer for each month in which a viral load at or below 100 copies/mL is maintained
62701534|NCT03598348|EXPERIMENTAL|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
62701535|NCT03598348|NO_INTERVENTION|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
62344481|NCT01488942|NO_INTERVENTION|no reinforcer|All subjects will receive HAART and standard medical care, but subjects in the control arm will not receive monetary reinforcers.
62701536|NCT03598348|EXPERIMENTAL|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
62701537|NCT00767780||3|Patients suffering from ankle fractures and instability
62701538|NCT00767780||4|Patients suffering from hip osteoarthritis
62701539|NCT00767780||5|Patients who underwent total knee replacement or total hip replacement
62701540|NCT00767780||1|Patients suffering from bilateral knee osteoarthritis
62701541|NCT00767780||2|Patients suffering fron non specific low back pain
62701542|NCT00378092|EXPERIMENTAL|Risperidone Long-Acting Injection (RLAI) (Period 1)|Participants will receive 25 milligram (mg) to 50 mg of RLAI intramuscularly (into the muscle) which will be tapered and discontinued over a period of up to 6 weeks. Participants will be followed-up until their first disease relapse or maximum of 36 months.
62701543|NCT00378092|EXPERIMENTAL|Oral risperidone and RLAI (Period 2)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus (a muscle) for up to 24 months. Supplementation with oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injections becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
62701544|NCT06517290||Fever during labor|
62701545|NCT06517290||Child|
61954632|NCT00730132||New Statin|Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
61954633|NCT00730132||Statin Dose Titration|Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
61954634|NCT00730132||Ezetimibe added to existing statin|Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment
61954635|NCT01156870|EXPERIMENTAL|SAR566658|SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
62344482|NCT05344625|EXPERIMENTAL|Ketamine Assisted Psychotherapy|3 KAP sessions lasting approximately 3 hours using less than or equal to 60mg or 1mg/kg of intramuscular Ketalar as the facilitating chemical. KAP sessions will be supplemented with integration sessions occurring the following day and 1 month after the final KAP session.
62701546|NCT02385071|EXPERIMENTAL|Panel1: Sequence 1 (ABC)|Participants will receive Treatment A (150 milligram (mg) simeprevir (SMV) capsule with water under fed conditions) in Period 1; followed by Treatment B (3\*50 mg capsules of SMV \[including 50 mini-tablets of 1 mg each\] with water under fed conditions) in Period 2; followed by Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701547|NCT02385071|EXPERIMENTAL|Panel1: Sequence 2 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701548|NCT02385071|EXPERIMENTAL|Panel1: Sequence 3 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701549|NCT02385071|EXPERIMENTAL|Panel1: Sequence 4 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
61954636|NCT05338515|EXPERIMENTAL|Selpercatinib Cohort 1|Selpercatinib administered orally.
61954637|NCT05338515|EXPERIMENTAL|Selpercatinib Cohort 2|Selpercatinib administered orally.
61954638|NCT05338515|EXPERIMENTAL|Selpercatinib Cohort 3|Selpercatinib administered orally.
62344483|NCT02810652|EXPERIMENTAL|Perioperative Geriatrics Intervention|Evaluation with a board-certified geriatric clinician, both pre- and post-operatively.
62344484|NCT02810652|ACTIVE_COMPARATOR|Standard Care|Usual care participants will not meet with a geriatric clinician perioperatively, but may receive a geriatric consult upon request or at the discretion of their treating clinician(s).
62344485|NCT02190747|EXPERIMENTAL|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
62701550|NCT02385071|EXPERIMENTAL|Panel1: Sequence 5 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701551|NCT02385071|EXPERIMENTAL|Panel1: Sequence 6 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701552|NCT02385071|EXPERIMENTAL|Panel 2: Sequence 1 (DEF)|Participants will receive Treatment D (3\*50 mg SMV capsules \[including 50 mini-tablets of 1 mg each\] with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 1; followed by Treatment E (3\*50 mg SMV capsules \[including 50 mini-tablets of 1 mg each\] with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions) in Period 2; followed by Treatment F (3\*50 mg SMV capsules \[including 50 mini-tablets of 1 mg each\] with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
61954639|NCT01205906|EXPERIMENTAL|Internet-based guided self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
62701553|NCT02385071|EXPERIMENTAL|Panel 2: Sequence 2 (EFD)|Participants will receive Treatment E in Period 1; followed by Treatment F in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701554|NCT02385071|EXPERIMENTAL|Panel 2: Sequence 3 (FDE)|Participants will receive Treatment F in Period 1; followed by Treatment D in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701555|NCT02385071|EXPERIMENTAL|Panel 2: Sequence 4 (FED)|Participants will receive Treatment F in Period 1; followed by Treatment E in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701556|NCT02385071|EXPERIMENTAL|Panel 2: Sequence 5 (EDF)|Participants will receive Treatment E in Period 1; followed by Treatment D in Period 2; followed by Treatment F in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
61954640|NCT01205906|EXPERIMENTAL|Cognitive-behavior group therapy|This well-established, cognitive-behavior group therapy was developed by Hiller and Haerkötter (2005) and consists of 10 weekly group sessions of 90 minutes. The strictly manualized program includes the following components focusing on the special needs of chronic tinnitus patients: Education, relaxation techniques, cognitive restructuring, the role of attentional processes for tinnitus perception, analysis of avoidance behaviors, tinnitus and the health care system as well as relapse prevention. For each session participants receive written materials, exercises and homework assignments to enhance understanding and to transfer the new information into the daily routine.
61954641|NCT01205906|ACTIVE_COMPARATOR|Discussion forum group|To the participants of the control group the group therapy or the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
61954642|NCT01995474|EXPERIMENTAL|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
61954643|NCT01995474|ACTIVE_COMPARATOR|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
61954644|NCT06349772|EXPERIMENTAL|Patients who receive zynrelef|Those who get zynrelef injected at the at the 12mm port incision
61954645|NCT06349772|EXPERIMENTAL|Patients who receive exparel|those who get exparel injected at the 12mm port incision
61954646|NCT03501459|EXPERIMENTAL|Rituximab|
61954647|NCT01211730|ACTIVE_COMPARATOR|140 Group|Insulin treatment to target blood glucose at 140 mg/dl
61954648|NCT01211730|ACTIVE_COMPARATOR|180 Group|Insulin treatment to target blood glucose at 180 mg/dl
61954649|NCT01212315|NO_INTERVENTION|Control group|Ordinary sutures (Vicryl / Monocryl) is used for wound closure
61954650|NCT01212315|ACTIVE_COMPARATOR|Group A|Triclosan coated sutures (Vicryl Plus / Monocryl Plus) is used for wound closure
62344486|NCT02190747|EXPERIMENTAL|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
62344487|NCT02190747|EXPERIMENTAL|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
62344488|NCT02190747|PLACEBO_COMPARATOR|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
62344489|NCT01731613|ACTIVE_COMPARATOR|Standard Fortification|receive human milk fortified with human milk fortifier(HMF) in the standard amount (4 packs /100 ml of HM) throughout the study
62344490|NCT01731613|EXPERIMENTAL|Adjustable fortification|encompasses increasing/decreasing the amount of human milk fortifier(HMF) and adding supplemental protein guided by periodic determinations of the protein concentration of human milk (PCHM), body weight, blood urea nitrogen(BUN)
62344491|NCT04689594|EXPERIMENTAL|CLS2702C/CLS2702D|
61954651|NCT06498830||The formation of any atherosclerotic plaque on the follow-up CCTA|
61954652|NCT06498830||The regression of any atherosclerotic plaque on the follow-up CCTA|
61954653|NCT05309642|ACTIVE_COMPARATOR|ICR Arm|On 2 non-consecutive days per week, participants in the ICR (5:2 diet) group will be instructed to consume 500 kcal/day for women and 600 kcal/day for men.
62344492|NCT03763903|OTHER|3D training|Basic laparoscopic skills (FLS tasks) training using 3D visualization
62701557|NCT02385071|EXPERIMENTAL|Panel 2: Sequence 6 (DFE)|Participants will receive Treatment D in Period 1; followed by Treatment F in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
62701558|NCT04994977|EXPERIMENTAL|Intra-arterial Chemotherapy|Subjects are pre-treated with heparin, and then given single doses of Melphalan, Carboplatin, and Topotecan consecutively via intra-arterial infusion. Multiple arteries may be used, with the total dose of the drugs remaining the same.
62701559|NCT06495567|EXPERIMENTAL|Baseline - no creatine supplementation|Each participant will complete a baseline study day. For 7 days prior to the study day each participant will eat a controlled diet of 1g protein/kg body weight/day.
62701560|NCT06495567|EXPERIMENTAL|Treatment - Creatine Supplementation 20mg|Each participant will complete a supplemented study day. For 7 days prior to the study day each participant will eat a controlled diet of 1g protein/kg body weight/day, and the provided 20mg creatine supplement.
62701561|NCT03386162|EXPERIMENTAL|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
62142116|NCT05028933|EXPERIMENTAL|EPCAM CAR-T|"The first stage: single dose escalation The classic 3+3 dose escalation test. The starting dose refers to the results of the previous test of subsequent subjects. In this study, 3 increasing dose levels were set up, with 3 to 6 cases per dose.~* The first dose group is 3×10\^5/kg, allowing 10% dose error.~* The second dose group is 1×10\^6/kg, allowing 10% dose error.~* The third dose group is 3×10\^6/kg, allowing 10% dose error. Each dose group must complete the DLT observation before entering the next dose group; when the first subject in the same dose group has no DLT observed for at least 14 days after cell infusion, the subsequent subjects can receive cell infusion.~The second stage: combined radiofrequency/microwave ablation for the treatment of advanced digestive system malignant tumors with liver metastases"
62142117|NCT00724126|PLACEBO_COMPARATOR|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
62142118|NCT00724126|EXPERIMENTAL|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
62142119|NCT04205669|ACTIVE_COMPARATOR|Individual Treatment|
62142120|NCT04205669|ACTIVE_COMPARATOR|Household Treatment|
62142121|NCT06515873|EXPERIMENTAL|a group of 55 patients|
62344493|NCT03763903|OTHER|2D training|Basic laparoscopic skills (FLS tasks) training using 2D visualization
62344494|NCT00063583|PLACEBO_COMPARATOR|Placebo|Placebo
62344495|NCT00063583|EXPERIMENTAL|Pirfenidone 1200 mg/day|Pirfenidone will be administered at a dose of 1200 mg/day
62701562|NCT03386162|ACTIVE_COMPARATOR|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
62701563|NCT03087071|EXPERIMENTAL|Cohort 1 (panitumumab)|Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
62701564|NCT03087071|EXPERIMENTAL|Cohort 2 (panitumumab, trametinib)|Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62701565|NCT03087071|EXPERIMENTAL|Cohort 3 (panitumumab)|Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
62701566|NCT02056769|EXPERIMENTAL|CT Perfusion|All patients enrolled in the study
62701567|NCT00829998|EXPERIMENTAL|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
61954654|NCT05309642|PLACEBO_COMPARATOR|Soc Arm|The SoC group will receive 80% of standard calorie (1,200-1,500 kcal/day or reducing 500-1000 kcal/day from standard calorie).
62701568|NCT00829998|ACTIVE_COMPARATOR|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
62701569|NCT06266546|EXPERIMENTAL|Intervention|Prophylactic TXA arm
61954655|NCT04456959||Adult R/R ALL patients who have received InO|Relapsed/refractory ALL patients who are 18 years and over and initiated InO between 1st of June 2016 and date of data collection (to be confirmed). They will have accessed InO treatment via NHS commissioning, via the CUP, or via private purchase and will have at least 3 months follow up from the index date unless death occurs within that time.
61954656|NCT00402415|EXPERIMENTAL|1|
62142122|NCT03897699|EXPERIMENTAL|active tDCS + Mindful Breathing Training|20 minutes of active or sham stimulation will be applied at 2.0 mA in parallel with mindful breathing training
62701570|NCT06266546|NO_INTERVENTION|Control|Data collected retrospectively from patients undergoing the same procedure one year prior to the study initiation
61954657|NCT04345809||GROUP A. MESH WITH OMEGA-3|Group A - 6.4-cm diameter circular prosthesis C-QUR V-Patch with an omega-3 coating
62142123|NCT03897699|SHAM_COMPARATOR|sham tDCS + Mindful Breathing Training|The sham condition will apply stimulation only for the first and last 30 seconds of the 20-minute session
62142124|NCT01824225|ACTIVE_COMPARATOR|PRN injection of aflibercept|Intravitreal aflibercept
62142125|NCT01824225|ACTIVE_COMPARATOR|Two months injection of aflibercept|Intravitreal afilibercept
62142126|NCT01673399|ACTIVE_COMPARATOR|Atosiban|Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.
62142127|NCT01673399|PLACEBO_COMPARATOR|placebo|Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours
62142128|NCT05142774|EXPERIMENTAL|tapinarof cream|"Subjects entering with vIGA-AD (Validated Investigator Global Assessment of Atopic Dermatitis) ≥1 receive treatment with study drug until they achieve vIGA-AD=0, at which time treatment is discontinued and subjects are monitored for durability of response (remittive response). If/when disease worsening occurs (vIGA-AD ≥2), treatment is re-initiated and continued until vIGA-AD =0 is achieved.~Subjects entering with a vIGA-AD=0 discontinue treatment and are monitored for duration of remittive response. If/when disease worsening occurs (vIGA-AD ≥2), treatment is re-initiated and continued until vIGA-AD =0 is achieved.~This treatment and re-treatment pattern of use continue until the end of the study."
62142129|NCT00564421|EXPERIMENTAL|Epinastine low concentration:low dose volume|
62142130|NCT00564421|EXPERIMENTAL|Epinastine low concentration:high dose volume|
62142131|NCT00564421|EXPERIMENTAL|Epinastine high concentration:low dose volume|
62344496|NCT00063583|EXPERIMENTAL|Pirfenidone 2400 mg/day|Pirfenidone will be administered at 2400 mg/day
61954658|NCT04345809||GROUP B. MESH WITHOUT OMEGA-3|Group B - 6.4-cm diameter circular prosthesis BARD Hernia Patch , without omega-3 in its composition
61954659|NCT02288052|EXPERIMENTAL|Writing program|The program will train participants in maintaining writing amplitude, writing speed, writing fluently and automatization of writing.
61954660|NCT02288052|PLACEBO_COMPARATOR|Stretch & Relaxation program|The program will learn participants to alleviate tension in the upper limbs and will consist of exercises performed while lying down or sitting.
62142132|NCT00564421|EXPERIMENTAL|Epinastine high concentration:high dose volume|
62344497|NCT03986008|EXPERIMENTAL|Benaglutide|Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
62142133|NCT00564421|PLACEBO_COMPARATOR|Placebo nasal spray|
62701571|NCT06328712|ACTIVE_COMPARATOR|Cohort 1|EN001 1.25×10\^6 cells/kg
62701572|NCT06328712|ACTIVE_COMPARATOR|Cohort 2|EN001 2.5×10\^6 cells/kg
62701573|NCT05575466||Patients|Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
61954661|NCT05581862|EXPERIMENTAL|3 Meals+3 Snacks|This group was followed up for 3 months with an energy restricted weight loss plan composed of 3 main meals and 3 snacks
61954662|NCT05581862|EXPERIMENTAL|3 Meals|This group was followed up for 3 months with an energy restricted weight loss plan composed of 3 main meals
61954663|NCT01831648|EXPERIMENTAL|Volonteers|Blood sample
61954664|NCT02030041|EXPERIMENTAL|Simvastatin and placebo|"Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl.~This arm will receive Simvastatin 40 mg once daily and placebo once weekly, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
61954665|NCT02030041|ACTIVE_COMPARATOR|Simvastatin and vitamin D|"Eleven participants will be vitaminD deficient with LDL-C between 100 to 130mg/dl.~This arm will receive simvastatin 40 mg once daily and vitaminD 60,000 units once weekly , and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
61954666|NCT02030041|ACTIVE_COMPARATOR|Vitamin D and placebo|Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl This arm will receive vitamin D 60,000 units once weekly and placebo once daily, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week
61954667|NCT02489162|EXPERIMENTAL|MyotonPRO|Experimental: Measurement of biomechanical properties of mimic muscles on the ipsilateral palsy side with the healthy contralateral side ( case - control design)
61954668|NCT02489162|ACTIVE_COMPARATOR|Non-invasive electromyography (EMG)|Comparing experimental intervention with gold standard
62142134|NCT05316259|EXPERIMENTAL|Group A（Dosing in the fasted state followed by fed dosing）|Dosing in the fasted state followed by fed dosing.A washout period of 14 days will be maintained between the 2 treatment periods.
62701574|NCT05575466||Controls|Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
62701575|NCT06168773|EXPERIMENTAL|Group I (number of patients = 45):|will receive 1 mg haloperidol intravenously 3 times daily and magnesium sulfate 4 g intravenous infusion (IVI) in 1st day (diluted in 50 ml D5W over 24 hours) then 2g IVI over 24 hours (diluted in 50 ml D5W over 24 hours) for 3 days postoperatively starting the first dose 2- 4 hours after surgery. If the first prophylactic dose is delayed for more than 4 hours post admission, patient is excluded from the study.
62701576|NCT06168773|EXPERIMENTAL|Group II (number of patients= 45):|will receive 1 mg haloperidol intravenously 3 times daily and 50 ml of D5W IVI infusion over 24 hours for 4 days postoperatively starting the first dose 2- 4 hours after surgery.
61954669|NCT02154178|EXPERIMENTAL|Biomarker group|"Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.~Biomarker group"
62344498|NCT03986008|ACTIVE_COMPARATOR|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.
62701577|NCT06168773|PLACEBO_COMPARATOR|Group III (number of patients = 45)|will receive 1 mL 0.9% of sodium chloride intravenously 3 times daily and 50 ml of D5W IVI infusion for 4 days postoperatively starting the first dose 2- 4 hours after surgery.
62701578|NCT06336564|ACTIVE_COMPARATOR|Control Group|Pelvic floor muscle training
62701579|NCT06336564|EXPERIMENTAL|Intervention Group|Pelvic floor muscle training and microablative radiofrequency
62701580|NCT03375437|EXPERIMENTAL|NTRK, ROS and ALK molecular screening|"The molecular screening to detect NTRK1, 2, 3, ROS or ALK gene rearrangements will be a two step process, consisting of:~1. First, immunohistochemistry (IHC) assay to detect protein expression of TRKA/B/C (encoded by NRTK1,2,3), ROS1 or ALK.~2. Second, RNAseq analysis will be performed on positive IHC specimens to detect specific rearrangements in the NTRK1, NTRK2, NTRK3, ROS1 or ALK genes."
61954670|NCT02154178|NO_INTERVENTION|Control group|Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days).
61954671|NCT02814578|EXPERIMENTAL|Optical coherent tomography|Optical coherent tomography provides more detailed information about the morphology of scaffolds, microstructures and coronary vasculature based on tissue characteristics as compared to conventional IVUS. In spite of angiographic success in BVS placement, further scaffold optimization was required in over a quarter of cases based on OCT findings due to malapposition or scaffold under expansion.
62142135|NCT05316259|EXPERIMENTAL|Group B（Dosing in the fed state followed by fasted dosing）|Dosing in the fed state followed by fasted dosing.A washout period of 14 days will be maintained between the 2 treatment periods.
62142136|NCT00845520|EXPERIMENTAL|Lens implantation +1.00 diopter (D) postop target|Lens implant power calculated for postoperative MRSE target of +1.00 D
62701581|NCT01741129|ACTIVE_COMPARATOR|Nasal Continuous Positive Airway Pressure (CPAP)|"After 2 hours evaluation:~* Infants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of \>40% to maintain the targeted saturation of \>88% to 92%.~* Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
62701582|NCT01741129|ACTIVE_COMPARATOR|Nasal Intermittent Mandatory Ventilation (IMV)|"After 2 hours evaluation:~* Infants needed invasive MV or Required a fraction of inspired oxygen of \>40% to maintain the targeted saturation of \> 88% to 92%.~* Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
62701583|NCT04466358|EXPERIMENTAL|Modified CLOSE protocol|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol, confirmed with multipolar circular mapping catheter.
61954672|NCT02814578|ACTIVE_COMPARATOR|IntraVascular UltraSound|Intravascular ultrasound guidance has been associated with improved event-free survival compared with angiographic guidance after DES placement.
61954673|NCT06099366|EXPERIMENTAL|Standard-low (SL)|Induction-\> SL Consolidation(4weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion-\> Interim Maintenance 2nd-\> Maintenance
61954674|NCT06099366|EXPERIMENTAL|Standard-average (SA)|Induction-\> SH Consolidation(8weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion-\> Interim Maintenance 2nd-\> Maintenance
62701584|NCT04466358|ACTIVE_COMPARATOR|High density mapping guided pulmonary vein isolation|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol and confirmed with high density mapping of each pulmonary vein antrum, with additional ablation lesions at sites of gap or dormant conduction.
62701585|NCT03893357||Positive for antiphospholipid antibodies|Patients tested positive for antiphospholipid antibodies
62701586|NCT03893357||Negative for antiphospholipid antibodies|Patients tested negative for antiphospholipid antibodies
62701587|NCT00621283|EXPERIMENTAL|1|Drug + MR with MRCP
61954675|NCT06099366|EXPERIMENTAL|Standard-high 1 (SH1)|Induction-\> SL Consolidation(4weeks)-\> SH Consolidattion(4weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion 1st-\> Interim Maintenance 2nd-\> Delayed Intestificaion 2nd-\> Maintenance
62701588|NCT05761756|ACTIVE_COMPARATOR|Sleep Deprivation|Effect of sleep deprivation on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Ten subjects will be tested before and after 24 hours of sleep deprivation. The order of sleep deprivation vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water.
61954676|NCT06099366|EXPERIMENTAL|Standard-high 2 (SH2)|Induction-\> SH Consolidattion(8weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion 1st-\> Interim Maintenance 2nd-\> Delayed Intestificaion 2nd-\> Maintenance
61954677|NCT01317030||Contact Lens Wear|Senofilcon A Lenses, using Sensitive Eyes Saline Solution and/or Biotrue Multipurpose Solution
61954678|NCT01317030||Non-Contact Lens Wear|
61954679|NCT04768595|PLACEBO_COMPARATOR|Placebo|1g corn oil capsules
61954680|NCT04768595|EXPERIMENTAL|Ceto 10|1g capsules containing oil from north atlantic fish containing broad spectrum marine oil.
61954681|NCT04768595|ACTIVE_COMPARATOR|Omega-3|1 g capsules containing traditional, commericially available omega-3 marine oil.
61954682|NCT02975518|ACTIVE_COMPARATOR|Intra-venous infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
61954683|NCT02975518|ACTIVE_COMPARATOR|Intra-Arterial infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
61954684|NCT02975518|EXPERIMENTAL|Intra-venous injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
61954685|NCT02975518|EXPERIMENTAL|Intra-Arterial injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
61954686|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
62701589|NCT05761756|EXPERIMENTAL|Caffeine|Effect of caffeine and methylphenidate on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Twenty subjects will be similarly sleep-deprived, tested as above and then re-tested tested following oral administration of administration of either oral caffeine (N=10) or methylphenidate (N=10). Pre-dive caffeine will be administered 500 mg orally \[59\]. Pre-dive methylphenidate will be administered as a single dose of 5 mg \[60\]. The order of drug administration vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water. fNIRS will be used to assess cerebral oxygenation and regional blood volume.
62344499|NCT00236119|EXPERIMENTAL|CEP-701 20mg|Patient Cohort 1
62701590|NCT05761756|EXPERIMENTAL|Methylphenidate|Effect of caffeine and methylphenidate on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Twenty subjects will be similarly sleep-deprived, tested as above and then re-tested tested following oral administration of administration of either oral caffeine (N=10) or methylphenidate (N=10). Pre-dive caffeine will be administered 500 mg orally \[59\]. Pre-dive methylphenidate will be administered as a single dose of 5 mg \[60\]. The order of drug administration vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water. fNIRS will be used to assess cerebral oxygenation and regional blood volume.
61954687|NCT03906838|EXPERIMENTAL|Regional Nerve Block|Subjects in the regional anesthesia cohort will have a regional anesthesia block and/or catheter placement administered according to current hospital policies and our established standard of care.
61954688|NCT03906838|NO_INTERVENTION|No Regional Nerve Block|Subjects in the no regional anesthesia cohort will not get pre-operative regional anesthesia, and their surgery and anesthesia will be performed according to normal policies and standard of care in our hospital.
61954689|NCT01628315||Mulitple Sclerosis|Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
61954690|NCT02207296|OTHER|PVI group|Fluid optimisation using PVI
61954691|NCT02207296|NO_INTERVENTION|Control group|Standard care using a hemodynamic protocol during general anesthesia
61954692|NCT02033109|EXPERIMENTAL|PC-1005|"* 4.00 g dosed once daily for 3 days (safety run-in)~* 4.00 g dosed once daily for 14 days (main study)"
61954693|NCT02033109|PLACEBO_COMPARATOR|HEC gel|4.00 g dosed once daily for 14 days (main study only)
61954694|NCT02993757|EXPERIMENTAL|CYD Dengue Vaccine + Gardasil (Concomitant Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
62142137|NCT00845520|EXPERIMENTAL|Lens implantation -1.00 D postop target|Lens implant power calculated for postoperative MRSE target of -1.00 D
62142138|NCT00845520|EXPERIMENTAL|Lens implantation 0.00 D postop target|Lens implant power calculated for postoperative MRSE target of 0.00 D
62344500|NCT00236119|EXPERIMENTAL|CEP-701 40mg|Patient Cohort 2
62344501|NCT00236119|EXPERIMENTAL|CEP-701 60mg|Patient Cohort 3
62344502|NCT00236119|EXPERIMENTAL|CEP-701 80mg|Patient Cohort 4
62502278|NCT04056663|EXPERIMENTAL|Health-Circuit mobile application|"The intervention contemplates. (i) management of unexpected events; and, (ii) empowering the patient to improve self-efficacy.~Users of the intervention arm will have the Health-Circuit mobile application, which will offer them the possibility of contacting the case managers to notify a health event at any time and that this can be resolved by their health professionals through Health -Circuit. The improvement of the patient's self-efficacy for the management of their health problems through the use of Health-Circuit is considered through the virtual visits of follow-up with the manager, the possibility of interacting with the manager and the consultation of the shared documents reminders of the action plan agreed with the patient."
62502279|NCT04056663|NO_INTERVENTION|Conventional treatment|Patients assigned to this group will follow conventional treatment. Once the three months have passed, we will contact you again to ask the pertinent questions.
62701591|NCT05761756|EXPERIMENTAL|Carbon Dioxide Exposure|Effect of simulated chronic CO2 exposure on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Ten subjects will be studied before and after induction of metabolic alkalosis as described above with daily oral administration of sodium bicarbonate. Oral bicarbonate to simulate hypercapnia exposure will seek to increase serum bicarbonate to 30 mM/L via daily oral intake of 6 teaspoons of NaHCO3 for five days. Subsequently, blood will be drawn and intake adjusted as necessary \[61\]. The order of alkalization vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water.
62701592|NCT03038620|EXPERIMENTAL|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug~Other Names:~* Saxenda~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
62701593|NCT03038620|PLACEBO_COMPARATOR|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL~Other Names:~* Placebo~* Saline injection~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
62701594|NCT00995514||Clopidogrel|Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype
62701595|NCT00995514||Prasugrel|Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician
62701596|NCT06461507|EXPERIMENTAL|Group A: Muscle Energy Technique (METs)|▪ Apply METs to the iliopsoas muscle by instructing the patient to do hip flexion and resist movement by pushing their leg down towards the table, activating their iliopsoas muscle. (This contraction is known as an isometric contraction). Maintain the isometric contraction for approximately 5-10 seconds, encouraging the patient to exert maximal effort. After the contraction, relax the patient's leg as they exhale, and take the muscle to its new, slightly increased, passive range of motion.
62701597|NCT06461507|ACTIVE_COMPARATOR|Group B: Janda's Approach|For tightened structures stretching, use the Iliopsoas stretch and the Erector spinae stretch (5 repetitions of stretching with 30-s hold for each muscle) For Strengthening Weakened Structures: Glute bridge, Abdominal crunch (10 repetitions of each)
61954695|NCT02993757|EXPERIMENTAL|CYD Dengue Vaccine + Gardasil (Sequential Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Month 1 and Month 7. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the first 2 doses of CYD dengue vaccine.
61954696|NCT03498144||Patients with acquired punctal stenosis|Patients with acquired punctal stenosis with epiphora
61954697|NCT03498144||Control subjects|normal subjects, without evidence of any punctal abnormalities.
61954698|NCT01186471|EXPERIMENTAL|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
62701598|NCT04990583|EXPERIMENTAL|Carium Condition|Participants assigned to the Carium condition will receive a single session intervention and receive 12 months of access to the Carium adherence application.
62701599|NCT04990583|ACTIVE_COMPARATOR|Control Condition|Participants assigned to the Control condition will receive a single session intervention only.
61954699|NCT01186471|EXPERIMENTAL|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
61954700|NCT01186471|PLACEBO_COMPARATOR|003|placebo placebo - three times daily during each treatment period
61954701|NCT05001256||All Participants|"Individuals between the ages of 18-65 who applied to the physical therapy and rehabilitation outpatient clinic of a private hospital and voluntarily agreed to participate in the study will be included in the study. Written consent will be obtained from the participants.~Participants' information will be recorded on a pre-prepared questionnaire containing structured questions. Questionnaire questioning will be applied to individuals through face-to-face interviews. The questionnaire form consists of three parts: 1. Sociodemographic characteristics, 2. Mediterranean Diet Adherence Scale (MEDAS), 3. International Physical Activity Questionnaire (IPAQ)."
61954702|NCT05205811|EXPERIMENTAL|Combination zonisamide and bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with zonisamide (100 mg daily). The combination of zonisamide and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
61954703|NCT05205811|EXPERIMENTAL|Bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with placebo zonisamide. The combination of placebo and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
61954704|NCT05205811|PLACEBO_COMPARATOR|Placebo with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given placebo bupropion with placebo zonisamide. The combination of these placebos will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
62142139|NCT01009424|EXPERIMENTAL|1|R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
62142140|NCT01009424|EXPERIMENTAL|2|R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
62142141|NCT01009424|EXPERIMENTAL|3|R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
62142142|NCT01009424|EXPERIMENTAL|4|R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
62701600|NCT02695836|ACTIVE_COMPARATOR|Standard feedback|Facilities in this arm will receive an initial face-to-face dissemination workshop that includes feedback of research data on modifiable aspects of their microsystem context but no goal setting.
62701601|NCT02695836|EXPERIMENTAL|Basic assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive a face-to-face goal setting workshop focused on modifiable areas of their microsystem context and two virtual support workshops at six month intervals.
62701602|NCT02695836|EXPERIMENTAL|Enhanced assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive an additional face-to-face goal setting workshop focused on modifiable areas of their microsystem context, two additional face-to-face support workshops at six month intervals plus on-demand email and telephone support.
62701603|NCT06158152|ACTIVE_COMPARATOR|Active arm|Patients who will receive the study treatment (AM3 Technology in combination with Probiotic SynBalance Metsyn)
61954705|NCT02126995|EXPERIMENTAL|Metadoxine Immediate/Slow-release|Flexed and fixed-dose Metadoxine Immediate/Slow-release 700 mg and 1400 mg administered orally once daily
62502280|NCT05381051||original cohort|In the original cohort, 314 patients had catheter implantation between 1st Jan, 2005 to 31st Dec 2009. 269 patients started PD and followed up in our center. 26 patients were excluded due to missing baseline peritoneal membrane function data. 243 patients (n=243, age 53.2±16.3 year) entered the analysis.
62701604|NCT06158152|PLACEBO_COMPARATOR|Placebo arm|Patients who will receive placebo treatment, consisting of starch capsules
61954706|NCT02126995|PLACEBO_COMPARATOR|Placebo|Placebo tablet identical in appearance to study investigational product. Administered orally once daily
61954707|NCT03760978||dex group|Critically ill patients \<18 year-old receiving prolonged sedation with endovenous dexmedetomidine (dosage 0.2 mcg/Kg/hour to 1.8 mcg/Kg/hour) more than 24 hours
61954708|NCT02428517||Young/MSD|Patients who are \<55 years old, and will receive alloHCT for Young/MSD
61954709|NCT02428517||Young/MUD&FMD|Patients who are \<55 years old, and will receive alloHCT for Young/MUD\&FMD
61954710|NCT02428517||Old/MSD|Patients who are \>=55 years old, and will receive alloHCT for Old/MSD
61954711|NCT02428517||Old/MUD&FMD|Patients who are \>=55 years old, and will receive alloHCT for Old/MUD\&FMD
62142143|NCT01009424|EXPERIMENTAL|5|R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
62142144|NCT01009424|EXPERIMENTAL|6|R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
62142145|NCT03843606|EXPERIMENTAL|diet 1|60% fat, 15% protein, 25% carbohydrates
62142146|NCT03843606|EXPERIMENTAL|diet 2|70% fat, 15% protein, 15% carbohydrates
62142147|NCT03843606|EXPERIMENTAL|diet 3|80% fat, 15% protein, 5% carbohydrates
62142148|NCT04603300|ACTIVE_COMPARATOR|Active treatment|INT301 dosing as determined by cohort assignment
62142149|NCT04603300|PLACEBO_COMPARATOR|Placebo|Placebo as determined by cohort assignment
61954712|NCT04568044||Group A: Mild to moderate COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
61954713|NCT04568044||Group B: Severe to critical COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
62142150|NCT02446106|ACTIVE_COMPARATOR|Soup with MSG|0.5% MSG incorporated into a soup preload
62142151|NCT02446106|PLACEBO_COMPARATOR|Control Soup|Negative control match for sodium (no MSG + 0.635% salt)
62142152|NCT04230941|EXPERIMENTAL|MAAT-G Intervention|MAAT-G Workshops \& participant workbook use (8 workshops)
62701605|NCT06158152|SHAM_COMPARATOR|Control arm|Patients to be treated with AM3 Technology capsules
62701606|NCT00713973||1|Submitted to the American protocol for prophylaxis of deep vein thrombosis
61954714|NCT04568044||Group C: Controls (non-pregnant)|"Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness.~A blood sample will be taken on 1 day and at 1 time point."
61954715|NCT04568044||Group D: Pregnant or postnatal with COVID-19|"Current pregnant or postnatal COVID-19 infected (age 18-50 years old) Pregnant or postnatal who were diagnosed with COVID-19 less than 8 months previously (age 18-50 years old). Singleton pregnancies only.~For most participants in this group, blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months).~However, for pregnant women admitted to hospital with severe COVID-19, we will aim to collect earlier timepoints (day 1-3, day 5-7 and then day 7-14). Thereafter, we will follow the above mentioned the long-term schedule (i.e. 1, 4, 8, 12 months)."
62142153|NCT02498145|EXPERIMENTAL|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
62142154|NCT02498145|ACTIVE_COMPARATOR|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
62142155|NCT04063332||GROUP A|Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
62142156|NCT04063332||GROUP B|Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
62142157|NCT04063332||GROUP C|Patients with sepsis as defined by the Sepsis-3 classification criteria3
62142158|NCT02910999||NSCLC patients with squamous tumor histology|
62142159|NCT02910999||NSCLC patients with non-squamous tumor histology|
62701607|NCT00713973||2|Submitted to the Brazilian protocol for prophylaxis of deep vein thrombosis
62701608|NCT00713973||3|Submitted to the SBCP modified protocol for prophylaxis of deep vein thrombosis
61954716|NCT04568044||Group E: Pregnant or postnatal with influenza|"Current pregnant or postnatal influenza infected (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
61954717|NCT04568044||Group F: Pregnant and have received the influenza vaccine|"Current pregnant and due to receive the influenza vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
61954718|NCT04568044||Group G: SARS-CoV-2 vaccinated pregnant/postnatal women|"Current pregnant or postnatal (within 6 weeks of birth) and due to receive the SARS-CoV-2 vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
61954719|NCT04568044||Group H: SARS-CoV-2 vaccinated non-pregnant women|"Non-pregnant and due to receive the SARS-CoV-2 vaccine (age 18-50 years old).~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
61954720|NCT04713930|EXPERIMENTAL|JNJ-61393215|Participants will receive one of 3 single oral doses of JNJ-61393215 on Day 1, escalated sequentially based on the safety review in Cohorts 1, 2, and 3 up to Day 5.
62701609|NCT06625528|PLACEBO_COMPARATOR|open flap debridement|Immediately before surgery, patients rinsed with 0.12% chlorhexidine digluconate and povidone iodine solution was used to perform extra-oral antisepsis. The surgical site was anaesthetized. A mucoperiosteal flap was elevated and reflected followed by thorough debridement of all inflammatory granulation tissue from IBD until a sound, healthy bone surface was obtained. Root surface debridement was also performed. Copious irrigation with normal saline solution. The flap was repositioned and sutured.
61954721|NCT04713930|ACTIVE_COMPARATOR|Placebo|Participants will receive a single oral dose of placebo on Day 1 in Cohorts 1, 2, and 3 up to Day 5.
62142160|NCT01697683|ACTIVE_COMPARATOR|Probiotic Rhamnosus Lactobacilli|
62142161|NCT01697683|PLACEBO_COMPARATOR|Sugar pill|
62142162|NCT04047407||Fibromyalgia|
62142163|NCT04047407||Healthy volunteers|
62142164|NCT02106884|EXPERIMENTAL|Arm A|Nab-paclitaxel - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
62142165|NCT02106884|ACTIVE_COMPARATOR|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
62701610|NCT06625528|ACTIVE_COMPARATOR|lyophilized platelet rich fibrin|Immediately before surgery, patients rinsed with 0.12% chlorhexidine digluconate and povidone iodine solution was used to perform extra-oral antisepsis. The surgical site was anaesthetized. A mucoperiosteal flap was elevated and reflected followed by thorough debridement of all inflammatory granulation tissue from IBD until a sound, healthy bone surface was obtained. Root surface debridement was also performed. Copious irrigation with normal saline solution. The lyophilized-PRF granules was hydrated with a few drops of normal saline then, it was applied and packed to fill defect. The flap was repositioned and sutured.
62701611|NCT06625528|ACTIVE_COMPARATOR|lyo-PRF and nanocrystalline hydroxyapatite bone graft|Immediately before surgery, patients rinsed with 0.12% chlorhexidine digluconate and povidone iodine solution was used to perform extra-oral antisepsis. The surgical site was anaesthetized. A mucoperiosteal flap was elevated and reflected followed by thorough debridement of all inflammatory granulation tissue from IBD until a sound, healthy bone surface was obtained. Root surface debridement was also performed. Copious irrigation with normal saline solution. A mixture of Ly-PRF and n-HA (1:1by weight) was hydrated with a few drops of normal saline then, it was applied and packed to fill the defect. The flap was repositioned and sutured.
62142166|NCT05715684|OTHER|Standard treatment Plan|This is the main arm of the study in which all 25 anticipated participants will be enrolled into.
62701612|NCT06569550|ACTIVE_COMPARATOR|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
61954722|NCT03437096|OTHER|venipuncture pain|pain during venipuncture
61954723|NCT01471678|EXPERIMENTAL|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
61954724|NCT01471678|EXPERIMENTAL|Dutasteride (0.5mg)|Commercial formulation of dutasteride
61954725|NCT01471678|EXPERIMENTAL|Harnal-D Tablets and Harnal capsules|Commercial formulations of Harnal-D Tablets and Harnal Capsules both comprising 0.2mg tamsulosin HCl
61954726|NCT02158273|ACTIVE_COMPARATOR|TRICOR (fenofibrate)|
61954727|NCT02158273|PLACEBO_COMPARATOR|Sugar Pill|
61954728|NCT01826877|EXPERIMENTAL|Treatment (autologous dendritic cells)|Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
61954729|NCT02516046|EXPERIMENTAL|Flortaucipir PET Scan|
61954730|NCT03538548|EXPERIMENTAL|Treatment|Participants receive a standard 12-week course of Cognitive Behavioral Therapy for Relapse Prevention (CBT-RP; Carroll, 1998). The treatment protocol will be implemented over 12 weeks, with two 1-hour sessions per week for the first two weeks and one 1-hour session per week thereafter (i.e., a total of 14 sessions).
61954731|NCT01582165|ACTIVE_COMPARATOR|Angina. IMR. Statin.|
61954732|NCT01582165|PLACEBO_COMPARATOR|Angina. IMR. Placebo.|
61954733|NCT00549731||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study."
61954734|NCT00549731||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
62142167|NCT06466512|EXPERIMENTAL|Implementation|Pregnant women, women who needs to delivery done, and recently delivered women to received ANC, delivery, and postnatal care
62142168|NCT03132298|EXPERIMENTAL|Implicit Theories of Personality Program|"This program is self-administered, computer-based, and 30 minutes in length. Content is designed to maximize relevance for youths with internalizing distress. The program includes 5 elements: 1. An introduction the concept of neuroplasticity; 2. Testimonials from older youths describing beliefs that people's traits are malleable, given the brain's capacity for change; 3. Further vignettes by older youths describing times when they used growth mindsets to cope with peer rejection, hopelessness, and feared embarrassment; 4. A worksheet describing strategies for applying these principles to participants' lives; 5. An exercise wherein participants write notes to younger children, using newly-gleaned information about the malleability of personal traits to help them to cope with setbacks"
62701613|NCT06569550|SHAM_COMPARATOR|Sham Repetitive Transcranial Magnetic Stimulation|Sham Repetitive Transcranial Magnetic Stimulation
62701614|NCT03257891|EXPERIMENTAL|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
62701615|NCT03114865|EXPERIMENTAL|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
62701616|NCT04282148|EXPERIMENTAL|ABT NG DES 48 EECSS|Participants will receive ABT NG DES 48 EECSS device
61954735|NCT02085083|EXPERIMENTAL|Regular telephone and email access to an IBD Nurse|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the intervention arm each month. The email will include the following: Brief Questionnaire;The Option For Direct Nurse Contact; Educational modules; MyHealth Passport and a Comprehensive Study Questionnaire.
62502281|NCT05381051||validation cohort|The validation cohort started PD from 2015 to 2018. It was originally designed for a 12 month observational study around fluid balance. 187 patients were in the validation cohort (age 53.0±15.9 year).
61954736|NCT02085083|ACTIVE_COMPARATOR|Minimal Intervention|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the control arm every 3 months. The email will include the following: MyHealth Passport and Study Questionnaire. This intervention is not expected to significantly improve outcomes.
61954737|NCT04459728|EXPERIMENTAL|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
61954738|NCT03105791|NO_INTERVENTION|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
61954739|NCT03105791|ACTIVE_COMPARATOR|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
61954740|NCT00401531|EXPERIMENTAL|Group 1: DTaP IPV Hep B PRP T + Prevnar™|
61954741|NCT00401531|ACTIVE_COMPARATOR|Group 2: Infanrix hexa™ + Prevnar™|
62142169|NCT03132298|ACTIVE_COMPARATOR|Control Program|The Control Program is a computer-based session of supportive therapy (ST), designed to encourage youths to identify and express feelings. ST does not teach specific skills or beliefs and has been shown to be less effective than cognitive-behavioral interventions in reducing youth internalizing distress. Here, ST was designed to control for nonspecific intervention elements (eg. completing an interactive computer program) and to encourage youths to share emotions with others. ST included the same number of reading/writing activities as the experimental program and took the same amount of time (30 mins.) to complete.
62142170|NCT00981552|OTHER|Cervix Cancer|Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
62142171|NCT01969916|OTHER|Regadenoson|
62502282|NCT04139863|OTHER|aMMP-8 chairside test|Test group. The aMMP-8 chairside mouth rinse test is performed for the test group.It identifies adolescents with poor oral hygiene at risk for subclinical periodontitis without detectable and visible manifestations of the illness, such as periodontal deepened pockets.
62502283|NCT04139863|NO_INTERVENTION|No test|The other group is control group. No test administered.
62502284|NCT06468202|EXPERIMENTAL|81 mg Aspirin|Treatment A consisting of 81mg of aspirin (1 pill of 81mg \& 1 matching placebo) daily
62502285|NCT06468202|EXPERIMENTAL|162 mg Aspirin|Treatment B consisting of 162mg of aspirin (2 pills, each of 81mg) daily
62502286|NCT03620617|EXPERIMENTAL|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
62701617|NCT04049513|EXPERIMENTAL|WZTL002-1 (1928T2z CAR T-cells)|"A starting WZTL-002 dose of 5 × 10\^4 CAR T-cells/kg has been selected with four possible dose level cohorts proposed.~Escalation to a higher dose cohort will be based on assessment of dose limiting toxicities to determine safety at a given dose level."
61954742|NCT00873912|EXPERIMENTAL|Monovalent influenza virus vaccine|Frozen monovalent vaccine containing new strain
61954743|NCT00873912|PLACEBO_COMPARATOR|Placebo|Placebo
61954744|NCT02610725|OTHER|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
61954745|NCT01814514|ACTIVE_COMPARATOR|Timolol-trusopt|Dosage:One drop/12hours,duration:3 months
61954746|NCT01814514|PLACEBO_COMPARATOR|placebo,Artificial tear|dosage:one drop/12 hours,duration:3 months
61954747|NCT03069300|EXPERIMENTAL|prednisolone+NAC|40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
61954748|NCT03069300|NO_INTERVENTION|prednisolone|40mg prednisolone for 28 days
61954749|NCT03703115|ACTIVE_COMPARATOR|Fasting|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet with 2-3 litres of water and non calorie fluids allover the day."
61954750|NCT03703115|NO_INTERVENTION|Nonfasting|Patients will have usual balanced diet as 3 meals and 2 snacks all over the day. Both groups should take adequate water and non calorie beverages intake daily ( 2-3 liters daily)
61954751|NCT01637935||Pioglitazone exposed group|Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
62701618|NCT05012579|EXPERIMENTAL|TAPS delivered by Cala device|Two 40-minute TAPS sessions daily for 28 days, recommended as once in the morning and once in the evening.
62701619|NCT05985239||Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
62701620|NCT05985239||Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
62701621|NCT04434183|ACTIVE_COMPARATOR|isokinetic exercise|The group (isokinetic exercise group, n = 25) was given isokinetic exercise.
62701622|NCT04434183|ACTIVE_COMPARATOR|home exercise|The group(home exercise group, n=25) was given home exercise program.
61954752|NCT01637935||Pioglitazone unexposed group|Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
61954753|NCT01534962|EXPERIMENTAL|Ranolazine low dose|Ranolazine, low dose, oral, BID
61954754|NCT01534962|EXPERIMENTAL|Ranolazine intermediate dose|Ranolazine, intermediate dose, oral, BID
61954755|NCT01534962|EXPERIMENTAL|Ranolazin high dose|Ranolazine, high dose, oral, BID
61954756|NCT01534962|PLACEBO_COMPARATOR|Placebo|Placebo (sugar pill), oral, BID.
61954757|NCT02940912|ACTIVE_COMPARATOR|Apomorphine (5 mg/ml)|Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
61954758|NCT02940912|PLACEBO_COMPARATOR|Physiologic serum|Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.
61954759|NCT05176145|OTHER|single arm|Only one arm. The urine collection from each patient will be used for VisioCyt® test and conventional cytology
61954760|NCT04905758|EXPERIMENTAL|Maxi-Z plus dental implant|platform switched dental implants
61954761|NCT04905758|ACTIVE_COMPARATOR|Maxi-Z dental implant|platform matched dental implants
61954762|NCT02298608|EXPERIMENTAL|Irreversible Electroporation|Percutaneous, CT guided, Irreversible Electroporation of renal mass
61954763|NCT03989895|EXPERIMENTAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
61954764|NCT01116115|ACTIVE_COMPARATOR|Standard vegetable oil based formula|
61954765|NCT01116115|ACTIVE_COMPARATOR|InFat™ based infant formula|
61954766|NCT01116115|NO_INTERVENTION|Breast-fed|
62142172|NCT01942915|EXPERIMENTAL|umbilical cord blood mononuclear cells|Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation.
62142173|NCT01214031|OTHER|Confocal Laser Endomicroscopy Arm|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy.
62502287|NCT03620617|NO_INTERVENTION|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
61954767|NCT00304746|ACTIVE_COMPARATOR|testosterone gel|AndroGel (1% testosterone transdermal gel), 2.5 g to 10 g daily
61954768|NCT00304746|PLACEBO_COMPARATOR|placebo gel|Placebo gel
61954769|NCT03210311|NO_INTERVENTION|control group|"* Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~* Perform skin care~* Perform twice a day upper limb exercises at home. They are advised to use the arm as normal as possible."
61954770|NCT03210311|ACTIVE_COMPARATOR|intervention group|"* Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~* Perform skin care~* Perform upper limb exercises at home twice a day. They are advised to use the arm as normal as possible~* Wear a compression sleeve"
61954771|NCT00603174|EXPERIMENTAL|A|Intubated and mechanically ventilated infants with respiratory failure (age \< 1 year old). see inclusion-exclusion criteria.
61954772|NCT03954665|ACTIVE_COMPARATOR|Baseline Testing|Baseline testing for a 10km cycle time trial and a 30s Wingate cycle test.
61954773|NCT03954665|EXPERIMENTAL|Dietary Supplement: Exogenous Ketone Salt|Ketone salt supplementation (0.6-0.8g•kg-1•d-1) 7-days. Participants will perform two exercise performance tests (a 10km cycle time trial and a 30s Wingate cycle test on separate days) after supplementation.
61954774|NCT05806411||Patients|Patients with calcific aortic sclerosis (stage III and IV) that are going to be treated with traditional surgery according to International Guidelines will be enrolled as cases.
61954775|NCT05806411||Controls|Patients that will undergo a cardiac transplantation (for nonvalvular cardiac disease) or patients with aortic valve insufficiency will be enrolled as controls
61954776|NCT06294782|EXPERIMENTAL|STereotactic Arhythmia Radioablation (STAR)|Patients fulfilling the inclusion and exclusion criteria will undergo (or already underwent) a single-session 25 Gy STAR for the treatment of refractory monomorphic VT.
61954777|NCT03267108|ACTIVE_COMPARATOR|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
61954778|NCT03267108|PLACEBO_COMPARATOR|Placebo|Pulsed inhaled N2, 99.999% gas
61954779|NCT03267108|OTHER|Open Label Extension|Pulsed inhaled iNO 45 mcg/kg IBW/hr
61954780|NCT01487200|EXPERIMENTAL|FX006 10mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
61954781|NCT01487200|EXPERIMENTAL|FX006 40mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
61954782|NCT01487200|EXPERIMENTAL|FX006 60 mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
61954783|NCT01487200|ACTIVE_COMPARATOR|TCA IR (40 mg)|Single 1 mL intra-articular (IA) injection Immediate-release formulation
61954784|NCT04571814|EXPERIMENTAL|Parent and child intervention|Both parent and child will receive a computerized intervention to reduce error sensitivity.
61954785|NCT04571814|EXPERIMENTAL|Parent intervention and child control|Parent will receive a computerized intervention to reduce error sensitivity and child will receive an active control (a computerized program targeting health behaviors).
61954786|NCT04571814|EXPERIMENTAL|Parent control and child intervention|Child will receive a computerized intervention to reduce error sensitivity and parent will receive an active control (a computerized program targeting health behaviors).
61954787|NCT04571814|ACTIVE_COMPARATOR|Parent and child control|Both parent and child will receive an active control (a computerized program targeting health behaviors).
62142174|NCT05527808|EXPERIMENTAL|Neoadjuvant ICI combined with chemotherory|intravenous injection :Tislelizumab + pemetrexed + platinum Q3W 2-4 cycles
62142175|NCT03559205|NO_INTERVENTION|MSK-Tracker (before)|Before - (Usual care in clinic consultations)
61954788|NCT03404115|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|
61954789|NCT03404115|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.1%)|
61954790|NCT03404115|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
61954791|NCT00415168|EXPERIMENTAL|Pemetrexed + Cisplatin|
61954792|NCT00916942|EXPERIMENTAL|NGX-4010 patch|
61954793|NCT00916942|EXPERIMENTAL|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
61954794|NCT04377620|PLACEBO_COMPARATOR|Placebo + Standard of Care (SoC)|Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
61954795|NCT04377620|EXPERIMENTAL|Ruxolitinib 5mg + Standard of Care (SoC)|Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
61954796|NCT04377620|EXPERIMENTAL|Ruxolitininb 15mg + Standard of Care (SoC)|Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
61954797|NCT02759783|ACTIVE_COMPARATOR|Standard of Care|Standard of care (SOC) is at the discretion of the local oncologist.
61954798|NCT02759783|EXPERIMENTAL|Standard of Care + SBRT|Patients randomised to SBRT will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC.
61954799|NCT04338074|EXPERIMENTAL|Tranexamic Acid Treatment|
61954800|NCT04338074|PLACEBO_COMPARATOR|Placebo Treatment|
62142176|NCT03559205|ACTIVE_COMPARATOR|MSK-Tracker (after)|After - (MSK-Tracker in clinic consultations)
62142177|NCT03773471|NO_INTERVENTION|Control Arm|Standard of care
62502288|NCT03336879|EXPERIMENTAL|Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
62142178|NCT03773471|EXPERIMENTAL|Intervention Arm|Mobile Health App
61954801|NCT00903799|OTHER|1|"Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months.~After the cross-over period, device activated until the end of the trial"
61954802|NCT00903799|OTHER|2|"Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months.~After the cross-over period, device activated until the end of the trial"
61954803|NCT02276001|EXPERIMENTAL|K-877|K-877
61954804|NCT02276001|EXPERIMENTAL|K-877 with Cyclosporine|K-877 with Cyclosporine
61954805|NCT06264414|EXPERIMENTAL|DTT106|1 hard capsule once a day, consistently 30 minutes after the same meal each day
61954806|NCT06264414|ACTIVE_COMPARATOR|dutasteride and tamsulosin|1 hard capsule once a day, consistently 30 minutes after the same meal each day
61954807|NCT03533868|NO_INTERVENTION|Standard of Care (SOC)|Patients in this arm will have their viral load monitored using the standard of care method, using the Roche Cobas TaqMan HIV-1® v2 (Roche) assay.
62142179|NCT03955926|NO_INTERVENTION|Control group|kept fasted from midnight until surgery
62502289|NCT04039490|NO_INTERVENTION|Ultrasound-only Pediatric Vessel Cannulation|The standard of care for vessel cannulation currently employed at CNMC
62502290|NCT04039490|EXPERIMENTAL|SCENERGY-guided Pediatric Vessel Cannulation|The addition of the SCENERGY guidance combined with the ultrasound for pediatric vessel cannulations.
61954808|NCT03533868|EXPERIMENTAL|Point-of-care (POC)|Patients in this arm will have their follow-up viral loads (after baseline) monitored using a Point-of-care viral load monitoring test, the Cepheid Xpert HIV-1 Viral Load assay.
61954809|NCT05733780|EXPERIMENTAL|Arm 1|ProLectin M 1,400 mg Tab. Number of Doses -04 Dosing Frequency-once every 2 hours Total Dose/Day-5600 mg
61954810|NCT05733780|EXPERIMENTAL|Arm 2|ProLectin M 1,400 mg Tab. Number of Doses -08 Dosing Frequency-Hourly Total Dose/Day-11200mg
61954811|NCT05733780|EXPERIMENTAL|Arm 3|ProLectin M 1,400 mg Tab. Number of Doses -12 Dosing Frequency-Hourly Total Dose/Day-16800
61954812|NCT05733780|NO_INTERVENTION|Arm 4|Matching Placebo. Number of Doses -08 Dosing Frequency-Hourly Total Dose/Day-0 mg
61954813|NCT05998044|ACTIVE_COMPARATOR|control group|Before starting the study for the Control Group, the participants were informed about the research and their consent will be obtained. Afterwards, evaluation surveys will be applied. They will be asked not to participate in any regular exercise for 8 weeks. At the end of 8 weeks, re-evaluation surveys will be applied.
62142180|NCT03955926|EXPERIMENTAL|NO-NPO group|drink carbohydrate beverage until 2 h before surgery
62142181|NCT03606551||New Orthodontic Patients|"New patient subjects who are just initiating full orthodontic treatment will have their premolars, canines, and incisors bonded with the EXD-959 Bracket System, using the related EXD-961 instruments, according to the manufacturer's IFU.~Their remaining teeth will be bonded with the brackets of the orthodontist's choice. Three of the 5 new patients recruited may be patients that the orthodontist will choose to initiate treatment with the EXD-959 study brackets being applied to the upper teeth only. Having this option will allow the investigators to recruit subjects with deeper over-bites where their standard of care would be to apply esthetic brackets on the upper teeth and metal brackets on the lower teeth."
61954814|NCT05998044|EXPERIMENTAL|pilates group|After people fill out the evaluation questionnaires, they will watch the video recording of pilates based exercises via the link sent to them via Google Drive, and they will be applied twice a week for 8 weeks. All exercises in the video recording will be explained in written, applied and verbal form by the physiotherapist, and they will be asked to practice. Every week, feedback will be received from people that they have done the exercises via their contact numbers. The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). Participants will be asked to open the video recording each time they exercise and follow them to do the exercises. At the end of 8 weeks, re-evaluation surveys will be applied.
61954815|NCT02587234|EXPERIMENTAL|Active|2 hours of active peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
61954816|NCT02587234|SHAM_COMPARATOR|Sham PNS|2 hours of sham peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
61954817|NCT03298867|ACTIVE_COMPARATOR|Teprotumumab 20 mg/kg|Approximately 38 participants will receive 8 infusions of teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
61954818|NCT03298867|PLACEBO_COMPARATOR|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
61954819|NCT04051528|EXPERIMENTAL|combinatorial training group|Combinatorial training group will have the same procedure with the sequential training group in the first 8 sessions. After that the procedure for sessions from 9th to 16th will be 60 minutes of guiding training.
61954820|NCT04051528|EXPERIMENTAL|sequential training group.|Sequential training group will first undergo aerobic exercise training for 30 minutes followed by 30 minutes of computerized cognitive training. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
61954821|NCT01548820||Chronic HBV Egyptian patients|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology \& Tropical Medicine Research Institute in Egypt.
61954822|NCT03513458|EXPERIMENTAL|Anakinra then Placebo|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
61954823|NCT03513458|EXPERIMENTAL|Placebo then Anakinra|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
61954824|NCT01306903|EXPERIMENTAL|MECC|Minimal extracorporeal circuit
62344503|NCT03355794|EXPERIMENTAL|Dose level 1 (starting dose level) (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 300mg daily (DIPG only); \</=21 yrs of age 120 mg/m2/day) Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; dose calculation age dependent (\>21yrs 2.5mg/day (DIPG only); \</=21yr 1.2 mg/m2/day) BSA \>/=0.75m2
62344504|NCT03355794|EXPERIMENTAL|Dose level 2 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.2 mg/m2/day BSA \>/=0.45m2
62344505|NCT03355794|EXPERIMENTAL|Dose level 3 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.5 mg/m2/day BSA \>/=0.45m2
62344506|NCT03355794|EXPERIMENTAL|Dose level 1 (DIPG participants > 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 300mg daily Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 2.5mg/day
61954825|NCT01306903|PLACEBO_COMPARATOR|MOPS|
61954826|NCT01306903|PLACEBO_COMPARATOR|Super MOPS|
61954827|NCT02532088|ACTIVE_COMPARATOR|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 12 months
62344507|NCT01321840|EXPERIMENTAL|Treatment|This group will be treated with SART.
62344508|NCT01321840|NO_INTERVENTION|No treatment|This group will not be treated with SART but will regularly be examined by a gynecologist to detect sudden aggravation of the disease.
61954828|NCT02532088|PLACEBO_COMPARATOR|Placebo|Placebo
62344509|NCT03737422|ACTIVE_COMPARATOR|hesperidin and flaxseed|
62344510|NCT03737422|PLACEBO_COMPARATOR|control|
62344511|NCT03722784|EXPERIMENTAL|Invigor A (test)|Subjects will be randomized to wear Invigor A (test) for one month of daily wear during the study.
62344512|NCT03722784|ACTIVE_COMPARATOR|Invigor B (Control)|Subjects will be randomized to wear Invigor B (Control) for one month of daily wear during the study.
62502291|NCT04445233||COV Participants|COVID-positive index cases (COV): Participants who are greater than or equal to 18 years of age who test positive for COVID-19 by positive NP swab
61954829|NCT00307177|EXPERIMENTAL|Arm D|25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
61954830|NCT00307177|EXPERIMENTAL|Arm C|25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
61954831|NCT00307177|EXPERIMENTAL|Arm B|25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
61954832|NCT00307177|ACTIVE_COMPARATOR|Arm A|25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
61954833|NCT00190671|EXPERIMENTAL|Pemetrexed 600 mg/m2|
61954834|NCT00190671|EXPERIMENTAL|Pemetrexed 1800 mg/m2|
61954835|NCT06284291|EXPERIMENTAL|Genetic epilepsy|Patients with epilepsies of genetic etiology
61954836|NCT06284291|EXPERIMENTAL|Patients with primary headache|Patients with primary headache with non-migraine features
61954837|NCT00753467|EXPERIMENTAL|1|IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
61954838|NCT00753467|EXPERIMENTAL|2|IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
61954839|NCT00753467|ACTIVE_COMPARATOR|3|Adefovir dipivoxil monotherapy (10 mg QD) 30 days
61954840|NCT00845104|EXPERIMENTAL|Arm I|See Detailed Description
61954841|NCT01842022|OTHER|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
62344513|NCT04096352|EXPERIMENTAL|Indirect+Direct method|"Indirect method: one session of information on voice function and voice hygiene.~Direct method: three sessions of voice training using virtual reality simulations over a course of 3 weeks."
62344514|NCT04096352|ACTIVE_COMPARATOR|Indirect method|Indirect method: one session of information on voice function and voice hygiene.
62344515|NCT05614713|EXPERIMENTAL|Study group|received a modified selected physical therapy program to increase sensory input.
61954842|NCT01842022|OTHER|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
61954843|NCT01842022|OTHER|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
61954844|NCT01842022|OTHER|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
61954845|NCT00511446|EXPERIMENTAL|1|docetaxel, oxaliplatin, capecitabine
62701623|NCT05580705|ACTIVE_COMPARATOR|ROUTINE PHYSICAL THERAPY GROUP|This group will receive routine physical therapy including strength training intervention. This protocol will be given for two weeks (6 sessions on alternate days, 3 sessions per week), outcomes will be measured at baseline, at the end of 1st week and 2nd week.
62701624|NCT05580705|EXPERIMENTAL|VIBRATION THERAPY|This group will receive routine physical therapy and vibration therapy. This protocol will be given for two weeks (6 sessions on alternate days, 3 sessions per week), outcomes will be measured at baseline, at the end of 1st week and 2nd week.
62701625|NCT01233947|EXPERIMENTAL|AFP464|74 mg/m2 AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycle.
62701626|NCT01233947|EXPERIMENTAL|AFP464 + Faslodex|AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycles and Faslodex administered per package label.
62701627|NCT06174571||1|patients diagnosed with breast cancer at different stages of the disease.
62701628|NCT06174571||2|apparently healthy females as a control group.
62701629|NCT04940078|EXPERIMENTAL|Part A: Cagrilintide and semaglutide in separate syringes|Participants will up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks treatment with cagrilintide and semaglutide administered as separate injections. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination). Followed by a 38 days follow-up period.
62701630|NCT04940078|EXPERIMENTAL|Part A: Cagrilintide and semaglutide combined in DV3384 device|Participants will be up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks of treatment with cagrilintide and semaglutide administered using the DV3384 manual syringe. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination. Followed by a 38 days follow-up period.
61954846|NCT04194580|EXPERIMENTAL|Physical activity|In the program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors
61954847|NCT04194580|NO_INTERVENTION|Physical activity control|This group will not participate in the intervention
61954848|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
61954849|NCT02707939||Controls|Patients with no developmental diagnoses
62502292|NCT04445233||COV-HC Participants|Household contact of COVID-positive index case (COV-HC): Household contacts greater than 1 year of age currently living in the same home as the COVID-positive index case
62142182|NCT03606551||Intercept Orthodontic Patients-Progress|This group will include a minimum of three, and up to 5 patients at each study site who have moved into rectangular wires; and in whom, the orthodontist- investigator believes they will be able to evaluate rotation corrections using the EXD-959 Bracket System. For example, rotation correction of the upper central incisor which will test the width of the bracket's holding points in situations that have wide teeth and greater inter-bracket distance.
62142183|NCT03606551||Intercept Orthodontic Patients-Finishing|This group will include a minimum of three, and up to 5 patients per study site who are estimated to be within 4 months of completing their orthodontic treatment; and in whom, the orthodontist-investigator believes they will be able to evaluate both torque control and debonding experiences using the EXD-959 Bracket System.
62142184|NCT05473806|EXPERIMENTAL|Pioglitazone 15mg|pioglitazone hydrochloride. PO. 2 tablets once a day.
62142185|NCT05473806|EXPERIMENTAL|Evogliptin 5mg|Evogliptin tartrate. PO. 1 tablets once a day.
62142186|NCT05900466|ACTIVE_COMPARATOR|1: Metformin Treatment|500 mg metformin ER tablets once daily in the morning with a glass of water for 8 weeks.
62502293|NCT01448148|EXPERIMENTAL|Cognitive intervention|Use of Memo protocol for 8 weeks
62502294|NCT01448148|EXPERIMENTAL|Psychosocial intervention|"Use of Programme d'intervention psychosociale axé sur le bien-être psychologique for 8 weeks"
62502295|NCT01448148|NO_INTERVENTION|no contact control group|waiting list
62142187|NCT05900466|PLACEBO_COMPARATOR|2: Placebo|Matching metformin ER placebo tablets once daily in the morning with a glass of water for 8 weeks.
62502296|NCT03393481|EXPERIMENTAL|MAA868 dose 1|MAA868 dose 1, single administration, subcutaneous
62502297|NCT03393481|EXPERIMENTAL|MAA868 dose 2|MAA868 dose 2, single administration, subcutaneous
62502298|NCT03393481|ACTIVE_COMPARATOR|Enoxaparin|Enoxaparin 40mg, once daily (o.d.) for 10 days
62502299|NCT00359671|EXPERIMENTAL|1|Arm 1: study drug
62701631|NCT04940078|EXPERIMENTAL|Part B: Cagrilintide and semaglutide combined in DV3384 device|Participants will receive a single injection of Cagrilintide 0.25 mg/semaglutide 0.25 mg using the DV3384 manual syringe followed by a 28 days follow-up period.
62701632|NCT05878704|EXPERIMENTAL|Treatment|GBT021601
62701633|NCT06637098|EXPERIMENTAL|Oral tube group+routine rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with routine rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~The oral tube group will be given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62701634|NCT06637098|ACTIVE_COMPARATOR|Gastrostomy group+routine rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with routine rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~The Gastrostomy group will be given enteral nutritional support with Gastrostomy. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
62701635|NCT05599100|EXPERIMENTAL|STAR-VTF|Participants will receive the STAR-VTF intervention.
62701636|NCT04975620|EXPERIMENTAL|Franseen needle with three symmetric cutting edges|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using the Franseen needle (Acquire FNB needle; Boston Scientific): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
62701637|NCT04975620|EXPERIMENTAL|Multi-blade needle with three-prong tip with one tip longer than the other two|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using a multi-blade three-prong tip needle (Trident; Microtech): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
62701638|NCT01349478|EXPERIMENTAL|study arm|
62701639|NCT01829451|EXPERIMENTAL|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
62701640|NCT01829451|PLACEBO_COMPARATOR|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
62701641|NCT05453084|EXPERIMENTAL|Intervention Arm|"The exercise intervention tool will be Fitwalking, which is structured, organized, supervised and administered through a Walking Group"
62701642|NCT04682847||Primary and metastatic liver tumors and hepatic cirrhosis|This study is a single arm prospective study that will enroll 25 patients with primary and metastatic liver tumors and hepatic cirrhosis eligible for liver SBRT who will be receiving treatment at a single center - Allegheny General Hospital.
62701643|NCT04876287||patients treated by 1.1 GBq|
62701644|NCT04876287||patients treated by 3.7 GBq|
62701645|NCT02531191|EXPERIMENTAL|New Tablet Preceding Group|Each subject received an ASP015K small tablet in period 1 and an ASP015K current tablet in period 2 under fasted conditions with 200 mL of water.
62701646|NCT02531191|EXPERIMENTAL|Current Tablet Preceding Group|Each subject received an ASP015K current tablet in period 1 and an ASP015K small tablet in period 2 under fasted conditions with 200 mL of water.
62701647|NCT05016271|EXPERIMENTAL|True air purifier group|Children in this group will receive an intervention of air purifiers with high-efficiency particulate air (HEPA) filters.
62701648|NCT05016271|SHAM_COMPARATOR|Sham air purifier group|Children in this group will receive an intervention of air purifiers without high-efficiency particulate air (HEPA) filters.
62701649|NCT04643379|EXPERIMENTAL|Olaparib + Pembrolizumab + Carboplatin AUC|"-Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows:~* Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles.~* Pembrolizumab 200 mg intravenous (IV) Day 1.~* Carboplatin AUC 5 IV on Day 1 for up to six cycles."
61954850|NCT06317727||Pulsed Field Ablation group|The EndoVE (Endoscopic vacuum electrode) is moved endoscopically into surface contact with the polyp. A vacuum is employed through the EndoVE as required to assist contact with the device. An electrical field depth of 8-10mm and surface area of 2cm3 is treated per pulse application. The electrical pulses are produced by an electroporation generator (ePORE device). Larger polyps will require multiple applications to ensure the full surface area has been treated. An overlap with previously pulsed areas is preferable to ensure all of the polyp tissue is ablated. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged on the same day. The patient will be requested to attend the clinic for an endoscopy follow up at 4-6 weeks post EndoVE polyp treatment to investigate the response.
61954851|NCT06108388||Type 2 Diabetes|Participants living with type 2 diabetes for less than 10 years will be recruited.
61954852|NCT06108388||No Diabetes|Participants not living with diabetes will be recruited.
62142188|NCT04061759|ACTIVE_COMPARATOR|Soft tissue mobilization&stabilization exercises|"The following manual therapy techniques will be applied:~1. Soft Tissue Mobilization;~2. Pretzel Maneuvers;~3. Pelvis Backward-Distraction;~4. Trunk Rotation;~5. Multifidus Mobilization; and~6. Piriformis Transverse Friction Massage"
62142189|NCT04061759|ACTIVE_COMPARATOR|Kinesiotape&stabilization exercises|The Kinesio® Taping muscle technique, with 10-25% of the stretch of the tape, will be applied to the sacrospinalis, quadratus lumborum, gluteus medius/maximus and piriformis muscles, based on the the weakness that patient's muscles had. Factors interfering with tape adhesion, such as sweat or hair, will be removed before the application. The tape can stay in place for 3-5 days due to its water resistant and breathable properties
62344516|NCT05614713|ACTIVE_COMPARATOR|Control group|received a selected physical therapy
62701650|NCT00070304|EXPERIMENTAL|Treatment|Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing for at least 7 days and until blood counts recover. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 2 courses may proceed directly to stem cell transplantation off study OR receive 2 additional courses. Patients with stable disease after 2 courses receive at least 2 additional courses. Patients with continued stable or responding disease (with no disease progression) after 4 courses may continue to receive study treatment for up to 1 year or discontinue study for alternative therapy at the discretion of the treating physician.
61954853|NCT01020175|OTHER|Bone marrow transplantation|Patients received bone marrow transplantation
61954854|NCT01020175|OTHER|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
61954855|NCT05497154|EXPERIMENTAL|Training Arm|
61954856|NCT02082860|EXPERIMENTAL|Cohort A|rAAV2/5-PBGD vector dosage 1
62344517|NCT04564430|PLACEBO_COMPARATOR|Control group|IV Saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland) in an equal quantity as the study drug is administered at tourniquet inflation
62502300|NCT00359671|OTHER|2|Arm 2: study drug + comparator
62701651|NCT05508347|EXPERIMENTAL|Experimental group|3 cycles of docetaxel combined with cisplatin induction chemotherapy combined with 9 times of 200mg nituzumab targeted therapy, and sequential 2-3 cycles of concurrent chemoradiotherapy based on cisplatin chemotherapy combined with 7 times of nituzumab targeted therapy.
62344518|NCT04564430|EXPERIMENTAL|Intervention group|Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) is administered at tourniquet inflation
62344519|NCT01477372|EXPERIMENTAL|Exercise group|Supervised exercise program
62701652|NCT05508347|PLACEBO_COMPARATOR|control group|3 cycles of docetaxel combined with cisplatin induction chemotherapy combined with 9 times of placebo treatment, and sequential 2-3 cycles of concurrent chemoradiotherapy based on cisplatin chemotherapy combined with 7 times of nituzumab targeted therapy
62701653|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
62701654|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
62701655|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
62701656|NCT06172140|EXPERIMENTAL|Ciprofol group|Intravenous injection of ciprofol
62701657|NCT06172140|EXPERIMENTAL|Propofol group|Intravenous injection of propofol
61954857|NCT02082860|EXPERIMENTAL|Cohort B|rAAV2/5-PBGD vector dosage 2
61954858|NCT02082860|EXPERIMENTAL|Cohort C|rAAV2/5-PBGD vector dosage 3
61954859|NCT02082860|EXPERIMENTAL|Cohort D|rAAV2/5-PBGD vector dosage 4
61954860|NCT04176497|EXPERIMENTAL|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
62142190|NCT04061759|ACTIVE_COMPARATOR|Stabilization exercises|The core stabilization exercise treatment program consisted of the following exercises: a posterior pelvic tilt exercise, lower abdominal muscle isometric strengthening, hip adductor muscle isometric strengthening, lumbar stabilization exercises with a Swiss ball, upper and lower abdominal muscle strengthening exercises with a Swiss ball, oblique abdominal muscle strengthening exercises with a Swiss ball, quadratus lumborum muscle stretching with a Swiss ball, back extensor muscle strengthening exercises with a Swiss ball, a slump exercise (sciatic nerve stretching), lumbar lordosis exercises with a Swiss ball, bridge exercises with a Swiss ball, single leg bridge exercises on a Swiss ball, posture exercises, push-up exercises with a Swiss ball, and squat exercises with a Swiss ball
62142191|NCT04061759|ACTIVE_COMPARATOR|Reflex therapy&Stabilization exercises|Mobilization of each vertebra and pulls were applied from the medial side of the toe to the medial malleolus and to the heel by hand or with the help of an apparatus, including the cervical, thoracic and lumbar spine reflex zones. Finally, the procedure was finished by making a V-shaped maneuver with a thumb in the direction of spinal nerve exits.
62502301|NCT05696509|OTHER|Propofol|Anesthetic
62701658|NCT05527769||pre-pectoral prosthesis|breast cancer patients with an indication for total mastectomy + immediate breast reconstruction (IBR) by prosthesis using a pre-pectoral technique
62701659|NCT05527769||retropectoral prosthesis|breast cancer patients with an indication for total mastectomy + immediate breast reconstruction (IBR) by prosthesis using the retropectoral technique
62701660|NCT01217892|EXPERIMENTAL|1|Dapagliflozin 2.5 mg twice-daily plus open-label metformin
62142192|NCT03397823||head and neck cancer pre RT|head and neck cancer patients before and after RT
62142193|NCT03397823||head and neck cancer treated|head and neck cancer patients treated with radiotherapy
62142194|NCT03397823||control group|age gender matched subjects
62502302|NCT05696509|OTHER|Isofluran|Anesthetic
62502303|NCT05696509|OTHER|Sevofluran|Anesthetic
62701661|NCT01217892|EXPERIMENTAL|2|Dapagliflozin 5.0 mg twice-daily plus open-label metformin
62701662|NCT01217892|EXPERIMENTAL|3|Dapagliflozin 10 mg once-daily plus open-label metformin
62701663|NCT01217892|PLACEBO_COMPARATOR|4|Placebo plus open-label metformin
61954861|NCT00608816|EXPERIMENTAL|1|Hyperinsulinemic euglycemic glucose clamp study on day 1 Hyperinsulinemic euglycemic clamp study on day 2 with epinephrine infusion
61954862|NCT00608816|EXPERIMENTAL|2|Hyperinsulinemic hypoglycemic glucose clamp x 2 on day 1 Hyperinsulinemic euglycemic clamp with epinephrine infusion on Day 2
62142195|NCT01335867|EXPERIMENTAL|Vigabatrin|Vigabatrin titrated to 3 grams daily for 8 weeks
61954863|NCT03880734|EXPERIMENTAL|study|Vitamin D.Generic name-Cholecalciferol (40,000 IU).Dose- 80,000. Dosage-2 capsule/week for consecutive 26 weeks
61954864|NCT03880734|EXPERIMENTAL|control|Placebo oral capsule.Dose 80,000.Dosage-2 capsules for consecutive 26 weeks
61954865|NCT00807729|ACTIVE_COMPARATOR|ERCP|All ERCP's were performed by one of the authors (JPC), a fulltime faculty member and gastroenterology fellowship instructor in the presence and concurrence of the principal author/ surgeon (SJR). Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
62344520|NCT01477372|NO_INTERVENTION|Control|Sedentary pregnant woman
62344521|NCT06019910|EXPERIMENTAL|Snus with or without tobacco|Snus cessation followed by potential snus relapse
62502304|NCT05108259|EXPERIMENTAL|PBP1502|Adalimumab single dose 40 mg (100 mg/mL) by SC injection via pre-filled syringe (PFS)
62502305|NCT05108259|ACTIVE_COMPARATOR|EU-licensed Humira|Adalimumab single dose 40 mg (100 mg/mL) by SC injection via PFS
62502306|NCT05108259|ACTIVE_COMPARATOR|US-licensed Humira|Adalimumab single dose 40 mg (100 mg/mL) by SC injection via PFS
62701664|NCT05062525||Immunotherapy|
62701665|NCT05062525||Non-Immunotherapy|
62701666|NCT05078957||Frail PLWH|
62701667|NCT05078957||Pre frail PLWH|
62701668|NCT05078957||No frail PLWH|
62701669|NCT02318433|EXPERIMENTAL|Dexamethasone|Subjects receive dexamethasone (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
62701670|NCT02318433|PLACEBO_COMPARATOR|Saline|Subjects receive sterile saline (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
62502307|NCT04736862|EXPERIMENTAL|Continuous monitoring group|
61954866|NCT00807729|ACTIVE_COMPARATOR|Lap CBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
61954867|NCT04742998||Patients treated for an oral or oropharyngeal tumor for at least 6 months|Patients treated for an oral or oropharyngeal tumor for at least 6 months
61954868|NCT04198298|ACTIVE_COMPARATOR|Group 1 EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
61954869|NCT04198298|ACTIVE_COMPARATOR|Group 2 ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
61954870|NCT04198298|ACTIVE_COMPARATOR|Group 3 Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
61954871|NCT02728596|ACTIVE_COMPARATOR|Clinic group 1 (clinics with existing automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on existing automated system recommendations: CSF is recommended for drugs with high risk of FN; CSF is not recommended for drugs with low risk of FN.
62344522|NCT05123612|EXPERIMENTAL|Fiber|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day.
62502308|NCT04736862|ACTIVE_COMPARATOR|Intermittent monitoring group|
62502309|NCT05553587|EXPERIMENTAL|Amara Drops|Phytopharmaceutical / therapeutic intervention
62701671|NCT00643279|EXPERIMENTAL|CHRONICLE|Subjects randomized to the CHRONICLE group were managed using data from an implantable hemodynamic monitoring (IHM) device, including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The Chronicle IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
61954872|NCT02728596|ACTIVE_COMPARATOR|Clinic group 2 (clinics with no automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on existing clinical practice guidelines.
61954873|NCT02728596|EXPERIMENTAL|Clinic group 3 (clinics with automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drugs with intermediate or high risk of FN; CSF is not recommended for drugs with low risk of FN.
61954874|NCT02728596|EXPERIMENTAL|Clinic group 4 (clinics with automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drug with high risk of FN; CSF is not recommended for drugs with intermediate or low risk of FN.
62142196|NCT01335867|PLACEBO_COMPARATOR|Placebo|Identical placebo daily for three weeks
62142197|NCT04221659|EXPERIMENTAL|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
62142198|NCT04221659|EXPERIMENTAL|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
62142199|NCT04221659|ACTIVE_COMPARATOR|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
62142200|NCT04153838||Children|A group of 'typically' developing children (aged between 6 years and 16 years 11 months) from the general paediatric population will be recruited; with the sample distributed evenly across 6 age bands (i.e. ages 6-7 years, 8-9 years, 10-11 years, 12-13 years, 14-15 years, and 16 years+).
62142201|NCT05673551|EXPERIMENTAL|Intervention Group|Participants will be using the VR-PAT during burn dressings.
62142202|NCT05673551|NO_INTERVENTION|Control Group|Participants will not be using the VR-PAT during burn dressings (other distraction methods available in the home allowed).
62142203|NCT00168415|EXPERIMENTAL|1|Botulinum Toxin Type A
62142204|NCT04332094|EXPERIMENTAL|Intervention|Early administration of tocilizumab associated with hydroxychloroquine and azithromycin.
62502310|NCT03601494|ACTIVE_COMPARATOR|Intervention|peri-neural platelet rich plasma injection under ultrasound guidance in addition to medical treatment.
62142205|NCT04332094|ACTIVE_COMPARATOR|Control|Treatment of SARS-COV-2 (COVID-19) infection with hydroxychloroquine and azithromycin.
62142206|NCT03926702|EXPERIMENTAL|Radiopharmaceutical administration|All participants receive radiopharmaceutical for positron-emission tomography (PET) study.
62142207|NCT04779853||Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM|serum samples will be taken and tested by enzyme-linked immunoassay (ELISA) using the SAVYON SeroPertussisTM kits (Savyon Diagnostics Ltd, Israel).
62142208|NCT01097811|ACTIVE_COMPARATOR|Erythromycin|
62142209|NCT01097811|ACTIVE_COMPARATOR|Neomycin|
62142210|NCT01562184|ACTIVE_COMPARATOR|Active tDCS|Active tDCS
62142211|NCT01562184|SHAM_COMPARATOR|Sham tDCS|Sham tDCS
62344523|NCT05123612|EXPERIMENTAL|Fermented Foods|Participants will be asked to consume 6 servings of fermented foods per day.
62344524|NCT05123612|EXPERIMENTAL|Fiber + Fermented Foods|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day and to consume 6 servings of fermented foods per day.
62344525|NCT05123612|NO_INTERVENTION|Comparator|Participants will receive usual care for pregnancy and postpartum.
62344526|NCT01079533|ACTIVE_COMPARATOR|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
62502311|NCT03601494|PLACEBO_COMPARATOR|Control|medical treatment only
62502312|NCT03799848|EXPERIMENTAL|Vadadustat|Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)
62502313|NCT00784979|NO_INTERVENTION|CMVIG followed by PP|MMF or rapamycin was given with CMVIG for 4 weeks followed by plasmapheresis
62701672|NCT00643279|PLACEBO_COMPARATOR|CONTROL|Subjects randomized to the CONTROL group implanted with the Chronicle implantable hemodynamic monitoring (IHM) device, but the intracardiac diagnostic information was blinded to both the patient and the physician during the randomized period of the study. Subjects were managed conventionally with standard of care. Physicians and patients have access to the intracardiac data after the randomized period of the study is over, at 6 months.
62701673|NCT05586750|EXPERIMENTAL|STAREE Statin group|
62701674|NCT05586750|PLACEBO_COMPARATOR|STAREE Placebo group|
62344527|NCT01079533|EXPERIMENTAL|Minimal Cue and TLC|Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
62344528|NCT03296787|EXPERIMENTAL|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
62344529|NCT03296787|EXPERIMENTAL|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
62344530|NCT03296787|EXPERIMENTAL|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
62701675|NCT03198403|EXPERIMENTAL|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS \> 3) will have a popliteal plexus block
62701676|NCT03198403|NO_INTERVENTION|No intervention|Patients with postoperative pain NRS \< or = 3
62344531|NCT03296787|EXPERIMENTAL|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
62344532|NCT03296787|EXPERIMENTAL|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
62344533|NCT04020146||group 1;|healthy controls (C, n=15),
62701677|NCT01140204|PLACEBO_COMPARATOR|Placebo control|Contrast medium without Paclitaxel
62701678|NCT01140204|ACTIVE_COMPARATOR|Iopromide Paclitaxel 0.85 mg|Iopromide Paclitaxel 0.85 mg
62701679|NCT01140204|ACTIVE_COMPARATOR|Iopromide Paclitaxel 4.27 mg|Iopromide Paclitaxel 4.27 mg
62344534|NCT04020146||group 2|periodontitis patients with stage 3 grade B; (P, n=15)
62344535|NCT04020146||group 3|peri-implantitis patients (PI, n=15).
62344536|NCT04568317|EXPERIMENTAL|Smartwatch group|iCBT intervention 'Space from Depression' with smartwatch as an additional means to self-report data on mood, sleep and physical activity in the 'Space from Depression' program (n=35).
62344537|NCT04568317|ACTIVE_COMPARATOR|Treatment as usual group|iCBT intervention 'Space from Depression' (n=35).
62344538|NCT05506553|ACTIVE_COMPARATOR|Control arm|Bilateral insertion of Alcon IQ Toric IOL in micro-monovision
62344539|NCT05506553|EXPERIMENTAL|Intervention arm|Bilateral insertion of Eyhance Toric II IOL
62344540|NCT03190226|EXPERIMENTAL|L-PRF membranes|"Intra-oral split thickness preparation - apically repositioned to the periosteum.~L-PRF membranes will be used to cover the site. Free Gingival Grafts will be used to cover the site."
62701680|NCT01140204|ACTIVE_COMPARATOR|Iopromide Paclitaxel 8.54 mg|Iopromide Paclitaxel 8.54 mg
62701681|NCT01140204|ACTIVE_COMPARATOR|Iopromide Paclitaxel 17.08 mg|Iopromide Paclitaxel 17.08 mg
62701682|NCT03781479|EXPERIMENTAL|Amifampridine Phosphate - Placebo|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
62701683|NCT03781479|EXPERIMENTAL|Placebo - Amifampridine Phosphate|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
62701684|NCT00003249|EXPERIMENTAL|Arm I|Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.
62701685|NCT03370315|EXPERIMENTAL|Dance Group|"This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.~Intervention administered: Dance classes inspired by the rhythm of Forró and Samba."
62344541|NCT01395836||Treatment|"The treatment group will be medically managed based on data obtained from monthly transmissions of the implanted Cardiac Monitor."
62344542|NCT01395836||Control Group|"The control group will be managed in the usual standard of care with physicians blinded to their ICM data."
62701686|NCT03370315|EXPERIMENTAL|Walking Group|"This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.~Intervention administered: Walking program with 3 different moments."
62701687|NCT01505855|EXPERIMENTAL|anti-TNF only|Crohn's disease, on an anti-TNF agent \[infliximab or adalimumab\] only
62701688|NCT01505855|EXPERIMENTAL|Combined immunosuppression|Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator \[azathioprine or 6-MP\])
62701689|NCT01505855|EXPERIMENTAL|Immunomodulator only|Crohn's disease, on an immunomodulator only
62701690|NCT01505855|EXPERIMENTAL|Non-immunosuppression|Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)
62701691|NCT04189614|EXPERIMENTAL|Cofetuzumab Pelidotin|Participants will receive 2.8mg/kg of cofetuzumab pelidotin by IV every 3 weeks
62701692|NCT04701554|EXPERIMENTAL|Qigong program|The experimental group participated in the Qigong program during 2 months, 16 sessions with a total of 16 hours.
62701693|NCT04701554|ACTIVE_COMPARATOR|Active comparator group|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
62701694|NCT06066086|EXPERIMENTAL|Hinge Flap group|Patients who will be included in this study will be treated by using hinge flap and buccal advancement flap to close their oroantral fistula. A circular incision will be performed at the oral side of the oroantral fistula. The tissues will be reflected and sutured by purse sutures. Then the tissues will be pushed up to close sinus membrane. A pyramidal flap will be reflected at the buccal tissues, then horizontal incisions will be performed at the base of the flap to allow advancement of the flap over the fistula and a tension-free suturing to the palatal tissues.
62701695|NCT06066086|ACTIVE_COMPARATOR|Palatal Flap group|Patients who will be included in this study will be treated by using he anteriorly based palatal rotational flap to close the oroantral fistula. Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
62701696|NCT04573985|EXPERIMENTAL|Serious Game Eurekoi intervention|1 session in group using the serious game eurekoi
62701697|NCT04573985|NO_INTERVENTION|Control group|no intervention
62502314|NCT01531257||Kidney Transplant Recipients|The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types. We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
62701698|NCT05338073||Cancer patients|Patients who have primary solid cancer that is being surgically resected, biopsied, or drained (via malignant pleural effusion) and are 18 years of age or older.
62701699|NCT01434784||Surgery alone|Patients undergoing any kind surgery for lung cancer, no additional surgery, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
62701700|NCT01434784||Surgery in combination with any other tx|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
62701701|NCT01434784||Surgery (late effects)|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer moduleat least 3 months after surgery and 3 months after any other active treatment
62701702|NCT01434784||Chemotherapy alone|Patient undergoing any kind of chemotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
61954875|NCT02509767|EXPERIMENTAL|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
61954876|NCT02509767|OTHER|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
61954877|NCT02497339|EXPERIMENTAL|Intervention group|Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
61954878|NCT02497339|EXPERIMENTAL|Control group|Control group (Self-help smoking cessation booklet): Only the self-help booklet related to quitting will be provided to the participants.
61954879|NCT06556407|OTHER|Treatment|Intervention: Renal denervation
61954880|NCT03415568|PLACEBO_COMPARATOR|LCT consumption|Muffin that contains 15g of long-chain triglyceride (LCT) oils were provided to conduct 6-h meal tolerance test.
61954881|NCT03415568|EXPERIMENTAL|MCDG consumption|Muffin that contains 15g of the mixture of medium-chain triglyceride and diacylglycerol (MCDG) oils were provided to conduct 6-h meal tolerance test.
62502315|NCT04413162|OTHER|measurement before and after capsular distention|
62701703|NCT01434784||Radiotherapy alone|Patient undergoing radiotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
62701704|NCT01434784||Sequential radiochemotherapy|Patient undergoing sequential radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
61954882|NCT05707767|EXPERIMENTAL|Chordoma Patients|Chordoma Patients
61954883|NCT04035798|EXPERIMENTAL|memantine (MM)|The participants will receive memantine 5mg (1 capsule) per day for 12 weeks.
61954884|NCT04035798|PLACEBO_COMPARATOR|Placebo|The participants will receive one capsule of placebo per day for 12 weeks.
62142212|NCT02159352|EXPERIMENTAL|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
62502316|NCT03604432|NO_INTERVENTION|Control group|Electric cardiac surgery only
62701705|NCT01434784||Concurrent radiochemotherapy|Patient undergoing concurrent radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
62701706|NCT01434784||Targeted therapy alone|Patient undergoing targeted therapy for lung cancer, no surgery, no radiochemotherapy , quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
62701707|NCT01434784||Targeted therapy in combination|Patient undergoing targeted therapy for lung cancer, additional therapies permitted, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
62701708|NCT02903862|EXPERIMENTAL|Intervention Arm|Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
62701709|NCT02903862|OTHER|Waitlist Control Arm|These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
62701710|NCT03965923|EXPERIMENTAL|Cohort 1: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
62701711|NCT03965923|EXPERIMENTAL|Cohort 1: Truvada Tablet|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
62701712|NCT03965923|EXPERIMENTAL|Cohort 2: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
62701713|NCT03965923|EXPERIMENTAL|Cohort 2: Truvada Tablet|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
62701714|NCT03965923|EXPERIMENTAL|Cohort 3: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 3 (12 0/7 weeks - 29 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
61954885|NCT02782637||Survey and interviews|"\*part one\* (quantitative)~Survey on:~A. prenatal counseling at the limits of viability, within three domains of interest:~* organization of prenatal counseling~* content of prenatal counseling~* decision-making in prenatal counseling Domains used to evaluate current counseling and counseling preferences~B. decision-making at the limits of viability: evaluation of the made decision (decisional conflict and regret)~\*part two\* (qualitative)~Individual interviews (qualitative) to in-depth explore preferences in prenatal counseling~* insight in the specific preferred content of prenatal counseling.~* study influencing factors on preferences in the domains of organization and decision-making."
61954886|NCT05626023|EXPERIMENTAL|Human TH-SC01 cell injection|Single injection of 0.6×10\^7, 1.2×10\^8, 1.8×10\^8 cells/kg
61954887|NCT03017495|EXPERIMENTAL|Food effect and Drug-Drug interaction|Treatments will be given to all subjects in the same fixed sequence: Treatment A (Day 1, single dose of midazolam, fasted), Treatment B (Day 2, single dose of ACT-541468 followed by single dose of midazolam, fasted), Treatment C (Day 4, single dose ACT-541468, fed), Treatment D (multiple doses of ACT-541468 from Day 5 to Day 8 + single dose of midazolam on Day 8, fasted).
61954888|NCT03822078|PLACEBO_COMPARATOR|Placebo|Participants received a single subcutaneous injection of placebo to denosumab on day 1.
61954889|NCT03822078|EXPERIMENTAL|Denosumab|Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
61954890|NCT00207350|OTHER|Brain tumor|Neurosurgical use of Interstitial Laser therapy
61954891|NCT04466020||Patients with Chronic Breathlessness|Patients with Chronic Breathlessness
61954892|NCT00635674|EXPERIMENTAL|Group I - compliant|CPAP use for more than 4 hr/night
62142213|NCT02159352|EXPERIMENTAL|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
62142214|NCT05112913|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2 according to 0,28-day immunization schedule.
62701715|NCT03965923|EXPERIMENTAL|Cohort 3: Truvada Tablet|Participants in Cohort 3 (12 0/7 weeks - 29 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
62701716|NCT05725031|EXPERIMENTAL|ER6|to receive rocuronium 0.6 mg/kg with ephedrine pretreatment
62701717|NCT05725031|EXPERIMENTAL|ER8|to receive rocuronium 0.8 mg/kg with ephedrine pretreatment
62142215|NCT05112913|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2 according to 0,28-day immunization schedule.
62701718|NCT05725031|ACTIVE_COMPARATOR|R12|to receive rocuronium 1.2 mg/kg with no pretreatment
62701719|NCT05095467|EXPERIMENTAL|Group A|"patients with locally resectable GC (cT4aNxM0, P0)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
62701720|NCT05095467|EXPERIMENTAL|Group B|"patients with peritoneal metastasis stage P1a or P1b (cTxNxM1, P1a or P1b)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
62142216|NCT05112913|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2 according to 0,28-day immunization schedule.
61954893|NCT00635674|ACTIVE_COMPARATOR|Group 2-noncompliant|CPAP for less than 4 hr/night
61954894|NCT03217656||Mother-child birth cohort|
62502317|NCT03604432|EXPERIMENTAL|Treatment group|Elective cardiac surgery plus prophylactic maze procedure
61954895|NCT01190345|EXPERIMENTAL|WITH bevacizumab|"bevacizumab 15 mg/kg on day 1 of each cycle : 4 cycles of 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
62701721|NCT05095467|EXPERIMENTAL|Group C|"group C is patients with peritoneal metastasis stage P1c (cTxNxM1, P1c)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
62502318|NCT03417739|EXPERIMENTAL|BVD-523|BVD-523 is administered at the RP2D of 600mgs taken twice daily orally for 28 consecutive days (1 cycle). Planned does may modified based on toxicity.
62502319|NCT00919334|NO_INTERVENTION|single vision soft contact lens|Single vision soft contact lenses with same materials of the DISC lens
62502320|NCT00919334|EXPERIMENTAL|Defocus Incorporated Soft Contact (DISC) lens|The use of DISC lens to slow down the progression of myopia
62502321|NCT01157234|ACTIVE_COMPARATOR|Nebivolol|Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of \<140/90 and continued until month-12 of the study.
62502322|NCT01157234|ACTIVE_COMPARATOR|Metoprolol|Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of \<140/90 and continued until month-12 of the study.
62502323|NCT01380587||Acute Lymphoblastic Leukemia|We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
62502324|NCT05540522|EXPERIMENTAL|Quadrivalent influenza modRNA vaccine, 18 through 64 years of age|Quadrivalent influenza modRNA vaccine (single dose), participants 18 through 64 years of age
62502325|NCT05540522|ACTIVE_COMPARATOR|Quadrivalent influenza vaccine, 18 through 64 years of age|Licensed quadrivalent influenza vaccine (single dose), participants 18 through 64 years of age
62502326|NCT05540522|EXPERIMENTAL|Quadrivalent influenza modRNA vaccine, ≥65 years of age|Quadrivalent influenza modRNA vaccine (single dose), participants ≥65 years of age
62502327|NCT05540522|ACTIVE_COMPARATOR|Quadrivalent influenza vaccine, ≥65 years of age|Licensed quadrivalent influenza vaccine (single dose), participants ≥65 years of age
62502328|NCT06248645|OTHER|Oxygen followed by placebo|Treatment of each motor attacks by oxygen (gaz) during 15 minutes in the first 5 week-period and placebo (medical air) during 15 minutes in the second 5 week-period.
62502329|NCT06248645|OTHER|Placebo followed by oxygen|Treatment of each motor attacks by placebo (medical air) during 15 minutes, in the first 5 week-period and oxygen (gaz) during 15 minutes in the second 5 week-period.
62701722|NCT05775939|EXPERIMENTAL|Diagnostic (sarcoidosis FDG PET-CT)|Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy.
61954896|NCT01190345|ACTIVE_COMPARATOR|without bevacizumab|"4 cycles 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV of (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
61954897|NCT05970185|EXPERIMENTAL|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
61954898|NCT05970185|ACTIVE_COMPARATOR|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
61954899|NCT02695901|EXPERIMENTAL|Chlorhexidine gluconate (0,12%)|Subjects will rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%).
61954900|NCT02695901|EXPERIMENTAL|M. alternifolia oil (Nanoparticle solution)|Subjects will rinse twice daily with 15 ml mouthrinse containing nanoparticles of M. alternifolia oil (0.3%).
62502330|NCT00132834||Asthma/no ICS|Asthmatic children who are not currently taking ICS
62502331|NCT00132834||Asthma/ICS|Asthmatic children on ICS
62502332|NCT00132834||Non-asthmatic children|Children without asthma
62502333|NCT02302716|EXPERIMENTAL|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
62502334|NCT02302716|ACTIVE_COMPARATOR|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
62502335|NCT04668274|EXPERIMENTAL|Part 1: JOTROL (Resveratrol) 200 mg (Treatment A)|Participants received JOTROL (resveratrol) 200 (2\*100) milligram (mg) (Treatment A), gelatin capsule (gelcap), orally, once on Day 1 in fasted conditions in Study Period 1.
62502336|NCT04668274|EXPERIMENTAL|Part 1: JOTROL (Resveratrol) 500 mg (Treatment B)|Participants who completed Study Period 1 received JOTROL (resveratrol) 500 (5\*100) mg (Treatment B), gelcap, orally, once on Day 1 in fasted conditions in Study Period 2. A 14 days washout period was maintained in study period 1 and 2.
61954901|NCT02493140|ACTIVE_COMPARATOR|Cashew apple extract (Cashewin)|
61954902|NCT02493140|PLACEBO_COMPARATOR|Placebo|
61954903|NCT05346770||Individual Patient|Each case will represent one individual patient and patient case. The cases may not be related and may cover different clinical practice areas.
61954904|NCT00484432|EXPERIMENTAL|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
61954905|NCT02051504||Type 1 diabetes, HbA1c <7%|"Patients with Type 1 diabetes and adequate glycemic control: HbA1c \<7% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
62701723|NCT02423694|EXPERIMENTAL|Electroacupuncture|"Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).~Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5\~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks."
62701724|NCT02423694|ACTIVE_COMPARATOR|escitalopram oxalate tablets|0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.
61954906|NCT02051504||Type 1 diabetes, HbA1c >8%|"Patients with Type 1 diabetes and inadequate glycemic control: HbA1c \>8% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
61954907|NCT02051504||Healthy controls, Groupe 1|"Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
61954908|NCT02051504||Healthy controls, Group 2|"Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
61954909|NCT04504357|NO_INTERVENTION|Arm A- No intervention|Participants randomized to Arm A will receive no research intervention.
61954910|NCT04504357|EXPERIMENTAL|Arm B- U=U app|"Participants randomized to Arm B will receive controlled exposure to the tablet-based U=U app."
61954911|NCT04504357|ACTIVE_COMPARATOR|Arm C- clinical exposure demonstration|Participants randomized to Arm C will be shown U=U videos in clinic waiting rooms and the tablet-based app will be integrated into routine counseling
61954912|NCT03036007|ACTIVE_COMPARATOR|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
61954913|NCT03036007|EXPERIMENTAL|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
61954914|NCT03425877|EXPERIMENTAL|Parkinson's disease Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
61954915|NCT03425877|EXPERIMENTAL|Stroke Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
61954916|NCT03425877|EXPERIMENTAL|Healthy Subjects Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
61954917|NCT02191683||Health of women before conception|Tanzanian women aged 18-40 years focusing on prevalence of anaemia, infections, nutritional status, and NCDs.
62142217|NCT05112913|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3 according to 0,28-day immunization schedule.
62344543|NCT03730194|EXPERIMENTAL|Melatonin Only|"In stage 1, participants in this arm will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks.~In stage 2, responders to melatonin will take 3 mg of melatonin 30 minutes before bedtime for an additional 4 weeks (repeat stage 1, for a total of 8 weeks)."
62344544|NCT03730194|EXPERIMENTAL|The Bedtime Bank Only|"In stage 1, participants in this arm will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks.~In stage 2, responders to The Bedtime Bank will utilize The Bedtime Bank, a behavioral sleep intervention for an additional 4 weeks (repeat stage 1, for a total of 8 weeks)."
62701725|NCT01418456|EXPERIMENTAL|Active Antibiotic Group|Patients in the antibiotic group will remain on antibiotics until their foot ulcer heals or up to 20 weeks
62701726|NCT01418456|NO_INTERVENTION|Non antibiotic group|
62502337|NCT04668274|EXPERIMENTAL|Part 1: JOTROL (Resveratrol) 700 mg (Treatment C)|Participants who completed Study Period 2 received JOTROL (resveratrol) 700 (7\*100) mg (Treatment C), gelcap, orally, once on Day 1 in fasted conditions in Study Period 3. A 14 days washout period was maintained in study period 2 and 3.
62701727|NCT02007473||Patients requiring transfusion with plasma|Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.
62701728|NCT04890262||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) treatment in line with current Summary of Product Characteristics (SmPC) or local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.
62701729|NCT02733094|EXPERIMENTAL|Open-label|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.
62701730|NCT05697224|ACTIVE_COMPARATOR|chronicurinary schistosomiasis|
62701731|NCT05697224|ACTIVE_COMPARATOR|bladder cancer diseased patients|
62701732|NCT03774381|EXPERIMENTAL|Bifidobacterium breve B-3 group|160 mg mg of Bifidobacterium breve B-3 was orally administered per day for 12 weeks.
61954918|NCT02191683||480 women during pregnancy|"Describe how 1st and 2nd trimester anaemia compared to 3rd trimester anaemia alters foetal growth and newborns' body composition.~Evaluate anaemia's effect on villous branching in placenta, and uterine and umbilical artery blood flow.~Evaluate effect on vascular endothelial growth factor A/placental growth factor balance and insulin-like growth factor axis.~Determine which markers for foetal programming such as methylation of regulatory genes related to metabolism and haematopoiesis may be discovered early after exposure to anaemia."
61954919|NCT01762878|EXPERIMENTAL|GSK2269557 100 mcg arm|Each subject will receive 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 100 mcg in one of the 4 treatment periods.
61954920|NCT01762878|EXPERIMENTAL|GSK2269557 500 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 500 mcg in one of the 4 treatment periods
61954921|NCT01762878|EXPERIMENTAL|GSK2269557 3000 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 3000 mcg in one of the 4 treatment periods
61954922|NCT01762878|PLACEBO_COMPARATOR|Placebo arm|The subjects will receive single dose of placebo in each treatment period of part A and repeat doses of placebo in Part B of the study.
61954923|NCT01762878|EXPERIMENTAL|Part B GSK2269557 arm|The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
62344545|NCT03730194|EXPERIMENTAL|Melatonin than Bedtime Bank|"In stage 1, participants in this arm will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks.~In stage 2, non-responders to melatonin will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks."
62344546|NCT03730194|EXPERIMENTAL|Melatonin than Melatonin+Bedtime Bank Combo|"In stage 1, participants in this arm will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks.~In stage 2, non-responders to melatonin will take 3 mg of melatonin 30 minutes before bedtime for an additional 4 weeks (repeat stage 1, for a total of 8 weeks) AND utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks."
62344547|NCT03730194|EXPERIMENTAL|Bedtime Bank than Melatonin|"In stage 1, participants in this arm will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks.~In stage 2, non-responders to The Bedtime Bank will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks."
62502338|NCT04668274|EXPERIMENTAL|Part 2: JOTROL (Resveratrol) 500 mg (Treatment D)|Participants who completed Study Period 3 (Part 1) received JOTROL (resveratrol) 500 (5\*100) mg (Treatment D), gelcap, orally, once on Day 1 in fed conditions in Study Period 4. A 14 days washout period was maintained in study period 3 and 4.
62701733|NCT03774381|PLACEBO_COMPARATOR|Control group|160 mg of placebo was orally administered per day for 12 weeks.
62701734|NCT03401866|OTHER|DSC-MRI scan|All subjects will receive a double dose injection protocol that will be split into multiple doses for sequential DSC-MRI scans.
62701735|NCT06486064|EXPERIMENTAL|probiotics|heat-treated Limosilactobacillus fermentum PS150
62701736|NCT06486064|PLACEBO_COMPARATOR|placebo|microcrystalline cellulose
62701737|NCT04962516||Test group|
62701738|NCT04962516||Control group|
62701739|NCT01096004|EXPERIMENTAL|1|
62701740|NCT01096004|PLACEBO_COMPARATOR|2|
62701741|NCT03573050|EXPERIMENTAL|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
62701742|NCT03573050|ACTIVE_COMPARATOR|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
62701743|NCT05892107|EXPERIMENTAL|Toy Group|"1. Before the toy is given to the child, the child's pre-procedure pain will be assessed with the Wong-Baker Faces Pain Rating Scale.~2. 2 minutes before the procedure, the parent will be asked to assess the child's pain with VAS (Visual Analog Scale) and their own anxiety level with State Anxiety Inventory.~3. Body temperature will be measured before the procedure.~4. Children will be given a toy 1 minute before the procedure.~5. The child's pain during the procedure will be assessed by the child using the Wong-Baker Faces Pain Rating Scale.~6. 2 minutes after the procedure, the mother will re-evaluate the child's pain during the procedure using the Visual Analog Scale (VAS) and anxiety during the procedure using the State Anxiety Scale."
62701744|NCT05892107|EXPERIMENTAL|Mask group with cartoon characters|"1. The child's pain will be assessed with the Wong-Baker Faces Pain Rating Scale before the procedure.~2. 2 minutes before the procedure, the parent will be asked to assess the child's pain with VAS (Visual Analog Scale) and their own anxiety level with State Anxiety Inventory.~3. Body temperature will be measured before the procedure.~4. 1 minute before the procedure, the nurse will greet the child with a mask.~5. During the procedure, the child's pain will be assessed by the child using the Wong-Baker Faces Pain Rating Scale.~6. 2 minutes after the procedure, the mother will reassess the child's pain during the procedure using the Visual Analog Scale (VAS) and anxiety during the procedure using the State Anxiety Scale."
62701745|NCT05892107|ACTIVE_COMPARATOR|Control Group|"1. Before the procedure, the child's pain will be assessed with the Wong-Baker Faces Pain Rating Scale.~2. 2 minutes before the procedure, the parent will be asked to assess the child's pain with VAS (Visual Analog Scale) and their own anxiety level with State Anxiety Inventory.~3. Body temperature will be measured before the procedure.~4. 1 minute before the procedure, the nurse will greet the child with a white mask on his/her face.~5. Children in the control group will be subjected to routine procedures (presence of the mother) during blood collection.~6. During the procedure, the child's pain will be assessed by the child using the Wong-Baker Faces Pain Rating Scale.~7. 2 minutes after the procedure, the mother will reassess the child's pain during the procedure using the Visual Analog Scale (VAS) and anxiety during the procedure using the State Anxiety Scale."
62701746|NCT00565747|EXPERIMENTAL|Test culture|Culture with GM-CSF
62701747|NCT00565747|PLACEBO_COMPARATOR|Control culture|Culture without GM-CSF
62701748|NCT05871060|ACTIVE_COMPARATOR|whey concentrate supplement|2,2 grams of whey concentrate dissolved in 100 mL of water
62701749|NCT05871060|EXPERIMENTAL|whey hydrolysate supplement|2,2 grams of whey hydrolysate dissolved in 100 mL of water
62701750|NCT05871060|PLACEBO_COMPARATOR|still flavoured water|100 mL of vanilla-flavoured water
61954924|NCT02546453|OTHER|Tumoral specific genetic alterations|NGS techniques (next generation sequencing) will be used to identify specific genetic alterations of tumoral cells of a patient. If specific genetic alterations is detected, they will be used to detect circulating tumor DNA and/or circulating/disseminated tumoral cells (CTC/DTC) in peripheral samples (blood, bone marrow, cerebral spinal fluid) collected before, during and after treatment.
61954925|NCT02443766||Healthy Subjects|Healthy subjects will attend the weeklong meditation retreat.
62142218|NCT05112913|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3 according to 0,28-day immunization schedule.
62142219|NCT05112913|EXPERIMENTAL|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3 according to 0,28-day immunization schedule.
62344548|NCT03730194|EXPERIMENTAL|Bedtime Bank than Bedtime Bank+Melatonin Combo|"In stage 1, participants in this arm will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks.~In stage 2, non-responders to The Bedtime Bank will utilize The Bedtime Bank, a behavioral sleep intervention for an additional 4 weeks (repeat stage 1, for a total of 8 weeks) AND take 3 mg of melatonin 30 minutes before bedtime for 4 weeks."
62344549|NCT01134757|OTHER|house dust mite and alternaria allergy|As the intervention patients with house dust mite or alternaria allergy will undergo a bronchial allergen challenge with mite or alternaria extract. The early asthmatic response (EAR) and the late asthmatic response (LAR) will be measured before and after one year of allergen specific immunotherapy. Except of the challenge no further interventions are planned.
62502339|NCT06002178||Patients undergoing surgical procedure|"The following variables will be collected: age, weight, height, gender, previous neck surgery/radiotherapy, previous tracheostomy.~Subsequently, through ultrasound examination, the vascular anatomy of the neck will be studied by dividing it into twelve anatomical quadrants: Four medial quadrants (thyroid membrane, cricoid membrane, and cricothyroid membrane; first tracheal ring, from the beginning of the second tracheal ring to the end of the third tracheal ring), laterally on both right and left sides of each quadrant, the lateral quadrants will be identified. An ultrasound examination with a linear probe with doppler technique will be performed for each quadrant to identify the vascular structures.~For each quadrant, the presence of vessels, arterial or venous nature, and their diameter will be collected."
62701751|NCT04871620||Hemodynamic optimization|Patients scheduled for intermediate and high-risk abdominal surgery were eligible to participate
62701752|NCT03007433|EXPERIMENTAL|healthy volunteers|60 healthy volunteers with no functional dyspepsia as defined by the Rome Questionnaire and no more than mild symptoms on maximum 1 days a week on the GSRS, that meet inclusion and exclusion criteria will be recruited. Eligible subjects will be block randomized by sex and age such that 10 men and women in each age group (\<40, 41-60, \>60) are recruited.
62701753|NCT03007433|EXPERIMENTAL|Functional dyspeptic patients|20 patients with functional dyspepsia with postprandial distress syndrome as defined by the Rome IV Questionnaire and at least moderate symptom severity on at least 3 days a week that meet the inclusion and exclusion criteria will be recruited to provide pilot data in the local patient population
62701754|NCT02532101|EXPERIMENTAL|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 3 months
62701755|NCT01146197|EXPERIMENTAL|Amiloride, Indometacin, Eplerenone|Amiloride, indometacin(+Omeprazole), Eplerenone
62701756|NCT01146197|EXPERIMENTAL|Amiloride, Eplerenone, indometacin|Amiloride, Eplerenone, indometacin (+Omeprazole)
62701757|NCT01146197|EXPERIMENTAL|Eplerenone, Amiloride, indometacin|Eplerenone, Amiloride, indometacin (+Omeprazole)
62142220|NCT05112913|ACTIVE_COMPARATOR|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1 according to 0,28-day immunization schedule.
62142221|NCT05031923|EXPERIMENTAL|SMV and antimicrobial photodynamic therapy|Application SMV and antimicrobial photodynamic therapy in intrabony defect
62142222|NCT05031923|ACTIVE_COMPARATOR|SMV application|Application SMV in intrabony defect
62142223|NCT05413200||Patients|Patients diagnosed with moderate and severe AV accompanied by atrophic acne scars
62142224|NCT04756271|EXPERIMENTAL|Health-care workers|Healthy health-care workers at Zagazig University Hospital who opt by their free well to administer 2 doses of SARS-Cov-2 inactivated vaccine at 0 and 21 days. Blood samples will be withdrawn from them to investigate the immune response to the given vaccine
62142225|NCT02509715|NO_INTERVENTION|Standard Conventional group|Standard conventional thyroid surgery
62142226|NCT02509715|ACTIVE_COMPARATOR|IONM group|Intraoperative nerve monitoring used thyroid surgery
62142227|NCT04224415|OTHER|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
62701758|NCT01146197|EXPERIMENTAL|Eplerenone, Indometacin, Amiloride|Eplerenone, Indometacin, Amiloride
62701759|NCT01146197|EXPERIMENTAL|Indometacin, Eplerenone, Amiloride|Indometacin, Eplerenone, Amiloride
62701760|NCT01146197|EXPERIMENTAL|Indometacin, Amiloride, Eplerenone|Indometacin, Amiloride, Eplerenone
62701761|NCT01202162|ACTIVE_COMPARATOR|Desflurane|Administration of Desflurane
62701762|NCT01202162|ACTIVE_COMPARATOR|Sevoflurane|Administration of Sevoflurane
62701763|NCT02477748|ACTIVE_COMPARATOR|MDX|Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
62701764|NCT02477748|PLACEBO_COMPARATOR|Placebo|Inert tablets
62701765|NCT04817956|EXPERIMENTAL|Atezolizumab|Atezolizumab used outside of current indication, based on biomarkers
62701766|NCT04817956|EXPERIMENTAL|Atezilizumab combined with bevacizumab|Atezilizumab combined with bevacizumab used outside of indication, based on biomarkers
62502340|NCT04187950|PLACEBO_COMPARATOR|Yogurt with inactivated B. lactis and added cane sugar|Participants will consume yogurt with heat inactivated B. lactis and added cane sugar twice daily for 14 days.
62701767|NCT04817956|EXPERIMENTAL|Phesgo (trastuzumab og pertuzumab)|Phesgo used outside of indication, based on biomarkers.
62701768|NCT04817956|EXPERIMENTAL|Alectinib|Alectinib used outside of indication, based on biomarker
62701769|NCT04817956|EXPERIMENTAL|vismodegib|vismodegib used outside of indication, based on biomarker
62701770|NCT04817956|EXPERIMENTAL|entrectinib|entrectinib used outside of indication, based on biomarker
62701771|NCT04817956|EXPERIMENTAL|Zelboraf + Cotellic|Zelboraf + Cotellic used outside of indication, based on biomarker
62701772|NCT04817956|EXPERIMENTAL|Alpelisib|Alpelisib used outside of indication, based on biomarker
61954926|NCT02798601|EXPERIMENTAL|Hypernatremia|Serum sodium between 150 - 155 milliequivalent/L. 7,5% sodium chloride (2 ml/kg every 4 hours), with controls of serum sodium every 4 hours, to achieve a goal of serum sodium between 150 - 155 milliequivalent/L. If after 4 doses of 7.5% sodium chloride the serum sodium is below the target, a bolus of 1 ml/kg of 12% sodium chloride will be used every 4 hours. The goal of serum sodium will be maintained for 48 hours.
62502341|NCT04187950|EXPERIMENTAL|Yogurt with B. lactis and added honey|Participants will consume yogurt with B. lactis and added honey twice daily for 14 days.
62502342|NCT05287087|ACTIVE_COMPARATOR|My Symptoms 1 (MySt-1)|"GPs will receive an introduction to the overall content of the eHealth programme MySt-1. The information will be given to participating GPs and their staff during a 1½-hour session in the practice. The research assistant will go through the logistics of the patient recruitment and evaluation step-by-step and GPs and relevant staff will subsequently have access to the programme.~The patients will get access to a basic eHealth programme (My Symptoms 1). The programme is an internet-delivered self-help programme supporting patients' selfefficacy and behavioural changes. The programme is activated by the patient after prescription by the GP."
62701773|NCT04817956|EXPERIMENTAL|Dabrafenib + trametinib|Used outside of indication, based on biomarker
62701774|NCT04817956|EXPERIMENTAL|Melfalan|Melfalan used outside ofcurrent indication
62701775|NCT04817956|EXPERIMENTAL|Pemazyre|Pemazyre used outside ofcurrent indication
62701776|NCT04817956|EXPERIMENTAL|Selpercatinib|used outside ofcurrent indication
62142228|NCT01602185|EXPERIMENTAL|memantine|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
62701777|NCT04817956|EXPERIMENTAL|Olaparib|Used outside of current indication, for patients with bi-allelic BRCA-inactication
62701778|NCT04817956|EXPERIMENTAL|Capmatinib|Used outside of current indication,
62701779|NCT04817956|EXPERIMENTAL|Imatinib|Used outside of current indication,
62701780|NCT04817956|EXPERIMENTAL|Bortezomib|Used outside of current indication,
62701781|NCT04817956|EXPERIMENTAL|Actinomycin D|Used outside of current indication,
62701782|NCT04817956|EXPERIMENTAL|Niraparib|Used outside of current indication,
62701783|NCT04817956|EXPERIMENTAL|Dostarlimab|Used outside of current indication
62701784|NCT04817956|EXPERIMENTAL|Ceritinib|Used outside of current indication
62701785|NCT05640557|EXPERIMENTAL|Experimental group|The participants of the study will take part in exercises (proprietary exercise program), 2 times per week, 45 minutes, for 6 weeks. They will be measured before and after the 6-week exercise program.
62701786|NCT05640557|NO_INTERVENTION|Control group|The study participants will not be subjected to any intervention, they will be measured twice, 6 weeks apart. They will be asked to lead their habitual lifestyle.
62701787|NCT05399173|EXPERIMENTAL|an infrared (gallium aluminum arsenide laser)|Each female in study group will be treated by laser acupuncture for 3 sessions per week, for 6 weeks. An infrared (gallium aluminum arsenide) laser will be used at a wavelength of 808 nm and a power of 200 m W applied for 26 s to produce energy of less than 4 J/cm. participants will receive the same medical treatment (desmopressin acetate) and advice as in control group in addition to low level laser therapy 3 session / week for 6 weeks.
62701788|NCT05399173|ACTIVE_COMPARATOR|conventional therapy|They will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice.
62701789|NCT04046744|ACTIVE_COMPARATOR|BAX|
62701790|NCT04046744|EXPERIMENTAL|BAX-Asso|
62701791|NCT04818710|PLACEBO_COMPARATOR|skin incision with a scalpel|In the scalpel group, the incision was made by the traditional method, with proper homeostasis by applying pressure to skin blood vessels and ligating the subcutaneous bleeding.
62701792|NCT04818710|ACTIVE_COMPARATOR|skin incision with diathermy|In the diathermy group, the incision made using a small flat blade pen electrode, set on cutting mode and delivering a 120 watt (maximum) sinusoidal current, electrosurgical cutting performed without pressure or mechanical displacement.
62701793|NCT04987814|EXPERIMENTAL|Elderly patients suspected of sarcopenia|
62701794|NCT04918459||EUS guided cyanoacrylate injection|EUS guided cyanoacrylate injection to prevent EV rebleeding.
62701795|NCT04918459||variceal band ligation|variceal band ligation to prevent EV rebleeding.
62701796|NCT06101459||COPD patient with significant smoking history|"Patients with following conditions~1. smoking history more than 30 pack\*year~2. FEV1/FVC ratio \<0.7~3. No acute exacerbation history within 3 months"
62142229|NCT01602185|EXPERIMENTAL|dextromethorphan|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
62502343|NCT05287087|EXPERIMENTAL|My Symptoms 2 (MySt-2)|"GPs will attend a one-day training course of 7 hours including: in depth insight into the My Symptoms 2 eHealth programme, comprehensive understanding of PPS, training of communication skills and the use of contextual (non-specific/common psychological) factors. The training programme has been developed in cooperation with the national GP association offering CME (PLO-e). Lecturers and trainers will be GPs and psychologists from the research team.~The patients will get access to an advanced eHealth programme (My Symptoms 2). The programme is an internet-delivered self-help programme supporting patients' selfefficacy and behavioural changes. The programme is activated by the patient after prescription by the GP."
62502344|NCT00857818|EXPERIMENTAL|Aripiprazole|
61954927|NCT02798601|NO_INTERVENTION|Normonatremia|Serum sodium between 135 - 145 milliequivalent/L. Mannitol 100 ml every 4 hours for the first three days; 80 ml every 4 hours the fourth day; 60 ml every 4 hours the fifth day and 40 ml every 4 hours the sixth day and then stopping. The mannitol protocol will be interrupted at any moment if serum sodium is below 135, the systolic blood pressure is below 90 mmHg or the patient has signs of hypovolemia. In this case, 2 ml/kg of 3% sodium chloride every 4 hours will be used until the target of serum sodium is achieved and both, normovolemic state and blood pressure are restored. In addition, the mannitol protocol will be suspended when serum osmolality is above 320.
61954928|NCT05833074|EXPERIMENTAL|Couples HIV testing and counseling retesting|Couples HIV testing and counseling is completed following Centers for Disease Control and Prevention (CDC) standard protocol. Participants also complete any adjunct CHTC components associated with their originally assigned condition in NCT05000866.
61954929|NCT05833074|ACTIVE_COMPARATOR|Individual HIV testing|Individual HIV testing and counseling.
61954930|NCT00393029|EXPERIMENTAL|Patients with metastatic melanoma|Melanoma is a serious form of skin cancer that develops in the skin cells that make our skin color (melanocytes).
61954931|NCT00393029|EXPERIMENTAL|Patients with other metastatic cancers|
61954932|NCT05419869|EXPERIMENTAL|ALTO-100|ALTO-100 tablet PO ; twice daily dosing 8 weeks
61954933|NCT03675477|EXPERIMENTAL|SHR0302 8mg QD|"Participants randomized in this arm will receive SHR0302 8mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 8mg QD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
61954934|NCT03675477|EXPERIMENTAL|SHR0302 4mg BD|"Participants randomized in this arm will receive SHR0302 4mg BD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg BD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
62142230|NCT01602185|PLACEBO_COMPARATOR|placebo|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
62142231|NCT00766909|EXPERIMENTAL|CsA|Cyclosporine
62142232|NCT00766909|EXPERIMENTAL|Tac|Tacrolimus
62344550|NCT04727502|ACTIVE_COMPARATOR|( Group Duloxetine )|• Dosing and administration (Group A) Duloxetine 30 mg /day oral intake at bed time
62344551|NCT04727502|ACTIVE_COMPARATOR|(Group Pregablin )|control group Pregablin 150mg /day( 75 mg /12 hours ) oral intake.
62344552|NCT05369026|EXPERIMENTAL|Fortetropin|Foretetropin, which is non-thermal pasteurized, freeze-dried fertilized egg yolk, per day
62344553|NCT05369026|PLACEBO_COMPARATOR|Placebo|Cheese powder, which is isonitrogenous, isoenergetic, and macronutrient-matched with Fortetropin
62344554|NCT04962503|EXPERIMENTAL|Afamelanotide|
62344555|NCT03334396|EXPERIMENTAL|4 milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
62344556|NCT03334396|EXPERIMENTAL|2 mg Baricitinib|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
62344557|NCT03334396|EXPERIMENTAL|1 mg Baricitinib|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
62344558|NCT03334396|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once daily.
62344559|NCT03334396|EXPERIMENTAL|4 mg Baricitinib Maximum Extended Enrollment Cohort|4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
62344560|NCT03334396|EXPERIMENTAL|2 mg Baricitinib Maximum Extended Enrollment Cohort|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
62344561|NCT03334396|EXPERIMENTAL|1 mg Baricitinib Maximum Extended Enrollment Cohort|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
62344562|NCT03334396|PLACEBO_COMPARATOR|Placebo Maximum Extended Enrollment Cohort|Placebo administered orally once daily.
62344563|NCT02658994|EXPERIMENTAL|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
62502345|NCT00857818|ACTIVE_COMPARATOR|Control group (Oanzapine, risperidone, or quetiapine)|
62502346|NCT02086344|EXPERIMENTAL|TLH_plus_PBS|TLH plus PBS
62701797|NCT06101459||COPD patient without significant smoking history|"Patients with following conditions~1. smoking history less than 0.5 pack\*year~2. FEV1/FVC ratio \<0.7~3. No acute exacerbation history within 3 months"
62701798|NCT06101459||Healthy smoker|"Patients with following conditions~1. smoking history more than 30 pack\*year~2. FEV1/FVC ratio ≥0.7~3. No current use of medication for any chronic respiratory disease"
62142233|NCT00766909|PLACEBO_COMPARATOR|Placebo|placebo/saline
62701799|NCT05534646|ACTIVE_COMPARATOR|Apalutamide monotherapy|After progression, subjects will crossover to combination therapy
62701800|NCT05534646|EXPERIMENTAL|Combination therapy (Apalutamide + Carotuximab)|
62701801|NCT04628806||HSP70CTC|Isolation of circulating tumor cells by HSP70
62701802|NCT03787615|OTHER|The sipIT tools|The wrist-worn sensors used to detect a drinking event (FitBit Versa with custom algorithm), an H2OPal connected water bottle and fluid consumption monitoring mobile applications.
62701803|NCT06532188|EXPERIMENTAL|Verum|Ear acupuncture using permanent needles on predefined acupuncture points followed by a standardized medical hypnosis, needles remain in place for a total of 7 days
62701804|NCT06532188|SHAM_COMPARATOR|Sham|Ear acupuncture using permanent needles on predefined acupuncture sham points followed by a standardized story without induction of a hypnotic trance, needles remain in place for a total of 7 days
62701805|NCT00748774||MDASI-BT|MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) questionnaire given to patients with a primary brain tumor and their caregivers.
62701806|NCT06291987|EXPERIMENTAL|Dose Level -1|Ivosidenib 500mg daily + Ruxolitinib 5mg twice a day
62701807|NCT06291987|EXPERIMENTAL|Dose Level 1|Ivosidenib 500mg daily + Ruxolitinib 10mg twice a day
61954935|NCT03675477|EXPERIMENTAL|SHR0302 4mg QD|"Participants randomized in this arm will receive SHR0302 4mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg QD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
61954936|NCT03675477|PLACEBO_COMPARATOR|placebo|"Participants randomized in this arm will receive the placebo until week 8, and then will be re-randomized into one of the 3 active arms ( 4mg QD, 4mg BD, 8mg QD of SHR0302) in a 1:1:1 allocation ratio until the end of the study at week 16.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).~Placebos: Placebo Oral Tablet"
61954937|NCT03172442|EXPERIMENTAL|orthodontic removable traction appliance|"Patients in this group will be treated using the orthodontic removable traction appliance (vacuum plate with two hooks between lateral incisor and canine in each side). An rapid maxillary expander will be applied to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.~Class III elastic traction from upper first molar to the hook in both side. This appliance will be used full-time with Class III elastics (6- to 8-ounce) traction."
61954938|NCT03172442|NO_INTERVENTION|Control group|without intervention
61954939|NCT06008431|EXPERIMENTAL|tDCS intervention|Ten, once-daily, 20-min sessions of tDCS will be provided over two consecutive weeks.
61954940|NCT06008431|SHAM_COMPARATOR|Sham and then tDCS|Five, once-daily, 20-min sessions of sham in week one followed by five, once-daily, 20-min sessions of tDCS in week two.
61954941|NCT02714374|EXPERIMENTAL|GL-ONC1|Cohort 3, 5, 7, 8, 9
62502347|NCT02086344|ACTIVE_COMPARATOR|TLH _adnexal preservation|Standard TLH without PBS
61954942|NCT01999179|OTHER|low-molecular-weight heparin or direct oral anticoagulant|"Enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing that was obtained by clinical team.~Apixaban, rivaroxaban, dabigatran, or edoxaban at standard dosing per FDA package insert for direct oral anticoagulants."
62701808|NCT06291987|EXPERIMENTAL|Dose Level 2|Ivosidenib 500mg daily + Ruxolitinib 20mg twice a day
62701809|NCT00916487|EXPERIMENTAL|Arm1|single arm of study in cross-over design
62701810|NCT05305651|EXPERIMENTAL|Participants receiving Sotrovimab|Immunocompromised non-hospitalized participants will receive sotrovimab as standard of clinical care for COVID-19 in sentinel sites
62701811|NCT02534922|EXPERIMENTAL|Daily dosing|Daily subcutaneous dosing of Prolanta, a human prolactin receptor antagonist
62502348|NCT02762994|EXPERIMENTAL|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
62502349|NCT02762994|EXPERIMENTAL|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
62502350|NCT02762994|EXPERIMENTAL|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
62502351|NCT02762994|PLACEBO_COMPARATOR|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
62502352|NCT00676741||A|
62502353|NCT00676741||B|
62502354|NCT00676741||C|
62502355|NCT03055741|EXPERIMENTAL|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
62701812|NCT04502914|EXPERIMENTAL|The experimental group|The experimental group will consist of wounds treated with the open-to-air strategy.
62701813|NCT04502914|OTHER|The control group|The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.
62701814|NCT05849766|PLACEBO_COMPARATOR|Control|Group 1 received only standard therapy ACE/ ARB, BB, and diuretics
62701815|NCT05849766|EXPERIMENTAL|Interventional|Group 2 received dapagliflozin 10 mg once daily in addition to standard therapy ACE/ ARB, BB, and diuretics
62701816|NCT02852330|EXPERIMENTAL|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
62701817|NCT05984290|EXPERIMENTAL|Safety and effectiveness of the Arise Orthokeratology Lens|Treatment effect of overnight orthokeratology over a 3-month period
62701818|NCT01852981|EXPERIMENTAL|Lifestyle counseling|Physical activity promotion using methods based on health education.
62701819|NCT01852981|EXPERIMENTAL|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
62701820|NCT01852981|NO_INTERVENTION|Control|Control group.
62701821|NCT04883463|EXPERIMENTAL|Epidural Stimulation for Respiratory Function|Self-controlled longitudinal safety and feasibility of stimulation and respiratory training.
62701822|NCT05945225|EXPERIMENTAL|Group using sonic toothbrush|Patient will be asked to use a sonic toothbrush for 3 months
62701823|NCT05945225|EXPERIMENTAL|Group using hydrosonic toothbrush|Patient will be asked to use a hydrosonic toothbrush for 3 months
62701824|NCT05945225|EXPERIMENTAL|Group using manual toothbrush with 5460 strands|Patients will be asked to use a manual toothbrush with 5460 strands for 3 months
62701825|NCT05945225|PLACEBO_COMPARATOR|Group using manual toothbrush|Patients will be asked to use a manual toothbrush for 3 months
62701826|NCT02577809|ACTIVE_COMPARATOR|Morphine100|1.8ml 0.5% hyperbaric bupivacaine with 0.1mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
62701827|NCT02577809|ACTIVE_COMPARATOR|Morphine50|1.8ml 0.5% hyperbaric bupivacaine with 0.05mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
62701828|NCT02577809|ACTIVE_COMPARATOR|Fentanyl25|1.8ml 0.5% hyperbaric bupivacaine with 25μg fentanyl (2.3ml volume) administered into the intrathecal space
62701829|NCT06254261|EXPERIMENTAL|RAY1225 (cohort 1)|Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks.
62701830|NCT06254261|PLACEBO_COMPARATOR|Placebo (cohort 1)|Participants received Placebo administered SC once two weeks for 24 weeks.
62701831|NCT06254261|EXPERIMENTAL|RAY1225 (cohort 2)|Escalating doses of RAY1225 administered subcutaneously (SC) once two week
62701832|NCT06254261|PLACEBO_COMPARATOR|Placebo (cohort 2)|Participants received Placebo administered SC once two week
62701833|NCT03906409|ACTIVE_COMPARATOR|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
61954943|NCT01546883|EXPERIMENTAL|Dabigatran|Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
62142234|NCT00180232||1|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
62502356|NCT03055741|EXPERIMENTAL|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
62502357|NCT03055741|PLACEBO_COMPARATOR|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
62502358|NCT02304978|EXPERIMENTAL|Group CRC|patient with a colorectal cancer
62502359|NCT02304978|EXPERIMENTAL|Group control|Control - volunteers
62701834|NCT03906409|EXPERIMENTAL|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
62701835|NCT02149966|EXPERIMENTAL|AG-348|Multiple oral doses of AG-348
62701836|NCT02149966|PLACEBO_COMPARATOR|Placebo|Multiple oral doses of placebo.
61954944|NCT04896541|EXPERIMENTAL|AZD7442|Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
61954945|NCT04896541|EXPERIMENTAL|placebo|Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
62701837|NCT04656912||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin \>5% (\>10% in smokers).
62701838|NCT04250792|EXPERIMENTAL|single arm|Low dose naltrexone was prescribed to the patients affected with psoriasis.
62701839|NCT06409260|OTHER|N. tibialis|Objective neuromuscular monitoring done on n. tibialis bilaterally
62142235|NCT03529994||Enrollment|
62142236|NCT04454476|EXPERIMENTAL|Trametinib treatment|
62701840|NCT06409260|OTHER|N. ulnaris|Objective neuromuscular monitoring done on n. ulnaris bilaterally
62701841|NCT00397540|ACTIVE_COMPARATOR|percutaneous ethanol injection therapy|Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
62701842|NCT00397540|ACTIVE_COMPARATOR|radiofrequency thermal ablation|Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
62142237|NCT05240794|EXPERIMENTAL|Experimental group|Participants receive active ABM-01 for the study
62502360|NCT00003404|EXPERIMENTAL|Adjuvant Radiotherapy|Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.
62502361|NCT05424250|EXPERIMENTAL|Exposure + occasional aversive imagination|repeated imaginations of the participants' most feared apprehension during extinction training with seven standardized exposure steps
62502362|NCT05424250|ACTIVE_COMPARATOR|Exposure|Standard extinction training with seven standardized exposure steps
62701843|NCT03955978|EXPERIMENTAL|TSR-042 and Brachytherapy|"* Patients will receive four doses of TSR-042. The first dose is given 21 days prior to the first planned brachytherapy fraction. The second dose is given 21 (+3) days later, corresponding to the time of brachytherapy fraction #1. The third dose is given 21 (+3) days after dose 2, corresponding to the time of brachytherapy fraction #4. The fourth dose is given 21 (+3) days after dose corresponding to 1 weeks after brachytherapy fraction #6.~* Brachytherapy will consist of 6 weekly fractions of 6 Gy per fraction (total 36Gy)"
62701844|NCT01156844|EXPERIMENTAL|Indacaterol 37.5 µg (twice a day)|"Indacaterol 37.5 µg twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
62701845|NCT01156844|EXPERIMENTAL|Indacaterol 75 µg (once a day)|"Indacaterol 75 µg once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
61954946|NCT04498520|EXPERIMENTAL|Treatment (abexinostat tosylate, palbociclib, fulvestrant)|Patients receive abexinostat PO BID on days 1-4, 8-11, and 15-18, palbociclib PO QD on days 1-21, and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61954947|NCT05173805|EXPERIMENTAL|YL-15293|"Single arm, open, single and multiple doses; Dosage form: YL-15293 tablets Specification: 50mg, 200mg Storage conditions: refrigerated and sealed at 2-8℃~Way of administration:~Single-dose study: Oral administration, once a day, with warm water, fasting administration, fasting 1 hour before and 2 hours after administration. Multiple administration studies: oral administration, warm water delivery, fasting administration, fasting 1 hour before administration and 2 hours after administration, continuous administration for 21 days as a treatment cycle. The way of taking the medicine is twice a day."
61954948|NCT03752983||cases|patients with SLE
61954949|NCT03752983||controls|Healthy people
61954950|NCT02370745|EXPERIMENTAL|Post absorptive insulin without GLP-1|"Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition."
61954951|NCT02370745|EXPERIMENTAL|Postabsorptive insulin with GLP-1|"Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
61954952|NCT02370745|EXPERIMENTAL|Postprandial insulin without GLP-1|"Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition"
61954953|NCT02370745|EXPERIMENTAL|Postprandial insulin with GLP-1|"Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
61954954|NCT02370745|EXPERIMENTAL|Oral amino acids-Young|"Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.~The intervention here is: 15g of mixed essential amino acid drink."
61954955|NCT02370745|EXPERIMENTAL|Intravenous (IV) amino acids- Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids"
61954956|NCT02370745|EXPERIMENTAL|IV amino acids, GLP-1, GIP -Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion"
61954957|NCT02370745|EXPERIMENTAL|Oral amino acids- Older|"Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.~The intervention in this arm: 15 gram of oral mixed essential amino acid drink"
61954958|NCT05106686|EXPERIMENTAL|Aureobasidium pullulans produced β-glucan group|This group takes Aureobasidium pullulans produced β-glucan for 12 weeks.
61954959|NCT05106686|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks.
61954960|NCT05465434|ACTIVE_COMPARATOR|Group 2|25 patients will receive 50mg Zinc Sulphate plus the standard direct acting anti-viral therapy for 3 months.
61954961|NCT05465434|NO_INTERVENTION|Group 1|25 patients will receive their standard direct acting anti-viral therapy for 3 months
61954962|NCT06475586|EXPERIMENTAL|semaglutide|The initial dose of the medicine is 0.25 mg once a week, for the duration of 4 weeks. Then the dose is increased to 0.5 mg per week, for the duration of 4 weeks. After at least 4 weeks, the dose can be increased from 0.5 mg to 1 mg per 4 week. Totally 12 weeks
61954963|NCT06475586|NO_INTERVENTION|controled group|Patients with DMT2 and psoriasis, who are already on metformin therapy in the maximally tolerated dose and other oral antidiabetics, except on therapy with GLP-1 RA and SGLT-2 inhibitors.
61954964|NCT04769804||Patients with recurrent pityriasis versicolor|
61954965|NCT04769804||Healthy age and sex-matched controls|
62502363|NCT05066568|OTHER|Sequence of interventions starting with tDCS as the first intervention|"Week 1 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 4 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes.~Week 5 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes"
62701846|NCT01156844|EXPERIMENTAL|Indacaterol 150 µg (every other day)|"Indacaterol 150 µg every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 µg inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
62142238|NCT05240794|PLACEBO_COMPARATOR|Placebo Control|Participants receive a digital control for the study
62502364|NCT05066568|OTHER|Sequence of interventions starting with Hypnosis as the first intervention|"Week 1 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 4 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes~Week 5 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes."
62502365|NCT04506320||Patients with Multiple myeloma|Adult with diagnosis of multiple myeloma treated with Allo-HSCT from related - HLA identical or volunteer unrelated donor or haploidentical related donor performed from January 1, 2009 to december 31, 2018
62502366|NCT02568280|EXPERIMENTAL|Faster aspart|
62502367|NCT02568280|ACTIVE_COMPARATOR|Insulin aspart|
62502368|NCT02913131|EXPERIMENTAL|Part A: Feasibility Run-In|Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s).
62502369|NCT02913131|EXPERIMENTAL|Part B: Biomarker Cohort|Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.
62502370|NCT06667141|EXPERIMENTAL|Dose escalation|ACR-2316 will be administered using a 3-week schedule.
62502371|NCT06667141|EXPERIMENTAL|Dose expansion|ACR-2316 will be administered using a 3-week schedule.
62502372|NCT03819920|PLACEBO_COMPARATOR|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
62502373|NCT03819920|ACTIVE_COMPARATOR|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
62502374|NCT03850964|ACTIVE_COMPARATOR|Part B (Severe Anemia) Pazopanib - 150 mg|150 mg pazopanib oral capsules (six 25 mg placebo capsules daily).
62502375|NCT03850964|PLACEBO_COMPARATOR|Part B (Severe Anemia) Placebo|Placebo oral capsules (six 25 mg placebo capsules daily).
62502376|NCT03850964|ACTIVE_COMPARATOR|Part B (Severe Epistaxis) Pazopanib - 150 mg|Pazopanib 150 mg oral daily dosing (six 25 mg Pazopanib capsules).
62502377|NCT03850964|PLACEBO_COMPARATOR|Part B (Severe Expistaxis) Placebo|Placebo oral capsules (six 25 mg placebo capsules daily).
62502378|NCT03850964|EXPERIMENTAL|Part C Pazopanib - 150 mg|Pazopanib 150 mg oral daily dosing (six 25 mg Pazopanib capsules).
62502379|NCT06202534||Before radiotherapy,|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients before radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
62502380|NCT06202534||During radiotherapy|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients during radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
62502381|NCT06202534||After radiotherapy|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients after radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
62502382|NCT06202534||3 months after radiotherapy|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients 3 months after radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
62502383|NCT01143831|EXPERIMENTAL|All study participants|Three blood collections, one at baseline, one two weeks later, and the final blood collection 4 weeks from baseline, after taking Vitamin K orally for 14 days.
62502384|NCT01486108|EXPERIMENTAL|Tonic|5 hz stimulation at an amplitude that the patient find bearable (+/- 1.5 mA)
62502385|NCT01486108|EXPERIMENTAL|Sham|no stimulation, patient receive a sham stimulation (actually the IPG is not running)
62502386|NCT01486108|EXPERIMENTAL|burst|500 hz burst at 5 hz stimulation
62502387|NCT05427045|EXPERIMENTAL|Intervention group|Adult patients \< 50 years old who have multiple sclerosis and back pain who are undergoing home exercise
62701847|NCT01156844|PLACEBO_COMPARATOR|Placebo|"Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
62701848|NCT03484897|EXPERIMENTAL|P927 - LICHTENA DermAD CREMA CORPO|Application of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
62701849|NCT06537687|ACTIVE_COMPARATOR|Control|The control group will be given a standardized handout
62701850|NCT06537687|EXPERIMENTAL|Intervention|The intervention group will be shown an educational video
62502388|NCT02498691|EXPERIMENTAL|Type exposed|endometriosis
62502389|NCT02498691|EXPERIMENTAL|Type unexposed|Without endometriosis
62701851|NCT03626766|ACTIVE_COMPARATOR|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
62701852|NCT03626766|ACTIVE_COMPARATOR|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
62701853|NCT03626766|ACTIVE_COMPARATOR|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
62701854|NCT03626766|NO_INTERVENTION|No Photo|No patient photographs displayed in the electronic health record.
62701855|NCT01392157|ACTIVE_COMPARATOR|copper intrauterine device|100 women will be allocated to receive a TCu380A intrauterine device
62701856|NCT01392157|ACTIVE_COMPARATOR|LNG-releasing intrauterine system|100 women were allocated to receive a LNG-IUS
62701857|NCT01392157|ACTIVE_COMPARATOR|ENG-releasing implant|100 women will receive an LNG-IUS
62701858|NCT01174563|EXPERIMENTAL|Single Arm|
61954966|NCT04959422|EXPERIMENTAL|Active scheduling|Children who fail instrument vision screens will be scheduled at a community vision specialist office before departure from clinic and all no shows at the vision specialist office will be tracked and rescheduled.
61954967|NCT03534960|OTHER|High Flow Nasal Oxygen Therapy|Patients are randomized to the high flow nasal oxygen therapy group
61954968|NCT03534960|OTHER|Nasal CPAP|Patients are randomized to the nasal continuous positive airway pressure treatment group
61954969|NCT04966039||monochorionic twin pregnancies with demise of one fetus|Twin pregnancy was diagnosed and one fetus died in utero, 20 pregnant women
61954970|NCT04966039||Twin control group|Twin pregnancy with one abnormal fetus, 20 pregnant women
61954971|NCT04966039||Singleton control group|Singleton pregnancy with abnormalities outside the fetal brain, 20 pregnant women
61954972|NCT05909748|EXPERIMENTAL|GEMINUS Transcatheter Aortic Valve Implantation system|Clinical follow up for all patients will be performed at 30 days, 6 months, 1, 2, 3, 4 and 5 years post-implantation
61954973|NCT00636558|EXPERIMENTAL|CVA21|IV administration of CVA21 in a dose escalation manner
62344564|NCT02658994|ACTIVE_COMPARATOR|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
62344565|NCT04494555|EXPERIMENTAL|Adaptable Prosthetic Socket|Using measurements of limb-socket displacements from sensors embedded within the socket wall, adaptable sockets make small adjustments to socket size so as to maintain consistent displacements while prosthesis users are active. They do not require the user to stop activity or to touch or modify the prosthesis, and they do not distract users from their objectives.
61954974|NCT04013204|EXPERIMENTAL|Intervention group|Intervention group: Before the patient returns to the doctor and the prescription is issued, the EDCM system will feed back the EndoPAT test results to the responsible doctor through the automatically generated information on the doctor's mobile phone, but will not let the patient know the endothelium test results (blinded to the patient).
61954975|NCT04013204|NO_INTERVENTION|Control group|Control group: The EDCM system will not report the EndoPAT test results to the responsible doctor (the doctor cannot see the final EFT results), nor can the patients know the EFT results.
61954976|NCT01935297|ACTIVE_COMPARATOR|Exercise|8 weeks of supervised, structured, combined endurance and resistance training
61954977|NCT01935297|NO_INTERVENTION|Control|Patients receive usual care, regular exercise is not recommended but also not prohibited
61954978|NCT02840500||Breakthrough Cancer Pain|No intervention (Non-interventional study)
62344566|NCT05905341|EXPERIMENTAL|Part 1 Dose Escalation-Dose Level 1|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
62344567|NCT05905341|EXPERIMENTAL|Part 1 Dose Escalation-Dose Level 2|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
62344568|NCT05905341|EXPERIMENTAL|Part 1 Dose Escalation-Dose Level 3|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
62701859|NCT06247748|EXPERIMENTAL|Exendin-4 Fc fusion protein (JY09) injection|D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29 to D78 received continuous subcutaneous abdominal injections of 2.4 mg of JY09 injection in the morning, once weekly (total of 8 administrations). All doses were to be administered within 3 min.
62701860|NCT00693758|NO_INTERVENTION|1|healthy volunteers without intervention
62701861|NCT00693758|NO_INTERVENTION|2|patients with suspected coronary artery disease without intervention
61954979|NCT05496530|ACTIVE_COMPARATOR|Diabetic macular edema|Cases with diabetic macular edema with central macular thickness more than 300 microns measured by optical coherence tomography.
62701862|NCT00693758|EXPERIMENTAL|3|Healthy volunteers during adenosine infusion
62701863|NCT00693758|EXPERIMENTAL|4|Healthy volunteers during changes of breathing gases (CO2, O2)
62701864|NCT00693758|EXPERIMENTAL|5|patients with suspected coronary artery disease during adenosine infusion
61954980|NCT05496530|ACTIVE_COMPARATOR|Vogt-koyanagi harada|Cases with vogt-koyanagi harada and complicated with exudative retinal detachment confirmed by optical coherence tomography.
62701865|NCT00693758|EXPERIMENTAL|6|patients with suspected coronary artery disease during changes of breathing gases
62701866|NCT00693758|EXPERIMENTAL|7|Assessment of reactive hyperemia in arms of healthy volunteers to improve sequences
62701867|NCT06244589|ACTIVE_COMPARATOR|Laparoscopic cholecystectomy|Cases that laparoscopic cholecystectomy performed without need for open-conversion
62701868|NCT06244589|EXPERIMENTAL|Open-conversion cholecystectomy|Cases converted to open surgery based on intraoperative findings.
62701869|NCT03022721||Patients with diabetes|"Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.~No interventions are planned."
62344569|NCT05905341|EXPERIMENTAL|Part 1 Dose Escalation-Dose Level 4|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
62142239|NCT04769141||Hypertension patients|a prospective 4-month, cohort feasibility study will evaluate blood pressure (n=20) using the CURATE.AI platform.
62142240|NCT04769141||Diabetic patients|a prospective 4-month, cohort feasibility study will evaluate glycaemic (n=20) control using the CURATE.AI platform.
61954981|NCT05496530|ACTIVE_COMPARATOR|Retinal vein occlusion|Cases with retinal vein occlusion and complicated with macular edema confirmed by optical coherence tomography.
62344570|NCT05905341|EXPERIMENTAL|Part 1 Dose Escalation-Dose Level 5|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
62344571|NCT05905341|EXPERIMENTAL|Part 2 - Arm A|In Part 2 Arm A, PF-07224826 will be evaluated in combination with fulvestrant in HR positive HER2 negative advanced or mBC participants who have received prior CDK4/6 inhibitor. PF-07224826 will be administered orally, once daily, on a continuous basis.
62344572|NCT05905341|EXPERIMENTAL|Part 2 - Arm B|In Part 2 Arm B, PF-07224826 will be evaluated in combination with fulvestrant in HR-positive HER2-negative locally advanced or mBC participants whose disease has progressed on prior endocrine therapy and is naïve to CDK4/6 inhibitors. PF-07224826 will be administered orally, once daily, on a continuous basis.
62344573|NCT00721422|EXPERIMENTAL|Group 1-Normal|
62344574|NCT00721422|EXPERIMENTAL|Group 2-Mild|
62344575|NCT00721422|EXPERIMENTAL|Group 3-Moderate|
62344576|NCT00721422|EXPERIMENTAL|Group 4-Severe|
62344577|NCT00699101|EXPERIMENTAL|A|Conture Multi-Lumen Balloon
62701870|NCT03022721||Pre-Diabetics|"Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.~No interventions are planned."
61954982|NCT00172133|EXPERIMENTAL|1|All patients entering the study will receive 100mcg daily for up to 6 months, making their total exposure 24 months
61954983|NCT01972113|PLACEBO_COMPARATOR|Placebo-Control|The placebo-control group will take one placebo softgel capsules every day for 8 weeks.
62142241|NCT04936386||Healthcare professionals|Healthcare professionals (medical specialists and general practitioners, medical residents, midwives, professional nurses, medical students).
62142242|NCT02807857|OTHER|Patients' heart failure and non-heart failure|No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians
62142243|NCT04359017|EXPERIMENTAL|Lidocaine Hematoma Block|
62142244|NCT05948774|EXPERIMENTAL|MT200605 for injection|The Single Ascending Dose (SAD) and Muliple Ascending Dose (MAD) stages were built up in the study. The MT200605 in SAD and MAD following Intravenous Infusion Administration by using infusion pump in Healthy Subjects.
62142245|NCT05948774|PLACEBO_COMPARATOR|MT200605 Placebo|The Single Ascending Dose (SAD) and Muliple Ascending Dose (MAD) stages were built up in the study. The MT200605 Placebo in SAD and MAD following Intravenous Infusion Administration by using infusion pump in Healthy Subjects.
62142246|NCT05194696||Caffeine questionnaire|A questionnaire concerning caffeine habits will be handed out to the patients
62142247|NCT01953679|ACTIVE_COMPARATOR|5mg UPA|Continuous regimen of oral daily 5 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
62701871|NCT03022721||Healthy controls|"Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.~no interventions are planned."
62142248|NCT01953679|ACTIVE_COMPARATOR|10mg UPA|Continuous regimen of oral daily 10 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
62142249|NCT02576691||The PCI group|The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA.
62344578|NCT05551338|EXPERIMENTAL|Intervention|Patients will be asked to perform two 30-minute sessions per week of training using serious games over a 3-month period in their home setting in addition to their conventional care
61954984|NCT01972113|ACTIVE_COMPARATOR|Low-Dose Vitamin K2 (45 mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
61954985|NCT01972113|ACTIVE_COMPARATOR|High-Dose Vitamin K2 (90 mcg/d)|The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
61954986|NCT01203098|EXPERIMENTAL|DU-176b 30mg once daily|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
61954987|NCT01203098|ACTIVE_COMPARATOR|Enoxaparin sodium twice daily|Enoxaparin sodium 20mg (=2000IU) / 0.2mL twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
61954988|NCT01203098|EXPERIMENTAL|DU-176b 15mg once daily|DU-176b 15mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
62142250|NCT02576691||Non-PCI group|Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA
62142251|NCT03192501||Study group (A group)|In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
62142252|NCT03192501||Control group (B group)|In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
62344579|NCT05551338|NO_INTERVENTION|Control|Patients will undergo only their conventional care
62701872|NCT05161468|ACTIVE_COMPARATOR|Lidocaine|50 Subjects will be randomized to this group and will receive a lidocaine injection in their ACJ.
61954989|NCT04351685|EXPERIMENTAL|VPM1002|"Total 3470 subjects will be enrolled in VPM1002 arm.~Single dose of VPM1002 will be administered."
61954990|NCT04351685|ACTIVE_COMPARATOR|BCG SII|"Total 3470 subjects will be enrolled in BCG SII arm.~Single dose of BCG SII will be administered."
61954991|NCT04054505|ACTIVE_COMPARATOR|Vitamin A|Rise or fall of Vitamin A after three months
61954992|NCT04054505|ACTIVE_COMPARATOR|Vitamin E|Rise or fall of Vitamin E after three months
62142253|NCT03192501||Control group (C group)|In this group, patients with advanced cancers (matched with Group A) will be treated with appropriate targeted drugs according to IHC detection of more than 20 protein molecules with blank tissue slides from the cancer.
62142254|NCT02093169|EXPERIMENTAL|Part A: Lu AF35700|
62344580|NCT04436874|EXPERIMENTAL|Han ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Han ethnic by endoscopy
62502390|NCT04621656||Type 2 Diabetes|Individuals that have been previously diagnosed with Type 2 Diabetes. Those with Fasting Blood Glucose levels 126 mg/dL in two separate tests and/or HbA1C values greater than 6.5%. Individuals may take Metformin, SGLT2 inhibitors, of GLP-1 therapeutics. Not including those using Insulin therapeutics.
62502391|NCT04621656||Pre-Diabetes|Individuals that have been previously diagnosed with Pre-Diabetes. This group may include individuals with pre-diabetes that may be unaware of their condition. HbA1C values between 5.7% and 6.4%.
62502392|NCT04621656||Healthy|Individuals that have not been previously diagnosed with Metabolic Syndromes including Type 2 Diabetes, obesity, or increased levels of blood sugar. HbA1C values below 5.7%.
62502393|NCT03481855||Progressive bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with progressive increase of negative pressure by a step-wise approach (-15mmHg, -30mmHg, -45mmHg).
62502394|NCT03481855||Prolonged bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with prolonged exposure to a negative pressure of -15mmHg.
61954993|NCT04054505|ACTIVE_COMPARATOR|Vitamin B1|Rise or fall of Vitamin B1 after three months
61954994|NCT04054505|ACTIVE_COMPARATOR|Vitamin B2|Rise or fall of Vitamin B2 after three months
61954995|NCT04054505|ACTIVE_COMPARATOR|Vitamin B6|Rise or fall of Vitamin B6 after three months
61954996|NCT04054505|ACTIVE_COMPARATOR|Vitamin B12|Rise or fall of Vitamin B12 after three months
62142255|NCT02093169|EXPERIMENTAL|Part B: Lu AF35700|
62142256|NCT00877305|ACTIVE_COMPARATOR|RIPC|Remote Ischemic Preconditioning
62344581|NCT04436874|EXPERIMENTAL|Han ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Han ethnic by endoscopy
62344582|NCT04436874|EXPERIMENTAL|Dai ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Dai ethnic by endoscopy
62142257|NCT00877305|PLACEBO_COMPARATOR|CONTROL|Control
62142258|NCT01833455|PLACEBO_COMPARATOR|PVC Suppression then Placebo|This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
62142259|NCT01833455|PLACEBO_COMPARATOR|Placebo then PVC Suppression|This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
62142260|NCT01765374|EXPERIMENTAL|rituximab|Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
62142261|NCT02241785|EXPERIMENTAL|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
62344583|NCT04436874|EXPERIMENTAL|Dai ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Dai ethnic by endoscopy
62502395|NCT01166815|ACTIVE_COMPARATOR|Zinc supplemented|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
62502396|NCT01166815|PLACEBO_COMPARATOR|Placebo|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
62502397|NCT05086770|EXPERIMENTAL|Test group|The test group will be administered 300-500 ㎛ range of Gelatin microsphere (Nexsphere™). A suspension in which a contrast medium and physiological saline are mixed will be administered until the embolization is sufficiently achieved.
61954997|NCT04054505|ACTIVE_COMPARATOR|Vitamin C|Rise or fall of Vitamin C after three months
61954998|NCT04054505|ACTIVE_COMPARATOR|Vitamin D|Rise or fall of Vitamin D after three months
61954999|NCT04054505|ACTIVE_COMPARATOR|Calcium|Rise or fall of Calcium after three months
62502398|NCT05086770|ACTIVE_COMPARATOR|Control group|The control group will be administered 500-700 ㎛ of Embospheres until sufficient embolization is achieved.
62502399|NCT04848779||Cohort 1|
62502400|NCT04119557|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered subcutaneously (SC) every 2 weeks for a period of 12 weeks.
62502401|NCT04119557|EXPERIMENTAL|Cohort 1 - 10 (Microgram Per Kilogram) μg/kg LY3471851|Participants received 10 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
61955000|NCT04054505|ACTIVE_COMPARATOR|Iron|Rise or fall of Iron after three months
61955001|NCT04054505|NO_INTERVENTION|IGF1|Rise or fall of IGF1 after three months
61955002|NCT04054505|NO_INTERVENTION|FT-3|Rise or fall of FT-3 after three months
61955003|NCT05136404|EXPERIMENTAL|Selpercatinib (Formulation 1)|Selpercatinib (formulation 1) given orally on days 1, 8 or 15.
61955004|NCT05136404|EXPERIMENTAL|Selpercatinib (Formulation 2)|Selpercatinib (formulation 2) given orally on days 1, 8 or 15.
62142262|NCT01613417|ACTIVE_COMPARATOR|MRI with Gadoteridol|MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.
62142263|NCT01613417|ACTIVE_COMPARATOR|MRI with Gadobutrol|MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.
62142264|NCT03912909|ACTIVE_COMPARATOR|Phase 1|Empagliflozin 10mg daily or placebo
62142265|NCT03912909|PLACEBO_COMPARATOR|Phase2|Empagliflozin 10mg daily or placebo
62142266|NCT00110669|ACTIVE_COMPARATOR|High Dose Prednisone|"Subjects who are randomized to the high-dose prednisone arm of the study will receive the following starting dose:~•Prednisone at 10.0 mg/kg/wk (divided into two doses given on Saturday and Sunday)"
61955005|NCT05136404|EXPERIMENTAL|Selpercatinib (Formulation 3)|Selpercatinib (formulation 3) given orally on days 1, 8 or 15.
61955006|NCT06143644||Cohort|Patients with stage I to IV colorectal cancer
61955007|NCT04669132|EXPERIMENTAL|Olanzapine + Netupitanto + Palonosetron|Olanzapine 5 mg/day d 0-4 + Netupitanto 300 mg/day d 1 + Palonosetron 0.56 mg/day d 1;
61955008|NCT01387932|EXPERIMENTAL|HepaSphere/QuadraSphere TACE|HepaSphere/QuadraSphere TACE
61955009|NCT01387932|ACTIVE_COMPARATOR|Conventional TACE|Conventional TACE
61955010|NCT04404205||Adult patient with cochlear implant|Adult patients who had cochlear implant surgery before will be included. We will call patients from our cochlear implant list.
61955011|NCT00955071|NO_INTERVENTION|Control|
61955012|NCT00955071|ACTIVE_COMPARATOR|Exercise: LVLI|low volume, low intensity
61955013|NCT00955071|ACTIVE_COMPARATOR|Exercise: HVLI|high volume, low intensity
61955014|NCT00955071|ACTIVE_COMPARATOR|Exercise: LVHI|low volume, high intensity
61955015|NCT03685968|EXPERIMENTAL|Glidescope AVL|
61955016|NCT03685968|EXPERIMENTAL|King Vision Channeled VL|
61955017|NCT03685968|EXPERIMENTAL|King Vision Non-Channeled (Standard) VL|
61955018|NCT04153669|NO_INTERVENTION|Control|This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
61955019|NCT04153669|EXPERIMENTAL|Exercise-No NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions."
62344584|NCT01605344|EXPERIMENTAL|Arm A|ARM A subjects will receive atorvastatin 20 mg orally once daily given for two weeks prior to FOLFIRI. The last dose of atorvastatin will be taken day 1 of FOLFIRI. ARM A will then receive no statin for the next 2 weeks. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
62344585|NCT01605344|EXPERIMENTAL|Arm B|ARM B subjects will receive no atorvastatin prior to day 1 of FOLFIRI. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks prior to day 15 of FOLFIRI. The last dose of atorvastatin will be taken day 15 of FOLFIRI. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
62344586|NCT05197478|OTHER|COVID 19 positive patients|COVID 19 positive patients receiving inpatient treatment were evaluated.
62344587|NCT04939025|NO_INTERVENTION|Historic cohort|
62502402|NCT04119557|EXPERIMENTAL|Cohort 2 - 24 μg/kg LY3471851|Participants received 24 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
62502403|NCT00418067|ACTIVE_COMPARATOR|Cypher|Sirolimus-eluting stent
61955020|NCT04153669|EXPERIMENTAL|Exercise-NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions. Additionally, this group will receive neuromuscular electrical stimulation (NMES) concomitant to the strength training."
61955021|NCT03673046|EXPERIMENTAL|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD.
61955022|NCT03673046|OTHER|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
61955023|NCT04751526|EXPERIMENTAL|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
61955024|NCT04751526|EXPERIMENTAL|EStim|EStim is transcutaneous electrical nerve stimulation.
61955025|NCT00358371|EXPERIMENTAL|Subjects receiving flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
62344588|NCT04939025|OTHER|Multi-interventional program cohort|
62344589|NCT05442294|EXPERIMENTAL|Juego de Llaves group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Juego de Llaves.~The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values"
62344590|NCT05442294|NO_INTERVENTION|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
62502404|NCT00418067|ACTIVE_COMPARATOR|Taxus Liberte|Paclitaxel-eluting stent
61955026|NCT00358371|EXPERIMENTAL|Subjects receiving flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
61955027|NCT01930864|EXPERIMENTAL|metfomin + irinotecan|Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
61955028|NCT05614505|ACTIVE_COMPARATOR|RUTF standard|PlumpyNut
62142267|NCT00110669|ACTIVE_COMPARATOR|Daily Prednisone|"Subjects who are randomized to the daily prednisone arm of the study will receive the following starting dose:~•Prednisone at 0.75 mg/kg/d"
62142268|NCT02429115|EXPERIMENTAL|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
61955029|NCT05614505|EXPERIMENTAL|RUTF local_1|Soybean RUTF
61955030|NCT05614505|EXPERIMENTAL|RUTF local_2|Mungbean-thick RUTF
61955031|NCT05614505|EXPERIMENTAL|RUTF local_3|Mungbean-thin RUTF
61955032|NCT05614505|EXPERIMENTAL|RUTF local_4|Wafer RUTF
61955033|NCT03674684||hydroxyethyl starch|Patients who received hydroxyethyl starch
61955034|NCT03674684||gelatin|Patients who received gelatin
61955035|NCT03674684||crystalloids|Patients who received crystalloids
61955036|NCT05495620||Relapsed and/or refractory multiple myeloma|Multiple myeloma in relapsed but not refractory, relapsed and refractory, and primary refractory status
61955037|NCT04993521|ACTIVE_COMPARATOR|bilateral superficial cervical plexus block (BSCPB)|Analgesia obtained by a ultrasound guided cervical plexus block using lidocain
61955038|NCT04993521|ACTIVE_COMPARATOR|local wound infiltration (LWI)|Analgesia obtained by local wound infiltration of lidocain
61955039|NCT02420171|ACTIVE_COMPARATOR|In Vitro culture media with insulin|We will add insulin to the single step culture media to monitor the embryogenesis
61955040|NCT02420171|NO_INTERVENTION|In Vitro culture media without insulin m|The embryos will be cultured in the media without insulin and compare this arm as the control arm with the interventional one.
61955041|NCT03954197|EXPERIMENTAL|Without injection group|no injection used as priming
61955042|NCT03954197|ACTIVE_COMPARATOR|hCG group|hCG used as priming
62344591|NCT05699772|EXPERIMENTAL|Telehealth GLB-TBI (tGLB-TBI)|"The goal of the tGLB-TBI program is to help the participant achieve and maintain a 5-7% weight-loss using a two-pronged approach:~1. Physical activity: This is based upon recommendations by the American Heart Association and the American College of Sports Medicine (ACSM) to achieve 150 minutes of moderate intensity activity each week. Walking is the primary activity recommended.~2. Healthy eating: Based on United States Department of Agriculture guidelines, the GLB emphasizes healthy eating patterns and tracking dietary intake.~The tGLB-TBI was modified from the DPP-GLB and is a one-year program with 22 sessions. It begins with 12 weekly sessions called the Core Program, followed by a Transition phase consisting of 2 bi-weekly and 2 monthly sessions, and a Support Phase consisting of 6 monthly sessions. Sessions will be delivered in a group setting via telehealth (Microsoft Teams)."
62344592|NCT05699772|ACTIVE_COMPARATOR|Brain Health Group (BHG)|The Brain Health Group (BHG) meets at the same frequency as the GLB-TBI (i.e., 22 group-based sessions, 12 weekly, 4 bi-monthly, and 6 monthly).The focus of the BHG is on brain health education, self-management, and problem-solving and the BHG did not receive any education on weight-loss strategies. Sessions will be delivered in a group setting via telehealth (Microsoft Teams).
61955043|NCT03954197|ACTIVE_COMPARATOR|GnRHa group|GnRH agonist used as priming
61955044|NCT01072331|EXPERIMENTAL|MP-513 10 mg, once a day, for 4 weeks|
61955045|NCT01072331|EXPERIMENTAL|MP-513 20 mg, once a day, for 4 weeks|
61955046|NCT01072331|PLACEBO_COMPARATOR|Placebo of MP-513|
61955047|NCT06506448||STEMI patients with multivessel disease|320 patients undergoing primary angioplasty for ST-elevation myocardial infarction (STEMI) who have bystander disease in a main coronary artery with at least one stenosis of 50% or more
62142269|NCT02429115|EXPERIMENTAL|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
62142270|NCT02429115|NO_INTERVENTION|Control|Will not receive peer mentoring.
62142271|NCT04124887|ACTIVE_COMPARATOR|Sodium fluoride|Duraphat Varnish containing 5% Sodium fluoride
62344593|NCT02130479|EXPERIMENTAL|Contingency Management-Family Engagement|The Contingency Management-Family Engagement or CM-FAM model integrates behavioral (e.g., drug testing linked with consequences) and cognitive behavioral (e.g., functional analyses of drug use, self-management and drug refusal skills training) strategies based on the Community Reinforcement Approach with effective family engagement strategies used in Multisystemic Therapy.
62344594|NCT02130479|ACTIVE_COMPARATOR|Treatment as Usual|Standard community-based substance abuse treatment services.
62502405|NCT00418067|EXPERIMENTAL|Endeavor|Zotarolimus-eluting stent
62502406|NCT04755673|EXPERIMENTAL|Experimental: Atrantil (Medical Food)|All participants in the trial will take two capsules of Atrantil three times a day for 28 days.
62502407|NCT05577494||Clinicians|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 100 clinicians are recruited in total. Then, they will receive an online questionnaire and complete the Clinician Questionnaire. Finally, the survey results need to be qualitatively analyzed.
62701873|NCT05161468|ACTIVE_COMPARATOR|Corticosteroid|50 Subjects will be randomized to this group and will receive a corticosteroid injection in their ACJ.
62701874|NCT05161468|ACTIVE_COMPARATOR|Platelet Rich Plasma (PRP)|50 Subjects will be randomized to this group and will receive a PRP injection in their ACJ.
62701875|NCT01203397|ACTIVE_COMPARATOR|GROUP 2|
62701876|NCT01203397|EXPERIMENTAL|GROUP 1|
62701877|NCT01292031|EXPERIMENTAL|Colistin|Colistin 4.5 MU/iv.plus Colistin 3 MU/iv./8 h. 30 minutes infusion
62701878|NCT01292031|ACTIVE_COMPARATOR|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
61955048|NCT05960799|EXPERIMENTAL|Contiplex C or CON|Patients who will receive a contiplex C block for interscalene nerve block. This catheter also calls Catheter over needle (CON), wich is a catheter that is inserted at the same time that the needle is advancing.
61955049|NCT05960799|ACTIVE_COMPARATOR|Contiplex or CTN|Patients who will receive a regular contiplex block for interscalene nerve block or also called Catheter throw needle (CTN). This catheter is the gold standard in this centre and the mechanism of insertion is to introduce the catheter throw the needle.
61955050|NCT00003473|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
61955051|NCT04218422|EXPERIMENTAL|Treatment|2 treatments of battlefield acupuncture to the bilateral ears spaced one week apart
61955052|NCT04218422|SHAM_COMPARATOR|Control|2 treatments with sham acupuncture to the bilateral ears at acupuncture points not associated with pain relief (2 liver and 1 stomach)
61955053|NCT03600818|PLACEBO_COMPARATOR|Placebo+52 Week Taper|Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
61955054|NCT03600818|EXPERIMENTAL|Sarilumab 200mg q2w+14 Week Taper|Participants received sarilumab 200 milligrams (mg) as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 14 weeks and prednisone-matching placebo from Week 14 up to Week 52.
61955055|NCT06359392|OTHER|No Message|Individuals assigned to this arm will take the surveys only and not be exposed to a palliative care message.
62142272|NCT04124887|EXPERIMENTAL|Tricalcium phosphate|Clinpro™ White Varnish containing 5% NaF with TCP
62142273|NCT04124887|EXPERIMENTAL|Xylitol-coated calcium and phosphate|Embrace ™ Varnish containing 5% NaF with CXP
62142274|NCT04124887|EXPERIMENTAL|Casein phosphopeptide amorphous calcium phosphate|MI Varnish containing 5% NaF with CPP-ACP
61955056|NCT06359392|OTHER|Culture-centric message|Individuals assigned to this arm will watch a 2 minute culture-centric palliative care video specific for these American Indian communities and then take the surveys after watching the videos.
61955057|NCT06359392|OTHER|General message|Individuals assigned to this arm will watch a 2 minute palliative care video created for the general US population and then take the surveys after watching the videos.
61955058|NCT01753505|EXPERIMENTAL|MDCTA|
61955059|NCT01478477|EXPERIMENTAL|Arm I (omega-3 fatty acid supplement)|Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)
61955060|NCT01478477|PLACEBO_COMPARATOR|Arm II (placebo)|Typical American Diet oils (TAD)
61955061|NCT01478477|EXPERIMENTAL|Clinical Assessments|Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)
61955062|NCT01478477|EXPERIMENTAL|Assessment of therapy complications|Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.
61955063|NCT01478477|EXPERIMENTAL|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained
61955064|NCT01478477|EXPERIMENTAL|Correlative/special studies|Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.
61955065|NCT02358174|EXPERIMENTAL|Group I|Patients with symptomatic hemorrhoids - Grade I to IV sec. Goligher. Grade III to IV underwent Hemorrhoidectomy. Blood sampling for MMPs and NGAL plasma levels evaluation will be performed. Tissue sampling (obtained during hemorrhoidectomy) for MMPs and NGAL tissue levels evaluation will be performed in grade III-IV patients.
61955066|NCT02358174|EXPERIMENTAL|Group II|Healthy subjects without hemorrhoids as control groups for MMPs and NGAL plasma evaluation will be performed by means of Blood sampling.
61955067|NCT00451308|EXPERIMENTAL|1|Foley balloon wih 60cc fluid
61955068|NCT00451308|ACTIVE_COMPARATOR|2|Foley balloon with 30cc
61955069|NCT04407364||Intervention Cohort|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
61955070|NCT04407364||Historical Cohort|Primary and Revision total hip arthroplasty patients between 18-85 years of age
61955071|NCT01524471|EXPERIMENTAL|POEM|Endoscopic Myotomy
61955072|NCT04580069|EXPERIMENTAL|Lymphatic drainage|Patients subjected to manual lymphatic drainage
62701879|NCT00425620|EXPERIMENTAL|Amphotericin B|
61955073|NCT04580069|EXPERIMENTAL|Connective tissue|Patients subjected to connective tissue massage
61955074|NCT04580069|ACTIVE_COMPARATOR|control group|Subjects hat followed standard rehabilitative treatment
62142275|NCT06700122|ACTIVE_COMPARATOR|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) only|"* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler and a manual universal curette where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more will be done to preserve any residual fibers attached and to avoid unintentional curettage and prevent any possible shrinkage.~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* All teeth will be polished with a rubber cup. Photodynamic therapy will be done with a blue halogen curing light of wavelength 470 nm with intensity 620 mW/cm2, a continuous mode for 5 min.~* The photosensitizer will be applied to the bottom of the periodontal pocket with the help of an applicator. After 5 min, the photosensitizer will be rinsed with saline and will be exposed to on blue halogen curing light 0 day, which will be repeated on 7th and 21st day."
62344595|NCT03337139|ACTIVE_COMPARATOR|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
62344596|NCT03337139|EXPERIMENTAL|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
62344597|NCT03604237|EXPERIMENTAL|Targeted forceps biopsy|In this group, an endoscopist takes a forceps biopsy at depressed mucosa or large nodular area of large colorectal tumors after meticulous surface evaluation.
62701880|NCT01085903|ACTIVE_COMPARATOR|normal subjects|Normal subjects are persons without stroke who receive baseline, CPS, Post CPS and Follow up interventions.
61955075|NCT02717585|NO_INTERVENTION|Control Group|For the no intervention group (Control), patients will only receive standardized treatment for FM at the Pain Clinic. All patients will receive a multifaceted tailored regimen that incorporates one or more lines of pharmacological and/or non-pharmacological therapy. All assessment and management will be performed according to evidence-based therapeutic recommendations put forward by the Canadian Rheumatology Association and Canadian Pain Society.
61955076|NCT02717585|ACTIVE_COMPARATOR|Treatment Group (CPAP)|In addition to standard FM treatment at the Pain Clinic, patients who are randomized to the treatment will meet with a sleep physician for possible therapy with a Continuous Positive Airway Pressure (CPAP) machine. A CPAP titration study will be arranged for in a laboratory setting, where in addition to the regular parameters of a diagnostic sleep study, CPAP will be titrated upwards starting from 5cm H2O to an optimal setting where the obstructive respiratory events are abolished. Patients will undergo regular follow-up as determined by their sleep physician. Adherence to CPAP treatment will be recorded at follow-up visits.
61955077|NCT03909841||DM|DM without DPN (Diabetic Peripheral Neuropathy)
61955078|NCT03909841||DPN|DM with DPN (Diabetic Peripheral Neuropathy)
61955079|NCT03909841||DPN-P|DM with DPN-P (Diabetic Peripheral Neuropathic Pain)
62701881|NCT01085903|ACTIVE_COMPARATOR|stroke subjects|Stroke subjects are persons who have had a stroke affecting the right hemisphere and are subject to neglect or dysphagia who receive modafinil, placebo, baseline, CPS, Post CPS and Follow up interventions.
62701882|NCT01644331|EXPERIMENTAL|Tolvaptan|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)
61955080|NCT04214769||Head and Neck Cancer patients|
61955081|NCT00868985|EXPERIMENTAL|PEG 3350 plus electrolytes|Patients were dosed with PEG 3350 with electrolytes
61955082|NCT00868985|EXPERIMENTAL|PEG 3350 without electrolytes|Patients were dosed with PEG 3350 without electrolytes
61955083|NCT03733470|EXPERIMENTAL|Nonsusceptible Smokers (NS)|8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
62701883|NCT01644331|PLACEBO_COMPARATOR|Placebo|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)
61955084|NCT03733470|EXPERIMENTAL|Susceptible Smokers (SS)|11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume. For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
61955085|NCT03633656|EXPERIMENTAL|Treatment|Model predictive control recommendation of iron dosing in combination with an erythropoietic stimulating agent.
61955086|NCT06064812|EXPERIMENTAL|Part A: Dose Escalation of FWD1802 as a Monotherapy|"Part A study will be conducted in subjects diagnosed with ER+/HER2- unresectable locally advanced or metastatic breast cancer.~A maximum of 27 subjects will be enrolled. They will be sequentially allocated to 5 planned dose cohorts: 25 mg, 75 mg, 150 mg, 300 mg and 450 mg.~Subjects enrolled will be orally administered a single dose of FWD1802 Tablet on C0D1, followed by a 3-day observation period. Starting on C1D1, FWD1802 Tablet will be orally administered continuously QD for 28 consecutive days of each cycle. The DLT observation period is set as 32 days(C0D1-C1D28). The second cycle and subsequent cycles will last for 28 days per cycle. The patients will continue to receive the study treatment until PD, death, unacceptable toxicity, withdrawal of informed consent, or other reasons to discontinue study treatment occurs, whichever comes first."
61955087|NCT06064812|EXPERIMENTAL|Part B- Dose Escalation of FWD1802 in combination with palbocilib|"The dose expansion study will be conducted in approximately 12 eligible subjects diagnosed with ER+/HER2- unresectable locally advanced or metastatic breast cancer, to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of FWD1802 in combination with palbocilib.~The starting dose level for Part B study will be determined by SMC based on safety data (including the AE rate of non-DLT) , PK, PD and preliminary efficacy in Part A. Every treatment cycle consists of 28 days.~In brief, based on the available data obtained from Part A, 1 to 2 dose levels may be selected as the recommended dose levels (RDs) to evaluate FWD1802 in combination with palbocilib in these patients."
61955088|NCT06064812|EXPERIMENTAL|Part C - Dose Expansion Study|"Part C (Dose Expansion of FWD1802 as a Monotherapy) can be conducted in parallel with Part A provided that the following two conditions are met:~1. The starting dose of Part C study should be lower than the dose of monotherapy RP2D or the dose that has been explored and confirmed as safe for monotherapy.~2. The SMC will review all available PK, PD, safety, tolerability and efficacy data for Part A study and decide whether the study may proceed to Part C portions.~The dose expansion study will be conducted in approximately 60 eligible subjects diagnosed with ER+/HER2-/ESR1 mutation unresectable locally advanced or metastatic BC, to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of FWD1802 Tablet at the recommended 1\~2 dose level(s) for expansion."
61955089|NCT06046885|EXPERIMENTAL|Electricalstimulation|
61955090|NCT02996513|EXPERIMENTAL|Retinol Isotope dilution (RID)|A once-off dose of 0.4 mg 13C4-retinyl acetate will be administered to subjects as a capsule
62142276|NCT06700122|EXPERIMENTAL|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D|"* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler and a manual universal curette where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more will be done~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* All teeth will be polished with a rubber cup. Photodynamic therapy will be done with a blue halogen curing light of wavelength 470 nm with intensity 620 mW/cm2, a continuous mode for 5 min.~* The photosensitizer will be applied to the bottom of the periodontal pocket with the help of an applicator. After 5 min, the photosensitizer will be rinsed with saline and will be exposed to on blue halogen curing light 0 day, which will be repeated on 7th and 21st day. Serum vitamin D levels will be assessed by blood sample at baseline and 6 weeks after intervention in test group."
62142277|NCT04988542|EXPERIMENTAL|Sleep supplement|Circadian Wellness sleep SL strip nightly for 30 days.
62142278|NCT04988542|PLACEBO_COMPARATOR|Control Group|Participants in the control group will have no intervention and no change in their usual daily routine or supplements. They will be asked to not take any sleep aid supplement during the study period.
62142279|NCT02553889|EXPERIMENTAL|PK Cohort|A 4-week screening period followed by a 4-week treatment period followed by a 6-week post-treatment evaluation period. Treatment period includes 1 dose of 300 mg ISIS 416858 on Day 1 and again on Day 29. Both doses of Study Drug will be administered subcutaneously (SC).
62344598|NCT03604237|NO_INTERVENTION|Conventional forceps biopsy|In this group, an endoscopist takes a forceps biopsy at the most convenient area of large colorectal tumors.
62344599|NCT02771652|ACTIVE_COMPARATOR|e-training intervention|Resistance and endurance training
62344600|NCT02771652|OTHER|Control|no exercise
62344601|NCT01527227||children of mentally ill|This research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population
61955091|NCT01555450|EXPERIMENTAL|With Patient Navigator|People in this arm receive the Intervention of a Patient Navigator
61955092|NCT01555450|NO_INTERVENTION|Control - Without Patient Navigator|People in this arm receive just the usual care of colorectal cancer screening
61955093|NCT06504940|EXPERIMENTAL|Cohort A|For individuals under 70 years of age with good fitness,
61955094|NCT06504940|EXPERIMENTAL|Cohort B|For individuals aged 70 or older or those under 70 years with poor fitness
62344602|NCT02871193|SHAM_COMPARATOR|Group C（Control）|Group C received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml combined with general anesthesia and intravenous patient controlled analgesia pump.
62344603|NCT02871193|EXPERIMENTAL|Group R(Ropivacaine)|Group R received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20 ml combined with general anesthesia and intravenous patient controlled analgesia pump.
62701884|NCT02966548|EXPERIMENTAL|Monotherapy|Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
62701885|NCT02966548|EXPERIMENTAL|Combination Therapy|Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation
61955095|NCT00258869||1|Emergency department patients with sepsis
61955096|NCT05209425|ACTIVE_COMPARATOR|Regular Vitamin D3 1000IU|The first group receives regular Vitamin D3 1000IU
61955097|NCT05209425|ACTIVE_COMPARATOR|Microencapsulated Vitamin D3 1000IU|The second group receives microencapsulated Vitamin D3 1000IU
61955098|NCT05209425|ACTIVE_COMPARATOR|Regular Vitamin D3 2500IU|The third group receives regular Vitamin D3 2500IU
62142280|NCT02553889|PLACEBO_COMPARATOR|Cohort A|"Patients in Cohort A will be randomized to receive either 200 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort A, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort A will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
62142281|NCT02553889|PLACEBO_COMPARATOR|Cohort B|"Patients in Cohort B will be randomized to receive either 300 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort B, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort B will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
62344604|NCT02871193|EXPERIMENTAL|Group D(Dexamethasone)|Group D received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg combined with general anesthesia and intravenous patient controlled analgesia pump.
62344605|NCT03353753|ACTIVE_COMPARATOR|Arm 1|150 mg QD DCC-2618
62344606|NCT03353753|PLACEBO_COMPARATOR|Arm 2|Placebo
61955099|NCT05209425|ACTIVE_COMPARATOR|Microencapsulated Vitamin D3 2500IU|The fourth group receives microencapsulated Vitamin D3 2500IU
62142282|NCT05626374|ACTIVE_COMPARATOR|Basic case management|Basic case management with bi-weekly meetings between case manager and trainees that includes check-ins, frequent visits to construction sites and monitoring of feedback forms from mentors. Case managers attempt to connect trainees with external support services as needed.
62142283|NCT05626374|EXPERIMENTAL|Basic case management supplemented by self-reporting distress tool (DT)|Basic case management plus access to the self-report daily distress tool. The trainees are provided web-based access to the daily distress tool and report their distress levels using a validated visual analog scale (Distress Thermometer), along with reporting their risk of missing work/class or dropping out of the program. The case manager responds to the distress tool by coordinating external support services as needed.
62142284|NCT05626374|EXPERIMENTAL|Basic case management supplemented by rapid access healthcare services|Basic case management supplemented by a fit-for-purpose rapid referral process for trainees with active mental health and/or substance use disorders affecting their program participation.
62142285|NCT05626374|EXPERIMENTAL|Basic case management supplemented by DT and rapid access healthcare services|Basic case management supplemented by both the self-report distress tool and rapid referral process for those trainees at-risk of program absence or drop-out from either mental health or addictions issues.
62142286|NCT03926026|EXPERIMENTAL|NCX 4251 QD|NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
62344607|NCT04102735|ACTIVE_COMPARATOR|Over-the-nose facemask|The AF541 oro-nasal mask is used with the over-the-nose mask cushion.
62344608|NCT04102735|EXPERIMENTAL|Under-the-nose facemask|The AF541 oro-nasal mask is used with the under-the-nose mask cushion.
62344609|NCT04899713||Experimental group (neo-adjuvant chemotherapy combined with ZOMETA®) (zoledronic acid)|Patients treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : zoledronic acid 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with zoledronic acid 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
62344610|NCT04899713||Control group (neo-adjuvant chemotherapy alone)|Patients treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
62344611|NCT00174785|EXPERIMENTAL|Dronedarone 400mg bid|Dronedarone 400mg tablets twice daily (bid)
61955100|NCT01626456|EXPERIMENTAL|ALKS 9072, Low|
61955101|NCT01626456|EXPERIMENTAL|ALKS 9072, High|
61955102|NCT03485339||Case|Ketamine user with psychotic disorders
61955103|NCT03485339||Control Group 1|Ketamine user without psychotic disorders
61955104|NCT03485339||Control Group 2|Non-ketamine-using drug user with psychotic disorders
61955105|NCT03485339||Control Group 3|Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system)
61955106|NCT04263220|EXPERIMENTAL|Prototype exoskeleon 1|The experimental trial will be performed with the prototype exoskeleton
61955107|NCT04263220|EXPERIMENTAL|Prototype exoskeleon 2|The experimental trial will be performed with the prototype exoskeleton
61955108|NCT04263220|EXPERIMENTAL|No exoskeleton|The experimental protocol will be performed without exoskeleton.
61955109|NCT04600557|EXPERIMENTAL|Self-compassion only|Describing a shameful experience using a self-compassionate prompt and receiving no verbal responses from confederates
61955110|NCT04600557|EXPERIMENTAL|Compassion from others only|Describing a shameful experience using a neutral prompt and receiving compassionate responses from confederates
61955111|NCT04600557|EXPERIMENTAL|Self-compassion plus compassion from others|Both describing a shameful experience using a self-compassionate prompt and receiving compassionate responses from confederates
61955112|NCT04600557|ACTIVE_COMPARATOR|Sharing-only control|Describing a shameful experience using a neutral prompt and receiving no verbal responses from confederates
61955113|NCT02959307|EXPERIMENTAL|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
62142287|NCT03926026|PLACEBO_COMPARATOR|Placebo QD|Placebo once daily for 14 days
62142288|NCT03926026|EXPERIMENTAL|NCX 4251 BID|NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
62142289|NCT03926026|PLACEBO_COMPARATOR|Placebo BID|Placebo twice daily for 14 days
62344612|NCT00174785|PLACEBO_COMPARATOR|Placebo|matching placebo tablets
62344613|NCT04312438|EXPERIMENTAL|13 mo to 15 yo children diagnosed with Cow's Milk Allergy|oral food challenge with cow's milk proteins
61955114|NCT02959307|SHAM_COMPARATOR|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
61955115|NCT03460821||Employees|Male and female employees (≥ 18 years of age) of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité Universitätsmedizin Berlin experienced in the field of neurocognitive testing: residents, specialist physician for anesthesiology, senior physicians, medical students engaged in research projects
61955116|NCT01434667|ACTIVE_COMPARATOR|APOE Genotype Non-Disclosure|Subjects will receive Alzheimer's disease risk disclosure. This assessment is based on age and MCI status alone.
61955117|NCT01434667|EXPERIMENTAL|APOE Genotype Disclosure|Subjects will receive both APOE genotype and Alzheimer's disease risk disclosure. The assessment is based on age, MCI status, and genotype.
61955118|NCT03746652|EXPERIMENTAL|DId|Daratumumab, Ixazomib, Dexamethasone
61955119|NCT05459038|EXPERIMENTAL|Interventional group|Patients assigned to the interventional group will undergo an identical surgical procedure as patients assigned to the control group. The only difference with the control group is that tibial alignment will be obtained according to the standardized CARV-protocol.
61955120|NCT05459038|NO_INTERVENTION|Control group|Patients assigned to the control group will undergo an identical surgical procedure as patients assigned to the interventional group. The only difference with the intervention group is that tibial alignment will be obtained according to present unstandardized clinical standards
62142290|NCT03661463|EXPERIMENTAL|Aspirin|Aspirin (Acetylsalicylic Acid \[ASA\]) tablets, 300mg once a day, for 90 days.
62344614|NCT06195826||gravity infusion|women who received hysteroscopic myomectomy with gravity infusion method
62344615|NCT06195826||pump infusion|women who received hysteroscopic myomectomy with pump infusion method
62344616|NCT01843400||Group 1|
62344617|NCT03665428|EXPERIMENTAL|PAMB group|PAMB treatment (modified quadruple therapy) for 14 days
62344618|NCT03665428|ACTIVE_COMPARATOR|PMBT group|PBMT treatment (bismuth-containing quadruple therapy) for 14 days
61955121|NCT04946383|EXPERIMENTAL|Quercetin and Dasatinib supplements|500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.
61955122|NCT06267105|EXPERIMENTAL|Longitudinal incision|Incision performed longitudinally
61955123|NCT06267105|EXPERIMENTAL|Transverse incision|Incision performed transversally
62142291|NCT03661463|NO_INTERVENTION|No Treatment|No medical treatment
62142292|NCT04378894|EXPERIMENTAL|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
62344619|NCT03497234|EXPERIMENTAL|All women eligible to participate|All women presenting who sign the consent and found eligible will have a VF and AF sample taken and analyzed on the Perilynx Analyzer to measure AF and VF fluid. This does not affect their regular standard of care and diagnosis
62344620|NCT02466568|EXPERIMENTAL|Phase I and Phase II Treatment Arm|Participants will receive nivolumab and GM.CD40L. Treatment will be administered on an outpatient basis. The nivolumab will be given first followed by the GM.CD40L vaccine for those enrolled on this arm.
62344621|NCT02466568|ACTIVE_COMPARATOR|Phase II Control Arm|Nivolumab treatment without GM.CD40L. Nivolumab will be given every 2 weeks at a dose of 3mg/kg.
62344622|NCT03811717|EXPERIMENTAL|FAST+EX - FAST|FAST+EX then FAST alone
62344623|NCT03811717|EXPERIMENTAL|FAST - FAST+EX|FAST alone then FAST+EX
62344624|NCT00289185|EXPERIMENTAL|RTS,S/AS02D Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of the RTS,S/AS02D vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
62344625|NCT00289185|ACTIVE_COMPARATOR|Engerix-B Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh..
62344626|NCT01293149|EXPERIMENTAL|Ropivacaine plus clonidine|Ropivacaine plus clonidine for femoral block
62344627|NCT01293149|ACTIVE_COMPARATOR|Ropivacaine|Ropivacaine alone for femoral block
62344628|NCT06170801|EXPERIMENTAL|Kiesler Circle Training (KCT) + Cognitive Behavioral Therapy (CBT)|The Kiesler Circle Training (KCT) consists of 12 weekly group sessions of 100 minutes each (in a group of max. 10 patients). In addition, all patients receive weekly individual state-of-the-art CBT sessions (50 minutes each).
62344629|NCT06170801|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|The patients receive weekly individual state-of-the-art CBT sessions (50 minutes each).
61955124|NCT03138603|EXPERIMENTAL|Metoprolol|Metoprolol group, 3-intravenous doses of 5mg metoprolol tartrate (over 15-minutes), and oral dose(s) of 25mg metoprolol approximately every 8 hours postoperatively for up to 3-days (or 72 hrs).
61955125|NCT03138603|PLACEBO_COMPARATOR|Placebo|Placebo comparator group, up-to-three intravenous doses of placebo comparator (over 15-minutes), and oral dose(s) of a placebo comparator approximately every 8 hours postoperatively for up to 3-days (or 72 hrs).
61955126|NCT05367622|EXPERIMENTAL|Continuous glucose monitoring group|Self-regulation model of health education will be given for 1-1.5 hrs and telecommunication 10 to 15 minutes for 7 days
61955127|NCT05367622|PLACEBO_COMPARATOR|Self-monitoring of blood glucose group|Usual diabetes health education will be given for 1 hr.
62142293|NCT04378894|ACTIVE_COMPARATOR|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Families in the wait-listed control group will participate in a special awareness program but not MOCEP. Although the families in the wait-listed control group will start as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
61955128|NCT04468854|EXPERIMENTAL|Experimental intervention|In the experimental phase we will administer 500 mg Luteolin (2x250 mg capsules) per day formulated for oral administration for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning). The last intake on visits 2 resp. 4 is important as the participants then have to recall the learned material from visits 1 resp. 3 during a steady-state status of Luteolin.
62701886|NCT05913674|EXPERIMENTAL|mEPIC|Adults (male and female) with a diagnosis of appendicular or colorectal cancer with peritoneal carcinomatosis will undergo mEPIC on post-operative days 1 and 2 following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
61955129|NCT04468854|PLACEBO_COMPARATOR|Control Intervention|Control intervention consists of identical looking placebo capsules containing mannitol formulated for oral administration to be taken twice daily (e.g. every morning and evening) for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning) with water.
61955130|NCT01489800|EXPERIMENTAL|Early Feeding|Introduction of clear liquid diet 24 hours after extubation with advancement to regular diet 24 hours thereafter if there is no significant nausea or vomiting.
62701887|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
61955131|NCT01489800|NO_INTERVENTION|Control Feeding|Standard of care with introduction of clear liquid diet at time of return of bowel function as determined by flatus. Advancement to full diet 24 later if clear diet well tolerated.
61955132|NCT05332197|EXPERIMENTAL|17D Yellow fever vaccine|"All children will receive a single shot of the 17D Yellow fever vaccine. This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. This vaccine is presented as a 10 dose vial with freeze-dried content which is reconstituted with a diluent, provided with the vaccine by the manufacturer. Reconstituted vaccines have to be kept in a vaccine carrier at 2-8°C as per WHO and manufacturer requirements. Any remaining reconstituted vaccine not used has to be discarded after 6 h. The standard dose is 0·5 ml and is administered subcutaneously in the deltoid region using standard vaccination syringes (needle size 25G × 3/4) with a 45° injection angle"
61955133|NCT00875875|ACTIVE_COMPARATOR|1|This is the approved treatment regimen for travelers' diarrhea (600 mg)
61955134|NCT00875875|ACTIVE_COMPARATOR|2|This is the same dose as the standard dose, given once daily (200 mg)
61955135|NCT05478369|EXPERIMENTAL|storybook|anxiety and fear
62142294|NCT05449366|EXPERIMENTAL|Treatment arm|According to standard of care work-up for CRS-HIPEC, patients will undergo diagnostic laparoscopy to determine the feasibility of complete cytoreduction with HIPEC. In case CRS-HIPEC is not considered feasible, a peritoneal port-a-cath (PAC) system will be placed. Through this PAC, 8-16 weekly cycles of intraperitoneal chemotherapy will be administered.
62344630|NCT01883934|EXPERIMENTAL|Enhanced clinic-based support/counseling|Scheduling a consult with a licensed social worker to discuss embryo disposition options. Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
62344631|NCT01883934|ACTIVE_COMPARATOR|Patients receiving standard of care|Patients who receive standard of care regarding embryo disposition options
61955136|NCT05478369|NO_INTERVENTION|control|not anxiety and fear
62142295|NCT00387075|EXPERIMENTAL|[123I]β-CIT and SPECT imaging|To Assess \[123I\]β-CIT and SPECT imaging
62142296|NCT05437666|EXPERIMENTAL|Education group|The education program was given both an educational presentation and a booklet related to the pelvic floor health
62142297|NCT05437666|OTHER|Control group|The control group will be given a booklet related to the pelvic floor health
62344632|NCT04656444||phone call to emergency department|
62344633|NCT04255836|EXPERIMENTAL|Durvalumab therapy|Chemo+Durvalumab (PD-L1 monoclonal antibody)1500 mg every 3 weeks \[q3w\] intravenously \[iv\] for 4 cycles, then SBRT 50-60 Gy/≤10f + Durvalumab 1500 mg q4w, then Durvalumab 1500 mg q4w for up to 24 months or until progression or other discontinuation criteria are met.
62344634|NCT05908812||Sarcopenic obesity|BMI\>30, bioelectric impedance positive for sarcopenic obesity (FM% \[fat mass percentage\] female \>43%, male \>31% AND SMM/W \[skeletal muscle mass/weight\] female \<28%, male \<37%), any one of the physical performance test positive (5-times chair stand test \>17 s OR handgrip strength test \<35,5 kg for males, \<20 kg for females).
62344635|NCT05908812||Non-sarcopenic obesity|BMI\>30, bioelectric impedance negative for sarcopenic obesity.
62502408|NCT05577494||Clinician interviewers|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 30 clinicians are recruited in total (10 in each clinical institution). Each clinical institution shall select 2-3 interviewers, who shall participate in interview consistency training. Semi-structured interviews are conducted with the enrolled clinicians using the Clinician Interview Guide. The interview process needs to be recorded, and the interview results need to be qualitatively analyzed.
62502409|NCT05577494||Outpatients with MDD:|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 600 patients with MDD are recruited in outpatient clinics (200 in each institution). The patient questionnaire will be completed online. The enrolled patients need to conduct an online questionnaire survey and complete the Patient Questionnaire. Finally, the survey results need to be qualitatively analyzed.
62701888|NCT01021527|EXPERIMENTAL|Treatment Sequence 1|A-B-C-C
62701889|NCT01021527|EXPERIMENTAL|Treatment Sequence 2|B-C-A-C
62701890|NCT01021527|EXPERIMENTAL|Treatment Sequence 3|C-A-B-C
62701891|NCT01021527|EXPERIMENTAL|Treatment Sequence 4|A-C-B-C
62701892|NCT01021527|EXPERIMENTAL|Treatment Sequence 5|B-A-C-C
62701893|NCT01021527|EXPERIMENTAL|Treatment Sequence 6|C-B-A-C
61955137|NCT04307303|EXPERIMENTAL|Abdominal functional electrical stimulation|
61955138|NCT04307303|SHAM_COMPARATOR|Low dose abdominal functional electrical stimulation arm|
61955139|NCT05648383|EXPERIMENTAL|Pre-diabetes group, mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
61955140|NCT05648383|EXPERIMENTAL|Diabetes group, mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
62142298|NCT06379516|ACTIVE_COMPARATOR|Moisturising Cream A|
61955141|NCT05648383|ACTIVE_COMPARATOR|Prediabetes group, control|Participants will receive standard care, including lifestyle recommendations
61955142|NCT05648383|ACTIVE_COMPARATOR|Diabetes group, control|Participants will receive standard care, including lifestyle recommendations
61955143|NCT04432285||Deep Brain Stimulation (GPi-DBS)|Patients with cervical dystonia (CD) who were operated at Oslo University Hospital between June 2004 and December 2017 with a DBS-device targeting the GPi bilaterally, and who have been treated with chronic GPi-DBS for a minimum of 3 years.
61955144|NCT04432285||Botulinum toxin treatment|CD patients who for a minimum of 3 years have received treatment with botulinum neurotoxin (BoNT) injections at regular intervals (minimum 12 injection cycles) and still are receiving them (Age- and gender matched to the GPi-DBS group)
61955145|NCT01785069|EXPERIMENTAL|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
61955146|NCT01785069|EXPERIMENTAL|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
61955147|NCT01785069|EXPERIMENTAL|Revision-Augmentation|Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.
61955148|NCT01785069|EXPERIMENTAL|Revision-Reconstruction|Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.
61955149|NCT06045884|EXPERIMENTAL|FNB|sono-guided femoral nerve injection with 20ml ropivacaine
61955150|NCT06045884|PLACEBO_COMPARATOR|No FNB|sono-guided femoral nerve injection with 20ml 0.9% saline
62142299|NCT06379516|ACTIVE_COMPARATOR|Moisturising Cream B|
62142300|NCT06379516|PLACEBO_COMPARATOR|Test Oil|
62701894|NCT03145220|ACTIVE_COMPARATOR|EA-230|Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
62502410|NCT05577494||Patients with MDD receiving focus group discussion|Each center will hold 1-2 focus group symposiums for 8-10 patients according to the Patient Focus Group Symposium Manual. The content of the symposium needs to be recorded and written. Finally, the interview results need to be qualitatively analyzed.
62142301|NCT06379516|NO_INTERVENTION|Untreated|
62142302|NCT05964426||Parent and Infant Information Form|This form consists of a total of 19 questions in line with the literature, including the parents' age, education level, family type, place of residence, whether they have other children, how many days their baby is, gender of the baby, maternal blood type, paternal blood type, and whether the baby is given formula in addition.
62502411|NCT05858775||Nulliparous cohort|Nulliparous pregnant woman
62701895|NCT03145220|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of NaCl (equivalent osmolarity with active intervention EA-230). Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
62701896|NCT00601367|EXPERIMENTAL|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
62701897|NCT00775658|ACTIVE_COMPARATOR|olopatadine then placebo|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
61955151|NCT05666609|ACTIVE_COMPARATOR|Group 4weeks|Duration of placed seton 4 weeks
61955152|NCT05666609|ACTIVE_COMPARATOR|Group 12weeks|Duration of placed seton 12 weeks
61955153|NCT01095055|EXPERIMENTAL|Group 1|AdCh63 AMA1
61955154|NCT01095055|EXPERIMENTAL|Group 2|AdCh63 AMA1 followed by MVA AMA1
61955155|NCT03787732|ACTIVE_COMPARATOR|Fluid Bolus|For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
61955156|NCT03787732|ACTIVE_COMPARATOR|No Fluid Bolus|For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
61955157|NCT02542904|ACTIVE_COMPARATOR|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
61955158|NCT02542904|ACTIVE_COMPARATOR|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
61955159|NCT03716037|EXPERIMENTAL|Physical Activity|Physical Activity for Life (PAL) is an 8-week exercise program, meeting three times per week for one hour sessions.
61955160|NCT03716037|NO_INTERVENTION|Contact Control|those in the attentional contact control group will receive a phone call from research personnel three times per week asking them about their physical exercise routines.
61955161|NCT01634009|ACTIVE_COMPARATOR|Standard RUTF (control)|Children will receive standard RUTF in this arm and will be considered as control arm
62502412|NCT05858775||Multiparous cohort|Multiparous pregnant woman
62502413|NCT01027403||Healthy volunteers|
62502414|NCT01027403||Acute decompensated heart failure|
62502415|NCT02020967||Acromegaly patients|
61955162|NCT01634009|NO_INTERVENTION|Standard RUTF|Will act as control
61955163|NCT01392443|EXPERIMENTAL|Ruxolitinib|Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count \>200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.
61955164|NCT06245031|EXPERIMENTAL|Active|All subjects will receive a device with Active settings for use daily at home for 60-minutes for 12 months.
61955165|NCT03399721|ACTIVE_COMPARATOR|Chordate S101 Active|Active treatment With Device Chordate S101
61955166|NCT03399721|PLACEBO_COMPARATOR|Chordate S101 Placebo|Placebo treatment With Device Chordate S101
61955167|NCT00730769|EXPERIMENTAL|Single arm|Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
61955168|NCT00786734|EXPERIMENTAL|Pitavastatin Group|
61955169|NCT00786734|OTHER|Usual Care Group|
61955170|NCT05633823|EXPERIMENTAL|Game group|Children and parents will be introduced to mobile application game training and they will be provided to download the application to their mobile device or tablet. The data collection forms will be applied again immediately after the children complete each part of the game, 4 months and 6 months after the training.
61955171|NCT05633823|NO_INTERVENTION|Control group|No application will be made to children and parents, and the forms will be re-applied 4 months and 6 months after the first application of the data collection forms.
61955172|NCT02116946|EXPERIMENTAL|Leukocyte-rich Platelet Rish Plasma + exercise|Leukocyte-rich PRP injection and a 12 week exercise program.
61955173|NCT02116946|EXPERIMENTAL|Leukocyte-poor Platelet Rich Plasma + exercise|Leukocyte-poor PRP injection and a 12 week exercise program.
61955174|NCT02116946|PLACEBO_COMPARATOR|Saline + exercise|Saline injection and a 12 week exercise program.
61955175|NCT03282643|EXPERIMENTAL|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
61955176|NCT03282643|EXPERIMENTAL|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
61955177|NCT03282643|ACTIVE_COMPARATOR|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
61955178|NCT02998567|EXPERIMENTAL|Escalation|Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
61955179|NCT02998567|EXPERIMENTAL|Expansion|Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
61955180|NCT02998567|EXPERIMENTAL|B2: Lung Expansion|To further explore the safety and activity of the combination of ASTX727 (replacement of guadecitabine to an oral dose tablet) with pembrolizumab in patients with NSCLC with primary or secondary resistance to PD-1/PD-L1 inhibitors.
62701898|NCT00775658|ACTIVE_COMPARATOR|placebo then olopatadine|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
62701899|NCT04167735|ACTIVE_COMPARATOR|Hearing Aid without Reverberation Canceller (no_RevC)|Hearing Aid without Reverberation Canceller (RevC)
62701900|NCT04167735|EXPERIMENTAL|: Hearing Aid Reverberation Canceller enabled (RevC_1)|Hearing Aid Reverberation Canceller enabled (RevC_1)
62701901|NCT05573672|EXPERIMENTAL|Immediate Start|Dietary Counselling (7 bi-weekly sessions) plus omega-3 supplementation
61955181|NCT03787264|EXPERIMENTAL|BAAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated~Induction: 6 cycles (q 28d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance treatment will be continued until (whichever occurs first):~* 12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity~* maintenance cycle 8~* progression of CLL or start of a subsequent therapy~* unacceptable toxicity"
61955182|NCT05744284||Sex, age, kind of disease in relation to the organ affected|Sex, age, kind of disease in relation to the organ affected and type of surgical procedure and related incision have been investigated. Patients with diabetes mellitus, coagulation disorders and those submitted to a treatment of steroids and anticoagulant; patients previously operated with scar in the site of the second operations, or with anemia or with active source of infection in any part of the body where excluded from the study.
61955183|NCT05901428|EXPERIMENTAL|TCb arm|Chemotherapy: Intensive intravenous dose of docetaxel (75 mg/m2) + intravenous (IV) carboplatin \[area under the curve (AUC) =5-6\] repeated administration of Q3W for a total of 6 doses
61955184|NCT05901428|ACTIVE_COMPARATOR|EC-T arm|Chemotherapy: Intensive intravenous dose of epirubicin (80-90 mg/m2) + IV cyclophosphamide (600 mg/m2) repeated administration of Q3W for a total of 4 doses, followed by (IV) docetaxel (80 mg/m2) (Q3W) for 4 doses
61955185|NCT02702804|EXPERIMENTAL|High Intensity Interval Training|Participants will attend two sessions per week for the 6 week intervention. Each session will consist of 6-10 sets of 60 second high intensity intervals interspersed with 60 seconds recovery. The workload during each interval will be set at 80-90% of peak power achieved during the VO2peak test. This is predicted to elicit 85-95% heart rate reserve in the participants. After each interval the participant's heart rate and rate of perceived exertion (RPE) will be collected. After each session a researcher will complete an Adverse Event form to record if an event occurred or not. Additionally the participant will complete a physical activity enjoyment (Perceived activity enjoyment scale) after one session per week.
61955186|NCT02951065|EXPERIMENTAL|Bristle-less brush|Subjects will be assigned to use a bristle-less manual tooth brush with short, rubbery cones for one year twice daily
61955187|NCT02951065|ACTIVE_COMPARATOR|Soft bristle brush|Subjects will be assigned to use a soft, nylon-bristled tooth brush for one year twice daily
61955188|NCT06556446||DOAC+IVT|Acute ischemic Stroke patients with recent DOACs intake receive IVT.
61955189|NCT06556446||DOAC|Acute ischemic Stroke patients with recent DOAC intake do not receive IVT.
61955190|NCT06556446||IVT Controls|Acute ischemic Stroke patients without recent DOAC intake receive IVT.
62701902|NCT05573672|NO_INTERVENTION|Waitlist Control|Participants will wait 12 weeks and then complete the same intervention as the Immediate Start arm.
61955191|NCT01671800|EXPERIMENTAL|Botulinum Type B (Myobloc)|Each vial of active drug will contain 5000 unit/ml of Myobloc, with a total volume of 1 mL. The injections will be spaces 6 cm apart and will cover the entire area to be injected. Each site will receive a volume of 0.08 ml (400 units).
61955192|NCT01671800|PLACEBO_COMPARATOR|Saline solution|The volume to be injected will be calculated assuming the injectate is an active drug, and will therefore be an equivalent volume as an active drug (i.e. 0.08 mL per injection site with a 6 cm spacing interval)
62701903|NCT04118764|EXPERIMENTAL|Focused ultrasound treatment|Neuronavigation-guided focused ultrasound treatment in Alzheimer's disease patients using a single-element transducer in conjunction with Definity Microbubbles (10 μl/kg).
62701904|NCT04986150|EXPERIMENTAL|Milk Protein|4 daily 20-gram doses of milk protein (dairy yoghurt) consumed for 4 consecutive days after the exercise bout
62701905|NCT04986150|PLACEBO_COMPARATOR|Placebo|4 daily doses of low-protein placebo product (oat-based yoghurt) consumed for 4 consecutive days after the exercise bout
62344636|NCT02387372|EXPERIMENTAL|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Those with Creatinine clearance (CLCR) \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
62344637|NCT02387372|EXPERIMENTAL|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
62502416|NCT06677814||Training cohort|This cohort data will be used to screen for independent risk factors for anxiety disorders in patients with premature ejaculation and to initially construct a risk prediction model.
62344638|NCT05539105||Double tract reconstruction|Double tract reconstruction would be applied after proximal gastrectomy
62701906|NCT00800644||Evaluation Group|Bone Mineral Density Test + MRI or CT + Blood Test
62701907|NCT03524599|EXPERIMENTAL|Intervention municipality|In the intervention municipalities, primary health care providers will receive ongoing training and support in undertaking screening and brief advice for heavy drinking. They will also receive community-based five adoption mechanisms and five support systems.
62701908|NCT03524599|NO_INTERVENTION|Comparator municipality|In the comparator municipalities, the primary health care providers will be given a summary card of screening and brief advice for heavy drinking, with no instruction
62701909|NCT00756340|EXPERIMENTAL|1|"* Dose Level 0, Bevacizumab IV every 2 weeks 8 mg/kg, Everolimus 4 mg/m\^2~* Dose Level 1 (starting dose), Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 4 mg/m\^2~* Dose Level 2, Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 5 mg/m\^2"
62701910|NCT01868412|EXPERIMENTAL|Resin & honey|Abilar 10% resin salve
62701911|NCT01868412|ACTIVE_COMPARATOR|Resin vs. honey|Activon Tube 25 g
61955193|NCT02885103|PLACEBO_COMPARATOR|inhalation with nebulizer|inhalation with an nebulizer via mouth
61955194|NCT02885103|ACTIVE_COMPARATOR|inhalation with nebulizer and NHF|inhalation with combination of nebulizer and nasal high flow (NHF) via nasal cavity
61955195|NCT05164185|ACTIVE_COMPARATOR|Ischemia reperfusion +remote ischemic conditioning|Active administration of short cykcles of ischemia.
61955196|NCT05164185|SHAM_COMPARATOR|Ischemia reperfusion +sham|Placebo experiment without remote ischemic conditioning.
61955197|NCT01698515||Anti-TNF subgroup|"anti - TNF subgroup~20 subjects with RA, who are starting TNF inhibitors based on the decision of their treating rheumatologist, will be recruited from the clinic. Patients will be starting commercially available anti-TNF agents that have already been authorized for insurance coverage. We are not requesting anti-TNFs or other drugs specifically for patients enrolled in this study from any pharmaceutical company. Patients will also continue on their background MTX and corticosteroids if they are taking these agents, and MTX will be required for patients taking Infliximab or Golimumab as per approved indication. No medications will be supplied through the study.~--------------------------------------------------------------------------------"
61955198|NCT05893576|EXPERIMENTAL|R group (reference formulation group)|
61955199|NCT05893576|EXPERIMENTAL|T group (test formulation group)|
61955200|NCT00886574|ACTIVE_COMPARATOR|Aspirin|Aspirin 100 mg once a day
62344639|NCT05539105||Gastric conduit reconstruction|Gastric conduit reconstruction would be applied after proximal gastrectomy
62344640|NCT05539105||Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after proximal gastrectomy
62344641|NCT04979949|ACTIVE_COMPARATOR|CoronaVac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
62344642|NCT04979949|EXPERIMENTAL|Turkovac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
62502417|NCT06677814||Validation cohort|This cohort data will be used to verify the performance and stability of the risk prediction model to ensure the promotion and use of the model.
62502418|NCT01198249|EXPERIMENTAL|amlodipine monotherapy|
62502419|NCT01198249|EXPERIMENTAL|losartan monotherapy|
62502420|NCT01198249|EXPERIMENTAL|HCTZ|
62502421|NCT01198249|EXPERIMENTAL|mlodipine and Losartan and HCTZ|
62502422|NCT00603512|PLACEBO_COMPARATOR|CP-690,550, 0mg|
62502423|NCT00603512|EXPERIMENTAL|CP-690,550, 10mg|
62502424|NCT00603512|EXPERIMENTAL|CP-690,550, 1mg|
62701912|NCT05005416|EXPERIMENTAL|GOALS Intervention|The experimental arm is an 8-week cognitive-behavioral based physical therapy (PT) intervention for chronic spine pain. The manualized intervention utilizes a hybrid tele-rehabilitation delivery model. GOALS comprises an initial in-person evaluation (60 min) by a research physical therapist, followed by 6 remote treatment sessions (30-45 min each) conducted by the same physical therapist once a week by telephone. A second in-person evaluation is conducted at the midpoint of the GOALS intervention to assess progress and advance the participant's home exercise program.
61955201|NCT00886574|ACTIVE_COMPARATOR|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
61955202|NCT02576002||Pediatric PAH patients|US pediatric population with PAH in MarketScan database during the period 2010-2013
61955203|NCT03873844|EXPERIMENTAL|CI Cognitive Therapy|The treatment will have 2 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily life.
62701913|NCT05005416|ACTIVE_COMPARATOR|Usual Care Physical Therapy|The control arm is Usual Care physical therapy (PT) at a local Federally Qualified Health Center (FQHC), which offers PT services at 4 outpatient clinics across San Diego county. Participants in the Usual Care group attend an initial PT evaluation at a FQHC Physical Rehabilitation Clinic. The frequency and type of PT intervention are then determined by the treating physical therapist in accordance with standard clinical practice at the FQHC.
62701914|NCT03990987||Day group|patients in Day group accept operation from 8：00～12：00
61955204|NCT01425996|EXPERIMENTAL|Lipotecan® (TLC388)|"Dosage form: 40mg TLC388 base/vial lyophilized cake Dose: Chemotherapy, i.v. q.w. x 6 doses (dose-escalation)~\* The dosage regimen would be escalated gradually until MTD had been found out."
61955205|NCT05111873||waiting-list control|Participants enquired prior to the treatment appointment in the neurological day clinic service, no intervention
62142303|NCT05964426||Parent Information Form on Neonatal Jaundice|This form consists of a total of 6 questions in line with the literature, including whether the parent has sufficient information about neonatal jaundice, from whom he/she received the information, what his/her reaction will be if his/her baby gets jaundice, and information about the causes, symptoms and side effects of jaundice.
62344643|NCT05843110|OTHER|Decision-making process|1 arm with 25 couples who had an isolated CCA announcement during pregnancy and who decided to continue the pregnancy and 25 couples who had an isolated CCA announcement during pregnancy and who decided to terminate the pregnancy
62344644|NCT03058172|OTHER|Odors (food and non-food)|Odorants diluted in mineral oil.
62344645|NCT03058172|OTHER|Pictures (food and non-food)|Pictures of objects or scenes.
62344646|NCT03355235||Cognitive assessment using standardized tools|cognitive assessment using standardized tools pre and post transplant.
62344647|NCT00589979|EXPERIMENTAL|Lidoderm (Lidocaine 5% Patch)|Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
62701915|NCT03990987||Night group|patients in Night group accept operation from 18：00～22：00
62701916|NCT02979119||Cohort I|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX \<1%) haemophilia A or B, born from January 1st 2000 until December 31st 2009 who have been or are to be treated with coagulation proteins in one of the participating centres
62701917|NCT02979119||Cohort II|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX \<1%) haemophilia A or B, born from January 1st 2010 until December 31st 2019 who have been or are to be treated with coagulation proteins in one of the participating centres
61955206|NCT05111873||post-treatment group|Participants enquired after the treatment in the Neurological day clinic service
61955207|NCT02647060||idiopathic pulmonary hypertension|"1. diagnose as idiopathic pulmonary arterial hypertension~2. clinical stable over 3 months~3. able to walk and can do bicycle cardiopulmonary exercise testing"
61955208|NCT02647060||secondary pulmonary hypertension|"1. diagnose as pulmonary hypertension~2. clinical stable over 3 months~3. able to walk and can do bicycle cardiopulmonary exercise testing"
61955209|NCT02362269|ACTIVE_COMPARATOR|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
61955210|NCT02362269|EXPERIMENTAL|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
61955211|NCT01301352|NO_INTERVENTION|Nasojejunal feeding (control)|
61955212|NCT01301352|EXPERIMENTAL|Nasogastric feeding (intervention)|
61955213|NCT02504840||healthy volunteers|healthy volunteers
61955214|NCT02504840||patient controls|Participants with diseases that share features with MS.
61955215|NCT02504840||patients with suspected or confirmed multiple sclerosis|Participants with definite, probable, or possible MS.
61955216|NCT03132818||Patients undergoing AMP with oocyte donation|
61955217|NCT03132818||Couples supported in AMP with sperm donation|
61955218|NCT03132818||Couples supported in AMP intra torque|
61955219|NCT01234948||Chronic periodontitis patients|Chronic periodontitis patients had at least one site per quadrant with clinical probing depth (CPD) \> 5mm and radiographic evidence of bone loss
61955220|NCT01234948||Generalised chronic gingivitis patients|Generalised chronic gingivitis patients presented with bleeding on probing (BOP) at \> 30% of sites, CPDs \< 4mm and no evidence of bone loss
61955221|NCT01234948||Periodontally healthy subjects|Healthy subjects had \< 10% sites with BOP and no sites with CPD \> 3mm
61955222|NCT00824720|EXPERIMENTAL|High Dose Device|device worn continuously for 14 days
61955223|NCT00824720|EXPERIMENTAL|Low Dose Device|device worn continuously for 14 days
62344648|NCT00589979|PLACEBO_COMPARATOR|Placebo Patch|Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
62344649|NCT01801722||NT-proBNP,ejection fraction ,COPD stage.|The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
62344650|NCT03522493|ACTIVE_COMPARATOR|Young group|This arm include 20 young subjects that will perform the same experiment as the old group for a comparison reasons.
62344651|NCT03522493|EXPERIMENTAL|Old group|This group us the group of interest. This group will wear the mask and is expected to show differences from the younger group.
62344652|NCT03287752||BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant.
62344653|NCT03287752||Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube ETT.
62502425|NCT00603512|EXPERIMENTAL|CP-690,550, 3mg|
61955224|NCT00824720|PLACEBO_COMPARATOR|Placebo Device|device worn continuously for 14 days
62502426|NCT00603512|EXPERIMENTAL|CP-690,550, 5mg|
61955225|NCT03996733|ACTIVE_COMPARATOR|GControl|Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.
61955226|NCT03996733|EXPERIMENTAL|GModel|"Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.~Participants in this group will also practice jugular vein puncture on our homemade jugular central venous catheterization training model."
61955227|NCT02981017|NO_INTERVENTION|Control|Subjects within the control arm will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, no Cook Biodesign Porcine intestinal submucosal graft will be used to cover the operative site. Light nasal packing will be placed in the nasal cavity for hemostasis. No placebo will be utilized.
62344654|NCT01695850|EXPERIMENTAL|MZRW|MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
62344655|NCT01695850|ACTIVE_COMPARATOR|Senna|Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
62344656|NCT01695850|PLACEBO_COMPARATOR|Placebo|Placebo MZRW and Placebo Senna
62344657|NCT02572895|ACTIVE_COMPARATOR|Optimal dose|One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
62344658|NCT02572895|PLACEBO_COMPARATOR|Control dose|One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
62701918|NCT02979119||Cohort III|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX \<1%) haemophilia A or B, born from January 1st 2020 until December 31st 2029 who have been or are to be treated with coagulation proteins in one of the participating centres
62701919|NCT03290027|EXPERIMENTAL|Active|DFD-03 (0.1% tazarotene) Lotion
62344659|NCT00773565|OTHER|Optifast|Patients included take part at a weight reduction program over one year.
62344660|NCT03116373|ACTIVE_COMPARATOR|maxilla fixing then mandible fixing|The tracheal tube is first fixed on the maxilla. After the measures of the outcomes, its site of fixation is changed for the mandible for the outcome measurement in the second site of fixation.
62344661|NCT03116373|ACTIVE_COMPARATOR|mandible fixing then maxilla fixing|The tracheal tube is first fixed on the mandible. After the measures of the outcomes, its site of fixation is changed for the maxilla for the outcome measurement in the second site of fixation.
62502427|NCT01652586|EXPERIMENTAL|dexmedetomidine-remifentanil|intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min
62502428|NCT01652586|ACTIVE_COMPARATOR|midazolam-remifentanil|remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg
62502429|NCT02715232|EXPERIMENTAL|Female-to-Males|Female-to-Male Transsexuals receiving Testosterone treatment
62502430|NCT02715232|EXPERIMENTAL|Male-to-Females|Male-to-Female Transsexuals receiving Estradiol and Anti-androgen treatment
62502431|NCT02715232|NO_INTERVENTION|Female Controls|Female Controls receiving no intervention
62502432|NCT02715232|NO_INTERVENTION|Male Controls|Male controls receiving no intervention
62502433|NCT01245842|NO_INTERVENTION|Usual care|
62502434|NCT01245842|EXPERIMENTAL|Exercise group|
62502435|NCT01785394|ACTIVE_COMPARATOR|5 grass allergen extract|30 patients will receive the active component 5 grass allergen extract daily during the active pollen season (February-July)
62502436|NCT01785394|PLACEBO_COMPARATOR|Placebo|30 patients will receive placebo
62502437|NCT02339740|EXPERIMENTAL|Treatment (tretinoin, arsenic trioxide, chemotherapy)|See Detailed Description
61955228|NCT02981017|EXPERIMENTAL|Cook Biodesign|Subjects within the experimental group will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, a small piece of Cook Biodesign porcine intestinal submucosal xenograft will be used to cover the exposed bone of the operative site along the frontal beak. It will be bolstered with light nasal packing to keep the graft in place during healing.
62502438|NCT01230645|EXPERIMENTAL|RV568 treatment group|
61955229|NCT03204019|EXPERIMENTAL|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
61955230|NCT03204019|ACTIVE_COMPARATOR|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
61955231|NCT01204437|ACTIVE_COMPARATOR|EC standard chemotherapy 4 cycles|
61955232|NCT01204437|ACTIVE_COMPARATOR|CMF standard chemotherapy 6 cycles|
61955233|NCT01204437|EXPERIMENTAL|Nab-Paclitaxel + Capecitabine 6 cycles|6 cycles of weekly nab-Paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
62502439|NCT01230645|PLACEBO_COMPARATOR|Placebo treatment group|
62502440|NCT03019562|EXPERIMENTAL|Oxycodone|4mg of oxycodone iv bolus
62502441|NCT03019562|ACTIVE_COMPARATOR|Fentanyl|50ug of fentanyl iv bolus
62502442|NCT01662024|EXPERIMENTAL|Endoscopic gastric restrictive procedure|Restrict gastric size by approximating tissue endolumenally via an incisionless/per-oral approach.
62502443|NCT00697801|EXPERIMENTAL|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
62502444|NCT00697801|EXPERIMENTAL|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
62502445|NCT00697801|PLACEBO_COMPARATOR|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
62701920|NCT03290027|PLACEBO_COMPARATOR|Vehicle|Vehicle (0% tazarotene) Lotion
62701921|NCT03137823|OTHER|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
62701922|NCT00955578||Segmental Dysplastic Nevi|One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
62701923|NCT01280669|EXPERIMENTAL|Group 1|Intravitreal injections of 440mcg sirolimus (low-dose monthly group)
61955234|NCT01201005|ACTIVE_COMPARATOR|Hydroxycobalamin|"Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma) is given as a singel intramuscular injection.~The syringe is covered so it is impossible to see whether it contains any substance"
62502446|NCT06137781|EXPERIMENTAL|Six weeks of digital prehabilitation|The digital prehabilitation programme comprises three 35-minute exercise sessions per week, including a warm-up, vigorous intensity aerobic and resistance exercises, and breathing exercises. The digital prehabilitation programme will be tailored to the participant's mobility level and fitness level, which will be assessed via in-platform questionnaires and functional assessments. Functional assessments will be repeated every two weeks to adapt the prehabilitation programme according to changes in fitness level. Within PreActiv's website, participants will be enrolled into a managed community forum of patients and healthcare professionals where they can post their achievements and questions. Alongside access to PreActiv's digital prehabilitation, patients will be given educational materials that summarise the benefits of prehabilitation and how to realise them.
62502447|NCT01352052|NO_INTERVENTION|waiting list assignment|6 months waiting list assignment followed by the 2-week interdisciplinary rehabilitation programme
62701924|NCT01280669|EXPERIMENTAL|Group 2|Intravitreal injections of 880mcg sirolimus (high-dose every other month group)
62701925|NCT06259019|OTHER|Liquid Biopsy System|Main trial arm, all recruited and enrolled patients will undergo intracoronary blood sampling using the Liquid Biospy System Device.
61955235|NCT01201005|SHAM_COMPARATOR|needle injection|"The controls receive an intramuscular injection: which is merely an introduction of the needle into the muscle whithout any injection. The syringe is covered so it is not possible to see whether the syringe contains any substance"
61955236|NCT06145672|ACTIVE_COMPARATOR|Mature Alopecic Scars|Follicular Unit Extraction and implantation for Alopecic Scars in beard Follicular Unit Extraction and implantation for Alopecic Scars in scalp Follicular Unit Extraction and implantation for Alopecic Scars in eyebrow Follicular Unit Extraction and implantation for Alopecic Scars in Moustache
61955237|NCT06145672|EXPERIMENTAL|Immature Alopecic Scars|Follicular Unit Extraction and implantation for Alopecic Scars in beard Follicular Unit Extraction and implantation for Alopecic Scars in scalp Follicular Unit Extraction and implantation for Alopecic Scars in eyebrow Follicular Unit Extraction and implantation for Alopecic Scars in Moustache
61955238|NCT04444895|EXPERIMENTAL|Lanadelumab 300 mg Every 2 Weeks|Participants received 300 milligrams (mg) lanadelumab subcutaneous (SC) injection, every 2 weeks (Q2W) for up to 26 weeks with an option to switch to lanadelumab 300 mg every 4 weeks (Q4W) if attacks were well-controlled based on the investigator's discretion and consultation with the sponsor's medical monitor.
61955239|NCT00764283|EXPERIMENTAL|1|Tegaderm dressing
61955240|NCT00764283|ACTIVE_COMPARATOR|2|Epi-Fix dressing
61955241|NCT00764283|ACTIVE_COMPARATOR|3|Lockit-Plus dressing
61955242|NCT06114225|EXPERIMENTAL|treatment arm|The participant receive metastasectomy, immunotherapy and Stereotactic Body Radiotherapy (SBRT)
61955243|NCT06504797|EXPERIMENTAL|massage group|massage application
62344662|NCT04388098||Asthmatic children|Asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
62502448|NCT01352052|ACTIVE_COMPARATOR|Intervention: interdisciplinary rehabilitation programme|A two-weeks non-residential, group-based, psycho-educative treatment course conducted by an interdisciplinary team.
62502449|NCT05831735|NO_INTERVENTION|Control|This group will be provided with a video showing the movement to do in case of pain, or endometriosis crisis
61955244|NCT02330237|ACTIVE_COMPARATOR|patients|natural gels
62344663|NCT04388098||Non-asthmatic children|Non-asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
61955245|NCT02330237|PLACEBO_COMPARATOR|subjects|These patients will receive that placebo (vehicle) products.
61955246|NCT05544734|ACTIVE_COMPARATOR|Hydrocodone 5mg/acetaminophen 325mg|Participants receive oral hydrocodone 5 mg/acetaminophen 325 mg every 4 hours for 2 days, followed by oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 4 days
61955247|NCT05544734|ACTIVE_COMPARATOR|Acetaminophen 1000mg + Ibuprofen 400mg|Participants receive oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 6 days
61955248|NCT04452682||Era of COVID 19|Total number of cases admitted during first six months of 2020
62344664|NCT02238795||Purpura fulminans|Patients diagnosed with Purpura fulminans in association with sepsis
62344665|NCT01461512|PLACEBO_COMPARATOR|Placebo|
62701926|NCT05089916|EXPERIMENTAL|Osimertinib plus Radiation|Osimertinib 80 mg Radiation as per SOC
61955249|NCT04452682||Era of Non COVID 19|Total number of cases admitted the first six months of 2019
61955250|NCT06315348|EXPERIMENTAL|Collagen matrix|a cross-linked volume stable collagen matrix (VCMX; Geistlich Fibro-Gide, Geistlich Pharma AG)
61955251|NCT06315348|ACTIVE_COMPARATOR|Xenograft|a graft consisting of bovine hydroxyapatite xenograft (Geistlich Bio-Oss; Geistlich Pharma AG), covered by a native collagen membrane (Geistlich Bio-Gide; Geistlich Pharma AG), tagged with pins at the ends.
61955252|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
61955253|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
61955254|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
62344666|NCT01461512|EXPERIMENTAL|Heme arginate treatment|
62344667|NCT04700852|EXPERIMENTAL|allergic rhinitis|Puressentiel protective nasal spray
62344668|NCT00873769|EXPERIMENTAL|Healthy smokers|Healthy smokers, male and female
62344669|NCT00873769|EXPERIMENTAL|Healthy nonsmokers|Healthy nonsmokers, Healthy smokers, male and female
62701927|NCT02997085|EXPERIMENTAL|Live-Action 360° Video Virtual Reality|
62701928|NCT02997085|ACTIVE_COMPARATOR|CGI 360° Video Virtual Reality|
62701929|NCT02997085|NO_INTERVENTION|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
62701930|NCT06486220|EXPERIMENTAL|Flora Transplantation group|5-Fu+DDP+anti-PD-1 mAb+FMT
62701931|NCT06486220|NO_INTERVENTION|Control group|5-Fu+DDP+anti-PD-1 mAb
62701932|NCT05734196|EXPERIMENTAL|INZ-701|"The first 2 study participants will receive 1 dose of 0.2 mg/kg on Day 1 and start at Dose Level A (0.2 mg/kg twice weekly) on Day 8.~The Data Review Committee (DRC) comprised of representatives of the Sponsor, the study Investigators, and a physician who is a subject matter expert not affiliated with the study or Sponsor, will review the safety data of the first study participant through Day 8. Contingent upon this review, the Sponsor will decide if additional study participants can begin receiving INZ-701.~After the second study participant completes Day 32, the DRC will perform a cumulative review of safety and PK/PD data and will make dosing recommendations, for example, modifying the dose of the ongoing study participants and/or changing the starting dose for future participants.~Dose Level A: 0.2 mg/kg twice weekly~Dose Level B: 0.6 mg/kg twice weekly~Dose Level C: 0.2 mg/kg once weekly~Dose Level D: 0.6 mg/kg once weekly~Dose Level E: 1.8 mg/kg once weekly"
62701933|NCT02256748|EXPERIMENTAL|BIRT 2584 XX + Midazolam|"BIRT 2584 XX: Multiple doses for 12 days (bid on days 1 and 2, qd from days 3 to 12)~Midazolam: Administration on days -2, 1, 3, and 12"
62701934|NCT06033560||Full analysis|All eligible patients.
62701935|NCT06033560||P/F ratio subgroups|Patients with a P/F ratio split in groups of \<=100; 100-150; 150-200
62701936|NCT06033560||Respiratory rate subgroups|Patients with a respiratory rate split in groups of \<=25; \>25 breaths/min
62344670|NCT04621669|EXPERIMENTAL|digoxin, Rosuvastatin calcium,SHR3680|
62344671|NCT04621669|EXPERIMENTAL|metformin hydrochloride ,SHR3680|
62344672|NCT03910647|EXPERIMENTAL|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
62344673|NCT03910647|EXPERIMENTAL|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
62344674|NCT04008901|ACTIVE_COMPARATOR|Treatment group|The randomly assigned target was given a Lonicera Flos extract (BST104) 175 mg/day for eight weeks.
62344675|NCT04008901|PLACEBO_COMPARATOR|Placebo group|The randomly assigned target was given a placebo for eight weeks.
62502450|NCT05831735|EXPERIMENTAL|Physical activity|This group will be provided with a video showing the movement to do in case of pain, or endometriosis crisis + with 1h to 3 h of adapted physical activity delivered by videoconference.
62502451|NCT05831735|EXPERIMENTAL|Physical activity and education|This group will be provided with a video showing the movement to do in case of pain, or endometriosis crisis + with 1h to 3 h of adapted physical activity delivered by videoconference + 6 session of educational and discussion groups
62502452|NCT01465932|ACTIVE_COMPARATOR|No proprioception|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, in addition to cryotherapy reduction of pain.
62701937|NCT06033560||Body mass index (BMI) subgroups|Patients with BMI split in groups of \<=25; 25-30; 30-35; \>35 kg/m\^2
62701938|NCT06033560||Immunocompromised subgroups|Immunocompromised patients due to medication or an underlined condition.
62701939|NCT06033560||Intensive care unit (ICU) subgroup|Only patients eligible within 24 hours of ICU admission.
62701940|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
62701941|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010) and CSBD according to ICD-11.
62344676|NCT01588353|EXPERIMENTAL|AK160 0.58 mg|
62344677|NCT05240638|EXPERIMENTAL|TD Drainage|Short term TD drainage
62344678|NCT01784952|EXPERIMENTAL|Whole grains and lequmes|
62344679|NCT01784952|PLACEBO_COMPARATOR|refined rice|
62344680|NCT04662216|ACTIVE_COMPARATOR|control group|Scaling and root planing
62344681|NCT04662216|EXPERIMENTAL|test group|"scaling and root planing + Perisolv +Hyadent BG gels."
62502453|NCT01465932|EXPERIMENTAL|Proprioceptive exercises|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, proprioception exercises to improve motor control, besides cryotherapy for reduction of pain.
62502454|NCT03527654||Hispanic Immigrants|
62344682|NCT00760604|ACTIVE_COMPARATOR|A|En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
62344683|NCT00760604|ACTIVE_COMPARATOR|B|Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
62502455|NCT05801029|EXPERIMENTAL|Osimertinib+Amivantamab|Participants will receive osimertinib and amivantamab.
62502456|NCT02460835|EXPERIMENTAL|Adaptive Radiation Therapy|
62502457|NCT00361478|EXPERIMENTAL|1|"Mother and Baby Program comprising exercise and education."
62502458|NCT00361478|ACTIVE_COMPARATOR|2|Education only
61955255|NCT01564914|EXPERIMENTAL|TRC105, Bevacizumab|Single arm study
62502459|NCT00456482|EXPERIMENTAL|Fluocinolone Acetonide 0.59mg|Fluocinolone acetonide intravitreal implant 0.59mg
62502460|NCT00456482|EXPERIMENTAL|Fluocinolone Acetonide 2.1mg|Fluocinolone acetonide intravitreal implant 2.1mg
62502461|NCT00456482|NO_INTERVENTION|No Intervention|Fellow eye
62502462|NCT03429049|PLACEBO_COMPARATOR|Placebo|Matching placebo of 2.0 mL for IA injection
62502463|NCT03429049|EXPERIMENTAL|CNTX-4975-05|Pre-filled glass syringes administered as a single 2.0 mL IA injection
62502464|NCT03634059|EXPERIMENTAL|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
62502465|NCT00700245|ACTIVE_COMPARATOR|EXO|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction),
62344684|NCT04755465|EXPERIMENTAL|Resistance Exercise Group|The lower extremity resistance exercise (REx) program was designed by reviewing the exercise principles recommended by the ACSM and the literature on physical activity and hematological cancer patients. The patients were treated for 40-60mins, 6 weeks. The exercise program includes active movements of the upper and lower extremities, stretching exercises, and resistance exercises for the lower extremities. REx to be applied with resistance bands of different resistance or with the patient's body weight. Clinical force generation of therapy bands follows a progression. Our proposed training protocol includes 4-6 different exercises for each extremity. Intensity, sets, and reps were adjusted to a target score of 12 to 14 using the Borg scale. Patients performed 1 set of 10 repetitions of each REx based on their fatigue level. Intensity (\~ RPE 15-16) and resistance were gradually increased. When the patient complained of extreme fatigue, the resistance was reduced to the previous level.
62344685|NCT04755465|EXPERIMENTAL|NMES Training Group|In addition to resistance exercises, NMES will be applied to the quadriceps muscles in both legs of the patients in this group. The application will be made with a portable device using disposable electrodes. One of the electrodes will be placed proximally, that is, at the midpoint of the quadriceps muscle, while the second electrode will be placed on the distal part. In order to ensure that the patients get used to the device, low-intensity current with a frequency range of 5 Hz, 10-30 minutes. Afterward, the treatment program will continue with a high-frequency current with a frequency range of 50 Hz, 15 minutes. Participants were instructed to voluntarily contract the quadriceps muscles during periods of HF-NMES stimulation to increase the strengthening effect and improve NMES tolerance.
61955256|NCT05223933|EXPERIMENTAL|Intervention fokontany|
61955257|NCT05223933|NO_INTERVENTION|Control fokontany|
62701942|NCT02806661|EXPERIMENTAL|VPRDG for AGC|Vagus nerve-preserving Robot-assisted distal subtotal gastrectomy (VPRDG) with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
62701943|NCT02806661|ACTIVE_COMPARATOR|CRDG FOR AGC|Conventional Robot-assisted distal subtotal gastrectomy (CRDG) with D2 lymphadenectomy without preserving vagus nerve will be performed for the treatment of patients assigned to this group.
61955258|NCT05662007||Young swimmers group|
61955259|NCT05662007||Healthy Control Group|
61955260|NCT05656495|EXPERIMENTAL|Ambervin intramuscularly|Arm 1 (n=104) receives the study drug Ambervin for intramuscularly administration 1 mg 1 time per day. The course of treatment is 10 days.
61955261|NCT05656495|EXPERIMENTAL|Ambervin inhaled|Arm 2 (n=105) receives the study drug Ambervin for inhalation administration 10 mg 1 time per day. The course of treatment is 10 days.
62344686|NCT01429077|ACTIVE_COMPARATOR|Levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
61955262|NCT05656495|ACTIVE_COMPARATOR|Standard of care|Arm 3 (n=104) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the InterimGuidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site
62344687|NCT01429077|PLACEBO_COMPARATOR|Inactive pill|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
62344688|NCT04414696|EXPERIMENTAL|Intervention|Participants will be asked to use a web-based (eHealth) exercise intervention for 3 months. This eHealth exercise intervention includes over 90, 10-minute exercise videos with options for exercise type, time, and intensity, customized to the weight of the infant. Users can either select up to three 10-minute videos to create a 10 to 30-minute workout or choose a 'Ready Made' workout that is either 10, 20, or 30-minutes long.
62502466|NCT00700245|ACTIVE_COMPARATOR|DIO|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet)
62502467|NCT00700245|ACTIVE_COMPARATOR|DEX|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).
62502468|NCT05268419|ACTIVE_COMPARATOR|Ethanol inhalation|100 ml spray of 35% ethanol were provided and all of participants were instructed to use spray three times every 6 hours from a distance of 20-30 cm from their face, while wearing a mask and closing their eyes, and take a deep breath as they feel nebulized liquid droplets in their nose, mouth, throat, larynx and lungs. Investigators emphasized participants that this protocol must be repeated every six hours to 7 days.
62502469|NCT05268419|PLACEBO_COMPARATOR|Water Distilled inhalation|100 ml spray of water distilled (placebo) were provided and all of participants were instructed to use spray three times every 6 hours from a distance of 20-30 cm from their face, while wearing a mask and closing their eyes, and take a deep breath as they feel nebulized liquid droplets in their nose, mouth, throat, larynx and lungs. Investigators emphasized participants that this protocol must be repeated every six hours to 7 days.
61955263|NCT01211470|EXPERIMENTAL|PMX-30063|3 arms of PMX-300063
61955264|NCT01211470|ACTIVE_COMPARATOR|Daptomycin.|Daptomycin will be administered according to the approved product monograph information for ABSSSI.
61955265|NCT01577420|EXPERIMENTAL|Group A|Reflexology Sessions: One session per week performed by certified reflexologist for four consecutive weeks.
61955266|NCT01577420|PLACEBO_COMPARATOR|Group B|Placebo Sessions: One session per week performed by research aide for four consecutive weeks.
61955267|NCT01577420|NO_INTERVENTION|Group C|Control; no foot sessions
61955268|NCT06558513|EXPERIMENTAL|XNW5004|Phase 1：treated with escalated doses of XNW5004 respectively； Phase 2：treated with RP2D of XNW5004 respectively
61955269|NCT00948636||Related Donors|Related Hematopoietic Stem Cell Donors
62502470|NCT01086228||XIENCE V / PROMUS stent|Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
62502471|NCT06310005|EXPERIMENTAL|SRD part: Dose group 1|Low dose.
62502472|NCT06310005|EXPERIMENTAL|SRD part: Dose group 2|Medium dose.
62502473|NCT06310005|EXPERIMENTAL|SRD part: Dose group 3|High dose.
62502474|NCT06310005|EXPERIMENTAL|MD part: Dose group 4|High dose.
62502475|NCT05374915|EXPERIMENTAL|REM-001 photodynamic therapy (PDT)|Single arm study. All enrolled patients receive REM-001 therapy
62502476|NCT06311019|NO_INTERVENTION|1 (Standard care)|In this arm the patients continue to measure blood glucose with fingerprick and use standard insulin pens
62502477|NCT06311019|ACTIVE_COMPARATOR|2 (CGM and connected pen)|In this arm the patients switch from glucose measurement with fingerprick to continuous glucose monitoring and they switch from standard insulin pen for bolusinsulin to connected pen for bolusinsulin
62502478|NCT04130217|NO_INTERVENTION|Control group|patients will be intraoperatively mechanically ventilated without PEEP nor RM.
62502479|NCT04130217|EXPERIMENTAL|PEEP Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
62502480|NCT04130217|EXPERIMENTAL|PEEP and RM Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
62502481|NCT00880334|EXPERIMENTAL|vandetanib & Docetaxel|vandetanib orally and Docetaxel intravenously
61955270|NCT02984111|ACTIVE_COMPARATOR|group A|20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
61955271|NCT02984111|ACTIVE_COMPARATOR|group B|20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
61955272|NCT02984111|PLACEBO_COMPARATOR|control|50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
62344689|NCT04414696|NO_INTERVENTION|Usual Care|Participants in the usual care condition will follow their usual standard care as suggested by their provider. Participants will complete the same assessments and incentives as the active intervention but will not receive the eHealth exercise intervention.
61955273|NCT01815216|EXPERIMENTAL|Bariatric surgery|patients participating in the intervention group , i.e. assessing effects of bariatric surgery on: Brain activity in resting state Memory performance
62344690|NCT03497260|EXPERIMENTAL|Fructose in water first, water only second|Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
62344691|NCT03497260|EXPERIMENTAL|Water only first, Fructose in water second|Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
62344692|NCT04348656|EXPERIMENTAL|Convalescent plasma|\~500 mL ABO compatible convalescent apheresis plasma
62344693|NCT04348656|NO_INTERVENTION|Standard of care|Treated as per institutional standard of care.
62344694|NCT00776932||Knee OA|Those over the age of 50 who have frequent pain in their knee that has lasted for at least six months.
62344695|NCT04143763|ACTIVE_COMPARATOR|Intervention group|receive mobile messages supporting caregivers' psychological well-being, according to the participants' preferences in intervention group.
62344696|NCT04143763|NO_INTERVENTION|Control group|receive general health information through a mobile message.
62502482|NCT00880334|ACTIVE_COMPARATOR|Placebo and Docetaxel|Placebo orally and docetaxel intravenously
62502483|NCT05762731||First degree relatives of lung cancer patients|Age 50-75, men or women, smokers or non-smokers. Being first degree relatives (siblings, children and parents) of lung cancer subjects. Having no known lung cancer before.
62502484|NCT05762731||Control group|Non-lung cancer subjects who are not related any lung cancer patients
62502485|NCT04583150||Obese women with planned surgery (BS group)|Obese women with planned BS procedure in standard care
62502486|NCT04583150||Obese women with no planned surgery (control group)|Obese women matched for age and BMI who did not undergo surgery
62502487|NCT02573285|ACTIVE_COMPARATOR|Simple Aspiration|Subjects in this arm will undergo initial management of their pneumothorax with a simple aspiration procedure. The procedure will involve placement of a small catheter into the chest cavity and applying negative pressure to manually aspirate the air out of the chest cavity, which will allow the lung to re-expand.
62502488|NCT02573285|ACTIVE_COMPARATOR|Surgeon Preference|Subjects that choose the surgeon preference arm of the study are enrolling for prospective data collection only. These subjects will not have any portion their care directed by the study protocol. The decision to proceed with any treatment or intervention will be made jointly by the surgeon and the patient and his or her legal guardian. Any standard treatment option may be utilized, including simple aspiration, chest tube placement, or an operation (VATS).
62502489|NCT04643002|ACTIVE_COMPARATOR|Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)|"* Isatuximab, intravenous (IV) doseweekly (QW) × 4 weeks (Cycle 1), followed by every two weeks (Q2W) (subsequent cycles).~* Pomalidomide dose by mouth daily Day 1 to Day 21.~* Dexamethasone dose by mouth QW."
62502490|NCT04643002|EXPERIMENTAL|isatuximab + SAR439459 + dexamethasone (Substudy 02)|"SAR439459 in combination with isatuximab and dexamethasone~Part 1:~2 dose levels (DLs) of IV SAR439459:~* DL1 SAR439459 dose Q2W.~* DL2 SAR439459 dose Q2W.~* Isatuximab dose IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~* Dexamethasone fixed dose and schedule: QW by mouth In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).~Part 2:~* SAR439459 IV dose Q2W.~* Isatuximab IV dose QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~* Dexamethasone fixed dose and schedule: QW by mouth. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8)."
62701944|NCT01331590|EXPERIMENTAL|G-CSF + Ifosfamide + Etoposide + Dexamethasone + Mesna|"G-CSF = 10 mcg/kg/d SQ starting on day 1 and continuing until ANC \>=1000/mcL x 2 days~Ifosfamide = 3330 mg/m2/d CIVI over 24 hours on Days 4-6~Etoposide = 150 mg/m2 IV over 2 hours BID on Days 4-6~Dexamethasone = 5 mg/m2 PO or IV BID on Days 4-10~Mesna = 2660 mg/m2/d continuous IV infusion over 24 hours on Days 4-6. 2000 mg/m2 continuous IV infusion over 12 hours on Day 7 to be started immediately after completion of ifosfamide."
62701945|NCT04125602|EXPERIMENTAL|High fat low carbohydrate diet|
62701946|NCT04125602|EXPERIMENTAL|Low fat high carbohydrate diet|
61955274|NCT01815216|ACTIVE_COMPARATOR|Control|"Patients in the control group will not undergo surgery during study.~These patients will be examined twice:~1. 9 weeks before the operation (i.e. clinical intervention to reduce body weight has not started).~2. after 4 weeks of low-calorie diet (which will be a week before their surgery, when patients are in a catabolic metabolism because they eat much less energy than is needed) to assess effect of acute weight loss on: Brain activity in resting state Memory performance"
62701947|NCT06187909|ACTIVE_COMPARATOR|PECS II block group|First group 44 patients
62701948|NCT06187909|ACTIVE_COMPARATOR|MTP block group|Second group 44 patients
61955275|NCT05142163|ACTIVE_COMPARATOR|Stroke Volume Variation Guided Fluid Therapy|Patients will receive maintenance Fluids as crystalloids intraoperative to maintain SVV \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
61955276|NCT05142163|ACTIVE_COMPARATOR|Plethysmography Variability Index Guided Fluid Therapy|Patients will receive maintenance Fluids as crystalloids intraoperative to maintain PVI \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
61955277|NCT03617497|ACTIVE_COMPARATOR|Healthy control participants|Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography
61955278|NCT03617497|ACTIVE_COMPARATOR|Alzheimer disease|Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography
61955279|NCT03617497|EXPERIMENTAL|Alzheimer disease with high seizure risk|Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography
62344697|NCT03747744|EXPERIMENTAL|CD1c (BDCA-1)+ myDC|CD1c (BDCA-1)+ myDC
62344698|NCT01545609|EXPERIMENTAL|Text messaging|Text messaging
62344699|NCT01545609|NO_INTERVENTION|No intervention|No intervention
62344700|NCT00895193|ACTIVE_COMPARATOR|Apple-pectin 2000mg|Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
62344701|NCT00895193|ACTIVE_COMPARATOR|Regular Non-enteric coated aspirin 325mg|Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
62344702|NCT00895193|ACTIVE_COMPARATOR|Apple pectin + aspirin|Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
62344703|NCT00895193|PLACEBO_COMPARATOR|Placebo Comparator|Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
62344704|NCT02193256|ACTIVE_COMPARATOR|Varenicline plus Prazosin|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
62344705|NCT02193256|PLACEBO_COMPARATOR|Varenicline plus Placebo|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Placebo: placebo will be given instead of prazosin (Weeks 1-3)
62344706|NCT04580823|NO_INTERVENTION|Control|Fasting without exogenous ketone salt supplement
62344707|NCT04580823|EXPERIMENTAL|Fasting with exogenous ketone salt supplement|Fasting with exogenous ketone salt supplement
61955280|NCT02165969|EXPERIMENTAL|endoscopic endonasal surgery with UPSIT|endoscopic endonasal surgery with UPSIT prior to surgery and at months 1, 3, 6, and 12 after surgery.
61955281|NCT02166905|EXPERIMENTAL|Arm I (CDX-1401, poly ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly ICLC as in Phase I.
61955282|NCT02166905|EXPERIMENTAL|Arm II (CDX-1401, poly ICLC, IDO1 inhibitor INCB024360)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 as in Phase I.
61955283|NCT04158115|EXPERIMENTAL|Entire Spinal Mobilization|Entire Spinal Mobilization( All spinal segment from Co-C1to L5-S1 Moist heat. Soft tissue Mobilization Exercises. (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
61955284|NCT04158115|ACTIVE_COMPARATOR|Segmental Mobilization|Segmental Mobilization. (All lumbar segment from L1-L2 to L5-S1) Moist heat. Soft tissue Mobilization Exercises (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
62344708|NCT04580823|EXPERIMENTAL|Post-Prandial with exogenous ketone salt supplement|Post-Prandial with exogenous ketone salt supplement
62344709|NCT01595165|PLACEBO_COMPARATOR|Control|Control group receiving saline instead of ropivacaine
62344710|NCT01595165|EXPERIMENTAL|TAP|TAP group receiving ropivacaine total of 150 mg at TAP under US
62344711|NCT00994656||posterior spinal fusion subject|Subject will have a history of either idiopathic or neuromuscular scoliosis who is now scheduled to have a posterior spinal fusion.
62344712|NCT01766570|EXPERIMENTAL|Phenol|Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.
62344713|NCT01766570|PLACEBO_COMPARATOR|Control|Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.
62344714|NCT01476384|EXPERIMENTAL|Glucose drink|75 gram glucose, dissolved in 250 ml water
62344715|NCT01476384|PLACEBO_COMPARATOR|Placebo|250 ml water
62701949|NCT04580550|OTHER|Axial length variability|Aim of this study is to evaluate the magnitude of changes in pre and postoperative measurements of AL.
62701950|NCT03683433|EXPERIMENTAL|Treatment (azacitidine, enasidenib mesylate)|Patients receive azacitidine SC or IV over 30 minutes on days 1-7 and enasidenib mesylate PO QD beginning on day 1. Cycles repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
62701951|NCT01951391|OTHER|Control Soap vs. Benzalkonium Chloride Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with benzalkonium chloride soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The benzalkonium chloride forearm will be swabbed at baseline and 6 hours.
61955285|NCT03021460|EXPERIMENTAL|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61955286|NCT00750997||Hypertonic saline|Hypertonic resuscitation
61955287|NCT00750997||Control: normal saline|Normal saline resuscitation
61955288|NCT03978832|EXPERIMENTAL|Oral Risperidone followed by PERSERIS|All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.
61955289|NCT06135753|EXPERIMENTAL|Experimental: psychosomatic intervention based on cognitive restructuring followed by Museum Therapy|"A psychosomatic intervention based on cognitive restructuring will be used as the non-pharmacological therapeutic strategy and 4 sessions will be delivered every other week with a duration of 120 minutes each in a group format with 10 participants.~The museum therapy will include 4 sessions, directed by the clinical psychologist and a museum educator, aimed at facilitating emotional expressions and participants' behavioral activation. The sessions will be delivered starting 2 weeks after the last session of the psychosomatic intervention as part of the Benessere al Museo Project by Uffizi Galleries.~A final additional session will be proposed."
62502491|NCT04643002|EXPERIMENTAL|isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)|"Belantamab mafodotin in combination with isatuximab and dexamethasone~Part 1:~1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:~* DL1 belantamab mafodotin IV dose QW4 or de-escalation dose DL-1 QW8~* Isatuximab dose, IV QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~* Dexamethasone fixed dose and schedule: QW by mouth.~Part 2:~* Isatuximab IV dose QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~* Belantamab mafodotin IV dose Q4W or Q8W~* Dexamethasone fixed dose and schedule: QW by mouth."
62502492|NCT04643002|EXPERIMENTAL|Isatuximab + pegenzileukin (Substudy 04)|"Pegenzileukin in combination with isatuximab~Part 1- dose escalation:~* Up to 3 DLs of IV pegenzileukin are planned to be evaluated:~  * DL1 will explore pegenzileukin at Q2W.~ * DL2 will explore pegenzileukin at Q2W.~ * DL3 will explore pegenzileukin at Q2W.~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).~Part 1 - dose optimization:~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).~* Pegenzileukin at potential doses (DL A and DL B) Q2W.~Part 2 (dose expansion):~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).~* Pegenzileukin IV dose Q2W."
62701952|NCT01951391|OTHER|Control Soap vs. Triclocarban Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with triclocarban soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The triclocarban forearm will be swabbed at baseline and 6 hours.
61955290|NCT06135753|PLACEBO_COMPARATOR|Placebo Comparator: Control condition followed by Museum Therapy|"The control condition will include 4 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) Guidelines (https://www.nice.org.uk/guidance/lifestyleandwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.~The museum therapy will include 4 sessions, directed by the clinical psychologist and a museum educator, aimed at facilitating emotional expressions and participants' behavioral activation. The sessions will be delivered starting 2 weeks after the last control group's session as part of the Benessere al Museo Project by Uffizi Galleries.~A final additional session will be proposed."
61955291|NCT06504836|EXPERIMENTAL|Gait training with biofeedback group|The intervention is a single 60-minute session.
61955292|NCT06504836|ACTIVE_COMPARATOR|Gait training without biofeedback group|The intervention is a single 60-minute session.
61955293|NCT02859311|EXPERIMENTAL|Withdrawal of therapy|Gradual, supervised withdrawal of medical therapy over 4-16 weeks
61955294|NCT02859311|NO_INTERVENTION|Control|Continuation of usually prescribed pharmacological therapy
61955295|NCT03342716||Main cohort|Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
61955296|NCT03342716||Nested cohort|Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
61955297|NCT01463488|EXPERIMENTAL|SAR113945 - Dose 1|
61955298|NCT01463488|EXPERIMENTAL|SAR113945 - Dose 2|
61955299|NCT01463488|EXPERIMENTAL|SAR113945 - Dose 3|
61955300|NCT01463488|PLACEBO_COMPARATOR|Placebo|
61955301|NCT05545709||remote group|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
61955302|NCT05545709||local group|Local orthopedic robot-assisted spine surgeries were performed according to the guidelines for thoracolumbar pedicle screw placement assisted by orthopedic surgical robots.
61955303|NCT01744574|PLACEBO_COMPARATOR|Placebo|Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
61955304|NCT01744574|EXPERIMENTAL|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
62344716|NCT05638763|EXPERIMENTAL|Dasatinib and ketoconazole|Patients will receive dasatinib at a dose of 25mg orally daily for one year and ketoconazole 200mg orally two times per day for one year.
62344717|NCT01140802||IBD patients|Crohn's disease or ulcerative colitis patients
62701953|NCT06489015|EXPERIMENTAL|20g dose group|
61955305|NCT04153331|EXPERIMENTAL|Patients admitted to emergency department with medical cause|Patient included in emergency with a nasal swab
61955306|NCT04036890|EXPERIMENTAL|2% minocycline hydrochloride controlled-delivery system (MHS)|Mechanical ultrasonic/ hand instrumentation and subsequent administration of MHS on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
61955307|NCT04036890|PLACEBO_COMPARATOR|Placebo|Mechanical ultrasonic/ hand instrumentation and subsequent administration of a placebo gel on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
61955308|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
61955309|NCT05209360|EXPERIMENTAL|Arm 1|Testing Order: NoCDO, CDO, Lateral, Medial
61955310|NCT05209360|EXPERIMENTAL|Arm 2|Testing Order: NoCDO, CDO, Medial, Lateral
61955311|NCT05209360|EXPERIMENTAL|Arm 3|Testing Order: NoCDO, Medial, CDO, Lateral
61955312|NCT05209360|EXPERIMENTAL|Arm 4|Testing Order: NoCDO, Medial, Lateral, CDO
61955313|NCT05209360|EXPERIMENTAL|Arm 5|Testing Order: NoCDO, Lateral, Medial, CDO
61955314|NCT05209360|EXPERIMENTAL|Arm 6|Testing Order: NoCDO, Lateral, CDO, Medial
61955315|NCT04600375|OTHER|Verbal Consultation, then Written Action Plan|"CONTROL GROUP~1. Survey A~2. Routine clinic visit~3. Verbal consultation only~4. Survey B~5. Verbal consultation AND Written Action Plan~6. Survey C"
61955316|NCT04600375|EXPERIMENTAL|Experimental: Written Action Plan|"INTERVENTION GROUP~1. Survey A~2. Routine clinic visit~3. Verbal consultation AND Written Action Plan~4. Survey C"
61955317|NCT01044628|EXPERIMENTAL|Nocturnal oxygen therapy (N-O2)|Oxygen will be delivered overnight to the patients to allow their oxygen saturation to be \>90%
61955318|NCT01044628|SHAM_COMPARATOR|Sham concentrator|Sham therapy with ambient air will be given to the patients at night
61955319|NCT02486497|ACTIVE_COMPARATOR|5-FU group|Grades of hENT1 immunostaining are 0 or 1.
61955320|NCT02486497|ACTIVE_COMPARATOR|Gemcitabine group|Grade of hENT1 immunostaining is 2.
61955321|NCT03220360|EXPERIMENTAL|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
61955322|NCT03220360|EXPERIMENTAL|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
61955323|NCT03220360|EXPERIMENTAL|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
61955324|NCT02399722|ACTIVE_COMPARATOR|VAC mono therapy|negative pressure wound therapy alone
61955325|NCT02399722|ACTIVE_COMPARATOR|WICVAC combined therapy|Polymeric membrane dressing combined with negative pressure wound therapy
62344718|NCT01140802||Healthy controls (non-IBD)|Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
62344719|NCT01140802||Relatives of IBD patients|They will be a first degree relative of a IBD patient.
62344720|NCT05444010|EXPERIMENTAL|mental health|The effect of mandala painting on mental health. Mental health-related anxiety, depression, well-being, distress and death anxiety and depression will be measured.
61955326|NCT04180358|EXPERIMENTAL|Impact group|The impact group will receive the interventions in the classrooms
61955327|NCT04180358|PLACEBO_COMPARATOR|Comparison group|Comparison group will not receive the intervention
61955328|NCT00134082|EXPERIMENTAL|Immunotherapy|All participants received two days of rituximab, then four days of high-dose cyclophosphamide followed by filgrastim. Participants then received six doses of KGEL vaccine over 24 weeks interspersed with four additional doses of rituximab.
62701954|NCT06489015|EXPERIMENTAL|30g dose group|
62701955|NCT06489015|EXPERIMENTAL|40g dose group|
61955329|NCT02592356|EXPERIMENTAL|Cabozantinib or Lenvatinib|Patients treated with cabozantinib s-malate or lenvatinib mesylate are observed for body weight, skeletal muscle and adipose tissue changes. Patients complete 3 to 4 questionnaires every 2 weeks for 6 months and then monthly up to 12 months. Patients also undergo physical assessments and body composition measurements by DXA and CT scans at baseline, months 3, 6, and 12.
61955330|NCT05797675|EXPERIMENTAL|Test group|Implant therapy and closed sinus lifting with A-PRF
61955331|NCT03764384||Hospital Monitoring Group - ALSFRS-R cohort|All patients will be first recruited to this cohort unless at their first visit the investigator deems them eligible for the Home Monitoring Device Group. At the initial screening visit, all patients recruited into the study will undergo routine assessments according to the existing MND protocol, and additionally complete the ALSFRS-R symptom-based assessment questionnaire by interview with the study researchers (with assistance from spouse, family member or carer if required). Patients will continue to complete the ALSFRS-R symptom-based questionnaire at each clinic attendance.
61955332|NCT03764384||Home Monitoring Cohort|"If eligible patients will use the N Tidal CTM, up to 3 times a day (morning, midday and evening) throughout the home monitoring period until the final outpatient clinic visit.~In addition subjects will complete a weekly diary symptom monitoring diary which asks them about their respiratory symptoms, GP attendances, respiratory infections. Patients routine standard of care assessments will also be documented according to the protocol as well as completing the ALSFRS-R at each visit."
62344721|NCT02842112||CD34+ CD38-|A first cell population, which expressed the CD34 antigen and lacked CD38 (CD34+ CD38-), and often contained very few events requiring to be tightly clustered in a forward light scatter /side light scatter (FSC/ SSC) and CD45/SSC plot;
62344722|NCT02842112||CD34+ CD38low|A second population characterized by expression of the CD34 antigen and by a low density of CD38 antigen (CD34+ CD38low)
62701956|NCT03910595|EXPERIMENTAL|Mepitel Film Arm|This is a single arm trial where all patients will receive the intervention of Mepitel Film.
62701957|NCT05291910|EXPERIMENTAL|Inetetamab+ Toripalimab+ Albumin-Bound Paclitaxel|Drug: Inetetamab Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks Drug: Toripalimab 240mg intravenously every 3 weeks Drug: Albumin-Bound Paclitaxel 130mg/m2, IV , D1, D8, q3w
62502493|NCT04643002|EXPERIMENTAL|Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)|"Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.~* Belumosudil by mouth at Dose Level (DL) 1, DL2, DL3, and DL4~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~* Dexamethasone fixed dose and schedule: QW by mouth~Part 1- dose optimization:~* Belumosudil at potential doses (DL A and DL B), daily by mouth~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~* Dexamethasone fixed dose and schedule: QW by mouth~Part 2- dose expansion:~* Belumosudil dose daily, by mouth~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~* Dexamethasone fixed dose and schedule: QW by mouth"
62502494|NCT04643002|EXPERIMENTAL|Isatuximab + evorpacept + dexamethasone (Substudy 06)|"Isatuximab in combination with evorpacept and dexamethasone~Part 1- dose escalation:~* Evorpacept IV dose Q2W~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~* Dexamethasone fixed dose and schedule: QW by mouth Part 1- dose optimization~* Evorpacept IV at potential doses (DL A and DL B), Q2W~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~* Dexamethasone fixed dose and schedule: QW by mouth~Part 2- dose expansion:~* Evorpacept IV dose Q2W~* Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~* Dexamethasone fixed dose and schedule: QW by mouth"
62701958|NCT05872412|EXPERIMENTAL|Platinum-based regimen|Patients will be treated with doxorubicin 60 mg/m2 IV on day 1 and cyclophosphamide 600 mg/m2 IV on day 1 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 IV weekly for 12 weeks concurrently with carboplatin (area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles).
61955333|NCT00899574|EXPERIMENTAL|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
61955334|NCT00795496||AD patients|AD patients who fulfill the inclusion criteria for the study
62701959|NCT05872412|ACTIVE_COMPARATOR|Non-platinum based regimen|Patients will be treated with doxorubicin 60 mg/m2 IV on day 1 and cyclophosphamide 600 mg/m2 IV on day 1 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 IV weekly for 12 weeks.
61955335|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
61955336|NCT00626223|EXPERIMENTAL|A|patients treated with intravenous 5-MTHF (Prefolic®, Knoll, Milan, Italy) 50 mg at the end of each hemodialysis session; The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week
61955337|NCT00626223|ACTIVE_COMPARATOR|B|"treated with 5 mg per day of oral folic acid (Folina® Schwarz Pharma, Milan, Italy).~The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week"
61955338|NCT00687466|EXPERIMENTAL|1|Insulin yes
61955339|NCT00687466|NO_INTERVENTION|2|Insulin no
61955340|NCT04508101||drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty with suction drainage positioning
61955341|NCT04508101||non-drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty without suction drainage positioning
61955342|NCT01443182|EXPERIMENTAL|STAIR + MPE|A two-phased treatment with Skills Training in Affective and Interpersonal Regulation (STAIR) in Phase 1 en modified prolonged exposure (MPE) in Phase 2
62701960|NCT04185779||Group A (Cross-sectional arm)|This group will comprise of 10,000 patients who have been referred for a colonoscopy. We will be collecting information on their past medical history, smoking history, alcohol history, medication history and family history in addition to their colonoscopy findings. In 6000 of these patients, they will have blood tests, Faecal Immunochemical Test (FIT) level, blood or saliva for DNA extraction and stool microbiome taken. In 4000 of these patients, we will record recent blood tests of interest and they will have no new samples taken. All 10000 patients will also either complete a food frequency questionnaire or endoscopy patient experience questionnaire.
62701961|NCT04185779||COLO-SPEED (Group B, consent for contact arm)|This will be 10,000 patients who will consent for future contact for future research studies.
62701962|NCT04636996|EXPERIMENTAL|artificial intelligence assisted follow-up group|artificial intelligence assisted follow-up group
61955343|NCT01443182|ACTIVE_COMPARATOR|STAIR + EMDR|a two-phase treatment Phase 1: Skills Training in Affective and Interpersonal Regulation (STAIR) Phase 2: Eye Movement Desensitization and Reprocessing (EMDR)
62344723|NCT02842112||CD34+ CD38+|A third population characterized by a large density of CD38 and CD34 antigens (CD34+ CD38+). Antigens were expressed as percent positively stained cells as well as intensity of the fluorescence signal quantified as mean fluorescence intensity (MFI) from CD34+ gated cells and from CD45low/SSC total immature cells
62701963|NCT04636996|PLACEBO_COMPARATOR|Control group|Control group
62701964|NCT01179373|ACTIVE_COMPARATOR|TMS, High Frequency|High Frequency TMS with H coil to prefrontal cortex
62701965|NCT01179373|ACTIVE_COMPARATOR|TMS, Low Frequency|Low Frequency TMS to Prefrontal cortex
61955344|NCT02109211|OTHER|Standard care - Magill forceps|Patients will be intubated, as per standard care, with Magill forceps.
61955345|NCT02109211|EXPERIMENTAL|Altered Magill forceps|Patients will be intubated with modified Magill forceps.
62344724|NCT05580471|EXPERIMENTAL|Use 4DryField|One group use 4DryField before wound closure.
62344725|NCT05580471|NO_INTERVENTION|Not Use 4DryField|One group do not use 4DryField before wound closure.
62344726|NCT01562366|EXPERIMENTAL|Group 1|
62344727|NCT01562366|ACTIVE_COMPARATOR|Group 2|
62344728|NCT01327872|EXPERIMENTAL|Treatment A|
62344729|NCT01327872|EXPERIMENTAL|Treatment B|
62344730|NCT01327872|EXPERIMENTAL|Treatment C|
62502495|NCT00128817|EXPERIMENTAL|1|Concurrent Chemoradiation
62502496|NCT00128817|ACTIVE_COMPARATOR|2|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
62502497|NCT01763255|EXPERIMENTAL|CD133 transplantation|The patients with cerebral palsy that underwent CD133 transplantation.
62502498|NCT01763255|NO_INTERVENTION|Control|The patients with cerebral palsy that underwent regular observation.
62502499|NCT05301816|EXPERIMENTAL|IPG Activated|The group of participants who have had a successful trial (\>50% pain relief) during the trial phase
62502500|NCT02746419|EXPERIMENTAL|Experimental|Subjects will receive renal denervation.
62502501|NCT02746419|SHAM_COMPARATOR|Control|Subjects will receive all procedures as experimental group but renal denervation system will not be turned on.
62344731|NCT01327872|EXPERIMENTAL|Treatment D|
61955346|NCT04706091|EXPERIMENTAL|Treatment --> Placebo|This group will receive suvorexant during the first 4-week phase, and placebo during the second 4-week phase.
61955347|NCT04706091|EXPERIMENTAL|Placebo --> Treatment|This group will receive placebo during the first 4-week phase, and suvorexant during the second 4-week phase.
61955348|NCT03894332||SBT Success|Patients took part of this cohort when succeeding the Spontaneous Breathing Trial (SBT).
61955349|NCT03894332||SBT Failure|"Patients took part of this cohort when failing the Spontaneous Breathing Trial (SBT).~SBT Failure is defined by one or more of the following criteria occurring during the SBT:~1. loss of ≥ 2 points of Glasgow Coma Scale~2. respiratory rate/ tidal volume ≥105 breaths/min/L~3. arterial partial pressure of oxygen ≤60 mmHg on inspired oxygen fraction (FiO2) ≥0.5 and/or pH \<7.32 or a decrease in pH ≥0.07 units at the end of the SBT~4. systolic Blood Pressure \<90 mmHg or ≥180 mmHg or increased by ≥20%~5. Heart Rate \>140 beats/min or increased by 20%~6. onset of major heart arrhythmias, or electrocardiographic signs of cardiac ischemia~7. Respiratory Rate ≥35 breaths/min or increased by ≥50%~8. increased effort, respiratory distress (as indicated by diaphoresis, accessory respiratory muscles recruitment, facial signs of distress and/or paradoxical breath)"
61955350|NCT03894332||Extubation Success|Patients took part of this cohort when, after extubation, did not need continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours.
61955351|NCT03894332||Extubation Failure|"Need for continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours from extubation, as defined by:~1. Respiratory Rate \>25 breaths/min for 2 hours~2. Heart Rate \>140 beats/min or sustained increase or decrease \>20%~3. clinical signs of respiratory muscle failure~4. arterial partial pressure of oxygen (PaO2) \<80 mmHg on inspired oxygen fraction (FiO2) ≥50%~5. Arterial partial pressure of carbon dioxide \>45 mmHg with pH \<7.33"
61955352|NCT01364818||Placebo Comparator: Placebo|No treatment/ performance of somatosensory task (cortical metrics) without any intervention. The somatosory task will be performed before any intervention/at the midpoint/ and finally at the end.
62344732|NCT02123030||Experimental|patients with pulmonary disease; and, patients with known or suspected lung or other cancers
62344733|NCT02123030||Control|healthy subjects (for example, family members of the patient or graduate students
62344734|NCT02930616|EXPERIMENTAL|group 1|Patients in Group 1 will receive probe-based confocal endomicroscopy (pCLE) at first and Wight light endoscopy (WLE) 2 months later
62344735|NCT02930616|ACTIVE_COMPARATOR|goup 2|patients in Group 2 will receive WLE at first and pCLE 2 months later.
62502502|NCT04290494||CNSR I (2007 to 2008)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
62502503|NCT04290494||CNSR II (2012 to 2013)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
62701966|NCT01179373|PLACEBO_COMPARATOR|Sham Stimulation|Sham TMS with H Coil on Prefrontal Cortex
61955353|NCT01364818||Active Comparator: Active Medication|Treatment (memantine, lurasidone)/ performance of somatosensory task (cortical metrics) with intervention. The somatosory task will be performed before any intervention has started/at the midpoint/ and finally at the end.
61955354|NCT00443261|EXPERIMENTAL|1 (SCCHN)|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Patients will receive Azacitidine and cisplatin.
61955355|NCT02014025|EXPERIMENTAL|laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept laparoscopic hepatectomy: tumors are totally resected through laparoscopic.
61955356|NCT02014025|EXPERIMENTAL|open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
62344736|NCT01680770||Hypotensive patients in shock|
61955357|NCT03240965||Volunteers <60 years|Volunteers, who are able to consent to participation in the study, as control.
61955358|NCT03240965||Volunteers >60 years|Volunteers, who are able to consent to participation in the study, as control.
62344737|NCT05271396||Temporomandibular Joint Dysfunction Group|Being diagnosed with Temporomandibular Joint Dysfunction
62344738|NCT05271396||Healthy-matched Group|Being healthy according to WHO criteria
62701967|NCT01221116|NO_INTERVENTION|1: Type of surgery|Two types of patients are compared (placebo vs levosimendan): CABG - coronary artery bypass grafting and AVR - aortic valve replacement (either with or without CABG - coronary artery bypass grafting)
62502504|NCT04290494||CNSR III (2015 to 2017)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
61955359|NCT03240965||Stroke patients|Stroke patients with supratentorial stroke, who are able to consent to participation in the study.
62502505|NCT03532750|NO_INTERVENTION|Control|This arm will undergo no study procedures and continue with best medical management. This entails managing pain and draining excess fluid.
62502506|NCT03532750|EXPERIMENTAL|Particle|Randomized to receive either the Embozene or Embosphere particles
62502507|NCT03532750|EXPERIMENTAL|Coil|Randomized to receive either Ruby or Interlock detachable coils
62502508|NCT03885869||Type 2 Diabetics|Type 2 diabetic individuals aged 30-65 years
62502509|NCT01937351|EXPERIMENTAL|Pantheris Treatment Arm|Intervention: Atherectomy using the Pantheris system.
62502510|NCT01310361|EXPERIMENTAL|Amoxicillin|Once-daily Therapy for Streptococcal Pharyngitis With Amoxicillin
62502511|NCT01310361|ACTIVE_COMPARATOR|Benzathin Penicillin G|Once-daily Therapy for Streptococcal Pharyngitis With Intramuscular Benzathin Penicillin G
62502512|NCT06112834|EXPERIMENTAL|Vaccine|rBV A/B
62502513|NCT03824561||Vedolizumab 300 mg|Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
62502514|NCT02020109||Patients with Chronic Lymphatic Leukemia|Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
62502515|NCT06222658|EXPERIMENTAL|Patient assigned to pharmacomechanichal thrombectomy|
62502516|NCT02193607|ACTIVE_COMPARATOR|No TVT-O|Improved reconstruction pelvic surgery
62502517|NCT02193607|EXPERIMENTAL|Combined surgery group|Improved reconstruction pelvic surgery TVT-O procedure
62502518|NCT06506942|EXPERIMENTAL|Transcatheter Tricuspid Valve Replacement|Treatment with the TRiCares Topaz Tricuspid Transcatheter Valve Replacement System
62502519|NCT04073134|ACTIVE_COMPARATOR|Evolocumab|Participants will receive evolocumab 140 mg subcutaneous injections once every 2 weeks.
62502520|NCT04073134|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo subcutaneous injections once every 2 weeks.
62701968|NCT06243770|EXPERIMENTAL|Sequence 1: mRNA-0184|Participants will receive infusion duration 1 of mRNA-0184 on Day 1, followed by a washout period of approximately 21 days. They will then receive infusion duration 2 of mRNA-0184 on Day 22.
62701969|NCT06243770|EXPERIMENTAL|Sequence 2: mRNA-0184|Participants will receive infusion duration 2 of mRNA-0184 on Day 1, followed by a washout period of approximately 21 days. They will then receive infusion duration 1 of mRNA-0184 on Day 22.
62344739|NCT03975374|EXPERIMENTAL|Tobramycin/Dexamethasone opthamic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days
62344740|NCT03975374|ACTIVE_COMPARATOR|Tobradex Opthalmic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days
62344741|NCT04679259|EXPERIMENTAL|Cardiac surgical patients|
62502521|NCT05515107|ACTIVE_COMPARATOR|Blade will placed on vallecula|Active Comparator: Children will be intubated by the C-MAC VL size 1 Miller blade will placed on the base of the tongue (vallecula)
62502522|NCT05515107|PLACEBO_COMPARATOR|Blade will placed under the epiglottis|Placebo Comparator: Children will be intubated by the C-MAC VL size 1 Miller blade will placed under the epiglottis
62502523|NCT05072119||Patients with PM|All patients underwent PM implantation
62502524|NCT05072119||Patients with ICD|All patients undeerwent ICD implantation
62502525|NCT05072119||Patients with ILR|All patients underwent ILR implantation
62502526|NCT06677827|EXPERIMENTAL|group bupivacaine|
62502527|NCT06677827|EXPERIMENTAL|group magnesium sulphate &bupivacaine|
62502528|NCT03241745|EXPERIMENTAL|Nivolumab|Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
62502529|NCT05589259|EXPERIMENTAL|Axillary Brachial Plexus Block plus Physiotherapy|Participants who are randomized to the experimental group (EXP arm) will receive a single-shot axillary-approach brachial plexus block with 1.5mg/kg (up to 50mg total) bupivacaine 0.25% at the Kingston Health Sciences Centre Chronic Pain Clinic (KHSC-CPC). Prior to treatment, a blinded third party will perform a baseline physical exam. Under the brachial plexus block, the physiotherapist will provide standard of care, including manual therapy. The patient will then complete a 6-week physiotherapy program, including GMI. Following the 6 week program, a blind observer will repeat the physical exam.
62502530|NCT05589259|ACTIVE_COMPARATOR|Physiotherapy alone|Participants who are randomized to not receive a block (CON arm) will also have a baseline physical exam performed by a blinded third party. Following baseline data collection, the physiotherapist will provide standard of care, including manual therapy. They will then complete a 6-week home exercise program, including GMI. Following the 6 week program, a blinded observer will repeat the physical exam.
61955360|NCT02378259|EXPERIMENTAL|Bariatric surgery|Roux-en-Y gastric bypass surgery
62344742|NCT02557412|PLACEBO_COMPARATOR|Conventional treatment|Hygiene and diet recommendations on sleep.
62502531|NCT02828280||NuMask|Pt's randomized to Numask first will be ventilated for 10 breaths with the NuMask device first, followed by 10 breaths with the traditional face mask
62502532|NCT02828280||Traditional mask|patients randomized to traditional mask first will receive 10 breaths by traditional mask, followed by 10 breaths with NuMask
62502533|NCT03438006||Cervarix group|Healthy female Chinese subjects aged between 9 and 45 years, vaccinated according to the Prescribing Information (PI) as per routine practice.
62502534|NCT03431337|EXPERIMENTAL|High dose|Amoxicillin/clavulanate 875mg/125mg \& amoxicillin 875 mg twice a day x 7 days
62502535|NCT03431337|ACTIVE_COMPARATOR|Standard dose|Amoxicillin/clavulanate 875 mg/125mg \& placebo (lactase) twice a day x 7 days.
62502536|NCT04724499|EXPERIMENTAL|High-Intensity Intervals Training|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the exercise group (HIIT), will receive an exercise bike and have 3 weekly supervised exercise training sessions for four (4) months/16weeks.~Participants can choose to participate in the exercise sessions at home via zoom or in clinic.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post High-Intensity Intervals Training (HIIT) tests and four (4) month follow up test and receive 3 MRIs over the span of 9 months."
62701970|NCT04252079|OTHER|We compare different endovascular techniques as an alternative|We compare different endovascular techniques as an alternative to surgical reconstruction to repair JAAS regarding ; success rates, 30-day mortality, endoleak events secondary intervention rates
62701971|NCT05478317|ACTIVE_COMPARATOR|Control group: Crown lengthening using a traditional open-flap approach (OF).|Esthetic Crown lengthening done using a traditional open-flap approach (OF).
61955361|NCT02378259|ACTIVE_COMPARATOR|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
61955362|NCT02687997|EXPERIMENTAL|Diagnostic|Patients enrolled in lung cancer screening subjected to a sleep study.
61955363|NCT02687997|NO_INTERVENTION|Contro|Patients enrolled in lung cancer screening not included in the diagnostic intervention arm
61955364|NCT00436839|EXPERIMENTAL|1|Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
61955365|NCT00436839|ACTIVE_COMPARATOR|2|Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
61955366|NCT05009654|EXPERIMENTAL|carnitine + leucine|1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
61955367|NCT05009654|PLACEBO_COMPARATOR|leucine|4000 mg L-leucine per day for 24 weeks
61955368|NCT02946944|EXPERIMENTAL|double drug therapy|
61955369|NCT02946944|ACTIVE_COMPARATOR|mono drug therapy|
61955370|NCT05765396||COVID-19, Flu, and/or RSV positive patients|Participants screened with known COVID-19, Flu, and/or RSV positive test results obtained within 48hrs of recruitment.
61955371|NCT05765396||COVID-19, Flu, and/or RSV negative patients|Participants screened with known COVID-19, Flu, and/or RSV negative test results obtained within 48hrs of recruitment.
62701972|NCT05478317|EXPERIMENTAL|Test group: Crown lengthening using a minimally invasive approach by piezoelectric (PZ).|Esthetic Crown lengthening done using a minimally invasive approach using piezoelectric (PZ).
61955372|NCT02124083|EXPERIMENTAL|Vorinostat|Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.
61955373|NCT02167087|EXPERIMENTAL|Sentinel node mapping|Sentinel node mapping with indocyanine green injected orally and anally to the tumor.
61955374|NCT01326143||ORM Narval MRD|
61955375|NCT03123913|EXPERIMENTAL|Combination therapy|Testosterone Enanthate and Somatropin
61955376|NCT00260481|PLACEBO_COMPARATOR|Control Group|During the Infusion periods, participants in the placebo condition will receive pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg), delivered at the same rate and delivery system to match the active condition. All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
61955377|NCT00260481|ACTIVE_COMPARATOR|Prometa|During the infusion periods, participants assigned to the PROMETA pharmacotherapy condition will receive pre-treatment with hydroxyzine (50mg) followed by intravenous flumazenil (2mg) over a 2-hour period. Before bedtime, patients will again take 50mg of hydroxyzine orally, as well as 300mg of oral gabapentin (participants will titrate up their dosage of gabapentin each day - 300mg on day 0, 600mg on day 1, 900mg on day 2). All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
62701973|NCT01993550|EXPERIMENTAL|Telephone counseling|Telephone counseling to enhance symptom management and reduce distress
62701974|NCT01993550|ACTIVE_COMPARATOR|Education|Overview of resources for psychosocial support and health information
62701975|NCT03286868|PLACEBO_COMPARATOR|Standard of Care TKA|Standard of Care Total Knee Arthroplasty (TKA): No data from the Verasense sensor will be used to influence the surgery
61955378|NCT02688478|ACTIVE_COMPARATOR|Filtered air|Exposure for 3 hours to filtered air followed by subject specific inhaled allergen challenge
61955379|NCT02688478|EXPERIMENTAL|Phthalate|Exposure for 3 hours to dibutyl phthalate followed by subject specific inhaled allergen challenge
62701976|NCT03286868|EXPERIMENTAL|TKA with Verasense sensor|Total Knee Arthroplasty (TKA) with Verasense sensor for Intraoperative Balancing: Surgeon will attempt to optimize the intraoperative pressures using the data from the Verasense sensor
62701977|NCT05663684|EXPERIMENTAL|Participants with no obstruction of the lacrimal system|Patients will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
61955380|NCT00419276|EXPERIMENTAL|Prolonged infusion|At least 100 hours of femoral perineural ropivacaine infusion.
61955381|NCT00419276|PLACEBO_COMPARATOR|Standard-of-Care|Overnight femoral perineural ropivacaine infusion followed by a femoral perineural normal saline infusion (placebo) until postoperative day 4.
61955382|NCT04995991|EXPERIMENTAL|RRT rhythm only|10 RRT rhythm only sessions of 60 minutes, twice a week under the supervision of a trainer
61955383|NCT04995991|EXPERIMENTAL|RRT rhythm + visual cue|10 RRT rhythm + visual cue sessions of 60 minutes, twice a week under the supervision of a trainer
61955384|NCT04995991|NO_INTERVENTION|No intervention|5 weeks no intervention period
61955385|NCT00709761|EXPERIMENTAL|Single Arm|Single arm combination therapy of Lap and NabPaclitaxel combination
61955386|NCT03365492|EXPERIMENTAL|Treatment Arm|Patients with CAD who receive the BioFreedom™ Biolimus A9™ stent.
61955387|NCT03282682|EXPERIMENTAL|hypogonadal males without TRT|Strength training
61955388|NCT03282682|EXPERIMENTAL|hypogonadal males with TRT|Strength training and regular prescribed testosterone therapy given by participant urologist.
61955389|NCT03282682|ACTIVE_COMPARATOR|healthy eugonadal males|Strength training
61955390|NCT04846296||study group|Between 10-16 years old Cobb angle 10-40 degrees Being treated with conservative treatment (brace- exercise) for scoliosis Accepted to answer the questionnaire
61955391|NCT01503918|EXPERIMENTAL|Valaciclovir/Aciclovir|
61955392|NCT01503918|EXPERIMENTAL|Valganciclovir/Ganciclovir|
61955393|NCT01503918|NO_INTERVENTION|control|
61955394|NCT01208792|EXPERIMENTAL|Disease group|Two hundred patients with PAH will be included: 50 patients with idiopathic PAH (iPAH), 20 with PAH associated with HIV infection, 20 with porto-pulmonary hypertension, 20 with PAH secondary to congenital heart disorders, 40 with SSc, 20 with SLE, 20 with MCTD and 10 with a PAH associated with a Sjögren's syndrome. Two hundred patients without PAH will also be included: 80 patients with SSc and 20 in each of the following groups: HIV infection, porto-pulmonary hypertension, SLE, congenital heart disorders, MCTD and with Sjögren's syndrome.
61955395|NCT01208792|OTHER|Control group 1|Two hundred healthy blood donors age and sex-matched with patients with PAH, will be included as controls.
61955396|NCT01208792|OTHER|Control group 2|Twenty patients with proximal chronic thromboembolic pulmonary hypertension (CTPH) will also be included in a control arm of the study.
61955397|NCT03155568|ACTIVE_COMPARATOR|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
61955398|NCT03155568|ACTIVE_COMPARATOR|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
62344743|NCT02557412|ACTIVE_COMPARATOR|Intensive lifestyle intervention|Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
61955399|NCT03155568|ACTIVE_COMPARATOR|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
61955400|NCT03509558|ACTIVE_COMPARATOR|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous electrical stimulation combined with physical therapy that targets rehabilitation of walking and standing functions
61955401|NCT03509558|ACTIVE_COMPARATOR|Physical therapy only|Physical therapy that targets rehabilitation of walking and standing functions
61955402|NCT03773263|EXPERIMENTAL|sequential oocyte IVM group|From day 7\~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. COCs were removed from aspirated follicular fluid and transferred into HEPES-buffered collection medium. The immature oocytes will be cultured in sequential IVM medium 1 for 6 hours (37℃, 5% CO2), and removed into sequential IVM medium 2 for further cultivation. After 24 and 40 hours cultivation, the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle.
61955403|NCT03773263|ACTIVE_COMPARATOR|traditional oocyte IVM group|From day 7\~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. On the day of ovulation, COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed and the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle. If biochemical pregnancy is not achieved, thawed blastocysts transfer will be performed.
61955404|NCT04329403|EXPERIMENTAL|Test Group|Adapalene Gel, 0.1%, applied as thin film once daily for 12 weeks
61955405|NCT04329403|ACTIVE_COMPARATOR|Reference Group|Differin® (Adapalene) Gel, 0.1%, applied as thin film once daily for 12 weeks
61955406|NCT04329403|PLACEBO_COMPARATOR|Placebo Group|Placebo Gel, 0.1%, applied as thin film once daily for 12 weeks
61955407|NCT02809612|EXPERIMENTAL|Internet-based intervention|"Patients randomized to the internet-based intervention will be given access to the information in the internet-based platform directly after randomization. During the first 6 weeks, information will be offered in a structured way, with a theme changing weekly. After this time-point, the patients will have the possibility to navigate through all information. The platform encompasses internet-based training including information on the disorder, psycho-education and information of simple self-implemented intervention strategies cope with vulvodynia and ameliorate dyspareunia. The platform will also include videos where team members will describe their role in treating patients with the disorder, but also short videos from former patients willing to share their individual stories."
61955408|NCT02809612|NO_INTERVENTION|Control group|Patients randomized to the control group through the platform will immediately be informed about the fact that there is available information and resources on the internet and that they will be called for a visit to the physiotherapist-midwife at due time, according to the present guidelines of care followed in the respective clinic (Uppsala, Falun, Gävle).
61955409|NCT05881915|ACTIVE_COMPARATOR|phenylephrine|
61955410|NCT05881915|ACTIVE_COMPARATOR|epinephrine|
62502537|NCT04724499|ACTIVE_COMPARATOR|Attention Control|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the Attention Control group, will receive instruction on a 16 week home-based stretching program.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post home-based stretching program tests and receive 3 MRIs over the span of 9 months.~At the end of the 16-week home-based stretching program, participants will be provided the option to participate in the High-Intensity Intervals Training (HIIT) program."
62502538|NCT06616077|PLACEBO_COMPARATOR|Mife + PLA|Oral mifepristone 200 mg two days after positive LH (LH+2) and vaginal placebo during LH+3 until LH+5
62502539|NCT06616077|EXPERIMENTAL|Mife + P4|Oral mifepristone 200 mg two days after positive LH (LH+2) and vaginal micronized progesterone (600 mg/day) during LH+3 until LH+5
62502540|NCT06616077|ACTIVE_COMPARATOR|PLA + P4|An oral placebo pill two days after positive LH (LH+2) and vaginal micronized progesterone (600 mg/day) during LH+3 until LH+5
62502541|NCT06616077|PLACEBO_COMPARATOR|PLA + PLA|An oral placebo pill two days after positive LH (LH+2) and a vaginal placebo during LH+3 until LH+5
62502542|NCT02751216|EXPERIMENTAL|spinal cord stimulation|
62502543|NCT05853783||OPMDs that progressed to OSCC|No dysplasia, mild, moderate, severe dysplasia, CIS
62502544|NCT05853783||OPMDs that did not progress to OSCC|No dysplasia, mild, moderate, severe dysplasia, CIS
62502545|NCT06613048|EXPERIMENTAL|Experimental (breathing exercise)|"The researcher has a certificate in breathing exercises. Those who consent to participate in the study that meets the research criteria will be given training with a prepared training brochure about correct breathing technique, introduction and function of the diaphragm muscle, box breathing technique, diaphragm breathing technique and benefits of correct breathing before the exercise.~Box breathing technique will be applied in addition to standard treatment, 3 sets per day (morning, noon and evening) for 6 weeks, 10 repetitions in each set.~Diaphragm breathing exercise will be applied in addition to standard treatment, lasting 2 minutes in the first week, then increasing each week and reaching 12 minutes in the 6th week, as 3 sets (morning, noon and evening)."
62502546|NCT06613048|NO_INTERVENTION|Control|The control group will receive standard care. No intervention will be applied to these patients during the follow-up period, only data collection forms will be applied. Data collection forms will be collected in the same time period as the intervention group.
62502547|NCT03840382|EXPERIMENTAL|Tele-PrEP Intervention|The telemedicine intervention will allow participants to discuss HIV prevention and PrEP with PrEP specialists at an academic medical center via videoconference from their local community based organization (CBO). During the intervention, participants will gain information related to HIV and PrEP, view a video to improve motivation for engagement in PrEP related care, and receive resources to address barriers to care.
62502548|NCT05504824|EXPERIMENTAL|Experimental group|"Students in both experimental groups were applied the student information form and the pretest of the CRCF between May 18 and 20, 2021 before the education. The schedule of the education intervention was determined according to the convenience of the students in the experimental group. Accordingly, the experimental group was given education between June 8 and 11, 2021. After the education sessions were completed, experimental groups were applied the CRCF as a posttest on June 28, 2021. The students in the experimental group were asked to fill out the Student Satisfaction with Education Questionnaire and the Form for Views on the Education online."
62502549|NCT05504824|NO_INTERVENTION|Control group|Students in control groups were applied the student information form and the pretest of the CRCF between May 18 and 20, 2021 before the education. The students in the control group continued their current standard education process. After the education sessions were completed, control groups were applied the CRCF as a posttest on June 28, 2021.
62502550|NCT02682550||Ctrl|healthy volunteers, sex- and age matched Blood drawing at one time point: 20 ml
62502551|NCT02682550||PT|"polytrauma patients fulfilling the following criteria:~* injury severity score ≥25~* age ≥ 18 Blood drawing at admission to the emergency room, 8 h, 24h, 48 h, 120 h and 240 h post trauma: 20 ml"
62502552|NCT06256549|EXPERIMENTAL|GZR18|GZR18 injection s.c.
62502553|NCT06256549|ACTIVE_COMPARATOR|Semaglutide|Semaglutide injection s.c.
62502554|NCT01288391|EXPERIMENTAL|100 mcg/kg|
62502555|NCT01288391|EXPERIMENTAL|200 mcg/kg|
62344744|NCT02557412|ACTIVE_COMPARATOR|Continuous positive airway pressure|Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).
62502556|NCT05735158|EXPERIMENTAL|KB105|Weekly topical application
62701978|NCT05663684|EXPERIMENTAL|Participants with obstruction of the lacrimal system|Participants who have a blockage in their tear drainage system on probing and irrigation. Participants will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
62701979|NCT00694863|EXPERIMENTAL|1|In this open-label study all patients included are treated in the experimental group.
62701980|NCT05552404|OTHER|Conservative therapy|will receive conservative therapy such as bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
62344745|NCT00789269|EXPERIMENTAL|1|rhubarb
62502557|NCT05735158|PLACEBO_COMPARATOR|Placebo|Weekly topical application
62502558|NCT01261624|EXPERIMENTAL|Givinostat 1.0 mg/kg daily|
62502559|NCT01261624|EXPERIMENTAL|Givinostat 1.5 mg/kg daily|
62502560|NCT02209116|ACTIVE_COMPARATOR|QB Open|Participants and their clinician will receive results of the Qb Test
62502561|NCT02209116|OTHER|Qb Blind|Participants and their clinician will be blind to the results of the Qb test
62502562|NCT00351351|EXPERIMENTAL|A|Cyberwand
62502563|NCT00351351|ACTIVE_COMPARATOR|B|Currently available lithotripsy technology
62502564|NCT05135273|EXPERIMENTAL|1a (Pilot Group)|(n=5) to receive 12.5 µg Pfs230D1-EPA/25 µg Matrix-M on D1, D29, D57
62502565|NCT05135273|EXPERIMENTAL|1b (Pilot Group)|(n=5) to receive 20 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
62502566|NCT05135273|EXPERIMENTAL|1c (Pilot Group)|(n=5) to receive 40 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
62502567|NCT05135273|ACTIVE_COMPARATOR|1d (Pilot Group)|(n=4) to receive rabies vaccine (standard dose) on D1, D29, D57
62344746|NCT00789269|PLACEBO_COMPARATOR|2|
62502568|NCT05135273|EXPERIMENTAL|2a (Main Group)|(n=15) to receive 12.5 µg Pfs230D1-EPA/25 µg Matrix-M on D1, D29, D57
62502569|NCT05135273|EXPERIMENTAL|2b (Main Group)|(n=15) to receive 20 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
62502570|NCT05135273|EXPERIMENTAL|2c (Main Group)|(n=15) to receive 40 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
62502571|NCT05135273|ACTIVE_COMPARATOR|2d (Main Group)|(n=16) to receive rabies vaccine (standard dose) on D1, D29, D57
62502572|NCT04072315|EXPERIMENTAL|PLN-74809 Dose Level 1 (60 mg)|PLN-74809 Dose Level 1 (60mg)
62502573|NCT04072315|EXPERIMENTAL|PLN-74809 Dose Level 2 (80 mg)|PLN-74809 Dose Level 2 (80 mg)
62502574|NCT04072315|EXPERIMENTAL|PLN-74809 Dose Level 3 (120 mg)|PLN-74809 Dose Level 3 (120 mg)
62502575|NCT04072315|EXPERIMENTAL|PLN-74809 Dose Level 4 (240 mg)|PLN-74809 Dose Level 4 (240 mg)
62502576|NCT04072315|EXPERIMENTAL|PLN-74809 Dose Level 4 (320 mg)|PLN-74809 Dose Level 4 (320 mg)
62502577|NCT05244317|PLACEBO_COMPARATOR|cast group|treatment of the participant of this group will be by the standard method which is by casting
62502578|NCT05244317|EXPERIMENTAL|splint group|treatment of the participant of this group will be by the removable splint
62502579|NCT03538925|EXPERIMENTAL|Treatment Group|AAC Generative Language Intervention
62502580|NCT03538925|ACTIVE_COMPARATOR|Business as Usual|Standard of Care / Business as Usual
62502581|NCT05686824||Midwives and student midwives at one Trust|No intervention - this is an exploratory case study
62502582|NCT06617143|EXPERIMENTAL|Experimental group|In this study, it is planned to apply MBCT to asthmatic inpatients in the patient room in groups of 2 or 3. This application is planned to continue for one hour.
62502583|NCT06617143|ACTIVE_COMPARATOR|Control group|No application will be made to the patients in the control group.
62502584|NCT02902055|ACTIVE_COMPARATOR|Rocuronium 1 mg/kg i.v.|Neuromuscular blocking agent
62502585|NCT02902055|ACTIVE_COMPARATOR|Isotonic saline|
62502586|NCT01304186|EXPERIMENTAL|Tailored Information|Participants in this arm receive the computer-based tailored information application that focuses on improving health literacy related to treatment of HIV infection.
61955411|NCT02201641|EXPERIMENTAL|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
61955412|NCT02201641|EXPERIMENTAL|Cone Beam computed tomography (CBCT)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
61955413|NCT02201641|ACTIVE_COMPARATOR|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
62502587|NCT06157853|ACTIVE_COMPARATOR|Active Post-Procedure Cream|"Dosage Form: reverse emulsion (water in oil) cream containing bioactive ingredients, botanical actives, peptides, and antioxidants.~Frequency of Dosage: Twice daily (morning and evening). Subjects will be asked to massage 2 to 3 pumps of test material onto face, forehead, under eyes, cheeks, upper lips, chin, nose, and neck.~Study duration: 14 days. Active Post-Procedure Cream duration 7-days."
62502588|NCT06157853|OTHER|Comparator Anhydrous Cream|"Dosage Form: anhydrous cream containing peptides, and antioxidants.~Frequency of Dosage: Twice daily (morning and evening). Subjects will be asked to massage 2 to 3 pumps of test material onto face, forehead, under eyes, cheeks, upper lips, chin, nose, and neck.~Study duration: 14 days. Comparator Anhydrous Cream duration 7-days."
62502589|NCT03698487|NO_INTERVENTION|Retrospective Chart Review|"Specifically, it consists of:~* A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).~* A before/after intervention~* A multiple case study (a sub-study of the before/after intervention)"
62502590|NCT03698487|ACTIVE_COMPARATOR|Intervention|"* A before/after intervention~* A multiple case study (a sub-study of the before/after intervention)"
62701981|NCT05552404|ACTIVE_COMPARATOR|Aminophylline|will receive conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
62502591|NCT06126328|ACTIVE_COMPARATOR|Materna Prep Device|Materna Prep Device
62502592|NCT06126328|NO_INTERVENTION|Standard of Care (SOC)|Standard of Care Control
62502593|NCT01345734||Liraglutide|
62502594|NCT06009588|EXPERIMENTAL|Self-expandable valve group|Patients using self-expandable valves
62701982|NCT05552404|ACTIVE_COMPARATOR|transnasal spheno-palatine ganglion block|will receive the conservative therapy plus transnasal spheno-palatine ganglion block under strict protective and safety measures against COVID-19, using a hollow cotton swab soaked in lidocaine 2% for 5 minutes in each nostril then 0.5ml of lidocaine 2% will be injected slowly through the hollow swab and repeated once after another 5 minutes where the patient will stay in the supine position for 10 minutes.
62701983|NCT03274778|EXPERIMENTAL|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
62502595|NCT06009588|EXPERIMENTAL|Balloon-expandable valve group|Patients using balloon-expandable valves
62502596|NCT01265667|EXPERIMENTAL|CF101 2 mg|CF101 2mg oral tablets
62502597|NCT01265667|PLACEBO_COMPARATOR|Placebo|Placebo oral tablets
62502598|NCT00568711|ACTIVE_COMPARATOR|1|a 5-day course of daily 200-mg doses of doxycycline
62502599|NCT00568711|ACTIVE_COMPARATOR|2|a 5-day course of daily 600-mg doses of rifampin
62502600|NCT04618939|EXPERIMENTAL|BR-TD-1001|Randomized subjects were assigned to receive a single dose of BR-TD-1001
62502601|NCT04618939|ACTIVE_COMPARATOR|Td-pur inj|Randomized subjects were assigned to receive a single dose of Td-pur inj
62502602|NCT02666027|EXPERIMENTAL|FIVA ON|The FIVA will be turned on for cases randomized to an even number. The ON light will be covered by tape. Routine induction and maintenance of anesthesia and rate and manner of delivery of IV fluid will be administered at the discretion by the anesthesiologist. The FIVA monitor will only monitor the first IV fluid bag since the study will be unblinded once the FIVA monitor alarm is triggered. When the IV bag is empty and the FIVA alarm is triggered, the anesthesiologist will turn off the FIVA and change the IV bag. The following will be recorded by the anesthesiologist: Type of surgical procedure; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA during the procedure; VAS assessment of ease of use of the FIVA; Loudness of audial alarm of the FIVA.
62502603|NCT02666027|PLACEBO_COMPARATOR|FIVA OFF|The FIVA will be off for cases randomized to odd numbers. The indicator lights will be covered by tape. Routine induction and maintenance of anesthesia and rate/manner of delivery of IV fluid will be administered at the discretion of the anesthesiologist. The IV bag may run dry with or without being noticed by the anesthesiologist. When they detect the empty bag, it will be changed after the removal of the FIVA. The anesthesiologist will record the presence or absence of air in the IV tubing following the termination of the study. The following will be recorded by the anesthesiologist: Type of surgery; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA device; VAS assessment of ease of use of the FIVA; Assessment of audial alarm of the FIVA.
62502604|NCT06128187|ACTIVE_COMPARATOR|Control Group|Participants will undergo a conventional upper extremity rehabilitation program for 45 minutes daily, 5 days a week, for 6 weeks. After the conventional rehabilitation program, 30 minutes of virtual reality training for the upper extremity will be applied.
62701984|NCT02663193||Enzalutamide Group|Participants who are receiving enzalutamide in a clinical practice setting will be observed for tolerability and quality of life.
62701985|NCT02663193||Abiraterone Acetate plus Prednisone group|Participants who are receiving abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
62701986|NCT05099315||Dupilumab treated Patients (observational)|Patients with atopic dermatitis with indication for dupilumab treatment will be observed.
62701987|NCT05099315||Cyclosporine treated Patients (observational)|Patients with atopic dermatitis with indication for cyclosporine treatment will be observed.
62701988|NCT05099315||Baricitinib treated Patients (observational)|Patients with atopic dermatitis with indication for baricitinib treatment will be observed.
62701989|NCT06489509|ACTIVE_COMPARATOR|Supine position|Supine experimental position
62142304|NCT05964426||Turkey Health Literacy Scale (TSOY-32)|It is a 32-question scale developed based on the Conceptual Framework of the European Health Literacy Scale Study. The Turkish Health Literacy Scale (TSOY-32) was developed to assess health literacy in literate people over the age of fifteen. Unlike the original scale, the scale consists of eight components including two dimensions (treatment and service, disease prevention and health promotion) and four processes (accessing health-related information, understanding health-related information, evaluating health-related information, and using/applying health-related information). The overall internal consistency coefficient of the scale was 0.92. The Cronbach's alpha coefficient of the first dimension 'Treatment and Service Subdimension' is 0.88. The Cronbach's alpha coefficient of the second dimension 'Disease Prevention and Health Promotion Dimension' is 0.86. Permission to use the scale was obtained.
62142305|NCT06274099|EXPERIMENTAL|EXPERIMENTAL GROUP|This group will be given designated nursing care.
62142306|NCT06274099|ACTIVE_COMPARATOR|CONTROL GROUP|Routine nursing care will be provided to this group.
62142307|NCT05782699|EXPERIMENTAL|patch monitoring|
62701990|NCT06489509|ACTIVE_COMPARATOR|Right position|Right lateral decubitus
62701991|NCT06489509|ACTIVE_COMPARATOR|Left position|Left lateral decubitus
62701992|NCT05107076||STEMI patients who underwent PPCI|"2D Echocardiography with color Doppler assessment will be done within 24 h after PPCI~Biochemical measurements:~Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.~Follow up 2D Doppler echocardiography will be repeated at 40 days of the event."
62701993|NCT05892900|EXPERIMENTAL|Transcutaneous vagus nerve stimulation (tVNS)|"1 tVNS session of ca 45 minutes~The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve"
62142308|NCT05782699|ACTIVE_COMPARATOR|standard BP monitoring|
62142309|NCT00775866|EXPERIMENTAL|MRI guided prostate biopsy|
62142310|NCT02113267|EXPERIMENTAL|Mometasone furoat|Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
62142311|NCT02113267|PLACEBO_COMPARATOR|Placebo spray|Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
62701994|NCT05892900|SHAM_COMPARATOR|Sham Transcutaneous vagus nerve stimulation (tVNS)|"1 sham tVNS session of ca 45 minutes~The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation"
62701995|NCT00216190|EXPERIMENTAL|Dexmedetomidine|
62701996|NCT00216190|ACTIVE_COMPARATOR|Midazolam|
62701997|NCT02988076|NO_INTERVENTION|Control|The Control group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Treatment/Experimental group. A clinician treating a Control Group subject will NOT receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
62142312|NCT04163237|EXPERIMENTAL|PD-1 & Sorafenib|
62142313|NCT04163237|OTHER|Sorafenib|
62344747|NCT00748085|EXPERIMENTAL|Cryospray Ablation|Cryospray Ablation 4, 5-second spray cycles
62344748|NCT01671956|EXPERIMENTAL|Bertilimumab|Bertilimumab 10 mg/kg will be administered by IV infusion over 30 minutes
62502605|NCT06128187|ACTIVE_COMPARATOR|Study Group|Participants will undergo a conventional upper extremity rehabilitation program for 45 minutes a day, 5 days a week, for 6 weeks. In addition to the conventional rehabilitation program, dual-task training will be provided with a 30-minute virtual reality training program. Cognitive tasks will be given in addition to virtual reality training as dual-task training.
62502606|NCT01030094||Topiramate|Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
62502607|NCT01030094||Carbamazepine|Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
62502608|NCT01030094||Valproic acid|Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
62502609|NCT01030094||Normal Control|Healthy female participants will be observed in Normal control group.
62502610|NCT04067154|EXPERIMENTAL|ALPE-TAC|ARDS patients on mechanical ventilation. Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O to evaluate potential for recruitment and measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
62502611|NCT06024967|EXPERIMENTAL|GenSci004|
62502612|NCT04141878|ACTIVE_COMPARATOR|Aerobic Exercise Group|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise will vary, but will primarily focus on in-class walking tutorials. Participants will work with a Personal Trainer to create their own physical activity program that will fit their needs and schedule. The Personal Trainer will supervise the participants directly for the first 6 weeks. Once participants are consistently and safely meeting their goals, their Personal Trainer will allow unsupervised exercise sessions.
62502613|NCT04141878|ACTIVE_COMPARATOR|Diet Skills Group|Participants will attend weekly classes focused on incorporating heart healthy foods (e.g., fruits and vegetables) into their existing dietary plan. We will ask them to limit the number of calories they take in and will show them how to use portion control with the goal of losing body weight. Participants will also learn hands-on skills for preparing healthy meals at home in cooking classes led by professional chefs.
62502614|NCT04214288|EXPERIMENTAL|AZD9833 Dose A|The patients will receive AZD9833 (Dose A).
62502615|NCT04214288|EXPERIMENTAL|AZD9833 Dose B|The patients will receive AZD9833 (Dose B).
62502616|NCT04214288|EXPERIMENTAL|AZD9833 Dose C|The patients will receive AZD9833 (Dose C).
62502617|NCT04214288|ACTIVE_COMPARATOR|Fulvestrant 500 mg|The patients will receive Fulvestrant (500 mg).
62502618|NCT01776528|EXPERIMENTAL|Cohort 1 SAD|NGM282 Dose 1 vs Placebo
62502619|NCT01776528|EXPERIMENTAL|Cohort 2 SAD|NGM282 Dose 2 vs Placebo
62502620|NCT01776528|EXPERIMENTAL|Cohort 3 SAD|NGM282 Dose 3 vs Placebo
62502621|NCT01776528|EXPERIMENTAL|Cohort 4 SAD|NGM282 Dose 4 vs Placebo
62502622|NCT01776528|EXPERIMENTAL|Cohort 5 SAD|NGM282 Dose 5 vs Placebo
62502623|NCT01776528|EXPERIMENTAL|Cohort 6 SAD|NGM282 Dose 6 vs Placebo
62502624|NCT01776528|EXPERIMENTAL|Cohort 7 MAD|NGM282 Dose 1 vs Placebo
62502625|NCT01776528|EXPERIMENTAL|Cohort 8 MAD|NGM282 Dose 2 vs Placebo
62502626|NCT01776528|EXPERIMENTAL|Cohort 9 MAD|NGM282 Dose 3 vs Placebo
62502627|NCT01776528|EXPERIMENTAL|Cohort 10 MAD|NGM282 Dose 4 vs Placebo
62502628|NCT01776528|EXPERIMENTAL|Cohort 11 MAD|NGM282 Dose 5 vs Placebo
62701998|NCT02988076|ACTIVE_COMPARATOR|Treatment|Intervention - Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report - Treatment group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Control group. A clinician treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
61955414|NCT02201641|ACTIVE_COMPARATOR|Glass ionomer cement ( Fuji IX™)|Glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
61955415|NCT03925480|EXPERIMENTAL|Azithromycin|A single 2g dose of Azithromycin
62502629|NCT01776528|EXPERIMENTAL|Cohort 12 MAD|NGM282 Dose 6 vs Placebo
62502630|NCT01413945||Normal volunteers|Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
62502631|NCT01413945||Irritable bowel syndrome|Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.
62502632|NCT02690935|EXPERIMENTAL|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH~Impregnated on lactose saccharose globules (380 mg/capsule)"
62502633|NCT02690935|PLACEBO_COMPARATOR|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
62502634|NCT00810706|NO_INTERVENTION|1: observation only|Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
62502635|NCT00810706|ACTIVE_COMPARATOR|2: Exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment
62502636|NCT06367647||apparently healthy individuals|
62502637|NCT06367647||parenteral virus infected patients|
62502638|NCT03147924|EXPERIMENTAL|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
62502639|NCT00040794|EXPERIMENTAL|Stratum I (gefitinib, radiotherapy)|"Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
62502640|NCT00040794|EXPERIMENTAL|Stratum II (gefitinib, radiotherapy, chemotherapy)|"Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
62502641|NCT04878237|PLACEBO_COMPARATOR|Non Allergic Patients|
62502642|NCT04878237|ACTIVE_COMPARATOR|Allergic Asthma Patients|Allergy to Grass Pollen
62502643|NCT04878237|ACTIVE_COMPARATOR|Allergic Rhinitis Patients|Allergy to Grass Pollen
62502644|NCT01752530|EXPERIMENTAL|Computer program C8 + treatment as usual|Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
62502645|NCT01752530|OTHER|Treatment as usual|Treatment as usual at the clinic
62502646|NCT03227133|EXPERIMENTAL|Single arm|Psychiatric interview, Neuropsychological evaluations, cardiovascular risk assessment
62502647|NCT03321045|EXPERIMENTAL|[89Zr]-Df-Trastuzumab|\[89Zr\]-Df-Trastuzumab \[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 millicurie (mCi) at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.
62701999|NCT06307457||Palbociclib in combination with AI|Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI, in Denmark.
62702000|NCT05164653|EXPERIMENTAL|Sacubitril Valsartan Sodium Hydrate|Entresto® Tablets
62702001|NCT05164653|ACTIVE_COMPARATOR|No Sacubitril Valsartan Sodium Hydrate|Standard treatment for HF (ARB, ACE inhibitor etc.)
62702002|NCT04391335||Group 1|Participants who meet the screening criteria for the development of bronchiolitis obliterans syndrome (BOS) according to the NIH criteria
62702003|NCT04391335||Group 2|Participants who may or may not have abnormal spirometry; however they do not fulfill the NIH criteria for the development of BOS
61955416|NCT03925480|PLACEBO_COMPARATOR|Placebo|Matching Placebo
61955417|NCT02398760|EXPERIMENTAL|Motor Control Exercises|(Costa LOP et al. 2009; Hodges PW et al. 2009)
61955418|NCT00926328|ACTIVE_COMPARATOR|A -Experimental toothpaste|triclosan/copolymer/fluoride toothpaste
61955419|NCT00926328|PLACEBO_COMPARATOR|B - control toothpaste|sodium fluoride only toothpaste (placebo)
62142314|NCT02615132|EXPERIMENTAL|Treatment Group|The study SLP will instruct the patient to use the ipad apps as intervention for at least one-hour per day, until they are admitted to outpatient SLP services or for a maximum of 8 weeks, whichever comes first. Throughout the telemedicine treatment phase, patients' progress will be monitored remotely by a study SLP through Apps/Skype/Facetime/Telephone consultation on a weekly basis.
62142315|NCT02615132|NO_INTERVENTION|Control|Patients will be sent home with standard of care.
62142316|NCT01589341||Correlative studies|Archived DNA samples are analyzed (laboratory biomarker analysis) for segmental chromosome aberrations by MLPA, a PCR-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
62502648|NCT06679205|ACTIVE_COMPARATOR|Pharmacological control|The subjects in the control group will be treated following a pharmacological approach according to the latest clinical guidelines for patients with chronic low back pain. Thus, the pharmacological options to be considered in each patient will be those included in the first and second analgesic steps of the WHO (preferably without including minor opioids).
62502649|NCT06679205|EXPERIMENTAL|PAINDOC program|The PAINDOC Program is a multidisciplinary treatment that integrates four parts provided by different health professionals and consists of 7 sessions carried out in the pain unit of the Hospital Clinic of Barcelona over 2 months. It consists of a therapeutic education session (Empowered Relief®) given by a physician from the unit, a pain psychology session given by a psychologist, and 2 pain neuroscience education sessions and 3 therapeutic exercise sessions given by a physiotherapist. This program is already part of the pain unit's routine care practice, so it is considered that the sessions of this program do not represent an additional and specific visit for the patients.
62702004|NCT01427439||Major Depressive Disorder|
62702005|NCT01657357||PAO, osteoarhritis, THA|
62702006|NCT01831908|SHAM_COMPARATOR|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
62702007|NCT01831908|NO_INTERVENTION|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
62702008|NCT04994613|NO_INTERVENTION|Control Group|The patient will be reserved a standard room in the preoperative area of main campus. This room will not include any additional sensory equipment. The child will be allowed to use any comfort items the family brought with them or offered a hospital iPad, as is current practice for all outpatient surgery patients.
62142317|NCT06071052|EXPERIMENTAL|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer|liver metastasis of colorectal cancer patients who fail the second line, receive transhepatic artery irinotecan vehicle microsphere embolization and perfusion chemotherapy combined with regorafenib
62702009|NCT04994613|EXPERIMENTAL|Sensory Adaptive Environment Group|One of the three dedicated adaptive sensory rooms in the preoperative area of main campus will be set up by nursing and child life staff in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli. The equipment may include a portable popcorn tube with fiberoptic cart, handheld marble panel, color changing floor tiles, other sensory friendly objects, and individual sensory toys. This room will be set up prior to the patient's arrival the day of surgery and reserved for their use.
62702010|NCT05032378||People with movement disorders|Adults with acquired movement disorders secondary to neurological injury.
62702011|NCT05032378||Professionals|Professionals providing physical or occupational therapy to participants with acquired movements disorders.
62702012|NCT02090764|EXPERIMENTAL|Ozenoxacin|ozenoxacin cream 1%
62702013|NCT02090764|PLACEBO_COMPARATOR|Placebo|Placebo cream
62344749|NCT01671956|PLACEBO_COMPARATOR|Placebo|Phosphate buffered saline (PBS) placebo will be administered by IV infusion over 30 minutes.
62502650|NCT00003317|ACTIVE_COMPARATOR|Surgery + paclitaxel + carboplatin|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
62502651|NCT00003317|EXPERIMENTAL|Surgery + paclitaxel + carboplatin + radiotherapy|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients receive radiotherapy 5 days a week for 5 weeks to the mediastinum, beginning 2.5 to 4 weeks after completion of chemotherapy. Patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
62502652|NCT01260337|ACTIVE_COMPARATOR|Diabetes Support and Education (DSE)|
62502653|NCT01260337|EXPERIMENTAL|Portion controlled diet (PCD)|behavior modification
62502654|NCT02824185|EXPERIMENTAL|FCH-PET/MRI|FCH-PET/MRI exam performed in addition to the usual examinations for monitoring hepatocellular carcinoma.
62502655|NCT06453824|ACTIVE_COMPARATOR|Single Ascending Dose (SAD) 1|MDI-2517 tablet, single oral dose or placebo
62502656|NCT06453824|ACTIVE_COMPARATOR|SAD 2|less than or equal to twice the highest MDI2517 dose administered to date, or placebo
62502657|NCT06453824|ACTIVE_COMPARATOR|SAD 3|less than or equal to twice the highest MDI2517 dose administered to date, or placebo
62702014|NCT01943227||6ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 6ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
62702015|NCT01943227||9ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 9ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
62702016|NCT01241123|PLACEBO_COMPARATOR|Traditional Ambulation regimen|All patients will receive pedometers to record the total amount of ambulation. These patients will ambulate without limitations or goals. Most surgeons request that post-operative patients ambulate at least 2 to 3 times a day.
62702017|NCT01241123|ACTIVE_COMPARATOR|Walkers|All patients will receive pedometers to record the total amount of ambulation. Patients in the experimental group will have assigned nursing staff assisting in ambulation in these patients at least three times a day.
62702018|NCT06526234||Patients with Crohn's disease or suspected Crohn's disease|
61955420|NCT04058730|EXPERIMENTAL|LRYGBP|"Laparoscopic Roux en Y Gastric by pass surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic RYGB is primarily a restrictive procedure with a small element of malabsorption.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge."
61955421|NCT04058730|EXPERIMENTAL|LSG|Laparoscopic Sleeve Gastrectomy surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic Sleeve Gastrectomy is a pure restrictive procedure. Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge
62502658|NCT06453824|ACTIVE_COMPARATOR|SAD 4|less than or equal to twice the highest MDI2517 dose administered to date, or placebo
62502659|NCT06453824|ACTIVE_COMPARATOR|SAD 5|less than or equal to twice the highest MDI2517 dose administered to date, or placebo
62502660|NCT06453824|ACTIVE_COMPARATOR|SAD 6|less than or equal to twice the highest MDI2517 dose administered to date, or placebo
62502661|NCT06453824|ACTIVE_COMPARATOR|SAD 7|less than or equal to twice the highest MDI2517 dose administered to date, or placebo
62502662|NCT06453824|ACTIVE_COMPARATOR|SAD 8|less than or equal to twice the highest MDI2517 dose administered to date, or placebo
62502663|NCT00485004|EXPERIMENTAL|Cutting balloon|Cutting balloon
62702019|NCT01715558||RYTHMIQ study group|
62702020|NCT01715558||Historical control from OPTI-MIND|
62702021|NCT00758563|PLACEBO_COMPARATOR|A|
62702022|NCT00758563|ACTIVE_COMPARATOR|B|
62702023|NCT03622151|EXPERIMENTAL|Intervention group|Primer la Llar Program (housing first model): to live in permanent and individual housing and receiving weekly visits from a multidisciplinary team.
62702024|NCT03622151|NO_INTERVENTION|Control group|"Treatment as usual:~attention from the resources of the homeless network in Barcelona."
62702025|NCT02299999|EXPERIMENTAL|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
62502664|NCT00485004|ACTIVE_COMPARATOR|Sirolimus-eluting stent|Sirolimus-eluting stent
62502665|NCT02910024|ACTIVE_COMPARATOR|Real-rTMS|Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
62502666|NCT02910024|SHAM_COMPARATOR|Sham-rTMS|Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
62502667|NCT02579538||Total Knee Arthroplasty|Patients undergoing unilateral total knee arthroplasty
62502668|NCT02579538||Thoracic/Breast Surgery|Patients undergoing mastectomy, thoracotomy, or video-assisted thoracoscopic surgery (VATS)
62502669|NCT03029117||corrected and uncorrected rheumatic valve lesions|
62502670|NCT00480324|EXPERIMENTAL|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
62502671|NCT00480324|PLACEBO_COMPARATOR|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
62502672|NCT01557920|ACTIVE_COMPARATOR|Propofol|The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
62502673|NCT01557920|ACTIVE_COMPARATOR|Sevoflurane|The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
62502674|NCT06465875|EXPERIMENTAL|Intervention group|The intervention group will be read a storybook for three nights outside the routine practices of the clinic.
62502675|NCT06465875|NO_INTERVENTION|Control group|The control group will not be subjected to any practice other than the routine practices of the clinic.
62502676|NCT02136706|NO_INTERVENTION|10/30 min rest/stress|Rest and stress T99m-MPI obtained 10 minutes and 30 minutes after tracer injection. After the myocardial perfusion imaging the investigators will have 10 minute waiting period to take images and then wait the 30 minutes, standard of care to take the images.
62502677|NCT01735786||Treatment group|Subjects in this group will received Endoclot treatment immediately after EMR.
62502678|NCT01735786||Control group|Subjects in this group will not received any hemostasis treatment after EMR.
62502679|NCT05496673|EXPERIMENTAL|Participants with meningitis or risk factors for meningitis|Patients who are assessed at outpatient clinics near Lira, Uganda, Lira Regional Referral Hospital emergency room or are admitted to Lira Regional Referral Hospital with meningitis symptoms (defined as headache or irritability in combination with fever, confusion or Glasgow coma scale (GCS) \<14, photophobia, neck pain/stiffness, seizure or bulging fontanel) or are deemed at risk for meningitis will be approached to participate in the study. Experimental molecular diagnostic testing such as cryptococcal antigen lateral flow assay, Pastorex antigen agglutination assay and/or Biofire PCR assay will be performed based on HIV status and a clinical assessment identify infectious agents.
62502680|NCT01463982|EXPERIMENTAL|Oratecan and Capecitabine|"Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14"
62502681|NCT05678517||Patients|Patients with AMD
62502682|NCT06678906|NO_INTERVENTION|Control arm|Control group will receive standard information about physical activity and sedentary lifestyle.
62502683|NCT06678906|EXPERIMENTAL|Intervention arm|All patients in the intervention group will benefit from the standard information phase on physical activity and sedentary behavior, as well as personalized support for behavior change in the form of a serious game and remote coaching.
62502684|NCT04523246|EXPERIMENTAL|Shingrix|Shingrix Dosage: two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90).
62502685|NCT04523246|PLACEBO_COMPARATOR|Normal Saline|Sterile Normal Saline Solution, two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90)
62502686|NCT05889273|EXPERIMENTAL|ML-004 (IR)/(ER) tablet|ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets).
62502687|NCT05188924|EXPERIMENTAL|DKF-306|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
62502688|NCT05188924|PLACEBO_COMPARATOR|Placebo|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
62502689|NCT06466005||Active non-medical opioid user|Person who has used an opioid, e.g., heroin, fentanyl, non-medically in the past 30 days.
62502690|NCT06466005||Active prescription medical opioid user|Person who has used an opioid, e.g., hydrocodone, with a medical prescription in the past 30 days.
62502691|NCT06466005||Person in recovery from opioid misuse|Person who formerly used opioids non-medically and/or is on opioid replacement therapy.
62502692|NCT06466005||Caregiver/family members of groups 1, 2, 3|Person who is caring for or a family member of active non-medical user, medical user, or person in recovery.
62502693|NCT06466005||Concerned community member|Person in the community who is concerned about the opioid overdose crisis and is interested addressing the problem.
62502694|NCT00722839|EXPERIMENTAL|Group A|Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
62502695|NCT00722839|EXPERIMENTAL|Group B|Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
62502696|NCT04650750|EXPERIMENTAL|Xiao-Feng-San; Shian-Fang-Hwa-Ming-Yiin|Xiao-Feng-San 2g+ Shian Fang Hwa Ming Yiin 2g; twice a day for two months
62344750|NCT04433624|ACTIVE_COMPARATOR|Group (B)|will receive The bilateral ESP blocks before surgery
62502697|NCT04650750|PLACEBO_COMPARATOR|Placebo|Similar placebo 4g twice a day for two months
62502698|NCT05467982|EXPERIMENTAL|Integrated Illness Management and Recovery (I-IMR) PLUS COVID-19 ENHANCEMENT:|In addition to the primary intervention (Integrated Illness Management and Recovery), participants received 3 additional COVID-19 related educational/skills training sessions provided individually, remotely by I-IMR Specialists.
61955422|NCT04058730|EXPERIMENTAL|SMM|"Standard Medical Management will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Standard Medical management will be as per the recommendation of ADA 2010 guidelines.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients 1 month, 3 months, 12 months and 24 months post consult"
62502699|NCT05467982|EXPERIMENTAL|Stanford Chronic Disease Self-Management Program (CDSMP) ONLY:|No additional COVID-19 intervention was provided to this group. These participants only received the primary disease management intervention (CDSMP)
62502700|NCT04975451|EXPERIMENTAL|ADCb|Anlotinib (anlotinib 12mg qd p.o. d1-14/21day/cycle)and Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve \[AUC\] 6, intravenously every 3 weeks) for six cycles
62502701|NCT00585312|EXPERIMENTAL|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
62502702|NCT00585312|PLACEBO_COMPARATOR|Placebo|Masked, placebo comparator
62502703|NCT05806931|EXPERIMENTAL|Tolerability of TAS-102, oxaliplatin, irinotecan with bevacizumab|Each treatment cycle will be fourteen days long. TAS-102 25 mg/m2 will be taken orally twice daily on days 1-5 of each cycle. Oxaliplatin 85 mg/m2 infusion will be given on day one for one cycle alternating with Irinotecan 150 mg/m2 infusion, which will be given on day one the next cycle.
61955423|NCT04564261|EXPERIMENTAL|myPlan Teen Group|Personalized Healthy Relationship and Safety Planning Tool.
62142318|NCT01212822|EXPERIMENTAL|Treatment (bevacizumab, FOLFOX)|"NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab.~ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity."
62344751|NCT04433624|ACTIVE_COMPARATOR|Group B MG|will receive bilateral ESP blocks performed by each side) before surgery
61955424|NCT04564261|ACTIVE_COMPARATOR|Usual Care Teen Control Group|Usual Care Teen Relationships and Health Resource.
62344752|NCT00223691|EXPERIMENTAL|1: active intervention|atomoxetine, pyridostigmine bromide, yohimbine, midodrine hcl, modafinil, octreotide, water intake, ranitidine hcl, diphenhydramine hydrochloride, tranylcypromine, ergotamine/ caffeine, celecoxib, pseudoephedrine, methylphenidate, indomethacin, ibuprofen, Oxymetazoline 0.05% nasal solution, acarbose, Rivastigmine tartrate, acetazolamide, carbidopa/levodopa, inflatable abdominal binder or bovril
62344753|NCT00223691|PLACEBO_COMPARATOR|2: Placebo or sham device|placebo pill or inflatable abdominal binder (sham)
61955425|NCT05409326|EXPERIMENTAL|TQH2722 injection|Participants will receive single dose of TQH2722 injection under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of TQH2722 injection once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
62344754|NCT04840706|ACTIVE_COMPARATOR|Airvo|Patients allocated to use Airvo device
62344755|NCT04840706|PLACEBO_COMPARATOR|Control|Patients not using Airvo, standard care
62344756|NCT05831618|EXPERIMENTAL|Interactive Visuo-Vestibular training|"Interactive Visuo-Vestibular training consists of exercises that stimulate saccadic movements during motor activities on the treadmill. Furthermore, a dynamic blindfolded training will be performed with the support and supervision of the physiotherapist.~Patients will perform 5 sessions, 1 session per week."
62344757|NCT05831618|ACTIVE_COMPARATOR|Vestibular rehabilitation training|"The conventional vestibular rehabilitation training will train the vestibular reflexes.~Patients will perform 5 sessions, 1 session per week."
62344758|NCT01806376|EXPERIMENTAL|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
62344759|NCT05044585|EXPERIMENTAL|Remote Automated Monitoring System|Two MultiSense® patches will be placed on each volunteer. The monitoring will last no more than 3 hours, during an induced and controlled hypoxia.
62344760|NCT00661349|ACTIVE_COMPARATOR|1|Nevirapine
62344761|NCT00661349|EXPERIMENTAL|2|Lopinavir/ritonavir
62344762|NCT00901147|EXPERIMENTAL|panobinostat and bortezomib|Oral Panobinostat and intravenous bortezomib
62344763|NCT02863939|OTHER|NICAS|There is only one arm - a single cohort. All patients undergoing the nuclear stress test will also have the NICAS evaluation.
62344764|NCT03677310|EXPERIMENTAL|3% sodium chloride|Subjects in this group will receive 3% sodium chloride over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
62344765|NCT03677310|SHAM_COMPARATOR|Normal Saline|This group will receive normal saline over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
62344766|NCT03536598|EXPERIMENTAL|Test|Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
62344767|NCT03536598|ACTIVE_COMPARATOR|Reference 1|Amlodipine 10mg + Valsartan 160mg
62344768|NCT03536598|ACTIVE_COMPARATOR|Reference 2|Valsartan 160mg + Rosuvastatin 20mg
62344769|NCT02063919||endomicroscopy|
62344770|NCT01894529||Ischemic stroke|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis
62344771|NCT01894529||Healthy subjects|Age-matched individuals free of acute neurological injury
62344772|NCT04699552|EXPERIMENTAL|2J 20 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 20Hz
62344773|NCT04699552|EXPERIMENTAL|2J 40 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 40Hz
62344774|NCT04699552|EXPERIMENTAL|2J 60 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 60Hz
62344775|NCT01927419|EXPERIMENTAL|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
62502704|NCT03935841|EXPERIMENTAL|3-OHB orally|36 gram 3-OHB salt consumed orally
62702026|NCT02299999|ACTIVE_COMPARATOR|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
61955426|NCT05409326|PLACEBO_COMPARATOR|Placebo to match TQH2722|Participants will receive single dose of matching placebo under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of matching placebo once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
61955427|NCT00884728||Indigenous children aged <15 years|Indigenous children aged \<15 years within participating communities of the Northern Territory
61955428|NCT00840892|EXPERIMENTAL|Intercom|INTERdisciplinary COMmunity-based COPD management (INTERCOM)
61955429|NCT00840892|NO_INTERVENTION|Usual Care|
61955430|NCT03896386|OTHER|Use of seizure diary|People diagnosed with epilepsy that lives with a dog that is able to anticipate the onset of a seizure. They will be ask to use a diary (bespoke smartphone app) to register the occurrence of seizures and the alerting behaviour of the dogs.
61955431|NCT03673852|OTHER|Peer Wellness Enhancement (WE Harambee)|This project employs a pragmatic, stepped wedge experimental design in which 60 BHH participants are randomly assigned to one of 3 waves of WE Harambee implementation (20 in each wave) during the 2 year study. Participants in this arm receive the WE Harambee Wellness Enhancement and are enrolled in a Behavioral Health Home. WE Harambee is a 6-month peer-delivered whole health intervention intended to address the 8 dimensions of wellness and the social determinants of health.
61955432|NCT03673852|OTHER|Behavioral Health Home enrollment|"In the stepped wedge experimental design, 40 participants at any time during the 2 year study are receiving only the Behavioral Health Home (BHH) intervention. The 2010 Patient Protection and Affordable Care Act (ACA) established a health home option under Medicaid that serves enrollees with chronic conditions including serious mental illness and chronic physical illness."
61955433|NCT01743716||MDD Mothers|Adult women with a history of major depressive disorder (MDD) and a healthy adolescent daughter between the ages of 12-14
61955434|NCT01743716||Healthy Control Mothers|Adult women with no history of psychopathology and an adolescent daughter between the ages of 12-14
61955435|NCT01743716||High Risk Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the MDD Mothers cohort
61955436|NCT01743716||Healthy Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the Healthy Control Mothers cohort.
61955437|NCT05239208|EXPERIMENTAL|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
61955438|NCT05239208|ACTIVE_COMPARATOR|Control Group|Dietary counseling
61955439|NCT06445881|EXPERIMENTAL|Modified Si Jun Zi Tang Combined with Chemotherapy and Immunotherapy|Participants will receive Modified Si Jun Zi Tang combined with chemotherapy (albumin-bound paclitaxel or pemetrexed + carboplatin) and PD1 monoclonal antibody, followed by surgery if feasible. Postoperatively, they will continue with Modified Si Jun Zi Tang and PD1 monoclonal antibody for up to one year.
61955440|NCT06445881|NO_INTERVENTION|Standard Chemotherapy and Immunotherapy|Participants will receive standard chemotherapy (albumin-bound paclitaxel or pemetrexed + carboplatin) and PD1 monoclonal antibody, followed by surgery if feasible. Postoperatively, they will continue with PD1 monoclonal antibody for up to one year.
61955441|NCT01935791|ACTIVE_COMPARATOR|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of gelofusine without a cooling vest."
61955442|NCT01935791|EXPERIMENTAL|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min without a cooling vest.
62502705|NCT03935841|ACTIVE_COMPARATOR|3-OHB intravenously|Variable amounts of 3-OHB salt given i order to replicate the same individual plasma concentrations measured during the experimental arm.
62502706|NCT01458613||Observation|Patients with Maroteaux-Lamy disease
62702027|NCT02299999|EXPERIMENTAL|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
61955443|NCT01935791|ACTIVE_COMPARATOR|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~No brown adipose tissue (BAT) identified on visit 1, therefore no visit 2."
62702028|NCT02299999|ACTIVE_COMPARATOR|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
62702029|NCT01827189||Comprehensive primary care practices|Comprehensive primary care practices are the intervention group.
62702030|NCT01827189||Comparison practices|Comparison practices are the case-control group--the matched set of practices in a comparison area--whose patients' outcomes will be compared to those of intervention practices.
62702031|NCT06639529|EXPERIMENTAL|normal control|Tests of the expression of CXCL3 in various tissues
62702032|NCT06639529|EXPERIMENTAL|diabetic mellitus|Tests of the expression of CXCL3 in various tissues
62702033|NCT06639529|EXPERIMENTAL|diabetic kidney disease|Tests of the expression of CXCL3 in various tissues
62702034|NCT01766687|EXPERIMENTAL|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
61955444|NCT01935791|EXPERIMENTAL|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius. Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
62502707|NCT02565017||Breast Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
62502708|NCT02565017||Lung Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
62502709|NCT02565017||Colorectal Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
62502710|NCT04459676|ACTIVE_COMPARATOR|ANG-3777 + SOC|"ANG-3777 Administered IV for 30 min and SOC~Repeat within 24 hours after previous dosing for a total of 4 days"
61955445|NCT01935791|EXPERIMENTAL|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius."
62702035|NCT01766687|NO_INTERVENTION|Control|
61955446|NCT01935791|EXPERIMENTAL|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius."
62344776|NCT01927419|EXPERIMENTAL|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
62344777|NCT03195504|EXPERIMENTAL|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
62344778|NCT03195504|ACTIVE_COMPARATOR|CON (control)|Standard flow oxygen during induction of anesthesia
62344779|NCT01167582|EXPERIMENTAL|Liberal Transfusion Strategy|Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.
62344780|NCT01167582|EXPERIMENTAL|Restrictive transfusion strategy|"Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.~Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension."
62344781|NCT03110419|EXPERIMENTAL|Intervention|The training group will perform a Physical Exercise as multicomponent training.
62502711|NCT04459676|PLACEBO_COMPARATOR|Standard of Care + Placebo|Standard of Care + Placebo
62702036|NCT01313533|ACTIVE_COMPARATOR|Lactated Ringers Solution with Arginine|100 ml of LRS with arginine
62702037|NCT01313533|PLACEBO_COMPARATOR|Lactated Ringers Solution|Lactated ringers solution
62344782|NCT03110419|NO_INTERVENTION|Control|The control group will only be evaluated, without any intervention.
62344783|NCT01935336|EXPERIMENTAL|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62344784|NCT04147871|ACTIVE_COMPARATOR|ADV7103 1.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
62344785|NCT04147871|ACTIVE_COMPARATOR|ADV7103 3.0 mEq/Kg/day|Patients receive ADV7103 twice a day.
62344786|NCT04147871|ACTIVE_COMPARATOR|ADV7103 4.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
62344787|NCT04147871|PLACEBO_COMPARATOR|Placebo|Patients receive placebo twice a day.
62344788|NCT06362460|EXPERIMENTAL|[14C]RAY1216|
62344789|NCT01336166|EXPERIMENTAL|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
62344790|NCT01336166|EXPERIMENTAL|split-virion, non-adjuvanted vaccine of 30 μg|split-virion, non-adjuvanted H1N1 vaccine of 30 μg.
62344791|NCT01336166|EXPERIMENTAL|split-virion, non-adjuvanted vaccine of 45 μg|split-virion, non-adjuvanted H1N1 vaccine of 45 μg.
61955447|NCT01935791|EXPERIMENTAL|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius."
62702038|NCT05495568|EXPERIMENTAL|Switching CT-P17|"On Day 1, Week 0, patients will be enrolled in the study and receive Humira. The patients will receive initial dose of Humira (80 mg; 2 shots of 40 mg) on Day 1 and Humira (40 mg) EOW starting one week after the initial dose until Week 11.~Prior to the study drug administration at Week 13, patients will be randomized to receive either CT-P17 (40 mg) or Humira (40 mg) and the CT-P17 Switching group will receive CT-P17 (40mg) at Week 13, Week 15, Week 21, Week 23 and Week 25. The Switching group will receive Humira at Week 17 and Week 19.~From Week 27, patients will receiAve CT-P17 (40 mg) EOW only as open-label up to Week 49."
61955448|NCT01935791|EXPERIMENTAL|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
61955449|NCT01935791|EXPERIMENTAL|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|"Visit 1 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius"
61955450|NCT05121896|ACTIVE_COMPARATOR|Patients with facial synkinesis|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
61955451|NCT05121896|ACTIVE_COMPARATOR|Control participants|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
61955452|NCT04219007|EXPERIMENTAL|Genetic Short Stature|"Vosoritide, also known as BMN 111 or modified recombinant human C-type natriuretic peptide (CNP), is a 39-amino-acid peptide analog that includes the 37 C-terminal amino acids of the human CNP53 sequence plus the addition of 2 amino acids (Pro-Gly) on the N-terminus. This structural modification conveys resistance to neutral endopeptidase (NEP) degradation, resulting in prolonged half-life (t1/2) in comparison to endogenous CNP. This increase in t1/2 allows once daily subcutaneous (SC) administration.~Vosoritide will be administered as a single 15 μg/kg subcutaneous injection given daily for 12 months."
61955453|NCT02109471||corneal opacities|
61955454|NCT03452423|EXPERIMENTAL|ACRFP|Patient suffering from osteoarthritis of knee joints, and planning to receive ACRFP, are enrolled into this study. Gait pattern is obtained preoperatively, 3 months, and 6 months postoperatively.
62344792|NCT01336166|PLACEBO_COMPARATOR|Placebo control|Placebo control
62344793|NCT00961922|EXPERIMENTAL|Neurofeedback|Children in this group receive 30 sessions of neurofeedback
62344794|NCT00961922|SHAM_COMPARATOR|Placebo feedback|The children in this group receive 30 sessions of placebo feedback, based on muscular tension.
62344795|NCT00961922|NO_INTERVENTION|Siblings|The siblings will be tested 1 time, they will function as a healthy control group.
62344796|NCT00390416|EXPERIMENTAL|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
62344797|NCT03285763|EXPERIMENTAL|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
62344798|NCT00691262|EXPERIMENTAL|1|
62502712|NCT04815018||Patients with New Cases of SARS-CoV-2|Newly recruited residents who have been identified as positive through Ohio's Post-Acute Regional Rapid Testing (PARRT) Program will undergo at at least 4 weeks, but no more than 8 weeks, of nasal swab and exhaled breathe particles specimen collection for Covid testing. Previously enrolled residents will submit weekly collections of nasal swab specimens and exhaled breathe particles once they exhibit respiratory-related symptoms, or once a test is ordered by the provider for suspicion of exposure. Collection will continue until these subjects fulfill their 8 weeks of testing.
61955455|NCT01737320|EXPERIMENTAL|short-course|antibiotic treatment stopped on day 7 if the patient has been afebrile for 48 hours and clinically stable. Continued hospitalization will be left to the discretion of the treating physician. Antibiotics will be restarted if fever recurs in at least 2 consecutive measurements above 38 or in cases of clinically or microbiologically documented infections.
61955456|NCT01737320|ACTIVE_COMPARATOR|accepted prolonged antibiotic treatment|"antibiotic treatment continued for 14 days according to accepted hospital local guidelines. Duration of hospital stay will also be left to the discretion of the treating physician.~Type of empiric antibiotic treatment and later, specific antibiotic treatment, will be chosen by the treating physicians in consultation with the infectious diseases unit.~The decision on timing of switch to oral antibiotic therapy will also be left to the discretion of the treating physician."
62344799|NCT01254513|EXPERIMENTAL|Arm A - Docetaxel every 3 weeks + Prednisone|"* Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously"
62502713|NCT04815018||Patients without SARS-CoV-2|This cohort will consist of previously enrolled residents who submitted nasal swabs and exhaled breathe particles for Covid testing once a week for 8 weeks. The patients will have been identified as negative for a SARS-CoV-2 infection each week.
62502714|NCT05458037|EXPERIMENTAL|Fast tenaculum application|
62502715|NCT05458037|EXPERIMENTAL|Slow tenaculum application|
62502716|NCT00220727|EXPERIMENTAL|Group 1|Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week \<6) IGIV-C (0.14 mL/kg/min)
62702039|NCT05495568|ACTIVE_COMPARATOR|Humira maintenance|"On Day 1, Week 0, patients will be enrolled in the study and receive Humira. The patients will receive initial dose of Humira (80 mg; 2 shots of 40 mg) on Day 1 and Humira (40 mg) EOW starting one week after the initial dose until Week 11.~Prior to the study drug administration at Week 13, patients will be randomized to receive either CT-P17 (40 mg) or Humira (40 mg) and the Humira maintenance group will receive Humira (40mg) EOW up to Week 25.~From Week 27, patients will receive CT-P17 (40 mg) EOW only as open-label up to Week 49."
62702040|NCT05299190|EXPERIMENTAL|Yoga intervention plus TAU|"Participants randomized to the yoga intervention will attend 8-weekly 90-minute group sessions. The intervention will be delivered by certified instructors with experience facilitating yoga classes for pregnant women. Monthly drop-in classes will be scheduled in order to motivate women to maintain their practice during the follow-up period. The yoga intervention will be based on the hatha yoga system modified for pregnancy. TAU will include treatment based on the recommendation of participants' healthcare provider/team."
61955457|NCT03924453||Pearl Powered by Proov|Participants are given hormone tests strips and a digital app and all instructions for use, collectively called the Pearl Power by Proov kit. The app will analyze hormonal test strip information to predict and confirm ovulation
61955458|NCT05002062|SHAM_COMPARATOR|G1 ( Conventional Physical Therapy Program group)|"Patients in G1 underwent conventional physical therapy program continued for 3 months, included (aerobic training 20 minutes, resistive training for 15 minutes and flexibility program for 15 minutes).~The whole treatment session lasted from 50 minutes to one hour, 3 times per week for 3 consecutive months."
61955459|NCT05002062|ACTIVE_COMPARATOR|G2 ( Computer-based Cognitive Therapy group)|"Patients in G2 underwent Computer-based cognitive training continued for 3 months, included (attention/concentration, memory and reaction behavior training).~The whole treatment session timing lasted 50 minutes to one hour, 3 times per week for 3 consecutive months."
61955460|NCT04456530|EXPERIMENTAL|Testosterone Group|Participants receiving two IM Testosterone injections.
61955461|NCT04456530|PLACEBO_COMPARATOR|Control Group|Participants receiving two IM Normal Saline Injections.
61955462|NCT01207791|OTHER|Minimal screening only (MSO)|Minimal screening
61955463|NCT01207791|ACTIVE_COMPARATOR|Screening, assessment, and referral (SAR)|
61955464|NCT01207791|EXPERIMENTAL|Brief intervention plus telephone boosters (BI-B)|
62142319|NCT01760226|EXPERIMENTAL|DA-EPOCH-R for DLBCL, PTLD & PMBCL|"Minimum of 6 cycles (cycle=3 weeks), possibly 8. Dosages of the drugs will be determined by the subject's weight and height for cycle 1. Thereafter, the dosages of some drugs will be adjusted up or down for the next cycle, dependent on the blood tests results.~DA-EPOCH-R for 2 cycles then two more cycles of DA-EPOCH-R. If complete response (CR), then DA-EPOCH-R for more 2 cycles. If no CR, DA-EPOCH-R for 4 more cycles."
62142320|NCT02219659|ACTIVE_COMPARATOR|Sedation protocol with interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays within the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min continuous positive airway pressure (CPAP) trial is performed.
62344800|NCT01254513|EXPERIMENTAL|Arm B - Docetaxel weekly + Prednisone|"* Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously"
62344801|NCT04030780|ACTIVE_COMPARATOR|Cohort 1FD (on-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks on-PPI+ sporebiotics (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
62502717|NCT00220727|EXPERIMENTAL|Group 2|Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week \<6) IGIV-C (0.08 mL/kg/min)
62344802|NCT04030780|PLACEBO_COMPARATOR|Cohort 1FD (on-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks on-PPI+ placebo (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
62502718|NCT01936311|NO_INTERVENTION|Control Group|This group will receive usual care.
62344803|NCT04030780|ACTIVE_COMPARATOR|Cohort 2FD (off-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks of sporebiotics (2) followed by 8 weeks of sporebiotics (open label)
62344804|NCT04030780|PLACEBO_COMPARATOR|Cohort 2FD (off-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks of placebo (2) followed by 8 weeks of sporebiotics (open label)
61955465|NCT03513328|EXPERIMENTAL|Group A--Thiotepa single dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
61955466|NCT03513328|EXPERIMENTAL|Group A--Thiotepa escalated dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
61955467|NCT03513328|ACTIVE_COMPARATOR|Group B--Thiotepa single dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with \<10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
62502719|NCT01936311|EXPERIMENTAL|Self-Management Goal Elicitation|This group will receive usual care alongside a form that helps elicit self-management goals as well as preferred treatment modalities.
61955468|NCT03513328|ACTIVE_COMPARATOR|Group B--Thiotepa escalated dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with \<10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
62502720|NCT03756337|EXPERIMENTAL|Neuro 2 Upgrade|Participant wears Neuro 1 sound processor and is tested, then is upgraded with the new sound processor Neuro 2 and tested.
62502721|NCT03756337|EXPERIMENTAL|Neuro 1 Downgrade|Participant wears Neuro 2 sound processor and is tested, then is downgraded with the sound processor Neuro 1 and tested.
62502722|NCT06267183|EXPERIMENTAL|SV001|
62502723|NCT06267183|PLACEBO_COMPARATOR|Placebo|
62502724|NCT04329234||acute heart failure|Patients with acute heart failure
62502725|NCT06230380|NO_INTERVENTION|Control group|Patients will be operated with a standard exploratory PTX, with visual identification of PTGs. Unilateral or bilateral parathyroid exploration will be determined by the surgeon, depending on preoperative imaging and intraoperative findings. Usually, the procedure will be terminated when intraoperative parathyroid hormone (PTH) measurement shows a \>50% decline, after removal of suspected pathological PTGs.
62502726|NCT06230380|EXPERIMENTAL|Surgery with EleVision IR camera system|"Patients randomized to the experimental group will have surgery performed in the exact same manner as in the control group.~In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern."
62502727|NCT04492397|EXPERIMENTAL|Test Contact lens|Subjects will be randomized to wear test lenses for one week and then switch to control lenses for one week.
62502728|NCT04492397|ACTIVE_COMPARATOR|Control Contact Lens|Subjects will be randomized to wear control lenses for one week and then switch to test lenses for one week.
62502729|NCT01122316|EXPERIMENTAL|Metformin|
62502730|NCT02297841|EXPERIMENTAL|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
62502731|NCT06557408||Minimally invasive enucleation cohort|Surgical approaches to minimally invasive enucleation include laparoscopic or robotic-assisted procedures. During surgery, intraoperative ultrasonography is used to verify the position of the tumour in relation to the main pancreatic duct to ensure that injury to the main pancreatic duct is avoided and to help identify tumours within the pancreatic parenchyma. If injury to the main pancreatic duct is unavoidable, suture repair or bridging reconstruction techniques are used. If intraoperative freezing reveals the presence of high-grade dysplasia or invasive cancer, the procedure is converted to an oncological resection.
62502732|NCT03842670|ACTIVE_COMPARATOR|Cognitive-Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein \& McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
62502733|NCT03842670|ACTIVE_COMPARATOR|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz \& Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
62502734|NCT02577068|ACTIVE_COMPARATOR|nefopam group|
62502735|NCT02577068|ACTIVE_COMPARATOR|propacetamol group|
62502736|NCT02577068|EXPERIMENTAL|nefopam and propacetamol group|
62502737|NCT04950686|EXPERIMENTAL|Intervention - Media Aware for Young Adults|This arm will receive Media Aware for Young Adults between the pretest and posttest questionnaire. Media Aware for Young Adults is a web-based sexual and relationship health promotion program that uses a media literacy education (MLE) approach. The program is self-paced and includes four modules.
62502738|NCT04950686|ACTIVE_COMPARATOR|Active Control - Health Aware for Young Adults|This arm will receive Health Aware for Young Adults in between the pretest and posttest questionnaire. Health Aware for Young Adults is a web-based sexual and relationship health promotion program. The program contains the same health content as Media Aware for Young Adults but without the media literacy education components. The program is self-paced and includes four modules.
62702041|NCT05299190|OTHER|Clinical Monitoring plus TAU|Clinical monitoring will be conducted by telephone and include a 15-20 minutes discussions of how the participant has been feeling over the past two weeks. A standard format will be used for conducting the clinical monitoring telephone calls. TAU will include treatment based on the recommendation of participants' healthcare provider/team.
62702042|NCT04548960|OTHER|cancer patients|cancer patients To explore the phenomena of resistance during the therapeutic response and/or the progression of the pathology, the investigatorswill used a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq) from blood and tumor samples and immunological profil by ELISA
62702043|NCT06363292|EXPERIMENTAL|PRO-231|"* PRO-231: Moxifloxacin 0.5% Ophthalmic solution.~* Dosage: 1 drop every 6 hours (3 daily applications \[TID\], in the right eye).~* Route of administration: Topical ophthalmic."
61955469|NCT03682133||Prehabilitation|The care as given in a participating hospital is according to the local guideline and will not be changed for this study. Whether prehabilitation is applied in a participating hospital is based on a predefined definition of oncological surgical prehabilitation.
61955470|NCT03682133||Usual care|Guideline based colon cancer surgery, without prehabilitation.
62502739|NCT04950686|NO_INTERVENTION|Delayed Intervention Control|Participants in this condition will not receive a sexual or relationship health promotion program until after the 12-month follow-up survey. After that survey is complete, they will receive access to the Media Aware for Young Adults program.
62502740|NCT02149394|EXPERIMENTAL|Ice|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale.The experimental group received an ice popsicle made of 10 mL mineral water.The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice was supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
62502741|NCT02149394|ACTIVE_COMPARATOR|Water|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
62502742|NCT05038891||Digital Cervical Assessment performed first|A digital cervical exam will be performed by an experienced senior obstetrics and gynecology resident, using index finger and middle finger to measure the dilation and thickness of the cervix. This is the gold standard measurement utilized to assess the labor course. In this group, the digital cervical exam is done first, followed by a participant-performed ultrasound imaging assessment of the cervix.
62502743|NCT05038891||Ultrasound Assessment performed first|Ultrasound imaging will be first taught by an experienced RN, then self-performed by the participant in the presence of junior obstetrics and gynecology resident and the RN. The junior resident will ensure the ultrasound device is functioning properly and the images are saved. In this group, the participant-performed imaging assessment is done first, followed by a digital cervical exam performed by an experienced senior obstetrics and gynecology resident.
62702044|NCT06363292|ACTIVE_COMPARATOR|VIGAMOXI®|"* VIGAMOXI® :Moxifloxacin 0.5% Ophthalmic Solution.~* Dosage: 1 drop every 6 hours (3 daily applications \[TID\], in the right eye).~* Route of administration: Topical ophthalmic."
62702045|NCT06044792||DRM negative|"The cohort of patients, who will meet inclusion criteria, with HIV infections and no drug resistance mutations detected.~Epidemiological (age, sex, origin, sexual preferences) and clinical data (HIV viral load, CD4+ cell count, presence of AIDS-defining diseases, co-infection with HBV and HCV) will be collected at the time of diagnosis.~Subsequent controls of HIV viral load, level of CD4 and CD4/CD8 ratio will be carried out in accordance with the standard of care for an HIV-infected patient (usually every 6-12 months)."
61955471|NCT05497583|EXPERIMENTAL|Acetone based HEMA free Universal Adhesive|Patients with non-carious cervical lesions will be treated with Acetone Based HEMA-free Universal Adhesive (BeautiBond universal adhesive ) applied in a self-etch approach with (SE) selective enamel etching.
62344805|NCT03600714|EXPERIMENTAL|Treatment|Treatment with Lonafarnib, Ritonavir, and Peginterferon lambda
62344806|NCT01373866|EXPERIMENTAL|Multimodal MRI-guided rTMS|
62344807|NCT01373866|ACTIVE_COMPARATOR|Conventional T3-P3 rTMS|
62344808|NCT04533815|EXPERIMENTAL|LOCK sleep intervention|Nursing home staff receive the LOCK sleep intervention training and thus provide to nursing home residents with dementia the LOCK sleep intervention
62502744|NCT05876351|EXPERIMENTAL|Eculizumab|Participants will receive Eculizumab in a single dose vial.
62502745|NCT01109576|EXPERIMENTAL|DSL workshop participants|Three to five Veterans with DSL.
62502746|NCT04702035|EXPERIMENTAL|iNPH patients|20 patients with completed diagnostics concerning NPH, in which the indication for implantation of a VP shunt for NPH treatment was found by the responsible surgeon independently from the study.
62502747|NCT04702035|ACTIVE_COMPARATOR|Healthy volunteers|20 volunteers, matched with group 1 concerning sex and age.
62502748|NCT04702035|ACTIVE_COMPARATOR|Young healthy volunteers|20 volunteers, matched with group 1 concerning sex only and between 18 and 40 years old.
61955472|NCT05497583|ACTIVE_COMPARATOR|Isopropanol based HEMA-free universal Adhesive|Patients with non-carious cervical lesions will be treated with isopropanol-based HEMA-free universal Adhesive (Prime\&Bond universal™ Adhesive system) applied in a self-etch approach with (SE) selective enamel etching.
62344809|NCT04658381|EXPERIMENTAL|Genetic analysis|
62344810|NCT02490917|EXPERIMENTAL|ACT™ device|Patients randomized to receive the Adjustable Continence Therapy device ACT™
62344811|NCT02490917|OTHER|AMS 800 ™ device|Patients randomized to receive the artificial urinary sphincter AMS 800 ™
62344812|NCT05847244|NO_INTERVENTION|control|Lifestyle counseling plus standard evidence based therapy
62344813|NCT05847244|EXPERIMENTAL|intervention (metformin)|Lifestyle counseling plus standard evidence based therapy and metformin (target dose 1000 mg bid)
62344814|NCT05102396|EXPERIMENTAL|Topical oxybutynin spray|Participants with axillary hyperhidrosis will receive topical oxybutynin spray (10%) in an appropriate dose of 2 puffs in each armpit twice a day for 35 days.
62344815|NCT05102396|PLACEBO_COMPARATOR|Topical placebo spray|Participants with axillary hyperhidrosis will receive topical placebo spray in an appropriate dose of 2 puffs in each armpit twice a day for 35 days.
62344816|NCT05102396|ACTIVE_COMPARATOR|Oral oxybutynin|Participants with axillary hyperhidrosis will receive oral oxybutynin for 35 days as follows: during the first week, participants will receive 2.5 mg of oxybutynin once a day in the evening; from the 8th to the 14th day, they will receive 2.5 mg twice a day; and from the 15th day to the end of the 35th day of treatment, they will receive 5 mg twice a day.
62344817|NCT05564910||Coffe group|Pregnant women who referred caffeine intake.
62502749|NCT05276076|EXPERIMENTAL|Part 1 Single Ascending Dose, Cohort 1|Cohort 1 : 1X10\^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the two subjects: Begin enrollment for Cohort 2.
62344818|NCT05564910||Control group|Pregnant women without caffeine intake.
62344819|NCT05946759|ACTIVE_COMPARATOR|Prospective|50 prospective subjects
62502750|NCT05276076|EXPERIMENTAL|Part 1 Single Ascending Dose, Cohort 2|Cohort 2 : 3X10\^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the two subjects: Begin enrollment for Cohort 3.
62502751|NCT05276076|EXPERIMENTAL|Part 1 Single Ascending Dose, Cohort 3|Cohort 3 : 5X10\^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP.
62502752|NCT05276076|EXPERIMENTAL|Part 2 Multiple Ascending Dose, Cohort 1|Cohort 1 : two doses in total, 1X10\^6 cells/kg per dose, weekly The safety of 3 subjects is evaluated for 4 week after two dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the three subjects: Begin enrollment for Cohort 2.
62502753|NCT05276076|EXPERIMENTAL|Part 2 Multiple Ascending Dose, Cohort 2|Cohort 2 : four doses in total, 1X10\^6 cells/kg per dose, weekly The safety of 3 subjects is evaluated for 8 week after two dose of IP.
62502754|NCT00640458|PLACEBO_COMPARATOR|Placebo|Study Period 1 or 2
62502755|NCT00640458|EXPERIMENTAL|Experimental|Study Period 1 or 2
62502756|NCT04225065|ACTIVE_COMPARATOR|Chlorhexidine prep|Chlorhexidine prep prior to their operation
62502757|NCT04225065|ACTIVE_COMPARATOR|Betadine prep|Betadine prep prior to their operation
62502758|NCT00741754|EXPERIMENTAL|I, II|compare the amount of salivary flow of the same patient at different times.
62344820|NCT05946759|NO_INTERVENTION|Historical|40 historical subjects
62502759|NCT03915561|ACTIVE_COMPARATOR|Study group|This group will be received intravenous injection with 10ml transparent mixture solution with 40mg Dynastat and 0.9% saline twice
62344821|NCT03658993|ACTIVE_COMPARATOR|Rifaxamine 550 mg|Study drug Oral Rifaximin 550 mg TID for 4 weeks .
62344822|NCT03658993|PLACEBO_COMPARATOR|Placebo|Placebo TID for 4 weeks
62344823|NCT00469638|EXPERIMENTAL|Agilis sheeth group|
62344824|NCT00469638|ACTIVE_COMPARATOR|Non-steerable sheeth group|
62344825|NCT00845546|EXPERIMENTAL|1|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets of Ranbaxy
62502760|NCT03915561|PLACEBO_COMPARATOR|Placebo|This group will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice
62502761|NCT01358396||HBA1c|
62502762|NCT00658957|EXPERIMENTAL|A|Daily standard wound care and topical application of the gentamicin-collagen sponge twice weekly
62502763|NCT00658957|PLACEBO_COMPARATOR|B|Daily standard wound care and topical application of the placebo sponge twice weekly
62502764|NCT04408534|ACTIVE_COMPARATOR|continuous positive airway pressure|Patients receive continuous positive airway pressure as a mode of noninvasive ventilation
62502765|NCT04408534|EXPERIMENTAL|bilevel positive airway pressure|Patients receive bilevel positive airway pressure as a mode of noninvasive ventilation
62502766|NCT03513536|EXPERIMENTAL|Intervention 1|The women in this arm will receive the Citrus-Based Aromatherapy product to apply regularly for 6 days.
62502767|NCT03513536|EXPERIMENTAL|Intervention 2|The women in this arm will receive the Mint-Based Aromatherapy product to apply regularly for 6 days.
62344826|NCT00845546|ACTIVE_COMPARATOR|2|(Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
62344827|NCT05899712|ACTIVE_COMPARATOR|Group A|Digitally obtained altered cast for construction of mandibular free end saddle removable partial denture
62344828|NCT05899712|ACTIVE_COMPARATOR|Group B|Conventionally obtained altered cast for construction of mandibular free end saddle removable partial denture
62344829|NCT02086721|EXPERIMENTAL|Oligometastatic cancer patients; N=18|
62344830|NCT03269890|EXPERIMENTAL|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks per side. once before surgery
62344831|NCT03269890|ACTIVE_COMPARATOR|US-intermediate cervical plexus block|15 mL of 0.5% isobaric bupivacaine + Epinephrine 5 microgram/ ml. per side. once before surgery
62344832|NCT06157047|EXPERIMENTAL|Patients included|Patients' recruitment was guided by their actual need to solve edentulism through the use of implant therapy. The diagnosis was made clinically and radiographically.
62702046|NCT06044792||DRM positive|"The cohort of patients, who will meet inclusion criteria, with HIV infections and detected primary drug resistance mutations.~Epidemiological (age, sex, origin, sexual preferences) and clinical data (HIV viral load, CD4+ cell count, presence of AIDS-defining diseases, co-infection with HBV and HCV) will be collected at the time of diagnosis.~Subsequent controls of HIV viral load, level of CD4 and CD4/CD8 ratio will be carried out in accordance with the standard of care for an HIV-infected patient (usually every 6-12 months)."
62344833|NCT01954069|OTHER|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (SQPT) (dBest One Step hCG Panel Test Kit)
62344834|NCT00996021|EXPERIMENTAL|Arm 1|This is a three way crossover study with 3 periods. Subjects will receive a single dose of either GSK1349572 250 mg suspension, placebo suspension or moxifloxacin 400 mg tablet in each of the three periods. The order in which the treatments are given will be randomized. There is a screening visit within 30 days prior to the first dose of study drug and a follow-up visit within 10-14 days after the last dose of study drug.
62502768|NCT03513536|EXPERIMENTAL|Intervention 3|The women in this arm will receive the Spice-Scented Aromatherapy product to apply regularly for 6 days.
62502769|NCT03513536|PLACEBO_COMPARATOR|Control|The women in this arm will receive a vegetable oil roll-on product to apply regularly for 6 days.
62502770|NCT03743610|EXPERIMENTAL|Effect of heart rate training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining \>65% max heart rate during room air based maximal peak work.
62502771|NCT03743610|EXPERIMENTAL|Effect of saturation of oxygen training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.
62502772|NCT03743610|ACTIVE_COMPARATOR|Effect of optimized training in simulated altitude|Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.
61955473|NCT02393183|EXPERIMENTAL|ASTED|"Antioxidant Supplements for TED (ASTED):~to evaluate the effect of selected antioxidant vitamins and minerals supplement (Twice daily)~1. β- Carotene (30 mg)~2. Vit C (100 mg)~3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU~4. Calcium phosphate dihydrate (40 mg)~5. Zinc oxide (4 mg, elemental)~6. Copper gluconate (3.5 mg)~7. Sodium selenite 23 mg= Selenium 100 µg~8. Nicotinamide (a form of vit.B3) (10 mg)"
61955474|NCT02393183|ACTIVE_COMPARATOR|Selenium|Selenium (100mic) Twice daily
61955475|NCT02393183|PLACEBO_COMPARATOR|Placebo|Placebo Twice daily
61955476|NCT03400878|ACTIVE_COMPARATOR|BCG-JAPAN|Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.
61955477|NCT03400878|ACTIVE_COMPARATOR|BCG-RUSSIA|BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.
61955478|NCT04561830|ACTIVE_COMPARATOR|group 1|underwent laparoscopic-assisted excision of mesorectum
62344835|NCT02731807|EXPERIMENTAL|Dose A, B, C, D, E|All participants will receive all doses throughout the course of the study.
62344836|NCT02731807|EXPERIMENTAL|Dose D, E, C, B, A|All participants will receive all doses throughout the course of the study.
62702047|NCT06376825|EXPERIMENTAL|MyLife Group|In this concurrent multiple-baseline single-case experimental study, participants will have seven to fifteen days of baseline measurement with randomization.
62702048|NCT06303310|EXPERIMENTAL|Group A|Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.
62344837|NCT02731807|EXPERIMENTAL|Dose C, D, E, A, B|All participants will receive all doses throughout the course of the study.
62344838|NCT02731807|EXPERIMENTAL|Dose E, D, C, B, A|All participants will receive all doses throughout the course of the study.
62502773|NCT03743610|PLACEBO_COMPARATOR|Effect of placebo training in non-simulated altitude|Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.
62702049|NCT06303310|EXPERIMENTAL|Group B|Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.
61955479|NCT04561830|ACTIVE_COMPARATOR|group 2|open excision of mesorectum
61955480|NCT00440583|EXPERIMENTAL|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
61955481|NCT03706079|EXPERIMENTAL|Tezepelumab|Tezepelumab subcutaneous injection
61955482|NCT03706079|PLACEBO_COMPARATOR|Placebo|Placebo: Placebo subcutaneous injection
61955483|NCT03280901|EXPERIMENTAL|Standard HD|HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions
61955484|NCT03280901|EXPERIMENTAL|Thermocontrolled HD|HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions
61955485|NCT02273778|OTHER|Routine radiotherapy treatment plus MRI scan and PET-CT scan|
61955486|NCT02273778|OTHER|Routine radiotherapy treatment|
61955487|NCT00813306|EXPERIMENTAL|A|AZD2066
61955488|NCT00813306|PLACEBO_COMPARATOR|B|Placebo
61955489|NCT00813306|EXPERIMENTAL|C|AZD2066
61955490|NCT00813306|EXPERIMENTAL|D|AZD2066
61955491|NCT00813306|PLACEBO_COMPARATOR|E|Placebo
61955492|NCT05163977|ACTIVE_COMPARATOR|Cattell Warren Anastomosis|
62344839|NCT05830188|EXPERIMENTAL|CERIA|Participants in the experimental group will receive six-weekly 45-60 minutes CERIA sessions in a classroom setting.
62344840|NCT05830188|ACTIVE_COMPARATOR|Control|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group. There will be no face-to-face meeting between the participants in the control group and the interventionist.
62344841|NCT03160105|NO_INTERVENTION|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
62344842|NCT03160105|EXPERIMENTAL|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
62502774|NCT02459886|EXPERIMENTAL|Cohort 1|Single intravenous (IV) low dose infusion with staggered participant dosing
62502775|NCT02459886|EXPERIMENTAL|Cohort 2|Single IV ascending dose infusion with staggered participant dosing
62502776|NCT02459886|EXPERIMENTAL|Cohort 3|Single IV ascending dose infusion with staggered participant dosing
62502777|NCT02459886|EXPERIMENTAL|Cohort 4|Single IV ascending dose infusion with staggered participant dosing
62702050|NCT02569606||Timeframe 2005 - 2007|Data of timeframe 2005 up to 2007 will be included
62702051|NCT02569606||Timeframe 2012 - 2014|Data of timeframe 2012 up to 2014 will be included
62702052|NCT01763762|EXPERIMENTAL|Electrical pudendal nerve stimulation|At a frequency of 2.5 Hz and an intensity (45\~55 mA) as high as the patient can tolerate without discomfort; 60 minutes three times a week for a total of four weeks
61955493|NCT05163977|EXPERIMENTAL|Blumgart Anastomosis|
61955494|NCT05909150|ACTIVE_COMPARATOR|Hypertonic Saline Solution 3,5% (HSS)|
61955495|NCT05909150|PLACEBO_COMPARATOR|Normal Saline Solution (NS)|
61955496|NCT04340778|EXPERIMENTAL|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion.
61955497|NCT04340778|ACTIVE_COMPARATOR|lidocaine prilocaine cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
61955498|NCT04340778|PLACEBO_COMPARATOR|placebo|inert placebo Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
61955499|NCT02508181|ACTIVE_COMPARATOR|I-gel intra ocular pressure|supraglottic airway device
61955500|NCT02508181|ACTIVE_COMPARATOR|LMA Supreme intra ocular pressure|supraglottic airway device
61955501|NCT01885403|EXPERIMENTAL|Respiratory Parameters Measurements|
61955502|NCT06290479|EXPERIMENTAL|Air Up® Peach Pod|Participants in this arm will use the air up® drinking system with a peach-flavored pod. The intervention aims to test if the flavored scent encourages increased water intake, which will be assessed by self-reported questionnaires and hydration-related health outcomes over 12 weeks.
61955503|NCT06290479|EXPERIMENTAL|Air Up® Orangeade Pod|Participants in this arm will use the air up® drinking system with an orangeade-flavored pod. Similar to Arm 1, the intervention will assess the impact of the flavored scent on water consumption and health outcomes, using the same methods of evaluation.
61955504|NCT06290479|NO_INTERVENTION|Control - Unscented Pod|Participants in this control arm will use the air up® drinking system with an unscented pod. This group will serve as the control to evaluate the effectiveness of the scented pods in comparison to a baseline with no added scent.
61955505|NCT05292508|EXPERIMENTAL|CRP Tests in addition to Usual Standard of Care|For the clusters (health posts) in this arm, the health worker will prick the finger of the eligible patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained which will be added to specimen dilution buffer and the dipstick will be placed into the diluted sample. It will be removed after the liquid rises and the timer will be started and result will be interpreted in 5 minutes. Interpretation of CRP levels: Only red color line (No blue line): \<10 mg/L One blue line: 10-40 mg/L Two blue lines: 40-80 mg/L Three blue lines: \>80 mg/L. CRP levels of 40 mg/L or above will be considered as increased CRP levels. The decision on antimicrobial use and other treatments will be made with the help of CRP results in addition to information obtained from the history and physical examination.
61955506|NCT05292508|NO_INTERVENTION|Usual Standard of Care Alone|For the clusters (health posts) in this control arm, Usual Standard of Care Alone will be provided. This usual standard of care is given to patients with febrile illness at health posts. Commonly, this involves taking a brief history and conducting a simple physical examination followed by symptomatic treatment such as paracetamol, cough medication or analgesics such as NSAIDs. Often antimicrobial treatment is also prescribed based on clinical suspicion of bacterial infection.
61955507|NCT01809483|EXPERIMENTAL|Bandage contact lens group|subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and bandage contact lens. Bandage contact lenses maintained for 24 hours. Antibiotic eye drops were instilled without removing the contact lenses
61955508|NCT01809483|ACTIVE_COMPARATOR|Pressure patching group|Subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and pressure patching. Pressure patching maintained for 24 hours and only opened for drug application. Subject and their families were educated on how to perform a good pressure patching
61955509|NCT00415805|EXPERIMENTAL|1|
62502778|NCT02459886|EXPERIMENTAL|Cohort 5|Single IV ascending dose infusion with staggered participant dosing
62702053|NCT01763762|ACTIVE_COMPARATOR|PFM training with Transvaginal ES|"PFM training: EMG-biofeedback assisted PFMT was performed by specially trained therapists, 20 min three times a week for a total of four weeks. Patients conduct 30 maximal high intensity PFM contractions for 2-6 sec (with 2-6 sec rest), three sessions a day at home for a total of four weeks.~Transvaginal ES: At a current intensity of \< 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min three times a week for a total of four weeks."
62702054|NCT01655056|EXPERIMENTAL|low male dose|Japanese and Caucasian males
62702055|NCT01655056|EXPERIMENTAL|medium male dose|Japanese and Caucasian males
62702056|NCT01655056|EXPERIMENTAL|high male dose|Japanese and Caucasian males
62702057|NCT01655056|EXPERIMENTAL|high female dose|Japanese and Caucasian females
62702058|NCT01655056|EXPERIMENTAL|highest male dose|Japanese and Caucasian males
61955510|NCT00415805|ACTIVE_COMPARATOR|2|
61955511|NCT03501290|OTHER|Oral Nutritional Supplement Group|All patients will be in one group, receiving the active product, Oral Nutritional Supplement with 'Fortimel® Protein supplementation'
61955512|NCT05534737|EXPERIMENTAL|Intervention|Comprehensive and Person-Centered Care Model (AICP Model) +regular assistance from social services
61955513|NCT05534737|OTHER|Control|regular assistance from social services
61955514|NCT00827333|NO_INTERVENTION|Phase I-Usual Care|
61955515|NCT00827333|ACTIVE_COMPARATOR|Phase 2 - Intervention|
61955516|NCT05756491|EXPERIMENTAL|Experimental: Group1|In group 1: 5 centers will be randomized for the inclusion of unaccompanied patients for 24 months
61955517|NCT05756491|EXPERIMENTAL|Experimental: Group2|In group 2: 5 other centers will be randomized for the inclusion of unaccompanied patients for 18 months
61955518|NCT05756491|EXPERIMENTAL|Experimental: Group3|In group 3: 5 other centers will be randomized for the inclusion of unaccompanied patients for 12 months
62502779|NCT02459886|EXPERIMENTAL|Cohort 6|Single IV ascending dose infusion with staggered participant dosing
62502780|NCT02459886|EXPERIMENTAL|Cohort 7|Single IV ascending dose infusion with staggered participant dosing
62702059|NCT05586373|ACTIVE_COMPARATOR|Group 1|Ibuprofen 400mg 6/6h, oral, maximum 5 days
62702060|NCT05586373|EXPERIMENTAL|Group 2|Dipyrone 1g 6/6h, oral, maximum 5 days
62502781|NCT01679054||EOX|Epirubicin + Oxaliplatin + Capecitabine (EOX) Epirubicin 50 mg/m2 iv bolus d1 q3w x 8 cycles Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles Capecitabine (Xeloda) 625 mg/m2 po bid x 6 months
62502782|NCT01679054||FOLFOX4|FOLFOX4 Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
62502783|NCT06019117|ACTIVE_COMPARATOR|Arm 1 - volunteers with parkinson's disease|26 patients in this arm. in this arm will receive the probiotic K10 (2mg/kg/dia).
62502784|NCT06019117|PLACEBO_COMPARATOR|Arm 2 - volunteers with parkinson's disease|26 patients in this arm. In this arm will receive the controlled placebo.
62702061|NCT01539031|EXPERIMENTAL|10 mg group|
62702062|NCT01539031|ACTIVE_COMPARATOR|23 mg group|
62702063|NCT02014467|EXPERIMENTAL|Denosumab 60mg|injection
62142321|NCT02219659|ACTIVE_COMPARATOR|Sedation protocol without Interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Daily interruption of fentanyl and midazolam is not performed. Every morning 120-min CPAP trial is performed as long as the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen.
62344843|NCT03160105|EXPERIMENTAL|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
62344844|NCT03160105|EXPERIMENTAL|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
62344845|NCT03888859|EXPERIMENTAL|Intravenous (i.v.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intravenous (IV) infusion
62502785|NCT06019117|ACTIVE_COMPARATOR|Arm 3- volunteers with alzheimer's disease|26 patients in this arm. in this arm will receive the probiotic K10 (2mg/kg/dia).
62502786|NCT06019117|PLACEBO_COMPARATOR|Arm 4- volunteers with alzheimer's disease|26 patients in this arm. In this arm will receive the controlled placebo.
62502787|NCT02868723|NO_INTERVENTION|Control; standard of care|All the subjects enrolled in this arm will receive counseling as the usual standard of care by the stroke neurologists. These will include procedures and guidelines as approved by American Heart Association (AHA), follow up and guidance as offered by Hamad General Hospital's policies.
62502788|NCT02868723|ACTIVE_COMPARATOR|Intervention; Lifestyle counselling: Behavioural|Subjects in this group will receive a more detailed guidance on rigorous management of stroke and will be provided assistance from a stroke trained nurse and pharmacist additional to the counseling offered by the Stroke Neurologist.
62502789|NCT01772355|OTHER|tissue core|semi automated core needle biopsy of the orbital tumors
62502790|NCT00152906|EXPERIMENTAL|Stereotactic RT or highly conformal RT|
62502791|NCT02124902|EXPERIMENTAL|Washington University: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion. A total of 6 cycles will be given.
62502792|NCT02124902|EXPERIMENTAL|Baylor: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
62702064|NCT02014467|PLACEBO_COMPARATOR|Placebo|injection
62702065|NCT05500534|EXPERIMENTAL|RevoLix HTL+|Laser lithotripsy using the RevoLix HTL+ with active stone recognition
62702066|NCT05500534|OTHER|Historic control group|Laser lithotripsy without active stone recognition
62344846|NCT03888859|EXPERIMENTAL|Intra-hepatic artery (i.a.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intra-hepatic artery (IA) infusion
62344847|NCT03888859|EXPERIMENTAL|Intratumoral Injections (i.t.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intratumoral injections (i.t.) infusion
62344848|NCT01486784|EXPERIMENTAL|Phase 1 DL1|26mg/m2/dose IV once per week x 3 weeks of 4 week cycle
62344849|NCT01486784|EXPERIMENTAL|Phase 1 DL-1|17mg/m2 IV/dose once per week x 3 weeks of 4 week cycle
62344850|NCT01486784|EXPERIMENTAL|Phase 1 DL-1a|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
62702067|NCT03682367|PLACEBO_COMPARATOR|Control|Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
62702068|NCT03682367|EXPERIMENTAL|Intervention|Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.
61955519|NCT05756491|EXPERIMENTAL|Experimental: Group4|In group 4: 5 other centers will be randomized for the inclusion of unaccompanied patients for 6 months
62344851|NCT01486784|EXPERIMENTAL|Phase 1 DL-1b|17mg/m2/dose IV three times per week x 3 weeks of 4 week cycle
62344852|NCT01486784|EXPERIMENTAL|Phase 1 DL-1c|22mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
62344853|NCT01486784|EXPERIMENTAL|Phase 1 DL-1d|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
62344854|NCT04224818|EXPERIMENTAL|Dual trigger|Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
62502793|NCT04979923|EXPERIMENTAL|Lidocaine group|
62502794|NCT04979923|PLACEBO_COMPARATOR|Salbutamol group|
62502795|NCT04979923|ACTIVE_COMPARATOR|Beclomethasone plus salbutamol|
62702069|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
62702070|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
62142322|NCT02219659|ACTIVE_COMPARATOR|Fentanyl push first|This arm attempts to manage patient's pain and agitation with analgesia first. Fentanyl intravenous (IV) pushes are administered every 5 minutes as needed to target pain and sedation score, up to 4 doses per hour. Every morning 120-min CPAP trial is performed as long as patient's RASS score is 0 to -2 and patient passes the SBT safety screen. If fentanyl IV push doses alone cannot manage patient's pain and agitation (could not reach the target score), notify the study team. Fentanyl infusion is started and titrated to target pain and sedation score up to 6 hours. If fentanyl infusion is titrated up twice consecutively and target pain and sedation score are not met, notify the study team. Propofol infusion is started and titrated to target RASS score up to 6 hours.
62142323|NCT05406947||Low risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into low risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
62502796|NCT03476031||study group|patients with hepatitis c nephropathy detected by lab and renal biopsy
62502797|NCT04987749|ACTIVE_COMPARATOR|Active|"Participants received the real intervention of TBS (iTBS 600) over the right inferior frontal gyrus for 8 weeks (2 days/week).~\*iTBS = intermittent theta burst stimulation"
62142324|NCT05406947||Middle risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into middle risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
62142325|NCT05406947||High risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into high risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
62142326|NCT02950883|EXPERIMENTAL|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
62142327|NCT02950883|ACTIVE_COMPARATOR|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
62142328|NCT01411566|EXPERIMENTAL|Treatment|
62142329|NCT01411566|ACTIVE_COMPARATOR|Control|
62142330|NCT06700213||Heart Failure|Cohort will be comprised of a minimum of 75 participatns with HFrEF and a minimum of 25 participants with HFmrEF/HFpEF. At each visit, presence of intolerances to GDMT will be sought and recorded. Medications will include those outlined by GDMT, including angiotensin receptor/neprilysin inhibitors (ARNI), angiotensin II receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEi), evidence based beta blockers (eBBB), aldosterone receptor antagonists (MRA), and sodium-glucose co-transporter 2 (SGLT2) inhibitors.
62142331|NCT06700213||Research Patient Data Repository (RPDR)|Patients will be selected from those with available data following May of 2020 (after regulatory approval of SGLT2 inhibitors for treatment of HFrEF) or in the case of HFpEF following February 2022.
62142332|NCT01892176|EXPERIMENTAL|Coenzyme Q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
62142333|NCT00219466|ACTIVE_COMPARATOR|1|
62142334|NCT00219466|ACTIVE_COMPARATOR|2|
62142335|NCT04547660|EXPERIMENTAL|Convalescent Plasma|Transfusion of 2 aliquots of 300 ml of frozen convalescent plasma, 2 days apart, thawed at 37 degrees Celsius before infusion. Best supportive care except for investigational interventions.
62142336|NCT04547660|ACTIVE_COMPARATOR|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
62142337|NCT02363049|EXPERIMENTAL|colectomy|surgery followed by chemotherapy +/- targeted therapy regime according to each centre
62142338|NCT02363049|ACTIVE_COMPARATOR|no colectomy|Chemotherapy +/- targeted therapy alone, regime according to each centre.
62142339|NCT01560494|EXPERIMENTAL|STAC curriculum|
62344855|NCT04224818|ACTIVE_COMPARATOR|hCG (standard)|HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
62344856|NCT00111917|EXPERIMENTAL|Infliximab|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
62344857|NCT00111917|PLACEBO_COMPARATOR|Placebo|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
62142340|NCT01560494|NO_INTERVENTION|Conventional Curriculum|
62344858|NCT06289842|ACTIVE_COMPARATOR|Unipolar depressed patients with suicidality|The participants will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 120% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
62502798|NCT04987749|SHAM_COMPARATOR|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the right inferior frontal gyrus for 8 weeks (2 days/week).
62702071|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
62702072|NCT03161873||avaBBT|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition, participants will measure their basal body temperature (BBT) daily.
62702073|NCT05950321|ACTIVE_COMPARATOR|Cervical epidural group|Paramedian cervical epidural injection for cervical radiculopathy
62344859|NCT06289842|ACTIVE_COMPARATOR|Bipolar depressed patients with suicidality|The participants will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 120% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
62702074|NCT05950321|ACTIVE_COMPARATOR|Radiofrequency group|Pulsed radiofrequency applied to nerve roots for cervical radiculopathy
62344860|NCT05450458|EXPERIMENTAL|Hyaluronic Acid group|All overuse knee syndrome participants after both knee joint infiltration with two doses each of Synolis VA (2ml = 40 milligrams of hyaluronic acid with 80 milligrams of sorbitol).
62344861|NCT00887146|EXPERIMENTAL|Arm A (RT, procarbazine, lomustine, vincristine)|Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62344862|NCT00887146|EXPERIMENTAL|Arm B (RT, temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO QD on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
62502799|NCT03695211|ACTIVE_COMPARATOR|LM group|LM group use conventional landmark technique, which selects the midpoint of the posterior border of the sternocleidomastoid muscle as the puncture point of superficial cervical plexus block
62702075|NCT04277130|EXPERIMENTAL|Intervention group|Intervention with active video games
62702076|NCT04277130|NO_INTERVENTION|Control group|No intervention
62142341|NCT01379651|EXPERIMENTAL|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of food antigen
62502800|NCT03695211|EXPERIMENTAL|GAN Group|This group firstly locate the superficial cervical plexus by ultrasound scanning of the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle (GAN Point). GAN Group apply the precise block technique, selects the GAN Point as the puncture point of superficial cervical plexus block
62502801|NCT03904550|ACTIVE_COMPARATOR|Cisatracurium + Neostigmine|Patients in the cisatracurium/neostigmine group will receive 0.2 mg/kg of cisatracurium for neuromuscular paralysis during induction. Additional cisatracurium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
62344863|NCT02456376|EXPERIMENTAL|Children with Cerebral palsy|"1. Sensory integration testing~2. SR stimulation and Sensory integration testing"
61955520|NCT02849041|EXPERIMENTAL|Screening program|Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires
62344864|NCT02456376|ACTIVE_COMPARATOR|Children with Typical Development|"1. Sensory integration testing~2. SR stimulation and Sensory integration testing"
62344865|NCT05019755|EXPERIMENTAL|A(First period) to B(Second period) order|"A: Oral Administration of IN-A002(IN-115314) in fasting status~B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~There will be a wash out period of 7days between period"
62344866|NCT05019755|EXPERIMENTAL|B(First period) to A(Second period) order|"B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~A: Oral Administration of IN-A002(IN-115314) in fasting status~There will be a wash out period of 7days between period"
62344867|NCT06171672||semi-structured interview for nurses|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
62344868|NCT05518175|ACTIVE_COMPARATOR|Route A: Traditional laparoscopy|
62344869|NCT05518175|EXPERIMENTAL|Route B: Single site laparoscopy|
62344870|NCT05518175|EXPERIMENTAL|"Route C:V-Notes surgery"|
62344871|NCT03363217|EXPERIMENTAL|Neurofibromatosis Type 1 (NF1) with low-grade glioma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a progressing/refractory low-grade glioma.
62344872|NCT03363217|EXPERIMENTAL|Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibroma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a plexiform neurofibroma
62344873|NCT03363217|EXPERIMENTAL|Progressing/refractory low grade-glioma, KIAA1549-BRAF fusion|Patients presenting with a progressing/refractory low-grade glioma with a KIAA1549-BRAF fusion.
62344874|NCT03363217|EXPERIMENTAL|Progressing/Refractory central nervous system (CNS) glioma.|Patients presenting with a progressing/refractory central nervous system glioma with an activation of the MAPK/ERK pathway who do not meet criteria for inclusion in other study groups.
62344875|NCT02296437|EXPERIMENTAL|tDCS + CT|
62344876|NCT04498819|EXPERIMENTAL|Single Arm|Only one arm, one intervention; this is a feasibility study.
62344877|NCT05073965|EXPERIMENTAL|Intervention Group|Subject receive a 1000IU vitamin D supplement dose daily for 6 months
62502802|NCT03904550|ACTIVE_COMPARATOR|Rocuronium + Sugammadex|Patients in the rocuronium/sugammadex group will receive 0.6 mg/kg of rocuronium for neuromuscular paralysis during induction. Additional rocuronium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
62502803|NCT05002777|EXPERIMENTAL|Rilzabrutinib|Oral rilzabrutinib 400 mg BID
62502804|NCT02057536|EXPERIMENTAL|Arm A|8 week directed exercise program
62344878|NCT05073965|PLACEBO_COMPARATOR|Placebo group|Subject receive a placebo daily for 6 months
62344879|NCT05366270|EXPERIMENTAL|Whole Body Hyperthermia (WBH)|A single treatment of Whole Body Hyperthermia will be administered using the Heckel Hyperthermia device. During this procedure, participants' core body temperature will be elevated to 38.5 degrees Celsius.
62344880|NCT05366270|SHAM_COMPARATOR|Sham|Under the sham condition, participants will enter the Heckel Hyperthermia device as in the active treatment condition, but will not receive the whole body hyperthermia treatment, and will instead only receive mild heating.
62344881|NCT04727606|EXPERIMENTAL|Open label|The study provides for a single group, which will be its own control (pre/post intervention study). Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day) for 1 month
62344882|NCT05017714|EXPERIMENTAL|Active plus SOC|
62502805|NCT02057536|ACTIVE_COMPARATOR|Arm B|No directed exercise other than patients normal level of activity
61955521|NCT06557798||Redo TAVI|Redo Trans-catheter Aortic Valve Implantation for Bioprosthetic Valve Failure of a Trans-catheter Aortic Valve
62344883|NCT05017714|PLACEBO_COMPARATOR|Placebo plus SOC|
62344884|NCT00861861|ACTIVE_COMPARATOR|1|pitavastatin group
62344885|NCT00861861|ACTIVE_COMPARATOR|2|atorvastatin group
62344886|NCT04363437|ACTIVE_COMPARATOR|Colchine|
62344887|NCT04363437|ACTIVE_COMPARATOR|Usual Care|
62344888|NCT05991674||Allergic Contact Dermatitis Patients|
62502806|NCT01325506||Prostatectomy subjects|
61955522|NCT06557798||Explant|Surgical explantation with surgical aortic valve replacement (SAVR)
61955523|NCT06557798||Optimal Medical Therapy|Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
61955524|NCT01540838|EXPERIMENTAL|Infusion with paracetamol|Cefotaxime is administered as 12 hourly infusions, together with high dose paracetamol (acetaminophen)
62502807|NCT05020106||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
62502808|NCT05020106||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
62344889|NCT02523820|EXPERIMENTAL|fluticasone propionate|Fluticasone 1 mg + Normal saline (NSS) upto 4 ml nebulized after extubation
62344890|NCT02523820|PLACEBO_COMPARATOR|placebo|Normal saline (NSS) 4 ml nebulized after extubation
62344891|NCT00878631|ACTIVE_COMPARATOR|1 Normal Saline|infusion of 250 ccs of Normal Saline within 4 hours of the accident
62702077|NCT01853280|EXPERIMENTAL|L-Methylfolate|15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.
62142342|NCT01379651|NO_INTERVENTION|control|controls were kept on an egg-free diet for 6 months
62142343|NCT06387966|EXPERIMENTAL|Flunotinib treatment group|Subjects in this group will take flunotinib
62502809|NCT05020106||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
62502810|NCT05020106||Cognitively normal controls|Individuals with normal cognitive function
62142344|NCT06387966|PLACEBO_COMPARATOR|placebo group|Subjects in this group will take flunotinib placebo
62344892|NCT00878631|EXPERIMENTAL|2 - hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
62344893|NCT06410079||resurfacing|involves removing damaged cartilage and bone from the hip joint, half of the femoral head is cut, the neck and the other half are preserved, the acetabulum is covered by a metal cup
62344894|NCT06410079||total hip prosthesis|dual mobility total hip prosthesis in polyethylene, ceramic hip prosthesis, total hip prosthesis in ceramic or metal and polyethylene
62502811|NCT05817006|EXPERIMENTAL|Long-COVID-19|conducting laboratory tests, questionnaires, physical examination
62502812|NCT05148533|EXPERIMENTAL|TJ1133 Injection|
62344895|NCT01573507|EXPERIMENTAL|sodium lactate infusion|Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
62344896|NCT01413542|PLACEBO_COMPARATOR|Placebo then sitagliptin (DPP4 inhibition) group 1|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to bradykinin and substance P are studied after administration of placebo or sitagliptin (DPP4 inhibition).
62344897|NCT01413542|PLACEBO_COMPARATOR|Sitagliptin (DPP4 inhibition) then placebo group 1|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to substance P and bradykinin are studied after administration of sitagliptin (DPP4 inhibition) or placebo
62344898|NCT01413542|PLACEBO_COMPARATOR|Placebo then sitagliptin group 2|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to glucagon-like peptide-1 and brain natriuretic pepdie are studied after administration of placebo or sitagliptin (DPP4 inhibition).
62344899|NCT01413542|PLACEBO_COMPARATOR|Sitagliptin (DPP4 inhibition) then comparator group 2|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to glucagon-like peptide and brain natriuretic peptide are studied after administration of placebo or sitagliptin (DPP4 inhibition).
62344900|NCT06391957|EXPERIMENTAL|Spirulina supplement|3g of spirulina supplement three times daily for 5 days.
62344901|NCT06391957|PLACEBO_COMPARATOR|Placebo supplement|macronutrient matched placebo supplement three times daily for 5 days.
62344902|NCT06275243|ACTIVE_COMPARATOR|Group of cases diagnosed with Alzheimer's disease|Participants: Men and women with age between 60 and 90 years
62502813|NCT04773509|ACTIVE_COMPARATOR|PVB group|Patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides
62502814|NCT04773509|NO_INTERVENTION|Control group|PVB are not performed in the control group.
62502815|NCT05201079|EXPERIMENTAL|MBK-01|Participants will receive MBK-01 capsules of fecal microbiota coming from healthy donors (33 patients).
62502816|NCT05201079|ACTIVE_COMPARATOR|Fidaxomicin|Participants will receive Fidaxomicin (33 patients).
62502817|NCT03417609||Sarcopenia|Elderly patients with sarcopenia
62502818|NCT03417609||Control|Elderly patients without sarcopenia
62502819|NCT01142141|OTHER|Manual therapy, kinesiotherapy|
62502820|NCT05903339|EXPERIMENTAL|Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum|3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
62142345|NCT03085407|ACTIVE_COMPARATOR|early cholecystectomy|Early cholecystectomy was done within 48 after admission
62142346|NCT03085407|SHAM_COMPARATOR|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
62142347|NCT00297349||001|
62142348|NCT05637905||psoriatic arthritis patients group|
62142349|NCT05637905||health control group|
62142350|NCT02331485|EXPERIMENTAL|PICO + Acticoat group|Patients randomized to negative pressure group will received negative pressure dressing (Pico Wound Management System - manufacture by Smith \& Nephew) associated with Acticoat Flex dressing which will be applied immediately after skin closure in a conventional way and left in place for 7 days. Negative pressure dressing will be changed once during 7 days period - after day 2 to 4. Wound complications within first 30 days of surgery will be recorded on clinical examination.
62142351|NCT02331485|ACTIVE_COMPARATOR|Standard Wound management|If a patient is randomized to standard wound treatment group - he/she will receive standard skin closure and standard Mepore dressing, which will be changed on a daily basis.
62142352|NCT03058757|NO_INTERVENTION|Control arm|No intervention applied.
62142353|NCT03058757|EXPERIMENTAL|Intervention arm|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation
62344903|NCT06275243|SHAM_COMPARATOR|Control group of healthy individuals without a diagnosis of Alzheimer's disease|Participants: Men and women with age between 60 and 90 years
62344904|NCT03390712||Paliperidone Palmitate|Patients who have received a minimum of 3 months of treatment with an injection of paliperidone palmitate.
62344905|NCT03390712||Risperidone Long-acting injection.|Patients who have received a minimum of 3 months of treatment with Risperidone long-acting injection.
62344906|NCT06419647|EXPERIMENTAL|Intervention|Participants complete daily mood tracking and weekly timeline followbacks of alcohol use
62344907|NCT06419647|NO_INTERVENTION|Control|Participants complete daily logs of time spent online and weekly timeline followbacks of alcohol use
62344908|NCT01308723|EXPERIMENTAL|Part I|
62344909|NCT01308723|EXPERIMENTAL|Part II (A)|
62502821|NCT05903339|EXPERIMENTAL|Group 2: Low dose V3G CH848 Pr-NP1 with ACU-026-001-1|3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
62502822|NCT05903339|EXPERIMENTAL|Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum|3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
62702078|NCT01853280|PLACEBO_COMPARATOR|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
62702079|NCT05763667|NO_INTERVENTION|No TAP block|
61955525|NCT01540838|ACTIVE_COMPARATOR|Bolus with placebo|Cefotaxime is administered as bolus q.i.d. with a placebo of paracetamol
62344910|NCT01308723|ACTIVE_COMPARATOR|Part II (B)|
62344911|NCT05750134||Moderately obese patients|Moderately obese patients undergoing endoscopic sleeve gastroplasty
62702080|NCT05763667|ACTIVE_COMPARATOR|TAP block with liposomal and plain bupivacaine|
62702081|NCT05763667|ACTIVE_COMPARATOR|TAP block with plain bupivacaine alone|
62702082|NCT06052592||Group A|Newborns fed with formula milk supplemented with 20 mg/day of fermented FOS from Lactobacillus paracasei strain CNCM I-5220 and Vitamin D (0.5 ml of SMART D3 MATRIX)
62702083|NCT06052592||Group B|Newborns fed with formula milk
62702084|NCT06052592||Group C|Newborns fed with exclusive breast milk
62702085|NCT04886531|EXPERIMENTAL|A|"Weeks 1-3\* patients receive either (a) Neratinib, (b) Letrozole or Anastrozole or (c) Neratinib + Letrozole or Anastrozole~Weeks 4-24 patients receive Neratinib + Letrozole or Anastrozole and Trastuzumab~\*Starting drug intervention varies for the first 3 weeks depending on arms: a, b, and c by randomization."
62702086|NCT05432973|EXPERIMENTAL|PENS|
62702087|NCT05432973|ACTIVE_COMPARATOR|Neurodynamics and manual therapy|
62702088|NCT06529484|EXPERIMENTAL|Experimental Group|"The experimental group will receive interactive training and an educational booklet on fatigue, its definition, causes, development, coping strategies, and water temperature adjustment. Each patient gets a marked plastic basin for 8 liters and a thermometer.~Starting the next day, patients will take a 38-40ºC warm water bath for 20 minutes between 21:00-22:00 nightly for 7 days to manage fatigue. This time ensures the child rests after the bath.~In the initial 30-minute meeting, evaluation tools will assess the patient's personal and disease-related characteristics, fatigue level on the treatment day, impact due to fatigue, and coping strategies. Patients will be called daily for 7 days to assess fatigue levels using the Scale. On the 7th day, the final interview will use the 12-Item Scale and the Parental Fatigue Scale for 7-12 Year old patients."
62502823|NCT05903339|EXPERIMENTAL|Group 4: V3G CH848 Pr-NP1 with ACU-026-001-1|3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
62702089|NCT06529484|NO_INTERVENTION|Control Group|The control group will receive interactive training and an educational booklet covering the definition, causes, development, and effective coping strategies for chemotherapy-related fatigue. Patients in this group will be assessed between 21:00-22:00 in the evening, without the warm water foot bath intervention. The evaluations will focus on fatigue levels and other related outcomes over the 7-day period. On the 7th day, the final interview will use the 12-Item Pediatric Oncology Fatigue Scale and the Parental Fatigue Scale for 7-12 Year Old Pediatric Oncology Patients, concluding the study.
62702090|NCT01220687|PLACEBO_COMPARATOR|Placebo 20ppm|Nitrogen at 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
62702091|NCT01220687|EXPERIMENTAL|Inhaled Nitric Oxide (iNO) 20 ppm|Inhaled Nitric Oxide 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
62702092|NCT06750939||Cardiovascular collapse|"- At least one documented episode of SpO₂ \< 80%, ensuring accuracy of measurement.~* At least one episode of systolic arterial blood pressure (SAB) \< 65 mmHg.~* SAB \< 90 mmHg sustained for a duration of 30 minutes.~* Initiation of norepinephrine therapy.~* Escalation of pre-existing norepinephrine infusion dose.~* Administration of \>15 mL/kg crystalloid fluids to achieve SAB \> 90 mmHg.~* Occurrence of cardiac arrest. The occurrence of any of the above-mentioned events within the first 30 minutes following the initiation of the intervention will be considered as cardiovascular collapse."
62702093|NCT06750939||No Cardiovascular collapse|
62702094|NCT06748339||contol group|6 healthy participants
62702095|NCT06748339||CRC group|12 newly diagnosed CRC patients
62702096|NCT05035030|EXPERIMENTAL|Odevixibat (A4250)|Capsules for oral administration once daily for 72 weeks.
62702097|NCT06749925|EXPERIMENTAL|DC Vaccine Arm|This group is receiving the dendritic cell vaccine.
61955526|NCT03807518|EXPERIMENTAL|Structured Exercise Intervention|The exercise training program was designed to improve physical fitness while the patients are receiving neoadjuvant treatment prior to surgery and for a 6 week period after surgery once patients are deemed fit to return to training.
62142354|NCT01232166|EXPERIMENTAL|Endobronchial Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
62344912|NCT02787330|ACTIVE_COMPARATOR|Control Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
62702098|NCT06749925|ACTIVE_COMPARATOR|DC Vaccine + Pembrolizumab Arm|This group is receiving the dendritic cell vaccine combined with pembrolizumab.
61955527|NCT03807518|NO_INTERVENTION|Standard Oncological Care|This group will receive standard oncological care and will receive no formal education of exercise intervention.
62142355|NCT01232166|ACTIVE_COMPARATOR|Endobronchial Intubation, Observation|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
62344913|NCT02787330|EXPERIMENTAL|Experimental Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program which focuses on education, therapeutic problem solving, and social support. Each intervention session is structured by theme relevant to the cancer experience and themes are addressed through fun activities, games, arts, and crafts.To maximize the therapeutic effect of the intervention fun work (homework) will be assigned after each session. Training for the EG facilitators requires reading and studying the manual to become fully familiarized with the intervention approaches, observing group sessions through a one-way mirror prior to participation as a group facilitator, and participating as a group facilitator assistant for the intervention program.
62344914|NCT04822272|EXPERIMENTAL|Thermometry MRI|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
62344915|NCT02946541|EXPERIMENTAL|evogliptin 5mg|evogliptin 5mg QD
62344916|NCT02946541|PLACEBO_COMPARATOR|placebo|Placebo QD
62344917|NCT01635010|NO_INTERVENTION|Control|
62344918|NCT01635010|EXPERIMENTAL|Obstructive sleep apnea|
62344919|NCT00884052|EXPERIMENTAL|levetiracetam dose escalation|6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day
62344920|NCT05866393|NO_INTERVENTION|Usual Care|Based on the literature reviewed and previous studies, the enrollment and the control group (Group 1- Usual Care) will begin within 24 hours of participants' admission to medical surgical units (4A, 4B, 5A, 5B- Cleveland VA and 9B, 9C, 11C, 7A MetroHealth). Data collection times are: the day of admission (Baseline, Day 0-1) and Day 3-4 between 2pm and 5pm. Participants will be consented for the research study staff to collect swabs for their nares on Day 0-1 and Day 3-4 and their hands at admission Day 0-1 and Day 3-4. No education or hand hygiene products will be provided. It is established that at both institutions a lemon towelette packet is provided with each meal.
62142356|NCT01232166|ACTIVE_COMPARATOR|Endobronchial intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
61955528|NCT06139107|EXPERIMENTAL|Combined Pre-Operative Therapy with Abemaciclib, Letrozole, and Radiation in HR+/HER2- Breast Cancer|"Part A:~* 28-day treatment cycle based on abemaciclib~* Abemaciclib 150mg BID (twice a day).~* Letrozole 2.5mg daily and Abemaciclib 150mg twice a day for three cycles prior to undergoing radiation therapy.~* On-treatment biopsy conducted between cycle 3, day 16, and cycle 4, day 1.~* This occurs two weeks prior to transitioning to Part B.~Dose Level 0 150mg Twice daily with at least 6 hours between doses Dose Level 1 100mg Twice daily with at least 6 hours between doses Dose Level 2 50mg Twice daily with at least 6 hours between doses~Part B:~* Continue treatment from Part A, 28-day cycle based on abemaciclib.~* Abemaciclib 150mg BID (twice a day) with letrozole 2.5mg daily.~* Part B focuses on the administration of radiation therapy following the three cycles of combined abemaciclib and letrozole.~* Targeted radiation treatment.~Part C:~* Two cycles of abemaciclib, 150mg twice a day.~* Letrozole 2.5mg daily.~Part D:~Surgery"
61955529|NCT02571075|EXPERIMENTAL|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
61955530|NCT02571075|NO_INTERVENTION|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
61955531|NCT01185756|EXPERIMENTAL|ICD implantation|"MIBG for diagnostic purpose:~MIBG scintigraphy for diagnostic purpose"
61955532|NCT02563743|EXPERIMENTAL|Problem-solving based intervention|Problem-solving based intervention with a participative approach. During the intervention a systematic assessment of the match between the employee and the work environment is considered. The intervention applies a participatory approach where the supervisor and the employee are guided by the OHS consultant and encouraged to actively take part in problem solving concerning the work situation. The intervention consists of three meetings, one between the OHS consultant and a representative for the employer (usually the nearest supervisor), one between the consultant and the employee and then a third meeting where all three parties participate.
61955533|NCT02563743|ACTIVE_COMPARATOR|Treatment as usual|The control intervention consists of the usual interventions given at the participating OHS. These interventions are also work-directed and usually also include participation of both the employee and the supervisor. However, structured problem solving methods and the systematic consideration of the match between the employee and the job situation are not applied. The content of the control condition will vary between different occupational health service units.
62702099|NCT06749925|PLACEBO_COMPARATOR|Placebo Control Arm|This group is receiving a placebo and serves as the control.
61955534|NCT05959031|EXPERIMENTAL|active kTMP|Participants received 0.5 - 8 V/m of active stimulation.
61955535|NCT05959031|SHAM_COMPARATOR|sham kTMP|Participants received 0.01 V/m of sham stimulation.
61955536|NCT03812107|EXPERIMENTAL|Moderate Treatment Approach|Participants in this arm who relapse will be able to move more freely between follow up steps and are hypothesized to require fewer provider visits than those in the intensive treatment arm.
61955537|NCT03812107|ACTIVE_COMPARATOR|Intensive Treatment Approach|Participants in this arm who relapse will follow the current guidelines follow up steps of weekly, then every two weeks and finally monthly provider visits.
61955538|NCT05014893|NO_INTERVENTION|Control|Control group, without specific treatments
61955539|NCT05014893|EXPERIMENTAL|Cognitive training|This group receives treatments to improve cognitive function.
62702100|NCT06749639|EXPERIMENTAL|PUMCH-E101 Treatment Arm（Low dose）|Intraocular injection of a single low dose of PUMCH-E101
62702101|NCT06749639|EXPERIMENTAL|PUMCH-E101 Treatment Arm（High dose）|Intraocular injection of a single high dose of PUMCH-E101
62702102|NCT03311503|EXPERIMENTAL|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
62702103|NCT06748248|EXPERIMENTAL|suspension therapy|Universal Exercise Unit also named Spider cage and Monkey cage. This device will used in this study. This system helps the children to weight shift, more independent movement and assisted movement such as sit to stand, squats and jumping.
62702104|NCT06748248|OTHER|Routine Treatment|These routine exercises will consist of stretching exercises (particularly upper and lower body stretches and full body stretches). Stretches will be gentle and avoid bouncing. Hold for each stretch will be 15-30 seconds. Balance and coordination exercises (Walking on balance beams, obstacle courses) will be performed as RPT. The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. These exercises will be carried out 5 days in a week for one hour daily.
62714858|NCT01889992|ACTIVE_COMPARATOR|Cardiac MRI|Cardiac Magnetic Resonance Imaging (MRI) produces no side effects from the magnetic fields and radio waves and doesn't carry a risk of cancer or birth defects. Serious reactions to the special contrast dyes used for MRI are very rare. The MRI examination poses almost no risk to the average patient when appropriate safety guidelines are followed, however side effects are possible and include headache, nausea, dizziness, change in taste and allergic reaction. Such reactions usually are mild and easily controlled by medication.
61955540|NCT06300931||Intern dentists|Group of interns to take KAP survey followed by a lecture and then another KAP survey
61955541|NCT02022852|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy
61955542|NCT02022852|EXPERIMENTAL|Sequential therapy|XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy
61955543|NCT00244010|OTHER|1|
61955544|NCT02478775|EXPERIMENTAL|Frequent Blood Sampling, Degarelix|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period. This arm was terminated due to Adverse Events and the study was continued with the Cetrorelix product.
61955545|NCT02478775|EXPERIMENTAL|Frequent Blood Sampling, Cetrorelix|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Cetrorelix blockade over a 2-day period.
61955546|NCT00454883||1 cohort of patients treated with ziprasidone|
61955547|NCT01100671||Healthy patients|
61955548|NCT02221791|ACTIVE_COMPARATOR|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
61955549|NCT02221791|ACTIVE_COMPARATOR|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
61955550|NCT02221791|PLACEBO_COMPARATOR|Placebo|Participants will consume 70g white chocolate + placebo capsules
61955551|NCT01629524||Colorectal cancer patients|Colorectal cancer patients undergoing elective colorectal resection
61955552|NCT01264900|EXPERIMENTAL|Cognitive Behavioral Therapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment
61955553|NCT01264900|ACTIVE_COMPARATOR|Supportive Psychotherapy|Twelve weekly 50-minute sessions of individual supportive (client-centered) psychotherapy
62142357|NCT01232166|ACTIVE_COMPARATOR|Endobronchial intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
62142358|NCT01232166|EXPERIMENTAL|Endotracheal Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the trachea, 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
62142359|NCT01232166|ACTIVE_COMPARATOR|Endotracheal Intubation, observation|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5-3cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
62344921|NCT05866393|EXPERIMENTAL|Clean Hands Accessible and Manageable for Patients|"CHAMPs participants will receive a patient hand-sanitation system attached via an R-shape clip to the bed rail. After it is placed on the bed rail, the personalized verbal electronic audio reminder with the RA's voice to insert the participants' name,  ____ it is (breakfast, lunch, dinner) time, please clean your hands. The times will be within an hour window of 7 a.m., noon, and 5 p.m. The CHAMPs system will be labeled For Patient Use Only. The times were chosen around meal times because these times also are similar to around the time when medications are being administered. The hands can be a vector for germs to the face and mouth as shown in the literature. On Day 3 or 4 whichever comes later without anticipated discharge, the Interventionist will provide the evaluation of intervention questionnaires, clean the system turn it in to the project manager to retrieve SD card which contains the month, day, time, and number of system usages."
62502824|NCT02948426|EXPERIMENTAL|Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml)|Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
62502825|NCT02948426|EXPERIMENTAL|Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (75x10\^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
62502826|NCT02948426|EXPERIMENTAL|Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (750x10\^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
61955554|NCT00667875|PLACEBO_COMPARATOR|1|
61955555|NCT00667875|ACTIVE_COMPARATOR|2|Naltrexone
61955556|NCT00667875|ACTIVE_COMPARATOR|3|Naltrexone + Aripiprazole
61955557|NCT03166735|EXPERIMENTAL|BI 1467335 dose 1|
61955558|NCT03166735|EXPERIMENTAL|BI 1467335 dose 2|
61955559|NCT03166735|EXPERIMENTAL|BI 1467335 dose 3|
61955560|NCT03166735|EXPERIMENTAL|BI 1467335 dose 4|
61955561|NCT03166735|PLACEBO_COMPARATOR|Placebo|
61955562|NCT02041884|EXPERIMENTAL|iCBT|A skill training internet-based treatment program based on CBT and DBT interventions .
61955563|NCT02041884|ACTIVE_COMPARATOR|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
61955564|NCT02041884|OTHER|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
61955565|NCT04303819||newly diagnosed T2DM participants|newly diagnosed T2DM participants without anti-diabetic drugs intake
61955566|NCT04736407||Repositioned|Allocated to sampling performed around a standard clinical repositioning (lateral side to side), or a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling.
61955567|NCT04736407||Non-repositioned|Allocated to sampling performed with a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling
61955568|NCT05094583||Intervention Arm|Patients who expressed wish to quit smoking and accept use of the SmokeFree app
61955569|NCT05094583||Control Arm|Patients who expressed wish to quit smoking but declines all support or use of SmokeFree app
61955570|NCT02185092|PLACEBO_COMPARATOR|Sugar Pill|1 pill orally daily
61955571|NCT02185092|ACTIVE_COMPARATOR|Lactobacillus GG|1 pill (2 x 10x 9 CFU) daily orally
61955572|NCT01901120||Betanis|the usual adult dosage of mirabegron once daily after a meal
61955573|NCT06292520|EXPERIMENTAL|ABLLS-R protocol|The study will evaluate the ABLLS-R (Assessment of Basic Language and Learning Skills test) and compare their effectiveness in developing the Receptive.
61955574|NCT06292520|EXPERIMENTAL|Portage Guide Protocol|The study will evaluate Portage guidance and compare their effectiveness in developing the Receptive Language Skills in children with Autism Spectrum Disorder.
61955575|NCT04718298|EXPERIMENTAL|Inguinal hernia repair laparoscopic|recurrent inguinal hernia after open repair or bilateral hernia patients
61955576|NCT01968759|ACTIVE_COMPARATOR|Ramipril and Irbesartan|Best available therapy including dual RAS blockade with Ramipril and Irbesartan
61955577|NCT01968759|EXPERIMENTAL|Sevelamer|Two tablets of Sevelamer carbonate 800 mg will be orally administered three times per day during the meals for 3 months.
61955578|NCT06204887|EXPERIMENTAL|Manual dynamic activation|
61955579|NCT06204887|EXPERIMENTAL|Passive ultrasonic activation|
61955580|NCT06204887|EXPERIMENTAL|Laser activation|
61955581|NCT06204887|NO_INTERVENTION|Non-activated Control|
61955582|NCT06258941|EXPERIMENTAL|12-Week Mindful High-Intensity Interval Training (MF-HIIT)|
61955583|NCT06258941|ACTIVE_COMPARATOR|12-Week High-Intensity Interval Training (HIIT-only)|
61955584|NCT06258941|ACTIVE_COMPARATOR|12-Week Mindfulness (MF-only)|
61955585|NCT06258941|PLACEBO_COMPARATOR|12-Week Sedentary Activities|
61955586|NCT04556188||Cases|RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital
61955587|NCT04556188||RHD controls|RHD patients not offered Cardiac surgery
61955588|NCT04556188||Anticoagulation controls|Norwegian patients on anticoagulant therapy due to mechanical valve implants
61955589|NCT05267886|ACTIVE_COMPARATOR|Inotrope|Participants randomized to receive the inotrope will be initiated on inotrope therapy at starting doses and titrated according to standard clinical care. During reassessment, the treating physicians will make a decision about adjustment of the inotrope dose (increase, maintain or decrease) based on hemodynamics, end-organ perfusion, vasopressor support and clinical exam. Dobutamine doses will be 2.5, 5.0, 7.5, 10 and \>10 ug/kg/min and milrinone doses will be 0.125, 0.250, 0.375, 0.5 and \>0.5 ug/kg/min. These dose stages are identical to those used in Capital Do-Re-Mi and reflect current standard of care.
61955590|NCT05267886|PLACEBO_COMPARATOR|Placebo|Participants in the placebo arm will have an intravenous solution of 0.9% NaCl running at a standardized rate, comparable to the infusion rate of the inotrope arm.
62142360|NCT01232166|ACTIVE_COMPARATOR|Endotracheal intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5 - 4 cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
61955591|NCT02695225|OTHER|Lay-led tobacco abstinence|Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
61955592|NCT02695225|OTHER|Lay-led promotion of Ohio Quit Line|Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
61955593|NCT00882895|EXPERIMENTAL|Allogeneic Transplant|"* TLI - 80 cGy on days -14, -11, -10, -9, -8, -7, -4, -3, -2, -1~* Anti-thymocyte globulin (ATG) 1.5 mg/kg on days -11, -10, -8, -7~* Solumedrol - 1 mg/kg on days -11, -10, -9, -8, -7~* Tacrolimus - beginning on day -3 with starting dose of 0.3 mg/kg PO BID. Will be continued per institutional guidelines.~* Stem cell infusion - day 0~* Mycophenolate mofetil (MMF) - beginning on day 0 with dose of 15 mg/kg PO (5-10 hours after transplant)"
61955594|NCT04916431|EXPERIMENTAL|mRNA-6231 Dose Level 1|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 1 of mRNA-6231 once every 2 weeks."
61955595|NCT04916431|EXPERIMENTAL|mRNA-6231 Dose Level 2|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 2 of mRNA-6231 once every 2 weeks."
61955596|NCT04916431|EXPERIMENTAL|mRNA-6231 Dose Level 3|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 3 of mRNA-6231 once every 2 weeks."
61955597|NCT02570074|EXPERIMENTAL|Fosfomycin - 3 doses QoD/7 doses QD|Fosfomycin given as a 3 gm dose, every other day for 3 doses, followed by 3 gm dose, once a day for 7 doses.
61955598|NCT02570074|EXPERIMENTAL|Fosfomycin - 7 doses QD/3 doses QoD|Fosfomycin given as a 3 gm dose, once a day for 7 doses, followed by 3 gm dose, every other day for 3 doses.
61955599|NCT00967057|EXPERIMENTAL|Arm I (induction therapy)|Patients receive idarubicin IV over 1 hour on days 1 and 2; oral dexamethasone twice daily on days 1-5 and 15-19; intrathecal (IT) methotrexate on days 1 and 8; vincristine sulfate IV on days 3, 10, 17, and 24; and pegaspargase intramuscularly (IM) on days 3 and 17 or asparaginase IM on days 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25.
61955600|NCT00967057|EXPERIMENTAL|Arm II (induction therapy)|Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.
62142361|NCT01232166|ACTIVE_COMPARATOR|Endotracheal intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
62142362|NCT00716300||1|obese and insulin resistant subjects
62142363|NCT00716300||2|lean and normolipidaemic subjects
62502827|NCT02948426|EXPERIMENTAL|Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml)|Monocytes (750x10\^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
61955601|NCT02519257|EXPERIMENTAL|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
61955602|NCT02519257|EXPERIMENTAL|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
61955603|NCT01002222|EXPERIMENTAL|MCS-2|
61955604|NCT05250882|EXPERIMENTAL|Double Check enhanced perioperative care protocol|Perioperative care according to a best practice protocol focussing on optimizing the intraoperative condition of the patient and thereby minimalize exposure to 6 known modifiable independent intraoperative risk factors: anemia, hypothermia, epidural anesthesia, vasopressor drug administration, incorrect antibiotic prophylaxis and hyperglycemia.
62142364|NCT03705663||Women interested in HIV PrEP|Cis-gender women at high risk for HIV interested in or initiating HIV PrEP
62344922|NCT01894464|EXPERIMENTAL|Teacher led intervention|Teachers will conduct teacher-led interventions that are individualized for each student to prevent emerging truancy among elementary students.
62344923|NCT01894464|NO_INTERVENTION|Control Group|
62344924|NCT02168933|EXPERIMENTAL|active excimer laser|308 nm excimer laser treatment: treatment with the laser by a dose protocol with increasing output.
62344925|NCT02168933|SHAM_COMPARATOR|Sham excimer laser|Sham 308 nm excimer laser treatment: laser dose was administered with a cap that blocks all active UV passing through the device, therefore is a placebo, but because the procedure is the same, maintains a blind.
62344926|NCT05478330|EXPERIMENTAL|Group A (Flutamide group)|"Flutamide was supplied in the form of yellow powder and obtained from Sigma Pharmaceutical Industries, Egypt.~Tween 80 and Propylene glycol were obtained from Sigma Pharmaceutical Industries, Egypt.~Oleic acid was purchased from El Gomhouria Company for Trading Chemicals and Medical Appliances, Egypt."
62344927|NCT05478330|PLACEBO_COMPARATOR|Group B (control group)|"Tween 80 and Propylene glycol were obtained from Sigma Pharmaceutical Industries, Egypt.~Oleic acid was purchased from El Gomhouria Company for Trading Chemicals and Medical Appliances, Egypt."
62502828|NCT02948426|EXPERIMENTAL|EX1 Dose Expansion Arm|10 additional patients will be treated at the maximum tolerated dose (MTD)
62714859|NCT01889992|ACTIVE_COMPARATOR|Coronary Angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
61955605|NCT05250882|NO_INTERVENTION|Current practice|Perioperative care according to usual practice. Historical controls from the previously conducted LekCheck study will be used as replacement of a control arm.
61955606|NCT03133169||on chelation|"patients with B-thalassemia major samples of which will be examined for renal and liver function, Erythrocyte Glutamine level, ferritin level and complete blood picture. Also Echo will be done for measuring the Tricuspid regurge velocity.~group 1: cases on chelation: deferasirox 500mg oral tablet with initial dose 20 mg/kg guided by ferritin level~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
62344928|NCT00078559|EXPERIMENTAL|Alemtuzumab|
62344929|NCT00207259|NO_INTERVENTION|Control|Standard weekly treatments with radiation oncologist and nurse. All control patients offered intervention at end of 8-week course of radiotherapy.
61955607|NCT03133169||No chelation|"group 2: cases without chelation~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
61955608|NCT03133169||splenectomy|"group 3: cases with splenectomy~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
61955609|NCT03133169||no splenectomy|group 4: cases without splenectomy Diagnostic Test: blood sample Diagnostic Test: Tricuspid regurge velocity
61955610|NCT03390816||Transversal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital
61955611|NCT03390816||Longitudinal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital Forward-looking follow-up of 6 months of a sub-sample during the first year
61955612|NCT00249756|EXPERIMENTAL|Re-entry Modified Therapeutic Community (Re-entry MTC)|
62142365|NCT06699719|NO_INTERVENTION|Control|Participants are not asked to complete the online writing intervention
62344930|NCT00207259|EXPERIMENTAL|Relaxation Therapy|Weekly relaxation therapy with PhD psychologist and home cognitive restructering practice
62344931|NCT00207259|EXPERIMENTAL|Reiki|Weekly Reiki therapy with a Reiki therapist, involves laying of the therapist's hands on the patient to rechannel energy, considered pleasant and calming
62344932|NCT03350178|EXPERIMENTAL|treated patients|Treated wit FMT
61955613|NCT00249756|ACTIVE_COMPARATOR|Parole Supervision and Case Management|
61955614|NCT02178371|EXPERIMENTAL|UTWC (control group)|the control group performs the same tasks than the experimental group, but without healthy hand constraint/containment.
62142366|NCT06699719|EXPERIMENTAL|Expressive writing|Participants are asked to complete four 20-minute sessions of an online writing task on consecutive days.
62502829|NCT01156896|EXPERIMENTAL|Iron intervention|"All study subjects with malaria and all control subjects will receive an iron intervention (supplement or fortification dose of iron).~Control subjects will be studied on only one occasion.~Study subjects with malaria will receive the same iron intervention two weeks later, after the malarial episode has been successfully treated."
62502830|NCT05425745|PLACEBO_COMPARATOR|Placebo|one placebo tablet once daily
62502831|NCT05425745|EXPERIMENTAL|Obicetrapib 10 mg|one 10 mg Obicetrapib tablet once daily
62502832|NCT03847974|EXPERIMENTAL|LIB003|LIB003
62502833|NCT05795348|OTHER|Knee Osteoarthritic Patients|Patients candidate for knee arthroplasty; Age: 65-80 years; Body Mass Index: 18.5-30 kg/m²; ASA Classification: 1 or 2; Diagnosis of primary osteoarthritis at the knee; Suspect sarcopenia.
61955615|NCT02178371|EXPERIMENTAL|mCIMT|"The study is conducted over a period of 5 weeks of treatment, using a movement restriction time healthy upper extremity of 2 hours daily.~The restriction applied in the study is performed with the closed hand position and thumb inside the fist through a transparent film that reaches the wrist joint.~In periods mCIMT, monitored the activities designed to enhance their functionality, based on motivation, avoiding frustrations are made."
61955616|NCT02737696|ACTIVE_COMPARATOR|Control|Participants in this group will have access to Drug Enforcement Administration's website (JustThinkTwice.gov). The JustThinkTwice website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz. Youth in this group will be informed that they will be prompted (by email and phone; described below) when the next online survey is available to complete. Youth will be asked to use this website for 30 minutes, twice per week (for a total of 60 minutes per week) for about 3-4 weeks.
61955617|NCT02737696|EXPERIMENTAL|Experimental|"Participants assigned to the Web-based prescription opioid prevention for adolescents will immediately (post-group assignment) be asked to start completing modules. All youth can choose to access modules in any order. Youth will be encouraged to complete 1-2 modules per login, 2x/week (about 30 mins. minimum per login to parallel the manner in which other evidence-based prevention programs have been provided to youth. We do not plan to place an artificial constraint on module access but will encourage youth to use the flexible, web- based tool in a manner that is most useful to them. In our experience providing online interventions, we expect that most youth will complete all 9 modules within 3-4 weeks."
61955618|NCT03727230|EXPERIMENTAL|Asian-type DEL recipients|"First, to identify Asian-type DEL patients by phenotyping and genotyping methods in the Chinese recipients having a serologically apparent RhD-negative phenotype.~Then, blood transfusion of RhD+ blood rather than rare RhD-negative blood to the Asian-type DEL recipients which met the inclusion criteria."
61955619|NCT02721485|OTHER|Normal Saline|Half of the hospitals will be allocated to start the 90-day test period using Normal Saline administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Ringer's Lactate following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
61955620|NCT02721485|OTHER|Ringer's Lactate|Half of the hospitals will be allocated to start the 90-day test period using Ringer's Lactate administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Normal Saline following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians in for the final 90-day test period.
61955621|NCT04530916|EXPERIMENTAL|Blueberry|22 g blueberry powder per day
61955622|NCT04530916|PLACEBO_COMPARATOR|Control|22 g placebo control powder per day
62502834|NCT02993705|EXPERIMENTAL|Trabectedin|Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter.
62502835|NCT06260501||High volume liposuction under general anesthesia with super-wet technique|Patients who underwent high-volume liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter under general anesthesia
61955623|NCT06413381||Focus group|non-responsive patients to medical treatment
61955624|NCT06413381||Control group|responsive patients to medical treatment
61955625|NCT03245515|EXPERIMENTAL|BMS-986195|A single oral solution dose of BMS-986195
61955626|NCT03543150||Subjects receiving BOTOX|Subjects with a diagnosis of spasmodic dysphonia, for which BOTOX is indicated, will be included.
62142367|NCT05555901|EXPERIMENTAL|Fruquintinib+ chemotherapy|Patients will receive fruquintinib+ FOLFIRI once every four weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive fruquintinib + capecitabine as maintenance treatment.
62714860|NCT01889992|ACTIVE_COMPARATOR|Cardiopulmonary Exercise Test (CPET)|Is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
61955627|NCT03438747|EXPERIMENTAL|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
61955628|NCT03438747|ACTIVE_COMPARATOR|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
61955629|NCT02099994|EXPERIMENTAL|A - AM|Ad35-GRIN 5 x 10\^10 vp IM at week 0, MVA.HIVconsv 2 x 10\^8 pfu IM at week 8.
62142368|NCT05555901|ACTIVE_COMPARATOR|Bevacizumab+ chemotherapy|Patients will receive bevacizumab+ FOLFIRI once every two weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive bevacizumab + capecitabine as maintenance treatment.
62142369|NCT06509763|EXPERIMENTAL|Left Bundle Branch electrode implant|
62142370|NCT05879276|EXPERIMENTAL|Empaglifozin in addition to standard management|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks
62502836|NCT06679751|EXPERIMENTAL|ID-TOUCH Program|Participants will receive the ID-TOUCH intervention while incarcerated and meet with the study team three times for data collection: once before release, once one week after release, and once three months after release. Information collected will include: utilization of HIV services while in jail and while in the community and an exploration of self-reported high-risk behavior, perceived stigma and discrimination, and medical mistrust.
62502837|NCT02890225|OTHER|3|Patients in 3 days
62502838|NCT02890225|OTHER|10|Patients in10ys
61955630|NCT02099994|EXPERIMENTAL|B - DDDAM|pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10\^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10\^8 pfu or saline placebo at week 20.
61955631|NCT02099994|EXPERIMENTAL|C - DeDeDeAM|"Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.~Ad35-GRIN 5 x 10\^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10\^8 pfu or saline placebo at week 20."
61955632|NCT04898595|NO_INTERVENTION|Usual Process of Care|No intervention
61955633|NCT04898595|EXPERIMENTAL|Standardized approach to discontinuation of CRRT|Criteria-driven approach
61955634|NCT06049862|EXPERIMENTAL|MariTensi app and usual care|Patients use the MaRitensi application to manage their hypertension by utilizing various menus in the application and continue receiving treatment as usual for 12 weeks.
61955635|NCT06049862|NO_INTERVENTION|Usual care|The patient was not given the MaRitensi application and only received treatment as usual.
61955636|NCT00477256||Child|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer.
61955637|NCT00477256||Parent|Parent(s) or caregiver(s) of children with cancer.
61955638|NCT00477256||Medical Staff|Medical staff (i.e., physicians, nurse practitioners) involved in the children's medical decision-making.
61955639|NCT01948297|EXPERIMENTAL|Part A|Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
61955640|NCT01948297|EXPERIMENTAL|Part B|Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
61955641|NCT04778930|EXPERIMENTAL|Group A_Intervention Group|It will consist of 18 sessions, 3 times a week, for 6 consecutive weeks; on the one hand, 12 face-to-face sessions of approximately 90 minutes duration, in which the Physical Therapy treatment will be carried out based on training of specific tasks directed to objectives and training of gait with a treadmill; In addition, a therapeutic education program will be carried out, with 6 telehealth sessions lasting approximately 60 minutes, which will include action observation activities. The face-to-face sessions will be held at the Physical Therapy Teaching Unit at University of Alcalá, and the telehealth sessions of the Therapeutic Education program will be carried out by remote assistance through a digital platform. All will be carried out by specialist Physical Therapists, members of the research team.
61955642|NCT04778930|EXPERIMENTAL|Group B_Control Group|The subjects in this group will receive their usual Physical Therapy intervention regimen for 6 weeks at their referral center and the same telehealth Therapeutic Education program of the intervention group.
62142371|NCT05879276|NO_INTERVENTION|Standard management|Patients in cardiogenic shock receiving a standard management. SGLT2 inhibitor, which are now standard of care in chronic heart failure, in the strict respect of their indications, could be prescribed in the standard management group after hospitalization discharge.
62344933|NCT03837353|EXPERIMENTAL|Cohort 1A|In dose-escalation Cohort 1A, the dose of docetaxel 75 mg/m2 will remain fixed. The DKN-01 dose level will start with 300 mg and be escalated to 600 mg or de-escalated to 150 mg depending on the absence or presence of identified DLTs. DKN-01 will be administered in combination with docetaxel on Day 1 and as monotherapy on Day 15 of each 21-day cycle. Patients will be treated with the combination of DKN-01 and Docetaxel until Prostate Cancer Working Group 3 (PCWG3) progression or unacceptable toxicity.
62502839|NCT02890225|EXPERIMENTAL|30|Patients in10ys
62502840|NCT04815109||critical ill COVID-19|Critically ill COVID-19 patients with need for ventilation and appropriate sedation
62502841|NCT04439110|EXPERIMENTAL|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61955643|NCT02764060|EXPERIMENTAL|Tongue scraper|In this group the subjects are explained how to use a plastic loop-formed tongue cleaner (Halita® tongue cleaner (Dentaid, Spain)) to clean their tongues.
62142372|NCT04433091|ACTIVE_COMPARATOR|2-HOBA|2-Hydroxybenzylamine(2-HOBA) 250 mg three tabs TID (po) for seven days prior to ablation and 28 days post ablation.
62502842|NCT06678815||Those either working as, with, or treated by Community First Responders|Those either working as, with, or treated by Community First Responders
62502843|NCT03365791|EXPERIMENTAL|PDR001+LAG525|PDR001 300 mg and LAG525 400 mg administered via i.v. infusion over 30 minutes once every 3 weeks (Q3W). LAG525 was given first followed by PDR001.
61955644|NCT02764060|EXPERIMENTAL|Toothbrush|In this group the subjects are explained how to use a toothbrush (Oral-B® Indicator® medium tooth brush) to clean their tongues.
61955645|NCT01135420|ACTIVE_COMPARATOR|Usual Care|Psychiatry inpatient usual care
61955646|NCT01135420|EXPERIMENTAL|Telephone Monitoring|Patients in the TM condition will receive an in-person session while in treatment, followed by monitoring over the telephone for three months after discharge. The intervention will incorporate motivational interviewing to monitor patients' substance use, facilitate entry into outpatient treatment, and encourage 12-step self-help group participation.
61955647|NCT02941991||uniocular subretinal injection of hESC-RPE cells|Cohort 1. 50,000 cells transplanted; Cohort 2. 100,000 cells transplanted; Cohort 3. 150,000 cells transplanted; Cohort 4. 200,000 cells transplanted
61955648|NCT00592930|EXPERIMENTAL|1|olanzapine
61955649|NCT00592930|PLACEBO_COMPARATOR|2|matching placebo
61955650|NCT01881347|EXPERIMENTAL|Active First|Active resveratrol first, placebo second
61955651|NCT01881347|EXPERIMENTAL|Placebo first|Placebo first, active resveratrol second
61955652|NCT01832831||Continent Men|
61955653|NCT01832831||Incontinent Men|
61955654|NCT02050516|ACTIVE_COMPARATOR|single embryo culture|single embryo culture in single drops inside micro-well group culture dish
61955655|NCT02050516|EXPERIMENTAL|group embryo culture|group embryo culture in a single drop inside micro-well group culture dish
61955656|NCT04961931|OTHER|diabetes group|After qualifying for the study subjects with diabetes and chornic kidney disease received oral empagliflozin 10 mg once daily for 7 days.
61955657|NCT04961931|OTHER|non-diabetes group|After qualifying for the study subjects with chronic kidney disease without diabetes received oral empagliflozin 10 mg once daily for 7 days.
62502844|NCT06002958|NO_INTERVENTION|FEP Providers|Approximately 20 FEP providers (clinicians and peer support specialists) affiliated with first episode psychosis (FEP) clinics in North Carolina (OASIS, SHORE, Encompass, Eagle, AEGIS) will be recruited to share their perspectives of barriers and facilitators in implementing and integrating a digital intervention in clinical practice. They will be asked to complete a survey examining their perspective and beliefs at two time points (baseline, 9 months) as well as a qualitative interview based on the Consolidated Framework for Implementation Science at 9 months.
62502845|NCT06002958|EXPERIMENTAL|FEP Clients|Approximately 50 individuals experiencing FEP and receiving services from FEP clinics (OASIS, SHORE, Encompass, Eagle, AEGIS) or their step down care clinics (STEP and TIDES) will be recruited to participate in a digital platform, Horyzons, for 12 months (for individuals enrolled at the initial opening of the platform; at a minimum 3 months of engagement) as part of their clinical care. Participants will have access to and encouraged to use the therapeutic content as well as the moderated online community network during their time engaging with the platform. They will be asked to complete a small battery of measures at baseline, 6-months, 12 months for individuals enrolled at the initiation of the study, while those enrolled later due to rolling recruitment may experience less assessment visits due to closing of the platform at the end of August 2024.
62502846|NCT04738838|EXPERIMENTAL|Oxytocin Nasal Spray|Single dose of intranasal oxytocin (48 IU) prior to testing protocol.
62502847|NCT04738838|PLACEBO_COMPARATOR|Placebo Nasal Spray|Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
62502848|NCT05121168|EXPERIMENTAL|Active Treatment|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
62502849|NCT05121168|PLACEBO_COMPARATOR|Placebo|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
62502850|NCT06149091|ACTIVE_COMPARATOR|Tranexamic Acid Group|Patients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with tranexamic acid for hemostasis.
62502851|NCT06149091|ACTIVE_COMPARATOR|Adrenalin Group|Patients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with Adrenalin for hemostasis.
62702105|NCT06751030||Women living with HIV|"During the screening process:~* Women testing negative for high-risk HPV (HrHPV) will complete participation one year after their test results, at which time they will be invited to retest.~* Women living with HIV (WLWH) testing positive for HrHPV will have endpoints based on treatment outcomes:~  * Other HrHPV types (not 16/18/45):~    * Endpoint: One year post-VIA (visual inspection with acetic acid).~   * VIA-positive patients will receive thermal ablation treatment.~   * VIA-negative patients will have repeat VIA or standard screening after one year.~ * HrHPV types 16/18/45:~    * Endpoint: Two years post-treatment.~   * Follow-up includes repeat HPV self-collection, VIA, biopsies, and further treatment (thermal ablation or excision) if needed.~WLWH testing positive for HrHPV 16/18/45 via self-collection will be notified by a Mentor Mother, who, along with Nigerian clinical staff, will assist in scheduling VIA. Treatment follows the standard of care protocol."
62702106|NCT06748430|PLACEBO_COMPARATOR|Variety 1 (timpson)|Reference variety
61955658|NCT04961931|OTHER|control|After qualifying for the study healthy subjects received oral empagliflozin 10 mg once daily for 7 days.
61955659|NCT00067665|NO_INTERVENTION|1|Control group of 50 patients where dry weight is not changed.
62142373|NCT04433091|PLACEBO_COMPARATOR|Placebo|Placebo- three tabs TID (po) for seven days prior to ablation and 28 days post-ablation
62142374|NCT06294249|EXPERIMENTAL|Laser-induced Incision|The Biolase Epic 10 diode laser device (Biolase, USA) with 940 nm wavelength, 10 W of max output power, 20 KHz of pulse repetition rate, and continuous pulse mode was used.
62344934|NCT03837353|EXPERIMENTAL|Cohort 1B|In dose-expansion Cohort 1B, either the maximum tolerated dose (MTD) or highest dose tested of DKN-01 in combination with docetaxel in Cohort 1A will be the dose used. The dose of docetaxel 75 mg/m2 will remain fixed. DKN-01 will be administered in combination with docetaxel on Day 1 and as monotherapy on Day 15 of each 21-day cycle. Patients will be treated with the combination of DKN-01 and Docetaxel until PCWG3 progression or unacceptable toxicity.
62344935|NCT03837353|EXPERIMENTAL|Cohort 2A|In dose-escalation Cohort 2A, DKN-01 dose level will start with 300 mg and be escalated to 600 mg or de-escalated to 150 mg depending on the absence or presence of identified DLTs. DKN-01 will be administered as monotherapy on Days 1 and 15 of each 28-day cycle. Patients will be treated with DKN-01 until PCWG3 progression or unacceptable toxicity.
62344936|NCT03837353|EXPERIMENTAL|Cohort 2B|In dose-expansion Cohort 2B, the MTD or highest dose tested of DKN-01 monotherapy in Cohort 2A will be the dose used. DKN-01 will be administered as monotherapy on Days 1 and 15 of each 28-day cycle. Patients will be treated with DKN-01 until PCWG3 progression or unacceptable toxicity.
62344937|NCT04365998|EXPERIMENTAL|BUBOLight® Device|
62344938|NCT02251444|EXPERIMENTAL|outpatient rehabilitation program|whole-body resistance training, psychological interventions, sessions for information related to ergonomics and healthy alimentation
62344939|NCT02251444|ACTIVE_COMPARATOR|physical therapy|prescribed physical therapy
62344940|NCT03117166|EXPERIMENTAL|Lidocaine|treatment arm
62344941|NCT03117166|PLACEBO_COMPARATOR|Saline|placebo arm
62344942|NCT05398133||COPD patients|
62344943|NCT05398133||asthma patients|
62344944|NCT05398133||control subjects|
62344945|NCT04706169||Older adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Older adult group: over 65 years.
62344946|NCT04706169||Adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Adult groups: 20 to 64 years.
62344947|NCT06099691||Older adults with frailty|Participants will be interviewed about what matters to them. They will then give their opinions on questionnaires that aim to measure what matters to them.
62344948|NCT02488096|ACTIVE_COMPARATOR|TRUS-Guided Biopsy|Transrectal Ultrasound (TRUS)-guided biopsy systematic 12-core biopsy (standard care)
62344949|NCT02488096|EXPERIMENTAL|MRI + TRUS-Guided biopsy|Prostate MRI later followed by systematic 12-score TRUS-guided biopsy + targeted biopsy of additional MRI-detected scores.
62502852|NCT06149091|EXPERIMENTAL|Hemagglutinase Group|Patients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with Hemagglutinase for hemostasis.
62502853|NCT00005858|EXPERIMENTAL|Arm I|"Patients receive LMB-9 immunotoxin IV continuously for 10 days. Treatment continues every 30 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62502854|NCT00172016|EXPERIMENTAL|ZOL446 (zoledronic acid)|
62502855|NCT02090231|EXPERIMENTAL|Real 5 Hz rTMS|real 5 Hz rTMS, 10 minutes per day, for 10 weekdays.
62502856|NCT02090231|SHAM_COMPARATOR|sham 5 Hz rTMS|sham 5Hz rTMS, 10 minutes per day, for 10 weekdays.
62502857|NCT05380219|EXPERIMENTAL|dual task strength training|The participants of this group will perform their training following the dual task described.
62502858|NCT05380219|ACTIVE_COMPARATOR|strength training|The participants of this group will perform the work of strengthening the upper limb in a conventional way.
62502859|NCT03395015||Full-face 3-D images|3-D images acquisition of CLP patients' faces at rest is set at different timepoints: 1 week preoperative, 1- and 6-months postoperative. Therefore, laypeople's assessment of the facial appearance of CLP patients is based on full facial views.
62502860|NCT03395015||Nasolabial 3-D images|The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
62502861|NCT01358084|EXPERIMENTAL|Arm A: NGR-hTNF + Best Supportive Care|NGR-hTNF + Best Supportive Care
62344950|NCT03016546|EXPERIMENTAL|BEST-maCARE|BEST-maCARE intervention will be refined to accommodate our target population using pertinent information attained through interviews conducted with patients representative of the target group and stakeholders from the clinics where the intervention will be pilot tested.
62502862|NCT01358084|PLACEBO_COMPARATOR|Arm B: Placebo + Best Supportive Care|Placebo + Best Supportive Care
62702107|NCT06748430|ACTIVE_COMPARATOR|Variety 2 (18INV-1438-10)|First comparator
62344951|NCT03016546|ACTIVE_COMPARATOR|time-matched attention control condition|Participants will be randomly assigned. The control group will receive an intervention that is time and attention equivalent to the experimental condition, though substantively neutral.
61955660|NCT00067665|EXPERIMENTAL|2|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
62142375|NCT06294249|ACTIVE_COMPARATOR|Punch Incision|The soft tissue Osstem punch (South Korea) was used.
62142376|NCT06397196|EXPERIMENTAL|Laser Guided Proprioceptive Exercises + Routine therapy|Participants in Group A will receive Laser guided Proprioceptive exercises with routine physical therapy on alternate days (3 days a week) for 3 weeks. total number of sessions will be 9
62344952|NCT02425007|EXPERIMENTAL|Spiro|Incentive spirometry
62344953|NCT02425007|NO_INTERVENTION|Control|Control group
62344954|NCT00987922|EXPERIMENTAL|Hypothermia|
62502863|NCT01814358|EXPERIMENTAL|Whey protein|Subjects on this arm will receive whey protein
62502864|NCT01814358|ACTIVE_COMPARATOR|Gelatin protein|Subjects on this arm will consume gelatin protein
62702108|NCT06748430|ACTIVE_COMPARATOR|Variety 3 (18-1465-110)|Second comparator
62702109|NCT06750926|EXPERIMENTAL|patients placed SaCoVLM checked position by real-time video image|patients placed SaCoVLM checked position by real-time video image, including native camera and fiberoptic endoscopy
62702110|NCT06750965||Physical examination population （Screening stage）|Subjects of different age groups in different sub-centers nationwide for physical examination
62702111|NCT06750965||Positive subjects for M-protein screening （Follow up stage）|Each sub-center will include subjects who are positive for M protein screening based on their actual situation.
62142377|NCT06397196|ACTIVE_COMPARATOR|Routine Therapy|Participants in Group B will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9.
62344955|NCT00987922|NO_INTERVENTION|Control|
62502865|NCT01814358|NO_INTERVENTION|Control arm|Subjects on this arm will receive no intervention
62502866|NCT01788241||CAG and CT group|CAG group = patients included based on coronary angiography screening; CT group = patients included based on computed tomography screening
62502867|NCT03180528|EXPERIMENTAL|Treatment (remetinostat)|Patients receive topical remetinostat 1% gel applied TID directly to the lesion, for 6 weeks in the absence of disease progression or unacceptable toxicity.
62502868|NCT06044584||Pain|Patients suffering from acute/chronic nociceptive and neuropathic pain
62502869|NCT06044584||Control|Healthy controls
62502870|NCT04311944|EXPERIMENTAL|Early Fast-Track Care|Participants will be eligible for fast-track care after 8 to 12 weeks, if viral load is suppressed (\<200 copies/mL)
62502871|NCT04311944|ACTIVE_COMPARATOR|Standard (Deferred Fast-track) Care|Participants will be eligible for fast-track care after 24 weeks, if viral load is suppressed (\<200 weeks)
62502872|NCT00826072||ALI|patients with acute lung injury at 24h after cardiac surgery
62502873|NCT00826072||Control|patients without acute lung injury 24h after cardiac surgery
62502874|NCT00559364|EXPERIMENTAL|Viokase® 16|
62502875|NCT00559364|PLACEBO_COMPARATOR|Placebo|
62502876|NCT02887924|ACTIVE_COMPARATOR|group 1|SLI group In this group the preterm infants will receive sustained lung inflation (SLI) via short binasal prongs in the delivery room.
62702112|NCT06750965||Negative control subjects （Follow up stage）|Each sub-center matched control subjects with negative M protein detection by age and gender parameter 1:1.
61955661|NCT00615511|PLACEBO_COMPARATOR|placebo|Approximately one third of subjects
61955662|NCT00615511|EXPERIMENTAL|Pregnenolone|
61955663|NCT01933061|EXPERIMENTAL|Abraxane 150 mg/m² Intravenous (IV)|
62502877|NCT02887924|PLACEBO_COMPARATOR|group 2|Preterm infants will be assisted in the delivery room without sustained lung inflation.
62502878|NCT06503887||Infected Children|collection of the stool sample within a week after a positive PCR or antigen test for SARS-CoV-2
62502879|NCT06503887||recovered|represent the group of children who were infected before the stool collection
62502880|NCT06503887||Controls|children enrolled and stool sample taken before the covid-19 pandemic
62502881|NCT00294892|ACTIVE_COMPARATOR|Carbamazepine|An oral dose of 400mg Carbamazepine is added to the 200mg oral dose Nevirapine intake prior delivery
62502882|NCT00294892|PLACEBO_COMPARATOR|Nevirapine|Standard therapy of 200mg Nevirapine oral prior to delivery
62502883|NCT01228227|ACTIVE_COMPARATOR|ROSUVASTATIN|
62502884|NCT01228227|EXPERIMENTAL|ATORVASTATIN|
62502885|NCT01341587|NO_INTERVENTION|Control|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
62502886|NCT01341587|ACTIVE_COMPARATOR|Intervention|"Home diabetes monitoring by patient using cellular enabled glucometer to communicate information and receive feedback.~Care provider can access raw and analyzed patient data; Physician receives report summary."
62502887|NCT02124473|EXPERIMENTAL|Homeopathy|A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).
62502888|NCT02124473|PLACEBO_COMPARATOR|Placebo|Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials
62502889|NCT01411488|EXPERIMENTAL|Fecal Management System- Company 1|80 adult patients to be randomly assigned to receive a fecal management system by Bard Medical
62502890|NCT01411488|ACTIVE_COMPARATOR|Fecal Management System- Company 2|80 adult patients to be randomly assigned to receive a fecal management system by ConvaTec
62502891|NCT06237101|EXPERIMENTAL|High dose|Propofol concentration which generate burst suppression at high dose of remifentanil
61955664|NCT01933061|EXPERIMENTAL|CC-486 orally plus Abraxane IV|
61955665|NCT06223178|EXPERIMENTAL|Thumb-tack needle acupuncture|53 Patients in this group will achieve 24 sessions treatment of thumb-tack needle in 12 consecutive weeks. Treatment will be operated by trained acupuncturists.
61955666|NCT06223178|SHAM_COMPARATOR|Sham acupuncture group|A sham thumb-tack needle, which has no difference in appearance with the verum thumb-tack needle but is lack of needle, are used for 53 patient in this group. 24 sessions of treatment will be performed in 12 consecutive weeks. Treatment will be operated by trained acupuncturists.
62344956|NCT01671722|EXPERIMENTAL|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
62502892|NCT06237101|ACTIVE_COMPARATOR|Medium dose|Propofol concentration which generate burst suppression at medium dose of remifentanil
62502893|NCT03027908|EXPERIMENTAL|Fluoride Toothpaste 1|Toothpaste containing Sodium Fluoride at 1450 ppm F
61955667|NCT00143637|EXPERIMENTAL|2|Office dust with added glucan
62344957|NCT01671722|ACTIVE_COMPARATOR|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp \& Dohme Ltd., USA
62502894|NCT03027908|ACTIVE_COMPARATOR|Fluoride Toothpaste 2|Toothpaste containing Sodium Fluoride at 1450 ppm F
62502895|NCT00683787|ACTIVE_COMPARATOR|Arm I|Patients receive docetaxel IV once every 3 weeks.
62344958|NCT04891055||patients treated with nivolumab|Patients candidates for II line therapy with Nivolumab from clinical practice
62344959|NCT04891055||patients treated with TKI|Patients candidates for II line therapy with TKI from clinical practice
62502896|NCT00683787|EXPERIMENTAL|Arm II|Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
61955668|NCT00143637|EXPERIMENTAL|1|Clean air exposures in climate chamber
61955669|NCT00496652|ACTIVE_COMPARATOR|1|Radiotherapy (+cisplatin to stage 3+4)
61955670|NCT00496652|EXPERIMENTAL|2|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4) + Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
61955671|NCT06301334|ACTIVE_COMPARATOR|Group CTB|n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25%
61955672|NCT06301334|ACTIVE_COMPARATOR|Group ESPB|patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
62344960|NCT03227965|OTHER|ELITE|
62344961|NCT00915044||IBD patients|Approximately 40 patients (adults and children) suffering from IBD will be enrolled.
62502897|NCT00683787|EXPERIMENTAL|Arm III|Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.
62502898|NCT02822196|EXPERIMENTAL|Serratus Anterior Muscle Plane Block|The US probe will be placed in the mid-axillary line at the level of the 5th intercostal space. The latissimus dorsi, teres major and serratus muscles will be identified. Using in-plane approach, the block needle (22 G, 50 mm) will be inserted until the tip is visualized between the serratus anterior muscle and the intercostal muscles. As an extra reference point thoracodorsal artery will be used which aids in the identification of the plane superficial to the serratus muscle. After negative aspiration of blood, local anesthetic (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time.
62502899|NCT02822196|ACTIVE_COMPARATOR|Thoracic Paravertebral Block|The spinous processes of T1- T5 will be identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1% lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is located. The depth from skin to transverse process will be marked/identified by needle marking. The needle will be withdrawn 1-2 cm and angled down.The needle will be re-advanced 1cm past the initial marking. After negative aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not exceed the maximum dose recommended.
62502900|NCT06616558|EXPERIMENTAL|Sunscreen Home Usage|Participants will use the Sunscreen in normal conditions at home for 28 +/- 2 days, returning to the Site after 7 days of product use, then make the last study visit to complete the final analysis.
61955673|NCT05752630||Healthy control|Healthy controls who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (\< and \> 150min/MVPA/week)
62142378|NCT04318834|EXPERIMENTAL|Individuals with advanced biliary tract cancer|Following a tumour biopsy for molecular profiling, chemo-naive patients with advanced biliary tract cancer will receive first-line gemcitabine-based chemotherapy or an investigational drug on a participating clinical trial.
62344962|NCT00915044||Controls|Approximately 100 healthy controls
61955674|NCT05752630||Persons with MS|Persons suffering from MS who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (\< and \> 150min/MVPA/week)
61955675|NCT04915144|ACTIVE_COMPARATOR|Standard PRRT|For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.
61955676|NCT04915144|EXPERIMENTAL|Personalized PRRT|For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.
61955677|NCT01544933||burst fractures in vertebrae with true ribs|between T1 and T10
61955678|NCT01544933||burst fractures in vertebrae with floating ribs|between T11 and T12
61955679|NCT02584816|EXPERIMENTAL|Group 1 - BRV-PV Lot A|BRV-PV Lot A + DPT- HepB-Hib + OPV
61955680|NCT02584816|EXPERIMENTAL|Group 2 - BRV-PV Lot B|BRV-PV Lot B+ DPT- HepB-Hib + OPV
61955681|NCT02584816|EXPERIMENTAL|Group 3 - BRV-PV Lot C|BRV-PV Lot C + DPT- HepB-Hib + OPV
61955682|NCT02584816|ACTIVE_COMPARATOR|Group 4 - ROTARIX|ROTARIX + DPT-HepB-Hib + OPV
61955683|NCT04352712||Healthy Children|healthy children, untreated, donors of monocytes
61955684|NCT04352712||GHD children|GHD children, untreated, donors of monocytes
61955685|NCT06265246|NO_INTERVENTION|Habitual Diet (Control)|33 participants in this arm will continue to take their usual diet without any intervention.
62702113|NCT06750822||Trauma patients|Any patient admitted for trauma in the Emergency Department receiving a whole-body contrast CT scan.
62702114|NCT06748157|ACTIVE_COMPARATOR|Participants with CardiaCare RR2|Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users.
62702115|NCT06748157|SHAM_COMPARATOR|Participants with Sham Device|Sham device will be dispensed, which will create a sensation but not provide therapy
61955686|NCT06265246|EXPERIMENTAL|Habitual Diet + 1.5 Servings of Milk|
62344963|NCT02011867|EXPERIMENTAL|Cork Electrode|Using Cork Electrode for CSF leak prevention for inner ear malformations.
62344964|NCT01653158|EXPERIMENTAL|CP-751,871 combined with docetaxel|
61955687|NCT06265246|EXPERIMENTAL|Habitual Diet + 2 Servings of Yogurt|
62344965|NCT00645294|OTHER|Treatment Group A|ADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
62344966|NCT00645294|OTHER|Treatment Group B|ADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
62344967|NCT00645294|OTHER|Treatment Group C|ADV 10 mg single dose on Day 1 in 12-17 year old age group
61955688|NCT01578187|EXPERIMENTAL|Hair2Go device|
61955689|NCT06095583|EXPERIMENTAL|Experimental group A|Tifcemalimab (200 mg intravenous infusion \[IV\]) and toripalimab (240 mg IV)
61955690|NCT06095583|EXPERIMENTAL|Experimental group B|Placebo for tifcemalimab (IV) and toripalimab (240 mg IV)
61955691|NCT06095583|PLACEBO_COMPARATOR|Placebo group C|Placebos for both tifcemalimab and toripalimab (IV)
61955692|NCT02571777|EXPERIMENTAL|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
61955693|NCT02571777|EXPERIMENTAL|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
61955694|NCT02571777|ACTIVE_COMPARATOR|QMF149 150/320 µg o.d.|QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
61955695|NCT02571777|ACTIVE_COMPARATOR|QMF149 150/160 µg o.d.|QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
61955696|NCT02571777|ACTIVE_COMPARATOR|Salmeterol/fluticasone 50/500 μg b.i.d.|Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®
61955697|NCT02619175|EXPERIMENTAL|Perturbation-based balance training|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
61955698|NCT02619175|ACTIVE_COMPARATOR|Weight shifting and gait training|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
61955699|NCT01949077||Sustained virological response|Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
61955700|NCT01949077||Non-responders|Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
61955701|NCT00934830|ACTIVE_COMPARATOR|Antibiotic|
61955702|NCT00934830|EXPERIMENTAL|Therapeutic ultrasound|
61955703|NCT00561808|EXPERIMENTAL|Observational|
62142379|NCT02777541|OTHER|Early enteral nutrition|3 hours after PEG implantation
62142380|NCT02777541|OTHER|Late enteral nutrition|8 hours after PEG implantation
62142381|NCT06041165|EXPERIMENTAL|Experimental: JS401 injection|
62142382|NCT06041165|PLACEBO_COMPARATOR|Placebo|
62702116|NCT06749574|ACTIVE_COMPARATOR|Group A|
62702117|NCT06749574|EXPERIMENTAL|Group B|
62702118|NCT06750757|EXPERIMENTAL|BMAC Arm|
62702119|NCT06750757|ACTIVE_COMPARATOR|No BMAC (Control)|
62702120|NCT06749730|EXPERIMENTAL|adebrelimab combined with apatinib and gemcitabine and cisplatin|
61955704|NCT03895541|OTHER|Stratification|All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity.
61955705|NCT04205968|EXPERIMENTAL|Arm I (ramucirumab, paclitaxel)|Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15, and paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61955706|NCT04205968|EXPERIMENTAL|Arm II (irinotecan, leucovorin, fluorouracil)|Patients receive irinotecan IV over 90 minutes on days 1 and 15, leucovorin IV over 2 hours on days 1 and 15, and fluorouracil IV bolus on days 1 and 15. Patients also receive fluorouracil IV over 46-48 hours on days 1-3 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61955707|NCT04324775||Group 1|Exercise+Manual Lymphatic Drainage
61955708|NCT04324775||Group 2|Exercise+Swedish Massage
62502901|NCT06616558|EXPERIMENTAL|Oil Control Assessment Product Application|An amount of Investigational Product will be topically applied to malar and forehead areas (after cleansing the face) on one randomized side of the participant's face by a qualified technician to perform the assessment of a 12-hour kinetics. After the evaluations the product will be removed.
62502902|NCT06616558|NO_INTERVENTION|Oil control Assessment (Control)|On the randomized half-side (malar and forehead areas), no product will be applied and this will be the control for evaluating the product's oil control during the 12-hour kinetics.
62502903|NCT01247844|OTHER|Day 7|removal of Shang Ring at 7 days
62702121|NCT06748586|ACTIVE_COMPARATOR|Hyperbaric oxygen therapy (HBOT) active treatment|The HBOT protocol is 90 minutes, 5 times/week, for at least 40 sessions, 100% oxygen at 2 ATA with five-minute air breaks every 20 minutes
62702122|NCT04869761|EXPERIMENTAL|Dose Arm 1|Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10\^6 cells at day 0 and month 3.
62702123|NCT04869761|EXPERIMENTAL|Dose Arm 2|Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10\^6 cells at day 0.
62702124|NCT06748482|NO_INTERVENTION|control group|Will receive standard care for post pacemaker implantation surgery which include a physician interview giving the advice and restrictions regarding the proper position of the left hand and the activities that should be avoided, in addition, a printed paper includes the medication with their doses and the advice that was given orally by the physician
61955709|NCT02552771|ACTIVE_COMPARATOR|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
61955710|NCT02552771|ACTIVE_COMPARATOR|Mitral repair with leaflet resection|Removal of one or both of the mitral leaflets that flop or bulge back.
61955711|NCT00957580|EXPERIMENTAL|Regimen 1 (Part 1)|
61955712|NCT00957580|EXPERIMENTAL|Regimen 2 (Part 1)|
61955713|NCT00957580|EXPERIMENTAL|Regimen 3 (Part 1)|
62714861|NCT01889992|EXPERIMENTAL|MTor Immunosuppression|"Sirolimus~Sirolimus dosage is based on blood levels.~To assess the potential of mTOR immunosuppressant Sirolimus in attenuation of CAR in HTx recipients and therefore, improve pre-existing cardiac allograft function, vasculopathy, and exercise capacity."
62714862|NCT01889992|EXPERIMENTAL|Cardiac Allograft Remodeling|A surgical procedure in wich a diseased heart is replaced with a healthy heart from a deceased person.
61955714|NCT00957580|EXPERIMENTAL|Regimen 1 (Part 2)|
61955715|NCT00957580|EXPERIMENTAL|Regimen 2 (Part 2)|
61955716|NCT05434000|OTHER|Children with sickle cell anaemia and abnormal TCD values (200cm/s)|The children identified with abnormal TCD values will be given hydroxyurea and followed for one year
61955717|NCT06097286|ACTIVE_COMPARATOR|external oblique intercostal plane block|
61955718|NCT06097286|ACTIVE_COMPARATOR|erector spinae plane block|
61955719|NCT06097286|NO_INTERVENTION|control group|
61955720|NCT05235555||Patients with symptomatic severe AS undergoing TAVI.|
61955721|NCT00707720|EXPERIMENTAL|TERIS procedure|TERIS procedure for the treatment of obesity
62502904|NCT01247844|OTHER|Day 14|removal of Shang Ring at 14 days
62502905|NCT01247844|OTHER|Day 21|removal of Shang Ring at 21 days
62502906|NCT02402491|ACTIVE_COMPARATOR|24 months of P2Y12 receptor antagonist|Receive 24 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
62502907|NCT02402491|PLACEBO_COMPARATOR|12 months of P2Y12 receptor antagonist|Receive 12 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
61955722|NCT00640068||1|All patients in whom a clinical CCTA was ordered by their physician at a participating site. Patient must have a prescription for CCTA ordered by their physician.
61955723|NCT01519271|PLACEBO_COMPARATOR|Placebo Patch|
61955724|NCT01519271|ACTIVE_COMPARATOR|Exelon Patch (rivastigmine transdermal system)|
61955725|NCT03162588|EXPERIMENTAL|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
61955726|NCT00099008|EXPERIMENTAL|Arm I|Genistein
61955727|NCT00099008|PLACEBO_COMPARATOR|Arm II|Placebo
61955728|NCT02437266|EXPERIMENTAL|Scapular mobilization|The participants will receive a twenty minutes session of scapular mobilization onto the scapular
61955729|NCT02437266|NO_INTERVENTION|Control|Rest on the bed for twenty minutes
61955730|NCT02044705|EXPERIMENTAL|Family group sessions|Active and Healthy Families
61955731|NCT02044705|NO_INTERVENTION|Wait-list control|Controls may participate in Active and Healthy Families after the study
61955732|NCT05206578|EXPERIMENTAL|AGT2, AGZ|
61955733|NCT05206578|ACTIVE_COMPARATOR|AGT2|
61955734|NCT05206578|EXPERIMENTAL|AGT4, AGZ|
61955735|NCT05206578|ACTIVE_COMPARATOR|AGT4|
61955736|NCT01125267|EXPERIMENTAL|multifamily group-adherence|multifamily group treatment with a focus on improving adherence to antipsychotic medication
61955737|NCT01125267|ACTIVE_COMPARATOR|multifamily group-standard|multifamily group focused on problems identified by group participants
61955738|NCT01125267|NO_INTERVENTION|treatment as usual|
61955739|NCT02958514|OTHER|traditional treatment group|Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.
62344968|NCT05124977|EXPERIMENTAL|Experimental group|Antimicrobial stewardship based on daily clinical assessment of clinical cure (experimental group). Discontinuation of antibiotic therapy antibiotics if criterions of clinical cure (regression of tracheal secretions, regression of temperature, improvement of PaO2/FiO2 ratio, absence of hemodynamic failure) of confirmed VAP are met. In the intervention group, intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
62502908|NCT01958515||Chemoradiation with Research Samples|Standard of care chemoradiation therapy will be given as clinically indicated by the treating physicians. 4 research blood and tissue samples will be obtained. One before treatment starts, 2 while treatments are being received and finally one after treatments are completed.
62502909|NCT06591572|EXPERIMENTAL|Single-port robotic transanal total mesorectal excision|Single-port robotic transanal total mesorectal excision
62344969|NCT05124977|OTHER|Control group|Standard management: duration of appropriate antibiotic therapy for confirmed VAP according to guidelines. In the control group, intensivists will perform clinical assessment daily, but a minimum duration of 7 days, as highly recommended of antibiotic therapy will be mandatory whatever the clinical cure.
62344970|NCT00523276||HCWs|Who may/may not have contact with SARS patients
62344971|NCT00523276||Family/close contacts|No illness but household/close contact
62344972|NCT00523276||SARS subjects|Diagnosed with active disease
62344973|NCT04353336|EXPERIMENTAL|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine with standard of care treatment.
62344974|NCT04353336|NO_INTERVENTION|No intervention|standard of care treatment alone.
62344975|NCT01147081|EXPERIMENTAL|Arm 1|
62344976|NCT03374553|EXPERIMENTAL|MINIject DO Integrated System CS636 (MINI DO636)|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery. In this arm the implant is placed using Dual Operator Delivery Tool (DODT)."
62344977|NCT03374553|EXPERIMENTAL|MINIject SO Integrated System CS636 (MINI SO636)|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery. In this arm the implant is placed using Single Operator Delivery Tool (SODT)."
62344978|NCT03519516|EXPERIMENTAL|PRO-174|"Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
62344979|NCT03519516|ACTIVE_COMPARATOR|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
62502910|NCT06591572|ACTIVE_COMPARATOR|Laparoscopic transanal total mesorectal excision|Laparoscopic transanal total mesorectal excision
62502911|NCT04979845|EXPERIMENTAL|Telerehabilitation|
62502912|NCT04979845|ACTIVE_COMPARATOR|Video exercise|
62502913|NCT02405572|ACTIVE_COMPARATOR|Formula 1|infant formula
62502914|NCT02405572|ACTIVE_COMPARATOR|Formula 2|infant formula
62502915|NCT04329676|EXPERIMENTAL|Deep Brain Stimulation|Patients will undergo bilateral implant of directSTIM system in the STN.
62344980|NCT01951248|EXPERIMENTAL|CPAP treatment|Patients with chronic kidney disease and moderate to severe obstructive sleep apnea is treated 3 months with CPAP treatment
62344981|NCT04766138|EXPERIMENTAL|Fecobionics studies|Single-arm study
62344982|NCT03026335|EXPERIMENTAL|Positive Action Curriculum|"A school-wide program was implemented in the experimental schools referred to as Positive Action and was integrated with the existing Health and Family Life Education curriculum."
62344983|NCT03026335|ACTIVE_COMPARATOR|Control/Comparison Group|Business as usual with students in non-intervened schools
62344984|NCT06226688|EXPERIMENTAL|Affected arm at the same side of mastectomy|There is 2 arms Arm1:-arm at side of mastectomy without lymphedema trained by biofeedback
62344985|NCT06226688|EXPERIMENTAL|2 arms one trained by biofeedback and other control without biofeedback|Arm2:-arm at side of mastectomy on other group but not trained with biofeedback Training using shoulder ladder ,shoulder wheel ,shoulder mobilization and IPC
62344986|NCT04591795|EXPERIMENTAL|100 mg SHT extract|Drug: Sahastara remedy alcoholic extract comparison with diclofenac
62344987|NCT04591795|EXPERIMENTAL|25 mg dicolfenac|Drug: diclofenac comparison with diclofenac
62344988|NCT03230162|EXPERIMENTAL|sildenafil citrate|50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.
62344989|NCT03230162|EXPERIMENTAL|low molecular weight heparin|50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow \< 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily \> 170 kg 75 u/kg/day
62344990|NCT01930526|EXPERIMENTAL|Pulmonary Rehabilitation|Patients will undergo the usual pulmonary rehabilitation programme but instead of two-legged cycling they will undergo single leg cycling where they cycle with one leg for 10-15mins and then the other in the same session.
62502916|NCT05878041||Peripartum cardiomyopathy|Diagnosis of Peripartum cardiomyopathy (PPCM) will be defined according to the ESC guidelines as: (i) the development of the disease in the last month of pregnancy or within 5 months of delivery; (i) absence of an identifiable cause of heart failure; (iii) absence of recognizable heart disease before the last month of pregnancy; (iv) left ventricle systolic dysfunction demonstrated by classical echocardiographic criteria.
62502917|NCT05878041||Healthy pregnant volunteers|Healthy pregnant women
62502918|NCT05484141|EXPERIMENTAL|With Blood Flow Restriction|
62502919|NCT05484141|ACTIVE_COMPARATOR|Without Blood Flow Restriction|
62502920|NCT00980408|PLACEBO_COMPARATOR|Sugar pill, behavioral glutamic acid|Placebo condition for D-Cycloserine
62502921|NCT00980408|PLACEBO_COMPARATOR|Sugar pill, fMRI, glutamic acid|Placebo condition for D-Cycloserine, fMRI
62502922|NCT00980408|PLACEBO_COMPARATOR|Sugar pill, memantine, behavioral|Placebo condition Memantine, behavioral
62502923|NCT00980408|PLACEBO_COMPARATOR|Sugar pill, memantine, fMRI|Placebo condition Memantine, fMRI
62502924|NCT00980408|ACTIVE_COMPARATOR|D-Cycloserine behavioral|
61955740|NCT02958514|EXPERIMENTAL|IPL treatment group|Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.
61955741|NCT01160978|ACTIVE_COMPARATOR|Simvastatin 80 mg group|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
61955742|NCT01160978|EXPERIMENTAL|Control Rx|The transplant recipients who have received an organ from non-treated donors.
61955743|NCT04836572|OTHER|Wear Period|
61955744|NCT05089149|EXPERIMENTAL|Patients with chronic heart failure coming for scheduled day hospitalization|"* Clinical examination focusing on congestion~* Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~* Blood sample retrieved for biological assessment and biobanking~* Telephone follow-up"
61955745|NCT01354340|EXPERIMENTAL|Limicol simple dose|
61955746|NCT01354340|EXPERIMENTAL|Limicol double doses|
61955747|NCT01354340|PLACEBO_COMPARATOR|Placebo|
62142383|NCT01160588||Sertraline treatment|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and sertraline treatment.
62142384|NCT01160588||Healthy Controls|Healthy control participants will undergo MRI scanning and EEG's.
62142385|NCT01160588||Cognitive Behavioral Therapy|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and talk therapy (CBT).
62344991|NCT03905395|ACTIVE_COMPARATOR|Meditation and mindfulness intervention|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
62344992|NCT03905395|NO_INTERVENTION|Control group|Women in the no intervention arm will receive no introduction to meditation and mindfulness - only questionnaires at the same time as the intervention group receives questionnaires.
62344993|NCT02089620|ACTIVE_COMPARATOR|Yasmin|Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.
62502925|NCT00980408|ACTIVE_COMPARATOR|D-Cycloserine, fMRI|
62502926|NCT00980408|ACTIVE_COMPARATOR|Memantine, behavioral|
62502927|NCT00980408|ACTIVE_COMPARATOR|Memantine, fMRI|
62502928|NCT05049668||RACE 1 patients|After exiting the RACE trial (NCT02099747) patient will be invited to participate in this study
62502929|NCT05103657|EXPERIMENTAL|BI 1358894 125 mg|
62502930|NCT05103657|PLACEBO_COMPARATOR|Placebo|
62502931|NCT02654015|EXPERIMENTAL|Medical Management plus Apollo MIES|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo System for clot evacuation.
62502932|NCT04282239|EXPERIMENTAL|Pectoral nerves block type 2 (PECS2)|The intervention is the PECS2 block, a previously developed modality for preventing pain in the anterior chest. The medication used in the block is Ropivicaine 0.5%, Lidocaine 1% + 1:100,000 epinephrine, and 40 μg dexmedetomidine. Patients will receive a standard post-operative pain regimen per institutional protocol.
62502933|NCT04282239|NO_INTERVENTION|Control Group: standard post-operative pain regimen|Patients will receive a standard post-operative pain regimen per institutional protocol.
62714863|NCT06305208||Primary bariatric endoscopic procedures|
62502934|NCT03607045|PLACEBO_COMPARATOR|control group|bouquet technique
62502935|NCT03607045|ACTIVE_COMPARATOR|test group|headless screw
62502936|NCT04220775|EXPERIMENTAL|Treatment (bintrafusp alfa, SBRT)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 15 of cycle 1, patients also undergo SBRT over 5 fractions once QOD for 2 weeks in the absence of disease progression or unacceptable toxicity.
62714864|NCT06305208||Revisional bariatric endoscopic procedures|
61955748|NCT05196204|EXPERIMENTAL|Trunk-oriented task combined with functional electrical stimulation training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training combined with functional electrical stimulation.
61955749|NCT05196204|ACTIVE_COMPARATOR|Trunk-oriented task training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training.
62714865|NCT06305208||Primary metabolic endoscopic procedures|
61955750|NCT05196204|NO_INTERVENTION|Control group|Healthy participants will be recruited based on the age and sex of the participants with spinal cord injury to realize clinical, biomechanical and cortical evaluations
61955751|NCT01826630|ACTIVE_COMPARATOR|CLn BodyWash|CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
61955752|NCT01826630|ACTIVE_COMPARATOR|Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis
61955753|NCT05386810|EXPERIMENTAL|Safety group in adults|24 adults will receive one dose of 5-person sIPV vaccine to evaluate the safety of msIPV vaccine.
61955754|NCT05386810|EXPERIMENTAL|Safety group in children|24 children will receive one dose of 5-person sIPV vaccine to evaluate the safety of msIPV vaccine.
61955755|NCT05386810|EXPERIMENTAL|Safety group in infants|24 infants will receive 4 doses of vaccine according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months to evaluate the safety of msIPV vaccine .
62142386|NCT01218009|EXPERIMENTAL|Albuterol Spiromax|Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
62142387|NCT01218009|PLACEBO_COMPARATOR|Placebo Spiromax|Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
62142388|NCT06507345|ACTIVE_COMPARATOR|Opioid Analgesia (OA)|
62714866|NCT02878395||Crohn's disease|
62714867|NCT04676906|EXPERIMENTAL|Study compound 1|Up to 6 volunteers will receive one dose of study compound 1
62502937|NCT01755975|EXPERIMENTAL|Romidepsin and Lenalidomide|This will be a multicentered, open label, phase Ib/IIa trial of romidepsin and lenalidomide in patients with relapsed or refractory lymphomas or multiple myeloma. Lenalidomide will be provided in accordance with the Celgene Corporation's Revlimid REMS® program. Per standard Revlimid REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, and all research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS® program. Only enough lenalidomide for one cycle of therapy will be supplied to the patient each cycle.
62702125|NCT06748482|OTHER|Intervention group|patients will receive standard care for post PM implantation surgery plus clinical pharmacist consultation through direct interview on day 0 pre-discharge and by telephone on days 1 and 7 post discharge a 15-minute-consultation session with the clinical pharmacist will include detailed and personalized advice on how each patient should take his prescribed medications, the best time to take them, the possible drug-drug interactions, the possible adverse effects such as post operative nausea and vomiting (PONV), bleeding, fever and infection and the required action. A written paper outlining the main points including the detailed protocol with times and doses will be handed to the patient at the end of the consultation. Moreover, a recorded voice note with the detailed protocol will be sent to the patients via the WhatsApp application
62142389|NCT06507345|EXPERIMENTAL|Opioid-Free Analgesia (OFA)|
62142390|NCT01170845|PLACEBO_COMPARATOR|Control group|Patients in the control group received saline for 7 days starting at the beginning of surgery
62344994|NCT02089620|ACTIVE_COMPARATOR|Calver|Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days
62702126|NCT06747520|EXPERIMENTAL|mild renal insufficiency（group A）|0.8mg/kg group
62702127|NCT06747520|EXPERIMENTAL|moderate renal insufficiency（group B）|0.8mg/kg group
62344995|NCT02089620|PLACEBO_COMPARATOR|Placebo|A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days
62344996|NCT03411772|ACTIVE_COMPARATOR|TAP block|Patients undergoing bariatric surgery having TAP block upon completion of the procedure
62344997|NCT03411772|SHAM_COMPARATOR|Non TAP block|Patients undergoing bariatric surgery without having TAP block
62702128|NCT06747520|EXPERIMENTAL|normal renal function（group C）|0.8mg/kg group
62344998|NCT02000518||external beam radiotherapy|emergency radiotherapy within 12 hours after neurological deficit due to MSCC
62344999|NCT02717065|EXPERIMENTAL|Characterization, Audiovisual|"Characterization: Tinnitus characterization tools (Minimal Masking Level, Tinnitus Functional Index, Tinnitus Handicap Inventory, and Subjective rating scale) are assessed in an individual over time to determine baseline variability.~Audiovisual: The individual will watch a series of silent videos of a person speaking, both with and without a tone matched to their tinnitus as well as videos of a still face with and without the matched tone."
62345000|NCT05904184|ACTIVE_COMPARATOR|Epoxy resin-based sealers (ERS)|After root canal preparation, canal obturation was performed with Epoxy resin-based sealers (ERS)
62345001|NCT05904184|ACTIVE_COMPARATOR|calcium silicate-based sealers (CSS)|After root canal preparation, canal obturation was performed with Calcium silicate-based sealers (CSS)
62345002|NCT01495338|EXPERIMENTAL|AC-170 0.17%|
62702129|NCT05728489|EXPERIMENTAL|BI 765250 very low dose group|
62702130|NCT05728489|PLACEBO_COMPARATOR|Placebo group|
62702131|NCT05728489|EXPERIMENTAL|BI 765250 low dose group|
62702132|NCT05728489|EXPERIMENTAL|BI 765250 medium dose group|
62702133|NCT05728489|EXPERIMENTAL|BI 765250 high dose group|
62345003|NCT01495338|EXPERIMENTAL|AC-170 0.24% (Formulation 1)|
62345004|NCT01495338|EXPERIMENTAL|AC-170 0.24% (Formulation 2)|
62345005|NCT01495338|PLACEBO_COMPARATOR|Olopatadine hydrochloride 0.2%/Tears Naturale II|
62345006|NCT04046406|EXPERIMENTAL|Pelvic pain syndromes|Patients with pelvic pain syndromes who will undergo MR neurography-guided cryoanalgesia
62702134|NCT05728489|EXPERIMENTAL|BI 765250 very high dose group|
62702135|NCT06750731||Participants with IBD receiving vedolizumab|
62702136|NCT03937817||1|Healthy volunteers and patients with hematologic and hemolytic diseases, including alpha and beta globin variants, sickle cell disease, malaria, or other diseases involving inflammation or endothelial dysfunction.
62142391|NCT01170845|ACTIVE_COMPARATOR|S group|Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery
62142392|NCT01397006|EXPERIMENTAL|Pregabalin|
62142393|NCT01397006|PLACEBO_COMPARATOR|Placebo|
62142394|NCT00980213||sunitinib|advanced renal cell cancer patients treated with sunitinib as first-line therapy
62345007|NCT06443476|ACTIVE_COMPARATOR|conventional group|Using a tent pole to gain bone in the atrophic posterior mandible.
62345008|NCT06443476|ACTIVE_COMPARATOR|study group|Using a Tenting abutment to gain bone in the atrophic posterior mandible
62345009|NCT02699242|EXPERIMENTAL|Simulator arm|In the Simulation arm group the subjects will be trained on the virtual reality bronchoscopic simulator (ORSIM simulator) for up to 60 minutes as active intervention, before they undertake the 2nd Fiber optic intubations.
62345010|NCT02699242|NO_INTERVENTION|Control arms|The control arm will be exposed only to the didactic teaching. The subjects will not undergo simulator training before undergoing 2nd fiber optic intubations.
62345011|NCT03336827|OTHER|Experimental Group|Patients include in the experimental group (EG) will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will resort to usual care only after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
62502938|NCT06612827||Blood and tumor collection|Blood and tumor collection before treatment initiation
62502939|NCT01223209|EXPERIMENTAL|LTX-315|The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.
62502940|NCT02785627||Group A: ADT|Men with non-metastatic prostate cancer, about to start or within 2 weeks of starting ADT
62702137|NCT02720445|EXPERIMENTAL|Nicotine Transdermal Patch|190 participants will wear nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment
61955756|NCT05386810|EXPERIMENTAL|Experimental Vaccine-lot 1|300 infants will receive 4 doses of 5-person sIPV vaccine of commercial scale lot 1 according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
61955757|NCT05386810|EXPERIMENTAL|Experimental Vaccine-lot 2|300 infants will receive 4 doses of 5-person sIPV vaccine of commercial scale lot 2 according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
61955758|NCT05386810|EXPERIMENTAL|Experimental Vaccine-lot 3|300 infants will receive 4 doses of 5-person sIPV vaccine of commercial scale lot 3 according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
61955759|NCT05386810|ACTIVE_COMPARATOR|IPV control group|300 infants will receive 4 doses of IPV vaccine produced by Pasteur according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
61955760|NCT05386810|ACTIVE_COMPARATOR|single-person sIPV control group|300 infants will receive 4 doses of single-dose sIPV vaccine produced by Pasteur according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
62142395|NCT06698913|EXPERIMENTAL|Lateral Positioning|Sample1- Ventilator settings where adjusted with PEEP based on BMI, followed by a 2 cmH2O increase and 20 minutes in a lateral position at 30 degrees for lung recruitment for both sides. And at the end were subjected to an alveolar recruitment maneuver with pressure increases up to a plateau pressure of 45 cmH2O. Sample2- A recruitment maneuver followed by PEEP titration is performed, selecting the PEEP that is above the crossing point between the collapse and hyperdistension curves provided by EIT. And the the PEEP-ARDSNet will be selected according to the low PEEP-FIO2 table from the ARDSNet protocol. Observations are made at 4 and 24 hours, with PEEP at 24 hours adjusted to the level identified by EIT.
62142396|NCT06698913|NO_INTERVENTION|Control Group|Sample 1- The ventilator settings adjusted with PEEP based on BMI and remained in the supine position for the entire time. And at the end were subjected to an alveolar recruitment maneuver with pressure increases up to a plateau pressure of 45 cmH2O.Sample 2- A recruitment maneuver followed by PEEP titration is performed, selecting the PEEP that is above the crossing point between the collapse and hyperdistension curves provided by EIT. And the the PEEP-ARDSNet will be selected according to the low PEEP-FIO2 table from the ARDSNet protocol. Observations are made at 4 and 24 hours, with PEEP at 24 hours adjusted to the level identified by EIT
62142397|NCT04920253|EXPERIMENTAL|debritom+|Group 1: Medaxis debritom+
61955761|NCT01423305|EXPERIMENTAL|Treatment A|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
62142398|NCT04920253|ACTIVE_COMPARATOR|Sharp Scalpel|Group 2: SOC (Sharp Scalpel Debridement)
62142399|NCT01847859|EXPERIMENTAL|Ultrasound performed by nurses|Focused examination of the pleural and pericardial cavity. Cardiologists perform reference ultrasound examinations.
62142400|NCT04798378|EXPERIMENTAL|Treatment Arm|Participants will received a customized NuroSleeve and undergo 8 weeks of occupational therapy using the NuroSleeve (135 minutes per week for 8 weeks: this can be done as 45 minutes three times per week, 68 minute sessions twice per week, or one 135 minute once per week).
62142401|NCT01005849|EXPERIMENTAL|Protecflor|
62142402|NCT01005849|PLACEBO_COMPARATOR|Placebo|
62142403|NCT03664882|EXPERIMENTAL|Fexofenadine|Fexofenadine, single administration
62142404|NCT03664882|PLACEBO_COMPARATOR|Placebo|Placebo, single administration
61955762|NCT01423305|EXPERIMENTAL|Treatment B|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
62345012|NCT03336827|OTHER|Waiting-List Control Group|Patients include in the waiting-list control group (CG) will resort to usual care only after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
62345013|NCT00581906||pts undergoing surgery or chemo-radiation treatment|
61955763|NCT05278767|EXPERIMENTAL|application group|The mobile health application (https://play.google.com/store/apps/details?id=com.sanberk.bariatriksurgery) prepared for patients undergoing bariatric surgery was completed in 6 stages. After the mobile application has been developed, a short (20-minute) brief contains information about the mobile application in the pre-operative polyclinic for the patients who are planned for bariatric surgery. The patient was followed for three months. Data were collected from the patient every month (4 times).
61955764|NCT05278767|NO_INTERVENTION|control group|Standard care and follow-up protocols were applied to the patients.The patient was followed for three months. Data were collected from the patient every month (4 times).
61955765|NCT06437496|EXPERIMENTAL|68Ga-AAZTA-093 PET/ CT|Drug: 68Ga-AAZTA-093 Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
61955766|NCT06437496|EXPERIMENTAL|68Ga-PSMA-11/68Ga-PSMA-617 PET/ CT|Drug: 68Ga-PSMA-11/68Ga-PSMA-617 Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11/68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
62142405|NCT02386332||umbilical cord blood transplant (UCBT)|Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care
62345014|NCT02043405|EXPERIMENTAL|Exercise Training and Weight Loss Intervention|Combination weight loss/exercise training, on insulin sensitivity, muscle lipid composition and localization in skeletal muscle.
62345015|NCT02043405|ACTIVE_COMPARATOR|4 Month Weight Loss Only Intervention|Use exercise training and weight loss as separate interventions in obese subjects with and without pre-diabetes.
61955767|NCT01281865|EXPERIMENTAL|Treatment (everolimus and imatinib mesylate)|Patients receive everolimus PO once daily and imatinib mesylate PO once daily on days 1-28. Course repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and tumor tissue sample collection at baseline and periodically during study for correlative biomarker and protein expression studies.
61955768|NCT00726986|EXPERIMENTAL|Sorafenib, Cisplatin, and Etoposide|
61955769|NCT04079608|EXPERIMENTAL|FLASH curriculum|Students who will receive the FLASH high school curriculum.
62345016|NCT02462733|ACTIVE_COMPARATOR|Tools of the Mind (TOM)|These 10 classrooms will be exposed to the TOM program.
61955770|NCT04079608|ACTIVE_COMPARATOR|Sexual Health Education for Adolescents|Students will receive a five-session knowledge-based sexual health curriculum designed for classroom settings.
61955771|NCT01844128||overweight women with infertility|
61955772|NCT01225432|EXPERIMENTAL|Gait Training|
62142406|NCT02386332||HLA-haploidentical hematopoietic stem cell transplantation|Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care
62345017|NCT02462733|ACTIVE_COMPARATOR|Playing to Learn (PTL)|These 10 classrooms will be exposed to the PTL program.
62345018|NCT02219087|EXPERIMENTAL|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
62345019|NCT02219087|ACTIVE_COMPARATOR|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
61955773|NCT04257981|EXPERIMENTAL|Experimental group|"Transcranial direct stimulation + virtual related group:~Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp Virtual reality (KVR) is the use of a computer interface involving upper limb activity in pediatric rehabilitation. VR creates an artificial environment, presented to the user through appropriate sensory stimulations."
61955774|NCT04257981|SHAM_COMPARATOR|Control group|Sham Transcranial direct stimulation Group + virtual related group; The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies.
61955775|NCT01113567|PLACEBO_COMPARATOR|Diet and lactose-free milk|Lactose-free milk
61955776|NCT01113567|ACTIVE_COMPARATOR|Diet and whole milk|Whole milk with lactose
61955777|NCT00283452|EXPERIMENTAL|Intervention Group|Participation in phone/mail-based intervention to maintain physical activity.
61955778|NCT00283452|NO_INTERVENTION|Control|No intervention; participation in surveys only
61955779|NCT03355716|PLACEBO_COMPARATOR|Group A (placebo):|instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion
62702138|NCT02720445|PLACEBO_COMPARATOR|Placebo Patch|190 participants will wear matching placebo patches during waking hours.
62702139|NCT06749860|EXPERIMENTAL|treated|Patients with locally advanced or metastatic NSCLC who have received prior ≥1-line systemic therapy
61955780|NCT03355716|ACTIVE_COMPARATOR|Group B|Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)
62345020|NCT01464242|EXPERIMENTAL|Glucantime® + pentoxifylline|Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
61955781|NCT03355716|ACTIVE_COMPARATOR|Group C|Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)
61955782|NCT03355716|ACTIVE_COMPARATOR|Group D|Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg).
61955783|NCT00917566|ACTIVE_COMPARATOR|Airtraq group|Use Airtraq for intubation
61955784|NCT00917566|ACTIVE_COMPARATOR|Macintoch gorup|Use Macintoch laryngoscope for intubation
61955785|NCT00375648|EXPERIMENTAL|zoledronate|
61955786|NCT05977140|EXPERIMENTAL|SAD Cohort 1A|first single-dose level
61955787|NCT05977140|EXPERIMENTAL|SAD Cohort 1B|second single-dose level
61955788|NCT05977140|EXPERIMENTAL|SAD Cohort 1C|third single-dose level; food-effect cohort
61955789|NCT05977140|EXPERIMENTAL|SAD Cohort 1D|fourth single-dose level
61955790|NCT05977140|EXPERIMENTAL|MAD Cohort 2A|first multiple-dose level
61955791|NCT05977140|EXPERIMENTAL|MAD Cohort 2B|second multiple-dose level
61955792|NCT05977140|EXPERIMENTAL|MAD Cohort 2C|third multiple-dose level
61955793|NCT05977140|EXPERIMENTAL|SAD Cohort 1e|fifth dose level; food effect cohort
61955794|NCT05977140|EXPERIMENTAL|SAD Cohort 1f|sixth dose level
61955795|NCT04746963|EXPERIMENTAL|Low Dose|AXT107 0.1 mg/eye
61955796|NCT04746963|EXPERIMENTAL|Mid Dose|AXT107 0.25 mg/eye
61955797|NCT04746963|EXPERIMENTAL|High Dose|AXT107 0.5 mg/eye
62142407|NCT06452069|EXPERIMENTAL|Group 1|Group 1: (n=140) Investigational Product 10 ml, drinkable ampoule (1 ampoule) (1 time only)
62345021|NCT01464242|PLACEBO_COMPARATOR|Glucantime® + placebo|Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
61955798|NCT04779125|EXPERIMENTAL|Gluteus plasty enhanced with Progrip self gripping mesh|All study patietns will have a gluteus enhanced plasty after abdominoperineal reconstruction.
61955799|NCT02023281|NO_INTERVENTION|Control Group|Control group will serve as a wait list and not be exposed to the intervention.
61955800|NCT02023281|EXPERIMENTAL|Experimental Group|The experimental group will engage in a mild-moderate level of structured and clinically supervised exercise program for approx. 30-45 mins 2-3 days per week for 12 weeks
61955801|NCT06260332|EXPERIMENTAL|Supportive Care (Fitbit)|Patients wear a Fitbit and use the Fitbit application to monitor their physical activity daily in weeks 2-12 with the goal of increasing their number of steps per day and their number of active hours per day. Starting at week 2, patients also receive educational materials and attend 6 calls over 20-60 minutes each with their health coach in weeks 2, 3, 5, 7, 9, and 11.
61955802|NCT04186728|PLACEBO_COMPARATOR|Placebo to magnesium|Participants will be asked to consume a daily placebo (cellulose) capsule for 12 weeks. They will then cross-over and consume 200mg of elemental magnesium in the form of magnesium glycinate daily for 12 weeks.
62142408|NCT06452069|PLACEBO_COMPARATOR|Group 2|Group 2: (n=140) Placebo 10 ml (1 ampoule) (1 time only)
62345022|NCT05874687||1: hypotension +,|hypotension +: hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg
62702140|NCT06749860|EXPERIMENTAL|treatment-navie|Patients with locally advanced or metastatic NSCLC who have not received prior systemic therapy
62702141|NCT06749327|EXPERIMENTAL|High UPF, high hPDI diet|High ultra-processed foods (UPFs) and healthy plant based diet
62702142|NCT06749327|ACTIVE_COMPARATOR|Low UPF, high hPDI diet|Low ultra-processed foods (UPFs) and high healthy plant-based diet
62702143|NCT06748274|OTHER|Frontal Mapping|To identify the individual TMS stimulation spot and intensity, the Heart-Brain Coupling protocols described by Dijkstra and colleagues (2023) are applied over 8 different spots. To identify the individual stimulation intensity, trains of 10 Hz for 5 seconds with an inter-train interval of 11 seconds are applied (Dash protocol). The subjects are stimulated with 15 different intensities, raising in 2% machine output steps. The starting intensity is set as 28% below the motor threshold (MT), leading to the highest intensity level of 120% MT at step 15. The intensity causing the HR to decelerate the most will be taken as the individual stimulation intensity for subsequent sessions.
61955803|NCT04186728|EXPERIMENTAL|Magnesium to placebo|Participants will be asked to consume 200mg of elemental magnesium in the form of magnesium glycinate daily. They will then cross-over and consume a daily placebo (cellulose) capsule for 12 weeks.
61955804|NCT01581788|EXPERIMENTAL|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
61955805|NCT01581788|ACTIVE_COMPARATOR|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
61955806|NCT01201850|EXPERIMENTAL|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses.
62345023|NCT05874687||2:hypotension -|hypotension -:none hypotension (hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg)
62345024|NCT04953117|EXPERIMENTAL|small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter≥2.00 mm) in small vessel cohort
62345025|NCT04953117|ACTIVE_COMPARATOR|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB in small vessel cohort
62345026|NCT04953117|OTHER|very small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter\<2.00 mm) in very small vessel cohort
62345027|NCT05451472|EXPERIMENTAL|pediatric group|
62345028|NCT02541006|EXPERIMENTAL|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
62502941|NCT02785627||Group B: ADT + chemotherapy|Men with newly diagnosed hormone sensitive metastatic prostate cancer, starting ADT and who will have chemotherapy
62502942|NCT02785627||Group C: Controls|Healthy age matched men
62502943|NCT02285933|EXPERIMENTAL|VRT|sitting balance exercises delivered via virtual reality training
62502944|NCT02285933|ACTIVE_COMPARATOR|control|virtual reality training requiring limited arm movements and no challenge to sitting balance
62502945|NCT03686215|EXPERIMENTAL|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015.
62502946|NCT03686215|NO_INTERVENTION|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
61955807|NCT03445715|EXPERIMENTAL|Cohort I|Single intra-articular injection ART-I02: 2.4x10E12 vg / wrist joint
61955808|NCT03445715|EXPERIMENTAL|Cohort II|Single intra-articular injection of ART-I02: 2.4x10E13 vg / wrist joint
61955809|NCT03445715|EXPERIMENTAL|Cohort III|Single intra-articular injection in the wrist joint of ART-I02 Maximum Tolerated Dose (MTD) as assessed in cohorts I and II:
61955810|NCT05548816||Subgroup (1) Male|Includes swimmers from 12 to less than 14 years.
61955811|NCT05548816||Subgroup (2) Male|Includes swimmers from 14 to less than 16 years.
61955812|NCT05548816||Subgroup (3): Male|Includes swimmers 16 to less than 18 years.
62345029|NCT02541006|ACTIVE_COMPARATOR|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
62345030|NCT01053117|EXPERIMENTAL|Protocolized approach|Protocolized approach to convert catheter to arteriovenous fistula
62502947|NCT06668116|OTHER|Ropivacaine-Placebo Arm|Participants will first receive a nerve block with ropivacaine, starting at 0.1% concentration and adjusted according to Dixon's up-and-down method as described in the intervention section. Pain sensitivity and presence of sensory or motor block will be assessed 60 minutes post-injection using a Numerical Rating Scale (NRS). After a washout period, participants will cross over to receive a placebo (saline) injection, followed by the same assessments.
62502948|NCT06668116|OTHER|Placebo-Ropivacaine Arm|Participants will first receive a placebo (saline) nerve block injection. Pain sensitivity and any reported sensory or motor changes will be assessed 60 minutes post-injection using a Numerical Rating Scale (NRS). After a washout period, participants will cross over to receive the ropivacaine injection, with concentration determined by Dixon's up-and-down method as described in the intervention section, followed by the same assessments.
61955813|NCT05548816||Subgroup (4) Male|Includes swimmers from 18 to less than 20 years
62502949|NCT03797001|EXPERIMENTAL|anakinra|Anakinra subcutaneous injection, 100 mg daily for 24 weeks
62502950|NCT03797001|PLACEBO_COMPARATOR|placebo|Placebo subcutaneous injection, daily for 24 weeks
62502951|NCT02093923|EXPERIMENTAL|DX-2930, Cohort 1|Participants will receive 30 milligram (mg) dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
62502952|NCT02093923|EXPERIMENTAL|DX-2930, Cohort 2|Participants will receive 100 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
61955814|NCT05548816||Subgroup (5) Male|(1st Team) includes swimmers from 20 - 25 years.
62502953|NCT02093923|EXPERIMENTAL|DX-2930, Cohort 3|Participants will receive 300 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
61955815|NCT05548816||Subgroup (1) Female|Includes swimmers from 12 to less than 14 years.
61955816|NCT05548816||Subgroup (2) Female|Includes swimmers from 14 to less than 16 years.
62345031|NCT01053117|NO_INTERVENTION|Current Care Model|
62345032|NCT00964158|EXPERIMENTAL|Group A|
62502954|NCT02093923|EXPERIMENTAL|DX-2930, Cohort 4|Participants will receive 400 mg dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
61955817|NCT05548816||Subgroup (3) Female|Includes swimmers 16 to less than 18 years.
62345033|NCT02591004|EXPERIMENTAL|Magesium sulphate|"* Patients in group A will receive Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first).~* Doppler on fetal middle cerebral artery"
62345034|NCT02591004|ACTIVE_COMPARATOR|Nifedipine|"* Patients in group B will receive Nifedipine ( Epilat 10mg ® EIPICO Egypt ), as there is no recommended dose for the use of nifedipine as neuroprotectant, the dose given in this study will be same as that used for tocolysis. Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses.~* Doppler on fetal middle cerebral artery"
62345035|NCT05279664|EXPERIMENTAL|Intervention (RIC + standard of care for NEC)|Neonates randomized to the intervention arm will receive RIC and will continue to receive the standard of care for NEC.
62345036|NCT05279664|SHAM_COMPARATOR|Control (Standard of care for NEC)|Neonates randomized to the control arm will receive the standard of care for NEC. The research fellow or nurse responsible for performing RIC will be performing sham inflation/deflation of the blood pressure cuff connected to a dummy arm to mimic the noise of the cuff for neonates in the control arm.
62502955|NCT02093923|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to 30, 100, 300 and 400 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
62502956|NCT03516487|EXPERIMENTAL|SAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10\^10 colony-forming units \[CFU\]) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
62502957|NCT03516487|EXPERIMENTAL|SAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10\^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
62502958|NCT03516487|EXPERIMENTAL|SAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
61955818|NCT05548816||Subgroup (4) Female|Includes swimmers from 18 to less than 20 years.
61955819|NCT05548816||Subgroup (5) Female|(1st Team) includes swimmers from 20 - 25 years.
61955820|NCT01819298||bacteria colonization in CAT less 20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores less than 20
61955821|NCT01819298||the PPM in change of CAT >2|the change of potential pathogenic microorganism in CAT difference more than 2 while follow-up
61955822|NCT01819298||the change of CAT<=2|the change of potential pathogenic microorganism in CAT difference less than or equal to 2 while follow-up
61955823|NCT01819298||PPM in CAT>=20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores more than or equal to 20
61955824|NCT01876420|EXPERIMENTAL|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
61955825|NCT00210405|ACTIVE_COMPARATOR|Food aid only|Children in this arm received fortified food aid commodities supplied through the maternal and child health and nutrition program implemented by World Vision. They received fortified corn-soy blend, which contained iron.
61955826|NCT00210405|EXPERIMENTAL|Micronutrient sprinkles + food aid|Children in this arm were enrolled in the food assisted program, and therefore received fortified food aid, as well as 60 sachets of a multiple micronutrient powder (Sprinkles) containing iron, zinc, vitamin A, vitamin C and folic acid
61955827|NCT06266910|EXPERIMENTAL|Three-dimensional (3D) viewing group|Participants in this group watch a 10-minute training video displayed in 3D mode, twice a day (totaling 20 minutes), five days a week, for four consecutive weeks.
62345037|NCT01728753|PLACEBO_COMPARATOR|Placebo|Placebo
62345038|NCT01728753|EXPERIMENTAL|T-705 A|Favipiravir regimen 1: 1200 mg 3x daily (TID) on Day 1, then 600 mg TID on Days 2-5
62345039|NCT01728753|EXPERIMENTAL|T-705 B|Favipiravir regimen 2: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
62345040|NCT01728753|EXPERIMENTAL|T-705 C|Favipiravir regimen 3: 1800 mg BID on Day 1, then 800 mg BID for Days 2-5
62345041|NCT03638882|EXPERIMENTAL|Duolingo Spanish Course|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
62345042|NCT03638882|ACTIVE_COMPARATOR|BrainHQ|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
62345043|NCT03638882|PLACEBO_COMPARATOR|Passive Control|No intervention.
62345044|NCT06295432|EXPERIMENTAL|DZD9008+AZD4205|All subjects will receive both DZD9008 tablets and AZD4205 capsules orally. DZD9008 dosing will start at 200 mg daily, AZD4205 dosing will start at 75 mg daily.
62502959|NCT03516487|EXPERIMENTAL|SAD HV SB: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1). On Day 1, subjects in this cohort receive a solid breakfast (SB) that contains approximately the same amount of calories and protein as the meal supplement shake given to subjects in the other SAD cohorts.
62502960|NCT03516487|EXPERIMENTAL|SAD HV: SYNB1618 (2 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (2 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
61955828|NCT06266910|PLACEBO_COMPARATOR|Two-dimensional (2D) viewing group|Participants in this group watched a 10-minute training video displayed in 2D mode, twice a day (totaling 20 minutes), five days a week, for four consecutive weeks.
62502961|NCT03516487|EXPERIMENTAL|SAD HV: SYNB1618 (5 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
62502962|NCT03516487|PLACEBO_COMPARATOR|SAD HV: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
62142409|NCT03267537|ACTIVE_COMPARATOR|Conventional office-based CBT-I|CBT-I will be delivered by a licensed clinical psychologist in weekly sessions lasting up to 1 hour. There will be 6 CBT-I sessions over the course of therapy with the option of an additional 2 treatments if deemed necessary by the clinical psychologist.
62142410|NCT03267537|EXPERIMENTAL|Telemedicine based CBT-I|The treatment will be the exact same as the active comparator group, with the same clinical psychologist doing the office-based CBT-I, but will be administered through a telemedicine modality
62502963|NCT03516487|EXPERIMENTAL|SAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive a single oral dose of SYNB1618 (7 x 10\^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
62502964|NCT03516487|PLACEBO_COMPARATOR|SAD PKU: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
62502965|NCT03516487|EXPERIMENTAL|MAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive oral SYNB1618 (1 x 10\^10 CFU) in a chilled buffered solution 3 times per day (TID) for 7 days in the MAD study (Part 2).
62502966|NCT03516487|EXPERIMENTAL|MAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive oral SYNB1618 (5 x 10\^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
62502967|NCT03516487|EXPERIMENTAL|MAD HV: SYNB1618 (7 x 10^10 CFU)|HV subjects receive oral SYNB1618 (7 x 10\^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
62502968|NCT03516487|EXPERIMENTAL|MAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive oral SYNB1618 (1 x 10\^11 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
62502969|NCT03516487|PLACEBO_COMPARATOR|MAD HV: Placebo|HV subjects receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
62502970|NCT03516487|EXPERIMENTAL|MAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive oral SYNB1618 (7 x 10\^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
62502971|NCT03516487|PLACEBO_COMPARATOR|MAD PKU: Placebo|Subjects with PKU receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
62142411|NCT00485693|ACTIVE_COMPARATOR|Bupivacaine HCl|Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
62502972|NCT04759079|EXPERIMENTAL|Acupuncture Needles and Antiemetic Drug|
62502973|NCT04759079|ACTIVE_COMPARATOR|Antiemetic Drug|
62502974|NCT01195155|ACTIVE_COMPARATOR|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
62502975|NCT01195155|PLACEBO_COMPARATOR|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
62502976|NCT01195155|NO_INTERVENTION|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
62502977|NCT00035555|EXPERIMENTAL|Belatacept: More intensive (MI) regimen|The MI regimen was designed to achieve projected serum trough concentrations of belatacept of approximately 20 μg/mL through Day 99, and approximately 5 μg/mL through Day 183 (10 mg/kg on Days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, and 169). After Day 169, patients were reallocated and dosed to achieve projected trough serum concentrations of approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 197). Those patients who received belatacept every 8 weeks received placebo infusions on scheduled treatment dates between infusions of active drug to maintain the blind between treatment regimens. Patients initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the patient was able to tolerate medications by mouth. Corticosteroids given daily.
61955829|NCT05419999|EXPERIMENTAL|tDCS plus WET|Subjects will receive transcranial direct current stimulation (tDCS) plus written exposure therapy (WET)
61955830|NCT05419999|SHAM_COMPARATOR|Sham plus WET|Subjects will receive sham transcranial direct current stimulation (tDCS) treatment plus written exposure therapy (WET)
62502978|NCT00035555|EXPERIMENTAL|Belatacept: Less intensive (LI) regimen|The LI regimen was designed to achieve projected trough serum concentrations of belatacept of approximately 20 μg/mL through Day 29, and approximately 5 μg/mL through Day 99 (10 mg/kg on Days 1, 15, 29, 57 and 85). After Day 85, these subjects were reallocated and dosed to achieve projected trough serum concentrations of either approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 113). Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
62702144|NCT06748274|EXPERIMENTAL|TMS - Grid-spot|Subjects receive active rTMS over the individual DLPFC spot. Both sessions follow the same protocol and procedures. The 10Hz Dash protocol is applied for about 18.75minutes with the individual intensity defined in the frontal mapping session (arm 1).
62702145|NCT06748274|ACTIVE_COMPARATOR|TMS control (Cz)|Subjects receive active TMS over the central midline. Both sessions follow the same protocol and procedures. The rTMS 10 Hz Dash protocol is applied for about 18.75 minutes with the individual intensity defined in the frontal mapping session (arm 1)
61955831|NCT04036019|EXPERIMENTAL|C-CAR066|Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
61955832|NCT06065397|EXPERIMENTAL|People after a stroke event|Implementation of improvement program
61955833|NCT06065397|EXPERIMENTAL|Healthcare professionals|Implementation of improvement program
61955834|NCT06065397|EXPERIMENTAL|Close relatives of people after a stroke|Implementation of improvement program
61955835|NCT05346874|EXPERIMENTAL|SOX-TACiE|Preoperative transcatheter arterial chemoinfusion and embolism alternated with intra-venus chemotherapy.
62142412|NCT00485693|OTHER|SKY0402|SKY0402 at various dosage levels. Single administration.
62142413|NCT02043041||1 Dried Blood Spot (DBS)|Number of DBS Spots Participants will be asked to fill one spot on a dried blood spot collection card.
62142414|NCT02043041||3 DBS Spots|Number of DBS Spots Participants will be asked to fill three spots on a dried blood spot collection card.
62142415|NCT02043041||5 DBS Sports|Number of DBS Spots Participants will be asked to fill five spots on a dried blood spot collection card.
62345045|NCT05786014|EXPERIMENTAL|Moderate Intensity Walking|Subjects allocated to moderate intensity walking will be given a gift card to purchase a paid of running shoes. A chest-based heart rate monitor and an activity tracker watch will be provided. Subjects will aim to achieve 150 minutes a week of moderate intensity walking. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
62345046|NCT05786014|EXPERIMENTAL|High Intensity Interval Exercise|Subjects will receive a recumbent bike to be delivered and assembled to their home as well as a heart rate monitor and activity tracker. Subjects will undergo high intensity interval exercise 3 days a week, with the goal of achieving 85-90% of their heart rate max. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
62345047|NCT03904524|EXPERIMENTAL|SET-to-MEET|This is a single arm, open trial that will be conducted in parallel in 3 separate ICUs. Each site will receive the SET-to-MEET intervention.
62345048|NCT01396993||iTOP|Patients undergoing immediate techniques for oncoplastic surgery (level I only parenchmyl rotation and breast undermining as well as level II using complex reduction plastics for nipple-areola-complex movings) and patients with mastectomy and immediate reconstruction
62345049|NCT01396993||BCT|patients undergoing conservative breast surgery
62345050|NCT01345097|EXPERIMENTAL|Younger Group|
62345051|NCT01345097|EXPERIMENTAL|Elderly Group|
62345052|NCT02961517||Patients|All patients with type 2 diabetes and/or cardiovascular disease who will complete the questionnaire
62345053|NCT03608904|EXPERIMENTAL|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
62345054|NCT03608904|PLACEBO_COMPARATOR|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
62345055|NCT02649530|EXPERIMENTAL|WNT974|Patients will receive 10 mg of WNT974 daily by mouth.
62345056|NCT00941889|PLACEBO_COMPARATOR|Placebo|Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment.
62345057|NCT00941889|ACTIVE_COMPARATOR|Gardasil|The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at two months and six months after enrollment.
62345058|NCT04163107|EXPERIMENTAL|Combination treatment of carfilzomib/dexamethasone/HCQ|
62345059|NCT04130828|EXPERIMENTAL|Thrice-weekly group|Ferrous fumarate 200 mg PO PC Thrice-weekly
62345060|NCT04130828|ACTIVE_COMPARATOR|Thrice-daily group|Ferrous fumarate 200 mg PO PC Thrice-daily
62345061|NCT02611063|EXPERIMENTAL|fostamatinib|Subjects will receive fostamatinib 100 mg qd, 150 mg qd, or 100 mg bid with dosage determined by the modified continual reassessment method. The treatment period begins at baseline 90 days after transplant and continues for up to 1 year after transplant. In patients with steroid-refractory cGVHD who are also included on this study, these subjects also receive fostamatinib 100mg qd, 150mg qd, or 100mg bid dosage determined by the modified continual reassessment method.
62345062|NCT05109130||laparoscopic surgery|Laparoscopic total mesorectal excision was performed on the enrolled patients.
62345063|NCT05109130||Transanal endoscopic surgery|Transanal total mesorectal excision was performed on the enrolled patients.
62702146|NCT06748274|EXPERIMENTAL|HD-tDCS (anodal)|Subjects receive anodal tDCS over the personalized stipulation spot (arm 1) for a total of 18.75 minutes with an intensity of 2mA.
61955836|NCT02121431|EXPERIMENTAL|Online-Delivered Parenting Intervention|The Online-Delivered Parenting Intervention, which is based on the Triple P--Positive Parenting Program system of interventions, is an interactive website designed to engage and activate the participant through sequenced, personalized, interactive, and video-based content. The intervention emphasizes a self-regulatory process, parent specification of goals, practical and straightforward parenting strategies, modeling, and action activation.
61955837|NCT02121431|ACTIVE_COMPARATOR|Staff-Delivered Parenting Intervention|The Staff-Delivered Parenting Intervention is based on the Triple P--Positive Parenting Program system and involves 10 face-to-face sessions with each family. This intervention is the well-established Level 4 Standard Triple P program.
61955838|NCT01466335|EXPERIMENTAL|Ronacaleret 100mg once daily|1 x 100mg oral tablet
61955839|NCT01466335|EXPERIMENTAL|Ronacaleret 100mg twice daily|1 x 100mg oral tablet twice daily
61955840|NCT01466335|EXPERIMENTAL|Ronacaleret 200mg once daily|2 x 100mg oral tablet
61955841|NCT01466335|EXPERIMENTAL|Ronacaleret 200mg twice daily|2 x 100mg tablets twice daily
62345064|NCT03247413|EXPERIMENTAL|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
62345065|NCT03247413|PLACEBO_COMPARATOR|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
62345066|NCT01029015||Group 1 -OAB|Subjects with overactive bladder (OAB)
62345067|NCT01029015||Group 2 - Insomnia|Subjects with insomnia
62345068|NCT01029015||Group 3 - Normal|Normal Subjects
62345069|NCT01154179|NO_INTERVENTION|Normocaloric feeding|This control group will receive energy and protein intakes as recommended by the use of Schofield equations, as is current practice (100% of requirements)
62345070|NCT01681576|EXPERIMENTAL|LCZ696 followed by Valsartan|Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
62345071|NCT01681576|EXPERIMENTAL|Valsartan followed by LCZ696|Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks
62345072|NCT03075748|EXPERIMENTAL|Primary study|Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
62345073|NCT03075748|EXPERIMENTAL|Expanded selection|Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
62702147|NCT06748274|ACTIVE_COMPARATOR|HD-tDCS control (cathodal)|Subjects receive cathodal tDCS over the personalized stimulation spot (arm 1) for a total of 18.75 minutes with an intensity of 2mA.
62702148|NCT06748274|ACTIVE_COMPARATOR|rTMS - Beam F3|Subjects receive active TMS over the Beam-F3 spot. All 3 TMS sessions follow the same protocol and procedures. The rTMS 10 Hz Dash protocol is applied for about 18.75 minutes with the individual intensity defined in the frontal mapping session (arm 1).
61955842|NCT01466335|EXPERIMENTAL|Ronacaleret 400mg once daily|4 x 100mg tablets
62502979|NCT00035555|EXPERIMENTAL|Cyclosporine regimen|The initial daily dose was 7±3 mg/kg. Subsequent doses were adjusted to maintain a predefined range of serum concentrations: 1st month, target level 150-400 ng/mL; after 1st month, target level of 150-300 ng/mL. Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
62702149|NCT06750991|EXPERIMENTAL|CDR-CHOP|Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of R-CHOP, followed by the remaining 5 cycles courses of chidamide and decitabine combined with a standard-dose R-CHOP regimen.
62702150|NCT06748391||Cardiac Surgery|The study focused on adult patients undergoing cardiovascular surgery. Patients meeting the following criteria were excluded from the study: 1) minors under the age of 18; 2) pregnant women; 3) individuals with preexisting preoperative delirium or a history of psychiatric disorders like schizophrenia and major depressive conditions; 4) those with an extensive history of psychotropic medications; 5) Use of nitrates after admission; and 6) patients with significant neurological disorders, such as severe traumatic brain injuries or recent strokes within the past 6 months.
61955843|NCT01466335|PLACEBO_COMPARATOR|Placebo|Matching number of identical placebo tablets
61955844|NCT02621697|EXPERIMENTAL|Cognitive motor training|Evaluate the effectiveness of a 12-week training based on dual-task (motor and cognitive) in institutionalized elderly.
61955845|NCT02621697|ACTIVE_COMPARATOR|Control Group|kinesiotherapeutic conventional treatment
61955846|NCT02929667|ACTIVE_COMPARATOR|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
61955847|NCT02929667|PLACEBO_COMPARATOR|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
61955848|NCT05987228|EXPERIMENTAL|Thymus vulgaris group|500 mg of Thymus vulgaris (capsules) was given orally twice daily
61955849|NCT05987228|PLACEBO_COMPARATOR|control group|500 mg starch (capsules) was given orally twice daily
61955850|NCT00870883|EXPERIMENTAL|N-acetylcysteine plus deferoxamine|
61955851|NCT06273410|EXPERIMENTAL|Cention N without adhesive.|
62142416|NCT03244800|PLACEBO_COMPARATOR|Placebo Cohort 1|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
62714868|NCT04676906|EXPERIMENTAL|Study compound 2|Up to 6 volunteers will receive one dose of study compound 2
62714869|NCT04676906|EXPERIMENTAL|Study compound 3|Up to 6 volunteers will receive one dose of study compound 3
62142417|NCT03244800|EXPERIMENTAL|MEDI0382 Cohort 1|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 7 days, followed by Dose 2 for 7 days, Dose 3 for 7 days, and Dose 4 for 28 days
62142418|NCT03244800|PLACEBO_COMPARATOR|PLacebo Cohort 2|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
62142419|NCT03244800|EXPERIMENTAL|MEDI0382 Cohort 2|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 14 days, followed by Dose 2 for 14 days, Dose 3 for 14 days, and Dose 4 for 7 days.
62714870|NCT00871078||A|HIV-positive patients with CD4 cell counts below 100 cells/mm³ at some point of time in their medical history lasting for at least 6 months
62714871|NCT00871078||B|HIV-positive patients with CD4 cell counts never below 100 cells/mm³ in their medical records
61955852|NCT06273410|EXPERIMENTAL|Cention N with adhesive|
61955853|NCT06273410|ACTIVE_COMPARATOR|Filtek Bulk Fill posterior composite|
61955854|NCT03256097|EXPERIMENTAL|XDP - VG - XDP|order of testing: XDP - VG - XDP
61955855|NCT03256097|EXPERIMENTAL|VG - XDP - VG|order of testing: VG - XDP - VG
61955856|NCT00270790|EXPERIMENTAL|AMIFOSTINE +CARBOPLATIN, TAXOL +RT|EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.
61955857|NCT00702039||1|Those patients receiving intravitreal injections who will be listening to classical music during injection.
61955858|NCT00702039||2|Those patients receiving intravitreal injections who will not be listening to any music during injection.
61955859|NCT03118635|EXPERIMENTAL|Intervention|Daily, four-hour physical activity intervention
61955860|NCT03118635|NO_INTERVENTION|Control|No treatment control
61955861|NCT04874584|EXPERIMENTAL|CTNSM Group|Culturally Tailored Nurse Symptom Management group (CTNSM) - participants in the CTNSM group will receive one in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message during the first 12 weeks of standard of care chemotherapy. In addition, participants can receive standard of care chemotherapy education.
61955862|NCT04874584|ACTIVE_COMPARATOR|Standard of Care (control) Group|Participants in the control group will only be receiving the standard of care chemotherapy education.
61955863|NCT03885258|EXPERIMENTAL|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
61955864|NCT06297577|EXPERIMENTAL|Albumin Platelet Rich Fibrin (Alb-PRF)|For the production of Alb-PRF membrane, two 10 ml vacuum plastic tubes will be centrifuged at 700 g for 8 minutes. After centrifugation, the upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet-poor plasma (PPP) will be collected in a syringe and then will be heated in a heat block device at 75°C for 10 minutes to create denatured albumin (albumin gel). After heating, the albumin gel will be cooled to room temperature for approximately 10 minutes. An injectable albumin gel was then prepared. The liquid platelet-rich layer (liquid-PRF), including the buffy coat layer with accumulated platelets, leukocytes and growth factors, will be collected in a separate syringe and will be reserved at room temperature (20°C). The albumin gel and liquid PRF will be then thoroughly mixed by utilizing a female-female luer lock connector
62502980|NCT00930033|ACTIVE_COMPARATOR|A|Nephrectomy + sunitinib
62502981|NCT00930033|EXPERIMENTAL|B|Sunitinib alone
62345074|NCT01106625|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
61955865|NCT06297577|ACTIVE_COMPARATOR|Minimally Invasive Surgical Technique (MIST)|"Surgical approach will be the Minimally Invasive Surgical Technique (MIST) approach according to; simplified or modified papilla-preservation flap design upon the papilla width.~Defects will be thoroughly debrided using Gracey curettes and ultrasonic scalers.~Then, a single internal mattress suture using 5-0 polypropylene sutures will be placed at the defect-associated inter-dental area."
62345075|NCT01106625|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
62502982|NCT01736748|EXPERIMENTAL|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
62502983|NCT01736748|OTHER|Traditional PA counseling|In this arm, while children will wear the same sensors as in the intervention arm, the intervention will not rely on data gathered using the wearable sensors. Rather, a traditional physical activity counseling strategy will be adopted in this control group.
62502984|NCT06678230|EXPERIMENTAL|This is a single-arm, single-center, phase II clinical trial of eribulin in combination with erlotin|"This trial is planned to enroll 40 subjects with HER-2 negative locally advanced or metastatic breast cancer who have received prior chemotherapy with anthracyclines and paclitaxel, treated with eribulin in combination with erlotinib.~Trial drug: eribulin 1.4 mg/m2, D1,8; one cycle every 3 weeks; Amlotinib 12 mg, QD, po, applied for 14 days and stopped for 7 days, one cycle every 3 weeks.~All subjects will receive long-term dosing until intolerable toxicity or disease progression or death or voluntary withdrawal or the end of this trial (meaning completion of the trial or early termination of the trial).~During the treatment period, all subjects will be evaluated for antitumor efficacy every 6 weeks and disease status will be determined by the investigator according to RECIST 1.1 criteria until disease progression or death or refusal to come to the hospital for follow-up or the end of the trial (meaning completion of the trial or early termination of the trial), whichever event occurs"
62502985|NCT04851067|ACTIVE_COMPARATOR|Dry Needling and Therapeutic Exercises (DNTEx)|"Dry Needling - A fine needle, of 5-10 mm, will be used to penetrate the skin, subcutaneous tissues, and muscle with the intent to stimulate Myofascial Trigger Point (MTrP) or mechanically disrupt tissue without the use of an anesthetic.~Therapeutic Exercises - Are exercises will be performed to achieve a specific physical benefit, including increasing and maintaining range of motion, strengthening weak muscles, increasing joint flexibility, or improving cardiovascular and respiratory function."
62502986|NCT04851067|ACTIVE_COMPARATOR|Manual Therapy and Therapeutic Exercises (MTTEx)|"Joint Mobilization - A manual therapy technique comprising of a continuum of skilled passive movements to the joint complex will be applied at varying speeds and amplitudes. It will include a low-grades/velocity (grades I and II), high grades (grades III and IV), and small- or large-amplitude passive movement techniques within the patient's physiological range of motion and within the patient's control with the intent to restore optimal motion, function, and/ or to reduce pain.~Joint Manipulation - A passive, high velocity, low amplitude thrust will be applied to a localized joint segment/s within its anatomical limit with the intent to restore optimal motion, function, and/ or to reduce pain."
62502987|NCT00973089|NO_INTERVENTION|Complete caries removal|Control group
62502988|NCT00973089|OTHER|Incomplete caries removal|Test group
62502989|NCT02710214|EXPERIMENTAL|Duavee|1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
62702151|NCT06750627|ACTIVE_COMPARATOR|Continuous Erector Spinae Plane Block|"Participants will:~* Undergo routine pain assessments, and recovery evaluations using tools using the Visual Analogue Scale (VAS) and Quality of Recovery-15 (QoR-15).~* Receive continuous ESPB for analgesia with USG guidance after the surgery.~* Receive Morphine Patient Controlled Analgesia + NSAIDs + Paracetamol~* NSAIDs used is ketorolac, with dose of 30 mg every 8 hours~* Paracetamol 1000 mg every 8 hours will be given~* The PCA settings will include 30 mg of morphine diluted to 30 ml, a bolus dose of 1 ml, a lockout time of 6 minutes, 10 mg maximum dose/ 4 hours~* Participate in follow-up visits for data collection on pain, opioid usage, and recovery quality."
62702152|NCT06750627|ACTIVE_COMPARATOR|Multimodal Intravenous Analgesia|"Participants will:~* Undergo routine pain assessments, and recovery evaluations using tools using the Visual Analogue Scale (VAS) and Quality of Recovery-15 (QoR-15).~* Receive Morphine Patient Controlled Analgesia + NSAIDs + Paracetamol~* NSAIDs used will be ketorolac of 30 mg every 8 hours~* Paracetamol 1g every 8 hours will be given~* The PCA settings will include 30 mg of morphine diluted to 30 ml, a bolus dose of 1 ml, a lockout time of 6 minutes, 10 mg maximum dose/ 4 hours.~* Participate in follow-up visits for data collection on pain, opioid usage, and recovery quality."
62702153|NCT05743621|EXPERIMENTAL|TVB-2640 in combination with Enzalutamide|
62702154|NCT00314119||1|Men and women between 20 and 50 years of age diagnosed with NF1 and their biological parents are eligible for this study.
61955866|NCT05821478|EXPERIMENTAL|Experimental treatment|"a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day)~+ oral metronidazole (daily dose 1500mg) followed by a 3-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg) + metronidazole (daily dose 1500mg) followed by a 6-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg).~A placebo for lymecycline will also be administered during this intensive treatment phase"
62142420|NCT05701579||Patients with ACL Degeneratio Mucosa|Patients with ACL Degeneratio Mucosa
62345076|NCT01106625|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
62345077|NCT01464463|EXPERIMENTAL|CBT-active|Patients with Major Depression (N = 50) get a common CBT treatment in combination with physical exercise.
62345078|NCT01464463|ACTIVE_COMPARATOR|CBT-euthymic|"Patients with Major Depression (N = 50) get the same common CBT treatment as the CBT-active-group, but instead of physical exercise they receive an enjoyment training, which is based on exercises from the Kleine Schule des Genießens (Koppenhöfer, 2004)"
62345079|NCT01464463|ACTIVE_COMPARATOR|CBASP|Patients with Major Depression (N=50) get a cognitive therapy according to the Cognitive Behavioral Analysis System of Psychotherapy (CBASP).
62502990|NCT02710214|PLACEBO_COMPARATOR|Placebo|Placebo pill daily for 8 weeks.
62502991|NCT06437028|EXPERIMENTAL|Dual-layer perinatal tissue allograft|Patients will receive weekly applications of a dual-layer perinatal tissue allograft in addition to standard of care wound management.
62502992|NCT06437028|EXPERIMENTAL|Three-layer fenestrated perinatal tissue allograft|Patients will receive weekly applications of a three-layer fenestrated perinatal tissue allograft in addition to standard of care wound management.
62502993|NCT06437028|ACTIVE_COMPARATOR|Standard of care (SOC) wound management|Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.
62502994|NCT01054352|EXPERIMENTAL|001|JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
62502995|NCT01054352|EXPERIMENTAL|002|JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
62502996|NCT01054352|EXPERIMENTAL|003|JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
62502997|NCT01054352|EXPERIMENTAL|004|JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
62502998|NCT01737255||TP53 mutation carriers|Carriers of TP53 mutation not known to be low penetrance
62502999|NCT01737255||Population controls|Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
62503000|NCT02043158||Ovarian Cancer Survivors|Short-term and long-term ovarian cancer survivors
62503001|NCT02754128|ACTIVE_COMPARATOR|BeFAST|Motor learning-based program involving athletic lower extremity training of gait-related skills.
62503002|NCT02754128|ACTIVE_COMPARATOR|BeSTRONG|Lower limb strength training program involving progressive muscle resistance exercises.
62503003|NCT04611581||PD patients with apathy|PD patients with apathy according to the diagnostic criteria by Robert et al. 2018
62503004|NCT04611581||PD patients with impulse control disorder|PD patients with a) at least one item \>2 or b) at least two items \>1 on the hyperdopaminergic subscale of the Ardouin Scale of Behaviour in Parkinson's Disease
62503005|NCT04611581||PD patients without any relevant neuropsychiatric symptoms|PD patients with a score \<2 on each item of the Ardouin Scale of Behaviour in Parkinson's Disease
62503006|NCT06677658||Group 1|Patients diagnosed with COVID-19 pneumonia treated with pulse steroids (250 mg/day) for three days and routinely consumed at least 20 ml/day olive oil in their diets were defined as Group 1.
62503007|NCT06677658||Group 2|Patients of similar age and gender with COVID-19 pneumonia who received the same treatment but did not consume olive oil were defined as Group 2.
62503008|NCT00756717|EXPERIMENTAL|MK-0752|Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days
62503009|NCT04636450|ACTIVE_COMPARATOR|Adult manual instrumentation|Primary mandibular molars who are treated with a manual pulpectomy and a K-file system.
62503010|NCT04636450|EXPERIMENTAL|Pediatric manual instrumentation|Primary mandibular molars treated with a manual pulpectomy and a Kedo-SH system.
62503011|NCT04636450|ACTIVE_COMPARATOR|Adult rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system.
61955867|NCT05821478|ACTIVE_COMPARATOR|Control|12-week course of oral lymecycline (Tetralysal daily dose 452mg) Placebos for all experimental drugs will also be administered during this intensive treatment phase
61955868|NCT02661659|OTHER|Weekly Vaccination|Maintenance multipeptide vaccine (S-588210) administered every week
61955869|NCT02661659|OTHER|Every other Week Vaccination|Maintenance multipeptide vaccine (S-588210) administered every other week
61955870|NCT03600571|EXPERIMENTAL|AM groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
62503012|NCT04636450|EXPERIMENTAL|Pediatric rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a Kedo-S system
61955871|NCT03600571|EXPERIMENTAL|MMP groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
62503013|NCT01817686|EXPERIMENTAL|Comfort Default|ADs with pre-selected defaults that focus on providing comfort at end-of-life.
62503014|NCT01817686|EXPERIMENTAL|Life Extension Default|ADs with pre-selected defaults that focus on extending life.
62503015|NCT01817686|EXPERIMENTAL|Standard Default|ADs without pre-selected defaults.
62503016|NCT03430011|EXPERIMENTAL|JCARH125|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
62503017|NCT03430011|EXPERIMENTAL|JCARH125 + anakinra|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by prophylactic treatment with anakinra and a single dose of JCARH125
62503018|NCT03380416|EXPERIMENTAL|Portfolio Diet|The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
62702155|NCT04486716|EXPERIMENTAL|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml) administered at baseline, Day 7, Day 14 and monthly thereafter
62714872|NCT00871078||C|HIV-negative patients (control group)
62503019|NCT03380416|ACTIVE_COMPARATOR|MUFA Diet|The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)
62503020|NCT02466386|EXPERIMENTAL|SPD489|Participants will receive 5 milligrams (mg) of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 52 weeks.
62503021|NCT06427369|EXPERIMENTAL|Diagnostic|Patients receive 124I-hJAA-F11 IV on day 0. Patients then undergo PET/CT on day 1 (20-28 hours post 124I-hJAA-F11), day 2 (48-96 hours post 124I-hJAA-F11), day 5-6 (120-144 hours post 124I-hJAA-F11), and day 7-8 (168-192 hours post 124I-hJAA-F11). Patients also undergo FDG PET/CT during screening and undergo blood sample collection throughout the trial.
62503022|NCT01589601|NO_INTERVENTION|Usual heart failure care|Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
62503023|NCT01589601|ACTIVE_COMPARATOR|Usual care + palliative care|Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.
62503024|NCT02077335|EXPERIMENTAL|HDR brachytherapy monotherapy|Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
62503025|NCT01514123|EXPERIMENTAL|Arm A - VGX-100 alone|Dose escalation of VGX-100 monotherapy
62345080|NCT01464463|NO_INTERVENTION|Waiting List|Patients randomized to the waiting list receive psychological treatment after waiting for 4 month.
62345081|NCT03870256|ACTIVE_COMPARATOR|TA plus misoprostol|Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm
61955872|NCT03600571|EXPERIMENTAL|AM groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
62142421|NCT00526994|EXPERIMENTAL|Screened|Screened w/4 questions on intimate partner violence; if positive, receives referral information
62345082|NCT03870256|ACTIVE_COMPARATOR|Carbetocin|Patient receives 100 mic gm carbetocin IV
62345083|NCT03141268||Healthy volunteers|Normal subjects aged 18-80 years. No chronic diseases.
62345084|NCT03141268||IBS patients, lactose intolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose intolerant. No concomitant diseases.
62345085|NCT03141268||IBS patients, lactose tolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose tolerant. No concomitant diseases.
62142422|NCT00526994|ACTIVE_COMPARATOR|Universal education|all participants receive partner violence referral information
62142423|NCT00526994|NO_INTERVENTION|Control|no screen and no referral
62345086|NCT02947022|EXPERIMENTAL|Calcium DTPA followed by Zinc DTPA|Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.
62345087|NCT04813536||nurses in Assiut university hospitals|currently working nurses exposed to shift work
62345088|NCT04813536||control group|currently working nurses not exposed to shift work
62345089|NCT03304470|EXPERIMENTAL|ATx201 2% CREAM|
62345090|NCT03304470|PLACEBO_COMPARATOR|ATx201 Cream Vehicle|
62345091|NCT03985748|EXPERIMENTAL|Breath Actuated Nebulizers (BAN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
62345092|NCT03985748|ACTIVE_COMPARATOR|Standard Nebulizer (SN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
62345093|NCT02800473|OTHER|Experimental|"Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care.~Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices.~24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects"
62345094|NCT05218057|ACTIVE_COMPARATOR|Thulium-fibre laser (TFL)|The laser used in this group for surgical procedure ureteroscopic lithotripsy will be the Olympus SOLTIVETM Premium SuperPulsed laser system with a 365micron laser fibre. The laser pulse setting will be 1J x 10Hz, short pulse duration (adjusted up to 600microseconds).
62503026|NCT01514123|EXPERIMENTAL|Arm B - VGX-100 plus bevacizumab|Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
62503027|NCT04646824|EXPERIMENTAL|ahead|A110 mg QD and platinum-based chemotherapy. A 110 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by A 110mg daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Dose may be reduced to allow for the management of IP related toxicity.
62142424|NCT03336892|EXPERIMENTAL|Intervention|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
62142425|NCT03336892|NO_INTERVENTION|Control|Enhanced usual care with written mental health resources and system navigation information.
62503028|NCT04985838|EXPERIMENTAL|Online HEADS: UP|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered using a video communication platform e.g. Zoom. An informal introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course.
62503029|NCT04985838|NO_INTERVENTION|Control|No intervention provided.
62702156|NCT04969471|EXPERIMENTAL|Thrombectomy Arm|enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot
61955873|NCT03600571|EXPERIMENTAL|MMP groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
61955874|NCT03944421|EXPERIMENTAL|Red and Processed Meat|240 grams (raw weight) of red and processed meat every day for 2 weeks
61955875|NCT03944421|EXPERIMENTAL|Quorn|240 grams (uncooked weight) of Quorn every day for 2 weeks
62345095|NCT05218057|ACTIVE_COMPARATOR|Holmium: yttrium-aluminum-garnet (Ho: YAG)|The laser used in this group for surgical procedure ureteroscopic lithotripsy will be the Lumenis VersaPulse® PowerSuiteTM 100W laser system with a 365micron laser fibre. The laser pulse setting will be 1J x 10Hz. Pulse duration is not adjustable in this machine (up to 600microseconds).
62345096|NCT05727085||twins|
62503030|NCT03304431|NO_INTERVENTION|Control group(Group C)|After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
62503031|NCT03304431|OTHER|Group L|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
62702157|NCT04969471|EXPERIMENTAL|Conventional Treatment Arm|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
61955876|NCT03048734||Group (1): Men with Nocturia ≥2.|
62345097|NCT01010711|OTHER|migraine dietary supplement|"the average days of migraine during a 4 week-run-in-period are compared with the average days of migraine during intervention with a specific dietary supplement from week 8 - 12"
62345098|NCT01818388||IVTM system, therapeutic hypothermia|Induced therapeutic hypothermia post cardiac arrest
62345099|NCT01397448|EXPERIMENTAL|E3810 5 mg|
62503032|NCT03092596|EXPERIMENTAL|Patient-administered screening tool|Patients will complete a screener for alcohol and drug misuse.
62503033|NCT03092596|EXPERIMENTAL|Patient health navigator-administered screening tool|Patient health navigators will administer a screener for alcohol and drug misuse to patients.
62702158|NCT05673148|EXPERIMENTAL|Arm 1 (TAT, SOC chemotherapy|Patients undergo TAT on study, consisting of SABR with or without surgical resection and/or microwave ablation. Patients also receive SOC chemotherapy on study. Patients also undergo CT or MRI or PET/CT scans throughout the trial.
62702159|NCT05673148|ACTIVE_COMPARATOR|Arm 2 (SOC chemotherapy)|Patients receive SOC chemotherapy on study. Patients also undergo Patients also undergo CT or MRI or PET/CT scans throughout the trial.
62702160|NCT05334069||Screening (questionnaire, biospecimen collection)|Participants complete a questionnaire at baseline. Participants undergo collection of blood samples at registration and at 12 months after registration. Patients with a cancer diagnosis may undergo collection of tissue samples at registration and 12 months after registration.
61955877|NCT03048734||Group (2): Men with no nocturia (0-1).|
62345100|NCT01397448|EXPERIMENTAL|E3810 10 mg|
62345101|NCT01397448|ACTIVE_COMPARATOR|Teprenone 150 mg|
62345102|NCT04561921|EXPERIMENTAL|megnesium sulphate|Injection of 1.8 mL of an anaesthetic solution containing 1% magnesium sulphate , and 1.8% mepivacaine HCL with .06mg Levonordefrin HCl during inferior alveolar nerve block.
62345103|NCT04561921|ACTIVE_COMPARATOR|mepivacaine HCl|Injection of 1.8 mL of a local anaesthetic solution containing 1.8% mepivacaine HCL with .06mg Levonordefrin HCL during inferior alveolar nerve block
62345104|NCT03689413|EXPERIMENTAL|1 mg/kg|"For '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
62345105|NCT03689413|ACTIVE_COMPARATOR|2 mg/kg|"For '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
62345106|NCT02275767|EXPERIMENTAL|Combination 50% cortical/50% cancellous FDBA|Ridge preservation with Combination 50% cortical/50% cancellous freeze-dried bone allograft (FDBA)
62345107|NCT02275767|ACTIVE_COMPARATOR|100% cortical FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
62345108|NCT02275767|ACTIVE_COMPARATOR|100% cancellous FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
62503034|NCT03092596|EXPERIMENTAL|Patient health navigator-assisted linkage to treatment|Patient health navigators will be trained in motivational interviewing to engage patients about linkage to substance abuse treatment.
61955878|NCT04080375|EXPERIMENTAL|dinoprostone 3 mg|patients will take 1 tablet of vaginal dinoprostone 1 hour before the surgery
61955879|NCT04080375|PLACEBO_COMPARATOR|placebo|patients will take 1 tablet of placebo 1 hour before the surgery
61955880|NCT05700097|EXPERIMENTAL|Low Dose Arm|Dengzhanxixin injection 40ml/day, placebo 40ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day; placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day.
61955881|NCT05700097|EXPERIMENTAL|High Dose Arm|Dengzhanxixin injection 80ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
61955882|NCT05700097|PLACEBO_COMPARATOR|Placebo Arm|Placebo injection 80ml/day. Placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
61955883|NCT04326556|EXPERIMENTAL|Prospective cohort for etiological and prognostic purposes|
61955884|NCT01941875|NO_INTERVENTION|No Luteal Support|Control group: No luteal phase support or medication will be used
62503035|NCT03092596|NO_INTERVENTION|Treatment as usual|Patients will receive standard care.
62503036|NCT06502990|EXPERIMENTAL|Metreleptin|Metreleptin \[Recombinant-methionyl human Leptin; rmetHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
61955885|NCT01941875|EXPERIMENTAL|Luteal Vaginal Progesterone|Experiment group: Vaginal progesterone for luteal support beginning the first day after IUI
61955886|NCT04238260|ACTIVE_COMPARATOR|Usual Physical Therapy Care|Physical Therapists continue usual care
61955887|NCT04238260|EXPERIMENTAL|Enhanced Physical Therapy Usual Care|Best practice implemented
61955888|NCT01399515|ACTIVE_COMPARATOR|Valproic acid|
61955889|NCT01399515|NO_INTERVENTION|Control|
61955890|NCT02742441|EXPERIMENTAL|122-0551 Foam|"122-0511 Foam, topically applied twice daily~Intervention: Drug: 122-0551 Foam"
61955891|NCT02742441|PLACEBO_COMPARATOR|Vehicle Foam|"Vehicle Foam, topically applied twice daily~Intervention: Drug: Vehicle Foam"
61955892|NCT00481078|EXPERIMENTAL|Arm I (vorinostat, paclitaxel, carboplatin)|Patients receive oral vorinostat (SAHA) at 400 mg once daily on days 1-14 and paclitaxel IV 200 mg/m2 over 3 hours and carboplatin IV dosed to achieve an area under the concentration versus time curve of 6 mg/mLXmin over 30 minutes on day 3.
61955893|NCT00481078|ACTIVE_COMPARATOR|Arm II (placebo, paclitaxel, carboplatin)|Patients receive an oral placebo once daily on days 1-14 and paclitaxel and carboplatin as in arm l.
61955894|NCT06044883|EXPERIMENTAL|Men suffering from erectile dysfunction not responsive to phosphodiesterase-5 inhibitors (PDEI5Is)|"Our study involves male participants aged 18-70 years old suffering from erectile dysfunction and not responding to oral PDE5Is All patients are sexually active. They had no history of pelvic or spinal surgeries or trauma. Patients will be recruited from the Andrology department and outpatient clinics - Kasr Alainy- Cairo University hospitals.~The study will be conducted in the ultrasound unit in the Radiology department- Kasr Alainy- Cairo University hospitals."
61955895|NCT01496248|EXPERIMENTAL|Korean Red Ginseng|Extract of Korean red ginseng was administrated to subjects through capsule form.
61955896|NCT01744197|EXPERIMENTAL|Arm 1|First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch
61955897|NCT01744197|EXPERIMENTAL|Arm 2|First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch
61955898|NCT02485197|OTHER|Low 25(OH)D|We will recruit individuals with low 25(OH)D (\<30ng/mL).
61955899|NCT02485197|OTHER|High 25(OH)D|"We will recruit individuals with higher 25(OH)D (at least 20ng/mL units higher then that of the low 25(OH)D group)."
61955900|NCT01539538|EXPERIMENTAL|Sufentanil NanoTab PCA System/15 mcg|
61955901|NCT01539538|ACTIVE_COMPARATOR|morphine IV PCA|
62503037|NCT06012578|EXPERIMENTAL|ISM5411|
62503038|NCT06012578|PLACEBO_COMPARATOR|Placebo|
62702161|NCT02327884||Group 1|Healthy Volunteers matched with Sjogren's Syndrome patients
62702162|NCT02327884||Group 2|Family Members, affected and unaffected
62702163|NCT02327884||Group 3|any other cause salivary gland dysfunction
62714873|NCT06717607|EXPERIMENTAL|Clareon T2 IOL implantation|low cylinder toric IOL
61955902|NCT04372901|EXPERIMENTAL|digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
61955903|NCT04372901|ACTIVE_COMPARATOR|digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement
61955904|NCT01500161|EXPERIMENTAL|Single Arm|The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.
61955905|NCT04765696||Persons 55 years or older considering relocation|No intervention is administered.
61955906|NCT01482845|EXPERIMENTAL|Group 1|
61955907|NCT01482845|EXPERIMENTAL|Group 2|
61955908|NCT05543733|EXPERIMENTAL|Home exercise program|
61955909|NCT06275724||inclisiran|Patients prescribed with inclisiran
61955910|NCT06324669|EXPERIMENTAL|Ketone supplementation|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com)
61955911|NCT06324669|PLACEBO_COMPARATOR|Placebo|Placebo with stevia and bitter agent to flavour match
61955912|NCT04173585|EXPERIMENTAL|Bortezomib-Gemtuzumab Ozogamicin Treatment|"one cycle of combined chemotherapy:~* Bortezomib (1.3 mg/m2) sc on day 1 and 3. Dose will be given 3 hours prior to Cytarabine on day 1 and 3~* Cytarabine (1g/m² twice daily) iv over 3 hours on day 1, 2 and 3 Gemtuzumab Ozogamicin (3 mg/m²,up to a maximum of one 5 mg vial) iv over 2 hours on day 1 after first dose of Cytarabine and day 4~* Pegfilgrastim 6 mg sc on day 8 (optional)"
61955913|NCT01929005|NO_INTERVENTION|Standard of Care|If patients are randomized to standard of care, they are not assigned to a Comprehensive Care Physician. They are asked to continue receiving their care as they normally would.
62142426|NCT01786876|EXPERIMENTAL|Radiolabeled SPD557|
62345109|NCT02694627|EXPERIMENTAL|Intervention|See intervention description
62345110|NCT02694627|NO_INTERVENTION|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but do not receive any intervention.
62345111|NCT03810001|NO_INTERVENTION|standard ICSI procedure|a single spermatozoon was injected into the ooplasm
62345112|NCT03810001|EXPERIMENTAL|modified ICSI procedure|slight mechanical stimulation before standard ICSI procedure
62345113|NCT03286712|EXPERIMENTAL|Incident Peritoneal Dialysis|After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.
62345114|NCT05314712|OTHER|Sleep Intervention|Pre and post test of 9-week intervention
61955914|NCT01929005|EXPERIMENTAL|Comprehensive Care|Patients randomized to the Comprehensive Care group are assigned to a Comprehensive Care physician and are asked to see their assigned CCP for their primary care. The patients will receive their care by the CCP in the outpatient clinic and also if they were to be hospitalized.
61955915|NCT03744091|ACTIVE_COMPARATOR|10 mg P1|10 mg of P1 will be administered and compared with an active dose of 20 mg P1 on crossover
61955916|NCT03744091|ACTIVE_COMPARATOR|20 mg P1|20 mg of P1 will be administered and compared with an active dose of 10 mg P1 on crossover
61955917|NCT01408446|ACTIVE_COMPARATOR|Menthol|Interventions Drug: Menthol Arms: Group 1
61955918|NCT01408446|PLACEBO_COMPARATOR|Placebo|Interventions Drug: Placebo Arms: Group 2
61955919|NCT01782820||dexamethasone late|dexamethasone during induction of anesthesia
61955920|NCT01782820||no dexamethasone|no dexamethasone during measurements
61955921|NCT01782820||dexamethasone early|dexamethasone before induction of anesthesia
61955922|NCT00560456|EXPERIMENTAL|1|snorers
62503039|NCT02221063|ACTIVE_COMPARATOR|low [thiamin] fortified fish sauce|Fish sauce will contain 2 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
62503040|NCT02221063|ACTIVE_COMPARATOR|higher [thiamin] fortified fish sauce|Fish sauce will contain 8 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
62503041|NCT02221063|PLACEBO_COMPARATOR|Placebo fish sauce|Fish sauce will contain only iron (as NaFeEDTA), no thiamin
62503042|NCT05333315|EXPERIMENTAL|Investigation Product 1 (IP1) in softchews form|0,5 g of glucomannan per softchew
62503043|NCT05333315|EXPERIMENTAL|Investigation Product 2 (IP2) in powder form|Fiber of light Indian plantain, 7 g; glucomannan, 4,3 g; Inulin 2,5 g; Apple fiber, 1g; Choline, bitartrate 90 mg; Apple pectin,50 mg; Inositol, 40 mg
62714874|NCT06717607|ACTIVE_COMPARATOR|Clareon non-toric IOL implantation|Non-toric IOL
62142427|NCT03511144|ACTIVE_COMPARATOR|Measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
62142428|NCT03511144|ACTIVE_COMPARATOR|Ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
62345115|NCT05611840|EXPERIMENTAL|Robotic group|One-stage robotic common bile duct exploration and cholecystectomy
61955923|NCT00560456|OTHER|2|healthy volonters (control)
61955924|NCT00560456|EXPERIMENTAL|3|young subjects
61955925|NCT00560456|EXPERIMENTAL|4|mature subjects
61955926|NCT02265874|ACTIVE_COMPARATOR|Treatment|Habitrol Nicotine patch - 7,14,21 mg patches Qd
61955927|NCT02265874|PLACEBO_COMPARATOR|Control|Placebo patch
61955928|NCT06505512||Survival group|
61955929|NCT06505512||Death group|
61955930|NCT01786083|EXPERIMENTAL|Lifestyle counseling|Application of Problem Solving Technique
61955931|NCT01786083|NO_INTERVENTION|No counseling|Usual care by caregiver
61955932|NCT03147261|EXPERIMENTAL|lifestyle intervention|Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.
61955933|NCT03147261|NO_INTERVENTION|No intervention|Healthy diet recommendations following the usual pediatric advice
61955934|NCT03375775|EXPERIMENTAL|Treatment group|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
62142429|NCT04055818|EXPERIMENTAL|Nicotinamide|Oral Nicotinamide 1000 mg twice daily
62142430|NCT04055818|EXPERIMENTAL|THU Decitabine|Oral 250 mg THU and 5 mg decitabine Once per week
62345116|NCT05611840|ACTIVE_COMPARATOR|Endo-laparoscopic group|Two stage therapeutic endoscopic retrograde cholangiopancreatography (ERCP) with interval laparoscopic cholecystectomy
62345117|NCT05154513||Cohort 1|Children living with perinatally-acquired HIV who received early treatment in IMPAACT network studies or other research studies sponsored by the United States National Institutes of Health.
62345118|NCT02834234||Peritoneal mesothelioma specimens|"The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group.~The CGH arrays will be realized on frozen samples (for the comparative genomic analysis)."
62345119|NCT05902429|EXPERIMENTAL|Cladribine tablets|
62345120|NCT01221688|OTHER|group 2 (cN0)|Patients without proven axillary involved nodes will undergo SLN biopsy and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLN biopsy alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
62345121|NCT01221688|EXPERIMENTAL|group 1 (pN+)|group 1 : patients with proven involved axillary nodes will undergo SLN biopsy and complete level I-II axillary lymphadenectomy.
62345122|NCT02943018||anovaginal distance variation|3 measurements
62345123|NCT01363557|EXPERIMENTAL|Arm A : Gefitinib + WBRT|Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance
62345124|NCT01363557|EXPERIMENTAL|Arm B : Gefitinib|Arm B : Gefitinib alone
62345125|NCT02299765|EXPERIMENTAL|Arm A|"Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days"
62345126|NCT02299765|ACTIVE_COMPARATOR|Arm B|Gefitinib 250mg/d until disease progression
62345127|NCT03475576|OTHER|all participants|The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian.
62345128|NCT02035150|EXPERIMENTAL|Oatmeal Breakfast|Participants will consume oatmeal breakfast daily for 4 weeks
62345129|NCT02035150|EXPERIMENTAL|Frosted Flakes|Participants will consume a frosted flakes breakfast daily for 4-weeks
62345130|NCT02035150|PLACEBO_COMPARATOR|No Breakfast|Participants will consume no breakfast for a 4-week period
62345131|NCT06092853||systemically and periodontally healthy (CG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses.
62345132|NCT06092853||systemically healthy and periodontitis (PG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
61955935|NCT03375775|ACTIVE_COMPARATOR|Control group|No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
61955936|NCT03322631|EXPERIMENTAL|Tirzepatide|Participants received escalating doses of 2.5 milligrams (mg), 5 mg, 10 mg and 15 mg of tirzepatide administered into the subcutaneous (SC) tissue of the abdominal wall.
61955937|NCT03322631|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered into the SC tissue of the abdominal wall.
61955938|NCT02969369|EXPERIMENTAL|SEP-363856|SEP-363856 (25, 50, or 75mg/day), once daily
61955939|NCT02969369|PLACEBO_COMPARATOR|Placebo Capsule|Placebo once daily
61955940|NCT01427972|EXPERIMENTAL|0.2 milligrams (mg) LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
61955941|NCT01427972|EXPERIMENTAL|1.5 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
61955942|NCT01427972|EXPERIMENTAL|10 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
61955943|NCT01427972|ACTIVE_COMPARATOR|50 mg Eplerenone|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
61955944|NCT05096793|EXPERIMENTAL|Control|the distance in the 6-MRT compared to baseline
61955945|NCT05096793|EXPERIMENTAL|Low doses|the distance in the 6-MRT compared to baseline
61955946|NCT05096793|EXPERIMENTAL|High doses|the distance in the 6-MRT compared to baseline
61955947|NCT04496271|EXPERIMENTAL|Successor of Phonak Audéo M-90|Phonak Hearing aid with modified precalculation.
62702164|NCT05176223|EXPERIMENTAL|Treatment (68GA PSMA PET/CT)|Patients undergo 68GA PSMA PET/CT scans at baseline, and after 3, 6, 9, and 12 cycles of standard of care immunotherapy in the absence of disease progression or unacceptable toxicity.
62702165|NCT06275022|EXPERIMENTAL|Macro/mixed cystic lymphatic A|Inflow occlusion assisted by indocyanine green-fluorescence imaging combined with perforation of septation and sclerotherapy
62702166|NCT06275022|ACTIVE_COMPARATOR|Macro/mixed cystic lymphatic B|Perforation of septation and sclerotherapy
62142431|NCT02466958|ACTIVE_COMPARATOR|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
62345133|NCT06092853||Metabolic syndrome and periodontally healthy (MG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
62345134|NCT06092853||Metabolic syndrome and periodontitis (MPG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
62345135|NCT03226132|EXPERIMENTAL|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
62345136|NCT03226132|ACTIVE_COMPARATOR|Repeated Contact|Repeated Contact
62345137|NCT01397916||CLL-patients|
62345138|NCT01397916||Controls|
62345139|NCT00598169|EXPERIMENTAL|CD20+ Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, rituximab 375mg/m2 on Day 1 of a 21-day cycle."
62702167|NCT06275022|EXPERIMENTAL|Microcystic lymphatic A|Indocyanine green-fluorescence imaging-guided partial resection and sclerotherapy
62702168|NCT06275022|ACTIVE_COMPARATOR|Microcystic lymphatic B|Partial resection and sclerotherapy
62702169|NCT06749886|EXPERIMENTAL|cohort1|The subjects in this cohort will receive denosumab combined with tislelizumab and docetaxel.
61955948|NCT04496271|ACTIVE_COMPARATOR|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent Receiver In Canal hearing aid by Phonak which will be fitted to the participants individual hearing loss.
61955949|NCT05722782|ACTIVE_COMPARATOR|NSAI|Piroxicam: 20 mg per pill; one pill per day for five days
61955950|NCT05722782|ACTIVE_COMPARATOR|Acetaminophen|Paracetamol: 1000 mg per day for five days
61955951|NCT05722782|PLACEBO_COMPARATOR|Placebo|Placebo: one pill per day for five days
61955952|NCT00508716|NO_INTERVENTION|A|Usual Care - Education about CHF by Primary Nurse on discharge. No teach-back is used in this arm.
61955953|NCT00508716|EXPERIMENTAL|B|"Tailored Intervention for patients with low health literacy and nurse-directed teachback: Educational leaflet which has been developed for low-health literacy patients. Adminstered by dedicated Nurse-educator. Nurse-educator asks Patient for teachback after Intervention. This means that the Patient repeats in his/her own words the Information received. Education ends once Patient has been able to repeat the Information back."
61955954|NCT00437307|ACTIVE_COMPARATOR|1|Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.
61955955|NCT00437307|NO_INTERVENTION|2|Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.
61955956|NCT01667380||Cohort|
61955957|NCT05947396|EXPERIMENTAL|SMARTO ONE|
61955958|NCT05947396|PLACEBO_COMPARATOR|placebo|
61955959|NCT03571425|PLACEBO_COMPARATOR|Oral Placebo|Placebo drink
62702170|NCT03049462|EXPERIMENTAL|Cohort 1|Females taking 100 mg of mirabegron
62702171|NCT03049462|ACTIVE_COMPARATOR|Cohort 2A|Males taking 200 mg mirabegron
62702172|NCT03049462|PLACEBO_COMPARATOR|Cohort 2B|Males taking placebo drug
62702173|NCT03049462|ACTIVE_COMPARATOR|Cohort 3A|Females taking 100 mg of mirabegron
62702174|NCT03049462|PLACEBO_COMPARATOR|Cohort 3B|Females taking placebo drug
61955960|NCT03571425|ACTIVE_COMPARATOR|Oral Protein|Protein drink, ingested orally
61955961|NCT03571425|ACTIVE_COMPARATOR|Enteral Protein|Protein drink, administered via enteral tube
61955962|NCT00839891|PLACEBO_COMPARATOR|3|"Group 1: 56 subjects to receive active study drug (VI-0521) at steady state, PHEN/TPM 7.5/46 (a potential therapeutic dose), escalating to PHEN/TPM 22.5/138 (a supra-therapeutic dose);~Group 2: 28 subjects to receive placebo preceded by a single oral dose of moxifloxacin on Day 2;~Group 3: 28 subjects to receive placebo followed by a single oral dose of moxifloxacin on Day 24;"
61955963|NCT01325584|EXPERIMENTAL|Omegaven (compassionate use)|This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.
61955964|NCT02647814|EXPERIMENTAL|Salud al Día|The participants in the intervention group will receive interactive text-messages with a link to support if needed for: clinic appointment reminders, follow-up on medicine and referral adherence, and illness care needs and use. Participants will additionally receive reminders for insurance renewal, food stamp applications, and health-promoting community events. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
61955965|NCT02647814|NO_INTERVENTION|Usual Care|The participants in the usual care group will receive the clinic's usual care in terms of receiving no text messages. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
61955966|NCT06555536|EXPERIMENTAL|Telemedicine and e-Health care method for patients with Osteogenesis Imperfecta.|This study seeks to formalize the association between the use of technology and the effective treatment of patients with Osteogenesis Imperfecta, not yet explored in the literature.
61955967|NCT03162991|EXPERIMENTAL|12-Week Aerobic Exercise Intervention|
61955968|NCT03162991|NO_INTERVENTION|12-Week Control Period|
61955969|NCT06045351|EXPERIMENTAL|VD supplementation|"Experimental Group (Group A; n=71):~The intervention (experimental) group will receive VD injections 600,000 I.U I/M once with 1 gram calcium supplemental daily in the initial 12 weeks. After that standard PCOS care; i) Glucophage XR 750 mg (once for 15 days then twice daily) ii) progesterone supplementation (1 capsule Progeffik 100 mg every 3 weeks, then 1 week off) and iii) calcium supplements will be given for next 12 weeks."
61955970|NCT06045351|ACTIVE_COMPARATOR|Control|"Control Group (Group B; n=71):~Participants will receive standard PCOS treatment; Glucophage XR 750 mg once at dinner for 15 days then twice daily and Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off for initial-- 12 weeks.~Then VD supplementation (600,000 IUI/M) will be given once during the study period with Calcium 1000 mg/day and continued Standard PCOS treatment from 12- 24 weeks"
61955971|NCT04201093|EXPERIMENTAL|Tavapadon 5 mg|Participants will receive tavapadon tablet titrated up to 5 milligram (mg) once daily (QD) orally for 27 weeks.
61955972|NCT04201093|EXPERIMENTAL|Tavapadon 15 mg|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) QD orally for 27 weeks.
61955973|NCT04201093|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
61955974|NCT06404502|EXPERIMENTAL|PRISMA|The intervention, PRISMA, addresses the issue of poor mental health of inmates during pretrial detention and after release. PRISMA has been adapted for the context of the model trial from Problem Management Plus (PM+). PRISMA has a total of four sessions provided during the first two weeks after entry such that most inmates can benefit from it before their potential release. The four sessions involve stress management, problem solving, meaningful activities (behavioral activation, and strengthening social support) and relapse prevention (staying well, looking forward). Additionally, participants will receive 2 booster sessions, 4 and 9 weeks after the final session.
61955975|NCT06404502|NO_INTERVENTION|Control group|REGULAR PRETRIAL: participants in this group experience the same pretrial system, conditions, and services that they would have experienced if the RCT did not exist. They will not be offered PRISMA.
61955976|NCT01845831|EXPERIMENTAL|Sitagliptin + glargine (Hospital)|Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
62503044|NCT05333315|EXPERIMENTAL|Investigation Product 3 (IP3) in powder form and capsules form|POWDER: Plantain fibre 10 g; Inulin, 2 g; Apple fibre, 1,5 g; Root of pellitory, 500 mg; Apple pectin, 450 mg CAPSULE: Pumpkin seed extract, 300 mg; Garlic extract odourless, 300 mg; Artichoke leaf extract, 150 mg; Cumin seed extract, 150 mg; Peppermint leaf extract, 150 mg; Anise seed extract, 150 mg; Curcuma rhizome extract, 150 mg; Vitamin C, 42 mg; Zinc (in gluconate),10 mg; Vitamin B6, 1,5 mg
61955977|NCT01845831|ACTIVE_COMPARATOR|Basal bolus (Hospital)|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
61955978|NCT01845831|EXPERIMENTAL|Metformin and Sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
61955979|NCT01845831|EXPERIMENTAL|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
61955980|NCT01845831|EXPERIMENTAL|Metformin and sitagliptin + glargine 80%|Patients with HbA1c \> 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
61955981|NCT04636190|OTHER|Triathlon All-Polyethylene Tibia Knee|All subjects enrolled will have received the Triathlon All-Polyethylene Tibia Knee device.
61955982|NCT04545060|EXPERIMENTAL|VIR-7831 (Sotrovimab)|Participants received 500 mg sotrovimab administered intravenously (IV)
62142432|NCT02466958|PLACEBO_COMPARATOR|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
61955983|NCT04545060|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered intravenously (IV)
62142433|NCT05635357||Anastrozole|Exposure group
62142434|NCT05635357||Exemestane/Letrozole|Reference group
62503045|NCT05333315|EXPERIMENTAL|Investigation Product 4 (IP4) in liquid form|LIQUID: Arabinogalactan, 700 mg; Inulin, 700 mg; Beta-glucans, 30 mg
62702175|NCT06750874|EXPERIMENTAL|Perioperative Acceptance and Commitment Therapy Workshop|Participants assigned to this arm will complete a 1-day ACT workshop followed by a telephone booster after surgery
61955984|NCT00695409|EXPERIMENTAL|Treatment (RIT, ZBEAM, ASCT)|RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8\*. NOTE: \* Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.
61955985|NCT02271568||Obese patients|15 Obese patients (BMI\>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI\>35) accepted for bariatric surgery.
62503046|NCT05333315|EXPERIMENTAL|Investigation Product 5 (IP5) in two capsules form|CAPSULE 1:L-arginine, 100 mg; Choline bitartrate, 100 mg; L-carnosine, 100 mg; L-taurine, 100 mg; Soy lecithin, 50 mg; R-alfa lipoic acid,10 mg; Vitamin B6,2 mg; Folic acid, 200 µg; Vitamin D3, 5 µg; Vitamin B12, 2 µg CAPSULE 2: Schisandra fruit extract, 400 mg; Milk thistle fruit extract associated with phospholipids, 200 mg; Grape seed extract associated with phospholipids, 50 mg; Grape seed extract (Vitis vinifera),50 mg
62702176|NCT05523973|EXPERIMENTAL|Lingual Endurance Training Only (Group 1)|Intervention group 1 will complete lingual endurance training only.
61955986|NCT02271568||Control patients|15 matched controls receiving Intensive medical therapy
61955987|NCT00003211|EXPERIMENTAL|Average-risk|"Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
62142435|NCT06465550|EXPERIMENTAL|BD211 Single-Dose group|Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: ≥ 5×10\^6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211
62142436|NCT05179265|PLACEBO_COMPARATOR|Control group|0.45 g/bottle，50 mL
62142437|NCT05179265|EXPERIMENTAL|test group|10 g/bottle (20%, 50 mL)
62142438|NCT03905278|EXPERIMENTAL|Parental guidance|"In the experimental condition, the two significant caregivers of the child or the individual caregiver receive the intervention composed of an informational booklet and a psychological intervention. The intervention consists of four sessions, centered on supporting the child in the context of parental cancer principally through communication.~Assessments are conducted at two periods : before and after the intervention."
62142439|NCT03905278|NO_INTERVENTION|Waiting List group|"In the control condition, the participants receive the informational booklet before being registered in a waiting list for the psychological intervention. The intervention should ideally last two months.~Assessments are conducted at 9 weeks of interval."
62142440|NCT03597087|EXPERIMENTAL|General anesthesia|Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol
62503047|NCT02342041|PLACEBO_COMPARATOR|Single ascending dose|Single dose of SUVN-G3031or placebo in healthy male subjects
62503048|NCT02342041|PLACEBO_COMPARATOR|Multiple ascending dose|Multiple doses of SUVN-G3031 or placebo in healthy male subjects
62702177|NCT05523973|EXPERIMENTAL|Lingual Endurance Training + Transference Exercise (Group 2)|Intervention Group 2 will complete lingual endurance exercise plus a transference exercise.
62702178|NCT01375530||1|Healthy adults 18 - 60 years old
62142441|NCT03597087|EXPERIMENTAL|Spinal anesthesia|Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine
62142442|NCT06700304|OTHER|CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface|Open label
62142443|NCT06270524|EXPERIMENTAL|IgG4-RD patient|Patients suffering from Immunoglobulin G4-related disease (IgG4-RD).
62142444|NCT06270524|EXPERIMENTAL|patient in remission|Patients suffering from Immunoglobulin G4-related disease (IgG4-RD) but in remission.
62142445|NCT06270524|OTHER|healthy volunteers|
62142446|NCT03496558|EXPERIMENTAL|150 pregnant women with a history of risk|
62142447|NCT03496558|NO_INTERVENTION|150 healthy pregnant women|
62142448|NCT03347409|NO_INTERVENTION|Standard Perioperative (SP) care|
62142449|NCT03347409|EXPERIMENTAL|ERAS protocol|
62142450|NCT05726526|EXPERIMENTAL|Intervention Group|Participants randomized to the intervention group will be provided with a wireless BP cuff, weight scale, transcutaneous O2 sat monitor, wearable motion tracker and mobile tablet with the VIEWER application. Patients will be trained to use the VIEWER platform either virtually or in person. Patients will be guided through a daily self-assessment routine via the app (BP, weight, O2 saturation, step count upload) and weekly ESAS-r survey. Participants will use the VIEWER platform for 12 months ( or until dialysis initiation) in addition to receiving usual care. Additionally, participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months (or every 3 months until dialysis initiation), and the System Usability Scale (SUS) at 12 months.
62142451|NCT05726526|NO_INTERVENTION|Control Group|Participants randomized to the control group will continue to receive usual care either virtually via telephone or video call or in person depending on COVID-19 restrictions in place. Participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months (or every 3 months until dialysis initiation).
62503049|NCT06502210||neuroblastoma group|The resected tumor tissue of patients with neuroblastoma was taken by surgical operation as experimental group.
62503050|NCT06502210||Normal tissue adjacent to the tumor group|The normal tissue adjacent to tumor of patients with neuroblastoma was taken by surgical operation as control group.
62142452|NCT02461979|OTHER|Hepatocellular carcinoma (HCC)|The VDR genotype in 20 HCV cirrhotic patient with HCC
62142453|NCT02461979|OTHER|Liver cirrhosis|The VDR genotype in 20 HCV cirrhotic patient without HCC
62142454|NCT02461979|OTHER|Control group|The The VDR genotype in 10 healthy individuals as control
62714875|NCT06519136|EXPERIMENTAL|Distance Reiki Group|"According to Usui, the second level Reiki application will be applied for 20 minutes a day between 19.00 and 21.00 in the evening for four consecutive days by the researcher who has completed his second level training, in accordance with the Second Level Reiki Application Protocol."
62714876|NCT06519136|SHAM_COMPARATOR|Sham Reiki Group|It will be stated that remote energy application will be applied to the Sham Reiki group and no application will be made.
61955988|NCT00003211|EXPERIMENTAL|High-risk|"Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
62142455|NCT06522919|EXPERIMENTAL|Sequential immunochemotherapy with Pembrolizumab plus DC Vaccine, followed by FTD/TPI + Bevacizumab|"Induction phase: In the immunological induction phase patients will be given DCs intradermally every week for up to 4 doses and then a further administration after 3 weeks and Pembrolizumab 200 mg IV q3w for up to 3 cycle.~Maintenance phase: patients will receive FTD/TPI combined with Bevacizumab.Treatment with FTD/TPI and Bevacizumab will start regardless of the response obtained with the induction combo immunotherapy, and will continue until confirmed disease progression, unacceptable toxicity or withdrawal of the consent by the patient, whichever occurs first."
62503051|NCT01896505|EXPERIMENTAL|Arm 1|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 30 milligrams per meter square (mg/m\^2) orally twice weekly in treatment sequence ABCD (Treatment A: fasted, tablet formulation on Day 1 of Week 1; Treatment B: high-fat meal, tablet formulation on Day 1 of Week 2; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 3; Treatment D: low-fat meal, capsule formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).
62503052|NCT01896505|EXPERIMENTAL|Arm 2|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received selinexor 30 mg/m\^2 orally twice weekly in treatment sequence BADC (Treatment B: high-fat meal, tablet formulation on Day 1 of Week 1; Treatment A: fasted, tablet formulation on Day 1 of Week 2; Treatment D: low fat meal, capsule formulation on Day 1 of Week 3; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
62702179|NCT05400486|ACTIVE_COMPARATOR|Therapeutic exercise group|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
62714877|NCT06716242||Pregnant patients aged 18 years or older|Pregnant patients aged 18 years or older recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals.
62142456|NCT05424666|EXPERIMENTAL|Patient going Oncoplastic Breast surgeries|Lipofilling After Oncoplastic Breast surgeries : Evaluation of Outcomes and Patient Satisfaction
62142457|NCT05371951|EXPERIMENTAL|Erchonia HLS|635 nanometers (nm) laser application
62142458|NCT02304757|EXPERIMENTAL|99Tc-MDP|15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.
62345140|NCT00598169|EXPERIMENTAL|CD20- Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, 21-day cycle."
62345141|NCT01928836||Non-suspected lung cancer group|"1. Aged 40 to 75 years;~2. Male smoker (≥400 cig/year), female smoker or non-smoker;~3. Visible lung nodule lesion in the chest (based on local CT result);~4. Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
62345142|NCT01928836||Suspected lung cancer group|"1. Aged 40 to 75 years;~2. Male smoker (≥400 cig/year), female smoker or non-smoker;~3. Visible lung cancer lesion in the chest (based on local CT result);~4. With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
62345143|NCT04633057|EXPERIMENTAL|TJ101|TJ101 1.2 mg/kg once a week for 52weeks
62503053|NCT01896505|EXPERIMENTAL|Arm 3|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 50 mg/m\^2 first generation tablets twice weekly on Days 1 and 3 of each week within 30 minutes of solid food consumption.
62503054|NCT01896505|EXPERIMENTAL|Arm 4|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence ABC (Treatment A: current \[1st generation\] tablets on Day 1 of Week 1; Treatment B: new \[2nd generation\] tablets on Day 1 of Week 2; Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
62503055|NCT01896505|EXPERIMENTAL|Arm 5|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence CAB (Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 1; Treatment A: current \[1st generation\] tablets on Day 1 of Week 2; Treatment B: new \[2nd generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
62714878|NCT04076332|NO_INTERVENTION|Controlled group|Standard oral explanation with booklet
62714879|NCT04076332|EXPERIMENTAL|Decision aid group|Shared decision making using decision aid
61955989|NCT04149626|ACTIVE_COMPARATOR|Group A|Dexmedetomidine sedation
61955990|NCT04149626|ACTIVE_COMPARATOR|Group B|Midazolam sedation
61955991|NCT04149626|ACTIVE_COMPARATOR|Group C|Remifentanil sedation
61955992|NCT02160535|EXPERIMENTAL|Treatment with OnabotulinumtoxinA|OnabotulinumtoxinA
62142459|NCT02304757|ACTIVE_COMPARATOR|Fosamax|70mg po every week for 12 months.
62345144|NCT04633057|ACTIVE_COMPARATOR|NordiFlex|NordiFlex Injection 0.034 mg/kg once a day for 52 weeks
62345145|NCT02204826|EXPERIMENTAL|V + KRG group (n = 20)|three capsules of KRG (500 mg/dose) daily and varicocelectomy.
62345146|NCT02204826|ACTIVE_COMPARATOR|non-V + KRG group|three capsules of KRG (500 mg/dose) daily
62345147|NCT02204826|ACTIVE_COMPARATOR|V + P group (n = 20)|placebo capsules and varicocelectomy
61955993|NCT03329573|EXPERIMENTAL|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
62702180|NCT05400486|EXPERIMENTAL|Therapeutic exercise group + high frequency TENS|This group will consist of 25 participants. Initially, TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce impedance at the skin-electrode interface. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012). After the application of TENS, the same program of therapeutic exercises applied in the first group will be applied, in the same sequence, evolution, times, and repetitions.
61955994|NCT03329573|EXPERIMENTAL|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
61955995|NCT03329573|EXPERIMENTAL|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
61955996|NCT03329573|EXPERIMENTAL|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
61955997|NCT00690274|PLACEBO_COMPARATOR|Placebo|Volunteers are given Placebo, up to 20mg per day
61955998|NCT00690274|ACTIVE_COMPARATOR|BF2.649|Volunteers are given BF2.649, up to 20mg per day
61955999|NCT04356391|ACTIVE_COMPARATOR|Connective Tissue Graft harvest from Palate|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Technique. The tooth assigned to the CTG technique will receive the graft harvested from the palate.
61956000|NCT04356391|EXPERIMENTAL|collagen resorbable membrane material|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Surgical Technique (PST). The tooth assigned to the PST technique will receive the collagen resorbable membrane material.
61956001|NCT01929096|EXPERIMENTAL|Low-dose group|Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days
61956002|NCT01929096|EXPERIMENTAL|Medium-dose group|Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
62142460|NCT04263051|EXPERIMENTAL|UCPVax + Nivolumab|"UCPVax vaccine (0,5 mg)~Nivolumab (480 mg)"
62142461|NCT04263051|OTHER|Standard second line chemotherapy|"Standard second line chemotherapy at the choice of the investigator.~This arm will permit to assess the good calibration of the hypothesis on the experimental arm."
62345148|NCT02204826|PLACEBO_COMPARATOR|non-V + P group|non-V + P group (n = 20) placebo capsules
62345149|NCT05684653|EXPERIMENTAL|Orelabrutinib Tablets|Subjects take Single dose of 50 mg orelabrutinib tablet under fasting state
62345150|NCT02791087||Coronary Artery Disease for CABG|Patients undergoing or underwent Coronary Bypass Surgery with at least one saphenous vein graft. Intra-operative graft flow rate measurement will be done during CABG surgery.
62714880|NCT04412954|EXPERIMENTAL|Intervention|Health coach with Smartphone application for diet and physical activity
62714881|NCT04412954|NO_INTERVENTION|Control|No intervention, using a Smartphone application for sleep monitoring
62714882|NCT01897532|EXPERIMENTAL|Linagliptin|
62345151|NCT02791087||Stable/Unstable Angina|Patients with no known history of coronary artery disease undergoing Computed Tomography Angiography scan due to stable/Unstable Angina.
62345152|NCT04426838|EXPERIMENTAL|PLwD Cognitive Behavioral Therapy for Insomnia (CBTi)|Persons living with dementia in a dyad receiving the CBTi intervention in a videoconferencing format.
62345153|NCT04426838|EXPERIMENTAL|Caregiver Cognitive Behavioral Therapy for Insomnia (CBTi)|Caregivers in a dyad receiving the CBTi intervention in a videoconferencing format.
62714883|NCT01897532|PLACEBO_COMPARATOR|Placebo|
61956003|NCT01929096|EXPERIMENTAL|High-dose group|Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days
61956004|NCT01929096|ACTIVE_COMPARATOR|Control group|Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days
61956005|NCT06262880|PLACEBO_COMPARATOR|Placebo treatment|Placebo treatment (Microcrystaline cellulose): 1 capsule/d
61956006|NCT06262880|ACTIVE_COMPARATOR|Active low dose of plant derived phenolics|Active low dose of plant derived phenolics via 1 capsule/d
61956007|NCT06262880|ACTIVE_COMPARATOR|Active high dose of plant derived phenolics|Active high dose of plant derived phenolics via 1 capsule/d
61956008|NCT01393496|EXPERIMENTAL|"liberal transfusion triggers"|"liberal guidelines for red blood cell transfusions"
62142462|NCT04806841|EXPERIMENTAL|Intervention group|Participants will have access to 4 weekly supervised training sessions for 3 months. The intervention group will also take part in 3 group meetings (behavioral intervention) and will receive follow-up phone calls from month 4 to 6.
61956009|NCT01393496|ACTIVE_COMPARATOR|"restrictive transfusion triggers"|"restrictive guidelines for red blood cell transfusions"
61956010|NCT06440096||Modic changes type I|24 patients with type I Modic changes
61956011|NCT06440096||Modic changes type II|24 patients with type II Modic changes
62142463|NCT04806841|EXPERIMENTAL|Control group|Participants will have access to 4 weekly supervised training sessions for 3 months without any behavioral intervention.
62142464|NCT04205799|EXPERIMENTAL|CABOZANTINIB|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
62345154|NCT03299738|EXPERIMENTAL|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
62345155|NCT04028999|EXPERIMENTAL|the EO31 shoulder sling|To develop and evaluate the effects of the EO31 shoulder sling for the prevention of pain, subluxation, spasticity, as well as effect on increasing functional use of the UL in activities of daily living.
62345156|NCT03411265|EXPERIMENTAL|RETAIN|Participants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
61956012|NCT05662150|ACTIVE_COMPARATOR|Questionnaires|Patients with DM1 were asked to complete a questionnaire to rate a 25-item activity scale (DM1-Activ) and the Myasthenia Gravis Activity of Daily Life scale (MG-ADL) to rate their level of functional burden. For the DM1-Activ a score of 40 alludes no impairment and a score of 0 indicates the highest functional burden of physical activity. This scale has proven to be practical, reliable and valid. For the MG-ADL the total score ranges from 0 to 24, a score of 0 denotes no and 24 the highest functional burden. It should be noted that this scale is not adjusted for DM1. The rationale was to gain information about muscle fatigue and consequently the neuromuscular junction.
61956013|NCT05662150|ACTIVE_COMPARATOR|grip strength via dynamometer|The isometric grip strength was tested by using a dynamometer. The subject will be asked to perform an increasing force against the dynamometer over a period of several seconds.
61956014|NCT05662150|ACTIVE_COMPARATOR|short exercise test|The subject was asked to contract the ADM muscle as hard as possible in isometric conditions for 10 seconds. CMAP's was recorded 2 seconds after the end of the exercise and then every 10 seconds for 50 seconds.
61956015|NCT05662150|ACTIVE_COMPARATOR|needle EMG|The electrical myotonia of each examined muscle was scored according to the Streiss and Sun scale.
62345157|NCT03179007|EXPERIMENTAL|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
62345158|NCT02292316|EXPERIMENTAL|Fall with fracture|Fall with fracture in the last 6 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
62345159|NCT02292316|SHAM_COMPARATOR|controls|Fall without fracture in the last 12 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
62345160|NCT00441103|EXPERIMENTAL|Rebif® New Formulation (IFN-beta-1a, RNF)|
62503056|NCT01896505|EXPERIMENTAL|Arm 6|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence BCA (Treatment B: new \[2nd generation\] tablets on Day 1 of Week 1; Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 2; Treatment A: current \[1st generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
62503057|NCT01601691|EXPERIMENTAL|Spacer|Subjects with spacer injection
62503058|NCT06364072|EXPERIMENTAL|CT001|
62503059|NCT04021758|EXPERIMENTAL|Peer to peer program intervention|The experimental condition for the proposed project is the Airman's Edge program, a peer to peer program in which peer mentors will be trained to provide a series of interventions aimed at reducing risk for suicidal behaviors both directly and indirectly through the targeting of emotion dysregulation, cognitive rigidity, and contextual risk factors (e.g., insomnia, meaning in life, social support, firearm availability).
62702181|NCT05400486|EXPERIMENTAL|Therapeutic exercise group + Interferential|This group will consist of 25 participants. Initially, the protocol of exercises performed in the therapeutic exercise group will be applied. In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
62702182|NCT00404560||healthy blood relatives|relatives not ill with a known or suspected infection susceptibility syndrome
62702183|NCT00404560||Patients|patients who either have, or are suspected of having, an infection or infection susceptibility in order to further characterize such conditions
62702184|NCT05976763|EXPERIMENTAL|Induction therapy (Zanubrutinib, rituximab)|Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.
62702185|NCT05976763|EXPERIMENTAL|Arm A (Zanubrutinib)|Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
62345161|NCT00441103|PLACEBO_COMPARATOR|Placebo/RNF|
62345162|NCT04894812|ACTIVE_COMPARATOR|Group A|Neurodevelopmental Treatment. Total duration of treatment will be 20 minutes, 3 sessions per for 3 months
62503060|NCT04021758|NO_INTERVENTION|Wait list|
61956016|NCT02985957|EXPERIMENTAL|Cohort A (Arm A)|
61956017|NCT02985957|EXPERIMENTAL|Cohort B (Arm B)|
61956018|NCT02985957|EXPERIMENTAL|Cohort C (Arm C)|
61956019|NCT02985957|EXPERIMENTAL|Cohort D (Arm D1)|
61956020|NCT02985957|EXPERIMENTAL|Cohort D (Arm D2)|
61956021|NCT02985957|EXPERIMENTAL|Cohort D (Arm D3)|
61956022|NCT02985957|EXPERIMENTAL|Cohort D (Arm D4)|
61956023|NCT00916097|EXPERIMENTAL|1|docetaxel 75mg/m2 in combination with cisplatin 75mg/m2 given every 3 weeks for 3 cycles
62345163|NCT04894812|EXPERIMENTAL|Group B|Neurodevelopmental Technique and Vestibular stimulation. Total duration of treatment will be 50 minutes (20 min NDT+ 30 MIN VS) 3 sessions per week for 3 months.
62345164|NCT06339333|EXPERIMENTAL|ACT Now GAIN Later|This group will receive a 7-week psychologist guided parenting intervention.
62345165|NCT06339333|ACTIVE_COMPARATOR|Waitlist Group|This group will receive pre and post measures but will not receive an intervention until after the final measures have been administered.
61956024|NCT04057612||Pediatric participants|"Participants' temperature measured at 2 places at the same time~* Esophagus~* Skin near to carotid artery"
62345166|NCT00258388|ACTIVE_COMPARATOR|OGX011, Docetaxel and Prednisone|
62345167|NCT00258388|ACTIVE_COMPARATOR|Docetaxel plus prednisone|
62345168|NCT03317249||Pregnant Healthy|Pregnant females aged between 18-45 years who do not have IST syndrome
61956025|NCT00838747||Gynaecological Cancer|Gynaecological Cancer
61956026|NCT04406376|ACTIVE_COMPARATOR|Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days, 40 mg for 2 days, 20 mg for 2 days (Total 11 days)
61956027|NCT04406376|ACTIVE_COMPARATOR|No Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days (Total 7 days)
61956028|NCT02817308|EXPERIMENTAL|Patients|"Patients with a proven diagnosis of ductal adenocarcinoma of the pancreas with elevated levels of CA19-9 and possibly elevated CEA levels.~intervention: samples of blood, saliva and urine"
62345169|NCT03317249||Pregnant IST|Pregnant females aged between 18-45 years who have IST syndrome
62702186|NCT05976763|ACTIVE_COMPARATOR|ARM B (Observation)|Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
62503061|NCT04024319||Genicular Nerve Block|GNB will be performed on this group of patients undergoing TKR. The patient will be positioned in the supine position, with the extremity to operate slightly in external rotation. The anesthesiologist will be located ipsilateral to the knee to intervene; asepsis will be performed with 70% chlorhexidine, sterile gloves will be used and the ultrasound probe will be protected with a sterile cover. The ultrasound transducer will be placed in a long axis of the knee in the corresponding area to block according to anatomical repairs. 4 ml of 0,2% ropivacaine was administered in each GN.
62702187|NCT05237986||Cohort 1|Participants with relapsed/refractory leukemias or lymphomas, scheduled to receive CAR T-cell therapy.
62345170|NCT05675111||Nanjing|The First Affiliated Hospital of Nanjing Medical University
62345171|NCT05675111||Zhengzhou|Henan Provincial People's Hospital
62345172|NCT05675111||Qingdao|The Affiliated Hospital of Qingdao University
62345173|NCT05675111||Urumqi|People' s Hospital of Xinjiang Uygur Autonomous Region
62345174|NCT05675111||Jinan|Shandong Provincial Hospital Affiliated to Shandong First Medical University
62702188|NCT05237986||Cohort 2|Caregivers (informants)
62702189|NCT05773274|EXPERIMENTAL|Arm I (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV Q8W. Treatment repeats for two cycles in the absence of disease progression or unacceptable toxicities. Patients also undergo CT scan and collection of blood samples while on study.
62702190|NCT05773274|ACTIVE_COMPARATOR|Arm II (everolimus)|Patients receive everolimus PO QD. Treatment continues in the absence of disease progression or unacceptable toxicities. Patients whose cancer worsens may cross over to ARM I. Patients also undergo CT scan and collection of blood samples while on study.
61956029|NCT02817308|OTHER|Control|"Patients or healthy volunteers with out a known evidence of malignancy with presumably normal levels of CA19-9 and CEA.~intervention: samples of blood, saliva and urine"
61956030|NCT00746083|EXPERIMENTAL|Intervention group|
61956031|NCT00746083|NO_INTERVENTION|Control group|
61956032|NCT05802511|EXPERIMENTAL|Exablate treatment|Exablate treatment on Neuropathic Pain
62345175|NCT03354702|EXPERIMENTAL|Group aerobic activity (experimental)|Group aerobic exercise (experimental). Patients perform aerobic exercise per 30 minutes (moderate intensity: 70% to 85% of estimated maximum heart rate), more 10 minutes stretching, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions.
62345176|NCT03354702|ACTIVE_COMPARATOR|Group stretching (control)|Group stretching (control). Patients perform stretching per 30 minutes, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions
62345177|NCT03484351|EXPERIMENTAL|Fall Monty Activity Programme (FallMAP)|A multifactorial falls prevention activity programme
62345178|NCT01625312||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
62345179|NCT01625312||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization.
62345180|NCT01625312||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
61956033|NCT01764672|EXPERIMENTAL|Attention Deficit Hyperactivity Disorder|Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
61956034|NCT01764672|EXPERIMENTAL|Healthy adults|Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
61956035|NCT06557655|EXPERIMENTAL|caffeine gum|15 minutes before exercise
61956036|NCT06557655|PLACEBO_COMPARATOR|placebo|15 minutes before exercise
61956037|NCT01919606|EXPERIMENTAL|EXPAREL Group 1|EXPAREL 266 mg diluted with saline to a volume of 40 mL
61956038|NCT01919606|EXPERIMENTAL|EXPAREL Group 2|EXPAREL 266 mg diluted with saline to a volume of 60 mL
62345181|NCT00897325||Ancillary-Correlative (Collecting and banking ALL specimens)|Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
61956039|NCT01056653|EXPERIMENTAL|Group A Teal|Standard Dose - Two intervention home visits (at 4 and 6 months of age)
61956040|NCT01056653|EXPERIMENTAL|Group B Purple|High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
62345182|NCT04096326|PLACEBO_COMPARATOR|Cohort 1: Placebo|Participants received AGN-151586-matching placebo, intramuscular (IM) injections in the glabellar complex on Day 1 in Cohort 1.
62345183|NCT04096326|EXPERIMENTAL|Cohort 1: AGN-151586|Participants received AGN-151586 lowest dose, IM injections in the glabellar complex on Day 1.
62345184|NCT04096326|PLACEBO_COMPARATOR|Cohort 2: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 2.
62345185|NCT04096326|EXPERIMENTAL|Cohort 2: AGN-151586|Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
62345186|NCT04096326|PLACEBO_COMPARATOR|Cohort 3: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 3.
62345187|NCT04096326|EXPERIMENTAL|Cohort 3: AGN-151586|Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
62345188|NCT04096326|PLACEBO_COMPARATOR|Cohort 4: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 4.
62345189|NCT04096326|EXPERIMENTAL|Cohort 4: AGN-151586|Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
62503062|NCT04024319||Local Infiltration Analgesia|Retrospectively, the data of the patients belonging to the control group (LIA) were collected through the electronic file in the SAPP program of the internal network of the Barcelona Clinic Hospital in chronological order until completing 35 cases. To include them in the control group, the patients had to meet the same criteria as those belonging to the intervention group (GNB), therefore, the surgery should have been performed under spinal anesthesia and subsequently followed with an oral analgesia schedule meeting criteria of fast track hospitalization. The same data were obtained as in the GNBG, demographic data (age, sex, weight, height, hematocrit, hemoglobin, ASA), duration of the surgery and ischemia time, PACU VAS, AM VAS, PM VAS and finally some data of the post-operative period (hematocrit, hemoglobin, transfusion, hospital stay)
62503063|NCT06677801|ACTIVE_COMPARATOR|Participant Group|SLE patients treated with Telitacicept
61956041|NCT01056653|SHAM_COMPARATOR|Group C Yellow|Comparison Group - One home visit, information only (at 4 months of age)
61956042|NCT01227759|EXPERIMENTAL|Verum|
61956043|NCT01227759|NO_INTERVENTION|Untreated|
61956044|NCT01227759|PLACEBO_COMPARATOR|Vehicle|
61956045|NCT04688970||Acute stroke with affection of the upper extremity|"* Subject is 18 years or above.~* Subject has an acute stroke affecting one UE (FMA less than 50).~* Subject or caregiver understands the study and its procedures and gives informed consent.~* If the subject is not able to give informed consent:~  * The assumed will of the patient is to be determined by the patient's provision (if existing), the health care proxy (if existing) and/or the moral concepts expressed by the patient to close relatives.~ * The legal representative gives informed consent because participation is the assumed will of the patient as assessed by the aforementioned points."
61956046|NCT01558232|EXPERIMENTAL|Tibion Arm|Arm of the study in which enrolled subacute post-stroke subjects undergo lower extremity physical therapy using the Tibion Bionic Leg.
61956047|NCT03483740|EXPERIMENTAL|Cognitive remediation group therapy|8 weekly 3-hour sessions of CRGT
61956048|NCT03483740|ACTIVE_COMPARATOR|Mutual aid support group|8 weekly 3-hour sessions of HIV group therapy
61956049|NCT01631344|NO_INTERVENTION|Physical Therapy|Conventional Physical Therapy
61956050|NCT01631344|EXPERIMENTAL|Daily physical activity consultation, Using Stage of change|
61956051|NCT01906398|OTHER|Experimental: ketogenic diet|Treatment will consist of KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, \[fat\]: \[protein + carbohydrate\] weight ratio will be increased to 4:1
62503064|NCT02301858|OTHER|Study arm|Genome analysis of tissue samples.
62345190|NCT04096326|PLACEBO_COMPARATOR|Cohort 5: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 5.
61956052|NCT01602159|ACTIVE_COMPARATOR|Open Bypass Surgery|Open Bypass Surgery
62345191|NCT04096326|EXPERIMENTAL|Cohort 5: AGN-151586|Participants received AGN-151586 highest dose, IM injections in the glabellar complex on Day 1.
62345192|NCT02525419|EXPERIMENTAL|Weight Loss Phase|12 week weight loss phase consisting of High Protein - Intermittent Fast-Low Calorie diet in 43 Obese Men and Women
62503065|NCT01908205|EXPERIMENTAL|Intranasal Oxytocin (Syntocinon)|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
61956053|NCT01602159|ACTIVE_COMPARATOR|Angioplasty and Stenting|
61956054|NCT05169385|EXPERIMENTAL|Parent SMART|Parent SMART is a technology-assisted parenting intervention combining an off-the-shelf computer program (Parenting Wisely), up to four telehealth coaching sessions, and access to an app-based networking forum.
61956055|NCT05169385|ACTIVE_COMPARATOR|Treatment as Usual|The active comparator is defined as residential treatment services as usual.
61956056|NCT03129165|EXPERIMENTAL|Screening and prevention of CVD|
61956057|NCT03824314|EXPERIMENTAL|Group M|. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
61956058|NCT03824314|EXPERIMENTAL|group F|"group F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally.~Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position"
61956059|NCT00365508|EXPERIMENTAL|Arm I|Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.
61956060|NCT00365508|EXPERIMENTAL|Arm II|Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).
62345193|NCT02525419|EXPERIMENTAL|Weight Loss Maintenance Phase|52 week weight loss maintenance phase consisting of either High Protein - Intermittent Fast (HP-IF) or Heart Healthy (HH) diet
62345194|NCT03615911|EXPERIMENTAL|Vaccination with 10^7 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10\^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
62345195|NCT03615911|EXPERIMENTAL|Vaccination with 10^8 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10\^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
62345196|NCT06482580|EXPERIMENTAL|PNF exercise group|All groups will be subjected to exercise training for 6 weeks: PNF exercise group will receive 3-dimensional (3D) foot-ankle extension exercise and short-foot exercise. The exercise will be performed 2 days a week under the supervision of a physiotherapist and 1 day as home exercise; KA exercise will be performed daily, 2 days under the supervision of a physiotherapist and the other days as home exercise.
62503066|NCT01908205|PLACEBO_COMPARATOR|Placebo|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
62503067|NCT03498924||CASES|Patients with endometrial cancer
62503068|NCT03498924||CONTROLS|Matched controls without neoplasm disease
62503069|NCT01655251|EXPERIMENTAL|Intervention|Video (DVD) discharge instructions
62503070|NCT01655251|NO_INTERVENTION|Control|
62503071|NCT00873834|EXPERIMENTAL|Fluoxetine arm|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
61956061|NCT05622175|EXPERIMENTAL|Drug: F8IL10|"Overall, 32 patients will participate in case no DLT would occur.~1. In the standard 3+3 dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of F8IL10 (from 0.5 to 10 mg) in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 3 patients with escalating doses of F8IL10 until the MAD is reached and won't exceed 10 mg dose level. In case a DLT would be detected, further 3 patients will be enrolled for that cohort in order to confirm the MAD or to proceed with the next dose level. Therefore, up to 30 patients could be enrolled in the dose escalation part.~2. Following successful identification of the RD, the study will proceed with a dose expansion part and 20 patients will be treated at the RD dose level (patients treated at the RD in the course of the dose escalation phase will contribute to the total sample size)."
61956062|NCT01221792|ACTIVE_COMPARATOR|carvedilol|Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
61956063|NCT01221792|PLACEBO_COMPARATOR|Sugar Pill|Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
61956064|NCT05248048|EXPERIMENTAL|NKG2D CAR-NK|CAR-T infusion
61956065|NCT05487144|EXPERIMENTAL|Treatment|
61956066|NCT04490850|EXPERIMENTAL|Participants|Blood sample
61956067|NCT05663190||1|Less than 10-year-old, with cone beam computed tomography imagess with the mental foramen included in field of vision
61956068|NCT06236672||GLP-1 RA group|adult patients with T2D and CKD who initiated GLP-1 RA therapy
61956069|NCT06236672||basal insulin group|adult patients with T2D and CKD who initiated basal insulin therapy
61956070|NCT01696825|EXPERIMENTAL|Diazepam Tablet, 5 mg, Vaginal|
61956071|NCT01696825|EXPERIMENTAL|Diazepam Suppository, 5 mg, Vaginal|
61956072|NCT01696825|EXPERIMENTAL|Diazepam Cream, 5 mg, Vaginal|
61956073|NCT01696825|ACTIVE_COMPARATOR|Diazepam Tablet, 5 Mg, Oral|
61956074|NCT04945122|EXPERIMENTAL|Pitavastatin|Patients diagnosed AMI with abnormal glucose metabolism use pitavastatin (4mg po Qn) to control cholesterol for 6 months.
61956075|NCT04945122|ACTIVE_COMPARATOR|Atorvastatin|Patients diagnosed AMI with abnormal glucose metabolism use atorvastatin (20mg po Qn) to control cholesterol for 6 months.
61956076|NCT05560477|EXPERIMENTAL|Treated with repair and AM3101|Syringe containing AM3101 for injection.
61956077|NCT05560477|PLACEBO_COMPARATOR|Treated with repair and 0.9% sodium chloride (saline)|Syringe containing commercially available 0.9% sodium chloride for injection.
61956078|NCT01728597||healthy volunteers|MR compliant volunteers with no history of cardiovascular diseases
62345197|NCT06482580|EXPERIMENTAL|Clam exercise group|All groups will be subjected to exercise training for 6 weeks: Clam exercise group will receive mussel exercise and short-foot exercise. The exercise will be performed 2 days a week under the supervision of a physiotherapist and 1 day as home exercise; KA exercise will be performed daily, 2 days under the supervision of a physiotherapist and the other days as home exercise.
62345198|NCT06482580|ACTIVE_COMPARATOR|Control group|All groups will be subjected to exercise training for 6 weeks: Control group will receive only KA exercise and this exercise will be performed daily, 2 days under the supervision of a physiotherapist and the other days as home exercise.
62345199|NCT01240148|EXPERIMENTAL|1|150 μL intradermal injection of 1 μmol/L AZD3161
62345200|NCT01240148|EXPERIMENTAL|2|150 μL intradermal injection of 6 μmol/L AZD3161
62345201|NCT01240148|EXPERIMENTAL|3|150 μL intradermal injection of 30 μmol/L AZD3161
62345202|NCT01240148|ACTIVE_COMPARATOR|4|150 μL intradermal injection of 10 mg/mL Lidocaine
62345203|NCT01240148|PLACEBO_COMPARATOR|5|150 μL intradermal injection of AZD3161 placebo
62345204|NCT01244347|EXPERIMENTAL|folic acid 4 mg|
62503072|NCT00873834|PLACEBO_COMPARATOR|placebo arm|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
62503073|NCT02988271|EXPERIMENTAL|Group I (meditation)|Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
62702191|NCT03895658|EXPERIMENTAL|ECT|ECT treatment, Within subject cross-over
62702192|NCT03895658|EXPERIMENTAL|MRI|Structural and functional neuroimaging pre and post ECT treatment
61956079|NCT02252913|EXPERIMENTAL|Volitinib+docetaxel|"Dose escalation stage: oral administration, Volitinib 600mg/800 QD + docetaxel 75mg/m2.~If the dose of docetaxel 75mg/m2 is not tolerable, docetaxel dose will be reduced to 60mg/m2 while keep volitinib at 600mg QD as the initial dose. Volitinib dose escalation will be re-started and end at the dose of 800mg QD.~Dose expansion Stage:Volitinib with docetaxel. Use the prefer dose from escalation stage"
62345205|NCT01244347|ACTIVE_COMPARATOR|folic acid 0.4 mg|
62345206|NCT03121833|EXPERIMENTAL|Endostar & AIM regimen / GT regimen|Endostar \& AIM regimen / GT regimen; Endostar 15mg, into 500ml 0.9% sodium chloride intravenous infusion of 3 \~ 4h, d1 \~ d14, 21-28 days for a cycle; AIM regimen is Pirarubicin (THP) + Ifosfamide (IFO), the specific dose is IFO 8-12g / m2, given 4-5 days; THP 75mg / m2, given 1-2 days; 21-28 days for a cycle; GT regimen is Docetaxel (TXT) + Gemcitabine (GEM), specific dose of Gemcitabine 1000mg / m2 (D1, D8) and Docetaxel 75mg / m2 (D8); 21-28 days for a cycle; Preferred AIM regimen, AIM regimen chemotherapy failure or can not tolerate anthracycline chemotherapy in patients with GT regimen.
62345207|NCT03121833|PLACEBO_COMPARATOR|Placebo & AIM regimen / GT regimen|Placebo + AIM regimen / GT regimen; Placebo is 500ml 0.9% sodium chloride, Intravenous 3 \~ 4h, d1 \~ d14, 21-28 days for a cycle; The chemotherapy regimen is the same as the experimental group.
62702193|NCT03895658|EXPERIMENTAL|TMS|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
62702194|NCT02211768|EXPERIMENTAL|1/FDG and FLT PET scans|Subjects will undergo FDG-PET and FLT-PET scans at least one day apart
62702195|NCT02211768|OTHER|2/FDG-PET scan|Subjects will undergo FDG-PET scan
61956080|NCT03890445||Adalimumab Biosimilar (Hyrimoz)|Patients with moderate-to-severe CD receiving Hyrimoz™ treatment according to the Hyrimoz™ label at the discretion of the investigator
61956081|NCT03890445||Infliximab Biosimilar (Zessly)|Patients with moderate-to-severe CD receiving Zessly™ treatment according to the Zessly™ label at the discretion of the investigator
61956082|NCT04246450|NO_INTERVENTION|LVEF between 35%-50%, no noninvasive risk factors (NIRFs)|Follow up, no further intervention
62702196|NCT06092333|OTHER|Single arm, open label|open label
62702197|NCT00794352||Healthy Volunteer|Healthy patients with NO inflammatory and/or demyelinating/dysmyelinating diseases of the CN
61956083|NCT04246450|NO_INTERVENTION|LVEF between 35%-50%, NIRFs present, noninducible|Follow up, no further intervention
62345208|NCT06159166|EXPERIMENTAL|Phase 1|"For the Phase 1 portion, treatment will be administered continuously (Dose regimens 1, 2, 4) or intermittently (Dose regimen 3; 3 weeks on/1 week off) in 28-day cycles). All participants will receive study drug until:~1. cessation of study treatment due to death, intolerance, or withdrawal of consent from the study;~2. completion of 24 cycles of treatment (unless the investigator's benefit-risk assessment supports continued treatment);~3. participants enroll in the phase 2a portion of the study;~4. disease progression; or~5. Investigator's decision.~Treatment period ends with the administration of the last dose. The study ends 30 days after the last dose"
62345209|NCT06159166|EXPERIMENTAL|Phase 2|"For the Phase 2 portion, treatment will be administered based on recommended RP2D from Phase 1. All participants will receive study drug until:~1. cessation of study treatment due to death, intolerance, or withdrawal of consent from the study;~2. completion of 24 cycles of treatment (unless the investigator's benefit-risk assessment supports continued treatment;~3. disease progression; or~4. Investigator's decision.~Treatment period ends with the administration of the last dose. The study ends 30 days after the last dose."
62503074|NCT02988271|ACTIVE_COMPARATOR|Group II (waitlist control)|Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
62503075|NCT02304068|OTHER|Intra-vitreal injection|
62503076|NCT06679491|EXPERIMENTAL|N-PF (Natural Cycle - Follicular Phase-Intensified Training)|"Female athletes with natural menstrual cycles who follow a resistance training program with increased intensity during the follicular phase and reduced intensity during the luteal phase. This arm aims to evaluate the impact of follicular-phase-focused training on neuromuscular performance, leveraging the potential effects of elevated estrogen levels during this phase.~Intervention:~Resistance Training Program: 13 weeks, 2 sessions per week, with higher intensity training scheduled during the follicular phase (early and late) and reduced intensity during the luteal phase."
62503077|NCT06679491|EXPERIMENTAL|N-PL (Natural Cycle - Luteal Phase-Intensified Training)|"Description: Female athletes with natural menstrual cycles who undergo a resistance training program with increased intensity during the luteal phase and reduced intensity during the follicular phase. This approach assesses the impact of training when progesterone levels are elevated.~Intervention:~Resistance Training Program: 13 weeks, 2 sessions per week, with higher intensity training during the luteal phase (early and late) and reduced intensity during the follicular phase."
62702198|NCT00794352||Patient Cohort|Patients who present with CNS white matter injury (including inflammatory and/or demyelinating/dysmyelinating diseases of the CNS)
61956084|NCT04246450|ACTIVE_COMPARATOR|LVEF between 35%-50%, NIRFs present, inducible|All patients in this group will receive an ICD
61956085|NCT04246450|SHAM_COMPARATOR|LVEF <35%, no NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF\<35%
61956086|NCT04246450|SHAM_COMPARATOR|LVEF <35%, NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF\<35%
61956087|NCT04246450|SHAM_COMPARATOR|LVEF <35%, NIRFs present, inducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF\<35%
61956088|NCT03704480|EXPERIMENTAL|Amended ARM A|"One cycle equals 4 weeks (D1=D28);~Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.~Tremelimumab: 300 mg by IV infusion on D1 at cycle 1 only."
61956089|NCT06233617|PLACEBO_COMPARATOR|placebo|0.2% ropivacaine for erector spinae plane block
61956090|NCT06233617|ACTIVE_COMPARATOR|Dexamethasone|0.2% ropivacaine + 4mg Dexamethasone for erector spinae plane block
62345210|NCT01906866|ACTIVE_COMPARATOR|Circadin 2/5/10 mg|Active arm
62345211|NCT01906866|PLACEBO_COMPARATOR|Placebo|Placebo arm
62345212|NCT04653142|EXPERIMENTAL|BI 765063 (Part A) and BI 765063 + BI 754091 (Part B)|
62345213|NCT05143762|ACTIVE_COMPARATOR|group (A)|will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day).
62702199|NCT03254914||Control Site|Measure Clinic Blood Pressure
62702200|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
62702201|NCT06247774|EXPERIMENTAL|Cardiac Rehabilitation|Participants will participate in a 12-week cardiac rehabilitation program
62702202|NCT06247774|PLACEBO_COMPARATOR|Attention Control|Participants will not participate in a cardiac rehabilitation program and will receive phone calls in place of cardiac rehabilitation visits.
62702203|NCT03412435||Myocardial infarction|diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
62702204|NCT04172532|EXPERIMENTAL|Phase I (hypofractionated radiation therapy, M3814)|Patients in Phase I undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
62702205|NCT04172532|EXPERIMENTAL|Phase II Group I (hypofractionated radiation therapy M3814)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
61956091|NCT06233617|ACTIVE_COMPARATOR|Dexmedetomidine|0.2% ropivacaine + 50ug Dexmedetomidine for erector spinae plane block
61956092|NCT03368794|EXPERIMENTAL|Intervention|Telephone alert signal from ambulance staff to out-patient substance use disorder treatment facility, for active outreach aiming to locate and include the patient in long-term evidence-based treatment for the substance use disorder.
62503078|NCT06679491|EXPERIMENTAL|N-C (Natural Cycle - Continuous Training)|"Description: Female athletes with natural menstrual cycles who participate in a continuous intensity training program across all phases of the menstrual cycle. This group provides a comparison to determine the effects of a non-phase-specific training protocol on neuromuscular function.~Intervention:~Resistance Training Program: 13 weeks, 2 sessions per week, maintaining a consistent training intensity across both follicular and luteal phases."
62503079|NCT06679491|ACTIVE_COMPARATOR|OCP-C (Oral Contraceptive - Continuous Training, Control Group)|"Description: Female athletes using oral contraceptives, following a continuous intensity training program regardless of menstrual phase. This group serves as a control, providing insight into the neuromuscular effects of training under the hormonal conditions set by oral contraceptive use.~Intervention:~Resistance Training Program: 13 weeks, 2 sessions per week, with continuous intensity across all training sessions due to the stable hormonal environment induced by oral contraceptives."
62503080|NCT00631007|EXPERIMENTAL|INT131 besylate 0.5 mg|INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
62503081|NCT00631007|EXPERIMENTAL|INT131 besylate 1 mg|INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
62503082|NCT00631007|EXPERIMENTAL|INT131 besylate 2 mg|INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
62503083|NCT00631007|EXPERIMENTAL|INT131 besylate 3 mg|INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
62503084|NCT00631007|ACTIVE_COMPARATOR|pioglitazone HCl 45 mg|pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
62503085|NCT00631007|PLACEBO_COMPARATOR|placebo|placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
62702206|NCT04172532|PLACEBO_COMPARATOR|Phase II Group II(hypofractionated radiation therapy, placebo)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
61956093|NCT03368794|ACTIVE_COMPARATOR|Control|Information-only. Ambulance staff hand over written information to the individual about how to seek treatment for the substance use disorder.
61956094|NCT05219305|EXPERIMENTAL|Freeze-Dried Bone Allograft|edentulous site grafted with FDBA in previous study.
61956095|NCT05219305|EXPERIMENTAL|Partially-demineralized tooth graft|edentulous site grafted with partially-demineralized tooth graft in the previous study.
62142465|NCT04236700||beach workers|"Workers must undergo clinical examinations of the upper and lower lips, performed by previously calibrated researchers, through semi-technical inspection and palpation maneuvers, in order to identify injuries. Photo cameras can be used to improve the visibility of the lips using the image enhancement feature, to confirm the diagnosis. The clinical examination will include: dryness, atrophy, scaly lesions, lip swelling, erythema, ulcerations, cloudy demarcations between the vermilion of the lip and skin, demarcated folds along the lip, white spots or plaques, crusts, stained or pale areas.~They should be evaluated with the application of a previously validated questionnaire containing information related to personal data, information on occupation and health was completed according to the responses of the volunteers. The OHIP-14 quality of life questionnaire will be applied together"
62702207|NCT04129450|EXPERIMENTAL|Mindfulness Pain Program + Usual PCP Care|Participants will undergo 8 weekly 90 minute sessions of Mindfulness-Based Stress Reduction in addition to receiving usual PCP care for chronic lower back pain.
62702208|NCT04129450|ACTIVE_COMPARATOR|Usual PCP Care|Participants will receive usual PCP care for chronic lower back pain.
62702209|NCT03534245||1|Healthy children aged 2 - 9 years
62702210|NCT04627285|EXPERIMENTAL|Lacosamide|Subjects in this arm will receive various single doses of lacosamide
62702211|NCT04708470|EXPERIMENTAL|1/Arm 1|Dose escalation/de-escalation of entinostat and dose escalation of PDS01ADC with fixed dose of bintrafusp alfa
61956096|NCT05219305|EXPERIMENTAL|mineralized tooth graft|edentulous site grafted with mineralized tooth graft in the previous study.
61956097|NCT02412618|ACTIVE_COMPARATOR|Mifepristone|Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once
61956098|NCT02412618|PLACEBO_COMPARATOR|Placebo|Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once
62345214|NCT05143762|ACTIVE_COMPARATOR|group (B)|will receive dexamethasone 0.5mg/kg IV.
62702212|NCT04708470|EXPERIMENTAL|2/Arm 2|RP2D of entinostat, PDS01ADC, and bintrafusp alfa
62702213|NCT04708470|EXPERIMENTAL|3/Arm3|Entinostat and PDS01ADC (without bintrafusp alfa)
61956099|NCT05509920|ACTIVE_COMPARATOR|patients with root carious lesions will be treated by SDF varnish|Silver diamine fluoride (SDF) contains high concentrations of silver and fluoride ions, which prevents and arrests root caries, as well as dentin caries in the primary teeth of young children. Unlike other fluoride products that mainly reduce the formation of new carious lesions, 38% SDF is an effective agent that can efficiently arrest the carious process, remineralize the decayed dental tissues, and protect the tooth structure against the for-mation of new caries lesions. The use of SDF can result in more caries-resistant tooth structures.
62702214|NCT06170619||All subjects|
61956100|NCT05509920|EXPERIMENTAL|patients with root carious lesions will be treated by PRG barrier coat.|PRG barrier coat is a Giomer varnish from Shofu. It is a light cured Surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix. It has an immediate and long lasting effect. The (S-PRG) favors the re-lease of fluoride ions and its recharging that aid in remineraliza-tion and protection of the tooth structure in a way similar to the glass ionomer. The fluoride ions aid in the neutralization of the acidity of the oral cavity and decrease the plaque accumulation
61956101|NCT05442814|ACTIVE_COMPARATOR|Posterior suprascapular block|Suprascapular block performed by posterior approach
61956102|NCT05442814|ACTIVE_COMPARATOR|Anterior suprascapular block|Suprascapular block performed by anterior approach
61956103|NCT03265769|ACTIVE_COMPARATOR|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
62503086|NCT05155579|EXPERIMENTAL|Groups 1a, 2a and 3a|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a two vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1a is 20 children aged 5-11 months, group 2a is 20 children aged 12-23 months, and group 3a is 20 children aged 24-36 months.
62503087|NCT05155579|EXPERIMENTAL|Group 1b, 2b and 3b|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a single vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1b is 20 children aged 5-11 months, group 2b is 20 children aged 12-23 months, and group 3b is 20 children aged 24-36 months.
61956104|NCT03265769|ACTIVE_COMPARATOR|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
61956105|NCT05673889|EXPERIMENTAL|Dabigatran etexilate with and without ARV-471|Dabigatran etexilate administered as a single dose in Period 1 and Period 2. ARV-471 administered as a single dose in Period 2.
61956106|NCT03589560|EXPERIMENTAL|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
61956107|NCT03589560|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
61956108|NCT04329897|EXPERIMENTAL|Software Messaging|Acceptance and Commitment Therapy Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy
61956109|NCT04329897|NO_INTERVENTION|Control|Subjects randomizing into this arm did not receive the text message study intervention.
61956110|NCT01101880|EXPERIMENTAL|Treatment (chemotherapy and colony stimulating factor)|"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.~CONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.~Treatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity."
62702215|NCT04079712|EXPERIMENTAL|Treatment (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
61956111|NCT01552941|EXPERIMENTAL|Vagal Nerve Stimulation|
61956112|NCT03334539|EXPERIMENTAL|0.10% HL036 Ophthalmic Solution|Participants self-administered HL036 0.10 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
62702216|NCT04902443|EXPERIMENTAL|1/Dose De-Escalation|Treatment with pomalidomide at de-escalating doses if necessary and nivolumab at a fixed dose
62702217|NCT04902443|EXPERIMENTAL|2/Dose Expansion|Nivolumab + pomalidomide (at optimal dose determined in dose escalation portion of the study) for up to 30 participants
62142466|NCT04720612|EXPERIMENTAL|Omalizumab|Participants in this arm will receive the study drug, omalizumab.
62142467|NCT04720612|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive a placebo treatment.
62142468|NCT00087022|EXPERIMENTAL|Arm I|Patients receive monoclonal chimeric antibody cG250 (synonym names: Rencarex®, girentuximab, and WX-G250) IV over 15 minutes once weekly for 24 weeks.
62345215|NCT05143762|PLACEBO_COMPARATOR|group(C)|will received placebo 10 ml normal saline IV.
62142469|NCT00087022|PLACEBO_COMPARATOR|Arm II|Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
62142470|NCT03764020|EXPERIMENTAL|Melatonin|"Intervention group1:~Melatonin,capsule,3 mg, one dose one hour before bedtime, three weeks"
62345216|NCT05426369|EXPERIMENTAL|Dose Escalation|For single dose escalation, the dose level will be 2µg/kg -15 µg/kg.
62345217|NCT05426369|EXPERIMENTAL|Dose Expansion - Group A|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered once weekly (group A) for a treatment cycle(21 days).
62345218|NCT05426369|EXPERIMENTAL|Dose Expansion - Group B|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered once weekly ( group B )for a treatment cycle(21 days).
62345219|NCT05426369|EXPERIMENTAL|Dose Expansion - Group C|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered twice weekly (C group) for a treatment cycle(21 days).
61956113|NCT03334539|EXPERIMENTAL|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
61956114|NCT03334539|PLACEBO_COMPARATOR|Placebo|Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
61956115|NCT06468332||Group A|very-low aggressiveness, 20% of participants
61956116|NCT06468332||Group B|low aggressiveness, 20% of participants
61956117|NCT06468332||Group C|intermediate aggressiveness, 20% of participants
61956118|NCT06468332||Group D|high aggressiveness, 30% of participants
61956119|NCT06468332||Group E|high aggressiveness, 10% of participants
61956120|NCT01954719|EXPERIMENTAL|cervix dilated after surgery|Digital cervical dilatation performed by surgeon
61956121|NCT01954719|NO_INTERVENTION|control group|cervix not dilated after surgery
62503088|NCT05155579|EXPERIMENTAL|Group 4a|150 participants, aged 6-7 months at the time of randomisation (to ensure third vaccination is given at approximately 9 months), who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart. At the time of the third dose they will receive their measles-rubella and yellow fever vaccinations at the same time as R21/Matrix-M.
62142471|NCT03764020|PLACEBO_COMPARATOR|Placebo|"Intervention group2 :~Placebo, capsule, 3 mg, one dose one hour before bedtime, for three weeks"
62142472|NCT05121142|NO_INTERVENTION|Arm 1: Existing patients with chronic GVHD|Participants with established diagnosis of chronic GVHD and currently on treatment with ruxolitinib for chronic GVHD for at least 3 weeks. Participants in this arm are receiving ruxolitinib clinically and will not receive ruxolitinib as part of this research study.
62702218|NCT04268277|EXPERIMENTAL|Rituximab & Pembrolizumab|"Cycle 1 (21 days cycle):~Rituximab: 375 mg/m2 day 1, 8, 15 Pembrolizumab: 200 mg IV fixed dose day 2~Cycle 2-18 (21 days cycle) or until progression or non-tolerable toxicity:~Rituximab: 375 mg/m2 day 1 every second cycle Pembrolizumab: 200 mg IV fixed dose day 1"
61956122|NCT05374369||Subjects with positive SDC2 Gene Methylation Test|"Subjects must meet both of the following criteria to be eligible for the study:~1. Subjects with positive SDC2 Gene Methylation Test;~2. Subjects with colonoscopy results and/or pathological results."
61956123|NCT05374369||Subjects with positive Q-FIT Test|"Subjects must meet both of the following criteria to be eligible for the study:~1. Subjects with positive Q-FIT Test;~2. Subjects with colonoscopy results and/or pathological results."
61956124|NCT05374369||Subjects with positive SDC2 Gene Methylation Test and Q-FIT Test|"Subjects must meet both of the following criteria to be eligible for the study:~1. Subjects with positive SDC2 Gene Methylation Test and Q-FIT Test;~2. Subjects with colonoscopy results and/or pathological results."
61956125|NCT03993795|EXPERIMENTAL|A19010-W, B19010-F Use Group|Use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
61956126|NCT03993795|EXPERIMENTAL|B19010-F, A19010-W Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
62142473|NCT05121142|EXPERIMENTAL|Arm 2: Acute GVHD ages 0-<12 years|Participants with acute GVHD will receive ruxolitinib on this arm.
62345220|NCT01747785||Healthy controls|Individuals without history of cardiovascular disease and at least 18 years of age will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 3 visits over a 12 week period.
62345221|NCT01747785||Patients at risk of heart failure|Individuals at risk of heart failure and a preserved ejection fraction of at least 50% will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a baseline cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 6 visits over a 12 week period. A cardiac rehabilitation exercise program will also occur over 12 weeks.
62503089|NCT05155579|ACTIVE_COMPARATOR|Group 4b|150 participants, aged 6-7 months at the time of randomisation, who will receive a measles-rubella and yellow fever vaccination 2 months after randomisation.
62503090|NCT05155579|EXPERIMENTAL|Group 4c|Group 4c is 50 participants, aged 6-7 months at the time of randomisation, who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart.
62702219|NCT05887908|EXPERIMENTAL|co-administration of cefepime and nacubactam|co-administration of 2 g cefepime and 1 g nacubactam q8h (60 min. infusion)
62702220|NCT05887908|EXPERIMENTAL|co-administration of aztreonam and nacubactam|co-administration of 2 g aztreonam and 1 g nacubactam q8h (60 min. infusion)
61956127|NCT04399317|EXPERIMENTAL|Group A|This is the treatment group. Patients will be ventilated using the new device (Evone) applying flow controlled ventilation for 48 hours. Ventilation parameters will be assessed every 6-8 hours. All other treatment will be unchanged and according to institutional standards.
61956128|NCT04399317|NO_INTERVENTION|Group B|These patients will be treated according to institutional standards. Only data will be collected. This is the control group.
61956129|NCT02543437|OTHER|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
62702221|NCT05887908|ACTIVE_COMPARATOR|imipenem/cilastatin|combination of 1 g imipenem/1 g cilastatin q8h (60 min. infusion)
61956130|NCT02154776|EXPERIMENTAL|LEE011 + buparlisib + letrozole|open label, dose escalation evaluating max tolerated dose of the triple combination
61956131|NCT03804697|EXPERIMENTAL|selective anticoagulation group|"Selective anticoagulation group used anticoagulant when thromboelastogram（TEG） indicated hypercoagulability.~TEG was performed 1 day before the surgery, 1 day after the surgery, 3 days after the surgery, and 5 days after the surgery.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
61956132|NCT03804697|ACTIVE_COMPARATOR|conventional anticoagulation group|"The Intervention for conventional anticoagulation group was using anticoagulant until one month after surgery routinely.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
62142474|NCT05121142|EXPERIMENTAL|Arm 3: New onset chronic GVHD ages 0-≤18 years|Participants with new onset chronic GVHD will receive ruxolitinib on this arm.
62702222|NCT03739814|EXPERIMENTAL|Cohort 1 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description
61956133|NCT05112471|EXPERIMENTAL|Guided Biofilm Therapy|Airflow with erythritol powder to remove supra and sub gingival biofilm and plaque, perioflow with erythritol powder at deep pathological pockets (PPD \> 4mm) and ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus.
61956134|NCT05112471|ACTIVE_COMPARATOR|Scaling and Root Planning - Ultrasonic Debridement|Ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus, manual debridement with curettes at deep pathological pockets (PPD \> 4mm) and rubber cup with polishing to remove supra gingival biofilm and plaque.
61956135|NCT00970372||Involuntary patients|Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
62503091|NCT05155579|EXPERIMENTAL|Group 5a|30 children who will receive 3 doses of 5µg R21/50µg Matrix-M, pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
62702223|NCT03739814|EXPERIMENTAL|Cohort 2 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description.
61956136|NCT00970372||Voluntary patients|Voluntary patients on the same wards. Most patients have dual-diagnosis.
61956137|NCT03591991|ACTIVE_COMPARATOR|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
61956138|NCT03591991|PLACEBO_COMPARATOR|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
61956139|NCT02753868|EXPERIMENTAL|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
61956140|NCT02753868|EXPERIMENTAL|Hemodialysis with Exercise (1-st hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
62142475|NCT02579915|EXPERIMENTAL|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
62142476|NCT02579915|ACTIVE_COMPARATOR|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
62142477|NCT02959385|EXPERIMENTAL|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
62142478|NCT02959385|ACTIVE_COMPARATOR|Neoadjuvant Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
62142479|NCT01530334|EXPERIMENTAL|open label single arm with Gefitinib 250MG once daily|Gefitinib 250 mg/day open label until progression disease / toxicity / consent withdrawal
62142480|NCT05957510|EXPERIMENTAL|Cohort 1|Patients who met the inclusion criteria, did not meet the exclusion criteria, and agreed to accept the treatment plan of this study will undertake a combination chemotherapy regimen, comprised of serplulimab (300mg), etoposide (100 mg/m2), and carboplatin (AUC 5 mg/mL/min, up to 750mg). These agents will be administered intravenously in 3-week intervals over a span of 4 to 6 cycles.
62142481|NCT05957510|EXPERIMENTAL|Cohort 2|Patients who met the specific inclusion criteria, did not meet the specific exclusion criteria, and agreed to accept the treatment of this study will undertake the same treatment as cohort 1 in the form of ' compassionate use '.
62142482|NCT05957510|EXPERIMENTAL|Cohort 3|Patients with treatment contraindications or unwillingness to accept the treatment of this study will be treated with the clinical routine treatment recommended by the investigator.
62503092|NCT05155579|ACTIVE_COMPARATOR|Group 5b|30 children who will receive 3 doses of pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
62702224|NCT00042614||Controls|Matched to patients for age, gender and race
62142483|NCT05193799|EXPERIMENTAL|Investigational device#1 = Kolmi® Op-AirTM KALM|
62503093|NCT05155579|EXPERIMENTAL|Group 6a|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 6 months after the first dose.
62702225|NCT00042614||Patients|Who have had heart transplants, awaiting, or controls screened.
62702226|NCT01087294|EXPERIMENTAL|1A/T cell Arm (closed)|Dose escalation of CAR+ T cells based on the patients actual body-weight
62702227|NCT01087294|EXPERIMENTAL|1B/T memory stem cell arm|Dose Escalation with 5 dose levels of CAR+ T memory cells based on the patients actual body-weight
62702228|NCT01087294|OTHER|2/Donor arm|Leukapheresis
61956141|NCT02753868|EXPERIMENTAL|Hemodialysis with Exercise (3-rd hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment
61956142|NCT05581628||Celiac Patients Group|Patients previously diagnosed with celiac disease by the gastroenterology clinic.
61956143|NCT02320383|EXPERIMENTAL|B + GA101|"Induction:~Bendamustine + GA101; a maximum of 6 cycles of BG will be administered; each cycle with a duration of 28 days~Maintenance:~GA101 i.v. 1000 mg (flat dose): every 84 days starting on final restaging continued until progression or to a maximum of 2 years"
62142484|NCT05193799|EXPERIMENTAL|Investigational device#2 = Kolmi® Op-Air OneTM|
61956144|NCT03713359|ACTIVE_COMPARATOR|Trial arm (MRVAC)|"Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components:~Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection"
61956145|NCT03713359|ACTIVE_COMPARATOR|Control arm|"Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm.~Subcutaneous injection"
61956146|NCT01377883|SHAM_COMPARATOR|Standard intervention|"Preparation and information: the doctor and nurse explained the steps of the procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Memory change and positive reinforcement: medical staff present spoke to the child positively and offered prizes, among which the child could choose.~Volunteer attendance: as part of the control session, receiving no particular instructions in relation to the child's potential pain during the procedure."
62142485|NCT05193799|EXPERIMENTAL|Investigatonal device#3 = Kolmi® Op Air-Pro® Oxygen|
62345222|NCT02503774|EXPERIMENTAL|Dose-escalation: Oleclumab Dose 1|Participants will receive oleclumab Dose 1 intravenously (IV) every two weeks (Q2W) until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345223|NCT02503774|EXPERIMENTAL|Dose-escalation: Oleclumab Dose 2|Participants will receive oleclumab Dose 2 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345224|NCT02503774|EXPERIMENTAL|Dose-escalation: Oleclumab Dose 3|Participants will receive oleclumab Dose 3 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62503094|NCT05155579|EXPERIMENTAL|Group 6b|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 12 months after the first dose.
62345225|NCT02503774|EXPERIMENTAL|Dose-escalation: Oleclumab Dose 4|Participants will receive oleclumab Dose 4 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345226|NCT02503774|EXPERIMENTAL|Dose-escalation: Oleclumab Dose 1 + Durvalumab Dose 1|Participants will receive oleclumab Dose 1 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345227|NCT02503774|EXPERIMENTAL|Dose-escalation: Oleclumab Dose 2 + Durvalumab Dose 1|Participants will receive oleclumab Dose 2 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345228|NCT02503774|EXPERIMENTAL|Dose-escalation: OleclumabDose 3 + Durvalumab Dose 1|Participants will receive oleclumab Dose 3 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345229|NCT02503774|EXPERIMENTAL|Dose-escalation: OleclumabDose 4 + Durvalumab Dose 1|Participants will receive oleclumab Dose 4 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345230|NCT02503774|EXPERIMENTAL|Dose-expansion (CRC): Oleclumab Dose 4 + Durvalumab Dose 1|Participants with previously treated microsatellite stable-colorectal cancer (MSS-CRC) will receive oleclumab Dose 4 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345231|NCT02503774|EXPERIMENTAL|Dose-expansion (Pancreatic adenocarcinoma): Oleclumab Dose 4+ Durvalumab Dose 1|Participants with previously treated pancreatic adenocarcinoma will receive oleclumab Dose 4 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62503095|NCT05108376|EXPERIMENTAL|Intervention Arm|The Visensia Safety Index (VSI) will be used to alert RACE staff of patient deterioration.
62503096|NCT06147414||pregnant women undergoing invasive PND in a context of family history of SGD|SGD-NIPD will be proposed by CPDPN recruitment centres to pregnant women undergoing invasive PND in a context of family history of SGD because of parental pathogenic mutation.s in one of the following gene: HBB, CFTR, FMR1, SMN1, DMPK, DMD, NF1, HTT, F8, F9, GCK, L1CAM, PKHD1 or ATP7A
62503097|NCT06147414||pregnant women undergoing prenatal counselling in a context of maternal history of diabetes MODY-GCK|
62503098|NCT00878787|EXPERIMENTAL|Theta-burst Trancranial Magnetic Stim|
62702229|NCT06749080|ACTIVE_COMPARATOR|Intervention group - ASSIST intervention groups Uppsala/Stockholm|All staff in the intervention group will recieve an on-line reablement education. The occupational and physcial therapist in the intervention group will provide mentoring including reflection for the homecare staff. Together the team will focus on the older persons everyday occuations and deliver reablement to the older persons.
62702230|NCT06749080|NO_INTERVENTION|Control group Uppsala/Stockholm|The older person will recieve home care as usual without a reablement education or support from occupational or physical therapists.
61956147|NCT01377883|EXPERIMENTAL|clown care|Cognitive coping: encouraging a child to cope with the challenge. Imagery: a cognitive technique used to encourage the child to cope with the pain and distress of the procedure by imagining a pleasant object or experience Empowerment: the child is made to feel empowered by controlling the actions of the clown Reflecting emotions: the clown, sensing the state of the child, plays it out in an exaggerated fashion.
61956148|NCT00518284|NO_INTERVENTION|No Drug Treatment Control|Following revascularization, participants did not receive any study drug treatment.
62142486|NCT00678925|ACTIVE_COMPARATOR|1|Choline supplement given from 18-weeks pregnancy through 90 days postpartum
62142487|NCT00678925|PLACEBO_COMPARATOR|2|Placebo capsules given from 18 weeks pregnancy through 90 days postpartum
61956149|NCT00518284|EXPERIMENTAL|Proximal to Lesion + IV|Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m\^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m\^2 at 7 days.
61956150|NCT00518284|EXPERIMENTAL|During Flow Arrest|Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m\^2 nanoparticle paclitaxel immediately following revascularization.
62702231|NCT03974854|EXPERIMENTAL|Arm A: XELOXIRI-3|capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days
61956151|NCT00518284|EXPERIMENTAL|During Flow Arrest + IV|Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m\^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m\^2 at 7 days.
61956152|NCT01670240|ACTIVE_COMPARATOR|Adalimumab|Every second week, mg: 160-80-40-40-40-40 12 weeks in all
61956153|NCT01670240|PLACEBO_COMPARATOR|Placebo|Given as the active comparator, every second week
62345232|NCT02503774|EXPERIMENTAL|Dose-expansion (NSCLC): Oleclumab Dose 4 + Durvalumab Dose 1|Participants with previously treated EGFRm NSCLC will receive oleclumab Dose 4 IV followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
62345233|NCT05751486|EXPERIMENTAL|JS001sc Q3W|
62345234|NCT05751486|EXPERIMENTAL|JS001sc long period|
62345235|NCT05751486|EXPERIMENTAL|JS001 IV (if applicable)|the Safety Monitor Committe (SMC) will discuss whether to conduct an IV cohort and determine the dose/frequency of the IV cohort, based on the initial safety and clinical pharmacological data of triprilimab injection in combination with the GP regimen;
62702232|NCT03974854|ACTIVE_COMPARATOR|Arm B: Gemcitabine|1000 mg / m2 on D1, D8 and D15, every 28 days
62345236|NCT05751486|EXPERIMENTAL|Additional cohort (if applicable)|The exploration of additional dosing/frequency will be discussed by the SMC based on prior safety and clinical pharmacological data
62345237|NCT03341923|OTHER|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
62702233|NCT06063967|EXPERIMENTAL|Period A: Risankizumab Dose A|Participants randomized to receive risankizumab Dose A administered by subcutaneous (SC) injection for up to 12 weeks during Period A.
61956154|NCT01511198|EXPERIMENTAL|0.045 mg|
61956155|NCT01511198|EXPERIMENTAL|0.225 mg|
61956156|NCT01511198|EXPERIMENTAL|0.45 mg|
61956157|NCT01511198|EXPERIMENTAL|0.60 mg|
61956158|NCT01511198|EXPERIMENTAL|0.75 mg|
61956159|NCT01511198|ACTIVE_COMPARATOR|Met|
61956160|NCT03964623||smokers|
61956161|NCT03964623||vapers|
61956162|NCT03964623||non smokers/non vapers|
61956163|NCT00285805|OTHER|Rosiglitazone-placebo|
61956164|NCT00285805|OTHER|placebo-rosiglitazone|
61956165|NCT00635167|EXPERIMENTAL|Contrast Enhanced Transrectal Ultrasound (TRUS)|
61956166|NCT02955160|EXPERIMENTAL|Multivalent|Pneumococcal conjugate vaccine
61956167|NCT02955160|ACTIVE_COMPARATOR|Tdap|Tetanus, diphtheria, and pertussis vaccine
61956168|NCT01929343|EXPERIMENTAL|lidocaine following cue-induced craving|Lidocaine will be administered immediately following craving induction. Lidocaine will administered at a loading dose of 2mg/kg(milligrams per kilogram) initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
61956169|NCT01929343|ACTIVE_COMPARATOR|lidocaine following neutral stimulus|Lidocaine will be administered immediately following neutral stimulus. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
61956170|NCT01929343|PLACEBO_COMPARATOR|saline|Saline will be administered at same volume of lidocaine in active arms.
61956171|NCT02895230||Men with prostate cancer with androgen-deprivation therapy|Using the French Health Reimbursement Agency database and French hospital discharge database, the investigators will identify all men with prostate cancer who had either, at least one dispensation in a 1.5-year period (1st July 2010 to 31st December 2011) of an androgen-deprivation therapy or a hospitalization for orchiectomy. The French Health Insurance System covers the entire French population (65.3 million inhabitants in 2012).
62142488|NCT00570388|ACTIVE_COMPARATOR|2|Subjects in the active Prometa group will receive flumazenil, gabapentin, and hydroxyzine per the Prometa Protocol.
62345238|NCT03341923|OTHER|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
62503099|NCT06617754||Patients from Danish registry of global airways|Patients included in the Danish Global Airways Registry
62702234|NCT06063967|PLACEBO_COMPARATOR|Period A: Placebo|Participants randomized to receive placebo for risankizumab administered by Subcutaneous (SC) injection for up to 12 weeks during Period A.
62702235|NCT06063967|EXPERIMENTAL|Period B: Risankizumab Dose B|Participants randomized to receive risankizumab Dose A in Period A that achieved adequate response to receive risankizumab Dose B administered by subcutaneous (SC) injection for up to 12 weeks.
62702236|NCT06063967|PLACEBO_COMPARATOR|Period B: Placebo|Participants randomized to receive placebo risankizumab in Period A that achieved adequate response to continue to receive placebo for risankizumab administered by Subcutaneous (SC) injection for up to 12 weeks in Period B.
61956172|NCT01742702||DYNAMIC (ongoing)|Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
61956173|NCT01742702||AERO-DYNAMIC (recordings completed)|Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.
61956174|NCT01742702||Liquorice (recordings completed)|Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.
61956175|NCT01742702||Milk polypeptides (recordings completed)|Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.
62345239|NCT02895776||General Sedation|Case patients: Endovascular Acute Stroke Therapy scheduled to be performed under local sedation and finally performed under General anesthesia
62702237|NCT06063967|EXPERIMENTAL|Period B: Risankizumab Dose C|Participants with inadequate response in Period A to receive Dose C administered by Subcutaneous (SC) injection for up to 12 weeks during Period B.
62702238|NCT06063967|EXPERIMENTAL|Period C: Open-Label Risankizumab Dose D|Participants who complete the Period B Week 24 visit to receive open-label risankizumab Dose D administered by subcutaneous (SC) injection for up to 52 weeks during Period C.
62702239|NCT02788227|EXPERIMENTAL|Boosted Group|Group randomized at Month 18 to receive booster vaccination
62345240|NCT02895776||local sedation|Control patients: Endovascular Acute Stroke Therapy scheduled to be performed, and actually performed under conscious Sedation
62345241|NCT04566822|EXPERIMENTAL|High-touch intervention|"* 6 live video coaching sessions~* Coaching/feedback is tailored to the individual and adaptive to their progress~* Member can send the Coach messages between sessions, but the Coach will not respond until the live session"
62345242|NCT04566822|EXPERIMENTAL|medium-touch intervention|"* 3 live video coaching sessions~* 2 live videos are optional (recommended for end of Weeks 3 and 5, but member can take advantage of them anytime)~* 2-4 pre-recorded video sessions at end of the week. Pre-recorded videos provided in the absence of live sessions~* Chat messaging between sessions with 24-48 hour response time"
62345243|NCT04566822|EXPERIMENTAL|low-touch intervention|"* 1 Live video coaching session (week 1)~* Chat messaging with 24-48 hour response time"
62345244|NCT04566822|SHAM_COMPARATOR|Sleep education control|"* Weekly sleep education for six weeks~* No interaction with coach"
62345245|NCT00506948|EXPERIMENTAL|Thymoglobulin + Sirolimus + MMF|Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.
62345246|NCT00228670||IPF-Clinic|Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
62345247|NCT00228670||Controls - Clinic|Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
62345248|NCT00228670||IPF-Transplant|IPF patient undergoing lung transplant
62345249|NCT00228670||Controls-Transplant|Lung tissue from organ donor
62345250|NCT03604510|EXPERIMENTAL|Electroencephalographic recordings|Electroencephalographic recordings
62702240|NCT02788227|EXPERIMENTAL|Non-boosted Group|Group randomized to 'no booster' at Month 18
62702241|NCT00001406||1|Volunteers with elevated eosinophil counts in the peripheral blood or tissues; or a relative of a volunteer with eosinophilia
62702242|NCT06751277|EXPERIMENTAL|Experimental|QL1706（iparomlimab and tuvonralimab a bifunctional MabPair® product of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies） plus carboplatin and paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706 until disease progression, development of unacceptable toxicity, lack of benefit as judged by the investigator, withdrawal of consent, completion of 2 years of QL1706 treatment, or other reasons specified in the protocol.
62345251|NCT01120379||XV-LTF cohort|
62702243|NCT06750198|EXPERIMENTAL|Hip focused exercises|will receive hip focused exercises and standard rehabilitation protocol with the frequency of 2 sets and 10 repetitions thrice per week for a total of 12 weeks. Pre and post intervention values will be taken on 1st day and after 12 weeks.
62702244|NCT06750198|ACTIVE_COMPARATOR|Standerd rehab protocol|will receive only standard rehabilitation protocol with the frequency of 2 sets and 10 repetitions thrice per week for a total of 12 weeks. Pre and post intervention values will be taken on 1st day and after 12 weeks
61956176|NCT01742702||Bisoprolol (recordings completed)|Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.
62142489|NCT00570388|PLACEBO_COMPARATOR|1|"Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine"
62345252|NCT06106646||Offspring of smokers who received Vitamin C|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo.
62345253|NCT06106646||Offspring of smokers who received Placebo|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo.
62345254|NCT06106646||Offspring of non-smokers|
62345255|NCT04362449|EXPERIMENTAL|Shortened hydration time with dispensary of Akynzeo|ABC-02 regime - gemcitabine and cisplatin with a shortened hydration time and administration of a newer antiemetic
62345256|NCT04362449|ACTIVE_COMPARATOR|Standard of care|ABC-02 regime - gemcitabine and cisplatin with currently approved hydration time and administration of the current choice of antiemetic
62345257|NCT01405118|EXPERIMENTAL|Metformin/CP-690,550|
62345258|NCT06113497|NO_INTERVENTION|Group 1|The group that received normal saline 40ml injection into the deep fascia and muscular layer during wound closure.
62345259|NCT06113497|EXPERIMENTAL|Group 2|The group that received cocktail therapy injection into the deep fascia and muscular layer during wound closure.
61956177|NCT01742702||Aortic stenosis (ongoing)|Subjects with aortic stenosis confirmed by echocardiography
62345260|NCT04095754|OTHER|Group I (control group)|Patients will be positioned supine.
62345261|NCT04095754|EXPERIMENTAL|Group II|patients will be positioned 10° anti-trendelenburg position.
62345262|NCT04095754|EXPERIMENTAL|Group III|patients will be positioned 20° anti-trendelenburg position.
62345263|NCT01480492|NO_INTERVENTION|therapy|
62345264|NCT05237180|EXPERIMENTAL|patient group|8 training sessions on spatial localisation
62345265|NCT05237180|NO_INTERVENTION|control croup|Non training sessions
62702245|NCT06750354|EXPERIMENTAL|Study group|will receive papworth technique and aerobic training programme in addition to medical treatment 3 sessions per week for 12 weeks.
61956178|NCT01742702||Methodological (recordings completed)|35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner
62345266|NCT02877355|EXPERIMENTAL|Semaglutide|
62345267|NCT02461836|EXPERIMENTAL|Chemo|adjuvant chemotherapy using Gemcitabine for 6 rounds
62345268|NCT02461836|EXPERIMENTAL|Chemo+SBRT|SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
62345269|NCT05391568|EXPERIMENTAL|Dry Needling|One single session of DN
62503100|NCT06617754||Patients from the Belgian registry of global airways|Patients included in the Belgian Global Airways Registry
62702246|NCT06750354|ACTIVE_COMPARATOR|Control group|aerobic training programme only in addition to medical treatment3 sessions per week for 12 weeks
61956179|NCT01742702||Participants of Ironman Triathlon|Altogether 80 athletes participating in a full length Ironman competition. Non-invasive recordingds are performed under normal conditions during the training period and after completion of a full-length Ironman competition.
61956180|NCT06317207||observation group|patients who underwent reoperation for locally rRCC after pNSS
61956181|NCT04958135|EXPERIMENTAL|Sequence 1: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fasted conditions.~Period 2: Acoramidis as an immediate-release tablet under fed conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
61956182|NCT04958135|EXPERIMENTAL|Sequence 2: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fed conditions.~Period 2: Acoramidis as an immediate-release tablet under fasted conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
62142490|NCT05822752|ACTIVE_COMPARATOR|Arm 1: Lenvatinib or Sorafenib|Participants will receive Lenvatinib or or Sorafenib, as part of an approximately 2 year treatment period.
62345270|NCT05391568|SHAM_COMPARATOR|Sham Dry Needling|One single session of Sham DN
62345271|NCT02092441|ACTIVE_COMPARATOR|Alcohol prep pad group|isopropyl alcohol prep pad
62345272|NCT02092441|PLACEBO_COMPARATOR|Normal Saline prep pad|normal saline prep pad
62345273|NCT04474119|EXPERIMENTAL|Experimental arm|KN046 plus Carboplatin and Paclitaxel
62345274|NCT04474119|PLACEBO_COMPARATOR|Control arm|Placebo plus Carboplatin and Paclitaxel
62345275|NCT05412537|ACTIVE_COMPARATOR|CAU|"A sickness funds provides a physician or paramedic's consultation with people on work disability 3 to 6 months after the onset of the sickness period. The goal of this conversation is (1) to gather information on the reason of work disability, (2) gather information of the treatment plan and (3) to encourage people to RTW.~CAU stands for consult as usual"
62345276|NCT05412537|EXPERIMENTAL|Motivational Interviewing|Motivational Interviewing involves a conversation about behavioral change in terms of recovery or RTW. The role of the MI practitioner is to evoke change talk. By change talk, the patient expresses a desire, a reason, an ability or a need for change. It is of importance that patients themselves generate the motivation for change, and it is the practitioner's task to assist them in making informed and contemplated choices to act. The core idea is that people have to become motivated themselves to change such that the new behavior is something that they want instead of something that someone else wants. There are 4 processes: engaging, focusing, evoking and planning. Training in MI for health care professionals typically is provided in 1- to 3-day workshops. This is consistent with the 2-day training in the current research. MI was planned 3 to 6 months after the onset of work disability.
62345277|NCT05261880|EXPERIMENTAL|Neural mobilization|Neural mobilization will be given for 15 minutes with 3 repetitions. After mobilization, Kinesio taping will be applied and it will bandage till the next session.
62345278|NCT05261880|EXPERIMENTAL|Scaphoid, hamate mobilization|Scaphoid and hamate mobilization for 20 minutes, at the end of session kinesio taping will bandage till the next session.
62345279|NCT03043729|ACTIVE_COMPARATOR|Arm A|6 cycles chemotherapy with Oxaliplatin 85 mg/m\^2 and Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
62345280|NCT03043729|EXPERIMENTAL|Arm B|6 cycles chemotherapy with Oxaliplatin 85 mg/m\^2 and Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
62345281|NCT05338281|EXPERIMENTAL|Negative Pressure Wound Therapy|This group will receive the usual care of the abdominal donor wound following DIEP flap-based breast reconstruction surgery, AND the negative pressure wound therapy. The Prevena™ Incision Management System will be placed at the abdominal flap donor site after incision is closed. The Prevena™ will remain for up to 5 days, or until patient is discharged from the hospital.
62345282|NCT05338281|ACTIVE_COMPARATOR|Standard Dressing|This group will receive the usual care of the abdominal donor wound following DIEP flap-based breast reconstruction surgery, and standard dressing which will be composed of gauze, secured with paper tape.
62345283|NCT01904734|ACTIVE_COMPARATOR|No previous male hormone treatment|Clomiphene
62345284|NCT01904734|ACTIVE_COMPARATOR|Previously treated with testosterone|Clomiphene
62345285|NCT00720421|OTHER|1|AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy
62503101|NCT06617754||Patients from the Netherlands registry of global airways|Patients included in the Netherlands registry of global airways
62503102|NCT06617754||Patients from the German registry of global airways|Patients included in the German registry of global airways
62503103|NCT06617754||Patients from the Swiss registry of global airways|Patients included in the Swiss registry of global airways
62503104|NCT06617754||Patients from the Italian registry of global airways|Patients included in the Italian registry of global airways
62702247|NCT06750861|EXPERIMENTAL|QL1706+AG|"QL1706+AG~Every 3 weeks as a cycle:~QL1706: 5mg/kg, IV, D3; Q3W Nab-paclitaxel: 125mg/m2, IV，D1、8; Q3W Gemcitabine: 1000mg/m2，IV，D1、8; Q3W Re-evaluate patients every two cycles. If the patient has been treated for more than 8 cycles, they will enter maintenance therapy, and the regimen is QL1706 monotherapy."
62702248|NCT06750211|ACTIVE_COMPARATOR|METs|Hot pack along with Neck isometrics and muscle energy technique protocol
62142491|NCT05822752|EXPERIMENTAL|Arm 2: Livmoniplimab Dose A + Budigalimab|Participants will receive Livmoniplimab Dose A in combination with budigalimab, as part of an approximately 2 year treatment period.
62142492|NCT05822752|EXPERIMENTAL|Arm 3: Livmoniplimab Dose B + Budigalimab|Participants will receive Livmoniplimab Dose B in combination with budigalimab, as part of an approximately 2 year treatment period.
62503105|NCT06617754||Patients from the Portuguese registry of global airways|Patients included in the Portuguese registry of global airways
62503106|NCT06617754||Patients from the Finnish registry of global airways|Patients included in the Finnish registry of global airways
61956183|NCT01798511|EXPERIMENTAL|Nasogastric Tube Feeding|Patients who are to have NTF will receive enteral nutrition within 6 hours after randomisation via a nasogastric tube placed into the stomach. A commercially available low fat semi-elemental feed (Peptisorb®, Nutricia Clinical NZ) will be used. The caloric target will be 2000 kcal per day. Enteral tube feeding will be commenced at a rate of 30 mL/h and increased gradually until 100 mL/h over 24-48 h.
61956184|NCT01798511|ACTIVE_COMPARATOR|Conventional Nutritional Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case enteral tube feeding will be introduced) or the signs of AP mitigate,in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced.
62345286|NCT00720421|OTHER|2|AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 1mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy
62345287|NCT00720421|OTHER|3|AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy
62345288|NCT00720421|OTHER|4|AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy
62345289|NCT02221271|EXPERIMENTAL|NPB-01|
62345290|NCT03711994|NO_INTERVENTION|Repeat C/S Control|Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
62345291|NCT03711994|ACTIVE_COMPARATOR|Repeat C/S Treatment|Repeat C/S done with spinal with Alkantis ice pack.
62345292|NCT03711994|NO_INTERVENTION|Primary C/S - Control|Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
62345293|NCT03711994|ACTIVE_COMPARATOR|Primary C/S Treatment|Primary C/S done with Epidural with Alkantis ice pack.
62142493|NCT04684095|NO_INTERVENTION|routine follow-up group|only according to the routine follow-up frequency to the center visit.
62345294|NCT02932189|NO_INTERVENTION|Control|Procedure: Ventilator weaning in the conventional way with a tracheal collar.
62345295|NCT02932189|EXPERIMENTAL|Intervention|"Procedure: Ventilator weaning with a tracheal collar after inspiratory muscle training with an isokinetic device.~Device: K5 Power Breath"
62345296|NCT03634904|EXPERIMENTAL|Drug Blood sampling|"* Drug Blood sampling~* Pharmacokinetic study measuring total and free ceftazidime concentrations"
62345297|NCT01354041|NO_INTERVENTION|Treatment-as-usual|Participants in the Treatment as usual (TAU) arm will not receive any specific Fear of Cancer Recurrence (FCR) intervention during the study period. However, they will be offered an optional full-day workshop at the end of the study.
62345298|NCT01354041|EXPERIMENTAL|Acceptance and Commitment Therapy|"Participants in the intervention arm will receive seven sessions of a mindfulness and values-based living intervention, led by a trained licensed facilitator, conducted in groups of 10-12 participants and include components specifically designed to reduce FCR. The intervention arm will include six weekly 90 minute group sessions and one followup 90 minute group session booster session held three weeks later. The group sessions will be interactive and experiential and include homework practice for generalizing skills."
62503107|NCT06617754||Patients from the US registry of global airways|Patients included in the US registry of global airways
62503108|NCT06617754||Patients from the Australian registry of global airways|Patients included in the Australian registry of global airways
62345299|NCT04602676|EXPERIMENTAL|Diarrheal Assessment with DEP, then diarrheal assessment|Participants will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application.
62345300|NCT04602676|EXPERIMENTAL|Diarrheal Assessment, then Diarrheal assessment with DEP|Participants will go through a 4 week period where clinicians will use a rehydration calculator. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm.
62345301|NCT06010355|EXPERIMENTAL|Arm I (Aim 1) (focus group)|Participants participate in a focus group over 1 hour in support of the development of a culturally tailored educational video on study.
62345302|NCT06010355|EXPERIMENTAL|Arm II (Aim 2) (video, interview)|Participants watch a culturally tailored educational video over 3-5 minutes and then immediately undergo an interview in support of the refinement of a culturally tailored educational video on study.
62345303|NCT06010355|EXPERIMENTAL|Arm III (Aim 3) (video, test)|Participants watch a culturally tailored educational video over 3-5 minutes and complete a brief test pre- and post-video over 30 minutes on study.
62345304|NCT02101840|ACTIVE_COMPARATOR|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
62345305|NCT02101840|ACTIVE_COMPARATOR|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
62345306|NCT02101840|PLACEBO_COMPARATOR|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
62345307|NCT03265743||Patients with Cystic Fibrosis|Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
62345308|NCT01587573||oral lesions|oral lesions suspicious for squamous cell carcinoma with saliva collection prior to clinically driven oral biopsy
62503109|NCT06617754||Patients from Spanish registry of global airways|Patients included in the Spanish Global Airways Registry
62503110|NCT06617754||Patients from Polish registry of global airways|Patients included in the Polish Global Airways Registry
62503111|NCT06617754||Patients from French registry of global airways|Patients included in the French Global Airways Registry
62503112|NCT01560819|EXPERIMENTAL|Study Participants|Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
61956185|NCT03544658|EXPERIMENTAL|Dental prophylaxis|Visit 1: tooth color assessment (by patient, dentist and spectrophotometer) and professional dental prophylaxis Visit 2: tooth color assessment (by patient, dentist and spectrophotometer)
61956186|NCT00117481|EXPERIMENTAL|1|
61956187|NCT00117481|EXPERIMENTAL|2|
61956188|NCT00117481|PLACEBO_COMPARATOR|3|
61956189|NCT05489744|EXPERIMENTAL|125 mg [14C]Afuresertib|125 mg/150 µCi \[14C\]Afuresertib (125 mg of Afuresertib containing 150 µCi of \[14C\]Afuresertib)
61956190|NCT01944592|EXPERIMENTAL|Gynaecology Training Associates (GTA's)|Final year (Year 5) medical undergraduates embarking upon their O\&G clinical placement trained in pelvic examination with GTA's
61956191|NCT01944592|ACTIVE_COMPARATOR|Manikin training|Final year (Year 5) medical undergraduates embarking upon their O\&G clinical placement trained in pelvic examination on manikins.
61956192|NCT06193291|NO_INTERVENTION|Thermoneutral|Participant sits at room temperature during an oral glucose tolerance test
61956193|NCT06193291|EXPERIMENTAL|Feet heating|Participant sits with feet placed in hot water during an oral glucose tolerance test
61956194|NCT06193291|EXPERIMENTAL|Calf heating|Participant sits with legs, up to calves, placed in hot water during an oral glucose tolerance test
61956195|NCT01403961||HbA1c > 7|Diabetic patients with HbA1c \> 7
61956196|NCT01403961||HbA1c ≤ 7|Diabetic patients with HbA1c ≤ 7
61956197|NCT04632810|EXPERIMENTAL|Ketogenic low energy diet|Ketogenic low energy diet for 8 weeks
61956198|NCT04632810|ACTIVE_COMPARATOR|non-Ketogenic low energy diet|non-Ketogenic low energy diet for 8 weeks
61956199|NCT04586907|EXPERIMENTAL|LY3537021 (Part A/Healthy)|LY3537021 administered subcutaneously (SC) to healthy participants.
61956200|NCT04586907|EXPERIMENTAL|LY3537021 (Part A/Type 2 Diabetes)|LY3537021 administered SC to participants with type 2 diabetes mellitus (T2DM).
61956201|NCT04586907|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC.
61956202|NCT04586907|EXPERIMENTAL|LY3537021 (Part B/Healthy)|LY3537021 administered SC to healthy participants.
61956203|NCT04586907|EXPERIMENTAL|LY3537021 (Part B/Type 2 Diabetes)|LY3537021 administered SC to participants with T2DM.
61956204|NCT04586907|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC.
61956205|NCT06486376|ACTIVE_COMPARATOR|Active comparator|Control Group: These will be schools where no intervention will be implemented, and routine practices are continued.
61956206|NCT06486376|NO_INTERVENTION|Control|No intervention group
61956207|NCT00506480|EXPERIMENTAL|OD|patients artificially prepared for OD will undergo a mock cycle consisting of estrogen and later by progesterone. a pipelle sample will be taken after 6 days of progesterone supplementation.
61956208|NCT00506480|EXPERIMENTAL|IVF|A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
61956209|NCT01927172|OTHER|AirSonea|Use of AirSonea to detect wheeze sounds.
61956210|NCT01277991|EXPERIMENTAL|Sequence 1|
61956211|NCT01277991|EXPERIMENTAL|Sequence 2|
61956212|NCT03725202|EXPERIMENTAL|Arm A|Upadacitinib dose A administered daily + 26-week CS taper regimen
61956213|NCT03725202|EXPERIMENTAL|Arm B|Upadacitinib dose B administered daily + 26-week CS taper regimen
61956214|NCT03725202|PLACEBO_COMPARATOR|Arm C|Placebo administered daily + 52-week CS taper regimen
61956215|NCT04835532|EXPERIMENTAL|Control group|"Vertical alveolar bone augmentation was performed by GBR technique before implantation.~BIO-OSS+ BIO-GIDE barrier membrane"
61956216|NCT04835532|EXPERIMENTAL|Treatment group 1|"Vertical alveolar bone augmentation was performed by GBR technique and tenting screws before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws"
61956217|NCT04835532|EXPERIMENTAL|Treatment group 2|"Vertical alveolar bone augmentation was performed by GBR technique in combination with tenting screws and A-PRF, I-PRF before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws+A-PRF, I-PRF"
61956218|NCT01847274|ACTIVE_COMPARATOR|Niraparib|2:1 Ratio administered once daily continuously during a 28 day cycle.
61956219|NCT01847274|PLACEBO_COMPARATOR|Placebo|Administered once daily continuously over a 28 day cycle.
61956220|NCT01191333|EXPERIMENTAL|Active rTMS|Those receiving experimental treatment will receive 20 to 30 sessions of rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
61956221|NCT01191333|PLACEBO_COMPARATOR|Sham rTMS|Those receiving the sham rTMS will receive 20 to 30 sessions of sham rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
61956222|NCT05679219|ACTIVE_COMPARATOR|Structured Pes Planus Exercise Group|23 individuals will be included in this group. Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. The purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
61956223|NCT05679219|ACTIVE_COMPARATOR|Wii Based Exergame Group|23 individuals will be included in this group. Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
62142494|NCT04684095|EXPERIMENTAL|ePRO group|ePRO group : self-evaluation in ePRO mode was accepted, and the patients were visited in the center according to the routine follow-up frequency.
62142495|NCT03224806|OTHER|Wholegrain bread|
62142496|NCT03224806|OTHER|White bread|
62142497|NCT03224806|OTHER|15% fiber-rich bread|
62142498|NCT03224806|OTHER|30% fiber-rich bread|
62142499|NCT06699147||Nasolabial Folds|Wrinkle Severity Rating Scale(WSRS) assessed 3 or 4
62702249|NCT06750211|EXPERIMENTAL|MCTE along with METs|MCTE included cranio-cervical flexion, cranio-cervical extension, co-contraction of flexion and extension and synergistic exercise of neck flexor along with hot pack, neck isometrics and muscle energy technique protocol
61956224|NCT05679219|ACTIVE_COMPARATOR|Wii Based Serious Game Group|23 individuals will be included in this group. The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
61956225|NCT06440720|EXPERIMENTAL|Group A|Group A will receive ELDOA exercises. At first hot pack will applied for 7-8 minutes after that participants will explain specific body movements. Four ELDOA positions will once shown to the participants then ask them to maintain that positions. Once they make these positions stop watch will be set for one minute for each position. these positions will apply for three times per week for four weeks.
61956226|NCT06440720|EXPERIMENTAL|Group-B|Group B will receive the UPPER THORACIC MOBILIZATION AND MOBILITY exercise. At first, a hot pack will be applied for 7-8 minutes after that participants will be in a prone position and the physiotherapist will stand toward the side where mobilization will be applied and the index and middle finger of the left hand of the physiotherapist will be placed on the vertebral transverse processes of the participants to the caudal side. The lateral side of the palm of the right hand will be placed over the left-hand index and middle finger and then thoracic mobilization after that mobility exercise will be performed.
61956227|NCT01409330|EXPERIMENTAL|hypocaloric diet containing increased fibers and coffee|In the intervention group the patients are allowed to eat only white meat and fish. They also need to increase their daily fiber intake to 50grams and drink 5 cups of coffee a day.
61956228|NCT01409330|ACTIVE_COMPARATOR|hypocaloric diet containing red meat|control group (n=20): diet according to the ADA/EASD guidelines (50% carbohydrates, 20% proteins, 30% fat). In the control group the patients should eat 150 grams of red meat a day and are not allowed to consume alcohol, coffee and whole grains.
61956229|NCT04803071|EXPERIMENTAL|Adjuvant therapy trial group|N-3pufas improved cognitive formula adjuvant therapy intervention group
61956230|NCT04803071|ACTIVE_COMPARATOR|Adjuvant treatment control group|General fish oil formula product adjuvant treatment control group
61956231|NCT04803071|PLACEBO_COMPARATOR|Placebo assisted treatment control group|
61956232|NCT04803071|NO_INTERVENTION|Healthy group|
61956233|NCT04497493|EXPERIMENTAL|tDCS group|participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
61956234|NCT04497493|SHAM_COMPARATOR|Sham group|Participants receive sham stimulation that administered similarly, but with current turned off after 30s combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
61956235|NCT05315401|EXPERIMENTAL|Probiotic 9 log CFU/day|The intervention consists of daily administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
62702250|NCT06748261||Cardiomyopathy cohort|Patients who have underwent CCTA examination and have recorded diagnosis of cardiomyopathy are enrolled in the cardiomyopathy cohort. Clinical diagnosis of cardiomyopathies based on patients' complete electrical medical record (EMR), encompassing clinical presentations, family history, laboratory results, ECG, echocardiogram, all available imaging assessments (if any, i.e. cardiac magnetic resonance, single-photon emission computed tomography, and invasive coronary angiography), and myocardial biopsy (if any). Clinical diagnoses are retrieved from (EMR) and used as ground truth for AI-assisted CCTA-based screening and diagnostic model developing.
61956236|NCT05315401|PLACEBO_COMPARATOR|Placebo|placebo contains primarily carrier and without probiotic. The placebo are identical in taste and appearance and appear as a light-yellow powder.
61956237|NCT05315401|EXPERIMENTAL|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week
61956238|NCT05493046|EXPERIMENTAL|Interactive Hand Exercise Game|Participants will receive an Interactive Hand Exercise Game for 30 minutes every day for consecutive two months.
61956239|NCT05493046|ACTIVE_COMPARATOR|Soft ball exercise ( routine care)|Participants will receive a soft ball exercise for 30 minutes every day for consecutive two months.
61956240|NCT01714011|ACTIVE_COMPARATOR|Ziprasidone|Ziprasidone is a psychotropic agent with chemical name: 5-\[2-\[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl\]ethyl\]-6-chloro-1,3-dihydro-2H-indol-2-one.Ziprasidone is a potent antagonist of both serotonin 5-HT2A and dopamine D2 receptors, although its affinity for 5-HT2A receptors is about 10 times higher than for D2 receptors.
62702251|NCT06748261||Control cohort|Participants who have CCTA examination are recruited in the control cohort given that his or her medical record rules out cardiovascular diseases (including cardiomyopathy, history of myocardial infarction, history of cardiac surgery, stent implantation, ICD implantation and so on) and secondary cardiac abnormalities due to systemic diseases.
62702252|NCT06751433|ACTIVE_COMPARATOR|Participants of both sexes, 18 - 70 y|Participants of both sexes, 18 - 70 y, who have recent scars.
62142500|NCT06699147||Mid-Face Volume|Midface Volume Deficit Scale(MFVDS) assessed 3 or higher
62142501|NCT06699147||Lip Volume|Medicis Lip Fullness Scale(MLFS) assessed 1 or 2
62345309|NCT00419913|EXPERIMENTAL|A|Dehydroepiandrosterone (DHEA) 25mg tid
62702253|NCT06751433|EXPERIMENTAL|Exp.: Participants of both sexes, 18 - 70 y|Participants of both sexes, 18 - 70 y, with recent scars
62702254|NCT06749678|EXPERIMENTAL|Prehabilitation group|In addition to routine nursing measures, the prehabilitation group underwent prehabilitation measures during the conversion therapy period.
62702255|NCT06749678|PLACEBO_COMPARATOR|Control group|During the conversion therapy period, the control group only took routine nursing measures.
62503113|NCT05472896|EXPERIMENTAL|cTACE with TP21|In experimental groups, the dosage of dicycloplatin (TP21) was based on the body surface area (550 mg/m2) according to previous research. If grade III or above myelosuppression was observed, an adjusted dose of 450 mg/m2 was then considered, or the patient was removed from the group at the investigator's discretion.The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1.The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL. Standardized gelatin sponge particles of 150-350 μm or 350-560 μm in diameter were injected following embolization with ethiodized oil-chemoembolic emulsion.
62345310|NCT00419913|PLACEBO_COMPARATOR|B|
62345311|NCT02530671|ACTIVE_COMPARATOR|Manual toothbrush|ADA reference manual toothbrush
61956241|NCT01714011|ACTIVE_COMPARATOR|Aripiprazole|Aripiprazole is a psychotropic drug that is available as tablets for oral administration. Aripiprazole is 7-\[ 4-\[ 4-(2,3-dichlorophenyl)-1-piperazinyl\]butoxy\]-3-4-dihydrocarbostyril. Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha 1-adrenergic and histamine H1 receptors and moderate affinity for serotonin reuptake site (Ki = 98nM).
62503114|NCT05472896|ACTIVE_COMPARATOR|cTACE with epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL. Standardized gelatin sponge particles of 150-350 μm or 350-560 μm in diameter were injected following embolization with ethiodized oil-chemoembolic emulsion.
62503115|NCT05655429|EXPERIMENTAL|physical therapy|Physical therapy mainly include aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months.
61956242|NCT01193595|EXPERIMENTAL|AVE8062/ bevacizumab|The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.
61956243|NCT03634657|ACTIVE_COMPARATOR|Plain X-ray protection shield|
61956244|NCT03634657|EXPERIMENTAL|Protection shield & X-ray protective strips|
61956245|NCT03634657|EXPERIMENTAL|Protection shield & protective strips & patient cut-outs|
61956246|NCT05267847|EXPERIMENTAL|Cryotherapy during inferior alveolar nerve block|
62345312|NCT02530671|EXPERIMENTAL|Power toothbrush|Multi-directional power toothbrush
61956247|NCT05267847|ACTIVE_COMPARATOR|Inferior alveolar nerve block|
61956248|NCT01865110|EXPERIMENTAL|Induction experimental arm|R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.
61956249|NCT01865110|ACTIVE_COMPARATOR|Standart induction arm|8 cycles of R-CHOP administered in 3 week cycles
61956250|NCT01865110|EXPERIMENTAL|Maintenance experimental arm|lenalidomide + rituximab : 13 cycles of rituximab SC 1400 mg administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
62503116|NCT05655429|ACTIVE_COMPARATOR|arthroscopic partial meniscectomy|The torn meniscus and unstable part were removed with arthroscopic instruments.
62503117|NCT03754504|EXPERIMENTAL|Cranberry|Whole Cranberry Powder Supplements
62503118|NCT03754504|PLACEBO_COMPARATOR|Placebo|Placebo
62503119|NCT03876028|EXPERIMENTAL|Ibrutinib (before leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment before leukapheresis
62503120|NCT03876028|EXPERIMENTAL|Ibrutinib (after leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment after leukapheresis.
61956251|NCT01865110|ACTIVE_COMPARATOR|Maintenance standart arm|13 cycles of rituximab SC 1400 mg administered in 8 week cycles for 24 months
61956252|NCT02285192|EXPERIMENTAL|intracervical 18F-FDG injection during a dynamic PET/CT|The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.
61956253|NCT00920998|EXPERIMENTAL|1. Z-338|3-way cross-over study (drug administration 3-times in fasted and 2 fed conditions)
61956254|NCT04753645|EXPERIMENTAL|HBCC and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
61956255|NCT04753645|EXPERIMENTAL|No HBCC project and no soap|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
62345313|NCT02131012|EXPERIMENTAL|Celecoxib|1-4 mg intravitreal injection ofCelecoxib
62345314|NCT03937258|OTHER|PF-04965842 single dose|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
62345315|NCT03937258|OTHER|PF-04965842 multiple doses|In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions.
62345316|NCT03937258|OTHER|Probenecid and PF-04965842|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
62503121|NCT02902133|OTHER|Acetazolamide Arm|Acetazolamide 500 mg twice per day for 5 consecutive days post standard-of-care endoscopic skull base surgery
62503122|NCT04443569|EXPERIMENTAL|Lidocaine Patch Group|This group will be women who were randomized to receive a lidocaine patch for postoperative pain following cesarean delivery in addition to routine postoperative pain management.
62702256|NCT06748209|OTHER|Open label Clinical TMS for Depression|This will be FDA approved Left Prefrontal TMS for treating depression, we will be performing this within a VA, located at clinics throughout SC.
62503123|NCT04443569|PLACEBO_COMPARATOR|Control Group|This group will be women randomized to routine postoperative pain management following cesarean delivery. A placebo patch will be placed superior to the Pfannenstiel incision in the same manner as the lidocaine patch treatment group.
62503124|NCT04857151|NO_INTERVENTION|control|Control
62345317|NCT03210779|ACTIVE_COMPARATOR|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
62503125|NCT04857151|EXPERIMENTAL|App based mindfulness program (ABMP)|Participants in this group will participate in App based mindfulness program (ABMP)
62345318|NCT03210779|PLACEBO_COMPARATOR|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
62345319|NCT06108349|EXPERIMENTAL|Cannabidiol|Participants will receive 5mL syringe with Cannabidiol (Investigational drug) in it.
62503126|NCT00786630|EXPERIMENTAL|Case Management|
62503127|NCT00786630|EXPERIMENTAL|Facilitated Treatment Alliance|
62503128|NCT03683329|EXPERIMENTAL|Antibiotic de-escalation|"* According to the results of the antibiogram of the suspected causative bacteria, the ''pivotal'' antibiotic (antipseudomonal betalactam) used for empirical treatment is switched to an antibiotic with a spectrum as narrow as possible according to the targeted pathogens,~* Stop the companion antibiotic (aminoglycoside, fluoroquinolone, macrolide) between day 2 and day 3 of antibiotic treatment as much as possible,~* Stop the empirical antibiotic directed against methicillin-resistant staphylococcus aureus (MRSA) or an enterococcus in the absence of these bacteria in the culture."
62503129|NCT03683329|ACTIVE_COMPARATOR|Standard treatment without de-escalation|"* The companion antibiotic is stopped between day 3 and day 5 of antibiotic treatment as much as possible and according to the local prescription,~* Empirical antibiotics directed against MRSA or enterococcus were used according to local prescription and/or international guidelines,~* The pivotal antibiotic of the empirical treatment is continued for the entire duration of the treatment, independently of microbiological results. For prolonged treatment, the physician has the choice of de-escalating after 8-15 days of treatment."
62503130|NCT00726895|EXPERIMENTAL|Quinine Sulfate Capsules 1 x 324 mg Dose|Quinine Sulfate 1 x 324 mg capsule dose.
62503131|NCT00726895|EXPERIMENTAL|Quinine Sulfate Capsules 2 x 324 mg Dose|Quinine Sulfate 2 x 324 mg capsules dose.
62503132|NCT00820508|EXPERIMENTAL|1|Oral, once daily administration of CHR-2845 to determine safety and tolerability
62503133|NCT03907241|EXPERIMENTAL|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
62503134|NCT03448276|EXPERIMENTAL|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
62503135|NCT03448276|ACTIVE_COMPARATOR|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
62503136|NCT01848717|EXPERIMENTAL|Lift thread|
62503137|NCT04319458|EXPERIMENTAL|Fotonovela|Fotonovela mental health literacy intervention: Secret Feelings/Sentimientos Secretos
62503138|NCT04319458|ACTIVE_COMPARATOR|Control|Control mental health literacy intervention: NIH publication - Depression: What You Need to Know
62503139|NCT04467099||Os Trigonum Excision with Tear|Participants with flexor hallucis tendon tear
62345320|NCT06108349|NO_INTERVENTION|Placebo|Participants will receive 5mL syringe with Shea Butter cream (Placebo) in it.
62345321|NCT01383967|EXPERIMENTAL|LY2979165 Part A, Cohort 1|20 mg LY2979165 administered orally, daily for 14 days
62702257|NCT06750393|EXPERIMENTAL|Barre exercise with gym ball exercise|"The Barre exercises will be administered to the participant of Group A for a period of 3 month. Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. Gym ball exercises program include Knee tucks, leg curls, back extension exercises"
61956256|NCT04753645|EXPERIMENTAL|Soap received but no HBCC|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
62345322|NCT01383967|EXPERIMENTAL|LY2979165 Part A, Cohort 2|60 mg LY2979165 administered orally, daily for 14 days
62345323|NCT01383967|EXPERIMENTAL|LY2979165 Part A, Cohort 3|100 mg LY2979165 administered, orally daily for 14 days
62345324|NCT01383967|EXPERIMENTAL|LY2979165 Part A, Cohort 4|150 mg LY2979165 administered orally, daily for 14 days
62503140|NCT04467099||Os Trigonum Excision without Tear|Participants without flexor hallucis tendon tear
62503141|NCT06233539||Retrospective section|
62503142|NCT06233539||Prospective section|
62503143|NCT06382506|EXPERIMENTAL|The effect of cornbread consumption blood glucose fluctuations in participants.|The bread contained 50 grams of digestible carbohydrates. Participants consumed these loaves of bread when they were hungry. Blood glucose measurements were taken at 0 (fasting),15, 30, 45, 60, 90, and 120 minutes.
62503144|NCT06382506|EXPERIMENTAL|The effect of cornbread with hazelnut bread consumption blood glucose fluctuations in participants.|The bread contained 50 grams of digestible carbohydrates. Participants consumed these loaves of bread when they were hungry. Blood glucose measurements were taken at 0 (fasting),15, 30, 45, 60, 90, and 120 minutes.
62345325|NCT01383967|EXPERIMENTAL|LY2979165 Part B, Cohort 5|Dose to be determined by safety review of doses administered in Part A, administered, orally daily for 14 days
62345326|NCT01383967|PLACEBO_COMPARATOR|Placebo|Administered orally, daily for 14 days in a ratio of 3:1 in each Cohort of Part A
62345327|NCT01383967|EXPERIMENTAL|LY2979165 Part A, Cohort 6|250 mg LY2979165 administered orally, daily for 14 days
62503145|NCT01451320|ACTIVE_COMPARATOR|rapid streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
62503146|NCT01451320|ACTIVE_COMPARATOR|high dose tpa|5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
62503147|NCT01451320|ACTIVE_COMPARATOR|slow streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
62702258|NCT06750393|ACTIVE_COMPARATOR|Barre exercises|"The Barre exercises for a period of 3 month Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. During"
62503148|NCT01451320|ACTIVE_COMPARATOR|half-dose slow infusion tpa|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
61956257|NCT04753645|EXPERIMENTAL|Both HBCC project and Soap received|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
61956258|NCT06434259||Digi-physical treatment group|Usual care (behavioral treatment) plus the support system for self- monitoring of weight and communication with the clinic during three years of treatment.
61956259|NCT06434259||Control group|Children treated with usual care according to regular treatment routines registered in the Swedish childhood obesity treatment register, BORIS
61956260|NCT05693389|ACTIVE_COMPARATOR|patients with bipolar disorder who will partaicpmg in acceptance and commitment therapy|patients with bipolar disorder who will participate in acceptance and commitment therapy
62142502|NCT01994057||sensitive group; resistant group|"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.~resistant patients were defined as patients reached PD after first month administration and first three months administration"
61956261|NCT05693389|PLACEBO_COMPARATOR|patients with bipolar disorder who will be under routine hospital care|patients with bipolar disorder who will be under routine hospital care
62142503|NCT01473069|EXPERIMENTAL|Dose 1 JTK-853, 400 mg ketoconazole|
62142504|NCT01473069|EXPERIMENTAL|Dose 2 JTK-853|
62142505|NCT01473069|EXPERIMENTAL|Dose 3 JTK-853|
62142506|NCT01473069|EXPERIMENTAL|Dose 4 JTK-853|
62142507|NCT01473069|PLACEBO_COMPARATOR|Placebo|
62142508|NCT03876886|ACTIVE_COMPARATOR|AC-T(dose-dense)|A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）
62345328|NCT01383967|EXPERIMENTAL|LY2979165 Part A, Cohort 7|400 mg LY2979165 administered orally, daily for 14 days
61956262|NCT03355820|EXPERIMENTAL|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.
61956263|NCT06062082||Pheochromocytoma|Patients operated on for pheochromocytoma by unilateral adrenalectomy
62142509|NCT03876886|EXPERIMENTAL|TP(dose-dense)|T: paclitaxel (PTX） P: carboplatin (CBP)
62142510|NCT01828671|ACTIVE_COMPARATOR|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
62345329|NCT06390631|EXPERIMENTAL|CPAP treatment|CPAP treatment in COPD patients
62345330|NCT06509711|EXPERIMENTAL|PLYOMETRICS jump training with HIIT|"Alternate Jump Lunge (4 REPS, 3 SETS with 25 SECONDS recovery period between each SET )~Split squat jump (4 REPS, 3 SETS with 25 SECONDS recovery between each SET) Pop Squat (4 REPS, 3 SETS with 25 SECONDS recovery period between each set)"
62345331|NCT06509711|EXPERIMENTAL|PLYOMETRICS JUMP TRAINING WITHOUT HIIT|Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
62345332|NCT04733846||corneal trauma sutured with Vicryl 10-0 monofilament|corneal trauma sutured with Vicryl 10-0 monofilament will be included. They will have data collection of medical records.
62345333|NCT03721393||Group 1: Syncope patients|Patients that have undergone an ARS assessment and diagnosed with orthostatic hypotension or reflex syncope.
62345334|NCT03721393||Group 2: Control patients|Patients that have undergone an ARS assessment and are control subjects.
62345335|NCT02608034|EXPERIMENTAL|Part 1: Vemurafenib+Itraconazole|Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).
62345336|NCT00423735|EXPERIMENTAL|Treatment (dasatinib)|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
62345337|NCT05584930|OTHER|Cancer patient|Collection of blood sample
62345338|NCT05387252|EXPERIMENTAL|Low volume mulberry juice|10 ml mulberry juice containing about 48 mg polyphenols
62345339|NCT05387252|EXPERIMENTAL|Middle volume mulberry juice|50 ml mulberry juice containing about 240 mg polyphenols
62345340|NCT05387252|EXPERIMENTAL|High volume mulberry juice|100 ml mulberry juice containing about 480 mg polyphenols
62345341|NCT04410198|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant requires roxadustat \<60 milligrams (mg)/week to maintain Hb levels, the dose frequency will be reduced in a stepwise manner, for example, to BIW, and then QW. For participants converted from CERA, the initial roxadustat dose will be based on the average prescribed CERA dose in the last 8 weeks prior to conversion. For participants with \<6 weeks of prior CERA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.
62345342|NCT05650931|EXPERIMENTAL|Patients who underwent the upper limb amputation and have phantom limb pain|
62345343|NCT02471911|EXPERIMENTAL|All subjects|"All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle.~RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone."
62345344|NCT00731848|EXPERIMENTAL|1|Intervention 1
62345345|NCT04703127|ACTIVE_COMPARATOR|Patients with lifelong premature ejaculation and non-responding to dapoxetine alone|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
62345346|NCT04703127|ACTIVE_COMPARATOR|Patients with Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
62142511|NCT01828671|ACTIVE_COMPARATOR|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
62345347|NCT00980343|EXPERIMENTAL|Arm I (pre-surgery vismodegib)|"Patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily for 7 days before therapeutic conventional surgery. Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis"
62503149|NCT01451320|ACTIVE_COMPARATOR|low dose slow infusion tpa|6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
62503150|NCT03746535|ACTIVE_COMPARATOR|patients without endometriosis|Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
61956264|NCT06062082||Control|Patients operated on for adrenal tumor other than pheochromocytoma by unilateral adrenalectomy
62142512|NCT01828671|ACTIVE_COMPARATOR|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
62142513|NCT01828671|ACTIVE_COMPARATOR|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
62345348|NCT00980343|EXPERIMENTAL|Arm II (no vismodegib pre-surgery)|"Patients do not receive treatment before therapeutic conventional surgery.~Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
62345349|NCT05435144|EXPERIMENTAL|Intervention Arm|Participants will receive a 13-week supply of ElderCraft® (European black elderberry extract standardized to 15% anthocyanins). Each capsule contains 300mg of extract; participants will take a total of two capsules each day.
62345350|NCT05435144|PLACEBO_COMPARATOR|Placebo Arm|Participants will receive a 13-week supply of inert placebo capsules matched for polysaccharide content. Participants will take a total of two capsules each day.
62345351|NCT02193828|EXPERIMENTAL|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
62345352|NCT02193828|EXPERIMENTAL|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
62345353|NCT02193828|EXPERIMENTAL|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
62345354|NCT02193828|PLACEBO_COMPARATOR|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
62345355|NCT03655717|EXPERIMENTAL|Phase 2A|In a double-blind placebo-controlled, random order cross-over study of single dose dronabinol, participants received dronabinol or identical placebo on two separate study visits in randomized order.
62345356|NCT03655717|EXPERIMENTAL|Phase 2B|In a randomized, double-blind, 4-treatment, 4-period, crossover study with THC or placebo administration and ethanol or placebo administration, participants were randomly assigned to 1 of 4 sequences and received each of the following treatments: placebo dronabinol + placebo ethanol, placebo dronabinol + ethanol, dronabinol + placebo ethanol, \& dronabinol + ethanol.
62345357|NCT01844830|EXPERIMENTAL|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
62345358|NCT01844830|PLACEBO_COMPARATOR|Placebo|Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
62345359|NCT05992415|ACTIVE_COMPARATOR|Arm 1: Intervention Using Patient Navigators|Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care at either Columbia Harkness Eye Institute or Harlem Hospital Ophthalmology, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
62503151|NCT03746535|EXPERIMENTAL|patients with endometriosis|Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
62503152|NCT00558623|PLACEBO_COMPARATOR|1|Placebo
62503153|NCT04449458|EXPERIMENTAL|Positively Me|Positively Me is a 12-session (8 \[1.5\] hour main sessions plus four booster sessions) intervention guided by Social Cognitive Theory to promote smoking cessation in people with certain health conditions.
62503154|NCT04449458|SHAM_COMPARATOR|Positively Living|Positively Living is a modified updated version of a healthy living intervention based on Social Cognitive Theory that is designed for people with certain health conditions and attention-matched to the experimental condition (8 \[1.5\] hour main sessions plus four booster sessions).
62503155|NCT03558035|EXPERIMENTAL|Induction chemotherapy and concurret chemoradiotherapy group|Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.
62503156|NCT03558035|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy group|Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy
62503157|NCT02024594|EXPERIMENTAL|Nitrous Oxide-Oxygen|Children in this group were sedated by rapid induction method by means of Nitrous Oxide-Oxygen gas.
62503158|NCT02024594|EXPERIMENTAL|cognitive-behavioral therapy|Children in this group were asked to come to playroom before entering operation room. Modeling , Benson relaxation and positive self-talking were instructed to them.
62503159|NCT02024594|NO_INTERVENTION|control|No intervention
62503160|NCT01351051||No endometriosis|
62503161|NCT01351051||Superficial endometriosis|
62503162|NCT01351051||Endometrioma|
62503163|NCT01351051||Deep infiltrating endometriosis|
62503164|NCT00736398||Observation|Spinal fusion
62503165|NCT03132311|EXPERIMENTAL|HIV positive subjects|"300 HIV positive adults with CD4 \> 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, \>500 cells/mm3).~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
62503166|NCT03132311|ACTIVE_COMPARATOR|HIV negative subjects|"100 HIV negative adults.~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
62503167|NCT04125615|EXPERIMENTAL|Protected Non-Clinical Time|Protected non-clinical time
62503168|NCT04125615|NO_INTERVENTION|Control Period|No protected non-clinical time
62503169|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
62503170|NCT05252247|EXPERIMENTAL|Conditions|Participants will attend three sessions where two consist of immobilisation or exercise interventions.
62503171|NCT04118868|EXPERIMENTAL|All participants|Pembrolizumab administered intralymphatically using the Sofusa® DoseConnect™device
62702259|NCT06748456|EXPERIMENTAL|Cluster package intervention group|"The intervention consists of:~* A pre-recorded podcast to be heard by the GP's prior to the cluster meeting.~* A two-hour meeting with a specific slideshow about PSA, data from the clinics within the cluster, current guidelines, cases and group discussions.~* Two sets of hand-outs for the GP's to use in their own clinics.~The intervention group will be offered the intervention during the intervention period of six months."
62702260|NCT06748456|NO_INTERVENTION|Standard care control group|The control group will be offered the intervention at the end of the intervention period.
62702261|NCT06751329|EXPERIMENTAL|Dose Level 1|1.0 mg/kg
62345360|NCT05992415|PLACEBO_COMPARATOR|Arm 2: Usual Care + Automated Appointment Reminders|Consented participants referred from the 5 developments randomized to the Usual Care Arm +Automated Appointment Reminders who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Columbia Harkness Eye Institute or Harlem Hospital Ophthalmology. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.
62345361|NCT01841918|EXPERIMENTAL|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
62345362|NCT01841918|PLACEBO_COMPARATOR|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
62345363|NCT01745991||Biliary Atresia undergoing Kasai op|Randomisation for the use of CoSeal at the time of Kasai and assessment at the time of Transplantation.
62345364|NCT03314714|EXPERIMENTAL|Acute bout of endurance exercise|Intramyocellular lipid metabolism will be assessed in insulin resistant and healthy, sedentary individuals after an acute bout of endurance exercise.
62345365|NCT03666975|EXPERIMENTAL|LIV 30 Hz, 0.4 g|LIV 30 Hz, 0.4 g Low intensity vibration to short leg 3x / week x 10 wks
62345366|NCT03666975|EXPERIMENTAL|LIV 30 Hz, 1.0 g|LIV 30 Hz, 1.0 g Low intensity vibration to short leg 3x/week x 10 wks
62345367|NCT02517151|EXPERIMENTAL|Ferric carboxymaltose|200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
62345368|NCT02517151|PLACEBO_COMPARATOR|Placebo|normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
62345369|NCT04392336|EXPERIMENTAL|Trust/Respect feedback|Clinicians with consumers in this arm receive feedback on trust/respect in addition to symptom feedback.
62345370|NCT04392336|NO_INTERVENTION|No Trust/Respect feedback|Clinicians with consumers in this arm do not receive feedback on trust/respect and only receive symptom feedback.
62345371|NCT01107769||VISIONAIRE™|Total knee arthroplasty with VISIONAIRE™ patient-matched cutting blocks
62345372|NCT01107769||Standard Instrumentation|Total knee arthroplasty with standard instrumentation
62345373|NCT05551598|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group|
62345374|NCT05551598|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group|
62345375|NCT05551598|PLACEBO_COMPARATOR|Placebo Injection every 12 weeks (Q12W).|
62345376|NCT03364335|PLACEBO_COMPARATOR|Placebo|Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.
62345377|NCT03364335|EXPERIMENTAL|Leu Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
62345378|NCT03364335|EXPERIMENTAL|Leu Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
62345379|NCT03364335|EXPERIMENTAL|Leu Met Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
62503172|NCT01291641|PLACEBO_COMPARATOR|Group A|HMGCoA reductase inhibitor continued
62503173|NCT01291641|ACTIVE_COMPARATOR|Group B|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID
62503174|NCT01291641|ACTIVE_COMPARATOR|Group C|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID + Cilostazol 100 mg PO, BID
62503175|NCT03504124|EXPERIMENTAL|Intervention group|Patients will receive a multicomponent intervention.
62702262|NCT06751329|EXPERIMENTAL|Dose Level 2|≤2.0 mg/kg
62702263|NCT06751329|EXPERIMENTAL|Dose Level 3|≤3.0 mg/kg,
62345380|NCT03364335|EXPERIMENTAL|Leu Met Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
62345381|NCT00941902||Patients scheduled to bariatric surgery|
62345382|NCT03736174||Compartment Pressure Testing|Patients who present with symptoms of CECS will be consented and tested per protocol with compartment pressure testing. Concurrently, patients will undergo a high frequency ultrasound to observe any patterns in structure to assist future research in noninvasively diagnosing CECS. Evaluation of ultrasonographic findings will be dependent on tissue density as measured by hypoechoic versus hyperechoic signal as well as muscle compartment thickness at its largest dimension.
62345383|NCT03736174||Control|Control subjects will undergo exercise protocol and ultrasound, but will not have compartment pressure testing completed.
62345384|NCT03687138||Control 1|This is the control LES population. The analysis will be done with a 24h urin sample. We will compare this population with the other control population and the study population.
62345385|NCT03687138||Study population|This is the study population. The analysis will be done with a 24h urin sample. We will compare this population with the controls populations.
62345386|NCT01442532|EXPERIMENTAL|1|
62345387|NCT01442532|EXPERIMENTAL|2|
62345388|NCT01442532|EXPERIMENTAL|3|
62345389|NCT01442532|PLACEBO_COMPARATOR|4|
62345390|NCT01442532|EXPERIMENTAL|5|
62345391|NCT02157506|EXPERIMENTAL|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
62345392|NCT02157506|EXPERIMENTAL|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
62345393|NCT02157506|EXPERIMENTAL|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
62345394|NCT02157506|EXPERIMENTAL|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
62345395|NCT02157506|EXPERIMENTAL|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
62345396|NCT02157506|EXPERIMENTAL|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
62345397|NCT02157506|PLACEBO_COMPARATOR|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
62345398|NCT00594204|ACTIVE_COMPARATOR|varenicline|
62345399|NCT00594204|PLACEBO_COMPARATOR|placebo|
62345400|NCT03004469|EXPERIMENTAL|P-3074 + Finasteride Placebo|Participants received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 milligram (mg) tablet orally once daily for 24 weeks.
62345401|NCT03004469|PLACEBO_COMPARATOR|P-3074 Vehicle + Finasteride Placebo|Participants received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.
62345402|NCT03004469|ACTIVE_COMPARATOR|Oral Finasteride + P-3074 Vehicle|Participants received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.
62345403|NCT04276129|EXPERIMENTAL|post-surgical CHX mouth-rinses (treatment group - CHX)|periodontal surgery + post-surgical CHX mouth-rinses + buccal attached gingival (G) biopsies 24 hr after surgical procedure
62345404|NCT04276129|OTHER|NO post-surgical mouth-rinses treatment (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
62345405|NCT04742426|ACTIVE_COMPARATOR|WHO group|minimal setting of personal protective equipment (COVID 19) recommended by WHO
62345406|NCT04742426|EXPERIMENTAL|Super-safe setup|maximal super-safe setup of personal protective equipment
62345407|NCT06041646|OTHER|Active Treatment - 180 mcg of Igalmi (dexmedetomidine)|An initial dose of 180 µg of Igalmi as needed for the treatment of agitation over a period of 7 days. In the event of persistent or recurrent agitation, investigators may choose to repeat dose at 90 μg after the 2-hour time point in the absence of dose-limiting adverse events or safety concerns. A maximum of 2 repeat doses will be allowed in a 24-hour period.
62345408|NCT01885858|OTHER|Sequence 1|Clinics receive first the indigenous and then the mestizo profile.
62345409|NCT01885858|OTHER|Sequence 2|Clinics receive first the mestizo and then the indigenous profile.
62345410|NCT00939224||Cohort Phase 1|Cardiac Catheterization
62345411|NCT03452891|EXPERIMENTAL|Simvastatin Methylcellulose|simvastatin in methylcellulose gel
62345412|NCT03452891|PLACEBO_COMPARATOR|Methylcellulose Gel|Methylcellulose gel
62345413|NCT00004992|PLACEBO_COMPARATOR|Placebo|
62345414|NCT00004992|ACTIVE_COMPARATOR|Metformin|
62345415|NCT00004992|ACTIVE_COMPARATOR|Intensive Lifestyle|
62345416|NCT03303092|EXPERIMENTAL|TEV-48125 (225/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
62345417|NCT03303092|EXPERIMENTAL|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
62345418|NCT03303092|PLACEBO_COMPARATOR|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
62345419|NCT01213095|EXPERIMENTAL|Rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
62345420|NCT06433518||Women defined as poor responders according to POSEIDON criteria group 4 undergoing IVF|This group of women, who have low serum AMH levels and low antral follicle count obviusly reveal unfavorable ovarian stimulation and reproductive outcomes in daily practice. Since the most important outcome measure is the live birth rate in assisted reproduction, rates have been reportedly very low for this cohort. Depending from the reports, live birth rates particularly cumulative rates directly correlated with collected numbers of oocytes. Therefore, studies should focus on this entity.
62503176|NCT03504124|NO_INTERVENTION|Control group|Patients will receive the usual care.
62503177|NCT00272272|EXPERIMENTAL|Balance and Music Listening|Music therapy
62503178|NCT01999088|EXPERIMENTAL|Functional meat|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
61956265|NCT06141187|ACTIVE_COMPARATOR|Vertebroplasty|Polymethyl-methacrylate (PMMA) cement is prepared and injected slowly into the vertebral body under constant bi-plane fluoroscopy
62142514|NCT01828671|ACTIVE_COMPARATOR|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
62345421|NCT03463096|EXPERIMENTAL|Centrifuge study|High G acceleration on a long-arm human centrifuge
62142515|NCT02022657|ACTIVE_COMPARATOR|33%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
62142516|NCT02022657|ACTIVE_COMPARATOR|33%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
62345422|NCT00349752|EXPERIMENTAL|Certolizumab pegol 400 mg|Certolizumab pegol 400 mg
62345423|NCT00349752|PLACEBO_COMPARATOR|Placebo|Placebo
62345424|NCT05138406|EXPERIMENTAL|Graded Motor Imagery|Individuals will receive standard rehabilitation and graded motor imagery treatment.
61956266|NCT06141187|SHAM_COMPARATOR|Sham vertebroplasty|A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.
61956267|NCT02957669|EXPERIMENTAL|Practice Self-Regulation (PS-R)|Practice Self-Regulation (PS-R) is the treatment condition. PS-R is an in-person, individual-level, clinic-based intervention that aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
61956268|NCT02957669|ACTIVE_COMPARATOR|Therapy Practice Group|Therapy Practice Group is the control counterfactual condition. It is an individual-level, therapy as usual in which the therapist addresses mental health concerns of the participant.
62142517|NCT02022657|ACTIVE_COMPARATOR|67%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
62142518|NCT02022657|ACTIVE_COMPARATOR|67%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
62142519|NCT02022657|ACTIVE_COMPARATOR|100%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
62345425|NCT05138406|ACTIVE_COMPARATOR|Standard Rehabilitation Group|Standard rehabilitation will be applied.
62503179|NCT01999088|PLACEBO_COMPARATOR|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
62142520|NCT02022657|ACTIVE_COMPARATOR|100%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
62142521|NCT05381090|ACTIVE_COMPARATOR|Healthy control|Venous blood collection
62142522|NCT05381090|EXPERIMENTAL|Parkinson's disease|Venous blood collection
62142523|NCT05381090|EXPERIMENTAL|Parkinson's disease dementia|Venous blood collection
62142524|NCT05381090|EXPERIMENTAL|Dementia with Lewy Bodies|Venous blood collection
62142525|NCT05381090|EXPERIMENTAL|Alzheimer's disease|Venous blood collection
62142526|NCT06342700|ACTIVE_COMPARATOR|Treatment A: SAR444671 amorphous fasted|Participants will receive single oral dose of amorphous tablet formulation rilzabrutinib (SAR444671) under fasted conditions on Day 1 for one period
62142527|NCT06342700|EXPERIMENTAL|Treatment B: SAR444671 crystalline fasted|Participants will receive single oral dose of crystalline tablet formulation rilzabrutinib (SAR444671) under fasted conditions on Day 1 for one period
62142528|NCT06342700|ACTIVE_COMPARATOR|Treatment C: SAR444671 amorphous fed|Participants will receive single oral dose of amorphous tablet formulation rilzabrutinib (SAR444671) under fed conditions on Day 1 for one period
62142529|NCT06342700|EXPERIMENTAL|Treatment D: SAR444671 crystalline fed|Participants will receive single oral dose of crystalline tablet formulation rilzabrutinib (SAR444671) under fed conditions on Day 1 for one period
62142530|NCT02873559|NO_INTERVENTION|Controls|A control group, which is 20 weeks with placebo injections without training.
62142531|NCT02873559|EXPERIMENTAL|Testosterone|A testosterone group given 20 weeks on testosterone injections without training
62142532|NCT02873559|EXPERIMENTAL|Training|A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
62142533|NCT02873559|EXPERIMENTAL|Testosterone and training|A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
62142534|NCT06311266|ACTIVE_COMPARATOR|robotic|In the robotic group the endoscope will be guided with the EndoGuide robotic system
62345426|NCT01427283|EXPERIMENTAL|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
62345427|NCT01427283|ACTIVE_COMPARATOR|OXY|Oxycodone HCl controlled-release tablets (OXY)
62345428|NCT01427283|PLACEBO_COMPARATOR|Placebo|Placebo tablets to match OXN or OXY
62345429|NCT01693055|EXPERIMENTAL|UltheraTM|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
62702264|NCT06751329|EXPERIMENTAL|Dose Level 4|≤4.5 mg/kg
62702265|NCT06751329|EXPERIMENTAL|Dose Level 5|≤6.0 mg/kg
62702266|NCT06751329|EXPERIMENTAL|Dose Level 6|≤7.5 mg/kg
62702267|NCT06750809|EXPERIMENTAL|PermeaDerm Temporary Biosynthetic Wound Matrix|
62702268|NCT06750809|EXPERIMENTAL|Frozen Human Cadaveric Allograft (FHCA)|
62702269|NCT06749093|PLACEBO_COMPARATOR|Filtered Air (FA)|Participants will be exposed to 2 hours of high-efficiency particulate air (HEPA) filtered air (FA).
62345430|NCT04314479|EXPERIMENTAL|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes
62503180|NCT03209349|EXPERIMENTAL|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
62702270|NCT06749093|ACTIVE_COMPARATOR|Wood Smoke (WS)|Participants will be exposed to 2 hours of controlled wood smoke (WS) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
62702271|NCT06749093|ACTIVE_COMPARATOR|Diesel Exhaust (DE)|Participants will be exposed to 2 hours of controlled diesel exhaust (DE) as a model of traffic-related air pollution (TRAP) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
62702272|NCT06749093|ACTIVE_COMPARATOR|Diesel Exhaust and Wood Smoke (DEWS)|Participants will be exposed to 2 hours of combined controlled diesel exhaust (DE) and wood smoke (DEWS) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
62702273|NCT06748833|EXPERIMENTAL|SMILE Intervention Group|The intervention group used the SMILE App, and the Predicting Risk and Outcomes of Social InTerActions (PROSIT) app, which is a mobile sensing app.
62702274|NCT06748833|NO_INTERVENTION|Control Non-SMILE Intervention Group|Participants in the control group downloaded and used only the PROSIT app, they did not use the SMILE App.
62702275|NCT06749275|ACTIVE_COMPARATOR|5,000 ppm fluoride toothpaste|"Toothbrushing twice per day with 5,000 ppm fluoride toothpaste + individualized Oral Hygiene Instruction (OHI).~Toothpaste of 5,000 ppm of fluoride are considered as the control, since according to international clinical guidelines (Slayton et al. 2018) it would be the treatment of choice to treat RCLs."
61956269|NCT06354400|EXPERIMENTAL|Study group|Isometric exercises of the abdominal muscles in the supine, prone, and squatting positions; isotonic exercises in the supine, prone, squatting, and side-lying positions; isotonic exercises in coordination with the extremity movements in the supine, prone, and crawling positions; and trunk rotation exercises in the sitting position will be performed. The Swiss ball will be used for dynamic exercises. It will include isometric and isotonic exercises of the abdominal muscles. Exercises will start with 3 sets of 20 repetitions, gradually increase in intensity on static and dynamic surfaces, and progress towards difficulty. Each exercise will be performed in coordination with breathing control.Breathing control will be coordinated with every exercise.
61956270|NCT06354400|NO_INTERVENTION|Control group|Since no training will be given to the control group during the study, we consider it ethically necessary to provide the same training to the control group if it proves effective after the study is over.
61956271|NCT05493475|EXPERIMENTAL|Intervention Arm|Each participant in the intervention arm will receive one-on-one education on the purpose, benefits, and limitations of fentanyl test strip (FTS) testing and undergo a brief 20-minute FTS educational intervention (including a 2-3-minute video and hands-on demonstrations on how to use FTS). They will also receive a supply of 10 FTS upon enrollment and continued supply upon request throughout the 2-year follow up period. Each participant will also receive Opioid overdose education and a naloxone kit upon enrollment and re-supply of naloxone as needed throughout the 2-year follow up period.
61956272|NCT05493475|NO_INTERVENTION|Non-Intervention Arm|Each participant will receive Opioid overdose education and a naloxone kit upon enrollment and re-supply of naloxone as needed throughout the 2-year follow up period. Fentanyl test strip (FTS) education and a supply of FTS will be offered to participants in the non-intervention arm of the study during the final quarter of year 3.
61956273|NCT04538430|OTHER|Axial Low Back Pain|Patient diagnosed with axial low back pain not responding to conservative measures and no symptoms of radiculopathy, that is scheduled to have a SPRINT percutaneous peripheral nerve stimulator placed as standard of care.
62702276|NCT06749275|EXPERIMENTAL|22,600 ppm fluoride varnish|Applications of 5% fluoride varnish (22,600 ppm) every 3 months + toothbrushing twice per day with 1,450 ppm fluoride toothpaste + individualized OHI.
62702277|NCT06749275|EXPERIMENTAL|38% SDF|Biannual applications of 38% SDF solution + toothbrushing twice per day with 1,450 ppm fluoride toothpaste + individualized OHI.
62702278|NCT06748170|ACTIVE_COMPARATOR|Intervention group|Group will be given access to ChatGPT and standardized initial prompt
62702279|NCT06748170|NO_INTERVENTION|Control group|Group will not be given access to any LLMs including ChatGPT but will be motivated to use other resources (such as online search enginges, Pubmed)
62702280|NCT06751342||Subjects with Unilateral Congenital Cataract Undergoing Surgery|
61956274|NCT01748084|PLACEBO_COMPARATOR|NaCl|NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone
61956275|NCT01748084|EXPERIMENTAL|Rituximab|Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone
61956276|NCT02003846||Premature infant|Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours
61956277|NCT03100500|EXPERIMENTAL|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
61956278|NCT06278701|NO_INTERVENTION|the control group|Patients who voluntarily accept a regular diet and do not eat again 1h before bedtime
61956279|NCT06278701|EXPERIMENTAL|the test group|Patients who voluntarily accepted to have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
61956280|NCT02887638|EXPERIMENTAL|headache|Patients diagnosed (neurologist - anesthesiologist - manual therapist) with tension-type and/or cervicogenic headache. During a first phase the sitting-posture, dura mater profile and pain-profile of the Headache-group will be analyzed. In a second phase, the patients will be sub-classified according to the data-analysis and receive intervention (Individual Profile Analysis +Physical therapy Intervention)
61956281|NCT02887638|NO_INTERVENTION|asymptomatic controls|Asymptomatic controls, matched for gender and age. During a first phase the sitting-posture, dura mater profile and pain-profile of the control-group will be analyzed.
61956282|NCT04889807||Patients who need fluid perfusion|
61956283|NCT00763620|EXPERIMENTAL|1|Catheter for mini bronchoalveolar lavage
61956284|NCT03210571|EXPERIMENTAL|eyeWatch device|
61956285|NCT06149832|EXPERIMENTAL|MSCs treatment group|
61956286|NCT02790203|EXPERIMENTAL|Celecoxib|"Celecoxib will be given orally to patients participating in the study and allocated to the treatment group, for an intervention period of 6 days, starting from the day of surgery.~Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses, a dose which is within the recommended and a widely used dosage and is expected to induce a significant inhibition of prostaglandin synthesis by the COX2 pathway. Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses."
62142535|NCT06311266|ACTIVE_COMPARATOR|standard freehand|In the standard freehand group the endoscope will be guided freehand throughout the surgery
62142536|NCT04880018|EXPERIMENTAL|Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd|Specification model: CTR1109、CTR1210、CTR1311、CTR1412、CTR1513 Manufacturer: Eyebright Medical Technology (Beijing) Co., Ltd.
62142537|NCT04880018|ACTIVE_COMPARATOR|Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd|Specification model: TENSIOBAG 10、TENSIOBAG 11、TENSIOBAG 12、TENSIOBAG 13、TENSIOBAG14 Manufacturer: Carl Zeiss Medical Technology Co., Ltd.
62142538|NCT01282957|NO_INTERVENTION|Active Control|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 6 months
62345431|NCT04314479|OTHER|Symptom Assessment Only|For participants randomized to the control condition weekly symptom assessment telephone calls will be completed by staff at the University of Arizona Cancer Center Behavioral Measurements Interventions Shared Resource (BMISR). At week 13 an exit interview will be completed by the study coordinator to record participants feedback regarding study intervention, length, coaches, etc... In addition, staff from BMISR will call to repeat all baseline measures with the exception of the demographic questionnaires. Symptom assessment calls will take approximately 15 minutes.
62345432|NCT03827668|EXPERIMENTAL|Single arm|The study will have only one study group in a fixed-sequence type of design with two periods
62345433|NCT05344027||ACC on mitotane|Individuals in this group were under care by the Endocrinology Team with a diagnosis of an ACC and on mitotane. These individuals were further divided into 3 groups, depending on whether they had a mitotane plasma concentration, within (14-20mg/L), above or below the therapeutic concentration range.
62345434|NCT05344027||Adrenal neoplasm without mitotane|Individuals within this category had an adrenal neoplasm and were not being treated with mitotane therapy.
62702281|NCT06751342||Subjects with Bilateral Congenital Cataract Undergoing Surgery|
62142539|NCT01282957|EXPERIMENTAL|Financial Incentive Group I|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $100 and 2 in 10 odds of winning $10. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
62142540|NCT01282957|EXPERIMENTAL|Financial Incentives Group II|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $50 and 2 in 10 odds of winning $5. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
62142541|NCT03488550|EXPERIMENTAL|ANX007-GLA-01|
62142542|NCT06699602|EXPERIMENTAL|Cemiplimab and Fianlimab|All patients will be treated as follows: cemiplimab and fianlimab every 3 weeks for a total of 3 treatments, or until unacceptable toxic effects, overt disease progression, or withdrawal from study.
62702282|NCT06751342||Control Group of Children|
62142543|NCT00822900|EXPERIMENTAL|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone will be combined with a 20% Intralipid mixture for infusion.
62345435|NCT05344027||Pregnant group|Individuals did not have an adrenal neoplasm during this period, nor were they being treated with mitotane. These were healthy pregnant females, who were under the care at KCL during their pregnancy.
62345436|NCT03054987|ACTIVE_COMPARATOR|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
62345437|NCT03054987|ACTIVE_COMPARATOR|ERCP|At ERCP, the common bile duct will be selectively cannulated using a sphincterotome and guide wire technique. Once biliary access is obtained a stent will be deployed to facilitate biliary drainage.
62702283|NCT06751342||Subjects with Comparable Degrees of Bilateral Age-Related Cataract|
62702284|NCT06751342||Subjects with Different Degrees of Bilateral Age-Related Cataracts|
62702285|NCT06751342||Subjects with Shallow Anterior Chambers in Both Eyes|
62702286|NCT06751017|EXPERIMENTAL|S-892216|Participants will receive S-892216 and carbamazepine.
62702287|NCT06750770||AKI group|Participants who were diagnosed acute kidney injury(AKI)
62702288|NCT06750770||Non-AKI group|Participants who were not diagnosed AKI
62345438|NCT02637726|EXPERIMENTAL|TIVA0|Propofol : TIVA guided by clinical signs. Remifentanil
62503181|NCT03209349|ACTIVE_COMPARATOR|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
62503182|NCT00603395|OTHER|ReCap|ReCap Total Hip Resurfacing System
62503183|NCT02121041|NO_INTERVENTION|Usual Care|Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
62503184|NCT02121041|ACTIVE_COMPARATOR|ABPM Guided|Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
62503185|NCT06677853|EXPERIMENTAL|Group1-Timolol Maleate Gel + Placebo|56 patients will be randomized to group 1.
62503186|NCT06677853|EXPERIMENTAL|Group 2-Timolol Maleate Gel|56 patients will be randomized to group 2.
62503187|NCT06677853|PLACEBO_COMPARATOR|Group 3-Placebo|56 patients will be randomized to group 3.
62503188|NCT05752435|ACTIVE_COMPARATOR|BLEOMYCIN|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
62503189|NCT05752435|ACTIVE_COMPARATOR|CRYOTHERAPY|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
62503190|NCT01023776|OTHER|live monovalent H1N1 vaccine|A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
62503191|NCT00769314|EXPERIMENTAL|1|Acyclovir Lauriad 50mg
62503192|NCT00769314|PLACEBO_COMPARATOR|2|
62503193|NCT01133717||Control without Sleep Apnea|
62142544|NCT00822900|PLACEBO_COMPARATOR|Placebo|"Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion."
62142545|NCT01935063|EXPERIMENTAL|Cognitive Behavioral Couple Therapy|CBCT is a 12-session therapy that includes the following: re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviours and couple interactions; psychoeducation about PVD and its impact upon sexuality, defining/working the sexual script, mindfulness techniques, communication skills training, and sexual approach/avoidance goals work, defusion and acceptance approaches to coping with pain, among others.
62142546|NCT01935063|ACTIVE_COMPARATOR|Topical lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, \& Steege, 2003).
62142547|NCT01083732|EXPERIMENTAL|dabigatran etexilate|treatment with dabigatran oral solution as a single dose
62345439|NCT02637726|EXPERIMENTAL|TIVA BIS|propofol : TIVA guided by EEG Monitoring. Remifentanil
62345440|NCT02637726|EXPERIMENTAL|TCI KBIS|Propofol : TCI Kataria guided by EEG Monitoring. Remifentanil.
62345441|NCT02637726|EXPERIMENTAL|TCI SBIS|Propofol : TCI Schnider guided by EEG Monitoring. Remifentanil.
62345442|NCT04961099|EXPERIMENTAL|low-dose group|low-dose group: HY01 10mg（20mg/ml）
62345443|NCT04961099|EXPERIMENTAL|high-dose group|high-dose group: HY01 20mg（40mg/ml）
62345444|NCT00986310|ACTIVE_COMPARATOR|fluoxetine|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
62714884|NCT04562116|EXPERIMENTAL|CYP 450 Substrates plus Nemolizumab|Participants will receive 1 single oral dose of selected, commercially available, cytochrome P450 substrates (CYP450-S) on Day 1 and after a 1-week washout period, participants will receive a 60 milligram (mg) loading dose of nemolizumab via 2 consecutive subcutaneous (SC) 30-mg injections at the Week 1 visit, followed by a single 30-mg injection once in every 4 weeks (Q4W) at Week 5 and Week 9. Participants will receive a second oral dosing of CYP450-S at Week 10.
62345445|NCT00986310|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
62503194|NCT01133717||Subjects with Sleep Apnea|
62503195|NCT00957216|PLACEBO_COMPARATOR|sugar pill|
62503196|NCT00957216|ACTIVE_COMPARATOR|Coenzyme Q10|The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias
62503197|NCT04386109||Neonates COVID-19 positive|1. Neonatal COVID-19 in babies (\<29 days old) in neonatal units, paediatric intensive care units and other in-patient locations.
62503198|NCT04386109||Neonates born to COVID-19 positive mothers|2. Neonates (\<29 days old) born to COVID-19 positive mothers requiring neonatal care
62503199|NCT00313508|EXPERIMENTAL|A: Peptide-pulsed DC, ALI and Low Dose Fludarabine|Fludarabine: 5 mg/m\^2/day, Auto Lymphocyte Infusion, DC Infusion
61956287|NCT02790203|PLACEBO_COMPARATOR|Placebo|"Placebo will be given orally to patients participating in the study and allocated to the control group that will receive placebo, for an intervention period of 6 days, starting from the day of surgery.~Placebo will be given throughout the intervention period of the study orally in capsules that resemble the drug, twice a day."
61956288|NCT00268593|EXPERIMENTAL|130 mg PI-88 + docetaxel|130 mg PI-88 7 days/week + docetaxel 75 mg/m2
61956289|NCT00268593|EXPERIMENTAL|250 mg PI-88 + docetaxel|250 mg PI-88 4 days/week + docetaxel 75 mg/m2
61956290|NCT03799731|EXPERIMENTAL|Cohort I: GM102 single agent|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22 of each 28-day cycle
61956291|NCT03799731|EXPERIMENTAL|Cohort II: GM102 + trifluridine/tipiracil|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22, and trifluridine/tipiracil will be orally administered at the dose of 35 mg/m² twice daily on Days 1 to 5 and days 8 to 12 of each 28-day cycle
62702289|NCT06751459|EXPERIMENTAL|Experimental Group|"Participants in this clinical trial will undergo a total of three remote electrocardiographic (ECG) monitoring sessions during the study period following catheter ablation:~1. st Monitoring: At the time of discharge after catheter ablation, remote ECG monitoring will be performed for 14 days using both the MEMO Patch 2 and MEMO Link.~2. nd Monitoring: Approximately three months after catheter ablation, remote ECG monitoring will be performed for 14 days using only the MEMO Patch 2.~3. rd Monitoring: Approximately one year after catheter ablation, remote ECG monitoring will again be performed for 14 days using only the MEMO Patch 2."
62702290|NCT06751459|ACTIVE_COMPARATOR|Active Comparator Group|"Participants in this clinical trial will undergo a total of three remote electrocardiographic (ECG) monitoring sessions during the study period following catheter ablation:~1. st Monitoring: At the time of discharge after catheter ablation, remote ECG monitoring will be conducted for 14 days using both the MEMO Patch 2 and MEMO Link.~2. nd Monitoring: Approximately three months after catheter ablation, remote ECG monitoring will be conducted for 1 day using only the MEMO Patch 2.~3. rd Monitoring: Approximately one year after catheter ablation, remote ECG monitoring will be conducted for 14 days using only the MEMO Patch 2."
61956292|NCT03799731|EXPERIMENTAL|Cohort II expansion: GM102 + trifluridine/tipiracil|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22, after a loading dose of 10 mg/kg q1w during 28-day cycle 1, and trifluridine/tipiracil will be orally administered at the dose of 35 mg/m² twice daily on Days 1 to 5 and days 8 to 12 of each 28-day cycle
61956293|NCT03613844|EXPERIMENTAL|DHA|oral DHA supplementation at 2 grams per day
61956294|NCT03613844|PLACEBO_COMPARATOR|Placebo|Placebo for DHA
61956295|NCT00571545|EXPERIMENTAL|1|Subjects recruited from the community with a history of traumatic brain injury were enrolled into a 10 week supervised exercise program and encouraged to exercise at home as well.
61956296|NCT00571545|OTHER|2|Controls were wait-listed for the supervised exercise program but were not treated during the 10 week wait period.
61956297|NCT04670198|EXPERIMENTAL|Intervention|The intervention arm will receive the Youth Empowerment Skills (YES) programme.
62345446|NCT01705197|ACTIVE_COMPARATOR|Avanfil 100 or 200mg|All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization. When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed. For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
62345447|NCT01705197|PLACEBO_COMPARATOR|Placebo 100mg or 200mg|When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
61956298|NCT04670198|OTHER|Waiting-list control|The waiting-list control arm will receive usual care for six months before receiving the Youth Empowerment Skills (YES) programme.
61956299|NCT06208683|EXPERIMENTAL|1MCV: MV|100 students with a history of 1 dose of MCV will receive 1 dose of MV.
62503200|NCT00313508|EXPERIMENTAL|B: Peptide-pulsed DC, ALI and High Dose Fludarabine|Fludarabine: 25 mg/m\^2/day, Auto Lymphocyte Infusion, DC Infusion
62503201|NCT05919745|EXPERIMENTAL|Ibuprofen group or Test Group|Subjects will be given ibuprofen 600mg tab 1h prior to surgery.
62503202|NCT05919745|PLACEBO_COMPARATOR|Placebo group or Control group|Subjects will be given a placebo tab 1h prior to surgery.
61956300|NCT06208683|EXPERIMENTAL|1MCV: QIV|100 students with a history of 1 dose of MCV will receive 1 dose of QIV.
61956301|NCT06208683|EXPERIMENTAL|1MCV: MV +QIV|100 students with a history of 1 dose of MCV will receive 1 dose of MV and 1 dose of QIV simultaneously.
61956302|NCT06208683|EXPERIMENTAL|2MCV: MV|100 students with a history of 2 dose of MCV will receive 1 dose of MV.
61956303|NCT03416946|ACTIVE_COMPARATOR|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
61956304|NCT03416946|ACTIVE_COMPARATOR|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
61956305|NCT05865067|EXPERIMENTAL|Yoga Therapy|Participation will consist of 1) a telephone survey to screen for exclusion factors; 2) filling out two questionnaires and consent at the first visit; 3) filling out four questionnaires on orientation day (day 2); 4) receiving an orientation for you and your child and receive an educational pamphlet on the 2nd and 15th (closing); 5) participate in the 12 Yoga sessions with your child (Saturdays) with a weekly call to remind you of your appointment; 6) fill out a questionnaire on day 8 (6th yoga class); 7) fill out five questionnaires on the 15th (closing); 8) a possible assessment of your child's heartbeat at the 12 intervention sessions (will be randomly selected); 9) an evaluation of your child's sweating at the first visit (orientation) and at visit 15 (closing); 10) a last visit to finish and offer additional information (day 15; closing); 11) a telephone survey three months (day 16) after completing the study.
61956306|NCT05865067|ACTIVE_COMPARATOR|Wait-List with Exercise|Participation consists of 1) a telephone survey to screen for exclusion factors; 2) filling out two questionnaires and informed consent at the first visit; 3) filling out four questionnaires in the second meeting (day 2 of orientation); 4) filling out six questionnaires in the last meeting (day 15; closure); 4) receive a 30-45 minute video orientation and psychoeducation (where you will also receive an educational brochure) and a series of exercise recommendations for you and your child on day 2 (orientation); 5) 12 phone calls (once a week); 6) an evaluation of your child's sweating at the first visit (orientation) and last visit (day 15; closure); 7) an evaluation of your child's heart rhythm at the first visit (orientation) and last visit (day 15; closure); 8) a telephone survey (day 16; follow-up) 3 months after completing the study; 9) a call at the end of the study to coordinate the Yoga sessions for you and your child once the first group has finished.
61956307|NCT02701400|EXPERIMENTAL|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
61956308|NCT02701400|ACTIVE_COMPARATOR|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
61956309|NCT06197750|EXPERIMENTAL|Vestibular stimulation|Group A received the vestibular stimulation by swing in different positions supine, prone and with or without support in each position for 10minnts 3 times a week for 10 weeks along with general strengthening exercises of upper and lower limb and
61956310|NCT06197750|ACTIVE_COMPARATOR|general strengthening exercises|group B will receive general strengthening exercises of whole body for same time period.
61956311|NCT03517098|EXPERIMENTAL|The ERAS group|Patients will be treated with the ERAS pathway
61956312|NCT03517098|OTHER|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
62142548|NCT01692769|ACTIVE_COMPARATOR|Normal Saline|Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
62142549|NCT01692769|ACTIVE_COMPARATOR|Ringer's Lactate|Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
62503203|NCT01831986|EXPERIMENTAL|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
62503204|NCT01831986|PLACEBO_COMPARATOR|Sugar caps.|Placebo (4 caps/day)
62503205|NCT04724460|ACTIVE_COMPARATOR|Long DOAC|Administration of Rivaroxaban for 18 months
62503206|NCT04724460|ACTIVE_COMPARATOR|Short DOAC|Administration of Rivaroxaban for 6 months
62503207|NCT03860337|EXPERIMENTAL|Alginate then Control|This group will be given the alginate then the control sausages
62503208|NCT03860337|EXPERIMENTAL|Control then Alginate|This group will be given the control then alginate sausages
61956313|NCT02036697|EXPERIMENTAL|Low Dose Spinal|"Hyperbaric bupivacaine 4.5mg with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be positioned right side down and head down 20-30 degrees for the dural puncture and then positioned supine in the left lateral tilt position after the anesthetic solution has been given. The OR table will be kept in 20-30 degrees head down for the cesarean section."
62142550|NCT05856656|EXPERIMENTAL|Music therapy arm|A music therapy will be offered to patients before the first 3 chemotherapy cycles
62142551|NCT05856656|NO_INTERVENTION|Standard care arm|Standard patient care, no intervention
62142552|NCT01128595|ACTIVE_COMPARATOR|ICS|
62142553|NCT01128595|ACTIVE_COMPARATOR|ICS/LABA|
62142554|NCT01128595|ACTIVE_COMPARATOR|LABA|
62142555|NCT01128595|PLACEBO_COMPARATOR|Placebo|
62142556|NCT01357057||Derivation cohort|Arm 1: Derivation cohort (from 2003 to 2007)
62142557|NCT01357057||Validation cohort|Arm 2: Validation cohort (from 2008 to 2009)
62142558|NCT05066022|EXPERIMENTAL|Experimental: CT0590 CAR T cells|Dose-escalated CAR T cells infusion
62142559|NCT04006834||MDD with hypersomnia|Patient with a history of MDD and ESS \>10
62142560|NCT04006834||MDD without hypersomnia|Patient with a history of MDD and ESS \<=10
62503209|NCT06466356|EXPERIMENTAL|Psychoeducational group therapy|Group therapy session, 3 meetings. Each group includes 8-10 participant to receive a group based psychoeducative intervention (three for patients, one for next of kin) and TAU.
62503210|NCT06466356|ACTIVE_COMPARATOR|Individual therapy session|The participants in the control group receive one individual therapy session with focus on suicide risk and safety plan with a psychologist or physician and TAU
62503211|NCT00930241|EXPERIMENTAL|Advagraf|Advagraf® (one daily dose of Tacrolimus)
62503212|NCT00930241|ACTIVE_COMPARATOR|Prograf|Prograf® (two daily doses of Tacrolimus)
62503213|NCT02930668|PLACEBO_COMPARATOR|Placebo|"The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.~Subjects will take 2 capsules three times a day, 30 mins before meals."
62503214|NCT02930668|EXPERIMENTAL|Low dose (Glucosanol 350mg)|"Each capsule contains Glucosanol / Phaselite 350mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
62503215|NCT02930668|EXPERIMENTAL|High dose (Glucosanol 500mg)|"Each capsule contains Glucosanol / Phaselite 500mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
62503216|NCT05283330|EXPERIMENTAL|²¹²Pb-DOTAM-GRPR1|In the dose escalation portion, a classic 3+3 design will be utilized. Doses will be increased by approximately 30% in subsequent cohorts. The maximum total dose that may be administered to a subject per cycle is 5.5 mCi +/- 10%. The maximum total dose that may be administered to a subject in the MAD regimen is 24 mCi over 4 cycles.
62503217|NCT03232736||Healthy Control|Individuals free of cardiovascular disease and not on any medications to treat a cardiovascular-related condition
62503218|NCT03232736||LVAD Group|Individuals with history of advanced heart failure who are supported by left ventricular assist devices
61956314|NCT02036697|ACTIVE_COMPARATOR|Control Spinal Group|"Hyperbaric bupivacaine 1.2cc (9mg) with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be in the sitting position for the dural puncture and then positioned supine, in the left lateral tilt position after the anesthetic solution has been given. Once block height has been established the patient will be placed in 20-30 degrees trendelenberg for the cesarean section."
61956315|NCT05163236||CRC in excluded population|CRC diagnosed in the population excluded from screening
61956316|NCT05163236||Screen-detected colorectal cancers (SD-CRCs)|CRC diagnosed after a positive fecal immunochemical test (FIT)
61956317|NCT05163236||Colorectal cancers (CRCs) with delayed diagnosis|CRCs diagnosed after a positive fecal immunochemical (FIT) test, but without colonoscopy or \> 2 years after a positive fecal immunochemical test
61956318|NCT05163236||Fecal immunochemical test interval colorectal cancers (FIT IC)|CRCs diagnosed 2 years after a negative FIT
61956319|NCT05163236||colorectal cancers (CRCs) in non-responders|CRCs diagnosed in the FIT non-responders population
61956320|NCT05163236||Post-colonoscopy interval cancers|CRCs diagnosed within 5 years after a colonoscopy performed following a positive test that did not find colorectal cancer
61956321|NCT04113109|EXPERIMENTAL|placebo, icatibant, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
61956322|NCT04113109|EXPERIMENTAL|placebo, icatibant, icatibant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
61956323|NCT04113109|EXPERIMENTAL|icatibant, placebo, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
62503219|NCT01438476|EXPERIMENTAL|IV Pain Management|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
62503220|NCT01438476|EXPERIMENTAL|Epidural Pain Management|Thoracic epidurals placed preoperatively in either holding area or in operating room. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
62503221|NCT02846844||Group A|"* Whole body vibration training~* manuelle therapy~* exercises for power and coordination~* performance training as needed"
62503222|NCT02846844||Group B|"* manuelle therapy~* Exercises for power and coordination~* Performance training as needed"
62503223|NCT06679374|PLACEBO_COMPARATOR|Placebo|
62736627|NCT01951989|EXPERIMENTAL|Imiglucerase|"Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.~Secondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
61956324|NCT04113109|EXPERIMENTAL|icatibant, placebo, icatibant placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
61956325|NCT05547685|EXPERIMENTAL|Methylene blue intradermal injection|Methylene blue intradermal injection
61956326|NCT02381145|PLACEBO_COMPARATOR|Placebo|micro-cellulose-filled Placebo
61956327|NCT02381145|ACTIVE_COMPARATOR|EGCG+RSV-supplementation|EGCG+RSV: 300mg/d + 80mg/d
61956328|NCT05877352|ACTIVE_COMPARATOR|No IOERT|Extended margin surgery
61956329|NCT05877352|EXPERIMENTAL|Low Dose IOERT|Extended margin surgery and IOERT at standard dose (10 Gy)
61956330|NCT05877352|EXPERIMENTAL|High Dose IOERT|Extended margin surgery and IOERT at higher dose (15 Gy)
61956331|NCT06147362|EXPERIMENTAL|68Ga-NOTA-PEG2-RM26|Participants will be injected with 2 MBq/kg of 68Ga-NOTA-PEG2-RM26 limited to 100-200 MBq and then undergo PET/CT examination.
61956332|NCT05037071|EXPERIMENTAL|Upper body compression|An arm compression sleeve with a graduated compression between 18-25 mmHg will be worn on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy.
61956333|NCT05037071|NO_INTERVENTION|No compression|Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. .
61956334|NCT02099578|PLACEBO_COMPARATOR|Control Group|Freeze-dried placebo powder - two doses of 25 g/day for 8 weeks
61956335|NCT02099578|ACTIVE_COMPARATOR|25 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry and placebo powder - one dose of 25 g/day of each for 8 weeks
61956336|NCT02099578|EXPERIMENTAL|50 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry powder - two doses of 25 g/day for 8 weeks
61956337|NCT01540240|ACTIVE_COMPARATOR|standard dosage zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
61956338|NCT01540240|ACTIVE_COMPARATOR|low dosage zidovudine|
62503224|NCT06679374|EXPERIMENTAL|Varenicline|
62503225|NCT04687241|EXPERIMENTAL|Almonertinib|
62503226|NCT04687241|PLACEBO_COMPARATOR|Placebo Almonertinib|
62142561|NCT05443698|OTHER|Ultrasound Device|All women who choose to enroll in the trial will undergo an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
62142562|NCT01849107|EXPERIMENTAL|Plasma citrulline|
62503227|NCT06142292|EXPERIMENTAL|Clients|"All participants will be asked to complete the following:~participate in 12 individual mental health counseling sessions participate in 3 group counseling sessions"
61956339|NCT03750708|OTHER|Ara® KOLIBREE toothbrush|The Ara® KOLIBREE tooth brush is given to the child at the usual consultation one month before alveolar bone graft.
62345448|NCT02500602|EXPERIMENTAL|Doxazosin|Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
62345449|NCT02500602|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to placebo. Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
62345450|NCT02793895|EXPERIMENTAL|Enhanced cardiac rhythm monitoring|Subjects in this group will receive up to 30 days of continuous cardiac rhythm monitoring with an adhesive monitor. Cardiac rhythm monitoring will begin on the day of randomization. The device that will be used is the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
62345451|NCT02793895|ACTIVE_COMPARATOR|Usual care|Subjects randomized to the usual care arm will be discharged from hospital without protocol-mandated continuous cardiac rhythm monitoring. Within the first 30 days after randomization, no protocol-mandated cardiac rhythm assessment will be arranged. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
62345452|NCT04823767|EXPERIMENTAL|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
62345453|NCT03155295||Physical reality simulation (rehearsal)|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. Participants with patients assigned to preoperative rehearsal will undergo pre-operative simulation only once.
62345454|NCT03155295||Virtual reality simulation|The DaVinci surgical skills simulator (DVSSS) uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. Participants with patients assigned to preoperative simulation will complete a refresher module on the Virtual reality simulator.
62345455|NCT03018912|EXPERIMENTAL|Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. Investigators or research associates will review the Sleep VS, and patients that screen positive on their Sleep VS will be asked to complete an extended set of sleep questions. A triaging algorithm will be available based on answers to the extended sleep questions to assist the primary care physician with assessment and triaging care. Patients that screen negative will not be asked the extended sleep questions nor will they be brought to the attention of the primary care physician and proceed with usual care."
62345456|NCT03018912|NO_INTERVENTION|Usual Care|"Patients check-in for their primary care physician visit and proceed with usual care. Although the sleep vital sign will not be collected, the medical providers can still use the extended sleep questionnaire and triaging algorithm, if in the course of caring of the patient a potential sleep disorder is recognized."
62345457|NCT01461408|EXPERIMENTAL|Beauty Salon #1b|Females ages 18-26
62345458|NCT01461408|EXPERIMENTAL|Beauty Salon #1a|Mothers of 9-18 year old females
62345459|NCT01461408|EXPERIMENTAL|Beauty Salon #2b|Females ages 18-26
62345460|NCT01461408|EXPERIMENTAL|Beauty Salon #3a|Mothers of 9-18 year old females
62345461|NCT01461408|EXPERIMENTAL|Beauty Salon #3b|Females ages 18-26
62345462|NCT01461408|EXPERIMENTAL|Beauty Salon #4a|Mothers of 9-18 year old females
62345463|NCT01461408|EXPERIMENTAL|Beauty Salon #4b|Females ages 18-26
61956340|NCT03750708|NO_INTERVENTION|Without Ara® KOLIBREE tooth brush|Usual consultation one month before alveolar bone graft.
62345464|NCT01461408|EXPERIMENTAL|Beauty Salon #2a|Mothers of 9-18 year old females
62345465|NCT01461408|EXPERIMENTAL|Beauty Salon #5a|Mothers of 9-18 year old females
62345466|NCT01461408|EXPERIMENTAL|Beauty Salon #5b|Females ages 9-26
62503228|NCT04599166|EXPERIMENTAL|Participant arm|Participants will be recruited to complete the WWYC intervention.
62503229|NCT03023709|OTHER|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
61956341|NCT00196755|EXPERIMENTAL|Sevelamer Hydrochloride (Renagel®)|
62142563|NCT03353636|EXPERIMENTAL|Natural Calm Magnesium|150mg elemental magnesium in a single oral dose
62142564|NCT03353636|ACTIVE_COMPARATOR|Magnesium Bis-glycinate|150mg elemental magnesium in a single oral dose
62142565|NCT03353636|ACTIVE_COMPARATOR|MAGSmart|150mg elemental magnesium in a single oral dose
62142566|NCT03353636|ACTIVE_COMPARATOR|Magnesium citrate|150mg elemental magnesium in a single oral dose
62142567|NCT03353636|PLACEBO_COMPARATOR|Placebo|
61956342|NCT00196755|ACTIVE_COMPARATOR|Calcium acetate (PhosLo® )|
61956343|NCT01245621|ACTIVE_COMPARATOR|Early entry group|Early entry group will begin the intervention at time of diagnosis of advanced cancer
62142568|NCT02798900|EXPERIMENTAL|Functional task-training and Ultrasound|This group will receive 16 sessions of functional task-training program and therapeutic ultrasound will be applied prior to functional task-training.
62503230|NCT03023709|OTHER|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
62345467|NCT01461408|EXPERIMENTAL|Beauty Salon #6a|Mothers of 9-18 year old females
62142569|NCT02798900|ACTIVE_COMPARATOR|Functional task-training|This group will receive 16 sessions of functional task-training program.
62345468|NCT01461408|EXPERIMENTAL|Beauty Salon #6b|Females ages 18-26
62503231|NCT00867854||Experimental|25 evaluable subjects from the experimental arm of ATN 061 who undergo de-intensification to boosted atazanavir (ATV) with VL suppression of \< 100 copies/ml and CD4+ T cells \> 350 cells/mm3 at week 48 and maintain VL suppression to \< 400 copies/ml with stable CD4+ T cell counts after week 48.
62503232|NCT00867854||Control|25 evaluable subjects from ATN 071 will also be enrolled. These subjects will have initiated HAART according to current DHHS guidelines (CD4+ T cells \< 350 cells/mm3), had viral load suppression to \< 100 copies/ml at 24 through 48 weeks on HAART and maintained suppression to \< 400 copies/ml through week 80.
62503233|NCT05193409|EXPERIMENTAL|225 mg BNC210|
62503234|NCT05193409|EXPERIMENTAL|675 mg BNC210|
62503235|NCT05193409|PLACEBO_COMPARATOR|Placebo|
62503236|NCT05810857|OTHER|Motor Relearning Program|
62345469|NCT01461408|EXPERIMENTAL|Beauty Salon #7a|Mothers of 9-18 year old females
62503237|NCT05810857|OTHER|Mirror Therapy|
62503238|NCT03818386|EXPERIMENTAL|AGuIX® + Whole Brain Radiation Therapy|"Intervention: Drug: AGuIX® + WBRT~Other Names:~Gadolinium-chelated polysiloxane based nanoparticles~3 intravenous injections at 100mg/kg~* D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~* Fr1: AGuIX® injection before the first radiation session~* Fr6: AGuIX® injection before the sixth radiation session~  30 Gy in 10 fractions of 3 Gy over 2-3 weeks"
62503239|NCT03818386|ACTIVE_COMPARATOR|Whole Brain Radiation Therapy|Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
62503240|NCT06417437|ACTIVE_COMPARATOR|Medication Group|Patients with anhedonia will be using either Bupropion or Voxetine. Patients without anhedonia will be given SSRIs. Frequency and dosage will be guided by psychiatrist. Treatment will last 4 weeks.
62503241|NCT06417437|EXPERIMENTAL|Traditional rTMs Group|In addition to medication using SSRIs, patients will be also treated with rTMS. The stimulated brain region has decided to be dlpfc. Treatment will last 4 weeks.
62503242|NCT06417437|EXPERIMENTAL|New rTMS Group|In addition to medication using SSRIs, patients will be also treated with rTMS. The stimulated brain region has not been decided, but rbitofrontal cortex, cerebellum and others are considered. Treatment will last 4 weeks.
62503243|NCT06417437|EXPERIMENTAL|Neuro-Feedback Group|In addition to medication using SSRIs, patients will be also treated with Neuro-Training. The process will be guided under fNIRS and monitored by EGG. Treatment will last 4 weeks.
62503244|NCT06417437|EXPERIMENTAL|Game-regulation Group|In addition to medication using SSRIs, patients will be also treated with games that can regulate emotions. Details are not yet decided. Treatment will last 4 weeks.
62503245|NCT01324544|EXPERIMENTAL|Buprenorphine IV|Buprenorphine IV
62142570|NCT02298556||Hypertensive patients|Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
62345470|NCT01461408|EXPERIMENTAL|Beauty Salon #7b|Females ages 18-26
62503246|NCT05741931|EXPERIMENTAL|Intervention Group|Pregnant women and midwives will use the REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting) mobile application to monitor the condition of maternal pregnancy. Mothers and midwives will implementation 3 times of pregnancy class until mothers give birth
62503247|NCT05741931|NO_INTERVENTION|Control Group|Pregnant women and midwives will conduct pregnancy monitoring as usual. The pregnancy class will be implemented in accordance with government program standards. Mothers will take pregnancy class 3 times until the mother gives birth
62345471|NCT01461408|EXPERIMENTAL|Beauty Salon #8a|Mothers of 9-18 year old females
62345472|NCT01461408|EXPERIMENTAL|Beauty Salon #8b|Females ages 9-18
62345473|NCT01892449|EXPERIMENTAL|prolonged I:E ratio (1:1) group|
62345474|NCT01892449|ACTIVE_COMPARATOR|conventional I:E ratio (1:2) group|
62345475|NCT02359695|EXPERIMENTAL|GH cycle|Subsequent IVF cycle, supplemented with a low dose of growth hormone.
62345476|NCT00794014|EXPERIMENTAL|Conservative strategy|
62345477|NCT00794014|EXPERIMENTAL|Aggressive strategy|
62345478|NCT01288508|ACTIVE_COMPARATOR|Supra Fiber|
62345479|NCT01288508|ACTIVE_COMPARATOR|Psyllium|
62345480|NCT00945802|EXPERIMENTAL|FST-201 (dexamethasone 0.1%) Otic Suspension|
62345481|NCT00945802|ACTIVE_COMPARATOR|ciprofloxacin 0.3%, dexamethasone 0.1%|
62503248|NCT00536588|EXPERIMENTAL|SCH 721015 with SCH 209702|
62503249|NCT03546829|EXPERIMENTAL|Arm 1 - Experimental|Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
62503250|NCT05757037|EXPERIMENTAL|Laser acupuncture group|The participants in this group will receive low level laser therapy 3 times weekly for 4 weeks. A diode laser emitter with a 650 nm wavelength, an average power of 30 mW, and a 0.15 cm2 spot size, with continuous wave, and exposure of 90 s per acupuncture point had been used in the current study at each of the following acupoints: : ST25, ST37 , LI11 , BL60 , and BL25 Also, participants will recieve received behavioral therapy advice: Sitting on the toilet for 10-15 min after breakfast and after dinner and maintaining the same bathroom schedule every day, sitting in the correct position on the toilet (leaning forward while resting forearms on thighs, raising both feet on a small block (like a step stool) with feet apart, relax and lower the shoulders, and do not suppress urges to defecate and relax stomach muscles). Dietary modifications include a high-fiber diet, fruits, vegetables, whole grain, dairy, and wheat
62503251|NCT05757037|SHAM_COMPARATOR|Sham laser acupuncture|"The participants in the control group will receive sham laser acupuncture treatment, without any laser output. The participants are unable to recognize whether they are being treated or not because laser acupuncture is a low-intensity and non-thermal laser irradiation.~Also, participants will receive behavioral therapy advice."
62736628|NCT00475085|ACTIVE_COMPARATOR|Arm I|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
62503252|NCT03666325|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg, IV infusion on Day 1 of each 3 week cycle. After 3 cycles patient will be evaluated. In case of disease control (SD, PR, CR) the patient will continue to receive pembrolizumab. In case of progression the patient will receive also Cetuximab (250 mg/m2 after loading dose of 400mg/m2 IV infusion every week.
62503253|NCT05462353|EXPERIMENTAL|Cohort 1 Low Dose|1 tablet of ASC41 (2 mg) for 52 weeks
62503254|NCT05462353|EXPERIMENTAL|Cohort 2 High Dose|2 tablet of ASC41 (4 mg) for 52 weeks
62503255|NCT05462353|PLACEBO_COMPARATOR|Placebo tablet|Placebo tablet for 52 weeks
62503256|NCT04561713|EXPERIMENTAL|Attention Deficit Hyperactivity Disorder (ADHD)|Children aged 8 to 12 diagnosed with ADHD
61956344|NCT01245621|ACTIVE_COMPARATOR|Later entry group|Later entry group will begin the intervention 12 weeks after enrollment in the study.
61956345|NCT05435495||Participants undergoing 177Lu-PSMA-617 treatment|Participants undergoing PSMA targeted radioligand therapy with at least four cycles of treatment planned will undergo the following: SPECT/CTs will be performed 24 hours after the first treatment and after the fourth treatment, a tumor biopsy will be performed prior to the first 177Lu-PSMA radioligand therapy, a blood will be drawn prior to treatment for future research, and an optional tumor biopsy and blood draw for future research, may also be obtained at time of progression.
61956346|NCT04959903|EXPERIMENTAL|Adult patients affected by hematological malignancies|Adult patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) or myelodysplastic syndrome eligible for a T depleted allogeneic HSCT
61956347|NCT04959903|EXPERIMENTAL|Pediatric patients affected by hematological malignancies|Pediatric patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) eligible for a T depleted allogeneic HSCT
61956348|NCT01664546||Molecular blastocyst karyotype|Trophectoderm biopsy for genetic study by aCGH
62503257|NCT04561713|SHAM_COMPARATOR|Control|Control group of healthy ADHD children matched in age, gender and laterality to children in ADHD group
62702291|NCT06750263|EXPERIMENTAL|Balance exercises with clamshell|balance was assessed by the Berg's Balance Scale exercise. Participants were instructed to walk (step) from one end of the mat to the other according to the step pattern provided. When reached the end of the mat, instructed to return to their starting position by walking normally off the mat and starting the next stepping. repeat every sequence five times and then started a new pattern. Duration would be 30 min. clamshell exercises a Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, knees flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
62736629|NCT00475085|EXPERIMENTAL|Arm II|Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
62736630|NCT00475085|ACTIVE_COMPARATOR|Arm III|Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
61956349|NCT03336671|ACTIVE_COMPARATOR|Adenoidectomy|Current standard of care for pediatric chronic rhino sinusitis.
62503258|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
62503259|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
62503260|NCT05547906|EXPERIMENTAL|ASCA101 IV|The study drug, ASCA101(300mg/vial), will be reconstituted in water for injection and diluted with saline to a dose calculated according to individual body surface area or body weight.
62503261|NCT00578838||1|25 patients with metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
62503262|NCT00578838||2|25 patients with non-metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
62503263|NCT00578838||3|11 healthy volunteers, who will also undergo two scans 2-3 weeks apart.
62503264|NCT03096067|ACTIVE_COMPARATOR|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
62503265|NCT03096067|EXPERIMENTAL|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
62503266|NCT01550367|EXPERIMENTAL|Hydroxychloroquine + IL-2|One course of treatment (84 days) will consist of high dose (600,000 IU/kg) bolus IL-2 administered intravenously every 8 hours on days 1-5 and 15-19 (maximum 14 doses/5 days of administration) and hydroxychloroquine (HCQ) orally started two weeks prior to IL-2 infusions and continued while able to take oral medication for up to 3 courses.
62503267|NCT06679465|EXPERIMENTAL|Tiotropium treatment|2 puffs tiotropium
62503268|NCT06679465|PLACEBO_COMPARATOR|Placebo|2 puffs placebo
62503269|NCT00458289|NO_INTERVENTION|1|P-containing meal alone
62503270|NCT00458289|ACTIVE_COMPARATOR|2|P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
61956350|NCT03336671|EXPERIMENTAL|Adenoidectomy plus Endoscopic Sinus Surgery|endoscopic sinus surgery in addition to adenoidectomy
61956351|NCT06278350|EXPERIMENTAL|D-2570 group 1|D-2570 group 1
61956352|NCT06278350|EXPERIMENTAL|D-2570 group 2|D-2570 group 2
61956353|NCT06278350|EXPERIMENTAL|D-2570 group 3|D-2570 group 3
61956354|NCT06278350|PLACEBO_COMPARATOR|Placebo group|Placebo group
61956355|NCT04188782||Pediatric patients undergoing radiotherapy|"Pediatric patients undergoing general anesthesia for radiotherapy treatment. General anesthesia will be accomplished exclusively by the administration of sevoflurane.~The inhalatory induction will be performed with sevofluorane at 8% with O2 4Lt/min. The maintenance will be with sevofluorane at an end tidal of 2.5% with 1Lt/min of O2.~The EEG will be obtain with SedLine monitor"
61956356|NCT05262127|ACTIVE_COMPARATOR|Flash Version of EMDR|Flash methods (e.g. positive engaging focus) are used in addition to the standard EMDR techniques conveyed by video viewed online
61956357|NCT05262127|ACTIVE_COMPARATOR|EMDR - alone|Use of standard EMDR techniques conveyed by video online
61956358|NCT04048928|EXPERIMENTAL|Strength group|Receives maximal strength training
61956359|NCT04048928|NO_INTERVENTION|Control group|receives no active treatment
61956360|NCT01140893|EXPERIMENTAL|exenatide|55 subjects
62142571|NCT03944200|EXPERIMENTAL|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
62345482|NCT01785810|EXPERIMENTAL|Maraviroc|Phase II, single arm, single center trial, assessing the efficacy of the combination of tacrolimus, methotrexate and maraviroc as graft-versus-host disease (GVHD) prophylaxis after unrelated donor peripheral blood stem-cell transplantation in patients with hematologic malignancies. Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
62345483|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
62345484|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
62503271|NCT00458289|ACTIVE_COMPARATOR|3|P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
62503272|NCT01466036|EXPERIMENTAL|Metastatic or Unresectable PNET|An anticipated 35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
62702292|NCT06750263|ACTIVE_COMPARATOR|balance exercise|Group B will be recieve balance exercises balance was assessed by the Berg's Balance Scale exercise include square stepping exercises The SSE comprised a progression of forward, in reverse, sidelong, and inclining steps. Participants were instructed to walk (step) from one end of the mat to the other according to the step pattern provided. When they reached the end of the mat, they were instructed to return to their starting position by walking normally off the mat and starting the next stepping. Each participant repeated every sequence five times and then started a new pattern. Duration of exercise would be 30 min
61956361|NCT01140893|PLACEBO_COMPARATOR|Placebo|55 subjects
61956362|NCT06087081|EXPERIMENTAL|Group A|Baseline treatment along with Mill's manipulation
61956363|NCT06087081|EXPERIMENTAL|Group B|Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena
61956364|NCT05214885||the ccRCC patient group|The age and gender of patients are not limited. The patient was preliminarily diagnosed as renal carcinoma by imaging examination and finally diagnosed as clear cell renal cell carcinoma by pathology.
61956365|NCT05214885||the healthy control group|The age and sex of the healthy control group were matched with that of ccRCC patient group. There was no tumor in the kidney or other parts of the body, and no tumor in the blood system. The healthy control group did not have any renal benign diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. There are no inflammatory diseases in other parts of the body. The functions of the liver, kidney, and heart were normal.
61956366|NCT05214885||the benign kidney disease group|The age and sex of this group were matched with that of ccRCC patient group. The patient did not have any tumor but had one of the benign kidney diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. The functions of the liver and heart were normal.
61956367|NCT06338371|EXPERIMENTAL|Training Content|Group receiving training on pelvic floor exercise
62345485|NCT03512977|EXPERIMENTAL|Sphenopalatine Ganglion Block Group|patients will be performed transnasal sphenopalatine block and conservative treatment ( iv hydration, analgesic agents, caffeine or theophylline)
62345486|NCT03512977|ACTIVE_COMPARATOR|Standard Treatment Group|patients will receive standard supportive treatment ( Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline)
62345487|NCT01925859|EXPERIMENTAL|EryDex System|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
62345488|NCT04779671|EXPERIMENTAL|VR group|
62503273|NCT01466036|EXPERIMENTAL|Metastatic or Unresectable Carcinoid|An anticipated 35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib
61956368|NCT06338371|NO_INTERVENTION|Control Group|Untrained group
61956369|NCT05912010||case group|patients from fever clinics and pediatric wards
61956370|NCT05912010||control group|healthy community children
61956371|NCT02989714|EXPERIMENTAL|HD IL2 and Nivolumab|
61956372|NCT03863054||>40% wound area reduction after 1 month|Subjects to continue with standard practice for the next 12 weeks, or until the wound has completely healed.
61956373|NCT03863054||<40% wound area reduction after 1 month|Subjects to be fitted with NATROX™ after 1 month, over a period of 12 weeks or until the wound has completely healed.
61956374|NCT04367428|EXPERIMENTAL|Probiotics|Patients will receive the previously mentioned combination of probiotics pre- and postoperatively
61956375|NCT04367428|NO_INTERVENTION|No probiotics|Patients will not receive probiotics
61956376|NCT05182905|EXPERIMENTAL|Arm A: Recurrent Grade 4 Glioma Surgical Cohort Time Escalation|
61956377|NCT05182905|EXPERIMENTAL|Arm B: Recurrent Grade 4 Glioma Dose Escalation|
61956378|NCT05182905|EXPERIMENTAL|Arm C: Newly-diagnosed Grade 4 Glioma|
61956379|NCT04997382|EXPERIMENTAL|Arm A: Chemotherapy plus immune checkpoint inhibitors with or without Bevacizumab.|Patients who progressed from first line Alectinib will be treated with chemotherapy plus immune checkpoint inhibitors with or without Bevacizumab following the patients' preferences.
61956380|NCT04997382|EXPERIMENTAL|Arm B: Chemotherapy with or without Bevacizumab.|Patients who progressed from first line Alectinib will be treated with chemotherapy with or without Bevacizumab following the patients' preferences.
61956381|NCT00329238|EXPERIMENTAL|Dabigatran|Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
62345489|NCT04779671|ACTIVE_COMPARATOR|control group|
62345490|NCT01142284|PLACEBO_COMPARATOR|Placebo|Placebo
62345491|NCT01142284|EXPERIMENTAL|Cilostazol|cilostazol
62503274|NCT01004445|EXPERIMENTAL|Arm 1|
61956382|NCT00329238|ACTIVE_COMPARATOR|Warfarin (INR of 2.0-3.0)|Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
61956383|NCT03258268|EXPERIMENTAL|Standard of Care with DSS|"Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
61956384|NCT03258268|ACTIVE_COMPARATOR|Standard of Care without DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
61956385|NCT00820846|EXPERIMENTAL|Part A, Group 1|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
61956386|NCT00820846|PLACEBO_COMPARATOR|Part A, Group 2|Participants will receive four placebo injections
61956387|NCT00820846|EXPERIMENTAL|Part B, Group 3|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
61956388|NCT00820846|EXPERIMENTAL|Part B, Group 4|Participants will receive three injections of the MVA/HIV62 vaccine and one injection of the placebo
61956389|NCT00820846|PLACEBO_COMPARATOR|Part B, Group 5|Participants will receive four placebo injections
61956390|NCT01197261|ACTIVE_COMPARATOR|OXN PR|Oxycodone Naloxone tablets
62503275|NCT01004445|EXPERIMENTAL|Arm 2|
61956391|NCT01197261|PLACEBO_COMPARATOR|PLA|
61956392|NCT05152030||hyposmic patients|
61956393|NCT05152030||anosmic patients|
61956394|NCT05152030||normosmic group|
61956395|NCT04720469|EXPERIMENTAL|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy
61956396|NCT04883931|EXPERIMENTAL|Intervention group|With in 48-72 hour after birth, infants will receive 0.5 ml breast milk for own mother as a eye drop twice in a day until the discharge or need for laser coagulation. Fresh milk was used as eye drop ( not exceed 6 hours after milking).
62345492|NCT01142284|EXPERIMENTAL|Probucol|probucol
62345493|NCT01142284|EXPERIMENTAL|Cilostazol + Probucol|cilostazol and probucol
62345494|NCT00974051|ACTIVE_COMPARATOR|Control|Subjects complete the same exercise routine, however no treatment is given at 9:00pm.
62503276|NCT01004445|PLACEBO_COMPARATOR|Arm 3|
62503277|NCT06199960|EXPERIMENTAL|Double GnRH-antagonist protocol (Duostim protocol)|In Duostim group, both follicular and luteal phases stimulation will perform with 150-225 IU of recombinant FSH (Gonal-F®, Merck-sereno, Germany) and HMG (Humegnan, Darou Pakhsh Co., Iran) in GnRH antagonist treatment. The follicular stimulation will be started on day 2-3 of the menstrual. Daily administration of 0.25 mg of GnRH antagonist (Cetrotide®, Merck-Serono; Germany) will be started when the leading follicle are 13-14mm and continue until the day of the oocyte trigger. When one follicle reached 17-18 mm ovulation will be triggered with 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran) and oocyte retrieval will be performed after 34-36 hours. Five days after the ﬁrst oocyte retrieval, a GnRH antagonist protocol identical to the ﬁrst one will start. When at least two follicles reached 17-18 mm, the ovulation will be triggered with a subcutaneous bolus GnRH-agonist and the second oocyte retrieval will be performed.
61956397|NCT04883931|PLACEBO_COMPARATOR|Placebo group|With in 48-72 hour after birth, infants will receive 0.5 ml 0.9% normal saline as a eye drop twice in a day until the discharge or need for laser coagulation.
61956398|NCT02784431|EXPERIMENTAL|Contour Neurovascular System placement|Treatment of intracranial aneurysm with the Contour Neurovascular System device.
61956399|NCT04144660||Cardiogenic Shock Treated with ECMO|This cohort of participants required clinical intervention with ECMO for treatment of their index cardiogenic shock episode while pregnant or post delivery of their infant.
61956400|NCT00686933|EXPERIMENTAL|1|
61956401|NCT04650711|EXPERIMENTAL|Study group|All eligible participants as one group accept P16INK4A testing, with cytology and/or hrHPV assay.
61956402|NCT02356575|ACTIVE_COMPARATOR|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
61956403|NCT02356575|ACTIVE_COMPARATOR|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
61956404|NCT02304679|EXPERIMENTAL|LIESWT arm|"Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
61956405|NCT02304679|PLACEBO_COMPARATOR|Sham arm|"Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
61956406|NCT01822171|EXPERIMENTAL|Discharge counseling and MTM follow-up|"At the time of hospital discharge the subject will receive:~* Discharge medication counseling from a pharmacist~* Home medication if needed~* Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic."
61956407|NCT00867568|EXPERIMENTAL|TPI 287|
62345495|NCT00974051|EXPERIMENTAL|Terbutaline|Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.
62345496|NCT00974051|EXPERIMENTAL|20% Basal Insulin Reduction|All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for six hours.
62345497|NCT06148012|EXPERIMENTAL|RTEU Oral and Maxillofacial Surgery|
61956408|NCT03041883|EXPERIMENTAL|Kpro with crosslinked graft-support|Patient will receive a crosslinked corneal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then one drop of riboflavin 0.1%/dextran 20% will be applied to 3 minutes on the de-epithelialized cornea for 15 minutes. Then, the source of ultraviolet A (UVA) will be irradiating the cornea for 30 minutes with a wavelength of 370 nanometer(nm) length with 5.4 joules(J)/ square centimeter (cm2) and 3 milliwatts(mW)/cm2. Meanwhile, the instillation of a drop of 0.1% riboflavin/dextran 20% continues every 5 minutes. Goggles against UVA are mandatory. The crosslinked graft-support will be forwarded to the surgeon according to standard procedure.
62702293|NCT06748859|EXPERIMENTAL|Strain-counterstrain technique|Participants in this group will receive strain-counterstrain technique and exercise therapy within two weeks.
62702294|NCT06748859|ACTIVE_COMPARATOR|Exercise therapy|Participants in this group will receive exercise therapy within two weeks.
62702295|NCT06749262|EXPERIMENTAL|Walking at Incline|Subjects will walk on treadmill at slope equal to 60% of their peak heart rate as determined on baseline cardiopulmonary exercise test.
61956409|NCT03041883|ACTIVE_COMPARATOR|KPro with normal graft-support|Patient wil receive a normal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then, one drop of riboflavin 0.1% / dextran 20% will be applied to 30 secondes for 5 minutes on the de-epithelialized cornea.The minimally manipulated normal graft-support will be forwarded to the surgeon according to standard procedure.
61956410|NCT02863952|OTHER|EARLY POST-STRESS EF CHANGE|There is only a single arm. All patients undergoing the routine myocardial perfusion SPECT study will also have additional (earlier) image acquisition in order to assess the relation of early wall motion abnormalities to the severity of myocardial ischemia.
61956411|NCT01695187|EXPERIMENTAL|NB-001 (0.3%)|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and two surfactants: polysorbate (Tween) 20 and cetylpyridinium chloride (CPC).
61956412|NCT01695187|PLACEBO_COMPARATOR|Vehicle|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and one surfactant: polysorbate (Tween) 20.
61956413|NCT05310461|EXPERIMENTAL|Early transcatheter or surgical aortic valve replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
61956414|NCT05310461|OTHER|Control Intervention|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention.
61956415|NCT02724345||CK18 positive|HCC patients with CK18 high expression levels in tumor tissue.
61956416|NCT02724345||CK18 negative|HCC patients with CK18 high expression levels in tumor tissue.
61956417|NCT04607954|EXPERIMENTAL|Treatment (durvalumab, lurbinectedin)|Patients receive durvalumab IV over 60 minutes on day 1 and lurbinectedin IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62142572|NCT03944200|ACTIVE_COMPARATOR|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
62702296|NCT06749262|EXPERIMENTAL|Walking at Speed|Subjects will walk on treadmill at speed equal to 60% of their peak heart rate as determined on baseline cardiopulmonary exercise test.
62702297|NCT06750224|EXPERIMENTAL|alexander|Group A will receive therapy according to Alexander techniques for every alternate day (3 days per week) for 8 weeks. Total 40 minutes of session.
62702298|NCT06750224|EXPERIMENTAL|feldenkrais|Group B will receive therapy according to Feldenkrais method for every alternate day (3 days per week) for 8 weeks. Total 40 minutes of session
62702299|NCT06750133|EXPERIMENTAL|CNK-UT cell Therapy|"1. Dose Escalation：Single-dose intravenous injection of CNK-UT cells (3×10\^7 CNK+ cells/kg).~2. Dose Expansion：Multiple-dose intravenous injection of CNK-UT cells (6-10×10\^7 CNK+ cells/kg)according to the results of dose escalation."
62702300|NCT03647163|EXPERIMENTAL|Safety Run-in Dose Level 1|Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
61956418|NCT01703039|EXPERIMENTAL|sertraline + riluzole|sertraline 100 mg po daily and riluzole 50 mg po bid
61956419|NCT01703039|ACTIVE_COMPARATOR|sertraline + placebo|sertraline 100 mg po daily and placebo
61956420|NCT06262516|EXPERIMENTAL|Nephroureterectomy With Lymph Node Dissection|Participants will undergo nephroureterectomy for UTUC and will receive LND.
61956421|NCT06262516|ACTIVE_COMPARATOR|Nephroureterectomy Without Lymph Node Dissection|Participants will undergo nephroureterectomy for UTUC and will not receive LND.
61956422|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity
61956423|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity
61956424|NCT03119298||Control group|Healthy subjects matched for age and sex
61956425|NCT04353518|EXPERIMENTAL|Suspension of Mw|"Intradermal suspension of Mw will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal Mw in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal Mw administered."
61956426|NCT04353518|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal placebo in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal placebo."
61956427|NCT02186990|ACTIVE_COMPARATOR|propofol|
61956428|NCT02186990|ACTIVE_COMPARATOR|etomidate|
61956429|NCT02186990|ACTIVE_COMPARATOR|propofol-etomidate|
62142573|NCT00705406|EXPERIMENTAL|Peramivir 600 mg|600 mg peramivir administered as bilateral 2-mL intramuscular injection.
62702301|NCT03647163|EXPERIMENTAL|Safety Run-in Dose Level 2|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
62702302|NCT03647163|EXPERIMENTAL|Expansion NEC|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
61956430|NCT04821947|ACTIVE_COMPARATOR|RIB Group|Drug: Bupivacaine 0.25% patients will receive 20 ml of bupivacaine 0.25% in the rhomboid plane under rhomboid major muscle
61956431|NCT04821947|ACTIVE_COMPARATOR|LA Group|Drug: Bupivacaine 0.25% patients will receive wound infiltration of VATS incision, single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine .
61956432|NCT00855569||1|Each donor site will act as it own control - both dressings will be applied to the donor site and assessments will be made
61956433|NCT03963037||Patients|The family members of our two kindreds who carry the truncating mutation in the Apolipoprotein B gene.
62702303|NCT03647163|EXPERIMENTAL|Expansion NSCLC arm|Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
62702304|NCT03647163|EXPERIMENTAL|Expansion Part D|Patients with non small cell lung cancer (NSCLC) or Neuroendocrine Carcinoma (NEC) will receive a single IV dose of VSV-IFNβ-NIS on Day 4 in combination with ipilumumab + nivolumab at standard labeled dose administered on Day 1 then every 21 days up to 2 years.
61956434|NCT03963037||Controls|The family members of our two kindreds who are no carriers of the truncating mutation in the Apolipoprotein B gene.
62702305|NCT03647163|EXPERIMENTAL|Expansion Renal Cell Carcinoma (RCC) Part E|Arm Description: Renal Cell Carcinoma (RCC) will receive a single IV dose of VSV-IFNβ-NIS on Day 4 in combination with ipilumumab + nivolumab at standard labeled dose administered on Day 1 then every 21 days for a total of 4 Cycles. Nivo Single agent will be administered every 28 days starting with Cycle 5 for a total treatment period of up to 2 years.
62702306|NCT04367506|EXPERIMENTAL|BecomeAnEX|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital.
62702307|NCT04367506|ACTIVE_COMPARATOR|Usual Care|Brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
62702308|NCT03811015|EXPERIMENTAL|Arm A (cisplatin, IMRT, nivolumab)|Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions. Within 4 weeks after completion of concurrent therapy, patients receive nivolumab IV once weekly over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT or FDG PET/CT scans throughout the trial. Patients may undergo ECHO as clinically indicated. Additionally, patients undergo blood sample collection during screening.
62702309|NCT03811015|ACTIVE_COMPARATOR|Arm B (cisplatin, IMRT, observation)|"Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions, and then go on observation.~Patients will be offered the option to cross-over to Arm C if they have clearly documented progression within 12 months from the end of cisplatin/radiation therapy. Patients undergo CT or FDG PET/CT scans throughout the trial. Patients may undergo ECHO as clinically indicated. Additionally, patients undergo blood sample collection during screening."
62702310|NCT03811015|EXPERIMENTAL|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT or FDG PET/CT scans throughout the trial. Patients may undergo ECHO as clinically indicated. Additionally, patients undergo blood sample collection during screening.
62702311|NCT06401798|PLACEBO_COMPARATOR|placebo control group|After proper scaling and root planning, placebo gel will be applied topically to the affected sites.
62702312|NCT06401798|ACTIVE_COMPARATOR|CWP group|Topical application of CWP gel will be applied topically to the affected sites.
62702313|NCT06401798|ACTIVE_COMPARATOR|NCWP group|CWP nanoparticles gel will be applied topically to the affected sites.
61956435|NCT04688957|ACTIVE_COMPARATOR|osteotome sinus lifting|
61956436|NCT04688957|EXPERIMENTAL|oseodensification sinus lifting|
61956437|NCT03588039|EXPERIMENTAL|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
61956438|NCT03588039|EXPERIMENTAL|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
61956439|NCT03588039|EXPERIMENTAL|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
61956440|NCT03588039|EXPERIMENTAL|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
61956441|NCT03588039|EXPERIMENTAL|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
61956442|NCT03588039|EXPERIMENTAL|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
62702314|NCT06749067|EXPERIMENTAL|Experiment 1 Group: Mindfulness Based Practices|Experiment 1 Group Intervention: In the first session preparation session; face-to-face meeting with the women in the experimental group and then general information about the definition, purpose and applications of the mindfulness-based practice will be given, and the lack of information about the practice, if any, will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent.
61956443|NCT03588039|EXPERIMENTAL|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
62503278|NCT06199960|NO_INTERVENTION|Double mild stimulation protocol|In double mild stimulation protocol, Clomiphene citrate 25 mg/day (Ovumid®; Iran Hormone pharmaceutical Co., Iran) and co-treatment with letrozole 2.5 mg/day (Femati®, Atipharmed Co., Iran) will be given from cycle day 3. Letrozole is given for 4 days and clomiphene citrate is used daily before the trigger day. Patients take 150 IU of Human menopausal gonadotropin (HMG) (Humegnan®, Darou Pakhsh Co., Iran) every other day beginning on cycle day 6. When one dominant follicle will reach 18 mm, the ﬁnal triggering will induce 34-36 h after 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran) administration. In luteal phase stimulation a total of 225 IU HMG and letrozole 2.5 mg will administered daily from3 to 5 days after oocyte retrieval. Letrozole administration will be stopped when the dominant follicles reached 12 mm. When one dominant follicle will reach 18 mm, the ﬁnal triggering will be induced with 0.5 cc of Buserelin acetate.
62503279|NCT04855591|EXPERIMENTAL|SHR-1703 Dose Level 1|Dose level 1 SHR-1703
62503280|NCT04855591|EXPERIMENTAL|SHR-1703 Dose Level 2|Dose level 2 SHR-1703
62503281|NCT04855591|EXPERIMENTAL|SHR-1703 Dose Level 3|Dose level 3 SHR-1703
62503282|NCT04855591|EXPERIMENTAL|SHR-1703 Dose Level 4 (optional)|Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review
62503283|NCT05531682|EXPERIMENTAL|Experimental: HB0017 dosing regimen 1|HB0017 low dose short intervals of subcutaneous injection
62503284|NCT05531682|EXPERIMENTAL|Experimental: HB0017 dosing regimen 2|HB0017 low dose long intervals of subcutaneous injection
62503285|NCT05531682|EXPERIMENTAL|Experimental: HB0017 dosing regimen 3|HB0017 high dose long intervals of subcutaneous injection
62503286|NCT05531682|PLACEBO_COMPARATOR|Placebo Comparator: placebo group|Placebo was subcutaneously injected into the 12 weeks turnover HB0017 subcutaneous injection
62702315|NCT06749067|EXPERIMENTAL|Experiment 2 Group: Occupational Practices|Experiment 2 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent.
61956444|NCT03588039|EXPERIMENTAL|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
61956445|NCT02158234|EXPERIMENTAL|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m\^2
61956446|NCT04667871||Eyes for cataract surgery|Eyes for cataract surgery
61956447|NCT04667871||Eyes without cataract surgery|Eyes without cataract surgery
62345498|NCT02172092|EXPERIMENTAL|Ketoacidosis|Patients treated for diabetic ketoacidosis at the Intensive care unit, Vrinnevi Hospital, Norrköping.
62345499|NCT04000087|EXPERIMENTAL|Intervention|Care teams randomized to intervention will have access to the screening tool.
62345500|NCT04000087|NO_INTERVENTION|Control|Care teams randomized to control will continue routine practice.
61956448|NCT01552200|EXPERIMENTAL|A-Standard Colonoscopy, G-Eye procedure|Standard Colonoscopy,G-Eye procedure
62345501|NCT01965912|EXPERIMENTAL|Kuvan®|
62345502|NCT01689402||Intracerebral Hemorrhage Patients|Patients admitted with acute intracerebral hemorrhage within 72 hours after symptom onset.Patients are included in the study for MRI studies
62345503|NCT01925638|EXPERIMENTAL|BAY86-9766|The study will be conducted in two parts and study treatments will be administered as follows: •Part A: Three subjects will be enrolled and will receive 10 mg of refametinib on Day 1. Once daily dosing of ketoconazole 400 mg will be initiated on Day 5 and will continue until Day 12 with 10 mg of refametinib administered concomitantly on Day 8 •Part B: Fifteen subjects will be enrolled and will receive refametinib doses of 10 mg, 20 mg or 30 mg on Days 1 and 8 with the same dose administered on both days. Refametinib dose for Part B will be based on safety and refametinib pharmacokinetics in Part A. Ketoconazole 400 mg will be administered once daily on Days 5 to 12. Subjects will stay in the investigational site for a total period of 15 consecutive days
62345504|NCT00918086|EXPERIMENTAL|Vitamin D pill|
62345505|NCT00918086|PLACEBO_COMPARATOR|Placebo|
62345506|NCT03125876|EXPERIMENTAL|CT053PTSA|60mg-100mg
62345507|NCT00218920|EXPERIMENTAL|strength training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
62345508|NCT00218920|EXPERIMENTAL|continuous moderate-intensity aerobic training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
62503287|NCT01847924|ACTIVE_COMPARATOR|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
61956449|NCT01552200|ACTIVE_COMPARATOR|B- G-Eye procedure, Standard Colonoscopy|G-Eye procedure,Standard Colonoscopy
61956450|NCT05965154|EXPERIMENTAL|Carrilizumab combined with bevacizumab plus capecitabine|This study is a one-arm, exploratory study and does not involve randomization.There was only one trial group of carrilizumab plus bevacizumab plus capecitabine.
61956451|NCT00517816|EXPERIMENTAL|1|
61956452|NCT00517816|EXPERIMENTAL|2|
61956453|NCT00517816|EXPERIMENTAL|3|
62702316|NCT06749067|EXPERIMENTAL|Experiment 3 Group: Mindfulness-Based Occupational Practice|"Experiment 3 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent.~In the first session, before starting the Mindfulness-Based Engagement Practice, women will be focused on the moment with a 3-minute breathing exercise, followed by a raisin exercise."
62736631|NCT00475085|EXPERIMENTAL|Arm IV|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
61956454|NCT00517816|EXPERIMENTAL|4|
61956455|NCT00517816|EXPERIMENTAL|5|
61956456|NCT00517816|EXPERIMENTAL|6|
61956457|NCT00517816|EXPERIMENTAL|7|
61956458|NCT00517816|EXPERIMENTAL|8|
61956459|NCT01134276|ACTIVE_COMPARATOR|PTBD|biliary drainage : PTBD procedure for obstructive jaundice in patients with periampullary cancer
61956460|NCT01134276|ACTIVE_COMPARATOR|ERBD|biliary drainage : ERBD/ENBD procedure for obstructive jaundice in patients with periampullary cancer
62503288|NCT01847924|PLACEBO_COMPARATOR|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
62503289|NCT01989676|EXPERIMENTAL|PF-05280014|
62503290|NCT01989676|ACTIVE_COMPARATOR|Herceptin®|
62503291|NCT00950716|ACTIVE_COMPARATOR|Usual care|The 'control arm' will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
62345509|NCT00218920|EXPERIMENTAL|high-intensity interval aerobic training|Over a 12-week period, 14 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
62345510|NCT04480242||Asthma Research in Children and Adolescents - Spanish Cohort|Groups defined according to treatments prescribed during regular clinical practice and to the exposure to inhalation techniques monitoring
62503292|NCT00950716|ACTIVE_COMPARATOR|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
62503293|NCT06243172||Type 2 Diabetes|Individuals with type 2 diabetes
62503294|NCT06243172||Controls|Individuals without type 2 diabetes matched on age and body mass index
61956461|NCT03691259|EXPERIMENTAL|Dance Group|Dance group will participate in one-hour ballet classes twice per week for 10 weeks
61956462|NCT03691259|NO_INTERVENTION|Control Group|The control group will not participate in the ballet classes
61956463|NCT04741282|EXPERIMENTAL|pulmonary telerehabilitation plus progressive muscle relaxation training|This group will perform six week pulmonary rehabilitation program and progressive muscle relaxation exercise at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
61956464|NCT04741282|ACTIVE_COMPARATOR|pulmonary telerehabilitation|This group will perform six week pulmonary rehabilitation program at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
61956465|NCT02313792|ACTIVE_COMPARATOR|Palifermin|The patients belong to this arm will be given palifermin, keratinocyte growth factor, in addition to the conventional supportive care for oral mucositis. Palifermin will be given at a dose of 60 mcg/kg for 3 days before commencement of the preparative regimen and for 3 days after stem cell infusion
61956466|NCT02313792|PLACEBO_COMPARATOR|Normal saline|The patients belong to this arm will be given normal saline as placebo plus conventional supportive care for oral mucositis. Normal saline will be given at the same volume and schedule with the study drug.
61956467|NCT03856892|EXPERIMENTAL|Active Study Group|"Participants randomized to the Active Study Group are asked to follow a daily routine of the three protocols of psycho-physical yoga component techniques: Slow Engaged Dynamic Asana (SEDA), Breath Regulated Engaged Meditation (BREM), Sound Heart Engaged Meditation (SHEM). This intervention involves more hours in daily practice to equate to a high dose of breath and meditative techniques."
61956468|NCT03856892|ACTIVE_COMPARATOR|Active Control|"Participants randomized to the Active Control study arm are asked to follow a daily routine of low-to mid-intensity body posture practice that is body-based and has minimal breath or meditative elements. This intervention involves fewer hours in daily practice to equate to a medium dose of body focused techniques"
61956469|NCT03856892|NO_INTERVENTION|Passive Control|Participants randomized to the Passive Control study arm do not receive a study intervention.
61956470|NCT03739593|EXPERIMENTAL|AR-1105-CF1|Single dose of AR-1105-CF1 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
61956471|NCT03739593|EXPERIMENTAL|AR-1105-CF2|Single dose of AR-1105-CF2 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
61956472|NCT05430932|EXPERIMENTAL|Laparoscopic sleeve gastrectomy|After sleeve gastrectomy, assessment of vitamin D, calcium and parathormone levels is performed.
62142574|NCT00705406|PLACEBO_COMPARATOR|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
61956473|NCT05310890|EXPERIMENTAL|Tai chi training plus group activity|"Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.~Group activity: a organizer will lead the subjects to participate in group activities, once per quarter."
62702317|NCT06749067|NO_INTERVENTION|Control Group|Control Group: Telephone numbers will be taken to communicate with menopausal women who meet the inclusion criteria for the study. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. No treatment will be applied to women in this group. At the end of 8 weeks, all participants will be asked to complete the Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale as a post-test application.
62702318|NCT06749340|EXPERIMENTAL|Face-to-face Exercise Group|Participants will undergo exercise sessions 3 days a week for 12 weeks. Sessions will include a warm-up, upper and lower extremity strengthening (1/3 set - 8/12 repetitions) and cool-down program. Theraband will be used in strengthening exercises. Theraband offers different resistance levels with its different colors. In order from lightest to heaviest; skin color, yellow, red, green, blue, black, grey, gold. Exercises (theraband color, intensity, number of sets and repetitions) will be made into a personalized program according to the tolerance level of the participants in the first session. Exercise intensity will be determined using the OMNI - Resistance Exercise Scale (OMNI - RES). The warm-up and cool-down periods in the exercise program will be carried out at levels 9 - 12 according to the Borg Scale.
62702319|NCT06749340|EXPERIMENTAL|Home-based Exercise Group|Participants will follow the same program as in the face-to-face exercise group. The first meeting with the participants will be held face to face and the details of the study will be explained. Home-based exercises will be carried out with the Fiziu (Fiziu Sağlık Hizmetleri Teknoloji A.Ş., Istanbul, Türkiye) program and the exercise program will be delivered to the participants through this program. Therabands with which the participants will do their exercises will be provided by the researchers. The progression program will be determined in line with the difficulty and effort felt by the participants through weekly meetings.
62702320|NCT06749340|OTHER|Control Group|Participants assigned to the control group will have the same evaluation sessions as participants assigned to the experimental groups. The first evaluation will be made at the beginning of the study, the second evaluation after the 8-week period, the third evaluation after the 12-week period, the fourth evaluation after the 6-month follow-up, and the fifth evaluation after the 12-month follow-up. Participants who will not be included in any study sessions during this process will be included in the study program that appears to be effective as a result of the study. Participants in this group will be offered the program recommended by the US Office of Disease Prevention and Health Promotion and used in individuals who have previously had a liver transplant. This program consists of aerobic exercises (walking, cycling, etc.) starting from 60-65% of the maximum heart rate and progressing to 75-80%.
62702321|NCT03968822|EXPERIMENTAL|Intralipid 20% IV Bolus|"This is 1 out of the 2 study visits. The patient will receive 6 injections (3 in each thigh). The 6 injections are:~1. lidocaine 1%~2. lidocaine 2%~3. bupivacaine 0.5%~4. bupivacaine 0.25%~5. saline~6. no injection~Each test solution will be injected over 5 seconds through a 27G needle and tuberculin syringe at a 30 degree angle.~The patient will also receive an intravenous bolus in the arm of Intralipid 20%.~Participant will be blindfolded for these activities so they will not know what they received during the visit."
62702322|NCT03968822|PLACEBO_COMPARATOR|Saline|"This is 2 out of the 2 study visits. The patient will receive 6 injections (3 in each thigh). The 6 injections are:~1. lidocaine 1%~2. lidocaine 2%~3. bupivacaine 0.5%~4. bupivacaine 0.25%~5. saline~6. no injection~Each test solution will be injected over 5 seconds through a 27G needle and tuberculin syringe at a 30 degree angle.~The patient will also receive an intravenous bolus in the arm of Saline.~Participant will be blindfolded for these activities so they will not know what they received during the visit."
62702323|NCT06749301||Patients with primary squamous cell carcinoma (SCC) of the hypopharynx, oropharynx, or oral cavity c|Patients over 18 years of age with primary squamous cell carcinoma of the head and neck (hypopharynx, oropharynx or oral cavity, confirmed by histology) will be prospectively enrolled and, according to standard procedures, will have to undergo an MRI examination for diagnostic purposes.
62702324|NCT06750744||only one group of patients|to identify the predictors of antibiotic resistance using rates of resistance,comprehensive data of each patient chest X ray,CT,ultrasound
62702325|NCT06749158|ACTIVE_COMPARATOR|spontaneous bone regeneration|after cyst enucleation, the intra-bony defect will be covered by Titanium mesh that is fixed by mono-cortical titanium screws.
62702326|NCT06749158|EXPERIMENTAL|guided bone regeneration|"cyst enucleation will be followed by filling the intra-bony defect with Deproteinized Bovine Bone.~-Titanium mesh will cover the bone window completely and will be fixed to the bone using mono-cortical titanium screws."
62702327|NCT06748196||Pediatric Physiotherapists|• Physical Therapists working across Khyber Pakhtunkhwa representative of all divisions of the province. • Physical Therapists working as clinicians or working in healthcare vicinities from at least 2 years.
61956474|NCT05310890|OTHER|Only group activity|Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
61956475|NCT05389397|PLACEBO_COMPARATOR|Mailed Letter|
61956476|NCT05389397|ACTIVE_COMPARATOR|Secure Message|
62142575|NCT06698380|ACTIVE_COMPARATOR|Control|The participants of control participants received conventional Physical Therapy (CPT) based on their routine physical therapy neurological evaluation. The CPT was individualized based on the needs of the subjects. It included: normalization of muscle tone, strengthening of weak muscles, lengthening of tight muscles, training for transfers like supine to sit, sit to stand, balance training, and gait training. The upper extremity training for ADLs also were incorporated using mobilization, reaching, grasping and dexterity movements
61956477|NCT05389397|ACTIVE_COMPARATOR|Telephone Outreach|
62345511|NCT02325947|EXPERIMENTAL|Study group|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
62345512|NCT02325947|SHAM_COMPARATOR|Placebo group|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
62345513|NCT01136668|EXPERIMENTAL|Treatment group|Bupivacine-TAP block
62345514|NCT01136668|ACTIVE_COMPARATOR|Control Group|Bupivacaine- wound infiltration
62345515|NCT02477293|EXPERIMENTAL|Hyeonggaeyeongyo-tang|
62345516|NCT05310994|PLACEBO_COMPARATOR|Placebo drink|
62345517|NCT05310994|EXPERIMENTAL|Wasabi Leaf Extract Drink|
61956478|NCT03273114|EXPERIMENTAL|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
61956479|NCT03273114|ACTIVE_COMPARATOR|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
61956480|NCT04779060|ACTIVE_COMPARATOR|fentanyle group|
61956481|NCT04779060|ACTIVE_COMPARATOR|dexamethasone group|
61956482|NCT04779060|PLACEBO_COMPARATOR|control group|
61956483|NCT06467474|EXPERIMENTAL|Clinical Group|Participants will receive treatment as usual (TAU) associated with the psychoeducational program.
61956484|NCT06467474|ACTIVE_COMPARATOR|Control Group|The usual treatment will consist of outpatient follow-up for a period of twelve months.
62503295|NCT02507817||31-32 with Mg for neuroprotection|"Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
62503296|NCT02507817||33-34 without Mg for neuroprotection|"Women in 33-34 weeks gestation that per protocol are not entitled for treatment with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
62503297|NCT02507817||PET with Mg after 34 weeks|"Women that had severe preeclamsia and where treated with Magnesium Sulphate for seizure prophylaxis and delivere after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
62702328|NCT05605444|EXPERIMENTAL|Isometric exercise-one repetition|Isometric exercise consisting of 1 session only. The session will last for around 5 minutes which will include asking the patient to do 1 repetition of wall squat for 3 min or to volitional fatigue at 100° knee angle.
62702329|NCT05605444|EXPERIMENTAL|Isometric exercise-three repetitions|Isometric exercise consisting of 1 session only. The session will last for around 10 minutes which will include asking the patient to perform 3 repetition of wall squat (each time the exercise will be performed for 3 min or to volitional fatigue at 100°degree knee angle); patient will be given 30 sec rest between repetitions.
61956485|NCT01858389|EXPERIMENTAL|Cohort A|Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
61956486|NCT01858389|EXPERIMENTAL|Cohort B|Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
61956487|NCT02829632|EXPERIMENTAL|Experimental: Group Sessions|Participants will be asked to attend 3 group meetings over a 12 week period. Groups will meet for approximately 1 hour on weeks 2, 4 and 8. At each of the group meetings, the participant will be weighed and a group leader will present information on topics related to eating and exercise.
61956488|NCT02829632|EXPERIMENTAL|Active Comparator: Self-Monitoring|Active Comparator: Self-monitoring Participants will record diet, activity and weight as described above in the participant's smartphone app to assist the participant in losing weight.
62702330|NCT05605444|NO_INTERVENTION|Control (no intervention)|Will not receive any intervention
62702331|NCT06749613|EXPERIMENTAL|digestive enzymes group|Patients will be instructed to use a powder formulation according to manufacturer instructions and according to the meals that they consume per day, for 1 month. To reduce the placebo effect, patients will be misinformed that half will take a placebo formulation, randomly.
61956489|NCT02829632|EXPERIMENTAL|Experimental: Feedback|"Participants will be sent via the participant's smartphone between~1 and 4 feedback messages a day about whether the participant has been self monitoring, or the amount of calories, fat or sugar the participant has consumed."
61956490|NCT05192109|ACTIVE_COMPARATOR|Addressed|Children participate via video in an interaction with an experimenter who uses the word to be learned.
61956491|NCT05192109|EXPERIMENTAL|Overheard|Children watch via video while an experimenter uses the word to be learned in an interaction with another experimenter.
62345518|NCT00954317|ACTIVE_COMPARATOR|Low epidural|epidural placed in the lower lumbar vertebral column
62345519|NCT00954317|EXPERIMENTAL|high epidural|high epidural
62345520|NCT01379352||High MELD group|Preoperative MELD score greater than 20
62503298|NCT02507817||control|"Low risk pregnanacies in similar weeks to group 3 that did not require any special teatment and delivered after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
62503299|NCT05328700|EXPERIMENTAL|kinesiotaping|
62503300|NCT05328700|PLACEBO_COMPARATOR|Tape|
61956492|NCT02123888|EXPERIMENTAL|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy.
61956493|NCT02285842||Primary Hip Resurfacings|Single study group previously implanted with CONSERVE® Press-Fit Femoral Components
61956494|NCT06298591|OTHER|subcision|
61956495|NCT05678933|EXPERIMENTAL|AC-CHOP|Azacitidine administered IV at day 1-5 and Chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)
61956496|NCT05678933|ACTIVE_COMPARATOR|CHOP|CHOP administered every 3 weeks for 6 cycles.
61956497|NCT05817825|EXPERIMENTAL|Treatment Group|"The intervention to be developed and tested has two components: 1) the remotely delivered IOP (Smart IOP), and 2) a peer recovery coach to provide support and accountability to the participant."
61956498|NCT04833543|ACTIVE_COMPARATOR|Tilt Table|
61956499|NCT04833543|EXPERIMENTAL|Robotic Mobility Device (REX)|
61956500|NCT02217878|ACTIVE_COMPARATOR|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
61956501|NCT02217878|PLACEBO_COMPARATOR|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
61956502|NCT02231008|EXPERIMENTAL|Tasimelteon|Single dose oral capsule or equivalent age-appropriate oral formulation, daily dosage
61956503|NCT02231008|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62345521|NCT01379352||Low MELD group|Preoperative MELD score lesser than 20
62345522|NCT06504485||Hepatis Delta naive|Patients with HDV infection naïve to Bulevirtide therapy
62345523|NCT06504485||Hepatis Delta in therapy|Patients with HDV cirrhosis consecutively started on Bulevirtide therapy during the study enrollment period
62345524|NCT01948895|EXPERIMENTAL|Single-arm study|Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day
61956504|NCT02287857|EXPERIMENTAL|Domestic Tenofovir Disoproxil Fumarate Tablets|
62345525|NCT00966810|EXPERIMENTAL|CML allogeneic stem cell transplantation|Patients with chronic myeloid leukemia suitable for allogeneic stem cell transplantation with a matched related donor.
62345526|NCT04880850|EXPERIMENTAL|insulin icodec + insulin aspart|Participants will get once weekly injections in combination with 2-4 times daily injections of insulin aspart
62345527|NCT04880850|ACTIVE_COMPARATOR|Insulin glargine + insulin aspart|Participants will get once daily injections in combination with 2-4 times daily injections of insulin aspart
62345528|NCT04534036|ACTIVE_COMPARATOR|Multi-Strain Synbiotic (PDS-08)|PDS-08 is a rationally defined microbial consortium consisting of 9 strains, with FOS-inulin as prebiotic. Participants will be instructed to take 1 sachet daily for the duration of the trial.
62345529|NCT04534036|PLACEBO_COMPARATOR|Placebo|Placebo sachets for PDS-08 will contain potato or tapioca maltodextrin matched for color and texture. Participants will be instructed to take 1 sachet daily for the duration of the trial.
62345530|NCT05720442|EXPERIMENTAL|Tangweian Recipe Group|"1. Tangweian formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.~2. 1 mosapride citratetablet per time, 3 times a day, take it with meals."
62345531|NCT05720442|ACTIVE_COMPARATOR|Mosapride Citrate Group|1 mosapride citratetablet per time, 3 times a day, take it with meals.
62345532|NCT02716194|EXPERIMENTAL|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants\]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
62345533|NCT02716194|EXPERIMENTAL|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants\]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
62345534|NCT02716194|EXPERIMENTAL|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants\]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
62345535|NCT05663736|EXPERIMENTAL|Gemiglipitin|A DPP4 inhibitor gemigliptin treatment group
62345536|NCT05663736|ACTIVE_COMPARATOR|Glimepiride|A sulfonylurea glimepiride treatment group
62345537|NCT02670330|EXPERIMENTAL|Experimental: SD-101-6.0 cream|All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
62345538|NCT02303873|EXPERIMENTAL|an open label, prospective, self-controlled study|Children or adolescents under the age of 18 years old with minor trauma fracture were recruited from 30 provinces of China. The diagnosis of OI was made by endocrinology department of Peking Union Medical College Hospital(PUMCH).
62345539|NCT02863367|EXPERIMENTAL|Treatment group|Apatinib：500 mg，po，qd, d1-14, every 3 week Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
62345540|NCT05347784||Patients without postoperative complications|
62345541|NCT05347784||Patients with postoperative complications|
62345542|NCT02119234|EXPERIMENTAL|CHF5993 pMDI + Spacer|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer
62345543|NCT02119234|ACTIVE_COMPARATOR|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only
62345544|NCT02119234|PLACEBO_COMPARATOR|Placebo pMDI|Placebo pMDI x 4 inhalations
62345545|NCT01522625|EXPERIMENTAL|TDF|tenofovir disoproxil fumarate (TDF) 300mg
62345546|NCT01522625|PLACEBO_COMPARATOR|Placebo|
62345547|NCT00780052|EXPERIMENTAL|1|c-myb AS ODN as a 24-hour continuous infusion over 7 days
61956505|NCT02287857|ACTIVE_COMPARATOR|Tenofovir Disoproxil Fumarate Tablets of Gilead|
62345548|NCT01018719||Left side breast cancer|
62345549|NCT01018719||Right side breast cancer|
61956506|NCT06005350|EXPERIMENTAL|NR-Treatment|"NR-Chloride Preparation 1000mg/day for 10 days~(500mg - 0 - 500mg -0)"
61956507|NCT06005350|PLACEBO_COMPARATOR|Placebo|"Placebo for 10 days~(1 - 0 - 1 - 0)"
61956508|NCT03615378|PLACEBO_COMPARATOR|Placebo|
61956509|NCT03615378|ACTIVE_COMPARATOR|Vitamin D 1000 IU D3 daily|
61956510|NCT03615378|ACTIVE_COMPARATOR|Vitamin D 5000 IU D3 daily|
62345550|NCT00360919|EXPERIMENTAL|A|Cheese
62345551|NCT00360919|PLACEBO_COMPARATOR|B|Fruits and vegetables
62345552|NCT00507416|EXPERIMENTAL|Bortezomib and Dexamethasone (VD)|Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
62345553|NCT00507416|EXPERIMENTAL|Bortezomib, Thalidomide, and Dexamethasone (VTD)|Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
62345554|NCT00507416|EXPERIMENTAL|Bortezomib, Melphalan and Prednisone (VMP)|Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
62345555|NCT01884168||gene expression profile|T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
62345556|NCT02178501|EXPERIMENTAL|Omega-3 PUFA|OMEGA-3 PUFA 2000 mg once daily (1000 mg EPA and 1000 mg DHA)
62345557|NCT02178501|PLACEBO_COMPARATOR|Placebo|Placebo once daily
61956511|NCT05417282|EXPERIMENTAL|Safety and tolerability evaluation|"Part A: Open Label sentinel cohort 10 subjects will receive MW151 in an open label safety evaluation.~Part B: Open Label 30 subjects will receive MW151."
61956512|NCT04524910||mCNV patients|Adult Canadian patients diagnosed with myopic choroidal neovascularization (mCNV) and naïve for anti-VEGF treatment
61956513|NCT02975505|EXPERIMENTAL|Strict SBP Target|Target Systolic Blood Pressure \<120 mm Hg
61956514|NCT02975505|NO_INTERVENTION|Usual SBP Target|Target Systolic Blood Pressure 130-140 mm Hg
61956515|NCT04355520|EXPERIMENTAL|TQ-B3525 tablets combined with fulvestrant injection|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
61956516|NCT04967144||Carpal Tunnel syndrome|.Patients with carpal tunnel syndrome
61956517|NCT04967144||Control subjects|Healthy subjects
61956518|NCT01443871|EXPERIMENTAL|Aromatherapy|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the odor for 10 minutes as during inhalation. The last part, the odor was dispersed and assessed EEG activity for 10 minutes as after inhalation.
61956519|NCT01443871|PLACEBO_COMPARATOR|Pure water|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the water for 10 minutes as during inhalation. The last part, the water was dispersed and assessed EEG activity for 10 minutes as after inhalation.
61956520|NCT00258401|ACTIVE_COMPARATOR|low-residue diet|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.
61956521|NCT00258401|ACTIVE_COMPARATOR|no dietary intervention|At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.
61956522|NCT00583609|EXPERIMENTAL|1|PEG3350
61956523|NCT01202812|EXPERIMENTAL|LOVAZA|
61956524|NCT01202812|PLACEBO_COMPARATOR|Placebo capsule|
61956525|NCT02099175|EXPERIMENTAL|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~* Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~* Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~* 5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:~First Cycle and every other cycle:~* Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~* Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Second Cycle and every other cycle:~* Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~* Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Intestinal Type Adenocarcinoma with functional p53:~* Leucovorin\* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w~* Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~* 5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by Radiotherapy"
61956526|NCT02050191|NO_INTERVENTION|program feasibility|
61956527|NCT02468674|OTHER|Follow-up (arm 1)|Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.
61956528|NCT02468674|NO_INTERVENTION|Follow-up (arm 2)|Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.
61956529|NCT01269632|OTHER|HIV infected|young adult infected by HIV
61956530|NCT01269632|OTHER|HIV uninfected|a control group of HIV uninfected young adult will be included for comparison in physiopathological module (metabolic, cardiovascular, and immunological)
62345558|NCT00657124|EXPERIMENTAL|1|receive a preoperative supplementation with carbohydrate and branched-chain amino acids-enriched nutrient
62345559|NCT00657124|PLACEBO_COMPARATOR|2|receive a preoperative supplementation without carbohydrate and branched-chain amino acids-enriched nutrient
62345560|NCT03132168|OTHER|Subjects undergoing radical cystectomy|Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
61956531|NCT01637272|EXPERIMENTAL|SOM230|Subjects with dumping syndrome treated with pasireotide
61956532|NCT03176498|EXPERIMENTAL|Experimental group|Basic medication：Aspirin Enteric-coated Tablets \& Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells
61956533|NCT03176498|PLACEBO_COMPARATOR|Control group|Basic medication：Aspirin Enteric-coated Tablets \& Atorvastatin Calcium; Placebo：saline
62345561|NCT01958125|ACTIVE_COMPARATOR|gammacore|gammacore active device to be used noninvasively to the vagal nerve in the neck.
62345562|NCT01958125|PLACEBO_COMPARATOR|inactive gammacore|same as the active treatment, but without the therapy treatment provided
62345563|NCT05326217|NO_INTERVENTION|Control Group|non-dysmenorrhea population with original lifestyle
62345564|NCT05326217|NO_INTERVENTION|Dysmenorrhea|dysmenorrhea population without exercise intervention
62345565|NCT05326217|EXPERIMENTAL|Dysmenorrhea+Aerobic Exercise|dysmenorrhea population with aerobic exercise intervention
62345566|NCT05326217|EXPERIMENTAL|Dysmenorrhea+Resistant Exercise|dysmenorrhea population with resistant exercise intervention
62345567|NCT03126331|EXPERIMENTAL|Cohort I: Intermittent Nivolumab|Nivolumab monotherapy. Participants who have initial 10% or greater tumor burden reduction will discontinue nivolumab until they experience a pre-specified disease progression at which time nivolumab will be restarted
62702332|NCT06748625|EXPERIMENTAL|Luci intervention|Participants enrolled in this group will receive the Luci intervention for a 24-week period.
61956534|NCT04352816|EXPERIMENTAL|Control Group|Participants who do not receive an ICD therapy and have normal Echocardiogram findings and no evidence of arrhythmia will form this group. These participants will receive an MCG scan in addition to their standard care plan We will record the findings of any/all investigations participants receive as per their standard care plan, such as imaging providing left ventricular ejection fraction and usual care blood tests although their research activity/involvement in the trial will cease after the baseline observation. There will be no follow up. We aim to recruit 210 participants to this group to match the anticipated size of the group who receive an ICD but don't receive a shock.
61956535|NCT04352816|EXPERIMENTAL|Observation group|The participants who go on to receive an ICD therapy, as part of standard care, will constitute the 'Observation' group. These participants will undergo an MCG, lying and standing blood pressure and undertake a quality of life questionnaire. Participants in this group will undergo additional blood tests, circulating vascular biomarkers such as (High sensitivity Troponin, Nt pro BNP, CRP, High sensitivity CRP, mRNA, IL-6). All scans and tests that are conducted as part of standard care for evaluation of requirement of ICD implantation will be collected, for example; Echocardiographic, CMRI or MUGA measurements of the heart chambers and function. We will record these findings as this will enable us to substratify patients according to different degrees of cardiac dysfunction
61956536|NCT04352816|EXPERIMENTAL|Device in situ group|"To achieve the secondary objectives of exploring whether features consistent with arrhythmogenesis are extractable from MCG scans on participants with ICDS and pacemakers in situ, the investigators will recruit an additional 30 participants separate from the main trial. Twenty participants will be recruited from the ICD clinic. These participants, who have already had an ICD implanted will be selected with a 50:50 split as to whether they have had previous therapy from the ICD. The presence of an ICD can impact the analysis of MCGs in these patients due to the background signal noise subtraction required to obtain a usable signal. We will use these scans to trial different signal noise reduction strategies. These will be analysed to determine whether the features seen in the main trial can be extracted from this data set.~10 participants will be recruited who have got an upgrade from a pacemaker to an ICD."
61956537|NCT06376396|EXPERIMENTAL|Albendazole and Praziquantel|This arm includes combined albendazole with praziquantel, given to approximately 150 participants. Subjects will also receive dexamethasone as an adjunct treatment. An appropriate dose will be calculated per participant's body weight and administered to each participant daily for 10 days. Participants will be monitored for 30 minutes following oral medication, and a repeat dose will be administered if a participant vomits within this observation period. Additional doses (the whole cycle) will be supplied for participants failed to clear NCC in six months.
61956538|NCT06376396|ACTIVE_COMPARATOR|Albendazole|This arm includes albendazole monotherapy, given to approximately 150 participants. Subjects will also receive dexamethasone as an adjunct treatment. An appropriate dose will be calculated per participant's body weight and administered to each participant daily for 10 days. Participants will be monitored for 30 minutes following oral medication, and a repeat dose will be administered if a participant vomits within this observation period. Additional doses (the whole cycle) will be supplied for participants failed to clear NCC in six months.
61956539|NCT03521908||Participants treated with apixaban|
61956540|NCT03521908||Participants treated with warfarin|
61956541|NCT01862874|EXPERIMENTAL|V501|Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
61956542|NCT01862874|PLACEBO_COMPARATOR|Placebo|Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
61956543|NCT00850590|EXPERIMENTAL|Low Dose|NRL001 at 5, 7.5, and 10 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
61956544|NCT00850590|EXPERIMENTAL|High Dose|NRL001 at 10, 12.5, and 15 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
61956545|NCT05124314|EXPERIMENTAL|Mifepristone and Misoprostol|Patients receive oral mifepristone (600 mg) 48 hours before medical treatment with vaginal misoprostol (800 mcg repeated after 24 hours if no pregnancy tissue is lost).
62503301|NCT06678958|EXPERIMENTAL|Adult patients with acetabular defects requiring reconstruction|The acetabular defect was reconstructed by tarbecular metal augments in the flying buttress position
62702333|NCT06748625|NO_INTERVENTION|Wait-list Control|Participants in the waiting-list control group will not receive any intervention during the study. They will be invited to participate in the program at the end of the trial.
62702334|NCT05757570|EXPERIMENTAL|Part 1: Povetacicept 240mg|Participants grouped in 3 cohorts by diagnosis will be administered Povetacicept
62702335|NCT05757570|EXPERIMENTAL|Part 2: Povetacicept Dose A|Based on the findings of Part 1, one or two dose levels may be assessed in Part 2; if two dose levels are assessed participants will be randomized to receive one of the two dose levels of Povetacicept
62702336|NCT06748326|OTHER|Laparoscopic reduction of intussusception in children|The abdomen is insufflated through an umbilical ring incision and a trocar is inserted to act as a camera Port. Two other ports for manipulation are placed depend on the position of the intussusception either in the right lower quadrant and the left upper quadrant or both the upper left and lower left quadrants of the abdomen. These ports position is assuming that radiological reduction has carried the intussusceptum to the right colon. Two atraumatic bowel clamps are used for bowel manipulation. The reduction is achieved by traction placed on the proximal bowel (intussusceptum) out of the distal segment (the intussuscepien).
62702337|NCT06750666||Emergency rooms in North Denmark Region|Data from all emergency rooms in North Denmark Region will be retrieved. This includes sites at Aalborg University Hospital and North Denmark Regional Hospital.
62702338|NCT06750666||Control hospital in Central Denmark Region|We aim to retrieve data from a hospital outside the North Denmark Region that continues to use urine dipsticks. Specifically, we plan to collect data from Aarhus University Hospital, the largest hospital in the Central Denmark Region.
62702339|NCT06750666||Control urine cultures from general practice|The count of urine cultures ordered in the primary sector outside hospitals in the North Denmark Region (general practice), where dipsticks remain in use, will serve as a control.
62503302|NCT05377294|EXPERIMENTAL|MOL therapy|Participants with Psychosis and/or Suicidality receiving MOL therapy
62503303|NCT03710044|EXPERIMENTAL|Cyclosporine A treatment|Oral cyclosporine A treatment
62503304|NCT03888534|EXPERIMENTAL|Ixazomib|Ixazomib, injection, intravenously, once on Days 1, 4, 8, and 11 in a single 29-day treatment cycle in combination with multiagent reinduction therapy. Participants \>= 1 year will receive the starting dose of 1.0 milligram per square meter (mg/m\^2) and \<1 year will receive the starting dose of 0.03 milligram per kilogram (mg/kg). The dose escalation phase will determine the MTD or RP2D of Ixazomib. Dose of Ixazomib will be escalated based on the observed safety and tolerability data.
62503305|NCT03769532|EXPERIMENTAL|Pembrolizumab + Azacitidine|"Pembrolizumab (IMP): 200 mg i.v. (fixed dose) / Azacitidine (SOC): 75 mg/m2 s.c.~maximum duration of treatment: up to 24 weeks"
62503306|NCT05193773|NO_INTERVENTION|comparison group|The Control Group received no extra care.
62503307|NCT05193773|EXPERIMENTAL|Intervention Group|Intervention Group, Intervention with follow-up, will have a multifactorial interventions to reduce physical restraint.
61956546|NCT05124314|ACTIVE_COMPARATOR|Misoprostol|Medical treatment with vaginal misoprostol (800 mcg repeated after 24 hours if no pregnancy tissue is lost).
61956547|NCT02582983|EXPERIMENTAL|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
61956548|NCT00491816|EXPERIMENTAL|erlotinib with neoadjuvant chemotherapy|Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
61956549|NCT00694174|ACTIVE_COMPARATOR|1|2 ml sucrose 25% oral solution one time only dose by mouth
61956550|NCT00694174|PLACEBO_COMPARATOR|2|sterile water 2 ml one time only dose given by mouth prior to heel lance
62503308|NCT04799223|EXPERIMENTAL|Group receiving the 4 designed foods|The experimental group consumes the 4 foods designed for the study and will follow healthy eating guidelines.
62503309|NCT04799223|ACTIVE_COMPARATOR|Group with no designed foods|The control group follows healthy eating guidelines.
62503310|NCT01710605|ACTIVE_COMPARATOR|Standard|Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.
62503311|NCT01710605|EXPERIMENTAL|Circulating Tumor Cells|"Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :~If \<5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy"
62503312|NCT01348204|EXPERIMENTAL|quercetin|health food supplement
62503313|NCT03964363|EXPERIMENTAL|Prehabilitation|Participants are scheduled for elective surgery and follow the home-based prehabilitation for 11-17 days
61956551|NCT05561699|EXPERIMENTAL|Penpulimab Combined With Chemoradiotherapy(CRT)|
61956552|NCT05337228|EXPERIMENTAL|IN-C006 Peri inj.|IN-C006 Peri inj. 1904 mL
61956553|NCT05337228|ACTIVE_COMPARATOR|RPN301|RPN301 2020 mL
61956554|NCT06312605|ACTIVE_COMPARATOR|Intramucosal vitamin C injection|After surgical gingival depigmentation, injectable vitamin C (Redox C 500 mg) using insulin syringe(29 Gauge 1cc 0.33mm x 8mm 5/16 needle) is applied at gingival sites 0.1 ml for each point that should be 3 mm. The regimen is done once weekly for a month then once a month for additional 5 months.
62142576|NCT06698380|EXPERIMENTAL|Experimental|"The experimental group received combination therapy that is MT combined with CPT treatment. The subjects were asked to be seated on a comfortable chair with feet and back supported and the upper extremity was on a tabletop surface of two-by-two- meter size.~A mirror was positioned in front of the subjects to shield the involved upper extremity, reflecting the image of the uninvolved side. The involved upper extremity was placed in a relaxed posture beside the mirror, mirroring the same posture on the uninvolved side to enhance illusional movements. The MT for the experimental group included reaching, grasping, and dexterity movements of the unaffected upper limb, followed by imitation on the involved side. Subjects performed five activities: finger flexion and extension, finger opposition, counting with fingers, wrist flexion and extension, and forearm supination and pronation. Each activity was done 10 times, with mirror therapy lasting 15 minutes and 30 minutes / 6 weeks."
62142577|NCT01054859|EXPERIMENTAL|Treatment A|0.5 g/Kg alcohol plus 200 mg avanafil tablet
62142578|NCT01054859|ACTIVE_COMPARATOR|Treatment B|0.5 g/kg alcohol
62142579|NCT01054859|ACTIVE_COMPARATOR|Treatment C|200 mg avanafil tablet
62503314|NCT03964363|EXPERIMENTAL|Prehabilitation + TAVI|Study participants who will undergo a TAVI form a subgroup with a modified enrolment procedure and longer duration of the intervention. The prehabilitation period is extended to 30 days.
62503315|NCT03964363|NO_INTERVENTION|Control|Participants are initially evaluated for frailty prior to scheduled surgery but subsequently receive regular care without a prehabilitation program. All pre- and postsurgical evaluations will be identical to the prehabilitation group.
62503316|NCT03964363|NO_INTERVENTION|Control+TAVI|The subgroup of participants who undergo a TAVI will be compared to a group of patients who will have had the same procedure. Hence the control group will also receive a screening via phone but then receive regular care. Follow-up after surgery will be identical in all groups.
62503317|NCT05444543|NO_INTERVENTION|Control|Participants in this arm will continue with their normal standard of care regimen of daily topical steroids
62503318|NCT05444543|EXPERIMENTAL|Intervention|Participants in this arm will cycle their topical steroid therapy in a three-months on three-months off fashion
62702340|NCT06749457|EXPERIMENTAL|Phase I: Cohort 1 (AZD7760 Dose A and Placebo)|Participants will receive a single dose of AZD7760 Dose A or matching placebo intravenously on Day 1.
62702341|NCT06749457|EXPERIMENTAL|Phase I: Cohort 2 (AZD7760 Dose B and Placebo)|Participants will receive a single dose of AZD7760 Dose B or matching placebo intravenously on Day 1.
62142580|NCT01836159|OTHER|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
62142581|NCT01836159|EXPERIMENTAL|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
62142582|NCT04263714|EXPERIMENTAL|Exercise|All subjects will perform both aerobic and resistance exercise
62142583|NCT04638738||Pre-implementation|Pre-implementation of digital alerting sensor systems
62142584|NCT04638738||Post-implementation|Implementation of digital alerting sensor systems
61956555|NCT06312605|ACTIVE_COMPARATOR|(Vitamin C topical gel|After surgical gingival depigmentation, patients in this group apply ascorbic acid containing gel prepared by Nawah Scientific Research Center. The micro emulsion was prepared by mixing tween 20 (4.66% w/w) as surfactant and isopropanol (2.3% w/w) as co-surfactant using magnetic stirring then diluted drop-wise with Vitamin C solution in water (10% w/w). The formed micro emulsion was then converted into gel using Poloxamer 407 (20% w/w) that was added at 4°C under continuous magnetic stirring
61956556|NCT06312605|PLACEBO_COMPARATOR|Control group|Surgical gingival depigmentation is carried out for these patients
61956557|NCT02779829|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61956558|NCT01018966|EXPERIMENTAL|Ixabepilone|
61956559|NCT06309732|EXPERIMENTAL|GAMEC - S|Day 4 PEG Filgrastim 6mg Day 1 Actinomycin D 1mg/m2 Day 1 Methotrexate (dependent on creatinine clearance) Days 1,2, 3, 4 Etoposide 90mg/m2 Days 2, 3 Cisplatin 50mg/m2 Day 8 Cisplatin 50mg/m2 (cycle 1\&2 only)
61956560|NCT06309732|EXPERIMENTAL|GAMEC-A|Day 1 Actinomycin-D 1m/m2 Day 2, 3 and 8 Methotrexate 8g/m2 (dependent on creatinine clearance) Day 2, 3 and 8 Cisplatin 50mg/m2 (Day 8 dose omitted from week 6 onwards) Day 1 and 2 Epirubicin 37.5mg/m2 Day 3 Pegfilgrastim 6mg Treatment given on weeks 1, 3, 6, 8 and 10.
61956561|NCT01826604|EXPERIMENTAL|Alexis O C-section retractor|Alexis O C-section retractor will be used.
61956562|NCT01826604|OTHER|Control- Conventional retractors|Conventional retractors for C-sections will be used.
61956563|NCT05488730|OTHER|shocked patient with impaired cardiac contractility|
62702342|NCT06749457|EXPERIMENTAL|Phase I: Cohort 3 (AZD7760 Dose C and Placebo)|Participants will receive a single dose of AZD7760 Dose C or matching placebo intravenously on Day 1.
61956564|NCT01407315|EXPERIMENTAL|GlucoMenDay - Multiple sampling (A)|
62702343|NCT06749457|EXPERIMENTAL|Phase IIa: Study Group 1 (AZD7760 Dose D and Placebo)|Participants will receive Dose D AZD7760 on Day 1 and placebo on Day 91.
61956565|NCT01407315|EXPERIMENTAL|GlucoMenDay - Meal/Insulin test (B)|
61956566|NCT05081973||Intubated preterm infants|Infants with a birth weight \< 1250 grams who have required endotracheal tube and mechanical ventilation within the first 7 days of life, and have been on an invasive mechanical ventilator for at least 48 hours, and have not completed 60 days after birth, and have met the traditional extubation criteria of the institution, and have been considered for elective extubation for the first time.
61956567|NCT05894408||patients with portal vein occlusion|
61956568|NCT05894408||patients without portal vein occlusion|
61956569|NCT04276571|EXPERIMENTAL|GRAIL|
61956570|NCT04276571|NO_INTERVENTION|No treatment|
61956571|NCT01695590|EXPERIMENTAL|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
61956572|NCT00156052|EXPERIMENTAL|Hypofractionated whole breast radiation|Subjects treated with 4250 cGY in 16 fractions
61956573|NCT00156052|ACTIVE_COMPARATOR|Conventional whole breast radiation|Subjects treated with 5000 cGY in 25 fractions
61956574|NCT00040365|EXPERIMENTAL|Amifostine|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
61956575|NCT00211510|EXPERIMENTAL|Paradigm 722 sensor augmented pump|subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring
61956576|NCT00211510|ACTIVE_COMPARATOR|Paradigm 715 insulin pump|subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin
61956577|NCT03367221|EXPERIMENTAL|NAVA group|NAVA ventilation
61956578|NCT04817748||Acute ST segment elevation myocardial infarction（STEMI）|the patients' coronary and venous blood were drawn for metabolomics study
61956579|NCT04817748||Acute non ST segment elevation myocardial infarction（NSTEMI）|the patients' coronary and venous blood were drawn for metabolomics study
62702344|NCT06749457|EXPERIMENTAL|Phase IIa: Study Group 2 (AZD7760 Dose E)|Participants will receive Dose E AZD7760 on Day 1 and Day 91.
62702345|NCT06749457|PLACEBO_COMPARATOR|Phase IIa: Study Group 3 (Placebo)|Participants will receive placebo on Day 1 and on Day 91.
62702346|NCT06749665|ACTIVE_COMPARATOR|Polidacanol|will receive intralesional injection of (polidacanol 3% (Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany) During the study, the dosage of the drug and frequency of treatment will be uniform in all patients. The base of each wart will inject until the lesion blanch using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 6 sessions.
61956580|NCT04817748||Acute myocardial infarction with no obstructive coronary atherosclerosis（MINOCA）|the patients' coronary and venous blood were drawn for metabolomics study
61956581|NCT04817748||Patients with normal coronary artery（NCA)|the patients' coronary and venous blood were drawn for metabolomics study
61956582|NCT00159120|ACTIVE_COMPARATOR|1|further maintenance antipsychotic treatment and prodrome-based early intervention
61956583|NCT00159120|EXPERIMENTAL|2|stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
61956584|NCT04449926|EXPERIMENTAL|BCG Vaccinated|"Experimental: BCG Group FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing \~1x10\^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (\~2x10\^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area. A follow up booster dose will be given one month after the initial dose."
61956585|NCT02993393||Teachers|Anesthesiologists who have involved in SBL and PBL with more than 3 years of experience in teaching
61956586|NCT02993393||Students|Students were nurse anesthetist students in the academic years of 2015
61956587|NCT03008603|EXPERIMENTAL|Procedures with XACT Robotic System|CT-guided minimally invasive percutaneous procedures using the XACT Robotics system
62142585|NCT00964236||Sapropterin|Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
62702347|NCT06749665|ACTIVE_COMPARATOR|Candida|will receive intralesional injection of candida antigen at a dose of 0.2 ml. Each treatment will inject into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 6 treatment sessions.
61956588|NCT06290661|EXPERIMENTAL|Participants receiving active electrostimulation after implantation procedure|Twenty-eight participants (anticipated) from different 4 hospital in China whose mean VAS scores decreased more than 30% compared with baseline scores after electrode implantation. They will still receive electrostimulation therapy during randomized withdrawal period.
61956589|NCT06290661|PLACEBO_COMPARATOR|Participants receiving placebo electrostimulation after implantation procedure|Twenty-eight participants (anticipated) from different 4 hospital in China whose mean VAS scores decreased more than 30% compared with baseline scores after electrode implantation. The electrostimulation of them will be turned off during randomized withdrawal period.
61956590|NCT01909674|EXPERIMENTAL|Oronasal Mask|Initial administration of oronasal CPAP mask
61956591|NCT01909674|EXPERIMENTAL|Nasal Mask|Initial administration of nasal CPAP mask
61956592|NCT01021046|EXPERIMENTAL|GCCT,corneal allograft survival ,DALK|experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue
62142586|NCT00964236||Control|Healthy individuals without phenylketonuria (PKU).
62345568|NCT03126331|EXPERIMENTAL|Cohort II: combination ipilimumab/nivolumab|"Combination of ipilimumab/nivolumab for previously untreated intermediate and poor risk mRCC~Includes participants treated front-line ipilimumab/nivolumab. Participants with treatment-naïve mRCC who receive up to four doses of induction ipilimumab/nivolumab and 24 weeks (+/- 8 weeks; minimum 3 infusions) of maintenance nivolumab and achieve stable disease (SD), complete response (CR), or partial response (PR) will be eligible for inclusion. Participants who achieve SD will continue with nivolumab maintenance per standard of care while those who achieve a PR or CR will enter an observation period off therapy. Upon disease progression, participants will be re-challenged with combination ipilimumab/nivolumab."
62345569|NCT01789853|EXPERIMENTAL|Intensive Walking|High intensity walking training in variable context for 8 weeks
62345570|NCT01789853|ACTIVE_COMPARATOR|Conventional Physical Therapy|Regular physical therapy for 8 weeks
62345571|NCT03372668|OTHER|All Participants|Each study participant will progress through the three, 4-week study periods in the ABA withdrawal design in the same, designated order. The first and third 4-week study periods (or the A periods) have no intervention and only consist of twice weekly data collection. The second 4-week study period (or the B period) will include the twice weekly delivered massage therapy combined with components of mirror therapy intervention.
62345572|NCT05089344|EXPERIMENTAL|mild stimulation protocol + growth hormone adjuvant|"Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.~Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .~. For those in the GH group, 8 IU recombinant human GH will be administered starting from Day 14 of the previous cycle Till administration of HCG for ovulation triggering"
62702348|NCT06749665|ACTIVE_COMPARATOR|Polidacanol and candida|will receive intralesional candida antigen injection in the largest wart and intralesional injection of (polidacanol 3%) in all warts using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 6 treatment sessions
62702349|NCT06750848|EXPERIMENTAL|Chidamide，Fulvestrant ，angiogenesis inhibitors|
62736632|NCT05664503|NO_INTERVENTION|Booklet|Control-Classical patient education before the operation, the patient is educated with the classical method brochure.
62142587|NCT06621771|EXPERIMENTAL|Piano group|Participants will engage in a step-by-step musical training consisting of two supervised, individual 45-min sessions per week for 6 consecutive weeks, for a total of 12 sessions. They will also be asked to practice 2x/week for 15 minutes and they will report on their practice duration and content in a logbook after each practice session.
62142588|NCT06621771|ACTIVE_COMPARATOR|Conventional group|Participants will engage in two supervised and individual 45-min session per week for 6 consecutive week, consisting in usual occupational therapy treatment. They will be asked to practice 2x/week for 15 minutes and they will report on their practice duration and content in a logbook after each practice session.
62142589|NCT05168397||RV4857A arm|"Application of the product before and during each sun exposure, at least twice a day.~During sun exposures, the applications were renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, the product was applied in the morning and at the beginning of the afternoon."
62142590|NCT06211595|EXPERIMENTAL|The treament of DragonFire Transcatheter myocardial ablation system|If drug therapy does not work or drug side effects are not tolerated, transaortic interventional surgery can be evaluated
62142591|NCT03407976|EXPERIMENTAL|Apatinib and Pembrolizumab, all patients|
61956593|NCT01021046|EXPERIMENTAL|FCT,corneal allograft survival ,DALK|control group: deep anterior lamellar keratoplasty using fresh corneal tissue
61956594|NCT02576795|EXPERIMENTAL|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at escalating doses.
61956595|NCT02318771|EXPERIMENTAL|A1: RT (1 fraction, 8 Gy) + MK-3475|Patients undergo RT on day 1 per standard of care and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 IV over 30 minutes on day 1. Courses of MK-3475 repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61956596|NCT02318771|EXPERIMENTAL|A2: RT (5 fractions, 4 Gy) + MK-3475|Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
61956597|NCT02318771|EXPERIMENTAL|B1: MK-3475 + RT (1 fraction, 8 Gy) + MK-3475|Patients receive one dose of MK-3475 IV over 30 minutes on day 1 and then undergo 1 fraction of RT. Patients then receive MK-3475 IV over 30 minutes in the absence of disease progression or unacceptable toxicity.
61956598|NCT02318771|EXPERIMENTAL|B2: MK-3475 + RT (5 fractions, 4 Gy) + MK-3475|Patients receive MK-3475 as in Arm B1 and undergo 5 fractions of RT.
61956599|NCT03968770|EXPERIMENTAL|Experimental group|Probiotic product plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
61956600|NCT03968770|PLACEBO_COMPARATOR|Control group|Sham probiotical plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
62702350|NCT06750913|EXPERIMENTAL|Experimental group|In the study group, the patient is directly placed in the split-leg prone position. A 10-cm soft pillow is used to elevate the upper abdomen, making the lower edge of the pubic symphysis exceed the lower edge of the operating table by 5 cm. The patient's legs are spread in a V-shaped manner. The thigh on the healthy side is abducted as much as possible, while the thigh on the affected side is slightly abducted, so that the angle between the two legs is approximately 80°. The lumbar back and perineum are disinfected and covered with sterile drapes, and an indwelling urinary catheter is inserted for open drainage. The target renal calyx is punctured percutaneously under the guidance of ultrasound, and an 18 - 24 Fr tract is established under the guidance of a guidewire. A peel-away working sheath is then left in place, completing the establishment of the tract.
62142592|NCT05690230|EXPERIMENTAL|Intervention 1: Virtual reality|
61956601|NCT00758836|PLACEBO_COMPARATOR|Placebo|Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
62142593|NCT05690230|NO_INTERVENTION|Control 1|Standard of care without change, in parallel with intervention 1: Virtual reality.
62345573|NCT05089344|ACTIVE_COMPARATOR|Mild stimuation protocol|"Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.~Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .~."
62345574|NCT06050967|EXPERIMENTAL|individualized treatment plan with random dosage and time of administration|Baseline clinical and laboratory parameters acquired at the screening included: a physical examination, complete blood count (CBC), Lyso-GB1 , and a 36-item short-form survey (SF-36) for quality-of-life examination. Once providing informed consent, the Altus Care™ application was installed on the patient's cellular phone. In coordination with the patient's treating physician and the home treating nurse5 , an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks ERT dosages and timing frames for its administration. Per protocol, the patient's monthly dose wasn't changed, but each dose and the timing of administration was changed randomly using the app.
62345575|NCT00004095|EXPERIMENTAL|Irinotecan Plus Gemcitabine|
62345576|NCT05402098|ACTIVE_COMPARATOR|Endodontic treatment using traditional access|Straight line access will be achieved following complete removal of pulp chamber roof
62345577|NCT05402098|EXPERIMENTAL|Endodontic treatment using conservative access|Part of pulp chamber roof will be preserved and no efforts will be directed to achieve straight line access
62345578|NCT01529385|EXPERIMENTAL|Mild Compression Diabetic Sock|Diabetic socks that provide 18-25mm Hg of pressure to the lower extremities.
62345579|NCT01529385|OTHER|Standard Diabetic Sock|A standard diabetic sock that is designed to limit foot ulcer formation, but does not provide compression to the leg.
62345580|NCT03835000||Pre operative patient|Patients who will require orthopedic surgery for corrective, replacement or repair
62503319|NCT03730181|EXPERIMENTAL|Single Arm Rifapentine and Isoniazid|Single arm, open label and exposure-controlled. Intervention is rifapentine given in a new fixed dose combination once-weekly, in combination with isoniazid for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years in whom LTBI treatment is indicated. The protocol allows for parallel enrolment of children into cohorts 1 and 2, simultaneously, using a predetermined modeled initial dose for each cohort, separately. Similarly, cohorts 3 and 4 will be enrolled in parallel, using modeled doses for each cohort, based on data from cohorts 1 and 2 and historical data from TBTC trials.
62503320|NCT00623636|EXPERIMENTAL|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks.
62503321|NCT00623636|OTHER|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks.
62503322|NCT04742894|EXPERIMENTAL|Aphasia Group|
62736633|NCT05664503|EXPERIMENTAL|STOMA-M|Patients are educated with the mobil aplikasyon method.
61956602|NCT00758836|EXPERIMENTAL|Telcagepant 280 mg +Ibuprofen 400 mg|Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
61956603|NCT00758836|EXPERIMENTAL|Telcagepant 280 mg +APAP 1000 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
62142594|NCT05690230|EXPERIMENTAL|Intervention 2: Environmental changes|
62142595|NCT05690230|NO_INTERVENTION|Control 2|Standard of care without change, in parallel with intervention 2: Environmental changes.
62142596|NCT06324344|ACTIVE_COMPARATOR|Intervention Group|"The intervention group will be undergoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy on a daily basis with a high-dose TENS device for 8 weeks.~The high-dose TENS device elicits 1 hour of TENS per session. Subjects are instructed to complete at least 3 sessions per day. To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side on a weekly basis."
62345581|NCT02327221|ACTIVE_COMPARATOR|Ovasave - Dose 10e4|
62345582|NCT02327221|ACTIVE_COMPARATOR|Ovasave - Dose 10e6|
62345583|NCT02327221|ACTIVE_COMPARATOR|Ovasave - Dose 10e7|
62345584|NCT02327221|PLACEBO_COMPARATOR|Placebo|
62345585|NCT01933750|NO_INTERVENTION|Randomized/Control|7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21
62345586|NCT01933750|EXPERIMENTAL|Non-Randomized/Treatment|Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device
62345587|NCT01243099||In-stent (BMS) restenosis|
62345588|NCT01243099||De-novo coronary lesion|
62503323|NCT04742894|EXPERIMENTAL|Control Group|
62503324|NCT06057506|EXPERIMENTAL|Investigational Device|"Medical device for the treatment of head lice infestation: Paranix® Shampoo, already in the market in Europe~Single topical application administered to hair and scalp for 10 minutes. Applied by principal investigator on site."
62503325|NCT06057506|ACTIVE_COMPARATOR|Comparator Device|"Medical device for the treatment of head lice infestation: Paranix® Lotion, already in the market in Europe~Single topical application administered to hair and scalp for 10 minutes. Applied by principal investigator on site."
62503326|NCT01544517|EXPERIMENTAL|5d-QCT|5-day eradication regimen consisting in the concomitant administration of esomeprazole 40mg bid + amoxicillin 1g bid + levofloxacin 500mg bid + tinidazole 500mg bid
62503327|NCT01544517|ACTIVE_COMPARATOR|10-day sequential regimen|5 days of esomeprazole 40mg bid + amoxicillin 40mg bid followed by 5 more days of esomeprazole 40mg bid + levofloxacin 500mg bid + tinidazole 500 mg bid
62503328|NCT06535555|EXPERIMENTAL|Investigational Arm|"Patients in the investigational arm will ingest 400mg PO riboflavin pre-operatively. At the start of their procedure, after the surgeon gain laparoscopic access using their standard procedures and equipment, the updated version of the ActivSight device will be placed through a standard laparoscopic trocar and attempts will be made to visualize the ureter under direct imaging using light in the visible spectrum.~When the surgeon is complete with the attempted visualization, they will remove the ActivSight device and proceed with their normal operative course and equipment.~No surgical decisions will be made based upon this information, and the device will only be used during the aforementioned time."
62503329|NCT02767934|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
62503330|NCT05685017||Metablic syndrome vs. non-metabolic syndrome|Obese adolescents were grouped on MetS vs. non-MetS based on The International Diabetic Federation criteria
62345589|NCT00695240|EXPERIMENTAL|Bupiv analgesia|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. The catheter was placed in the operating room with a peel-away trocar and attached to the pump. The trocar was inserted through a 5 mm stab incision made near the superior part of the pubic bone between the genitoinguinal fold and the midline of the symphysis. Once through the incision, the trocar is advanced subcutaneously and made to exit the posterior fourchette just beneath the posterior vaginal mucosa where it is advanced by tenting up the skin.
62503331|NCT03658148||Study Group|Neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease (CHD) between 2008-2017.
62503332|NCT05536531|EXPERIMENTAL|NMES group|NMES will be implemented simultaneously on quadriceps femoris muscles of both lower limbs using an electrical stimulator (TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile). Four rubber surface electrodes will be placed over motor points. However, since the electrodes will cover big proportion of muscle surface, anatomical distribution of the belly muscle plus visible contraction of it will be considered for correct setting. The stimulation will be delivered by biphasic current, symmetric (compensated) impulses of 45-50 Hz frequency, 400 μsec pulse duration. With a stimulus duration of 25 minutes, and an on-off programming of 5 seconds on (including 0.8 second rise time, 3.4 seconds of plateau and 0.8 second of fall time) and 5 seconds off, at current intensities able to cause maximal visible contractions. The session duration will be 30 minutes and will be applied twice a day.
62503333|NCT05536531|NO_INTERVENTION|Control|Sham NMES will not be provided. Standard care won´t be altered and passive mobilization will be performed according to routine ICU procedures.
62503334|NCT00754468|EXPERIMENTAL|Group 1: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 4 cycles x 10 seconds
62503335|NCT00754468|EXPERIMENTAL|Group 2: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 2 cycles x20 seconds
62503336|NCT01030887|ACTIVE_COMPARATOR|Exercise Programme|This will consist of an 8-week exercise programme, performed twice per week.
62503337|NCT01030887|PLACEBO_COMPARATOR|Usual Care|Standard practice including opportunistic exercise advice and patients' self-directed physical activity
62503338|NCT01287455|ACTIVE_COMPARATOR|vitamin D|vitamin D deficient asthmatic patients receiving vitamin D supplement
62503339|NCT01287455|PLACEBO_COMPARATOR|placebo|vitamin D deficient asthmatic patients receiving placebo
62503340|NCT00820599|EXPERIMENTAL|TAVR|Transaortic Valve Replacement
62503341|NCT05967936|ACTIVE_COMPARATOR|Paracervical block|10cc Bupivacaine 1% at 0.5-1 cm depth of the cervicovaginal junction at 5 and 7 o'clock positions (20cc in total).
62503342|NCT05967936|EXPERIMENTAL|Transcervical block|10cc Bupivacaine 1% through the endocervix using an 17-gauge epidural catheter
62503343|NCT01899196|OTHER|no Arm|
62503344|NCT06533072|EXPERIMENTAL|experimental group|Patients who received routine medical treatment and nursing care + IR LED Light application after surgery (n = 40). It is applied on Post-Operative Day 1-2. It will be given four times in total, from a distance of 45-60 cm, for 20 minutes at 8 hour intervals (Wolters and Feaarnly, 2023). The patient will be asked to remain in the supine position during the procedure and the patient's vital signs will be checked again after the procedure. After the third and last Infrared LED application on post-op Day 2, the patient's wound was re-evaluated and the wound was dressed and closed. On the 15th and 30th post-operative day, the patient will be asked to come to the hospital and the wound site will be re-evaluated and the data collection form will be filled out again.
62345590|NCT04986020||Parkinson disease|Participants with a clinical diagnosis of Parkinson's disease
62345591|NCT04986020||Control|Controls
62345592|NCT00804375|EXPERIMENTAL|2PX|Pain medication
62345593|NCT00804375|PLACEBO_COMPARATOR|placebo|placebo
62345594|NCT00078988|EXPERIMENTAL|Arm I (high-dose chemotherapy and ASCR)|Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
62345595|NCT00078988|EXPERIMENTAL|Arm II (intermediate-dose chemotherapy and ASCR)|Patients receive intermediate-dose chemotherapy comprising carboplatin IV over 4 hours and thiotepa IV over 3 hours on days 1-2 and G-CSF IV or SC once daily beginning on day 4 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 3. Treatment repeats every 28 days for a total of 3 courses.
62345596|NCT00078988|EXPERIMENTAL|Arm III (isotretinoin)|Patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for a total of 6 courses.
62345597|NCT00078988|NO_INTERVENTION|Arm IV (no isotretinoin)|Patients do not receive maintenance therapy.
62503345|NCT06533072|NO_INTERVENTION|Control group|This is the group of patients who received routine medical treatment and nursing care after surgery (n=40). After the patient's vital signs were taken postoperative one day and after the Informed Consent Form was obtained from patients who met the inclusion criteria and volunteered to participate in the study; Data collection form (demographic information form, Bates-Jensen wound assessment scale, observer scar assessment scale, VAS, Newcastle Nursing Care Satisfaction Scale) will be filled out.
62503346|NCT03441139|EXPERIMENTAL|Cryotherapy + medical analgesics|Percutaneous Cryotherapy and medical analgesics according to the investigator's discretion
62503347|NCT03441139|ACTIVE_COMPARATOR|Medical analgesics|Medical analgesics alone according to the investigator's discretion
62503348|NCT05103917|EXPERIMENTAL|X4P-001-201|trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination with Toripalimab in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
62503349|NCT04546269|EXPERIMENTAL|Fully-guided|Single-tooth implant placed using a fully computer-guided approach
62503350|NCT04546269|ACTIVE_COMPARATOR|Conventionally guided|Single-tooth implant placed using a conventionally guided approach
62503351|NCT01801917|PLACEBO_COMPARATOR|Placebo|5 placebo tablets daily during non-titration phase
62503352|NCT01801917|EXPERIMENTAL|BAF312 2mg|1 tablet of BAF312 2 mg + 4 tablets of Placebo daily during non-titration phase
62503353|NCT01801917|EXPERIMENTAL|BAF312 10 mg|5 tablets of BAF312 2 mg daily during non-titration phase
62503354|NCT04647734|EXPERIMENTAL|High intensity interval training|The experimental group will on top of standard care undergo a 12 weeks supervised exercise high intensity interval exercise training on an ergometer bike three times a week for 38 minutes. The specific intervals will be determined from our ongoing pilot study (NCT04549337)
62503355|NCT04647734|ACTIVE_COMPARATOR|Control group|This group will be allocated to standard care and therefore no supervised exercise regimen.
62503356|NCT03754387|ACTIVE_COMPARATOR|Antibiotic therapy group|Ceftazidime will chosen as the antibiotic for this study because of its efficacy as a monotherapy for serious intraabdominal infections, requiring only a single, daily dose. Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) is administered for 3 days to patients in the AT group, with the first dose given in the emergency department. The clinical status of patients in the AT group is reevaluated within 12 to 24 hours after admission by the surgeon on call. If the surgeon suspected progressive infection, perforated appendicitis, or peritonitis, the patient will underwent appendectomy. Intravenous antibiotic treatment will followed by 7 days of oral cefuroxime (250mg twice daily).
62503357|NCT03754387|EXPERIMENTAL|Laparoscopic Appendectomy group|Laparoscopic appendectomy will performed using. Prophylactic antibiotics (ceftazidime sodium 50mg/kg/dose ) will administered approximately 30 minutes before the incision was made. No further antibiotics will given to patients in the surgical group unless a wound infection was suspected postoperatively.
62503358|NCT01728740|EXPERIMENTAL|Acarbose/Metformin FDC|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)
62345598|NCT04121520||Observational|At time of consent and within the same day of HVPG measurement, participants will be asked to complete a pre-operative assessment. Relevant statistics will be recorded during the HVPG procedure. Post-operative complication will also be collected and the satisfaction survey will be conducted.
62503359|NCT01728740|ACTIVE_COMPARATOR|Acarbose+Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg
62503360|NCT01728740|ACTIVE_COMPARATOR|Acarbose|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg
62736634|NCT02894957|EXPERIMENTAL|Gradual smoking cessation|"Gradual cessation Patients randomized to the gradual cessation group will receive varenicline (0,5 mg once daily for 3 days, 0,5 mg twice daily for 4 days, and 1,0 mg bid thereafter) as an aid for smoking reduction. This pre-treatment phase will last 6 weeks at the end of which all participants must stop smoking altogether. After quitting, they will continue to receive varenicline 1,0 mg bid for a further 12 weeks.~Smoking reduction: Participants will be recommended to reduce their smoking by 25% in the first two weeks, 50% in weeks 3-4, and 75% in weeks 5-6; however, this will be given only as an indication and every subject will be allowed to chose his/her own goal and rate of progress."
61956604|NCT00758836|PLACEBO_COMPARATOR|Telcagepant 280 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine
61956605|NCT00534391|PLACEBO_COMPARATOR|B|Artificial tear containing antibiotic solution base
62345599|NCT05747755|NO_INTERVENTION|Pre-intervention (usual care)|Patients admitted to study hospitals in the 12 months prior to the start of the intervention
62503361|NCT01728740|ACTIVE_COMPARATOR|Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg
62503362|NCT06293391||ODM measurements of patients undergoing open surgery in supine and trendelenburg position|After intubation, serial ODM measurements were performed in the supine and trendelenburg position of the patient and CO: Cardiac output, FTc: Flow time corrected, PV: Peak velocity, SD: Stroke distance values were recorded.
62503363|NCT06293391||ODM measurements of patients undergoing laparoscopic surgery in supine and trendelenburg position|After intubation, serial ODM measurements were performed in the supine and trendelenburg position of the patient and CO: Cardiac output, FTc: Flow time corrected, PV: Peak velocity, SD: Stroke distance values were recorded.
62503364|NCT01287715|EXPERIMENTAL|STOP-arm|Discontinuation of etanercept
62503365|NCT01287715|NO_INTERVENTION|CONTROL-arm|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
62503366|NCT05864924|EXPERIMENTAL|BRG01 injection|Intravenous infusion
62503367|NCT03992651|EXPERIMENTAL|Experimental group|One single group of healthy subjects
62503368|NCT03868111|EXPERIMENTAL|Sufentanil|Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.
62503369|NCT03868111|EXPERIMENTAL|Remifentanil|Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.
62503370|NCT01086930|EXPERIMENTAL|Intervention Group|"In addition to standard care participants in Group A will receive:~• One hour of extra hand training five times per week for 8 weeks using the ReJoyce Workstation.~The training will be supervised by a therapist and provided to the target hand. The hand exercises will be incorporated into computer games and will involve the following tasks using different manipulanda:~* reaching~* grasping~* manipulating~* pulling~* rotating~* releasing"
62503371|NCT01086930|OTHER|Standard Care Group|Participants in the control group will not receive any training on the instrumented workstation or electrical stimulation to the hand or upper limb. They will however continue to receive standard care as well as three 15-minute specific hand activity sessions per week specifically devoted to the practice of hand activities in a one-to-one format with a therapist (as per the treatment received by the experimental group).
62503372|NCT04747132|EXPERIMENTAL|Intervention group|Individualized geriatric medical counseling, psychological counseling, nutritional counseling and physical activity counseling through the internet
62503373|NCT04747132|NO_INTERVENTION|Control group|Health guidance through standardized audiovisual educational material through Intenert
62702351|NCT06750913|NO_INTERVENTION|Control group|In the control group, the patient is first placed in the lithotomy position. A 5 Fr ureteral catheter is retrogradely inserted into the ureter on the affected side via a cystoscope, along with a 16 Fr Foley catheter. Then, the patient is turned to the prone position, and a 10-cm soft pillow is used to elevate the upper abdomen. The surgical area is disinfected and draped again. Sterile normal saline is injected through the ureteral catheter to create artificial hydronephrosis. The target renal calyx is punctured percutaneously under the guidance of ultrasound, and retrograde contrast is performed when necessary, combined with X-ray-guided percutaneous puncture. Subsequently, an 18 - 24 Fr tract is established under the guidance of a guidewire, and a peel-away working sheath is left in place, thus completing the establishment of the tract.
62503374|NCT02221440|PLACEBO_COMPARATOR|air, second stage of labor|"Patients randomized to the group will receive sham administered by nasal catheter.~The therapy will continue until after delivery"
62503375|NCT02221440|EXPERIMENTAL|oxygen, second stage of labor|"Patients randomized to the group will receive oxygen administered by low flow nasal oxygen at a flow rate of 2 L/min.~The therapy will continue until after delivery"
62503376|NCT06143462|ACTIVE_COMPARATOR|Group A: usual care (UC)|Group A (UC) will receive conventional medications.
62503377|NCT06143462|EXPERIMENTAL|Group B: vestibular rehabilitation treatment (VRT)|Group B (VRT) will receive outpatient VRT in combination with home practice based on conventional treatment.
62503378|NCT05600023|EXPERIMENTAL|Nitrofurantoin|
62503379|NCT05600023|EXPERIMENTAL|Double antibiotic paste|
62503380|NCT05600023|NO_INTERVENTION|Control|
62702352|NCT05663320|OTHER|1|Intervention Study Arm 1 participants will receive an approximately 11minute educational video on CAH that focuses on transitional goals (at baseline, 3 months, and 6 months. This will be done via a NIH approved webbased REDCap. Completion will be recorded.
62702353|NCT05663320|NO_INTERVENTION|2|Usual care Study Arm 2 participants will have their usual six-month CAH follow up to coincide with study visits at 0, 6 and 12 months. During their visit, study participants will receive standard care that includes self-injection teaching and sick day rules
62702354|NCT06182163|EXPERIMENTAL|Sedentary time intervention|
62503381|NCT04238208|ACTIVE_COMPARATOR|Group LL|Group LL patients received the 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm containing 700 mg of Lidocaine for 60 minutes
62503382|NCT04238208|PLACEBO_COMPARATOR|Group LP|Group LP received an identical placebo patch
62503383|NCT04238208|EXPERIMENTAL|Group LC|Group LC received the 8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK).
62503384|NCT03507686|EXPERIMENTAL|BIIB111|Participants will receive a single dose of sub-retinal injection of BIIB111 in each eye at Day 0 separated by an interval of \<6 months, 6-12 months, or \>12 months.
62503385|NCT03097939|EXPERIMENTAL|Nivolumab and Ipilimumab|
62503386|NCT04330495|EXPERIMENTAL|Testing and prophylaxis of SARS-CoV-2|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
62702355|NCT06748573|ACTIVE_COMPARATOR|Control arm|conventional compression bandage
62702356|NCT06748573|EXPERIMENTAL|Study arm|Study device (inflatable and see-through)
62702357|NCT06748820||Remote Therapeutic Patient Education (e-TPE)|TPE is a set of practices aiming at allowing a patient to acquire and preserve abilities and skills to manage actively their disease, cares, and surveillance, in collaboration with the caregivers
62736635|NCT02894957|ACTIVE_COMPARATOR|Abrupt smoking cessation|Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
61956606|NCT00534391|EXPERIMENTAL|A|combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
61956607|NCT00249860|EXPERIMENTAL|Interferon-beta-1a|
62345600|NCT05747755|EXPERIMENTAL|Intervention|Patients admitted to study hospitals during the 36 months of the intervention
62345601|NCT02240745||All patients|Patients with a suspicion of coronary heart disease
62345602|NCT03333330|EXPERIMENTAL|Carotid imaging with Visipaque 320 and SonoVue|"Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview.~Intervention is related to the administration of contrast agents:~Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS"
62345603|NCT05984797|EXPERIMENTAL|intervention arm|Integrated Short-term Palliative Rehabilitation + usual care
62503387|NCT04330495|ACTIVE_COMPARATOR|placebo|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
62503388|NCT05070962||Clinical population|having experienced repeated and prolonged traumatic exposure
62503389|NCT05070962||General population|Student volunteers from the University of Lille
62503390|NCT04066413|NO_INTERVENTION|Breastfed group|Non-randomized breastfed reference group
62503391|NCT04066413|PLACEBO_COMPARATOR|Control formula|Group receiving standard infant formula
62702358|NCT06748560|ACTIVE_COMPARATOR|Eccentric training|"The group is consist of 13 participants who did the following treatment protocol:~The Nordic exercise served as the foundation for the intervention, focusing on eccentric loading as participants resisted falling forward. To minimize DOMS and ensure adherence, a two-week preparatory phase of mixed concentric/eccentric leg curls using a stability ball was implemented. Following this, the gradual progression outlined by Mjolsnes et al. led to a four-week Nordic hamstring curl regimen. Weekly supervision ensured proper technique and compliance throughout the program."
62702359|NCT06748560|ACTIVE_COMPARATOR|Neurodynamic sliding technique|"The group is consist of 14 participants who did the following treatment protocol:~The neurodynamic sliding technique (NST) was applied to the dominant leg's sciatic nerve in the NST and ETNST groups. The technique involves alternating stress proximally and distally to promote nerve sliding. Participants performed two sets of movements-cervical flexion with knee and ankle flexion, and cervical extension with knee and ankle extension-repeated actively for 60 seconds, five times per session. Over six weeks, both groups underwent three supervised sessions per week led by an experienced researcher."
62503392|NCT04066413|ACTIVE_COMPARATOR|Formula with HMO|Group receiving standard infant formula supplemented with HMO
62503393|NCT03712124|EXPERIMENTAL|CNSA-001|Participants will receive CNSA-001 20 mg/kg/day (10 mg/kg twice daily \[BID\]) as an oral suspension for 14 days.
62702360|NCT06748560|EXPERIMENTAL|Eccentric training and neurodynamic sliding technique|"The group consist of 13 participants who did the following treatment protocol:~They underwent a combined treatment incorporating both eccentric training (ET) and the neurodynamic sliding technique (NST). Participants followed the graduated Nordic hamstring exercise protocol for eccentric strengthening, alongside the nerve-sliding movements targeting the sciatic nerve. This combined approach aimed to optimize muscle flexibility, strength, and neural mobility. The interventions were performed over six weeks, with three supervised sessions per week to ensure proper execution and adherence."
62702361|NCT06748560|NO_INTERVENTION|Control|
62702362|NCT06749691|EXPERIMENTAL|Liposomal Irinotecan and Apatinib|
62702363|NCT06748976||Healthy|"Volunteers: Adults aged 18-60 years with normal or corrected vision, no clinical history of photosensitive epilepsy, psychiatric disorders, significant hearing loss, migraines, or substance abuse.~Interventions:~Positive sham-neurofeedback Negative sham-neurofeedback Control (no feedback)"
61956608|NCT00249860|ACTIVE_COMPARATOR|Ribavarin plus interferon-beta-1a|
61956609|NCT04959916|EXPERIMENTAL|Group Meta-Cognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT)
61956610|NCT05279183|ACTIVE_COMPARATOR|Erythritol|20 volunteers receive erythritol dissolved in 300 mL tap water as oral preloads (3 times 100mL). The dosage will be calculated based on the participants ratings of the sweetness intensity (matched sweetness to 10 % sucrose).
62142597|NCT06324344|PLACEBO_COMPARATOR|Placebo Group|"The placebo group will be undergoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy on a daily basis with a low-dose TENS device for 8 weeks.~The low-dose TENS device is identical to the high-dose TENS device in all respects except that it delivers 6 minutes of TENS therapy per session (10% out of 60 minutes). Subjects are instructed to complete at least 3 sessions per day. To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side on a weekly basis."
62142598|NCT06356532|EXPERIMENTAL|experimental group|The participants in the intervention group received the intensive care unit diary writing and reading. Participants are required to write at least one sentence daily. The primary writers will be the patients themselves, and in cases where patients are unable to write, their family members will write on their behalf. After completion, the diary will be handed over to the patients to review its contents for at least 10 minutes before bedtime, allowing them to write down their immediate reflections and thoughts on when they read. This process will continue until the 14th day post-operation.
62142599|NCT06356532|NO_INTERVENTION|control group|The participants in the control group received the routine care including communication and companionship provided by the nurses of the intensive care unit.
62142600|NCT01351376|PLACEBO_COMPARATOR|Placebo|CDT + inactive LLL
62345604|NCT05984797|NO_INTERVENTION|control arm|usual care
62345605|NCT03418051|NO_INTERVENTION|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
62345606|NCT03418051|EXPERIMENTAL|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
62345607|NCT03418051|EXPERIMENTAL|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
62345608|NCT04540081|EXPERIMENTAL|CLOVER arm|This arm will contain clinics that utilize the CLOVER intervention
62345609|NCT04540081|NO_INTERVENTION|Standard of Care arm|This arm will contain clinics that do not utilize the CLOVER intervention
62345610|NCT01872091|EXPERIMENTAL|cryotherapy by immersion|Cryotherapy group immersion (GI) composed of 20 volunteers, which will be subjected to immersion cryotherapy upper limb dominant in cold water (6°C ± 2°C), at the level of the elbow joint.
62345611|NCT01872091|EXPERIMENTAL|Control group|(CG) consisted of 20 volunteers, which will be submitted to immersion of the dominant upper limb in water at room temperature indifferent to the level of the elbow joint;
62345612|NCT04973410|OTHER|Group A|FFR negative/non-significant (\>0.80) and IMR negative (\<25)
62345613|NCT04973410|OTHER|Group B|FFR negative/non-significant (\>0.80) and IMR positive (\>25)
62345614|NCT05208723|EXPERIMENTAL|Stress and emotion management|A locally adapted self-help guidebook originally developed by the World Health Organization (WHO), 'Doing what matters in times of stress' for managing disruptive emotions and psychological distress, will be delivered to female entrepreneurs at their residence, followed by 5-6 phone calls from a trained mental health helper to reinforce the materials over a 6-week period. The intervention is intended to help people manage their psychological distress associated with a range of adversities but is not intended for participants with severe mental health problems such as psychosis or imminent risk of suicide.
62345615|NCT05208723|NO_INTERVENTION|Control group|No intervention. May receive intervention post study if findings are indicative of any benefit.
62702364|NCT06215664|EXPERIMENTAL|Singularities Game|Singularities is an online game.
62702365|NCT06215664|ACTIVE_COMPARATOR|Food4Thought|"Food4Thought is an attention control condition in which we provide participants with similar amounts of research team contact and program contact as the intervention. Participants will play the game BAM! Dining Decisions developed by the Center for Disease Control and Prevention (CDC), which was designed to help teens make healthy food choices. Food4Thought will be delivered via Qualtrics."
62702366|NCT06750562|EXPERIMENTAL|experimental intervention|"This group will receive online sleep hygiene training for 4 weeks. The training will be given one day a week and last 30 minutes.~is foreseen. After each training, an interactive sleep hygiene game will be shared online. A total of 4 interactive sleep hygiene games will be shared. The total duration of a game will not exceed 20 minutes."
61956611|NCT05279183|ACTIVE_COMPARATOR|Sucrose|20 volunteers receive 30g sucrose dissolved in 300 mL tap water as oral preloads (3 times 100mL).
61956612|NCT05279183|ACTIVE_COMPARATOR|Sucralose|20 volunteers receive sucralose dissolved in 300 mL tap water as oral preloads (3 times 100mL). The dosage will be calculated based on the participants ratings of the sweetness intensity (matched sweetness to 10 % sucrose).
61956613|NCT02510196|ACTIVE_COMPARATOR|reminder|participants in this group will be reminded to use ultrasound for neuraxial anesthesia on a regular basis
61956614|NCT02510196|NO_INTERVENTION|control|participants in this group will not be reminded to use ultrasound for neuraxial anesthesia
61956615|NCT06022744|EXPERIMENTAL|LX109|
61956616|NCT04342156|EXPERIMENTAL|Intervention|"Treatment arm will be given Hydroxychloroquine sulfate. Dose: 800 milligrams (mg) (4 pills of 200mg) in two divided doses on day 1 followed by 400mg (2 pills of 200mg) in two divided doses on day 2, 3,4, 5.~Mode of administration: Oral pills of 200mg of HCQ; Supply: The total supply of all the pills (12 pills of 200mg per subject in the study group) will be given to the recruited subject from day 1."
61956617|NCT04342156|OTHER|Standard Preventive Measures|No intervention. Standard recommended preventive measures by the ministry of health.
62503394|NCT03712124|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to CNSA-001 BID for 14 days.
62702367|NCT06750562|NO_INTERVENTION|control group|this group will be given online sleep hygiene training once a week for a total of 4 weeks. The duration of each training will not exceed 30 minutes.
61956618|NCT05469828|EXPERIMENTAL|treatment|The effects of Crizanlizumab will be assessed in 20 nontransfused SCD subjects. After comprehensive baseline assessment one month prior the time of study initiation, patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses). Safety laboratories will be drawn at each infusion visit. There will be a follow up phone call the day after receiving the medication. Comprehensive blood and vascular testing will be repeated at Week 11 and Week 23 of treatment.
61956619|NCT05469828|ACTIVE_COMPARATOR|control|A total of 10 SCD subjects will be recruited from the hematology clinic at CHLA, generating a similar distribution of SS and Sß0 hemoglobin. They will be studied twice, once at the beginning of the study, time 0, and once at the end of study, after 6 months. They will undergo the same cerebral, peripheral and cardiopulmonary testing procedures as the patients undergoing therapy. They will also have monthly phone calls to determine clinical outcomes such as crisis frequency, medication use, hospitalizations and other pertinent clinical findings that may arise.
61956620|NCT05830968|EXPERIMENTAL|Device treatment|Treatment area will include affected areas over the entire face (presence of comedones, pustules, papules, nodules and cysts
62503395|NCT05793554||Rectal tumour without prior evidence of cancer|"400 patients with a known rectal tumour that has not demonstrated evidence of cancer to date - may be benign or indeterminate on biopsy or without biopsy performed to date.~Patients in this cohort will undergo examination under anaesthesia as is standard of care. During this examination the pattern of fluorescence seen in NIR camera within the tumour will be observed following administration of ICG (dose 0.25mg/kg) and recorded. Following this, patients will continue with standard of care at the discretion of their surgeon.~The operative video will be uploaded to a secure cloud based system and annotated by the surgeon where further mathematical analysis will be carried out for the purposes of tissue classification."
62503396|NCT05793554||Rectal tumour previously confirmed as cancerous|"200 patients with a rectal tumour that has proven previously to contain cancer. Both patients who have and have not undergone neoadjuvant therapy are suitable for inclusion in this group.~Patients in this group will undergo the same processes as the patients in cohort 1."
62503397|NCT02600208|EXPERIMENTAL|Single Experimental Arm|Alpha Beta T cell depletion is performed for all PBSC grafts using the CliniMACs device
62503398|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
62503399|NCT02396290|EXPERIMENTAL|fractional CO2 laser with PRP|fractional carbon dioxide laser followed by intradermal injection of platelet rich plasma
62503400|NCT02396290|ACTIVE_COMPARATOR|fractional CO2 laser with NS|fractional carbon dioxide laser followed by intradermal injection of NS
61956621|NCT05073783||Cohort A|Pompe disease patients receiving Myozyme® (alglucosidase alfa) in a home-care setting.
62503401|NCT00959569|EXPERIMENTAL|esmolol|the study group will receive esmolol (1-3 mg/kg)
62503402|NCT00959569|PLACEBO_COMPARATOR|normosaline|normosaline (same ml of the study drug)
62702368|NCT06750341|EXPERIMENTAL|QLC7401 100mg|QLC7401 100 mg subcutaneous injection
62702369|NCT06750341|EXPERIMENTAL|QLC7401 300mg|QLC7401 300 mg subcutaneous injection
62702370|NCT06750341|EXPERIMENTAL|QLC7401 500mg|QLC7401 500 mg subcutaneous injection
62702371|NCT06750341|PLACEBO_COMPARATOR|Placebo|Placebo 100/300/500 mg subcutaneous injection
62702372|NCT06748989|PLACEBO_COMPARATOR|Placebo|Participant will receive matching placebo supplement daily over a period of 6 weeks.
61956622|NCT05073783||Cohort B|MPS I patients receiving Aldurazyme® (laronidase) in a home-care setting.
61956623|NCT05770687||SGLT-2 inhibitor|Patients with naive use of SGLT-2 inhibitors after PCI
62702373|NCT06748989|EXPERIMENTAL|Treatment|Participants will receive Cortexium (a specially formulated dietary supplement with pyrroloquinoline quinone, γ-aminobutyric acid and B vitamins).
62702374|NCT06749119|ACTIVE_COMPARATOR|Young group: Aged 20-35 years|They received free gingival operation. Graft was harvested from palatal region and placed to the recipient site. Wound fluid samples were collected from 4 regions of the wound at baseline, 4-,7-,14-days. Clinical measurements were done at baseline, 1-,3-,6-months postoperatively.
62503403|NCT00537017|EXPERIMENTAL|Preladenant 5 mg BID|Preladenant 5 mg twice daily (BID) given open-label for 36 weeks to participants with moderate to severe Parkinson's Disease who are on a long-term and stable L-dopa treatment regimen.
62503404|NCT01016340|ACTIVE_COMPARATOR|MCS-5|Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
62503405|NCT01016340|PLACEBO_COMPARATOR|Placebo|Group 4: Placebo for 16 weeks
62503406|NCT01463839||Children 3 to 6|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo
62503407|NCT05786417|EXPERIMENTAL|Beta-Blockers (BB) Therapy|Participants randomized to this arm will be given a beta-blocker. Specific and appropriate drug selection from the class of beta blockers (i.e. type of BB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All BB will be administered orally (i.e. pills).
62503408|NCT05786417|EXPERIMENTAL|Calcium Channel Blockers (CCB) Therapy|Participants randomized to this arm will be given a calcium channel blocker. Specific and appropriate drug selection from the class of calcium channel blockers (i.e. type of CCB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All CCB will be administered orally (i.e. pills).
62503409|NCT05400798|EXPERIMENTAL|Adipose Derived Regenerative Cells|a single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
62503410|NCT05400798|ACTIVE_COMPARATOR|Corticosteroid|a single corticosteroid injection into the subacromial space of the index arm
62503411|NCT03619876|ACTIVE_COMPARATOR|Non- Tumor necrosis factor (TNF) inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
62503412|NCT03619876|ACTIVE_COMPARATOR|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
62503413|NCT04547933||OAB-wet|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency and urinary incontinence (UI) were allocated to the overactive bladder syndrome (OAB) -wet group.
62142601|NCT01351376|ACTIVE_COMPARATOR|LLL combined with CDT|CDT + active LLL
62142602|NCT01475266|EXPERIMENTAL|EO9 (Apaziquone)|
62142603|NCT01475266|PLACEBO_COMPARATOR|Placebo|
62503414|NCT04547933||OAB-dry|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency but without incontinence were allocated to the OAB-dry group.
62503415|NCT04547933||UI|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of UI but without urgency were allocated to the UI group.
62503416|NCT04547933||Nocturia|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 2 episodes of nocturia but without urgency and UI were allocated to the nocturia group.
62503417|NCT04547933||Frequency|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 8 episodes of daytime frequency but without urgency, UI and nocturia were allocated to the frequency group.
62503418|NCT04547933||Normal|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women without urgency, UI, nocturia nor frequency were allocated to the normal group.
62503419|NCT04869371|EXPERIMENTAL|Androgen Deprivation Therapy with Docetaxel|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus docetaxel and prednisone, as per standard of care. Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks. Docetaxel (75 mg/m2 body surface area) will be administered as intravenous drip every 3 weeks for 6 cycles. Robot assisted radical prostatectomy will be followed in 2 weeks when 24-week treatment cycle is finished.
62503420|NCT04869371|ACTIVE_COMPARATOR|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robot assisted radical prostatectomy. Triptorelin Pamoate 15mg will be administered once per 12 weeks.
62503421|NCT03380130|EXPERIMENTAL|SIRT and Nivolumab|SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated
62503422|NCT02688387|EXPERIMENTAL|Part 1|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
62142604|NCT03124472|ACTIVE_COMPARATOR|uterine artery ligation|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~* The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~* Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged.~* Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
62142605|NCT03124472|ACTIVE_COMPARATOR|Traditional lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~* The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~* Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
62142606|NCT02525822|EXPERIMENTAL|IDP-123 Lotion|IDP-123 Lotion, applied topically to the face, once daily for 12 weeks.
61956624|NCT04739904||Preterm born|Premature born but otherwise healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
61956625|NCT04739904||Full-term control|Full-term born healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
61956626|NCT04185545|EXPERIMENTAL|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 1|3 oral doses of RV3 vaccine (Bio Farma) batch 1; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
62503423|NCT02688387|EXPERIMENTAL|Part 2|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
62503424|NCT02688387|EXPERIMENTAL|Part 3|Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
62142607|NCT02525822|ACTIVE_COMPARATOR|Tazorac Cream, 0.1%|Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.
62503425|NCT04006119|EXPERIMENTAL|Ad-RTS-hIL-12 + veledimex in combination with cemiplimab-rwlc|Intratumoral Ad-RTS-hIL-12 and oral veledimex (activator ligand, 20mg) given in combination with cemiplimab-rwlc via infusion.
62503426|NCT01047033|ACTIVE_COMPARATOR|Microcredit only|
62503427|NCT01047033|EXPERIMENTAL|Microcredit plus health education|Thirty minutes of a health education module administered to clients by loan officer at their monthly group meetings over the course of 8 months.
62503428|NCT01029392|EXPERIMENTAL|Required Vitamin D|Those children whose Vitamin D level was low (\<30 ng/mL) are given Vitamin D supplementation
62503429|NCT01029392|NO_INTERVENTION|Normal Vitamin D|Those children whose Vitamin D level was normal (50-80 ng/mL) did not receive Vitamin D supplementation
62503430|NCT04984187|OTHER|Laser group|High Intensity Laser Therapy only , this group will receive laser for 4 weeks three times /week
62142608|NCT02525822|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle Cream, applied topically to the face, once daily for 12 weeks.
62142609|NCT02525822|PLACEBO_COMPARATOR|Vehicle Lotion|Vehicle Lotion, applied topically to the face, once daily for 12 weeks.
62142610|NCT05377918|EXPERIMENTAL|Spiritual Diary Group|"-What did you feel today? Spiritual Diary: According to the randomization, the participants in Cluster 1 were asked to write their bad/good memories about the four elements (self, others/family, nature, God/God) in John Fisher's Four Domains model, ask family, others, and God/ God was asked to write down his wishes and wishes, and the child in this group generally wrote the question What did I feel today? in his diary."
62503431|NCT04984187|OTHER|Exercise group|Exercise , selected physiotherapy exercises will receive for 4 weeks ,3times/week
62702375|NCT06749119|ACTIVE_COMPARATOR|Adult group: Aged 50-65 years|They received free gingival operation. Graft was harvested from palatal region and placed to the recipient site. Wound fluid samples were collected from 4 regions of the wound at baseline, 4-,7-,14-days. Clinical measurements were done at baseline, 1-,3-,6-months postoperatively.
62345616|NCT05329779|EXPERIMENTAL|brexanolone|Participants will receive a continuous 60-hr intravenous infusion of brexanolone
62345617|NCT05329779|PLACEBO_COMPARATOR|placebo|Participants will receive a continuous 60-hr infusion of placebo
62345618|NCT02496117|ACTIVE_COMPARATOR|RNS-checked RDN|20 patients with hypertension will be enrolled undergoing RNS-checked RDN
62142611|NCT05377918|EXPERIMENTAL|Diary Group|"What Did You Do Today? Diary: According to randomization, the children in the Cluster 2 group were asked to write down their daily activities and activities (eating, watching TV, time spent with their friends at school, etc.) and the children in this group were asked to generally ask, What did I do today? answered the question."
62503432|NCT04984187|EXPERIMENTAL|High intensity laser grouo|High intensity laser plus exercise will receive the selected exercises and laser 4 weeks, 3 times/week
62503433|NCT04395079|EXPERIMENTAL|Arm I (durvalumab, brachytherapy)|Patients receive durvalumab IV on day 1. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
62503434|NCT04395079|EXPERIMENTAL|Arm II (tremelimumab, brachytherapy)|Patients receive tremelimumab IV on day 1. Treatment repeats every 28 days for 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
62503435|NCT02192294|EXPERIMENTAL|Bosutinib|
61956627|NCT04185545|EXPERIMENTAL|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 2|3 oral doses of RV3 vaccine (Bio Farma) batch 2; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
61956628|NCT04185545|EXPERIMENTAL|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 3|3 oral doses of RV3 vaccine (Bio Farma) batch 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
61956629|NCT04185545|PLACEBO_COMPARATOR|Immunogenicity Group - Placebo|3 oral doses of Placebo; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
61956630|NCT04185545|EXPERIMENTAL|Other Efficacy Group - RV3 Vaccine (Bio Farma)|3 oral doses of RV3 vaccine (Bio Farma) administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
61956631|NCT04185545|PLACEBO_COMPARATOR|Other Efficacy Group - Placebo|3 oral doses of Placebo administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
61956632|NCT05021497|EXPERIMENTAL|Global Positional Re-education|Global Positional Re-education
61956633|NCT05021497|ACTIVE_COMPARATOR|Conventional Physical Therapy Program|Conventional therapy will consist of a combination of manual techniques
62142612|NCT05377918|NO_INTERVENTION|Control Group|Control Group
62345619|NCT02496117|EXPERIMENTAL|RNS-guided RDN|20 patients with hypertension will be enrolled undergoing RNS-guided RDN
62345620|NCT02319096|EXPERIMENTAL|Patients with stress incontinence|Patients who present to urogynaecology clinic with proven stress urinary incontinence who will be offered Whole body vibration therapy.
62503436|NCT01653795|ACTIVE_COMPARATOR|LMA Unique|
62702376|NCT05713799|ACTIVE_COMPARATOR|MG+ALA|Participants take mirabegron + alpha lipoic acid daily for 4 weeks. There is testing pre- and post-treatment. Will evaluate the effects of MG+ALA on metabolic heath.
61956634|NCT02228200|EXPERIMENTAL|Nurse-led care|Subjects in the nurse-led care arm received nurse-led care and routine care.
61956635|NCT02228200|ACTIVE_COMPARATOR|Routine care|Subjects in the routine care arm received routine care provided by the study hospital.
61956636|NCT01251237|EXPERIMENTAL|Moviprep Orange|All patients receive 2 litres of NRL0706 solution.
61956637|NCT01930123|EXPERIMENTAL|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
62503437|NCT01653795|ACTIVE_COMPARATOR|LMA Supreme|
62503438|NCT04402606|EXPERIMENTAL|Evaluation on skin toxicities|This evaluation consists on a clinical examination of the skin and the realization of the cutaneous measurements of reference on 4 sites frequently exposed to the cutaneous toxicities: face, neckline, palms of the hands and soles of the feet.
62503439|NCT06674421||Basketball players|Participants will be adolescent athletes attending the basketball course at Alaağaç Sports Club. Being between the ages of 10-19 years and being playing basketball.
62503440|NCT02824887||Exposed group|Long term curative effect of electroacupuncture treatment of lumbar intervertebral disc herniation in exposure group
62503441|NCT02824887||control group|Long term efficacy of conventional treatment of lumbar disc herniation in the control group
62503442|NCT02078011|EXPERIMENTAL|HIFU treatment|The high intensity focused ultrasound (HIFU) will be administered to the targeted site to create heat and cause the cells to die
62503443|NCT03334149|EXPERIMENTAL|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
62503444|NCT03334149|NO_INTERVENTION|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
62503445|NCT05656690||Healthy older Adults|Healthy older Adults: older adults without disability indicators
62503446|NCT05656690||Disability Older Adults|Disability Older Adults: older adults with disability indicators
62503447|NCT06678737|EXPERIMENTAL|Experimental group|Youth with chronic tics randomized to a combined treatment involving Comprehensive Behavioral Intervention for Tics (CBIT) and inhibition of the supplementary motor area (SMA) using transcranial magnetic stimulation (TMS). TMS involves theta burst stimulation (cTBS).
61956638|NCT01930123|ACTIVE_COMPARATOR|Health controls|15 healthy controls for comparison with NAFLD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
61956639|NCT01416272|EXPERIMENTAL|KeraSoft IC Soft Contact Lenses|KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
62345621|NCT03977350||Patients over 65 years undergoing heart surgery|Patients over 65 years undergoing heart surgery under anesthesia, EEG monitored
62345622|NCT03121118||Scan opportunity|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
62345623|NCT03121118||Comparison group|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
61956640|NCT06505876|EXPERIMENTAL|Oral Tube Feeding+Basic treatment|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure."
61956641|NCT06505876|ACTIVE_COMPARATOR|Nasogastric Tube Feeding+Basic treatment|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding."
61956642|NCT05253729|EXPERIMENTAL|Focused Extracorporeal Shock Wave Therapy (F-ESWT)|Participants in the intervention group received low-intensity F-ESWT once a week for three sessions plus conservative treatment.
61956643|NCT05253729|ACTIVE_COMPARATOR|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
62345624|NCT03148626|EXPERIMENTAL|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
62345625|NCT03148626|PLACEBO_COMPARATOR|Control|Usual education.
62345626|NCT00674518|EXPERIMENTAL|Counseling|One-on-one sessions conducted by a professional motivational counselor to explore ways to help motivate participants to exercise, eat healthier, and lose weight.
62345627|NCT00674518|EXPERIMENTAL|Group|A nutrition and exercise specialist will lead and teach a group of 4 to 5 subjects in healthy nutrition, exercise and weight loss habits
62345628|NCT00674518|ACTIVE_COMPARATOR|MD Advice|A physician will provide exercise and nutrition advice to participants immediately following testing
62345629|NCT02062463|NO_INTERVENTION|Stage 1: Empty Spiromax Followed by Empty Turbohaler|Participants will be trained on the proper use of empty Spiromax followed by empty Turbohaler devices.
62345630|NCT02062463|NO_INTERVENTION|Stage 1: Empty Turbohaler Followed by Empty Spiromax|Participants will be trained on the proper use of empty Turbohaler followed by empty Spiromax devices.
62503448|NCT06678737|SHAM_COMPARATOR|Control group|Youth with chronic tics randomized to CBIT and sham stimulation for TMS
62503449|NCT01402973|EXPERIMENTAL|High-AGE Diet|The high-AGE diet will be approximately four times higher in AGEs than the low-AGE diet.
62503450|NCT01402973|EXPERIMENTAL|Low-AGE Diet|The low-AGE diet will be approximately four times lower in AGEs than the high-AGE diet.
62503451|NCT05316389||A Retrospective|A = retrospective cohort including all patients treated at the ICO Angers between January 2017 and September 2021
62503452|NCT05316389||B Prospective|B = prospective including all patients treated at the ICO from February 2022 (2 years of recruitment)
62503453|NCT01992913|EXPERIMENTAL|iCBT|integrated CBT with computerized cognitive remediation
62503454|NCT01992913|OTHER|UC|usual care
61956644|NCT04848298|EXPERIMENTAL|Mobile Health Arm|
61956645|NCT04848298|NO_INTERVENTION|Control Arm|The Control Arm will receive standard of care including tailored prescription of physical activity
61956646|NCT05981898|EXPERIMENTAL|OPTIVF predicted drug dosage|This arm will use dosage, trigger predicted by Opt-IVF
61956647|NCT05981898|ACTIVE_COMPARATOR|Traditional drug treatment|Traditional drug treatment
61956648|NCT03670888|EXPERIMENTAL|JHL1101|Single dose IV infusion of 375 mg/m2 of JHL1101
61956649|NCT03670888|ACTIVE_COMPARATOR|Rituxan|Single dose IV infusion of 375 mg/m2 of Rituximab
61956650|NCT03052491|EXPERIMENTAL|Stem Cell 100+ Intervention|Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks
61956651|NCT04713215||Patients where MCAs are currently being used|Intervention: Patient questionnaire - Part A - patients where MCAs are currently being used
61956652|NCT04713215||Patients where an MCA was discontinued|Intervention: Patient questionnaire - Part B - patients where an MCA was discontinued
61956653|NCT04713215||Patients where an MCA was declined|Intervention: Patient questionnaire - Part C - patients where an MCA was declined
61956654|NCT04713215||Carers where MCAs are currently being used|Intervention: Carer questionnaire - Part A - carers where MCAs are currently being used
61956655|NCT04713215||Carers where an MCA was discontinued|Intervention: Carer questionnaire - Part B - carers where an MCA was discontinued
61956656|NCT04713215||Carers where an MCA was declined|Intervention: Carer questionnaire - Part C - carers where an MCA was declined
62503455|NCT06328374||Healthy community dwelling adults|Healthy adults between the ages of 60-100 with no prior history of neurological, respiratory, or gastrointestinal diseases or swallowing or voice impairments, or history of head and neck surgery, cancer, or radiation to the head or neck will be enrolled in this study.
62503456|NCT06328374||Adults with Alzheimer's Disease and their caregivers|Adults with a diagnosis of Alzheimer's disease and their caregivers will be enrolled in this study.
62503457|NCT00785681|EXPERIMENTAL|1|Dermacyd PH_DETINBACK (Lactic Acid)
61956657|NCT04850521||Remote monitoring|Remote monitoring software + connected devices
61956658|NCT02780375||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
61956659|NCT01893632|EXPERIMENTAL|Gabapentin|All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.
61956660|NCT01893632|PLACEBO_COMPARATOR|Placebo|Capsules filled with riboflavin.
61956661|NCT01864655|EXPERIMENTAL|Saracatinib group 1|This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
62142613|NCT03087318|EXPERIMENTAL|Rehabilitation medical center|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~* during 3 months."
62142614|NCT03087318|EXPERIMENTAL|Private sport club|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~* during 3 months."
62503458|NCT03002792||general anesthesia|caries treatment under general anesthesia
61956662|NCT01864655|EXPERIMENTAL|Saracatinib group 2|Group 2 will receive saracatinib at a daily oral dose determined by the response to 50mg P.O. daily. Duration is 4 weeks.
61956663|NCT01864655|EXPERIMENTAL|Saracatinib group 3|Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
61956664|NCT01864655|PLACEBO_COMPARATOR|Placebo group 1-3|Subjects receiving saracatinib in groups 1-3 will be compared to subjects receiving daily, oral, placebo drug.
61956665|NCT03441308|ACTIVE_COMPARATOR|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
62142615|NCT03087318|EXPERIMENTAL|Sport association|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~* during 3 months."
62142616|NCT01588093|PLACEBO_COMPARATOR|Saline|
62142617|NCT01588093|ACTIVE_COMPARATOR|Increlex|
62503459|NCT03002792||caries treatment only|caries treatment without general anesthesia
61956666|NCT03441308|PLACEBO_COMPARATOR|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
61956667|NCT02792881|EXPERIMENTAL|Laparoscopic Completion Total Gastrectomy Group|Patients who underwent laparoscopic completion total gastrectomy with D2 lymphadenectomy will be assigned to this group.
61956668|NCT01961193|EXPERIMENTAL|bandage contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
61956669|NCT01961193|EXPERIMENTAL|punctal plug|A punctal plug (Painless Silicon Plugs),will be inserted into each eye. Lubricant drops will be instilled four times daily into each eye. The punctal plug will remain in- situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
62702377|NCT05713799|PLACEBO_COMPARATOR|MG+Placebo|Participants take mirabegron + placebo daily for 4 weeks. There is testing pre- and post-treatment. Will evaluate the effects of MG+Placebo on metabolic heath.
62702378|NCT06749444|EXPERIMENTAL|Cognitive Behavioral Therapy for insomnia|8-10 sessions CBT-I tailored for insomnia symptoms
62503460|NCT05229055|ACTIVE_COMPARATOR|Intranasal ketamine|Ketamine solution 250 mg/5ml was used. It was applied intranasally using a nasal spray pump whereeach spray delivered approximately 0.4 ml of solution corresponding to 20 mg of ketamine. After initial evaluation, each patient having the inclusion criteria receives one pulverisation (0.4 ml) per nostril of ketamine corresponding to a total dose of 20 mg of ketamine. Ketamine dosing was based on previous reports of intranasal ketamine use in ED patients, doses ranged from 0.45mg/kg to 1.25mg/kg (9).
62142618|NCT02089295|EXPERIMENTAL|Treatment A|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62503461|NCT05229055|ACTIVE_COMPARATOR|subcutanous ketamine|Ketamine dosing by subcutanous route was based on previous reports use for post operative pain management. . The results of these reports revealed that low-dose ketamine 20-60 mg (0.5mg/kg for patients weighing 40-120 kg) showed an over all decrease in either the amount of opioid used or the amount of pain experienced (10, 11).For our study, we decided to chose a dose of 20mg of ketamine for all patients administered via 1ml insulin syringe once subcutaneously.
62503462|NCT05442437|EXPERIMENTAL|Low-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 2.5×10\^7 cells.
62503463|NCT05442437|EXPERIMENTAL|medium-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 5.0×10\^7 cells.
62503464|NCT05442437|EXPERIMENTAL|High-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 1.0×10\^8 cells.
62503465|NCT04805385|EXPERIMENTAL|PS128|Subjects will consume the PS128 capsules every day, 2 capsules at a time, for 12 weeks.
62503466|NCT04805385|PLACEBO_COMPARATOR|Placebo|Subjects will consume the placebo capsules every day, 2 capsules at a time, for 12 weeks.
62503467|NCT04805385|NO_INTERVENTION|Healthy Control|
62503468|NCT06320158||patients who are candidates for hip surgery|cohort of patients who are candidates for hip surgery: completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
62503469|NCT06320158||healthy subjects|cohort of healthy subjects recruited in 2016-2017 completion of scales, questionnaires and performance of the Short Physical Performance Battery test, venous blood sampling, muscle ultrasound scan
62702379|NCT06749444|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|8-10 sessions CBT tailored for general psychopathology
62702380|NCT06749704|ACTIVE_COMPARATOR|Standard Treatment Group|"The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 20 Kcal/Kg BW/day, with a protein intake of 0.9 gm/Kg BW/day i.e., around 15 % of total calories from protein, 25% from fats and 60% from carbohydrates.~Physical activity recommendations: Brisk walking on a treadmill (at a speed 5-6 Kmph for 60 minutes) OR 5000 steps per day by pedometer counting."
62702381|NCT06749704|EXPERIMENTAL|High Protein Diet|"The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 20 Kcal/Kg BW/day, with a protein intake of 1.3 gm/Kg BW/day i.e., around 25 % of total calories from protein, 25% from fats and 50% from carbohydrates. Major portion of the protein would be met by dairy, legumes and pulses along with egg whites.~Physical activity recommendations: Brisk walking on a treadmill (at a speed 5-6 Kmph for 60 minutes) OR 5000 steps per day by pedometer counting."
62702382|NCT06748144|EXPERIMENTAL|Intraosseous Vancomycin|Participants in this group will receive other antibiotics according to the Houston Methodist Hospital orthopedic surgeon's standard of care regimen, which typically involves ancef or cefepime being administered in pre-op within 1 hour of the incision. IO Vancomycin will be administered in the OR after incision (500mg in 100-150mL normal saline (NS)), and the injection will be placed into the posterior ilium.
62702383|NCT06748144|ACTIVE_COMPARATOR|Intravenous Vancomycin|Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for lumbar fusion patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin), which will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500mL NS).
62702384|NCT06750068|ACTIVE_COMPARATOR|Conventional band and loop space maintainer|"Impressions will be taken from the patients with sterilized plastic pedodontic impression trays and alginate under standard conditions by the same researcher. Alginate will be mixed in accordance with the manufacturer's instructions. After the impressions, plaster study casts will be produced and sent to the laboratory. Conventional SMs will be produced by soldering the 0.7-mm bent orthodonic wires (Dentaurum, Germany) onto previously selected prefabricated molar bands. Prefabricated molar bands (Dentaurum, Germany) in the patient's mouth will be chosen by the physician and then sent to the laboratory with the casts.~All SMs will be cemented by the same investigator under standard conditions using a glass-ionomer luting cement (Nova Glass-L, Imicryl, Konya, Turkey)."
62736636|NCT02342691|EXPERIMENTAL|BLXA4-ME oral rinse|The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
62736637|NCT02342691|PLACEBO_COMPARATOR|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
62736638|NCT02342691|NO_INTERVENTION|No Rinse Control|The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients
62142619|NCT02089295|EXPERIMENTAL|Treatment B|Single dose of 20 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62142620|NCT02089295|EXPERIMENTAL|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
62142621|NCT02231736||Type 2 diabetes, HbA1c>7.5|
62142622|NCT02231736||Type 2 diabetes, HbA1c<7.5|
62142623|NCT06681350|OTHER|Occyo One Anterior Segment Imaging|Imaging of the anterior segment of the eye for telemedical assessment.
62142624|NCT04256148|EXPERIMENTAL|ALXN1830 Dosing Regimen 1|
62142625|NCT04256148|EXPERIMENTAL|ALXN1830 Dosing Regimen 2|
62142626|NCT04256148|EXPERIMENTAL|ALXN1830 Dosing Regimen 3|
62142627|NCT04256148|ACTIVE_COMPARATOR|Placebo|
62142628|NCT04164446|PLACEBO_COMPARATOR|Placebo|Two capsules containing starch and glucose, once per day, 60 days duration
62503470|NCT04906876|EXPERIMENTAL|Stratum A: Soft Tissue Sarcoma|Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62503471|NCT04906876|EXPERIMENTAL|Stratum B: Bone Sarcoma|Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
62503472|NCT05290493|ACTIVE_COMPARATOR|NB-001|Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
62503473|NCT05290493|PLACEBO_COMPARATOR|Placebo|Placebo: Two (2) capsules (matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
62503474|NCT06679439|ACTIVE_COMPARATOR|Cartilage graft group|Patients with stable lower eyelid retraction that are submitted to surgical treatment using cartilage graft as spacer
62736639|NCT01127672|ACTIVE_COMPARATOR|control|corticosteroid injection into the origin of the plantar fascia
62345631|NCT02062463|EXPERIMENTAL|Stage 2: BF Spiromax|Participants who have currently received 800 to 1000 micrograms (μg) beclomethasone-equivalent inhaled corticosteroid (ICS) per day will receive budesonide/formoterol twice daily using the BF Spiromax 160/4.5 device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 640 μg and 18 μg, respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the BF Spiromax 320/9 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 1280 μg and 36 μg, respectively.
62345632|NCT02062463|ACTIVE_COMPARATOR|Stage 2: Symbicort Turbohaler|Participants who have currently received 800 to 1000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 800 μg and 24 μg respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 1600 μg and 48 μg respectively.
62345633|NCT00818571|EXPERIMENTAL|Vildagliptin 25 mg qd in Renal Impaired (RI) patients|
62345634|NCT00818571|EXPERIMENTAL|Vildagliptin 50 mg qd in RI Patients|
62503475|NCT06679439|ACTIVE_COMPARATOR|Dermis graft group|Patients with stable lower eyelid retraction that are submitted to surgical treatment using dermis graft as spacer
62503476|NCT06535763||professional caregiver|nurse, care assistant, gerontological care assistant, psychologist, coordinating doctor, psychomotrician, occupational therapist in one of the 3 EHPADs in the study
62503477|NCT05567627|EXPERIMENTAL|Initial dose cohort|1.2x10\^14 vg/kg of GC301 administered via intravenous infusion
62736640|NCT01127672|ACTIVE_COMPARATOR|experimental|platelet rich plasma injection into the origin of the plantar fascia
61956670|NCT01961193|NO_INTERVENTION|Control group|Hydroxyethylcellulose drops will be inserted into each eye four times a day and erythromycin ophthalmic ointment will be applied three times a day as well.
62345635|NCT00818571|EXPERIMENTAL|Vildagliptin 25 mg qd in matched Healthy Volunteer (HV)|
62345636|NCT00818571|EXPERIMENTAL|Vildagliptin 50 mg qd in matched HV|
62345637|NCT02322268|EXPERIMENTAL|Diabetic Cosmos caudatus treated group|Subjects in this arm will receive Cosmos caudatus for 8 weeks.
62345638|NCT02322268|NO_INTERVENTION|Diabetic control group|Subject in this group will not receive Cosmos caudatus. However, they will be educated for the same calorie intake and lifestyle intervention as in Cosmos caudatus treated group.
62345639|NCT01226212|EXPERIMENTAL|Synbiotic|Synbiotic (Synergy 1/B. longum)
62345640|NCT01226212|PLACEBO_COMPARATOR|Placebo|maltodextrose
62345641|NCT05704439|ACTIVE_COMPARATOR|Model 1-Neurologist Initiation of Treatment for Hypertension or Hyperlipidemia|Neurologist Initiation of antihypertensive or treatment for hyperlipidemia
62503478|NCT02734524|EXPERIMENTAL|NK infusion+chemotherapy|Treatment includes four cycles. For each cycle: Taxol and carboplatin will be given at the first week. Lymphodepletion will be conducted at the second week. Autologous NK cells will be infused at the third week. Each cycle includes four weeks.
62503479|NCT02734524|ACTIVE_COMPARATOR|chemotherapy|Receive the same taxol and carboplatin in experimental arm without NK cell infusion.
62736641|NCT01335256|EXPERIMENTAL|Arm 1|
62736642|NCT02021890|EXPERIMENTAL|ballroom and Latin dance program|two-hour dancing session twice a week
62736643|NCT02021890|ACTIVE_COMPARATOR|Self-selected physical activity|self-selected program of physical activity
62345642|NCT05704439|PLACEBO_COMPARATOR|Model 2-Usual Care|Usual care
62345643|NCT03585192|EXPERIMENTAL|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
62345644|NCT03585192|ACTIVE_COMPARATOR|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
62345645|NCT04260919|NO_INTERVENTION|Control|The participants just received standard medical treatment
62345646|NCT04260919|EXPERIMENTAL|Intervention|The participants received medical treatment and chest physiotherapy sessions
62345647|NCT01187784|ACTIVE_COMPARATOR|CBT|Coping Cat cognitive-behavioral therapy protocol
62345648|NCT01187784|NO_INTERVENTION|Waitlist Control|Treatment as usual
62345649|NCT01586806|PLACEBO_COMPARATOR|Control|
62736644|NCT03456349|EXPERIMENTAL|Low dose|HTL0018318
62345650|NCT01586806|ACTIVE_COMPARATOR|Dexamethasone 1 mg|
62736645|NCT03456349|EXPERIMENTAL|Medium dose|HTL0018318
62736646|NCT03456349|EXPERIMENTAL|High dose|HTL0018318
62736647|NCT03456349|PLACEBO_COMPARATOR|Placebo|Placebo
61956671|NCT03408483|EXPERIMENTAL|quadratus lumborum block (QLB)|"* Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~* Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.~* After QLB is placed, patients will have THA under spinal anesthesia."
61956672|NCT03408483|ACTIVE_COMPARATOR|Standard of Care|"* Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~* Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected."
61956673|NCT00934492|ACTIVE_COMPARATOR|Cotrimoxazole dispersible tablet|Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
62714885|NCT06268899|EXPERIMENTAL|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
61956674|NCT00934492|PLACEBO_COMPARATOR|Placebo dispersible tablet|Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
61956675|NCT02087397|EXPERIMENTAL|AD-SVF Cell Injection|
61956676|NCT00560781|ACTIVE_COMPARATOR|1|Pregnenolone
62142629|NCT04164446|ACTIVE_COMPARATOR|Oil Palm Phenolics 250 mg|One capsule 250 mg active compound (OPP) and one capsule containing starch and glucose, once per day, 60 days duration
61956677|NCT00560781|PLACEBO_COMPARATOR|2|Placebo
61956678|NCT06052085|ACTIVE_COMPARATOR|Pain Neuroscience Education|"Pain Neuroscience Education; Four sessions of education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.~Standard Physiotherapy Program; Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks.~Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks."
62142630|NCT04164446|ACTIVE_COMPARATOR|Oil Palm Phenolics 1000 mg|One capsule containing 1000 mg active compound (OPP) and one capsule starch and glucose, once per day, 60 days duration
62142631|NCT04164446|ACTIVE_COMPARATOR|Oil Palm Phenolics 2000 mg|Two capsules, 1000 mg active compound (OPP) each, once per day, 60 days duration
62142632|NCT06150417|ACTIVE_COMPARATOR|Standard of Care (SOC)|"* Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy \[RT\] or radical prostatectomy \[RP\]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm.~* SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20."
62142633|NCT06150417|EXPERIMENTAL|SOC + MDRT|"* Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy \[RT\] or radical prostatectomy \[RP\]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm.~* SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20.~* MDRT should be completed by the end of Week 24. Depending on the participant, there are different approaches to MDRT dosing and fraction size."
62142634|NCT02683174|EXPERIMENTAL|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
62142635|NCT00955162|ACTIVE_COMPARATOR|Subutex|
62142636|NCT00955162|EXPERIMENTAL|Suboxone|
62142637|NCT02117310|EXPERIMENTAL|ICG|Angiography with administered ICG
62142638|NCT00692913|EXPERIMENTAL|FOSAVANCE 5600|alendronate sodium (+) cholecalciferol
62142639|NCT00692913|OTHER|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.
62345651|NCT01586806|ACTIVE_COMPARATOR|Dexamethasone 4 mg|
62345652|NCT04871685||Covid Center UOC Vanvitelli, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345653|NCT04871685||Covid Center Cotugno Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345654|NCT04871685||"Covid Center Del Mare Hospital, Naples"|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345655|NCT04871685||Covid Center Santa Maria delle Grazie Hospital, Pozzuoli|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345656|NCT04871685||Covid Center Monaldi Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345657|NCT04871685||Covid Center Vannini Hospital, Rome|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345658|NCT04871685||Covid Center Bassini Hospital, ASST Milano Nord|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345659|NCT04871685||Covid Center Melfi Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
61956679|NCT06052085|ACTIVE_COMPARATOR|Biomedical Pain Education|"Biomedical Pain Education; 4 sessions of education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.~Standard Physiotherapy Program; Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks.~Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks."
61956680|NCT00631995|EXPERIMENTAL|Group 1|
62503480|NCT00003850|EXPERIMENTAL|Arm I|Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
62503481|NCT05418985|EXPERIMENTAL|Intervention group|Women in this group were given training on breast self-examination (BSE). In the three-month period following the training, a reminder text message was sent to mobile phones by the researcher to perform BSE. The text message was sent to women with regular and regular menstrual cycles on the seventh day after the bleeding ceased, and on the first day of the month to menopausal women with irregular menstrual cycles.
61956681|NCT00631995|EXPERIMENTAL|Group 2|
61956682|NCT00631995|EXPERIMENTAL|Group 3|
61956683|NCT00631995|EXPERIMENTAL|Group 4|
61956684|NCT00631995|EXPERIMENTAL|Group 5|
61956685|NCT00631995|ACTIVE_COMPARATOR|Group 6|
61956686|NCT01340612|ACTIVE_COMPARATOR|coiling|endovascular coiling with any type of currently approved coil (first or second generation)
61956687|NCT01340612|ACTIVE_COMPARATOR|coiling plus stenting|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.
61956688|NCT00851370|EXPERIMENTAL|Omalizumab|
61956689|NCT00851370|PLACEBO_COMPARATOR|Placebo|
61956690|NCT02983344|ACTIVE_COMPARATOR|fascia iliaca compartment block|Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
62503482|NCT05418985|NO_INTERVENTION|Control droup|Women in this group were given training on breast self-examination (BSE). No intervention was made afterwards.
62503483|NCT00387205|EXPERIMENTAL|Arm 1|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
62503484|NCT04339595|EXPERIMENTAL|Tildrakizumab|
61956691|NCT02983344|ACTIVE_COMPARATOR|intravenous fentanyl|Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia
61956692|NCT02658903|EXPERIMENTAL|Study arm with Oxys-Cathter|The study group is treated with a modified urinary catheter, which delivers electromagnetic therapy to prevent and treat bacterial colonization during the study period. The intervention is the insertion of the study urinary catheter (foley) into the bladder.
61956693|NCT02658903|OTHER|Control-arm with commercial catheter|The control group is treated with a commercial urinary catheter. The intervention is the insertion of the control urinary catheter (foley) into the bladder,
61956694|NCT01319890||Right Colectomy for colonic tumors|The group of patients enrolled will be patients with biopsy proven right colon tumors, both benign and malignant. These patients will then be subdivided into those having conventional laparoscopic right colectomy and SILS right colectomy
61956695|NCT01364649|EXPERIMENTAL|Vortioxetine|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
61956696|NCT01364649|ACTIVE_COMPARATOR|Escitalopram|Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
61956697|NCT03821649|EXPERIMENTAL|SOONER Training and Naloxone Kit|Participants in this arm will be shown the SOONER overdose response training video at the time of recruitment and given the SOONER Naloxone kit to take home.
62345660|NCT04871685||Covid Center Messina University Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
62345661|NCT00890071||Acute circulatory failure|Patients for whom the decision to give fluids was taken because the presence of one or more clinical signs of acute circulatory failure.
62345662|NCT05664334|EXPERIMENTAL|IVX-A12 Vaccine - Low Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 virus-like particles \[VLPs\]), administered intramuscularly (IM) once on Day 0.
62345663|NCT05664334|EXPERIMENTAL|IVX-A12 Vaccine + MF59® - Low Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
61956698|NCT03821649|ACTIVE_COMPARATOR|Community or Hospital-Based Training|Control arm - participants in this arm will be referred to the standard of care for Naloxone training. This standard of care includes community-based OEND programs and/or an existing hospital-based OEND program..
62345664|NCT05664334|EXPERIMENTAL|IVX-A12 Vaccine - Medium Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
61956699|NCT00773656||1|patients treated for a prostate adenocarcinoma
61956700|NCT05307068||Grade B-C stage III-IV periodontitis group|"Grade B: Moderate Moderate bone loss is observed compared to biofilm and % Root Bone Loss/age 0.25 to 1.0 is determined as grade B.~Stage III: Severe Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4.~Grade C: Rapid Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age \>1.0 is determined as grade C.~Stage IV:Advanced Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≥5. Need for complex rehabilition due to: Masticatory dysfunction, Secondary occlusal trauma(tooth mobility degree ≥2) Severe ridge defect,Bite collapse, drifting, flaring. Less than 20 remaining teeth (10 opposing pairs)"
61956701|NCT05307068||Healthy control group|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
61956702|NCT03298815|ACTIVE_COMPARATOR|Amniotic Fluid Eye Drops (AFED) - All participants, One eye|
61956703|NCT03298815|PLACEBO_COMPARATOR|Saline Solution - All participants, One eye|
61956704|NCT02787096|EXPERIMENTAL|laxIRM|Patients will have dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
61956705|NCT04482374||Transgender females|Transgender females who plan to start a gonadotropin releasing hormone agonist clinically in the next 2 months
62142640|NCT03884842|ACTIVE_COMPARATOR|dupilumab|"Dupilumab 300 mg subcutaneously (SC) every 2 weeks as an investigational drug. For those randomized to dupilumab, a loading dose of 600 mg will be given only at randomization/Visit 2.~Sterile dupilumab of will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total volume) to deliver 300 mg in 2 mL."
62345665|NCT05664334|EXPERIMENTAL|IVX-A12 Vaccine + MF59® - Medium Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
62503485|NCT05362214||Audio (no visual cue)|The condition that a participant has to perform Baduanjin exercise by following the audio guidance/illustration according to the reference of Baduanjin practicing video.
62503486|NCT05362214||Video (2D visual cue)|The condition that a participant has to perform Baduanjin exercise by following the video guidance/illustration according to the reference of Baduanjin practicing video.
62503487|NCT05362214||Drone (3D visual cue)|The condition that a participant has to perform Baduanjin exercise by following the drone guiding system including a guidance from drone and audio illustration regarding the reference of Baduanjin practicing video.
62503488|NCT02438696|EXPERIMENTAL|3 BI 1060469 low dose|TF2 followed by iFF followed by TF1
62503489|NCT02438696|EXPERIMENTAL|1 BI 1060469 high dose|TF1 followed by TF2 followed by iFF
62345666|NCT05664334|EXPERIMENTAL|IVX-A12 Vaccine - High Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
62503490|NCT02438696|EXPERIMENTAL|2 BI 1060469 high dose|iFF followed by TF1 followed by TF2
62503491|NCT02438696|EXPERIMENTAL|3 BI 1060469 high dose|TF2 followed by iFF followed by TF1
62503492|NCT02438696|EXPERIMENTAL|1 BI 1060469 low dose|TF1 followed by TF2 followed by iFF
62702385|NCT06750068|EXPERIMENTAL|3D printed space maintainer|"Patients in this group will be scanned under standard conditions with Medit i500 (Medit Corp. Seoul, South Korea). The scanned data of the patients will be sent to the laboratory via email in Standard Triangle Language (STL) file format.The design of SMs will be carried out on the DentalCAD 2.2 Valletta (Exocad GmbH, Darmstadt, Germany) program to mimic the conventional space maintainer, and the production will be made by the 3D Selective laser melting (SLM Solutions, Germany) method using titanium-based metal powder (Ti64 Gd23; LPW Technology Ltd., Cheshire, UK). The production of 3D-SMs will start in accordance with the C-SM design in many points, such as the fit of the part surrounding the abutment tooth, thickness, and the position of the loop of 3D-SM.~All SMs will be cemented by the same investigator under standard conditions using a glass-ionomer luting cement (Nova Glass-L, Imicryl, Konya, Turkey)."
61956706|NCT04482374||Cisgender males|Cisgender male controls
61956707|NCT01311479|ACTIVE_COMPARATOR|Osteopathic Manipulation|"Patients will be evaluated and examined by an Osteopathic physician. This examination will consist of full osteopathic structural exam, and a focused examination of the sacroiliac joint and the surrounding musculature.~Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction."
61956708|NCT01311479|ACTIVE_COMPARATOR|Massage Therapy|Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
62345667|NCT05664334|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo, administered IM once on Day 0.
62345668|NCT04841720|EXPERIMENTAL|HSK16149|HSK16149（D1-D5）
62345669|NCT04841720|EXPERIMENTAL|Metformin|Metformin
61956709|NCT01405456|EXPERIMENTAL|Eplerenone and Lifestyle|First 6 months: eplerenone 50mg daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: same (eplerenone open label during second 6 months)
62142641|NCT03884842|PLACEBO_COMPARATOR|matched placebo|Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to deliver 2 mL.
62345670|NCT04841720|EXPERIMENTAL|HSK16149+Metformin|HSK16149+Metformin
62142642|NCT01596413|EXPERIMENTAL|Sancuso Arm|Transdermal Patch 34.3mg graniestron per patch, size 52cm2 Dose: 3.1mg/24 hrs
62142643|NCT01596413|ACTIVE_COMPARATOR|IV Granisetron|"Aqueous solution for IV administration~1 mg/mL ampoules Dose: 0.01mg/kg (maximum 1 mg)"
62345671|NCT04083898|EXPERIMENTAL|Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m\^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
62345672|NCT04083898|EXPERIMENTAL|Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m\^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
62503493|NCT02438696|EXPERIMENTAL|2 BI 1060469 low dose|iFF followed by TF1 followed by TF2
62503494|NCT05434351||Chinese women with moderate to severe symptoms of genitourinary syndrome of menopause|It is a single-group study.
62503495|NCT06175715|ACTIVE_COMPARATOR|Regional anesthesia for carotid endarterectomy in patients with acute stage of ischemic stroke.|
62503496|NCT06175715|ACTIVE_COMPARATOR|General anesthesia for carotid endarterectomy in patients with acute stage of ischemic stroke.|
62503497|NCT01764750|EXPERIMENTAL|Low Dose Intrasite Vancomycin|10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
62503498|NCT01764750|EXPERIMENTAL|Mid-dose Intrasite Vancomycin|10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
62503499|NCT01764750|EXPERIMENTAL|High-dose Intrasite Vancomycin|10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
62702386|NCT06749912|EXPERIMENTAL|Lower back pain wrap|During this arm the participants will wear the low back pain wrap device
61956710|NCT01405456|PLACEBO_COMPARATOR|Placebo and Lifestyle|First 6 months: placebo pill daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: eplerenone (open label) 50mg daily along with continued lifestyle modification
62702387|NCT06749912|NO_INTERVENTION|No device|No device will be used, but symptoms and function will be reported
61956711|NCT01774968|EXPERIMENTAL|Human Regular U-500 Insulin TID|Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
62702388|NCT06750172||Primary aldosteronism(PA)|"Inclusion criteria:~Patients with hypertension and hypokalemia who have been diagnosed with primary aldosteronism following the latest version international guidelines for primary aldosteronism.~Exclusion criteria:~* Other causes of endocrine hypertension including pheochromocytoma, Cushing syndrome, etc.~* Renal artery stenosis and low potassium due to other factors, such as renal tubular acidosis, Bartter syndrome, Gitelman syndrome, etc.~* History of hyperthyroidism, hepatic and renal insufficiency, malignant tumors, metabolic diseases, cardiovascular diseases, and mental diseases,menstrual disorders~* Special drugs such as glucocorticoids, immunosuppressants, and oral contraceptives should~* Diabetes mellitus with HbA1c\>7.0% or with insulin or SGLT2 inhibitors were also excluded."
62702389|NCT06750172||healthy control|"Inclusion criteria:~* Age: 20-70 years old, male and female;~* BMI: 18.5-23.9 kg/m2;~* Blood pressure: 90-120/60-80 mmHg on three consecutive office blood pressure readings;~* Female must have regular menstrual cycle (blood and urine samples should be ▪taken during the non-menstrual period);~* Regular dietary habits;~* No medications taken within the past 1 month.~Exclusion criteria:~History of hypokalemia. History of liver and kidney dysfunction, malignant tumors, metabolic disorders, cardiovascular diseases, and psychiatric disorders, etc.~Menstrual irregularities and taking contraceptive pills.~* History of hypertension~* Have taken any drugs including anti-inflammatory drugs, potassium diuretics, or special health products in the 4 weeks prior to the examination,"
62702390|NCT06748092|EXPERIMENTAL|iCare IC1000 vs GAT, iCare IC200 and Perkins|
62702391|NCT06748495||Serplulimab|the combination of Serplulimab and chemotherapy regimen
61956712|NCT01774968|EXPERIMENTAL|Human Regular U-500 Insulin BID|U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
61956713|NCT06505902|EXPERIMENTAL|COPD-patients|COPD-patients during diffusing capacity measurement during incremental exercise
61956714|NCT06505902|EXPERIMENTAL|Matched healthy volunteers|Healthy matched controls during diffusing capacity measurement during incremental exercise
61956715|NCT05332665||Angle opening distance (AOD)|The AOD measured as perpendicular distance between anterior iris surface and point at trabecular meshwork at 500 μm anterior to the scleral spur
61956716|NCT05332665||Trabecular iris space area (TISA) 500|TISA 500 was measured as an area bounded anteriorly by the AOD 500, posteriorly by a line drawn from the scleral spur perpendicular to the plane of the inner scleral wall to the opposing iris, superiorly by the inner corneoscleral wall, and inferiorly by the iris surface
62702392|NCT06750081|EXPERIMENTAL|Experimental|receive an experimental intervention
62702393|NCT06750081|ACTIVE_COMPARATOR|Control|another therapy used to treat the same condition
62702394|NCT06750692|EXPERIMENTAL|Experimental: Mirror therapy|The first group of participants will receive mirror therapy for 4 weeks, 5 sessions per week for a total of 20 sessions of upper extremity mirror therapy.
61956717|NCT05332665||Anterior chamber depth (ACD)|The ACD was measured as the perpendicular distance from the corneal endothelium at the corneal apex to the anterior lens surface
62142644|NCT02593760|ACTIVE_COMPARATOR|Placebo + Ruxolitinib|Participants will receive placebo (PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
62142645|NCT02593760|EXPERIMENTAL|Vismodegib + Ruxolitinib|Participants will receive vismodegib (150 mg PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
61956718|NCT04662125|ACTIVE_COMPARATOR|group A|Group A (conservative treatment): oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
61956719|NCT04662125|ACTIVE_COMPARATOR|group B|Group B (oral prednisolone): patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days.
61956720|NCT04662125|ACTIVE_COMPARATOR|group C|Group C (oral pregabalin): patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
61956721|NCT01517711|EXPERIMENTAL|Tramadol ER|Tramadol in an extended release formulation with an initial dosage of 100 mg daily, increased weekly over the next two weeks, as tolerated, to a maximum of 300 mg daily
61956722|NCT01517711|PLACEBO_COMPARATOR|Placebo capsule|Lactose encapsulated to match appearance of experimental drug
61956723|NCT01628575||PAO|patients undergoing orthodontic treatment with the addition of pretreatment periodontal surgery for bone decortication.
61956724|NCT03673215|EXPERIMENTAL|A|
61956725|NCT03673215|EXPERIMENTAL|B1|
61956726|NCT03673215|PLACEBO_COMPARATOR|B2|
61956727|NCT03673215|EXPERIMENTAL|C1-1|
61956728|NCT03673215|PLACEBO_COMPARATOR|C1-2|
61956729|NCT03673215|EXPERIMENTAL|C2-1|
61956730|NCT03673215|PLACEBO_COMPARATOR|C2-2|
62142646|NCT01856569||observational|
62142647|NCT01683409|PLACEBO_COMPARATOR|Placebo|Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
62142648|NCT01683409|EXPERIMENTAL|Baricitinib 0.75 mg/0.5 mg QD|Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
62503500|NCT01764750|ACTIVE_COMPARATOR|Optimally-dosed IV Vancomycin|10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)
61956731|NCT03673215|EXPERIMENTAL|C3-1|
62142649|NCT01683409|EXPERIMENTAL|Baricitinib 0.75 mg/0.5 mg BID|Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
62503501|NCT01195116|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.
62503502|NCT01195116|PLACEBO_COMPARATOR|Normal Saline|
62503503|NCT05387070|EXPERIMENTAL|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
62503504|NCT05387070|PLACEBO_COMPARATOR|placebo|Placebo for TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
62142650|NCT01683409|EXPERIMENTAL|Baricitinib 1.5 mg/1 mg|Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
62503505|NCT05345951|EXPERIMENTAL|e-PBI+|The e-PBI+ is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens, with additional content on cannabis use.
62142651|NCT01683409|EXPERIMENTAL|Baricitinib 4 mg/2.75 mg|Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
62503506|NCT05345951|EXPERIMENTAL|e-PBI|the e-PBI is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens.
62345673|NCT04083898|EXPERIMENTAL|Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m\^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
62345674|NCT04083898|EXPERIMENTAL|Phase II: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
62503507|NCT05345951|NO_INTERVENTION|e-AC|The e-AC is the attention matched control. They will receive general university-related materials to read, sections on parent and family resources (e.g., message from administrators, getting involved, academic calendar), advising, money matters, financial aid, campus life (arts, entertainment, housing, etc.), health and safety (health, counseling services, alcohol and drug laws). It is equivalent to the e-PBI+ and e-PBI on length of content and time to read. This group will not receive an intervention.
62503508|NCT06678802||1 - Chronic ischemic heart disease|
62503509|NCT06678802||2 - Acute coronary syndromes|
62503510|NCT06678802||3 - Healthy volunteers|
61956732|NCT03673215|PLACEBO_COMPARATOR|C3-2|
61956733|NCT02279563|EXPERIMENTAL|Azelastine HCl and Fluticasone Propionate Nasal Spray|"The investigational product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL1981, Expiry Date Mar 2015."
61956734|NCT02279563|ACTIVE_COMPARATOR|Dymista™ Nasal Spray|"The reference product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number G30349, Expiry Date Mar 2015."
61956735|NCT02279563|PLACEBO_COMPARATOR|Placebo Nasal Spray|"The placebo was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL0781, Expiry Date Mar 2015."
61956736|NCT01807975|EXPERIMENTAL|post allogreffe patients|Functional evaluation of distal airway by forced oscillation technique : relevance earlier diagnostic of pulmonary syndrom of oblitérant bronchiolit in post allogreffe patients
62345675|NCT03067129|EXPERIMENTAL|Cohort 1: Adult Formulation; 12 to < 18 years|Adolescents aged 12 to \< 18 years old received the adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 100 mg/ 40 mg co-formulated film-coated tablets for a once daily (QD) total dose of 300 mg/120 mg by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.
62345676|NCT03067129|EXPERIMENTAL|Cohort 2: Pediatric Formulation; 9 to < 12 years|"Children aged 9 to \< 12 years old received a pediatric formulation of GLE + PIB as small film-coated granules taken with a small amount of food once daily for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.~The initial proposed dose for children 9 to \< 12 years old (30 to \< 45 kg) was GLE 200 mg + PIB 75 mg. After PK analysis from the first 6 enrolled participants the dose was adjusted to GLE 250 mg + PIB 100 mg."
62345677|NCT03067129|EXPERIMENTAL|Cohort 3: Pediatric Formulation; 6 to < 9 years|"Children aged 6 to \< 9 years old received a pediatric formulation of GLE + PIB as small film-coated granules taken with a small amount of food once daily for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.~The initial proposed dose for children 6 to \< 9 years old (20 to \< 30 kg) was GLE 160 mg + PIB 60 mg. After PK analysis from the first 6 enrolled participants the dose was adjusted to GLE 200 mg + PIB 80 mg."
62503511|NCT05829850|EXPERIMENTAL|SYNOLIS VA 40/80|SYNOLIS VA 40/80 (hyaluronic acid 40 mg, sorbitol 80 mg), intra-articular injection
62503512|NCT03813225|NO_INTERVENTION|Conventional Analgesia|"These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation for handling an analgesic in cardiovascular surgery, this start in surgery with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.~and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus."
61956737|NCT06556537|EXPERIMENTAL|Intervention group|Participants will undergo a face-to-face and video-assisted physical exercise intervention.
61956738|NCT06556537|NO_INTERVENTION|Control group|Participants in the control group will maintain their usual lifestyle throughout the project. They will receive physical activity recommendations for older people and will attend monthly health promotion meetings.
61956739|NCT01702805|ACTIVE_COMPARATOR|Low Threshold Transfusion|Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group
61956740|NCT01702805|ACTIVE_COMPARATOR|High Threshold Transfusion|Transfusions will be administered using a higher threshold hemoglobin value.
62345678|NCT03067129|EXPERIMENTAL|Cohort 4: Pediatric Formulation; 3 to < 6 years|"Children aged 3 to \< 6 years old received a pediatric formulation of GLE + PIB as small film-coated granules taken with a small amount of food once daily for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.~The initial proposed dose for children 3 to \< 6 years old (12 to \< 20 kg) was GLE 120 mg + PIB 45 mg. After PK analysis from the first 5 enrolled participants the dose was adjusted to GLE 150 mg + PIB 60 mg."
62503513|NCT03813225|EXPERIMENTAL|Serrato intercostal plane Block|These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.In this Arm the patient will give a bilateral serratus intercostal plane block, will be performed echo-guided puncture in the line anterior axillar with fifth costal arch, whit 21 ml of anesthetic mass, 20 ml of Levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone. and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus
62503514|NCT02176057|EXPERIMENTAL|Antibiotic|Azithromycin, suspension (liquid), 1 gram, one-time dose
62503515|NCT02176057|NO_INTERVENTION|Observation|
62503516|NCT03510338|EXPERIMENTAL|Sublingual sildenafil (fasted)|Subjects receive a single dose of 100 mg sildenafil
62503517|NCT03510338|ACTIVE_COMPARATOR|Oral sildenafil (fed)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
62503518|NCT03510338|EXPERIMENTAL|Sublingual sildenafil (fed)|Subjects receive a single dose of 100 mg sildenafil
61956741|NCT01433705|OTHER|Rb-82 and N-13 ammonia Pet scans|Rest and vasodilator stress Rb-82 images and N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 and N-13 ammonia by intravenous administration (IV) in the patient's arm.
61956742|NCT01433705|OTHER|F-18 FDG Imaging and Rb-82|Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.
62503519|NCT03510338|ACTIVE_COMPARATOR|Oral comparator (fasted)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
62503520|NCT00337896||observation|healthy adults ages 18-64 years, enrolled at Stanford University Hospital and participating in another clinical trial (DMID Protocol 04-062)
62503521|NCT04501094|EXPERIMENTAL|1/Arm 1-Treatment with Bintrafusp alfa (M7824)|Treatment with Bintrafusp alfa (M7824)
62503522|NCT00754871|EXPERIMENTAL|Arm 1|
62503523|NCT00754871|EXPERIMENTAL|Arm 2|
62503524|NCT00754871|EXPERIMENTAL|Arm 3|
62503525|NCT00754871|EXPERIMENTAL|Arm 4|
62503526|NCT03079388|EXPERIMENTAL|Ready-to-use supplementary food + anti-infective bundle|The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
61956743|NCT01433705|OTHER|F-18 FDG Imaging and N-13 ammonia|Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.
61956744|NCT05450952|ACTIVE_COMPARATOR|Active|Dietary Supplement (Theanine Formulation)
62503527|NCT03079388|ACTIVE_COMPARATOR|Corn-soy-blend|The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.
62503528|NCT02868996|EXPERIMENTAL|Low dose (Part A)|Recombinant human tissue kallikrein
62503529|NCT02868996|EXPERIMENTAL|Medium low dose (Part A)|Recombinant human tissue kallikrein
62503530|NCT02868996|EXPERIMENTAL|Medium high dose (Part A)|Recombinant human tissue kallikrein
62503531|NCT02868996|EXPERIMENTAL|High dose (Part A)|Recombinant human tissue kallikrein
62503532|NCT02868996|EXPERIMENTAL|Subcutaneous (Part B)|Recombinant human tissue kallikrein
62503533|NCT02868996|EXPERIMENTAL|IV (Part B)|Recombinant human tissue kallikrein
62503534|NCT06678061|ACTIVE_COMPARATOR|radiofrequency splanchnic denervation|Radiofrequency ablation of splenic nerve. The nerves were then anesthetized with 2 mL of 2% lidocaine before RF performed. In RFA group, lesion will be performed at 80 degrees celsius for 3 lesions 2 minutes each on both sides.
61956745|NCT05450952|PLACEBO_COMPARATOR|Placebo|Placebo Tablet
61956746|NCT01651039|EXPERIMENTAL|Panobinostat, Lenalidomide and Dexamethasone|All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
61956747|NCT04029831|EXPERIMENTAL|K61|Patients in K61 group received propofol and ketamine in a ratio of 6:1. The 6:1 ketofol mixture was made by mixing 30 mL of 1% propofol (10 mg/mL) and 1 mL of ketamine (50 mg/ml), then 19 mL of 0.9% NaCl was added until the volume of the mixture was 50 mL. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
62503535|NCT06678061|ACTIVE_COMPARATOR|Celiac plexuc block|Neurolytic ablation of the celiac plexus.Two milliliter of contrast material will be injected in each side for confirmation a test injection with 5 mL of 2% lidocaine to both sides, and wait for 5 minutes then inject 5 ml of 100% alcohol will in each side after 5 minutes to allow the local anesthetic to take action. 1 ml of 2%
61956748|NCT04029831|EXPERIMENTAL|K41|Patients in K41 group received propofol and ketamine in a ratio of 4:1. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
61956749|NCT01939652|ACTIVE_COMPARATOR|Drag: Crystalloids and Colloids|Drag: Crystalloids and Colloids Intraoperative 10 ml/kg/per hour, postoperative 70-100 ml/per hour
62503536|NCT03703453|EXPERIMENTAL|REBOA|Patients undergoing REBOA for medical cardiac arrest
61956750|NCT01939652|EXPERIMENTAL|Standard fluid regime|Drag: Crystalloids and Colloids Intraoperative 15 ml/kg/per hour, postoperative 150-200 ml/per hour
62142652|NCT04149132||Patients without sepsis|Patients admitted and hospitalized for infections without sepsis and for other reasons in departments of Internal Medicine and Intensive Care Units
62142653|NCT02701296|EXPERIMENTAL|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
62702395|NCT06750692|EXPERIMENTAL|Experimental: Low Frequency rTMS Protocol|The second group will receive a total of 20 sessions of Repetitive Transcranial Magnetic Stimulation (rTMS) to the contralateral M1 upper extremity motor cortex region at low frequency (1Hz) and intensity of 100%-110% of the resting motor threshold, 5 sessions per week for 4 weeks.
62142654|NCT02701296|ACTIVE_COMPARATOR|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
62503537|NCT05386173||Fetal intervention group|Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria
62503538|NCT05386173||Fetal non-intervention group|Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria which are identical with the criteria in the Fetal intervention group
62503539|NCT01894230|EXPERIMENTAL|Genotype results plus usual care|SLCO1B1\*5 allele testing, results reported at randomization: genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization.
62503540|NCT01894230|ACTIVE_COMPARATOR|Usual care only|SLCO1B1\*5 allele testing, results reported at end of study: genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study
62503541|NCT01639716||Lymphoma group|
62503542|NCT01639716||healthy group|
62702396|NCT06750692|EXPERIMENTAL|Experimental: Robotic-assisted hand therapy|In the Robot Assisted Therapy group, a total of 20 sessions will be applied to the hemiplegic upper extremity with AMADEO (Tyromotion Austria) 5 days a week for 4 weeks.
62503543|NCT01639716||IL-10 high|
62503544|NCT01639716||IL-10 low|
62702397|NCT06749210|NO_INTERVENTION|Control|4 weeks of usual care followed by optional 1-way crossover to 8 weeks of Intervention (partnered, adapted tango dance)
62702398|NCT06749210|EXPERIMENTAL|Experimental|8 weeks of intervention (partnered, adapted tango dance)
61956751|NCT04931407|EXPERIMENTAL|Interdisciplinary complex intervention|The intervention includes patient education, physical exercise, a group-based cognitive behavioral program and individual nutritional counseling
61956752|NCT04505462|EXPERIMENTAL|Study diet|7-day therapeutic diet intervention as experimental group
62142655|NCT04129099|EXPERIMENTAL|CAR-T treatment group|The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
62142656|NCT06051799|EXPERIMENTAL|TREATMENT GROUP|The Pressure Release Technique will be applied. One session per week will be carried out for four weeks. It will be performed on as many trigger points as we find in each muscle associated with the study, leaving a record of them. Also adding postural hygiene and home exercise guidelines. A progression of exercises involving contraction of the deep neck flexor muscles Subjects will be taught to perform slow and controlled craniocervical flexion. It should be performed a minimum of once daily during the treatment regimen. A follow-up of the patients will be carried out with respect to home therapeutic exercise and postural hygiene guidelines.
62702399|NCT06750016||Coronary Artery Disease (CAD)|Patients in whom occlusive coronary artery disease has been diagnosed by angiography or CT angiography
61956753|NCT04505462|NO_INTERVENTION|Usual diet|7-day usual diet as control group, no dietary intervention in this group, participants consumed their habitual diet
62503545|NCT01639716||IL-4 high|
61956754|NCT02126020|EXPERIMENTAL|topical infliximab|topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months
62503546|NCT01639716||IL-4 low|
62503547|NCT01639716||lymphopenia|
62503548|NCT05814393|EXPERIMENTAL|JW0201+C2202+C2203|Treatment period for 24 weeks (After the treatment period, take JW0201+C2202+C2203 for 28 weeks)
62503549|NCT05814393|PLACEBO_COMPARATOR|C2202+C2203|Treatment period for 24 weeks (After the treatment period, take JW0201+C2202+C2203 for 28 weeks)
62503550|NCT04461340|EXPERIMENTAL|Group A|20 patients will receive sirolimus ( oral dose of 6 mg on day 1 followed by 2 mg daily for 9 days) plus national standard of care therapy against COVID 19
62503551|NCT04461340|NO_INTERVENTION|Group B|20 patients will receive only national standard of care therapy against COVID 19
62503552|NCT03066791|ACTIVE_COMPARATOR|Turmeric group|"Turmeric Tablets:~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.~Supplied by Sabinsa Corporation"
62503553|NCT03066791|ACTIVE_COMPARATOR|Curcumin Group|"Curcumin and Bioperine tablets:~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.~Supplied by Sabinsa corporation"
62503554|NCT03066791|PLACEBO_COMPARATOR|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 6 placebo tablets per day"
62503555|NCT05950217|EXPERIMENTAL|Experimental Group|The experimental group patients will be educated by the nurse in the preoperative period with the support of visual education material
62702400|NCT06750016||Control|Healthy volunteers and/or patients in whom no CAD has been identified on angiography or CT angiography
61956755|NCT01146418|EXPERIMENTAL|Corifollitropin alfa 150 μg|Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
61956756|NCT01146418|ACTIVE_COMPARATOR|recFSH 300 IU|Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
61956757|NCT03035370|EXPERIMENTAL|Viaskin PT 25 mcg|Viaskin PT 25 mcg
61956758|NCT03035370|EXPERIMENTAL|Viaskin PT 50 mcg|Viaskin PT 50 mcg
61956759|NCT03035370|PLACEBO_COMPARATOR|Viaskin PT Placebo|Viaskin PT Placebo
61956760|NCT04874298|EXPERIMENTAL|Intervention Arm 1 (Ginger Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use ginger oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
61956761|NCT04874298|EXPERIMENTAL|Intervention Arm 2 (Peppermint Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
61956762|NCT04874298|NO_INTERVENTION|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
61956763|NCT06105229||Acute kidney injury|Patients with AKI who meet KDIGO criteria
61956764|NCT06105229||Healthy controls|Healthy people without other underlying medical conditions
62142657|NCT06051799|ACTIVE_COMPARATOR|CONTROL|Postural hygiene guidelines will be given, as well as home therapeutic exercise (identical to the treatment group). About therapeutic exercise, a progression of exercises involving contraction of the deep neck flexor muscles shall be included in the first session. Subjects will be taught to perform slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed a minimum of once daily during the treatment regimen. To this end, patients will be monitored and their understanding and correct follow-up of the treatment will be assessed in each face-to-face session per week, for four weeks, the same as in experimental group.
62142658|NCT02667366|EXPERIMENTAL|Tel-PT|Tel-PT receives a manualized short-term CBT. Treatment consists of one initial face-to-face appointment and 8-12 subsequent telephone sessions between patient and licensed therapist. Each telephone contact lasts between 20 and 30 minutes and take place on a weekly and later biweekly basis.
62345679|NCT05528770|ACTIVE_COMPARATOR|Full closed-loop (FCL) with Bolus Priming System (BPS) followed by FCL without BPS|"Two separate 24-hour periods during where fully closed loop (FCL) control is used with \& without the Bolus Priming system (BPS) active (BPS is designed to recognize meal ingestion \& deliver a quick priming dose of insulin prior to extreme blood sugar excursions.) These will be separated by a 24-hour challenge period which will involve further meal \& exercise challenges. During these 24-hour periods, participants will be followed for the experimental meals as part of the Study Controller Sessions to compare blood glucose control with \& without the BPS. The study meals \& activities will be standardized between study sessions.~During a washout period, we will test the RocketAP system in FCL with further challenges:~* A session of high-intensity interval training~* A high-carbohydrate, high-fat meal~* Ingestion of a bolus of simple sugar"
62503556|NCT05950217|NO_INTERVENTION|Control Group|The control group will take rutin patient care.
62503557|NCT04263233||Other|This program, which is provided for all patients new to dialysis at the participating units, will be evaluated by assessing patient clinical outcomes and the results of surveys measuring patient-reported symptoms, quality of life, knowledge and activation. In addition, satisfaction with the program will be assessed.
62702401|NCT05564390|ACTIVE_COMPARATOR|MM1MDS-A01 Arm A (ASTX727)|Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Arm B. Patients who experience CR, PR, or stable disease (SD) any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
62702402|NCT05564390|EXPERIMENTAL|MM1MDS-A01 Arm B (ASTX727, enasidenib)|Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
61956765|NCT05719532||Healthy adults|Healthy adults between 18 and 35 years
61956766|NCT04179708|EXPERIMENTAL|pain neuroscience education|
61956767|NCT04179708|ACTIVE_COMPARATOR|Conventional education|"patient receiving a classical education on spinal physiology and ergonomics"
61956768|NCT03196102|EXPERIMENTAL|BTI + Cigarette smoking military tailored pamphlet|BTI + Cigarette smoking military tailored pamphlet
61956769|NCT03196102|ACTIVE_COMPARATOR|Cigarette smoking military tailored pamphlet|Cigarette smoking military tailored pamphlet
61956770|NCT03196102|ACTIVE_COMPARATOR|Standard smoking cessation pamphlet|Standard smoking cessation pamphlet
61956771|NCT03218904|EXPERIMENTAL|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
62503558|NCT03026517|EXPERIMENTAL|Dabrafenib, Trametinib & Phenformin|This is a multi-institution single-arm phase I trial with an expansion cohort at the MTD of Phenformin, in patients with metastatic BRAFV600E/K mutated melanoma. In the dose escalation phase, cohorts of patients will be treated with standard dose Dabrafenib (150 mg PO BID) plus Trametinib (2 mg PO QD) and increasing doses of Phenformin. In the dose-escalation phase of the trial, both patients who have already been treated with a BRAF and/or MEK inhibitor, and treatment-naïve patients will be eligible. The maximally tolerated Phenformin dose was determined to be 100 mg BID. The dose-expansion cohort will enroll up to 10 patients who are treatment- naïve for BRAF inhibitor. In this cohort, patients may be treated with any of the 3 FDA-approved BRAFi/MEKi combinations: dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib.
62503559|NCT03307811|EXPERIMENTAL|22 gauge needle liver biopsy|EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
61956772|NCT03218904|EXPERIMENTAL|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of Glycosade®
61956773|NCT03543475|EXPERIMENTAL|Pessary|Silicon device applied on the cervix
62714886|NCT06268899|NO_INTERVENTION|Control|No intervention was made to the control group, only data were collected at the same time as the study group.The patients in the control group was mobilized by the researchers according to the routine clinical mobilization practice.
61956774|NCT03543475|ACTIVE_COMPARATOR|No Pessary|standard care, no pessary
61956775|NCT02456441|EXPERIMENTAL|Intervention group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after TENS application, through Heart Hate Variability analysis.
61956776|NCT02456441|PLACEBO_COMPARATOR|Placebo group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after placebo current application, through Heart Hate Variability analysis. p. The placebo group will receive transcutaneous electric stimulation, for 30 seconds and then will gradually decrease by 15 seconds to not pass any current. This approach will aim to masking of the subject.
61956777|NCT06022939|ACTIVE_COMPARATOR|Consolidation Arm I (Chemotherapy)|Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes on days 1 and 15 as well as bortezomib SC over 3-5 minutes, cyclophosphamide PO or IV, and dexamethasone PO or IV on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening and at progression. Patients undergo bone marrow aspiration and biopsy within14-28 days post consolidation treatment and at progression. Patients undergo blood and urine sample collection at screening, at the start of each cycle, and the end of treatment and during follow up or at progression.
61956778|NCT06022939|EXPERIMENTAL|Consolidation Arm II (Chemotherapy, ASCT)|Patients undergo collection of peripheral blood stem cells. Patients receive melphalan IV for 1 cycle and then 2 days later receive the stem cell transplant IV in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening and at progression. Patients undergo bone marrow aspiration and biopsy within 60-90 days post initiation of stem cell transplant. Patients undergo blood and urine sample collection at screening, during treatment, and the end of treatment and during follow up or at progression.
61956779|NCT06022939|EXPERIMENTAL|Induction (Chemotherapy)|Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes on days 1, 8, 15 and 22 for 2 cycles and then days 1 and 15 for cycle 3. Patients receive bortezomib SC over 3-5 minutes, cyclophosphamide PO or IV, and dexamethasone PO or IV on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI or PET-CT and fat pad aspiration at screening. Patients undergo echocardiography at screening, the completion of induction, and at progression. Patients undergo bone marrow aspiration and biopsy at screening, post induction treatment and at progression. Patients undergo blood and urine sample collection at screening, at the start of each cycle, and the end of treatment and during follow up or at progression.
61956780|NCT06022939|EXPERIMENTAL|Maintenance (daratumumab and hyaluronidase-fihj)|Patients receive maintenance daratumumab and hyaluronidase-fihj SC over 3-5 minutes on day 1 of each cycle. Cycles repeat every 28 days for up 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening, 12 months post consolidation treatment and at progression. Patients undergo bone marrow aspiration and biopsy 12 months post consolidation treatment and at progression. Patients undergo blood and urine sample collection at screening, during treatment, 12 months post consolidation treatment and during follow up or at progression.
61956781|NCT05517915|EXPERIMENTAL|IMT group|IMT training with 70% threshold was given.
61956782|NCT05517915|SHAM_COMPARATOR|Sham group|unloaded IMT training was given.
62503560|NCT05592483||HER2+ Cohort|Patients with HER2+ unresectable and/or mBC who are prescribed T-DXd and have received a prior anti-HER2 based regimen.
62503561|NCT05592483||HER2-low cohort|Patients with HER2-low unresectable and/or mBC who are prescribed T-DXd and have received a prior chemotherapy.
62714887|NCT01088503||ADP receptor inhibitor treatment|Participants admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
61956783|NCT02048605|EXPERIMENTAL|Psycho-social (CBT) based training|Psycho-social Training in Neurological Diseases - Parkinson's Disease ( Training according to Ellgring et al., 2006)
62503562|NCT03904901|ACTIVE_COMPARATOR|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, drink with water and drink before bed. Probiotics contain a dose of 10 9 CFU per capsule.
62503563|NCT03904901|PLACEBO_COMPARATOR|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
62503564|NCT05947097|EXPERIMENTAL|Mild Renal Impairment|
62503565|NCT05947097|EXPERIMENTAL|Moderate Renal Impairment|
62503566|NCT05947097|EXPERIMENTAL|Severe Renal Impairment|
62503567|NCT05947097|EXPERIMENTAL|Normal Renal function|
62503568|NCT06350994||Cardio CAR-T|Transthoracic bedside echocardiography
62503569|NCT02484430|EXPERIMENTAL|Treatment (sapanisertib)|Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62503570|NCT06601751|EXPERIMENTAL|Neurobic exercise program|Neurobic exercise program + Traditional Brain Exercises
62702403|NCT05564390|EXPERIMENTAL|MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
61956784|NCT02048605|PLACEBO_COMPARATOR|Unspecific group training|"Health Enhancement Program~The validation of an active control intervention for Mindfulness Based Stress Reduction (MBSR) (MacCoon et al., 2012)"
61956785|NCT03461913|ACTIVE_COMPARATOR|normal pregnancy|women at full term healthy pregnancy who underwent elective Cesarean section
61956786|NCT03461913|ACTIVE_COMPARATOR|pregnancy hypertension|women at full term pregnancy associated with hypertension who underwent elective Cesarean section
61956787|NCT02531204|EXPERIMENTAL|ASP1585 granules preceding group|
61956788|NCT02531204|ACTIVE_COMPARATOR|ASP1585 capsules preceding group|
61956789|NCT00935363|EXPERIMENTAL|glyburide + fluconazole|
61956790|NCT00935363|EXPERIMENTAL|glyburide + rifampin|
62345680|NCT05528770|ACTIVE_COMPARATOR|Full closed-loop (FCL) without Bolus Priming System (BPS) followed by FCL with BPS|"Two separate 24-hour periods during where fully closed loop (FCL) control is used with \& without the Bolus Priming system (BPS) active (BPS is designed to recognize meal ingestion \& deliver a quick priming dose of insulin prior to extreme blood sugar excursions.) These will be separated by a 24-hour challenge period which will involve further meal \& exercise challenges. During these 24-hour periods, participants will be followed for the experimental meals as part of the Study Controller Sessions to compare blood glucose control with \& without the BPS. The study meals \& activities will be standardized between study sessions.~During a washout period, we will test the RocketAP system in FCL with further challenges:~* A session of high-intensity interval training~* A high-carbohydrate, high-fat meal~* Ingestion of a bolus of simple sugar"
62345681|NCT02140203|ACTIVE_COMPARATOR|Young Yoga Group|People who are younger than 60 year-old They have received Yoga training in one-year experimental period
62345682|NCT02140203|NO_INTERVENTION|Young Control Group|People who are younger than 60 year-old No Yoga training through out the one-year experimental period
62345683|NCT02140203|NO_INTERVENTION|Aged Control Group|People who are equal or older than 60 year-old They have not received any yoga training during the one-year experimental period
62345684|NCT02140203|ACTIVE_COMPARATOR|Aged Yoga Group|People who are equal or older than 60 year-old They have received any yoga training during the one-year experimental period
62345685|NCT01768468|EXPERIMENTAL|LAYLA|Drug : LAYLA tablet/ bid
62345686|NCT01768468|ACTIVE_COMPARATOR|JOINS|Drug : JOINS tablet/ tid
62345687|NCT00966394||ADHD medication|Children with ADHD and pharmacologic treatment
62345688|NCT00966394||ADHD without medication|Children with ADHD without pharmacologic treatment
62503571|NCT06601751|ACTIVE_COMPARATOR|Traditional brain exercises|Traditional brain exercises calculation or memory games.
62503572|NCT00685750|OTHER|ME1|Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment
61956791|NCT00935363|ACTIVE_COMPARATOR|glyburide|
61956792|NCT00935363|EXPERIMENTAL|glyburide + fluconazole + rifampin|
61956793|NCT01412515|EXPERIMENTAL|Everolimus|everolimus 10 mg per day
61956794|NCT03266536|NO_INTERVENTION|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
62142659|NCT02667366|ACTIVE_COMPARATOR|TAU and text messages|Control Group receives treatment as usual and additionally weekly text messages containing general information about depression.
62345689|NCT00966394||healthy|Healthy children ASA1
62503573|NCT00685750|OTHER|ME2|Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only
62503574|NCT00685750|OTHER|ME3|Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment
62503575|NCT00685750|OTHER|ME4|Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions
62503576|NCT00685750|OTHER|ME5|Patients with cutaneous metastatic melanoma receiving local imiquimod
62503577|NCT00685750|OTHER|NSC|Non-small cell lung cancer patients
62503578|NCT00685750|OTHER|ME6|Patients with cutaneous metastatic melanoma receiving ipilimumab
62503579|NCT01074008|EXPERIMENTAL|ABT-450/r (50/100 mg) once daily (QD) + pegIFN/RBV|Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62503580|NCT01074008|EXPERIMENTAL|ABT-450/r (100/100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62503581|NCT01074008|EXPERIMENTAL|ABT-450/r (200/100 mg) once daily (QD) + pegIFN/RBV|Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62702404|NCT05564390|EXPERIMENTAL|MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
61956795|NCT03266536|EXPERIMENTAL|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
61956796|NCT06394817||Total|All subjects
61956797|NCT01132430|PLACEBO_COMPARATOR|Usual care|Standard medical care within 4-6 week period
61956798|NCT01132430|EXPERIMENTAL|Motivational interviewing|Brief MI sessions within 4-6 week period
61956799|NCT05129215||Development|A primary cohort of eligible patients from the Sixth Affiliated Hospital of Sun Yat-sen University is used for model derivation.
61956800|NCT05129215||Internal cross-validation|A cohort of consecutive patients from the Sixth Affiliated Hospital of Sun Yat-sen University is used for internal cross-validation.
61956801|NCT05129215||External validation|An independent cohort of eligible patients from other hospitals is used for external validation.
61956802|NCT03699605|EXPERIMENTAL|VESMP|"Participants used VESMP at least half hour session thrice a week over an average of 4 months. The instruction before every domain included using it independently on the participant's own smart phone, or with a trained person either in the clinic or on their phone brought to the participant's home.~Total 25 patients with diagnosis of severe non-fluent aphasia included, ages 40+, at least 3 months post-onset of single unilateral CVA affecting the language dominant hemisphere at the time of baseline testing also including, Participant demographics, aphasia classification and severity. All subjects participated in an intensive 2-week VESMP treatment program prior to beginning the individualized programs."
61956803|NCT03699605|ACTIVE_COMPARATOR|Traditional Therapy|Control group received traditional therapy total 25 patients with diagnosis of severe non-fluent aphasia included, All subjects participated in an traditional therapy group in routine and received language therapy for 4 months of periods with three sessions per week.
61956804|NCT04180228||Systemic lupus erythematosus|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire with systemic lupus erythematosus.
61956805|NCT04180228||Idiopathic juvenile arthritis|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire, with idiopathic juvenile arthritis.
61956806|NCT05036824||COVID-19 patients|"Patients admitted to hospital with COVID-19, PCR+ SARS-CoV-2 infection administered thromboprophylaxis with tinzaparin.~Dosage: intermediate or therapeutic dose Frequency of tinzaparin administration: once daily Duration: Unknown"
61956807|NCT03024060|EXPERIMENTAL|ALA 20 mW|ALA + IBL 10J at 20 mW (8min 20 sec)
61956808|NCT03024060|EXPERIMENTAL|ALA 10 mW|ALA + IBL 10J at 10 mW (16 min 40 sec)
62345690|NCT05557734|ACTIVE_COMPARATOR|caudal epidural group|"the patient will be positioned in lateral position, sterilized from the iliac crest margin to the lower buttock by betadine and will be covered by sterile drapes exposing the sacral area. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound. Short axis (transverse) will be used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) will be used for direct puncture of sacrococcygeal membrane out of plane then the probe will be rotated to long axis (longitudinal) and the needle will be seen in plane in the epidural space. Injection of 40 ml 0.125% bupivacaine will expand the epidural space. The patient will be repositioned to lithotomy position and surgery will start after 5 min. of preparing the patient and sterilization to the surgery"
62345691|NCT05557734|ACTIVE_COMPARATOR|perianal block group|, the patient will be in the lithotomy position, paint and drape the area of the block under strict aseptic precaution, draw a circle with a radius of 2.5cm around anal opening, mark a point at 2,4,8,10 clock position, prepare 40 ml 0.125% bupivacaine, use 1.5-inch 23/24 gauge needle connected to 10 ml syringe, insert full length of the needle into the ischiorectal fat immediately peripheral to the external sphinchter. This injection scheme target the terminal nerve branches of the anus rather than blocking the trunk of major nerves. At 2 clock position, inject 2-3 ml of LA with tilting in lateral direction,withdraw needle 1cm and after every 1cm inject 2-3ml of LA, repeat procedure at 4,8,10 clock position, remaining around 10 ml of LA is used to infiltrate in subcutaneous tissue in circumference of anal opening.
62345692|NCT05447598|EXPERIMENTAL|Intervention|Remote monitoring program
62345693|NCT05447598|ACTIVE_COMPARATOR|Usual care|Current clinical pratice at the participating hospitals
62345694|NCT03571841|EXPERIMENTAL|Educational Intervention|"For breast cancer survivors currently on chemical ovarian suppression who are experiencing sexual dysfunction.~* Group Session~* Telephone Booster Session"
62345695|NCT06114394|EXPERIMENTAL|UPV/EHU technique (Aguirre-Zorzano et al 2017)|Harvesting a connective tissue graft from palate by the UPV/EHU technique.
62345696|NCT06114394|ACTIVE_COMPARATOR|Single incision technique (Huerzeler & Weng 1999)|Harvesting a connective tissue graft from palate by the single incision technique
62503582|NCT01074008|EXPERIMENTAL|ABT-072 (100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62503583|NCT01074008|EXPERIMENTAL|ABT-072 (300 mg) once daily (QD) + pegIFN/RBV|Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62503584|NCT01074008|EXPERIMENTAL|ABT-072 (600 mg) once daily (QD) + pegIFN/RBV|Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62503585|NCT01074008|EXPERIMENTAL|ABT-333 (400 mg) twice a day (BID) + pegIFN/RBV|Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62702405|NCT05564390|EXPERIMENTAL|MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
62702406|NCT05564390|ACTIVE_COMPARATOR|MM1OA-S03 Arm 1 (ASTX727, venetoclax)|Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
62702407|NCT05564390|EXPERIMENTAL|MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)|Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
61956809|NCT03024060|PLACEBO_COMPARATOR|Vehicle|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving light treatment delivered at 20 mW/cm2 OR 10 mW/cm2. Subjects receiving VEH will be considered a single treatment group
61956810|NCT04244682|OTHER|Healthy participants receiving rTMS|Participation will require up to three visits. One visit will take up to an hour, and the other visits will each take up to three hours each. During the first visit, participants will be consented, and their brains will be scanned using magnetic resonance imaging. Participants will receive rTMS during two study visits.
61956811|NCT05175053|EXPERIMENTAL|Early RRT group|Patients who will undergo renal replacement therapy (RRT) within 6 hours of diagnosis of stage 2 acute kidney injury (AKI).
62345697|NCT05371067|OTHER|Healthy volunteers|
62345698|NCT05848206||Primary LAAD Cohort|Patients with ≥1 SAC/VAL transactions from plans of interest identified in LAAD
61956812|NCT05175053|ACTIVE_COMPARATOR|Delayed RRT group|Patients who will undergo renal replacement therapy (RRT) if one of the absolute indications for RRT is present.
62503586|NCT01074008|EXPERIMENTAL|ABT-333 (800 mg) twice daily (BID) + pegIFN/RBV|Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62702408|NCT05564390|EXPERIMENTAL|MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)|Patients receive daunorubicin IV, cytarabine IV, and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
62736648|NCT06547333|EXPERIMENTAL|CM310 300mg Q2W|CM310 is injected subcutaneously (SC) 300 mg each time, once every 2 weeks (Q2W) for a total of 26 doses.
61956813|NCT04561466|EXPERIMENTAL|treatment group|"14 adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative.~Befizal® 200 mg will be tested for one year"
61956814|NCT03773692|EXPERIMENTAL|Passive feedback and JITAI|"Passive feedback and JITAI~Second Phase - PA Level Feedback Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)"
61956815|NCT04850937|EXPERIMENTAL|Group S|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction During administration, blood pressure and heart rate were observed.
61956816|NCT04850937|PLACEBO_COMPARATOR|Group C|The control group will receive the same amount of normal saline after anesthesia induction
61956817|NCT05494931|NO_INTERVENTION|control group|In this first group, the same classic method of Gunderson conjunctival flap surgery will be used.
62345699|NCT05848206||Secondary LAAD Cohort|Patients with SAC/VAL abandonment or rejection identified in LAAD
62345700|NCT02733406|OTHER|Target Controlled Infusion|This group of patients will have their anaesthesia induced with Target Controlled Infusion (TCI)
62345701|NCT02733406|OTHER|Velocity Controlled Infusion|This group of patients will have their anaesthesia induced with Velocity Controlled Infusion (VCI)
62345702|NCT04780958|OTHER|Study population|During the study period, babies born at this hospital with a gestational week of \<30 were included .
62345703|NCT02581358|EXPERIMENTAL|Scolioscan (Ultrasound imaging system)|This diagnostic study is a single arm study with all participants receiving investigation with the Scolioscan (a diagnostic ultrasound machine) for quantitative assessment of spinal deformity
61956818|NCT05494931|ACTIVE_COMPARATOR|intervention group|in the this group, Gunderson conjunctival flap surgery will be performed adjuncted by corneal neurotomy
61956819|NCT02981121|NO_INTERVENTION|Conventional Management|A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
61956820|NCT02981121|EXPERIMENTAL|Life style modification|"Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).~* Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)~* Diet remedies: Train Calorie intake, nutrient intake and Monitoring."
61956821|NCT02981121|ACTIVE_COMPARATOR|Metformin|After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
61956822|NCT02677532|ACTIVE_COMPARATOR|Epidural infusion|Thoracic epidural bolus of 10 ml levobupivacaine 0.25% plus sufentanil 0.15 mcg/kg before end of surgery, followed by continuous epidural infusion of 0.12% levobupivacaine plus 0.4 mcg/ml at 5 ml/h infusion rate for 48 hours.
61956823|NCT02677532|EXPERIMENTAL|Wound infusion plus morphine bolus|Intravenous slow bolus of 10 mg morphine, wound infiltration with 10 ml levobupivacaine 0.5%, followed by pre-peritoneal continuous wound infusion of levobupivacaine 0.25% at 4 ml/h infusion rate for 48 hours.
62142660|NCT03998098||Oxygen Saturation (Oximetry)|Arm to determine the performance of the Oxygen Saturation measurement in LifeLight First
62142661|NCT03998098||Heart Rate (Pulse)|Arm to determine the performance of the Heart Rate measurement in LifeLight First
62142662|NCT03998098||Respiratory Rate|Arm to determine the performance of the Respiratory Rate measurement in LifeLight First
62142663|NCT03998098||Blood Pressure|Arm to determine the performance of the Blood Pressure measurement in LifeLight First
62142664|NCT02203032|EXPERIMENTAL|Open-label ustekinumab|
62142665|NCT02203032|EXPERIMENTAL|Double-blind guselkumab|
62345704|NCT01807260|ACTIVE_COMPARATOR|conventional Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
62702409|NCT05564390|EXPERIMENTAL|MM1YA-CTG01 Arm II (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
62702410|NCT05564390|ACTIVE_COMPARATOR|MM1YA-CTG01 Arm III (daunorubicin, cytarabine)|Patients receive daunorubicin IV and cytarabine IV on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
61956824|NCT06081868|EXPERIMENTAL|Toothbrush/toothpaste/fluoride varnish|Children will be instructed to use toothbrush/toothpaste/fluoride varnish.
61956825|NCT06081868|EXPERIMENTAL|Education on nutrition/oral hygiene|Children receive individual education on nutrition/oral hygiene.
61956826|NCT03290092|EXPERIMENTAL|Treatment|
61956827|NCT04123314|EXPERIMENTAL|Psilocybin|Participants will complete an 8-week course of study treatment including weekly psychological support and two moderate to high dose psilocybin administrations in weeks 4 and 6.
61956828|NCT05016999|NO_INTERVENTION|Control|Volunteers in this group will not take any products.
61956829|NCT05016999|EXPERIMENTAL|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
61956830|NCT03246893|PLACEBO_COMPARATOR|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
61956831|NCT03246893|EXPERIMENTAL|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
61956832|NCT06220565|EXPERIMENTAL|"Products for graded exercise interventions Graded Exercise"|Through digital means, patients are able to execute a personalized exercise program based on their rehabilitation plan and incorporate digital assessment methods to receive real-time feedback and recommendations for adjustments. By providing a personalized rehabilitation program and regular telecare, the aim is to focus on the patient's rehabilitation needs in a holistic manner.
62142666|NCT02203032|EXPERIMENTAL|Double-blind ustekinumab|
62142667|NCT02031809||No additional unplanned major surgery|uneventfull intra-operative and postoperative course
62142668|NCT02031809||Additional unplanned major surgery|"Additional per-operative or post-operative unplanned major surgery such as unforeseen pneumonectomy, bilobectomy, lobectomy or additional segmentectomy, repair of major vessels or bronchi, bronchopleural fistula, unplanned surgery to other organs, within 30 days after the primary surgery.~These do not include:~* Conversions without additional unplanned major surgery or suddne blood loss less than 500cc~* Conversions or additional resection for unforeseen oncologic reasons.~* Plasty, repair or sleeve resection of vessels after deliberate resection or transection for oncologic reasons"
62345705|NCT01807260|ACTIVE_COMPARATOR|stepwise Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the stepwise group, the voltage was started at 10 kV and increased stepwise (every 250 shock waves) to 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
62142669|NCT05001659|OTHER|computer simulator|training students ACLS by one computer simulator
62142670|NCT05001659|OTHER|mannequin simulator|training students ACLS by one mannequin simulator
62736649|NCT06547333|EXPERIMENTAL|CM310 150mg Q2W|CM310 is injected subcutaneously (SC) 150 mg each time, once every 2 weeks (Q2W) for a total of 26 doses.
62503587|NCT01074008|PLACEBO_COMPARATOR|Placebo + pegIFN/RBV|Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62503588|NCT05120791|PLACEBO_COMPARATOR|Placebo|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
62702411|NCT05564390|ACTIVE_COMPARATOR|MM1YA-S01 Arm I (cytarabine, daunorubicin)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62702412|NCT05564390|EXPERIMENTAL|MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)|Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62702413|NCT05564390|EXPERIMENTAL|MM1YA-S01 Arm III (azacitidine, venetoclax)|Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62702414|NCT05564390|EXPERIMENTAL|MM1YA-S01 Arm IV (Vyxeos)|Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62702415|NCT05564390|EXPERIMENTAL|MM1YA-S01 Arm V (Vyxeos, venetoclax)|Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
62702416|NCT05564390|ACTIVE_COMPARATOR|MM2YA-EA01 Arm A (cytarabine)|Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
61956833|NCT06220565|PLACEBO_COMPARATOR|Education group|Educational Manual on Exercise Rehabilitation for Patients with Osteoarthritis of the Knee
61956834|NCT06133205|EXPERIMENTAL|intervention group|"In both groups, catgut embedding using disposable single-strand surgical suture Polydioxanone threads was embedded to the following abdominal acupoints: ST-24 (Huaroumen), ST-25 (Tianshu), ST26 (Wailing), REN-12 (Zhongwan), REN-9 (Shuifen), REN-6 (Qihai), REN-4 (Guanyuan) as baseline treatment.~Patients in this arm also received auricular acupressure using ear seeds (Vaccaria seeds) in the following auricular acupoints: Shen Men, Stomach, Endocrine. Those points were chosen due to function that are related to weight loss."
61956835|NCT06133205|SHAM_COMPARATOR|sham group|"In both groups, catgut embedding using disposable single-strand surgical suture Polydioxanone threads was embedded to the following abdominal acupoints: ST-24 (Huaroumen), ST-25 (Tianshu), ST26 (Wailing), REN-12 (Zhongwan), REN-9 (Shuifen), REN-6 (Qihai), REN-4 (Guanyuan) as baseline treatment.~Patients in this arm also received auricular acupressure using ear seeds (Vaccaria seeds) in the following auricular acupoints:Lung, Eye, Ear Apex. The points were selected as control points as there is no clear indication on their ability to contribute to weight loss."
62142671|NCT05062343|ACTIVE_COMPARATOR|Dilapan-S|After randomization, the patient will have Dilapan-S placed via sterile speculum exam with placement of 3-5 rods. The rods will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the rods will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
62503589|NCT05120791|ACTIVE_COMPARATOR|Microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
61956836|NCT05184985|SHAM_COMPARATOR|Placebo|Patients receive a placebo procedure using a sham TrueRelief device that looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
62142672|NCT05062343|ACTIVE_COMPARATOR|Cook Catheter|After randomization, the patient will have the Cook catheter placed via sterile vaginal or speculum exam with the uterine component of the balloon inflated to maximum 60mL. The balloon will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the Cook catheter will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
62142673|NCT06509386|EXPERIMENTAL|Major Depressive Disorder without treatment or role fulfillment|
62142674|NCT06509386|EXPERIMENTAL|Major Depressive Disorder with treatment but no role fulfillment|
61956837|NCT05184985|EXPERIMENTAL|Experimental|Patients receive an experimental procedure using a TrueRelief device.
62142675|NCT06509386|EXPERIMENTAL|Major Depressive Disorder without treatment but with role fulfillment|
62503590|NCT05120791|ACTIVE_COMPARATOR|Beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
62503591|NCT05120791|ACTIVE_COMPARATOR|Combi Microalgae phaeodacytlum and Beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
61956838|NCT01617018||Exposed group|Biotherapy
61956839|NCT01617018||Non-exposed group|Major conventional systemic therapy (methotrexate or cyclosporine)
62503592|NCT01529086||Group 1|"Subjects on Dutasteride that meet the following criteria:~1. . A rise in PSA from nadir at any time post-nadir~2. . PSA change from baselin \>0.2 mg/ml at any time post-baseline~3. . Abnormal DRE at any time post-baseline~4. . Free-PSA \<12% at any time post-baseline~5. . At least one of the above 4 criteria~6. Subjects on Dutasteride that do not meet the above criteria"
62503593|NCT01529086||Group 2|"Subjects on placebo treatment that meet the following criteria:~1. Change from baseline PSA between 0.0 and 0.35 (ie, 0.0 ≤ change from baseline PSA \< 0.35) at any time post-baseline. Note that in REDUCE PSA was recorded to the nearest 0.1.~2. Abnormal DRE at any time post-baseline~3. Change from baseline PSA ≥ 0.35 at any time post-baseline~4. Change from baseline PSA ≥ 0.75 at any time post-baseline~5. PSA ≥ 2.5 at any time post-baseline~6. PSA ≥ 4.0 at any time post-baseline~7. Percent Free PSA \< 12% at any time post-baseline~8. At least one of the above 7 criteria.~9. Subjects on placebo that do not meet the above criteria"
62503594|NCT06678555||Lorlatinib|Patients with ROS1(+) advanced/metastatic NSCLC had been treated with lorlatinib.
62345706|NCT05092880|ACTIVE_COMPARATOR|Standard of care first-line systemic therapy|capecitabine plus anti-VEGF antibody
62345707|NCT05092880|EXPERIMENTAL|Radioembolization|radioembolization of liver with holmium-166 microspheres
62702417|NCT05564390|EXPERIMENTAL|MM2YA-EA01 Arm B (cytarabine, venetoclax)|Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
62702418|NCT05564390|EXPERIMENTAL|MM2YA-EA01 Arm C (Vyxeos, venetoclax)|Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
62702419|NCT05564390|EXPERIMENTAL|MM2YA-EA01 Arm D (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
62142676|NCT06509386|EXPERIMENTAL|Major Depressive Disorder with treatment and role fulfillment|
62702420|NCT05564390|EXPERIMENTAL|Screening (mutation carrier screening)|Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP.
62702421|NCT05564390|EXPERIMENTAL|TAP (SOC treatment, mutation carrier screening)|Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment.
62702422|NCT04830410|EXPERIMENTAL|Fructan powder|2 g of fructan powder 3 times per day for 7 days
62702423|NCT04830410|PLACEBO_COMPARATOR|Placebo|2g of placebo (maltodextrin) 3 times per day for 7 days.
62142677|NCT06509386|EXPERIMENTAL|Schizophrenia without treatment or role fulfillment|
62345708|NCT03780036|EXPERIMENTAL|porous collar|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous, to allow for bone ingrowth and stabilization of the implant.
62345709|NCT03780036|EXPERIMENTAL|porous collar with hydroxyapathite|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous and covered with hydroxyapathite particles, to allow for bone ingrowth and stabilization of the implant.
62702424|NCT06136559|EXPERIMENTAL|Nemtabrutinib|Participants will receive nemtabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.
62702425|NCT06136559|ACTIVE_COMPARATOR|Ibrutinib/Acalabrutinib|Participants will receive investigator's choice of ibrutinib or acalabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.
62714888|NCT06716541|EXPERIMENTAL|Management of anastomotic biliary strictures with biodegradable stents|Initially, a single biodegradable stent is used for treatment of an anastomotic biliary stricture. If needed, this may be followed by usage of another biodegradable stent or plastic stents.
62142678|NCT06509386|EXPERIMENTAL|Schizophrenia with treatment but no role fulfillment|
62142679|NCT06509386|EXPERIMENTAL|Schizophrenia without treatment but with role fulfillment|
62142680|NCT06509386|EXPERIMENTAL|Schizophrenia with treatment and role fulfillment|
62142681|NCT05969600||relapse group|
62142682|NCT05969600||non-relapse group|
61956840|NCT05022082|EXPERIMENTAL|Chest Physiotherapy- Aspiration- Inhaler drugs group|The study group (n=21) will first receive chest physiotherapy (tapotement or vibration) and aspiration, followed by inhaler drug therapy.
61956841|NCT05022082|OTHER|Inhaler drugs- Chest Physiotherapy- Aspiration group|The control group (n=21) will be administered the inhaler drug routinely administered in the intensive care unit where the study is conducted and then receive chest physiotherapy (tapotement or vibration), then nasopharyngeal and oropharyngeal aspiration
61956842|NCT05223244|ACTIVE_COMPARATOR|dimethyl sulfoxide (DMSO)|Six weekly bladder instillations with 50mL of DMSO and 1mL of triamcinolone (10mg/mL)
62142683|NCT06387810|EXPERIMENTAL|Combined treatment group|"After screening and signing informed consent, patients who met the admission requirements received 4 cycles of neoadjuvant therapy with irinotecan liposome II combined with 5-FU/LV and oxaliplatin before surgery.~Surgery was performed within 2 to 4 weeks after the end of neoadjuvant therapy. 4 to 6 weeks after surgery, 4 cycles of postoperative adjuvant therapy with irinotecan liposome II combined with 5-FU/LV and oxaliplatin was performed according to the investigator's judgment (once every 2 weeks, a 2-week cycle)."
62142684|NCT05249153|NO_INTERVENTION|Sufen|PCIA: continue with 0.05ug/kg/h sufentanil, 0.05ug/kg sufentainil bolus
62345710|NCT00205699|ACTIVE_COMPARATOR|aripiprazole|Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.
62345711|NCT00205699|ACTIVE_COMPARATOR|olanzapine|Participants in this group will be randomized to flexibly-dosed treatment with olanzapine.
62345712|NCT00205699|ACTIVE_COMPARATOR|risperidone|Participants in this group will be randomized to flexibly-dosed treatment with risperidone.
62345713|NCT01824264|EXPERIMENTAL|LIK066 2.5 mg|Patients receive 2.5 mg of LIK066 once daily for 12 weeks
62345714|NCT01824264|EXPERIMENTAL|LIK066 5 mg|Patients receive 5 mg of LIK066 once daily for 12 weeks
62345715|NCT01824264|EXPERIMENTAL|LIK066 10 mg|Patients receive 10 mg of LIK066 once daily for 12 weeks
62345716|NCT01824264|EXPERIMENTAL|LIK066 25 mg|Patients receive 25 mg of LIK066 once daily for 12 weeks
62345717|NCT01824264|EXPERIMENTAL|LIK066 50 mg|Patients receive 50 mg of LIK066 once daily for 12 weeks
62345718|NCT01824264|EXPERIMENTAL|LIK066 100 mg|Patients receive 100 mg of LIK066 once daily for 12 weeks
62345719|NCT01824264|EXPERIMENTAL|LIK066 150 mg|Patients receive 150 mg of LIK066 once daily for 12 weeks
62345720|NCT01824264|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Patients receive 100 mg sitagliptin once daily for 12 weeks
62345721|NCT01824264|PLACEBO_COMPARATOR|Placebo|Patients receive placebo for 12 weeks
62345722|NCT02567617|ACTIVE_COMPARATOR|Intervention group|Group receiving capsules with polyphenols.
62345723|NCT02567617|PLACEBO_COMPARATOR|Placebo controlled group|Group receiving capsules with starch.
62345724|NCT01422590|ACTIVE_COMPARATOR|Sitagliptin|
62345725|NCT01422590|ACTIVE_COMPARATOR|Mitiglinide|
62345726|NCT01422590|EXPERIMENTAL|Sitagliptin + Mitiglinide|
62345727|NCT04460417|EXPERIMENTAL|Enhanced care|Participants will take part in an approximate one-hour health and smoking feedback session at the University of Chicago in Dr. King's Clinical Addictions Research Laboratory (CARL). The session will follow the Courage to Quit™ (CTQ) Roadmap program (developed by Dr. King with the Respiratory Health Association). This roadmap shorter version of the larger CTQ program has been specifically designed as an inpatient bedside or outpatient brief intervention guide to assess smoking cessation motivation, consequences of smoking, facts and myths about smoking, barriers to making a change, approved medications, de-bunking myths about medications or treatments without scientific evidence (e-cigarette, laser treatments, herbals, etc.), and gaining social support.
62345728|NCT04460417|ACTIVE_COMPARATOR|Treatment as Usual|"Participants will receive the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information."
62345729|NCT05010525|EXPERIMENTAL|ATG-016-20mg|20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
62345730|NCT05010525|EXPERIMENTAL|ATG-016-35mg|35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
62345731|NCT05010525|EXPERIMENTAL|ATG-016-50mg|50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
62345732|NCT05010525|EXPERIMENTAL|ATG-016-65mg|65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
62345733|NCT02305654|ACTIVE_COMPARATOR|Arm A - Standard Surgery (ILND)|"Part of randomisation 1.~The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery."
62345734|NCT02305654|EXPERIMENTAL|Arm B - neoadjuvant chemotherapy|"Part of randomisation 1.~Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).~Administration on an outpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5~Administration on an inpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3"
62702426|NCT04609046|EXPERIMENTAL|Treatment (rituximab, methotrexate, lenalidomide, nivolumab)|"INDUCTION: Patients receive rituximab IV on day 1, methotrexate IV over 2 hours or PO on day 2, lenalidomide PO daily on days 5-9, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.~MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo MRI, CT, PET/CT, lumbar puncture, bone marrow aspirate and biopsy, testicular ultrasound and ECHO. (See Detailed Description)"
62142685|NCT05249153|EXPERIMENTAL|Sufen with low DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine bolus
62503595|NCT06122155|EXPERIMENTAL|Posterior parietal cortex (PPC)|In the motor adaptation phase, a 20-minute, 2 mA anodal tDCS was delivered through two 5cm x 7cm electrodes using the DC-STIMULATOR MR (neuroConn, Germany). The electrical current gradually ramps up and down in 20 seconds. In the PPC group, the anodal electrode was placed over the P3 or P4 areas on the skull, covering the PPC area on the opposite side of the testing foot (according to the international 10-20 EEG system), and the reference electrode was placed over the supraorbital region on the same side of the testing foot.
61956843|NCT05223244|EXPERIMENTAL|bupivacaine, triamcinolone, and heparin (BTH)|Six weekly bladder instillations with 30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
62345735|NCT02305654|EXPERIMENTAL|Arm C - neoadjuvant chemoradiotherapy|"Part of randomisation 1.~Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.~Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR\>45mls/min."
62345736|NCT02305654|EXPERIMENTAL|Arm P - prophylactic PLND|"Part of randomisation 2.~Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.~Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:~Cisplatin 40mg/m2 will be given weekly, subject to GFR\>45mls/min.~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~1. Any macroscopic tumour or pathological lymph nodes~2. Electively to external iliac nodes in patient with high disease burden~Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone."
61956844|NCT06505564|EXPERIMENTAL|AVATAR therapy|All participants will initially undergo a 12-week waiting period (control period) starting from the initial screening at week 0. Baseline assessments will be conducted at week 12. Subsequently, participants will receive AVATAR therapy for 12 weeks. Post-therapy assessments will be conducted at week 24. Caregivers and therapists will also provide evaluations to gather additional insights into the therapy's impact
61956845|NCT04245852|EXPERIMENTAL|Experimental group|Experimental group will receive standard physical therapy care in addition to being provided a strength education video.
61956846|NCT04245852|ACTIVE_COMPARATOR|Control Group|The control group will receive standard physical therapy care at the University of Illinois at Chicago Faculty Practice.
61956847|NCT03210246|EXPERIMENTAL|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
61956848|NCT03210246|PLACEBO_COMPARATOR|COC + Placebo|COC + Placebo
61956849|NCT03193203|EXPERIMENTAL|Sequence 1|SB4 (etanercept) 50 mg/mL PFS and AI
61956850|NCT03193203|EXPERIMENTAL|Sequence 2|SB4 (etanercept) 50 mg/mL AI and PFS
61956851|NCT03601975|EXPERIMENTAL|anlotinib plus Gemcitabine/Cisplatin|patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
61956852|NCT03601975|PLACEBO_COMPARATOR|placebo plus Gemcitabine/Cisplatin|patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
61956853|NCT03715530|EXPERIMENTAL|Pregnant subjects|These are pregnant women that are admitted to Labor \&Delivery (L\&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
61956854|NCT03715530|ACTIVE_COMPARATOR|Pregnant controls|These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
61956855|NCT03715530|SHAM_COMPARATOR|Non pregnant controls|These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.
61956856|NCT06204601|EXPERIMENTAL|Experimental group|Experimental group
61956857|NCT06204601|NO_INTERVENTION|Control group|Control group
61956858|NCT00256750|ACTIVE_COMPARATOR|Cyclosporine (CsA)|
62702427|NCT05712200|EXPERIMENTAL|Abelacimab (MAA868)|Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
61956859|NCT00256750|EXPERIMENTAL|Belatacept LI (less intensive)|
62345737|NCT02305654|NO_INTERVENTION|Arm Q - Surveillance no prophylactic PLND|"no prophylactic PLND Part of randomisation 2.~For patients who have NOT received neoadjuvant chemoradiotherapy:~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden"
62702428|NCT05712200|PLACEBO_COMPARATOR|Placebo|Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
62714889|NCT06716541|ACTIVE_COMPARATOR|Management of anastomotic biliary strictures with multiple plastic stents in|Multiple plastic stents are used for treatment of an anastomotic biliary stricture.
61956860|NCT00256750|EXPERIMENTAL|Belatacept MI (more intensive)|
61956861|NCT00925093|ACTIVE_COMPARATOR|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
61956862|NCT00925093|ACTIVE_COMPARATOR|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
62736650|NCT06547333|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 26 doses.
61956863|NCT00925093|ACTIVE_COMPARATOR|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
61956864|NCT06313775|ACTIVE_COMPARATOR|Spinal anesthesia|spinal anesthesia : 0.5%hyperbaric bupivacaine 10-15 mg/dose injected at L3-L5
61956865|NCT06313775|EXPERIMENTAL|spermatic cord block|1%Xylocaine with adrenaline (Max 7 mg/kg/dose) divided to inject into each side of the spermatic cord 6-8 ml and infiltration into the scrotal incision area 3-4 ml.
61956866|NCT02194244|EXPERIMENTAL|Granules Fasted|
61956867|NCT02194244|EXPERIMENTAL|Granules Fed|
61956868|NCT02194244|ACTIVE_COMPARATOR|Tablet Fasted|
61956869|NCT02194244|ACTIVE_COMPARATOR|Tablet Fed|
62142686|NCT05249153|EXPERIMENTAL|Sufen with high DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine bolus
62142687|NCT01190852|EXPERIMENTAL|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
61956870|NCT02100514|EXPERIMENTAL|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
61956871|NCT02100514|PLACEBO_COMPARATOR|placebo|
61956872|NCT05607901|ACTIVE_COMPARATOR|Tacrolimus Group|50 patients will be treated with a thin layer of 0.03% topical tacrolimus ointment on the affected areas twice daily for 4 months.
61956873|NCT05607901|ACTIVE_COMPARATOR|Hydrocortisone Group|50 patients will be treated with a thin layer of 1% hydrocortisone cream on the affected areas twice daily for 4 months.
61956874|NCT02098967|EXPERIMENTAL|Acute myeloid leukemia patients|
61956875|NCT02098967|EXPERIMENTAL|Cohort 0|
61956876|NCT02098967|EXPERIMENTAL|Solid tumor patients|
61956877|NCT06505044|EXPERIMENTAL|Group (A)|25 patients receive aerobic exercise attended the program of walking on a treadmill machine for eight weeks according to specific parameters, in addition to their usual daily calcium intake.
62345738|NCT03335956|PLACEBO_COMPARATOR|SAD Part 1 Placebo Cohort 1 Period 1|
62345739|NCT03335956|EXPERIMENTAL|SAD Part 1 Active Cohort Period 1|
62345740|NCT03335956|PLACEBO_COMPARATOR|SAD Part 1 Placebo Cohort 1 Period 2|
62345741|NCT03335956|EXPERIMENTAL|SAD Part 1 Active Cohort 1 Period 2|
62345742|NCT03335956|PLACEBO_COMPARATOR|SAD Part 1 Placebo Cohort 1 Period 3|
62345743|NCT03335956|EXPERIMENTAL|SAD Part 1 Active Cohort 1 Period 3|
62503596|NCT06122155|EXPERIMENTAL|Cerebellum|In the motor adaptation phase, a 20-minute, 2 mA anodal tDCS was delivered through two 5cm x 7cm electrodes using the DC-STIMULATOR MR (neuroConn, Germany). The electrical current gradually ramps up and down in 20 seconds. In the cerebellum group, the anodal electrode was placed 1\~2 cm under and 3\~4 cm lateral to the inion on the same side of the testing foot, with the reference electrode placed on the buccinator on the same side of the testing foot.
61956878|NCT06505044|ACTIVE_COMPARATOR|Group (B)|25 patients receive resisted exercise in addition to their usual daily calcium intake for 12 weeks.
62345744|NCT03335956|PLACEBO_COMPARATOR|SAD Part 2 Placebo Cohort 2 Period 4|
62345745|NCT03335956|EXPERIMENTAL|SAD Part 2 Active Cohort 2 Period 4|
62345746|NCT03335956|PLACEBO_COMPARATOR|SAD Part 2 Placebo Cohort 2 Period 5|
61956879|NCT04563351|ACTIVE_COMPARATOR|conventional inferior alveolar nerve block (IANB)|37 patients received Inferior Alveolar Nerve Block (IANB) for dental treatment of mandibular posterior teeth.
62345747|NCT03335956|EXPERIMENTAL|SAD Part 2 Active Cohort 2 Period 5|
62345748|NCT03335956|PLACEBO_COMPARATOR|SAD Part 2 Placebo Cohort 2 Period 6|
62345749|NCT03335956|EXPERIMENTAL|SAD Part 2 Active Cohort 2 Period 6|
62345750|NCT03335956|PLACEBO_COMPARATOR|MAD Placebo Cohort 1|
62345751|NCT03335956|EXPERIMENTAL|MAD Active Cohort 1|
62345752|NCT03335956|PLACEBO_COMPARATOR|MAD Placebo Cohort 2|
62345753|NCT03335956|EXPERIMENTAL|MAD Active Cohort 2|
62345754|NCT03335956|PLACEBO_COMPARATOR|MAD Placebo Cohort 3|
62345755|NCT03335956|EXPERIMENTAL|MAD Active Cohort 3|
62345756|NCT03335956|PLACEBO_COMPARATOR|MAD Placebo Cohort 4|
62345757|NCT03335956|EXPERIMENTAL|MAD Active Cohort 4|
61956880|NCT04563351|EXPERIMENTAL|Intraligamentary Anesthesia (ILA)|35 patients received Intraligamentary Anesthesia (ILA) for dental treatment of mandibular posterior teeth.
62345758|NCT00671814|EXPERIMENTAL|1|Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
62345759|NCT00671814|PLACEBO_COMPARATOR|2|Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
62345760|NCT00671814|ACTIVE_COMPARATOR|3|Oral doses of 600mg linezolid given twice daily for 21 days.
62345761|NCT01892397|EXPERIMENTAL|Optune (NovoTTF-100A)|The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
61956881|NCT04603456|EXPERIMENTAL|Probiotic Group|consisted of 15 cases who received probiotics only. A drug called Lacteol fort (Rameda Company) . A sachet was taken once daily for three months. Each sachet contains 10 billions lactobacilli.
61956882|NCT04603456|EXPERIMENTAL|SLIT Group|included 15 children who received SLIT for 6 months. Standardized Timothy Grass Pollen (Phleum pratense)
62345762|NCT02874183|EXPERIMENTAL|Pharmacist intervention group|"The intervention group will receive:~1. A phone call 48h-72h after discharge from the hospital to ensure that the patient filled their prescriptions and started taking their medication.~2. A phone call five to seven days after discharge to reinforce the education using the teach back technique1. Patients will be asked about their medications, what are they for, how to use them, and what side effects to watch for, based on the education and information that was provided to them at discharge."
62345763|NCT02874183|NO_INTERVENTION|usual care group|The control group will receive the usual standard care available at West Kendall Baptist Hospital.
62345764|NCT00641524|OTHER|treatment|Iron depletion via phlebotomy
62345765|NCT04913415|OTHER|Low Suction Strategy of Chest Tube Management|
62503597|NCT06122155|SHAM_COMPARATOR|Sham|In the motor adaptation phase, a 20-minute, 0 mA anodal tDCS was delivered through two 5cm x 7cm electrodes using the DC-STIMULATOR MR (neuroConn, Germany) for the sham group. Participants were informed that they might experience itchiness, burning, or mild discomfort during the tDCS period regardless of which group they were assigned to, so they would not use their sensation as a basis for determining whether they received actual stimulation or not.
61956883|NCT04603456|EXPERIMENTAL|Combined treatment Group|included 15 children who received probiotics and SLIT. A drug called Lacteol fort was administered A sachet was taken once daily for 3 months . Standardized Timothy Grass Pollen was taken for 6 months
61956884|NCT06312345|EXPERIMENTAL|Experimental: ciprofol|
61956885|NCT06312345|PLACEBO_COMPARATOR|Placebo Comparator: propofol|
62142688|NCT01190852|ACTIVE_COMPARATOR|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
62142689|NCT01190852|ACTIVE_COMPARATOR|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
62142690|NCT05483088||Patients with KDIGO stage 2 or 3 AKI|
62142691|NCT03627637|EXPERIMENTAL|Experimental: Soy nuts|
62345766|NCT04913415|OTHER|Standard Suction Strategy of Chest Tube Management|
62345767|NCT05875558|EXPERIMENTAL|M-TACE|
62345768|NCT02557854|EXPERIMENTAL|Doxil + MR-HIFU Hyperthermia|Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
62345769|NCT04565366||Spinal Cord Injury|Individuals recently admitted to hospital and diagnosed with acute, traumatic spinal cord injury.
62345770|NCT04565366||Trauma Control|Individuals recently admitted to hospital and diagnosed with an acute, traumatic injury that is not spinal cord injury.
62345771|NCT04565366||Healthy Control|Generally healthy individuals not recently diagnosed with an acute, traumatic injury (including spinal cord injury).
62345772|NCT06087952|OTHER|Continue anticoagulation|Patients with high recurrent VTE risk and low major bleeding risks are advised to continue anticoagulant therapy.
61956886|NCT05728905|EXPERIMENTAL|Therapeutic exercise|The patients assigned to this group performed a self-treatment program that included three coordination exercises, two post-isometric relaxation (contraction-relaxation) and one self-traction. All exercises were performed in front of a mirror. It was performed every 3 hours, 5 times a day, for 4 weeks. The patient was instructed and supervised by a physiotherapist until they were executed correctly. All participants were provided with a video where the procedure and dosage of each exercise was described in detail.
61956887|NCT05728905|EXPERIMENTAL|Therapeutic exercise + orthopedic manual therapy|The patients assigned to this group performed the exercise program and also received a manual therapy treatment applied by a physiotherapist. Two sessions were held per week for 4 weeks (8 sessions). Treatment consisted of traction, mobilization, and friction massage of the muscles of mastication.
61956888|NCT05728905|NO_INTERVENTION|Control|The patients assigned to this group did not receive any type of intervention during the 4 weeks. They were asked not to change their habits or receive any other type of treatment.
61956889|NCT02157987|EXPERIMENTAL|bevacizumab|bevacizumab spray
61956890|NCT04765956|EXPERIMENTAL|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
61956891|NCT03187275|EXPERIMENTAL|Swedish Massage Therapy|Participants in this arm will receive Swedish massage, which is the most commonly offered and best-known type of massage.
61956892|NCT03187275|ACTIVE_COMPARATOR|Light Touch Intervention|Participants in this arm will receive light touch only.
61956893|NCT04590222||Female, BMI≥30, mild|"Females:~Obese BMI≥30 With Mild infection n = 10"
61956894|NCT04590222||Female, BMI≥30, severe|"Females:~Obese BMI≥30 With severe infection n = 10"
62503598|NCT05303961|EXPERIMENTAL|SA001|"Part 1: 24 subjects are assigned to single dose groups(240mg, 480mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1:1 and receiving each dose of SA001 in the period 1.~Part2: 18 subjects are assinged to multiple dose groups(360mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1 and receiving each dose of SA001."
62503599|NCT05303961|ACTIVE_COMPARATOR|Rebamipide|Part 1: 12 subjects are assigned to single dose groups(200mg, 600mg of Rebamipide) in a ratio of 1:1 and receiving each dose of Rebamipide in the period 2.
61956895|NCT04590222||Female, BMI<30, mild|"Females:~Non-Obese BMI\<30 With Mild infection n = 10"
61956896|NCT04590222||Female, BMI<30, severe|"Females:~Non-Obese BMI\<30 With severe infection n = 10"
61956897|NCT04590222||male, BMI≥30, mild|males: Obese BMI≥30 With Mild infection n = 10
61956898|NCT04590222||male, BMI≥30, severe|males: Obese BMI≥30 With severe infection n = 10
61956899|NCT04590222||male, BMI<30, mild|males: Non-Obese BMI\<30 With Mild infection n = 10
61956900|NCT04590222||male, BMI<30, severe|males: Non-Obese BMI\<30 With severe infection n = 10
61956901|NCT04590222||Healthy donors from the EFS (Etablissement Français du Sang, St Louis)|Healthy donors from the EFS (Etablissement Français du Sang, St Louis) including 5 men and 5 women
62503600|NCT05303961|PLACEBO_COMPARATOR|Placebo|"Part 1: 8 subjects receiving a single dose of Placebo in the period 1.~Part2: 6 subjects receiving multiple dose of Placebo."
62714890|NCT01920490|EXPERIMENTAL|GUILT-INCREASE-CORRELATION|Patients in this group will receive visual feedback that reinforces increasing the correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will reinforce stabilization of the preceding degree of correlation.
61956902|NCT02049424||transplanted patients|T-repleted haploidentical transplanted patients in Italy
61956903|NCT03484091|EXPERIMENTAL|H group|Single dose of Hyruan-One 3 mL intra-articular knee injection.
61956904|NCT03484091|ACTIVE_COMPARATOR|S group|Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.
61956905|NCT03484091|PLACEBO_COMPARATOR|N group|Single dose of normal saline 6 mL intra-articular knee injection.
61956906|NCT04437186|EXPERIMENTAL|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
61956907|NCT04437186|NO_INTERVENTION|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
61956908|NCT00288054|EXPERIMENTAL|Cetuximab + Radiotherapy (no Docetaxel)|
61956909|NCT00288054|EXPERIMENTAL|Cetuximab + Radiotherapy + Docetaxel|
61956910|NCT05045014||Patient group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task. In addition, X-ray images taken during routine follow-ups will be used to determine the location, type of curvature and Cobb angle of the scoliosis. The degree of rotation will be measured with a mobile application called Scoliodetector. Quality of life is planned to be evaluated with the Scoliosis Research Society-22 questionnaire.
61956911|NCT05045014||Control group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task.
61956912|NCT01550289|EXPERIMENTAL|Group 1: CYD dengue vaccine|Subjects will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.
61956913|NCT01550289|PLACEBO_COMPARATOR|Group 2: Placebo|Subjects will receive a dose of placebo at 0, 6, and 12 months, respectively
62503601|NCT03895229|EXPERIMENTAL|Experimental Arm|Subjects will receive a single oral dose of Empagliflozin 10 MG Oral Tablet \[Jardiance\]
62503602|NCT04316195||Patient admitted for an acute traumatic spinal cord injury|
62503603|NCT00879541|OTHER|PK Biostate® [SP]|"Part 1: PK subjects are randomized to receive Biostate® \[SP\] either on Day 1 or Day 8.~Part 3: All PK subjects receive Biostate® \[SP\] on Day 180."
61956914|NCT04389853|ACTIVE_COMPARATOR|Flexible ureteroscopy (fURS)|Retrograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
61956915|NCT04389853|ACTIVE_COMPARATOR|Mini-percutaneous nephrolithotomy (mini-PCNL)|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs)4
61956916|NCT04103658|NO_INTERVENTION|Standard of care (control)|This will be the standard of care group. The excision of the non-melanoma skin cancer will be based on standard visual inspection with 4-6mm margins.
61956917|NCT04103658|EXPERIMENTAL|NIR heating|This will be the NIR heating group, where the excision of the non-melanoma skin cancer will be based on the lesion margins based on the application of near-infrared radiation (with 4-6mm margins).
61956918|NCT03268369|ACTIVE_COMPARATOR|Control group|
61956919|NCT03268369|EXPERIMENTAL|Non lesional diurnal partial epilepsy|
62702429|NCT03271151|EXPERIMENTAL|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
62702430|NCT03271151|PLACEBO_COMPARATOR|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
62702431|NCT02153957|EXPERIMENTAL|1|enhanced PA home intervention group for the first 12 weeks; followed by 12 weeks of PA maintenance on their own.
62702432|NCT02153957|ACTIVE_COMPARATOR|2|usual physical activity (no intervention) for 12 weeks; followed by the enhanced PA home intervention for 12 weeks.
61956920|NCT03268369|EXPERIMENTAL|Idiopathic generalized epilepsy|
61956921|NCT03268369|EXPERIMENTAL|Nocturnal frontal lobe epilepsy|
61956922|NCT03268369|EXPERIMENTAL|Epileptic patients with Vagus Nerve Stimulation (VNS)|
61956923|NCT00999089|ACTIVE_COMPARATOR|CCAB|Conventional Coronary Artery Bypass
62142692|NCT03627637|NO_INTERVENTION|Control - no soy nuts|
62142693|NCT05328466|EXPERIMENTAL|video game in CP children|Children in this arm will play the computer game which was developed by the researcher team 3 session/weeks for 5 weeks. Each session will last for 40 minutes.
62142694|NCT05328466|NO_INTERVENTION|Conventional therapy|children in this arm will receive a conventional program by occupational therapists 3 times/week for 5 weeks. Each session will last for 40 minutes.
61956924|NCT00999089|ACTIVE_COMPARATOR|OPCAB|Off-Pump Coronary Artery Bypass
61956925|NCT00999089|ACTIVE_COMPARATOR|PACAB|Pump-Assisted Coronary Artery Bypass
61956926|NCT05160493|EXPERIMENTAL|S-ketamine and pregabalin|"Drug: S-ketamine and pregabalin~* Drug: Pregabalin 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
61956927|NCT05160493|PLACEBO_COMPARATOR|Normal saline and placebo capsule|"Drug: Normal saline and placebo capsule~* Drug: Placebo capsules :Two placebo capsules(2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline• 0.9% saline bolus after induction of anesthesia +intravenous infusion for 48 hours"
61956928|NCT00647881|EXPERIMENTAL|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
61956929|NCT00647881|ACTIVE_COMPARATOR|2|Paxil CR™ Tablets 25 mg
62142695|NCT03577106|EXPERIMENTAL|Transcranial magnetic stimulation (TMS)|
61956930|NCT05191771|EXPERIMENTAL|Investigational product|
61956931|NCT05191771|ACTIVE_COMPARATOR|Comparator|
61956932|NCT02527005|ACTIVE_COMPARATOR|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
62142696|NCT06075082|EXPERIMENTAL|Sleep positional therapy by using the LEFT smartwatch app|
62142697|NCT06318559|EXPERIMENTAL|3D group|"in Group 3D, an intrafascial nerve-sparing (NS) technique will be performed on the side of the lesion; contralaterally an intra-, inter- or extra-fascial NS technique will be performed. After removal of the prostate, virtual images of the prostate will be projected into the lodge using AI software and will be displayed thanks to the Tile-Pro. The virtual 3D model will allow identifying the extracapsular extension of the tumor lesion, projected at the level of the preserved neurovascular bundle.~A first selective excisional biopsy at the level of the suspected ECE on the NVB will be sent for extemporaneous histological examination. Under 3D AR guidance, a second selective biopsy will then be performed on the NVB at the same level as the first, however involving a larger and thicker layer of tissue. the biopsies will be sent for extemporaneous histological examination. In case of positivity, the entire NVB will be removed"
62702433|NCT06246643|EXPERIMENTAL|Regorafenib|Adult and pediatric patients from completed Bayer-sponsored regorafenib trials who are benefiting from regorafenib treatment.
62702434|NCT06584799|ACTIVE_COMPARATOR|Group 1|Group will include 50 patients, which will be treated by MPFF 1000 mg once daily for 2 months
62702435|NCT06584799|ACTIVE_COMPARATOR|Group 2|Group will include 50 patients which will be treated by Diosmin 600 mg once daily for 2 months
62702436|NCT06584799|ACTIVE_COMPARATOR|Group 3|Group will include 50 patients which will be treated by combination Hespiridin+Diosmin 1000 mg once daily for 2 months
62702437|NCT04439253|EXPERIMENTAL|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61956933|NCT02527005|ACTIVE_COMPARATOR|Sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets every 4 weeks for 3 doses
61956934|NCT05789160|EXPERIMENTAL|the MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
61956935|NCT05789160|NO_INTERVENTION|the waiting-list group|no treatment.
61956936|NCT05999929|EXPERIMENTAL|Memory Support System participants|
61956937|NCT04365296|EXPERIMENTAL|Aerobic group|This group will include 30 burned patients who will receive aerobic exercises 8 weeks (3times/week) in form of treadmill exercise in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
61956938|NCT04365296|EXPERIMENTAL|Resistance group|This group will include 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
61956939|NCT05379738|EXPERIMENTAL|adapted physical activity|6 sessions of physical activity
61956940|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
61956941|NCT03078049||Sitagliptin|Patients take sitagliptin
61956942|NCT02140086|EXPERIMENTAL|Buteyko based Remedial Breathing Therapy|Buteyko based Remedial Breathing Therapy
61956943|NCT02140086|NO_INTERVENTION|Waiting List|Training in the course of the study
61956944|NCT02059395|ACTIVE_COMPARATOR|Time based|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course
62345773|NCT06087952|OTHER|Discontinue anticoagulation|Patients with low recurrent VTE risk are advised to discontinue anticoagulant therapy.
61956945|NCT02059395|EXPERIMENTAL|Mastery based|Participants do follow the content of the Canadian Heart and Stroke Foundation Heartsaver Course content based on their own pace (timeframe)
62345774|NCT06087952|OTHER|Randomised to continue anticoagulation|Patients with intermediate recurrent VTE risk or high recurrent VTE risk and high major bleeding risk are randomised to continue or discontinue anticoagulant therapy.
61956946|NCT05789810|EXPERIMENTAL|Manuel pressure group|10-second manual pressure was applied on the insulin injection area. The injection point was pressed by the diabetes nurse's right thumb over the site until resistance was felt and the pressure was then maintained for 10 seconds before the insulin injection. Then insulin injection was administered.
61956947|NCT05789810|EXPERIMENTAL|ShotBlocker group|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
62503604|NCT00879541|OTHER|PK Biostate® [RP]|Part 1: PK subjects are randomized to receive Biostate® \[RP\] either on Day 1 or Day 8.
62503605|NCT00879541|EXPERIMENTAL|Efficacy|Part 2: This arm includes all subjects during the efficacy component of the study.
62503606|NCT03723837|ACTIVE_COMPARATOR|Study Arm A|Children {Age \> 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
62503607|NCT03723837|ACTIVE_COMPARATOR|Study arm B|Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month
61956948|NCT05789810|EXPERIMENTAL|Control group:|No intervention was performed to reduce pain and fear.
61956949|NCT06075862||Patients with lumbar spinal stenosis|Patients diagnosed with lumbar spinal stenosis and referred to operation. Balance will be measured once in this group before operation, and four times again after operation.
61956950|NCT00714441|ACTIVE_COMPARATOR|2|Computer Automated Self-Management (CASM). Please see description below for CASM.
61956951|NCT00714441|ACTIVE_COMPARATOR|3|Computer Automated Self-Management and Problem Solving Therapy (CAPS). Please see descriptions below for CAPS (also refer to CASM with is included in the CAPS program).
61956952|NCT00714441|ACTIVE_COMPARATOR|1|Lifestyle and Activities Education Program (LEAP-AHEAD). Please see description below for LEAP-AHEAD.
62142698|NCT06318559|ACTIVE_COMPARATOR|no3D group|"For the no-3D group, the intra-, inter- or extra-fascial NS technique during robotic prostatectomy will be performed according to the clinical indication.~At the end of the demolitive phase a selective biopsu was performed in a cognitive fashion accordin with the information provided by MRI images.~Reconstructive phase was performed according to our previously described total anatomical reconstruction (TAR) technique for both arms."
62142699|NCT05075499|ACTIVE_COMPARATOR|MS no immunomodulatory treatment|MS patients receiving no immunomodulatory treatment
62142700|NCT05075499|ACTIVE_COMPARATOR|MS Teriflunomide treatment|MS patients under treatment with Teriflunomide
62142701|NCT05075499|ACTIVE_COMPARATOR|MS Alemtuzumab treatment|MS patients under treatment with Alemtuzumab
62142702|NCT05462067|ACTIVE_COMPARATOR|Binocular EDOF IOL|Binocular EDOF IOL for treatment of cataract
61956953|NCT01507298||Capsule endoscopy|
61956954|NCT01507298||24 hour oesophageal pH study|
62345775|NCT06087952|OTHER|Randomised to discontinue anticoagulation|Patients with intermediate recurrent VTE risk or high recurrent VTE risk and high major bleeding risk are randomised to continue or discontinue anticoagulant therapy.
62345776|NCT04392206|EXPERIMENTAL|Adipose Derived Mesenchymal Stem Cells|Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment.
62345777|NCT04994652|EXPERIMENTAL|Videolaryngoscope|Intubation attempted with C-MAC videolaryngoscope
62345778|NCT04994652|ACTIVE_COMPARATOR|Standard laryngoscope|Intubation attempted with standard laryngoscope
62345779|NCT06072859|ACTIVE_COMPARATOR|Group 1|Humidified Forest Oils with Limonene
62503608|NCT06427044|EXPERIMENTAL|Anterior serratus block group|Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
61956955|NCT03292562|ACTIVE_COMPARATOR|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
61956956|NCT03292562|ACTIVE_COMPARATOR|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
61956957|NCT03339908|EXPERIMENTAL|patients with Multiple Sclerosis|Patients will benefit from unilateral thalamotomy by Gamma Knife radiosurgery
61956958|NCT03931161|PLACEBO_COMPARATOR|Placebo|Matching Placebo.
61956959|NCT03931161|ACTIVE_COMPARATOR|Evolocumab|Evolocumab Auto-Injector \[Repatha\]
62702438|NCT02167867|EXPERIMENTAL|Lay End Users|Employees of the test sites (that were fitness centers or spas) who were provided with a User's Manual to operate the ZERONA Z6 to administer 6 40-minute evenly spaced treatments over 2 consecutive weeks to the front and back of the waist, hips and thighs of one Treatment Subject.
61956960|NCT01682109|EXPERIMENTAL|new paediatric valacyclovir formulation|Newly developed formulation
61956961|NCT01682109|ACTIVE_COMPARATOR|reference valacyclovir formulation|Formulation derived from FDA label information
61956962|NCT01734356|OTHER|inherited arrhythmias|6 patient with inherited arrhythmias
62345780|NCT06072859|ACTIVE_COMPARATOR|Group 2|Humidified Forest Oils with Limonene \& Virtual Reality using a Surface Pro tablet with headphones to experience walking on a forest path and ambient forest sounds.
61956963|NCT01734356|OTHER|valvulopathies|6 patient with valvulopathies
61956964|NCT01734356|OTHER|controle|8 healthy people for these pathologies
62345781|NCT04260061|EXPERIMENTAL|exoskeleton group|The Hand of Hope therapy device will be used in this group. The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
62503609|NCT06427044|NO_INTERVENTION|Control group|
61956965|NCT01920321|EXPERIMENTAL|Endoscopic lung volume reduction|After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
61956966|NCT03721744|EXPERIMENTAL|GB201+Paclitaxel+Gemcitabine|"Patients randomized to Arm 1 will receive GB201 in combination with weekly paclitaxel and low-dose gemcitabine, with one treatment cycle defined as 4 weeks (28 days). GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine.~Paclitaxel and low-dose gemcitabine will be administered on Days 1, 8 and 15 of every 28-day cycle."
61956967|NCT03721744|ACTIVE_COMPARATOR|Standard of care treatment options|Patients randomized to Arm 2 will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5- FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC). Patients who have failed gemcitabine previously and were randomized to Arm 2 will not be eligible to receive gemcitabine as a treatment option.
62142703|NCT05462067|EXPERIMENTAL|Combined Edof and Trifocal IOL|Combined EDOF and Trifocal IOL - EDOF in the distance dominant eye / Trifocal in the non-dominant eye
62503610|NCT06417151||Healthy children between the ages of 5 months and 6 years of Polish nationality|
62503611|NCT00985231|EXPERIMENTAL|PureVision Multi-Focal contact lenses|
62503612|NCT00985231|ACTIVE_COMPARATOR|SofLens59 contact lens|
62503613|NCT02671682|EXPERIMENTAL|Immunoadsorption|Immunoadsorption on 5 consecutive days with protein A columns and 2,5-fold patient's plasma volume
61956968|NCT01783262|ACTIVE_COMPARATOR|Extracorporeal shock wave therapy|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
61956969|NCT01783262|PLACEBO_COMPARATOR|sham extracorporeal shock wave therapy|The second grouop of patients received 0.04 mJ/mm2, 2400 pulses once a week for 4 weeks.
61956970|NCT02229370||ECAA|all patients diagnosed with an extracranial carotid artery aneurysm
61956971|NCT00842608|EXPERIMENTAL|Haloperidol Eligible Intervention|0.5-1mg Haloperidol Q8h for 7 days, reduced exposure to anticholinergics, reduced exposure to benzodiazepines
61956972|NCT00842608|ACTIVE_COMPARATOR|Haloperidol Eligible Usual Care|Usual care
61956973|NCT00842608|EXPERIMENTAL|Haldol-Ineligible Arm|"Haldol-Ineligible arm for patients with contraindications for Haldol, unresolvable prolonged QTc, history of torsades de pointes, or history of seizures.~Patients are randomized and will still receive:~reduced exposure to anticholinergics, reduced exposure to benzodiazepines"
61956974|NCT00842608|ACTIVE_COMPARATOR|Haldol Ineligible Usual Care|Usual Care
61956975|NCT01965301|EXPERIMENTAL|BP1.5375|Single oral administration ranging from 0.5 mg to 100 mg
61956976|NCT01965301|ACTIVE_COMPARATOR|Diphenhydramine|Single oral dose of diphenhydramine 50mg
61956977|NCT01965301|PLACEBO_COMPARATOR|Placebo|Single oral dose
61956978|NCT02872207|EXPERIMENTAL|Suncare agent 1 + control|Application of control and test product into one of the subjects two eyes.
61956979|NCT02872207|EXPERIMENTAL|Suncare agent 2 + control|Application of control and test product into one of the subjects two eyes.
61956980|NCT01617200|EXPERIMENTAL|Asenapine 2.5 mg BID|
61956981|NCT01617200|EXPERIMENTAL|Asenapine 5 mg BID|
61956982|NCT01617200|ACTIVE_COMPARATOR|Olanzapine 15 mg QD|
61956983|NCT01617200|EXPERIMENTAL|Placebo switched to Asenapine 2.5 mg BID|
62142704|NCT01201772|ACTIVE_COMPARATOR|Prasugrel 60mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
62503614|NCT02671682|ACTIVE_COMPARATOR|Plasmapheresis|Plasmapheresis on 5 consecutive days with 2l plasma exchange
61956984|NCT02862171|EXPERIMENTAL|Dapivirine Vaginal Ring-004|Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.
61956985|NCT03482544|ACTIVE_COMPARATOR|Pregabalin Group|We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
61956986|NCT03482544|ACTIVE_COMPARATOR|Control Group|In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
61956987|NCT04229784|EXPERIMENTAL|RF ARM|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
61956988|NCT03228264|EXPERIMENTAL|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
61956989|NCT03228264|ACTIVE_COMPARATOR|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
61956990|NCT02131207||Diagnostic (MRI and biopsy)|Participants undergo pelvic magnetic resonance imaging (MRI). Within 1-2 weeks, patients undergo scheduled prostate biopsy.
62503615|NCT06616519|EXPERIMENTAL|BenQ Materials MSENCI lenses|BenQ Materials Daily disposable contact lens wears for 1 month
62503616|NCT06616519|ACTIVE_COMPARATOR|Visco Oxypure lens|
62503617|NCT03212378||CHIP 1 - low risk patients|
61956991|NCT04102787|EXPERIMENTAL|experimental group|Experimental group who received the Cardiac educational program and will be applied for Coronary Artery Disease patients, and measure the level of knowledge and satisfaction in pre and post test.
62503618|NCT03212378||CHIP 2 - medium risk patients|
62503619|NCT03212378||CHIP 3 - high risk patients|
62503620|NCT01863186|ACTIVE_COMPARATOR|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
62503621|NCT01863186|ACTIVE_COMPARATOR|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
62503622|NCT01863186|PLACEBO_COMPARATOR|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
62503623|NCT01863186|OTHER|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
62503624|NCT06396637|EXPERIMENTAL|Treatment arm|PD-1 Antibody combined with Sapropterin Dihydrochloride
62503625|NCT04608201|EXPERIMENTAL|NICOTINE transdermal patch|NICOTINE 7 mg / 24h, transdermal patch
62503626|NCT04608201|PLACEBO_COMPARATOR|Placebo of NICOTINE transdermal patch|Placebo of nicotine patch
61956992|NCT04102787|NO_INTERVENTION|control group|Control group who received the usual care and measure the level of knowledge and satisfaction in pre and post test.
61956993|NCT03013738|EXPERIMENTAL|Growing Pro-Social (GPS) program|"The Growing Pro-Social (GPS) program is a cognitive-behavioral group program for offenders. GPS is based on schema therapy, which conceptualizes aggressiveness as a result of a distorted view of the self and of the others. The ultimate goal of the GPS is to promote change in dysfunctional core beliefs about the self and the others.~GPS consists of 40 sessions, each lasting about 90 minutes. Sessions must be carried out by two therapists who should be skillful in schema therapy. Sessions are grouped into five modules: (1) human communication, (2) interpersonal relationships, (3) cognitive distortions, (4) function and meaning of emotions, and (5) early maladaptive schemas.~The treatment group attended the GPS program in addition to the Treatment AsUsual (TAU) delivered at Portuguese prisons."
61956994|NCT03013738|OTHER|Treatment As Usual|Subjects in this group received Treatment As Usual in Portuguese prisons (supervision of school frequency, occupational and job-related tasks and sentence planning supervision over time) and did not attend the GPS program or any other structured program during the research period.
61956995|NCT06201741|EXPERIMENTAL|[131I]/[18F]/[68Ga]ZT-111|\[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
61956996|NCT04158297|ACTIVE_COMPARATOR|ESWL|Extracorporeal shock wave lithotripsy for the treatment of pancreatic duct stones
62142705|NCT01201772|ACTIVE_COMPARATOR|Prasugrel 30mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
62142706|NCT01201772|NO_INTERVENTION|Prasugrel 10mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
62503627|NCT05302219|EXPERIMENTAL|Measurement of plethysmography curve|Calm measurement of plethysmography curve using pulse oximetry with simultaneous monitoring of the breath cycle. In this experimental arm, participants will vary their breath cycle (different respiratory rates and different tidal volumes).
62503628|NCT04868565|EXPERIMENTAL|ongoing caffeine with oxygen supplement (group 1)|"samples assigned to the ongoing caffeine with oxygen supplement (group 1) will continue caffeine administration combining with oxygen supplement until the patients are weaned from oxygen."
62503629|NCT04868565|ACTIVE_COMPARATOR|discontinuing caffeine with oxygen supplement (group 2)|"samples assigned to the discontinuing caffeine with oxygen supplement (group 2) will discontinue caffeine immediately after randomization, while oxygen supplement is going on."
62503630|NCT02503813|EXPERIMENTAL|Experimental|Venous blood gas will be obtained at the same time points as arterial blood gas in the apnea challenge test.
62503631|NCT01133236|EXPERIMENTAL|Salt and Fluid|Intervention: Fluid 800 Ml and Salt 2 g per day Control: FLuid and Salt Free
62736651|NCT03076060|EXPERIMENTAL|Migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of VLCKD by meal replacements poor in fats and carbohydrates."
61956997|NCT04158297|ACTIVE_COMPARATOR|SOPIL|Single Operator Pancreatoscopy and intraductal lithotripsy for the treatment of pancreatic duct stones
62702439|NCT02167867|EXPERIMENTAL|Treatment Subject Group|Treatment subjects received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) laser diodes.
61956998|NCT00228384|ACTIVE_COMPARATOR|Gore VIABAHN Endoprosthesis|
61956999|NCT00228384|ACTIVE_COMPARATOR|Bare Nitinol Stent (BNS)|
61957000|NCT01178957||Type 1 diabetes|
61957001|NCT00569881||1|Corneal epithelial wound healing with moxifloxacin
61957002|NCT00569881||2|Corneal epithelial wound healing with gatifloxacin
61957003|NCT05776615|EXPERIMENTAL|Mobile Application Group|"In the collection of Mobile Application data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months. Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Detection Questionnaire in the Neonatal Intensive Care Unit; System Availability Scale will be applied."
61957004|NCT05776615|NO_INTERVENTION|Control group|"Participants included in the control group, Nurse Descriptive Characteristics form; Nursing Diagnoses Perception Scale, Missing Nursing Care Detection Questionnaire will be applied in the Neonatal Intensive Care Unit. Nursing Diagnoses Perception Scale at the end of the 1st month and at the end of the 3rd month; The Missing Nursing Care Identification Questionnaire will be applied again in the Neonatal Intensive Care Unit, and the System Usability Scale will not be applied to the control group."
62142707|NCT02903875||laryngectomised patients since 1 month|laryngectomised patients since 1 month and their close relative
62142708|NCT02903875||laryngectomised patients since 3 months|laryngectomised patients since 3 months and their close relative
62142709|NCT02903875||laryngectomised patients since 6 months|laryngectomised patients since 6 months and their close relative
62142710|NCT02903875||laryngectomised patients since 12 months|laryngectomised patients since 12 months and their close relative
61957005|NCT05466656|EXPERIMENTAL|Quasi-experimental uncontrolled, before-and-after.|The intervention will consist of the use of a continuous quality improvement cycle model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.
62142711|NCT05820763|EXPERIMENTAL|Consolidation: Selinexor, Lenalidomide, and Dexamethasone|Consolidation will begin between Days 80 and 140 following standard of care autologous hematopoietic stem cell transplant and the treatment will consist of selinexor, lenalidomide, and dexamethasone for 4 28-day cycles.
62503632|NCT01811368|EXPERIMENTAL|Treatment (ibritumomab tiuxetan, allogeneic PBSCT)|"CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28."
62503633|NCT06678204|EXPERIMENTAL|Optimized illustrated pamphlets|Participants in the experimental group received optimized illustrated educational pamphlets designed to enhance understanding of self-care during radiation therapy (RT). These pamphlets included images with key text highlights tailored for better cognitive retention. Pretests were administered before the start of treatment, and posttests were conducted two weeks after the completion of RT.
62503634|NCT00566280|OTHER|Molecular Breast Imaging|
62702440|NCT06191549|EXPERIMENTAL|To explore the effect of brain stimulation on locomotor skill acquisition in stroke survivors|To explore the trends of locomotor skill acquisition in stroke survivors after anodal tDCS (a-tDCS, real brain stimulation), stroke survivors after sham tDCS (s-tDCS), and stroke with no brain stimulation (control; CON).
61957006|NCT01919593|EXPERIMENTAL|2% Chlorhexidine Gluconate|apply 2% Chlorhexidine Gluconate in 70% Alcohol on skin before venipuncture
61957007|NCT01919593|ACTIVE_COMPARATOR|10% povidone iodine|apply 10% povidone iodine on the skin before venipuncture
62142712|NCT05820763|EXPERIMENTAL|Maintenance: Selinexor and Lenalidomide|Maintenance will consist of selinexor and lenalidomide for a maximum of 8 28-day cycles.
62142713|NCT06412094|SHAM_COMPARATOR|Standard care|Upon enrollment in the study at the end of the screening visit, participants in all groups receive a recommended treatment plan, according to the clinical severity of the AD, and. are instructed to contact the doctor via messenger for any questions related to their treatment.
62142714|NCT06412094|ACTIVE_COMPARATOR|"Standard care with access to the AtopicApp mobile application"|"Subjects in the experimental and observational groups receive access to the AtopicApp mobile application, in addition to receiving standard medical care."
62142715|NCT06412094|EXPERIMENTAL|"Standard care with access to the AtopicApp mobile application with potential virtual oversight"|The experimental group receives standard medical care, the AtopicApp mobile application, and information about doctor's virtual oversight through the app (monitoring registration and usage).
61957008|NCT03862222||Cognitively normal - low risk|Adults aged 55-80 without subjective memory complaints, family history of Alzheimer's disease, or genetic risk for Alzheimer's disease.
61957009|NCT03862222||Cognitively normal - high risk|Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer's disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer's disease
61957010|NCT03862222||mild cognitive impairment|Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
61957011|NCT03862222||mild dementia|Adults aged 55-80 with mild dementia due to probable Alzheimer's disease.
61957012|NCT01944605||Cardiac Arrest patients undergoing Therapeutic Hypothermia|Cardiac Arrest subjects with Return Of Spontaneous Circulation (ROSC) and undergoing treatment with Therapeutic Hypothermia will undergo sampling of blood, stool, and expired gas data at physiologically predetermined time points.
62503635|NCT06198647|EXPERIMENTAL|tui-na|Application of tui-na techniques for the women while being in prone lying position.
62702441|NCT06191549|EXPERIMENTAL|To explore improvements in learning capacity between healthy adults and stroke participants.|Compare stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group.
61957013|NCT03915821|EXPERIMENTAL|Patients diagnosed as major depression according to DSM V|"All patients presented with major depression disorder not received ECT previously within 6 monthes, admitted to the study site ( Psychiatry department, in Assiut University Hospital, Assiut, Egypt). They Fulifilled will be recruited within 6 monthes duration .~The patients classified into group A comprised that will be treated with Unipolar ECT, and group B comprised that will be treated Biploar ECT."
61957014|NCT02468232|EXPERIMENTAL|LCZ696|Before randomization, all patients received 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm started with 100 mg twice daily (b.i.d.) for 4 weeks. Patients were then up-titrated to 200 mg b.i.d. at week 4 if they were tolerant to 100 mg b.i.d. Total duration of treatment was up to approximately 40 months.
61957015|NCT02468232|ACTIVE_COMPARATOR|Enalapril|Before randomization, all patients received 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind period, all randomized patients in this arm received enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients were then up-titrated to 10 mg b.i.d. at week 4 if they were tolerant to 5 mg b.i.d. Total duration of treatment was up to approximately 40 months.
61957016|NCT02215187|EXPERIMENTAL|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
61957017|NCT02215187|SHAM_COMPARATOR|Attention Control|Attention/social contact control. Health education (non-skill focused).
61957018|NCT04092582|EXPERIMENTAL|MTPS9579A|
61957019|NCT04092582|PLACEBO_COMPARATOR|Placebo|
62345782|NCT04260061|EXPERIMENTAL|end effector group|The Amadeo Hand-Therapy-System will be used in this group. The Amadeo is a mechatronic rehabilitation device that allows each individual finger to move independently and separately. The main target group are patients suffering from functional motor disabilities of the distal upper extremity. The Amadeo consists of the electrically driven moment mechanism, a supportive framework which is adjustable in height and includes a hand-arm support, and a control and operating unit (all-in-one PC). The finger slides can produce flexion/extension movement of the fingers and the thumb. The fingers and the thumb of the affected hand are attached to the slides and then passive, assistive, active or interactive therapy regime can be started. The integrated sensors for force and position measurement enable quantitative recording and evaluation of the finger range of movement and force.
62345783|NCT00067470|PLACEBO_COMPARATOR|Placebo|
62345784|NCT00067470|ACTIVE_COMPARATOR|rhASB|
62345785|NCT01991938|EXPERIMENTAL|VS-5584|Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
62345786|NCT01344252|EXPERIMENTAL|Topical|
61957020|NCT03821883|EXPERIMENTAL|Aspirin group|Study patients assigned to Aspirin group will receive enteric coated aspirin (100 mg/day).
62503636|NCT06198647|ACTIVE_COMPARATOR|positional release techniques|Application of positional release techniques for the women while being in prone lying position.
61957021|NCT03821883|PLACEBO_COMPARATOR|Control group|Study patients assigned to control group will receive placebo.
61957022|NCT02057731||Ia carriers|Carriers of GSD type Ia will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
61957023|NCT02057731||Ib carriers|Carriers of GSD type Ib will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
61957024|NCT02057731||III carriers|Carriers of GSD type III will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
61957025|NCT02057731||0, VI, IX carriers|Carriers of GSD types 0, VI, and IX will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
61957026|NCT02057731||Noncarriers|Noncarriers of any type of GSD will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to ensure their noncarrier status. A questionnaire will also be filled out.
61957027|NCT03708081||Group 1|Root canal treatments will be completed by ProTaper Next instruments with rotational motion
61957028|NCT03708081||Group 2|Root canal treatments will be completed TF Adaptive instruments with adaptive motion.
61957029|NCT01015898|EXPERIMENTAL|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
61957030|NCT05865262||treated transgender people|Transgender individuals consulting at the Endocrinology department of the Haut-Leveque hospital in Pessac (France), whether they are (one unique visit) or not (2 visits) already on GAHT (feminizing hormone treatment in transgender women and masculinizing treatment in transgender men, respectively). Men and women not already on GAHT will have two visits in total, one inclusion visit before GAHT start and one at least after one month of GAHT (and maximum within 2 years of start). Transgender individuals already on GAHT will have one unique inclusion visit without any planned follow-up visit.
62142716|NCT01673594|EXPERIMENTAL|Naltrexone|Arm 1: Naltrexone + SODAS MPH
62142717|NCT01673594|PLACEBO_COMPARATOR|Placebo|Arm 2: Placebo + SODAS MPH
62142718|NCT00188305|EXPERIMENTAL|1 In person|In person general health, colorectal cancer risk information and screening recommendations.
62345787|NCT01344252|ACTIVE_COMPARATOR|subtenon|
62702442|NCT06191549|EXPERIMENTAL|To explore the trends of functional improvements after single a-tDCS session in stroke survivors.|To explore functional improvements (gait performance, brain neural activation) between a-tDCS, s-tDCS, and control groups.
62503637|NCT06493409|EXPERIMENTAL|Part 1|
62503638|NCT06493409|EXPERIMENTAL|Part 2|
62702443|NCT06191549|EXPERIMENTAL|To explore the accumulated effects of brain stimulation on gait improvements in stroke survivors|To explore the accumulated, longitudinal trends of a four-week visuomotor stepping training in conjunction with brain stimulation on treadmill walking training and gait improvements for persons with chronic stroke.
62702444|NCT05695339|EXPERIMENTAL|Resiniferatoxin|Resiniferatoxin
61957031|NCT05050539|ACTIVE_COMPARATOR|Early Responders to Low Intensity|Early responders will include those with targeted levels of fidelity by the October assessment. They will continue to receive low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
61957032|NCT05050539|ACTIVE_COMPARATOR|Non-Responders Continue Low Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to continue receiving low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
61957033|NCT05050539|EXPERIMENTAL|Non-Responders Increasing to High Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to have high intensity support added (low intensity + holistic individualized facilitation, tailored educational materials).
61957034|NCT00900965|ACTIVE_COMPARATOR|Electroacupuncture treatment|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
61957035|NCT00900965|SHAM_COMPARATOR|Sham acupunture treatment|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
61957036|NCT06239766||Non-Cisgender Adults Considering Chest Masculinization Surgery|Persons assigned female or intersex at birth who identify as TGD and are considering gender-affirming chest masculinization surgery.
61957037|NCT00367900||NIH-AARP Diet and Health Study sub study: PAGE|Diet and Health Study members who self-reported a Parkinson's disease (PD) diagnosis on a follow-up questionnaire, and randomly selected controls, will participate in the PAGE sub study.
61957038|NCT04729868|OTHER|group Levo-bupivacaine|Group A (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 1ml normal saline under the guidance of ultrasound for infraclavicular brachial plexus block.
61957039|NCT04729868|OTHER|group levo-bupivacaine plus 50µg dexmedetomidine|Group B (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 50µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
62702445|NCT05879757||MM Participants With SID|Participants with MM diagnosed with SID will be treated with HyQvia as part of routine clinical care and will be followed prospectively from the date of starting HyQvia treatment through 12 months of follow-up.
62702446|NCT06413706|EXPERIMENTAL|Abemaciclib + Temozolomide - Arm A|Participants will receive abemaciclib administered orally in addition to temozolomide administered orally or intravenously (IV).
62702447|NCT06413706|ACTIVE_COMPARATOR|Temozolomide - Arm B|Participants will receive temozolomide administered orally or IV.
62702448|NCT06748508|ACTIVE_COMPARATOR|XELOX regimen plus sintilimab|sintilimab 200mg ivgtt d1+oxaliplatin 130mg/m2 ivgtt d1+xeloda 1000mg/m2 bid po d1-14，q3w
61957040|NCT04729868|OTHER|group levo-bupivacaine plus 100µg dexmedetomidine|Group C (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 100µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
61957041|NCT00936559|EXPERIMENTAL|1|Arm A
61957042|NCT00936559|EXPERIMENTAL|2|Arm B
61957043|NCT00936559|EXPERIMENTAL|3|Arm C
61957044|NCT01371916||ESAT-6 positive|
61957045|NCT01371916||ESAT-6 negative|
62142719|NCT00188305|ACTIVE_COMPARATOR|2 Telephone|Telephone general health counselling, colorectal cancer risk information and screening recommendations.
62702449|NCT06748508|EXPERIMENTAL|Nab-POF regimen plus sintilimab|sintilimab (200mg for the first time, 100mg for the second time, in alteration) ivgtt d1+oxaliplatin 85mg/m2 ivgtt d1+Nab-paclitaxel 125 mg/m2 ivgtt d1+5FU 2.4g/m2 civ48h, q2w
62702450|NCT06748508|EXPERIMENTAL|XELOX regimen plus sintilimab plus lenvatinib|sintilimab 200mg ivgtt d1+oxaliplatin 130mg/m2 ivgtt d1+xeloda 1000mg/m2 bid po d1-14+lenvatinib 8mg(\<60kg) or 12mg(≥60kg) po qd，q3w
62702451|NCT06750055||lumbar spinal stenosis patient group|Assessment of Disability Status (Oswestry Disability Index) Pain Assessment (Visual Analog Scale-VAS) Quality of Life Assessment (SF-12) Evaluation of Gait Parameters: 10 Meter Walk Test-BTS G-Walk gait analysis system
61957046|NCT02407860|EXPERIMENTAL|treatment|one single osteopathic treatment in addition to usual breastfeeding counselling
61957047|NCT02407860|ACTIVE_COMPARATOR|control|usual breastfeeding counselling. Osteopathic evaluation of entire body
61957048|NCT02129998||Standard IVF/ICSI treatment|
61957049|NCT01007266|OTHER|Group A|Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
61957050|NCT01007266|ACTIVE_COMPARATOR|Group B|Individuals receive conventional treatment for type 2 diabetes
61957051|NCT04564937|EXPERIMENTAL|SCT510A dose level 1 treatment|SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously
61957052|NCT04564937|EXPERIMENTAL|SCT510A dose level 2 treatment|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously
61957053|NCT04564937|EXPERIMENTAL|SCT510A dose level 3 treatment|SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously
62142720|NCT00188305|PLACEBO_COMPARATOR|3 Control|Standard care for 2 months followed by summary letter with general health information, colorectal cancer risk information and screening recommendations.
62142721|NCT06046196|EXPERIMENTAL|Sarpogrelate SR 300mg, QD|Sarpogrelate SR 300mg, QD
62142722|NCT06046196|ACTIVE_COMPARATOR|Sarpogrelate 100mg, TID|Sarpogrelate 100mg, TID
62142723|NCT04050956||Myocardial infarction|As it is an observational study, no intervention is planned. However, nested clinical interventional trials are planned for which a specific registration will be done
62142724|NCT01353274||Patients with hypertension|
62702452|NCT06750055||healthy control group|Quality of Life Assessment (SF-12) Evaluation of Gait Parameters: 10 Meter Walk Test-BTS G-Walk gait analysis system
62702453|NCT04468399||Patients who initiated HIV treatment|
62702454|NCT04468399||Service providers at study facilities|
62702455|NCT03407079|EXPERIMENTAL|Study Arm 1|Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
61957054|NCT04564937|EXPERIMENTAL|SCT510A dose level 4 treatment|SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously
61957055|NCT05476198|ACTIVE_COMPARATOR|Group BPB|The investigators performed a brachial plexus block on that patient group for preoperative anxiety
61957056|NCT05476198|ACTIVE_COMPARATOR|Group GA|The investigators performed general anesthesia on that patient group for preoperative anxiety
61957057|NCT04360629|EXPERIMENTAL|high dose TXA|TXA will be given as a 20mg/kg bolus followed by infusion of 5mg/ kg/hr per our anesthesia protocol
61957058|NCT04360629|EXPERIMENTAL|low dose TXA|TXA will be given as a 10mg/kg bolus followed by infusion of 1mg/ kg/hr per our anesthesia protocol
61957059|NCT04360629|PLACEBO_COMPARATOR|normal saline|saline will be given as a 4ml/kg bolus followed by infusion of 1ml/ kg/hr per our anesthesia protocolprotocol4ml/kg
61957060|NCT03194230|NO_INTERVENTION|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
61957061|NCT03194230|EXPERIMENTAL|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
61957062|NCT02231944|EXPERIMENTAL|Replenine®-VF|
61957063|NCT02530060|EXPERIMENTAL|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive single oral dose of fixed dose combination (FDC) tablet comprising of Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine on Day 1.
61957064|NCT02981420|NO_INTERVENTION|Pre-intervention|Pre-intervention baseline comparison
61957065|NCT02981420|EXPERIMENTAL|Safety Planning|Intervention group
61957066|NCT02981420|NO_INTERVENTION|Regression discontinuity|Subthreshold no intervention
61957067|NCT01105728|EXPERIMENTAL|Study arm|Endoscopic resection
61957068|NCT06495827||response cohort|CRC patients with response status after chemotherapy
61957069|NCT06495827||resistance cohort|CRC patients with resistance status after chemotherapy
61957070|NCT03331367|ACTIVE_COMPARATOR|Total Cyrotherapy of the Prostate|Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
61957071|NCT03331367|ACTIVE_COMPARATOR|Focal Cryotherapy of the Prostate|Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
62702456|NCT03407079|PLACEBO_COMPARATOR|Study Arm 2|Participants will receive placebo capsules by mouth for 28 days.
62702457|NCT05828069|EXPERIMENTAL|Treatment (tovorafenib)|Patients receive tovorafenib PO QW on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO scans, and FDG-PET or CT throughout the trial, and collection of blood samples on study. Patients with suspicion of bone marrow and/or central nervous system involvement will also undergo bone marrow biopsy and aspiration and lumbar puncture on study and during follow up.
62702458|NCT06748703|EXPERIMENTAL|CPAP Treatment Group|Patients with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) who are eligible for CPAP therapy.
62702459|NCT06749964|EXPERIMENTAL|Pain focused CBT for chronic pain|"Baseline consists of a random assigned period between 7 and 21 days with measurements and no intervention.~Intervention consists of a maximum of 8 sessions of psychological flexibility training."
61957072|NCT03331367|ACTIVE_COMPARATOR|Cyberknife SBRT of the Prostate|Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
61957073|NCT03331367|ACTIVE_COMPARATOR|Radical Prostatectomy|Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
61957074|NCT02200211|EXPERIMENTAL|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
61957075|NCT02200211|ACTIVE_COMPARATOR|Patching Treatment|Patching 2 hours per day, 7 days per week
61957076|NCT01429415|EXPERIMENTAL|Experimental Group|Magnesium Sulfate Sandoz/PPC 600mg and Salbutamol (GlaxoSmithKline/Pharmascience) 5mg by inhalation via Aeroneb Go nebulizer (Philips) with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
61957077|NCT01429415|PLACEBO_COMPARATOR|Control Group|Sodium Chloride USP PPC/Omega (5.5%) placebo and salbutamol GlaxoSmithKline/Pharmascience 5 mg by inhalation via Aeroneb Go nebulizer Philips with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
61957078|NCT06491940|EXPERIMENTAL|Losartan group|Patients will receive Losartan (LS) 50 mg per day.
61957079|NCT06491940|EXPERIMENTAL|Losartan + Hydrochlorothiazide|Patients will be given losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
61957080|NCT02528396|EXPERIMENTAL|BioChaperone insulin lispro|
61957081|NCT02528396|ACTIVE_COMPARATOR|Humalog®|
61957082|NCT05887414||Surgery|Patients who chose to receive surgery as treatment for their appendicitis.
61957083|NCT05887414||Antibiotics|Patients who chose to receive antibiotics as treatment for their appendicitis.
61957084|NCT02430012|ACTIVE_COMPARATOR|Intervention group|The intervention group will take the secondary prevention quality improvement strategies into implementation.
61957085|NCT02430012|NO_INTERVENTION|Control group|The control goup will maintain the routine practice pattern.
61957086|NCT04575116|EXPERIMENTAL|Tafamidis Free acid tablet then tafamidis meglumine capsule|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
61957087|NCT04575116|EXPERIMENTAL|Tafamidis meglumine capsule then Tafamidis Free acid tablet|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
61957088|NCT01916720|EXPERIMENTAL|SB-480848 40 mg|SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.
62142725|NCT01987518||digestive polyposis|Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis
62142726|NCT00804219|EXPERIMENTAL|TBE low responder|
62503639|NCT05964673|NO_INTERVENTION|education program group|"this group will receive patient education program for four weeks.~1. limiting screen time~2. blinking awareness training~3. keeping the home environment cool and moist~4. using artificial tears (Hylo®gel) twice daily~5. contact lens use can preferably be limited,~6. adding omega-3 poly unsaturated fatty acids in the diet or as dietary supplements."
61957089|NCT01916720|EXPERIMENTAL|SB-480848 80 mg|SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.
62142727|NCT00804219|EXPERIMENTAL|FSME responder|
61957090|NCT01916720|PLACEBO_COMPARATOR|Matching Placebo|Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.
61957091|NCT00530946|ACTIVE_COMPARATOR|CI-1038 2.5mg/5mg|
62142728|NCT00804219|EXPERIMENTAL|hepatitis B non-responder|
61957092|NCT00530946|ACTIVE_COMPARATOR|CI-1038 2.5mg/10mg|
62142729|NCT04909619|EXPERIMENTAL|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|Patients randomized to this arm will receive an ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg of 0.2% ropivacaine per side, for a total of 0.3 ml/kg immediately after induction of general anesthesia and prior to incision. Participants will also receive local infiltration of the palate with an equivalent injection volume of 0.9% saline with 1:400,000 epinephrine at 2 ml/kg. Pediatric anesthesiologists with fellowship training in regional anesthesia will perform the nerve block. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
62345788|NCT03271788|EXPERIMENTAL|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
61957093|NCT00530946|ACTIVE_COMPARATOR|CI-1038 5mg/5mg|
61957094|NCT00530946|ACTIVE_COMPARATOR|CI-1038 5mg/10mg|
61957095|NCT01417442|EXPERIMENTAL|BRAF V600E POSITIVITY|This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
61957096|NCT05256329||Oncology patients|Patients suffering from specific solid cancers or hematological malignancies
61957097|NCT05566743|EXPERIMENTAL|the maintenance arm|in this arm patients will receive 4 months of induction FOLFRINOX then maintenance capecitabine
62702460|NCT06751303|OTHER|HRD Tested|HRP patients are given a decision aid, while HRD patients are not given a decision.
62142730|NCT04909619|ACTIVE_COMPARATOR|Local anesthetic infiltration of the palate|Patients randomized to this arm will receive local infiltration of the palate using 0.125% bupivacaine + 1:400,000 epinephrine at a dose of 2 ml/kg intraoperatively. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
62142731|NCT01389921|EXPERIMENTAL|healthy testpersons|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
62345789|NCT04169061|EXPERIMENTAL|All participants|"Participants receive:~* a shot of Acthar (80 units) under the skin twice a week for 12 weeks~* a shot of Acthar (40 units) twice a week for 2 weeks~* a shot of Acthar (40 units) once a week for 2 more weeks~At each visit they will have medical tests and answer questions about their symptoms."
62345790|NCT05833685||Female sexual dysfunction group|
62345791|NCT05833685||Normal females|
62345792|NCT04005950||medical doctors|
62345793|NCT04005950||paramedics|
62345794|NCT00776399|EXPERIMENTAL|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
62345795|NCT02321618|EXPERIMENTAL|BP measurement & pharmacy|BP measurements performed by barber, role model poster exposure in barbershop, and BP medication management visits with study pharmacist
62345796|NCT02321618|OTHER|BP educational materials|Exposure to hypertension educational materials in barbershop
62345797|NCT01157052|ACTIVE_COMPARATOR|Ca2+/Mg2+ pre & post cycle 1|Arm A:Ca2+/Mg2+: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1
62345798|NCT01157052|ACTIVE_COMPARATOR|Ca2+/Mg2+pre & post cycle 2|Arm B:Ca2+/Mg2+: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 2
62503640|NCT05964673|EXPERIMENTAL|bioptron light therapy group|Patients will be sitting in a comfortable chair, with their eyes closed, with cleaned eyelids, and occasionally blinking. Bioptron lamp will be lined at an angle of 90°, at a distance from 5 cm to 10 cm, exposure time will be 5 min. Energy is very low, 1 - 2.4 J/cm without thermal effects, energy density is 40mW. Bioptron light is polychrome, wave frequency is from 400 nm (including blue, visible radiation) up to 2000 nm (representing infrared waves)
61957098|NCT05566743|OTHER|the control arm|in this arm patients will receive 4 months of FOLFRINOX then kept under follow-up
61957099|NCT05810883||Insulin Resistant Group|HOMA-IR score of ≥ 3.4
61957100|NCT05810883||Non-Insulin Resistant|HOMA-IR score of less than 3.4
61957101|NCT03591835|ACTIVE_COMPARATOR|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
61957102|NCT03591835|ACTIVE_COMPARATOR|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
61957103|NCT00580684|ACTIVE_COMPARATOR|G1|G1: prevenar
61957104|NCT00580684|ACTIVE_COMPARATOR|G2|G2: pneumo 23
61957105|NCT02702154|EXPERIMENTAL|High-frequency rTMS|20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
61957106|NCT02702154|EXPERIMENTAL|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
62702461|NCT06748664|EXPERIMENTAL|Group A1:Rimegepant ODT 75mg, EOD|Rimegepant ODT 75mg, EOD treatment for 4/12\* weeks
61957107|NCT02702154|SHAM_COMPARATOR|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
62503641|NCT04751630|EXPERIMENTAL|Therapeutic Exercise group|The study participants corresponding to the Therapeutic Exercise (ET) intervention group will follow the prescriptions given to them by their primary care physician. In addition, and as the main part of the intervention, they will undergo a six-week ET program with two sessions per week, for a total of 12 sessions. Full participation in 10 sessions will be necessary to be included in the ET group during the statistical analysis. Each session will be one hour long. The sessions will be given and supervised by a physiotherapist expert in therapeutic exercise prescription through the online modality.
62503642|NCT04751630|NO_INTERVENTION|Control group|Study participants in the control group will follow the prescriptions given to them by their primary care physician and will receive a weekly call to assess their recovery. At the end of the study follow-up, when their participation in the study as a control group ends, participants in this group will be offered to participate in the structured ET program to be carried out by the ET group. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of the research.
62702462|NCT06748664|PLACEBO_COMPARATOR|Group A2: Placebo, EOD|Placebo, EOD treatment for 4/12\* weeks
61957108|NCT03646318|EXPERIMENTAL|Ketanserin|Ketanserin is a serotonin type 2-receptor blocker (5-HT2). In normal endothelium, the 5-HT1 effects (vasodilation) are the most prominent \[Dabire 1990\]. In endothelium that is damaged, which is the case in sepsis, the 5HT2 effects (vasoconstriction) surpass the 5-HT1 effects. Blocking the 5-HT2 receptor with ketanserin can attenuate this pathological vasoconstriction. In addition, ketanserin has favourable α1-adrenergic blocking properties in the endothelium (vasodilation) that may further reverse the pathological vasoconstriction. In these ways ketanserin can reduce vasoconstriction and can improve the microcirculation.
61957109|NCT03646318|PLACEBO_COMPARATOR|Placebo|The placebo is a standard glucose 5% solution.
62702463|NCT06749587|EXPERIMENTAL|TEOSYAL RHA® 1|
62702464|NCT06749587|NO_INTERVENTION|Control group (non treated)|
62702465|NCT06748443|EXPERIMENTAL|Intervention group receiving support for implementation of Knee Control+|"Teams in the intervention group will gain access to digital Knee Control+ programme material from the Swedish Football Association website in the pre-season and be introduced to the programme during a digital workshop prior to season start. Additionally, coaches will be offered a smorgasbord of support interventions that they can choose from depending on their specific needs:~1. physical and digital workshops aiming to increase coach self-efficacy and formalisation of action and coping plans,~2. site visits to their teams by a study designated fitness coach, aiming to increase coach self-efficacy and player autonomous motivation,~3. digital programme material with films aiming to increase coach knowledge and inspiration to use Knee Control+,~4. leaflets about Knee Control+ as inspiration and reminder to use the programme,~5. social media support as reminder to use the programme.~Site visits and physical workshops will be led by specifically trained fitness coaches."
62702466|NCT06748443|ACTIVE_COMPARATOR|Control group with standard introduction of Knee Control+|The control group will gain access to the same digital Knee Control+ programme material from the Swedish Football Association website in the pre-season and will be introduced to the programme during a digital workshop prior to study start.
61957110|NCT01389635||Abdominoplasty patients|All patients who underwent abdominoplasty at our institution without concurrent operations
61957111|NCT00283400|ACTIVE_COMPARATOR|dosage tier 1|0.625 g/kg 25% human albumin
62142732|NCT01389921|EXPERIMENTAL|patients with non-neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
62345799|NCT00192036|EXPERIMENTAL|Gemcitabine + Cisplatin|"Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).~Cisplatin: 80 mg/m2, IV, every 21 days x 5 cycles.~Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."
62345800|NCT02916095|EXPERIMENTAL|Kanitinib|Subjects will be enrolled in cohorts at different dose levels in order to evaluate the safety,tolerability and determine the maximum tolerated dose and recommended phase II dose of kanitinib.
62345801|NCT06082869|EXPERIMENTAL|Experimental|Protegera™ toothpaste (NaF), brushing twice daily for one minute
62345802|NCT06082869|ACTIVE_COMPARATOR|Control|Crest™ Cavity Protection toothpaste (NaF), brushing twice daily for one minute
62345803|NCT02500394|PLACEBO_COMPARATOR|standard care|Patients in the standard care population receive - if biomarkers are elevated -treatment of AKI in accordance with KDIGO 2012 guidelines
62503643|NCT03785769|ACTIVE_COMPARATOR|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by HVGIC restoration.
62736652|NCT03076060|SHAM_COMPARATOR|Sham diet migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of non-ketogenic VLCD by meal replacements poor in fats and proteins."
61957112|NCT00283400|ACTIVE_COMPARATOR|dosage tier 2|1.25 g/kg 25% human albumin
61957113|NCT00283400|ACTIVE_COMPARATOR|dosage tier 3|1.875 g/kg 25% human albumin
61957114|NCT00283400|ACTIVE_COMPARATOR|dosage tier 4|2.5 g/kg 25% human albumin
61957115|NCT04637230||Sinus Rhythm|Subjects/patients in normal sinus rhythm
61957116|NCT04637230||Atrial Fibrillation|Patients with atrial fibrillation
61957117|NCT04637230||Atrial Premature Complexes|Patients with atrial premature complexes in between sinus beats
61957118|NCT04637230||Ventricular Premature Complexes|Patients with ventricular premature complexes in between sinus beats
62142733|NCT01389921|OTHER|patients with neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome
62142734|NCT03805672|ACTIVE_COMPARATOR|Low Dose Enoxaparin|Subjects are randomized to receive or begin prophylactic dosing (30 mg BID) of enoxaparin for 6 weeks or until DVT resolution.
61957119|NCT04637230||Ventricular Tachycardia, Nonsustained|Patients with episodes of nonsustained ventricular tachycardia in between sinus beats
61957120|NCT01483755|EXPERIMENTAL|Postconditionned|36 postconditionned patients
61957121|NCT01483755|SHAM_COMPARATOR|Conventional intervention|36 control patients with conventional primary percutaneaous intervention (PCI)
61957122|NCT04427566|EXPERIMENTAL|Radiation Arm|Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
61957123|NCT02153034||Buruli ulcer patients, no intervention|Buruli ulcer patients administered standard standard care by the attending physician
61957124|NCT02153034||Healthy contacts, no intervention|Healthy volunteers who will be contacts of patients recruited or non-endemic controls. No intervention will be administered
61957125|NCT05787275|ACTIVE_COMPARATOR|Control|received, traditional medical treatment and no exercise
61957126|NCT05787275|EXPERIMENTAL|diaphragmatic positioning group|received diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
61957127|NCT05787275|EXPERIMENTAL|incentive spirometer group|received diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
61957128|NCT04193098|EXPERIMENTAL|Arm: CTL plus PD-1 inhibitor|CTL , Toripalimab Toripalimab intravenous infusion 240mg d1; CTL, 1x10\^9, intravenous infusion,d14; Q3W.
61957129|NCT00745836|EXPERIMENTAL|atorvastatin 10 mg, 80 mg|
61957130|NCT01805154||CRT patients|Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
61957131|NCT01600469|EXPERIMENTAL|DAOI-B|
61957132|NCT01600469|PLACEBO_COMPARATOR|Placebo|
61957133|NCT04138121|EXPERIMENTAL|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
61957134|NCT04673422|EXPERIMENTAL|Montelukast|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
61957135|NCT04673422|PLACEBO_COMPARATOR|Placebo|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
61957136|NCT02256631|EXPERIMENTAL|Dose Group 1|Infants in Dose Group 1 received a single VRC01 20 mg/kg injection less than 72 hours after birth.
61957137|NCT02256631|EXPERIMENTAL|Dose Group 2|Infants in Dose Group 2 received a single VRC01 40 mg/kg injection less than 72 hours after birth.
61957138|NCT02256631|EXPERIMENTAL|Dose Group 3|Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
62142735|NCT03805672|ACTIVE_COMPARATOR|High Dose Enoxaparin|Subjects are randomized to begin therapeutic dosing (1 mg/kg body weight BID) of enoxaparin for 6 weeks or until DVT resolution.
61957139|NCT02256631|EXPERIMENTAL|Dose Group 4, Cohort 1|Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
61957140|NCT02256631|EXPERIMENTAL|Dose Group 4, Cohort 2|Infants in Cohort 2 received an initial VRC01LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC01LS was administered at Week 12 if an infant was still breastfeeding.
61957141|NCT02256631|EXPERIMENTAL|Dose Group 5, Cohort 1|Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
61957142|NCT02256631|EXPERIMENTAL|Dose Group 5, Cohort 2|Infants in Cohort 2 received an initial VRC07-523LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC07-523LS was administered at Week 12 if an infant was still breastfeeding.
61957143|NCT04353271|EXPERIMENTAL|Hydroxychloroquine|Subjects in this arm will receive the study drug
62142736|NCT05804825|ACTIVE_COMPARATOR|Simple forewarning message|Participants will receive a simple short forewarning message to read and rate.
62142737|NCT05804825|EXPERIMENTAL|Argument inoculation messages|Participants will view a random sample of 3 text-only short messages (from a corpus of 100 arguments) to read and rate.
62142738|NCT04288167|EXPERIMENTAL|Patients with suspected brain injury|This arm will consist of up to 30 pediatric patients who entered the Emergency Room and who are suspected of having mild traumatic brain injury. Two sample sets will be collected within the first 10 hours from the injury.
62142739|NCT04288167|ACTIVE_COMPARATOR|Healthy controls|This arm will consist of up to 30 healthy control subjects, the samples of whom will be compared to the samples of brain injury patients (Arm 1). One sample set will be collected from healthy children without any known brain injury.
61957144|NCT04353271|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will take placebo for 6 days
61957145|NCT01994447|NO_INTERVENTION|Traditional Nurse Enrollment|Research nurses will obtain verbal consent from patient/caregiver.
61957146|NCT01994447|EXPERIMENTAL|Student Enrollment|Trained research students will use digital video discs (DVD's) of primary investigators explaining study information to obtain informed consent
61957147|NCT05598541||Shoulder|Patients with shoulder problems presenting to the orthopaedic outpatient clinic of the Helsinki University Hospital
61957148|NCT05598541||Elbow|Patients with elbow problems presenting to the orthopaedic outpatient clinic of the Helsinki University Hospital
61957149|NCT01615068||Cohort|
62142740|NCT04688684|EXPERIMENTAL|Family-based intervention|These participants will undergo the health coach based intervention with fitness tracker and diet changes, which will be delivered to all family members who meet the inclusion criteria and are enrolled in the study.
62345804|NCT02500394|ACTIVE_COMPARATOR|interventional care|Patients in the interventional population receive - if biomarkers are elevated - individualized treatment/volume substitution (balanced electrolyte solution = Ionosteril; 1,25-5 ml/kg/bw/6 hours) ) on the basis of predefined criteria
61957150|NCT01754701|EXPERIMENTAL|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
62142741|NCT00898521|EXPERIMENTAL|DGD|
62736653|NCT00179062|ACTIVE_COMPARATOR|1|
62503644|NCT03785769|EXPERIMENTAL|HVGIC restoration with non pre-etching|HVGIC restoration without the pre-etching of the surface.
62503645|NCT04234555||Provoked vestibulodynia (PVD)|Provoked vestibulodynia (PVD) is characterized by severe sharp and/or burning pain felt at the entrance to the vagina (i.e. the vulvar vestibule) when pressure is applied to this area or during attempts at vaginal insertional activities (i.e. provoked).
62345805|NCT06457815||Acute Myocardial Infarction - Type 1|Patients presenting with acute MI will have a blood test to understand their iron status.
62345806|NCT02344420|OTHER|Single Arm|As it is not a randomize trial there is only one study arm. Described interventions as echocariography, six minute walk test, Quality of Life test or self assessment score should be done in all patients.
62503646|NCT04234555||Provoked vestibulodynia (PVD) + Vaginismus (VAG)|PVD is sometimes accompanied by intense, involuntary contraction of the PFMs3, termed vaginismus (VAG).
62345807|NCT03864809||psoriasis patients|sleep disturbance
61957151|NCT01754701|EXPERIMENTAL|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
62345808|NCT03864809||atopic dermatites patients|sleep disturbance
62702467|NCT06047444|EXPERIMENTAL|"Dysport® dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~Double-blind placebo-controlled (DBPC) Phase: Dysport® dose A administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
62142742|NCT06698445|EXPERIMENTAL|Short Film Video|The short film training video will be prepared by researchers based on literature and appropriate for the level of children aged 7-12. The content will include topics such as preparation for KİAB, KİAB environment and the process after KİAB. Since the short film will be shot in a realistic manner, the scenario will include a doctor, a nurse, a child patient and a parent. The short film will be shot in the clinic where the data will be collected, at the appropriate time for the clinic. After the short film is shot, the editing process will be done and the final version will be given.
62345809|NCT03864809||control|sleep disturbance
62345810|NCT03095716||elderly patients|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
62345811|NCT05432102||Participants having respiratory polygraphy|This label will used to describe participants having respiratory polygraphy at Royal Papworth Hospital over a 3 month period.
62345812|NCT05432102||Participants having pulse oximetry|This label will used to describe participants having pulse oximetry at Royal Papworth Hospital over a 3 month period.
62345813|NCT01396902|ACTIVE_COMPARATOR|Standard of care|
62345814|NCT01396902|EXPERIMENTAL|Text Messaging|
62345815|NCT02435641||ICU Questionnaires|"After enrollment, all subjects (patients and their primary caregiver) will be given baseline measures assessing: sociodemographics, depression, anxiety, distress, stress, PTSD, coping, mindfulness, quality of life, satisfaction with life, resiliency/self efficacy (patient only), patient caregiver interaction, caregiver preparedness (caregiver only), caregiver self efficacy (caregiver only), quality of adherence measure, and health care satisfaction.~Subjects will complete the same measures again at time 2 (3 months) and time 3 (6 months). The study endpoint is time 3 follow up (6 months)."
62345816|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
62345817|NCT00312299|EXPERIMENTAL|Arm 1 A - Square edge PMMA IOL|50 patientes will recieve square edge PMMA IOL
62345818|NCT00312299|ACTIVE_COMPARATOR|1B|In group 1, 50 eyes will receive round edge PMMA IOL
62345819|NCT00312299|EXPERIMENTAL|2A|In group 2, 50 eyes will receive square edge PMMA IOL
62503647|NCT04234555||Control|Participants matched by age (within 2 years), parity (parous vs nulliparous) and use of oral contraceptive medications (yes vs no) to women in the PVD group, with no signs and symptoms of PVD.
62503648|NCT04912375|EXPERIMENTAL|Low EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
62503649|NCT04912375|NO_INTERVENTION|Low EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a similar puzzle task but the statements they searched are neutral.
62345820|NCT00312299|ACTIVE_COMPARATOR|2B|In group 2, 50 eyes will receive acrysof IOL
62503650|NCT04912375|EXPERIMENTAL|High EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
62736654|NCT00179062|ACTIVE_COMPARATOR|2|
62142743|NCT06698445|NO_INTERVENTION|Control|The control group will be given verbal information as a routine clinical practice.
62142744|NCT04252157|EXPERIMENTAL|kinesiotaping|Kinesotape will be apply with suitable tension and necessery region.
62345821|NCT01763866|PLACEBO_COMPARATOR|A10 PBO Q2W|Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.
62345822|NCT01763866|PLACEBO_COMPARATOR|A10 PBO QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
62345823|NCT01763866|ACTIVE_COMPARATOR|A10 EZE (Q2W)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.
62345824|NCT01763866|ACTIVE_COMPARATOR|A10 EZE (QM)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
61957152|NCT01411007||Smokers|Nicotine addicted smokers, smoking an average of at least 10 cigarettes per day.
61957153|NCT01411007||Non-Smokers|
61957154|NCT03414060|EXPERIMENTAL|Intervention (Menstrual Cup)|The menstrual cup is a 100% silicone, flexible reservoir cup that, when inserted correctly in the vagina, is sanitary and efficacious in preventing leakage of menstrual blood and in eliminating odor.
62503651|NCT04912375|NO_INTERVENTION|High EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a similar puzzle task but the statements they searched are neutral.
61957155|NCT02280304|EXPERIMENTAL|Inner Resources for Veterans (IRV) mindfulness and mantra|Complete a mindfulness and mantra therapy
62503652|NCT02226991|EXPERIMENTAL|TPV/RTV/EFV|tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23
62702468|NCT06047444|EXPERIMENTAL|"Dysport® dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Dysport® dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
62702469|NCT06047444|PLACEBO_COMPARATOR|"Placebo - Dysport dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose A administered intramuscularly on Day 1 and Week 12~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
62702470|NCT06047444|PLACEBO_COMPARATOR|"Placebo - Dysport dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)."
62702471|NCT06487481|EXPERIMENTAL|Preop RT + surgery|Preoperative radiotherapy at escalating doses followed by surgical resection
61957156|NCT02280304|ACTIVE_COMPARATOR|Essential Skills therapy|Learn symptoms of mTBI and PTSD, coping skills
61957157|NCT03725475||Stage III|stage III Non-small Cell Lung Cancer (NSCLC )
61957158|NCT05454098|EXPERIMENTAL|Fed states in healthy subjects|A single 40mg dose of Clifutinib administered in a fed state.
61957159|NCT05454098|EXPERIMENTAL|Fasted states in healthy subjects|A single 40mg dose of Clifutinib administered in a Fasted state.
61957160|NCT02971254|ACTIVE_COMPARATOR|Sevoflurane group|inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
61957161|NCT02971254|ACTIVE_COMPARATOR|Desflurane group|inhalation anaesthetic Desflurane, 1 M.A.C. during surgery
62345825|NCT01763866|EXPERIMENTAL|A10 EvoMab Q2W|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
62345826|NCT01763866|EXPERIMENTAL|A10 EvoMab QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks
62345827|NCT01763866|PLACEBO_COMPARATOR|A80 PBO Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
62345828|NCT01763866|PLACEBO_COMPARATOR|A80 PBO QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.
62345829|NCT01763866|ACTIVE_COMPARATOR|A80 EZE (Q2W)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
62345830|NCT01763866|ACTIVE_COMPARATOR|A80 EZE (QM)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
62345831|NCT01763866|EXPERIMENTAL|A80 EvoMab Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
62345832|NCT01763866|EXPERIMENTAL|A80 EvoMab QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
62345833|NCT01763866|PLACEBO_COMPARATOR|R5 PBO Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
62345834|NCT01763866|PLACEBO_COMPARATOR|R5 PBO QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
62345835|NCT01763866|EXPERIMENTAL|R5 EvoMab Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
62345836|NCT01763866|EXPERIMENTAL|R5 EvoMab QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
62345837|NCT01763866|PLACEBO_COMPARATOR|R40 PBO Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
62345838|NCT01763866|PLACEBO_COMPARATOR|R40 PBO QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
62503653|NCT05735418|EXPERIMENTAL|GI Biome #7|The intervention consists of daily administration of probiotics GI Biome #7 for four weeks.
62503654|NCT05735418|PLACEBO_COMPARATOR|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
61957162|NCT06505304||Post-operative CD|Patients undergoing surgery or with a previous (within 3 months from the enrolment) surgery for CD
61957163|NCT04173988|EXPERIMENTAL|alloCART-19|"For the very first patient, the initial dose could be administered via one or three intravenous infusions within 1 to 5 days. Starting from the second patient, the investigator will decide whether to use single or multiple alloCART-19 infusions, based on the treatment experience at previous dose level(s) and the patient's baseline disease burdens.~A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before alloCART-19 infusion."
61957164|NCT04453371|EXPERIMENTAL|Study group|Thrombolysis
61957165|NCT04453371|PLACEBO_COMPARATOR|Control group|Ringer's solution infusion
61957166|NCT01658462|EXPERIMENTAL|Arm A|Docetaxel + Nintedanib
61957167|NCT01658462|ACTIVE_COMPARATOR|Arm B|Docetaxel + increase of the dose
61957168|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
61957169|NCT06438458|EXPERIMENTAL|Hb in different positions|Hemoglobin concentration after sitting in bed (passively) for \>30 min, and after mobilization to a chair for \>30 min
61957170|NCT05032664|EXPERIMENTAL|Intervention Group|Home-based aromatherapy programme
61957171|NCT05032664|OTHER|Control Group|Wait-list control
61957172|NCT03845985|EXPERIMENTAL|Seeking Safety + Signs of Safety toolkit|Participants randomized to receive the intervention will be provided 12 one-hour weekly individual treatment sessions with one of four ASL-fluent study clinicians in Massachusetts. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
61957173|NCT03845985|NO_INTERVENTION|Assessment-only Waitlist Control|Participants randomized to the waitlist control condition will be offered the opportunity to receive the 12-session Seeking Safety + Signs of Safety toolkit intervention after an approximate 16 week waiting period. This 16 week waiting period is equivalent to the current waitlist to receive psychotherapy services through the PI's outpatient clinic. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
61957174|NCT04546061|EXPERIMENTAL|Project Uplift Intervention|A 6-month long intervention for young adult sexual and gender minorities, ages 18-35.
61957175|NCT00361569|EXPERIMENTAL|1|
61957176|NCT00361569|EXPERIMENTAL|2|
61957177|NCT00361569|PLACEBO_COMPARATOR|3|
61957178|NCT00361569|PLACEBO_COMPARATOR|4|
61957179|NCT01258582|EXPERIMENTAL|Oral HIV testing|
61957180|NCT01258582|ACTIVE_COMPARATOR|Fingerstick HIV testing|
61957181|NCT01333254|NO_INTERVENTION|Indwelling urinary catheter|Patients in this group with hip fracture will get an indwelling catheter at arrival to the orthopaedic ward. The patients with arthrosis get the indwelling catheter in the morning at the day of surgery. In both cases the indwelling catheter is inserted after shower with skin disinfectant. The catheter system is kept close. The catheter will be removed in the morning on day 2 after surgery. The patients are bladder-scanned every four-hour until normal bladder function is recaptured. If the bladder volume exceeds 400ml and the patient is unable to urinate, the patient will be re-catheterised. The procedure of the patients in this arm is in accordance with common practice in the Orthopaedic clinic.
61957182|NCT01333254|EXPERIMENTAL|Intermittent urinary catheterisation|Patients randomised to this arm will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 400 ml urine in the bladder, the patient will be intermittent catheterised.
61957183|NCT03112395|EXPERIMENTAL|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
61957184|NCT00523562|EXPERIMENTAL|normal weight male high fructose diet|"Effects of diet intervention  high fructose in normal weight subjects"
61957185|NCT00523562|EXPERIMENTAL|offsprings of T2DM high fructose diet|"Effect of diet intervention high fructose in healthy non-obese offsprings of patients with type 2 diabetes"
62702472|NCT03094663|ACTIVE_COMPARATOR|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~1. Injection prior to cementation~   1. bupivacaine 0.5% with epinephrine 30cc;~  2. methylprednisolone, 40 mg/ml, 1 ml~  3. cefazolin, 500 mg in 10 ml~  4. normal saline, 22cc~2. Superficial injection prior to closure.~   1. 20cc 0.25% bupivacaine~  2. 2 mg IV dexamethasone."
61957186|NCT00523562|EXPERIMENTAL|normal weight subjects high fat diet|"effects of diet intervention high fat in healthy male subjects"
61957187|NCT00523562|EXPERIMENTAL|Normal weight high fat+protein diet|"effect of diet intervention high fat + protein subjects in healthy male subjects"
61957188|NCT00743483|EXPERIMENTAL|rhBSSL|170 mg rhBSSL three times daily for 5 to 6 consecutive days
62702473|NCT03094663|EXPERIMENTAL|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~1. Injection prior to cementation~   1. bupivacaine 0.25% with epinephrine 30cc;~  2. methylprednisolone, 40 mg/ml, 1 ml~  3. cefazolin, 500 mg in 10 ml~  4. normal saline, 22cc~2. Superficial injection prior to closure.~   a. 20cc 0.25% bupivacaine~3. Adductor canal block technique (supine position, post IV sedation)~   a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone~4. IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
61957189|NCT02614092|EXPERIMENTAL|Water based Activity+ Cognitive Training|water-based physical activity + classroom based cognitive training
61957190|NCT02192138|EXPERIMENTAL|Therapeutic thoracentesis|Patients with pleural effusion who require therapeutic thoracentesis will be enrolled into the study
61957191|NCT02746796|EXPERIMENTAL|ONO-4538 + SOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
61957192|NCT02746796|EXPERIMENTAL|ONO-4538 + CapeOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
61957193|NCT02746796|EXPERIMENTAL|ONO-4538 + chemotherapy group (Part 2)|"With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
62142745|NCT04252157|PLACEBO_COMPARATOR|plesebo taping|Tape will be appy with randomly region without tension.
62142746|NCT04252157|OTHER|control|Nothing will be applied
62702474|NCT05907746|EXPERIMENTAL|Arm A|JSP191, Fludarabine, Total Body Irradiation
61957194|NCT02746796|PLACEBO_COMPARATOR|Placebo + Chemotherapy group (Part 2)|"With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
61957195|NCT03572062|EXPERIMENTAL|Arm 1|Low dose formulation A and SIIV
62702475|NCT05907746|EXPERIMENTAL|Arm B|JSP191, Fludarabine, Cyclophosphamide, Total Body Irradiation
62702476|NCT04450797|ACTIVE_COMPARATOR|US -G VPS placement|
62702477|NCT04450797|ACTIVE_COMPARATOR|Stereotactic navigation for VPS placement|
62503655|NCT04731493||therapeutic Education Program|"individual and group sessions will be set up with educational workshops specialized by age group (child / adolescent / transition / adult / entourage / parents), socio-administrative workshops, etc.~The objectives will be adapted to each age group and to each patient individually."
62503656|NCT01062334|EXPERIMENTAL|Microdialysis|
62702478|NCT06749743||training group|images used to train the AI models on detection of dental caries from intraoral images.
62702479|NCT06749743||test group|images used to test the accuracy of the AI models in diagnosis of dental caries from intraoral images.
62702480|NCT06330493|EXPERIMENTAL|PCB Group|use PCB catheter(trade name: AcoArt Litos) to treat the stenosis or occlusion in infrapopliteal artery of experimental arm
62702481|NCT06330493|ACTIVE_COMPARATOR|PTA Group|use standard PTA balloon catheter to treat stenosis or occlusion in infrapopliteal artery of control group
62702482|NCT00114101|EXPERIMENTAL|Arm I (melphalan, autologous PBSCT, lenalidomide)|Beginning between day 100-110, patients receive lenalidomide PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
61957196|NCT03572062|EXPERIMENTAL|Arm 2|Low dose formulation B and SIIV
61957197|NCT03572062|EXPERIMENTAL|Arm 3|Mid dose formulation A and SIIV
62702483|NCT00114101|PLACEBO_COMPARATOR|Arm II (melphalan, autologous PBSCT, placebo)|Beginning between day 100-110, patients receive placebo PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
62702484|NCT05509582|EXPERIMENTAL|Fostamatinib Arm|The subjects will receive oral fostamatinib daily for up to 2 years.
62702485|NCT06748677||endoscopic and robotic surgery|nipple-sparing mastectomy under endoscopic/robotic surgery combined with immediate prosthesis reconstruction
61957198|NCT03572062|EXPERIMENTAL|Arm 4|Mid dose formulation B and SIIV
61957199|NCT03572062|EXPERIMENTAL|Arm 5|High dose formulation A and SIIV
62142747|NCT02340013|ACTIVE_COMPARATOR|Medroxyprogesterone acetate|Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate
62142748|NCT02340013|NO_INTERVENTION|Control|Women are assigned to start clomiphene citrate 50mg tabs x 5 days on an assigned day, without any vaginal bleeding
62702486|NCT06748677||conventional surgery|conventional nipple-sparing mastectomy combined with immediate prosthesis reconstruction
62702487|NCT06749977|EXPERIMENTAL|Treatment of WSL with SAP11-4|WSL were treated with SAP11-4 corresponding to the manufacturer's instructions.
62702488|NCT06749977|EXPERIMENTAL|Treatment of WSL with sodium fluoride varnish|WSL were treated with sodium fluoride varnish corresponding to the manufacturer's instructions.
62702489|NCT06749977|NO_INTERVENTION|No treatment|No treatment
62702490|NCT01934660||Group 1|Healthy volunteers
61957200|NCT03572062|EXPERIMENTAL|Arm 6|High dose formulation B and SIIV
61957201|NCT03572062|EXPERIMENTAL|Arm 7|High dose formulation C and SIIV
61957202|NCT03572062|PLACEBO_COMPARATOR|Arm 8|Placebo and SIIV
62142749|NCT01320800|ACTIVE_COMPARATOR|Expert-led CBT|Expert SASS is the Skills for Academic and Social Success protocol delivered by a postdoctoral fellows.
62142750|NCT01320800|EXPERIMENTAL|School Counselor-led CBT|"School Counselor SASS is the Skills for Academic and Social Success protocol delivered by School Counselors.~Intervention: Behavioral: Skills for Social and Academic Success"
62503657|NCT06480604|EXPERIMENTAL|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.
62503658|NCT06480604|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive an equivalent placebo for the duration of the study (6 months).
62702491|NCT01934660||Group 2|Subjects diagnosed with diabetes
62702492|NCT01934660||Group 3|Subjects diagnosed cardiovascular disease
62702493|NCT02361723|EXPERIMENTAL|ovarian cancer, fallopian cancer, or primary peritoneal cancer|60mg BID oral.
62702494|NCT02361723|EXPERIMENTAL|Breast Cancer|60mg BID Ora
62702495|NCT02361723|EXPERIMENTAL|Prostate Cancer|60mg BID Oral
62702496|NCT02361723|EXPERIMENTAL|Small Cell Lung Cancer|60mg BID Oral
62702497|NCT02361723|EXPERIMENTAL|Gastric Cancer|60mg BID Oral
62702498|NCT06255782|EXPERIMENTAL|Cohort 1|Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion.
62702499|NCT06255782|EXPERIMENTAL|Cohort 2|Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion.
62702500|NCT06255782|EXPERIMENTAL|Additional Cohorts|Additional Cohorts based on recommendations of DMC review of safety and efficacy data.
62702501|NCT04907929|EXPERIMENTAL|post-implantation care|
62702502|NCT06163157|NO_INTERVENTION|Control roup|The control group will receive standard treatment (lifestyle recommendations).
62702503|NCT06163157|EXPERIMENTAL|CTM group|In addition to the standard treatment, connective tissue massage will be applied to the CTM group.
62702504|NCT03537586|EXPERIMENTAL|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells.
62702505|NCT03433339|EXPERIMENTAL|Active Treatment|Thoracic anodal transcutaneous spinal direct current stimulation 2.5 milliampere (mA) for 20 min/ three times per week for 8 weeks.
62702506|NCT03433339|SHAM_COMPARATOR|Sham Treatment|Thoracic anodal transcutaneous spinal direct current sham stimulation session of 20min/ three times per week for 8 weeks.
62702507|NCT06246916|EXPERIMENTAL|fianlimab+cemiplimab|Randomized 1:1
62702508|NCT06246916|ACTIVE_COMPARATOR|relatlimab+nivolumab|Randomized 1:1
61957203|NCT03572062|EXPERIMENTAL|M0M2 Arm 1|High dose formulation B
61957204|NCT03572062|PLACEBO_COMPARATOR|M0M2 Arm 2|Placebo
62702509|NCT06467084|OTHER|75 mg Dose Group|Patients will take a single 75 mg dose of KVD900.
62702510|NCT06467084|OTHER|150 mg Dose Group|Patients will take a single 150 mg dose of KVD900 dose.
62702511|NCT06467084|OTHER|300 mg Dose Group|Patients will take a single 300 mg dose of KVD900.
62702512|NCT03767348|EXPERIMENTAL|Dose escalation of RP1 by intratumoral (IT) injection in superficial tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors
62702513|NCT03767348|EXPERIMENTAL|Dose escalation of RP1 by intratumoral (IT) injection in deep/visceral tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in deep/visceral tumors
61957205|NCT05120778|EXPERIMENTAL|conventional medical treatment|Volunteers will maintain habitual medical treatment.
61957206|NCT05120778|EXPERIMENTAL|exercise training + conventional medical treatment|Volunteers will maintain habitual medical treatment and will participate in a 16-week exercise training based on high-intensity interval training (stationary bikes), and strength training (weight-bearing exercises).
62142751|NCT01320800|ACTIVE_COMPARATOR|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors. Intervention: Behavioral: Skills for Life
62702514|NCT03767348|EXPERIMENTAL|Dose expansion of RP1 and nivolumab (IV) in superficial tumors|Doses of RP1 (IT) in superficial tumors with nivolumab (IV)
62345839|NCT01763866|EXPERIMENTAL|R40 EvoMab Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
62702515|NCT03767348|EXPERIMENTAL|Dose expansion of RP1 and nivolumab (IV) in deep/visceral tumors|Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)
62702516|NCT03767348|EXPERIMENTAL|RP1 (IT) and nivolumab (IV) in melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma
62702517|NCT03767348|EXPERIMENTAL|RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors
61957207|NCT00826943|ACTIVE_COMPARATOR|Levocetirzine|5 mg daily x 7 days (note = cross over = all participants receive active comparators and placebo)
61957208|NCT00826943|ACTIVE_COMPARATOR|cetirizine|10 mg daily x 7 days. Note = crossover study, so all participants recieve all active comparators and placebo.
61957209|NCT00826943|PLACEBO_COMPARATOR|placebo|one tablet daily x 7 days; note that this is a crossover study so all participants receive all active comparators and placebo
61957210|NCT04966624|EXPERIMENTAL|interventional|
61957211|NCT04966624|ACTIVE_COMPARATOR|control|
61957212|NCT00750815|EXPERIMENTAL|A. Phase I - Dose Escalation|"Dose of Cyclophosphamide to depend on how many patients we treated:~* Dose Level 1: Cyclophosphamide 250 mg /m\^2 IV Day 1; VELCADE, 1.0 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~* Dose Level 2: Cyclophosphamide 500 mg /m\^2 IV Day 1; VELCADE, 1.0 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~* Dose Level 3: Cyclophosphamide 750 mg /m\^2 IV Day 1; VELCADE, 1.0 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~* Dose Level 4: Cyclophosphamide 750 mg /m\^2 IV Day 1; VELCADE, 1.3 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12"
62142752|NCT03750682|ACTIVE_COMPARATOR|Physical Activity Intervention (PA)|The PA intervention will consist of a twice per week group-based moderate-intensity program that includes aerobic, strength, flexibility, and balance training.
62345840|NCT01763866|EXPERIMENTAL|R40 EvoMab QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
62345841|NCT01763866|PLACEBO_COMPARATOR|S40 PBO Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
62345842|NCT01763866|PLACEBO_COMPARATOR|S40 PBO QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
62345843|NCT01763866|EXPERIMENTAL|S40 EvoMab Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
62702518|NCT03767348|EXPERIMENTAL|RP1 (IT) and nivolumab (IV) in NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer
62702519|NCT03767348|EXPERIMENTAL|RP1(IT) and nivolumab (IV) in anti-PD1 Failed Cutaneous Melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy
62702520|NCT03767348|EXPERIMENTAL|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer who have been previously treated with anti-PD1/PD-L1 therapy
62702521|NCT03767348|EXPERIMENTAL|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NSCLC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non small cell lung cancer who have been previously treated with anti-PD1/PD-L1 therapy
62702522|NCT05237973||Neuromuscular disorders|Diagnosed with a neuromuscular disorder such as motor neuron disorder, myopathy or have findings consistent with a peripheral neuropathy.
62702523|NCT05237973||Normal volunteers|No known abnormal muscle or nerve disorders
62702524|NCT06237855|NO_INTERVENTION|Standard of Care|Drain removal will occur during clinic visit by provider per standard of care procedure.
61957213|NCT00750815|EXPERIMENTAL|B. Phase II - Maximum Planned Dose (MPD)|Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
61957214|NCT06492317|EXPERIMENTAL|Disitamab vedotin plus cadonilimab|Disitamab vedotin: 2.5mg/kg, D1, ivdrip, Q2W (every 2 weeks) ; Cadonilimab: 6mg/kg, D1, ivdrip, Q2W (every 2 weeks) ; until progressive disease (PD) or intolerable toxicity
61957215|NCT05697315|SHAM_COMPARATOR|Control group|No block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
61957216|NCT05697315|ACTIVE_COMPARATOR|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
61957217|NCT00807378||1|AIDS PATIENTS
61957218|NCT00807378||2|NON-AIDS PATIENTS
61957219|NCT01698372|EXPERIMENTAL|Prevena device (Group A)|Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
61957220|NCT01698372|NO_INTERVENTION|Conventional dressing (Group B)|Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
61957221|NCT05993377||Derivation and testing cohort|It will contain 1000 ARDS patients
61957222|NCT05993377||Confirmatory cohort|It will contain 303 patients (for external validation)
61957223|NCT05495490|EXPERIMENTAL|Osseodensification Internal Sinus Lift / Sticky Bone graft material|Osseodensification Internal Sinus Lift will be performed using sticky bone as a graft material.
61957224|NCT05495490|ACTIVE_COMPARATOR|Osteotome Internal Sinus Lift /Sticky Bone graft material|Osteotome Internal Sinus Lift will be performed using sticky bone as a graft material.
61957225|NCT01267760|ACTIVE_COMPARATOR|conventional HD|conventional 4-hour HD
61957226|NCT01890291||Non-treatment Group|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
61957227|NCT01890291||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
61957228|NCT02795832|EXPERIMENTAL|Cohort 1a|ZPL-5212372 1% w/w Ointment BID
61957229|NCT02795832|PLACEBO_COMPARATOR|Cohort 1b|Placebo Ointment BID
62142753|NCT03750682|PLACEBO_COMPARATOR|Health Education Intervention (HE)|The HE intervention will consist of bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics including relevance to older adults, including nutrition, understanding the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services, information on resources, etc.
61957230|NCT02795832|EXPERIMENTAL|Cohort 2a|ZPL-5212372 1% w/w Ointment BID
61957231|NCT02795832|PLACEBO_COMPARATOR|Cohort 2b|Placebo Ointment BID
62142754|NCT03324724|EXPERIMENTAL|Adolescents with Eating Disorder|Adolescents with bulimia nervosa or binge eating disorder, with one or more of their parents, will receive integrative cognitive-affective therapy for adolescents (ICAT-A).
62702525|NCT06237855|EXPERIMENTAL|Self-drain removal training|"Subjects will remove drain at home Training will consist of a detailed online video of a provider instructing how to remove the drain and practicing on a model created specifically to mimic the following actions during drain self-removal:~* Tension required to remove the drain~* Placing and taping gauze after suture and drain removal"
62142755|NCT02276599||Cardiac catheterization|Patients with a diagnosis of atrial septal defect who are having a cardiac catheterization.
62702526|NCT06460168|EXPERIMENTAL|Mulligan(MWM) Technique|Group of post prp knee osteoarthritis patients are given Mulligan (MWM) Mobilization technique
62702527|NCT06460168|ACTIVE_COMPARATOR|Maitland Technique|Patients are given Maitland Mobilization technique.
62702528|NCT06460168|NO_INTERVENTION|Baseline treatment|This group are given baseline treatment.
62702529|NCT06325696|EXPERIMENTAL|Treatment|Adults, male and female with a diagnosis of interstitial lung disease, take 2 doses of 400 mg H01, morning and evening
61957232|NCT02795832|EXPERIMENTAL|Cohort 3a|ZPL-5212372 1% w/w OIntment BID
61957233|NCT02795832|PLACEBO_COMPARATOR|Cohort 3b|Placebo Ointment BID
61957234|NCT04920019|EXPERIMENTAL|Thoracic continuous epidural analgesia|"Thoracic continuous epidural analgesia at T7-8 or T8-9 combined with IV PCA fentanyl (bolus mode only 15 ug/bolus, 5 minutes lockout, 4 hours limit 200 ug).~Multimodal analgesia Intraoperative : thoracic epidural infusion with 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h, morphine 2 mg epidurally are given.~Postoperative: 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h is given combined with IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug, multimodal analgesia: paracetamol 1000 mg iv every 6 hours until patient can take orally, change to 1000 mg orally every 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (etoricoxib 90 mg orally x2 days)"
61957235|NCT04920019|ACTIVE_COMPARATOR|No CEA|IV PCA fentanyl, IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug multimodal analgesia: paracetamol 1000 mg IV every 6 hours until patient can take orally, change to 1000 mg orally q 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (Etoricoxib 90 mg orally x2 days)
61957236|NCT00418457|ACTIVE_COMPARATOR|General anesthesia and opioid|General anesthesia followed by opioid administration
61957237|NCT00418457|ACTIVE_COMPARATOR|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
61957238|NCT01427257|ACTIVE_COMPARATOR|PB1023 Formulation A|
61957239|NCT01427257|ACTIVE_COMPARATOR|PB1023 Formulation B|
61957240|NCT01427257|ACTIVE_COMPARATOR|PB1023 Formulation B (2-8C)|
61957241|NCT03326466||Patients with SAP|
61957242|NCT03326466||Healthy Controls|
61957243|NCT03668860|ACTIVE_COMPARATOR|Treatments A & B (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
61957244|NCT03668860|ACTIVE_COMPARATOR|Treatments B & A (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
61957245|NCT03668860|ACTIVE_COMPARATOR|Treatments C & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
61957246|NCT03668860|ACTIVE_COMPARATOR|Treatments D & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))"
61957247|NCT03668860|ACTIVE_COMPARATOR|Treatments E & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
61957248|NCT03668860|ACTIVE_COMPARATOR|Treatments D & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
61957249|NCT03668860|ACTIVE_COMPARATOR|Treatments C & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)"
62142756|NCT02163200||pressure of total hip replacement|Patients 60 y.o. or more both sex with a history of hip arthropathy without previous bedsores or CVA
62503659|NCT01919541|OTHER|Prehabilitation|All patients will receive a prehabilitation program involving an individualized exercise and nutrition program 4 weeks before surgery. Whole body protein kinetics and insulin resistance will be determined at the beginning of the program and at the end of the program.
62142757|NCT00838461|ACTIVE_COMPARATOR|1|HSD-016
62142758|NCT00838461|PLACEBO_COMPARATOR|2|placebo
62345844|NCT01763866|EXPERIMENTAL|S40 EvoMab QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
62345845|NCT05467462|EXPERIMENTAL|Carbetocin|100-mg carbetocin was intravenously administered immediately after birth of the baby
62345846|NCT05467462|EXPERIMENTAL|Oxytocin Group|The oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord
62503660|NCT02091310|PLACEBO_COMPARATOR|Placebo (Study Part I)|Hard gelatin capsules, oral administration, 5 or 6 capsules per day before breakfast with a glass of water
62503661|NCT02091310|EXPERIMENTAL|GFT505 300 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 5 capsules per day before breakfast with a glass of water
62503662|NCT02091310|EXPERIMENTAL|GFT505 360 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 6 capsules per day before breakfast with a glass of water
62702530|NCT05223036|EXPERIMENTAL|Arm I (OCA)|Patients receive OCA PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study.
62702531|NCT05223036|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study.
62702532|NCT05830929|EXPERIMENTAL|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Ovarian tissue freezing and subsequent auto-transplantation after thawing
62503663|NCT02091310|PLACEBO_COMPARATOR|Placebo (Study Part II)|Hard gelatin capsules, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
62702533|NCT03370276|EXPERIMENTAL|Phase I - Affiliate Sites Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m\^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m\^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m\^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m\^2; Nivolumab 240 mg."
61957250|NCT03668860|ACTIVE_COMPARATOR|Treatments E & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)"
61957251|NCT00760097|EXPERIMENTAL|AtCDS|Transcranial direct stimulation
62702534|NCT03370276|EXPERIMENTAL|Phase I - Moffitt Site Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m\^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m\^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m\^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m\^2; Nivolumab 240 mg."
62702535|NCT03370276|EXPERIMENTAL|Phase II - Affiliate Sites Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
61957252|NCT00634374|NO_INTERVENTION|1|Oral Syringe
61957253|NCT00634374|ACTIVE_COMPARATOR|2|Rx medibottle
61957254|NCT06158373|EXPERIMENTAL|Infant Massage Group|infant massage
61957255|NCT06158373|EXPERIMENTAL|Safe Swaddling Group|safe swaddling
61957256|NCT06158373|SHAM_COMPARATOR|Control Group|control group
61957257|NCT02478996|EXPERIMENTAL|Internet-based exercise program|The intervention group is supervised by a sports scientist eight to twelve weeks before and after surgery. Patients receive an individually designed intensive exercise program based on the functional and Fitness measurements at first diagnosis.
61957258|NCT02478996|NO_INTERVENTION|Basis therapy|Participants of the Treatment as usual (TAU) group receive written information material enlightening the importance of regular physical activities and general releases on preparation for esophagectomy.
61957259|NCT04229420|ACTIVE_COMPARATOR|Rectus sheath block group (RSB)|After preparing the skin, a high frequency (5-10 MHz) ultrasound probe will be placed in a longitudinal orientation above the level of the umbilicus with the Patient in the supine position. After identifying the rectus abdominis muscle, A 22 G echogenic needle using the in plane technique will be inserted just below the costal margin then, a total of 20 ml of 0.25% bupivacaine will be injected into the plane between the rectus muscle and posterior rectus sheath. Negative aspiration will be confirmed every 5 ml. The block will then be repeated on the other side.
61957260|NCT04229420|ACTIVE_COMPARATOR|Erector spinae plane block group (ESPB)|After induction of anesthesia; the patient will be positioned on the lateral position. The skin will be prepared with povidone iodine, and a high frequency (5-10 MHz) ultrasound probewill be placed in a transverse orientation on the T9 spinous process which will be located by palpating and counting down from the C7 spinous process. The tip of the T9 transverse process will be identified and centred on the ultrasound screen, the probe will then be rotated into a longitudinal orientation to produce a parasagittal view. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is conﬁrmed by injecting 0.5-1 ml saline and seeing the ﬂuid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20 ml of 0.25% bupivacaine will then be injected into the ESP of both sides.
61957261|NCT02955602|EXPERIMENTAL|MBX-8025 (2 mg)|MBX-8025 2 mg capsule once daily
61957262|NCT02955602|EXPERIMENTAL|MBX-8025 (5 mg)|MBX-8025 5 mg capsule once daily
61957263|NCT02955602|EXPERIMENTAL|MBX-8025 (10 mg)|MBX-8025 10 mg capsule once daily
61957264|NCT02590367|EXPERIMENTAL|FOLFOX regimen&HD6610 Granule|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
61957265|NCT02590367|PLACEBO_COMPARATOR|FOLFOX regimen&HD6610 Granule placebo|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
61957266|NCT01392274||pCLE|This trial will study only one group which will receive a standard ERCP procedure followed by pCLE
62142759|NCT05913791|EXPERIMENTAL|Nutrients-fortified egg|Each subject will be provided with 2 nutrients-fortified eggs from N\&N Agriculture Pte Ltd to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet.
62142760|NCT05913791|PLACEBO_COMPARATOR|Regular egg|Each subject will be provided with 2 regular eggs to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet.
62702536|NCT03370276|EXPERIMENTAL|Phase II - Moffitt Site Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
61957267|NCT01728909|EXPERIMENTAL|Oxytocin|40 IU Oxytocin
61957268|NCT01728909|PLACEBO_COMPARATOR|Saline Nasal Spray|Placebo Comparator
61957269|NCT05929664|EXPERIMENTAL|Treatment (cemiplimab)|Patients receive cemiplimab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may transition to SOC HHI therapy. Patients undergo CT or MRI scans and collection of blood samples throughout the trial. Patients also undergo biopsies during screening and on study.
62142761|NCT01822756|EXPERIMENTAL|Regimen A -ruxolitinib, gemcitabine|Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).
62142762|NCT01822756|EXPERIMENTAL|Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim|"Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food.~Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored.~nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle."
61957270|NCT03831399|PLACEBO_COMPARATOR|Control Group|"Subjects in control group will receive placebo (lactose) 6g/day in two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
61957271|NCT03831399|ACTIVE_COMPARATOR|Intervention Group|"Subjects in intervention group will receive leucine 6g/day, in tin two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
62503664|NCT02091310|EXPERIMENTAL|GFT505 120 mg (Study Part II)|Hard gelatin capsules dosed at 60mg, oral administration, 2 capsules per day plus 2 to 4 capsules of placebo per day before breakfast with a glass of water
62503665|NCT02091310|EXPERIMENTAL|GFT505 xx mg (Study Part II)|Supra-therapeutic dose: hard gelatin capsules dosed at 60mg, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
62503666|NCT02091310|ACTIVE_COMPARATOR|Moxifloxacin 400 mg (Study Part II)|On days 1 to 13, 4 to 6 placebo capsules per day, then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14
61957272|NCT06310317|EXPERIMENTAL|experimental group|15 children belonging to the experimental group will undergo the treatment carries out the procedure by means of stimuli presented with technologies supports
61957273|NCT06310317|OTHER|control group|15 children belonging to the control group will undergo the treatment by performing the procedure with images printed on laminated A4 sheets.
61957274|NCT06506344|EXPERIMENTAL|5S Trial|Participants will receive an intervention aimed at suicide prevention in this group.
61957275|NCT06506344|NO_INTERVENTION|No-Contact Control Group|Participants will be able to engage with healthcare services as usual and will have no knowledge of their involvement in the study.
61957276|NCT00747760||1|Extended family members
61957277|NCT00747760||2|Control- subjects from the same town without known thyroid diseases
61957278|NCT04642443|ACTIVE_COMPARATOR|Intracranial Hemorrhage|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~1. A molded plastic headpiece containing the antenna array~2. An intermediate control unit that contains:~   a. The driving electronics for the array of antennae~3. A processing control unit that contains:~   1. A spectrum analyzer~  2. The operating software that controls the device function and data acquisition, processing and archiving.~  3. The user interface for inputting patient information and displaying the output of the data"
61957279|NCT04642443|ACTIVE_COMPARATOR|Traumatic Brain Injury|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~1. A molded plastic headpiece containing the antenna array~2. An intermediate control unit that contains:~   a. The driving electronics for the array of antennae~3. A processing control unit that contains:~   1. A spectrum analyzer~  2. The operating software that controls the device function and data acquisition, processing and archiving.~  3. The user interface for inputting patient information and displaying the output of the data"
61957280|NCT04146233|OTHER|Orange Juice without pulp|Drink orange juice without pulp and have gastric ultrasound performed 2 hours later
61957281|NCT04146233|OTHER|Orange juice with pulp|Drink orange juice with pulp and have gastric ultrasound performed 2 hours later
61957282|NCT01619696|EXPERIMENTAL|Intervention|
62503667|NCT05703841|EXPERIMENTAL|Cohort 1: JNJ-77242113 Dose 1|Participants will receive a single oral dose of JNJ-77242113 Dose 1 on Day 1.
62503668|NCT05703841|EXPERIMENTAL|Cohort 2: JNJ-77242113 Dose 2|Participants will receive a single oral dose of JNJ-77242113 Dose 2 on Day 1.
62503669|NCT05703841|EXPERIMENTAL|Cohort 3: JNJ-77242113 Dose 3|Participants will receive a single oral dose of JNJ-77242113 Dose 3 on Day 1.
61957283|NCT00608621||1-physostigmine|"Physostigmine 4 mg in 50 ml NaCl 0.9% per 24 h as syringe pump continuously for 48 hours, plus physostigmine 2mg (in NaCl 0.9% 50 ml)at termination of sedation~PCA: Patient-controlled analgesia with piritramide 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
61957284|NCT00608621||2-placebo|"NaCl 0.9% 50 ml per 24 h continuously over 48 hours, plus 50 ml NaCl 0.9% at termination of sedation~PCA: Patient-controlled analgesia with piritramid 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
61957285|NCT01256931||organ transplant patients|
61957286|NCT01256931||healthy controls|
61957287|NCT02145780|EXPERIMENTAL|2g of grape polyphenol extract supplement|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
61957288|NCT02145780|PLACEBO_COMPARATOR|2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
61957289|NCT02119364|ACTIVE_COMPARATOR|Working memory training|After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start training immediately and will have 6 weeks to perform the 25 training sessions.
61957290|NCT02119364|NO_INTERVENTION|Passive control group|"The control group will receive treatment as usual (special education, physiotherapy etc)."
61957291|NCT03775629|EXPERIMENTAL|Polmacoxib and Tramadol combination|Tramadol + Polmacoxib capsule
61957292|NCT03775629|ACTIVE_COMPARATOR|Polmacoxib|Polmacoxib
61957293|NCT03775629|ACTIVE_COMPARATOR|Tramadol|Tramadol hydrochloride (HCl)
61957294|NCT04234750|NO_INTERVENTION|control group|no intervention
61957295|NCT04234750|EXPERIMENTAL|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
61957296|NCT01970215|PLACEBO_COMPARATOR|Group 1|TA-8995 0mg (placebo) \& placebo statin
61957297|NCT01970215|EXPERIMENTAL|Group 2|TA-8995 1mg \& placebo statin
61957298|NCT01970215|EXPERIMENTAL|Group 3|TA-8995 2.5mg \& placebo statin
62503670|NCT00647894|EXPERIMENTAL|1|Alprazolam Extended-Release Tablets 1 mg
62503671|NCT00647894|ACTIVE_COMPARATOR|2|Xanax XR Tablets 1 mg
62503672|NCT00367016|EXPERIMENTAL|Omalizumab|Subjects will receive subcutaneous Omalizumab for 6 months. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
61957299|NCT01970215|EXPERIMENTAL|Group 4|TA-8995 5mg \& placebo statin
62503673|NCT00367016|EXPERIMENTAL|Placebo|Subjects will receive subcutaneous placebo for 6 months. Prior to placebo administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
62503674|NCT04544137|EXPERIMENTAL|BOKS + SFSP|Children randomized to the BOKS + SFSP will be invited to attend the one-hour BOKS program four days per week for eight weeks during the summer. The BOKS program will be run by Lifespan employed staff in the hour before the SFSP lunch service at two community locations.
62503675|NCT04544137|NO_INTERVENTION|SFSP|Children randomized to the SFSP alone group will be asked to participate in the SFSP as they would have otherwise.
62503676|NCT02178124|EXPERIMENTAL|dosage 1|drug : 9 people(87.5mg/25cm2) placebo : 3 people(0mg/25cm2)
62503677|NCT02178124|EXPERIMENTAL|dosage 2|"dosage2 period 1 : oral administration drug : 12 people(10mg)~dosage 2 period 2: transdermal administration drug : 9 people(175mg/50cm2) placebo : 3 people(0mg/50cm2)"
62503678|NCT03706391||ALS and PMA Reversals|
62503679|NCT02593019|EXPERIMENTAL|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
62503680|NCT03355352||Patients treated with conventional i.v. PCA|
62503681|NCT03355352||Patients treated with Zalviso|
62503682|NCT02156154|PLACEBO_COMPARATOR|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
62503683|NCT02156154|EXPERIMENTAL|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
62503684|NCT02495376|ACTIVE_COMPARATOR|Group A|Group A participates in the first available MBSR course.
62503685|NCT02495376|ACTIVE_COMPARATOR|Group B|Group B waits 16 weeks before participating in the MBSR course.
62503686|NCT06390865|EXPERIMENTAL|Treatment (sapanisertib [MLN0128 (TAK-228)])|Patients receive sapanisertib (MLN0128 \[TAK-228\]) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.
62503687|NCT01899326|EXPERIMENTAL|Treatment (desipramine, filgrastim)|Participants received desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection began on day 6.
62503688|NCT01334957|EXPERIMENTAL|Intravenous ibuprofen|Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.
62503689|NCT00491257|EXPERIMENTAL|Study Group 1|Participants aged 18 to 60 years at enrollment
62503690|NCT00491257|EXPERIMENTAL|Study Group 2|Participants aged 61 years or older at enrollment.
62503691|NCT02583308|ACTIVE_COMPARATOR|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
62503692|NCT02583308|EXPERIMENTAL|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
62503693|NCT04504006||Cohort A|PMMR + TCL, followed by systematic lymphadenectomy in node positive patients.
62503694|NCT04504006||Cohort B|Therapy according to actual guidelines
62503695|NCT01485471||Medical Tool|Diffuse optical spectroscopy imaging ear exam
61957300|NCT01970215|EXPERIMENTAL|Group 5|TA-8995 10mg \& placebo statin
62503696|NCT01426087|EXPERIMENTAL|endoscopic and somatostatin treatment|
62503697|NCT01426087|OTHER|endoscopic therapy|
61957301|NCT01970215|ACTIVE_COMPARATOR|Group 6|TA-8995 0mg (placebo) \& atorvastatin 20mg
62503698|NCT00819767|EXPERIMENTAL|Aliskiren|For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
62503699|NCT00819767|ACTIVE_COMPARATOR|Valsartan|For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
62503700|NCT04681508|EXPERIMENTAL|All patients|All patients undergo chest CT without contrast enhancement and chest X-ray. Blood and urine sampling from patients subsequently undergoing emergency laparoscopy or laparotomy. Otherwise standard care
62503701|NCT01318161|EXPERIMENTAL|Epidural anesthesia and analgesia|
62503702|NCT01318161|ACTIVE_COMPARATOR|Patient controlled analgesia|
62702537|NCT01563341|EXPERIMENTAL|Deep Brain Stimulation|Parkinson's disease patients who would otherwise be undergoing subthalamic nucleus (STN) deep brain stimulation (DBS) will have dual hemispheric stimulation of the STN and globus pallidus interna (GPi).
61957302|NCT01970215|ACTIVE_COMPARATOR|Group 7|TA-8995 10mg \& atorvastatin 20mg
61957303|NCT01970215|ACTIVE_COMPARATOR|Group 8|TA-8995 0mg (placebo) \& rosuvastatin 10mg
61957304|NCT01970215|ACTIVE_COMPARATOR|Group 9|TA-8995 10mg \& rosuvastatin 10mg
61957305|NCT03369093|ACTIVE_COMPARATOR|Ampicillin arm|Ampicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days
61957306|NCT03369093|EXPERIMENTAL|Amoxicillin arm|Amoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days
61957307|NCT04997434|EXPERIMENTAL|Intervention|After 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. The patient will have 15 to 20 minutes to carry out an artistic activity, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session.
61957308|NCT04997434|NO_INTERVENTION|Control|The questionnaires and VAS will be offered to the control group at the beginning of the wait, then after 30 minutes of waiting under usual conditions.
61957309|NCT02084654|ACTIVE_COMPARATOR|exenatide 5 and 10 mcg 2 times a day|Exenatide in addition to weight loss. Starting dose 5 mcg titrate to 10 mcg
61957310|NCT02084654|PLACEBO_COMPARATOR|placebo|placebo in addition to weight loss
61957311|NCT02829697|ACTIVE_COMPARATOR|Peroneal nerve: Ropivacaine 0.2%, 2.5 mL|Perineural injection of ropivacaine 0.2 %, 2,5 mL
61957312|NCT02829697|ACTIVE_COMPARATOR|Peroneal nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
62503703|NCT04554147|EXPERIMENTAL|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
62503704|NCT06214416|ACTIVE_COMPARATOR|Abstention|These participants will be encouraged to totally avoid alcohol consumption.
62503705|NCT06214416|ACTIVE_COMPARATOR|Mediterranean alcohol-drinking pattern|These participants will be encouraged to change their pattern of consumption to a more Mediterranean way, which includes 5 aspects: moderate alcohol consumption (maximum of 2 drinks/day for women and 4 drinks/day for men), spread consumption throughout the week, drink with meals and never with an empty stomach, prefer wine and mainly red wine, as well as completely avoid episodes of binge-drinking.
61957313|NCT02829697|ACTIVE_COMPARATOR|Peroneal nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
61957314|NCT02829697|ACTIVE_COMPARATOR|Peroneal nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
61957315|NCT02829697|ACTIVE_COMPARATOR|Peroneal nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
61957316|NCT02829697|ACTIVE_COMPARATOR|Sciatic nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
62142763|NCT00294736|EXPERIMENTAL|Arm A|Arm A (Tarceva MTD established in Part I)
62142764|NCT00294736|EXPERIMENTAL|Arm B|Arm B (150 mg Tarceva daily).
62503706|NCT06214416|NO_INTERVENTION|Control of abstainers|This group will include all participants who consume less than 3 alcohol drinks a week at the time of recruitment.
62503707|NCT06214416|NO_INTERVENTION|Control of drinkers|This group will include all participants who don't want to change their alcohol-drinking pattern.
62702538|NCT05600972|NO_INTERVENTION|non-FSH priming|Routine CAPA-IVM treatment will be performed. The oocyte retrieval will be performed 2 days after the randomization accordingly to the current routine procedures. An ultrasound scan will be performed to exclude the development of any dominant follicle.
61957317|NCT02829697|ACTIVE_COMPARATOR|Sciatic nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
61957318|NCT02829697|ACTIVE_COMPARATOR|Sciatic nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
61957319|NCT02829697|ACTIVE_COMPARATOR|Sciatic nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
61957320|NCT02829697|ACTIVE_COMPARATOR|Sciatic nerve: Ropivacaine 0.2%, 30 mL|Perineural injection of ropivacaine 0.2 %, 30 mL
61957321|NCT00713323|EXPERIMENTAL|Sativex|Active treatment
62345847|NCT05467462|EXPERIMENTAL|Carbetocin and Tranexamic acid Group|100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
61957322|NCT02171377|EXPERIMENTAL|Group 2 : quadricipital electrical stimulation|stimulation in addition to rehabilitation (30 min bilateral quadricipital electrical stimulation pd, 5 days per week, 8 weeks)
61957323|NCT02171377|ACTIVE_COMPARATOR|Group 1 : Pulmonary rehabilitation|Pulmonary rehabilitation 3 to 5 times per week, 8 weeks
61957324|NCT05404776|EXPERIMENTAL|Without tension (tension free)|The study group will undergo induction of labor by placement of a transcervical Foley balloon. The balloon tubing will be left free of tension and will hang freely.
61957325|NCT05404776|ACTIVE_COMPARATOR|Tension|The control group will undergo induction of labor by placement of a transcervical Foley balloon. The balloon tubing will be pulled to create tension and will then be taped to the patient's inner thigh.
62142765|NCT06510751||Postoperative meningitis mortality|Patients with postoperative meningitis and mortality in the intensive care unit.
62142766|NCT06510751||Postoperative meningitis survival|Patients who developed postoperative meningitis and were discharged from the intensive care unit.
62142767|NCT01960738|EXPERIMENTAL|Intervention|The intervention group received a pre-dive checklist and a post-dive log
62142768|NCT01960738|NO_INTERVENTION|Control|The control group received the post-dive log only.
62142769|NCT05033327|OTHER|Nutrition and Exercise App|The exercise and nutrition app intervention will be provided to study participants. The app offers self-directed and supervised (virtual) programming to support nutrition and exercise self-management. Each participant follows a program that has been tailored to their overall health, physical function, and needs.
62142770|NCT03936192|EXPERIMENTAL|glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)|glucosamine sulfate 1500mg plus meloxicam 15mg combination, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
61957326|NCT03606499||Inflammatory Bowel Disease (IBD) Participants with EIMs and/or IMIDs|IBD (Crohn's Disease \[CD\] or Ulcerative Colitis \[UC\]) participants with suspected extra-intestinal manifestations (EIMs) and/or one or more immune-mediated inflammatory diseases (IMIDs) will be enrolled into the study to assess effectiveness of ustekinumab on EIMs and/or IMIDs associated with IBD (both CD and UC). Participants will receive ustekinumab at study entry (Week 0) as treatment for IBD according to standard clinical practice and will be followed up to 24 weeks (+/- 3 weeks). Only data available per clinical practice will be collected within this study.
61957327|NCT02211040|EXPERIMENTAL|No general practitioner involvement|The selection and motivation of adults will be conducted by a researcher in the waiting room. There is no extra motivation of the general practitioner.
61957328|NCT02211040|EXPERIMENTAL|General practitioner involvement|An intervention group in which general practitioners select and motivate adults to be more physical active and eat more fruit and vegetables.
61957329|NCT05036759|EXPERIMENTAL|68Ga-FAPI, PET/MR|inject 68Ga-FAPI，and then perform PET/MR
61957330|NCT00571012||Only one group- A|Healthy young subjects aged 18-45.
61957331|NCT05515081|OTHER|vaccinated healthy subject|Procedure/Surgery: blood sample collection at regular intervals
62702539|NCT05600972|ACTIVE_COMPARATOR|FSH priming|Routine CAPA-IVM treatment will be performed. Patients who are randomized into the FSH priming arm will receive two days of FSH injections of 150 IU/day. Oocyte retrieval will be scheduled at 42 hours after the last FSH injection.
61957332|NCT02803632|EXPERIMENTAL|suicide attempt|questionnaires actigraphic recording
61957333|NCT02151383|EXPERIMENTAL|Serelaxin|Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.
61957334|NCT05179798|EXPERIMENTAL|Mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
61957335|NCT05179798|NO_INTERVENTION|Standard of care|Lifestyle modification, insulin therapy if needed; conventional care without a mobile app.
61957336|NCT02378961|EXPERIMENTAL|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
61957337|NCT02378961|EXPERIMENTAL|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
61957338|NCT02378961|EXPERIMENTAL|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
61957339|NCT02378961|EXPERIMENTAL|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
61957340|NCT02378961|EXPERIMENTAL|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
61957341|NCT02378961|EXPERIMENTAL|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
61957342|NCT02378961|EXPERIMENTAL|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
61957343|NCT04003012|ACTIVE_COMPARATOR|EMLA|The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.
61957344|NCT04003012|ACTIVE_COMPARATOR|Lidocaine|The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (\~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.
61957345|NCT04070430|ACTIVE_COMPARATOR|2 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
62142771|NCT03936192|ACTIVE_COMPARATOR|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg plus Chondroitin Sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.
61957346|NCT04070430|ACTIVE_COMPARATOR|4 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
61957347|NCT05613478|EXPERIMENTAL|Experimental group|Preoperative TACE treatment → preoperative camrelizumab combined with apatinib mesylate (q2w, 2 cycles) → radical surgery → postoperative TACE treatment → sequential camrelizumab and apatinib mesylate (q3w, at least 6 cycles) (Note: Surgery at least 1 week after the last administration of neoadjuvant therapy, postoperative TACE treatment within 4\~8 weeks after surgery, camrelizumab combined with apatinib mesylate at 1 week after TACE treatment)
61957348|NCT05613478|ACTIVE_COMPARATOR|Radical surgery|Radical surgery→postoperative TACE treatment
61957349|NCT02473432|EXPERIMENTAL|RMT + usual care|Device: Orygen-Dual® valve trainer Intensity: 30% of maximal respiratory pressures (increasing intervals: 10 cmH2O per week) Training schedule: 5 sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, two sessions per day, 5 days per week, for 3 weeks.
61957350|NCT02473432|EXPERIMENTAL|NMES + usual care|Device: Vital Stim (Chattanooga Group, Hixson, TN, USA) Administration of 80 Hz transcutaneous electrical biphasic stimulus Schedule: 40 minutes per day, 5 sessions per week during hospitalization in the Neurorehabilitation ward (3 weeks approx).
61957351|NCT02473432|ACTIVE_COMPARATOR|Usual care|Usual care (standard multidisciplinary inpatient rehabilitation program) consisting of physical, occupational and speech therapy sessions to improve activities of daily life, mobility and communication skills (minimum 3 hours per day, 5 days a week, during 3 weeks), Standard swallow therapy (usual care of dysphagia in stroke patients) consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
61957352|NCT01725503|EXPERIMENTAL|Creatine and amino acid supplement|
62142772|NCT03936192|PLACEBO_COMPARATOR|Placebo|Placebo administered once daily for 12 weeks
62142773|NCT05454059|ACTIVE_COMPARATOR|Group 1 (HH)|17 systemically healthy + periodontally healthy (normoglycemic)
62142774|NCT05454059|EXPERIMENTAL|Group 2 (HP)|17 systemic healthy + grade A periodontitis
62142775|NCT05454059|ACTIVE_COMPARATOR|Group 3 (T2D+H)|17 T2DM (HbA1c\<%7) + periodontally healthy
62142776|NCT05454059|EXPERIMENTAL|Group 4 (T2D+P)|17 T2DM (HbA1c\<%7) + grade B periodontitis
62142777|NCT05454059|ACTIVE_COMPARATOR|Group 5 (T2D-H)|17 T2DM (HbA1c≥%7) + periodontally healthy
62702540|NCT02911129||Healthy Volunteer|Inclusion Criteria for Healthy Volunteers/Age-matched Controls
61957353|NCT01721655|ACTIVE_COMPARATOR|Spironolactone|Oral spironolactone suspension dosed at 3 mg/kg/day will be administered once-daily to the patients assigned to the treatment arm.
61957354|NCT01721655|PLACEBO_COMPARATOR|Placebo suspension|An oral placebo suspension dosed at 3 mg/kg/day administered once-daily will be given to patients in the placebo arm.
61957355|NCT00885846|ACTIVE_COMPARATOR|Qigong Therapy|
61957356|NCT00885846|ACTIVE_COMPARATOR|PRT|
61957357|NCT00885846|NO_INTERVENTION|Control|
61957358|NCT04546438|EXPERIMENTAL|MiraDry® treatment|"The miraDry System is a noninvasive method that utilizes microwave energy to destroy the sweat glands at the dermal-fat interface.~Each participant will be scheduled one MiraDry ® treatment with the possiblity of a second intervention approximately three months apart if the primary objective is not fullfilled efter the first."
62142778|NCT05454059|EXPERIMENTAL|Group 6 (T2D-P)|17 T2DM (HbA1c≥%7) + grade C periodontitis
62142779|NCT06699914||Naive Group|Japanese patients diagnosed with nAMD who did not receive any anti-vascular endothelial growth factor (VEGF) injections during the 12 months before receiving brolucizumab.
62503708|NCT03069417|EXPERIMENTAL|Intervention: INSPireD|"This 5-8 session group intervention, Integrating Nuanced Support for Perinatal adherence and Depression, aimed to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women. Intervention content was based on two established cognitive-behavioral interventions: problem-solving therapy and Cognitive Behavioral Therapy for Adherence and Depression."
62503709|NCT03069417|OTHER|Treatment-as-usual + abbreviated intervention|This group received treatment-as usual, plus the option of completing an abbreviated version of the intervention (one session of problem-solving related to adherence and mental health) at the conclusion of study.
62503710|NCT02351635||IBD|Adult subjects with inflammatory bowel disease, confirmed by endoscopy and histologic support. Fecal calprotectin Level.
61957359|NCT01244269|EXPERIMENTAL|Methylphenidate 10|Methylphenidate 10mg three times daily for a total of 7 doses.
61957360|NCT01244269|PLACEBO_COMPARATOR|Placebo 10|Placebo capsule three times daily for a total of 7 doses.
61957361|NCT01244269|EXPERIMENTAL|Methylpheindate 20|Methylphenidate 20mg three times daily for a total of 7 doses.
61957362|NCT01244269|PLACEBO_COMPARATOR|Placebo 20|Placebo capsule three times daily for a total of 7 doses.
61957363|NCT00870441|EXPERIMENTAL|1. ASP2151|
62142780|NCT06699914||Pre-treated Group|Japanese patients diagnosed with nAMD who received at least one injection of another anti-VEGF treatment during the 12 months before receiving brolucizumab.
61957364|NCT00870441|ACTIVE_COMPARATOR|2. Valacyclovir|
61957365|NCT00870441|PLACEBO_COMPARATOR|3. Placebo|
61957366|NCT05281211|EXPERIMENTAL|Preoperative Nutrition+Exercise|Preoperative nutrition and exercise pre-habilitation followed by major liver resection.
61957367|NCT05281211|NO_INTERVENTION|Upfront Surgery|Upfront major liver resection.
62142781|NCT04242212||Clinic-based|Women who get misoprostol from a clinic-based provider
62503711|NCT02351635||IBS|Adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria. Fecal calprotectin Level.
62142782|NCT04242212||PMV-based|Women who get misoprostol from a patent medicine vendor
61957368|NCT02661893|EXPERIMENTAL|JNJ-42847922 and Rifampin|A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ-42847922 on Day 1; A single oral dose of 40 mg (=2\*20 mg) dose of JNJ-42847922 dosed with one oral dose of rifampin 600 mg (2\*300 mg) on Day 5; A single oral dose of 40 mg (=2\*20 mg) dose of JNJ-42847922 dosed on Day 12, following once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5-12.
61957369|NCT06008821|EXPERIMENTAL|Intervention Group|Bilateral, single level, paravertebral blockade with 0.25% ropivicaine
61957370|NCT06008821|SHAM_COMPARATOR|Control Group|Bilateral, single level, subcutaneous sham block with normal saline
61957371|NCT01937416|EXPERIMENTAL|autologous bone marrow mononuclear cells|Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
61957372|NCT02848040|EXPERIMENTAL|Single Arm|All patients will receive the same interventions. Single are only
61957373|NCT03164135|EXPERIMENTAL|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
61957374|NCT00927602|EXPERIMENTAL|fondaparinux|
61957375|NCT00545662|EXPERIMENTAL|Placebo|Placebo tablets formulated to resemble the citicoline treatment.
61957376|NCT00545662|EXPERIMENTAL|Citicoline|Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
61957377|NCT06504784|EXPERIMENTAL|Dietary Fibre Mixture|Study participants receive 10g/day of dietary fibre mixture (a mixture of oligo-and polysaccharides), divided into two doses and administered orally for 6 weeks.
61957378|NCT06504784|PLACEBO_COMPARATOR|Placebo|Study participants receive 10g/day of placebo (glucose) matching the fibre mixture in colour and flavor, divided into two doses and administered orally for 6 weeks.
61957379|NCT01219569||2. Sevoflurane|Subjects will receive sevoflurane at 1.5% and 2.5% end tidal after steady state maintenance has been achieved and have pupillometry readings taken and every 10 minutes for 30 minute at each drug dose.
62142783|NCT00999596||FFDM (Full Field Digital Mammography)|Mammograms from the Philips Digital System
62142784|NCT01772212|EXPERIMENTAL|A(test)/B(reference)|Initial administration of test and crossover to reference
62142785|NCT01772212|EXPERIMENTAL|B(reference)/A(test)|Initial administration of reference and crossover to test
62142786|NCT06698627|ACTIVE_COMPARATOR|Poise Impressa|Participants will be asked to use Poise Impressa for 7 days based on package insert
62142787|NCT06698627|ACTIVE_COMPARATOR|Revive|Participants will be asked to use Revive continence device based on package insert.
62142788|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
62142789|NCT01241526|EXPERIMENTAL|Disease management program|
62142790|NCT01241526|ACTIVE_COMPARATOR|Usual site management|
62142791|NCT03653364|EXPERIMENTAL|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
61957380|NCT01219569||1.Propofol|1.Subjects will receive propofol infusion and have pupillometry readings taken in both eyes after induction, after steady state maintenance has been achieved and at 30 minutes
61957381|NCT02250781|EXPERIMENTAL|Treatment (Oral ONC201)|Patients receive Oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61957382|NCT01606800|EXPERIMENTAL|44 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.
61957383|NCT01606800|EXPERIMENTAL|20 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.
61957384|NCT01256008|PLACEBO_COMPARATOR|stage 1 Clinical Management|The group will receive clinical management treatment only each session.
62503712|NCT02351635||other GI disorders|Adult subjects with gastrointestinal disorders other than IBD or IBS. Fecal calprotectin Level.
61957385|NCT01256008|EXPERIMENTAL|stage1 CBT|The experimental group will receive CBT
61957386|NCT01256008|NO_INTERVENTION|stage1 Control group|Participants with breast cancer in the control group received standard medical care, but don't receive any other interventions.
61957387|NCT04096729||patients who have consulted and need compression therapy using|1) age from 18 to 75 years; 2) compression therapy prescribed by a phlebologist. The exclusion criterion is hearing impairment, which could interfere with a telephone questionnaires.
61957388|NCT03839979||HCV positive patients|Patients tested positive for the hepatitis c virus antibodies by BIOLINE HCV kits.
61957389|NCT03839979||HCV negative patients|Patients tested negative for the hepatitis c virus antibodies by BIOLINE HCV kits.
62142792|NCT01753167|EXPERIMENTAL|MCMV5322A/MCMV3068A|Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).
62503713|NCT02351635||pediatric|Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
62503714|NCT02351635||healthy controls|Normal adult subjects with no abdominal complaints. Fecal calprotectin Level.
62503715|NCT04366284|ACTIVE_COMPARATOR|NOCTEM only (NOCTEM)|No external or internal facilitation
62142793|NCT01753167|PLACEBO_COMPARATOR|Placebo|Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.
62503716|NCT04366284|ACTIVE_COMPARATOR|External Facilitation (NOCTEM+EF)|External facilitation only
62503717|NCT04366284|ACTIVE_COMPARATOR|External and Internal Facilitation (NOCTEM+EF/IF)|External and internal facilitation
62503718|NCT06513949|EXPERIMENTAL|IC14 (atibuclimab)|IC14 (atibuclimab) is a recombinant monoclonal antibody against human CD14
62503719|NCT06513949|PLACEBO_COMPARATOR|Identical-appearing placebo|Sterile normal saline
62503720|NCT01302457||Healthy Same Subjects|The control group will be 19 years or older and be randomly picked from from volunteer staff at Saint Elizabeth Regional Medical Center. This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects
62503721|NCT01302457||Health Volunteers|"The control group will be 19 years or older and be randomly picked from volunteer staff at Saint Elizabeth Regional Medical Center.~DESIGN This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects"
62503722|NCT01422928|NO_INTERVENTION|Standard treatment|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~* before radiation~* at 1st follow up 4-10 weeks after radiation completion~* at second follow up 6 months after 1st follow up"
61957390|NCT05706532||Healthy|30 healthy subjects; age \>18; sinus rhythm; absence of autonomic diseases or dysfunctions.
61957391|NCT04655638|EXPERIMENTAL|High Flow Nasal Therapy|High flow nasal therapy
61957392|NCT04655638|ACTIVE_COMPARATOR|Conventional Oxygen Therapy|Conventional Oxygen therapy
61957393|NCT00884871||Laparoscopic adjustable gastric banding|100 obese women undergoing laparoscopic adjustable gastric banding
61957394|NCT00717197|EXPERIMENTAL|Capecitabine|Capecitabine (1,000-1,250 mg/m2) taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
61957395|NCT06095947||There was an immunological history group|l Children who have received two or more doses of influenza vaccine (4 weeks apart) before the influenza season (2 doses of influenza vaccine do not need to be administered in the same epidemic season or consecutive epidemic season, and can be interpreted as children who have received two or more cumulative doses).
61957396|NCT06095947||There was no immunological history group|l Children who have not received or previously received \<2 doses of influenza vaccine before the epidemic season.
61957397|NCT00006237|ACTIVE_COMPARATOR|Arm I|Patients receive interferon alfa IV on days 1-5 of weeks 1-4 followed by interferon alfa subcutaneously (SC) on days 1, 3, and 5 of weeks 5-52 in the absence of disease progression or unacceptable toxicity.
62142794|NCT00989118|EXPERIMENTAL|Laser treatment|
62142795|NCT00989118|ACTIVE_COMPARATOR|Endometrioma cystectomy|
62142796|NCT00145145|EXPERIMENTAL|MAGE-3.A1 Peptide mixed with CpG 7909|Patients were vaccinated every two weeks on six occasions. On each vaccination day, the MAGE-3.A1 peptide (300 mcg) mixed with CpG 7909 (5 mg) was administered twice intradermally (10% of the dose each) and twice subcutaneously (40% of the dose each) in the arms and thighs.
62142797|NCT06167434|EXPERIMENTAL|Single Arm|Insertable Cardiac Monitor Implant.
62503723|NCT01422928|EXPERIMENTAL|Acupuncture|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers with concurrent acupuncture once a week for 4 weeks.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~* before radiation~* at 1st follow up 4-10 weeks after radiation completion~* at second follow up 6 months after 1st follow up"
62702541|NCT02911129||Patients|Patients with neglect after a right hemisphere brain lesion
61957398|NCT00006237|EXPERIMENTAL|Arm II|Patients receive cisplatin IV over 30 minutes followed by vinblastine IV on days 1-4. Patients also receive dacarbazine IV over 1 hour on day 1, interleukin-2 IV over 96 hours on days 1-4, and interferon alfa SC on days 1-5, 8, 10, and 12. In addition, patients receive filgrastim (G-CSF) SC on days 6-15. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
61957399|NCT00528788|EXPERIMENTAL|Pre and post doxicalciferol|ESRD: all patients with secondary hyperparathyroidism who are vitamin D naive will receive doxercalciferol 2 mcg or 4 mcg 3 times per week fopr 30 days (1 month). Blood work and vascular laboratory studies will be performed pre and post treatment.
61957400|NCT00354536|ACTIVE_COMPARATOR|albiglutide|albiglutide injection
61957401|NCT00354536|PLACEBO_COMPARATOR|albiglutide placebo|placebo injection
61957402|NCT04213079|EXPERIMENTAL|Vestibulo-ocular reflex (VOR)|Treatment by re-adaptation of the vestibulo-ocular reflex (VOR) for participants with motion triggered MdDS
61957403|NCT04213079|EXPERIMENTAL|Habituation of velocity storage|Participants with motion triggered MdDS
61957404|NCT04978961|EXPERIMENTAL|Focused Acceptance and Commitment Therapy (FACT)|"Focused Acceptance \& Commitment Therapy (FACT): FACT is a brief type of cognitive behavioral therapy that helps patients reduce disability through increased acceptance, reconnection with values, and reduced unhelpful control/coping strategies. Patients randomized to the intervention group received FACT per the study manual, delivered by an integrated Behavioral Health Consultant (BHC). Patients had one individual visit (30 minutes) and three consecutive weekly group visits (one hour) followed by a booster visit two months later. These classes (group visits) were rolling, not cohort-driven, meaning new and returning patients will be attending together. After the individual BHC visit and each class, patients had behavioral homework to complete."
61957405|NCT04978961|ACTIVE_COMPARATOR|Enhanced Treatment as Usual (ETAU)|"Patients randomized to the Enhanced-Treatment As Usual (ETAU) group received enhancement of usual primary care via 1-page (2-sided) educational handouts on four topic areas: Sleep, Pacing, Relaxation and Goal Setting. All topics have an evidence base in standard Cognitive Behavioral Therapy treatment of pain. One handout per assessment visit was given to each patient. Patients will continue to see their primary care clinicians and have access to all routine clinical services throughout the study."
61957406|NCT03806790|EXPERIMENTAL|LEO 90100 foam|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g
61957407|NCT03806790|ACTIVE_COMPARATOR|Dovobet® ointment|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g
61957408|NCT04017078||Patients who referred for periodontal therapy|Patients who referred to Baskent University, Faculty of Dentistry, Department of Periodontology, during 2016-2018
61957409|NCT03047057|EXPERIMENTAL|Lidocaine|IV Lidocaine infusion
61957410|NCT03047057|PLACEBO_COMPARATOR|Control|IV normal saline infusion
61957411|NCT00972868|EXPERIMENTAL|COPD|Thirty adult (\> 18 years of age) patients in acute hypercapnic respiratory failure resulting from COPD and requiring Noninvasive Positive Pressure Ventilation (NPPV)
61957412|NCT03648983|ACTIVE_COMPARATOR|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
61957413|NCT03648983|EXPERIMENTAL|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
61957414|NCT03311633|EXPERIMENTAL|3 week percutaneous pinning group|Percutaneous pinning time will be for three weeks and short cast immobilization for six weeks.
61957415|NCT03311633|ACTIVE_COMPARATOR|6 week percutaneous pinning group|Percutaneous pinning time will be for six weeks and also short cast immobilization.
61957416|NCT02056496|EXPERIMENTAL|Pomegranate extract|The same group will consume the two types of pomegranate extract (crossover study).
61957417|NCT04578639|EXPERIMENTAL|Rituximab|Rituximab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial dose; 1000 mg Subsequent doses; 500 mg
61957418|NCT04578639|ACTIVE_COMPARATOR|Ocrelizumab|Ocrelizumab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial and subsequent doses; 600 mg
61957419|NCT04790422|EXPERIMENTAL|Dietary fiber 1|
61957420|NCT04790422|EXPERIMENTAL|Dietary fiber 2|
61957421|NCT04790422|EXPERIMENTAL|dietary fiber 3|
61957422|NCT04790422|EXPERIMENTAL|caseine protein hydrolisate|
62142798|NCT04954885||Ancillary-correlative (biospecimen, questionnaire, testing)|Patients receive treatment by their treating physician as described in the INSIGNA protocol based on their designated treatment arm. Patients then undergo stool sample collection, complete questionnaires and functional status assessments, such as short physical performance battery over 10 minutes and 6 minute walk test, at baseline, days 40 (cycle 3), day 80 (cycle 5), day 180 (cycle 10) and end of treatment (up to 2 years).
62503724|NCT00559637|EXPERIMENTAL|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
62142799|NCT01449760|NO_INTERVENTION|No treatment|
61957423|NCT04790422|PLACEBO_COMPARATOR|Maltodextrine|
61957424|NCT01628978||Auscultation group|The depth of endotracheal tube placement is determined by auscultation.
61957425|NCT01628978||Ultrasonography group|The depth of placement of endotracheal tube placement is determined by ultrasonographic finding of pleural sliding sign.
61957426|NCT02988843|EXPERIMENTAL|Brentuximab Vedotin & Bevacizumab|"* Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.~* Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
62142800|NCT01449760|ACTIVE_COMPARATOR|Physical Therapy|
62142801|NCT01449760|EXPERIMENTAL|Wii Balance group|
61957427|NCT06084234|ACTIVE_COMPARATOR|Arm A: Semi-annual surveillance using liver ultrasound +/- alpha-fetoprotein|Participants in this arm will undergo current standard of care surveillance procedures i.e. liver ultrasound with or without alpha fetoprotein (AFP) measurement.
61957428|NCT06084234|EXPERIMENTAL|Arm B: Semi-annual surveillance using GALAD|For participants in this arm, study team will order GALAD measurement every 6 months +/- 3 months.
62142802|NCT06700252|EXPERIMENTAL|Vestibular Rehabilitation|This arm of the study received the vestibular rehabilitation treatment in addition to following traditional protocol.
62142803|NCT06700252|ACTIVE_COMPARATOR|Traditional Treatment|This arm of the study received the traditional protocol in a stepwise progression only.
62702542|NCT06750783|EXPERIMENTAL|Atorvastatin group|According to routine clinical practice, patients with dyslipidemia with prediabetes were given atorvastatin at a dose of 20 mg qd；
62702543|NCT06750783|EXPERIMENTAL|Xuezhikang group|The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;
62702544|NCT05998395|EXPERIMENTAL|Ruxolitinib|Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-73 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
62702545|NCT05008848|EXPERIMENTAL|Group I (SGR program, text messages)|Patients participate in schedule gradual reduction program over 8 weeks to reduce the frequency of cigarette use. Patients also receive cessation support messages via text messages for 12 weeks.
62702546|NCT05008848|ACTIVE_COMPARATOR|Group II (booklet)|Patients receive NCI's Clearing the Air booklet to help plan to gradually quit smoking.
62702547|NCT03701282|EXPERIMENTAL|Arm A (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO daily on days 1-28 and obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-28 of cycles 3-14. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and CT scans before and after treatment and collection of blood throughout the study.
62702548|NCT03701282|ACTIVE_COMPARATOR|Arm B (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO and obinutuzumab as in arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and CT scans before and after treatment and collection of blood throughout the study.
62702549|NCT06748183|EXPERIMENTAL|Functional Power Training|Group A will participate in Functional Power Training (FPT) alongside routine physical therapy for children with Cerebral Palsy. The standard therapy includes hot packs for muscle relaxation, isometric exercises for motor skills, muscle strength, and coordination, as well as passive stretching. Therapists will also utilize sit-to-stand exercises to enhance gait and overall functional abilities. Over a 14-week intervention period, FPT will include three 60-minute sessions each week, focusing on improving walking capacity and muscle strength. Each session will consist of a 10-minute warm-up, 35 minutes of 3 to 4 power exercises, and a 15-minute cool-down phase, conducted in small groups of 3-6 children with a supervising therapist. Participants will wear sports shoes without orthoses, and power exercises will target functional, multi-joint movements, emphasizing ankle push-off and velocity, with adjustments made for progressive challenges.
62702550|NCT06748183|OTHER|Routine Physical therapy|Routine physical therapy for children with Cerebral Palsy includes hot packs for muscle relaxation and isometric exercises aimed at improving motor skills, muscle strength, and coordination. Passive stretching is also part of the treatment plan. Therapists use sit-to-stand exercises to enhance gait, posture, and overall functional abilities. Regular progress evaluations are conducted to adjust interventions as needed, ensuring continuous improvement. The overall goal is to optimize mobility, enhance walking ability, and improve the child's quality of life.
62702551|NCT03244384|EXPERIMENTAL|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, CT urography, and/or MRI throughout the trial. Patients may also undergo a cystoscopy and blood sample collection during screening and on study.
62702552|NCT03244384|ACTIVE_COMPARATOR|Arm B (observation)|Patients undergo observation. Patients undergo a CT scan, CT urography, and/or MRI throughout the trial. Patients may also undergo a cystoscopy and blood sample collection during screening and on study.
62702553|NCT06748378|EXPERIMENTAL|Conventional rehabilitation|"In conventional rehabilitation, patients performed daily physiotherapy, which included intensive preparatory training for standing and sitting positions, strengthening exercises, weight-bearing exercises, and balance and coordination exercises (from 40 to 60 minutes of therapy).~Interventions:~Procedure: Conventional rehabilitation, the Erigo®Pro table, motor imagery"
62736655|NCT02934841|EXPERIMENTAL|Conbercept|The patients are followed on a monthly basis until 12 months. Three intravitreal injections of conbercept at a dosage of 0.5 mg are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
61957429|NCT06310538|EXPERIMENTAL|Kou Sha group|Generally, the Kou Sha therapy group needs to kou sha 2-3 times, and after each kou sha, it is necessary to rest for 1 week or all the shas in the part fade before they can be kou sha again. The duration of treatment is 1 menstrual cycle.
61957430|NCT06310538|ACTIVE_COMPARATOR|Control group|The control group is treated with conventional Western medicine, and according to the patient's condition, Chinese patent medicine treatment, psychological counseling and lifestyle adjustment are carried out. The duration of treatment is 1 menstrual cycle. Stop all medications during menstruation. During this period, avoid excessive fatigue and mental stimulation, and avoid spicy and irritating foods
61957431|NCT04826991|ACTIVE_COMPARATOR|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat \>99.9% of all bacteria, protozoa, and most viruses in water supplies.
61957432|NCT04826991|SHAM_COMPARATOR|Inactive UV Device|A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).
62142804|NCT02656147|EXPERIMENTAL|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
62142805|NCT02656147|EXPERIMENTAL|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
62142806|NCT02656147|EXPERIMENTAL|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
61957433|NCT05438394|EXPERIMENTAL|melphalan hydrochloride for injection|Drug Name: melphalan hydrochloride The dosage of different dosage groups were: 9 mg/m2; 18 mg/m2; 27 mg/m2; 40 mg/m2 Administration frequency: once for each subject
61957434|NCT05823129|NO_INTERVENTION|Standard Group|"Usual clinical protocol is followed, the caregiver is given verbal training and assistive instructions by therapists and clinicians before patient discharge. Brief pamphlets are provided on post-operative care of patients. Patients are encouraged to perform rehabilitative exercises according to what they have learned during the in-patient stay.~Remote-TUG app is only used in the first and final assessment at day 30."
61957435|NCT05823129|EXPERIMENTAL|Intervention Group|"A recruitment assessment videoconference is scheduled at the 1st post-discharge week providing clear instructions on how to perform daily TUG test. The TUG test is to be performed at least twice in the morning and twice afternoon and complimented by other specific training exercises as specified in HSH1. Training instructions and assessment is performed by videoconference to ascertain that both the patient and the caregiver can follow instructions in using the remote-TUG smartphone app and safety measures are understood and applied when assisting the patients in exercises. Clear video instructions and multimedia for review will be provided. Interim videoconference will be conducted again after week 2 to ascertain adherence. Non-adherence can be immediately detected by remote data collection from the remote-TUG server interface. Non-adherence will trigger phone calls and videoconferences serving as reminders and performing troubleshooting."
61957436|NCT03424863|EXPERIMENTAL|Aortic stent graft patients|Patients who have received an aortic stent graft who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
61957437|NCT03424863|EXPERIMENTAL|Healthy volunteers|Healthy volunteers in general good health with no history of heart disease who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
61957438|NCT00985569||Lubiprostone|Subjects switching from current bowel medicines to lubiprostone
61957439|NCT02458040||Biomarker-positive patients|
61957440|NCT02458040||Biomarker-negative patients|
61957441|NCT02458040||All patients|
61957442|NCT00798980||Arm 1|
61957443|NCT04527705|ACTIVE_COMPARATOR|1-vist endodontic retreatment|Non-surgical root canal retreatment performed in one visit
61957444|NCT04527705|ACTIVE_COMPARATOR|2-vist endodontic retreatment|Non-surgical root canal retreatment performed in two visits
61957445|NCT04260152|ACTIVE_COMPARATOR|Control: CAF + CTG|Following root preparation and conditioning, the CTG is obtained from the palate according to the randomization scheme and shaped to the recipient site and may be sutured to the papilla region and the coronally advanced flap (CAF) is sutured into place.
62142807|NCT04257799||Women with breast cancer diagnosis|Women with diagnosis of invasive breast cancer based on pre-surgical biopsy, and scheduled for breast-conserving surgery in the Dartmouth-Hitchcock (DH) Outpatient Surgical Center.
62142808|NCT01920932|EXPERIMENTAL|Treatment|Participants receive AEPA regimen (brentuximab vedotin, etoposide, prednisone, doxorubicin), and CAPDac regimen (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine(R)). Filgrastim may be given as clinically indicated. For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given. Some participants may volunteer to complete the quality of life assessment.
62142809|NCT04274530|EXPERIMENTAL|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy (CBT). Participants will complete a series of online modules via a mobile application in addition to standard of care for their fracture injury. Participants will be assigned a dedicated CBT therapist, and receive feedback and support from their therapist via in-app messaging. The CBT program will last approximately 6-8 weeks.
62142810|NCT04274530|NO_INTERVENTION|Control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
62142811|NCT00145587|OTHER|1|
62503725|NCT04590781|EXPERIMENTAL|Part A: XmAb18087 Monotherapy|Part A, will enroll participants with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.
62503726|NCT04590781|EXPERIMENTAL|Part B: XmAb18087 + pembrolizumab|Part B, will enroll participants with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.
62702554|NCT06748378|EXPERIMENTAL|Erigo®Pro|"Interventions: Effective therapy included 1 session on a tilting table at an angle of 42° for 20 minutes, 5 times a week (Monday to Friday) at a speed of 32 steps per minute, followed by a physiotherapy session for two weeks.~Interventions:~Procedure: Conventional rehabilitation, the Erigo®Pro table, motor imagery"
61957446|NCT04260152|EXPERIMENTAL|Test: CAF + Geistlich Fibro-Gide® (test)|Following root preparation and conditioning, Geistlich Fibro-Gide® is cut to size and shaped to the recipient and may be sutured and the coronally advanced flap (CAF) is sutured into place.
61957447|NCT00730145|EXPERIMENTAL|PD-0332334|
61957448|NCT00291577|EXPERIMENTAL|1|
61957449|NCT01781143|EXPERIMENTAL|Perform echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
61957450|NCT00319553|EXPERIMENTAL|Adacel® Vaccine Group|
61957451|NCT00319553|ACTIVE_COMPARATOR|BOOSTRIX® Vaccine Group|
61957452|NCT01073033|EXPERIMENTAL|oral supplement1|Oral supplement for pregnant and lactating mothers
61957453|NCT01073033|ACTIVE_COMPARATOR|oral supplement 2|Oral supplement for pregnant and lactating mothers
61957454|NCT01073033|NO_INTERVENTION|Reference|No oral supplementation during pregnancy and lactating.
61957455|NCT03447704|EXPERIMENTAL|BCD-085 (netakimab)|
61957456|NCT03447704|PLACEBO_COMPARATOR|Placebo|
61957457|NCT04014816||Group I|Patients who had GI dysfunction (Group I) for one or more occasions.
61957458|NCT04014816||Group II|Patients who had normal GI function (Group II) for one or more occasions.
61957459|NCT03178903|ACTIVE_COMPARATOR|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
61957460|NCT03178903|SHAM_COMPARATOR|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
62142812|NCT03594305|EXPERIMENTAL|Educational Intervention Arm|Villages randomized to this arm will receive a one-day educational seminar, which their religious leaders of all denominations will be invited to attend. The seminar will address religious, cultural, and medical aspects of family planning. Leaders who attend will also have the opportunity to participate in mentorship group discussions after the intervention. In addition, both villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
62142813|NCT03594305|NO_INTERVENTION|Control arm|Villages randomized to this arm will not receive the educational seminar. These villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
62142814|NCT06487702|EXPERIMENTAL|Experimental:fruquintinib+Candonilimab + Tegafur，Gimeracil and Oteracil Potassium|"Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w"
62503727|NCT04590781|EXPERIMENTAL|Part C: XmAb18087 monotherapy|Part C will enroll participants with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.
62503728|NCT05966207|EXPERIMENTAL|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation (ICS) program to be implemented is called Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers (MD3). It was specifically designed to be applied in a home context, with informal/family caregivers taking charge of implementing the stimulation sessions (Apostolo, Silva, Costa \& Bobrowicz-Campos, 2019; Yates et al., 2015). The MD3 program has been translated and validated for the Portuguese culture and language (Silva, 2019)."
62503729|NCT00817141||Without urinary catheter|
62503730|NCT05377125|EXPERIMENTAL|Response Inhibition Training (RIT)|Response Inhibition Training (RIT) is a about 40-level computer game designed to offer systematic practice of RI. Participants use the computer keyboard and mouse to respond to the demands of trials that are designed to offer training on response inhibition abilities, including suppressing pre-potent but irrelevant stimuli and responses. Each training session will last approximately 45 minutes. All participants will be offered a minimum of 8 sessions. Throughout training, we will continually monitor their behavioral RI index (= stop signal reaction time; SSRT) using a stop-signal task. If a participant's Index SSRT fails to reach a criterion-level reduction (i.e., approximately 1 SD) after the standard 8 session intervention, the RIT intervention will be extended up to 16 sessions until the criterion-level improvement in behavioral RI is attained.
61957461|NCT05282862|ACTIVE_COMPARATOR|Freehand|Conventional bone augmentation using a particulate graft material (DBBM) and a collagen barrier membrane.
61957462|NCT05282862|EXPERIMENTAL|Guided|Bone augmentation performed using the materials as in the Freehand group, but using a surgical guide to help define the shape of the guide.
62142815|NCT03611088|EXPERIMENTAL|Newborns submitted to Kangaroo Position.|
62142816|NCT03611088|NO_INTERVENTION|Newborns not submitted to Kangaroo Position.|
62142817|NCT01180231|ACTIVE_COMPARATOR|Moxonidine|
62142818|NCT01180231|ACTIVE_COMPARATOR|Diet|
62503731|NCT05377125|PLACEBO_COMPARATOR|Placebo Training (PLT)|This training condition is designed to serve as an appropriate control condition for RIT, by providing no active ingredient of RI training components, while maintaining the overall training materials and structure similar. Similar to RIT, PLT uses the same task materials and a similar 40-level game structure. However, PLT will present simple RI-irrelevant visual judgment tasks to avoid changing RI-relate processes. The number of 45-min training sessions will be determined by their counterpart RIT participants through a yoked-control design.
62503732|NCT05008562||COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|"Patients over the age of 18 who are hospitalized in our intensive care unit with a diagnosis of COVID-19 will be included in the study.~The day the patients are admitted to the intensive care unit will be considered the 1st day of the study. SOFA, qSOFA, APACHE II, CRP, procalcitonin values will be recorded on the first day. On the first day of our patients, rectus femoris muscle thickness measurement will be done ultrasonographically (bilateral). In addition, bilateral thigh circumference will be measured anthropometrically (with a tape measure). It is planned to evaluate the muscle strength of the patients according to the MRC (Medical Research Council) scoring.~In addition to these measurements, the creatine kinase values in the routine clinical follow-up of the patients, the differences between the fluid intake and output values, inotropic supplements used in their treatment, diuretic needs, and neuromuscular blocker use will also be noted."
62503733|NCT04655235||patients with schizophrenia|200 patients with a DSM 5- diagnosis of schizophrenia
62142819|NCT01180231|ACTIVE_COMPARATOR|Moxonidine and diet|Subjects will be asked to take moxonidine and follow dietary plan designed by a qualified nutritionist for 6 months.
62142820|NCT01180231|NO_INTERVENTION|Control|Subjects will not be asked to take any interventions.
62142821|NCT02684435|EXPERIMENTAL|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
62142822|NCT01263496|EXPERIMENTAL|Alogliptin 6.25 mg QD|
62142823|NCT01263496|EXPERIMENTAL|Alogliptin 12.5 mg QD|
62142824|NCT01263496|EXPERIMENTAL|Alogliptin 25 mg QD|
62142825|NCT01263496|EXPERIMENTAL|Alogliptin 50 mg QD|
62142826|NCT01263496|ACTIVE_COMPARATOR|Voglibose 0.2-mg TID|
61957463|NCT00339521||Case-Parent Triad|Childhood Asthmatics (aged 4-17) are Cases; biologic parents of cases are genetic Controls.
61957464|NCT05090007||mTBI|A TBI is caused by a bump, blow, or jolt to the head that disrupts the normal function of the brain. Not all blows or jolts to the head result in a TBI.
61957465|NCT05090007||HC|Healthy controls
62503734|NCT04655235||healthy relatives of patients with schizophrenia|200 healthy relatives of the patients with schizophrenia
62503735|NCT04655235||healthy control subjects|healthy control subjects without relatives with mental disorders
62503736|NCT05774652|EXPERIMENTAL|Diet + physical activity|Diet + physical activity Dietary advise and advise on physical activity
62503737|NCT05774652|NO_INTERVENTION|Control group|No intervention
62503738|NCT05049031|EXPERIMENTAL|Breast cancer treated with hormone therapy|Adult patients with T1-T3, N0-N2, M0 breast cancer and referred to the Menopause Center of Toulouse Hospital for their breast cancer
62503739|NCT01322334|EXPERIMENTAL|Singing exercises|
62503740|NCT04174573|EXPERIMENTAL|Group therapy only (GTO)|Patients in GTO group will receive structured group therapy programme
62503741|NCT04174573|EXPERIMENTAL|Group therapy with tDCS (GT-tDCS)|Patients in this group will receive group therapy along-with tDCS intervention
62503742|NCT06504303|EXPERIMENTAL|3D-printed socket|The 3D scan of the participant's residual limb will be digitally-modified and fabricated using 3D printing.
62503743|NCT00232479|EXPERIMENTAL|arm 1|single arm study evaluating the efficacy of neoadjuvant taxotere, herceptin and carboplatin given in a dose dense fashion
62503744|NCT04792489|EXPERIMENTAL|Single, open label|
62503745|NCT00792207|EXPERIMENTAL|Intervention|"Intervention Group:~The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data recorded by an activity monitor."
62503746|NCT00792207|ACTIVE_COMPARATOR|Control|The control group will use an activity monitor and will have access to a website to monitor activity, but will not receive the Virtual Coach program.
62503747|NCT06435832|ACTIVE_COMPARATOR|just absorbable gelatin|After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
62345848|NCT05467462|EXPERIMENTAL|Oxytocin and Tranexamic acid Group|The oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
62345849|NCT02491697|ACTIVE_COMPARATOR|Capecitabine Monotherapy|"Patients with advanced breast cancer accept capecitabine monotherapy.~Drug: Capecitabine"
62345850|NCT02491697|EXPERIMENTAL|DC-CIK Immunotherapy+Capecitabine|"Biological/Vaccine: DC-CIK DC-CIK immunotherapy combined with capecitabine are used to treat advanced breast cancer.~Drug: Capecitabine"
62503748|NCT06435832|ACTIVE_COMPARATOR|absorbable gelatin with Chlorhexidine gel|After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
62503749|NCT06435832|ACTIVE_COMPARATOR|absorbable gelatin with tranexamic acid|Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
62345851|NCT05931055||ovarian cancer group|patients confirmed with ovarian cancer
62345852|NCT05931055||ovarian cyst group|patients confirmed with benign ovarian csyt
62345853|NCT00599027|EXPERIMENTAL|Mometasone furoate nasal spray|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
62503750|NCT02752386|EXPERIMENTAL|Biofeedback Training 1|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide pain relief when relaxation is achieved.
62503751|NCT02752386|ACTIVE_COMPARATOR|Biofeedback Training 2|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide a painful context in which to practice relaxing.
62503752|NCT02752386|ACTIVE_COMPARATOR|Biofeedback Training 3|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback.
62503753|NCT01374724|EXPERIMENTAL|Ban & Informational Pamphlet|Following 8.5 weeks of cessation subjects are given an informational pamphlet on tobacco cessation and relapse prevention.
61957466|NCT03800797|EXPERIMENTAL|LX-P group|loxoprofen sodium hydrogel patch (LX-P) 100 mg per day for 4 weeks
62345854|NCT00599027|PLACEBO_COMPARATOR|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
62345855|NCT04945824|EXPERIMENTAL|Novel Intracanalicular Insertion Device|
62345856|NCT01861054|EXPERIMENTAL|Treated patients - Total|Patients eligible will be treated with Reparixin as add-in monotherapy
62345857|NCT00985556|EXPERIMENTAL|Arm I|Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
62345858|NCT00985556|EXPERIMENTAL|Arm II|Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
62503754|NCT01374724|EXPERIMENTAL|Ban & Tailored Pamphlet|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force
62736656|NCT02934841|SHAM_COMPARATOR|sham|The patients are followed on a monthly basis until 12 months. Three intravitreal sham injections are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
61957467|NCT03800797|ACTIVE_COMPARATOR|LX-T group|loxoprofen sodium tablet (LX-T) 60 mg t.i.d. for 4 weeks
62345859|NCT03308565|EXPERIMENTAL|Phase I|Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
62345860|NCT01509872|EXPERIMENTAL|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behaviour Therapy (Cohen, Mannarino, Deblinger, 2006; Smith and Saunders, 2005) is a child-friendly, manualised psychological intervention for children who experience nightmares, flashbacks, anxiety, anger, social isolation, poor concentration or self-blame after experiencing or witnessing a violent and terrifying life event (e.g. rape, murder, abduction etc). This intervention was culturally modified for use with war-affected children.
62503755|NCT01374724|EXPERIMENTAL|Ban & Tailored Pamphlet & Intervention|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force. In addition they are given a face to face relapse prevention intervention.
62503756|NCT03110016|EXPERIMENTAL|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
62503757|NCT02909517||Choroidal nevus|Requires distinction from melanoma through diagnostic testing (low-risk features)
62503758|NCT02909517||Choroidal indeterminate melanocytic lesion|Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
62503759|NCT02909517||Choroidal melanoma|Requires confirmation of diagnosis and evaluation for potential metatstases
62503760|NCT02909517||Suspected metastatic tumour|Requires identification of primary tumour (ie, primary tumour elsewhere)
62503761|NCT02909517||Locally treated ocular tumour|Requires followup to evaluate response to treatment and potential change or repeat therapy
62503762|NCT05660863|EXPERIMENTAL|cohort 1：MN-08 24 mg/day|2 x 6 mg MN-08 tablets for a total dose of 12 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
61957468|NCT04660877|EXPERIMENTAL|Cheddar chese|Once enrolled, participants will either ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (\~1 month) for Metabolic Study #2.
61957469|NCT04660877|ACTIVE_COMPARATOR|Milk|Once enrolled, participants will ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (\~1 month) for Metabolic Study #2.
62345861|NCT01509872|ACTIVE_COMPARATOR|A Child Friendly Space|A Child Friendly Space is a psychosocial intervention combining creative (e.g. art), imaginative (e.g. drama), physical (e.g. football), communicative (e.g. group discussions) and manipulative activities (e.g. story telling). It aids children's natural development by providing a safe place for children to learn, express themselves, grow and develop, supported by trained animators and peer educators.
62345862|NCT03357913||Co morbidities after lung transplantation in cystic fibrosis|The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
62345863|NCT05539469|EXPERIMENTAL|Trial group|Patients from this group will be assisted by Orthodontika application during orthopedic treatment. Reminders will be sent for the activation of Rapid Maxillary Expander and for oral hygiene maneuvers. Written information about orthopedic treatment and oral hygiene tips can be read.
62345864|NCT05539469|OTHER|Control group|Patients from this group will not have access to Orthodontika application during orthopedic treatment. Patients will receive only verbal instruction about the activation of Rapid Maxillary Expander and for oral hygiene maneuvers.
62345865|NCT05529290|ACTIVE_COMPARATOR|Dexketoprofen Trometamol + Thiocolchicoside|(25mg + 4mg, 2x1)
62345866|NCT05529290|ACTIVE_COMPARATOR|Dexketoprofen Trometamol + Paracetamol|(25mg + 300mg, 2x1)
62345867|NCT05529290|ACTIVE_COMPARATOR|Dexketoprofen Trometamol|(25mg, 2x1)
62345868|NCT05529290|ACTIVE_COMPARATOR|Paracetamol|(500 mg, 4x1)
62345869|NCT03007121|EXPERIMENTAL|Morphine intrathecal|An intrathecal administration of preservative-free morphine 0.3 mg in 3 ml NS prepared in a sterile ampoules by a hospital pharmacy will be performed before induction of anaesthesia in a sitting position between L2 and L3 - L4/L5 vertebrae. Standard general anaesthesia will be performed. After surgery, the patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
62345870|NCT03007121|ACTIVE_COMPARATOR|Bupivacaine + Sufentanil epidural|An epidural catheter will be inserted before induction of anaesthesia in a sitting position between T9 and T10 - T12 and L1 vertebrae. A test dose of 4 ml 0.5 bupivacaine will be administered to rule out intravascular injection or subarachnoid or subdural block. Standard general anaesthesia will be performed. Thirty minutes before the end of the surgery, patients will be administered a bolus of a mixture of bupivacaine 0.5% (3 ml) + sufentanil 10 mcg (2 ml) + NS 5 ml followed by a continuous infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h. At the same time patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
62345871|NCT03007121|ACTIVE_COMPARATOR|Morphine intravenous|Patients will be administered standard general anaesthesia. After surgery, bolus doses of morphine 2 mg will be administered until level of pain will be \< 4 (VAS 0 - 10). Analgesia will be continued by PCA device using morphine, bolus dose 1 mg, lock-out interval 5 min. for 3 days at surgical ICU.
62345872|NCT01271387|EXPERIMENTAL|Moderate Hepatic Impairment|
62503763|NCT05660863|EXPERIMENTAL|cohort 2：MN-08 60 mg/day|5 x 6 mg MN-08 tablets for a total dose of 30 mg or 5 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
62503764|NCT04029454|EXPERIMENTAL|Intervention period|Intervention : birth dose vaccination against hepatitis B strategy Birth dose of vaccine against hepatitis B + routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
62142827|NCT03225625|EXPERIMENTAL|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
62142828|NCT03225625|EXPERIMENTAL|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Exoskeleton or equivalent stimulation following this treatment."
62503765|NCT04029454|NO_INTERVENTION|Control period|Routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
62503766|NCT05393349|EXPERIMENTAL|Intervention Group|
62736657|NCT04209634|EXPERIMENTAL|Active PLE|Patients aged 1 year and older with a clinical diagnosis of CD55-deficient PLE disease
62736658|NCT02388477|ACTIVE_COMPARATOR|Doxycycline|oral doxycycline, 2 weeks, twice a day,
62736659|NCT02388477|PLACEBO_COMPARATOR|sugar pill|sugar pill, same size, shape, and color as comparator, twice a day for 2 weeks.
61957470|NCT03677362|EXPERIMENTAL|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (\~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (\~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
61957471|NCT00433121|EXPERIMENTAL|A|Discontinuation of neuroleptic or anti depressants
61957472|NCT03261973|OTHER|DV8 esophageal deviation tool|This is a non-randomized one arm study.
61957473|NCT01337232|ACTIVE_COMPARATOR|1 session per week|
61957474|NCT01337232|EXPERIMENTAL|2 sessions per week|
61957475|NCT03064984|ACTIVE_COMPARATOR|CBS eyedrops|Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
61957476|NCT03064984|ACTIVE_COMPARATOR|PBS eyedrops|Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
61957477|NCT05856032|EXPERIMENTAL|Use of Acapella device|"* Experimental group will receive treatment with Acapella device twice a day for 6 days post-operatively.~* Participants in this group will also receive conventional chest physiotherapy protocol as: incentive spirometry, Active Cycles of Breathing Technique (ACBT), Diaphragmatic breathing exercises except manual chest physiotherapy techniques."
62503767|NCT05393349|NO_INTERVENTION|Standard Group|
62503768|NCT03610919|EXPERIMENTAL|Oxytocin nasal spray(5 doses)|Oxytocin nasal spray for 5 days, 24 IU per day
62503769|NCT03610919|EXPERIMENTAL|Oxytocin nasal spray(3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day.
62503770|NCT03610919|PLACEBO_COMPARATOR|Placebo nasal spray(control group)|Placebo nasal spray for 5 days,24 IU per day.
62503771|NCT02076516|EXPERIMENTAL|Drug-eluting stent: CORACTO®|Single arrm
62503772|NCT06353750||Individuals with heart failure with preserved ejection fraction (HFpEF)|"* Clinical diagnosis of HFpEF~* HFA-PEFF score ≥ 5"
62503773|NCT06353750||Healthy controls|"* HFA-PEFF \< 3~* No known diagnosis of heart failure"
62503774|NCT06353750||Matched controls|"* HFA-PEFF \< 3~* No known diagnosis of heart failure~* Age and sex-matched individuals to the HFpEF cohort"
62503775|NCT01083862|EXPERIMENTAL|Educational Intervention - Video & Text|"Educational Intervention - Video \& Text describing Living with Coronary Artery Disease."
61957478|NCT05856032|ACTIVE_COMPARATOR|Conventional treatment|•Participants in control or comparative group will receive conventional chest physiotherapy protocol as incentive spirometry, ACBT's, Diaphragmatic breathing exercises along with manual chest physiotherapy techniques as percussion and vibration.
61957479|NCT06053996|EXPERIMENTAL|MSI-H mCRC|high dose radiation therapy (SBRT) targeted to the lung and liver metastases
61957480|NCT06053996|EXPERIMENTAL|MSS mCRC.|high dose radiation therapy (SBRT) targeted to the lung and liver metastases
61957481|NCT01704378|EXPERIMENTAL|BIAsp|
61957482|NCT06261502|EXPERIMENTAL|CBD First|Participants will start with CBD to stimulate the eCB for 12 weeks, undergo an 8-week washout period, and then receive a 12-week placebo.
62702555|NCT06748378|EXPERIMENTAL|motor imagery (MI)|"in addition to conventional physiotherapy, activity imagery during passive walking on the Erigo®Pro table was introduced. During the exercises on the table, the patients wore headphones that blocked out any external sounds, closed their eyes and their task was to imagine the sensation of their body moving (first-person imagination), differentiating the idea of walking in various real environments (park, forest, beach, snow, streets). in the city, walking at different speeds, going up and down stairs, running, etc.).~Interventions:~Procedure: Conventional rehabilitation, the Erigo®Pro table, motor imagery"
62702556|NCT06469970|EXPERIMENTAL|Glucose administration|
61957483|NCT06261502|EXPERIMENTAL|Placebo First|Participants will start with a placebo for 12 weeks, undergo an 8-week washout period, and then receive a 12-week CBD to stimulate the eCB system.
61957484|NCT01346449|ACTIVE_COMPARATOR|Visual cue absent|
62503776|NCT01083862|ACTIVE_COMPARATOR|Educational Intervention - Text Only|"Educational Intervention - Text Only describing Living with Coronary Artery Disease."
62503777|NCT00571415||cervix cancer patients|
62503778|NCT01583634||Healthy volunteers|9 subjects (male and female)
62503779|NCT03969316|ACTIVE_COMPARATOR|Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
62702557|NCT01176006|ACTIVE_COMPARATOR|Group A|10/10 HLA Matched Related or Unrelated Donor Transplant
62702558|NCT01176006|ACTIVE_COMPARATOR|Group B|9/10 HLA Matched Related or Unrelated Donor Transplant
62702559|NCT01176006|OTHER|Group C|Donor (closed)
61957485|NCT01346449|EXPERIMENTAL|Calorie information present|
61957486|NCT01346449|ACTIVE_COMPARATOR|Calorie information absent|
61957487|NCT01346449|EXPERIMENTAL|Visual cue present|
61957488|NCT04380415|ACTIVE_COMPARATOR|Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist. ECG will be collected from a single lead ambulatory ECG patch worn on the chest. The data from both the commercial wrist-worn device and the ECG patch are not analyzed real-time.
61957489|NCT04380415|NO_INTERVENTION|Non Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist.
61957490|NCT01475994|EXPERIMENTAL|Challenge with grass pollen|
61957491|NCT01475994|PLACEBO_COMPARATOR|Challenge with clean air|
62702560|NCT01176006|OTHER|Group D|Family Interview (closed)Participation in research interview
62702561|NCT01176006|NO_INTERVENTION|Group E|Patient and caregiver psychosocial and QOL assessments during HSCTParticipation in interview and questionnaires
62702562|NCT06489522|EXPERIMENTAL|Threat, harm, risk, investigation, vulnerability and engagement (THRIVE) intervention|The THRIVE intervention will be offered by a trained therapist to participants (mother-child dyads) in the SOFAR Clinic.
61957492|NCT01233531|OTHER|A--Monthly cash transfers|Monthly cash transfer payments
62702563|NCT05097430|EXPERIMENTAL|Alcohol-focused brief intervention|Intervention arm participants will be provided with an electronically-delivered, personalized drinking feedback report that compares their drinking with other Canadian males of the same age. This report also includes other relevant feedback, including an assessment of severity of alcohol use, and it provides recommendations for safe levels of alcohol consumption.
61957493|NCT01233531|OTHER|B--No cash transfers|No cash transfers.
61957494|NCT05032859|EXPERIMENTAL|tapinarof cream|tapinarof cream, 1%, applied topically once daily
61957495|NCT05032859|PLACEBO_COMPARATOR|vehicle cream|vehicle cream, applied topically once daily
61957496|NCT04442867|EXPERIMENTAL|Intervention group|Subjects will receive nurse-led case management supported by a social service team.The nurse, functioning as a case manager, is involved in the initial assessment of the participant using the Omaha system. After the initial assessment, the NCM will equip participants with the skills required to perform self-care in health maintenance, including self-monitoring of vital signs, medication adherence, and sources of help if needed.
61957497|NCT04442867|OTHER|Control group|Participants in the control group will receive a monthly social control call from a trained research assistant
62142829|NCT03225625|EXPERIMENTAL|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Virtual Reality or equivalent visualization following this treatment."
62142830|NCT04031794||Conventional ARDS treatment group|Patients who they or their 1st degree relative refuse to initiate ECMO. They will receive conventional ARDS treatment.
62142831|NCT04031794||ECMO group|Patients who ECMO is initiated for treat refractory hypoxemia. They will receive conventional ARDS treatment and ECMO support
62142832|NCT01709006|OTHER|Radiation therapy|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
62142833|NCT05775159|EXPERIMENTAL|Cohort 1A|Volrustomig monotherapy
62142834|NCT05775159|EXPERIMENTAL|Cohort 1B|Volrustomig combination with bevacizumab
62142835|NCT05775159|EXPERIMENTAL|Cohort 1C|Volrustomig combination with lenvatinib
62142836|NCT05775159|EXPERIMENTAL|Cohort 2A|Rilvegostomig combination with Gemcitabine and Cisplatin
62142837|NCT05775159|EXPERIMENTAL|Cohort 2B|Volrustomig combination with Gemcitabine and Cisplatin
62702564|NCT05097430|NO_INTERVENTION|Treatment as usual|Treatment as usual (TAU) participants will not receive the intervention.
62702565|NCT06751056|EXPERIMENTAL|Cervical Traction Group|Patients who are on a stable dosage of gabapentin or pregabalin for scalp, arm or upper back pruritus without primary rash
62702566|NCT04930432|EXPERIMENTAL|Part 1: dose escalation and dose expansion|Participants will receive intravenous infusion of MCLA-129 every two weeks (Q2W) or every weeks (QW) at different dose in each dose level.
62702567|NCT04930432|EXPERIMENTAL|Part 2: cohort expansion|Participants will receive intravenous infusion of MCLA-129 every two weeks (Q2W) at the recommended Phase II dose (RP2D) in each cohort.
62702568|NCT01875588||DOD|Participants that are from IDCRP
61957498|NCT03217630||Diabetic patients|
61957499|NCT03217630||Non-diabetic patients|
62702569|NCT01875588||HIV negative controls|Participants that do not have HIV infection
62702570|NCT01875588||HIV positive|Participants that have HIV infection
62702571|NCT04120766|EXPERIMENTAL|Treatment|Nicorandil 20mg qd
62702572|NCT04120766|PLACEBO_COMPARATOR|Placebo|Matched placebo qd
61957500|NCT00794378|EXPERIMENTAL|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
61957501|NCT02770560||Chronic hemodialysis patients with a tunneled cuffed catheter|In case of thrombotic dysfunction of the dialysis catheter : administration of Urokinase (100 000 units in total) as locking solution in the dead space of the catheter lumen, interdialytic (between two dialysis sessions) or intradialytic (during the dialysis in case of complete obstruction of the dialysis catheter)
61957502|NCT03943147|EXPERIMENTAL|BMS-986165 Dose 1|Specified Dose on Specified Days
61957503|NCT03943147|EXPERIMENTAL|BMS-986165 Dose 2|Specified Dose on Specified Days
61957504|NCT03943147|PLACEBO_COMPARATOR|Placebo for BMS-986165|Specified Dose on Specified Days
61957505|NCT03943147|EXPERIMENTAL|Mycophenolate Mofetil (MMF)|Specified Dose on Specified Days
61957506|NCT04899869|OTHER|Group A (active microbiota first)|Patients will first receive two enemas of active study microbiota mixture (deep-frozen stored stool microbiota mixed from eight donors in order to increase its diversity), then after eight weeks they will receive two enemas with placebo.
61957507|NCT04899869|OTHER|Group B (inactive microbiota first)|Patients will first receive placebo, then the active study microbiota mixture.
61957508|NCT04899869|OTHER|Group C (inactive microbiota only)|Patients will receive similarly timed enemas with placebos only.
62142838|NCT05775159|EXPERIMENTAL|Cohort 1D|Volrustomig combination with rilvegostomig and bevacizumab
62142839|NCT05775159|EXPERIMENTAL|Cohort 1E|Rilvegostomig combination with bevacizumab
62142840|NCT02479672|ACTIVE_COMPARATOR|VividTrac video laryngoscope|VividTrac® Videolaryngoscope, A device for endotracheal intubation
62142841|NCT02479672|ACTIVE_COMPARATOR|Direct laryngoscopy|Direct laryngoscopy, A device for endotracheal intubation
62142842|NCT04350294||Serious Mental Illness *RECRUITMENT IN THIS GROUP IS CLOSED|"Mothers with a serious mental illness\*~\*received hospitalisation, treatment or intervention from a secondary care (mental health) service in the last 5 years."
62142843|NCT04350294||Healthy Controls|Mothers with no history of mental illness, who have given birth since February 2021
62142844|NCT01015872|EXPERIMENTAL|CPAP|the subjects introduced with CPAP treatment
62142845|NCT02575365|EXPERIMENTAL|Fingolimod arm|0.5 mg p.o fingolimod daily
62142846|NCT00000170|ACTIVE_COMPARATOR|Patching|
62142847|NCT00000170|ACTIVE_COMPARATOR|Atropine|Atropine
62345873|NCT01271387|EXPERIMENTAL|Mild Hepatic Impairment|
62345874|NCT01271387|EXPERIMENTAL|Healthy Volunteers|
61957509|NCT04038684|EXPERIMENTAL|Mindfulness-Based Weight Control|All participants will be randomly assigned to a 12-session group-based Mindfulness-Based Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the MBWC intervention will receive mindfulness curriculum informed by Mindfulness-Based Stress Reduction plus the standard behavioral weight control components. Group sessions will be approximately 60 minutes each week. Outside of group sessions, participants will be asked to engage in dietary self-monitoring (MBWC and SBWC groups) and practice mindfulness skills (MBWC only).
61957510|NCT04038684|ACTIVE_COMPARATOR|Standard Behavioral Weight Control|All participants will be randomly assigned to a 12-week group-based Mindfulness-Based Behavioral Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the SBWC intervention will receive the SBWC without mindfulness components. Each of the 12 group sessions will be approximately 60 minutes. Outside of group sessions, participants will be asked to practice dietary self-monitoring at home during the week.
62503780|NCT03969316|ACTIVE_COMPARATOR|Transversus Abdominis Plane Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound between internal oblique and transversus abdominis muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
61957511|NCT01007097|EXPERIMENTAL|TAK-875 6.25 mg QD|
61957512|NCT01007097|EXPERIMENTAL|TAK-875 25 mg QD|
61957513|NCT01007097|EXPERIMENTAL|TAK-875 50 mg QD|
61957514|NCT01007097|EXPERIMENTAL|TAK-875 100 mg QD|
61957515|NCT01007097|EXPERIMENTAL|TAK-875 200 mg QD|
62142848|NCT05985408|EXPERIMENTAL|LVSP-CRT|Patients received LVSP based CRT implantation; LVSP, left ventricular septal pacing; CRT, cardiac resynchronization therapy.
62142849|NCT05985408|ACTIVE_COMPARATOR|RVAP-CRT|Patients received RVAP based CRT implantation; RVAP, right ventricular apical pacing; CRT, cardiac resynchronization therapy.
62142850|NCT02841449|EXPERIMENTAL|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water \[63.75 kg \* 3 mL\])
62345875|NCT00367198|ACTIVE_COMPARATOR|1|30 ml per serving
62345876|NCT00367198|ACTIVE_COMPARATOR|2|60 ml per serving
61957516|NCT01007097|ACTIVE_COMPARATOR|Glimepiride 2 mg or 4mg QD|
61957517|NCT01007097|PLACEBO_COMPARATOR|Placebo QD|
61957518|NCT02550990|ACTIVE_COMPARATOR|Cognitive training group|One 60-min session of cognitive training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
61957519|NCT02550990|ACTIVE_COMPARATOR|Aerobic exercise training group|One 60-min session of aerobic exercise training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
62345877|NCT00367198|NO_INTERVENTION|3|chronic hemodialysis patients
62345878|NCT00367198|NO_INTERVENTION|4|healthy subjects
62345879|NCT00954837|OTHER|Fine needle aspiration|Patient with solid nodules more than 10 mm in diameter will be biopsied by ultrasound-guided fine-needle aspiration(FNA)after consultation with an endocrinologist or ENT specialist.
62345880|NCT02790554|EXPERIMENTAL|Moyo strap-on|Continous fetal heart rate monitoring
62345881|NCT02790554|ACTIVE_COMPARATOR|Hand-held Doppler|Intermittent fetal heart rate monitoring
62345882|NCT03143972|EXPERIMENTAL|Dexmedetomidine only|"Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.~A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min)."
62345883|NCT03143972|EXPERIMENTAL|Remifentanil only|Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).
62345884|NCT03143972|EXPERIMENTAL|Dexmedetomidine-Remifentanil interaction|"A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).~Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes."
62345885|NCT03074994|EXPERIMENTAL|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
62345886|NCT03074994|EXPERIMENTAL|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
62345887|NCT03074994|NO_INTERVENTION|Control group|Don't receive any route of TXA
62345888|NCT03712332|EXPERIMENTAL|Distress Tolerance Group|6 session inpatient distress tolerance group intervention twice a week for 1.5 hours for up to three weeks.
62345889|NCT03630978||Liver resection|
62345890|NCT03434704|EXPERIMENTAL|Single Arm Treatment|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis."
62345891|NCT03489681|EXPERIMENTAL|Acupuncture, low dosage|treat as six acupoints
62345892|NCT03489681|EXPERIMENTAL|Acupuncture, high dosage|treat as 18 acupoints
62345893|NCT03489681|NO_INTERVENTION|Control group|no acupuncture treatment, healthy control
61957520|NCT02550990|EXPERIMENTAL|Sequential training group|"One 30-min session of aerobic exercise training + one 30-min session of cognitive training.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
62142851|NCT02841449|EXPERIMENTAL|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL \[63.75 kg \* 40 mL\] + 1125 mL \[750 g \* 1.5\], totalling 3675 mL).
62503781|NCT01719562|EXPERIMENTAL|ADDENDUM: Physical Activity Intervention|Participants will be offered one to two training sessions per week at onsite rehab facilities and 1-2 sessions per week at home consisting of slow 15 minute aerobic warm-up followed by 20 minutes of strength training, 15 minutes of progressive intensity aerobic exercise and 10 minute cool down.
62503782|NCT01719562|EXPERIMENTAL|ADDENDUM: Healthy Living Instruction Group (Control Arm)|Organized various health workshops lasting for 60 minutes to match the number of visits to the rehab centers for participants in Arm 1 with 2 sessions offered per month onsite and remaining sessions offered over the phone for 6 months. .
62503783|NCT01719562|EXPERIMENTAL|MRI (Diagnostic)|Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
62503784|NCT00006228|EXPERIMENTAL|Treatment (trastuzumab and aldesleukin)|Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
62503785|NCT02810249||African American YMSM|
62503786|NCT03559725|EXPERIMENTAL|VLN Menthol Cigarettes (A)|Subjects will smoke VLN menthol cigarettes
62503787|NCT03559725|EXPERIMENTAL|Usual Brand Menthol Cigarettes (B)|Subjects will smoke their usual brand menthol cigarettes
62503788|NCT03559725|EXPERIMENTAL|Nicotine Gum (C)|Subjects will chew nicotine gum
62503789|NCT05654194|EXPERIMENTAL|AVA（Azacitidine Combined With Venetoclax and ATRA）group|(1)Inductive therapy: AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles or progression; (2)Consolidate therapy:ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles or progression; (3) Maintenance therapy:ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month untill progression;
62503790|NCT02911935|ACTIVE_COMPARATOR|Oral azithromycin|Oral Azithromycin
62503791|NCT02911935|PLACEBO_COMPARATOR|Placebo|Oral Placebo
62503792|NCT02928458|ACTIVE_COMPARATOR|Omnipaque|Arm 1
62503793|NCT02928458|ACTIVE_COMPARATOR|MD-Gastroview|Arm 2
62503794|NCT02822482|EXPERIMENTAL|Copanlisib + Cetuximab|All patients will be treated by Copanlisib in association with Cetuximab.
62503795|NCT03957694|EXPERIMENTAL|AMG531|
62503796|NCT01487434|EXPERIMENTAL|Check & Connect|Check and Connect Structured Mentoring and Case Management
62503797|NCT03992313|EXPERIMENTAL|Facility-based testing intervention|Community Health Workers (CHWs) will provide information inside their groups on the possibility to be tested in health centers for HCV infection. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center that will be in charge to give result to the participant and to refer to care in case of active infection.
62142852|NCT01714076||cohort isolation|patients with bronchiolitis are cohorted together irrespective of viral agent diagnosed, thus respiratory syncytial virus (RSV)-positive patient stay in the same room as RSV-negative patients
62503798|NCT03992313|EXPERIMENTAL|Community-based testing intervention|After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the village of participants. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS and sent to Phnom Penh for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center of each cluster and CHWs will be in charge to give result to the participant and to refer to care in case of active infection.
62503799|NCT02365909|ACTIVE_COMPARATOR|Acitve|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
62503800|NCT02365909|PLACEBO_COMPARATOR|Placebo|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
62503801|NCT04611594|EXPERIMENTAL|Fluid restriction|Prescription to ingest approximately 20 ml / kg of ideal weight.
62503802|NCT04611594|NO_INTERVENTION|Control|Prescription to ingest approximately 30 ml / kg of ideal weight, considered a normal amount of daily water intake.
62503803|NCT01992341|EXPERIMENTAL|AMG 386 15mg/kg and paclitaxel 80mg/m2|
62503804|NCT02231996||gene mutation|
62503805|NCT04692857|EXPERIMENTAL|group 30|participants received a supra inguinal fascia iliaca compartment block with 30 ml of 0.2% ropivacaine
62503806|NCT04692857|EXPERIMENTAL|group 40|participants received a supra inguinal fascia iliaca compartment block with 40 ml of 0.2% ropivacaine
61957521|NCT01265368|EXPERIMENTAL|Study medication|
61957522|NCT04858243|ACTIVE_COMPARATOR|Facility-Based ART|Men escorted to nearest health facility for ART initiation and continuation.
62142853|NCT00893334||BMD:|Patients diagnosed with Becker Muscular Dystrophy
62142854|NCT00893334||LGMD2A|patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
62142855|NCT00893334||LGMD2B|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
62142856|NCT00893334||LGMD2I|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
62142857|NCT00893334||Control|Healthy Controls
62142858|NCT02919748|EXPERIMENTAL|Intervention arm|Choral Singing
62142859|NCT02919748|ACTIVE_COMPARATOR|Control arm|General Health Education Program and Group Activities
62503807|NCT04692857|EXPERIMENTAL|group 50|participants received a supra inguinal fascia iliaca compartment block with 50 ml of 0.2% ropivacaine
62503808|NCT05780996|ACTIVE_COMPARATOR|Very high-power short-duration|A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. In this group vHPSD (90W) will be performed. This power settings will be used for all ablation points.
62503809|NCT05780996|ACTIVE_COMPARATOR|High-power short-duration|A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. Ablation of the anterior aspect of the pulmonary veins will be performed with high-power short-duration (50 W) with target ablation index =550. Ablation of the posterior wall of the pulmonary veins will be performed with vHPSD (90W).
62503810|NCT00964353|ACTIVE_COMPARATOR|Clinically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
61957523|NCT04858243|EXPERIMENTAL|Home-Based ART|Home-based ART initiation and continuation provided for 3-months.
62503811|NCT00964353|EXPERIMENTAL|Pharmacogenetically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
62503812|NCT02505724|ACTIVE_COMPARATOR|Conventional training|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice
62503813|NCT02505724|EXPERIMENTAL|Intervention|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice. In addition, they received two 1/2 hour peer-coaching sessions
62503814|NCT02528058||Myopic traction maculopathy|
62503815|NCT03037424|ACTIVE_COMPARATOR|Fibrinogen concentrate Octafibrin|
62503816|NCT03037424|ACTIVE_COMPARATOR|Cryoprecipitate|
62503817|NCT02246686|EXPERIMENTAL|STW5-II|Half of study population, assigned randomly
62503818|NCT02246686|PLACEBO_COMPARATOR|Placebo|Half of study population, assigned randomly
62503819|NCT02837133|EXPERIMENTAL|other techniques group|theory and practice of pair massage with tapping, stretching of the ankle and neck, and autogenic training
62503820|NCT01625117|NO_INTERVENTION|Control Group|
62503821|NCT01625117|EXPERIMENTAL|A variant of Narrative exposure therapy|
62503822|NCT00768352|OTHER|Education Intervention|
62503823|NCT02435316|ACTIVE_COMPARATOR|Group 1|Group 1 will receive 1 hour of compare-contrast basic science teaching of cell recognition to enhance recognition of those photographs, followed by 1 hour Case vignette-based teaching of cell recognition 2 weeks later
62503824|NCT02435316|ACTIVE_COMPARATOR|Group 2|Group 2 will receive 1 hour of Case vignette-based teaching of cell recognition followed by compare-contrast basic science teaching of cell recognition 2 weeks later
62503825|NCT04546152||HYAPROF® SOFT|HYAPROF® SOFT is indicated for volume replacement (filling of folds), fine to medium folds, lip augmentation, periorbital region.
62503826|NCT04546152||HYAPROF® BALANCE|HYAPROF® BALANCE is indicated for volume replacement (filling of folds), deep folds, nasolabial folds, cheek area, glabella folds. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
62503827|NCT01098617||hemorrhage|The patients who had bleeding induced by endoscopic sphincterotomy
62142860|NCT06497699|EXPERIMENTAL|Study Group|Single injection of DEXYCU in the treatment eye after cataract surgery.
62345894|NCT03617367|EXPERIMENTAL|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
62503828|NCT04310254|ACTIVE_COMPARATOR|EDTA and CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA and CHX solution.
62142861|NCT06497699|NO_INTERVENTION|Control Group|The clinical routine treatment after cataract surgery was adopted without intervention
62345895|NCT06180759|EXPERIMENTAL|Intravenous infusion of DMT|Participants will be administered intravenous DMT.
62345896|NCT06180759|ACTIVE_COMPARATOR|Intravenous infusion of ketamine|Participants will be administered intravenous racemic ketamine.
62345897|NCT06180759|PLACEBO_COMPARATOR|Intravenous infusion of placebo|Participants will be administered intravenous lacebo (saline infusion).
62345898|NCT04875949|EXPERIMENTAL|Anti-AChRs Abs positive patients|Immunoabsorption
62345899|NCT02264899|EXPERIMENTAL|Alzheimer's disease and related disorders|
62345900|NCT00750165|EXPERIMENTAL|Titration Night|Treatment with the Fisher \& Paykel Sleep Style 200 Auto CPAP device
62345901|NCT02755610|EXPERIMENTAL|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
62345902|NCT02755610|NO_INTERVENTION|Control|Standard care
62345903|NCT01900678|EXPERIMENTAL|VytronUS Ablation System|Treatment with the VytronUS Ablation System.
62345904|NCT04874467|EXPERIMENTAL|Keratinized Mucosa ≥ 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
62345905|NCT04874467|EXPERIMENTAL|Keratinized Mucosa < 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
62345906|NCT01236742|EXPERIMENTAL|single-vision glasses and ortho-k lenses|Children who are currently wearing ortho-k lenses at night for correction of refractive errors will be switched to wear single-vision glasses for the first 7 months and then switched back to ortho-k lenses for the next 7 months
62345907|NCT01236742|ACTIVE_COMPARATOR|ortho-k lenses|Children who are currently wearing ortho-k lenses at night for the correction of refractive errors will continue with the current treatment and serve as the first control group
62345908|NCT01236742|OTHER|single-vision glasses|Children who are currently wearing single-vision spectacles in the daytime for correcting their refractive errors will continue with the current treatment and serve as the second control group
62345909|NCT05577091|EXPERIMENTAL|Autologous Tris-CAR-T cell|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity.
62345910|NCT03162055|EXPERIMENTAL|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
62503829|NCT04310254|ACTIVE_COMPARATOR|EDTA solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA solution.
62503830|NCT04310254|ACTIVE_COMPARATOR|CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for CHX solution.
62503831|NCT01835535|EXPERIMENTAL|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
62503832|NCT00838981|ACTIVE_COMPARATOR|Modafinil Plus Contingency Magagement|Modafinil from 200mg up to 400mg plus Contingency Management
62503833|NCT00838981|PLACEBO_COMPARATOR|Sugar Pill Plus Contingency Management|Placebo: sugar pill
62503834|NCT00838981|ACTIVE_COMPARATOR|Modafinil Plus Voucher Control|
62503835|NCT00838981|PLACEBO_COMPARATOR|Sugar Pill Plus Voucher Control|
62503836|NCT05534048|EXPERIMENTAL|PTX-COVID19-B|
62503837|NCT05534048|ACTIVE_COMPARATOR|Comirnaty®|
62503838|NCT04847999|EXPERIMENTAL|Conventional Dark Chocolate|A standard dark chocolate bar.
62503839|NCT04847999|EXPERIMENTAL|Ross Dark Chocolate|A dark chocolate bar sweetened with stevia, erythritol, and inulin.
62503840|NCT02248662||Surveillance, Epidemiology, and End Results (SEER) Database|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER) with a diagnosis of ductal carcinoma in situ (DCIS) between 1990 and 2011 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
62503841|NCT02248662||Surveillance, Epidemiology, and End Results (SEER)-Medicare|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER)-Medicare with a ductal carcinoma in situ (DCIS) diagnosis between 1991 and 2009 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
62503842|NCT06615999||Locking Plate fixation for simple fractured OFs (sLPF)|Patients allocated to this treatment group received a locking plate fixation after the first coded diagnosis of simple fractured OF.
62503843|NCT06615999||Locking Plate fixation for multi-fragmented OFs (LPF)|Patients allocated to this treatment group received a locking plate fixation after after the first coded diagnosis of multi-fragmented OF.
62503844|NCT06615999||Tension band wiring for simple fractured OFs (sTBW)|Patients allocated to this treatment group received a tension band wiring fixation after the first coded diagnosis of simple fractured OF.
62503845|NCT06615999||Tension band wiring for multi-fragmented OFs (TBW)|Patients allocated to this treatment group received a tension band wiring fixation after the first coded diagnosis of multi-fragmented OF.
62503846|NCT02735694|ACTIVE_COMPARATOR|Cycloserine|Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
62503847|NCT02735694|PLACEBO_COMPARATOR|Placebo|Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose
62503848|NCT04223284|ACTIVE_COMPARATOR|Experimental1|"During the Cross-Over study, patients will be randomly assigned to one of the arms:~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with D-Limonene at visit 2 and olfactory Stimulation with lavender oil (SLVO) at visit 3"
62702573|NCT06751407|ACTIVE_COMPARATOR|Group Single level SPSIPB|The procedure will be performed with the patient in the prone position in the preoperative period. After the scapula is slightly shifted laterally, the US probe is held sagittally at the upper corner of the scapula spine, and the 3rd rib and the serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and entered between the serratus posterior superior and the 3rd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be used.
62345911|NCT03162055|ACTIVE_COMPARATOR|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
62345912|NCT04545788|ACTIVE_COMPARATOR|A|4-6 INH EMB PZA Pto AM Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, AM: Amikacin, Cfz: Clofazimine, Mfx: Moxifloxacin) A group is the control group which includes injectable drugs (AM).
62345913|NCT04545788|EXPERIMENTAL|B|4-6 INH EMB PZA Pto LZD Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, LZD: Linezolid, Cfz: Clofazimine, Mfx: Moxifloxacin) B group is the experimental groups which is total oral short-term therapy.
62345914|NCT04545788|EXPERIMENTAL|C|4-6 BDQ LZD MFX CS CFZ / 5MFX CS CFZ (BDQ: Bedaquiline, LZD: Linezolid, Mfx: Moxifloxacin, CS: Cycloserine, Cfz: Clofazimine) C group is another experimental groups which is also total oral short-term therapy, and includes new anti-TB drugs: BDQ.
62345915|NCT00599261|EXPERIMENTAL|1|Removal of the fibrotic pocket surrounding the generator and leads
62345916|NCT00599261|EXPERIMENTAL|2|Tissue is not removed
62345917|NCT02957149|EXPERIMENTAL|Platelet Rich Plasma (PRP) Treatment|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
62345918|NCT06441110|EXPERIMENTAL|Postoperative Instillation Therapy Group|Tislelizumab in Combination with Bacillus Calmette-Guérin for the Treatment of Intermediate and High-Risk NMIBC Group
62345919|NCT06033950|EXPERIMENTAL|Finerenone|
62345920|NCT06033950|PLACEBO_COMPARATOR|Placebo|
62345921|NCT04368455|EXPERIMENTAL|Primary Care Clinic|Physician participants will receive the self-directed app based curriculum. The physician participants will engage in the VR simulations independently.Next, we will implement VICTORI with staff including nurses and medical assistants in groups of up to 15-20 participants (phase II; secondary outcome). Staff will watch a 5-minute video on evidence-based practices in recommending the HPV vaccine and observe a facilitator and clinician participating in the VICTORI VR simulations, and then engage in a 5-minute debriefing.
62345922|NCT04368455|ACTIVE_COMPARATOR|Control Primary Care Clinic|Physician participants will receive the self-directed app based curriculum component of VICTORI though will not undergo the VR simulations.
62345923|NCT03991559|ACTIVE_COMPARATOR|Dose-Escalation, intranasally|With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.
62345924|NCT03991559|ACTIVE_COMPARATOR|Dose-Escalation, inhalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
62503849|NCT04223284|ACTIVE_COMPARATOR|Experimental2|"During the Cross-Over study, patients will be randomly assigned to one of the arms:~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with SLVO at visit 2 and olfactory Stimulation with D-Limonene at visit 3"
62503850|NCT01264913||Shift Workers|
62503851|NCT01264913||Day Workers|
61957524|NCT05841485||Stable angina patients with a history of severe COVID-19 infection requiring mechanical ventilation|Patients with a history of severe COVID-19 infection (confirmed by a polymerase chain reaction test) requiring mechanical ventilation. This group includes patients who have been recently diagnosed with stable angina and have previously experienced a severe COVID-19 infection that necessitated mechanical ventilation support during their illness.
62345925|NCT01206452|EXPERIMENTAL|Ablation plus prednisone|Participants undergo ablation procedure and receive predinisone at protocol determined times.
62345926|NCT01206452|PLACEBO_COMPARATOR|Ablation plus placebo|Participants undergo ablation procedure and receive placebo at protocol determined times.
62345927|NCT04439370||Aim 1: Postmenopausal Women|Participants in this group are postmenopausal women.
62345928|NCT04439370||Aim 1: Premenopausal Women|Participants in this group are premenopausal women.
62345929|NCT04439370||Aim 2: Premature/Early Menopause|Participants in this group women who experienced premature or early menopause.
62345930|NCT04439370||Aim 2: Typical-Age Menopause|Participants in this group are women who experienced menopause at a typical age.
62345931|NCT04369755|OTHER|MRI|A MRI on PTX mode will be done on healthy subjects (approx. 90 min of sequences)
62345932|NCT01148563|NO_INTERVENTION|Standard Care|The Standard Care group will continue regular LSU HCSD disease management care for heart failure patients with no additional intervention.
62345933|NCT01148563|ACTIVE_COMPARATOR|Tele-health Monitoring Group|The tele-monitoring intervention group will have the continual standard care from their physician plus the tele-health monitoring. The tele-health monitor will collect the following data: weight, blood pressure, pulse oximetry, pulse rate, \& patient responses to disease-specific questions regarding changes in state of health for 6 months.
62345934|NCT01077388|EXPERIMENTAL|Dietician electronic counseling|This arm will receive care and supportive emails and phone calls from a study dietician for about 6 months. We will also provide a blood pressure monitor, a pedometer, and a scale with instructions for using them at home.
62345935|NCT01077388|NO_INTERVENTION|Self Care|This arm will continue to get care as usual from their regular doctor. They will also get a blood pressure monitor and a scale at the end of the study.
62345936|NCT00020566|EXPERIMENTAL|Group 1|Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
62345937|NCT00020566|EXPERIMENTAL|Group 2, arm I|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
62345938|NCT00020566|EXPERIMENTAL|Group 2, arm II|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
62345939|NCT05776914|EXPERIMENTAL|Donor Fecal Microbiota Transplantation Group|Subjects will receive a fecal microbiota transplantation (FMT) using stool from a donor
62345940|NCT05776914|PLACEBO_COMPARATOR|Autologous Fecal Microbiota Transplantation Group|Subjects will receive a fecal microbiota transplantation (FMT) using their own stool
62503852|NCT00084799|EXPERIMENTAL|hu3S193 10 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 10 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
62503853|NCT00084799|EXPERIMENTAL|hu3S193 20 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 20 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
62503854|NCT02312479|EXPERIMENTAL|Nyxoah SAT therapy|
62345941|NCT03827590|EXPERIMENTAL|HLIM|HLIM+SA160021 Placebo+SA160022 Placebo
62345942|NCT03827590|ACTIVE_COMPARATOR|SA160021|HLIM Placebo+SA160021+SA160022 Placebo
62345943|NCT03827590|ACTIVE_COMPARATOR|SA160022|HLIM Placebo+SA160021 Placebo+SA160022
62345944|NCT03827590|PLACEBO_COMPARATOR|Placebo|HLIM Placebo+SA160021 Placebo+SA160022 Placebo
62345945|NCT03694041|EXPERIMENTAL|SAD: APX-115|Experimental: APX-115 SAD group
62345946|NCT03694041|PLACEBO_COMPARATOR|SAD: Placebo|Experimental: Placebo group
62345947|NCT03694041|EXPERIMENTAL|MAD: APX-115|Experimental: APX-115 MAD group
62345948|NCT03694041|PLACEBO_COMPARATOR|MAD: Placebo|Experimental: Placebo group
62345949|NCT03694041|ACTIVE_COMPARATOR|Food effect - Fasting condition|Experimental: APX-115 under fasting condition
62345950|NCT03694041|ACTIVE_COMPARATOR|Food effect - fed condition|Experimental: APX-115 under fed condition
62345951|NCT03694041|PLACEBO_COMPARATOR|Drug Interaction - metabolic probe|Experimental: metabolic probe
62345952|NCT01481168|ACTIVE_COMPARATOR|"Pacemaker on"|DDD+/-R pacing
62345953|NCT01481168|PLACEBO_COMPARATOR|"Pacemaker off"|ODO pacing
62345954|NCT01481168|EXPERIMENTAL|Implantable Loop Recorder|Implantable loop recorder in adenosine test negative patients
62345955|NCT04149639|EXPERIMENTAL|NeuroQ|Directions: take 2 capsules at the same time daily
62345956|NCT00050791|EXPERIMENTAL|VLCD and leptin|Very low calorie diet formula providing 800 calories per day and leptin treatment.
61957525|NCT05841485||Patients with stable angina without a history of COVID-19 (Group B)|Patients without a history of COVID-19. This group consists of patients who have been diagnosed with stable angina but have no history of COVID-19 infection. This group serves as a comparison group to assess the potential impact of severe COVID-19 infection on coronary microvascular dysfunction in patients with stable angina.
62503855|NCT04593303|ACTIVE_COMPARATOR|Internal iliac artery group|Bilateral internal Iliac artery ligation will be done followed by urinary bladder dissection then bilateral uterine artery ligation then manual removal of the placenta then cervico isthmic compression suture. (holding the upper border of the cervix by 4 Allis's forceps then suturing the cervix with the anterior uterine wall using continuous suture), Nelaton catheter18 gauge or Hegar's dilator will be inserted inside cervical canal during Cervico isthmic tamponed suture to ensure patency of cervical canal. .
61957526|NCT04935320|EXPERIMENTAL|Oral Solution Fasted|HTL0016878.HCl 10 mg, single dose, oral solution, fasted
61957527|NCT04935320|EXPERIMENTAL|Oral Capsule Fasted|HTL0016878.citrate 10 mg, single dose, oral capsule, fasted
61957528|NCT04935320|EXPERIMENTAL|Oral Capsule Fed|HTL0016878.citrate 10 mg, single dose, oral capsule, fed
61957529|NCT03140943|EXPERIMENTAL|Carfilzomib, Thalidomide and Dexamethasone|
61957530|NCT01930266|NO_INTERVENTION|Observational|Patients will receive general dietary instructions with an annual follow-up. At this follow up, a repeat BMD, dietary and laboratory evaluation will be performed.
62702574|NCT06751407|ACTIVE_COMPARATOR|Group Two-level SPSIPB|The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 2nd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 10 ml of 0.25% bupivacaine will be used. Then, the US probe will be held sagittally in the medial part of the scapula spine, and the 4th rib and serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 4th rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block site is confirmed, 10 ml of 0.25% bupivacaine will be used. A total of 20 ml of 0.25% bupivacaine will be used.
61957531|NCT01930266|ACTIVE_COMPARATOR|Interventional.|Patients will receive detailed dietary instructions with periodic (3 month) follow up. At the follow-up patients will be assessed whether they reached their calcium intake goals both quantitatively and whether appropriate calcium sources were utilized.
61957532|NCT01930266|EXPERIMENTAL|Active interventional|Patients will receive detailed dietary instructions and active follow up with diary and email reports. Inclusion in group C will be predicated upon intake of 100% DRI of calcium primarily by food sources, with the addition of Calcium Carbonate 600 mg, if necessary
61957533|NCT03811028|EXPERIMENTAL|SOBI003|"SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to administration. For a bodyweight \< 25 kg, the total infusion volume is 100 mL. For a bodyweight ≥ 25 kg, the total infusion volume is 250 mL.~SOBI003 is administered as i.v. infusions given once weekly for a duration of 80 weeks (from Week 25 until Week 104 following the first 24 weeks of SOBI003 administration in the FIH study (SOBI003-001) study. The SOBI003 dose will be adjusted to the highest dose that has been declared safe by the safety review committee on the FIH study.Hence, dose adjustments may occur a couple of times on the extension study until the final decided dose has been determined."
62503856|NCT04593303|OTHER|No internal iliac artery group|Bladder dissection then bilateral uterine artery ligation then cervico isthmic suture without internal iliac artery ligation
62503857|NCT03304717|EXPERIMENTAL|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir \[TDF\] and Emtricitabine \[FTC\]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
61957534|NCT02537119|EXPERIMENTAL|Dynamic massage therapy|Rubbing on hamstrings combined with articular movement
61957535|NCT02537119|ACTIVE_COMPARATOR|Massage therapy|Rubbing on hamstrings
61957536|NCT03214939|EXPERIMENTAL|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
62503858|NCT03304717|EXPERIMENTAL|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir \[TDF\] and Emtricitabine \[FTC\]) for 6 months.
62503859|NCT06678282|EXPERIMENTAL|JY231 Injection for the Treatment of relapsed or refractory B cell lymphoma/ leukemia|Subjects who meet the Inclusion Criteria will receive intravenous JY231. JY231 infusion will produce in vivo CAR-T cells in the body.
62503860|NCT01947309||Multiple Myeloma Patients Treated with Revlimid (lenalidomide)|Single Cohort of Multiple Myeloma Patients Treated with Revlimid
62503861|NCT05321875|EXPERIMENTAL|Candesartan|Candesartan, 16 mg oral tablets. Target dose 32 mg or maximum tolerated dose after dose escalation from 16 mg
61957537|NCT03732235||TACE+ systemic Bevacizumab|"TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.~Bevacizumab (5 mg/kg) therapy was initiated 15 days after first round of TACE and was repeated every two weeks, for a total of 8 cycles."
62503862|NCT05321875|PLACEBO_COMPARATOR|Placebo|Matching placebo. Target dose 2 tablets or maximum tolerated dose after dose escalation from 1 tablet
62503863|NCT03091257|EXPERIMENTAL|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS~* BRAF V600 mutated~* Treat cohort with Dabrafenib~* Analysis~* Treat cohort with Dabrafenib"
62503864|NCT03091257|EXPERIMENTAL|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~* BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated~* Treat cohort with Dabrafenib and Trametinib~* Analysis~* Treat cohort with Dabrafenib and Trametinib"
61957538|NCT03732235||FOLFIRI+Bevacizumab|FOLFIRI consists of 5-FU administered as a 48-hour continuous infusion to a total dose of 3,200 mg/m2 without a bolus, leucovorin 200 mg/m2, irinotecan 165 mg/m2 Bevacizumab (5 mg/kg) therapy was repeated every two weeks, for a total of 8 cycles.
62503865|NCT03091257|EXPERIMENTAL|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~* KRAS or NRAS mutated~* Treat cohort with Trametinib~* Analysis~* Treat cohort with Trametinib"
61957539|NCT03732235||TACE|TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
61957540|NCT05446805||depression|All participants will receive two one time PET scans with tracers AV1451 and PIB to detect tau and amyloid in the brain.
61957541|NCT05446805||control|All participants will receive two one time PET scans with tracers AV1451 and PIB to detect tau and amyloid in the brain.
61957542|NCT00654680|EXPERIMENTAL|Arm 1|
61957543|NCT00654680|PLACEBO_COMPARATOR|Arm 2|
61957544|NCT06049238|EXPERIMENTAL|Maitland Mobilization|Maitland mobilization will be applied 2-3 oscillations per second for 1 minute, 5 set each day, 5 days a week for 4 weeks.
61957545|NCT06049238|ACTIVE_COMPARATOR|post facilitation stretch|PFS will be performed 6-10s isometric contraction with 100 % force followed by 15s passive stretch, 4-5 repetitions per day, 5 days a week for 4 weeks.
61957546|NCT02515825||AMBIENCE|CADence System testing followed by coronary angiogram
61957547|NCT02515825||AMBIENCE plus R&R Substudy|CADence System testing for repeatibility and reproducibility (4x by 2 operators) followed by coronary angiogram
61957548|NCT02096731||LABA + tiotropium|
61957549|NCT02096731||LABA mono|
61957550|NCT02096731||neither tiotropium nor LABA|
61957551|NCT02096731||tiotropium + LABA|
61957552|NCT02096731||tiotropium mono|
61957553|NCT05943015|ACTIVE_COMPARATOR|Quadratus Lumborum Block II|Quadratus Lumborum Block II
61957554|NCT05943015|ACTIVE_COMPARATOR|Quadratus Lumborum Block III|Quadratus Lumborum Block III
62345957|NCT00050791|ACTIVE_COMPARATOR|placebo|Very low calorie diet and placebo treatment
62345958|NCT04350736|EXPERIMENTAL|TD-0903 for SAD (Part A)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
62345959|NCT04350736|EXPERIMENTAL|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
62345960|NCT04350736|EXPERIMENTAL|TD-0903 for MAD (Part B)|8 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
62345961|NCT04350736|EXPERIMENTAL|Placebo for MAD (Part B)|2 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
62345962|NCT05933252|EXPERIMENTAL|Augmented reality (AR)|"Augmented reality (AR)~Participants will view the real world through a device's camera and application (app) but adds virtual or digital characters and items to the image"
62345963|NCT02723266|EXPERIMENTAL|Intervention|Treatment receives the STOPPING-GDM intervention. Control does not receive the intervention.
62503866|NCT04928664|ACTIVE_COMPARATOR|Liposoaml Bupivacaine (LB) Group|Intervention group
62503867|NCT04928664|EXPERIMENTAL|Standard Bupivacaine (SB) Group|Control group
62503868|NCT06097702|EXPERIMENTAL|BX-001N Part 1|Part 1 is SAD with 5 cohorts where each participant will receive single IV bolus following a 8hr fast.
62503869|NCT06097702|EXPERIMENTAL|BX-001N Part 2|Part 2 is MAD with 3 cohorts where each participant will receive 7 sequential daily IV bolus doses following a 8hr fast.
61957555|NCT05943015|ACTIVE_COMPARATOR|Paravertebral Block|Paravertebral Block
61957556|NCT00585143|EXPERIMENTAL|1|
61957557|NCT02893670|OTHER|Tailored re-evaluation|"Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation:~Following enrollment each patient will undergo a structured re-evaluation and transition process which will include radiologic intervention (MRE) for Crohn's patients and endoscopic intervention (sigmoidoscopy) for UC patients"
61957558|NCT01292746|EXPERIMENTAL|Erchonia ML Scanner (MLS)|Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light
61957559|NCT03533764|EXPERIMENTAL|Asthma Self-Management for Adolescents|Asthma Self-Management for Adolescents (ASMA) consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
61957560|NCT03533764|NO_INTERVENTION|Attention Control|In 3 group sessions and 5 one-on-one sessions, held at school during the school day, students will receive information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). They will learn to monitor their health by using diaries to record behaviors, such as what they eat, and/or their sleep patterns. Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
61957561|NCT02130232|EXPERIMENTAL|Lifestyle Intervention|The goal of the intervention is to help women achieve the lower bound of the GWG range recommended by the Institutes of Medicine (IOM) for a given prepregnancy BMI category (i.e., 11 lbs for obese women and 15 lbs for overweight women). The pregnancy lifestyle intervention will be delivered by trained study dieticians via individual counseling sessions: 2 in-person and 11 telephone sessions delivered on a weekly basis, followed by telephone sessions delivered every other week through the end of pregnancy.
61957562|NCT02130232|ACTIVE_COMPARATOR|Usual Care|Usual Medical Care
61957563|NCT05588908|EXPERIMENTAL|SSGJ-613 100 mg (phase Ib)|Dose Arm 1 (phase Ib): SSGJ-613 100 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.
62345964|NCT02723266|NO_INTERVENTION|Control|Control does not receive the intervention.
62345965|NCT04511819|EXPERIMENTAL|Losmapimod|COVID-19 patients with PCR confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 14 days.
62345966|NCT04511819|PLACEBO_COMPARATOR|Placebo|COVID-19 patients with PCR confirmation will receive Placebo twice daily given as two tablets per dose by mouth; for a total of 4 tablets daily for 14 days.
62345967|NCT04101760|EXPERIMENTAL|Study group|Patients in study group accept prophylactic treatment of long-acting granulocyte colony stimulating factor
62345968|NCT04101760|ACTIVE_COMPARATOR|Control group|Patients in control group accept regular or prophylactic treatment of short-acting granulocyte colony stimulating factor according to current guidelines
62503870|NCT06097702|PLACEBO_COMPARATOR|Placebo|Matching doses of placebo
62503871|NCT02735330|ACTIVE_COMPARATOR|GROUP 1|68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol
62503872|NCT02735330|PLACEBO_COMPARATOR|GROUP 2|68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline
62503873|NCT05367635|EXPERIMENTAL|Phase 1a：Dose escalation|Eleven dose levels are tentatively planned for Phase 1a
62503874|NCT05367635|EXPERIMENTAL|Phase 1b: Dose expansion|The dose of SKB315 for injection in Phase 1b is selected based on the Phase 1a monotherapy dose escalation study.
62503875|NCT01150162|EXPERIMENTAL|Mucosta and Omeprazole|
62702575|NCT06055933||ESWT|To the ESWT group, with the ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shock/session values was applied with a 15 mm head in a single session. Shock waves were applied directly to the most sensitive point detected in the medial of the calcaneus.
62702576|NCT06055933||Placebo ESWT|The placebo ESWT group was given the ESWT device sound recorded from the external audio device and the application was performed without the ESWT device operating.
61957564|NCT05588908|EXPERIMENTAL|SSGJ-613 200 mg (phase Ib)|Dose Arm 2 (phase Ib): SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.
61957565|NCT05588908|EXPERIMENTAL|SSGJ-613 300 mg (phase Ib)|Dose Arm 3 (phase Ib): SSGJ-613 300 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.
61957566|NCT05588908|EXPERIMENTAL|SSGJ-613 200 mg (phase II)|Dose Arm 4 (phase II): SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.
62142862|NCT01502813|EXPERIMENTAL|Citicoline, Creatine, and Omega-3 Arm|Each participant will be given a supplement log at the end of visit 1. They will be asked to complete the log during the 28 days to indicate that the daily dose of supplements were taken according to instructions. The study coordinator will check the log on the second and third visits as well as count the remaining supplement pills. If participants do not comply with the daily supplement schedule, then the PI will determine if the participant should be withdrawn from the study.
62345969|NCT03886025|EXPERIMENTAL|Combined anodal tDCS and cognitive training|Combined anodal tDCS and cognitive training. Anodal tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). Anodal tDCS will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration of each tDCS session will be 20 minutes.
62345970|NCT03886025|SHAM_COMPARATOR|Combined sham tDCS and cognitive training|Combined sham tDCS and cognitive training. Sham tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). For sham tDCS, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each tDCS session will be 20 minutes.
62345971|NCT02570529|EXPERIMENTAL|Albis®|The intervention group
62345972|NCT02570529|PLACEBO_COMPARATOR|Placebo|The placebo comparator group
62345973|NCT02591342||CPT stem|Patients treated with a polished, tapered femoral stem as a hip arthroplasty for a displaced femoral neck fracture
62345974|NCT02591342||SP2 stem|Patients treated with a anatomic femoral stem as a hip arthroplasty for a displaced femoral neck fracture
62345975|NCT05426629|EXPERIMENTAL|Treatment|"4 sessions of treatment at 1-week interval for first 4 weeks 3 sessions of treatment each 4 weeks apart, at week 8, week 12 and week 16~1 Follow-up visit: Follow up 4 weeks after the last treatment at week 20"
62345976|NCT06216587|PLACEBO_COMPARATOR|Placebo group|
62345977|NCT06216587|EXPERIMENTAL|Probiotic group|
62345978|NCT01767519|EXPERIMENTAL|BOTOX®|Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.
62345979|NCT01767519|ACTIVE_COMPARATOR|solifenacin|Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
62345980|NCT01767519|PLACEBO_COMPARATOR|placebo|Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
62345981|NCT04910074|EXPERIMENTAL|Low-level therapy intervention|Patients will receive low-level laser therapy on the skin overlying the mandible for 40 seconds per side. All other post-operative care will be as per clinic routine.
62345982|NCT04910074|PLACEBO_COMPARATOR|dummy intervention|Patients will receive no dose of laser, but the handpiece will be used against their skin top mimic the LLLT. All other post-operative care will be as per clinic routine.
62503876|NCT01150162|ACTIVE_COMPARATOR|Omeperazole|
62503877|NCT03102879|EXPERIMENTAL|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
62503878|NCT03102879|ACTIVE_COMPARATOR|Conventional Root Canal Treatment|Conventional endodontic procedure
62503879|NCT01806610|EXPERIMENTAL|BPS804|Single dose BPS804 administration.
62503880|NCT01806610|PLACEBO_COMPARATOR|Placebo|Single dose placebo administration.
62503881|NCT06599138|OTHER|Injection of 2ml in the pterygopalatine fossa|Perfom an ultrasound-guided maxillary nerve block with injection of 2 ml of contrast in the pterygopalatine fossa
62503882|NCT06599138|OTHER|Injection of 5ml in the pterygopalatine fossa|Perfom an ultrasound-guided maxillary nerve block with injection of 5 ml of contrast in the pterygopalatine fossa
62503883|NCT05135819|EXPERIMENTAL|Intergenerational educational program|
62142863|NCT06430424||Patients operated for primary and recurrent glioblastoma|Patients operated for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
62142864|NCT01163981|NO_INTERVENTION|Blind cannulation|Cannulation without guidance
62142865|NCT01163981|EXPERIMENTAL|Ultrasound guided cannulation|Ultrasound guided cannulation
61957567|NCT05588908|EXPERIMENTAL|SSGJ-613 300 mg (phase II)|Dose Arm 5 (phase II): SSGJ-613 300 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.
61957568|NCT05588908|ACTIVE_COMPARATOR|Compound Betamethasone Injection 1 mL (phase II)|Dose Arm 6 (phase II): Compound betamethasone injection 1 mL intramuscularly (i.m) once. The i.m. injection is recommended to be administered deeply into the gluteal muscle. Randomized patients will receive compound betamethasone injection 1 mL i.m. once and placebo matching SSGJ-613 s.c. once, on Day 1.
61957569|NCT01599767|EXPERIMENTAL|Active tDCS|Subjects will undergo 20 minutes active tDCS.
61957570|NCT01599767|SHAM_COMPARATOR|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
61957571|NCT03567304|NO_INTERVENTION|EFV-based|"HIV-infected patients, who has been taking efavirenz (EFV)-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to continue EFV-based regimen.~EFV based regimen defines as efavirenz 600 mg per oral once daily (OD) + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."
61957572|NCT03567304|EXPERIMENTAL|RPV-based|"HIV-infected patients, who has been taking efavirenz-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to switch antiretroviral therapy to rilpivirine (RPV)-based regimen.~RPV based regimen defines as rilpivirine 25 mg PO OD + 2 NRTIs."
61957573|NCT05719766|NO_INTERVENTION|Routine follow-up group|
61957574|NCT05719766|EXPERIMENTAL|IBD Disease Management Research Group|
61957575|NCT00083863||Framingham Heart Study Offspring|
61957576|NCT00083863||FHS Gen 3|
61957577|NCT05180084|EXPERIMENTAL|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
62503884|NCT05372497|EXPERIMENTAL|Conventional physiotherapy plus central nervous system focused treatment group (CP+CNS group)|For the patients participating in the study, a protocol focused on the central nervous system and aimed at reducing hypersensitivity was applied with pain, graded sensory discrimination and graded motor imagery (GMI) training in addition to conventional physiotherapy. Graded sensory dicrimination training includes localization training level 1, localization training level 2 and graphesthesia training. GMI training includes right/left discrimination training, visual imagery, isometric and functional exercises, and mirror therapy. The treatment was applied in 20 sessions, for 45-60 minutes, 5 days a week.
61957578|NCT05180084|NO_INTERVENTION|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
61957579|NCT04154735|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with fludarabine, cyclophosphamide, mesna, and alemtuzumab. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant until engraftment. Rifaximin and tacrolimus will be administered for 6 and 12 months, respectively, beginning one day before the infusion of stem cells.
61957580|NCT03478930|EXPERIMENTAL|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
61957581|NCT03478930|EXPERIMENTAL|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
62503885|NCT05372497|ACTIVE_COMPARATOR|Conventional Physiotherapy Group (CP Group)|In the conventional physiotherapy group of the study, in addition to physiotherapy modalities for 20 sessions, 5 days a week, for 45-60 minutes each session, 5 days a week, electrotherapy, scapular mobilization, passive stretching, stick exercises, finger ladder exercises, pendulum exercises and shoulder flexion, extension, abduction, internal rotation, external rotation strengthening exercises were applied.
61957582|NCT03478930|EXPERIMENTAL|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
61957583|NCT03478930|EXPERIMENTAL|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
61957584|NCT06124833||Newly Diagnosed Cohort|Patients who have been diagnosed with inflammatory bowel disease (IBD, including Crohn's disease and ulcerative colitis) for the first time within the last 6 months prior to study enrollment.
61957585|NCT06124833||Disease Progression Cohort|Patients who were previously diagnosed with IBD and have been followed for over a year to understand disease progression and prognosis.
61957586|NCT06124833||Drug Cohort|Patients with IBD who, during their tracking observations, begin using biological agents and small molecule drugs for the first time.
61957587|NCT06124833||Familial IBD cohort|Cases where there are 2 or more diagnosed IBD patients among the patient's first-degree relatives (≥ 2 IBD-affected First Degree Relatives, FDR).
61957588|NCT06124833||Family Control Group|First-degree blood relatives of the patient who have never been diagnosed with IBD up to the point of study enrollment and who reside with the patient.
62702577|NCT06055933||ESWT+KT|With ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shocks/session was applied in a single session with a 15 mm head. Shock waves will be applied directly to the most sensitive point detected in the medial calcaneus, then a tape consisting of 96% cotton and 4% lycra, water-resistant, porous and adhesive, 5 cm wide and 0.5 mm thick will be used. Taping will be done after the ESWT session and the tape will be asked to remain for a week.
61957589|NCT04316065|OTHER|Group 1|15 subjects, Cross-over, Single dose of comparator on day 1, Single dose of YHP1906 on day 8
61957590|NCT04316065|OTHER|Group 2|15 subjects, Cross-over, Single dose of YHP1906 on day 1, Single dose of comparator on day 8
61957591|NCT04546230|EXPERIMENTAL|E group|Low-Thoracic Epidural Anesthesia
61957592|NCT04546230|ACTIVE_COMPARATOR|G group|General Anesthesia
61957593|NCT00999232|EXPERIMENTAL|Erythromycin|
61957594|NCT00999232|PLACEBO_COMPARATOR|Placebo|
61957595|NCT01497158|ACTIVE_COMPARATOR|Control Group|Participants who received only self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home.
61957596|NCT01497158|ACTIVE_COMPARATOR|Active Group|Participants who received self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home and biomarker feedback from the urine of cohabitating adult non-smoker in the home.
61957597|NCT03910374|PLACEBO_COMPARATOR|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
61957598|NCT03910374|ACTIVE_COMPARATOR|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
61957599|NCT05115903|EXPERIMENTAL|Tapered doses of TNFi|Tapering of TNFi through standardized increases in the dosing interval between drug administration. The tapering dose intervals for each TNFi are designed to decrease the dose from baseline by 75% for 12 weeks, 50% for 24 weeks, and 25% for 12 weeks
61957600|NCT05115903|ACTIVE_COMPARATOR|Standard dose of TNFi|Stable doses of TNFi according to the approved summary of product characteristics for biologic agents used in axial spondyloarthritis
61957601|NCT02756013|EXPERIMENTAL|Paclitaxel + Carboplatin|Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
61957602|NCT00496470|ACTIVE_COMPARATOR|Symbicort+TIO|Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
61957603|NCT00496470|ACTIVE_COMPARATOR|Spiriva® + Placebo Turbuhaler|Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily
62503886|NCT00006371|ACTIVE_COMPARATOR|Hydrocortisone with Ketoconazole|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
61957604|NCT05914805|EXPERIMENTAL|Clascoterone Part 1 and Part 2|Subjects treated for 12 months with Clascoterone 5% solution (both in double-blind Part 1 and in the single-blind Part 2 of the study).
61957605|NCT05914805|OTHER|Clascoterone Part 1 + Vehicle Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Clascoterone 5% solution followed by 6 months Part 2 in the single-blind label with Vehicle.
62503887|NCT00006371|ACTIVE_COMPARATOR|Hydrocortisone with Aminoglutethimide|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
61957606|NCT05914805|OTHER|Vehicle Part 1 + Clascoterone Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Vehicle followed by 6 months Part 2 in the single-blind label with Clascoterone 5% solution.
61957607|NCT05914805|PLACEBO_COMPARATOR|Vehicle Part 1 and Part 2|Subjects treated for 12 months with Vehicle (both in double-blind Part 1 and in the single-blind Part 2 of the study).
61957608|NCT02197520|EXPERIMENTAL|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
61957609|NCT02197520|ACTIVE_COMPARATOR|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
62702578|NCT04692831|EXPERIMENTAL|HER2-positive malignancy|Participants will have a diagnosis of HER2-positive malignancy
62702579|NCT04692831|EXPERIMENTAL|HER2-low malignancy|Participants will have a diagnosis of HER2-low malignancy
62702580|NCT06601998||Healthy controls|Controls with no or one comorbidity, predisposing to significant CV events and without a medical history of severe pneumonia.
62702581|NCT06601998||CVRD controls|Controls with comorbidities predisposing to major CV events and without a medical history of severe pneumonia
62702582|NCT06601998||COVID-19 survivors|Patients cured of acute COVID-19
62702583|NCT06601998||sCAP survivors|Patients cured of severe community-acquired pneumonia
62702584|NCT05647265|EXPERIMENTAL|Treatment (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV, ipilimumab IV, and may undergo surgery on study. Patients also undergo CT or MRI and PET throughout the trial.
62702585|NCT06750107|EXPERIMENTAL|Intervention|This experimental behavioral intervention is designed to (a) lower incidence of sexually transmitted infections (gonorrhea, chlamydia and HIV); and (b) reductions in Intimate Partner Violence (IPV) perpetration frequency and decreased endorsement of IPV supportive attitudes
62702586|NCT06750107|NO_INTERVENTION|Control|The control arm will receive standard care. In South Africa, at the time of study planning there are no integrated HIV-IPV interventions that are evidence-based for this age group so the control group will not receive anything, reflective of what would be standard care in this setting.
62714891|NCT01920490|ACTIVE_COMPARATOR|GUILT-STABILIZE-CORRELATION|Patients in this group will receive visual feedback that reinforces stabilization of the preceding degree of correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will also reinforce stabilization of the preceding degree of correlation.
62714892|NCT02750514|ACTIVE_COMPARATOR|Nivolumab|Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
61957610|NCT02221947|ACTIVE_COMPARATOR|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
61957611|NCT02221947|PLACEBO_COMPARATOR|placebo|single dose of placebo, intravenous infusion over 1 hour
61957612|NCT02837328|EXPERIMENTAL|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
61957613|NCT02837328|PLACEBO_COMPARATOR|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
61957614|NCT00935571||Group I, Group II|"Group I: anesthetized with TIVA (Propofol + Remifentanil)~Group II: anesthetized with inhalation (sevoflurane)"
61957615|NCT04904328|ACTIVE_COMPARATOR|Lumishade® active lens|Treatment of photosensitive migraine with a Lumishade® active device.
62714893|NCT02750514|EXPERIMENTAL|Nivolumab & Dasatinib|Nivolumab in combination with Dasatinib
61957616|NCT04904328|SHAM_COMPARATOR|Lumishade® sham lens|Treatment of photosensitive migraine with a Lumishade® sham device.
61957617|NCT03037775|OTHER|Investigated group|Subjects underwent procedures: hemodynamic indices will be measured at baseline and during 1/ e-cigarette without nicotine smoking, 2/ e-cigarette with nicotine and during 3/ traditional cigarette smoking in random order
61957618|NCT00571948|ACTIVE_COMPARATOR|Babyfood with usual meat content and corn oil|Infants in the control group received vegetable-potato-meat-meals as part of complementary food containing common amounts of meat and corn oil marketed in Germany.
61957619|NCT00571948|EXPERIMENTAL|more meat and a vegetable oil rich in omega-3 fatty acids|Infants in the intervention group received vegetable-potato-meat-meals as part of complementary food containing higher amounts of meat than the control group and rapeseed oil instead of corn oil.
62702587|NCT05872932|EXPERIMENTAL|Only gastric balloon|After analgesia endoscopy will be performed. After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented. After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.
62714894|NCT02750514|EXPERIMENTAL|Nivolumab & Relatlimab|Nivolumab in combination with Relatlimab
61957620|NCT03212924|EXPERIMENTAL|Pupillometry|"Measure of pupil dilatation while listening to speech (monosyllabic words) in quiet and in noise.~Evaluation of speech comprehension in quiet~Evaluation of speech comprehension in noise~Measure of cognitive functions with the MOCA (Montreal Cognitive Assessment)~Auto evaluation of listening effort in quiet~Auto evaluation of listening effort in noise"
61957621|NCT04633018|EXPERIMENTAL|Patient-centered asthma intervention feasibility|Investigate the effect of the patient-centered asthma intervention using the AsthmaMD app on school days missed and medication adherence.
61957622|NCT04633018|EXPERIMENTAL|Wait list control|Control group with usual care (not using app).
61957623|NCT04534959|NO_INTERVENTION|Pre-Implementation|The control (pre-implementation) group will be trauma patients admitted to the surgical/trauma ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
61957624|NCT04534959|EXPERIMENTAL|Post-Implementation Targeting Normoxemia in Trauma ICU|The intervention (post-implementation) group will be patients admitted to the surgical/trauma ICU during the targeted normoxemia intervention period of the stepped-wedge implementation process (up to 25 months).
61957625|NCT02052531|EXPERIMENTAL|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, twice daily for 28 days
61957626|NCT02052531|EXPERIMENTAL|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, twice daily for 28days
61957627|NCT02052531|PLACEBO_COMPARATOR|Vehicle|Vehicle, twice daily for 28days
61957628|NCT02325037|EXPERIMENTAL|GLPG1837 single dose|Single oral dose of GLPG1837 suspension - ascending doses
61957629|NCT02325037|PLACEBO_COMPARATOR|Placebo single dose|Single oral dose of placebo suspension
61957630|NCT02325037|EXPERIMENTAL|GLPG1837 muliple doses|Multiple oral doses of GLPG1837 suspension - ascending doses
61957631|NCT02325037|PLACEBO_COMPARATOR|Placebo multiple doses|Multiple oral doses of placebo suspension
61957632|NCT01925534|EXPERIMENTAL|Optiflow|High-flow humidified nasal oxygen delivery system
61957633|NCT01925534|ACTIVE_COMPARATOR|Oxygen therapy|Standard oxygen therapy
61957634|NCT06373107|EXPERIMENTAL|High intensity gait training|Participants will receive 20 sessions of vigorous walking practice. These sessions are 2-3 times a week.
61957635|NCT03717818|EXPERIMENTAL|Good Psychiatric Management-Brief|
61957636|NCT03717818|PLACEBO_COMPARATOR|Treatment as Usual-Brief|
61957637|NCT06015685|EXPERIMENTAL|Embedded clinic at Midtown|Using the Emory Clinical Data Warehouse (CDW), all patients of Emory Primary Care Midtown with HbA1c \>9% who are not currently under the care of an endocrinologist or the diabetes management program at Emory will be invited to participate in this embedded DM management clinic.
61957638|NCT06015685|OTHER|Routine Care- Dunwoody Family Medicine Clinic|The control population will be drawn using electronic health record data of diabetes patients at Dunwoody Family Medicine Clinic. Information from the Electronic Health Record will be de-identified after extraction. Control participants will be frequency matched.
61957639|NCT00541931|OTHER|Nonsmoker|Nonsmokers Intervention: Dietary Supplement: LifePak Nano
61957640|NCT00541931|OTHER|Smoker|Smoker arm Intervention: Dietary Supplement: LifePak Nano
61957641|NCT04960501||New tension band system|
61957642|NCT04960501||Patella reduction band system|
61957643|NCT04178564|EXPERIMENTAL|Intervention Group|Intervention group will receive 47 sessions of group CS and participate in 3 evaluation sessions. The CS program will last 1 year and each group CS session will last approximately 60 minutes.
61957644|NCT04786990|EXPERIMENTAL|Open-Label Treatment|"Subjects 6-11 years of age: 100 to 400mg SPN-812 (100 mg oral capsule)~Subjects 12-17 years of age: 100 to 600mg SPN-812 (100 mg, 200 mg oral capsule)"
61957645|NCT01955096|EXPERIMENTAL|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
62714895|NCT02750514|EXPERIMENTAL|Nivolumab & Ipilimumab|Nivolumab in combination with Ipilimumab
61957646|NCT01955096|OTHER|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
62714896|NCT02750514|EXPERIMENTAL|Nivolumab & BMS-986205|Nivolumab in combination with BMS- 986205
62503888|NCT02114112|EXPERIMENTAL|Group A-NCPAP Cycling group|Infants in Group A were cycled between NCPAP and nasal prongs. For the first 12 hours, infants received 10 hours of NCPAP and 2 hours of 1 litre per minute of nasal prongs (NP). For the next 12 hours, infants received 8 hours of NCPAP and 4 hours of NP. In the subsequent 24 hours, infants alternated between 6 hours of NCPAP and 6 hours of NP. In the last 24 hours of intervention they alternated between 4 hours of NCPAP and 8 hours of NP.
62503889|NCT02114112|ACTIVE_COMPARATOR|Group B-Continuous NCPAP|Infants randomized to group B received continuous NCPAP at a CPAP distending pressure of 4 cm of water for 72 hours. Both the groups after 72 hours of intervention were weaned to 1litre per minute NP. During the intervention period all infants were scored using the ACoRN respiratory score on a 12 hourly basis.
62503890|NCT01391845|EXPERIMENTAL|UPA, 300UI FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
62503891|NCT01391845|PLACEBO_COMPARATOR|No UPA, 300FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
62345983|NCT04992039|NO_INTERVENTION|Control Arm|Participants of this arm will not receive the total WHO HEARTS package as an intervention. These participants will be screened in the designated area for universal BP screening via A\&D arm-in device. Their diagnosis will be confirmed by measuring their BP by a Medical Officer via an Omron desktop oscillometer. The Medical Officers and UHC nurses of the control sites will be trained up on BP measurement using standard techniques, patient registration, data collection, etc.
62503892|NCT01391845|EXPERIMENTAL|UPA, FSH 225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
62503893|NCT01391845|PLACEBO_COMPARATOR|no UPA, FSH225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
62503894|NCT04157972|ACTIVE_COMPARATOR|SIMEOX|Participants will have to perform 20 minutes of SIMEOX. Passive exhalation is required using the SIMEOX, starting from tidal volume and going until achieving residual volume.
62503895|NCT04157972|ACTIVE_COMPARATOR|PEP|Participants will have to perform 20 minutes of PEP. Active exhalation is required using a PEP device, starting from tidal volume and going until achieving residual volume.
61957647|NCT01230632|EXPERIMENTAL|Dietary Supplement|3 days high fat food
62503896|NCT04779034|EXPERIMENTAL|Group 1|Basketball players
62503897|NCT02976350||Patients with HFpEF|Male patients with heart failure with preserved ejection fraction
62503898|NCT06465758||Acute stroke patients|Subjects admitted in the neurology unit at San Raffaele Hospital for acute stroke meeting the inclusion criteria will be enrolled in the observational study.
62503899|NCT03889691||Control group|The control group consisted of patients who verbal explanation of the surgical procedure and the potential postoperative complications was given with a written informed consent document
62503900|NCT03889691||Study group|Participants in the study group asked to watch impacted lower third molar extraction video which was previously uploaded to the internet with their own device. This video includes only visual components of the surgery such as anesthesia, incision, extraction and suturing. Patients in the second group were also informed verbally about the surgical procedure-possible postoperative complications and was given with a written informed consent document.
62503901|NCT01461291|EXPERIMENTAL|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
62503902|NCT01461291|ACTIVE_COMPARATOR|Cataract surgery|Cataract surgery alone
62503903|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
62503904|NCT05815368|EXPERIMENTAL|REMO training|REMO training will consist of sEMG-biofeedback exercises provided by REMO device.
62702588|NCT05872932|EXPERIMENTAL|sequential botulinum toxin A injection and then gastric balloon|After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for Botox injection and balloon placement, 200 U of botulinum toxin A will be injected to the antrum and the fundus. After 24 hour or 1 week the second procedure (placement of gastric balloon) will be performed. And Starting from first hour until 1 week, patient's nausea-vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.
62702589|NCT04731467|EXPERIMENTAL|Part A- Dose escalation of CM24 in combination with nivolumab|
61957648|NCT06393829|NO_INTERVENTION|pre-implementation|The proportion of patients mobilized pre-intervention period
62503905|NCT05815368|ACTIVE_COMPARATOR|Task-Oriented training|Task-Oriented training will consist of task-specific functional exercises
62345984|NCT04992039|EXPERIMENTAL|Intervention Arm|Participants of this arm will receive all the components of WHO HEARTS technical package components as an intervention.
62503906|NCT05141786|EXPERIMENTAL|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
62503907|NCT06472271||Conventional initial dose|Colistin 5mg/kg/day
62503908|NCT06472271||High initial dose|Colistin 7.5mg/kg/day
62702590|NCT04731467|EXPERIMENTAL|Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine|
62702591|NCT04731467|EXPERIMENTAL|Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV|
62702592|NCT04731467|EXPERIMENTAL|Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine|
61957649|NCT06393829|EXPERIMENTAL|Implementation|The proportion of patients mobilized during the intervention implementation period
62702593|NCT04731467|EXPERIMENTAL|Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV|
62702594|NCT04731467|ACTIVE_COMPARATOR|Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine|
62702595|NCT04731467|ACTIVE_COMPARATOR|Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV|
62702596|NCT03517917||Arm 1|Tumour tissue, blood and leukapheresis collection to enable a manufacturing process for immunotherapies to be developed.
61957650|NCT06393829|NO_INTERVENTION|Post-implementation|The proportion of patients mobilized post-intervention period
62345985|NCT00744016|PLACEBO_COMPARATOR|2|Placebo
62345986|NCT00744016|ACTIVE_COMPARATOR|1|Granulated mesalamine
62345987|NCT05605483||Schools with salad bars|Schools with salad bars
62345988|NCT05605483||Schools without salad bars|Schools without salad bars
61957651|NCT04986423|EXPERIMENTAL|Cohort A - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
62503909|NCT06286761||Single arm|"For blood assay validation and/or reproducibility testing, blood samples will be taken after an overnight fast or after oral glucose or a mixed meal and analyzed. Measurements will be made by: using different assays to determine best conditions of measurement, or repeat testing on different days. Endothelial cells will be collected from a 20-gauge intravenous catheter. One to six 0.025 J-wires will be sequentially inserted into the catheter. These measurements will allow us to determine: the reproducibility and variability of assays used, best timing of blood and endothelial cell collection and best blood volumes and endothelial cell collection wire passes to reliably perform routine assays. For imaging validation, algorithm development, and/or reproducibility testing, participants may undergo DEXA, MRI, or MRS testing to develop or improve analysis algorithms, to evaluate variability of the measurements, or testing different equipment that measure the same variable."
62503910|NCT04172324|EXPERIMENTAL|Hibbot|
62503911|NCT04172324|ACTIVE_COMPARATOR|Standard Care|
62142866|NCT04237909|EXPERIMENTAL|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
62142867|NCT03472352|EXPERIMENTAL|Single Arm|The subjects will be given an anticancer medication (A01) and immune cells (IC01).
62345989|NCT05605483||Schools with salad parts post COVID-19|A subset schools with salad bars that were examined pre-COVID-19 will undergo methods again.
62345990|NCT01174953|OTHER|Finasteride plus soy|Finasteride and soy
62345991|NCT00280319|EXPERIMENTAL|IPT arm|interpersonal psychotherapy for groups (IPT-G). this consists of psychotherapy provided to participants in a group format.
62345992|NCT00280319|EXPERIMENTAL|CP arm|Creative Play therapy consists of play activities provided to participants in groups.
62503912|NCT05708482|EXPERIMENTAL|Sling-Swing Group|"1. While the pregnant woman has 6 cm cervical dilatation examination, the flexible fabric will pass under the arms of the pregnant woman to form a hanger shape. The pregnant woman will be asked to hold the fabric on her feet in a squat and the hanging technique will be applied for 10 minutes. Then, a swing shape will be created in such a way that the flexible fabric will wrap around the chest area of the pregnant woman. The pregnant woman will be asked to hold the fabric in a squat above the knee and the rocking technique will be applied for 10 minutes. Subsequently, uterine contractions, fetal heart rate, fetal head level, position and presence of molding will be evaluated.~2. Until the completion of the first stage of labor (10 cm cervical dilatation, 100% cervical effacement), this applicant will be experienced by them as the same procedure, hourly.~3. A Birth Satisfaction Form will be filled at the 2nd hour after delivery.."
62702597|NCT06748352|EXPERIMENTAL|FASTER-assisted ESD group|Patients in this group undergo ESD with the assistance of the FASTER system.
62702598|NCT06748352|ACTIVE_COMPARATOR|Conventional ESD group|Patients in this group undergo ESD following the clinically established pattern.
62702599|NCT06750952|EXPERIMENTAL|Ivonescimab|Ivonescimab combined with chemotherapy：Ivonescimab，20mg/kg， iv. drip, D1, Q3W；Paclitaxel, 175mg/m2 or albumin paclitaxel, 260mg/m2, iv. drip, D1, Q3W；Carboplatin, AUC5， iv.drip,D1, Q3W。After 4-6 cycles of combination therapy, Ivonescimab was maintained until PD or toxicity was intolerable.
61957652|NCT04986423|ACTIVE_COMPARATOR|Cohort A - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
62142868|NCT03732807|EXPERIMENTAL|Sequence A|Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
62142869|NCT03732807|EXPERIMENTAL|Sequence B|Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
62142870|NCT03732807|EXPERIMENTAL|Sequence C|Maintenance dose #1 given QD for 48 weeks
62142871|NCT03732807|EXPERIMENTAL|Sequence D|Maintenance dose #2 given QD for 48 weeks
62142872|NCT03732807|EXPERIMENTAL|Sequence E|Maintenance dose #3 given QD for 48 weeks
62142873|NCT03732807|EXPERIMENTAL|Sequence F|Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
62142874|NCT03732807|EXPERIMENTAL|Sequence G|Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks
62142875|NCT03512782|NO_INTERVENTION|CONTROL|
62142876|NCT03512782|EXPERIMENTAL|INTERVENTION|
62345993|NCT00280319|NO_INTERVENTION|control|those who are wait-list controls
62345994|NCT00822484|ACTIVE_COMPARATOR|ILV-095|6 SC single dose injections
62345995|NCT00822484|PLACEBO_COMPARATOR|Placebo|Placebo
62345996|NCT01956266|EXPERIMENTAL|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
62345997|NCT02860754|OTHER|Six-minute walk test|All patients will perform six-minute walk test before surgery, in the preoperative clinic
62345998|NCT00857753|EXPERIMENTAL|1|Fentanyl patch 25 ug/hr Sandoz
62345999|NCT00857753|ACTIVE_COMPARATOR|2|Duragesic Patch 25 ug/hr
62346000|NCT05239377||Baseline|Pre-prostatectomy conferences conducted without the use of digital support
62346001|NCT05239377||ISPM -MiProstate|Pre-prostatectomy conferences conducted with the use of digital support (ISPM- MiProstate)
62346002|NCT05940597|ACTIVE_COMPARATOR|Cryoablation arm|Market approved cryoablation system
62346003|NCT05940597|EXPERIMENTAL|PFA arm|Market approved PFA ablation system (Farapulse - Boston Scientific system).
62346004|NCT02581566|ACTIVE_COMPARATOR|Intrathecal Dexmedetomidine Group|30 patients will be given Intrathecal Dexmedetomidine plus Intrathecal Bupivacaine
62702600|NCT06749652|EXPERIMENTAL|Soft silicone stent arm|Patients who recieved soft silicone ureteral stent (Universa, Cook medical) at the end of the ureteroscopy
62346005|NCT02581566|ACTIVE_COMPARATOR|Intraarticular Dexmedetomidine Group|30 patients will be given Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
62346006|NCT02581566|OTHER|control Group|30 patients will be given Intrathecal Bupivacaine
62346007|NCT01702662|EXPERIMENTAL|Photopill treatment|Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
62346008|NCT05310513||ICU group|patients admitted to ICU with PRES.
62346009|NCT05310513||Non-ICU group|patients not admitted to ICU with PRES.
62346010|NCT06256029|EXPERIMENTAL|Experimental group|All participants will undergo the recruitment maneuver. The patients will be divided into non-obese patients (BMI 18.5-24.9 kg/m²) and patients with increased body mass (BMI 25-34.9 kg/m²).
62346011|NCT06485986|ACTIVE_COMPARATOR|PD DBS, no ICD|Patients with Parkinson's disease who are treated with deep brain stimulation (DBS) but have not developed impulsive or compulsive behaviours will undertake a computerised task with their DBS turned on and off with simultaneous magnetoencephalography. After each experiment, normal therapy will be resumed.
62346012|NCT06485986|EXPERIMENTAL|PD DBS with ICD|Patients with Parkinson's disease who are treated with deep brain stimulation (DBS) who have developed impulsive or compulsive behaviours will undertake a computerised task with their DBS turned on and off with simultaneous magnetoencephalography. After each experiment, normal therapy will be resumed.
62346013|NCT03978624|EXPERIMENTAL|A: Pembrolizumab alone|Subjects will be administered pembrolizumab alone 200 mg IV on day 1 and day 22
62346014|NCT03978624|EXPERIMENTAL|B: Pembrolizumab plus Entinostat|Subjects will be administered pembrolizumab on day 1 and day 22 and entinostat 5 mg given orally on day 1, day 8 and day 15
62346015|NCT01656317|ACTIVE_COMPARATOR|Mobilisation of patients after SAH|"Patients which were treated after SAH in 2012 will receive early multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~Mobilisation will be initiated and completed according to mobilisations guidelines which are developed and adjusted to the patients in early stage after aneurysmal SAH."
62346016|NCT01656317|NO_INTERVENTION|Patients after SAH from 2011|Patients after SAH from 2011 which did not receive early rehabilitation and mobilisation will be followed up 3-6 annd 12 months after SAH and outcome measures compared with patients from 2011.
62346017|NCT02451436|ACTIVE_COMPARATOR|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
62346018|NCT02451436|ACTIVE_COMPARATOR|Study Skills Control Group|The control group will receive four sessions of study skills training.
62346019|NCT04888351||Mastectomies with IBR|Every women\>18 years who underwent mastectomies followed by IBR (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) for breast cancer in Hôpital de la Croix-Rousse between January 2016 and January 2020
62346020|NCT04888351||Mastectomies without IBR|Every women\>18 years who underwent mastectomies for breast cancer followed by delayed reconstructions (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) or no reconstructions between January 2016 and January 2020 in Hôpital de la Croix-Rousse
62346021|NCT02480179|EXPERIMENTAL|single arm pilot feasibility study|Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
62142877|NCT00263757|EXPERIMENTAL|Therapeutic Positive Airway Pressure|Subjects randomized to this arm received nightly Adaptive Servo-Ventilation during sleep for 12 months.
62346022|NCT01506050|EXPERIMENTAL|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
62346023|NCT01506050|ACTIVE_COMPARATOR|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
62346024|NCT02732340|EXPERIMENTAL|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
62346025|NCT05275621|EXPERIMENTAL|Subjects requiring PICC|Subjects requiring a PICC. Positioning is first tried under Virtual Reality distraction. If failure (movements or discomfort) standard procedural sedation is applied. No kind of physical restraint is allowed.
62346026|NCT01594294|EXPERIMENTAL|AOSEPT Plus|AOSEPT® Plus contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
62346027|NCT01594294|ACTIVE_COMPARATOR|ReNu MultiPlus|ReNu MultiPlus® contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
62346028|NCT01594294|OTHER|Complete MPS Easy Rub|COMPLETE® MPS Easy Rub® Formula contact lens solution used with etafilcon A contact lenses (14 days) or lotrafilcon B contact lenses (30 days), Screening Phase
62346029|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
62346030|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
62346031|NCT04825119||MND patients|Patients with ''clinically definite ALS'' or ''clinically probable ALS'' or ''clinically probable ALS - laboratory supported'' according to the revised El Escorial diagnostic criteria or with the diagnosis of PMA or PLS will be included.
62346032|NCT04825119||SMA patients|SMA patients type I, II, III, and IV will be included.
62346033|NCT02217228|EXPERIMENTAL|Sebacia microparticles and laser|Gold microparticle suspension + laser treatment x 3 over the course of two weeks
62702601|NCT06749652|EXPERIMENTAL|Firm silicone stent arm|Patients who recieved firm silicone ureteral stent (percuflex plux, boston scientificl) at the end of the ureteroscopy
62702602|NCT06750432|EXPERIMENTAL|Cohort 1 PMN310 350 mg or placebo|PMN310 350 mg or placebo administered as a 60-minute infusion.
62702603|NCT06750432|EXPERIMENTAL|Cohort 2 PMN310 700 mg or placebo|PMN310 700 mg or placebo administered as a 60-minute infusion.
62142878|NCT00263757|OTHER|Usual Care|Subjects randomized to this arm received medical management for 12 months as prescribed by their cardiologist.
62346034|NCT02217228|EXPERIMENTAL|Vehicle suspension and laser|Vehicle suspension + laser treatment x 3 over the course of two weeks
62702604|NCT06750432|EXPERIMENTAL|Cohort 3 PMN310 1400 mg or placebo|PMN310 1400 mg or placebo administered as a 60-minute infusion.
62503913|NCT05708482|NO_INTERVENTION|Standard Care Group|"1. While the pregnant woman has 6 cm cervical dilatation examination, uterine contractions, fetal heartbeat, fetal head level, position and presence of molding will be evaluated.~2. Until the completion of the first stage of labor (10 cm cervical dilatation, 100% cervical effacement), uterine contractions, fetal heartbeat, fetal head level, position and presence of molding will be evaluated every hour.~3. A Birth Satisfaction Form will be filled at the 2nd hour after delivery. At the end of the study, delivery times and satisfaction of pregnant women will be analyzed."
62702605|NCT06748898|EXPERIMENTAL|T group|Patients received TENS-WAA with current stimulation
62702606|NCT06748898|SHAM_COMPARATOR|C group|Patients received TENS-WAA without current stimulation
62702607|NCT04206319|EXPERIMENTAL|1|Participants will receive radium-223 treatment every 4 weeks for up to 6 cycles. 18F-NaF PET scans will be used to assess response in bone.
62702608|NCT06749015||No interventional|All BRAFV600E mutant patients having initiated treatment for mCRC between 01 October, 2020 and 01 October, 2025 (both days inclusive) with drugs registered for mCRC in respective study center
62702609|NCT06748937|EXPERIMENTAL|Cohort 1 Arm 1 (A45E125)|Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
62702610|NCT06748937|EXPERIMENTAL|Cohort 1 Arm 2 (A45E250)|Alpibectir 45 mg OD plus Ethionamide 250 mg OD
62702611|NCT06748937|ACTIVE_COMPARATOR|Cohort 1 Arm 3 (HRZE)|Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
62702612|NCT06748937|ACTIVE_COMPARATOR|Cohort 2 Arm 3 (HRZE)|Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
62702613|NCT06748937|EXPERIMENTAL|Cohort 2 Arm 4 (A45E250RZE)|Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
62702614|NCT06750237|EXPERIMENTAL|Isometrics|will be an interventional group and will be treated by training the patients on unstable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week
61957653|NCT04986423|EXPERIMENTAL|Cohort B - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
62142879|NCT05841407|EXPERIMENTAL|High nitrate|High nitrate isotonic drink
62142880|NCT05841407|ACTIVE_COMPARATOR|No nitrate|No nitrate isotonic drink
62346035|NCT02217228|EXPERIMENTAL|Sebacia microparticles without laser|Gold microparticle suspension treatment x 3 over the course of two weeks
62346036|NCT03506022|OTHER|patients with type 1 mellitus diabetes|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters
62346037|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
62346038|NCT05184309|EXPERIMENTAL|Conventional exercise group|Conventional Exercises
62346039|NCT05184309|EXPERIMENTAL|Serious game group|Serious Games
62346040|NCT02589795|EXPERIMENTAL|Group 1: ID/EP + IM|"0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly without electroporation, at Weeks 0, 4 and 8.~50 µg CN54gp140, intradermally without electroporation, at Week 20."
62346041|NCT02589795|EXPERIMENTAL|Group 2: ID + IM/EP|"0.6 mg DNA-C CN54ENV, intradermally without electroporation, at Weeks 0, 4 and 8.~2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20."
62346042|NCT02589795|EXPERIMENTAL|Group 3: ID/EP + IM/EP|0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20.
62503914|NCT06616584|ACTIVE_COMPARATOR|Arm I (ramucirumab, docetaxel)|Patients receive dexamethasone PO BID on days 0-2, ramucirumab IV over 30-60 minutes on day 1 and docetaxel IV over 60 minutes on day 1 of each cycle (each cycle is 21 days). Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and CT or MRI throughout the study.
62503915|NCT06616584|EXPERIMENTAL|Arm II (cemiplimab, ramucirumab, docetaxel)|Patients receive dexamethasone PO BID on days 0-2, ramucirumab IV over 30-60 minutes on day 1, docetaxel IV over 60 minutes on day 1, and cemiplimab IV over 30 minutes on day 1 of each cycle (each cycle is 21 days). Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and CT or MRI throughout the study.
62702615|NCT06750237|ACTIVE_COMPARATOR|Stable surface and isometrics|will be an interventional group and will be treated by training the patients on stable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week.
62702616|NCT06750185|EXPERIMENTAL|BNT317 DL1|BNT317 monotherapy
62702617|NCT06750185|EXPERIMENTAL|BNT317 DL2|BNT317 monotherapy
62702618|NCT06750185|EXPERIMENTAL|BNT317 DL3|BNT317 monotherapy
62702619|NCT06750185|EXPERIMENTAL|BNT317 DL4|BNT317 monotherapy
62702620|NCT06750185|EXPERIMENTAL|BNT317 DL5 (optional, intermediate)|BNT317 monotherapy
62702621|NCT06750185|EXPERIMENTAL|BNT317 DL6 (optional, intermediate)|BNT317 monotherapy
62702622|NCT06750185|EXPERIMENTAL|BNT317 DL7 (optional, additional)|BNT317 monotherapy
61957654|NCT04986423|ACTIVE_COMPARATOR|Cohort B - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
61957655|NCT04826575|NO_INTERVENTION|Control|No intervention will be done in this group.
61957656|NCT04826575|EXPERIMENTAL|Pre-Habilitation|Two weeks of high intensity respiratory muscle training, optional smoking cessation and psychological support.
61957657|NCT01776112|EXPERIMENTAL|SZ-Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
61957658|NCT01776112|PLACEBO_COMPARATOR|SZ-TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
61957659|NCT01776112|EXPERIMENTAL|HC-Exercise|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
61957660|NCT01691339|EXPERIMENTAL|Fluzone vaccine (Group 1)|Adults 18 to \< 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
61957661|NCT01691339|EXPERIMENTAL|Fluzone Intradermal vaccine (Group 2)|Adults 18 to \< 65 years of age randomized to receive one dose of Fluzone Intradermal vaccine intradermally
61957662|NCT01691339|EXPERIMENTAL|Fluzone vaccine (Group 3)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
61957663|NCT01691339|ACTIVE_COMPARATOR|Fluzone High-Dose Vaccine (Group 4)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone High-Dose vaccine intramuscularly
61957664|NCT00224042|EXPERIMENTAL|IV iron|
61957665|NCT00224042|ACTIVE_COMPARATOR|oral iron|
61957666|NCT03449797|SHAM_COMPARATOR|Group A|AAVS performed with no intraprocedural rapid cortisol assay
61957667|NCT03449797|EXPERIMENTAL|Group B|AVS performed plus intraprocedural rapid cortisol assay
62702623|NCT06749509||Face-to-face musculoskeletal rehabilitation (A)|Participation in a face-to-face rehabilitation course organized by the Social Insurance Institution of Finland (Kela) for those with musculoskeletal disorders (MSD) (A)
61957668|NCT06444971|EXPERIMENTAL|PIR Group|"Post isometric relaxation technique will be applied to sternocleidomastoid and scalene muscles in all the participants with following parameters~* Participant will perform isometric contractions using 20 -30% of their strength~* HOLD TIME: 5-7 sec followed by 20 to 30 sec stretch~* REST TIME: 5 sec~* REPETITIONS: 3-5 repetitions"
61957669|NCT01910025|EXPERIMENTAL|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
61957670|NCT04646837|EXPERIMENTAL|Experimental Arm|Durvalumab 1000 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IB-IIIA NSCLC adult patients followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 15000mg Q4W for 8 months
62702624|NCT06749509||Musculoskeletal telerehabilitation (B)|Participation in a telerehabilitation course organized by Kela for those with MSD (B)
62142881|NCT01394276||Tocilizumab|Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra \[Tocilizumab (TCZ)\] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
62702625|NCT06749509||Controls (C)|Persons with MSD who had contacted their occupational health care because of musculoskeletal symptoms, and will not participate in Kela's musculoskeletal rehabilitation course during the study period
62503916|NCT06422481|EXPERIMENTAL|Fluids|
62503917|NCT06422481|EXPERIMENTAL|Norepinephrine|
62702626|NCT06749756|EXPERIMENTAL|Experimental group|In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
61957671|NCT03798405|EXPERIMENTAL|Proactive|"Proactive Analgesic Inpatient Narcotic-Sparing:~Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a protocol."
61957672|NCT03798405|NO_INTERVENTION|Reactive (Control Group)|Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.
61957673|NCT05026255|EXPERIMENTAL|mechanically ventilated intensive care patients.|Observational data collected for patients in intensive care under mechanical ventilation.
61957674|NCT06047483|EXPERIMENTAL|HRF2105 patch|
61957675|NCT06047483|ACTIVE_COMPARATOR|Loxoprofen patch|
61957676|NCT06047483|PLACEBO_COMPARATOR|placebo|
62503918|NCT00679250|EXPERIMENTAL|Levocetirizine|Active drug
61957677|NCT01299740|OTHER|Control Group|Treatment as usual
61957678|NCT01299740|EXPERIMENTAL|Research Group|Participation in the DBT skills group
62503919|NCT00679250|PLACEBO_COMPARATOR|placebo|placebo to levocetirizine
62702627|NCT06749756|ACTIVE_COMPARATOR|Control group 1|In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
62702628|NCT06749756|ACTIVE_COMPARATOR|Control group 2|On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
62702629|NCT06749756|ACTIVE_COMPARATOR|Control group 3|The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
62702630|NCT06748105|EXPERIMENTAL|Dapagliflozin|Participants in this arm will receive dapagliflozin (10 mg/day) administered orally. The dose will be synchronized with glucocorticoid administration, with a maximum allowable time difference of 12 hours. Patients and their families will be trained in self-administration, and adherence will be monitored through nursing service reports.
61957679|NCT02892578|EXPERIMENTAL|electrocardiogram|Patient will take an electrocardiogram in order to detect atrial fibrillation
61957680|NCT05776498|EXPERIMENTAL|immediate implant placement with particulate bone graft using the dual zone technique.|immediate implant placement with particulate bone graft using the dual zone technique.
61957681|NCT05776498|EXPERIMENTAL|immediate implant placement with connective tissue grafting|immediate implant placement with connective tissue grafting
61957682|NCT05473390|ACTIVE_COMPARATOR|study group|20 patient with hemiplegia
62702631|NCT06748105|ACTIVE_COMPARATOR|Standard Monitoring Arm|Participants will undergo standard glycemic monitoring (SGM), including preprandial capillary glucose measurements during three daily shifts and fasting central glucose assessments (6-8 hours fasting).
61957683|NCT05473390|ACTIVE_COMPARATOR|control group|20 patient with hemiplegia
61957684|NCT02097004|EXPERIMENTAL|Concomitant:Pegasys, Euvax B, Baracrude|"* Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks~* HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks~* Continue Entecavir(0.5mg) for 100 weeks(once daily)"
62702632|NCT06750978|EXPERIMENTAL|Self-reflection|Participants actively review their smartphone usage data each day, which will be verified by the app.
62702633|NCT06750978|EXPERIMENTAL|Self-reflection + Alternative activity engagement|Participants actively review their smartphone usage and engage in alternative activities which are identified by the participants, which will be recorded and verified via the app.
61957685|NCT02097004|EXPERIMENTAL|Sequential:Pegasys, Euvax B, Baracrude|"* Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks~* HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks~* Continue Entecavir(0.5mg) for 100 weeks(once daily)"
62702634|NCT06750978|EXPERIMENTAL|Self-reflection + Contingency management|Participants will actively review their smartphone usage each day, which will be verified via the app. If the participant meets their daily PSU reduction goal, they will receive an incentive ($8); if they do not meet their goal, they will receive nothing.
62702635|NCT06750978|NO_INTERVENTION|Control|Participants will not engage in any behavioral intervention strategies
61957686|NCT02097004|ACTIVE_COMPARATOR|Control Group|"* Continue Entecavir(0.5mg) for 100 weeks(once daily)~* After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks"
61957687|NCT02898883|EXPERIMENTAL|Intervention group|Early intervention Program The early intervention program (EIP) will consist of 4 sessions with one parent/guardian of the injured child and a clinical psychology graduate student therapist. All sessions are one on one for one hour. The first session will be conducted in the hospital within an average of 24- 48 hours after the traumatic event. The subsequent three sessions will be conducted electronically via web-based video chat once per week. In general, the EIP will utilize psychoeducation, skills implementation, and daily monitoring to facilitate communication regarding the traumatic event, maintain daily and sleep routines, increase child's access to social support and mitigate the impact of life stress.
61957688|NCT02898883|NO_INTERVENTION|Treatment as Usual (TAU)|As part of routine hospital protocol, all participants who screen positively for PTSD risk are provided with a packet of educational materials and potential referrals for behavioral healthcare.
61957689|NCT03616600|EXPERIMENTAL|Treatment|Wearing the orthokeratology lenses for 3 months
62142882|NCT00233714|ACTIVE_COMPARATOR|1|Single-dose Sirolimus-Eluting Coronary stent
62503920|NCT06069856|EXPERIMENTAL|MMS with 60 mg of iron first, then IFA with 60 mg of iron|Women will receive the first regimen (MMS with 60 mg of iron) for 2 months and then crossover on to the second regimen (IFA with 60 mg of iron) for 2 months
62702636|NCT06748807|EXPERIMENTAL|APRVplus|An Early Pathophysiology-driven Airway Pressure Release Ventilation
62702637|NCT06748807|OTHER|TCAV|Time Controlled Adaptive Ventilation (TCAV)
62702638|NCT06750588|ACTIVE_COMPARATOR|Cohort 1|Dose 1
61957690|NCT03616600|NO_INTERVENTION|Control|Not wearing any contact lenses
61957691|NCT05851066|EXPERIMENTAL|VSA003|single dose of VSA003 by subcutaneous (sc) injections: 50 mg, 100 mg, 200 mg
61957692|NCT05851066|PLACEBO_COMPARATOR|placebo|sterile normal saline (0.9% NaCl) calculated volume to match active treatment
61957693|NCT02794883|ACTIVE_COMPARATOR|Treatment (durvalumab)|Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
61957694|NCT02794883|ACTIVE_COMPARATOR|Treatment (tremelimumab and durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
61957695|NCT02794883|EXPERIMENTAL|Treatment (tremelimumab)|Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62142883|NCT00233714|ACTIVE_COMPARATOR|2|Double-dose Sirolimus-Eluting Coronary stent
62142884|NCT03678792|OTHER|Buprenorphine-Naloxone|Standard of Care
62142885|NCT03678792|EXPERIMENTAL|Morphine|
62142886|NCT03678792|EXPERIMENTAL|Tramadol|
62702639|NCT06750588|ACTIVE_COMPARATOR|Cohort 2|Dose 2
62702640|NCT06750588|ACTIVE_COMPARATOR|Cohort 3|Dose 3
62702641|NCT06750588|ACTIVE_COMPARATOR|Cohort 4|Dose 4
62702642|NCT06750471|ACTIVE_COMPARATOR|Arm A - Regular Adminstration|Eligible patient will receive 300 mg Subcutaneous Dupilumab every 2 weeks for 28 weeks
62702643|NCT06750471|EXPERIMENTAL|Arm B - Alternate Administration|Eligible patient will receive 300 mg Subcutaneous Dupilumab every 2 weeks for 8 weeks and then every 4 weeks up until 28 weeks
62702644|NCT06749171||Women|Women undergoing CABG
62702645|NCT06749171||Men|Men undergoing CABG
62702646|NCT06749483||ICU patients with antibiotic treatment|ICU patients treated with piperacillin/tazobactam or meropenem
62702647|NCT06749483||ICU patients without antibiotic treatment|ICU patients without antibiotic treatment during their ICU stay
62503921|NCT06069856|EXPERIMENTAL|IFA with 60 mg of iron first, then MMS with 60 mg of iron|Women will receive the first regimen (IFA with 60 mg of iron) for 2 months and then crossover on to the second regimen (MMS with 60 mg of iron) for 2 months
62702648|NCT06749483||Long-term survivors of critical illness|Long-term survivors at least six months or more after the beginning of critical illness.
62503922|NCT05108844|EXPERIMENTAL|Early small bowel investigation|Patients in the early small bowel investigation group will undergo VCE immediately after their initial negative gastroscopy
62702649|NCT03189524|EXPERIMENTAL|Part I: 160 mg BID|"Safety Evaluation: Two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily \[BID\]) administered in the morning and at night, or 320 mg (once daily \[QD\]), and a 3+3 design was adopted for Part I of the study to determine recommended Phase 2 dose (RP2D)."
62702650|NCT03189524|EXPERIMENTAL|Part I: 320 mg QD|"Safety Evaluation: Two regimens of zanubrutinib 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and a 3+3 design was adopted for Part I of the study to determine RP2D."
62142887|NCT06301867||Extubated Patients|All patients receiving mechanical ventilation who are extubated in the intensive care units during the study period.
62142888|NCT03258866|EXPERIMENTAL|group A|In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22).
62142889|NCT03258866|EXPERIMENTAL|group B|In group B, Rituximab was given with a single dose of 375mg/m2
62142890|NCT02851134||Crohn disease subject|Crohn disease affected subject
62142891|NCT02851134||family control subject|family control unaffected subject
62142892|NCT03653897|EXPERIMENTAL|ID-Capsules- Active|Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded.
62142893|NCT00733174|EXPERIMENTAL|1|Rosiglitazone
62142894|NCT00733174|PLACEBO_COMPARATOR|2|Placebo
62503923|NCT05108844|ACTIVE_COMPARATOR|Colonoscopy|Participants with negative gastroscopy will undergo bowel preparation and colonoscopy the next day
62503924|NCT04467320|EXPERIMENTAL|Intervention Group|Receiving the Teaching Recovery Techniques intervention (delivered online).
62503925|NCT04467320|ACTIVE_COMPARATOR|Care-As-Usual Group|Receiving care-as-usual.
62503926|NCT02007668|EXPERIMENTAL|Kinesio Taping|Patients will receive an application of Kinesio taping in their lumbar spine.
62503927|NCT02007668|PLACEBO_COMPARATOR|Kinesio Taping Placebo|Patients will receive an application of medical adhesive tape in their lumbar spine.
62702651|NCT03189524|EXPERIMENTAL|Part II: 160 mg BID|Dose Expansion: The RP2D determined in Part I was used in Part II to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL).
62702652|NCT06749405|EXPERIMENTAL|Transfusion algorithm based on Quantra®|Patients managed using a transfusion algorithm based on Quantra®.
62702653|NCT06749405|ACTIVE_COMPARATOR|Conventional transfusion algorithm|Patients managed using a conventional transfusion algorithm.
62714897|NCT06669455|EXPERIMENTAL|Intervention|"Intervention group receiving:~* Intake with lifestyle coach~* Usual Care~* Integrated, combined lifestyle approach (SENSS), including continuous monitoring by lifestyle coach."
62714898|NCT06669455|NO_INTERVENTION|Control|"Control group receiving:~* Intake with lifestyle coach~* Usual care"
62714899|NCT06648486|EXPERIMENTAL|Robot-assisted Rehabilitation|
61957696|NCT01450995|ACTIVE_COMPARATOR|Treximet|
61957697|NCT01450995|ACTIVE_COMPARATOR|Imitrex and Aleve|
61957698|NCT02781831|ACTIVE_COMPARATOR|Standard Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation program
62142895|NCT05794841||Patients with digestive tract malignant tumors|Patients with malignant tumors of the esophagus, stomach or colon confirmed by pathology, have not received anti-tumor therapy, and have not had malignant tumors in the past.
62142896|NCT05794841||Healthy volunteer|Healthy individuals with no digestive tract malignancies confirmed by gastroscopy and colonoscopy.
62142897|NCT05445557|ACTIVE_COMPARATOR|RZL-012 50mg/ml|Subjects flanks treated with RZL-012 (in the double blind phase) will undergo a single treatment session with 50-55 injections. The maximal number of injections will be 55 with maximal doses 412.5 mg. Each injection point will be dosed with 7.5 mg for in a volume of 0.15 mL/injection site.
62142898|NCT05445557|PLACEBO_COMPARATOR|Placebo|Subjects flanks treated with placebo (in the double blind phase) will undergo a single treatment session with 50-55 injections. The maximal number of injections will be 55 with maximal volume of 8.25mL. Each injection point will be dosed with 0.15 mL/injection site.
62142899|NCT03511794||hep B vaccine|1. Patient must have received at least one dose of the hepatitis B vaccine
62142900|NCT02234141|EXPERIMENTAL|Selonsertib 2 mg|Participants will receive selonsertib 2 milligrams (mg) for 24 weeks and may continue on this dose during the long-term treatment phase.
62142901|NCT02234141|EXPERIMENTAL|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
62142902|NCT02234141|EXPERIMENTAL|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
62142903|NCT02234141|EXPERIMENTAL|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
62142904|NCT00439686|EXPERIMENTAL|Single Arm|
62142905|NCT01580306|EXPERIMENTAL|BI 201335 relevant treatment dose (A)|Capsule for oral administration
62142906|NCT01580306|EXPERIMENTAL|BI 201335 relevant treatment dose (B)|Capsule for oral administration
62142907|NCT04972526||Out-of-hospital Cardiac Arrest|Patients receiving TEE as part of their clinical evaluation during cardiac arrest that occurred outside the hospital (e.g. in/at a home or residence, in a public area, during transport to the emergency department, etc.)
62142908|NCT04972526||In-hospital Cardiac Arrest|Patients receiving TEE as part of the clinical evaluation during cardiac arrest that occurred within a hospital (e.g in the emergency department, an Intensive Care Unit, a hospital ward, the operating room, etc.)
62503928|NCT02007668|NO_INTERVENTION|Control|This participants will not receive intervention
62714900|NCT01926743|EXPERIMENTAL|NIR with ICG group|
62714901|NCT00529360|EXPERIMENTAL|Part A|Part A will be the dose escalation phase to determine the MTD and/or safe/tolerated dose of clofarabine.
61957699|NCT02781831|EXPERIMENTAL|Robot-assisted Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation as well as robot-assisted gait rehabilitation program
61957700|NCT05590130|EXPERIMENTAL|Nonin oximeter with a 90% SpO2 target|During this periods , oxygen will be administered in an manual titration with the FreeO2 device (fixed flow mode) to reach 90% of SpO2.
61957701|NCT05590130|EXPERIMENTAL|Philips oximeter with a 90% SpO2 target|During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 90% of SpO2.
62503929|NCT04440280|ACTIVE_COMPARATOR|NAC 10% group|Subjects in this group will be treated with eye drops containing a 10% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
62503930|NCT04440280|ACTIVE_COMPARATOR|NAC 20% group|Subjects in this group will be treated with eye drops containing a 20% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
62503931|NCT04440280|PLACEBO_COMPARATOR|Placebo group|Subjects in this group will be treated with a placebo (Visine Tears Dry Eye Relief artificial tears ophthalmic solution.)
62503932|NCT02084368|EXPERIMENTAL|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block guided by PNS.
62503933|NCT02084368|PLACEBO_COMPARATOR|combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group.
61957702|NCT05590130|EXPERIMENTAL|Nonin oximeter with a 94% SpO2 target|During this periods , oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode) to reach 94% of SpO2.
62503934|NCT01909739|EXPERIMENTAL|Statin group|
62503935|NCT01909739|PLACEBO_COMPARATOR|Placebo group|
62503936|NCT04167618|EXPERIMENTAL|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).
62503937|NCT04390230||Patient with peniale implantation|All patients who underwent implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France.
61957703|NCT05590130|EXPERIMENTAL|Philips oximeter with a 94% SpO2 target|During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 94% of SpO2.
61957704|NCT05862415|ACTIVE_COMPARATOR|strength+aerobic group (SAG)|"All training sessions began with a 5- to 7-minute warm- up (consisting low-intensity walking and running, and dynamic mobility exercises) and active recovery of 4- to 5-minute (based on stretching and relaxation exercises). Sessions lasted approximately 50 minutes (warm-up and cold down included), with an overall weekly volume of 105-120 minutes.~The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The resistance training program was performed using the circuit training method in which two or three sets were performed. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc."
61957705|NCT05862415|EXPERIMENTAL|aerobic+strength group (ASG)|Similar to the active comparator group, but the order of the training reverse.
61957706|NCT01979887||Non-MGD Participants|Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
62503938|NCT05920330|OTHER|Single Arm|A device-nasal plug will be self-inserted into the nose with a diagonal channel embedded to redirect nasal airflow patterns to different nasal regions. A nose clip will be used to pinch the nose externally, similar to what synchronized swimmers use.
62503939|NCT05840471|ACTIVE_COMPARATOR|Tranexamic acid group|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
62503940|NCT05840471|PLACEBO_COMPARATOR|Glucose water group|Participants will receive 30 mL of 5% glucose water slowly intravenously immediately during the attack of the bleeding, twice daily for 48 hours. Accompanied with the usual expectant management care.
62503941|NCT06519760|EXPERIMENTAL|68Ga-C1|Subjects with suspected or confirmed clear cell renal cell carcinoma will receive an intravenous injection of 68Ga-C1 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
61957707|NCT01979887||Mild-Moderate MGD Participants|Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
62503942|NCT02077296||Preoperative chemoradiotherapy|The group consists of patients aged ≥18 with a pathohistological diagnosis of locally advanced rectal adenocarcinoma (\<15 cm from the anal verge). They are found eligible for preoperative chemoradiotherapy (chemotherapy: oral capecitabine / radiotherapy: 45-50 Gy in total; fractions of 1.8-2 Gy) and surgery (stage 2 or 3 rectal cancer).
62503943|NCT02126384|EXPERIMENTAL|pneumovax|Single arm, open label pneumovax vaccination of healthy subjects
62503944|NCT04152369|ACTIVE_COMPARATOR|24 hour prophylaxis|In this group patients received a AMP for the day of the procedure
62503945|NCT04152369|ACTIVE_COMPARATOR|72 hour prophylaxis|In this group patients received a AMP one day prior, on the day of the procedure and the following day.
62503946|NCT01593969|ACTIVE_COMPARATOR|Standard RUTF|Standard RUTF given according to National Guidelines
62503947|NCT01593969|EXPERIMENTAL|RUTF/Flax Oil|RUTF/Flax Oil is reformulated RUTF to increase n3 content
62503948|NCT01593969|EXPERIMENTAL|RUTF/Flax Oil plus additional Fish Oil|RUTF/Flax Oil plus additional Fish Oil is RUTF reformulated to increase n3. Fish oil to provide long chain n3
62503949|NCT01503333|NO_INTERVENTION|Control|The control condition will complete data collection activities and receive their usual school offerings.
62503950|NCT01503333|EXPERIMENTAL|Physical activity intervention|Receiving Physical activity intervention which includes individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
62702654|NCT04989803|EXPERIMENTAL|KITE-363|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable."
62714902|NCT00529360|EXPERIMENTAL|Part B|Part B will accrue patients to further define the event free, disease free and overall survival at the MTD or safe/tolerated dose of clofarabine.
62503951|NCT02992613|EXPERIMENTAL|Ultra-Congruent(UC) group|Ultra-Congruent(UC) insert will be used in total knee arthroplasty.
62503952|NCT02992613|ACTIVE_COMPARATOR|posterior-stabilized(PS) group|Posterior-stabilized(PS) insert will be used in total knee arthroplasty.
62503953|NCT00565513|OTHER|A|cord blood and maternal milk tests
62503954|NCT01443689|EXPERIMENTAL|Group1 :Conventional plus hUCMSCs treatment|Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.
62503955|NCT01443689|EXPERIMENTAL|Group 2: Conventional plus hCBMNCs and hUCMSCs therapy|Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.
62503956|NCT01443689|ACTIVE_COMPARATOR|Group 3:Conventional therapy|Participants will be given conventional therapy only with a 6 months follow-up.
62503957|NCT02586363|ACTIVE_COMPARATOR|Baraclude Tab. 0.5mg, fasting|Single dose Baraclude Tab. 0.5mg, fasting state
62503958|NCT02586363|EXPERIMENTAL|Cavir Tab. 0.5mg, fasting|Single dose Cavir Tab. 0.5mg, fasting state
62503959|NCT02586363|EXPERIMENTAL|Cavir Tab. 0.5mg, high fatty meal|Single dose Cavir Tab. 0.5mg, high fatty meal
62503960|NCT06013111|EXPERIMENTAL|Anti-CEA-CAR-T cell infusion|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10\^7 CAR-T cells/kg, 1×10\^7 CAR-T cells/kg, and 3×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.The patients will receive lymphocyte clearance therapy with cyclophosphamide and fludarabine before the infusion.
62503961|NCT02463838|EXPERIMENTAL|Care Support Intervention|Eligible members are assigned a CareSupport Coordinator who carries a caseload of 25-35 members. A team of 5 Coordinators is supervised by a master's level Social Worker. Community Coordinators work with members to conduct standardized assessments to develop a Care Plan shared with other providers within and outside of SFHP. Coordinators provide members advocacy and navigation across systems of care, to improve coordination focus on treatment goals. Coordinator focus on prevention and early intervention around disease management, advocacy, appointment reminders and accompaniment, home visits, and regular communication with primary care and other providers. Coordinators are encouraged to be accountable for coordinating and following through on all aspects of a member's needs.
62503962|NCT02463838|NO_INTERVENTION|Usual Care|All eligible SFHP members randomized to usual care will receive medical and health plan by virtue of enrollment in the SFHP and Medi-Cal. Services include assignment to a primary care physician and access to all services available through Medi-Cal in the county of San Francisco.
62503963|NCT03012659|EXPERIMENTAL|Intervention Arm|Full-day contraceptive counseling training for health center staff
62503964|NCT03012659|NO_INTERVENTION|Control Arm|Usual care
62503965|NCT04141644|EXPERIMENTAL|Treatment: all patients|Patients entering trial should be on stable dose of osi for ≥4 weeks. Patients will self-administer osi by mouth regardless of food once daily. Doses should be taken at about the same time every day (±6hrs) and recorded on the patient dosing diary. Doses missed outside of the dosing window should not be made up but patients should be instructed to take their next dose at their regularly scheduled time. Ipi will be administered at the assigned dose level every 21 days (±3days) for a max of 4 doses. Ipi must be infused using a volumetric pump over 90min (±10min) through an IV line. Upon completion of the ipilimumab regimen, patients will continue osimertinib daily until disease progression, initiation of new anti-cancer therapy, or death by any cause.
62142909|NCT04972526||Undifferentiated Shock or Acute Hemodynamic Decompensation|Patients receiving TEE as part of the initial evaluation of undifferentiated shock or acute hemodynamic decompensation
62142910|NCT04972526||Hemodynamic Monitoring in a Critically Ill Patient|Critically ill patients receiving TEE as part of hemodynamic monitoring
62503966|NCT02553655|ACTIVE_COMPARATOR|4x 5min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 5 minutes following by 5 minutes of rest. This will be repeated for 4 times.
61957708|NCT01979887||Severe MGD Participants|Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
61957709|NCT00970060|EXPERIMENTAL|Exercise program|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
62142911|NCT04972526||Procedural Guidance|Patients receiving TEE as a means to assist providers performing procedures (e.g. intravenous pacemaker placement, veno-arterial or veno-venous extracorporeal membrane oxygenation \[ECMO\], impella heart pump placement, intra-aortic balloon pump placement, etc.)
62142912|NCT02923479|EXPERIMENTAL|Experimental: ARBOT Group|"The patients in the ARBOT Group underwent to following interventions:~1. General Rehabilitation~2. Specific ankle rehabilitation by ARBOT device"
62142913|NCT02923479|OTHER|Control Group|"The patients in the Control Group underwent to following interventions:~1. General Rehabilitation~2. Specific ankle rehabilitation performed by physiotherapist~3. Specific ankle rehabilitation by Biodex System 3 dynamometer~4. Specific ankle rehabilitation by ProKin PK254 platform."
61957710|NCT04700371|ACTIVE_COMPARATOR|Interwoven stent|Use of an interwoven nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
62702655|NCT04989803|EXPERIMENTAL|KITE-753|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-753.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-753 at 1 or more dose-level deemed to be tolerable."
62702656|NCT06750497|EXPERIMENTAL|Participants with Type 2 Diabetes|Two days of standardized meal consumption
62702657|NCT06750497|EXPERIMENTAL|Participants without Type 2 Diabetes|Two days of standardized meal consumption
61957711|NCT04700371|ACTIVE_COMPARATOR|Laser-cut stent|Use of a laser-cut nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
61957712|NCT05116618||Cohort 1|10 evaluable enrollments to Cohort 1 with EGFR-mutant NSCLC
61957713|NCT05116618||Cohort 2|10 evaluable enrollments to Cohort 2 with ALK-rearranged NSCLC
61957714|NCT05116618||Cohort 3|10 evaluable enrollments to Cohort 3 with ROS1-rearranged NSCLC
61957715|NCT00941785|EXPERIMENTAL|DHA-PQ|Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.
62142914|NCT03877783|EXPERIMENTAL|group of intervention|"participants receive~1. personalized advice of a dietician about mediterranean diet~2. individualized training program,~3. recommendation about optimized pharmacological treatment as in high risk groups for cardiovascular diseases"
62142915|NCT03877783|NO_INTERVENTION|group of control|"participants receive~1. written information about the advantages of a healthy diet~2. written information about the advantages of physical activity,~3. medical treatment according to the latest version of the national guidelines issued by the Swedish Medical Product Agency"
62142916|NCT03589768|EXPERIMENTAL|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).~N=133"
62142917|NCT03589768|ACTIVE_COMPARATOR|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.~N=67"
62142918|NCT03860454||Lamin DCM (LMNA+)|Adults with known pathogenic lamin (LMNA+) gene mutation.
62142919|NCT03860454||Wild types DCM (DCMwt)|Adults with heart muscle failure but normal (wild-type) LMNA gene (DCMwt).
62142920|NCT03860454||Healthy Volunteers (HV)|Matched healthy volunteers (HV).
62142921|NCT03876184|EXPERIMENTAL|RMO FLi® Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 RMO FLi® Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
62142922|NCT03876184|EXPERIMENTAL|G&H G4 Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 G\&H G4 Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
62142923|NCT03876184|EXPERIMENTAL|Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
62142924|NCT03876184|ACTIVE_COMPARATOR|Conventional superelastic Nickel Titanium|"This group has been allocated with conventional upper and lower round 0.014 superelastic Nickel Titanium archwires for a duration of 8 weeks."
62142925|NCT03987074|EXPERIMENTAL|Semaglutide|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
62142926|NCT03987074|EXPERIMENTAL|Semaglutide + Firsocostat 20 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
62142927|NCT03987074|EXPERIMENTAL|Semaglutide + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
62142928|NCT03987074|EXPERIMENTAL|Semaglutide + Cilofexor 100 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
62142929|NCT03987074|EXPERIMENTAL|Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
62142930|NCT03184987|EXPERIMENTAL|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
62142931|NCT03184987|EXPERIMENTAL|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
62142932|NCT06075030|EXPERIMENTAL|AND017 Dose A three times weekly|
62142933|NCT06075030|EXPERIMENTAL|AND017 Dose B three times weekly|
62142934|NCT06075030|EXPERIMENTAL|AND017 Dose C three times weekly|
62142935|NCT00291694|ACTIVE_COMPARATOR|1|Oral Celecoxib 400 mg twice daily for 12 months
62142936|NCT00291694|PLACEBO_COMPARATOR|2|Matched blinded placebo twice daily for 12 months
62142937|NCT05987774|EXPERIMENTAL|Intervention Group|This group will receive the treatment (AI conversation modules) available through the application.
62142938|NCT05987774|NO_INTERVENTION|Control Group|This waitlist control group will not receive treatment until the experimental group completes their intervention.
62142939|NCT04682457||Late Onset|Participants diagnosed with Type 1 diabetes at over 30 years of age.
62142940|NCT04682457||18 to 30|Participants diagnosed with Type 1 diabetes between 18 and 30 years of age
62142941|NCT02610322|EXPERIMENTAL|Whole soy group|Whole soy replacement diet: to incorporate 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods.
62142942|NCT02610322|PLACEBO_COMPARATOR|Control group|Usual diet: to receive a conventional lifestyle education on MetS.
62702658|NCT06749197|EXPERIMENTAL|Early cognitive training, followed by standard care|Rehacom, standard care
62702659|NCT06749197|ACTIVE_COMPARATOR|Standard care, followed by cognitive training|Standard care, Rehacom
62346043|NCT02246023|ACTIVE_COMPARATOR|Fractionated propofol administration|"Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy"
62346044|NCT02246023|EXPERIMENTAL|Propofol-TCI|"Flexible bronchoscopy in moderate sedation with TCI propofol perfusor:~Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively."
62503967|NCT02553655|ACTIVE_COMPARATOR|3x 10min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
61957716|NCT00941785|ACTIVE_COMPARATOR|SP-AQ|Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine
61957717|NCT03914378||Discovery Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
62142943|NCT04968509|EXPERIMENTAL|Treatment with PCSK9 inhibitors and conventional lipid-lowering therapy based on statins|Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
62346045|NCT03670524|EXPERIMENTAL|Targeted neighborhoods for Greenness|Using greenness as a therapeutic intervention, we will plant shrubs, grasses, young and mature trees (40-50 ft in height), so that we can evaluate changes in health and pollution, 2 years after planting.
62346046|NCT03670524|NO_INTERVENTION|Control Group|No intervention
62346047|NCT06329999|EXPERIMENTAL|CMGV regime|Mitoxantrone liposomes，Cytarabine，G-CSF，Venetoclax
62346048|NCT03734952|EXPERIMENTAL|Group A|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program+Postoperative radiotherapy program
62346049|NCT03734952|OTHER|Group B|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program
62346050|NCT04793854||Case|Children with sickle cell anemia attending the centre of reference for sickle cell disease in Guadeloupe.
62346051|NCT04793854||Control|Control children without chronical disease
62346052|NCT04908917|EXPERIMENTAL|PAC with HEPA|Intervention group (N=100) to use a portable air cleaner (with a HEPA filter in PAC)
62346053|NCT04908917|SHAM_COMPARATOR|PAC without HEPA|control group (N=100) with a sham portable air cleaner (no HEPA filter in PAC)
62346054|NCT00518921|EXPERIMENTAL|Arm 1|
62346055|NCT00518921|EXPERIMENTAL|Arm 2|
62346056|NCT00518921|EXPERIMENTAL|Arm 3|
62346057|NCT00518921|PLACEBO_COMPARATOR|Arm 4|
62346058|NCT00939575||Preeclampsia|Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure \> 90 mmHg recorded twice at least four hours apart or \> 110 mmHg, with proteinuria \> 300 mg/24h or \> 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
62346059|NCT00939575||control|Women will be matched to women with pre-eclampsia according to gestational age at diagnosis of preeclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: \<20, 20-25, 26-30, 31-35 and \<35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
62346060|NCT00611221|ACTIVE_COMPARATOR|1|Massage therapy by a regulated massage therapist
62503968|NCT02553655|SHAM_COMPARATOR|3x 10min Sham Preconditioning|Either the right or left leg of the participant(s) will be squeezed without causing ischemia for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
62503969|NCT01134198|ACTIVE_COMPARATOR|Mifepristone|Mifepristone 600mg
62503970|NCT01134198|PLACEBO_COMPARATOR|placebo|Placebo
62503971|NCT04359537|EXPERIMENTAL|Arm 1|Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks
61957718|NCT03914378||Discovery Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
62142944|NCT04968509|OTHER|Treatment with only conventional lipid-lowering therapy based on statins|Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
62346061|NCT00611221|ACTIVE_COMPARATOR|2|Massage by anyone else, eg. husband, nurse, doula
62346062|NCT04583111|EXPERIMENTAL|Domperidone group|Patients in Domperidone group took 10mg of domperidone 30min before PEG.
62346063|NCT04583111|EXPERIMENTAL|Sulpiride group|Patients in Sulpiride group took 100mg of sulpiride 30min before PEG.
62346064|NCT04583111|NO_INTERVENTION|Control group|Patients in Control group followed the regular routine of 3L split-dose of PEG.
62503972|NCT04359537|EXPERIMENTAL|Arm 2|Hydroxychloroquine Sulphate will be admoinistered at a dose of 400 mg on day 1 followed by 400mg once every 3 weeks for at total of 12 weeks
62503973|NCT04359537|EXPERIMENTAL|Arm 3|Hydroxychloroquine Sulphate will be administered at a dose of 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks
62503974|NCT04359537|PLACEBO_COMPARATOR|Arm 4|Control group will recieve Placebo 200mg on day 1 followed by Placebo 200mg every three weeks for 12 weeks
62503975|NCT06616467|EXPERIMENTAL|Tummy Time Group|This group will receive the 12-week intervention, which will have follow-up measurements during the implementation of the intervention.
62503976|NCT06616467|NO_INTERVENTION|Hospital Group|This group receives the usual hospital care where the mother is provided with general information on breastfeeding, vaccination and infant screening.
61957719|NCT03914378||Validation Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
61957720|NCT03914378||Validation Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
61957721|NCT03914378||Retrospective Cohort|50 patients who previously received unilateral radiotherapy for head / neck cancer up to 5 years post-treatment
61957722|NCT03914378||Normal Hearing Controls for Retrospective Cohort|50 controls with normal hearing, age- and sex-matched to retrospective cohort
61957723|NCT03914378||Hearing Impaired Controls for Retrospective Cohort|50 controls with impaired hearing, age-, sex-, and audiogram-matched to retrospective cohort
61957724|NCT06524284|EXPERIMENTAL|EVNS treatment|EVNS, see intervention
61957725|NCT01284829|EXPERIMENTAL|adrenal tumors|adrenal tumors
61957726|NCT03090802|EXPERIMENTAL|Intervention|The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
61957727|NCT03090802|NO_INTERVENTION|Control|Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
61957728|NCT02671175|ACTIVE_COMPARATOR|dihydroartemisinin-piperaquine|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrollment)
62346065|NCT02795546|EXPERIMENTAL|Test group|400µg Alendronate sodium+ β-TCP + saline. 400µg alendronate sodium is combined with beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
62346066|NCT02795546|ACTIVE_COMPARATOR|Control group|β-TCP + saline Beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
62346067|NCT05907993|NO_INTERVENTION|Group (A):|30mg ketorolac in 200cc normal saline intravenously every 6hours for 24hours postoperatively.
62503977|NCT05632692|EXPERIMENTAL|Intervention|A menthol solution is going to be formulated by crushing and dissolving one noncalorific menthol candy drop (15 mg) in 150 ml of warm water, in order to obtain a solution with a concentration of 0.01%. Prior to use, solutions are going to be aliquoted for mouth rinse and warmed at room temperature. Then, it will be served to each participant on individual bottles in a total dose of 75 ml before exercise and 75 ml during exercise.
62503978|NCT05632692|PLACEBO_COMPARATOR|Placebo|A placebo beverage is going to be prepared using noncaloric berry-flavored sweetener consisting of sucralose candy drops, which will be crushed and dissolved in 150 ml of warm water. Prior to use, solutions are going to be aliquoted for mouth rinse and warmed at room temperature. Then, it will be served to each athlete on individual bottles in a total dose of 75 ml before exercise and 75 ml during exercise.
62503979|NCT01241682|EXPERIMENTAL|DC immunotherapy + CTX|Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.
62503980|NCT00908882|EXPERIMENTAL|Enhanced PTSD Health Buddy and Motivational Interviewing|Veterans with PTSD who smoke are exposed to an intervention which included a 90-day smoking cessation curriculum that is integrated into the PTSD Health Buddy Program and weekly motivational interviewing counseling by a nurse plus usual smoking cessation care
61957729|NCT02671175|PLACEBO_COMPARATOR|dihydroartemisinin-piperaquine Placebo|Placebo comparator (matching tablets containing no active ingredients)
61957730|NCT06111807||Chemo-radiotherapy|Stage 3 NSCLC eligible for chemoradiotherapy
61957731|NCT06111807||Neoadjuvant and surgery|Stage 3 NSCLC eligible for neoadjuvant chemo-immunotherapy followed by surgery
61957732|NCT06111807||Surgery and adjuvant immunotherapy|Stage 3 NSCLC eligible for surgery followed by immunotherapy
61957733|NCT02321878||Liraglutide|
61957734|NCT03284398||Parenteral nutrition bag type|Groups with different parenteral nutrition bags (3CBs or HCBs)
61957735|NCT04207775||NSCLC|Patients with confirmed EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed from first line EGFR-TKI therapy who will receive different treatment
61957736|NCT02794038|ACTIVE_COMPARATOR|Soberlink Cellular Device|BAC reading with Soberlink Cellular Device
61957737|NCT02794038|ACTIVE_COMPARATOR|BACtrack S80 Pro|BAC reading with BACtrack S80 Pro
61957738|NCT05654220|NO_INTERVENTION|Active Control|Participants in the control group will receive a summary flyer providing contact information for benefits enrollment navigators at BenePhilly, which includes a unique study phone line provided by Benefits Data Trust. Currently, the standard of care is for ED patients to receive no information about public benefits. Therefore, the flyer represents an augmentation of usual care for patients randomized to the control group.
62346068|NCT05907993|ACTIVE_COMPARATOR|Group (B):|800mg ibuprofen in 200cc normal saline intravenously every 6 hours for 24hours postoperatively.
62346069|NCT03528889|ACTIVE_COMPARATOR|Goniometer|Extension FDO: classic procedure with goniometer controlled extension and derotation
62346070|NCT03528889|EXPERIMENTAL|EMT|Extension FDO: procedure with electromagnetic tracking (EMT) controlling extension and derotation
62346071|NCT03696706|ACTIVE_COMPARATOR|LED group|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
62346072|NCT03696706|PLACEBO_COMPARATOR|Placebo group|For the placebo group, all measures described for the LED group will be adopted, however, the equipment will be switched off.
62346073|NCT03696706|NO_INTERVENTION|Control group|In this group, the participants will only be evaluated. No intervention will take place.
61957739|NCT05654220|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive a summary flyer providing contact information for benefits enrollment navigators at BenePhilly and will be instructed that study personnel will contact them one-day post-discharge to help connect them to a BDT enrollment navigator to help them submit their applications for public benefits. At Day 1 post-discharge, participants in the intervention group will receive a text message to prompt them to call the BDT enrollment navigators to complete their applications for public benefits they screened for while in the ED. On Day 3, patients will receive a follow-up message to assess whether they have contacted BDT. Those participants who indicate they have not yet connected with BDT on Day 3 will receive reminder text messages at Day 7 and 14 post-discharge.
62503981|NCT00908882|NO_INTERVENTION|Usual PTSD Health Buddy Care|Veteran with PTSD who smoke randomly assigned to this arm received standard of care for smoking cessation and used the standard PTSD Health Buddy
62503982|NCT04619550|OTHER|Exercise intensity|Jogging or walking at RPE 9, 11, 13, and 15
62503983|NCT00432055|EXPERIMENTAL|I|Botox
62503984|NCT00432055|PLACEBO_COMPARATOR|II|
62503985|NCT01085448|OTHER|Low back pain|Individuals with current low back pain.
62503986|NCT00932594|ACTIVE_COMPARATOR|1.Arthrocentesis only|Patients only have Arthrocentesis, but without adjusting the pressure of the TMJ
62702660|NCT06477107|EXPERIMENTAL|Phase I - Health Volunteer Group: Active Stimulation, Then Sham Stimulation|Healthy subjects will receive 20 minutes of 2 mA tDCS concurrently with MRI cerebral blood flow (CBF) imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive sham stimulation concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
62702661|NCT06477107|EXPERIMENTAL|Phase I - Health Volunteer Group: Sham Stimulation, Then Active Stimulation|Healthy subjects will receive sham stimulation concurrently with MRI CBF imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive 20 minutes of 2 mA tDCS concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
62702662|NCT06477107|EXPERIMENTAL|Phase I Disease Group: Active Stimulation, Then Sham Stimulation|Subject diagnosed with Moyamoya disease or severe extracranial atherosclerotic disease will receive 20 minutes of 2 mA tDCS concurrently with MRI cerebral blood flow (CBF) imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive sham stimulation concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
61957740|NCT01687998|EXPERIMENTAL|Evacetrapib|Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
61957741|NCT01687998|PLACEBO_COMPARATOR|Placebo|Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
62702663|NCT06477107|EXPERIMENTAL|Phase I Disease Group: Sham Stimulation, Then Active Stimulation|Subject diagnosed with Moyamoya disease or severe extracranial atherosclerotic disease will receive sham stimulation concurrently with MRI CBF imaging immediately followed by no stimulation and CBF imaging. Next, subjects will receive 20 minutes of 2 mA tDCS concurrently with CBF imaging immediately followed by no stimulation and CBF imaging.
61957742|NCT00547482|SHAM_COMPARATOR|Control|They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
62142945|NCT01116206|EXPERIMENTAL|Prucalopride|prucalopride 2- milligram (mg), orally once daily for 12 weeks
62142946|NCT01116206|PLACEBO_COMPARATOR|Placebo|Matching placebo, orally once daily for 12 weeks
62346074|NCT02578823|EXPERIMENTAL|TTM-36|"Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.~After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).~A total of 40 participants will be enrolled."
62346075|NCT02578823|ACTIVE_COMPARATOR|Conventional treatment|"Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).~A total of 20 participants will be enrolled."
62346076|NCT01832012|ACTIVE_COMPARATOR|Video refresher|Group 3, received 7 minute video refresher prior to examination.
62346077|NCT01832012|EXPERIMENTAL|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
62346078|NCT01832012|NO_INTERVENTION|No intervention|Group 2
62346079|NCT04705441|EXPERIMENTAL|SMART intervention|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions over 10-12 weeks. The intervention sessions are held over Zoom.
62346080|NCT04705441|NO_INTERVENTION|Waitlist|Individuals randomized to WL will continue in their usual care. After they complete their 13-week and 6-month assessments, they will begin participating in the SMART program.
62346081|NCT06293664|EXPERIMENTAL|α-MSH infusion|Pharmaceutical grade α-MSH will be dissolved in 0.9% saline containing 0.5% human albumin.
62346082|NCT06293664|PLACEBO_COMPARATOR|Saline infusion|Saline infusion: Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
62346083|NCT04136795||Conventional surgery|Patients having had esophageal atresia (type III, long gap excluded) repair by conventional surgery (right thoracotomy) or patients having had minimally invasive surgery converted to thoracotomy between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
62503987|NCT00932594|ACTIVE_COMPARATOR|3.Arthroscopic Treatment|Patient receives Arthroscopic treatments without adjusting the TMJ pressure
62503988|NCT00932594|ACTIVE_COMPARATOR|4.Arthroscopic with Adjust Pressure|Arthroscopic Treatment with Adjust TMJ Pressure Treatment, during the Arthroscopic treatment adjust the pressure of TMJ to normal value
62503989|NCT00932594|ACTIVE_COMPARATOR|5.The TMJ Orperation Treatment|The TMJ Operation Treatment without adjusting the pressure of TMJ
62503990|NCT00932594|ACTIVE_COMPARATOR|6.The TMJ Operation with Adjust Pressure|The TMJ Operation with Adjust TMJ Pressure Treatment, during the treatments to adjust the TMJ pressure to normal value
62503991|NCT00932594|ACTIVE_COMPARATOR|7.Bite Plate Treatment|Bite Plate Treatment for Temporomandibular Disorders without adjusting the pressure of TMJ
62503992|NCT00932594|ACTIVE_COMPARATOR|8.Bite Plate with Adjust pressure|Bite Plate and Adjust Pressure Treatment for Temporomandibular Disorders, during the treatments adjust the pressure of TMJ to normal value
62503993|NCT00932594|ACTIVE_COMPARATOR|2.Arthrocentesis with adjust pressure|Arthrocentesis with adjust pressure according to the pressure of TMJ
62503994|NCT05135624|EXPERIMENTAL|Cohort dose 1 of SP16|Patients in cohort 1 (low dose SP16) will receive a single dose of SP16 (0.1 mg/kg or 6 mg) by subcutaneous injection
62702664|NCT06477107|EXPERIMENTAL|Phase II Active Stimulation, Then Sham Stimulation|Subjects first receive active tDCS plus cognitive training every weekday for 10 days. After washout period of 4 weeks, they will perform at-home sham tDCS plus cognitive training every weekday for 10 days.
61957743|NCT00547482|ACTIVE_COMPARATOR|Treatment|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation). They will be followed for the Initial Study Period (24 weeks), followed by the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA."
62503995|NCT05135624|EXPERIMENTAL|Cohort dose 2 of SP16|Patients in cohort 2 (high dose SP16) will receive a single dose of SP16 (0.2 mg/kg or 12 mg) by subcutaneous injection
62503996|NCT05135624|PLACEBO_COMPARATOR|Placebo|Patients in placebo arm will receive sterile water by subcutaneous injection.
62503997|NCT02711033|EXPERIMENTAL|Laparoscopic-assisted total gastrectomy|Patients including in the laparoscopic-assisted total gastrectomy (LATG) group will undergo LATG with spleen-preserving splenic hilum lymph nodes dissection.
62503998|NCT02711033|ACTIVE_COMPARATOR|Open total gastrectomy|Patients who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
62503999|NCT01877694|EXPERIMENTAL|Auriclosene Solution 0.3%|Dosed QID for 4 Days
62504000|NCT01877694|PLACEBO_COMPARATOR|Auriclosene Vehicle|Dosed QID for 4 days
62504001|NCT01275716|EXPERIMENTAL|Patients who are shown the images|
62504002|NCT01275716|NO_INTERVENTION|Patients who are not shown the images|
62504003|NCT01832519||CF group|Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
62504004|NCT01832519||Non-CF Control|1 chest MRI with contrast and blood for proteomics and metabolomics
62504005|NCT03818295|EXPERIMENTAL|Healthy Male Volunteers|Single oral dose of \[14C\]-praliciguat
62504006|NCT00929058|EXPERIMENTAL|Bevacizumab|
62504007|NCT06401408||case group|Before starting the skin prick test, the child and his/her family who meet the inclusion criteria of the study will be informed about the use of virtual reality headsets(VRH) and volunteer consent forms will be obtained. Before starting the test, the Introductory Characteristics Form for Children and Their Families and scales will be applied to the children and the child's physiological parameters will be taken. Then, the children will be fitted with an VRH and watched an animated film determined in line with the child's age group, developmental characteristics and expert opinions.After the child starts watching the video, skin prick test procedures will be initiated and the child will be allowed to watch the video until the test ends. After the test is completed, physiological parameters will be taken again and scales will be applied.
61957744|NCT04108065||Patients with gestational diabetes mellitus (GDM)|GDM diagnosed according to current Danish guidelines (plasma glucose (PG) concentration at 120 min after a 75 g oral glucose tolerance test (OGTT) ≥9.0 mM)
62346084|NCT04136795||Minimally invasive surgery|Patients having had esophageal atresia (type III, long gap excluded) repair through minimally invasive surgery between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
62504008|NCT06401408||control group|No intervention/application will be performed on the children who will be included in the control group. The Introductory Characteristics of Children and Their Families Form and scales will be administered to the children in the control group simultaneously with the experimental group (in the form of pretest-posttest). Additionally, physiological parameters will be taken simultaneously with the experimental group.
62504009|NCT05680792|OTHER|Administration of nitazoxanide alone|Participants in this arm will receive 1000 mg of nitazoxanide tablets alone
62504010|NCT05680792|OTHER|Administration of nitazoxanide plus atazanavir/ritonavir|Participants in this arm will receive 1000 mg of nitazoxanide tablets twice daily together with one tablet of atazanavir/ritonavir (300 mg/100 mg) once daily in the morning.
62504011|NCT03381937|NO_INTERVENTION|Spontaneous breathing|Spontaneous breathing without mechanical ventilation
62702665|NCT06477107|EXPERIMENTAL|Phase II Sham Stimulation, Then Active Stimulation|Subjects first receive sham tDCS plus cognitive training daily for 10 days. After a washout period of 4 weeks, they will perform at-home active tDCS plus cognitive training daily for 10 days.
62702666|NCT06486779||CHRONOS cohort|Patients prescribed with ofatumumab in a real world setting
62702667|NCT06193928||Alagille syndrome (ALGS)|"* A clinically and/or genetically confirmed ALGS diagnosis~* Participant prescribed Livmarli"
62504012|NCT03381937|EXPERIMENTAL|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
62702668|NCT02749955|EXPERIMENTAL|PS-PrEP Intervention Group|
62702669|NCT02749955|ACTIVE_COMPARATOR|PrEPLine Control Group|
62702670|NCT02749955|NO_INTERVENTION|CDPH Prevention Projects|
61957745|NCT04108065||Pregnant women with normal glucose tolerance (control group)|Pregnant women with normal glucose tolerance (fasting plasma glucose (PG) concentration ≤6.0 mM and PG concentration at 120 min after a 75 g-OGTT \<7.8 mM)
61957746|NCT02355457||Suspected acute myocardial infarction|Patients with recent onset symptoms suggesting acute myocardial infarction
62504013|NCT03381937|EXPERIMENTAL|Speech specific mechanical ventilation|Mechanical ventilation with specific parameters to improve speech
62702671|NCT06749899|EXPERIMENTAL|QL1706 Arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
62702672|NCT06749899|ACTIVE_COMPARATOR|Chemoradiation Arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
62702673|NCT06750042||Duchene's muscular Dystrophy|age ranging from 6 to 16 years, diagnosed with Duchene's muscular Dystrophy (DMD) will participate in the study. They will be selected from the Pediatric Rehabilitation Center of Deraya University's outpatient clinic in El-Minia district, Minia-Egypt.
62702674|NCT06749808|ACTIVE_COMPARATOR|Active|Nutritional Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 10 mg Lutein, 2 mg Zeaxanthin, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
62702675|NCT06749808|PLACEBO_COMPARATOR|Placebo|Placebo Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
62702676|NCT06749353|NO_INTERVENTION|No intervention group|In the control group, we will perform the surgical procedure as usual, without any distraction maneuvers, under local anesthesia.
62702677|NCT06749353|EXPERIMENTAL|Intervention group|In the study group, we will perform the vasectomy under local anesthesia and provide patients with virtual reality glasses as a distraction technique, aiming to reduce intraoperative anxiety.
61957747|NCT01938456|EXPERIMENTAL|Trametinib + Docetaxel + Filgrastim|Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
62702678|NCT06748716|PLACEBO_COMPARATOR|Clear glasses|
61957748|NCT04152278||study group|The study group included 300 women presenting with unexplained spontaneous miscarriage or missed abortion during the first and early second trimester of pregnancy (8-16 weeks gestational age). The included women aged 18 to 45 years old.
61957749|NCT04152278||control group|The control group included 300 women with normal pregnancy, recruited from women attending the antenatal clinic of gestational age 8-16 weeks. The included women aged 18 to 45 years old.
61957750|NCT03495219||Esophageal Manometry|Esophageal manometry is a test to assess motor function of the upper esophageal sphincter, esophageal body and lower esophageal sphincter
62346085|NCT05123898|OTHER|1 group|The patients underwent implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuber region on the upper jaw.
61957751|NCT02650674|EXPERIMENTAL|Product A: NP-0148|Cereal product belVita Milk \& Cereals - High in SDS
61957752|NCT02650674|EXPERIMENTAL|Product B: NP-0149|Cereal product belVita Honey \& Nuts - High in SDS
61957753|NCT02650674|EXPERIMENTAL|Product C: NP-0150|Cereal product belVita Mixed Berry - High in SDS
61957754|NCT02650674|EXPERIMENTAL|Product D: NP-0151|Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
61957755|NCT02650674|EXPERIMENTAL|Product E: NP-0152|Cereal product Kellogg's Trésor Duo Choco - Low in SDS
61957756|NCT02650674|EXPERIMENTAL|Glucose reference|Glucose solution performed on three occasions
61957757|NCT01416064|OTHER|Molindone|Extension study, all subjects will be given Molindone at different (established) dosage levels based on the patient's weight, response and investigator discretion.
61957758|NCT00788567|EXPERIMENTAL|1|
61957759|NCT05262608|EXPERIMENTAL|Intervention/Treatment|Subjects will receive a regimen of Olaparib tablets 300 mg twice daily until radiographic disease progression (assessed by the investigator according to RECIST1.1 and PCWG 3) or intolerable adverse events (assessed by the investigator according to the actual clinical situation).
61957760|NCT03205332|EXPERIMENTAL|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
62346086|NCT05123898|EXPERIMENTAL|2 group|"The patients underwent implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibromatrix"
62346087|NCT01680978|EXPERIMENTAL|Aleglitazar|
62346088|NCT01680978|PLACEBO_COMPARATOR|Placebo|
62346089|NCT00197652||Diarrheal specimens from infants born to HIV infected mothers|400 diarrheal specimens will suffice to determine the prevalence of specific pathogens in the region. Of these, 300 specimens will be collected from infants born to HIV infected mothers, and 100 specimens will be collected from infants born to HIV uninfected mothers.
62702679|NCT06748716|EXPERIMENTAL|Orange glasses|Intervention group
62702680|NCT06750653|ACTIVE_COMPARATOR|CeraVe First|CeraVe for 4 weeks; then no moisturizer for 4 weeks. CeraVe Moisturizing Cream containing ceramides and hyaluronic acid manufactured by L'Oréal, for topical skin use.
62702681|NCT06750653|ACTIVE_COMPARATOR|CeraVe Second|No moisturizer for 4 weeks, then CeraVe for the second 4-week study period. CeraVe Moisturizing Cream containing ceramides and hyaluronic acid manufactured by L'Oréal, for topical skin use
62702682|NCT06750653|ACTIVE_COMPARATOR|Vaseline First|Vaseline for 4 weeks then no moisturizer for 4 weeks. Vaseline white petrolatum, manufactured by Unilever, for topical skin use.
61957761|NCT03205332|NO_INTERVENTION|Control|Assessment only.
61957762|NCT00816530||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have \> 50% parenchymal density on mammography.
62504014|NCT05906069|EXPERIMENTAL|iCBT intervention|Participants will enroll in an internet-based cognitive behavioral program during 14 weeks. The program comprises 10 modules and three videoconferencing psychotherapy sessions.
61957763|NCT05769829||Cohort 1: Pre-diagnosis/+Gastrointestinal Symptoms|"Up to 450 participants with gastrointestinal symptoms, undergoing endoscopy with biopsy will have blood drawn, metadata collected, and tissue from endoscopy collected for analysis. Additional blood draws at various timepoints during the study; at follow up visits, at time of flare, medication change, surgery, or repeat endoscopy.~In addition to the 450 participants enrolled, 50 more participants that meet inclusion/exclusion for cohort 1 will be enrolled to complete only the initial visit and endoscopy visit. Participants will have blood drawn, metadata collected, and tissue from endoscopy collected for analysis."
61957764|NCT05769829||Cohort 2: Diagnosed Inflammatory Bowel Disease, Pre-treatment|Up to 400 participants recently diagnosed with inflammatory bowel disease but not yet started on a medication regimen to address their symptoms will have blood drawn with metadata attached. Additional blood draws at various timepoints during the study; at follow up visits, at time of flare, medication change, surgery, or repeat endoscopy.
61957765|NCT05769829||Cohort 3: Potential Cross-Reactive Diseases|Patients will be eligible for this cohort if they fail to be diagnosed with inflammatory bowel disease but have a confirmed diagnosis of potential cross reactive disease states including Irritable Bowel Syndrome, Functional Diarrhea, Celiac Disease.
62346090|NCT00197652||Breast milk from HIV infected and HIV uninfected women|Breast milk from HIV infected and HIV uninfected women who are breastfeeding is collected at 2 days, 2 weeks, 2 months, and 5 months post-partum. This breast milk will be compared for in vitro functional quality of immunoglobulins to selected diarrheal and respiratory pathogens.
62504015|NCT05906069|NO_INTERVENTION|Wait list|Participants will be enrolled in the iCBT program after 14 weeks
61957766|NCT05769829||Cohort 4: Healthy Controls|Up to 228 participants free from GI symptoms for the last 90 days and no previous medical history or clinical diagnosis of GI illness.
62142947|NCT05113134|EXPERIMENTAL|Transvaginal natural orifice specimen extraction (NOSE)|The outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who underwent multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder
62142948|NCT05329519|EXPERIMENTAL|Music group|Patients in this groups underwent VATS with wedge recession, performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player and head phones on postoperative three days.
62346091|NCT05298644|EXPERIMENTAL|Dose finding ≥5 to <12 years|on Day 1 and Day 29 either VLA2001 half dose or VLA2001 full dose
62346092|NCT05298644|EXPERIMENTAL|Dose finding ≥2 to <5 years|on Day 1 and Day 29 either VLA2001 half dose or VLA2001 full dose
62346093|NCT05298644|OTHER|Confirmatory ≥5 to <12 years|Day 1: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 29: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 57: Active Comparator
62346094|NCT05298644|OTHER|Confirmatory ≥2 to <5 years|Day 1: Active Comparator Day 29: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 57: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose)
62346095|NCT06352242|OTHER|Patients|Blood sample for Flow cytometry analysis
62346096|NCT06352242|OTHER|healthy volunteer donor|Blood sample for Flow cytometry analysis
62346097|NCT05291416||1|healthy children aged between 4-16 years
62346098|NCT05291416||2|children aged between 4-16 years, suffering from juvenile idiopathic arthritis
62346099|NCT01478152|EXPERIMENTAL|Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
62346100|NCT03101059|EXPERIMENTAL|MKS pax|Munier-Kuhn Syndrome patients
62346101|NCT01831206|EXPERIMENTAL|Collagen cross-linking|Collagen cross-linking with standard treatment
62346102|NCT01831206|NO_INTERVENTION|standard treatment|Standard treatment alone
62504016|NCT00685035|ACTIVE_COMPARATOR|HFCWC with higher pressure/variable frequency settings|Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
62504017|NCT00685035|ACTIVE_COMPARATOR|HFCWC with lower pressure/mid-frequency settings|lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency
62504018|NCT03589196|ACTIVE_COMPARATOR|Photoselective Vaporization|
62504019|NCT03589196|ACTIVE_COMPARATOR|Plasma Kinetic Vaporization|
62504020|NCT03589196|ACTIVE_COMPARATOR|Transurethral Resection Of The Prostate|
62504021|NCT03657238|EXPERIMENTAL|Experimental|Doses were escalated from 0.2μg/kg up to 4.8μg/kg
62504022|NCT03657238|PLACEBO_COMPARATOR|Placebo|
62504023|NCT06015022|EXPERIMENTAL|Epigallocatechin gallate 600 - 800mg|Epigallocatechin gallate (EGCG) 600mg will be administered daily via oral route for the initial 12 consecutive weeks on an outpatient basis. The dose of 600 mg will be continued for the second 12 weeks if an interim HCC biomarker test at the end of week 8 improves. If the interim test does not improve without dose-limiting adverse events, the dose will be increased to 800mg for the second 12 weeks, All participants will receive 24 weeks of treatment in total.
62504024|NCT06015022|PLACEBO_COMPARATOR|Placebo|Oral administration of placebo for 24 weeks
62504025|NCT06090890|ACTIVE_COMPARATOR|control group|DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary)
62504026|NCT06090890|EXPERIMENTAL|Colchicine group|DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary) + Colchicine (0.5mg QD, orally)
62504027|NCT06090890|EXPERIMENTAL|Prednisone group|DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary) + Prednisone (0.5mg/kg QD, orally)
61957767|NCT06451601|EXPERIMENTAL|IHHT Group|"IHHT group with 35 patients: The patients in the IHHT group underwent intermittent hypoxia-hyperoxia therapy using the CellOxy Device.Initially, patients performed hypoxic tests 1 and 2, to determine the optimal oxygen level and to be included in a typology (type I, II, or III).~Starting from the following day, patients in the IHHT group were subjected to intermittent hypoxia-hyperoxia as follows: hypoxia with 9-16% O2 for 5-7 minutes, followed by exposure to hyperoxia with \~35% O2 for 2-5 minutes.~In total, patients in the IHHT group performed 9 sessions of hypoxic-hyperoxic therapy: testing on the first day (hypoxic tests 1 and 2), followed by 4 days of sessions in the first week, 2 days of rest on the weekend and then another 5 days of sessions in the second week. Simultaneously with the intermittent hypoxia-hyperoxia therapy, the patients benefited from complex balneo-physical-kinetic treatment."
62142949|NCT05329519|NO_INTERVENTION|Controlled group|Patients in this groups underwent VATS with wedge recession, performed deep breathing and coughing exercises for postoperative three days without music
62142950|NCT04495140|EXPERIMENTAL|Oral [14C]PF-06882961, 50 mg|In this arm, a single oral dose of \[14C\]PF-06882961, 50 mg will be administered as a liquid formulation.
62346103|NCT03019744|EXPERIMENTAL|MeCFES|25 daily sessions (45 minutes each) of MeCFES-assisted task-oriented upper limb rehabilitation
62346104|NCT03019744|ACTIVE_COMPARATOR|Control|25 daily sessions (45 minutes each) of usual care task-oriented upper limb rehabilitation
62346105|NCT05866653|ACTIVE_COMPARATOR|Control Arm|This group will consist of 45 patients who are scheduled to receive oxaliplatin based chemotherapy regimen. After receiving 2 cycles of chemotherapy usually patient develops OIPN. Patients who will develop OIPN with pain intensity ≥4 in VAS scores will be included. The patients will be treated with one lidocaine transdermal patch/day for 12 hours for 10 days as add on therapy with standard treatment by oncologist.
62346106|NCT05866653|PLACEBO_COMPARATOR|Placebo Arm|This group will consist of 45 patients who are scheduled to receive oxaliplatin based chemotherapy regimen. After receiving 2 cycles of chemotherapy usually patient develops OIPN. Patients who will develop OIPN with pain intensity ≥4 in VAS score will be included. The patients will be treated with one placebo patch/day for 12 hours for 10 days as add on therapy with standard treatment by oncologist.
62346107|NCT03695393|EXPERIMENTAL|Intervention- ACT Therapy|Participants randomized to this group will receive three ACT sessions over 1 month
62346108|NCT03695393|NO_INTERVENTION|Standard of Care|Participants in the control group will receive standard care as normally provided to patients by civil society organizations.
62346109|NCT04768335|ACTIVE_COMPARATOR|Patient group with schizophrenia|The schizophrenic subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
62346110|NCT04768335|ACTIVE_COMPARATOR|Healthy control subjects|Healthy control subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
62346111|NCT00131664|ACTIVE_COMPARATOR|Avandamet|Avandamet 2 mg / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily over 6 months
62346112|NCT00131664|ACTIVE_COMPARATOR|Avandia and Amaryl|Avandia + Amaryl 4 mg + 1 mg once daily titration up to 8 mg + 2 mg once daily over 6 months
62346113|NCT00131664|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg twice daily titration up to 1000 mg twice daily over 6 months
62346114|NCT01608490|EXPERIMENTAL|RePneu Lung Volume Reduction Coil System|The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
62346115|NCT01608490|NO_INTERVENTION|Control arm is standard medical care|The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.
62346116|NCT00847756||rAOM|Children 0-5 years of age suffering from recurrent acute otitis media and waiting for tympanostomy tube insertion.
62346117|NCT00847756||COME|Children 0-5 years of age suffering from chronic otitis media with effusion and waiting for tympanostomy tube insertion.
62346118|NCT00847756||CSOM|Children 0-5 years of age suffering from chronic suppurative otitis media and waiting for tympanostomy tube insertion. Note: Only 3 patients with CSOM were recruited and therefore not suitable for publication.
62346119|NCT02350933|OTHER|0° rigid endoscope|Endoscopy of the trachea is performed using a 0° rigid endoscope
62346120|NCT00762294||644-001|Women treated for breast cancer who will be starting Arimidex or Femara
62346121|NCT03213977|ACTIVE_COMPARATOR|Arm I:R-DA-EPOCH|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
62346122|NCT03213977|EXPERIMENTAL|Arm II:R-CEOP90|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
62346123|NCT01290445||Exposed|Infants exposed in utero to varenicline
62346124|NCT01290445||Unexposed|infants exposed in utero to cigarette smoke from maternal smoking
62346125|NCT01290445||Reference|infants not exposed in utero to either varenicline or cigarette smoke from maternal smoking
62346126|NCT01208701|ACTIVE_COMPARATOR|Atorvastatin|
62346127|NCT01208701|PLACEBO_COMPARATOR|Placebo|
62346128|NCT00061919|EXPERIMENTAL|Active arm (thalidomide)|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
62504028|NCT01188226|EXPERIMENTAL|Nano Hybrid Composite Denture teeth|Denture teeth are made of nano hybrid composite material
62504029|NCT02853539|EXPERIMENTAL|Denosumab|One per 6 months subcutaneous injection of Denosumab (2 doses in total)
62504030|NCT02853539|NO_INTERVENTION|No Denosumab|No intervention, just observation of HPN patients
62504031|NCT03877926|EXPERIMENTAL|AV7909 Lot 1|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
62504032|NCT03877926|EXPERIMENTAL|AV7909 Lot 2|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
62504033|NCT03877926|EXPERIMENTAL|AV7909 Lot 3|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
62504034|NCT03877926|ACTIVE_COMPARATOR|BioThrax|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. In Group 4, one lot of BioThrax® vaccine will be administered, per the study visit schedule.
62504035|NCT06309914|PLACEBO_COMPARATOR|Placebo|One dose (1 capsule) will be consumed twice daily for 28 days. The placebo product will be rice flour (other ingredients: hypromellose, magnesium stearate and chlorophyll). Its appearance will be green/green oblong veggie capsule with white to off-white powder fill.
62504036|NCT06309914|EXPERIMENTAL|Enovita Dietary Supplement|One dose (1 capsule) will be consumed twice daily for 28 days. A single dose contains: 150mg grape seed extract (Vitis vinifera L) and dried seed (cultivated), and 27.50mg 95% polyphenols.
62504037|NCT06309914|EXPERIMENTAL|Mirtoselect Dietary Supplement|One dose (1 capsule) will be consumed twice daily for 28 days. A single dose contains: 160mg bilberry extract (Vaccinium myrtillus L.) and 57.6mg 36% anthocyanosides.
62504038|NCT06309914|EXPERIMENTAL|Virtiva Dietary Supplement|One dose (1 capsule) will be consumed twice daily for 28 days. A single dose contains: 240mg Ginkgo biloba extract (leaf), 28.8mg 12% phosphatidylserine (from sunflower), and 12mg 5% ginkgo flavonglycosides.
62504039|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
62504040|NCT00030407|EXPERIMENTAL|Celecoxib & Docetaxel|"Celecoxib: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals~Docetaxel: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days."
62504041|NCT00341692||Samples of normal breast tissue|Samples of normal breast tissue from organ donors for assessment of histology.
61957768|NCT06451601|ACTIVE_COMPARATOR|Control Group|Control group with 35 patients: The control group completed only the comprehensive balneo-physical-kinetic treatment (hydrokinetotherapy and hydrothermotherapy using specific natural environmental factors: sapropelic mud and salt water from Lake Techirghiol, electrotherapy, massage therapy and kinetotherapy), without intermittent hypoxia-hyperoxia therapy, neither real nor simulated.
61957769|NCT02376231|NO_INTERVENTION|Standard Surgery without trial (PJ) device|Standard debulking surgery for EOC without interventional device
61957770|NCT02376231|ACTIVE_COMPARATOR|Surgery with trial (PJ) device|Debulking surgery for EOC with interventional trial device (PJ)
61957771|NCT00653055|EXPERIMENTAL|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fasting conditions
62346129|NCT00061919|PLACEBO_COMPARATOR|Placebo arm|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
61957772|NCT00653055|ACTIVE_COMPARATOR|B|Subjects received the reference product, Dostinex under fasting conditions
62346130|NCT00790101|EXPERIMENTAL|1|Risedronate 35mg once a week
62346131|NCT00790101|ACTIVE_COMPARATOR|2|Raloxifene 60mg daily
62346132|NCT00790101|PLACEBO_COMPARATOR|3|
62346133|NCT04094766|EXPERIMENTAL|BLLCAR-L10D treatment group|In BLLCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10\^6, 1.5×10\^6, 2.0×10\^6 CAR-T cells/kg.
62346134|NCT01353144|NO_INTERVENTION|esomeprazole|esomeprazole (40 mg/day) for 8 weeks
62346135|NCT01353144|ACTIVE_COMPARATOR|esomeprazole plus aspirin|esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks
62346136|NCT01499901|EXPERIMENTAL|sequential|implantation bilateral sequential
62346137|NCT01499901|EXPERIMENTAL|simultaneous|implantation bilateral simultaneous
62346138|NCT04306055|EXPERIMENTAL|Questionnaire with precaution information|Questionnaire in this group includes information about precaution of blood donation during epidemic of COVID-19.
62346139|NCT04306055|EXPERIMENTAL|Questionnaire without precaution information|Questionnaire in this group dose not include information about precaution of blood donation during epidemic of COVID-19.
62346140|NCT04306055|NO_INTERVENTION|No questionnaire group|Ever donors in this group would not receive the questionnaire.
62346141|NCT02058485|ACTIVE_COMPARATOR|Group HD|Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
62346142|NCT02058485|SHAM_COMPARATOR|Group ND|Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
62346143|NCT02058485|ACTIVE_COMPARATOR|Group HM|Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
62346144|NCT02058485|SHAM_COMPARATOR|Group NM|Midazolam was administered 0.025 mg. kg-1 in normotensive patient.
61957773|NCT01699906|EXPERIMENTAL|Dietary intervention|Diet regimen to induce weight loss
61957774|NCT01927653||The patients with amnestic MCI|"The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:~1. memory complaint~2. normal general cognition~3. normal activities of daily living~4. not demented"
62346145|NCT01703299||imipenem-treated patients|imipenem-treated patients
62346146|NCT01703299||ertapenem-treated patients|ertapenem-treated patients
62346147|NCT03927053||HIV infected youth who use marijuana only|
62346148|NCT03927053||HIV infected youth who use tobacco only|
62346149|NCT03927053||HIV infected youth who use tobacco and marijuana|
62346150|NCT03927053||HIV infected youth with no substance use|
62346151|NCT04024059|EXPERIMENTAL|Buprenorphine Adherence and Opiate Abstinence|Participants will receive financial incentives for buprenorphine use and opiate abstinence.
62346152|NCT04024059|EXPERIMENTAL|Buprenorphine Adherence Only|Participants will receive financial incentives for buprenorphine use.
62346153|NCT04024059|NO_INTERVENTION|Control|Participants will not receive any intervention.
61957775|NCT01927653||The patients with dysexecutive MCI|"The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:~1. relatively focal executive dysfunction~2. Within reference range on tests of memory, language and visuospatial skills~3. normal general cognition~4. normal activities of daily living~5. not demented"
62346154|NCT02806466|ACTIVE_COMPARATOR|Asthmatic children|
62346155|NCT02806466|SHAM_COMPARATOR|Non-asthmatic children|
62346156|NCT05165992|ACTIVE_COMPARATOR|Nebulized Fentanyl|Intervention group (n=100): Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
62346157|NCT05165992|PLACEBO_COMPARATOR|Nebulized 0.9% Saline Solution|Control group (n=100): Administration of nebulized 0.9% saline solution (5 ml of normal saline), over 15 minutes, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
62346158|NCT03822871|EXPERIMENTAL|Dose Escalation|Escalating doses of 0.75 GBq - 2.0 GBq of CTT1403
62504042|NCT04703517|OTHER|Self Controlled|Patients will active as their own comparator
62504043|NCT04478708|EXPERIMENTAL|Part A: maridebart cafraglutide|Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
62504044|NCT04478708|PLACEBO_COMPARATOR|Part A: Placebo|Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
62346159|NCT03822871|EXPERIMENTAL|Dose Escalation/Expansion|Escalating doses of 3.0 GBq - 9.0 GBq of CTT1403
62504045|NCT04478708|EXPERIMENTAL|Part B: maridebart cafraglutide|Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
62504046|NCT04478708|PLACEBO_COMPARATOR|Part B: Placebo|Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
62504047|NCT04478708|EXPERIMENTAL|Part C: maridebart cafraglutide|Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.
62142951|NCT04495140|EXPERIMENTAL|Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug|In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961, 100 ug, will be administered via intravenous infusion.
62142952|NCT01945320||HD-BCM|"1. Patients at National Taiwan University Hospital~2. Patients who have received HD more than 3 months~3. Patients who sign the informed consents~4. Patients who aged between 20-90 years"
62142953|NCT04923022|EXPERIMENTAL|Vegan diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last for eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
62346160|NCT03548974|ACTIVE_COMPARATOR|Interventiongroup1|passive, motor-driven movement therapy followed by intermittent active and passive training
62346161|NCT03548974|ACTIVE_COMPARATOR|Interventiongroup2|intermittent active and passive training followed by no intervention
62346162|NCT04208334|EXPERIMENTAL|Curcumin|Curcumin 4000mg/day x 60 days
62346163|NCT04208334|PLACEBO_COMPARATOR|Placebo|Placebo x 60 days
62346164|NCT05643157|EXPERIMENTAL|Retinal Disease|Subjects with either retinal toxicity or inherited retinal degeneration will undergo multimodal clinical imaging and Adaptive Optics Optical Coherence Tomography (AO-OCT) imaging at each study visit to document regions of disease and healthy retina over time.
62346165|NCT01079429||MGUS or SMM|Patients with Monoclonal gammopathy of undetermined significance or smoldering myeloma
62504048|NCT01268241||Observation|Hemizygous male or heterozygous female patients of any age with genetically confirmed diagnosis of Anderson-Fabry disease.
62504049|NCT05291351|EXPERIMENTAL|Pea|Treatment 1: crackers made with 25% whole pea flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse pea flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine pea flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
62504050|NCT05291351|EXPERIMENTAL|Lentil|Treatment 1: crackers made with 25% whole lentil flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse lentil flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine lentil flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
61957776|NCT01927653||The healthy volunteers|"The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:~1. Age and gender matched healthy subjects without significant neuropsychiatric disorder~2. Able to understand and provide signed informed consent"
61957777|NCT00564772|EXPERIMENTAL|single arm|all subjects dosed the same
62504051|NCT05291351|EXPERIMENTAL|Oats|Treatment 1: porridge made with whole oat flour; Treatment 2: porridge made with coarse oat flour; Treatment 3: porridge made with fine oat flour; Treatment 4: porridge made with commercial oat flour (control)
62504052|NCT04845841|EXPERIMENTAL|Participants receive study medication on time point 1|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
62504053|NCT04845841|EXPERIMENTAL|Participants receive study medication on time point 2|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
62504054|NCT04998448||Cases|women aged 18 to 50 years, premenopausal, with polycystic ovary syndrome
62504055|NCT04998448||Controls|women aged 18 to 50 years, premenopausal, without polycystic ovary syndrome.
62504056|NCT04479748|OTHER|Dextenza insert|Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).
62504057|NCT04479748|OTHER|Fellow-eye|The fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID, QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in patient baseline demographic and systemic characteristics.
61957778|NCT00299104|EXPERIMENTAL|Rituximab (0.5 g x 2) + Methotrexate|Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
62504058|NCT06031220|EXPERIMENTAL|study group|30 women with twin pregnancy during the third trimester at 27th weeks gestation will make deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks, pulmonary function test will be applied at 27th week gestation and at 36th weeks gestation.
61957779|NCT00299104|EXPERIMENTAL|Rituximab (1.0 g x 2) + Methotrexate|Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
61957780|NCT00299104|PLACEBO_COMPARATOR|Placebo + Methotrexate|"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks."
61957781|NCT05899036|EXPERIMENTAL|Treatment Arm|Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove the thrombus in the neuro-vasculature using the RapidPulseTM Aspiration System.
61957782|NCT02284984|EXPERIMENTAL|Rituximab with belimumab|Rituximab 1000mg on day 0 and day 14 Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks.
61957783|NCT03486548|SHAM_COMPARATOR|control group|adductor canal block with sham block
61957784|NCT03486548|EXPERIMENTAL|sciatic group|adductor canal block with popliteal sciatic nerve block
61957785|NCT03570073|ACTIVE_COMPARATOR|Manual vitrification|
61957786|NCT03570073|EXPERIMENTAL|Automatic vitrification|
61957787|NCT01099605|PLACEBO_COMPARATOR|Pump device|One arm will have continuous subcutaneous infusion of normal saline.
61957788|NCT01099605|ACTIVE_COMPARATOR|Bupivacaine|will receive continuous infusion of bupivacaine
61957789|NCT03500354|EXPERIMENTAL|Nutrient|Nutrient drink
61957790|NCT02213367|ACTIVE_COMPARATOR|20 mg Bilastin|20mg Bilastine once daily
61957791|NCT02213367|ACTIVE_COMPARATOR|Bilastin 40mg|40 mg Bilastine once daily, intake of two tablets 20mg Bilastine
61957792|NCT02213367|ACTIVE_COMPARATOR|Bilastin 80mg|80 mg Bilastine once daily, intake of four tablets 20mg Bilastine
61957793|NCT02798133|EXPERIMENTAL|OLA|recruitment maneuver + individualized PEEP
61957794|NCT02798133|ACTIVE_COMPARATOR|RM-5|recruitment maneuver + fixed standard PEEP
61957795|NCT04962178|EXPERIMENTAL|Early Invasive Strategy|Procedure: Primary PCI
61957796|NCT04962178|ACTIVE_COMPARATOR|Conservative Strategy|Procedure: Optimal medical therapy with primary PCI not performed.
61957797|NCT01022229|EXPERIMENTAL|Compound Natural Health Product|15 study participants who will receive the compound natural health product.
61957798|NCT01022229|PLACEBO_COMPARATOR|Placebo|15 participants will receive placebo natural health product.
61957799|NCT04563611|NO_INTERVENTION|Muscle strength|Participants hamstring muscle strengths will be evaluated with ISOMED 2000 isokinetic dynamometer
61957800|NCT04563611|NO_INTERVENTION|Hamstring Flexibility|In this study, Individuals' evaluations of hamstring flexibility will be assessed by the active knee extension test (ICC: 0.96) with maximum hip flexion.
61957801|NCT04563611|NO_INTERVENTION|Cognitive Function|The lower (reaction time and visual-perceptual ability) and upper level (working memory, inhibitory control, and cognitive flexibility) cognitive functions of the individuals participating in the study will be evaluated with the computer assisted CNSVS test battery
61957802|NCT04563611|NO_INTERVENTION|Injury risk|Injury risk analysis of individuals will be made using the strength differences between the two sides, H: Q ratios (conventional and functional ratio) and functional movement screen (FMS), which will be obtained from the isokinetic measurement results.
61957803|NCT04563611|EXPERIMENTAL|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. The hands and arms will be positioned on the chest and held by the physical therapist at the heels of the individuals. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed
61957804|NCT04563611|EXPERIMENTAL|Supine Sliding Leg Curls|The persons will be started to exercise in the hook position, with hands-on their back, with their knees next to the body, in a flexion position of approximately 60 °. Participants will be asked to first build a bridge, then maintain this position and slowly slide the slippery apparatus under their feet to bring their knees to full extension.
61957805|NCT04563611|EXPERIMENTAL|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
61957806|NCT04563611|NO_INTERVENTION|Agility|Agility performances of individuals will be evaluated with the Agility T-test.
61957807|NCT05813951|ACTIVE_COMPARATOR|continuous infusion|seventy Patients in the continuous infusion group will receive an intravenous loading dose of 600 mg of Linezolid for 60 min, followed by a continuous infusion of 1200 mg/day (50 mg/h)
61957808|NCT05813951|ACTIVE_COMPARATOR|intermittent infusion|seventy patients in the intermittent infusion group will administrate 600 mg of linezolid IV every 12 h for 60 min
62346166|NCT06350565|OTHER|Half-dose study|A total of 24 Chinese pregnant subjects with 34+0-35+6 GW requiring dexamethasone treatment for preterm labour with preterm prematurity in China were planned to be enrolled in this study. A total of 12 subjects receiving 5 mg dexamethasone (intramuscular injection, q12h, 4 doses) were enrolled in the full-dose group; 12 subjects receiving 2.5 mg dexamethasone (intramuscular injection, q12h, 4 doses) were enrolled in the half-dose group.
62702683|NCT06750653|ACTIVE_COMPARATOR|Vaseline Second|No moisturizer for 4 weeks; then Vaseline for 4 weeks. Vaseline white petrolatum, manufactured by Unilever, for topical skin use.
62702684|NCT04752774|EXPERIMENTAL|Dose escalation|One single administration of study medication (IPN10200, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.
62702685|NCT04752774|EXPERIMENTAL|Dose ranging|"Two fixed doses of IPN10200 will be administrated as a single injection into several muscle groups of the upper limb.~Participants will be randomised in the ratio of 3:3:2 (total IPN10200 dose 1: 30 participants; total IPN10200 dose 2: 30 participants; Dysport: 20 participants)"
61957809|NCT02803255|EXPERIMENTAL|Assist-As-Needed Control|"Subjects in this group will interact with a robotic exoskeleton, the MAHI Exo-II, programmed with an adaptive mode. In this mode, the robot will continuously assist motion along pre-defined trajectories, but will employ an assist-as-needed protocol.~Here, the amount of assistance provided by the robot will not be always the 100% of that required to complete the task (as in the position control mode), but only a fraction of it. The robot will continuously estimate the residual movement capabilities of the subject, depending on the specific joint addressed in the movement, and will estimate the remaining contribution needed to complete the movement following a predefined trajectory, thus avoiding to over-support motion."
61957810|NCT02803255|ACTIVE_COMPARATOR|Subject-Triggered Control|Subjects in group B will interact with a robotic exoskeleton, the MAHI Exo-II, controlled via the subject-triggered mode, as in a previous clinical trial with the MAHI Exo II robotic system. In the subject triggered mode, the MAHIExo II is commanded to regulate joints motion following a position-control control scheme, and using as desired trajectories standardized single-joints profiles that require motion of one of the axes of the exoskeleton (i.e. elbow flexion and extension, forearm pronation and supination, wrist radial and ulnar deviation, wrist flexion and extension). The switch to position control of the exoskeleton is triggered by the application of sufficient force by the subject, in a previous phase where the robot implements a virtual wall.
61957811|NCT01910857|EXPERIMENTAL|Lifestyle counseling|Lifestyle counseling. 6 group meetings,facilitated by community health worker, focusing on lifestyle change, eg, weight loss, physical activity, low salt, stress reduction
61957812|NCT01910857|NO_INTERVENTION|Control|Standard care
61957813|NCT05963594|ACTIVE_COMPARATOR|T2D Sequence AB|Where A = 50 g Oligomalt and B = 50 g Glucidex 40.
61957814|NCT05963594|ACTIVE_COMPARATOR|T2D Sequence BA|Where A = 50 g Oligomalt and B = 50 g Glucidex 40.
62504059|NCT06031220|NO_INTERVENTION|control group|30 women with twin pregnancy during the third trimester at 27th weeks gestation will not receive any special treatment and will be assessed with pulmonary function test at 27th week gestation and at 36th weeks gestation.
62504060|NCT01657526|EXPERIMENTAL|Group A|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
62504061|NCT01657526|PLACEBO_COMPARATOR|Group B|Subjects in this group will receive placebo in Step 1 of the study
61957815|NCT05963594|ACTIVE_COMPARATOR|HAO Sequence ABCD|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
61957816|NCT05963594|ACTIVE_COMPARATOR|HAO Sequence BDAC|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
61957817|NCT05963594|ACTIVE_COMPARATOR|HAO Sequence DCBA|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
62346167|NCT06350565|OTHER|An exploratory study|This study was planned to enrol 24 pregnant women with 34+0-38+6 GW preterm labour with confirmed gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy in a dose exploratory study in this population. A total of 12 subjects were enrolled in the full-dose group to receive 5 mg dexamethasone (intramuscular injection, q12h, 4 doses) and 12 subjects were enrolled in the half-dose group to receive 2.5 mg dexamethasone (intramuscular injection, q12h, 4 doses).
62346168|NCT01025011||healthy volunteers, anemic patients|healthy volunteers from the eye and gynecology department pregnant patients with anemia
62346169|NCT05608148|EXPERIMENTAL|GAIA-102 alone|GAIA-102: 5 x 10\^6 cells / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks
62504062|NCT01657526|EXPERIMENTAL|Group C|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
62702686|NCT04752774|EXPERIMENTAL|Total dose|"One single injection of study medication will be administered locally into several muscle groups of the upper limb.~Participants will be randomized in the ratio of 2:1 (Total IPN10200 dose: 30 participants; placebo: 15 participants, resulting in a total of 45 participants in Stage 3).~Or~Participants will be randomized in the ratio of 3:1 (IPN10200 lower dose: 30 participants; placebo: 10 participants, then IPN10200 higher dose: 30 participants; placebo: 10 participants, resulting in a total of 80 participants in Stage 3)."
62702687|NCT05833789|EXPERIMENTAL|Colonoscopy for colorectal cancer screening|All patients in this group will have their colonoscopy for colorectal cancer screening completed with a legacy colonoscope followed by colonoscopy with the Magnetic Flexible Endoscope (MFE).
62702688|NCT03465865||ILM-flap|Patients after surgical repair of macular holes with ILM-flap transposition are invitied to a follow-up for optical coherence tomography and visual acuity testing one year after surgery
62702689|NCT06748963|EXPERIMENTAL|Fasted Exercise|Exercise training will be performed in the fasted state (i.e., before breakfast).
62346170|NCT05608148|EXPERIMENTAL|GAIA-102 with Dinutuximab, Filgrastim, Teceleukin combination|GAIA-102: 5 x 10\^6 cells / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks Filgrastim: 5 µg/kg/day on Day1-14 Teceleukin: 750,000 units/m2/day on Day29-31 and 1,000,000 units/m2/day on Day 36- 39 Dinutuximab: 17.5mg/m2/day on Day4-7 and Day36-39
62346171|NCT05608148|EXPERIMENTAL|GAIA-102 with Nivolumab combination|GAIA-102: 5 x 10\^6 cells / dose at a fixed dose, 3 doses / week for 3 consecutive weeks Nivolumab: 3mg/kg/day(Children) or 240mg/day(Adults) on Day1
62346172|NCT03264794|EXPERIMENTAL|trial group|Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
62504063|NCT01657526|PLACEBO_COMPARATOR|Group D|Subjects in this group will receive placebo in Step 2 of the study
62702690|NCT06748963|ACTIVE_COMPARATOR|Postprandial Exercise|Exercise will be performed in the postprandial period (i.e., after breakfast)
62702691|NCT06750289|ACTIVE_COMPARATOR|Medium-dose ICS-LABA + benralizumab|Participants will be randomised 1:1 to one of the 2 study arms. Participants will receive up to 7 SC injections during study, with the first 3 doses administered every 4 weeks and then subsequent doses every 8 weeks.
61957818|NCT05963594|ACTIVE_COMPARATOR|HAO Sequence CADB|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
61957819|NCT05041205|PLACEBO_COMPARATOR|Placebo control group|placebo drink powder without active ingredients, 1 sachet per day with 50 ml water for 12 weeks
61957820|NCT05041205|EXPERIMENTAL|Beauty drink powder group|Beauty drink powder is the test article provide to participants, 1 sachet per day with 50 ml water for 12 weeks
61957821|NCT05041205|PLACEBO_COMPARATOR|cosmetic apparatus group|This group is designed for a cosmetic apparatus control group without consumption of placebo or test article. Together with the specified cleanser, the apparatus is used for daily facial cleaning, two times in the morning and evening for 12 weeks.
61957822|NCT05041205|EXPERIMENTAL|Beauty drink powder + cosmetic apparatus group|In this group, Beauty drink powder is consumed 1 sachet daily with 50 ml water and the cosmetic apparatus is used together with the specified cleanser for daily facial cleaning, two times in the morning and evening for 12 weeks.
61957823|NCT06065943|ACTIVE_COMPARATOR|Ultrasound guidance|
62142954|NCT04923022|EXPERIMENTAL|Therapeutic exercise|"The participants in the therapeutic exercise group will perform the following therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.~1. The patient, sitting in the cervical spine neutral position, performs flexion, extension and rotation of the cervical spine, unloaded and in the maximum possible range of motion.~2. While the patient is in the supine position, she performs passive lateral mobilization to the neck with the help of a physiotherapist.~3. In the supine position, the patient performs isometric neck flexion, lateral flexion and rotation movements against the manual resistance given by the physiotherapist~4. The patient lying on his back does isometric neck extension movement against gravity~5. The patient performs isometric neck flexion, lateral flexion and rotation movements against the elastic band in the sitting position"
62504064|NCT04744428|EXPERIMENTAL|Autism Parent Navigators Intervention|Autism Parent Navigators Intervention is a manualized, in-home, peer support model for parents with a young child recently diagnosed with ASD.
62702692|NCT06750289|ACTIVE_COMPARATOR|High-dose ICS-LABA + placebo|Participants will be randomised 1:1 to one of the 2 study arms. Participants will receive up to 7 SC injections during study, with the first 3 doses administered every 4 weeks and then subsequent doses every 8 weeks.
62702693|NCT06751147|EXPERIMENTAL|group A|Lateral Femoral cutaneous nerve mobilization with muscle energy techniques
62702694|NCT06749847|EXPERIMENTAL|Outreach|Women receive invitation letter with HPV self-sampling kit; Direct mailing of HPV self-sampling kit; Women receive HPV self-sampling kit with instructions; SMS reminder at 3 months if no participation; Assistance provided for triage cytology if HPV positive.
62702695|NCT06749847|EXPERIMENTAL|Choice|"Women receive an invitation letter offering a choice between ordering a free self-sampling kit or visiting a healthcare provider.~Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation."
62702696|NCT06749847|NO_INTERVENTION|Control arm|Standard invitation to visit healthcare provider for cervical cancer screening. Standard screening procedure. Follow standard organized screening program procedure. HPV self-sampling offered at 12-month reminder if no participation.
62702697|NCT06750887||NORMAL CONDITION|The normal condition is measured as a lumbar flexion without VR until the onset of pain.
62702698|NCT06750887||UNDERSTATED CONDITION|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% less movement in the VR (understated visual feedback)
62702699|NCT06750887||OVERSTATED CONDITION|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% more movement in the VR (understated visual feedback)
62702700|NCT06748599||group A|patients who are assigned for transepithelial PRK
62702701|NCT06748599||group B|patients who are mechanical PRK using a spatula
62702702|NCT06751251||OX40 (CD134) expression levels of sarcoma specimens in treatment-native sarcoma patients|Before delivering neoadjuvant chemotherapy, using IHC to test the protein expression of OX40 and using RNA-seq to test the RNA of OX40
62702703|NCT06751251||OX40 (CD134) expression levels of sarcoma specimens in chemotherapy treated sarcoma patients|After neoadiuyant chemotherapy, using IHC to test the protein expression of OX40 and using RNA-seq to test the RNA of OX40
62702704|NCT06749951|EXPERIMENTAL|Cognitive Behavioural Therapy for insomnia (CBT-I)|
62702705|NCT06749951|ACTIVE_COMPARATOR|Sleep Hygiene Advice|
62702706|NCT06749054|EXPERIMENTAL|LEN|"Participants will receive oral LEN 600 mg on Days 1 and 2. Participants will also receive 2 doses of LEN 927 mg as subcutaneous (SC) injection on Day 1 and Week 26 along with their OBR per clinical practice.~At the Week 52, participants will be given the option to receive SC LEN every 6 months while continuing their OBR for at least another 2 SC LEN doses in the extension phase."
62702707|NCT04667949|EXPERIMENTAL|Fingolimod|Fingolimod 0.5 mg capsule taken orally once daily
62702708|NCT06748651|EXPERIMENTAL|Intra-articular Injection of Allocetra performed once on Day 1 of the study|
62702709|NCT02987530|EXPERIMENTAL|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
62702710|NCT02987530|ACTIVE_COMPARATOR|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
62702711|NCT06748742||Control group|Patients who underwent radical resection of prostate malignant tumor with anterior approach at Shanghai First People's Hospital
61957824|NCT06065943|OTHER|Palpation and Fluoroscopy|
61957825|NCT05638568|EXPERIMENTAL|Intervention arm LS guided treatment|"all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.~The GAS will be analyzed immediately at the bedside by a LS-test POC device. For infants allocated to the interventional group the LS-result will be displayed as treat with surfactant or  do not treat with surfactant depending on wether the LS-ratio is under or above the cut-off ratio for treatment.~Those with LS-ratio above the cut-off ratio will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30) - ie same as in control group."
62142955|NCT04923022|NO_INTERVENTION|Control group|Participants in this group will not receive any intervention.
62142956|NCT02285218||1) Normal control|metabolically healthy with no obesity
61957826|NCT05638568|NO_INTERVENTION|Control arm - routine surfactant treatment|"all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.~The GAS will be analyzed immediately at the bedside by a LS-test POC device, but result will remain blinded.~Infants allocated to the control group will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30). The LS-ratio for those infants will remain blinded"
61957827|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
61957828|NCT02901314|EXPERIMENTAL|MyRoad|Receives usual care heart failure education before discharge AND a card at discharge that provided pre-recorded audio messages that can be played back on-demand on 4 themes: heart failure signs/symptoms assessment, medications, activity and exercise and diet and a general message about the importance of follow-up post discharge and following the plan of care.
61957829|NCT02901314|NO_INTERVENTION|Usual care|Receives usual care heart failure education before discharge
61957830|NCT04602988||Patients admitted to an inpatient hospital unit|Patients admitted to an inpatient hospital unit will receive EEG based monitoring of mental status
61957831|NCT04063930|ACTIVE_COMPARATOR|Lokelma|"Sodium zirconium cyclosilicate Lokelma® 5 g, powder (Astra Zeneca)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
61957832|NCT04063930|PLACEBO_COMPARATOR|Placebo|"Matching placebo (indistinguishable from the active comparator)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
61957833|NCT01966159|EXPERIMENTAL|SYNERGY Investigational Device|SYNERGY Stent System
61957834|NCT01966159|ACTIVE_COMPARATOR|PE Plus Investigational Device|PE Plus Stent System
61957835|NCT06234917|EXPERIMENTAL|EEG-NFB protocol aimed at increasing the low-β(SMR)/high-β ratio|EEG neuromodulation at central (rolandic) cortical level
61957836|NCT06234917|ACTIVE_COMPARATOR|EEG-NFB protocol aimed at increasing the α(μ)/θ ratio|EEG neuromodulation at central (rolandic) cortical level
61957837|NCT00092989|EXPERIMENTAL|Montelukast 7 mg|Participants receive montelukast 7 mg intravenously (IV) until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
61957838|NCT00092989|PLACEBO_COMPARATOR|Placebo|Participants receive placebo IV until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
61957839|NCT03280498|OTHER|Intubation with Cole formula|ASA I-II pediatric patients in the age range of 2-10 years, planned to undergo elective surgeries under general anesthesia with endotracheal entubation,
62702712|NCT06748742||Experiment Group|Patients who used ICG to identify and separate the bladder neck during anterior robot-assisted radical prostatectomy
62702713|NCT06749821|ACTIVE_COMPARATOR|Kinesio Tape Group|Kinesio tape was applied to this group.
62702714|NCT06749821|PLACEBO_COMPARATOR|Placebo Tape Group|Placebo tape was applied to this group.
61957840|NCT06270667|EXPERIMENTAL|Aerobic Exercise|Aerobic Exercise twice weekly for 5 months.
61957841|NCT06270667|EXPERIMENTAL|Combined Aerobic and Resistance Exercise|Combined Aerobic and Resistance Exercise twice weekly for 5 months.
61957842|NCT06270667|NO_INTERVENTION|Standard Care|Standard Care, i.e no exercise intervention.
61957843|NCT06270667|ACTIVE_COMPARATOR|Reference Aerobic Exercise|Aerobic Exercise twice weekly for 5 months.
61957844|NCT02256020|OTHER|Original lifestyle|Original lifestyle, watching TV 50 minutes, three times a week for 6 months.
61957845|NCT02256020|EXPERIMENTAL|Wheel-chair music aerobic exercise|Wheel-chair music aerobic exercise with 3 times of 50-minute session (10 minutes warm up, 30 minutes exercise and 10 minutes cool down) a week for 6 months.
62142957|NCT02285218||2) dyslipidemia|high triglyceride levels or LDL-C levels
62702715|NCT06749821|OTHER|Control Group|No application was made to this group. Just rest
61957846|NCT02654340||Participants with Tuberous Sclerosis Complex (TSC)|Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.
61957847|NCT03758209|EXPERIMENTAL|Prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~* Physical status (walking, respiratory training)~* Nutrition (nutritional supplements)~* Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
61957848|NCT03758209|ACTIVE_COMPARATOR|ERAS|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
61957849|NCT02900339|EXPERIMENTAL|MR parameters optimization|The study will be conducted on the MRI of the Neurinfo platform, in the radiology department of the University Hospital of Rennes.
61957850|NCT03949361||Patients starting glucocorticoids|Patients starting a glucocorticoid therapy measuring primary and secondary endpoints before and after at least 4 weeks of treatment.
61957851|NCT03949361||Patients stopping glucocorticoids|Patients stopping a glucocorticoid therapy measuring primary and secondary endpoints before weaning off glucocorticoids and after a period of at least 3 months.
62142958|NCT02285218||3) type 2 diabetes|defined in 'inclusion criteria'
61957852|NCT04568070|EXPERIMENTAL|Stroke|Stroke patients who applied to the Physical Medicine and Rehabilitation outpatient clinic, met the inclusion criteria and volunteered to participate in the study
61957853|NCT00822783|ACTIVE_COMPARATOR|Omalizumab|
61957854|NCT00822783|PLACEBO_COMPARATOR|Placebo|
61957855|NCT04218825|EXPERIMENTAL|Adult patients with early stage MF-CTCL (stage IA-IB)|Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.
61957856|NCT05113017||SBRT group|Patients with residual lung nodules are treated with SBRT
61957857|NCT04578431|EXPERIMENTAL|Intervention groups|The participants will be given a beverage containing four artificial sweeteners (intervention) at baseline
61957858|NCT03267706|ACTIVE_COMPARATOR|Palliative Care Comprehensive Tool|Clinicians within the study will be randomly assigned and trained on the use of the Palliative Care Comprehensive Tool
61957859|NCT03267706|NO_INTERVENTION|Usual Care|Clinicians within the study will be randomly assigned to usual palliative care (without the newly introduced tool)
61957860|NCT02054260|EXPERIMENTAL|Surgicel add therapy|
61957861|NCT02541019|EXPERIMENTAL|Palonosetron|Palonosetron (iv) one minute before anesthesic induction.
61957862|NCT02541019|EXPERIMENTAL|Ondansetron|ondansetron (iv) one minute before anesthesic induction and ondansetron regular three times a day for two days after the surgery.
61957863|NCT02080949|EXPERIMENTAL|HSRT - 4fx x 5 Gy|It'll be recruited 3 patients to the initial regimen of four fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered that the study was initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with the next dose level.
61957864|NCT00763100||Breast cancer|Patients in treatment or post-treatment for breast cancer
62702716|NCT06750679|ACTIVE_COMPARATOR|Compression Group|In compression therapy, multicomponent inelastic compression bandages bandages will be applied (Misra et al., 2023). The individual will be fitted with a stockinet beforehand. Fingers will be bandaged. Then, the extremity will be cylindricalized with a cotton roller or sponge. Subsequently, the foot and ankle will be bandaged using a 6 cm short-stretch bandage. An 8 cm short-stretch bandage will be applied starting from the foot and progressing upward above the ankle. A 10 cm short-stretch bandage will then be applied, beginning at the ankle and wrapping upward. The next bandages will be wrapped upwards starting from the places where the pressure is low. The compression bandage will remain on the patient's leg for approximately 23 hours. When the individual arrives the next day, the bandage will be removed and reapplied. The application time of the inelastic bandage is approximately 20-30 minutes. Compression therapy will be applied 5 days a week for 4 weeks (20 sessions)
62714903|NCT06330116|ACTIVE_COMPARATOR|Oral screen|Strength training of the oral and pharyngeal muscles is performed with an oral screen (OS)(IQoro). The OS is a device that has an effect both on the brain plasticity and a strengthening effect of oral and pharyngeal muscles. (9) The OS is placed pre-dentally behind closed lips. The patient pulls the OS forward in a horizontal direction with strong pressure for 5 to 10 seconds while firmly resisting the pressure with tightened lips. The exercise is repeated three times, with 3 seconds of rest between repetitions, and is performed 3 times per day. Training for 3 months.
61957865|NCT03992001|EXPERIMENTAL|Sequence A-B|Patients in this arm will receive blood component A for 6 months and blood component B for the next 6 months
61957866|NCT03992001|EXPERIMENTAL|Sequence B-A|Patients in this arm will receive blood component B for 6 months and blood component A for the next 6 months
62142959|NCT02285218||4) non-alcoholic fatty liver disease|defined in 'inclusion criteria'
62142960|NCT00764582|EXPERIMENTAL|1|
62142961|NCT00764582|ACTIVE_COMPARATOR|2|
62142962|NCT01292213||Cases|Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
61957867|NCT03442205|EXPERIMENTAL|Group A|
62142963|NCT01292213||Controls|Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.
62142964|NCT03905642|EXPERIMENTAL|560 mg Arikayce™|Subjects in this cohort will receive 560 mg of Arikayce™
61957868|NCT03442205|EXPERIMENTAL|Group B|
61957869|NCT03442205|EXPERIMENTAL|Group C|
61957870|NCT00870792|ACTIVE_COMPARATOR|Received report|
61957871|NCT00870792|PLACEBO_COMPARATOR|Routine care|Patients receive usual, routine, care.
61957872|NCT05626985||Hepatocellular Carcinoma patients|Blood samples are collected before liver resection.
61957873|NCT05626985||Liver cirrhosis|The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
61957874|NCT05626985||Hepatitis|Patients with various hapatitis.
61957875|NCT05626985||Benign tumor-like lesions|Benign hepatic tumors were diagnosed based on imaging findings and histological examinations after hepatic resection.
61957876|NCT05626985||Healthy control|The healthy control group consist of people undergoing routine medical examination. Blood samples are collected.
61957877|NCT04564573||antidepressant treatment group|participants who had received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
61957878|NCT04564573||non-antidepressant treatment group|participants who had not received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
62142965|NCT00687869|EXPERIMENTAL|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
62142966|NCT00687869|ACTIVE_COMPARATOR|usual care|Usual stroke aftercare plus patient-information-notes
62142967|NCT00786864|EXPERIMENTAL|1. Experimental Group|Exercise Intervention Group
62714904|NCT06330116|ACTIVE_COMPARATOR|Neuromuscular electrical training (NMES)|Strength training of the oral and pharyngeal muscles is performed by an oral device used for 20 minutes every day (eXciteosa). The device gives electrical pulses to the surrounding tissue, mainly the tongue. Training for 3 months.
61957879|NCT05729646|EXPERIMENTAL|Arm A (Chemotherapy+Toripalimab)|"Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.~Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery."
61957880|NCT05729646|EXPERIMENTAL|Arm B (Toripalimab monotherapy)|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
61957881|NCT05729646|ACTIVE_COMPARATOR|Arm C (Chemotherapy)|Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery.
61957882|NCT05317182|ACTIVE_COMPARATOR|Analogic-Analogic|Occlusal splints made by conventional impression and conventional fabrication.
61957883|NCT05317182|ACTIVE_COMPARATOR|Analogic-Digital|Occlusal splints made by conventional impression and digital design and fabrication.
61957884|NCT05317182|ACTIVE_COMPARATOR|Digital-Digital|Occlusal splints performed by intra-oral scanner and digital design and fabrication.
61957885|NCT02801396|ACTIVE_COMPARATOR|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
61957886|NCT02801396|ACTIVE_COMPARATOR|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
61957887|NCT02801396|ACTIVE_COMPARATOR|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
61957888|NCT02801396|ACTIVE_COMPARATOR|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
61957889|NCT02801396|ACTIVE_COMPARATOR|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
61957890|NCT02801396|ACTIVE_COMPARATOR|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
61957891|NCT01947582|OTHER|Application of ankle foot orthosis|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
62142968|NCT00786864|NO_INTERVENTION|2. Control Group|Control group - no intervention
62142969|NCT05608070|EXPERIMENTAL|IV Oxytocin|
61957892|NCT00796198|ACTIVE_COMPARATOR|Xalatan+Cosopt|Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
61957893|NCT00796198|ACTIVE_COMPARATOR|Xalatan|when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
61957894|NCT03207854||Ancillary-correlative (biospecimen collection)|Patients and healthy normal volunteers undergo collection of peripheral blood samples for analysis via flow cytometry, RNASeq, immunohistochemistry, CyTOF experiments, cell cultures, and functional studies of immune cell subsets obtained by FACS. Patients also undergo collection of bone marrow and leukopheresis/leukoreduction specimens, and single cell suspensions and bulk excised tumor biopsies are obtained from routine testing for analysis via immunohistochemistry or CyTOF.
61957895|NCT05282758|EXPERIMENTAL|Interdisciplinary team treatment + add on Intervention - Free Movement Dance|Interdisciplinary team treatment + add on Intervention - Free Movement Dance as a physiotherapy intervention
61957896|NCT05282758|ACTIVE_COMPARATOR|Interdisciplinary team treatment + add on Modified person-centered progressive resistance exercise|Interdisciplinary team treatment + add on Control group - modified person-centered progressive resistance exercise as a physiotherapy intervention
61957897|NCT04008576|OTHER|Group Blended Transdiagnostic treatment|
61957898|NCT02555683|EXPERIMENTAL|QAW039 150 mg|QAW039 150 mg once daily
61957899|NCT02555683|EXPERIMENTAL|QAW039 450 mg|QAW039 450 mg once daily
61957900|NCT02555683|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62142970|NCT05608070|PLACEBO_COMPARATOR|Placebo- NaCl 0.9%|
62142971|NCT02124252|NO_INTERVENTION|Control|Women will be offered HPV testing within the health facilities in the communities randomized to this arm. Women who test HPV positive will be referred to care at the sub-district and district hospitals (current standard of care).
62142972|NCT02124252|ACTIVE_COMPARATOR|Standard Intervention|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
62346173|NCT03264794|ACTIVE_COMPARATOR|control group|Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
62346174|NCT04965129|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Placebo Comparator: Placebo All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given four tablet/day for four mounths.
62346175|NCT04965129|EXPERIMENTAL|Experimental: Fish oil|All subjects will be given fish oil with a dose of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
62346176|NCT02930369|ACTIVE_COMPARATOR|4PD diameter of ILM peeling in surgery|patients in this group was given 4papillary diameter (PD) diameter of internal limiting membrane (ILM) peeling in surgery
61957901|NCT00039130|EXPERIMENTAL|Rituximab with High Intensity Chemotherapy|Cycle1: Cyclophosphamide 100 mg/m\^2/day (d) IV (d 1-5), Prednisone 60 mg/m\^2/d oral (d 1-7), Allopurinal 300 mg/d oral (d 1-14) Cycle 2, 4 \& 6 (21 day): Ifosfamide 800 mg/m\^2/d (d 1-5), Dexamethasone 10 mg/m\^2/d (d1-5), Methotrexate 150 mg/m\^2 load, then 1.35 g/m\^2 over 23.5 h (d 1), Leucovorin 25 mg/m\^2 36 h after methotrexate (d 2) then 10 mg/m\^2 every 6 h, Vincristine 2 mg push (d 1), Cytarabine 1000 mg/m\^2/d over 2 h (d 4-5), Etoposide 80 mg/m\^2.d over 1 h (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 50 mg/m\^2 d 8 cycle 2 only, 375 mg/m\^2/d (d 10, 12 cycle 2, d 8 cycle 4 \& 6) Cycle 3, 5 \& 7 (21 day): Cyclophosphamide 200 mg/m\^2/day (d) IV (d 1-5), Dexamethasone 10 mg/m\^2/d (d1-5), Methotrexate 150 mg/m\^2 load, then 1.35 g/m\^2 over 23.5 h (d 1), Leucovorin 50 mg/m\^2 36 h after methotrexate (d 2) then 10 mg/m\^2 every 6 h, Vincristine 2 mg push (d 1), Doxorubicin 25 mg/m\^2/d (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 375 mg/m\^2/d (d 8)
61957902|NCT06558032|EXPERIMENTAL|Test Tamsulosin 0.4 SR PT Dexa Medica|Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)
61957903|NCT06558032|ACTIVE_COMPARATOR|Reference Harnal OCAS 0.4 mg PR Astellas, Combiphar|Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)
61957904|NCT03791489|EXPERIMENTAL|Active Treatment|Cryotherapy of the posterior nasal nerve using the ClariFix device
61957905|NCT04081974||Minimally invasive cardiac surgery|All consecutive patients presenting for minimally invasive cardiac surgery will be screened for participation to the study.
61957906|NCT06103123||mRNA COVID-19 vaccine associated myocarditis|Participants who had developed myocarditis within 42 days of getting a mRNA COVID-19 vaccine
61957907|NCT06103123||mRNA COVID-19 vaccine associated pericarditis|Participants who had developed pericarditis within 42 days of getting a mRNA COVID-19 vaccine
61957908|NCT06103123||COVID-19 infection associated myocarditis|Participants who had developed myocarditis within 42 days of being infected with the SARS-COV-2 virus
62504065|NCT04744428|ACTIVE_COMPARATOR|Peer mentoring|Peer mentors will offer an equivalent number of in-home or telephone visits for families, providing non-manualized peer support.
62504066|NCT02462434|EXPERIMENTAL|Early palliative care team consultation|Early pediatric palliative care team consultation for single ventricle patients will occur in this group following birth but prior to the first stage palliative surgery.
62504067|NCT02462434|NO_INTERVENTION|Usual care|Usual care for single ventricle patients will be provided with palliative care team consultation occurring at any point (if it is determined the child and family would benefit from palliative care consultation) during the child's neonatal hospital stay.
62504068|NCT03788135|EXPERIMENTAL|Quadriceps cooling|Participants in this group will receive a cold pack on anterior thigh muscles for 20 minutes.
61957909|NCT06103123||COVID-19 infection associated pericarditis|Participants who had developed pericarditis within 42 days of being infected with the SARS-COV-2 virus
61957910|NCT06103123||Alternative etiology myocarditis|Any participants with myocarditis that is not associated with the mRNA COVID-19 vaccine or SARS-COV-2 viral infection
62142973|NCT02124252|ACTIVE_COMPARATOR|Enhanced Intervention|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
62504069|NCT03788135|EXPERIMENTAL|Hamstring cooling|Participants in this group will receive a cold pack on posterior thigh muscles for 20 minutes.
62504070|NCT03788135|EXPERIMENTAL|Calf cooling|Participants in this group will receive a cold pack on posterior leg muscles for 20 minutes.
62504071|NCT03788135|EXPERIMENTAL|Back cooling|Participants in this group will receive a cold pack on posterior low back muscles for 20 minutes.
61957911|NCT02637284|EXPERIMENTAL|Intervention 1a (cohort 1)|Single dose of 1 oral tablet of PCO-02 containing 1 mg of Bepecin (12 subjects)
61957912|NCT02637284|EXPERIMENTAL|Intervention 1a (cohort 2)|Single dose of 3 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
61957913|NCT02637284|EXPERIMENTAL|Intervention 1a (cohort 3)|Single dose of 6 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
62346177|NCT02930369|EXPERIMENTAL|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
62504072|NCT03788135|NO_INTERVENTION|Control|The participants in the control group will be rested for 20 minutes without any intervention.
62504073|NCT05671952|EXPERIMENTAL|intervention group|Application of integrated intervention system programs
62504074|NCT05671952|NO_INTERVENTION|Control group|No intervention
62504075|NCT02243345||Delayed|Time from surfacing to recompression \>=48 hours
62504076|NCT02243345||Early|Time from surfacing to recompression \<48 hours
62504077|NCT01531504|OTHER|Hysterectomy|candidate for a conventional laparoscopic-assisted
61957914|NCT02637284|PLACEBO_COMPARATOR|Control group 1a (cohort 1)|Single dose of 1 oral tablet of PCO-03 as placebo (2 subjects)
61957915|NCT02637284|PLACEBO_COMPARATOR|Control group 1a (cohort 2)|Single dose of 3 oral tablets of PCO-03 as placebo (2 subjects)
61957916|NCT02637284|PLACEBO_COMPARATOR|Control group 1 a (cohort 3)|Single dose of 6 oral tablets of PCO-03 as placebo by mouth (2 subjects)
61957917|NCT02637284|EXPERIMENTAL|Intervention 1b|Multiple dose regime of 3 oral tablets of PCO-02 containing 1 mg Bepecin every 8 hours during 2 weeks (36 subjects)
61957918|NCT02637284|PLACEBO_COMPARATOR|Control group 1b|Multiple dose regime of 3 oral tablets of PCO-03 as placebo every 8 hours during 2 weeks (6 subjects)
62346178|NCT05260892||Narrow GM|Patients presenting at least onde edentulous site rehabilitated with Narrow GM implant
62346179|NCT01360762|EXPERIMENTAL|Pentamidine Secondary Prophylaxis (PSP)|"Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period."
62346180|NCT01021514||Type 2 DM, Healthy control|Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
62346181|NCT01021514||Type 2 DM, Heatlhy control|
62346182|NCT03451500|EXPERIMENTAL|Carbidopa-levodopa 2 tablets daily|carbidopa-levodopa 25-100 mg 2 tablets daily hs
62504078|NCT04060914|EXPERIMENTAL|Ticagrelor(90mg)|
62504079|NCT04060914|EXPERIMENTAL|Ticagrelor(90/60mg)|
62504080|NCT04060914|ACTIVE_COMPARATOR|Clopidogrel(75mg)|
62702717|NCT06750679|EXPERIMENTAL|Compression+MLD Group|"Participants in the group receiving MLD in addition to compression therapy will undergo a 30-40-minute MLD session to facilitate the entry of interstitial fluid into lymphatic capillaries and enhance lymph propulsion (Misra et al., 2023). The MLD will be performed with gentle pressure of approximately 30-40 mmHg, ensuring the skin and connective tissue move together without sliding on the skin.~After the MLD session, a multilayer bandaging will be applied to the extremity, which the patient will wear for approximately 23 hours. The bandage will be removed and reapplied during the patient's visit the following day.~The combined therapy of compression and MLD will be administered five days a week for four weeks (20 sessions in total). Each session will last approximately 50-70 minutes."
62346183|NCT03451500|EXPERIMENTAL|carbidopa-levodopa 6 tablets daily|carbidopa-levodopa 25-100 mg, 2 tablets, 3 times daily, with breakfast, with supper and hs
62702718|NCT06749600||Primary leiomyosarcoma of the ovary (POLMS)|The study population includes patients aged between 18 and 99 years diagnosed with primary ovarian leiomyosarcoma (POLMS) afferent to participating centers. This population encompasses both historical cases diagnosed since 1980 and new cases identified during the study period.
61957919|NCT02325960|ACTIVE_COMPARATOR|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter
61957920|NCT02325960|ACTIVE_COMPARATOR|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
61957921|NCT03515876||Control|Patients will receive intravenous propofol infusion.
61957922|NCT03515876||Dexmedetomidine 0.5 microgram/kg group|Patients will receive dexmedetomidine 0.5 microgram/kg and then intravenous propofol infusion.
61957923|NCT03515876||Dexmedetomidine 1 microgram/kg group|Patients will receive dexmedetomidine 1 microgram/kg and then intravenous propofol infusion.
61957924|NCT00126191|EXPERIMENTAL|Low Risk|"Low-risk patients receive 3 cycles of regimen A.~Regimen A:~Rituximab (375 mg/m\^2) on Days 1 and 3. Cyclophosphamide (800 mg/m\^2) on days 1 and 2. Vincristine (1.4 mg/m\^2) on days 1 and 10. Doxorubicin (50 mg/m\^2) on Day 1. Methotrexate (3000 mg/m\^2) on Day 10. Intrathecal Cytarabine (50mg) will be given on Day 1 and intrathecal methotrexate (12mg) will be given on Days 1 and 10.~Leucovorin on days 11 and 12.~Rituximab is given on Days 1 and 3 in cycle 1, and on Day 1 of all other cycles."
62346184|NCT03451500|PLACEBO_COMPARATOR|Placebo|Placebo, 2 tablets, 3 times daily, with breakfast, with supper and hs
62346185|NCT00645918|ACTIVE_COMPARATOR|A|"Tailored clopidogrel regimen - an additional clopidogrel 600-mg loading dose (eight 75-mg tablets taken orally; daily 150 mg clopidogrel dose plus additional 450 mg clopidogrel) on the day of randomization and then 150-mg clopidogrel every day thereafter for 6 months."
62346186|NCT00645918|PLACEBO_COMPARATOR|B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months."
62346187|NCT00645918|PLACEBO_COMPARATOR|C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.
62346188|NCT06089161|ACTIVE_COMPARATOR|Standard of Care Group|Participants in this group receive the standard of care treatment for sleep apnea for up to six months.
62346189|NCT06089161|EXPERIMENTAL|Personalized OSA Treatment Group|Participants in this group receive personalized OSA treatment for sleep apnea for up to six months.
62346190|NCT05071352|EXPERIMENTAL|Nefopam group|"Adjunct continuous infusion of nefopam plus standard of care in ICU for assessment and management of pain, sedation, and delirium.~Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours."
62346191|NCT05071352|PLACEBO_COMPARATOR|Control group|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
62346192|NCT00240539|EXPERIMENTAL|HBsAg(+) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive \[HBsAg(+)\] and hepatitis B envelope antigen negative \[HBeAg(-)\] mothers, who received 4 doses of Engerix™ in the primary study.
62346193|NCT00240539|EXPERIMENTAL|HBsAg(+) & HBeAg(+) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive \[HBsAg(+)\] and hepatitis B envelope antigen positive \[HBeAg(+)\] mothers, who received 4 doses of Engerix™ in the primary study.
62346194|NCT00240539|EXPERIMENTAL|HBsAg(+) & HBeAg(+) 5-dose Group|Newborns of anti-hepatitis B surface antigen positive \[HBsAg(+)\] and hepatitis B envelope antigen positive \[HBeAg(+)\] mothers, who received 5 doses of Engerix™ in the primary study.
62346195|NCT00240539|EXPERIMENTAL|HBsAg(-) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen negative \[HBsAg(-)\] and hepatitis B envelope antigen negative \[HBeAg(-)\] mothers, who received 4 doses of Engerix™ in the primary study.
62346196|NCT04799184|EXPERIMENTAL|Group I Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug/ml completing a volume of 20 ml."
62346197|NCT04799184|ACTIVE_COMPARATOR|Group II no Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine completing a volume of 20 ml."
62504081|NCT05746130|EXPERIMENTAL|plastic-free diet program|Plastic-free nutrition program will include plastic-free diet, peer mentoring, interactive education and BPA exposure feedback.
62504082|NCT05746130|ACTIVE_COMPARATOR|plastic free diet education program|This group will take peer mentoring, interactive education and BPA exposure feedback.
62504083|NCT05746130|ACTIVE_COMPARATOR|BPA exposure feedback|This group will take only BPA exposure feedback.
62504084|NCT02067702||Limb Cooling Assessment of ET Control|Healthy, volunteers with no known dermatological lesions, sensitivity to cold, or peripheral vascular disease.
62504085|NCT02067702||Limb Cooling Assessment of ET Experimental|Patients with known essential tremor for at least a year, and +2 or worse action or kinetic tremor of one or both upper limbs involving at least the forearm and/or hand.
62702719|NCT06751264|EXPERIMENTAL|Peritoneal water isolation|Peritoneal water isolation
61957925|NCT00126191|EXPERIMENTAL|High Risk|"High-risk patients receive 4 alternating cycles of regimens A and B (A-B-A-B).~Regimen A (as described earlier).~Regimen B:~Rituximab (375mg/m\^2) on Day 1. Ifosfamide (1500mg/m\^2) on Days 1-5. Mesna (275 mg/m\^2) on Days 1-5. Etoposide (60mg/mg\^2) on Days 1-5. Cytarabine (2 gm/m\^2) twice a day on Days 1 and 2. Intrathecal methotrexate (12mg) on Day 5, and intrathecal methotrexate (50mg) on Day 3 (also on Day 1 for patients with central nervous system involvement)."
62346198|NCT04184115|EXPERIMENTAL|DPI-386 Nasal Gel + placebo patch|DPI-386 Nasal Gel: Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
62346199|NCT04184115|PLACEBO_COMPARATOR|Placebo nasal gel + Placebo patch|Placebo
62346200|NCT04184115|ACTIVE_COMPARATOR|placebo nasal gel + TDS patch|Transderm Scop® is a commercial transdermal scopolamine (TDS) patch worn behind the ear containing a 1.5 mg reservoir of scopolamine to be delivered over a 72-hour period.
62346201|NCT03998917||Chronic Kidney Disease (CKD) Patients|Patients with chronic kidney disease and a glomerular filtration rate less than 60 ml/min of creatinine. Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
62346202|NCT03998917||Control cohort|The control cohort will consist of a group of people from the same age group as the CKD group but without chronic kidney disease. The exclusion criteria apply to this group. They will be selected from the spouses and other volunteers. This group will also perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
62346203|NCT05978687|EXPERIMENTAL|Topical lidocaine gel|All patients will receive topical 2% lidocaine gel (Ophtesic lidocaine gel) prior to surgery
62346204|NCT05978687|ACTIVE_COMPARATOR|Subconjunctival xylocaine injection|All patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle
62504086|NCT01134341|EXPERIMENTAL|Bexarotene (Targretin) & Pralatrexate (Folotyn)|"Bexarotene (Targretin): administered po qd. The initial daily dose of bexarotene will depend on the cohort to which each patient is assigned. Bexarotene will be self-administered except in patients who underwent plasma PK sampling on cycle 1, dose 1 and cycle 1, dose 3, at which time bexarotene was to be administered at the investigational site 1 hour (± 5 minutes) prior to pralatrexate administration.~Pralatrexate (Folotyn): administered weekly via IV push over a minimum of 30 seconds up to a maximum of 5 minutes. One cycle is 4 weeks in duration consisting of weekly dosing of pralatrexate for 3 weeks followed by 1 week of rest. The initial dose of pralatrexate will depend on the cohort to which each patient is assigned."
62504087|NCT03064243|EXPERIMENTAL|apatinib group|apatinib 500mg po qd
62504088|NCT01213836|ACTIVE_COMPARATOR|First Seroquel XR then Seroquel IR|Patients randomised to Seroquel XR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel IR for 10-16 days
62504089|NCT01213836|ACTIVE_COMPARATOR|First Seroquel IR then Seroquel XR|Patients randomised to Seroquel IR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel XR for 10-16 days
62504090|NCT00272649|EXPERIMENTAL|Single Arm|Single Arm study
62504091|NCT02206841||NAFLD|Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as targeted SNP arrays, super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, metabolomics, fecal microbiome, metabolite, metagenome/metatranscriptome analyses.
62702720|NCT06751264|EXPERIMENTAL|Peritoneal combined with intrauterine water isolation|Peritoneal combined with intrauterine water isolation
62142974|NCT04000399|EXPERIMENTAL|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinician trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE.; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
62142975|NCT01121328|EXPERIMENTAL|Autologous cord blood transfusion|Collected cord blood at birth will be transfused for the preterm neonate
62142976|NCT00772902|EXPERIMENTAL|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
62702721|NCT06750900||NORMAL CONDITION|The normal condition is measured as a lumbar extension without VR until the onset of pain.
62702722|NCT06750900||UNDERSTATED CONDITION|It involves an illusion with virtual reality where the patients perform a lumbar extension until the onset of pain and the feel a 10% less movement in the VR (understated visual feedback)
62702723|NCT06750900||OVERSTATED CONDITION|It involves an illusion with virtual reality where the patients perform a lumbar extension until the onset of pain and the feel a 10% more movement in the VR (understated visual feedback)
62714905|NCT06330116|ACTIVE_COMPARATOR|Group training with an occupational therapist|Strength training of the oral and pharyngeal muscles is performed in group, led by an occupational therapist. Training for 3 months.
61957926|NCT05866172|EXPERIMENTAL|HAIC with zoledronic Acid|
61957927|NCT05866172|ACTIVE_COMPARATOR|HAIC without zoledronic Acid|
61957928|NCT06461364|EXPERIMENTAL|Group A|About 10 participants faced Self-adhesive composite (Surefil one)
61957929|NCT06461364|EXPERIMENTAL|Group B|About 10 participants faced Viscalor
61957930|NCT06461364|EXPERIMENTAL|Group C|About 10 participants faced Equiaforte
61957931|NCT04800354|EXPERIMENTAL|Nurse-led Mindfulness Based Intervention|
61957932|NCT04800354|ACTIVE_COMPARATOR|Nurse-led Pain Psychoeducation|
61957933|NCT04145557|PLACEBO_COMPARATOR|skaling root planing|
62702724|NCT06749145|EXPERIMENTAL|Intervention|The intervention arm will undergo sequential screening for aortic stenosis using portable 1-lead electrocardiograms (ECGs), followed by point-of-care ultrasound (POCUS), if indicated, by artificial intelligence (AI)-based risk algorithms.
62702725|NCT06749145|SHAM_COMPARATOR|Control|The control arm will undergo a portable 1-lead electrocardiogram (ECG), with 10% randomly assigned to undergo point-of-care ultrasound (POCUS).
62702726|NCT06388954|PLACEBO_COMPARATOR|Control group (GA)|Patients in the control group (GA) will be treated by 12 sessions of sham transcutaneous auricular Vagus nerve stimulation for 30 minutes immediately, will be followed by 30 minutes of a selected physical therapy program, three sessions per week for four consecutive weeks. Sham transcutaneous vagal nerve stimulation was performed using the same procedures as the study group but without electrical stimulation.
62702727|NCT06388954|EXPERIMENTAL|Study group (GB)|Patients in the study group (GB) will be treated by 12 sessions of true transcutaneous auricular Vagus nerve stimulation for 30 minutes , then immediately followed by 30 minutes of a selected physical therapy program (GA), three sessions per week for four consecutive weeks. The stimulation of the auricular branch of the Vagus nerve will be performed by conventional TENS device with one channel and two electrodes.
61957934|NCT04145557|ACTIVE_COMPARATOR|skaling root planing and diode laser|
61957935|NCT06051227|ACTIVE_COMPARATOR|Fentanyl IV|Opioid analgesic Form: fentanyl solution for injection/infusion Administration: intravenous Initial dose: 1 ug/kg Second dose (if required): 0.6ug/kg
62346205|NCT05950347|ACTIVE_COMPARATOR|Active Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
61957936|NCT06051227|EXPERIMENTAL|Fentanyl IN|Opioid analgesic Form: fentanyl solution for injection/infusion Administration: intranasal using nasal atomizer Initial dose: 1.25 ug/kg to a maximum of 100ug Second dose (if required): 1ug/kg to a maximum total dose of 2ug/kg
62504092|NCT05460962|EXPERIMENTAL|Deep breathing excercises|is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
62504093|NCT05460962|EXPERIMENTAL|Deep breathing excercise and progressive muscle relaxation|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
62702728|NCT02143414|EXPERIMENTAL|Cohort I (blinatumomab, POMP)|See Detailed Description
61957937|NCT06051227|EXPERIMENTAL|Esketamine IV|Anesthetic, in lower doses the analgesic effect is dominant Form: esketamine solution for injection/infusion Administration: intravenous Initial dose: 0.2mg/kg Second dose (if required): 0.12mg/kg
62504094|NCT03263078|EXPERIMENTAL|TIVA with Propofol in free flap surgery|Total intravenous anesthesia(TIVA) with Propofol
61957938|NCT06051227|EXPERIMENTAL|Esketamine IN|Anesthetic, in lower doses the analgesic effect is dominant Form: esketamine solution for injection/infusion Administration: intranasal using a nasal atomizer Initial dose: 0.625mg/kg to a maximum of 50mg Second dose (if required): 0.5mg/kg to a maximum total dose of 1mg/kg
62142977|NCT00772902|ACTIVE_COMPARATOR|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
62346206|NCT05950347|SHAM_COMPARATOR|Sham Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
62504095|NCT03263078|ACTIVE_COMPARATOR|Sevoflurane in free flap surgery|Inhalation anesthesia with Sevoflurane
62346207|NCT05820620|PLACEBO_COMPARATOR|Control group|No intervention + Patient Control Analgesia (PCA)
62504096|NCT01590251|EXPERIMENTAL|Yoga|Gentle yoga for chronic pain and opioid dependence
62702729|NCT02143414|EXPERIMENTAL|Cohort II (dasatinib, prednisone, blinatumomab)|See Detailed Description
62702730|NCT05390762|ACTIVE_COMPARATOR|Conventional care in a day hospital|"1. A common face to face day hospital, combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.~2. A Second phase of 5 weeks of care face to face day hospital of the reconditioning type of 15 sessions."
62702731|NCT05390762|EXPERIMENTAL|Telecare rehabilitation|"1. A common face to face day hospital, combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.~2. A Second phase of 5 weeks of Telecare rehabilitation of the reconditioning type of 15 sessions."
62702732|NCT06750718|EXPERIMENTAL|Virtual Reality|The virtual reality group will engage in targeted cervical sensorimotor training through VR Oculus Quest 2 (OQ2)
62504097|NCT01590251|ACTIVE_COMPARATOR|Educational Counseling|Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
62142978|NCT04828109|ACTIVE_COMPARATOR|VR and Fitbit|Daily VR use every 3 hours up to 30 minutes at a time and Fitbit daily step goal of 2,000 steps
62142979|NCT04828109|ACTIVE_COMPARATOR|VR Only|Daily VR only. Daily VR use every 3 hours up to 30 minutes at a time.
62504098|NCT01527838|EXPERIMENTAL|Single FT1050 treated UCB Unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
62504099|NCT02966496|EXPERIMENTAL|the test group|The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
62504100|NCT02966496|EXPERIMENTAL|the control group|The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
61957939|NCT04859361|EXPERIMENTAL|Treatment with imiquimod|Colposcopy with PAP smear and punch biopsy is scheduled at 10 weeks to rule out progression, and at 20 weeks to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present and additional biopsies will be performed on any visible lesions. At 20 weeks, in case of disease progression or persistence, treatment with LLETZ will be offered.
62504101|NCT05140668|ACTIVE_COMPARATOR|Supraclavicular central venous catheterization approach group|supraclavicular central venous catheterization group catheter is inserted in supraclavicular fossa (an indentation immediately above the clavicle) with a long-axis in plane approach
62504102|NCT05140668|ACTIVE_COMPARATOR|Infraclavicular central venous catheterization approach group|infraclavicular central venous catheterization group catheter is inserted in infraclavicular fossa (an indentation, immediately below the clavicle, above the third rib and between the deltoid muscle laterally and medioclavicular line medially) with a short-axis out-of-plane approach
62504103|NCT02361957|ACTIVE_COMPARATOR|Probiotics|Multispecies probiotic product Ecologic 825, 2x10-9 colony forming units per gram, 6 grams per day.
62504104|NCT02361957|PLACEBO_COMPARATOR|Placebo|Similar in appearance as the probiotics, but not containing any bacteria.
62504105|NCT02966158|EXPERIMENTAL|AIT Group|"The AIT Group will perform usual care CR exercise for the 1st month of the program. This includes performing aerobic exercise 5 times/week and resistance training twice/week (offered 2 weeks after program start). In month two, this group will begin to perform AIT three days/week, along with two MICE and two RT sessions.~The AIT exercise protocol includes the following components:~1. Warm Up Period: 5-10 minutes of walking performed at an intensity that will feel fairly light. Heart rate monitors and watches will be used to gauge their effort.~2. Intervals: Between two to four 4-minute intervals of walking/jogging performed at an intensity that is close to participants' maximal effort, based on the exercise tests that were performed at the beginning of the program. These hard intervals will be separated by 3-minutes of active recovery performed at a very light intensity.~3. Cool Down Period: 5 minutes of walking performed at a fairly light intensity."
62504106|NCT02966158|NO_INTERVENTION|MICE Group|"This group will perform usual care CR for 6 months, which includes both resistance and aerobic exercise (MICE) training. Aerobic exercise is prescribed in the first exercise class and performed 5 times/week, the resistance training program is offered after 2 weeks in the program and performed 2 times/week. Participants will be asked to keep a record of the exercise that they do.~Resistance/Strength Training: Patients will be performing 1-2 sets of 5 to 10 resistance training exercises using a combination of hand-held dumbbells, elastic bands of varying thicknesses, as well as their own body weight for resistance.~Aerobic Training: Patients will have their aerobic exercise prescription set at an intensity and duration that will be comfortable for them, based on the tests conducted at the beginning of the program to ensure their safety."
62504107|NCT04867811|EXPERIMENTAL|group A|received conventional therapy
62504108|NCT04867811|EXPERIMENTAL|group B|received TENS in addition to conventional therapy
62504109|NCT04867811|EXPERIMENTAL|group C|received cupping therapy with conventional therapy
61957940|NCT04859361|ACTIVE_COMPARATOR|Treatment with LLETZ|Standard treatment will be scheduled after patients' first period.
62504110|NCT04867811|EXPERIMENTAL|group D|TENS and cupping therapy plus conventional therapy
62504111|NCT04258280|ACTIVE_COMPARATOR|Usual Care|
62702733|NCT06750718|ACTIVE_COMPARATOR|Comprehensive Sensorimotor Training|An exercise program consisting of Cervical JPSM, Cervical movement sense, and Oculomotor control exercises.
62702734|NCT06750419|EXPERIMENTAL|Experimental arm receiving the IP|"Approximately 82 evaluable adult patients will be recruited from approximately 8 renal cancer care specialist centres with access to state-of-the-art PET/CT imaging in mainland China. The number of enrolled participants may be increased to ensure sufficient confidence in measuring sensitivity and specificity of 89Zr-TLX250 PET/CT imaging.~Following pre-screen morphological imaging to confirm evidence of IRM (to occur within 90 days of study enrolment), participants will attend a screening visit within 30 days of study enrolment, at which time baseline examinations will be undertaken.~On Day 0, all successfully screened participants will undergo a slow IV administration of 89Zr- TLX250, at the nuclear medicine service of the respective study site. For all subjects, a PET/CT scan of the abdomen will occur on visit Day 5 (±2 days post administration \[p.a.\]) with nephrectomy to be performed any time after the PET/CT imaging visit, but no later than 90 days p.a. 89Zr-TLX250."
62714906|NCT05930561|EXPERIMENTAL|4D-150 Part 1 Dose Confirmation Dose Level 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62714907|NCT05930561|EXPERIMENTAL|4D-150 Part 1 Dose Confirmation Dose Level 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
61957941|NCT00520936|EXPERIMENTAL|Pemetrexed|
61957942|NCT00289991|ACTIVE_COMPARATOR|Itraconazole|
62346208|NCT05820620|EXPERIMENTAL|QLB group|QLB group Block will be applied + Patient Control Analgesia (PCA)
61957943|NCT00289991|EXPERIMENTAL|Voriconazole|
61957944|NCT02643680|EXPERIMENTAL|The novel biocellulose wound dressing|
61957945|NCT02643680|ACTIVE_COMPARATOR|Bactigras|
61957946|NCT05492344|EXPERIMENTAL|Personalized ventilation|If a patient is assigned to the intervention group, ventilator settings will be adjusted based on the lung morphology (focal or non focal) results of the lung ultrasound.
61957947|NCT05492344|ACTIVE_COMPARATOR|Standard care|Patients assigned to the control group will be ventilated according to the current standard of care.
61957948|NCT06413563||juvenile idiopathic arthritis|"Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children JIA is an umbrella term defining several forms of chronic arthritis with an onset before the age of 16 years, persisting for more than six weeks and with an unknown cause.~Based on the current International League of Associations in Rheumatology classification criteria (ILAR 2003) , different subtypes of JIA can be distinguished, essentially by a very limited set of clinical features (number of affected joints in the first six months of disease, extra-articular manifestations like fever or features of psoriasis) and serology (presence or absence of rheumatoid factor, RF). The most frequently diagnosed JIA subtypes are oligoarticular JIA (oJIA), polyarticular JIA (pJIA), and systemic JIA (sJIA). Less frequently occurring subtypes are enthesitis-related JIA, psoriatic arthritis, and undefined arthritis. complete blood count will be done for all patients"
61957949|NCT06413563||control group|control
62346209|NCT05820620|EXPERIMENTAL|TAP group|TAP Block group will be applied + Patient Control Analgesia (PCA)
62504112|NCT04258280|EXPERIMENTAL|Enhanced Care|
62702735|NCT06749418|EXPERIMENTAL|High-salt supplement|Participants will be counseled to consume a low-salt diet (\<2000 mg/day of sodium) for 10 days. After 3 days of a low-salt diet, participants will consume the high-salt supplement (4500 mg/day) for 7 days while maintaining a low-salt diet. On days 3 and 10, participants will arrive at the laboratory where the investigators will assess microvascular endothelial function. Blood will be collected to investigate circulating angiotensin II responses to low- (day 3) and high- (day 10) salt diet. On days 2 and 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
62504113|NCT03126422|EXPERIMENTAL|Dexmedetomidine 0 μg/kg/min|
62504114|NCT03126422|EXPERIMENTAL|Dexmedetomidine 0.03 μg/kg/min|
62504115|NCT03126422|EXPERIMENTAL|Dexmedetomidine 0.06 μg/kg/min|
62504116|NCT03126422|EXPERIMENTAL|Dexmedetomidine 0.09 μg/kg/min|
62504117|NCT06230159|ACTIVE_COMPARATOR|Menthol cigarette|Participants participate in an ad libitum smoking session with a menthol cigarette for this condition. Participants also participate in an ad libitum smoking session with either their usual brand cigarette or the menthol study cigarette at the end of each study visit.
62504118|NCT06230159|ACTIVE_COMPARATOR|Non-menthol cigarette|Participants participate in an ad libitum smoking session with a non-menthol control cigarette for this condition. Participants also participate in an ad libitum smoking session with either their usual brand cigarette or the non-menthol study cigarette at the end of each study visit.
62504119|NCT06230159|ACTIVE_COMPARATOR|Cigarette with synthetic cooling agents|Participants participate in an ad libitum smoking session with a synthetic cooling agent cigarette for this condition. Participants also participate in an ad libitum smoking session with either their usual brand cigarette or the synthetic cooling agent study cigarette at the end of each study visit.
62504120|NCT02419625|OTHER|subgroup-specific HEV in Israel|The study will involve patient interviews using questionnaires
62504121|NCT03561922|EXPERIMENTAL|RETINA IMPLANT Alpha AMS|All participants receive the subretinal device RETINA IMPLANT Alpha AMS
62504122|NCT00792441|NO_INTERVENTION|intervention group|Patients with mechanical ventilated who met the criteria for weaning from medical doctor in Srinagarind hospital, Khon Kaen University
62702736|NCT06749041||Adult patients with treatment resistant schizophrenia spectrum disorders receiving clozapine.|Adult patients (age between 18 and 70) with treatment resistant schizophrenia of schizoaffective disorder, treated with oral, once or twice-daily clozapine.
62702737|NCT06748313|EXPERIMENTAL|G1= Mango Pickle (Water-Based)|This group will use 50 grams of Mango Pickle (Water-Based) daily as an intervention.
62702738|NCT06748313|EXPERIMENTAL|G2= Mango Pickle (Oil Based)|This group will use 50 grams of Mango Pickle (oil-based) daily as an intervention.
62702739|NCT06748313|EXPERIMENTAL|G3= Carrot Pickle (Water-Based)|This group will use 50 grams of Carrot Pickle (Water-Based) daily as an intervention.
62702740|NCT06748313|EXPERIMENTAL|G4= Radish Pickle (Water-Based)|This group will use 50 grams of Radish Pickle (Water-Based) daily as an intervention.
62702741|NCT06748313|EXPERIMENTAL|G5= Onion Pickle (Water-Based)|This group will use 50 grams of Onion Pickle (Water-Based) daily as an intervention.
62702742|NCT06748313|EXPERIMENTAL|G6= Lemon & Chili Pickle (Water-Based)|This group will use 50 grams of Lemon \& Chili Pickle (Water-Based) daily as an intervention.
61957950|NCT04401085||Population area cohort - Control Cohort|A population cohort of asymptomatic individuals (only adults). This is a representative sample of the population, which are part of the research project of Institute for Clinical and Experimental Medicine and Czech Academy of Sciences. The second subsample included individuals from the official household survey of Czech Statistical Office. This cohort allowed better comparative analysis of other population cohorts from specific geographical areas.
62504123|NCT05918341|EXPERIMENTAL|Piracetam arm (single arm)|The single to take once weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg piracetam consecutively. Urine was collected 24 and 72 hours after the weekly doses were taken. It was chosen to administer all these doses in each healthy volunteer to account for inter-individual differences in urine concentrations, as these concentrations depend on individual characteristics such as volume intake and renal function.
62504124|NCT03482206|EXPERIMENTAL|Healthy subjects|Healthy adult volunteers (age 18 or greater) that are not claustrophobic, do not have hyperventilation or panic disorders, not pregnant, have no metal implants and can pass the MRI screening questions.
62504125|NCT03655119|NO_INTERVENTION|Baseline|Youth and parents will complete surveys at index PES visit regarding suicide related risk and protective factors. Parents and youth will complete a follow-up survey at 3 days (parents only) and 2 weeks (parents and youth) post discharge. At 3 days and 2 weeks, parents will complete a survey that evaluates adherence to safety recommendations. The 2-week follow-up survey for parents will also re-assess self-efficacy, parental distress, and mental health treatment stigma. The 2-week follow-up survey for youth assesses mood and suicidal thoughts, perceptions of parent support post discharge, and outpatient treatment. It reassesses suicidal risk, depression, connectedness, and alcohol use.
62504126|NCT03655119|EXPERIMENTAL|Phase I|Families will complete baseline measures, and receive enhanced usual care from PES clinical staff during their visit as well as a parent toolkit that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth. The same follow-up methodology as in Baseline will be utilized.
62702743|NCT06748313|NO_INTERVENTION|Control (non-fermented vegetables or fruits)|"This group will serve as Control (non-fermented vegetables or fruits)."
62702744|NCT06749236|EXPERIMENTAL|test formulation(T) then reference formulation (R) of deuteriumremidvir hydrobromide for suspension|On day 1 of the 1st period, participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension), and on day 1 of the 2nd period, participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).The two periods are separated by a washout of 3 days.
62714908|NCT05930561|EXPERIMENTAL|4D-150 Part 2 Dose Expansion Dose Level 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62714909|NCT05930561|EXPERIMENTAL|4D-150 Part 2 Dose Expansion Dose Level 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
62142980|NCT04828109|ACTIVE_COMPARATOR|Fitbit Only|Fitbit daily step goal of 2,000 steps.
62142981|NCT04828109|NO_INTERVENTION|Control|Standard of care
61957951|NCT04401085||Population cohort from specific geographical areas|"This cohort is based on epidemiologically defined demographic parameters. These are populations from the following geographical areas:~Brno and the South Moravian Region; Praha; Olomouc; Litoměřice; Litovel and Uničov."
61957952|NCT04401085||Chronically ill patients cohort|A cohort of chronically ill people enrolled by Institute for Clinical and Experimental Medicine with chronic cardiovascular problems, hypertension, or diabetes.
61957953|NCT03680105|EXPERIMENTAL|Part 1; Cohort 1; RJX or Placebo|Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.
61957954|NCT03680105|EXPERIMENTAL|Part 1; Cohort 2; RJX or Placebo|Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.
61957955|NCT03680105|EXPERIMENTAL|Part 1; Cohort 3; RJX or Placebo|Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.
61957956|NCT03680105|EXPERIMENTAL|Part 1; Cohort 4; RJX or Placebo|Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.
61957957|NCT03680105|EXPERIMENTAL|Part 1; Cohort 5; RJX or Placebo|Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.
62702745|NCT06749236|EXPERIMENTAL|reference formulation (R) then test formulation(T) deuteriumremidvir hydrobromide for suspension|On day 1 of the 1st period, participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension), and on day 1 of the 2nd period, participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).The two periods are separated by a washout of 3 days.
62702746|NCT06751134|EXPERIMENTAL|CNK-UT cells therapy|"1. Dose Escalation： Single-dose intravenous injection of CNK-UT cells (3\~34×10\^7 CNK+ cells/kg).~2. Dose Expansion:~Multiple-dose intravenous injection of CNK-UT cells according to the results of dose escalation."
62142982|NCT02351791|EXPERIMENTAL|Patch 1, 3 and 5|"Patch 1, Patch 3 and Patch 5 applied on peristomal skin. Patch 1 - Patch 6 applied on healthy abdominal skin~Measurements of skin at three locations of each patch: Center and under adhesive."
62346210|NCT06322524||insomnia group|"insomnia participants participants underwent polysomnography (PSG), the Insomnia Severity Index (ISI), the Pittsburgh Sleep Quality Index (PSQI), the Self-Rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS). prior to the commencement of the study.~8 weeks of the intervention of Gamma sensory flicker, 30 min per day. After 8 weeks study, participants underwent polysomnography again. In the first week of study, participants were required to keep a daily sleep diary everyday.~In the eighth week of study ,participants were required to keep a daily sleep diary everyday."
62504127|NCT03655119|EXPERIMENTAL|Phase II|Families will complete baseline measures and receive Phase I interventions (enhanced care and parent toolkit). Parents will receive caring contacts post discharge, which may occur by phone, text, or email. Caring follow-up messages will provide support, additional education, and problem solving assistance. The same follow-up methodology as in Baseline will be utilized.
62504128|NCT03342430||Early Dieting in Girls cohort|A cohort of 197 non-Hispanic white girls, observed from age 5 to age 15 years
62504129|NCT03785691|EXPERIMENTAL|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
62504130|NCT03785691|EXPERIMENTAL|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
62702747|NCT06748534|EXPERIMENTAL|Interventional group I|
62702748|NCT06748534|ACTIVE_COMPARATOR|Interventional group II|
61957958|NCT03680105|EXPERIMENTAL|Part 1; Cohort 6; RJX or Placebo|Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.
61957959|NCT03680105|EXPERIMENTAL|Part 2; Cohort 1; RJX or Placebo|"Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.~The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile."
61957960|NCT03680105|EXPERIMENTAL|Part 2; Cohort 2; RJX or Placebo|Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
61957961|NCT03680105|EXPERIMENTAL|Part 2; Cohort 3; RJX or Placebo|Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
61957962|NCT01785927|OTHER|ABCD|ABCD A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
62346211|NCT06239506||type 2 diabetes|Case group participants were recruited from patients diagnosed with type 2 diabetes and undergoing medical treatment at the First Affiliated Hospital of Shandong First Medical University(Shandong Provincial hospital)
62346212|NCT06239506||Control group|Control group participants were recruited from residents living in Jinan and undergoing physical examinations at the same hospital.
62714910|NCT05930561|ACTIVE_COMPARATOR|4D-150 Part 2 Dose Expansion Control|Aflibercept at a fixed regimen will be administered.
61957963|NCT01785927|OTHER|BCDA|BCDA A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
61957964|NCT01785927|OTHER|CDAB|CDAB A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
61957965|NCT01785927|OTHER|DABC|DABC A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
62142983|NCT02351791|EXPERIMENTAL|Patch 2, 4 and 6|Patch 2, Patch 4 and Patch 6 applied on peristomal skin. Patch 1- Patch 6 applied on healthy abdominal skin Measurements of skin at three locations of each patch: Center and under adhesive.
61957966|NCT00078442|EXPERIMENTAL|1|Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.
61957967|NCT01024452|EXPERIMENTAL|DAWN AC|
61957968|NCT01024452|ACTIVE_COMPARATOR|Hamilton Nomogram|
61957969|NCT00804674|ACTIVE_COMPARATOR|1 bupivacain|
62504131|NCT03785691|PLACEBO_COMPARATOR|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
61957970|NCT00804674|PLACEBO_COMPARATOR|2 placebo|
61957971|NCT00920712|EXPERIMENTAL|Weiqi decoction|
61957972|NCT00920712|PLACEBO_COMPARATOR|low dose of Weiqi decoction|
62702749|NCT06749834|EXPERIMENTAL|Intravenous thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，or intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg).
61957973|NCT03290872|ACTIVE_COMPARATOR|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral Valve Annuloplasty Ring Repair using Carpentier Edwards Physio 2 Complete flexible mitral ring
61957974|NCT03290872|ACTIVE_COMPARATOR|Simplici T Partial flexible mitral annuloplasty ring|Mitral Valve Annuloplasty Ring Repair using Simplici T Partial flexible mitral annuloplasty ring
61957975|NCT05433324||Group A|Persons previously infected with COVID-19 experiencing CNS-PASC within 6 months of recovery
61957976|NCT05433324||Group B|Persons previously infected with COVID-19 without CNS-PASC symptoms within 6 months of recovery
61957977|NCT05433324||Group C|A control group of persons not previously infected with COVID-19.
61957978|NCT02124330|EXPERIMENTAL|montmorillonite 5 g|5g Montmorillonite + 15 g protein (ratio 1:3)
61957979|NCT02124330|EXPERIMENTAL|Montmorillonite 3 g|3g Montmorillonite + 15 g protein (ratio 1:5)
61957980|NCT02124330|EXPERIMENTAL|Montmorillonite 1 g|1g Montmorillonite + 15 g protein (ratio 1:15)
61957981|NCT02124330|NO_INTERVENTION|Control|A control goup will intake 15 g of protein alone
61957982|NCT04945005||Lead implantation with transesophageal echocardiography|All patients undergoing pacemaker/CRT implantation with concomitant transesophageal echocardiography in addition to fluoroscopic guidance
61957983|NCT04945005||Lead implantation without transesophageal echocardiography (retrospective)|All patients undergoing standard pacemaker/CRT implantation guided by fluoroscopy only (retrospective historical control group)
61957984|NCT02165215|EXPERIMENTAL|Open-Label Induction Phase: Etrolizumab|All participants will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) up to Week 10.
61957985|NCT02165215|EXPERIMENTAL|Double-Blind Maintenance Phase: Etrolizumab|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive etrolizumab 105 mg SC injection Q4W from Week 12 up to Week 62.
62346213|NCT04201977|ACTIVE_COMPARATOR|Exercise session followed passive recovery|Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). The interval between each exercise session will be one week. Volunteers will not perform any form of recovery for 20 min after resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
62504132|NCT04622124|PLACEBO_COMPARATOR|Part 1 Single Ascending Dose (SAD) study|The single ascending dose trial set up 7 dose groups of 2.5, 5, 10, 20, 40, 60 and 80 mg. The 2.5 mg dose group was the exploratory part with open label, while the other dose groups were double-blind. 8 subjects were randomly enrolled in each dose group, 6 of whom received FCN-207 tablets and 2 of whom received placebo. This part of the study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic studies of single dose FCN-207 tablets in healthy volunteers.
62504133|NCT04622124|EXPERIMENTAL|Part 2 Food-effect study|Twelve subjects were enrolled and randomly divided into two groups. The subjects were given FCN-207 tablets after fasting and high-fat diet with double Cross experiment , and feces samples were collected for metabolism/excretion characteristics study.
62702750|NCT06749834|NO_INTERVENTION|Standard therapy|Standard therapy
62702751|NCT06751316|EXPERIMENTAL|Conventional Pulpectomy|Conventional pulpectomy using Zinc Oxide/Eugenol
61957986|NCT02165215|PLACEBO_COMPARATOR|Double-Blind Maintenance Phase: Placebo|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive placebo (matched to etrolizumab) SC injection Q4W from Week 12 up to Week 62.
61957987|NCT02949869|EXPERIMENTAL|Infant Lumbar Punctures|Infants will all be assigned to received two sets of skin markings and sonography exam to assess lumbar puncture landmarks and anatomy.
61957988|NCT04861389|EXPERIMENTAL|Distal transradial access (dTRA)|Distal transradial access for primary percutaneous coronary intervention in STEMI patients
61957989|NCT04861389|ACTIVE_COMPARATOR|Transradial access (TRA)|Transradial access for primary percutaneous coronary intervention in STEMI patients
61957990|NCT01384526||history of hormone therapy|
61957991|NCT01384526||no history of hormone therapy|
61957992|NCT05827510|EXPERIMENTAL|Acne scars|All subjects will be treated with the BTL-585F system. Parameters' settings should be individually evaluated by the operator based on the treatment area and on the patient's medical and wound healing history. Parameters can be modified during subsequent visits, as per the practitioner's discretion.
61957993|NCT05827510|EXPERIMENTAL|Facial wrinkles|All subjects will be treated with the BTL-585F system. Parameters' settings should be individually evaluated by the operator based on the treatment area and on the patient's medical and wound healing history. Parameters can be modified during subsequent visits, as per the practitioner's discretion.
61957994|NCT02080234|EXPERIMENTAL|concurrent chemoradiotherapy with GELOX|"GELOX:~gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days~IFRT~IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.~the first cycle of chemotherapy was initiated on the same day of radiotherapy."
61957995|NCT05384093|ACTIVE_COMPARATOR|Adhesive Capsulitis Study|The purpose of this study is to compare treatment efficacy of patients with symptoms of primary and secondary adhesive capsulitis between three groups: 1) Patients treated with Physical Therapy alone; 2) Patients treated with the ERMI Shoulder Flexionater® alone; 3) Patients treated with PT + Device in the treatment.
62702752|NCT06751316|EXPERIMENTAL|MTA Pulpotomy|Pulpotomy using MTA
62346214|NCT04201977|ACTIVE_COMPARATOR|Exercise session followed active recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Active recovery for 20 minutes (MIKA et al., 2016; CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010);
62504134|NCT04622124|PLACEBO_COMPARATOR|Part 3 Multiple Ascending Dose (MAD) study|A total of 16 subjects were randomly assigned to each dose group for multiple dose study , including 12 who received FCN-207 tablets and 4 who received placebo for a 10-day administration cycle. The dosage of multiple administration was based on the results of single ascending dose study results , and the method of drug administration refers to the results of the food influence test.
62504135|NCT01953172|PLACEBO_COMPARATOR|Placebo capsules|Placebo capsules
62504136|NCT01953172|EXPERIMENTAL|AMP-886 (alpha-tocotrienol) in capsules|AMP-886 (alpha-tocotrienol) in capsules
62702753|NCT06748924||Patients with Chronic Coronary Syndrome|The study will include patients who align with the criteria set by the 2019 ESC Guidelines on CCS and that have been receiving medical care in accordance with these guidelines across 5 broad CCS categories: i) patients with angina and/or dyspnoea, and suspected coronary artery disease; ii) patients with new onset of heart failure or reduced left ventricular function; iii) patients with a long-standing diagnosis of CCS (i.e., those with stabilized symptoms \<1 year after an acute coronary syndrome or with recent revascularization, and those \>1 year after initial diagnosis or revascularization); iv) patients with angina without obstructive disease in the epicardial coronary arteries (i.e., microvascular angina, vasospastic angina); v) asymptomatic subjects referred to screening for coronary artery disease.
62702754|NCT06700330||Children with necrotizing pancreatitis|children who have suffered acute pacreatitis
62702755|NCT06750250|ACTIVE_COMPARATOR|patient education|Patient Education: Providing information on the benefits of physical activity, proper exercise techniques, and self-care strategies. Self-Management Programs: Empowering women to take an active role in managing their health and fitness. Frequency: 3 session/ month, Intensity: Mild to moderate, Type: Walking, Time: 30 to 45mints /sessions
62702756|NCT06750250|EXPERIMENTAL|Aerobic exercises|Group B will perform the aerobic exercises (such as bicycling, treadmill and running) these exercises. Aerobic exercises performed 30 to 45min/session. Frequency: 3 session /month Intensity: Mild to moderate, Type: treadmill, bicycling, running ,Time: 30 to 45min/month
62702757|NCT06701357|EXPERIMENTAL|Cluster1 DEL：CR-CHOP+PD1 inhibitor|Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of CR-CHOP, followed by stratification of the remaining 5 cycles based on genetic subtypes. C1 plus PD1 inhibitor.
62702758|NCT06701357|EXPERIMENTAL|Cluster 2 and 3 DEL：CR-CHOP plus Orelabrutinib|Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of CR-CHOP, followed by stratification of the remaining 5 cycles based on genetic subtypes. C2 and C3 were treated with Orelabrutinib.
62714911|NCT06714305|ACTIVE_COMPARATOR|Group A will be assigned to hand instrumentation.|the canal will be prepared by hand hedstorm files, manually by step back technique.
61957996|NCT05384093|ACTIVE_COMPARATOR|Post operative Shoulder Stiffness Study|The purpose of this study is to compare treatment efficacy of patients with post-operative stiffness indicative of secondary adhesive capsulitis between three groups: I) Patients treated with Physical Therapy alone; II) Patients treated with the ERMI Shoulder Flexionater® alone; III) Patients treated with PT + Device in the treatment.
61957997|NCT05384093|ACTIVE_COMPARATOR|Secondary Surgery Study|The purpose of this study is to compare recovery of patients who have undergone a manipulation under anesthesia or a lysis of adhesions between three groups: 1) Patients treated with Physical Therapy alone; 2) Patients treated with the ERMI Shoulder Flexionater® alone; 3) Patients treated with PT + Device in the treatment.
62504137|NCT03170869|EXPERIMENTAL|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
62504138|NCT02902887|EXPERIMENTAL|Monitored CIAO therapy|Participants wear 3-hour CIAO therapy
62504139|NCT02902887|NO_INTERVENTION|Observation|No intervention, just observation
62504140|NCT03468712|EXPERIMENTAL|Experimental group|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
61957998|NCT06264375|EXPERIMENTAL|Specific physical training|3 times training per week for approx. 30 minutes for 8 weeks. The training contains high intensity interval training (HIIT) elements. Moreover, exercises to improve grip strength, reaction times and anticipation are included.
62702759|NCT06701357|EXPERIMENTAL|Tp53 mut DEL：CR-CHOP plus Decitabine|Participants who met the inclusion/exclusion criteria signed informed consent and received 1 course of CR-CHOP, followed by stratification of the remaining 5 cycles based on genetic subtypes.TP53mut plus decitabine.
62702760|NCT06751446|EXPERIMENTAL|Intervention group|After the block randomisation, the students who are allocated into the intervention group will take the scenario-based simulation training. PI and GCCN faculty will show them the PI-developed video and scenario. The PI will use different cases (scenarios) showing abnormal signs and symptoms that elicit active learning and challenge the students to apply practical skills. A week later, the students will engage in the skills training in group for repeated practice.
62702761|NCT06751446|EXPERIMENTAL|Control group|"After the block randomisation, the students who are allocated into the control group will take the traditional skills training. PI and GCCN faculty will demonstrate \& train them in postoperative nursing management. A week later, the students will practice by themselves in a skill lab where PI \& GCCN faculty will guide them. Finally, every student will appear on skill evaluation, knowledge post-test, and free comments.~To ensure any potential ethical concerns of the control group, after completing the study, PI and GCCN faculty will also show them video and train them about scenario-based simulation on postoperative nursing management."
61957999|NCT06264375|EXPERIMENTAL|General physical training|3 times training per week for approx. 30 minutes for 8 weeks. The training contains high intensity interval training (HIIT) elements.
61958000|NCT06264375|NO_INTERVENTION|No Training|Control group
62702762|NCT06700980||Focus Group|Four groups of participants will meet for online focus groups, identifying barriers and facilitators to the use of technological translation tools in Brussels out-of-hours primary care services for Dutch-speaking patients and French-speaking general practitioners.
62702763|NCT06748846|EXPERIMENTAL|Focal Muscle Vibration|Patients receive 10 sessions of integrated rehabilitation, including 45 minutes of physiotherapy, 15 minutes of therapeutic Focal Muscle Vibration, and 30 minutes of occupational therapy
62702764|NCT06748846|SHAM_COMPARATOR|Sham Focal Muscle Vibration|Patients receive an identical protocol, but the Focal Muscle Vibration is sham (the vibration device produces sound but no actual vibration).
62702765|NCT06749496|EXPERIMENTAL|Test/Control|Eligible subjects will be randomized into the Test/Control sequence, to wear each study lens (Test lens and Control lens) in a daily disposable modality for approximately one week with a washout period of one week between study lens wear periods.
61958001|NCT03019575|EXPERIMENTAL|Corifollitropin alfa (CFA)+human Chorionic Gonadotropin (hCG)|Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was \>60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.
62702766|NCT06749496|EXPERIMENTAL|Control/Test|Eligible subjects will be randomized into the Control/Test sequence, to wear each study lens (Control lens and Test lens) in a daily disposable modality for approximately one week with a washout period of one week between study lens wear periods.
62702767|NCT06696716|ACTIVE_COMPARATOR|ONO-4059|
61958002|NCT01846234||MS patients|MS patients
61958003|NCT01343420|ACTIVE_COMPARATOR|Dog Hair Extract, ALK-Abelló, Inc.|
61958004|NCT02733432|EXPERIMENTAL|Cohort 1|CD101 Vaginal Gel (3%) topically self-administered intravaginally as a single dose on days 1 and 2 and for symptomatic relief CD101 External Gel (1%)topically self-applied to external vulva up to twice per day over 72 hours.
61958005|NCT02733432|EXPERIMENTAL|Cohort 2|CD101 Vaginal Ointment (6%) topically self-administered intravaginally as a single dose on day 1 and for symptomatic relief CD101 External Ointment (1%) topically self-applied to external vulva up to twice per day over 72 hours.
61958006|NCT02733432|ACTIVE_COMPARATOR|Cohort 3|Oral fluconazole (150mg) administered on day 1.
62702768|NCT06696716|PLACEBO_COMPARATOR|Placebo|
62702769|NCT06697678||patients with severe autoimmune encephalitis|No intervention
62702770|NCT06697678||patients with non-severe autoimmune encephalitis|
62702771|NCT06696781||Pacemaker|Mechanically ventilated postoperative adult patients, admitted to the intensive care unit (ICU) within 6 hours after elective cardiac surgery, undergo pacemaker stimulation at various rates to observe how this influences the NOL Index.
62714912|NCT06714305|EXPERIMENTAL|rotary instrumentation of primary second molar tooth|NiTi rotary protaper system will be used for canal preparation by crown down technique in primary second molar tooth
61958007|NCT03045315|EXPERIMENTAL|women included in a IVF program|
61958008|NCT00003931||blood or bone marrow samples|"All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769.~Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1."
61958009|NCT02018185|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
61958010|NCT02018185|SHAM_COMPARATOR|Sham rTMS|Sham Transcranial Magnetic Stimulation
61958011|NCT02746744|EXPERIMENTAL|Rituximab|Infusion of Mabthera/Rituximab every 6 months
61958012|NCT02746744|ACTIVE_COMPARATOR|Dimethyl Fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
61958013|NCT02746744|SHAM_COMPARATOR|Sodium Chloride solution|Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)
61958014|NCT02464020|EXPERIMENTAL|primary sclerosing cholangitis|Two week course of oral vancomycin 500mg twice a day.
61958015|NCT02464020|NO_INTERVENTION|Control group|A control group of participants without Primary Sclerosing Cholangitis. Control group will consist of both healthy subjects and subjects with Inflammatory Bowel Disease.
61958016|NCT01382212|EXPERIMENTAL|Paricalcitol|Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.
61958017|NCT03522389|EXPERIMENTAL|AOT with gait training group|Action observation training with gait training
61958018|NCT03522389|ACTIVE_COMPARATOR|Gait training group|Gait training
61958019|NCT03522389|OTHER|Control group|Education
61958020|NCT01372462|EXPERIMENTAL|NIOV - Room air|Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
62504141|NCT05091216|EXPERIMENTAL|Traditional Chinese Medicine Mouthwash Group|The subjects use traditional Chinese medicine mouthwash after three meals a day and before going to bed, four times a day for 7 consecutive days. After 7 days, record the PLI value and conduct a xerostomia questionnaire, and then retrieve the mouthwash bottle the remaining dose was checked to determine compliance. Those with significantly poor compliance were excluded from the experiment, and then the daily cleaning measures were resumed. The subjects still followed the way of mouthwash four times a day until the end of the 21st day after the xerostomia questionnaire.
62346215|NCT04201977|ACTIVE_COMPARATOR|Exercise session followed immersion in cold water recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will be immersed in cold water immediately after exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009).
62504142|NCT05091216|ACTIVE_COMPARATOR|Dilute 50 times of Traditional Chinese Medicine Mouthwash Group|The subjects use dilute 50 times traditional Chinese medicine mouthwash after three meals a day and before going to bed, four times a day for 7 consecutive days. After 7 days, record the PLI value and conduct a xerostomia questionnaire, and then retrieve the mouthwash bottle the remaining dose was checked to determine compliance. Those with significantly poor compliance were excluded from the experiment, and then the daily cleaning measures were resumed. The subjects still followed the way of mouthwash four times a day until the end of the 21st day after the xerostomia questionnaire.
62504143|NCT06479278|EXPERIMENTAL|Talk With Me Baby|
62504144|NCT06615778|NO_INTERVENTION|Waitlist Control Group|The waitlist control arm consists of participants who are randomly assigned to not receive any treatment. This group will continue with their regular school curriculum and activities, without any additional programming or modifications. The purpose of the control group is to provide a point of comparison for the outcomes measured in the two experimental groups that receive different intervention. If the study shows that the intervention is effective, they will receive all the intervention components of MSEL the in following school year.
62504145|NCT06615778|EXPERIMENTAL|Curriculum-based Social-Emotional Learning (CSEL)|6-session SEL training will be delivered as the experimental component in this arm. The primary goal of the SEL training is to reduce bullying and cyberbullying perpetration and victimization by enhancing students' social-emotional competence, which has been examined to be the protective factor for bullying-related behaviors (Espejo-Siles et al., 2020; Zych et al., 2018). Additionally, due to the interactive and cooperative nature of the SEL curriculum, it is also beneficial for improving interpersonal relatedness (i.e., peer relationships, teacher-student relationships) within the class, which according to past research, is also associated with reduced bullying behaviors (Durlak, Mahoney, \& Boyle, 2022). Each session lasts 40 minutes and will be delivered by the headteacher who will received systematic training on SEL instructions in each class.
62504146|NCT06615778|EXPERIMENTAL|Motivated Social Emotional Learning|MSEL arm consists of three intervention components: 1) CSEL, 2) the Class Ambassador (meaningful role-taking), and 3) Secret Angel . Participants in this arm will receive the same 6-session SEL training as participants in the CSEL arm. Other than CSEL, the second component is the Class Ambassador, adapted from the pupil responsibilities intervention developed by Ellies et al. (2016). The main goal of Class Ambassador is to offer autonomous, prosocial ways of acquiring recognition and social status through a variety of daily classroom jobs. The objective of Class Ambassador is to provide opportunities for students to 1) practice their social-emotional skills, 2) establish healthy peer relationships, 3) autonomously performing prosocial roles and fulfilling social responsibilities. The third component is the Secret Angel. Students will be observe, record, recognize each other's performance anonymously through appraisal notes.
62504147|NCT03624855||Description of BJI due to Pseudomonas aeruginosa|patients having bone and joint infection on implant due to Pseudomonas aeruginosa
62504148|NCT02508116|EXPERIMENTAL|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
62504149|NCT02508116|NO_INTERVENTION|Control group|Antiplatelet therapy will be decided based on usual care
62504150|NCT02546024||Treatment responder|Participants who receive standard care and achieve HAM-D score reduction of 50% or more, or score below 8 at Week 12.
62504151|NCT02546024||Treatment non-responder|Participants who receive standard care but have HAM-D score reduction less than 50% at Week 12.
61958021|NCT01372462|EXPERIMENTAL|NIOV - Oxygen|Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
62504152|NCT03355196|EXPERIMENTAL|LRX712|LRX712 given intra-articularly
62504153|NCT03355196|PLACEBO_COMPARATOR|Placebo|Placebo given intra-articularly
62504154|NCT00894933|EXPERIMENTAL|Continuum|Verify the consistency of performance of the AMS CONTINUUM device in facilitating a sustainable anastomosis following a radical prostatectomy using updated Device design elements and Physician training materials on Device implant technique.
62504155|NCT04253236|EXPERIMENTAL|Cohort 1|Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
62504156|NCT04253236|EXPERIMENTAL|Cohort 2|Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
61958022|NCT01372462|ACTIVE_COMPARATOR|Nasal Cannula Oxygen|Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
62346216|NCT04201977|ACTIVE_COMPARATOR|Exercise session followed foam roller recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will undergo an FR session immediately after resistance exercise session (PEARCEY et al., 2015).
62346217|NCT03927638||Normal Weight|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
62346218|NCT03927638||Overweight/Obese|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
62504157|NCT05917691||Dependent functional status|"223 patients; dependent for those documented as partially dependent or totally dependent."
62504158|NCT05917691||Independent functional status|"65404 patients; independent for those documented as such."
62504159|NCT02400515|OTHER|Moderate Exercise|Aerobic physical exercise was applied during 3 months, 3x/week on women with type 2 diabetic. The evaluation occurred before and after exercise in the same (and only) group, considering that this is a quasi-experimental study.
62504160|NCT05509959|PLACEBO_COMPARATOR|Control Arm|Women assigned to the control arm (n=180) will receive one 60-minute group session facilitated by the licensed clinical therapist (LCT) on self-care and well-being as it relates to HIV, interpersonal violence, trauma, adverse mental health, and substance use. During this session, women will be provided with resources to HIV care, interpersonal violence, trauma, mental health, and substance use, through a static website created for Women SHINE. The content will include: 1) names and locations of clinics and organizations, services provided, and contact information; 2) links to support websites and hotlines and 3) testimonials from WLHA.
62504161|NCT05509959|EXPERIMENTAL|Women SHINE|Women SHINE consists of a four-month intervention that includes video-based one-on-one peer navigation and 7 weekly psycho-education support group sessions co-facilitated by a licensed clinical therapist (LCT) and peer navigator (PN). 180 women will be enrolled in the Women SHINE intervention and will remain in their assigned psycho-education support group sessions with the same members over the course of the intervention.
62504162|NCT04169555|EXPERIMENTAL|Ultrasound|
62504163|NCT04169555|OTHER|Standard care|
62504164|NCT04414033|EXPERIMENTAL|research group|
61958023|NCT01372462|NO_INTERVENTION|No treatment|Control arm. Subjects exercise without using supplemental oxygen or NIOV.
62346219|NCT04475822|EXPERIMENTAL|Intermittent fasting|During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
62346220|NCT04475822|EXPERIMENTAL|Low carb diet|According to the definition of low carbon diet given by R. D. Feinman et al. (Nutrition, 2015), the daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
62346221|NCT04475822|EXPERIMENTAL|Low carbon diet and intermittent fasting group|Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
62346222|NCT01491555||DMD patients|35 boys ages 2 through 30 with DMD
62346223|NCT01491555||Control Group|35 healthy boys ages 2 through 30
62346224|NCT04402853||COVID 19 Patients|hospitalized patients with COVID 19
62346225|NCT04238884|EXPERIMENTAL|Experimental group|Based on the genetic study carried out and the patient's characteristics (age, weight, indication), the Pharmacogenetics Unit of the University Hospital La Paz will indicate the dose to be administered based on the therapeutic individualization protocol guided by pharmacogenetics.
62346226|NCT04238884|ACTIVE_COMPARATOR|Control group|No information will be provided and procedure will be carried out according to normal clinical practice, with clinical monitoring by the doctor in charge.
62346227|NCT01926847|EXPERIMENTAL|Riociguat+Placebo|Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo
62346228|NCT01926847|EXPERIMENTAL|Placebo+Riociguat|Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521
62504165|NCT00354562|ACTIVE_COMPARATOR|A|Docetaxel + ABT-751
62504166|NCT00354562|PLACEBO_COMPARATOR|B|Docetaxel + placebo
62504167|NCT04439188|EXPERIMENTAL|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62504168|NCT04559750|EXPERIMENTAL|Internet-delivered behavior therapy (I-BT|10 weeks of (I-BT) delivered via the Internet.
62504169|NCT01454440|EXPERIMENTAL|Eptifibatide|Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure).
62504170|NCT01454440|PLACEBO_COMPARATOR|Placebo|
62504171|NCT02919111|EXPERIMENTAL|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
62504172|NCT00535028|EXPERIMENTAL|A|AER 001 s.c. once daily for 28 days
62504173|NCT00535028|PLACEBO_COMPARATOR|P|placebo s.c. once daily for 28 days
62504174|NCT06319248|ACTIVE_COMPARATOR|Standard of Care Group|
62504175|NCT06319248|EXPERIMENTAL|Standard of Care with Midodrine Group|
62504176|NCT04415437||healthy|Healthy participants
61958024|NCT03298165|EXPERIMENTAL|disinfection the cavity with diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
61958025|NCT03298165|PLACEBO_COMPARATOR|no cavity disinfection|placebo is used as no cavity disinfection will be done as after excavation the restoration will be placed .
61958026|NCT05636059|EXPERIMENTAL|Exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
61958027|NCT05636059|EXPERIMENTAL|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
61958028|NCT05636059|EXPERIMENTAL|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
61958029|NCT00444912|EXPERIMENTAL|G-CSF plus plerixafor|Participants with CD20- lymphoma
61958030|NCT00444912|EXPERIMENTAL|G-CSF plus plerixafor and rituximab|Participants with CD20+ lymphoma
61958031|NCT05690373|EXPERIMENTAL|Probiotic|2B Colony Forming Unit/ day
61958032|NCT05690373|PLACEBO_COMPARATOR|Placebo|Equivalent placebo
61958033|NCT06111820|EXPERIMENTAL|iACT service users|All participants enrolled in the programme will participate in the iACT service referring to the aforementioned details.
62346229|NCT01204541||AMD|
62504177|NCT04415437||mentally ill|Participants with mental disorders
61958034|NCT01620671|ACTIVE_COMPARATOR|Conventional surgery|The patients who will have a conventional surgical treatment will be included.
61958035|NCT01620671|ACTIVE_COMPARATOR|Fast-track surgery|The patients who will have fast-track surgery will be included.
61958036|NCT02740881|EXPERIMENTAL|Training Support System|Participants receive training in Contingency Management and immediately receive the full training support system and quality assurance feedback for 15 months while they provide the treatment.
61958037|NCT02740881|ACTIVE_COMPARATOR|CM-CAT then TSS|Participants are trained in Contingency Management and use the treatment without training support and quality assurance feedback for 9 months. After 9 months they continue using Contingency Management but now receive the full training support system and quality assurance feedback for 6 months.
61958038|NCT02217267|PLACEBO_COMPARATOR|Placebo group|Normal Saline 50 ml intravenous infusion in 1 hour once a week 4 times
61958039|NCT02217267|ACTIVE_COMPARATOR|Lidocaine group|Lidocaine 3mg/kg in Normal Saline to 50 ml intravenous infusion in 1 hour once a week 4 times
61958040|NCT04848597|EXPERIMENTAL|Single Arm|Recombinant humanized anti-PD-1 monoclonal antibody injection:200mg once every 3 weeks
61958041|NCT00376727|EXPERIMENTAL|Phase I dose escalation study|
61958042|NCT03167190|OTHER|Control|Traditional landmark-based lumbar puncture technique by palpation
61958043|NCT03167190|EXPERIMENTAL|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
61958044|NCT02862444||intervention group|Culturally Appropriate Intervention
61958045|NCT06024590|ACTIVE_COMPARATOR|Group A: irrigation with Irrisept™|Group A: standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.
62142984|NCT05950607|EXPERIMENTAL|TRAIN AD 2.0|Nursing homes randomized to the experimental arm will emply a multicomponent intervention among their providers designed to improve the management of suspected infections in residents with dementia. The components include: a.Orientation sessions for providers, b.On-line case based course for providers, c.Infection management algorithms for providers, d. Guidelines for providers to communicate with proxies, and e. Education booklet about infections in dementia for providers.
62346230|NCT01204541||Young normals|
62504178|NCT04415437||physically ill|Participants with organic disease
61958046|NCT06024590|ACTIVE_COMPARATOR|Group B: irrigation or irrigation with normal saline|Group B: standard of care wound treatment with 150 mL ration of normal saline irrigation of the wound at each follow up visit.
61958047|NCT00709930|ACTIVE_COMPARATOR|1,Exposed to ELF-EMF|Device: Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF
62346231|NCT01204541||Older normals|
61958048|NCT00709930|PLACEBO_COMPARATOR|2,Placebo|Device: Placebo device with no magnetic fields
61958049|NCT02460627|EXPERIMENTAL|Lidocaine adhesive tape|
61958050|NCT02460627|PLACEBO_COMPARATOR|Adhesive tape|
61958051|NCT03715881|ACTIVE_COMPARATOR|Oral prednisolone administration|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
61958052|NCT03715881|ACTIVE_COMPARATOR|Intravenous Erythropoietin injection|2. 1000 units of erythropoietin every 12 hours for three days
61958053|NCT03148132|ACTIVE_COMPARATOR|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
61958054|NCT03148132|EXPERIMENTAL|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
62142985|NCT05950607|ACTIVE_COMPARATOR|Usual Care|Nursing homes randomized to the conrol arm will employ usual care to manage nursing home residents with dementia with suspected infections.
62346232|NCT02567214|EXPERIMENTAL|Ultibro® versus sham Spiriva®|"Indacaterol 110 µg/Glycopyrronium 50 µg Inhaled~1 time per day 21 days"
62346233|NCT02567214|EXPERIMENTAL|Sham Ultibro® versus Spiriva®|"Tiotropium 18 µg Inhaled~1 time per day 21 days"
62346234|NCT05674201||Group DP|"Propofol (Dexmedetomidine (Sedadomide 200 µg/2 ml, KOÇAK FARMA Turkey)~1mcg/kg bolus was administered to Group DP in 10 minutes, then 0.2-1.4 mcg/kg/hour infusion dose was started.-®Lipuro 1%(10 mg/ml), B. Braun Indonesia ) 1mg/kg bolus was administered."
62346235|NCT05674201||Group RP|Propofol (Propofol-®Lipuro 1%(10 mg/ml), B. Braun Indonesia ) 1mg/kg bolus was administered, After a 0.25mcg/kg bolus of Remifentanil (Ultiva®, GlaxoSmithKline, Belgium) was administered to Group RP, a 0.025-0.1mcg/kg/minute infusion dose was started.
62504179|NCT04415437||mentally and physically ill|Participants with mental disorders and organic disease
62504180|NCT02223468||CASE-CONTROL|CASE: Liver transplant recipients (n=20) CONTROL: A healthy person with a similar age (±10 years) to the control selected from the same family setting (n=20)
61958055|NCT03198247|ACTIVE_COMPARATOR|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
61958056|NCT03198247|EXPERIMENTAL|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
61958057|NCT04950998|OTHER|Target Users - Moving Up-A app|In this single-arm trial, target users (participants) will use a physical activity smartphone app for a two-month period. The app includes motivational messages, tips to increase the intensity level of everyday activities, and strategies to reduce sedentary behaviors. Users can also track their physical activity levels and sedentary activity.
61958058|NCT04950998|OTHER|Study Partners - Moving Up-A app|In this single-arm trial, study partners were invited to support target users (participants) in using a physical activity smartphone app for a two-month period. The app includes motivational messages, tips to increase the intensity level of everyday activities, and strategies to reduce sedentary behaviors. Users can also track their physical activity levels and sedentary activity.
61958059|NCT00160290|EXPERIMENTAL|A|Lactulose Group
61958060|NCT00160290|ACTIVE_COMPARATOR|B|Plantago Group
61958061|NCT02179242|NO_INTERVENTION|Control arm|This arm will receive routine care following their heart failure which includes no cardiac rehab intervention.
61958062|NCT02179242|EXPERIMENTAL|Cardiac rehab|This arm will receive cardiac rehab intervention 3 times per week for 4 weeks following discharge.
61958063|NCT01849198|OTHER|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
61958064|NCT01849198|OTHER|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
61958065|NCT04475991|ACTIVE_COMPARATOR|Currently used therapy (CT) only|"Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present."
61958066|NCT04475991|EXPERIMENTAL|Maraviroc+CT|"Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
61958067|NCT04475991|EXPERIMENTAL|Favipiravir+CT|"Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
61958068|NCT04475991|EXPERIMENTAL|Maraviroc+Favipiravir+CT|"Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients"
61958069|NCT05683964|EXPERIMENTAL|Androgen Receptor Antagonist Monotherapy|"* Participants will receive pre-determined doses of apalutamide, darolutamide, or enzalutamide per standard care.~* Participants will undergo Prostate-Specific Membrane Antigen (PSMA) PET/CT scans at weeks 1 and 4."
61958070|NCT01394432|ACTIVE_COMPARATOR|Group 1 (PCI+SC implantation)|Endocardial Stem cells implantation with Noga system
61958071|NCT01394432|PLACEBO_COMPARATOR|Group 2 (PCI+Placebo)|Placebo
62142986|NCT03040856|EXPERIMENTAL|Alpha Linolenic Acid enriched diet|Enriched diet with 2 capsules of ALA supplementation a day - 630 mg in each capsule. Total amount of 1260 mg (Daily recommended dose is 1-2 g).
61958072|NCT02927730||positive retainted placenta histology|base on chorionic villi in the pathalogic sample
61958073|NCT02927730||negative retainted placenta histology|
61958074|NCT01600638|EXPERIMENTAL|Zeltiq System Treatment Group|Individuals with sharp flank curvatures were treated on one (1) flank with the Zeltiq CoolSculpting System and the CoolCurve+ applicator at protocol-defined temperatures and durations.
62346236|NCT01667393|EXPERIMENTAL|IDEV SUPERA Stent|Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.
62346237|NCT01667393|ACTIVE_COMPARATOR|Percutaneous Transluminal Angioplasty|The target lesion will be treated by PTA alone.
61958075|NCT02235909|EXPERIMENTAL|Double-blind: Azilsartan Medoxomil - Low dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil Low-dose (AZM-L), 10 mg once daily.
61958076|NCT02235909|ACTIVE_COMPARATOR|Double blind phase: Losartan|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Starting at Losartan 25/50 and force titrated to 50/100 mg daily at Week 2.
61958077|NCT02235909|ACTIVE_COMPARATOR|WITHDRAWAL Phase: Azilsartan medoxomil LOW-dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil low dose) that was taken in Double blind OR to be switched to placebo.
61958078|NCT02235909|PLACEBO_COMPARATOR|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil LOW DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil LOW dose) in Double blind then randomized (1:1) to placebo for withdrawal phase
61958079|NCT02235909|EXPERIMENTAL|Open Label Phase: Azilsartan Medoxomil|Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects \<50 kg or up to 80 mg for subjects ≥50 kg)
61958080|NCT02235909|OTHER|"Open Label Phase: Other"|If add-on therapy is needed, a calcium channel blocker, such as amlodipine; a diuretic, such as hydrochlorothiazide; or a beta-blocker such as metoprolol will be determined per the investigator's clinical judgment.
61958081|NCT02235909|ACTIVE_COMPARATOR|Withdrawal Phase: Losartan 50 mg|Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
62346238|NCT02767453|ACTIVE_COMPARATOR|TSA with drain placement|Hemovac drains are placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
62142987|NCT03040856|EXPERIMENTAL|Omega 3 enriched diet ( DHA+EPA)|Enriched diet with 2 capsules of DHA+EPA supplementation a day (Each capsule consist of 240 mg DHA and 360 mg EPA).
62142988|NCT03040856|PLACEBO_COMPARATOR|Placebo|Control group - Will receive 2 placebo capsule a day - containing olive oil
62346239|NCT02767453|ACTIVE_COMPARATOR|TSA without drain placement|Hemovac drains will not be placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
61958082|NCT02235909|PLACEBO_COMPARATOR|Withdrawal Phase: PLACEBO to Losartan|Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
61958083|NCT02235909|EXPERIMENTAL|Double-blind: Azilsartan Medoxomil - Medium dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase), Azilsartan medoxomil Medium-dose (AZM-M), 20 mg once daily at Week 2.
61958084|NCT02235909|EXPERIMENTAL|Double-blind: Azilsartan Medoxomil - High dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil High-dose (AZM-H), 40 mg AZM-M
61958085|NCT02235909|EXPERIMENTAL|WITHDRAWAL Azilsartan Medoxomil - Medium dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil MEDIUM dose) that was taken in Double blind OR to be switched to placebo.
61958086|NCT02235909|EXPERIMENTAL|WITHDRAWAL Azilsartan Medoxomil - High dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil HIGH dose) that was taken in Double blind OR to be switched to placebo.
61958087|NCT02235909|EXPERIMENTAL|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil MEDIUM DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil MEDIUM dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
62702772|NCT06700044|ACTIVE_COMPARATOR|High-risk probiotic|50 pregnant women with high risk of developing PE will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until partus.
62702773|NCT06700044|PLACEBO_COMPARATOR|High-risk placebo|50 pregnant women with high risk of developing PE will take one stick/placebo per day from gestational week 12 until partus.
62142989|NCT06509204|EXPERIMENTAL|Consumer|"AQP Pharmaceuticals, Inc. (Company) developed a powdered supplement sachet that can be added to meals targeting consumers who follow carbohydrate-heavy Asian diets. The product is formulated with the patented ingredient, Reducose®, a natural water extract of novel White Mulberry Leaf that has been scientifically proven to reduce the absorption of sugars and other carbs by up to 40%. The effects have been confirmed previously via Randomized, Double-Blind, Controlled Trials.~The Company is looking to conduct a real-world study of blood glucose responses to JBA GlucoTrojan (see specifications here) with a 5% concentration of Reducose®. The study will observe the real-world efficacy of GlucoTrojan when taken with high carbohydrate meals."
62346240|NCT06033846|EXPERIMENTAL|Experimental: Treatment group|Drug: Minocyclin 200 mg oral minocycline for a total of 30 days
62702774|NCT06700044|ACTIVE_COMPARATOR|Low-risk probiotic|25 pregnant women with low risk of developing PE will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until partus.
62702775|NCT06700044|PLACEBO_COMPARATOR|Low-risk placebo|25 pregnant women with low risk of developing PE will take one stick/placebo per day from gestational week 12 until partus.
62346241|NCT06033846|NO_INTERVENTION|Control group|first/second-line drugs for autoimmune encephalitis
62702776|NCT06750523|EXPERIMENTAL|Mother and infants at term of physiologically gestation (<37 weeks)|Assessment of bone mineral density (BMD) of the femur in the mother and fetus at term gestational age, and subsequently in the newborns at 48 hours after birth, at 1 month, at 3 months, at 6 months, and at 12 months of life, using REMS technology.
62702777|NCT06566820|EXPERIMENTAL|AD109|Open Label AD109
61958088|NCT02235909|EXPERIMENTAL|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil HIGH DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil HIGH dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
61958089|NCT00459628|ACTIVE_COMPARATOR|Conventional radiotherapy|Conventional Long schedule Radiotherapy Arm
62346242|NCT00565058|EXPERIMENTAL|Pilot|Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group, addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.
62346243|NCT00565058|EXPERIMENTAL|Phase II arm|Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group, GTI-2040 is given 24 hours prior to addition of HiDAC.
61958090|NCT00459628|EXPERIMENTAL|Tomotherapy|Short course schedule by tomotherapy
62346244|NCT05339386||Initiating Therapy|PAH patients who are newly initiating background therapy to treat pulmonary arterial hypertension.
62346245|NCT05339386||Stable|PAH patients who are stable on therapy (On stable doses of background PAH therapy and diuretics for at least 90 days prior to screening).
62702778|NCT02839161|EXPERIMENTAL|Low-dose (0,2,4 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
62702779|NCT02839161|EXPERIMENTAL|Low-dose (0,2,6 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
62702780|NCT02839161|EXPERIMENTAL|Medium-dose (0,2,4 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
61958091|NCT03874637|EXPERIMENTAL|Treatment|Active therapy
61958092|NCT03874637|SHAM_COMPARATOR|Sham Control|Sham Control
61958093|NCT03552731||Subsequent|Patients who have been receiving chemotherapy more than once. A intervention survey will be administered.
61958094|NCT03552731||First Time|Patients who have been receiving chemotherapy first time. A intervention survey will be administered.
61958095|NCT03815942|EXPERIMENTAL|Intermediate risk prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
62142990|NCT00777894|EXPERIMENTAL|Radiation: 3-dimensional conformal radiation therapy|
62142991|NCT02430766|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Lymph Node Metastase
62714913|NCT06148818|EXPERIMENTAL|Myofascial|Myofascial Temporomandibular Dysfunction
62346246|NCT02858687|EXPERIMENTAL|Patients with clinical diagnosis of tonsillitis|
62346247|NCT01621724|EXPERIMENTAL|Single arm cohort study|WT1 TCR-transduced T cells
62346248|NCT05107349|OTHER|1|
62346249|NCT01026389|ACTIVE_COMPARATOR|Gadovist|Patient received contrast-enhanced MRA with Gadovist
62346250|NCT01026389|EXPERIMENTAL|Dotarem, interventional|Patients received contrast-enhanced MRA with Dotarem
61958096|NCT03815942|EXPERIMENTAL|Advanced metastatic prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
61958097|NCT04557878|EXPERIMENTAL|Hypertonic Dextrose Solution|
61958098|NCT04557878|ACTIVE_COMPARATOR|Liquid Phase Concentrated Growth Factor (LPCGFs)|
61958099|NCT03572764|EXPERIMENTAL|CPX-351|"* CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction~* If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3~* In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
61958100|NCT00603668|EXPERIMENTAL|milatuzumab|different doses of hLL1
61958101|NCT01974804||Pts having an MRI|Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations \[1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment\] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
61958102|NCT00701675|EXPERIMENTAL|Sertraline 50mg|sertraline 50 mg daily
61958103|NCT00701675|EXPERIMENTAL|Sertraline 100mg|sertraline 100mg daily
61958104|NCT00701675|PLACEBO_COMPARATOR|Placebo|placebo 50 or 100mg
62142992|NCT02430766|NO_INTERVENTION|Control|The patients without treatment
62504181|NCT03806335|EXPERIMENTAL|Infiltration|Patients will receive pre-incision infiltration of 2.5 ml local anesthesia mixture in each tonsil.
62504182|NCT03806335|PLACEBO_COMPARATOR|Placebo|Patients will receive pre-incision infiltration of 2.5 ml saline in each tonsil.
62504183|NCT03558139|EXPERIMENTAL|Magrolimab 30 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in)|"Participants with solid tumors will be treated with starting priming dose of 1 mg/kg of body weight magrolimab IV infusion (over 3 hours) on Day 1 of Cycle 1 followed by maintenance dose of 30 mg/kg of body weight magrolimab IV infusion (over 2 hours) on Days 8, 15, 22, and 29 of Cycle 1 and Days 1 and 15 of Cycle 2 and subsequent cycles, in combination with 800 mg avelumab IV infusion (over 1 hour) on Days 8 and 22 of Cycle 1 and Days 1 and 15 of Cycle 2 and subsequent cycles.~Cycle 1 will consist of 35 days and Cycle 2 and subsequent cycle will consist of 28 days. Avelumab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until confirmed tumor progression, unacceptable toxicity, clinically significant change in the participant's status that precluded further treatment, voluntary withdrawal, or physician decision."
62702781|NCT02839161|EXPERIMENTAL|Medium-dose (0,2,6 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
62702782|NCT02839161|EXPERIMENTAL|High-dose (0,2,4 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
62702783|NCT02839161|EXPERIMENTAL|High-dose (0,2,6 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
62142993|NCT04192357|EXPERIMENTAL|WLM3P|Participants will receive the M3F program. The M3F program is divided into three phases, being the first two of weight loss and the third phase of weight maintenance.
62142994|NCT04192357|ACTIVE_COMPARATOR|Low-carb diet|Participants will receive the low-carb diet program. The low-carb diet program is divided into two phases, being the first of weight loss which follows a low carb diet, and a second phase of weight maintenance.
62142995|NCT01023542|ACTIVE_COMPARATOR|1|Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low level cyclosporine \[start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)\] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.
62142996|NCT01023542|ACTIVE_COMPARATOR|2|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).
62142997|NCT01023542|EXPERIMENTAL|3|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).
62142998|NCT05977985|EXPERIMENTAL|Dextrose 5%|Rotator interval hydro-dissection with dextrose 5% solution
62142999|NCT05977985|ACTIVE_COMPARATOR|Corticosteroid|Rotator interval hydro-dissection with corticosteroid solution
62143000|NCT03428438|OTHER|Study group SMS to home phone|A physical reminder by a physiotherapist, and a daily reminder of physical exercise by SMS on weekdays A through E.
62143001|NCT03428438|OTHER|Controlled group hospital based|Physical rehabilitation in the ward physiotherapist
62143002|NCT01595451|ACTIVE_COMPARATOR|Traditional Acupuncture|Acupuncture will be delivered to 12 points traditionally used to treat chronic low back pain.
62143003|NCT01595451|PLACEBO_COMPARATOR|Non-traditional Acupuncture|You will receive non-traditional acupuncture at 12 points for chronic low back pain.
62143004|NCT03090711|EXPERIMENTAL|TMS|Real transcranial magnetic stimulation (TMS).
62702784|NCT02839161|ACTIVE_COMPARATOR|Comparator (0,2,4 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.
61958105|NCT02197247|EXPERIMENTAL|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
62143005|NCT03090711|SHAM_COMPARATOR|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
61958106|NCT03435484|ACTIVE_COMPARATOR|Arm A|Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
61958107|NCT03435484|ACTIVE_COMPARATOR|Arm B|Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
61958108|NCT01256801||cytokine|The patients are randomized to receive the cytokine infusion in the pleural cavity
62504184|NCT03558139|EXPERIMENTAL|Magrolimab 45 mg/kg + Avelumab 800 mg (Part 1, Safety Run-in)|"Participants with solid tumors will be treated with starting priming dose of 1 mg/kg of body weight magrolimab IV infusion (over 3 hours) on Day 1 of Cycle 1 followed by maintenance dose of 45 mg/kg of body weight magrolimab IV infusion (over 2 hours) on Days 8, 11, 15, 22, and 29 of Cycle 1; Days 1, 8, 15 and 22 of Cycle 2 and Days 1 and 15 of subsequent cycles, in combination with 800 mg avelumab IV infusion (over 1 hour) on Days 8 and 22 of Cycle 1 and Days 1 and 15 of Cycle 2 and subsequent cycles.~Cycle 1 will consist of 35 days and Cycle 2 and subsequent cycle will consist of 28 days. Avelumab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until confirmed tumor progression, unacceptable toxicity, clinically significant change in the participant's status that precluded further treatment, voluntary withdrawal, or physician decision."
62504185|NCT03558139|EXPERIMENTAL|Magrolimab 45 mg/kg + Avelumab 800 mg (Part 2, Ovarian Cancer Expansion)|"Participants with checkpoint inhibitor-naïve ovarian cancer will be treated with starting priming dose of 1 mg/kg of body weight magrolimab IV infusion (over 3 hours) on Day 1 of Cycle 1 followed by maintenance dose of 45 mg/kg of body weight magrolimab IV infusion (over 2 hours) on Days 8, 11, 15, 22, and 29 of Cycle 1; Days 1, 8, 15 and 22 of Cycle 2 and Days 1 and 15 of subsequent cycles, in combination with 800 mg avelumab IV infusion (over 1 hour) on Days 8 and 22 of Cycle 1 and Days 1 and 15 of Cycle 2 and subsequent cycles.~Cycle 1 will consist of 35 days and Cycle 2 and subsequent cycle will consist of 28 days. Avelumab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until confirmed tumor progression, unacceptable toxicity, clinically significant change in the participant's status that precluded further treatment, voluntary withdrawal, or physician decision."
62504186|NCT04701424|EXPERIMENTAL|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 8 weeks~The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data"
62504187|NCT04701424|ACTIVE_COMPARATOR|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 8 week study period. Participants will be wear a masked continuous glucose monitoring (CGM) system during the 8 week study period
62504188|NCT02240186|EXPERIMENTAL|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
62504189|NCT02758548|OTHER|Capillary Blood Sampling|Capillary blood sampling, collected as two fingerprick samples with POCT device and two venous samples
62504190|NCT05139758|EXPERIMENTAL|hemiplegic cp|it will be classified into two subgroups according to body mass index to underweight and healthy weight .
62504191|NCT05139758|EXPERIMENTAL|diplegic cp|it will be classified into two subgroups according to body mass index to underweight and healthy weight .
62504192|NCT01985464|EXPERIMENTAL|Umbilical cord mesenchymal stem cells|
62504193|NCT06494098|EXPERIMENTAL|NAM group|
61958109|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
61958110|NCT02788812|ACTIVE_COMPARATOR|Open modified Lichtenstein repair|
61958111|NCT02788812|ACTIVE_COMPARATOR|Laparoscopic TAPP inguinal hernia repair|
61958112|NCT04455113||Normo-phosphatemia|238 patients included in this group. Phosphorus level \>2.5 mg/dl
61958113|NCT04455113||Hypophosphatemia|79 patients included in this group. Phosphorus level \<2.5 mg/dl
62143006|NCT03090711|EXPERIMENTAL|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
62504194|NCT06494098|EXPERIMENTAL|MNAM|
62504195|NCT05623852|EXPERIMENTAL|Arm A: Fucoidan arm|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
62504196|NCT05623852|NO_INTERVENTION|Arm B, Observational arm|observation
62702785|NCT02839161|ACTIVE_COMPARATOR|Comparator (0,2,6 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.
62714914|NCT06148818|EXPERIMENTAL|disc displacement with reduction|Temporomandibular joint disc displacement with reduction
62714915|NCT06148818|EXPERIMENTAL|disc displacement without reduction|Temporomandibular joint disc displacement without reduction
62714916|NCT06148818|OTHER|Myofascial2|Myofascial Temporomandibular Dysfunction
61958114|NCT03704467|EXPERIMENTAL|Part A: Carboplatin + M6620 + Avelumab|
61958115|NCT03663998|ACTIVE_COMPARATOR|A|CN54ENV IM EP 400 g
61958116|NCT03663998|ACTIVE_COMPARATOR|B|CN54ENV IM EP 1000 g
61958117|NCT03663998|ACTIVE_COMPARATOR|C|CN54ENV IM EP 4000 g
61958118|NCT03663998|ACTIVE_COMPARATOR|D|CN54ENV ID EP 600 g
61958119|NCT03663998|ACTIVE_COMPARATOR|E|CN54ENV ID EP 1200 g
61958120|NCT03663998|ACTIVE_COMPARATOR|F|CN54ENV ID EP 1800 g
61958121|NCT03663998|ACTIVE_COMPARATOR|G|"CN54ENV IM1 EP~+ pIL-12 (500 g)"
61958122|NCT03663998|ACTIVE_COMPARATOR|H|"CN54ENV IM1 EP~+ pIL-12 (1500 g)"
61958123|NCT03663998|ACTIVE_COMPARATOR|I|"CN54ENV IM1 EP~+ ID2 EP"
61958124|NCT04600128|ACTIVE_COMPARATOR|Dairy-based Greek yogurt|Plain dairy-based Greek yogurt
61958125|NCT04600128|ACTIVE_COMPARATOR|Dairy-based cheddar cheese|Mild dairy-based cheddar cheese
61958126|NCT04600128|ACTIVE_COMPARATOR|Plant-based Greek yogurt|Plain plant-based Greek yogurt
61958127|NCT04600128|ACTIVE_COMPARATOR|Plant-based cheese|Medium cheddar plant-based cheese
61958128|NCT00332007|EXPERIMENTAL|1|Tonabersat 40 mg daily
62702786|NCT06750146|EXPERIMENTAL|Hot AXIOS™ Recipients|The Hot AXIOS™ Stent is a flexible, fully covered self-expanding metal stent that is preloaded within the Electrocautery Enhanced Delivery System. Patients who meet all eligibility criteria will receive the Hot AXIOS™stent and their quality of life will be measured at baseline, two weeks after stent placement and two months after stent placement by the jaundice dimension of the EORTC QLQ-BIL21 questionnaire. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study.
62702787|NCT06749769|NO_INTERVENTION|Control group|Patients in the control group will receive routine verbal instructions and demonstration education about their stoma care.
61958129|NCT00332007|PLACEBO_COMPARATOR|2|
61958130|NCT02046161|EXPERIMENTAL|colon cleansing room group|All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
61958131|NCT02046161|PLACEBO_COMPARATOR|standard colon preparation group|All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.
61958132|NCT00727493|ACTIVE_COMPARATOR|1|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
61958133|NCT00727493|PLACEBO_COMPARATOR|2|placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
62143007|NCT03090711|SHAM_COMPARATOR|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
62143008|NCT01030237|EXPERIMENTAL|FID 114657|FID 114657
62143009|NCT01030237|ACTIVE_COMPARATOR|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
62346251|NCT02271867|ACTIVE_COMPARATOR|Levobupivacaine 0,5%|Levobupivacaine 0,5% 15 ml once
62346252|NCT02271867|ACTIVE_COMPARATOR|Levobupivacaine 0,5% with epinephrine|Levobupivacaine 0,5% with 1/200000 epinephrine 15 ml once
62346253|NCT02271867|ACTIVE_COMPARATOR|Ropivacaine 0,75%|Ropivacaine 0,75% 15 ml once
62346254|NCT05224154|EXPERIMENTAL|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).
62346255|NCT05224154|ACTIVE_COMPARATOR|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
62346256|NCT01471860|EXPERIMENTAL|Device and Medical Management|"Medical Management, to be determined by the participant's physician, described as:~* Optimal pharmacological therapy: Prescribed to a beta blocker, a diuretic, and an ACE (Angiotensin-converting-enzyme) inhibitor or ARB (Angiotensin Receptor Blocker) unless contraindicated or not tolerated. These drugs must be used in a manner consistent with their labeling.~* Stable pharmacological therapy: No more than a 50% increase or a 50% decrease of the dosage of any one medication, and post titration of all heart failure medications.~Participants should remain on their prescribed heart failure medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. Additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study."
62702788|NCT06749769|EXPERIMENTAL|Study Group|Participants in this group will receive a simulation-based stoma care education.
62702789|NCT06750796|OTHER|Control group|The group that will not be treated with half swaddling
62702790|NCT06630650||COLQ-related CMS|Genetically confirmed COLQ-related CMS
62702791|NCT06750614|ACTIVE_COMPARATOR|Mood|During concurrent iTBS/fNIRS, stimuli with positive and negative valence will be presented to participants to induce the corresponding mood.
62702792|NCT06750614|ACTIVE_COMPARATOR|Cognitive Task|During concurrent iTBS/fNIRS, the effects of participants' cognitive load will be assessed by performing the backward counting task.
62702793|NCT06750614|ACTIVE_COMPARATOR|Relax|During concurrent iTBS/fNIRS, participants will be instructed to relax.
62702794|NCT06749795|EXPERIMENTAL|LIV001|LIV001 will be given orally and daily from baseline until end of study
62143010|NCT06140550|EXPERIMENTAL|Experimental group|
62143011|NCT06140550|EXPERIMENTAL|Control group|
62143012|NCT02795884|EXPERIMENTAL|Intercalation arm|"* Intercalation phase (Duration: 3wks x 4 cycles = 12 wks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Erlotinib 150mg D8-21 q3wks~* Maintenance phase (Duration: 1 year) Erlotinib 150mg D1-28"
62346257|NCT00280150|EXPERIMENTAL|Cohort 1|Bevacizumab 10 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
62346258|NCT00280150|EXPERIMENTAL|Cohort 2|Bevacizumab 10 mg + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
62702795|NCT06749795|PLACEBO_COMPARATOR|Placebo|Placebo will be given orally and daily from baseline until end of study
62702796|NCT06751095|EXPERIMENTAL|Maitland's Mobilization in End Range|End-range mobilization will be performed individually in flexion and extension end range of the tibiofemoral joint(0-135 degree).
62702797|NCT06751095|EXPERIMENTAL|Maitland's Mobilization in Mid Range|Mid range Maitland's mobilization will be performed in (approx. 50-70° knee flexion) of the tibiofemoral joint.
62143013|NCT02795884|ACTIVE_COMPARATOR|Chemotherapy alone arm|Duration: 3wks x 4 cycles = 12 wks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3wks
62143014|NCT01513616|EXPERIMENTAL|Pulmonary rehabilitation|A supervised 8-wk outpatient pulmonary rehabilitation program consisting of multi-modality exercise training and COPD self-management education.
62346259|NCT00280150|EXPERIMENTAL|Cohort 3|Bevacizumab + Erlotinib 150 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
62346260|NCT00280150|EXPERIMENTAL|Phase II|Bevacizumab + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
62346261|NCT01701219|OTHER|Cohort A|S. aureus on at least 1 blood culture within 72 hours of beginning study drug
62346262|NCT01701219|OTHER|Cohort B|MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment
62702798|NCT06694948|OTHER|pimicotinib (test capsule-reference capsule)|subjects in sequence A will receive a single oral dose of 50 mg test capsule administered as 2 x 25 mg (the capsule is commercial formulation to be marketed) in period 1 day 1 and receive a single oral dose of 50 mg reference capsule administered as 2 x 25 mg (the capsule was used in phase 3 study Part 1) in period 2 day 1.
62702799|NCT06694948|OTHER|pimicotinib (reference capsule-test capsule)|subjects in sequence B will receive a single oral dose of 50 mg reference capsule administered as 2 x 25 mg (the capsule was used in phase 3 study Part 1) in period 1 day 1 and receive a single oral dose of 50 mg test capsule administered as 2 x 25 mg (the capsule is commercial formulation to be marketed) in period 2 day 1 .
62702800|NCT06751069|EXPERIMENTAL|Home-based Pulmonary Rehabilitation with Health Coaching Group|Twelve-week intervention with home-based pulmonary rehabilitation and health coaching.
62702801|NCT06751069|NO_INTERVENTION|Non-use Waitlist Control Observation Group|12-week non-use usual care waitlist with transition to intervention group at the end of the observation period.
62702802|NCT06748469||patients with lumbosacral radicular pain|patients with lumbosacral radicular pain resistant to conservative treatments
62702803|NCT05645172||Cohort 1|adult CLL patients (≥ 18 years of age) newly prescribed with acalabrutinib according to clinical routine will be included independent of the patient age, disease stage, existence of genetic risk factors, comorbidities, therapy line, and of the application as combination therapy with obinutuzumab or as monotherapy.
61958134|NCT00727493|NO_INTERVENTION|3|dental implant, calcium 1000mg and Vitamin D 800 IU daily
61958135|NCT06259721|EXPERIMENTAL|Combination Treatment|
62346263|NCT01830296|ACTIVE_COMPARATOR|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
62702804|NCT06748872|EXPERIMENTAL|Administration of MDG1015|MDG1015 is a first-in-class, 3rd generation TCR-T therapy consisting of autologous, patient-derived CD8+ T cells that are transduced with a New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/ L antigen family member-1a (LAGE-1a)-specific, human leukocyte antigen (HLA)-A\*02:01-restricted T cell receptor (TCR) and the costimulatory switch protein (CSP) programmed cell death protein 1 (PD1)-41BB administered following lymphodepletion chemotherapy.
62702805|NCT06750367|EXPERIMENTAL|Klapp method exercises|Four pointwalk followedby twopointwalk\&backwalk: This exercise is basic, it is a mobility exercise and always applied at the beginning of the program. Breathing exercise from a kneeling position: (raising hands with inhalation lowering hands with exhalation). Simple bounce glide with simultaneous breathing: (a stretching,strengthening and corrective exercises) Bunny hop: (for stretching and strengthening). Greeting: (Stretching and mobilization of thalamus)
62702806|NCT06750367|ACTIVE_COMPARATOR|At-Home exercises program|The researcher will prescribe stretching of neck, upper limb and thoracic region of participants as a baseline treatment. The control group will continue with their normal activities and pain relief methods. Additionally, they will be given printed information on an at-home exercise program, such corrective exercises (Chin tuck, stretching of neck extensor muscles and pectoral muscle groups in standing and supine positions) (16), posture correction exercises (This exercise program consisted of 2 strengthening (of the deep cervical flexors and shoulder retractors), and breathing exercises (Deep breathing is an exercise that can regulate breathing patterns and improve posture. The deep breathing that is done repeatedly can overcome stiffness in the thoracic cage and straighten the curve of thoracic kyphosis).They will be asked to perform the period of 1-month twice in a week for 50 min with10 repetitions of each exercise
62702807|NCT06750640||HC group|There were 40 healthy control participants in the HC group.
62702808|NCT06750640||MDD group|There were 60 MDD patients in the MDD group. 26 MDD subjects were detected by 2 investigators and 2 investigators both made 2 independent measurements in a week. 30 MDD subjects were detected the bilateral same name acupoint temperatures.
62346264|NCT01830296|ACTIVE_COMPARATOR|IV morphine PCA|IV remifentanil+morphine PCA
62346265|NCT05193981||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
62702809|NCT03777657|EXPERIMENTAL|Tislelizumab (BGB-A317) + chemotherapy|Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
62702810|NCT03777657|PLACEBO_COMPARATOR|Placebo + chemotherapy|Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
62702811|NCT06694454|EXPERIMENTAL|1/ Phase I Dose Escalation|Histology specific SOC platinum-based chemotherapy with durvalumab plus escalating/de-escalating doses of aerosolized azacytidine
62702812|NCT06694454|EXPERIMENTAL|2/ Phase II Dose Expansion|Histology specific SOC platinum-based chemotherapy with durvalumab plus RP2D of aerosolized azacytidine
62702813|NCT06124664||Symptomatic pelvic varicose veins (PVV)|40 patients will include patients with symptomatic PVV (pelvic pain, dyspareunia, heaviness in the hypogastrium) and without symptoms and signs of CVD.
62702814|NCT06124664||Asymptomatic PVV|40 pdtients will consist of women with asymptomatic PVV with signs of CVD.
61958136|NCT00603616|PLACEBO_COMPARATOR|1|Placebo pills
61958137|NCT00603616|ACTIVE_COMPARATOR|2|Rifaximin
61958138|NCT02439138|EXPERIMENTAL|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
61958139|NCT03630861||GBM|Primary glioblastoma (GBM)
61958140|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
61958141|NCT03630861||Brain metastases|Brain metastases (BM)
61958142|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
61958143|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
61958144|NCT00530244|EXPERIMENTAL|1|Infants will be fed formula supplemented with docosahexaenoic acid
61958145|NCT00530244|PLACEBO_COMPARATOR|2|Infants will be fed standard formula (Enfamil)
62143015|NCT01513616|SHAM_COMPARATOR|Usual care control|An 8-wk control period consisting of usual medical care which included optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education.
62143016|NCT05190172|EXPERIMENTAL|Radiation therapy with protons|Radiation therapy with protons at The Skandion Clinic, Uppsala, Sweden
61958146|NCT02971397|EXPERIMENTAL|Treatment (cytarabine, daunorubicin hydrochloride, biopsy)|"INDUCTION: Patients receive cytarabine IV continuously over 24 hours on days 1-7 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 14. Patients with bone marrow cellularity \>= 10% and \> 5% leukemic blasts, may receive a second induction of cytarabine IV continuously over 24 hours on days 1-5 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving remission receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with CBF AML may receive 4 courses of therapy."
62702815|NCT06124664||varicose veins of the lower limb|10 patients with varicose veins of the lower limb without PVV and pelvic congestion syndrome (PCS)
62702816|NCT04014348||Female|Diagnostic
62702817|NCT04743973|EXPERIMENTAL|Practicing Physicians|Practicing physicians at Mayo Clinic caring for patients during the COVID 19 pandemic will receive the Muse S™ Headband system, and will be asked to utilize it at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
61958147|NCT05012332|OTHER|Erector Spinae Plane Block|All volunteers will be given the choice of procedural pain relief in the form of rapifen 0,5-1 mg. All volunteers included will receive an unilateral ESPB at the T7 level with 30 ml of 2,5 mg/ml ropivacaine and a total of 0,3 mmol gadolinium. The intervention will be performed by the PhD candidate connected to the study. The ESPB will be performed under ultrasound guidance, where the needle target is the transverse process of the Th7 vertebra, under the musculus (m.) erector spinae. All volunteers will be tested for cold and pinprick sensation 30 minutes after block completion, and the results plotted on a dermatome map before they undergo an MRI.
61958148|NCT05353283|EXPERIMENTAL|Intervention Arm|POC adherence testing by a urine tenofovir assay with motivational interviewing counselling
62702818|NCT06692192|EXPERIMENTAL|Group 1: Psilocybin and intravenous (IV) midazolam|Psilocybin (25 mg) + IV midazolam
62702819|NCT06692192|EXPERIMENTAL|Group 2: Psilocybin and IV saline|Psilocybin (25 mg) + IV saline (placebo for midazolam)
61958149|NCT05353283|NO_INTERVENTION|Standard of Care|Adherence counselling provided by the participant's PrEP care provider
61958150|NCT02664844|EXPERIMENTAL|Obese adolescent|
62346266|NCT01995279|EXPERIMENTAL|French ear acupuncture|Application of single session of French ear acupuncture at specific points used to reduce low back pain.
62346267|NCT01995279|PLACEBO_COMPARATOR|Sham Ultrasound|Sham ultrasound will be applied at lumbar spine.
62346268|NCT05150834||ChAdOx1 vaccinated group|From Febrary 25, 2021 to July 16, 2021, healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get ChAdOx1 (Oxford/AstraZeneca) (n=26) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results.
62346269|NCT05150834||BNT162b2 vaccinated group|From Febrary 25, 2021 to July 16, 2021, 53 healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get BNT162b2 (n=27) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results.
62346270|NCT01160653|EXPERIMENTAL|1|Gait training and Cognitive Training
62346271|NCT01160653|NO_INTERVENTION|2|Able Bodied
62346272|NCT02977013||Patients with pulmonary embolism treated with enoxaparin|Anti-Xa assay correlation to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
62702820|NCT06692192|EXPERIMENTAL|Group 3: Psilocybin and IV midazolam|Psilocybin (1 mg/control) + IV midazolam
62346273|NCT03300752|EXPERIMENTAL|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
62346274|NCT03300752|ACTIVE_COMPARATOR|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
62702821|NCT06692192|EXPERIMENTAL|Group 4: Psilocybin and IV saline|Psilocybin (1 mg/control) + IV saline
62702822|NCT05410145|EXPERIMENTAL|D3S-001 monotherapy|"Part 1: Dose Escalation, D3S-001 administered orally.~Part 2 and Part 3a Arm C: Dose Expansion, D3S-001 administered orally in selected cancer type patients."
62346275|NCT02215408|NO_INTERVENTION|Control|Patient received usual care from the provider in the local clinic.
62346276|NCT02215408|EXPERIMENTAL|CVRS Intervention|CVRS pharmacist followed the patient for 12 months in order to decrease the patient's risk of developing cardiovascular disease.
62346277|NCT05363709|EXPERIMENTAL|Balstilimab|Participants will receive Balstilimab by vein over about 30 minutes on Days 1 and 15 of each cycle (every 2 weeks)
62346278|NCT02028585|ACTIVE_COMPARATOR|Low-fat milk group|The low-fat milk group was instructed to consume 2 packs of low-fat milk per day (200 mL twice daily) for 6 weeks.
62346279|NCT02028585|NO_INTERVENTION|Control group|Control group maintained their usual diet without low-fat milk supplement.
62346280|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
62346281|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
62504197|NCT02958930|EXPERIMENTAL|TEMT Treatment|Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.
62702823|NCT05410145|EXPERIMENTAL|D3S-001 and pembrolizumab|"Part 3a Arm A: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.~Pembrolizumab administered intravenously."
62714917|NCT06148818|OTHER|disc displacement with reduction2|Temporomandibular joint disc displacement with reduction
62714918|NCT06148818|OTHER|disc displacement without reduction2|Temporomandibular joint disc displacement without reduction
61958151|NCT02023567|EXPERIMENTAL|MDD group|Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
61958152|NCT02023567|NO_INTERVENTION|Healthy controls|This group just receive baseline evaluation and did not receive any intervention.
61958153|NCT05758298|PLACEBO_COMPARATOR|Non-medicated gum Arm|Participants in this group will receive the non-medicated gum in mint flavor.
62504198|NCT01910337||Screening|this first day, the patient will be evaluated with polar and blood pressure monitor. These data will be the basal one.
62504199|NCT01910337||Intervation|One week later the screening, the patient underwent to the surgery to remove his lower third molar. In this day, will be analyzed 4 points: basal, after the anesthesia, after the avulsion and 20 minutes after the surgery.
62504200|NCT01910337||Post operative|One week later the surgery, the patients will be evaluated again.
61958154|NCT05758298|EXPERIMENTAL|Nicotine 2mg gum Arm|Participants in this group will receive the 2mg Nicotine gum in mint flavor.
61958155|NCT05758298|EXPERIMENTAL|Nicotine 4mg gum Arm|Participants in this group will receive the 4mg Nicotine gum in mint flavor.
62346282|NCT01764256|EXPERIMENTAL|10 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 10 μg of active ingredient.
62504201|NCT05878431|EXPERIMENTAL|Experimental groups|"patients in the experimental group during the pre-test phase; Patient Information Form, Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were administered by face-to-face interview technique. Then to the patients in the experimental group; A total of 12 sessions of foot reflexology, two sessions per week, were applied for 6 weeks. patients in the experimental group during the pos-test phase; Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were administered by face-to-face interview technique"
62504202|NCT05878431|NO_INTERVENTION|Control groups|"patients in the control group at the pre-test stage; Patient Information Form, Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were applied. with face-to-face interview technique. patients in the control group during the pos-test phase; Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were administered by face-to-face interview technique"
62504203|NCT01795235|OTHER|Saline s.c. injection and placebo tablet|Saline s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
62504204|NCT01795235|OTHER|glucagon s.c. injection and placebo tablet|1 mg glucagon s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
62504205|NCT01795235|OTHER|Saline s.c. injection and atenolol tablet|Saline s.c. injection and 100 mg atenolol tablet
62504206|NCT01795235|OTHER|glucagon s.c. injection and atenolol tablet|1 mg glucagon s.c. injection and 100 mg atenolol tablet
62504207|NCT04975347|NO_INTERVENTION|Arm 1|one period of frequent blood sampling with no medication administered
62702824|NCT05410145|EXPERIMENTAL|D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + permetrexed)|"Part 3a Arm B: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.~Cisplatin + pemetrexed administered intravenously~or~Carboplatin + permetrexed administered intravenously"
62702825|NCT05410145|EXPERIMENTAL|D3S-001 and Cetuximab|"Part 3b: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.~Cetuximab administered intravenously."
62702826|NCT06697405||CPB time ≥ 120 minutes|Patients will be grouped into a prolonged CPB group (CPB ≥120 minutes)
62702827|NCT06697405||CPB time < 120 minutes|Patients will be grouped into a normal CPB group (CPB \<120 minutes) .
61958156|NCT01603498|EXPERIMENTAL|Dexamethasone 8mg|
61958157|NCT01603498|EXPERIMENTAL|Methylprednisolone|Methylprednisolone 40mg
61958158|NCT03676010||Sarcoma and GIST|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Sarcoma and GIST
62143017|NCT05190172|ACTIVE_COMPARATOR|Radiation therapy with photons|Radiation therapy with photons at an University Hospital nearby subject's home address
62143018|NCT06261437|EXPERIMENTAL|Close Combat Assault Ration|The CCAR will be consumed as the sole nutrition source during a 7-day physically demanding military training exercise
62702828|NCT03716739|ACTIVE_COMPARATOR|Treatment Arm|Weekly IM administration of 100 mg testosterone cypionate for 12 weeks.
62702829|NCT03716739|PLACEBO_COMPARATOR|Control Arm|Weekly IM administration of placebo for 12 weeks.
62714919|NCT06709079|EXPERIMENTAL|Allergic rhinitis|Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
61958159|NCT03676010||Breast cancer|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Breast cancer
61958160|NCT03676010||Pancreatic cancer|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Pancreatic cancer
61958161|NCT03676010||Renal cell carcinoma|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Renal cell carcinoma
61958162|NCT03676010||Colon Cancer (adjuvant setting)|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Colon Cancer (adjuvant setting)
61958163|NCT03676010||Solid tumours undergoing image-guided tumor ablation|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Solid tumours undergoing image-guided tumor ablation
62143019|NCT06261437|ACTIVE_COMPARATOR|First Strike Ration|The FSR will be consumed as the sole nutrition source during a 7-day physically demanding military training exercise
61958164|NCT05173662|EXPERIMENTAL|Intervention Group|"To the mothers in this group; At least 12 hours before the heel blood collection (guthrie screening test), training was given, lasting 25 minutes, on average, through the training brochure on non-pharmacological pain management prepared by the researcher. The training was carried out in a language that the mother could understand, in the form of direct lectures and questions and answers, using the visuals in the brochure. In the training content; There are five non-pharmacological methods. These;~* Expressed breast milk~* Wrapping~* Skin-to-skin contact~* Cuddling~* They are methods of making calming sounds."
61958165|NCT05173662|NO_INTERVENTION|Control Group|In the control group, as in the clinical routine, the heel stick procedure was performed in the newborn's own bed next to his mother. No other action has been applied.
61958166|NCT05176730|EXPERIMENTAL|Patients with hemodialysis receiving mindfulness meditation|The ABC standardized version of mindfulness meditation was used. The experimental group received 30-minute mindfulness meditation sessions 3 times a week for 5 weeks (450 minutes). An additional two-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. To ensure the consistent delivery of the intervention, the researcher recorded the intervention instructions in Arabic based on the intervention protocol and sent the audio-recorded instructions to the participants via WhatsApp or email. The audio-recorded intervention contents were validated by two psychologists and experts in meditation. The recorded intervention instructions were accessed by the participants during the sessions using their cell phones and headsets, as recommended. This method allowed for up to 3-5 participants to listen to the instructions and perform the intervention simultaneously.
61958167|NCT05176730|NO_INTERVENTION|Control group|The participants in the control group were instructed to sit with their eyes closed and relaxed for 30 minutes 3 times a week for 5 weeks during hemodialysis sessions to control for the nonspecific effects of social interaction and environment. The timings of the control group sessions were similar to those of the experimental group, whereby if a given experimental group intervention lasted for 30 minutes, the control group participants would be asked to sit with their eyes closed and relax for 30 minutes also.
61958168|NCT02303366|EXPERIMENTAL|SABR + MK-3475|SABR treatment (20Gy in 1 fraction) to at least one metastases (to a maximum of 5 metastases) followed by 8 cycles of 3 weekly treatment with MK-3475 (200mg IV per dose).
62143020|NCT03789357||Single Arm|All patients admitted to the Acute Stroke Unit
62143021|NCT03136822|OTHER|Control|Standard dressing
62143022|NCT03136822|EXPERIMENTAL|Treatment|Standard dressing + Wound dressing (DERMALIX)
62143023|NCT00780806|EXPERIMENTAL|1|Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months
62346283|NCT01764256|EXPERIMENTAL|30 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 30 μg of active ingredient.
62346284|NCT01764256|EXPERIMENTAL|60 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 60 μg of active ingredient.
62346285|NCT01764256|PLACEBO_COMPARATOR|Placebo|3 doses of placebo delivered intramuscularly.
62346286|NCT01954251|EXPERIMENTAL|Co-Ad Group|The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
62346287|NCT01954251|ACTIVE_COMPARATOR|Control Group|The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
62346288|NCT01158729|EXPERIMENTAL|ATIII experimental group|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive Antithrombin (Recombinant) prior to initiation of bypass
62346289|NCT01158729|PLACEBO_COMPARATOR|Placebo Controls|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive placebo prior to initiation of bypass
62346290|NCT01458314|ACTIVE_COMPARATOR|Rehabilitation without NIV|A usual rehabilitative training will be performed in patients using nocturnal NIV, without adoption of daily NIV
62346291|NCT01458314|EXPERIMENTAL|Daily NIV during rehabilitation|Daily NIV will be adopted during the rehabilitation program in patients already using nocturnal NIV
62346292|NCT05265143|OTHER|bolus feeding group|In bolus feednig group preterm fed by via gravity drip over a short period, usually 15-20 min. it administrated 8-12 times daily
62346293|NCT05265143|OTHER|intermittant feeding group|Intermittant feeding is delivered over a 30-60 min by infusion pump. it administrated 8-12 times daily
62504208|NCT04975347|EXPERIMENTAL|Arm 2|one period of frequent blood sampling with no medication administered; one period of frequent blood sampling with IV administration of naloxone (one bolus and an infusion over an up to 12-hour period.)
62714920|NCT06087133|EXPERIMENTAL|Routine Care + StEP:Prenatal|Participants will receive routine care and up to 8 StEP:Prenatal sessions. Routine care will follow through the post-partum period.
62143024|NCT05559645|EXPERIMENTAL|Cohort 1: EGFR sensitizing mutations, T790M neg|
62346294|NCT00194025|EXPERIMENTAL|valproate|All participants received open-label, add-on valproate.
62346295|NCT04972916|OTHER|Patient Navigation-based Tobacco Harm Reduction Intervention|All participants will receive a smoking cessation educational brochure and patient navigation intervention delivered over 2 months.
62504209|NCT05053724|EXPERIMENTAL|Start to move group|In the Start to move group, physical therapy was included according to the Gosselink protocol, which establishes 6 levels of care divided according to system stability and state of consciousness. At level 0, no physical mobilization therapy was applied due to systemic lability. From level 1 to 5, passive mobilizations, use of muscle electrostimulation, active mobilizations and exercises against resistance, application of conventional cycloergometer, up to walking with assistance if the subject is able to perform it.
62714921|NCT06087133|ACTIVE_COMPARATOR|Routine Care|Participants will receive routine care during pregnancy and the post-partum period.
62714922|NCT04084041|EXPERIMENTAL|Device|Device group
62143025|NCT05559645|EXPERIMENTAL|Cohort 2: EGFR sensitizing mutations|
62143026|NCT05559645|EXPERIMENTAL|Cohort 3: EGFR uncommon mutations|
62714923|NCT04084041|ACTIVE_COMPARATOR|Conventional chest physiotherapy|Control group
61958169|NCT04946747|ACTIVE_COMPARATOR|Trained|"Both groups will be shown how to use the Virtual Reality goggles. The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.~Both groups will also wear our smart head-impact sensor system to measure their response to training."
61958170|NCT04946747|ACTIVE_COMPARATOR|Control|Both groups will be shown how to use the Virtual Reality goggles. The Control group will also receive the same CS and the same US, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge. Both groups will also wear our smart head-impact sensor system to measure their response to training.
62504210|NCT05053724|ACTIVE_COMPARATOR|Conventional treatment group|In the conventional treatment group, passive mobilization, active-assisted mobilization and exercises against resistance, facilitation of high functional positions such as sedentary, bipedal and walking were applied, according to conventional treatment protocol.
62504211|NCT05607563|EXPERIMENTAL|PM1009 120 mg monotherapy|PM1009 120 mg
62504212|NCT05607563|EXPERIMENTAL|PM1009 300 mg monotherapy|PM1009 300 mg
62346296|NCT02590887|EXPERIMENTAL|drink manufactured from lupine peptides|"Beverage drink containing 0.5mg/ml of protein hydrolysate extracted from food grade lupine flour. The drink will be formulated as 200 mL tetra brik subjected to a test of microbiological safety according to the Spanish law (RD 135/2010 of 12 February 2010).~The final beverage shall consist of:~* Oily phase: refined sunflower oil 5% w/w of the emulsion~* Aqueous phase (water) 95% w/w of the emulsion, containing equal volumes of solution A and B:~  * Solution A:~    * Hydrolyzed Lupine (1.17% w/w)~   * Sucrose (14.03% w/w)~   * Vanilla flavor (0.42% w/w)~   * Drinking water (84.38% w/v)~ * Solution B:~    * Xanthan gum (0.28% w/w)~   * Drinking water (99.72% w/v)~The samples will guard and kept by the investigator until the day of delivery to the volunteers.~The duration of treatment 4 weeks, during which the volunteers daily consume the contents of a tetra brik."
61958171|NCT03817788|ACTIVE_COMPARATOR|polyethylene glycol group (group P)|For all patients of this group, polyethylene glycol solution should be taken orally for colonic cleansing of colonoscopy
62346297|NCT04785391||Patients with KDIGO stage 2 or 3 AKI|
62504213|NCT05607563|EXPERIMENTAL|PM1009 600 mg monotherapy|PM1009 600 mg
62504214|NCT05607563|EXPERIMENTAL|PM1009 1200 mg monotherapy|PM1009 1200 mg
62504215|NCT03095755|EXPERIMENTAL|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
62504216|NCT03095755|SHAM_COMPARATOR|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
62504217|NCT05811819|EXPERIMENTAL|Neurorehabilitation of the Hand|Participants will undergo a 1-hour training session 5 days per week, over 3 weeks for a total of 15 sessions. Hand function therapy will be administered using the gamified protocol to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
62504218|NCT04108832|EXPERIMENTAL|TCM OA2|TCM OA2 3G BID FOR 8 WEEKS
62504219|NCT04108832|PLACEBO_COMPARATOR|PLACEBO|PLACEBO
62504220|NCT03668951|EXPERIMENTAL|Buccal DEX 2 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
62143027|NCT05559645|EXPERIMENTAL|Cohort 4: EGFR Exon20ins|
62346298|NCT04944329||COLCOVID|adults undergoing hip fracture surgery
62504221|NCT03668951|EXPERIMENTAL|Intranasal DEX 3 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
62714924|NCT06716840|EXPERIMENTAL|Remimazolam group|
62504222|NCT03668951|EXPERIMENTAL|Intranasal DEX 4 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
62504223|NCT06352203|ACTIVE_COMPARATOR|Probiotic|
62504224|NCT06352203|PLACEBO_COMPARATOR|Placebo|
62714925|NCT06716840|ACTIVE_COMPARATOR|propofol group|
62714926|NCT02817958|EXPERIMENTAL|A-Adjuvant Chemotherapy TIP|Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapy TIP modified bilateral lymphadenectomy 4 cycles every 21 days
62143028|NCT05559645|EXPERIMENTAL|Cohort 5: EGFR sensitizing mutations|
62504225|NCT01413763|ACTIVE_COMPARATOR|Imiquimod cream|
62504226|NCT01413763|PLACEBO_COMPARATOR|Placebo cream|
62504227|NCT01866176|EXPERIMENTAL|Knee osteoarthritis patients|Knee osteoarthritis patients with Kellgren \& Lawrence grade I, II or III Stabilizing Knee Brace Valgus Knee Brace New Knee Brace
62504228|NCT03078478|EXPERIMENTAL|IDeg 200 U/mL|
62504229|NCT03078478|ACTIVE_COMPARATOR|IGlar 300 U/mL|
62504230|NCT01447225|EXPERIMENTAL|MM-121 plus Gemcitabine|escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
62504231|NCT01447225|EXPERIMENTAL|MM-121 plus Carboplatin|carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
62504232|NCT01447225|EXPERIMENTAL|MM-121 plus Pemetrexed|pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
62714927|NCT02817958|EXPERIMENTAL|B-Neoadjuvant Chemotherapy TIP|fine needle biopsy or sentinel node + neoadjuvant chemotherapy TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days
62143029|NCT05559645|EXPERIMENTAL|Cohort 6: EGFR sensitizing mutations,T790M pos|
62143030|NCT05559645|EXPERIMENTAL|Cohort 7: EGFR Exon20ins treatment naive|
61958172|NCT03817788|EXPERIMENTAL|sodium phosphate group (group S)|For all patients of this group, sodium phosphate solution should be taken orally for colonic cleansing of colonoscopy
61958173|NCT05775874|OTHER|An open evaluation of AZD4547 combined with Tislelizumab in UC patients|"AZD4547 : Initiation dose 80mg BID,po;Until disease progression, death, loss to follow-up, voluntary withdrawal of informed consent, development of intolerable toxicity, investigator decision to discontinue treatment, or completion of the entire study.~Tislelizumab:200mg Q3W, Until disease progression, death, loss to follow-up, voluntary withdrawal of informed consent, development of intolerable toxicity, investigator decision to discontinue treatment, or completion of the entire study."
61958174|NCT04023435|EXPERIMENTAL|PNE education|All subjects will be tested before and after receiving PNE education
62143031|NCT05897905|NO_INTERVENTION|Standard care|All participants will receive a brief routine stroke medical follow-up appointment.
62143032|NCT05897905|EXPERIMENTAL|Personalised, holistic based follow-up appointments underpinned by self determination theory.|Participants will receive two follow-up appointments at two and six weeks after discharge.
62143033|NCT03770520|EXPERIMENTAL|QFR-guided|This group will be performed a CABG surgery based on CAG and QFR, whether graft the moderate stenosis vessels will be based on the result of QFR.
62143034|NCT03770520|ACTIVE_COMPARATOR|Angio-guided|This group will be performed a CABG surgery only based on CAG, the final surgery strategy will be decided after the discussion of heart team.
62143035|NCT06509282|EXPERIMENTAL|Concurrent training|Concurrent training group
62143036|NCT06509282|NO_INTERVENTION|Control|Control group
62143037|NCT02170532|ACTIVE_COMPARATOR|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
62504233|NCT01447225|EXPERIMENTAL|MM-121 plus Cabazitaxel|escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
62504234|NCT02621463|EXPERIMENTAL|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
62504235|NCT03356106|EXPERIMENTAL|CPAP|Nocturnal administration of continuous positive airway pressure treatment (CPAP) until delivery
62504236|NCT03356106|NO_INTERVENTION|Control|Usual antenatal care for high risk pregnancy
62504237|NCT05486832|EXPERIMENTAL|Cardiovalve TR replacement Group|Cardiovalve TR valve replacement System
62504238|NCT05925725|ACTIVE_COMPARATOR|Loxacon and Physical Therapy|physical therapy(exercise) + caps Loxacon
62504239|NCT05925725|PLACEBO_COMPARATOR|Physical therapy and Placebo Loxacon caps|Physical therapy + Placebo caps Loxacon
62504240|NCT05925725|ACTIVE_COMPARATOR|Pphysical therapy(alone)|Physical therapy
62504241|NCT02981316|ACTIVE_COMPARATOR|RBX7455 Group A|4 days of 4 capsules twice daily RBX7455 for 10 subjects.
62702830|NCT06748118|EXPERIMENTAL|Intervention period|"Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.~During this period, the message will be delivered to the patient by each of the healthcare professionals involved in his or her hospital care. It will be formalized by a checklist that will enable them to reformulate the 3 points defined as key elements of therapeutic adherence. Each healthcare professional is free to deliver this message at any time during their consultation/interview with the patient. They will be asked to note the date and tick off each point on the checklist.~The intervention period will take place after the control and wash-out periods, and after healthcare professionals have been trained in the intervention."
62702831|NCT06748118|NO_INTERVENTION|Control period|The control period is the period before healthcare professionals are trained in the intervention. Patients included during this period will not receive the simple, standardized and redundant message.
62702832|NCT06751394|EXPERIMENTAL|Group A|The patients will receive 2 cycles of XELOX or XELIRI and PD-1 antibody, followed by long course radiotherapy (45-50Gy/25f or 30Gy/25f), concurrent with Capecitabine and 1-2 cycles of PD-1 antibody, then receive 2-3 cycles of XELOX or XELIRI and PD-1 antibody. Curative surgery is scheduled after neoadjuvant treatment.
62702833|NCT06698042|EXPERIMENTAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
61958175|NCT04027244||Primary cohort|Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).
61958176|NCT04027244||Frailty & cognitive additional assessments|Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).
61958177|NCT04027244||Cardiac MRI additional assessments|Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).
61958178|NCT04027244||Biomarkers additional assessments|Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).
61958179|NCT04027244||Historical cohort|Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).
62143038|NCT02170532|ACTIVE_COMPARATOR|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
62143039|NCT02170532|ACTIVE_COMPARATOR|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
62143040|NCT02170532|ACTIVE_COMPARATOR|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
62143041|NCT02170532|ACTIVE_COMPARATOR|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
62504242|NCT02981316|ACTIVE_COMPARATOR|RBX7455 Group B|2 days of 4 capsules twice daily RBX7455 for 10 subjects.
62504243|NCT02981316|ACTIVE_COMPARATOR|RBX7455 Group C|2 days of 2 capsules twice daily RBX7455 for 10 subjects.
62504244|NCT02981316|ACTIVE_COMPARATOR|RBX7455 Group D|2 days of 1 capsule twice daily RBX7455 for 10 subjects.
62504245|NCT05050981||Hormone Therapy|Women using hormone replacement therapy (estrogen only or oestrogen and progestin) for treating climacteric symptoms.
62504246|NCT05050981||Selective Serotonin Reuptake Inhibitors|Women using selective serotonin reuptake inhibitors for treating climacteric symptoms.
62504247|NCT05050981||Control Group|Women not using hormone replacement therapy or selective serotonin reuptake inhibitors
61958180|NCT05342194|EXPERIMENTAL|Toripalimab, lenvatinib, and gemcitabine-based chemotherapy-Arm A|Toripalimab plus lenvatinib and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
61958181|NCT05342194|EXPERIMENTAL|Toripalimab, oral placebo, and gemcitabine-based chemotherapy -Arm B|Toripalimab plus lenvatinib placebo and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
61958182|NCT05342194|ACTIVE_COMPARATOR|Intravenous placebo, oral placebo, and gemcitabine-based chemotherapy-Arm C|Toripalimab placebo plus lenvatinib placebo and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
61958183|NCT04002713||ALT&AMT free flap reconstruction|Patients who underwent ALT or AMT free flap reconstruction after head and neck cancer surgery between March 1, 2008 and February 28, 2017
61958184|NCT00864331|ACTIVE_COMPARATOR|Radiotherapy|For patients in Group A (Stage IIIA or IIIB), EBRT 39 Gy in 13 daily fractions over, with no chemotherapy.
61958185|NCT00864331|EXPERIMENTAL|Chemotherapy and radiotherapy|For patients in Group A (either stage IIIA or IIIB) receive a course of up to 3 cycles of chemotherapy followed by EBRT of 10 Gy in a single fraction or 16 Gy in 2 fractions 1 week apart.
62143042|NCT02792855|EXPERIMENTAL|snifﬁng Position|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
62143043|NCT02792855|EXPERIMENTAL|Simple Head Extension|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
62702834|NCT06698042|ACTIVE_COMPARATOR|Pembrolizumab|"Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course,"
62702835|NCT06750276|OTHER|Cohort A|Participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.
62702836|NCT06750276|OTHER|Cohort B|Participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.
62702837|NCT06749873||Group 1|Sp was asked with the following baseline information: 1. 20 years of age and gender; 2. positive urea breath test; 3. no symptoms; 4. no family history of gastric cancer; 5. gastroscopy: non-atrophic gastritis; 6. no treatments; and 7. no history of drug allergies.
62702838|NCT06002113|EXPERIMENTAL|GOCD Tool|Intensive care unit-facilitated goals-of-care discussion using web-based shared-decision making software tool
62702839|NCT06002113|ACTIVE_COMPARATOR|usual care|Usual discussions conducted by attending physician with patient
62702840|NCT03698669|EXPERIMENTAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
62702841|NCT03698669|ACTIVE_COMPARATOR|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
62714928|NCT01105663||Sedated, Intubated, Morphine|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
61958186|NCT00864331|ACTIVE_COMPARATOR|Chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive up to 3 cycles of chemotherapy, and no radiotherapy.
61958187|NCT00864331|EXPERIMENTAL|Palliative radiotherapy and chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive EBRT of 10 Gy in a single fraction or 16 Gy in two fractions 1 week apart, followed by up to 3 cycles of chemotherapy.
61958188|NCT04243798|EXPERIMENTAL|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
61958189|NCT04243798|SHAM_COMPARATOR|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
62346299|NCT01660139||Dermatology Clinic Patients|Patient attending dermatology clinics
61958190|NCT04386252|EXPERIMENTAL|Phase 1 Antigen Dose Exploration|AV-COVID-19 consisting of autologous DC loaded with 0.1 mcg, 0.33 mcg or 1.0 mcg SARS-CoV-2 spike protein, with or without GM-CSF
61958191|NCT04386252|EXPERIMENTAL|Phase 2|Separate cohorts of patients who have 0 or \>1 risk factor related to poor outcome for COVID-19 infection will receive AV-COVID-19 consisting of optimal antigen and GM-CSF formulation.
61958192|NCT00749645|ACTIVE_COMPARATOR|1 - FANG(30)|1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)
61958193|NCT00749645|PLACEBO_COMPARATOR|2 - Placebo|2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)
61958194|NCT05458843|EXPERIMENTAL|Fluid replacement|
61958195|NCT05458843|SHAM_COMPARATOR|No fluid replacement|
62143044|NCT01034488|ACTIVE_COMPARATOR|Heparin sodium - APP|5000UI / mL
62143045|NCT01034488|EXPERIMENTAL|Heparin - Eurofarma|5000 UI/ mL
62346300|NCT01660139||Primary Clinic Patients|Patient attending primary care clinics
61958196|NCT05853068||Patients on non-invasive ventilatory support to IMV|Patients with AHRF treated with non-invasive ventilatory support \[for the purpose of this study we included High-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV)\] who required endotracheal intubation and invasive mechical ventilation.
61958197|NCT05575531|EXPERIMENTAL|Experimental Group|"MEWSS and Nursing Guide Application will be used in the study group. MEWSS: The Modified Early Warning Score (MEWS) consists of a simple to use algorithm based on physiological parameters such as heart rate, respiratory rate, systolic blood pressure, temperature and level of consciousness.~Nursing Guide Application (NGA): According to the follow-up carried out in this study: If the patient's MEWSS is 4 or below, a ten-minute follow-up was performed. If the MEWSS is five, then five-minute follow-up is passed, and if the score has not changed as a result of the follow-ups, five-minute follow-ups are continued. If the score decreased to four or less, ten-minute follow-up was started, if the score increased, five-minute follow-ups were continued, and the emergency team was informed and the patient was evaluated (the emergency team was informed about the study)."
62504248|NCT03081910|EXPERIMENTAL|Autologous CD5.CAR/28zeta CAR T cells (Group A)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
62702842|NCT06750549|EXPERIMENTAL|Intervention|The ENGAGE-HF intervention is a combination of a patient-facing mobile application that is integrated with a remote blood pressure cuff and scale along with a clinician-facing dashboard. The mobile application helps complete standard ambulatory monitoring recommended by heart failure clinicians. Simultaneously, the application includes visualizations of that data and education for patients that is intended to promote patient engagement and patient understanding of heart failure care. The information is then made available to treating clinicians via a PDF summary to facilitate outpatient management of the patient by the clinician. There are also a select set of notifications triggered by the ENGAGE-HF platform that will be transmitted to the treating clinician.
62702843|NCT06750549|NO_INTERVENTION|Control Group|Participants randomized to the control group will receive usual heart failure care.
62702844|NCT06749392|EXPERIMENTAL|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy for depressive disorder for 16 weeks.
62702845|NCT06749392|NO_INTERVENTION|Waiting list|Participants will wait for treatment for 16 weeks. After the waiting the participants will receive in a supportive-expressive treatment for depressive disorder for 16 weeks.
62702846|NCT05083481|EXPERIMENTAL|ASP1570 Monotherapy Dose Escalation (Part 1)|Participants will receive daily dose of ASP1570 in a 21-day cycle.
62702847|NCT05083481|EXPERIMENTAL|ASP1570 + pembrolizumab Combination therapy Dose Escalation (Part 1)|Participants will receive daily dose of ASP1570 in a 21-day cycle. pembrolizumab will be administered every 6 weeks on day 1 of every other ASP1570 cycle.
62702848|NCT05083481|EXPERIMENTAL|ASP1570 + Docetaxel Combination therapy Dose Expansion - NSCLC 2L+ (Part 2)|Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle. Docetaxel will be administered every 6 weeks on day 1 of every other ASP1570 cycle.
61958198|NCT05575531|NO_INTERVENTION|Control Group|In the control group, the patients followed according to the Modified Early Warning Scoring System received routine care in the clinic.
62346301|NCT02665364|EXPERIMENTAL|IFNα-Kinoid|IFNα-Kinoid (IFN-K) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at W0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
62346302|NCT02665364|PLACEBO_COMPARATOR|Placebo|Placebo normal saline (0.9% Sodium Chloride) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at week (W)0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
62346303|NCT04284943|ACTIVE_COMPARATOR|Long limb Roux-en-Y reconstruction|Long limb Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
62702849|NCT05083481|EXPERIMENTAL|ASP1570 Monotherapy Dose Expansion - Food Effect (Part 2)|Participants will receive RP2D of ASP1570 after the meal in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
62702850|NCT05083481|EXPERIMENTAL|ASP1570 Monotherapy Dose Expansion - Prophylactic (Part 2)|Participants will receive RP2D of ASP1570 along with the standard prophylactic medication in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
62702851|NCT05083481|EXPERIMENTAL|ASP1570 Monotherapy Dose Expansion - Intermittent dosing (Part 2)|Participants will receive RP2D of ASP1570 with some periodical drug holiday in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
61958199|NCT02158403|OTHER|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
61958200|NCT03166384|ACTIVE_COMPARATOR|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.~interventions: 'conventional suture and tie'"
62346304|NCT04284943|ACTIVE_COMPARATOR|Conventional Roux-en-Y reconstruction|Conventional Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
62346305|NCT04284943|ACTIVE_COMPARATOR|Billroth II reconstruction|Billroth II reconstruction method follows subtotal gastrectomy for gastric cancer
62346306|NCT03179436|EXPERIMENTAL|Escalation: Dose Level (DL) 1 Quavonlimab + Pembro: Cohort 1|On Cycle 1, Day 1 of the Dose Escalation Phase, advanced solid tumor participants receive a single monotherapy dose lead-in with quavonlimab at dose level 1 (DL1). On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL1 in combination with pembrolizumab (pembro) at pembrolizumab dose level 1 (PDL1) according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
62702852|NCT05083481|EXPERIMENTAL|ASP1570 Monotherapy Dose Expansion - Stepwise dosing (Part 2)|Participants will receive ASP1570 administered by intra-subject dose escalation with gradual multiple dose steps (e.g., 3 steps) and increased dose up to RP2D in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
62346307|NCT03179436|EXPERIMENTAL|Escalation: DL 2 Quavonlimab + Pembro: Cohort 2|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL2. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
62504249|NCT03081910|EXPERIMENTAL|Allogeneic CD5.CAR/28zeta CAR T cells (Group B)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
61958201|NCT03166384|EXPERIMENTAL|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.~interventions: electrosurgical bipolar sealing devices"
61958202|NCT00386048||Standard of Care Observation Group|This group is randomized to continue their current medical management strategies for pain as recommended/prescribed by health care providers. Primary and secondary outcomes are collected at the same time intervals as the biopsychosocial intervention group.
61958203|NCT00386048||Biopsychosocial Intervention Group|This group continues all standard of care procedures for managing pain and adds to this additional cognitive-behavioral treatment (CBT) strategies for managing pain. The intervention explicitly frames the CBT strategies as added, complimentary pain management methods to add to the standard of care treatment.
61958204|NCT03962842|EXPERIMENTAL|Pilates group|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
61958205|NCT03962842|NO_INTERVENTION|Control group|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
61958206|NCT03557099|EXPERIMENTAL|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
62702853|NCT05083481|EXPERIMENTAL|ASP1570 Monotherapy Dose Expansion Microsatellite stable - colorectal cancer (MSS-CRC) (Part 2)|Participants who have MSS-CRC will receive ASP1570 in a 21-day cycle.
62702854|NCT05083481|EXPERIMENTAL|ASP1570 + TAS-102 + Bevacizumab Combination therapy Dose Expansion - MSS-CRC 3L+ (Part 2)|Participants who have MSS-CRC will receive ASP1570 daily in a 28-day cycle. TAS-102 (Trifluridine + Tipiracil) will be administered on days 1 through 5 and days 8 through 12 of each 28-day cycle. Bevacizumab will be administered every 2 weeks.
62702855|NCT03970057|EXPERIMENTAL|MoodUP|It consisted of six weekly online sessions, homework, and forums. It covered six topics, namely managing mood, psychoeducation, cognitive restructuring, behavioural activation, lifestyle modification, and problem-solving. Each session began with an autoplay video that introduced the session goal and included video and case vignettes, short quizzes, take-home messages, and homework. We also provided an online forum for peer support and regularly monitored it.
62702856|NCT03970057|PLACEBO_COMPARATOR|HealthyMUM|It consisted of six weekly online sessions. Each session provided information on essential antenatal care using text and photos. The sessions covered topics such as parenthood, diet, exercise, breastfeeding, rest and sleep, and common problems in pregnancy.
62702857|NCT06624657||control group|Participants are women with osteoporosis Characterized by normal daily activities and diets
62702858|NCT06624657||Exercise group|Participants are women's with osteoporosis participated in HIIT-exercise program interventions for 16 weeks
61958207|NCT00407797|EXPERIMENTAL|Pregabalin|
61958208|NCT01957722|EXPERIMENTAL|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
61958209|NCT01957722|ACTIVE_COMPARATOR|Microfracture|considered a typical treatment for articular cartilage repair
61958210|NCT01421004|EXPERIMENTAL|500 mg FMI capsule + 250 mg FMI tablet|BE phase sequence 1= 3 weeks on FMI capsule then 1 week on FMI tablet
61958211|NCT01421004|EXPERIMENTAL|500 mg TKI258 FMI capsule +250 mg FMI tablet|BE phase sequence 2= 3 weeks on FMI tablet then 1 week on FMI capsule
61958212|NCT03291730|EXPERIMENTAL|Hand Lettering|"* The participant will engage in art-therapy by tracing and coloring a detailed letter or word~* Participants will also be guided through a relaxation breathing and journaling exercise that can be incorporated into the art activity."
62504250|NCT04690569||Infectious|Eligible pediatric and adult patients from ED\\Urgent care and hospital admitted, with symptoms consistent with acute bacterial or viral infection.
62702859|NCT06624657||Vitamin D group|Participants are women's with osteoporosis who received vitamin D 800IU/ day for 16 weeks
62702860|NCT06624657||Concurrent group|Participants are women's with osteoporosis who shared for HIIT exercise program plus vitamin D for 16 weeks
61958213|NCT01774604|EXPERIMENTAL|Indomethacin|Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
61958214|NCT01774604|PLACEBO_COMPARATOR|Placebo|Placebo suppositories (#2)
61958215|NCT04889079||Adolescent females, aged 15-18|Adolescents females aged 15-18, who selected a contraceptive implant to prevent pregnancy.
61958216|NCT04889079||Adolescent females, aged 19-24|Adolescents females aged 19-24, who selected a contraceptive implant to prevent pregnancy.
61958217|NCT01746745|EXPERIMENTAL|[^14C]-LY2940680|Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 (\[\^14C\]-LY2940680)
61958218|NCT01257087|EXPERIMENTAL|Intensive glycaemic control|Intensive glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
61958219|NCT01257087|ACTIVE_COMPARATOR|Conservative glycaemic control|Conservative glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
61958220|NCT05091047|EXPERIMENTAL|Erchonia EVRL|635 nanometers (nm) and 405 nm laser application
61958221|NCT03991572|ACTIVE_COMPARATOR|Real Stimulation|The Real Stimulation of rTMS lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . Behavior and MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
61958222|NCT03991572|SHAM_COMPARATOR|Sham Stimulation|The procedure of Sham Stimulation protocol was performed by a placebo coil,lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
61958223|NCT06436365|EXPERIMENTAL|expert IMN with poller screws|Twenty-one patients underwent IMN fixation by placing in a supine position with the knee flexed at 90 degrees above the radiolucent table to enable intraoperative imaging and a bolster was put below the thigh to enable knee flexion up to 110 degrees. Multiple interlocking screws were inserted in the expert nail which costed the double compared to the ordinary nail.
61958224|NCT06436365|ACTIVE_COMPARATOR|distal tibial locked plate|patients underwent distal locked plates by placing in a supine position and raising of the contralateral iliac crest which enhanced the rotation and made it easier for medial side access. Thigh was elevated and torniquet was put up to 300 mmHg. By reduction preservation, proximal screws were inserted by small incisions which was followed by insertion of the remained distal screws.
61958225|NCT06275698|EXPERIMENTAL|Treatment|Manuka honey, 15ml, three times a day, for 14 days. To be kept on the tongue for at least 10 seconds prior to swallowing.
61958226|NCT06275698|PLACEBO_COMPARATOR|Placebo|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
61958227|NCT03757325|EXPERIMENTAL|DNL747 First, Placebo Second|Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
61958228|NCT03757325|EXPERIMENTAL|Placebo First, DNL747 Second|Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
61958229|NCT00691860|EXPERIMENTAL|1|Patients receiving conventional sigmoid end colostomy plus a lightweight mesh Ultrapro®
61958230|NCT00691860|OTHER|2|Patients receiving conventional sigmoid end colostomy, without mesh
62143046|NCT04203966||Common mental disorders/ versus no common mental disorders|No intervention This is a prevalence study- presence of common mental disorders (CMDs) will be assessed using the 12-item general Health Questionnaire, with responses above validated cut-points taken to indicate presence of CMDs
62143047|NCT04203966||Alcohol use disorders/ versus no alcohol use disorders|No intervention This is a prevalence study- presence of alcohol use disorders will be assessed using the World Health Organization (WHO) AUDIT, with responses above validated cutpoints taken to indicate presence of alcohol use disorders
62346308|NCT03179436|EXPERIMENTAL|Escalation: DL 3 Quavonlimab + Pembro: Cohort 3|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL3. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL3 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
62504251|NCT04690569||Healthy|For the purpose of establishing a normal reference range.
62504252|NCT00399893|EXPERIMENTAL|Octreotide|Octreotide to be administered by subcutaneous injection three times daily while on study
62504253|NCT00399893|PLACEBO_COMPARATOR|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
62702861|NCT06749626|EXPERIMENTAL|Group undergoing progressive relaxation exercise after laparoscopic cholecystectomy surgery|Progressive relaxation exercises lasting approximately 30 minutes were applied to the patients in the experimental group, accompanied by the researcher, at the 6th hour, when the nonsteroidal anti-inflammatory drug administered by the clinic was half-done, and at the 10th hour after the surgery.
61958231|NCT01445561|EXPERIMENTAL|1|100,000 international units/m2 SQ daily for 5 days
62143048|NCT00527267|EXPERIMENTAL|AMG 073|AMG 073
62143049|NCT00527267|PLACEBO_COMPARATOR|Placebo|Placebo
62504254|NCT04204226|EXPERIMENTAL|Social Worker vs Autism Behavioral Health Navigation (ABHN)|"Phase 1: Families providing informed consent will then be randomized to social work consultation or to the Autism Behavioral Health Navigation (ABHN) intervention.~Non-responders to ABHN will move to ABHN + Complex Autism Program (CAP)."
62504255|NCT04204226|EXPERIMENTAL|Social work + ABHN vs Social work + ABHN + CAP|"At 3 months, children who are considered to be responders to their current treatment will continue; children who are nonresponders in the social work arm of the study will be randomized to either ABHN or ABHN+CAP. Children in the ABHN arm who are non-responders will receive ABHN + CAP"
62504256|NCT03170102|OTHER|Building capacity through education|Building capacity process through education - Occupational therapy students participate in online webinars and discussions following completion of readings.
62702862|NCT06749626|NO_INTERVENTION|Group without progressive relaxation exercise after laparoscopic cholecystectomy surgery|Patients in the control group were treated only according to the clinical analgesia protocol.
62143050|NCT02994524|OTHER|transsphincteric perianal fistula|Rerouting technique done in patients with high transsphincteric fistula or with high internal opening.
62702863|NCT01019343|PLACEBO_COMPARATOR|Healthy Volunteers|Healthy Volunteers
62702864|NCT01019343|ACTIVE_COMPARATOR|Movement Disorder|Subjects diagnosed with movement disorder
62702865|NCT06303297|EXPERIMENTAL|REFLEXOLOGY|
62702866|NCT06303297|ACTIVE_COMPARATOR|GENERALIZED STRETCHING|
62702867|NCT06751225|EXPERIMENTAL|Contact Lens Wear Experience|One week replacement soft contact lenses will be worn for 3 weeks.
62504257|NCT04323462|EXPERIMENTAL|Intensive Glucose Control|"Intensive Glucose control Insulin ≥3 times per day; Goals: prePBG 80-130 \& post PBG \<180 (60% of all readings); HbA1c \<8% at 3 months SMBG at least 14 readings/week (3-5 FBG, rest PPBG) and/or CGMS readings Reexamined weekly for 1 month; then fortnightly for 3 months and then monthly till 6 months~Intensive subgroup will receive a standard glucometer with strips as one-week supply or CGMS for glycemic monitoring. They will receive a diabetic monitoring log/chart for home use. The chart and glucometer will have to be shown at each week of follow up. Number of hypoglycemic events in past week will be checked for each patient. This sub group will receive instructions to use 3 times bolus (regular/analogue) and single time basal insulin (glargine). Treatment goals will be conveyed at first contact and reinforced at each visit. Insulin dose modulation will be done telephonically. Patients will be reviewed weekly for 1 month and then fortnightly."
62504258|NCT04323462|ACTIVE_COMPARATOR|Conventional Glucose control|Fixed dosage of oral anti-diabetic drugs/insulin per week as patient is receiving prior; Insulin \<3 times per day SMBG \<3 times per day
62504259|NCT03614533|EXPERIMENTAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
62504260|NCT03614533|ACTIVE_COMPARATOR|Inactivated Poliovirus Vaccine (IPV)|Children will receive a single 0.5-ml dose of Inactivated Poliovirus Vaccine (IPV) by the intramuscular route.
62346309|NCT03179436|EXPERIMENTAL|Confirmation: DL 1 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm A|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
62504261|NCT05775848|ACTIVE_COMPARATOR|BBP-418|BBP-418 Granules for Oral Solution will be supplied as granules in tri-ply PET/Aluminum/PE sachets for unit dose. The number of sachets to reconstitute will depend on the applicable dose to be delivered, 9 g BID or 12 g BID, as determined by the weight of the participant. The granules will be reconstituted in water for oral administration.
62504262|NCT05775848|PLACEBO_COMPARATOR|Placebo to Match BBP-418|The placebo will be identical to the BBP-418 Granules for Oral Solution in appearance, packaging, labeling, and storage conditions.
62504263|NCT05499234|EXPERIMENTAL|High concentration|Epidural analgesia with 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl solution
62504264|NCT05499234|EXPERIMENTAL|Low concentration|Epidural analgesia with 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution
62143051|NCT02646618|ACTIVE_COMPARATOR|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
62143052|NCT02646618|ACTIVE_COMPARATOR|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
62504265|NCT03856606|EXPERIMENTAL|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (\~14 hours) of 1 day and will not be asked to perform interval exercise.
62143053|NCT05389618||Older adults 65-80 years|
62143054|NCT05389618||Older adults above 80 years|
62143055|NCT01372085|EXPERIMENTAL|Part A: 25 mg RF|A single 25 mg dose of LY2584702 RF
62346310|NCT03179436|EXPERIMENTAL|Confirmation: DL 1 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm B|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL1 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
62346311|NCT03179436|EXPERIMENTAL|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm C|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and at DL2 quavonlimab according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
62346312|NCT03179436|EXPERIMENTAL|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (SCLC): Arm D|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with SCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
62346313|NCT03179436|EXPERIMENTAL|Confirmation: DL 2 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm E|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
62346314|NCT03179436|EXPERIMENTAL|Expansion: DL1 Quavonlimab Schedule 2+PDL2 Pembro Schedule 2: Arm F|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 in combination with pembrolizumab at pembrolizumab dose level 2 (PDL2). Both quavonlimab and pembrolizumab will be administered according to Schedule 2 for up to 24 months on study.
62504266|NCT03856606|EXPERIMENTAL|Prolonged sitting with interval exercise|Subjects will be asked to undergo prolonged sitting (\~14 hours) of 1 day and will be asked to perform interval exercise every hour on the hour.
62702868|NCT05938296|EXPERIMENTAL|BS006 injection|Subjects will receive BS006 every two weeks, and up to 4mL BS006 will be given. BS006 will be given intratumorally.
62143056|NCT01372085|PLACEBO_COMPARATOR|Part A: Placebo|Placebo taken orally
61958232|NCT01445561|EXPERIMENTAL|2|200,000 international units/m2 SQ daily for 5 days
61958233|NCT00843024|EXPERIMENTAL|Sumatriptan and Naproxen 1|Sumatriptan succinate and naproxen sodium combination 10mg/60mg
62346315|NCT03179436|EXPERIMENTAL|Expansion: DL1 Quavonlimab Schedule 2 Monotherapy: Arm G|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 according to Schedule 2 for up to 24 months on study. Participants who demonstrate radiographically confirmed progressive disease in Arm G will be eligible to receive combination therapy with pembrolizumab (crossover).
62702869|NCT06748222|EXPERIMENTAL|Mindfulness (MAPs) Live Online|Participants assigned to MAPs Live Online (MAPs LO) will be asked to attend 2-hour group sessions once a week for 6 weeks conducted live online over Zoom. Both English and Spanish language participants will be randomized to Arm 1. Sessions will be conducted on an encrypted internet connection and recorded for quality assurance and intervention fidelity. Participants who do not have a home computer, smartphone, tablet, or internet to access the Zoom sessions will have a tablet and hotspot provided by the UCLA research team. Each session provides structured lessons and guided exercises in mindfulness as well as opportunities for reflection and group discussion. Exercises include breath, body, and sound meditations; eating and walking meditations; managing pain; working with difficult thoughts and emotions; and cultivating loving kindness. Home practice is a key component of MAPs, and participants will be instructed to practice mindfulness techniques daily, beginning with 5 minutes
61958234|NCT00843024|EXPERIMENTAL|Sumatriptan and Naproxen 2|Sumatriptan succinate and naproxen sodium combination 30mg/180mg
61958235|NCT00843024|EXPERIMENTAL|Sumatriptan and Naproxen 3|Sumatriptan succinate and naproxen sodium combination 85mg/500mg
61958236|NCT00843024|PLACEBO_COMPARATOR|Placebo|Placebo to match
61958237|NCT00779285|EXPERIMENTAL|Single-arm|Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
61958238|NCT04678245|EXPERIMENTAL|Immediate Above the Influence-Vaping Intervention|School receives Above the Influence-Vaping (ATI-V) prevention program training after baseline assessment. Training and intervention continue over two school years (approximately 18 months). Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade).
61958239|NCT04678245|ACTIVE_COMPARATOR|Delayed Above the Influence-Vaping Intervention|Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade). ATI-V prevention program training after 4th assessment - after 28 months.
61958240|NCT01125605||Adults > 12 years|adult patients and patients older than 12 years
61958241|NCT01125605||Children 6-12 years|children between 6 and 12 years
61958242|NCT01125605||Children 1-6 years|children between 1 and 6 years
61958243|NCT00541593|EXPERIMENTAL|NOTES pancreatic pseudocystgastrostomy|Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.
61958244|NCT01114256||Fine needle aspiration (FNA) biopsies|Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
61958245|NCT02159417|EXPERIMENTAL|Therapeutic Education|Intensive training individual or collective teaching
61958246|NCT04109183|EXPERIMENTAL|Active Comparator: FNC 2 mg+ TDF+EFV|
61958247|NCT04109183|EXPERIMENTAL|Active Comparator: FNC 3 mg+ TDF+EFV|
61958248|NCT04109183|EXPERIMENTAL|Active Comparator: FNC 4 mg+ TDF+EFV|
62346316|NCT03179436|EXPERIMENTAL|Coformulation: Pembrolizumab/Quavonlimab Schedule 2: Arm I|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants with advanced/metastatic solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
61958249|NCT04109183|EXPERIMENTAL|Postive Comparator: 3TC+ TDF+EFV|
61958250|NCT02469298|EXPERIMENTAL|Danirixin + Oseltamivir matching placebo|Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
61958251|NCT02469298|PLACEBO_COMPARATOR|Danirixin matching placebo + Oseltamivir matching placebo|Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
61958252|NCT02469298|EXPERIMENTAL|Danirixin + Oseltamivir|Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
61958253|NCT02469298|ACTIVE_COMPARATOR|Danirixin matching placebo + Oseltamivir|Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
61958254|NCT01556711||Head Injury|Males and females ages 18 to 80 (the entire age range), who are admitted to the ED, who are suspected of a traumatically induced structural brain
61958255|NCT01556711||Control|"A 'normal' control group will be recruited for comparison and will consist of ED patients (ED normal control group) who have sustained an injury but do not exhibit any trauma above the clavicle and no history of MVA requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope"
61958256|NCT05433493|EXPERIMENTAL|Intervention group|"Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving individual CS or to the control group receiving treatment as usual (participating in the activities previously established in their individual intervention plan).~Participants in the intervention group will participate in two individual CS sessions per week for 12 weeks in addition to their treatment as usual. The sessions will include the same protocol in every participant site."
61958257|NCT05433493|NO_INTERVENTION|Control group|Participants in the control group will receive treatment/activities as usual, participating in the activities previously established in their individual intervention plan.
61958258|NCT05820178|EXPERIMENTAL|tDCS treatment group|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
61958259|NCT05820178|EXPERIMENTAL|rTMS treatment group|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
61958260|NCT05820178|NO_INTERVENTION|conventional treatment group|Not receiving any neuromodulation treatment.
61958261|NCT00837642||ART (Assited reproductive technologies)|In participants born after IVF will be performed a transthoracic echocardiography
61958262|NCT00837642||Control|In participants naturally conceived will be performed a transthoracic echocardiography
61958263|NCT01832974|OTHER|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
61958264|NCT01832974|OTHER|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
61958265|NCT01832974|OTHER|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
61958266|NCT01832974|EXPERIMENTAL|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
61958267|NCT04546945||control cases|normal healthy person
61958268|NCT04546945||Patients|Patients with hematologic malignancies. Newly diagnosed.
61958269|NCT03675100|SHAM_COMPARATOR|IBS group|Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.
61958270|NCT03675100|ACTIVE_COMPARATOR|Control group|Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.
61958271|NCT03198572|EXPERIMENTAL|Berberine|Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
61958272|NCT03198572|PLACEBO_COMPARATOR|Placebo|Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
61958273|NCT05232396|EXPERIMENTAL|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg, single dose usage
62702870|NCT06748222|EXPERIMENTAL|Mindfulness (MAPs) Digital App|"Participants assigned to this condition will be asked to access the MAPs App on their home computer, smartphone, or study supplied tablet over the 6-week intervention period. This will be provided by the UCLA research team. Only English language speakers will be assigned to Arm 2, as the app is currently available only in English at this time. Participants who do not have a home computer, smartphone, tablet, or internet to access the digital app will be provided with a tablet and hotspot by the UCLA research team. The MAPs App translates the content of the MAPs intervention into an app-based format, with lessons, exercises, and guided discussions from the six 2-hour sessions separated into shorter micro-sessions. The digital program is sequential with new content and exercises building on previous sessions. Lessons and other materials are gradually unlocked as participants progress through the program. Engagement with the MAPs App will be tracked to determine dose of the inte"
61958274|NCT05232396|EXPERIMENTAL|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg, single dose usage
61958275|NCT05232396|EXPERIMENTAL|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg, single dose usage
61958276|NCT05232396|ACTIVE_COMPARATOR|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg，as active comparator, single dose usage.
61958277|NCT02083783|EXPERIMENTAL|TRI102|Active, amphetamine extended-release oral suspension
61958278|NCT02083783|PLACEBO_COMPARATOR|Placebo|Placebo
62346317|NCT03179436|EXPERIMENTAL|Coformulation Phase in China: Pembrolizumab/Quavonlimab Schedule 2: Arm K|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants in mainland China with advanced solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
62346318|NCT00943488|EXPERIMENTAL|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
61958279|NCT04933877|ACTIVE_COMPARATOR|Serratus Anterior Plan block|The SAPB was performed in the operative room (OR) after anesthesia induction using the same ultrasound machine (SonoSite) and linear ultrasound transducer 8- 12 Hz. The patient was positioned in a lateral position with the operative side up and arm flexed forward; then, a linear ultrasound transducer was placed in a sagittal plane over the mid-clavicular line of the thoracic cage. Then, moving inferior-lateral direction till the fifth rib was identified in the mid-axillary line. The following structures were recognized: the rib, pleura, teres major muscle (superior), latissimus dorsi muscle (superficial and posterior), and serratus muscles muscle (deep and inferior). Under complete sterile conditions, a 22-gauge echogenic needle was introduced in-plane with respect to the ultrasound probe targeting the plane deep to the serratus anterior muscle. Then, 0.4 ml/kg of 0.25% bupivacaine was injected with continuous ultrasound guidance.
61958280|NCT04933877|ACTIVE_COMPARATOR|Erector spinae plane block|Patients in Group ESPB receive US erector spinae plane block by injecting 0.4ml/kg (bupivacaine 0.25%). Under strict aseptic precautions, The T3 spinous process is located by palpating and counting down from the C7 spinous process. A high-frequency 12 MHz linear ultrasound transducer is placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Using an in-plane approach a 22 G needle is inserted in caudal-cephalad direction until the tip is deep to erector spinae muscle. Correct needle tip location is confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, bupivacaine is injected, and visualizing the fascial plane.
61958281|NCT05492838|ACTIVE_COMPARATOR|Flapless Surgery|
61958282|NCT05492838|ACTIVE_COMPARATOR|Surgery With Flap Elevation|
61958283|NCT03200860|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
61958284|NCT03200860|PLACEBO_COMPARATOR|Placebo|Matching Placebo 10 mg daily, oral, 30 days
61958285|NCT04974840|EXPERIMENTAL|Treadmill training combined with thera-band|Participants will receive walking training on treadmill with thera-band at the waist. The direction of the thera-band resistance will be straight backward, backward-toward-right, and backward-toward-left. For each direction, the level of resistance and treadmill speed will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'.
61958286|NCT04974840|ACTIVE_COMPARATOR|Treadmill training alone|Participants will receive treadmill walking training at a speed that will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'. For each session, there will be three 10-min treadmill walking bouts.
61958287|NCT05504031|EXPERIMENTAL|Hybrid Group|Revascularization in the form of a combined MIDCAB (LIMA-LAD graft trough a minimal invasive left anterior thoracotomy) and PCI (of all non-LAD stenoses)
61958288|NCT05504031|ACTIVE_COMPARATOR|CABG Group|Conventional CABG through a sternotomy
61958289|NCT03504657|EXPERIMENTAL|Drug-coated balloon angioplasty|
61958290|NCT03504657|ACTIVE_COMPARATOR|stenting angioplasty|
62702871|NCT06748222|ACTIVE_COMPARATOR|Meditation Only Control Group|"The participants assigned to this condition will be provided with access to guided audio mindfulness meditations developed by the UCLA MARC and available on an app. Both English and Spanish speakers will be assigned to Arm 3, and the meditations will be available in both languages. Participants who do not have a home computer, smartphone, tablet, or internet to access the meditations will be provided with a tablet and hotspot by the UCLA research team. Use of the meditations will be tracked to determine dose of the intervention received.~All three study groups will have access to the UCLA MARC mindfulness meditation app throughout the study duration out to 6 months of follow-up."
62702872|NCT06748235|EXPERIMENTAL|Experimental group will received Comprehensive Hand Repetitive Intensive Strength Training|Physical Therapy 60 minutes per session, three sessions a week, at a total of 30 sessions per ten weeks. Comprehensive hand repetitive intensive strength training included treadmill training for the upper limb with body weight supporting the using upper limb. The posture of an arm swing was to maintain the joints of the elbows and wrist as much as possible, and the shoulder joint was allowed to be flexed by 160 degrees.
62702873|NCT06748235|OTHER|Routine Physical Therapy|control will received 60 minutes per a session, three sessions a week, at a total of 30 sessions per 10 weeks by creating a home program, which consisted of a total of 8 exercises that enhanced the muscular strength of the upper limb including the triceps brachii and extensor carpi radialis, and conveyed an effect of reaching the muscles out.
62702874|NCT06751186|EXPERIMENTAL|Teté Dance Intervention|Participants in this group will receive guided sessions of the Teté Dance facilitated by trained individuals over a seven-day period to improve breastfeeding session duration.
62702875|NCT06751186|NO_INTERVENTION|Standard Breastfeeding Support|Participants in this group will receive standard breastfeeding support as provided by usual care practices, without any additional interventions.
62702876|NCT02520791|EXPERIMENTAL|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62702877|NCT06690294||Healthy Volunteer|adults, age 18-60 years
61958291|NCT03121638|ACTIVE_COMPARATOR|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
61958292|NCT03121638|ACTIVE_COMPARATOR|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
61958293|NCT03121638|EXPERIMENTAL|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
61958294|NCT03121638|EXPERIMENTAL|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
62504267|NCT00129116|EXPERIMENTAL|Menhibrix F1/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
62504268|NCT00129116|EXPERIMENTAL|Menhibrix F2/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
62702878|NCT06628310|EXPERIMENTAL|Stage 1: Dose Escalation ABBV-400|Participants will receive escalating doses of ABBV-400 in combination with a fixed dose of fluorouracil, leucovorin and budigalimab as part of the approximately 6 year study duration.
62702879|NCT06628310|EXPERIMENTAL|Stage 2 Arm 1: Dose Optimization ABBV-400 Dose A|Participants will receive ABBV-400 dose A in combination with a fixed dose of fluorouracil, leucovorin and budigalimab as part of the approximately 6 year study duration.
62702880|NCT06628310|EXPERIMENTAL|Stage 2 Arm 2: Dose Optimization ABBV-400 Dose B|Participants will receive ABBV-400 dose B in combination with a fixed dose of fluorouracil, leucovorin and budigalimab as part of the approximately 6 year study duration.
62702881|NCT06628310|EXPERIMENTAL|Stage 2 Arm 3: Dose Optimization Standard of Care (SOC)|Participants will receive a fixed dose of leucovorin (folinic acid), fluorouracil, oxaliplatin (FOLFOX) and budigalimab as part of the approximately 6 year study duration.
62702882|NCT06072924|EXPERIMENTAL|Lingual Endurance Exercise|The experimental exercise group will participate in 3 training sessions per day for 8 weeks. Endurance exercise will include completing isotonic endurance repetitions 3 times a day. Number of repetitions per session will be determined during baseline testing, and re-evaluated every 2 weeks, for each participant.
61958295|NCT03121638|EXPERIMENTAL|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
61958296|NCT00488462|NO_INTERVENTION|Control|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the control arm, half of the study clinics will not use the NASG but the NASG will be available at the referral hospital for patients transported there.
61958297|NCT00488462|OTHER|Intervention|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the intervention arm, half of the study clinics will use the NASG on patients before transporting to the referral hospital.
62702883|NCT06072924|SHAM_COMPARATOR|Sham Exercise|The sham control group will be instructed to press the lingual sensor 30 times at a very low-pressure threshold (approximately 1-15 kPa), which will be monitored weekly via device output sent to the study team to avoid use of excessive force that would qualify as exercise.
62143057|NCT01372085|EXPERIMENTAL|Part B: Sequence 1|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
62346319|NCT00943488|EXPERIMENTAL|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
62702884|NCT06299826|EXPERIMENTAL|Cohort A & B: AZD5462 low dose|Participants will receive low dose of AZD5462 as OD tablets for 24 weeks.
62702885|NCT06299826|EXPERIMENTAL|Cohort A & B: AZD5462 medium dose|Participants will receive medium dose of AZD5462 as OD tablets for 24 weeks.
61958298|NCT03050554|EXPERIMENTAL|SBRT+Avelumab|"SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)~Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles"
62346320|NCT04791267|EXPERIMENTAL|Intervention|Community health navigator program for six months
62346321|NCT04791267|OTHER|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program
61958299|NCT03859505|PLACEBO_COMPARATOR|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
62346322|NCT06512025|NO_INTERVENTION|Usual Care|Participants will received the postpartum usual care at the Sexual and Reproductive Health Service (ASSIR).
62346323|NCT06512025|EXPERIMENTAL|WWWT psychoeducative intervention|Participants will received the postpartum routine usual care plus two psychoeducative intervention WWWT sessions at the Sexual and Reproductive Health Service (ASSIR).
62702886|NCT06299826|EXPERIMENTAL|Cohort A & B: AZD5462 high dose|Participants will receive high dose of AZD5462 as OD tablets for 24 weeks.
62702887|NCT06299826|EXPERIMENTAL|Cohort A & B: Placebo|Participants will receive matching placebo OD tablets for 24 weeks.
62346324|NCT01305213|ACTIVE_COMPARATOR|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62346325|NCT01305213|EXPERIMENTAL|Arm II (bevacizumab, fosbretabulin tromethamine)|Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62346326|NCT03532984||adults aged 20-29|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
62702888|NCT04071223|EXPERIMENTAL|Arm A (radium Ra 223 dichloride, cabozantinib s-malate)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1 of cycles 1-6 and cabozantinib S-malate PO QD on days 1-28 of every cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, CT, or MRI, and may undergo FDG-PET or NaF-PET throughout the study.
62346327|NCT03532984||adults aged 30-39|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
62346328|NCT03532984||adults aged 40-49|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
62702889|NCT04071223|ACTIVE_COMPARATOR|Arm B (cabozantinib s-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, CT, or MRI, and may undergo FDG-PET or NaF-PET throughout the study.
62702890|NCT04153136|EXPERIMENTAL|Sacubitril/Valsartan|Sacubitril/Valsartan 49-51mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
62702891|NCT04153136|PLACEBO_COMPARATOR|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
62702892|NCT06626269|EXPERIMENTAL|blood test|"In cohort A: patients with advanced digestive or gynecological cancers eligible to immunotherapies.~In cohort B: patients with advanced digestive or gynecological cancers eligible to treatment without immunotherapy.~In cohort C: patients with advanced digestive or gynecological cancers eligible to surgery of metastasis after chemotherapy."
61958300|NCT03859505|ACTIVE_COMPARATOR|Active PBMT|Application of PBMT (Photobiomodulation Therapy) active.
61958301|NCT00418015||Labor analgesia|Labor analgesia receiving fentanyl labor analgesia
61958302|NCT00418015||Cesarean delivery analgesia|Cesarean delivery analgesia consisting of spinal fentanyl and morphine
61958303|NCT03274024|EXPERIMENTAL|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
61958304|NCT03274024|ACTIVE_COMPARATOR|Trabeculectomy|Trabeculectomy with mitomycin C surgery
61958305|NCT06382259|EXPERIMENTAL|Exercise (EX): Low-intensity movement breaks condition|Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.
61958306|NCT06382259|NO_INTERVENTION|Control (CON) Non-exercise control condition|No structured exercise on two consecutive days.
61958307|NCT02828696|OTHER|No prep|"No prep treatment of worn dentition with CAD-CAM composite (PICN)"
61958308|NCT05200091|EXPERIMENTAL|Combined explosive strength and specific balance training group|This group will be formed with participants with incomplete spinal cord injury. This group will perform 4 weeks of combined explosive strength and specific balance training.
61958309|NCT05200091|NO_INTERVENTION|Spinal cord injury control group|This group will be formed with participants with incomplete spinal cord injury. They will perform all the evaluation before and after a 4-week period of rest (no training).
61958310|NCT05200091|NO_INTERVENTION|Healthy control group|Healthy participants will be recruited based on the age and sex of the participants with incomplete spinal cord injury to realize clinical and neurophysiological cortical evaluations.
61958311|NCT00425295|ACTIVE_COMPARATOR|1|
61958312|NCT00425295|EXPERIMENTAL|2|
62702893|NCT06623630|EXPERIMENTAL|Cyclophosphamide + Cilta-Cel + TBI|All patients will undergo T-cell collection and CAR T manufacturing as per standard of care. Patients will receive cyclophosphamide per standard of care Day -5 to Day -3. They will subsequently receive TBI on Day -1 then and will receive cilta-cel infusion on Day 0.
62702894|NCT06625320|EXPERIMENTAL|RMC-6236|Study drug
62702895|NCT06625320|ACTIVE_COMPARATOR|Investigator's choice of standard of care therapy|"Patients randomized to Investigator's choice of standard of care chemotherapy will receive one of the following four treatments:~* Gemcitabine and nab-paclitaxel (GnP)~* Oxaliplatin, leucovorin, irinotecan, and 5-FU (Modified FOLFIRINOX: mFOLFIRINOX)~* Liposomal irinotecan (Nal-IRI + 5-FU/LV)~* Oxaliplatin, leucovorin and 5-FU IV (FOLFOX)"
62702896|NCT05319730|ACTIVE_COMPARATOR|Paclitaxel or irinotecan|Participants receive paclitaxel 80-100 mg/m\^2 intravenously (IV) on days 1, 8, and 15 every 28-day cycle until progressive disease (PD) or discontinuation, or irinotecan 180 mg/m\^2 IV on day 1 of every 14-day cycle until PD or discontinuation.
62702897|NCT05319730|EXPERIMENTAL|Pembrolizumab + MK-4830 + paclitaxel or irinotecan|Participants receive pembrolizumab 200 mg IV once every 3 weeks (Q3W) for up to 35 cycles (cycle=21 days) or until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + paclitaxel 80-100 mg/m\^2 IV on days 1, 8, and 15 every 28-day cycle until PD or discontinuation or irinotecan 180 mg/m\^2 180 mg/m\^2 on day 1 every 14-day cycle until PD or discontinuation.
62702898|NCT05319730|EXPERIMENTAL|Pembrolizumab + MK-4830 + lenvatinib|Participants receive pembrolizumab 200 mg IV Q3W up to 35 cycles (cycle=21 days) until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + lenvatinib 20 mg oral administration every day until PD or discontinuation.
62702899|NCT05319730|EXPERIMENTAL|Sacituzumab tirumotecan|Participants will receive 4 mg/kg of sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation.
62702900|NCT06685757|EXPERIMENTAL|Felzartamab|
62702901|NCT06685757|PLACEBO_COMPARATOR|Placebo|
61958313|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
61958314|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
61958315|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
61958316|NCT01605162|EXPERIMENTAL|E7016 plus TMZ|
62143058|NCT01372085|EXPERIMENTAL|Part B: Sequence 2|Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
62702902|NCT06015529|NO_INTERVENTION|Control group - current practices|The investigating physicians of the participating centers in the control group will be free to provide care as they see fit. However, a reminder of national and European guidelines for PE management will be given to them and they will have the recommendation to apply a validated strategy. To make it easier, the different scores will be included in the clinical help-decision support software called SPEED. Investigators will be asked to enter data about the included patients directly into SPEED, which will act as the study's electronic case report form (eCRF). A paper version of the CRF will also be available.
62702903|NCT06015529|ACTIVE_COMPARATOR|Intervention group - 4PEPS strategy|Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. To make it easier to apply, the 4PEPS score will be included in SPEED. Investigators will be asked to enter the information relating to patients included in the study directly into SPEED before performing any testing. Entering these data will enable the 4PEPS score to be calculated automatically and specific recommendations to be provided. A paper version of the CRF will also be available
62702904|NCT06149481|EXPERIMENTAL|Arm 1|Retifanlimab + TriAdeno Vaccine + N-803
62702905|NCT06149481|EXPERIMENTAL|Arm 2|Retifanlimab + TriAdeno Vaccine + N-803 + SX-682
61958317|NCT05984615||Immunotherapy (IO) Cohort|
61958318|NCT05984615||Targeted Therapy (TT) Cohort|
61958319|NCT02940535|EXPERIMENTAL|Low Dose GnRHa|Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.
61958320|NCT02940535|ACTIVE_COMPARATOR|GnRHa Ultra-short Protocol|Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
61958321|NCT04073069|EXPERIMENTAL|The DR group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, 0.5ml diprospan, plus 14.5ml saline;
61958322|NCT04073069|ACTIVE_COMPARATOR|The R group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, plus 15ml saline;
62702906|NCT01799538|EXPERIMENTAL|1|Nebullizer
62702907|NCT01799538|ACTIVE_COMPARATOR|2|Inhaler
62702908|NCT03141684|EXPERIMENTAL|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT imaging, and collection of blood and urine at baseline. (CLOSED TO ACCRUAL)
61958323|NCT01217359|EXPERIMENTAL|Interferon Alfa-2b|Patients will receive a single dose of interferon
61958324|NCT02616406||Open repair|Repair group to be monitored with wearable activity monitors pre and post op.
61958325|NCT02616406||Laparoscopic group|Laparoscopic surgical repair group to be monitored with wearable activity monitors pre and post op.
61958326|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
61958327|NCT00607971|EXPERIMENTAL|1|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
61958328|NCT00621153|ACTIVE_COMPARATOR|1|Candesartan cilexetil 16mg monotherapy
62702909|NCT03141684|EXPERIMENTAL|Arm II (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT imaging, and collection of blood and urine at baseline.
61958329|NCT00621153|EXPERIMENTAL|2|Candesartan cilexetil 16mg/HCT combination therapy
61958330|NCT00621153|ACTIVE_COMPARATOR|3|candesartan cilexetil 32mg monotherapy
61958331|NCT00621153|EXPERIMENTAL|4|Candesartan Cilexetil 32 mg/HCT combination therapy
61958332|NCT02215512|EXPERIMENTAL|RRx-001 + WBRT|RRx-001 administered intravenously twice a week (10, 17, 33, 55 mg) in subjects with brain metastases receiving whole brain radiation therapy (WBRT).
61958333|NCT04784377|EXPERIMENTAL|High laser group|
61958334|NCT04784377|EXPERIMENTAL|low laser group|
62346329|NCT03532984||adults aged 50-59|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
62504269|NCT00129116|EXPERIMENTAL|Menhibrix F3/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
62702910|NCT06750029|EXPERIMENTAL|Investigation Group|Investigation group will be receiving standard care plus 15-minute MC visits twice daily during the first 48 hours of hospitalization
61958335|NCT04784377|OTHER|control group|
61958336|NCT04893538||A|First analysis: Patients with high Lymphocyte count Second analysis: Patients with low International Prognosis Score Third analysis: Patients with high Lymphocyte/monocyte ratio
61958337|NCT04893538||B|First analysis: Patients with low Lymphocyte count Second analysis: Patients with high International Prognostic Score Third analysis: Patients with low Lymphocyte/monocyte ratio
61958338|NCT00119106|EXPERIMENTAL|tenofovir disoproxil fumarate|Participants in the Tenofovir arm will receive daily oral tenofovir
61958339|NCT00119106|PLACEBO_COMPARATOR|Placebo|Participants in the Placebo are will receive daily oral placebo
61958340|NCT03119831|EXPERIMENTAL|C31G (Group A)|C31G
61958341|NCT03119831|EXPERIMENTAL|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
61958342|NCT03119831|EXPERIMENTAL|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
61958343|NCT03628820|EXPERIMENTAL|Therapy Dog|"This group is exposed to the therapy dog and handler. On a convenience sample of shifts, a dog will be available. Participants will not know when dogs will be present and will not be informed of whether or not they will see a dog on any given shift. The dog and handler will be kept out of site of other providers. Participants who agree to participate will be approached by study personnel between 3 and 7 hours into his or her shift and asked would now be a good time to see a therapy dog? If the physician answers yes, then the physician will be escorted to a separate private, quiet room away from the usual work area to interact with a therapy dog and handler. We will ask the physician to spend approximately 5 minutes with the therapy dog, but will not specify or mandate any time. Study personnel will record the time spent. Only the handler and dog will be present in the room."
61958344|NCT03628820|EXPERIMENTAL|Mandala Coloring|This group is not exposed to the therapy dog or handler. At 3-7 hours into the shift, study personnel will encourage providers to take a 5 min period of mindfulness, achieved by coloring mandalas. Participants will be escorted out of the work area to the same private, quiet room where the interaction occurs with the dog and handler in the therapy dog group. Participants will have their choice of one of three mandalas to color and will be provided a full palette of colored pencils. When the provider's time is up, study personnel will notify them of the five minute period. Study personnel will not be present in the room but will photograph the work when the participant is done with the session and record the image in REDcap. The original art work will be returned to the provider.
61958345|NCT03628820|NO_INTERVENTION|No Intervention|This group is not exposed to the therapy dog or handler.
62346330|NCT03532984||adults aged 60-69|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
62504270|NCT00129116|EXPERIMENTAL|Menitorix/Infanrix-penta Group|Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
62504271|NCT00129116|ACTIVE_COMPARATOR|Menjugate/Infanrix-hexa Group|Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
62504272|NCT02251509|EXPERIMENTAL|Carvedilol|carvedilol BID for 2 weeks
62702911|NCT06750029|NO_INTERVENTION|Control Group|Control Group will be receiving standard care without MC visits.
61958346|NCT05357313|EXPERIMENTAL|Bright light therapy group|10,000lux bright light
61958347|NCT05357313|PLACEBO_COMPARATOR|Placebo group|inactive negative ion generator
61958348|NCT01925937|EXPERIMENTAL|Coenzyme Q10 & Atorvastatin|10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
62702912|NCT03422848|ACTIVE_COMPARATOR|Water intervention arm|The water intervention group will increase their habitual daily water intake with 1.5 L of tap water. Furthermore they will receive general life style advice (general oral and written advice on diet and physical activity).
61958349|NCT01925937|ACTIVE_COMPARATOR|Atorvastatin & placebo|10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
61958350|NCT05801874||Hemiparetic patients|Hemiparetic patients assessed during gait and stance performance by means of different instrumental tools (smart and portable device vs 3D laboratory gait analysis) in order to evidence gait pattern; kinematics, kinetics and spatio-temporal data.
62143059|NCT01372085|EXPERIMENTAL|Part B: Sequence 3|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
62143060|NCT01372085|EXPERIMENTAL|Part B: Sequence 4|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
62143061|NCT00610558|EXPERIMENTAL|Arm 1: Juvenile Myoclonic Epilepsy|Juvenile Myoclonic Epilepsy group of subjects will participate for imaging assessment
62143062|NCT00610558|EXPERIMENTAL|Arm 2: Frontal Lobe Epilepsy|Frontal Lobe Epilepsy group of subjects will participate for imaging assessment
62346331|NCT03532984||adults aged 70-79|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
62346332|NCT03532984||adults aged 80+|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
62346333|NCT03532984||geriatric patients|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
62346334|NCT02027168||CPA treatment|CPA treatment group receives 20 hours of patient centered manual physical therapy
62346335|NCT03400137|ACTIVE_COMPARATOR|Healthy Volunteers|No family history (first degree relative) of glaucoma.
62346336|NCT03400137|ACTIVE_COMPARATOR|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness \< 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
62346337|NCT03400137|ACTIVE_COMPARATOR|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
61958351|NCT05801874||Healthy age matched subjects|Healthy age matched subjects assessed during gait and stance performance by means of different instrumental tools (smart and portable device vs 3D laboratory gait analysis) in order to evidence gait pattern; kinematics, kinetics and spatio-temporal data.
61958352|NCT01963585||Negative metacholine|Healthy control
61958353|NCT01963585||Positive metacholine|Hyperreactive airway disease - study group
61958354|NCT02326129||Obese with Type 2 Diabetes|Obese adolescents with Type 2 Diabetes
61958355|NCT02326129||Obese without Type 2 Diabetes|Obese adolescents without Type 2 Diabetes
61958356|NCT02326129||Normal weight|Normal weight adolescents
61958357|NCT03324308|EXPERIMENTAL|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
62143063|NCT00610558|EXPERIMENTAL|Arm 3: Normal Controls|Normal Controls, eligible subjects don't have Juvenile Myoclonic Epilepsy or Frontal Lobe Epilepsy will be placed in this group
62143064|NCT05364840|EXPERIMENTAL|STI-1558|Subjects will receive in each part either a single ascending dose (SAD): 300 mg, 600 mg, 1200 mg, 2000 mg on Day1 or as part of the multiple ascending dose (MAD): 300 mg, 600 mg, and 800 mg twice a day for 7.5 days
62346338|NCT05696262|EXPERIMENTAL|6-walking program|Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner.
62346339|NCT05696262|NO_INTERVENTION|Usual care|Usual care
62346340|NCT05628025||Trainees|Residents in urology or urologists with little LEP experience. Trainee group will be stratified by level of experience.
62346341|NCT05628025||Experts|Urologists with at least 5 years LEP experience.
62346342|NCT06382363|NO_INTERVENTION|Control|Subjects in the control group will be offered a free venous HbA1c test. Consistent with current practice at GOPCs, the venous sampling will be scheduled on a separate clinic visit at a set time within 1-2 weeks of recruitment. Test results will be available within one week. The subject will be informed via phone call regarding his/her DM risk, and if his/her HbA1c≥5.6%, he/she will be scheduled for a confirmatory OGTT within 2-4 weeks, ideally at the same clinic.
62346343|NCT06382363|EXPERIMENTAL|Intervention|Subjects in the intervention group will be offered a free POC-cHbA1c test to screen for hyperglycemia. The test will be performed on-site (i.e. during the same clinic visit of recruitment). Test results will be available within 10 minutes and the subject will be immediately informed of his/her DM risk, and for those with HbA1c≥5.6%, a confirmatory OGTT will be arranged on-site, scheduled within 2-4 weeks and ideally at the same clinic.
62346344|NCT02435550|EXPERIMENTAL|Acute Myeloid Leukemia|Patients with acute myeloid leukemia will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
62346345|NCT02435550|EXPERIMENTAL|Acute Lymphoblastic Leukemia|Patients with acute lymphoblastic leukemia will have blood, bone marrow aspirate , and saliva collected from them as part of routine care.
62702913|NCT03422848|OTHER|Control arm|Control group that will receive general life style advice (general oral and written advice on diet and physical activity).
62702914|NCT04339777|ACTIVE_COMPARATOR|Arm A|Low Intensity, Intermediate Intensity and High Intensity Conditioning with or without alemtuzumab
62702915|NCT04339777|ACTIVE_COMPARATOR|Arm B|Intermediate Intensity Conditioning with or without Alemtuzumab
62702916|NCT06444451|EXPERIMENTAL|Amlitelimab dose group 1|Subcutaneous injection as per protocol
62702917|NCT06444451|EXPERIMENTAL|Amlitelimab dose group 2|Subcutaneous injection as per protocol
62702918|NCT06444451|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection as per protocol
62702919|NCT01829724||Healthy volunteer|The control groups for each participant cohort will consist of up to 50 individuals spanning Objectives 1 and 2, for a total recruitment of up to 100 healthy volunteers within the same age range.
62702920|NCT01829724||Individuals with childhood-onset brain or peripheral injury|The childhood-onset brain injury group 120 individuals spanning the three objectives.
62702921|NCT06547346|EXPERIMENTAL|Patients well established on tube feeds will act as their own control|
62702922|NCT06748417|EXPERIMENTAL|Acute Cognitive Training Followed by Non-stimulating Rest Group|Participants will be in this group for approximately 11-14 days
62143065|NCT05364840|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo orally following either the SAD or MAD dosing schedule
62702923|NCT06748417|EXPERIMENTAL|Non-stimulating rest followed by acute cognitive training Group|Participants will be in this group for approximately 11-14 days
62143066|NCT01642719|PLACEBO_COMPARATOR|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline
62143067|NCT01642719|EXPERIMENTAL|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks. For example, if they spend 9 hr TIB during baseline, they will reduce their TIB to 8 hr.
62143068|NCT03489785||Movement|If there is unexpected movement
62702924|NCT06750406|EXPERIMENTAL|mind body exercises|The intervention consists of a structured program of mind-body exercises designed specifically for pregnant women. This involves a combination of yoga sessions, mindfulness meditation practices, deep breathing exercises, and progressive muscle relaxation techniques. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for eight weeks
62702925|NCT06750406|ACTIVE_COMPARATOR|Relaxation exercises|this includes Awareness about relaxation exercises including relax postures and generalized exercise interventions. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for eight weeks
62702926|NCT06751199|EXPERIMENTAL|Experimental|allogeneic islet combined with hUCMSCs
62702927|NCT06751199|ACTIVE_COMPARATOR|Comparator|allogeneic islet
62702928|NCT06679985|EXPERIMENTAL|Arm A: Casdozokitug Lower Dose + Toripalimab + Bevacizumab|
62702929|NCT06679985|EXPERIMENTAL|Arm B: Casdozokitug Higher dose + Toripalimab + Bevacizumab|
62702930|NCT06679985|ACTIVE_COMPARATOR|Arm C: Toripalimab + Bevacizumab|
62702931|NCT06749470|EXPERIMENTAL|Test Group|Jieyu Chufan Capsules Strength: 0.4 g/capsule, 3 × 12 capsules/plate/box Administration: 4 capsules, tid, 8 weeks
62143069|NCT03489785||No movement|If there is no unexpected movement
62143070|NCT04092322||Patients with subacute chronic stroke|Patients with subacute chronic stroke between the ages of 40-80
62143071|NCT04136990|ACTIVE_COMPARATOR|Isolated ACL reconstruction|Isolated ACL reconstruction only.
62143072|NCT04136990|EXPERIMENTAL|ACL + LEAT|ACL reconstruction combined with Lateral Extra-Articular Tenodesis (LEAT).
62143073|NCT06194695||DEB-TACE-len-anti-PD(L)1|Patients with advanced intrahepatic cholangiocarcinoma who was initially evaluated unsuitable for the radical therapy and received combined DEB-TACE plus lenvatinib (Len) and anti-PD1 or anti-PD-L1 antibodies as conversion therapy for downstaging.
62346346|NCT02435550|EXPERIMENTAL|Myelodysplastic Syndrome|Patients with myeloplastic syndrome will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
62346347|NCT02435550|EXPERIMENTAL|Myelofibrosis|Patients with myelofibrosis will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
62504273|NCT02251509|EXPERIMENTAL|Metoprolol tartrate|Metoprolol tartrate BID for 2 weeks
62702932|NCT06749470|PLACEBO_COMPARATOR|Control Group|Jieyu Chufan Capsules Placebo Strength: 0.4 g/capsule, 3 × 12 capsules/plate/box. Administration: 4 capsules, tid; 8 week
62702933|NCT04767568|EXPERIMENTAL|Blood test|"In Cohort A: 200 patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) OR with gross bleeding~In cohort B: 200 patients who have already performed colonoscopy candidates for surgery on their colorectal tumor"
62702934|NCT06750575||Chronic kidney disease stage 3-5|Participants with an age of 18 years or older and with CKD stage 3-5 (an estimated glomerular filtration rate of 60 mL/min/1.73m\^2 or lower for at least three months). Participants need to have an indication to start with furosemide as part of routine patient care.
62702935|NCT02790931|EXPERIMENTAL|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months.
62702936|NCT02790931|NO_INTERVENTION|Control Group|Patients will not receive any exercise treatment, will not have acess to the software, but they will keep their recommended clinical treatment.
62702937|NCT06681766|EXPERIMENTAL|Nomlabofusp|Subcutaneous injection of 0.8 mg/kg, with a maximum dose of 50 mg, once daily for 7 days
62702938|NCT06681766|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection once daily for 7 days
62702939|NCT06748300|EXPERIMENTAL|Web taban|
62702940|NCT06748300|EXPERIMENTAL|face to face|
62702941|NCT06748300|NO_INTERVENTION|control|
62702942|NCT06141473|EXPERIMENTAL|Frexalimab|Participants will receive Frexalimab infusion and placebo tablet.
62702943|NCT06141473|ACTIVE_COMPARATOR|Teriflunomide|Participants will receive teriflunomide tablet and placebo infusion.
62702944|NCT05034952|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to VX-548 and Hydrocodone bitartrate/ acetaminophen (HB/APAP) for 2 days.
62702945|NCT05034952|ACTIVE_COMPARATOR|HB/APAP|Participants received HB 5 mg / APAP 325 milligrams (mg) every 6 hours (q6h) for 2 days.
62702946|NCT05034952|EXPERIMENTAL|VX-548: Low Dose|Participants received VX-548 60 mg as first dose, followed by VX-548 30 mg every 12 hours (q12h) for 2 days.
62702947|NCT05034952|EXPERIMENTAL|VX-548: High Dose|Participants received VX-548 100 mg as first dose, followed by VX-548 50 mg q12h for 2 days.
62702948|NCT02320435|EXPERIMENTAL|Pertuzumab (Single-Agent or Combination Therapy)|Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.
62702949|NCT06749288|PLACEBO_COMPARATOR|Placebo control 4.1.0|Revive product form 4.1 - control
62702950|NCT06749288|EXPERIMENTAL|Active product 4.1.1|Revive product form 4.1 - active product 1
62702951|NCT05997082|EXPERIMENTAL|Participants in the intervention|Participants in the intervention will participate in the 6-week mindfulness self-compassion course delivered online.
62702952|NCT06748911|EXPERIMENTAL|Long Segment Barrett's Esophagus (LSBE)|Subjects diagnosed with Long Segment Barrett's Esophagus (LSBE)
62702953|NCT06748911|EXPERIMENTAL|Short Segment Barrett's Esophagus (SSBE)|Subjects diagnosed with Short Segment Barrett's Esophagus (SSBE)
62702954|NCT06748911|EXPERIMENTAL|Gastro Esophageal Reflux Disease|Subjects with Gastro Esophageal Reflux Disease (GERD) who are eligible for Barrett's Esophagus screening
62702955|NCT06749028|ACTIVE_COMPARATOR|Group B: Comparator Arm: Omega-3 alone.|Comparator Arm: Omega-3 alone
62702956|NCT06749028|EXPERIMENTAL|Group A: Intervention Arm: Omega-3 + Phospholipids.|Intervention Arm: Omega-3 + Phospholipids.
62702957|NCT06750328||Follow up after PPCI|To assess procedural success and short term clinical outcomes of primary PCI to isolated LCx acute
61958358|NCT00318630|EXPERIMENTAL|Subjects receiving treatment 1|Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.
61958359|NCT00318630|EXPERIMENTAL|Subjects receiving treatment 2|Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
62143074|NCT04666181|EXPERIMENTAL|Dual-task training|Dual-task training will consist of balancing on the dynamic stability platform and responding to auditory stimuli. Participants will perform 18 trials total in 3 blocks of 6 trials. Each trial will be 30 seconds (s) in duration followed by 30 s of rest (i.e. quiet standing on the platform while holding onto the rails.) Between each training block, the participant will step off the platform and rest for 2 minutes. Dual-task training will occur on consecutive visits 2-6.
62346348|NCT02435550|EXPERIMENTAL|Multiple Myeloma|Patients with multiple myeloma will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
62346349|NCT02937532|PLACEBO_COMPARATOR|GHE + TOBT training|Subjects will receive general health education and task-oriented balance training.
62702958|NCT05825469|EXPERIMENTAL|Nutrition Algorithm (NACHO)|"Study procedures will be conducted as follows:~* Development of nutrition algorithm by dietitian panel participants with oncology clinician consultation via convened group meetings.~* Refinement of draft algorithms through feedback from participants and Family Advisory Council (PFAC) members.~* Baseline questionnaires for participants.~* Semi-structured interviews and/or focus groups with participants to evaluate algorithm usability and acceptability.~* Participant questionnaires."
62702959|NCT06750705|EXPERIMENTAL|PechaKucha presentation|This arm of the study will involve nursing students receiving reinforcement training using the PechaKucha presentation method.
62702960|NCT06750705|ACTIVE_COMPARATOR|PowerPoint presentation|This arm of the study will involve nursing students receiving reinforcement training using a traditional PowerPoint presentation.
62702961|NCT06751004|EXPERIMENTAL|BALLISTIC SIX EXERCISES|The Ballistic Six exercise uses resistance-band latex tube (red) and fitness balls (2-lb for one extremity training / 6-lb for dual extremity training). The 6 exercises includes; External rotation with latex tube, 90/90 external rotation with latex tube, overhead soccer throws using a fitness ball, 90/90 external rotation side-throw using a fitness ball, deceleration baseball throws using a fitness ball and baseball throws using a medicine ball
62702962|NCT06751004|EXPERIMENTAL|RESISTANCE-BAND EXERCISES|Week wise resistance-band training includes; 1-4 weeks: Standing Shoulder Press, Chest Fly, Triceps French Press, Biceps Curl, Rhomboid Squeeze, 5-6 weeks: Trunk Twist, Reverse Flies, Concentration Curl Scapular, Retraction, 7-8 weeks: Straight Arm Pull down, Chest Press, Triceps Kick Back, Rear Deltoid, Dead Lift
62702963|NCT06683846|EXPERIMENTAL|Ivocizumab (20mg/kg）in rare tumors|Participants will receive Ivocizumab 20mg/kg of body weight via intravenous (IV) infusion on Days 1 of a 21-day treatment cycle until disease progression or unacceptable toxicity, or full 2 years of treatment, whichever occurs first.
62702964|NCT06750835|ACTIVE_COMPARATOR|SPSIP block|Serratus posterior superior intercostal plane block
62702965|NCT06750835|ACTIVE_COMPARATOR|SAP block|Serratus anterior plane block
62702966|NCT06750835|ACTIVE_COMPARATOR|Paravertebral block|Paravertebral block
61958360|NCT06064643||Survey Arm|All participants will be asked to complete an online survey
61958361|NCT06064643||Interview Arm|A sample of the survey group will be asked to take part in a single qualitative interview
61958362|NCT06064643||Bleed Diary Arm|A sample of the survey group will be asked to take part in a 30 day bleed diary
61958363|NCT05043129||HIV infenction/AIDS|experimental group
62143075|NCT01933997|EXPERIMENTAL|MG01CI 1400 mg|
62143076|NCT01448109|ACTIVE_COMPARATOR|Hydrocortisone|
62143077|NCT01448109|PLACEBO_COMPARATOR|Sterile air filled vial|
62143078|NCT01233934|ACTIVE_COMPARATOR|Dexchlorpheniramine 1% Cream|
61958364|NCT05043129||Healthy population|Control group
61958365|NCT02362061||pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant
62143079|NCT01233934|EXPERIMENTAL|Dexchlorpheniramine 1% Gel|
62346350|NCT02937532|ACTIVE_COMPARATOR|CBT + TOBT training|Subjects will receive group-based cognitive behavioral therapy and task-oriented balance training.
62702967|NCT05245032||Feasibility testing|During the screening visit, blood and/or a bone marrow sample will be obtained for the patient's standard clinical evaluation. An aliquot of the blood and/or marrow sample will be obtained for ex vivo drug sensitivity assay
61958366|NCT02362061||Non pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant
61958367|NCT03208244|EXPERIMENTAL|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet
61958368|NCT06385600|ACTIVE_COMPARATOR|labetalol in the managment of severe preeclampsia|labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient
61958369|NCT06385600|ACTIVE_COMPARATOR|phentolamine in the managment of severe preeclampsia|phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient
61958370|NCT06485167|ACTIVE_COMPARATOR|Experimental: Group 1 Active Treatment Group (AG)|"Group 1 Active treatment group (AG)~● The AG group consists six HIFEM® treatments of 28 minutes at a frequency of one session/week for six consecutive weeks at program level 1 of 2. The woman will be sitting fully clothed on the HIFEM-chair. Before the first treatment, the woman answers questions about the degree of urinary leakage and records the frequency of urinary leakage before treatment and to next treatment."
62346351|NCT02475395|EXPERIMENTAL|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
62702968|NCT06748287|EXPERIMENTAL|iGrow Hair Growth System|male or female subjects ages 21-85 with alopecia randomized to use iGrow Hair Growth System photobiomodulation device.
62702969|NCT06748287|ACTIVE_COMPARATOR|Capillus352|male or female subjects ages 21-85 with alopecia randomized to use Capillus352 photobiomodulation device.
62346352|NCT02475395|EXPERIMENTAL|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
62702970|NCT06748287|EXPERIMENTAL|HairMax Ultima 12 Lasercomb|male or female subjects ages 21-85 with alopecia randomized to use HairMax Ultima 12 Lasercomb photobiomodulation device.
62702971|NCT06748287|EXPERIMENTAL|HairMax Laserband 82|male or female subjects ages 21-85 with alopecia randomized to use HairMax Laserband 82 photobiomodulation device.
62702972|NCT05652504|EXPERIMENTAL|Arm 1|(n = 30) pregnant women will receive three doses of PfSPZ Vaccine (9x10\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, 29 days
62702973|NCT05652504|PLACEBO_COMPARATOR|Arm 2|(n = 30) pregnant women will receive normal saline via DVI at 1, 8, 29 days
62702974|NCT03117946|EXPERIMENTAL|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.~Tumor tissues will be collected if available."
62702975|NCT03253172|PLACEBO_COMPARATOR|Placebo|Placebo
62702976|NCT03253172|EXPERIMENTAL|Potassium Chloride|Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
62702977|NCT03253172|EXPERIMENTAL|Potassium Citrate|Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
62702978|NCT04751370|EXPERIMENTAL|Treatment (nivolumab, ipilimumab, radiation therapy, TME)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for 2 cycles. Starting at least 2 weeks but no longer than 6 weeks after completion of cycle 2 of nivolumab and ipilimumab, patients undergo short-course radiation therapy of 5 fractions daily for 1 week. Patients then continue to receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. 8-12 weeks after completion of 4th cycle of nivolumab and ipilimumab, patients undergo TME. Patients also undergo MRI and CT prior to TME and during follow up, and undergo sigmoidoscopy prior to TME.
62702979|NCT00001975||Group 1|Patients will be those already diagnosed with TSC (definite or possible)
62702980|NCT03896503|ACTIVE_COMPARATOR|Cohort I Arm I (topotecan hydrochloride)|Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants may crossover to Arm II at disease progression. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study.
62346353|NCT01995136|EXPERIMENTAL|TRAVATAN Z|Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
61958371|NCT06485167|SHAM_COMPARATOR|Experimental: Group 2 Sham-treatment Control Group (CG)|"Group 2 Sham-treatment Control Group (CG)~● The CG group consists six non-active HIFEM® treatments (sham-treatment) of 28 minutes at a frecquency of one session/week for six consecutive weeks. The sham-treatment will provide some sensation but without active HIFEM technology. The programming for the sham treatment will be amplitude limited, with the setting below the therapeutic level (\<10% effect).The participants will be placed on the HIFEM-chair in the same way as the AG group. Before the first treatment, the woman answers questions about the degree of urinary leakage and records the frequency of urinary leakage."
61958372|NCT00514111||HVC Patients|HVC patients attended in SAE e HD.
61958373|NCT00569608|EXPERIMENTAL|EDA|Neonates submitted to the protocol of early discharge.
61958374|NCT00569608|NO_INTERVENTION|SDP|Discharge following the standard protocol of the neonatal intensive care unit.
61958375|NCT02301000|EXPERIMENTAL|Intestinal microbiota therapy|The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
61958376|NCT02301000|ACTIVE_COMPARATOR|Metronidazole|The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days
61958377|NCT00950105|EXPERIMENTAL|CPSI-2364 1 mg p.o.|Single dose
61958378|NCT00950105|EXPERIMENTAL|CPSI-2364 10 mg p.o.|single dose
62346354|NCT01016691|EXPERIMENTAL|High Dose Drug Device/ bimatoprost 0.03%|drug device containing 65 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
62504274|NCT03191838|EXPERIMENTAL|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
62504275|NCT03191838|NO_INTERVENTION|Controls|The control group will not be given distraction equipment.
61958379|NCT00950105|EXPERIMENTAL|CPSI-2364 30 mg p.o.|single dose
61958380|NCT00950105|EXPERIMENTAL|CPSI-2364 90 mg|single dose
61958381|NCT00950105|EXPERIMENTAL|CPSI-2364 270 mg p.o.|single dose
61958382|NCT04552847|EXPERIMENTAL|Patients|"In the main part of the trial (part A) 75 patients with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/CT scan.~In part B of the trial 10 up to 20 patients with with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/MR scan."
61958383|NCT03266965|EXPERIMENTAL|Histidine Intervention Group|A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.
61958384|NCT01785693|OTHER|NaC1|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
61958385|NCT01785693|OTHER|Levobupivacaine + clonidine|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
61958386|NCT00303784|ACTIVE_COMPARATOR|LHRH agonists|"Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended anti-flare medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice."
62346355|NCT01016691|EXPERIMENTAL|Low Dose Drug Device / bimatoprost 0.03%|drug device containing 45 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
62346356|NCT01016691|OTHER|Placebo Device / bimatoprost 0.03%|placebo drug device worn over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
62346357|NCT04699071|EXPERIMENTAL|patients with recurrent clear cell carcinoma of gynecological origin (CCGC)|Recurrent clear cell carcinoma of gynecological origin (ovarian and endometrial primary) after progression on chemotherapy.
62346358|NCT01431144|ACTIVE_COMPARATOR|Connective tissue autograft|A connective tissue autograft harvested from the palate was grafted onto the facial of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
62346359|NCT01431144|EXPERIMENTAL|connective tissue allograft|An acellular dermal matrix allograft was grafted on the facial surface of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
62346360|NCT04752124|ACTIVE_COMPARATOR|HIIT+CT|HIIT combined with conventional rehabilitation.
62346361|NCT04752124|PLACEBO_COMPARATOR|Conventional therapy|Conventional rehabilitation will be provided to this group of patients.
62346362|NCT00796133|ACTIVE_COMPARATOR|1|0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
62346363|NCT00796133|ACTIVE_COMPARATOR|2|1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
62346364|NCT00796133|ACTIVE_COMPARATOR|3|1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
62346365|NCT03385382||Dexamethasone group|Patients with diabetic macular edema receiving dexamethasone
62346366|NCT03385382||ranibizumab|Patients with diabetic macular edema receiving ranibizumab
62346367|NCT04426370||Case|100 rheumatoid arthritis patients (age from 20 to 70 years)
62346368|NCT04426370||Control|95 healthy volunteer
62346369|NCT03968614|EXPERIMENTAL|Electrical Dry Needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
62346370|NCT03968614|ACTIVE_COMPARATOR|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
62346371|NCT01767870|EXPERIMENTAL|FIT-Sigmoidoscopy|This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.
62346372|NCT01767870|EXPERIMENTAL|Colonoscopy|This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.
62504276|NCT02071368|EXPERIMENTAL|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
62504277|NCT02071368|EXPERIMENTAL|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x \[150 mg/500 mg\]) formulation 1, under fed conditions.
62504278|NCT02071368|EXPERIMENTAL|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x \[150 mg/500 mg\]), formulation 2, under fed conditions.
62504279|NCT03388502|EXPERIMENTAL|Text Messaging (SMS) Bot|Patients undergoing total joint (hip \& knee) arthroplasty will be enrolled in their physician's automated 'Text Messaging (SMS) Bot' in addition to receiving the routine perioperative education and instructions.
62702981|NCT03896503|EXPERIMENTAL|Cohort I Arm II (topotecan hydrochloride, berzosertib (M6620))|Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study.
62702982|NCT03896503|EXPERIMENTAL|Cohort II (exploratory cohort: topotecan, berzosertib (M6620))|Cohort II: Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study.
62702983|NCT04181060|ACTIVE_COMPARATOR|Arm A (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, MUGA, CT and may undergo MRI and blood and urine sample collection on study.
62702984|NCT04181060|EXPERIMENTAL|Arm B (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, MUGA, CT and may undergo MRI and blood and urine sample collection on study.
62702985|NCT00039676||Standard|People that have blood or lymph node cancer, or a family history of leukemia or lymphoma.
62702986|NCT05751668|EXPERIMENTAL|Arm I (paclitaxel, GM1)|Patients receive GM1 IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.
62702987|NCT05751668|PLACEBO_COMPARATOR|Arm II (paclitaxel, placebo)|Patients receive placebo IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.
62702988|NCT02339012||Frail|frail individuals ages 50-64 years; 65-79 years; 80+ years
62702989|NCT02339012||Healthy|healthy individuals ages 20-34 years; 35-39 years; 50-64 years; 65-79 years; 80+ years
62702990|NCT02339012||Non-Healthy/Non-Frail|non-healthy/non-frail individuals ages 20-34 years; 35-39 years; 50-64 years; 65-79 years; 80+ years
62702991|NCT02014246||1|Participants with confirmed or suspected movement disorder or dementia diagnosis and their affected and unaffected family members will be potential candidates for the study, well as unrelated, healthy individuals (known as control samples.
62702992|NCT02014246||2|We plan to enroll 12,000 study subjects (10,000 patients, 1,000 asymptomatic family members, 1,000 neurological normal controls) for this study
61958387|NCT00303784|EXPERIMENTAL|Oestrogen Patches|Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
62346373|NCT03102320|EXPERIMENTAL|Cholangiocarcinoma|"Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin. Please note the study is no longer recruiting for the cholangiocarcinoma safety lead-in phase.~During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin. Please note the main study phase for cholangiocarcinoma will no longer be going ahead."
62702993|NCT03964532|EXPERIMENTAL|Phase I/Phase II|Talazoparib (1mg by mouth \[PO\] daily D1-28) will be provided as monotherapy for the first cycle. Starting with cycle 2 and for all subsequent cycles, treatment with avelumab (800 mg intravenously \[IV\] D1 every 2 weeks) will be added to talazoparib.
62702994|NCT02723955|EXPERIMENTAL|Part 1A: Dose escalation feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.
62702995|NCT02723955|EXPERIMENTAL|Part 1B: Expansion feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.
62346374|NCT03102320|EXPERIMENTAL|Adenocarcinoma of the pancreas|Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine
62346375|NCT03102320|EXPERIMENTAL|Other solid tumors|(Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors
62504280|NCT03388502|ACTIVE_COMPARATOR|Routine Perioperative Instructions|Patients undergoing total joint (hip \& knee) arthroplasty will receive only their 'Routine Perioperative Instructions'.
62504281|NCT03001024|EXPERIMENTAL|Implementation of WayToServe Español|The experimental design to be employed in the trial evaluation of WayToServe Español (WTS-E) in this direct-to-Phase II project is a two-arm randomized field trial design (WTS-E vs. Usual and Customary \[UC\] training) with three assessment points (pretest - immediate post-test - 9 month follow-up).This constitutes a 2 (level of RBS training intervention) x 3 (level of time assessment) mixed factorial design. Spanish dominant onsite and off-site licensed alcohol premises will be the unit of analysis, stratified by type of premise (onsite vs. off-site sales) and state (New Mexico vs. Texas).
62702996|NCT02723955|EXPERIMENTAL|Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
62702997|NCT02723955|EXPERIMENTAL|Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.
62702998|NCT02723955|EXPERIMENTAL|Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy)|Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.
62702999|NCT02723955|EXPERIMENTAL|Part 2B: Expansion-feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
62703000|NCT02723955|EXPERIMENTAL|Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.
62346376|NCT04603391|EXPERIMENTAL|CBD, then placebo|"Subjects received a three day run in of CBD 750 mg orally twice daily (administered as as 7.5 mL of Epidiolex® solution \[100 mg/ml\]). On day four, all subjects returned to the clinical research center to receive one oral dose of CBD 750 mg (administered as as 7.5 mL of Epidiolex® solution \[100 mg/ml\]) and one 10 mg tablet of dl-methylphenidate (Ritalin®) orally in a fed state (a 30 minute standardized breakfast).~After a minimum washout period of five days, subjects received a three day run in of 7.5 ml of Epidiolex® placebo solution (no CBD) orally twice daily. On day four, all subjects returned to the clinical research center to receive one oral dose of 7.5 mL of Epidiolex® placebo solution (no CBD) and one 10 mg tablet of dl-methylphenidate (Ritalin®) orally in a fed state (a 30 minute standardized breakfast)."
62346377|NCT04603391|EXPERIMENTAL|Placebo, then CBD|"Subjects received a three day run in of 7.5 ml of Epidiolex® placebo solution (no CBD) orally twice daily. On day four, all subjects returned to the clinical research center to receive one oral dose of 7.5 mL of Epidiolex® placebo solution (no CBD) and one 10 mg tablet of dl-methylphenidate (Ritalin®) orally in a fed state (a 30 minute standardized breakfast).~After a minimum washout period of five days, subjects received a three day run in of CBD 750 mg orally twice daily (administered as as 7.5 mL of Epidiolex® solution \[100 mg/ml\]). On day four, all subjects returned to the clinical research center to receive one oral dose of CBD 750 mg (administered as as 7.5 mL of Epidiolex® solution \[100 mg/ml\]) and one 10 mg tablet of dl-methylphenidate (Ritalin®) orally in a fed state (a 30 minute standardized breakfast)."
62346378|NCT06251219||Case cohort|Clinically diagnosed HFMD children of either sex, aged 6 months - 18 years old in the study sites
62346379|NCT05202769||Healthy Volunteers|20 healthy volunteers above the age of 18 in a laboratory setting with video clips taken under varying conditions of lighting, distance between the cameras and the participants' faces and with various positions and limb movements involved.
62346380|NCT05202769||ICU patients|Group/Cohort Description: 20 patients above the age of 18 years and able to provide consent, admitted to the ICU with various underlying conditions and comorbidities. Video clips are taken under varying conditions of lighting, positions and with ongoing care and procedures.
62346381|NCT04084626|EXPERIMENTAL|PD-1 antibody|PD-1 antibody and lenalidomide administered in 2 week cycles for 6 cycles.
62346382|NCT02595047|EXPERIMENTAL|tissue/ organ prefabrication|in vivo generation of autologous tissue for joint replacement
62346383|NCT01240655|EXPERIMENTAL|LCL161 + Paclitaxel|
62346384|NCT02469792|EXPERIMENTAL|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
62346385|NCT04172753|EXPERIMENTAL|Rectal and anal cancer|In this arm patients with rectal and anal cancer are recruited.
62346386|NCT04172753|EXPERIMENTAL|Prostate cancer|In this arm patients with prostate cancer are recruited.
62346387|NCT04172753|EXPERIMENTAL|Head and neck cancer|In this arm patients with head and neck cancers are recruited.
62346388|NCT04172753|EXPERIMENTAL|Esophageal cancer|In this arm patients with esophageal cancer are recruited.
62346389|NCT04172753|EXPERIMENTAL|Breast Cancer|In this arm patients with breast cancer are recruited.
62346390|NCT04172753|EXPERIMENTAL|Central nervous system tutors|In this arm patients with tumors of the central nervous system are recruited.
62346391|NCT04172753|EXPERIMENTAL|Palliative treatments|In this arm patients with palliative treatments are recruited.
62346392|NCT04172753|EXPERIMENTAL|Other|In this arm patients with other tumors are recruited.
62346393|NCT04172753|EXPERIMENTAL|Imaging only|In this arm patients receive only imaging on the MR-Linac
62346394|NCT05517330|EXPERIMENTAL|Treatment Cohort|"* Tislelizumab administration on days 1 and 22, and afatinib continuous administration from days 1 to 42~* Standard of care surgery"
62346395|NCT01193140|EXPERIMENTAL|Arm A|
62346396|NCT06209814|ACTIVE_COMPARATOR|Conventional denture|
62346397|NCT06209814|EXPERIMENTAL|maxillary open-faced denture|
62346398|NCT03543358|EXPERIMENTAL|Arm A: Post-Treatment Follow-Up/Optional Retreatment|Arm A includes participants who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone per participant per retreatment period.
62346399|NCT03543358|EXPERIMENTAL|Arm B: Continued Treatment|Arm B includes participants who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
62346400|NCT02679209|EXPERIMENTAL|Bone allograft|commercially available demineralized bone matrix putty allograft will be used to fill in the defect after opening a periodontal flap
62346401|NCT02679209|EXPERIMENTAL|Amnion chorion membrane|Amnion chorion commercially available allograft bioresorbable membrane as a guided tissue regeneration technique will be used to in the defect after opening a periodontal flap
62346402|NCT00542724|EXPERIMENTAL|A|VIAject™
62346403|NCT00542724|ACTIVE_COMPARATOR|B|Regular Human Insulin
62703001|NCT02723955|EXPERIMENTAL|Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.
62703002|NCT02723955|EXPERIMENTAL|Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.
62346404|NCT01795586|EXPERIMENTAL|Dose Escalation|Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
62346405|NCT00470652||1|Pre-intervention patients admitted to our ED in the month prior to the intervention, before the 'computer-assisted decision support' is turned on (the intervention)
62346406|NCT00470652||2|Short-term post-intervention cohort of patients admitted in the month following the initiation of the 'computer-assisted decision support' for pain management
62346407|NCT00470652||3|long-term post-intervention cohort of patients admitted on the 6th month following the initiation of the 'computer-assisted decision support' for pain management
62346408|NCT00326417|EXPERIMENTAL|Cyclophosphamide 150mg|Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)
62346409|NCT00326417|EXPERIMENTAL|Cyclophosphamide 100mg|Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)
62346410|NCT00326417|EXPERIMENTAL|Cyclophosphamide 50mg|Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)
62703003|NCT04470726|EXPERIMENTAL|AIV001 Treatment Dose 1|Intradermal/intratumoral, Dose 1
62703004|NCT04470726|EXPERIMENTAL|AIV001 Treatment Dose 2|Intradermal/intratumoral, Dose 2
62504282|NCT03001024|ACTIVE_COMPARATOR|Usual and Customary RBS Training|The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
62504283|NCT06535802||Observational cohort I|Consumer advocates attend a focus group on study.
62504284|NCT06535802||Observational cohort II|Clinicians complete interviews on study.
62703005|NCT04470726|EXPERIMENTAL|AIV001 Treatment Dose 3|Intradermal/intratumoral, Dose 3
62703006|NCT04470726|EXPERIMENTAL|AIV001 Treatment Dose 4|Intradermal/intratumoral, Dose 4
62703007|NCT06750380|EXPERIMENTAL|Tailored mat exercise program|The Group A will receive TENS plus moist hot pack and follow the Tailored mat exercise program for 10 weeks, two times per week, in 45-min sessions under supervision of trained physical therapist. The choice of exercises will be made based on the suggested exercises of Wood for the treatment of back pain, while the easiest versions of each exercise would be selected in order for the program to be adapted to older adults. Patient's outcomes will be measured at baseline and after 10 weeks.
62346411|NCT00326417|EXPERIMENTAL|Fludarabine|Fludarabine only (no Cyclophosphamide administered)
62346412|NCT01898364|EXPERIMENTAL|GZ402666 (neoGAA) Group 1 - 5 mg|Intravenous infusion of 5mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks
62346413|NCT01898364|EXPERIMENTAL|GZ402666 (neoGAA) Group 1 - 10 mg|Intravenous infusion of 10mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
62346414|NCT01898364|EXPERIMENTAL|GZ402666 (neoGAA) Group 1 - 20 mg|Intravenous infusion of 20mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
62346415|NCT01898364|EXPERIMENTAL|GZ402666 (neoGAA) Group 2 - 5 mg|Intravenous infusion of 5mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
62346416|NCT01898364|EXPERIMENTAL|GZ402666 (neoGAA) Group 2 - 10 mg|Intravenous infusion of 10mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
62346417|NCT01898364|EXPERIMENTAL|GZ402666 (neoGAA) Group 2 - 20 mg|Intravenous infusion of 20mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
62346418|NCT01084642||survey|Participants will be asked to complete a survey as a one time assessment.
62346419|NCT03303040|EXPERIMENTAL|Stimulation|Electrical stimulation of hemidiaphragm
62346420|NCT03303040|NO_INTERVENTION|Control|No stimulation of hemidiaphragm
62346421|NCT06070740|EXPERIMENTAL|Combination therapy as first-line treatment|Durvalumab combined with XELOX chemotherapy as the first-line treatment
62504285|NCT06535802||Observational cohort III|iCCaRE project representatives test the virtual health intervention, complete a survey, and attend a focus group on study.
62504286|NCT06535802||Observational cohort IV|Non iCCaRE affiliated member tests the virtual health intervention, complete a survey, and attends a focus group on study.
62703008|NCT06750380|ACTIVE_COMPARATOR|McKenzie exercises|The Group B will receive McKenzie exercises plus moist hot pack and TENS in the region of lumbar spine for 10 minutes and Mckenzie exercises of seven to ten repetitions for 45 min/session two times per week for ten weeks. Patient's outcomes will be measured at baseline and after 10 weeks
62703009|NCT05063565|EXPERIMENTAL|TheraSphere followed by Durvalumab and Tremelimumab|TheraSphere followed by Tremelimumab plus Durvalumab administered once, then repeated administration of Durvalumab monthly up 18 months.
62703010|NCT05554393|EXPERIMENTAL|ARM I (daunorubicin, cytarabine, venetoclax)|Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment, patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
61958388|NCT06096753||Test Group|The Test Group will include patients rehabilitated according to the full-arch method (Columbus Bridge ProtocolTM) with immediate loading for at least 6 months prior to the first nocturnal recording using Bruxoff®.
62346422|NCT04295200|EXPERIMENTAL|Dry needling with electrical stimulation|Use of dry needles (this is the generic name for sterile, solid filament needles) are inserted into the lumbar multifidi. Intramuscular electrical stimulation will then be applied by attaching a six-lead electrical stimulation unit to the needles. Electrical stimulation will be applied through the needles at the participant's desired frequency (between 4-6 Hz) and for up to 10 minutes total.
62346423|NCT02616016|OTHER|MRI guided High Intensity Focused Ultrasound Treatment|"Intervention Group The interventional radiologist will locate the target tissue and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan.~An individual treatment sonication will last approximately 30 seconds."
62346424|NCT06061042|EXPERIMENTAL|Early time-restricted eating|"* 50% of daily calories at breakfast, 35% at lunch and 15% at dinner. 85% of calories consumed in 6h, i.e., between 7AM and 1PM.~* Eating period, 10h (7AM-5PM); fasting period, 14h; Breakfast between 7 and 8 AM; lunch between 12 AM and 1 PM; dinner between 4 and 5 PM."
62346425|NCT06061042|EXPERIMENTAL|Late time-restricted eating|"* 15% of daily calories at breakfast, 35% at lunch and 50% at dinner. 85% of calories consumed in 6h, i.e., between 2PM and 8PM.~* Eating period, 10h (10AM-8PM), fasting period, 14h; Breakfast between 10 and 11 AM; lunch between 2 and 3 PM; dinner between 7 and 8 PM."
61958389|NCT06096753||Control Group|The Control Group will include healthy subjects and volunteers awaiting implant-prosthetic rehabilitation of intercalated edentulism (i.e. single-tooth gap) who have natural dentition up to the first molar.
62703011|NCT05554393|EXPERIMENTAL|ARM II (azacitidine, venetoclax)|Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
62714929|NCT01105663||Sedated, Intubated, Midazolam|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
61958390|NCT02261155|OTHER|Hypnosis|hypnotic induction followed by relaxation and pleasant imagery
61958391|NCT03218644|ACTIVE_COMPARATOR|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
61958392|NCT03218644|EXPERIMENTAL|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
61958393|NCT04556513||Patient|Patient hospitalized in ICU for PCR-proven SARS-COV-2 infection
61958394|NCT02705469|EXPERIMENTAL|Dose Escalation and Dose Confirmation - ZEN003694 Single Agent|ZEN003694 will be administered orally as a single agent once daily in 28-day cycles, enrolling mCRPC patients.
61958395|NCT00602797|EXPERIMENTAL|Treatment (vinorelbine tartrate, paclitaxel)|Patients receive vinorelbine tartrate IV over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks.
61958396|NCT02216734|EXPERIMENTAL|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
61958397|NCT02216734|NO_INTERVENTION|Standard of Care Arm|Standard of Care: Nurses may identify HIV+ mothers lost to follow-up (LTFU); village health workers (VHWs) may conduct home visits to reduce LTFU of HIV+ mothers. LTFU activities are not standardised throughout all Ministry of Health and Child Care facilities.
61958398|NCT00456014|EXPERIMENTAL|1 - SSRI|Participants will receive standardized pharmacotherapy with the SSRI escitalopram over 8 weeks. Non-remitters after 8 weeks will be offered standardized pharmacotherapy with desipramine
61958399|NCT06504095|EXPERIMENTAL|intervention group (Flipped Teaching Method Group)|"The Flipped Teaching method will be used to provide patient safety training to the intervention group of students."
62346426|NCT05125107||Group 1|Predominant focal residual disease without major gradient
62346427|NCT05125107||Group 2|Predominant focal residual disease with major gradient
62346428|NCT05125107||Group 3|Predominant diffuse residual disease without major gradient
62346429|NCT05125107||Group 4|Predominant diffuse residual disease with major gradient
62346430|NCT01806636||Treatment|Patients treated with PneumRx Coil System
62346431|NCT01017809|OTHER|Oxali/Topotecan|Patients enrolled to NYU 03-67 will be receiving Oxaliplatin 85 mg/m2 IV over 120 minutes on Day 1 and 15 Topotecan 0.4mg/m2/day CIV from D1 to 15 (in addition to the assigned intervention)
62346432|NCT02065596|EXPERIMENTAL|Immunomodulation with Fludarabine prior to HSCT|Fludarabine given beginning at 25mgm/m2 three times per day. Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
62346433|NCT04658472|EXPERIMENTAL|SOC-Refractory Initial Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately (\~)at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they will not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
62504287|NCT06535802||Observational cohort V|Patients complete surveys and participate in the virtual health intervention on study. Patients complete survey and an interview during follow up.
61958400|NCT06504095|NO_INTERVENTION|Control group (Traditional Method Group)|"The control group of students will receive patient safety training using the traditional method. No intervention will be applied."
61958401|NCT01983813|EXPERIMENTAL|PHCVRS intervention|Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
61958402|NCT01983813|OTHER|Usual care/Personal Health Record|Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
61958403|NCT02517983||Chronic respiratory disease|
61958404|NCT06304129|EXPERIMENTAL|Blood ponction|All patients are in the experimental group
62504288|NCT01216410|ACTIVE_COMPARATOR|Metoclopramide|Prophylaxis with metoclopramide and phenylephrine infusion.
62504289|NCT01216410|PLACEBO_COMPARATOR|Phenylephrine infusion|Prophylactic phenylephrine infusion and placebo antiemetics
62504290|NCT01216410|ACTIVE_COMPARATOR|Combination Group|Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion
62504291|NCT05424133|EXPERIMENTAL|Active cycle of breathing technique|Group A will receive Active cycle of breathing technique with routine chest physiotherapy.
62504292|NCT05424133|ACTIVE_COMPARATOR|High frequency chest wall oscillation|Group B will receive High frequency chest wall oscillations with routine chest physiotherapy
61958405|NCT02959320|ACTIVE_COMPARATOR|Direct Anterior Approach|All patients receiving a hip hemiarthroplasty through a Direct Anterior Approach (DAA) will have their surgeries performed with the aid of fluoroscopy on an OSI Hana table that allows the operative limb to be manipulated through range of motion and traction while keeping the pelvis stabilized. This table also has a radiolucent platform about the pelvis, enabling the surgery to be fluoroscopically assisted. The incision for the DAA will extend from a proximal point about 2 cm distal and 2 cm lateral to the ASIS to a point 8-12 cm distal and slightly lateral to this.
61958406|NCT02959320|ACTIVE_COMPARATOR|Anterolateral Approach|All patients receiving a hip hemiarthroplasty through an the Anterolateral Approach (ALA) will have their surgeries performed on a standard OR table in a contralateral lateral decubitus position. With the leg in the position of sleep, a straight 8-12 cm incision will be made, centered over the greater trochanter and femoral shaft with 1/3 of the incision extending superior to the tip of the greater trochanter.
61958407|NCT02908360||Patients with allergic rhinitis|Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria
61958408|NCT02908360||Patients with atopic dermatitis|The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD\> 50).
61958409|NCT02908360||Patients with allergic asthma|The patient has allergic asthma diagnosed according to the criteria GINA21
62143080|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
62143081|NCT02070809|EXPERIMENTAL|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
62143082|NCT02070809|ACTIVE_COMPARATOR|split-thickness skin graft method|This method is traditional split-thickness skin graft
62143083|NCT05499663|EXPERIMENTAL|POSTHOC app|
62143084|NCT05499663|NO_INTERVENTION|Control|
62143085|NCT02934932|EXPERIMENTAL|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
62143086|NCT02934932|EXPERIMENTAL|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
62143087|NCT02934932|PLACEBO_COMPARATOR|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
62143088|NCT05949866|EXPERIMENTAL|Movement and Cognition Intervention group (MAC)|Movement and Cognition group is the behavioral treatment group.
62143089|NCT05949866|PLACEBO_COMPARATOR|Health Tracker group (Control)|Health tracker group is the control group.
62143090|NCT03963466|EXPERIMENTAL|group 1|(left side of cheek) 1064-nm Q-Switched fractional laser+drug Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period\>2days)
62143091|NCT03963466|EXPERIMENTAL|group 2|(right side of cheek) 1064-nm Q-Switched laser+drug Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period\>2days)
62143092|NCT03963466|EXPERIMENTAL|group 3|(left side of cheek) 1064-nm Q-Switched fractional laser Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24
62143093|NCT03963466|EXPERIMENTAL|group 4|(right side of cheek) 1064-nm Q-Switched laser Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24
62143094|NCT04148560|OTHER|Study sample|Individuals who participate in this validation study
62143095|NCT04973306|EXPERIMENTAL|Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody|Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
62143096|NCT04973306|ACTIVE_COMPARATOR|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
62143097|NCT04919395|EXPERIMENTAL|Clip device removal|
62143098|NCT04919395|ACTIVE_COMPARATOR|Standard of Care removal|
62143099|NCT06002035||patients without spontaneous abortion(SA0)|The patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
62143100|NCT06002035||patients with a spontaneous abortion(SA1)|The patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
62143101|NCT06002035||patients with RSA (SA2 and above)|The patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
62143102|NCT04436016|EXPERIMENTAL|Ivabradine|"Ivabradine will be administered in an individualized regimen adapted to the subject's heart rate at each visit in a dosage ranging from 0-7.5mg twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:~* If heart rate is ≥101 bpm: capsule D (Ivabradine 7.5 mg);~* If heart rate is 86-100 bpm: capsule C (Ivabradine 5 mg);~* If HR is 71-85 bpm: capsule B (Ivabradine 2.5 mg);~* If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (placebo)."
61958410|NCT05147025|EXPERIMENTAL|Revasularization|Revascularization of failed previously revascularized younge permenant inciors
61958411|NCT03267758|EXPERIMENTAL|Goodbelly First|Subjects in this arm will consume 1 serving of lactobacillus plantarum 299v daily for first 6 weeks.
61958412|NCT03267758|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will consume 1 serving of heat-killed placebo daily for first 6 weeks.
61958413|NCT06478485||MCSM|This study collected MRI images and baseline information of patients with multilevel cervical spondylotic myelopathy (MCSM) and underwent Laminoplasty (LAMP) surgery in Nantong First People's Hospital. No interventions would be used. This study just collect the MRI images pre- or postoperation to investigate the effect of the combination of mk-line and mSC-line on the selection of the surgical approach and whether could be used to predict sufficient decompression of cervical spinal cord and clinical outcome in patients after LAMP.
62346434|NCT04658472|EXPERIMENTAL|SOC-Refractory Low Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility and will be given the option to roll into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
61958414|NCT01152697|EXPERIMENTAL|Patient Noncompliance|There was only one arm for this study.
61958415|NCT04027062|OTHER|Diabetes Continuing Education Program|"the physicians will be assessed before and after intervention~the intervention group will be enrolled to the intervention program proposed to be (lecture + interactive workshop + group discussion + role play)"
61958416|NCT06218641|ACTIVE_COMPARATOR|CP- Conventional protocol|A group of patients a group of patients to whom attachments will be bonded at the beginning of the first aligner.
61958417|NCT06218641|EXPERIMENTAL|DP - delayed protocol|A group of patients to whom attachments will be bonded at the beginning of the third aligner, approximately one month after the start of orthodontic treatment.
62346435|NCT04658472|EXPERIMENTAL|SOC-Treated Initial Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects of SOC therapy; Weeks 13-24: SAR445088 given.~Participants who do not enroll into Part B will attend final safety follow-up visit at 22 weeks after Week 24 (\~Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (\~week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit at 22 weeks after the last SAR445088 dose."
62346436|NCT04658472|EXPERIMENTAL|SOC-Naive|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose (approximately week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study. Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose."
62346437|NCT04658472|EXPERIMENTAL|SOC-Treated Low Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects SOC therapy; Weeks 13-24: SAR445088. Participants who do not enroll into Part B will attend a final safety follow-up visit that will take place 22 weeks after Week 24 (\~Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility, will be given the option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (\~week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study. Participants who discontinue at any time in Part C will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
62346438|NCT04015414|ACTIVE_COMPARATOR|Varenicline (Champix)|Varenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues.
62504293|NCT01405469|EXPERIMENTAL|Peroral Endoscopic Myotomy|Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment
62504294|NCT04969354|EXPERIMENTAL|CAR-T cell immunotherapy|The registered patients will received CAR-T cell immunotherapy for the new specific chimeric antigen receptor of CAIX antigen by infusion.
62703012|NCT05554393|ACTIVE_COMPARATOR|ARM III (daunorubicin, cytarabine)|Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment, patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
62703013|NCT06362226|EXPERIMENTAL|Group A: 5-FU/Kenalog|
61958418|NCT02019329|PLACEBO_COMPARATOR|Placebo + risperidone|
61958419|NCT02019329|EXPERIMENTAL|RO5545965 + risperidone|
61958420|NCT00373152|EXPERIMENTAL|RadioFrequency Ablation for Breast Cancer|
61958421|NCT06400862|EXPERIMENTAL|eOCT Treatment|In a pre-treatment visit, bone marrow aspiration will be conducted to harvest autologous bone marrow for mesenchymal stem/stromal cells (MSCs) isolation for subsequent eOCT manufacturing. Cartilage lesion will be addressed in the treatment visit by delivering eOCT through arthroscopic surgery roughly 13 weeks after the pre-treatment visit.
61958422|NCT04187729||Diseased|Subjects with a known disease.
61958423|NCT04187729||Non-diseased|Subjects without a known disease and reportedly healthy.
61958424|NCT00969917|EXPERIMENTAL|IPI-504|IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
62504295|NCT05365035|EXPERIMENTAL|cladribine, cytarabine, venetoclax, and azacitidine|Participants will receive cladribine, cytarabine, and venetoclax for 2 cycles and then azacitidine and venetoclax for 2 cycles. Participants will repeat this pattern of 2 cycles each for up to a total of 18
62504296|NCT03105973|EXPERIMENTAL|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
62504297|NCT02438540|EXPERIMENTAL|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
62504298|NCT02438540|PLACEBO_COMPARATOR|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
62504299|NCT04832971|EXPERIMENTAL|ARO-ANG3 50 mg|Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
62504300|NCT04832971|EXPERIMENTAL|ARO-ANG3 100 mg|Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
62504301|NCT04832971|EXPERIMENTAL|ARO-ANG3 200 mg|Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
62504302|NCT04832971|PLACEBO_COMPARATOR|Placebo|Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
62346439|NCT04015414|ACTIVE_COMPARATOR|Cytisine (Tabex)|Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
61958425|NCT00052481||Quality of life questionnaire|"Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy).~Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071."
61958426|NCT05111171||6F sheath CAG group|No PCI is required, only diagnostic CAG is required.
62703014|NCT06362226|EXPERIMENTAL|Group B: Steroid/Antibiotic|
61958427|NCT05111171||6F sheath PCI group|PCI is required, simple lesions are group.
62504303|NCT06098651|EXPERIMENTAL|DCR-STAT3|DCR-STAT3
62703015|NCT05702060|EXPERIMENTAL|Left distal radial artery approach|Coronary angiography and intervention were performed using the left distal radial artery approach
62703016|NCT05702060|ACTIVE_COMPARATOR|Right Radial Artery Approach|Coronary angiography and intervention were performed using the Right Radial Artery Approach
62714930|NCT04596644|EXPERIMENTAL|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
62714931|NCT03690908||IgG4-related orbital inflammation|patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy
62714932|NCT03690908||non IgG4-related orbital inflammation|patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy
61958428|NCT05111171||7F sheath PCI group|PCI is required for the complicated disease.
61958429|NCT00531323|OTHER|1|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
61958430|NCT00531323|OTHER|2|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
61958431|NCT06504680|ACTIVE_COMPARATOR|Splinted cases|Repair cut flexor zone ll using 8-strand with splint the wrist
61958432|NCT06504680|ACTIVE_COMPARATOR|Non splinting cases|Repair cut flexor zone ll using 8-strand without splint the wrist
61958433|NCT00217620|EXPERIMENTAL|sorafenib|sorafenib
61958434|NCT01644565|EXPERIMENTAL|Group A-1|Recombinant fimbrial adhesin dscCfaE: 1 ug of dscCfaE ID on study days 0, 21 and 42
61958435|NCT01644565|EXPERIMENTAL|Group A-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5: 2.6 ug of Chimera ID on study days 0, 21 and 42
61958436|NCT01644565|EXPERIMENTAL|Group A-3|Modified E. coli heat labile enterotoxin LTR192G: 100 ng of LTR192G ID on study days 0, 21 and 42
61958437|NCT01644565|EXPERIMENTAL|Group B-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
61958438|NCT01644565|EXPERIMENTAL|Group B-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 2.6 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
61958439|NCT01644565|EXPERIMENTAL|Group C-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 5 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
62346440|NCT06069011|EXPERIMENTAL|Interdisciplinary|Interdisciplinary model for management of low acuity msk complaint
62504304|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
62504305|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
62504306|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
62504307|NCT00458445|EXPERIMENTAL|SPD465 then Placebo|
62504308|NCT00458445|EXPERIMENTAL|Placebo then SPD465|
62504309|NCT05416099||Grid laser|grid laser is one of the more conventional treatments for diabetic macular edema
61958440|NCT01644565|EXPERIMENTAL|Group C-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 12.9 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
61958441|NCT01644565|EXPERIMENTAL|Group D-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 25 ug dscCfaE + 100 ng LTR192G ID on study days 0, 21 and 42
62143103|NCT04436016|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:~* If heart rate is ≥101 bpm: capsule D (Placebo)~* If heart rate is 86-100 bpm: capsule C (Placebo)~* If HR is 71-85 bpm: capsule B (Placebo)~* If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (Placebo)."
62504310|NCT05416099||micropulse laser|micropulse laser is one of the more recent treatments for diabetic macular edema
62504311|NCT05348837||Subthalamic nucleus (STN) DBS|Patients undergoing evaluation for subthalamic nucleus DBS implantation will be included in this group.
62504312|NCT05348837||Globus pallidus interna (GPi) DBS|Patients undergoing evaluation for globus pallidus interna DBS implantation will be included in this group.
62504313|NCT06617663|EXPERIMENTAL|EMDR online|The investigators will use the Association for EMDR (called VEN in the Netherlands) protocol for individuals up to age 18 through videoconferencing with a therapist, supported by MOOVD as a digital intervention platform.
62504314|NCT06617663|ACTIVE_COMPARATOR|EMDR on-site|The investigators will use the Association for EMDR (called VEN in the Netherlands) protocol for individuals up to age 18 at a physical location . Various working memory load techniques may be used, including the light bar.
62504315|NCT06617663|EXPERIMENTAL|ACT online|ACT, along with an e-health program, will be offered through video conferencing.
62504316|NCT06617663|ACTIVE_COMPARATOR|ACT on-site|ACT will be offered at a physical location without additional e-health modules.
62504317|NCT04480372|EXPERIMENTAL|NSCLC (cohort 1) and inoperable MPM (cohort 2)|"Cohort 1 consists of NSCLC patients. Cohort 2 consists of MPM patients.~Patients will be treated with gemcitabine at the dose of 1000 mg/m2 i.v. on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).~The trial treatments will be continued for max. 2 years or until discontinuation criteria are met (see Ch. 9.3), whichever occurs first. The follow-up phase will last up to 5 years from treatment start."
62504318|NCT02543151|EXPERIMENTAL|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
62504319|NCT04028856||Continuous interferon treatment group|Patients with chronic hepatitis B treated with continuous interferon for 48 weeks
62504320|NCT04028856||Intermittent interferon treatment group|patients with chronic hepatitis B treated with intermittent interferon for 48 weeks, in which interferon therapy was intermittent for 3 months
62504321|NCT03671187|EXPERIMENTAL|Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
62504322|NCT03671187|EXPERIMENTAL|Ex- Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
62504323|NCT05420116|EXPERIMENTAL|Intervention group|"Physical Activity: Prescription in physical activity include to perform 1 session a week of exercice led by a sports professional, and 2 sessions of authonomus exercice at 60-80% of participants maximum heart rate.~Nutritional: Visits and checks every 2 months with a nutritionist with the aim of improving healthy eating habits.~Positive Mental Health: There are 4 group psycho-emotional sessions based on improving self-esteem, self-control, proactive social attitude and conflict resolution"
61958442|NCT01644565|EXPERIMENTAL|Group D-2|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1250 ug dscCfaE + 50 ng LTR192G TCI on study days 0, 21 and 42
61958443|NCT04447456||Surgery|
61958444|NCT04447456||Radiotherapy|
61958445|NCT05572450|EXPERIMENTAL|Infectious Titre 1|Dose Arm 1 (Part A): Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
61958446|NCT05572450|EXPERIMENTAL|Infectious Titre 2|Dose Arm 2 (Part A): Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
62143104|NCT05201599|EXPERIMENTAL|Flexible ureteroscope with intelligent control of renal pelvic pressure(FURL-ICP)|Patients will be placed in supine lithotomy position with 60-90° oblique on the affected side upward. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The pressure sensory and suctioning channels are connected to the irrigation and suctioning platform.
62346441|NCT06069011|ACTIVE_COMPARATOR|Usual care|usual care
62504324|NCT05420116|NO_INTERVENTION|Control group|Participants follow the habitual controls in nursing consultation. Recomendations of physical activity and diet.
62504325|NCT04088747||Fibromyalgia|Patients who display symptoms and have a history of Fibromyalgia, between 20-65 years of age.
62504326|NCT04088747||Healthy Controls|Age-matched, healthy controls, between 20-65 years of age who present no signs of chronic pain.
62504327|NCT01139606|EXPERIMENTAL|Vibration trainig|
62504328|NCT06535490||EUS-FNA for PCL with ATBp|Patients undergoing EUS-FNA for pancreatic cystic lesions WITH ATBp
62504329|NCT06535490||EUS-FNA for PCL without ATBp|Patients undergoing EUS-FNA for pancreatic cystic lesions without ATBp
62504330|NCT05507528|EXPERIMENTAL|Reborn treatment group|The Lightfective ReBorn System is a Diode Light Emitting Diode (LED) System, Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
62504331|NCT00529217|EXPERIMENTAL|Open-Label Active rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS)
62714933|NCT03448042|EXPERIMENTAL|Dose Escalation|Participants will be assigned sequentially to escalating doses of runimotamab up to the maximum tolerated dose (MTD).
62714934|NCT03448042|EXPERIMENTAL|Dose Expansion|Participants will receive runimotamab based on the MTD or maximum allowed dose (MAD) identified during dose escalation.
61958447|NCT05572450|EXPERIMENTAL|Infectious Titre 3|Optional Dose Arm 3 (Part B): to be determined (TBD), depending on outcome of Part A
61958448|NCT05572450|EXPERIMENTAL|Infectious Titre 4|Optional Dose Arm 4 (Part B): TBD, depending on outcome of Part A
61958449|NCT01631981|EXPERIMENTAL|PGL2001|PGL2001 + NETA followed by NETA-only follow-up period
61958450|NCT01631981|PLACEBO_COMPARATOR|Placebo|Placebo + NETA followed by NETA-only follow-up period
62504332|NCT01009515|EXPERIMENTAL|Chemotherapy Combination|Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.
62504333|NCT04082806|EXPERIMENTAL|healthy controls|
62504334|NCT04082806|EXPERIMENTAL|Major Depressive Disorder|
61958451|NCT05913492||Group 1|Each volunteer went through two simulation scenarios of difficult airway management on the first time
61958452|NCT05913492||Group 2|Each volunteer went through two simulation scenarios of difficult airway management after training in difficult airway management according to DAS guidelines, using the same equipment as during the simulation
62703017|NCT06750445|EXPERIMENTAL|Fluoxetine Treatment Group|Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. The dose could be increased to 60 mg/day if symptoms persisted or reduced if mild adverse effects (e.g., dizziness, nausea, tremors) occurred. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).
62703018|NCT06750445|ACTIVE_COMPARATOR|PEG Treatment Group|The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.
62703019|NCT00942981||healthy volunteers|healthy volunteers
61958453|NCT05913492||Group 3|Each volunteer went through two simulation scenarios of difficult airway management after 6 month
62703020|NCT00942981||patients|patients with schizophrenia, schizoaffective disorder or other psychotic disorders aged18-60
61958454|NCT01866293|EXPERIMENTAL|Cabozantinib (XL184)|Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
62143105|NCT05201599|NO_INTERVENTION|Traditional flexible ureteroscope(f-URL)|Each procedure is completed under general anesthesia in lithotomy position. A semi-rigid ureteroscopy is used to place a 0.032-inch guidewire. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The irrigation and suctioning platform will be not used. A 7.5 Fr flexible ureteroscopy is used to break the stone with a holmium laser (fiber diameter 200 µm). A basket is used to remove the stone fragments. A 4-6Fr ureteral stent is left for 2 weeks after the operation. Stone composition is analyzed. If the UAS is failed to be placed, ureteral stent will be placed for 2 weeks and a second stage traditional f-URL will be performed.
61958455|NCT03198897||Observation|Patients with a Homozygous familial Hypercholesterolemia or high-grade suspicion for Homozygous familial Hypercholesterolemia
61958456|NCT00462618|ACTIVE_COMPARATOR|CBT|
61958457|NCT04893278||Virtual reality|
61958458|NCT05191524|EXPERIMENTAL|Constrained induced movement therapy|"In this group of patients, they will use the CIMT technique for treatment. Patient will perform following tasks, while unaffected limb in constrains for 3 hours/day~* Sit-to-Stand~* Forward and Backward stepping~* Stair Climbing and Descending (only the first stair will be used)~* Side-to-Side stepping with the affected limb"
61958459|NCT05191524|ACTIVE_COMPARATOR|Proprioceptive Neuromuscular facilitation therapy|"Different PNF components (such as commands, stretching, timing, and manual resistance) will be used for optimizing patients' output. We will do ten repetitions of each pattern before~Proceeding to the next pattern. The PNF patterns in the set used in the study will be :~Lower extremity:~\< Flexion-abduction-external rotation (knee flexed and knee extended) \< Extension-adduction-internal rotation (knee flexed and knee extended) \< Flexion-adduction-internal rotation (knee flexed and knee extended) \< Extension-abduction-external rotation (knee flexed and knee extended"
61958460|NCT00908713|EXPERIMENTAL|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
61958461|NCT00908713|PLACEBO_COMPARATOR|Placebo|
62143106|NCT03490032|EXPERIMENTAL|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase I)|All eligible participants received recommended dose of \[68Ga\]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].
62346442|NCT05723315|EXPERIMENTAL|Experimental Group 1|The experimental group was given neoptin within 3h after PCI for 72 hours (first at 1.5μg /kg intravenous load, then at 0.015μg /kg/min).
62504335|NCT03195673|EXPERIMENTAL|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.~Procedure: Carotid Artery Stenting"
62504336|NCT03195673|OTHER|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
62504337|NCT03474328|EXPERIMENTAL|Treatment arm|
62504338|NCT06052813|EXPERIMENTAL|200mg QD|The starting dose cohort(200mg QD) where accelerated titrated dose-escalation method is applied, a patient will initially receive a single dose BN104 on Day 1 of Cycle 0 (3 days prior to Day 1 of Cycle 1) to evaluate the concentration of BN104 up to 72 hours after administration and the safety of single dose of BN104. Then the patient begins continuous treatment with BN104 200 mg QD on Day 1 of Cycle 1 by every 28-day treatment cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
62714935|NCT05589909||Infection Group|Both suspected and confirmed sepsis occurred ≤72 hours after delivery were counted as cases of EONS.
62714936|NCT05589909||None Infection Group|No evidence clinical or laboratory of infection
62714937|NCT06714864|EXPERIMENTAL|DefenCath®|
62714938|NCT06714864|ACTIVE_COMPARATOR|Control|
61958462|NCT04639375|EXPERIMENTAL|Vaccinated with polio vaccine (IPV)|All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States
61958463|NCT00345839|EXPERIMENTAL|Cinacalcet|
61958464|NCT00345839|PLACEBO_COMPARATOR|Placebo|
62714939|NCT05874089|ACTIVE_COMPARATOR|VSL#3®|VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 28 days
62504339|NCT06052813|EXPERIMENTAL|200mg BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
62504340|NCT06052813|EXPERIMENTAL|400mg BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
62504341|NCT06052813|EXPERIMENTAL|600 BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
61958465|NCT06556316||Patients with Moderate to Severe TBI who will receive cognitive rehabilitation|Adults with a history of moderate to severe TBI who will receive cognitive rehabilitation through the Categorization Program, a hierarchical remedial intervention
61958466|NCT06556316||Patients with Moderate to Severe TBI who will receive psychosocial intervention|Adults with a history of moderate to severe TBI who will receive group intervention via the Social Cognitive Communication Program (SocCom)
61958467|NCT06556316||Patients with a history of CVA who will receive psychosocial intervention|Adults with a history of CVA (hemorrhagic or ischemic) who will receive group intervention via the Social Cognitive Communication Program (SocCom)
61958468|NCT06556316||Patients with a history of CVA who will receive psychosocial intervention and tDCS|Adults with a history of CVA (hemorrhagic or ischemic) who will receive group intervention via the Social Cognitive Communication Program (SocCom) and tDCS treatment
61958469|NCT06556316||Patients with TBI who will receive psychosocial intervention & TDCS|Adults with a history of moderate to severe TBI who will receive group intervention via the Social Cognitive Communication Program (SocCom) and tDCS treatment
61958470|NCT06556316||Patients with TBI receiving group psychosocial intervention and the Categorization Program|Adults with a history of moderate to severe TBI who will receive cognitive rehabilitation through the CP and group intervention with the SocCom treatment
62143107|NCT03490032|EXPERIMENTAL|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase II)|All eligible participants received recommended dose of \[68Ga\]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].
62143108|NCT03490032|EXPERIMENTAL|Metastatic Prostate Cancer (mPCa) (Phase II)|All eligible participants received recommended dose of \[68Ga\]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].
62143109|NCT06079736|EXPERIMENTAL|PGN-EDO51 at Dose Level 1 every 4 weeks|
62143110|NCT06079736|EXPERIMENTAL|PGN-EDO51 at Dose Level 2 every 4 weeks|
62346443|NCT05723315|NO_INTERVENTION|Control Gruop|The experimental group was given an intravenous infusion of the same amount of normal saline
61958471|NCT03725930|ACTIVE_COMPARATOR|Clonidine|This arm will receive intra nasal Clonidine as a premedication before surgery
61958472|NCT03725930|PLACEBO_COMPARATOR|Placebo|This arm will receive intra nasal Placebo as a premedication before surgery
62703021|NCT04847453|EXPERIMENTAL|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO QD on days 1-28, ixazomib citrate PO on days 1, 8 and 15, and dexamethasone PO on days 1, 8, 15 and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo x-ray imaging and abdominal ultrasound during screening. Patients undergo bone marrow biopsy and/or aspiration as well as blood sample collection throughout the study. Patients may undergo CT scans, and/or MRI, and/or PET scans throughout the study.
62703022|NCT04038957|EXPERIMENTAL|SEP-363856|SEP-363856 50mg, 75mg flexible dosing, dosed once daily
62703023|NCT02843191|ACTIVE_COMPARATOR|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
61958473|NCT04232995|EXPERIMENTAL|Experimental Group|"Balance training by 9 positions with 1 min hold, repeated twice~1. Stand with feet together, eyes remain open~2. Stand with together, eyes closed~3. \& 4) Tandem Standing with Right and Left in front alternately~5) Forward Reaching 6) \& 7) Single Leg Standing, with Right and Left foot alternately 8) \& 9) Step up, with Right and Left foot alternately~General Exercises for 25 min~* Active Range of Motion Exercises and Foot Care Education-5 min~* Treadmill- 15 min~* Cycling -5 min~No. Of Sessions 24, thrice a week for 8 weeks"
61958474|NCT04232995|ACTIVE_COMPARATOR|Control Group|"General Exercises for 25 min~* Active Range of Motion Exercises and Foot Care Education-5 min~* Treadmill- 15 min~* Cycling -5 min~No. Of Sessions 24, thrice a week for 8 weeks"
61958475|NCT00993070|EXPERIMENTAL|Capsaicin|
61958476|NCT00993070|PLACEBO_COMPARATOR|placebo|
62143111|NCT06079736|EXPERIMENTAL|PGN-EDO51 at Dose Level 3 every 4 weeks|
62143112|NCT00431054|EXPERIMENTAL|Perifosine + Docetaxel|
62143113|NCT01020266|ACTIVE_COMPARATOR|Electroacupuncture|
62143114|NCT01020266|SHAM_COMPARATOR|Control|
62346444|NCT06027073|ACTIVE_COMPARATOR|omalizumab|standard antiasthmatic therapy and omalizumab
62346445|NCT06027073|ACTIVE_COMPARATOR|oral tablet HDM-immunotherapy|standard antiasthmatic therapy and oral immunotherapy
62346446|NCT06027073|ACTIVE_COMPARATOR|combi therapy|standard antiasthmatic therapy and omalizumab, and oral immunotherapy
62346447|NCT06027073|NO_INTERVENTION|control|
62504342|NCT06052813|EXPERIMENTAL|800 BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
62504343|NCT05557370|EXPERIMENTAL|Interventional|Patient between the age of 18 and 45 years with at least 6 months post-solid-organ transplant who has not received GARDASIL 9.
62504344|NCT01231373|EXPERIMENTAL|polidocanol injectable foam, 0.125%|
62504345|NCT01231373|EXPERIMENTAL|polidocanol injectable foam, 0.5%|
62504346|NCT01231373|EXPERIMENTAL|polidocanol injectable foam, 1.0%|
62504347|NCT01231373|PLACEBO_COMPARATOR|Vehicle|
62504348|NCT03749954||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
62504349|NCT01429831|EXPERIMENTAL|Aripiprazole|
62504350|NCT00468338||BIS monitor used for all subjects|BIS monitor applied to all subjects
62504351|NCT03767062|ACTIVE_COMPARATOR|Topiramate|Topiramate will be introduced 25 mg/day b.i.d. for the first week and increased to 100 mg/day b.i.d. for the second week.
62504352|NCT03767062|ACTIVE_COMPARATOR|Greater Occipital +Supratrochlear Nerve Block|"Greater occipital nerve block (GONB) will be applied to medial of the occipital artery which localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg) and 1 ml 0,9% sodium chloride (NaCl). The injection is performed using a 22 gauge (G) × 1¼ (0.7 × 40mm) injector when the patient is lying prone on the table. The scalp is cleaned with iodine before procedure and injections are performed bilaterally with a volume of 2 mL after negative aspiration for blood. Supratrochlear nerve block (STNB) is applied 1 cm medial to superior orbital fissure using a mixture of 8 mg bupivacaine and 1.4 ml 0,9% NaCl. STNB is performed bilaterally with a volume of 1.5 mL after negative aspiration for blood."
62504353|NCT03457090|EXPERIMENTAL|Patient treated with ECMO|Patient treated with ECMO will have Examination : a TCD and Trans-Thoracic Echocardiography (TTE)
62504354|NCT02666924|EXPERIMENTAL|Cooking class|The addition of diabetes cooking educational classes to standard diabetes education classes. Cooking classes are a series of four, four-hour sessions. These cooking classes will be led by a registered dietitian, a registered nurse and a chinese chef. Conducted in Mandarin or Cantonese. The cooking education focus is culturally specific teaching for Chinese-Canadian persons living with diabetes.
62504355|NCT02666924|ACTIVE_COMPARATOR|Control|Type 2 diabetes educational classes, consisting of two sessions, one week apart, four-hour classes. These classes are taught by a registered dietitian and nurse, in Mandarin or Cantonese.
62504356|NCT00117806|EXPERIMENTAL|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury
62504357|NCT00117806|PLACEBO_COMPARATOR|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
62703024|NCT02843191|EXPERIMENTAL|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
62504358|NCT05298592|EXPERIMENTAL|Part 1A: BMS-986406 (Monotherapy Dose Escalation)|
62504359|NCT05298592|EXPERIMENTAL|Part 1B: BMS-986406 + Nivolumab (Combination Dose Escalation)|
62504360|NCT05298592|EXPERIMENTAL|Part 1C: BMS-986406 + Nivolumab (Indication-Specific Dose Expansion)|
62504361|NCT05298592|EXPERIMENTAL|Part 2: BMS-986406 + Nivolumab (Expansion Cohorts)|
62504362|NCT05298592|EXPERIMENTAL|Part 1D: BMS-986406 + Nivolumab + Carboplatin with Pemetrexed or Paclitaxel|
62703025|NCT06684483||Healthy volunteers|Age, smoking status and gender matched healthy volunteers.
62504363|NCT04745949|EXPERIMENTAL|Treatment (brentuximab vedotin, nivolumab, R-CHP)|Patient will receive an immune lead-in of 2 cycles of Brentuximab vedotin and Nivolumab (A-O) (cycles 1 and 2), which has an appropriate futility rules in place to close early if efficacy targets are not met. At cycle 3 and 4, patients will receive A-O with R-CHP. Patients who will have achieved complete response (CR) at PET/CT before cycle 5 will receive 2 more cycles of A-O-R-CHP (cycle 5 and 6) and A-O only for cycle 7 and 8. If these patients still present CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. In case of stable disease or progressive disease at PET/CT after cycle 4, the patient will be taken off the trial. Patients who present further response but no CR, at PET/CT before cycle 5 will receive 4 more cycles A-O-R-CHP (cycles 5-8). If they reach CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. All patients will receive a total of 8 cycles of A-O. The cycle duration is 21 days.
62504364|NCT06428851|ACTIVE_COMPARATOR|Laser therapy Group|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises. Group 1 Laser therapy group (n:25) in addition to classical physical therapy, laser was applied to the shoulder group muscles for 5 minutes a day, 3 days a week for 4 weeks.
62703026|NCT06684483||Patients with AUD|Patients with alcohol use disorder seeking inpatient treatment.
62703027|NCT06750458|PLACEBO_COMPARATOR|GroupⅠ(n=25) (Control group)|This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive placebo tablets once daily for 14 days pre-operative.
62143115|NCT01354145|EXPERIMENTAL|Chondroitin sulfate (Condrosan)|CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
62504365|NCT06428851|ACTIVE_COMPARATOR|Neuromuscular electrical nerve stimulation Group|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises. In Neuromuscular electrical nerve stimulation group, in addition to these exercises, Neuromuscular electrical nerve stimulation was applied to the shoulder flexor and abductor muscle groups for 20 minutes a day, 5 days a week for a total of 4 weeks.
62504366|NCT06428851|ACTIVE_COMPARATOR|Control Group|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises.
62703028|NCT06750458|EXPERIMENTAL|GroupII (n=25) (Dapagliflozin group)|This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive Dapagliflozin 10 mg once daily for 14 days pre-operative.
62714940|NCT05874089|PLACEBO_COMPARATOR|Placebo|Placebo sachets, two sachets per day for 28 days
62703029|NCT06750458|ACTIVE_COMPARATOR|Group III (n=25) (Dexamethasone group)This group will include twenty-five non-diabetic glioma patien|This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.
62703030|NCT06749106||acute ischemic stroke|Patients with acute ischemic stroke, who received non-contrast carotid MRI for routine diagnostic work-up
62703031|NCT05231018|EXPERIMENTAL|Psychotherapy|The population of interest includes COVID-19 patients previously or currently hospitalized at the Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, according to inclusion and exclusion criteria.
62703032|NCT05569967|EXPERIMENTAL|Group 1|Individuals in this group will receive spinal stabilization training through telerehabilitation.
62703033|NCT05569967|ACTIVE_COMPARATOR|Group 2|Individuals in this group will receive spinal stabilization training face-to-face.
61958477|NCT00279305|EXPERIMENTAL|Rituximab Intravenous Infusion|Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
61958478|NCT00279305|PLACEBO_COMPARATOR|Placebo Intravenous Infusion|Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.
62143116|NCT01354145|ACTIVE_COMPARATOR|Celecoxib|CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
62143117|NCT03488459|OTHER|Routine preoperative information from a nurse|
62143118|NCT03488459|EXPERIMENTAL|Additional information support from a psychologist|
62143119|NCT03932214|EXPERIMENTAL|Infrared illumination group|The nurse uses the Accuvein® device to identify the veins before puncture.
62346448|NCT04385615|EXPERIMENTAL|FMD Group|Participants will be requested to follow a Fasting Mimicking Diet, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
62346449|NCT04385615|NO_INTERVENTION|Control Group|Participants will be requested to continue with their habitual eating habits, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
62346450|NCT01196650|ACTIVE_COMPARATOR|1|IN 10 003 formulation A
62346451|NCT01196650|ACTIVE_COMPARATOR|2|IN 10 003 formulation B
62703034|NCT06306014|EXPERIMENTAL|Part A (Open-Label EXL01)|
62143120|NCT03932214|NO_INTERVENTION|Control group|The nurse proceeds as usual (visual identification in the light of the room and palpation)
62143121|NCT01555138|EXPERIMENTAL|Indacaterol|Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
62346452|NCT01196650|PLACEBO_COMPARATOR|3|Placebo capsules
62346453|NCT01644942|OTHER|Insulin sensitive patients|
62346454|NCT01644942|OTHER|Insulin resistant patients|
62346455|NCT03182465|OTHER|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
62346456|NCT06098196||Aminophylline|Patients who received Aminophylline bolus (4 mg/kg) at the end of general anesthesia conducted with Eleveld or Schnider TCI model (this model was chosen at anesthesiologist's discretion)
62346457|NCT06098196||Not Aminophylline|Patients who did not received Aminophylline bolus (4 mg/kg) at the end of general anesthesia conducted with Eleveld or SchniderTCI model (this model was chosen at anesthesiologist's discretion
62703035|NCT06306014|EXPERIMENTAL|Part B (EXL01)|
62703036|NCT06306014|PLACEBO_COMPARATOR|Part B (Placebo)|
62143122|NCT01555138|ACTIVE_COMPARATOR|Salmeterol/fluticasone propionate|Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)
62143123|NCT01472406|EXPERIMENTAL|Closed-loop session|The study consists of an evaluation of the Sansum Closed-loop Artificial Pancreas Device, insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, and a Safety Health Monitoring System. during a 24-hour closed-loop in a clinic environment (Sansum Diabetes Research Institute, Santa Barbara, CA).
62143124|NCT01286532||1|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination therapy with ICS(inhalation glucocorticosteroids) and LABA ( long-acting b2-agonist) who have completed at least one valid CACT assessment after the study entry
62703037|NCT05421325|EXPERIMENTAL|QBKPN SSI|QBKPN SSI (0.1 mL) by subcutaneous injection 3 times per week (Monday, Wednesday \& Friday) for 4 weeks.
62703038|NCT05421325|PLACEBO_COMPARATOR|Placebo|Placebo (Normal Saline) (0.1 mL) by subcutaneous injection 3 times per week (Monday, Wednesday \& Friday) for 4 weeks.
62703039|NCT05282121|EXPERIMENTAL|Avenciguat (BI 685509) HBV treatment group|Hepatitis B Virus (HBV)
62703040|NCT05282121|EXPERIMENTAL|Avenciguat (BI 685509) HCV treatment group|Hepatitis C Virus (HCV)
62703041|NCT05282121|EXPERIMENTAL|Avenciguat (BI 685509) NASH treatment group|Non-Alcoholic Steatohepatitis (NASH)
62703042|NCT05282121|EXPERIMENTAL|Avenciguat (BI 685509) + empagliflozin NASH treatment group|
62703043|NCT05593341|NO_INTERVENTION|Control Group|Patients are referred to the Hospital's standard 1-hour virtual patient education webinar prior to surgery.
62703044|NCT05593341|EXPERIMENTAL|In-person and PDF|Patients will receive two in-person education sessions (1st session before surgery and 2nd session after surgery). Patients will also receive pdf handouts about opioids and pain management.
62703045|NCT05593341|EXPERIMENTAL|Video and PDF|Patients will receive two video education sessions (1st session before surgery and 2nd session after surgery). Patients will also receive pdf handouts about opioids and pain management.
62703046|NCT04736199|EXPERIMENTAL|Darolutamide+ADT|Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy
62703047|NCT04736199|PLACEBO_COMPARATOR|Placebo+ADT|Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy
62703048|NCT04366310||capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
62703049|NCT06315543|EXPERIMENTAL|Adequate drinking water intervention group|increase drinking water by 1650mL per day (3 bottles of 550mL bottled water) on the basis of original drinking water
62703050|NCT06315543|NO_INTERVENTION|Water intake observation group|maintain original water intake
62703051|NCT05948709|EXPERIMENTAL|Treatment|Fitabase collects data from Fitbits worn by the participants. Under the treatment functionality, participants earn a meal donation for each day that they meet the step goal and a monetary incentive for each day they meet the step goal (for upto 5 days a week). The investigators identified 7,500 steps as an appropriate goal as studies show older adults walk 4,000 steps on average. Meals are donated by the investigators on behalf of participants.
62703052|NCT05948709|NO_INTERVENTION|Control|The control group will not have the functionality to earn meal donations or monetary incentives by walking, and will only be asked to wear their Fitbit so that step count data can be collected.
61958479|NCT05738954||Second trimester|Second trimester fetal morphology Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.
61958480|NCT05999032|ACTIVE_COMPARATOR|Low-Intensity (Virtual) Intervention Implementation|During low intensity implementation, families of children with poorly controlled asthma will be referred to the remote version of HARP (HARP-V) and will receive CASE remotely (CASE-V). Children with not well controlled asthma will receive only CASE-V remotely.
61958481|NCT05999032|ACTIVE_COMPARATOR|High Intensity (in-Person) Intervention Implementation|"During high intensity implementation, all interventions are administered in person.~Specifically, families of children with poorly controlled asthma will receive in-person versions of HARP and CASE. Children with not well controlled asthma will receive an in-person version of CASE only."
61958482|NCT04503785||Dysphagia|Patients with Esophageal dysphagia
61958483|NCT03380403|ACTIVE_COMPARATOR|PDT|Methylene blue and Photon Irradiation , every each week, until total ulcer healing.
61958484|NCT03380403|ACTIVE_COMPARATOR|Ciprofloxacin|Diabetic foot patients were treated on conventional way, using antibiotics and surgery.
61958485|NCT04343963|ACTIVE_COMPARATOR|Pyridostigmine|Pyridostigmine bromide tablet (60mg P.O. once per day for 14 days)
61958486|NCT04343963|PLACEBO_COMPARATOR|Placebo|Placebo tablet (60mg P.O. once per day for 14 days)
61958487|NCT01090271|EXPERIMENTAL|Eccentric training|
61958488|NCT04893044|EXPERIMENTAL|Exposure|These participants watched a 3 minute long video prior to a long weekend. The intent was to see if watching the video altered their alcohol consumption compared to a group that did not watch the video. Urine alcohol metabolites were measured before and after the weekend.
61958489|NCT04893044|NO_INTERVENTION|Control|These participants did not watch a video, and their urine alcohol metabolites were measures at the same dates as the exposure group above.
61958490|NCT04927260||COHORTE PROSPECTIF|
61958491|NCT04927260||COHORTE RETROSPECTIF|
61958492|NCT01081678|PLACEBO_COMPARATOR|Placebo|Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
61958493|NCT01081678|EXPERIMENTAL|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
61958494|NCT01081678|EXPERIMENTAL|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
61958495|NCT01081678|EXPERIMENTAL|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
62703053|NCT05016882|EXPERIMENTAL|NNC0194-0499 7.5 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
62703054|NCT05016882|PLACEBO_COMPARATOR|Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
62703055|NCT05016882|EXPERIMENTAL|NNC0194-0499 15 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
62703056|NCT05016882|PLACEBO_COMPARATOR|Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
61958496|NCT03711110|EXPERIMENTAL|Primary prevention strategy|Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.
61958497|NCT03711110|OTHER|Secondary prevention strategy (control)|Current clinical practice: cardiac care is based on the onco-hematologist criteria.
62703057|NCT05016882|EXPERIMENTAL|NNC0194-0499 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
62703058|NCT05016882|EXPERIMENTAL|NNC0194-0499 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
62703059|NCT05016882|ACTIVE_COMPARATOR|Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
61958498|NCT04753983|EXPERIMENTAL|Anterior Nucleus of the Thalamus (ANT) Deep Brain Stimulation (DBS)|"Subjects that have undergone DBS placement for treatment of refractory epilepsy will undergo a fMRI scan. During the fMRI, the subject will undergo alternating short periods of their DBS in the on and off state with high- and low frequency settings to measure the brain activation changes induced by the DBS."
61958499|NCT04774328|ACTIVE_COMPARATOR|CA-008 (vocacapsaicin)|Single administration
61958500|NCT04774328|PLACEBO_COMPARATOR|Placebo|Single administration
61958501|NCT01867437|ACTIVE_COMPARATOR|RM-493|Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days
61958502|NCT01867437|PLACEBO_COMPARATOR|Placebo|Double blind placebo will be administered via subcutaneous infusion for 3 days
61958503|NCT01115101|EXPERIMENTAL|Oxycodon|
61958504|NCT01115101|ACTIVE_COMPARATOR|Patient controlled analgesia (PCA) device with Pritramid|
62143125|NCT02140879|PLACEBO_COMPARATOR|Capsule 1|Placebo is a mixture of corn and soy oils.
62143126|NCT02140879|ACTIVE_COMPARATOR|Capsule 2|Active supplement group, will take capsules containing oil '2' which is an algal oil.
62346458|NCT06241287|EXPERIMENTAL|Intervention group|The intervention group will receive the Better Living with Non-memory led Dementia programme, an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups.
62346459|NCT06241287|OTHER|Control group|The waiting list control group will receive signposting to the publicly available Rare Dementia Support website (https://www.raredementiasupport.org/) and any kind of support the participants may already being receiving (e.g. psychological support, online information, support groups, etc). This a wait list study where the control group will be given access to the intervention ́s educational modules and material after the individuals' last point of data collection.
62504367|NCT02496208|EXPERIMENTAL|Part I (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 21 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography or magnetic resonance imaging and collection of blood samples throughout the trial. Patients may also undergo echocardiography at baseline and biopsies throughout the trial.
62504368|NCT02496208|EXPERIMENTAL|Part II (cabozantinib s-malate, nivolumab, ipilimumab)|See detailed description.
62504369|NCT01668823|EXPERIMENTAL|Treatment (PDT using HPPH)|Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
62504370|NCT04526899|EXPERIMENTAL|BNT111 + cemiplimab|
62504371|NCT04526899|EXPERIMENTAL|BNT111 monotherapy|
62504372|NCT04526899|EXPERIMENTAL|Cemiplimab monotherapy|
62504373|NCT05308368|EXPERIMENTAL|Tremor Group|Individuals with either parkinson's disease or essential tremor will be recruited in this group
62504374|NCT05308368|EXPERIMENTAL|Able Body Group|Individuals with no disorders will be recruited in this group
62504375|NCT04139031||Fluid loading group|Mechanically ventilated patients with low tidal volume in the intensive care unit whom clinician decided to provide fluid for correction of hypovolemia
62504376|NCT04060134||SimpliDerm HADM|Patients who had SimpliDerm human acellular dermal matrix used in their breast reconstruction procedure.
62504377|NCT04060134||AlloDerm HADM|Patients who had AlloDerm human acellular dermal matrix used in their breast reconstruction procedure.
62504378|NCT04060134||AlloMax HADM|Patients who had AlloMax human acellular dermal matrix used in their breast reconstruction procedure.
62504379|NCT04060134||FlexHD HADM|Patients who had FlexHD human acellular dermal matrix used in their breast reconstruction procedure.
62504380|NCT04060134||DermACELL HADM|Patients who had DermACELL human acellular dermal matrix used in their breast reconstruction procedure.
62504381|NCT04767958|EXPERIMENTAL|Patients consulted upon by ICU, internal medicine, or cardiology for hospital admission|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
62504382|NCT04767958|EXPERIMENTAL|patients undergoing cardiac testing/procedures|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
62714941|NCT06590181|EXPERIMENTAL|Yoga Nidra|This protocol is derived from The Origin and Clinical Relevance of Yoga Nidra (Pandi-Perumal, S. R. 2022) and is approximately 20 minutes total time.
62143127|NCT06116968|EXPERIMENTAL|Aficamten|Patients in this arm take daily dose of Aficamten. Each patient will start at the lowest dose (5 mg) in the pre-specified dose range and undergo dose titration up to a maximum of 20 mg.
62143128|NCT06497920|ACTIVE_COMPARATOR|Active rTMS|Autistic adults receiving active rTMS to the motor cortex.
62143129|NCT06497920|SHAM_COMPARATOR|Sham rTMS|Autistic adults receiving sham rTMS to the motor cortex.
62143130|NCT01812759|EXPERIMENTAL|Fentanyl Nasal Spray + Hydromorphone PCA|Fentanyl 100 mcg nasal spray administered plus hydromorphone PCA. All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
62504383|NCT04767958|EXPERIMENTAL|patients awaiting surgery|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
62504384|NCT04767958|EXPERIMENTAL|Health Care Workers|Health Care Workers who are being screened for COVID-19 will have both standard care and point-of-care NP swabs performed.
62504385|NCT06669663||Pimonidazole Group|Will receive Pimonidazole (as a non-CTIMP) to enable hypoxic tumour stratification
62504386|NCT06669663||Biosampling Group|Participants will undergo blood, urine and breath sampling on their morning of their surgery on their OG tumour. Intra-operatively, tumour samples will be taken.
62504387|NCT06227351|ACTIVE_COMPARATOR|completely limiting computer generated surgical three-dimensional guide|patients in this group will receive zygomatic implant placed in a completely fully guided technique using surgical guide,keys and sleeves.
62504388|NCT06227351|ACTIVE_COMPARATOR|Partially limiting computer generated surgical three-dimensional guide|patients in this group will receive zygomatic implant placed in a partially guided technique using surgical guide.The first drill only will be used with the guide then the guide will be removed and the whole procedure with the remaining drills will be completed in a free hand technique.
62504389|NCT00602537|EXPERIMENTAL|I|Antidepressant therapy
62504390|NCT00602537|ACTIVE_COMPARATOR|II|Mood stabilizer therapy
62504391|NCT04096339|ACTIVE_COMPARATOR|EGD followed by Colonoscopy|Randomized to group Esophagogastroduodenoscopy followed by Colonoscopy
62504392|NCT04096339|ACTIVE_COMPARATOR|Colonoscopy followed by EGD|Randomized to group Colonoscopy followed by Esophagogastroduodenoscopy
62504393|NCT02091349|PLACEBO_COMPARATOR|Group A- placebo|control- snack bar or muffin containing no fiber
61958505|NCT03144947|EXPERIMENTAL|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~After surgery, study patients will receive trastuzumab IV x 14 cycles"
62346460|NCT02661841|EXPERIMENTAL|LI-Guided Therapy|One hundred and fifty chronic heart failure patients treated based on guidelines and LI-Guided Therapy.
62703060|NCT05016882|PLACEBO_COMPARATOR|Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
61958506|NCT03144947|EXPERIMENTAL|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
61958507|NCT01758432|EXPERIMENTAL|Module 1 (90 mg bolus)|90 mg PRT064445 given as a single IV
61958508|NCT01758432|EXPERIMENTAL|Module 1 (210 mg bolus)|210 mg PRT064445 given as a single IV bolus
61958509|NCT01758432|EXPERIMENTAL|Module 1 (420 mg bolus)|420 mg PRT064445 given as a single IV bolus
62346461|NCT02661841|ACTIVE_COMPARATOR|Control|One hundred and fifty chronic heart failure patients treated based on guidelines only.
62346462|NCT02322684|ACTIVE_COMPARATOR|Group Q|Blind endotracheal intubation will be performed through the air-Q
62346463|NCT02322684|ACTIVE_COMPARATOR|Group B|Blind endotracheal intubation will be performed through the air-Q with bougie assisted
62346464|NCT04722484|EXPERIMENTAL|Patients with normal creatine clearance (CLCR)|Subjects with renal impairment according to their medical history and estimated glomerular filtration rate (eGFR) at screening but had normal creatinine clearance at the pre-profile day (-01day)
62346465|NCT04722484|EXPERIMENTAL|Normal renal function (Healthy subjects)|Subjects with creatinine clearance at pre-profile day \>80 ml/min
62346466|NCT04722484|EXPERIMENTAL|Mildly impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 50-80 ml/min
62346467|NCT04722484|EXPERIMENTAL|Moderately impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 30-\<50 ml/min
62346468|NCT04722484|EXPERIMENTAL|Severely impaired renal function|Subjects with creatinine clearance at pre-profile day \<30 ml/min
61958510|NCT01758432|EXPERIMENTAL|Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min|600 mg PRT064445 given as follows: 420 mg IV over \~14 minutes (\~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)
61958511|NCT01758432|EXPERIMENTAL|Module 1 (420 mg bolus + 180 mg bolus) 30mg/min|600 mg PRT064445 given as follows: up to 420 mg IV over \~14 minutes (\~30 mg/min), followed by a second bolus of 180 mg IV over \~6 minutes (\~30 mg/min), 45 minutes after completion of the bolus
61958512|NCT01758432|EXPERIMENTAL|Module 1 (420 mg bolus + 480 mg infusion) 4mg/min|900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
61958513|NCT01758432|PLACEBO_COMPARATOR|Module 1 Placebo|Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.
61958514|NCT00873197|EXPERIMENTAL|Sancuso® patch/IV granisetron|Subjects will receive 1 Sancuso® patch worn for 7 days (168 hours). Immediately after the patch has been applied on Day 1, IV granisetron will be administered over 30 seconds. Following patch removal at 168 hours, a new patch will be immediately applied to the opposite arm and will remain in place for a further 7 days (168 to 336 hours).
61958515|NCT02385500|PLACEBO_COMPARATOR|Placebo|Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
61958516|NCT02385500|EXPERIMENTAL|Fesoterodine|Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.
61958517|NCT05014789|EXPERIMENTAL|Control-IQ 2.0 technology 2.0 on the t:slim X2 insulin pump|"Each subject will use different combinations of new features of the system each week, in random order, over the next 4 weeks, using the t:slim X2 insulin pump with Control-IQ technology 2.0.~The first 5 subjects in the study will complete a 48 hour session with multiple challenges during use of Control-IQ technology 2.0, before moving on the outpatient portion of the trial."
62346469|NCT03798249|ACTIVE_COMPARATOR|Gluten|Patients will receive acutely 16 g of gluten and 2 muffins glutenfree with 8 g of gluten, twice a day, during 5 days
62346470|NCT03798249|PLACEBO_COMPARATOR|Placebo|Patients will receive acutely 16 g of whey protein and 2 glutenfree muffins, twice a day, during 5 days
62346471|NCT02721251|EXPERIMENTAL|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
62346472|NCT02721251|EXPERIMENTAL|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
62346473|NCT02721251|EXPERIMENTAL|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
62346474|NCT01967524|EXPERIMENTAL|botulinum toxin A + ropivacaïne|
62346475|NCT01967524|ACTIVE_COMPARATOR|Ropivacaïne|
62346476|NCT05429229|EXPERIMENTAL|Q10 coenzyme, vitamin E and cross-linked hyaluronic acid|This arm will administer eye drops with a combination of cross-linked hyaluronic acid, Q10 coenzyme and vitamin E, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
62346477|NCT05429229|ACTIVE_COMPARATOR|Sodium hyaluronate|This arm will administer eye drops with sodium hyaluronate, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
62346478|NCT05429229|ACTIVE_COMPARATOR|Sodium hyaluronate and chondroitin sulfate|This arm will administer eye drops with a combination of sodium hyaluronate and chondroitin sulfate, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
62346479|NCT04966195|OTHER|radiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
62346480|NCT01690689|EXPERIMENTAL|Surgery|Implant surgery
62714942|NCT06590181|ACTIVE_COMPARATOR|Yoga Nidra and Pain Acceptance Intention|Yoga Nidra plus a Pain Acceptance Intention.
62703061|NCT05016882|EXPERIMENTAL|NNC0174-0833 2.4 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
61958518|NCT03873831|ACTIVE_COMPARATOR|Social Skills Control (A-A)|"The children in the A-A condition, a true control, will remain without a dog for the full 10 weeks."
62346481|NCT02245451|EXPERIMENTAL|TPV/r with methadone|
62346482|NCT06096285||Preserved ratio impaired spirometry (PRISm)|People with post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ≥ 0.70 and FEV1 and/or FVC \< 80% predicted, or FEV1/FVC ≥ lower limit of normal (LLN) and FEV1 \< LLN.
62346483|NCT06096285||COPD Stage 0|People who had COPD-related risk factor exposure (e.g. cigarette smoke) and/or presented with respiratory symptoms (e.g. chronic cough, and/or sputum production) whereas with normal pulmonary function.
62346484|NCT06096285||Pre-COPD|People (importantly, of any age) who had respiratory symptoms (e.g. cough, sputum production, dyspnea, and/or exacerbation) with or without detectable structural (e.g. thoracic computed tomography (CT) emphysema, small and/or large airway impairments) and/or functional (e.g. low diffusion capacity for carbon monoxide (DLCO), hyperinflation, small airway obstruction, and/or accelerated FEV1 decline) abnormalities, in the absence of airflow limitation, and who might (or not) develop persistent airflow limitation (i.e. COPD) over time.
62346485|NCT06096285||Early COPD|People who were younger than 50 years with ten or more pack-years smoking history and any of these abnormalities: i) early airflow limitation (post-bronchodilator FEV1/FVC \< LLN), ii) compatible thoracic CT abnormalities, iii) rapid decline in FEV1 (\> 60 ml/year) that was accelerated relative to FVC.
62346486|NCT06096285||Young COPD|COPD patients with post-bronchodilator FEV1/FVC \< 0.70 diagnosed in the 20-50 year age range.
62346487|NCT06096285||Mild COPD|COPD patients with post-bronchodilator FEV1/FVC \< 0.70 and FEV1 ≥ 80% predicted.
62346488|NCT06096285||Controls|People who were not belonged to any of above six early COPD status, and with pre- and post-bronchodilator FEV1/FVC ≥ 0·70, and with post-bronchodilator FEV1/FVC ≥ LLN.
62346489|NCT06097767|OTHER|Control group|It includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks receives regular intervention for RDS
62346490|NCT06097767|ACTIVE_COMPARATOR|Caffeine-treated group|It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
62346491|NCT05136378|NO_INTERVENTION|Control Arm|Wait and Watch.
62346492|NCT05136378|EXPERIMENTAL|Low Dose Selenious Yeast|Receive 200μg Selenious Yeast per day.
62346493|NCT05136378|EXPERIMENTAL|High Dose Selenious Yeast|Receive 400μg Selenious Yeast per day.
62504394|NCT02091349|EXPERIMENTAL|Group B- polydextrose|polydextrose- randomly bonded polysaccharide of glucose which is poorly digested in small intestine
61958519|NCT03873831|EXPERIMENTAL|Social Skills Dog (A-B)|"The A-B condition will involve standard instruction for 5 weeks (A), followed by 5 weeks of group instruction while a therapy dog is present in the room (B)."
62346494|NCT02292992|EXPERIMENTAL|Nasal pillow CPAP|Nasal pillow CPAP
62346495|NCT01479894||Sample Collection|This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
62346496|NCT01949727||AIM 1/AIM 2: AECOPD Admitted Patients|"AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.~AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health."
62346497|NCT03059719|EXPERIMENTAL|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
62346498|NCT03059719|ACTIVE_COMPARATOR|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
62346499|NCT04203563|EXPERIMENTAL|Group 1|Group 1 participants attend twice weekly progressive strength training classes with CPR certified and Strong People trained educators in fall 2019 for 12 weeks. Intervention Group.
62504395|NCT02091349|EXPERIMENTAL|Group C- soluble corn fiber|Soluble corn fiber made from corn starch and contains oligosaccharides with random glyucosyl bonds and may contain minor amounts of monosaccharides
62504396|NCT04381676||Flipped Classroom|Residents in the flipped classroom were assigned a pre-class video lecture prior to completing the flipped classroom in-class case-based activity in groups of 2-3 each.
62504397|NCT04381676||Traditional Classroom|Residents in the traditional classroom were assigned a pre-class reading assignment followed by a 44-minute lecture that was delivered in-person using PowerPoint.
62703062|NCT05016882|PLACEBO_COMPARATOR|Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
62703063|NCT05693935|EXPERIMENTAL|TV-44749 - Dose level 1|Low dose regimen
61958520|NCT03873831|EXPERIMENTAL|Social Skills Dog (B-A)|"The B-A condition will be identical, except the first 5 weeks of instruction will include the dog, followed by 5 weeks of standard instruction with no dog."
62346500|NCT04203563|OTHER|Group 2|Group 2 participants receive twice weekly progressive strength training classes in January 2020 for 12 weeks. Delayed Intervention Group.
62346501|NCT03565848||Women underwent colorectal resection for endometriosis|Women referred for colorectal resection for deep infiltrating endometriosis that underwent laparoscopic segmental colorectal resection performed with mesenteric vascular and nerve sparing surgery.
62346502|NCT03140995|ACTIVE_COMPARATOR|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
62703064|NCT05693935|EXPERIMENTAL|TV-44749 - Dose level 2|Medium dose regimen
62703065|NCT05693935|EXPERIMENTAL|TV-44749 - Dose level 3|High dose regimen
62703066|NCT05693935|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62703067|NCT06137170||TAS±BEV-R|Eligible patients who started with trifluridine/tipiracil +/- bevacizumab (TAS+/-Bev) first, followed by regorafenib (R), without other therapies in-between.
62703068|NCT06137170||R-TAS±BEV|Eligible patients who started with regorafenib first, followed by TAS+/-Bev without other therapies in-between.
61958521|NCT03131778|ACTIVE_COMPARATOR|Open Liver Resection|Conventional open liver resection trough subcostal incision
61958522|NCT03131778|EXPERIMENTAL|Laparoscopic Liver Resection|Pure laparoscopic liver resection without hand assistance
61958523|NCT02781597|ACTIVE_COMPARATOR|Tranexamic acid|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.
61958524|NCT02781597|PLACEBO_COMPARATOR|Placebo|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
61958525|NCT03655509|OTHER|ACTH stimulation test|
62143131|NCT01812759|EXPERIMENTAL|Placebo Nasal Spray + Hydromorphone PCA|Placebo nasal spray administered plus hydromorphone PCA . All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
62346503|NCT03140995|NO_INTERVENTION|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
62346504|NCT06018610|EXPERIMENTAL|Intervention Group|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group. Patients will be re-evaluated 3 days after the completion of the interventions.
62346505|NCT06018610|ACTIVE_COMPARATOR|Control Group|The control group will receive conventional rehabilitation practices (in and out of bed strengthening exercises, for 3 days).
62346506|NCT02000453|EXPERIMENTAL|GSK2586184|A total of 15 subjects to be administered 400 mg GSK2586184 Tablet (200 mg X 2) twice daily for up to 56 days
62346507|NCT01670656|EXPERIMENTAL|NOMAC-E2 700/300 mcg|NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62346508|NCT01670656|EXPERIMENTAL|NOMAC-E2 900/300 mcg|NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62346509|NCT01670656|EXPERIMENTAL|ENG-E2 100/300 mcg|ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62346510|NCT01670656|EXPERIMENTAL|ENG-E2 125/300 mcg|ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62346511|NCT01670656|PLACEBO_COMPARATOR|Placebo|Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
62504398|NCT04266652|EXPERIMENTAL|Autogenous bone block|the monocortical block grafts were harvested from the retromolar region (i.e. linea oblique) by using of rotating (i.e. carbide burs)
62504399|NCT04266652|EXPERIMENTAL|Tooth block|In the first group, a second mucoperiosteal flap was elevated to surgically remove the respective wisdom tooth. After its removal and during the same surgery, the crown was decapitated at the cemento -enamel junction using a rotating carbide bur under gentle sterile saline cooling and the exposed pulp was preserved. The separated tooth root was adapted to match the size and shape of the defect area. To improve ankylosis between the graft and the defect site, the layer of cementum at the respective downward aspects of the root was carefully removed using a diamond bur until the underlying dentin was entirely exposed
62504400|NCT01280344|EXPERIMENTAL|0.03 mg/kg BID|Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
62504401|NCT01280344|EXPERIMENTAL|0.06 mg/kg BID|Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
62504402|NCT01280344|EXPERIMENTAL|0.06 mg/kg TID|Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
62504403|NCT01280344|PLACEBO_COMPARATOR|Placebo|Matching placebo, TID (3 placebo infusions)
62504404|NCT00983476|EXPERIMENTAL|Arm 1|in-person MOVE! SMI
62504405|NCT00983476|EXPERIMENTAL|Arm 2|web-based MOVE! SMI
62504406|NCT00983476|NO_INTERVENTION|Arm 3|usual care + educational handouts regarding weight loss
62504407|NCT01979198||fusion group|close reduction with posterior short-segment transpedicular screw fixation with posterior fusion
62504408|NCT01979198||non-fusion group|close reduction with posterior short-segment transpedicular screw fixation without posterior fusion
62703069|NCT04514107|ACTIVE_COMPARATOR|Control|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD). n=1740
62703070|NCT04514107|EXPERIMENTAL|Intervention|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD) and Wolbachia-infected Aedes aegypti (wMel) mosquitoes. n=1740
62703071|NCT00837369|EXPERIMENTAL|1 Real time perfusion (RTPE) imaging following Regadenoson|RTPE studies (resting and following Regadenoson 400 ug IV bolus injection) will be performed during a continuous infusion of lipid encapsulated microbubbles (Definity, Lantheus Medical Imaging) to qualitatively and quantitatively examine wall motion and myocardial contrast enhancement.
61958526|NCT02318147|EXPERIMENTAL|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
61958527|NCT02318147|OTHER|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
61958528|NCT05482412|EXPERIMENTAL|T3 Subgroup|"Two T3 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 3 SI Marker (Sexual Incitation) note: incitation/stimulation"
61958529|NCT05482412|EXPERIMENTAL|T5 (Young Adult) Subgroup|"Two T5 Subgroups Age-Play Subgroup (APSI):~Paraphilia with androphilic or gynephilic Tanner 5 SI Marker (Sexual Incitation)"
61958530|NCT05482412|SHAM_COMPARATOR|Sham Comparator|Medical Device Sham Comparator taVGN (Cranial Ten - Vagus Nerve) Selection of Random Participants In Any Subgroup Class Androphilic or gynephilic SI Marker (Sexual Incitation)
62143132|NCT01391767||NuOss XC|Bone grafting material used in this group will be NuOss XC.
62346512|NCT03013244|NO_INTERVENTION|Waitlist Control|Participants in this condition completed assessments at baseline, 1 week, and 5 weeks.
62346513|NCT03013244|EXPERIMENTAL|The Body Project: More Than Muscles|Participants in this condition competed the 2-session dissonance-based eating disorder prevention protocol (2 hours per session).
62346514|NCT04248790|EXPERIMENTAL|Experimental: the mobile App|Participants in the intervention arm will receive access to all the app capabilities. The app features include information on HIV testing locations, sex and PrEP diary and reminder of taking PrEP.
62346515|NCT04172909|EXPERIMENTAL|Child life group with LEGO bricks|Patients in this group will be prepped by a Certified Child Life Specialist with the use of LEGO bricks model MR
62346516|NCT04172909|NO_INTERVENTION|Control group|Age matched controls will be found retrospectively, and will be patients of the same age, undergoing their first non-contrast brain MRI with no Child Life intervention.
62346517|NCT04172909|EXPERIMENTAL|Child life group with Mock MRI tube|Patients in this group will be prepped by a Certified Child Life Specialist with the use of a Mock MRI tube
62346518|NCT03983928|EXPERIMENTAL|TQB2450 Combined with Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62346519|NCT02483104|EXPERIMENTAL|veliparib (ABT-888)|
62346520|NCT04043403|EXPERIMENTAL|Device: Summit RC+S|"1. Open Loop DBS: Standard DBS therapy at a constant frequency and voltage~2. Adaptive (Closed Loop) DBS: DBS that responds to neural or kinematic features of patient's current state~3. Intermittent Open Loop DBS: Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals."
62346521|NCT04043403|EXPERIMENTAL|Device: Percept PC|"1. Open Loop DBS: Standard DBS therapy at a constant frequency and voltage~2. Adaptive (Closed Loop) DBS: DBS that responds to neural features of patient's current state"
62346522|NCT05685888||The Ursodeoxycholic acid (UDCA) group|The Ursodeoxycholic acid (UDCA) group was defined as individuals who have received regular Ursodeoxycholic acid treatments during the two weeks before diagnosed COVID-19 infection (The frequency and dosage of UDCA were also recorded). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
62346523|NCT05685888||The non-Ursodeoxycholic acid (non- UDCA) group|The non-Ursodeoxycholic acid (non- UDCA) group was defined as individuals who didn't received regular Ursodeoxycholic acid treatments during the two weeks before diagnosed as COVID-19 infection. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
62346524|NCT01807195||the medical records of those in whom a contrast medium|
62346525|NCT01248494|EXPERIMENTAL|BEZ235 + Letrozole|
62346526|NCT01248494|EXPERIMENTAL|BKM120 + Letrozole|
62346527|NCT01248494|EXPERIMENTAL|Intermittent BKM120 + Letrozole|
62346528|NCT04686019|EXPERIMENTAL|Intervention group|"* 2 x IMT (5-10 min) 2 times a day 7 days a week for 3 weeks with or without supervision~* Log-book~* Conventional neurorehabilitation"
62346529|NCT04686019|ACTIVE_COMPARATOR|Control group|Conventional neurorehabilitation
62346530|NCT04223024|EXPERIMENTAL|CCRT + Nimotuzumab|Patients whose plasma EBV DNA\> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
62346531|NCT04223024|ACTIVE_COMPARATOR|CCRT alone|Patients whose plasma EBV DNA\> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
62346532|NCT02066753|ACTIVE_COMPARATOR|24 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 24 hours after reaching the target temperature between 32-34°C.
62346533|NCT02066753|EXPERIMENTAL|48 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 48 hours after reaching the target temperature between 32-34°C.
62346534|NCT00757926|EXPERIMENTAL|1|
62143133|NCT01391767||NuOss Particulate|Bone grafting material used in this group will be NuOss Particulate.
62346535|NCT00757926|PLACEBO_COMPARATOR|2|
62346536|NCT05949606|EXPERIMENTAL|Study treatment|Participants will receive treatment during the first cycle. Participants with clinical benefits received more cycles of additional therapy. Administration will be discontinued due to disease progression or occurrence of intolerable toxicity or other reasons.
62504409|NCT03730779|EXPERIMENTAL|O2 recieving|Patients who receive hyperoxia
62504410|NCT00440115|EXPERIMENTAL|High intensity disease management|High intensity disease management, free nicotine replacement therapy or bupropion
62504411|NCT00440115|EXPERIMENTAL|Low intensity disease management|Low intensity disease management, free nicotine replacement therapy or bupropion
62504412|NCT00440115|OTHER|Comparison group|Comparison group, free nicotine replacement therapy or bupropion
62504413|NCT04823130|NO_INTERVENTION|Healthy Participants: Control|Healthy participants with site, age, gender, race, location of targeted lesional and non-lesional skin area matched to selected AD participants, received no treatment, and were considered as a control group.
62504414|NCT04823130|EXPERIMENTAL|Participants With AD: Dupilumab|Participants with moderate to severe AD received dupilumab 600 milligrams (mg) subcutaneous (SC) injection on Day 1, followed by dupilumab 300 mg SC injection every 2 weeks (Q2W) from Week 3 to Week 15.
61958531|NCT05482412|EXPERIMENTAL|T2 Subgroup|"Two T2 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 2 SI Marker (Sexual Incitation)"
61958532|NCT05482412|EXPERIMENTAL|T4 Subgroup|"Two T4 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 4 SI Marker (Sexual Incitation)"
61958533|NCT02617381|EXPERIMENTAL|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
62143134|NCT06285409|ACTIVE_COMPARATOR|Carbetocin|Dose-response testing with increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
62143135|NCT06285409|ACTIVE_COMPARATOR|Oxytocin|Dose-response testing with increasing concentrations of oxytocin from 10-10 M to 10-5 M.
62143136|NCT06285409|ACTIVE_COMPARATOR|Ergometrine|Dose-response testing with increasing concentrations of ergometrine from 10-10 M to 10-5 M
62346537|NCT01231360|ACTIVE_COMPARATOR|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
62346538|NCT01231360|ACTIVE_COMPARATOR|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
62346539|NCT03466021|ACTIVE_COMPARATOR|Liraglutide|Liraglutide injection 3.0 mg daily
62346540|NCT03466021|PLACEBO_COMPARATOR|Placebo|Placebo, matching injection pen
62346541|NCT04578106|EXPERIMENTAL|Omission of surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Adjuvant period: If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB,patients will be eligible to omit loco-regional surgery. Whole breast radiotherapy without nodal radiotherapy will then be performed. Trastuzumab and pertuzumab FDC will be continued to complete 1 year of treatment and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
62346542|NCT04578106|NO_INTERVENTION|Surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Surgery: If invasive tumor cells and/or in situ disease are identified, patients will undergo surgery. Adjuvant period: All patients will continue with Trastuzumab-emtansine (T-DM1) completing 1 year of treatment (14 cycles) and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
62346543|NCT05342467|ACTIVE_COMPARATOR|Gemeprost|Gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours.
62504415|NCT01867606|EXPERIMENTAL|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
62504416|NCT01867606|PLACEBO_COMPARATOR|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
62504417|NCT06679010|EXPERIMENTAL|Intervention group|
62504418|NCT06635876|ACTIVE_COMPARATOR|EPT-C|The EPT-C group will receive two coaching sessions to assist with the completion of the EPT.
62504419|NCT06635876|NO_INTERVENTION|EPT-A|The EPT-A group will be responsible for completing the EPT alone, without coaching sessions.
62504420|NCT01065389|EXPERIMENTAL|Prgressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
62143137|NCT06285409|ACTIVE_COMPARATOR|Carboprost|Dose-response testing with increasing concentrations of carboprost from 10-10 M to 10-5 M
62143138|NCT06285409|PLACEBO_COMPARATOR|Control|No drug added to physiological salt solution (PSS).
62143139|NCT04694066|EXPERIMENTAL|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (followup; 8 hours). The sessions will be supervised by an experienced qigong master.
62143140|NCT04694066|ACTIVE_COMPARATOR|Light flexibility exercise|The control group will practice light flexibility exercise only, with the same duration and frequency of supervised sessions identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
62504421|NCT01065389|ACTIVE_COMPARATOR|Unstructured Resistance Exercise|Unstructured Resistance Exercise thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
62143141|NCT05136794||Opioid free anaesthesia|patient anesthtesized with lidocaine
62504422|NCT01263886|EXPERIMENTAL|AVE8062 and combination|"Day 1: AVE8062~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
62714943|NCT06590181|ACTIVE_COMPARATOR|Yoga Nidra with Pain Acceptance Intervention and Motor Imagery|Yoga Nidra plus pain acceptance and motor imagery
62714944|NCT06714721|EXPERIMENTAL|Treatment group receiving pulmonary rehabilitation and repetitive peripheral magnetic stimulation|The treatment group will receive 24 sessions of pulmonary rehabilitation and repetitive peripheral magnetic stimulation to strengthen the diaphragm muscle.
61958534|NCT01758562|NO_INTERVENTION|State-of-the-art mouth care|
62143142|NCT05136794||Opioid anaesthesia|patients anesthetized with sufentanil
62143143|NCT04778813|EXPERIMENTAL|Artemether-lumefantrin (AL)|"The tablets will be given orally according to patients' age and under supervision of study team as follows:~* Day 0: H0 and H8~* Day 1: H24 and H36~* Day 2: H48 and H60"
62143144|NCT04778813|EXPERIMENTAL|Dihydro-artemisinin-piperaquin (DHA-PPQ)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
62504423|NCT01263886|PLACEBO_COMPARATOR|Placebo|"Day 1: placebo~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
62504424|NCT02041858|NO_INTERVENTION|Control|Control arm with organizational-based alarm parameter settings
62504425|NCT02041858|EXPERIMENTAL|Altered Alarm Settings|Altered set of alarm parameter settings.
62504426|NCT05220969||Elite male youth footballers|Elite male youth footballers at an English championship / premier league football club
62504427|NCT00916695|ACTIVE_COMPARATOR|Complex PCI strategy for bifurcation coronary lesions|Stenting main vessel and T-stenting for the side branch
62504428|NCT00916695|ACTIVE_COMPARATOR|Simple PCI strategies for bifurcation coronary lesions|Stenting main vessel, with provisional stenting for the side branch.
62504429|NCT01696565|EXPERIMENTAL|125 mg/day Treatment Arm|125 mg/day PG2 treatment continuously for 7 days
62346544|NCT05342467|ACTIVE_COMPARATOR|Dinoprostone|Dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours.
62346545|NCT05283863|EXPERIMENTAL|High-Frequency Stimulation, Then Placebo Stimulation|Participants first receive sub-threshold high-frequency spinal cord stimulation (1200 Hz frequency, 200 μsec pulse width, and an amplitude 90% of the threshold for detection of a sensory percept) for 2 weeks. After a 2-week washout period, they then receive sham spinal cord stimulation (1200 Hz at 0 V amplitude) for 2 weeks.
62346546|NCT05283863|SHAM_COMPARATOR|Placebo Stimulation, Then High-Frequency Stimulation|Participants first receive sham spinal cord stimulation (1200 Hz at 0 V amplitude) for 2 weeks. After a 2-week washout period, they then receive sub-threshold high-frequency spinal cord stimulation (1200 Hz frequency, 200 μsec pulse width, and an amplitude 90% of the threshold for detection of a sensory percept) for 2 weeks.
62346547|NCT02026206|EXPERIMENTAL|LLLT group|low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles.
62504430|NCT01696565|EXPERIMENTAL|250 mg/day Treatment Arm|250 mg/day PG2 treatment continuously for 7 days
62504431|NCT01696565|EXPERIMENTAL|500 mg/day Treatment Arm|500 mg/day PG2 treatment continuously for 7 days
62504432|NCT00807209|EXPERIMENTAL|High Dose SKY0402|
62504433|NCT00807209|ACTIVE_COMPARATOR|Standard of Care|
62504434|NCT00807209|EXPERIMENTAL|Low Dose SKY0402|
62504435|NCT04721496|EXPERIMENTAL|Trained|Athletes who had at least 2 years of continuous strength training experience, and at least 6 months of training with unstable situations and device
62703072|NCT05112601|EXPERIMENTAL|Arm I (nivolumab and ipilimumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or CR. Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.~Additionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial."
61958535|NCT01758562|ACTIVE_COMPARATOR|Mouth rinse Caphosol|Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.
62346548|NCT02026206|PLACEBO_COMPARATOR|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
62346549|NCT02001597||Surgery patients|
62346550|NCT01595659|PLACEBO_COMPARATOR|no alcohol and passenger|Blood alcohol concentration (BAC) = 0.00% and risk accepting or averse passenger
62346551|NCT01595659|EXPERIMENTAL|low alcohol dose and passenger|BAC = 0.02% and risk accepting or averse passenger
62346552|NCT01595659|EXPERIMENTAL|moderate alcohol dose and passenger|BAC = 0.05% and risk accepting or averse passenger
62504436|NCT04721496|EXPERIMENTAL|Untrained|Athletes who had at least 2 years of continuous strength training experience, but no training experience with unstable situations and devices
62504437|NCT06677879|EXPERIMENTAL|Proton therapy|Proton radiotherapy will be offered to patients who require adjuvant radiotherapy after lumpectomy or mastectomy for breast cancer.
62504438|NCT06677879|ACTIVE_COMPARATOR|photon therapy|Photon radiotherapy will be offered to patients who require adjuvant radiotherapy after lumpectomy or mastectomy for breast cancer.
62504439|NCT05931393|EXPERIMENTAL|Cohort 1: Cabozantinib Dose Escalation|cabozantinib 80mg PO daily
62504440|NCT05931393|EXPERIMENTAL|Cohort 2: cabozantinib + nivolumab|cabozantinib 40mg PO daily + nivolumab 480 mg IV every 4 weeks (q4w)
62504441|NCT01118507||TRISOMY|mothers of a trisomic fetus 21
62504442|NCT01118507||NORMAL KARYOTYPE|mothers of DISOMIQUE foetus 21
62714945|NCT06714721|SHAM_COMPARATOR|Sham group|The sham group will receive 24 sessions of pulmonary rehabilitation and sham application of repetitive peripheral magnetic stimulation will be done.
61958536|NCT03722966|EXPERIMENTAL|Varenicline/Counseling + Med Reminders (VAR+REM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and automated medication reminders via their smartphones.
62346553|NCT05943067|OTHER|Single-arm|Donor lymphocytes from allogeneic donors depleted of CD45RA lymphocytes.
62346554|NCT03441568|EXPERIMENTAL|BAY987534|Infants and children with quiescent atopic dermatitis
62346555|NCT04485091|EXPERIMENTAL|Group A: 20% TCM and PBM|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with photobiomodulation (PBM) with red spectrum LED (660nm) on the back of the hands.
62504443|NCT05452434|EXPERIMENTAL|Experimental group|300 cases, mirabegron 50mg QD + behavior intervention (timed urination + left head wagging 3 times and right head wagging 3 times in urgent urination) for 12 weeks.
62504444|NCT05452434|ACTIVE_COMPARATOR|Control group|300 cases, mirabegron 50mg QD for 12 weeks
62504445|NCT01439724|PLACEBO_COMPARATOR|Placebo|Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
62504446|NCT01439724|EXPERIMENTAL|Low Level Laser Therapy|The investigators used a Low Level Laser Therapy, diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
61958537|NCT03722966|EXPERIMENTAL|Varenicline/Counseling (VAR+NREM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and no automated medication reminders.
62346556|NCT04485091|PLACEBO_COMPARATOR|Group B: 20% TCM and PBM placebo|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with simulated photobiomodulation on the back of the hands.
62346557|NCT01750944|EXPERIMENTAL|Healthy Volunteers 1|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: ankle first"
62346558|NCT01750944|EXPERIMENTAL|Healthy Volunteers 2|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: toe first"
62346559|NCT03255993|EXPERIMENTAL|SPH3127 100mg|A single dose of SPH3127 50 mg\*2 qd \*7 days
62346560|NCT03255993|PLACEBO_COMPARATOR|Placebo to SPH3127 100mg|A single dose of placebo matching to SPH3127 50mg\*2 qd \*7 days
62346561|NCT03255993|EXPERIMENTAL|SPH3127 200mg|A single dose of SPH3127 100 mg\*2 qd \*7 days
62346562|NCT03255993|PLACEBO_COMPARATOR|Placebo to SPH3127 200mg|A single dose of placebo matching to SPH3127 100mg\*2 qd \*7 days
62346563|NCT03255993|EXPERIMENTAL|SPH3127 400mg|A single dose of SPH3127 100 mg\*4 qd \*7 days
62346564|NCT03255993|PLACEBO_COMPARATOR|Placebo to SPH3127 400mg|A single dose of placebo matching to SPH3127 100mg\*4 qd \*7 days
62346565|NCT04413721|EXPERIMENTAL|Short-term storage RBCs (stored for ≤ 14 days)|patients in this group were transfused with short-term storage RBCs (stored for ≤ 14 days).
62346566|NCT04413721|ACTIVE_COMPARATOR|Longer-term storage RBCs (stored for ≥21 days)|patients in this group were transfused with longer-term storage RBCs (stored for ≥21 days).
62346567|NCT00824928||Observational|Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
62346568|NCT00071422|PLACEBO_COMPARATOR|placebo|1.5 mL SC injection, once daily for 90 days
62346569|NCT00071422|EXPERIMENTAL|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
62346570|NCT00071422|EXPERIMENTAL|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
62346571|NCT02819505|EXPERIMENTAL|Beta-alanine supplementation|Participants will be supplemented with 6.4g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets four times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
62346572|NCT02819505|PLACEBO_COMPARATOR|Placebo supplementation|Participants will be supplemented with 6.4g·d-1 placebo (maltodextrin; NAI, USA).
62346573|NCT03230747|EXPERIMENTAL|TMVR|Subjects will undergo transcatheter mitral valve replacement
62346574|NCT05861804|EXPERIMENTAL|Block group|Participants who will be receiving a rhomboid intercostal nerve block
62346575|NCT05861804|NO_INTERVENTION|Control group|Participant who will not be receiving any intervention
62346576|NCT03737292|EXPERIMENTAL|Exparel|Intercostal injection of 266mg of Exparel diluted to 30 ml.
62346577|NCT03737292|ACTIVE_COMPARATOR|Bupivacaine|Intercostal injection of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml.
62346578|NCT03047850||Study Group|All patients included in this study.
62504447|NCT03480685|OTHER|IVUS Imaging vs. OCT Imaging|A vessel segment will be imaged with intravascular ultrasound (IVUS). The same vessel segment will be imaged with optical coherence tomography (OCT).
62504448|NCT05470595|EXPERIMENTAL|Atezolizumab/Platinum/Etoposide|Atezolizumab/Platinum/Etoposide Platinum will be cisplatin or carboplatin at the investigators discretion.
62504449|NCT02973581|EXPERIMENTAL|metamizol|analgesic drug
62346579|NCT05767710|EXPERIMENTAL|AI telerehabilitation - Tai Chi|All sessions were conducted online, with participants practicing along with Tai Chi videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
62346580|NCT05767710|ACTIVE_COMPARATOR|general telerehabilitation - Tai Chi|All sessions were conducted in an online format, with participants practicing along with Tai Chi videos while the professional Tai Chi instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
62346581|NCT05767710|ACTIVE_COMPARATOR|traditional rehabilitation - Tai Chi|All sessions were conducted offline and implemented by professional Tai Chi instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Tai Chi group.
62346582|NCT05767710|EXPERIMENTAL|AI telerehabilitation - Yi Jin Jing|All sessions were conducted online, with participants practicing along with Yi Jin Jing videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
62504450|NCT02973581|EXPERIMENTAL|acetaminophen|analgesic drug
62504451|NCT02973581|EXPERIMENTAL|0,5 % bupivacaine with of 2% lidocaine|a volume of 5 ml of analgesic solution for regional peribulbar block
62504452|NCT02973581|EXPERIMENTAL|Proxymetacaine|topical analgesia
62504453|NCT02973581|PLACEBO_COMPARATOR|control group|patients will receive no pre-emptive analgesia. standard doses of fentanyl will be used intraoperatively.
61958538|NCT03722966|EXPERIMENTAL|Varenicline/Counseling + Oral NRT (VAR+NRT+NREM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and no automated medication reminders.
61958539|NCT03722966|EXPERIMENTAL|Varenicline/Counseling + Oral NRT + Med Reminders (VAR+NRT+REM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and automated medication reminders via their smartphones.
61958540|NCT05699031|EXPERIMENTAL|APP-GROUP|Patients allocated in the app-group will use the app to rehabilitate.
61958541|NCT05699031|ACTIVE_COMPARATOR|PHYSIO-GROUP|Patients allocated in the physio-group will rehabilitate according to the usual care protocol
61958542|NCT00810030|EXPERIMENTAL|FERINJECT® (Ferric carboxymaltose)|
61958543|NCT00810030|ACTIVE_COMPARATOR|VENOFER® (Iron Sucrose)|
61958544|NCT02798874|EXPERIMENTAL|Ticagrelor Group|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
61958545|NCT02798874|ACTIVE_COMPARATOR|Clopidogrel Group|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
61958546|NCT02883270|EXPERIMENTAL|RAGT treatment group|Robotic-assisted gait training （RAGT）is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation after some neuropathy. The investigators use LokoHelp for training, which is provided to the feet and the patient actively controls the knee and hip joints. The participants of RAGT treatment group receive 30 min conventional rehabilitation and 30 min robotic-assisted gait training daily for 8 weeks.
61958547|NCT02883270|PLACEBO_COMPARATOR|controls|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
61958548|NCT02547844|ACTIVE_COMPARATOR|efavirenz + emtricitabina + tenofovir|Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
61958549|NCT02547844|EXPERIMENTAL|rilpivirina + emtricitabina + tenofovir|Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
61958550|NCT04191031|EXPERIMENTAL|Superficial Genicular Nerves|Subjects will receive iovera° cryoneurolysis treatment of superficial genicular nerves (anterior femoral cutaneous nerve \[AFCN\] and infrapatellar branches of the saphenous nerve \[ISN\]) of the target knee
61958551|NCT04191031|SHAM_COMPARATOR|Sham Comparator|Subjects will receive sham iovera° treatment of superficial genicular nerves (AFCN and ISN) of the target knee
61958552|NCT02123121|PLACEBO_COMPARATOR|Vegetable cellulose|Participants will orally consume one capsule of vegetable cellulose following each of their main meals (i.e. breakfast, lunch, and dinner) for 90 days.
61958553|NCT02123121|ACTIVE_COMPARATOR|Resveratrol 1000 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1000 mg/day for 90 days.
61958554|NCT02123121|ACTIVE_COMPARATOR|Resveratrol 1500 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1500 mg/day for 90 days.
61958555|NCT01386827|ACTIVE_COMPARATOR|A) primary immunization with MB-JEV|Volunteers immunized with MB-JEV
61958556|NCT01386827|ACTIVE_COMPARATOR|Primary and booster MBJEV vaccinations|Booster immunization with MB-JEV of vaccinees primed with MB-JEV
62143145|NCT04778813|EXPERIMENTAL|Artesunate-Pyronaridin (As-Pyr)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
62504454|NCT00987025|EXPERIMENTAL|Telehealth|Telehealth participants will be recruited from centers that have a telehealth blood pressure station installed. Participants will be asked to use the station once per week. Blood pressure measures will be monitored by nurse researchers - out of range values will result in appropriate medical recommendations.
61958557|NCT01386827|ACTIVE_COMPARATOR|C) primary immunizations with Ixiaro|Primary immunization with Ixiaro 2 dose
61958558|NCT01386827|ACTIVE_COMPARATOR|S) Ixiaro booster to MBJEV primed|Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV
61958559|NCT00718952|EXPERIMENTAL|A|Patients in group A will receive vardenafil in double-blinded treatment period.
61958560|NCT00718952|PLACEBO_COMPARATOR|B|Patients in group A will receive placebo in double-blinded treatment period.
61958561|NCT03673449|EXPERIMENTAL|SilkBridge treatment|Surgery for digital nerve reconstruction with SilkBridge
61958562|NCT01587820|EXPERIMENTAL|Intra-arterial cisplatin and radiation|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
62143146|NCT03890484|EXPERIMENTAL|New Peers|Participants will drink with two new peers (i.e. strangers), who they did not know prior to the study and their Peer Type.
62504455|NCT00987025|ACTIVE_COMPARATOR|Control|Control participants will receive education material.
62143147|NCT03890484|EXPERIMENTAL|Close Friends|Participants will recruit and drink with two of their close friends and their Peer Type
62346583|NCT05767710|ACTIVE_COMPARATOR|general telerehabilitation - Yi Jin Jing|All sessions were conducted in an online format, with participants practicing along with Yi Jin Jing videos while the professional Yi Jin Jing instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
62504456|NCT03408431|EXPERIMENTAL|Group E|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neck extension positioning.
62504457|NCT03408431|ACTIVE_COMPARATOR|Group C|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neutral head and neck position.
62504458|NCT02001155||Trabeculectomy|Individuals in this group will have undergone a trabeculectomy for the treatment of glaucoma.
62504459|NCT02001155||Tube Shunt|Individuals in this group will have undergone a tube shunt for the treatment of glaucoma.
62504460|NCT05396417||Cesarean delivery|Any urgency any reason
61958563|NCT01587820|ACTIVE_COMPARATOR|Intravenous cisplatin and radiation|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
61958564|NCT01741597|EXPERIMENTAL|Diagnostic (DCE-MRI, tumor-homing peptide iRGD)|Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
61958565|NCT01378637|EXPERIMENTAL|AMES Leg treatment|An investigational device flexes and extends the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the foot. The subject's task is to assist the motion of the device by pulling or pushing with the foot. Feedback of ankle torque or the electrical signal produced by the muscles (EMG) while the subject is assisting the motion is provided during the 30 treatment sessions.
61958566|NCT02978430|ACTIVE_COMPARATOR|Standard of care|This group (started retrospectively before the first included patient of the closed-loop goal-directed fluid therapy group) consists of patients undergoing major abdominal surgery where fluid management is carried out based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output).
61958567|NCT02978430|ACTIVE_COMPARATOR|Computer-assisted GDFT|"This group consists of patients undergoing major abdominal surgery where fluid management is carried out with a closed-loop (automated) system to deliver fluid by a goal-directed fluid therapy (GDFT) standardized protocol.~Confer: Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery (NCT02312999)"
61958568|NCT00841646|OTHER|1|
61958569|NCT00005639|EXPERIMENTAL|Regimen A: 14-day 5-AC with intermittent phenylbutyrate|"Participants receive low-dose regimen of 5-AC with intermittent phenylbutyrate 400 mg/m2/day by continuous intravenous (CIV) over 24 hours on Days 6 and 13. Each cycle lasts 35 days.~Cohort A1: 25 mg/m2/day subcutaneous (SC) Cohort A-1: 18.75 mg/m2/day SC Cohort A-2: 15 mg/m2/day SC Cohort A-3: 10 mg/m2/day SC"
61958570|NCT00005639|EXPERIMENTAL|Regimen B: 7-day 5-AC with sequential phenylbutyrate|"Participants receive 5-AC 75mg/m2/day SC for 7 days, followed sequentially by two different doses of phenylbutyrate CIV starting on Day 8 and continuing for 7 days. Each cycle lasts 35 days~Cohort B1: Phenylbutyrate 200 mg/m2/day CIV Cohort B2: Phenylbutyrate 400 mg/m2/day CIV"
61958571|NCT00005639|EXPERIMENTAL|Regimen C: 21-day 5-AC with weekly phenylbutyrate|"Participants receive two different daily doses of 5-AC SC for 21 days and phenylbutyrate 400 mg/m2/day CIV over 24 hours once-per-week. Each cycle lasts 42 days.~Cohort C1: 5-AC 10mg/m2/day SC Cohort C2: 5-AC 12.5mg/m2/day SC"
61958572|NCT05544604|ACTIVE_COMPARATOR|group 1: active primary motor cortex stimulation|active tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day)
61958573|NCT05544604|SHAM_COMPARATOR|group 2 : sham primary motor cortex stimulation|sham tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds.
61958574|NCT05544604|ACTIVE_COMPARATOR|group 3 : active insula stimulation|active tDCS (2 mA) targeting the insula of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day)
61958575|NCT05544604|SHAM_COMPARATOR|group 4 : sham insula stimulation|sham tDCS over the insula in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds.
61958576|NCT04702061|ACTIVE_COMPARATOR|Group E|Patients who receive general anesthesia after erector spina plane block
61958577|NCT04702061|ACTIVE_COMPARATOR|Group T|Patients who receive general anesthesia after thoracic epidural block
61958578|NCT00844831|EXPERIMENTAL|Treatment with lubiprostone|Subjects receive lubiprostone and bacteria is measured before and after
61958579|NCT00187577|ACTIVE_COMPARATOR|application to eyelid of latanoprost solution|Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
61958580|NCT00187577|ACTIVE_COMPARATOR|Application of bimatoprost to eyelid|Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
61958581|NCT00388960|EXPERIMENTAL|Amrubicin|Amrubicin 45mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
61958582|NCT00388960|EXPERIMENTAL|Amrubicin plus Cisplatin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> IV day 1 of each 21-day cycle until disease progression.
61958583|NCT00388960|ACTIVE_COMPARATOR|Cisplatin plus etoposide|Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 each 21-day cycle until disease progression.
61958584|NCT00756756|EXPERIMENTAL|1|post MI post PCI and G-CSF infusion
61958585|NCT00756756|PLACEBO_COMPARATOR|2|post MI and post PCI only placebo infused
61958586|NCT06383078|EXPERIMENTAL|HR070803+Oxaliplatin+S-1|"Drug: HR070803（Irinotecan Liposome）; Oxaliplatin; Tegafur HR070803 60 mg/\^2 D1 over 90 minutes. Oxaliplatin 85 mg/\^2 D1 over 2 hours. Tegafur The initial dose of S-1 is determined according to the body surface area，orally, D1-7.~These drugs are given once every 2 weeks, 4 weeks as one cycle, 6 treatment cycles."
62504461|NCT00704496|PLACEBO_COMPARATOR|Placebo|Placebo
61958587|NCT06383078|ACTIVE_COMPARATOR|HR070803+Oxaliplatin+5-FU/LV|"Drug: HR070803; Oxaliplatin; 5-Fluorouracil; Calcium folinate HR070803 60 mg/\^2 D1 over 90 minutes. Oxaliplatin 85 mg/\^2 D1 over 2 hours. Folinic acid 400 mg/\^2 D1, IV infusion over 1 hours. 5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 4 weeks as one cycle, 6 treatment cycles."
61958588|NCT03589872||Study Group|patients with parkinson disease
61958589|NCT03965039|ACTIVE_COMPARATOR|Marketed stannous fluoride toothpaste|Brush twice daily
61958590|NCT03965039|ACTIVE_COMPARATOR|Marketed potassium nitrate toothpaste|Brush Twice Daily
61958591|NCT03965039|PLACEBO_COMPARATOR|Marketed sodium monofluorophosphate toothpaste|Brush Twice Daily
61958592|NCT03965039|EXPERIMENTAL|Experimental dipotassium oxalate toothpaste|Brush Twice Daily
61958593|NCT03338998|EXPERIMENTAL|BAF312|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally
62504462|NCT00704496|ACTIVE_COMPARATOR|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
61958594|NCT03338998|PLACEBO_COMPARATOR|Placebo|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally - matching placebo
61958595|NCT00653575||1|Women who report a history of childhood sexual abuse
61958596|NCT00653575||2|Women who do not report a history of childhood sexual abuse
61958597|NCT01335191|EXPERIMENTAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.
61958598|NCT01335191|PLACEBO_COMPARATOR|Placebo|Two subcutaneous injections of placebo at Day 0 and Week 3.
61958599|NCT00957970|ACTIVE_COMPARATOR|Stemless femoral component|Stemless PROXIMA femoral component
61958600|NCT00957970|ACTIVE_COMPARATOR|Stemmed femoral component|IPS, proximal anatomical fit stemmed femoral component
61958601|NCT02578316|EXPERIMENTAL|Lenvatinib 24 mg|Participants with advanced solid tumors or lymphomas, who are unsuitable for, or had failed, existing therapies.
61958602|NCT06014203||Patients undergoing shoulder arthroscopy surgery|Patients who underwent arthroscopic shoulder surgery by a single surgeon at Gazi Hospital Department of Orthopedics and Traumatology (rotator cuff repair, slap, bankart repair)
61958603|NCT00680017|EXPERIMENTAL|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
61958604|NCT00680017|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
62703073|NCT05112601|ACTIVE_COMPARATOR|Arm II (nivolumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.~Additionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial."
61958605|NCT02077920|EXPERIMENTAL|Chlorhexidine before intubation|Group A: Oropharyngeal decontamination with chlorhexidine before intubation, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation, and every 6 hours after intubation.
61958606|NCT02077920|EXPERIMENTAL|Chlorhexidine after intubation|Group B: Oropharyngeal decontamination with chlorhexidine after intubation, n=48. Oral cleansing with chlorhexidine will be performed every 6 hours after endotracheal intubation.
61958607|NCT02077920|EXPERIMENTAL|Subglottic secretion drainage|"Group C: Suctioning of subglottic secretions, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation and every 6 hours after intubation, and fiberoptic bronchoscopy-guided suctioning of subglottic secretions will be performed at 10:00 a.m. every day. The procedure will be as follows:~1. Routine cleaning of the bronchoscope.~2. Oral or nasal insertion of the bronchoscope (according to the decision of the attending physician based on the patient's condition). Rinsing of the subglottic region with 5-20 mL of chlorhexidine solution followed by suctioning. The rinsing procedure will be repeated 3-5 times.~3. Routine cleaning of the bronchoscope. The patient will be monitored during all procedures."
61958608|NCT02077920|EXPERIMENTAL|0.9% sodium chloride injection|Group D: 0.9% sodium chloride injection, n=48. After endotracheal intubation, oral cleansing with normal saline will be performed every 6 hours.
62504463|NCT04211766|EXPERIMENTAL|Cross-over Randomization 1: Fiber plus Fish Oil followed by Comparator|Participants first received a fiber supplement and a fish oil supplement PO daily for 30 days (Period 1). Participants entered a washout period for at least 60 days. For period 2 they received similarly packaged comparator (maltodextrin and corn oil)
61958609|NCT05751265|EXPERIMENTAL|Tislelizumab combined with chemotherapy|
61958610|NCT02204878|PLACEBO_COMPARATOR|A|1ml of saline was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. 1ml saline Q12h will be given within 72 hours after surgery
61958611|NCT02204878|EXPERIMENTAL|AT|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
61958612|NCT04141488|EXPERIMENTAL|Experimantel Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own. The experimantel group was given strengthening exercises of the upper trapezoidal, middle trapezoidal and serratus anterior muscles with extra scapula muscles.
62143148|NCT02110381|ACTIVE_COMPARATOR|Device Guided Breathing/Combination Therapy|Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
62143149|NCT02110381|ACTIVE_COMPARATOR|Isometric Hand Grip/Combination Therapy|Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
62143150|NCT01747304||Screening population|Healthy post-menopausal women attending bone mineral density screening clinic with leg/hip/groin pain/discomfort/weakness an has been on anti-resorptive therapy for at least 5 years.
62143151|NCT01747304||Comparator Group|Control group from Toronto CaMOS cohort willing to participate.
62703074|NCT05946109|ACTIVE_COMPARATOR|ACTIVE-AGE@home by professionals|"Training program of 24 weeks supervised by professionals with a relevant background in the treatment and/or training of the older adults.~The older adults are trained by either a physiotherapist, an occupational therapist or an exercise professional. The professionals will receive a 3x4h training course to gain more knowledge and practice regarding following aspects:~* Frailty and ageing.~* Physical training principles + ACTIVE-AGE@home exercise program~* Motivational coaching.~All participants in the three arms will receive the same monthly newsletter with tips and tricks to obtain good health in older age."
62143152|NCT01747304||AFF group|participants in the AFF Cohort study at UHN
61958613|NCT04141488|OTHER|Control Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own.
61958614|NCT05007392|EXPERIMENTAL|Drug: Dotinurad + Febuxostat Matched Placebo|Participants will receive one dotinurad 1 mg tablet and one febuxostat 20 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then one dotinurad 2 mg tablet and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two dotinurad 2 mg tablets and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
62703075|NCT05946109|EXPERIMENTAL|ACTIVE-AGE@home by volunteers|"Training program of 24 weeks supervised by volunteers who are presented by the older adults themselves or who are recruited by the research group.~The older adults are trained by an informal caregiver or a newly recruited volunteer. The informal caregivers and volunteers will receive a 3x4h training course to gain more knowledge and practice regarding following aspects:~* Frailty and ageing.~* Physical training principles + ACTIVE-AGE@home exercise program~* Motivational coaching.~All participants in the three arms will receive the same monthly newsletter with tips and tricks to obtain good health in older age."
61958615|NCT05007392|ACTIVE_COMPARATOR|Drug: Febuxostat + Dotinurad Matched Placebo|Participants will receive one febuxostat 20 mg tablet and one dotinurad 1 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then two febuxostat 20 mg tablets and one dotinurad 2 mg matched placebo tablet, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two febuxostat 20 mg tablets and two dotinurad 2 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
62504464|NCT04211766|EXPERIMENTAL|Cross-over Randomization 2: Comparator followed by Fiber plus Fish Oil|Participants first received the comparator (maltodextrin and corn oil) supplement PO daily for 30 days (Period 1). Participants enter a washout period for at least 60 days. For period 2 they received the fiber supplement and a fish oil supplement
62504465|NCT02093871|EXPERIMENTAL|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
61958616|NCT06237829|EXPERIMENTAL|Identifying and synthesizing high-contrast tactile materials without physical features|Beyond the few materials investigators previously identified, it is unknown which materials are useful for creating tactile sensations. Common material properties such as a friction coefficient or hydrophilicity are insufficiently detailed to accurately predict friction forces-the basis of tactile stimuli. The investigators will use expertise in connecting tactile sensations with chemical structure through mechanical testing, theory, and human testing. The investigators' goal is to identify materials that lead to high tactile contrast without relying on physical features. (Tactile contrast is defined by the investigators as large differences in friction which are easily distinguishable by humans during free tactile exploration.)
61958617|NCT06237829|EXPERIMENTAL|Building tactile aids with designer materials for plots, games, and object labeling|Investigators will build static tactile aids with designer materials, i.e., silanes and polymers coatings. These aids will be a mathematical plot, a board game, and simulated money. Investigators will compare the speed, accuracy, and amount of information of hybrid tactile aids made from designer materials and physical features to traditional tactile aids made only with bumps.
62143153|NCT00637104|EXPERIMENTAL|A - Mar-tyn|It includes the implant of the Mar-tyn TiN coated stent
62143154|NCT00637104|ACTIVE_COMPARATOR|B - Vision|Includes all the patients treated with the Vision stent
62346584|NCT05767710|ACTIVE_COMPARATOR|traditional rehabilitation - Yi Jin Jing|All sessions were conducted offline and implemented by professional Yi Jin Jing instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Yi Jin Jing group.
62346585|NCT05767710|EXPERIMENTAL|AI telerehabilitation - Ba Duan Jin|All sessions were conducted online, with participants practicing along with Ba Duan Jin videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
62504466|NCT05389670|EXPERIMENTAL|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
62504467|NCT05389670|SHAM_COMPARATOR|Sham Theta-burst stimulation|
62504468|NCT04783545|EXPERIMENTAL|Single Ascending Dose Cohorts 1-6|Drug: VLX-1005
62504469|NCT04783545|PLACEBO_COMPARATOR|Single Ascending Dose Cohorts 1-6, Placebo|Drug: Placebo
62504470|NCT04783545|EXPERIMENTAL|Multiple Ascending Dose Cohorts 7-9|Drug: VLX-1005
62504471|NCT04783545|PLACEBO_COMPARATOR|Multiple Ascending Dose Cohorts 7-9, Placebo|Drug: Placebo
62703076|NCT05946109|NO_INTERVENTION|Standard care for frail older adults|"The two intervention conditions will be compared with the current standard care for frail community-dwelling elderly that does not include physical activity interventions.~All participants in the three arms will receive the same monthly newsletter with tips and tricks to obtain good health in older age."
62504472|NCT04208256|SHAM_COMPARATOR|Energy Neutral|Bottled water (300 ml) with added fruit punch-flavored non-nutritive sweetener (aspartame) will be used as the energy neutral stimulus.
62504473|NCT04208256|ACTIVE_COMPARATOR|Energy Surplus|300ml fruit punch-flavored Glucola (75-gram\[g\], Azer Scientific) will be used as the energy surplus stimulus.
62504474|NCT03164187||Diabeton MR 60|
62504475|NCT01110317|EXPERIMENTAL|001|paliperidone palmitate 100 mg Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1 8 36 and 64.
61958618|NCT06237829|EXPERIMENTAL|Optimal design of bumps and designer materials in tactile aids|Reflecting the lack of standardized methods or benchmarks for tactile technologies, the known limits of tactile sensitivity was narrowed from millimeters, microns, to nanometers within the last 10 years by use of metal wires, wrinkled plastics, and silanes, respectively. Investigators will determine the optimal design of traditional bumps which yields the highest tactile stimulus in the smallest area. Investigators expect to find that current bumps are larger than necessary, and that the same information could be placed into a smaller area (higher information density). Then, investigators will augment bumps with designer materials to increase the tactile stimulus from a bump, thereby permitting even smaller bumps to increase information density. Beyond optimal design methods, the investigators' quantitative methods, enabled by making the mechanical stimulus the dependent variable, also serve as benchmarks between tactile aids.
61958619|NCT03207230|EXPERIMENTAL|Standard|All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.
61958620|NCT03039283||Nucleus CI532 cochlear implant|
61958621|NCT06041867|EXPERIMENTAL|Agaricus bisporus group|Dietary supplement: 10 capsules containing 500 mg Agaricus bisporus powder each
61958622|NCT06041867|PLACEBO_COMPARATOR|Placebo group|Dietary supplement: 10 placebo capsules, capsules that do not contain Agaricus bisporus powder
61958623|NCT04420143||MLX - Medial Lateral Expandable Lumbar Interbody System|Patients who underwent lumbar interbody fusion with the MLX expandable interbody implant will be included in the MLX - Medial Lateral Expandable Lumbar Interbody System cohort.
61958624|NCT04420143||XLX ACR Interbody System|Patients who underwent lumbar interbody fusion with the XLX ACR expandable interbody implant will be included in the XLX ACR Interbody System cohort.
61958625|NCT02446483|EXPERIMENTAL|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
62143155|NCT03057600|EXPERIMENTAL|Cohort 1 - African ancestry, 3rd line+|"Intervention = Paclitaxel- CB-839 (Pac-CB) combination~1. Participants must self-identify as African ancestry (includes African American).~2. At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~   * Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~  * Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
62346586|NCT05767710|ACTIVE_COMPARATOR|general telerehabilitation - Ba Duan Jin|All sessions were conducted in an online format, with participants practicing along with Ba Duan Jin videos while the professional Ba Duan Jin instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
62346587|NCT05767710|ACTIVE_COMPARATOR|traditional rehabilitation - Ba Duan Jin|All sessions were conducted offline and implemented by professional Ba Duan Jin instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Ba Duan Jin group.
62346588|NCT01840228|ACTIVE_COMPARATOR|Micronized progesterone suppository|Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
62346589|NCT01840228|PLACEBO_COMPARATOR|Placebo suppository|One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
62346590|NCT04417114|EXPERIMENTAL|Single-Arm Open label|This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.
62346591|NCT02624011|EXPERIMENTAL|Physical inactivity|Study arm consisting of 7 days of habitual physical activity followed by 7 days of step reduction and exercise cessation.
62504476|NCT04983342|EXPERIMENTAL|Apollo Armband|Armband that can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain.
61958626|NCT02446483|EXPERIMENTAL|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
61958627|NCT06498492||Early cholecystectomy group|For group division patients were asked to select a paper randomly from a box, offering them the choice between early or delayed laparoscopic cholecystectomy although the ultimate decision was influenced by patient preference. Those patients whose paper came early underwent early laparoscopic cholecystectomy within index hospital.
61958628|NCT06498492||Late cholecystectomy group|Those patients whose paper came delayed were discharged after symptoms subside and were readmitted after 6 weeks to undergo laparoscopic cholecystectomy.
61958629|NCT01495117|ACTIVE_COMPARATOR|Povidone Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
61958630|NCT01495117|ACTIVE_COMPARATOR|Chlorhexidine Gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
61958631|NCT03524898|EXPERIMENTAL|nab-paclitaxel and gemcitabine|Treatment consists of the combination treatment of nab-paclitaxel and gemcitabine, which is given every 2 weeks during 28-day cycle intervals until disease progression.
61958632|NCT01818232|EXPERIMENTAL|[14C]-LX4211|400 mg LX4211 administered orally
61958633|NCT05902455||Patients diagnosed with oral squamous cell carcinoma|
61958634|NCT00289965|ACTIVE_COMPARATOR|1|in-person brief motivational intervention
61958635|NCT00289965|ACTIVE_COMPARATOR|2|Alcohol 101plus
61958636|NCT00289965|ACTIVE_COMPARATOR|3|AlcoholEdu (a Web-based tutorial).
62143156|NCT03057600|EXPERIMENTAL|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination~1. Participants must self-identify as African ancestry (includes African American).~2. No prior systemic therapy for advanced or metastatic disease.~   * Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was \> 12 mo."
62504477|NCT01876368|EXPERIMENTAL|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
61958637|NCT02650856|EXPERIMENTAL|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10ml X-GEN pharmaceuticals inc.) diluted in 80ml of physiologic solution and will be divided in two applications.~First application: 40ml of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.~Second application: The rest of 40ml of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
61958638|NCT02650856|ACTIVE_COMPARATOR|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.~First application: 8 ml of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.~Second application: The rest of the 8 ml are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
61958639|NCT05240313|EXPERIMENTAL|keepin' it REAL (kiR)|The standard keepin' it REAL intervention, adapted for an online format. This includes 10 one-hour small group sessions focused on helping youth to develop drug refusal skills and improve decision making, risk assessment, and emotion regulation. Additionally, short videos highlight various aspects of the program (refuse, explain, avoid, leave). All materials are available in Spanish and English.
62504478|NCT01876368|ACTIVE_COMPARATOR|Olmesartan 20 mg|Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
62703077|NCT06049212|EXPERIMENTAL|Arm 1: Sacituzumab tirumotecan Monotherapy|Participants receive single doses of sacituzumab tirumotecan monotherapy once every 2 weeks (Q2W).
62346592|NCT03895112|EXPERIMENTAL|AVID200|intravenous in dose cohorts of 70mg/m2 or 180 mg/m2
61958640|NCT05240313|EXPERIMENTAL|kiR + aggression|The standard keepin' it REAL intervention, adapted for an online format, plus content on interpersonal aggression
61958641|NCT05240313|ACTIVE_COMPARATOR|Stress Management|A single session focused on stress management skills.
61958642|NCT01007773|EXPERIMENTAL|Dexmedetomidine|In conjunction with conventional sedative and analgesic agents.
62346593|NCT03608891|ACTIVE_COMPARATOR|Control Arm|Conventional titanium miniplates
62346594|NCT03608891|EXPERIMENTAL|Intervention arm|Patient specific 3D plates
62346595|NCT01608399|EXPERIMENTAL|Metacognitive therapy|
62346596|NCT01608399|NO_INTERVENTION|Waiting list control|
61958643|NCT01007773|ACTIVE_COMPARATOR|Standard of Care|Patients randomized to conventional sedation will have as the main pharmacologic agents to achieve sedation and analgesia propofol and fentanyl, respectively.
61958644|NCT06120387||Kidney sparing surgery+Postoperative radiotheray cohort|Kidney sparing surgery+Postoperative radiotheray cohort
62346597|NCT00370240|EXPERIMENTAL|Ropivacaïne|
62346598|NCT00370240|PLACEBO_COMPARATOR|placebo|
62346599|NCT00363051|EXPERIMENTAL|Everolimus 10 mg|"Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day.~Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy.~Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day."
62346600|NCT02022072|OTHER|measure of assisted vital capacity by mechanical insufflation|measure of assisted vital capacity by a mechanical insufflation/exsufflation
62346601|NCT04419324|OTHER|esophago-gastroscopy endoscopy with narrow band imaging|a transoral flexible endoscope with magnifying narrow band imaging in nasopharyngeal examination
62703078|NCT06049212|EXPERIMENTAL|Arm 2: Pembrolizumab + Sacituzumab tirumotecan Combination Therapy|Participants receive sacituzumab tirumotecan Q2W in combination with pembrolizumab once every 6 weeks (Q6W).
62346602|NCT05363670|ACTIVE_COMPARATOR|1 mg/100 µL dose of ARS-1|
62346603|NCT05363670|ACTIVE_COMPARATOR|2 mg/100 µL dose of ARS-1|
62346604|NCT05363670|ACTIVE_COMPARATOR|albuterol MDI (180 mcg)|
62346605|NCT05363670|PLACEBO_COMPARATOR|placebo|
62346606|NCT01152736|EXPERIMENTAL|NSC018|Nicotine
62346607|NCT01152736|ACTIVE_COMPARATOR|Nicotine Gum|Nicorette® Gum
62346608|NCT01369212|EXPERIMENTAL|Tenofovir|Tenofovir 192 weeks
62346609|NCT01369212|EXPERIMENTAL|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks
62703079|NCT06362265|EXPERIMENTAL|LY3209590|LY3209590 administered subcutaneously (SC).
62703080|NCT06193863||Rivaroxaban|Pediatric patients with CHD who had undergone the Fontan procedure were prescribed with Xarelto before enrollment.
61958645|NCT06120387||Radical surgery cohort|Preoperative CT/MRI, chest CT and other examinations are performed to determine the stage of the patient's disease. The surgical plan is the same as the current conventional treatment. After surgery, there is no restriction on the use of postoperative adjuvant chemotherapy or postoperative adjuvant radiotherapy according to the patient's pathological stage and the patient's wish.
61958646|NCT02172768|EXPERIMENTAL|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
61958647|NCT02172768|ACTIVE_COMPARATOR|daily dosing|micafungin daily for 8 days
62346610|NCT06402669||Transferred from Outside Hospital|Patients with blunt or penetrating trauma that are transferred from an outside hospital to admitting level 1 trauma center
62346611|NCT06402669||Direct Admission to Hospital|Patients with blunt or penetrating trauma that are directly brought to level 1 trauma center
62346612|NCT01794013|ACTIVE_COMPARATOR|Parent trianing|The parent training group will learn about DIR/ Floortime™ model approach through one on one coaching for 1 hour at the beginning of the study, the end of 1st and 3th month and through 2 hours DVD lecture and a pocket book.
62346613|NCT01794013|ACTIVE_COMPARATOR|Routine care|The children in the control group will continue their standard routine care.
62346614|NCT04000919|SHAM_COMPARATOR|Effects of single-dose of carbidopa (50mg) on CNS excitability|Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
61958648|NCT03335098|EXPERIMENTAL|Study arm|Subcutaneous bortezomib 1.3mg/m2 on days 1, 4, 8, and 11 (every 4 weeks, up to 6 cycles) Oral thalidomide 50mg daily on days 1-28 (every 4 weeks, up to 6 cycles) Intravenous or oral dexamethasone 40mg on days 1-4 (every 4 weeks, up to 6 cycles)
62346615|NCT04000919|PLACEBO_COMPARATOR|Effects of single-dose placebo on CNS Excitability|Participants will visit the lab and on one of four different occasions and will receive a placebo. Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
61958649|NCT03491371|EXPERIMENTAL|osteosarcoma|all patients had been given apatinib alone
61958650|NCT03491371|EXPERIMENTAL|Ewing sarcoma|Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
62346616|NCT04000919|ACTIVE_COMPARATOR|Effects of single-dose 5HTP/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive 5HTP combined with carbidopa (50-200mg HTP/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
62346617|NCT04000919|ACTIVE_COMPARATOR|Effects of single-dose L-DOPA/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive L-DOPA combined with carbidopa (50-200mg L-DOPA/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
62346618|NCT04799951||Breast Surgeon|surgeons having experience in and regularly conducting breast conservation surgery and mastectomy surgeries
62346619|NCT03372629|EXPERIMENTAL|ID-085, single ascending dose (Part A)|ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)
62346620|NCT03372629|PLACEBO_COMPARATOR|Placebo, single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to ID-085
62346621|NCT03372629|EXPERIMENTAL|ID-085 multiple ascending dose (Part B)|ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A
62346622|NCT03372629|PLACEBO_COMPARATOR|Placebo, multiple ascending dose (Part B)|Matched placebo administered as single ascending doses in parallel to ID-085
61958651|NCT03491371|EXPERIMENTAL|soft tissue sarcoma|Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
61958652|NCT03491371|EXPERIMENTAL|Chondrosarcoma|Patients were given apatinib alone
62346623|NCT03427541||Patients with surgeries|NSCLC patients with surgeries
62346624|NCT04173052|EXPERIMENTAL|Infertile Males|It represents the participants, all the participants in the study are infertile.
62346625|NCT02072772|EXPERIMENTAL|Positively Smoke Free group treatment|"Eight 90 minute group sessions (6-8 HIV-infected smokers per group) led by a pair of trained group leaders: a professional with psychology or social work training and a peer HIV-infected ex-smoker with tobacco treatment training.~All subjects will be offered a 3 month supply of nicotine patches"
62346626|NCT02072772|ACTIVE_COMPARATOR|Standard care|Brief (\<5 minutes) advice to quit Offer of nicotine patches Self-help brochure
62346627|NCT03554070|EXPERIMENTAL|Infravesical Obstruction|Patients with infravesical obstruction due to BPH (IPSS \> 20, Qmax \< 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.
62346628|NCT05602610||VL patients|VL infected individuals residing in/ with travel history to VL-endemic areas in Northern Ethiopia
61958653|NCT05251571|ACTIVE_COMPARATOR|Conventional Exercise Group with Telerehabilitation|Exercises such as muscle strengthening exercises applied to antigravity muscles, agonist antagonist spastic muscles, stretching exercises for spastic muscles, weight transfer will be applied, and a telerehabilitation platform will be used in the home exercise program.
61958654|NCT05251571|EXPERIMENTAL|Balance Coordination Group with Telerehabilitation|Sit and stand exercise from chair, standing posture, weight transfer to right and left extremities, stepping over obstacles, standing on one leg with support from the table, standing on two legs with support from the table, hip abduction with support from the table, extension, flexion, supported tandem walking exercises such as stepping on the stairs, standing functional stretches will be applied. Whatsapp application-based Telerehabilitation platform will be used to deliver the home exercise program.
61958655|NCT02109380|EXPERIMENTAL|Bed rest|One week of bed rest.
62143157|NCT03057600|EXPERIMENTAL|Cohort 3 - Non-African ancestry, 3rd line+|"Intervention = Pac-CB combination~1. Participants do not self-identify as African ancestry.~2. Otherwise have the same criteria as Cohort 1."
62143158|NCT03057600|EXPERIMENTAL|Cohort 4 - Non-African ancestry, 1st line|"Intervention = Pac-CB combination~1. Participants do not self-identify as African ancestry.~2. Otherwise have the same criteria as Cohort 2."
62346629|NCT05627570|EXPERIMENTAL|Diet A then Diet B, followed by a 6-month behavioural support programme|8-weeks of Diet A then 8-weeks of Diet B, then 6 months of goal-based behavioural support for consuming a healthy, balanced diet, increasing physical activity and reducing sedentary behaviour.
62346630|NCT05627570|EXPERIMENTAL|Diet B then Diet A, followed by a 6-month behavioural support programme|8-weeks of Diet B then 8-weeks of Diet A, then 6 months of goal-based behavioural support for consuming a healthy, balanced diet, increasing physical activity and reducing sedentary behaviour.
62346631|NCT01560442||buprenorphine|
62346632|NCT01560442||Methadone Hydrochloride|
62346633|NCT00700531|EXPERIMENTAL|1|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on the Gambro HCO 1100 dialysers
62346634|NCT00700531|ACTIVE_COMPARATOR|2|Patients receive standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
62346635|NCT05549648|OTHER|Self-controlled Study|Hong Kong citizens over 50 years old
62703081|NCT05610163|ACTIVE_COMPARATOR|Group I (LCRT, FOLFOX or CAPOX)|Patients receive long-course chemoradiation therapy on study and then receive either: FOLFOX regimen consisting of leucovorin IV, fluorouracil IV, and oxaliplatin IV or CAPOX consisting of capecitabine PO, and oxaliplatin IV on study. Patients undergo CT scan, MRI, and biospecimen collection throughout the trial. Patients also undergo sigmoidoscopy throughout the trial and biopsy during screening.
61958656|NCT03222960|EXPERIMENTAL|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
61958657|NCT03222960|EXPERIMENTAL|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
61958658|NCT04770129||Time period 2010-2014|Data from Turkish participants with metastatic breast cancer diagnosed January 2010-December 2014 will be retrospectively collected.
61958659|NCT04770129||Time period 2015-2019|Data from Turkish participants with metastatic breast cancer diagnosed January 2015-December 2019 will be retrospectively collected.
62703082|NCT05610163|EXPERIMENTAL|Group II (LCRT, FOLFIRINOX)|Patients receive long-course chemoradiation therapy on study and then receive FOLFIRINOX regimen consisting of leucovorin IV, fluorouracil IV, irinotecan IV, and oxaliplatin IV on study. Patients undergo CT scan, MRI scan, and blood specimen collection throughout the trial. Patients undergo sigmoidoscopy throughout the trial and biopsy during screening.
61958660|NCT02068183||World Trade Center exposed group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the World Trade Center exposed group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
61958661|NCT02068183||Unexposed comparison group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the unexposed comparison group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
61958662|NCT06084663|EXPERIMENTAL|Apremilast 30 mg Tablets|One tablet was administered orally to each subject as per randomization schedule in each period
61958663|NCT06084663|ACTIVE_COMPARATOR|Otezla 30 mg film-coated tablets|One tablet was administered orally to each subject as per randomization schedule in each period
61958664|NCT02826902|ACTIVE_COMPARATOR|TIVA group|
61958665|NCT02826902|ACTIVE_COMPARATOR|Inhalation anesthesia group|
61958666|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 1 breast implants
61958667|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 1 breast implants
61958668|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 2 breast implants
61958669|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 2 breast implants
61958670|NCT00681083|EXPERIMENTAL|1|Heated breathing tube
62504479|NCT03244605|EXPERIMENTAL|Rehabilitation training plus TCM|"Rehabilitation training include aerobic exercise training and Liu Zi Jue lung exercises, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.The patient will take TCM granules for 3 months."
61958671|NCT00681083|ACTIVE_COMPARATOR|2|Non heated breathing tube
61958672|NCT05343845||Group NS, Nonsmoker (n= 50)|Pregnant women who did not smoke during pregnancy will be separated as Group NS. Local anesthetic dose adjusted for height and weight and 20 µg fentanyl will be administered intrathecally. Results regarding the effectiveness of spinal anesthesia will be monitored.
61958673|NCT05343845||Group S, Smoker (n= 50)|Pregnant women who smoked 5 or more cigarettes in a day will be separated as Group S. A local anesthetic dose adjusted for height and weight and 20 µg fentanyl will be administered intrathecally. Results regarding the effectiveness of spinal anesthesia will be monitored.
61958674|NCT05270343|EXPERIMENTAL|Vitamin D|In 99 subjects of 3-18yr with newly-onset T1D, oral administration of 140IU/kg qd of cholecalciferol will be given until the serum 25(OH)D3 was maintained at the upper limit of normal range(50-80 ng/ml\[125-200 nmol/L\], ≤100 ng/ml\[≤250 nmol/L\]) for the loading peroid. And then oral administration of 70IU/kg qd of cholecalciferol for the maintenance period, meanwhile combined with intensive Insulin therapy for 12 months.
61958675|NCT05270343|NO_INTERVENTION|Insulin|In 99 subjects of 3-18yr with newly-onset T1D, only intensive insulin therapy will be given for 12 months.
62346636|NCT04753047||Children practicing football|Children in late childhood (age 10-12 years) practicing sport, which is high dynamic (\> 75%), and low static (\<10\&) and in the same time it is open skill exercise sport (football)
61958676|NCT04638933||OSA patients|Patients with proven OSA (apnea-hypopnea index ≥20/h, ESS \>10, age ≥18 years) and initiation of CPAP treatment
61958677|NCT01509950|ACTIVE_COMPARATOR|Staples|Use of staples for skin closure at cesarean section
61958678|NCT01509950|ACTIVE_COMPARATOR|Prolene non-absorbable sutures|Use of Prolene non-absorbable sutures for skin closure at cesarean section
61958679|NCT01509950|ACTIVE_COMPARATOR|Absorbable sutures|Use of absorbable sutures for skin closure at cesarean section; monocryl or vicryl.
61958680|NCT01006096|EXPERIMENTAL|Erlotinib|
61958681|NCT01006096|PLACEBO_COMPARATOR|Placebo tablets|
61958682|NCT01875770||Treated with Ranibizumab in previous trial|Treated with Ranibizumab in previous trial
61958683|NCT04091594|EXPERIMENTAL|Flexible orthotic|Sensory input flexible ankle foot orthotic (SIAFO) with appropriate lycra garments
61958684|NCT04091594|ACTIVE_COMPARATOR|Standard of care|Standard of care solid ankle foot orthotic (AFO)
61958685|NCT00555971|PLACEBO_COMPARATOR|Placebo Group|Subjects randomized to placebo
62346637|NCT04753047||Children practicing gymnastics|Children in late childhood (age 10-12 years) practicing sport, which is low dynamic (\<50%), high static (\>30%) and in the same time it is closed skill exercise sport (sport gymnastics)
62346638|NCT04753047||Comparative group|A comparative group of children that do not attend sport classes or sports clubs, but carrying out sports activity and / or in other areas
62346639|NCT04151095|EXPERIMENTAL|BFR|
61958686|NCT00555971|ACTIVE_COMPARATOR|Omalizumab Group|Subjects randomized to omalizumab
61958687|NCT02174250|EXPERIMENTAL|Istradefylline 40mg|Period 1: Day 1, istradefylline 40mg then crossover to Period 2
61958688|NCT02174250|EXPERIMENTAL|Rifampin 300mg BID + istradefylline 40mg|Period 2: Days 1-20 rifampin 300mg BID + istradefylline 40mg Day 8 only
61958689|NCT01120002|PLACEBO_COMPARATOR|Placebo pill|
62346640|NCT04151095|EXPERIMENTAL|CTL|
61958690|NCT01120002|ACTIVE_COMPARATOR|Tamibarotene|
61958691|NCT05889377|EXPERIMENTAL|Bovine Bone|
61958692|NCT05889377|EXPERIMENTAL|Platelet Rich Fibrin|
61958693|NCT05889377|EXPERIMENTAL|Bovine Bone + PRF|
61958694|NCT05889377|NO_INTERVENTION|Control|
61958695|NCT03748758|ACTIVE_COMPARATOR|Drug: OP0201 (30 mg)|Cohort A- 30 mg per day X 14 days
61958696|NCT03748758|PLACEBO_COMPARATOR|Drug: Placebo|Cohort A- 0 mg per day X 14 days Cohort B- 0 mg per day X 14 days
61958697|NCT03748758|ACTIVE_COMPARATOR|Drug: OP0201 (60 mg)|Cohort B-60 mg per day X 14 days
61958698|NCT05773482|EXPERIMENTAL|Breathing and Attention Training (BAT)|Participants will be asked to do 20-minutes of focused breathing and attention training, involving focusing on taking deep breaths and becoming aware of the changing body sensations associated with breathing (mindfulness).
61958699|NCT05773482|ACTIVE_COMPARATOR|Controlled Deep Breathing|Participants will be asked to do 20-minutes of deep breathing and letting the body relax.
61958700|NCT03719885|EXPERIMENTAL|Intervention|
61958701|NCT04847011|EXPERIMENTAL|RA - longitudinal arm|
61958702|NCT04847011|EXPERIMENTAL|PD - longitudinal arm|
61958703|NCT04847011|NO_INTERVENTION|RA - crosssectional arm|
61958704|NCT04847011|NO_INTERVENTION|PD - crossectional arm|
62143159|NCT01957163|EXPERIMENTAL|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via a DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
62143160|NCT01957163|EXPERIMENTAL|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
62143161|NCT01957163|EXPERIMENTAL|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
62143162|NCT06162182|EXPERIMENTAL|Reference test: Radiographic examination|
62346641|NCT03039933|ACTIVE_COMPARATOR|Fear of Hypoglycemia Intervention|Cognitive behavioral therapy based psychological intervention occurring every other week for 12 weeks.
62346642|NCT03039933|OTHER|Treatment As Usual|Control group completes questionnaires but does not receive any study intervention. Receives medical care as usual.
62346643|NCT00126581|EXPERIMENTAL|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62703083|NCT05559580|EXPERIMENTAL|Avenciguat (BI 685509)|Avenciguat (BI 685509)
61958705|NCT04847011|NO_INTERVENTION|Healthy controls - crosssectional arm|
61958706|NCT04071561||Non-conversion|In 13 patients, 14 posterior retroperitoneal adrenalectomy procedures were successfully completed and form the non-conversion group
61958707|NCT04071561||Conversion|Conversion to lateral transperitoneal adrenalectomy was necessary in 1 patient after starting posterior retroperitoneal adrenalectomy.
61958708|NCT00820560|EXPERIMENTAL|INCB07839 100mg, immediate release (IR) capsules|
61958709|NCT00820560|EXPERIMENTAL|INCB07839 200 mg IR capsules|
61958710|NCT00819806|EXPERIMENTAL|A|PF-3512676, and three MHC class I Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102 will be administered in three separate subcutaneous (under the skin) injections.
61958711|NCT00819806|EXPERIMENTAL|B|This vaccine injection contains all the same components of Arm A and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm). Cyclophosphamide is an agent that is thought to increase the anti-tumor response of vaccines.
61958712|NCT00819806|EXPERIMENTAL|C|PF-3512676, Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102, NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-1 157-170 will be administered in three separate subcutaneous injections.
61958713|NCT00819806|EXPERIMENTAL|D|This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
61958714|NCT00819806|EXPERIMENTAL|E|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein will be administered in three separate subcutaneous injections.
61958715|NCT00819806|EXPERIMENTAL|F|This vaccine injection contains all the same components of Arm E and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
61958716|NCT03681405|EXPERIMENTAL|Group I (eMMB)|Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
61958717|NCT03681405|ACTIVE_COMPARATOR|Group II (AC)|Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
61958718|NCT00592696||Observation|
62143163|NCT06162182|EXPERIMENTAL|Index test: electrical impedance device, Prepometer|
62143164|NCT03192189||Patients with acute kidney injury|Requiring treatment with dialysis
62143165|NCT05136066|EXPERIMENTAL|Group massaged with peppermint oil|Group of experimental
62703084|NCT05559580|PLACEBO_COMPARATOR|Placebo|Placebo
62703085|NCT00084305||Family|Family members of patients with pulmonary fibrosis
61958719|NCT02859168|EXPERIMENTAL|Myofascial Induction session|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
62504480|NCT03244605|PLACEBO_COMPARATOR|Rehabilitation education plus placebo|"Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.~The patient will take placebo granules for 3 months."
61958720|NCT02859168|PLACEBO_COMPARATOR|Placebo session|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
61958721|NCT01996852|ACTIVE_COMPARATOR|Standard ED Care|Standard medical treatment of erectile dysfunction (ED) including administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)
62504481|NCT05425342|EXPERIMENTAL|ECG single group|Patients will be instructed how to record an ECG on a smartwatch using the front camera of an iPad. In a second step, a standard ECG will be recorded by medical staff. The ECGs will then be compared by two board certified cardiologists
61958722|NCT01996852|EXPERIMENTAL|Standard ED Care + Cognitive-Behavioral Intervention|standard medical treatment of ED (administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)) in addition to cognitive-behavioral meetings
61958723|NCT01996852|NO_INTERVENTION|Usual Care (UC)|Study participants will not receive any study intervention, but will continue with standard care.
61958724|NCT01830478|EXPERIMENTAL|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
61958725|NCT03800329|ACTIVE_COMPARATOR|Snap40 Monitor|Patients randomly assigned to wear the Snap40 monitor will wear the device for 48 hours following discharge from the hospital.
61958726|NCT03800329|PLACEBO_COMPARATOR|No Monitor|Patients randomly assigned to not wear the Snap40 monitor will continue with their follow-up surgical care in the ordinary fashion.
62346644|NCT00126581|EXPERIMENTAL|Arm II (erlotinib hydrochloride, paclitaxel, carboplatin)|Patients receive erlotinib hydrochloride as in arm I. Patients also receive paclitaxel IV over 1-3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of treatment, patients may continue to receive erlotinib hydrochloride alone as above.
62346645|NCT05321940|EXPERIMENTAL|Combination STAVs and DC Vaccine Group|Participants will receive STAV-loaded cells for a total of 5 doses on Days 3, 17, 31, 45 and 59. Participants will also receive up to 4 doses of dendritic vaccine on Days 10, 17, 24 and 31.
62346646|NCT01842841|EXPERIMENTAL|velaglucerase alfa|15 to 60 U/kg, EOW via intravenous infusion
62346647|NCT04296006|EXPERIMENTAL|Active Treatment|Cocaine choice during d-amphetamine maintenance
62346648|NCT04296006|PLACEBO_COMPARATOR|Placebo Treatment|Cocaine choice during placebo maintenance
62346649|NCT04810585|EXPERIMENTAL|Treatment|
62346650|NCT00371111|ACTIVE_COMPARATOR|1|Intravitreal injection of Triamcinolone
62346651|NCT00371111|ACTIVE_COMPARATOR|2|Intravitreal injection of Avastin
62346652|NCT02130154||Young males|Healthy, Lean, Caucasian, Young males
62346653|NCT02130154||Old males|Healthy, Lean, Caucasian, Older males
62346654|NCT00729326|EXPERIMENTAL|Sequence A|
62346655|NCT00729326|EXPERIMENTAL|Sequence B|
62346656|NCT02808741|EXPERIMENTAL|F901318 SDD|Liquid formulation
62504482|NCT02293460|EXPERIMENTAL|I10E Arm|
62504483|NCT03710096|EXPERIMENTAL|Mac grath group|
62504484|NCT03710096|ACTIVE_COMPARATOR|Macintosh Group|
62346657|NCT02808741|EXPERIMENTAL|F901318 IR|Solid formulation
62346658|NCT02808741|EXPERIMENTAL|F901318 IR Fasting|Fasting solid formulation
62504485|NCT00625326|EXPERIMENTAL|75 µg/g COL-121 Ointment|75 µg/g COL-121 Ointment
62504486|NCT00625326|EXPERIMENTAL|150 µg/g COL-121 Ointment|150 µg/g COL-121 Ointment
62504487|NCT00625326|EXPERIMENTAL|300 µg/g COL-121 Ointment|300 µg/g COL-121 Ointment
62504488|NCT00625326|ACTIVE_COMPARATOR|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment (active control)
62703086|NCT00084305||Healthy Volunteers|Healthy Volunteers
62703087|NCT00084305||Pulmonary Fibrosis|Patients with pulmonary fibrosis
62703088|NCT02803437||Xofigo / Cohort 1|Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
61958727|NCT02348905|EXPERIMENTAL|ACTHAR Gel 40 units twice weekly|ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.
61958728|NCT02348905|EXPERIMENTAL|ACTHAR Gel 80 units twice weekly|ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.
61958729|NCT00823095|EXPERIMENTAL|Topically applied Nitric Oxide|Topically applied Nitric Oxide for 8 hours daily for 2 weeks.
62346659|NCT02808741|EXPERIMENTAL|F901318 IR Fed|Fed solid formulation
62346660|NCT01593579||Patients with Melanoma|Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
62346661|NCT01873092||Patients with COPD|Patients who meet criteria for chronic obstructive pulmonary disease
62346662|NCT01314625||one arm|
62346663|NCT04123418|EXPERIMENTAL|WVT078 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
62346664|NCT04123418|EXPERIMENTAL|WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
62346665|NCT01560221|EXPERIMENTAL|Therapeutic Workplace|Participants will receive all standard services plus the Therapeutic Workplace intervention, in which access to stipend supported training and/or wage subsidies for community employment is contingent upon drug abstinence as verified by urinalysis.
62346666|NCT01560221|ACTIVE_COMPARATOR|Standard Services|Participants will receive methadone treatment or buprenorphine treatment, depending upon medical recommendations of their physicians, slot availability, and their own preferences. Participants who remain in treatment for at least 90 days will have the charge of prostitution that is pending against them dropped.
61958730|NCT05459272|EXPERIMENTAL|Experimental: Aquilea Sueño Forte|Patients included in this group will be administered dietary supplement with melatonin and herbal products, one tablet daily 30 min before to go to bed during 7 days (from day 7 to day 14).
61958731|NCT05459272|PLACEBO_COMPARATOR|Control|"The control will consist of a placebo based on excipients without active ingredients so that the tablet has the same appearance as the test product.~Patients should take one tablet daily 30 min before to go to bed during 7 days (from day 7 to day 14)."
61958732|NCT03385460|EXPERIMENTAL|ESWL BOTOX|Each patient will be subjected to Low Energy Shock Waves.The target dose of low energy shock waves will be 3000 shock delivered into SP region in 3 horizontal points at SP transverse crease . all patients will be catheterized using nylaton catheter 16 ch, the study group will be injected with 100 IU botulinium toxin A. vial will be dissolved in saline half of the estimated bladder capacity. All patients will be kept for 2 hours without micturation giving a chance of BOTOX absorption .
61958733|NCT02077244|EXPERIMENTAL|Follow up talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Nurse led follow up talks at the ward and one and two months later.
61958734|NCT02077244|NO_INTERVENTION|No talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual
61958735|NCT02077244|NO_INTERVENTION|Observation group|Patients with a score below 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual.
61958736|NCT05523752|OTHER|Proseal Laryngeal Mask|
61958737|NCT05523752|OTHER|Classic Laryngeal Mask|
61958738|NCT05523752|OTHER|I-gel|
61958739|NCT05523752|OTHER|Suprema Laryngeal Mask|
61958740|NCT05532761||diffuse lare B cells lymphoma|Diffuse large B cells lymphoma patients eligibles for CAR-T cells therapy
61958741|NCT05754931|EXPERIMENTAL|deep neck flexor group|"Deep neck flexors stretch~Conventional Therapy:~Moist heat therapy for 10 minutes, TENS 10 min, cervical active ROMS, Non-thrust mobilizations"
61958742|NCT05754931|ACTIVE_COMPARATOR|muscle energy technique|"Post isometric stretch on trapezious and suboccipital muscles~Conventional Therapy:~Moist heat therapy for 10 minutes, TENS 10 min, cervical active ROMS, Non-thrust mobilizations"
62504489|NCT00625326|PLACEBO_COMPARATOR|Placebo Ointment|Placebo Ointment
61958743|NCT06289270||1-muscle invasive bladder cancer., 2-Non-muscle invasive invasive. 3- Control.|"Samples: Total number of studied samples: The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample ( one samble).~Group I: Non-muscle invasive bladder cancer,16 patients, 16 for bladder tissue, and 16 for urine samples. Total 32 samples. (The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample (1 samble).~Group II: Muscle invasive bladder cancer, 11 patients. 22 samples 11 for bladder tissue and 11 for urine samples obtained from the same patients. Group III: 11 Normal adults: urine samples from serves as control group of the study.~Total number of participants is 38 individuals."
61958744|NCT02502578|EXPERIMENTAL|CNT-01|Patients will receive CNT-01 500 mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
61958745|NCT05367401|EXPERIMENTAL|1L higher risk MDS|Participants with 1L MDS will receive sabatolimab and magrolimab in combination with azacitidine
61958746|NCT05367401|EXPERIMENTAL|1L unfit AML|Participants with 1L AML unfit for intensive chemotherapy will receive sabatolimab and magrolimab in combination with azacitidine
61958747|NCT05367401|EXPERIMENTAL|Relapsed/refractory AML previously treated with venetoclax and azacitidine|Participant with relapsed/refractory AML will receive sabatolimab and magrolimab (in absence of complete response (CR), Complete Remission with incomplete hematologic recovery (CRi) or Morphologic Leukemia-Free State (MLFS) after 2 cycles, participants will be allowed to also receive azacitidine)
62143166|NCT01237067|EXPERIMENTAL|Group 1|Dose esc: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis
62346667|NCT03307954|EXPERIMENTAL|Ekso Therapy|Up to 12 weeks of Ekso Therapy. Three sessions per week. One hour per session
62504490|NCT02675374|EXPERIMENTAL|Treatment group|24 patients
61958748|NCT03231605|EXPERIMENTAL|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
61958749|NCT03231605|ACTIVE_COMPARATOR|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
61958750|NCT00772291|PLACEBO_COMPARATOR|placebo|
61958751|NCT00772291|ACTIVE_COMPARATOR|pregabalin|
61958752|NCT04194398||OCS Expand Trial Cohort|All patients previously enrolled in the EXPAND Lung trial.
61958753|NCT03796793|EXPERIMENTAL|Wound Edge Debridement Group|Participants in this group will receive wound edge debridement in addition to standard of care (SOC) treatment for up to 4 weeks.
61958754|NCT03796793|ACTIVE_COMPARATOR|Standard care group|Participants in this group will receive only the standard care of treatment for up to 4 weeks.
61958755|NCT01486732|EXPERIMENTAL|Umbilical Cord Blood & Rehabilitation|Allogeneic umbilical cord blood infusion and active rehabilitation
61958756|NCT01486732|ACTIVE_COMPARATOR|Placebo Umbilical Cord Blood & Rehabilitation|Placebo Umbilical Cord Blood infusion and active rehabilitation
62504491|NCT02675374|PLACEBO_COMPARATOR|Control group|24 patients
62504492|NCT05622994|ACTIVE_COMPARATOR|Rimonabant|Rimonabant 5mg
62504493|NCT05622994|PLACEBO_COMPARATOR|Placebo|Placebo
62504494|NCT04651920||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
62504495|NCT04651920||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
62504496|NCT01626651|EXPERIMENTAL|Ibrutinib and Ketoconazole|
62504497|NCT06207292|EXPERIMENTAL|SABR in oligo-M NSCLC|Synchronous and Metachronous oligo-M NSCLC patients will be enrolled to stereotactic ablative radiotherapy (SABR) of primary tumour (T) and/or regional node(s) (N) and oligo-metastatic site (M) with the aim of maintaining ongoing therapy or delaying delaying the start of systemic therapy
61958757|NCT04614064|EXPERIMENTAL|COPD patients|As per inclusion and exclusion criteria for COPD patients
61958758|NCT04614064|EXPERIMENTAL|Healthy volunteers|As per inclusion and exclusion criteria for healthy volunteers
61958759|NCT01322269|EXPERIMENTAL|HQK-1001 (30 mg/kg)|
61958760|NCT01322269|EXPERIMENTAL|HQK-1001 (40 mg/kg)|
61958761|NCT01322269|EXPERIMENTAL|HQK-1001 (50 mg/kg)|
61958762|NCT04598230|ACTIVE_COMPARATOR|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy and one of three study medications (fluoxetine, sertraline, or escitalopram).
62346668|NCT03307954|ACTIVE_COMPARATOR|Control|Up to 12 weeks of usual physiotherapy care. Three sessions per week. One hour per session.
62703089|NCT05832151|EXPERIMENTAL|CIN-102: Dose 15mg or 10mg|CIN-102, Dose 15 mg or 10 mg, twice daily for 12 weeks
62703090|NCT05832151|PLACEBO_COMPARATOR|Placebo|Placebo for CIN-102, twice daily for 12 weeks
61958763|NCT04598230|ACTIVE_COMPARATOR|Cognitive behavioral therapy (CBT)|Participants randomized to this arm will receive cognitive behavioral therapy (CBT) only
61958764|NCT03547583|EXPERIMENTAL|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
61958765|NCT03547583|EXPERIMENTAL|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
61958766|NCT03547583|PLACEBO_COMPARATOR|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
61958767|NCT04051866|OTHER|Control|Usual care (provided in Primary Health Care Centres) Oral hygiene instructions
61958768|NCT04051866|EXPERIMENTAL|Intervention|Usual care (provided in Primary Health Care Centres) Non-surgical periodontal treatment: Scaling and root planing (SRP) Oral hygiene instructions
61958769|NCT01255917||Chronic pancreatitis|
61958770|NCT04185428|EXPERIMENTAL|Standard of care with integrative therapy|For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.
61958771|NCT04185428|NO_INTERVENTION|Standard of care only|For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.
61958772|NCT01944397||Atrial fibrillation|Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
61958773|NCT03689348|PLACEBO_COMPARATOR|Placebo|Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
61958774|NCT03689348|EXPERIMENTAL|300mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x2 placebo capsules (described above) and x1 300mg capsule of Avena sativa per day for 28 days.
61958775|NCT03689348|EXPERIMENTAL|600mg Avena sativa|If in the 600mg of Avena sativa group, participants will consume x1 placebo capsule (described above) and x2 300mg capsule of Avena sativa per day for 28 days.
61958776|NCT03689348|EXPERIMENTAL|900mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x3 300mg capsule of Avena sativa per day for 28 days.
61958777|NCT01032837|EXPERIMENTAL|Oseltamivir standard dose 5 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
61958778|NCT01032837|EXPERIMENTAL|Oseltamivir standard dose 10 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 10 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 10 days.
62346669|NCT01825980|EXPERIMENTAL|BZF961|
62346670|NCT01825980|PLACEBO_COMPARATOR|Placebo|
62346671|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
62703091|NCT05911841|EXPERIMENTAL|LY3454738 Dose 1|Participants will receive LY3454738 subcutaneously (SC).
62703092|NCT05911841|EXPERIMENTAL|LY3454738 Dose 2|Participants will receive LY3454738 SC.
62703093|NCT05911841|EXPERIMENTAL|LY3454738 Dose 3|Participants will receive LY3454738 SC.
62703094|NCT05911841|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62703095|NCT05977322|EXPERIMENTAL|Arm 1|Patients will receive 68Ga-FF58 and only patients with tumor uptake of 68Ga-FF58 will receive 177Lu-FF58.
62703096|NCT01744782|EXPERIMENTAL|RP103|From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.
62703097|NCT04071236|ACTIVE_COMPARATOR|Arm A (radium-223 dichloride)|Patients receive radium-223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, and CT or MRI throughout the study.
61958779|NCT01032837|EXPERIMENTAL|Oseltamivir high dose 5 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
61958780|NCT01032837|EXPERIMENTAL|Oseltamivir high dose 10 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 10 days. Children aged 1- 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 10 days.
61958781|NCT02047396||Myocardial Infarction subjects|Subjects with first Myocardial Infarction presenting to one of the Mayo Clinic Hospitals in Rochester, Minnesota.
61958782|NCT00847379|EXPERIMENTAL|Overall Participants: High-Dose Ataluren|All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.
62143167|NCT01237067|EXPERIMENTAL|Group 2A|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
62504498|NCT01956708|ACTIVE_COMPARATOR|Remote ischemic preconditioning|"Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil"
62504499|NCT01956708|PLACEBO_COMPARATOR|Placebo|"No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: the cuff is left uninflated"
62504500|NCT02626208|EXPERIMENTAL|Nestorone®/ Estradiol 75|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 75 ug/day of estradiol
62703098|NCT04071236|ACTIVE_COMPARATOR|Arm B (radium-223 dichloride, nedisertib)|Patients receive radium-223 dichloride as in Arm A and peposertib PO or BID on days 3-26. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, and CT or MRI throughout the study.
62703099|NCT04071236|EXPERIMENTAL|Arm C (radium-223 dichloride, nedisertib, avelumab)|Patients receive radium-223 dichloride IV as in Arm A and peposertib PO QD or BID as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 15 of cycles 2-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, and CT or MRI throughout the study.
61958783|NCT05417139|EXPERIMENTAL|Immunotherapy+induction chemotherapy+radiotherapy|
61958784|NCT05869266|ACTIVE_COMPARATOR|Professional-fitting|"Subject receives hearing aids and a licensed professional performs the hearing aid fitting using professional programing tools, and the thresholds that were obtained from the traditional audiometry.~Subject uses the professionally fitted hearing aids for two weeks then completes COSI and the IOI-HA questionnaires."
61958785|NCT05869266|ACTIVE_COMPARATOR|Self-fitting|"Subject receives hearing aids, downloads the Tuned self fitting App and performs self-fitting of the hearing aids including a self-hearing test.~Subject uses the self fitted hearing aids for two weeks then completes COSI and the IOI-HA questionnaires."
61958786|NCT04875182||group delirium|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score over 14 points will be included in the Group Delirium. And second blood samples for zonulin and interleukin-8 levels will be taken at the time of diagnosis.~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
62143168|NCT01237067|EXPERIMENTAL|Group 2B|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
62143169|NCT01691677|EXPERIMENTAL|beclomethasone dipropionate|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
62143170|NCT01691677|PLACEBO_COMPARATOR|placebo|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
62346672|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
62346673|NCT04394455|EXPERIMENTAL|Brief cognitive behavioral therapy|Medical staff (medical doctors and residents) who will receive brief cognitive behavioral therapy through telepsychiatry.
62504501|NCT02626208|EXPERIMENTAL|Nestorone®/Estradiol 100|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 100 ug/day of estradiol
62504502|NCT02626208|EXPERIMENTAL|Nestorone®/ Estradiol 200|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 200 ug/day of estradiol
62703100|NCT06748547||1|Group pre-incisional: received 0.5% 20 ml bupivacaine preincisional before the nail head was placed
62703101|NCT06748547||2|Group post-incisional: received 0.5% 20 ml bupivacaine postcisional after the skin incision was closed
61958787|NCT04875182||group control|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score under 14 points for postoperative 72 hours will be included in the Group Control. And second blood samples for zonulin and interleukin-8 levels will be taken at the postoperative 72. hour.~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
61958788|NCT02680080|ACTIVE_COMPARATOR|Positive control group|"subjects will receive a single 400 mg tablet of Moxifloxacin - the most commonly used positive control in thorough QTc (TQT) studies. Subjects will be continuously recorded by a Holter monitor for 24 hours"
61958789|NCT02680080|ACTIVE_COMPARATOR|Grapefruit group|subjects will drink one liter of fresh pink-grapefruit juice as fast as possible. The pink-grapefruit juice will be squeezed in the morning of the experiment in the cardiology department. ECG will be performed immediately pre dose and at 1, 2, 3, 4, 6, 8, 12, 24 after fresh pink-grapefruit juice administration. In addition, subjects will be continuously recorded by a Holter monitor for 24 hours
61958790|NCT01350297|EXPERIMENTAL|Patients|Patients
61958791|NCT04444388|EXPERIMENTAL|Cocoa group|5 g/day of flavonoid-rich defatted cocoa for 10 weeks
61958792|NCT04444388|PLACEBO_COMPARATOR|Placebo group|5 g/day of maltodextrin for 10 weeks
61958793|NCT01375244|EXPERIMENTAL|A|Subjects received the Par formulated product.
61958794|NCT01375244|ACTIVE_COMPARATOR|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
61958795|NCT05338593||prolonged veno-venous extracorporeal membrane oxygenation|Critically affected patients treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO). Based on severe acute respiratory distress syndrome (ARDS) and prolonged therapy for more than 2 weeks.
61958796|NCT01095731|PLACEBO_COMPARATOR|Sugar Pill, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
61958797|NCT01095731|EXPERIMENTAL|Tiopronin, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
61958798|NCT01095731|EXPERIMENTAL|Tiopronin, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
61958799|NCT01095731|PLACEBO_COMPARATOR|Sugar Pill, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
61958800|NCT03821155|ACTIVE_COMPARATOR|Neuritis vestibularis (group 1)|"Corticosteroid (prednisolone)"
61958801|NCT03821155|EXPERIMENTAL|Neuritis vestibularis (group 2)|"Corticosteroid (prednisolone) + vestibular rehabilitation"
61958802|NCT03903068|EXPERIMENTAL|NEXALIN Stimulator Group|In this study, the group is the treatment group. Patients are randomly assigned to participate, and patients will be given current parameters for setting time and flow.
62703102|NCT01036581|EXPERIMENTAL|MR Methodology Development and Evaluation|Methodology development and evaluation consists of pulse sequence development, testing, and parameter optimization. For each method we develop or evaluate, we may recruit up to 40 participants to come in for up to 4 visits each. Each participant will be scanned for up to 2 sessions per visit, not to exceed 4 total scan hours per visit.
61958803|NCT03903068|SHAM_COMPARATOR|Pseudo-Stimulator Group|In this study, the group is the control group. Patients are randomly assigned to participate, and patients will be given simulated electrical stimulation.
61958804|NCT04464629|EXPERIMENTAL|Intracanalicular Sustained Release Dexamethasone, 0.4 mg|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of post-surgical inflammation and pain associated with ocular surgery.
61958805|NCT04464629|ACTIVE_COMPARATOR|topical prednisolone acetate 1%.|
61958806|NCT00135096|EXPERIMENTAL|1|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
61958807|NCT00135096|EXPERIMENTAL|2|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
61958808|NCT01202292|EXPERIMENTAL|Lifestyle counseling|
61958809|NCT03913312|EXPERIMENTAL|DAC combined with unrelated cord blood transplantation|Decitabine (DAC) 15mg/m2/d, d-7 to d-3;Ara-C 1000g/m2/q12h, d-2 to d-1.Single unrelated cord blood (TNC\>1.5\*107/kg), d0.
62504503|NCT05753813|EXPERIMENTAL|Study group|This is a single-arm study. all participants are assigned to this arm. all study participants will receive Phexxi, the study drug. 8 pre-filled vaginal inserters with vaginal gel, Phexxi, will be provided to each of the participants with verbal and written instructions for application. Patients will be instructed to use Phexxi twice per week, on the same days every week.
62504504|NCT04193319|OTHER|Single arm|
62143171|NCT04237857||LSG|Chinese patients who received laparoscopic sleeve gastrectomy at Prince of Wales Hospital, The Chinese University of Hong Kong for more than 36 months
62504505|NCT06617416|EXPERIMENTAL|AK104 group|AK104 Q3W
62504506|NCT06617416|ACTIVE_COMPARATOR|Sugemalimab group|Sugemalimab 1200mg Q3W
62504507|NCT01999894|EXPERIMENTAL|Memantine|Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
62714946|NCT06336213|EXPERIMENTAL|Ampicillin/sulbactam intervention group|If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
62714947|NCT06336213|NO_INTERVENTION|Cefazolin|If presepsin \< 519,5 pg/ml at the end of surgery, cefazolin 2 g every 6 h at least 72 h p/o is continued further
61958810|NCT00896571|EXPERIMENTAL|Arm 1|
61958811|NCT02072018|ACTIVE_COMPARATOR|H-100|H-100, gel, daily, 6 months
61958812|NCT02072018|PLACEBO_COMPARATOR|Placebo|Placebo gel, daily, three months then switch to H-100 for three months
61958813|NCT01065285|EXPERIMENTAL|Evaluation of vaccines against flu|Evaluation of vaccines against flu
61958814|NCT02673138|ACTIVE_COMPARATOR|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
61958815|NCT02673138|EXPERIMENTAL|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
62143172|NCT06195813|EXPERIMENTAL|Asparagus capsule|Participants were randomized to receive an arm. In this arm, participants received asparagus capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.
62504508|NCT04998812|EXPERIMENTAL|Women with CIS or MS|Women with CIS or MS (in line with the locally approved indications) receiving commercial ocrelizumab up to 6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13), due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice.
62504509|NCT04383717|ACTIVE_COMPARATOR|Proposed treatment group|Levamisole and isoprinosine
62703103|NCT01036581|EXPERIMENTAL|TMS-fMRI Experiment 1|To evaluate the relationship between BOLD activation and MEP and establish a BOLD activation marker of cortical excitability. Participants will start with a set of two short task-based EPI scans and anatomical scan. RMT will then be determined. Participants will undergo a single-pulse TMS-fMRI scan with stimulation intensities relative to the RMT over the motor cortex and/or the DLPFC. In total, six (6) intensities will be tested, 80% 100%, 105%, 110%, 115%, and 120% relative to the RMT. The fMRI design will be event-related. Each intensity (event type) will be presented 50 times. The order of the intensities will be randomized, and the inter-stimulus-interval (ISI) will range from 12s to 20s (centered at 16s plus random jittering in between, about 0.06Hz). The highest intensity of stimulation will be 120% RMT. EMG recordings in the corresponding hand muscle will be simultaneously acquired during the scan. Total approximate time required for this experiment is about 6-8 hours.
62703104|NCT01036581|EXPERIMENTAL|TRPMS Experiment 1|To evaluate the prolonged effect of TPRMS on motor cortex excitability and help interpret and design subsequent experiments investigating the effect of TRPMS on BOLD signal. The experiment design consists of four groups, each group will include 10 participants (8 completers/group). For TRPMS stimulation sessions, our test conditions will be a 10 stimuli-session (approximately 2min), 50 stimuli-session (approximately 7min), 100 stimuli-session (approximately 14min), and 150 stimuli-session (20min) for each of the four groups, respectively. Therefore, the outcome will be measured with the spontaneous motor unit potentials (sMUPs) in the contralateral abductor pollicis brevis muscle (APB). After the stimulation session, we will measure sMUPs continuously for another 20min to observe the prolonged effect of the TRPMS stimulation and to compare these four conditions. The total approximate time required for this experiment is about 2-2.5 hours.
62703105|NCT01036581|EXPERIMENTAL|TRPMS Experiment 2|To evaluate cortical excitability changes caused by TRPMS measured with simultaneous TMS-fMRI. Participants will undergo a baseline TMS/fMRI session to get a measurement of baseline cortical excitability in the form of single-pulse TMS induced BOLD activation and determine motor hot-spot and RMT. We will then conduct an event-related single-pulse TMS/fMRI session with TMS stimulus at 120% RMT, 50 events with jittered inter-stimulus-interval (ISI) averaging 16s. Simultaneous EMG recording will be gathered from the corresponding hand muscle. Next we will use TRPMS to stimulate the left motor cortex over the hot-spot : 20-min application of TRPMS, 100ms duration, 0.2Hz (one stimulus every 5s), total 240 stimuli. Then we will evaluate the modulatory effect of the TRPMS stimulation via a second TMS/fMRI session with a similar procedure as the baseline session using the RMT determined at baseline. Total time for this experiment is about 5-6 hours.
62703106|NCT06407830|ACTIVE_COMPARATOR|Intervention physical therapy|Motor Relearning programme training
62703107|NCT06407830|EXPERIMENTAL|Electrical Muscle Stimulation|Electrical Muscle Stimulation with Motor Relearning programme
62703108|NCT05458297|EXPERIMENTAL|Cohort A, Relapsed or Refractory MCL with 2 Prior Lines of Therapy|Participants will receive zilovertamab vedotin intravenous (IV) infusion at Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation.
62143173|NCT06195813|PLACEBO_COMPARATOR|Placebo capsule|Participants were randomized to receive an arm. In this arm, participants received placebo capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.
62143174|NCT00649857|EXPERIMENTAL|1|Cetirizine HCl Tablets 10 mg
62346674|NCT04394455|ACTIVE_COMPARATOR|Crisis intervention therapy|Medical staff (medical doctors and residents) who will receive 3 sessions of crisis intervention therapy through telepsychiatry.
62504510|NCT04383717|ACTIVE_COMPARATOR|Control group|hydroxychloroquine and azithromycin
62703109|NCT05458297|EXPERIMENTAL|Cohort B, Relapsed or Refractory RT with 1 Prior Line of Therapy|Participants will receive zilovertamab vedotin IV infusion at Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation.
62346675|NCT00030615|EXPERIMENTAL|Treatment (decitabine)|"Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62346676|NCT00993395|EXPERIMENTAL|Peer Mentor Intervention|peer mentor-based disease management focusing on three domains: medical care, recovery, and social stabilization
62346677|NCT03242005|EXPERIMENTAL|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
62504511|NCT03237117|EXPERIMENTAL|GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. Additionally, these patients are co-treated with growth hormone (GH).
61958816|NCT04974697|EXPERIMENTAL|JJVC Investigational Multifocal Toric Contact Lens|Eligible subjects that are adapted contact lens wearers with presbyopia, ametropia (hyperopia or myopia) and astigmatism will be dispensed the study lens in a bilateral fashion.
62143175|NCT00649857|ACTIVE_COMPARATOR|2|Zyrtec® 10 mg
62346678|NCT03151252|OTHER|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
62346679|NCT03151252|OTHER|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
62346680|NCT03151252|OTHER|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
62143176|NCT05618041|EXPERIMENTAL|CAR-T Autologous T cell injection|Patients will be treated with CAR-T cells
61958817|NCT01218373|ACTIVE_COMPARATOR|Intervention Group: HOMESWEETHOME services|Monitoring and alarm handling services. eInclusion services. Domotica services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
61958818|NCT01218373|PLACEBO_COMPARATOR|Control Group: No HOMESWEETHOME services|Normal care.
61958819|NCT06507813|EXPERIMENTAL|ADC189 tablets Group (Part 1)|Around 30 patients, 6-11 years old.
61958820|NCT06507813|ACTIVE_COMPARATOR|Baloxavir marboxil tablets Group (Part 1)|Around 15 patients, 6-11 years old.
61958821|NCT06507813|EXPERIMENTAL|ADC189 granules Group (Part 2A)|Around 60 patients, 5-11 years old.
61958822|NCT06507813|ACTIVE_COMPARATOR|Baloxavir marboxil tablets (Part 2A)|Around 30 patients, 5-11 years old.
61958823|NCT06507813|EXPERIMENTAL|ADC189 granules (Part 2B)|Around 20 patients, 2-4 years old.
61958824|NCT06507813|ACTIVE_COMPARATOR|Oseltamivir granules (Part 2B)|Around 10 patients, 2-4 years old.
61958825|NCT04317469||ARDS group ,|
61958826|NCT04317469||non ARDS group|
61958827|NCT02654743|EXPERIMENTAL|SF|"Sulforaphane (SF) will be administered in an approximate dosage of 1 µmol SF/lb (2.2 kg µmol/kg) body weight. This dosage roughly approximates the dosage that was used in the Singh et al, (2014; PNAS) clinical trial of sulforaphane in male adolescents and adults with autism. The sulforaphane will be supplied as glucoraphanin (GR)-enriched broccoli seed extract tablets (manufacturing details follow). Each active tablet will contain 125 mg broccoli seed extract (containing 37 µmol GR, which is equivalent to about 15 µmol SF), 50 mg dried broccoli sprouts (a source of myrosinase, the enzyme that converts GR to SF), 15 mg ascorbic acid, 55.90 mg microcrystalline cellulose, and other minor GRAS excipients used for tablet forming.~The total dose per day will depend of study participants' body weight."
61958828|NCT06004999|EXPERIMENTAL|Vibration group|An exercise program organized by the researchers on the vibration platform will be applied to the pre-frail participants in the vibration group. The exercises will be applied 5 days a week for 6 weeks.
61958829|NCT06004999|ACTIVE_COMPARATOR|Control group|An exercise program organized by the researchers (same exercise program as the vibration group) will be applied to the pre-frail participants in the control group on a flat surface. The exercises will be applied 5 days a week for 6 weeks.
61958830|NCT02252783|EXPERIMENTAL|BFPET|BFPET will be administered as a single intravenous injection of up to 2 mCi (74 MBq) at rest and a single intravenous injection of up to 8mCi (296 MBq) following a stress protocol. Total amount not to exceed 10mCi (370 MBq).
62143177|NCT01296230|EXPERIMENTAL|Hormone/semen measurements before and after varicocelectomy|We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.
62143178|NCT00154115|EXPERIMENTAL|1|Levosimendan
62143179|NCT00154115|PLACEBO_COMPARATOR|2|
62143180|NCT01989689|EXPERIMENTAL|Etanercept/Placebo|The subjects will receive subcutaneous etanercept therapy at 50mg twice weekly for 3 months then will be switched to placebo therapy for an additional 3 months.
62703110|NCT05458297|EXPERIMENTAL|Cohort C, Relapsed or Refractory MCL with 1 Prior Line of Therapy|Participants will receive zilovertamab vedotin IV infusion at Dose 2 every 3 weeks (Q3W) combined with nemtabrutinib oral dose daily until disease progression or discontinuation.
62143181|NCT01989689|ACTIVE_COMPARATOR|Placebo/Etanercept|The subjects will receive placebo injections for 3 months then will be switched to etanercept therapy for an additional 3 months.
62143182|NCT00780494|EXPERIMENTAL|bevacizumab+ carboplatin +capecitabine|Participants receive bevacizumab 15 mg/kg intravenously followed by carboplatin AUC 6 intravenously on Day 1 of a 21-day cycle, concurrently with capecitabine 850 mg/m2 twice-daily by mouth on Cycle Days 1-to-14, followed by a 1-week break.
62346681|NCT00780702|EXPERIMENTAL|Arm 1|
62346682|NCT00780702|PLACEBO_COMPARATOR|Arm 2|
62346683|NCT04446026|EXPERIMENTAL|teneligliptin|
62504512|NCT03237117|ACTIVE_COMPARATOR|non-GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the GH group, only that no GH is added.
61958831|NCT03940040|ACTIVE_COMPARATOR|Usual Care|Patients will under go usual care ( pulmonary rehabilitation on room air or with nasal oxygen supplementation)
61958832|NCT03940040|EXPERIMENTAL|High flow nasal oxygen|Patients will undergo pulmonary rehabilitation with high flow nasal oxygen
61958833|NCT04052347|EXPERIMENTAL|Shared decision-making with a patient decision-aid|
61958834|NCT04052347|ACTIVE_COMPARATOR|routine shared decision-making|control group
61958835|NCT06284746|EXPERIMENTAL|Tirelizumab combined with neoadjuvant chemotherapy|Four cycles of tirolizumab combined with SOX/XELOX neoadjuvant chemotherapy regimen before surgery, followed by laparoscopic D2 gastric cancer radical surgery, and four cycles of adjuvant chemotherapy after surgery.
61958836|NCT06284746|ACTIVE_COMPARATOR|standard chemotherapy|Four cycles of standard chemotherapy regimen (SOX/XELOX regimen) were administered before and after surgery.
61958837|NCT03734276|EXPERIMENTAL|High intensity exercise|
61958838|NCT03734276|ACTIVE_COMPARATOR|Control|
61958839|NCT05053100||Observational (record review, blood collection)|Patients' electronic health record are reviewed for 12 months and/or undergo collection of blood at pretreatment and on days 7, 28, 90, and 180.
62143183|NCT03958526|ACTIVE_COMPARATOR|Active|Active stimulation over M1
62143184|NCT03958526|PLACEBO_COMPARATOR|Sham|Sham stimulation over M1
62143185|NCT06159959||Group A: Obese Pregnant Females|About 122 Pregnant women candidate for elective cesarean section suffering from obesity where as Body mass index (BMI) is ≥30 kg/m2
62143186|NCT06159959||Group B: Non-Obese Pregnant Females|About 122 Pregnant women candidate for elective cesarean section and not obese obesity where as Body mass index (BMI) is \< 30 kg/m2
62346684|NCT04446026|PLACEBO_COMPARATOR|placebo|
62346685|NCT05496322|EXPERIMENTAL|cNIBP|Continuous non invasive blood pressure monitor (Volume clamp)
62346686|NCT05496322|ACTIVE_COMPARATOR|iNIBP|Intermittent Non Invasive Blood Pressure (Brachial Cuff)
62346687|NCT03006471|EXPERIMENTAL|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
61958840|NCT02074644|EXPERIMENTAL|Prostatic Arterial Embolization|Selective catheterization of the prostatic arteries followed by slow injection of Bead Block 300-500 or PVA 100+200 micra particles under fluoroscopic control.
61958841|NCT02074644|SHAM_COMPARATOR|Sham procedure|Selective catheterization of the prostatic arteries followed by removal of the catheter with no particles injected.
61958842|NCT01396798||Children with an acute illness|Children aged 1 month to 16 years of age, which attend the A\&E department of UZLeuven with an acute illness episode of maximum 5 days.
61958843|NCT06504823|PLACEBO_COMPARATOR|placebo group|
61958844|NCT06504823|EXPERIMENTAL|experimental group|
61958845|NCT02149498||Parkinson Disease (PD)|Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause)
61958846|NCT02149498||Healthy Controls|Healthy individuals
61958847|NCT06099197|EXPERIMENTAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
62703111|NCT05458297|EXPERIMENTAL|Cohort D, Relapsed or Refractory FL and CLL with 2 Prior Lines of Therapy|Participants will receive either zilovertamab vedotin IV infusion Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation.
61958848|NCT06099197|ACTIVE_COMPARATOR|Attention Control App|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
61958849|NCT03777774|ACTIVE_COMPARATOR|No subgaleal drains|Drains will be placed during closing stage of craniectomy but will be clamped so that no drainage takes place. Drains can be opened if needed
61958850|NCT03777774|ACTIVE_COMPARATOR|Passive subgaleal drains|Passive non-vacuum drains will be placed during closing stage of craniectomy
61958851|NCT03777774|ACTIVE_COMPARATOR|Vacuum subgaleal drains|Active vacuum drains will be placed during closing stage of craniectomy
61958852|NCT03928119|EXPERIMENTAL|Intervention group|community public education, non-PCI center and emergency transfer system improvement, and inhospital green-channal optimization for PCI center.
61958853|NCT03928119|NO_INTERVENTION|Control group|Usual care of AMI public and medical health service
61958854|NCT02914470|EXPERIMENTAL|carbo, cyclo, atezolizumab|The starting dose is carboplatin AUC 5mg/ml\*min (d1), cyclophosphamide 600mg/m2(d1) and atezolizumab 840 mg (D1, 15), all administered intravenously
61958855|NCT01459471|EXPERIMENTAL|bleeding, leak, operative time|
61958856|NCT06497621|EXPERIMENTAL|Single step PVS impression|Single-step final impression method for complete denture fabrication using medium body PVS for border molding and wash impression in a single-step (i.e., one insertion of impression tray in mouth).
62143187|NCT03965949||Group 1|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support
62143188|NCT03965949||Group 2|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)
62143189|NCT03965949||Group 3|Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)
62143190|NCT03965949||Group 4|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
62143191|NCT04248868|EXPERIMENTAL|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
61958857|NCT06497621|ACTIVE_COMPARATOR|Conventional two-step PVS impression|Two-step final impression method for complete denture fabrication, i.e., border molding with heavy-body PVS first, followed by wash impression with light-body PVS.
62703112|NCT05458297|EXPERIMENTAL|Cohort E, Relapsed or Refractory FL with 2 Prior Lines of Therapy|Participants will receive either zilovertamab vedotin IV infuison Dose 1 every 3 weeks (Q3W) until disease progression or discontinuation.
62703113|NCT02926859|EXPERIMENTAL|Cannabidiol|Cannabidiol as add-on to individualized pharmacological treatment
62703114|NCT02926859|PLACEBO_COMPARATOR|Placebo|Placebo as add-on to individualized pharmacological treatment
62703115|NCT05548881||Group 1|Women who have submitted clinical samples for prenatal aneuploidy screening test with the finding of X mosaicism
62703116|NCT05548881||Group 2 (Control)|Control group of Female volunteers of appropriate age, ethnicity, BMI, SES and parity
62703117|NCT01333969|ACTIVE_COMPARATOR|Ishcemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components).
62703118|NCT01333969|NO_INTERVENTION|Control|In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
62714948|NCT06719388|EXPERIMENTAL|Experimental Group|Participants in the experimental group will receive a combination of exercise therapy and a jaw-mobilizing device. The intervention includes structured exercise therapy sessions and the use of the jaw-mobilizing device for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
61958858|NCT00523016|EXPERIMENTAL|Electroacupuncture|Subjects will receive Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP) electroacupuncture protocol for 20 minutes per treatment session; a total of 13 treatments will be administered over 3-4 weeks.
61958859|NCT00523016|SHAM_COMPARATOR|Sham acupuncture|Subjects will receive simulated acupuncture that includes insertion of acupuncture needles on the head. During each treatment session, needles will be stimulated with electricity for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
61958860|NCT05645575|EXPERIMENTAL|Open-label TMS|
61958861|NCT01309594|EXPERIMENTAL|Hematopoietic stem cell transplantation|Extraction of bone marrow cells from HIV positive patients with advanced liver cirrhosis and transplant their bone marrow back into the patients
62143192|NCT02562937|EXPERIMENTAL|Intervention|text messages related to sedentary behaviour
62143193|NCT02562937|NO_INTERVENTION|Control|text messages unrelated to sedentary behaviour.
61958862|NCT05829304|ACTIVE_COMPARATOR|Collagen based pulpotomy|"Application of rubber dam for isolation, then a standardized pulpotomy procedure will be performed. Remove pulpal tissues to the orifice level. Haemostasis will be achieved by the application of a wet cotton pellet.~Group I collagen-based Pulpotomy:~1. After complete haemostasis, collagen based pulpotomy will be applied according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm then the rest of the pulp chamber will be filled with glass ionomer cement.~2. Tooth will be restored with stainless steel crown."
61958863|NCT05829304|ACTIVE_COMPARATOR|MTA based pulpotomy|"Application of rubber dam for isolation, then a standardized pulpotomy procedure will be performed. Remove pulpal tissues to the orifice level. Haemostasis will be achieved by the application of a wet cotton pellet.~Group II MTA pulpotomy:~1. After complete hemostasis, MTA+ Cerkamed will be manipulated to obtain a putty mix. This mix will be placed over the radicular pulp. condensation of the mix with a moistened cotton pellet, followed by application of glass ionomer cement.~2. Tooth will then be restored with stainless steel crown."
61958864|NCT06028139|EXPERIMENTAL|Intervention|
61958865|NCT06028139|OTHER|Control|
61958866|NCT03384238|EXPERIMENTAL|Cohort 1a|A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. Cohort 1a will receive 25 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
61958867|NCT03384238|EXPERIMENTAL|Cohort 1b|Cohort 1b will receive 50 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
61958868|NCT03384238|EXPERIMENTAL|Cohort 1c|Cohort 1c will receive 75 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab.A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
61958869|NCT03384238|EXPERIMENTAL|Cohort 1d|Cohort 1d will receive a 50 mg dose of Panitumumab IRDye800 and no test/loading dose. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
61958870|NCT03384238|EXPERIMENTAL|Cohort 2- Dose Expansion|Cohort 2 will receive the optimal dose of Panitumumab-IRDye800 as determined in Cohort 1
61958871|NCT06468566||Whether to use ultrasound light scattering imaging equipment|
61958872|NCT06468566||Conventional ultrasound|
61958873|NCT06468566||Device Assistant physician|
61958874|NCT01494571||90 pediatric, 7 to 14 year old subjects|
61958875|NCT01494571||30 pediatric, 5 to 6 year old subjects|
62703119|NCT03737981|ACTIVE_COMPARATOR|Arm I (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Treatment repeats every 28 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 15, patients receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity.
61958876|NCT01494571||30 pediatric, 3 to 4 year old subjects|
61958877|NCT01494571||30 pediatric, 1 to 2 year old subjects|
61958878|NCT01494571||30 pediatric, 6 to 12 month old subjects|
61958879|NCT01494571||30 pediatric, 4 to 6 month old subjects|
61958880|NCT01494571||30 pediatric, 2 to 4 month old subjects|
61958881|NCT00844896|ACTIVE_COMPARATOR|DEF-only|Distress Emotional Support and Family Assessment Treatment
61958882|NCT00844896|EXPERIMENTAL|DEF + COPE|Distress Emotional Support and Family Assessment Treatment and Creating Opportunities for Parent Empowerment Treatment
61958883|NCT01962896|EXPERIMENTAL|Erlotinib + sirolimus|
61958884|NCT04028921||Normal weight, active|Male and female adolescents (age 14-17 years), BMI percentile \>=5th to \<75th for age/sex, \>=60 min/day of moderate/vigorous physical activity.
61958885|NCT04028921||Normal weight, sedentary|Male and female adolescents (age 14-17 years), BMI percentile \>=5th to \<75th for age/sex, \<60 min/day of moderate/vigorous physical activity.
61958886|NCT04028921||Overweight/obese, active|Male and female adolescents (age 14-17 years), BMI percentile \>=85th to \<99th for age/sex, \>=60 min/day of moderate/vigorous physical activity.
61958887|NCT04028921||Overweight/obese, sedentary|Male and female adolescents (age 14-17 years), BMI percentile \>=85th to \<99th for age/sex, \<60 min/day of moderate/vigorous physical activity.
62143194|NCT06304051|ACTIVE_COMPARATOR|Intermittent Oro-esophageal Tube Feeding|the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure.
62143195|NCT06304051|ACTIVE_COMPARATOR|Nasogastric Tube|This group was provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding.
62143196|NCT01479010|EXPERIMENTAL|Anakinra|
62143197|NCT04996225|EXPERIMENTAL|Group (A): (study group)|Group (A): (study group) 15 patients received aerobics exercises and balancing exercises in addition to relaxation exercises for 4 weeks, 3sessions/week.
62346688|NCT03006471|PLACEBO_COMPARATOR|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
62346689|NCT03771599|ACTIVE_COMPARATOR|Control group|"Routine physical therapy~\[Time Frame: Twelve weeks\]"
61958888|NCT00071097|EXPERIMENTAL|001|TMC114/rtv 400mg TMC114/100mg rtv once daily
61958889|NCT00071097|NO_INTERVENTION|005|Control Group Control Group, no intervention
61958890|NCT00071097|EXPERIMENTAL|004|TMC114/rtv 600mg TMC114/100mg rtv twice daily
61958891|NCT00071097|EXPERIMENTAL|003|TMC114/rtv 400mg TMC114/100mg rtv both twice daily
61958892|NCT00071097|EXPERIMENTAL|002|TMC114/rtv 800mg TMC114/100mg rtv once daily
61958893|NCT01773811|NO_INTERVENTION|Control|Individuals will write objectively about the events of their day.
61958894|NCT01773811|EXPERIMENTAL|Narrative Writing: Trauma-Assigned|Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
61958895|NCT01773811|ACTIVE_COMPARATOR|Narrative Writing: Trauma-Spontaneous|Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
61958896|NCT02710396|EXPERIMENTAL|Cohort 1|Subjects will receive single agent pembrolizumab 200 mg IV will be administered every 3 weeks for up to 2 years.
61958897|NCT02710396|EXPERIMENTAL|Cohort 2|Subjects will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of nab-paclitaxel and carboplatin administered with cycles 1 and 2.
61958898|NCT02710396|EXPERIMENTAL|Cohort 3|Subject will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of pemetrexed and carboplatin administered with cycles 1 and 2.
61958899|NCT02503657|PLACEBO_COMPARATOR|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
61958900|NCT02503657|OTHER|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
61958901|NCT05384574|EXPERIMENTAL|Intervention|Patients with low levels of Vitamin D on admission to ICU randomized to receive vitamin D supplementation
61958902|NCT05384574|NO_INTERVENTION|Control|Patients with low levels of Vitamin D on admission to ICU not receiving vitamin D supplementation
61958903|NCT02695329|ACTIVE_COMPARATOR|Vanguard with KneeAlign 2|Having total knee arthroplasty surgery with the use of a navigation system KneeAlign 2.
61958904|NCT02695329|NO_INTERVENTION|Vanguard without KneeAlign 2|Having total knee arthroplasty surgery with the use of conventional surgical instruments, and without a navigation system KneeAlign 2.
61958905|NCT01475357|OTHER|Arm 1: NPO pre-operative|1) Current care - NPO (nothing by mouth) postnatal intestinal function of neonates with complex CHD who receive enteral trophic breastmilk (10cc/kg/day) feeds (intervention) vs NPO (nothing by mouth) in the pre-operative period.
61958906|NCT01475357|ACTIVE_COMPARATOR|Arm 2: Fresh Breast Milk pre-operative|2) Intervention - Trophic mother's own fresh (non-frozen) breastmilk gavage feeds via nasogastric tube every 3 hours at 10 cc/kg/day
61958907|NCT01116583|ACTIVE_COMPARATOR|Gabapentin|Gabapentin group
61958908|NCT01116583|PLACEBO_COMPARATOR|Placebo|Placebo group
61958909|NCT02956239|EXPERIMENTAL|Thermocoagulation (device)|VIA Positive women will be treated by the new device for thermocoagulation
61958910|NCT02956239|ACTIVE_COMPARATOR|Cryotherapy (device)|VIA positive women will be treated by cryotherapy
61958911|NCT02956239|ACTIVE_COMPARATOR|LEEP (device)|VIA Positive women not suitable for thermo-coagulation or cryotherapy will be treated by LEEP
61958912|NCT05478785|EXPERIMENTAL|Cisplatin micelle injection (HA132)|"Dose-escalation: Five dose levels have been selected for evaluation in the Phase Ⅰ of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle.~Dose-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD).~Cohort-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD)."
61958913|NCT04678661|EXPERIMENTAL|My Dose Coach (Insulin Dosing Support App)|"Phase 1 Titration: Patients receive insulin therapy education from diabetes educator (DE). Plus, DE trains patients to use My Dose Coach (MDC) for titration guidance according to an algorithm prepared by endocrinology provider (EP). Patients are asked to return for a 3-month (mo) follow-up clinic visit. Patients who successfully reach glycemic target are invited to Phase 2. Other patients are invited to continue titrating for another 3 months.~Phase 2 Maintenance: At 3-mo clinic visit, an EP or DE trains patients the MDC Maintenance Module to support proper insulin dosing. Patients are asked to return for follow-up clinic visits at mo 6.~Patients are surveyed (0, 3, 6 mo) to assess changes in behavioral and psychosocial factors that influence diabetes self-management and MDC acceptability."
61958914|NCT04678661|ACTIVE_COMPARATOR|Usual Care Group|A retrospective comparative group will be selected from eligible patients who previously were treated at the University of Pittsburgh Medical Center (UPMC) Diabetes Outpatient Clinics following standard insulin therapy education. Patients in the usual care group will be identified using data available in the electronic medical record system. Propensity score matching will be used to pair intervention and usual care participants during phase 1 of the study (baseline to 3 months).
61958915|NCT00814164|EXPERIMENTAL|Clorafarbine with daunorubicin|Patients receive clofarabine IV over 1 hour on days 1-5 and daunorubicin hydrochloride IV over 5 minutes on days 1, 3, and 5.
62143198|NCT04996225|PLACEBO_COMPARATOR|Group (B): (Control group)|2-Group (B): (Control group) 15 patients received relaxation exercises in the form of physical relaxation exercise for 4 weeks, 3 sessions/week. the participants who received aerobics exercises and balancing exercises in addition to relaxation exercises (experimental group A), showed significant decrease in anxiety and dizziness more than (placebo group B)
62143199|NCT01736449|PLACEBO_COMPARATOR|Pterygium Excision Alone|
62143200|NCT01736449|EXPERIMENTAL|Pterygium Excision with Bevacizumab Injection|
62143201|NCT01115140|ACTIVE_COMPARATOR|Group A1|metformin plus placebo
62143202|NCT01115140|EXPERIMENTAL|Group A2|metformin plus folic acid
62143203|NCT01115140|ACTIVE_COMPARATOR|Group A3|placebo plus folic acid
62143204|NCT01115140|PLACEBO_COMPARATOR|Group A4|placebo cp, 2 cps daily
62143205|NCT01115140|NO_INTERVENTION|Group B|observation
61958916|NCT01235143|EXPERIMENTAL|desflurane anesthesia|maintenance anesthesia with desflurane
61958917|NCT01235143|ACTIVE_COMPARATOR|sevoflurane|maintenance anesthesia with sevoflurane
61958918|NCT03391037||Intervention|diagnostic criteria for volume assessment were heart rate (HR), mean arterial blood pressure (MABP), central venous pressure (CVP), and urine output hourly (UOP) in ml/hr. During period of hypovolemia, all enrolled patients had left IJV scanned (T0) and measured by one anesthesiologist experienced in point-of-care ultrasound. This point-of-care anesthesiologist is not involved in the anesthetic management of the patient and blinded to the volume status of the patient values. Hypovolemic patients were given a fluid bolus in the form of ringer acetate 5 ml / Kg. Ultrasonic and hemodynamic measurements are reassessed 10 minutes (T 10) after the fluid resuscitation.
61958919|NCT03256643|EXPERIMENTAL|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
61958920|NCT03256643|EXPERIMENTAL|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
61958921|NCT03256643|EXPERIMENTAL|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
61958922|NCT00993200|ACTIVE_COMPARATOR|Warfarin, control|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by usual care dosing.
61958923|NCT00993200|EXPERIMENTAL|Warfarin: PERMIT|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by warfarin pharmacogenetic dosing (warfarin dosing using genetic information incorporated into the PERMIT algorithm).
61958924|NCT01678430|ACTIVE_COMPARATOR|Ofatumumab-Chlorambucil|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Chlorambucil: 10mg/m2 po days 1-7
61958925|NCT01678430|EXPERIMENTAL|Ofatumumab-Bendamustine|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Bendamustine: 70mg/m2 iv days 1 and 2
61958926|NCT04170816|ACTIVE_COMPARATOR|DN plus KT group|"DN plus KT therapy is going to be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy is going to be applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.~Kinesio Taping Application: Tapes is going to be left on the patient's body for 5 days."
61958927|NCT04170816|ACTIVE_COMPARATOR|DN group|DN will be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy was applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.
62143206|NCT01746576|OTHER|All|All subjects will undergo spontaneous ventilation through an impedance threshold device and ScvO2 will be recorded before and after
61958928|NCT01304316|EXPERIMENTAL|Kovacaine Nasal Spray|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 6 sprays of 0.1 mL - total of 18 mg tetracaine HCl and 0.3 mg oxymetazoline HCl followed by 12 sprays of 0.1 mL - total of 36 mg tetracaine HCl and 0.6 mg oxymetazoline HCl
61958929|NCT02848872||NSCLC patients|Resected patients
62143207|NCT05443516||Systemic Lupus Erythematosus - Lupus Nephritis Cohort|Systemic Lupus Erythematosus - Lupus Nephritis Cohort
61958930|NCT02277145|EXPERIMENTAL|treatment group|Patients will receive 10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions
61958931|NCT00519831|EXPERIMENTAL|Vinflunine + Cetuximab|Patients may receive more than 4 cycles of therapy if they continue to demonstrate response to therapy, have limited toxicity, and if the treating physician determines that they are deriving clinical benefit from the treatment. The decision of continuing therapy beyond 4 cycles must be discussed with the principal investigator.
61958932|NCT04332146|EXPERIMENTAL|Mindfulness-based intervention|
61958933|NCT04332146|ACTIVE_COMPARATOR|Booklet-based psychoeducation group|
61958934|NCT05119517|EXPERIMENTAL|Osteopathic manipulative medicine pedal pump|
62143208|NCT04226456|NO_INTERVENTION|Control|"Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
62143209|NCT04226456|EXPERIMENTAL|N-acetylcysteine|"Experimental arm (Arm B):~* 0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.~* Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
62143210|NCT05224986|NO_INTERVENTION|Variable Schedule|Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks.
62346690|NCT03771599|EXPERIMENTAL|Intervention group|"Traditional massage + Routine physical therapy~\[Time Frame: Twelve weeks\]"
61958935|NCT02406716||HF|Heart failure patients
61958936|NCT02406716||Controls|Healthy donors
61958937|NCT04640285|EXPERIMENTAL|Product Use Sequence 1|Period 1 - RELX ENDS Tobacco Flavor Period 2 - RELX ENDS Menthol Flavor Period 3 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 4 - Usual Brand Cigarette
61958938|NCT04640285|EXPERIMENTAL|Product Use Sequence 2|Period 1 - RELX ENDS Menthol Flavor Period 2 - Usual Brand Cigarette Period 3 - RELX ENDS Tobacco Flavor Period 4 - Nicorette White Ice Mint Nicotine Polacrilex Gum
61958939|NCT04640285|EXPERIMENTAL|Product Use Sequence 3|Period 1 - Usual Brand Cigarette Period 2 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 3 - RELX ENDS Menthol Flavor Period 4 - RELX ENDS Tobacco Flavor
61958940|NCT04640285|EXPERIMENTAL|Product Use Sequence 4|Period 1 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 2 - RELX ENDS Tobacco Flavor Period 3 - Usual Brand Cigarette Period 4 - RELX ENDS Menthol Flavor
61958941|NCT02499783|EXPERIMENTAL|Placebo Induction Regimen|"Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24."
62143211|NCT05224986|EXPERIMENTAL|Fixed Schedule|Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks.
62143212|NCT01077700|EXPERIMENTAL|ABT-288 Dose 1|low dose of ABT-288
61958942|NCT02499783|EXPERIMENTAL|Adalimumab Induction Regimen|"Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24."
61958943|NCT00967590|EXPERIMENTAL|1|
61958944|NCT00967590|PLACEBO_COMPARATOR|2|
61958945|NCT05661799|EXPERIMENTAL|Intervention Group|The proposed intervention consists of one hour of adapted physical activity per week for 12 weeks, led by a professional. In addition to this intervention, the intervention includes two 15-minute sessions, one before and one after the session. At the end of each session, a PA challenge and a positive reinforcement exercise will be proposed. The participants will have a week to try to achieve these. In addition to these two 15-minute sessions, participants will benefit from a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different topics related to diabetes.
61958946|NCT05661799|ACTIVE_COMPARATOR|Control group|The proposed intervention consists of one hour of adapted physical activity per week for 12 weeks, led by a professional.
61958947|NCT03886805|EXPERIMENTAL|Dual task with variable- and fixed-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks. From the 1st to 12th week the participants were trained under variable-priority instructions (half the session was focused on balance motor task and half the session focused on cognitive task performance). From the 13th to 24th week) the participants performed dual tasks under fixed-priority instructions (simultaneous focus attention on balance and cognitive tasks). The motor tasks were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks will include activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, working memory, among other cognitive tasks.
61958948|NCT03886805|ACTIVE_COMPARATOR|Dual-task with variable-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks (48 sessions). From the 1st to 24th week, the participants were trained under variable-priority instructions, in which they were asked to spend half the session focused on balance (motor task) and half the session focused on cognitive task performance. The motor tasks (gait and postural balance) of this protocol were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks included activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, rescue working memory, among other cognitive tasks.
61958949|NCT04998786|EXPERIMENTAL|assessment of treatment Ixazomib, dexamethasone, iberdomide|Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression
61958950|NCT02745444|OTHER|low-calorie formula diet|Donor taking low-calorie formula diet, 50% of basal energy rate, individually calculated with Mifflin-St. Jeor formula.
62703120|NCT03737981|EXPERIMENTAL|Arm II (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Beginning cycle 3, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity. All patients will then receive a 15th cycle of ibrutinib. Beginning cycle 16, patients who do not achieve a BM MRD negative CR, receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a BM MRD negative CR undergo observation every 3 cycles for 6 years, then every 6 cycles thereafter.
62714949|NCT06719388|PLACEBO_COMPARATOR|Control Group|Participants in the control group will receive exercise therapy only. This intervention involves the same structured exercise therapy sessions as the experimental group for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
61958951|NCT02745444|NO_INTERVENTION|no diet|Donor ingesting food as usual.
61958952|NCT02745444|OTHER|protein-restricted diet|Donor taking protein-restricted diet according to diet plans of clinical dietetics of University Hospital of Cologne, with unchanged calorie supply, individually calculated with Mifflin-St. Jeor formula.
61958953|NCT02745444|NO_INTERVENTION|Normal protein supply|Donor taking same dishes as protein-restricted diet group but with customary protein levels, with unchanged calorie supply.
61958954|NCT00956020|EXPERIMENTAL|Treatment|Skin injection with platelet rich fibrin matrix on the inner aspect of the upper arm, with biopsies over a period from 30 minutes to 12 weeks after treatment.
61958955|NCT01354678|ACTIVE_COMPARATOR|group of bone marrow cell therapy|
61958956|NCT01354678|SHAM_COMPARATOR|group of sham therapy|
61958957|NCT04525378|NO_INTERVENTION|Control|Patients will receive standard care.
61958958|NCT04525378|EXPERIMENTAL|MSC - low dose (2.5x10ˆ7)|Patients will receive standard care plus cell therapy.
62714950|NCT02740465|EXPERIMENTAL|COPD Patients|
61958959|NCT04525378|EXPERIMENTAL|MSC - intermediate dose (5x10ˆ7)|Patients will receive standard care plus cell therapy.
61958960|NCT04525378|EXPERIMENTAL|MSC - high dose (10x10ˆ7)|Patients will receive standard care plus cell therapy.
61958961|NCT03627143|OTHER|Local implementation of AAFF guidelines|The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
61958962|NCT02627937||pediatric sleep apnea|The children were confirmed to have OSAHS by comprehensive polysomnography (PSG).
61958963|NCT01501175||patients with suspected SVT|patients with suspected SVT and inhabitants of the Saint Etienne region
61958964|NCT01595997|PLACEBO_COMPARATOR|Placebo|
61958965|NCT01595997|EXPERIMENTAL|DLX105|
61958966|NCT04533373|EXPERIMENTAL|Neurotized Patients|Neurotization will be performed at the time of reconstruction.
61958967|NCT04533373|NO_INTERVENTION|Non-Neurotized Patients|No Neurotization will be performed at the time of reconstruction.
61958968|NCT02728609||Blue towel: vacuum pack device|Trauma subjects undergoing temporary abdominal closure with vacuum pack technique
61958969|NCT02728609||ABThera abdominal closure|Trauma subjects undergoing temporary abdominal closure with the commercially available ABThera vacuum device
61958970|NCT06457880|EXPERIMENTAL|PENG block|Before surgery, Patients undergo to ultrasound guided PENG block administering ropivacaine 0.5 % 20 mL.
61958971|NCT06457880|ACTIVE_COMPARATOR|Femoral nerve block + Obturator nerve block|Before surgery, Patients undergo to ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL) + obturator nerve block (ropivacaine 0.5% 5 mL).
61958972|NCT03730571|EXPERIMENTAL|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
61958973|NCT01502930|EXPERIMENTAL|IRT|Imagery Rehearsal Therapy
61958974|NCT01502930|ACTIVE_COMPARATOR|CONT|Stress reduction and positive imagery
61958975|NCT01502930|NO_INTERVENTION|REG|Registration only
61958976|NCT05777850|ACTIVE_COMPARATOR|Conventional ablation|CTI ablation with electroanatomic navigation system using individual 25-40 W applications of unlimited duration until achieving in each application the minimum value of one of the currently accepted and used lesion markers: Ablation Index \>500 at the anterior half of the CTI and \>400 at the posterior half with de CARTO 3 system. Minimum contact force required is 5 grams. Maximum distance between applications must be 6 mm.
61958977|NCT05777850|EXPERIMENTAL|High-power short-duration ablation|CTI ablation with electroanatomic navigation system using individual high power (90W) short duration (4 seconds) applications in a catheters' stable position with a minimum contact force of 15-30 g at the anterior half and 10-25 g at the posterior one. Maximum distance between applications is settled at 4 mm.
61958978|NCT05438264|EXPERIMENTAL|Experimental|Donepezil 5 mg, daily
61958979|NCT05438264|PLACEBO_COMPARATOR|Control|Placebo, daily
61958980|NCT01410201|EXPERIMENTAL|PPV + MP + DEX|Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
61958981|NCT01410201|ACTIVE_COMPARATOR|PPV + MP|Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.
61958982|NCT06266078|EXPERIMENTAL|Innovative PPE|The healthcare workers will perform tasks using non-traditional personal protective equipments.
61958983|NCT06266078|ACTIVE_COMPARATOR|Traditional PPE|The healthcare workers will perform tasks using traditional personal protective equipments.
61958984|NCT02846311||Group with support that will be usually performed|"During the first phase (before), the assumption will be that usually achieved.~The doctor continues to support according to information it has and according to good practice and service protocols."
61958985|NCT02846311||Group with a flu test|"During the second phase (after), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.~The doctor continues to support according to information it has and according to good practice and service protocols."
61958986|NCT02968771||Patients with Physical Cardiac Stress|Patients with Physical Cardiac Stress
61958987|NCT02968771||Patients with Physical and Pharmacological Cardiac Stress|Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
61958988|NCT02968771||Patients with Pharmacological Cardiac Stress|Patients with Pharmacological Cardiac Stress with adenosine agonist
61958989|NCT02920372|EXPERIMENTAL|EPOETIN ALFA|
61958990|NCT02462460||Patients with BRCA mutation|The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
61958991|NCT00596375|NO_INTERVENTION|Routine Care Group|The routine care group will help us to quantify the routine amount of distress associated with catheterization.
61958992|NCT00596375|EXPERIMENTAL|Lidocaine Group|A experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention.
61958993|NCT00596375|EXPERIMENTAL|Instillation|This group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress.
61958994|NCT04486105|PLACEBO_COMPARATOR|control|vehicle only for one week
61958995|NCT04486105|EXPERIMENTAL|40g sucrose ingestion|40g sucrose treatment on top of habitual diet for one week
61958996|NCT04486105|EXPERIMENTAL|80g sucrose ingestion|80g sucrose treatment on top of habitual diet for one week
61958997|NCT04486105|EXPERIMENTAL|120g sucrose ingestion|120g sucrose treatment on top of habitual diet for one week
61958998|NCT04112784|EXPERIMENTAL|INVSENSOR00039|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00039 sensor.
61958999|NCT00669929||1|patients visited to Severance hospital
61959000|NCT00669929||2|patients visited to Youngdong Severance hospital
61959001|NCT00669929||3|patients visited to Wonju Christian hospital
61959002|NCT03978000|ACTIVE_COMPARATOR|IBP-9414|
61959003|NCT03978000|PLACEBO_COMPARATOR|Placebo|
61959004|NCT03783364|EXPERIMENTAL|preoperative|preoperative radiotherapy
61959005|NCT03783364|ACTIVE_COMPARATOR|postoperative|postoperative radiotherapy
62143213|NCT01077700|EXPERIMENTAL|ABT-288 Dose 2|high dose of ABT-288
62143214|NCT01077700|PLACEBO_COMPARATOR|Sugar Pill|inactive substance
62504513|NCT03237117|NO_INTERVENTION|positive control group|35 infertile women undergoing their first oocyte donation attempt are included as a positive control group. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the non-GH group, with no GH added.
62504514|NCT01774331||Immunoglobulin Therapy|Immunoglobulin Therapy
62504515|NCT06030856|EXPERIMENTAL|STI test kits for home use coupled with self-administered behavioural risk assessment|The adolescent will receive STI test kits (NG, CT and TV) for home use coupled with self-administered behavioural risk assessment at the screening and enrolment visit.
62504516|NCT06030856|ACTIVE_COMPARATOR|Self-administered behavioural risk assessment only (standard of care)|The adolescent will receive a self-administered behavioural risk assessment at the screening and enrolment visit
62504517|NCT03815240|OTHER|no dressing (A)|No dressing will be applied at sacrum before 3.5 hours loading period in supine position
62504518|NCT03815240|ACTIVE_COMPARATOR|Mepilex (B)|'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
62504519|NCT03815240|ACTIVE_COMPARATOR|Allevyn (C)|'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
62504520|NCT03815240|ACTIVE_COMPARATOR|Optifaom (D)|'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position
62504521|NCT05440695||CNAP Group|The CNAP finger cuff and NIBP cuff were on the same arm of the patient while the intravenous catheter was on the contralateral side. After intrathecal injection, systolic, diastolic, and mean blood pressures were measured and were recorded manually at every minute on the CNAP monitor.
62504522|NCT05440695||NIBP Group|In the control group, only oscillometric NIBP measurements were done in pregnant women similar to the study group without a CNAP. After intrathecal injection, systolic, diastolic, and mean blood pressures with oscillometric method were set at the frequency of 3 minutes for the first 15 minutes, and at 5-minute intervals thereafter, and were recorded manually.
62143215|NCT02430454|EXPERIMENTAL|Experimental|Subjected to increased cognitive load
61959006|NCT02453178|EXPERIMENTAL|Steady state moderate intensity cycling|Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
61959007|NCT02453178|ACTIVE_COMPARATOR|Intermittent cycling|The intermittent cycling group will come to the exercise lab for the same duration and frequency each week and complete primarily passive cycling such that a motor in the stationary bicycle moves the pedals for them. To maintain interest in this intervention, we will include short bouts of moderate intensity activity. The short bouts of moderate intensity cycling will be designed to be ineffective for substantially increasing cardiorespiratory fitness over the course of the intervention.
61959008|NCT00454896|EXPERIMENTAL|1|
61959009|NCT00454896|PLACEBO_COMPARATOR|2|
61959010|NCT01796561|ACTIVE_COMPARATOR|Olive leaf extract liquid|20ml of polyphenol-rich olive leaf extract liquid to be consumed daily for 6 weeks
61959011|NCT01796561|PLACEBO_COMPARATOR|Placebo liquid|20ml of polyphenol-free placebo liquid (containing water, glycerin, flavours, colours and aromas) to be consumed daily for 6 weeks
61959012|NCT02197130|EXPERIMENTAL|20 mg PF-02545920 BID|20 mg PF-02545920 BID
61959013|NCT02197130|EXPERIMENTAL|5 mg PF-02545920 BID|5 mg PF-02545920 BID
61959014|NCT02197130|PLACEBO_COMPARATOR|Placebo BID|Matching placebo
62143216|NCT02430454|NO_INTERVENTION|Control|Not subjected to increased cognitive load
62143217|NCT02630966|EXPERIMENTAL|Group 1: Vedolizumab IV 300 mg + Placebo|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.
62504523|NCT04505826|EXPERIMENTAL|OP-1250 Phase I Part A (Dose Escalation) and Part B (Dose Expansion)|Phase I Part A will evaluate the safety and pharmacokinetics (PK)of a range of OP-1250 doses to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Phase I Part B will evaluate the safety and PK of OP-1250 to confirm the RP2D dose.
62504524|NCT04505826|EXPERIMENTAL|OP-1250 Phase II|"This portion of the study further explores the clinical activity, safety, and PK of OP-1250 monotherapy at the RP2D and will estimate preliminary anti-tumor efficacy in 3 cohorts.~Cohort A will enroll subjects with measurable disease without evidence of CNS metastases; Cohort B will enroll subjects with non-measurable (evaluable) disease without evidence of CNS metastases; and Cohort C will enroll subjects with evaluable disease (measurable and non-measurable) with CNS metastases."
62504525|NCT02656251|ACTIVE_COMPARATOR|0.12% Clorhexidine with alcohol|0.12% Clorhexidine with alcohol, 15ml every 12 hour for 4 days
61959015|NCT01523353|ACTIVE_COMPARATOR|Exercise Intervention|4 week personalised exercise program on a static bicycle.
61959016|NCT01523353|NO_INTERVENTION|Control Arm|Patients having standard preoperative preparation and advice.
61959017|NCT02837445|ACTIVE_COMPARATOR|Treatment|Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
62143218|NCT02630966|EXPERIMENTAL|Group 2: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
62143219|NCT02233556|EXPERIMENTAL|Memantine|This study has only one arm. i.e. Single dose of memantine 20mg
62346691|NCT02912598|ACTIVE_COMPARATOR|Mallinckrodt™ Endobronchial Tube|Usage of a left-sided Mallinckrodt™ double-lumen tube (DLT) to achieve lung isolation and one lung ventilation.
62346692|NCT02912598|ACTIVE_COMPARATOR|Fuji Uniblocker™|Usage of a Fuji Uniblocker™ in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
62346693|NCT02912598|EXPERIMENTAL|ETView VivaSight™-SL+EB|Usage of a ETView VivaSight™-EB endobronchial blocker in a ETView VivaSight™-SL single-lumen tube to achieve lung isolation and one lung ventilation.
61959018|NCT02837445|PLACEBO_COMPARATOR|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
61959019|NCT03841669|EXPERIMENTAL|Aerobic Exercise Group|This is the experimental group. Exercise is prescribed for 150 min/week. Due to COVID-19 restrictions the exercise supervision was allowed to be either remotely or in the context of a laboratory setting.
61959020|NCT03841669|ACTIVE_COMPARATOR|Physical Activity & Health Information Group|This is the control group. Participants will engage in daily life monitoring every 6 weeks.
61959021|NCT06185283|OTHER|milled bar group|". O-Ball impression copings were snapped directly onto each O-Ball mini dental Implants. A Pick-Up closed tray impression technique was made using polyether impression material. MDI Lab Analog was pressed into the coping until a snap fit was observed .The impression was poured into dental stone to form a stone model for scanning~The cast was scanned using 3SHAPE TRIOS and the bar constructed throughout the production steps:~Step 1: Order Creation ,Step 2: scan the lab analog of MDI on the stone model scanned with D700 scanner. Step 3: CAD Designing (first select preparation in teeth view from canine to canine-click abutment button-choose restoration type (bar)-choose restoration material (wax) .Step 4: Sending to CAM for Manufacturing, Step 5: Manufacturing (cutting from disc of modeling wax)."
61959022|NCT06185283|OTHER|round bar|"Prefabricated plastic bar pattern (RHIN 83 OT BAR multi use) was pre scanned for standardization of all cases. After cast scanning the abutment copy was designed and again standardized for all MDI. The pre scanned bar was inserted over the copies. The same procedure for manufacturing was followed as that of milled -in bar.~The finished bar is brought to the patient's mouth, seated accurately. The denture is then tried, fitted and extensions adjusted in the usual manner. The denture fitting surface was; the hygienic space under the bar was blocked-out with wax.~plastic clip was adapted to their metal sleeve, adapted to the bar, the occlusion was checked and then they were picked-up using auto-polymerized acrylic resin while the patient was instructed to close lightly in centric occlusion. After finishing and polishing procedures, the mandibular denture was clinically remounted to adjust any interferences in the centric and eccentric the occlusal contacts."
61959023|NCT04987346|EXPERIMENTAL|Treadmill walking|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
61959024|NCT01471470|EXPERIMENTAL|neoadjuvant|
62346694|NCT02912598|ACTIVE_COMPARATOR|COOK© Arndt Endobronchial Blocker|Usage of a COOK© Arndt Endobronchial Blocker in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
62346695|NCT03407508|PLACEBO_COMPARATOR|Baseline|No dietary changes.
62346696|NCT03407508|PLACEBO_COMPARATOR|Comparison of Diets|Okinawan-based Nordic Diet or Control Diet.
62346697|NCT02284685|EXPERIMENTAL|A (opt-out, loss, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, social norming).
62504526|NCT02656251|EXPERIMENTAL|0.12% Clorhexidine without alcohol|0.12% Clorhexidine without alcohol, 15ml every 12 hour for 4 days
62504527|NCT02656251|PLACEBO_COMPARATOR|control|placebo 15ml every 12 hour for 4 days
62504528|NCT04440709|EXPERIMENTAL|Brain/neural hand exoskeleton (B/NHE)|
62703121|NCT05612971|EXPERIMENTAL|iAmHealthy Parents First|"iAmHealthy Parents First families will take part in a group program with other adults over Zoom. Children will not be involved during this time. Adults will participate in these group sessions weekly for three months. Each meeting will last approximately an hour. Fifteen dyads from each cohort will be randomized to the iAmHealthy Parents First group.~After 3 months, both iAmHealthy Parents First and iAmHealthy families will take part in an educational group program with parents and their children. These meetings will be focused on living healthy lifestyles and engaging in healthy habits as a family and will occur three weeks out of four for four months. There will be three additional family-based group sessions spread over the final two months of the program. iAmHealthy Parents First adults will continue to meet monthly during the family-based program (on weeks when the family-based group does not meet) to continue the adult program."
62703122|NCT05612971|ACTIVE_COMPARATOR|iAmHealthy|"iAmHealthy families will receive an informational newsletter once a month for three months. This group will be given the flexibility to start their weight loss journey using self-guided methods. No formal group sessions will be provided for three months. Fifteen dyads from each cohort will be randomized to the iAmHealthy group.~After 3 months, both iAmHealthy Parents First and iAmHealthy families will take part in an educational group program with parents and their children. These meetings will be focused on living healthy lifestyles and engaging in healthy habits as a family and will occur three weeks out of four for four months. There will be three additional family-based group sessions spread over the final two months of the program."
62504529|NCT04010734|ACTIVE_COMPARATOR|peroral Cholangioscopy examination|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to the peroral Cholangioscopy examination with both visual and tissue diagnosis. The visual diagnosis is based on morphological and vascular patterns (presence or not of nodular or papilary masses, irregularity of the surface, morphology of the vessels and the fragility of mucosa). The tissue diagnosis consists on cytopathological evaluation after tissue sampling using minuature biopsy forceps (SpyBite). During this, 5-8 samples are taken under visual control, from different parts of the lesion."
62703123|NCT02281747||affected with arthritis|arthritis may be either rheumatoid, osteoarthritis, or ankylosing spondylitis
62703124|NCT02281747||unaffected with arthritis|in some analyses, the comparison is by arthritis status. in other analyses, it is within arthritis status by clinically relevant subgroups.
62703125|NCT00397111||Healthy Volunteer|Healthy Volunteer/control group
62703126|NCT00397111||Major Depressive Disorder|Individuals with Major Depressive Disorder
62703127|NCT05196035|EXPERIMENTAL|Finerenone (Kerendia, BAY94-8862)|Participants will receive finerenone treatment.
62703128|NCT05196035|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo to finerenone.
62703129|NCT04103346|ACTIVE_COMPARATOR|air filtration with hepa filter|air purifier used is the Holmes HAP8650B-NU-1 with the hepa filter inserted.
62504530|NCT04010734|ACTIVE_COMPARATOR|ERCP examination with sampling|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to ERCP examination with both sampling by brushing and forceps biopsy, with subsequent pathological evaluation and an additional fluorescence in situ hybridization(FISH) examination of the specimens.~ERCP (Endoscopic retrograde cholangiopancreatography) is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Brushing and endocanal forceps biopsies were the most used techniques, both with different specificity and sensitivity. It was demonstrated that Fluorescence in Situ Hybridization (FISH) improved the diagnostic yield of routine cytology. That is the reason why the investigators will combine FISH with the sampling methods to maximize the chance to make early diagnosis of the biliary stenosis."
62504531|NCT04346563|EXPERIMENTAL|Kinesio tape, functional correction applying|The experimental group, trained by Certified Kinesio tape researcher will attache the kinesio tape. Attaching the kinesio tape by using functional correction techniques, apply tape from the front of the acromion process to the spinous process T10 on both sides, providing 50% of the tape's tension (Kase, 2003, Han JT et al) to create a scapular retraction.
62504532|NCT04346563|PLACEBO_COMPARATOR|Placebo Kinesio taping apply|Apply kinesio tape without tension.
62504533|NCT03916224||Intubated critically ill patients|Critically ill patients older than 18 years old, intubated in an Intensive Care Unit.
62504534|NCT01302509|ACTIVE_COMPARATOR|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
62504535|NCT01860872||CF Group|Cystic Fibrosis group with MRI and CT of chest
62504536|NCT01860872||Control group|Non-CF controls will have MRI and no CT of chest
62504537|NCT01860872||Combined Group|MRI Quality \& Image Relatedness
62504538|NCT00808717|EXPERIMENTAL|High dose Atorvastatin 80 mg|Administered Atorvastatin 80 mg before intervention
62504539|NCT00808717|ACTIVE_COMPARATOR|Control|Administered Atorvastatin 10 mg before intervention
62504540|NCT02721719||Healthy Adults|\[Not receiving Vedolizumab\] Healthy adults who have not donated blood within the past two months and who have no history of blood-borne diseases.
62504541|NCT02721719||Adults with no Inflammatory Bowl Disease|\[Not receiving Vedolizumab\] Adult patients undergoing endoscopy for indications other than Inflammatory Bowel Disease or other inflammatory conditions of the bowel (such as colon cancer screening or polypectomy)
62504542|NCT02721719||Donors with Ulcerative Colitis|\[Set to receive Vedolizumab\] Adults with an established diagnosis of UC (≥ 6 months preceding involvement in study) who are both scheduled for an endoscopy and are about to receive Vedolizumab treatment (standard of care).
62504543|NCT00468208|EXPERIMENTAL|1|Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
62504544|NCT06602492|ACTIVE_COMPARATOR|Switching Arm: High to Low Nicotine|Baselined with a high nicotine eliquid and switched to a low nicotine eliquid.
62504545|NCT06602492|PLACEBO_COMPARATOR|Control Arm: High to High Nicotine|Baselined with a high nicotine eliquid and continue with the same high nicotine eliquid.
62504546|NCT05352724|EXPERIMENTAL|Hydration drink A|Water with electrolytes and glucose 625 ml 3 times a week for 4 weeks, during exercise
62504547|NCT05352724|ACTIVE_COMPARATOR|Hydration drink B|Water with electrolytes and calorie-free sweetener 625 ml 3 times a week for 4 weeks, during exercise
62504548|NCT05352724|PLACEBO_COMPARATOR|Hydration drink C|Water with flavoring and coloring 625 ml 3 times a week for 4 weeks, during exercise
62504549|NCT03436953|EXPERIMENTAL|CX-8998 T-type calcium channel blocker|
62504550|NCT03436953|PLACEBO_COMPARATOR|Comparator|
62504551|NCT01914016|OTHER|prolonged walk|
62504552|NCT00263887|EXPERIMENTAL|Group 1|Prolastin
62504553|NCT00263887|PLACEBO_COMPARATOR|Group 2|
62504554|NCT05567016|EXPERIMENTAL|Active Case Detection using molecular testing (ACDm)|"Per standard of care, children will receive passive case detection (PCD) using rapid diagnostic test (RDT) if they present with fever.~Children will receive malaria active case detection (ACD) using RDT and qPCR (quantitative polymerase chain reaction) three times yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive."
62504555|NCT05567016|EXPERIMENTAL|Passive Case Detection using molecular testing (PCDm)|"Children who present with fever will receive PCD using RDT and qPCR with treatment using AL if RDT or qPCR positive.~Per standard of care, children will not receive malaria ACD."
62504556|NCT05567016|ACTIVE_COMPARATOR|Standard passive case detection (PCD)|"Per standard of care, children will receive PCD using RDT.~Per standard of care, children will not receive malaria ACD."
62504557|NCT06105801|ACTIVE_COMPARATOR|EBUS-TBNA Group|The same needle gauge will be used for these participant to acquire the initial diagnosis on ROSE (either 21 or 22G). Using standard sampling techniques, the mass or LN will be penetrated with the needle as confirmed by ultrasound, and the needle will be passed back from the proximal to the distal ends of the node to obtain the samples for an adequate cell block.
62504558|NCT06105801|EXPERIMENTAL|Transbronchial Mediastinal Cryobiopsy Group|The operator will switch to a flexible, single-use, 1.1 mm cryoprobe (Erbe 20402-401, Erbe, Tübingen, Germany) for these participants to obtain cryobiopsies. The operator will introduce the probe into the working channel of the EBUS bronchoscope. The cryoprobe will then be advanced toward the puncture site and inserted gently through the previous puncture site created by the initial EBUS-TBNA needle. The operator will confirm the placement of the probe via the EBUS image, and photo capture will be done. The cryo-probe will be activated and cooled for 3 seconds before retracting with the bronchoscope with the frozen biopsy tissue attached to the tip.
62504559|NCT04290234||Non-medicated healthy adults with childhood maltreatment|The 25-item retrospective Childhood Trauma Questionnaire (CTQ) will be administered to assess history of abuse and neglect. The CTQ measures five types of maltreatment: emotional, physical, and sexual abuse and emotional and physical neglect.
62504560|NCT06676293|EXPERIMENTAL|combination therapy|The patients will receive asparaginase 10000IU/vail IM QD for three or five days, followed by pembrolizumab treatment. and Pembrolizumab 100mg in normal saline 100ml infusion over 30 minutes.
62504561|NCT06676293|PLACEBO_COMPARATOR|anti-PD1 alone|The patients will receive pembrolizumab treatment.
62504562|NCT01556867|ACTIVE_COMPARATOR|dry cord care|
61959025|NCT03746457|NO_INTERVENTION|Control ART Center|Control arm with no intervention throughout the course of the study
61959026|NCT03746457|ACTIVE_COMPARATOR|Control and Cycle 3 integrated package|Control arm in Cycles 1 and 2 and in Cycle three converts to experimental
61959027|NCT03746457|EXPERIMENTAL|GI + CA + IC|Receives one alternative sequence of three interventions
61959028|NCT03746457|EXPERIMENTAL|IC + GI + CA|Receives a second alternative sequence of three interventions
61959029|NCT03746457|EXPERIMENTAL|CA + IC + GI|Receives a third alternative sequence of three interventions
61959030|NCT01626391|EXPERIMENTAL|TRx0237|
61959031|NCT01626391|PLACEBO_COMPARATOR|Placebo|
61959032|NCT00873574||1|2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
61959033|NCT00873574||2|1 control for each family
61959034|NCT02521545|EXPERIMENTAL|BIIB061|Single oral dose of 30 mg BIIB061 of the new formulation
61959035|NCT01209559||air-Q Intubating Laryngeal Airway|
61959036|NCT01209559||LMA FastrachTM or ILMA|
61959037|NCT03072992|ACTIVE_COMPARATOR|Group A: Paclitaxel & Curcumin|75 patients, treatment with Curcumin (CUC-01, yellow solution), 300mg i.v. plus i.v. Paclitaxel (colorless solution) 80 mg /m2 BS i.e., once weekly for 12 weeks.
61959038|NCT03072992|PLACEBO_COMPARATOR|Group B: Paclitaxel & Placebo|Group B, 75 patients, treatment with Paclitaxel (colorless solution) 80 mg /m2 BS, i.v. plus placebo i.v. solution (250 ml, yellow solution for masking/blinding), once weekly for 12 weeks.
61959039|NCT06558552|OTHER|Neuromodulation of the Posterior Tibial Nerve in the Heel Spur (Epin Calcanei)|
62703130|NCT04103346|SHAM_COMPARATOR|air filtration with hepa filter removed|sham comparator uses the Holmes HAP8650B-NU-1 air purifier to be operated with the filter removed.
61959040|NCT06558552|OTHER|extracorporeal shock wave therapy (ESWT)|
61959041|NCT01148472|EXPERIMENTAL|Escitalopram|
61959042|NCT01148472|ACTIVE_COMPARATOR|Duloxetine|
62143220|NCT02374736|EXPERIMENTAL|Human normal immunoglobulin G (IgG > 98 % purity)|"All subjects will be treated for 6 months. The treatment will start the day of inclusion (M0).~Privigen will be given as 2 g/kg for 2 days/month. The maximum daily dose authorized will be 80g.~The infusion rates are the recommended rates for Privigen in other indications and are in line with the market authorization for Privigen:~* Infusions should start at a rate of 0.5 mg/kg/min (0.005 mL/kg/min; 0.3 mL/kg/h; 30 mg/kg/h). If well tolerated within 30 min, the rate can be increased in a first step to 1.0 mg/kg/min (0.01 mL/kg/min; 0.6 mL/kg/h; 60 mg/kg/h) for another 30 min.~* If well tolerated, a stepwise increase to a maximum of 8 mg/kg/min (0.08 mL/kg/min; 4.8 mL/kg/h; 480 mg/kg/h) is allowed at the discretion of the investigator."
62703131|NCT06478459|EXPERIMENTAL|CAR-NK：intratumoral injection combined with intravenous infusion|
62143221|NCT02317172|EXPERIMENTAL|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
62143222|NCT02666404|EXPERIMENTAL|Volume Resuscitation|We would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
62504563|NCT01556867|ACTIVE_COMPARATOR|antiseptic care|
62703132|NCT06273241|PLACEBO_COMPARATOR|Berberine intake in fasted condition|Intake of 1000 mg berberine in the fasted condition (intake of last meal: before 20:00 on the day before the study visit)
61959043|NCT00639678|EXPERIMENTAL|1|
61959044|NCT00639678|EXPERIMENTAL|2|
61959045|NCT00639678|PLACEBO_COMPARATOR|3|
61959046|NCT00639678|PLACEBO_COMPARATOR|4|
61959047|NCT04510012||Mild COVID-19|SARS-Cov-2 infected individuals with mild symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 1-2)
61959048|NCT04510012||Moderate COVID-19|SARS-Cov-2 infected individuals with moderate symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 3-4)
61959049|NCT04510012||Severe COVID-19|SARS-Cov-2 infected individuals with severe symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 5-8)
61959050|NCT05713175|ACTIVE_COMPARATOR|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
61959051|NCT05713175|ACTIVE_COMPARATOR|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
61959052|NCT05713175|ACTIVE_COMPARATOR|Fixtoe device|Fixtoe device, simulating the metatarsophalangeal joint stabilization tape technique . Worn for one month, prior to definitive treatment.
61959053|NCT03481907|OTHER|Internalized Control|Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.
61959054|NCT04550208||Healthy basketball or volleyball players|Basketball and volleyball players Landing biomechanics of different landing tasks is investigated in a population of volleyball and basketball players
61959055|NCT05410691|NO_INTERVENTION|Conventional|AVF/AVG cannulation by renal nurses in standardised manner
61959056|NCT05410691|ACTIVE_COMPARATOR|ultrasound guided|AVF/AVG cannulation by renal nurses by handheld US device
62504564|NCT06093204||Patients with eosinophilic esophagitis|Pediatric patients with a sure diagnosis of eosinophilic esophagitis
62703133|NCT06273241|ACTIVE_COMPARATOR|Berberine intake after a low caloric meal|Intake of 1000 mg berberine after a light caloric meal (2 toasts, butter, cheese, marmalade)
62703134|NCT06273241|ACTIVE_COMPARATOR|Berberine intake after a high caloric meal|Intake of 1000 mg berberine after a high caloric meal (2 toasts with butter, 2 fried eggs, 2 slices of bacon, 3 hash brown and 240ml of whole milk)
62703135|NCT05889182|EXPERIMENTAL|Period 1: Upadacitinib Dose A|Participants will receive Upadicitinib Dose A once daily for 16 weeks.
61959057|NCT00573612|PLACEBO_COMPARATOR|1|Telephone Call for the Attention Control Group Each AC call will follow the same format as the MI call. During the AC call, study subjects will receive health information on important topics relevant to their illness. Specifically, there will be one topic during each phone call that includes the following: (a) overview of FMS, (b) pain, (c) fatigue (d) sleep, (e) stress, and (f) living well with FMS. The AC calls will be an avenue to transfer relevant health information from the RA to the study subject. The scheduled topics during each contact will give the call face validity (i.e., establish a credible pretense for the contact) while being neutral with respect to encouragement of exercise.
61959058|NCT00573612|ACTIVE_COMPARATOR|2|Telephone-delivered Motivational Interviewing Participants will receive 6 telephone calls throughout the study. Harland et al reported that the most effective intervention for promoting exercise in the primary care setting was the most intensive treatment arm that included six MI sessions (208). Importantly, in our pilot study, participants who completed 5 to 6 phone calls achieved greater symptomatic benefits than participants who had ≤ 4 phone calls. The phone calls will be scheduled at week 3, 4, 6, 8, 10 and 12 of the study. Telephone sessions may run for 30 minutes on the average
61959059|NCT05947825|EXPERIMENTAL|Experimental: Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug: Sitagliptin Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug: Gemcitabine Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug: Nab-Paclitaxel Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
61959060|NCT01915082|EXPERIMENTAL|Azithromycin|"A first dose of azithromycin (25 mL po syrup = 1000 mg) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of azithromycin (6.25 mL = 250 mg) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
61959061|NCT01915082|PLACEBO_COMPARATOR|Ora-Plus|"A first dose of placebo (25 mL po syrup) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of placebo (6.25 mL) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
62346698|NCT02284685|EXPERIMENTAL|B (opt-out, gain, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, social norming).
62346699|NCT02284685|EXPERIMENTAL|C (opt-out, loss, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, no social norming).
62346700|NCT02284685|EXPERIMENTAL|D (opt-out, gain, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, no social norming).
62346701|NCT02284685|EXPERIMENTAL|E (opt-in, loss, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, social norming).
62346702|NCT02284685|EXPERIMENTAL|F (opt-in, gain, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, social norming).
62504565|NCT06093204||Sex and age matched healthy controls|Matched healthy controls for age and gender, without eosinophilic esophagitis
62504566|NCT00578968|EXPERIMENTAL|Tiotropium|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
62504567|NCT00578968|PLACEBO_COMPARATOR|Placebo|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
62504568|NCT00578968|NO_INTERVENTION|Healthy Controls|Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.
62703136|NCT05889182|PLACEBO_COMPARATOR|Period 1: Placebo|Participants will receive Placebo once daily for 16 weeks.
62504569|NCT03319069|EXPERIMENTAL|group (1)|Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
62504570|NCT03319069|ACTIVE_COMPARATOR|group(2)|Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
62703137|NCT05889182|EXPERIMENTAL|Period 2: Group 1 - Upadacitinib Dose A|Participants who were randomized to placebo in Period 1 who did not achieve HiSCR 50 (clinical non-responder, CNR) at Week 16 will receive Upadacitinib Dose A once daily for 20 weeks.
62703138|NCT05889182|PLACEBO_COMPARATOR|Period 2: Group 2 - Placebo|Participants who were randomized to placebo in Period 1 who achieve HiSCR 50 (clinical responder, CR) at Week 16 will continue to receive placebo once daily for 20 weeks.
62703139|NCT05889182|EXPERIMENTAL|Period 2: Group 3 - Upadacitinib Dose A|Participants who were randomized to upadacitinib Dose A in Period 1 who did not achieve HiSCR 50 (CNR) at Week 16 will continue to receive upadacitinib Dose A once daily for 20 weeks.
62703140|NCT05889182|EXPERIMENTAL|Period 2: Group 4 - Upadacitinib Dose A|Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive upadacitinib Dose A once daily for 20 weeks.
62703141|NCT05889182|EXPERIMENTAL|Period 2: Group 5 - Upadacitinib Dose B|Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive upadacitinib Dose B once daily for 20 weeks.
62703142|NCT05889182|EXPERIMENTAL|Period 2: Group 6 - Placebo|Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive placebo once daily for 20 weeks.
62703143|NCT05889182|EXPERIMENTAL|Period 3: Long-Term Extension|Eligible participants will continue to receive upadacitinib or placebo for 68 weeks. Participants will be followed-up for approximately 30 days.
61959062|NCT00966329|EXPERIMENTAL|to switch from the NNRTI/PI to maraviroc|to switch from the NNRTI/PI to maraviroc
61959063|NCT00966329|ACTIVE_COMPARATOR|to continue with the same approach|to continue with the same approach
61959064|NCT02646137|ACTIVE_COMPARATOR|Transarterial chemoembolization (TACE)|treated by transarterial chemoembolization
61959065|NCT02646137|EXPERIMENTAL|Radiofrequency ablation with TACE|Radiofrequency ablation combined with TACE
61959066|NCT02646137|EXPERIMENTAL|Microwave ablation combined with TACE|Microwave ablation combined with TACE.
61959067|NCT01371175|EXPERIMENTAL|Group A|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
61959068|NCT01371175|EXPERIMENTAL|Group B|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
61959069|NCT01371175|EXPERIMENTAL|Group C|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intradermally. Vaccine:Placebo =18/3
61959070|NCT01371175|EXPERIMENTAL|Group D|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
62703144|NCT05391893|ACTIVE_COMPARATOR|Diltiazem with oral and intravenous treatment|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg. 15 minutes following Diltiazem Infusion administer oral Diltiazem 60mg IR Tablet, do not give if BP\<100
62703145|NCT05391893|PLACEBO_COMPARATOR|traditional atrial fibrillation with rapid ventricular response|these patients will receive traditional treatments at provider discretion. To be included in teh study their initial heart rate must also be over 125, and they must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
62703146|NCT05116709|EXPERIMENTAL|BAT6005 single drug dose escalation study|"The whole is divided into two phases.The first stage: 10mg group, 30mg group, 100mg group using accelerated titration method to increase the dose.The second stage: 300mg group, 600mg group, 900mg group according to the standard 3+3 rule dose increase study."
62703147|NCT06523621|EXPERIMENTAL|Single Arm|Nivolumab
62703148|NCT01841736|EXPERIMENTAL|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT, MRI, and chest x-ray throughout the trial. Patients may optionally undergo blood sample collection during screening and on study.
62703149|NCT01841736|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I. Patients undergo ECHO or MUGA during screening. Patients also undergo CT, MRI, and chest x-ray throughout the trial. Patients may optionally undergo blood sample collection during screening and on study.
62143223|NCT05885516|PLACEBO_COMPARATOR|Single intrauterine insemination group|When the leading follicle is greater than 17 mm following ovulation induction with follicle stimulating hormone (FSH) daily injections, ovulation trigger injection will be given to the participant. 36 hours after ovulation trigger injection single intrauterine insemination with partner's sperm collected on the same day will be done.
62143224|NCT05885516|EXPERIMENTAL|Double intrauterine insemination group|When the leading follicle is greater than 17 mm following ovulation induction with follicle stimulating hormone (FSH) daily injections, ovulation trigger injection will be given to the participant. 24 and 48 hours after ovulation trigger injection intrauterine insemination will be done twice with partner's sperm collected on the specified days.
62504571|NCT01474915|ACTIVE_COMPARATOR|Aprepitant|"Aprepitant is given orally, along with an oral or PO placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy 40mg Aprepitant PO + IV placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
62703150|NCT06750094|EXPERIMENTAL|Arm A: Amivantamab + FOLFIRI|Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \[folinic acid\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
61959071|NCT01371175|EXPERIMENTAL|Group E|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
61959072|NCT01371175|EXPERIMENTAL|Group F|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
61959073|NCT01371175|EXPERIMENTAL|Group G|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
61959074|NCT01371175|EXPERIMENTAL|Groups C2/D2/E2 (Subgroups of C,D,E)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered ID, SC, or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in C2/D2/E2 = 16.
61959075|NCT01371175|EXPERIMENTAL|Group F2/G2 (Subgroup of F and G)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered either SC or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in F/G= 29.
61959076|NCT04742985|EXPERIMENTAL|Green tea combined extracts group A|This group takes Green tea combined extracts (62.5 mg) for 8 weeks.
61959077|NCT04742985|EXPERIMENTAL|Green tea combined extracts group B|This group takes Green tea combined extracts (125 mg) for 8 weeks.
62346703|NCT02284685|EXPERIMENTAL|G (opt-in, loss, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, no social norming).
62346704|NCT02284685|EXPERIMENTAL|H (opt-in, gain, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, no social norming).
62346705|NCT01313208|PLACEBO_COMPARATOR|Placebo|"Participants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks.~All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period."
62143225|NCT02263105|EXPERIMENTAL|CDDP plus Temozolomide|"Patients were treated with CDDP and TMZ. CDDP was administered iv from Day 1 to 3 with everyday dose of 30mg. TMZ was orally administered from Day 1 to 7 and Day 15 to 21, with everyday dose of 125mg/m2 (Level 2). The period of one chemotherapy cycle is 28 days. TMZ dose levels were listed in Table 1.~Table 1 TMZ dose levels Dose levels Daily TMZ dose( mg/m2/d ) TMZ dose per cycle(mg/m2)~1. 150 2100~2. 125 1750~3. 100 1400~4. 75 1050"
62143226|NCT03637036|OTHER|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
62143227|NCT03637036|OTHER|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
62143228|NCT03637036|OTHER|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
62346706|NCT01313208|EXPERIMENTAL|Etanercept|"Participants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks.~All participants continued their DMARD treatment throughout the 24-week study period."
62346707|NCT04973215||work package 1|all participants in Norwegian introduction program and their family relations
62346708|NCT04973215||work package 2|strategic sample of refugees with health problems currently participating in the introduction program
62346709|NCT04973215||work package 3|3-6 families from which one or more participate in the introduction program and one or more have health problems
62346710|NCT02726113|ACTIVE_COMPARATOR|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
62346711|NCT02726113|PLACEBO_COMPARATOR|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
62346712|NCT03172858|EXPERIMENTAL|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
62504572|NCT01474915|ACTIVE_COMPARATOR|Ondansetron|"Ondansetron is given via IV, along with an oral or IV placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication (25mg promethazine, 10mg dexamethasone, and either 4mg ondansetron or 40mg aprepitant) plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy~4mg Ondansetron IV + PO placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
62703151|NCT06750094|ACTIVE_COMPARATOR|Arm B: Cetuximab or Bevacizumab + FOLFIRI|Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
61959078|NCT04742985|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 8 weeks.
61959079|NCT04483141||non-communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (hetero-assessment of pain).
61959080|NCT04483141||communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (including hetero-assessment and auto-assessment of pain)
61959081|NCT01986283|PLACEBO_COMPARATOR|Treatment A|Placebo solution +placebo capsule + placebo capsule chewed.
62143229|NCT03637036|OTHER|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
62143230|NCT01619059|EXPERIMENTAL|Arm 1: Saxagliptin+Dapagliflozin+Metformin IR|
62346713|NCT03172858|ACTIVE_COMPARATOR|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
62346714|NCT05719051||High-dose group|Total Intravenous albumin infusion \>1.5g/kg per week while hospitalization
62504573|NCT04406194|EXPERIMENTAL|FAVICOVIR then AVIGAN|Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
62504574|NCT04406194|EXPERIMENTAL|AVIGAN then FAVICOVIR|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state.
61959082|NCT01986283|EXPERIMENTAL|Treatment B|PF-00345439 taken whole + placebo solution + placebo chewed
62346715|NCT05719051||Medium-dose group|Total Intravenous albumin infusion 1.0 to 1.5g/kg per week while hospitalization
62346716|NCT05719051||Low-dose group|Total Intravenous albumin infusion \<1.0g/kg per week while hospitalization
62346717|NCT01009983|EXPERIMENTAL|Arm 1|Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.
62346718|NCT01064076|EXPERIMENTAL|S-ICD System|This is a single arm study
62346719|NCT02779673|EXPERIMENTAL|Test group|Subjects randomized to the test group consumed yoghurt drink containing 3.4g plant stanol as ester for 1 per day for a period of 4 weeks.
62346720|NCT02779673|PLACEBO_COMPARATOR|Placebo group|Subjects randomized to the placebo group consumed yoghurt drink without plant stanol as ester for 1 per day for a period of 4 weeks.
62143231|NCT01619059|EXPERIMENTAL|Arm 2: Placebo+Dapagliflozin+Metformin IR|
62143232|NCT05576103||Primary brain tumour patients receiving RT|Primary brain tumor patients are screened at time of consultation for this observational study, and the study population is diverse across sex/gender, and racial/ethnic groups.
62143233|NCT03418545|EXPERIMENTAL|JUVÉDERM VOLBELLA® XC|JUVÉDERM® VOLBELLA™ XC injectable gel was injected into the infraorbital and adjacent area at Randomization as determined by the investigator. Participants were eligible to receive an optional touch-up treatment 1 month later and an optional repeat treatment 12 months after last treatment, if applicable. A maximum of 2.2 milliliter (mL) per side was injected for initial and touch-up treatments combined.
62346721|NCT04744636|OTHER|Healthy volunteers aged of 18-30 years|
62346722|NCT04744636|OTHER|Healthy volunteers aged of 50-59 years|
62346723|NCT04744636|OTHER|Healthy volunteers aged of 60-70 years|
62346724|NCT04744636|OTHER|Type 2 diabetic patients aged of 50-70 years|
62346725|NCT05263817|EXPERIMENTAL|POEMS Syndrome|
62346726|NCT05263817|EXPERIMENTAL|Amyloidosis|
62346727|NCT05263817|EXPERIMENTAL|Autoimmune Hemolytic Anemia|
62703152|NCT06055439|EXPERIMENTAL|Autologous CDH17 CAR T-cell Therapy|"After receiving three daily doses of IV fludarabine and cyclophosphamide, participants will receive a single dose of IV CHM-2101.~The dose of CHM-2101 during Phase 1 will be based on 3+3 rules of dose escalation.~The recommended Phase 2 dose will be based on results from the Phase 1."
61959083|NCT01986283|EXPERIMENTAL|Treatment C|PF-00345439 chewed + placebo solution + placebo taken whole
61959084|NCT01986283|ACTIVE_COMPARATOR|Treatment D|Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed
61959085|NCT01149187||IGRA in solitary pulmonary nodules|Inpatients who undergo percutaneous needle biopsy for diagnosis of pulmonary nodules in Seoul National University hospital for six months are going to be included. Patients who are not tolerable for PCNB or do not agree the enrollment of study will be excluded.
61959086|NCT04957004||OSA patients|Patients with OSA who have not been treated with CPAP
62346728|NCT05263817|EXPERIMENTAL|Vasculitis|
62346729|NCT05177822|EXPERIMENTAL|anakinra|
62346730|NCT05177822|PLACEBO_COMPARATOR|placebo|
62346731|NCT06264349|EXPERIMENTAL|Group A: frontal lessons|50 women will receive a Lifestyle Educational Intervention (LEI) from research staff regarding a correct lifestyle during pregnancy and lactation through 6 interactive online lectures lasting approximately 30 minutes each.
62346732|NCT06264349|EXPERIMENTAL|Group B: web-mobile app|50 women will receive Lifestyle Educational Intervention (LEI) from research staff regarding a correct lifestyle during pregnancy and lactation through a digital tool (web-mobile app), previously developed.
62346733|NCT06264349|NO_INTERVENTION|Control Group|50 women of the same age as the intervention group will be selected within the LIfestyle and Microbiome InTeraction) Early Adiposity Rebound in Children (LIMIT) project cohort. The LIMIT protocol is registered on clinicaltrials.gov (NCT04960670)
61959087|NCT04957004||control group|health control except OSA by using sleep monitorin
61959088|NCT03953937||ICP cohort|Patients with idiopathic pancreatitis
61959089|NCT01435369|ACTIVE_COMPARATOR|CT-011 at dose level 1 (1.5 mg/kg).|
62346734|NCT06141941|OTHER|CGM|A CGM device (Dexcom sensor and transmitter) will be placed by research personnel upon presentation to Labor and Delivery unit.
62346735|NCT05753332||The control group|the invited volunteers live in Yangzhou, Jiangsu, China (low PM2.5 level based on previous official PM2.5 records)
62346736|NCT05753332||The PM2.5 exposure group|the invited volunteers live in Xuzhou, Jiangsu, China (high PM2.5 level based on previous official PM2.5 records)
62346737|NCT03178812|ACTIVE_COMPARATOR|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
62346738|NCT03178812|ACTIVE_COMPARATOR|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
62504575|NCT03635983|EXPERIMENTAL|Combination|NKTR-214 + Nivolumab
62504576|NCT03635983|EXPERIMENTAL|Monotherapy|Nivolumab
62504577|NCT01004315|EXPERIMENTAL|KUC-7483|
62504578|NCT01004315|PLACEBO_COMPARATOR|Placebo|
62504579|NCT01004315|ACTIVE_COMPARATOR|Tolterodine|
62346739|NCT03605199|EXPERIMENTAL|Denosumab active treatment|Denosumab active treatment
62346740|NCT03583320|EXPERIMENTAL|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
62346741|NCT03583320|NO_INTERVENTION|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. \>50% stenosis in the left main (LM) coronary artery, and/or \>50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
62346742|NCT06474429||CLBP Patients|Patients who have experienced LBP for longer than three months and are undergoing physical therapy for their symptoms will be recruited from the Texas Back Institute.
62346743|NCT02493114||Patients with lung cancer|No study intervention
62346744|NCT02493114||Healthy controls|No study intervention
62346745|NCT06036134|EXPERIMENTAL|Baseline and Digital Storytelling (DST)|Once participants complete the consent, they will be asked to complete a baseline assessment using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DST arm. The intervention group participants will watch the four selected digital stories about COVID-19 vaccine experiences among Hispanic parents of children. Each story was made with voice, images, and sound (3-5 minutes each). Intervention group participants will complete the Time 2 (T2) online survey immediately after the DST intervention. Two months later, the investigators will contact all participants and ask them to complete another follow-up (T3) assessment of participants' vaccine hesitancy and COVID-19 vaccination behaviors (since T1 and T2).
62346746|NCT06036134|ACTIVE_COMPARATOR|Baseline and Control|Once participants complete the consent, they will be asked to complete a baseline assessment using the web-based data collection platform, Research Electronic Data Capture before the random assignment to control arm. Control group participants will receive a CDC COVID-19 Vaccine Information Sheet appropriate for their child's age before completing the T2 assessment. Two months later, the investigators will contact all participants and ask them to complete another follow-up (T3) assessment of participants' vaccine hesitancy and COVID-19 vaccination behaviors (since T1 and T2).
62346747|NCT05467930||Participant|Individuals who were positive for COVID-19 and visited CUIMC/ New York Presbyterian (NYP) Hospital
62346748|NCT04865185|ACTIVE_COMPARATOR|Xylocaine spray 100mg/ml|Topical application
62346749|NCT04865185|PLACEBO_COMPARATOR|Ethanol|Topical application
62346750|NCT03712800|EXPERIMENTAL|Rhythmical massage|Participants who receive rhythmical massage for three months.
62346751|NCT03712800|EXPERIMENTAL|HRV biofeedback|Participants who perform HRV biofeedback for three months.
62346752|NCT03712800|NO_INTERVENTION|Control group|Participants who do not receive an intervention during the three-month intervention period but are advised to stay with their usual care during menstrual pain. For ethical and compliance reasons, these participants receive a series of rhythmical massage treatments after the initial three-month intervention/control period.
62346753|NCT03486210||Phase 1 Group 1|Healthy volunteers
62346754|NCT03486210||Phase 1 Group 2|Health professionals
62346755|NCT03486210||Phase 2 Group 1|Control group : patients obese without surgery
62346756|NCT03486210||Phase 2 Group 2|Patients who have underwent a sleeve gastrectomy
62346757|NCT03486210||Phase 2 Group 3|Patients who have underwent a gastric bypass
62346758|NCT01991405|SHAM_COMPARATOR|Computerized Working Memory Training.|The Working Memory Training, includes both auditive and visual tasks, administrated on a computer, under guidance. 5 x 45 minutes per week, for 5 weeks. The placebo group will train at an fixed level (non-adaptive), but with otherwise identical computer programs.
62346759|NCT01178736||Cancer Screening and Diagnosis|Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
62346760|NCT02270684|EXPERIMENTAL|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
62504580|NCT04376359|EXPERIMENTAL|hyperbaric oxygen therapy|Patients with stroke will receive the hyperbaric oxygen therapy (HBOT) for 40 times, which were completed on 40 business days over a 2-month period and each session lasted 90 minutes at 100% oxygen concentration and 2 atmospheres.
62346761|NCT02270684|NO_INTERVENTION|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
62504581|NCT04376359|NO_INTERVENTION|Control|Stroke patients were not treated with HBOT except for the same routine treatment as the experimental group.
62504582|NCT05772572||Patients|Children aged 7 to 17 inclusive, and young adults operated (or re-operated) for a Moya Moya in the previous 7 years and followed at the Necker-Enfants Malades hospital, and their parents.
61959090|NCT01435369|ACTIVE_COMPARATOR|CT-011 at dose level 2 (6 mg/kg).|
61959091|NCT03228927||twin A|Sampling of the facial and fecal microbiome
62504583|NCT01489735||1|
62504584|NCT03821792|EXPERIMENTAL|Treatment (abiraterone acetate, prednisone, apalutamide)|Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
62504585|NCT06674135|EXPERIMENTAL|Introduction of Basaglar to insulin treatment regimen|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
62346762|NCT03196193|EXPERIMENTAL|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
62346763|NCT03196193|ACTIVE_COMPARATOR|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
62346764|NCT00425711|EXPERIMENTAL|DUI Court Participants|Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.
62346765|NCT01022346|PLACEBO_COMPARATOR|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
62346766|NCT01022346|EXPERIMENTAL|RO5217790|RO5217790 will be administered at a dose of 5\*10\^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
62346767|NCT02603354|ACTIVE_COMPARATOR|3x12 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 3 times of 12 minutes session for in office bleaching teeth
62346768|NCT02603354|EXPERIMENTAL|1-36 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 1 time of 36 minutes session for in office bleaching teeth
62346769|NCT00111579|ACTIVE_COMPARATOR|1|CAIV-T
62346770|NCT00111579|OTHER|2|TIV
62346771|NCT05233982|EXPERIMENTAL|OLAPARIB|
62346772|NCT05841264||children's in urban area|children's in this have good socioeconomic state, small family number, good hygiene
62346773|NCT05841264||children in rural area|children's in this have bad socioeconomic state, large family number, bad hygiene
62346774|NCT05841264||children in semi urban area|children's in this have bad socioeconomic state, small family number, bad hygiene
62346775|NCT03419221|ACTIVE_COMPARATOR|A: Patients with PET/CT performs at day 14 after the drawing|Arm A: Patients with PET/CT performs at day 14 after the drawing of the first blood culture
62346776|NCT03419221|PLACEBO_COMPARATOR|B : Patients' routine care with performance of explorations|Arm B : Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
62346777|NCT01763463||Patients with COPD who develop severe pneumonia|Patients with COPD who develop severe pneumonia
62346778|NCT01763463||Patients with COPD who do not develop severe pneumonia|Patients with COPD who do not develop severe pneumonia
62346779|NCT04828785|EXPERIMENTAL|Medically Tailored Meal (MTM)|The Medically Tailored Meal (MTM) intervention consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
62346780|NCT04828785|ACTIVE_COMPARATOR|Food Subsidy|As a comparison group, those not randomized to receive the MTM intervention will receive usual care provided by their clinicians not associated with the study, plus a food subsidy ($40/month) for 6 months, along with healthy eating information to guide use of that subsidy.
62346781|NCT00303758|ACTIVE_COMPARATOR|LV5FU2 simplifié + cisplatine puis gemcitabine si progression|LV5FU2 simplifié + cisplatine puis gemcitabine si progression
62346782|NCT00303758|EXPERIMENTAL|gemcitabine puis LV5FU2 simplifié + cisplatine si progression|gemcitabine puis LV5FU2 simplifié + cisplatine si progression
62346783|NCT01839175|EXPERIMENTAL|Group 1|
62346784|NCT01839175|ACTIVE_COMPARATOR|Group 2|
62346785|NCT01640990|EXPERIMENTAL|Cohort 1|slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg), and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg)
62346786|NCT01640990|EXPERIMENTAL|Cohort 2|Dose to be determined after analysis of Cohort 1
62346787|NCT02031822|ACTIVE_COMPARATOR|US-guided Distal GON Block (Group D)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
62346788|NCT02031822|ACTIVE_COMPARATOR|US-guided Proximal GON Block (Group P)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
62346789|NCT02260648|EXPERIMENTAL|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered PO once a day for 12 weeks.
62346790|NCT02260648|ACTIVE_COMPARATOR|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered PO once a day for 12 weeks as a reference arm.
62346791|NCT02260648|PLACEBO_COMPARATOR|Placebo|Placebo and 10 mg atorvastatin administered PO once a day for 12 weeks.
62346792|NCT04375241||Screening with Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
62346793|NCT00803543|ACTIVE_COMPARATOR|Valacyclovir|This is the arm taking Valacyclovir
62346794|NCT00803543|PLACEBO_COMPARATOR|Placebo|This is the arm taking the placebo
62346795|NCT01186718||Control Group|Control group = functional symmetric cervical motion.
62346796|NCT01186718||Experimental subject group|Experimental subject group = asymmetric cervical motion
62346797|NCT02098694|EXPERIMENTAL|Physiotherapy follow-up|Consultation at Physiotherapy-led Outpatient Clinic every 4 month.
62346798|NCT02098694|NO_INTERVENTION|Usual care|Consultation every 4 months, twice a year by rheumatologist as usual, once a year by nurse.
62346799|NCT04965376|ACTIVE_COMPARATOR|Glenohumeral joint injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
62504586|NCT05554172|EXPERIMENTAL|Vagal Nerve Stimulation (taVNS)|taVNS stimulation administered during intervention
62504587|NCT05554172|SHAM_COMPARATOR|Sham Stimulation (Sham)|Sham stimulation administered during intervention
62504588|NCT04556916|EXPERIMENTAL|Men over 40 being suspicious of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent and performing before the 1st prostate biopsy
62504589|NCT04556916|EXPERIMENTAL|Men over 40 with no suspicion of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent
62504590|NCT02562287|EXPERIMENTAL|Clozapine|Clozapine, P.O., flexible dose, for up to 6 months
62504591|NCT02562287|ACTIVE_COMPARATOR|Risperidone, olanzapine or quetiapine|Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months
62504592|NCT04217148|EXPERIMENTAL|ATRA and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and ATRA 10mg bid po, 12 consecutive weeks
62504593|NCT04217148|ACTIVE_COMPARATOR|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
62504594|NCT02252445|ACTIVE_COMPARATOR|Propofol|Propofol will be administered as the anesthetic maintenance agent.
62504595|NCT02252445|EXPERIMENTAL|Sevoflurane|Sevoflurane will be administered as the anesthetic maintenance agent.
62504596|NCT04336332|EXPERIMENTAL|Arm 1: Hydroxychloroquine Sulfate + Azithromycin|"* Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days~* Azithromycin 500 mg taken by mouth on Day 1, followed by~* Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days."
62504597|NCT04336332|EXPERIMENTAL|Arm 2: Hydroxychloroquine Sulfate alone|• Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
62504598|NCT04336332|NO_INTERVENTION|Arm 3: Placebo|"* Placebo pills Days 1-6.~* If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days"
62504599|NCT03639220|ACTIVE_COMPARATOR|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
62504600|NCT03639220|PLACEBO_COMPARATOR|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
62504601|NCT01267916|EXPERIMENTAL|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
62504602|NCT01267916|EXPERIMENTAL|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
62703153|NCT04579224|ACTIVE_COMPARATOR|Arm I (standard of care chemotherapy)|Patients receive 1 of the 4 standard of care chemotherapy regimens based on treating investigator's choice: Choice A: Patients receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Choice B: Patients receive gemcitabine IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Choice C: Patients receive paclitaxel IV on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Choice D: Patients receive sacituzumab govitecan IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI and bone scan throughout the trial. Patients also undergo blood and urine sample collection on the trial.
62703154|NCT04579224|EXPERIMENTAL|Arm II (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI and bone scan throughout the trial. Patients also undergo blood and urine sample collection on the trial. (CLOSED TO ACCRUAL)
62346800|NCT04965376|ACTIVE_COMPARATOR|Suprascapular nerve block|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
62346801|NCT04243252|EXPERIMENTAL|Intervention Food Pantries|Food pantries will complete online training to help them rank foods by nutritional value and promote those foods to pantry clients; the effect on pantries and their clients will be measured.
62346802|NCT04243252|ACTIVE_COMPARATOR|Control Food Pantries|Food pantries will continue to operate as usual during the study period; the effect on pantries and their clients will be measured.
62346803|NCT02094053|EXPERIMENTAL|E2020 3 mg|3 mg of E2020 (oral) once daily, for 24 weeks
62346804|NCT02094053|EXPERIMENTAL|E2020 5 mg|5 mg of E2020 (oral) once daily, for 24 weeks
62346805|NCT02094053|PLACEBO_COMPARATOR|Placebo|placebo (oral) once daily, for 24 weeks
62346806|NCT04503928|EXPERIMENTAL|Experimental: Kansui 1g per day x 7 days|Study participants will be given 1 g of Euphorbia kansui Pill for a total of 7 consecutive daily doses.
62346807|NCT04564326|ACTIVE_COMPARATOR|Group C|Patients will be assigned to receive opioids analgesia before spinal anesthesia in the form of intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between before positioning the patient for spinal anesthesia.
62346808|NCT04564326|EXPERIMENTAL|Group P|Patients will be assigned to receive Pericapsular Nerve Group Block (PENG Block) before positioning the patient for spinal anesthesia.
62504603|NCT01267916|EXPERIMENTAL|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
62504604|NCT01267916|EXPERIMENTAL|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
62504605|NCT01267916|EXPERIMENTAL|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
62504606|NCT01267916|EXPERIMENTAL|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
62504607|NCT06384482|EXPERIMENTAL|Single Arm|
62346809|NCT04564326|EXPERIMENTAL|Group F|Patients will be assigned to receive Fascia Iliaca Block (F.I Block) before positioning for spinal anesthesia.
62504608|NCT06388031|EXPERIMENTAL|Immunotherapy|Immune checkpoint inhibitor (anti-PD/1 or anti-PD-L1) monotherapy
62504609|NCT05920161|EXPERIMENTAL|Acute Stress|Participants complete the socially evaluated cold pressor test (SECPT), a validated laboratory-based stress induction procedure involving submerging an arm in an ice bath
62504610|NCT05920161|ACTIVE_COMPARATOR|No Stress|Participants complete a matched condition with no stress-related exposure involving submerging an arm in warm water
62504611|NCT06347926|EXPERIMENTAL|Questionnaires, scale and score|Questionnaires, numeric visual scale and clinical score
62504612|NCT01954914|EXPERIMENTAL|Plerixafor, Mozobil|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
62504613|NCT04750668|EXPERIMENTAL|Multisensory Balance Training Group|Multisensory balance training manipulate sensory inputs of vision, vestibular and proprioception.
62504614|NCT04750668|NO_INTERVENTION|Control Group|Participants in control group maintain their regular activity without any intervention.
62504615|NCT01692886|ACTIVE_COMPARATOR|7vPnC (3-, 4-, 5-, 12-Month)|
62504616|NCT01692886|EXPERIMENTAL|13vPnC (3-, 4-, 5-, 12-Month)|
62504617|NCT01692886|EXPERIMENTAL|13vPnC (2-, 4-, 6-, 12-Month)|
62504618|NCT01692886|EXPERIMENTAL|13vPnC (3-, 5-, 12-Month)|
62504619|NCT03111381|EXPERIMENTAL|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
62504620|NCT03111381|NO_INTERVENTION|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
62504621|NCT03941834|ACTIVE_COMPARATOR|BHV3000|
62504622|NCT03941834|PLACEBO_COMPARATOR|Placebo|
62504623|NCT06291090|EXPERIMENTAL|OUD intervention|Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
62504624|NCT06148779||Joint Academy|
62504625|NCT06148779||BOA|
62504626|NCT03888521|EXPERIMENTAL|Resound Relief|All participants are in the same group, and receive the same intervention - use of the Resound Relief smartphone app for 6 months
62504627|NCT02084927|EXPERIMENTAL|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
62504628|NCT02084927|OTHER|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
62504629|NCT00705315|EXPERIMENTAL|1|Bevacizumab-\>Epirubicin-\>Docetaxel
62504630|NCT00709306|PLACEBO_COMPARATOR|Education|Participants were given a packet of standard skin cancer prevention educational brochures and handouts from major professional organizations to review independently for 10-15 minutes.
62504631|NCT00709306|ACTIVE_COMPARATOR|Motivational Interviewing|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
62504632|NCT00709306|ACTIVE_COMPARATOR|UV-detect photos|"Participants were shown a regular black and white photo and a black and white UV-filtered photo of their face. Participants were told that Any dark, spotted, freckled, wrinkled, uneven, or pitted areas indicate existing underlying skin damage that is difficult to reverse. However, protecting the skin from UV radiation can prevent future damage. Participants were asked what they noticed about the photos, what their reactions were, and how this might affect their behavior. These sessions took 12 minutes on average."
62504633|NCT00709306|EXPERIMENTAL|UV-detect photos & MI|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. In addition to baseline feedback, participants were also interviewed about the black \& white and UV-filtered photos of their faces. These sessions took about 25 minutes.
62504634|NCT03370822||Study Participants|Women who have continuous fetal monitoring using the MONICA AN24 device. The MONICA AN24 is a wearable monitor with five adhesive electrodes placed on the mother's abdomen. This records the fetal heart rate, maternal heart rate and uterine contractions.
62504635|NCT04353258|EXPERIMENTAL|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
62504636|NCT04353258|ACTIVE_COMPARATOR|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
62504637|NCT05385367|OTHER|Regional anesthetic|Patients only have nerve block with or without sedation
62504638|NCT05385367|OTHER|General anesthetic|Patients only have general anesthetic
62504639|NCT05385367|OTHER|Combined general anesthetic and regional anesthetic|Patients have both general anesthetic and regional anesthetic together
62504640|NCT05683691|EXPERIMENTAL|Vanquish System Treatment|
62504641|NCT05712317|EXPERIMENTAL|Exergame Intervention|8-week exergame-based intervention consisting of 3 sessions per week lasting between 20-40 Minutes. The intervention will consist of playing the game Sphery racer in the exergame called ExerCube.
62504642|NCT05712317|ACTIVE_COMPARATOR|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise consisting of 3 sessions per week lasting between 20-40 minutes. The intervention will consist of a running exercise on a treadmill or riding on a bicycle ergometer.
62504643|NCT05044663||NASH related cACLD|NASH related cACLD (Liver Stiffness ≥10 kPa).
62504644|NCT05044663||Viral hepatitis (HBV / HCV) related cACLD|Viral hepatitis (HBV / HCV) related cACLD
62703155|NCT04579224|EXPERIMENTAL|Arm III (eribulin, gemcitabine)|Patients receive eribulin IV over 2-5 minutes and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI and bone scan throughout the trial. Patients also undergo blood and urine sample collection on the trial.
62346810|NCT04724733|NO_INTERVENTION|Control|The control group will receive incentives for study participation but will not be introduced to the Smoke Sense app.
62703156|NCT05966519||TKA with ROSA Knee|Total Knee Arthroplasty (TKA) is conducted using with robotic surgical assistant (ROSA) system
62504645|NCT04608630|ACTIVE_COMPARATOR|Denosumab|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
62504646|NCT04608630|ACTIVE_COMPARATOR|Zoledronic acid|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
62703157|NCT05894694|EXPERIMENTAL|first-line scheme + compound kushen injection|Compound Kushen injection+first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)+
62703158|NCT05894694|OTHER|first-line scheme|first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)
61959092|NCT03228927||twin B|Sampling of the facial and fecal microbiome
61959093|NCT01088997|EXPERIMENTAL|High Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
61959094|NCT01088997|EXPERIMENTAL|Low Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
61959095|NCT03626883|EXPERIMENTAL|1 hamstring|Patients will receive the intervention of 'single-bundle, single-hamstring ACL reconstruction'.
61959096|NCT03626883|ACTIVE_COMPARATOR|2 hamstrings|Patients will receive the intervention of 'single-bundle, double-hamstring ACL reconstruction'.
61959097|NCT06120998||Patients with rotator cuff tears pending for arthroscopic rotator cuff repair|"This is a Longitudinal Study. Patients were evaluated by orthopedic surgeons as having a rotator cuff tear, confirmed by magnetic resonance imaging (MRI) or ultrasound. If the patients required surgery and were willing to participate in the trial, the research assistant provided informed consent. The exclusion criteria were as follows.~1. Acromioclavicular arthritis requiring distal clavicular resection.~2. Severe glenohumeral arthritis (Hamada classification grade 3 or higher)15.~3. History of shoulder fracture.~4. Absolute contraindications to MRI, such as claustrophobia, pacemakers, neurostimulators, drug infusion pumps, artificial inner ear implants, and metallic implants."
61959098|NCT02937883|EXPERIMENTAL|empowerment intervention|Empowerment intervention
61959099|NCT02937883|NO_INTERVENTION|regular care|Regular care, care as usual
61959100|NCT04660669|OTHER|ESDM 15h|This arm receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center.
61959101|NCT04660669|OTHER|ESDM 8h + MOOC|This arm receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.
61959102|NCT04729270|EXPERIMENTAL|EXPERIMENTAL GROUP|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
62504647|NCT04608630|PLACEBO_COMPARATOR|Placebo|Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml or 5% Dextrose administered via intravenous infusion over at least 15 minutes on Day 1.
62703159|NCT06160986|EXPERIMENTAL|Horizons Group|Participants will receive the Horizons Group intervention for up to 8 weeks.
62703160|NCT06561165|EXPERIMENTAL|HD-tDCS with standard intervention|Participants will have three daily sessions.
61959103|NCT04729270|EXPERIMENTAL|CONTROL GROUP|The intervention for this group consisted of 10 sessions with Transcutaneous Electrical Nerve Stimulation (TENS) for a month.
61959104|NCT06337266||Observational|Cohort
61959105|NCT04770181|ACTIVE_COMPARATOR|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
61959106|NCT04770181|SHAM_COMPARATOR|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
61959107|NCT04390191|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP)|Patients will be given CPAP at fixed pressure of 8-10 cm water pressure for 72 hours continuously
61959108|NCT04390191|NO_INTERVENTION|Control|Patients in this arm will be not be given any intervention and will be monitored for 72 hours continuously, and then daily for a total of 14 days.
62504648|NCT01629537|OTHER|Placebo|Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.
62703161|NCT06561165|EXPERIMENTAL|Personalized dose-controlled multifocal network-targeted HD-tDCS.|Participants will have three daily sessions.
62703162|NCT03513614|ACTIVE_COMPARATOR|ALND|Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla.
62703163|NCT03513614|ACTIVE_COMPARATOR|No ALND|Tailored axillary surgery followed by regional nodal irradiation including the full axilla.
62703164|NCT06749366||Patients with Ollier disease (OD) and Maffucci syndrome (MS)|Patients with Ollier disease (OD) and Maffucci syndrome (MS).
62703165|NCT06323161|ACTIVE_COMPARATOR|CagriSema Dose 1|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.
62346811|NCT04724733|EXPERIMENTAL|Smoke Sense|
62346812|NCT04724733|ACTIVE_COMPARATOR|Smoke Sense Plus|
62346813|NCT05307445|ACTIVE_COMPARATOR|peri-implant mucositis treated with standard of care-professional mechanical debridement|patients with peri-implant mucositis are treated with standard of care, i.e. professional mechanical debridement
61959109|NCT04430218|EXPERIMENTAL|iSens|3 months trial with the iSens system
61959110|NCT04430218|NO_INTERVENTION|State of the Art Prosthesis|3 months trial with their own prosthesis.
61959111|NCT01318993|EXPERIMENTAL|GSK1605786A|500 milligrams twice daily
62504649|NCT01629537|EXPERIMENTAL|Stellate Ganglion Block (SGB)|Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.
61959112|NCT02042183|EXPERIMENTAL|Lubiprostone|Participants receive lubiprostone twice daily (BID) up to 12 weeks
61959113|NCT02042183|PLACEBO_COMPARATOR|Placebo|Participants receive placebo BID up to 12 weeks
61959114|NCT05117788||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study. The specimens will be tested with~1. Bioneer Accupower Q-FRIA assay using the Iron q-PCR instrument (investigational product)~2. Xpert MTB/RIF Ultra and Xpert MTB/XDR (comparators products)"
61959115|NCT01793896|SHAM_COMPARATOR|control period|control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
61959116|NCT01793896|EXPERIMENTAL|Diet group|Mediterranean diet prescription during 3 months
62346814|NCT05307445|EXPERIMENTAL|peri-implant mucositis treated with photobiomodulation in addition to standard treatment|patients with peri-implant mucositis are treated with photobiomodulation in addition to standard treatment
62703166|NCT06323161|ACTIVE_COMPARATOR|CagriSema Dose 2|Participants will receive once-weekly s.c injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema(cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.
61959117|NCT01793896|EXPERIMENTAL|Exercise group|Subjects will be trained 3 times a week during 3 months
61959118|NCT01793896|EXPERIMENTAL|Diet + Exercise|Both a dietary prescription plus exercise training during 3 months
61959119|NCT02621060|PLACEBO_COMPARATOR|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
61959120|NCT02621060|EXPERIMENTAL|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
61959121|NCT00303732|EXPERIMENTAL|PTK787, RAD001|PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily
61959122|NCT01154582|EXPERIMENTAL|Egg|
61959123|NCT01154582|EXPERIMENTAL|Cottage cheese|
61959124|NCT02454491|ACTIVE_COMPARATOR|standard of care|intraradial heparin (5000 UI) immediately after a 6 F sheath insertion
61959125|NCT02454491|EXPERIMENTAL|experimental therapy|intraradial verapamil (5 mg) immediately after a 6 F sheath insertion
61959126|NCT02548780|EXPERIMENTAL|Chemoembolization + Pharmacokinetics|"First cohort: Chemoembolization with Doxorubicin-loaded LifePearl™ microspheres (TACE): Escalation of dose loaded in microspheres from 75 mg to 150 mg. Pharmacokinetic testing in all patients.~Second cohort: Chemoembolization with doxorubicin-loaded LifePearl™microspheres: microspheres loaded with maximum tolerated dose as established with dose escalation arm. Pharmacokinetic testing in all patients."
61959127|NCT01131754|EXPERIMENTAL|Heparin sol 100U/L|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
61959128|NCT01131754|ACTIVE_COMPARATOR|saline|peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.
61959129|NCT02805101|EXPERIMENTAL|Biodentine|The perforation area of the root is going to be covered by Biodentine
62346815|NCT04782986|EXPERIMENTAL|Pan-intestinal capsule endoscopy|PillCam Crohn's capsule protocol
62346816|NCT04782986|ACTIVE_COMPARATOR|Conventional colonoscopy|Same-day colonoscopy under propofol sedation
62703167|NCT06323161|PLACEBO_COMPARATOR|Placebo Dose 1|Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 1 (cagrilintide and semaglutide) for 40 weeks.
62703168|NCT06323161|PLACEBO_COMPARATOR|Placebo Dose 2|Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 2 (cagrilintide and semaglutide) for 40 weeks
62703169|NCT04305431|EXPERIMENTAL|1/All Subjects|Second phase participants
62703170|NCT04360941|EXPERIMENTAL|Two-part phase 1b trial of induction palbociclib with avelumab|"Recruitment to Part A will be conducted at the Royal Marsden Hospital only. Up to 18 patients will be recruited for dose escalation of palbociclib in combination with fixed dose avelumab.~Part B will recruit at up to 8 high volume centres. Up to 27 patients will be recruited to treatment with the maximum tolerated dose and schedule established in part A. In Part B of the study, additional selection by triple negative histology and positive androgen receptor status will define the study population."
61959130|NCT02805101|ACTIVE_COMPARATOR|MTA|The perforation area of the root is going to be covered by MTA.
61959131|NCT02749071|SHAM_COMPARATOR|Control Group|This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.
61959132|NCT02749071|EXPERIMENTAL|Treatment Group|The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
61959133|NCT00825578|ACTIVE_COMPARATOR|1|Upper-lobe predominant emphysema
61959134|NCT00825578|ACTIVE_COMPARATOR|2|Non-upper lobe predominant emphysema
61959135|NCT02349321|EXPERIMENTAL|School Strengthening|Skhokho Supporting Success for Schools: (a) Full year Grade 8 Life Orientation Learner Workbook (following the national curriculum), Educator Guide, and LO Educator support workshops; (b) Educator workshops including values, positive discipline skills, adolescent development, and stress and coping; (c) Learner club workshops (Grade 8s-11s) including creating change for a safe and vibrant school community, human rights at school, communication and conflict resolution skills, and stress and coping.
62143234|NCT03418545|NO_INTERVENTION|No-treatment Control|Participants randomized to the No-treatment Control group completed a 3-month No-treatment Period. Participants were then eligible to receive optional treatment with JUVÉDERM® VOLBELLA™ XC injectable gel injected into the infraorbital and adjacent area followed by an optional touch-up treatment 1 month later.
62346817|NCT04914377|EXPERIMENTAL|Active Drug|Capsules containing TQ Formula
62346818|NCT04914377|PLACEBO_COMPARATOR|Placebo|Capsules containing corn oil
62346819|NCT00928356|EXPERIMENTAL|Hybrid CABG/PCI|Patients undergo hybrid, same sitting CABG/PCI as described.
62346820|NCT00928356|OTHER|Off-pump CABG|Standard of Care Off Pump CABG
62346821|NCT03430583||MZ101|Dosing per treatment regimen
61959136|NCT02349321|EXPERIMENTAL|School + Family Strengthening|"Skhokho Supporting Success for Schools: See description above.~Skhokho Supporting Success for Families: Participatory four-day workshop for parents/caregivers and their young adolescent children including parallel and joint dialogue sessions. This workshop aims to promote supportive, open relationships between parents/caregivers and their teens and includes communication, negotiation and conflict resolution skills; positive discipline skills; challenging traditional gender constructions; understanding the impact of child abuse; stress and coping."
62504650|NCT03298516|EXPERIMENTAL|Arm A: DCLL9718S|Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
62504651|NCT03298516|EXPERIMENTAL|Arm B: DCLL9718S and Azacitidine|Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m\^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m\^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
61959137|NCT02349321|NO_INTERVENTION|Arm 3: Control (Delayed Intervention)|"This group will continue with treatment as usual (i.e: school services, activities, and textbooks without specialised intervention). At the end of primary data collection, these schools will be eligible to receive the Schools Strengthening Intervention."
61959138|NCT04982809|ACTIVE_COMPARATOR|Betamethasone group|
61959139|NCT04982809|ACTIVE_COMPARATOR|Dexamethasone group|
62143235|NCT01217866||LAVH, techniques|Women aged 35-75 who underwent laparoscopic assisted vaginal hysterectomy via either suture technique vaginally or Enseal coagulation cutting device vaginally
62143236|NCT01450007|EXPERIMENTAL|Dexamethasone block|Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
62143237|NCT01450007|ACTIVE_COMPARATOR|Dexamethasone IV|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
62143238|NCT01450007|PLACEBO_COMPARATOR|Placebo|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline
62346822|NCT01678716|ACTIVE_COMPARATOR|Essential Health Care (EHC) only|This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
62346823|NCT01678716|EXPERIMENTAL|EHC + Micronutrient Powders|This arm will be based on the EHC platform but will also include EHC platform health workers promoting and selling the micronutrient powders.
62346824|NCT01678716|EXPERIMENTAL|EHC + BCC|This arm will have a behavior chance communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
62504652|NCT01136928|EXPERIMENTAL|American ginseng and efavirenz|This is a sequential study. Healthy volunteers will receive efavirenz alone for 14 days followed by efavirenz plus American ginseng for an additional 14 days.
62703171|NCT05999799|EXPERIMENTAL|GSK1070806 Dose 1|Participants will receive GSK1070806 dose 1.
62703172|NCT05999799|EXPERIMENTAL|GSK1070806 Dose 2|Participants will receive GSK1070806 dose 2.
62703173|NCT05999799|EXPERIMENTAL|GSK1070806 Dose 3|Participants will receive GSK1070806 dose 3.
62346825|NCT01678716|EXPERIMENTAL|EHC + BCC + Micronutrient powders|This arm will contain both the behavior change communication and the micronutrient powder sales intervention.
62346826|NCT06412419||Low-grade intraepithelial neoplasia of esophageal squamous epithelium|
62346827|NCT06412419||High-grade intraepithelial neoplasia of esophageal squamous epithelium|
62346828|NCT06412419||Stage T1a esophageal squamous cell carcinoma|
62346829|NCT06412419||Stage T1b esophageal squamous cell carcinoma|
62346830|NCT03624218|NO_INTERVENTION|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
62504653|NCT06555263|EXPERIMENTAL|Luveltamab tazevibulin|"4.3 mg/kg q3w~Eligible subjects with stable disease (SD) may escalate to 5.2 mg/kg q3w after Cycle 4, with Sponsor approval."
62504654|NCT03702634|NO_INTERVENTION|Control (Usual Care)|Surrogate will receive usual care in the hospital, which could include visits from the unit chaplain or other staff from the spiritual care department.
62504655|NCT03702634|EXPERIMENTAL|Intervention|Spiritual Care Assessment and Intervention (SCAI) framework
62703174|NCT05999799|EXPERIMENTAL|GSK1070806 Dose 4|Participants will receive GSK1070806 dose 4.
62703175|NCT05999799|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62703176|NCT00601900|EXPERIMENTAL|Arm I (endocrine therapy with monoclonal antibody)|Patients receive endocrine therapy\* (tamoxifen citrate\* or letrozole) PO QD on days 1-21 and bevacizumab 15 mg/kg IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
61959140|NCT04982809|ACTIVE_COMPARATOR|Prednisolone group|
61959141|NCT05979870||Aortic valve disease-operation|"Surgery of the aortic valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment."
61959142|NCT05979870||Aortic valve disease-intervention|"Interventional treatment of the aortic valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment."
61959143|NCT05979870||Pulmonary valve disease-operation|"Surgery of the pulmonary valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment."
62703177|NCT00601900|ACTIVE_COMPARATOR|Arm II (endocrine therapy)|Patients receive endocrine therapy\* (tamoxifen citrate\* or letrozole) PO QD on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62703178|NCT05161481|EXPERIMENTAL|Avenciguat (BI 685509), dose group 1|
61959144|NCT05979870||Pulmonary valve disease-intervention|"Interventional treatment of the pulmonary valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment"
61959145|NCT03303365|EXPERIMENTAL|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
61959146|NCT03303365|ACTIVE_COMPARATOR|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
61959147|NCT06242158||Case with massive rotator cuff tear|Case with massive rotator cuff tear defined as more than 2 complete tendon tear that is repairable
62143239|NCT03491566|EXPERIMENTAL|Clinic Pilates Group|Initial assessments of participants were made and they were taught key components of the Clinical Pilates exercises. Exercises were administered for 4 weeks, 3 days/week, 40-50 minutes/session under the supervision of a physiotherapist. Groups of 9-10 people with similar physical characteristics and fitness level for session times were created. The sessions were started with level 1 exercises requiring more support and less control. Each exercise was repeated 8-10 times; as the physical level of the participants increased, exercises progressed towards level 3 exercises requiring more attention, concentration and control. Each session consisted of an average of 10 minutes warm-up, 20 to 30 minutes of matt and 10 minutes cooling of of Clinical Pilates exercises.
62143240|NCT03491566|EXPERIMENTAL|Aerobic Exercise Group|"Initial assessments of participants were made before the first session. Using an elliptical bicycle or bicycle, or treadmill under the supervision of a physiotherapist, a total of 150 minutes moderate intensity (50-70% of maximal heart rate (HRmax)) aerobic exercise in accordance with the World Health Organization's guideline was applied, 3 days/week (50 mins/session) or 5 days/week (30 mins /session) for 4 weeks. The instruments to be used for the exercises were chosen according to the preference of the individual. HRmax was calculated using the 220-years. For example; at the age of 20 years, the target heart rate was determined as 100-140 beats/min for moderate physical activity in a person with HRmax 200 beats/min."
62504656|NCT06675890||patients having coronary arterial disease.|patients with different types of coronary arterial disease and their homocysteine levels.
62504657|NCT03825367|OTHER|Open label design|Nivolumab and 5-azacytidine,
62703179|NCT05161481|EXPERIMENTAL|Avenciguat (BI 685509), dose group 2|
62703180|NCT05161481|PLACEBO_COMPARATOR|Placebo|Placebo
62703181|NCT02752035|EXPERIMENTAL|Dose escalation of ASP2215 given with azacitidine|Subjects will be treated with ASP2215 daily (days 1-28) and azacitidine daily for 7 days (days 1-7).
62703182|NCT02752035|EXPERIMENTAL|Arm A: ASP2215|Subjects will be treated daily each 28-day cycle.
62703183|NCT02752035|EXPERIMENTAL|Arm AC: ASP2215 + azacitidine|Subjects will be treated with ASP2215 daily and azacitidine daily for 7 days (days 1-7) each 28-day cycle.
62703184|NCT02752035|ACTIVE_COMPARATOR|Arm C: azacitidine|Subjects will be treated with azacitidine for 7 days (days 1-7) each 28-day cycle.
62703185|NCT03667196||Observational|
61959148|NCT05214495|EXPERIMENTAL|Topical oral Omega-3 hydrogel group|Patients will be given topical oral Omega-3 hydrogel
61959149|NCT05214495|ACTIVE_COMPARATOR|Conventional preventive treatment group|Patients will be given conventional preventive treatment
61959150|NCT01434030|OTHER|Behavioral Observer|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
61959151|NCT01599845||Nanoparticle exposed|
61959152|NCT04742010|EXPERIMENTAL|Zoledronic Acid|Active treatment
61959153|NCT04742010|PLACEBO_COMPARATOR|Placebo|Placebo
61959154|NCT03597776|EXPERIMENTAL|Lidocaine Group|Bolus of intravenous lidocaine of 2mg/kg over 5 mins will be given before skin incision.
61959155|NCT03597776|PLACEBO_COMPARATOR|Placebo Group|Normal Saline of 2mg/kg over 5 mins will be given as bolus before skin incision
61959156|NCT01402414|ACTIVE_COMPARATOR|NB-UVB|NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
61959157|NCT01402414|ACTIVE_COMPARATOR|Bath-PUVA|Phototherapy with UVA irradiation following bathing in psoralen water
61959158|NCT01402414|ACTIVE_COMPARATOR|NB-UVB plus salt water baths|Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths
61959159|NCT05410483|EXPERIMENTAL|Docetaxel dose level|Initial dose of 60mg/m2 and increase the remaining dose gradient by 5 mg/m2
61959160|NCT06298383|EXPERIMENTAL|Trypsin, Bromelain and Rutoside (TBR) Group|patients will receive Trypsin, Bromelain and Rutoside combination (2 tablets of flamogen a combination of Trypsin 48mg, Bromelain 90mg and Rutoside 100mg) as a single oral dose 1 hour before treatment.
61959161|NCT06298383|ACTIVE_COMPARATOR|NSAIDs Group|Patients will receive diclofenac potassium (50mg) as a single oral dose 1 hour before treatment.
61959162|NCT06298383|ACTIVE_COMPARATOR|Steroid Group|Patients will receive a single oral dose of a steroid drug (30 mg prednisolone) 1 hour before treatment.
62703186|NCT05827926|EXPERIMENTAL|Part 1 Cohort A2: mRNA-1083.1 Dose B|Participants will receive single intramuscular (IM) injection of mRNA-1083.1 at Dose Level B on Day 1.
62703187|NCT05827926|EXPERIMENTAL|Part 1 Cohort A3: mRNA-1083.1 Dose C|Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.
62703188|NCT05827926|EXPERIMENTAL|Part 1 Cohort A4: mRNA-1083.2 Dose A|Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.
62703189|NCT05827926|EXPERIMENTAL|Part 1 Cohort A5: mRNA-1083.2 Dose B|Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.
62504658|NCT06321354|EXPERIMENTAL|The diprospan plus ropivacaine group|Patients in the diprospan plus ropivacaine group will receive a peri-incisional scalp infiltration with 15ml diprospan and 15mg of 1% ropivacaine and normal saline miscible liquids.
62504659|NCT06321354|ACTIVE_COMPARATOR|The ropivacaine group|Patients in the ropivacaine group will receive a peri-incisional scalp infiltration with 15mg of 1%
62504660|NCT02148445|ACTIVE_COMPARATOR|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
62504661|NCT02148445|EXPERIMENTAL|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
62504662|NCT05249972|EXPERIMENTAL|AKP02|cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
62504663|NCT05249972|ACTIVE_COMPARATOR|Enstilar|cutaneous foam (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
62504664|NCT05249972|PLACEBO_COMPARATOR|Placebo|cutaneous spray
62504665|NCT02263417|ACTIVE_COMPARATOR|Deep Brain Stimulation|Stimulation is on
62504666|NCT02263417|SHAM_COMPARATOR|Placebo|Stimulation is off
62504667|NCT06614907|EXPERIMENTAL|QL2108 injection|QL2108 injection; 300mg/2.0mL; subcutaneous injection
62504668|NCT06614907|ACTIVE_COMPARATOR|Dupixent®|Dupixent®; 300mg/2.0mL; subcutaneous injection
62504669|NCT00545688|EXPERIMENTAL|1|
62504670|NCT00545688|EXPERIMENTAL|2|
62504671|NCT00545688|EXPERIMENTAL|3|
62504672|NCT00545688|EXPERIMENTAL|4|
62703190|NCT05827926|EXPERIMENTAL|Part 1 Cohort A6: mRNA-1083.2 Dose C|Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.
62703191|NCT05827926|EXPERIMENTAL|Part 1 Cohort A7: mRNA-1083.3|Participants will receive single IM injection of mRNA-1083.3 on Day 1.
62703192|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort A8: Investigational Influenza Vaccine 1|Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.
62703193|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort A9: Investigational COVID-19 Vaccine 1|Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.
62703194|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort A10: COVID-19 Vaccine 1|Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.
62703195|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort A11: Investigational Influenza Vaccine 2|Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.
61959163|NCT06298383|PLACEBO_COMPARATOR|Placebo group|Patients will receive a single oral dose of placebo (compressed tablets of powdered milk) 1 hour before treatment
62504673|NCT02872350|EXPERIMENTAL|Premature with necrotizing enterocolitis|
62504674|NCT00400062||ICU survivors|The investigators will measure the independent contribution of risk factors such as delirium and exposure to sedative and analgesic medications to the incidence of long-term CI.
62504675|NCT01884064|EXPERIMENTAL|inhibitory rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
62504676|NCT01884064|PLACEBO_COMPARATOR|Sham rTMS|Sham Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
62504677|NCT01996423|EXPERIMENTAL|Vitamin D3 supplementation|Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
62504678|NCT01996423|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
62504679|NCT03471988|EXPERIMENTAL|AK1820|Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
62504680|NCT03471988|ACTIVE_COMPARATOR|Voriconazole|Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.
62504681|NCT06678750|ACTIVE_COMPARATOR|Comparison Group: TKA patients whose surgery was conducted with traditional, manual instrumentation|The comparison groups includes TKA patients whose surgery is conducted using traditional, manual, non-navigated instrumentation.
62504682|NCT06678750|EXPERIMENTAL|Intervention Group: Patients whose TKA surgery was conducted using Exactech GPS navigation|The intervention group will include TKA patients whose surgery is conducted with a tibia first gap balancing surgical workflow using the NewtonTM Knee Protocol and navigation-assistance (ExachtechGPS®).
62504683|NCT00378027||Stable Acute Pulmonary Embolism|Administer weight dosed Fondaparinux
62504684|NCT01940263|PLACEBO_COMPARATOR|Placebo|placebo 320 mg daily for twelve weeks
62504685|NCT01940263|EXPERIMENTAL|Anthocyanin|Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.
62504686|NCT06274424|EXPERIMENTAL|Group Cognitive Behavioral Therapy Intervention|The Friends Program
62504687|NCT04226339|EXPERIMENTAL|total knee arthroplasty with a kinetic alignment|
62504688|NCT04226339|ACTIVE_COMPARATOR|total knee arthroplasty with a mechanical alignment|
62703196|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort A12: Influenza Vaccine 1|Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.
62703197|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort A13: Influenza Vaccine 2|Participants will receive single IM injection of Influenza Vaccine 2 on Day 1.
62703198|NCT05827926|EXPERIMENTAL|Part 1 Cohort B1: mRNA-1083.1 Dose A|Participants will receive single IM injection of mRNA-1083.1 at Dose Level A on Day 1.
62703199|NCT05827926|EXPERIMENTAL|Part 1 Cohort B2: mRNA-1083.1 Dose B|Participants will receive single IM injection of mRNA-1083.1 at Dose Level B on Day 1.
62504689|NCT05284084|PLACEBO_COMPARATOR|Negative Control|Matched subjects by age, sex and BMI with no BA events, from a pool of 20,032 admission (01JAN2010 to 31DEC2019).
62504690|NCT05284084|ACTIVE_COMPARATOR|Positive Control|Matched subjects by age, sex and BMI with BA events, from a pool of 20,032 admission (01JAN2010 to 31DEC2019).
62504691|NCT05284084|EXPERIMENTAL|Experimental group|"Consecutive subjects admitted to the ICU (these subjects will be matched with historical controls with and without BA events) from 30MAR2021 to 30MAR2022 on three subgroups:~* Head up from the bed 15 degrees + H2 blockers + mouth wash BID~* Head up from the bed 30 degrees + H2 blockers + mouth wash BID~* Head up from the bed 45 degrees + H2 blockers + mouth wash BID"
61959164|NCT05185193|EXPERIMENTAL|radiofrequency stimulation|Participants received radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
61959165|NCT05185193|SHAM_COMPARATOR|sham stimulation|Participants received a sham stimulation similar to a radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
61959166|NCT01269463|EXPERIMENTAL|Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule)|"Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Placebo: Capsule without active drug for 1 week Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Dosed once daily in the morning"
61959167|NCT01269463|EXPERIMENTAL|Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo)|"Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Placebo: Capsule without active drug for 1 week Dosed once daily in the morning"
61959168|NCT03220178|EXPERIMENTAL|CANKADO active|CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
61959169|NCT03220178|OTHER|CANKADO inform|CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
62143241|NCT05770609|EXPERIMENTAL|SPH3127 Tablets with Dose A|Oral daily dose of SPH3127 Tablets for up to 8 weeks
61959170|NCT00867724|EXPERIMENTAL|Aer-O-Scope Colonoscopy|Screening Colonoscopy
62143242|NCT05770609|EXPERIMENTAL|SPH3127 Tablets with Dose B|Oral daily dose of SPH3127 Tablets for up to 8 weeks
62143243|NCT05770609|PLACEBO_COMPARATOR|SPH3127 Tablets placebo|Oral daily dose of SPH3127 Tablets placebo for up to 8 weeks
62143244|NCT04160559|PLACEBO_COMPARATOR|Control group|chemotherapy plus water
62504692|NCT05683860|EXPERIMENTAL|Experimental: WVE-004 (Dose A)|
62504693|NCT06494397|EXPERIMENTAL|Sequence A: VHX-896 then iloperidone|
62703200|NCT05827926|EXPERIMENTAL|Part 1 Cohort B3: mRNA-1083.1 Dose C|Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.
61959171|NCT01412320|EXPERIMENTAL|Flavanol rich cocoa|
61959172|NCT01412320|EXPERIMENTAL|Flavanol poor|
61959173|NCT06557460|EXPERIMENTAL|Active treatment group receiving the CPCB-RPE1 implant (up to 18 subjects).|Active treatment group receiving the CPCB-RPE1 implant (up to 18 subjects).
61959174|NCT06557460|SHAM_COMPARATOR|"Control group receiving a simulated sham implantation procedure (up to 6 subjects)"|"Control group receiving a simulated sham implantation procedure (up to 6 subjects)"
61959175|NCT04195087||Non-hypotension|Patients with a mean arterial pressure reduction of less than 20% and/or systolic arterial pressure above 80 mmHg after spinal anesthesia.
61959176|NCT04195087||Hypotension|Patients with a 20% reduction in mean arterial pressure and/or systolic arterial pressure below 80 mmHg after spinal anesthesia.
61959177|NCT02359760|EXPERIMENTAL|Piezocision group|The experimental group will consist of 14 adults, subjects from 18 to 40 years-old (10 women, 4 men).
61959178|NCT02359760|NO_INTERVENTION|conventional orthodontics|The control group will consist of 30 matched patients with the same inclusion and exclusion criteria, who have been already treated by conventional orthodontics in the orthodontic clinic of the University of Montreal.
62143245|NCT04160559|EXPERIMENTAL|Test group|chemotherapy plus green tea
62143246|NCT00128973||Healthy Volunteers|Healthy adult M/F 18-85 y/o.Hgb\>=11.Wt\>110 lbs. No heart,lung,kidney,bleeding disorders. No hep BorC since age 11. No IV drug use. No exposure to the AIDS virus. Not pregnant.
62143247|NCT00128973||Patients|Patients with abnormalities of immune function
62143248|NCT00128973||Relatives of Patient:|Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and first cousins to a patient.
62143249|NCT05611385||Positive for Amphetamine|Patients admitted to the burn unit that are positive for amphetamine
62143250|NCT05611385||Negative for Amphetamine|Patients admitted to the burn unit that are negative for amphetamine
62504694|NCT06494397|EXPERIMENTAL|Sequence B: Iloperidone then VHX-896|
62504695|NCT01418950|ACTIVE_COMPARATOR|Control group|The control group will receive standard verbal counseling regarding outcome of premature infants
62504696|NCT01418950|EXPERIMENTAL|Study Group|Study Group will receive gestational age specific written information prior to receiving standard verbal counseling about outcome of premature infants.
62504697|NCT03139240|EXPERIMENTAL|Gestational age <7 weeks|Women with a gestational age \<7 weeks will be randomized to oxycodone 10mg oral vs placebo
62703201|NCT05827926|EXPERIMENTAL|Part 1 Cohort B4: mRNA-1083.2 Dose A|Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.
61959179|NCT05975892|EXPERIMENTAL|Allogeneic MSCs transplantation in periodontal disease|Allogeneic MSC harvested and cultured in osteogenic medium are seeded on collagen scaffold, mixed with autologous platelet rich plasma clot. The MSCs construct (MSCs/Coll/PRP clot) is implanted in the bone defect.
61959180|NCT05190159||Monster Screw System|
61959181|NCT00672243|EXPERIMENTAL|Erlotinib + Sirolimus|Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
61959182|NCT00880009|EXPERIMENTAL|1|Combination of Bosutinib and Letrozole
62346831|NCT03624218|EXPERIMENTAL|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
62346832|NCT06315205|EXPERIMENTAL|Cohort 1: Letrozol LEBE 75 mg|
62703202|NCT05827926|EXPERIMENTAL|Part 1 Cohort B5: mRNA-1083.2 Dose B|Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.
62703203|NCT05827926|EXPERIMENTAL|Part 1 Cohort B6: mRNA-1083.2 Dose C|Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.
62703204|NCT05827926|EXPERIMENTAL|Part 1 Cohort B7: mRNA-1083.3|Participants will receive single IM injection of mRNA-1083.3 on Day 1.
62703205|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort B8: Investigational Influenza Vaccine 1|Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.
62703206|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort B9: Investigational COVID-19 Vaccine 1|Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.
62346833|NCT06315205|EXPERIMENTAL|Cohort 2: Letrozol LEBE 150 mg|
62346834|NCT06315205|EXPERIMENTAL|Cohort 3: Letrozol LEBE 225 mg|
62504698|NCT03139240|EXPERIMENTAL|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
62703207|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort B10: COVID-19 Vaccine 1|Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.
62703208|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort B11: Investigational Influenza Vaccine 2|Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.
62703209|NCT05827926|ACTIVE_COMPARATOR|Part 1 Cohort B12: Influenza Vaccine 1|Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.
62703210|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 1 Dose A|Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level A on Day 1.
62703211|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 2 Dose A|Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level A on Day 1.
62703212|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 1 Dose B|Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level B on Day 1.
62703213|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 2 Dose B|Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level B on Day 1.
62703214|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 1 Dose C|Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level C on Day 1.
62703215|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 2 Dose C|Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level C on Day 1.
62703216|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 1 Dose D|Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level D on Day 1.
61959183|NCT00880009|ACTIVE_COMPARATOR|2|Letrozole
62143251|NCT03510195|EXPERIMENTAL|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
62346835|NCT04282057|EXPERIMENTAL|shockwave therapy group|This group performed aerobic exercise just after shock wave therapy in the abdominal region.
62346836|NCT04282057|EXPERIMENTAL|radiofrequency group|This group performed aerobic exercise just after radiofrequency in the abdominal region.
62346837|NCT04282057|ACTIVE_COMPARATOR|control group|This group only performed aerobic exercise.
62504699|NCT03770793|EXPERIMENTAL|Lung-sono guided|Before starting one-lung ventilation, alveolar recruitment is performed under the examination with ultrasound. Find the minimal airway pressure that actually starts to resolve the observed atelectasis. Repeat alveolar recruitment with the minimal pressure untill the atlelectasis is not visible.
62504700|NCT03770793|NO_INTERVENTION|Conventional|Before starting one-lung ventilation, alveolar recruitment is performed with the pressure of 30mmHg for 10 seconds which is a conventional method.
62703217|NCT05827926|EXPERIMENTAL|Part 2: mRNA-1083 Composition 2 Dose D|Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level D on Day 1.
62703218|NCT05827926|ACTIVE_COMPARATOR|Part 2: Investigational Influenza Vaccine 1 Dose A|Participants will receive single IM injection of Investigational Influenza Vaccine 1 at Dose Level A on Day 1.
62703219|NCT05827926|ACTIVE_COMPARATOR|Part 2: Investigational Influenza Vaccine 1 Dose B|Participants will receive single IM injection of Investigational Influenza Vaccine 1 at Dose Level B on Day 1.
62703220|NCT05827926|ACTIVE_COMPARATOR|Part 2: Investigational COVID-19 Vaccine 2|Participants will receive single IM injection of Investigational COVID-19 Vaccine 2 on Day 1.
62703221|NCT05827926|ACTIVE_COMPARATOR|Part 2: COVID-19 Vaccine 2|Participants will receive single IM injection of COVID-19 Vaccine 2 on Day 1.
61959184|NCT01691209|EXPERIMENTAL|Phoenix|Application over 29 days twice daily
61959185|NCT01691209|ACTIVE_COMPARATOR|Hydrocortison|Application over 29 days twice daily
61959186|NCT01691209|NO_INTERVENTION|Untreated skin|Participants will be observed over 29 days without study treatment
61959187|NCT04309539|ACTIVE_COMPARATOR|Fascia iliaca block|Patients will receive Fascia iliaca block
61959188|NCT04309539|ACTIVE_COMPARATOR|combined LFCN block with PENG block|Patients will receive a combined lateral femoral cutaneous nerve block with pericapsular nerve group block
61959189|NCT02403492|NO_INTERVENTION|Observational (No OSAS)|Comprised of obese children are not found to have obstructive sleep apnea and do not require cPAP
61959190|NCT02403492|EXPERIMENTAL|Experimental - cPAP, Continuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who continue using cPAP during the 2 week RCT
62504701|NCT01889472|ACTIVE_COMPARATOR|oro-nasal mask|Oro-nasal mask during 1 month of auto CPAP
62504702|NCT01889472|EXPERIMENTAL|Nasal mask and oral appliance|Nasal mask and oral appliance during 1 month of auto CPAP
62504703|NCT02615184|EXPERIMENTAL|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 weeks.
62504704|NCT02615184|EXPERIMENTAL|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 weeks.
62504705|NCT02615184|EXPERIMENTAL|Maintenance of Healed EE: Dexlansoprazole 30 mg|Participants on Dexlansoprazole 60 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
62504706|NCT02615184|EXPERIMENTAL|Maintenance of Healed EE: Dexlansoprazole 15 mg|Participants on Dexlansoprazole 30 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
61959191|NCT02403492|EXPERIMENTAL|Experimental - cPAP Discontinuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who discontinue using cPAP during the 2 week RCT
61959192|NCT03550456||ECC, ECC with CLE, speech therapy|"After the standard diagnostic (spirometry, body plethysmography, exhaled NO, skin prick test) all patients with dyspnea while exercising undergo exercise challenges in a cold chamber (ECC).~In case of a positive reaction in the ECC the patients get asthma medication (ICS/LABA combination).~Both groups negative and positive should fill out a symptom diary and the next visit will be booked 6 weeks later.~If they still have dyspnea while exercising with ICS/LABA combination or hat a negative ECC the patients undergo an ECC with continuous laryngoscopy. In case of an EILO diagnosis patients will be sent to speech therapy and checked at a follow up visit.~All patients and their parents should complete questionnaires for symptoms and quality of life at every visit."
62504707|NCT05535660||LGA neonates|Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates.
62504708|NCT05535660||non-LGA neonates|Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates.
62504709|NCT02106533|EXPERIMENTAL|Group 1 peak VO2 <17.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP.
62504710|NCT02106533|EXPERIMENTAL|Group 2 peak VO2 > 17.5 < 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
62504711|NCT02106533|EXPERIMENTAL|Group 3 peak VO2 > 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill . Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
62504712|NCT00830167|PLACEBO_COMPARATOR|Placebo|
62504713|NCT00830167|EXPERIMENTAL|Pregabalin|
62504714|NCT03631173|ACTIVE_COMPARATOR|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
62504715|NCT03631173|NO_INTERVENTION|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
61959193|NCT01351922||A|
61959194|NCT06241833||PPI group|Patients receiving PPI concomitant with dual antiplatelet therapy after PCI for AMI
61959195|NCT06241833||no PPI group|Patients receiving dual antiplatelet therapy only after PCI for AMI
62504716|NCT01114997|ACTIVE_COMPARATOR|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
62504717|NCT01114997|ACTIVE_COMPARATOR|Esmolol|Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min
62504718|NCT01114997|EXPERIMENTAL|Lidocaine + Esmolol (Combo)|"Performed with the administration of both drugs.~Pre-induction:~Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)~Post-induction:~Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
62504719|NCT01876953|EXPERIMENTAL|Dasatinib 100mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
62703222|NCT05827926|ACTIVE_COMPARATOR|Part 2: Influenza Vaccine 1|Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.
62703223|NCT03056040|EXPERIMENTAL|Ravulizumab|"On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 4 years."
61959196|NCT04177797|EXPERIMENTAL|Toripalimb|Single arm, non randomized, open label study.The patients will receive Toripalimb concurrently caboplatin and paclitaxel treatment.
61959197|NCT06066983|EXPERIMENTAL|Treatment|Parent-child dyads will receive DINOSAUR, a group-based cognitive-behavioral therapy (CBT) intervention, adapted for young children and delivered via telehealth. This 14 week intervention teaches parents and children strategies to reduce anxiety and intolerance of uncertainty, an underlying construct of anxiety.
62504720|NCT01876953|EXPERIMENTAL|Dasatinib 140mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
62504721|NCT01007019|EXPERIMENTAL|YH4808 30mg|"1.Single dose~2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62143252|NCT06067776|EXPERIMENTAL|Treatment (tucatinib, osimertinib, cetuximab)|Patients receive tucatinib 200mg orally BID, osimertinib 80mg orally daily, and cetuximab 250mg/m\^2 IV every 2 weeks of a 28-day cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62143253|NCT04105387|NO_INTERVENTION|Control Group|Tracheostomy change at day 7
62703224|NCT03056040|ACTIVE_COMPARATOR|Eculizumab|"Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 4 years."
61959198|NCT06066983|ACTIVE_COMPARATOR|Active Control|Parents in the active control condition will participate in three psychoeducational groups focused on presenting information regarding anxiety prevalence, differentiating anxiety from autism, and anxiety triggers. These groups will be delivered via telehealth across a 14-week period.
61959199|NCT05288244|EXPERIMENTAL|foot bath|"It will be applied to the patients in group A (foot bath) every evening between 21.00-21.20 for 14 days. The steps of the procedure are as follows:~* To be used in the footbath, a footbath tub, water at 38-40°C, a thermometer to measure the temperature of the water, foot towels, clean socks, gloves are prepared.~* With the water temperature adjustment button in the foot bath tub, wait until the temperature of the water reaches 38-40 °C~* Between 21:00 and 21:20, the feet are kept in water with a constant temperature of 38-40 °C for 20 minutes. (While the process is in progress, the water temperature is checked intermittently with a laser thermometer.)"
62143254|NCT04105387|EXPERIMENTAL|Treatment Group|Tracheostomy change at day 4
62143255|NCT03082313|EXPERIMENTAL|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time.
62143256|NCT04154007||Adult Patients who met the diagnosis of ARDS|ARDS patients were followed for the development of AKI during their ICU stay
62346838|NCT01791699|PLACEBO_COMPARATOR|Control group|"The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal \<= 140/90)."
62346839|NCT01791699|ACTIVE_COMPARATOR|Moxonidine group|"Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal \<= 140/90)."
62346840|NCT01582971|EXPERIMENTAL|Intervention|Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member
62346841|NCT01582971|NO_INTERVENTION|Control|Standard medical care: no reflexology
62346842|NCT03034408|OTHER|Alcohol Use Disorder|30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
62346843|NCT03034408|OTHER|Healthy Control|30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
62346844|NCT01374217|EXPERIMENTAL|Tadalafil|Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)
62346845|NCT04180995|EXPERIMENTAL|Toripalimab, Axitinib|The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
62346846|NCT01054976|EXPERIMENTAL|Galantamine|
62346847|NCT06379867|EXPERIMENTAL|HSK3486|
62346848|NCT06379867|PLACEBO_COMPARATOR|Placebo|
62346849|NCT06379867|ACTIVE_COMPARATOR|Moxifloxacin|
62504722|NCT01007019|EXPERIMENTAL|YH4808 50mg|"1.Single dose~2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62703225|NCT03253705||Controls|Healthy Controls
62703226|NCT03253705||Research Subjects|Research Subjects already enrolled on other NIH protocols
62346850|NCT00411736|EXPERIMENTAL|A|Stratification group: Age under 8 years, no CF siblings at home.
62346851|NCT00411736|EXPERIMENTAL|B|Stratification group: Age \>/= 8 years, no CF siblings at home.
62346852|NCT00411736|EXPERIMENTAL|C|Stratification group: Age \>/= 8 years, CF siblings at home.
62504723|NCT01007019|EXPERIMENTAL|YH4808 100mg|"1.Single dose~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62504724|NCT01007019|EXPERIMENTAL|YH4808 200mg|"1.Single dose~2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62504725|NCT01007019|EXPERIMENTAL|YH4808 400mg|"1.Single dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62504726|NCT01007019|EXPERIMENTAL|YH4808 100mg(repeat doses)|"1.Repeat doses~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62504727|NCT01007019|EXPERIMENTAL|YH4808 200mg(repeat doses)|"1.Repeat doses~2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)"
62504728|NCT01007019|EXPERIMENTAL|YH4808 400mg(repeat doses)|"1.Repeat dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62504729|NCT01007019|EXPERIMENTAL|YH4808 600mg|"1.Single dose~2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62504730|NCT01007019|EXPERIMENTAL|YH4808 800mg|"1.Single dose~2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
62504731|NCT01007019|PLACEBO_COMPARATOR|Placebo|
62504732|NCT01007019|ACTIVE_COMPARATOR|Esomeprazole 40mg|
62504733|NCT06442410|EXPERIMENTAL|Test Group - DTM™ SCS programming approach with Conventional Medical Management (CMM)|"Subjects will undergo a Trial Phase with DTM™ SCS programming. Stimulation will be delivered from an external neurostimulator. Those who have a successful Trial Phase will proceed to permanent implantation of the Intellis™ SCS system to evaluate DTM™ SCS therapy and will undergo up to 24 months of stimulation delivery.~Subjects randomized to either treatment group will have the optional possibility to crossover to the alternative treatment arm after the 6-month visit. If the subject and investigator believe that the DTM™ SCS + CMM treatment has not generated sufficient pain relief to warrant continued treatment, then the subject will be provided with the option to crossover to the CMM group. If all SCS programming attempts fail, then DTM™ SCS therapy will be switched off and the subject will continue with their CMM treatment and will visit the clinic approximately a total of 18 months follow-up in the study (i.e. 6 months DTM™ SCS and 12 months CMM)."
62504734|NCT06442410|ACTIVE_COMPARATOR|Control Group - Conventional Medical Management (CMM) alone|"The choice of appropriate CMM will be made by the Investigator as determined to be the best standard of care for each individual subject i.e. optimized individual conventional therapy. These treatments would be generally consistent with the American College of Physicians and the American Pain Society Guidelines as published in the Annals of Internal Medicine and European/UK guidelines. Subjects in this group will also undergo up to 24 months of CMM.~Subjects randomized to either treatment group will have the optional possibility to crossover to the alternative treatment arm after the 6-month visit. If the subject and investigator believe that the CMM treatment has not generated sufficient pain relief to warrant continued treatment, then the subject will be provided with the option to crossover to the DTM™ SCS therapy group. Following their device activation, they will attend visits approximately a total of 18 months follow-up in the study (i.e. 6 months CMM and 12 months DTM™ SCS)."
62703227|NCT06456762|ACTIVE_COMPARATOR|iPEACE: Intervention for Parent Education About Care after the ED|Parents in the iPEACE condition will receive an 8-week text-messaging intervention to build skills in mental health literacy and self-efficacy. Texts will be delivered several days per week over an 8-week period. The intervention is fully automated.
62703228|NCT06456762|ACTIVE_COMPARATOR|Text Reminders Only|Parents in the text-reminders only condition will receive weekly reminders to make an outpatient therapy appointment for their child. Texts will be fully automated, and will be delivered once a week for 8-weeks.
61959200|NCT05288244|EXPERIMENTAL|lavender oil snuff|"The L group (lavender oil sniffing) will be applied, the lavender oil sniffing process will be applied every evening between 21.00-21.05 for 14 days, and the process steps will be as follows;~* Essential lavender oil to be used for the enterprise is obtained from a company that has business registration and TS EN ISO 9001: 2008 quality certificates with the number G06-3231 from the Ministry of Food, Agriculture and Livestock.~* 3 drops of the obtained lavender oil are dripped onto the cotton pad.~* The prepared cotton pad is fixed on the patient's clothing in the upper chest and shoulder area with a locked needle and the patient is asked to sniff for 5 minutes (Özkaraman et al., 2018)."
61959201|NCT05288244|EXPERIMENTAL|foot bath and lavender oil snuff|AL group (both foot bath and lavender oil sniffing),for 14 days, every evening between 21.00-21.20, foot bath and lavender oil sniffing between 21.00-21.05 will be applied together.
62143257|NCT00004474|EXPERIMENTAL|1|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
62143258|NCT00004474|EXPERIMENTAL|2|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
62346853|NCT05941858|EXPERIMENTAL|Arm I (Tai Chi)|Participants receive access to the online WaQi program to practice Tai Chi supervised and home-based over 8 weeks. Participants also receive standard cessation treatment that includes a prescription or recommendation for NRT and CO testing on study.
62346854|NCT05941858|ACTIVE_COMPARATOR|Arm II (Standard cessation)|Participants receive standard cessation treatment that includes a prescription or recommendation for NRT and undergo CO testing on study. Participants also receive an 8-week online Tai Chi self-administered teaching module subscription at the end of the study.
62346855|NCT05640856||Group D|STOP BANG Score \<3
62346856|NCT05640856||Group Y|STOP BANG Score ≥ 3
62346857|NCT03670069|EXPERIMENTAL|Treatment (itacitinib)|Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62346858|NCT00966303|EXPERIMENTAL|Cardiac Rehabilitation|9 patients with cardiomyopathy in functional class III or IV, submitted to an 8-week program with exercises and respiratory muscle training.
62346859|NCT05663242|EXPERIMENTAL|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
62346860|NCT05663242|EXPERIMENTAL|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
62143259|NCT02644122|EXPERIMENTAL|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
62346861|NCT02570282|EXPERIMENTAL|Sildenafil|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
62346862|NCT02570282|PLACEBO_COMPARATOR|Placebo|Placebo IP will be the same as SST-6007 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6007
62346863|NCT04059406|EXPERIMENTAL|Sapablursen Dose Level 1 (Cohort A)|A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
62346864|NCT04059406|EXPERIMENTAL|Sapablursen Dose Level 1 (Cohort B)|A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
62346865|NCT04059406|EXPERIMENTAL|Sapablursen Dose Level 1 (Cohort C)|A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
62346866|NCT03897868|EXPERIMENTAL|Experimental 1|HCP1803 High
61959202|NCT05989750|ACTIVE_COMPARATOR|Control procedure|Ultrasonic scaling and polishing will be performed every 6 months for subgingival cleaning
61959203|NCT05989750|EXPERIMENTAL|Test procedure|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning
61959204|NCT00919919|EXPERIMENTAL|Progesterone vaginal tablet|Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
61959205|NCT00919919|OTHER|Activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
62346867|NCT03897868|EXPERIMENTAL|Experimental 2|HCP1803 Middle
62346868|NCT03897868|EXPERIMENTAL|Experimental 3|HCP1803 Low
62346869|NCT03897868|ACTIVE_COMPARATOR|Active Comparator 1|HGP0904 High
62346870|NCT03897868|ACTIVE_COMPARATOR|Active Comparator 2|HGP0904 Low
61959206|NCT00811369|EXPERIMENTAL|1|Fulvestrant + ZACTIMA Group
61959207|NCT00811369|PLACEBO_COMPARATOR|2|Fulvestrant + Placebo Group
61959208|NCT02850965|EXPERIMENTAL|BI 695501|
61959209|NCT02850965|ACTIVE_COMPARATOR|Humira|
61959210|NCT02801383|ACTIVE_COMPARATOR|Treatment group|received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment
61959211|NCT02801383|PLACEBO_COMPARATOR|controlled group|received 1g gel (without biological active ingredient) every other day for consecutive 6-10 courses of treatment
61959212|NCT02121730||Kidney Transplantation|Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
61959213|NCT03602144|ACTIVE_COMPARATOR|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
61959214|NCT03602144|EXPERIMENTAL|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
62143260|NCT01264172|ACTIVE_COMPARATOR|PCCP, Proximal femur fracture|Patients, who received a minimal-invasive surgical treatment with the PCCP-plate
62143261|NCT01264172|ACTIVE_COMPARATOR|Osteosythesis with nails, prox. femur frac.|Patients, who received a minimal-invasive surgical treatment including a osteosynthesis with nails
62143262|NCT01264172|ACTIVE_COMPARATOR|DHS, proximal femur fracture|Patients, who received a conventional surgical treatment with the dynamic hip screw (DHS)
62143263|NCT01489774|PLACEBO_COMPARATOR|Placebo|
62703229|NCT06456762|NO_INTERVENTION|Treatment as Usual|Parents in the TAU condition will receive typical treatment in the emergency department, including outpatient referrals and safety planning if needed prior to discharge.
61959215|NCT05641519|PLACEBO_COMPARATOR|Enhanced Standard Intervention|Families randomized to enhanced standard intervention (ESI) will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care. At 12, 24, and 36 months they will be asked to return for in person follow-up to collect bio measures again and complete follow up surveys at the UCI FQHC in Santa Ana or during scheduled community data collection events. All adults will be asked to take their blood pressure with the device once a week.
62143264|NCT01489774|EXPERIMENTAL|CJ-12406|CJ-12406 Tablet, daily for 1 day or bid for 10 days
61959216|NCT05641519|EXPERIMENTAL|SERVE OC Intervention|"In the SERVE OC intervention, participants will receive AHA informational materials, access to the app/web portal, and will be assigned a CHW to work with over the 3 years of the study. The CHW will facilitate the intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations. All adults will be asked to take their blood pressure with the device once a week."
61959217|NCT03955744|EXPERIMENTAL|3D translabial ultrasound|3D translabial ultrasound with concurrent vaginal manometry
62143265|NCT05774626||DMPA-SC|All married women of reproductive age who receive family planning counseling at a participating health facility and who choose to receive injectable contraception will be given an option of either DMPA-IM (current health worker administered standard of care) or DMPA-SC (new administration method, with option for self-injection after completing training). Those opting for DMPA-SC will receive training on self-injection procedures and an opportunity to practice injection procedures on a model (e.g. condom filled with salt) to demonstrate confidence and proficiency to inject herself under the supervision of a healthcare provider. Clients will then be shown how to use a calendar to determine when their next injection is due, and provided a calendar/reminder card, job aids that illustrate self-injection steps (including safe disposal of needles), and 3 doses of DMPA-SC to take home for future use.
62346871|NCT03897868|ACTIVE_COMPARATOR|Active Comparator 3|HGP0608
61959218|NCT03602183|EXPERIMENTAL|Normal airway scenario|intubation in normal airway scenario
62346872|NCT03897868|PLACEBO_COMPARATOR|Placebo Comparator|Placebo
62346873|NCT01552187|PLACEBO_COMPARATOR|Placebo|Placebo
61959219|NCT03602183|EXPERIMENTAL|Tongue edema scenario|intubation in the tongue edema scenario. Tongue edema was obtain using simulator indicators
61959220|NCT03602183|EXPERIMENTAL|Spinal immobilization with normal airway scenario|intubation in spinal immobilization with normal airway scenario
61959221|NCT03602183|EXPERIMENTAL|Spinal immobilization with tongue edema scenario|endotracheal intubation with immobilized cervical spine and tongue edema scenario
62346874|NCT01552187|ACTIVE_COMPARATOR|Colchicine|Colchicine
62346875|NCT02626741|EXPERIMENTAL|meal replacement group|the participants receive a meal replacement plus life style modification
62346876|NCT02626741|EXPERIMENTAL|control group|the participants receive life style modification only.
62346877|NCT03546790|EXPERIMENTAL|Flavor 1|Grape flavored tobacco cigar wrapper
62346878|NCT03546790|EXPERIMENTAL|Flavor 2|Chocolate flavored tobacco cigar wrapper
62346879|NCT03546790|EXPERIMENTAL|Flavor 3|Tobacco flavored tobacco cigar wrapper
62346880|NCT05356741|EXPERIMENTAL|Part 1 (dose escalation)|Participants will receive single-agent AMX-818
62346881|NCT05356741|EXPERIMENTAL|Part 2 (dose escalation)|Participants will receive AMX-818 plus pembrolizumab
62346882|NCT05356741|EXPERIMENTAL|Part 3 (dose expansion)|Participants will receive single-agent AMX-818
62703230|NCT05372627||1|Adults undergoing clinically-indicated contrast-enhanced time-resolved cardiac CT for suspected structural heart disease
62703231|NCT04899661||Molidustat|Participants diagnosed with renal anemia treated with Molidustat at the discretion of investigators
62703232|NCT06130683||Secondary Hyperparathyroidism|Patients who were diagnosed as secondary hyperparathyroidism
61959222|NCT05639426|EXPERIMENTAL|Strengthening Opportunities for Achievement and Resilience|Strengthening Opportunities for Achievement and Resilience (SOAR) is an intervention condition consisting of both Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS) and Culturally Responsive Practices (CRP). It is a year-long, school-level intervention.
61959223|NCT06164678|EXPERIMENTAL|Ottawa Model for Smoking Cessation|"The OMSC group will receive counselling and pharmacotherapy if they choose (specifically NRT) with follow-up calls to support medication titration. Participants will be provided with quit cards, which are pre-loaded with $300 worth of funds that can only be used by the assigned study participant to purchase NRT (if they choose).~For those in the intervention group, the study counsellor who is a trained Nicotine Addiction Treatment Specialist (NATS) will facilitate follow-up, monitor NRT use, and advise participants to titrate NRT dose as required based on their minimum daily nicotine intake. These counselling calls will be conducted at day 3, 7, 14, 21, 30, 60, 90, and 180 as is standard in OMSC for people who smoke and are interested in quitting. A diary will also be provided to the participants to track their usage."
61959224|NCT06164678|NO_INTERVENTION|Usual Care|The usual care group will receive the initial counselling session but no further follow-up or NRT. They will be able to self-initiate a follow-up call if they choose. Participants will not be excluded if they choose to initiate NRT on their own at their own expense.
61959225|NCT01861964|PLACEBO_COMPARATOR|Sugar Pill|
61959226|NCT01861964|ACTIVE_COMPARATOR|Xylooligosarcharide 2.8g|Xylooligosarcharide 2.8grams
61959227|NCT01861964|ACTIVE_COMPARATOR|Xylooligosarcharide 1.4g|
61959228|NCT01191229|NO_INTERVENTION|Tecnis One-Piece MF IOL|It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery
61959229|NCT01191229|NO_INTERVENTION|Crystalens AO|It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO
61959230|NCT00519402||Partial Tonsillectomy|Patients who received a partial tonsillectomy
61959231|NCT00519402||Complete Tonsillectomy|Patients who received a complete tonsillectomy
61959232|NCT03323541||Group of patients treated with Zarxio|All consecutive patients, treated for lymphoma or myeloma, which underwent autologous stem cell transplantation in the University Hospital of Brest. All these patients were treated with biosimilars of Filgrastim: Zarzio®.
61959233|NCT02004210|EXPERIMENTAL|The TARE group|transarterial radioembolization group
61959234|NCT02004210|EXPERIMENTAL|The TACE group|Transarterial chemoembolization group
61959235|NCT01129817|EXPERIMENTAL|Cognitive Functional Therapy|
61959236|NCT01129817|ACTIVE_COMPARATOR|Manual Therapy and Exercise|
61959237|NCT03558178|EXPERIMENTAL|Doin with Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated.
62346883|NCT05356741|EXPERIMENTAL|Part 4 (dose expansion|Participants will receive AMX-818 plus pembrolizumab
61959238|NCT03558178|ACTIVE_COMPARATOR|Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
61959239|NCT03692130|ACTIVE_COMPARATOR|New Treatment|"The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called Mindfulness, Acceptance and Commitment-Therapy for depressive Patients."
61959240|NCT03692130|SHAM_COMPARATOR|Known Treatment|"The participants will be treated with a relaxation-treatment, long time established as jacobson muscle relaxing technique."
62346884|NCT04559542||Female material art athletes|Females practicing material art during recruitment time, in Oslo-area in Norway
62346885|NCT03726619|EXPERIMENTAL|e-CHEC-uP|Group 1 will receive the education study intervention after the first baseline questionnaire. Participants will be asked to take part in a one-time, 1 to 1.5-hour online education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker to help address any barriers in order to help receive a mammogram or a Pap test.
62346886|NCT03726619|ACTIVE_COMPARATOR|CHEC-uP|Group 2 will receive a similar education intervention but the education is offered face-to-face instead. Participants will be asked to take part in a one-time, 1 to 1.5-hour face-to-face education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker.
62346887|NCT00086944|EXPERIMENTAL|Treatment (genase, combination chemotherapy)|See detailed description.
62346888|NCT02831842||mCRC Participants|Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively.
62346889|NCT02659605|EXPERIMENTAL|Delayed cord clamping above the perineum|
62346890|NCT02659605|ACTIVE_COMPARATOR|Delayed cord clamping below the perineum|
62703233|NCT06130683||Primary Hyperparathyroidism|Patients who were diagnosed as primary hyperparathyroidism
62703234|NCT06130683||Normal group|Parathyroid tissue obtained incidentally during other neck surgeries, derived from people without parathyroid disease.
62703235|NCT01712672||1|Healthy participants
62703236|NCT05225922|EXPERIMENTAL|Experimental|Communication Partner Training:The group will receive usual care in addition to a CPT program, which will consist of face-to-face education and counselling sessions, a manual and telephone support.
61959241|NCT04903990||Patients|"women 18-50 years~* with previous history of a male birth~* scheduled for malignant breast tumor surgery"
61959242|NCT04903990||Controls|"women 18-50 years~* with previous history of a male birth~* scheduled for benign breast tumor surgery~* or cancer free"
62504735|NCT02056652|EXPERIMENTAL|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
62504736|NCT02056652|NO_INTERVENTION|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
62504737|NCT02063217|EXPERIMENTAL|Sleep Induction|7.5 grams of sodium oxybate
62703237|NCT05225922|ACTIVE_COMPARATOR|Comparison Group|This group will receive usual speech therapy sessions.
62703238|NCT06479811|EXPERIMENTAL|1/Dosimetry Arm 1|Escalating doses of \[212Pb\]VMT-alpha-NET, imaging with \[203Pb\]VMT-alpha-NET
61959243|NCT04396678|NO_INTERVENTION|PrEP Standard of Care|PrEP standard of care, administered through the Baltimore City Health Department
61959244|NCT04396678|EXPERIMENTAL|PrEP standard of care+behavioral intervention|PrEP standard of care, administered through the Baltimore City Health Department, and the behavioral intervention.
61959245|NCT04160195|ACTIVE_COMPARATOR|1/Conditioning chemotherapy plus Chimeric Antigen Receptors (CAR) T-cells dose escalation|All participants will be receiving escalating dose of Anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) CAR T cells/kg + conditioning chemotherapy
61959246|NCT04160195|ACTIVE_COMPARATOR|2/Conditioning chemotherapy plus Chimeric Antigen Receptors (CAR) T-cells expansion phase|Maximum tolerated dose (MTD) dose of Anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) CAR T cells/kg + Conditioning chemotherapy
61959247|NCT00764647|EXPERIMENTAL|Single arm|Education program for family caregivers of frail elders.
62346891|NCT03848611|EXPERIMENTAL|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
62346892|NCT04084132|EXPERIMENTAL|Early re-valving|60 patients who are assigned to early re-valving undergo pulmonary valve replacement within 3 months from randomization.
62346893|NCT04084132|EXPERIMENTAL|Later re-valving|60 patients who are assigned to later re-valving undergo pulmonary valve replacement when the current European guideline criteria are met.
62346894|NCT02310906|EXPERIMENTAL|Part 1: SRP-4053|Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
62346895|NCT02310906|PLACEBO_COMPARATOR|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
62346896|NCT02310906|EXPERIMENTAL|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
62346897|NCT02310906|NO_INTERVENTION|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic \[PK\] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
62346898|NCT01354431|EXPERIMENTAL|Arm 1: nivolumab - 0.3 mg/kg|
62346899|NCT01354431|EXPERIMENTAL|Arm 2: nivolumab - 2.0 mg/kg|
62346900|NCT01354431|EXPERIMENTAL|Arm 3: nivolumab - 10.0 mg/kg|
62346901|NCT05043246||Basic diseases Patients/Healthy People|Hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease,Chronic Liver Diseases, Cancer diseases Patients
62703239|NCT06479811|EXPERIMENTAL|2/Arm 2|Escalating doses of \[212Pb\]VMT-alpha-NET
62346902|NCT04185441|EXPERIMENTAL|TANZÂNIA|"The study is double-dummy. The patient must take 2 pills, as follow:~1 capsule Tanzânia association, oral, once a day, and~1 tablet tamsulosin placebo, oral, once a day."
62346903|NCT04185441|ACTIVE_COMPARATOR|Omnic Ocas|"The study is double-dummy. The patient must take 2 pills, as follow:~1 tablet Omnic Ocas, oral, once a day, and~1 capsule Tanzânia association placebo, oral, once a day."
61959248|NCT01370356|ACTIVE_COMPARATOR|Varenicline Tartrate|
61959249|NCT01370356|PLACEBO_COMPARATOR|Placebo|
61959250|NCT04397107|EXPERIMENTAL|Recombinant Human Interleukin-2|Induced remission period,recombinant human IL-2(500,000 unit per square meter) infusions five days;Maintenance treatment period,recombinant human IL-2 infusions five days then once every two weeks for 6 months.
62346904|NCT02411383|EXPERIMENTAL|NeuRx Diaphragm Pacing System (DPS)®|The NeuRx Diaphragm Pacing System (DPS)® is placed in the diaphragm during lung transplant.
62346905|NCT04768699|EXPERIMENTAL|TQG203(30µg/kg)|
62346906|NCT04768699|EXPERIMENTAL|TQG203(90µg/kg)|
62346907|NCT04768699|ACTIVE_COMPARATOR|NovoSeven®(90µg/kg)|NovoSeven®,manufactured by Novo Nordisk Inc.
62504738|NCT02063217|EXPERIMENTAL|Sleep Deprivation|Sleep deprivation for up to 36 hours with no naps or other sleep periods
62504739|NCT02063217|NO_INTERVENTION|Control|Participant will sleep as normal under the same controlled conditions in a clinical research unit
61959251|NCT04397107|NO_INTERVENTION|Traditional therapy|Patients were treated with glucocorticoid and/or immunosuppressor.
62504740|NCT00403949|ACTIVE_COMPARATOR|Azelaic acid 15% Gel|Azelaic acid 15%
62504741|NCT00403949|PLACEBO_COMPARATOR|Placebo|Non-active base from Azelaic acid 15% gel
62504742|NCT05231369|EXPERIMENTAL|group 1: 25 ug of ChulaCov19 BNA159 mRNA vaccine|The participants will receive 25 ug of the vaccine.
62703240|NCT06479811|EXPERIMENTAL|3/Arm 3|\[212Pb\]VMT-alpha-NET at MTD
62703241|NCT05089630|EXPERIMENTAL|Pentamer(low)/gB(low)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
62703242|NCT05089630|EXPERIMENTAL|Pentamer (med)/gB(low)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
62703243|NCT05089630|EXPERIMENTAL|Pentamer (med)/gB(med)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
61959252|NCT03209596|EXPERIMENTAL|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
61959253|NCT03209596|ACTIVE_COMPARATOR|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
61959254|NCT00656383|ACTIVE_COMPARATOR|1|Client is randomized to receive leg ulcer treatment in the home
61959255|NCT00656383|ACTIVE_COMPARATOR|2|Client randomized to receive leg ulcer care in the clinic
61959256|NCT03461497||Patients Cohort|Patients undergoing abdominal surgery
62346908|NCT04768699|EXPERIMENTAL|TQG203(180µg/kg)|
62346909|NCT06198075|OTHER|Control group|Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks
62346910|NCT06198075|EXPERIMENTAL|Experimental group|Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted. Final assessment will be done after 6 weeks.
62346911|NCT05738499|EXPERIMENTAL|CSSTEP Group|"On the basis of routine post-stroke care, the CSSTEP programme was added for a total of three weeks. Each week includes one session course and three after-session strengths-based practicing activities. The names of the three sessions are: 1. Individualised education on character strengths and guidance on daily life skills in stroke; 2. Practicing activities onthree good things of character strengths and physical rehabilitation training for stroke; 3. New ways to use signature strengths and secondary stroke prevention."
62346912|NCT05738499|PLACEBO_COMPARATOR|Control Group|On the basis of routine post-stroke care, the regular structured treatment and education programme will be comducted for a total of three weeks. Each week includes one session course of structured treatment and education programme.
62346913|NCT05780346|EXPERIMENTAL|CARE Parenting Group Treatment|Participants (i.e., caregivers of gender diverse youth) receive the CARE mentalizing-focused group parenting intervention.
62346914|NCT00843843|ACTIVE_COMPARATOR|9 hour sleep, then 3 hour nap and 6 hour sleep|
62346915|NCT00843843|ACTIVE_COMPARATOR|3 hour nap and 6 hour sleep, then 9 hour sleep|
62346916|NCT01298622||controls|
62346917|NCT01298622||OCD patients|
62346918|NCT01298622||OCD parents|
62346919|NCT01497535|EXPERIMENTAL|Insulin detemir|
62346920|NCT01497535|ACTIVE_COMPARATOR|Insulin glargine|
62346921|NCT00736788|EXPERIMENTAL|1|Four different oral dose levels of a suspension containing AZD1704
62346922|NCT00736788|PLACEBO_COMPARATOR|2|oral suspension
62143266|NCT05774626||DMPA-IM|All married women of reproductive age who receive family planning counseling at a participating health facility and who choose to receive injectable contraception will be given an option of either DMPA-IM (current health worker administered standard of care) or DMPA-SC (new administration method, with option for self-injection after completing training).
62143267|NCT01825850|EXPERIMENTAL|Gemigliptin|Gemigliptin 50mg q.d. during 7 days
62346923|NCT01899677|EXPERIMENTAL|symbiotic|symbiotic preparation 1/2 sachet twice daily during 30 days
62346924|NCT01899677|PLACEBO_COMPARATOR|distilled water|2 x 0.5 cc distilled water will be given during 30 days
62346925|NCT00386490|EXPERIMENTAL|Larazotide acetate 0.25 mg|larazotide acetate 0.25 mg capsule TID for 10 days
62143268|NCT01825850|EXPERIMENTAL|Irbesartan|Irbesartan 300mg q.d. during 7 days
62346926|NCT00386490|EXPERIMENTAL|Larazotide acetate 1 mg|larazotide acetate 1 mg capsule TID for 10 days
62346927|NCT00386490|EXPERIMENTAL|Larazotide acetate 4 mg|larazotide acetate 4 mg capsule TID for 10 days
62346928|NCT00386490|EXPERIMENTAL|Placebo|Placebo capsule TID for 10 days
62346929|NCT02438215|EXPERIMENTAL|IRX4204|IRX4204 20 mg QD for Days 1-30
62346930|NCT01594333|EXPERIMENTAL|Methotrexate|Methotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week
62346931|NCT01594333|PLACEBO_COMPARATOR|Placebo|Placebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week
62346932|NCT06314529||BRL-101|All patients who have received BRL-101
62346933|NCT02539355|ACTIVE_COMPARATOR|Diet A|Standard Healthy Diet (Diet A)
62346934|NCT02539355|EXPERIMENTAL|Diet B|Alternative Test Diet (Diet B)
62346935|NCT01374763|ACTIVE_COMPARATOR|Oxycodone|Drug: prolonged-release oxycodone
62346936|NCT01374763|ACTIVE_COMPARATOR|Oxycodone/naloxone|Prolonged-release oxycodone/naloxone
62346937|NCT03908710|OTHER|home Home blood pressure levels in hypertensive participants|Only one arm. No control group.
62346938|NCT04358198|EXPERIMENTAL|GIM patient|The patients with GIM will be assessed at both GIM and normal mucosa during endoscopy.
62703244|NCT05089630|EXPERIMENTAL|Pentamer (high)/gB(med)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of study (Day 546).
61959257|NCT03560232|ACTIVE_COMPARATOR|Cefazolin + Gentamicin|"\[Cefazolin\]~Initial dose:~* Cefazolin 2g IV x1 dose (patient weight \< 120kg)~* Cefazolin 3g IV x1 dose (patient weight \>/= 120kg)~Subsequent dose:~* Cefazolin 2g IV every 8 hrs (CrCl \>/= 40 mL/min)~* Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)~* Cefazolin 2g IV every 24 hrs (CrCl \< 20 mL/min)~Duration:~* 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first~\[Gentamicin\]~Initial dose:~* If Patient age \</= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~* If Patient age \>80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~* Pharmacy Consult to dose gentamicin~Duration:~* 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first"
61959258|NCT03560232|ACTIVE_COMPARATOR|Ceftriaxone|"Initial dose:~* Ceftriaxone 2g IV x1 dose~Subsequent dose:~* Ceftriaxone 2g IV every 24 hours~Duration:~* One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first"
61959259|NCT03560232|ACTIVE_COMPARATOR|Ampicillin/Sulbactam|"Initial dose:~* Ampicillin/Sulbactam 3g IV x1 dose~Subsequent dose:~* Ampicillin/Sulbactam 3g IV every 6 hours (CrCl \>/= 30 mL/min)~* Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)~* Ampicillin/Sulbactam 3g IV every 24 hours (CrCl \<15 mL/min)~Duration:~* 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
62143269|NCT01825850|EXPERIMENTAL|Gemiglitin + Irbesartan|Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
62143270|NCT01959958||Sickle cell disease|In this study, children and adolescents with sickle cell disease ages 6-18 years and their parents/guardians will complete a questionnaire/interview.
62143271|NCT03004625|EXPERIMENTAL|Study Arm|HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin)
62703245|NCT05089630|PLACEBO_COMPARATOR|Placebo Group|Participants receive placebo (saline) at 0,2 and 6 months and are followed up until end of study (Day 546).
62703246|NCT01148381||controls|healthy non-smoking, participants with no substance use disorders
62703247|NCT01148381||psychiatric disorders|individuals with other psychiatric disorders
62703248|NCT01148381||smokers|healthy individuals with nicotine use disorder
62703249|NCT01148381||substance use disorders|healthy individuals with other substance use disorders
62703250|NCT01148381||treatment seeking individuals|treatment seeking individuals with substance use disorders
62703251|NCT01306084||1|NIH campus employees who have recently recovered from COVID-19
62703252|NCT01306084||2|Clinical Center health care workers and ancillary staff who have close patient contact and possible exposures to SARS-CoV-2
62703253|NCT01306084||3|Healthy and immunocompromised subjects who have or are suspected to have a viral infection
62143272|NCT05270460|EXPERIMENTAL|PCS12852 0.1mg|PCS12852 0.1mg tablet
62346939|NCT04997824|EXPERIMENTAL|Artificial Intelligence-based atrial fibrillation catheter ablation|catheter ablation
62346940|NCT04997824|ACTIVE_COMPARATOR|Medical Therapy|catheter ablation
62703254|NCT01306084||4|Healthy and immunocompromised subjects exposed to someone who has a viral infection or is suspected of having a viral infection
62703255|NCT01306084||5|Healthy subjects who grew up in dengue endemic areas.
62703256|NCT01306084||6|Healthy subjects with a history of viral hepatitis
62703257|NCT06048120|EXPERIMENTAL|i.v. infusion cohorts|Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of short time i.v. infusion. Up to 8 dose steps are planned to be investigated for i.v. administration.
62346941|NCT00218790|NO_INTERVENTION|Control group|The control group received standard dialysis at a temperature of 37 degrees Celcius
62346942|NCT00218790|EXPERIMENTAL|Experimental group|Subjects in the experimental group received cool dialysate during treatment
62346943|NCT05314361|EXPERIMENTAL|Treatment - 1 Day CBT-Based Workshop|Participants assigned to the treatment arm will attend a day long CBT-based workshop delivered by two trained public health nurses in addition to receiving usual care.
62346944|NCT05314361|NO_INTERVENTION|Control - usual care|Participants assigned to the control arm will continue to receive standard postnatal care from their healthcare providers.
62703258|NCT06048120|EXPERIMENTAL|s.c. injection cohorts|Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of s.c. injection. Up to 2 dose steps are planned to be investigated for s.c. administration.
62703259|NCT04392037|EXPERIMENTAL|Iberdomide plus low-dose cyclophosphamide and dexamethasone|"Iberdomide 1.6mg on days 1-21~Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle~Dexamethasone 40 mg once weekly (20 mg in patients aged \> 75 years)"
62703260|NCT05858593|EXPERIMENTAL|Treatment|In the treatment group, the child will receive the VR-based curriculum in addition to receiving the devices to use for 8 weeks.
62346945|NCT04643223|ACTIVE_COMPARATOR|Kinesio tape with tension|The intervention group will receive the elastic bandage - kinesio tape with tension between seventy to ninety percent on the selected hypertrophic scar. The application of kinesio tape follows a protocol, which involves the cleaning of the selected scar with liquid soap, drying, alcohol application for sebum removal, scar measurement and marking of the therapeutic zone and anchors. Following the application of the kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the Vancouver assessments and collections of scarring material for the histopathology will be carried out, in the time intervals corresponding to the beginning of the study intervention / entry (time 0), 45 days and 90 days after being eligible, to agree to participate in the study study and intervention.
62346946|NCT04643223|SHAM_COMPARATOR|Kinesio tape without tension|The controlled sham group will receive the application of kinesio tape without tension will follow the same protocol above, including the three moments of evaluation, beginning of the intervention (time 0), 45 days and 90 days, after the beginning of the intervention.
62346947|NCT04075526|EXPERIMENTAL|Povidone iodine and vancomycin powder|
62703261|NCT05858593|ACTIVE_COMPARATOR|Control|In the control group, the child will still receive the devices to use for 8 weeks, but will not have the VR-based curriculum.
61959260|NCT03560232|ACTIVE_COMPARATOR|Piperacillin/Tazobactam|"Initial dose:~* Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes~Subsequent dose:~* Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl \>/= 20 mL/min)~* Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl \< 20 mL/min)~Duration:~* 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
61959261|NCT03560232|OTHER|Clindamycin + Gentamicin|"Patients with known Penicillin allergy will receive:~\[Clindamycin\]~Initial dose:~* Clindamycin 900mg IV x1 dose~Subsequent dose:~* Clindamycin 600mg IV every 8 hours~Duration:~* 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first~\[Gentamicin\]~Initial dose:~* If Patient age \</= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~* If Patient age \>80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~* Pharmacy Consult to dose gentamicin~Duration:~* 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
61959262|NCT01270412|EXPERIMENTAL|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml of platelet-derived preparation rich in growth factors
61959263|NCT01270412|ACTIVE_COMPARATOR|Hyaluronic acid|Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease
61959264|NCT03194607||Patients|
61959265|NCT03194607||Controls|
61959266|NCT04108793|EXPERIMENTAL|Intervention Arm|The Intervention group will be given a program of progressive balance and lower limb strengthening exercises twice a week for 3 months. All exercises will include 5 minutes warm-up exercises. The lower limb extensor muscle groups (hip \& knee extensors and ankle plantar flexors) will be targeted with exercises designed to enhance postural control (i.e. balance) and muscle strength. The balance exercises include standing with a decreased base of support, forwards and sideways stepping/walking, and graded reaching activities in standing. Strengthening exercises will include sit-to-stand, forward and lateral step-ups onto a small block, semi squats and heel raises in standing. Standard principles governing frequency, volume, duration, intensity and progression of exercise will be applied. Cueing strategies will be used to reduce freezing. T
62504743|NCT05231369|EXPERIMENTAL|group 2: 50 ug of ChulaCov19 BNA159 mRNA vaccine|If 25 ug is safe, then will proceed to enroll 12 more participants to receive 50 ug.
62504744|NCT04148105|PLACEBO_COMPARATOR|Placebo|Implement standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway.
62504745|NCT04148105|EXPERIMENTAL|Experimental|Administer 100 mg cilostazol, twice daily for 14 days. In addition, implement the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days, and the standard aneurysmal subarachnoid treatment pathway.
61959267|NCT04108793|NO_INTERVENTION|Control Arm|The control arm will receive the usual standard postoperative rehabilitation after a bipolar hemiarthroplasty/ total hip arthroplasty which will include in hospital rehabilitation and a maximum of 5 visits postoperatively
61959268|NCT04589806|EXPERIMENTAL|2-stage ridge splitting with simultaneous implant placement|
62703262|NCT00334815|EXPERIMENTAL|Group 1 (cisplatin, etoposide, radiotherapy)|Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
61959269|NCT03472183|OTHER|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
61959270|NCT03472183|OTHER|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
61959271|NCT03472183|OTHER|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
61959272|NCT00649324|EXPERIMENTAL|1|Hydrochlorothiazide Tablets 50 mg
62346948|NCT04075526|EXPERIMENTAL|Povidone iodine alone|
62346949|NCT04075526|ACTIVE_COMPARATOR|Vancomycin powder alone|
62504746|NCT06212193|EXPERIMENTAL|Innoventric Trillium™ Stent Graft|Transcatheter cross-caval tricuspid valve replacement with the Innoventric Trillium™ Stent Graft
61959273|NCT00649324|ACTIVE_COMPARATOR|2|Hydrochlorothiazide Tablets 50 mg
62504747|NCT05672745|EXPERIMENTAL|WB-LIFE|
62504748|NCT03636087|ACTIVE_COMPARATOR|Conventional|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
62504749|NCT03636087|EXPERIMENTAL|Enhanced sterile protocol|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Changing gloves before obturation Disinfecting rubber dam The use of new instruments at time of obturation Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
62703263|NCT00334815|EXPERIMENTAL|Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
61959274|NCT05329610|EXPERIMENTAL|Beta-alanine|Slow-release beta-alanine (Natural Alternatives International, Carlsbad, CA, USA). Dose: 4.8 grams per day for 3-months (potential total intake of 432 g beta-alanine). The daily intake will be split into four doses of 2 x 600 mg. Participants will be instructed to consume each dose alongside their main daily meals (e.g., breakfast, lunch, and dinner) and before bed.
62346950|NCT04075526|ACTIVE_COMPARATOR|Conventional|neither povidone iodine, vancomycin powder, nor polymyxin/bacitracin irrigation
62346951|NCT03110198|EXPERIMENTAL|Mesalazine with hydrocortisone sodium succinate|Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema
62346952|NCT03110198|ACTIVE_COMPARATOR|Mesalazine|Mesalazine （4g）enema
61959275|NCT05329610|PLACEBO_COMPARATOR|Placebo|Taste and appearance-matched placebo (tapioca starch) (Natural Alternatives International, Carlsbad, CA, USA). Doses equivalent to the experimental arm.
61959276|NCT06247020|EXPERIMENTAL|Oral sodium-butyrrate supplementation|Participants consumed 8 capsules of sodium butyrate per day for a week. The capsules were consumed with main meals (2 for breakfast, 2 for lunch and 2 for dinner). Each capsule contained 200 mg of sodium butyrate, for a total of 1.6 grams of sodium butyrate per day.
62703264|NCT00334815|EXPERIMENTAL|Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
61959277|NCT06247020|PLACEBO_COMPARATOR|Placebo|Participants consumed 8 capsules of placebo. The capsules were consumed with main meals (2 for breakfast, 2 for lunch and 2 for dinner). Each capsule contained cornstarch
61959278|NCT04329533|EXPERIMENTAL|Intervention Group - access to meditation app|"Will receive a 30-day free trial of the mobile meditation app Calm on study day 0"
61959279|NCT04329533|NO_INTERVENTION|Control Group - no access to meditation app|"Will not have the intervention until after the 30 day study period and then will receive a 30-day free trial of the mobile meditation app Calm on study day 30"
61959280|NCT04080128|OTHER|Contact lens|Depending upon the study lens proven to be the most effective in the BLINK Study, this contact lens will be used for the first two years of the study. The last year of the study, all subjects will be wearing single vision contact lenses.
61959281|NCT05391516||All Participants|Participants; 18-80 years old, who volunteered to participate in the study, patients with shoulder problems.
61959282|NCT01308554|PLACEBO_COMPARATOR|Sterile normal saline|Control group will receive sterile normal saline in the block
61959283|NCT01308554|ACTIVE_COMPARATOR|Marcaine|Study group will receive a bilateral TAP block using 20 ml of Marcaine 2,5 mg/ml on each side.
61959284|NCT01425281|ACTIVE_COMPARATOR|XIENCE™|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
61959285|NCT01425281|EXPERIMENTAL|ABSORB BVS™|Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
61959286|NCT06394297|EXPERIMENTAL|SBRT for cervical cancer|SBRT to LACC following whole pelvis external beam radiotherapy
61959287|NCT05063604|EXPERIMENTAL|Citalopram 20-40 mg|Participants received citalopram 20 mg tablet once or twice daily for 12 weeks.
61959288|NCT05063604|EXPERIMENTAL|Psychotherapy|Participants received one psychotherapy session weekly for 12 weeks.
61959289|NCT03478020|EXPERIMENTAL|Pre-Treatment, Treatment Cycles A & B|"Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days"
61959290|NCT03047915|NO_INTERVENTION|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
61959291|NCT03047915|EXPERIMENTAL|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
62346953|NCT03110198|ACTIVE_COMPARATOR|Hydrocortisone sodium succinate|Hydrocortisone sodium succinate (100mg ) enema
62346954|NCT00855257|EXPERIMENTAL|1|treatment by acid nicotinique
62346955|NCT00855257|PLACEBO_COMPARATOR|2|Treatment by placebo
62703265|NCT01362803|EXPERIMENTAL|Arm 1|Phase 1: AZD6244 PO BID x 28 DAYS
62703266|NCT01362803|EXPERIMENTAL|Arm 2|Phase 2: AZD6244 PO BID x 28 DAYS
61959292|NCT01215383||psychiatric patients|20 in patients and outpatients with schizophrenia, schizoaffective and bipolar disorder based on psychiatrist diagnostic evaluation using DSM-IV criteria, before and at least two months after antipsychotic therapy will be enrolled.
61959293|NCT01215383||healthy volunteers|"Ten healthy volunteers will be checked as controls:~Employee from the hospital staff with no metabolic disease (Diabetes mellitus, hypertension or dyslipidemia) and non-smokers."
61959294|NCT03493594|NO_INTERVENTION|Control|"Control group will receive standard health care.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
61959295|NCT03493594|EXPERIMENTAL|Nutrition education program|"The intervention group will receive an early nutrition program for 12 months. Workshops format will be mainly in form of talks and experience sharing groups which run by lactation consultants, nutritionists / dietitians. All classes and workshops will be run for 4-6 times to cater for subjects recruited in different phases.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
61959296|NCT02282579||Patient with metastatic renal cell carcinoma treated|Patient with metastatic renal cell carcinoma treated with Pazopanib
61959297|NCT02198066|OTHER|Dry Sterile Dressing|Subjects in this study arm received a dry sterile dressing (Primapore®, Smith \& Nephew), a one-piece, peel-and-stick, non-transparent dressing. This dressing is the standard of care at the study facility for this population and was left in place for either 24 to 48 hours.
62143273|NCT05270460|EXPERIMENTAL|PCS12852 0.5mg|PCS12852 0.5mg tablet
62143274|NCT05270460|PLACEBO_COMPARATOR|Placebo|Similar in appearance to active study drug
62143275|NCT03844698||Patients with Sarcoidosis and Cancer|These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
62346956|NCT03272360||Chronic Pelvic Pain|
62346957|NCT03272360||Elective Tubal Ligation|
61959298|NCT02198066|ACTIVE_COMPARATOR|Metallic Silver Dressing|Subjects in this arm received a metallic silver dressing (Acticoat Post-Op®, Smith \& Nephew), a one-piece, peel-and-stick and non-transparent dressing. This dressing is an absorbent postoperative dressing consisting of a nanocrystalline silver-coated polyurethane layer, a white polyurethane foam and an adhesive coated waterproof polyurethane film layer. Acticoat Post-Op may be left in place over a wound for up to 7 days. The manufacturers note that the product should not be used in patients with known silver allergies and that it may cause transient discoloration of the skin.
61959299|NCT02198066|ACTIVE_COMPARATOR|Ionic Silver Dressing|Subjects in this arm received an ionic silver dressing (Dermanet Ag®, DeRoyal), a semi-transparent dressing that includes silver, alginate, and maltodextrin. The dressing was cut to fit the incision and then covered with a transparent dressing (Transseal®, DeRoyal). This dressing should not be used on patients with known sensitivity to alginates (a seaweed based component).
62504750|NCT05260034|ACTIVE_COMPARATOR|Otago Group|The control group will receive balance exercises adapted from the evidenced-based Otago Exercise program. Briefly, all eight sessions (\~30 min) will involve balance exercises and strength exercises using ankle weights, and will progressively increase as performance improves by increasing resistance or the difficulty of the balance exercises (e.g., reducing base of support).
62703267|NCT03191149|EXPERIMENTAL|Treatment (osimertinib)|Patients receive osimertinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA, MRI or CT with contrast, and collection of blood samples throughout the trial.
61959300|NCT01727297|OTHER|REVEAL Implantable Cardiac Monitor|
61959301|NCT01195558||Blind with sleep problems|Blind individuals with no light perception and with sleep-related problems who may suffer from Non-24
62504751|NCT05260034|EXPERIMENTAL|FAST Group|Participants randomized to the intervention arm will undergo the FAST program, a progressive safe-falling training based on the tuck and roll strategy. As part of the FAST program, participants will train 30 minutes twice a week for a period of four weeks under the supervision of a trained researcher. Participants will wear protective gear (knee, hip, head) and they will complete a 10-minute stretching exercise routine to minimize the risk of injury.
62504752|NCT01150006||Healthy male participants|
61959302|NCT06505668|ACTIVE_COMPARATOR|Atenolol 25mg|Patients will be receiving Atenolol 25mg OD for 2 months.
62504753|NCT02289937|EXPERIMENTAL|Ropivacaine|8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.
62504754|NCT02289937|PLACEBO_COMPARATOR|Placebo|8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided
62703268|NCT06010914||mHSPC patients to treat with darolutamide in combination with docetaxel and ADT|Patients over the age of 18 years with a diagnosis of mHSPC and for whom a decision to treat with darolutamide in combination with docetaxel and ADT has been made by the treating physician before study enrollment.
62703269|NCT06226883|EXPERIMENTAL|Group 1|Blinded MORF-057 Dosing Regimen 1 for Induction Period and open-label MORF-057 for Maintenance Period
62504755|NCT05531604||AN-Restricting (AN-R)|Meet Diagnostic and Statistical Manual (DSM-5) criteria for anorexia nervosa, restricting subtype
62703270|NCT06226883|EXPERIMENTAL|Group 2|Blinded MORF-057 Dosing Regimen 2 for Induction Period and open-label MORF-057 for Maintenance Period
62703271|NCT06226883|PLACEBO_COMPARATOR|Group 3|Blinded matching placebo for Induction Period and open-label MORF-057 for Maintenance Period
62703272|NCT06484868|EXPERIMENTAL|Metreleptin|Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
62703273|NCT05479812|EXPERIMENTAL|WTX-124 monotherapy dose escalation|WTX-124 monotherapy dose escalation
62703274|NCT05479812|EXPERIMENTAL|WTX-124 in combination with pembro dose escalation|WTX-124 in combination with pembrolizumab (pembro) dose escalation
62703275|NCT05479812|EXPERIMENTAL|Arm A: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic RCC.|Arm A: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic RCC.
62703276|NCT05479812|EXPERIMENTAL|Arm B: WTX-124 monotherapy dose expansion. Advanced or metastatic cutaneous malignant melanoma.|Arm B: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cutaneous malignant melanoma.
61959303|NCT06505668|ACTIVE_COMPARATOR|Ivabradine 10mg|Patients will be receiving Ivabradine 10mg (5mg BD) for 2 months.
61959304|NCT01367210|EXPERIMENTAL|MARAVIROC, DARUNAVIR/r|"Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy"
61959305|NCT01367210|SHAM_COMPARATOR|current ART with 3 drugs|Patients on HAART with three drugs and HIV RNA below 50 copies/mL
61959306|NCT01486667|PLACEBO_COMPARATOR|sugar pill|
61959307|NCT01486667|ACTIVE_COMPARATOR|Levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients. Serum levels of TSH and FT4 will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
61959308|NCT02295488|EXPERIMENTAL|Desensitization|Blood intake for biological sampling during validated desensitization protocol (Alyostall®)
61959309|NCT01003288|EXPERIMENTAL|Pandemic influenza H1N1 vaccine|Influenza vaccine
62504756|NCT05531604||Weight Restored AN-Restricting (WRAN-R)|"* History of anorexia nervosa, restricting type - previously meeting full DSM-5 criteria.~* Eating Disorder Examination Questionnaire (EDE-Q) ≤ 2 (within 1 standard deviation \[SD\] of community norms and lower than 1 standard deviation from clinical norms for female anorexia nervosa, restricting type populations)"
62504757|NCT05531604||Healthy controls|Healthy females from any racial or ethnic background, not meeting DSM-5 criteria for any psychiatric disorder.
62504758|NCT03627598|ACTIVE_COMPARATOR|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
62504759|NCT03627598|EXPERIMENTAL|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
61959310|NCT03743623|EXPERIMENTAL|Treatment Group|Study treatment with Neurocytotron, which is a device is designed to generate a controlled beam of electromagnetic waves of certain frequencies in the presence of a magnetic field with pre-determined strength.
61959311|NCT03743623|PLACEBO_COMPARATOR|Placebo Group|The placebo control is a mock treatment in which a subject will go through the same procedures as subjects assigned to the treatment group, only without being actually exposed to electromagnetic waves and magnetic fields.
61959312|NCT02632981|ACTIVE_COMPARATOR|chronic periodontitis patients|gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
61959313|NCT02632981|PLACEBO_COMPARATOR|periodontally healthy controls|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
61959314|NCT01683383|ACTIVE_COMPARATOR|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
61959315|NCT01683383|EXPERIMENTAL|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
61959316|NCT01657669|OTHER|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).
61959317|NCT04978727|EXPERIMENTAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
61959318|NCT04978727|EXPERIMENTAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
61959319|NCT04978727|EXPERIMENTAL|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
61959320|NCT06506747||FastMap Navigated Photogrammetry|Following implant surgery, the patient will then receive a provisional that was manufactured using the data from FastMap Navigated Photogrammetry.
61959321|NCT06506747||Standard Stereophotogrammetry|Following implant surgery, the patient will then receive a provisional that was manufactured using the data from Standard Stereophotogrammetry.
61959322|NCT00592215|EXPERIMENTAL|A|Mifepristone followed by labor induction with misoprostol after 6-8 hours
61959323|NCT01587001|ACTIVE_COMPARATOR|Oral N-acetyl-cysteine|oral NAC 900mg three times daily for 8 weeks
61959324|NCT01587001|PLACEBO_COMPARATOR|Matching Placebo|oral placebo three times daily for 8 weeks
61959325|NCT05965492|ACTIVE_COMPARATOR|Bottled pain formulations Group|Participants in this group will use the standard-of-care medication treatment for ambulatory spinal surgery prescribed to them in different bottles for 7 days.
62346958|NCT04473144|NO_INTERVENTION|Control|Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery.
62346959|NCT04473144|SHAM_COMPARATOR|Ulistin|"In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.~Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery."
62346960|NCT06043661||BI-RADS score 1 or 2 or 3 (Cohort A)|Subjects with a standard risk of breast cancer aged 40 years and above at the time of mammography with the BI-RADS score 1 or 2 or 3
62346961|NCT06043661||BI-RADS score 4 or 5 (Cohort B)|Subjects aged 40 years and above at the time of mammography with the BI-RADS score 4 or 5
62346962|NCT05782166|PLACEBO_COMPARATOR|Betel Quid Cessation via Educational Booklet|Participants will be given only an educational booklet on screening day (Day-1) and will be followed up on Day-22 and Month-3 to assess their current chewing status and other related parameters.
62346963|NCT05782166|EXPERIMENTAL|Betel Quid Cessation via Educational Booklet & Intervention Module|Participants will undergo a 5-intervention sessions which will enhance their self-efficacy o quit their chewing behaviour. During the intervention sessions, they will be guided on how to monitor their chewing triggers, the lifestyle changes that they can potentially make, how to tap on their social support system to aid in their cessation efforts and others. The intervention will last for 22 days and a follow-up session will be made on Month-3.
62346964|NCT05816967|EXPERIMENTAL|Intervention group|In the monocentric interventional part of the study, the effect of discharge counseling on the acceptance of pharmacotherapeutic recommendations will be evaluated 1 and 3 months after discharge.
62703277|NCT05479812|EXPERIMENTAL|Arm C: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cSCC.|Arm C: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cSCC.
61959326|NCT05965492|EXPERIMENTAL|Multi-Modal regimen Group|Participants in this group will receive the same drugs used during the standard-of-care treatment for ambulatory spinal surgery. However, the drugs will be prescribed using a simple multimodal medication pre-formulated package for 7 days.
61959327|NCT01957930|EXPERIMENTAL|Intensified insulin treatment|Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day
61959328|NCT01957930|ACTIVE_COMPARATOR|Standard treatment|Mixed Insulin (2-3 times a day)
62504760|NCT03011060|EXPERIMENTAL|NAC not achieving pCR|"Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.~Capecitabine 1000mg/m2 tablets twice a day for 8 cycles."
62504761|NCT03011060|EXPERIMENTAL|NAC achieving pCR|Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.
62504762|NCT03011060|NO_INTERVENTION|Adjuvant Chemotherapy|Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.
62703278|NCT05479812|EXPERIMENTAL|Arm D: WTX-124 in combination with pembro dose expansion. Advanced or metastatic RCC.|Arm D: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic RCC.
62703279|NCT05479812|EXPERIMENTAL|Arm E: WTX-124 with pembro dose expansion. Advanced or metastatic cutaneous melanoma.|Arm E: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic cutaneous melanoma.
62703280|NCT05479812|EXPERIMENTAL|Arm F: WTX-124 in combination with pembro dose expansion. Advanced/metastatic PD-L1-positive NSCL|Arm F: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic PD-L1-positive NSCLC lines.
62703281|NCT04708418|EXPERIMENTAL|Arm A (pembrolizumab)|"NEOADJUVANT PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial."
62703282|NCT04708418|EXPERIMENTAL|Arm B (CMP-001, pembrolizumab)|"NEOADJUVANT PHASE: Patients receive CMP-001 SC on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial."
62703283|NCT05291091|EXPERIMENTAL|Adult Cohort 1|Drug: Sevasemten Drug: Placebo
62703284|NCT05291091|EXPERIMENTAL|Adult Cohort 2|Drug: Sevasemten Drug: Placebo
62703285|NCT05291091|EXPERIMENTAL|Adult Cohort 6|Drug: Sevasemten Drug: Placebo
62703286|NCT05291091|EXPERIMENTAL|Adolescent Cohort 4|Drug: Sevasemten Drug: Placebo
62703287|NCT05291091|EXPERIMENTAL|Adolescent Cohort 5|Drug: Sevasemten Drug: Placebo
62703288|NCT06751173|EXPERIMENTAL|Group A|"The Group A will be treated with Static Core Stability exercises and common treatment.~i. Plank:Press hands and knees to the floor with back in a neutral position and wrists aligned directly under your shoulders.~ii. Side Plank: Lie on side with knees bent, and prop upper body up on elbow. iii. Shoulder Bridge: Raise pelvis off the floor until only head, neck, shoulders (and feet) are touching the mat. Place hands at the waist.~iv. Static Crunch: Lie on your back, with your feet flat on the floor and your knees bent at a 90-degree angle.~v. Leg Lift: lay straight on floor, keep arms at side and slowly lift both legs in air."
62504763|NCT00005087|EXPERIMENTAL|Radiation (BID) and chemotherapy|Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.
62504764|NCT02462486|EXPERIMENTAL|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
62504765|NCT02462486|EXPERIMENTAL|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
62504766|NCT02462486|ACTIVE_COMPARATOR|Ranibizumab (rQ4)|Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
61959329|NCT01957930|NO_INTERVENTION|Healthy controls|These people were solely controls for the iontophoresis method used in the study. With no intervention or follow-up-
61959330|NCT02609269||Decipher GRID Patients|Patients who have been tested with any of the Decipher clinical tests
61959331|NCT05644353|EXPERIMENTAL|Mirikizumab Solution (Reference)|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS) at 3 different injection sites (arm, thigh, and abdomen).
62346965|NCT01913808|EXPERIMENTAL|Ferric carboxymaltose|Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit \[mg\] = 2.4 x patient's weight \[kg\] x (target Hb \[13 g/dL\] - current Hb \[g/dL\]) + 500 \[mg iron stores\]
62504767|NCT01082224|EXPERIMENTAL|Waitlisted with HCC-Exception Points|Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
62703289|NCT06751173|ACTIVE_COMPARATOR|Group B|"Second group will be consist of Mckenzie exercises with common treatment Prone Extension (Positioned): Lie on stomach with pillows under chest for comfort.~ii. Prone Extension on Elbow: Keep your back and buttocks relaxed and rise up on elbows as high as possible.~iii. Prone Press-ups: Place hands beside shoulders.Keep your back and buttocks relaxed and use your arms to press up.~iv. Standing extension: Stand with your feet apart and hands on the small of your back with fingers pointing backwards.Bend backwards at the waist, supporting the trunk with your hands.~v. Sideglide in Standing: Stand at a right angle to the wall about 2 feet out from the wall. Lean shoulder into the wall.~13 Common Treatment: Spinal Mobilization with Central-Unilateral posterio anterior and lateral glide."
62703290|NCT06161116|EXPERIMENTAL|Base Study: Dose 1|Participants receive subcutaneous (SC) MK-6194 dose regimen 1.
62703291|NCT06161116|EXPERIMENTAL|Base Study: Dose 2|Participants receive SC MK-6194 dose regimen 2.
62703292|NCT06161116|PLACEBO_COMPARATOR|Base Study: Placebo|Participants receive an SC placebo regimen.
62703293|NCT06161116|EXPERIMENTAL|Extension: Dose 1|"Participants receive SC MK-6194 dose regimen 1. Participants from the arms Base Study: Dose 1 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
62703294|NCT06161116|EXPERIMENTAL|Extension: Dose 2|"Participants receive SC MK-6194 regimen 2. Participants from the arms Base Study: Dose 2 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
62703295|NCT04242095||Observational (biospecimen collection, medical record review)|Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.
62703296|NCT06750120|EXPERIMENTAL|Intervention Arm|"Two intervention components will be provided from enrollment through 12 months postpartum:~1. Monthly household food rations providing 5 daily food groups and a mean of 165 kcal/per capita/day~2. Behavioral counselling by frontline health workers to promote healthy gestational weight gain and post partum weight loss.~Participants will also receive enhanced usual care as described for the active comparator arm."
62703297|NCT06750120|ACTIVE_COMPARATOR|Enhanced Usual Care Arm|"The comparator will be enhanced usual care alone, which will include:~Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost."
62703298|NCT06383676|EXPERIMENTAL|Functional balance based reaction exercise training.|Functional balance-based balance reaction exercises will be integrated into functional balance exercises with the help of the BlazePod™ training device panel.
62143276|NCT03658252|EXPERIMENTAL|Intervention|"Participants in the intervention arm will be shown a 2 minute educational video, and given an information leaflet on topical steroids. At 1 month of follow up, a link encouraging participants to sign up for a pre-selected, disease specific, moderated online support group would be sent to their emails.~Participants will continue to receive standard medical care and counselling by their dermatologists as clinically indicated."
62703299|NCT06383676|EXPERIMENTAL|Functional balance training|The exercises will consist of functional balance activities, such as maintaining a standing posture, transitioning from sitting to standing, walking and balancing on one leg.
62346966|NCT01913808|ACTIVE_COMPARATOR|Ferrous glycine sulphate|Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery
62346967|NCT04009213|EXPERIMENTAL|LiquiBand FIX8®|LiquiBand FIX8® is an n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
62346968|NCT04009213|ACTIVE_COMPARATOR|AbsorbaTack™|AbsorbaTack™ is an absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2
62346969|NCT04876989|ACTIVE_COMPARATOR|US-SGB|5 ml of 1% mepivacaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
62346970|NCT04876989|ACTIVE_COMPARATOR|US-TPVB|10 ml of 1% mepivacaine is injected for thoracic paravertebral block using the Ultrasound(US)-guided sagittal approach at the second thoracic paravertebral space.
62346971|NCT04980313|EXPERIMENTAL|Xenogenic collagen matrix|Volumetrically stable xenogenic collagen matrix
62346972|NCT04980313|ACTIVE_COMPARATOR|Autogenous connective tissue graft|Autogenous connective tissue graft obtained from the tuberosity area
62346973|NCT04536649|EXPERIMENTAL|Standard-dose Photon Radiotherapy|The patients will receive standard-dose photon radiation (60Gy/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle)
62346974|NCT04536649|EXPERIMENTAL|Standard-dose Proton Radiotherapy|The patients will receive standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
62346975|NCT04536649|EXPERIMENTAL|Standard-dose Proton Radiotherapy plus Carbon-Ion Boost|The patients will receive carbon-ion radiation boost (15GyE/3F for residual lesion) priot to standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), then adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
62346976|NCT03485092|ACTIVE_COMPARATOR|Empagliflozin|Empagliflozin 10mg tablets for oral self-administration once daily
62346977|NCT03485092|PLACEBO_COMPARATOR|Placebo Oral Tablet|placebo tablets for oral self-administration once daily
62504768|NCT03649425||hydroxyapatite coated pins|Patients submitted to surgical treatment with external fixators using pins coated with hydroxyapatite.
62703300|NCT00001778||healthy volunteers|At least 18 years old and have no history of any medical illness that may confound study results or make participation in this protocol impossible
62703301|NCT00001778||individuals seropositive for HTLV|Positive HTLV-1 ELISA followed by a positive Western Blot
62143277|NCT03658252|NO_INTERVENTION|Control|Patients in the control arm will receive only standard medical care and counseling by their dermatologist as clinically indicated.
62703302|NCT00001778||individuals with indeterminate HTLV sero-status|Positive HTLV ELISA but a Western Blot that only partially fulfills criteria
62703303|NCT04822181|EXPERIMENTAL|Semaglutide OW (once weekly )|Semaglutide administrated subcutaneously once weekly
61959332|NCT05644353|EXPERIMENTAL|Mirikizumab Solution (Test)|Mirikizumab administered by SC via a PFS at 3 different injection sites (arm, thigh, and abdomen).
61959333|NCT00834171||1|Loteprednol etabonate ophthalmic suspension 0.5%
61959334|NCT00834171||2|Loteprednol etabonate (0.5%) and tobramycin (0.3%)
61959335|NCT04753060|ACTIVE_COMPARATOR|Waxing|Waxing of patients donor site who are undergoing a skingraft procedure, prior to surgery taking place.
61959336|NCT04753060|NO_INTERVENTION|Standard care|Standard wound preparation
61959337|NCT03602482|EXPERIMENTAL|Standing|Participants will complete cognitive testing while standing.
62143278|NCT02955199|EXPERIMENTAL|Mothering From the Inside Out|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
62143279|NCT02955199|ACTIVE_COMPARATOR|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
62143280|NCT02797587|ACTIVE_COMPARATOR|Varenicline + Nicotine Replacement Therapy placebo|Study participants will receive active varenicline and be instructed to take the medication for 12 weeks; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
62143281|NCT02797587|PLACEBO_COMPARATOR|Varenicline placebo + Nicotine Replacement Therapy|Study participants will receive placebo varenicline and be instructed to take the placebo medication for 12 weeks; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
62346978|NCT04873076|EXPERIMENTAL|Audiovisual distraction using 2d video glasses from HappyMed GmbH|"During the catheter ablation, the patients in the intervention group receive 2D video glasses with headphones. Immediately before and after the procedure they receive a questionnaire. During the procedure vital parameters of all patients regardless of the studygroup are monitored using Zoll X-Series Monitor Defibrillator. The study includes blood pressure (in mmHg), heart rate (in beats per minute) and patient's level of alertness, which is assessed using the Richmond Agitation-Sedation Scale(RAAS). During the procedure the patients in the intervention group receive the glasses and remote control. All patients receive their individual dosage to ensure painless ablation. The drugs used are limited to the opioids remifentanil and benzodiazepine midazolam."
62504769|NCT03649425||uncoated steel pins|Patients submitted to surgical treatment with external fixators using uncoated steel pins.
62504770|NCT03762837||Exposure group：Benign gallbladder disease|Patients with benign gallbladder diseases, such as gallbladder polyps, gallstones, etc.
62703304|NCT04822181|PLACEBO_COMPARATOR|Placebo|Placebo administrated subcutaneously once weekly
62143282|NCT02797587|ACTIVE_COMPARATOR|Cytisine + Nicotine Replacement Therapy placebo|Study participants will receive active cytisine and be instructed to take the medication for 25 days; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
62143283|NCT02797587|PLACEBO_COMPARATOR|Cytisine placebo + Nicotine Replacement Therapy|Study participants will receive placebo cytisine and be instructed to take the medication for 25 days; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
62143284|NCT03844685|EXPERIMENTAL|Treatment group|1 tablet /day of MCE-11 (Promensil) taken orally for 24 months
62504771|NCT03762837||Non-exposed group: healthy people|Patients without benign gallbladder diseases
62703305|NCT06287801|EXPERIMENTAL|Annual Wellness Visits (AWV)|Randomized Vanderbilt Health Affiliated Network (VHAN) practice to AWV and assess impact on the population deemed by study algorithm as high-risk and recruit 50 participants from the VHAN primary care clinical practice (n=50/practice) to complete surveys prior to the intervention and 6 months later.
62703306|NCT06287801|EXPERIMENTAL|Annual Wellness Visits + Geriatric Resources and Assessment for the Care of Elders (AWV + GRACE)|Randomized Vanderbilt Health Affiliated Network (VHAN) practice to AWV + GRACE and assess impact on the population deemed by study algorithm as high-risk and recruit 50 participants from the VHAN primary care clinical practice (n=50/practice) to complete surveys prior to the intervention and 6 months later.
62143285|NCT03844685|PLACEBO_COMPARATOR|Placebo group|Placebo tablet (without active principle) given once a day for 24 months
62504772|NCT05138926|EXPERIMENTAL|Cervical manipulation group|high speed, low amplitude cervical manipulation
62504773|NCT05138926|SHAM_COMPARATOR|Control group|placebo mobilization without manipulation
62703307|NCT04770909|EXPERIMENTAL|Combined|Weekly incentives for dietary self-monitoring and weight loss
62703308|NCT04770909|EXPERIMENTAL|Dietary self-monitoring|Weekly incentives for dietary self-monitoring
62703309|NCT04770909|EXPERIMENTAL|Weight loss|Weekly incentives for weight loss
62703310|NCT04770909|NO_INTERVENTION|Control|
61959338|NCT03602482|ACTIVE_COMPARATOR|Supine|Participants will complete cognitive testing while supine.
61959339|NCT03978338|EXPERIMENTAL|Intervention group|The experimental group will take the brain polypeptide solution .
61959340|NCT03978338|PLACEBO_COMPARATOR|Control group|The control group was treated with the same package of placebo .
61959341|NCT04333797|OTHER|Transitional age youth|Assessed group.
61959342|NCT01824641|EXPERIMENTAL|Eliminate|Eliminate aspiration catheter
61959343|NCT01824641|ACTIVE_COMPARATOR|Conventional primary angioplasty|Patients treated with conventional primary angioplasty
61959344|NCT02516163|OTHER|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
61959345|NCT04540029||COVID-19 Exposed Pregnancy (CEP)|Women who were pregnant and delivered during the outbreak of COVID-19 pandemic in Italy, and their infants.
62504774|NCT01706263|EXPERIMENTAL|MAXCLARITY II|MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over-the-counter.
62504775|NCT05909969|EXPERIMENTAL|Pelvi-Fit Group|The experiment group will receive the treatment protocol for urinary incontinence based on evidence-based protocol through the Pelvi-Fit app.
62504776|NCT05909969|OTHER|Control|This group will receive the same treatment protocol in a descriptive form (non-app-based treatment) for urinary incontinence.
62504777|NCT04299776|EXPERIMENTAL|IPR therapy|Intrathoracic pressure regulation (IPR) therapy level of -10 cmH2O (-7 cmH2O for run-in) provided by the CirQPOD device during shoulder surgery in the sitting position
62703311|NCT04256941|EXPERIMENTAL|Arm I (ribociclib, palbociclib, abemaciclib, fulvestrant)|Patients receive ribociclib PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive fulvestrant IM for 2 injections over 1-2 minutes each on days 1 and 15 of cycle 1 and day 2 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61959346|NCT00450281||Male, Never-smokers|Male subjects who smoked less than 100 cigarettes during their lifetime.
61959347|NCT00450281||Male, Ever-smokers|Male subjects who have smoked at least 100 cigarettes during their lifetime.
62143286|NCT01898767||Mild asthma|Diagnosis of mild asthma as defined by pre-albuterol forced expiratory volume in the first second (FEV1) of \>70% predicted.
62143287|NCT05402566||Healhy volunteers|Repeated MRI and DMI for simplification of protocols. Repeated within 6 +/- 2 weeks.
62346979|NCT04873076|NO_INTERVENTION|Controll arm|"In patients in the control group, catheter ablation is performed as usual without the use of video glasses. They receive immediately before and after the ablation the same questionnaire as the patients in experimental arm. (Omitting the question about the videoglasses).~While the procedure is performed, the analgosediation is as well in the controll arm as in the experimental arm titrated until the patient is treated, sedated and painless."
62346980|NCT05521100|EXPERIMENTAL|Proglide group|Vascular Sutures for Transvenous Cardiac Interventions Using Proglide
62346981|NCT05521100|ACTIVE_COMPARATOR|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
62346982|NCT02227108|EXPERIMENTAL|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
62346983|NCT04611178||CIV-ABAO|CIV-ABAO
62346984|NCT05385874||Training cohort|The training cohort will be used for model development.
62504778|NCT04299776|ACTIVE_COMPARATOR|Standard airway|Standard airway pressure (PEEP of +5 cmH2O) during shoulder surgery in the sitting position
61959348|NCT00450281||Female, Ever-smokers|Female subjects who have smoked less than 100 cigarettes during their lifetime.
61959349|NCT00450281||Female, Never-smokers|Female subjects who have smoked at least 100 cigarettes during their lifetime.
62346985|NCT05385874||Testing cohort|The testing cohort, a new cohort compared with the training cohort, will be used for model external validation.
62504779|NCT06207669|EXPERIMENTAL|Music therapy group|A musical concert will be held for the participants in the Hicaz makam.
62504780|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
62504781|NCT02991352|EXPERIMENTAL|Experimental|Image guided needle placement into vascular malformations based on MRI
62504782|NCT00260689|EXPERIMENTAL|Horse ATG/CsA taper|h-ATG (Anti-thymocyte globulin (horse)) + 6 months CsA (Cyclosporine) followed by an 18 month CsA taper
62504783|NCT00260689|EXPERIMENTAL|Rabbit ATG/CsA|r-ATG (Anti-thymocyte globulin (rabbit)) + 6 months CsA (Cyclosporine)
62504784|NCT00260689|EXPERIMENTAL|Alemtuzumab|Alemtuzumab administered for 10 days
62504785|NCT04533906|EXPERIMENTAL|Carrageenan|Subjects sucking carageenan containing lozenge
62504786|NCT05783037|EXPERIMENTAL|New Organic Infant Formula|New organic infant formula for healthy term infants
62504787|NCT05783037|ACTIVE_COMPARATOR|Commercial Organic Infant Formula|Commercially available organic infant formula for healthy term infants
62504788|NCT05783037|NO_INTERVENTION|Breastfed Reference Group|Breastmilk
62504789|NCT06204016||premenopausal women|naturally cycling women without hormonal contraception
62703312|NCT04256941|ACTIVE_COMPARATOR|Arm II (ribociclib, palbociclib, abemaciclib, letrozole)|Patients receive ribociclib orally PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive letrozole PO QD or anastrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61959350|NCT04344509||COVID19-positive patients|
61959351|NCT04344509||COVID19-negative patients|
61959352|NCT01354990||Participants treated with sitagliptin|
61959353|NCT01898806|EXPERIMENTAL|IL TAC 2.5 mg/ml|"Intralesional Triamcinolone 2.5 mg/ml (IL TAC 2.5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20"
61959354|NCT01898806|EXPERIMENTAL|IL TAC 5 mg/ml|"Intralesional Triamcinolone 5mg/ml (IL TAC 5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
62143288|NCT05402566||Alzheimer's disease patients|MRI and DMI to assess cerebral glucose metabolism. Single examination. Compared with PET.
62143289|NCT05402566||Healthy controls|MRI and DMI for comparison with AD patients.
62143290|NCT04433780|EXPERIMENTAL|Delstrigo|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
62143291|NCT05116098|ACTIVE_COMPARATOR|100 pulmonary positive patients on tb protocol adding to supplement zinc 50 mg 400 mg once daily|
62143292|NCT05116098|PLACEBO_COMPARATOR|control group 100 patients only on tuberculosis national protocol|
62143293|NCT01275859|EXPERIMENTAL|Letrozole, Lapatinib|Letrozole 2.5mg po qd + Lapatinib 1500mg po qd for 18-21 wks
62504790|NCT06204016||postmenopausal women|women after menopause (min. 12 months no menstrual bleeding)
62703313|NCT05950945|EXPERIMENTAL|Cohort 1: HR-negative, HER2-low|Participants with HR-negative HER2-low unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.
61959355|NCT01898806|EXPERIMENTAL|IL TAC 10 mg/ml|"Intralesional Triamcinolone 10mg/ml (IL TAC 10 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
62143294|NCT02071316|ACTIVE_COMPARATOR|Treatment group, hexacapron , esomeprazole|Treatment group - receive I.V. esomeprazole 80 mg and 8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days.
61959356|NCT01898806|PLACEBO_COMPARATOR|Placebo|"Intralesional Saline (Placebo):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders."
62143295|NCT02071316|PLACEBO_COMPARATOR|Standard of care group, esomeprazole|\* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously
62346986|NCT02766322||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose \~ 16% of their presurgery body weight.
62346987|NCT02766322||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose \~ 16% of their presurgery body weight.
62346988|NCT02766322||Sleeve gastrectomy longitudinal|Morbidly obese subjects undergoing sleeve gastrectomy surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose \~ 16% of their presurgery body weight..
62346989|NCT02766322||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
62346990|NCT02766322||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
62346991|NCT02766322||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
62346992|NCT02766322||Non-surgical group|Subjects who are age and body mass index equivalent to gastric bypass (cross-sectional) and Sleeve gastrectomy (cross-sectional) but did not undergo any type of bariatric surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
62346993|NCT06006884||Sequelae group|COVID-19 convalescents that recover from prior severe acute diseases requiring hospitalization and who will be at high risk of chronic lung sequelae (with an estimate of \>50% having moderate to severe sequelae based on current literature)
62346994|NCT06006884||Recovery group|Age and gender matched individuals who had mild SARS-CoV-2 infection and experienced complete resolution of symptoms
62346995|NCT00773123||1|Primary open angle glaucoma
62346996|NCT00773123||2|Normal controls
62346997|NCT01833780||GBS carriage status|
62346998|NCT01833780||GBS status during labor|
62346999|NCT06248905|EXPERIMENTAL|exercise plus shockwaves|"Enrolled subject will be treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician, using a device powered by an electromagnetic generator.~Focusing: (out-of-line) ultrasound-guided with the patient lying in lateral decubitus.~Dosimetry: 1500-1800 shots per session with an energy flux density equal to 0.10-0.20 mJ/mm2 (frequency=4Hz).~The experimental group will then start a physiotherapy program for the following 8 weeks. The program is made up of strengthening and stretching exercises of gluteal muscles, planned to be daily performed at home. Four supervised physiotherapy session will be planned on week 0-1-2-4, during which the exercise loading will be implemented."
62347000|NCT06248905|ACTIVE_COMPARATOR|shockwaves|"Enrolled subject will be treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician, using a device powered by an electromagnetic generator.~Focusing: (out-of-line) ultrasound-guided with the patient lying in lateral decubitus.~Dosimetry: 1500-1800 shots per session with an energy flux density equal to 0.10-0.20 mJ/mm2 (frequency=4Hz)."
62347001|NCT05041322|PLACEBO_COMPARATOR|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
62143296|NCT01079806|ACTIVE_COMPARATOR|Entecavir|Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
61959357|NCT05131698|EXPERIMENTAL|Patients with advanced unresectable liver cancer|
62504791|NCT06679361|EXPERIMENTAL|Motor Exercise Group|Participants in this group will receive motor exercises targeting the wrist, including active range of motion exercises (flexion, extension, ulnar, radial deviation, and finger flexion) and nerve mobilization exercises (medial, radial, and ulnar nerves). These exercises aim to improve motor function in the wrist and hand.
62703314|NCT05950945|EXPERIMENTAL|Cohort 2: HR-negative, HER2 IHC 0|Participants with HR-negative HER2 IHC 0 unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.
61959358|NCT04653961|EXPERIMENTAL|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro Decision Support System-MDI algorithm. During the feasibility segment an approval of the study physician (may override the suggestions for safety reasons) will be required prior to sending the recomendations to participants. During the Proof of Concept segment, the recomendations will be sent directly to participants. Participants will be asked to follow the tretment plan for the following 2.5 weeks.
61959359|NCT03439553|EXPERIMENTAL|Intervention|People shown ads with referral to target websites.
61959360|NCT03439553|ACTIVE_COMPARATOR|Intervention with control websites|People shown ads with referral to control websites.
61959361|NCT03439553|NO_INTERVENTION|Control|People who make target queries, but are not shown the ads.
61959362|NCT02444520|EXPERIMENTAL|Integrated GP Care|"* GP training in utilising cognitive behavioural skills during 10-minute consultations;~* GP Supervision;~* Audio-visual and written materials/guidelines for GP's;~* Copies of self-help materials for patients;• Integrated case management discussion prior to secondary care referral. GPs will be encouraged to consult with a colleague before making a referral;~* Booklets for patients once consent gained."
61959363|NCT02444520|NO_INTERVENTION|Waiting List Control Group|Patients in the waiting list control group will continue to receive treatment as usual (TAU), and will be crossed over to receive 'Integrated GP Care' at 6 months post randomization.
61959364|NCT02398175||Pediatric polytraumatized patients with thoracic injuries|Pediatric polytraumatized patients (age \< 18), (ISS \> 16) with thoracic injuries
62347002|NCT05041322|ACTIVE_COMPARATOR|Buspirone|"Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.~Other Names:~Buspar"
62347003|NCT05147974|EXPERIMENTAL|Intervention arm|A cohort of YAC patients to be studied, pre \& post-intervention, prospectively. All participants will be assigned to the intervention (complete DOZE app: Sleep diary and DOZE modules).
62347004|NCT00379262|EXPERIMENTAL|1A|Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy
62347005|NCT00379262|EXPERIMENTAL|1B|Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy
62347006|NCT00379262|EXPERIMENTAL|2A|Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy
62347007|NCT00379262|EXPERIMENTAL|2B|Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy
62347008|NCT00379262|EXPERIMENTAL|3A|Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy
62347009|NCT00379262|EXPERIMENTAL|3B|Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy
62347010|NCT06293677|ACTIVE_COMPARATOR|Control Group 1c|Group 1c includes patients with augmented renal clearance (ARC) who have been randomized to receive a standard dosage of antibiotic (méropenem or piperacilline-tazobactam)
62347011|NCT06293677|EXPERIMENTAL|Intervention DAR-ARC Group 1i|Group 1i (DAR-ARC) includes patients with ARC who have been randomized to receive an experimental dosage of antibiotic (méropenem or piperacilline-tazobactam)
62347012|NCT06293677|ACTIVE_COMPARATOR|Control Group 2|Control Group 2 includes patients with normal or decreased renal function who will receive standard dosage of antibiotic (méropenem or piperacilline-tazobactam)
62347013|NCT00997321|ACTIVE_COMPARATOR|Propofol|propofol 1 milligram per kilogram intravenous bolus followed by 0.5 millligrams per kilogram as needed for mooderate procedural sedation
62347014|NCT00997321|ACTIVE_COMPARATOR|Ketamine|ketamine 1 milligram per kilogram followed by 0.5 millgram per kilogram as needed for moderate procedural sedation
62504792|NCT06679361|EXPERIMENTAL|Sensory Exercise Group|This group will engage in sensory exercises designed to enhance sensory awareness in the hand and wrist. Exercises will include interaction with varied textures (such as sand and sensory balls), different fabrics (fur, satin, linen), and multisensory foam gels. The goal is to improve sensory function and tactile discrimination.
61959365|NCT03362008|EXPERIMENTAL|Group I|Period I: administration of Zeropix Period II: administration of Champix®
61959366|NCT03362008|EXPERIMENTAL|Group II|Period I: administration of Champix® Period II: administration of Zeropix
62347015|NCT04453904|EXPERIMENTAL|"sequential radiochemotherapy in a sanwich mode"|Two courses of TC regimen chemotherapy (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) will be given first, followed by external pelvic radiation (± vaginal brachytherapy), and then four courses of the same regime consolidation chemotherapy.
62347016|NCT04453904|ACTIVE_COMPARATOR|concurrent chemoradiotherapy followed by chemotherapy|External pelvic radiation (± vaginal brachytherapy) will be given after operation. On the first day and the 29th day of radiotherapy, concurrent intravenous cisplatin (50mg/m2) will be given. After the concurrent radiochemotherapy, four courses of TC regimen (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) chemotherapy will be given.
62347017|NCT04882709|ACTIVE_COMPARATOR|Receiver-in-canal hearing aid 1 default|Receiver-in-canal hearing aid with current default compression strategy
62347018|NCT04882709|ACTIVE_COMPARATOR|Receiver-in-canal hearing aid 2|Receiver-in-canal hearing aid from a different manufacturer with default compression strategy
62347019|NCT04882709|EXPERIMENTAL|Receiver-in-canal hearing aid 1 strategy 1|Receiver-in-canal hearing aid with modified compression strategy 1
62347020|NCT04882709|EXPERIMENTAL|Receiver-in-canal hearing aid 1 strategy 2|Receiver-in-canal hearing aid with modified compression strategy 2
62347021|NCT04882709|NO_INTERVENTION|No device|Stimuli recordings without hearing aid
62504793|NCT06679361|EXPERIMENTAL|Combined Motor and Sensory Exercise Group|Arm Description: Participants in this group will perform both motor and sensory exercises as described for the first two groups. By combining motor and sensory interventions, this group aims to improve both motor skills and sensory awareness in the wrist and hand, potentially enhancing overall hand function more effectively.
62504794|NCT06679361|NO_INTERVENTION|control|The control group did not receive any additional treatments during the study period, allowing for a clear comparison between the experimental group and the baseline conditions.
62504795|NCT04055545|ACTIVE_COMPARATOR|MICT|
62504796|NCT04055545|ACTIVE_COMPARATOR|HIIT|
62504797|NCT02722616|ACTIVE_COMPARATOR|Pancreatic Cancer|"A 4D ultrasound scan of the pancreas will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor pancreas motion. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
61959367|NCT00404261|OTHER|Arm 1|Fluticasone/Salmeterol HFA MDI without counter
61959368|NCT00404261|OTHER|Arm 2|Fluticasone/Salmeterol HFA MDI with counter
61959369|NCT01925105|EXPERIMENTAL|Optimization of treatment|Optimization of treatment of diseases and symptoms
61959370|NCT01925105|PLACEBO_COMPARATOR|Control|Treatment as usual
62504798|NCT02722616|ACTIVE_COMPARATOR|Liver Cancer|"A 4D ultrasound scan of the liver will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor liver motion. The system will record all relevant images, but will not be used in clinical decision making. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
61959371|NCT06248801|EXPERIMENTAL|Sequence 1-Vildagliptin and Metformin test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Vildagliptin and Metformin tablets 50/1000 mg test product, treatment 2= Vildagliptin and Metformin tablets 50/1000 mg reference product.
61959372|NCT06248801|EXPERIMENTAL|Sequence 1-Vildagliptin and Metformin reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Vildagliptin and Metformin tablets 50/1000 mg test product, treatment 2= Vildagliptin and Metformin tablets 50/1000 mg reference product.
61959373|NCT02140372|EXPERIMENTAL|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
62143297|NCT01079806|PLACEBO_COMPARATOR|Placebo|Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
62143298|NCT06143007|EXPERIMENTAL|BB3008 monotherapy|The study is composed of fasted dose cohorts and fed dose cohort. BB3008 will be administered orally daily alone as monotherapy in all cohorts. In the fasted dose cohorts, the subjects will receive once daily of BB3008 monotherapy fasted across approximately 6 ascending dose levels. The starting dose is 80 mg/day. In the fed dose cohort, the subjects will receive once daily of BB3008 monotherapy in a fed condition. The dose selected for fed dose cohort must be deemed safe as assessed by safety monitoring committee (SMC).
61959374|NCT01831050|EXPERIMENTAL|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
61959375|NCT01831050|EXPERIMENTAL|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
61959376|NCT01831050|EXPERIMENTAL|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
61959377|NCT01831050|EXPERIMENTAL|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
61959378|NCT01831050|EXPERIMENTAL|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
61959379|NCT01831050|EXPERIMENTAL|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
62143299|NCT01888484|EXPERIMENTAL|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
62143300|NCT02245529||Patients with benign prostatic hyperplasia (BPH)|
62143301|NCT04762914||Prehabilitation (PH)|Patients who underwent prehabilitation prior to colorectal cancer resection
62504799|NCT02722616|OTHER|Healthy Volunteer|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images. Additional registration of ultrasound images will be performed with Velocity software to evaluate accuracy of automated registration software in the ultrasound system.
61959380|NCT01831050|EXPERIMENTAL|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
61959381|NCT01831050|EXPERIMENTAL|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
61959382|NCT01831050|EXPERIMENTAL|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
61959383|NCT06110611|EXPERIMENTAL|dental implant and a screw-retained implant-supported zirconia restoration|patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration
61959384|NCT05230290|EXPERIMENTAL|KD6001 Injection|Participants will be administered KD6001 at an applicable dose as monotherapy
61959385|NCT03054441||Experimental group|Children, Adolescents and Young with hemiplegia
61959386|NCT03054441||Control group|Children, Adolescents and Young with typical development
62504800|NCT02574338|ACTIVE_COMPARATOR|group - 1 Foley's Catheter|will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours
62504801|NCT02574338|ACTIVE_COMPARATOR|Group - 2 Prostaglandin E1 Analogue|will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)
62504802|NCT05373641|EXPERIMENTAL|Pain documentation audit and repeated feedback|Pain documentation audit and repeted feedback
62504803|NCT05373641|ACTIVE_COMPARATOR|Pain documentation audit|Pain documentation audit
62504804|NCT02389842|EXPERIMENTAL|Palbociclib + Taselisib|The starting dose of palbociclib in combination with taselisib will be 100mg OD of palbociclib and 2mg taselisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
62504805|NCT02389842|EXPERIMENTAL|Palbociclib + Pictilisib|The starting dose of palbociclib in combination with pictilisib will be 100mg OD of palbociclib and 195 mg pictilisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
61959387|NCT01804283|SHAM_COMPARATOR|CON|Patients undergoing double valve replacement (aortic and mitral).
61959388|NCT01804283|EXPERIMENTAL|IPO|Patients undergoing double valve replacement (aortic and mitral) with ischemic postconditioning.
61959389|NCT03921944|OTHER|total shoulder replacement surgery|Subjects will be assessed for the outcome measures at one year and two year timepoints post total shoulder replacement surgery
61959390|NCT03809052|EXPERIMENTAL|A1 - 5 mg GB1211 single dose and Placebo|6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
61959391|NCT03809052|EXPERIMENTAL|A2 - 20 mg GB1211 single dose and Placebo|6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
62143302|NCT04762914||Non-Prehabilitation (NPH)|Patients who did not undergo prehabilitation prior to colorectal cancer resection
62347022|NCT06141655|EXPERIMENTAL|QIV-HD vaccine|EFLUELDA, Suspension for injection, one dose
62347023|NCT06141655|ACTIVE_COMPARATOR|QIV-SD vaccine|INFLUVAC TETRA, Suspension for injection, one dose
62347024|NCT01480557|ACTIVE_COMPARATOR|Liquefaction group|Subjects that were operated for cataract using liquefaction technology
62347025|NCT01480557|ACTIVE_COMPARATOR|Torsional ip group|Subjects that were operated for cataract using torsional ip technology
62347026|NCT03719482|EXPERIMENTAL|[18F]MNI-1054|To measure blood metabolites of \[18F\]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.
62347027|NCT05475574|NO_INTERVENTION|Before discontinuation of contact precautions for ESBLE|Implementation of contact precaution in addition to standard precaution for any patient carrying (infected or colonized) ESBLE
62347028|NCT05475574|EXPERIMENTAL|After discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
62347029|NCT05677191|EXPERIMENTAL|proximal femoral nail|20 patient with trochanteric fractures , unstable type will use proximal femoral nail
62504806|NCT00076245|EXPERIMENTAL|1 Light therapy|
62504807|NCT00076245|EXPERIMENTAL|2 Cognitive behavioral therapy|
62143303|NCT03029299|NO_INTERVENTION|Control|Subjects receive standard of care testing as determined by the clinician.
62143304|NCT03029299|EXPERIMENTAL|Intervention|Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)
62143305|NCT01702376|EXPERIMENTAL|Retosiban 100 mg|Each subject will be randomized to single dose of retosiban 100 mg in one of the four treatment sequences.
62143306|NCT01702376|EXPERIMENTAL|Retosiban 800 mg|Each subject will be randomized to single dose of retosiban 800 mg in one of the four treatment sequences
62347030|NCT05677191|ACTIVE_COMPARATOR|Dual Mobility Arthroplasty|20 patient with trochanteric fractures , unstable type will use dual mobility arthroplasty
62347031|NCT04090047|EXPERIMENTAL|PF-06700841 and Itraconazole|This fixed sequence, 2-period arm will consist of two treatments. Participants will receive a single oral dose of 30 milligrams (mg) PF-06700841 on Day 1 in Period 1. On Days 1-7 in Period 2, Itraconazole 200mg will be administered once daily(QD). On Day 4 of Period 2, co-administration of Itraconazole 200 mg and 30 mg PF-06700841 tablets will occur.
62347032|NCT00164736|ACTIVE_COMPARATOR|Maternal ARVs & Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) \& daily nutritional supplement given to the mother
62347033|NCT00164736|ACTIVE_COMPARATOR|Infant NVP & Nutrition Supplement|Extended infant nevirapine for prophylaxis \& daily nutritional supplment given to the mother
62504808|NCT00076245|EXPERIMENTAL|3 Light therapy plus cognitive behavioral therapy|
62504809|NCT00076245|NO_INTERVENTION|4 Control|
62504810|NCT05722028||Patients with benign uterine findings (polyp / retained products of conception)|Female patients undergoing diagnostic hysteroscopy with a diagnosis of uterine polyp or retained products of conception. These patients are then invited to a surgical office procedure without anaesthesia to remove these findings.
62504811|NCT02010996|EXPERIMENTAL|Vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
62504812|NCT02010996|ACTIVE_COMPARATOR|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
61959392|NCT03809052|EXPERIMENTAL|A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo|6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.
61959393|NCT03809052|EXPERIMENTAL|A4 - 100 mg GB1211 single dose and Placebo|6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
61959394|NCT03809052|EXPERIMENTAL|A5 - 200 mg GB1211 single dose and Placebo|6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
62703315|NCT05950945|EXPERIMENTAL|Cohort 3: HR-positive, HER2-low|"Participants with HR-positive HER2-low unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.~Participants must also have recurrent disease \<2 years from the initiation of adjuvant ET or have disease progression on CDK4/6 inhibitor-based regimen within 12 months of completion of adjuvant therapy with a CDK4/6 inhibitor or have disease progression within the first 12 months of CDK4/6 in the first line metastatic setting."
62703316|NCT05950945|EXPERIMENTAL|Cohort 4: HR-positive, HER2 IHC 0|Participants with HR-positive HER2 IHC 0 unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.
62703317|NCT05549258|EXPERIMENTAL|Inebilizumab|Infusion of Inebilizumab
62703318|NCT06152003|NO_INTERVENTION|Enhanced Treatment as Usual (ETAU)|We anticipate the control condition will contain the following: the enhanced treatment as usual (ETAU; n=30) will consist of PWH receiving treatment at their HIV primary care clinic as usual, enhanced by supplemental food parcels and referrals for mental health care and food service organizations. Treatment as usual for mental health care is evaluation by a nurse and referral to a medical officer or to a traveling psychologist available 1 day per week. Because there is no standard of care for food insecurity, we propose that all participants will receive food parcels, but ETAU participants will not receive case management or psychosocial intervention.
62143307|NCT01702376|PLACEBO_COMPARATOR|Placebo|Each subject will be randomized to single dose of matching placebo in one of the four treatment sequences
62143308|NCT01702376|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|Each subject will be randomized to single dose of moxifloxacin 400 mg in one of the four treatment sequences
62504813|NCT06157463||observation|Ga-68 FAPI study before and during TNT
62504814|NCT02119962|EXPERIMENTAL|Working memory training|
62703319|NCT06152003|EXPERIMENTAL|Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)|We anticipate the intervention condition (CBT-SA) will contain the following: cognitive behavioral therapy for syndemics and adherence (CBT-SA; n=30) likely will be comprised of both psychosocial and structural intervention components, based on the results of Aim 1 and refinement in Aim 2. In addition to food parcels, we expect the CBT-SA condition will also receive nutritional counseling, linkage to care, and case management. Only the CBT-SA condition will receive the psychological intervention for depression and PTSD and adherence counseling. Specific intervention components will be informed by prior aims.
62703320|NCT04741542|EXPERIMENTAL|Group A|Study subjects will receive a 14mg/kg starting dose of SP-420 three times a week
62703321|NCT04741542|EXPERIMENTAL|Group B|Study subjects will receive a 28mg/kg starting dose of SP-420 three times a week
62703322|NCT04741542|EXPERIMENTAL|Group C|Study subjects will receive a 42mg/kg starting dose of SP-420 three times a week
62703323|NCT04741542|EXPERIMENTAL|Group D|Study subjects will receive a 56mg/kg starting dose of SP-420 three times a week
62703324|NCT06748404|EXPERIMENTAL|ARM A|TriCalm Hydrogel® during cycles 1 and 2
62703325|NCT06748404|ACTIVE_COMPARATOR|ARM B|Triamcinolone cream during cycle 1 followed by Tricalm Hydrogel® during cycle 2
62703326|NCT06751160|EXPERIMENTAL|Dry Needling|Dry Needling along with baseline treatment
62143309|NCT00890591|EXPERIMENTAL|Treatment|
62143310|NCT03488043||Retrospective cohort|All patients having a CT-guided transthoracic biopsy from September 2012 and September 2017.
62143311|NCT03488043||Prospective cohort|All patients having a CT-guided transthoracic biopsy from April 2018.
62143312|NCT02116075|EXPERIMENTAL|Epidural Steroid|80mg depo-medrol 9mL 1% lidocaine
62143313|NCT02116075|ACTIVE_COMPARATOR|Epidural Prolotherapy|10ml of 5% generic dextrose
62143314|NCT00773500||1|Providers adopting electronic prescribing in New York City, New York
62143315|NCT00773500||2|Providers adopting electronic prescribing in the Taconic region of New York
62347034|NCT00164736|ACTIVE_COMPARATOR|Maternal ARVs & No Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) \& no nutritional supplement given to the mother
62504815|NCT02119962|PLACEBO_COMPARATOR|Placebo training|
62504816|NCT04025294|EXPERIMENTAL|Students playing videogame|The experimental group will consist of our videogame intervention including the five mini-games.
62504817|NCT04025294|ACTIVE_COMPARATOR|Students receiving school climate assessment|The control group differs from the experimental group as it includes the school climate assessment tool but excludes the mini-games
62504818|NCT02116894|EXPERIMENTAL|PF-03446962 plus regorafenib|
62504819|NCT05939804|EXPERIMENTAL|TENS group|60 minutes of TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher. After the procedure, the amount of analgesic consumed by the experimental group in the first hour will be questioned and recorded.
62504820|NCT05939804|NO_INTERVENTION|Control group|The routine treatment and care of the control group will not be interfered with.
62703327|NCT06751160|EXPERIMENTAL|Soft Tissue Mobilization|Soft Tissue Mobilization along with baseline treatment
61959395|NCT03809052|EXPERIMENTAL|B1 - GB1211 multiple ascending doses, 50mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.
61959396|NCT03809052|EXPERIMENTAL|B2 - GB1211 multiple ascending doses, 100mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..
61959397|NCT03809052|EXPERIMENTAL|A6 - 50mg GB1211 single dose and Placebo|8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
61959398|NCT03809052|EXPERIMENTAL|A7 - 400 mg GB1211 single dose and Placebo|8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
61959399|NCT03809052|EXPERIMENTAL|Part A - Placebo for GB1211|In Part A - 2 subjects from each arm (A1-A5) will receive placebo.
61959400|NCT03809052|EXPERIMENTAL|Part B - Placebo for GB1211 (BID)|Part B - 3 subjects from each arm B1 and B2 will receive placebo.
61959401|NCT04946188|EXPERIMENTAL|Opuz NICGM|Participants will be provided with one non-invasive, custom-built prototype device (study device), which they will use throughout their day-to-day life/activities over the study period.
61959402|NCT02521870|EXPERIMENTAL|Dose Escalation Phase 1b|Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).
61959403|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 1)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
61959404|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 2)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
62504821|NCT05054049|EXPERIMENTAL|Abbott i-stat Allinity|Randomised patients to this arm receive the application of the point of care testing device to provide further diagnostic information to assist clinical decision making.
61959405|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 3)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
61959406|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 4)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
62143316|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
62347035|NCT00164736|ACTIVE_COMPARATOR|Infant NVP & No Nutrition Supplement|Extended infant nevirapine for prophylaxis \& no nutritional supplment given to the mother
62504822|NCT05054049|PLACEBO_COMPARATOR|Usual Care|Randomised patients to this arm receive usual care.
62703328|NCT06410534|EXPERIMENTAL|1: nivolumab and ipilimumab|Nivolumab (3 mg/kg) every 3 weeks for up to an initial 4 cycles (an additional 4 cycles may be given depending on response, for a total of 8 cycles); low-dose ipilimumab at 1 mg/kg every other cycle (every 6 weeks) for up to an initial 2 doses (an additional 2 doses may be given depending on response, for a maximum of 4 doses).
62703329|NCT06410534|EXPERIMENTAL|2: nivolumab|Nivolumab (3 mg/kg) every 3 weeks for up to an initial 4 cycles (an additional 4 cycles may be given depending on response, for a total of 8 cycles).
62143317|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
62143318|NCT01171053|PLACEBO_COMPARATOR|Attention control|Weekly support from therapist without CBT-interventions
62143319|NCT01171053|EXPERIMENTAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support
62504823|NCT04366596|EXPERIMENTAL|DEB group|angioplasty with paclitaxel eluting balloon
62504824|NCT04366596|PLACEBO_COMPARATOR|POB group|Angioplasty with plain old balloon
62504825|NCT04861740|EXPERIMENTAL|Screening + Autism ALERT|Clinics in the intervention arm receive Autism ALERT plus an ASD screening intervention (START Autism).
62504826|NCT04861740|ACTIVE_COMPARATOR|Screening Only|Clinics in the comparison intervention (control) arm receive the ASD screening intervention only (START Autism).
62504827|NCT01362673|EXPERIMENTAL|Single dose|
62504828|NCT01362673|EXPERIMENTAL|Multiple dose|
62504829|NCT02748655|PLACEBO_COMPARATOR|Tap water|Oral consumption of tap water
62504830|NCT02748655|ACTIVE_COMPARATOR|Alkaline ionized water|Oral consumption of alkaline ionized water
62703330|NCT00001373||Affected|Patients with auto-inflammatory disorders
62703331|NCT00001373||Family Members|Family members of patients
62703332|NCT00001373||Healthy Volunteers|Healthy Volunteers
62703333|NCT00902044|EXPERIMENTAL|Autologous HER2-specific T cells|"THIS ARM IS CLOSED~Dose Level 1: 1x10\^4 cells/m2~Dose Level 2: 3x10\^4 cells/m2~Dose Level 3: 1x10\^5 cells/m2 (NOT BEING USED)~Dose Level 4: 3x10\^5 cells/m2 (NOT BEING USED)~Dose Level 5: 1x10\^6 cells/m2~Dose Level 6: 3x10\^6 cells/m2~Dose Level 7: 1x10\^7 cells/m2~Dose Level 8: 3x10\^7 cells/m2~Dose Level 9: 1x10\^8 cells/m2"
61959407|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 5)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
61959408|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 6)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
61959409|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 7)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.
61959410|NCT02521870|EXPERIMENTAL|Dose Expansion Phase 2 (Cohort 8)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.
61959411|NCT00684346|EXPERIMENTAL|1|
61959412|NCT02170597|EXPERIMENTAL|BIBR 1018 MS HPMC capsule fasted|
61959413|NCT02170597|EXPERIMENTAL|BIBR 1048 MS HPMC capsule after high fat meal|
61959414|NCT02170597|ACTIVE_COMPARATOR|BIBR 1048 MS gelatine capsule fasted|
61959415|NCT02644135|EXPERIMENTAL|Halo Oral Spray|Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
61959416|NCT02644135|PLACEBO_COMPARATOR|Halo Placebo|The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
61959417|NCT02241629|EXPERIMENTAL|levo phencynonate hydrochloride 1mg|levo phencynonate hydrochloride tablet 1mg
61959418|NCT02241629|PLACEBO_COMPARATOR|placebo|Placebo
62347036|NCT00164736|ACTIVE_COMPARATOR|No Drugs & Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis \& daily nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
62504831|NCT02618382|EXPERIMENTAL|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
62703334|NCT00902044|EXPERIMENTAL|HER2-specific T cells+fludarabine|"Autologous HER2-specific T cells+fludarabine:~Dose Level 9A: fludarabine followed by 1x10\^8 cells/m\^2"
62703335|NCT00902044|EXPERIMENTAL|HER2-specific T cells+fludarab.+cycloph.|"Autologous HER2-specific T cells+fludarabine+cyclophosphamide:~Dose Level 9B: fludarabine + cyclophosphamide followed by 1x10\^8 cells/m\^2"
62703336|NCT00902044|EXPERIMENTAL|CAR Positive cells|Dose Level 9C: fludarabine + cyclophosphamide followed by 1x10\^8 cells/m\^2 CAR positive cells/m\^2
61959419|NCT02241629|EXPERIMENTAL|levo phencynonate hydrochloride 2mg|levo phencynonate hydrochloride 2mg
61959420|NCT02849678|ACTIVE_COMPARATOR|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
62703337|NCT04418466|EXPERIMENTAL|DLP-114 alpha-4 (6-months)|Group 1: 6-month implant arm Oral phase: 3mg of Risperidone for 2 weeks Implant phase: 2 implants (360mg of Risperidone per implant) for 6 months
61959421|NCT02849678|ACTIVE_COMPARATOR|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
61959422|NCT01405742|EXPERIMENTAL|Arm A|"The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds."
61959423|NCT01405742|EXPERIMENTAL|Arm B|"The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds"
61959424|NCT06218485|EXPERIMENTAL|Experimental group|The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making.
61959425|NCT06218485|ACTIVE_COMPARATOR|Control group|The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy.
61959426|NCT05349916|EXPERIMENTAL|Control|
61959427|NCT05349916|EXPERIMENTAL|Isomaltodextrin Low Dose|
61959428|NCT05349916|EXPERIMENTAL|Isomaltodextrin High Dose|
61959429|NCT05349916|EXPERIMENTAL|GPC partially digestible maltodextrin|
61959430|NCT05349916|EXPERIMENTAL|Resistant Starch Type 4|
61959431|NCT06557447|OTHER|Test Group|Subjects treated between 2019 and 2020 with the NobelActive TiUltra implant and On1 Base Xeal abutment on a previous clinical study protocol approaved by Ethics Committee.
61959432|NCT06557447|OTHER|Control Group|Subjects treated in 2017 with NobelActive TiUnite implant and On1 machined abutment on a previous clinical study protocol approaved by Ethics Committee.
62143320|NCT05616494|EXPERIMENTAL|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) will be administrated once every 3 weeks.
61959433|NCT00541710|PLACEBO_COMPARATOR|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
61959434|NCT00541710|EXPERIMENTAL|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
61959435|NCT01666574|EXPERIMENTAL|Test cereal 1, Oat-based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based cereal will cause people to eat less at lunch.
61959436|NCT01666574|EXPERIMENTAL|Test Cereal 2, Oat based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based ready-to-eat cereal will cause people to eat less at lunch.
61959437|NCT04686071|EXPERIMENTAL|PNF method|
61959438|NCT04686071|OTHER|standard rehabilitation|
61959439|NCT00025493|EXPERIMENTAL|docetaxel|docetaxel
61959440|NCT03338374|EXPERIMENTAL|Biventricular Pacemaker|All subjects to be in a single study group experiencing all interventions.
61959441|NCT06119945|EXPERIMENTAL|DWJ1568|DWJ1568
61959442|NCT06119945|ACTIVE_COMPARATOR|DWC202215|DWC202215
61959443|NCT06085612||Internal Carotid Artery Stenosis|Group of patients with internal carotid stenosis detected via ultrasound examination.
61959444|NCT06085612||Non stenotic Internal Carotid Artery|Group of patients without internal carotid stenosis on ultrasound examination.
61959445|NCT02613975|EXPERIMENTAL|on positional device|patients who could not tolerate cpap will be provided with positional device for treatment of OSA which will vibrate when patients lie in prone position
61959446|NCT02613975|EXPERIMENTAL|patients on dental device|patients on dental devices but not optimally treated for OSA will be provided positional device for optimization of treatment for OSA, which will vibrate when patients lie in prone position
61959447|NCT02469753|EXPERIMENTAL|Patients treated with anti-TNF and continuous daily NSAIDs|
61959448|NCT02469753|ACTIVE_COMPARATOR|Patients treated with anti-TNF and NSAIDs on demand|
61959449|NCT01372267|EXPERIMENTAL|CBT for pain|
61959450|NCT01372267|ACTIVE_COMPARATOR|Psychoeducational control group|This group is designed to be an active control which provides detailed information about substance us and chronic pain without providing any CBT or other specific therapy.
61959451|NCT04533581|EXPERIMENTAL|ME-401|
61959452|NCT00176228|EXPERIMENTAL|lamotrigine|The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg. Increasing the medication to final dose will take 8 weeks and the response on full and tolerable dose is further monitored for response over 6 weeks. Therefore, this is a 18-26 week trial (2 to 12 weeks=screening and wash out; 8 weeks=dosing; 6 weeks=acute trial period on full dose).
62347037|NCT00164736|NO_INTERVENTION|No Drugs & No Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis \& no nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
62347038|NCT05665244||Upper airway cough syndrome|
62347039|NCT03270553|EXPERIMENTAL|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
62504832|NCT02249117|EXPERIMENTAL|BIWH 3|single escalating dose
61959453|NCT05496062|EXPERIMENTAL|F&P Toffee Nasal and Toffee Nasal Pillows Mask|Participants will be placed in the experimental arm for 14 days, during which they will be using either the Toffee Nasal or Toffee Nasal Pillows mask for PAP therapy.
61959454|NCT04397783|NO_INTERVENTION|Cruciate incision|the classic cruciate incision in the colostomy construction
61959455|NCT04397783|EXPERIMENTAL|longitudinal incision|longitudinal incision with two proline sutures
61959456|NCT05199129|EXPERIMENTAL|HCP1904-3|
61959457|NCT05199129|ACTIVE_COMPARATOR|RLD2001-1|
61959458|NCT06505889|EXPERIMENTAL|Cryo-analgesic group (Ice pack)|"A standard cold pack chilled to -4°C will be applied to the arterial puncture site for 2 minutes. Following antiseptic cleaning and the physician will immediately perform the arterial blood sampling procedure with heparinized 3mL arterial blood gas syringe with a 22G x 1 needle."
62504833|NCT02249117|PLACEBO_COMPARATOR|Placebo|
62703338|NCT04418466|EXPERIMENTAL|DLP-114 alpha-7 (12-months)|Group 2: 12-month implant arm Oral phase: 3mg of Risperidone for 2 weeks Implant phase: 2 implants (435mg of Risperidone per implant) for 12 months
61959459|NCT06505889|EXPERIMENTAL|Analgesic drug group (10% lidocaine spray)|"10% lidocaine spray will be applied to the puncture site, covering a circular area (2-3 cm radius) around the puncture site for 2 minutes. Following antiseptic cleaning and the physician will immediately perform the arterial blood sampling procedure with heparinized 3mL arterial blood gas syringe with a 22G x 1 needle."
61959460|NCT06505889|NO_INTERVENTION|Control group (2% Chlorhexidine alcohol)|"This group will receive standard antiseptic preparation with chlorhexidine in alcohol applied in a circular area (2-3 cm radius) around the puncture site for 2 minutes. Following antiseptic cleaning and the physician will immediately perform the arterial blood sampling procedure with heparinized 3mL arterial blood gas syringe with a 22G x 1 needle."
61959461|NCT05574790||Admitted|We will include patients who had been admitted by meeting Ollero et al categories in hospitalization ward
61959462|NCT01499056|EXPERIMENTAL|hip osteoarthritis|The patients with hip joint osteoarthritis who underwent cell injection
61959463|NCT04566679|EXPERIMENTAL|Butyrate|oral butyrate (500mg) once or twice per day
61959464|NCT04566679|PLACEBO_COMPARATOR|Placebo|oral placebo once or twice per day
62143321|NCT06294834|OTHER|Group 1: therapists|Group 1 will receive the active intervention (intervention A) of remote wheelchair skills training. They will cross-over to receive the control intervention (intervention B) of education on wheelchair provision at 6 months.
61959465|NCT02336971|EXPERIMENTAL|CBCT for PTSD|"CBCT for PTSD is a time-limited, problem-focused treatment that aims to improve PTSD and relationship functioning. The study investigators have developed a 15-session treatment plan each session lasting 75-minutes.~The treatment is sequenced such that the rationale and psychoeducation provide the basis for the behavioral skills training designed to improve communication and relationship functioning, and to overcome behavioral and experiential avoidance. These skills are used in the final phase of the treatment that is focused on cognitive mechanisms contributing to PTSD and relationship dysfunction."
61959466|NCT02336971|EXPERIMENTAL|Prolonged Exposure|"PE for combat-related stress disorders \[13-14\] serves as the comparison treatment.~The therapy is usually conducted in 10-12 sessions, each lasting 90-minutes, with the majority of the sessions devoted to imaginal exposure to traumatic memories and homework assignments that include in vivo exposure assignments. In the present study, participants will complete 12 sessions of PE to equate the number of sessions with those of CBCT. Partners of individuals with PTSD are not typically incorporated into the treatment program and so for this study a revised version of PE \[1-3\] will be administered in which the partner is seen during the second session to discuss PTSD, other reactions to trauma and the treatment procedures."
61959467|NCT01496612|EXPERIMENTAL|Study Phase|
61959468|NCT01496612|PLACEBO_COMPARATOR|Alternate Study Phase|
61959469|NCT02703662|ACTIVE_COMPARATOR|Strattice biologic mesh|Strattice mesh is made of noncross-linked porcine dermis, which is used to support abdominal wall reconstruction.
61959470|NCT02703662|EXPERIMENTAL|Permacol biologic mesh|Permacol mesh is made of cross-linked porcine dermis, which is used to support abdominal wall reconstruction.
61959471|NCT00705198||Newly diagnosed patients|Patients treated with temozolomide for newly diagnosed malignant glioma
62703339|NCT05627362|EXPERIMENTAL|Double-Blind Period: Elafibranor 80 mg|Participant will receive two tablets per day (one tablet of elafibranor 80 mg + 1 tablet of placebo matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.
62703340|NCT05627362|EXPERIMENTAL|Double-Blind Period: Elafibranor 120 mg|Participant will receive 2 tablets per day (one tablet of elafibranor 120 mg + 1 tablet of placebo matching the 80 mg sized tablet) over the 12 weeks in Double-blind period.
61959472|NCT00705198||Relapsed patients|Patients treated with temozolomide for relapsed malignant glioma
62347040|NCT03270553|EXPERIMENTAL|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
62703341|NCT05627362|PLACEBO_COMPARATOR|Double-Blind Period: Placebo|Participant will receive 2 placebo tablets per day (one matching the 80 mg sized tablet + one matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.
62703342|NCT05627362|EXPERIMENTAL|Open-Label Extension Period: Elafibranor 120 mg|Participant will receive one tablet per day (elafibranor 120 mg) over the 96 weeks in Open-Label extension period.
61959473|NCT00705198||Newly diagnosed anaplastic astrocytoma patients|Patients treated with temozolomide for newly diagnosed anaplastic astrocytoma
61959474|NCT03499704|EXPERIMENTAL|Pioglitazone + Alogliptin + Metformin (PAM)|Pioglitazone 15 milligram (mg) and alogliptin 25 mg in fixed dose combination (FDC) tablet (SYR-322-4833), orally once daily and metformin greater than or equal to (\>=) 500 mg, tablet, orally, twice a day for up to 26 weeks. At Week 12, if participants has HbA1c \>=7.5%, pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 26.
61959475|NCT03499704|ACTIVE_COMPARATOR|Dapagliflozin + Alogliptin + Metformin (DAM)|Dapagliflozin 10 mg, tablet, orally, once daily with alogliptin 25 mg, tablet, orally, once daily, and metformin \>=500 mg, tablet, orally, twice a day, for up to Week 26.
61959476|NCT05682898||More than 7 weeks|Timing of colorectal cancer surgery is more than 7 weeks after confirmed COVID-19 infection by COVID-19 nucleic acid test.
62347041|NCT05915494|EXPERIMENTAL|group A|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
62347042|NCT05915494|ACTIVE_COMPARATOR|group B|traditional physiotherapy group (n = 20 inhalation injury children). In this inhalation group, traditional physical therapy program will be handled only for 12 weeks. Also, free walking for 30 minutes daily will be performed by children.
62347043|NCT02450734||Carotid endarterectomy|Realisation of an ultrasound-guided intermediate cervical plexus block for anesthesia of carotid endarterectomy
62347044|NCT02247401|ACTIVE_COMPARATOR|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent \[DAA\]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
62347045|NCT02247401|ACTIVE_COMPARATOR|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
62347046|NCT02247401|ACTIVE_COMPARATOR|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
62347047|NCT00245414|EXPERIMENTAL|1|Interferon (IFN)-Treated
62347048|NCT00245414|EXPERIMENTAL|2|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is positive at week 1
62347049|NCT00245414|EXPERIMENTAL|3|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
62703343|NCT05777889||Study CRPS Group|"Enrolled patients with complex regional pain syndrome undergoing a surgical procedure that requires spinal cord stimulation.~All participants in the group will have an image of their feet taken perpendicularly with a 1-inch space from all four sides using a FLIR T420 or T62101 camera with 320\*240 resolution.~All participants will also answer questionnaires about: their average pain score, CRPS severity, quality of life, and neuropathic pain."
62714951|NCT06423508||storage buffer standardisation|Identifying the most effective storage buffer for preserving protein integrity during the transportation of fecal samples from collection to processing sites, is essential for establishing consistent sample collection protocols, particularly for large-scale human fecal proteomic studies. Achieving consistency in sample collection is crucial for enabling individuals to have their gut health assessed via metaproteomics, unlocking the potential for personalized medicine and therapeutic interventions based on microbial communities.
62504834|NCT04459130|EXPERIMENTAL|Child Obesity Program|"Firstly, overweight and obese students will be determined by measuring their height and weight. While selecting children for the experimental group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Experiment group. Child Obesity Program (COP) will be applied to students in the experimental group for 10 weeks. Before the program is implemented, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed.~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales~* - Children's Dietary Self- Efficacy Scale-CDSS~* - Food Behavior Scale~* - Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)~* -Daily Food Consumption Form~* -Drink Consumption Form~* Health Perception Form~Follow-ups will be performed in the 6th and 9th months after the intervention"
62703344|NCT04340141|EXPERIMENTAL|Arm I (perioperative chemotherapy, surgery)|Patients receive oxaliplatin intravenously (IV) over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Within 2-8 weeks of completing neoadjuvant chemotherapy, patients undergo surgical resection. Patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
61959477|NCT05682898||Less than 7 weeks|Timing of colorectal cancer surgery is less than 7 weeks after confirmed COVID-19 infection by COVID-19 nucleic acid test.
61959478|NCT01893164|EXPERIMENTAL|moderate cubital tunnel syndrome|Sensory,Intermittent paresthesias; vibratory perception normal or decreasedMotor,Measurable weakness in pinch or grip strengthTests,Elbow flexion test or Tinel's sign is positive; finger crossing may be abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
62703345|NCT04340141|ACTIVE_COMPARATOR|Arm II (surgery, adjuvant chemotherapy)|Patients undergo surgical resection. Beginning 3-12 weeks after surgery, patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
62703346|NCT06389942|EXPERIMENTAL|9MW3011 Dose 1|Ascending IV doses administered per protocol
62143322|NCT06294834|OTHER|Group 2|Group 2 will complete the control intervention (intervention B) of education on wheelchair provision. They will cross-over to receive the active intervention (intervention A) of remote wheelchair skills training at 6 months.
62143323|NCT06294834|OTHER|Group 3|Groups 3 will mirror Group 1 but for intervention A will only complete Part 1 of the training and then be cued weekly to practice.
62143324|NCT06294834|OTHER|Group 4: rehab professionals, not therapists|Group 4 will mirror Group 3 but receive access to both interventions at the same time.
62143325|NCT03765749||Community onset 3rd generation cephalosporin resistant entero|Patient with Community onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received inappropriate Antibiotic
62347050|NCT00245414|EXPERIMENTAL|4|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
62347051|NCT01541527||severe, moderate and mild HA patients|one Arm: biological collection of 300 severe, moderate and mild HA patients
62143326|NCT03765749||Nosocomial onset 3rd generation cephalosporin resistant ente|Patient with Nosocomial onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received appropriate Antibiotic
62143327|NCT01513733|EXPERIMENTAL|Tasquinimod single dose|
62143328|NCT01513733|EXPERIMENTAL|tasquinimod 0.25 mg followed by 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
62143329|NCT01513733|EXPERIMENTAL|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
62347052|NCT03943979|SHAM_COMPARATOR|Active Control group|This group will receive CT and sham tDCS each day, for four days.
62347053|NCT03943979|ACTIVE_COMPARATOR|Active group|This group will receive both CT and tDCS, each day, for four days.
62347054|NCT01890512||ImageReady Pacemaker|patients previously implanted with a Boston Scientific MR Conditional pacemaker(ImageReady)
62347055|NCT01214317|ACTIVE_COMPARATOR|mitoxantrone and plasmapheresis|Monthly Plasmapheresis (plasma exchange machine: Haemonetics, model TCS2, USA) 25 ml/kg for 5 cycles, with replacement of 0.9% saline and 5% human serum albumin followed by monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) at the end of each Plasmapheresis course for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
62347056|NCT01214317|NO_INTERVENTION|mitoxantrone|Monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
62347057|NCT01921946|OTHER|Part A|Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)
62347058|NCT01921946|OTHER|Part B|Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)
62347059|NCT04209894||Psoriasis|They will undergo dermatological assessment and a blinded ultrasound (US) evaluation.
62347060|NCT04209894||Control|They will also undergo dermatological assessment and a blinded ultrasound (US) evaluation.
62347061|NCT01199055|EXPERIMENTAL|CS-7017+Carboplatin/Paclitaxel|"Drug: CS-7017 from 0.25 mg twice a day (BID) to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)~Drug: Carboplatin IV, Area under the curve (AUC) of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)~Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)"
62143330|NCT02067819|EXPERIMENTAL|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
62143331|NCT02067819|PLACEBO_COMPARATOR|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
62143332|NCT01399450|EXPERIMENTAL|paliperidone add on|paliperidone add on
61959479|NCT01893164|EXPERIMENTAL|severe cubital tunnel syndrome|Sensory,Persistent paresthesias; vibratory perception decreased; abnormal two-point discrimination(static \>6 mm, moving \>4 mm)Motor,Measurable weakness in pinch and grip plus muscle atrophyTests,Positive elbow flexion test or positive Tinel's sign may be present; finger crossing usually abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
61959480|NCT01322139|PLACEBO_COMPARATOR|High dose placebo and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
61959481|NCT01322139|ACTIVE_COMPARATOR|Low dose Sativex and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily) + 16 or 28 placebo sprays (8 or 14 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
62504835|NCT04459130|NO_INTERVENTION|Control Grup|"Firstly, overweight and obese students will be determined by measuring their height and weight. When selecting children for the control group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Control group. First, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed. The control group will be trained for a daily healthy diet and physical activity.~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales~* - Children's Dietary Self- Efficacy Scale-CDSS~* - Food Behavior Scale~* - Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)~* -Daily Food Consumption Form~* -Drink Consumption Form~* Health Perception Form~Follow-ups will be performed in the 6th and 9th months after the intervention"
62504836|NCT05550831|EXPERIMENTAL|Radiofrequency|"Radiofrequency procedure prior to the removal of morton's neuroma.~* Radiofrequency Machine: Multilesion Generator 3 Channels TLG-10 STP.~* Temperature: 80-85ºC~* Time: 90 seconds~* Active needle size: 1 cm~* Number of Applications: 3~* Impedance: less than 550~* Ultrasound. General Electric Logic R7 with 12 Mgh probe."
62504837|NCT02968719|EXPERIMENTAL|Donepezil TDS Version A|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
62504838|NCT02968719|EXPERIMENTAL|Donepezil TDS Version B|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
62504839|NCT02968719|ACTIVE_COMPARATOR|10 mg Aricept|5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days
62504840|NCT02968719|EXPERIMENTAL|Donepezil TDS Version D|Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.
62504841|NCT02968719|EXPERIMENTAL|Donepezil TDS Version E|Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week
62504842|NCT01185860|ACTIVE_COMPARATOR|A|
62504843|NCT01185860|EXPERIMENTAL|B|
62504844|NCT01185860|PLACEBO_COMPARATOR|C|
61959482|NCT01322139|ACTIVE_COMPARATOR|High dose Sativex and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
61959483|NCT01322139|ACTIVE_COMPARATOR|High dose placebo and single oral moxifloxacin 400 mg tablet|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
62504845|NCT04284553|EXPERIMENTAL|Base Order Entry Alert|
61959484|NCT03539471||psychiatric resident in NTUH|
61959485|NCT01866696|EXPERIMENTAL|guided implant insertion and immediate loading|This work was designed as a prospective case series clinical study. Twenty patients have been consecutively rehabilitated with an immediately loaded oral implant supported fixed full prosthesis. A total of 120 oral implants (Nobel Replace Tapered Groovy; Nobel Biocare AB, Goteborg, Sweden) supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. 117 out of 120 oral implants were immediately loaded.
62347062|NCT03219892|EXPERIMENTAL|High-frequency rTMS|Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.
62504846|NCT04284553|EXPERIMENTAL|Base Open Encounter Alert|
62504847|NCT04284553|EXPERIMENTAL|Order Entry + Follow-up booster Alert|
62504848|NCT04284553|EXPERIMENTAL|Open Encounter + Follow-up booster Alert|
62504849|NCT04284553|EXPERIMENTAL|Order Entry + Cold State outreach|
62504850|NCT04284553|EXPERIMENTAL|Open Encounter + Cold State outreach|
62504851|NCT04284553|EXPERIMENTAL|Order Entry + Simplified|
62504852|NCT04284553|EXPERIMENTAL|Open Encounter + Simplified|
62504853|NCT04284553|EXPERIMENTAL|Order Entry + Sign-off alert|
62504854|NCT04284553|EXPERIMENTAL|Open Encounter + Sign-off alert|
62347063|NCT03219892|SHAM_COMPARATOR|Sham rTMS|Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
62504855|NCT04284553|EXPERIMENTAL|Order Entry + Pre-commitment|
61959486|NCT01619423|ACTIVE_COMPARATOR|FOLFOX6 + PledOx 2 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
61959487|NCT01619423|ACTIVE_COMPARATOR|FOLFOX6 + PledOx 5 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
62504856|NCT04284553|EXPERIMENTAL|Open Encounter + Pre-commitment|
62504857|NCT04284553|EXPERIMENTAL|Order Entry + Different Risks|
62504858|NCT04284553|EXPERIMENTAL|Open Encounter + Different Risks|
62504859|NCT04284553|EXPERIMENTAL|Standard Epic Basic Alert|
62504860|NCT04284553|NO_INTERVENTION|No Alert (Usual Care)|
62504861|NCT03934996|NO_INTERVENTION|Assesment Runners|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week.
62504862|NCT03934996|EXPERIMENTAL|Runners with educational training|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week with educational training about pelvic floor muscles.
62143333|NCT01847534|OTHER|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
62504863|NCT00109850|EXPERIMENTAL|Treatment|Cetuximab+Cisplatin+Irinotecan followed by radiation therapy (RT) in Cycle 3.
62504864|NCT05595122|EXPERIMENTAL|Intervention|EUS-CDS using FCSEMS through LAMS
62504865|NCT00622687|ACTIVE_COMPARATOR|A|low dose iloprost therapy 0.5 ng/kg x min
61959488|NCT01619423|ACTIVE_COMPARATOR|FOLFOX6 + PledOx 10 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
61959489|NCT01619423|PLACEBO_COMPARATOR|FOLFOX6 + 0,9% NaCl|Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
62703347|NCT06389942|EXPERIMENTAL|9MW3011 Dose 2|Ascending IV doses administered per protocol
62703348|NCT06389942|EXPERIMENTAL|9MW3011 Dose 3|Ascending IV doses administered per protocol
62703349|NCT06389942|EXPERIMENTAL|9MW3011 Dose 4|Ascending IV doses administered per protocol
62703350|NCT06389942|EXPERIMENTAL|9MW3011 Dose 5|Ascending IV doses administered per protocol
62703351|NCT06389942|EXPERIMENTAL|9MW3011 Dose 6|Ascending IV doses administered per protocol
62703352|NCT05918211|EXPERIMENTAL|Drug|Approximately 218 subjects dosed with udenafil will be enrolled at approximately 30 sites.
62143334|NCT01847534|EXPERIMENTAL|Supplemental PN|"Supplemental PN to complete inadequate EN provision~1. Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.~2. EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.~3. The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
62504866|NCT00622687|ACTIVE_COMPARATOR|B|high-dose therapy
62504867|NCT02270034|EXPERIMENTAL|Cohort crizotinib|Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
62504868|NCT06317389||Oncoral patients|All adult patients with cancer, treated with oral anticancer drugs and benefiting of the ONCORAL program at the Lyon-Sud hospital
62703353|NCT05918211|EXPERIMENTAL|Placebo|Approximately 218 subjects dosed with matching placebo will be enrolled at approximately 30 sites.
62703354|NCT04781309|EXPERIMENTAL|NT-I7|480 microgram/kg IM (initial dose)
62703355|NCT05171387|EXPERIMENTAL|Darolutamide in addition to Androgen deprivation therapy|
62703356|NCT02116764||Cross Sectional|3 years after Transplant
61959490|NCT00795860|ACTIVE_COMPARATOR|Weight loss - diet only|
61959491|NCT00795860|EXPERIMENTAL|Weight loss plus exercise|
61959492|NCT02295384||Audit Group|"Patients attending HHMP in Darlinghurst, Sydney, New South Wales with documented HIV-1 infection from 1st January 2005 to 31st July 2014, who were considered linked to care (Attendance during the study period for at least 2 visits \>3 months and \<12 months apart with measured laboratory virological or immunological markers (either on-site or at a co-management site))."
62143335|NCT01904097|SHAM_COMPARATOR|Pregabalin, Sham tDCS|Patients will receive pregabalin 150 mg oral (PO) twice per day (BID), and sham transcranial direct current stimulation (sham tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
61959493|NCT00952575|ACTIVE_COMPARATOR|polyclonal anti-D immunoglobulin|
61959494|NCT00952575|EXPERIMENTAL|Monoclonal anti-D immunoglobulin|
61959495|NCT00558558|OTHER|Fermented Soy Supplement|4 oz Haelan orally twice daily for 8 weeks
62143336|NCT01904097|EXPERIMENTAL|Pregabalin, tDCS|Patients will receive pregabalin 150 mg oral(PO) twice per day (BID), and transcranial direct current stimulation (tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
62504869|NCT01662934|SHAM_COMPARATOR|Sham|Using not functioning device
62504870|NCT01662934|EXPERIMENTAL|Experimental|Using functioning device
62504871|NCT04917627|ACTIVE_COMPARATOR|vancomycin group (intervention arm)|We will use one vial of vancomycin that contains 1000 mg of the drug in powder form on the surgical site before closing the wound
62504872|NCT04917627|NO_INTERVENTION|control group|no vancomycin powder will be used
62504873|NCT00587431|EXPERIMENTAL|1|
62504874|NCT00587431|ACTIVE_COMPARATOR|2|
62504875|NCT00401154|EXPERIMENTAL|Intervention Stationary Cycling|Subjects receiving the intervention performed stationary cycling 3 times a week for 30 sessions over 12 weeks.
62504876|NCT06358001||EchoTip AcuCore|Patients with use of AcuCore 22 gauge FNB to collect specimens from GI tract
62703357|NCT02116764||No Transplant|These patients were diagnosed with CGD but have not been transplanted
62703358|NCT02116764||Prospective|Prior to Transplant Conditioning
62703359|NCT02116764||Retrospective|1 year after Transplant
62703360|NCT05982015|EXPERIMENTAL|Intervention group|Remote ischemic conditioning (RIC) -200mmHg and best medical management
62703361|NCT05982015|SHAM_COMPARATOR|Sham group|Remote ischemic conditioning (RIC) -60mmHg and best medical management
62703362|NCT04530565|ACTIVE_COMPARATOR|Arm A (steroid, TKI), Single Arm Pre-Induction|Patients receive prednisone PO QD on days 1-21 and ponatinib PO QD or dasatinib PO QD on days 1-21 based on investigator's choice.
62703363|NCT04530565|EXPERIMENTAL|Arm B (steroid, TKI, chemotherapy)|See Detailed Description.
62703364|NCT04530565|EXPERIMENTAL|Arm C (steroid, TKI, chemotherapy, immunotherapy)|"CYCLE 1: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrexate IT on day 29 or 30.~CYCLE 2: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28.~Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity."
62703365|NCT04530565|EXPERIMENTAL|Arm D (steroid, TKI, chemotherapy, immunotherapy)|"Patients treated on Arm B who remain MRD positive at the end of induction therapy receive blinatumomab based re-induction identical to the regimen described for Arm C.~Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care."
62504877|NCT00732160|EXPERIMENTAL|HS-V/A; LS-V/A|High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion
62504878|NCT00732160|EXPERIMENTAL|HS-A/V; LS-A/V|High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion
62504879|NCT00732160|EXPERIMENTAL|LS-V/A; HS-V/A|Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion
61959496|NCT05904197|OTHER|School age children with nephrotic syndrome and their Caregivers|"Children with NS will be expected to have higher knowledge scores about nephrotic syndrome post-intervention than pre-intervention.~Children with NS will be expected to have higher scores in healthcare-related practices including higher medication adherence post-intervention than pre-intervention.~Children with NS will be expected to have lower psychosocial problems post-intervention than pre-intervention.~Caregivers of children with NS will be expected to have higher knowledge scores about nephrotic syndrome post-intervention than pre-intervention.~Caregivers of children with NS will be expected to have higher scores in health care-related practices post-intervention than pre-intervention."
61959497|NCT06324539||Celiac Disease subjects|
61959498|NCT06324539||Controls subjects|
61959499|NCT00838578|EXPERIMENTAL|KRN330 + Irinotecan|open label, single arm
61959500|NCT01292434|EXPERIMENTAL|Lunch in the Bag Intervention|Lunch is in the Bag behavioral intervention: Parents receive a behavioral intervention that includes handouts/newsletters sent to parents from the early care and education (ECE) center, classroom activities and projects, an implementation support calendar, and teacher training.
62504880|NCT00732160|EXPERIMENTAL|LS-A/V; HS-A/V|Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion
61959501|NCT01292434|NO_INTERVENTION|Control|Parents received no specific nutrition education intervention at the ECE center, other than usual practice.
61959502|NCT04696315||SCD subjects with positive amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with positive amyloid show the evidence of amyloid deposition in brain. They have higher risk of conversion to mild cognitive impairment and dementia compared with SCD with negative amyloid. They are also considered as preclinical AD.
61959503|NCT04696315||SCD subjects with negative amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with negative amyloid do not show the evidence of amyloid deposition in brain. They have lower risk of conversion to mild cognitive impairment and dementia compared with SCD with positive amyloid.
61959504|NCT00810238|EXPERIMENTAL|1|Optimal standard of care + C-Cure
61959505|NCT00810238|NO_INTERVENTION|2|Optimal standard of care
61959506|NCT01008592||Group 1|Subjects with chronic idiopathic urticaria exhibiting dermatographism.
61959507|NCT00833794|EXPERIMENTAL|1 Tramadol Once A Day|
61959508|NCT00833794|PLACEBO_COMPARATOR|2 Placebo|
61959509|NCT00598988|EXPERIMENTAL|Acupuncture|Traditional Chinese acupuncture in conjunction with standard medical care
61959510|NCT00598988|ACTIVE_COMPARATOR|Standard medical care|standard medical care
61959511|NCT02575937|EXPERIMENTAL|Diabetes group|During the trial period, the participants who are diagnosed of diabetes are instructed to consume low glycemic diet every day
61959512|NCT02575937|EXPERIMENTAL|Fatty group|During the trial period, the participants who are diagnosed of obesity are instructed to consume low glycemic diet every day
62143337|NCT04913103|EXPERIMENTAL|single arm, open-label|combination of polatuzumab-vedotin, bendamustine and rituximab
62143338|NCT06132659|EXPERIMENTAL|Veritable-NF|
62143339|NCT06132659|ACTIVE_COMPARATOR|Sham-NF|
62143340|NCT01156454||Surgery followed by x-ray assessment|After nodes are removed they are taken to radiology to be x-rayed
62143341|NCT05416476|EXPERIMENTAL|Anisodine Hydrobromide|Participants in this group took oral Anisodine Hydrobromide tablets 1 mg bid for 12 consecutive weeks and were followed up for 12 weeks.
62504881|NCT06611150|EXPERIMENTAL|nab-paclitaxel arm|All patients enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively from 180 mg/m² to a maximum of 260 mg/m².
62504882|NCT01182519||Diagnosed with metastatic breast cancer|"The primary objective of this study is to examine the association between urinary PGE-M and the presence or absence of lung metastases in patients with breast cancer. These patients will be subdivided into a set with lung metastases (group 1A; clinically assessed as per guidelines below) versus those with no evidence of lung metastases (group 1B; no known lung metastases). Group #2 (control) will have been treated for early stage breast cancer and will have no known metastases."
62703366|NCT04530565|EXPERIMENTAL|Arm E (steroid, TKI, chemotherapy)|"Patients treated on Arm C who remain MRD positive at the end of induction therapy receive chemotherapy based re-induction which is identical to regimen described for Arm B according to patient's age and the pre-specified chemotherapy arm.~Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care."
62703367|NCT05794581|EXPERIMENTAL|CT-868|SC injection of CT-868 Intervention
62504883|NCT01182519||History of early breast cancer|History of early breast cancer and currently no evidence of disease
62703368|NCT05794581|PLACEBO_COMPARATOR|Placebo|SC injection of placebo matching CT-868 dose
62703369|NCT05794581|ACTIVE_COMPARATOR|Victoza|SC injection of active comparator
61959513|NCT02575937|EXPERIMENTAL|Impaired glucose tolerance group|During the trial period, the participants who are diagnosed of impaired glucose tolerance are instructed to consume low glycemic diet every day
61959514|NCT02250378|EXPERIMENTAL|Treatment (stereotactic radiosurgery, wedge resection)|Patients undergo stereotactic radiosurgery every other day for 3 or 5 fractions (depending on the size tumor and proximity to the chest wall). Within 4-6 weeks after completion of stereotactic radiosurgery, patients undergo wedge resection.
62504884|NCT05614219|EXPERIMENTAL|Biochemistry interpretive comment on LDL-C levels|"The general practitioners and hospital wards will be allocated in cluster according to their providing lab, and stepwise implement the comment on LDL-C \> 4 mmol/L in persons under the age of 40 and over 5 mmol/L in persons over the age of 40 years. Raising awareness on familial hypercholesterolemia an encouraging to referral.~Cluster 1. Will from the 01.12.2022 implement comment on LDL-C Cluster 2. Will from the 01.03.2023 implement comment on LDL-C Cluster 3. Will from the 01.06.2023 implement comment on LDL-C Cluster 4.Will from the 01.09.2023 implement comment on LDL-C"
62504885|NCT05614219|NO_INTERVENTION|Control|"The clusters will act as their own controls, due to the stepwise implementation of the comment.~Cluster 2: Will not implement the comment before the 01.03.2023 Cluster 3: Will not implement the comment before the 01.06.2023 Cluster 4: Will not implement the comment before the 01.09.2023"
62504886|NCT04849364|EXPERIMENTAL|Arm 1|"Arm 1a: Patients who are ctDNA-positive and harbor a genomic target. DNA repair pathway = talazoparib + capecitabine (CLOSED)~Arm 1b: Patients who are ctDNA-positive and harbor a genomic target. Immunotherapy pathway = pembrolizumab + capecitabine (CLOSED)~Arm 1c: Patients who are ctDNA-positive and harbor a genomic target. PI3K Pathway = inavolisib + capecitabine ---\> +/- standard of care pembrolizumab~Arm 1d: Patients who are ctDNA-positive and harbor a genomic target. DNA Repair + Immunotherapy = talazoparib + capecitabine +/- standard of care pembrolizumab"
62504887|NCT04849364|ACTIVE_COMPARATOR|Arm 2|Arm 2 subjects have plasma ctDNA positive but do not have a genomically driven treatment option. Treatment of physician's choice will be given with consideration for capecitabine and pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.
61959515|NCT02966262||Optical Coherence Tomography registry group|Patients who had undergone optical coherence tomography within coronary intervention
61959516|NCT02073760||Infection Prevention Experts|Adult caregivers of cardiac surgery patients (e.g. surgeons, nurses, infection preventionists) and administrators
61959517|NCT02672865|EXPERIMENTAL|HIPEC|The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of the abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.
61959518|NCT01560364||Hemofilter|
61959519|NCT01227434|EXPERIMENTAL|Surgical Group|PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection as clinical care for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
61959520|NCT01227434|EXPERIMENTAL|Non-surgical group|Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
61959521|NCT03718832|EXPERIMENTAL|Treatment Group-Begin Now|"Group 1- Will be randomized to the treatment (Begin Now) group for the Fresh Food Farmacy program. Subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program right away when the program opens in their geographic area. Data will be collected during the first 12 months of subject participation and EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total)."
61959522|NCT03718832|NO_INTERVENTION|Control Group-Begin Later|"Group 2- Will be randomized to the control (Begin Later) group for the FFF program. These subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program approximately 6 months after the program opens in their geographic area. Data will be collected during the first 6 months of subject participation and used as control data for the study. EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total from the start of the trial)."
61959523|NCT05649397|EXPERIMENTAL|cervical manipulation|in the cervical manipulation, provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
61959524|NCT05649397|ACTIVE_COMPARATOR|conventional therapy|"* 15 mins moist hot pack~* Neck Isometric exercise~* hold for 5-8 seconds and repeat 10 times~* Cervical range of motion~* 10 repetitions of movement in rotation within pain free range"
61959525|NCT05096897||IBD patients|
61959526|NCT05096897||Non-IBD patients (irritable bowel syndrome)|
61959527|NCT03118648||stroke|"* Patients over 18 years old leaving the correctional institution with orientation back home~* First stroke deficit with non-regressive clinical expression in 24 hours~* Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities~* Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)~* No psychiatric history that led to hospitalization for more than six months~* Written informed consent after reading the briefing note~* Patient affiliated or beneficiary of a social security scheme."
61959528|NCT05307146|EXPERIMENTAL|micro/macro electrode|
61959529|NCT05081141||SOT Donors|Solid organ transplantation donors
61959530|NCT05081141||LuTx candidates and recipients|Lung transplant candidates and recipients
61959531|NCT05081141||LTx candidates and recipients|Liver transplant candidates and recipients
61959532|NCT05081141||KTx candidates and recipients|Kidney transplant candidates and recipients
61959533|NCT01297712|ACTIVE_COMPARATOR|Hi Line|This arm is examined with latest generation HDTV colonoscopes
61959534|NCT01297712|NO_INTERVENTION|Classic Line|control group undergoing colonoscopy with older generation scope currently in use in most centers
62504888|NCT04849364|ACTIVE_COMPARATOR|Arm 3|Arm 3 subjects have plasma ctDNA negative. Treatment of patient and physician's choice will be given with consideration for capecitabine and pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.
62504889|NCT05157048|EXPERIMENTAL|Light pack color|Participants will be randomized to one of two pack color conditions: light or dark. Those in the light pack color condition will be given Natural American Spirit Sky packs.
62504890|NCT05157048|EXPERIMENTAL|Dark pack color|Participants will be randomized to one of two pack color conditions: light or dark. Those in the dark pack color condition will be given Natural American Spirit Black packs.
62504891|NCT02096822|ACTIVE_COMPARATOR|non-nutritive sucking alone|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water.
62504892|NCT02096822|EXPERIMENTAL|Facilitated tucking + non-nutritive sucking|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water combined with facilited tucking.
62504893|NCT02083172||Hemodynamically stable patients|Hemodynamically stable patients will be defined as patients with normal hemodynamic profile as evidenced by normal age-determined vital signs and normal perfusion.
61959535|NCT01245660|EXPERIMENTAL|Patient|
61959536|NCT01341145|EXPERIMENTAL|Aerobic Exersice|12-week moderate aerobic exercise program
61959537|NCT01341145|ACTIVE_COMPARATOR|Relaxation|12-week at home progressive muscle relaxation program
62347064|NCT03258697|NO_INTERVENTION|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
62347065|NCT03258697|ACTIVE_COMPARATOR|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
62347066|NCT03258697|EXPERIMENTAL|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
62347067|NCT03894774|EXPERIMENTAL|Intensive InPatient Psychotherapy Treatment Group (IG)|Intensive non-pharmaceutical inpatient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic frame where patients live over the whole treatment (approximately a 1:1-ratio caregiver per patient is given) of 6 to 8 month treatment duration.
61959538|NCT04434898||Ｍild cognitive impairment patients|"The patients with mild cognitive impairment have a Clinical Dementia Rating score of 0.5. First, we will evaluate the correlation between diffusion MRI and the clinical severity and cognitive decline of patients. Second, we will evaluate if diffusion MRI can predict if these patients will develop Alzheimer's Disease and hence be involved in the third year of the study. Patients with mild cognitive impairment should meet the following criteria:~1. Between 50-80 years old~2. Right-handed~3. Clinical Dementia Rating score equal to 0.5~4. For patients who have a CDR score of 0.5, should be diagnosed by clinician's judgement of clinical information, daily living activities, and extent of neuropsychological disorders~5. Able to understand study requirements and give informed consent"
61959539|NCT04434898||Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD), 15 patients with Progressive Supranuclear Paralysis (PSP), 15 patients with Multiple System Atrophy (MSA), and 15 patients with Cortico-Basal Degeneration (CBD). In differential diagnosis in the first year of the study, diffusion MRI will be used for a retrospective study.
61959540|NCT04434898||Healthy volunteers|"The healthy volunteers should meet the following criteria:~1. Between 50-80 years old~2. Right-handed~3. MMSE score greater than or equal to 26~4. Able to understand study requirements and give informed consent"
61959541|NCT05970562|EXPERIMENTAL|Conversation Training Therapy with Ambulatory Voice Biofeedback|Conversation Training Therapy will be administered one time per week for 1 hour. Ambulatory Voice Monitoring with Biofeedback will be administered during the second therapy session and for 5 days between the second and third therapy sessions.
61959542|NCT05970562|ACTIVE_COMPARATOR|Conversation Training Therapy alone|Conversation Training Therapy will be administered one time per week for 1 hour.
61959543|NCT01169493|EXPERIMENTAL|VVI-40 to RV DDD-40 to Bi-V DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
62347068|NCT03894774|ACTIVE_COMPARATOR|Waiting Control Group (WCG)|"Treatment as usual (mostly combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy).~Duration: At least 3 month to a maximum of 6 month."
62347069|NCT03894774|NO_INTERVENTION|Healthy Control Group (HCG)|"Matched Pairs design to control for gender, age and handedness. HCG measurements are planned and conducted according to the exact durations of their matched inpatient pair of the IG.~Mandatory to control for effects of factors such as brain maturation."
62347070|NCT05060783||Renal Call Carcinoma|Patrients with renal cancer
62347071|NCT05060783||Oncocytoma|Patients with oncocytoma
62347072|NCT05060783||Healthy persons|Patients with CT scan shows no renal cancer
62504894|NCT02083172||Hemodynamically unstable patients|Hemodynamically unstable patients will be defined as patients who are admitted to the Pediatric Critical Care Unit (PCCU), in whom there is a clinical diagnosis of shock as evidenced by signs and symptoms of hypoperfusion, requiring fluid resuscitation and/or inotropic support.
62504895|NCT02083172||Mechanically ventilated patients|Patients requiring mechanical ventilation
62504896|NCT01632163|EXPERIMENTAL|Lixisenatide|24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
62504897|NCT01632163|PLACEBO_COMPARATOR|Placebo|24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
62504898|NCT03988101|EXPERIMENTAL|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
62504899|NCT03988101|PLACEBO_COMPARATOR|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
61959544|NCT01169493|EXPERIMENTAL|VVI-40 to Bi-V DDD-40 to RV DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
61959545|NCT01169493|EXPERIMENTAL|Bi-V DDD-40 to VVI-40 to RV DDD-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
61959546|NCT01169493|EXPERIMENTAL|Bi-V DDD-40 to RV DDD-40 to VVI-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
61959547|NCT01169493|EXPERIMENTAL|RV DDD-40 to VVI-40 to Bi-V DDD-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
61959548|NCT01169493|EXPERIMENTAL|RV DDD-40 to Bi-V DDD-40 to VVI-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
61959549|NCT03005314|OTHER|Surgery|Postoperative chemotherapy group
61959550|NCT03005314|OTHER|Chemotherapy|Preoperative chemotherapy group
61959551|NCT04391647||HPV vaccinated group|"Women (18-25 years old) whom are previously fully vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
61959552|NCT04391647||HPV unvaccinated group|"Women (18-25 years old) whom are not previously vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
61959553|NCT03230097|EXPERIMENTAL|BI 409306|Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for attenuated psychosis syndrome (APS) per the Structured Interview for Psychosis-Risk Syndromes (SIPS) took 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
61959554|NCT03230097|PLACEBO_COMPARATOR|Placebo|Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for attenuated psychosis syndrome (APS) per the Structured Interview for Psychosis-Risk Syndromes (SIPS) took placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
61959555|NCT00395304|EXPERIMENTAL|Sequence #1|fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
61959556|NCT00395304|EXPERIMENTAL|Sequence #2|fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
61959557|NCT00395304|EXPERIMENTAL|Sequence #3|fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
61959558|NCT00395304|EXPERIMENTAL|Sequence #4|fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
61959559|NCT00395304|EXPERIMENTAL|Sequence #5|fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
62143342|NCT05416476|PLACEBO_COMPARATOR|Anisodine Hydrobromide Placebo|Participants in this group took oral Anisodine Hydrobromide placebo tablets 1 mg bid for 12 consecutive weeks and were followed up for 12 weeks.
62504900|NCT05676983|EXPERIMENTAL|Spiky balance disc study group|Bobath therapy will be studied with the children in this group and balance training will be given on the rough (spiky) surface of the extra balance disc.
62504901|NCT05676983|EXPERIMENTAL|Smooth balance disc study group|Bobath therapy will be studied with the children in this group and balance training will be given on the smooth (flat) surface of the extra balance disc.
62504902|NCT05140317||Group 1|The direct stargegy group included patients with implanation of the THV without predilatation The reference group included patients with direct implanation of tne THV withour predilaation
62504903|NCT05140317||Group 2|the echographists were blinded regarding the groups of the patients
61959560|NCT00395304|EXPERIMENTAL|Sequence #6|fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol
62504904|NCT02447887|EXPERIMENTAL|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
62504905|NCT05183087||Special Operations Forces (SOF) Personnel|n=30 SOF Personnel
61959561|NCT03644212|ACTIVE_COMPARATOR|Vitamin D treatment|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
61959562|NCT03644212|NO_INTERVENTION|Non treated|Sixteen vitamin D deficient women (6 with PCOS and 10 without PCOS) were not supplemented vitamin D3. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
61959563|NCT04664712|ACTIVE_COMPARATOR|shock wave|
61959564|NCT04664712|ACTIVE_COMPARATOR|shock wave and tendon supplement|
61959565|NCT00545610||Test 1 (n=50)|1 x 10\^5 (+/-10%) CD34+ cells/kg of body weight
61959566|NCT00545610||Test 2 (n=50)|5 x 10\^5 (+/-10%) CD34+ cells/kg of body weight
61959567|NCT00545610||Placebo (n=50)|Saline plus 5% autologous plasma
62143343|NCT01687920|EXPERIMENTAL|BAY94-8862 (1.25mg)|single dose BAY94-8862 IR tablet 1.25mg
62504906|NCT02951195|PLACEBO_COMPARATOR|Part 1: Placebo|
62504907|NCT02951195|EXPERIMENTAL|Part 1 Cohort 1A: TC|
62504908|NCT02951195|EXPERIMENTAL|Part 1 Cohort 1B: TC|
62504909|NCT02951195|EXPERIMENTAL|Part 1 Cohort 1C: TC|
62504910|NCT02951195|ACTIVE_COMPARATOR|Part 2 Cohort 2A: TEZ/IVA|
62504911|NCT02951195|EXPERIMENTAL|Part 2 Cohort 2A: TC|
62504912|NCT02951195|ACTIVE_COMPARATOR|Part 2 Cohort 2B: TEZ/IVA|
62504913|NCT02951195|EXPERIMENTAL|Part 2 Cohort 2B: TC|
61959568|NCT02523248|ACTIVE_COMPARATOR|Tonsillectomy|Tonsillectomy with cold steel
61959569|NCT02523248|ACTIVE_COMPARATOR|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty; using cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
61959570|NCT04945954|EXPERIMENTAL|Cyclophosphamide|
61959571|NCT06497998|EXPERIMENTAL|EGG sensor|"Mechanical characterization is performed using a glass indenter that applies a load to the oocyte.~The indenter is a sterile, single-use, blunt-edged glass cylinder with a flat support end featuring a small foam formation, approximately the diameter of a micropipette.~Except for the mechanical characterization, all oocytes are managed similarly according to validated procedures: in the same location, under the same metrological constraints (temperature and pH (potential of hydrogen) monitoring), and are handled by the same competent ART personnel."
61959572|NCT06497998|NO_INTERVENTION|Standard|Usual ICSI procedures
62347073|NCT05108480|EXPERIMENTAL|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 2 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; Release of the myofascial components of the back of the leg using a Foam Roller; Release of the myofascial components of the anterior part of the leg using a Foam Roller; Release of myofascial components of the hamstring region using a Foam Roller; Release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; Release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; Release of the myofascial components of the pelvitrochanterian muscles using a Foam Roller in a sitting position.
62347074|NCT05108480|NO_INTERVENTION|Control group|The subjects included in the control group will not receive Physiotherapy sessions and will continue with their usual routine of activity and physical exercise, and with the same drug treatment schedule with FVIII / FIX and analgesic drugs.
62347075|NCT03101514|EXPERIMENTAL|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
62347076|NCT03314558||COPD patients following a pulmonary rehabilitation program|COPD patients following a pulmonary rehabilitation program
62347077|NCT04324918|EXPERIMENTAL|HCP1102|
62347078|NCT04324918|ACTIVE_COMPARATOR|HGP1408|
62347079|NCT05731843|EXPERIMENTAL|BEM vs BEM + Ruzasvir n=16|
62347080|NCT05731843|EXPERIMENTAL|Ruzasvir vs Ruzasvir + BEM n=16|
62347081|NCT01195363|ACTIVE_COMPARATOR|quetiapine SR|quetiapine SR, 200-600mg, po, qd
62347082|NCT01195363|PLACEBO_COMPARATOR|quetiapine sr Placebo|quetiapine SR placebo, 200-600mg, po qd
62347083|NCT03497442|EXPERIMENTAL|Treatment Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of brimonidine 0.33% gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
62347084|NCT03497442|PLACEBO_COMPARATOR|Placebo Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of vehicle gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
62347085|NCT02585726|ACTIVE_COMPARATOR|Historical Control with Propensity Analysis|
62347086|NCT02585726|EXPERIMENTAL|VenaSeal Treatment Arm|
62347087|NCT00565656|EXPERIMENTAL|A|Bevacizumab
62703370|NCT04976634|EXPERIMENTAL|Arm 1: Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg (For HCC: 8 mg \[body weight \<60kg\] or 12 mg \[body weight ≥ 60 kg\]). Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
61959573|NCT05535699|EXPERIMENTAL|scapular muscle strengthening exercises|Group A (n=22): will receive a program of scapular muscle strengthening exercises for 18 sessions (3 sessions per week for six weeks)
61959574|NCT05535699|EXPERIMENTAL|PNF exercise|Group B (n=22): will receive a scapular PNF exercise program for the same frequency as in group A
61959575|NCT05535699|NO_INTERVENTION|control|Group C (n=22): will be a control group who will not receive any treatment during the study period.
61959576|NCT03623815|OTHER|Sham tDCS followed by active tDCS|Within subjects design. This group received sham (placebo) transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received 2mA of active tDCS for 20 minutes in session two.
61959577|NCT03623815|OTHER|Active tDCS followed by sham tDCS|Within subjects design. This group received 2mA of active transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received sham (placebo) tDCS for 20 minutes in session two.
61959578|NCT01634724|EXPERIMENTAL|GnRH agonist withdrawal|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group.
61959579|NCT01634724|NO_INTERVENTION|control group|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. In the control group, GnRHa (triptorelin, 0.05mg/d,)was used to the day of ovulation trigger.
61959580|NCT03486223|EXPERIMENTAL|Placebo then GSK2256294|Subjects will receive placebo oral capsule daily by mouth for 7 days, then seven week washout and then GSK2256294 daily by mouth for 7 days.
62143344|NCT01687920|EXPERIMENTAL|BAY94-8862 (2.5mg)|single dose BAY94-8862 IR tablet 2.5mg
62504914|NCT04569058|EXPERIMENTAL|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
61959581|NCT03486223|EXPERIMENTAL|GSK2256294 then Placebo|Subjects will receive GSK2256294 daily by mouth for 7 days, then seven week washout and then placebo oral capsule daily by mouth for 7 days.
62504915|NCT03722862|PLACEBO_COMPARATOR|Control Arm|Healthy volunteers will continue normal healthy diet with a placebo.
62504916|NCT03722862|EXPERIMENTAL|Low fiber|Healthy volunteers will be randomized to receive 3 grams of Sunfiber.
62504917|NCT03722862|EXPERIMENTAL|High fiber|Healthy volunteers will be randomized to receive 6 grams of Sunfiber.
61959582|NCT03253276|ACTIVE_COMPARATOR|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
61959583|NCT03253276|PLACEBO_COMPARATOR|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
61959584|NCT02416921|EXPERIMENTAL|Weight-gain Prevention|Subjects in this group will engage in a 4-week weight-gain prevention curriculum delivered via Facebook
61959585|NCT02416921|ACTIVE_COMPARATOR|Women's Health|Subjects in this group will engage in a 4-week women's health curriculum delivered via Facebook
61959586|NCT03393130||Participants possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who possess at least one copy of the APOE-ε4 allele.
61959587|NCT03393130||Participants not possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who do not possess a copy of the APOE-ε4 allele.
62703371|NCT04976634|EXPERIMENTAL|Arm 2: Pembrolizumab + Lenvatinib|Participants with IO resistant ESCC will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
62143345|NCT01687920|EXPERIMENTAL|BAY94-8862 (5mg)|single dose BAY94-8862 IR tablet 5mg
62703372|NCT05574946|EXPERIMENTAL|All-inside technique|Both of the femoral and tibial tunnel will be drilled in a retrograde manner using flip-cutter and femoral and tibial sockets will be created. Graft will be passed from the portal. Adjustable suspensory cortical fixation both on tibial and femoral side will be used.
62703373|NCT05574946|ACTIVE_COMPARATOR|Complete tibial tunnel technique|Femoral tunnel will be drilled in an inside-outside manner using standard technique. Then the tibial tunnel will be drilled completely. Graft will be passed from the tibial tunnel. Adjustable suspensory cortical fixation both on the tibial and femoral side will be used.
61959588|NCT00687323|EXPERIMENTAL|Temozolomide|Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m\^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m\^2/day for 7 days in 1 28 day cycle), then 200 mg/m\^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m\^2/day for 21 days of each 28-day cycle (12 cycle maximum).
61959589|NCT05202652|PLACEBO_COMPARATOR|Control Group|The control group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing 455mg of the carrier substance (magnesium stearate)
61959590|NCT05202652|ACTIVE_COMPARATOR|HealthSpan(HS) Group|The HS group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing the 455mg of the mixture of the active compounds along with the carrier.
61959591|NCT02057679|ACTIVE_COMPARATOR|Group A (Amoxicillin Clavulanic)|Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
61959592|NCT02057679|PLACEBO_COMPARATOR|Placebo|Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
61959593|NCT04250220|EXPERIMENTAL|intervention group|e-health-based strategy
61959594|NCT04250220|NO_INTERVENTION|control group|symptom based AF-screening
61959595|NCT06163729|EXPERIMENTAL|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|
61959596|NCT03778762|ACTIVE_COMPARATOR|Blind tracheal intubation through AirQ|Patients were intubated through the air-Q blindly
62143346|NCT01687920|EXPERIMENTAL|BAY94-8862 (7.5mg)|single dose BAY94-8862 IR tablet 7.5mg
62143347|NCT01687920|EXPERIMENTAL|BAY94-8862 (10mg)|single dose BAY94-8862 IR tablet 10mg
62143348|NCT01130870|ACTIVE_COMPARATOR|Sensory threshold - Amplitude|Stimulation amplitude set at sensory threshold.
62143349|NCT01130870|EXPERIMENTAL|25% below sensory threshold - Amplitude|Stimulation amplitude 75% of sensory threshold.
62143350|NCT01130870|EXPERIMENTAL|50% below sensory threshold - Amplitude|Stimulation with amplitude set 50% below sensory threshold
61959597|NCT03778762|PLACEBO_COMPARATOR|Fiberscopic tracheal intubation through AirQ|Patients were intubated through the air-Q using fibreoptic bronchoscope
61959598|NCT02643381|EXPERIMENTAL|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
61959599|NCT02643381|EXPERIMENTAL|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
62143351|NCT02760654|EXPERIMENTAL|Online Self Management|Participants will interact with an online self management program based on cognitive behavioral principles for 8 weeks as much as they want.
62143352|NCT02760654|NO_INTERVENTION|Control|Treatment as usual
62143353|NCT03208465|EXPERIMENTAL|Patients with Empagliflozin|
62143354|NCT03208465|ACTIVE_COMPARATOR|Patients with Sitagliptin|
62143355|NCT02410278|EXPERIMENTAL|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
62504918|NCT04155827|EXPERIMENTAL|SIT for males|
62504919|NCT04155827|EXPERIMENTAL|SIT for females|
62504920|NCT00179673|EXPERIMENTAL|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
62703374|NCT05753306|EXPERIMENTAL|Treatment (gastrectomy, HIPEC)|Patients undergo collection of stool and blood sample before and after surgery. Patients also undergo robotic gastrectomy and HIPEC with docetaxel and cisplatin on study. Patients undergo CT, MRI, or PET/CT scans throughout the trial.
62347088|NCT06467123|EXPERIMENTAL|Tissue Intervention|Participants will attend eight sessions. During each session, participants will receive education on positions of comfort, progressing activities, and return to function. Participants will complete shoulder stretching and strengthening exercises according to a protocol.
62347089|NCT06467123|ACTIVE_COMPARATOR|Biopsychosocial Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
62347090|NCT02294318|ACTIVE_COMPARATOR|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
62347091|NCT02294318|EXPERIMENTAL|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
62347092|NCT02943005|ACTIVE_COMPARATOR|Rotator cuff repair with sling|Patients wear a sling during 4 weeks, they also move passively during this period. Then progressive active mobilization is done.
62347093|NCT02943005|EXPERIMENTAL|Rotator cuff repair without sling|Patients don't wear any sling, they move passively in all axes during 4 weeks. Then progressive active mobilization is done.
62347094|NCT00000450|ACTIVE_COMPARATOR|Naltrexone Tablet|
62347095|NCT00000450|PLACEBO_COMPARATOR|Matched Placebo Tablet|
62347096|NCT01922778|EXPERIMENTAL|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD device can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting. If the biopsy cannot be performed due to technical difficulty (cervical stenosis) or inadequate sampling, we will try again on a different day after a trial of vaginal misoprostol (Cytotec) 400 or 600 mcg per vagina the night before."
62347097|NCT03019224|PLACEBO_COMPARATOR|Group 1|The use of desensitizing dentifrice \[Sucralose (S) Control dentifrice)\] in plastic tray.
62347098|NCT03019224|EXPERIMENTAL|Group 2|The use of desensitizing dentifrice \[Sodium fluoride (FS) with 1450ppm of fluorine (Close up triple, Unilever)\] in plastic tray.
62347099|NCT03019224|EXPERIMENTAL|Group 3|The use of desensitizing dentifrice \[Arginine, calcium carbonate (ACC) and sodium monofluorophosphate with 1450 ppm fluorine (Colgate sensitive pro-relief, Colgate-Palmolive)\] in plastic tray.
62347100|NCT03019224|EXPERIMENTAL|Group 4|The use of desensitizing dentifrice \[Sodium fluoride based dentifrice with 1450 ppm of fluorine associated with 5% potassium nitrate\] in plastic tray.
62347101|NCT03177265|EXPERIMENTAL|Text to Engage|This group will get 8 text messages that target common misperceptions around quitting and use of quit services prior to receiving the first counseling phone call.
62347102|NCT03177265|OTHER|Mail Notice|This group will only get a mailing indicating that they will receive a call from a quitline counseling in two weeks.
62347103|NCT03177265|EXPERIMENTAL|Text to Enhance|Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks.
62347104|NCT03177265|ACTIVE_COMPARATOR|Telephone Counseling|Telephone counseling condition will receive standard 8 weeks of telephone counseling only.
62347105|NCT05437393|EXPERIMENTAL|Deep brain stimulation|"Deep Brain stimulation using a novel device: Bioinduction Picostim Deep Brain Stimulation system."
62347106|NCT03411057||Mindfulness Based Stress Reduction (MBSR)|Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis) and scleroderma participants in this group will attend an 8 week MBSR course. The MBSR course meets once per week for 2.5 hours with a 4-hour retreat on week 8.
62504921|NCT02805309|EXPERIMENTAL|Exercise & Cognitive Behavioral Int.|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program and cognitive behavioral interventions.
62504922|NCT02805309|EXPERIMENTAL|Exercise Alone|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program, without cognitive behavioral interventions.
62504923|NCT02805309|ACTIVE_COMPARATOR|Attention Control Education Program|Participants will receive telephone-based education sessions from a study health professional.
62504924|NCT01942447|EXPERIMENTAL|FMT|FMT
62504925|NCT01942447|ACTIVE_COMPARATOR|Standard|Vancomycin
62504926|NCT03730740|EXPERIMENTAL|Lenalidomide|Administer the study drug in the following way with 28 days as one cycle. Lenalidomide 25mg Days 1-21 Dosing continues until disease progression is confirmed.
62504927|NCT02690051|EXPERIMENTAL|BeSmooth Peripheral Stent system|Patients treated with the BeSmooth Peripheral Stent System
61959600|NCT05236049|EXPERIMENTAL|SclerFIX|Strip of umbilical cord lining membrane allograft wrapped around the bioceramic enucleation implant. The assembly is placed inside the void orbital cavity and the muscles are sutured to the SclerFIX strips.
62143356|NCT02410278|EXPERIMENTAL|DMF plus placebo|DMF as described in the USPI plus matched placebo
62504928|NCT04993131|EXPERIMENTAL|Liver transplant|The patients will be transplanted according to standard procedures by the institutional protocol. Median time of surgery is 7 hours and 20 minutes. Each surgical procedure will be performed by specialists at the Rikshospitalet liver transplantation team, which consists of seven specialists at the unit. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Complete clearance of the lymphatic tissue around the hepatoduodenal ligament. Frozen section is obtained from the distal end of the common bile duct. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
61959601|NCT05651997|EXPERIMENTAL|Matrix-Assisted Autologous Chondrocytes Transplantation (MACT)|Matrix-Assisted Autologous Chondrocytes Transplantation (MACT, also called third generation of autologous chondrocyte implantation) is based on the use of type I/III collagen membrane as a three-dimensional structural support on which autologous articular chondrocytes are seeded and cultured to form cartilage prior to implantation.
62504929|NCT02809768|EXPERIMENTAL|Avatrombopag plus fluconazole|Part A: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, fluconazole (400-mg) will be administered once daily on Days 1 to 16, and a single dose of avatrombopag (20-mg) on Day 7 in Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
62703375|NCT04927741|EXPERIMENTAL|Method 1: Sweet Marjoram Essential Oil + Grapeseed Oil with Massage|Subjects randomized will receive dilution of sweet marjoram essential oil (mixed with grapeseed oil), which will be applied topically with massage after IUD insertion.
62703376|NCT04927741|ACTIVE_COMPARATOR|Method 2: Grapeseed Oil with Massage|Subjects randomized will grapeseed oil applied topically with massage after IUD insertion.
61959602|NCT05651997|ACTIVE_COMPARATOR|The Augmented Microfracture Technique (AMT)|The Augmented Microfracture Technique (AMT, also called Autologous Matrix-Induced Chondrogenesis or AMIC) which is part of a therapeutic continuum, combines a microfracture treatment with the application of a type I/III collagen membrane. The principle is to cover the microfractured area with a resorbable membrane to stabilize the formed blood clot in order to increase the concentration of mesenchymal stem cells and promote their differentiation into a repaired tissue.
61959603|NCT05239247|EXPERIMENTAL|Mckenzie extension exercise|
61959604|NCT05239247|EXPERIMENTAL|Eldoa stretch technique|
61959605|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
61959606|NCT04906291|EXPERIMENTAL|H.A.F. toothpaste (1000 ppm F-)|The children were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
61959607|NCT04906291|ACTIVE_COMPARATOR|Fluoridated toothpaste (1000 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
61959608|NCT04906291|EXPERIMENTAL|H.A.F. toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
61959609|NCT04906291|ACTIVE_COMPARATOR|Fluoridated toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
61959610|NCT01782222|EXPERIMENTAL|Rotigotine, high dose|Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
62504930|NCT02809768|EXPERIMENTAL|Avatrombopag plus itraconazole|Part B: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, itraconazole (200-mg) will be administered twice daily on Day 1 and 200-mg once daily on Days 2 to 16. A single dose of avatrombopag (20-mg) will be administered on Day 7 of Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
62703377|NCT04927741|NO_INTERVENTION|Method 3: Control Group (no oil or massage)|Subjects will serve as control and no essential oils or massage will be applied.
61959611|NCT01782222|EXPERIMENTAL|Rotigotine, low dose|Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
62703378|NCT04898777|ACTIVE_COMPARATOR|ERCP-BD|ERCP Biliary Drainage by papillary approach with stent placement.
62703379|NCT04898777|ACTIVE_COMPARATOR|EUS-BD|Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.
61959612|NCT01782222|PLACEBO_COMPARATOR|Placebo|Placebo transdermal patches
61959613|NCT00952978|EXPERIMENTAL|10 mg ilaprazole|
61959614|NCT00952978|ACTIVE_COMPARATOR|20 mg omeprazole|
61959615|NCT03310775|EXPERIMENTAL|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
61959616|NCT03310775|EXPERIMENTAL|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
61959617|NCT01755078|EXPERIMENTAL|Sevelamer HCl|Sevelamer HCl regular treatment 1-3 tablets TID
61959618|NCT01755078|ACTIVE_COMPARATOR|Calcium-based binder|Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID
61959619|NCT05805904|EXPERIMENTAL|Group 1|
61959620|NCT05805904|EXPERIMENTAL|Group 2|
61959621|NCT00680706|EXPERIMENTAL|Thiamine|Receives thiamine
61959622|NCT00680706|PLACEBO_COMPARATOR|Control|
61959623|NCT00586001|EXPERIMENTAL|1|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders The UP is a form of transdiagnostic cognitive-behavioral therapy (CBT) for individuals diagnosed with anxiety disorders, depression and related disorders.
62347107|NCT03411057||Control|Rheumatoid Arthritis, Psoriatic Arthritis, and scleroderma participants in this group will watch an educational stress reduction video (10 minutes).
62504931|NCT02809768|EXPERIMENTAL|Avatrombopag plus rifampin|Part C: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, rifampin (600-mg) will be administered once daily on Days 1 to 16. In order to avoid a food-effect on rifampin absorption, each dose will be administered 1 hour before participants consume a meal. On Day 7 of Treatment Period 2, rifampin (600-mg) and avatrombopag (20-mg) will be administered 1 hour before meal and 30 minutes after starting meal consumption.
62703380|NCT04963803|EXPERIMENTAL|Active transcranial direct current stimulation (tDCS) paired with speech-language therapy|Active transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
62703381|NCT04963803|SHAM_COMPARATOR|Sham transcranial direct current stimulation (tDCS) paired with speech-language therapy|Sham transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
62703382|NCT02325154|EXPERIMENTAL|THA Patients|Patients undergoing unilateral total hip arthroplasty
62703383|NCT05674240||Cancer associated pain treated with conservative medical management (CMM) only|Subjects in this group are patients who opted for conservative medical management for their chronic pain that is cancer associated, including physical therapy, oral or transdermal medications and injections
62703384|NCT05674240||Cancer associated pain treated with Intrathecal Drug Delivery system (IDDs) along with CMM|Patients in this group are those that opted for targeted drug delivery along with conservative medical management of their cancer-associated pain
62703385|NCT04028687||Taperloc Complete Stems|Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.
62703386|NCT02522611|EXPERIMENTAL|Resiniferatoxin|Schedule a maximum of 3 periganglionic DRG injection(s) at contiguous level(s) to treat targeted DRG responsible for chronic CIBP
62347108|NCT02614287|EXPERIMENTAL|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
62347109|NCT02614287|EXPERIMENTAL|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
62703387|NCT05473429|EXPERIMENTAL|1/ID patients|ID Patients
62703388|NCT05473429|ACTIVE_COMPARATOR|2/Healthy controls|Healthy controls
62703389|NCT05925582|EXPERIMENTAL|Group 1|All the participants in Group 1 will receive a 8-week vestibular based exercises program 3 times in a week.
62703390|NCT05925582|ACTIVE_COMPARATOR|Group 2|All the participants in Group 1 will receive a 8-week calistenic based exercises program 3 times in a week.
62703391|NCT06480487|EXPERIMENTAL|Face to face by researchers with peer comparision|Feedback will be provided face-to-face by the researchers by visiting health facilities. The feedback report will include peer comparison data.
61959624|NCT00586001|NO_INTERVENTION|2|Wait-list control: Participants were asked to wait 16 weeks before receiving treatment.
61959625|NCT05045248|EXPERIMENTAL|Patients|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.
61959626|NCT01023620|EXPERIMENTAL|Pioglitazone|10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
62347110|NCT04632537|ACTIVE_COMPARATOR|TICE BCG (for intravesical use, Merck) BCG LIVE|Participants randomized to the BCG arm will receive Tice® BCG (for intravesical use) BCG LIVE is a live freeze-dried vaccine made from an attenuated strain of Mycobacterium bovis. The freeze-dried vaccine will be delivered in vials, each containing 1 to 8 x108 colony forming units (CFU). Tice® BCG (for intravesical use) BCG LIVE will be reconstituted in \~5 mL of preservative-free saline, as needed for yielding 2- x107 CFU/ mL. \[34\] Administration of 0.1 mL will contain 2x106 CFU, which accounts for approximately 0.1 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally. A sterile tuberculin 1mL syringe and sterile fine short needle (25 or 26 gauge with 3/8-3/4 length), will be used for each injection. The injection should be made slowly after inserting the needle \~2 mm into the superficial layer of the dermis of the upper arm (usually deltoid area), to make a symmetrical superficial bleb.
62347111|NCT04632537|PLACEBO_COMPARATOR|placebo vaccine|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
62504932|NCT05934357|EXPERIMENTAL|Intervention Treatment|Experimental treatment will contain a cereal product that contains a dietary fiber. This will be consumed three times daily for two weeks.
62504933|NCT05934357|PLACEBO_COMPARATOR|Control treatment|Control treatment will contain a corn meal cereal product that will be consumed three times daily for two weeks.
62504934|NCT04429542|EXPERIMENTAL|BCA101 Monotherapy|Route: IV Infusion Frequency: QW Current Dose: 1500mg
62703392|NCT06480487|EXPERIMENTAL|Face to face by authoritative bodies with peer comparision|Feedback will be provided face-to-face by the authoritative bodies by visiting health facilities. The feedback report will include peer comparison data.
62703393|NCT06480487|EXPERIMENTAL|Face to face by researchers without peer comparision|Feedback will be provided face-to-face by the researchers by visiting health facilities. The feedback report will not include peer comparison data.
62504935|NCT04429542|EXPERIMENTAL|BCA101 + pembrolizumab|Route: IV Infusion Frequency: Q3W Dose: 200mg
62504936|NCT04674709|PLACEBO_COMPARATOR|Safety of Oleander 4X HPUS|: To evaluate the clinical safety of OLEANDER 4X HPUS in healthy volunteers relative to the control arm (placebo group).
62504937|NCT04674709|EXPERIMENTAL|Pharmacokinetics evaluation of Oleander 4X HPUS|To evaluate the pharmacokinetics of OLEANDER 4X HPUS versus placebo.
62703394|NCT06480487|EXPERIMENTAL|Electronic mail by researchers with peer comparision|Feedback will be provided through electronic mail by the researchers. The feedback report will include peer comparison data.
62143357|NCT03056378|EXPERIMENTAL|Pooled RBCs|Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated
62347112|NCT02546427|EXPERIMENTAL|Treatment|"Step 1: Pelvic Lymph Node Irradiation~Helical TomoTherapy (HT): 41.25 Gy in 15 fractions of 2.75 Gy each~Step 2: Treat boost volume to prostate and seminal vesicles~Acceptable treatment modalities:~CyberKnife SBRT: 19 Gy in 2 fractions of 9.5 Gy each with SBRT~Permanent prostate implant (PPI):~108 Gy for low dose rate PPI with I-125 90 Gy for low dose rate PPI with Pd-103 HDR brachytherapy: 15 Gy in one fraction for HDR"
62347113|NCT00664209|OTHER|Active-placebo|These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
62347114|NCT00664209|OTHER|Placebo-active|These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
62347115|NCT03798184|EXPERIMENTAL|Selective-etch with bioglass surface roughening|
62347116|NCT03798184|ACTIVE_COMPARATOR|Selective-etch without bioglass surface roughening|
62347117|NCT03798184|EXPERIMENTAL|Self-etch with bioglass surface roughening|
62504938|NCT01040793|EXPERIMENTAL|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
62504939|NCT01040793|EXPERIMENTAL|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
62504940|NCT01040793|PLACEBO_COMPARATOR|Placebo|Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler
62504941|NCT05751876||Women with adenomyosis under dienogest|Perimenopausal women with symptomatic adenomyosis receiving dienogest
62504942|NCT02769650|EXPERIMENTAL|Stress-MRI + Chronic total occlusion PCI|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Coronary angioplasty with stenting of RCA CTO
62347118|NCT03798184|ACTIVE_COMPARATOR|Self-etch without bioglass surface roughening|
62347119|NCT01511107|ACTIVE_COMPARATOR|Amoxicillin-Clavulanate, 10 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
62347120|NCT01511107|OTHER|Amoxicillin-Clavulanate, 5 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days
62347121|NCT00598715|EXPERIMENTAL|Same drug|sirolimus-eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
62347122|NCT00598715|ACTIVE_COMPARATOR|Different drug|paclitaxel eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
62347123|NCT05611099|EXPERIMENTAL|Dreem + WatchPAT One|Single arm of 15 subjects wearing simultaneously the Dreem 3 + WatchPAT One devices for 3 nights, and then undergoing an end of study usability questionnaire.
61959627|NCT01023620|SHAM_COMPARATOR|Observation/Comparison|10 male patients with lipodystrophy not taking daily Pioglitazone
61959628|NCT04166175|ACTIVE_COMPARATOR|group 1 botox group|48 patients subjected to 80 IU botox injection under GAin lithotomy position in the 5,7,11, and 1 O'clock positions
62143358|NCT03056378|ACTIVE_COMPARATOR|Standard RBCs|Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)
62143359|NCT00695188|OTHER|Standard dose|Escalating dose
62347124|NCT03795818|OTHER|IPT-A|Interpersonal psychotherapy for adolescents (IPT-A) is a psychosocial treatment for adolescents. It has been shown to be effective for adolescents with depression. It is now being studied as to its benefit for adolescents who meet criteria for PTSD or have subthreshold PTSD symptoms.
62143360|NCT00695188|ACTIVE_COMPARATOR|High dose|25 mg
62504943|NCT02769650|ACTIVE_COMPARATOR|Stress-MRI + Optimal medicamentous treatment|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Optimal medicamentous treatment
62504944|NCT06458257||HSCT-group|patients received allogeneic hematopoietic stem cell transplantation after consolidation treatment
62504945|NCT06458257||Chemo-group|patients received chemotherapy after consolidation treatment
62504946|NCT05017649|OTHER|Healthy volunteers|volunteers showing no hypercholesterolemia
62504947|NCT05017649|EXPERIMENTAL|Patients with untreated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia with no treatment at the time of inclusion
62504948|NCT05017649|EXPERIMENTAL|Patients with treated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia and treated at the time of inclusion
62347125|NCT02368080||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
62347126|NCT02368080||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
62347127|NCT04840017|EXPERIMENTAL|Study group I|excessive body weight and flat feet
62347128|NCT04840017|EXPERIMENTAL|Study group II|normal body weight and flat feet
62347129|NCT04840017|NO_INTERVENTION|Study group III|control, healthy children
62347130|NCT04641390||Casos|altered vaginal microbiome resistant to drug treatment
62504949|NCT05746052|OTHER|atrophic acne scar in face|
62504950|NCT06461377|NO_INTERVENTION|control|In the control group, no other intervention was used except the basic drugs for diabetes treatment
62504951|NCT06461377|EXPERIMENTAL|GLP-1RA intervention group|Subcutaneous injection of semaglutide 0.5-1mg （dosage depends on individual body weight）once a week (not off-label use)，lasting 12 weeks
62504952|NCT04982367|EXPERIMENTAL|Sirolimus-eluting balloon angioplasty|Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
62504953|NCT04982367|ACTIVE_COMPARATOR|Paclitaxel-eluting balloon angioplasty|Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
62504954|NCT00487331|EXPERIMENTAL|Acupuncture|Acupuncture sessions 1-3 times per week. 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment.
62703395|NCT06480487|EXPERIMENTAL|Face to face by authoritative bodies without peer comparision|Feedback will be provided face-to-face by the authoritative bodies by visiting health facilities. The feedback report will not include peer comparison data.
62703396|NCT06480487|EXPERIMENTAL|Electronic mail by authoritative bodies with peer comparision|Feedback will be provided through electronic mail by the authoritative bodies. The feedback report will include peer comparison data.
62703397|NCT06480487|EXPERIMENTAL|Electronic mail by researchers without peer comparision|Feedback will be provided through electronic mail by the researchers. The feedback report will not include peer comparison data.
62703398|NCT06480487|EXPERIMENTAL|Electronic mail by authoritative bodies without peer comparision|Feedback will be provided through electronic mail by the authoritative bodies. The feedback report will not include peer comparison data.
62703399|NCT06389656|EXPERIMENTAL|WBI+BWM|WBI+BWM will be a multicomponent behavioral weight loss intervention designed to address both weight bias internalization and weight status in adolescents. The first four sessions of the intervention will be focused on targeted WBI/weight stigma content, followed by 16 sessions addressing both weight stigma/WBI and evidence-based weight management strategies. Weekly meetings are scheduled for 75 minutes and are facilitated by a behavioral expert (e.g., PhD in clinical psychology). Caregivers attend 4 of the 20 weekly groups with their teens.
62703400|NCT04130854|EXPERIMENTAL|APX005M on day 3 of RT & day 3 of cycles 1-5 of mFOLFOX|On Day 3 of Cycles 1-5 of each mFOLFOX treatment, participants will receive another dose of APX005M. The sequence of administration of APX005M in combination with mFOLFOX. In Cycle 6, participants will receive only mFOLFOX. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
62347131|NCT04641390||Controles|Altered vaginal microbiome not resistant to drug treatment
62347132|NCT04641390||semen donors|The semen donors included in the present work will be men between 18 and 35 years old who are included in the donation program of Instituto Bernabeu after having passed a series of physical, psychological, analytical, genetic and serological evaluations and are considered suitable for donation as established by Royal Decree-Law 9/2014. Likewise, donors are subjected to a series of seminal quality evaluations and seminal freeze-thaw tests in order to guarantee their fertile potential. In this way, the donors who are part of the Instituto Bernabeu donation program also comply with current legal regulations with a strict evaluation to be considered the gold standard of potentially fertile semen. In addition, it will be necessary for them to provide a signed informed consent accepting their participation in the study.
62347133|NCT04157868|EXPERIMENTAL|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
62347134|NCT04157868|PLACEBO_COMPARATOR|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
62347135|NCT01314976|EXPERIMENTAL|Metronidazole|Active treatment.
62347136|NCT01314976|PLACEBO_COMPARATOR|Placebo|Passive treatment.
62347137|NCT02201381|EXPERIMENTAL|Metabolic Treatment|"Subjects will take the following treatments and have their data collected from their medical records every 3 months.~* Oral atorvastatin up to 80mg uid, for study duration.~* Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration.~* Oral doxycycline 100mg uid, for study duration.~* Oral Mebendazole 100mg uid, for study duration."
62347138|NCT01615796|EXPERIMENTAL|Cohort A1|GSK2140944 200mg single dose
62347139|NCT01615796|EXPERIMENTAL|Cohort A2|GSK2140944 600mg single dose
62347140|NCT01615796|EXPERIMENTAL|Cohort A3|GSK2140944 1200mg single dose
62347141|NCT01615796|EXPERIMENTAL|Cohort A4|GSK2140944 1800mg single dose
62347142|NCT01615796|EXPERIMENTAL|Cohort A5|GSK2140944 1800mg single dose
62347143|NCT01615796|EXPERIMENTAL|Cohort A6|GSK2140944 dose to be determined, single dose
62347144|NCT01615796|EXPERIMENTAL|Cohort B1|GSK2140944 400 mg repeat dose BID up to 7 days
62347145|NCT01615796|EXPERIMENTAL|Cohort B2|GSK2140944 750 mg repeat dose BID up to 7 days
62347146|NCT01615796|EXPERIMENTAL|Cohort B3|GSK2140944 1000 mg repeat dose BID up to 7 days
62347147|NCT01615796|EXPERIMENTAL|Cohort B4|GSK2140944 to be determined repeat dose BID up to 7 days
62347148|NCT01615796|EXPERIMENTAL|Cohort B5|GSK2140944 to be determined repeat dose TID up to 14 days
62347149|NCT01615796|EXPERIMENTAL|Cohort B6|GSK2140944 to be determined repeat dose TID up to 14 days
62347150|NCT06430710|EXPERIMENTAL|Mninscrew|Miniscrews for incisor intrusion
62347151|NCT06430710|EXPERIMENTAL|Intrusive arch|Continuous arch technique for incisor intrusion
62347152|NCT02759302||Patients with LGMD2N|Five patients over 18 years old with genetically verified LGMD2N
62347153|NCT04684914|EXPERIMENTAL|HepTcell|Dose administered at intervals of 4 weeks for 6 doses
62347154|NCT04684914|PLACEBO_COMPARATOR|Placebo|Dose administered at intervals of 4 weeks for 6 doses
62347155|NCT00274768|EXPERIMENTAL|Capecitabine|26 patients received the pre-defined starting dose of capecitabine of 3,000 mg orally daily given in two divided doses. Two thirds of the patients received either the same dose or a 500 mg lower dose compared to what would have been administered with a commonly used body surface area (BSA)-dosing schedule (2,000 mg/m2 with rounding down to nearest 500 mg multiple).
62347156|NCT01107405|ACTIVE_COMPARATOR|Loteprednol etabonate base (QD)|Loteprednol etabonate ophthalmic base dosed once/day.
62347157|NCT01107405|ACTIVE_COMPARATOR|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base dosed two times/day
62347158|NCT01107405|ACTIVE_COMPARATOR|Loteprednol etabonate base (QID)|Loteprednol etabonate ophthalmic base dosed four times/day.
62347159|NCT01107405|ACTIVE_COMPARATOR|Loteprednol etabonate suspension (QID)|Loteprednol etabonate ophthalmic suspension dosed four times/day
62347160|NCT01107405|PLACEBO_COMPARATOR|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate, dosed either QD, BID, or QID
62703401|NCT04130854|ACTIVE_COMPARATOR|Radiation Therapy 5Gy x 5 days, mFOLFOX|Participants randomized to Arm 2 will receive short-course RT and mFOLFOX regimen, except that participants will not receive any of the study drug. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
62703402|NCT03250377|EXPERIMENTAL|Brivaracetam|Subjects randomized to this arm will receive open-label Brivaracetam
62703403|NCT06379360|EXPERIMENTAL|HMA maintenance therapy|All enrolled patients received maintenance therapy consisting of azacitidine or decitabine.
62703404|NCT05440617||Subjects Treated with Gonadotoxic therapy|Subjects who have planned to undergo OTC for gonadotoxic therapy based on current standard of care.
61959629|NCT04166175|ACTIVE_COMPARATOR|group 2 lateral sphincterotomy group|48 patients subjected to lateral internal sphincterotomy under GAin lithotomy position
61959630|NCT02956421|ACTIVE_COMPARATOR|RABIPUR®|Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
61959631|NCT02956421|EXPERIMENTAL|PIKA Rabies vaccine|PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
61959632|NCT00766311|OTHER|1|This single-arm feasibility trial will evaluate the administration of an aggressive exercise regimen.
61959633|NCT06341868|SHAM_COMPARATOR|Standard of Care + KneeStim controlled low intensity|Low intensity range
61959634|NCT06341868|EXPERIMENTAL|Standard of Care + KneeStim flexible intensity|Flexible to high intensity range
61959635|NCT02660502|EXPERIMENTAL|BioChaperone insulin lispro 0.1 U/kg|
61959636|NCT02660502|EXPERIMENTAL|BioChaperone insulin lispro 0.2 U/kg|
62347161|NCT00425477|EXPERIMENTAL|Bexarotene + GM-CSF|BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.
62347162|NCT05879627|EXPERIMENTAL|Cohort 1|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347163|NCT05879627|EXPERIMENTAL|Cohort 2|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347164|NCT05879627|EXPERIMENTAL|Cohort 3|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347165|NCT05879627|EXPERIMENTAL|Cohort 4|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347166|NCT05879627|EXPERIMENTAL|Cohort 5|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347167|NCT05879627|EXPERIMENTAL|Cohort 6|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347168|NCT05879627|EXPERIMENTAL|Cohort 7|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347169|NCT05879627|EXPERIMENTAL|Cohort 8|BAT8007 for Injection does according to protocol (frequency: Q3W)
62347170|NCT01309841|EXPERIMENTAL|1|Oral treatment
62347171|NCT01309841|EXPERIMENTAL|2|Oral treatment
62347172|NCT01309841|PLACEBO_COMPARATOR|3|Oral treatment
62347173|NCT01578785|EXPERIMENTAL|Glatiramer Acetate|Glatiramer acetate (GA) 20 mg/0.5 ml solution in prefilled syringe for subcutaneous injection once daily.
62347174|NCT01578785|PLACEBO_COMPARATOR|Placebo|Placebo solution in prefilled syringe for subcutaneous injection once daily.
62347175|NCT03560635|ACTIVE_COMPARATOR|Control|Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
61959637|NCT02660502|EXPERIMENTAL|BioChaperone insulin lispro 0.4 U/kg|
61959638|NCT02660502|ACTIVE_COMPARATOR|Humalog®|
61959639|NCT03823001|EXPERIMENTAL|Virtual prostate biopsy (VB) monitoring|"Prostate-specific antigen (PSA) and digital rectal exam (DRE) are standard of care for monitoring patients on active surveillance or at risk of having low-risk prostate cancer. A novel virtual biopsy (VB) monitoring protocol will be implemented:~1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
61959640|NCT02232165|EXPERIMENTAL|Hypotension avoidance (MAP >= 65 mmHg)|Mean arterial blood pressure is maintained \>= 65 mmHg for 7 days following acute SCI.
61959641|NCT02232165|ACTIVE_COMPARATOR|Induced hypertension (MAP >= 85 mmHg)|Induced hypertension with mean arterial blood pressure \>= 85 mmHg for 7 days following acute SCI.
61959642|NCT06321783|OTHER|Group 1|Individuals with forward head posture
61959643|NCT06321783|OTHER|Group 2|Individuals with normal head posture
62347176|NCT03560635|EXPERIMENTAL|Reverse Diet|Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
62347177|NCT02615795|NO_INTERVENTION|Control|Best practice
61959644|NCT00339534||Cases|Cases were recruited at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012.
61959645|NCT00339534||Controls|Controls were selected in a population-based component using a probability sample designed with the 2000 Ghana Population and Housing Census data between 2004 and 2006.
61959646|NCT04395443|EXPERIMENTAL|patients admitted to emergency department|the intervention is the medication reconciliation
62347178|NCT02615795|EXPERIMENTAL|Intervention|Best practice + Tele Monitoring of physiological parameters (heart frequence, oxygen saturation, weight, FEV1), and answers to disease specific questions, using Tunstall monitoring device.
62504955|NCT05665517|EXPERIMENTAL|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed."
62504956|NCT02653729|EXPERIMENTAL|Espidone, Olepra, Donu & C.B.T|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days
62504957|NCT02653729|ACTIVE_COMPARATOR|Espidone, Olepra & Donu|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night
62504958|NCT04979858|NO_INTERVENTION|Control Group|The subjects will choose their own mask and masking practices.
62347179|NCT05670405|EXPERIMENTAL|Trauma PORTAL Intervention|The treatment group will complete the Trauma PORTAL intervention in 9 weeks. The participants will be asked to complete clinical measures at baseline, 8 weeks, and 16 weeks.
62347180|NCT05670405|NO_INTERVENTION|Care-as-Usual|The control group will receive care-as-usual, remaining on the waitlist for the regular TTP R\&R groups. Participants in the CUC group will be asked to complete clinical measures at time points corresponding to the ITC group's baseline (prior to starting week one) and post-intervention (i.e. primary endpoint, end of week 8). Both groups will complete the clinical measures eight weeks later (16-week time point).
62347181|NCT04875403|EXPERIMENTAL|Respiratory muscle training group|Inspiratory muscle training with linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).The resistance training protocol will consist of the exercises of the front pull, the extension chair and the vertical bench press, covering large muscle groups in the dorsal region of the quadriceps and chest, respectively. Each year consist of three sets of 10 repetitions with a load equivalent to 60% of a test Repetition Maximum (1RM), which will be changed every week (1 to week 60%, 2 to week 65%;. 3 the . week 70%, 4 to week. 75%, 5 to week 80%).
62347182|NCT04875403|ACTIVE_COMPARATOR|Aerobic exercise group|Exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate, training has to be equivalent to 40% to 60%% target intensity.
61959647|NCT01623583|EXPERIMENTAL|Enhanced Needle Phobia Intervention|Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
62504959|NCT04979858|EXPERIMENTAL|Treatment Group|The treatment group will receive and use the focal mask.
62504960|NCT03843515|EXPERIMENTAL|Neoadjuvant nivolumab|All subject will receive 400mg flat dose nivolumab in the neoadjuvant setting
62504961|NCT05840276|EXPERIMENTAL|CRYO|Receives cryoneurolysis treatment on the anterior femoral cutanous nerve and the infrapatellar branch of the saphenous nerve.
62347183|NCT05239364|EXPERIMENTAL|Standard approach|Patients will receive a standard approach for ablation of atrial tachycardia.
62347184|NCT05239364|EXPERIMENTAL|Minimalized approach|Patients will receive a minimalized approach for ablation of atrial tachycardia.
62703405|NCT06356571|EXPERIMENTAL|Isatuximab in combination with weekly carfilzomib and dexamethasone|Participants will receive isatuximab via SC-OBDS administration in combination with weekly carfilzomib and dexamethasone. Isatuximab will be administered on days 1, 8, 15 and 22 for Cycle 1 and then on days 1, 15 for subsequent cycles. Carfilzomib will be administered intravenously (IV) at a starting dose on Day 1 of Cycle 1 and then escalated dose on Days 8 and 15 of Cycle 1, followed by Days 1, 8 and 15 of subsequent cycles. Dexamethasone will be given on Days 1, 8, 15, and 22 of Cycle 1 and then on Days 1, 8 and 15 of subsequent cycles. Dexamethasone will be administered IV on Cycle 1 Day 1, and IV or PO in the subsequent administrations. 1 cycle = 28 days.
62703406|NCT04163523|EXPERIMENTAL|Treatment Sequence 1|5 Subjects received Period 1- 320 mg BGB-3111 administered after an overnight fast; Period 2- 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 3 - Day 15: 320 mg BGB-3111 administered after Low Fat/Calorie Meal
62703407|NCT04163523|EXPERIMENTAL|Treatment Sequence 2|5 Subjects received Period 1 - Day 1: 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 2- Day 8: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 3- Day 15: 320 mg BGB-3111 administered after an overnight fast
62703408|NCT04163523|EXPERIMENTAL|Treatment Sequence 3|Approximately 5 Subjects receive Period 1-Day 1: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 2-Day 8: 320 mg BGB-3111 administered after an overnight fast; Period 3- Day 15: 320 mg BGB-3111 administered after High Fat/Calorie Meal
62347185|NCT01362686|EXPERIMENTAL|Donepezil|See intervention note.
62347186|NCT01362686|EXPERIMENTAL|Galantamine|See intervention note.
62347187|NCT01362686|EXPERIMENTAL|Rivastigmine|See intervention note.
62504962|NCT05840276|SHAM_COMPARATOR|SHAM|Receives similar procedures as in CRYO but with no freezing temperatures.
62504963|NCT02310763|EXPERIMENTAL|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
62504964|NCT02310763|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62504965|NCT06210204|NO_INTERVENTION|In-Person|Patients will follow-up in-person after surgery
61959648|NCT01623583|ACTIVE_COMPARATOR|Standard Needle Phobia Intervention|Patients will receive the standard intervention for needle phobia
62504966|NCT06210204|EXPERIMENTAL|Telehealth|Patients will follow-up via phone after surgery
62504967|NCT00350987|EXPERIMENTAL|PCT|PCT guidance
62504968|NCT00350987|ACTIVE_COMPARATOR|Guidelines|enforced guidelines
62504969|NCT06166758|EXPERIMENTAL|Educational Video|Educational video about germline genetic testing, which is 7 minutes long
62504970|NCT05057793|NO_INTERVENTION|Standard of care|Multilayer, multicomponent compression intended for the treatment of VLU
62504971|NCT05057793|ACTIVE_COMPARATOR|Standard of care + geko 12h|Multilayer multicomponent compression intended for the treatment of VLU in conjuction with geko™ therapy 12 hours daily
62504972|NCT00225563|ACTIVE_COMPARATOR|e-prescribing|Providers who used electronic prescriptions. electronic health records were used as opposed to paper based prescriptions
62504973|NCT00225563|NO_INTERVENTION|Paper-based prescriptions|providers who used paper based prescriptions
62703409|NCT06406881|ACTIVE_COMPARATOR|manual therapy|ocular muscle exercise like palm , blinking and pencil pushups neck isometric exercise
61959649|NCT03895385|EXPERIMENTAL|Bimekizumab|Subjects randomized to this arm will receive a single dose bimekizumab followed by inactivated influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
61959650|NCT03895385|NO_INTERVENTION|No Treatment|Subjects randomized to this arm will receive the influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
61959651|NCT01486537||theeth undergoing pulpotomy|
61959652|NCT01486537||teeth undergoing pulpectomy|
62703410|NCT06406881|EXPERIMENTAL|myofascial release therapy|myofascial release technique along with ocular and neck isometric exercise.
62703411|NCT01316783||Healthy Volunteers|African ancestry and whites (who will serve as a comparison group)
62703412|NCT04083235|EXPERIMENTAL|Irinotecan liposome injection + Oxaliplatin + 5-FU/LV|Irinotecan liposome injection, oxaliplatin, 5 FU/LV, will be administered on Days 1 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
62504974|NCT01947686||Patellofemoral Knee Arthroplasty|Patient who have received a robotically guided isolated patellofemoral implant.
62504975|NCT02349074|EXPERIMENTAL|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy during Intensive Care Unit stay after out-of-hospital cardiac arrest
62504976|NCT01339377|EXPERIMENTAL|AO-1000 Treatment|Oxygen-ozone treatment with the AO-1000 device
62504977|NCT03779568|EXPERIMENTAL|Dose adjustment of bupivacaine|Patient will receive isobaric bupivacaine based on previous patient experience.
62504978|NCT02157363|ACTIVE_COMPARATOR|Repositioning Group|The patient is placed on a vacuum mattress in supine position for the abdominal part using a midline laparotomy. After completion of the abdominal part, the abdomen is closed and dressed in standard fashion and the patient is repositioned under full anesthesia is a left-lateral decubitus (LLD) position. After the thorax is sterile prepped and draped, a right dorso-lateral thoracotomy in the 4th to 6th intercostal space under preservation of body of the serratus muscle is performed.
62504979|NCT02157363|EXPERIMENTAL|Single positioning|The patient is placed on a vacuum mattress and in a left-screwed supine position for the entire operative procedure. The pelvis and the lower extremities are placed at 0° rotation, whereas the torso is rotated leftwards to an angle of 45° (Fig. 1). The patient is prepped and draped from the shoulders to the inguinal region. A midline laparotomy is done for the abdominal part and the abdomen closed afterwards. For the thoracic part, the operating table is tilted about 30° to the left, and a right anterolateral thoracotomy is performed in the 4th to 6th intercostal space.
62504980|NCT06348524|EXPERIMENTAL|Single arm utilizing ferumoxytol|
62143361|NCT06006572|ACTIVE_COMPARATOR|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive|After surgery, the closure technique utilized by the surgeons will be wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
62504981|NCT00402519|EXPERIMENTAL|APBI|Accelerated Partial Breast Irradiation with multicatheter brachytherapy
62504982|NCT00402519|ACTIVE_COMPARATOR|EBRT|Standard External Beam Whole Breast Irradiation
62504983|NCT04053673|EXPERIMENTAL|RBN-2397|Dose Escalation: Multiple doses of RBN-2397 for oral administration Dose Expansion: Oral dose of RBN-2397 as determined during Dose Escalation
62504984|NCT03801317|EXPERIMENTAL|BC/ egg|4.3 grams egg powder + 5.7 grams bovine colostrum
62504985|NCT03801317|PLACEBO_COMPARATOR|Control|15 grams corn-soya blend
62504986|NCT01812629|EXPERIMENTAL|Experimental Infant Formula|Complete peptide amino acid-based infant formula
61959653|NCT05288920|ACTIVE_COMPARATOR|Radiofrequency group|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
61959654|NCT05288920|PLACEBO_COMPARATOR|Steroids group|Transforaminal injection of Steroids alone
61959655|NCT05388331||RIS/1-2 criteria|
61959656|NCT05388331||RIS/3-4 criteria|
62504987|NCT00952224||Acute myocardial infarction patients|Patients undergoing primary percutaneous coronary intervention in ST-elevation myocardial infarction plus magnetic resonance imaging
62504988|NCT03255434|ACTIVE_COMPARATOR|Folfox 4|Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²
62504989|NCT03255434|EXPERIMENTAL|Folfox 4 LBM|Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)
62504990|NCT05750706||Acute lymphoblastic leukemia, no invasive fungal infection|
62504991|NCT05750706||Acute lymphoblastic leukemia, invasive fungal infection|
62504992|NCT03883555||Optiflow tm|High flow nasal therapy (HFNT)
62504993|NCT03883555||Non invasive ventilation (NIV)|Non invasive ventilation (NIV)
62504994|NCT02710253|EXPERIMENTAL|Treatment (SBRT or EBRT)|Patients undergo either 4, 5, or 10 fractions of SBRT, or 5-15 fractions of EBRT to any site of metastatic disease daily for any time between 4 days and 3 weeks as determined by the treating radiation oncologist. Patients with at least SD after the second imaging evaluation may undergo additional SBRT in 4 fractions or EBRT in 3 fractions.
61959657|NCT05388331||NON RIS/0 criteria|
61959658|NCT01458938||Healthy volunteers|
61959659|NCT01458938||surgery for spinal radiculopathy|
62347188|NCT04659434|EXPERIMENTAL|treatment group|Sintilimab 200mg ivdrip Q3W; Rituximab 375mg/m2 ivdrip; Gemcitabine 1000mg ivdrip; Oxaliplatin 100mg/m2 ivdrip
62504995|NCT03684889|EXPERIMENTAL|SCRI-huCAR19v2|Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
62703413|NCT04083235|ACTIVE_COMPARATOR|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel and gemcitabine will be administered on Days 1, 8 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
62703414|NCT06448429|EXPERIMENTAL|Collaborative care group|"Enrolled participants assigned to the intervention arm will be offered free consultation services with a behavioral health specialist, who is also a licensed clinical social worker.~Participants randomized into the intervention group will consult with a behavioral health consultant (BHC) one or more times over the intervention period (based on the assessment of the BHC) via phone or Zoom based on the participant's preference.~The BHC will participate in systematic caseload reviews to facilitate the medical management of depression if indicated."
62703415|NCT06448429|ACTIVE_COMPARATOR|Usual Care|Participants randomized to the usual care will continue their routine clinical care at the diabetes clinic at Grady.
62703416|NCT05285982|EXPERIMENTAL|Patients rolling over from the InPedILD® study|
62703417|NCT05285982|EXPERIMENTAL|Patients newly enrolled in this study|
61959660|NCT01458938||surgery for axial spine pain|
61959661|NCT01458938||myelography for spinal pain|
62504996|NCT03684889|EXPERIMENTAL|SCRI-huCAR19v1 - [CLOSED]|Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
62703418|NCT06141486|EXPERIMENTAL|Frexalimab|Frexalimab IV administration
62703419|NCT06141486|PLACEBO_COMPARATOR|Placebo|Matching placebo
62703420|NCT05616650|EXPERIMENTAL|1/Focal SBRT|Focal SBRT to the tumor focus within the prostate, with response assessed by biopsy and imaging, including 18F-DCFPyL PET/CT.
62143362|NCT06006572|ACTIVE_COMPARATOR|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive|After surgery, the closure technique utilized by the surgeons will be wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
62143363|NCT02669576|EXPERIMENTAL|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
62347189|NCT03786198|EXPERIMENTAL|a) Home-based walking intervention|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy
62703421|NCT04828486|EXPERIMENTAL|Treatment (futibatinib, pembrolizumab)|Patients receive futibatinib PO QD on days 1-21 for cycles 1-9, and days 1-42 for subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-9 and every 42 days for subsequent cycles for up to 2 years in the absence of disease progression or unacceptable toxicity.
62703422|NCT05112198|EXPERIMENTAL|Noona web-based symptom tracking tool|In addition to usual care for their disease, patients interact with Noona system and system questioners to record their symptoms over a period of 6 months.
62703423|NCT05112198|NO_INTERVENTION|Usual Care|Participants will receive the standard of care for their disease
62143364|NCT02669576|OTHER|Usual care|Patients continue usual care by their practitioner
62347190|NCT03786198|ACTIVE_COMPARATOR|b) Physical activity according to standard recommendations|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
62347191|NCT00947999||Healthy Control Group|Subjects in particular group will not have a diagnosis of SCI and do not experience chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
62347192|NCT00947999||Subjects with SCI and Chronic Pain|Individuals recruited into this particular group will have a diagnosis of a spinal cord injury and experience pain on a daily basis with an average intensity of 4 out of 10 on a 0-10 scale.
62504997|NCT01142661|EXPERIMENTAL|Eribulin mesylate|
62703424|NCT06300411|EXPERIMENTAL|SRG-514|SRG-514
62703425|NCT05674617|EXPERIMENTAL|Written Exposure Therapy (WET)|5 individual therapy sessions of WET via video telehealth
62703426|NCT05674617|ACTIVE_COMPARATOR|PTSD Education Control|5 individual sessions of PTSD psychoeducation via video telehealth
62703427|NCT05703685|OTHER|one arm|All subjects will receive the same testsGroup D will have a baseline and block with apremilastGroup A \&amp; D will have a lung scan
62703428|NCT06503952||case group|Case group: All the patients who would have benefitted (with informed consent) of a uterine immune profile and a fresh Day-5 SET or a day-5 or-6 SET between January 2020 and march 2024 would be enrolled
62703429|NCT06503952||control group|Pair-matched group: Group without uterine immune profile before the SET Matching criteria will be maternal age (+/-1year) and, number of previous egg retrievals (including the ones without any transfer) and, number of previous ETs and technique used (IVF, ICSI, frozen embryo transfer) and degree of expansion of blastocoel (B1-B2/B3-B4/B5-B6) to reflect the quality of the embryo transferred
62703430|NCT00977977|EXPERIMENTAL|Combination of Rituximab plus cyclosporine|2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months. Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued.
62703431|NCT05797376|EXPERIMENTAL|Rivaroxaban + Aspirin group|patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
62703432|NCT05797376|NO_INTERVENTION|Aspirin group|patients are prescribed aspirin at a daily dose of 100mg
61959662|NCT04944069|EXPERIMENTAL|Almonertinib With Bevacizumab|Almonertinib 110 mg oral once daily with Bevacizumab 15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
61959663|NCT05012683|NO_INTERVENTION|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
61959664|NCT05012683|EXPERIMENTAL|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, \~30 days post-fitting, and \~60 days post-fitting
61959665|NCT01119417|EXPERIMENTAL|BQ123|endothelin blocker
61959666|NCT01119417|PLACEBO_COMPARATOR|Saline|IV saline
61959667|NCT05724563|EXPERIMENTAL|Zimberelimab and Domvanalimab|Individual will be given Zimberelimab (AB122) 360 mg IV in a 1 hour infusion + 30 minute rest + Domvanalimab (AB154) 1200 mg IV in a 1 hour infusion every three weeks. Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason
62504998|NCT04542707|EXPERIMENTAL|Joint manipulation|Grade V-Thrust manipulation with audible sound and without audible sounds of C1-C2, T7, MTP 2 and MCP2 joints.
62504999|NCT04542707|EXPERIMENTAL|Exercise|Aerobic, anaerobic, and yoga exercises
62505000|NCT04542707|EXPERIMENTAL|Soft tissue massage|Instrument assisted soft tissue massage
62703433|NCT04744116|ACTIVE_COMPARATOR|Arm 1 (ruxolitinib)|Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
61959668|NCT03308734|EXPERIMENTAL|Exercise Intervention Group|Reduced-Exertion High-Intensity Interval Training Following baseline testing, participants will start a 6-week training protocol involving reduced-exertion high-intensity training on a cycle ergometer based in a gym in Gloucestershire used by the Macmillan Cancer Support's Next Steps project.
61959669|NCT03308734|NO_INTERVENTION|Control Group|Following baseline testing, participants will receive usual care only.
61959670|NCT01632488||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting Rome III criteria of irritable bowel syndrome.
61959671|NCT01632488||Inflammation|Patients with long standing history or short onset of inflammatory bowel disease.
61959672|NCT01632488||Normal controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
61959673|NCT01145443||Continuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when a single intensivist was the sole attending physician of record for intervals of 2 weeks (or 1/2 month).
61959674|NCT01145443||Discontinuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when, for intervals of 2 weeks (or 1/2 month), there was a single intensivist who was the primary attending of record during Mondays-Fridays, but cross-covering colleagues took over that role during the weekends.
61959675|NCT00844714|EXPERIMENTAL|Rituxan|
62347193|NCT00947999||Subjects with SCI and No Chronic Pain|Subjects in particular group will have a diagnosis of SCI and not have chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
62347194|NCT04354155|EXPERIMENTAL|Thromboprophylaxis|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 mg/kg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
62347195|NCT00355849|EXPERIMENTAL|1|Intensified Glargine
62347196|NCT00355849|EXPERIMENTAL|2|HIIP
62347197|NCT00355849|EXPERIMENTAL|3|Intensified Glargine plus HIIP
62347198|NCT02822872||infertile couples|"couples addressing IVF treatment due to known infertility will fill questionnaire in order to assess their stress level (as mentioned above), after filling the questionnaire scalp hair sample will be taken to assess chronic cortisol secretion.~during the IVF treatment the stress level will be assessed every 3 month by using the same system (in order to find match between the stress level and cortisol secretion with the fertility treatment"
62505001|NCT06079255||IscAlert sensor in patient with risk of acute compartment syndrome|Patients admitted with leg injury at risk of acute compartment syndrome will receive IscAlert sensor(s) in the anterior compartment of the lower limb. A duration of maximum 10 days.
62505002|NCT00503113|EXPERIMENTAL|1|
61959676|NCT03990454|EXPERIMENTAL|Dose escalation|"The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented.~A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met."
61959677|NCT04700761|EXPERIMENTAL|Group OFA (Opioid-free anesthesia)|Not using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (except a single dose of alfentanil for endotracheal intubation)
61959678|NCT04700761|ACTIVE_COMPARATOR|Group OUA (Opioid-using anesthesia)|Using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (continuous infusion of remifentanil)
61959679|NCT04459533||TOF group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, for whom a NMB monitor use (TOF) was reported in the electronic health records (EHR).
61959680|NCT04459533||Control group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, with no NMB monitor use reported in the EHR
61959681|NCT01352858|EXPERIMENTAL|TolDC|Experimental arm - TolDC administered arthroscopically
62347199|NCT00825019|EXPERIMENTAL|1|
62347200|NCT00825019|PLACEBO_COMPARATOR|2|
62347201|NCT00825019|ACTIVE_COMPARATOR|3|paroxetine
62347202|NCT05627700|EXPERIMENTAL|AVL200 IOL|The AVL200 is a modular fluid-filled, shape-changing intraocular lens (IOL) designed to restore visual function across a range of focal points
62347203|NCT00546793|EXPERIMENTAL|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.
62347204|NCT05186766|EXPERIMENTAL|Intervention Group|Video-Assisted Operating Room Introduce Program (VIASP-OR)
62703434|NCT04744116|EXPERIMENTAL|Arm 2 (ruxolitinib, lower dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
61959682|NCT01352858|PLACEBO_COMPARATOR|Control|Arthroscopy \& saline irrigation alone
61959683|NCT03465306|EXPERIMENTAL|Intensive digital CBT|
61959684|NCT03465306|ACTIVE_COMPARATOR|Standard digital CBT|
61959685|NCT06497413|EXPERIMENTAL|Transcranial Photobiomodulation|Transcranial Photobiomodulation (tPBM) is a novel and non-invasive strategy that utilizes a helmet that delivers low-level laser therapy to activate intracellular enzymatic pathways leading to an increase in mitochondrial activity, cerebral oxygenation, and thus neural and overall brain function. Importantly, this approach improves cognitive function in various animal models and limited human populations. Furthermore, there is limited evidence to suggest that these neurocognitive improvements are in-part related to increases in cerebral blood flow and cerebral vascular function/health.
62347205|NCT05186766|NO_INTERVENTION|Control Group|Standart Nursing Care
62505003|NCT00503113|EXPERIMENTAL|2|
62505004|NCT00503113|ACTIVE_COMPARATOR|3|
62505005|NCT06252207|EXPERIMENTAL|Desflurane|General anesthesia with desflurane.
62505006|NCT06252207|EXPERIMENTAL|Isoflurane|General anesthesia with isoflurane.
62505007|NCT04593394||Severe asthma|Gina-guidlines treatment-step 5
62703435|NCT04744116|EXPERIMENTAL|Arm 3 (ruxolitinib, higher dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
61959686|NCT06497413|PLACEBO_COMPARATOR|Sham condition|In this condition the participants will wear the Transcranial Photobiomodulation (tPBM) headgear; however, no light will be delivered.
61959687|NCT05180279|EXPERIMENTAL|Sleep Lab|
61959688|NCT01445262||Subjects prescribed levocetirizine tablets|Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
61959689|NCT05840991|EXPERIMENTAL|Short-term compression group|Patients randomised to group A will be provided with bandages to wear for 48 hours only
61959690|NCT05840991|ACTIVE_COMPARATOR|Long-term compression group|Patients randomised to group B will be asked to wear bandages for the first 24h and then a Class 2 compression full-length stocking (23-32mm Hg) for 1 week
61959691|NCT01209260|EXPERIMENTAL|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
61959692|NCT01209260|ACTIVE_COMPARATOR|Mechanical needle|Mechanical (Brockenbrough) needle for transseptal access
61959693|NCT03293290|EXPERIMENTAL|PrEP|For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.
61959694|NCT05881928|OTHER|50 epileptic patients receive SV for 6 months , for whom add lamotrigine for 6 month|50 epileptic patients receive SV for 6 months at dose 30 mg.kg.day, for whom add lamotrigine for 6 month at dose 0.5 mg.kg.day then add 0.5 mg.kg.day every 2 weeks
61959695|NCT03732157||outpatient management of parathyroidectomy|
62703436|NCT06548542|EXPERIMENTAL|Monotherapy: Risankizumab|Participants will receive Risankizumab Dose A as IV infusion and Risankizumab Dose B as SC injection.
61959696|NCT03732157||conventional management of parathyroidectomy|
61959697|NCT05489510|OTHER|Pulsed lighting|
61959698|NCT05489510|OTHER|Continuous lighting|
61959699|NCT02321800|EXPERIMENTAL|Cefiderocol|Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
61959700|NCT02321800|ACTIVE_COMPARATOR|Imipenem/cilastatin|Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
61959701|NCT04404361|EXPERIMENTAL|Pacritinib and SOC|Pacritinib 400 mg once daily \[QD\] on Day 1, then 200 mg twice daily \[BID\] from Day 2 to Day 14) + SOC
61959702|NCT04404361|PLACEBO_COMPARATOR|Placebo and SOC|4 capsules once daily \[QD\] on Day 1, then 2 capsules twice daily \[BID\] from Day 2 to Day 14) + SOC
61959703|NCT04659161|EXPERIMENTAL|KarXT|
61959704|NCT04659161|PLACEBO_COMPARATOR|Placebo|
61959705|NCT04505189|EXPERIMENTAL|Treatment|Psilocybin
62703437|NCT06548542|EXPERIMENTAL|Combination Therapy: Risankizumab and ABBV-382|Participants will receive Risankizumab Dose A as IV infusion and Risankizumab Dose C as SC injection; and ABBV-382 Dose A as IV infusion and ABBV-382 Dose B as SC injection.
62703438|NCT06548542|EXPERIMENTAL|Monotherapy: ABBV-382|Participants will receive ABBV-382 Dose A as IV infusion and ABBV-382 Dose B as SC injection.
62703439|NCT06548542|EXPERIMENTAL|Combination Therapy: Risankizumab and Lutikizumab|Participants will receive Risankizumab Dose A as IV infusion and Risankizumab Dose C as SC injection; and Lutikizumab Dose A, Dose B and Dose C as SC injection.
62703440|NCT06548542|EXPERIMENTAL|Monotherapy: Lutikizumab|Participants will receive Lutikizumab Dose A, Dose B and Dose C as SC injection.
61959706|NCT02231775|EXPERIMENTAL|Treatment (dabrafenib, trametinib, surgery)|Patients receive dabrafenib PO BID and trametinib PO QD for 8 weeks. After completion of 8 weeks of dabrafenib and trametinib, patients undergo surgery. Approximately 1 week after surgery, patients receive dabrafenib PO BID and trametinib PO QD for 44 additional weeks in the absence of disease progression or unacceptable toxicity.
61959707|NCT06266572|EXPERIMENTAL|Pre-Intervention|Research participants will receive access to a web-based platform designed to provide information about Opioid Use Disorder. Prior to receiving access to this application, research participants will complete online, self-reported surveys assessing stigma, empowerment, and knowledge of opioids.
61959708|NCT06266572|EXPERIMENTAL|Post-Intervention|Research participants will have access to the web-based platform for 7 to 14 days prior to receiving a second, identical series of self-report surveys assessing stigma, empowerment, and knowledge of opioids. Additionally, after using the platform, research participants will complete a measure of system usability.
61959709|NCT00716534|EXPERIMENTAL|A|12.5 mg ABT-869 + Carboplatin/Paclitaxel
61959710|NCT00716534|EXPERIMENTAL|B|7.5 mg ABT-869 + Carboplatin/Paclitaxel
61959711|NCT00716534|PLACEBO_COMPARATOR|C|Placebo (7.5 mg or 12.5 mg) + Carboplatin/Paclitaxel
62505008|NCT04593394||Mild-moderate asthma|Gina-guidlines treatment-step 1-4
62505009|NCT04593394||Subjects without asthma|Matches control-group without asthma
61959712|NCT06116760|EXPERIMENTAL|Anodal Occipital tDCS + audio-visual training|Anodal tDCS on ipsilesional occipital cortex. Anode electrode placed on O1/O2 (10-20 EEG system) and reference electrode placed on the contralateral forehead. Stimulation delivered at 2mA during the first 30 minutes of the audio-visual training.
61959713|NCT06116760|EXPERIMENTAL|Anodal Parietal tDCS + audio-visual training|Anodal tDCS on ipsilesional posterior parietal cortex. Anode electrode placed on P3/P4 (10-20 EEG system) and reference electrode placed on the contralateral forehead. Stimulation delivered at 2mA during the first 30 minutes of the audio-visual training.
61959714|NCT06116760|SHAM_COMPARATOR|Sham tDCS + audio-visual training|Arm 3: sham tDCS. Half of participants with Group 1 montage, the other half with Group 2 montage. Stimulator is turned off after 30s of the audio-visual training.
61959715|NCT01246271||Sub urethral sling|
61959716|NCT01246271||sus with anterior vainal wall repair|
62703441|NCT06548542|EXPERIMENTAL|Long-Term Extension: Risankizumab Monotherapy|Participants will receive Risankizumab Dose A as IV infusion and/or Risankizumab Dose B as SC injection for up to 72 weeks.
62703442|NCT06548269||Patients with acute ischemic stroke and atrial fibrillation|Adult patients with an acute ischemic stroke and atrial fibrillation will undergo a baseline work-up and cardiologic work-up. Baseline work-up includes admission 12-lead ECG，blood analysis, brain CT/MRI, brain CTA/MRA/vessel ultrasound. Cardiologic work-up includes prolonged ECG monitoring, echocardiography and cardiac CTA. Treatment will follow the current guidelines.
62505010|NCT05602779|EXPERIMENTAL|tVNS Program|Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
62505011|NCT05602779|EXPERIMENTAL|Phone App Program|Adolescents will use a specially designed phone app to communicate with peers to help them cope with emotions, and to foster connection with peers to establish social connections. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey. The phone app will not be monitored during the night. If your adolescent needs immediate care during the night, please call 911 or your doctor's emergency contact number.
62703443|NCT05669846|EXPERIMENTAL|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy (Treatment Phase 1) and by a sigmoidoscopy (Treatment Phase 2). FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.~Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle."
62703444|NCT06047457|EXPERIMENTAL|"Dysport® dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~Double-blind placebo-controlled (DBPC) Phase: Dysport® dose A administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
62703445|NCT06047457|EXPERIMENTAL|"Dysport® dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Dysport® dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
62703446|NCT06047457|PLACEBO_COMPARATOR|"Placebo - Dysport dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose A administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)."
62703447|NCT06047457|PLACEBO_COMPARATOR|"Placebo - Dysport dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)."
62703448|NCT03366129||Cohort|Stroke patients with white matter hyperintensities (WMH)
62703449|NCT02875548|EXPERIMENTAL|Open-label Tazemetostat|"Participants will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol.~For participants on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study."
62703450|NCT05843643|EXPERIMENTAL|Study 1- Upadacitinib Dose A|Participants will receive upadacitinib dose A once daily for 52 weeks.
62703451|NCT05843643|PLACEBO_COMPARATOR|Study 1- Placebo|Participants will receive upadacitinib matching placebo once daily for 52 weeks.
62703452|NCT05843643|EXPERIMENTAL|Study 2- Upadacitinib Dose A|Participants will receive upadacitinib dose A once daily for 52 weeks.
62703453|NCT05843643|PLACEBO_COMPARATOR|Study 2- Placebo|Participants will receive upadacitinib matching placebo once daily for 52 weeks.
62703454|NCT05843643|EXPERIMENTAL|Study 3- Low Disease Activity Upadacitinib (LDA) Dose A|Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose A once daily for 52 weeks.
62703455|NCT05843643|EXPERIMENTAL|Study 3- Low Disease Activity Upadacitinib Dose B|Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose B once daily for 52 weeks.
62703456|NCT05843643|EXPERIMENTAL|Study 3- No LDA Upadacitinib Dose A|Participants in the upadacitinib arms from Study 1 or Study 2 with no LDA will receive upadacitinib dose A once daily for 52 weeks.
62703457|NCT05843643|EXPERIMENTAL|Study 3- Upadacitininb Dose A|Participants in the placebo arms of Study 1 or Study 2 will receive upadacitinib Dose A once daily for 52 weeks.
61959717|NCT06295289|EXPERIMENTAL|Hybrid closed-loop insulin delivery system group|After patients signed the informed consent form in the ward, the nurse installed the insulin pump and the subcutaneous, real-time, continuous glucose monitor (CGM). The insulin pump was installed in the abdomen or upper arm, and the CGM was installed in the upper arm. A Hybrid closed-loop insulin delivery system with an open-source algorithm was set up for participants by the clinical trial investigators. The algorithm was initialized with the participant's weight and basal insulin requirements. The control algorithm modulated insulin delivery every 5 min based on the CGM glucose level, anticipated glucose trends, and patient-specific information such as the basal rate profile to guarantee blood glucose control within the target range. The perioperative patients in the hybrid closed-loop insulin delivery group who were admitted to the hospital received 3-5 days of glucose-lowering therapy.
61959718|NCT06295289|PLACEBO_COMPARATOR|Insulin pump therapy group (Control group)|The insulin treatment with a pump and CGM was applied according to the local clinical guidelines. The insulin pump was installed in the abdomen or upper arm, and the CGM was inserted in the upper arm by the investigator. Doctors adjust the insulin dose according to the patient's glucose level.
62703458|NCT05843643|EXPERIMENTAL|Study 3- Open Label Upadacitinib Dose A|Participants who experience a suspected systemic lupus erythematosus (SLE) flare may receive open label upadacitinib Dose A once daily for the remainder of the study.
62703459|NCT05843643|EXPERIMENTAL|Study 3- Open Label Upadacitinib Dose B|Participants who reach \>= 65 years of age and are still on study drug may receive open-label upadacitinib Dose B once daily, and participants who experience a suspected SLE flare while on upadacitinib Dose B may receive upadacitinib Dose A for the remainder of the study.
62703460|NCT00581763||Observation|Those with a condition
62703461|NCT02023866|EXPERIMENTAL|Cysteamine Bitartrate Delayed-release|Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
62703462|NCT00001352||Genetic Relatives|Will be placed in a control group. Must be a blood (genetic) relative of a patient enrolled in the study. Participant age must be 18 years or older. Relatives may be excluded if they have a condition that may interfere with evaluation of an immune system abnormality.
62505012|NCT05602779|EXPERIMENTAL|tVNS and Phone App Program|Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
62505013|NCT05602779|SHAM_COMPARATOR|Enhanced Treatment as Usual|Enhanced TAU participants will be referred to and have access to available services within the community and, in addition to reports of their daily experiences via the sham app, will be called weekly to complete risk assessments during the active 30-day intervention stage.
62505014|NCT03437057|EXPERIMENTAL|Patients treated with acethylsalicylic acid 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
62505015|NCT05240092|EXPERIMENTAL|Haptonomy Group|A home visit was made to the experimental group, and haptonomy was applied for at least 30 minutes, once a week, for 7 weeks (with the researcher for 3 weeks, with the husband by providing the training brochure and video that will help the practice for the next 4 weeks).
62505016|NCT05240092|NO_INTERVENTION|Standard of care Group|The control group did not receive any treatment.
62505017|NCT03934827|EXPERIMENTAL|Part A|"Open label, preliminary phase~20 participants"
62505018|NCT03934827|EXPERIMENTAL|Part B|"Randomised, double blinded phase~100 participants"
62703463|NCT00001352||Healthy Volunteers|Will be placed in a control group. Participant age must be 18 years or older. Healthy volunteers will be excluded if they have HIV, viral hepatitis (B or C), history of recurrent or severe infections, history of intravenous drug use, history of engaging in high-risk activities for HIV exposure, receiving chemotherapeutic agents, immunosuppressants, have underlying malignancies, pregnancy, or a history of heart disease, lung disease, kidney disease, or bleeding disorders.
62703464|NCT00001352||Patient Population|Previously healthy adult patients diagnosed with Cryptococcosis and have no predisposing conditions, such as HIV.
62347206|NCT04163640|EXPERIMENTAL|Intervention Group|Patients randomized to this group will receive the intra-ovarian platelet rich plasma injection
62505019|NCT04266431|EXPERIMENTAL|EMPOWER|EMPOWER is a multichannel, behavioral lifestyle intervention delivered remotely. The goals of EMPOWER are to induce a loss of 5% or more of initial weight within 6 months and to maintain these improvements at 12 and 24 months, by meeting dietary and physical activity goals. Coach-participant contacts will occur by phone and email, without in-person visits. Coaching contacts will be weekly for the first 12 weeks and then monthly thereafter. Men will have access to a web-based system that (1) provides support for behavioral methods of weight management and (2) allows coaches to review participant self-monitoring data and monitor participant progress towards goals. Men will record diet, exercise, and weight on the web or on a smart phone application.
62703465|NCT00001360||1|Normal volunteer participants aged 18-65 who are in good general health.
62703466|NCT04802967|EXPERIMENTAL|KLS-GABA (part A and B)|"KLS-GABA 80 mg-34 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules are administered with 240 mL of water.~KLS-GABA (40 mg-17mg, 80 mg-34 mg, or 160 mg-68 mg) in Part B are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.~To maintain he blind, subjects assigned to receive 160 mg-68 mg KLS-GABA are administered two co-crystal KLS-GABA 114 mg (80 mg-34 mg) capsules, and subject assigned to receive 40 mg-17 mg KLS-GABA or 80 mg-34 mg KLS-GABA also receive a placebo capsule (dummy placebo)."
62703467|NCT04802967|ACTIVE_COMPARATOR|KLS (part A and B)|"KLS 80 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules will be administered with 240 mL of water.~In the part B KLS (40 mg, 80 mg or 160 mg) are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water. To maintain the blind, subjects assigned to receive 160 mg KLS alone are administered two KLS 80 mg capsules and subjects assigned to receive either 40 mg KLS alone or 80 mg KLS alone also receive a placebo capsule (dummy placebo)."
61959719|NCT06455644|EXPERIMENTAL|CT group|CT-Guided Size Selection for LAA Occluder
62505020|NCT04266431|NO_INTERVENTION|Standard of Care|Men randomized to the standard of care group will continue to receive treatment from the mens' medical oncologist. These men will also be provided with a one page informative brochure on lifestyle recommendations adapted from the American Cancer Society Prostate Cancer Survivorship Care Guidelines, at the time of randomization. At the end of the trial, men in this arm will be offered a one-time counseling session with an intervention coach on healthy lifestyle.
62505021|NCT06083987|ACTIVE_COMPARATOR|Control Group - No Interventions|Arm 1 will have not be given any of the interventions and will be a control group.
62505022|NCT06083987|EXPERIMENTAL|Intervention 1 - Intersectionality and Identity|Arm 2 will be given access to intervention 1. It will have video and text content focused on identity and intersectionality.
62505023|NCT06083987|EXPERIMENTAL|Interventions 1 and 2 - Intersectionality and Identity/Confidentiality and Privacy|Arm 3 will be given access to with the video and text content focused on intersectionality and confidentiality
61959720|NCT06455644|ACTIVE_COMPARATOR|DSA group|DSA-Guided Size Selection for LAA Occluder
62347207|NCT04163640|NO_INTERVENTION|Control Group|Patients randomized to this group will not receive the intra-ovarian platelet rich plasma injection
62347208|NCT01372371|ACTIVE_COMPARATOR|Vancomycin|
62347209|NCT01372371|ACTIVE_COMPARATOR|Vancomycin and Gentamycin|
62347210|NCT01372371|ACTIVE_COMPARATOR|Intravenous Antibiotic|
61959721|NCT06506136|EXPERIMENTAL|Fluoxetine Treatment Group|
61959722|NCT06506136|PLACEBO_COMPARATOR|Placebo Control Group|
61959723|NCT04100265|EXPERIMENTAL|Panel 1 - High risk for postoperative ileus|Intervention in patients at high risk to develop prolonged postoperative ileus. Monitoring postoperative gastric motility for 2 consecutive days in patients who require preventive placement of a nasogastric feeding tube due to a high risk to develop postoperative ileus. Allowing to explore associations between gastric motility and general clinical evolution.
61959724|NCT04100265|EXPERIMENTAL|Panel 2 - Postoperative ileus arm with investigational device|Intervention in a population of patients with clinical signs of postoperative ileus, requiring a nasogastric feeding tube for symptom relief. The investigational medical device will be applied. Allowing to explore the association of gastric motility and clinical signs of postoperative ileus in an enriched population with true postoperative ileus.
61959725|NCT04100265|NO_INTERVENTION|Panel 3 - Postoperative ileus arm with standard of care|Standard of care control group of patients with clinical signs of postoperative ileus requiring a standard nasogastric feeding tube for symptom relief. Symptoms will be surveyed as control group to assess safety and tolerability of the investigational medical device.
61959726|NCT04736030|EXPERIMENTAL|Conmigo PA Intervention|12-week program (90 minutes/week)
62703468|NCT04802967|ACTIVE_COMPARATOR|Gabapentin (part B)|Gabapentin 300 mg are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.To maintain the blind, subjects assigned to receive 300 mg gabapentin also receive a placebo capsule (dummy placebo).
61959727|NCT04736030|NO_INTERVENTION|Delayed Abbreviated Intervention|No intervention during experimental phase; participants in control group receive abridged program after the final measurement point (wait list control).
61959728|NCT05074667|OTHER|Continuous Glucose Monitor|All participants will be included in this arm
61959729|NCT02400632|EXPERIMENTAL|MAGIC-TOUCH Drug-eluting balloon|in-stent restenosis treated with drug-eluting balloon
61959730|NCT02927665||Study Subjects|Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
61959731|NCT05298631|EXPERIMENTAL|Treatment group 1: stabilization exercises|"stabilization exercises~1. Chin tuck~2. Cervical extension~3. Shoulder shrugs~4. Shoulder rolls~5. Scapular retraction (15 repetitions 1 set) with TENS(10 mins before each session for 10 min at the back of the neck), stretching of trapezius, Pectorals minor, sternocleidomastoid, levator scapulae (5 rep 10 sec hold 1 set in both sides ) and cold pack (10 min at the back of neck at the end of each session)"
61959732|NCT05298631|ACTIVE_COMPARATOR|Treatment group 2: dynamic exercises|"dynamic exercises~1. Cervical extension-dynamic isometric.~2. Cervical Flexion-Dynamic isometric.~3. Chest flies exercises (15 repetitions 1 set) with TENS(10 mins before each session for 10 min at the back of the neck), stretching of trapezius, Pectorals minor, sternocleidomastoid, levator scapulae (5 rep 10 sec hold 1 set in both sides ) and cold pack (10 min at the back of neck at the end of each session)"
62143365|NCT00016107|EXPERIMENTAL|Treatment (chemotherapy, bevacizumab)|Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour followed by bevacizumab IV over 30-90 minutes on day 2. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62347211|NCT05865873|EXPERIMENTAL|Interventional group|Intervention group: will receive routine plus pre-recorded audio-based HEI package for six months until date of delivery.
62347212|NCT05865873|ACTIVE_COMPARATOR|Comparator group|Comparator group: will receive the routine health education package for six months until the date of delivery as per the Ethiopian guidelines.
62703469|NCT04802967|PLACEBO_COMPARATOR|Placebo (part B)|To maintain the blind subjects assigned to receive placebo receive 2 placebo capsules. Capsules will be administered with 240 mL of water.
61959733|NCT04010149|EXPERIMENTAL|Active tDCS|During cognitive training in the first 2 weeks, participants will also received brain stimulation. The investigators will use a total current intensity of 2mA for 20 minutes, preceded by 30 seconds ramping up and followed by 30 seconds ramping down (total stimulation time = 21s).
61959734|NCT04010149|SHAM_COMPARATOR|SHAM tDCS|During sham stimulation, concurrent with the cognitive training, The investigators will use the same setup as in the active condition but after ramping up, the current will be brought back to zero and the process repeated 30 seconds before the end of the 21 minutes time interval (total sham stimulation time = 21s).
61959735|NCT02900196|EXPERIMENTAL|1 - Test|
61959736|NCT02900196|PLACEBO_COMPARATOR|2 - Placebo|
62143366|NCT00713596|SHAM_COMPARATOR|Control group|Septorhinoplasty with postoperative application of nasal taping and an external nasal cast. The tape and cast will be left in place for one week. No tissue glue will be used during the operation, although the nurse and surgical assistant will simulate the preparation and insertion of tissue glue using a syringe containing saline.
62347213|NCT00699842|EXPERIMENTAL|Lenalidomide|Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.
62347214|NCT06134713|EXPERIMENTAL|Root canal treatment cryotherapy group|Conventional root canal treatment with final irrigation using sterile saline at 2.5ºC
62347215|NCT06134713|EXPERIMENTAL|Root canal RE-treatment cryotherapy group|Conventional root canal RE-treatment with final irrigation using sterile saline at 2.5ºC
62347216|NCT06134713|ACTIVE_COMPARATOR|Root canal treatment control group|Conventional root canal treatment with final irrigation using sterile saline at room temperature
61959737|NCT04694742||ARDS COVID-19|Patients who meet Berlin's ARDS diagnostic criteria, with confirmed SARS-CoV-2 infection, requiring invasive mechanical ventilation.
61959738|NCT02591290|EXPERIMENTAL|Menactra® Vaccine|Participants received 2-dose series of the study vaccine with 8-week interval.
61959739|NCT06263205|EXPERIMENTAL|Non-Dressing Group|Participants in this group will receive standard wound disinfection and initial postoperative care with dressings applied immediately after their gastrointestinal tumor surgery. However, 48 hours post-surgery, these dressings will be removed and the wounds will be left exposed without any further dressing. This arm aims to evaluate the outcomes of wound healing, pain levels, and healthcare costs when the surgical wound is kept open postoperatively, in contrast to traditional dressing methods.
62505024|NCT06083987|EXPERIMENTAL|Interventions 1, 2, and 3 - Intersectionality/Confidentiality/Educational Tools|Arm 4 will be given access to with the video and text content focused on intersectionality, confidentiality, and education about identity
62703470|NCT05303792|EXPERIMENTAL|Arm A (inotuzumab ozogamicin, chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive inotuzumab ozogamicin IV and IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients \>= 70 years of age receive either 2 or 4 cycles of treatment. Patients \< 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
62703471|NCT05303792|ACTIVE_COMPARATOR|Arm B (chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, doxorubicin IV on day 4, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients \>= 70 years of age receive either 2 or 4 cycles of treatment. Patients \< 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
62703472|NCT00542230||Healthy Volunteers|Healthy Volunteers
62703473|NCT00542230||Sickle Cell Trait|Patient with sickle cell trait or disease
62703474|NCT04939090|EXPERIMENTAL|Arm I (olanzapine)|Patients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
62703475|NCT04939090|ACTIVE_COMPARATOR|Arm II (megestrol acetate)|Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
62703476|NCT05508737|EXPERIMENTAL|Single arm, Pembrolizumab, trifluridine/tipiracil|Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
62703477|NCT05092958|ACTIVE_COMPARATOR|Arm A (avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo CT or MRI and biospecimen collection throughout the trial. Patients may undergo urine sample collection as clinically indicated.
61959740|NCT06263205|ACTIVE_COMPARATOR|Dressing Group|Participants in this group will receive standard postoperative care, which includes regular wound dressings. Their surgical wounds will be covered with dressings, which will be changed every 48-72 hours following the surgery. This group serves as a comparator to assess the effectiveness and safety of the non-dressing approach in terms of wound healing, pain management, and associated healthcare costs.
61959741|NCT06332911||complex endovascular thoracic aortic repair|Patients submitted to complex endovascular thoracic aortic repair with hostile iliac access vessels using the Shockwave device to gain access.
61959742|NCT05075122|EXPERIMENTAL|Vaccination arm|Pembrolizumab flat dose iv every 3 weeks + UV1 vaccination (UV1 plus GM-CSF/Sargramostim as adjuvant per vaccination)
61959743|NCT05075122|OTHER|Calibration arm|Pembrolizumab flat dose iv every 3 weeks
61959744|NCT04771039||patients with chronic inflammatory bowel disease who consulted in ophthalmology|
61959745|NCT03989271|ACTIVE_COMPARATOR|Quercetin|Quercetin 2000 mg/day Quercetin is provided as orange flavored soft chews and each chew will have 250 mg of quercetin Quercetin will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.
61959746|NCT03989271|PLACEBO_COMPARATOR|Placebo|"Placebo is also provided as soft chews that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.~Placebo will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months."
61959747|NCT05122832||The study Group|Population of Kazakhstan
61959748|NCT05375370|EXPERIMENTAL|Patient with hepatocellular carcinoma|Circulating tumor DNA dosage will be done to patients with hepatocellular carcinoma
62143367|NCT00713596|EXPERIMENTAL|Fibrinogen, tape, and cast|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, fibrin sealant will be applied by the surgical assistant to the surgical site. Approximately 0.5 cc to 2 cc of tissue sealant will be applied. After closure, tape and cast will be applied and left in place for one week.
62143368|NCT00713596|EXPERIMENTAL|Fibrinogen and tape|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, 0.5 cc to 2 cc of tissue sealant will be applied. Nasal tape will be applied after closure.
62347217|NCT06134713|ACTIVE_COMPARATOR|Root canal RE-treatment control group|Conventional root canal RE-treatment with final irrigation using sterile saline at room temperature
61959749|NCT03678129|OTHER|AZD7325|Prepandemic. Single Dose of Placebo or AZD7325 10mg or AZD7325 20mg random order on visits separated by 1 week
61959750|NCT03678129|OTHER|Clobazam|Post pandemic: Single Dose Placebo or 5mg Clobazam random order on visits separated by 1 week
61959751|NCT05154591|EXPERIMENTAL|Bilateral Treatment|Intra-arterial injection of SVF cells into the kidneys.
61959752|NCT04032860|EXPERIMENTAL|ETV group|group in which patients take ETV as antiviral therapy after curative treatment
61959753|NCT04032860|EXPERIMENTAL|TDF group|group in which patients take TDF as antiviral therapy after curative treatment
62505025|NCT06083987|EXPERIMENTAL|Interventions 1, 2, and 4 - Intersectionality/Confidentiality/Finding Affirming Care|Arm 5 will be given access to interventions 1, 2, and 4, with the video and text content focused on intersectionality, confidentiality, and determining if caregivers are affirming
62347218|NCT02793323|EXPERIMENTAL|Superficial cervical block|Patients will receive superficial cervical nerve block in which we inject 5 ml of local anaesthetic mixture. Each 17 ml of the mixture contain: 6 ml lidocaine 2%, 6 ml lidocaine 2% with adrenaline 5 µg/ml, and 5 ml bupivacaine 0.5. Patients will also receive 100 ml IV saline.
62505026|NCT06083987|EXPERIMENTAL|Interventions 1, 2, 3 and 4 - Intersectionality/Confidentiality/Educational Tools/Affirming Care|Arm 6 will be given access to all 4 interventions, with the video and text content focused on intersectionality, confidentiality, education about identity, and determining if caregivers are affirming
62505027|NCT06083987|EXPERIMENTAL|Interventions 1 and 3 - Intersectionality and Identity/Educational Tools|Arm 7 will be given access to interventions 1 and 3, with the video and text content focused on intersectionality and education about identity
62703478|NCT05092958|EXPERIMENTAL|Arm B (avelumab, cabozantinib)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle and cabozantinib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo CT or MRI and biospecimen collection throughout the trial. Patients may undergo urine sample collection as clinically indicated.
61959754|NCT05011565||Fontan Group|"Fontan Group Inclusion Criteria~* be between the ages of 8-50~* Having undergone Fontan operation in our hospital or another center~* Clinical stability of the patients (preserved ventricular function),~* No change in ongoing drug therapy that adversely affects clinical stability,~* At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital~Fontan Group Exclusion Criteria:~* Inability to access the patient's medical data~* Neurological and/or genetic musculoskeletal disease~* Having orthopedic and cognitive problems that prevent testing~* The patient's and/or family's unwillingness to participate in the study"
61959755|NCT05011565||Control Group|"Control Group Inclusion Criteria:~* Not have cardiovascular, neurological and/or genetic musculoskeletal disease~* Not having orthopedic and cognitive problems that prevent testing~* The patient's and/or family's willingness to participate in the study"
61959756|NCT05193370|EXPERIMENTAL|angiotensin II (intervention)|For patients randomized to the intervention group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, angiotensin II will be started at a dose of 20 ng/kg/min (recommended starting dose in package insert). Thereafter, angiotensin II and norepinephrine will both be titrated according to the schema in UNM Hospitals Nursing Department Titration Guideline. Angiotensin II treatment will be capped at 72h, at which point (if a second vasopressor is still needed) the patient will be started on an alternative agent.
61959757|NCT05193370|ACTIVE_COMPARATOR|vasopressin (standard of care)|In patients randomized to the control group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, vasopressin will be used at a fixed dose of 0.04 units/min and norepinephrine will be titrated per usual standard of care (as also outlined in the UNM Hospitals Nursing Department Titration Guideline).
61959758|NCT02312102|EXPERIMENTAL|Velcade and Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each treatment cycle lasts 28 days (4 weeks). The first two cycles are called the induction cycles. If the participant respond to treatment during the first two cycles, they can continue on to the maintenance cycles.~During the induction and maintenance cycles, patients receive up to the MTD of lenalidomide on days 1-21 days only. During days 22-28 (4th week) there is a rest period.~Bortezomib: During the induction cycles, the medication will be given on days 2, 5, 9, and 12 followed by a 17-day rest period. During the maintenance cycles, bortezomib will be given on days 2, and 5 followed by 23-day rest period."
61959759|NCT00865696|EXPERIMENTAL|A|Mirtazapine 15 mg tablets, single dose
61959760|NCT00865696|ACTIVE_COMPARATOR|B|REMERON® 15 mg tablets, single dose
61959761|NCT02563223|OTHER|electromyographic (EMG) measurements|Interaction between gravity (weightlessness, hypergravity, and normal gravity) and pull-down force ont EMG amplitude and EMG timing.
61959762|NCT01247909|EXPERIMENTAL|Ceftriaxone|Ceftriaxone in infants with sepsis and bacterial meningitis
62703479|NCT03955445|EXPERIMENTAL|Cohort A: participants with native kidneys from CLNP023X2202|C3G participants from study CLNP023X2202 with native kidneys receiving iptacopan capsules 200 mg b.i.d
62703480|NCT03955445|EXPERIMENTAL|Cohort B: participants with transplanted kidneys from CLNP023X2202|C3G participants from study CLNP023X2202 who have undergone kidney transplant and have recurrence of C3G receiving iptacopan capsules 200 mg b.i.d
61959763|NCT01247909|ACTIVE_COMPARATOR|Penicillin and gentamicin|Penicillin and Gentamicin in infants with sepsis and bacterial meningitis
62703481|NCT03955445|EXPERIMENTAL|Cohort C: Participants with native C3G from CLNP023B12301 randomized to placebo|Native C3G Participants (adults and adolescents) from CLNP023B12301 study who were randomized to placebo in the core study receiving iptacopan capsules 200mg b.i.d
61959764|NCT01969968|OTHER|sleeve bariatric surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
61959765|NCT01969968|OTHER|morbidly obese adults with by pass surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
62347219|NCT02793323|PLACEBO_COMPARATOR|NSAID|Patients will receive 100 mg (100 ml) IV NSAIDs (Profenid) before induction of anesthesia. Superficial cervical nerve block containing 5 ml placebo will be performed.
62703482|NCT03955445|EXPERIMENTAL|Cohort D: particpants with native C3G from CLNP023B12301 randomised to iptacopan|Native C3G participants (adults and adolescents) from study CLNP023B12301 who were randomized to iptacopan in the core study. Receiving iptacopan capsules 200mg b.i.d
61959766|NCT01969968|OTHER|non obese|non obese patients
61959767|NCT03046004|EXPERIMENTAL|Decision aid|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
61959768|NCT03046004|ACTIVE_COMPARATOR|Control|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
61959769|NCT01666496|EXPERIMENTAL|Experimental Video Game|Participants will play the experimental videogame for 6 weeks. The intervention will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
61959770|NCT01666496|OTHER|Off the Shelf Video Game|Participants will play the off the shelf videogame for 6 weeks. The intervention be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
61959771|NCT05530421|EXPERIMENTAL|XVenD Group|"Participants will receive XVenD combination therapy of Selinexor (X), Venetoclax (Ven) and Dexamethasone (D) orally during each 28-day cycle. Doses will be administered as follows:~* Cycle 1 Days 1 to 7:~  * Venetoclax 400 mg orally (PO), Days 1-7~ * Dexamethasone 40 mg PO, Day 1~* Cycle 1 Days 8 to 28:~  * Venetoclax 800 mg PO, Days 8-28~ * Dexamethasone 40 mg PO, Days 8, 15, and 22~* Cycles 2 to 4:~  * Selinexor 80 mg PO, Days 1, 8, 15, and 22~ * Venetoclax 800 mg PO, Days 1-28~ * Dexamethasone 40 mg PO, Days 1, 8, 15, and 22~* Cycle 5 and beyond:~  * Selinexor 80 mg PO, Days 1, 8, 15, and 22~ * Venetoclax 800 mg PO, Days 1-28~ * Dexamethasone 20 mg PO, Days 1, 8, 15, and 22~Selinexor dose will be reduced to 60 mg for remaining participants if after the first 6 participants complete the first cycle and 2 or more out of these first 6 participants experience dose-limiting toxicities (DLTs)."
61959772|NCT04238702|EXPERIMENTAL|Empagliflozin + Losartan|Empagliflozin + Losartan
61959773|NCT04238702|EXPERIMENTAL|Losartan + Placebo|Losartan + Placebo
61959774|NCT04238702|EXPERIMENTAL|Empagliflozin + Placebo|Losartan + Placebo
61959775|NCT04238702|PLACEBO_COMPARATOR|Placebo + Placebo|Placebo + Placebo
62703483|NCT03955445|EXPERIMENTAL|Cohort E: participants with IC-MPGN from CLNP023B12302 randomized to placebo|IC-MPGN participants (adults and adolescents) from study CLNP023B12302 who were randomized to placebo in the core study receiving iptacopan capsules 200mg b.i.d
62703484|NCT03955445|EXPERIMENTAL|Cohort F: participants with IC-MPGN from CLNP023B12302 randomized to ipatocan|IC-MPGN participants (adults and adolescents) from study CLNP023B12302 who were randomized to iptacopan in the core study receiving iptacopan capsules 200mg b.i.d
62143369|NCT01989052|EXPERIMENTAL|Phase 1: CTO and lomustine|The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
62347220|NCT05136846|EXPERIMENTAL|Treatment (papaverine, RT, paclitaxel, carboplatin)|Patients receive PPV IV or SC and undergo 5 fractions of RT per week. Patients also receive paclitaxel IV over 1 hour and carboplatin IV QW over 1-6 weeks or pemetrexed IV over 10 minutes followed by carboplatin IV every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 month of completing CRT, patients with PD-L1 positive disease receive durvalumab IV Q2W for 12 months.
62347221|NCT04819802||Covid-19 patients|Adult Covid-19 patients admitted to intensive care units
62703485|NCT06503146|EXPERIMENTAL|1/Arm 1|\[18F\]FAPI-74 and 18F-FDG PET imaging
61959776|NCT04661839|EXPERIMENTAL|COVID-HIGIV Dose Level 1 (100 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 1 (100 mg/kg).
61959777|NCT04661839|EXPERIMENTAL|COVID-HIGIV Dose Level 2 (200 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 2 (200 mg/kg).
61959778|NCT04661839|EXPERIMENTAL|COVID-HIGIV Dose Level 3 (400 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 3 (400 mg/kg).
61959779|NCT04661839|PLACEBO_COMPARATOR|Dose Placebo (saline)|Eligible subjects randomized to receive a single IV infusion of saline placebo.
61959780|NCT02109783|ACTIVE_COMPARATOR|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
62143370|NCT01989052|EXPERIMENTAL|Phase 2: CTO alone|CTO alone at the MTD established in the Phase 1 portion of this study
61959781|NCT02109783|ACTIVE_COMPARATOR|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
61959782|NCT02109783|PLACEBO_COMPARATOR|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
61959783|NCT02258698||Elective on-pump cardiac surgery|Observation of perioperative Insulin resistance in patients undergoing elective on-pump cardiac surgery (CABG and/or valve repair)
61959784|NCT04487392|ACTIVE_COMPARATOR|Estrogen vaginal cream group (group A)|22 participants will be included in this group. The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home.
62347222|NCT05431049||combined spino-epidural anesthesia (CSEA)|Percutaneous nephrolithotomy under combined spino-epidural anesthesia
62347223|NCT05431049||general anesthesia (GA)|Percutaneous nephrolithotomy under general anesthesia
62347224|NCT01313364|EXPERIMENTAL|All subjects to self-administer 4 IM injections|Subjects will be recruited and stratified into BMI groups: \<18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and \>30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
62347225|NCT03111550|OTHER|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Tecnis Model ZHR00
62347226|NCT03111550|OTHER|Investigational Lens Device #2|Investigational Intraocular Lens Device #2: Tecnis Model ZQR00
62347227|NCT03111550|OTHER|Control Device|Control TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
62703486|NCT06271187|EXPERIMENTAL|Dynamic-orthosis training group|Participants will undergo traditional occupational therapy (2-3 times per week, one hour per session, for a total of six weeks), supplemented with an additional home-based dynamic orthotic therapy program (five days per week, one hour per session, for six weeks). The style of the dynamic orthosis will be selected by the researchers based on the participants' movement performance and rehabilitation goals, and it will be adjusted or replaced as their abilities progress.
61959785|NCT04487392|EXPERIMENTAL|Photobiomodutation group (group B)|22 participants will be included in this group. The participants selected for group B will be undergo photobiomodulation with red LED.
61959786|NCT05228171||Standard Recall|Standard interviewer-administered 24-hour dietary recall.
61959787|NCT05228171||Augmented Recall|Interviewer use of the mCC app for 24-hour dietary recall.
61959788|NCT00294437|EXPERIMENTAL|zoledronic acid|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
61959789|NCT00294437|NO_INTERVENTION|no intervention|no reference therapy
61959790|NCT02825056|ACTIVE_COMPARATOR|Bupivacaine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%).
61959791|NCT02825056|EXPERIMENTAL|Bupivacaine + Morphine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%) and 250 microgram of preservative free Morphine (VERMOR).
61959792|NCT04456608|EXPERIMENTAL|Low and High n-3 PUFA|Individuals with low or high n-3 PUFA RBC concentration will be given aspirin (81 mg of aspirin once a day, for 6 days)
61959793|NCT02195583|EXPERIMENTAL|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
61959794|NCT02195583|EXPERIMENTAL|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
61959795|NCT02195583|EXPERIMENTAL|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
61959796|NCT02195583|EXPERIMENTAL|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
61959797|NCT02195583|EXPERIMENTAL|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
61959798|NCT02195583|PLACEBO_COMPARATOR|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
61959799|NCT02114216|SHAM_COMPARATOR|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
62703487|NCT06271187|OTHER|Regular training group|Participants will receive traditional occupational therapy (2-3 sessions per week, one hour per session, for a total of six weeks). The training program includes muscle strength training, reaching and grasping exercises, manual tone control, motor facilitation, and activities of daily living training. During the study period, participants will not wear any hand dynamic orthosis during training.
61959800|NCT02114216|ACTIVE_COMPARATOR|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
61959801|NCT02114216|ACTIVE_COMPARATOR|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
61959802|NCT04805424|ACTIVE_COMPARATOR|Abdominoplasty|Standard abdominoplasty
61959803|NCT04805424|EXPERIMENTAL|Lipo-abdominoplasty|Abdominoplasty plus liposuction
61959804|NCT00458211|EXPERIMENTAL|Experimental|Open label change to ziprasidone
61959805|NCT04068870|EXPERIMENTAL|Contraceptive management program|
61959806|NCT04068870|NO_INTERVENTION|Usual care|
62505028|NCT06083987|EXPERIMENTAL|Interventions 1, 3, and 4 - Intersectionality and Identity/Educational Tools/Finding Affirming Care|Arm 8 will be given access to interventions 1, 3, and 4, with the video and text content focused on intersectionality, education about identity and determining if caregivers are affirming.
62505029|NCT06083987|EXPERIMENTAL|Interventions 1 and 4 - Intersectionality and Identity/Finding Affirming Care|Arm 9 will be given access to interventions 1 and 4, with the video and text content focused on intersectionality and determining if caregivers are affirming.
61959807|NCT05675397|EXPERIMENTAL|MOM supplemented with PDM (group A)|VLBW Infants fed with mother's own milk (MOM) supplemented with preterm donor milk (PDM)
61959808|NCT05675397|ACTIVE_COMPARATOR|MOM supplemented with TDM (group B)|VLBW infants fed with mother's own milk (MOM) supplemented with term donor milk (TDM)
61959809|NCT03931538|ACTIVE_COMPARATOR|Culture Only|Physician receives only culture result
61959810|NCT03931538|ACTIVE_COMPARATOR|Guidance 4.0 PCR test only|Physician receives Guidance report only
62505030|NCT06083987|EXPERIMENTAL|Intervention 2 - Confidentiality and Privacy|Arm 10 will be given access to intervention 2, with the video and text content focused on confidentiality
61959811|NCT03931538|ACTIVE_COMPARATOR|Culture and Guidance 4.0 PCR test Group|Physician receives both results, gets Culture report immediately before Guidance
61959812|NCT03931538|ACTIVE_COMPARATOR|Guidance 4.0 PCR test and culture group|Physician receives both results, gets Guidance report immediately before culture
61959813|NCT02560571|EXPERIMENTAL|all patients|all study patients will undergo ultrasound and blood test
61959814|NCT00858130|EXPERIMENTAL|Veinoplus|Every subject enrolled in study will be in this experimental arm. VeinoPlus device will be used by all enrolled subjects.
61959815|NCT04148053||Active TB|"Subjects met the following:~1. Either Pulmonary or Extra-pulmonary tuberculosis patients~2. TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen."
61959816|NCT04148053||Latent TB|"Subjects met the following:~1. TB Contact in history.~2. Chest X-ray suggestive of non-TB.~3. without any symptoms suggestive of TB.~4. TST and/or IGRA positive."
61959817|NCT04555083||CAI group|Case group is CAI group that recruit patients complain of ankle insatiability and giving way mainly
61959818|NCT04555083||control group|control group recruits participants with non injured ankle, matched with case group in gender and dominant limb
61959819|NCT05004025|EXPERIMENTAL|TTF Plus Chemotherapy|Novacure Optune with Opdivo and Yervoy
61959820|NCT03794297|EXPERIMENTAL|Treatment (dabrafenib mesylate, trametinib dimethyl sulfoxide)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
61959821|NCT01201018|EXPERIMENTAL|Oshadi DR|
61959822|NCT03889444||OZURDEX®|Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.
62143371|NCT01989052|EXPERIMENTAL|Phase 2: CTO and lomustine|CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
62505031|NCT06083987|EXPERIMENTAL|Interventions 2 and 3 - Confidentiality and Privacy/Educational Tools|Arm 11 will be given access to interventions 2, and 3. Video and text content will focus on confidentiality and education about identity.
61959823|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
61959824|NCT06279091|EXPERIMENTAL|tell show do technique|apply normal treatment with basic behavioral technique as a control group.
61959825|NCT06279091|EXPERIMENTAL|Diaphragmatic breathing technique|apply normal treatment with breathing exercises as relaxation and distruction technique to reduce the dental anxiety.
61959826|NCT06279091|EXPERIMENTAL|Bubble Blower breathing technique|apply normal treatment with breathing exercises by bubbleblower which is a play therapy as relaxation and distruction technique to reduce the dental anxiety.
61959827|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
61959828|NCT06055010||Healthy individuals|Healthy individuals who received an abdominal CT-scan (controls).
61959829|NCT06055010||Individuals with pancreatic lesions|Patients who received diagnostic procedures and/or treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database
61959830|NCT00297830|EXPERIMENTAL|Active Zoledronic Acid & Placebo Alendronate|Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
61959831|NCT00297830|EXPERIMENTAL|Placebo Zoledronic Acid & Active Alendronate|Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.
61959832|NCT04551755|ACTIVE_COMPARATOR|Ivermectin plus Doxycycline plus standard care|Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours 2) Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes 3) Standard symptomatic and supportive treatment; Tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements
61959833|NCT04551755|PLACEBO_COMPARATOR|Placebo plus standard care|"1) Standard symptomatic and supportive treatment with placebo; Standard treatment includes tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements.~Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days"
61959834|NCT01896102|EXPERIMENTAL|Lenti-D Drug Product|Participants received a single intravenous (IV) infusion of Lenti-D Drug Product at a dose of greater than or equal to (\>=) 5.0 × 10\^6 CD34+ cells/kilogram (kg) (autologous CD34+ cell-enriched population that contained cells transduced with lentiviral vector encoding ABCD1 cDNA for human adrenoleukodystrophy protein, suspended in a cryopreservative solution) on Day 0.
62143372|NCT01989052|EXPERIMENTAL|Phase 2: Lomustine alone|Oral lomustine alone at 110 mg/m2 every 6 weeks
61959835|NCT02380781|NO_INTERVENTION|Control|Patients will receive current standard postpartum contraceptive counseling.
61959836|NCT02380781|EXPERIMENTAL|Intervention|Patients will receive current standard postpartum contraceptive counseling and will be shown a 10 minute video from the CHOICE project which outlines the different contraceptive options
61959837|NCT04923191|OTHER|Angiography-derived Physiology Guidance: angio-FFR (QFR and caFFR)|Quantitative Flow Ratio- QFR, Coronary angiography-derived FFR - caFFR
61959838|NCT04923191|OTHER|Local routine diagnostic procedure (LRDP) and usual care|
61959839|NCT02949037|EXPERIMENTAL|Intervention|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, integrated with the mobile health care environment (MHCE) system. The MHCE system will provide tailored behavioral messages triggered by clinical values and survey responses.
61959840|NCT02949037|NO_INTERVENTION|Control|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, NOT integrated with the mobile health care environment (MHCE) system.
61959841|NCT01419678|EXPERIMENTAL|'collection of blood samples for PK testing'|collection of PK samples around a dosing of Posaconazole
61959842|NCT03558698|OTHER|Group 1|"* One night of good ventilation with a CO2 level of maximum 800 ppm~* One night of good ventilation with high levels of CO2 (3000 ppm)~* One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
61959843|NCT03558698|OTHER|Group 2|"* One night of good ventilation with a CO2 level of maximum 800 ppm~* One night of good ventilation with high levels of CO2 (3000 ppm)~* One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
61959844|NCT03558698|OTHER|Group 3|"* One night of good ventilation with High CO2 level of maximum 800 ppm~* One night of good ventilation with high levels of CO2 (3000 ppm)~* One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
62143373|NCT02994667||Pacemaker After TAVR|The study cohort will comprise all consecutive patients who undergo permanent pacemaker placement for new conduction disturbances after TAVR at THHBP between 1/1/2015 and 12/31/2016.
62143374|NCT00747006|EXPERIMENTAL|TI Inhalation Powder (original protocol)|Under the original protocol, subjects with Type 1 and Type 2 diabetes will have TI Inhalation Powder administered prandially during dose optimization visits and meal challenge visits (with meals of varying carbohydrate contents). Subjects with Type 2 diabetes will also use TI Inhalation Powder daily at each meal between visits.
62347228|NCT05341570|EXPERIMENTAL|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BPI-21668 administered, once daily (QD).
62703488|NCT04738942|EXPERIMENTAL|Vedolizumab 300 mg in UC cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
61959845|NCT03558698|OTHER|Group 4|"* One night of good ventilation with a CO2 level of maximum 800 ppm~* One night of good ventilation with high levels of CO2 (3000 ppm)~* One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
62505032|NCT06083987|EXPERIMENTAL|Interventions 2, 3 and 4 - Confidentiality and Privacy/Educational Tools/Finding Affirming Care|Arm 12 will be given access to interventions 2, 3, and 4. Video and text content will focus on confidentiality, education about identity, and determine if caregivers are affirming.
62703489|NCT04738942|EXPERIMENTAL|Vedolizumab 300 mg in CD cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
61959846|NCT03558698|OTHER|Group 5|"* One night of good ventilation with a CO2 level of maximum 800 ppm~* One night of good ventilation with high levels of CO2 (3000 ppm)~* One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
62143375|NCT00747006|OTHER|TI Inhalation Powder and Humalog (Amendment 1)|Under Amendment 1, TI Inhalation Powder will be administered prandially to a new subset of subjects with Type 2 diabetes during TI dose optimization visits and TI meal challenge visits (with meals of varying carbohydrate contents). Subjects will be crossed over to administration of Humalog 15 minutes before meals during Humalog dose optimization visits and Humalog meal challenge visits (with meals of varying carbohydrate contents). Subjects will also use TI Inhalation Powder daily at each meal between visits.
62505033|NCT06083987|EXPERIMENTAL|Interventions 2 and 4 - Confidentiality and Privacy/Finding Affirming Care|Arm 13 will be given access to interventions 1, 3, and 4. Video and text content will focus on confidentiality and determining if caregivers are affirming.
62505034|NCT06083987|EXPERIMENTAL|Intervention 3 - Educational Tools|Arm 14 will be given access to intervention 3. Video and text content will focus on education about identity
62505035|NCT06083987|EXPERIMENTAL|Interventions 3 and 4 - Educational Tools/Finding Affirming Care|Arm 15 will be given access to interventions 3 and 4. Video and text content will focus on educational tools about identity and determining if caregivers are affirming.
62505036|NCT06083987|EXPERIMENTAL|Intervention 4 - Finding Affirming Care|Arm 16 will be given access to intervention 4, with video and text content focusing on determining if caregivers are affirming.
61959847|NCT03558698|OTHER|Group 6|"* One night of good ventilation with a CO2 level of maximum 800 ppm~* One night of good ventilation with high levels of CO2 (3000 ppm)~* One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
62703490|NCT03289403|EXPERIMENTAL|Study group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D and immunomodulatory drugs(prednisolone, hydroxychloroquine, azathioprin, IV immunoglobulins)
61959848|NCT06341842|EXPERIMENTAL|Active group - Dapagliflozin 10 mg|
61959849|NCT06341842|NO_INTERVENTION|Control group - Standard of care|
61959850|NCT04507737|EXPERIMENTAL|Critical Care Outreach Team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Critical Care Outreach Team Model consisting of an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
61959851|NCT04507737|NO_INTERVENTION|Medical Emergency team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Medical Emergency Team Model, consisting of an ICU-trained Doctor as well as an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
61959852|NCT05972876|EXPERIMENTAL|Blood flow restriction training (BFRT)|Patients in the BFRT group will perform four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press, seated leg extension, deadlift and squat exercises with 30s inter-set rest periods throughout a 0-90° range of motion at 30% one-repetition maximum
61959853|NCT05972876|ACTIVE_COMPARATOR|Resistance training (RT)|Patients in the resistance training group will perform 3x10 reps (30s inter-set rest) of unilateral leg press, seated leg extension, deadlift and squat exercises exercise throughout a 0-90° range of motion with incremental increase in external-load up to 70% of patients' one-repetition maximum
62505037|NCT01311427|ACTIVE_COMPARATOR|Group education|The control condition received standard group education, which met in small groups two times weekly for 60 minutes over 12 weeks.
62143376|NCT03152435|EXPERIMENTAL|anti-tumor response of CART-EGFR|
62505038|NCT01311427|EXPERIMENTAL|8-form Yang-style Tai chi program|This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
62505039|NCT01518335|EXPERIMENTAL|Platelet Rich Plasma|Patients receive Platelet rich plasma injection + standard of care therapy(bandaging or boot and crutches) + non-NSAID pain medicine
62703491|NCT03289403|ACTIVE_COMPARATOR|Control group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D.
62703492|NCT06451354|NO_INTERVENTION|Control group|Patients will receive the standard spinal anesthesia with 0.5% hyperbaric bupivacaine (2.2ml)
62143377|NCT04597866||CRPS|
62505040|NCT01518335|PLACEBO_COMPARATOR|Placebo/Standard of Care|Patient receives Placebo Comparator: Placebo/Standard of Care \[saline injection + standard of care (bandaging or boot and crutches)\] + non-NSAID pain medicine
62505041|NCT05312476|EXPERIMENTAL|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|Chimeric antigen receptor T cells targeting Igβ targets (CAR-T)
62505042|NCT06351696|ACTIVE_COMPARATOR|Intervention|Bromleine
62505043|NCT06351696|PLACEBO_COMPARATOR|Placebo|Placebo
62703493|NCT06451354|EXPERIMENTAL|Erector spinae plane block group|Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.
61959854|NCT03699657|ACTIVE_COMPARATOR|RFA with DSM mode|RFA is performed in dual switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
61959855|NCT03699657|ACTIVE_COMPARATOR|RFA with SSM mode|RFA is performed in single switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
61959856|NCT03213522|ACTIVE_COMPARATOR|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
61959857|NCT03213522|ACTIVE_COMPARATOR|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
61959858|NCT06083662|EXPERIMENTAL|A arm|Neratinib + herzuma
62505044|NCT04522804|EXPERIMENTAL|Treatment: all patients|"Subjects will participate in a total of seven group sessions. There will be 4 or 6 subjects per group and one therapist will be assigned to each subject for a total of 4 or 6 therapists. In addition, there will be one Group Leader that will facilitate the group sessions. Group sessions will occur once per week for approximately five weeks. The first three sessions are Preparatory sessions followed by three Integration sessions. During the week following the third Preparatory session and prior to the first Integration session, participants will participate in a psilocybin session."
62505045|NCT05098132|EXPERIMENTAL|Part A: STK-012 weekly (QW) monotherapy dose escalation|STK-012 will be administered in sequential ascending doses as monotherapy subcutaneously (SC) QW until unacceptable toxicity, disease progression, or withdrawal of consent.
61959859|NCT04851834|EXPERIMENTAL|NTX-301 Monotherapy Dose Escalation|NTX-301 monotherapy dose escalation in patients with advanced solid tumours
61959860|NCT04851834|EXPERIMENTAL|NTX-301 platinum-based doublet therapy Dose Escalation|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian \& bladder cancer
61959861|NCT04851834|EXPERIMENTAL|NTX-301 platinum-based doublet therapy Dose Expansion|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian \& bladder cancer
61959862|NCT04851834|EXPERIMENTAL|NTX-301 Temozolomide doublet therapy Dose Escalation|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
61959863|NCT04851834|EXPERIMENTAL|NTX-301 Temozolomide doublet therapy Dose Expansion|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
61959864|NCT01674296||Group 1 (2012-2013)|Monitoring of Dietary Intake, Physical Activity and Stress
61959865|NCT01674296||Group 2 (2013-2014)|Monitoring of Dietary Intake, Physical Activity and Stress
61959866|NCT06304376|OTHER|study group|This study group contains of patient who had alveolar cleft, indicated for late secondary alveolar grafting
61959867|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
62143378|NCT04983615|EXPERIMENTAL|fentanyl-based sedation group|
62143379|NCT04983615|ACTIVE_COMPARATOR|midazolam-based sedation group|
62143380|NCT03011047|EXPERIMENTAL|endoscopic trans-antral approach|The maxillary sinus and prolapsed orbital contents will be visualized employing a 30-degree endoscope for the repair of orbital blow out fracture (sinus scope 4 mm, 30 degrees short one 17 cm).
62143381|NCT03011047|ACTIVE_COMPARATOR|trans-orbital surgical approach|trans-orbital surgical approach through the lower eyelid Sub-ciliary incision ( through the lower eyelid) The skin incision is made just below the eyelashes.
62143382|NCT05741450|EXPERIMENTAL|Lens 1|All participants wore Lens 1 for 15 minutes (Period 1)
62143383|NCT05741450|EXPERIMENTAL|Lens 2|All participants wore Lens 2 for 15 minutes (Period 2)
62143384|NCT03019341||Patients with enhanced CT scan|Patients undergo CT examination after the administration of non-ionic contrast media for clinical need.
62347229|NCT05341570|EXPERIMENTAL|Dose Expansion|Oral tablets administered at MTD/RP2D. Each treatment cycle will be 28 days in duration with BPI-21668 administered, once daily (QD).
62347230|NCT01144234|EXPERIMENTAL|Invitation letter to male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
62505046|NCT05098132|EXPERIMENTAL|Part B: STK-012 every three weeks (Q3W) monotherapy dose escalation|STK-012 will be administered in sequential ascending doses as monotherapy SC Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
62505047|NCT05098132|EXPERIMENTAL|Part C: STK-012 Q3W + pembrolizumab dose escalation|STK-012 will be administered in sequential ascending doses SC Q3W in combination with a fixed dose of pembrolizumab intravenously (IV) Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
62703494|NCT06451354|EXPERIMENTAL|Posterior Quadratus lumborum plane block group|Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
62347231|NCT01144234|PLACEBO_COMPARATOR|Information letter|In this arm the pregnant women got an information letter about antenatal care.
62347232|NCT04591041|EXPERIMENTAL|Training by Mixed Reality Simulation|
61959868|NCT01413529|EXPERIMENTAL|HEART to HAART|HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
61959869|NCT01413529|ACTIVE_COMPARATOR|Adherence counseling|Adherence counseling with the addition of a smart phone control
61959870|NCT02366052|ACTIVE_COMPARATOR|Nutritional Counseling|The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.
61959871|NCT02366052|EXPERIMENTAL|Nutritional Counseling and LCS|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.
61959872|NCT02366052|EXPERIMENTAL|Lactobacillus Casei Shirota|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.
61959873|NCT05251974||Compliant with beta blocker therapy|Patients observed to be compliant with beta blocker therapy by blood assay
61959874|NCT05251974||Non-compliant with beta blocker therapy|Patients observed to be non-compliant with beta blocker therapy by blood assay
62505048|NCT05098132|EXPERIMENTAL|Part D: STK-012 Q3W monotherapy and STK-012 Q3W + pembrolizumab dose expansions|STK-012 will be administered at the RP2D SC as monotherapy and in combination with a fixed dose of pembrolizumab IV Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
62703495|NCT06451354|EXPERIMENTAL|Lateral Transversus abdominis plane block group|Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
61959875|NCT06557005|NO_INTERVENTION|Routine Care|Routine postpartum care
62703496|NCT04716634|EXPERIMENTAL|Tislelizumab + Fruquintinib|Participants with one of the tumors will be enrolled: GC,CRC and NSCLC
61959876|NCT06557005|ACTIVE_COMPARATOR|Facilitated Transition Group|The intervention is integrated into routine inpatient postpartum care and includes the following components: default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.
61959877|NCT03432702|ACTIVE_COMPARATOR|Alveolar ridge augmentation without ABG|Horizontal ridge augmentation using guided bone regeneration without autogenous block graft (ABG)
61959878|NCT03432702|EXPERIMENTAL|Alveolar ridge augmentation with ABG|Horizontal ridge augmentation using guided bone regeneration with autogenous block graft (ABG).
62347233|NCT04591041|ACTIVE_COMPARATOR|Training by Mannequin Based Simulation|
62505049|NCT05098132|EXPERIMENTAL|Part E: STK-012 Q3W + pembrolizumab, pemetrexed and carboplatin dose escalation|STK-012 will be administered in sequential ascending doses SC Q3W in combination with pembrolizumab IV Q3W, pemetrexed IV Q3W and carboplatin IV Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
62505050|NCT05098132|EXPERIMENTAL|Part F: STK-012 Q3W + pembrolizumab, pemetrexed and carboplatin dose expansion|STK-012 will be administered at the RP2D SC in combination with pembrolizumab IV Q3W, pemetrexed IV Q3W and carboplatin IV Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
62505051|NCT01745198||Treatment Group|This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin®/CerefolinNAC® in the past or are currently being treated with Cerefolin®/CerefolinNAC®.
62505052|NCT01745198||Non-Treatment Group|This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin®/CerefolinNAC®.
62703497|NCT04314401||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, post treatment and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 5 years.
62703498|NCT01352962|EXPERIMENTAL|Arm 1|Standard of Care plus escalating doses of Lenalidomide
62703499|NCT01352962|EXPERIMENTAL|Arm 2|Lenalidomide Lead for 14 days + standard of care + lenalidomide MTD
62703500|NCT04150718|EXPERIMENTAL|Subjects with Major Depressive Disorder|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine is they meet criteria for MDD.
62703501|NCT04150718|ACTIVE_COMPARATOR|Control|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine they do not meet criteria for MDD.
61959879|NCT06083285||Control group|
61959880|NCT06083285||Observation group|
62347234|NCT03011450|PLACEBO_COMPARATOR|12 Week Efficacy|K-877 or placebo comparator for 12 weeks
62347235|NCT03011450|ACTIVE_COMPARATOR|40 week extension|K-877 or fenofibrate comparator for 40 weeks
62347236|NCT04782193|EXPERIMENTAL|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
62703502|NCT05760313|EXPERIMENTAL|Part 1, Linaclotide Dose A|Linaclotide Dose A capsules, mixed with water and administered orally, once daily for 4 weeks
62703503|NCT05760313|EXPERIMENTAL|Part 1, Linaclotide Dose B|Linaclotide Dose B capsules, mixed with water and administered orally, once daily for 4 weeks
62703504|NCT05760313|EXPERIMENTAL|Part 1, Linaclotide Dose C|Linaclotide Dose C capsules, mixed with water and administered orally, once daily for 4 weeks
61959881|NCT01699204|PLACEBO_COMPARATOR|Filtered air with placebo|Exposure for 2 hours to filtered air and placebo tablets 3 times daily for 6 days
61959882|NCT01699204|ACTIVE_COMPARATOR|Diesel exhaust with placebo|Exposure for 2 hours to diesel exhaust and placebo tablets 3 times daily for 6 days
62347237|NCT02812446||IAI patients group|patients with Staphylococcus aureus of implant-associated infections
62347238|NCT02812446||control group|patients with Staphylococcus aureus nasal carriage
62143385|NCT05511545|EXPERIMENTAL|Patient Education Booklet|"One day before surgery:~The patients in the training group were informed about the study one day before the operation and their verbal and written consents were obtained. Afterwards, the Descriptive Information Form, the State-Trait Anxiety Inventory, and the Surgery-Specific Anxiety Inventory were administered. A training booklet was prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. The training took an average of 25-30 minutes. Afterwards, the questions of the patients were answered and the training booklet was given to the patient.The scales were reapplied on the morning of the surgery.~Before discharge, the State Anxiety Scale and the Readiness to Discharge Scale-Patient Self-Assessment Form were administered. Then, the Adult Patient Discharge Readiness Scale-Nurse Evaluation Short Form was filled by the clinical nurse caring for the patient."
62143386|NCT03701906|ACTIVE_COMPARATOR|Lactobacillus PS11603 & Bifidobacterium PS10402|A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1\*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
62143387|NCT03701906|ACTIVE_COMPARATOR|Placebo|1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
62143388|NCT02311621|EXPERIMENTAL|A: 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10\^6 cells/kg, 5x10\^6 cells/kg, 1x10\^7 cells/kg, 5x10\^7 cells/kg, and 1x10\^8 cells/kg will be evaluated."
62703505|NCT05760313|EXPERIMENTAL|Part 2, Linaclotide|Participants will receive Linaclotide capsules mixed with water and administered orally in Part 2 for 4 weeks.
62703506|NCT05760313|EXPERIMENTAL|Part 2, Placebo|Participants will receive placebo capsules mixed with water and administered orally in Part 2 for 4 weeks.
62347239|NCT04003337|NO_INTERVENTION|GROUP A: Morphological embryo selection|Patients enrolled in group A will receive an embryo transfer according to classical morphological criteria.
62505053|NCT06677645||Prospective group|258 subjects in the prospective group
62703507|NCT00246857||patients referred by physician with a suspected inherited immune deficiency|patients referred by physician with a suspected inherited immune deficiency
62703508|NCT05683756|ACTIVE_COMPARATOR|Brief Parent Behavioral Intervention|A brief parent behavioral intervention with evidenced based strategies for treatment of ADHD.
61959883|NCT01699204|EXPERIMENTAL|Diesel exhaust with N-acetylcysteine|Exposure for 2 hours to diesel exhaust and N-acetylcysteine tablets (600 mg) 3 times daily for 6 days
61959884|NCT01537393|OTHER|0-7d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 0 to 7 days prior to transplant.
61959885|NCT01537393|OTHER|8-14d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 8 to 14 days prior to transplant.
61959886|NCT02685085|EXPERIMENTAL|Misoprostol|in this group misoprostol 25 ug will be administrated for induction of labor every 6 hours
61959887|NCT02685085|EXPERIMENTAL|Foley's catheter|In this group foley's catheter 30 cc will be used for induction of labor
62703509|NCT05683756|EXPERIMENTAL|Sleep-Focused Parent Behavioral Intervention|A modified version of the brief parent behavioral intervention that specifically targets sleep disrupting behaviors.
61959888|NCT02685085|EXPERIMENTAL|Combined|Both misoprostol 25 ug and foley's catheter will be used for induction
61959889|NCT05019352|EXPERIMENTAL|CRRT with cytokine adsorption|Patients will be treated with CRRT and extracorporeal hemoadsorption for 72 hours
62703510|NCT05751967|PLACEBO_COMPARATOR|Placebo|1 tablet/ day
62703511|NCT05751967|EXPERIMENTAL|Fenofibrate|200 mg/day
62703512|NCT04422899|EXPERIMENTAL|AIV007 Treatment Dose 1|Intravitreal, Dose 1
62703513|NCT04422899|EXPERIMENTAL|AIV007 Treatment Dose 2|Intravitreal, Dose 2
62703514|NCT04422899|EXPERIMENTAL|AIV007 Treatment Dose 3|Intravitreal, Dose 3
62703515|NCT05768906||Life-sustaining therapies limitation decision situations - observation only|For each participating center, consecutive inclusion of the first 10 life-sustaining therapies limitation decision situations from the study start date over a maximum of 12 months. Data collection for these patients especialy information concerning disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians.
62703516|NCT06459518|EXPERIMENTAL|Bowen Therapy along with Conventional Therapy|Group A will receive Bowen Therapy along with Conventional Therapy
62703517|NCT06459518|ACTIVE_COMPARATOR|Muscle Energy Technique along with conventional Therapy|Group B will receive Muscle Energy Technique along with Conventional Therapy
61959890|NCT05019352|EXPERIMENTAL|CRRT without cytokine adsorption|Patients will be treated with CRRT without extracorporeal hemoadsorption for 72 hours
61959891|NCT05019352|NO_INTERVENTION|no CRRT, no cytokine adsorption|Patients will not receive CRRT, nor extracorporeal hemoadsorption. CRRT will only be initiated in case of severe electrolyte disorders or unmanageable fluid overload
61959892|NCT04856189|EXPERIMENTAL|Treatment (selinexor, pembrolizumab)|Patients receive selinexor PO on days 1, 8 and 15, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
61959893|NCT01686815||Olanzapine|Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
61959894|NCT01686815||Risperidone|Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
61959895|NCT01686815||Iloperidone|Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
61959896|NCT05505682|EXPERIMENTAL|Intervention clusters|Residential areas that receive releases of male Wolbachia-infected Aedes aegypti
61959897|NCT05505682|NO_INTERVENTION|Non-intervention clusters|Residential areas that do not receive releases of male Wolbachia-infected Aedes aegypti
61959898|NCT03937011||Stratafix Arm|The single study arm would comprise of two different specialties in Robotic surgical procedures: Bariatric Sleeve gastrectomy (Staple line reinforcement) and Hysterectomy (Vaginal cuff closure).
61959899|NCT03421665||Titan 3-D Wedge System|Subjects who receive one or more Titan 3D wedge(s).
61959900|NCT05015244|EXPERIMENTAL|Von Willebrand Disease Type 2B patient with neurological symptoms|evaluation of patients using 3T (Tesla) Magnetic Resonance Imaging (MRI) and series of neuropsychological tests that cover virtually all cognitive domains.
61959901|NCT06166667|EXPERIMENTAL|experimental group|Fecal Microbiota Transplant
62703518|NCT03062319|ACTIVE_COMPARATOR|Dual-therapy group|Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those \<70 years and 1.6-2.6 for those =\>70 years is recommended according to the Japanese guidelines.
62703519|NCT03062319|ACTIVE_COMPARATOR|Single-therapy group|Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those \<70 years and 1.6-2.6 for those =\>70 years is recommended according to the Japanese guidelines.
62703520|NCT03650764|EXPERIMENTAL|Phase I: Ramucirumab + Pembrolizumab|-Ramucirumab will be administered IV over 1 hour on Day 1 of each 21-day cycle. Pembrolizumab will be administered as per standard of care (IV at a dose of 200 mg over 30 minutes on Day 1 of each 21-day cycle). On Day 1, pembrolizumab will be given after ramucirumab.
62703521|NCT03650764|EXPERIMENTAL|Phase II: Ramucirumab + Pembrolizumab|-Patients will be treated with ramucirumab at the RP2D on Day 1 and SOC pembrolizumab (200 mg IV over 30 minutes) on Day 1 of each 21-day cycle.
62703522|NCT04971733|EXPERIMENTAL|Cohort A, Phase 1b and 2: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 12 weeks in Phase 1b and over 96 weeks in Phase 2.
62703523|NCT04971733|EXPERIMENTAL|Cohort B: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 52 weeks.
62703524|NCT04336722|EXPERIMENTAL|Odevixibat (A4250)|Capsules for oral administration once daily for 104 weeks.
62703525|NCT04336722|PLACEBO_COMPARATOR|Placebo|Capsules for oral administration (to match active) once daily for 104 weeks.
62703526|NCT00004571||Healthy volunteers|Healthy subjects from the community
62703527|NCT00004571||Schizophrenia|Patients with schizophrenia and psychosis
62703528|NCT00004571||Williams Syndrome|Individuals with copy number variation in the Williams Syndrome Region
62703529|NCT05758077|EXPERIMENTAL|SCD + CKRT Arm|In addition to standard of care CKRT therapy for these subjects, these subjects will have up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) in-line with their existing CKRT circuit.
61959902|NCT04991909|EXPERIMENTAL|Treatment group A|
61959903|NCT04991909|PLACEBO_COMPARATOR|Treatment group B|
62703530|NCT05758077|OTHER|CKRT Alone Arm (standard of care)|This arm will receive standard of care CKRT therapy for their condition as appropriate.
61959904|NCT05812196||Post-COVID|Patients with COVID-19 infections.
62703531|NCT05650632|EXPERIMENTAL|Arm A (Part 1): ABBV-383 Dose Escalation|B-cell maturation antigen (BCMA) naïve participants will receive different doses of ABBV-383 in 28 day cycles.
61959905|NCT05812196||Control|Patients without earlier diagnosis of COVID-19.
61959906|NCT03641443|EXPERIMENTAL|Non-invasive measurement of intracranial pressure|Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement
62347240|NCT04003337|ACTIVE_COMPARATOR|GROUP B: Morpho-kinetics embryo selection|Patients enrolled in group B will receive an embryo transfer according to new morphokinetics criteria.
62703532|NCT05650632|EXPERIMENTAL|Arm A (Part 2): ABBV-383 Dose Expansion|BCMA naïve participants will receive the dose of ABBV-383 dose A in 28 day cycles.
62703533|NCT05650632|EXPERIMENTAL|Arm B: ABBV-383 BCMA Exposed|Participants previously exposed to BCMA-targeted agents will receive ABBV-383 Dose A in 28 day cycles.
62703534|NCT05650632|EXPERIMENTAL|Arm C: ABBV-383 Step Up|Participants will receive step up dose and full target dose of ABBV-383 in 28 day cycles.
61959907|NCT03392701|EXPERIMENTAL|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
61959908|NCT03392701|PLACEBO_COMPARATOR|Placebo|NaCl
61959909|NCT01023932||Auditory Neuropathy Patients|
61959910|NCT02164500|EXPERIMENTAL|Ruxolitinib|
61959911|NCT00721500|EXPERIMENTAL|narafilcon A / etafilcon A - etafilcon A - narafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.
61959912|NCT00721500|EXPERIMENTAL|narafilcon A / etafilcon A - narafilcon A - etafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.
61959913|NCT00721500|EXPERIMENTAL|narafilcon A - etafilcon A - narafilcon A / etafilcon A|First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
61959914|NCT00721500|EXPERIMENTAL|etafilcon A - narafilcon A - narafilcon A / etafilcon A|First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
61959915|NCT00287885|EXPERIMENTAL|Metronomic Docetaxel|Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
61959916|NCT02877381|ACTIVE_COMPARATOR|Single IV Dose|• 1 gram IV TXA administered at time of prepping and draping
62347241|NCT01544803|NO_INTERVENTION|Control group|
61959917|NCT02877381|ACTIVE_COMPARATOR|Double Dose IV|"* 1 gram IV TXA administered at time of prepping and draping~* 1 gram IV TXA administered prior to tourniquet deflation"
62505054|NCT06677645||Retrospective group|3968 subjects in the retrospective group, i.e 1984 subjects in 2021 and 1984 subjects in 2022
62703535|NCT01784068|EXPERIMENTAL|Nilotinib followed by treatment-free|Patients who received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 entered the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase entered the Treatment-Free Remission (TFR) phase where no treatment was given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).
62703536|NCT01961557|EXPERIMENTAL|There is a single study arm in this feasibility study.|All participants will be evaluated using the different configurations of the EA-KAFO (see Table 1 in the protocol), which includes the configuration that contains the Active Motorized KAFO and the configuration that contains the Powerwalk Knee Exoskeleton. Each subject will serve as their own control to assess the effect of each configuration of the EA-KAFO interventions.
62703537|NCT05170399|EXPERIMENTAL|Chronic Lymphocytic Leukemia Not Receiving Active Treatment|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62703538|NCT05170399|EXPERIMENTAL|Chronic Lymphocytic Leukemia Treatment Break for BTKi|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62703539|NCT05170399|EXPERIMENTAL|Chronic Lymphocytic Leukemia Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62703540|NCT05170399|EXPERIMENTAL|Chronic Lymphocytic Leukemia Treatment with BTKi|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62703541|NCT05170399|EXPERIMENTAL|Follicular Lymphoma|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62703542|NCT05170399|EXPERIMENTAL|Follicular Lymphoma Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62703543|NCT05170399|EXPERIMENTAL|Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62505055|NCT03699033|EXPERIMENTAL|Radiation|2.5 Gy/Fraction
62703544|NCT05170399|EXPERIMENTAL|Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia - Treatment with Targeted Therapies|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
62703545|NCT05170399|EXPERIMENTAL|Participants diagnosed with Chronic Lymphocytic Leukemia (CLL)|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
62505056|NCT00648245|EXPERIMENTAL|1|
62505057|NCT00648245|EXPERIMENTAL|2|
62505058|NCT00648245|EXPERIMENTAL|3|
62505059|NCT00648245|PLACEBO_COMPARATOR|4|
62505060|NCT00648245|EXPERIMENTAL|5|
62505061|NCT00314782|EXPERIMENTAL|Part A|Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m\^2 intravenous infusion once per cycle
62505062|NCT00314782|EXPERIMENTAL|Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)|Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m\^2 intravenous infusion once per cycle
62505063|NCT00314782|EXPERIMENTAL|Part B|Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m\^2 intravenous infusion once per cycle
62505064|NCT00314782|EXPERIMENTAL|Part B (placebo)|Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m\^2 intravenous infusion once per cycle
62505065|NCT02094261|EXPERIMENTAL|AZD9291|Once daily tablet 80 mg
61959918|NCT02877381|ACTIVE_COMPARATOR|IV + Topical|"* 1 gram IV TXA administered at time of prepping and draping~* 1 gram topical TXA injected intra-articular following closure of the arthrotomy"
61959919|NCT02877381|ACTIVE_COMPARATOR|Repeated Oral Dose|• Three 650 mg tablets of TXA administered two hours prior surgery with a second dose given 6 hours postoperatively and a final dose given the morning of postoperative day 1
62505066|NCT00865449|ACTIVE_COMPARATOR|1|Peritoneal Dialysis patients on aldactone for 6 months
62505067|NCT00865449|PLACEBO_COMPARATOR|2|Peritoneal dialysis Patients on the placebo arm for 6 months
62505068|NCT00190450|EXPERIMENTAL|1|Early Graft (Early G)
62505069|NCT00190450|EXPERIMENTAL|2|Late Graft (Late G)
61959920|NCT04056078||Team Handball Players Playing with Shoulder Pain|Team Elite Handball players playing with shoulder pain i their dominated shoulder for more than 3 months.
61959921|NCT04056078||Team Handball Players playing without shoulder pain|Team Elite Handball players who never have experience shoulder pain i their dominated shoulder.
61959922|NCT04056078||Team Handball Players playing with previous shoulder pain|Team Handball players who have had shoulder pain i their dominated shoulder, but currently have been playing without shoulder pain in the previous 6 months.
61959923|NCT00816764|EXPERIMENTAL|1. AGS-8M4 Dose 1|
61959924|NCT00816764|EXPERIMENTAL|2. AGS-8M4 Dose 2|
61959925|NCT00816764|EXPERIMENTAL|3. AGS-8M4 Dose 3|
62505070|NCT05290233|EXPERIMENTAL|TRE+RT|Participants will confine eating between either 10am-6pm or 12-8pm and fast from 6pm-10am or 8pm-12pm daily combined with 3-4 days of supervised resistance training per week.
62505071|NCT05290233|ACTIVE_COMPARATOR|TRE+AT|Participants will confine eating between either 10am-6pm or 12-8pm and fast from 6pm-10am or 8pm-12pm daily combined with 3-4 days of supervised aerobic training per week.
61959926|NCT00816764|EXPERIMENTAL|4. AGS-8M4 Dose 4|
61959927|NCT03130257|ACTIVE_COMPARATOR|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure at their clinic once within the subsequent three weeks.
61959928|NCT03130257|ACTIVE_COMPARATOR|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over three weeks.
62505072|NCT00004188|EXPERIMENTAL|Arm I (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0\&1, doxorubicin hydrochloride \& vincristine sulfate day 0-2 \& filgrastim(G-CSF) day 3 crs 1,2,4 \& 6.) Crs 3 \& 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin \& etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
62703546|NCT06201728|EXPERIMENTAL|Intervention|"The intervention will include 3 follow-up visits in the flare up clinic - one month after hospital discharge (from ED or admission), 3 months after the first visit, 6 months after the second visit. 18 months after the first visit there will be an additional phone-call with structured interview.~Each clinic visit will include:~i. Pulmonologist examination, review of disease state and care, and adjustment of treatment.~ii. Vital signs (blood pressure, saturation in room air, pulse). iii. Blood sample for complete blood count. iv. Filling Asthma Quality of Life Questionnaire (AQLQ). v. Spirometry. vi. Impulse oscillometry and FeNO tests. vii. Arrangement of next follow-up visit."
62703547|NCT06201728|NO_INTERVENTION|Control|"The control group will undergo 4 phone-call follow-ups with structured interview based on a predefined questionnaire, at the following time frames - 1, 4, 10, and 19 months after hospital discharge.~Each follow-up call will include:~i. Assessment of ACT score. ii. Whether they attend pulmonologist follow-up visit, additional evaluations (IOS or spirometry), and interventions (pulmonary rehabilitation and smoking cessation programs).~iii. Current treatment. iv. Asthma exacerbations, use of systemic steroids, and relevant management."
62703548|NCT06548217|EXPERIMENTAL|ONO-4538HSC|
62703549|NCT05947851|EXPERIMENTAL|Nemtabrutinib + Venetoclax|Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks.
62703550|NCT05947851|ACTIVE_COMPARATOR|Venetoclax + Rituximab|Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m\^2 up to 500 mg/m2 intravenous infusion once per 28-day cycle starting at C2D1, for 6 total cycles. Treatment will continue until progressive disease (PD) or discontinuation.
61959929|NCT03130257|ACTIVE_COMPARATOR|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
61959930|NCT01516437|EXPERIMENTAL|HNS Group|Healthy non-smokers aged between 45-75 years
61959931|NCT01516437|EXPERIMENTAL|HS Group|Healthy smokers aged between 45-75 years
61959932|NCT01516437|EXPERIMENTAL|FeCOPD Group|COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years
61959933|NCT01516437|EXPERIMENTAL|NFeCOPD Group|COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years
61959934|NCT04786145|ACTIVE_COMPARATOR|Cryoneurolysis|40 patients are randomized to receive one treatment of cryoneurolysis on the facet joints of three lumbar level corresponding to their facet joint pain generator
61959935|NCT04786145|ACTIVE_COMPARATOR|Radiofrequency ablation|40 patients are randomized to receive one treatment of radiofrequency ablation on the facet joints of three lumbar level corresponding to their facet joint pain generator
61959936|NCT04786145|SHAM_COMPARATOR|Placebo|40 patients are randomized to receive sham treatment. Subjected to similar procedures as cryoneurolysis and radiofrequency ablation, but without active treatment.
61959937|NCT01007084|EXPERIMENTAL|Propranolol|
61959938|NCT01007084|PLACEBO_COMPARATOR|Sugar pill|
61959939|NCT03470441|EXPERIMENTAL|FDY-5301 Low Dose|Anticipated n=20
61959940|NCT03470441|EXPERIMENTAL|FDY-5301 Intermediate Dose|Anticipated n=20
61959941|NCT03470441|EXPERIMENTAL|FDY-5301 High Dose|Anticipated n=20
61959942|NCT03470441|PLACEBO_COMPARATOR|Placebo|Anticipated n=20
61959943|NCT01472302|EXPERIMENTAL|ASV|Adaptive Support Ventilation
61959944|NCT01472302|ACTIVE_COMPARATOR|PCV|Pressure Controlled Ventilation
61959945|NCT02697864|EXPERIMENTAL|48.8 mgA tafamidis free acid tablet|
61959946|NCT02697864|EXPERIMENTAL|58 mgA tafamidis free acid tablet|
61959947|NCT02697864|EXPERIMENTAL|4 soft gel capsules of 20 mg tafamidis meglumine|
61959948|NCT02481232|EXPERIMENTAL|freeze-dried group ACYW135 MCV 4μg|4μg group: vaccines serial number is A0001-A0100（18-55 years-old group A0001-A0020，7-17 years-old group A0021-A0040，1-6 years-old group A0041-A0060，7-10 months-old group A0061-A0080，2 months-old group A0081-A0100）
61959949|NCT02481232|EXPERIMENTAL|freeze-dried group ACYW135 MCV 8μg|8μg group: vaccines serial number is B0001-B0100（18-55 years-old group B0001-B0020，7-17 years-old group B0021-B0040，1-6 years-old group B0041-B0060，7-10 months-old group B0061-B0080，2 months-old group B0081-B0100）
61959950|NCT03026400|OTHER|Subumbilical incision|The subumbilical incision was standardised. A curvilinear horizontal incision was performed to be able to reach the base of the umbilicus. The aponeurosis was incised with a scalpel and the peritoneal layer was open with a Kelly clamp. The incision was completed with the Hasson technique and a X-stitch was used for closure.
61959951|NCT03026400|OTHER|Transumbilical incision|The transumbilical incision was also standardised, inverting the umbilicus with graspers, then incising vertically the skin to reach the umbilical physiological hernia to enlarge it. The incision was also completed with the Hasson technique and a X-stitch was used for closure.
62505073|NCT00004188|EXPERIMENTAL|Arm II (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0\&1, doxorubicin hydrochloride \& vincristine sulfate day 0-2 \& filgrastim(G-CSF) day 3 crs 1,2,4 \& 6.) Crs 3 \& 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin \& etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
62703551|NCT06573801|ACTIVE_COMPARATOR|Aktiia|Participants will wear the Aktiia Bracelet for 24h alongside a cuffed ambulatory BP monitor. Both devices will be recording BP at pre programmed intervals.
62703552|NCT06573801|ACTIVE_COMPARATOR|Healthstats|Participants will wear the Healthstats BPro Evo smart watch for 24h alongside a cuffed ambulatory BP monitor. Both devices will be recording BP at pre programmed interval
61959952|NCT05004870|EXPERIMENTAL|Women with a known history of submucosal fibroids (that have not been surgically removed)|
61959953|NCT00993083|EXPERIMENTAL|Vaccinated|14 volunteers (2 in lead safety group and 12 in main study group) to receive MVA-NP+M1 via the IM route. Volunteers will then be challenged with Influenza 30 days post vaccination.
61959954|NCT00993083|NO_INTERVENTION|Control|12 volunteers who will not receive vaccine but will also be challenged with Influenza on day 30
62505074|NCT05988424|ACTIVE_COMPARATOR|Pentaray|Initial map collected with Pentaray
62703553|NCT05540860|EXPERIMENTAL|Cohort 1|Drug: Sevasemten Drug: Placebo
62505075|NCT05988424|ACTIVE_COMPARATOR|Octaray|Initial map collected with Octaray
62505076|NCT00136890|NO_INTERVENTION|1|Conventional Staging
62505077|NCT00136890|EXPERIMENTAL|2|PET Imaging
62703554|NCT05540860|EXPERIMENTAL|Cohort 2|Drug: Sevasemten Drug: Placebo
62703555|NCT05540860|EXPERIMENTAL|Cohort 3|Drug: Sevasemten Drug: Placebo
62703556|NCT05540860|EXPERIMENTAL|Cohort 4|Drug: Sevasemten Drug: Placebo
62703557|NCT05540860|EXPERIMENTAL|Cohort 5|Drug: Sevasemten Drug: Placebo
61959955|NCT01911078|OTHER|Renal Denervation Group|Subjects receiving renal denervation procedure.
61959956|NCT01911078|NO_INTERVENTION|Control Group|"Subjects not receiving renal denervation procedure.~Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group."
61959957|NCT05277181||Runners|"Recreational runners will be recruited and assessed over one season (June 2021 to January 2024).~Participants will be asked to complete a battery of sub-maximal walking and running trials.~Participants will be stratified according to gender (males n≈20, and females n≈20). Participants may also be further stratified based on injury status (i.e. injury history and location) and performance level (i.e. 5km personal best time)."
61959958|NCT05199662|PLACEBO_COMPARATOR|Control group|Placebo administered as a single bolus injection over 5 seconds
61959959|NCT05199662|EXPERIMENTAL|Intravenous tenecteplase (TNK)|Intravenous thrombolysis with Tenecteplase (TNK) at a dose of 0.25 mg/Kg (maximum 25mg, administered as a bolus over 5 seconds)
62347242|NCT01544803|EXPERIMENTAL|Web based self-monitoring|
62505078|NCT04100096|EXPERIMENTAL|Brexpiprazole 2-3 Milligrams Per Day|Participants received brexpiprazole, 2-3 milligrams per day (mg/day) tablets, orally, up to Week 12 during the treatment phase.
62505079|NCT04100096|PLACEBO_COMPARATOR|Placebo|Participants received brexpiprazole-matching placebo tablets, orally, up to Week 12 during the treatment phase.
62703558|NCT05540860|EXPERIMENTAL|Cohort 2NS|Drug: Sevasemten Drug: Placebo
62703559|NCT04373330|EXPERIMENTAL|Intensive lifestyle intervention|The intensive lifestyle intervention used in HELP PD and that will be used in HELP-VM was a modification of the successful Diabetes Prevention Program (DPP) core curriculum adapted for use in groups. The 16-session core curriculum used in DPP, covering key concepts related to energy balance, nutrition, and physical activity, was expanded to include regular sessions focused on group problem-solving of barriers and issues specific to the members and to incorporate presentations from local community groups on topics relevant to healthy living (exercise resources, etc.) The same intervention will be used in HELP-VM and will target moderate intensity physical activity (goal ≥180 min/wk). A DVD series was developed in HELP PD to standardize this core content, improve fidelity of intervention delivery, and to allow the CHWs to focus on group facilitation and problem-solving. This DVD series will also be used in HELP-VM.
62703560|NCT04373330|NO_INTERVENTION|Medical Treatment as Usual|Subjects randomized to MTAU will be encouraged to continue engaging in medical treatment as per their usual. The MTAU group will complete baseline and 6-month follow-up assessments, and participants will complete daily symptom self-monitoring on the same schedule as HELP-VM participants.
62703561|NCT06428409|EXPERIMENTAL|Sacituzumab tirumotecan + Chemotherapy|Participants will receive sacituzumab tirumotecan in one of two dose levels and chemotherapy by intravenous (IV) infusion, every 2 weeks. Participants will continue to receive the treatment until the cancer gets worse or they don't tolerate treatment.
62505080|NCT05443919|EXPERIMENTAL|treatment group|The arm contains patients with acute pulmonary embolism who undergoing interventional therapy with transcatheter pulmonary embolectomy system which named 'TwiFlow-Thrombectomy Catheter System'
62505081|NCT02508259|ACTIVE_COMPARATOR|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
62505082|NCT02508259|PLACEBO_COMPARATOR|Saline|50 ml of saline by intravenous infusion over 30 minutes
62505083|NCT04593147|EXPERIMENTAL|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with Sn-2 Palmitate, Alpha Lactalbumin and Lactoferrin to better mimic human milk.
62505084|NCT04593147|ACTIVE_COMPARATOR|Brand|A commercially available Infant Formula, for healthy term infants 0 to 2 months of age (Enfamil TM, Milk-Based Powder with Iron).
62505085|NCT01324856|EXPERIMENTAL|Pancreaticogastro anastomosis|
62505086|NCT01324856|ACTIVE_COMPARATOR|Pancreaticojejuno anastomosis|
62505087|NCT05530941|EXPERIMENTAL|Intervention group|Participants in this group (all participants) were asked to complete a questionnaire and then received access to the online prevention campaign during three days, after which they were asked to complete another questionnaire.
62505088|NCT00630578|ACTIVE_COMPARATOR|1|Cognitive Processing Therapy
62505089|NCT00630578|NO_INTERVENTION|2|Arm 2 participants will monitor their symptoms for a period of 10 weeks, prior to being crossed over into active treatment. This will allow investigators to account for the passage of time without intervention when tracking symptoms.
62505090|NCT05486299|EXPERIMENTAL|Single-port Endoscopic Surgical System|A novel robotic surgical system that can be configured for multi-port, single-port, or hybrid-port procedures. In the single-port configuration, a four-channel trocar shall be used. The surgical tools are steered through the curved access channels in the trocar to enter a patient's abdomen.
62703562|NCT06428409|EXPERIMENTAL|Sacituzumab tirumotecan|Participants will receive sacituzumab tirumotecan every 2 weeks via IV infusion. Participants will continue to receive the treatment until the cancer gets worse or they don't tolerate the treatment.
62143389|NCT02311621|EXPERIMENTAL|B: 3rd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10\^6 cells/kg, 5x10\^6 cells/kg, 1x10\^7 cells/kg, 5x10\^7 cells/kg, and 1x10\^8 cells/kg will be evaluated."
62347243|NCT01544803|ACTIVE_COMPARATOR|Web based self-help|
62505091|NCT04264819|EXPERIMENTAL|RTH258/Brolucizumab|This is a single arm study in which all patients will be treated with brolucizumab 6mg; 3 loading injections (at Screening/Baseline, week 4 and week 8) followed by treat-to-control phase with adjustable treatment frequency based on disease activity from every 8 to up to 16 weeks; last treatment at week 44/46 based on the treatment regimen.
62703563|NCT00001620||Subjects undergoing screening|Adults and children being screened for an active NHLBI protocol
62347244|NCT02505542|OTHER|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
62347245|NCT02505542|EXPERIMENTAL|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
62347246|NCT02505542|EXPERIMENTAL|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
62347247|NCT02505542|PLACEBO_COMPARATOR|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
62347248|NCT02505542|OTHER|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
62347249|NCT02505542|OTHER|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
62347250|NCT02505542|OTHER|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
62347251|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
62347252|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
62347253|NCT03915236|EXPERIMENTAL|Group 1: MON4STRAT Strategy|
62347254|NCT03915236|ACTIVE_COMPARATOR|Group 2: Conventional treatment|
62347255|NCT03445754|EXPERIMENTAL|Interventional Arm|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
62347256|NCT03445754|SHAM_COMPARATOR|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
62347257|NCT00673894|EXPERIMENTAL|Glutamine+Sitagliptin|Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin
62347258|NCT00673894|PLACEBO_COMPARATOR|Glutamine+Placebo|Glutamine 30 g/d (15 g with breakfast and dinner) + placebo
62347259|NCT04658420|EXPERIMENTAL|Ketamine|One group will receive IV ketamine 0.5mg/kg infused over forty minutes
62347260|NCT04658420|EXPERIMENTAL|Ketamine + Music|One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music
61959960|NCT05139238|ACTIVE_COMPARATOR|Oral Nifedipine|Oral nifedipine: Once diagnosis of hypertensive emergency is confirmed on repeat blood pressure, patients randomized to oral nifedipine will receive 10mg initially, with repeated doses of 20mg every 20min, for up to a maximum of 5 doses or until the therapeutic blood pressure goal of \<160 systolic and \<105 diastolic is achieved. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
61959961|NCT05139238|ACTIVE_COMPARATOR|Intravenous labetalol|Intravenous Labetalol: Patients randomized to IV labetalol will receive 20mg initially, followed by escalating doses of 40mg, 80mg, 80mg, then 80mg every 20 minutes until the therapeutic goal is achieved, for a maximum of 5 doses. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
61959962|NCT02642328|EXPERIMENTAL|HIIT Training|Circuit training with strength and power. The chosen exercises were (random order): Sit-Ups, Mountain Climbers, Plank, Side Skater, Push Ups, Ground Support with Vertical Jump, Overhead Squat, Box Jump.Time total = 4 minutes
61959963|NCT02642328|ACTIVE_COMPARATOR|Control|Running aerobic exercise at 65% of VO2Max
61959964|NCT06237998||Matched control group|Sex and age matched control group (5:1) from the Swedish heart failure register (1500 patients). No intervention.
61959965|NCT06237998||Telemonitored group|Patients with new or worsening heart failure with, assessed to be in need of follow-up in a cardiology clinic (n=300).
61959966|NCT04234191|EXPERIMENTAL|Rapid Micro-Induction|On Day 1, participants will receive 0.5mg bup/nx sublingually (SL) every 3 hours (Q3H) - total daily dose of 4mg. On Day 2, they will receive 1mg bup/nx SL Q3H - total daily dose of 8mg. On Day 3, they will receive 8mg bup/nx SL once and 1-4mg bup/nx SL Q3H as needed (PRN) for withdrawal symptoms and/or craving and/or pain - maximum daily dose of 32mg. Afterwards, their day 3 total dose will be consolidated to once daily dosing - maximum daily dose of 32mg. On Days 1 and 2, participants will concurrently receive 1-48mg hydromorphone orally, intravenously, subcutaneously, or intramuscularly (PO/IV/SC/IM) Q1 to 3H PRN for withdrawal symptoms and/or craving and/or pain, titrated to effect (start at lower end of dosing range). Hydromorphone will be discontinued on Days 3 onwards.
61959967|NCT04234191|ACTIVE_COMPARATOR|Standard Induction|Day 1 is initiated when participants score 11 or above on the Clinical Opiate Withdrawal Scale (COWS), and when they have been abstinent from short-acting opioids for at least 6-12 hours or from long-acting opioids for 24-72 hours. On Day 1, participants will start with 2 or 4mg bup/nx SL. If their COWS score increases, bup/nx will be held. If their COWS score remains the same or decreases, additional dosing can be done in increments of 2mg bup/nx SL every 2 hours (Q2H) as needed (PRN). On Day 2, dosing will be consolidated to once daily dosing. The maximum total daily dose for Day 1 and 2 is 32mg.
61959968|NCT01737697|EXPERIMENTAL|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
61959969|NCT01737697|PLACEBO_COMPARATOR|Placebo (acute phase)|Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.
61959970|NCT01737697|EXPERIMENTAL|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
61959971|NCT01737697|PLACEBO_COMPARATOR|Placebo (subacute phase)|Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.
61959972|NCT00394147|EXPERIMENTAL|Pemetrexed and gemcitabine|pemetrexed 500mg/m2 and gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
61959973|NCT00289783|EXPERIMENTAL|Menhibrix A Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
61959974|NCT00289783|EXPERIMENTAL|Menhibrix B Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot B co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
61959975|NCT00289783|EXPERIMENTAL|Menhibrix C Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
61959976|NCT00289783|EXPERIMENTAL|Menhibrix Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A, B or C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
62703564|NCT05564403|ACTIVE_COMPARATOR|Arm 1 (mFOLFOX6)|Patients receive leucovorin IV over 2 hours and oxaliplatin IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated.
61959977|NCT00289783|ACTIVE_COMPARATOR|ActHIB Group|Subjects were primed with 3 doses of ActHIB co-administered with Pediarix and boosted with 1 dose of PedvaxHIB, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. ActHIB, PedvaxHIB vaccines were administered intramuscularly in the right upper thigh and Pediarix vaccine in the left upper thigh. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
61959978|NCT01760460|EXPERIMENTAL|Anacetrapib|Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
61959979|NCT01760460|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.
61959980|NCT06383221|EXPERIMENTAL|intervention group|Pregnant women in the intervention group attend a one-week Mental Fitness Boot Camp, are assessed at 3 weeks, and receive 3 one-on-one counseling sessions with their obstetrician if they still screen positive for depression.
61959981|NCT06383221|NO_INTERVENTION|control group|The control group received routine care
61959982|NCT04481854|EXPERIMENTAL|Cricoid pressure group|Patients of this group will recieve cricoid pressure during direct laryngoscopy.
61959983|NCT04481854|EXPERIMENTAL|left paratracheal pressure group|Patients of this group will recieve left paratracheal pressure during direct laryngoscopy.
61959984|NCT00851747|EXPERIMENTAL|C Phosphatidylcholine Deoxycholate|Phosphatidylcholine Deoxycholate Injections. Group C will receive only study drug injections
61959985|NCT00851747|PLACEBO_COMPARATOR|A Saline|Group A will serve as a control and will receive only injections of saline as a placebo.
61959986|NCT00851747|ACTIVE_COMPARATOR|B PhosphatidylcholineDeoxycholate/Saline|Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side.
61959987|NCT03613545|EXPERIMENTAL|fecal microbiota transplantation|fecal microbiota transplantation
61959988|NCT03613545|SHAM_COMPARATOR|placebo fecal microbiota transplantation|Infusion of sham
62703565|NCT05564403|EXPERIMENTAL|Arm 2 (binimetinib, mFOLFOX6)|Patients receive binimetinib PO on days 1-14, and leucovorin IV, oxaliplatin IV, and fluorouracil IV as in Arm 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA and collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated.
62703566|NCT03687528||Patient with minor head injury trauma|The emergency protocol for antiplatelet inhibitors treated patient with head injury trauma and meeting others NICE criteria involves a clinical exam followed by a CT-scanner.
62347261|NCT04658420|EXPERIMENTAL|Music|One hour of pre-planned music without ketamine
62703567|NCT06486844||Patients who received vericiguat prescription|Patients who were new users of vericiguat between September 2021 and September 2023 from the InGef database and the WIG2 database.
62703568|NCT04284787|ACTIVE_COMPARATOR|Arm I (AZA, VEN)|See Detailed Description
61959989|NCT03613545|SHAM_COMPARATOR|Traditional treatments|Traditional treatments according to associated guidelines such as probiotics, antibiotics or antidepressants
62703569|NCT04284787|EXPERIMENTAL|Arm II (AZA, VEN, pembrolizumab)|See Detailed Description
61959990|NCT05325671|EXPERIMENTAL|transarticular multimodal drug infiltration|infiltration the mixture into intraarticular by catheter guided approach
61959991|NCT05325671|ACTIVE_COMPARATOR|periarticular multimodal drug infiltration|"3 location of infiltration~1. hip capsule~2. gluteus medius and short external rotator~3. gluteus maximus"
61959992|NCT04717791|OTHER|Procedure|Subjects will be followed from the Vivaer® treatment date out to 24 months post index procedure.
62347262|NCT04658420|NO_INTERVENTION|Treatment as usual|No music nor ketamine given
62347263|NCT04003753|EXPERIMENTAL|Exposure|"Study phase 1: The experimental intervention in the experimental group consists of three 20-minutes VR exposures (total duration in VR: 60 minutes).~Study phase 2: The experimental intervention in the experimental group consists of six 30-minutes VR exposures as home training (total duration in VR: 3 hours) within two weeks."
62347264|NCT04003753|NO_INTERVENTION|Control|"Study phase 1: The control group will not receive any active treatment. Instead they will use an App to make virtual tours (three times 20 minutes, total duration in VR: 60 minutes).~Study phase 2: The control group will not receive any active treatment (untreated comparison group)."
62347265|NCT03587870|EXPERIMENTAL|Bolus enteral nutrition with Fresubin Intensive|Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
62347266|NCT03587870|ACTIVE_COMPARATOR|Continuous enteral nutrition with Fresubin Intensive|Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
62347267|NCT00214968|EXPERIMENTAL|Modafinil|Subjects began taking Provigil at a dosage of 100 mg/day (1 tablet) and increased their dosage by 100 mg/day each week for up to 4 weeks
62347268|NCT00443235|ACTIVE_COMPARATOR|A|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
62703570|NCT05606965|EXPERIMENTAL|Parts A and B - Arm 1: mRNA-1010 (Age Group 18-50 years)|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
61959993|NCT02094677|ACTIVE_COMPARATOR|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
61959994|NCT02094677|ACTIVE_COMPARATOR|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
62505092|NCT06165692|EXPERIMENTAL|Test Group|Placement of PRF in the post-extraction socket after third molar surgery
62505093|NCT06165692|NO_INTERVENTION|Control Group|No positioning PRF in the post-extraction socket after third molar surgery
62347269|NCT00443235|EXPERIMENTAL|B|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
62347270|NCT05631548|EXPERIMENTAL|iTBS to dmPFC, Then Sham iTBS|
62505094|NCT04015531|ACTIVE_COMPARATOR|Conventional radiotherapy|"50 Gy in 25 fractions to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla), followed by tumor bed boost of 10 Gy in 5 fractions in case of breast conserving surgery.~Total time: 5-6 weeks."
62505095|NCT04015531|EXPERIMENTAL|Hypofractionated radiotherapy|"40 Gy in 15 fractions (2.67 Gy each) to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla).~Patients undergoing breast conserving surgery will receive concomitant boost with total dose of 48 Gy in 15 fractions (3.20 Gy each) to tumor bed.~Total time: 3 weeks."
62505096|NCT00779220|PLACEBO_COMPARATOR|1|
62347271|NCT05631548|SHAM_COMPARATOR|Sham iTBS, Then iTBS to dmPFC|
62347272|NCT00423241|EXPERIMENTAL|SEMPERFLO Pain Management System|
62505097|NCT00779220|EXPERIMENTAL|2|
62505098|NCT00779220|EXPERIMENTAL|3|
62505099|NCT00779220|EXPERIMENTAL|4:|
62505100|NCT02452879|EXPERIMENTAL|Electroacupuncture group|Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
62505101|NCT02452879|PLACEBO_COMPARATOR|Placebo group|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
62505102|NCT02452879|ACTIVE_COMPARATOR|Solifenacin Succinate group|Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
62505103|NCT03554317|EXPERIMENTAL|Bipolar Androgen Therapy + Nivolumab|All participants must have a rising PSA and/or radiographic progression and prior treatment with at least one novel androgen receptor (AR) targeted therapy (i.e. abiraterone acetate, enzalutamide). Up to one taxane agent for metastatic castration-resistant prostate cancer is permitted. Patients will be treated with testosterone cypionate 400mg IM every 4 weeks for a lead-in period of 12 weeks. After the lead-in period, all patients will be treated with nivolumab 480mg IV every 4 weeks and maintained on testosterone cypionate 400mg IM every 4 weeks. Treatment \[with a minimum drug exposure of 12 weeks\] will be continued until PSA progression (PCGW3 criteria) or clinical/radiographic progression (whichever comes first), or until unmanageable toxicity requiring drug cessation.
62505104|NCT04458961|ACTIVE_COMPARATOR|One-stage|
62505105|NCT04458961|ACTIVE_COMPARATOR|Two-stage|
62347273|NCT00423241|ACTIVE_COMPARATOR|ON-Q PainBuster Post-Op Pain Relief System|
62347274|NCT05071729|EXPERIMENTAL|Moderate renal impairment|Participants with estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m\^2
62505106|NCT05693831||Singula|Patients with a diagnosis of cancer who have already received first line therapy
62505107|NCT05693831||Ventura|Patients with a diagnosis of relapsed or refractory cancer
62703571|NCT05606965|ACTIVE_COMPARATOR|Parts A and B - Arm 2: Egg-based Quadrivalent Influenza Vaccine (Age Group 18-50 years)|Participants will receive a single dose of egg-based quadrivalent influenza vaccine by IM injection on Day 1.
62703572|NCT05606965|ACTIVE_COMPARATOR|Parts A and B - Arm 3: Adjuvanted Quadrivalent Influenza Vaccine (Age Group 65-80 years)|Participants will receive a single dose of adjuvanted quadrivalent influenza vaccine by IM injection on Day 1.
62703573|NCT05606965|ACTIVE_COMPARATOR|Parts A and B - Arm 4: Inactivated Influenza Vaccine (Age Group 65-80 years)|Participants will receive a single dose of inactivated influenza vaccine by IM injection on Day 1.
62703574|NCT05606965|EXPERIMENTAL|Parts A and B - Arm 5: mRNA-1010 (Age Group 65-80 years)|Participants will receive a single dose of mRNA-1010 by IM injection on Day 1.
62703575|NCT05606965|EXPERIMENTAL|Part C - Arm 1: mRNA-1010 and mRNA-1345 (Age Group 18-50 years)|Participants will receive one dose of mRNA-1010 concomitantly injected with one dose of mRNA-1345 in the contralateral arm at Day 1.
62347275|NCT05071729|EXPERIMENTAL|Severe renal impairment|Participants with eGFR \< 30 mL/min/ 1.73 m\^2
62347276|NCT05071729|EXPERIMENTAL|Normal renal function|Participants with ≥ 90 mL/min/1.73 m\^2
62347277|NCT03051841|EXPERIMENTAL|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
62347278|NCT05753098|EXPERIMENTAL|estrogen therapy in addition to clomiphene citrate|received clomiphene citrate 50 mg (Tecnovula®) orally twice daily from the 2nd to 7th day of the cycle and estrogen (Cyclopregnova® 2mg, white tablets, BAYER Schering pharma), one tablet every 12 hour from day 8th till triggering of ovulation.
62347279|NCT05753098|EXPERIMENTAL|sildenafil in addition to clomiphene citrate|received clomiphene citrate 50 mg (Tecnovula®) orally twice daily from the 2nd to 7th day of the cycle as and Sildenafil (Respatio® 20mg film coated tablets for 5 days) from last day of menstruation till reaching optimal size of follicle and endometrial thickness
62703576|NCT05606965|EXPERIMENTAL|Part C - Arm 2: mRNA-1010 and mRNA-1345 (Age Group 18-50 years)|Participants will receive one dose of mRNA-1010 at Day 1 followed by one dose of mRNA-1345 in the contralateral arm at Day 29.
62703577|NCT05606965|EXPERIMENTAL|Part C - Arm 3: mRNA-1045 (Age Group 18-50 years)|Participants will receive a single dose of mRNA-1045 by IM injection on Day 1.
61959995|NCT04905485|OTHER|Intervention|All participants received the intervention in this trial. They received recommendations on their diets and supplements based on their results of microbiome expression.
62505108|NCT04226131|OTHER|Early Rheumatoid Arthritis (RA)|"Early RA defined as duration of disease/symptoms of less than 6 months (where duration denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic Disease-modifying anti-rheumatic drugs (bDMARD) therapy"
62703578|NCT06100744|EXPERIMENTAL|Risankizumab|Participants will receive risankizumab for 24 weeks, in Period 1. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. There will be a 140 day safety follow up after the treatment period.
62703579|NCT06100744|EXPERIMENTAL|Adalimumab|Participants will receive adalimumab for 24 weeks, in Period 1. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. There will be a 70 day safety follow up after the treatment period.
62703580|NCT04035005|EXPERIMENTAL|Ocrelizumab|Participants will receive ocrelizumab by IV infusion every 24 weeks.
62703581|NCT04035005|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.
62703582|NCT05949060|EXPERIMENTAL|Compassion Intervention|
62703583|NCT05949060|NO_INTERVENTION|No Training|
62703584|NCT01319565|EXPERIMENTAL|1/ACT|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin
62703585|NCT01319565|EXPERIMENTAL|2/ACT + TBI|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin + TBI
62703586|NCT06269653||Healthy Individuals: 20 - 29 years of age|Age group: 20 -29 (3 men and 3 women)
62703587|NCT06269653||Healthy Individuals: 30 - 39 year of age|Age group: 30 - 39 (3 men and 3 women)
62703588|NCT06269653||Healthy Individuals: 40 - 49 years of age|Age group 40 - 49 (3 men and 3 women)
62703589|NCT06269653||Healthy Individuals: 50 - 59 years of age|Age group: 50 - 59 (3 men and 3 women)
62703590|NCT06269653||Healthy Individuals: 60 - 69 years of age|Age group: 60 - 69 (3 men and 3 women)
62703591|NCT06269653||Healthy Individuals: 70 +|Age group: 70+ (3 men and 3 women)
62703592|NCT05877014|EXPERIMENTAL|Unipolar interlocking group|
62703593|NCT05877014|ACTIVE_COMPARATOR|Bipolar interlocking group|
62703594|NCT06310577|EXPERIMENTAL|Leak free bronchoscope adapter|"As a standard part of procedure, bronchoscopy will be performed using the standard commercial adapter. Following the standard bronchoscope adapter use, leak-free bronchoscope adapter will be tested to compare the amount, and quality of air leaked between thestandard commercial adapter and the leak-free adapter."
62505109|NCT04226131|OTHER|Age-, Sex-, BMI-matched Healthy Controls|Healthy Controls.
62703595|NCT06479837||Tonsillectomy Patients|Patients undergoing tonsillectomy as part of their clinical care
62703596|NCT02965716|EXPERIMENTAL|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
62703597|NCT00001645||Diarrhea GI parasite|Subjects infected with a GI parasite
62505110|NCT01405274|EXPERIMENTAL|Physiotherapy intervention|
62703598|NCT00001645||Echinococcus|Subjects infected with echinococcus
62703599|NCT00001645||Intestinal worm|Subjects infected with parasitic intestinal worm
62703600|NCT00001645||Malaria|Subjects infected with malaria
62703601|NCT00001645||Parasitic infection|Subjects infected with a parasitic infection that is not included in the other cohorts
61959996|NCT02871297|EXPERIMENTAL|Vortioxetine|Vortioxetine tablets for 26 weeks. Single dose of vortioxetine oral drops (only a subset of participants).
61959997|NCT03426813|OTHER|Early mobilization|Historical control group for early mobilization
61959998|NCT01627600||Atahualpa residents aged ≥ 40 years|All Atahualpa residentes aged 40 ≥ years will be screened by field questionnaires. Then, those with suspected stroke or ischemic heart disease will be evaluated by neurologists and cardiologists. Cardiovascular health metrics will be evaluated in those negative for stroke or ischemic heart disease.
61959999|NCT00689234|PLACEBO_COMPARATOR|A|"At time of inclusion randomised in the no intervention arm (the subjects will be re-evaluated 6 months later and will get intervention at that time (cross-over protocol)"
61960000|NCT00689234|ACTIVE_COMPARATOR|B|At time of inclusion the subject get the intervention
62703602|NCT04339751|EXPERIMENTAL|single center, prospective pilot study|effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease
62703603|NCT06115499|EXPERIMENTAL|Arm I (nab-paclitaxel, gemcitabine, cisplatin)|Patients receive nab-paclitaxel IV over 30-40 minutes, gemcitabine IV over 30-40 minutes, and cisplatin IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.
62703604|NCT06115499|ACTIVE_COMPARATOR|Arm II (nab-paclitaxel, gemcitabine)|Patients receive nab-paclitaxel IV over 30-40 minutes and gemcitabine IV over 30-40 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.
62703605|NCT06487910|EXPERIMENTAL|3D scan measurment|"patients included in the study will undergo a 3D scan measurement of on or more burn scars. This measurement will then be digitally modified in preparation for the manufacture of the differential pressure distribution orthosis. The orthosis will then be manufactured using a 3D printing process."
62703606|NCT04573062||Post COVID patients|Individuals whom have previously had COVID -19 infection.
62703607|NCT05421390|NO_INTERVENTION|≤1 dairy serving/day|Limited dairy intake
62703608|NCT05421390|EXPERIMENTAL|2-3 servings/day reduced-fat|2-3 servings/day of skim milk, fat-free yogurt, and low-fat cheese
62703609|NCT05421390|EXPERIMENTAL|2-3 servings/day regular-fat|2-3 servings/day of regular-fat milk, yogurt, and cheese
62703610|NCT03667820|EXPERIMENTAL|Osimertinib|Osimertinib in combination with Stereotactic Ablative Radiation (SABR)
61960001|NCT02549937|EXPERIMENTAL|Escalation 50 mg|Escalation cohort at 50 mg/day
61960002|NCT02549937|EXPERIMENTAL|Escalation 100mg|Escalation cohort at 100 mg/day
61960003|NCT02549937|EXPERIMENTAL|Escalation 200 mg|Escalation cohort at 200 mg/day
61960004|NCT02549937|EXPERIMENTAL|Escalation 300 mg|Escalation cohort at 300 mg/day
61960005|NCT02549937|EXPERIMENTAL|Escalation 400 mg|Escalation cohort at 400 mg/day
61960006|NCT02549937|EXPERIMENTAL|Expansion|Subjects will receive RP2D surufatinib daily treatment continuously with every 28-day treatment cycle. Four expansion cohorts will enroll BTC, pNET, EP-NET, and STS patients, respectively.
61960007|NCT04532944|OTHER|patients with MS|20 relapsing-remitting and 20 progressive MS patients
61960008|NCT04532944|OTHER|healthy controls|15 age- and sex-matched healthy controls
61960009|NCT00589251|OTHER|penicillin skin test|Patients will have the skin test placed
61960010|NCT02031068|ACTIVE_COMPARATOR|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~1. An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms~2. A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
61960011|NCT02031068|EXPERIMENTAL|Behavioral:Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~1. Sub-maximal aerobic training for up to 15 minutes~2. Light coordination and sport-specific exercises for up to 10 minutes~3. Visualization and imagery techniques~4. Home program.~A physiotherapist will supervise the rehabilitation."
62347280|NCT05753098|OTHER|clomiphene citrate alone|received clomiphene citrate 50 mg (Tecnovula®) orally twice daily from the 2nd to 7th day of the cycle as in the first and second groups in addition to placebo tablet.
62347281|NCT05257135|EXPERIMENTAL|Biological collection|"For all patients included in the study:~* Blood samples collected at different times: at inclusion and during treatment every 6 months~* In parallel to this biological collection, standardized clinical data will be entered into a database"
62505111|NCT01405274|NO_INTERVENTION|standard care|
62505112|NCT03695055|EXPERIMENTAL|Arm 1|Rituximab maintenance
62505113|NCT03695055|ACTIVE_COMPARATOR|Arm 2|DPP/DCEP-G alternation regimen
62703611|NCT03973320||Primary Total Hip Arthroplasty|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty
62703612|NCT05779748|EXPERIMENTAL|Isometric exercise-one repetition|"Isometric exercise consisting of 1 session only. The session will last for around 5 minutes which will include asking the patient to do 1 repetition of wall squat for 3 min or to volitional fatigue at 100° knee angle.~Intervention: Other: Single bout of exercise"
61960012|NCT02528929|ACTIVE_COMPARATOR|At-risk serology|Gluten-free diet
61960013|NCT02528929|ACTIVE_COMPARATOR|Not at-risk serology|Gluten-free diet
61960014|NCT03925974|EXPERIMENTAL|HER2 overexpression|HER2 IHC 3+ or IHC2+ and ISH+
61960015|NCT03925974|EXPERIMENTAL|HER2 expression|HER2 IHC 2+ISH- or IHC 1+ and ISH+
61960016|NCT03728790|NO_INTERVENTION|Usual Care|Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
61960017|NCT03728790|EXPERIMENTAL|Remote Patient Monitoring|Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
61960018|NCT01979445|EXPERIMENTAL|Prasugrel 30 Min After Cangrelor|Prasugrel 60 milligram (mg) administered orally 30 min after the discontinuation of cangrelor infusion on Day 1 (2.5 hours \[hrs\] after initiation of cangrelor infusion).
61960019|NCT01979445|EXPERIMENTAL|Clopidogrel Within 5 Min After Cangrelor|Clopidogrel 600 mg administered orally within 5 min after the discontinuation of the cangrelor infusion on Day 1 (2 hrs after initiation of cangrelor infusion).
61960020|NCT01979445|EXPERIMENTAL|Clopidogrel 1.5 Hrs During Cangrelor|Clopidogrel 600 mg administered orally 1.5 hrs after the initiation of cangrelor infusion on Day 1.
62347282|NCT06348953|ACTIVE_COMPARATOR|Conventional non-bioactive restorative system (Comparator)|deep carious molars restored with conventional resin based restorative system
62347283|NCT06348953|ACTIVE_COMPARATOR|Bioactive system (Intervention)|deep carious molars restored with bioactive resin based restorative system
62505114|NCT03695055|NO_INTERVENTION|Arm 3|
62505115|NCT03297086|ACTIVE_COMPARATOR|Bi-Flex|Medicontur Bi-Flex 677MY IOL was implanted into 24 eyes of 12 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
62505116|NCT03297086|ACTIVE_COMPARATOR|ReStor|and Alcon Acrysof Restor SN6AD1 IOL was implanted into 36 eyes of 18 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
61960021|NCT01979445|EXPERIMENTAL|Clopidogrel 1 Hr During Cangrelor|Clopidogrel 600 mg administered orally 1 hr after the initiation of cangrelor infusion on Day 1.
61960022|NCT02627105|EXPERIMENTAL|Beef group|Subjects in this group are asked to consume 4 or more servings of beef per week and to exclude all other red meats from their diet for the 6 month study.
61960023|NCT02627105|OTHER|Non-beef group|Subjects in this group are asked to avoid all red meats from their diet for the 6 month study.
61960024|NCT04528108|EXPERIMENTAL|ZYZQ Group|ZYZQ group is the experimental group which is treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine for 3 months.
61960025|NCT04528108|ACTIVE_COMPARATOR|GXN Group|GXN group is the active Comparator group which is treated with Gong Xue Ning capsules for 3 months
62505117|NCT05815849|ACTIVE_COMPARATOR|Olive oil|In our unit, according to the recommendations to start and increase enteral feeding in preterm infants in the Turkish Neonatal Society feeding group, Total Parenteral Nutrition (TPN) and Minimal Enteral Nutrition (MEN) are started from the first day. If the infant's weight is between 1000-1500 grams, it is increased to feed the infant as 15-20 ml/kg/day (for 1-2 days) and then 30 ml/kg/day every 2-3 hours. If the infant's weight is between 1500-1800 grams, he/she is fed as 20 ml/kg for 1 day and then 30 ml/kg/day, every 3 hours. BM fortification is initiated when feeding reaches 50-100 ml/kg (recommended 80 ml/kg) \[21\].At this stage (approximately from the seventh day after starting to take 25-30 ml/kg/day orally), 0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group.
62505118|NCT05815849|NO_INTERVENTION|Recommendations to start enteral feeding|In our unit, according to the recommendations to start and increase enteral feeding in preterm infants in the Turkish Neonatal Society feeding group, Total Parenteral Nutrition (TPN) and Minimal Enteral Nutrition (MEN) are started from the first day. If the infant's weight is between 1000-1500 grams, it is increased to feed the infant as 15-20 ml/kg/day (for 1-2 days) and then 30 ml/kg/day every 2-3 hours. If the infant's weight is between 1500-1800 grams, he/she is fed as 20 ml/kg for 1 day and then 30 ml/kg/day, every 3 hours. BM fortification is initiated when feeding reaches 50-100 ml/kg (recommended 80 ml/kg) \[21\].
62505119|NCT02148354|EXPERIMENTAL|Group with support by the therapist.|Intervention group that do the Smiling is Fun program and receives support by the therapist (a brief weekly two-minute call without clinical content).
62505120|NCT02148354|EXPERIMENTAL|Group without support by the therapist|Intervention group that do the Smiling is Fun program and does not receive support by the therapist.
62505121|NCT02148354|OTHER|Waiting list control group|"Control group that could access the Smiling is Fun program after waiting for 12 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
62505122|NCT00267358|ACTIVE_COMPARATOR|RC-1291 HCl|50 mg
62505123|NCT00267358|PLACEBO_COMPARATOR|Placebo|
62505124|NCT04066920|EXPERIMENTAL|IBER treatment arm|This is the only arm in a single-arm phase II study.
62505125|NCT00833573||1|For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
61960026|NCT01616667|ACTIVE_COMPARATOR|Modified direct lateral approach|The patients included is operated with a total hip arthroplasty using a modified direct lateral approach
61960027|NCT01616667|ACTIVE_COMPARATOR|Posterior approach|The patients included is operated with a total hip arthroplasty using posterior approach
61960028|NCT05453604|EXPERIMENTAL|Sample collection|This is a prospective study in which urine samples will be collected from healthy volunteers, urine samples and a blood sample from pregnant women and cancer patients with solid tumors with emphasis on breast- and prostate cancer. The participants will be asked to provide a urine sample collected with the Colli-Pee® device and fill out an online questionnaire to collect usability data.
62505126|NCT00833573||2|For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.
62505127|NCT04876937|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1-0.2 ug/kg/h during mechanical ventilation, for a maximum of 7 days.
62505128|NCT04876937|PLACEBO_COMPARATOR|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 7 days.
62505129|NCT02805413|OTHER|DETERMINATION OF BLOOD PRESSURE|"determination and comparison of blood pressure by/with :~* Pulse Curve Analysis~* Inert gas re-breathing~* Central blood pressure device~* Vascular ultrasound device~* Thoracic Impedance (ICG) - Electrocardiography (ECG) - Phonocardiography (Phono) - Carotid plethysmography (Pneumo)"
62505130|NCT05904262||Type 2 diabetic patients|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
62505131|NCT00964106|EXPERIMENTAL|Probe drugs|"Caffeine 100 mg CYP1A2 Pioglitazone 15 mg CYP2C8 Flurbiprofen 40 mg CYP2C9 Omeprazole 20 mg CYP2C19 Dextromethorphan 45 mg CYP2D6 Midazolam 3 mg (Part 1, Part 2 Cohorts B and C)~1 mg (Part 2 Cohort A) CYP3A4/5 Rosuvastatin 10 mg OATP1B1"
62505132|NCT00964106|EXPERIMENTAL|Default Inhibitors|A Ketoconazole 400 mg once-daily Day 1 through Day 9 CYP3A4 B Fluconazole 400 mg x1 dose on Day 1 200 mg once-daily Day 2 through Day 9 CYP2C9 C Rifampin 600 mg x1 dose on Day 1 and Day 8 OATP1B1
62505133|NCT06428513|EXPERIMENTAL|HCTP program|Complete a HCTP program which includes 12 weekly one-on-one 30-minute tele-sessions through Zoom. Follow up will be for a year in total.
62505134|NCT06428513|NO_INTERVENTION|Control|Control group participants do not receive the intervention but will receive HCTP after the end of the study.
61960029|NCT04162639|EXPERIMENTAL|One donor|Participants will receive skin allograft from 1 distinct cadavers.
61960030|NCT04162639|EXPERIMENTAL|Two donors|Participants will receive skin allograft from 2 distinct cadavers.
61960031|NCT04162639|EXPERIMENTAL|Three donors|Participants will receive skin allograft from 3 distinct cadavers.
61960032|NCT04162639|NO_INTERVENTION|Control|Participants will be burned patients with wounds that do not require skin allografts, but are instead reconstructed with their own skin (skin autografts) in a single stage.
61960033|NCT03523897|ACTIVE_COMPARATOR|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
62505135|NCT00932724|EXPERIMENTAL|CY-503|
62703613|NCT05779748|EXPERIMENTAL|Isometric exercise-three repetitions|"isometric exercise consisting of 1 session only. The session will last for around 10 minutes which will include asking the patient to perform 3 repetitions of wall squats (each time the exercise will be performed for 3 min or to volitional fatigue at 100°degree knee angle); the patient will be given 30-sec rest between repetitions.~Intervention: Other: Single bout of exercise"
61960034|NCT03523897|ACTIVE_COMPARATOR|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
61960035|NCT01448486|NO_INTERVENTION|Standard of Care HAART|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).
61960036|NCT01448486|EXPERIMENTAL|Raltegravir|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
61960037|NCT03078660|EXPERIMENTAL|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
61960038|NCT03078660|ACTIVE_COMPARATOR|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
61960039|NCT01722084|EXPERIMENTAL|Community-eùbedded reproductive health interventions|Members of communities that belonged to the intervention arm were exposed to complex interventions addressing different target groups (adolescents, parents, authorities and health providers) and focusing on various behaviours that were related to communication about sexuality, information seeking, access to health care and safe sexual intercourse.
61960040|NCT01722084|NO_INTERVENTION|Community members without intervention|
61960041|NCT05391698|EXPERIMENTAL|Parent Training - Child Training (Group PC)|Parents of families who will be randomized in Group PC will first take part in behavioral parent training. After the completion of the parent training program and the assessment (Time 2 assessment), their children will take part in the individualized child training program.
61960042|NCT05391698|EXPERIMENTAL|Child Training - Parent Training (Group CP)|Children of families who will be randomized in Group CP will first take part in the individualized child training program. After the completion of the child training program and the assessment (Time 2 assessment), parents will take part in the behavioral parent training program.
61960043|NCT03409835|EXPERIMENTAL|Ramosetron|
62347284|NCT02120157|EXPERIMENTAL|Haploidentical BMT with PTCy for acute leukemias and MDS|"Patients with AML and MDS:~Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV~For patients with ALL and lymphoblastic lymphoma:~Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV~Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days~All patients Day 0: Infuse unmanipulated bone marrow~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day~Day +30: Assess chimerism and disease status in bone marrow~Day +35: Discontinue MMF~Day +60: Assess chimerism and disease status in bone marrow~Day 180: Discontinue tacrolimus"
62347285|NCT03198780|EXPERIMENTAL|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
62347286|NCT02484612|EXPERIMENTAL|Lean adolescents|15 lean adolescents (BMI Under the national cut-offs for obesity), 12-15 years old, males, will be recruited
62347287|NCT02484612|EXPERIMENTAL|Obese adolescents|15 obese adolescents (BMI above the national cut-offs for obesity), 12-15 years old, males, will be recruited
62505136|NCT00932724|PLACEBO_COMPARATOR|Placebo|
62505137|NCT04529876||Tofacitinib|Reference group
62505138|NCT04529876||Abatacept|Exposure group
62703614|NCT05779748|NO_INTERVENTION|Control|Will not receive any intervention
62703615|NCT03221036|EXPERIMENTAL|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.
62703616|NCT03221036|PLACEBO_COMPARATOR|Induction Phase: Placebo|Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.
62505139|NCT01710124|EXPERIMENTAL|Incentive|Subjects in this group will receive financial incentives for using grocery coupons to purchase healthy foods.
62505140|NCT01710124|NO_INTERVENTION|No incentive|Subjects in this group will receive no financial incentives.
62505141|NCT02466334|ACTIVE_COMPARATOR|Active|1.5µg/min IV calcitonin-gene related peptide for 20 minutes
62703617|NCT03221036|EXPERIMENTAL|Maintenance Phase: Vedolizumab 300 mg|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.
62703618|NCT03221036|PLACEBO_COMPARATOR|Maintenance Phase: Placebo|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.
61960044|NCT03409835|PLACEBO_COMPARATOR|Control|
61960045|NCT01560793|EXPERIMENTAL|VAX161B|Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
62505142|NCT02466334|PLACEBO_COMPARATOR|Placebo|IV placebo for 20 minutes
62703619|NCT05593029|EXPERIMENTAL|SEP-363856 & ADT (Antidepressant Therapy)|
62703620|NCT05593029|PLACEBO_COMPARATOR|Placebo & ADT (Antidepressant Therapy)|
61960046|NCT02216591|EXPERIMENTAL|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
61960047|NCT02216591|SHAM_COMPARATOR|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
61960048|NCT03288129|EXPERIMENTAL|Perampanel|Perampanel will be administered orally once daily (QD) at bedtime. At the beginning of the Titration Period, oral perampanel will start at a dose of 2 milligrams (mg) QD. Doses of perampanel will then be up titrated in increments of 2 mg at no less than 2-week intervals according to the investigator's judgment. At the 4 mg dose, the investigator will confirm whether further dose escalation is needed based on participant response and tolerability. The investigator may adjust dosing further or leave the participant at 4 mg. The maximum dose is 12 mg. During the 39-week Maintenance Period, participants will continue to receive the perampanel dose level that was administered at the end of the Titration Period.
61960049|NCT02131194|EXPERIMENTAL|Lenstatin|Lenstatin (2) capsules orally per day for (6) months
62703621|NCT02610439||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
61960050|NCT02131194|PLACEBO_COMPARATOR|Sugar Pill|Placebo manufactured to mimic Lenstatin (2) capsules orally per day for (6) months
61960051|NCT01154790|EXPERIMENTAL|CG100649|By the amount of doses, the groups are classified
61960052|NCT01154790|ACTIVE_COMPARATOR|Naproxen|By the amount of doses, the groups are classified
61960053|NCT01154790|PLACEBO_COMPARATOR|Placebo|By the amount of doses, the groups are classified
61960054|NCT05969145|EXPERIMENTAL|hot-cold application|This group will be given a hot cold application to the bladder
61960055|NCT05969145|NO_INTERVENTION|control group|Routine clinical functioning will be applied to this group
61960056|NCT03760783|OTHER|Effect of microgravity on human sperm|Simulated microgravity flight
61960057|NCT00492583|PLACEBO_COMPARATOR|Placebo|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of placebo drink.
61960058|NCT00492583|EXPERIMENTAL|Bifidobacterium lactis (BB-12)|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of active drink.
62347288|NCT05812469|EXPERIMENTAL|experimental group|psychoeducation and counseling provided as part of the Brain Awareness Intervention for the experimental group of 39 patients
61960059|NCT03853408||First Admission|Cholecystectomy during first admission
62347289|NCT05812469|ACTIVE_COMPARATOR|control group|38 patients will receive education about Being Healthy
62347290|NCT03988608|EXPERIMENTAL|Eltrombopag|Subjects will start eltrombopag treatment at 25 mg/day since Day 1.
62347291|NCT03838562|EXPERIMENTAL|Virtual Reality Arm|
62347292|NCT03838562|ACTIVE_COMPARATOR|Control Arm|
62347293|NCT04339270|ACTIVE_COMPARATOR|Azithromycin according to symptoms|Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.
62347294|NCT04339270|EXPERIMENTAL|Azithromycin according to rheology|Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.
62703622|NCT05505643|EXPERIMENTAL|Cryoablation|Patients will be treated with cryoablation using the Endocare SlimLine Cyroprobe under real time ultrasound guidance and local anesthesia. The cryoablation consists of a 10 minute freeze phase followed by a 10 minute passive thaw, and ends with a second 10 minute freeze cycle. The freeze-thaw-freeze times may be adjusted at the physician's discretion depending on tumor size.
62703623|NCT05505643|ACTIVE_COMPARATOR|Lumpectomy|Lumpectomy will be performed under general anesthesia as per standard operative procedures at Washington University and Siteman Cancer Center.
61960060|NCT03853408||Second Admission|Cholecystectomy during second admission
61960061|NCT01182675|EXPERIMENTAL|T-cell Graft Permissive SCID|"Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only"
62347295|NCT02070406|EXPERIMENTAL|Treatment (gene-modified T-cells, vaccine therapy, ipilimumab)|"CONDITIONING CHEMOTHERAPY REGIMEN: Patients receive cyclophosphamide IV on days -5 and -4 and fludarabine phosphate IV over 30 minutes daily on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV on day 0.~IPILIMUMAB ADMINISTRATION: Patients receive ipilimumab IV over 90 minutes before the NY-ESO-1 TCR PBMC infusion on day 0 or after the infusion on day 1. Treatment repeats every 3 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC ADMINISTRATION: Patients receive NY-ESO-1(157-165) peptide pulsed DC vaccine ID on days 1, 14, and 30.~LOW DOSE IL-2 ADMINISTRATION: Patients receive aldesleukin (IL-2) SC BID on days 1-14."
62347296|NCT00545987|ACTIVE_COMPARATOR|intramuscular injection|administration of an HIV-1 vaccine by conventional intramuscular injection
62347297|NCT00545987|EXPERIMENTAL|TriGrid Delivery System|electroporation-mediated intramuscular delivery using the TriGridTM device by Ichor Medical Systems, Inc.
62703624|NCT05505643|OTHER|Rescue Arm: Lumpectomy|If there is evidence of residual or recurrent tumor on follow-up imaging evaluation (6 month MRI (if can tolerate) and yearly MRI/mammography), patients in the cryoablation safety lead-in and who were randomized to receive cryoablation only will be crossed over to receive a rescue lumpectomy followed by adjuvant treatment based on standard of care.
61960062|NCT01182675|EXPERIMENTAL|T-cell Graft Resistant SCID|Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
61960063|NCT01970046|PLACEBO_COMPARATOR|Placebo/Metformin|
61960064|NCT01970046|EXPERIMENTAL|SP2086 (50mg b.i.d)/Metformin|
62703625|NCT05505643|EXPERIMENTAL|Cryoablation - Safety Lead In|Patients will be treated with cryoablation (Day 1) using the Endocare SlimLine Cyroprobe followed by adjuvant treatment.
62703626|NCT03090152|ACTIVE_COMPARATOR|Periarticular Injection (PAI)|"* Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~* Peri-articular injection in the operating room~* Combined Spinal Epidural with 1.5% Mepivacaine 4cc~* A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV~* Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
62703627|NCT03090152|ACTIVE_COMPARATOR|Epidural Patient-Controlled Analg (EPCA)|"* Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~* Combined Spinal Epidural with 1.5% Mepivacaine 4cc~* A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~* Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
62703628|NCT03090152|EXPERIMENTAL|PAI + EPCA|"* Aspirin and nerve pain medications including duloxetine and clonidine~* Combined Spinal Epidural with 1.5% Mepivacaine 4cc~* Anesthetic, Antiemetic and peri-articular injection in the operating room~* A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~* Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
62703629|NCT05763407|EXPERIMENTAL|FIRE1 System|FIRE1 System
62703630|NCT06430658|EXPERIMENTAL|ChemoRT+Immuno|Surgery was evaluated after chemoradiotherapy (40-41.4Gy/1.8-2Gy/20-23 fractions) followed by two cycles of chemotherapy and immunotherapy.For inoperable patients, immunotherapy was used as maintenance therapy
62703631|NCT06430658|EXPERIMENTAL|Immuno+ChemoRT|Surgery was evaluated after two cycles of chemotherapy and immunotherapy followed by chemoradiotherapy(40-41.4Gy/1.8-2Gy/20-23 fractions).For inoperable patients, immunotherapy was used as maintenance therapy
62703632|NCT06430658|ACTIVE_COMPARATOR|ChemoRT|Surgery was evaluated after concurrent definitive chemoradiotherapy (50-50.4Gy/1.8-2Gy/25-28fractions) .For inoperable patients, immunotherapy was used as maintenance therapy
62703633|NCT00594672||AREDS participants|Participants who were enrolled in the AREDS or AREDS2 protocol and successfully completed the final AREDS or AREDS2 follow-up visit.
62703634|NCT06408051||singel|
62703635|NCT02839291|EXPERIMENTAL|quality of life questionaries|Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
62703636|NCT03237702|EXPERIMENTAL|MCS arm|The participants who will have Multi-Carotenoids for 8 weeks The intervention is Multi-Carotenoids 30 mg for 8 weeks.
62703637|NCT05447325|EXPERIMENTAL|Message exposure (sequence: regular PSAs then flavor PSAs)|Participants randomly assigned to this arm will receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the first 6 months of the study, and will then receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the second 6 months of the study.
62703638|NCT05447325|EXPERIMENTAL|Message exposure (sequence: flavor PSAs then regular PSAs)|Participants randomly assigned to this arm will receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the first 6 months of the study, and will then receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the second 6 months of the study.
62703639|NCT05447325|EXPERIMENTAL|No message exposure (control condition)|Participants will not be receiving any PSA exposure over the 12 months.
62703640|NCT06297447|ACTIVE_COMPARATOR|"Usual care"|"Usual Care: The control group receives unrestricted usual care. It could include a patient interview with individual goal setting and subsequent rehabilitation using cardio and strengthening exercises towards achieving the determined goals. It will be delivered by an authorized physiotherapist, and the intervention is determined by patient preferences, physiotherapist's clinical reasoning, and available resources."
62703641|NCT06297447|EXPERIMENTAL|PNE4Adults - pain science education|"PNE4Adults: In this group, the participants will receive an add-on individualized PSE in addition to the usual care with the PNE4Adults resource. The PNE4Adults session will follow the developed manual (http://www.paininmotion.be/pne4kids) and will be delivered by a physiotherapist in two sessions of each 30-45 minutes, shortly following the first meeting. Firstly, the function of a normal pain system is introduced, with examples of the pain being overly or under protective. Then, the patient teaches back giving the therapist the opportunity to evaluate the understanding and, if necessary, repeat essential key messages. Secondly, the sensitized pain system is explained. Thirdly, the subject is asked to reflect on this new information in relation to his/her own situation. Subsequently, the new knowledge is integrated in usual care with any additional measures that need to be included, e.g., graded exposure, stress relief, graded activity, and cognitive therapies."
62703642|NCT06311357|NO_INTERVENTION|Control|Nutritional advise
62703643|NCT06311357|EXPERIMENTAL|Intervention|Medical supplement and nutritional advise
62703644|NCT03691883||TB patients|TB patients diagnosed and followed-up in Barcelona, at the following Hospitals/Clinics: Servicios Clínicos, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron-Drassanes, Hospital del Mar.
62703645|NCT04008797|EXPERIMENTAL|Dose Escalation Part: HCC: E7386 QD Subpart + Lenvatinib|Participants with hepatocellular carcinoma (HCC) will receive E7386, once daily (QD) for 5 or 6 consecutive days followed by a period of time without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386, QD in combination with lenvatinib 8 milligram (mg) (participants with body weight of less than \[\<\] 60 kilograms \[kg\]) or 12 mg (participants with body weight \>=60 kg), capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
61960065|NCT01970046|EXPERIMENTAL|SP2086 (50mg q.d.)/Metformin|
61960066|NCT05830591||Children with autism disorders 1-5 years|Children coming to the Division of Child Neurology and Psychiatry for the first clinical evaluation (1 year to 5 years old)
61960067|NCT05830591||Children with autism disorders 6-17 years|Children with confirmed ASD diagnosis (6 years to 17 years old) coming to the Odonto-Stomatology Department for the periodical dental hygiene session
61960068|NCT05830591||Children control group|Children with matched demographic characteristics accessing our Institute for different purposes
61960069|NCT03548259|EXPERIMENTAL|Experimental|Platelet-rich plasma
61960070|NCT03548259|PLACEBO_COMPARATOR|Platelet-poor plasma|Platelet-poor plasma
61960071|NCT02249585|EXPERIMENTAL|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
61960072|NCT02249585|EXPERIMENTAL|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
61960073|NCT02249585|EXPERIMENTAL|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
61960074|NCT03217331|EXPERIMENTAL|CRD-102 Treatment|CRD102 Treatment
62143390|NCT02311621|EXPERIMENTAL|C: Long Spacer 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10\^6 cells/kg, 5x10\^6 cells/kg, 1x10\^7 cells/kg, 5x10\^7 cells/kg, and 1x10\^8 cells/kg will be evaluated."
62347298|NCT05262582|EXPERIMENTAL|Thymectomy performed with sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
61960075|NCT04352504|EXPERIMENTAL|Almonds|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
62143391|NCT01887275|EXPERIMENTAL|medical ozone therapy with humares|
62143392|NCT01887275|ACTIVE_COMPARATOR|conventional interferon-α|
62143393|NCT01144520||Normoglycemic|Healthy subjects that do not have diabetes
62143394|NCT01144520||Type II Diabetes (HbA1c <7 or 7%)|Subject that have Type II Diabetes with good glucose control with glycated hemoglobin (HbA1c \<7 or 7%)
62143395|NCT01144520||Type II Diabetes (HbA1c between 7.1-9)|Subjects with Type II Diabetes with moderate glucose control (HbA1c between 7.1-9)
62143396|NCT01144520||Type II Diabetes (HbA1c >9%)|Subjects with Type II Diabetes with poor glucose control (HbA1c \>9%)
62143397|NCT05845970|EXPERIMENTAL|Single Group|Single-group crossover trial with 100 total participants. Participants will use Pamprin Botanicals during their first period and both Pamprin Botanicals and over-the-counter Pamprin Menstrual Relief during their second period.
62143398|NCT02718339|EXPERIMENTAL|Intensive counseling by a pulmonologist|Counselor visit during hospitalization, telephone follow up for 4 weeks and a follow up visits.
62143399|NCT02718339|NO_INTERVENTION|Usual care|
62143400|NCT03591588|ACTIVE_COMPARATOR|high-saturated fat diet|Diet high in saturated fat (\~50% calorie from fat, \~25% from saturated fat)
62143401|NCT03591588|ACTIVE_COMPARATOR|low-fat diet|Diet with low fat (\~25% calorie from fat)
62143402|NCT03760653|EXPERIMENTAL|Physical Exercise and probiotic group|The subjects will receive 3 weekly sessions of combined exercise supervised by professionals in a specialized gym (60 minutes each one). The exercise will consist of a combination of aerobic and strength exercises involving the main muscle groups. They will take the probiotic supplementation at the established dose, 3 capsules/day before bedtime. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
62143403|NCT03760653|EXPERIMENTAL|Probiotic group|Participants will follow their usual sedentary lifestyle (i.e to practice less than 3 days a week of physical exercise, as is specified in the inclusion criteria). They will take the probiotic supplementation at the established dose. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum
62143404|NCT03760653|PLACEBO_COMPARATOR|Placebo group|They will follow their sedentary lifestyle. Placebo probiotic will consist of a maltodextrin capsule.
62143405|NCT04033250|EXPERIMENTAL|Interventional arm (group A)|"Patients with risk factors for IBP who will receive intensified bowel preparation"
62143406|NCT04033250|ACTIVE_COMPARATOR|Control arm (group B)|Patients with risk factors for IBP who will receive standard bowel preparation
62143407|NCT04033250|ACTIVE_COMPARATOR|Control arm (group c)|Patients without risk factors for IPB who will receive standard bowel preparation
62347299|NCT05262582|ACTIVE_COMPARATOR|Thymectomy performed with two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
62347300|NCT04556370|PLACEBO_COMPARATOR|Control group|Normal saline infusion simultaneous with subarachnoid block
61960076|NCT04352504|ACTIVE_COMPARATOR|Pretzels|Consume 2 oz. serving pretzels (216 calories) daily for 12 weeks
61960077|NCT05860478|EXPERIMENTAL|wearable device plus standard care|
62143408|NCT05108363|OTHER|Lifestyle modification program|Patients with obstructive sleep apnea and prediabetes will have lifestyle modification program for 12 months
62143409|NCT06142838|EXPERIMENTAL|Intervention arm|Community pharmacist intervention
62143410|NCT06142838|NO_INTERVENTION|Control arm|Usual care
62143411|NCT00637858|PLACEBO_COMPARATOR|1|
62143412|NCT00637858|ACTIVE_COMPARATOR|2|Lyc-o-Mato 5mg
61960078|NCT05860478|NO_INTERVENTION|standard care|
61960079|NCT00587210||Suspected or known Crohn Disease|Suspected or known Crohn Disease
62143413|NCT00637858|ACTIVE_COMPARATOR|3|Lyc-o-Mato 15mg
62143414|NCT00637858|ACTIVE_COMPARATOR|4|Lyc-o-Mato 30mg
62143415|NCT00637858|ACTIVE_COMPARATOR|5|Lycopene capsules (non Lyc-o-mato) 15 mg
62347301|NCT04556370|EXPERIMENTAL|0.025 μg/kg/min group|A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block
61960080|NCT02973698|OTHER|chin-down posture maneuver|The patients in received an intervention program consisting of four weekly individual sessions of 30 minutes. In these sessions, it was performed the training of Chin-down postural maneuver with saliva and water. The participants were trained to perform the maneuver twice a day, swallowing saliva, and during meals, throughout the week, at home. The participants received a form, so they recorded the number of times they performed the maneuver at home. It allowed the control of adherence, being reinforced at each session the importance of adherence to treatment. Besides, the subjects received instructions regarding feeding. All the instructions, as well as the explanation about the maneuver, were submitted to the patients through a written document.
62703646|NCT04008797|EXPERIMENTAL|Dose Escalation Part: HCC: E7386 BID Subpart + Lenvatinib|Participants with HCC will receive E7386, twice daily (BID) for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386, BID in combination with lenvatinib 8 mg (participants with body weight of \< 60 kg) or 12 mg (participants with body weight \>=60 kg) capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
62703647|NCT04008797|EXPERIMENTAL|Dose Escalation Part: Other ST: E7386 QD Subpart + Lenvatinib|Participants with solid tumor (ST) (except for HCC) will receive E7386, QD for 5 or 6 consecutive days followed by a period of time without treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386, QD in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
62505143|NCT02791802||Group A: Lipoprotein apheresis subjects|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol \< 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~Additional lipoprotein apheresis is established following enrolment using the following established systems: Dextran-sulfate adsorption (DSA) from plasma and whole blood, Heparin-induced LDL precipitation apheresis (HELP®), Polyacrylate adsorption from whole blood and simple DFPP (DALI® and Monet®), ApoB100-immunoadsorption (TheraSorbLDL®, Temperature-optimized double filtration plasmapheresis (DFPP)."
62505144|NCT02791802||Group B: Control group|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol \< 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~The control group will not undergo a sham apheresis procedure. It is an open trial."
62703648|NCT04008797|EXPERIMENTAL|Dose Escalation Part: Other ST: E7386 BID Subpart + Lenvatinib|Participants with ST (except for HCC) will receive E7386, BID for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386, BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
61960081|NCT02973698|OTHER|Control|The participants of this group underwent evaluation of swallowing, and the same assessment was repeated after four weeks, without any intervention during that period.
61960082|NCT02973698|OTHER|Orientations about swallowing|The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
61960083|NCT01606007|ACTIVE_COMPARATOR|Arm 1: Saxagliptin+Metformin XR+Placebo|
62505145|NCT00925873|ACTIVE_COMPARATOR|1|"Control arm without fludarabine~1. Induction course: Ara-C 100mg/m2 days 1-7, idarubicin 8mg/m2 days 1-5, GM-CSF (molgramostim, Novartis) 5 microg/kg days 1 to neutrophil recovery;~2. Consolidation course: Ara-C 1g/m2 q12h days 1-3, idarubicin 10mg/m2 days 2-3;~3. and 3 quarterly reinduction courses during maintenance including Ara-C 80mg/m2 days 1-5, CCNU 40mg and mitoguazone 350mg/m2 day 1, ± fludarabine days 1-2."
62505146|NCT00925873|EXPERIMENTAL|2|"Fludarabine arm~The same regimen with fludarabine 20 mg/m2/day IV for 30 minutes~1. induction course + fludarabine days 2-7;~2. consolidation course + fludarabine days 4-5;~3. during reinduction courses + fludarabine days 1-2."
62505147|NCT05363579|OTHER|Physiotherapy|It is a form of therapy.
62505148|NCT05363579|OTHER|Tuina Therapy|It is a form of therapy.
62505149|NCT05363579|OTHER|Physiotherapy mixed with Tuina|It is a form of therapy.
62505150|NCT02761603|ACTIVE_COMPARATOR|Healthy Aging Practice-centered Instruction (HAPI)|24 hours of group instruction in which experts present on a variety of health-related topics followed by class discussion, goal-setting, and goal review. Themes will include: sleep, nutrition, mental health, social support, bone-health, diabetes prevention, cognitive wellness, and resilience.
61960084|NCT01606007|ACTIVE_COMPARATOR|Arm 2: Dapagliflozin+Metformin XR+Placebo|
61960085|NCT01606007|EXPERIMENTAL|Arm 3: Saxagliptin+Dapagliflozin+Metformin XR|
61960086|NCT03569033|EXPERIMENTAL|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
61960087|NCT03569033|PLACEBO_COMPARATOR|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
62143416|NCT01536366|EXPERIMENTAL|Group 1|Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide
62143417|NCT01536366|EXPERIMENTAL|Group 2|Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide
62505151|NCT02761603|EXPERIMENTAL|Tai Chi (CHI)|24 hours of group instruction in 8 meditative Tai Chi movements.
62347302|NCT04556370|EXPERIMENTAL|0.050 μg/kg/min group|A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block
62347303|NCT04556370|EXPERIMENTAL|0.075 μg/kg/min group|A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block
62505152|NCT01600339|EXPERIMENTAL|CABAZITAXEL|cabazitaxel at a starting dose of 25 mg/m
62703649|NCT04008797|EXPERIMENTAL|Dose Expansion Part: HCC Subpart: Lenvatinib Only|Participants with HCC will receive lenvatinib 8 mg (participants with body weight of \<60 kg) or 12 mg (participants with body weight \>=60 kg), capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program
62347304|NCT04497298|EXPERIMENTAL|COVID-19 vaccine candidate (TMV-083/V-591) - Low dose|Volunteers will receive two administrations of the low dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28
62505153|NCT05791734||assessing preoperative skin cleanliness|2 skin swabs for ATPmetry measurement and direct skin visual observation by a nurse
62505154|NCT06678932||Fibromyalgia syndrome|
62505155|NCT06678932||Healthy controls|
62505156|NCT06679101|EXPERIMENTAL|Arm A: Belantamab Mafodotin + Lenalidomide + Dexamethasone|"Belantamab mafodotin, lenalidomide, and dexamethasone will be administered.~Treatment will continue in both arms until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first."
62347305|NCT04497298|EXPERIMENTAL|COVID-19 vaccine candidate (TMV-083/V-591) - High dose|Volunteers will receive two administrations of the high dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28.
62505157|NCT06679101|ACTIVE_COMPARATOR|Arm B: Daratumumab + Lenalidomide + Dexamethasone|"Daratumumab, lenalidomide, and dexamethasone will be administered.~Treatment will continue in both arms until PD, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first."
62505158|NCT06679036|EXPERIMENTAL|Treatment group A|HRS-2189 in combination with Fluvustat.
62505159|NCT06679036|EXPERIMENTAL|Treatment group B|HRS-2189 in combination with HRS-8080.
62505160|NCT06679036|EXPERIMENTAL|Treatment group C|HRS-2189 in combination with HRS-6209 and Fluvustat.
62505161|NCT06679036|EXPERIMENTAL|Treatment group D|HRS-2189 in combination with HRS-6209 and HRS-8080.
62505162|NCT06679036|EXPERIMENTAL|Treatment group E|HRS-2189 in combination with HRS-6209 and HRS-1358.
61960088|NCT01460888|EXPERIMENTAL|OLA-0 (de-escalation dose)|25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
61960089|NCT01460888|EXPERIMENTAL|OLA-1|50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
61960090|NCT01460888|EXPERIMENTAL|OLA-2|100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
61960091|NCT01460888|EXPERIMENTAL|OLA-3|200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
61960092|NCT01460888|ACTIVE_COMPARATOR|RT alone|
62347306|NCT04497298|EXPERIMENTAL|One COVID-19 vaccine candidate (TMV-083/V-591) - High and placebo|Volunteers will receive one administration of the high dose COVID-19 vaccine candidate on day 0 by intramuscular (i.m.) injection and one administration of the placebo on day 28 by intramuscular (i.m.) injection.
62347307|NCT04497298|PLACEBO_COMPARATOR|Placebo|Volunteers will receive physiological saline solution (0.9% NaCl), administered by intra muscular (i.m.) injection
62347308|NCT02147496|EXPERIMENTAL|2% M.F. Milk|Dietary treatment: 2% m.f. milk
62347309|NCT02147496|EXPERIMENTAL|1% M.F. Chocolate Milk|Dietary treatment: 1% m.f. chocolate milk
62347310|NCT02147496|EXPERIMENTAL|1.5% M.F. Drinkable Yogurt|Dietary treatment: 1.5% m.f. drinkable yogurt
62505163|NCT03316040|NO_INTERVENTION|Control 1|This arm represent control schools. No JIC will be implemented.
62505164|NCT03316040|EXPERIMENTAL|Treatment 1|This arm implements the JIC among a random subset of students within the pre-defined grade.
62505165|NCT03316040|EXPERIMENTAL|Treatment 2|This arm implements the JIC among indegree central students within the pre-defined grade.
62505166|NCT03316040|EXPERIMENTAL|Treatment 3|This arm implements the JIC among edge betweeness central students within the pre-defined grade.
62703650|NCT04008797|EXPERIMENTAL|Dose Expansion Part: HCC Subpart: E7386 + Lenvatinib|Participants with HCC will receive lenvatinib 8 mg (participants with body weight of \<60 kg) or 12 mg (participants with body weight \>=60 kg), capsule, orally QD in combination with E7386 y, BID in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
61960093|NCT05902780|ACTIVE_COMPARATOR|Group B (25 patients)|In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
61960094|NCT05902780|ACTIVE_COMPARATOR|Group D (25 patients)|In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
61960095|NCT02352402|EXPERIMENTAL|Ticagrelor|Ticagrelor 90mg twice daily for 1 year on top of ASA
61960096|NCT02352402|PLACEBO_COMPARATOR|Placebo|Placebo matching ticagrelor 90mg twice daily on top of ASA
61960097|NCT01505400||Advanced cancer|Advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas; as well as patients who are phase I trial candidates
62505167|NCT05186753|EXPERIMENTAL|(Part 1a) Bezuclastinib Dose 1 + BSC|
62505168|NCT05186753|EXPERIMENTAL|(Part 1a) Bezuclastinib Dose 2 + BSC|
62505169|NCT05186753|PLACEBO_COMPARATOR|(Part 1a) Placebo + BSC|
62505170|NCT05186753|EXPERIMENTAL|(Part 1b) Bezuclastinib Dose 1 + BSC|
62505171|NCT05186753|EXPERIMENTAL|(Part 1b) Bezuclastinib Dose 2 + BSC|
62505172|NCT05186753|PLACEBO_COMPARATOR|(Part 1b) Placebo + BSC|
62505173|NCT05186753|EXPERIMENTAL|(Part 2) Bezuclastinib Selected Dose + BSC|
62505174|NCT05186753|PLACEBO_COMPARATOR|(Part 2) Placebo + BSC|
62505175|NCT05186753|EXPERIMENTAL|(Part 3) Bezuclastinib + BSC|
62505176|NCT00927251|EXPERIMENTAL|Model 4296 LV Lead|Non-randomized study
62505177|NCT00460109|EXPERIMENTAL|rituximab + denileukin diftitox|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients also receive denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment with denileukin diftitox repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62505178|NCT00687882|EXPERIMENTAL|Intervention: A|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
62505179|NCT00687882|ACTIVE_COMPARATOR|B|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
62505180|NCT00687882|OTHER|Parallel Cohort: Persistent Occlusive Thrombosis|Patients with completely occlusive thrombosis at 6 weeks.
62505181|NCT00687882|OTHER|Parallel Cohort: Persistent Antiphospholipid Antibody|Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.
62505182|NCT04718649|EXPERIMENTAL|Celebrex + Joins|"The experimental group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and Joins (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only Joins (taken 3 times a day) at week 12. They will only take Joins for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
62505183|NCT04718649|PLACEBO_COMPARATOR|Celebrex + Placebo|"The control group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and placebo (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only placebo (taken 3 times a day) at week 12. They will only take Joins placebo for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
62505184|NCT00973934|EXPERIMENTAL|Magnetic Seizure therapy (MST)|Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
62703651|NCT04008797|EXPERIMENTAL|Dose Expansion Part: CRC Subpart: E7386 + Lenvatinib|Participants with colorectal cancer (CRC) will receive E7386, BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
62703652|NCT04008797|EXPERIMENTAL|Dose Expansion Part: EC Subpart: E7386 + Lenvatinib|Participants with endometrial cancer (EC) will receive E7386, BID in combination with lenvatinib 14 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
61960098|NCT04819568|EXPERIMENTAL|Terlipressin Bolus Arm|
61960099|NCT04819568|ACTIVE_COMPARATOR|Terlipressin Continuous Infusion Arm|
61960100|NCT02100085||Observational group|Subjects in the period less than 48 weeks after the final administration of GX-188E
61960101|NCT04764903||LUTS/Nocturia|Patients with LUTS / Nocturia
62347311|NCT02147496|EXPERIMENTAL|Tropical Punch|Dietary treatment: fruit-flavoured beverage
62347312|NCT02147496|EXPERIMENTAL|Water|Dietary treatment: calorie-free control
62505185|NCT00973934|ACTIVE_COMPARATOR|Right Unilateral Electroconvulsive Therapy|
62505186|NCT00067717|EXPERIMENTAL|Distant Healing|This group received distant healing but was blinded to the condition.
62505187|NCT00067717|PLACEBO_COMPARATOR|Non-blinded Distant Healing|This group received the distant healing intervention and was called every day they were receiving to be told they were receiving it, therefore enhancing expectancy.
62505188|NCT00067717|NO_INTERVENTION|Blinded Control|This group was blinded to the intervention condition and did not receive any distant healing.
62505189|NCT05536908|EXPERIMENTAL|resWET|Residential Written Exposure Therapy (resWET): Treatment as Usual (TAU) plus 5-individual Written Exposure Therapy (WET) sessions (40-60 min each; Marx \& Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
62703653|NCT04008797|EXPERIMENTAL|Dose Optimization Part: EC Participants|Participants with EC will be randomized to receive 2 different doses of E7386 in combination with lenvatinib capsule or lenvatinib capsule monotherapy in 28-days cycles, or treatment of physician's choice (TPC; doxorubicin in 21-day cycles or paclitaxel in 28-day cycles \[3 weeks on/1 week off\]), until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
62703654|NCT04821154||1) Revision Splined CCK|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, constrained condylar knee (CCK) articular surface, Persona Revision femoral component, and splined femoral stem.
62703655|NCT04821154||2) Revision Cemented CCK|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
61960102|NCT03118115|EXPERIMENTAL|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
61960103|NCT02164825|EXPERIMENTAL|Single-shot nerve block|Efficacy compared to epidural
61960104|NCT02164825|ACTIVE_COMPARATOR|Continuous epidural|Continuous epidural perfusion
61960105|NCT04394286|EXPERIMENTAL|Cohort 1|Cohort 1 participants will receive a single intravenous (IV) infusion of SHP648 on the day of dosing (Day 0).
61960106|NCT04394286|EXPERIMENTAL|Cohort 2|Cohort 2 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 1 on the day of dosing (Day 0).
61960107|NCT04394286|EXPERIMENTAL|Cohort 3|Cohort 3 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 2 on the day of dosing (Day 0).
61960108|NCT06255106||Group 1|Group 1, consisting of individuals treated with a cast
61960109|NCT06255106||Group 2|Group 2, comprising those who underwent surgical intervention (Open reduction volar plate fixation.
61960110|NCT05878145|EXPERIMENTAL|Intervention group|A 20-session structured rehabilitation exercise program in those with spinal cord injuries
61960111|NCT05878145|NO_INTERVENTION|Control group|No exercise intervention in those with spinal cord injuries
61960112|NCT04904562|ACTIVE_COMPARATOR|Treatment|Angiotensin II administered as an intravenous (IV) infusion will be increased every 5 minutes by 5-10ng/kg/min increments up to 80ng/kg/min
61960113|NCT04904562|PLACEBO_COMPARATOR|Control|Intravenous (IV) infusion (saline)
62347313|NCT00698061|EXPERIMENTAL|Group A|
62347314|NCT00698061|ACTIVE_COMPARATOR|Group B|
62347315|NCT06454851|EXPERIMENTAL|VR Intervention group|Participants in the intervention condition will be required to complete a 4-session gamified prosocial VR intervention program, one session a week for four consecutive weeks, each session lasts around 15-20 minutes.
62347316|NCT06454851|SHAM_COMPARATOR|Waitlist control group|Participants in the waitlist condition will be asked to continue their usual activity routines before their turn to receive the intervention.
62347317|NCT00583440|EXPERIMENTAL|1|
62703656|NCT04821154||3) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, posterior stabilized/constrained posterior stabilized (PS/CPS) articular surface, Persona Revision femoral component, and splined femoral stem.
62703657|NCT04821154||4) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
62703658|NCT04821154||5) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
62703659|NCT04821154||6) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
61960114|NCT04015336|EXPERIMENTAL|Arm 1-3x10^10 E7 T-Cell Receptor (TCR) T cells|Up to 3x10\^10 E7 T-Cell Receptor (TCR) T cells (based on the number of cells that can be generated in the shortened manufacturing process) will be administered intravenously over 20 to 30 minutes on day 0.
61960115|NCT03727529|EXPERIMENTAL|Intervention group|
61960116|NCT03727529|ACTIVE_COMPARATOR|Control group|
61960117|NCT02780310|EXPERIMENTAL|Lenvatinib|All eligible patients will receive a starting lenvatinib dose of 24 mg daily taken orally for each 4-week cycle. Patients may remain on study until progression of disease or unacceptable toxicity. Alternatively, Lenvatinib may be dissolved in fluid per the Food and Drug Administration (FDA) label and administered orally or via a feeding tube.
61960118|NCT01830270|EXPERIMENTAL|PET regimen|
61960119|NCT03723941|EXPERIMENTAL|A - adjuvant therapy|adjuvant therapy with four cycles of cisplatin plus etoposide +/- mitotane according to investigator's preference versus
61960120|NCT03723941|OTHER|B - observation or mitotane alone|observation or mitotane alone according to the investigator's preference
62143418|NCT05537532|EXPERIMENTAL|Competition group|"Programs with at least five interns were grouped into program-based teams. Interns within the same residency institution in programs that did not meet this criterion were grouped into institution-based teams, with a minimum of five participants per team.~For each week, an eligible team is randomized to either a steps competition or non-competition group with 50/50 chance. For those randomized to competition arm, teams were assigned an opponent team by total randomization, by which the opponent team was assigned regardless of institution and specialty."
62143419|NCT05537532|EXPERIMENTAL|Non-competition group|For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance.
62143420|NCT01209195|EXPERIMENTAL|MM-121 + Paclitaxel|Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW
61960121|NCT06072846|EXPERIMENTAL|enterprise group|Reiki therapy will be applied to the initiative group. Evaluation will be carried out with pre-test and post-test
62143421|NCT03261466|ACTIVE_COMPARATOR|Active group Bifidobacterium breve BR03 and B632|This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
62143422|NCT03261466|PLACEBO_COMPARATOR|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
62143423|NCT00022672|EXPERIMENTAL|trastuzumab + anastrozole|Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
62143424|NCT00022672|ACTIVE_COMPARATOR|anastrozole|1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
62347318|NCT00583440|ACTIVE_COMPARATOR|2|
62347319|NCT04198896||CAD-only|patients with diagnosed coronary artery diseases (CAD) without any other atherosclerotic cardiovascuar diseases at the entry of SHIP
62703660|NCT04821154||7) Revision Cemented CCK with 5 Degree Primary Tibia|Patients who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
62703661|NCT04821154||8) Primary Splined CCK/CPS/PS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and splined femoral stem.
61960122|NCT06072846|NO_INTERVENTION|Control group|The control group will not be interfered with. The control group will not be interfered with and will only be evaluated by pre-test and post-test by monitoring.
61960123|NCT01958333|EXPERIMENTAL|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
61960124|NCT01958333|EXPERIMENTAL|Exercise 2|Medium-intensity, medium-volume cardiorespiratory exercise and strength training
61960125|NCT01958333|EXPERIMENTAL|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
61960126|NCT00675493||A|
61960127|NCT01546207|OTHER|catheter-based ablation|catheter ablation - a medical procedure used to treat some types of arrhythmia
62703662|NCT04821154||9) Primary Cemented CCK/PS/CPS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
61960128|NCT01090986||1|Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV. Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
61960129|NCT02784275|EXPERIMENTAL|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
61960130|NCT02784275|EXPERIMENTAL|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
61960131|NCT02784275|EXPERIMENTAL|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
61960132|NCT02784275|PLACEBO_COMPARATOR|Dose D|Placebo
61960133|NCT01666782|EXPERIMENTAL|High-Dose Influenza Vaccine|
61960134|NCT01666782|ACTIVE_COMPARATOR|Standard Trivalent Influenza Vaccine|
61960135|NCT06260085|NO_INTERVENTION|Control|After the condition of the patients in the control group was stable, the pre-test was administered, then the patient was given routine information (Your mother/father/daughter/son/... is at the door, is there anything you want to tell them? I can convey and give feedback.). After the information, two more tests were administered at 15 and 30 minutes.
61960136|NCT06260085|EXPERIMENTAL|İntervention|In this randomised, controlled, experimental study, patients were randomised into intervention and control groups according to gender and age groups. In the preliminary interviews with the family members of the patients in the intervention group, the message content was discussed with the relatives of the patients before the voice recording was taken and carefully prepared to prevent negative effects. After the patient's condition was stable, the pretest was administered 15 minutes before (T1) the voice recording of the patient's relative was played through the music pillow.After the application, two more tests were applied at 15 (T2) and 30 (T3) minutes.
61960137|NCT03192111|EXPERIMENTAL|Mild Renal Impairment|Subjects with mild renal impairment
61960138|NCT03192111|EXPERIMENTAL|Moderate Renal Impairment|Subjects with moderate renal impairment
61960139|NCT03192111|EXPERIMENTAL|Severe Renal Impairment|Subjects with severe renal impairment
61960140|NCT03192111|EXPERIMENTAL|Healthy Subjects|Healthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
61960141|NCT00923338|EXPERIMENTAL|Vesico-vaginal fistula plug|Vesico-vaginal fistula plug
61960142|NCT01484847|EXPERIMENTAL|PF-00299804|Patients with locally advanced head and neck squamous cell carcinoma will be treated with a single dose (45mg) of PF-00299804 via G-Tube on an empty stomach
61960143|NCT02289417|EXPERIMENTAL|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks:~* Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)~* Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
61960144|NCT02289417|EXPERIMENTAL|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
62143425|NCT03690557|EXPERIMENTAL|IncentaHealth|All patients who decide to join the weight loss program will be enrolled in the commercially-available IncentaHealth program - a comprehensive, evidence-based, behavioral weight management program designed to help patients initiate and maintain weight loss. The program is delivered completely online, via website, emails, mobile app, and (if requested by the participant) text messaging over 12 months. Each participant will be given a digital scale that wirelessly syncs with a smartphone app. Participants' weights are automatically uploaded to the Incentahealth online portal. In the informed consent process, participants will need to agree to release their weight data to researchers at the University of Nebraska Medical Center in order to participate in this program.
62143426|NCT02727634|OTHER|Postoperative elective CABG patients|Patients included for coronary artery bypass graft (CABG) surgery, secondary to ischaemic heart disease.
62703663|NCT04821154||10) Primary Cemented CCK/PS/CPS with 5 Degree Primary Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
61960145|NCT02289417|PLACEBO_COMPARATOR|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)~After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
61960146|NCT05061732|EXPERIMENTAL|RBCL|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levofloxacin 0.5 g qd for 14 days
61960147|NCT05061732|EXPERIMENTAL|RBLM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levofloxacin 0.5 g bid for 14 days
62703664|NCT04821154||11) Infection Cases|Any configuration of PRK components used for end stage (non-temporary) treatment
61960148|NCT05061732|EXPERIMENTAL|RBCM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
61960149|NCT05061732|EXPERIMENTAL|RA|Rabeprazole 20 mg bid, and Amoxicillin 1.0 g tid for 14 days
61960150|NCT05061732|EXPERIMENTAL|RAB|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, and Amoxicillin 1.0 g tid for 14 days
61960151|NCT05061732|EXPERIMENTAL|RAM|Rabeprazole 20 mg bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
62143427|NCT02966652|ACTIVE_COMPARATOR|Testosterone undecanoate|Cohort 1: single dose of 120 mg (3 x 40 mg) DITEST followed by a single dose of 80 mg (2 x 40 mg) testosterone undecanoate or a single dose of 80 mg (2 x 40 mg) testosterone undecanoate followed by single dose of 120 mg (3 x 40 mg) DITEST. The two treatments are separated by a minimum of a 7-day washout period, with both treatments given in the fed state.
62347320|NCT04198896||CAD with poly-arterial diseases|patients with diagnosed coronary artery diseases (CAD) with other atherosclerotic cardiovascuar diseases such as any of aortic and/or peripheral artery diseases at the entry of SHIP
62505190|NCT05536908|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive substance use disorder (SUD) residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with Post-traumatic Stress Disorder (PTSD) are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
62505191|NCT00004241|EXPERIMENTAL|Schedule B (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62505192|NCT00004241|EXPERIMENTAL|Schedule C (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62703665|NCT03866382|EXPERIMENTAL|Treatment (cabozantinib, nivolumab, ipilimumab)|Patients receive cabozantinib PO QD on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography during screening and undergo CT or MRI, bone scan and blood and urine sample collection throughout the trial and may undergo PET/CT throughout the trial.
62703666|NCT06335303|EXPERIMENTAL|BI 1819479 low dose treatment group|
62703667|NCT06335303|EXPERIMENTAL|BI 1819479 medium dose treatment group|
62703668|NCT06335303|EXPERIMENTAL|BI 1819479 high dose treatment group|
62703669|NCT06335303|PLACEBO_COMPARATOR|Placebo group|
62703670|NCT05669755|EXPERIMENTAL|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 milligrams (mg) cagrilintide and 2.4 mg semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks.
62703671|NCT05669755|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks.
62703672|NCT05534971|ACTIVE_COMPARATOR|Standard technique|The conventional hollow bore needle on a syringe will be used
62703673|NCT05534971|EXPERIMENTAL|Peripheral IV|A peripheral intravenous catheter will be used to obtain initial central venous access
61960152|NCT05061732|EXPERIMENTAL|RBAM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
61960153|NCT05061732|EXPERIMENTAL|RBAM4|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g tid for 14 days
61960154|NCT05061732|EXPERIMENTAL|RBDM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
61960155|NCT05061732|ACTIVE_COMPARATOR|RBTM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and tetracycline 0.5 g qid for 14 days
61960156|NCT05650905||subjects previously infected with COVID-19|subjects previously infected with COVID-19
61960157|NCT05650905||subjects with long COVID-19|subjects with long COVID-19 according to the WHO-guideline
61960158|NCT05650905||healthy age-and sex- matched control subjects with no history of COVID-19 infection|healthy age-and sex- matched control subjects with no history of COVID-19 infection
62143428|NCT02966652|EXPERIMENTAL|DITEST|Cohort 2: single dose of 200 mg (5 x 40 mg) DITEST (fed) followed by a single dose of 200 mg DITEST (fasted) or a single dose of 200 mg DITEST (fasted) followed by single dose of 200 mg (5 x 40 mg) DITEST (fed). The two treatments are separated by a minimum of a 7-day washout period.
62347321|NCT01978158|EXPERIMENTAL|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
62347322|NCT01978158|EXPERIMENTAL|Hyperoxia|Subjects will be breathing 100% of oxygen
62347323|NCT01978158|ACTIVE_COMPARATOR|Normoxia|Subjects wil be breathing room air (21%)
62347324|NCT02816125|ACTIVE_COMPARATOR|Habitual supplemented|habitual diet with 1.2 g EPA+DHA in capsule form/day.
62347325|NCT02816125|EXPERIMENTAL|Low-fat supplemented|Reduce dietary fat to less than 20% energy, add 1.2 g EPA+DHA in capsule form/day.
62347326|NCT03541655|ACTIVE_COMPARATOR|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
62505193|NCT06678165|EXPERIMENTAL|The intervention group will receive YOLT-204 on day0|
62505194|NCT03858127||Male infants born <32 weeks gestation|
62505195|NCT04980456|OTHER|TOTAL30, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses as randomized. Each study product will be worn bilaterally (in both eyes) for approximately 30 days for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.
62505196|NCT04980456|OTHER|Biofinity, then TOTAL30|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each study product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.
62703674|NCT03321643|EXPERIMENTAL|Treatment (rituximab, gemcitabine, oxaliplatin, atezolizumab)|"INDUCTION PHASE: Patients receive rituximab IV, gemcitabine IV, and oxaliplatin IV every 2 weeks. Starting cycle 2, patients also receive atezolizumab IV over 30-60 minutes every 2 weeks. Treatment repeats every 14 days of cycle 1 and every 28 days for up to 4 cycles in the absence of disease progression or unaccepted toxicity. Patients also undergo CT, PET-CT, MRI, bone marrow biopsy, collection of blood samples, and tumor biopsy throughout induction phase.~MAINTENANCE PHASE: Patients receive rituximab IV and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unaccepted toxicity. Patients also undergo CT, PET-CT, MRI, bone marrow biopsy, and collection of blood samples throughout maintenance phase."
62703675|NCT03155620|EXPERIMENTAL|Subprotcol M (HRAS gene alterations)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
62505197|NCT00089076|EXPERIMENTAL|Treatment (ipilimumab)|"PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive MDX-010 as in phase I at the MTD."
62505198|NCT03129230|EXPERIMENTAL|Free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck.
62505199|NCT01617616||Normal tilt test|Patients with normal tilt table testing (they may have symptoms which precipitated the tilt, but in the end did not qualify as POTS, NMH, ETC.)
62505200|NCT01617616||confirmed POTS diagnosis|after review of tilt table results, this group will be the confirmed postural orthostatic tachycardic syndrome group patient
62143429|NCT05656066|EXPERIMENTAL|The Vibration Intervention Group (VI)|After the injection area was determined in the VI group, the vibration device was held for 30 seconds in the area to be injected, then the injection was applied by pulling up 3 cm while the device was operating.
62143430|NCT05656066|EXPERIMENTAL|The Pressure Intervention Group|After the injection area was determined in the PI group, 30 seconds light pressure was applied with the thumb and then the injection was given
62703676|NCT03155620|EXPERIMENTAL|Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)|Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib sulfate PO or via nasogastric- or gastric-tube BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62703677|NCT03155620|EXPERIMENTAL|Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)|Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
62703678|NCT03155620|EXPERIMENTAL|Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)|Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62703679|NCT03155620|EXPERIMENTAL|Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)|Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62703680|NCT03155620|EXPERIMENTAL|Subprotocol E (activating MAPK pathway gene mutation)|Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62143431|NCT05656066|NO_INTERVENTION|The Control Group|The routine IM injection was applied to the children in the control group.
62143432|NCT03120026|EXPERIMENTAL|Experimental Product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
62505201|NCT01617616||Neurocardiogenic syncope on tilt|This group is comprised of patients with confirmed diagnosis of neurocardiogenic syncope on tilt
62505202|NCT01617616||Neurally-mediated hypotension|Patients with confirmed diagnosis neurally mediated hypotension
62505203|NCT05429489|EXPERIMENTAL|Bilevel erector spinae plane block|Bilevel erector spinae block at 3rd and 5th thoracic vertebral levels
62505204|NCT05429489|EXPERIMENTAL|Single level erector spinae plane block|single level erector spinae plane block at 5th thoracic vertebral levels
62143433|NCT03120026|PLACEBO_COMPARATOR|Isocaloric Placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
62505205|NCT05429489|ACTIVE_COMPARATOR|Intravenous morphine|Intravenous morphine 0.1 mg/ kg
62505206|NCT05457634|EXPERIMENTAL|blu Disposable Flavor A|
62505207|NCT05457634|EXPERIMENTAL|blu Disposable Flavor B|
62505208|NCT05457634|EXPERIMENTAL|blu Disposable Flavor C|
62505209|NCT05457634|EXPERIMENTAL|blu Disposable Flavor D|
62505210|NCT05457634|EXPERIMENTAL|blu Disposable Flavor E|
62505211|NCT05457634|ACTIVE_COMPARATOR|Combustible cigarette|
62505212|NCT06267872|EXPERIMENTAL|Part A - Group 1|• 60 mcg of CD4BS CH505M5 Pr-NP1, to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4.
62703681|NCT03155620|EXPERIMENTAL|Subprotocol F (ALK or ROS1 gene alteration)|Patients with an ALK or ROS1 gene alteration receive ensartinib PO BID on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
62703682|NCT03155620|EXPERIMENTAL|Subprotocol G (BRAF V600 gene mutation)|Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
61960159|NCT05329701|EXPERIMENTAL|Individualized treatment duration|"Antibiotic treatment will be discontinued when both of the following two criteria are fulfilled:~1. The infant has had 24 hours without clinical symptoms of infection, after systematic clinical evaluation by a neonatologist. Clinical symptoms specified in Table 1.~2. CRP is \< 30 mg/l. If CRP is \> 30 at the time when the infant has been symptom-free for 24 hours, CRP will be assessed once every 24 -48 hours and antibiotics will be stopped when CRP \< 30."
61960160|NCT05329701|NO_INTERVENTION|Standard treatment duration|Standard treatment duration is seven days.
62505213|NCT06267872|EXPERIMENTAL|Part B - Group 2|"* 60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 1.0 mg of ACU-026-001-1 adjuvant to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~* Followed by 300 mcg of CH505TF chTrimer, admixed with 1.0 mcg of ACU-026-001-1 adjuvant to be administered at months 6 and 8."
62505214|NCT06267872|EXPERIMENTAL|Part B - Group 3|"* 60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 2.0 mg of ACU-026-001-1 adjuvant to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~* Followed by 300 mcg of CH505TF chTrimer, admixed with 2.0 mg of ACU-026-001-1 adjuvant to be administered at months 6 and 8."
62505215|NCT06267872|EXPERIMENTAL|Part B - Group 4|"* 60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~* Followed by 300 mcg of CH505TF chTrimer, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered to be administered at months 6 and 8."
62505216|NCT06267872|EXPERIMENTAL|Part C - Group 5|"Low dose:~* 100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 1.0 mg of ACU-026-001-1 adjuvant to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4,~* Followed by 300 mcg of CH505TF chTrimer, admixed with 1mg empty LNP adjuvant to be administered at months 6 and 8.~OR,~High Dose:~* 100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 2.0 mg of ACU-026-001-01 adjuvant to be administered as two 0.5 mL doses intramuscularly at month 0, 2, and 4,~* Followed by 300 mcg of CH505TF chTrimer, admixed with 2.0 mg of ACU-026-001-1 adjuvant to be administered at months 6 and 8."
62703683|NCT03155620|EXPERIMENTAL|Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)|Patients deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62703684|NCT03155620|EXPERIMENTAL|Subprotocol I (Rb positive, alterations in cell cycle genes)|Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62703685|NCT03155620|EXPERIMENTAL|Subprotocol J (MAPK pathway mutations)|Patients with MAPK pathway mutations receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62703686|NCT03155620|EXPERIMENTAL|Subprotocol N (activating RET mutations)|Patients with activating RET gene alterations receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
62703687|NCT06579872||Case group|Patients diagnosed with pre-COPD or COPD.
61960161|NCT03009981|ACTIVE_COMPARATOR|Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide|Patients will receive degarelix OR leuprolide with bicalutamide.
61960162|NCT03009981|EXPERIMENTAL|Arm B: Degarelix/Apalutamide|Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
61960163|NCT03009981|EXPERIMENTAL|Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone|Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
62703688|NCT06579872||Control group|Healthy individuals without cardiopulmonary disease.
62703689|NCT04128566|EXPERIMENTAL|Group 1: healthy subjects aged between 20 and 30 years|healthy subjects aged between 20 and 30 years
62703690|NCT04128566|EXPERIMENTAL|Group 2: previous ACL injury aged between 20 and 30 years|subjects with previous Anterior cruciate Ligament (ACL) injury aged between 20 and 30 years
62703691|NCT04128566|EXPERIMENTAL|Group 3: healthy subjects aged between 40 and 60 years|healthy subjects aged between 40 and 60 years
62703692|NCT04128566|EXPERIMENTAL|previous ACL injury aged between 40 and 60 years|subjects with previous ACL injury aged between 40 and 60 years
62703693|NCT06359782|EXPERIMENTAL|C1-esterase inhibitor (Cinryze)|One group receiving study medication (C1-esterase inhibitor Cinryze)
62703694|NCT06359782|PLACEBO_COMPARATOR|Placebo|One group receiving placebo medication
62703695|NCT04111458|EXPERIMENTAL|BI 1701963 monotherapy|
62703696|NCT04111458|EXPERIMENTAL|BI 1701963 + Trametinib|
61960164|NCT04178486|EXPERIMENTAL|Amnesia|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions to experience amnesia for the food pictures they had just seen.
62143434|NCT04909333|EXPERIMENTAL|Group A (EHH Patients)|Group A will receive a placebo injection (0.9% saline solution) on Day 1 and 10μg Exenatide injection on Day 2.
62143435|NCT04909333|EXPERIMENTAL|Group B (EHH Patients)|Group B will receive a 10μg Exenatide injection on Day 1 and placebo injection (0.9% saline solution) on Day 2.
62347327|NCT03541655|EXPERIMENTAL|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
62703697|NCT06569303|EXPERIMENTAL|Intervention|Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic \& Advanced Parent Training Program. It consists of twelve (12) 2-hour online workshops led by a certified peer coach in the Incredible Years Parent Training Series.
62703698|NCT06569303|OTHER|Control|Parents assigned to the control arm will be emailed and mailed written parent education materials from the American Academy of Pediatrics called the Bright Futures handouts. The control group is offered the Incredible Years® School Age Basic \& Advanced Parent Training Program after a 3-month wait list period.
62703699|NCT06173375|EXPERIMENTAL|Mailed Cologuard Outreach|Receipt of mailed Cologuard test for colorectal cancer screening to be completed and returned by participant. If test is negative, participant will be advised to undergo another test in 3 years. If test is positive, participant will be advised to schedule colonoscopy for further testing.
62703700|NCT06173375|ACTIVE_COMPARATOR|Mailed Fecal immunochemical test Outreach|Receipt of mailed FIT for colorectal cancer screening to be completed and returned by participant. If test is negative, participant will be advised to undergo another test in 1 year. If test is positive, participant will be advised to schedule colonoscopy for further testing.
62703701|NCT04896073|EXPERIMENTAL|1/Minnelide|Minnelide 2mg Days 1-21 of 28 day cycle (x12)
61960165|NCT04178486|EXPERIMENTAL|Cognitive Rehearsal|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a future where they will control their eating behaviors.
62703702|NCT04844606|EXPERIMENTAL|Mirikizumab Dose 1 for UC|"Dose 1 of Mirikizumab is administered subcutaneously (SC)~Dosing is based on the participant's weight."
62703703|NCT04844606|EXPERIMENTAL|Mirikizumab Dose 2 for UC|"Dose 2 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
62703704|NCT04844606|EXPERIMENTAL|Mirikizumab Dose 3 for UC|"Dose 3 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
62703705|NCT04844606|EXPERIMENTAL|Mirikizumab Dose 4 for CD|"Dose 4 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
62143436|NCT04909333|EXPERIMENTAL|Group C (control subjects)|Control subjects without evidence for EHH defined by no glucose levels below 3.0 mmol/l during a 7-day CGFS (Freestyle libre) and matched to EHH patients for age, gender and BMI will receive only on one study day a single intravenous injection of 10μg Exenatide and compared to group A patients on Day 2. They will not receive a Placebo injection.
62703706|NCT04844606|EXPERIMENTAL|Mirikizumab Dose 5 for CD|"Dose 5 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
61960166|NCT04178486|EXPERIMENTAL|Memory Substitution|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a past where they have always controlled their eating behaviors.
61960167|NCT04178486|PLACEBO_COMPARATOR|Control|Hypnosis formed from only hypnotic induction (an adapted version from Barber Suggestibility Scale).
61960168|NCT02872194|EXPERIMENTAL|Suncare agent A + control|Application of control and test product into one of the subjects two eyes.
61960169|NCT02872194|EXPERIMENTAL|Suncare agent B + control|Application of control and test product into one of the subjects two eyes.
61960170|NCT02872194|EXPERIMENTAL|Suncare agent C + control|Application of control and test product into one of the subjects two eyes.
62347328|NCT02623595|EXPERIMENTAL|SBRT+GM-CSF|Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in a cycle of 21 days.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
61960171|NCT01051323||1|
61960172|NCT05570500|PLACEBO_COMPARATOR|Control group, conventional oral health education group|
61960173|NCT05570500|ACTIVE_COMPARATOR|Comparison group, online oral health education group|
61960174|NCT02854631|EXPERIMENTAL|Selonsertib + Prednisolone|Selonsertib + prednisolone for 28 days
61960175|NCT02854631|PLACEBO_COMPARATOR|Prednisolone|Selonsertib placebo + prednisolone for 28 days
62143437|NCT04405310|EXPERIMENTAL|EXP-PC-F2|Patients with Pneumonia due to SARS-COV-2 phase 2 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
62347329|NCT04409652|PLACEBO_COMPARATOR|Control group|The endotracheal extubation is performed in head on bed without pillow.
62347330|NCT04409652|ACTIVE_COMPARATOR|Head elevation group|The endotracheal extubation is performed in head elevation on pillow (slight flextion of neck on chest) .
62703707|NCT04844606|EXPERIMENTAL|Mirikizumab Dose 6 for CD|"Dose 6 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
62703708|NCT04844606|EXPERIMENTAL|Mirikizumab Dose 7 for UC or CD|Intravenous (IV) rescue dosing, if response is lost.
62703709|NCT04936542|OTHER|Sequence 1|Participants will receive one cycle of aboBoNT-A followed by one cycle of onaBoNT-A in the selected overactive upper limb muscles
62703710|NCT04936542|OTHER|Sequence 2|Participants will receive one cycle of onaBoNT-A followed by one cycle of aboBoNT-A in the selected overactive upper limb muscles
62703711|NCT00001160||thyroid cancer|Patients with thyroid cancer
62703712|NCT00001160||thyroid nodules|Patients with thyroid nodules
62703713|NCT00943514||1|chronic or recurring respiratory infections including pulmonary nontuberculous mycobacterial disease
62703714|NCT00943514||2|Relatives
62703715|NCT00410241||A1|Self-referred individuals 45-65 at enrollment, 25% of whom had coronary artery disease
62703716|NCT00410241||A2|Individuals 45-65 at enrollment who self-identified as African, African-American, or Afro-Caribbean
62703717|NCT00410241||A3|Adults aged 18-65 at the time of enrollment, including subjects of both sexes, who have been identified as likely to return for follow up
62703718|NCT00410241||B|Family members of Group A1, A2, or A3
62703719|NCT04214990|ACTIVE_COMPARATOR|Aspirin|Enteric coated aspirin
62703720|NCT04214990|PLACEBO_COMPARATOR|Placebo|Enteric coated aspirin placebo
62703721|NCT05666713|EXPERIMENTAL|Treatment|Patients undergoing TAVR with BASILICA using the Transmural TELLTALE guidewire system for bioprosthetic aortic valve failure or native aortic stenosis ( on label TAVR)
62703722|NCT01676805||1|Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy
62703723|NCT01676805||2|Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy
62505217|NCT06267872|EXPERIMENTAL|Part C - Group 6|"* 100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 3 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4,~* Followed by 300 mcg of CH505TF chTrimer, admixed with 3 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered to be administered at months 6 and 8."
62505218|NCT06267872|EXPERIMENTAL|Part C - Group 7|"* 100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~* Followed by 300 mcg of CH505TF chTrimer, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered to be administered at months 6 and 8."
62505219|NCT06596499||CH-VAD|All patients implanted with the CH-VAD as the primary device
62505220|NCT04283370|EXPERIMENTAL|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
62505221|NCT04283370|ACTIVE_COMPARATOR|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
62505222|NCT01110044|EXPERIMENTAL|Group A|Subjects will be administered 251154 vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
62505223|NCT01110044|ACTIVE_COMPARATOR|Group B|Subjects will be administered no vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
62505224|NCT02374203|EXPERIMENTAL|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
62505225|NCT01148524|OTHER|rMenB06|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 6 months) and placebo (at 1 and 2 months) in V72P10 study had a blood draw.
61960176|NCT06140992||Site-Specific Therapy Group|These patients with cancer of unknown primary received site-specific therapy that matched the particular site predicted by the DNA methylation classifier.
61960177|NCT06140992||Empirical Therapy Group|These patients with cancer of unknown primary received empirical therapy that didn't match the particular site predicted by the DNA methylation classifier.
62505226|NCT01148524|OTHER|rMenB0|Subjects who had received 1 dose of rMenB+OMV-NZ (at 0 month) and 3 doses of placebo (at 1, 2 and 6 months) in V72P10 study had a blood draw.
61960178|NCT05166824|EXPERIMENTAL|Surgical- abdominoplasty|Subjects enrolled in the surgical arm were treated with the device being placed in contact with the skin on the abdomen. The hand piece, number of passes and parameters used for the treatment were determined by the Investigator.
62143438|NCT04405310|PLACEBO_COMPARATOR|EXP-NONPC-F2|20 Patients with Pneumonia due to SARS-COV-2 phase 2 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
61960179|NCT05166824|EXPERIMENTAL|Women's Health|Subjects enrolled in the women's health were treated with the device in the vaginal and perineal area.
62347331|NCT01835613|OTHER|Tocilizumab|"Biomarkers Measures~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
62505227|NCT01148524|OTHER|rMenB016|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 6 months) and 1 dose of placebo (at 2 months) in V72P10 study had a blood draw.
62505228|NCT01148524|OTHER|rMenB01|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 1 month) and placebo (at 2 and 6 months) in V72P10 study had a blood draw.
62505229|NCT01148524|OTHER|rMenB026|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 2 and 6 months) and 1 dose of placebo (at 1 month) in V72P10 study had a blood draw.
62505230|NCT01148524|OTHER|rMenB02|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 2 months) and placebo (at 1 and 6 months) in V72P10 study had a blood draw.
62505231|NCT01148524|OTHER|rMenB012|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 2 months) and 1 dose of placebo (at 6 months) in V72P10 study had a blood draw.
62505232|NCT01148524|OTHER|rMenB6|Subjects who had received 1 dose of rMenB+OMV-NZ (at 6 months) and 3 doses of placebo (at 0, 1 and 2 months) in V72P10 study had a blood draw.
62703724|NCT00001316||Individuals with HIV|Individuals with HIV
61960180|NCT05166824|EXPERIMENTAL|Skin Rejuvenation|The hand piece, applicator or tip was placed in contact with the skin. The entire defined treatment area was treated by delivering energy to the skin. The hand piece, number of passes and parameters used for the treatment was determined by the Investigator.
61960181|NCT05166824|EXPERIMENTAL|Surgical- blepharoplasty|Subjects enrolled in the surgical arm were treated with the device being placed in contact with the skin on the eyelids. The hand piece, number of passes and parameters used for the treatment were determined by the Investigator.
61960182|NCT02034201|ACTIVE_COMPARATOR|Lisdexamfetamine|Lisdexamfetamine will be admistered at 140 mg orally daily through week 6 of the protocol.
61960183|NCT02034201|PLACEBO_COMPARATOR|Placebo|Placebo will be administered orally daily through week 6 of the protocol.
61960184|NCT02974517||Time-lapse-Auto|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by KID Score system.
61960185|NCT02974517||Time-lapse-Manual|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by embryologist.
61960186|NCT02974517||Conventional Group|All embryos are cultured in our daily used incubators; embryo scores are evaluated on day 3 by embryologist.
62143439|NCT04405310|EXPERIMENTAL|EXP-PC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
62143440|NCT04405310|PLACEBO_COMPARATOR|EXP-NONPC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
62143441|NCT03846037|PLACEBO_COMPARATOR|Ground|Participants in this group perform protocol exercises on a stable surface.
62143442|NCT03846037|EXPERIMENTAL|vibrating platform|Participants in this group perform protocol exercises on a vibrating platform.
62143443|NCT06700161||Control group|Healthy group
62505233|NCT01148524|OTHER|Naive|An additional study group of naïve subjects that served as a baseline comparator for assessing antibody persistence in the vaccine groups and had blood draw for serological analyses at the time of enrollment.
62703725|NCT00001316||Individuals without HIV|Individuals without HIV
62703726|NCT06493422|EXPERIMENTAL|Reaching task|Mild cognitive impairment participants will make decisions while moving
62703727|NCT06493422|ACTIVE_COMPARATOR|Reaching Task|Age-match control participants will make decision while moving
62703728|NCT04929041|EXPERIMENTAL|Arm A (immunotherapy, +/- chemotherapy)|Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
62703729|NCT04929041|EXPERIMENTAL|Arm B (immunotherapy, +/- chemotherapy, radiation therapy)|Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
62703730|NCT03606642|EXPERIMENTAL|PCI with 30 day DAPT Therapy|Single group of patients undergoing IVUS stent placement for PCI with 30 day DAPT therapy regimen. DAPT therapy consists of Aspirin (325 mg loading dose \[if applicable\] and 81 mg for maintenance dose) and P2Y12 Inhibitor (INFO ABOUT THE DRUGS)
62703731|NCT00001252||healthy volunteer|Normal/healthy volunteers
62703732|NCT00001252||Impaired volunteer|volunteers with impairments of the neuromusculoskeletal system.
62703733|NCT04870788|EXPERIMENTAL|Group I (mindfulness program)|Patients and their partners participate together in mindfulness program over 60 minutes consisting of meeting with a mindfulness coach to build awareness of thoughts, emotions, feelings, and sensations QW for 4 weeks.
62703734|NCT04870788|EXPERIMENTAL|Group II (mindfulness program)|Patients and their partners participate separately in mindfulness program over 60 minutes consisting of meeting with a mindfulness coach to build awareness of thoughts, emotions, feelings, and sensations QW for 4 weeks.
62703735|NCT01231932||Cancer survivors|Individuals recently completed primary treatment for cancer
62505234|NCT05700396|EXPERIMENTAL|Breast Cancer Survivor Education Program|"Participants will complete study procedures as outlined:~- 6 weekly sessions of a modified version of the PAVING the Path to Wellness education program."
62505235|NCT01770002|ACTIVE_COMPARATOR|Everted suture technique|Technique that everts the skin; the edges will sit up against each other in a little peak, raised above the surrounding skin.
62143444|NCT06700161||Test group|Stage III Grade C Periodontitis
62143445|NCT02261805|EXPERIMENTAL|Ganetespib and doxorubicin - Phase Ib Dose Level 1|Ganetespib 100 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
62143446|NCT02261805|EXPERIMENTAL|Ganetespib and doxorubicin - Phase Ib Dose Level 2|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
62143447|NCT02261805|EXPERIMENTAL|Ganetespib and doxorubicin - Phase II Expansion|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
62505236|NCT01770002|ACTIVE_COMPARATOR|Non-everted suture technique|Surgical wound will be approximated such that the suture line is flat relative to the surrounding skin.
62703736|NCT01231932||Individuals receiving cancer treatment|Individuals receiving cancer treatment
62703737|NCT01231932||Individuals with cancer|Individuals with cancer
62703738|NCT06303193|EXPERIMENTAL|1/Phase I - Pediatric|Escalating doses of pacritinib (cohort 1)
62703739|NCT06303193|EXPERIMENTAL|2/Phase II - Adult|Low-risk cohort (cohort 2): Initiated on pacritinib 100 mg BID. After three cycles, pacritinib dose escalated to 200 mg BID, the adult phase II recommended dose, if not in complete remission.High-risk cohort (cohort 3): Initiated on pacritnib 200 mg BID, the adult phase II recommended dose.
62703740|NCT01150721||1/PNMI|Adult patients with Pulmonary Nontuberculous Mycobacterial Infection
62703741|NCT01150721||2/Healthy Volunteers|Healthy Volunteer adults
62703742|NCT05839548|ACTIVE_COMPARATOR|2% Mepivacaine with epinephrine 1:100,000.|Brand Name: 2% Medicaine with epinephrine 1:100,000.
62703743|NCT05839548|EXPERIMENTAL|4% Articaine with epinephrine 1:100,000|Brand Name: 4% Septanest with epinephrine 1:100,000.
62703744|NCT05761366|EXPERIMENTAL|Al18F-PSMA-BCH PET/CT|Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors.（including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.）
62703745|NCT06535854|EXPERIMENTAL|ISR Cohort Prevail DCB|To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.
62703746|NCT06535854|EXPERIMENTAL|DNSV Cohort (RVD 2.0 - 2.75mm)|To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.
62703747|NCT06293339|EXPERIMENTAL|Rechallenge group|Previous CoGA phase 1 study participants who were immunised with GA2 and who did not develop blood-stage malaria during CHMI (protected)
62703748|NCT06293339|PLACEBO_COMPARATOR|Infection control group|Malaria-naïve participants who have not been previously vaccinated with GA2
62143448|NCT05500352|EXPERIMENTAL|Cardiovascular effects of slowly declining plasma glucose in type 1 diabetes|
62143449|NCT05500352|EXPERIMENTAL|Cardiovascular effects of rapidly declining plasma glucose in type 1 diabetes|
62143450|NCT05500352|EXPERIMENTAL|Cardiovascular effects of rebound hyperglycemia in type 1 diabetes|
62143451|NCT05500352|EXPERIMENTAL|Cardiovascular effects of rebound euglycemia in type 1 diabetes|
62143452|NCT05500352|EXPERIMENTAL|Cardiovascular effects of hypoglycemia in type 1 diabetes|
62143453|NCT05500352|EXPERIMENTAL|Cardiovascular effects of hypoglycemia in type 2 diabetes|
62505237|NCT05043857|EXPERIMENTAL|Adjuvant Stereotactic Pancreatic Radiotherapy|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after pancreatic tumor resection.~Stereotactic Body Radiotherapy (SBRT) is a novel radiotherapy technique consisting of highly focused irradiation with a steep dose gradient, thus allowing the delivery of ablative radiation doses and significant sparing of proximity critical structures. Higher doses per fraction allows for more intensive treatments and shorter duration of the radiation course."
62505238|NCT00500318|EXPERIMENTAL|Aclidinium|
62703749|NCT05629286||Intervention Group 1|McConnell taping first and then patella stabilizing brace applied to healty participants and patients with PFPS
62703750|NCT05629286||Intervention Group 2|first patella stabilizing brace and then applied McConnell taping to healty participants and patients with PFPS
62703751|NCT05629286||No Intervention Group|no intervention to healty participants and patients with PFPS
62703752|NCT04436835|EXPERIMENTAL|Supportive care (ART)|Patients undergo ART over 60-90 minutes once a week for up to 5 sessions.
62703753|NCT05688410|EXPERIMENTAL|Assisted Exercise and I-STOP|"Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted exercise bike). Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP)."
62703754|NCT05688410|EXPERIMENTAL|Voluntary Exercise and I-STOP|"Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP)."
62703755|NCT05688410|EXPERIMENTAL|Assisted Exercise and No I-STOP|"Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted exercise bike). Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
62703756|NCT05688410|EXPERIMENTAL|Voluntary Exercise and No I-STOP|"Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
62703757|NCT05688410|EXPERIMENTAL|No Exercise and I-STOP|"Participants randomized to receive No Exercise will not receive structured assisted or voluntary rate cycling exercise. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
61960187|NCT01977794|EXPERIMENTAL|Bisoprolol failed group|Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
62703758|NCT05688410|NO_INTERVENTION|No Exercise and No I-STOP|"Participants randomized to receive No Exercise will not receive structured assisted or voluntary rate cycling exercise. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
62703759|NCT05286801|EXPERIMENTAL|Arm B (atezolizumab, tiragolumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and tiragolumab IV over 30-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients also undergo standard imaging scans including x-rays, CT, MRI, and/or FDG PET-CT throughout the trial. Patients also undergo blood sample collection on study.
62703760|NCT05286801|EXPERIMENTAL|Part A (atezolizumab, tiragolumab)|Patients receive tiragolumab IV over 30-90 minutes on day 1 of each cycle and atezolizumab IV over 30-60 minutes on day 1 of each cycle starting in cycle 2. Treatment repeats every 21 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients undergo standard imaging scans including x-rays, CT, MRI, and/or FDG PET-CT, throughout the trial. Patients also undergo blood sample collection on study.
62703761|NCT05372367|EXPERIMENTAL|Group 1: OATP1B1/B3 inhibitor|
61960188|NCT01977794|EXPERIMENTAL|Amlodipine failed group|Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
61960189|NCT00848471|EXPERIMENTAL|1|Quark RMR calorimeter (Cosmed)
61960190|NCT00848471|ACTIVE_COMPARATOR|2|Deltatrac II (GE health Care Clinical Systems)
61960191|NCT06266169|EXPERIMENTAL|intervention|People undergoing IVF treatment with developed medical decisions support models
61960192|NCT06266169|NO_INTERVENTION|control|People undergoing IVF treatment without developed medical decisions support models
61960193|NCT05698797|EXPERIMENTAL|Experimental group 1|In this group participants received hip abductor and external rotator strengthening exercises in addition to conventional physical therapy.
61960194|NCT05698797|ACTIVE_COMPARATOR|Experimental group 2|In this group participants received proprioceptive training and conventional physical therapy.
61960195|NCT05698797|ACTIVE_COMPARATOR|Control group|In this group participants received conventional physical therapy alone.
62505239|NCT00500318|PLACEBO_COMPARATOR|Placebo|
62505240|NCT05539534|EXPERIMENTAL|Training|This is a one-arm trial. The intervention group receives a training on suicide prevention.
62505241|NCT01903564||normal|pregnant women with uncomplicated pregnancies
62505242|NCT01903564||high-risk|pregnant women with pregnancies complicated by fetal arrhythmia or the risk of fetal arrhythmia
62505243|NCT05312411|EXPERIMENTAL|UB-TT170 following SCRI-E2CAR_EGFrtv1|Following CAR T cell administration, subjects will receive a first Course of 3 escalating doses of UB-TT170 over 2 weeks followed by fixed weekly dosing for 2 weeks. If eligible, subjects may proceed to Courses 2 - 4 consisting of 7 weekly doses of UB-TT170.
62703762|NCT05372367|EXPERIMENTAL|Group 2: CYP3A4 inhibitor|
62703763|NCT05383352|EXPERIMENTAL|Sequence RT: Reference Product followed by Test Product|"Cycle 1 (Crossover Phase) Day 1: One dose Onivyde® Reference product + 5-FU/LV.~Cycle 1 (Crossover Phase) Day 15: One dose Onivyde Test product + 5-FU/LV~Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV"
61960196|NCT04853212|ACTIVE_COMPARATOR|SPA patient|Patients with SPA
62143454|NCT05500352|EXPERIMENTAL|Cardiovascular effects of hypoglycemia in healthy controls|
62703764|NCT05383352|EXPERIMENTAL|Sequence TR: Test Product followed by Reference Product|"Cycle 1 (Crossover Phase) Day 1: One dose Onivyde Test product + 5-FU/LV.~Cycle 1 (Crossover Phase) Day 15: One dose Onivyde® Reference product + 5-FU/LV.~Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV."
62505244|NCT02608424|EXPERIMENTAL|Foot Mechanical Stimulation|"Intervention: Foot Mechanical Stimulation (FMS) will be performed on enrolled patients every 72 hours (total 5 stimulation sessions) by a pressure-controlled mechanical stimulator (Gondola®, European Community (CE) marking n° 0476) .~The sites of the stimulation will be the tip of the hallux and the lower big toe first metatarsal joint plantar surface. The FMS procedure consists in the application of the patient's calibrated pressure for 6 seconds, over the selected sites. Each of the 2 cutaneous sites of both feet will be mechanically stimulated. The procedure will be automatically repeated for 4 times in every subject so that the overall time of stimulation will be approximately 2 minutes."
62703765|NCT01780142||asthmatics|Subjects with confirmed diagnosis of asthma without other lung disease followed for collection of clinical data \&amp; specimens
62703766|NCT01780142||non-asthmatic healthy volunteers|Healthy volunteers in whom asthma has been ruled out and without other lung disease followed for comparison to asthmatics
62703767|NCT04835805|EXPERIMENTAL|Belvarafenib Monotherapy|Twice daily (BID), continuous dosing.
62703768|NCT04835805|EXPERIMENTAL|Belvarafenib Plus Cobimetinib|Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.
62703769|NCT04835805|EXPERIMENTAL|Belvarafenib Plus Cobimetinib Plus Nivolumab|Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus nivolumab IV infusion every 4 weeks (Q4W) in a run-in phase followed by an expansion phase
62703770|NCT04260698|EXPERIMENTAL|omidubicel|"Omidubicel is a cryopreserved stem/progenitor cell based product comprised of:~1. Ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (cultured fraction (CF))~2. the non-cultured cell fraction of the same Cord Blood Unit (CBU) (Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. CF and NF, will be kept frozen until they are thawed and infused on the day of transplantation."
62703771|NCT00408005|EXPERIMENTAL|Group 0 Induction Therapy|All patients (T-ALL and T-LLy) receive cytarabine intrathecally (IT) on day 1; vincristine sulfate IV on days 1, 8, 15, and 22; prednisone IV or PO twice daily BID on days 1-28; pegaspargase IM (may give IV over 1 to 2 hours) on day 4, 5, or 6; daunorubicin hydrochloride IV on days 1, 8, 15 and 22; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease).
61960197|NCT04853212|SHAM_COMPARATOR|Subject without SPA|Health subjects without SPA, planned to undergo a digestive endoscopy.
61960198|NCT05423145|EXPERIMENTAL|acupressure intervention|Receives access to the acupressure intervention
61960199|NCT05423145|NO_INTERVENTION|wait list control|No access to the acupressure intervention during the study period
62143455|NCT05500352|EXPERIMENTAL|Cardiovascular effects of hyperglycemia in type 2 diabetes|
62143456|NCT05500352|EXPERIMENTAL|Cardiovascular effects of hyperglycemia in healthy controls|
62143457|NCT04275960|EXPERIMENTAL|Arm_25 + 75 mg (Fasted)|Healthy male participants receive a single dose of 25 mg selitrectinib (Period 1) and 75 mg selitrectinib (Period 2) in fasted state.
61960200|NCT01446289|EXPERIMENTAL|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
61960201|NCT01446289|PLACEBO_COMPARATOR|Placebo|Pregnant women who received one injection of saline solution.
61960202|NCT01819831|EXPERIMENTAL|Preoperative proton radiation|Patients will receive 50 Gray equivalents (GyE) in 25 fractions with proton therapy, followed by surgery 4-8 weeks after completion of radiation.
61960203|NCT00257543|EXPERIMENTAL|single arm study|this is a single arm study
62143458|NCT04275960|EXPERIMENTAL|Arm_50 + 50 mg (Fasted/Fed)|Healthy male participants receive a single dose of 50 mg selitrectinib in fasted state (Period 1) and 50 mg selitrectinib in fed state (Period 2).
62143459|NCT04275960|EXPERIMENTAL|Arm_100 + 150 mg (Fasted)|Healthy male participants receive a single dose of 100 mg selitrectinib (Period 1) and 150 mg selitrectinib (Period 2) in fasted state.
61960204|NCT01795209|EXPERIMENTAL|Ranibizumab group|Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
62143460|NCT03041155|EXPERIMENTAL|treatment|Muscle respiratory training
62143461|NCT03041155|NO_INTERVENTION|control|No intervention
62143462|NCT04730206|EXPERIMENTAL|Camostat|4 x 200 milligram per day for 7 days
62143463|NCT04730206|PLACEBO_COMPARATOR|Placebo|4 x per day for 7 days
62143464|NCT04730206|EXPERIMENTAL|Molnupiravir|2 x 800 milligram per day for 5 days
62143465|NCT00881296|EXPERIMENTAL|1|"Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks"
62505245|NCT06054477|EXPERIMENTAL|Phase 1 Dose Escalation|ALE.C04 single agent: Three planned doses of ALE.C04 and ALE.C04 in combination with pembrolizumab. Once a certain dose level of ALE.C04 is considered safe and well tolerated, the first cohort of patients receiving ALE.C04 at a lower dose level combined with pembrolizumab will be initiated
61960205|NCT01795209|SHAM_COMPARATOR|Standard of care group|Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.
61960206|NCT00594438|EXPERIMENTAL|1, A|Femoral reaming with the Synthes Reamer-Irrigator-Aspirator (RIA)
61960207|NCT00594438|ACTIVE_COMPARATOR|2 B|Femoral reaming with a Zimmer Sentinel Reamer.
61960208|NCT04467060|EXPERIMENTAL|Anaprazole Sodium enteric-coated tablet|Single ascendinng dose (2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg), fasting oral administration.
62143466|NCT00881296|ACTIVE_COMPARATOR|2|Gemcitabine 1000mg/m2 Day 1, 8, 15
62505246|NCT06054477|EXPERIMENTAL|Phase 1 Recommended Dose for Expansion|Two ALE.C04 dose levels (higher or lower) will be considered for the combination with pembrolizumab
62143467|NCT04757194|EXPERIMENTAL|Intervention|Calculation of risk assessment score by machine learning algorithm and display of risk assessment information to dispatch nurses. Staff encouraged but not required to comply with suggested ranking.
62347332|NCT05520749||Luspatercept treated patients|Adult patients (i.e. aged \>=18 years) with diagnosis of MDS according to WHO 2016 classification that met IPSS-R criteria for very low, low, or intermediate-risk MDS treated with Luspatercept
62703772|NCT00408005|ACTIVE_COMPARATOR|Group 1 Arm IV (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35.
62703773|NCT00408005|ACTIVE_COMPARATOR|Group I Arm I (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT. Patients with standard risk T-LLy received Arm I, and those with high risk T-LLy were randomized between Arm I and Arm II combination chemotherapy.
62505247|NCT06054477|ACTIVE_COMPARATOR|Phase 2 Randomized Combination part|ALE.C04 at RP2D combined to pembrolizumab compared to pembrolizumab monotherapy
62505248|NCT03041207||Pre-antibiotic guideline|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection prior to the implementation of the antibiotic guideline
62505249|NCT03041207||After antibiotic guideline implementation|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection after the implementation of the antibiotic guideline
62505250|NCT03041207||Microbiome Study Group|Infants intubated and anticipated to require mechanical ventilation for at least several days
62505251|NCT06437184|NO_INTERVENTION|Enhanced Usual Diagnostic Procedure (EUDP)|The standard TB diagnostics in both settings consist of performing the sputum smear analysis by the clinical routine. Smear-negative cases will be followed as per standard routine (Figure 1A).
62505252|NCT06437184|ACTIVE_COMPARATOR|The Optimized Diagnostic Procedure (ODP) intervention|"1. Oral and mobile phone-guided instructions by study staff~2. Pooling of two spot sputum samples (9)~3. Smear-negative cases at the first visit will be assessed for persisting symptoms and referred to a CXR unit."
62505253|NCT04890964|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - DLPFC|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
62505254|NCT04890964|SHAM_COMPARATOR|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - DLPFC|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
62347333|NCT03292952|EXPERIMENTAL|Double-blind KP415|"KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
62505255|NCT04890964|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - M1|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
62505256|NCT04890964|PLACEBO_COMPARATOR|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - M1|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
62505257|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
62505258|NCT01090817|EXPERIMENTAL|Mesenchymal stromal cells|Mesenchymal stromal cells administered weekly for 4 weeks
62505259|NCT06380257||Study group|Adolescents diagnosed with anorexia nervosa or atypical anorexia nervosa.
62505260|NCT06380257||Control Group|Healthy adolescents.
62505261|NCT02358551|OTHER|Axillary vein|Lead Placement Through the Axillary Vein Technique
62505262|NCT02358551|OTHER|Subclaivan vein|Lead Placement Through the Subclavian Vein Technique
62505263|NCT06283121|EXPERIMENTAL|Combination therapy with BioTTT001 intraperitoneal infusion , SOX and Toripalimab|This study intends to enroll Her2-negative subjects with first-line treatment of peritoneal metastasis from gastric cancer. Subjects will be treated with BioTTT001 intraperitoneal perfusion combined with SOX and toripalimab after completing the screening period, and the subjects will first receive BioTTT001 monotherapy treatment with BioTTT001 1×10\^10 VP intraperitoneal perfusion (P.I.), D1 and D3, and enter the combination therapy stage 7 days (±1d) after the first dose of BioTTT001.Subjects will be treated with the regimen as follows: BioTTT001 injection, 1×10\^10 VP P.I., D1；toripalimab 160mg intravenous (i.v.), D1; Oxaliplatin 130mg/m\^2 i.v. , D1 ; Tegafur 40\~60mg Bis in die（b.i.d.） Peroral（p.o.）D1\~D14; 3 weeks per cycle.
61960209|NCT04467060|PLACEBO_COMPARATOR|Placebo|single dose, fasting oral administration
61960210|NCT01350492|EXPERIMENTAL|Arm 1|Resistance exercise training
62143468|NCT04757194|NO_INTERVENTION|Control|Ambulance dispatch per standard of care
62143469|NCT00606216||A|TBI and Chemotherapy Conditioning Regimen. Twenty (20) patients will undergo conditioning treatment with TBI and chemotherapy prior to receiving a myeloablative allogeneic or an autologous HSCT.
62143470|NCT00606216||B|Chemotherapy Alone Conditioning Regimen Twenty (20) patients will undergo conditioning treatment with an all chemotherapy regimen prior to receiving an allogeneic or an autologous HSCT.
62347334|NCT03292952|PLACEBO_COMPARATOR|Double-blind Placebo|Placebo oral capsule
62505264|NCT00781430|EXPERIMENTAL|1|
62505265|NCT00109486|EXPERIMENTAL|Arm 1|
62505266|NCT05167045||No Dementia|
62505267|NCT03691688||Aspirin|Aspirin 100mg
61960211|NCT01350492|NO_INTERVENTION|Arm 2|Waitlist Control
62505268|NCT03691688||Clopidogrel|Clopidogrel 75mg
62505269|NCT06589297|OTHER|Acute stroke patients|Acute stroke patients
62703774|NCT00408005|ACTIVE_COMPARATOR|Group I Arm I (Delayed intensification chemotherapy|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients \< 10 years of age) OR on days 1-7 and 15-21 (for patients \>= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10). Standard risk T-LLy patients were assigned to Arm I and those with high risk were randomized between Arm I and Arm II.
62703775|NCT00408005|ACTIVE_COMPARATOR|Group I Arm I (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL), all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
62703776|NCT00408005|ACTIVE_COMPARATOR|Group I Arm I (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase\* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31. Patients with DS also receive leucovorin calcium PO 48 and 60 hours after each methotrexate IT dose (DS patients excluded as of 09/29/10).~Note: \*Patients with an allergy to pegaspargase receive Erwinia asparaginase on days 2, 4, 6, 8, 10, 12, 22, 24, 26, 28, 30, and 32."
62143471|NCT00606216||C|A cohort of twenty (20) healthy controls, frequency matched on age, gender, and education, will be recruited at WCMC to participate in the study.
62143472|NCT05313412|EXPERIMENTAL|Lens A, Then Lens B|Participants will wear Lens A for six hours and then cross over to wear Lens B for six hours.
62143473|NCT05313412|EXPERIMENTAL|Lens B, Then Lens A|Participants will wear Lens B for six hours and then cross over to wear Lens A for six hours.
62143474|NCT02590094|ACTIVE_COMPARATOR|A|Study Group A: Subjects receive 2.5 mg intravitreal bevacizumab 1-3 days prior to vitrectomy.
62505270|NCT02414373|EXPERIMENTAL|Ropivacaine|Ropivacaine 2mg/ml (ROPIVACAIN Sintetica 2 mg/ml ™, Sintetica-Bioren, Couvet, Schweiz)
62505271|NCT02414373|ACTIVE_COMPARATOR|Bupivacaine|Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)
62505272|NCT04986124||MDD patients|No intervention.
62143475|NCT02590094|ACTIVE_COMPARATOR|B|Study Group B: Subjects receive 2.5 mg intravitreal bevacizumab 5-10 days prior to vitrectomy.
62143476|NCT02590094|ACTIVE_COMPARATOR|C|Study Group C: Subjects receive 1.25 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
62143477|NCT02590094|ACTIVE_COMPARATOR|D|Study Group D: Subjects receive 0.625 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
62143478|NCT02590094|ACTIVE_COMPARATOR|E|Study Group E: Subjects receive 2.5 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
62505273|NCT00432627|EXPERIMENTAL|Mild hepatic impaired|
62505274|NCT00432627|EXPERIMENTAL|Moderate hepatic impaired|
62505275|NCT00432627|EXPERIMENTAL|Severe hepatic impaired|
62143479|NCT02590094|ACTIVE_COMPARATOR|F|Study Group F: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy.
62143480|NCT02590094|ACTIVE_COMPARATOR|G|Study Group G: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-3 days prior to vitrectomy.
62143481|NCT02590094|ACTIVE_COMPARATOR|H|Study Group H: Subjects receive 1.25 mg intravitreal ziv-aflibercept 5-10 days prior to vitrectomy.
62143482|NCT02590094|ACTIVE_COMPARATOR|I|Study Group I: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy, and then receive 1.25 mg intravitreal ziv-aflibercept at the completion of the vitrectomy.
62143483|NCT03960957|EXPERIMENTAL|Experimental|AbobotulinumtoxinA
62143484|NCT03960957|PLACEBO_COMPARATOR|Placebo|
62143485|NCT01184885|EXPERIMENTAL|Hyper-CVAD and Sirolimus|Hyper-CVAD and Sirolimus
62505276|NCT00432627|EXPERIMENTAL|Healthy volunteers|Controlled group
62505277|NCT00230594|ACTIVE_COMPARATOR|1|desmopressin
62505278|NCT00230594|PLACEBO_COMPARATOR|2|placebo
62505279|NCT06678776||Endoscopic Surgery|patients who underwent endoscopic breast surgery
62505280|NCT06678776||Reduction Mammaplasty|patients who underwent reduction mammaplasty
62505281|NCT03649945|ACTIVE_COMPARATOR|Test Group 1|Docetaxel plus Nedaplatin combined with Endostar
62505282|NCT03649945|ACTIVE_COMPARATOR|Test Group 2|Docetaxel plus Nedaplatin
62505283|NCT03649945|NO_INTERVENTION|Control Group|No medicine intervention
62505284|NCT04118946|ACTIVE_COMPARATOR|intravesical instillation|Intravesical instillation of platelet enriched plasma every week for 6 weeks
62505285|NCT04118946|ACTIVE_COMPARATOR|submucosal injection|submucosal injectionof platelet enriched plasma
62505286|NCT05111886|EXPERIMENTAL|Primary Care Personnel Training|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition.
62505287|NCT05111886|ACTIVE_COMPARATOR|Primary Care Personnel Training Control|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition. Control group personnel will receive a written description of the referral process but no training.
61960212|NCT04284670|EXPERIMENTAL|Eccentric treadmill training|The intervention group will perform an 8 week program, 2 sessions a week for a total of 16 sessions. training will be done on a designated negative gradient treadmill. first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
62505288|NCT05111886|EXPERIMENTAL|Parents eHealth GenPMTO|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
62703777|NCT00408005|ACTIVE_COMPARATOR|Group I Arm II (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35. Patients with high risk T-LLy were either randomized to Arm I or Arm II. Patients with T-LLy who failed induction therapy were assigned to Arm II.
61960213|NCT04284670|EXPERIMENTAL|Control group|The control group will receive the same amount of training under neutral gradient surface(0%).The program will be 8 weeks while in each week there will be two exercise sessions and a total of 16 sessions. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. Training intensity will be 70%-80% out of maximal heart-rate.
61960214|NCT05866796||No graft loss|Patients receiving liver transplantation that do NOT experience graft loss within 3-months or 12-months after liver transplantation.
61960215|NCT05866796||Graft loss|"Patients receiving liver transplantation that experience graft loss within 3-months or 12-months after liver transplantation.~Graft loss is defined as either death of the liver transplant recipient (all-cause), or need for retransplantation of the liver."
61960216|NCT05968391||Chronic kidney failure|No interventions for the purpose of the study. They will simply undergo two PET scans consecutively
61960217|NCT01496807|EXPERIMENTAL|Yervoy with Sylatron|Participants are given Yervoy induction every 3 weeks for four doses, for 12 weeks, and all participants simultaneously receive Sylatron induction weekly, followed by Sylatron maintenance alone for up to 144 additional weeks (total 156 weeks = 3 years).
62143486|NCT04018300|EXPERIMENTAL|Ferrous sulfate|Subjects will take a 65 mg Fe capsule of ferrous sulfate, once daily for 21 consecutive days. The first treatment capsule will be consumed with a semi-purified meal (egg albumin, sugar, vanilla, maltodextrose and corn oil) and will have blood drawn hours 0, 1, 2, 3, 4, 6 and 8 post consumption. Serum will be used to determine non-transerrin bound iron, serum iron and percent saturation. Throughout the treatment period, subjects are informed to consume the capsule with food and report symptoms in an online questionnaire. Following three weeks treatment, participants return for a blood draw and oxidative stress indicators are measured. A three week washout period with placebo treatment takes place between treatment crossover.
62347335|NCT03292952|EXPERIMENTAL|Open-Label KP415|"KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
62347336|NCT00874679||Group 1|
62347337|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
62347338|NCT01401465|EXPERIMENTAL|Ciclesonide Nasal Aerosol|74 mcg ciclesonide nasal aerosol once daily
62347339|NCT01401465|ACTIVE_COMPARATOR|Mometasone Nasal Spray|200 mcg mometasone aqueous nasal spray once daily
62347340|NCT02596152|EXPERIMENTAL|Mini-trampoline|participants allocated to this group will participate in a 12-week mini-trampoline group instructed training twice a week.
62347341|NCT02596152|ACTIVE_COMPARATOR|Nordic Walking|participants allocated to this group will participate in a 12-week Nordic Walking group instructed training twice a week.
62347342|NCT06163560|EXPERIMENTAL|Babyapp group|This group will be provided access to the app and be asked for their feedback on the performance of the app.
62347343|NCT06163560|ACTIVE_COMPARATOR|Control group|This group will be given an information pack consisting of a parenting booklet from the Maternal and Child Health Centres (MCHC).
62347344|NCT00921882||Oral glucose tolerance test|oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.
62505289|NCT05111886|ACTIVE_COMPARATOR|Parents Control|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
62505290|NCT05111886|OTHER|Therapists|Community therapists trained to deliver GenPMTO.
62347345|NCT02466165|EXPERIMENTAL|MS patients intervention group|the feasibilty and influence of high intense interval exercise on the cardiometabolic risk state in MS patients will be investigated in a pilot trial.
62347346|NCT02466165|NO_INTERVENTION|healthy controls|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
62505291|NCT00860327||Newborns|Newborns with hypoplastic left heart syndrome who are receiving a right ventricle to pulmonary artery shunt as first stage palliation.
61960218|NCT03868020|EXPERIMENTAL|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.
61960219|NCT01391559|EXPERIMENTAL|arformoterol|beta-2 agonist bronchodilator
61960220|NCT01391559|ACTIVE_COMPARATOR|salmeterol|beta-2 agonist bronchodilator
62703778|NCT00408005|ACTIVE_COMPARATOR|Group I Arm II (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients \< 10 years of age) OR on days 1-7 and 15-21 (for patients \>= 10 years of age); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
61960221|NCT01172431|EXPERIMENTAL|Indapamide|Indapamide SR 1.5mg qd
61960222|NCT01172431|ACTIVE_COMPARATOR|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
61960223|NCT01348503|EXPERIMENTAL|Open Label, Single Arm|Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
62143487|NCT04018300|EXPERIMENTAL|Aspiron|AspironTM which is an iron-enriched supplement will follow the same guidelines and protocol as ferrous sulfate arm. Equivalent 65 mg Fe per capsule will be administered to participants.
62143488|NCT04018300|PLACEBO_COMPARATOR|Placebo|Participants will follow the same description for the other two experimental treatment groups. Capsules will be given to subjects in opaque formation, therefore will be unable to differentiate the iron supplements.
62347347|NCT02466165|NO_INTERVENTION|larger group of MS patients|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
62347348|NCT03803592|EXPERIMENTAL|Dyadic MCS program|"Participants from the experimental group will receive a dyadic multisensory and cognitive stimulation (MCS) programme.~The MCS program is a 15- week program. In the first 4 weeks, participants will attend the center-based Face-to-face (FTF) session twice a week (8 sessions), while in the remaining week (5th-15th Week), home-based sessions will be delivered by the caregivers with the PWD at home and was suggested to deliver the intervention 3 times/week at home. The home-based sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions over the intervention period."
62347349|NCT03803592|NO_INTERVENTION|Control group|Participants from the control group will receive usual care and no intervention will be received.
62347350|NCT02692456|ACTIVE_COMPARATOR|Double needle celiac neurolysis (DNCN)|Patients were subjected to CT guided celiac neurolysis using 2 needle antero-crural technique on each side with patient in prone position and both needles will be lateral to the aorta
61960224|NCT02130570|EXPERIMENTAL|Multi-Model Intensive Discharge Program|Multi-Model Intensive Discharge Program
61960225|NCT02130570|NO_INTERVENTION|Usual Care|Usual Care
61960226|NCT03182478|ACTIVE_COMPARATOR|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
61960227|NCT03182478|ACTIVE_COMPARATOR|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
61960228|NCT04007978|EXPERIMENTAL|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
62143489|NCT04174079|EXPERIMENTAL|Experimental group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
62143490|NCT04174079|NO_INTERVENTION|control group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma were reviewed regularly after surgery.
62143491|NCT04510324|ACTIVE_COMPARATOR|Red meat patties|Participants will be randomized to group 1: Red meat, ''Costco Kirkland Signature 1/4 lb Ground Beef Patties'' (Beef burger). Participants will be given two patties per day.
62347351|NCT02692456|PLACEBO_COMPARATOR|Single needle celiac neurolysis (SNCN)|Patients were subjected to CT guided celiac neurolysis using a single needle antero-crural approach from left side to be just in the front of the aorta near the origin of celiac trunk with patient in lateral position with his left side up then after the injection the patient were kept to his right side up for more homogenous spread of the dye.
62347352|NCT05075967|EXPERIMENTAL|Integrated Strategy|"Black MSM living in intervention communities will have access to the HPTN 096 integrated strategy in addition to standard HIV prevention and care services available in their communities.~The integrated strategy includes a combination of four community-, organizational-, and interpersonal-level components designed to impact individual-level outcomes."
62505292|NCT00860327||Infants|Infants who are undergoing complete repair for tetralogy of Fallot or similar pathology.
62505293|NCT00869661|EXPERIMENTAL|Group 1|RO5024048 500 mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
62505294|NCT00869661|EXPERIMENTAL|Group 2|RO5024048 1000mg bid + Pegasys + Copegus for 8 weeks, followed by SOC for 16 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
62505295|NCT00869661|EXPERIMENTAL|Group 3|RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
62505296|NCT00869661|EXPERIMENTAL|Group 4|Group 4 will receive RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 36 weeks
62505297|NCT00869661|ACTIVE_COMPARATOR|Group 5|Group 5 will receive SOC for 48 weeks
62505298|NCT00869661|EXPERIMENTAL|Group 6|Group 6 provides retreatment on an open-label basis for patients of Group 5 who failed treatment. Patients will receive RO5024048 1000mg bid + Pegasys + Copegus for 24 weeks, followed by SOC for 24 weeks.
62347353|NCT05075967|OTHER|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
62347354|NCT01609179|EXPERIMENTAL|IPI-926|
62347355|NCT03368625|OTHER|Arm 1|Neoadjuvant SRS
62347356|NCT04574388|ACTIVE_COMPARATOR|open label placebo|participants will take open label placebo pills TID and in conjunction with other PRN analgesics
62347357|NCT04574388|NO_INTERVENTION|treatment as usual|participants will take PRN analgesics as usual
62347358|NCT03537352||Surgical Disorders|"A. Surgical Disorders:~1. Current Hospitalization at the Surgical Inpatient Department or at the Inpatient Department of Otorhinolaryngology or at the Inpatient Department of Cardiology OR~2. Current Follow-up at the Surgical Outpatient Department or at the Outpatient Department of Otorhinolaryngology or at the Outpatient Department of Cardiology due to a disorder for which any appropriate surgical treatment (surgery) is a treatment option."
62347359|NCT03537352||Non-Surgical General Medical Disorders|"1. Current Hospitalization at the Internal Medicine Inpatient Department or at the Inpatient Department of Cardiology OR~2. Current Follow-up at the Internal Medicine Outpatient Department or at the Outpatient Department of Cardiology due to a disorder for which surgery is not a treatment option and any appropriate drug or non-drug treatment excluding surgery is a treatment option."
62347360|NCT06118567|ACTIVE_COMPARATOR|Nitrous Oxide Inhalation|60 minute session inhaling Nitrous Oxide gas.
62347361|NCT06118567|SHAM_COMPARATOR|Room Air|60 minute session inhaling Room Air.
62347362|NCT01382199|EXPERIMENTAL|Ven100|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
62347363|NCT01434264|EXPERIMENTAL|Self-selected energy healing|Self-selected healing in the self-selection arm
62347364|NCT01434264|NO_INTERVENTION|self-selected control|Self-selected control in the self-selection arm
62347365|NCT01434264|EXPERIMENTAL|randomized to energy healing|Randomized to healing in the randomization arm
62347366|NCT01434264|NO_INTERVENTION|Randomized control|Randomized to control in the randomization arm
62347367|NCT02219633|EXPERIMENTAL|LEO 39652 cream|Topical application
62347368|NCT02219633|PLACEBO_COMPARATOR|LEO 39652 cream vehicle|Topical application
62347369|NCT03444194|EXPERIMENTAL|Biopsi arm|
62347370|NCT03453021||mepolizumab|Patients will receive a subcutaneous injection of mepolizumab 100 mg every 4 weeks for one year, for a total of 12 injections
62505299|NCT00588315||skin lesions|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
62505300|NCT00588315||normal skin|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
62505301|NCT05848258|EXPERIMENTAL|LY3871801 Phase 2a|Participants will receive LY3871801 administered orally.
61960229|NCT03184831|ACTIVE_COMPARATOR|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
62143492|NCT04510324|EXPERIMENTAL|Plant-based patties|"Participants will be randomized to group 2: plant-based burger which contains no animal products. The Plant-based burger selected is ''Beyond Burger (https://www.beyondmeat.com/products/the-beyond-burger/ ). Participants will be given two patties per day."
62347371|NCT05101486|EXPERIMENTAL|Group 1: Ad26.RSV.PreF-based Vaccine|Participants will receive a single intramuscular (IM) injection of Ad26.RSV.PreF-based vaccine on Day 1 (non-aged lot).
62347372|NCT05101486|EXPERIMENTAL|Group 2: Ad26.RSV.PreF-based Vaccine|Participants will receive a single IM injection of Ad26.RSV.PreF-based vaccine on Day 1 (aged lot 1).
62347373|NCT05101486|EXPERIMENTAL|Group 3: Ad26.RSV.PreF-based Vaccine|Participants will receive a single IM injection of Ad26.RSV.PreF-based vaccine on Day 1 (aged lot 2).
62347374|NCT05999903||Observational Kinematic Driving Data|Longitudinal kinematic driving data paired with neurocognitive assessments at 3- and 6-months
62347375|NCT03038802|ACTIVE_COMPARATOR|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
62347376|NCT03038802|EXPERIMENTAL|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
62347377|NCT03905629||Patients aged 75 years and older hospitalized as an emergency|Patients considered will be all patients aged 75 years and older (on the day of the index admission) hospitalized as an emergency (i.e. after visit to ED) between january 2017 and december 2017.
62347378|NCT03134313|EXPERIMENTAL|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
62505302|NCT05848258|PLACEBO_COMPARATOR|Placebo Phase 2a|Participants will receive placebo.
62505303|NCT05848258|EXPERIMENTAL|LY3871801 Dose 1 Phase 2b|Participants will receive LY3871801 administered orally.
62505304|NCT05848258|EXPERIMENTAL|LY3871801 Dose 2 Phase 2b|Participants will receive LY3871801 administered orally.
62505305|NCT05848258|EXPERIMENTAL|LY3871801 Dose 3 Phase 2b|Participants will receive LY3871801 administered orally.
62505306|NCT05848258|PLACEBO_COMPARATOR|Placebo Phase 2b|Participants will receive placebo.
61960230|NCT03184831|EXPERIMENTAL|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
61960231|NCT04379024|EXPERIMENTAL|Immediate active agent|Duavee. One capsule daily for 6 months (+/- 1 month) of Duavee (Bazedoxifene 20 mg plus conjugated estrogens 0.45 mg)
61960232|NCT04379024|OTHER|Delayed active agent|No intervention for first 6 months. Then option to receive daily Duavee for 6 months.
61960233|NCT02066805||Cohort 1|
61960234|NCT06293001||Patients with shoulder pain|Patients with shoulder pain, pain for at least three months and aged between 18 and 64 years, and for the re-test only participants with unchanged health status were included in the study. Patients with rheumatological, neurological or musculoskeletal diseases, invasive intervention in the last 3 months, active infection, history of cancer, post-traumatic condition requiring surgery were excluded.
61960235|NCT03384095|EXPERIMENTAL|Hyaluronic Acid|Subjects in this arm will be given 100 mg of hyaluronic acid in capsule form. Subject in this arm will be asked to 1 capsule take twice daily for 26 weeks.
61960236|NCT03384095|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
61960237|NCT03944915|EXPERIMENTAL|ARM 1|Induction Therapy
61960238|NCT03944915|EXPERIMENTAL|ARM 2|Radiation therapy with chemotherapy
61960239|NCT03333447||Study Population|Patients of any age or gender with confirmed diagnosis of type 1 Gaucher disease, treated with VPRIV® at the beginning of the study. Patients should have one MRI data in the 5 previous years before starting VPRIV® treatment (up to 3 months after initiation of VPRIV®.
61960240|NCT02591069|EXPERIMENTAL|All patients will undergo the same procedure|
62143493|NCT04105751|EXPERIMENTAL|Use of Device with post-use interview/questionnaire|All patients will be asked to utilize device and will then be asked to provide feedback on their experiences. This may be done by interview or a questionnaire. There could be up to three sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, session could last up to one hour.
62143494|NCT02118922||Healthy volunteers|Volunteers with normal corneas
62143495|NCT02118922||Patients with keratoconus|Patients diagnosed with keratoconus
62143496|NCT02118922||post-LASIK no complications|Subjects who underwent LASIK refractive surgery with no complications
62505307|NCT06117787||Subject use both KD-7920 Wrist Automatic Electronic BPM and mercury sphygmomanometers|
62505308|NCT02998541|EXPERIMENTAL|SHP640|Participants will receive one drop of SHP640 (0.1 percent \[%\] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
61960241|NCT01866930|EXPERIMENTAL|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
61960242|NCT01866930|EXPERIMENTAL|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing \<75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
62143497|NCT02118922||post-LASIK who developed ectasia|patients who underwent LASIK refractive surgery and developed ectasia as a complications
62143498|NCT02118922||Volunteers to receive PRK surgery|This group includes patients who have been diagnosed with myopia and have been scheduled to undergo PRK surgery. Patients with high astigmatism \> 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen or artificial tears will be excluded.
62143499|NCT02118922||Volunteers to receive LASIK Surgery|This group includes myopic patients who are scheduled to receive LASIK surgery. Patients with high astigmatism \> 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen and artificial tears will be excluded.
61960243|NCT03622944|ACTIVE_COMPARATOR|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
62143500|NCT02118922||Patients with Fuch's Endothelial Corneal Dystrophy|This group includes subjects who are diagnosed with Fuch's corneal dystrophy, at early, mild and advanced stages. The inclusion also extends to subjects with, and without keratoconus. But this exclude patients with any other corneal disorders other than keratoconus, and/or history of ophthalmological surgeries that may affect endothelium cell status, e.g. cataract surgeries.
62143501|NCT02455427|ACTIVE_COMPARATOR|Active tDCS+ Physical Therapy|Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
62143502|NCT02455427|SHAM_COMPARATOR|Sham tDCS+Physical Therapy|"Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.~Number of treatment sessions: 6 (3 times a week, for 2 weeks)"
62143503|NCT02305511|EXPERIMENTAL|Peripheral venous catheterization|Peripheral venous catheterization during pediatric resuscitation
62143504|NCT02305511|EXPERIMENTAL|intraosseous access|Intraosseus access using intraosseous access devices during resuscitation
62505309|NCT02998541|ACTIVE_COMPARATOR|PVP-I 0.6%|Participants will receive one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
62505310|NCT02998541|PLACEBO_COMPARATOR|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID for 7 days.
62505311|NCT05796596|EXPERIMENTAL|Virtual Reality (VR) distraction|Distraction intervention using a virtual environment
61960244|NCT03622944|ACTIVE_COMPARATOR|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
61960245|NCT03622944|ACTIVE_COMPARATOR|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
61960246|NCT01469195||Group A - No lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
62505312|NCT05796596|ACTIVE_COMPARATOR|Distraction by the book|Distraction intervention using a book visualization
61960247|NCT01469195||Group B plus lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.
61960248|NCT00793091|ACTIVE_COMPARATOR|1|
62347379|NCT02392494|EXPERIMENTAL|MK-1075 100 mg (Panel A)|HCV-infected participants receive a single 100 mg dose of MK-1075.
62347380|NCT02392494|EXPERIMENTAL|MK-1075 200 mg (Panel B)|HCV-infected participants receive a single 200 mg dose of MK-1075.
62347381|NCT02392494|EXPERIMENTAL|MK-1075 400 mg (Panel C)|HCV-infected participants receive a single 400 mg dose of MK-1075.
62347382|NCT02392494|EXPERIMENTAL|MK-1075 800 mg (Panel D)|HCV-infected participants receive a single 800 mg dose of MK-1075.
62347383|NCT01025258|ACTIVE_COMPARATOR|frequent clinic visits|
62347384|NCT01403467|EXPERIMENTAL|NIPPV|
62347385|NCT02667548||patients receiving PCI|patients receiving PCI
62347386|NCT01571648|EXPERIMENTAL|Oral azacitidine|
62347387|NCT03516734|EXPERIMENTAL|Iron fortified lentils|Lentils will be fortified with iron in the lab setting at the Crop Development Center (CDC) of The University of Saskatchewan, Canada. The study will fortify lentil by spraying iron fortificant NaFeEDTA solution. A small sprayer will be placed at the beginning of the lentil polishing machine at a commercial lentil mill located near Saskatoon, Canada. The iron solution will be applied as a fine mist which will be absorbed into the lentil as it travels through the polishing drum. As the fortified lentil leaves the drum it will be bagged in 20 kg food grade bags. The expected concentration of Fe in the final product will be approximately 21 mg/100 g of lentil (fortified with NaFeEDTA solution with 1600 ppm of Fe).
62347388|NCT03516734|ACTIVE_COMPARATOR|Non iron-fortified lentils|It will be the same Saskatchewan (province of Canada) grown small cotyledon color lentil (Iron content 75-90ppm) without the iron fortification.
62347389|NCT03516734|PLACEBO_COMPARATOR|Usual Intake (no intervention)|It will be the usual intake of lentil- no additional lentil will be provided. However, participants will be free to consume lentils from anywhere (homemade or restaurants) if they want to, except our fortified lentils.
62347390|NCT04615702||application of recent guidelines in the management of acute biliary pancreatitis|all patients subjected to the following: Confirmation of the diagnosis of acute pancreatitis, Diagnosis of the cause either biliary or not, Severity scoring and Evidence based management regarding Initial management, Intervention as indicated, Prevention of recurrence and Follow up
62347391|NCT01204697|EXPERIMENTAL|A|
61960249|NCT00793091|PLACEBO_COMPARATOR|2|
62143505|NCT06618976|OTHER|Sotagliflozin then Empagliflozin|Subjects randomized to 'Arm A' will receive 1-month of 'Sotagliflozin' treatment first and then 1-month of 'Empagliflozin' treatment second, separated by a 1-month of washout period.
62347392|NCT01204697|EXPERIMENTAL|B|
62347393|NCT05962918|EXPERIMENTAL|perineal massage|intervention group with perineal massage
62347394|NCT05962918|NO_INTERVENTION|control group|The group that received routine hospital protocol and was not massaged.
62347395|NCT03128385|EXPERIMENTAL|Intensive CIT Model Program|"In day camp model, the therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Adventure Camp that decorating the treatment place as the adventure world and the participants take role as a warrior. This novel design is mean to enhance and motivate the engagement of participation."
62347396|NCT03128385|EXPERIMENTAL|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
62347397|NCT06118346|EXPERIMENTAL|Female-Specific Cognitive Behavioral Therapy|Participants in this arm will receive female-specific cognitive behavioral therapy and usual VA care for alcohol use disorder.
62347398|NCT06118346|ACTIVE_COMPARATOR|Usual Care|Participants in this arm will receive usual VA care for alcohol use disorder.
62347399|NCT02326467|EXPERIMENTAL|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
62347400|NCT02407041|EXPERIMENTAL|GR-MD-02|active arm
62347401|NCT03900754|EXPERIMENTAL|Intranasal Oxytocin|Dosages of oxytocin: 20IU or 40IU.
62505313|NCT05796596|NO_INTERVENTION|Usual care|Control group receiving usual care and no distraction.
62505314|NCT05381896|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive conventional scoliosis exercise program for 1 hour, 6 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
62505315|NCT05381896|EXPERIMENTAL|Training Group|In addition to the conventional scoliosis exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 6 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
62703779|NCT00408005|ACTIVE_COMPARATOR|Group I Arm II (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase\* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31.~Note: \*Patients with an allergy to pegaspargase receive Erwinia asparaginase on Monday, Wednesday and Friday for two consecutive weeks starting the day of asparaginase substitution."
62703780|NCT00408005|ACTIVE_COMPARATOR|Group I Arm II (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
62703781|NCT00408005|ACTIVE_COMPARATOR|Group I Arm III (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT.
62703782|NCT00408005|ACTIVE_COMPARATOR|Group I Arm III (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients \< 10 years of age) OR on days 1-7 and 15-21 (for patients \>= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10).
62703783|NCT00408005|ACTIVE_COMPARATOR|Group I Arm III (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
62703784|NCT00408005|ACTIVE_COMPARATOR|Group I Arm III (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL) and all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
62703785|NCT00408005|ACTIVE_COMPARATOR|Group I Arm IV (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients \< 10 years of age) OR on days 1-7 and 15-21 (for patients \>= 10 years of age); doxorubicin IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
62703786|NCT00408005|ACTIVE_COMPARATOR|Group I Arm IV (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
62347402|NCT03900754|PLACEBO_COMPARATOR|Placebo|Saline
62347403|NCT03111355|EXPERIMENTAL|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
62347404|NCT03231215|PLACEBO_COMPARATOR|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
61960250|NCT03797014|EXPERIMENTAL|B/F/TAF|Treatment group (1-arm study)
62347405|NCT03231215|ACTIVE_COMPARATOR|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
62347406|NCT05894044|EXPERIMENTAL|Russian current 10%|Subjects will receive a interventions (Russian Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
62347407|NCT05894044|EXPERIMENTAL|Aussie current 10%|Subjects will receive a interventions (Aussie Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
62347408|NCT05894044|EXPERIMENTAL|Pulsed current 500 µs phase|Subjects will receive a interventions (Pulsed current with 50 Hz, 500 µs phase). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
61960251|NCT05448183|EXPERIMENTAL|Toripalimab combined withTACE|
61960252|NCT01103648|ACTIVE_COMPARATOR|Simvastatin arm|A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
62347409|NCT05894044|EXPERIMENTAL|Pulsed current 200 µs phase|Subjects will receive a interventions (Pulsed current with 50 Hz, 200 µs phase). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
62347410|NCT04180501|EXPERIMENTAL|SRS sequential sintilimab|
61960253|NCT01103648|ACTIVE_COMPARATOR|Ezetimibe arm|A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
62703787|NCT00408005|ACTIVE_COMPARATOR|Group I Arm IV (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
62703788|NCT04826341|EXPERIMENTAL|1/Phase I|Dose escalated Sacituzumab Govitecan and Berzosertib
62703789|NCT04826341|EXPERIMENTAL|2/Phase II|Sacituzumab Govitecan and Berzosertib treatment with identified MTD based on phase I.
61960254|NCT01103648|EXPERIMENTAL|Simvastatin-Ezetimibe arm|To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).
61960255|NCT04092439|EXPERIMENTAL|Watermelon juice|The study participants consumed 500 ml of 100% watermelon juice for two weeks
62347411|NCT04416126|EXPERIMENTAL|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
62347412|NCT04416126|PLACEBO_COMPARATOR|Placebo|Single doses of 0.9% Saline administered intravenously
62347413|NCT02396342|EXPERIMENTAL|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
62505316|NCT00825864|ACTIVE_COMPARATOR|1diclofenac drops treatment|four times a day for 3 months
61960256|NCT04092439|PLACEBO_COMPARATOR|Placebo|The study participants consumed a watermelon flavored, fructose matched control
62505317|NCT00825864|ACTIVE_COMPARATOR|2dexamethasone drops|
62505318|NCT04502849||"Group Bypass (A)"|50 patients with indications for bypass surgery (chronic lower limb ischemia, stage 2b-4 Fontaine).
61960257|NCT04449900||The exudative CCH group|Treatment naïve patients with exudative CCH which caused subfoveal retinal detachment and/or intraretinal fluid
61960258|NCT04449900||The healthy eye control group|In the healthy eye control group, all eyes should have no ocular diseases and the best-corrected visual acuity (BCVA) should be 20/20 or better.
62505319|NCT04502849||"Group Endovascular (B)"|50 patients with indications for endovascular angioplasty and stenting (chronic lower limb ischemia, stage 2b-4 Fontaine).
62505320|NCT04502849||"Group Hybrid (C)"|50 patients with indications for hybrid surgery (endovascular angioplasty/stenting and bypass surgery; chronic lower limb ischemia, stage 2b-4 Fontaine).
62505321|NCT04502849||"Group Conservative (D)"|50 patients without indications surgery (conservative treatment, chronic lower limb ischemia, stage 2b-4 Fontaine).
62505322|NCT04502849||"Group Healthy volunteers (E)"|50 healthy subjects.
62703790|NCT03096262|EXPERIMENTAL|Stroke Patients|
61960259|NCT04503902|EXPERIMENTAL|JS001+Donafenib|Donafenib 100mg QD/100 mg BID/200 mg BID orally + JS001 240mg Q3W iv
61960260|NCT02912910||Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
61960261|NCT02912910||Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
61960262|NCT03474770|EXPERIMENTAL|BIS-001ER|Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
61960263|NCT02560597|EXPERIMENTAL|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
62347414|NCT02396342|EXPERIMENTAL|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
62347415|NCT00868166|EXPERIMENTAL|Olesoxime|2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid
62505323|NCT04335331||PreDM CDS|The PreDM CDS is a passive electronic health record button that appears automatically under the Assessment/ Plan only for patients with prediabetes. When clinicians choose to click on this button, the PreDM CDS displays the last three measurements of weight, body mass index (BMI), hemoglobin A1c (HbA1c), fasting glucose, random glucose, and creatinine. This tool included order options enabling prediabetes management in a single location within the electronic health record.
62505324|NCT03454282|EXPERIMENTAL|FMD Arm|The intervention consists in 5-day FMD (Fasting Mimicking Diet) to be followed for one cycle (Cohorts A and B) or for 4 consecutive every-four week cycles postoperatively.
62505325|NCT04854213|OTHER|Liquid biopsy|Blood samples for liquid biopsy
62505326|NCT01623804|ACTIVE_COMPARATOR|Low intensity, pulsed ultrasound|
62505327|NCT01623804|SHAM_COMPARATOR|Sham ultrasound|
61960264|NCT01752374||Palonosetron group|Patient recieving Palonosetron/granisetron and ramosetron
61960265|NCT01752374||Granisetron group|
62347416|NCT00868166|PLACEBO_COMPARATOR|Placebo Comparator|2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
62347417|NCT00504387||A: Patients|Patients with a primary burning mouth disorder Pain (VAS 0-10): 3\<x\<9 Patient understands and speaks german Age: \>18 years
62347418|NCT00504387||B: Controls|Age and sex matched persons/patients who do not have any history of an oral burning sensation or a burning mouth disorder.
62347419|NCT02388841||Pulmonary embolism|Distribution of the characteristics of Pulmonary Embolism patients according to thrombus localization
62347420|NCT02388841||tomographic pulmonary angiography|Distribution of the characteristics of Pulmonary Embolism patients according to the localization of thrombi in the most proximal level of Main pulmonary artery and other arterial branches as confirmed by Computed tomographic pulmonary angiography
62347421|NCT05352906|ACTIVE_COMPARATOR|Contact goldman applanation tonometry|The standard contact tonometer
62347422|NCT05352906|ACTIVE_COMPARATOR|Handheld digital contact tonometer|A contact digital tonometer's pen.
62505328|NCT01317979||Diabetes group I|metabolic surgery, laparoscopicly
62703791|NCT03096262|ACTIVE_COMPARATOR|Healthy Controls|
61960266|NCT01752374||Ramosetron group|
61960267|NCT01776892|EXPERIMENTAL|Collagenase and needle aponeurotomy|"Participants in this arm of the study will be treated once with needle aponeurotomy and up to 3 times at 4 week intervals with collagenase injection.~Affected Dupuytren's cords will be treated with 1-3 collagenase clostridium histolyticum injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained."
61960268|NCT01776892|ACTIVE_COMPARATOR|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained. Participant feedback is obtained throughout the procedure to prevent digital nerve or flexor tendon injury. Participants are asked to report Tinel's sign which indicates that the needle is in close proximity to the digital nerve and to report pain with needle advancement which indicates proximity to the flexor tendon.
61960269|NCT01776892|ACTIVE_COMPARATOR|Collagenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
62143506|NCT06618976|OTHER|Empagliflozin then Sotagliflozin|Subjects randomized to 'Arm B' will receive1-month of 'Empagliflozin' treatment first and then1-month of 'Sotagliflozin' treatment second, separated by a 1-month of washout peri od
62143507|NCT03906279||Myopic participants|
62505329|NCT03477383||Adult patients|Adult patients (18 years or older) undergoing heart transplantation
62505330|NCT03477383||Pediatric patients|Pediatric patients (0-17 years) undergoing heart transplantation
62505331|NCT04899492|ACTIVE_COMPARATOR|Group 1:Nicotine Replacement Therapy (NRT)|Patients enrolled in group 1 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study
61960270|NCT03702985|ACTIVE_COMPARATOR|Capecitabine and Irinotecan without Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
62505332|NCT04899492|EXPERIMENTAL|Group 2:Motivational Interviewing (MI)|Patients enrolled in group 2 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization
62505333|NCT04899492|EXPERIMENTAL|Group 3:Cognitive Behavioural Therapy (CBT)|Patients enrolled in group 3 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and 6 sessions of CBT after Motivational Interviewing up to 6 months after
62505334|NCT04899492|EXPERIMENTAL|Group 4: Hypnotherapy|Patients enrolled in group 4 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and about 3 sessions of hypnotherapy up to 6 months after
62505335|NCT00175097|OTHER|soybeans and products made thereof|Diet: soybeans and products made thereof (soynuts, soynut butter, soy flakes \& grits)
62505336|NCT00175097|OTHER|soybean flour and products made thereof|Diet: soybean flour and products made thereof (textured soybean)
62505337|NCT00175097|OTHER|soybean milk|Diet: soybean milk (tofu, soybean yogurt, cheese, etc.)
62505338|NCT00175097|OTHER|animal protein based diet|Diet: animal protein based diet
62505339|NCT03890562|EXPERIMENTAL|Auricular acupressure for NAS infants|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
61960271|NCT03702985|EXPERIMENTAL|Capecitabine and Irinotecan with Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) Amifostine: 400mg/m2 per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
61960272|NCT01784159|PLACEBO_COMPARATOR|Placebo|Placebo 1tb / day/ 7days
61960273|NCT01784159|ACTIVE_COMPARATOR|Aspirin|Intervention aspirin 200 mg/day for 7 days
61960274|NCT05230303|EXPERIMENTAL|Caffeine supplementation|Group taking 3 mg/kg of caffeine
62143508|NCT03906279||Emmetropic participants|
62143509|NCT03906279||Hyperopic participants|
62143510|NCT01796691||Standard therapy|Antiplatelet therapy following coronary stenting without platelet function testing
62143511|NCT01796691||Optimized antiplatelet therapy|"Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.~Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)"
62143512|NCT02268240|EXPERIMENTAL|Experimental|Stepped Care
62143513|NCT02268240|NO_INTERVENTION|Control|Usual Care
62143514|NCT02329691||Changes in the WHO checklist|Specific changes in the WHO checklist will be performed after observational studies to enhance the WHO checklist at the specific institution
62143515|NCT01928875|EXPERIMENTAL|Adequacy of Anesthesia (AoA) Monitoring|Adequacy of Anesthesia monitoring with SPI and Entropy
62143516|NCT01928875|ACTIVE_COMPARATOR|Routine (Standard) Anesthesia Monitoring|
61960275|NCT05230303|PLACEBO_COMPARATOR|Placebo treatment|Group taking placebo
62703792|NCT06029972|EXPERIMENTAL|Tilpisertib Fosmecarbil Dose A|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil Dose A for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug."
61960276|NCT05365178|EXPERIMENTAL|TQB3616 capsule + Fulvestrant injection|"TQB3616 capsule:~180mg was given orally with meals or within 2 hours after meals, once a day， every 28 days for a cycle.~Fulvestrant injection:~500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15"
61960277|NCT05365178|PLACEBO_COMPARATOR|Placebo capsule + Fulvestrant injection|"Placebo capsules:~0mg was given orally with meals or within 2 hours after meals, once a day, every 28 days for a cycle.~Fulvestrant injection:~500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15"
61960278|NCT02716428|EXPERIMENTAL|Cohort 1|12 weeks of Faldaprevir plus TD-6450 plus Ribavirin
61960279|NCT02716428|EXPERIMENTAL|Cohort 2|12 weeks of Faldaprevir plus TD-6450
61960280|NCT06409871|PLACEBO_COMPARATOR|Physiotherapy treatment|Conventional physiotherapy treatment will be applied. The duration will be two weekly sessions of about 50 minutes, for 6 weeks.
61960281|NCT06409871|EXPERIMENTAL|Physiotherapy treatment and modification of the biorhythm|The same physiotherapy treatment will be applied together with the modification of their biorhythm. This will be recorded in a diary for 6 weeks, in which the time of going to bed and waking up will be recorded, together with the observation of the change in biorhythm. This group will also be provided with a second informed consent form including a data collection commitment document. The duration will be two weekly sessions of about 50 minutes, for 6 weeks.
61960282|NCT03064997|ACTIVE_COMPARATOR|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
61960283|NCT03064997|PLACEBO_COMPARATOR|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
61960284|NCT03085381|EXPERIMENTAL|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
61960285|NCT03085381|PLACEBO_COMPARATOR|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
61960286|NCT03761160|EXPERIMENTAL|Mobile Health App|"The developed mobile health app will include the following facets:~* Physical activities~* Dietary regimen.~* The physical activities facet will encourage patients to engage in physical activities, with daily prompts, encouragement, and tips.~* Users will be asked to record the type of physical activity they engaged in during the week, and for how long.~* The dietary aspect will ask patients to log what they ate during the day and to rate how 'healthy' it is"
61960287|NCT03761160|ACTIVE_COMPARATOR|Usual Care|Usual care per hospital guideline
61960288|NCT01523171|EXPERIMENTAL|SAR302503 400 mg|once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
61960289|NCT03712072||Children with Cerebral Palsy|Data from the participants with Cerebral Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
61960290|NCT03712072||Children with BPBP|Data from the participants with Brachial Plexus Birth Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the TMS session.
61960291|NCT03712072||Typically Developing Children|Data from the typically developing participants will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
61960292|NCT00942253|EXPERIMENTAL|Dopamine Agonist Group|"Dialysis patients will receive dopamine agonist for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist and aerobic intradialytic exercise.~Patients will be given evening doses of dopamine agonists, 2 hours before bedtime. The dopamine agonists' dose will be 0.25 mg/dose and remain constant until the end of the study."
61960293|NCT00942253|PLACEBO_COMPARATOR|Placebo Group|"Dialysis patients will receive placebo for 24 weeks following a 24 weeks period of combined treatment with placebo and aerobic intradialytic exercise.~Patients will be given evening doses of placebo, 2 hours before bedtime."
61960294|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
61960295|NCT03945578|ACTIVE_COMPARATOR|Control Group|"This group performed a supervised Pelvic Floor Muscle Training (PFMT) protocol associated with a manual sham therapy (MST) sessions.~The PFMT protocol consisted of 20 sessions of 45-60 minutes each, twice a week, totalizing a five weeks treatment.~The MST protocol was performed once a week, during five weeks lasting approximately 15 minutes."
61960296|NCT03945578|EXPERIMENTAL|Experimental Group|"The experimental group performed the same PFMT protocol as the CG, but associated with a Visceral Manual Therapy (VMT) protocol.~The VMT sessions were held once a week, for five weeks. Each session lasted approximately 20 minutes."
61960297|NCT03570021|ACTIVE_COMPARATOR|Group 1|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].
61960298|NCT03570021|EXPERIMENTAL|Group 2|total thyroidectomy alone without neck dissection. This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
62143517|NCT04436432||Assessment|Children with ASD ages 3-5 years at baseline
62505340|NCT02812654|EXPERIMENTAL|Doxorubicin, Ifosfamide, radiotherapy|Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.
62703793|NCT06029972|EXPERIMENTAL|Tilpisertib Fosmecarbil Dose B|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil Dose B for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug."
62703794|NCT06029972|EXPERIMENTAL|Tilpisertib Fosmecarbil Dose C|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil Dose C for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug."
61960299|NCT06352489|ACTIVE_COMPARATOR|PCS with TAR|The posterior component separation technique utilizes the retro-rectus space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscle.
61960300|NCT06352489|ACTIVE_COMPARATOR|PCS without TAR|by performing posterior component separation technique through inscion in the posterior rectus sheath and mesh placement in this plane without performing more advancement towards tranversus abdominis muscle.
61960301|NCT00596284|EXPERIMENTAL|CBT-AD|Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
61960302|NCT00596284|ACTIVE_COMPARATOR|EUC|EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop.
61960303|NCT03191994|EXPERIMENTAL|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
61960304|NCT03191994|NO_INTERVENTION|MDD control group|This group will receive usual care with no exercise
62505341|NCT02820740|OTHER|NeuroBlate LITT Treatment|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.
62505342|NCT03966950|EXPERIMENTAL|melatonin group|for the melatonin group, 10 mg of melatonin will be taken per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
62505343|NCT03966950|PLACEBO_COMPARATOR|placebo group|For the placebo group, placebo will be administered per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
61960305|NCT03191994|EXPERIMENTAL|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
62505344|NCT05683782|ACTIVE_COMPARATOR|Test Group|"Split-thickness Apically Positioned Flap with topical Erythropoietin (Test group):~A split thickness horizontal incision will be done at the mucogingival junction of the targeted area to be augmented with a scalpel with blade number 15C. Around the teeth, the gingiva stays intact coronal to the horizontal incision. The horizontal incision will extend mesio-distally in accordance with the area to be augmented.(Mandibular anterior or premolar teeth).~A split-thickness flap is elevated, and the dissection is extended as far as necessary in the apical direction. The flap is secured to the periosteum with simple interrupted bio absorbable sutures.~A Chitosan based Erythropoietin gel will be prepared. 1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used. The patient will be instructed to use the gel on the surgical site two times daily for 14 days."
62505345|NCT05683782|ACTIVE_COMPARATOR|Control Group|"Split-thickness Apically Positioned Flap without Erythropoietin :~Local anesthesia is administered by infiltration technique. The same surgical procedure is performed with the application of Chitosan gel without being loaded with erythropoietin."
62703795|NCT06029972|PLACEBO_COMPARATOR|Tilpisertib Fosmecarbil Placebo|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil placebo for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved Clinical Response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve Clinical Response at Non-responder Treatment Phase Week 12 will discontinue study drug."
61960306|NCT03191994|NO_INTERVENTION|Healthy control|This group will not perform exercise
61960307|NCT01958931||Patients Suspicious for Lung Cancer|Subjects are symptomatic of lung cancer and have one or more lung nodules or lung masses suspicious for lung cancer.
61960308|NCT00582166|EXPERIMENTAL|Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance|
61960309|NCT04286243|ACTIVE_COMPARATOR|Model 1 - Clinic Based Screening|Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
62143518|NCT01691716|EXPERIMENTAL|Tendoactive|Tendoactive dosage: 3 capsules per day
62143519|NCT01691716|ACTIVE_COMPARATOR|Eccentric training|Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
62505346|NCT05463406|EXPERIMENTAL|The PLUS algorithm|"The PLUS clinical management algorithm:~EDs having switched to the intervention period (intervention group) will manage their patients using the PLUS algorithm.~The PLUS algorithm starts with a validated pneumonia clinical prediction score (score of Van Vugt), followed by LUS. In case of positive results of any of these tests, PCT is measured to identify patients who will most likely benefit from antibiotics. A validated clinical severity score will ensure the safety of the intervention in those with discordant results (LUS consolidation and low PCT)."
62505347|NCT05463406|OTHER|Usual care|Usual care: management as usual
62505348|NCT05103449|NO_INTERVENTION|Control Group (No Video Coaching)|Control Group (No Video Coaching)
62505349|NCT05103449|EXPERIMENTAL|Experimental Group (Video Coaching)|Video-based coaching group
62505350|NCT04234061|EXPERIMENTAL|Single|ibrutinib and Tisagenlecleucel
62505351|NCT05404451|EXPERIMENTAL|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
62505352|NCT05404451|EXPERIMENTAL|Mckenzie Exercises|Using Mckenzie Exercises
62505353|NCT02702869||uCL(A)|Children with unilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
62505354|NCT02702869||uCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, or Veau-III).
62505355|NCT02702869||bCL(A)|Children with bilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
62505356|NCT02702869||bCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
62505357|NCT02702869||CP|Children with cleft secondary palate only, but intact lip and alveolus. Subgroup analysis by severity (submucous, Veau-I, or Veau-II).
62505358|NCT00665951|ACTIVE_COMPARATOR|A|Kaletra tablets
62505359|NCT00665951|EXPERIMENTAL|B|Lopimune granules
62505360|NCT00665951|EXPERIMENTAL|C|Lopimune tablets
62505361|NCT05990231|EXPERIMENTAL|Cadonilimab combined with anlotinib|
62505362|NCT06427187|EXPERIMENTAL|distal vessel occlusion Mechanical thromectomy|Each presenting Patient with acute distal vessel occlusion of anterior circulation with (A1-A3)or (M2-M3) either mechanical thrombectomy (MT) with or without intra-venous thrombolysis (IVT) according to standard medical guidelines. MT was performed using approved aspiration catheters or stent-retrievers or both.
62703796|NCT06289257||Endometriosis|Women with endometriosis
61960310|NCT04286243|EXPERIMENTAL|Model 2 - Community Based Screening|Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
61960311|NCT00708968|EXPERIMENTAL|FOCUS Intervention|Dyads randomized to this arm received the FOCUS Program, 3 home visits and 2 phone calls by trained nurses.
61960312|NCT00708968|NO_INTERVENTION|Standard Care|
61960313|NCT02279537||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC)
61960314|NCT02845505||IVUS-CAMS|patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS
61960315|NCT05378880|EXPERIMENTAL|Intervention clusters|Intervention bundle consisting of 3 components introduced over 12 months: one to improve antibiotic use targeting health centres and medicine stores and two targeting the general population: one to increase community health literacy and one to improve water, hygiene and sanitation practices.
62505363|NCT06025552|EXPERIMENTAL|TU7710|TU7710 of escalating 5 doses
62505364|NCT06025552|PLACEBO_COMPARATOR|Normal Saline (placebo of TU7710)|Placebo of TU7710 at corresponding TU7710 dose level
62505365|NCT06393764||Cancer patients treated for MVTE|All the patients are included in one arm. They will undergo various type of samples.
62505366|NCT00183196|ACTIVE_COMPARATOR|1|Naltrexone plus placebo
62505367|NCT00183196|ACTIVE_COMPARATOR|2|naltrexone + gabapentin
62505368|NCT00183196|SHAM_COMPARATOR|3|Placebo plus placebo
62505369|NCT05825768|ACTIVE_COMPARATOR|MRI-group|This group of patients are allocated to a supplementary preoperative breast Magnetic Resonance Imaging (MRI) in addition to standard preoperative breast imaging (ultrasound and mammography).
62505370|NCT05825768|OTHER|Control group|This groups of patients are allocated to receive standard preoperative breast imaging only (ultrasound and mammography).
62505371|NCT06056791|EXPERIMENTAL|Cohort 1: 1 x 10^8 INKmune|"In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~* In Cohort 1, the initial planned dose is 1 x 10\^8 INKmune;~* In Cohort 2, the weekly dose will increase to 3 x 10\^8 INKmune;~* In Cohort 3, the weekly dose will increase to 5 x 10\^8 INKmune.~In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination."
62703797|NCT06289257||Control|Healthy women
62703798|NCT05424237|NO_INTERVENTION|Control group|"1. Sign consent form and baseline assessments~2. Usual care~3. Post intervention assessments"
61960316|NCT05378880|NO_INTERVENTION|Control clusters|
62703799|NCT05424237|EXPERIMENTAL|Interention group|"1. Sign consent form and baseline assessments~2. Usual care + app iNATAL~3. Post intervention assessments"
62703800|NCT06627231|EXPERIMENTAL|TEV-56286|
62703801|NCT06750003|ACTIVE_COMPARATOR|3D laparoscopy|Performed using 3D laparoscopy
62703802|NCT06750003|EXPERIMENTAL|4K laparoscopy|Performed using 4K laparoscopy
62703803|NCT06581432|EXPERIMENTAL|Zongertinib treatment|
62703804|NCT05675436||1|i. Phase 3: Mitapivat 50 mg BID
62703805|NCT05675436||2|ii. Phase 3: Mitapivat 100 mg BID
62703806|NCT05675436||3|iii. Phase 3: Mitapivat Open-Label Extension Period
62703807|NCT06687785||Entire Papilla Preservation Technique|The Entire Papilla Preservation Technique (EPP) is a novel surgical approach aimed at enhancing periodontal regeneration, particularly in the treatment of deep intrabony defects. This technique is characterized by its focus on preserving the entire interdental papilla, which is crucial for both functional and aesthetic outcomes in periodontal therapy. The EPP technique involves creating a tunnel-like undermining incision that allows access to the defect while maintaining the integrity of the papilla, thereby minimizing trauma to the surrounding soft tissues
61960317|NCT02706691|EXPERIMENTAL|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
61960318|NCT03201835|EXPERIMENTAL|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
61960319|NCT03201835|EXPERIMENTAL|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
61960320|NCT03201835|EXPERIMENTAL|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
62703808|NCT06687785||Conventional Flap Surgery|In periodontology, the traditional flap surgery technique is a well-established surgical approach used for the treatment of periodontal diseases, especially in cases with deep periodontal pockets. This technique involves the lifting of a mucoperiosteal flap in the buccal and lingual direction to gain access to the underlying periodontal tissues and allows for thorough debridement of root surfaces and removal of diseased tissue.
62703809|NCT06693362|PLACEBO_COMPARATOR|The Control Group|Received SC01009 placebo plus standard treatment
62703810|NCT06693362|EXPERIMENTAL|The Treatment Group|Received SC01009 in addition to standard treatment.
62703811|NCT05279690|EXPERIMENTAL|Cohort 1 low-dose colchicine|Participants with advanced/recurrent solid tumors who will receive low-dose colchicine (0.6 mg oral BID)
62703812|NCT05279690|EXPERIMENTAL|Cohort 1 high-dose colchicine|Participants with metastatic solid tumors who will receive high-dose colchicine (0.6 mg oral TID)
62703813|NCT05279690|EXPERIMENTAL|Cohort 2 Participants with post-radical surgery|Participants with post-radical surgery for high-risk clinically localized urothelial cancer will receive colchicine 0.6 mg oral BID.
62703814|NCT06136897|EXPERIMENTAL|Treatment (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
62143520|NCT01691716|ACTIVE_COMPARATOR|Tendoactive and eccentric training|Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
62703815|NCT00977574|EXPERIMENTAL|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62703816|NCT00977574|EXPERIMENTAL|Arm II (paclitaxel, carboplatin, temsirolimus)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
61960321|NCT03201835|EXPERIMENTAL|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
61960322|NCT03201835|ACTIVE_COMPARATOR|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
62703817|NCT00977574|EXPERIMENTAL|Arm III (ixabepilone, carboplatin, bevacizumab)|Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
61960323|NCT01025804||Infants|
62143521|NCT00830856|EXPERIMENTAL|1|Early initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and within 72hrs of diagnosis were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
62347423|NCT05352906|ACTIVE_COMPARATOR|Non-contact air-puff tonometer|A non-contact tonometer based on air-puff and corneal hysteresis.
62703818|NCT06714461||Leflunomide|Participants are healthcare professionals in Saudi Arabia completing a survey regarding experience prescribing/managing/dispensing leflunomide
62703819|NCT06748612|EXPERIMENTAL|Arm A|Arm A will receive wP-Penta at 6,10,14 weeks of age and 2 doses of IPV at 14 weeks and 9 months.
62703820|NCT06748612|EXPERIMENTAL|Arm B|Arm B will receive wP-Hexa at 6,10,14 weeks of age
62703821|NCT06748612|EXPERIMENTAL|Arm C|Arm C will receive wP-Hexa at 2,4,6 months of age.
62703822|NCT06748612|ACTIVE_COMPARATOR|Control Arm|Control group will receive EPI schedule of routine immunization: fIPV @ 6, 14 wk, bOPV @ 6, 10, 14 wk , wP-Penta @ 6, 10, 14 wk
61960324|NCT00967668|EXPERIMENTAL|ASPIRE-Phone Lifestyle Coaching|Phone-based coaching using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
61960325|NCT00967668|EXPERIMENTAL|ASPIRE-Group Lifestyle Coaching|On-site weekly group visits using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
61960326|NCT00967668|ACTIVE_COMPARATOR|MOVE! Usual Care|Usual care MOVE!, which consists of weekly on-site group visits that follow MOVE! protocols with unstructured follow-up phone support
61960327|NCT05422196|NO_INTERVENTION|Control group|No platelet-rich fibrin was added to the cleft site during grafting.
61960328|NCT05422196|EXPERIMENTAL|Study group|Platelet-rich fibrin was added to the cleft site during grafting.
61960329|NCT06131567|EXPERIMENTAL|Implantoplasty|Implantoplasty to all the implant surface
61960330|NCT06131567|ACTIVE_COMPARATOR|Implantoplasty on the supracrestal component|Implantoplasty only in the supra-crestal component and the infra bony hydrogen peroxide
61960331|NCT01567124|OTHER|Olanzapine|Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
62703823|NCT05723601|ACTIVE_COMPARATOR|cream used first and then switch to tablets|participants will start with 3 months of cream and then switch to tablets
62703824|NCT05723601|ACTIVE_COMPARATOR|tablets used first and switch to cream|participants will start with 3 months of tablets and switch to cream
62703825|NCT06714448||Sodium valporate|Participants are healthcare professionals completing a survey regarding women of childbearing potential using sodium valporate, prescribe or dispense the treatment
62703826|NCT04474353|EXPERIMENTAL|Novo-TTF|"Day 1: Subjects will wear the Optune (TTFields device) for ≥ 18 hours/day. They will take off the device when receiving stereotactic radiosurgery and brain MRI scans.~Days 1 to 8: Subjects will take oral temozolomide 75 mg/m2/day Days 2 to 8: Subjects will receive stereotactic radiosurgery (total of 35 Gy) divided equally over 5 days~• After the interventional treatment, subjects will receive standard of care adjuvant chemotherapy and routine surveillance brain MRI scans."
62703827|NCT06643832|EXPERIMENTAL|Rubbing Distraction group|rubbing and gently touching on proximal part of the intravenous injection site with the palm of the hand extending to the elbow. This will be started 5 seconds before propofol injection (not mixed with any drug) and continued until loss of consciousness. Also, a mobile video with duration of 10 seconds will be used for distraction and will be started 5 seconds before propofol injection so as to be ended at the time of first pain assessment.
62703828|NCT06643832|ACTIVE_COMPARATOR|Lidocaine group|patients will receive intravenous propofol mixed with 2ml of lidocaine 2% (40mg) before injection.
62703829|NCT06643832|PLACEBO_COMPARATOR|Saline group|patients will receive intravenous propofol not mixed with any drug (except for 2 ml of saline to ensure blindness of the outcome assessor).
62703830|NCT04356612||Achilles Tendon Rupture|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
62703831|NCT03575897|EXPERIMENTAL|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
62703832|NCT03575897|ACTIVE_COMPARATOR|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
61960332|NCT01567124|OTHER|Clozapine|Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
61960333|NCT05771376|EXPERIMENTAL|Intervention Group|Patients who performed the Qigong exercise program
62143522|NCT00830856|EXPERIMENTAL|2|Delayed initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and after completion of high dose fluconazole for 10 weeks, the patients in this group were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
62703833|NCT06746493||Stroke group|All patients from the stroke group were examined twice at the beginning and the end of this trial by a physical therapist. Patients participated in a rehabilitation program at the Neurological Rehabilitation Department between measurements.
62703834|NCT06746493||Control group|The control group consisted of healthy subjects.
62703835|NCT06750484|EXPERIMENTAL|Trastuzumab Deruxtecan|T-DXd will be administered intravenously every 3 weeks at a dose of 5.4 mg per kilogram of body weight until disease progression, limiting toxicity, withdrawal of consent, or death. For T-DXd, each cycle of treatment will be 21 days. The number of treatment cycles with T-DXd is not fixed.
62703836|NCT06479824|EXPERIMENTAL|Treatment|TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)
62703837|NCT06743828|EXPERIMENTAL|Fermented product|Participants consume a fermented pea- and legume-based product daily for three weeks within their diet.
62703838|NCT06743828|ACTIVE_COMPARATOR|Unfermented product|Participants consume an unfermented pea- and legume-based product daily for three weeks within their diet.
62703839|NCT06743828|NO_INTERVENTION|Habitual diet|Participants consume their habitual diet without any intervention products.
62703840|NCT06736041|EXPERIMENTAL|Group 1: PCV21|Participants will be administered via intramuscular injection (IM) a 3-dose primary series of PCV21 at approximately 2, 4 and 6 months of age (MoA) co- administered with Vaxelis or Hexaxim (for participants included in South Korea only) and RotaTeq. At toddler age (12 to 15 MoA), a 4th dose of PCV21 will be administered concomitantly with a single dose of M-M-M-R II and Varivax.
62703841|NCT06736041|ACTIVE_COMPARATOR|Group 2: 20vPCV|Participants will be administered via intramuscular injection (IM) a 3-dose primary series of 20vPCV at approximately 2, 4 and 6 months of age (MoA) co- administered with Vaxelis or Hexaxim (for participants included in South Korea only) and RotaTeq. At toddler age (12 to 15 MoA), a 4th dose of 20vPCV will be administered concomitantly with a single dose of M-M-M-R II and Varivax.
61960334|NCT05771376|EXPERIMENTAL|Control Group|Patients who performed a home exercise program
61960335|NCT05148598|EXPERIMENTAL|ADRC Arm|Subjects in the ADRC arm will receive standard care and active treatment (ADRCs)
61960336|NCT05148598|PLACEBO_COMPARATOR|Standard Care Arm|Subjects in the Standard Care arm will receive standard care and Placebo
62143523|NCT02104349|EXPERIMENTAL|Mindfulness meditation|Subjects who are instructed on use of the mindfulness meditation technique
62143524|NCT02104349|NO_INTERVENTION|Control|Subjects will receive standard surgery treatment without any mindfulness intervention.
62143525|NCT03498365|EXPERIMENTAL|Online MCDA|
62143526|NCT03498365|ACTIVE_COMPARATOR|Online Delphi|
62143527|NCT04758949|EXPERIMENTAL|FL-101 Monotherapy|30 patients will receive FL-101 prior to surgery.
62703842|NCT06744868|EXPERIMENTAL|THDBH120 injection (SAD)|
62703843|NCT06744868|PLACEBO_COMPARATOR|Placebo of THDBH120 injection (SAD)|
62703844|NCT06744868|EXPERIMENTAL|THDBH120 injection (MAD)|
62703845|NCT06744868|PLACEBO_COMPARATOR|Placebo of THDBH120 injection (MAD)|
62703846|NCT06747923|EXPERIMENTAL|SB17170 of 250mg, Single dose|
62703847|NCT06747923|EXPERIMENTAL|SB17170 of 500mg, Single dose|
62703848|NCT06747923|PLACEBO_COMPARATOR|Placebo|
62703849|NCT06746285|ACTIVE_COMPARATOR|Synbiotic Supplement|Participants aged 2 months to 24 months will receive daily synbiotic supplementation (probiotic+ prebiotic) for 1 month
62703850|NCT06746285|PLACEBO_COMPARATOR|Lactose|Participants aged 2 months to 24 months will receive daily placebo (lactose) for 1 month
61960337|NCT01306942|EXPERIMENTAL|Dasatinib + trastuzumab + paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg once daily (QD) (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
61960338|NCT02994212|EXPERIMENTAL|Intervention group|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF. Anthropometric measurements were taken on a weekly basis for 4 weeks to monitor treatment response.
61960339|NCT01927510|EXPERIMENTAL|early mobilisation|intervention of early mobilisation
61960340|NCT01927510|NO_INTERVENTION|Control|Standard care
61960341|NCT01312272|PLACEBO_COMPARATOR|Inactive nasal spray|A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
61960342|NCT01312272|EXPERIMENTAL|Intranasal Oxytocin|Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
61960343|NCT05608798|OTHER|Examination with the ODI-Tech medical device|"Diffuse reflectance spectroscopy (DRS) operating within the visible wavelength region will be used for the microvascular oxygen saturation and haematocrit measurements.~Computer-assisted microscopy (CAM) will be used for recording frames of skin microcirculation."
62505372|NCT06056791|EXPERIMENTAL|Cohort 2: 3 x 10^8 INKmune|"In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~* In Cohort 1, the initial planned dose is 1 x 10\^8 INKmune;~* In Cohort 2, the weekly dose will increase to 3 x 10\^8 INKmune;~* In Cohort 3, the weekly dose will increase to 5 x 10\^8 INKmune.~In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination."
62505373|NCT06056791|EXPERIMENTAL|Cohort 3: 5 x 10^8 INKmune|"In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~* In Cohort 1, the initial planned dose is 1 x 10\^8 INKmune;~* In Cohort 2, the weekly dose will increase to 3 x 10\^8 INKmune;~* In Cohort 3, the weekly dose will increase to 5 x 10\^8 INKmune.~In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination."
62143528|NCT04758949|EXPERIMENTAL|FL-101 + Nivolumab|30 patients will receive FL-101 and Nivolumab prior to surgery.
62505374|NCT04684680|EXPERIMENTAL|zamzam water|patient will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
62505375|NCT04684680|ACTIVE_COMPARATOR|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
62505376|NCT02724826|EXPERIMENTAL|Qigong therapy|The qigong treatment was done according to medical qigong, and is a way of affecting and directing qi (energy) for medical benefit. Each qigong practice included body posture adjustment, gentle movement, meditation, relaxation, breathing regulation practices and massage. The qigong was practiced in groups of ten to 15 participants. Each qigong session started with information about the philosophy and a general warm-up with soft movements and 14 selected qigong exercises according to the Biyun method.
62505377|NCT02724826|ACTIVE_COMPARATOR|Exercise therapy|Exercise therapy was carried out individually, adjusted for each participant. A physiotherapist instructed the participant with focused on the cervical and shoulder/thoracic regions. Each training session included stationary bicycle for ten minutes, 40 minutes of dynamic exercises. These exercises consisted of active movements in all neck directions and muscle exercises aimed to maintain/increase circulation, endurance and strength. The load at the muscle exercises was to achieve between 30 and 70% of maximum muscle capacity and was gradually increased as endurance and strength were gained.
62505378|NCT05409352|EXPERIMENTAL|Self-administered acupressure|The entire intervention will last 12 weeks, including a one-on-one, 90-min instructional session at week 1 and a one-hour follow-up visit at week 2, which are conducted by a trained traditional Chinese medicine practitioner. Participants will be instructed to perform self-acupressure on the acupoints according to individualized protocol once a day. Participants will be instructed to maintain self-practice after the intervention.
62703851|NCT04749615|PLACEBO_COMPARATOR|No PAI + ACB & IPACK|Control: saline injection (same injection technique and volumes as described for the active intervention, of normal saline)
62703852|NCT04749615|ACTIVE_COMPARATOR|PAI + ACB & IPACK|Active intervention: Periarticular injection: one deep injection prior to cementation and then a second more superficial injection prior to closure. The deep injection will consist of bupivacaine 0.25% with 1:200,000 epinephrine, 30 cc; morphine, 8 mg/ml, 1cc; methylprednisolone, 40 mg/ml, 1 ml; cefazolin, 500 in 10 ml; normal saline, 22cc. The superficial injection will be 20 ml 0.25% bupivacaine
62703853|NCT05308446|EXPERIMENTAL|Arm I (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61960344|NCT03384212|EXPERIMENTAL|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
61960345|NCT03384212|ACTIVE_COMPARATOR|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
61960346|NCT02871700|EXPERIMENTAL|Action observation therapy (AOT)|Action observation therapy (AOT)
61960347|NCT02871700|EXPERIMENTAL|Mirror therapy (MT)|Mirror therapy (MT)
62143529|NCT04758949|ACTIVE_COMPARATOR|Nivolumab + Placebo|30 patients will receive Nivolumab and placebo prior to surgery.
61960348|NCT02871700|ACTIVE_COMPARATOR|Control group|Customary bilateral UE training
61960349|NCT05609006|EXPERIMENTAL|Group A: High-Energy, Low-Volume ONS // High-Energy Standard ONS|Intervention: high-energy low-volume ONS (2.4kcal/ml; 125ml) for 28 days followed by high-energy standard ONS (2.0kcal/ml; 200ml) for 28 days
61960350|NCT05609006|EXPERIMENTAL|Group B: High-Energy Standard ONS // High-Energy, Low-Volume ONS|Intervention: high-energy standard ONS (2.0kcal/ml; 200ml) for 28 days followed by high-energy low-volume ONS (2.4kcal/ml; 125ml) for 28 days
61960351|NCT00509015|ACTIVE_COMPARATOR|1|Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
61960352|NCT00509015|PLACEBO_COMPARATOR|2|Placebo: lactose tablets (Albochin)
61960353|NCT02871414|EXPERIMENTAL|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
62505379|NCT05409352|ACTIVE_COMPARATOR|Aerobic exercise|The 12-week aerobic exercise program consists of a one-on-one, 90-min instructional session at week 1 and a one-hour follow-up visit at week 2, which are conducted by a trained exercise specialist. Participants will be advised to perform aerobic exercise of moderate intensity 3 times per week for 30 minutes each time. Accumulating 90 min of exercise per week through more frequent short bouts (e.g. 10-20 min daily) are allowed during the first week of each chemotherapy cycle due to increased symptom burden. Participants will be instructed to maintain self-practice after the intervention.
61960354|NCT02871414|EXPERIMENTAL|REST - Late Group|Control - No treatment for 7 weeks, then provided 7 weeks of sleep skills education provided in group and one-on-one format
61960355|NCT00971594|EXPERIMENTAL|WL+AEX|Weight loss plus aerobic exercise
61960356|NCT04698460|EXPERIMENTAL|Hybrid coronary revascularization (HCR)|Patients with multi-vessel CAD randomized to hybrid coronary revascularization
61960357|NCT04698460|ACTIVE_COMPARATOR|Conventional coronary artery bypass grafting (CABG)|Patients with multi-vessel CAD randomized to conventional CABG
61960358|NCT01752127|ACTIVE_COMPARATOR|DM arms|comparison of two different stents(Xience prime and Resolute integrity)
61960359|NCT01752127|ACTIVE_COMPARATOR|Small vessel arms|comparison of two different stents(Xience prime and Resolute integrity)
61960360|NCT04579757|EXPERIMENTAL|Surufatinib and tislelizumab (dose escalation_Part 1)|In Part 1 (dose escalation), surufatinib and will be administered orally (PO) once daily (QD) and tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).
62505380|NCT04225260|EXPERIMENTAL|QM1114-DP in the LCL and the GL areas|"The investigational product (QM1114-DP) is a BoNT Type A.~At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines."
62505381|NCT03278509|EXPERIMENTAL|Oral beta-blocker treatment|Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician. Metoprolol succinate will be strongly recommended as first choice. Bisoprolol will be allowed as an alternative. Atenolol (or any other beta-blocker therapy) will not be allowed. The treating physician will be encouraged to aim for a dose of ≥ 100 mg for metoprolol succinate and ≥ 5 mg for bisoprolol. Prescribed treatment and dosing will be registered. Initiation (whether the prescribed drug is dispensed) and adherence (defined as proportion of prescribed tablets that are dispensed), and persistence (time on treatment) will also be recorded via the Drug prescription registry.
62703854|NCT05308446|ACTIVE_COMPARATOR|Arm II (encorafenib, cetuximab)|Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61960361|NCT04579757|EXPERIMENTAL|Surufatinib and tislelizumab (indication specific_Part 2)|In Part 2, the indication-specific expansion portion of the study, patients will receive surufatinib at the Recommended Phase 2 Dose (RP2D) dose selected in Part 1 with 200 mg tislelizumab IV, Q3W
61960362|NCT05654337|EXPERIMENTAL|Dietary and physical activity plan and advice on lifestyle change|Dietary and physical activity schedules and instructed lifestyle change advice provided by a trained health coach and dietary education provided by a trained and licensed dietitian to the obese and overweight at the primary care centre.
61960363|NCT05654337|NO_INTERVENTION|Routine care for cases with obesity and overwieght|Adults with obesity and overweight attending routine primary care clinics
61960364|NCT03312101|EXPERIMENTAL|Experimental|exercise program
61960365|NCT03312101|NO_INTERVENTION|Control|observation
61960366|NCT02505867|EXPERIMENTAL|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
61960367|NCT02505867|NO_INTERVENTION|Control|No device provided
61960368|NCT05772832||GROUP USING REMIFENTANYL|THE GROUP USING PEROPERATIVE REMIFENTANYL AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.2 μg /kg /min Remifentanyl and 3-12 mg/kg/h propofol
61960369|NCT05772832||GROUP USING DEXMEDETOMIDINE|THE GROUP USING PEROPERATIVE DEXMEDETOMIDINE AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.02 μg/kg/min (\~0.5 μg/kg/h) continuous infusion of dexmedetomidine 1 mcg/kg 10 minutes after a loading dose and 3-12 mg/kg/h propofol
61960370|NCT02535117|EXPERIMENTAL|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
61960371|NCT02535117|ACTIVE_COMPARATOR|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
61960372|NCT01324908|EXPERIMENTAL|Treatment (Treg predictor of response to ECP)|Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.
61960373|NCT01369095|ACTIVE_COMPARATOR|Arm 1: Duloxetine / Escitalopram + BMS-820836 placebo|
62505382|NCT03278509|NO_INTERVENTION|No beta-blocker treatment|Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Patients assigned to no beta-blockade also receive best evidence-based care, without beta-blockers. For blood pressure control, other drugs than beta-blockers will be recommended as first-line treatment. Regarding later use of beta-blockade, follow up is performed in the Drug prescription registry. Patients will be asked to provide future physicians with the written information about the study when beta-blockade treatment is discussed.
62505383|NCT01848210|EXPERIMENTAL|Coumarin 30 mg + Troxerutin 180 mg|Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.
62505384|NCT01848210|PLACEBO_COMPARATOR|Placebo|Coumarin + troxerutin placebo-matching tablets, orally, three times daily for up to 16 weeks.
61960374|NCT01369095|EXPERIMENTAL|Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placebo|
62347424|NCT04816149|ACTIVE_COMPARATOR|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
62347425|NCT04816149|EXPERIMENTAL|Treatment for Relationships and Safety Together (TR&ST)|TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
62347426|NCT01408667|PLACEBO_COMPARATOR|Placebo|
62347427|NCT01408667|ACTIVE_COMPARATOR|TRC150094|
62347428|NCT02252575|EXPERIMENTAL|Electromagnetic field|Exposure to the elctromagnetic field of an electric motor
62347429|NCT03828149|ACTIVE_COMPARATOR|Drug: OP0201|20 mg dose one time, followed by a washout and then a 0 mg dose one time, cross over design
62347430|NCT03828149|PLACEBO_COMPARATOR|Drug: Placebo|0 mg dose one time, followed by a washout and then a 20 mg dose one time, cross over design
62347431|NCT06168500|EXPERIMENTAL|Test Group|
62347432|NCT06168500|EXPERIMENTAL|Control group|
62347433|NCT03698188|EXPERIMENTAL|Injectable platelet-rich fibrin|A platelet concentrate will be prepared from the patient's own blood in plain plastic tubes, without the use of anticoagulants, and applied immediately within the root canal before coagulation.
62347434|NCT03698188|ACTIVE_COMPARATOR|Platelet-rich plasma|A platelet concentrate will be prepared from the patient's own blood in tubes containing anticoagulants to maintain the fluid consistency and applied within the root canal.
62347435|NCT00697658||001|
62347436|NCT01986153||Home parenteral nutrition patients|Patients who receive home parenteral nutrition.
62347437|NCT01986153||Healthy controls|Those who don't receive home parenteral nutrition and consume a normal diet.
62347438|NCT04940507|EXPERIMENTAL|Tumor cohort|"Intervention 1:~Participants will undergo a partial tumor ablation with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel). Blood and CSF samples will be drawn on several timepoints before and after the procedure.~Intervention 2:~Participants will undergo a standard of care tumor biopsy/excision one day after the Intervention 1. Blood samples will be drawn on several timepoints before and after the procedure."
62347439|NCT04940507|OTHER|Essential tremor cohort|To identify the levels of circulating free DNA release after MRgFUS procedure in non-tumoral patients and to check whether the MRgFUS procedure induce tumoral mutations itself, we will draw blood samples from essential tremor patients before and after standard of care MRgFUS thalamotomy procedure.
62347440|NCT03409029|EXPERIMENTAL|MRI Scan|As part of the study patients will undergo 4 MRI scans during radiotherapy treatment. These will take place during the 1st, 2nd, 3rd and 4th week of treatment
62347441|NCT02655445|ACTIVE_COMPARATOR|Mini-craniotomy|"Intervention: Bone flap \> 30mm and replaced, placement of Jackson-Pratt drain~A linear incision located over the biggest bulk of the hematoma is made. Dura is opened and a wide opening of the pseudomembrane is done. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
62505385|NCT05016687|EXPERIMENTAL|Experimental Part I Cohort 1-5: CUR-N399|Healthy subjects 18-55 years will receive single ascending doses of CUR-N399. Planned doses for respective Cohorts: Cohort 1: 2.5 mg, Cohort 2: 7.5 mg, Cohort 3: 17.5 mg, Cohort 4: 35 mg, Cohort 5: 50 mg.
62505386|NCT05016687|PLACEBO_COMPARATOR|Experimental Part I Cohort 1-5: Placebo|Healthy subjects will receive Placebo to match treatment of CUR-N399.
62505387|NCT05016687|EXPERIMENTAL|Experimental Part IIa Cohort 1-3: CUR-N399|Healthy subjects 18-55 years will receive multiple ascending doses of CUR-N399 during a 7-day period. Planned doses for respective Cohorts: Cohort 1: 10 mg/day, Cohort 2: 25 mg/day, Cohort 3: 50 mg/day.
62505388|NCT05016687|PLACEBO_COMPARATOR|Experimental Part IIa Cohort 1-3: Placebo|Healthy subjects 18-55 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
62505389|NCT05016687|EXPERIMENTAL|Experimental Part IIb: CUR-N399|Healthy subjects \>/= 65 years will receive multiple ascending doses of CUR-N399 during a 7-day period. The dose to be administered will determined based on safety results in Part IIa.
61960375|NCT01369095|EXPERIMENTAL|Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placebo|
61960376|NCT01369095|EXPERIMENTAL|Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placebo|
61960377|NCT01369095|EXPERIMENTAL|Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placebo|
61960378|NCT06259747|EXPERIMENTAL|acutaping and traditional medical treatment|received acutaping in addition to traditional medical treatment (Doxylamine and Pyridoxine)
61960379|NCT06259747|EXPERIMENTAL|traditional medical treatment only|received traditional medical treatment only (Doxylamine and Pyridoxine
61960380|NCT04112056|EXPERIMENTAL|Study formula|The infants recruited are provided with the study formula named NAN Comfort producted by Nestle Deutschland AG, Werk Biessenhofen containing moderately hydrolyzed protein and low lactose for free during study, and asked to drink the study formula more than half of the total diet daily.
62703855|NCT02838381|OTHER|Additional biological samples|"Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.~Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available."
62703856|NCT06746779||Easy Access Group|Patients with successful ureteral access on the first attempt during retrograde intrarenal surgery (RIRS).
61960381|NCT01686529|EXPERIMENTAL|One subconjunctival injection|Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
61960382|NCT01686529|EXPERIMENTAL|Two subconjuctival injections|Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
61960383|NCT01686529|ACTIVE_COMPARATOR|Conventional treatment|Autoconjunctival grafting without subconjuntival bevacizumab injection
61960384|NCT04056910|EXPERIMENTAL|Concurrent dosing of ivosidenib and nivolumab|Ivosidenib will be administered concurrently with nivolumab on a Q28 day schedule.
61960385|NCT02200562|EXPERIMENTAL|Ipilimumab and Dabrafenib|
62143530|NCT01800305|EXPERIMENTAL|Pegylated rhEPO|Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg，3.2mcg/kg, 4.2mcg/kg, 5.5 mcg/kg, 7.2 mcg/kg, 9.3 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe.started with the second 3.2mcg/kg dose,Every subject takes Niferex 150mg every day, from day 1 to day 20. ) of the test drug (Pegylated rhEPO)
62703857|NCT06746779||Difficult Access Group|Patients requiring multiple attempts for ureteral access, alternative procedures, or cases where the planned surgery could not be completed due to access issues.
62703858|NCT04310007|EXPERIMENTAL|Step 1, Arm A (cabozantinib S-malate)|Patients in Step 1, Arm A receive cabozantinib S-malate PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
61960386|NCT00786500|ACTIVE_COMPARATOR|Gynostemma pentaphyllum tea|
61960387|NCT00786500|PLACEBO_COMPARATOR|Placebo tea|
61960388|NCT01095445|NO_INTERVENTION|Standard of care treatment|Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
61960389|NCT01095445|ACTIVE_COMPARATOR|Extended therapy|Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.
61960390|NCT00667069|OTHER|A Relapse|Radiotherapy and Hormonotherapy only if relapse
62143531|NCT01800305|ACTIVE_COMPARATOR|EPIAO®|Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, of the comparator drug(EPIAO®) at day 1, 3, 5, 8, 10, 12.
62347442|NCT02655445|ACTIVE_COMPARATOR|Twist Drill Craniostomy|"Intervention: twist drill burr hole \<5mm, placement of Integra basket-type drain~A stab incision to the scalp is made, at the approximate location of the thickest diameter of hematoma. The twist-drill hole \<5mm is placed obliquely to the surface of the skull, at an angle of about 45° until perforation of the dura. No irrigation is performed. A basket-type drain (Integra) is placed in the subdural space and tunneled underneath the skin"
62505390|NCT05016687|PLACEBO_COMPARATOR|Experimental Part IIb: Placebo|Healthy subjects \>/= 65 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
62505391|NCT00575380|ACTIVE_COMPARATOR|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days
62505392|NCT00575380|ACTIVE_COMPARATOR|Vigamox Eye Drops|One drop three times a day for seven days
62505393|NCT01247792|NO_INTERVENTION|"Before"|No Intervention Observation of current practice
62703859|NCT04310007|EXPERIMENTAL|Step 1, Arm B (cabozantinib S-malate, nivolumab)|Patients in Step 1, Arm B receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
62703860|NCT04310007|ACTIVE_COMPARATOR|Step 1, Arm C (standard chemotherapy)|Patients in Step 1, Arm C receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
61960391|NCT00667069|EXPERIMENTAL|B Immediate treatment|Radiotherapy and Hormonotherapy at randomization
61960392|NCT01278979|ACTIVE_COMPARATOR|Assessment of perineal tears|Consenting women sustaining perineal tear after child birth
61960393|NCT01278979|OTHER|Visual and digital assessment|Consenting women that sustained perineal tear after child birth.
61960394|NCT00753415|EXPERIMENTAL|Part A: V935 LD|Two intramuscular (IM) injections of V935 low dose (LD), 1 given every other week over a 3-week period.
61960395|NCT00753415|EXPERIMENTAL|Part A: V934 LD(3)+V935 LD|Three electroporation (EP) injections of V934 (LD) , 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (LD) will be administered, 1 given every other week over a 3-week period.
61960396|NCT00753415|EXPERIMENTAL|Part A: V935 HD|Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.
61960397|NCT00753415|EXPERIMENTAL|Part A: V934 HD(3)+V935 HD|Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
62143532|NCT01567787|EXPERIMENTAL|Proton Radiation for MPNST|Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
62143533|NCT01567787|EXPERIMENTAL|Proton Radiation for neurofibromas|Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
61960398|NCT00753415|EXPERIMENTAL|Part A: V934 HD(5)+V935 HD|Five EP injections of V934 (HD), 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
61960399|NCT00753415|EXPERIMENTAL|Part B: V935 LD/V934 Booster|Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.
61960400|NCT00753415|EXPERIMENTAL|Part B: V934 LD(3)+V935 LD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
61960401|NCT00753415|EXPERIMENTAL|Part B: V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
61960402|NCT00753415|EXPERIMENTAL|Part B: V934 HD(3)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
62505394|NCT01247792|OTHER|"After"|SOPs for decision-making and communication Assessment of practice after implementation of SOPs
62505395|NCT01923311|EXPERIMENTAL|Cohort 1 (12 to < 18 years of age)|"Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.~Part B: Participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
61960403|NCT00753415|EXPERIMENTAL|Part B: V934 HD(5)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
61960404|NCT06139029|EXPERIMENTAL|Patients in Group-A were nebulized with 3% normal saline|Patients in Group-A were nebulized with 3% normal saline 3 times a day at intervals of 8 hours until they improved enough for discharge
61960405|NCT06139029|EXPERIMENTAL|patients in Group-B were nebulized with steroid and salbutamol with 0.9% normal saline|patients in Group-B were nebulized with steroid (beclomethasone dipropionate 400 μg/day in 3 divided doses) and salbutamol with 0.9% normal saline 3 times a day at intervals of 8 hours until they improved enough for discharge
61960406|NCT01193868|EXPERIMENTAL|RO4929097|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for pharmacogenetic, pharmacodynamic, and biomarker studies by IHC, FISH, and TUNEL assay."
61960407|NCT03415035||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label
61960408|NCT02215291||Patients undergoing EGD or esophagoscopy|The cohort includes patients undergoing EGD or esophagoscopy for initial diagnosis or initial staging and mapping, surveillance of non-treated disease, and treatment (initial or ongoing) or post-treatment surveillance
61960409|NCT06354595|OTHER|Colorectal cancer survivors and their families|Using the Colorectal Cancer Survivor Metaverse Multidimensional Rehabilitation Platform, and provide feedback and suggestions.
61960410|NCT03060629|EXPERIMENTAL|Group 1|Participants will receive Ad26.Mos4.HIV 5\*10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 \[microgram\] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
61960411|NCT03060629|PLACEBO_COMPARATOR|Group 2|Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
61960412|NCT00042289||DRV/RTV 600 or 800 or 900/100mg b.i.d. then 800 or 900/100mg b.i.d. then 600/100mg b.i.d.|"HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received:~darunavir/ritonavir (DRV/RTV) 600/100 mg twice daily (b.i.d.) or 800/100 mg b.i.d. until 30 weeks gestation; then 800/100 mg b.i.d. until postpartum hospital discharge; then 600/100 mg b.i.d. after postpartum hospital discharge until 2 week postpartum PK samples are drawn.~OR darunavir/ritonavir twice daily 600/100 mg b.i.d. or 900/100 mg b.i.d. until 30 weeks gestation; then 900/100 mg b.i.d. until postpartum hospital discharge; then 600/100 mg b.i.d. after postpartum hospital discharge until 2 week postpartum PK samples are drawn."
61960413|NCT00042289||DTG 50mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received dolutegravir (DTG) 50 mg once a day (q.d.).
61960414|NCT00042289||TAF 25mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 25 mg q.d. without cobicistat or ritonavir boosting.
61960415|NCT00042289||TAF 10mg q.d. w/COBI|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 10 mg q.d. with cobicistat (COBI).
61960416|NCT00042289||TAF 25mg q.d. w/COBI or RTV boosting|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 25 mg q.d. with cobicistat (COBI) or ritonavir (RTV) boosting.
61960417|NCT00042289||EVG/COBI 150/150mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received elvitegravir/cobicistat (EVG/COBI) 150/150 mg q.d
61960418|NCT00042289||DRV/COBI 800/150 mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d.
61960419|NCT00042289||ATV/COBI 300/150 mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d.
61960420|NCT00042289||EFV 600 mg q.d. (outside THA)|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received efavirenz (EFV) 600 mg q.d. (Participants outside of Thailand only)
61960421|NCT00042289||EFV 600mg q.d. and at least one 1st line TB drug|"HIV-infected pregnant women ≥ 20 weeks gestation who received efavirenz (EFV) 600mg q.d.and TB treatment with at least one of the following TB drugs at study entry:~* rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
62505396|NCT01923311|EXPERIMENTAL|Cohort 2 (6 to < 12 years of age)|"Part A: Participants with HIV-1 RNA \< 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA \> 1,000 copies/mL will receive EVG along with a newly constructed background regimen that includes a Pl/r for 48 weeks. Participants with HIV-1 RNA \> 1,000 copies/mL can continue after Week 48.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. Participants who complete the 48-week follow-up in both Part A and Part B will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
62505397|NCT01923311|EXPERIMENTAL|Cohort 3 (2 to < 6 years of age)|"Part A: Participants with HIV-1 RNA \< 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
62505398|NCT01923311|EXPERIMENTAL|Cohort 4 (4 weeks to < 2 years of age)|"Part A: Participants with HIV-1 RNA \< 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
62505399|NCT06106334|EXPERIMENTAL|S-309309|"All participants will receive each of the following treatments:~* Days 1 and 19: S-309309 once daily (QD); in the fasted state)~* Day 15: Itraconazole twice daily (BID); in the fed state)~* Days 16 to 24: Itraconazole QD (in the fed state, except for Day 19 \[co-administration with S-309309 in the fasted state\])"
62505400|NCT03944161|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive an oral nutrition supplement bottle (200/220 ml) with \>20 % of protein and 1.5 Kcal/ml without fibre twice a day during 12 weeks and nutritional advice.
62505401|NCT03944161|ACTIVE_COMPARATOR|Control group|Participants in the control group will receive nutrition advice
62505402|NCT04231331|PLACEBO_COMPARATOR|Placebo|All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
62505403|NCT04231331|ACTIVE_COMPARATOR|Ertugliflozin|All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
62505404|NCT06418997|ACTIVE_COMPARATOR|CBI-Virtual Reality|Over 8 weekly 1-hour sessions, participants will learn about the cognitive-behavioral model from trained peer coaches, develop cognitive-behavioral skills that they can utilize in their daily lives (such as cognitive restructuring), and engage with a receptive community of peers. Participants randomized to this arm will access these sessions using a virtual reality headset.
62505405|NCT06418997|ACTIVE_COMPARATOR|CBI-Flat Screen|Over 8 weekly 1-hour sessions, participants will learn about the cognitive-behavioral model from trained peer coaches, develop cognitive-behavioral skills and habits that they can utilize in their daily lives (such as cognitive restructuring), and engage with a receptive community of peers. Participants randomized to this arm will access these sessions using a flat-screen device, such as a computer.
62505406|NCT06418997|NO_INTERVENTION|Delayed-Access Control|Participants randomized to this arm will be asked not to attend CBI sessions.
62505407|NCT03367936|ACTIVE_COMPARATOR|Self-monitoring group|All subjects will use a smartphone to self-monitor diet and monitor physical activity (Fitbit Charge 2), and a Withings or Fitibit digital scale for weight. Following randomization, participants will be oriented to Self-monitoring and provided a tutorial with images shown on the laptop and devices as well as printed materials showing the screen shots. At baseline, each participant will have a one-on-one session with the project interventionist, which covers the core principles of behavioral weight loss. The participant also will be given personalized fat, calorie, and PA goals for weight loss and information about how to access the intervention materials from the Diabetes Prevention Program (DPP) online which is publicly available (https://www.diabetesprevention.pitt.edu/).
61960422|NCT00042289||LPV/RTV 800/200mg b.i.d. and at least one 1st line TB drug|"HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV) 800/200mg b.i.d. and TB treatment with at least one of the following TB drugs at study entry:~* rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
61960423|NCT00042289||No ARVs and at least two 1st line TB drugs|"HIV-uninfected pregnant women ≥ 20 weeks gestation who received at least two of the following first line TB drugs at study entry:~* rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
61960424|NCT00042289||At least two 2nd line TB drugs w/ or w/out ARVs|"HIV-infected and HIV-uninfected pregnant women ≥ 20 weeks gestation who received at least two of the following second line TB drugs at study entry:~Injectable agents:~* kanamycin~* amikacin~* capreomycin~Fluoroquinolones:~* moxifloxacin~* levofloxacin~* ofloxacin~Oral bacteriostatic second-line agents:~* ethionamide/prothionamide~* terizidone/cycloserine~* para-aminosalicylic acid (PAS)~Other agents:~* high dose INH~* bedaquiline~* clofazamine~* delamanid~* linezolid~* pretomanid"
62703861|NCT04310007|EXPERIMENTAL|Step 2, Arm Z (cabozantinib S-malate, nivolumab)|Patients in Step 2, Arm Z receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
62505408|NCT03367936|EXPERIMENTAL|Self-monitoring+Feedback group|All subjects will be asked to do everything the self-monitoring group is asked to do. Subjects will receive up to 4 Feedback messages per day (messages will be delivered between the hours set by the participants on the participant's phone, e.g., 8 AM and 9:30 PM). Messages will be delivered automatically, remotely and in real-time. Messages will be tailored to each participant's progress based on standardized algorithms. The Feedback program will be explained to them and how this is responsive to information entered on the self-monitoring diaries.
62703862|NCT06747286|EXPERIMENTAL|Experiment group|Group to be applied virtual game simulation
61960425|NCT00042289||DRV/COBI 800/150mg q.d. or ATV/COBI 300/150mg q.d with 30-35ug EE|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d. or atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol
61960426|NCT00042289||DRV/COBI 800/150mg q.d. or ATV/COBI 300/150mg q.d with ENG|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d. or atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d. postpartum and starting etonogestrel (ENG) implant
61960427|NCT00042289||EFV 600mg q.d. with 30-35ug EE|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received efavirenz (EFV) 600mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
62703863|NCT06747286|NO_INTERVENTION|Control group|Control group
61960428|NCT00042289||ATV/RTV/TFV 300/100/300mg q.d. with 30-35ug EE|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received atazanavir/ritonavir/tenofovir (ATV/RTV/TFV) 300/100/300 mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
61960429|NCT00042289||NVP 200mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received nevirapine (NVP) 200 mg twice a day
61960430|NCT00042289||APV 1200mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received amprenavir (APV) 1200mg twice a day
61960431|NCT00042289||ABC 300mg b.i.d|HIV-infected pregnant women ≥ 20 weeks gestation who received abacavir (ABC) 300mg twice a day
61960432|NCT00042289||LPV/RTV Arm 1: 400/100mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received lopinavir/ritonavir (LPV/RTV) 400/100mg twice a day
62505409|NCT02609516||Healthy|Patients without any of the pre-specified chronic diseases
61960433|NCT00042289||IDV/RTV Arm 1: 800/100mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received indinavir/ritonavir (IDV/RTV) 800/100 mg twice a day
61960434|NCT00042289||FPV/RTV 700/100mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received fosamprenavir/ritonavir (FPV/RTV)700/100mg twice a day
61960435|NCT00042289||LPV/RTV Arm 2: 400/100mg b.i.d. then 533/133mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received Kaletra (LPV/RTV) 400/100 mg twice a day until 30 weeks gestation, then 533/133 mg twice a day until results of postpartum PK evaluation were available
62143534|NCT00853580|PLACEBO_COMPARATOR|2|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
62505410|NCT02609516||Multimorbid|Patients having any two or more of the pre-specified chronic diseases
62505411|NCT06679166||Cerebral palsy|23 children aged 5-12 years diagnosed with cerebral palsy
62505412|NCT06679166||Healthy children|A total of 23 children aged 5-12 years diagnosed with cerebral palsy and 23 healthy children without a diagnosis of cerebral palsy in the same age range will be included.
62505413|NCT06036680||Endoscopic balloon dilatation (EBD) treated CD patients|
62505414|NCT06036680||Self-expandable metal stent (SEMS) treated CD patients|
62703864|NCT06722664|EXPERIMENTAL|Recombinant Human Chymotrypsin(OsrhCT) 4000U|
62703865|NCT06722664|EXPERIMENTAL|Recombinant Human Chymotrypsin(OsrhCT) 8000U|
62703866|NCT06722664|PLACEBO_COMPARATOR|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|
62703867|NCT06704191|EXPERIMENTAL|Treatment (BCG, gemcitabine, docetaxel, mitomycin)|"INDUCTION (PHASE IB COHORT AND PHASE II COHORT): Patients receive BCG intravesically over 1-2 hours, gemcitabine intravesically over 1-2 hours, gemcitabine intravesically over 1 hour followed by docetaxel intravesically over 1 hour or mitomycin C intravesically over 1-2 hours in the urology clinic. Treatment repeats once weekly in the home for up to 5 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (PHASE II COHORT ONLY): Patients receive in-home BCG intravesically over 1-2 hours once weekly for 3 weeks, gemcitabine intravesically over 1-2 hours once monthly for 3 months, gemcitabine intravesically over 1 hour followed by docetaxel intravesically over 1 hour once monthly for 3 months or mitomycin C intravesically over 1-2 hours once monthly for 3 months in the absence of disease progression or unacceptable toxicity.~Additionally, patients undergo cystoscopy at end of study and receive access to CCBW home health visits throughout the study."
62703868|NCT02936752|EXPERIMENTAL|Treatment (entinostat, pembrolizumab)|Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.
62703869|NCT06727331|EXPERIMENTAL|Tirzepatide|This arm will receive tirzepatide (n=10) weekly 2.5mg injections for 4 weeks.
62703870|NCT06727331|PLACEBO_COMPARATOR|Saline Placebo|This arm will receive saline placebo injections (n=10) weekly for 4 weeks.
62703871|NCT06733155|NO_INTERVENTION|Observational Arm|Does not receive any mailer reminder to go for mammogram.
61960436|NCT00042289||ATV/RTV Arm 1: 300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received atazanavir/ritonavir (ATV/RTV) 300/100 mg once a day
61960437|NCT00042289||DDI 400mg or 250mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received didanosine delayed release (Videx® EC) (DDI) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
61960438|NCT00042289||FTC 200mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received emtricitabine (FTC) 200 mg once a day
61960439|NCT00042289||TFV 300mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir (TFV) 300 mg once a day
61960440|NCT00042289||TFV/ATV/RTV Arm 1: 300/300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir/atazanavir/ritonavir (TFV/ATV/RTV) 300/300/100 mg once a day
61960441|NCT00042289||NFV Arm 1: 1250mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received nelfinavir (NFV) \[625 mg tablets\] 1250 mg twice a day
61960442|NCT00042289||EFV 600mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received efavirenz (EFV) 600 mg once a day
61960443|NCT00042289||TPV/RTV 500/200mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tipranavir/ritonavir (TPV/RTV) 500/200 mg twice a day
61960444|NCT00042289||LPV/RTV Arm 3: 400/100mg b.i.d. then 600/150mg b.i.d. then 400/100mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV) tablets 400/100 mg \[2 tablets\] twice a day until 30 weeks gestation, then 600/150 mg \[3 tablets\] twice a day until postpartum hospital discharge; and 400/100 mg \[2 tablets\] twice a day after postpartum hospital discharge, until 2 week postpartum PK sample is drawn
61960445|NCT00042289||RAL 400mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received raltegravir (RAL) 400 mg twice a day
61960446|NCT00042289||ETR 200mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received etravirine (ETR) 200mg twice a day
61960447|NCT00042289||MVC 150 or 300mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received maraviroc (MVC)150 mg or 300 mg twice a day
61960448|NCT00042289||DRV/RTV 800/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received darunavir/ritonavir (DRV/RTV) 800/100 mg once a day
62703872|NCT06733155|EXPERIMENTAL|Arm 1 (control)|Receives a mail reminder with basic information about breast cancer and instructions on scheduling a mammogram
62703873|NCT06733155|EXPERIMENTAL|Arm 2: Financial incentive|Receives mail reminder + a $10 voucher for completing a mammogram within three months.
62703874|NCT06733155|EXPERIMENTAL|Arm 3: Lottery incentive|Receives mail reminder + chance to win a $5000 lottery for completing the screening within three months.
61960449|NCT00042289||DRV/RTV 600/100mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received darunavir/ritonavir (DRV/RTV) 600/100 mg twice a day
61960450|NCT00042289||ATV/RTV Arm 2: 300/100mg q.d. then 400/100mg q.d. then 300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received atazanavir/ritonavir (ATV/RTV) 300/100 mg once a day until 30 weeks gestation then 400/100 mg once a day until postpartum hospital discharge; then 300/100 mg once a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
61960451|NCT00042289||TFV/ATV/RTV Arm 2: 300/300/100mg q.d. then 300/400/100mg q.d then 300/300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir/atazanavir/ritonavir (TFV/ATV/RTV) 300/300/100 mg once a day until 30 weeks gestation; then 300/400/100 mg once a day until postpartum hospital discharge; then 300/300/100 mg once a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
61960452|NCT00042289||NFV Arm 2: 1250mg b.i.d. then 1875mg b.i.d. then 1250mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received nelfinavir (NFV) \[625 mg tablets\] 1250 mg twice a day until 30 weeks gestation; then 1875 mg twice a day until postpartum hospital discharge; then 1250 mg twice a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
62703875|NCT06733155|EXPERIMENTAL|Arm 4: Health messaging|Receives mail reminder + QR code to a 60-second video from an influential person, available in four languages (English, Chinese, Malay, Tamil).
62703876|NCT06733155|EXPERIMENTAL|Arm 5: Personal Health Concierge|Receives mail reminder + a dedicated hotline for scheduling mammograms with the help of a health concierge over eight weeks.
62703877|NCT00018044||Patient Relatives|Blood relatives of enrolled patients
61960453|NCT00042289||IDV/RTV Arm 2: 400/100mg q.d. (only THA)|HIV-infected pregnant women ≥ 20 weeks gestation who received indinavir/ritonavir (IDV/RTV) 400/100 mg twice a day only to participants enrolling in Thailand
61960454|NCT00042289||LPV/RTV Arm 4: 400/100mg b.i.d. then 600/150mg b.i.d. then 400/100mg b.i.d. (only African sites)|HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV, Alluvia tablets) 400/100 mg \[2 tablets\] twice day until 30 weeks gestation; then 600/150 mg \[3 tablets\] twice a day until postpartum hospital discharge; then 400/100 mg \[2 tablets\] twice a day after postpartum hospital discharge until 2 week postpartum PK sample drawn only to participants enrolling in Uganda
61960455|NCT00042289||RPV 25mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received rilpivirine (RPV) (25 mg q.d.)
61960456|NCT00042289||NVP 200mg b.i.d. and RIF and at least one 1st line TB drug|"HIV-infected pregnant women \> 20 weeks gestation who received nevirapine (NVP) 200 mg b.i.d AND rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w. and at least one of the following drugs at study entry:~* ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~* isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~* pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
62703878|NCT00018044||Patients|Patients with mycobacterial infections
62703879|NCT06748781|EXPERIMENTAL|• Pulpectomy using Calcium Hypochlorite 2.5% as root canal irrigant|Pulpectomy using 2.5% Calcium Hypochlorite root canal irrigant
62703880|NCT06748781|ACTIVE_COMPARATOR|• Pulpectomy using Saline as root canal irrigant|Pulpectomy using Saline as root canal irrigant.
62703881|NCT05308004|NO_INTERVENTION|Standard Care|Participants will receive the standard Medicare Skilled Nursing Facility care.
62703882|NCT05308004|EXPERIMENTAL|Palliative Care Consult|Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
62703883|NCT05090371|EXPERIMENTAL|Ofatumumab|20 mg
62703884|NCT05090371|ACTIVE_COMPARATOR|DMT continued therapy|Participants randomized to the continued therapy arm will continue to take their disease modifying treatment (DMT) as prescribed commercially by their physician.
61960457|NCT00042289||ATV/RTV/TFV 300/100/300mg q.d. with ENG|HIV- infected women 2-12 weeks postpartum who received atazanavir/ritonavir/tenofovir (ATV/RTV/TFV) 300/100/300 mg q.d. postpartum and starting postpartum etonogestrel (ENG) implant
62703885|NCT01212003||Active TB|subjects with active TB as determined by smear, culture, or biopsy or have appropriately documented clinically suspicious active TB without definitive microbiology confirmation
62703886|NCT01212003||Latent TB|subjects with documented evidence of a positive PPD skin test or Interferon Gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB
61960458|NCT00042289||LPV/RTV 400/100 b.i.d. with 30-35ug EE|HIV- infected women 2-12 weeks postpartum who received lopinavir/ritonavir (LPV/RTV) 400/100 b.i.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
61960459|NCT00042289||LPV/RTV 400/100 b.i.d. with ENG|HIV- infected women 2-12 weeks postpartum who received lopinavir/ritonavir (LPV/RTV) 400/100 b.i.d. postpartum and starting postpartum etonogestrel (ENG) implant
61960460|NCT00042289||EFV 600mg q.d. with ENG|HIV-infected women 2-12 weeks postpartum who received efavirenz (EFV) 600mg q.d. postpartum and starting postpartum etonogestrel (ENG) implant
61960461|NCT02442518||women with placenta praevia|women with placenta previa diagnosed at antenatal ultrasound in the third trimester of pregnancy (lower placental edge within 20 mm from the internal os above 26 week's gestation)
61960462|NCT01581645|EXPERIMENTAL|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
61960463|NCT01594762|PLACEBO_COMPARATOR|Topical placebo control|Drug: Topical placebo cream
61960464|NCT01594762|EXPERIMENTAL|Topical pexiganan cream 0.8%|Drug: Topical pexiganan cream 0.8%
61960465|NCT03159195||Breast Cancer Patients|HR+/HER2- advanced/metastatic breast cancer patients across multiple countries.
61960466|NCT00826904||Lean|Healthy, pregnant women with BMI of 20 - 26 kg/m2
61960467|NCT00826904||Obese|Healthy, obese pregnant women with BMI 30 - 38 kg/m2
61960468|NCT01155271|ACTIVE_COMPARATOR|ERGO|General endurance training on cycloergometer
62347443|NCT02655445|ACTIVE_COMPARATOR|Burr Hole Craniostomy|"Intervention: 2 Burr Holes \>5mm and \<30mm, placement of Jackson-Pratt drain~First burr hole at the site of maximal diameter, second anterior and superior to that point. The scalp incisions are so planned that they can be incorporated into a craniotomy if necessary. Visible membranes are opened with a sharp hook until the pia is visualized. Gentle irrigation is performed and continued until the returning liquid is clear. Two burr holes are placed to facilitate drainage. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
62505415|NCT04991012|EXPERIMENTAL|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
62505416|NCT04991012|ACTIVE_COMPARATOR|Triamcinolone (Substance) therapy side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
62505417|NCT03793530|EXPERIMENTAL|Bone marrow concentration group|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
62505418|NCT03793530|ACTIVE_COMPARATOR|Control group|Transforaminal lumbar interbody fusion with local bone graft
62703887|NCT05587296|EXPERIMENTAL|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
62703888|NCT05587296|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally once daily.
62703889|NCT03557697|ACTIVE_COMPARATOR|wait-list control|3 measurement visits, baseline, 3, and 6 months
62703890|NCT03557697|ACTIVE_COMPARATOR|SMS intervention|3 measurement visits, baseline, 3, and 6 months
61960469|NCT01155271|ACTIVE_COMPARATOR|ERGONIV/ ERGOSPIRO|General endurance training on cycloergometer using ventilatory assistance (ERGONIV) or additional respiratory muscle training (ERGOSPIRO)
62347444|NCT00660569||1|Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA
62703891|NCT05927090||Ascending Aorta Replacement (AAR) with or without Hemiarch Repair|Patients who will require a conservative prosthetic replacement of the ascending aorta with or without hemiarch.Patients who required a concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis
62703892|NCT05927090||Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)|Patient who will require the extensive procedure including ascending aorta replacement associated to root replacement with or without sparing of the aortic valve
62703893|NCT05927090||Ascending Aorta Replacement with Total Arch Replacement (TARP)|Patient who will require the extensive procedure including ascending aorta replacement associated to TARP
62703894|NCT05927090||Root and Ascending Aorta Replacement with Total Arch Replacement|Patient who will require the extensive procedure including root and ascending aorta replacement associated to TARP
61960470|NCT01796080|ACTIVE_COMPARATOR|Mueller manoeuvre|Mueller manoeuvre lasting for 20 seconds
61960471|NCT01796080|ACTIVE_COMPARATOR|Inspiratory threshold|One continuous inspiration through an inspiratory threshold load for 20 seconds
61960472|NCT01796080|ACTIVE_COMPARATOR|Expiratory apnoea|Expiratory apnoea (without respiratory effort) lasting for 20 seconds
61960473|NCT01796080|SHAM_COMPARATOR|Steady state normal breathing|Steady state normal breathing for 20 seconds
62703895|NCT05923073|EXPERIMENTAL|Open-label induction phase: Guselkumab Intravenously (IV)|Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase.
62703896|NCT05923073|EXPERIMENTAL|Open-label induction phase: Guselkumab Subcutaneously (SC)|Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase.
61960474|NCT04447300|ACTIVE_COMPARATOR|Standard power application|
61960475|NCT04447300|ACTIVE_COMPARATOR|High power application|
61960476|NCT04999176|EXPERIMENTAL|Rivaroxaban|Oral Rivaroxaban (10 mg once daily) for 30 days post-operative
61960477|NCT04999176|ACTIVE_COMPARATOR|Enoxaparin|Subcutaneous Enoxaparin (40 mg once daily) for 30 days post-operative
61960478|NCT05464069||Postpartum with migraine who used Nerivio during their pregnancy|Postpartum patients with migraine who used Nerivio at least 3 times during their pregnancy. Participants will be recruited from Nerivio's user database
61960479|NCT05464069||Postpartum with migraine who used other migraine therapy during their pregnancy|Postpartum patients with migraine who used did not used Nerivio prior to their pregnancy, during their pregnancy and at least 3 months postpartum. Participants will be referred to the study by site co-investigators, who are US-licensed healthcare providers seeing women with headache disorders and/or women during their pre-pregnancy and/or pregnancy period
61960480|NCT02658305||transoral group|orthognathic patients that were treated with a transoral surgical approach
61960481|NCT02658305||transbuccal group|orthognathic patients that were treated with a transbuccal surgical approach
61960482|NCT02223897|EXPERIMENTAL|Conventional treatment, huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
61960483|NCT02223897|PLACEBO_COMPARATOR|Conventional plus placebo|Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total).
61960484|NCT02936830|PLACEBO_COMPARATOR|Control|21 individuals with dentin hypersensitivity will receive a placebo solution of glycerol diluted in water in a 1:1 concentration applied on the sensitive area by the dentist
61960485|NCT02936830|ACTIVE_COMPARATOR|Fluoride group|21 individuals with dentin hypersensitivity will receive 5% Sodium Fluoride varnish applied on the sensitive area by the dentist
61960486|NCT02936830|EXPERIMENTAL|Nanohydroxyapetite|21 individuals with dentin hypersensitivity will receive 15% nanohydroxyapetite paste applied on the sensitive area by the dentist
61960487|NCT05604352|EXPERIMENTAL|Main study|Study to investigate the safety and clinical efficacy of the DiaSole insole.
61960488|NCT01411202|EXPERIMENTAL|Doxycycline|Pleurx insertion with injection of 500mg of doxycycline in 50cc of normal saline.
61960489|NCT01411202|PLACEBO_COMPARATOR|Normal Saline|Pleurx insertion with placebo injection of 50cc of normal saline
61960490|NCT05009121||Czech adult people after stroke|Czech adult people after stroke will be asked basic questions about present feelings according to their condition using a questionnaire. Then they will be tested by the Box and Block Test in only one session. Video of their performance will be obtained. The Box and Block Test will be done during their regular rehabilitation by occupational therapist.
61960491|NCT05366946||COPD - prevalence|Diagnosed with COPD (based on GOLD criteria and history of \> 10 pack years of smoking) and no history of recent musculoskeletal injuries (within last 4 weeks) - prevalence study
61960492|NCT05366946||Healthy controls - prevalence|Not diagnosed with COPD or other respiratory conditions or recent musculoskeletal injuries (within last 4 weeks) - prevalence study
62347445|NCT02709083|EXPERIMENTAL|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
62703897|NCT05923073|EXPERIMENTAL|Double-blind maintenance phase: Guselkumab SC Dose Regimen 1|At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48.
61960493|NCT04963335|EXPERIMENTAL|Intervention|Participants perform 16 exergame training (video game-based physical exercise) sessions over a period of 4 to 8 weeks (depending on in-patient or out-patient). Each training lasts between 15 to 25 minutes. Exergames automatically adjust the game difficulty to the abilities of the respective participant.
61960494|NCT04963335|NO_INTERVENTION|Control|Participants of the control group are instructed to continue their normal daily routine for eight weeks and to record their physical activities.
61960495|NCT01752998|ACTIVE_COMPARATOR|TOPPS Intervention|Individuals randomized into this arm will receive 7 individual sessions of the Treating Opioid Patients' Pain and Sadness (TOPPS) intervention, designed to reduce symptoms of pain and depression.
61960496|NCT01752998|PLACEBO_COMPARATOR|Health Education|Individuals randomized into this arm will receive 7 individual sessions on general health education.
61960497|NCT02478632|ACTIVE_COMPARATOR|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
61960498|NCT02478632|EXPERIMENTAL|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
61960499|NCT05059600|EXPERIMENTAL|ZULRESSO®|Participants received a 60-hour single continuous intravenous (IV) infusion of ZULRESSO®, at 30 micrograms per kilogram per hour (mcg/kg/hour) (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a dose taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.
61960500|NCT04897815||20 patients with type 2 diabetes mellitus|Fasting blood glucose and TCD will be measured in 20 patients with type 2 diabetes mellitus, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
62347446|NCT04532918|EXPERIMENTAL|Verinurad + allopurinol|The subjects will receive single oral dose of verinurad 7.5 mg and allopurinol 300 mg under fasted condition.
62505419|NCT06616402|OTHER|prosthetic group performs the entire protocol with the prosthesis prototype.|
61960501|NCT04897815||20 healthy volunteers whose sex and age and BMI matched with the experimental group|Fasting blood glucose and TCD will be measured in healthy control group, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
61960502|NCT00133471|EXPERIMENTAL|Group 1A: 3.75 mcg A/H9N2 no adjuvant|12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.
61960503|NCT00133471|EXPERIMENTAL|Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.
61960504|NCT00133471|EXPERIMENTAL|Group 3A: 15 mcg A/H9N2 no adjuvant|12 subjects to receive 15 mcg A/H9N2 with no adjuvant.
62703898|NCT05923073|EXPERIMENTAL|Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2|At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48.
62703899|NCT05923073|EXPERIMENTAL|Open-label maintenance phase: Guselkumab SC|Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.
62703900|NCT05280652|EXPERIMENTAL|Family intervention group|Families (dyads parent and child) will attend culinary-nutritional workshops with theoretical and practical nutritional and culinary information (knowledge and skills to prepare healthy and easy menus) to follow a sustainable Mediterranean diet.
61960505|NCT00133471|EXPERIMENTAL|Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.
62703901|NCT05280652|EXPERIMENTAL|Parent-only intervention group|Parents will attend culinary-nutritional workshops with theoretical and practical nutritional and culinary information (knowledge and skills to prepare healthy and easy menus) to follow a sustainable Mediterranean diet.
62703902|NCT05280652|ACTIVE_COMPARATOR|Control|Families (dyads parent and child) will attend nutritional workshops with theoretical information to follow a sustainable Mediterranean diet.
61960506|NCT00133471|EXPERIMENTAL|Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.
61960507|NCT00133471|EXPERIMENTAL|Group 4A: 30 mcg A/H9N2 no adjuvant|12 subjects to receive 30 mcg A/H9N2 with no adjuvant.
61960508|NCT00133471|EXPERIMENTAL|Group 2A: 7.5 mcg A/H9N2 no adjuvant|12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.
61960509|NCT00133471|EXPERIMENTAL|Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.
61960510|NCT02667054|ACTIVE_COMPARATOR|Active 4%|One dose of 4mL of RX0041 4% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
61960511|NCT02667054|PLACEBO_COMPARATOR|Placebo|One dose of 4mL of RX0041 placebo for one day in the mucous membrane prior to a diagnostic or surgical procedure.
61960512|NCT02667054|ACTIVE_COMPARATOR|Active 8%|One dose of 4mL of RX0041 8% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
61960513|NCT06211166||Acute Leukemia|Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
61960514|NCT06211166||MDS or MDS/MPN|Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and other subtypes of Myelodysplastic/Myeloproliferative Neoplasm
61960515|NCT06211166||CML|Chronic Myeloid Leukemia
62703903|NCT05104476|EXPERIMENTAL|Lu AF82422|Participants in the DBP will receive Lu AF82422 intravenous (IV) infusion every 4 weeks (Q4W) from Baseline for a minimum 48 weeks up to a maximum 72 weeks. In the optional OLE, all participants will receive Lu AF82422 IV infusion starting on Day 1 of the OLE up to week 92.
61960516|NCT03736447|ACTIVE_COMPARATOR|AR101 powder provided in capsules & sachets|Study product provided as peanut protein in pull-apart capsules or sachets
61960517|NCT03736447|PLACEBO_COMPARATOR|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
61960518|NCT04193332|EXPERIMENTAL|Plus NIR optical imaging|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery
61960519|NCT04193332|NO_INTERVENTION|Minus NIR optical imaging|Conventional identification of parathyroid glands during thyroid surgery
61960520|NCT05089942|EXPERIMENTAL|Recombinant Human Insulin Patch ZJSRM2021|health subjects or diabetic patients receive recombinant human insulin patch ZJSRM2021
62347447|NCT04532918|EXPERIMENTAL|Verinurad + allopurinol + cyclosporine|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and cyclosporine 600 mg under fasted condition.
62703904|NCT05104476|EXPERIMENTAL|Placebo|Participants in the DBP will receive Lu AF82422 matching placebo IV infusion Q4W from Baseline for a minimum 48 weeks up to a maximum 72 weeks.
61960521|NCT05089942|PLACEBO_COMPARATOR|Placebo|health subjects receive patch
61960522|NCT03799081|OTHER|Fetoscopy in missed abortion|Women who have decided to undergo fetoscopy in missed abortion
61960523|NCT00612040|EXPERIMENTAL|SIBA (D)|
61960524|NCT00612040|EXPERIMENTAL|SIBA (E)|
61960525|NCT00612040|EXPERIMENTAL|IGlar|
61960526|NCT03530878|EXPERIMENTAL|Hip Arthroscopy (HA)|This approach addresses intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH 3. Furthermore, capsular plication can be performed through HA to reduce instability of the joint.
61960527|NCT03530878|NO_INTERVENTION|Periacetabular Osteootmy (PAO)|The Bernese periacetabular osteotomy (PAO) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (DDH) in most patients with closed triradiate cartilage. First developed by Ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. Although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization.
61960528|NCT03443375|EXPERIMENTAL|Nonperiodized resistance training|The Nonperiodized group performed was an intervention based on resistance exercise program with a constant intensity.
61960529|NCT03443375|EXPERIMENTAL|Daily undulating periodized|The Daily undulating periodized program was an intervention based on daily alterations on exercise load. .
61960530|NCT03443375|NO_INTERVENTION|Control group|The control group remained their regular habits of life during all study period, without engaging in physical exercise programs.
61960531|NCT01142349|EXPERIMENTAL|Lifestyles A|Cognitive Behavioral Therapy for Pain and Insomnia
61960532|NCT01142349|EXPERIMENTAL|Lifestyle B|Cognitive Behavioral Therapy for Pain
61960533|NCT01142349|ACTIVE_COMPARATOR|Lifestyles C|Osteoarthritis Education
61960534|NCT03619954|EXPERIMENTAL|NK cells infusion|
61960535|NCT04240769||Knee Arthroplasty Patient|Patients undergoing primary total or unicompartmental knee arthroplasty for treatment of end-stage osteoarthritis.
61960536|NCT02730429|PLACEBO_COMPARATOR|Letrozole + placebo|"letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity. Letrozole is administered as standard of care in both study arms.~Placebo for palbociclib once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity."
62703905|NCT06744153|ACTIVE_COMPARATOR|3D Print|3D Print (Metal) - Additive Method: In this group, the functional space maintainer was fabricated from a metal alloy (Co 69%, Cr 25%, W 9.5%, Mo 3.5%, Si 1%, Scheftner, Germany) using a 3D printer (MySint100 Dual Laser, Italy).
62703906|NCT06744153|ACTIVE_COMPARATOR|Milling|Milling (Composite) - Subtractive Method: A dental milling machine (Wieland Zenotec Select Hybrid, Germany) was used to fabricate functional space maintainers from a polymer composite material (breCAM.HIPC, Bredent, Germany)
61960537|NCT02730429|EXPERIMENTAL|Letrozole + palbociclib|"Palbociclib 125mg once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity.~letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity.~Letrozole is administered as standard of care in both study arms."
61960538|NCT01516346|ACTIVE_COMPARATOR|Isosorbide dinitrate|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain placebo capsules.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
61960539|NCT01516346|ACTIVE_COMPARATOR|Isosorbide dinitrate + Hydralazine|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain the active ingredient Hydralazine.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks.~Dosage of Hydralazine will be 37.5mg (if Stage 1) OR 75mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
61960540|NCT01516346|PLACEBO_COMPARATOR|Placebo|"Research pharmacy-formulated capsules will be given to subjects in two bottles. For this interventional arm, both the bottles will contain placebo capsules.~Dosage will be same regardless of up-titration from Stage 1 dosing to Stage 2 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
61960541|NCT01061177|EXPERIMENTAL|Nilotinib|This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.
61960542|NCT02789202|EXPERIMENTAL|Silver Diamine Fluoride|Control treatment
61960543|NCT02789202|ACTIVE_COMPARATOR|Fluoride Varnish|Test treatment
62703907|NCT06732687|EXPERIMENTAL|Calisthenics|Experimental: Calisthenics Arm Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.
62703908|NCT06732687|EXPERIMENTAL|Plyometric|"Experimental: Plyometric~Arm Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump"
62703909|NCT06732687|EXPERIMENTAL|Combined( Calisthenics+ Plyometrics)|Arm Description: In combined both calisthenics and plyometrics would be performed. First calisthenics will be performed and then plyometrics will be performed.
62703910|NCT06747598||POC serum pregnancy test arm|Enrolled participants will provide a peripheral serum specimen for POC pregnancy testing
62143535|NCT00853580|EXPERIMENTAL|1|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
62703911|NCT06750302|ACTIVE_COMPARATOR|Penthrox|3mL Penthrox as an inhaled analgesic
62703912|NCT06750302|PLACEBO_COMPARATOR|Placebo|3mL placebo control (saline + one drop of methoxyflurane)
61960544|NCT06374901|EXPERIMENTAL|A (MHC-II positive with Tislelizumab and SOX/XELOX)|Preoperative treatment with Tislelizumab and SOX/XELOX for MHC-II positive patient.
61960545|NCT06374901|ACTIVE_COMPARATOR|B (MHC-II positive with SOX/XELOX)|Preoperative treatment with SOX/XELOX for MHC-II positive patient.
61960546|NCT06374901|EXPERIMENTAL|C (MHC-II negative with Tislelizumab and SOX/XELOX)|Preoperative treatment with Tislelizumab and SOX/XELOX for MHC-II negative patient.
62505420|NCT04158778|EXPERIMENTAL|MDMA assisted Psychotherapy|All participants receive 2 sessions of MDMA-assisted psychotherapy
62703913|NCT06706440||children with external pancreatic fistula|children who have suffered acute necrotizing pacreatitis and undergone drainage of parapancreatic accumulations, with the development of an external pancreatic fistula
62703914|NCT06739629|EXPERIMENTAL|Yellow mealworm-enriched porridge|Participants receive a daily meal of yellow mealworm-enriched porridge, served in schools. The porridge provides 420 Kcal/serving
62703915|NCT06739629|OTHER|Maize porridge|Participants receive a standard maize porridge served in schools. This porridge is comparable to the porridge served in the parent-led school feeding program.
62703916|NCT03952585|ACTIVE_COMPARATOR|Arm I (IMRT, IGRT, cisplatin)|Patients undergo IMRT or IGRT over 6 fractions per week and receive cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
62703917|NCT03952585|EXPERIMENTAL|Arm II (IMRT, IGRT, cisplatin)|Patients undergo reduced dose IMRT or IGRT QD over 5 fractions per week and receive cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
61960547|NCT06374901|ACTIVE_COMPARATOR|D (MHC-II negative with SOX/XELOX)|Preoperative treatment with SOX/XELOX for MHC-II negative patient.
61960548|NCT03234933|EXPERIMENTAL|Mobility Tracker|"* Each patient will be provided by the research team staff with a new mobility tracker~* The standard pre-operative assessment, surgical procedure and post-operative care will still be done~* Measurements of each patient (steps, distance and calories) will be obtained by the research staff"
62703918|NCT03952585|EXPERIMENTAL|Arm III (IMRT, IGRT, nivolumab)|Beginning 1 week prior to radiation, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks (14 days) for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo reduced dose IMRT or IGRT over 6 fractions per week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
61960549|NCT03093883|EXPERIMENTAL|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
61960550|NCT03093883|ACTIVE_COMPARATOR|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
61960551|NCT02657291|EXPERIMENTAL|Costoclavicular|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the costoclavicular approach
61960552|NCT02657291|ACTIVE_COMPARATOR|Paracoracoid|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the paracoracoid or standard approach
62505421|NCT05550792|ACTIVE_COMPARATOR|Optimizer device|"100 patients were enrolled sequentially, 100 patients were implanted with an optimizer smart against the background of optimal drug therapy for heart failure~100 patients were implanted with a CCM Optimizer device without an atrial lead, per the protocol specifications recived optimal drug therapy CHF The following studies were performed in the 100 patients with CHF and AF before implantation of the MCC device and after 2 and 6 и 12 months of follow-up: 12-channel ECG with an estimate of the width of the QRS complex, transthoracic EchoCG,Speckle-tracking EchoCG,Myocardial work, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), Holter ECG, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ)."
62703919|NCT06717659|EXPERIMENTAL|probiotic group|receive probiotics alongside standard pulmonary rehabilitation therapy
62703920|NCT06717659|ACTIVE_COMPARATOR|pulmonary rehabilitation group|undergo only the standard pulmonary rehabilitation program
62703921|NCT06722365||36 Weeks Pregnant|
62703922|NCT06726122|EXPERIMENTAL|Matrix Pro Treatment Group|Study subjects receive up to three (3) study treatments with the Matrix Pro applicator
62703923|NCT06740864|ACTIVE_COMPARATOR|40 Hz prefrontal Transcranial alternating current stimulation|During prefrontal tACS, an alternating electrical current with a 1 milliamp peak-to-peak amplitude will be delivered, featuring a 15-second ramp-up at the start and a 15-second ramp-down at the end. The stimulation duration is 20 minutes and four channels are used for delivering sinusoidal alternating currents to the head. The alternating current was delivered to the prefrontal cortex bilaterally with the electrodes at F3 and F4 and the return electrodes were placed at the ipsilateral mastoids at TP9 and TP10 (international 10-20 EEG electrode placement system).
62703924|NCT06740864|ACTIVE_COMPARATOR|40 Hz frontal-temporal Transcranial alternating current stimulation|During frontal-temporal tACS, an alternating electrical current with a personalized peak-to-peak stimulation intensity will be delivered, featuring a 15-second ramp-up at the start and a 15-second ramp-down at the end. The stimulation duration is 20 minutes and four channels are used for delivering sinusoidal alternating currents to the head. The alternating current was delivered to the prefrontal and temporal cortices with the active electrodes at AF3-T7 and the return electrodes over AF4-T8 (according international 10-20 EEG electrode placement system).
62703925|NCT06740864|SHAM_COMPARATOR|sham Transcranial alternating current stimulation|During sham tACS, an alternating artificial electrical current will be delivered, only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
62703926|NCT06741176|EXPERIMENTAL|Experimental|Breast Milk
62703927|NCT06741176|ACTIVE_COMPARATOR|Control|Control
62703928|NCT06743516|ACTIVE_COMPARATOR|Pancreaticojejunostomy with External stent|ureteric catheter (7Fr) insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
62703929|NCT06743516|ACTIVE_COMPARATOR|Pancreaticojejunostomy without stent|Pancreaticojejunostomy without stent
61960553|NCT04101877|EXPERIMENTAL|Avastin|bevacizumab 25 mg/ml, intravitreal administration, 0.05 ml (1.25 mg)
61960554|NCT04101877|ACTIVE_COMPARATOR|Eylea|aflibercept 40 mg/ml, intravitreal administration, 0.05 ml (2 mg)
61960555|NCT01044771|OTHER|change from tenofovir to raltegravir|"Single arm study:~Tenofovir containing nucleoside backbone changed over to raltegravir in all patients"
62143536|NCT04263740|EXPERIMENTAL|Kinesio Taping plus Traditional Physical Therapy|Kinesio Taping plus Traditional physical therapy
62143537|NCT04263740|OTHER|Traditional Physical Therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises.
61960556|NCT03546660|EXPERIMENTAL|SECM capsule imaging|Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
61960557|NCT01941121|EXPERIMENTAL|Linkage to PrEP or Care|Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status. After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information. When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
61960558|NCT00580021||1|Patients with breast and pancreas cancer.
61960559|NCT02433730|ACTIVE_COMPARATOR|placebo|intramuscular injection
61960560|NCT02433730|ACTIVE_COMPARATOR|testosterone|intramuscular injection
62347448|NCT04532918|EXPERIMENTAL|Verinurad + allopurinol + rifampicin|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and rifampicin 600 mg under fasted condition.
61960561|NCT04077827|EXPERIMENTAL|Total intravenous anesthesia|"The patients will recieve intravenous anesthesia (propofol-remifentanyl)~Recommended dosage:~Propofol: Induction dosage 1,5-2,5 mg/kg Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
62505422|NCT05550792|NO_INTERVENTION|Without Optimizer device|100 patients were enrolled sequentially,100 patients received only optimal drug therapy for chronic heart failure 100 patients ( Without Optimizer device ) with CHF and AF before study and after 2 and 6 и 12 months of follow-up: 12-channel ECG with an estimate of the width of the QRS complex, transthoracic EchoCG,Speckle-tracking EchoCG,Myocardial work, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), Holter ECG, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ).
62505423|NCT06357156||males age range 18-35|
62505424|NCT06357156||males age range 36- 55|
61960562|NCT04077827|EXPERIMENTAL|volatile anesthesia|"The patients will recieve volatile anesthesia (desflurane-remifentanyl)~Recommended dosage:~Desflurane dosage 6-7 MAC Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
61960563|NCT01150136||1|Children with proven CF and known genotype, age 0-17 yr
61960564|NCT04384211||Radiologists|A computer search of CT scans (2010.01.01-2018.09.30) was performed in Wan Fang Hospital. These CT images were retrospectively reviewed by an experienced radiologist who classified and marked with annotations of vertebral fractures by the Genant's semiquantitative method.
61960565|NCT04384211||Smart Bone|The same CT images were separately reviewed and processed by the artificial intelligence system (Smart Bone) by Quanta for compression fractures. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
61960566|NCT04535700|EXPERIMENTAL|pioglitazone|
61960567|NCT04535700|OTHER|Standard of care treatment|
62143538|NCT03673566|EXPERIMENTAL|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
62505425|NCT06357156||males age range 56-75|
62347449|NCT02756975|EXPERIMENTAL|transperineal prostate biopsy with coaxial method|The patients undergo transperineal biopsy with a coaxial Tru-Cut needle (18-gauge Core Biopsy Instrument with a 17-gauge Disposable Coaxial Needle).
62347450|NCT02756975|EXPERIMENTAL|transperineal prostate biopsy with noncoaxial method|The patients undergo transperineal biopsy with a noncoaxial 18-gauge needle.
62505426|NCT06357156||females age range 18-35|
62505427|NCT06357156||females age range 36- 55|
62505428|NCT06357156||females age range 56-75|
62505429|NCT03080376|EXPERIMENTAL|Web-based intervention without support|3 months Web-based intervention without support
62505430|NCT03080376|EXPERIMENTAL|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
62505431|NCT03080376|ACTIVE_COMPARATOR|Traditional intervention|3 months of Printed-based intervention
61960568|NCT02427893|ACTIVE_COMPARATOR|Cohort 1|Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib.
61960569|NCT02427893|ACTIVE_COMPARATOR|Cohort 2|Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
61960570|NCT05056545|EXPERIMENTAL|PPFP Intervention|The study team will train government clinic staff in ANC, L\&D, IV, or postpartum services to promote and provide the PPFP intervention at the selected facilities. Community Health Workers (CHW) and 'Happy Clients' will be trained as PPFP promotional agents. Video-based PPFP promotions will be shown at the intervention facilities. If interested in PPFP, women will be referred to the facility by their CHW.
61960571|NCT05056545|NO_INTERVENTION|Standard of Care|Currently, no systematic PPFP training, promotional, or service delivery activities are regularly taking place at the selected facilities. The team will compare the intervention with historical records from the facilities applying intervention and compare
62143539|NCT03673566|NO_INTERVENTION|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
62143540|NCT03673566|EXPERIMENTAL|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
62143541|NCT03034278||Post surgery patients|Patients prescribed with opioid analgesic medications following surgery.
62143542|NCT03351400|EXPERIMENTAL|Treatment group|Stem cells administered to participants
62505432|NCT06630260|EXPERIMENTAL|Phase 1b|The Phase 1b will evaluate the safety and tolerability of combination of avutometinib and defactinib and determine its preliminary antitumour activity when administered at the recommended Phase 2 dose (RP2D) in patients with molecularly defined malignant brain tumours.
62505433|NCT06630260|EXPERIMENTAL|Phase 2|The Phase 2 part of the study will determine the antitumour activity of investigational agents administered at the RP2D in patients with molecularly defined malignant brain tumours. Avutometinib and defactinib may be administered in combination with temozolomide (TMZ).
62505434|NCT02426541|EXPERIMENTAL|Dapagliflozin|Dapagliflozin Once Daily 10 mg
62505435|NCT02426541|PLACEBO_COMPARATOR|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
62347451|NCT04227392|EXPERIMENTAL|Experimental|women who undergo radiofrequency therapy
62505436|NCT06060184|EXPERIMENTAL|Retrospective cohort|Subjects with unclear molecular cause of the disease. The subjects are clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating locations.
62505437|NCT06060184|EXPERIMENTAL|Prospective cohort|Subjects with indication for genome diagnostics (e.g. within the initiative for genomic medicine (genomDE) based on §64e German Social Code (SGB) Fifth Book (V) (SGB V).
62703930|NCT06746051||Inpatients under 1 year of age|Participants \<12 months of age who are PCR confirmed RSV positive and hospitalized for further evaluation of an acute respiratory tract illness will be actively enrolled with observational data collected for up to 21 days.
62703931|NCT06746051||Outpatients under 1 year of age|Participants \<12 months of age who are PCR confirmed RSV positive and present in clinic for evaluation of an illness consistent with an acute respiratory tract infection will be actively enrolled with observational data collected for up to 21 days.
62505438|NCT02404857|EXPERIMENTAL|Chronic post-stroke|Patients \>6 months post-stroke with little to no hand movement. use of EEG based BCI in the neurorehabilitation process
62703932|NCT06746051||Inpatients 1 to 3 years of age inclusive|Participants ≥ 12 months to ≤ 36 months of age who are PCR confirmed RSV positive and hospitalized for further evaluation of an acute respiratory tract illness will be actively enrolled with observational data collected for up to 21 days.
62143543|NCT04465721|ACTIVE_COMPARATOR|HABIT Group|Participants randomized to the HABIT group will maintain their habitual eating schedule (≥13-h).
62505439|NCT01859026|EXPERIMENTAL|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.~Phase I will be followed by an expansion Phase Ib."
62703933|NCT06746051||Outpatients 1 to 3 years of age inclusive|Participants ≥ 12 months to ≤ 36 months of age who are PCR confirmed RSV positive and present in clinic for evaluation of an illness consistent with an acute respiratory tract infection will be actively enrolled with observational data collected for up to 21 days.
62703934|NCT06747078|ACTIVE_COMPARATOR|Group 1 (study group): Neurodevelopmental therapy (NDT) combined with core stabilization exercises (|In addition to neurodevelopmental treatment, which is 30 minutes per day, 3 sessions per week and 24 sessions in total, core stabilization training was applied 3 sessions per week for 8 weeks and 24 sessions in total. The core stabilization training session lasted 30 minutes.
61960572|NCT04664062|ACTIVE_COMPARATOR|Home|This induction arm is asynchronous and unobserved. The home induction is done primarily by the participant in their home or current residence. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. Home induction is initiated by the participant at a time and place (other than the practice) determined by the participant. The participant determines when to stop taking opioids, begins withdrawal, monitors symptoms, administers the SOWS, and determines when to take first dose of medication, per the instructions and protocol provided. The clinic team does not observe or have contact with the participant while the participant undergoes these steps or takes the first dose. The participant continues this process for additional doses. Follow-up contact with clinic team may occur after the first or second day, typically within a week.
61960573|NCT04664062|ACTIVE_COMPARATOR|Office|This induction arm is synchronous and observed by the clinical team. The participant receives instruction from clinic team at an in-person or telehealth visit. On a pre-determined day, the participant stops taking opioids and comes to office with mild to moderate withdrawal. The clinic team monitors the participant, assesses symptoms, administers COWS to determine time of first dose of medication, and administers first dose with the participant. The clinic team observes and has in-person contact with the participant. Office induction includes the observed administration of the first dose, followed by observation and evaluation 30-60 minutes after the first dose. After 30-60 minutes of observation, the clinic team and participant decide whether to administer the second dose in the office or for the participant to leave the clinic to administer subsequent doses. On rare occasions, a second dose may not be needed (if the participant has a low COWS score after just one dose).
61960574|NCT04664062|ACTIVE_COMPARATOR|Telehealth|This induction arm is synchronous via phone or video contact and observed. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. The participant undergoes the same process as an office induction but from a location other than the clinic. Like an office induction, the participant has regular contact with someone from the practice team on Day 1 of induction. Prior to initiating the first dose, the participant has contact by phone or video with the clinic team to assess symptoms and determine level of withdrawal (using COWS or SOWS). The administration of the first dose of medication is determine by the clinic team during phone or video contact, and the clinic team is in contact with the participant by phone or video when the first dose is taken. This process continues through the second and possible third dose. The participant is re-assessed via video or phone regularly by clinic staff and prescriber throughout this process.
62143544|NCT04465721|EXPERIMENTAL|TRE Group|Participants randomized to TRE will reduce their eating window to a self-selected eating window (≤10-h).
62143545|NCT04464031|EXPERIMENTAL|Alert group|
62143546|NCT04464031|NO_INTERVENTION|Control group|
62143547|NCT02797132|EXPERIMENTAL|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A (\<14 kg): Participants weighing less than (\<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part A (\>=14 kg): Participants weighing greater than or equal to (\>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part B (\<14 kg): Participants weighing \<14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.~Part B (\>=14 kg): Participants weighing \>=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B."
62143548|NCT01323790|EXPERIMENTAL|1|Oral treatment
62505440|NCT01859026|EXPERIMENTAL|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
62505441|NCT01859026|EXPERIMENTAL|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
62143549|NCT01323790|EXPERIMENTAL|2|Oral treatment
62143550|NCT01323790|PLACEBO_COMPARATOR|3|Oral treatment
62703935|NCT06747078|ACTIVE_COMPARATOR|Group 2 (study group) neurodevelopmental treatment combined with balance exercises|In addition to the neurodevelopmental treatment of 30 minutes per day, 3 sessions per week, and a total of 24 sessions, balance training was applied 3 sessions per week for 8 weeks and a total of 24 sessions. The balance training session lasted 30 minutes.
62703936|NCT06747078|ACTIVE_COMPARATOR|Group 3: Neurodevelopmental treatment control group|Only neurodevelopmental treatment was applied for 60 minutes per day, 3 sessions per week, for 8 weeks, for a total of 24 sessions.
62703937|NCT05829460|EXPERIMENTAL|Arm 1: Semaglutide + progestin|"* The progestin will be delivered via the levonorgestrel-releasing IUD and it is standard of care.~* Will receive injectable pens containing semaglutide and will be self-administered on a weekly basis for up to 104 weeks. Dosing will be escalated during weeks 1 through 16 (start at 0.24 mg up to 2.4 mg).~* Will be enrolled in a behavioral weight program that is optional to attend. The program will be delivered in a closed-group format. The group program will consist of 12 consecutive 60 minute weekly visits, and will recur every three months such that participants can join the soonest available Week 1 session after study enrollment. Each group session will focus on providing education and cognitive/behavioral strategies to achieve a healthier, reduced-calorie diet and a more physically active lifestyle. Cognitive/behavioral strategies will consist of goal setting, problem solving, cognitive restructuring, stimulus control, and stress management."
62703938|NCT05829460|ACTIVE_COMPARATOR|Arm 2: Placebo + Progestin|"* The progestin will be delivered via the levonorgestrel-releasing IUD and it is standard of care.~* Will receive injectable pens containing the placebo and will be self-administered on a weekly basis for up to 104 weeks.~* Will be enrolled in a behavioral weight program that is optional to attend. The program will be delivered in a closed-group format. The group program will consist of 12 consecutive 60 minute weekly visits, and will recur every three months such that participants can join the soonest available Week 1 session after study enrollment. Each group session will focus on providing education and cognitive/behavioral strategies to achieve a healthier, reduced-calorie diet and a more physically active lifestyle. Cognitive/behavioral strategies will consist of goal setting, problem solving, cognitive restructuring, stimulus control, and stress management."
62703939|NCT06715696|EXPERIMENTAL|"HANBIO Gauze"|
62703940|NCT00005902||1|250 subjects with von Hippel-Lindau (VHL) disease.
62703941|NCT06744881|EXPERIMENTAL|To evaluate the effectiveness and safety of CAPA-IVM in ovulatory infertile women in relation to the|
62703942|NCT06751355||SkinScan3D|Consenting and eligible patients will have tumor assessments performed at a single visit. These assessments will be done by ruler or calipers, cell phone 2D photographs, and SS3D camera.
62703943|NCT06748521|EXPERIMENTAL|treatment group|
62703944|NCT05618028|EXPERIMENTAL|ABBV-525 Dose Escalation|Participants will receive escalating doses of ABBV-525 until doses for optimization are determined, as part of an approximately 64 month study period.
62703945|NCT05618028|EXPERIMENTAL|ABBV-525 Dose Optimization|Participants will receive one of two doses of ABBV-525 until the recommended phase 2 dose (RP2D) is determined, as part of an approximately 64 month study period.
62703946|NCT05618028|EXPERIMENTAL|ABBV-525 Dose Expansion|Participants will receive the RP2D dose of ABBV-525, as part of an approximately 64 month study period.
62703947|NCT06471829|EXPERIMENTAL|Lu AG13909|Participants will first receive Lu AG13909 intravenously (IV) per predefined dosing schedule. Participants will then receive Lu AG13909 subcutaneously (SC) per predefined dosing schedule.
62703948|NCT06747130|EXPERIMENTAL|Montelukast|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
62703949|NCT06747130|PLACEBO_COMPARATOR|Placebo|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
62703950|NCT06749938|EXPERIMENTAL|Holistic Intervention|The holistic intervention comprises of Aerobic Exercise Prescription, Yoga and Meditation Exercise, Diet Intervention, and Psychosocial Support
62703951|NCT06744283||Participants with a diagnosis of Fanconi anemia|Participants enrolled in the Fanconi Anemia Cancer Screening Study (FACSS) protocol (NIH IRB #: 001109) who are 18 years of age or older are eligible for inclusion in this study.
62703952|NCT06744036|ACTIVE_COMPARATOR|Therapeutic Exercise Group|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises.
62703953|NCT06744036|EXPERIMENTAL|Therapeutic Exercises Group + Interferential Current|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The IC will be applied for 30 minutes.
62703954|NCT06744036|PLACEBO_COMPARATOR|Therapeutic Exercises + placebo interferential current (ET + placebo IC) group|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee.The device will only be turned on for the first minute.
62703955|NCT04806282||1/All Patients|Documented hearing instability
62703956|NCT06735768|ACTIVE_COMPARATOR|Active group|This group receives rTMS treatment.
62347452|NCT05015166|EXPERIMENTAL|Internet delivered self-help program with therapist support|"The intervention consists of 8 therapist-supported self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which they send to their therapist and receive feedback within a few days.~The treatment is based on principles from affect-focused psychodynamic psychotherapy."
62505442|NCT00978887|EXPERIMENTAL|A|Retorna (facial cream)
61960575|NCT01063452|EXPERIMENTAL|Truvalve|Atkinson Product Design urinary slide valve on the catheter
62505443|NCT00978887|PLACEBO_COMPARATOR|B|Placebo (facial cream)
62703957|NCT06735768|SHAM_COMPARATOR|Sham group|This group receives sham treatment.
62703958|NCT06717776|ACTIVE_COMPARATOR|Aspirin (intervention group)|"The intervention group received both compensation-bocused problem-solving therapy and standard rehabilitation services.~Standard Rehabilitation:The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays.~Compensation Based Problem Solving Therapy (CFPS) is an approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in activities of daily living."
62703959|NCT06717776|ACTIVE_COMPARATOR|Plasebo (control group)|"The control group received standard rehabilitation services.~Standard Rehabilitation:The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays."
62703960|NCT06705426|EXPERIMENTAL|Scapular mobilization group A|Scapular mobilization with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
62703961|NCT06705426|EXPERIMENTAL|Posterior capsular stretch group B|Posterior capsular stretch with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
62703962|NCT06577467||Neuro-PASC|1.\<TAB\>Neurologic and neuropsychiatric complaint is the primary clinical issue. 2.\<TAB\>Neuro-PASC clinical symptom burden is moderate or greater.3.\<TAB\>Other PASC complications, such as pulmonary, cardiovascular, or gastrointestinal symptoms, are not prominent case features.
61960576|NCT01063452|ACTIVE_COMPARATOR|Control|Drainage bag on the catheter
61960577|NCT03311724|EXPERIMENTAL|4,8,12mg Tirzepatide|Participants received Tirzepatide by subcutaneous (SC) injection in three dose escalations starting with 4 milligrams (mg) for four weeks followed by 8mg for four weeks followed by 12mg for four weeks.
61960578|NCT03311724|EXPERIMENTAL|2.5,5,10,15mg Tirzepatide|Participants received Tirzepatide by SC injection in four dose escalations starting with 2.5mg for two weeks followed by 5mg for two weeks followed by 10mg for four weeks followed by 15mg for four weeks.
61960579|NCT03311724|EXPERIMENTAL|2.5,7.5,15mg Tirzepatide|Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.
61960580|NCT03311724|PLACEBO_COMPARATOR|Placebo|Placebo administered by SC injection.
61960581|NCT02607033|EXPERIMENTAL|Exercise and Weight Loss|Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
62703963|NCT06577467||Recovered volunteers|1.\<TAB\>Reports no ongoing or new health issues attributable to a SARS-CoV-2 infection2.\<TAB\>Overall clinical symptoms burden is no greater than mild3.\<TAB\>No clinically substantial comorbid medical or psychiatric conditions
62703964|NCT06748950|EXPERIMENTAL|Arm 1: Ketogenic Diet Only|Participants will follow 12 weeks of the ketogenic diet, with monitoring of physical and psychological health and coaching support.
62703965|NCT06748950|EXPERIMENTAL|Arm 2: DAU- Ketogenic Diet Crossover|Participants will follow 12 weeks of their usual diet (Diet-as-Usual, DAU). Then, participants will crossover and follow 12 weeks of the ketogenic diet. Monitoring of physical and psychological health and coaching support will occur throughout participation.
61960582|NCT02607033|ACTIVE_COMPARATOR|Exercise|Individuals assigned to this group will be asked to complete the exercise intervention for xic months
61960583|NCT04736836|ACTIVE_COMPARATOR|interventional|50 patient take rifaximin plus lactulose for 6 months
61960584|NCT04736836|PLACEBO_COMPARATOR|control|50 patient take lactulose for 6 months
61960585|NCT06410612|ACTIVE_COMPARATOR|Block and Periarticular injection|regional anesthesia (Adductor canal block +IPACK) and Periarticular injection
62505444|NCT01737541|EXPERIMENTAL|Fluoxetine|fluoxetine per os 20 mg daily
62505445|NCT01737541|PLACEBO_COMPARATOR|Placebo|per os daily
62703966|NCT06066138|EXPERIMENTAL|Arm 1|Atezolizumab treatment course
61960586|NCT06410612|ACTIVE_COMPARATOR|Periarticular injectin alone|Periarticular injection alone
61960587|NCT03810560|NO_INTERVENTION|open flap debridement|surgical treatment of periodontal pocket without any intervention
61960588|NCT03810560|ACTIVE_COMPARATOR|laser device with open flap debridement|surgical intervention associated with application of Erbium chromium: YSGG laser therapy
61960589|NCT00356473|PLACEBO_COMPARATOR|Placebo|Placebo
61960590|NCT00356473|EXPERIMENTAL|Atorvastatin|Atorvastatin
61960591|NCT02873000|NO_INTERVENTION|Routine Care Group|Routine Care (R): Standard of care therapy based on admitting diagnosis
61960592|NCT02873000|EXPERIMENTAL|Experimental Group|"Intervention 1 (E1): addition of incentive spirometry every hour while awake;~There will be a computerized protocol with specific instructions documenting:~1. compliance~2. patient position while using \[sitting up vs laying flat in bed\]~3. inspiratory volume attained~4. effort, motivation and compliance will subjectively be documented using a visual analogue 0-5 point scale."
61960593|NCT05364125|EXPERIMENTAL|Treatment arm|Olfactory training by neurological chemosensory stimulation using aromatic substances delivered via diffusers. Four aromatic substances will be used. Each substance will be given for 20 seconds sequentially, providing a total of 80 seconds of olfactory stimulation three times per day for 3 months.
62143551|NCT04867382|EXPERIMENTAL|Intervention|This arm received a case-based training on how to use the Opioid Wizard tool, including patient narratives and videos and person-first language.
62505446|NCT01337882|EXPERIMENTAL|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
62505447|NCT01337882|EXPERIMENTAL|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
62505448|NCT04916275||Staff working in a nursing home in Occitanie|
62505449|NCT00875888|EXPERIMENTAL|HCO|High cut-off filters HCO1100
62505450|NCT00875888|ACTIVE_COMPARATOR|control|conventional high-flux filters
62505451|NCT02176278|NO_INTERVENTION|Usual Care Group|"Usual care (UC) group:~After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment."
62703967|NCT06736379|EXPERIMENTAL|Cohort A (1 x 10^9 viral particles per injection)|Recurrent or Metastatic Head and Neck Cancer not scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly, with an additional follow-up safety visit 30 days post the final injection.
62703968|NCT06736379|EXPERIMENTAL|Cohort B (1 x 10^9 viral particles per injection)|Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 2 doses VLPONC-01 administered IT once weekly prior to tumor resection surgery, follow-up safety visit 30 days post-surgery.
62703969|NCT06736379|EXPERIMENTAL|Cohort C - Group 1 (1 x 10^9 viral particles per injection plus Pembrolizumab)|Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery.
62703970|NCT06736379|EXPERIMENTAL|Cohort C - Group 2 (3 x 10^8 viral particles per injection plus Pembrolizumab)|Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery follow-up safety visit 30 days post-surgery.
62703971|NCT06736379|EXPERIMENTAL|Cohort C - Pembrolizumab only|Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery.
62703972|NCT06734351|EXPERIMENTAL|Cohort 1: NOA VOLUME|Participants will receive NOA VOLUME on Day 1 with optional touch-up treatment on Day 31 and Month 18.
62703973|NCT06734351|EXPERIMENTAL|Cohort 1: VOLUMA XC|Participants will receive VOLUMA XC on Day 1 with optional touch-up treatment on Day 31 and Month 18.
62703974|NCT06734351|EXPERIMENTAL|Cohort 2: NOA VOLUME|Participants will receive NOA VOLUME on Day 1 with optional touch-up treatment on Day 31 and at either Month 12, 15, or 18.
62703975|NCT06734351|EXPERIMENTAL|Cohort 2: VOLUMA XC|Participants will receive VOLUMA XC on Day 1 with optional touch-up treatment on Day 31 and at either Month 12, 15, or 18.
62703976|NCT05303467|EXPERIMENTAL|Treatment|The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.
62703977|NCT03520660|EXPERIMENTAL|Phase I|Phase I treatment
61960594|NCT05364125|PLACEBO_COMPARATOR|Control arm|Same diffuser will be given to control group. All of the four essential oils will be replaced by normal saline using the same packing. Same treatment regime of 20 seconds for each diffuser three times per day for 3 months will be instructed to control group patients.
61960595|NCT02649998|ACTIVE_COMPARATOR|Group 1|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV saline placebo, followed by IV saline placebo 6 mL/h
61960596|NCT02649998|ACTIVE_COMPARATOR|Group 2|Each patient will initially receive a bolus of IV saline placebo and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
62143552|NCT04867382|PLACEBO_COMPARATOR|Comparison training|This arm received a case-based training on how to use the Opioid Wizard tool.
62703978|NCT03520660|NO_INTERVENTION|Phase II after Phase I|Participants who achieved SVR12 in Phase I
62703979|NCT03520660|NO_INTERVENTION|Phase II without Phase I|Participants who achieved SVR 24 previously
62703980|NCT06722430|EXPERIMENTAL|Icalcaprant with Itraconazole|Participants will receive oral Icalcaprant with Itraconazole up to 8 days and then followed for 30 days.
62703981|NCT06722417|EXPERIMENTAL|Group 1: Icalcaprant Dose A- Japanese Participants|Participants will receive oral Icalcaprant dose A once, then a 30-day follow-up period.
62703982|NCT06722417|EXPERIMENTAL|Group 2: Icalcaprant Dose A- Han Chinese Participants|Participants will receive oral Icalcaprant dose A once, then a 30-day follow-up period.
62703983|NCT06707207||Healthy|Healthy young volunteers
62703984|NCT06725706||Single Group Assignment|Each subject receive a single intravenous injection of 18F-92/AV45, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.
62703985|NCT06263101||Biomarker-group|We considered for the study all patients diagnosed with colorectal cancer through preoperative colonoscopy, aged 18-80, underwent laparoscopic radical resection with confirmed pathology, without prior radiotherapy, chemotherapy, or immunotherapy, and voluntarily participated in and signed informed consent for the study, collected indicators of inflammation in the peripheral blood and post-operative drainage fluid of enrolled patients on post-operative days 1 and 3.
62703986|NCT06707142|EXPERIMENTAL|TBD11|"In Part 1 double-blind phase of the trial (SAD), cohorts 1 to 5 and an optional cohort 7 will receive doses of TBD11; 8 participants in each cohort will be randomized (6:2) to receive TBD11 or placebo.~The FE and relative bioequivalence (BE) components of Part 1 (cohort 6) is open-label and 12 participants will receive TBD11 to evaluate the food effect and an alternative formulation of TBD11.~In Part 2, double blind phase of the trial, MAD, 48 will be randomized (3:1) to receive TBD11 or placebo in Cohorts 1-3"
62703987|NCT06707142|PLACEBO_COMPARATOR|Placebo|Participants in in Part 1 (cohorts 1-5 and optional cohort 7) and Part 2 will receive placebos matched to TBD11
61960597|NCT02649998|ACTIVE_COMPARATOR|Group 3|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
61960598|NCT02223832|EXPERIMENTAL|ACT-128800|"A single oral dose of 40 mg ACT-128800 will be administered as~1 capsule given in the fasted state in the morning"
61960599|NCT00536562|NO_INTERVENTION|Usual Care|Usual Care as provided through the Stroke Prevention Clinic
61960600|NCT00536562|ACTIVE_COMPARATOR|Cardiac Rehabilitation|Usual Care plus Comprehensive Cardiac Rehabilitation Program
62143553|NCT04828096|ACTIVE_COMPARATOR|Penta-one retainer|Penta-one retainer is one wire that is been in use for many years. Penta-one retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retainers are going to be bonded with sandblasted enamel and half without.
62703988|NCT06751108||Steroid Concomitant Group|Patients who received systemic corticosteroids concomitantly during the initial continuous administration period of immune checkpoint inhibitors.
62703989|NCT06751108||Steroid Non-Concomitant Group|Patients who did not receive systemic corticosteroids concomitantly during the initial continuous administration period of immune checkpoint inhibitors.
62703990|NCT06701461|EXPERIMENTAL|Electrodermal Activity Measurement Subjects|Participants will have their baseline electrodermal activity (EDA) response to pain measured as well as their EDA response measured while participating in a set of standardized functional tests.
62505452|NCT02176278|EXPERIMENTAL|Empowered Care Group|"Empowered care (EC) group:~After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment."
62505453|NCT02176278|EXPERIMENTAL|Team-based, Empowered Care Group|"Team-based, empowered care (TEC) group:~After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment."
62505454|NCT03067740|ACTIVE_COMPARATOR|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
62505455|NCT03067740|EXPERIMENTAL|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
62505456|NCT01149382||islet cell transplant recipients|
62505457|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
62505458|NCT05218109|EXPERIMENTAL|tVNS + mindfulness|Transcutaneous vagus nerve stimulation plus behavioral: mindfulness
62505459|NCT05218109|SHAM_COMPARATOR|Sham + mindfulness|Sham transcutaneous vagus nerve stimulation plus behavioral: mindfulness
62505460|NCT05218109|ACTIVE_COMPARATOR|Mindfulness only|
62505461|NCT05218109|ACTIVE_COMPARATOR|Control|Control number puzzle task delivered via mobile device
62505462|NCT02588820|EXPERIMENTAL|Antiretroviral treatment|
62505463|NCT04973813|EXPERIMENTAL|Guideline + Active Choice + action&coping planning (GA+)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning.
61960601|NCT02139631|EXPERIMENTAL|Healthy volunteers|The volunteers initially underwent a clinical examination, spirometry and echocardiography to prove the health state. Then, different levels of positive end expiratory pressure (PEEP) is applied by the noninvasive ventilation in all individuals and the hemodynamic repercussions are evaluated by the doppler echocardiography
61960602|NCT01297660||patients with SCI for at least 5 years|Ages Eligibility: minimum 18 years Genders Eligibility: female and male
62703991|NCT06750510|EXPERIMENTAL|Intervention|Participants assigned to this condition will receive the 8-weeks intervention
62143554|NCT04828096|EXPERIMENTAL|Ortho-FlexTech retainer|Ortho-Flextech chain wire is relatively new in the market and needs to be evaluated. Ortho-Flextech retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
62505464|NCT04973813|EXPERIMENTAL|Guideline + Active Choice (GA)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
62505465|NCT04973813|EXPERIMENTAL|Guideline + Information (GI)|Participants received the national physical activity guideline, and information about pros and cons of physical activity, and possible barriers to physical activity.
62505466|NCT04973813|OTHER|Guideline (G)|Comparison arm. Participants received the national physical activity guideline.
62505467|NCT06580652||Tracheal Tube|participants in cardiac arrest in whom a tracheal tube is used as the airway device
62505468|NCT06580652||Supraglottic Airway|participants in cardiac arrest in whom a supraglottic airway is used as the airway device
62505469|NCT02187380||Control group|Pharmacists received no depression training, delivered usual care to patients starting a new treatment with depression.
62505470|NCT02187380||Intervention group|Pharmacists received a depression training day and provided structured medication counselling to patients starting a new treatment with antidepressants
62505471|NCT00280969|EXPERIMENTAL|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
62505472|NCT00280969|ACTIVE_COMPARATOR|efavirenz arm|Patients are treated with efavirenz 300mg along with Epzicom.
62505473|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
61960603|NCT02711397||Celiac patients|Celiac patients following a GFD for at least one year prior to the inclusion in the study.
61960604|NCT02711397||Positive controls|Healthy children and adults on an unrestricted gluten containing diet.
61960605|NCT02711397||Negative controls|Healthy infants who were exclusively fed with infant formula specifically labelled as gluten-free.
61960606|NCT03899571|ACTIVE_COMPARATOR|5 days|oral oseltamivir 75 mg once daily for 5 days post-exposure
62143555|NCT04828096|EXPERIMENTAL|Memotain retainer|Memotain wire is relatively new in the market. It requires digital scanning and the technique is said to be very exact. Memotain retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
62505474|NCT06430073||Total sample|The study cohort will be composed of 340 older patients hospitalized in a Geriatric Unit with no or mild frailty in the pre-admission period, and who will present acute infections at admission or during the hospital stay.
62505475|NCT04829812||Prospective cohort|Prospective cohort with inclusion of consecutive or pseudo-consecutive patients by vascular specialist at their place of practice. Patient follow-up to assess wound progression and compression tolerance
62505476|NCT00628082||HfpEF|Patients with Heart Failure with preserved ejection fraction
62505477|NCT00628082||Control|Healthy Volunteers
62703992|NCT06471257|EXPERIMENTAL|BDA MDI|BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 μg)
62703993|NCT06471257|ACTIVE_COMPARATOR|AS MDI|AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg)
62703994|NCT05562934|EXPERIMENTAL|Dose 1|Lowest dose
62703995|NCT05562934|EXPERIMENTAL|Dose 2|Dose 2
62143556|NCT04921709||IBD Patients with Renal Involvement|"1. Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have renal problems .~   Age (18-65 years)~2. Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
62703996|NCT05562934|EXPERIMENTAL|Dose 3|Dose 3
62703997|NCT05562934|EXPERIMENTAL|Dose 4|Highest dose
62703998|NCT05562934|PLACEBO_COMPARATOR|Dose 5|Placebo
62703999|NCT05904093|EXPERIMENTAL|Fostamatinib in participants with Sickle Cell Disease|Participants with Sickle Cell Disease will receive Fostamatinib which will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, taken orally, twice a day for 28 days (total 42 days).
62704000|NCT02242968||Healthy Volunteers|Male and Female healthy volunteers between aged 18 and 65 years.
62704001|NCT03106779|EXPERIMENTAL|Asciminib|Patients were randomized to asciminib 40mg BID
62505478|NCT06437392||Psoriatic arthritis|Psoriatic arthritis patient
62347453|NCT05015166|ACTIVE_COMPARATOR|Internet delivered self-help program without therapist support|The intervention consists of 8 self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which the participants are encouraged to try. The treatment is based on principles from affect-focused psychodynamic psychotherapy.
62505479|NCT06437392||Healthy volunteer|Healthy Volunteer
62505480|NCT00996424|EXPERIMENTAL|Acetylcysteine|Inhalation with N-Acetylcysteine
62505481|NCT00996424|PLACEBO_COMPARATOR|normal saline|Inhalation with normal saline solution
62505482|NCT06531642|EXPERIMENTAL|Early Initiation|Within 2 hours of emergency department (ED) admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40 mg, then followed by 40 mg q12hrs for 2 additional days
62505483|NCT06531642|ACTIVE_COMPARATOR|Usual Care|Administer 1st dose of 40 mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40 mg daily for 2 additional days.
62505484|NCT04063319|EXPERIMENTAL|High-fidelity simulation|The participants in the intervention group will receive an high-fidelity simulation intervention
62704002|NCT03106779|ACTIVE_COMPARATOR|Bosutinib|Patients were randomized to bosutinib 500mg QD
62704003|NCT05276973|EXPERIMENTAL|Treatment (paclitaxel, carboplatin, ipatasertib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ipatasertib PO QD until 24 hours before surgery in the absence of disease progression or unacceptable toxicity.
62704004|NCT06129149|EXPERIMENTAL|Intervention|All participants will participate in this single arm study consisting of three visits: visit 1 (baseline data collection), visit 2 (intervention followed by brief qualitative debrief interview), and visit 3 (30-day follow-up data collection)
62704005|NCT05932641|EXPERIMENTAL|Cohort 1 - AZD3152 300 mg IM direct anterolateral thigh injection|
62704006|NCT05932641|PLACEBO_COMPARATOR|Cohort 1 - Placebo IM direct anterolateral thigh injection|
62704007|NCT05932641|EXPERIMENTAL|Cohort 2 - AZD3152 600 mg IM direct anterolateral thigh injection|
62704008|NCT05932641|PLACEBO_COMPARATOR|Cohort 2 - Placebo direct anterolateral thigh injection|
62704009|NCT05932641|EXPERIMENTAL|Cohort 3 - AZD3152 1200 mg IV administration|
62704010|NCT05932641|PLACEBO_COMPARATOR|Cohort 3 - Placebo IV administration|
62704011|NCT06746675|ACTIVE_COMPARATOR|Healthy Families PrEP Counselling Intervention|Intervention Health Care Centers will offer the guideline-based PrEP standard of care plus trained staff will conduct the 3-session Healthy Families-PrEP intervention with HIV-uninfected women with plans for pregnancy in the next year and concerns about or exposure to HIV.
62704012|NCT06746675|PLACEBO_COMPARATOR|Standard of care Intervention|Control Health Care Centers will provide standard of care based on Ugandan Ministry of Health prevention guidelines for people vulnerable to HIV, including women with a partner with HIV who is not virally suppressed, who are pregnant, or breastfeeding.
62704013|NCT05690581|EXPERIMENTAL|CM369 Ia Dose Escalation|Dose escalation of CM369 as monotherapy
62704014|NCT05690581|EXPERIMENTAL|CM369 Ib Dose Expansion|Dose expansion of CM369 as monotherapy
62704015|NCT05426733|EXPERIMENTAL|Odevixibat (A4250)|Capsules for oral administration once daily for 104 weeks.
62704016|NCT06408207|EXPERIMENTAL|CGM Academy|"* receive an interactive workbook with problem-based learning scenarios and video links about CGM and glucose management strategies.~* participate in four in-depth online group sessions with diabetes care and education specialists~* complete questionnaires three times: at the time of study enrollment, week 4 and 6 months."
62704017|NCT06408207|NO_INTERVENTION|Standard Diabetes Education|"* receive standard education provided to all patients at CHLA~* complete questionnaires three times: at the time of study enrollment, week 4 and 6 months."
62704018|NCT00104325||1|white blood cells obtained through cytapheresis by healthy males and females 18 years and older
62704019|NCT01087281||1|Neurologically normal healthy volunteers in good general health.
62704020|NCT01087281||2|Patients with unilateral or bilateral focal lesions of prefrontal, parietal, occipital or temporal cortex, or amygdala.
62704021|NCT04153292|EXPERIMENTAL|TMVR - Main Cohort|Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).
62704022|NCT04153292|EXPERIMENTAL|TMVR - Failed TEER Registry|Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.
62704023|NCT04153292|EXPERIMENTAL|TMVR - MAC Registry|Subjects with mitral annular calcification (MAC) will have TMVR.
61960607|NCT03899571|ACTIVE_COMPARATOR|10 days|oral oseltamivir 75 mg once daily for 10 days post-exposure
62704024|NCT06459180|EXPERIMENTAL|Sacituzumab Tirumotecan|Participants will receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation.
62704025|NCT06459180|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|At the physician's discretion, participants will receive 2 mg/m\^2 of pemetrexed on day 1 of every 3-week cycle via IV infusion OR 2 mg/kg of tisotumab vedotin on day 1 of every 3-week cycle via IV infusion OR 1 mg/m\^2 (or 1.25 mg/m\^2 if tolerating well) topotecan on days 1, 2, 3, 4, and 5 of every 3-week cycle via IV infusion OR 30 mg/m\^2 of vinorelbine on days 1 and 8 of every 3-week cycle via IV infusion OR 1000 mg/m\^2 of gemcitabine on day 1 and 8 of every 3-week cycle via IV infusion OR 100 mg/m\^2 (or 125 mg/m\^2 if tolerating well) of irinotecan on days 1, 8, 15, and 22 of every 6 week cycle via IV infusion, until progressive disease or discontinuation.
62704026|NCT04049669|EXPERIMENTAL|Core Regimen, sub-cohort A|For patients not eligible for re-irradiation; Start with Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
62704027|NCT04049669|EXPERIMENTAL|Core Regimen, sub-cohort B|For patients who are eligible for partial re-irradiation; Start with indoximod plus up-front re-irradiation, using a palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
62704028|NCT04049669|EXPERIMENTAL|Core Regimen, sub-cohort C|For patients who are eligible for full-dose radiation; (All newly diagnosed DIPG patients and some relapsed ependymoma patients); Start with indoximod plus up-front radiation, using a palliative full-dose radiation plan to all known sites of disease (\>50 Gy to brain, \>45 Gy to spine); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
61960608|NCT04971408|OTHER|control|passive heat stress x1 visit then no intervention for 8 weeks. participants continue regular exercise habits as usual.
62143557|NCT04921709||IBD Patients without Renal Involvement|"1. Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have no renal problems .~   Age (18-65 years)~2. Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
62143558|NCT04388865|EXPERIMENTAL|Control|Usual Care
62347454|NCT05015166|NO_INTERVENTION|Waitlist|Participants will receive no intervention for 8 weeks.
62347455|NCT05519618||Participants|Patient planned to receive debulking or en bloc resection of vertebral tumor.
62505485|NCT04063319|NO_INTERVENTION|Control|The participants in the control group will not receive any instructional intervention
62347456|NCT03285906|EXPERIMENTAL|Treatment group|Apatinib：500 mg，po，qd
61960609|NCT04971408|EXPERIMENTAL|Passive heat stress|After arm 1, passive heat stress 3x/week x8 weeks.
62347457|NCT01705548|EXPERIMENTAL|Hypofractionated Radiosurgery|"HR (Hypofractionated Radiosurgery) delivered in 5 fractions, with a minimum of 2 and a maximum of 3 fractions being delivered per week, to patients with brain metastases or resection cavity greater than 3 cm and less than 6 cm.~Dose escalation will proceed according to the Escalation with Overdose Control (EWOC) method with a planned total enrollment of 24 patients, in 8 patient cohorts with 3 patients per cohort. A 4 month observation period will occur for each completed cohort prior to dose escalation, with a goal timeline for trial completion of 4 years from first patient enrollment."
62347458|NCT02766790|PLACEBO_COMPARATOR|Placebo|Placebo taken once daily in the morning and once daily in the evening
62347459|NCT02766790|ACTIVE_COMPARATOR|TA-65MD 100 units Dose|TA-65MD 100 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
62347460|NCT02766790|ACTIVE_COMPARATOR|TA-65MD 250 units Dose|TA-65MD 250 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
62704029|NCT04049669|EXPERIMENTAL|Salvage Regimen 1|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral metronomic cyclophosphamide and etoposide).
62704030|NCT04049669|EXPERIMENTAL|Salvage Regimen 2|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral lomustine and temozolomide).
62704031|NCT06096844|ACTIVE_COMPARATOR|Arm A (pembrolizumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 or 42 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo MRI at baseline and CT and/or PET on the trial at baseline and throughout the trial."
62704032|NCT06096844|EXPERIMENTAL|Arm B (pembrolizumab, chemotherapy)|See Detailed Description
62704033|NCT03434080||Autism Spectrum Disorder|The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD)
62704034|NCT03434080||Cerebral Palsy|The group with CP (including all infants less than 18 months who are identified as being athigh-risk for CP)
61960610|NCT00164775|ACTIVE_COMPARATOR|Imipramine|Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
61960611|NCT00164775|PLACEBO_COMPARATOR|Placebo|Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
61960612|NCT03206528||VSMS with ear unit|application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
61960613|NCT03206528||VSMS without ear unit|application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
61960614|NCT04382339|ACTIVE_COMPARATOR|Treatment-naive|"Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
62347461|NCT02766790|ACTIVE_COMPARATOR|TA-65MD 500 units Dose|TA-65MD 500 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
62347462|NCT02766790|ACTIVE_COMPARATOR|TA-65MD 250 units a.m. and p.m. Dose|Two TA-65MD 250 units capsules; one of them will be taken in the a.m. and one of them will be taken in the p.m.
62347463|NCT02097433|EXPERIMENTAL|Dacomitinib|
62347464|NCT06195501||Acute ischemic stroke|Patients with acute ischemic stroke and an indication for a transesophageal ecocardiography
61960615|NCT04382339|ACTIVE_COMPARATOR|Treatment-experienced|"Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
61960616|NCT02092493|NO_INTERVENTION|Non-ScopeGuide|This arm will have patients undertaking the procedure without ScopeGuide. All outcome measures will be recorded as usual
61960617|NCT02092493|EXPERIMENTAL|ScopeGuide|Patients have their colonoscopy done with ScopeGuide
61960618|NCT04589078||Interficial Intelligence|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
61960619|NCT04051073|SHAM_COMPARATOR|Blinded|CNAP monitoring applied, but screen and information not visible to treating anaesthetist
61960620|NCT04051073|ACTIVE_COMPARATOR|Unblinded|CNAP monitoring applied and available in full to the treating anaesthetist
61960621|NCT02932670|ACTIVE_COMPARATOR|costoclavicular inflaclavicular block|costoclavicular block with similar volume
61960622|NCT02932670|EXPERIMENTAL|costoclavicular block|costoclavicular block with decreasing volume
61960623|NCT02598544|OTHER|lean men|
61960624|NCT02598544|OTHER|Obese men without type 2 diabetes|
61960625|NCT02598544|OTHER|Obese men with type 2 diabetes|
61960626|NCT04762784|EXPERIMENTAL|Tocilizumab treatment|Tocilizumab is a recombinant humanized monoclonal antibody against human interleukin-6 (IL-6) receptor. Tocilizumab acts by inhibiting the activity of IL-6 receptor. IL-6 is a pro-inflammatory cytokine whose release can trigger a series of downstream pro-inflammatory responses. Tocilizumab inhibits IL-6 signal transduction by blocking the binding of IL-6 to soluble and membrane-bound IL-6 receptors, thereby reducing pathological inflammatory responses.
61960627|NCT04762784|ACTIVE_COMPARATOR|Glucocorticoids monotherapy|Glucocorticoids has fast onset of action and multiple anti-inflammatory effects.The conventional protocol is oral prednisone, followed by a slow tapering over 4 weeks. Besides, precautionary measures need to be taken against possible complications brought by the application of corticosteroids such as infections, diabetes mellitus, hypertension, Cushing's syndrome and osteoporosis, etc.
61960628|NCT04397224||CRT responder|
61960629|NCT04397224||CRT non-responder|
61960630|NCT04603690|EXPERIMENTAL|Complementary therapy group|This arm will receive a daily supplementation of 168 mg curcumin, 260 mg quercetin and 9 mcg/360 IU of vitamin D3 (cholecalciferol) as add-on to the standard of care for 14-days
62347465|NCT03587818|NO_INTERVENTION|Control group|"Conventional care. Patients were receiving several written patient education materials (PEMs), mostly related to specific parts or procedures related to the surgery and the recovery.~Communication between patients and professionals during consultations occurred according to conventional care practice."
61960631|NCT04603690|ACTIVE_COMPARATOR|Control group|This arm will receive standard care alone
61960632|NCT00764738|ACTIVE_COMPARATOR|Monthly|Ranibizumab injections every month for 12 months.
61960633|NCT00764738|ACTIVE_COMPARATOR|As Needed|Ranibizumab injections monthly for 4 months then as needed thereafter.
61960634|NCT05955105|EXPERIMENTAL|Treatment Arm|Subjects will receive ILB-2109 tablets and Toripalimab injection
61960635|NCT05117437||Athletic group|Healthy male athletes who have been doing regular anaerobic sports (such as basketball, volleyball and handball) for at least 3 months
62143559|NCT04388865|EXPERIMENTAL|Clinical Hovering|Remote monitoring with feedback to social support
61960636|NCT05117437||Control group|Healthy sedentary (not doing regular sports for at least 3 months) men with age and physical characteristics similar to the athlete group
61960637|NCT03167411|EXPERIMENTAL|Bexagliflozin alone|
61960638|NCT03167411|ACTIVE_COMPARATOR|Bexagliflozin with exenatide injection|
61960639|NCT00629707|ACTIVE_COMPARATOR|1|Slower infusion rate: Patients in this arm will receive an initial intravenous fluid bolus of 10cc/Kg followed by rehydration calculated to replace a deficit of 7.5% of body weight over 48 hours.
61960640|NCT00629707|ACTIVE_COMPARATOR|2|More rapid infusion: Patients in this arm will receive an initial bolus of 20 cc/Kg of intravenous fluids followed by replacement of an estimated deficit of 10% of body weight over 36 hours plus replacement of 1/2 of urine output volume.
62143560|NCT02442037|EXPERIMENTAL|UCMSC group|Human umbilical cord MSCs are administrated to patients by three intravenous infusion
62143561|NCT02442037|OTHER|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
62143562|NCT00979459|EXPERIMENTAL|MK-1006 80 mg DFC|Participants received a single dose of four 20 mg dry filled capsules of MK-1006
62143563|NCT00979459|EXPERIMENTAL|MK-1006 80 mg FCT|Participants received a single dose of two 40 mg film coated tablets of MK-1006
62143564|NCT01331772|OTHER|Control arm|Dietetic follow-up only
61960641|NCT02144012|EXPERIMENTAL|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
61960642|NCT02144012|ACTIVE_COMPARATOR|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
61960643|NCT06340373||Patients with native coronary lesions (2.0-3.5 mm diameter) after drug-coated balloon angioplasty|Patients with successful revascularization of native coronary lesions (diameter \>2.0 mm and ≦3.5 mm at visual estimation) by drug-coated balloon angioplasty and follow up after six month by coronary angiography
61960644|NCT01745133|PLACEBO_COMPARATOR|vehicle|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
61960645|NCT01745133|ACTIVE_COMPARATOR|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
62143565|NCT01331772|EXPERIMENTAL|Intervention arm|Dietetic + adapted physical activity
62505486|NCT03600181||orotracheal intubation|Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
62704035|NCT03434080||Typical Development toddlers infants|The control group will consist of 50 healthy volunteers with TD
62704036|NCT04033445|EXPERIMENTAL|Induction Study 1: Guselkumab Dose 1|Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
62704037|NCT04033445|EXPERIMENTAL|Induction Study 1: Guselkumab Dose 2|Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
62704038|NCT04033445|PLACEBO_COMPARATOR|Induction Study 1: Placebo IV|Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
62704039|NCT04033445|EXPERIMENTAL|Induction Study 2: Guselkumab IV|Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
62704040|NCT04033445|PLACEBO_COMPARATOR|Induction Study 2: Placebo IV|Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
62704041|NCT04033445|EXPERIMENTAL|Maintenance Study: Maintenance Dose Regimen 1|Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).
62704042|NCT04033445|EXPERIMENTAL|Maintenance Study: Maintenance Dose Regimen 2|Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).
62704043|NCT04033445|PLACEBO_COMPARATOR|Maintenance Study: Placebo SC|Participants will receive matching placebo SC q4w.
61960646|NCT01745133|ACTIVE_COMPARATOR|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
61960647|NCT03660540|EXPERIMENTAL|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
61960648|NCT03660540|NO_INTERVENTION|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
61960649|NCT03174834|OTHER|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
61960650|NCT05683769||erosive hand osteoarthritis|EHOA was diagnosed according to the American College of Rheumatology (ACR) criteria and to the presence of the classical central erosion in at least two IP joints. Further inclusion criteria were the availability of plain radiography of both hands performed in the previous 6 months. Plain radiographs of both hands were collected and scored by two readers according to Kallman's classification in a blind observation.
61960651|NCT05683769||psoriatic arthritis|PsA was diagnosed following the CASPAR classification guidelines and only patients with the peripheral arthritis pattern were considered; all PsA group had also the diagnosis of psoriasis confirmed by an expert dermatologist. These patients had also to be naive to conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) or have withdrawn any DMARDs for at least three months, because of inadequate response or intolerance.
62143566|NCT02972424|EXPERIMENTAL|Teriparatide Prefilled Syringe|TPTD is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
62347466|NCT03587818|EXPERIMENTAL|Intervention group|"I. Written interactive PEM structured into chapters/phases of the care process. Designed to serve three purposes:~1. generic information of the surgery and recovery process on a group level to promote high readability, suitability and comprehensibility~2. arena of dialogues between patient and professionals; voicing concerns, share perspectives~3. for the patient to personally reflect on generic information.~II. Person-centred communication in dialogues using the PEM as a supportive tool, facilitated by four communication strategies:~1. professionals guiding the patient through the care process~2. communicating an introduction, agenda and closing~3. being sensitive to the patient's questions, beliefs, experiences and resources~4. dialogue based on story, posing open-ended questions, and following up."
62704044|NCT05564377|EXPERIMENTAL|EAY191-A2 (Cohort 1, Arm A)|Cohort 1, Arm A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
62704045|NCT05564377|EXPERIMENTAL|EAY191-A2 (Cohort 2, Arm B)|Cohort 2, Arm B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
62704046|NCT05564377|EXPERIMENTAL|EAY191-A2 (Cohort 2, Arm C)|Cohort 2, Arm C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
62704047|NCT05564377|EXPERIMENTAL|EAY191-A2 (Cohort 3, Arm D)|Cohort 3, Arm D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
62704048|NCT05564377|EXPERIMENTAL|EAY191-A3 Combo Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)|Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
62704049|NCT05564377|EXPERIMENTAL|EAY191-A3 Monotherapy Cohort 1 (binimetinib)|Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
62704050|NCT05564377|EXPERIMENTAL|EAY191-A6 Arm I (RAS/RAF/MEK/ERK mutations)|Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
62704051|NCT05564377|EXPERIMENTAL|EAY191-A6 Arm II (RAS/RAF/MEK/ERK mutations)|Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated
62704052|NCT05564377|EXPERIMENTAL|EAY191-E4 (taxane therapy)|Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression.
62704053|NCT05564377|EXPERIMENTAL|EAY191-E5 Cohort I Arm A (sotorasib, panitumumab)|Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
61960652|NCT05683769||Control Group|The control group was represented by healthy volunteers age-and sex-matched to study patients and were recruited among the hospital staff; HC did not exhibit symptoms or signs attributable to OA, psoriasis, as well as to autoimmune disorders and systemic inflammatory arthropathies.
62704054|NCT05564377|ACTIVE_COMPARATOR|EAY191-E5 Cohort I Arm B (sotorasib)|Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
62704055|NCT05564377|EXPERIMENTAL|EAY191-E5 Cohort II (sotorasib)|Patients receive combination therapy as in EAY191-E5 Arm A.
62704056|NCT05564377|EXPERIMENTAL|EAY191-N2 Cohort I (Arm I) (NF1 mutations)|Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, MRI, or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study.
61960653|NCT04725461|EXPERIMENTAL|Low cost lower limb socket testing|Fabrication and testing of a low cost lower limb prosthetic socket and ensure this socket has appropriate suspension, comfort and f unction for a transtibial amputee.
61960654|NCT00745823|ACTIVE_COMPARATOR|Raltegravir 400 mg b.i.d.|
61960655|NCT00745823|EXPERIMENTAL|Raltegravir 800 mg q.d.|
61960656|NCT04388202|EXPERIMENTAL|Sertraline|Sertraline 100-200 mg daily for 8 weeks
61960657|NCT04388202|ACTIVE_COMPARATOR|Escitalopram|Escitalopram 10-20 mg daily for 8 weeks
61960658|NCT02389361|EXPERIMENTAL|Group Z|Postoperative Analgesia with Zaldiar
61960659|NCT02389361|ACTIVE_COMPARATOR|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
61960660|NCT03881566||Immunocompetent sepsis patients|Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
61960661|NCT03881566||Immunocompromised sepsis patients|Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
62347467|NCT05994586|EXPERIMENTAL|AP029 mix - type II diabetes|Patients with type II diabetes receiving metformin for up to 5 months
62347468|NCT05994586|EXPERIMENTAL|AP029 mix - prediabetes|Patients with pre-diabetic
62347469|NCT05994586|PLACEBO_COMPARATOR|Placebo - type II diabetes|Patients with type II diabetes receiving metformin for up to 5 months
62347470|NCT05994586|PLACEBO_COMPARATOR|Placebo - prediabetes|Patients with pre-diabetic
61960662|NCT03881566||Patients without sepsis|Patients who admitted intensive care unit without sepsis
61960663|NCT01050712|EXPERIMENTAL|Carbon Monoxide|
61960664|NCT01050712|PLACEBO_COMPARATOR|Synthetic Air|
62347471|NCT00845494|OTHER|medication history education|Four hospital unit nurses asked to participate in the study. Two nursing units will receive the cognitive behavioral intervention.
62347472|NCT02404883|NO_INTERVENTION|control group|care as usual (fertility preservation counseling)
62704057|NCT05564377|EXPERIMENTAL|EAY191-N2 Cohort I (Arm II) (NF1 mutations)|Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study.
62704058|NCT05564377|EXPERIMENTAL|EAY191-N2 Cohort II (NF1 mutations)|Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study.
62704059|NCT05564377|EXPERIMENTAL|EAY191-N4 Arm I (RAS pathway mutations)|Patients receive selumetinib PO and olaparib PO on study. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
62704060|NCT05564377|ACTIVE_COMPARATOR|EAY191-N4 Arm II (RAS pathway mutations)|Patients receive selumetinib PO on study. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
62704061|NCT05564377|ACTIVE_COMPARATOR|EAY191-N5 Arm I (neratinib maleate)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
62704062|NCT05564377|EXPERIMENTAL|EAY191-N5 Arm II (neratinib maleate,palbociclib)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
62704063|NCT05564377|EXPERIMENTAL|EAY191-S3 (activating AKT mutation)|Patients receive paclitaxel IV and ipatasertib PO on study. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.
62704064|NCT06639620||Foscarbidopa / Foslevodopa|Participants will receive foscarbidopa/ foslevodopa as prescribed by their physician according to local label
62704065|NCT06577454|ACTIVE_COMPARATOR|Active TMS|Participants will be blinded as to which sessions involve active TMS or sham. Those study staff involved in interacting with the participant will also be blinded. Participants will be randomized into either active-sham or sham-active session order.
62704066|NCT06577454|SHAM_COMPARATOR|Sham TMS|Participants will be blinded as to which sessions involve active TMS or sham. Those study staff involved in interacting with the participant will also be blinded. Participants will be randomized into either active-sham or sham-active session order.
62704067|NCT06751121|EXPERIMENTAL|DWP14012 40 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg|1 tablet of DWP14012 40 mg + 1 capsule of DWC202301 30 mg placebo + amoxicillin 1000 mg (2 capsules of 500 mg) + 1 tablet of clarithromycin 500 mg
62704068|NCT06751121|ACTIVE_COMPARATOR|DWC202301 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg|1 tablet of DWP14012 40 mg placebo + 1 capsule of DWC202301 30 mg + amoxicillin 1000 mg (2 capsules of 500 mg) + 1 tablet of clarithromycin 500 mg
62704069|NCT06712329|EXPERIMENTAL|extracorporeal shock wave therapy group|In the ESWT group, a total of 1800 to 2000 focused shock waves (0.15-0.25 mJ/mm² sessions with a frequency of 3-4 Hz) were applied
62704070|NCT06712329|EXPERIMENTAL|Prolotherapy Group|The prolotherapy group was administered a 3-ml injection of a 15% dextrose solution.
62505487|NCT01962649|EXPERIMENTAL|ICG & Optical Molecular Imaging|All patients will receive a dose of ICG 0.5mg/kg, with a maximum dose of 40mg, one day prior to the scheduled procedure. The patients will then undergo a routine image-guided biopsy on the day of the procedure; immediately prior to obtaining the biopsy sample, fluorescence intensity within the target lesion will be measured by a handheld optical molecular imaging device, which will be passed through the biopsy needle. Once the core sample is obtained using a standard biopsy needle, the specimen will be imaged using an epifluorescence, point-of-care imaging system and will then be submitted for standard pathologic analysis.
62505488|NCT04789967|ACTIVE_COMPARATOR|Guided Imagery (GI)|A 8 minute audio that focuses on evoking mental images in reducing the abdominal bloating sensation in patients
62704071|NCT06702553|EXPERIMENTAL|Intervention: iNO Group|Patients will receive 80 parts per million (ppm) NO during CPB through the oxygenator. After weaning of CPB, test gases will be delivered via inspiration limb of ventilator at a dose range of 40-80 ppm until 6 hours after ICU admission or until extubation after surgery, whichever comes first.
61960665|NCT00133952|EXPERIMENTAL|Ruboxistaurin|32 mg taken orally daily for up to 48 months
61960666|NCT00133952|PLACEBO_COMPARATOR|Placebo|Taken orally daily for up to 48 months
61960667|NCT04510584|EXPERIMENTAL|Atezolizumab and Bevacizumab|"A cycle will be every 3 weeks.~Atezolizumab will be given intravenously (by vein) at a dose of 1200 mg once every cycle. Bevacizumab will be given intravenously at a dose of 15 mg/kg once every cycle. Up to 17 cycles of study treatment may be given.~Participants may be able to receive the study treatment for more than 17 cycles if the participants and the study doctor thinks that they are benefiting."
62505489|NCT04789967|ACTIVE_COMPARATOR|Progressive Muscle Relaxation (PMR)|A 8 minute audio that focuses on contracting certain muscle groups and relaxing it progressively in reducing the abdominal bloating sensation in patients
61960668|NCT06392620|EXPERIMENTAL|Study group|An individually planned exercise program including stretching, strengthening, respiratory, aerobic and posture exercises will be applied via video conference method.
62505490|NCT04789967|PLACEBO_COMPARATOR|Audiobook|A 8 minute audio that focuses on providing educational information regarding functional gastrointestinal disorders and related knowledge.
62505491|NCT03584217|OTHER|Clinical Investigation|All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
62505492|NCT04712084|NO_INTERVENTION|Control group|Extubation procedure following standard of care
62505493|NCT04712084|EXPERIMENTAL|Pressure support group|Extubation procedure is performed with 100% of O2 but with application of positive pressure before and after extubation
62704072|NCT06702553|PLACEBO_COMPARATOR|Standard Care/Control Group|Patients in this group will receive standard care and 80 ppm nitrogen (N2, control group) are added to the gas mixture as control. In the circumstances when the N2 is not applicable, such as when the plasma-chemical NO synthesis device is employed for NO generatiaon and delivery, the device will be connected to the CPB and ventilator circuits, but the synthesis will remain inactive in the control group. Consequently, the circuit will be supplied with air devoid of NO.
62704073|NCT06713005|OTHER|4 min suprascapular pulsed RF|Suprascapular nerve pulsed RF is applied for 4 minutes.
62704074|NCT06713005|OTHER|9 min suprascapular pulsed RF|Suprascapular nerve pulsed RF is applied for 8 minutes.
62704075|NCT06719856||68Ga-MMP14|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-MMP14 PET/CT scan.
62704076|NCT06731530||PEX group (patients WITH pseudoexfoliation syndrome)|right or left eye of pseudophakic patients diagnosted with PEX syndrome pre-operatively (PEX positive, as recorded in the pre-operative medical file)
62704077|NCT06731530||Control group (patients WITHOUT pseudoexfoliation syndrome)|right or left eye of pseudophakic patients without a pre-operative diagnosis of pseudoexfoliation syndrome (PEX negative, as recorded in the pre-operative medical file)
62704078|NCT06741254|EXPERIMENTAL|Experimental (Stress Ball)|Pregnant women included in the experimental group will be asked for written informed consent before the NST application, and the Pregnant Descriptive Information Form, State Anxiety Scale and Visual Comfort Scale will be completed. Then, the NST device will be connected to the pregnant woman and the Stress ball application will be started. During the NST procedure (average 20-30 minutes), the pregnant woman will lie on her left side. A stress ball will be placed in the right hand of the pregnant woman. The pregnant woman will be instructed to squeeze the stress ball for 2-3 seconds and then relax the hand and arm. This process will be repeated throughout the NST. During the NST application, the pregnant researcher will remain under the supervision of the midwife/nurse. The State Anxiety Scale and Visual Comfort Scale will be repeated immediately after the NST procedure. The NST result form will be filled out according to the NST printout.
62704079|NCT06741254|NO_INTERVENTION|Control|Written informed consent will be obtained from the pregnant women in the control group before the NST application, and the Pregnant Descriptive Information Form, State Anxiety Scale and Visual Comfort Scale will be completed. Then the NST device will be connected to the pregnant woman. Pregnant women in this group will not be given a stress ball. During the NST procedure (average 20-30 minutes), the pregnant woman will lie on her left side. During the NST procedure, the pregnant woman will remain under the supervision of the researcher midwife/nurse. The State Anxiety Scale and Visual Comfort Scale will be repeated immediately after the NST procedure. The NST result form will be filled according to the NST trace.
62505494|NCT04340531|EXPERIMENTAL|Arm I (early arm)|Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 13-24. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
62143567|NCT02972424|PLACEBO_COMPARATOR|Placebo|Placebo is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
62505495|NCT04340531|ACTIVE_COMPARATOR|Arm II (delayed arm)|Female smokers receive usual care during months 13-24. Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 25-36. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
62505496|NCT04871009|PLACEBO_COMPARATOR|Standard of Care|routine clinical psychotherapy
62505497|NCT04871009|EXPERIMENTAL|Neurofeedback Intervention plus standard of care|routine clinical psychotherapy plus 3 to 4 neurofeedback interventions per week.
62505498|NCT04904484|EXPERIMENTAL|With i-zephyr|using the hood
62505499|NCT04904484|NO_INTERVENTION|Without i-zephyr|Not using the hood
62505500|NCT00745134|EXPERIMENTAL|Arm I (curcumin)|Patients undergo radiation therapy 5 days a week for a total of 28 fractions. Patients also receive capecitabine PO BID on the days of radiation therapy and curcumin PO BID in weeks 1-11.5.
62505501|NCT00745134|ACTIVE_COMPARATOR|Arm II (placebo)|Patients undergo radiation therapy and receive capecitabine as in Arm I. Patients also receive placebo PO BID in weeks 1-11.5.
62505502|NCT06315517|EXPERIMENTAL|Conventional lactose-free milk first|Participants will consume conventional lactose-free milk first, then each of the other milk types in random order
62505503|NCT06315517|EXPERIMENTAL|Non-conventional (A2) lactose-free milk first|Participants will consume non-conventional (A2) lactose-free milk first, then each of the other milk types in random order
61960669|NCT06392620|EXPERIMENTAL|Control group|It will be recommended a video on YouTube platform and will be asked to do the exercises by following the content of these videos
62505504|NCT06315517|EXPERIMENTAL|Non-conventional (A2) milk first|Participants will consume non-conventional (A2) milk first, then each of the other milk types in random order
61960670|NCT02723214|ACTIVE_COMPARATOR|Frame-based stereotactic brain biopsy|Brain biopsy
61960671|NCT02723214|ACTIVE_COMPARATOR|Frameless fiducial-less brain biopsy|Brain biopsy
62704080|NCT05298423|EXPERIMENTAL|pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy|For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray \[Gy\] in 2 Gy fractions for 30 days total) during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \~14 months). Cycles 1-20 are 21-day cycles. Investigator's choice of chemotherapy: cisplatin 75 mg/m\^2 and pemetrexed 500 mg/m\^2 on Day 1 of Cycles 1-3 for non-squamous histology only; cisplatin 50 mg/m\^2 on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3 and etoposide 50 mg/m\^2 on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3; carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3 and paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3.
61960672|NCT06485765|EXPERIMENTAL|Intervention group|"The daily energy requirement of the individuals included in the study was obtained by multiplying the physical activity level (PAL) calculated as a result of 24-hour physical activity recording and the Harris-Benedict formula used to calculate the basal metabolic rate.~Harris-Benedict Formula Male 66.5 + 13.75 x Weight (kg) + 5.003 x Height (cm) - 6.775 x Age (years) Female 655.1 + 9.563 x Weight (kg) + 1.85 x Height (cm) - 4.676 x Age (years)~After the daily energy requirement was calculated, a DASH eating plan specific to the individuals was created and they were asked to maintain it for 12 weeks. In addition, the personal contact information of the researcher was shared with the individuals and they were in constant communication about all questions related to the nutrition plan."
62704081|NCT05298423|ACTIVE_COMPARATOR|chemotherapy+radiotherapy+durvalumab|"For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy in 2 Gy fractions for 30 days total) during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles.~Investigator's choice of chemotherapy: cisplatin 75 mg/m\^2 and pemetrexed 500 mg/m\^2 on Day 1 of Cycles 1-3 for non-squamous histology only; cisplatin 50 mg/m\^2 on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3 and etoposide 50 mg/m\^2 on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3; carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3 and paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3."
62704082|NCT06483282|EXPERIMENTAL|Adebrelimab in combination with chemotherapy and apatinib mesylate|Adebrelimab 1200mg q3w for 4 cycles, Apatinib mesylate 250mg qod q3w 3 times/week concurrent with adebrelimab for 3 cycles, platinum-based chemotherapy (etoposide, 100mg/m2, q3w; Carboplatin, AUC=5, q3w), 4 cycles, and operation was performed within 4-8 weeks after treatment (Apatinib mesylate was discontinued for 4 weeks). According to the results of MDT discussion, adebrelimab, 1200mg q3w, and apatinib 250mg qod q3w 3 times/week were used 4 weeks after surgery, which with or without radiotherapy. Preoperative prophylactic radiotherapy (PCI) is recommended for patients with preoperative stage N1. Patients with postoperative stage N1 received postoperative thoracic radiotherapy.
62143568|NCT03455985|EXPERIMENTAL|Discharge Order Set (DOS)|Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Phone calls will assess adherence with instructions for self-titration. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider.
62143569|NCT03455985|OTHER|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
62143570|NCT03158506|EXPERIMENTAL|[C14]-labelled HMS5552|
62143571|NCT03800368|EXPERIMENTAL|High-endurance group|This group of subjects will receive 2-3 sessions of high-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will interchange between the aerobic and anaerobic state.
62347473|NCT02404883|EXPERIMENTAL|intervention group|Intervention: use of an online decision-aid tool after fertility preservation counseling
62505505|NCT01622530||Amputees|upper limb amputees
62505506|NCT01622530||Non-amputees|No longer recruiting non-amputees
62505507|NCT02096367|EXPERIMENTAL|Hemiplegia after vascular stroke|"* Muscle vibration stimulation~* Gait analysis with Gait Rite : quantitative and spatio-temporal gait parameters~* Kinematic gait analysis in lower limb measured by optoelectronic system (Optitrack).~* Analysis of static posture on force platform~* Evaluation of the gait on treadmill during 2 minutes"
62505508|NCT04291508|ACTIVE_COMPARATOR|IV Acetaminophen-Active|Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight \< 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).
62505509|NCT04291508|ACTIVE_COMPARATOR|IV Vitamin C-Active|Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses). Note: This arm is now closed.
62347474|NCT03520725|EXPERIMENTAL|No Intervention|This group did not have an intervention
62505510|NCT04291508|PLACEBO_COMPARATOR|Acetaminophen-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
62505511|NCT04291508|PLACEBO_COMPARATOR|Vitamin C-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses). Note: This arm is now closed.
62347475|NCT03520725|EXPERIMENTAL|Intervention pineapple|Daily consumption of 30 g of pineapple snack bar for 4 weeks.
62704083|NCT06739616|EXPERIMENTAL|Study 1: Longevity|Study 1: Longevity will evaluate the impact of matched and unmatched competing stimuli on reinforcement-based interventions as implementation durations are increased. Three conditions will be compared, using within-subjects single case designs: (a) baseline (no intervention), (b) intervention with competing stimuli matched to the hypothesized sensory consequences of SIB, and (c) intervention with competing stimuli unmatched to the hypothesized sensory consequences of SIB. Participants' specific intervention will be either noncontingent reinforcement (NCR) or differential reinforcement of other behavior (DRO), based on the outcomes of the pre-intervention assessments. During NCR, participants will receive access to competing stimuli on an ongoing and response-independent basis. During DRO, participants will receive access to competing stimuli contingent on the omission of SIB for a pre-determined length of time. Implementation will gradually increase up to a maximum of three hours.
62704084|NCT06739616|EXPERIMENTAL|Study 2: Schedule Thinning|Study 2: Schedule Thinning will evaluate the impact of matched and unmatched competing stimuli on reinforcement-based interventions as access to reinforcers decreases. Three conditions will be compared, using within-subjects single case designs: (a) baseline (no intervention), (b) intervention with competing stimuli matched to the hypothesized sensory consequences of SIB, and (c) intervention with competing stimuli unmatched to the hypothesized sensory consequences of SIB. Participants' specific intervention will be either noncontingent reinforcement (NCR) or differential reinforcement of other behavior (DRO), based on the outcomes of the pre-intervention assessments. During NCR, participants will receive access to competing stimuli on an ongoing and response-independent basis. During DRO, participants will receive access to competing stimuli contingent on the omission of SIB for a pre-determined length of time. Access to reinforcers will decrease across successful implementations.
62704085|NCT06745284|EXPERIMENTAL|Survodutide arm|
62704086|NCT06745284|ACTIVE_COMPARATOR|Semaglutide arm|
62704087|NCT06751043|ACTIVE_COMPARATOR|Fasting|Patients randomized to the Fasting arm will have tube feeding stopped at least 8 hours before the scheduled surgery or procedure time.
62704088|NCT06751043|ACTIVE_COMPARATOR|Not Fasting|Patients randomized to the Not Fasting arm will have tube feeding continued until transfer to the operating room/procedure area.
61960673|NCT06498154|EXPERIMENTAL|Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy|Patients who meet the criteria for enrollment initially receive four cycles of TCb (HP) \* neoadjuvant chemotherapy, followed by neoadjuvant radiotherapy starting from the fifth cycle of TCb (HP) \* neoadjuvant chemotherapy. After completion of six cycles of neoadjuvant chemotherapy, patients underwent breast magnetic resonance imaging. When a patient meets the MRI criteria suggestive of a complete clinical response (cCR), vacuum assisted core biopsy (VACB) targeting the primary lesion is performed under ultrasound or stereotactic guidance. A minimum of six cores, are obtained using a 7-10 G needle. Biopsy specimens are examined by a pathologist to assess the residual tumor and tumor bed. When no tumor or atypical cells are confirmed in the valid VACB specimen, breast and axillary surgery will be omitted.
61960674|NCT04789460||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT in two tertier hospital in Istanbul
62143572|NCT03800368|EXPERIMENTAL|Low-endurance group|This group of subjects will receive 2-3 sessions of low-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will maintain at an aerobic level.
62143573|NCT03800368|ACTIVE_COMPARATOR|Psycho-education|This group of subjects will receive 2-3 sessions of psycho-education class per week, for a total of 12 weeks. The content of the class includes non-exercise related psycho-education content to participants (e.g., food hygiene, psychological well being, food nutrition, etc).
62347476|NCT03520725|EXPERIMENTAL|Intervention mango|Daily consumption of 30 g of mango snack bar for 4 weeks.
62704089|NCT06749314|EXPERIMENTAL|Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression|using endoscopic decompression for treatment
62143574|NCT00920985|EXPERIMENTAL|Arm 1|
62143575|NCT00920985|ACTIVE_COMPARATOR|Arm 2|
62143576|NCT05951972|EXPERIMENTAL|Nutritional intervention|The trial will consist of two short periods in which increased intake of a pair of food items will be implemented. The first pair of food items is apples and bananas (pair A), and the second pair of food items is peanuts and cucumbers (pair B).
62143577|NCT03464955|NO_INTERVENTION|Control|The control group will be provided standard of care, which is no use of technologies.
62347477|NCT01205451|EXPERIMENTAL|BTX-A|Botulinum toxin type A
62347478|NCT00728312|ACTIVE_COMPARATOR|1|Aripiprazole (Abilify), flexible dosing 5-15 mg per day
62347479|NCT00728312|PLACEBO_COMPARATOR|2|Placebo look-alike, flexible dosing 5-15 mg per day
62347480|NCT06168370|EXPERIMENTAL|CT guided strategy|The intervention group will undergo CT scan after 3 months. If subclinical valve thrombosis is detected, anticoagulation will be started. If no subclinical valve thrombosis is detected, the SAPT is stopped, unless another indication is present.
62347481|NCT06168370|NO_INTERVENTION|Standard care|Standard of care with lifelong SAPT after TAVI
62347482|NCT02919683|EXPERIMENTAL|Nivolumab With Ipilimumab|"* Nivolumab to be delivered at a pre-determine dose for two weeks~* Ipilimumab to be delivered at a pre-determine dose for one week~* Blood Sample Collected~* Standard of Care Surgery"
62347483|NCT02919683|EXPERIMENTAL|Nivolumab|"* Nivolumab to be delivered at a pre-determine dose for two weeks~* Blood Sample Collected~* Standard of Care Surgery"
62347484|NCT06159829|EXPERIMENTAL|Virtual Reality|Virtual Reality glasses
62347485|NCT06159829|NO_INTERVENTION|Control|Patients in the control group underwent upper endoscopy following the standard protocol.
62347486|NCT05398393|OTHER|group A|normal blood lipid level at baseline
62347487|NCT05398393|OTHER|group B1|baseline blood lipid is elevated and treat with lipid-lowering drugs
62347488|NCT05398393|OTHER|group B2|baseline blood lipid is elevated and without lipid-lowering drugs treatment
62347489|NCT02207556|EXPERIMENTAL|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
62347490|NCT04408248||COVID-19 patients with acute respiratory disease|Adult patients with COVID-19 and moderate or severe respiratory disease
62347491|NCT00576251|EXPERIMENTAL|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
62505512|NCT02154802|EXPERIMENTAL|video: community member|Participant watches video of a community member
62505513|NCT02154802|EXPERIMENTAL|video: physician|Participant watches video of a physician
61960675|NCT01651247||Group A|Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
61960676|NCT01651247||Group B|Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
61960677|NCT03645798|EXPERIMENTAL|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
62505514|NCT02154802|EXPERIMENTAL|video: choice of video|Participant can choose to watch video of either the community member of the physician
62704090|NCT06749314|NO_INTERVENTION|MIS-TLIF: Minimal Invasive Surgery - Transforaminal Lumbar interbody Fusion|Using conventional treatment, minimal invasive decompression with interbody fusion surgery for treatment in control groups
61960678|NCT03645798|OTHER|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
62704091|NCT06748690|EXPERIMENTAL|MCB group|Use a disposable high-frequency cutting knife under endoscopy to cut open the surface mucosa of the tumor, and use biopsy forceps to extract tissue that can be fully evaluated for pathological examination. Use a disposable hemostatic clip to suture the mucosal incision, and after thorough observation of the hemostasis, withdraw from the endoscope.
61960679|NCT04165200|ACTIVE_COMPARATOR|Patients receiving FMT capsules and ART|"1. ART Start at week 0 non-stop.~2. FMT. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.~3. Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.~4. Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.~5. Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
61960680|NCT04165200|PLACEBO_COMPARATOR|Patients receiving placebo capsules|"1. ART Start at week 0 non-stop.~2. Placebo capsules. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.~3. Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.~4. Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.~5. Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
61960681|NCT05780918|EXPERIMENTAL|Best Case/Worst Case-ICU Communication Tool|Patients in the intervention group will receive care from a trauma team that routinely uses the Best Case/Worst Case-ICU communication tool.
62704092|NCT06748690|ACTIVE_COMPARATOR|EUS-FNA group|Using standard EUS-FNA technology, using endoscopic ultrasound scanning to locate lesions, and puncture needle aspiration biopsy.
62704093|NCT06747767|EXPERIMENTAL|Arthroscopy|Arthroscopic Reduction for Developmental Dysplasia of the Hip in Children
62143578|NCT03464955|EXPERIMENTAL|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
62143579|NCT03464955|EXPERIMENTAL|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
62347492|NCT00576251|ACTIVE_COMPARATOR|TOBRADEX|TOBRADEX 1 drop 4 times daily in both eyes
62347493|NCT01303809|ACTIVE_COMPARATOR|ERAS|The perioperative management of the patients in this arm will be according to a fast-track protocol designed by the investigators. The preoperative component of this program is the same as routine practice. Intraoperative and postoperative components which are different to routine practice are as described in the intervention section. This protocol is based on current literature regarding Enhanced Recovery After Surgery (ERAS).
62347494|NCT01303809|NO_INTERVENTION|non ERAS|The perioperative management of patients in this arm will be according to routine practice currently implemented at our institution.
62347495|NCT04717076|ACTIVE_COMPARATOR|App-based nutritional concept and fitness tracking|App-based nutritional concept and fitness tracking
62347496|NCT04717076|EXPERIMENTAL|Nutritional concept with individual nutritional counselling|Nutritional concept with individual nutritional counselling
62347497|NCT04717076|EXPERIMENTAL|Nutritional concept without individual nutritional counselling|Nutritional concept without individual nutritional counselling
62347498|NCT04717076|NO_INTERVENTION|Control group|Control group - no intervention
62347499|NCT03954444|ACTIVE_COMPARATOR|Oxymetazoline hydrochloride Cream, 1%|Oxymetazoline hydrochloride cream, 1%
62347500|NCT03954444|ACTIVE_COMPARATOR|RHOFADE Cream, 1%|RHOFADE Cream, 1%
62347501|NCT03954444|PLACEBO_COMPARATOR|Vehicle Cream|Vehicle cream
62505515|NCT02154802|NO_INTERVENTION|no video|
62505516|NCT00979212|ACTIVE_COMPARATOR|Induction CT+RT|Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
62505517|NCT00979212|EXPERIMENTAL|Induction CT+RT+Panitumumab|Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
62347502|NCT04273126|EXPERIMENTAL|Intervention|This arm consists of approximately 8-10 modules lasting approximately one hour and consisting of psychoeducation and core components including communication, problem solving, goal setting, and dealing with stress, tailored to families with experiences of homelessness and parental substance use.
62505518|NCT00964873|EXPERIMENTAL|1 Part 1|
62505519|NCT00051831|EXPERIMENTAL|1|
62505520|NCT02451306|EXPERIMENTAL|Quetiapine|"18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole."
62505521|NCT02451306|PLACEBO_COMPARATOR|Placebo|"18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~The placebo does not contain any psychoactive substance."
62704094|NCT06747767|EXPERIMENTAL|Open Reduction|Open Reduction for Developmental Dysplasia of the Hip in children
62704095|NCT06720350|EXPERIMENTAL|Romosozumab and denosumab combination|Romosozumab 210 mg subcutaneously per month combined with denosumab 60mg subcutaneously per 6 months
61960682|NCT05780918|NO_INTERVENTION|Usual Care|"Prior to implementation of the intervention, patients admitted to the trauma ICU will receive usual care. Usual care typically includes conversations focused on isolated problems, disarticulated from the patient's overall health trajectory. This is typified by the systems-base review, routinely summarizing each patient on rounds where the clinician lists each physiologic system, (e.g., neuro, cardiac, pulmonary...) with an assessment and plan to fix each abnormality with a new treatment. Deliberation about how these individual treatments align with patient preferences is typically prompted by major events like failure to liberate from a ventilator or imminent death. This pattern of usual care is well characterized and differs from daily scenario planning with the Best Case/Worst Case-ICU communication tool."
61960683|NCT03072147|ACTIVE_COMPARATOR|Group 1- Treatment|20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
61960684|NCT03072147|PLACEBO_COMPARATOR|Group 2- Placebo|Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.
61960685|NCT02337660|EXPERIMENTAL|Healthy, lean|"15 healthy, lean subjects.~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
62347503|NCT04165941|EXPERIMENTAL|DRI cell therapy|The only arm will receive the DRI modified gamma delta T cells following standard therapy with radiation and temozolomide chemotherapy concurrent.
62505522|NCT02451306|NO_INTERVENTION|Control-group|18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).
62704096|NCT06720350|ACTIVE_COMPARATOR|Romosozumab|Romosozumab 210 mg subcutaneously per month
62704097|NCT06720350|ACTIVE_COMPARATOR|Denosumab|denosumab 60mg subcutaneously per 6 months
62704098|NCT01621594|EXPERIMENTAL|1|Subjects with Clinical indication for a coronary CT angiography exam
62704099|NCT06717347|EXPERIMENTAL|Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP)|Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months).
62704100|NCT06717347|ACTIVE_COMPARATOR|Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP)|Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months).
62505523|NCT06674694|EXPERIMENTAL|20mg dosing group|The starting dose is 20 mg and the obtained research results will determine the adjustment of dosage in subsequent study groups.
62505524|NCT06674694|EXPERIMENTAL|40mg dosing group|The starting dose is 20 mg and the obtained research results will determine the adjustment of dosage in subsequent study groups.
62505525|NCT06674694|EXPERIMENTAL|80mg dosing group|The starting dose is 20 mg and the obtained research results will determine the adjustment of dosage in subsequent study groups.
62505526|NCT06674694|EXPERIMENTAL|160mg dosing group|The starting dose is 20 mg and the obtained research results will determine the adjustment of dosage in subsequent study groups.
62704101|NCT06716580|EXPERIMENTAL|ctDNA Assay|"All participants will be asked to provide blood samples and are administered a baseline questionnaire. The blood sample will be tested using the investigational cfDNA testing. If the investigational test is positive, these participants will be followed up by CLIA verification of results. A positive CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months. Participants will be notified of results.~Additionally, participants may participant in optional studies: 1) One-time survey regarding perception of lung cancer screening and cfDNA testing, 2) Virtual focus group, 3) Blood banking study"
62704102|NCT06746948||lung cancer caregiver-caregiver dyads|
62704103|NCT06749002|EXPERIMENTAL|Experimental group|It includes participants receiving Functional muscle training along with Turning based specific training over a period of 6 weeks.
62704104|NCT06749002|ACTIVE_COMPARATOR|Control Group|It includes participants recieving Turning based specific training only for 6 weeks.
62704105|NCT06746363||HFNC group|HFNC support post extubation
62704106|NCT06746363||oxygen therapy|oxygen therapy post extubation
62704107|NCT06746636|EXPERIMENTAL|Flow reduction|the flow will gradually be reduced by 10 L/ min/h. When it reaches 20 L/min, FiO2 reduction will then begin at 0.1 /h until it reaches 0.3.
62704108|NCT06746636|EXPERIMENTAL|Oxygen reduction|FiO2 will gradually be reduced by 0.1 /h until it reaches 0.3. At this point, the flow will be reduced by 10 L/min/h until it reaches 20 L/min.
62704109|NCT06746636|EXPERIMENTAL|Sudden reduction|HVNI will be abruptly discontinued after fulfilling weaning criteria provided that flow and Fio2 are less than 40 L\\min and 40%
62505527|NCT06674694|EXPERIMENTAL|240mg dosing group|The starting dose is 20 mg and the obtained research results will determine the adjustment of dosage in subsequent study groups.
62505528|NCT06674694|EXPERIMENTAL|320mg dosing group|The starting dose is 20 mg and the obtained research results will determine the adjustment of dosage in subsequent study groups.
62505529|NCT02310516|EXPERIMENTAL|Patient with preoperative device|patients undergoing brain awake surgery with adequate explanations which are provided preoperatively. Preoperative device corresponds to a pre/ perioperative coaching involving the provision of a comprehensive information support on the awake surgery (short video and information brochure) and an interview with an operating room nurse
62505530|NCT02310516|ACTIVE_COMPARATOR|Patient with standard procedure|patients undergoing brain awake surgery with standard procedure (without adequate explanations)
62505531|NCT02969876|OTHER|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical \& Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
62505532|NCT00098891|EXPERIMENTAL|Treatment (entinostat, isotretinoin)|Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
62505533|NCT01072799|EXPERIMENTAL|Low dose H1N1|
62505534|NCT01072799|EXPERIMENTAL|Mid dose H1N1|
61960686|NCT02337660|EXPERIMENTAL|Obese, otherwise healthy|"15 obese, otherwise healthy subjects~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
61960687|NCT03951571|EXPERIMENTAL|Anlotinib Gruop|
62505535|NCT01072799|EXPERIMENTAL|High dose H1N1|
62505536|NCT01072799|PLACEBO_COMPARATOR|Placebo|
62505537|NCT05794087|EXPERIMENTAL|Clean Air, Then Ozone|Subjects will be exposed to clean air for 3 hours at the first exposure visit and 0.2ppm ozone for 3 hours at the second exposure visit. The visits will be at least 2 weeks apart.
62505538|NCT05794087|EXPERIMENTAL|Ozone, Then Clean Air|Subjects will be exposed to 0.2 ppm ozone for 3 hours at the first exposure visit and clean air for 3 hours at the second exposure visit. The visits will be at least 2 weeks apart.
62143580|NCT04813224|EXPERIMENTAL|TRAUMA CENTERED EMDR-BASED TREATMENT|"Phase 1) Client history before session 1 Phase 2) Preparation for the treatment of the traumatic event, with psycho education and regulation strategies.~Phases 3 to 6) Gives the sense of Safety (safe place, past resource, desired future-PC, timeline) control structure, order, differentiation of past \& present (move concretely between past danger to present safety) EMD strategy gives containment boundaries to current T-Episode.~Phase 7) Session closure A group debriefing of the experience will take place, and some of the stabilization exercises Phase 8) Re-Evaluation This phase will take place immediately after the group intervention. It assesses which participants may need individual attention and which may need further evaluation to identify the nature and extent of their symptoms."
61960688|NCT03951571|PLACEBO_COMPARATOR|Placebo Group|
61960689|NCT03012165|EXPERIMENTAL|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
62505539|NCT01525576|NO_INTERVENTION|Control group|No offer of booster program.
62143581|NCT04813224|ACTIVE_COMPARATOR|TRAUMA-FOCUSED CBT-BASED TREATMENT|TF-CBT is an evidence-based therapeutic approach to improve symptoms of PTSD as well as affective or cognitive and behavioral problems. The treatment will consist of three phases that will include: Psychoeducation, Relaxation-Mindfulness, Emotional regulation skills, Cognitive coping skills, Narration and processing of trauma, Exposure / Desensitization of memories of the trauma, Self-esteem and future goals. The treatment is composed by 3 phases: 1) Phase 1: TF-CBT Coping Skills for Complex Traumas. Phase 2: Narration of trauma and processing of complicated trauma. Phase 3: Consolidation and closure of the treatment. Each case is delivered to the participants in a maximum of 3 sessions per phase.
62704110|NCT06746636|EXPERIMENTAL|Flow and oxygen reduction|both flow and FiO2 will be gradually reduced simultaneously at a rate of 10 L/min and 0.1 /h, respectively, until they reach 20 L/min for flow and 0.3 for FiO2
62704111|NCT06743945|EXPERIMENTAL|Experimental group|POLA-R-CHP
61960690|NCT03012165|EXPERIMENTAL|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
61960691|NCT03012165|PLACEBO_COMPARATOR|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops
61960692|NCT04339439|NO_INTERVENTION|Closure without vessel loop|These patients will receive standard of care closure of the carpal tunnel release incision.
61960693|NCT04339439|EXPERIMENTAL|Closure with vessel loop|These patients will receive closure of the carpal tunnel release incision with a vessel loop placed under the sutures.
62505540|NCT01525576|EXPERIMENTAL|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
62505541|NCT06269913|EXPERIMENTAL|Iron/yeast complex (FeSC)|Iron Supplement
62505542|NCT02215772|EXPERIMENTAL|BI 44370 BS|200 mg containing 2.43 megabecquerel (MBq) 14C-radioactivity
62505543|NCT05704673|ACTIVE_COMPARATOR|group (1)|who given intrathecal morphine thin IV nalbuphine and asize of 80 patients
62505544|NCT05704673|PLACEBO_COMPARATOR|group (2)|who given intrathecal morphine onInguinal hernia druing spinal anathesia
62505545|NCT02756637||Prognostic|Patients with NLR who completed curative therapy (surgery with or without chemo)
62505546|NCT02756637||Predictive|Patients with NLR who were assigned to a trial arm (chemo or no chemo)
62505547|NCT01544439|EXPERIMENTAL|Oral stabilization appliance,counselling|The reversible occlusal therapy by stabilizing appliance used by patients in Study Group shall be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. Patients receive oral and written instructions about self-care (counseling), including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
62704112|NCT03065335|EXPERIMENTAL|Metabolites Substudy|Open-label, single dose of 0.5 mg/kg IV ketamine
62704113|NCT03065335|EXPERIMENTAL|Phase I|Medication taper, drug-free period, and baseline assessments
62704114|NCT03065335|EXPERIMENTAL|Phase II, Arm 1|Double-blind, single dose of 0.5 mg/kg IV ketamine
62704115|NCT03065335|EXPERIMENTAL|Phase II, Arm 1b|Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG or MEG
62347504|NCT05341635||COVID-19 Symptomatic inpatients|Patients admitted to the Unit of Infectious Diseases of the ASST Monza for COVID-19 will run the collection of a nasopharyngeal swab, performed as part of the normal diagnostic routine; will take up to two samples collected in parallel to the development and optimization of the new method/process preanalitico and for the clinical validation of the performance of the pre-analytic method. The subjects will be adequately informed, both verbally and by means of a summary document of the study before signing a consent for participation in the study.
62347505|NCT05341635||COVID-19 Suspected subjects|To the subjects who present at the Emergency department of the ASST Monza for symptomatology referable to the COVID-19 and to patients on discharge from the Unit of Infectious Diseases of the ASST Monza for complete healing from COVID-19 will run the collection of a nasopharyngeal swab, performed as part of the normal diagnostic routine; will take up to two samples collected in parallel to the development and optimization of the new method/process preanalitico and for the clinical validation of the performance of the pre-analytic method. The subjects will be adequately informed, both verbally and by means of a summary document of the study before signing a consent for participation in the study.
62704116|NCT03065335|PLACEBO_COMPARATOR|Phase II, Arm 2|Double-blind, single dose of 0.5 mg/kg IV saline
62704117|NCT03065335|PLACEBO_COMPARATOR|Phase II, Arm 2b|Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG or MEG.
61960694|NCT05884905|EXPERIMENTAL|short hydration|Normal saline (NSS) 500 ml infusion in 1 hour cisplatin in NSS 100 ml with 20% mannitol 100 ml infusion in 1 hour other chemotherapy infusion in 1 hour (if available) NSS 500 ml infusion in 1 hour, then NSS 500 ml infusion in 2 hours
61960695|NCT05884905|OTHER|conventional hydration|NSS 1000 ml infusion in 8 hour cisplatin in NSS 100 ml with 20% mannitol 100 ml infusion in 1 hour other chemotherapy infusion in 1 hour (if available) NSS 2000 ml infusion in 16 hour
61960696|NCT05012488||Morton Neuroma + pes planus|The effect of unilateral morton neuroma on gait parameters and foot pressure distribution in patients with bilateral pes planus will be investigated. Foot pressure distributions and gait parameters of the patients; foot rotation, step length, stance phase percentage, swing phase percentage, cadence, velocity, rerefoot pressure, midfoot pressure and forefoot pressure will be recorded with Zebris FDM -T ( Force distiribution Measurement Treadmill ) system. Zebris is a name of company in German .
61960697|NCT05012488||Morton Neuroma + pes cavus|The effect of unilateral morton neuroma on gait parameters and foot pressure distribution in patients with bilateral pes cavus will be investigated. Foot pressure distributions and gait parameters of the patients; foot rotation, step length, stance phase percentage, swing phase percentage, cadence, velocity, rerefoot pressure, midfoot pressure and forefoot pressure will be recorded with Zebris FDM -T ( Force distiribution Measurement Treadmill ) system. Zebris is a name of company in German .
61960698|NCT02574468|ACTIVE_COMPARATOR|DPC+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
61960699|NCT02574468|ACTIVE_COMPARATOR|MP+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
62143582|NCT04230434|EXPERIMENTAL|Safety Plan Intervention|The Safety Plan Intervention (SPI) performed in ED or in ambulatory appointment
62143583|NCT02032836|EXPERIMENTAL|I-Neb - FOX|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer; followed by single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer in a cross-over fashion. A washout period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks in a cross-over fashion.
62704118|NCT03065335|EXPERIMENTAL|Phase III|Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
62704119|NCT03065335|NO_INTERVENTION|Phase IV|Follow-up evaluations
62704120|NCT06747169|EXPERIMENTAL|Locally Advanced/Advanced or Recurrent Metastatic Sq-NSCLC|This cohort includes patients with locally advanced, advanced, or recurrent metastatic squamous non-small cell lung cancer (Sq-NSCLC).
62704121|NCT06751238|EXPERIMENTAL|Secukinumab|Secukinumab administered intravenously in pediatric participants with JPsA
61960700|NCT03987217|EXPERIMENTAL|Group I (resistance training)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minute each for 12 weeks.
61960701|NCT03987217|EXPERIMENTAL|Group II (resistance training, creatine supplementation)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minutes each for 12 weeks and receive creatine monohydrate supplementation given orally 4 times daily during week 1, and then QD (once per day) during weeks 2-12.
61960702|NCT00517998|EXPERIMENTAL|Group1|Treatment will be administered in two sessions.
61960703|NCT00517998|EXPERIMENTAL|Group2|Treatment will be administered in a single session.
62704122|NCT05100251|EXPERIMENTAL|Once every other day (QOD)|(1) Once every other day (QOD): after a single-dose administration (C0) and 2-day washout period, subjects will start receiving multiple doses, for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle
62704123|NCT05100251|EXPERIMENTAL|Twice daily (BID)|(2) Twice daily (BID): dosing for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle;
61960704|NCT05395715|ACTIVE_COMPARATOR|Control|Control patients will receive cubital tunnel surgery and sham stimulation.
61960705|NCT05395715|EXPERIMENTAL|Conditioning electrical stimulation|Patients in the stimulation group will receive surgery as well as 1 hour of 20 Hz electrical stimulation 7 days prior to surgery
61960706|NCT04866225|EXPERIMENTAL|Study arm|One arm of healthy male participants administered a single oral dose of \[14C\]PF-06865571; followed by a single dose of unlabeled PF-06865571, and IV administration of \[14C\]PF-06865571 three hours later.
61960707|NCT04441814||Lung cancer screening subjects|Subjects enrolled in SMILE lung cancer screening trial
61960708|NCT05984966|EXPERIMENTAL|Supported Employment|Supported employment program (Peer Connect2Test) for people who inject drugs to provide SARS-CoV-2 rapid tests to others in their networks
61960709|NCT06268002|EXPERIMENTAL|Vernonia cinerea group|1 lozenges 3 times per day
61960710|NCT06268002|PLACEBO_COMPARATOR|Placebo group|1 placebo lozenges 3 times per day
61960711|NCT05780385|EXPERIMENTAL|nasotracheal intubation|
61960712|NCT05780385|ACTIVE_COMPARATOR|orotracheal intubation|
61960713|NCT04841460|EXPERIMENTAL|Low-fat ground beef|Participants will consume 25 low-fat ground beef patties, 5 patties per week for 5 weeks.
61960714|NCT04841460|EXPERIMENTAL|High-fat ground beef|Participants will consume 25 high-fat ground beef patties, 5 patties per week for 5 weeks.
61960715|NCT05944757|EXPERIMENTAL|PRP -plasma rich platelets group|Twenty patients (20) underwent 0.5 ml intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
61960716|NCT05944757|ACTIVE_COMPARATOR|Autologous serum group|Twenty patients (20) underwent intrastromal injection of 0.5 ml of autologous serum (second group) every 2 weeks for 1 month
62143584|NCT02032836|EXPERIMENTAL|FOX - I-Neb|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer; followed by single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer in a cross-over fashion. A wash-out period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks in a cross-over fashion.
61960717|NCT06506331||high-VFA|VFA≥74 cm2
61960718|NCT06506331||low-VFA|VFA\<74 cm2
61960719|NCT05662631|EXPERIMENTAL|Bone Marrow Transplant Participants|Study participants will complete an onboarding session into the Oncology at Home care program prior to discharge from the hospital. During the onboarding process, participants will be introduced to the RC care team, confirm understanding of their customized care plan treatment and goals as established by their BMT care provider, will receive an oral thermometer for use during the study, and will complete patient education. Working with the study team and RC RN, participants will receive, affix, activate, and test a wearable RPM device (the BioIntellisense BioSticker) prior to discharge from the BMT unit. As the BioSticker needs to be replaced every 30 days, patients will also receive three additional BioStickers new in packaging for use during months 2 and 3 as well as to have a back-up device in case of malfunction. Patients will return the BioSticker to BioIntelliSense with the postage paid return envelope provided at discharge.
61960720|NCT04189081|EXPERIMENTAL|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
62143585|NCT02587052||Tacrolimus|100 patients treated with generic tacrolimus
62704124|NCT05100251|EXPERIMENTAL|Once daily (QD)|Once daily (QD): dosing 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle
61960721|NCT04189081|SHAM_COMPARATOR|Water Control|Water will be used as a mouth rinse and can be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using water, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
61960722|NCT04189081|ACTIVE_COMPARATOR|Positive Control|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
61960723|NCT03506282|NO_INTERVENTION|No music|The participants will be required to run on a treadmill at 3 different speeds (6-8-10 km/h) with no music.
61960724|NCT03506282|ACTIVE_COMPARATOR|Traffic audio track|In addition to running on the treadmill, participants will be listening to an audio track resembling normal outdoor noise (70 dB) through earphones connected to a mobile phone.
61960725|NCT03506282|EXPERIMENTAL|Music at moderate volume|In addition to running on the treadmill, participants will be listening to music at a moderate volume (80 dB) through earphones connected to a mobile phone.
61960726|NCT03506282|EXPERIMENTAL|Music at moderate-to-high volume|In addition to running on the treadmill, participants will be listening to music at a moderate-to-high volume (85 dB) through earphones connected to a mobile phone.
61960727|NCT06506149|EXPERIMENTAL|Microwave ablation treatment|All participants will be treated by a device for USG-guided Microwave ablation treatment
61960728|NCT05132387||Out-of-hospital cardiac arrest|Patients with out-of-hospital cardiac arrest which occured in the predefined area of the city of Wroclaw.
61960729|NCT03902288|EXPERIMENTAL|Patients with type 2 diabetes|Patients with type 2 diabetes at early stages of type 2 diabetes (FSG: 7.1 15.8 mmol/L)
61960730|NCT03902288|ACTIVE_COMPARATOR|Healthy individuals|Healthy individuals match age and gender to the experimental group
61960731|NCT02485600||DUODOPA patients.|Patients starting DUODOPA treatment at time of enrollment.
62143586|NCT02587052||Prograf|100 patients treated with Prograf
62704125|NCT03038672|ACTIVE_COMPARATOR|Group I (nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
61960732|NCT06504641||Patients|"Up to 30 adults, aged 65 years or older, who are frail or pre-frail, and who are admitted as an inpatient to an acute Medicine for the Elderly ward during a three-month pilot phase~Intervention: Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud. Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password."
61960733|NCT06504641||Carers|"Carers of enrolled patients, who are in receipt of the Isla for Frailty intervention (described above)~Carers are those who provide the enrolled patient with assistance in their daily activities and are unpaid for these caring activities. A carer may be a member of the patient's family, a friend, or other person who provides the patient with unpaid care."
62704126|NCT03038672|EXPERIMENTAL|Group II (varlilumab, nivolumab)|Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.
62704127|NCT05608018|OTHER|Control Bluetooth|Participants receive a the same app as the intervention group, but the feature that notifies the teens parent when they are driving is turned off. They will self-report their smartphone communication while driving via periodic surveys. Participants will receive a Bluetooth device to keep in their primary vehicle for the duration of the study.
62143587|NCT00821288|EXPERIMENTAL|Survivorship Intervention|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention
62143588|NCT00821288|ACTIVE_COMPARATOR|Facing Forward|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention Facing Forward: Life after Cancer Treatment manual
62704128|NCT05608018|OTHER|Intervention Bluetooth|Participant received the app with all features turned on, so the parent gets a notification when the teen is driving before they go to send a text message to the teen. They will self-report their smartphone communication while driving via periodic surveys. Participants will receive a Bluetooth device to keep in their primary vehicle for the duration of the study.
62704129|NCT05608018|OTHER|Control non-Bluetooth|Participants receive a the same app as the intervention group, but the feature that notifies the teens parent when they are driving is turned off. They will self-report their smartphone communication while driving via periodic surveys. Participants will not receive a Bluetooth device.
62704130|NCT05608018|OTHER|Intervention non-Bluetooth|Participant received the app with all features turned on, so the parent gets a notification when the teen is driving before they go to send a text message to the teen. They will self-report their smartphone communication while driving via periodic surveys. Participants will not receive a Bluetooth device.
62704131|NCT06746922|EXPERIMENTAL|Active stimulation group|Patients will receive intermittent theta burst stimulation (iTBS) to the primary motor cortex, one session per day for a total of 10 sessions.
62704132|NCT06746922|SHAM_COMPARATOR|Sham stimulation group|Patients will receive sham treatment for one session per day for a total of 10 sessions.
61960734|NCT06504641||Ward team|"Clinical staff working on one of three Medicine for the Elderly wards at St Mary's Hospital, where the Isla for Frailty intervention (described above) will be subject to a feasibility trial.~Clinical staff must work regular shifts on the ward during study initiation and pilot phases."
62143589|NCT03374254|EXPERIMENTAL|Cohort A Part 1: Pembrolizumab +Binimetinib 30 mg|Participants in Cohort A will receive pembrolizumab (200 mg) intravenous (IV) every 3 weeks (Q3W) plus binimetinib orally at of 30 mg twice a day (BID) until disease progression or discontinuation.
62143590|NCT03374254|EXPERIMENTAL|Cohort A Part 1: Pembrolizumab +Binimetinib 45 mg|Participants in Cohort A will receive pembrolizumab (200 mg) IV Q3W plus binimetinib orally at 45 mg BID (Dose Level 2 \[DL2\]) until disease progression or discontinuation.
62347506|NCT03212846|EXPERIMENTAL|Treatment group|Children will receive hippotherapy by a licensed physical therapist. Before riding, stretching and warming exercises of the adductor muscles will be performed. Later, the patient will be seated astride with the therapist behind. In any case, the participant had no control of the horse. Therapist will be responsible for correctly positioning the subject on the horse, but no position changes or active intervention of the subject with the therapist will be made. This positioning consists on achieving the optimal body alignment with neutral pelvis.
62347507|NCT03212846|NO_INTERVENTION|Control group|Children will receive the conventional treatment, based on physiotherapy related techniques, such as neurodevelopmental treatment (twice a week).
62143591|NCT03374254|EXPERIMENTAL|Cohort B Part 1: Pembrolizumab + mFOLFOX7|Participants in Cohort B will receive pembrolizumab (200 mg) IV Q3W plus mFOLFOX7 (oxaliplatin 85 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; fluorouracil \[5-FU\] 2400 mg/m\^2 over 46-48 hours) IV Q2W until disease progression or discontinuation.
62143592|NCT03374254|EXPERIMENTAL|Cohort B Part 2: Pembrolizumab + mFOLFOX|During Part 2, participants in Cohort B will receive pembrolizumab (200 mg) IV Q3W plus mFOLFOX7 (oxaliplatin 85mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; fluorouracil \[5-FU\] 2400 mg/m\^2 over 46-48 hours) IV Q2W until disease progression or discontinuation.
62347508|NCT01556802|EXPERIMENTAL|Minocicline|minocicline 100mg oral twice a day for 5 days
62347509|NCT01556802|PLACEBO_COMPARATOR|Placebo|Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
62347510|NCT01738737|EXPERIMENTAL|Stretching|Seven stretching exercises for lower limbs during 24 sessions
62347511|NCT01738737|EXPERIMENTAL|Placebo laser + Stretching|application of placebo laser therapy during nine sessions plus stretching exercises during 24 sessions
62347512|NCT01738737|EXPERIMENTAL|Active laser + Stretching|application of active laser therapy during nine sessions plus stretching exercises during 24 sessions
62505548|NCT01544439|PLACEBO_COMPARATOR|Non-occluding splint, counselling|The non-occlusive splint (placebo) will also be made by the same dental technician. They differ by the plates did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. As not lead acrylic on the occlusal surfaces of teeth, adequate retention is given by an arch wire in orthodontic buccal surface of teeth. All patients will submitted a counseling approach / self-care. Patients receive oral and written instructions about self-care, including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
62505549|NCT02107222|NO_INTERVENTION|mechanical ventilation (MV)|mechanical ventilation according to guidelines
61960735|NCT00600652||1|glucocorticoid-resistant patients
62143593|NCT03374254|EXPERIMENTAL|Cohort C Part 1: Pembrolizumab + mFOLFOX7 + Binimetinib 30 mg|Participants in Cohort C will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 (oxaliplatin 85mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; fluorouracil \[5-FU\] 2400 mg/m\^2 over 46-48 hours) IV Q2W in combination with binimetinib orally at a starting dose of 30 mg BID until disease progression or discontinuation.
62704133|NCT02769962|EXPERIMENTAL|1/Phase I|EP0057 + olaparib
62704134|NCT02769962|EXPERIMENTAL|2/Phase II|EP0057 + olaparib at MTD/RP2D
62704135|NCT05505916|EXPERIMENTAL|KVD900 600 mg|
62143594|NCT03374254|EXPERIMENTAL|Cohort D Part 1: Pembrolizumab + FOLFIRI|Participants in Cohort D will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; 5-FU 2400 mg/m\^2 over 46-48 hours) IV Q2W until disease progression or discontinuation.
62347513|NCT01738737|EXPERIMENTAL|Active Laser|Application of active laser only during 24 sessions
62347514|NCT01738737|NO_INTERVENTION|Control|Control group that will receive a small book with informations about knee osteoarthritis and postural orientation.
62347515|NCT00818285|NO_INTERVENTION|1|Physicians in this arm will be using the standard electronic prescription interface.
62505550|NCT02107222|EXPERIMENTAL|MV + ECCO2-R(PALP-Device/MaquetCP)|MV according to the guidelines plus CO2-Removal with PALP
62505551|NCT03856905|ACTIVE_COMPARATOR|Physical therapy group|The children in this group will receive the conventional physical therapy program (CPTP). It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neuro-developmental techniques, and gait training. The total program will be conducted for 1 h, three sessions/week for 12 weeks.
62505552|NCT03856905|EXPERIMENTAL|Extra-corporeal shock wave therapy group|The children in this group only will receive the extra-corporeal shock wave therapy (ESWT). An electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG) will be used. The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode, one session/week for 12 weeks. The treatment is painless and does not require any kind of anesthesia or the use of analgesic drugs
61960736|NCT00600652||2|glucocorticoid-sensitive patients
61960737|NCT00600652||3|normal controls
61960738|NCT04380116|EXPERIMENTAL|Sb+Aware|Patients will access to the Soberlink device and receive treatment with Aware Recovery Care
61960739|NCT04380116|NO_INTERVENTION|Aware|Patients will only have access to Aware Recovery Care
62347516|NCT00818285|EXPERIMENTAL|2|In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
62347517|NCT02180217|EXPERIMENTAL|osilodrostat (LCI699)|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then osilodrostat during a double-blind, placebo controlled RW Period.
62347518|NCT02180217|PLACEBO_COMPARATOR|LCI699 Placebo|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then placebo during a double-blind, placebo controlled RW Period.
62505553|NCT03856905|EXPERIMENTAL|Functional electrical stimulation group|"The children in this group will receive the functional electrical stimulation (FES). The FES will be applied by using the WalkAide system (Innovative Neurotronics, Austin, TX, USA).~The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait."
62505554|NCT03798340|EXPERIMENTAL|Vibratory perturbed task-specific movement training|Intervention: 10 minutes of traditional sensorimotor facilitation followed by 20 minutes of vibratory perturbed task-specific movement training
62505555|NCT03798340|ACTIVE_COMPARATOR|Traditional task-oriented facilitation|Intervention:10 minutes of traditional sensorimotor training followed by 20 minutes of reach-to-grasp and hand release training.
62704136|NCT05505916|EXPERIMENTAL|KVD900 300 mg|
61960740|NCT00980057|EXPERIMENTAL|Adaptive CRT (aCRT) arm|Intervention: Cardiac resynchronization therapy (CRT-D) with Adaptive CRT algorithm ON
61960741|NCT00980057|ACTIVE_COMPARATOR|Echo-optimized arm|Intervention: Cardiac resynchronization therapy (CRT-D) with standard biventricular pacing (Adaptive CRT algorithm OFF)
61960742|NCT01731990|EXPERIMENTAL|Canakinumab (ACZ885)|Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
61960743|NCT01731990|PLACEBO_COMPARATOR|Placebo|Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
62704137|NCT06193954|EXPERIMENTAL|VasoStar guidewire system|The VasoStar guidewire system will be used to cross vascular occlusion lesions.
62704138|NCT06747338|EXPERIMENTAL|KN026 plus HB1801|KN026 HB1801
62704139|NCT06747338|ACTIVE_COMPARATOR|Pertuzumab and trastuzumab plus docetaxel|Pertuzumab Trastuzumab Docetaxel
62704140|NCT06745804|OTHER|68Ga-R10602 Imaging Optimization Portion (Cohort 1)|68Ga-R10602 injection at pre-defined dose levels. PET/CT imaging at pre-defined timepoints.
62704141|NCT06745804|OTHER|68Ga-R10602 Imaging Confirmation Portion (Cohort 2)|68Ga-R10602 injection at the selected dose level. PET/CT imaging at a single timepoint.
62704142|NCT06315374|ACTIVE_COMPARATOR|Simply using soft mist inhaler|Routine use of soft mist inhaler only
62704143|NCT06315374|EXPERIMENTAL|Use soft mist inhaler with a 3D assistive device|Use soft mist inhaler with a 3D-printed assist device
62704144|NCT04966481|EXPERIMENTAL|Arm 1: Palbociclib + Cetuximab|"* Palbociclib by mouth 125 mg/daily on Days 1-21 of each 28 day cycle~* Cetuximab: Initial dose 400mg/m\^2 intravenous (IV); Subsequent doses 250 mg/m\^2 IV, weekly"
62505556|NCT00602966||Slow Freeze|
62505557|NCT00602966||Vitrification|
61960744|NCT04119921|ACTIVE_COMPARATOR|usage of topical ketorolac in group1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
61960745|NCT04119921|ACTIVE_COMPARATOR|usage of artificial tear in group 2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
61960746|NCT04119921|ACTIVE_COMPARATOR|usage of artificial tear in group 1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval
61960747|NCT04119921|ACTIVE_COMPARATOR|usage of topical ketorolac in group2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval
61960748|NCT02418702|EXPERIMENTAL|0.2mg/kg ketamine|After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
61960749|NCT02418702|PLACEBO_COMPARATOR|placebo|After being assessed, and giving informed consent, participants would receive a placebo. Symptoms will be monitored.
61960750|NCT00612365||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) for abdominal aortic calcium (AAC) who have undergone computed tomography (CT) scans of the abdomen
61960751|NCT00640991|NO_INTERVENTION|Control|Patients assigned to the control arm will receive usual care for AMI, according to local practice of each participating centre.
61960752|NCT00640991|EXPERIMENTAL|Intervention|The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.
61960753|NCT02044016||Observational study|To compare results of the ATLM with goniometry and Ultrasound measures of the achilles tendon.
61960754|NCT01157260|EXPERIMENTAL|AST-120|AST-120 administration 2g three times a day
61960755|NCT01157260|NO_INTERVENTION|Control|Control Chronic Kidney disease stage 3,4
61960756|NCT05317832|ACTIVE_COMPARATOR|Web-based physical activity intervention (WI) program|Participants in the WI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24).
61960757|NCT05317832|EXPERIMENTAL|Web-based physical activity intervention (WI) program + just-in-time adaptive intervention (JITAI)|Participants in the WI + JITAI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24). In addition, participants will have access to the JITAI that will provide just-in-time feedback and physical activity recommendations (weeks 3 to 24). The type of the feedback and recommendation messages in the WI + JITAI arm will be delivered using micro-randomization, which involves random selection of intervention components at each possible time of delivery.
61960758|NCT02393170|EXPERIMENTAL|self-training using video-games|Participants will receive a video-game console and will be asked to play video-games for one hour a day X 6 days a week for 5 weeks.
62143595|NCT03374254|EXPERIMENTAL|Cohort D Part 2: Pembrolizumab + FOLFIRI|During Part 2, participants in Cohort D will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; 5-FU 2400 mg/m\^2 over 46-48 hours) until disease progression or discontinuation.
62505558|NCT03342235|EXPERIMENTAL|Surgical Group|Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
62143596|NCT03374254|EXPERIMENTAL|Cohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 30 mg|Participants in Cohort E will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; 5-FU 2400 mg/m\^2 over 46-48 hours) Q2W in combination with binimetinib orally at a starting dose of 30 mg BID until disease progression or discontinuation.
62347519|NCT01464788|EXPERIMENTAL|Low dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
62347520|NCT01464788|EXPERIMENTAL|High dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
62347521|NCT01464788|ACTIVE_COMPARATOR|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
62347522|NCT01191905|EXPERIMENTAL|High dose CRRT|Clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
62347523|NCT01191905|ACTIVE_COMPARATOR|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
62505559|NCT03342235|ACTIVE_COMPARATOR|Non-surgical Control Group|For participants assigned to the non-surgical control group, patching will be prescribed for 2 hours per day with optical correction, and will continue until the 8-month primary outcome visit.
62505560|NCT00689845|EXPERIMENTAL|Cohort 1|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also receive oral prednisolone on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62505561|NCT00689845|EXPERIMENTAL|Cohort 2|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
62704145|NCT04966481|ACTIVE_COMPARATOR|Arm 2: Cetuximab|-Cetuximab: Initial dose 400mg/m\^2 intravenous (IV); Subsequent doses 250 mg/m\^2 IV, weekly
62704146|NCT06740448|EXPERIMENTAL|Green Tea|200 mL green tea on first visit
62143597|NCT03374254|EXPERIMENTAL|Cohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 45 mg|During Part 2, participants in Cohort E received pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; 5-FU 2400 mg/m\^2 over 46-48 hours) Q2W plus binimetinib orally at the starting dose of 45 mg BID until disease progression or discontinuation. Cohort A During Part 2, participants in Cohort E received pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m\^2; leucovorin \[calcium folinate\] 400 mg/m\^2; 5-FU 2400 mg/m\^2 over 46-48 hours) Q2W plus binimetinib orally at the starting dose of 45 mg BID until disease progression or discontinuation.
62143598|NCT04855747|EXPERIMENTAL|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
62143599|NCT04855747|PLACEBO_COMPARATOR|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
62143600|NCT02413138|EXPERIMENTAL|Phase 2: Somavaratan (VRS-317)|Active treatment arm
62347524|NCT04580251||Magnetic marker Magseed|Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.
62347525|NCT04580251||Iodine seed 125I marker|Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
62347526|NCT04580251||Carbon suspension|Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
61960759|NCT02393170|ACTIVE_COMPARATOR|traditional self-training|Participants will receive a manual and kit of a traditional self-training program and will be asked to perform the program one hour a day X 6 days a week for 5 weeks.
61960760|NCT00698698||Non diabetic|Normal age and sex matched population
62347527|NCT02962219|EXPERIMENTAL|Intervention|A pre-operative personalised exercise programme (my-PEP).
62347528|NCT02962219|OTHER|Control|Standard care
62347529|NCT06101082|EXPERIMENTAL|Anti-HER2-CAR-T cell infusion|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.The patients will receive lymphocyte clearance therapy with cyclophosphamide and fludarabine before the infusion.
62347530|NCT00765128|EXPERIMENTAL|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
62347531|NCT00765128|PLACEBO_COMPARATOR|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
62505562|NCT00689845|EXPERIMENTAL|Cohort 3|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV and doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; methotrexate IV on days 8, 36, and 64; vincristine IV on days 8, 22, 36, 50 ,64, and 78; bleomycin IV on days 22, 50, and 78; and oral prednisolone on days 1-84, followed by a taper.
62505563|NCT00689845|EXPERIMENTAL|Cohort 4|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV on days 1, 29, and 57; doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; etoposide phosphate IV on days 15, 16, 43, 44, 71, and 72; vincristine IV and bleomycin IV on days 8, 22, 36, 50, 64, and 78; and oral prednisolone on days 1-84, followed by a taper.
62505564|NCT00689845|EXPERIMENTAL|Cohort 5|Patients receive rituximab IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1; vindesine IV and bleomycin IV on days 1 and 5; oral prednisone on days 1-5; methotrexate intrathecally on day 2; and G-CSF SC on days 6-13 for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses of R-ACVBP, patients receive consolidation therapy comprising high-dose methotrexate IV, rituximab IV, ifosfamide IV, etoposide phosphate IV, and cytarabine SC according to protocol GELA LNH03-2B.
62505565|NCT01659034|EXPERIMENTAL|Thienopyridine|Thienopyridine treatment for 3 months after implantation of everolimus-eluting Stents
62704147|NCT06740448|PLACEBO_COMPARATOR|Hot Water|200 mL hot water on first visit
61960761|NCT00698698||Grade 1|Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
62143601|NCT02413138|EXPERIMENTAL|Phase 3: Somavaratan (VRS-317)|Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
62143602|NCT00548444|EXPERIMENTAL|Group 1|Volunteers will receive a single dose of MVA85A followed by regular blood tests to measure the resulting cellular immune response.
62143603|NCT00548444|EXPERIMENTAL|Group 2|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
62143604|NCT00548444|EXPERIMENTAL|Group 3|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
62143605|NCT00827385||hypertensive|
62347532|NCT04470713||Group A - Retrospective data collection|Participants with a confirmed diagnosis, either deceased patients or patients whose survival status is not known at enrollment.
62347533|NCT04470713||Group B - Prospective data collection|Participants who are alive at enrollment. Data collection is retrospective for the time between birth and enrollment visit, and data collection is prospective from the enrollment visit onwards. Visits are performed as per local standard of care.
62347534|NCT05108610|ACTIVE_COMPARATOR|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
62505566|NCT05376137|ACTIVE_COMPARATOR|Default comfort settings|Comfort settings will be set to default (out of the box setttings)
62505567|NCT05376137|EXPERIMENTAL|Personalized Therapy Comfort Settings|Comfort settings will be personalized to each user
61960762|NCT00698698||Grade 2|Moderate non proliferative diabetic retinopathy
61960763|NCT00698698||Grade 3|Severe non proliferative diabetic retinopathy
61960764|NCT00698698||Grade 4|Proliferative diabetic retinopathy and advanced diabetic eye disease
61960765|NCT05315544|EXPERIMENTAL|CSI pVAD|
61960766|NCT03641430|EXPERIMENTAL|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
62143606|NCT00827385||normotensive|
62143607|NCT03076853||Patients with Pharmaceutical Record|
62143608|NCT02118311|EXPERIMENTAL|TREG|T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
62143609|NCT02118311|EXPERIMENTAL|Non-Myeloablative Only|Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
62347535|NCT05108610|EXPERIMENTAL|Shi-style manipulations|Shi-style manipulations is a cervical manipulation for cervical spondylosis.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
62505568|NCT04249596|EXPERIMENTAL|Open Treatment|All subjects will be treated for 8 weeks of treatment with Tianeptine (Tianeurax 12.5 mg) 3 times a day (9am, 1pm, 5pm).
62505569|NCT05846464|EXPERIMENTAL|Virtual Reality to Enhance Upper Extremity Physical Therapy and Recovery|This is a descriptive study assessing the feasibility of using VR rehabilitation with unilateral (or bilateral) impairment of the arm, wrist, and or hand resulting in reduced range of motion, dexterity, and/or strength of the hand. Phase I: Typical Home Exercise Program, Phase II: Use of VR headset in conjunction with current Home Exercise Program. Intervention sessions include the baseline, midpoint and final visits.
62505570|NCT02845089||Advanced/Metastatic NSCLC patients from UAE and KSA|A random sample of patients diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) from select oncology centers in Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE)
62505571|NCT05719831|EXPERIMENTAL|H-VA-dual-10|"10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
62505572|NCT05719831|EXPERIMENTAL|L-VA-dual-10|"10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 2 times/day, oral)"
62505573|NCT05719831|ACTIVE_COMPARATOR|H-VA-dual-14|"14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
62704148|NCT05027802|EXPERIMENTAL|Palovarotene Chronic/Flare-Up Regimen|"Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment.~Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days."
62704149|NCT06745037||Young adults with intracerebral haemorrhage|Cohort prospective study for detection of blood based biomarkers of intracerebral hemorrhage in young adults.
62704150|NCT06747546|ACTIVE_COMPARATOR|Control group|Treatment is routinely adjusted according to the changes of blood pressure and other monitoring indicators.Ventilation assistance is modified to sustain arterial oxygen partial pressure and oxygen saturation levels. Administer suitable fluid infusion to stabilize central venous pressure and maintain preload; Concurrent use of vasoactive agents to sustain heart rate and blood pressure; Effective diuresis can enhance urine production and decrease cardiac afterload. Blood transfusion is employed to enhance coagulation function and sustain adequate hematocrit levels.
62347536|NCT03591094|ACTIVE_COMPARATOR|PTI-428 dose level 1|
62347537|NCT03591094|ACTIVE_COMPARATOR|PTI-428 dose level 2|
62347538|NCT03591094|PLACEBO_COMPARATOR|Placebo PTI-428|
62347539|NCT01980212||first line advanced non-small cell lung cancer|patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
62347540|NCT02978664|ACTIVE_COMPARATOR|Air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
62143610|NCT01974258|EXPERIMENTAL|Dose-expansion: onartuzumab + cobimetinib|
62143611|NCT01974258|EXPERIMENTAL|Dose-expansion: onartuzumab + vemurafenib|
62143612|NCT01974258|EXPERIMENTAL|Dose-expansion: onartuzumab + vemurafenib + cobimetinib|
62347541|NCT02978664|ACTIVE_COMPARATOR|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
62347542|NCT02978664|ACTIVE_COMPARATOR|water exchange|Water will be infused and removed during insertion phase of colonoscopy
62347543|NCT01216449|EXPERIMENTAL|Intravenous Citalopram|
62347544|NCT01216449|PLACEBO_COMPARATOR|Normal Saline|250mL of 0.9% Sodium Chloride Solution
62347545|NCT03777202|EXPERIMENTAL|High-flow nasal oxygen during sleep endoscopy|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
62347546|NCT03777202|ACTIVE_COMPARATOR|Low-flow nasal oxygen during sleep endoscopy|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
62143613|NCT01974258|EXPERIMENTAL|Dose-finding: onartuzumab + vemurafenib + cobimetinib|
62143614|NCT01717066|EXPERIMENTAL|the ginsenoside Rg3|320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence
62143615|NCT01717066|PLACEBO_COMPARATOR|the placebo|160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group
62347547|NCT03922633|EXPERIMENTAL|Cohort 1 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
62505574|NCT06616792|EXPERIMENTAL|Group (A)|Each participant in this group will receive dexamethasone phonophoresis, US with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis. over maxillary and frontal sinuses for 3 sessions per week for one month, in addition to the traditional medication.
62505575|NCT06616792|EXPERIMENTAL|Group (B)|Each participant in this group will receive low level laser placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint, with a duration of 90 sec for each point three times per week for a month., in addition to the traditional medication.
61960767|NCT06244732|EXPERIMENTAL|RSB|In patients in the RSB Group, repeated blocks of the abdominal wall will be performed using special catheters positioned bilaterally in the rectus muscle fascia using ultrasound guidance (Ropivacaine 0.375% 20 ml per side, administered every 12 hours: at T0, T12 and T24)
61960768|NCT06244732|ACTIVE_COMPARATOR|EA|Patients of EA Group will receive analgesia via epidural catheter (Ropivacaine 0.15% with double initial bolus and subsequent continuous infusion 5 ml/h via elastomeric pump)
62505576|NCT06616792|ACTIVE_COMPARATOR|Group (C)|Each participant in this group will receive the traditional medication only.
61960769|NCT06534554|EXPERIMENTAL|Patient Navigation|A lay patient navigator will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
61960770|NCT06534554|NO_INTERVENTION|Control|Usual Care
61960771|NCT01087138|EXPERIMENTAL|Exercise|exercise class 3x's/week
61960772|NCT01087138|EXPERIMENTAL|exercise and calcium intake|exercise class 3x's/week and 1500mg calcium/day
61960773|NCT01087138|NO_INTERVENTION|usual exercise and calcium|usual exercise and calcium intake
61960774|NCT02139332|ACTIVE_COMPARATOR|Resource & Referral group|Individuals randomized to the control group will receive a resource \& Referral service immediately after their baseline research visit.
62505577|NCT01935648||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following hip arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery. This will be followed by a continuous infusion of 10mls/hour 0.2% ropivacaine for the subsequent 24 hours.
62505578|NCT01669031|NO_INTERVENTION|Control Group|No practice tests are performed in this arm
62714952|NCT06423508||inter- and intra-individual variability|the aim is to explore the inter- and intra-individual variability observed in gut microbiome composition and functions from a proteomic perspective. Understanding inter-individual variability differences is crucial for personalized medicine. Recognizing and characterizing intra-individual variability is essential for accurately interpreting research findings, particularly in longitudinal studies or clinical monitoring scenarios. This study aims to elucidate these variabilities using proteomic data from volunteers' fecal samples, shedding light on the variables detected in the gut microbiome and providing insights into its dynamic nature
62714953|NCT06420297|EXPERIMENTAL|Drug: Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
61960775|NCT02139332|EXPERIMENTAL|PFR Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
61960776|NCT04357132|OTHER|VR-Biofeedback|
62347548|NCT03922633|EXPERIMENTAL|Cohort 1 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
62347549|NCT03922633|EXPERIMENTAL|Cohort 2 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
61960777|NCT04357132|OTHER|VR-Distraction|
62347550|NCT03922633|EXPERIMENTAL|Cohort 2 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
62347551|NCT03922633|EXPERIMENTAL|Cohort 3 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
62347552|NCT03922633|EXPERIMENTAL|Cohort 3 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
62347553|NCT03922633|EXPERIMENTAL|Cohort 4 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
62347554|NCT03922633|EXPERIMENTAL|Cohort 4 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
62505579|NCT01669031|EXPERIMENTAL|Practice Program|"At the 3 study visits exposed to a training session (simulated visual field test on a computer).~Visit 1 they get 2 simulated tests tests per eye. At visits 2 and 3 they get 1 simulated test per eye. Each simulated test takes 3-15 minutes"
62505580|NCT03594825|EXPERIMENTAL|nighttime group|patients with nocturnal hypertension taking valsartan at nighttime
62505581|NCT03594825|ACTIVE_COMPARATOR|daytime group|patients with nocturnal hypertension taking valsartan at daytime
62505582|NCT02040519|EXPERIMENTAL|Evaluation by voiding diaries|
62505583|NCT03028623|OTHER|Control|Tubal sterilization will be performed by standard tubal ligation, either Parkland or Pomeroy technique, at the time of cesarean section
61960778|NCT03663816|EXPERIMENTAL|Healthy men and women|Participants will serve as their own control. Balance and gait measures will be collected during an initial visit and after one week of using the experimental foot device
61960779|NCT05015465||70 patients with juvenile SLE.|Anterior segment OCT for juvenile SLE patients.
61960780|NCT05015465||70 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
61960781|NCT02168634|EXPERIMENTAL|Botulinum toxin|5U Botulinum toxin in 1cc normal saline, administered in one of the two itchy points
61960782|NCT02168634|PLACEBO_COMPARATOR|Normal Saline|1cc normal saline, administered in the other itchy point
62505584|NCT03028623|EXPERIMENTAL|Experimental|Tubal sterilization will be performed by bilateral salpingectomy using a ligasure device at the time of cesarean section.
62505585|NCT05681416|OTHER|Healthy men with familial risk|≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age \<60
62505586|NCT05681416|OTHER|healthy men with genetic risk|BRCA1/2 Germline mutation
62505587|NCT05681416|OTHER|Men with PCA and genetic oder familial risk|familial risk = ≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age \<60 genetic risk= BRCA1/2 Germline mutation
61960783|NCT01525810||Subjects treated with Peginterferon Lambda-1a (BMS-914143)|Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
61960784|NCT02285803|ACTIVE_COMPARATOR|TRT and real tDCS|
61960785|NCT02285803|SHAM_COMPARATOR|TRT and sham tDCS|
62704151|NCT06747546|EXPERIMENTAL|Experimental group|"On the basis of routine treatment in the control group, PICCO is used to evaluate cardiac index (CI), bedside echocardiography is used to evaluate cardiac function, NIRS is used to measure rScO2, rSrO2 and rSsO2, and arterial and central venous blood gas are measured at the same time after operation. DO2, VO2, ERO2, and Pv-aCO2 gap are calculated according to the formula. The oxygen extraction rate immediately after CPB is set as E1, the oxygen extraction rate at 4 hours after surgery is E2, and the oxygen extraction rate at 8 hours after surgery is E3.A goal-directed treatment strategy based on oxygen supply and consumption balance is defined as: Combined with the value of E2 at 4 hours after CPB, the increasing VO2 after CPB is compensated by increasing DO2 to different degrees. The goal of E3 not increasing significantly compared with E1 is achieved at 8 hours after CPB, and the severity of low cardiac output is finally reduced within the golden 8 hours after CPB."
61960786|NCT03000140|EXPERIMENTAL|High Intensity Interval Training|Cycling on cycle ergometers (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) for 1 min at a subjective intensity of 8-10 points of the modified Borg scale of 1-10 points, and interspersed by inactive (without movement over the bicycle) of 2 minutes as recovery period.
61960787|NCT03000140|ACTIVE_COMPARATOR|Control group|Pre-hypertensive group was compared with healthy groups in the 2 manin variables systolic/diastolic blood pressure, as well as in other co-variables in pre-post changes. Thus, after the training intervention, and following the R and NR classification, we will compare the NR prevalence between both Pre-hypertensive and Healthy group.
61960788|NCT01558271|EXPERIMENTAL|LY2189265|Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
61960789|NCT01558271|PLACEBO_COMPARATOR|Placebo/LY2189265|Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
61960790|NCT01558271|ACTIVE_COMPARATOR|Liraglutide|Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
61960791|NCT04976660|EXPERIMENTAL|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-4 is determined
62505588|NCT04167384|EXPERIMENTAL|Hard nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
62704152|NCT06238531|NO_INTERVENTION|Control|Subjects will remain on their usual SLE medications
61960792|NCT04804969||At Risk Echo Referrals|Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram as standard of care. All will receive a MyoVista wavECG test.
61960793|NCT04444102|NO_INTERVENTION|Control group (CG)|Those subjects randomized to the CG will be offered reading options that do not evoke high emotional distress. They will spend an hour reading.
61960794|NCT04444102|EXPERIMENTAL|Stretching protocol 1, Mild Stretching Group (MSG)|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 50% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch and then corrected to 50%. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 50% with some feedback from the instructor.
61960795|NCT04444102|EXPERIMENTAL|Stretching protocol 2, Intense Stretching Group (ISG):|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 100% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 100% with some feedback from the instructor.
61960796|NCT00306215|EXPERIMENTAL|1|Blinded study arm
61960797|NCT00306215|EXPERIMENTAL|2|Blinded study arm
61960798|NCT00306215|EXPERIMENTAL|3|Blinded study arm
61960799|NCT00306215|EXPERIMENTAL|4|Blinded study arm
61960800|NCT05371691|EXPERIMENTAL|Myobrace group|Myobrace appliance will be used for children who have Cl.II div.a malocclusion
61960801|NCT05371691|EXPERIMENTAL|Twin-block group|Twin-block appliance will be used for children who have Cl.II div.a malocclusion
61960802|NCT04843293|EXPERIMENTAL|Experimental Group: Olfactory stimulation group|Preterm newborns in the initiative group were sniffed the smell of breast milk before and during feeding, except for routine application
62347555|NCT00830570||1|Historical control group. Patients in this group are drawn from the same plan populations as the intervention group, but they are identified during the 1-year period prior to the start of patient enrollment in the intervention group. The historical control group is closely matched with the intervention group on demographic characteristics, practice patterns, and benefit plan features that may affect resource utilization.
62505589|NCT04167384|EXPERIMENTAL|Soft nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
62505590|NCT06360029|EXPERIMENTAL|LvL UP|Downloading and using the LvL UP app
62505591|NCT06360029|EXPERIMENTAL|LvL UP + MI|Downloading and using the LvL UP app + taking part in motivational interviewing support sessions
62505592|NCT06360029|ACTIVE_COMPARATOR|Comparison|Receiving healthy lifestyle and mental well-being resources from Singapore's Health Promotion Board
62505593|NCT03496987|NO_INTERVENTION|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
62704153|NCT06238531|PLACEBO_COMPARATOR|Placebo|Subjects will receive a placebo that looks similar to the interventional drug.
62704154|NCT06492460|EXPERIMENTAL|2 courses of cisplatin chemoradiotherapy arm|Patients will receive intensity modulated radiotherapy (total dose: \> 66 Gy, split dose: 2-2.2 Gy/ time, once a day, 5 times a week) plus concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22).
61960803|NCT04843293|NO_INTERVENTION|Control Group|Premature newborns in the control group feeds gavage according to the routine of the clinic, and no attempt will be made during feeding.
61960804|NCT02519036|EXPERIMENTAL|ISIS 443139 10 mg|Participants received ISIS 443139, 10 milligrams (mg), by intrathecal injection, on Study Days 1, 29, 57, and 85.
62704155|NCT06492460|EXPERIMENTAL|3 courses of cisplatin chemoradiotherapy arm|Patients will receive intensity modulated radiotherapy (total dose: \> 66 Gy, split dose: 2-2.2 Gy/ time, once a day, 5 times a week) plus concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, once every 3 weeks, 3 times in total, days 1, 22, and 43).
62704156|NCT06746935|ACTIVE_COMPARATOR|Control Group B polytetrafluoroethylene membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with polytetrafluoroethylene membrane.
61960805|NCT02519036|EXPERIMENTAL|ISIS 443139 30 mg|Participants received ISIS 443139, 30 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
62704157|NCT06746935|EXPERIMENTAL|Study Group A native collagen membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with native collagen membrane.
62704158|NCT06730126|EXPERIMENTAL|Interventional|The initial dosage for stage 1 of this study is 200 mg twice daily for up to 360 days. If stage 1 is repeated because there are no successes at this dosage, then it will be increased to 400 mg twice daily for up to 360 days. Alternatively, if there are safety concerns at either dosage, then it will be decreased to 100 mg twice daily for up to 360 days.
62704159|NCT06727552|EXPERIMENTAL|Barzolvolimab 150 mg|Barzolvolimab loading dose of 450 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 32 weeks
62704160|NCT06727552|EXPERIMENTAL|Barzolvolimab 300 mg|Barzolvolimab loading dose of 450 mg subcutaneous injection followed by 300 mg administered every 4 weeks for 32 weeks
62704161|NCT06727552|EXPERIMENTAL|Placebo then barzolvolimab 150 mg|Placebo subcutaneous injection every 4 weeks for 16 weeks and then barzolvolimab loading dose of 450 mg followed by 150 mg administered every 4 weeks for 16 weeks.
62704162|NCT06727552|EXPERIMENTAL|Placebo then barzolvolimab 300 mg|Placebo subcutaneous injection every 4 weeks for 16 weeks and then barzolvolimab loading dose of 450 mg followed by 300 mg administered every 4 weeks for 16 weeks.
61960806|NCT02519036|EXPERIMENTAL|ISIS 443139 60 mg|Participants received ISIS 443139, 60 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
62704163|NCT06719609|EXPERIMENTAL|Running activity|Participants will run for 1 minute at varying speeds
62704164|NCT06719609|EXPERIMENTAL|Dynamic agility task|Participants will complete a 20-yard shuttle test
62704165|NCT06702618|EXPERIMENTAL|TQB3616 capsule+Fulvestrant Injection|
62704166|NCT06716190|EXPERIMENTAL|MRD: BI 3731579 dose group 1|MRD= Multiple rising doses
62704167|NCT06716190|EXPERIMENTAL|MRD: BI 3731579 dose group 2|
62704168|NCT06716190|EXPERIMENTAL|MRD: BI 3731579 dose group 3|
62704169|NCT06716190|EXPERIMENTAL|MRD: BI 3731579 dose group 4|
62704170|NCT06716190|PLACEBO_COMPARATOR|MRD: Placebo matching BI 3731579|
61960807|NCT02519036|EXPERIMENTAL|ISIS 443139 90 mg|Participants received ISIS 443139, 90 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
61960808|NCT02519036|EXPERIMENTAL|ISIS 443139 120 mg|Participants received ISIS 443139, 120 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
61960809|NCT02519036|PLACEBO_COMPARATOR|Placebo|Participants received placebo, by intrathecal injection, on Study Days 1, 29, 57, and 85.
61960810|NCT02646072|ACTIVE_COMPARATOR|Diabetes mellitus patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
61960811|NCT02646072|NO_INTERVENTION|Diabetes mellitus control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
61960812|NCT02646072|ACTIVE_COMPARATOR|Non diabetic patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
62704171|NCT06714318||Screening participants|All citizens referred to colonoscopy at Vejle Hospital or Hospital Sønderjylland in the colorectal cancer screening program are offered to participate in the study. If the participant agrees, they will have blood drawn and sign a declaration of consent before their colonoscopy.
61960813|NCT02646072|NO_INTERVENTION|Non diabetic control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
61960814|NCT00915213||Repeat Prostate Biopsy|Men who undergo repeat prostate biopsy
61960815|NCT02535988|EXPERIMENTAL|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of colorectal cancer receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy; Systemic agents are either capecitabine (Xeloda), paclitaxel or S-1;
61960816|NCT02299830|EXPERIMENTAL|cryotherapy|give the cases whose central airway stricture were caused by soft neoplasm tissues cryotherapy
62704172|NCT06732258|EXPERIMENTAL|Low-dose radiotherapy concurrent Chemotherapy combined with Toripalimab and Tifcemalimab|
62704173|NCT06280833||Genetic counselor|Genetic counselor at NIH
62704174|NCT04827875|EXPERIMENTAL|AIV001 Treatment Dose 1|Intradermal, Dose 1
62704175|NCT04827875|EXPERIMENTAL|AIV001 Treatment Dose 2|Intradermal, Dose 2
62704176|NCT06751381||Nasopharyngeal Carcinoma Patients|
62704177|NCT06058377|EXPERIMENTAL|Step 1 (MammaPrint testing)|Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2.
62714954|NCT06717906|OTHER|Adult patients with Ulcerative colitis|Adult patients (18-75 years) with Ulcerative colitis Pregnant, lactating and acute severe colitis excluded
62714955|NCT02828384|ACTIVE_COMPARATOR|low fodmap diet|Subjects receive formalized teaching in low fodmap diet by a dietician
62714956|NCT02828384|ACTIVE_COMPARATOR|psyllium|subjects receive 7.1 g of psyllium daily
62714957|NCT06593600|EXPERIMENTAL|Low Dose|Randomized 1:1:1
62714958|NCT06593600|EXPERIMENTAL|High Dose|Randomized 1:1:1
62714959|NCT06593600|PLACEBO_COMPARATOR|Matching Placebo|Randomized 1:1:1
62505594|NCT03496987|EXPERIMENTAL|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
62505595|NCT03616002|EXPERIMENTAL|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
62505596|NCT05144464|EXPERIMENTAL|Quadrivalent influenza vaccine|Subjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.
62505597|NCT04154358|EXPERIMENTAL|HPV Testing|Will perform HPV testing with self-collected specimen
62505598|NCT01557062|OTHER|Polysomnography|
62347556|NCT00830570||2|Concurrent control group. Patients in this group are drawn from different set of plan populations, but they initiate warfarin treatment during the same time period as patients in the intervention group. Outcomes data for the concurrent control group will be used to evaluate whether any differences between the intervention group and the historical control group can be attributed to changes in clinical practice over time. Baseline data for the concurrent control group will help validate the incidence assumptions used in the calculation of statistical power. This use of baseline population norms is an effective means of limiting bias in quasi-experimental studies.
62704178|NCT06058377|ACTIVE_COMPARATOR|Step 2, Arm 1 (chemotherapy)|"Patients receive paclitaxel IV over 30-60 minutes on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery, and undergo collection of blood samples prior to STEP 2 treatment, after cycle one of chemotherapy, and one month post-SOC surgery."
62704179|NCT06058377|EXPERIMENTAL|Step 2, Arm 2 (chemotherapy, durvalumab)|"Patients receive paclitaxel IV over 30-60 minutes on days 1 and 8 of each cycle and durvalumab IV over 60 minutes on day 1 of every other cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of every other cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery, and undergo collection of blood samples prior to STEP 2 treatment, after cycle one of chemotherapy, and one month post-SOC surgery."
62704180|NCT06745232||FAST MAP|Patients with complete arch restorations loaded immediately with a full digital workflow using stereophotogrammetry Intraoral impression
62704181|NCT06468228|EXPERIMENTAL|Period 1|Participants will be randomized to either Lutikizumab Dose B at baseline followed by Lutikizumab Dose A, or a matching placebo dose equivalent for both, every week through Week 16 .
61960817|NCT02299830|EXPERIMENTAL|argon plasma coagulation|give the cases whose central airway stricture were caused by hard neoplasm tissues argon plasma coagulation
62347557|NCT00830570||3|Active study group. For plans participating in the active arm of the study, enrollment is offered to every patient who initiates warfarin therapy during the enrollment period (beginning in July 2007) and who meets the eligibility criteria. Patients are identified for the active study group if they have a warfarin pharmacy claim and no prior warfarin claims during the preceding 180 days. Only patients who remain eligible for the pharmacy benefit throughout the study period are included in the final sample.
62347558|NCT04462757|ACTIVE_COMPARATOR|Subcutaneous Arm|100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.
62505599|NCT01557062|OTHER|Temperature measure|
62505600|NCT01557062|OTHER|Fibromyalgia Impact questionary|
62505601|NCT02104869|ACTIVE_COMPARATOR|Recommended dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
62505602|NCT02104869|ACTIVE_COMPARATOR|Healthy adults|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
62505603|NCT02104869|EXPERIMENTAL|Single double dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 1.0 mL dose."
62704182|NCT06468228|EXPERIMENTAL|Period 2: Lutikizumab Every Week|Participants randomized to lutikizumab in Period 1 who complete Week 16 of the study will be re-randomized to lutikizumab Dose A through Week 52
62704183|NCT06468228|EXPERIMENTAL|Period 2: Lutikizumab Every Other Week|Participants randomized to lutikizumab in Period 1 who complete Week 16 of the study will be re-randomized to lutikizumab Dose A every other week though week 52
62704184|NCT06468228|EXPERIMENTAL|Period 2: Placebo to Lutikizumab Group|Participants randomized to Placebo in Period 1 who complete Week 16 of the study will initiate lutikizumab with Dose B followed by Dose A every week.
62704185|NCT06468228|EXPERIMENTAL|Period 2: Placebo to Lutikizumab Group Every Week|Participants that were assigned Placebo in Period 1 and initiated lutikizumab in Period 2 will then be re-randomized to lutikizumab Dose A every week through Week 52
61960818|NCT02299830|EXPERIMENTAL|stent|give the cases whose central airway stricture were caused by neoplasm compression stent placement
61960819|NCT02299830|EXPERIMENTAL|snare|give the cases whose central airway stricture were caused by polypoid neoplasm tissues snare
62505604|NCT02104869|EXPERIMENTAL|Two sequential doses (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: two 0.5 mL doses 21 days apart."
62505605|NCT06013930|EXPERIMENTAL|External Qigong|Participants will meet individually with the Qigong practitioner once a week for three weeks for 30-minute segments.
62704186|NCT06468228|EXPERIMENTAL|Period 2: Placebo to Lutikizumab Group Every Other Week|The participants that were assigned Placebo in Period 1 and initiated lutikizumab in Period 2 will then be re-randomized to lutikizumab Dose A every other week through Week 52
61960820|NCT03851705|EXPERIMENTAL|Part 1 - Inclisiran|Participants who received a dose of 300 milligram (mg) inclisiran sodium for injection administered by SC injection on Day 1 and Day 90.
61960821|NCT03851705|PLACEBO_COMPARATOR|Part 1 - Placebo|Participants who received a dose of placebos administered by SC injection on Day 1 and Day 90.
61960822|NCT03851705|EXPERIMENTAL|Part 2 - Inclisiran|Participants who received a dose of 300 mg inclisiran sodium for injection administered by SC injection on Day 270, Day 450 and Day 630. In addition, participants who were assigned to the placebo arm in Part 1 will receive a dose of 300 mg inclisiran sodium administered by SC injection on Day 180 after completion of Part 1.
62347559|NCT04462757|ACTIVE_COMPARATOR|Intravenous Arm|100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours.
62347560|NCT04520828|EXPERIMENTAL|Postural repositioning|
62347561|NCT04624828|EXPERIMENTAL|Stereotactic body radiation treatment (SBRT)|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
62347562|NCT05684601|PLACEBO_COMPARATOR|rotating drills device|Third molar surgery performed with traditional rotating devices
62347563|NCT05684601|ACTIVE_COMPARATOR|Piezoelectric device|Third molar surgery performed with piezoelectric surgery device
62347564|NCT05085431|EXPERIMENTAL|Treatment of Sjogren's Syndrome|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4\*10E6/kg are administrated for each subject.
62347565|NCT03743233|ACTIVE_COMPARATOR|Hand file instrumentation|
62347566|NCT03743233|ACTIVE_COMPARATOR|Reciprocating instrumentation|
61960823|NCT03060538|EXPERIMENTAL|Multiple Ascending Dose BFKB8488A|Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
61960824|NCT03060538|PLACEBO_COMPARATOR|Placebo|Participants will receive BFKB8488A-matching placebo.
61960825|NCT03952104|EXPERIMENTAL|Experimental-Low Intensity Strength Training|Strength training (low intensity)
61960826|NCT03952104|EXPERIMENTAL|Experimental-Moderate Intensity Strength Training|Strength training (moderate intensity)
61960827|NCT03952104|EXPERIMENTAL|Experimental-High Intensity Strength Training|Strength training (high intensity)
61960828|NCT03952104|NO_INTERVENTION|Control|No intervention
61960829|NCT05482724|EXPERIMENTAL|Intervention group|Super Skills for Life intervention group
62347567|NCT02585999|OTHER|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
62347568|NCT05035823|OTHER|Single|Implantation of the motor neuroprosthesis medical device.
62347569|NCT00992004|EXPERIMENTAL|Arantal®|Highly bioavailable turmeric extract (food supplement)
62347570|NCT00992004|PLACEBO_COMPARATOR|Placebo|Same capsule without the active ingredients (only excipients)
61960830|NCT05482724|NO_INTERVENTION|Wait-list group|Group without any intervention. Participants in the wait-list group received no phycological (public or private) intervention during the eight-week duration of the SSL program. They were informed that children in this group will receive the intervention once the follow-up visit is completed.
61960831|NCT01408485|EXPERIMENTAL|Treatment Arm|Radio-frequency cardiac ablation for treatment of isthmus-dependant atrial flutter using the Therapy™ Cool Flex™ Irrigated Ablation System
62347571|NCT04683107|EXPERIMENTAL|Eccentric protocol|
62347572|NCT04683107|EXPERIMENTAL|Isometric protocol|
62347573|NCT03866148|ACTIVE_COMPARATOR|ILR|Participants who will receive the Implantable Loop Recorder (Reveal-LINQ) inserted just after baseline. This is single intervention and lasts for 3 years after which the patient has the option to have it removed.
62505606|NCT06013930|EXPERIMENTAL|Mindfulness Meditation|Participants will meet individually with the mindfulness practitioner once a week for three weeks for 30-minute segments.
62505607|NCT06013930|ACTIVE_COMPARATOR|Psychoeducation|In the psychoeducation arm, participants will receive recordings online, once a week for three weeks which will be approximately 30 minutes in length.
62347574|NCT03866148|NO_INTERVENTION|No ILR|Participants who will not get the Implantable Loop Recorder (Reveal-LINQ).
62347575|NCT02601183||Ischemic stroke|The patients in the group are diagnosed as ischemic stroke by CT or MRA examination within 8h following stroke attack.
62347576|NCT02601183||Hemorrhagic stroke|The patients in the group are diagnosed as hemorrhagic stroke by CT or MRA examination within 8h following stroke attack.
62505608|NCT04292015|EXPERIMENTAL|Standard then Intervention|Infant will undergo standard method of examination with binocular indirect opthalmoscope (BIO) followed by retinal imaging with Optos ultra-wide field retinal imaging device.
62704187|NCT02890342||Affected Patients with Propionic Acidemia|Patients with Propionic Acidemia, standard adult, parental permission
62347577|NCT02411526|EXPERIMENTAL|Cohort 1|60 mg of ZX003 administered 4 times (every 4 weeks)
62347578|NCT02411526|EXPERIMENTAL|Cohort 2|90 mg of ZX003 administered 4 times (every 4 weeks)
62347579|NCT02411526|EXPERIMENTAL|Cohort 3|120 mg of ZX003 administered 4 times (every 4 weeks)
62347580|NCT02411526|ACTIVE_COMPARATOR|Cohort 4|Risperdal Consta administered 5 times (once every 2 weeks) NOTE: Oral risperidone 2 mg will be given with the first injection of Risperdal Consta and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from Risperdal Consta.
62704188|NCT02890342||Healthy Volunteers|Healthy Volunteers, standard adult, parental permission
62704189|NCT02890342||Unaffected Family Members|Unaffected family members
61960832|NCT05687383|EXPERIMENTAL|Safe breastfeeding pillow|Safe breastfeeding pillow increase the comfort and safety of postpartum women during breastfeeding, thereby prolonging breastfeeding and ensuring optimal nutrition for the baby
61960833|NCT05687383|PLACEBO_COMPARATOR|Breastfeeding pillow|Providing a comfortable, supportive and safe environment for healthier and breastfeeding for women and babies
61960834|NCT01740947|NO_INTERVENTION|Standard treatment|Standard treatment for colorectal cancer
61960835|NCT01740947|EXPERIMENTAL|Selective decontamination of the digestive tract (SDD)|"Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively."
61960836|NCT02714582|EXPERIMENTAL|Bedside shift report|"The experimental group (nurses and patients) will:~* develop a tailored BSR-intervention by use of co-design, diagnostic interviews, and pilot testing~* use the tailored BSR-intervention, with participation of the patient, instead of the regular nurse shift report"
61960837|NCT02714582|NO_INTERVENTION|No bedside shift report|The control group will not use bedside shift report, but will use the regular nurse shift report without participation of the patient
62143616|NCT05522023|EXPERIMENTAL|Experimental group (group treated with aromatic solution)|"Informed consent form will be signed by the patients selected by randomization and a personal information form will be filled.~Hour 0: The patients will be completely awakened from the anesthesia resting unit, their vital signs will be stable, they will be transferred to the clinic where they lie normally with a 15 glaskow scale, the bed head will be elevated 45 degrees and the risk of aspiration will be ruled out. After controlling the vital signs of the patient, sore throat and thirst with VAS and nausea and vomiting with the verbal descriptive scale VDS will be evaluated. After the data are collected, the aromatic solution will be shaken and applied to the oral cavity and throat as a spray 4 times. After the aromatic solution application is finished, the patients' sore throat, thirst and nausea and vomiting will be re-evaluated with the same forms.~2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
62143617|NCT05522023|PLACEBO_COMPARATOR|Placebo group (group treated with drinking water)|"Patients included in this group as a result of randomization will have to sign an informed consent form and fill out a personal information form.~Hour 0: The patients will be completely awakened from the anesthesia resting unit, their vital signs will be stable, they will be transferred to the clinic where they sleep normally with a 15 glaskow scale, the bed head will be elevated 45 degrees and the risk of aspiration will be ruled out. Nausea and vomiting will be evaluated with a verbal descriptive scale. After the data are collected, drinking water will be applied to the oral cavity and throat in the form of a spray 4 times. After the drinking water application is finished, the patients' sore throat, thirst and nausea and vomiting will be re-evaluated with the same forms.~2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
62143618|NCT05522023|NO_INTERVENTION|Control Group|"Patients in the control group were planned to be followed according to their clinical procedures. Since there were no procedures or interventions in the clinical procedures, it was decided to follow up only the patient, and the control group patients to be followed up at the same times with the same forms.~Patients included in this group as a result of randomization will have to sign an informed consent form and fill out a personal information form. Hour 0: Patients will be transferred from the recovery unit to the clinic. After controlling the vital signs of the patient, sore throat and thirst with VAS and nausea and vomiting with a verbal descriptive scale will be evaluated. 2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
62143619|NCT04338451|ACTIVE_COMPARATOR|Music during the first part of ESWL|Patients listen to music during the first part of ESWL treatment (first 1800 SW).
62143620|NCT04338451|ACTIVE_COMPARATOR|Music during the second part of ESWL|Patients listen to music during the second part of ESWL treatment.
62143621|NCT05199506|EXPERIMENTAL|Each leg/buttock will be treated with the RAP device|Each leg will be treated with standard RAP treatment settings.One leg will receive treatments with 100Hz and the other with 50hz
62143622|NCT00390884|EXPERIMENTAL|Fluzone®-Primed Group|Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
62143623|NCT00390884|EXPERIMENTAL|Fluzone®-Naive Group|Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
62143624|NCT01046292|EXPERIMENTAL|Ginkgo biloba|
62143625|NCT01046292|PLACEBO_COMPARATOR|Placebo control|
62143626|NCT03470805|EXPERIMENTAL|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
62143627|NCT02915432|EXPERIMENTAL|3 mg/kg anti-PD-1 mAb JS001 Q2W|Subjects will be eligible for this study after they fulfill the inclusion criteria and exclusion criteria. Subjects diagnosed as the gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma will receive treatment at the dose of 3 mg/kg.
62143628|NCT02915432|EXPERIMENTAL|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
62704190|NCT05812807|ACTIVE_COMPARATOR|Arm I (pembrolizumab)|Patients receive pembrolizumab IV on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up.
61960838|NCT00476697|EXPERIMENTAL|UVA1 Irradiation|UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
61960839|NCT02459210|EXPERIMENTAL|CLUES|active treatment
61960840|NCT02459210|ACTIVE_COMPARATOR|therapy and computer games|supportive therapy + computer games
61960841|NCT06318182|EXPERIMENTAL|Training group|Group receiving training based on SIMTEKEP program
61960842|NCT06318182|NO_INTERVENTION|Control group|The group that did not receive training based on the SIMTEKEP program
61960843|NCT01068132|EXPERIMENTAL|1|Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
61960844|NCT00963937|ACTIVE_COMPARATOR|Sumatriptan 25 mg|
62505609|NCT04292015|EXPERIMENTAL|Intervention then Standard|Infant will undergo retinal imaging with Optos ultra-wide field retinal imaging device followed by standard method of examination with binocular indirect opthalmoscope (BIO).
62505610|NCT03689894|EXPERIMENTAL|Ibrutinib plus Rituximab|"Rituximab~\*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)~Ibrutinib~* 420 mg (140 mg capsule x3) by mouth daily~* May be given beyond 3-6 months (for maintenance)."
62505611|NCT00770068||Experimental group|All participants testing positive for tree and ragweed pollen allergies, as determined by levels of immunoglobulin E (IgE) antibodies
62704191|NCT05812807|EXPERIMENTAL|Arm II (observation)|Patients undergo observation on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up.
62704192|NCT06257485||Patients referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography|Patients with suspected transthyretin cardiac amyloidosis referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography
62704193|NCT06233591|EXPERIMENTAL|LP-10 0.25mg|0.25mg LP-10 / 10 mL twice daily oral rinse
62704194|NCT06233591|EXPERIMENTAL|LP-10 0.5 mg|0.5mg LP-10 / 10 mL twice daily oral rinse
62704195|NCT06233591|EXPERIMENTAL|LP-10 1.0 mg|1.0mg LP-10 / 10 mL twice daily oral rinse
62143629|NCT02915432|EXPERIMENTAL|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death
62347581|NCT02618343|EXPERIMENTAL|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
62347582|NCT02618343|ACTIVE_COMPARATOR|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
62347583|NCT03598569||lung cancer|
62347584|NCT03598569||other lung diseases|
62347585|NCT02527655|EXPERIMENTAL|Choice-Based Physical Activity and Active Transportation|Participants will meet one-on-one with an activity coach to develop a choice-based physical activity and active transportation plan based on their interest, abilities, and resources; attend group-based motivational meetings; and receive ongoing support and encouragement for physical activity and active transportation (e.g., telephone-assisted support, community centre and transit passes).
62347586|NCT02527655|NO_INTERVENTION|Wait-List Control|Participants will be offered the Choice-Based Physical Activity and Active Transportation intervention after the experimental arm has completed the study.
62505612|NCT00770068||Control group|All participants testing negative for tree and ragweed pollen allergies, as determined by levels of IgE antibodies
62505613|NCT03902301|ACTIVE_COMPARATOR|Dietary group|A diet based on general recommendations for people with insulin resistance for 20 weeks.
62505614|NCT03902301|EXPERIMENTAL|Lactobacillus rhamnosus group|Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.
62505615|NCT03285464|ACTIVE_COMPARATOR|Hip|This group will perform a known hip strengthening program
62505616|NCT03285464|EXPERIMENTAL|Trunk|This group will use the trunk as a lever to strengthen the hip
62505617|NCT03033524|EXPERIMENTAL|Cohort 1|Patients will be treated with 8mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
62704196|NCT06740981||Noninvasively ventilated patients|For patients admitted with acute respiratory failure requiring noninvasive ventilation, a food diary will be collected for five days.
62704197|NCT06751290|EXPERIMENTAL|Nutritional Counseling in Combination with Behavioral Counseling|Participants in the group will receive nutritional and behavioral counseling for up to 6 months
61960845|NCT00963937|ACTIVE_COMPARATOR|Sumatriptan 50 mg|
61960846|NCT00963937|PLACEBO_COMPARATOR|Placebo|
61960847|NCT05527340|EXPERIMENTAL|iberdomide + dexamethasone (IBERDEX)|"IBERDEX~* Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO).~* Dexamethasone will be given on days 1, 8, 15, and 22 at 40 mg (patients aged ≥ 75 years: 20 mg), every 4 weeks, PO."
62505618|NCT03033524|EXPERIMENTAL|Cohort 2|Patients will be treated with 12mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
62505619|NCT03033524|EXPERIMENTAL|Cohort 3|Patients will be treated with 12mg/kg of TTAC-0001 weekly in every 4 weeks of cycle.
62505620|NCT00876356|ACTIVE_COMPARATOR|1|Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
62505621|NCT00876356|PLACEBO_COMPARATOR|2|Olive oil 4.5g/day x 12 weeks.
62505622|NCT03747653||Arm 1|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.
62505623|NCT03747653||Arm 2|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.
62704198|NCT06751290|EXPERIMENTAL|Cyproheptadine|Participants in this group will receive the Cyproheptadine for up to 6 months
62704199|NCT06740916|ACTIVE_COMPARATOR|81-mg aspirin once daily|81-mg aspirin once daily
62704200|NCT06740916|EXPERIMENTAL|81-mg aspirin twice daily|81-mg aspirin twice daily
62704201|NCT06740890|EXPERIMENTAL|olanzapine-samidorphan plus exercise|
62704202|NCT06736236|OTHER|Control|Participants only performed a general warm-up exercise.
62704203|NCT06736236|PLACEBO_COMPARATOR|IMW %15 (Placebo)|In addition to the general warm-up, the participants performed IMW at 15% resistance intensity.
62704204|NCT06736236|EXPERIMENTAL|IWM %40 (Experimental)|In addition to the general warm-up, participants performed IMW at 40% resistance intensity.
62704205|NCT06738225||cases|Persons has Colorectal cancer
62704206|NCT06738225||Control|Persons do not have Colorectal cancer
62505624|NCT05308823|NO_INTERVENTION|Group 1|The paients in this group will receive traditional treatment of IIH for 3 months.
62704207|NCT06737380|EXPERIMENTAL|UC-MSC therapy|
62704208|NCT06726941|EXPERIMENTAL|Experimental Group|This group consists of post-stroke hemiplegia participants who will be included in a physiotherapy and rehabilitation program to evaluate the effects on neuroplasticity-related gene expression and histone modification levels, spasticity levels, motor functions, daily living activities, and quality of life.
62704209|NCT06727734|EXPERIMENTAL|LNG-piroxicam|Levonorgestrel-piroxicam combination
62704210|NCT06727734|ACTIVE_COMPARATOR|UPA|Ulipristal only
61960848|NCT05527340|EXPERIMENTAL|iberdomide + daratumumab + dexamethasone (IBERDARADEX)|"IBERDARADEX~* Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, PO.~* Dexamethasone will be given on days 1, 8, 15, and 22 at 40 mg (patients aged ≥ 75 years: 20 mg), every 4 weeks, PO.~* Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days)."
61960849|NCT06320002|EXPERIMENTAL|Fecal ostomy surgery participants receiving the CI-oSurg|This arm will include patients who are undergoing or have undergone fecal ostomy surgery and surgical clinicians caring for the patients who will receive the CI-oSurg intervention.
61960850|NCT04606030|EXPERIMENTAL|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
62505625|NCT05308823|EXPERIMENTAL|Group 2|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent.
62704211|NCT06269627|ACTIVE_COMPARATOR|Active|This arm has participants receiving acamprosate for 21 day as inpatients.
62704212|NCT06269627|PLACEBO_COMPARATOR|Placebo|This arm has participants receiving placebo for 21 day as inpatients.
62704213|NCT06707389|ACTIVE_COMPARATOR|control|Intratympanic injection of methylprednisolone (methylprednisolone succinic acid for injection) at a dose of 40mg/mL, three times a week. 40mg of methylprednisolone was dissolved in 0.2 ml of lidocaine injection and 0.8 ml of sterilized injection water.
62704214|NCT06707389|EXPERIMENTAL|apoVs(lower dose)|Intratympanic injection of autologous blood monocyte vesicles, three times a week. Autologous blood monocyte vesicles were extracted from 20 ml peripheral blood from patients and dissolved in 0.2 ml of lidocaine injection and 0.8 ml of sterilized injection water.
62505626|NCT00981227|EXPERIMENTAL|ESL 400 mg twice-daily|ESL 400 mg twice-daily
62505627|NCT00981227|EXPERIMENTAL|ESL 800 mg once-daily|ESL 800 mg once-daily
62505628|NCT00981227|EXPERIMENTAL|ESL 600 mg twice daily|ESL 600 mg twice daily
62505629|NCT00981227|EXPERIMENTAL|ESL 1200 mg once daily|ESL 1200 mg once daily
62505630|NCT00981227|EXPERIMENTAL|ESL 800 mg twice daily|ESL 800 mg twice daily
62505631|NCT00981227|PLACEBO_COMPARATOR|placebo|placebo
62505632|NCT05338476|EXPERIMENTAL|Midazolam|Midazolam administered orally.
62704215|NCT06707389|EXPERIMENTAL|apoVs(higher dose)|Intratympanic injection of autologous blood monocyte vesicles, three times a week. Autologous blood monocyte vesicles were extracted from 50 ml peripheral blood from patients and dissolved in 0.2 ml of lidocaine injection and 0.8 ml of sterilized injection water.
62704216|NCT06720298||68Ga-DOTA-AP9|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-DOTA-AP9 PET/CT scan.
62704217|NCT06710990|EXPERIMENTAL|Cohort 1: SHR-A1811 + Ritonavir|
62704218|NCT06710990|EXPERIMENTAL|Cohort 2: SHR-A1811 + Itraconazole|
62704219|NCT06704867|NO_INTERVENTION|Standard oxygen therapy|Standard oxygen therapy will be initiated utilizing 2-4 liters of oxygen with a nasal cannula.
62704220|NCT06704867|EXPERIMENTAL|High Flow Nasal Cannula|A high flow oxygen device with 100% FiO2 will be initiated prior to endoscopic ultrasound.
62704221|NCT06707077||Exposure|The patient receives three increasing target end-tidal concentrations of sevoflurane, depending on what is hemodynamically (i.e. arterial hypotension) feasible in the individual patient.
61960851|NCT04606030|ACTIVE_COMPARATOR|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
61960852|NCT06505421||Persons with Multiple sclerosis|Eccentric resistance training , traditional resistance training
61960853|NCT03502980|ACTIVE_COMPARATOR|Peripherally inserted central venous catheters|Bard PowerPICC
61960854|NCT03502980|ACTIVE_COMPARATOR|Midline|Bard PowerMidline catheter
61960855|NCT00970567|OTHER|Arm 1|stop after positive ketone bodies in urine
61960856|NCT00970567|OTHER|Arm 2|stop after positive ketone bodies in blood, normal therapy
61960857|NCT00970567|OTHER|Arm 3|stop after positive ketone bodies in blood, additional therapy
61960858|NCT05490511|ACTIVE_COMPARATOR|CYP3A5 expressers without chronic kidney disease|
61960859|NCT05490511|ACTIVE_COMPARATOR|CYP3A5 non-expressers without chronic kidney disease|
61960860|NCT05490511|ACTIVE_COMPARATOR|CYP3A5 expressers with chronic kidney disease|
61960861|NCT05490511|ACTIVE_COMPARATOR|CYP3A5 non-expressers with chronic kidney disease|
61960862|NCT05780658|EXPERIMENTAL|Compass Course|Four groups of up to 12 participants (48 total) will receive the study intervention during Spring and Fall 2022. All participants will complete study questionnaires before and after the sessions.
61960863|NCT03200405|EXPERIMENTAL|DynaMeshVisible|the umbilical hernia will be fixed with a mesh, which is incorporated with Fe3O4 particles to become visible in MRI
61960864|NCT03200405|ACTIVE_COMPARATOR|DynaMeshCICAT|the umbilical hernia will be fixed with a Non-MRI-visible PVDF Mesh
62505633|NCT05338476|EXPERIMENTAL|Selpercatinib and Midazolam|Selpercatinib and midazolam administered orally.
62505634|NCT00392782|EXPERIMENTAL|Natural Killer Cell Kir Epitope|
62505635|NCT03280940||Dolutegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a dolutegravir containing regimen
62505636|NCT03280940||Raltegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a raltegravir containing regimen
62505637|NCT03280940||Elvitegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a elvitegravir containing regimen
62505638|NCT03280940||Protease inhibitors treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a protease inhibitors containing regimen
61960865|NCT01389817|EXPERIMENTAL|Symptomatic LHON patients.|Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
61960866|NCT01389817|NO_INTERVENTION|Asymptomatic LHON mutation carriers|Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
61960867|NCT01949558|NO_INTERVENTION|Control group|The control group receives a brochure on healthy dietary habits according to regular care.
62704222|NCT06698939|EXPERIMENTAL|ORKA-001|Participants will receive subcutaneous injection of ORKA-001 at either 300 mg, 600 mg or 1200 mg.
61960868|NCT01949558|EXPERIMENTAL|Dietary intervention|12 week individual intervention based on a cognitive behavioral approach. It includes dietary restriction under guidance by a dietitian. Thereafter monthly follow-up takes place via email during the following 9 mo.
61960869|NCT06385899||Newly diagnosed diabetes|Patients who have been diagnosed with type 2 diabetes within a month
61960870|NCT06385899||Had controlled diabetes before|Patients who had at least two HbA1c levels =\<%7,5 before enrollment
61960871|NCT06385899||Had moderately uncontrolled diabetes|Patients who had at least two HbA1c levels between %7,5 and %9,49 before enrollment
61960872|NCT06385899||Had poorly controlled diabetes|Patients who had at least two HbA1c levels above %9,5 before enrollment
61960873|NCT01402778||Cather fixation by tunneling and suture|
61960874|NCT01402778||Catheter fixation by adhesive tape|
61960875|NCT02611219|EXPERIMENTAL|Arm 1: Pediatric patients|"* Patients will wear a Fitbit Flex during hospitalization~* Completion of Demographic Data Form at baseline, discharge from hospital, and at the six week clinic visit~* Assist in recording time out of bed using the SCT Daily Activity Log~* Fill out (some with help of parents) applicable questionnaires: Child Health Ratings Inventories-General Health Module (5-12 years), General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years) at baseline, discharge from hospital, and at six week clinic visit~* Patients will be assessed using standard physical therapy assessment tools to determine functioning, muscle strength, endurance, and mobility: The Functional Independence Measure for Children and Manual Muscle Testing is done weekly, discharge from hospital, and at six week clinic visit. The 3-Minute Step Test is done at admission, discharge from hospital, and at six week clinic visit."
61960876|NCT02611219|EXPERIMENTAL|Arm 2: Parents of pediatric patients|"* Parents will be considered participants as they will be completing study questionnaires.~* Completion of Demographic Data Form at baseline~* Assist in recording time out of bed using the SCT Daily Activity Log~* Fill out applicable questionnaires: General Health Module-Baseline Parent Report -Adolescent (13-18 Years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), and General Health Module Follow Up Parent Report-School Age (5-12 years), HSCT Module-Follow UP Parent Report School Age (5-12 years), HSCT Module-Follow Up Parent Report Adolescent (13-18 years), HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years) at baseline, discharge from hospital, and at six week clinic visit.~* Assist child with Child Health Ratings Inventories-General Health Module (5-12 years) at baseline, discharge at hospital, and at six week clinic visit"
61960877|NCT06499311|EXPERIMENTAL|Group A; Foot Reflexology|Foot reflexology for 15 minutes, 3 sessions per week for 6 weeks will applied at the medical border just above the heel, also at associated reflex points associated with the adrenal, hypothalamus, pituitary glands, heart and lung via manual pressure at reflexology zone.
61960878|NCT06499311|EXPERIMENTAL|Group B; Acupressure|Acupressure for 21 minutes, 3 sessions per week for 6 weeks will applied at four acupoints points (Shenmen point at wrist crease, Sanyinjiao point; at both feet, and Fengchi point; at hairline within occipital region on dorsal neck surface), bilaterally in addition to one in midline at the top of nose on centerline between eyebrows ends (Yintang point).
62505639|NCT01782755|ACTIVE_COMPARATOR|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of Lactobacillus rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in sterile water, administered through a nasogastric, nasoduodenal, percutaneous gastrostomy or percutaneous jejunal tube twice daily while patients are mechanically ventilated until 24 hours of spontaneous breathing. The first dose will be within 48 hours of intubation.
62505640|NCT01782755|PLACEBO_COMPARATOR|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in sterile water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population
62505641|NCT00781092|EXPERIMENTAL|1|Systane Ultra
62704223|NCT06698939|PLACEBO_COMPARATOR|Placebo|Participants will receive a subcutaneous injection of placebo comparator.
61960879|NCT04456660||Control group|"Monitoring of pregnancy, including data on:~* maternal age and other demographic characteristics;~* ultrasound measurement of fetal heart rate (FHR) and crown-rump length (CRL)"
61960880|NCT04456660||sFlt-1, Doppler and NK cells types group|"Monitoring of pregnancy, including data on:~* maternal age and other demographic characteristics;~* ultrasound measurement of fetal heart rate (FHR) and crown-rump length (CRL), uterine arteries PI, and other parameters;~* measurement of serum sFlt-1, PLGF, and glycodelin-A levels, as well as other parameters;~* measurement of CD16+, CD56+, and other subpopulations of NK cells;"
62505642|NCT00781092|ACTIVE_COMPARATOR|2|Bausch and Lomb Sensitive Eyes
62505643|NCT02262559|EXPERIMENTAL|BIBR 277 tablet|
62505644|NCT02262559|ACTIVE_COMPARATOR|BIBR 277 capsule|
62505645|NCT05529368|EXPERIMENTAL|conventional exercise group|Participants in the conventional exercise group attended an 8-week conventional exercise program, which consisted of the track, field, ball games et al. If the participant chooses to run, the mileage shall be more than 4km and the pace shall be within 10min. The conventional exercise treatment was performed 3 times a week, 1 hour each time.
62704224|NCT06703398|EXPERIMENTAL|GC101 TIL group|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
62505646|NCT05529368|EXPERIMENTAL|tai chi exercise group|Participants in the tai chi exercise group attended an 8-week Yang-style 24-form tai chi training program and tai chi (8 trigrams 5 steps) which was the tai chi style most commonly adopted and studied in the literature. The tai chi exercise treatment was performed 3 times a week, 1 hour each time.
62704225|NCT06703398|ACTIVE_COMPARATOR|Investigator's choice of chemotherapy|monotherapy or combination of dacarbazine, temozolomide, paclitaxel,carboplatin or cisplatin, and the chemotherapy's dosage could refer to the drug label or the relevant treatment guideline, the final decision is up to investigator.
62704226|NCT06699030|EXPERIMENTAL|Functional fatty acids|Oral Administration of functional fatty acids
62704227|NCT06699030|PLACEBO_COMPARATOR|Placebo|Oral Administration of Placebo
62143630|NCT00845364|EXPERIMENTAL|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
62347587|NCT00937794||No treatment|This is a screening study designed to evaluate the behavioral, physical, and neurodevelopmental status in pediatric patients with Hunter syndrome who have early signs and symptoms of CNS involvement and who are currently receiving treatment with Elaprase.
62347588|NCT02530957|EXPERIMENTAL|Interventional|In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
62347589|NCT02530957|OTHER|Reference|In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
62347590|NCT03794752|OTHER|Vision Aided by a Head Mounted Device|A Head-Mounted Visual Enhancement Device developed by Evergaze Technology LLC has designed an electronic visual enhancement device that is compact and similar to glasses. It will be powered by a battery pack connected to the device. The electronic display will be affixed over only one of the user's eyes. The vision through the unobstructed eye will aid with the subject's balance and spatial orientation.
62347591|NCT03591055|EXPERIMENTAL|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
62347592|NCT03591055|NO_INTERVENTION|Control group|Participants in the control group will receive the usual standard care and regular referrals.
62347593|NCT05009030||Study group|Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
62347594|NCT03160664|EXPERIMENTAL|magnetic seizure therapy|8-10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
62347595|NCT03160664|ACTIVE_COMPARATOR|electroconvulsive therapy|8-10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
62347596|NCT00844285||Cimzia Cohort:|Patients about to receive treatment with Cimzia® as part of pre-existing management plan for Crohn's disease or has already been receiving treatment with Cimzia® for ≤12 months. Patients must also receive a Cimzia dose within 2 months following enrollment.
62347597|NCT00844285||Comparison cohort|Patient must be about to receive treatment with any other medication as part of a pre-existing management plan for Crohn's disease or has already been receiving treatment (previous Cimzia® treatment is prohibited).
62347598|NCT00433446|EXPERIMENTAL|CNTO 328|
62347599|NCT00778986|EXPERIMENTAL|remote monitoring|group of patients that will be using the heart failure remote patient monitoring system in addition to the usual care they receive at the University Health Network Heart Failure Clinic
62704228|NCT06705764|ACTIVE_COMPARATOR|Tezepelumab|Tezepelumab 210 mg S/Q Q4W
62704229|NCT06705764|PLACEBO_COMPARATOR|Placebo|Matching Placebo S/Q Q4W
62704230|NCT06705764|OTHER|Tezepelumab Open Label|Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90
62704231|NCT06744647|PLACEBO_COMPARATOR|Placebo|Placebo will be administered during the Double-Blind Treatment Period of 52 weeks.
62704232|NCT06744647|EXPERIMENTAL|ALXN2030 Dose A|During the Double-Blind Treatment Period, participants will receive ALXN2030 dose A over 52 weeks. At Week 52, participants may continue into the Open Label Extension (OLE).
62704233|NCT06744647|EXPERIMENTAL|ALXN2030 Dose B|During the Double-Blind Treatment Period, participants will receive ALXN2030 dose B over 52 weeks. At Week 52, participants may continue into the OLE Period.
62143631|NCT00845364|PLACEBO_COMPARATOR|Placebo|Pre-operative administration of placebo tablets according to dosing schedule
62704234|NCT04711109|EXPERIMENTAL|Arm A (denosumab)|Patients receive denosumab SC q6m for up to 5 years in the absence of disease progression or unacceptable toxicity.
62347600|NCT00778986|NO_INTERVENTION|control|group of patients provided with usual care at the University Health Network Heart Failure Clinic
62347601|NCT04345497|EXPERIMENTAL|Diabetes-Specific Formula|Diabetes-specific formula 1-2 servings a day and Standard of Care
62704235|NCT04711109|PLACEBO_COMPARATOR|Arm B (placebo)|Patients receive placebo SC q6m for up to 5 years in the absence of disease progression.
62143632|NCT01481974|EXPERIMENTAL|Treprostinil|This is a single center, open-label, dose-escalation Phase I/II study of Treprostinil.
62143633|NCT04017611|EXPERIMENTAL|INVSENSOR00038|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00038 sensor.
62347602|NCT04345497|OTHER|Standard of Care|Standard of Care
62347603|NCT02787603|EXPERIMENTAL|group A|Interruption of antibiotic treatment due to PCT measurement
62347604|NCT02787603|NO_INTERVENTION|group B|Antibiotic therapy period will be determined by the physician without the knowledge of PCT levels.
62347605|NCT00792038||1|OCD patients
62347606|NCT00792038||2|Normal Controls
62347607|NCT02705118|EXPERIMENTAL|Automatic registration arm|"Automatic registration for fusion imaging of US and MRI will be performed.~Automatic Imaging fusion of ultrasonography and MRI"
62347608|NCT02705118|ACTIVE_COMPARATOR|Manual registration arm|"Manual registration for fusion imaging of US and MRI will be performed.~Manual Imaging fusion of ultrasonography and MRI"
61960881|NCT03315624|OTHER|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
61960882|NCT01858298|EXPERIMENTAL|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
61960883|NCT01858298|EXPERIMENTAL|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
61960884|NCT01646723|EXPERIMENTAL|VALID Intervention|Volunteers Adding Life in Dementia (VALID) Program
61960885|NCT03323710|EXPERIMENTAL|Propranolol plus Sunitinib|
61960886|NCT02957305|ACTIVE_COMPARATOR|Misoprostol 400 µg|Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
61960887|NCT02957305|EXPERIMENTAL|Misoprostol 200 µg|Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.
61960888|NCT06218693|EXPERIMENTAL|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
61960889|NCT06218693|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness within the catchment area of the study. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
62704236|NCT06203600|EXPERIMENTAL|Arm 1 (nivolumab, ramucirumab, paclitaxel)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle, and paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI throughout the study. Patients may also optionally undergo blood sample collection on study.
61960890|NCT05403281|EXPERIMENTAL|Sequence A|Period 1: Dapagliflozin and Sitagliptin / Period 2: DW6012
61960891|NCT05403281|EXPERIMENTAL|Sequence B|Period 1: DW6012/ Period 2: Dapagliflozin and Sitagliptin
61960892|NCT00804544|EXPERIMENTAL|1|Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.
61960893|NCT01980394|OTHER|prospective cohort study|
61960894|NCT05686811|ACTIVE_COMPARATOR|Myofascial release therapy|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
61960895|NCT05686811|EXPERIMENTAL|post isometric relaxation technique|This group will receive routine physical therapy with post isometric relaxation technique.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
61960896|NCT02430311|EXPERIMENTAL|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
61960897|NCT02430311|EXPERIMENTAL|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
62347609|NCT01125878|ACTIVE_COMPARATOR|Starch Composite B|fiber mixture
62704237|NCT06203600|ACTIVE_COMPARATOR|Arm 2 (ramucirumab, paclitaxel)|Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle and paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI throughout the study. Patients may also optionally undergo blood sample collection on study.
61960898|NCT04105101|EXPERIMENTAL|Prototype exoskeleon|The experimental trial will be performed with the prototype exoskeleton
61960899|NCT04105101|EXPERIMENTAL|Skel-Ex|The experimental protocol will be performed with the commercially available Skel-Ex 360 (Skel-Ex, Rotterdam, The Netherlands)
61960900|NCT04105101|EXPERIMENTAL|No exoskeleton|The experimental protocol will be performed without exoskeleton.
61960901|NCT00027898|EXPERIMENTAL|Treatment (bortezomib, carboplatin, and etoposide)|Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
61960902|NCT05862480|ACTIVE_COMPARATOR|Hypochlorous Acid Group (HClO)|Patients received one nasal spray in each nasal nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
61960903|NCT05862480|PLACEBO_COMPARATOR|Placebo Group|Patients received one nasal spray in each nasal nostril/3 hours and two oral sprays/3 hours by a Placebo for 5 days .
62143634|NCT06509529|EXPERIMENTAL|Experimental group|Motivational interviews based on the COM-B Model will be given to the women in the experimental group.
62143635|NCT06509529|NO_INTERVENTION|control group|They will receive routine cancer screening information provided by the institution.
62143636|NCT05305391|EXPERIMENTAL|A2 milk + placebo|A2 whole milk, 3.5% fat, heat-treated; placebo capsule without enzyme
62143637|NCT05305391|EXPERIMENTAL|A2 milk+ lactase enzyme|A2 whole milk, 3.5% fat, heat-treated; lactase capsule
62143638|NCT05305391|EXPERIMENTAL|Protein-hydrolyzed A1 milk + placebo|Protein-hydrolyzed lactose-free milk, 3% fat, heat-treated; placebo capsule without enzyme
62143639|NCT04934033|OTHER|Healthy volunteers|The participants will constitue a cohort of healthy volunteers, they will have a MRI, and language and cognitive assessment.
62347610|NCT01125878|ACTIVE_COMPARATOR|Starch Composite C|fiber mixture
62347611|NCT01125878|ACTIVE_COMPARATOR|Starch Composite D|fiber mixture
62347612|NCT01125878|PLACEBO_COMPARATOR|Placebo|Placebo
62347613|NCT00672360|EXPERIMENTAL|1|
62505647|NCT05529368|NO_INTERVENTION|control group|Participants in the control group received no intervention and keep their eating and living habits.
62505648|NCT02483936|EXPERIMENTAL|Test 1: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.
62704238|NCT05189925|EXPERIMENTAL|IV infusion of gp91-Grans at dose K: 1e6 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K, and safety of dose will be determined.
62704239|NCT05189925|EXPERIMENTAL|IV infusion of gp91-Grans at dose K+1:1e7 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+1, and safety of dose will be determined.
62347614|NCT00672360|PLACEBO_COMPARATOR|2|
62347615|NCT00369395|EXPERIMENTAL|Volociximab|Volociximab 15 mg/kg
62347616|NCT00862654|EXPERIMENTAL|C propionate 4/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
62704240|NCT05189925|EXPERIMENTAL|IV infusion of gp91-Grans at dose K+2: 1-5e8 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+2, and safety of dose will be determined.
62347617|NCT00862654|EXPERIMENTAL|C propionate 2/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
62347618|NCT00862654|EXPERIMENTAL|C propionate 2/week|Clobetasol propionate shampoo 0.05% (2/week)
62347619|NCT00862654|ACTIVE_COMPARATOR|Ketoconazole 2/week|Ketoconazole shampoo 2% (2/week)
62347620|NCT06007404||Normal weight|BMI ≥ 5th percentile \& \< 85th percentile
62347621|NCT06007404||Obese weight|BMI ≥ 95th percentile
62347622|NCT06007404||PreDiabetes|HbA1c \> 5.7%
62347623|NCT06007404||Type 2 Diabetes|Diagnosed with Type 2 Diabetes
62347624|NCT01606293||Carcinomas of the Cervix Survey|Women with small and large cell carcinomas of the cervix, who are members of the Facebook group found at the uniform resource locator https://www.facebook.com/SmallCellCC through an online link.
62505649|NCT02483936|EXPERIMENTAL|Test 2: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.
62505650|NCT02483936|ACTIVE_COMPARATOR|Comparator 1: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
62505651|NCT02483936|ACTIVE_COMPARATOR|Comparator 2: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.
62505652|NCT05524428|OTHER|Introduction of Implementation Strategies|The investigators will determine the best intervention and strategy (and thus implementers) based on high ranking barriers/facilitators identified in focus groups. A minimum of 2 implementation strategies will be developed and implemented at each level (patient, provider, system) at each site that considers (1) implementation strategy; (2) mechanism in which the strategy impacts the identified determinant (3) the determinant; (4) moderators that may influence the impact of the strategy; (5) the preconditions necessary for successful implementation; and (6) implementation outcomes affected. Each community health center (CHC) will serve as its own separate subject, and individual strategies will be tested using single case experimental design (SCED) at each CHC using component analysis to rapidly test and optimize our strategies. In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.
62505653|NCT05524428|NO_INTERVENTION|Withdrawal of Implementation Strategies|In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.
62714960|NCT06581575|EXPERIMENTAL|Investigational Product|Participants randomized to this arm will be given the investigational product (JCXH-105).
62347625|NCT04468334|EXPERIMENTAL|LARIAT + PVI Treatment Group|"Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation~Subgroup 1: Radiofrequency (RF) PVI catheter ablation treatment (n\<65) Subgroup 2: Cryoballoon PVI catheter ablation treatment (n\<20)"
62347626|NCT00511953|ACTIVE_COMPARATOR|Gabapentin ER|Active drug, Gabapentin extended release
62505654|NCT03187587|EXPERIMENTAL|imILT treatment|Immunostimulating Interstitial Laser Thermotherapy (imILT)
62505655|NCT03187587|ACTIVE_COMPARATOR|Standard chemotherapy treatment|This study arm recieves chemotherapy treatment as standard care at the clinical study site.
62714961|NCT06581575|ACTIVE_COMPARATOR|Active Control|Participants randomized to this arm will be given the FDA approved Shingrix.
62347627|NCT00511953|PLACEBO_COMPARATOR|Sugar Pill|Comparator arm is Placebo
62347628|NCT01409993|EXPERIMENTAL|sildenafil Aim 1|sildenafil 25 mg p.o. tid
62347629|NCT01409993|PLACEBO_COMPARATOR|placebo Aim 1|matching placebo p.o. tid
62347630|NCT01409993|EXPERIMENTAL|sildenafil Aim 2|sildenafil 25 mg p.o. tid
62347631|NCT01409993|PLACEBO_COMPARATOR|placebo Aim 2|matching placebo p.o. tid
62347632|NCT02188719|EXPERIMENTAL|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
62347633|NCT02188719|EXPERIMENTAL|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
62347634|NCT02188719|EXPERIMENTAL|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
62347635|NCT02188719|EXPERIMENTAL|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
62347636|NCT03823092||Normal|phakic participants with no evidence of eye disorders
62347637|NCT03823092||Cataract|participants with cataract
61960904|NCT05055362|EXPERIMENTAL|Honey Spice Group|The dietary intervention will be a 10-day feasibility trial, using a honey, spice infused baked good. The participants will receive the baked good on day 1 and will be asked to consume a 50-gram baked good daily for 10 days with or without their meals. The honey, spice infused baked good will contain 15g honey and 3g of spice blend (turmeric and cinnamon). A saliva sample will be taken at the start of the intervention (day 1) before consumption of the baked good and after the intervention ends (day 10), 2 hours after consuming the final baked good. Additionally, participants will provide a urine sample to determine microalbuminuria level, complete a spice-consumption survey and a semi-quantitative food frequency questionnaire (day 1). At day 10, participants will indicate if their spice consumption and dietary intake has changed over the past 10 days. Each day, they will tick off the amount of baked good consumed (100%, 75%, 50%, 25%, 0%).
62704241|NCT06709534|EXPERIMENTAL|Supportive Care (individualized online home-based exercise)|Participants meet with a certified exercise trainer and complete a functional capacity assessment using a treadmill or 6-minute walk test. Participants then complete an individualized online home-based exercise intervention via Zoom consisting of progressive, moderate-intensity walking corresponding to the RPE scale and receive social support over 30 minutes BIW for 12 weeks.
62704242|NCT05642468|EXPERIMENTAL|10 mg (Arm 1)|10mg tablet A3907 administered orally once daily for 12 weeks.
62143640|NCT03857321|EXPERIMENTAL|Insulin first, then placebo|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive placebo at visit 3 during second intervention period.
62143641|NCT03857321|EXPERIMENTAL|Placebo first, then insulin|Participants will be randomly assigned to receive placebo administered with an intranasal nebulizer-like device. At visit 3 during second intervention period, participants in this arm will receive insulin.
62347638|NCT03823092||AMD|participants with age related macular degeneration
62347639|NCT03823092||Pseudophakic|particpiants who have had cataract surgery with intraocular lens implant
62347640|NCT03823092||other macula|participants with macular ddisorders other than AMD
62347641|NCT03823092||DR|participants with diabetic retinopathy
62347642|NCT02186262||Primary gliomas, Recurrent gliomas|
62347643|NCT03328624|EXPERIMENTAL|DVT Cuff users|Current or previous DVT cuff users
62347644|NCT03971500|EXPERIMENTAL|IVUS-guidance|In the IVUS-guided DES implantation group, optimal stent deployment criteria included: 1) the MLA in the stented segment is \>5.0 mm\^2, or 90% of the MLA at the distal reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is \<55%; and 3) absence of \>=Type B edge dissection. Further treatment will be required if any of those 3 criteria was not met.
62347645|NCT03971500|ACTIVE_COMPARATOR|Angiography-guidance|In the Angiography-guided DES implantation group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at \>18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis \<20%, and the absence of \>Type B dissection.
62347646|NCT03971500|EXPERIMENTAL|SAPT group|Ticagrelor + aspirin for 1 month followed by ticagrelor plus matching placebo for an additional 11 months.
62347647|NCT03971500|ACTIVE_COMPARATOR|DAPT group|Ticagrelor + aspirin for 12 month.
62347648|NCT06161155|ACTIVE_COMPARATOR|Whey protein then bovine plasma protein|During the first dietary intervention, the diet is supplemented with whey protein isolate. During the second dietary intervention, the diet is supplemented with bovine plasma protein.
62347649|NCT06161155|ACTIVE_COMPARATOR|Bovine plasma protein then whey protein|During the first dietary intervention, the diet is supplemented with bovine plasma protein. During the second dietary intervention, the diet is supplemented with whey protein isolate.
62347650|NCT00625898|ACTIVE_COMPARATOR|1A: TCH-H|Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)
62347651|NCT00625898|EXPERIMENTAL|1B: TCHB-HB|Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)
62347652|NCT00625898|ACTIVE_COMPARATOR|2A: TH-FEC-H|Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)
62347653|NCT00625898|EXPERIMENTAL|2B: THB-FEC-HB|Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)
62347654|NCT01031485|ACTIVE_COMPARATOR|Spread with milk peptides and plant sterols|
62347655|NCT01031485|PLACEBO_COMPARATOR|Standard spread|
62347656|NCT04794556|EXPERIMENTAL|Group A|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
62347657|NCT04794556|EXPERIMENTAL|Group B|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
62347658|NCT04794556|EXPERIMENTAL|Group C|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
62505656|NCT03077009|EXPERIMENTAL|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
62505657|NCT02844010||patients with pneumonia|
62704243|NCT05642468|EXPERIMENTAL|30 mg (Arm 2)|30mg (3x10 mg tablets) A3907 administered orally once daily for 12 weeks.
62347659|NCT05603507|EXPERIMENTAL|inspiratory muscle training group|received both inspiratory muscle training and pulmonary rehabilitation
62704244|NCT05642468|EXPERIMENTAL|30 mg BID (Arm 3)|30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.
62704245|NCT05642468|EXPERIMENTAL|30 mg BID for CRS (Arm 4)|30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.
62704246|NCT06427798|EXPERIMENTAL|1/Dosimetry Arm 1|Escalating doses of \[212Pb\]VMT-alpha-NET, imaging with \[203Pb\]VMT-alpha-NET.
62704247|NCT06427798|EXPERIMENTAL|2/Arm 2|Escalating doses of \[212Pb\]VMT-alpha-NET.
62704248|NCT06427798|EXPERIMENTAL|3/Arm 3|\[212Pb\]VMT-alpha-NET at MTD.
62704249|NCT04439266|EXPERIMENTAL|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
62704250|NCT03895645||Study Participants|Participants on the studies' samples that are transferred to this protocol
62704251|NCT05730335|EXPERIMENTAL|Rapid Acoustic Pulse (RAP)|Participants will receive 2 separate RAP cellulite treatments sessions.
61960905|NCT03440268|EXPERIMENTAL|N Acetyl Cysteine|NAC in pre operatory 150mg/kg infusion in 2 hours. NAC during the surgery 50mg/kg in 6 hours. The influence of NAC will be assess in post operatory moment with routine exams
61960906|NCT03440268|PLACEBO_COMPARATOR|Placebos|Saline solution in pre operatory. Saline Solution duing the surgery. The post operatory datas of both groups will be compare
61960907|NCT06169696|OTHER|Patient Group / Arm|Use of non-invasive EEG headband device
61960908|NCT01651377|PLACEBO_COMPARATOR|Placebo|
61960909|NCT01651377|ACTIVE_COMPARATOR|Pramipexole|
61960910|NCT04281810|EXPERIMENTAL|TEDS|Subjects received transcutaneous electrical diaphragm stimulation (TEDS) for 30min/ day till the end of the weaning trial
61960911|NCT04281810|NO_INTERVENTION|Control|Subjects received similar medical treatment except for the TEDS program.
62505658|NCT00377572|EXPERIMENTAL|Omalizumab (Xolair) + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
61960912|NCT01594281|EXPERIMENTAL|Ranibizumab mono|Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
61960913|NCT01594281|ACTIVE_COMPARATOR|PRP mono|Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
61960914|NCT01594281|EXPERIMENTAL|Ranibizumab+PRP|Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed
61960915|NCT02973217|EXPERIMENTAL|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
61960916|NCT01294631|EXPERIMENTAL|001|"Canagliflozin 300 mg once daily and HCTZ 25 mg once daily Period 1: canagliflozin tablets oral 300 mg once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets oral 25 mg once daily for Days 1 to 28 followed by canagliflozin tablets oral 300 mg once daily taken with HCTZ tablets oral 25 mg once daily on Days 29 to 35.."
61960917|NCT04922775|OTHER|conventional taping-Chinese medicine technique taping|Participants will accept conventional taping before muscle fatigue exercise for the first course then accept Chinese medicine technique taping before muscle fatigue exercise for the second course.
62704252|NCT03150693|ACTIVE_COMPARATOR|Arm I (frontline chemotherapy)|See detailed description.
62704253|NCT03150693|EXPERIMENTAL|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
62704254|NCT03002207|EXPERIMENTAL|The defect is repaired and sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured.
62704255|NCT03002207|EXPERIMENTAL|The defect is repaired but not sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy.
61960918|NCT04922775|OTHER|Chinese medicine technique taping-conventional taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise for the first course then accept conventional technique taping before muscle fatigue exercise for the second course.
61960919|NCT03521934|EXPERIMENTAL|Sotagliflozin|Sotagliflozin 200 mg tablet once daily, with possible up-titration in the first 8 months to 400 mg, for up to 21.2 months.
61960920|NCT03521934|PLACEBO_COMPARATOR|Placebo|Matching placebo to sotagliflozin 200 mg once daily, with possible up-titration in the first 8 months to matching placebo to sotagliflozin 400 mg, for up to 21.6 months.
61960921|NCT05249374|ACTIVE_COMPARATOR|Control group|10 g/ bottle (20%, 50 mL)
61960922|NCT05249374|EXPERIMENTAL|test group|10 g/bottle (20%, 50 mL)
61960923|NCT05018130|EXPERIMENTAL|Bio-integrative|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm bio-integrative cannulated screws.
61960924|NCT05018130|ACTIVE_COMPARATOR|Metallic|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm metallic cannulated screws.
61960925|NCT00720538|EXPERIMENTAL|1|Thalidomide
61960926|NCT00720538|PLACEBO_COMPARATOR|2|Placebo
61960927|NCT01889004|EXPERIMENTAL|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion
61960928|NCT01889004|EXPERIMENTAL|Propofol|Intravenous propofol using target controlled infusion
61960929|NCT05388409||CASE|Kidney transplanted patients with PSVD
61960930|NCT05388409||Control 1|Kidney transplanted patients without PSVD
61960931|NCT05388409||Control 2|patient with PVSD without transplantation
61960932|NCT00003594|EXPERIMENTAL|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
62143642|NCT02193932|EXPERIMENTAL|EEG Triggered fMRI using Micro Maglink|EEG Triggered fMRI to be performed using the Micro Maglink
61960933|NCT00003594|EXPERIMENTAL|oxaliplatin + leucovorin + fluorouracil|"Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
61960934|NCT00003594|EXPERIMENTAL|oxaliplatin + irinotecan|"Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
61960935|NCT05988099|EXPERIMENTAL|Complex product (chokeberry extract, L-arginine, vitamin E, vitamin A, folic acid, chromium)|Single oral dose - 2 capsules
61960936|NCT05988099|ACTIVE_COMPARATOR|Chokeberry extract in liposomal formulation|Single oral dose - 2 capsules
61960937|NCT05988099|ACTIVE_COMPARATOR|Chokeberry extract in traditional formulation|Single oral dose - 2 capsules
62704256|NCT03002207|EXPERIMENTAL|The defect is sutured but not repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
62704257|NCT03002207|NO_INTERVENTION|The defect is neither sutured nor repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
61960938|NCT05988099|PLACEBO_COMPARATOR|Placebo|Single oral dose - 2 capsules
61960939|NCT02859454|EXPERIMENTAL|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
61960940|NCT05095545|EXPERIMENTAL|Group 1|"AV5080 80 mg/day (80 mg in the morning + placebo in the evening)"
61960941|NCT05095545|EXPERIMENTAL|Group 2|"AV5080 160 mg/day (80 mg in the morning + 80 mg in the evening)"
62143643|NCT05461755|EXPERIMENTAL|Combination therapy: Fractional radiofrequency and topical tretinoin|3 study treatments: at baseline, 1-month, 2-month with subsequent application of topical tretinoin. Home application of tretinoin between study visits
62143644|NCT05461755|ACTIVE_COMPARATOR|Fractional radiofrequency|3 study treatments: at baseline, 1-month, 2-month
62143645|NCT05461755|ACTIVE_COMPARATOR|Topical tretinoin|Application at study visits and home application between study visits
62143646|NCT05461755|NO_INTERVENTION|Untreated control|No study treatments
62143647|NCT05689606|EXPERIMENTAL|Exercise group|The exercise group performs acute high-intensity interval training.
62143648|NCT05689606|NO_INTERVENTION|Control group|The Control group includes the same participants. In this session, they do not exercise, and they watch a nature documentary.
62143649|NCT01798498|EXPERIMENTAL|Princess® VOLUME|"Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.~A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.~The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds"
62143650|NCT00968903|ACTIVE_COMPARATOR|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
62347660|NCT05603507|SHAM_COMPARATOR|pulmonary rehabilitation group|received only pulmonary rehabilitation and sham inspiratory muscle training
62143651|NCT00968903|PLACEBO_COMPARATOR|Saline|Saline iv pre-operatively in equivalent volume (placebo)
62143652|NCT03258398|EXPERIMENTAL|Part 1: eFT508 plus avelumab dose finding Arm|subjects will receive eFT508 in combination with a fixed dose of avelumab
62143653|NCT03258398|EXPERIMENTAL|Part 2: eFT508 plus avelumab|subjects will receive eFT508 in combination with a fixed dose of avelumab
62347661|NCT00426556|EXPERIMENTAL|Phase I - RAD001 5mg + PT, daily|Daily dosing schedule of EPT = Paclitaxel \& Trastuzumab verolimus 5mg plus Paclitaxel plus Trastuzumab.
61960942|NCT05095545|PLACEBO_COMPARATOR|Group 3|"Placebo (placebo in the morning + placebo in the evening)"
61960943|NCT01832649|EXPERIMENTAL|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
61960944|NCT01832649|ACTIVE_COMPARATOR|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
61960945|NCT01810874|ACTIVE_COMPARATOR|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
61960946|NCT01810874|EXPERIMENTAL|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
61960947|NCT04668625|EXPERIMENTAL|Experimental group|Participate in a massive musical event
61960948|NCT04668625|NO_INTERVENTION|Control Group|Not participate in a massive musical event
61960949|NCT01650844|EXPERIMENTAL|School-based Telemedicine Enhanced Asthma Mangement Group|We will use a web-based system to assess asthma severity or control and will send a symptom report to the child's primary care physician (PCP). Children randomized to the SB-TEAM group, will receive a telemedicine visit in the school health office at the start of the school year to provide an initial asthma assessment. The telemedicine provider will deliver brief asthma education and referrals to community resources, and will send a guideline-based preventive medication prescription electronically to a local pharmacy. The pharmacy will deliver the medications to home and school, and the school nurse will administer the medication as directly observed therapy throughout the school year. Follow-up telemedicine assessments will occur twice during the study period. These follow-up visits will focus on assessment of control, assessment of ongoing triggers or co-morbid conditions, and brief asthma education.
62143654|NCT03258398|EXPERIMENTAL|Part 2: eFT508 alone|subjects will receive eFT508 alone
62143655|NCT06698796|EXPERIMENTAL|Dazukibart|Participants will receive dazukibart via intravenous infusion every 4 weeks.
62347662|NCT00426556|EXPERIMENTAL|Phase I - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel \& Trastuzumab
62505659|NCT00377572|PLACEBO_COMPARATOR|Placebo + Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
61960950|NCT01650844|ACTIVE_COMPARATOR|Enhanced Usual Care Group|Children randomized to the enhanced usual care group will receive a symptom assessment using national care guidelines, a recommendation for appropriate preventive medications, and asthma education materials. We will use the web-based system to send a symptom report to the child's PCP with guideline-based recommendations for preventive care. We will provide systematic feedback to the family and providers at the same intervals as in the SB-TEAM group's telemedicine visits, by prompting providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the PCP.
62143656|NCT06402552|EXPERIMENTAL|prostate cancer|Patients who are suspicious of prostate cancers with abnormal digital examination, or abnormal ultrasound and having a pre-MRI and were scheduled to receive prostate biopsy will be enrolled in this study. Patients will be randomized in a 1:1 manner to bp-MRI and mp-MRI. Patients with clinical suspicion of prostate cancer on MRI with PI-RADS (Prostate Imaging-Reporting and Data System, version 2.1)
62505660|NCT02389699|EXPERIMENTAL|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
62505661|NCT02389699|ACTIVE_COMPARATOR|whole breast radiation|WRT:whole breast radiation after BCS with 46-50 Gy
62505662|NCT00047047|EXPERIMENTAL|Treatment (tanespimycin, gemcitabine hydrochloride, cisplatin)|"Cohort A (closed to accrual as of 3/2/04)\*: Patients receive escalating doses of gemcitabine hydrochloride intravenously (IV) over 30 minutes, tanespimycin IV over 1 hour, and cisplatin IV over 2 hours on days 1 and 8. NOTE: \*The maximum tolerated dose (MTD) of this 3-drug combination has been determined as of 3/2/04.~Cohort B (closed to accrual as of 3/2/05): Patients receive gemcitabine hydrochloride\*\* IV over 30 minutes, tanespimycin IV over 1 hour, and cisplatin\*\* IV over 2 hours on days 1 and 8.~Cohort C: Patients receive gemcitabine hydrochloride\*\* IV over 30 minutes and tanespimycin IV over 1-2 hours on days 2 and 9.~Cohort D: Patients receive cisplatin\*\* IV over 2 hours and tanespimycin IV over 1-2 hours on days 1 and 8.~Cohort E: Patients receive gemcitabine hydrochloride\*\*\*, tanespimycin\*\*\*, and cisplatin\*\*\* as in cohort B.~Continued (see detailed description)"
62505663|NCT05568316|EXPERIMENTAL|Experimental: Preoperative Immunonutrition (Group 1)|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for only 5 days before surgery, in addition to their standard isocaloric diet.~Duration: 5 days (preoperative) Dietary therapy: Standard oral nutrition and IMN product for 5 days before operation.~The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded."
62505664|NCT05568316|EXPERIMENTAL|Experimental: Perioperative Immunonutrition (Group 2)|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~Duration: 5 days preoperative and 5 days postoperative Dietary therapy: Standard oral nutrition and IMN product for 5 days before and after operation (perioperative).~The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded."
62505665|NCT05183711||Nurse anesthetist|In this study, the investigator team designs to use self-evaluating form as a tool for any competencies evaluation. The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. The participant could download the self-evaluating form (google form, no personal identity record) via QR code.
62505666|NCT01327417||Depressed|Patients with Major Depressive Disorder
62505667|NCT01327417||Healthy Controls|
62505668|NCT02305173|ACTIVE_COMPARATOR|dexamethasone group|patients receive one single dose of intravenous dexamethasone 8 mg.
62505669|NCT02305173|PLACEBO_COMPARATOR|placebo group|patients receive one single dose of intravenous placebo.
62505670|NCT05739734|EXPERIMENTAL|CRIS100 treatment|Administration of a single dose of CRIS100
62505671|NCT01829815|EXPERIMENTAL|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
62505672|NCT01829815|OTHER|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
62505673|NCT05085782|EXPERIMENTAL|Propranolol|"1. Pain neuroscience education (10 short videos - 2 to 4 mins each)~2. 6 weekly sessions of Reconsolidation therapy with propranolol. At the beginning of each session, participants will take 2 to 4 capsules of 20 mg propranolol (dose calculated based on sex and height). One hour after ingestion of the propranolol, participants will undergo a reactivation procedure, wherein they will be asked to describe/visualize painful movements/activities."
61960951|NCT01161862|EXPERIMENTAL|Bi-hormonal with meal-priming bolus|The first meal-priming bolus was solely based on weight (0.05 U/kg), after which meal-priming boluses were automatically adapted by the control system online targeting 75% of the anticipated insulin needed in the first four hours after the start of the meal
61960952|NCT01161862|EXPERIMENTAL|Bi-hormonal without meal-priming bolus|The insulin controller was entirely reactive to CGMG; there were no meal priming boluses and no meal announcements
61960953|NCT00496808|EXPERIMENTAL|Herceptin|8 mg/kg intravenously (IV) Over 90 Minutes
61960954|NCT02211937|ACTIVE_COMPARATOR|Treatment A|BI 44847 suspension high dose, fasted
61960955|NCT02211937|EXPERIMENTAL|Treatment B|BI 44847 tablet high dose, fasted
61960956|NCT02211937|EXPERIMENTAL|Treatment C|BI 44847 tablet high dose, fed
61960957|NCT02211937|ACTIVE_COMPARATOR|Treatment D|BI 44847 solution low dose, fasted
61960958|NCT02211937|EXPERIMENTAL|Treatment E|BI 44847 tablet low dose, fasted
62143657|NCT00862030||1|Study Cohort
62143658|NCT02298998||Intervention|The intervention group refers to surveillance based on the EAU guidelines.
62143659|NCT02298998||Control|The control group refers to surveillance based on the AUA guidelines.
62505674|NCT05085782|PLACEBO_COMPARATOR|Placebo|"1. Pain neuroscience education (10 short videos - 2 to 4 mins each)~2. 6 weekly sessions of Reconsolidation therapy with a placebo. At the beginning of each session, participants will take 2 to 4 capsules of 20 mg placebo (dose calculated based on sex and height). One hour after ingestion of the placebo, participants will undergo a reactivation procedure, wherein they will be asked to describe/visualize painful movements/activities."
62505675|NCT02595827|NO_INTERVENTION|Universal|In this group, caretakers of children will receive the standard advice under current iCCM guidelines in DRC. Specifically, the CHW will advise that the child come back in 2-3 days.
62505676|NCT02595827|ACTIVE_COMPARATOR|Conditional|In this Conditional Advice group, caretakers will be given advice that is modified from the current iCCM guidelines. Specifically, the CHW will advise that the child come back in 2-3 days if the child's symptoms continue.
62505677|NCT03304340|EXPERIMENTAL|TENS+SR|For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device \& Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
62505678|NCT03304340|EXPERIMENTAL|FES + SR|For each participant in the functional electrical stimulation (FES) group, standard rehabilitation (SR) in addition two dual-channel FES stimulators (MEDTRONIC Respond Select; EmpiInc) were used. The FES was delivered with 0.3-ms pulses at 30 pps and the stimulation intensity was set to the movement threshold to induce visible muscle contractions. For the FES group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
62505679|NCT03304340|ACTIVE_COMPARATOR|SR-only|All the participants received functional training and motor relearning physiotherapy treatment as early standard rehabilitation (SR) for 30 minutes per day, 5 days a week throughout the study. Subjects in the SR group received only SR .
62505680|NCT04948671||not bone looser|patients affected by primary hyperparathyroidism not bone looser
62505681|NCT04948671||bone looser|patients affected by primary hyperparathyroidism bone looser
61960959|NCT04674930|NO_INTERVENTION|Control group|Pharmacological management
62704258|NCT03641092|EXPERIMENTAL|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
61960960|NCT04674930|EXPERIMENTAL|Exercise group|"Aerobic training: The target training zone was set at 40-60% of the peak heart rate, as determined in the baseline 6min walk test (6MWT), with a rating of 11-13 on the Borg rating of perceived Exertion scale.~Resistance Training: This training was prescribed at 70% of one repetition maximum (RM). Patients were instructed to train a variety of upper and lower body muscle groups (e.g., latissimus, deltoid, biceps, quadriceps, and gastrocnemius muscles), using Thera-band"
62704259|NCT03641092|ACTIVE_COMPARATOR|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
62704260|NCT05689021|EXPERIMENTAL|Treatment (CJNJ-67652000 and prednisone)|Patients receive CJNJ-67652000 PO and prednisone PO on study. Patients also undergo blood specimen collection, CT or MRI, and bone scan throughout the trial.
61960961|NCT01756898|EXPERIMENTAL|Low dose ASB17061|Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
61960962|NCT01756898|EXPERIMENTAL|Middle dose ASB17061|Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
62505682|NCT01477424|EXPERIMENTAL|PA21 and Warfarin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day
62704261|NCT05710406|EXPERIMENTAL|Arm I (encorafenib, cetuximab)|Patients receive encorafenib PO and cetuximab IV on study. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.
62704262|NCT05710406|ACTIVE_COMPARATOR|Arm II (patient observation)|Patients undergo observation per usual care on study. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.
62704263|NCT06748638|EXPERIMENTAL|Lactulose group ( group 1)|lactulose oral solution, Duphalac, 15ml/ bag, 6 bags/box
62704264|NCT06748638|EXPERIMENTAL|Lactulose + linaclotide group（group 2）|Lactulose+ linaclotide 290μg (linaclotide capsule, Lingzeshu, 290ug/ capsule, 7 capsules/box) :
61960963|NCT01756898|EXPERIMENTAL|High dose ASB17061|Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
62143660|NCT04668729|NO_INTERVENTION|Control group|20 people will be included in the control group. 3 measurements will be taken one week apart in total. Measurements will consist of maximum isometric muscle strength, lumbar range of motion, balance performance, and pain intensity. And it will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD) and Modified Schober test, flamingo balance test, and visual analog scale.
62347663|NCT00426556|EXPERIMENTAL|Phase I - RAD001 30mg + PT, weekly|Weekly dosing schedule of Everolimus 30mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel \& Trastuzumab.
62704265|NCT06748638|EXPERIMENTAL|3L PEG group（group 3）|Polyethylene Glycol （PEG）：Heshuang, 137.15g/ bag ，
61960964|NCT01756898|PLACEBO_COMPARATOR|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
61960965|NCT04774315|EXPERIMENTAL|Omalizumab|
61960966|NCT01880229||non-frail|Categorized as non-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
61960967|NCT01880229||pre-frail|Categorized as pre-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
62347664|NCT00426556|EXPERIMENTAL|Phase II - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel \& Trastuzumab
62347665|NCT03699449|EXPERIMENTAL|olaparib + cediranib|olaparib+cediranib combination therapy
62347666|NCT03699449|EXPERIMENTAL|durvalumab + olaparib|durvalumab + olaparib combination therapy
62347667|NCT03699449|EXPERIMENTAL|durvalumab + chemotherapy|durvalumab +chemotherapy
61960968|NCT01880229||frial|Categorized as frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
62505683|NCT01477424|EXPERIMENTAL|No PA21; Warfarin with food|The maximum dosage of Warfarin will be 10 mg/day
62505684|NCT01477424|EXPERIMENTAL|PA21 with food and Warfarin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day
62505685|NCT03398590|EXPERIMENTAL|mHealth Intervention for Older Adults|"Pilot study to test the feasibility and acceptability of a self-regulation theory-based mHealth behavior intervention for overweight or obese older adults with T2DM.~This is a one Group Pretest-Posttest Designed study. Ten participants will be recruited from Joslin Diabetes Center, Boston, MA. They will receive a 2-month, self-regulation theory-based weight loss intervention (five 60-minute, biweekly group sessions) and will be provided with a technology toolkit for self-monitoring including an (1) iPhone Plus, (2) the Lose It! app for self-monitoring of dietary intake, (3) Fitbit for self-monitoring of physical activity, (4) Bluetooth-enabled scale for daily weight, and (5) Bluetooth-enabled blood glucose monitor for testing blood glucose levels."
62539202|NCT01808820|EXPERIMENTAL|Safety Pilot: DC Vaccine/Lysate|Participants in this group will undergo leukapheresis after standard of care surgical tumor resection. Leukapheresis will be used to obtain peripheral blood mononuclear cells (PBMC) from which the dendritic cells (DC) will be obtained. Retrieved DC will be used as a vaccine once weekly on Weeks 1-4 within 3 weeks from end of leukapheresis. Participants will also receive Imiquimod, which will be applied one evening prior to DC dose for 8 hours then for 8 hours each of the next two evenings. Enrollment of participants in the Pilot group will be staggered until the second participant has no treatment limiting toxicities. For the first five subjects to be enrolled in the pilot, the administration of DC to each subject will be delayed until the prior subject has received the second administration of DC. Participants will also receive Lysate of tumor administered every 4 weeks + 3 days on Weeks 8, 12, 16 and 28 (+ / - 3 days).
62539203|NCT01808820|EXPERIMENTAL|Expansion Cohort: DC Vaccine/Lysate|Participants in this group will undergo leukapheresis within after standard of care surgical tumor resection. Leukapheresis will be used to obtain peripheral blood mononuclear cells (PBMC) from which the dendritic cells (DC) will be obtained. Retrieved DC will be used as a vaccine once weekly on Weeks 1-4 within 3 weeks from end of pheresis. Participants will also receive Imiquimod, which will be applied one evening prior to DC dose for 8 hours then for 8 hours each of the next two evenings. Participants will also receive Lysate of tumor administered every 4 weeks + 3 days on Weeks 8, 12, 16 and 28 (+ / - 3 days).
62539204|NCT04472793||Full-Time CCHMC Employees|
62539205|NCT03190330|EXPERIMENTAL|Ibrutinib|Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
62539206|NCT00867503|EXPERIMENTAL|bendamustine|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
62539207|NCT02552303|ACTIVE_COMPARATOR|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
62704266|NCT06427967|EXPERIMENTAL|Novel Social-Emotional Learning (SEL) curriculum|Participants assigned to this arm will receive Project Dream Team, the new 5 session SEL curriculum for YWE.
62704267|NCT06518057|EXPERIMENTAL|Treatment (Proton or Photon VMAT CSI)|Patients undergo proton or photon VMAT CSI with HA over approximately 45 minutes once daily (QD) for 10 days (Monday-Friday) in the absence of unacceptable toxicity. Patients also undergo computed tomography (CT) or positron emission tomography (PET)/CT during screening, as well as additional CT for radiation planning during screening. Additionally, patients undergo magnetic resonance imaging (MRI) throughout the trial. They may also undergo lumbar puncture (LP) or alternative methods for cerebral spinal fluid (CSF) collection.
62704268|NCT03826030|SHAM_COMPARATOR|Sham tDCS + mCIMT|Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
62714962|NCT01812057|EXPERIMENTAL|Dexamethasone|Dexamethasone 8 mg IV given intraoperatively as a one-time dose.
62143661|NCT04668729|EXPERIMENTAL|Chiropractic group|20 people will be included in the experimental group. Lumbal chiropractic HVLA (High Velocity, Low amplitude: HVLA) spinal manipulation and sacroiliac joint chiropractic HVLA manipulation will be applied 3 times in total with a weekly interval. The maximum isometric muscle strength before and immediately after the application, lumbar joint range of motion, balance performance, and pain intensity will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD), and Modified Schober test, flamingo balance test, and visual analog scale.
62143662|NCT03376659|EXPERIMENTAL|Phase I - Safety|"* MVA-BN-CV301 (prime) - Day 1 and Day 29.~* FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~* Durvalumab - q2 weeks~* Capecitabine - twice a day, Monday - Friday Weekly~* Bevacizumab - q2weeks (colorectal cancer patients only)"
62143663|NCT03376659|EXPERIMENTAL|Phase II - Colorectal Cancer Arm|"* MVA-BN-CV301 (prime) - Day 1 and Day 29.~* FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~* Durvalumab - q2 weeks~* Capecitabine - twice a day, Monday - Friday Weekly~* Bevacizumab - q2weeks"
62143664|NCT03376659|EXPERIMENTAL|Phase II - Pancreatic Cancer Arm|"* MVA-BN-CV301 (prime) - Day 1 and Day 29.~* FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~* Durvalumab - q2 weeks~* Capecitabine - twice a day, Monday - Friday Weekly"
62143665|NCT03378791|EXPERIMENTAL|Group A|Iron bisglycinate (27mg of elemental iron)
62143666|NCT03378791|ACTIVE_COMPARATOR|Group B|Ferrous fumarate (115mg of elemental iron)
62143667|NCT03177707|EXPERIMENTAL|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
61960969|NCT02161731|ACTIVE_COMPARATOR|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
61960970|NCT02161731|EXPERIMENTAL|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17
61960971|NCT01337739|PLACEBO_COMPARATOR|Placebo Comparator|Continuous infusion of placebo during operative procedure
61960972|NCT01337739|ACTIVE_COMPARATOR|Active Comparator|Administration of Dexmedetomidine
62704269|NCT03826030|ACTIVE_COMPARATOR|2 mA tDCS + mCIMT|2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
61960973|NCT03792698|EXPERIMENTAL|Aidcube utilization|"Aidcube is a fully customizable, commercially available digital app-based platform to deliver home-based pulmonary rehabilitation for patients. On the patient-facing side, patients can view their daily exercise prescription, descriptions and videos demonstrating correct execution of the exercises, document completion of exercises, and message their health-care provider. On the provider-facing side, from over 150 available exercises, surveys, and activities, providers can design a fully-customized exercise prescription. Based on real-time patient feedback, the exercise prescription can be progressed (i.e., advanced and/or modified) by adding repetitions or time to specific exercises or adding new activities. The provider can also message the patient from within the Aidcube environment."
61960974|NCT01542125|EXPERIMENTAL|Liposomal Lidocaine group|Patients in this groups received 4% Liposomal Lidocaine that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing
62505686|NCT05848401|EXPERIMENTAL|Treatment Group|The treatment group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. The principal investigator will schedule two Biosound Therapy sessions per week for four weeks for all treatment group participants. The treatment sessions will not occur on consecutive days. All participants in the treatment group will listen to identical playlists. At the beginning of the BTS session, the participant will complete a session of HeartMath biofeedback. Next, the participant will receive approximately 30-40 minutes of music containing binaural beats synchronized with sound massage.The session will finish with gratitude-based video content.
62505687|NCT05848401|NO_INTERVENTION|Control Group|The control group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. Control group participants were given a complimentary Biosound Therapy session and a ten dollar gift card upon completion of their final assessments.
61960975|NCT01542125|PLACEBO_COMPARATOR|Placebo Group|This group received a placebo that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing.
61960976|NCT05559138||hemodialysis patients with omicron infection|hemodialysis patients with omicron infection
62143668|NCT03177707|OTHER|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
62347668|NCT03699449|EXPERIMENTAL|durvalumab + tremelimumab + chemotherapy|durvalumab + tremelimumab + chemotherapy
62347669|NCT03699449|EXPERIMENTAL|durvalumab + tremelimumab + paclitaxel|durvalumab + tremelimumab + paclitaxel
62347670|NCT03699449|EXPERIMENTAL|durvalumab +chemotherapy|durvalumab +chemotherapy
62347671|NCT05522894|EXPERIMENTAL|Cohort A|AK104 alone
62347672|NCT05522894|EXPERIMENTAL|Cohort B|AK104 in combination with chemotherapy
62347673|NCT03749798|EXPERIMENTAL|Intraoperative wavefront measurement|Patients will be measured with an intraoperative wavefront device during cataract surgery
62347674|NCT04584853|ACTIVE_COMPARATOR|Endocrine Therapy only|Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen
62505688|NCT04759534|EXPERIMENTAL|Treatment group 1|Received abdominal subcutaneous injection of IBI306 150 mg Q2W
62704270|NCT03826030|ACTIVE_COMPARATOR|4 mA + mCIMT|4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
62704271|NCT06066736||Patients with Ventilator-associated pneumonia|Patients having presented an episode of ventilator-associated pneumonia, undergoing invasive mechanical ventilation ≥ 48h
61960977|NCT05559138||non-hemodialysis patients with omicron infection|non-hemodialysis patients with omicron infection
61960978|NCT01523990|EXPERIMENTAL|Panel I (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
61960979|NCT01523990|PLACEBO_COMPARATOR|Panel I (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
61960980|NCT01523990|EXPERIMENTAL|Panel II (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
61960981|NCT01523990|PLACEBO_COMPARATOR|Panel II (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
61960982|NCT01523990|EXPERIMENTAL|Panel III (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
61960983|NCT01523990|PLACEBO_COMPARATOR|Panel III (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
62143669|NCT06062641|EXPERIMENTAL|SR-GDP|
62143670|NCT06477679|ACTIVE_COMPARATOR|group A|. Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily
62505689|NCT04759534|EXPERIMENTAL|Treatment group 2|Received abdominal subcutaneous injection of IBI306 150 mg Q4W
62505690|NCT04759534|PLACEBO_COMPARATOR|Placebo Group 1|Received a subcutaneous injection of placebo Q2W in the abdomen
61960984|NCT01523990|EXPERIMENTAL|Panel IV (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
61960985|NCT01523990|PLACEBO_COMPARATOR|Panel IV (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
61960986|NCT01523990|EXPERIMENTAL|Panel V (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
61960987|NCT01523990|PLACEBO_COMPARATOR|Panel V (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
61960988|NCT01523990|EXPERIMENTAL|Panel VI (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
62143671|NCT06477679|ACTIVE_COMPARATOR|group B|• Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back.
62143672|NCT00715351||A|
62143673|NCT00715351||B|
62347675|NCT04584853|EXPERIMENTAL|Endocrine Therapy with abemaciclib|"Abemaciclib administered at dose of 150mg twice daily (provided as 50mg tablets), for 2 years or until evidence of disease recurrence or other discontinuation criteria are met.~Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen"
62347676|NCT04870827||Affected Subjects|Subjects diagnosed with moderate- severe psoriasis
62347677|NCT04870827||Healthy Controls|Females and males 18 years of age or older
62347678|NCT06364631|OTHER|Arm A: ICI - ICI Combination|"Nivolumab (3 mg/kg infusion, every 3 weeks) x 4 doses + ipilimumab (1 mg/kg infusion, every 3 weeks) x 4 doses. At the end of the 4 injections carried out 21 days apart and in the absence of limiting side effects or progression justifying the cessation of the treatment according to the investigating doctor, maintenance treatment with nivolumab will be continued, at a rate of one injection every 2 weeks at a dose of 240 mg or every 4 weeks at a dose of 480 mg depending on the choice of the investigating doctor. Nivolumab will be administered for a maximum of 2 years.~Patients are required to receive all four doses of NIVO+IPI before beginning NIVO monotherapy except for ipilimumab-induced toxicity compatible with nivolumab maintenance."
62347679|NCT06364631|OTHER|Arm B: VEGFR-TKI- ICI arm (axitinib + pembrolizumab)|"Investigator's choice between:~* Axitinib (5 mg oral twice a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks).~* Cabozantinib (40 mg oral, once a day away from meals) + nivolumab infusion (480 mg flat dose every 4 weeks)~* Lenvatinib (20 mg oral, once a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks)"
62347680|NCT06364956|EXPERIMENTAL|Phase Ib clinical trial|Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
62347681|NCT06364956|EXPERIMENTAL|Phase II clinical trial|Tislelizumab, 200mg q3W, combined with RP2D dose of palbociclib was selected for phase II clinical trial.
62347682|NCT05912712|EXPERIMENTAL|Platelet-rich Plasma (PRP) Gel Treatment Group|Rectal 10ml platelet rich plasma gel enema + infliximab standard treatment at fixed time every day for seven consecutive days
62347683|NCT05912712|SHAM_COMPARATOR|Platelet Poor Plasma (PPP) Gel Treatment Group|Rectal 10ml PPP gel enema + infliximab standard treatment for 7 consecutive days
62347684|NCT05912712|ACTIVE_COMPARATOR|Mesalazine Suppository Treatment Group|Patients were given 1g mesalazine suppository and infliximab daily for 7 consecutive days
62347685|NCT04150562|EXPERIMENTAL|Arm 1- Experimental Treatment: Safety Run-in|Interleukin 15 (IL-15) by continuous intravenous (CIV) infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 4 cycles) with avelumab by intravenous (IV) infusion at a dose of 800mg on Day 8 and 22 of each cycle
62505691|NCT04759534|PLACEBO_COMPARATOR|Placebo Group 2|Received a subcutaneous injection of placebo Q4W in the abdomen
62505692|NCT04044560|EXPERIMENTAL|Blinatumomab Treatment|Eligible patients with detectable MRD will taper immunosuppressive medications, if applicable, and undergo treatment with blinatumomab. The duration of each cycle of blinatumomab treatment is 6 weeks. Adult and pediatric patients will be treated for 4 weeks followed by a 2-week treatment free period. Patients may receive up to 4 cycles total of blinatumomab therapy.
62505693|NCT06534541|ACTIVE_COMPARATOR|Food Cues|Attentional bias to Food cues experimental measurement
62505694|NCT06534541|ACTIVE_COMPARATOR|Control Cues|Attentional bias to food cues control measurement
62505695|NCT02145624|ACTIVE_COMPARATOR|Repevax|Repevax in pregnancy
62505696|NCT02145624|ACTIVE_COMPARATOR|Boostrix-IPV|Boostrix-IPV in pregnancy
62505697|NCT02145624|NO_INTERVENTION|unvaccinated|unvaccinated mothers
62505698|NCT05910528|EXPERIMENTAL|Treatment Sequence A; Drug: RO7790121 (RVT-3101) Induction dose A, Maintenance dose and OLE dose|
62505699|NCT05910528|EXPERIMENTAL|Treatment Sequence B; Drug: RO7790121 (RVT-3101) Induction dose B, Maintenance dose and OLE dose|
62347686|NCT04150562|EXPERIMENTAL|Arm 2-Experimental Treatment: Dose Expansion|Interleukin 15 (IL-15) by continuous intravenous (CIV) infusion at 4 mcg/kg/day on days 1-5 of each 28- day cycle (max 4 cycles) with avelumab by intravenous (IV) infusion at a dose of 800mg on Day 8 and 22 of each cycle
62347687|NCT04047758|EXPERIMENTAL|Palbociclib + Letrozole group|210 patients will be randomly assigned to receive treatment with palbociclib and letrozole (palbociclib + letrozole group) .
62505700|NCT03257215|ACTIVE_COMPARATOR|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
62505701|NCT03257215|ACTIVE_COMPARATOR|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
62505702|NCT03257215|PLACEBO_COMPARATOR|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
62505703|NCT01625507|EXPERIMENTAL|PANDA intervention|12 week nutritional intervention, including 6 classroom/community sessions, plus two sample collection visits.
62505704|NCT03518216|EXPERIMENTAL|ADAPT|Participants randomized to ADAPT will complete Aim to Decrease Anxiety and Pain Treatment (ADAPT), a remotely delivered tailored intervention that integrates mindfulness meditation with cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions are interactive with a trained psychological provider and the following 4 sessions are web-based. Each web-based session is followed by therapist support.
62505705|NCT03518216|NO_INTERVENTION|Waitlist Control|Participants randomized to waitlist control will receive medical treatment as usual. These participants will be given the opportunity to complete ADAPT upon completion of the post assessment.
62505706|NCT03992339|EXPERIMENTAL|ATG-010|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.
62505707|NCT03884725|ACTIVE_COMPARATOR|fibrinogen concentrate|patients randomized to fibrinogen group receive intravenous infusion of drug prepared based on ROTEM measurement of maximum clot firmness (MCF)
62505708|NCT03884725|PLACEBO_COMPARATOR|control|patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF)
62505709|NCT01951287|EXPERIMENTAL|Acute beverage (Water) consumption|Acute beverage (Water)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points.
62505710|NCT01951287|EXPERIMENTAL|Acute beverage (Black Coffee) consumption|Acute beverage (Black Coffee)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
62505711|NCT01951287|EXPERIMENTAL|Acute beverage (Orange Juice) consumption|Acute beverage (Orange Juice)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
62505712|NCT01951287|EXPERIMENTAL|Acute beverage (Whole Milk) consumption|Acute beverage (Whole Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
62505713|NCT01951287|EXPERIMENTAL|Acute beverage (2% Milk) consumption|Acute beverage (2% Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
62704272|NCT04379570|EXPERIMENTAL|Arm I (TMR)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
62704273|NCT04379570|EXPERIMENTAL|Arm II (MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
62704274|NCT04379570|EXPERIMENTAL|Arm III (TMR + MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
62704275|NCT04379570|ACTIVE_COMPARATOR|Arm IV (enhanced usual care)|Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
62704276|NCT06670287|ACTIVE_COMPARATOR|Single Sensor Sleep Tracking In-Lab|This condition will use only raw accelerometer data from a single sensor collected and processed using legacy actigraphy algorithms, comprising first of reducing accelerometer data into activity counts per epoch, which will then be categorized into sleep or wake in accordance with the Cole-Kripke algorithm.
62704277|NCT06670287|EXPERIMENTAL|Multi-Sensor Sleep Tracking In-Lab|This condition will also use raw accelerometer data collected but include raw data from additional sensors. All data will be processed with the machine learning algorithms. Signals will be time-aligned using epoch time to ensure time synchronization, and the quality and validity of the collected dataset will be ensured via visual inspection.
62347688|NCT04047758|PLACEBO_COMPARATOR|Letrozole group|210 patients will be randomly assigned to receive treatment with letrozole (letrozole group).
61960989|NCT01523990|PLACEBO_COMPARATOR|Panel VI (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
61960990|NCT01523990|EXPERIMENTAL|Panel VII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
61960991|NCT01523990|PLACEBO_COMPARATOR|Panel VII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
62347689|NCT04334915|EXPERIMENTAL|Arm A: Cenicriviroc Mesylate (CVC)|"Cenicriviroc mesylate (CVC) 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing antiretroviral (ARV) regimens.~For participants who are on an efavirenz (EFV)-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
62505714|NCT01951287|EXPERIMENTAL|Acute beverage (Skim Milk) consumption|Acute beverage (Skim Milk)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
62505715|NCT05352282|ACTIVE_COMPARATOR|Group A|
62505716|NCT05352282|ACTIVE_COMPARATOR|Group B|
62505717|NCT01185379|ACTIVE_COMPARATOR|Efalex Active 50+|
62505718|NCT01185379|ACTIVE_COMPARATOR|DHA-rich fish oil|
62505719|NCT01185379|PLACEBO_COMPARATOR|Placebo|
62505720|NCT05065437|EXPERIMENTAL|Virtual reality and spinal stimulation|Safety and feasibility of a virtual reality and spinal stimulation intervention will be tested.
62505721|NCT01767610|EXPERIMENTAL|micronized fenofibrate|
62505722|NCT01767610|EXPERIMENTAL|pitavastatin Ca|
62505723|NCT01767610|EXPERIMENTAL|micronized fenofibrate plus pitavastatin Ca|
62505724|NCT04493476|ACTIVE_COMPARATOR|Chineese Herbal formula|The study group will be given capsules containing Chinese herbal formula extract - Traditional Chinese MedicinalSubstances
61960992|NCT01523990|EXPERIMENTAL|Panel VIII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
61960993|NCT01523990|PLACEBO_COMPARATOR|Panel VIII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
61960994|NCT01523990|EXPERIMENTAL|Panel IX (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
61960995|NCT01523990|PLACEBO_COMPARATOR|Panel IX (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
61960996|NCT01523990|EXPERIMENTAL|Panel X (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
61960997|NCT01523990|PLACEBO_COMPARATOR|Panel X (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
61960998|NCT01523990|EXPERIMENTAL|Panel XI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
61960999|NCT01523990|PLACEBO_COMPARATOR|Panel XI (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
61961000|NCT01523990|EXPERIMENTAL|Panel XII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.
61961001|NCT01523990|EXPERIMENTAL|Panel XIII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.
61961002|NCT01523990|EXPERIMENTAL|Panel XIV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.
61961003|NCT01523990|EXPERIMENTAL|Panel XV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.
61961004|NCT01523990|EXPERIMENTAL|Panel XVI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.
61961005|NCT04195698|EXPERIMENTAL|Upadacitinib|Participants will be administered with upadacitinib once daily (QD)
61961006|NCT02385162||Observation|Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease
61961007|NCT04031937|ACTIVE_COMPARATOR|major depressive disorder|psychometric scales psychomotor assessment
62704278|NCT06670287|OTHER|Multi-Sensor Tracking At-Home|This condition includes 4 weeks of at-home sleep tracking using the multi-sensor approach. Daily sleep diaries will also be collected to enable data quality check. Once collected, all data will be processed with the same machine learning algorithm used in the in-lab experimental condition.
62704279|NCT06542653||CTO-PCI group|successful percutaneous coronary intervention (PCI)
61961008|NCT04031937|ACTIVE_COMPARATOR|Control|psychometric scales psychomotor assessment
61961009|NCT02575495|EXPERIMENTAL|7 days course of antibiotic treatment|To assign the 7 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
61961010|NCT02575495|ACTIVE_COMPARATOR|14 days course of antibiotic treatment|To assign the 14 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
61961011|NCT02423876|EXPERIMENTAL|Arm I (epidural placement, ERP)|Patients undergo epidural placement in the First Day Surgery pre-operative area or similar areas suitable for insertion of epidural catheters. In the post-operative anesthesia care unit, patients may receive medication via the epidural on an as needed basis, as determined by the anesthesia team. Dosing and rate of standardized medication will be managed by the anesthesia team until the epidural is removed. Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
62704280|NCT06542653||CTO-OMT group|optimal medical therapy (OMT)
62704281|NCT06676059||Adults who use substances|Adults 18 years or older who use drugs or alcohol
61961012|NCT02423876|ACTIVE_COMPARATOR|Arm II (ERP)|Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
62704282|NCT06433752||BRIUMVI® (Ublituximab-xiiy)|Participants will receive BRIUMVI® (Ublituximab-xiiy) intravenous (IV) infusion for the treatment of RMS.
61961013|NCT03001531|ACTIVE_COMPARATOR|HydroSun|application of ultraviolet light for 30 minutes
61961014|NCT03001531|ACTIVE_COMPARATOR|Hilotherm|application of heat (maximum of 43°C) for 30 minutes
61961015|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
62143674|NCT00808834|OTHER|Senofilcon A / Lotrafilcon A|Senofilcon A, followed by Lotrafilcon A
62704283|NCT05870865|EXPERIMENTAL|ASN008 1.25%|ASN008 1.25% twice daily topical application applied as a thin layer (approximately 2 mg/cm\^2) for 4 weeks (28 days)
62704284|NCT05870865|EXPERIMENTAL|ASN008 2.5%|ASN008 2.5% twice daily topical application applied as a thin layer (approximately 2 mg/cm\^2) for 4 weeks (28 days)
62704285|NCT05870865|EXPERIMENTAL|ASN008 5%|ASN008 5% twice daily topical application applied as a thin layer (approximately 2 mg/cm\^2) for 4 weeks (28 days)
62143675|NCT00808834|OTHER|Lotrafilcon A / Senofilcon A|Lotrafilcon A, followed by Senofilcon A
62704286|NCT05870865|PLACEBO_COMPARATOR|ASN008 Matching Vehicle|ASN008 matching vehicle twice daily topical application applied as a thin layer (approximately 2 mg/cm\^2) for 4 weeks (28 days)
62704287|NCT04873934|EXPERIMENTAL|Inclisiran with Usual Care|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
62704288|NCT04873934|NO_INTERVENTION|Usual Care|Usual Care Alone
61961016|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
61961017|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
61961018|NCT01340885|ACTIVE_COMPARATOR|atomoxetine|Strattera 10-30 mg b.i.d.
61961019|NCT01340885|ACTIVE_COMPARATOR|rivastigimine|Exelon 1.5-4.5 mg b.i.d.
61961020|NCT01340885|PLACEBO_COMPARATOR|Placebo|sugar pill
61961021|NCT04012983||diabetic patients with periodontitis|
61961022|NCT04012983||periodontitis patients|
61961023|NCT04012983||healthy control|
61961024|NCT01603056|EXPERIMENTAL|PANGRAMIN SLIT HDM MIX|PANGRAMIN SLIT HDM MIX Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
61961025|NCT01603056|PLACEBO_COMPARATOR|Placebo|Placebo Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
61961026|NCT04239144|NO_INTERVENTION|Medical therapy group|Arm 1 - 15 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming.
61961027|NCT04239144|ACTIVE_COMPARATOR|Catheter ablation|Intervention Arm 2 -15 patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).
61961028|NCT04239144|EXPERIMENTAL|Bilateral sympathectomy|Interventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers.
61961029|NCT00130598|ACTIVE_COMPARATOR|1|control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
61961030|NCT00130598|ACTIVE_COMPARATOR|2|7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
61961031|NCT00130598|ACTIVE_COMPARATOR|3|short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.
61961032|NCT04053114||Retrospective cohort|Tissue samples
62347690|NCT04334915|PLACEBO_COMPARATOR|Arm B: Placebo for CVC|"Placebo for CVC 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing ARV regimens.~For participants who are on an EFV-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
62505725|NCT04493476|PLACEBO_COMPARATOR|placebo|The control group tested will receive placebo capsules. Containing starch.
62505726|NCT02042833||Cohort|
62505727|NCT03983798||Simulation training in psychiatry|Convenient sample of 72 voluntary medical students, allocated among 6 groups of around 12 students, will be recruited at Paris Descartes, Paris Diderot and Brest Universities between september of 2018 and June of 2019.
62505728|NCT00176930|EXPERIMENTAL|PBSC: No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
62505729|NCT00176930|EXPERIMENTAL|Marrow : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
62505730|NCT00176930|EXPERIMENTAL|UCB : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
61961033|NCT03365583||Vitamin B12 deficiency|"No intervention will be administered for this study. Serum vitamin B12 \<203 pg/mL is considered as vitamin B12 deficiency.~Fecal microbiota composition will be analyzed with 16S rRNA sequencing. In a subgroup of infants (n=11), fecal samples will be recollected after the treatment as usual"
61961034|NCT03365583||Vitamin B12 sufficient|Serum vitamin B12 ≥203 pg/mL is considered as vitamin B12 sufficient Fecal microbiota composition will be analyzed with 16S rRNA sequencing.
61961035|NCT04489563|OTHER|Aged persons|A feasibility test of 20-30 minutes in aged persons with an adapted Kinect-based system, i.e. i-ACT.
61961036|NCT03608098|ACTIVE_COMPARATOR|Short Pulse Duration Group|A short pulse duration (300 μs or 350 μs) will be used in this group.
61961037|NCT03608098|ACTIVE_COMPARATOR|Long Pulse Duration Group|A long laser pulse duration (700 μs or 1500 μs) will be used in this group.
61961038|NCT02035930|OTHER|menstrual cycle,dexmedetomidine|
62143676|NCT06642402||Systemic lupus erythomatosus with lupus nephritis|SLE patients with kidney involvement
62505731|NCT00176930|EXPERIMENTAL|UCB : No TBI/Bu/Cy/ATG|Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
62505732|NCT00176930|EXPERIMENTAL|PBSC|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
62505733|NCT00176930|EXPERIMENTAL|Marrow|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
62505734|NCT00176930|EXPERIMENTAL|UCB|Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
62539208|NCT02552303|PLACEBO_COMPARATOR|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
61961039|NCT02744014|EXPERIMENTAL|Early intervention group|The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset \& physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.
61961040|NCT02744014|OTHER|Late intervention group|This group will receive the same training with a delay of 60-90 days, serving initially as control.
62347691|NCT05684952|EXPERIMENTAL|Treatment group|Subjects need to take the Chinese herbal medicine (Shenlingcao oral liquid) 200 ml twice per day for 4 weeks. Shenlingcao oral solution is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
62347692|NCT05684952|PLACEBO_COMPARATOR|Control group|Subjects need to take the placebo of Shenlingcao oral liquid 200 ml twice per day for 4 weeks.
62347693|NCT03411850|ACTIVE_COMPARATOR|Orencia (Abatacept)|Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
62347694|NCT03411850|PLACEBO_COMPARATOR|Placebo|Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
62347695|NCT04922697|EXPERIMENTAL|Prevention (educational videos, questionnaires)|Participants watch 2 educational videos during week 3 regarding air pollution, health effects, and personal preventive health behaviors to reduce air pollution exposure. Participants will use wearable air pollution sensors. Participants will complete questionnaires at weeks 1 and 5.
62347696|NCT04546464|EXPERIMENTAL|Experimental Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
62347697|NCT04546464|NO_INTERVENTION|Standard care|
62347698|NCT06051136|EXPERIMENTAL|Early pulmonary rehabilitation (RP)|RP immediately after enrollment.
62347699|NCT06051136|EXPERIMENTAL|Delayed pulmonary rehabilitation (RP)|RP after 3 months after enrollment.
62347700|NCT03360045|ACTIVE_COMPARATOR|Tranexamic acid group|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
62347701|NCT03360045|PLACEBO_COMPARATOR|Placebo group|5ml normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
62347702|NCT03360045|ACTIVE_COMPARATOR|Merocel Group|Merocel packing is applied.
62347703|NCT03453190|OTHER|Psoriasis Patients on Comb. Treatment|Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.
62347704|NCT06190405|EXPERIMENTAL|Universal hemoglobin A1c|Patients at \<16 weeks will have a hemoglobin A1c obtained
62347705|NCT06190405|ACTIVE_COMPARATOR|Risk-based screening by ACOG with two-step GTT|Patients at \<16 weeks will be assessed for risk factors for diabetes as described by ACOG. If patients meet criteria, they will be screened with two-step screening for gestational diabetes. If patients do not meet criteria, they will not be screened until the routine timing of screening for gestational diabetes.
62347706|NCT01559064||Age group A|Subjects 30 to 40 years old
61961041|NCT03612505|ACTIVE_COMPARATOR|Intervention|
62347707|NCT01559064||Age group B|Subjects 40 to 50 years old
62347708|NCT01559064||Age group C|Subjects over 50 years old
61961042|NCT03612505|NO_INTERVENTION|Control|
61961043|NCT00592943|ACTIVE_COMPARATOR|Armodafinil (100mg)|
62347709|NCT02058758||Healthy Volunteers|Device: Magnetic Resonance Imaging
62347710|NCT02058758||Breast Cancer Patients|Device: Magnetic Resonance Imaging
62347711|NCT00673517||1|Patients randomized to high frequency oscillation
62347712|NCT00673517||2|Patients randomized to conventional lung protective ventilation
62347713|NCT04695548|EXPERIMENTAL|Concentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
62347714|NCT04695548|EXPERIMENTAL|Isometric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
62505735|NCT00176930|EXPERIMENTAL|Co-Enroll From MT0403|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)
62505736|NCT01722955|EXPERIMENTAL|Pre-warmed fluids|Pre-warmed fluids will be prepared for 8hous in 41℃ set hot cabinet.
62505737|NCT01722955|EXPERIMENTAL|Room temperature fluids|Room temperature fluids will be stored at ambient temperature.
62505738|NCT01049347|ACTIVE_COMPARATOR|amitriptyline|
62505739|NCT01049347|ACTIVE_COMPARATOR|paroxetine|
62539209|NCT02552303|ACTIVE_COMPARATOR|Armodafinil|Medication (armodafinil) only, without CBTI.
61961044|NCT00592943|ACTIVE_COMPARATOR|Armodafinil (250 mg)|
61961045|NCT01427686|ACTIVE_COMPARATOR|Dobutamine|Start Dobutamine. If no success switch to Dopamine.
61961046|NCT01427686|ACTIVE_COMPARATOR|Dopamine|Start Dopamine. If no success switch to Dobutamine.
61961047|NCT02590081|ACTIVE_COMPARATOR|Normal saline|Normal saline will be used for wash back procedure at the end of hemodiaysis.
62539210|NCT02552303|PLACEBO_COMPARATOR|Placebo|Placebo only, without CBTI.
62714963|NCT01812057|PLACEBO_COMPARATOR|Placebo|Sodium chloride 0.9% (5 ml) given IV intraoperatively as a one time dose.
61961048|NCT02590081|EXPERIMENTAL|dextrose 5%|Dextrose 5% will be used for wash back procedure at the end of hemodiaysis.
61961049|NCT04833881||The control group|
62539211|NCT04129359|EXPERIMENTAL|FamilieTrivsel|Enhanced care as usual in general practice plus training in the use of the online mentalisation programme
62704289|NCT05752474|EXPERIMENTAL|Prehabilitation|This group will receive a multicomponent prehabilitation intervention (exercise, nutritional intervention, meditation, and cognitive behavioral intervention) for 3-4 weeks prior to surgery.
61961050|NCT04833881||Experimental group|
61961051|NCT04993248|EXPERIMENTAL|Intervention|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
61961052|NCT04993248|NO_INTERVENTION|Control|Usual intervention
61961053|NCT01965587|ACTIVE_COMPARATOR|novasure mirena IUS combined|novasure mirena IUS combined therapy
61961054|NCT01965587|ACTIVE_COMPARATOR|novasure alone|Sole treatment with Novasure
61961055|NCT06411197|EXPERIMENTAL|Gastrocnemius (painful condition)|1.5 mL injection of hypertonic saline (7%) to the gastrocnemius muscle.
61961056|NCT06411197|SHAM_COMPARATOR|Gastrocnemius (control condition)|1.5 mL injection of isotonic saline (0.9%) to the gastrocnemius muscle.
61961057|NCT06411197|EXPERIMENTAL|Biceps femoris (painful condition)|1.2 mL injection of hypertonic saline (7%) to the biceps femoris muscle.
61961058|NCT06411197|SHAM_COMPARATOR|Biceps femoris (control condition)|1.2 mL injection of isotonic saline (0.9%) to the biceps femoris muscle.
61961059|NCT06411197|EXPERIMENTAL|Semitendinosus (painful condition)|1.2 mL injection of hypertonic saline (7%) to the semitendinosus muscle.
61961060|NCT06411197|SHAM_COMPARATOR|Semitendinosus (control condition)|1.2 mL injection of isotonic saline (7%) to the semitendinosus muscle.
61961061|NCT04478539||COVID-19 patients admitted to the ICU|"COVID-19 patients will be treated with the Prismaflex® oXiris® system in the ICU.~Treatment will be initiated within 4 - 12 hours after admission upon establishing control of the haemostasis, ACT = Activated Coagulation Time of 180 seconds"
61961062|NCT04711044|EXPERIMENTAL|Study group|
62347715|NCT04695548|EXPERIMENTAL|Eccentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
62704290|NCT06517017|EXPERIMENTAL|Combination Treatment|Isatuximab
61961063|NCT01844518|EXPERIMENTAL|Short and Long Terms: Orencia|"Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months"
61961064|NCT06111300|EXPERIMENTAL|group d|Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery.
61961065|NCT06111300|PLACEBO_COMPARATOR|group c|Patients in this group will receive volume- matched normal saline infusion (NaCL 0.9%) as a placebo.
62143677|NCT06642402||Systemic lupus erythomatosus without lupus nephritis|SLE patients, fulfilling the 2019 EULAR/ACR classification criteria with no sign of kidney disease
62143678|NCT06642402||Healthy controls|Healthy controls
61961066|NCT03123718|OTHER|Intrathecal Methotrexate|
61961067|NCT03123718|ACTIVE_COMPARATOR|High-dose Intravenous Methotrexate|
61961068|NCT02601378|EXPERIMENTAL|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
61961069|NCT02601378|EXPERIMENTAL|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
62143679|NCT06642402||Biopsy controls|A biopsy control group with no predictive complement activation referred to biopsy
62347716|NCT04695548|EXPERIMENTAL|Analytic passive stretching.|After applying the dry needling technique to the upper trapezius muscle, the patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
62539212|NCT04129359|ACTIVE_COMPARATOR|control|Enhanced care as usual in general practice
62539213|NCT04939194|EXPERIMENTAL|Fast Track Protocol|the 22 items of ERAS (Early Recovery After Surgery) society
62539214|NCT04939194|NO_INTERVENTION|Conventional perioperative care program|standard perioperative care
61961070|NCT03925883|ACTIVE_COMPARATOR|Patient Navigation|Patients randomized to this arm will receive patient navigation with the goal of completing a follow-up colonoscopy within 12 months of a positive FIT result.
61961071|NCT03925883|NO_INTERVENTION|Usual Care|Patients will receive usual care screening opportunities
61961072|NCT04902794|EXPERIMENTAL|Light Emitting Diode|Light Emitting Diode in the Treatment of Menopause Genitourinary Syndrome
61961073|NCT04902794|SHAM_COMPARATOR|Light Emitting Diode Sham|Light Emitting Diode device Sham - turned off
61961074|NCT02259881|EXPERIMENTAL|Low dose of BIBT 986 CL|
61961075|NCT02259881|EXPERIMENTAL|Medium dose of BIBT 986 CL|
61961076|NCT02259881|EXPERIMENTAL|High dose of BIBT 986 CL|
61961077|NCT02259881|PLACEBO_COMPARATOR|Placebo|
61961078|NCT05878860|EXPERIMENTAL|Cohort 1|ATSN-201 at Low Dose
61961079|NCT05878860|EXPERIMENTAL|Cohort 2|ATSN-201 at High Dose
61961080|NCT05878860|EXPERIMENTAL|Cohort 4, High Dose|ATSN-201 at High Volume
61961081|NCT05878860|EXPERIMENTAL|Cohort 4, Low Dose|ATSN-201 at Low Volume
61961082|NCT05878860|NO_INTERVENTION|Cohort 4, Control|
62704291|NCT05081219|EXPERIMENTAL|Intranasal Insulin and Empagliflozin Placebo|"* 40 IU of intranasal insulin administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily~* Placebo capsules taken by mouth 30 minutes before breakfast once daily"
61961083|NCT05878860|EXPERIMENTAL|Cohort 5, Pediatric|ATSN-201 at High Volume
62347717|NCT04019652|EXPERIMENTAL|10 mg CS-3150 (Treatment Sequence 1)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 10-mg dose of CS-3150, a 40-mg dose of CS-3150, a 400-mg dose of moxifloxacin, followed by placebo.
62347718|NCT04019652|EXPERIMENTAL|40 mg CS-3150 (Treatment Sequence 2)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 40-mg dose of CS-3150, placebo, a 10-mg dose of CS-3150, followed by a 400-mg dose of moxifloxacin.
62347719|NCT04019652|EXPERIMENTAL|Moxifloxacin (Treatment Sequence 3)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 400-mg dose of moxifloxacin, 10-mg dose of CS-3150, placebo, 40-mg dose of CS-3150.
62505740|NCT03847194|EXPERIMENTAL|PRISM Intervention Arm|"The goal of the intervention is to teach resilience resource skills for use in current or future stressful situations. The total intervention consists of two, 45-60 minute, one-on-one sessions approximately 2-4 weeks apart followed by a family meeting discussing the skills learned. Following the family session through week 12, participants receive bi-weekly booster contacts (1:1 check-in sessions with the interventionist) to practice/refresh skills and check-ins on how skills have been utilized. These boosters will then be delivered monthly in months 4-6. In addition, all PRISM participants have access to the digital PRISM app, which offers an interactive practice and tracking interface to continue enhancing skills."
62505741|NCT03847194|NO_INTERVENTION|Usual Care|Families in both randomization arms will receive usual medical care for diabetes, including psychosocial care provided by the mental health professionals affiliated with the diabetes clinic if needed. At both sites, every diabetes patient is cared for by a team of diabetes specialists which includes a provider (MD, Physician Assistant and/or Nurse Practitioner), dietician, and social worker. Subspecialty referrals for additional mental health or other support are made at the discretion of the primary diabetes provider.
62505742|NCT01858987|ACTIVE_COMPARATOR|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
61961084|NCT05878860|EXPERIMENTAL|Cohort 3|ATSN-201 at Mid Dose
61961085|NCT05108155||THA|Patient with primary total hip arthroplasty
61961086|NCT02429544|EXPERIMENTAL|Experimental Support Group (ESG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
62347720|NCT04019652|EXPERIMENTAL|Placebo (Treatment Sequence 4)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral dose of placebo, 400-mg dose of moxifloxacin, 40-mg dose CS-3150, 10-mg dose of CS-3150.
62347721|NCT04176445|OTHER|Bedside Sitting followed by Orthostatic Board|Bedside sitting posture protocol followed by orthostatic board posture protocol.
62347722|NCT04176445|OTHER|Orthostatic Board followed by Bedside Sitting|Orthostatic board posture protocol followed by bedside sitting posture protocol.
62347723|NCT04237818|PLACEBO_COMPARATOR|Placebo drink|
62347724|NCT04237818|EXPERIMENTAL|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|
62347725|NCT05485259|EXPERIMENTAL|DL-alpha lipoic acid|600 mg (2x300 mg) of DL-alpha lipoic acid in capsules, per os daily for 3 months
62347726|NCT05485259|PLACEBO_COMPARATOR|Placebo|600 mg (2\*300 mg) of placebo (rice starch) in capsules, per os, daily for 3 months
62505743|NCT01858987|EXPERIMENTAL|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
62505744|NCT02371928|ACTIVE_COMPARATOR|Neuromuscular exercise program|"A 12-week physiotherapeutic, supervised exercise program with focus on neuromuscular shoulder control besides incorporation of kinetic chain exercises.~The exercise program contains the following focal points: Scapula and glenohumeral setting/control, dynamic shoulder stability, muscle co-contractions (weight-bearing upper extremity exercises) and proprioceptive training."
62505745|NCT02371928|ACTIVE_COMPARATOR|Standard home exercise program|"One physiotherapeutic-supervised instruction in 12 weeks of active exercises for the rotator cuff and scapular muscles.~Information about the shoulder injury and how to avoid pain provoking movements besides future implications is given. Also, participants receives one phone call after six weeks of training from a physiotherapist to ensure good compliance and answer any questions that the patient may have."
62505746|NCT02802215|ACTIVE_COMPARATOR|Metformin group|40 women will receive metformin in dose of 1500 mg per day orally (500 mg every 8 hrs in the middle of meal) starting from 12th week of gestation till delivery.
61961087|NCT02429544|EXPERIMENTAL|Standard Support Group (SSG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
62347727|NCT04839991|EXPERIMENTAL|Multi center open label Dose Escalation followed by Cohort Expansion: Part 2A|Patients will receive CB307 IV infused every 7 days. Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2A arm will enrol patients with PSMA+ solid tumours. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
62347728|NCT04839991|EXPERIMENTAL|Multi center open label Dose Escalation followed by Combination Cohort Expansion : Part 2B|Patients will receive CB307 IV infused every 7 days in combination with KEYTRUDA® (pembrolizumab) IV infused every 21 days . Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2B arm will enrol patients with PSMA+ metastatic castration-resistant prostate cancer. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
61961088|NCT02429544|OTHER|Standard of Care Group (SOC) - No Residential Program|"Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
61961089|NCT06062511|EXPERIMENTAL|Verum ESIT12 D|This arm receives 400 mg of ESIT12 and 150 mg of carriers from ESIT12
61961090|NCT06062511|EXPERIMENTAL|Verum ESIT12 4D|This arm receives 1600 mg of ESIT12 and 600 mg of carriers from ESIT12
61961091|NCT06062511|PLACEBO_COMPARATOR|Placebo|This arm receives 550 mg of carriers from ESIT12
61961092|NCT02298920|EXPERIMENTAL|Single Group|Open Label ADME Study
61961093|NCT00679315|EXPERIMENTAL|Alpha blocker|alfuzosin hydrochloride XL 10mg
61961094|NCT00679315|PLACEBO_COMPARATOR|Placebo|Placebo
61961095|NCT03435445|EXPERIMENTAL|Online platform group|Online platform with diet, physical activity and behavior change recommendations for 24 weeks
61961096|NCT03435445|EXPERIMENTAL|Online dietitian coaching|Diet, physical activity and behavior change recommendations for 24 weeks and online sessions with a dietitian specialist for 12 weeks
62347729|NCT00700895|EXPERIMENTAL|Pharmacogenetics-guided dosing group|For patients randomized to the pharmacogenetics-guided dosing group, this 10mls of blood will be immediately sent for genotyping studies. Genotyping results will be available for pharmacogenetics-guided dosing within 3 working days, (ranging 3 to 5 days). During this period, if patients need to be initiated on anticoagulation, a low molecular weight heparin, Fraxiparine, will be given. Fraxiparine will be overlapped with warfarin for 2 to 3 days until target INR is achieved. Elective cases should have the pharmacogenetics-based warfarin dose available at the time of warfarin therapy.
62347730|NCT00700895|EXPERIMENTAL|Traditional dosing group|For patients randomized to the traditional dosing regime, the blood will be stored and genotyped retrospectively at the end of the study. Overlapping of warfarin with Fraxiparine or heparin till target INR is achieved is allowed for this group as per normal clinical practice. All warfarin dosage adjustments based on INR results will be according to the current protocol used by the NUH Anticoagulant Clinic.
62704292|NCT05081219|EXPERIMENTAL|Empagliflozin and Intranasal Insulin Placebo|"* Empagliflozin 10 mg capsules taken by mouth 30 minutes before breakfast once daily~* 40 IU of intranasal insulin diluent (placebo) administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily"
62505747|NCT02802215|PLACEBO_COMPARATOR|control group|40 women will receive placebo which will be folic acid 500 micro gram which looks like metformin tablet.
61961097|NCT03435445|ACTIVE_COMPARATOR|Control group|Videos with diet, physical activity and behavior change recommendations for 24 weeks
62505748|NCT06678685|EXPERIMENTAL|spironolactone treatment|
61961098|NCT03969446|EXPERIMENTAL|Cohort I Arm I (pembrolizumab, decitabine)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10. Patients who achieve a CR receive decitabine on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
61961099|NCT03969446|EXPERIMENTAL|Cohort I Arm II (pembrolizumab, decitabine, venetoclax)|Patients with pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10 or 1-5. Patients who achieve a CR receive decitabine on days 1-5. Patients also receive venetoclax PO QD on days 1-14. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
61961100|NCT03969446|EXPERIMENTAL|Cohort II (pembrolizumab, decitabine)|Patients with MDS receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine over 1 hour on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
61961101|NCT04976751|EXPERIMENTAL|Electrophysiological treatment group|Two electrodes covered the two acupoints of Zhongliao and Huiyang, one electrode covered the three acupoints of Zhongji, Guanyuan and Qihai, and two skin paste electrodes covered the three acupoints of Sanyinjiao, and connected the electric stimulation therapy instrument for 30 minutes. The intensity was based on the patient's tolerance. 4 weeks before the course of treatment, the treatment was performed once a day, 3 times a week.In the last 4 weeks, 20 times were performed twice a week.Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
61961102|NCT04976751|NO_INTERVENTION|Regular treatment group|Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
61961103|NCT03260309|EXPERIMENTAL|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
61961104|NCT03260309|EXPERIMENTAL|control group|Routine infusion therapy tactic
61961105|NCT04007718|EXPERIMENTAL|Active|
62505749|NCT02898701|ACTIVE_COMPARATOR|No Overpractice (NoOVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the NoOVP group will cease practicing.
61961106|NCT04007718|SHAM_COMPARATOR|Control|
61961107|NCT05139589||Infective endocarditis, surgical arm|Patients with infective endocardits requiring valve surgery
61961108|NCT05139589||Infective endocarditis, conservative arm|Patients with infective endocardits, not requiring valve surgery
61961109|NCT05139589||Valve disease, heart, surgically repaired|Patients requiring valve surgery
61961110|NCT03258437|EXPERIMENTAL|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
61961111|NCT03258437|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks.
61961112|NCT05965505|EXPERIMENTAL|AXT-1003|"Dose Escalation: Level 1 (Starting Dose) Oral AXT-1003 100 mg BID; Level 2 Oral AXT-1003 200mg BID; Level 3 Oral AXT-1003 300mg BID ; Level 4 Oral AXT-1003 450mg BID; Level 5 Oral AXT-1003 600mg BID; Level 6 Oral AXT-1003 750mg BID~Dose Expansion: 1 or 2 cohorts at the dose levels selected from dose escalation part"
62539215|NCT04075591|EXPERIMENTAL|Wavefront-guided Lasik Monovision Treatment|Wavefront-guided LASIK monovision treatment of myopic subjects with presbyopia using the STAR S4 IR® Excimer laser System with the iDesign Refractive Studio.
61961113|NCT01749397|EXPERIMENTAL|Treatment (veliparib and floxuridine)|Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61961114|NCT06011044|EXPERIMENTAL|Intercostal nerve block with ropivacaine（0.5%）|This group of patients will be further divided into 2 groups. Group A (incision-specific multi-site injection) received intraoperative 3-8 intercostal nerve block with 0.5% ropivacaine. Group B (single injection) received intraoperative 3-5 intercostal nerve block with 0.5% .After completing lung surgery, fully exposing the lateral and posterior chest wall. From the inside view of the chest cavity, the intercostal nerve enters the correlated intercostal space between the posterior intercostal membrane and the parietal pleura. The needle of the 1ml syringe was held with a thoracoscopic ovale forceps and the target intercostal nerves were confirmed. It is only necessary to puncture the parietal pleura at the side of the intercostal nerve to perform the block. Inject ropivacaine(1ml, 0.5%) into the target nerve. At the same time, we recorded patients' mental status and vital signs to avoid systemic toxicity.
61961115|NCT06011044|NO_INTERVENTION|no intercostal nerve block.|This group of patients will not receive intraoperative intercostal nerve block with 0.5% ropivacaine. After completing lung surgery, fully exposing the lateral and posterior chest wall. From the inside view of the chest cavity, the intercostal nerve enters the correlated intercostal space between the posterior intercostal membrane and the parietal pleura. The needle of the 1ml syringe was held with a thoracoscopic ovale forceps and the target intercostal nerves were confirmed. Inject physiologic saline(1ml) into the target nerve.
61961116|NCT05747209||Standard High-load resistance training|Standard exercise regimen utilizes a mixture of compound and isolated movements, focusing on compound exercises. The regimen is a typical standard of care resistance training program and sports performance and strength and conditioning facilities. The observed classes will take place three times per week. Warm-up exercises focused on mobility, flexibility and core activation will be performed to reduce the risk of injury. Each individual exercise workout will generally progress from most intense, CKC, compound, and athletic movements to least intense throughout the workout to maximize safety. Additionally, each workout will provide full body resistance training to focus on functional exercises, intensity, and efficiency. Each workout will take approximately 45 minutes. The total exercise regimen will last 3 months.
61961117|NCT02454998|EXPERIMENTAL|Orthodontic treatment arm|Previous to the surgical alveolar bone grafting, orthodontic treatment is performed several months before surgery
61961118|NCT02454998|NO_INTERVENTION|No orthodontic treatment arm|No orthodontic treatment previous to surgical alveolar bone grafting
61961119|NCT02412605||Fertile embryo biopsy|Fertile couples requesting sex selection for family balancing
61961120|NCT02412605||Infertile embryo biopsy|Infertile women having embryo biopsy
62143680|NCT05926674|EXPERIMENTAL|Myofascial Release|"Myofascial release (MFR) is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.~Myofascial release will be provided to each subject assigned to the experimental group by the primary investigator (PI). The participant will be positioned in prone and the MFR will be applied along the lumbar paraspinals bilaterally for five minutes per side."
62143681|NCT05926674|SHAM_COMPARATOR|Light Touch Contact|Sham treatment will be provided to each subject assigned to the control group by the designated co-investigator. The sham treatment of light touch will be applied to the lumbar paraspinals in the same fashion as noted above. This form of light touch contact is not therapeutic and is meant to only mimic a manual therapy technique.
62505750|NCT02898701|EXPERIMENTAL|Overpractice (OVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the OVP group will continue to practice as part of the overpractice phase until they have completed 100% overpractice.
62505751|NCT02898701|ACTIVE_COMPARATOR|Standard of Care (SoC)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) until they have performed 144 practice trials over the course of one day. At that time, members of the SoC group will cease practicing.
62505752|NCT03245307|EXPERIMENTAL|Treament|In phase A, subjects receiving a single 30 mg oral dose of Nifedipine controlled-release tablets and wash-out for 2 days,a single 3 mg oral dose of warfarin tablets and wash-out for 12 days, then apatinib 750 mg once daily with a single 30 mg oral dose of Nifedipine controlled-release tablets co-administered on day 6 ,a a single 3 mg oral dose of warfarin tablets co-administered on day 9.
62505753|NCT02130778|ACTIVE_COMPARATOR|Saline infusion|infusion of saline
62505754|NCT02130778|ACTIVE_COMPARATOR|Saline infusion with GLP1|infusion of saline with GLP1
62505755|NCT02966184|NO_INTERVENTION|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
62505756|NCT02966184|EXPERIMENTAL|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
62505757|NCT04821739|EXPERIMENTAL|Treatment with AGN1 LOEP SV Kit|VCF is treated with the AGN1 LOEP SV Kit
62539216|NCT01789723|EXPERIMENTAL|Cohort 1: Fusilev - 10 doses|"Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
62539217|NCT01789723|EXPERIMENTAL|Cohort 2: Fusilev - 6 doses|"Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
62539218|NCT01789723|EXPERIMENTAL|Cohort 3: Fusilev - 4 doses|"5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
62539219|NCT01789723|EXPERIMENTAL|Cohort 4: Fusilev - 2 doses|"5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
61961121|NCT02412605||IVF/ICSI|Infertile women undergoing IVF/ICSI without embryo biopsy
61961122|NCT02967744|EXPERIMENTAL|NSAID treatment|8 weeks of NSAID treatment
61961123|NCT02034383|EXPERIMENTAL|Control|Diet will consist of a controlled diet without almonds for 3 weeks.
61961124|NCT02034383|EXPERIMENTAL|Whole Almonds|Diet will consist of a controlled diet with whole almonds for 3 weeks.
61961125|NCT02034383|EXPERIMENTAL|Roasted Whole Almonds|Diet will consist of a controlled diet with roasted whole almonds for 3 weeks.
62347731|NCT03222076|EXPERIMENTAL|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients continue nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62704293|NCT05081219|EXPERIMENTAL|Intranasal Insulin and Empagliflozin|"* 40 IU of intranasal insulin administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily~* Empagliflozin 10 mg capsules taken by mouth 30 minutes before breakfast once daily"
62704294|NCT05081219|PLACEBO_COMPARATOR|Placebo|"* 40 IU of intranasal insulin diluent (placebo) administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily~* Placebo capsules taken by mouth 30 minutes before breakfast once daily"
61961126|NCT02034383|EXPERIMENTAL|Diced Almonds|Diet will consist of a controlled diet with diced almonds for 3 weeks.
62347732|NCT03222076|EXPERIMENTAL|Arm B (ipilimumab, nivolumab)|Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
62347733|NCT02275598|EXPERIMENTAL|BV-ABVD|Treatment will consist of two three-weekly doses of Brentuximab vedotin, followed by standard treatment, ABVD (3 o 6 cycles q4w).
62347734|NCT00698035|ACTIVE_COMPARATOR|Testosterone Cream|Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
62347735|NCT00698035|ACTIVE_COMPARATOR|Estring|Estring 2mg ring inserted vaginally once every 12 weeks
62347736|NCT01770691|EXPERIMENTAL|TIPI vaginal pessary|Each subject will use different SMD'S (Slightly modified designs) of the TIPI vaginal pessary. Not all subjects will use all types of SMD's
62505758|NCT05962268|EXPERIMENTAL|Video based education|"The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.~Topics: Video recordings on of fistula care was done by the researchers in the vocational skills laboratory. The video flow plan included the introduction of the materials to be used in fistula care as well as the researcher's presentation of how to manage the fistula. Fistula care steps were performed on the simulation model. In addition, the precautions to be taken during the application and what to do in case of possible complications were also shown."
62505759|NCT05962268|EXPERIMENTAL|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
62505760|NCT04741529|EXPERIMENTAL|Massed condition|Participant will be asked to use the HMP app for 20 minutes per day in one 20-minute meditation session.
62505761|NCT04741529|EXPERIMENTAL|Spaced condition|Participant will be asked to use the HMP app for 20 minutes per day in two 10-minute meditation sessions.
62505762|NCT03176524|EXPERIMENTAL|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
62704295|NCT06409130|EXPERIMENTAL|NNC0194-0499 + semaglutide|Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 in combination with semaglutide.
62704296|NCT06409130|EXPERIMENTAL|NNC0194-0499 + semaglutide placebo|Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 in combination with semaglutide placebo.
62704297|NCT06409130|EXPERIMENTAL|NNC0194-0499 placebo + semaglutide|Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 placebo in combination with semaglutide.
62704298|NCT06409130|PLACEBO_COMPARATOR|NNC0194-0499 placebo + semaglutide placebo|Group A: Participants will receive subcutaneous (s.c.) injections of NNC0194-0499 placebo in combination with semaglutide placebo.
62704299|NCT06409130|EXPERIMENTAL|CagriSema|Group B: Participants will receive subcutaneous (s.c.) injection of cagrilintide in combination with semaglutide.
62704300|NCT06409130|EXPERIMENTAL|Cagrilintide + semaglutide placebo|Group B: Participants will receive subcutaneous (s.c.) injection of cagrilintide in combination with semaglutide placebo.
62704301|NCT06409130|PLACEBO_COMPARATOR|Cagrilintide placebo + semaglutide placebo|Group B: Participants will receive subcutaneous (s.c.) injection of cagrilintide placebo in combination with semaglutide placebo.
61961127|NCT02034383|EXPERIMENTAL|Almond Butter|Diet will consist of a controlled diet with almond butter for 3 weeks.
61961128|NCT00864383|PLACEBO_COMPARATOR|Regimen 1 - 2EHRZ/4HR (control regimen)|"* Eight weeks of chemotherapy with Ethambutol, Isoniazid, Rifampicin and Pyrazinamide plus the Moxifloxacin placebo, followed by~* Nine weeks of Isoniazid and Rifampicin plus the Moxifloxacin placebo, followed by~* Nine weeks of Isoniazid and Rifampicin only."
61961129|NCT00864383|EXPERIMENTAL|Regimen 2 - 2MHRZ/2MHR|"* Eight weeks of chemotherapy with Moxifloxacin, Isoniazid, Rifampicin and Pyrazinamide plus the Ethambutol placebo, followed by~* Nine weeks of Moxifloxacin, Isoniazid and Rifampicin, followed by~* Nine weeks of the Isoniazid placebo and the Rifampicin placebo."
61961130|NCT00864383|EXPERIMENTAL|Regimen 3 - 2EMRZ/2MR|"* Eight weeks of chemotherapy with Ethambutol, Moxifloxacin, Rifampicin and Pyrazinamide plus the Isoniazid placebo, followed by~* Nine weeks of Moxifloxacin and Rifampicin plus the Isoniazid placebo, followed by~* Nine weeks of the Isoniazid placebo and the Rifampicin placebo"
61961131|NCT02716454|EXPERIMENTAL|Early Surgery - ES|Early laparoscopic ileocaecal resection
61961132|NCT02716454|NO_INTERVENTION|Step-up therapy - STUP|Treatment with step-up conservative approach according to good clinical practice.
62347737|NCT04075773|EXPERIMENTAL|Religious Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported religious identity. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
62347738|NCT04075773|SHAM_COMPARATOR|Age Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported age. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
62347739|NCT06337682||Care home cohort|Individuals aged 65 or over registered to a GP practice which is part of the Connected Bradford Database who have been admitted to a CH between January 2016 and January 2020, with a recorded length of stay more than 6 weeks, will be included in the study.
62347740|NCT05270642|EXPERIMENTAL|HCC patients guided by Plan for Microwave Thermal Field|The plan for HCC patients undergoing microwave ablation would be refer to Plan for Microwave Thermal Field system
62505763|NCT03176524|EXPERIMENTAL|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
62505764|NCT03176524|ACTIVE_COMPARATOR|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
62505765|NCT03920306|EXPERIMENTAL|Intervention|"Drug administration for the experimental arm includes:~1. AgNO3 applied to the fistula tract.~2. A topical adhesive of either 2-Octylcyanoacrylate glue (Dermabond), or Fibrin glue, or Histoacryl glue (Tissue Seal), will be applied over the fistula's aperture.~3. Oral anti-reflux therapy of either Pantoprazole 20-40mg PO OD, or Ranitidine 5-10mg/kg/day PO divided twice daily or 150mg PO BID, for either 4 weeks or until gastrocutaneous fistula tract closure, whichever comes first."
62505766|NCT05274048|EXPERIMENTAL|Neratinib plus TDxD|Neratinib oral daily days 1-21 plus TDxD on day 1 administered intravenously of a 21 day treatment cycle.
62505767|NCT03781531||Venous thromboembolism|Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
62505768|NCT03181048|EXPERIMENTAL|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
62505769|NCT03181048|ACTIVE_COMPARATOR|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
62505770|NCT02172196|EXPERIMENTAL|Treatment sequence ABC|"1. Treatment A: BI 10773 once daily from day 1 to 5~2. Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5~3. Treatment C: Sitagliptin once daily from day 1 to 5"
62505771|NCT02172196|EXPERIMENTAL|Treatment sequence CAB|"1. Treatment C: Sitagliptin once daily from day 1 to 5~2. Treatment A: BI 10773 once daily from day 1 to 5~3. Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5"
62505772|NCT01813435|EXPERIMENTAL|Experimental treatment strategy|"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.~Dosage and frequency:~Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)"
62505773|NCT01813435|ACTIVE_COMPARATOR|Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.~Dosage and frequency:~Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd"
62505774|NCT06176755|EXPERIMENTAL|Treadmill training with weighted ankle cuffs|Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently
62505775|NCT06176755|ACTIVE_COMPARATOR|Treadmill training|Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently.
62505776|NCT05012176|EXPERIMENTAL|Arm I (EFT)|Patients participate in EFT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in EFT in their daily lives. Patients are asked to recall future positive experiences to create text cues which vividly describes these experiences.
62505777|NCT05012176|ACTIVE_COMPARATOR|Arm II (ERT)|Patients participate in ERT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in ERT in their daily lives. Patients are asked to recall past positive experiences to create text cues which vividly describes these experiences.
62505778|NCT03776617|EXPERIMENTAL|Group Ropivacaine|general anesthesia + scalp block with 20 ml xylocaine 1% and 20ml ropivacaine 0.5%
62505779|NCT03776617|EXPERIMENTAL|Group Ropivacaine-Dexmedetomidine|general anesthesia + scalp block with 20 ml xylocaine 1%, 20ml ropivacaine 0.5% and 1mcg/kg dexmedetomidine
62505780|NCT03776617|NO_INTERVENTION|Group control|general anesthesia
62505781|NCT03776617|SHAM_COMPARATOR|Group sham|general anesthesia + Scalp block with 40ml Normal Saline
62704302|NCT02506673|ACTIVE_COMPARATOR|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
61961133|NCT03638297|EXPERIMENTAL|PD-1 antibody + cox inhibitor|BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
61961134|NCT03986502|EXPERIMENTAL|Arm I (financial navigation program)|Patients and caregivers watch a web-based financial literacy video and receive information about financial counseling, direct medical cost and healthcare coverage assistance, and indirect and non-medical cost assistance.
61961135|NCT03986502|ACTIVE_COMPARATOR|Arm II (usual care)|Patients and caregivers participate in usual clinic procedures and utilize any available clinic or community-based financial resources. Patients and caregivers will also be provided the financial navigation videos and worksheets from the intervention.
62143682|NCT04746404||Control group|Control group : Major borderline patients followed up at the Health Unit of the Villeneuve-lès-Maguelone Remand Prison
62143683|NCT04746404||Test group|Test group : Major borderline patients followed up at the Health Unit of the Villeneuve-lès-Maguelone Remand Prison
62143684|NCT02428556|ACTIVE_COMPARATOR|Facts only|"Scenario describes study results without breakthrough language, promising language, no cautions about conditional approval"
62505782|NCT03651908|EXPERIMENTAL|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
62704303|NCT02506673|EXPERIMENTAL|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
62704304|NCT06664814|EXPERIMENTAL|open label, single arm|
62704305|NCT06609616|EXPERIMENTAL|Healthy Volunteers|Healthy volunteers of all genders and demographic groups who are ages 18 and older.
62704306|NCT06457958|ACTIVE_COMPARATOR|Sevoflurane Group|"Patients in this group will receive sevoflurane as the anesthetic agent during elective cholecystectomy surgery.~Sevoflurane is a commonly used inhalational anesthetic known for its rapid onset and recovery times."
62704307|NCT06457958|ACTIVE_COMPARATOR|Desflurane Group|"Patients in this group will receive desflurane as the anesthetic agent during elective cholecystectomy surgery.~Desflurane is another widely used inhalational anesthetic, notable for its low blood-gas solubility coefficient, leading to very rapid onset and recovery times."
62704308|NCT06253871|EXPERIMENTAL|IAM1363 Monotherapy|Treatment with IAM1363 capsules, dosed orally either once or twice daily in 21-day cycles.
62143685|NCT02428556|ACTIVE_COMPARATOR|promising language|"study description describes drug as promising; no warning about conditional approval"
62704309|NCT04628585||Subjects with sickle-cell disease|Subjects treated with ex vivo gene therapy drug product for sickle cell disease in a bluebird bio-sponsored study who agree to participate in this long-term follow-up study
62704310|NCT04387656||Observational Cohort (data collection, biospecimen collection)|Patients undergo collection of medical information about COVID-19 symptoms, treatments/cancer treatments and outcomes, and results from laboratory tests and imaging scans performed as part of routine care for up to 2 years. Patients also undergo collection of blood samples at the same times they receive routine bloodwork up to 8 times for adults and up to 5 times for children. Patients who are hospitalized for COVID-19 undergo collection of blood samples at up to 6 additional times for adults and up to 3 additional times for children. Adult patients also complete quality of life questionnaire.
62704311|NCT05934526|PLACEBO_COMPARATOR|Placebo|Placebo inhaled orally twice daily (BID) up to 48 weeks
62505783|NCT03651908|ACTIVE_COMPARATOR|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
62704312|NCT05934526|EXPERIMENTAL|Seralutinib 90 mg|Seralutinib inhaled orally BID up to 48 weeks
62704313|NCT03601897|EXPERIMENTAL|Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2|Dose escalation of rebastinib 50 milligram (mg) twice daily (BID) orally (PO) in combination with paclitaxel administered by intravenous (IV) infusion at 80 mg/meter squared (m\^2) on days 1, 8, and 15 of repeated 28-day cycles.
62704314|NCT03601897|EXPERIMENTAL|Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2|Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
62704315|NCT03601897|EXPERIMENTAL|Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2|Dose expansion in triple-negative breast cancer (TNBC). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
62704316|NCT03601897|EXPERIMENTAL|Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2|Dose expansion in TNBC. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
61961136|NCT01369758|EXPERIMENTAL|Intrauterine pathology, myomectomy|Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
62143686|NCT02428556|ACTIVE_COMPARATOR|"breakthrough with may warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
62143687|NCT02428556|ACTIVE_COMPARATOR|"breakthrough with is warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
62505784|NCT01765270|ACTIVE_COMPARATOR|Saxagliptin|Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
62505785|NCT01765270|PLACEBO_COMPARATOR|Placebo|Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
62704317|NCT03601897|EXPERIMENTAL|Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2|Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
61961137|NCT05382624||Patients undergoing cesarean with spinal anesthesia|The AC-to-hip ratio was calculated by dividing the values of the abdominal (cm) and hip circumference (cm). Spinal anesthesia in the sitting position was performed in all patients using 2.4 ml 0.5% hyperbaric bupivacaine (12 mg). Intravenous ephedrine (5 mg) was given in case of persistent hypotension. The number of patients requiring ephedrine and the total amount of ephedrine used during surgery were recorded.
61961138|NCT02725710|ACTIVE_COMPARATOR|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
61961139|NCT02725710|ACTIVE_COMPARATOR|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
61961140|NCT00074152|ACTIVE_COMPARATOR|Arm I|Patients receive radiotherapy\* within 6 months after surgery.
61961141|NCT00074152|EXPERIMENTAL|Arm II|Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.
61961142|NCT02364739|EXPERIMENTAL|Written information|Written information
61961143|NCT02364739|EXPERIMENTAL|Written and oral information|Written and oral information
61961144|NCT02364739|NO_INTERVENTION|No intervention|Control
61961145|NCT05393258|EXPERIMENTAL|Arm 1: temporally-modulated pulsed radiotherapy (TMPRT)|Patients receive TMPRT daily as 10 pulses of 0.2 Gy each with a 3-minute interval between pulses (effective dose rate = 0.0667 Gy/min) to a total dose of 54 Gy at 2 Gy per day. Treatment continues for a total of 27 fractions in the absence of disease progression or unacceptable toxicity.
62704318|NCT03601897|EXPERIMENTAL|Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2|Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
62704319|NCT03601897|EXPERIMENTAL|Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2|Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 repeated 28-day cycles.
61961146|NCT06184932|EXPERIMENTAL|Home-based Arm and Hand Exercise (HAHE)|An occupational therapist (OT) will incorporate participants' preference, goals, and current function to co-create UL exercise activities with participants. The exercise activities will be based on real-life activities that participants are familiar with. During the 6-week TeleRehab period, participants will complete 30 one-hour sessions of UL exercise activities, on their own without immediate supervision.
61961147|NCT06184932|EXPERIMENTAL|Exergame|An occupational therapist (OT) will incorporate participants' preference, goals, and current function to select UL exercise activities with participants from the RehabKit program software. During the 6-week TeleRehab period, participants will complete 30 one-hour sessions of UL exercise activities, on their own without immediate supervision.
61961148|NCT06379412||Colorectal Cancer(CRC)|People who are diagnosed with CRC by colonoscopy and pathological biopsy
61961149|NCT06379412||Colorectal adenoma(CRA)|People who are diagnosed with CRA by colonoscopy and pathological biopsy
61961150|NCT06379412||Colorectal polyp(CRP)|People who are diagnosed with CRP by colonoscopy and pathological biopsy
61961151|NCT06379412||Healthy|People who have no obvious abnormality in the whole colon
61961152|NCT01806298|EXPERIMENTAL|Saizen®|
61961153|NCT02414997|EXPERIMENTAL|RIPC group|Surround left upper limb with cuff, inflate cuff to 200 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
61961154|NCT02414997|SHAM_COMPARATOR|Sham RIPC group|Surround left upper limb with cuff, inflate cuff to 20 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
62704320|NCT03601897|EXPERIMENTAL|Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2|Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
62704321|NCT03601897|EXPERIMENTAL|Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2|Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
61961155|NCT04524390|EXPERIMENTAL|Maralixibat|"Maralixibat chloride oral solution administered twice daily, up to 600\* microgram per kilogram, for 26 weeks and in the OLE for all patients.~\*equivalent to 570 mcg/kg/day maralixibat free base"
61961156|NCT04524390|PLACEBO_COMPARATOR|Placebo|Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and continue in the open label extension (OLE) will receive maralixibat after Week 26.
61961157|NCT06293495|ACTIVE_COMPARATOR|Single Cephalic Screw System|A Gamma 3 nail (single cephalic screw system) will be used for osteosynthesis of the fracture.
62704322|NCT03601897|EXPERIMENTAL|Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2|Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
62704323|NCT03601897|EXPERIMENTAL|Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2|Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\^2 on days 1, 8, and 15 of repeated 28-day cycles.
62704324|NCT05954091|EXPERIMENTAL|OH2 Injection|Subjects will get OH2 injection every two weeks, and up to 8mL for each treatment. There will have three virus titers: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.
61961158|NCT06293495|EXPERIMENTAL|Double Cephalic Screw System|A Chimaera nail (system with double cephalic screw) will be used for osteosynthesis of the fracture.
61961159|NCT02088281|EXPERIMENTAL|Indigo naturalis extract in oil ointment|Indigo naturalis extract in oil ointment: each gram of ointment contains 200 μg±20 μg of indirubin.
61961160|NCT00730405|ACTIVE_COMPARATOR|Albaconazole 100mg|Albaconazole for 36 weeks
61961161|NCT00730405|ACTIVE_COMPARATOR|Albaconazole 200mg|Albaconazole for 36 weeks
61961162|NCT00730405|ACTIVE_COMPARATOR|Albaconazole 400mg|Albaconazole for 36 weeks
61961163|NCT00730405|ACTIVE_COMPARATOR|Albaconazole 400mg 24 weeks, Placebo 12 weeks|Albaconazole for 24 weeks, Placebo for 12 weeks
61961164|NCT00730405|PLACEBO_COMPARATOR|Placebo 400 mg|Placebo for 36 weeks
61961165|NCT04040114|NO_INTERVENTION|Lead-in phase|During the lead-in phase treating clinicians will not be given the Molemap artificial intelligence diagnosis in real-time (i.e. in clinic with the patient).
61961166|NCT04040114|ACTIVE_COMPARATOR|Active phase|During the active phase treating clinicians will be given the Molemap artificial intelligence diagnosis in real-time.
61961167|NCT01378949|ACTIVE_COMPARATOR|PsCB Group|Ultrasound-Guided Psoas Compartment Block will be used in patients for pain relief after THA
61961168|NCT01378949|ACTIVE_COMPARATOR|FICB Group|Ultrasound-Guided Fascia Iliaca Compartment Block will be used in patients for pain relief after THA
61961169|NCT01378949|ACTIVE_COMPARATOR|Patient-Controlled Analgesia|Patient-controlled analgesia will be used for pain relief after THA
61961170|NCT05847920|EXPERIMENTAL|SHR-2010 Injection|
61961171|NCT05847920|PLACEBO_COMPARATOR|Placebo|
61961172|NCT05705596|EXPERIMENTAL|Sucrose|10% (w/v) sucrose in water
61961173|NCT05705596|EXPERIMENTAL|Hesperetin|7% (w/v) sucrose in water + 50 mg/L Hesperetin
61961174|NCT02277756|EXPERIMENTAL|high functioning Autism|Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with high functioning Autism
61961175|NCT02277756|PLACEBO_COMPARATOR|witness|Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with a witness
61961176|NCT00961233|EXPERIMENTAL|inhaled/swallowed budesonide|
62143688|NCT02428556|EXPERIMENTAL|breakthrough only|"Scenario describes study results with breakthrough language, no cautions about conditional approval"
62143689|NCT03684993|EXPERIMENTAL|Arabic gum extract|natural product Arabic gum (acacia gum) prepared as a mouthwash
62539220|NCT01789723|EXPERIMENTAL|Cohort 5: Fusilev - 1 dose|"Fusilev: 5 mg/m2 once on Day 2.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
62143690|NCT03684993|EXPERIMENTAL|Licorice root extract|natural product Licorice (Glycyrrhiza Glabra) root extract prepared as a mouthwash
61961177|NCT00961233|ACTIVE_COMPARATOR|viscous/swallowed budesonide|
62143691|NCT03684993|ACTIVE_COMPARATOR|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
61961178|NCT00786149|EXPERIMENTAL|1|Participants will receive NRT and Motivational Interviewing counseling
62143692|NCT01579799|ACTIVE_COMPARATOR|Dose 0.5|
62143693|NCT01579799|ACTIVE_COMPARATOR|Dose 7.5|
62704325|NCT06656494|EXPERIMENTAL|ICP-248 in combination with azacitidine|
61961179|NCT00786149|ACTIVE_COMPARATOR|2|Varenicline plus brief advice
61961180|NCT03462303|PLACEBO_COMPARATOR|tDCS sham + balanced drink|
62143694|NCT01579799|ACTIVE_COMPARATOR|Dose 3|
62143695|NCT01579799|ACTIVE_COMPARATOR|Dose 1.2|
62347741|NCT01852695|EXPERIMENTAL|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
62539221|NCT02066948|ACTIVE_COMPARATOR|Skew meal pattern w/ wt loss&exercise|Skew meal pattern w/ wt loss\&exercise e
62704326|NCT06607406|ACTIVE_COMPARATOR|Conventional fractionation (5 Fractions)|5 fractions per week, daily treatment Monday-Friday; dosage at the discretion of the treating radiation oncologist per standard of care
61961181|NCT03462303|EXPERIMENTAL|tDCS sham + tyrosine depleted drink|
61961182|NCT03462303|EXPERIMENTAL|tDCS anodal + balanced drink|
62143696|NCT03288688|EXPERIMENTAL|Exercise program and education|An exercise program in the form of home exercise videos will be given to the participants in this group. They will be asked to perform a minimum of two 35-minute exercise sessions per week, over a period of 11 weeks. They will also be required to attend three group exercise sessions, to confirm correct execution of the exercises. A short educational presentation on injury prevention will be offered at the beginning of the study, followed by three informative e-mails over the course of the study.
62143697|NCT03288688|NO_INTERVENTION|No intervention|Participants in this group will be asked to continue their usual activities.
62143698|NCT00293761|EXPERIMENTAL|Travatan, Investigational|
62539222|NCT02066948|ACTIVE_COMPARATOR|even meal pattern w/ wt loss&exercise|even meal pattern w/ wt loss\&exercise
62704327|NCT06607406|EXPERIMENTAL|Accelerated fractionation (6 Fractions)|6 fractions per week, daily treatment plus twice daily treatment for 1 day Monday-Friday; dosage at the discretion of the treating radiation oncologist per standard of care
61961183|NCT03462303|EXPERIMENTAL|tDCS anodal +tyrosine depleted drink|
61961184|NCT01734863|EXPERIMENTAL|Radiotherapy Arm|"this study arm will take External Beam radiotherapy as follows :~* Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy \[IMRT\] is allowed.~* Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following:~  1. Age \< 18 years old.~ 2. Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~ 3. Negative surgical margins.~ 4. Patients show good safety profile and acceptable performance status."
61961185|NCT01734863|NO_INTERVENTION|No Radiotherapy Arm|"this arm will not take radiotherapy and their inclusion criteria as following:~1. Age \< 18 years old.~2. Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~3. Negative surgical margins.~4. Patients show good safety profile and acceptable performance status."
61961186|NCT01010061|EXPERIMENTAL|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
62143699|NCT00293761|ACTIVE_COMPARATOR|Travatan|
62143700|NCT02021396|EXPERIMENTAL|Embolization|this arm of the study was interventional (embolization) with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180) read by 2 expert radiologists blinded to the study arm
61961187|NCT01010061|ACTIVE_COMPARATOR|rituximab + chlorambucil (RClb)|Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
61961188|NCT01010061|ACTIVE_COMPARATOR|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
61961189|NCT02082275|EXPERIMENTAL|OB Nest|OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
61961190|NCT02082275|NO_INTERVENTION|Traditional Prenatal care|Traditional prenatal visits in clinic with OB providers.
61961191|NCT02614586|EXPERIMENTAL|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
61961192|NCT02614586|EXPERIMENTAL|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
61961193|NCT02614586|EXPERIMENTAL|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
61961194|NCT02614586|EXPERIMENTAL|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
62143701|NCT02021396|NO_INTERVENTION|Surveillance|this arm of the study was non-interventional (surveillance), with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180 ) read by 2 expert radiologists blinded to the study arm
62704328|NCT06615973||Patients|Participants who were enrolled in Natural History Study in past 6 years
62704329|NCT06616987|EXPERIMENTAL|mTNBC patient who is administered with Sacituzumab Govitecan|"▪ Sacituzumab Govitecan group~- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9"
62347742|NCT01852695|NO_INTERVENTION|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
62505786|NCT01780480|EXPERIMENTAL|Dynamic Chinese herbal granule formula|Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
62347743|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
62505787|NCT01780480|PLACEBO_COMPARATOR|Placebo|The process is the same as the experimental arm, except that the matched placebo granules should be in turn of Chinese herbal granules.
62505788|NCT06189911||transfused|Group of patients who received perioperative blood transfusions which was defined as the transfusion of packed red cells during the operation and 48 hours after surgery.
62143702|NCT04378205|EXPERIMENTAL|0.014/0.018 NiTi arch wire|0.014-inch NiTi on one side /0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
62347744|NCT01669642|EXPERIMENTAL|Ketamine|participants who get the ketamine sedation will be enrolled. there is no control or comparison group.
62347745|NCT03084289|EXPERIMENTAL|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10\^8 vp i.v.
62347746|NCT03084289|EXPERIMENTAL|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10\^9 vp i.v.
62347747|NCT03084289|EXPERIMENTAL|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10\^10 vp i.v.
62505789|NCT06189911||non-transfused|Group of patients who did not received perioperative blood transfusions
62505790|NCT01816568|ACTIVE_COMPARATOR|Group 1|SILS appendectomy
62704330|NCT05394857|EXPERIMENTAL|Treatment group|SHR-1314 s.c
62704331|NCT03427996||Coronary disease|
62704332|NCT05691465|EXPERIMENTAL|Treatment (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes. Cycles repeat Q6W for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gallium Ga 68-dotatate IV during screening then undergo PET/CT scan at baseline and collection of blood throughout the trial.
61961195|NCT02614586|EXPERIMENTAL|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
61961196|NCT02614586|EXPERIMENTAL|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
61961197|NCT01564381|EXPERIMENTAL|Resveratrol|The capsules will contain 90mg of resveratrol.
61961198|NCT01564381|EXPERIMENTAL|ResA|ResA is a product produced by using patented technology that physically binds resveratrol to arginine, creating a novel conjugate. The capsules will contain 90mg of resveratrol.
61961199|NCT01564381|PLACEBO_COMPARATOR|Placebo|The placebo will be cellulose.
61961200|NCT05704361|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD) IV: RO7121932- Dose Escalation Cohorts 1 to 6 and Later Cohorts|Participants will receive a single IV dose of RO7121932 on treatment Day 1. The planned starting dose of RO7121932 is 7 milligrams (mg) and will be escalated up to 2000 mg. The maximum dose will not exceed 4000 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.
62704333|NCT06668922|EXPERIMENTAL|Healthy volunteers|Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
62704334|NCT06668922|EXPERIMENTAL|Irritable Bowel Syndrome Patients with Diarrhea (IBS-D)|Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS.
61961201|NCT05704361|EXPERIMENTAL|Part 2: SAD SC: RO7121932- Dose Escalation Cohorts 1 to 2|Participants will receive a single SC dose of RO7121932 on treatment Day 1. The planned starting dose of RO7121932 is 70 mg and will be escalated up to 200 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.
61961202|NCT05704361|EXPERIMENTAL|Part 3: Multiple Ascending Dose (MAD) SC: RO7121932- Dose Escalation Cohorts 1 to 3|Participants will receive multiple SC doses of RO7121932, once weekly on treatment Day 1 through Day 22. The planned starting dose of RO7121932 is 70 mg and will be escalated up to 700 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.
62704335|NCT06668922|EXPERIMENTAL|Irritable Bowel Syndrome Patients with Constipation (IBS-C)|Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS.
62704336|NCT04464707|EXPERIMENTAL|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly for 3 months.~Participants weighing \< threshold will receive Dose B subcutaneously monthly for 3 months."
61961203|NCT06506786|EXPERIMENTAL|Garden First|Participants assigned to this study arm undergo the Garden-fresh Produce intervention during the first period and the Supermarket Produce intervention during the second period.
62143703|NCT04378205|EXPERIMENTAL|0.016/0.018 NiTi arch wire|0.016-inch NiTi on one side / 0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
62704337|NCT04464707|PLACEBO_COMPARATOR|Placebo|Matching placebo
62704338|NCT05757193|EXPERIMENTAL|250 mg/kg ketone ester|The first 5 patients within each SGLT2i stratum will receive ketone ester as (R)-3-hydroxybutyl (R)-3-hydroxybutyrate at 250 mg/kg.
62704339|NCT05757193|EXPERIMENTAL|500 mg/kg ketone ester|The second 5 patients within each SGLT2i stratum will receive ketone ester as (R)-3-hydroxybutyl (R)-3-hydroxybutyrate at 500 mg/kg.
62704340|NCT06661369|EXPERIMENTAL|Individual ASD Children|Activities were applied individually for the IND group. Individual training was applied according to the treatment protocol, activities done by step by step from simple to complex. Each activities for individuals training will be applied for 2 hours, three sessions per week, for ten successive months
62704341|NCT06661369|EXPERIMENTAL|Group of ASD Children|Activities were applied in group . Group training was applied according to the treatment protocol, activities done by step by step from simple to complex. each activities for group training will be applied for 2 hours, three sessions per week, for ten successive months
62704342|NCT06597019|EXPERIMENTAL|Inclisiran|Year 1 - inclisiran sodium subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium subcutaneous injection (given at Days 450 and 630)
62704343|NCT06597019|PLACEBO_COMPARATOR|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium subcutaneous injection (given at Days 360, 450, and 630)
62704344|NCT06663345|ACTIVE_COMPARATOR|TAP (Transversus Abdominis Plan) Block|A bilateral TAP or QLB-1 block will be performed. This block is a standard procedure in our hospital for the management of postoperative pain.
62704345|NCT06663345|EXPERIMENTAL|QLB-1 (Lateral Quadratum Lumborum ) Block|Investigation of the efficacy of QLB-1 block compared to TAP block.
62143704|NCT05197127|EXPERIMENTAL|Device Walking Group|Twelve participants over 65 years old completed a total of twelve 30-minute gait training sessions over a period of 4-6 weeks using the GEMS-H. All gait training sessions were completed in the community spaces at a senior living community. Gait training included dynamic over-ground walking (both self-selected and fast-paced),variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
62347748|NCT03084289|EXPERIMENTAL|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10\^10 vp s.c.
62347749|NCT03084289|EXPERIMENTAL|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10\^11 vp s.c.
62347750|NCT03084289|EXPERIMENTAL|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10\^6 pfu i.v.
62505791|NCT01816568|ACTIVE_COMPARATOR|Group 2|Three port laparoscopic appendectomy
62505792|NCT05108506|EXPERIMENTAL|No strict need to void following surgery before discharge|Participants randomized to this arm will have no strict need to void following surgery before they are discharged.
61961204|NCT06506786|EXPERIMENTAL|Supermarket First|Participants assigned to this study arm undergo the Supermarket Produce intervention during the first period and the Garden-fresh Produce intervention during the second period.
61961205|NCT03379168|PLACEBO_COMPARATOR|Placebo Injection|Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.
61961206|NCT03379168|ACTIVE_COMPARATOR|Corticosteroid Injection|Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.
61961207|NCT03379168|EXPERIMENTAL|Lipogems Injection|Patients who are randomized to the Lipogems treatment group will undergo a lipoaspiration from their abdomen and autologous injection of the harvested adipocytes into their knee. It is standard to harvest three to four times more adipose tissue than is planned to be injected to account for tissue processing by the Lipogems device. The investigators plan to inject 7cc of autologous adipose tissue. Thus, the investigators will harvest between 25 and 30 cc of adipose tissue from each patient. The tissue will be processed immediately and 7cc will be injected. Any remaining adipose tissue will be disposed of immediately in biohazardous waste.
62347751|NCT03084289|EXPERIMENTAL|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10\^7 pfu i.v.
62347752|NCT03084289|EXPERIMENTAL|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10\^8 pfu i.v.
62704346|NCT05106036|EXPERIMENTAL|Intervention Arm|Home BP data will be averaged each month via OmronConnect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health.Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the CDS (Clinical Decision Support) tool to assist their physicians with their blood pressure management. Study Team will not be involved in treatment decision making, it will be determined by subject's treating physician. .
62347753|NCT05556551|OTHER|Hybrid resin ceramic restoration|Dental restoration
62704347|NCT05106036|NO_INTERVENTION|Usual Care Arm|Physicians will continue to make decisions about the participant's blood hypertension management as usual without the CDS tool.
62704348|NCT06566378|EXPERIMENTAL|Placed under arm Buzzy Group|In children pre-procedure, buzzy was placed under the armpit. The children were made before starting the application. It continued until the end of vaccination procedure.
61961208|NCT03773991||Maintenance Hemodialysis Patients|"Patients on chronic hemodialysis therapy due to end-stage renal disease.~* Proton Lung MRI~* Sodium MRI of the leg~* Chest CT~* Transthoracic Echocardiography~* Fractional Exhaled Nitric Oxide~* Six-Minute Walk Test~* Pulmonary Function Tests~* Blood sampling~* Self-administered dyspnea questionnaires"
62347754|NCT05556551|OTHER|Full ceramic restoration|Dental restoration
61961209|NCT01583491|ACTIVE_COMPARATOR|prf group.peridontal problem|prf insert into surgical site immediate after surgery
61961210|NCT01583491|PLACEBO_COMPARATOR|control group|
61961211|NCT05460845|EXPERIMENTAL|Phase 2 Intervention|Low-Carbohydrate Diet
61961212|NCT01918774|OTHER|Cognitive behavior therapy for work success|Fifty participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.
61961213|NCT03641638||Low level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH\<4.78mIU/L，TPOAb at 34-102 IU/ml.
62347755|NCT03676153|EXPERIMENTAL|Nurse-guided arm|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
62347756|NCT03676153|ACTIVE_COMPARATOR|Non nurse-guided arm|Integrative medicine treatment program, with no nurse-provided guidance on patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
62347757|NCT00740922||1|
62347758|NCT02441855||pneumonia|patients with community-acquired pneumonia
62347759|NCT02441855||control|patients admitted to emergency department with shortness of breath
62347760|NCT05828732|EXPERIMENTAL|app user group|The participants in this group start using wearable devices to monitor their heart rate and a mobile app to assist with the management of hyperthyroidism after being diagnosed and beginning treatment with anti-thyroid medication.
62347761|NCT05828732|NO_INTERVENTION|non-user group|The participants in this group begin treatment with anti-thyroid medication after being diagnosed with thyrotoxicosis, but they do not use the wearable devices or mobile app used in this study.
62347762|NCT05765487|ACTIVE_COMPARATOR|Sildenafil Cream, 3.6%|Contains both Sildenafil and L-arginine
62347763|NCT05765487|PLACEBO_COMPARATOR|Placebo Cream|Contains L-arginine, no Sildenafil
62347764|NCT05765487|OTHER|Vehicle Cream|Contains no L-arginine, no Sildenafil
62347765|NCT02797691|EXPERIMENTAL|CaCBT plus Treatment As Usual|"Receiving CaCBT intervention in addition to the Treatment as usual"
62347766|NCT02797691|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Receiving Treatment as usual
62347767|NCT02892838|EXPERIMENTAL|mobile bearing knee prosthesis|use of the Scorpio mobile bearing knee system for total knee arthroplasty
62347768|NCT02892838|ACTIVE_COMPARATOR|fixed bearing|use of the Scorpio fixed bearing knee system for total knee arthoplasty
62347769|NCT05690334|EXPERIMENTAL|Control group|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia
62347770|NCT05690334|EXPERIMENTAL|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
62704349|NCT06566378|EXPERIMENTAL|Placed in standard Buzzy Group|In children pre-procedure, buzzy was placed on the arm. The children were made before starting the application. It continued until the end of vaccination procedure.
62704350|NCT06566378|NO_INTERVENTION|Control Group|In this group, children received routine vaccination procedure.
62704351|NCT05238922|EXPERIMENTAL|Phase 1a Dose Escalation|"INCB123667 will be administered at a protocol defined starting regimen once daily (QD) orally in 28-day cycles.~Subsequent dose regimens will be determined during study conduct."
61961214|NCT03641638||Medium level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH\<4.78mIU/L，TPOAb at 103-204 IU/ml.
61961215|NCT03641638||High level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH\<4.78mIU/L，TPOAb \>205IU/ml.
62347771|NCT05690334|EXPERIMENTAL|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
61961216|NCT03641638||Control group|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of negative Thyroid antibody, thyroid function: normal FT3 and FT4, TSH\<4.78mIU/L.
62347772|NCT06078787|EXPERIMENTAL|Olaparb|
62347773|NCT06255054||Non-Users|People who do not use cannabis.
62505793|NCT05108506|PLACEBO_COMPARATOR|Strict need to void following surgery before discharge|Participants randomized to this arm will have a strict need to void following surgery before they are discharged.
62704352|NCT05238922|EXPERIMENTAL|Phase 1b: Dose Expansion Cohort Disease Group 1|INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with gynecologic tumors (epithelial ovarian/fallopian/primary peritoneal carcinoma) will enroll in this group.
62704353|NCT05238922|EXPERIMENTAL|Phase 1b: Dose Expansion Cohort Disease Group 2|INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with Endometrial/Uterine cancer will enroll in this group.
62704354|NCT05238922|EXPERIMENTAL|Phase 1b: Dose Expansion Cohort Disease Group 3|INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with gastric, Gastro Esophageal Junction (GEJ), and esophageal adenocarcinomas will enroll in this group.
62704355|NCT05238922|EXPERIMENTAL|Phase 1b: Dose Expansion Cohort Disease Group 4|INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with Triple Negative Breast Cancer(TNBC) will enroll in this group.
61961217|NCT02837783|EXPERIMENTAL|290 μg linaclotide|Linaclotide Oral, once daily
62143705|NCT03650465|EXPERIMENTAL|CT/BTP|Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck \& Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
62347774|NCT06255054||Daily Flower Users|People who use cannabis flower daily.
62347775|NCT06255054||Daily Concentrate Users|People who use cannabis concentrate products daily.
62347776|NCT06255054||Occasional Flower Users|People who use cannabis flower at least once a month and no more than three times per week.
62347777|NCT03723005||Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
62347778|NCT03723005||Standard-of-Care Phototherapy|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
62347779|NCT04209257|EXPERIMENTAL|Functional Electrical Stimulation protocol|Participants will be evaluated with and without the use of functional electrical stimulation while walking to determine the neuroprosthetic and neurotherapeutic effects.
62347780|NCT05496894|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 4 mg/m\^2 every 3 months (Q3M).
62505794|NCT01836614|ACTIVE_COMPARATOR|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
62505795|NCT01836614|PLACEBO_COMPARATOR|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
62505796|NCT02625506|PLACEBO_COMPARATOR|Levobupivacaine|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
62704356|NCT05238922|EXPERIMENTAL|Phase 1b: Dose Expansion Cohort Disease Group 5|INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with HR+/HER2- breast cancer who have had disease progression on or been intolerant of a CDK4/6 inhibitor will enroll in this group.
61961218|NCT02837783|PLACEBO_COMPARATOR|Matching Placebo|Matching Placebo Oral, once daily
61961219|NCT05541952|EXPERIMENTAL|Intervention|The intervention arm will receive the 0.1 milliliter (mL) dose of BCG vaccine intradermally in the deltoid muscle region at the lower insertion level on the upper outer face of the right arm. When this recommendation can not be followed, the participant will be excluded from the study.
62347781|NCT05496894|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 8 mg/m\^2 every 3 months (Q3M).
62347782|NCT05496894|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 12 mg/m\^2 every 3 months (Q3M).
62347783|NCT02534194||Newborn Infant|Newborn babies (within 7 days of birth) born between 23-42 weeks.
62704357|NCT05238922|EXPERIMENTAL|Phase 1b: Dose Expansion Cohort Disease Group 6|INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors will enroll in this group.
61961220|NCT05541952|NO_INTERVENTION|Control|Participants assigned to the control arm will not receive any intervention and will be followed up with QFT and Genexpert for the detection of Mtb infection or diagnosis of tuberculosis.
61961221|NCT01507597|OTHER|Healthy Subjects|
61961222|NCT01507597|OTHER|T2DM|
61961223|NCT01507597|OTHER|T1DM|
61961224|NCT03706456|EXPERIMENTAL|Darvadstrocel 24 mL|Darvadstrocel (Cx601) 24 mL suspension of 120 million cells of expanded allogeneic adipose-derived stem cells (eASC) as an intralesional injection, once on Day 1.
61961225|NCT02697825|OTHER|changes in eye|Changes in both intraocular pressure and optic nerve sheath diameter will be correlated in robotic surgeries to find out any statistical relation existing between two.
61961226|NCT02639143|EXPERIMENTAL|ticagrelor|Ticagrelor, 180 mg, oral administration. followed by 90 mg bid
61961227|NCT02639143|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 600 mg loading dose taken orally, followed by 75 mg qd.
61961228|NCT05120128|EXPERIMENTAL|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will enter wearing their own lens, then given the TEST Lens for the remainder of the study.
61961229|NCT02067338|PLACEBO_COMPARATOR|normal saline|During posterior lumbar spinal surgery,one group of patient received normal saline soaked collagen sponge.
61961230|NCT02067338|ACTIVE_COMPARATOR|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery ,Another group of patients received 1 mg morphine-soaked in epidural oxidized cellulose.
61961231|NCT02742610|EXPERIMENTAL|Mindfulness with Contingency Management|The intervention (MSI-CM) will involve two individual pre-quit in-person sessions and two post-quit phone counseling sessions, a series of brief mindfulness trainings that will be delivered via smartphone, that prompts participants to practice a mindfulness exercise five times a day while abstinent during the 2-week incentivized abstinence period (using CM) plus an additional 2 weeks (without CM) following the participant's target quit date. The MSI-CM participants will be asked to provide CO video via smartphone twice daily with monetary incentives provided (CM). Participants will receive monetary incentives contingent on each confirmed CO level (less than 7 ppm) for the CM period. We will use CM as an adjunct strategy to enhance the efficacy of mindfulness training.
61961232|NCT02742610|ACTIVE_COMPARATOR|Active Control|Participants assigned to the control group will receive two individual pre-quit in-person sessions and two post-quit phone counseling sessions, similar to the MSI-CM except for mindfulness introduction/discussion. Participants in the control group will receive the same monetary incentives on average as the participants in the MSI-CM for submitting CO videos, regardless of CO levels (non-abstinent contingent), during the 2-week post-TQD period. Each participant in the group (the non-contingent CO group) will be yoked to a single participant (selected randomly with stratification) in the MSI-CM. The yoked participant receives the same amount of monetary incentives as his or her matched participant in the contingent CO (MSI-CM) group.
62143706|NCT03650465|EXPERIMENTAL|REBT|Cognitive-behavioral therapy (CBT) in the form of REBT was based on the approach of Dryden \& DiGiuseppe (1990), having as a central tenet changing dysfunctional emotions (e.g., anxiety) into functional ones (e.g., healthy anxiety/concern) by changing irrational beliefs into rational beliefs using cognitive, emotive, and behavioral techniques. The structure of an REBT session parallels the CT/BTP session structure including the same elements, but often with a different content. In its elegant/specific form, used here, REBT is focused on changing the core irrational beliefs (i.e., evaluative beliefs/appraisals) seen as the fundamental etiopathogenetic mechanism of GAD.
61961233|NCT01996293||Lamotrigine for Bipolar|antepartum and peripartum women taking lamotrigine for Bipolar Disorder
61961234|NCT01052350||Parkinson disease|individuals with Parkinson disease
61961235|NCT01052350||healthy control|individuals without Parkinson disease
61961236|NCT06366620|EXPERIMENTAL|FAST-B PEERS|Parents in FAST-B PEERS group will receive standard 5-week FAST-B program as well as weekly check-in support from trained 'Peer Support' parents who have previously been through parent behavioral management training programs.
62143707|NCT03650465|EXPERIMENTAL|ACT/ABBT|Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
62347784|NCT01478438|EXPERIMENTAL|Treat and Excise|All subjects will be treated with Interstitial Laser Therapy (ILT) followed by excision no later than 28 days post ablation.
62347785|NCT03737045|OTHER|Decision Aid Testing|Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
62505797|NCT02625506|ACTIVE_COMPARATOR|Levobupivacaine and Tramadol|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
62505798|NCT02039063|EXPERIMENTAL|1|E6011 2 mg/kg
62505799|NCT02039063|EXPERIMENTAL|2|E6011 5 mg/kg
62505800|NCT02039063|EXPERIMENTAL|3|E6011 10 mg/kg
62505801|NCT02039063|EXPERIMENTAL|4|E6011 15 mg/kg
62505802|NCT05799196||Microfracture|The patient with meniscus tear would be performed meniscus repair with additional microfracture
62505803|NCT05799196||Conventional|The patient with meniscus tear would be performed meniscus repair
62505804|NCT06614309|EXPERIMENTAL|Acute exposure: Placebo, Progressive Carbon Dioxide, Intermittent Hypoxia|Study group will receive the three interventions in this order: Placebo, Progressive Carbon Dioxide, then Intermittent Hypoxia
61961237|NCT06366620|ACTIVE_COMPARATOR|FAST-B|Parents in FAST-B group will receive standard FAST-B program with 5 weekly group sessions with clinician.
61961238|NCT05038436|EXPERIMENTAL|Polyglucosamine L112|composed of (beta-1.4 polymer of D-glucosamine and N-acetyl-D-glucosamine)
61961239|NCT05038436|PLACEBO_COMPARATOR|Placebo|Dicalcium phosphate, cellulose
61961240|NCT03947320|EXPERIMENTAL|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
61961241|NCT00147446|EXPERIMENTAL|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
61961242|NCT00147446|OTHER|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
61961243|NCT03056885|EXPERIMENTAL|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
61961244|NCT03056885|EXPERIMENTAL|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
61961245|NCT05930977||patient undergone total thyroidectomy followed by thyroid auto transplantation|
61961246|NCT06063824|EXPERIMENTAL|Intervention Arm|
61961247|NCT06332235||Experiment group|"1. Subject ≥ 20 years of age~2. Newly diagnosed of acute brain injury with Foley insertion with 5 days"
61961248|NCT04022993|ACTIVE_COMPARATOR|Lantus® SoloStar®|Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement
61961249|NCT04022993|EXPERIMENTAL|Insulin RinGlar®|Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement
61961250|NCT05214456|EXPERIMENTAL|Interventional group|The interventional group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include dry needling plus sham mobilization for the lumbar spine and routine physiotherapy. The needles will be inserted to obtain local twitch responses, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. Sham mobilization for the lumbar spine will be done in the same way as the real mobilization, with the difference that the mobilization will be applied only on the skin surface and less than the first degree of Maitland's mobilization. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
61961251|NCT05214456|ACTIVE_COMPARATOR|Control group|The control group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include anterior-posterior mobilization based on the Maitland technique for the lumbar spine plus sham dry needling and routine physiotherapy. Based on the findings of the patient evaluation, the severity, rhythm, time, the degree of mobilization and the place of force (spine or lamina) will be determined. For sham dry needling The needles will be inserted subcutaneously and there will be no local twitch response. Then the needles will be left in place for 20 minutes. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
61961252|NCT02906618|EXPERIMENTAL|LY3039478 - Oral|LY3039478 given once, orally
62505805|NCT06614309|EXPERIMENTAL|Acute exposure: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide|Study group will receive the three interventions in this order: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide
62704358|NCT05238922|EXPERIMENTAL|Phase 2a Dose Escalation Treatment Group A (TGA)|INCB123667 administered in combination with palbociclib at the recommended doses in participants with HR+/HER2- breast cancer and in participants with a different tumor as defined in the protocol.
62704359|NCT05238922|EXPERIMENTAL|Phase 2a Dose Escalation Treatment Group B (TGB)|INCB123667 administered in combination with palbociclib and fulvestrant at the recommended doses in participants with HR+/HER2- breast cancer as defined in the protocol.
62704360|NCT05238922|EXPERIMENTAL|Phase 2a Dose Escalation Treatment Group C (TGC)|INCB123667 administered in combination with ribociclib at the recommended doses in participants with HR+/HER2- breast cancer and in participants with a different tumor as defined in the protocol.
62347786|NCT04740736|EXPERIMENTAL|Saline Infusion|
62347787|NCT04740736|SHAM_COMPARATOR|Sham Infusion|
62505806|NCT06614309|EXPERIMENTAL|Acute exposure: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide|Study group will receive the three interventions in this order: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide
62505807|NCT06614309|EXPERIMENTAL|Acute exposure: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo|Study group will receive the three interventions in this order: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo
62704361|NCT05238922|EXPERIMENTAL|Phase 2a Dose Escalation Treatment Group D (TGD)|INCB123667 administered in combination with ribociclib and fulvestrant at the recommended doses in participants with HR+/HER2- breast cancer as defined in the protocol.
62704362|NCT05238922|EXPERIMENTAL|Phase 2a Dose Escalation Treatment Group E (TGE)|INCB123667 administered in combination with bevacizumab at the recommended doses in participants with HR+/HER2- breast cancer and in participants with a different tumor as defined in the protocol.
62704363|NCT05238922|EXPERIMENTAL|Phase 2a Dose Escalation Treatment Group F (TGF)|INCB123667 administered in combination with olaparib at the recommended doses in participants with HR+/HER2- breast cancer and in participants with a different tumor as defined in the protocol.
62704364|NCT05238922|EXPERIMENTAL|Phase 2a Dose Escalation Treatment Group G (TGG)|INCB123667 administered in combination with paclitaxel at the recommended doses in participants with HR+/HER2- breast cancer and in participants with a different tumor as defined in the protocol.
62347788|NCT02029495|EXPERIMENTAL|210 mg brodalumab|Administered via subcutaneous injections
62347789|NCT02029495|EXPERIMENTAL|140 mg brodalumab|Administered via subcutaneous injection
62347790|NCT02029495|PLACEBO_COMPARATOR|Placebo|Administered via subcutaneous injection until week 24.
62347791|NCT05424887|EXPERIMENTAL|100 mg AK3280|After the 4-week screening period, Eligible subjects will be administered daily 100 mg AK3280 b.i.d. for 24weeks
62347792|NCT05424887|EXPERIMENTAL|200 mg AK3280|After the 4-week screening period, Eligible subjects will be administered daily 200 mg AK3280 b.i.d. for 24weeks
61961253|NCT02906618|EXPERIMENTAL|13C 15N 2H-LY3039478 - IV|13C 15N 2H-LY3039478 given once, IV
61961254|NCT00669227|ACTIVE_COMPARATOR|1|autologous stem cells, Ficoll preparation, intracoronary administration at the same day of bone marrow cell aspiration
61961255|NCT00669227|PLACEBO_COMPARATOR|2|placebo is visually indistinguishable from verum due to integration of autologous erythrocytes, intracoronary administration the same day of bone marrow aspiration
61961256|NCT06177327||Adults with polyostotic fibrous dysplasia McCune Albright syndrome|A retrospective data collection and statistical analyses will be performed. Adults with polyostotic fibrous dysplasia McCune Albright syndrome, who underwent an hepato-bilio-pancreatic MRI since January 2002, during their follow-up
61961257|NCT02824952|EXPERIMENTAL|Tagrisso 80 mg|80 mg of Tagrisso(AZD9291) will be given every day for 6 or 12 weeks.
61961258|NCT02251184|EXPERIMENTAL|Aggrenox|extended release
61961259|NCT02251184|ACTIVE_COMPARATOR|dipyridamole+aspirin|immediate release
61961260|NCT05243836|ACTIVE_COMPARATOR|MiSight®|MiSight® Contact Lens (Omafilcon A, 60% water)
61961261|NCT05243836|EXPERIMENTAL|S.T.O.P® F2|S.T.O.P® F2 Contact Lens (Ocufilcon D, 55% water)
61961262|NCT05243836|EXPERIMENTAL|S.T.O.P® DT|S.T.O.P® DT Contact Lens (Ocufilcon D, 55% water)
61961263|NCT01163045|EXPERIMENTAL|neuromonitoring and neurostimulation|
61961264|NCT01163045|EXPERIMENTAL|neurostimulation of recurrent laryngeal nerve|
61961265|NCT06298994||study group|Patients with Chronic Obstructive Pulmonary Disease
61961266|NCT06298994||control group|Aged-matched healthy controls
62143708|NCT06272188|EXPERIMENTAL|Experimantal group|Couples applying to municipal marriage offices will be invited to participate in a study after obtaining permission. Those agreeing will be briefed by researchers about the study's purpose and methods, signing the IVCF afterward. Using a random number table, couples will be grouped as experimental or control. A month post-wedding, couples receive a call to confirm an online interview appointment. On the set date, a Zoom link for the interview will be shared. During this session, couples complete forms like IIF, PRRA, PCHLS, and PPHBS, followed by online preconception counseling lasting approximately an hour. This counseling, based on relevant literature and standardized by the research team, addresses risks identified during the Preconceptional Period Risk Assessment Form. After three months, couples revisit the PCHLS and PPHBS assessments.
62143709|NCT06272188|NO_INTERVENTION|Control group|No application will be made to the control group. Note: To act ethically, online preconception care counselling will be given to the participants in the control group after the data are obtained from the experimental and control groups. In addition, the website sagliklibaslangiclar.com will be introduced and it will be explained that they will be able to log in to the website with the username and password they will be given.
62143710|NCT05122026|EXPERIMENTAL|Arm 1: One month of daily isoniazid and rifapentine (4 weeks)|"* DTG 50 mg orally BID~  * DTG 50 mg + 2 NRTI each morning (non-study)~ * 2nd dose: DTG 50 mg each evening (during 1HP)~* 1HP: INH 300 mg + RPT 600 mg each morning for 4 weeks"
62143711|NCT05122026|EXPERIMENTAL|Arm 2: Three months of once-weekly isoniazid and rifapentine (12 weeks)|"* DTG 50 mg orally BID~  * DTG 50 mg + 2 NRTI each morning (non-study)~ * 2nd dose: DTG 50 mg each evening (during 3HP)~* 3HP: INH 900 mg + RPT 900 mg each week for 12 weeks"
62143712|NCT04486703|EXPERIMENTAL|Exercise with music group|physical therapy program combined with music therapy
61961267|NCT02550106|EXPERIMENTAL|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
61961268|NCT01751178|ACTIVE_COMPARATOR|Mouthwash with Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash with alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
61961269|NCT01751178|ACTIVE_COMPARATOR|Mouthwash without Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash without alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
61961270|NCT05776589||Group PCV-VG|In this group, pressure-controlled volume guaranteed ventilation (PCV- VG) was applied in patients undergoing vertebral surgery in the prone position.
61961271|NCT05776589||Group VCV|In this group, volume-controlled ventilation (VCV) was applied in patients undergoing vertebral surgery in the prone position.
61961272|NCT02480114|ACTIVE_COMPARATOR|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
61961273|NCT02480114|EXPERIMENTAL|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
61961274|NCT05006911|EXPERIMENTAL|PBOHB|Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac to evaluate safety and efficacy to improve uncorrected near vision in healthy presbyopic patients
62143713|NCT04486703|EXPERIMENTAL|Exercise group|physical therapy program without music
62143714|NCT03141918|EXPERIMENTAL|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
61961275|NCT01615185|EXPERIMENTAL|sulpiride plus amisulpride|sulpiride 800mg/d + amisulpride 400mg/d
61961276|NCT01615185|ACTIVE_COMPARATOR|full-dose amisulpride|amisulpride 800mg/d
61961277|NCT02176499|EXPERIMENTAL|Telmisartan, low dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
61961278|NCT02176499|EXPERIMENTAL|Telmisartan, high dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
61961279|NCT02176499|PLACEBO_COMPARATOR|Placebo|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
61961280|NCT03839901|EXPERIMENTAL|isometric training programme|'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
61961281|NCT03839901|EXPERIMENTAL|isotonic training programme|'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.
61961282|NCT00096070|EXPERIMENTAL|Arm I|Patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and fluorouracil IV continuously for 5.5 weeks. Beginning 4-6 weeks after the completion of chemoradiotherapy, patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment with gemcitabine repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
61961283|NCT06342414||Hepatocellular Carcinoma (Training)|A cohort of patients with histologically confirmed hepatocellular carcinoma (HCC)
61961284|NCT06342414||Intrahepatic Cholangiocarcinoma (Training)|A cohort of patients with histologically confirmed intrahepatic cholangiocarcinoma (ICC)
61961285|NCT06342414||Hepatocellular Carcinoma (Validation)|A cohort of patients with histologically confirmed hepatocellular carcinoma (HCC)
61961286|NCT06342414||Intrahepatic Cholangiocarcinoma (Validation)|A cohort of patients with histologically confirmed intrahepatic cholangiocarcinoma (ICC)
61961287|NCT02139228|EXPERIMENTAL|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
61961288|NCT02139228|ACTIVE_COMPARATOR|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
61961289|NCT05778097|EXPERIMENTAL|Apalutamide+ADT|Apalutamide (240 mg once daily) in combination with ADT for 12 cycles (28 days of each cycle)
61961290|NCT03785808|EXPERIMENTAL|Diet A (low carbohydrate)|Dietary Intervention A will be a low-carbohydrate/high fat, ketogenic-type diet. The diet will include salads, leafy green and non-starchy vegetables, nuts and seeds, eggs, fish and shellfish, and meats in most meals. Grains and added sugars will be excluded, and starchy vegetables, fruits, berries, and legumes will be limited to below 10% of total calorie intake. In addition full fat yogurt, cheeses, and butter will be allowed in moderate amounts. Participants will be encouraged to eat freely from whole-foods rich in fats such as avocados, nuts, seeds, olives, coconut and to use coconut, medium-chain triglyceride (MCT), olive, and avocado oils for cooking and baking on that diet. Participants will aim to fulfill at least 65% of their total calorie requirements from fats.
61961291|NCT03785808|EXPERIMENTAL|Diet B (low fat)|Dietary Intervention B will be low-fat, high carbohydrate whole-foods, plant-based diet. Most animal products and concentrated plant-based protein sources (such as soy isolates) will be excluded. Whole grains, particularly in their cooked form, legumes, vegetables, and fruits will be encouraged while excluding added sugars and refined grains. Added fats and oils will be discouraged on this diet as dietary fat should comprise less than 10% of total energy. Participants can eat freely from all types of fruits, vegetables, and cooked whole grains. Legumes will be emphasized as a replacement for meat and dairy products. Proteins similar to beef, pork, poultry, and dairy products, should be strictly limited, while lean proteins such as eggs, fish, and shellfish may be included occasionally.
61961292|NCT03785808|ACTIVE_COMPARATOR|Diet C (USDA control)|The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which \~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
61961293|NCT03870698|EXPERIMENTAL|Laparoscopic group|The patients who underwent laparoscopic procedures for periampullary tumors
61961294|NCT03870698|NO_INTERVENTION|Open group|The patients who underwent open procedures for periampullary tumors
62143715|NCT03141918|PLACEBO_COMPARATOR|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
62143716|NCT05259800|EXPERIMENTAL|Peppermint Oil|Subjects will be exposed to vapor of peppermint oil
62143717|NCT05259800|PLACEBO_COMPARATOR|Placebo|Subjects will be exposed to vapor of placebo (mineral oil)
62143718|NCT02431767|EXPERIMENTAL|Group 1: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.6 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL by intradermal (ID) injection over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
62143719|NCT02431767|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
62143720|NCT02431767|EXPERIMENTAL|Group 2: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
62143721|NCT02431767|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
62143722|NCT02431767|EXPERIMENTAL|Group 3: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
62505808|NCT06614309|EXPERIMENTAL|Acute exposure: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia|Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia
62505809|NCT06614309|EXPERIMENTAL|Acute exposure: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo|Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo
62505810|NCT06614309|PLACEBO_COMPARATOR|Placebo Group|Study group will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days intervention period. Subjects will then return within 7 days of their final training visit to repeat baseline testing
62505811|NCT06614309|EXPERIMENTAL|Training Group|Training Study group will be complete 6 cycles of either progressive CO2 ramp protocol or the intermittent hypoxia protocol for 60 minutes for every visit during the 14 days. Subjects will then return within 7 days of their final training visit to repeat baseline testing
61961295|NCT05916014||Chronic atrophic gastritis observed by white light endoscope|Get pictures from gastric antrum,gastric angle,lesser curvature of gastric body, cardia, gastric fundus, greater curvature of gastric body by white light endoscope
61961296|NCT02818400|EXPERIMENTAL|Composite tissue allotransplantation|
62704365|NCT05238922|EXPERIMENTAL|Phase 2b Dose Expansion Treatment Group H (TGH)|INCB123667 administered in combination with palbociclib at the recommended doses in participants with HR+/HER2- breast cancer and in participants with a different tumor as defined in the protocol.
61961297|NCT00501670||Group A|Collection of lesion samples and blood sampling from subjects aged \>=50 years with clinically diagnosed herpes zoster
61961298|NCT01725178|NO_INTERVENTION|Standard care|No intervention besides usual care
61961299|NCT01725178|ACTIVE_COMPARATOR|Cognitive and physical training|Patients will undergo the comprehensive program of cognitive and physical training.
62143723|NCT02431767|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
62505812|NCT02665884||Glaucoma EX-PRESS|Glaucoma patients who underwent glaucoma surgery between the years 2014-2015 and had diurnal intraocular pressure measurements over 24 hours.
62704366|NCT05238922|EXPERIMENTAL|Phase 2b Dose Expansion Treatment Group I (TGI)|INCB123667 administered in combination with palbociclib and fulvestrant at the recommended doses in participants with HR+/HER2- breast cancer as defined in the protocol
61961300|NCT03566147|EXPERIMENTAL|low dose group|300,000 HuRPE cells
61961301|NCT03566147|EXPERIMENTAL|middle dose group|500,000 HuRPE cells
61961302|NCT03566147|EXPERIMENTAL|high dose group|1,000,000 HuRPE cells
61961303|NCT02836730||Lumbar disc herniation|Patients with surgery for lumbar disc herniation;
61961304|NCT02836730||Spinal stenosis|Patients with surgery for lumbar spinal stenosis
61961305|NCT02836730||No surgery|Patients with no surgery for lumbar disc herniation; patients with no surgery for lumbar spinal stenosis;
61961306|NCT04970797||Conventional treatment group|Western medicine treatment
61961307|NCT04970797||Combination treatment group|Xinglouchengqi decoction combined with western medicine treatment
61961308|NCT01561170||Chronically venous ulcer|A group of 36 patients
61961309|NCT04026997|EXPERIMENTAL|Cohort 1|CIN-102 tablets by mouth twice daily for 14 days
62505813|NCT02665884||Control Group|Glaucoma patients who had been treated with anti-glaucoma drops and had diurnal intraocular pressure measurements over 24 hours.
61961310|NCT04026997|PLACEBO_COMPARATOR|Cohort 1 - Placebo|Placebo tablets by mouth twice daily for 14 days
61961311|NCT04026997|EXPERIMENTAL|Cohort 2|CIN-102 tablets by mouth twice daily for 14 days
61961312|NCT04026997|PLACEBO_COMPARATOR|Cohort 2- Placebo|Placebo tablets by mouth twice daily for 14 days
62505814|NCT00552149|ACTIVE_COMPARATOR|1|GEMOX
62505815|NCT00552149|EXPERIMENTAL|2|GEMOX + CETUXIMAB
62505816|NCT05445076|EXPERIMENTAL|BCD-180, low dose|Subjects in this arm will receive BCD-180 low dose infusions
62704367|NCT05238922|EXPERIMENTAL|Phase 2b Dose Expansion Treatment Group J (TGJ)|INCB123667 administered in combination with ribociclib at the recommended doses in participants with HR+/HER2- breast cancer and in participants with a different tumor as defined in the protocol.
62704368|NCT05238922|EXPERIMENTAL|Phase 2b Dose Expansion Treatment Group K (TGK)|INCB123667 administered in combination with ribociclib and fulvestrant at the recommended doses in participants with HR+/HER2- breast cancer as defined in the protocol.
62704369|NCT05238922|EXPERIMENTAL|Phase 2b Dose Expansion Treatment Group L (TGL)|INCB123667 administered in combination with bevacizumab at the recommended doses in participants with gynecologic tumors (epithelial ovarian/fallopian/primary peritoneal carcinoma) as defined by the protocol.
61961313|NCT04026997|EXPERIMENTAL|Cohort 3|CIN-102 tablets by mouth twice daily for 14 days
61961314|NCT04026997|ACTIVE_COMPARATOR|Cohort 3- Placebo|Placebo tablets by mouth twice daily for 14 days
61961315|NCT02338141|EXPERIMENTAL|Portable colposcopy|Diagnostic evaluation with 8x magnification portable colposcopy after visual inspection with acetic acid
61961316|NCT02338141|ACTIVE_COMPARATOR|Conventional colposcopy|Diagnostic evaluation with standard 25x magnification conventional colposcopy after visual inspection with acetic acid
62143724|NCT02431767|EXPERIMENTAL|Group 4: Treatment|Participants will receive the PENNVAX®-GP vaccine 8 mg admixed with IL-12 DNA 1 mg to be administered as 1 mL intramuscular (IM) injection in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
61961317|NCT04635462|EXPERIMENTAL|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
61961318|NCT04635462|EXPERIMENTAL|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
61961319|NCT04613960|ACTIVE_COMPARATOR|Magnesium arm|patients randomized to magnesium therapy at a fixed daily dose of 64 mmol reconstituted in 0.9% saline via continuous intravenous infusion for 14 days after hemorrhage onset, or until discharge or death if it occurred.
61961320|NCT04613960|PLACEBO_COMPARATOR|Placebo arm|patients randomized to placebo therapy with 0.9% saline (without active component) via same protocol.
61961321|NCT01184300|EXPERIMENTAL|Rapid Genotyping|Patients randomized to the Rapid Genotyping arm will have their CYP2C19\*2 carrier status determined at the time of percutaneous coronary intervention with subsequent alteration in anti-platelet therapy for \*2 carriers.
62143725|NCT02431767|PLACEBO_COMPARATOR|Group 4: Placebo|Participants will receive placebo to be administered as 1 mL IM in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
62143726|NCT06094166||NMDCC|non-myelopathic cervical spinal cord compression
62505817|NCT05445076|EXPERIMENTAL|BCD-180, high dose|Subjects in this arm will receive BCD-180 high dose infusions
62505818|NCT05445076|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will receive placebo till the assessment of the primary endpoint and then will be switched to BCD-180 low dose
62505819|NCT06269354||Traumatic bone defect in lower limb|Traumatic bone defect in lower limb
62505820|NCT06269354||Infective lower limb bone defect|Infective lower limb bone defect
61961322|NCT01184300|NO_INTERVENTION|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19\*2 carrier status will be verified.
61961323|NCT00205881|ACTIVE_COMPARATOR|1|Bilaterally Implanted with HiRes 90K device.
61961324|NCT00750932||T|Control
61961325|NCT00750932||M|Minor with cystic fibrosis
61961326|NCT00750932||A|Adult with cystic fibrosis
61961327|NCT04603443|EXPERIMENTAL|BCAA 20g/daily|Branched Chain Amino Acids, 10g BID x 12 weeks
61961328|NCT04603443|EXPERIMENTAL|BCAA 40g/daily|Branched Chain Amino Acids, 20g BID x 12 weeks
61961329|NCT04603443|EXPERIMENTAL|BCAA 60g/daily|Branched Chain Amino Acids, 30g BID x 12 weeks
61961330|NCT04603443|PLACEBO_COMPARATOR|Placebo 20g/daily|Protein without BCAA, 10g BID x 12 weeks
61961331|NCT00779701|OTHER|A|All subjects placed on insulin infusion.
61961332|NCT03334903|NO_INTERVENTION|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
61961333|NCT03334903|EXPERIMENTAL|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
61961334|NCT02414984||Golimumab|Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.
61961335|NCT02309684||Study Population|Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.
61961336|NCT01084369|EXPERIMENTAL|Testosterone, Vardenafil|All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
61961337|NCT00787891|EXPERIMENTAL|Rabeprazole 0.5 mg/kg|rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
61961338|NCT00787891|EXPERIMENTAL|Rabeprazole 1.0 mg/kg|rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
61961339|NCT01816282|EXPERIMENTAL|Evicel|
61961340|NCT01816282|NO_INTERVENTION|Control|
62143727|NCT06094166||healthy controls|subjects with no MR signs of cervical spinal cord compression
62505821|NCT06269354||Neoplastic bone defect in lower limb|Neoplastic bone defect in lower limb
61961341|NCT04554979||Group 1|Duration of COVID-19 symptoms less than 12 days
61961342|NCT04554979||Group 2|Duration of COVID-19 symptoms equal or more than 12 days
61961343|NCT03214965|ACTIVE_COMPARATOR|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
61961344|NCT03214965|NO_INTERVENTION|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
61961345|NCT01797653|PLACEBO_COMPARATOR|Placebo CPAP|patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks.
61961346|NCT01797653|ACTIVE_COMPARATOR|therapeutic CPAP|patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
62143728|NCT00783952|OTHER|1|Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes
62143729|NCT05252468|EXPERIMENTAL|TaffiX™|TaffiX™ is a Nasal powder personal spray that blocks viruses particles from entering the nasal cells.
62143730|NCT05252468|PLACEBO_COMPARATOR|Lactose powder|Lactose nasal powder will be used as a placebo. It has an identical appearance as TaffiX™ (white powder in an identical bottle).
61961347|NCT03604380|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
62143731|NCT00790569|EXPERIMENTAL|Arm I|Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
62143732|NCT00790569|PLACEBO_COMPARATOR|Arm II|Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
62143733|NCT00790569|ACTIVE_COMPARATOR|Arm III|Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
62505822|NCT03357354|EXPERIMENTAL|Obese Children in precarious situations|
61961348|NCT03604380|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
61961349|NCT02713347|EXPERIMENTAL|ADAPT Intervention|"The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist.~The nurse and social worker visits are in-person or by phone."
61961350|NCT02713347|NO_INTERVENTION|Enhanced usual care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referrals to and ongoing care from cardiology, pulmonary, palliative care, or mental health. They will also have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency. Patients' providers will be given the results of baseline depression surveys if they screen positive for depression, and patients will be given an information sheet that outlines self-care for CHF or COPD.
61961351|NCT03598621|EXPERIMENTAL|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
61961352|NCT03598621|EXPERIMENTAL|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
61961353|NCT03598621|EXPERIMENTAL|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
62505823|NCT01717937||PVOCT|Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.
61961354|NCT04481867|ACTIVE_COMPARATOR|intervention arm :densah bur group|at the maxillary molar area for implant placement ,,just after making initial drilling perforation close to the sinus floor, the direction of the drill is reversed and the cutting speed is raised to 1200 rpm, then 2 successive densah burs are used to elevate sinus membrane 2 mm and to prepare implant hole to the selected implant size .for both groups the selected implant size, 4.2 mm width and 10 mm. length
61961355|NCT04481867|OTHER|control group :osteotome group|at the maxillary molar area for implant placement .a set of concave osteotomes with different dimensions sequentially used to widen the osteotomy site by surgical mallet. Osteotome 2.5 mm is inserted into the osteotomy firstly to a depth of 1 mm away from the sinus floor with light malleting by the nylon cap mallet then 3 mm osteotome is used to fracture up the sinus floor and finally 3.5 mm osteotome is tapped gently to elevate the sinus floor to the desired depth of the implant in the maxillary sinus.
61961356|NCT03982407|EXPERIMENTAL|Ga68 PSMA PET-MR|68Ga labeled PSMA -11 (or PSMA-HBED_CC) PET/MRI scan
61961357|NCT00635596|EXPERIMENTAL|I|
61961358|NCT06183424|ACTIVE_COMPARATOR|Interventional|Active tDCS stimulation will be applied over the scalp for 20 minutes at an intensity of 2 mA. Stimulation will be given for 5 days. The application will be made to the patient who has had 30 Covid and has cognition complaints in a randomized manner.
61961359|NCT06183424|PLACEBO_COMPARATOR|Sham|For the pseudo-stimulation to be applied to the sham group, the electrodes will be placed on the scalp in exactly the same way as the experimental group. For all stimulations, the reference electrode will be placed in the right orbital region and given once for 15 seconds, so that the participant will feel a slight tingling, but no real stimulation will be given.
61961360|NCT01238471|EXPERIMENTAL|Propranolol|Oral propranolol for premature infants allocated to this arm by randomization
61961361|NCT01238471|PLACEBO_COMPARATOR|Oral sucrose 5%|Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization
61961362|NCT03651245||Participants with suspicion for Alpha-Mannosidosis|Participants with suspicion for Alpha-Mannosidosis based on their clinical symptoms aged from 2 months to 18 years
61961363|NCT02144428||Cow's milk allergy|Subjcets with a sure diagnosis of cow'a milk allergy on exclusion diet
61961364|NCT03387332|EXPERIMENTAL|APG-1252|The starting dose for this study was 40 mg and 1 patient would be enrolled at this dose level. The dose escalation will convert to a standard 3+3 design following the occurrence of DLT or two ≥ Grade 2 adverse event or at doses 80 mg.
62347793|NCT05424887|PLACEBO_COMPARATOR|placebo|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
62505824|NCT03245892|EXPERIMENTAL|Carboplatin and Paclitaxel Chemotherapy With Nivolumab (Closed)|Patients will be treated with nivolumab plus standard of care dose dense paclitaxel and carboplatin for three cycles, where each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen administered as adjuvant treatment. Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle. Carboplatin dose calculation instructions can be found in Appendix 4. Nivolumab 360mg will be infused IV over approximately 30min on Day 1 of Cycles 1-6. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks.
61961365|NCT04649060|EXPERIMENTAL|Arm A (melflufen+dexamethasone+daratumumab)|"Treatment was given in 28-day cycles in an outpatient treatment setting.~* Melflufen 30 mg intravenous (i.v.) infusion on Day 1 of each cycle~* Dexamethasone 40 mg per oral (p.o.) weekly (20 mg p.o. weekly if ≥75 years)~* Daratumumab 1800 mg subcutaneously (s.c.) on Days 1, 8, 15, and 22 in Cycles 1 and 2, on Days 1 and 15 in Cycles 3 to 6, and on Day 1 from Cycle 7"
61961366|NCT04649060|ACTIVE_COMPARATOR|Arm B (daratumumab)|"Treatment was given in 28-day cycles in an outpatient treatment setting.~• Daratumumab 1800 mg s.c. on Days 1, 8, 15, and 22 in Cycles 1 and 2, on Days 1 and 15 in Cycles 3 to 6, and on Day 1 from Cycle 7"
62143734|NCT01231178|ACTIVE_COMPARATOR|Alginate based beverage|
62143735|NCT01231178|PLACEBO_COMPARATOR|Control beverage|
62347794|NCT05424887|EXPERIMENTAL|Extension Study Cohort|The extension study includes a 24-week medication observation period and a 4-week safety follow-up period. Subjects who meet the requirements will enter the extension study after 24 weeks of treatment in the main study. Subjects entering the extension study will continue to orally take AK3280 200 mg for 24 weeks.
62347795|NCT00180219||1|20 to 22 years
62347796|NCT00180219||2|30 to 32 years
62347797|NCT00180219||3|40 to 42 years
62347798|NCT03833622|EXPERIMENTAL|Shared decision aid assessment|Patients will be selected to have a goals of care discussion with an emergency physician utilizing a pilot decision aid and will be asked for feedback to assist with refinement of the decision aid.
61961367|NCT02006719|EXPERIMENTAL|Collagenase Clostridium Histolyticum|Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
61961368|NCT02006719|PLACEBO_COMPARATOR|Placebo|Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
62704370|NCT05238922|EXPERIMENTAL|Phase 2b Dose Expansion Treatment Group M (TGM)|INCB123667 administered in combination with olaparib at the recommended doses in participants with gynecologic tumors (epithelial ovarian/fallopian/primary peritoneal carcinoma) as defined by the protocol.
61961369|NCT03293589||OR|patients treated with open revascularization
61961370|NCT03293589||EVT|patients treated with endovascular revascularization
61961371|NCT03088982||Lanmeur multimorbid patients|All multimorbid patients who met 12 FPs in the Lanmeur residential care home in the county of Finistere (in north-west France) from July 2014 to December 2014. These FPs were drawn from those physicians associated with the Lanmeur residential care home.
62704371|NCT05238922|EXPERIMENTAL|Phase 2b Dose Expansion Treatment Group N (TGN)|INCB123667 administered in combination with weekly paclitaxel at the recommended doses in participants with gynecologic tumors (epithelial ovarian/fallopian/primary peritoneal carcinoma) as defined by the protocol.
62704372|NCT06654050|EXPERIMENTAL|1/ Arm 1|APG-115
61961372|NCT01179568|ACTIVE_COMPARATOR|CGT with Citalopram|Targeted psychotherapy for complicated grief will be combined with SSRI medication.
61961373|NCT01179568|ACTIVE_COMPARATOR|Citalopram|Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
61961374|NCT01179568|PLACEBO_COMPARATOR|Placebo (Sugar pill)|Inactive medication. It will be combined with grief-focused clinical management.
61961375|NCT01179568|ACTIVE_COMPARATOR|CGT with Placebo|The targeted psychotherapy for complicated grief will be combined with inactive medication.
61961376|NCT05320120|EXPERIMENTAL|first 56mg esketamine (2x Spravato® 28 mg nasal spray), then placebo|
61961377|NCT05320120|EXPERIMENTAL|first placebo (0.9% saline solution nasal spray), then ketamine|
61961378|NCT01563302|EXPERIMENTAL|Group 1|IONIS-STAT3Rx
61961379|NCT05199012|PLACEBO_COMPARATOR|Placebo|Placebo is maltodextrin, delivered as 2 capsules.
61961380|NCT05199012|ACTIVE_COMPARATOR|Active|The active comparator is black pepper extract, delivered as 2 capsules.
61961381|NCT06106178|OTHER|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
61961382|NCT06106178|OTHER|Serious Video Game|"Serious video game Underwater that focuses on hand-eye coordination training using a 3D-printed ultrasound probe for maneuvering."
61961383|NCT04517812|EXPERIMENTAL|Intervention group|The intervention group will carry out a 12-week exercise-based intervention delivered via the VirtualRehab platform. The exercise-games have been designed from conventional physiotherapy exercises for stroke rehabilitation. A personalised training programme will be created for individual participants by a qualified physiotherapist member of the research team. Each participant will be asked to undertake their set exercise-based training programme for one hour a day, six days a week for 12 weeks.
61961384|NCT04517812|NO_INTERVENTION|Control group|The control group will undertake the measurement battery and provide the demographic details.
62704373|NCT06472622|OTHER|Single Arm|This is a single-arm study. The order of intervention administration will be counterbalanced within this single arm.
62704374|NCT03609216|EXPERIMENTAL|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage \< cT1 undergo bladder sparing.
62704375|NCT03609216|EXPERIMENTAL|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage \>= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
62704376|NCT03992404|EXPERIMENTAL|NT 201 (IncobotulinumtoxinA, Xeomin)|"Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
61961385|NCT04348773|EXPERIMENTAL|Dehydration|
61961386|NCT04348773|EXPERIMENTAL|Rehydration|
61961387|NCT01578460|ACTIVE_COMPARATOR|Control Group|Participants will self-select which group they wish to participate in at time of consent. The control group will use standard glucose meter testing to monitor their glucose levels.
61961388|NCT01578460|EXPERIMENTAL|Continuous Glucose Monitor (CGM) Group|Participants will self-select which group they wish to participate in at time of consent. The CGM group will utilize the iPro2 CGM to monitor their glucose levels during their 28, 32, and 36 week of gestation.
61961389|NCT06281106|ACTIVE_COMPARATOR|'Deucravacitinib'|Deucravacitinib 6mg oral intake once daily for 4 weeks
61961390|NCT06281106|PLACEBO_COMPARATOR|'Placebo'|Matching Placebo oral intake once daily for 4 weeks
61961391|NCT00390468|EXPERIMENTAL|Tandutinib (MLN518)|500 mg twice daily, a small-molecule inhibitor of the type III receptor tyrosine kinases. Tandutinib (MLN518) previously known as CT53518.
61961392|NCT04720898|EXPERIMENTAL|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG once a week for 12 weeks.
61961393|NCT04720898|NO_INTERVENTION|Control|The control group will receive its rehabilitation care.
61961394|NCT01255202||twin preganacies|
61961395|NCT01130012|OTHER|Lifestyle, follow-up, early care, standard care high/low risk|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
61961396|NCT01130012|OTHER|Close follow-up|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
61961397|NCT00168220||Drug hypersensitive group|HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz
61961398|NCT00168220||Drug tolerant group|HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.
61961399|NCT01845493|ACTIVE_COMPARATOR|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
61961400|NCT01845493|PLACEBO_COMPARATOR|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
61961401|NCT03326102|EXPERIMENTAL|DHP107|"The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.~Total 48 subjects (including PK subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days."
61961402|NCT03326102|EXPERIMENTAL|IV paclitaxel|Total 24 subject will receive IV paclitaxel 80 mg/m2 weekly.(3 weeks on/1 week off)
61961403|NCT03753529|EXPERIMENTAL|deep friction massage group|
61961404|NCT03753529|EXPERIMENTAL|pressure release group|
61961405|NCT03753529|EXPERIMENTAL|control group|
61961406|NCT03808532|EXPERIMENTAL|High-Risk with Moisturizer|
61961407|NCT03808532|NO_INTERVENTION|High-Risk without Moisturizer|
61961408|NCT05777577|EXPERIMENTAL|Rheumatoid Arthritis Probiotic (RAP)|patients with RA 30-50 yers old, who have 4 or more swollen and painful joints, who did not take probiotic and other drugs that affect the microbiome
62143736|NCT03307044|EXPERIMENTAL|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
62143737|NCT04624139|EXPERIMENTAL|Intervention, group 1|Combined intervention of stress reducing I-CBT and physiotherapy.
62143738|NCT04624139|ACTIVE_COMPARATOR|Active control group, group 2|Physiotherapy only
62143739|NCT05662436|EXPERIMENTAL|Intervention group|The exposure to nature consists of teachers bringing their students to the highest quality green space within 1 km of a school which could be located on or off campus. The class will spend a total of 2 hours (i.e. 2 one hour visits or one 2 hours visits) per week for 12 weeks (transportation included). The teacher be provided with a toolkit of activities (mental health and academic competencies) that they will carry out with their students. Teachers will be provided with training and support.
62143740|NCT05662436|NO_INTERVENTION|Control|Six months after the inception of the trial, elementary schools (and their teachers) in the control condition will receive an unguided version of the intervention, supplemented by an online peer support group. As the children of the control group will by then be in high school with different teachers, we will provide them with a toolkit of 10 mental health activities that they can practice alone, in addition of support via video-conference, phone or email if they require help practicing the activities from a member of the research team. As in the intervention group, we will provide support by licensed psychologists to any children who report high levels of psychological distress and orient children to appropriate services if needed.
62347799|NCT03031548||ultrasound exam|Child undergoing procedure in CVL requiring ETT and CXR as standard of care - received point-of-care ultrasound exam as part of the study
62347800|NCT06070116|ACTIVE_COMPARATOR|Ivermectin + Albendazole (IA)|Dose of oral Ivermectin (150 µg/kg) plus Albendazole (400 mg)
61961409|NCT05777577|ACTIVE_COMPARATOR|Rheumatoid Arthritis Probiotic1 (RAP1)|closest relatives (brothers and sister, children, parents) living in the same living area and corresponding to the age group, without RA, who did not take probiotic and other drugs that affect the microbiome
62143741|NCT02027350|EXPERIMENTAL|Pressure-volume relationship|Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration.
62143742|NCT04003324|EXPERIMENTAL|Intervention group|Self-monitoring tool (Activator) and general information
62347801|NCT06070116|EXPERIMENTAL|Ivermectin + Diethylcarbamazine + Albendazole (IDA)|Dose of oral Ivermectin (150 µg/kg), Diethylcarbamazine (6 mg/kg) and Albendazole (400 mg)
61961410|NCT00500669|EXPERIMENTAL|Betadine|
61961411|NCT00500669|ACTIVE_COMPARATOR|Saline|
61961412|NCT04229563||Study patients|Eligible PAD patients who are routinely treated with atherectomy by AURYON™ Atherectomy System.
62143743|NCT00705159|EXPERIMENTAL|Loteprednol etabonate and tobramycin|Drug: Zylet (loteprednol etabonate and tobramycin)
62143744|NCT00705159|ACTIVE_COMPARATOR|Loteprednol etabonate|Drug: Lotemax (loteprednol etabonate)
62143745|NCT00705159|ACTIVE_COMPARATOR|Tobramycin|Drug: Tobramycin
62143746|NCT00705159|PLACEBO_COMPARATOR|Vehicle|Vehicle of Zylet
62143747|NCT01888991|NO_INTERVENTION|water with resting condition|
62143748|NCT01888991|EXPERIMENTAL|glucose with resting condition|
62143749|NCT01888991|EXPERIMENTAL|water with exercise condition|
62143750|NCT01888991|EXPERIMENTAL|glucose with exercise condition|
62143751|NCT01522638||ADOA|This group includes subjects diagnosed with autosomal dominant optic atrophy
62143752|NCT01522638||Healthy subjects|
62143753|NCT05585632|EXPERIMENTAL|mRNA-1010|Participants will receive a dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
62143754|NCT05585632|EXPERIMENTAL|mRNA-1345|Participants will receive a dose of mRNA-1345 by IM injection on Day 1.
62347802|NCT06070116|EXPERIMENTAL|Moxidectin + Albendazole (MoxA)|Dose of oral Moxidectin (8mg) plus Albendazole (400 mg)
62347803|NCT06070116|EXPERIMENTAL|Moxidectin+ Diethylcarbamazine + Albendazole (MoxDA)|Dose of oral Moxidectin (8mg), Diethylcarbamazine (6 mg/kg) and Albendazole (400 mg)
62347804|NCT00436319|NO_INTERVENTION|1|In the control group (group 1) the initiation of the ovarian stimulation will be realized according to the typical long luteal protocol, two weeks after the initiation of the GnRH agonist administration.
61961413|NCT04316923||Children with cardiomyopathies|Children aged 0-18 years that have been diagnosed with DCM, HCM or LVNC on the basis of a two-dimensional echocardiography with color Doppler.
61961414|NCT04316923||Healthy children|The control group will be composed of healthy children, in whom heart disease will be excluded using echocardiography.
61961415|NCT04971122|OTHER|Trendeleburg -5 degree group,-10 degree group,-15 degree group|Norepinephrine was continuously pumped at 0.5ug/kg/min
61961416|NCT02309502|EXPERIMENTAL|Green Pascal|Single-session Barely Visible Pascal 532nm 3,000 burns 20ms
61961417|NCT02309502|EXPERIMENTAL|Yellow Pascal|Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management:70%
61961418|NCT02309502|NO_INTERVENTION|Observation|Observation
61961419|NCT04734015|EXPERIMENTAL|Together Overcoming Diabetes (TOD) curriculum|"A randomized waitlist control trial (RCT) design will be employed with 81 family dyads (adult caregiver and youth) randomly assigned to the Intervention group (Group A): Together Overcoming Diabetes (TOD).~Group A participant dyads will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months."
61961420|NCT04734015|NO_INTERVENTION|Waitlist Control|"A randomized waitlist control trial (RCT) design will be employed with 81 family dyads (adult caregiver and youth) randomly assigned to the Waitlist Control group (Group B). Waitlist family dyads will not initially receive the intervention. They will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months.~Waitlist participant dyads will begin to receive the intervention program (TOD) approximately 24 months (2 years) after enrollment in the RCT."
61961421|NCT02817100|EXPERIMENTAL|BAY1817080|Study Part 1: Dose 1 to 7 of BAY1817080 (increasing dose levels; redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]); Study part 2: Dose 1 to 4 of BAY1817080 together with an American breakfast (increasing dose levels; redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
61961422|NCT02817100|PLACEBO_COMPARATOR|Placebo|Study Part 1: Placebo Dose 1 to 7 of BAY1817080; Study Part 2: Placebo Dose 1 to 4 of BAY1817080
61961423|NCT04335461|PLACEBO_COMPARATOR|Placebo|Placebo group, with no regional nerve blockade administered.
61961424|NCT04335461|EXPERIMENTAL|Fracture block|Patients will have an intrafragmentary fracture block using fluoroscopy guidance after surgical fixation with 30cc 0.25% marcaine
61961425|NCT04335461|EXPERIMENTAL|Fascia iliaca block|Fascia iliaca compartment blockade administered after surgical fixation using the loss of resistance technique with 30cc 0.25% marcaine
61961426|NCT02665520|ACTIVE_COMPARATOR|stem cells injection in penis|Treatment Injection of adipose derived cells into penis experimental;randomised
61961427|NCT02665520|NO_INTERVENTION|controled arm|
62143755|NCT05585632|EXPERIMENTAL|mRNA-1273.214|Participants will receive a dose of mRNA-1273.214 by IM injection on Day 1.
61961428|NCT06060782|EXPERIMENTAL|subject group|
61961429|NCT00736684|ACTIVE_COMPARATOR|1|Proximal Femoral Nail AntirotationTM (PFNA)
62143756|NCT05585632|EXPERIMENTAL|mRNA-1045 Dose Level A|Participants will receive mRNA-1045 at Dose Level A by IM injection on Day 1.
62704377|NCT03992404|PLACEBO_COMPARATOR|Placebo|"Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
62704378|NCT03998202||Adults 60-74 years|
61961430|NCT00736684|OTHER|2|Gamma Nail 3TM (Gamma3)
61961431|NCT01332500||adult migraineurs with/without aura|Adult migraine patients \>18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
61961432|NCT04072497|EXPERIMENTAL|Zoster vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus \>=4.3 LgPFU per dose)
61961433|NCT04072497|ACTIVE_COMPARATOR|Varicella vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus \>=3.3 LgPFU per dose)
61961434|NCT04072497|PLACEBO_COMPARATOR|Placebo|Placebo with no live virus
61961435|NCT03971097|ACTIVE_COMPARATOR|Control Group (TAU)|Participants of the study who will receive the normal programming schedule or treatment as usual (TAU).
61961436|NCT03971097|EXPERIMENTAL|Experimental Group (TAU plus self-forgiveness model)|Participants of the study who will receive TAU plus six additional individual counseling sessions that include integration of a self-forgiveness model developed by Everett L. Worthington.
61961437|NCT04425694||F3B ward staff|The e-EWS system will be implemented in a selected surgical ward (F3B ward) in Tuen Mun Hospital. All F3B ward staff will use the system and evaluate its effectiveness.
61961438|NCT01940874||Cerebral oximetry|
61961439|NCT02137174|ACTIVE_COMPARATOR|Home and school visits|
61961440|NCT02137174|NO_INTERVENTION|Control|
61961441|NCT00726778||A, Observational|Healthy European American, African American, and Hispanic American children aged 7-12
61961442|NCT06411678|EXPERIMENTAL|68GA-DOTA-dPNE|Each patient receive a single intravenous injection of 68GA-DOTA-dPNE 0.5-0.6 mci/kg and undergo PET/CT
61961443|NCT04298801|EXPERIMENTAL|Nurse-driven HIV screening for key populations+UD|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing (UD)
61961444|NCT04298801|ACTIVE_COMPARATOR|Physician-directed diagnostic testing alone|
61961445|NCT02288897|EXPERIMENTAL|PV-10|Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
62143757|NCT05585632|EXPERIMENTAL|mRNA-1045 Dose Level B|Participants will receive mRNA-1045 at Dose Level B by IM injection on Day 1.
62143758|NCT05585632|EXPERIMENTAL|mRNA-1045 Dose Level C|Participants will receive mRNA-1045 at Dose Level C by IM injection on Day 1.
62704379|NCT03998202||Adults >= 75 years|
61961446|NCT02288897|ACTIVE_COMPARATOR|Chemotherapy or Oncolytic Viral Therapy|Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
62143759|NCT05585632|EXPERIMENTAL|mRNA-1230 Dose Level A|Participants will receive mRNA-1230 at Dose Level A by IM injection on Day 1.
62143760|NCT05585632|EXPERIMENTAL|mRNA-1230 Dose Level B|Participants will receive mRNA-1230 at Dose Level B by IM injection on Day 1.
62143761|NCT05585632|EXPERIMENTAL|mRNA-1230 Dose Level C|Participants will receive mRNA-1230 at Dose Level C by IM injection on Day 1.
62143762|NCT05252832|ACTIVE_COMPARATOR|Local Infitrate|
62704380|NCT06407297|EXPERIMENTAL|Experimental|
62704381|NCT06407297|PLACEBO_COMPARATOR|Placebo Comparator|
61961447|NCT02681562|EXPERIMENTAL|Olaparib triple negative|Olaparib short administration in triple negative breast cancer
61961448|NCT02681562|EXPERIMENTAL|Olaparib BRCA mutated|Olaparib short administration in BRCA mutated patients
62704382|NCT06595953|ACTIVE_COMPARATOR|Active-GCMRT|In the active form of the therapy, music stops when subjects view negative valence faces.
62704383|NCT06595953|SHAM_COMPARATOR|Sham-GCMRT|In the control condition, music plays continuously.
62143763|NCT05252832|EXPERIMENTAL|SCPB|
62143764|NCT02142946||RIS MS patients|Radiologically Isolated Syndrome (RIS) MS patients
62347805|NCT00436319|OTHER|2|In the study group (group 2) the initiation of the ovarian stimulation will be effectuated on the second day of the menstrual period.
62704384|NCT05707598||Laparoscopic multivisceral resection group|Patients who underwent laparoscopic multivisceral resection for clinical T4b colorectal cancer
62704385|NCT05707598||Open multivisceral resection group|Patients who underwent open multivisceral resection for clinical T4b colorectal cancer
62347806|NCT02293356|EXPERIMENTAL|Nimotuzumab Injection|200mg,Once a week，Intravenous infusion over 60 minutes
62539223|NCT04336943|EXPERIMENTAL|Treatment (durvalumab, olaparib)|All patients receive durvalumab IV over 1 hour on day 1 of each cycle. Patients with CDK12 mutation and MMRd/MSI-high also receive olaparib PO BID on days 1- 28 of cycles 3-6. Patients with homologous recombination mutation also receive olaparib PO BID on days 1-28 of cycles 1-6. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
62704386|NCT05871970|EXPERIMENTAL|TARA-002|TARA-002 is a lyophilized biological preparation for injection containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
62704387|NCT04130997|EXPERIMENTAL|Ublituximab Infusions|"RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.~RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.~For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study."
62704388|NCT05814055|EXPERIMENTAL|AB-free kava|
62704389|NCT05814055|PLACEBO_COMPARATOR|Placebo control|
62704390|NCT03388606||Adolescents with major depression|Adolescents with a current or past history of meeting full critieria for major depressive disorder
62704391|NCT03388606||Healthy volunteer adolescents/young adults|Adolescents with no history of significant psychiatric or medical disorders (as defined in the protocol) currently or in the past.
62704392|NCT03388606||Parents of adolescent participants|biological parent or legal guardian of an enrolled adolescent (who is a healthy volunteer, has s MDD \[subthreshold depression\], or has MDD \[Major Depressive Disorder\]) participant
62704393|NCT05057013|EXPERIMENTAL|HMBD-001 (Part A)|
62704394|NCT05057013|EXPERIMENTAL|HMBD-001 and enzalutamide (Part B Arm 1)|
62704395|NCT05488340|EXPERIMENTAL|Part 1- Arm 4 (previously 1)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10\^11 PFU) and oral TMP/SMX on D1 through D3.
61961449|NCT01101984|EXPERIMENTAL|DE-089|DE-089 ophthalmic solution
61961450|NCT01101984|ACTIVE_COMPARATOR|HA|0.1% sodium hyaluronate ophthalmic solution
61961451|NCT05979558|EXPERIMENTAL|Ropivacaine with dexmedetomidine|
61961452|NCT05979558|PLACEBO_COMPARATOR|Ropivacaine with Normal Saline|
61961453|NCT05475132|EXPERIMENTAL|Exergaming|App based exercise games for dexterity will be used
61961454|NCT05475132|ACTIVE_COMPARATOR|Conventional Dexterity Exercises|Dexterity exercises used conventionally will be done in this.
61961455|NCT00080808|ACTIVE_COMPARATOR|Arm I|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
62143765|NCT02142946||CIS MS patients|Clinically Isolated Syndrome (CIS) patients during a stable phase
62143766|NCT02142946||RRMS patients|Relapsing-remitting (RR) MS patients during a stable phase
62143767|NCT02142946||SPMS Patients|Secondary progressive MS patients (SPMS)
62143768|NCT02142946||PPMS Patients|Primary progressive MS patients (PPMS)
62143769|NCT02142946||Controls|Age and gender matched controls
62143770|NCT02142946||CI Patients|Cochlear Implant patients pre- and post-operatively
62143771|NCT02142946||UVL Patients|Unilateral vestibular loss patients in acute and compensated state
62143772|NCT02142946||Chronic UVL|Chronic unilateral vestibular loss patients
62143773|NCT02142946||Phobic|Phobic vertigo patients
62347807|NCT02882763|EXPERIMENTAL|Parents As Teachers (PAT)|c.f. intervention
62347808|NCT02882763|NO_INTERVENTION|control group condition|Families in the control group condition did not receive the home visiting program PAT, but were informed about support services in their community. The use of these services was permitted for ethical reasons; however, parents were regularly asked about the nature and intensity of the retrieved services. Additionally, all parents received incentives, such as greeting cards, small birthday presents, and monetary reimbursements.
62347809|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
62539224|NCT01329549|EXPERIMENTAL|BIBF 1120 (low) + Carboplatin + PLD|BIBF 1120 (low dose) + carboplatin (AUC5 mg/mL\*min) + PLD (30 mg/m2)
62704396|NCT05488340|EXPERIMENTAL|Part 1- Arm 5 (previously 2)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10\^10 PFU) and oral TMP/SMX on D1 through D3.
61961456|NCT00080808|ACTIVE_COMPARATOR|Arm II (No sural nerve grafting)|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.
61961457|NCT03164902|EXPERIMENTAL|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
61961458|NCT05634434||control group|Same patient, stone free kidney
61961459|NCT05634434||Study group|uric acid stone former, diseased kidney (stone harboring)
61961460|NCT05985577||Cancer tissues|Cancer tissues
61961461|NCT05985577||Normal adjacent tissues|Normal adjacent tissues
61961462|NCT04124276|EXPERIMENTAL|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day) for 6 weeks
61961463|NCT04124276|PLACEBO_COMPARATOR|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
61961464|NCT01452828|EXPERIMENTAL|Renal Impairment Nondialyzed|
61961465|NCT01452828|EXPERIMENTAL|Renal Impairment Dialyzed|
61961466|NCT01452828|EXPERIMENTAL|Matched Control|
61961467|NCT00885430|EXPERIMENTAL|Pico-Salax|
61961468|NCT01332955|EXPERIMENTAL|Telaprevir-pegIFN alfa-2a-ribavirine|Single Group Assignment
61961469|NCT05013684|ACTIVE_COMPARATOR|Older adults with BPPV|
61961470|NCT05013684|NO_INTERVENTION|Older adults without BPPV|
62143774|NCT03372694|EXPERIMENTAL|Chemotherapy+Training+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Rehabilitation training is mainly composed of gymnastic qigong, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
62347810|NCT04888234|EXPERIMENTAL|Treatment group|The treatment group receive topical treatment of Ru-Yi-Jin-Huang Powder.
61961471|NCT01388764|EXPERIMENTAL|L-arginine|
61961472|NCT01784978|EXPERIMENTAL|Rotational arm|Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
61961473|NCT01784978|ACTIVE_COMPARATOR|Sequential arm|The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.
61961474|NCT03262909|EXPERIMENTAL|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
61961475|NCT03262909|OTHER|Microfracture historical control arm|Microfracture historical control arm
61961476|NCT03556072||Intradiverticular papilla (IDP) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
61961477|NCT03556072||Juxtapapillary diverticulum (JPD) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
61961478|NCT03727347|EXPERIMENTAL|InSeca Stylus Treatment Group|Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)
62347811|NCT04888234|NO_INTERVENTION|Control group|The control group receive regular management for radiation-induced dermatitis.
62505825|NCT03245892|EXPERIMENTAL|Nivolumab plus Ipilimumab plus Paclitaxel & Carboplatin|Patients will be treated with nivolumab plus ipilimumab plus standard of care dose dense paclitaxel \& carboplatin chemotherapy for 3 cycles (up to a maximum of six), each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen. Paclitaxel 80mg/m2 IV will be administered over approx 1 hour on Days 1,8, \& 15 of each 21 day cycle. Carboplatin AUC6 will be administered as an approx 30 minute IV infusion, following paclitaxel admin on Day 1 of each 21 day cycle. Nivolumab 360mg will be infused IV over approx 30 min on Day 1 of Cycles 1-6 (to 9) of each 21 day cycle. Ipilimumab 1mg/kg will be infused IV over approx 30 min on Day 1 of Cycles 1 \& 3, as well as Cycle 4 \& Cycle 6. Of note, if patients receive more than 3 cycles in the pre-operative setting, then ipilimumab will be administered with the first \& third cycle in the post-operative setting. Nivolumab will then be infused Day 1 of each 28 day maintenance phase cycle.
62505826|NCT04651595|EXPERIMENTAL|Caudal|
62505827|NCT04651595|ACTIVE_COMPARATOR|Control|
61961479|NCT03098953|EXPERIMENTAL|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
61961480|NCT04873804|ACTIVE_COMPARATOR|LEFT DLPFC|The anode electrode of tDCS was applied to the left DLPFC and the cathode electrode was connected to the contralateral shoulder.
61961481|NCT04873804|ACTIVE_COMPARATOR|RİGHT PPC|The anode electrode of tDCS was applied to the right PPC and the cathode electrode was connected to the contralateral shoulder.
61961482|NCT04873804|SHAM_COMPARATOR|Sham|Placebo was applied by placing the electrodes in the right PPC and left DLPFC without applying current.
62347812|NCT05250193|EXPERIMENTAL|DK ScoreTM Coronary Scoring Balloon (DK Score)|DK ScoreTM Coronary Scoring Balloon Manufactured by DK Medical Technolgy CO.,LTD
62347813|NCT05250193|ACTIVE_COMPARATOR|Non-Slip Element Coronary Dilatation Catheter (NSE)|Non-Slip Element Coronary Dilatation Catheter Manufactured by GOODMAN CO.,LTD
62505828|NCT05482204|NO_INTERVENTION|Control (QR) label|QR label on all menu items
62505829|NCT05482204|EXPERIMENTAL|Low Climate Impact Label|'Low Climate Impact' label on all chicken, fish and vegetarian menu items
62505830|NCT05482204|EXPERIMENTAL|High climate Impact Label|'High Climate Impact' label on all beef menu items
62505831|NCT06533280|EXPERIMENTAL|Part A MAD: VH3739937|Part A MAD: VH3739937 group will contain 3 ascending repeat-dose cohorts (Cohorts A1- A3), where participants will receive a twice daily (BID) dose of VH3739937 for 1 (Cohort A1), 2 (Cohort A2) or 3 (Cohort A3) days in fed conditions.
62505832|NCT06533280|PLACEBO_COMPARATOR|Part A MAD: Placebo|Part A MAD: Placebo group will include participants that will receive BID dose of placebo in fed conditions
62539225|NCT01329549|EXPERIMENTAL|BIBF 1120 (medium) + Carboplatin + PLD|BIBF 1120 (medium dose) + carboplatin (AUC5 mg/mL\*min) + PLD (30 mg/m2)
61961483|NCT02984709|EXPERIMENTAL|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
62505833|NCT06533280|EXPERIMENTAL|Part B RBA/ optional FE: VH3739937|Part B RBA/FE: VH3739937 group will include participants that will receive treatment sequences (Treatment AB or BA) alternatively in Period 1 and Period 2 of the treatment. In Period 3 and Period 4, participants will receive 1 of 6 treatment sequences (CD, CE, ED, EC, DE, DC) in fed or fasted conditions.
61961484|NCT02984709|ACTIVE_COMPARATOR|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
62143775|NCT03372694|EXPERIMENTAL|Chemotherapy+Education+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
62143776|NCT03372694|PLACEBO_COMPARATOR|Chemotherapy+Education+Placebo|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages. The patient will take placebo granules for 3 months."
62347814|NCT03532581|EXPERIMENTAL|Treatment (ICG lymphangiography)|Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
62505834|NCT06533280|EXPERIMENTAL|Part C: Optional QW VH3739937|Participants in this group will receive a weekly administration (QW) of VH3739937 during a 3-week period in fed conditions.
62505835|NCT06533280|PLACEBO_COMPARATOR|Part C: Optional QW Placebo|Participants in this group will receive a weekly administration (QW) of placebo during a 3-week period in fed conditions.
62347815|NCT01789346|OTHER|532nm KTP|Cutera ExcelV 532nm potassium titanyl phosphate (KTP) laser
62347816|NCT01789346|ACTIVE_COMPARATOR|595nm PDL|Cynosure Cynergy 595nm pulsed-dye (PDL) laser
62505836|NCT06533280|EXPERIMENTAL|Part D: Optional DDI|Participants in this group will receive a dose of the probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) alone on Day 1, followed by a subsequent dose of probe cocktail together with a single dose of VH3739937 on Day 10, in fed conditions.
62704397|NCT05488340|EXPERIMENTAL|Part 1- Arm 6 (previously 3)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 infusion (1x10\^12 PFU) and oral TMP/SMX on D1 through D3.
61961485|NCT01812174|EXPERIMENTAL|17mm On-X Aortic Heart Valve|Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
62347817|NCT02229630|EXPERIMENTAL|Pregnant women|Foetuses with intra-uterine growth restriction, between 28 and 32 weeks of gestation, with an estimated foetal weight \< 5th percentile (Hadlock calculator)
61961486|NCT01812174|EXPERIMENTAL|23mm On-X Mitral Heart Valve|"Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.~Enrollment into the 23mm On-X mitral arm has been terminated."
62347818|NCT00879606|EXPERIMENTAL|1|Participants will be randomized to receive ALT-836.
62347819|NCT00879606|PLACEBO_COMPARATOR|2|Patients will be randomized to receive placebo.
62347820|NCT05058898||Risk factors transmission cases|Human cases of monkeypox confirmed by PCR
62347821|NCT05058898||Risk factors transmission contacts and co-exposures|Human contact of confirmed monkeypox cases
62347822|NCT05058898||Serological follow up cases|Human cases of monkeypox confirmed by PCR from Lobaye region
62347823|NCT05058898||Serological follow up contacts and co-exposures|Human contact of confirmed monkeypox cases from Lobaye region adjusted for age, month of the year and village of origin
62505837|NCT00328484|EXPERIMENTAL|1|Eleven month lifestyle activity program
62347824|NCT03146221|OTHER|Person to be surgically treated for arteritis|
62347825|NCT01969942|EXPERIMENTAL|allogeneic stem cell transplantation Plan A|Subjects will receive the vaccine, Busulfan and Melphalan.
62347826|NCT01969942|EXPERIMENTAL|allogeneic stem cell transplantation Plan B|If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.
62505838|NCT00328484|ACTIVE_COMPARATOR|2|Three month exercise program
62505839|NCT00987142|EXPERIMENTAL|CX501|Cultured chimeric skin
62505840|NCT00987142|ACTIVE_COMPARATOR|Non adherent dressing|Occlusive non adherent dressing
62505841|NCT06347718|OTHER|Active dose|"A prospective, open-label, non-randomized, single-dose interventional basket study.~Single intravenous infusion of a freshly prepared advanced therapy medicinal product (ATMP) from autologous and expanded T cells transduced ex vivo with a CD19-CAR construct.~No control intervention (e.g. another immunosuppressive therapy). Concomitant measures: Leukapheresis and lymphodepleting therapy for conditioning."
62505842|NCT03296813|ACTIVE_COMPARATOR|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
61961487|NCT05238090|OTHER|Control group|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
62347827|NCT05389059|OTHER|Control arm|Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I\&II gingival recession.
62347828|NCT05389059|OTHER|Experimental arm|Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I\&II gingival recession.
62143777|NCT06387550|EXPERIMENTAL|Eccentric Training Group|Patients in this group firstly passing through warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
62704398|NCT05488340|EXPERIMENTAL|Part 2: LBP-EC01|LBP-EC01 given by dose regimen selected from Part 1. IU LBP-EC01 on D1 and D2 with IV LBP-EC01 (1x10\^11 PFU) and oral TMP/SMX on D1 through D3.
62143778|NCT03700554|EXPERIMENTAL|Pleuralvent™|Patients treated with Pleuralvent™ device
62347829|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
62347830|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
62347831|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
62347832|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
62347833|NCT04082702|EXPERIMENTAL|Faith-enhanced DPP|A total of six churches were randomized to this arm that included 119 participants and received 10-month DPP with faith components.
62347834|NCT04082702|ACTIVE_COMPARATOR|Standard DPP|A total of five churches were randomized to this arm that included 102 participants who received the standard DPP on the church settings.
62347835|NCT04899960|NO_INTERVENTION|Observational Group|
62347836|NCT04899960|NO_INTERVENTION|Control (Validation) Group|
62347837|NCT04899960|EXPERIMENTAL|İnterventional Group|
62347838|NCT05388019|EXPERIMENTAL|Prospective interventional cohort of newly-implanted patients|This cohort will consist of patients who recently underwent LVAD implantation at Massachusetts General Hospital, and their caregivers. These patients will receive only multidisciplinary team care from the time of their implant.
62347839|NCT05388019|EXPERIMENTAL|Prospective interventional cohort of previously-implanted patients|This cohort will consist of patients who have previously undergone LVAD implantation at Massachusetts General Hospital who are being followed-up with standard-of-care VAD clinic visits, and their caregivers. These patients will receive a hybrid of multidisciplinary team care and standard-of-care visits.
62347840|NCT05388019|NO_INTERVENTION|Retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past and no longer have an LVAD implanted (due to transplant, death, explant, etc.).
62347841|NCT05388019|EXPERIMENTAL|Primary caregiver cohort|This cohort will consist of primary caregivers of VAD patients from the two interventional cohorts. They will be administered a questionnaire at two timepoints. Each VAD patient will be associated with only one primary caregiver for the duration of the study.
62347842|NCT04777578|EXPERIMENTAL|DN|
62347843|NCT04777578|NO_INTERVENTION|Control|
62347844|NCT03076125|EXPERIMENTAL|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
62347845|NCT03076125|SHAM_COMPARATOR|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
62347846|NCT02116816|EXPERIMENTAL|Polyphenol|Polyphenol preparations
61961488|NCT05238090|EXPERIMENTAL|Experimental|Passive and active analytical stretching exercises described by Neiger and Simons , applying them to the muscle chain involved in lateral epicondylitis described by Busquet
61961489|NCT04454268|OTHER|hydatid cyst|
62347847|NCT05273840|PLACEBO_COMPARATOR|life intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given to the patients until the end of the visit.
62143779|NCT03700554|ACTIVE_COMPARATOR|Chest tube|Patients treated with Chest tube
62347848|NCT05273840|EXPERIMENTAL|nutritional supplement intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given, and at the same time, nutritional supplements(Ivital Control) are given to instead a meal per day. 2 bags once a day until the end of the visit.
62347849|NCT02884830|PLACEBO_COMPARATOR|Sham CPAP|Sham continuous positive airway pressure is a CPAP given at too low pressure to have any physiological effect on upper airways patency and on lung volumes
62347850|NCT02884830|ACTIVE_COMPARATOR|Efficace CPAP|Continuous positive airway pressure is a CPAP given at effective pressure to decrease the work of breathing in COPD patients
62347851|NCT01046383|EXPERIMENTAL|IMN1207|"Dietary Supplement: IMN1207~Stratum A: CRP \<40 mg/L and WBC \< 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
62347852|NCT01046383|PLACEBO_COMPARATOR|Casein|"Dietary Supplement: Casein.~Stratum A: CRP \<40 mg/L and WBC \< 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
62704399|NCT05488340|PLACEBO_COMPARATOR|Part 2: Placebo|Placebo given by dose regimen selected from Part 1. IU placebo on D1 and D2 with IV placebo and oral TMP/SMX on D1 through D3.
62347853|NCT04032626|EXPERIMENTAL|Lenalidomide|Lenalidomide 10 mg/day taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
62347854|NCT04032626|PLACEBO_COMPARATOR|Placebo|Placebo taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
62347855|NCT05344976|EXPERIMENTAL|MSLN STAR-T cells|The patients will receive one dose of MSLN STAR-T.The dosage ranges from1×10\^7 to 1×10\^8 STAR-T+/kg.
62347856|NCT05654766||Control group|Group of healthy adult and pediatric participants, whose blood platelets will be used to evaluate normal ranges of parameters in the flow cytometry PFT.
62704400|NCT05454839||Participants|Adult patients within 6 months of ART initiation or re-initiation
61961490|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
61961491|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
61961492|NCT04173468|ACTIVE_COMPARATOR|MWM Group|This group will receive Mobilization with Movement (MWM) i.e. straight leg raised with traction,Tibial Gliding
61961493|NCT04173468|ACTIVE_COMPARATOR|Mulligan Taping Group|This group will receive Mulligan knee taping
62505843|NCT03296813|ACTIVE_COMPARATOR|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:~1 mg oral torsemide = 2-4 mg oral furosemide~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
62505844|NCT02250924|PLACEBO_COMPARATOR|Placebo|Subjects will wear a silicone bracelet for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
61961494|NCT01031355|EXPERIMENTAL|Arm 1|
61961495|NCT01031355|ACTIVE_COMPARATOR|Arm 2|
61961496|NCT01031355|ACTIVE_COMPARATOR|Arm 3|
61961497|NCT05495516||active group|The study group consisted of 86 patients with signs of CHF above class 2 (NYHA) 30 days after myocardial infarction.
61961498|NCT05495516||comparison group|This group consisted of 100 patients without signs of CHF or with CHF class 1 (NYHA) 30 days after myocardial infarction.
61961499|NCT00960778|EXPERIMENTAL|Women- denicotinized cigarette|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
61961500|NCT00960778|EXPERIMENTAL|Men- denicotinized cigarette|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
61961501|NCT00960778|EXPERIMENTAL|Women -nicotine patch|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
62143780|NCT05040152|EXPERIMENTAL|Arm I (telephone-based intervention)|Participants receive weekly telephone-based weight loss intervention for 15 weeks, including dietary recommendations tailored to their current weight and weight loss target, home-based aerobic and resistance exercise, and weekly telephone counseling session over 30-45 minutes.
62143781|NCT05040152|ACTIVE_COMPARATOR|Arm II (education brochures)|Participants receive education brochures describing the American Institute for Cancer Research physical activity and dietary guidelines.
62505845|NCT02250924|SHAM_COMPARATOR|Sugar-less Gum|Subjects will chew one stick of sugar-less gum for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
62505846|NCT02250924|EXPERIMENTAL|Caffeinated Gum|Subjects will chew one stick of caffeinated gum (100mg caffeine per stick) for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
62505847|NCT00108628|EXPERIMENTAL|Arm 1|Imagery Rehearsal Therapy
61961502|NCT00960778|EXPERIMENTAL|Men- nicotine patch|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
61961503|NCT03782792|EXPERIMENTAL|Spesolimab|
61961504|NCT03782792|EXPERIMENTAL|Placebo|
61961505|NCT02129400|EXPERIMENTAL|10min Xenon 15%, FiO2 75%|10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
61961506|NCT02129400|EXPERIMENTAL|10min Xenon 30%, FiO2 60%|10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
61961507|NCT02129400|EXPERIMENTAL|30min Xenon 15%, FiO2 75%|30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
61961508|NCT02129400|EXPERIMENTAL|30min Xenon 30%, FiO2 60%|30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
61961509|NCT02129400|EXPERIMENTAL|45min Xenon 15%, FiO2 75%|45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
62143782|NCT05499767|EXPERIMENTAL|HEPPI|The HEPPI group attends weekly 90-minute intervention sessions at the participants' homes.
62143783|NCT05499767|NO_INTERVENTION|Treatment as Usual (TAU)|The TAU group receives access to HEPPI at the end of the study.
62505848|NCT00108628|ACTIVE_COMPARATOR|Arm 2|Sleep and Nightmare Management
61961510|NCT02129400|EXPERIMENTAL|45min Xenon 30%, FiO2 60%|45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
61961511|NCT02129400|EXPERIMENTAL|90min Xenon 15%, FiO2 75%|90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
61961512|NCT02129400|EXPERIMENTAL|90min Xenon 30%, FiO2 60%|90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
61961513|NCT02129400|PLACEBO_COMPARATOR|10min air medicinalis, FiO2 75%|10 minutes of air medicinalis (with 75 % FiO2)
61961514|NCT02129400|PLACEBO_COMPARATOR|10min air medicinalis, FiO2 60%|10 minutes of air medicinalis inhalation (with 60 % FiO2)
61961515|NCT02129400|PLACEBO_COMPARATOR|30min air medicinalis, FiO2 75%|30 minutes of air medicinalis inhalation (with 75 % FiO2)
62143784|NCT02157948|ACTIVE_COMPARATOR|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
62143785|NCT02157948|EXPERIMENTAL|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
62143786|NCT03930940|EXPERIMENTAL|RIC group|RIC treatment and regular treatment.
62505849|NCT05394805||Participants treated with Humira (Adalimumab)|Participants prescribed Humira (adalimumab) for moderately to severely active crohn's disease (CD) in routine clinical practice.
62505850|NCT03992547|EXPERIMENTAL|robot assisted gait traing|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks.
62505851|NCT06535464|ACTIVE_COMPARATOR|Goal-directed therapy guided by Hypotension Prediction Index algorithm|
62505852|NCT06535464|SHAM_COMPARATOR|Goal-directed therapy alone|
61961516|NCT02129400|PLACEBO_COMPARATOR|30min air medicinalis, FiO2 60%|30 minutes of air medicinalis inhalation (with 60 % FiO2)
61961517|NCT02129400|PLACEBO_COMPARATOR|45min air medicinalis, FiO2 75%|45 minutes of air medicinalis inhalation (with 75 % FiO2)
62704401|NCT05500417|EXPERIMENTAL|Group 1A|Each subject will receive a 1 mL intramuscular (IM) injection containing 1 microgram of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
62704402|NCT05500417|EXPERIMENTAL|Group 1B|Each subject will receive a 1 mL intramuscular (IM) injection containing 1 microgram of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
62347857|NCT05654766||Hemorrhagic syndrome and Acute Leukemia|Group of pediatric participants with any manifestations of hemorrhagic syndrome and/or acute leukemia
62704403|NCT05500417|EXPERIMENTAL|Group 2A|Each subject will receive a 1 mL intramuscular (IM) injection containing 3 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
62704404|NCT05500417|EXPERIMENTAL|Group 2B|Each subject will receive a 1 mL intramuscular (IM) injection containing 3 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
62704405|NCT05500417|EXPERIMENTAL|Group 3A|Each subject will receive a 1 mL intramuscular (IM) injection containing 10 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
61961518|NCT02129400|PLACEBO_COMPARATOR|45min air medicinalis, FiO2 60%|45 minutes of air medicinalis inhalation (with 60 % FiO2)
61961519|NCT02129400|PLACEBO_COMPARATOR|90min air medicinalis, FiO2 75%|90 minutes of air medicinalis inhalation (with 75 % FiO2)
61961520|NCT02129400|PLACEBO_COMPARATOR|90min air medicinalis, FiO2 60%|90 minutes of air medicinalis inhalation (with 60 % FiO2)
61961521|NCT00828659|PLACEBO_COMPARATOR|Placebo|
62347858|NCT02306239|ACTIVE_COMPARATOR|norepinephrine|patients received norepinephrine
62347859|NCT02306239|EXPERIMENTAL|terlipressin|patients received terlipressin
62347860|NCT00793182|ACTIVE_COMPARATOR|1|Ioversol 320 mgI/mL
62347861|NCT00793182|ACTIVE_COMPARATOR|2|Iodixanol 320 mgI/mL
62347862|NCT06303492|EXPERIMENTAL|Gastric ultrasound (GUS) group|Aspiration risk assessment using GUS in addition to the standard clinical assessment.
62347863|NCT06303492|NO_INTERVENTION|Control|Aspiration risk assessment only by standard clinical assessment, and no GUS
62704406|NCT05500417|EXPERIMENTAL|Group 3B|Each subject will receive a 1 mL intramuscular (IM) injection containing 10 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
62704407|NCT05673759||75 Mild AD|75 patients diagnosed with Mild Alzheimer's disease.
62704408|NCT05673759||75 MCI due to any etiology|75 patients diagnosed with Mild Cognitive Impairment due to any etiology.
62704409|NCT05673759||25 Healthy Older Adults|25 Healthy older adults age: 50-90 (control).
62704410|NCT05673759||25 Healthy Younger Adults|25 Healthy younger adults age: 20-50 (control).
62704411|NCT06562595|EXPERIMENTAL|Video Assisted|Those participants who are automatically assigned to the video training arm will be required to complete a 25-point initial assessment, after which they will be presented with a video. Subsequently, the same test will be administered once more, and the initial and subsequent scores of the participant will be recorded in the case report form.
62704412|NCT06562595|EXPERIMENTAL|Classical Lectures|The initial assessment, comprising 25 items, will be administered to participants who have been randomly assigned to the control group. This group will be invited to attend a seminar at our clinic, during which a PowerPoint presentation will be delivered. Following the conclusion of the presentation, the same assessment will be repeated, and the participant's initial and second scores will be recorded in the case report form.
61961522|NCT00828659|ACTIVE_COMPARATOR|Active Comparator #1|
61961523|NCT00828659|ACTIVE_COMPARATOR|Active Comparator #2|
61961524|NCT00828659|ACTIVE_COMPARATOR|Active Comparator #3|
61961525|NCT00828659|EXPERIMENTAL|Lorcaserin Dose #1|
61961526|NCT00828659|EXPERIMENTAL|Lorcaserin Dose #2|
61961527|NCT00828659|EXPERIMENTAL|Lorcaserin Dose #3|
61961528|NCT05664971|EXPERIMENTAL|Cohort 1|NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w, maintained until disease progression
61961529|NCT05664971|EXPERIMENTAL|Cohort 2|NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression
61961530|NCT05664971|EXPERIMENTAL|Cohort 3|NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression
61961531|NCT05664971|EXPERIMENTAL|Cohort 4|NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
62347864|NCT04275050|EXPERIMENTAL|TQB3303 Tablet|TQB3303 Tablet administered orally once. Then TQB3303 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
62347865|NCT01368666|EXPERIMENTAL|Perceval S Valve Prosthesis|Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis
62347866|NCT05269550|EXPERIMENTAL|Men with high intermediate to very high risk protstate cancer|
62347867|NCT02189590|EXPERIMENTAL|air-Q|Patients will receive the air-Q with size based on manufacturer recommendations of body weight
61961532|NCT05664971|EXPERIMENTAL|Cohort 5|SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
61961533|NCT02512588|EXPERIMENTAL|BTD-001|
61961534|NCT02512588|EXPERIMENTAL|Placebo|
62347868|NCT02189590|EXPERIMENTAL|i-gel|Patients will receive the i-gel with size based on manufacturer recommendations of body weight
62347869|NCT05669300||Yilmaz Technique|the patients underwent ceserean section and uterus closed with Yilmaz Technique
62347870|NCT05669300||single layer continue locked suturation|the patients underwent ceserean section and uterus closed with single layer continue locked suturation
62347871|NCT02770313|EXPERIMENTAL|Intermittent Fasting|Water-only Intermittent Fasting
62347872|NCT02770313|NO_INTERVENTION|Control|ad libitum Usual Diet
62347873|NCT02415764|OTHER|Pilot test Intervention OnTrack>The Game|"Consumers who have been referred to OnTrackNY sites at Washington Heights Community Service or Mental Health Association Westchester in the past six months will be recruited to participate in a product evaluation of OnTrack\>The Game.~Intervention: This is a behavioral/attitudinal intervention, using OnTrack\>The Game, which will include each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes)."
62347874|NCT04857749|ACTIVE_COMPARATOR|Control group|Data from patients in the control group will be collected as in the experimental group. In the first interview, the patients in the control group will be given a training booklet. Apart from this, the standard approach, treatment and care of the clinic will be applied to all patients.
62347875|NCT04857749|EXPERIMENTAL|Navigation grup|While the standard treatment approaches of the hospital are applied to all patients, a nursing navigation program will be applied in addition to the patients in the experimental group. The navigation program will be started on the first day of radiotherapy by giving a 30-minute visual training and handbook related to expected side effects. Afterwards, patient follow-up will continue with phone reminders and weekly follow-up for seven weeks.
62347876|NCT05365009||EPIMAR group|EPIMAR (ARgentina's Autoimmune Mechanism Interstitial Pulmonary Disease) registry was created in 2016 by a group of multidisciplinary specialists with experience in the management of ILD.
62347877|NCT01682070|PLACEBO_COMPARATOR|SUBLIVAC FIX Phleum prat. 0 AUN/ml|
62347878|NCT01682070|EXPERIMENTAL|SUBLIVAC FIX Phleum prat. 3,333 AUN/ml|
62347879|NCT01682070|EXPERIMENTAL|SUBLIVAC FIX phleum prat. 10,000 AUN/ml|
62505853|NCT05263284|EXPERIMENTAL|Treatment (8-chloroadenosine, venetoclax)|Patients receive 8-Cl-Ado IV over 4 hours daily on days 1-5 and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62505854|NCT02194140|OTHER|oral contrast|oral iodinated contrast material
62505855|NCT00895037||1|Patients treated with Refacto AF
61961535|NCT00933972|EXPERIMENTAL|1 (normal)|
61961536|NCT00933972|EXPERIMENTAL|2 (mild)|
61961537|NCT00933972|EXPERIMENTAL|3 (moderate)|
61961538|NCT00933972|EXPERIMENTAL|4 (severe)|
61961539|NCT04318795|EXPERIMENTAL|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
61961540|NCT04318795|EXPERIMENTAL|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
62347880|NCT01682070|EXPERIMENTAL|SUBLIVAC FIX phleum prat. 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
62347881|NCT01682070|EXPERIMENTAL|SUBLIVAC FIX Phleum prat. 40,000 AUN/ml|Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee
62505856|NCT00251316|EXPERIMENTAL|Lithium Carbonate|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive lithium capsules.
62505857|NCT00251316|PLACEBO_COMPARATOR|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
62505858|NCT05332886|EXPERIMENTAL|MetaHealth Group|It is intervention group that aims to provide youth with healthy lifestyle behaviors by using metaverse technology.
62505859|NCT05332886|ACTIVE_COMPARATOR|MobileHealth Group|It is comparator group that aims to provide youth with healthy lifestyle behaviors by using mobile application materials with digital health education will be given to the MobileHealth Group.
61961541|NCT05135117|NO_INTERVENTION|Control|Passive rest - no intervention provided
61961542|NCT05135117|ACTIVE_COMPARATOR|Ice towel cooling|About 6-12 cooling periods of ice towel lasting between 5-20 minutes will be done and equally distributed throughout the respective trials. Towels dipped in ice water will be placed on subjects necks during this time.
61961543|NCT05135117|EXPERIMENTAL|NeuroRescue Neck Cooling Collar|About 6-12 cooling periods of neck cooling with the NeuroRescue collar lasting between 5-20 minutes will be done and equally distributed throughout the respective trials.
61961544|NCT00566371|EXPERIMENTAL|1|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
61961545|NCT00566371|PLACEBO_COMPARATOR|2|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
61961546|NCT03700775|EXPERIMENTAL|Telemonitoring intervention|
61961547|NCT05201703|EXPERIMENTAL|Fycompa 4 mg daily|
61961548|NCT05201703|ACTIVE_COMPARATOR|Fycompa 4 mg daily with a boost to 6 mg daily|
62505860|NCT01085578|PLACEBO_COMPARATOR|Cohort1|CG400549/placebo
62505861|NCT01085578|PLACEBO_COMPARATOR|Cohort2|CG400549/placebo
62505862|NCT01085578|OTHER|Cohort3|CG400549
62505863|NCT06616324|EXPERIMENTAL|Intervention|Standard treatment with Virtual Reality headset and Active-Noise-Cancelling headphones
62505864|NCT06616324|NO_INTERVENTION|Control Group|Standard treatment without VR headset and ANC-headphones
62505865|NCT04138784|EXPERIMENTAL|Comprehensive Rehabilitation program|19 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks individualized comprehensive rehabilitation program administered once a day.
62505866|NCT04138784|EXPERIMENTAL|Aquatic training|18 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks hydrotherapy intervention once a day.
62505867|NCT03567525|ACTIVE_COMPARATOR|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
62505868|NCT03567525|EXPERIMENTAL|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
62505869|NCT01701973|OTHER|Group A (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo."
62505870|NCT01701973|OTHER|Group B (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo."
62505871|NCT01701973|OTHER|Group C (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo."
62505872|NCT00968500||Parents Who Have Lost a Child to Cancer|The overall goal of the proposed cross-sectional study is to obtain information necessary to the development of an effective Meaning-Centered Grief Intervention for parents who lost a child to cancer. In order to identify a subset of parents with whom we will conduct qualitative interviews with a subset of participants to address Aims 1 and 2, we will first screen participants to determine their levels of Prolonged Grief Disorder symptoms using a quantitative assessment (PG-13). The screening measure (PG-13) and the additional questionnaires included in the quantitative battery of measures will be analyzed to achieve Aim 3.
62505873|NCT05930158|ACTIVE_COMPARATOR|Pulmonary Rehabilitation Group|Patients in this group will continue the classic rehabilitation programs determined in the Pulmonary Rehabilitation Unit. The program will continue for 8 weeks, 2 sessions per week.
62704413|NCT06562595|EXPERIMENTAL|Brochure|Those participants who are automatically assigned to the brochure arm will be required to complete a 25-point initial test. Participants assigned to this arm will receive a web-based brochure on HPV and smear information (via free messaging services). At the conclusion of the brochure review, the same test will be administered again, and the participant's initial and second scores will be recorded in the case report form.
61961549|NCT04991415|EXPERIMENTAL|Treatment|30 minutes of manual therapy three times a week for two weeks (six total sessions).
62347882|NCT02527122|EXPERIMENTAL|Allergen extracts|"Skin prick test of 4 concentrations of D. pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of one forearm. Assessment of the wheal size after 15 minutes.~Skin prick test of 4 concentrations of D. farinae allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the other forearm. Assessment of the wheal size after 15 minutes."
62347883|NCT05651516|EXPERIMENTAL|Tau PET/CT|"PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.~Participants will undergo approximately 30 minutes of static PET scanning of the brain and body starting approximately 45 minutes post injection of \[18F\]PI-2620. All images will be corrected for scatter and measured photon attenuation and reconstructed using standard reconstruction techniques. Standardized uptake value ratio (SUVr), the ratio of regional to reference uptake, will be calculated with cerebellum as reference, where NFTs are generally not present in neurodegenerative disorders, hence likely not in OUD.~Subjects in all three groups undergo a brain MRI including a structural MRI functional reactivity to an episodic memory task, and undergo a comprehensive neurocognitive battery."
61961550|NCT04991415|NO_INTERVENTION|Control|No intervention
61961551|NCT04165785|EXPERIMENTAL|OPT IPL followed by MGX|"Subjects in the experimental arm will receive OPT IPL followed by MGX: OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.~Interventions:~Device: IPL Procedure: MGX"
62539226|NCT01329549|EXPERIMENTAL|BIBF 1120 (high) + Carboplatin + PLD|BIBF 1120 (high dose) + carboplatin (AUC5 mg/mL\*min) + PLD (30 mg/m2)
62539227|NCT05393518|EXPERIMENTAL|Drug resistant epilepsy with GAD|Patients suffering from drug-resistant epilepsy and generalized anxiety disorders (GAD),explored by intracranial EEG (seteroelectroencephalography - SEEG) in Hospital
62539228|NCT05393518|ACTIVE_COMPARATOR|Drug resistant epilepsy without GAD|Patients suffering from drug-resistant epilepsy without generalized anxiety disorders (GAD),explored by intracranial EEG (seteroelectroencephalography - SEEG) in Hospital
62539229|NCT04648202|EXPERIMENTAL|FS120|Open-label study where FS120 will be administered as monotherapy or in combination with pembrolizumab in dose escalation and expansion cohorts
62704414|NCT06562595|EXPERIMENTAL|Sound Recording (Radio Broadcast)|Participants who have been automatically assigned to the Sound Recording (Radio Broadcast) arm will be required to complete a 25-point initial assessment. This assessment will be administered via a web-based platform, accessible through free messaging services. Following the completion of the Sound Recording (Radio Broadcast), the same assessment will be repeated. The initial and second scores will then be recorded in the case report form.
62143787|NCT03930940|OTHER|Control group|Regular treatment alone.
62704415|NCT06174402|EXPERIMENTAL|Fenofibrate-ursodesoxycholic acid（UDCA）|Fenofibrate 200 mg/day and UDCA 13-15mg/kg/day for 12 months
62704416|NCT06174402|PLACEBO_COMPARATOR|Placebo-UDCA|1 tablet/ day and UDCA 13-15mg/kg/day for 12 months
62704417|NCT02052882|EXPERIMENTAL|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
62347884|NCT06418126|EXPERIMENTAL|Women with TNBC breast cancer|"Patients will be recruited before the start of radiotherapy. A blood sample (20 ml) will be taken before radiotherapy and immediately after the 4th radiotherapy session.~They will be followed up annually for 5 years after the end of treatment, to determine whether their cancer has recurred."
62347885|NCT05239468|ACTIVE_COMPARATOR|Double Blind (DB) Phase Treatment A: BZF 100 milligrams (mg) Immediate Release (IR) tablet|Each Participant will take one OCA placebo tablet, one BZF 100 mg IR tablet and one BZF placebo tablet daily.
62347886|NCT05239468|ACTIVE_COMPARATOR|Double Blind (DB) Phase Treatment B: BZF 400 mg IR tablet|Each Participant will take one OCA placebo tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
61961552|NCT04165785|SHAM_COMPARATOR|Sham OPT IPL followed by MGX|"Subjects in the sham comparator arm will receive Sham OPT IPL followed by MGX: Sham OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.~Interventions:~Device: Sham IPL Procedure: MGX"
61961553|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
62347887|NCT05239468|EXPERIMENTAL|Double Blind (DB) Phase Treatment C: OCA 5 mg + BZF 100 mg IR|Each participant will take one OCA 5 mg tablet, one BZF 100 mg IR tablet and one BZF placebo tablet, daily.
62539230|NCT06430398||Case|"Age \> 18 years~Singleton pregnancy Live fetus at 11-13 weeks of pregnancy Women identified as high-risk during first-trimester screening for preeclampsia and fetal growth restriction"
62539231|NCT06430398||Control|Low-risk pregnancies at first-trimester screening for preeclampsia and fetal growth restriction, which will undergo physiological monitoring in subsequent follow-up visits until delivery (homogeneous control sample).
62539232|NCT01085721|EXPERIMENTAL|Dexchlorpheniramine pseudoephedrine guaifenesin|
62704418|NCT02828358|EXPERIMENTAL|Treatment (azacitidine, combination chemotherapy)|See Detailed Description
62704419|NCT06589154||Participants who are required to undergo prostatic or pelvic MR according to the investigators|
61961554|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
61961555|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
62143788|NCT05404997|EXPERIMENTAL|Shockwave Therapy|Common Treatment : Conventional physical therapy (lumbar stretching exercises and core strengthening exercises) Group A: Shockwave Therapy
62347888|NCT05239468|EXPERIMENTAL|Double Blind (DB) Phase Treatment D: OCA 5 mg + BZF 400 mg IR|Each participant will take one OCA 5 mg tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
62347889|NCT05239468|EXPERIMENTAL|Long Term Safety Extension (LTSE) Phase Treatment D of the DB phase: OCA 5 mg + BZF 400 mg IR|Each participant will take one OCA 5 mg tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
62347890|NCT01044420|EXPERIMENTAL|mFOLFIRI|
62347891|NCT01338883|EXPERIMENTAL|CVC 100 mg + Truvada|
62347892|NCT01338883|EXPERIMENTAL|CVC 200 mg + Truvada|
62347893|NCT01338883|ACTIVE_COMPARATOR|Sustiva + Truvada|
62347894|NCT03812523|ACTIVE_COMPARATOR|Control|Duloxetine 60 mg qd
62347895|NCT03812523|EXPERIMENTAL|Intervention|Lorcaserin 10 mg bid
62347896|NCT03090464||Standard of Care (SOC)|Participants have standard of care with no access to digital disease management tool
62539233|NCT01085721|ACTIVE_COMPARATOR|Dexchlorpheniramine|
62539234|NCT04851535|EXPERIMENTAL|Jaktinib 100mg Bid|Jaktinib twice daily for 6 consecutive 28-day cycles, orally, empty stomach
61961556|NCT03249883|ACTIVE_COMPARATOR|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
62347897|NCT03090464||SOC + digital disease management|Participants have access to the digital disease management tool in addition to standard of care
62347898|NCT03001583|EXPERIMENTAL|Education Program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
62347899|NCT03001583|ACTIVE_COMPARATOR|Education without cooking|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
62347900|NCT03623425|EXPERIMENTAL|68Ga-PSMA-11 PET before 18F-FCH PET|Crossover design
62347901|NCT03623425|EXPERIMENTAL|18F-FCH PET before 68Ga-PSMA-11 PET|Crossover design
62347902|NCT01507844|SHAM_COMPARATOR|ventilation|
62347903|NCT01105221|EXPERIMENTAL|Acupuncture|
62347904|NCT01105221|ACTIVE_COMPARATOR|Artificial tear drop|
62347905|NCT04606524||study group|25 postmenopausal females will be included in this study
62704420|NCT06477653|EXPERIMENTAL|Dupilumab in addition to mepolizumab, reslizumab, or benralizumab (at least 24 but up to 48 weeks)|Dosing for an individual will be determined based on the nature of their residual symptoms and the FDA-approved dosing for that indication. Patients will self-administer using pre-filled syringes with needle shield or pre-filled pens. Patients with asthma and/or atopic dermatitis will receive a loading dose of 600 mg subcutaneously (followed by 300 mg SC every 2 weeks. Patients with Chronic Rhinosinusitis with Nasal Polyposis will not receive a loading dose and will be treated with 300 mg subcutaneously every 2 weeks. Patients with Eosinophilic Esophagitis will not receive a loading dose of 600 mg subcutaneously and will be treated with 300 mg subcutaneously weekly. Patients who meet criteria for more than one indication will be treated with the higher dose.
61961557|NCT03249883|ACTIVE_COMPARATOR|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
61961558|NCT05806281|EXPERIMENTAL|MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems
61961559|NCT05806281|NO_INTERVENTION|Waitlist control group|no intervention.
61961560|NCT01747044|ACTIVE_COMPARATOR|Milnacipran|Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
61961561|NCT01747044|PLACEBO_COMPARATOR|Capsules of lactose|placebo over a period of 8 weeks to 24 weeks
61961562|NCT00506662|EXPERIMENTAL|Insulin detemir|Individually adjusted dose of insulin detemir once daily
61961563|NCT00506662|ACTIVE_COMPARATOR|Insulin NPH|Individually adjusted dose of insulin NPH once daily
62347906|NCT04606524||control group|25 premenopausal females will be included in this tudy
62347907|NCT03180827|EXPERIMENTAL|ovarian tissue cryopreservation|
62347908|NCT00178464|EXPERIMENTAL|Aspirin|One-arm study
62347909|NCT05700955|EXPERIMENTAL|temozolomide|Participants will take Temozolomide pills at home at a dose determined by body weight. They will take the pills for five days every 3 weeks. It will be dispensed by the pharmacy and must be stored in a closed container at room temperature, away from heat, moisture, and direct light and kept from freezing. It will be kept out of the reach of children. Outdated medicine or medicine no longer needed will be returned to the Brown Cancer Center pharmacy for disposal.
62347910|NCT05700955|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg as an IV infusion through a freely flowing IV. The diluted solution will be administered intravenously over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter. Other drugs will not be co-administered through the same infusion line. Pembrolizumab doses will be repeated every three weeks.
62347911|NCT03882398|EXPERIMENTAL|Experimental group|The experimental group (EG) participated in a once a week physical exercise program for 8 weeks. The session consisted of balance training, followed by aerobic endurance training with exercise peddlers. At the beginning of the program, each session lasted 25 minutes and progressed to 35 minutes, in the last two weeks
62347912|NCT03882398|ACTIVE_COMPARATOR|Control Group|The control group (CG) only performed routine balance exercises once a week (10 min)
62704421|NCT06016608||Polyvascular disease|
62704422|NCT06223542|EXPERIMENTAL|Arm A (twice weekly UAE inhibitor TAK-243)|Patients receive UAE inhibitor TAK-243 IV on days 1, 4, 8, and 11 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, and undergo CT, MRI, and collection of blood throughout the study, and may undergo ECHO as clinically indicated on study.
61961564|NCT05824793|NO_INTERVENTION|Control Group|Participants had their impacted mandibular third molar (IMTM) extracted according to the standard procedure.
61961565|NCT05824793|EXPERIMENTAL|Experimental Group|20ml of venous blood was collected from each participant in this group into two glass tubes (10ml, A-PRF by Choukroun) and centrifuge to create A-PRF+ using Dou Quattro Choukroun PRF machine with a speed of 1300 rpm in 8 minutes, centrifugal force at the bottom of the tube was RCFmax 208g (RCFmin=113g, RCFav=164g, RCFclot=145g). After the standard extraction procedure, place two A-PRF+ clots in the IMTM socket before suturing.
61961566|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 2 IU/h|The maintenance infusion rate of oxytocin will be 2 IU/h.
62347913|NCT02405585|EXPERIMENTAL|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.~Post adjuvant therapy: 6 monthly immunizations with HAPa"
62347914|NCT00255099|ACTIVE_COMPARATOR|001|TMC125 2 x 100 mg tablets b.i.d. / 96 weeks
62347915|NCT00255099|PLACEBO_COMPARATOR|002|Placebo 2 tablets b.i.d. / 96 weeks
62347916|NCT04846894|EXPERIMENTAL|Biochemical Recurrence|Prostate cancer patient with biochemical recurrence
62347917|NCT01240512|ACTIVE_COMPARATOR|High Dose Arm|4000 IU/day Vitamin D3 (cholecalciferol) supplementation
62347918|NCT01240512|ACTIVE_COMPARATOR|Low Dose Arm|400 IU/day Vitamin D3 (cholecalciferol) supplementation
61961567|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 4 IU/h|The maintenance infusion rate of oxytocin will be 4 IU/h.
61961568|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 6 IU/h|The maintenance infusion rate of oxytocin will be 6 IU/h.
61961569|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 8 IU/h|The maintenance infusion rate of oxytocin will be 8 IU/h.
61961570|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 10 IU/h|The maintenance infusion rate of oxytocin will be 10 IU/h.
61961571|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 12 IU/h|The maintenance infusion rate of oxytocin will be 12 IU/h.
61961572|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 14 IU/h|The maintenance infusion rate of oxytocin will be 14 IU/h.
61961573|NCT04946006|EXPERIMENTAL|Oxytocin infusion rate 16 IU/h|The maintenance infusion rate of oxytocin will be 16 IU/h.
61961574|NCT02289339||TAVI patients|all patients undergoing transcatheter aortic valve prostheses implantation
61961575|NCT02765295|ACTIVE_COMPARATOR|hydrogen inhalation|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixture gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min). Usual care referred to mucolytics (see below for details) alone or plus chest physiotherapy.
61961576|NCT02765295|SHAM_COMPARATOR|oxygen inhalation|Oxygen will be generated by an instrument provided by the sponsor, that would be capable of generating oxygen equivalent to that generated by the MUNHO (3L/min mixed gas containing 33.3% oxygen). Usual care referred to mucolytics \[\[ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily)/ serrapeptase (10mg thrice daily), or carbocisteine (500mg thrice daily)\] alone or in combination with chest physiotherapy.
62347919|NCT06411223|OTHER|Pharmacist lead CDTM+|Participants will meet with a clinic-based pharmacist via telehealth for an introductory visit to discuss CAB/RPV LA and possible switch from oral to injectable therapy. The tele-visit can occur by phone or video visit.
62347920|NCT01376726|EXPERIMENTAL|Previous HIV Vaccine Trial Participants (Group 1)|"Participants will receive the study vaccine administered as one 0.5 mL intramuscular injection (IM) in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
62347921|NCT01376726|EXPERIMENTAL|No Previous HIV Vaccine Trial (Group 2)|"Participants will receive the study vaccine administered as one 0.5 mL IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
62347922|NCT04319419|EXPERIMENTAL|Supplement with micronutrients|Nutrition education with a supplement
62347923|NCT04319419|EXPERIMENTAL|Nutrition education|Group received only nutrition education
62347924|NCT02279121|EXPERIMENTAL|TauroLock|solution of taurolidine-citrate
62347925|NCT02279121|OTHER|Control|saline solution
62347926|NCT03493867|OTHER|Vitaliti|The subject's blood pressure will be simultaneously determined and recorded using the invasive arterial line blood pressure reading and the test Vitaliti device readings.
62347927|NCT00488592|EXPERIMENTAL|PR1/WT1 Vaccine Response in Participants With Low-Risk Myeloid Cancers|"Subjects were given 6 subcutaneous injects of PR1:169-177 in Montanide adjuvant and 6 subcutaneous injections of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
62539235|NCT01724086|EXPERIMENTAL|Panel 1|10 chronic HCV genotype 1a (GT1a) infected treatment-naive patients/prior relapsers who will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
62539236|NCT01724086|EXPERIMENTAL|Panel 2 Arm 1|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
62539237|NCT01724086|EXPERIMENTAL|Panel 2 Arm 2|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
62704423|NCT06223542|EXPERIMENTAL|Arm B (once weekly UAE inhibitor TAK-243)|Patients receive UAE inhibitor TAK-243 IV on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, and undergo CT, MRI, and collection of blood throughout the study, and may undergo ECHO as clinically indicated on study.
62704424|NCT02626533||Total knee arthroplasty patients|"Patients undergoing total knee arthroplasty for osteoarthritis are enrolled in the study.~Blood and joint fluid samples will be obtained from patients. Pain type and severity will be assessed at baseline (enrollment), 4 weeks, 3 months, and 6 months postoperatively."
62704425|NCT06643481|EXPERIMENTAL|Arm 1|I.V. infusions every 4 weeks
62704426|NCT06643481|PLACEBO_COMPARATOR|Arm 2|I.V. infusions every 4 weeks
62704427|NCT04990167|EXPERIMENTAL|Tiotropium arm|"Subjects on this arm will start the study on tiotropium for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on the prescribed asthma controller medication."
62704428|NCT04990167|ACTIVE_COMPARATOR|ICS arm|"Subjects on this arm will start the study on the prescribed asthma medication for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on Tiotropium."
62704429|NCT00029445||Family members|Family members of individuals with innate control over HIV
61961577|NCT02627144||Advanced and/or Metastatic RCC participants|Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.
61961578|NCT00748501|ACTIVE_COMPARATOR|Cohort 1|SB-509 drug administration via IM injection of neck, arms, and legs
61961579|NCT00748501|ACTIVE_COMPARATOR|Cohort 2|SB-509 drug administration via IM injection of legs
61961580|NCT04890769||Participants|Patients with exuding wounds
61961581|NCT03558854|ACTIVE_COMPARATOR|ASA group|Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks
61961582|NCT03558854|PLACEBO_COMPARATOR|Placebo oral capsule group|Identical pill containing placebo, taken once daily for 04 weeks
62143789|NCT05404997|EXPERIMENTAL|Maitland's Lumbar Mobilizations|Common Treatment: Conventional Physical Therapy (lumbar stretching exercises and core strengthening exercises) Group B: Maitland's Lumbar mobilizations
62143790|NCT02015767||Roflumilast|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing authorization.
61961583|NCT03066804|EXPERIMENTAL|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
61961584|NCT03066804|ACTIVE_COMPARATOR|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
61961585|NCT01271062|ACTIVE_COMPARATOR|T2DM patients before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
61961586|NCT01271062|ACTIVE_COMPARATOR|Non-diabetic patient before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
61961587|NCT01271062|ACTIVE_COMPARATOR|non diabetic patients, non-bariatric abdominal surgery|oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.
61961588|NCT01271062|ACTIVE_COMPARATOR|severely obese T2DM patients following a very low caloric diet|oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.
61961589|NCT03031678|OTHER|Study procedures|
61961590|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
61961591|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
61961592|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
62347928|NCT02072512|ACTIVE_COMPARATOR|Fulvestrant|Goserelin plus High Dose Fulvestrant
62505874|NCT05930158|EXPERIMENTAL|Dual Task Exercises Group|"The patients in this group will continue the determined rehabilitation programs, during the walking and balance exercises in the program, they will also do the cognitive exercises that are different from the patients in the Pulmonary Rehabilitation group. The program will continue for 8 weeks, 2 sessions per week. Walking exercises and balance exercises will be planned for 15 minutes each. The intensity of the walking exercise will be planned as moderate intensity according to the results of 6 MWT, it will start with the warm-up period and end with a cool-down. A treadmill will be used for the exercise.~Balance exercises program will consist of tandem walking (walking with the heel touching the toe of the other foot), standing on one foot (eyes open-closed), walking in a straight line, and standing on soft ground with eyes closed.~Cognitive exercises to be added during walking and balance exercises will be given as a dual task."
62505875|NCT05930158|NO_INTERVENTION|Healthy Controls|Dual-task performances of healthy individuals with similar demographic characteristics in COPD patients will be compared. For this, the demographic information of healthy volunteers will be recorded, and the Timed Up and Go Test, which will be done as a dual task and a single task, and the 10-meter Walk Test will be evaluated.
62505876|NCT04043819|EXPERIMENTAL|PSC-01|All study participants will receive intraarticular injection of the investigational biological product, PSC-01.
62347929|NCT02072512|ACTIVE_COMPARATOR|Anastrozole|Goserelin plus Anastrozole
62505877|NCT00792584|EXPERIMENTAL|1|patients treats with etravirine for 6 weeks
62505878|NCT00792584|EXPERIMENTAL|2|patients treats with efavirenz for 6 weeks
62505879|NCT01637831|EXPERIMENTAL|Patients with OSA and IPF|Participants with Obstructive Sleep Apnea (OSA)and Idiopathic Pulmonary Fibrosis (IPF).This arm will complete pre-treatment questionnaires assessing sleep and quality of life, undergo six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and complete post-treatment the same questionnaires 1, 3 and 6 months later.
62505880|NCT01913717|EXPERIMENTAL|External beam radiotherapy|External beam radiotherapy
62704430|NCT00029445||HIV infection with one of the following HLA types: B*27+, B*35+,B*44+, B*57+, B*58+, and/or A*02.|People living with HIV with specific HLA-types.
61961593|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
62347930|NCT04605536|OTHER|Intervention|Give explanations about conventional capsule endoscopy and watch animation videos
62347931|NCT04605536|OTHER|Control|Give explanations about conventional capsule endoscopy
62505881|NCT04954690|PLACEBO_COMPARATOR|Usual Care|Patients randomized to usual care will receive recommendations for exercise based on the Surgeon General's recommendations for physical activity among adults as well as the American Heart Association and American College of Sports Medicine recommendations for older individuals or individuals with chronic conditions. These guidelines are applicable to this patient population. Patients will not receive coaching but will receive accelerometers to obtain data for comparison to the intervention groups at each time point (baseline, 8 weeks, and 3 months post-KT).
62143791|NCT03451695|EXPERIMENTAL|Morphine group|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
62143792|NCT03451695|PLACEBO_COMPARATOR|Placebo group|Placebo group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1 ml).
62143793|NCT00874588|EXPERIMENTAL|Phase I study|
62347932|NCT05157399|EXPERIMENTAL|OtoBand Efficacy on Vertigo and Dizziness|During the single site visit, participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand will be set to 92dB or 98dB bone conduction level (Re: 1 Dyne). The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
61961594|NCT05742594|EXPERIMENTAL|Intervention Sequence: ADBC|Participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention Period 1, followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention C (lazertinib test formulation) on Day 1 of Intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
62143794|NCT05481346|EXPERIMENTAL|Multidomain training group|Participants will use free weights and functional materials to work the main muscle groups. In addition, they will perform cardiorespiratory training and cognitive training with proposed tasks. Participants will follow the planned training progression. The researchers will record the number of sets completed and the load lifted for each exercise for each participant and the perception of effort in each class.
62505882|NCT04954690|ACTIVE_COMPARATOR|Weekly Coaching|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise
61961595|NCT05742594|EXPERIMENTAL|Intervention Sequence: BACD|Participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 2, followed by intervention C (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
62505883|NCT04954690|ACTIVE_COMPARATOR|Weekly Coaching + Caregiver Participation|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise with the addition of caregiver participation to promote adherence and engagement
62505884|NCT01711996||UPJO|0-3 year old hydronephrosis patients without ureter dilatation who undergo pyeloplasty
62505885|NCT01711996||Hydronephrosis|0-3 year old hydronephrosis patients without ureter dilatation who does not meet the indication of pyeloplasty
62505886|NCT01711996||Normal|0-3 year old children without hydronephrosis
62143795|NCT05481346|NO_INTERVENTION|Control group|The control group did not receive a training program and were asked not to modify their physical activity habits.
62347933|NCT05157399|PLACEBO_COMPARATOR|Placebo Device Efficacy on Vertigo and Dizziness|Participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand set to a bone conduction level 10dB lower than the level used in the experimental condition. Once fitted with the Otoband, participants will undergo the vestibular battery test. The investigator will record the outcome measurements.
62347934|NCT05157399|NO_INTERVENTION|No Device|Participants will wear the OtoBand, but turned off, to collect baseline data. This will be randomized. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
62347935|NCT02912728|ACTIVE_COMPARATOR|CGM + Family Behavioral Intervention|CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes.
62347936|NCT02912728|ACTIVE_COMPARATOR|Standard CGM|"Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.~A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.~Participants will be instructed to use the CGM as per the FDA labeling."
62347937|NCT02912728|NO_INTERVENTION|BGM - usual care control group|A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit.
62347938|NCT04352595|EXPERIMENTAL|1% Hemay808|
62347939|NCT04352595|EXPERIMENTAL|3% Hemay808|
62347940|NCT04352595|EXPERIMENTAL|7% Hemay808|
62347941|NCT04352595|PLACEBO_COMPARATOR|vehicle|
62143796|NCT00716170||A:|Patients with type 2 diabetes mellitus
62143797|NCT00326183|ACTIVE_COMPARATOR|1|Arm 1: vaccine
62143798|NCT00326183|ACTIVE_COMPARATOR|2|Arm 2: Active comparator
62143799|NCT05982366|EXPERIMENTAL|Distal transradial approach|Distal transradial approach as the default strategy
62505887|NCT01114581|ACTIVE_COMPARATOR|Guaifenesin|Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
62505888|NCT01114581|PLACEBO_COMPARATOR|Placebo|Given as 2 tablets
62505889|NCT01747577|EXPERIMENTAL|Solifenacin group|
62505890|NCT01747577|PLACEBO_COMPARATOR|Placebo group|
62505891|NCT01279382|OTHER|Care as usual (CON)|CON was given to a subgroup of patients as control treatment in IBS treatment
62505892|NCT01279382|OTHER|Hypnotherapy (HYP)|HYP was given to a subgroup of patients as intervention in IBS treatment
62505893|NCT01279382|OTHER|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
62505894|NCT04551287||Training dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Artificial Intelligence Cervical Cancer Screening (AICS).
62505895|NCT04551287||SYSMH internal validation dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Artificial Intelligence Cervical Cancer Screening (AICS).
62505896|NCT04551287||TAHGMU external validation dataset|600 slides from 600 eligible individuals were obtained in the Third Affiliated Hospital of Guangzhou Medical University (TAHGMU, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Artificial Intelligence Cervical Cancer Screening (AICS).
62505897|NCT04551287||GWCMC external validation dataset|600 slides from 600 eligible individuals were obtained in Guangzhou Women and Children Medical Center (GWCMC, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Artificial Intelligence Cervical Cancer Screening (AICS).
62505898|NCT04551287||Prospective validation dataset|A prospective validation dataset was conducted to distinguish the diagnostic performance of the cytopathologists, AICS, and AICS-assisted cytopathologists, in which 2,780 eligible slides from 2,780 individuals were obtained and prospectively labeled between August 28, 2020 and October 16, 2020 at SYSMH.
62505899|NCT04551287||Randomized controlled trial|A prospective randomized controlled trial was conducted to compare the performance of the cytopathologists, AICS, and AICS-assisted cytopathologists in SYSMH. Here, 618 slides were collected between August 13, 2020, and December 14, 2020, to build the SYSMH randomized controlled trial. The remaining 608 slides after quality control were randomly assigned (1:1:1) to the AICS group (n = 201), the cytopathologists group (n = 203), and the AICS-assisted cytopathologists group (n = 204).
61961596|NCT05742594|EXPERIMENTAL|Intervention Sequence: CBDA|Participants will receive intervention C (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
61961597|NCT05742594|EXPERIMENTAL|Intervention Sequence: DCAB|Participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention C (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 3 followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
61961598|NCT05471791|EXPERIMENTAL|App group|Participants will use the Back2Play App to support them in following the guidelines for recovery from concussion
61961599|NCT05471791|NO_INTERVENTION|Usual Care|Participants will receive usual care which often means they are provided concussion recovery guidelines in handout format and receive whatever follow up is deemed necessary by treating physician
61961600|NCT04482881|ACTIVE_COMPARATOR|women receiving isosorbide mononitrates lower dose|women who will receive isosorbide mononitrates lower dose
61961601|NCT04482881|ACTIVE_COMPARATOR|women receiving isosorbide mononitrates higher dose|women who will receive isosorbide mononitrates higher dose
62505900|NCT03446365|EXPERIMENTAL|ASMAS|ASMAS is an asthma self-management program based on NHLBI clinical guidelines for optimal school-based asthma management. It involves 4, 1½ hour sessions delivered in group format in the urban, middle school setting by a Latino High School Peer who has asthma. ASMAS focuses on asthma pathophysiology, symptom management, asthma medications, and trigger control.
62505901|NCT03446365|ACTIVE_COMPARATOR|Asthma education plus child health|"Asthma Education plus Child Health control condition will be delivered by an adult Health Educator , and includes 4 sessions (1 1/2 hrs long) of our existing asthma education (Asthma's Magic Number) with added general health topics (nutrition, physical activity, safety)."
62505902|NCT03446365|NO_INTERVENTION|No Treatment Control|Students randomly assigned to this arm , will receive standard of care, which is no treatment, and will not participate in any group intervention sessions.
62143800|NCT05982366|ACTIVE_COMPARATOR|Conventional transradial approach|Conventional transradial approach as the default strategy
62505903|NCT00063258|ACTIVE_COMPARATOR|Chemotherapy + Tarceva|
62505904|NCT00063258|ACTIVE_COMPARATOR|Chemotherapy Alone|
62505905|NCT03990116|EXPERIMENTAL|Lateral kangaroo|Placing the infant in lateral on the parents chest, keeping the head neutral and limbs flexed towards body midline
62505906|NCT03990116|ACTIVE_COMPARATOR|Prone Kangaroo|placing the baby in upright and ventral position between mother's breasts or over the father chest, in skin-to skin contact with no clothes in between and with lower limbs flexed
62505907|NCT01383850|ACTIVE_COMPARATOR|NCPAP + standard air|
62143801|NCT04642898|EXPERIMENTAL|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
62505908|NCT01383850|EXPERIMENTAL|NCPAP + Heliox|
62505909|NCT05576506||Deep learning algorithm group|After the patient has passed the screening, a routine colonoscopy will be performed, and the target tissue with suspected inflammation or neoplasia will be biopsied. The clinical investigators use the hyperspectral microscope to collect image information of the biopsy tissue in the endoscopy room. After collecting information, biopsy specimens will be routinely processed and sent for pathological diagnosis.
62704431|NCT00029445||Long term nonprogressors|Individuals with innate control over HIV
62704432|NCT06015893|PLACEBO_COMPARATOR|Placebo|Weekly subcutaneous (s.c.) injections of placebo.
62704433|NCT06015893|EXPERIMENTAL|Semaglutide|Weekly subcutaneous (s.c.) injections of semaglutide up to 2.4 mg/week or maximum tolerated dose (MTD). Consistent with current recommendations, the dose will be titrated at minimum every four weeks to maximize tolerability and minimize adverse events.
61961602|NCT04482881|ACTIVE_COMPARATOR|Women receiving misoprostol|Women who will receive misoprostol
61961603|NCT04672993|EXPERIMENTAL|Urine Collection Device for Men|Test of Urine Collection Device for Men for 7 (+/- 3/0 days).
62143802|NCT04642898|EXPERIMENTAL|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
62143803|NCT04642898|EXPERIMENTAL|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
62704434|NCT05722210||Adults >= 18 years of age|undergoing evaluation for hematopoietic stem cell transplant at the NIH Clinical Center
62704435|NCT05722210||Children 3-17 years of age|undergoing evaluation for hematopoietic stem cell transplant at the NIH Clinical Center
62704436|NCT06074588|EXPERIMENTAL|Sacituzumab tirumotecan|Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
62704437|NCT06074588|ACTIVE_COMPARATOR|Chemotherapy|Participants will receive 75 mg/m\^2 of docetaxel or 500 mg/m\^2 of pemetrexed by IV infusion on Days 1 and 22 of every 6-week cycle.
61961604|NCT06352801|EXPERIMENTAL|Self-Compassion Intervention Group|The intervention group consists of two parts: children training session and parent group sessions. All children participants will complete a total of 6 training sessions, and each session will last around 90 minutes. Parents of the children participants will also complete a total of 3 group sessions, and each session will last around 90 minutes. Participants will receive intervention in Phase 1.
61961605|NCT06352801|NO_INTERVENTION|Wait-list Control Group|Participants will receive the same intervention in Phase 2.
61961606|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
61961607|NCT02447042|EXPERIMENTAL|2 ml/Kg|Fluid challenge with crystalloids (2 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
62704438|NCT02413970|OTHER|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System.
62704439|NCT04704544|EXPERIMENTAL|Tele-rheumatology first visit and Usual Care second visit|Participants randomized to this visit will receive a tele-rheumatology visit first.
62704440|NCT04704544|EXPERIMENTAL|Usual Care first visit and Tele-rheumatology second visit|Participants randomized to this visit will receive a usual care visit first.
62704441|NCT04933539|EXPERIMENTAL|Arm 1|Daratumumab SC (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); Carfilzomib IV (Days 1, 8, 15 of the 28-day cycle); Dexamethasone PO/IV (Days 1, 8, 15, 22 of the 28-day cycle)
62704442|NCT06640478|ACTIVE_COMPARATOR|NUTRI-Beta Intervention Group|"We will provide healthy foods (NUTRI-Beta Food bag) to the intervention group weekly for 12 weeks, in addition to an intensive nutrition counseling program (NUTRI-Beta Counseling) and close 24-hour continuous glucose monitoring. The healthy foods bag will contain a combination of 6 types of foods including:~1. seasonal fruits (containing high amounts of vitamin C and E)~2. legumes,~3. nuts,~4. yogurt, and~5. seasonal vegetables (carotenoids, tomatoes, broccoli, celery, etc.).~6. seafood or seafood-related products~The portions of each food group component of the NUTRI-Beta basket will follow the current USDA dietary guidelines according to the age of the participant: a) Intervention group will receive NUTRI-Beta foods bag + intensive nutrition counseling (NUTRI-Beta dietary counseling) + standard insulin treatment (either insulin injections or insulin pump per patient preference) and T1D technology use"
61961608|NCT02447042|EXPERIMENTAL|3 ml/Kg|Fluid challenge with crystalloids (3 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
61961609|NCT02447042|EXPERIMENTAL|4 ml/kg|Fluid challenge with crystalloids (4 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
61961610|NCT02447042|EXPERIMENTAL|5 ml/Kg|Fluid challenge with crystalloids (5 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
62347942|NCT06184737|EXPERIMENTAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
62704443|NCT06640478|OTHER|Standard of care nutrition counseling (MyHealthy plate model and ADA clinical guidelines)|"STANDARD OF CARE NUTRITION COUNSELING:~1. A 12-week distribution of weekly grocery store gift cards of similar monetary value of the NUTRI-Beta food bag in addition to~2. MyPlate USDA model with similar frequency of nutrition counseling visits but following the American Dietary Association (ADA) Guidelines, and~3. Standard insulin treatment (either insulin injections or insulin pump per patient preference) and 24-hour continuous glucose monitor"
61961611|NCT05106283|ACTIVE_COMPARATOR|Deep Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
61961612|NCT05106283|ACTIVE_COMPARATOR|Deep and Superficial Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 10 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anteror area to superficial serratus anteror area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 10 ml of 0.25% bupivacaine will be injected for superficial serratus anetrior block into the interfacial area.
61961613|NCT02762357||Novosyn® Quick|episiotomy closure using suture material
61961614|NCT04952493|EXPERIMENTAL|anlotinib + RAI|Patients in this arm will receive anlotinib 6 cycles around RAI treatment ( 4 cycles before and 2 cycles after RAI)
61961615|NCT04952493|OTHER|RAI only|Patients in this arm will receive RAI treatment as scheduled.
61961616|NCT04952493|EXPERIMENTAL|Penpulimab + RAI|Patients in this arm will receive Penpulimab from one week prior to RAI treatment until the disease progressed or intolerable.
62143804|NCT04642898|EXPERIMENTAL|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
62143805|NCT04642898|EXPERIMENTAL|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
62143806|NCT04642898|EXPERIMENTAL|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
62143807|NCT02426255||ICU patients|Patients with severe trauma (with or without brain injury) or Patients with hemorrhagic shock Data concerning the ICU stay will be collected for these patients
62143808|NCT06146634|EXPERIMENTAL|Hazard Perception Training|
62143809|NCT06146634|PLACEBO_COMPARATOR|Vehicle Maintenance Training|
62143810|NCT06146634|ACTIVE_COMPARATOR|Attention Maintenance Training|
62143811|NCT06146634|NO_INTERVENTION|ZED Training|
61961617|NCT00477243||Palliative Care Clinic Patients|Department of Symptom Control and Palliative Care Center Patients
61961618|NCT03627247|EXPERIMENTAL|Cognitive Behavioral Stress Management|Women randomized to CBSM participated in an eight-week prenatal course called SMART Moms (Stress Management and Relaxation Training for Moms) aimed at teaching coping and relaxation skills that address stressors and daily challenges experienced during pregnancy and motherhood.
61961619|NCT03627247|NO_INTERVENTION|Attention Control Group|"Women randomized to the AC group participated in an eight-week program where they received printed materials (offered in Spanish and English) by mail once per week, on common prenatal health information topics (e.g., common discomforts of pregnancy, labor and delivery) chosen from the March of Dimes Foundation's Becoming a Mom handouts (March of Dimes, 2011). Women in this group were contacted once per week by phone by a research staff member to make sure that they received their mailed prenatal health information and to see if they had any questions."
61961620|NCT02997020||CRS Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
61961621|NCT02997020||Control Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
61961622|NCT06056037|EXPERIMENTAL|Making ART Work|A culturally tailored, theoretically grounded social support intervention that includes receipt of daily text messages and provider-facilitated group adherence counseling (4 sessions)
61961623|NCT06056037|ACTIVE_COMPARATOR|Standard of Care|Standard clinical care referrals and basic medication adherence education
61961624|NCT02154243|EXPERIMENTAL|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV\<15 will be given oral midodrine, 10 mg, once.
61961625|NCT02154243|EXPERIMENTAL|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV\>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
61961626|NCT02154243|NO_INTERVENTION|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
61961627|NCT04096963||The WATCHMAN FLX Delivery System|Patients who are eligible for a WATCHMAN FLX device according to current international and local guidelines (and future revisions) and per physician discretion;
61961628|NCT04644081|EXPERIMENTAL|LTP+CaCBT|The LTP+CaCBT intervention will consist of a total of 12 (social distancing) group training sessions (60-90 minutes) and will deliver two sessions on a weekly basis for six weeks.
61961629|NCT04644081|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of counselling services).
61961630|NCT05731778|EXPERIMENTAL|Stannous fluoride test toothpaste|Currently marketed as the new Colgate Total SF containing Stannous Fluoride
61961631|NCT05731778|PLACEBO_COMPARATOR|Colgate flouride toothpaste|Colgate Dental Cream containing Stannous Sodium Fluoride
61961632|NCT02418598|EXPERIMENTAL|Cohort1|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 200 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 50 µL per site) at a flow rate of 3 µL per minute.
61961633|NCT02418598|EXPERIMENTAL|Cohort2|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 600 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 150 µL per site) at a flow rate of 3 µL per minute.
61961634|NCT01757743||Interventional closure|Interventional catheterization closure
61961635|NCT01757743||Open Heart Surgery|Surgery for Atrial septal defect
61961636|NCT03466008|EXPERIMENTAL|Whole body cryotherapy arm|intervention consisted of 10 sessions of WBC (three minutes for each session) which were performed in addition to usual care in a standard cryotherapy room over a duration of 8 days.
61961637|NCT03466008|NO_INTERVENTION|Usual treatment arm|usual care
62347943|NCT06184737|ACTIVE_COMPARATOR|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
62704444|NCT04982419|ACTIVE_COMPARATOR|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
61961638|NCT05830721|ACTIVE_COMPARATOR|Standard of Care|This arm involves standard of care monitoring.
61961639|NCT05830721|EXPERIMENTAL|MY01 + standard of care group|This arm involves insertion of the MY01 device into the same leg as the arterial ECMO tubing to continuously monitor compartment pressures.
61961640|NCT05830721|EXPERIMENTAL|14-gauge slit catheter monitor + standard of care|This arm involves insertion of the 14g slit catheter into the same leg as the arterial ECMO tubing to continuously monitor compartment pressures.
61961641|NCT01101087|EXPERIMENTAL|Taurolock|
61961642|NCT01101087|PLACEBO_COMPARATOR|Placebo|
61961643|NCT04387032|EXPERIMENTAL|Experimental group|Experimental group (students with hypomobile SIJs)
62704445|NCT04982419|SHAM_COMPARATOR|Sham remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
61961644|NCT04387032|SHAM_COMPARATOR|Control group|control group (students without hypomobile SIJs)
61961645|NCT03996252|EXPERIMENTAL|Combination treatment arm|Combination of calcipotriene 0.005% foam (Sorilux) and Fluorouracil Cream, 5% USP (generic) applied for four consecutive nights for the treatment of scalp actinic keratoses.
62704446|NCT06291246|EXPERIMENTAL|Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
62704447|NCT06291246|ACTIVE_COMPARATOR|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling."
61961646|NCT06297161||Patients with newly diagnosed CP Ph+ CML|Patients newly-diagnosed with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)
61961647|NCT01709513|OTHER|Atorvastatin (statin rechallenge arm)|Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
61961648|NCT01709513|ACTIVE_COMPARATOR|Ezetimibe|Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
62704448|NCT04021108|OTHER|Cohort 1|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 1 will receive Nivolumab alone (every 2 weeks for two doses, and then every 4 weeks)"
62704449|NCT04021108|EXPERIMENTAL|Cohort 2|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 2 will receive Nivolumab (every 2 weeks for two doses, and then every 4 weeks) plus radiation therapy (total 5 sessions)"
62704450|NCT06269640|EXPERIMENTAL|SESAME Arm|
62704451|NCT06274749|PLACEBO_COMPARATOR|Placebo|50% of participants
61961649|NCT01709513|EXPERIMENTAL|Alirocumab 75 mg/ up to 150 mg|Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
62347944|NCT05708937|EXPERIMENTAL|Experimental group|Experimental group participants used the mindfulness mobile application. Then, the psychosocial status of the participants was measured with scales.
62347945|NCT05708937|NO_INTERVENTION|Control group|The control group participants did not receive any intervention. Classical care was applied. Then, the psychosocial status of the participants was measured with scales.
62347946|NCT05249985|EXPERIMENTAL|NMES plus protein supplementation|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps in addition to a daily protein supplement.
62704452|NCT06274749|ACTIVE_COMPARATOR|Urolithin A|50% of participants
61961650|NCT04113005|EXPERIMENTAL|Desmopressin|Aim to evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment.
61961651|NCT01393691|EXPERIMENTAL|CBT with parent combined play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
61961652|NCT01393691|ACTIVE_COMPARATOR|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
61961653|NCT04933994||Coronavirus disease; Influenza A(H1N1)|two independent cohorts of COVID-19 pneumonia (n=405) and H1N1 influenza pneumonia (n=78) retrospectively, all patients were confirmed by RT-PCR. Four hundred and five cases of COVID-19 pneumonia were confirmed in nine hospitals of Zhejiang province, China from January 21 to February 20, 2020. Seventy-eight cases of H1N1 influenza pneumonia were confirmed in our hospital from January 1, 2017 to February 29, 2020.
61961654|NCT01991691|EXPERIMENTAL|Tablet-based reported outcome|With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.
62347947|NCT05249985|ACTIVE_COMPARATOR|NMES|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.
61961655|NCT01868854||Radiographic Plane 1|the tip of peritoneal dialysis catheter is located at the bottom of the pelvis, below a line connecting the head of the femur
61961656|NCT01868854||Radiographic Plane 2|the tip of the peritoneal dialysis catheter is located above the plane 1 and below a line connecting the two iliac spines
61961657|NCT01868854||Radiographic plane 3|The location of the catheter tip is on the line connecting iliac spines and below a line connecting the iliac crests
61961658|NCT01868854||Radiographic plane 4|The location of the catheter tip is on the line connecting the iliac crests
62143812|NCT06082115|EXPERIMENTAL|Selected Physical and Occupational Therapy Program|Unilateral cerebral palsy children will receive selected physical and occupational therapy program for 1 hour. The duration of treatment will be 3 times/week for 12 weeks.
62347948|NCT01112423|EXPERIMENTAL|BMS-823778 (2 mg)|
62347949|NCT01112423|EXPERIMENTAL|BMS-823778 (10 mg)|
62347950|NCT01112423|EXPERIMENTAL|BMS-823778 (20 mg)|
62347951|NCT01112423|PLACEBO_COMPARATOR|Placebo|
62347952|NCT04005976||Patients with causal mutations in the known H-TAD genes|
62505910|NCT03424655|EXPERIMENTAL|Group TFA|Twisted files were used serially with a single controlled motion according to the manufacturer's instructions.
62505911|NCT03424655|EXPERIMENTAL|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
61961659|NCT00316849|EXPERIMENTAL|Treatment (temsirolimus, temozolomide, radiation therapy)|GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61961660|NCT03169556|EXPERIMENTAL|video-laryngoscope guided lightwand|
61961661|NCT03169556|ACTIVE_COMPARATOR|lightwand|
61961662|NCT05228132|EXPERIMENTAL|Pristine™ Long-Term Hemodialysis Catheter|The Pristine™ Long-Term Hemodialysis Catheter is a chronic hemodialysis catheter consisting of a dual lumen radiopaque shaft with a pre-formed split tip, which enables long-term vascular access for hemodialysis. The device is intended to be used in patients suffering from chronic kidney disease. The Pristine™ Catheter will be placed according to the Instructions for Use (IFU).
61961663|NCT04678271|EXPERIMENTAL|AFIX-OB Intervention Arm|Practices randomized to this arm will choose from a suite of quality improvement interventions that address patient, provider, and practice-level factors relating to maternal vaccination.
61961664|NCT04678271|NO_INTERVENTION|Control Arm|Practices randomized to this arm will continue to provide their normal standard of care to pregnant patients at their practice.
61961665|NCT04615481|EXPERIMENTAL|Elliptical Training Group|Total 30 minutes of elliptical cross training, including warm up, progressive elliptical training and cool down.
62347953|NCT04359719||Group mild melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
62704453|NCT03680092|EXPERIMENTAL|Cyclophosphamide and abatacept|The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
62347954|NCT04359719||Group Moderate-severe melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
62347955|NCT01235169|EXPERIMENTAL|Proximal Femoral Nail Antirotation|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation
62347956|NCT00981318|OTHER|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid|single arm
61961666|NCT04615481|EXPERIMENTAL|Ergo-metric Training Group|Total 30 minutes of ergometric training
61961667|NCT03152071|EXPERIMENTAL|Robot assisted thoracic surgery|RATS
61961668|NCT03152071|ACTIVE_COMPARATOR|Video assisted thoracic surgery|VATS
62347957|NCT01990014||craniectomy|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having received treatment by decompressive craniectomy.
61961669|NCT01877265|EXPERIMENTAL|LY2605541 - Source 1|Each healthy participant will receive a single subcutaneous (SC) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of 1 of 3 treatment periods
62347958|NCT03943173|EXPERIMENTAL|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After treatment, patients either undergo surgery then receive standard chemotherapy for up to 4 cycles or receive standard chemotherapy within 14 days for up to 4 cycles then undergo surgery in the absence of disease progression or unacceptable toxicity at the discretion of the treating physician.
62347959|NCT01207817||no condition|no condition - healthy volunteers
62704454|NCT03680092|ACTIVE_COMPARATOR|methotrexate and tacrolimus|The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus
61961670|NCT01877265|EXPERIMENTAL|LY2605541 - Source 2|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1of 3 treatment periods
61961671|NCT01877265|EXPERIMENTAL|LY2605541 - Source 3|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1 of 3 treatment periods
61961672|NCT02513953|EXPERIMENTAL|Endometriosis|Four port laparoscopy by way of intervention was needed for convenience in aspirating the cystic fluid and reversal of the cyst wall taking care not to destroy the normal ovarian tissue to minimize loss of ovarian reserve
61961673|NCT01328509||Sepsis|Patients with sepsis
61961674|NCT01328509||Control|Patients with no clinical evidence of sepsis, but who are critically ill
61961675|NCT00300391|EXPERIMENTAL|haloperidol|Once diagnosed as delirious, randomized to haloperidol 5 mg IV
61961676|NCT00300391|PLACEBO_COMPARATOR|placebo|once diagnosed as delirious, received 5 mg saline placebo
61961677|NCT04302298|EXPERIMENTAL|Virtual Reality Group|This group will go through the virtual reality simulation of a procedure prior to doing it on a plastic SawBone.
62704455|NCT04117347|EXPERIMENTAL|Light therapy A via the Re-Timer®|-15 minutes/day
61961678|NCT04302298|NO_INTERVENTION|Technique Guide Group|This group will go be able to read through a technique guide on the procedure prior to doing it on a plastic SawBone. This is the current method of learning in surgical residencies.
61961679|NCT04592315|EXPERIMENTAL|1|Dose 5 mg
61961680|NCT04592315|EXPERIMENTAL|2|Dose 10 mg
61961681|NCT04592315|EXPERIMENTAL|3|Dose 20 mg
61961682|NCT04592315|EXPERIMENTAL|4|Dose 40 mg
62143813|NCT06082115|EXPERIMENTAL|Mirror Therapy|Unilateral cerebral palsy children will receive selected physical and occupational therapy program for 1 hour in addition to mirror therapy for 30 minutes. The duration of treatment will be 3 times/week for 12 weeks.
61961683|NCT04592315|EXPERIMENTAL|5|Dose 60 mg
61961684|NCT04592315|EXPERIMENTAL|6|Dose 80 mg
61961685|NCT03949504||General population|Male and Female subjects (n=1000) over 34 years of age randomly recruited from the participants to the recall phase of the Moli-sani study
61961686|NCT03949504||Patients with type 2 Diabetes|Male and Female patients with type 2 diabetes (n=550) without (n=200) or with cardiovascular (n=200) or neurological (n=150) complications consecutively admitted to the IRCCS Neuromed
62143814|NCT06082115|EXPERIMENTAL|Task Oriented Training|Unilateral cerebral palsy children will receive selected physical and occupational therapy program for 1 hour in addition to task oriented training for 30 minutes. The duration of treatment will be 3 times/week for 12 weeks.
62347960|NCT03750071|EXPERIMENTAL|VXM01/Avelumab|Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
62347961|NCT01381029||HIV positive|HIV positive, receiving Influenza vaccine as standard of care.
62347962|NCT03909932||Patients enrolled in the cross-sectional study|Patients over 18 years old, consulting in neuro-urology department.
62347963|NCT03281447|EXPERIMENTAL|Nurse navigation|Coherent navigation and support from a family-centred viewpoint throughout the cancer trajectory, despite the individual patient's affiliation to any department.
62347964|NCT03281447|ACTIVE_COMPARATOR|Current care coordination|Department-specific coordination and answers to questions from a patient-centred viewpoint.
62505912|NCT03424655|EXPERIMENTAL|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
62505913|NCT03424655|EXPERIMENTAL|Group REC|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
62505914|NCT04916613|EXPERIMENTAL|ADT + darolutamide|ADT + darolutamide 600 mg po bid
62505915|NCT04916613|PLACEBO_COMPARATOR|ADT + placebo|ADT + placebo po bid
62505916|NCT01273857|SHAM_COMPARATOR|Control|Subjects will undergo standard staged-procedures without cell infusion
62505917|NCT01273857|EXPERIMENTAL|Cell infusion|Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
62505918|NCT03754530|EXPERIMENTAL|Icotinib|icotinib is administered orally three times per day. Until emerge the progression of the intracranial disease, then is given radiotherapy(\>3 with WBRT or \<=3 with SRS) after PD
61961687|NCT04220320||Classic BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation, effacement, texture, station and position.
62143815|NCT04326478|EXPERIMENTAL|Azithromycin Group|Enrolled children in a household randomized to the experimental group will receive a single weight-based dose of azithromycin administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera. They will then complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
62347965|NCT06197542|EXPERIMENTAL|Active Release Technique|Individuals in Group A will be subjected to Heat Therapy over the targeted muscles via hot pack for 5 minutes in every session along with passive stretching for 5 minutes Group A will receive Active release technique on targeted muscles. The participant was comfortably seated and rested the forehead on the forearms .To apply for the release, the active TrP was identified, and sustained and constant pressure was applied. For stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.The treatment regimen will span over 3 weeks with a follow up frequency of 2 sessions per week.
61961688|NCT04220320||Modified BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation and effacement alone.
61961689|NCT04220320||Cervical Length|Gynecological evaluation based on cervical length measured by transvaginal sonography.
61961690|NCT06385639|EXPERIMENTAL|Probiotic Group|Two sachets/day probiotics, before breakfast and dinner, respecitvely
61961691|NCT06385639|PLACEBO_COMPARATOR|Placebo Group|Maltodextrin, Two sachets/day probiotics, before breakfast and dinner, respecitvely
62347966|NCT06197542|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization|Group A will be subjected to Heat Therapy for 5minutes along with Stretching for 5 minutes .Group B will be Subjected to IASTM using M2T blade for approximately 3 minutes per muscle. Lubricant was applied and the tool was cleaned with an alcohol pad.the tool was used to locate soft tissue restrictions in the muscles. Then, the therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin Treatment time was 3 minutes. Cryotherapy was applied for 10 minutes after the session. The treatment regimen will span over 3 weeks with a follow up frequency of 2 sessions per week.
62347967|NCT04511780||Caregivers|• Caregivers (doctors senior and junior, nurses, aid nurses) involved in the staff (permanent or transient, full or partial time) of ICU patients during Covid-19 outbreak
62347968|NCT01965418|ACTIVE_COMPARATOR|Fufang Biejia Ruangan Tablet|Fufang Biejia Ruangan Tablet will be administered to all of subjects in this arm.
62347969|NCT01965418|PLACEBO_COMPARATOR|placebo|placebo of Fufang Biejia Ruangan Tablet
62505919|NCT03754530|EXPERIMENTAL|Icotinib plus radiation therapy|Standard whole brain radiotherapy (WBRT) is given with 30GY/10 times(\>3), or SRS(\<=3) plus concurrent icotinib, which was administered orally three times per day. Until the disease progresses.
62505920|NCT05845957|EXPERIMENTAL|Digital Education Group|"All participants in this group were given the Safe pediatric intravenous drug administration knowledge test prepared by the researchers as a pre-test.~The participants of this group, who were determined by randomization, were given training prepared using the digital storytelling method. The training took 25 minutes.~After the training, the Safe intravenous drug administration knowledge test was applied as a post-test."
61961692|NCT05238402||on statins|patients who received a statin
61961693|NCT05238402||not on statins|patients who not received a statin
61961694|NCT06261203|EXPERIMENTAL|Group A (Experimental Group)|About 125 Participants in the treatment group will receive 81 mg low-dose aspirin once daily starting from the time of enrollment and continuing until the end of pregnancy
61961695|NCT06261203|PLACEBO_COMPARATOR|Group B (Control Group)|About 125 Participants will receive only the routine care of pregnancy until the end of pregnancy
61961696|NCT02418364|PLACEBO_COMPARATOR|placebo reflexology|Placebo reflexology treatment
62143816|NCT04326478|PLACEBO_COMPARATOR|Non-antibiotic Placebo Group|Enrolled children in a household randomized to the placebo arm will receive a single dose of non-antibiotic placebo during their first study visit, which will occur within 12 hours of a member of their household testing positive for cholera. Like the participants in the intervention arm, they will complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
62505921|NCT05845957|NO_INTERVENTION|Control Group|"No intervention was made. All participants in this group were given the Safe pediatric intravenous drug administration knowledge test prepared by the researchers as a pre-test.~Afterward, theoretical information on the subject was given. After theoretical information, the Safe intravenous drug administration knowledge test was applied as a post-test."
62505922|NCT03010852|NO_INTERVENTION|Standard of care incentive spirometer|Patients in the SOC cohort will not receive the preoperative education and only one postoperative visit per day to collect their self-reported use of IS, if prescribed, and respiratory symptoms but avoiding increasing their awareness of POH, O2 therapy and IS.
62505923|NCT03010852|EXPERIMENTAL|Focused incentive spirometer education and monitoring|One of the study investigators will meet eligible patients in the preoperative visit to the UCH Weight Loss Surgery clinic, inform and consent the patient and introduce the first education on IS therapy, highlighting its possible benefits and the importance of compliance (patient's inspiratory effort and frequency). This IS education will be repeated in the preoperative area immediately before surgery. The site will then follow the patient postoperatively. The site will directly check on the patient in the PACU and later in his/her hospital room at least 3 times a day during the first 3 days or sooner if their O2 therapy is discontinued for 2h. During these PO check ups The site will reinforce the IS use, monitor the patient's performance of IS and ask him/her about other respiratory symptoms.
61961697|NCT02418364|NO_INTERVENTION|control group|Data will be taken from questionnaires
61961698|NCT02418364|EXPERIMENTAL|reflexology treatment|Reflexology treatment
61961699|NCT01013376|EXPERIMENTAL|Active|Topical administration of MC-1101
61961700|NCT01013376|PLACEBO_COMPARATOR|Vehicle|Vehicle
61961701|NCT03040102|EXPERIMENTAL|Hospice Video Educational Tool|"* The hospice video educational tool is a 6 minute video~* Participants will watch an approximately 6-minute digital video regarding hospice on an iPad"
61961702|NCT03040102|ACTIVE_COMPARATOR|Hospice Verbal Narrative|"* The RA will read a verbal narrative that is identical to the narrative of the video to participants~* Standard of Care practice is used"
61961703|NCT00920283|EXPERIMENTAL|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
61961704|NCT00920283|ACTIVE_COMPARATOR|Driver, Cobalt Alloy Coronary Stent|
61961705|NCT01004705|EXPERIMENTAL|Fixed Dose Combination Pill|Once daily oral dose of combination of acetylsalicylic acid, simvastatin, and ramipril (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 or 10 mg ramipril)
61961706|NCT01004705|ACTIVE_COMPARATOR|Simvastatin|Once daily oral dose of Simvastatin 40 mg
61961707|NCT00585247|EXPERIMENTAL|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
61961708|NCT00585247|PLACEBO_COMPARATOR|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
61961709|NCT05693558|EXPERIMENTAL|NVD-003 bone graft implant|"The study includes 2 important surgical procedures, the Adipose Tissue Collection (ATC) and the Grafting Surgery (GS) and 3 stages~* Stage 1: A screening, adipose tissue collection \& NVD 003 manufacturing period.~* Stage 2: Grafting surgery and 12-month post-GS follow-up period.~* Stage 3: long-term safety follow-up period (from post-month 12 to month 24)."
61961710|NCT01897454|EXPERIMENTAL|Treatment (FOLFIRINOX, IMRT, and gemcitabine hydrochloride)|"CHEMOTHERAPY REGIMEN: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on day 1, and fluorouracil IV over 46 hours on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving disease progression proceed to chemoradiotherapy.~CHEMORADIOTHERAPY REGIMEN: Beginning 4-6 weeks after completion of chemotherapy, patients undergo IMRT on 5 consecutive days per week for a total of 28 fractions and receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity."
62143817|NCT02871661|ACTIVE_COMPARATOR|Amitriptyline|This group will be treated with medication alone (amitriptyline hydrochloride, 25 mg) for chronic vulvar pain (vulvodynia).
62143818|NCT02871661|ACTIVE_COMPARATOR|Amitriptyline plus kinesiotherapy|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus pelvic floor exercises such as Kegel contractions and stretching of pelvic floor muscles with patients own hands.
62143819|NCT02871661|ACTIVE_COMPARATOR|Amitriptyline plus IC (Quark)|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus electrical stimulation with Interferential Current (manufacturer: Quark Medical; Model: Dualpex 961 - program number 42): two electrodes put into the perineal surface area emitting interferential current, once a week for twenty minutes each, for eight weeks long.
62143820|NCT03765658|EXPERIMENTAL|GRT0151Y dose escalation|GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
62143821|NCT02139241|EXPERIMENTAL|Ramosetron|Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia
62143822|NCT02139241|PLACEBO_COMPARATOR|Control|Intravenous administration of 2ml normal saline before the induction of general anesthesia
62505924|NCT01069731||Infants born at 30 to 36 weeks gestation|Infants will be considered eligible if they are born at 30 to 36 weeks gestation and have no exclusion criteria.
62704456|NCT04117347|EXPERIMENTAL|Light therapy B via the Re-Timer®|-30 minutes/day
61961711|NCT01165437||Suspected Arterial Disease|Patients with known or suspected arterial disease and patients screened using AHA/ACC criteria for P.A.D.
62143823|NCT05467566|EXPERIMENTAL|Stimulation + exercise group|30-minute exercise program (based on Pilates method) combined with active transcranial direct current stimulation.
62143824|NCT05467566|SHAM_COMPARATOR|Sham stimulation + exercise group|This arm will perform the same procedures of experimental group but the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
62143825|NCT00237224|EXPERIMENTAL|FEM345|
62143826|NCT03263611|PLACEBO_COMPARATOR|placebo|subject will receive single intradiscal injection of placebo
62143827|NCT03263611|EXPERIMENTAL|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
62143828|NCT03263611|EXPERIMENTAL|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
62143829|NCT03263611|EXPERIMENTAL|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
62143830|NCT02717819|EXPERIMENTAL|Resistance training and protein|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional \~25 g protein and 1953 kJ per day). Daily vitamin D supplements.
62143831|NCT02717819|PLACEBO_COMPARATOR|Resistance training and placebo|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.
62347970|NCT03428997|EXPERIMENTAL|Lotion|Test sites were patched with the lotion F #13451-131.
62347971|NCT03428997|OTHER|Negative Control|Test sites were patched with undosed occlusive patch.
62347972|NCT05923450||Tumor Deposits|Colorectal cancers with and without tumor deposits, undergoing curative surgery and adjuvant chemotherapy
62347973|NCT01867814|EXPERIMENTAL|Pneumoperitoneum|Patients undergoing laparoscopic surgery
62704457|NCT04117347|EXPERIMENTAL|Light therapy C via the Re-Timer®|-60 minutes/day
62704458|NCT06552754|EXPERIMENTAL|Intervention: Motion Reset|Participate in virtual reality activities
62704459|NCT06552754|NO_INTERVENTION|No intervention|
62143832|NCT01776320|EXPERIMENTAL|VITAROS|VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks
62143833|NCT01436175|EXPERIMENTAL|SPD489 + Antidepressant|
62143834|NCT03429816|EXPERIMENTAL|Interventional Arm|"Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.~Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients.~Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment."
62143835|NCT01281436|OTHER|Web-based Provider training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
62347974|NCT01703611|EXPERIMENTAL|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBPGN) (www.guidelines.gov)
62347975|NCT01703611|ACTIVE_COMPARATOR|Usual Nutrition Care|Visits for usual nutrition therapy (diet and lifestyle changes) provided by dietitians over a 12 month period.
62347976|NCT01086046|ACTIVE_COMPARATOR|Heparin|Heparin injection 10 IU/kg/hr within 24h
62347977|NCT01086046|EXPERIMENTAL|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days"
62347978|NCT01547468|ACTIVE_COMPARATOR|Intravenous Opioids|
62505925|NCT04908280|EXPERIMENTAL|Discoid lupus erythematosus|Patients with discoid lupus erythematosus will be given ruxolitinib cream to be used twice daily for 12 weeks.
62505926|NCT03898531||hip prosthesis metal/polyethylene in simple mobility|
62505927|NCT03898531||hip prosthesis metal/polyethylene in double mobility|
61961712|NCT05416398|NO_INTERVENTION|Control|They will only receive standard medical treatment. In addition to the evaluation parameters applied, no additional information and/or exercise will be recommended other than routine clinical treatment and recommendations.
62347979|NCT01547468|EXPERIMENTAL|Femoral Nerve Catheterization|
62347980|NCT03308162|EXPERIMENTAL|Group Intervention|Cognitive behavioral experiential group therapy for health behavior change
62347981|NCT04851002|EXPERIMENTAL|CGF TEST GROUP|Concentrated growth factor liquid applied into the implant cavity. Also CGF membrane covered the implant and the socket. That is the only difference between CGF control group and CGF test group
62505928|NCT03898531||hip prosthesis ceramic/polyethylene in simple mobility|
62704460|NCT06552754|PLACEBO_COMPARATOR|Placebo experience|Participate in virtual reality activities
62704461|NCT05253131|EXPERIMENTAL|Phase 1 and 2 Study of Selumentinib, BI and Durvalumab|"Part A will be a phase 1 dose escalation study of the combination with selumetinib and BI, and,~Part B will be phase 1 study combining the determined dose of selumetinib and BI from Part A with durvalumab.~Part C will be a phase 2 study combining selumetinib, BI with durvalumab in MPNST patients at the recommended doses from part B. A Simon's two-stage design will be used in the phase 2 trial to determine the clinical benefit in patients with unresectable or metastatic NF associated MPNST."
62704462|NCT01432847||Affected|Participants affected by ocular diseases/conditions.
62704463|NCT01432847||Healthy Volunteers|Age, gender, and ethnicity-matched to participants with ocular conditions or the unaffected relatives of participants with ocular conditions
62704464|NCT00026754||Cohort 1|Patients
61961713|NCT05416398|EXPERIMENTAL|Aerobic Exercise|Aerobic exercise group; 3 days a week, 45-60 minutes will be carried out in the form of walking and jogging on the treadmill. Initially, warm-up exercises (10 minutes) will perform walking at 35-70% of maximum heart rate (HRmax). Then, aerobic exercises, the resistance and duration of which are increased according to the tolerance of the patient on the treadmill for 30-35 minutes, and at 60-70% of the HRmax, attention will be paid to ensure that the fatigue severity perceived by the patients is within the range of 12-14 according to the Modified Borg scale. Afterwards, the exercise program will be terminated with a cooling period (10 minutes) consisting of walking at a light pace.
61961714|NCT05416398|EXPERIMENTAL|High-İntensity İnterval Training|The high-intensity interval training (HIIT) group, it will be performed as walking or jogging on the treadmill for 4X4 minutes (16 minutes in total) at ≥ 80% of HRmax, three times a week, with each session lasting a total of 38 minutes. Each training session will begin with a 10-minute warm-up period at 70% of HRmax. Between each 4-minute interval and after the last interval, patients will walk at 70% of HRmax for 3 minutes. Patients will check heart rate and target heart rate to control exercise intensity and will aim to reach their individual target heart rate after 1-1.5 minutes of exercise in each interval. The physical therapist, who oversees all training sessions, will check the patients' target heart rates.
62704465|NCT00026754||Cohort 2|Healthy Volunteers
62704466|NCT04470011||Patients who initiated HIV treatment|
61961715|NCT01095783|EXPERIMENTAL|Physiotherapeutic intervention|
61961716|NCT01095783|OTHER|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
61961717|NCT01950741|EXPERIMENTAL|aflibercept|Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).
61961718|NCT03374397|ACTIVE_COMPARATOR|SurgiGuard|Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery
61961719|NCT03374397|NO_INTERVENTION|Bipolar electrocauterization|Bipolar electrocauterization during surgery Drug(-)
61961720|NCT02792972|ACTIVE_COMPARATOR|Acmella oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers 3 minutes before the venipuncture
61961721|NCT02792972|PLACEBO_COMPARATOR|alcohol 70%|70% alcohol were used in the volunteers 3 minutes before the venipuncture
61961722|NCT04489680|EXPERIMENTAL|Surgical Trainees undergoing Cleft Palate Training|26 UK specialty trainees performed a vomerine mucosal flap and intra-velar veloplasty in a one-hour workshop. Pre- and post-simulation questionnaires assessing cleft knowledge and surgical confidence were compared for statistical significance.
61961723|NCT00929799|EXPERIMENTAL|Growth Hormone|Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD
61961724|NCT03535610|EXPERIMENTAL|Embolization|Uterine Embolization with PVA Microspheres
61961725|NCT03003390|EXPERIMENTAL|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously \<24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
61961726|NCT03003390|NO_INTERVENTION|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
62143836|NCT01281436|ACTIVE_COMPARATOR|HeartSmartKids with web-based training|The providers assigned to Group 2 will receive the web-based training described in the other arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
62347982|NCT04851002|EXPERIMENTAL|A-PRF TEST GROUP|Advanced Platelet Rich Fibrin liquid applied into the implant cavity. Also A-PRF membrane covered the implant and the socket. That is the only difference between A-PRF control group and A-PRF test group
62704467|NCT04470011||Service providers at study facilities|
62704468|NCT05653336|EXPERIMENTAL|Subjects implanted with PerQseal Vascular Closure Device|Subjects implanted with bioabsorbable implant to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
62704469|NCT06237335|EXPERIMENTAL|RCT2100 (Part 1)|RCT2100 single dose
62143837|NCT05710757|EXPERIMENTAL|Myofascial Release|The Experimental group will receive a myofascial release pectoralis minor release intervention.
62143838|NCT05710757|SHAM_COMPARATOR|Sham Myofascial Release|The Control group will receive a sham myofascial release pectoralis minor release intervention.
62704470|NCT06237335|PLACEBO_COMPARATOR|Placebo (Part 1)|Placebo single dose
62347983|NCT04851002|EXPERIMENTAL|CGF CONTROL GROUP|Dental implant applications were made with traditional methods.
62347984|NCT04851002|EXPERIMENTAL|A-PRF CONTROL GROUP|Dental implant applications were made with traditional methods.
62347985|NCT04579796|EXPERIMENTAL|women with first trimester missed abortion|
62347986|NCT04218799|EXPERIMENTAL|Intranasal Mupirocin and Topical Chlorhexidine|
62704471|NCT06237335|EXPERIMENTAL|RCT2100 (Part 2)|RCT2100 multiple dose
62704472|NCT04235777|EXPERIMENTAL|Arm 1|Treatment with M7824 and de-escalating doses of PDS01ADC if appropriate
62704473|NCT04235777|EXPERIMENTAL|Arm 2|Treatment with M7824 and de-escalating doses of PDS01ADC (if appropriate) with sequential SBRT
62704474|NCT04235777|EXPERIMENTAL|Arm 3|Treatment with M7824 and de-escalating doses of PDS01ADC (if appropriate) with concurrent SBRT
62704475|NCT06352658|ACTIVE_COMPARATOR|Conventional mandibular advancement device|
62704476|NCT06352658|EXPERIMENTAL|CAD CAM mandibular advancement device|
62704477|NCT06483334|EXPERIMENTAL|Sacituzumab tirumotecan plus EV|Participants will receive sacituzumab tirumotecan as an intravenous (IV) infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.
62704478|NCT06483334|EXPERIMENTAL|Sacituzumab tirumotecan plus EV and pembrolizumab|Participants will receive sacituzumab tirumotecan as an IV infusion and EV as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision. Participants will also receive pembrolizumab 200 mg as an IV infusion on Day 1 of every 3-week cycle for up to \~2 years (35 cycles).
62704479|NCT05149638|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers are those 18 years or older without prior diagnosis of adrenal insufficiency. Study participation by healthy volunteers helps us understand what cortisol levels should be in a healthy population. This information also helps us figure out what levels might be in people with adrenal insufficiency.
62704480|NCT05149638|ACTIVE_COMPARATOR|Patients with known adrenal insufficiency|This group consists of patients 18 years or older with an established diagnosis of adrenal insufficiency. Study participation by patients with adrenal insufficiency helps us understand what cortisol levels should be, in the new assays, among those with adrenal insufficiency.
61961727|NCT04483271|EXPERIMENTAL|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 2 months.
61961728|NCT04483271|NO_INTERVENTION|Control group|No intervention was given
61961729|NCT05363644|EXPERIMENTAL|Single Arm Study Group|Placement of a sheet of BioDFence G3 to the neurovascular bundle.
61961730|NCT06074367|EXPERIMENTAL|GROUP 1 (2g Vitamin C )|
61961731|NCT06074367|EXPERIMENTAL|GROUP 2 (1g Vitamin C )|
61961732|NCT06074367|PLACEBO_COMPARATOR|Control group|
61961733|NCT06172322|EXPERIMENTAL|NTQ1062 with Fulvestrant|NTQ1062 Tablets（200-500）+ Fulvestrant（500mg)
61961734|NCT03954145|ACTIVE_COMPARATOR|PUMICING GROUP|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle.Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors"
61961735|NCT03954145|EXPERIMENTAL|SANDBLASTING GROUP|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
61961736|NCT03621397|EXPERIMENTAL|Cognitive Intervention Group|Research participants in the cognitive intervention group will undergo a baseline neuropsychological evaluation. One week later, they will receive the online training program (brainHQ by Posit Science) three times a week for 45 minutes for a total of 12 weeks. This group will return one week after completing the online intervention program for their follow-up neuropsychological evaluation. They will then return again one year later for another follow-up neuropsychological evaluation.
61961737|NCT03621397|NO_INTERVENTION|Control Group|Research participants in the control group will undergo a baseline neuropsychological evaluation. They will then return 13 weeks after their baseline neuropsychological evaluation for a follow-up neuropsychological evaluation and again one year later.
61961738|NCT01565512|PLACEBO_COMPARATOR|saline injection|saline injection
61961739|NCT01565512|ACTIVE_COMPARATOR|Bupivacaine injection|penile block with bupivacaine
61961740|NCT00702611|EXPERIMENTAL|1|Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
61961741|NCT00702611|ACTIVE_COMPARATOR|2|Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks
61961742|NCT06086470|EXPERIMENTAL|Experimental Treatment Arm|Patients will receive one treatment of hemodialysis through the Qidni/D Hemodialysis System.
61961743|NCT00159406||cohort|Registry and Database
61961744|NCT05280782|EXPERIMENTAL|Dosimetry Group|Normal Volunteers will receive a single intravenous injection of 8 mCi ± 20% (6.4-9.6 mCi) of the PET radiotracer 68Ga-Galmydar. They will undergo whole-body PET/CT imaging at three-time points, immediately post \[68Ga\]Galmydar injection, and at 2 hours and 4 hours after injection. Serum chemistries, complete blood count, EKG, vital signs, and physical examination will performed before injection and at the completion of the examinations.
61961745|NCT04067544|OTHER|Acupuncture Treatment|All patients receive 10 acupuncture treatments over the course of 8 weeks.
61961746|NCT06077318||Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
62143839|NCT04255316|EXPERIMENTAL|Modified eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a modified eversion carotid endarterectomy
62505929|NCT03898531||hip prosthesis ceramic/polyethylene in double mobility|
62704481|NCT05149638|ACTIVE_COMPARATOR|Patients suspected to have adrenal insufficiency|This groups consists of patients 18 years or older who are suspected to have adrenal insufficiency. Study participation by this group will help us understand if the cortisol values we get from the new assay accurately diagnose adrenal insufficiency.
61961747|NCT06077318||Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
61961748|NCT02161081|EXPERIMENTAL|Myocardial CT perfusion (21-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 21-second scan duration.
61961749|NCT02161081|ACTIVE_COMPARATOR|Myocardial CT perfusion (30-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 30-second scan duration.
61961750|NCT02275468|PLACEBO_COMPARATOR|Control Group|Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90\~110g/L.
62505930|NCT03898531||Primary implanted hip prosthesis|
62505931|NCT03898531||metal / metal prosthesis removed|
62505932|NCT03898531||ceramic / ceramic prosthesis removed|
61961751|NCT02275468|EXPERIMENTAL|Fu-zheng-qu-zhuo oral liquid Group|Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.
61961752|NCT03930797|EXPERIMENTAL|Intimacy Enhancement|Participants attend four sessions (60-75 minutes) consisting of education and skills training to enhance physical and emotional intimacy.
62704482|NCT01810913|EXPERIMENTAL|Arm 1 (IMRT, cisplatin)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study.
61961753|NCT03930797|ACTIVE_COMPARATOR|Living Healthy Together|Participants attend four sessions (60-75 minutes) consisting of information and support across a range of breast cancer-related topics.
61961754|NCT00798499||1|Laboratory variables
61961755|NCT02864498|EXPERIMENTAL|1g DS107|1g DS107 (2 DS107 capsules and 2 placebo capsules) orally administered once-daily for 8 weeks.
61961756|NCT02864498|EXPERIMENTAL|2g DS107|2g DS107 (4 DS107 capsules) orally administered once-daily for 8 weeks.
61961757|NCT02864498|PLACEBO_COMPARATOR|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 8 weeks.
61961758|NCT03775655|ACTIVE_COMPARATOR|LD-DEX|This group will receive 7mg hyperbaric bupivacaine (about 1.4 ml of hyperbaric bupivacaine 0.5%) and 10μg dexmedetomidine (10 unit by U-100 insulin syringe using a preservative free dexmedetomidine 100μg/ml).
61961759|NCT03775655|NO_INTERVENTION|Control group|This group will receive 12 mg hyperbaric bupivacaine (about 2.2 ml of hyperbaric bupivacaine 0.5%).
61961760|NCT01372137|EXPERIMENTAL|NOX-H94|Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks
61961761|NCT01372137|PLACEBO_COMPARATOR|Glucose 5%|Group A to Group H get NOX-H94 or Placebo
61961762|NCT06296966|EXPERIMENTAL|VSJ-110 Solution|
61961763|NCT06296966|PLACEBO_COMPARATOR|Placebo Solution|
61961764|NCT04502693|EXPERIMENTAL|MenB_0_2_6 Group|Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.
61961765|NCT04502693|EXPERIMENTAL|MenB_0_6 Group|Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.
61961766|NCT04502693|EXPERIMENTAL|ABCWY-1 Group|Participants received 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
61961767|NCT04502693|EXPERIMENTAL|ABCWY-2 Group|Participants received 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
62505933|NCT02536469|EXPERIMENTAL|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
61961768|NCT04502693|EXPERIMENTAL|ABCWY-3 Group|Participants received 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
61961769|NCT04502693|ACTIVE_COMPARATOR|ACWY Group|Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.
61961770|NCT04502693|EXPERIMENTAL|ABCWY_Pooled|"Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding.~To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group."
61961771|NCT03431428|EXPERIMENTAL|transanal surgery|"To ensure the complete cutting edge with no residual tumor, the tumor with corresponding mesorectal excision was removed by the distance edge of 1cm.~The intestinal wall was sutured to ensure the integrity of the bowel."
61961772|NCT03431428|PLACEBO_COMPARATOR|Miles surgery|According to the total mesorectal excision(TME) principle, complete mesorectum, lymph node and the anus was excised. A sigmoid colostomy was finally performed.
62505934|NCT01341678|OTHER|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
62505935|NCT01341678|OTHER|Restricted Phosphorus Diet|Diet containing 750mg of phosphorus per day and administration of a phosphate binder (lanthanum carbonate)
62505936|NCT01341678|OTHER|High Phosphorus Diet|Diet containing 3000mg of phosphorus per day and phosphorus supplementation (NeutraPhos)
62505937|NCT06105021|EXPERIMENTAL|Dose Escalation|Subjects will be given a one-time infusion of AFNT-211 starting at dose level 1 and monitored for 28 days (DLT period). Each cohort will enroll 2-4 subjects at different dose levels for a total of 20 subjects in the escalation portion. The optimal biological dose and recommended phase 2 dose will be determined.
61961773|NCT02936570|EXPERIMENTAL|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
61961774|NCT05063487||Recent HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test recent on the rapid test for recent infection (RTRI).
62505938|NCT06105021|EXPERIMENTAL|Dose Expansion: PDAC|20 subjects with pancreatic ductal adenocarcinoma will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
62505939|NCT06105021|EXPERIMENTAL|Dose Expansion: CRC|20 subjects with colorectal carcinoma will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
61961775|NCT05063487||Long-Term HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test long-term on the rapid test for recent infection (RTRI).
61961776|NCT04404296|OTHER|25-gauge 20000 PPV|Eyes will undergo pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
62704483|NCT01810913|EXPERIMENTAL|Arm 2 (IMRT, docetaxel)|Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up. (CLOSED AS OF 20-MAR-2020)
61961777|NCT02853604|PLACEBO_COMPARATOR|Placebo|Participants with locally advanced cervical cancer at higher risk for recurrence (HRLACC) received ADXS11-001 matching placebo by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course placebo matching to either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
61961778|NCT02853604|EXPERIMENTAL|ADXS11-001|Participants with HRLACC received ADXS11-001 at a dose of 1x10\^9 colony forming units (CFU) by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course of either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
61961779|NCT03755297|OTHER|Rheumatoid arthritis|Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
61961780|NCT03755297|OTHER|Osteoarthritis|Control patients and Blood sample analysis of patients treated as standard care
61961781|NCT03755297|OTHER|Rheumatoid arthritis with JAK/STAT inhibitors|Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care
62347987|NCT05181904||Critically ill children ready for extubation|Children admitted to a paediatric intensive care unit, invasively ventilated and intubated, enterally fed and presenting with a clinical condition allowing for extubation. 45 children will be included.
62347988|NCT04895098||combination therapy group|750 Subjects in the statin and ezetimibe combination therapy group
62347989|NCT04895098||monotherapy group|250 Subjects in the statin monotherapy group
62347990|NCT04111172|EXPERIMENTAL|Arm A (low dose)|Patients receive low dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
62347991|NCT04111172|EXPERIMENTAL|Arm B (medium dose)|Patients receive medium dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
62347992|NCT04111172|EXPERIMENTAL|Arm C (high dose)|Patients receive high dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
62347993|NCT00696813||paliperidone ER|Newly switched to or started on Paliperidone ER, not longer than 2 weeks ago
62347994|NCT00696813||Any other oral antipsychotic|Newly switched to or started on any other oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago
62347995|NCT04101435|EXPERIMENTAL|Group A|Aged 3 to 8 years old vaccine naïve subject (without prior seasonal influenza vaccine exposure)
62347996|NCT04101435|ACTIVE_COMPARATOR|Group B|Aged 3 to 8 years old vaccine non-naïve subject (with prior seasonal influenza vaccine exposure)
62347997|NCT04101435|EXPERIMENTAL|Group C|Aged 9 to 17 years old subject
62347998|NCT05994313|EXPERIMENTAL|Habitual potato consumption|At least 220g of white potatoes, including fresh and frozen, baked, boiled, and mashed potatoes, will be consumed in the evening meal, in replacement of non-nutrient-dense starchy staples, for 12 weeks.
62347999|NCT05994313|ACTIVE_COMPARATOR|Habitual non-nutrient-dense staple consumption|Isocaloric amounts of non-nutrient-dense starchy staples, such as white rice, white pasta, and white couscous, will be consumed in the evening meal for 12 weeks.
62348000|NCT01113554|EXPERIMENTAL|Arm I|Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
62348001|NCT01995812|EXPERIMENTAL|Hula and heart health education|12 weeks of hula classes, 2 times a week for one hour. An additional 3 hours of heart health education was given to participants
62348002|NCT01995812|NO_INTERVENTION|Control group|
62348003|NCT04278508|ACTIVE_COMPARATOR|Group A|P \< 10.0 ng/ml with increasing P dosage from 800 mg to 1200 mg daily from the FET day.
62348004|NCT04278508|ACTIVE_COMPARATOR|Group B|P \< 10.0 ng/ml without change in drug regimen.
62348005|NCT04278508|ACTIVE_COMPARATOR|Group C|P ≥ 10.0 ng/ml without change in drug regimen.
62348006|NCT01644955|EXPERIMENTAL|Treatment (carboplatin)|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room and then receive carboplatin administered intracerebrally by convection enhanced delivery.
62348007|NCT02682030|ACTIVE_COMPARATOR|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
62505940|NCT06105021|EXPERIMENTAL|Dose Expansion: NSCLC|20 subjects with non-small cell cancer will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
62143840|NCT04255316|ACTIVE_COMPARATOR|Standard eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a standard eversion carotid endarterectomy
62348008|NCT02682030|ACTIVE_COMPARATOR|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
61961782|NCT03131765|EXPERIMENTAL|YS-ON-001|"Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur.~Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer"
61961783|NCT05628532|EXPERIMENTAL|Use of the DBLG1 system|After a 14-day baseline period during which the patient will use a Dexcom G6 Continuous Glucose Monitoring (CGM) and his current therapy (multiple daily injection or open-loop pump), the patient will start a 42-day treatment period with the DBLG1 system followed by an optional 42-day extension period.
61961784|NCT00695487|EXPERIMENTAL|1|Receives 0.125mg/kg THC before emergence
61961785|NCT00695487|PLACEBO_COMPARATOR|2|Receives NaCl before emergence
61961786|NCT02590614|EXPERIMENTAL|800 IU Vitamin D|Participants will be taking 800 IU/d of vitamin D3 for two months
61961787|NCT02590614|PLACEBO_COMPARATOR|Placebo|Placebo made by Vital Nutrients, Inc. to look exactly like the 800 IU/d caplets by the same company.
61961788|NCT03942263||Newly Diagnosed and RR cHL Participants|Participants diagnosed with RR cHL at the time of enrollment and RR cHL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed cHL, or RR cHL at the time of enrolment, or RR cHL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
61961789|NCT03942263||Newly Diagnosed and RR sALCL Participants|Participants diagnosed with RR sALCL at the time of enrollment and RR sALCL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed sALCL, or RR sALCL at the time of enrolment, or RR sALCL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
61961790|NCT02244606|EXPERIMENTAL|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
61961791|NCT02244606|EXPERIMENTAL|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
61961792|NCT02244606|ACTIVE_COMPARATOR|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
62143841|NCT04515992|EXPERIMENTAL|High Intensity Body-weight Circuit (HIBC)|The at home HIBC intervention program involved the use of both bodyweight and suspension training equipment (TRX® Fit System) with modified movements. The TRX® system was used to modify squats and rows while attached to the top of a door frame.
62143842|NCT01441284|ACTIVE_COMPARATOR|Process 1|10 weeks of pramipexole treatment 2 weeks wash-out period (cross-over) 10 weeks placebo treatment
62143843|NCT01441284|PLACEBO_COMPARATOR|Process 2|10 weeks of placebo treatment 2 weeks wash-out period (cross-over) 10 weeks pramipexole treatment
62143844|NCT05632666|EXPERIMENTAL|Active treatment group|
62143845|NCT05632666|SHAM_COMPARATOR|Sham-controlled group|
62348009|NCT02263495|ACTIVE_COMPARATOR|Paclitaxel & Gemcitabine(PG)|Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1\& Day8 every 3weeks
62505941|NCT06105021|EXPERIMENTAL|Dose Expansion: Adv Solid Tumors|20 subjects with solid tumors will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
62505942|NCT00522990|EXPERIMENTAL|1|Refractory Hematological Malignancies
62348010|NCT02263495|EXPERIMENTAL|Eribulin & Gemcitabine(EG)|Eribulin 1.0 mg/m2, 2-5min iv ,Day1\& Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1\& Day8 every 3weeks
62505943|NCT06617741||Participants|Those with Myasthenia Gravis
62505944|NCT03026309||depressed|un medicated diagnosed with major depression and scheduled to start SSRI treatment.
62505945|NCT03026309||healthy|healthy volunteers.
62505946|NCT00533806|EXPERIMENTAL|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy.
62505947|NCT00533806|ACTIVE_COMPARATOR|Relaxation therapy.|Participants will receive relaxation therapy.
62505948|NCT01677208|EXPERIMENTAL|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
62505949|NCT01677208|PLACEBO_COMPARATOR|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
62505950|NCT00005086|EXPERIMENTAL|Arm A|Methotrexate will be given as a short infusion (introduced into a vein) for approximately 5 minutes on the first day (day 1). ). A week later (day 8), both methotrexate and docetaxel will be given the same way, but this will take about 1 hour. The first course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks. X-rays or scans will then be performed to determine if your tumor is shrinking. You will then start treatment with gemcitabine and cisplatin. On the first day (day 1), you will receive both cisplatin and gemcitabine into your vein. A week later (day 8), you will receive only gemcitabine as an infusion into your vein over 100 minutes and no additional intravenous fluid will be required on that day. This second course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks.
62505951|NCT00116493|OTHER|1|Standard of care (Iron-folic acid + Deworming)
62505952|NCT00116493|EXPERIMENTAL|2|
62505953|NCT00116493|EXPERIMENTAL|3|
62505954|NCT00116493|EXPERIMENTAL|4|
62505955|NCT01780376|EXPERIMENTAL|WBV group|whole-body vibration (WBV) group
62505956|NCT03396588|ACTIVE_COMPARATOR|Clonidine|Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
62505957|NCT03396588|ACTIVE_COMPARATOR|Morphine|Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
62505958|NCT01363466|EXPERIMENTAL|with hysterectomy|
62505959|NCT01363466|NO_INTERVENTION|without hysterectomy|
62539238|NCT01724086|EXPERIMENTAL|Panel 3 - Arm 1|8 chronic HCV GT1a infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir + ribavirin.
61961793|NCT01754623|EXPERIMENTAL|Chemotherapy Followed by Radiation Treatment|"Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m\^2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m\^2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m\^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).~After radiation, participants will be re-evaluated for surgery."
61961794|NCT02304172|ACTIVE_COMPARATOR|Thunderbeat (Group A)|Patients submitted to thyroidectomy with the use of the Thunderbeat device.
61961795|NCT02304172|ACTIVE_COMPARATOR|Harmonic (Group B)|Patients submitted to thyroidectomy with the use of the Harmonic scalpel device
61961796|NCT01305902|NO_INTERVENTION|walking recommendations|Participants assigned to this condition will be instructed to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. Each week, they will be congratulated if they walked the target goal on any days, and encouraged to meet the goals for the upcoming week. However, they will not receive any tangible reinforcement for walking. The meetings will be brief (about 15 minutes) and will include discussions and handouts related to the health benefits of walking.
61961797|NCT01305902|EXPERIMENTAL|contingency management for walking|Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
61961798|NCT05564429|EXPERIMENTAL|High affinity binder (HAB) Translocator Protein (TSPO) genotype|Healthy participants with HAB TSPO genotype receive 18F-SF12051 intravenously followed by whole body or brain positron emission tomography (PET) scan. Participants were randomized to either phase 1, 2, or 3. Phases 1 \& 3 had whole body PET scan and phase 2 had brain PET scan.
61961799|NCT05564429|EXPERIMENTAL|Low affinity binder (LAB) Translocator Protein (TSPO) genotype|Healthy participants with LAB TSPO genotype receive 18F-SF12051 intravenously followed by whole body or brain positron emission tomography (PET) scan. Participants were randomized to either phase 1, 2, or 3. Phases 1 \& 3 had whole body PET scan and phase 2 had brain PET scan.
61961800|NCT05564429|EXPERIMENTAL|Mixed affinity binder (MAB) Translocator Protein (TSPO) genotype|Healthy participants with MAB TSPO genotype receive 18F-SF12051 intravenously followed by whole body or brain positron emission tomography (PET) scan. Participants were randomized to either phase 1, 2, or 3. Phases 1 \& 3 had whole body PET scan and phase 2 had brain PET scan.
61961801|NCT03879226|EXPERIMENTAL|PBMT + training/ PBMT + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
61961802|NCT03879226|EXPERIMENTAL|PBMT + training/ placebo + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
62704484|NCT01810913|EXPERIMENTAL|Arm 3 (IMRT, docetaxel, cetuximab)|Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive concurrent docetaxel once weekly for 6 weeks. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study.
62704485|NCT01810913|EXPERIMENTAL|Arm 4 (IMRT, cisplatin, atezolizumab)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study.
61961803|NCT03879226|EXPERIMENTAL|Placebo + training/ PBMT + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
61961804|NCT03879226|PLACEBO_COMPARATOR|Placebo + training/ placebo + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
61961805|NCT06507982|EXPERIMENTAL|Electronic working length method|Electronic apex locator was used
61961806|NCT06507982|EXPERIMENTAL|Simultaneous working length method|Working length was determined by EAL and then during root canal preparation, an endodontic motor using simultaneous working length control was selected
61961807|NCT06507982|PLACEBO_COMPARATOR|Radiologic working length method|30 patients in whom the radiologic working length (RWL) method. In this method, periapical radiographs were taken.
61961808|NCT04289675||Interferon-Beta|Patients with first treatment : interferon beta (1a subcutaneous 22 or 44 µg thrice a week OR 1a intramuscular 30 µg once a week OR 1b subcutaneous 250 µg every other day OR 1a PEGylated subcutaneous 125 µg every two weeks)
61961809|NCT04289675||Dimethyl fumarate|Patients with first treatment : dimethyl fumarate (oral, 240 mg twice a day)
61961810|NCT04289675||Teriflunomide|Patients with first treatment : teriflunomide (oral, 14 mg once a day)
61961811|NCT00871260|OTHER|Open Label|Approximately 25 healthy volunteers will be recruited as controls. Scan will be done with regadenoson contrast.
61961812|NCT00724022|OTHER|A|Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4
61961813|NCT00724022|EXPERIMENTAL|B|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4
61961814|NCT00724022|EXPERIMENTAL|C|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin
62143846|NCT02522598|EXPERIMENTAL|VVZ-149 injection|VVZ-149 Injections will be mixed with saline,then intravenous infusion for 8hr. The drug product will be administered with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 7.5 hours.
62143847|NCT02522598|PLACEBO_COMPARATOR|Placebo|placebo group will receive an water for injection the same volume and period of experimental group.
62348011|NCT00111475|EXPERIMENTAL|Part A: Romiplostim 0.2 µg/kg|Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
62704486|NCT06561828|EXPERIMENTAL|Experiment 1|Healthy volunteers in experiment 1
62704487|NCT06561828|EXPERIMENTAL|Experiment 2|Healthy volunteers in experiment 2
62704488|NCT06561828|EXPERIMENTAL|Experiment 3|Healthy volunteers in experiment 3
62704489|NCT06561828|EXPERIMENTAL|Experiment 4|Healthy volunteers in experiment 4
61961815|NCT04773860|EXPERIMENTAL|Experimental|The experimental group shall be receiving a 4 week programme of Muscle Energy Techniques on the following accessory muscles; Sternocleidomastoid, Pectoralis Minor, Trapezius, Scalene muscles and Latissimus Dorsi
61961816|NCT04773860|NO_INTERVENTION|Control group|The control group will be taking their prescribed medication and continue with any conventional physiotherapy recommended for the individual.
62348012|NCT00111475|EXPERIMENTAL|Part A: Romiplostim 0.5 µg/kg|Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
62505960|NCT06367699|ACTIVE_COMPARATOR|Usual Care|An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit. Both parent/guardian and adolescent participants do not have access to the ECA-HPV app. Adolescent participants will receive usual standard of care.
62505961|NCT06367699|EXPERIMENTAL|ECA-HPV App with Clinic Notification and Adolescent Functions Disabled|The ECA-HPV (Embodied Conversational Agent adapted for this project) system comprises of a smartphone-based ECA parent/guardian interface, where the parent/guardian participants can receive HPV vaccine promotion and counseling from an interactive agent. The clinic notification feature is disabled on the app. Adolescent participants do not receive the adolescent version of the ECA-HPV app. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.
62505962|NCT06367699|EXPERIMENTAL|ECA-HPV App with Clinic Notification Function Enabled|The ECA-HPV (Embodied Conversational Agent adapted for this project) system comprises of a smartphone-based ECA parent/guardian interface, where the parent/guardian participants can receive HPV vaccine promotion and counseling from an interactive agent. With the clinic notification function enabled, parent/guardian participants can communicate their concerns, questions, and logistical barriers to the clinic staff. Adolescent participants do not receive the adolescent version of the ECA-HPV app. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.
62704490|NCT06561828|EXPERIMENTAL|Experiment 5|Healthy volunteers in experiment 5
62704491|NCT06171178|EXPERIMENTAL|Part 1: ASP1012 Dose Escalation|Participants with previously treated solid tumor types will receive ASP1012 in a 21-day cycle.
62704492|NCT06171178|EXPERIMENTAL|Part 2: ASP1012 Dose Expansion (Monotherapy)|Participants with previously treated melanoma will receive ASP1012 with dose level(s) selected from dose escalation (Part 1) in a 21-day cycle.
62704493|NCT06171178|EXPERIMENTAL|Part 2: ASP1012 + Pembrolizumab Dose Expansion (previously treated solid tumors)|Participants with previously treated solid tumors, will receive ASP1012 in a 21-day cycle. Pembrolizumab will also be administered every three weeks in a 21-day cycle, for up to 3 doses.
62348013|NCT00111475|EXPERIMENTAL|Part A: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
61961817|NCT06147804|EXPERIMENTAL|Females after gynaecological and obstetric operations|Comaprison of the outcome
61961818|NCT05127668|EXPERIMENTAL|Airglove arm|Participants on the airglove arm were subjected to warming of their forearms using the Airglove device at 38.5oC.
61961819|NCT05127668|EXPERIMENTAL|Warm-water Immersion arm|Participants on the WWI arm were subjected to warming by immersing their forearms into a bucket of warm water at 38.5oC.
61961820|NCT02417831|ACTIVE_COMPARATOR|tamsulosin capsules|
61961821|NCT02417831|ACTIVE_COMPARATOR|tamsulosin HCl capsules|
61961822|NCT02581514|EXPERIMENTAL|Algorithm|Eosinophilia is assessed following the diagnosis algorithm
61961823|NCT06321887|EXPERIMENTAL|STAGE 1|"The first stage shall recruit 10 patients and is used to assess the incidence of oral iron related toxicity.~Patients will be prescribed:~• Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks.~If patients experience toxicity (defined as symptoms not tolerated by the patient), the trial medication would be stopped and IV Iron treatment given.~If toxicity occurs in 2 or more patients where we have to stop treatment, we will continue to recruit 30 patients only to the Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks. If the toxicity is acceptable and the Hb improves, we will continue to recruit to 22.5mg oral iron/day.~If the toxicity is acceptable but there is no improvement in haemoglobin the next patients will be recruited to stage 2."
62348014|NCT00111475|EXPERIMENTAL|Part A: Romiplostim 3 µg/kg|Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
62348015|NCT00111475|EXPERIMENTAL|Part A: Romiplostim 6 µg/kg|Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
62348016|NCT00111475|EXPERIMENTAL|Part A: Romiplostim 10 µg/kg|Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
62348017|NCT00111475|PLACEBO_COMPARATOR|Part B: Placebo|Participants received placebo subcutaneously once a week for 6 weeks.
62143848|NCT00829400|EXPERIMENTAL|Posit Science|Brain Fitness, Insight, and Aristotle Cognitive Software Training Suites Targeting 100 hours of training
62348018|NCT00111475|EXPERIMENTAL|Part B: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
62704494|NCT06171178|EXPERIMENTAL|Part 2: ASP1012 + Pembrolizumab Dose Expansion (treatment-naïve melanoma)|Participants with treatment-naïve melanoma will receive ASP1012 in a 21-day cycle. Pembrolizumab will also be administered every three weeks in a 21-day cycle, for up to 3 doses.
62704495|NCT06171178|EXPERIMENTAL|Part 3: ASP1012 Dose Expansion (previously treated gastric cancer)|Participants with previously treated gastric cancer will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
62704496|NCT06171178|EXPERIMENTAL|Part 3: ASP1012 Dose Expansion (colorectal cancer [CRC])|Participants with CRC will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
62143849|NCT00829400|ACTIVE_COMPARATOR|Nintendo Brain Age|Brain Age 2 Nintendo DS Portable Device for home or office use, targeting 100 hours of training
62143850|NCT01006057|EXPERIMENTAL|ESRD|
62143851|NCT01006057|EXPERIMENTAL|Mild|
62143852|NCT01006057|EXPERIMENTAL|Moderate|
62143853|NCT01006057|EXPERIMENTAL|Normal|
62505963|NCT06367699|EXPERIMENTAL|ECA-HPV App with Adolescent Function Enabled|The ECA-HPV (Embodied Conversational Agent adapted for this project) system comprises of a smartphone-based ECA parent/guardian interface, where the parent/guardian participants can receive HPV vaccine promotion and counseling from an interactive agent. Adolescent participants receive the adolescent version of the ECA-HPV app, which includes age-appropriate education and adolescent-focused engagement features, like games. The clinic notification feature is disabled on both the parent/guardian and adolescent apps. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.
61961824|NCT06321887|EXPERIMENTAL|STAGE 2|"Ten subjects each will then be sequentially assigned to one of the following groups:~* Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks.~* Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks.~If 2 or more patients experience toxicity at Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) or Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) we will reduce the dose to the previous level of Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) and continue to recruit.~30 patients shall be used to estimate the change in haemoglobin between baseline and the final analysis point.~If no dose reduction is required, only the last 20 patients shall be used to assess haemoglobin.~The overall endpoint is the haemoglobin level."
62143854|NCT01006057|EXPERIMENTAL|Severe|
62143855|NCT05937269|EXPERIMENTAL|Advanced Pneumatic Compression|Subjects who present with dermal lymphatic backflow will be asked to complete a session of advanced pneumatic compression therapy each day at home.
62348019|NCT00111475|EXPERIMENTAL|Part B: Romiplostim 3.0 µg/kg|Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
62348020|NCT00111475|EXPERIMENTAL|Part B: Romiplostim 6.0 µg/kg|Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.
62348021|NCT01809925|EXPERIMENTAL|psyllium fiber 6.8g|Two (2) packets Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g) thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
62348022|NCT01809925|PLACEBO_COMPARATOR|placebo|One (1) level teaspoon of placebo product thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
62348023|NCT01241396||001|Any MMY treatment Any line of treatment for MMY
62348024|NCT05271110|EXPERIMENTAL|Treatment cohort|Adult patients (ECOG 0-1) with a resectable (or previously resected) PDAC and either synchronous or metachronous liver metastases are the target population of this study.
62348025|NCT00797914||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
62348026|NCT01502475||Veteran Attitudes toward CAM|
62348027|NCT00664755|EXPERIMENTAL|Varenicline|Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
62348028|NCT00664755|ACTIVE_COMPARATOR|Transdermal Nicotine Patch|Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
62348029|NCT00685529|ACTIVE_COMPARATOR|A|12 µg of racemic formoterol fumarate BID
62348030|NCT00685529|EXPERIMENTAL|B|15 µg of nebulized arformoterol tartrate inhalation solution BID
62348031|NCT00685529|ACTIVE_COMPARATOR|C|24 µg of racemic formoterol fumarate BID
62348032|NCT03224585|EXPERIMENTAL|Anakinra|100 mg subcutaneous injection
62348033|NCT03224585|PLACEBO_COMPARATOR|Placebo|100 mg NaCl 0.9% subcutaneous injection
62348034|NCT04488848|PLACEBO_COMPARATOR|continous glucose|continous glucose infusion (60 grams over 3 hours)
62539239|NCT01724086|EXPERIMENTAL|Panel 3 - Arm 2|8 chronically HCV GT1b infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
62143856|NCT05937269|ACTIVE_COMPARATOR|Standard-of-Care|Subjects who present with dermal lymphatic backflow will continue under standard-of-care surveillance of lymphedema and will only receive treatment if they are diagnosed with head and neck cancer-acquired lymphedema.
62143857|NCT05937269|OTHER|No Dermal Backflow|Subjects who do not present with dermal lymphatic backflow at enrollment will be monitored at subsequent visits and if/when dermal lymphatic backflow is observed will be randomized into either Advanced Pneumatic Compression or Standard-of-Care arm.
62143858|NCT03734978||A blood group|prematurity with sepsis
62348035|NCT04488848|EXPERIMENTAL|bolus (excursion)|3 x 20 grams of glucose as a bolus over 6 minutes at t0, 60 minutes and 120 minutes
62348036|NCT04656418|EXPERIMENTAL|CSL312|Participants received a CSL312 loading dose of 400 mg as two 200 mg SC injections in Month 1 along with CSL312 of 200 mg subcutaneous (SC) injections, once monthly from Months 2 to 6.
62704497|NCT06171178|EXPERIMENTAL|Part 3: ASP1012 Dose Expansion (ovarian cancer)|Participants with ovarian cancer will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
61961825|NCT00901316|EXPERIMENTAL|Routine Measures|
61961826|NCT00901316|EXPERIMENTAL|Bleach Baths|
62143859|NCT03734978||O blood group|prematurity with sepsis
62143860|NCT03734978||B blood group|prematurity with sepsis
62143861|NCT03734978||AB blood group|prematurity with sepsis
62348037|NCT04656418|PLACEBO_COMPARATOR|Placebo|Participants received a CSL312 matched loading dose of placebo as two SC injections in Month 1 along with CSL312 matched placebo SC injections, once monthly from Months 2 to 6.
62348038|NCT02687750|EXPERIMENTAL|MRI|"Eppendorf tubes containing 10% fluorine-19 diluted in agar were taped to the upper thigh of participants. Investigational device was used to image the phantom with Magnetic resonance imaging (MRI). Imaging was performed for anatomical (proton) and fluorine (agent detection). Total scan time was under 1 hour.~Objectives:~* Verify RF coil functionality~* Obtain preliminary detection threshold limits using a human coil loading"
62348039|NCT04081376|EXPERIMENTAL|Treatment group|Subjects receive a single-dose treatment.Urine samples will be collected after administration (8 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-60h, 60-72h post-administration).
62348040|NCT04447703|EXPERIMENTAL|Aim I (Interview)|Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinic for 2 weeks. After 2 weeks, providers discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.
62505964|NCT06367699|EXPERIMENTAL|ECA-HPV App with Clinic Notification and Adolescent Functions Enabled|Participants will receive the full ECA-HPV (Embodied Conversational Agent adapted for this project) system on their smartphone app, which includes both the clinic notification and adolescent functions enabled. With the clinic notification function enabled, parent/guardian participants can communicate their concerns, questions, and logistical barriers to the clinic staff. Adolescent participants receive the adolescent version of the ECA-HPV app, which includes age-appropriate education and adolescent-focused engagement features, like games. An internet-based measure, REDCap, will be used for parent/guardian and adolescent participants to complete surveys at baseline, after the index well child visit, and after the second well child visit.
62505965|NCT05955469|ACTIVE_COMPARATOR|FS4 then TFS4|Cochlear Implant with FS4 first during 6 weeks then with TFS4 during 6 weeks
61961827|NCT01480050|EXPERIMENTAL|Dose Finding and Dose Expansion|"DOSE FINDING 4 Levels~For all Levels:~Cycle 1 Mibefradil QID dosing, Days 1-8 (to accommodate PKs) (\*2 doses on Days 1 and 8) Temozolomide daily at 150-200 mg/m2, Days 9-13;~Cycles 2+ Mibefradil QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12~DOSE EXPANSION 28-day cycles FLT PET scans, Baseline x2, Day 7 Mibefradil MTD determined at Dose Finding QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12"
61961828|NCT03802669||caries free children aged between 3-6|
61961829|NCT03802669||caries active children aged between 3-6|
62505966|NCT05955469|ACTIVE_COMPARATOR|TFS4 then FS4|Cochlear Implant with TFS4 first during 6 weeks then with FS4 during 6 weeks
61961830|NCT03802669||caries free children aged between 6-12|
61961831|NCT03802669||caries active children aged between 6-12|
61961832|NCT03802669||caries free adult aged between 18-25|
62505967|NCT06105164|ACTIVE_COMPARATOR|Active cerebellar rTMS|Cerebellar targeted iTBS
62505968|NCT06105164|SHAM_COMPARATOR|Sham cerebellar rTMS|Cerebellar targeted sham iTBS
62505969|NCT01675076|EXPERIMENTAL|Continued NOAC|- Patients continue on their chronic dose of Dabigatran or Rivaroxaban or Apixaban throughout
62505970|NCT01675076|ACTIVE_COMPARATOR|Interrupted NOAC|"Interrupted Dabigatran:~* Discontinue Dabigatran 1 day before surgery if GFR \> 50 mL/min or discontinue 2 days before surgery if GFR 30-50 mL/min~* Resume Dabigatran at next regular dose timing \>or = 24 hours after the end of surgery~Interrupted Rivaroxaban:~* Discontinue Rivaroxaban 1 full day before surgery~* Resume Rivaroxaban at next regular dose timing \>or = 24 hours after the end of surgery~Interrupted Apixaban:~* Discontinue Apixaban 1 full day before surgery~* Resume Apixaban at next regular dose timing \>or = 24 hours after the end of surgery"
62505971|NCT04221126|EXPERIMENTAL|TMFI +cream|TMFI + ALA cream
61961833|NCT03802669||caries active adult aged between 18-25|
61961834|NCT04964375|EXPERIMENTAL|ABSK043|"Dose escalation of oral ABSK043 with a starting dose of 200mg once daily will be guided byBOIN escalation rules based on safety data until an MTD has been identified or a RDE. For each dose,In the escalation part, sequential cohorts of patients will receive an oral dose of ABSK043 in repeated 28-day cycles. Starting dose level will be 200 mg QD. Cohort 3 on 800mg will be switched to 400mg BID.Then, patients will continuously receive ABSK043 （total daily dose） in repeated 28-day cycles.For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043 at the RDE in repeated 28-day cycles."
62505972|NCT04221126|EXPERIMENTAL|TMFI + gel|TMFI + ALA gel
62505973|NCT04221126|ACTIVE_COMPARATOR|ALA creAM|ALA cream
62704498|NCT06171178|EXPERIMENTAL|Part 3: ASP1012 Dose Expansion (other solid tumor type)|Participants with other solid tumor type will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
62704499|NCT05384860|ACTIVE_COMPARATOR|Active Acupuncture Group|For the patients randomized to the acupuncture group, once sedation has been deemed adequate by the anesthesiologist, a certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed.
62143862|NCT04732611|EXPERIMENTAL|Pilates|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
62704500|NCT05384860|PLACEBO_COMPARATOR|Placebo No Acupuncture Group|These patients will not receive acupuncture treatment during surgery, their surgery will continue as normal.
61961835|NCT02417597|EXPERIMENTAL|Experimental Group|Participants in this arm are aged over 65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
62348041|NCT04447703|ACTIVE_COMPARATOR|Aim II: Arm I (Genetic Counseling, Genetic Testing)|Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.
62348042|NCT04447703|EXPERIMENTAL|Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)|Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.
62704501|NCT01247597||Controls|People without pathogenic DICER1 germline variation
62348043|NCT03018457||patients who need a dental implants|
62704502|NCT01247597||DICER1 (cases)|People with pathogenic DICER1 germline variation or history of DICER1-associated tumors
62704503|NCT06479148|EXPERIMENTAL|enVista® Aspire ™|
61961836|NCT02417597|ACTIVE_COMPARATOR|Immunogenicity Control Group|Participants in this arm are aged beteen 18-65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
62143863|NCT04732611|ACTIVE_COMPARATOR|Walking|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks
62143864|NCT01052974|PLACEBO_COMPARATOR|physiological serum|ropivacaïne controlled by placebo (physiological serum).
62505974|NCT04221126|ACTIVE_COMPARATOR|ALA GEL|ALA gel
62505975|NCT04221126|NO_INTERVENTION|Control|Untreated control with no intervention
62704504|NCT06479148|ACTIVE_COMPARATOR|An IOL with a slightly extended depth of focus|
62348044|NCT04243616|EXPERIMENTAL|Drug Treatment|Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide
62704505|NCT06479148|OTHER|enVista® Monofocal IOL (MX60E)|Other
61961837|NCT02417597|NO_INTERVENTION|Safety Control Group|Participants in this arm are aged over 65 years.
61961838|NCT05165901|EXPERIMENTAL|Nociceptive pain|patients with joint pain (knee and shoulder), myofascial pain syndrome
61961839|NCT05165901|EXPERIMENTAL|Neuropathic pain|patients with postherpetic neuralgia, peripheral nerve injury (CRPS type II, brachial plexopathy, nerve entrapment syndrome)
61961840|NCT05165901|EXPERIMENTAL|Mixed pain|patients with spine or SIJ origin back and buttock pain or neck pain and SPINE-origin back pain과 neck pain, SIJ-origin back and buttock pain
62143865|NCT01052974|ACTIVE_COMPARATOR|ropivacaine|ropivacaïne controlled by placebo (physiological serum).
62505976|NCT01938235|EXPERIMENTAL|Exenatide|"o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV\* for 22 h (Rate 2)~\*Once the creatinine clearance is available, if the value is \<60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is \<60 mL/min.~If the creatinine clearance is \<30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.~A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
62348045|NCT05846295|NO_INTERVENTION|Control|No video tutorial, no feedback
62505977|NCT01938235|PLACEBO_COMPARATOR|Placebo|o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours\*.
61961841|NCT01535547|EXPERIMENTAL|isavuconazole and tacrolimus|
62348046|NCT05846295|ACTIVE_COMPARATOR|Feedback|Feedback only
62348047|NCT05846295|ACTIVE_COMPARATOR|Video|Video tutorial only
62505978|NCT05386095|ACTIVE_COMPARATOR|0.25%Bupivacaine group|"Axillary brachial plexus block will be done with patient in supine position under general anesthesia . A total volume of (0.5ml/kg) 0.25% bupivacaine + 1 µg/kg dexmedetomidine.this volume will be divided equally among the median,ulnar,radial and the musculocutaneous nerve.~The surgical procedure will be start after 15-20 min. At the end of surgery, residual neuromuscular block will be antagonized with IV neostigmine 0.05 mg/kg and atropine 0.02mg/kg. All patients will receive 15mg/kg paracetamol IV.~At recovery room motor power will be assisted using Modified Bromage scale , then each 30 min till full recover of motor power. post operative pain assessment will be done using (FLACC score) for Pain assessment.For patients with pain score more than 4\\10 ,Pethidine I.V will be given as rescue analgesic (1 mg/kg) when needed and total rescue analgesia will be recorded."
62505979|NCT05386095|EXPERIMENTAL|0.19%Bupivacaine group|"Axillary brachial plexus block will be performed with the patient in supine position under general anesthesia .~A total volume of (0.5ml/kg) 0.19% bupivacaine + 1 µg/kg dexmedetomidine will be divided equally among the median,ulnar,radial and the musculocutaneous nerve.~The surgical procedure will be start after 15-20 min.At the end of surgery, residual neuromuscular block will be antagonized with IV neostigmine 0.05 mg/kg and atropine 0.02mg/kg. All patients will receive 15mg/kg paracetamol IV.~At recovery room motor power will be assessed using Modified Bromage scale , then each 30 min till full recover of motor power. post operative pain assessment will be done using (FLACC score) for Pain assessment,For patients with pain score more than 4\\10 ,Pethidine I.V will be given as rescue analgesic (1 mg/kg) when needed and total rescue analgesia will be recorded.."
62505980|NCT03579134|EXPERIMENTAL|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
62505981|NCT03579134|ACTIVE_COMPARATOR|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
62505982|NCT05021887|EXPERIMENTAL|Test Product|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
61961842|NCT05746949|NO_INTERVENTION|jet ventilation group|Jet ventilation
61961843|NCT05746949|EXPERIMENTAL|Optiflow group|High flow nasal oxygen
61961844|NCT01912365||Above Elbow Cast + Collar/cuff|Participants randomized to this group will be treated with an Above Elbow Cast \& collar/cuff for 3 weeks
62348048|NCT05846295|EXPERIMENTAL|Video + Feedback|VIdeo tutorial and feedback
62505983|NCT05021887|ACTIVE_COMPARATOR|Reference Product|FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK
61961845|NCT01912365||Long Arms Splint + Collar/Cuff|Participants randomized to this group will be treated with a long arm splint \& collar/cuff for 3 weeks
61961846|NCT00542555|PLACEBO_COMPARATOR|Placebo bid|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
61961847|NCT00542555|EXPERIMENTAL|Naproxcinod 375 mg bid|
61961848|NCT00542555|ACTIVE_COMPARATOR|Naproxen 500 mg bid|
61961849|NCT00542555|EXPERIMENTAL|Naproxcinod 750 mg bid|
62143866|NCT00866619|EXPERIMENTAL|GSK257049 [5-17M] Group|Male or female children between and including 5 to 17 months of age \[5-17M\], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
62348049|NCT03707964|PLACEBO_COMPARATOR|Control|Subjects allocated to the control arm will receive standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles, as part of their regular teaching schedule.
62348050|NCT03707964|EXPERIMENTAL|Intervention|Subjects allocated to the intervention arm will receive education on crisis resource management (CRM) and teaching targeting the cognitive skills required to monitor and challenge a superior's decision, and conflict resolution tools, in addition to standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
62348051|NCT04494464||Patients with LDL cholesterol ≥250 mg/dL|Patients older than 18 years old and have a serum LDL-C≥250 mg/dL between January 2010 and December 2016. Patients with a serum TSH≥10 mIU/mL, patients with glomerulonephritis or nephrotic syndrome, patients with ALT or AST higher than 3 times of normal limits and patients with serum triglyceride \>400 mg/dL were excluded.
62348052|NCT01399749|EXPERIMENTAL|Autologous ASC implantation|Treatment with autologous ASC
62348053|NCT01399749|ACTIVE_COMPARATOR|Autologous Chondrocytes implantation|Treatment with autologous chondrocytes
61961850|NCT04955197||the histo-pathological picture|"In the present study, the exfoliated cytology of group II and III will be compared to the histo-pathological picture of the lesion reference standard. That is because the histopathology analysis is the definitive diagnosis of oral mucosal lesions"
61961851|NCT02197000|EXPERIMENTAL|DIM-Avail 100mg|women will receive DIM 100mg\*1/d, a nutritional supplement for 24 months.
61961852|NCT04511169|EXPERIMENTAL|remainder|The participants who are inactive for more than 48 hours after recieving new content will recieve a remainder, in the format of a text message and an email.
61961853|NCT04511169|NO_INTERVENTION|non-remainder|The participants who are inactive for more than 48 hours after recieving new content will NOT recieve a remainder, in the format of a text message and an email.
61961854|NCT06233981|EXPERIMENTAL|Radiotherapy and Tislelizumab|Moderate-dose hypofractionated intensity-modulated radiotherapy with a gross tumor dose of 25Gy/5f and a maximum dose of 35Gy/5f at the tumor center concurrent with Tislelizumab, followed Tislelizumab±lenvatinib for maintenance.
62143867|NCT00866619|EXPERIMENTAL|GSK257049 [6-12W] Group|Male or female children between and including 6 to 12 weeks of age \[6-12W\], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
62143868|NCT00866619|ACTIVE_COMPARATOR|VeroRab Comparator [5-17M] Group|Male or female children between and including 5 to 17 months of age \[5-17M\], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
62348054|NCT01799018||SAH Patients|Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
62505984|NCT04769115|OTHER|Response to Alerts|Monitor patients daily for response to temperature changes and provide referral to doctor as needed
62704506|NCT00843882|ACTIVE_COMPARATOR|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Patients undergo bone marrow biopsy at screening and during follow-up. Patients undergo blood specimen collection on study.
61961855|NCT04336085|EXPERIMENTAL|caudal group|Caudal block using ultrasound guidance. the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine and the depth and gain will be adjusted for optimal visual quality.the needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
61961856|NCT04336085|EXPERIMENTAL|PENG group|The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. the needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.
61961857|NCT05489198|EXPERIMENTAL|Centurion|Cataract surgery performed with the Centurion phacoemulsification system
61961858|NCT05489198|EXPERIMENTAL|Quatera 700|Cataract surgery performed with the Quatera 700 phacoemulsification system
61961859|NCT01246700|EXPERIMENTAL|Group A|Participants received 12 weeks of Sensory Attention Focused Exercise, then received 12 weeks of no exercise.
61961860|NCT01246700|EXPERIMENTAL|Group B|Participants received no treatment for 12 weeks, then received Sensory Attention Focused Exercise for 12 weeks.
61961861|NCT03542474|EXPERIMENTAL|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
61961862|NCT04243681|EXPERIMENTAL|Combination MSC and HSC|Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance
61961863|NCT04243681|ACTIVE_COMPARATOR|Standard of care for Cirrhosis management|Diuretics, Hepatoprotective agents and Lactulose
61961864|NCT03159767|EXPERIMENTAL|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
61961865|NCT03159767|EXPERIMENTAL|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
61961866|NCT04332562|NO_INTERVENTION|normotensive control group|Normotensive volunteer
61961867|NCT04332562|NO_INTERVENTION|hypertensive control group|Hypertensive patients with no restriction on their salt intake
61961868|NCT04332562|EXPERIMENTAL|hypertensive interventional group|intervention is going to be salt restriction
61961869|NCT05528354|EXPERIMENTAL|VEN and DEC based conditioning regimen followed with post-HSCT DEC maintenance therapy|
61961870|NCT03137290|ACTIVE_COMPARATOR|Neostigmine|1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10mls with Normal Saline 0.9% in a 10ml standard syringe.
61961871|NCT03137290|EXPERIMENTAL|Sugammadex sodium|100mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal Saline 0.9%.
61961872|NCT01685281|ACTIVE_COMPARATOR|Metadoxine (MG01CI) 1400 mg|single dose of Metadoxine (MG01CI) 1400 mg
61961873|NCT01685281|ACTIVE_COMPARATOR|Metadoxine (MG01CI) 700 mg|Single dose of Metadoxine (MG01CI) 700 mg
61961874|NCT01685281|PLACEBO_COMPARATOR|Placebo|Single dose of Placebo
61961875|NCT02432729||Study population|"Adult smokers who are willing to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.~Smokers who are not continuously abstinent from smoking or any nicotine/tobacco containing product from the actual quit date will be discontinued from the study."
61961876|NCT02809937|EXPERIMENTAL|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
61961877|NCT02809937|PLACEBO_COMPARATOR|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
61961878|NCT06446167|ACTIVE_COMPARATOR|Exercise group|All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.
61961879|NCT06446167|ACTIVE_COMPARATOR|Laser group|The MLS Laser applied to the treatment group was administered using an ASA brand Mphi model device. Patients in the Laser group were positioned in a prone position. Treatment was applied continuously for 7 minutes along the plantar fascia, sole of the foot, heel area, and Achilles tendon in accordance with the plantar fasciitis treatment program on the device, at a dose of 1.73 J/cm2 and a frequency of 700 Hz. A treatment program was established with 3 sessions per week, totaling 10 sessions. Patients receiving laser therapy also continued with their exercise programs.
61961880|NCT06446167|ACTIVE_COMPARATOR|ESWT group|The treatment group was administered with the Swiss DolorClast Master ESWT device, which produces radial shock waves. Patients in the ESWT group were positioned in a prone position. The most painful point in the heel area was identified through palpation. Gel was applied to this area, followed by the surrounding soft tissues, towards the plantar fascia and the attachment area of the Achilles tendon at the dorsal aspect of the heel. Radial ESWT treatment was applied at a frequency of 10 Hz, pressure of 2.5 bars, and 2000 impulses per session, once a week for a total of 4 sessions. Patients receiving ESWT therapy also continued with their exercise programs.
62348055|NCT01799018||Control Patients|Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.
62505985|NCT06267209||Observacional group|"Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
62505986|NCT01794754|OTHER|Control|Care as usual
62505987|NCT01794754|EXPERIMENTAL|Occupational therapy|Occupational therapy
62505988|NCT02294448|EXPERIMENTAL|cohort 1|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China） in low dosage(3.75mg)
61961881|NCT00427843|EXPERIMENTAL|Exercise Home-Based Program|Patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. The exercise program will be performed 3 times per week for 8 weeks.
62505989|NCT02294448|EXPERIMENTAL|cohort 2|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)
61961882|NCT00944905|EXPERIMENTAL|MDX-1203|Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study
61961883|NCT04194034|EXPERIMENTAL|TG6002 and flucytosine (5-FC) combination|
61961884|NCT00779714|EXPERIMENTAL|A (individualized combined chemotherapy)|
61961885|NCT00779714|ACTIVE_COMPARATOR|B (DTIC monochemotherapy)|
61961886|NCT03025477|ACTIVE_COMPARATOR|Control arm|"Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.~The regimen of administration of the chemotherapy is as following:~* Carboplatin AUC 6 - IV - Day (D) 1~* Paclitaxel 80mg / m² - IV - D1, D8, D15~one cycle every 3 weeks"
61961887|NCT03025477|EXPERIMENTAL|Experimental arm|"Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.~* Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.~* Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.~The regimen of administration of the chemotherapy is as following:~* Cisplatin 80mg / m² - IV or IP - D1~* Epirubicin 60mg / m² - IV - D3~one Cycle every 3 weeks."
61961888|NCT04785976||Surgical clipping|
61961889|NCT04785976||Endovascular coiling|
61961890|NCT00673803|OTHER|A|cataract surgery, implantation of a Polylens Y10
61961891|NCT00673803|OTHER|B|cataract surgery, implantation of a Polylens Y30
61961892|NCT05948020|EXPERIMENTAL|CBT102-A group|10 subjects receive oral CBT102-A with three meals per day for a total of 20 days
61961893|NCT05948020|PLACEBO_COMPARATOR|Placebo group|5 subjects receive oral placebo with three meals per day for a total of 20 days
61961894|NCT00674245|ACTIVE_COMPARATOR|Pantoprazole|40 mg once daily for four weeks improves sleep quality in patients with GERD
61961895|NCT00674245|PLACEBO_COMPARATOR|placebo|To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.
61961896|NCT00598104|EXPERIMENTAL|1|
61961897|NCT00598104|PLACEBO_COMPARATOR|2|
62348056|NCT02195934|OTHER|Standard orange juice (OJ) followed by blood OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
62348057|NCT02195934|OTHER|Blood orange juice followed by standard OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
62348058|NCT04000347|ACTIVE_COMPARATOR|2.5% benzoyl peroxide|43 patients with 2.5% benzoyl peroxide gel
62348059|NCT04000347|ACTIVE_COMPARATOR|5% benzoyl peroxide|43 patients with 5% benzoyl peroxide gel
62505990|NCT02294448|EXPERIMENTAL|cohort 3|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China）in high dosage(15mg)
62505991|NCT01873781||30 healthy male and female subjects|30 healthy male and female subjects aged 18-35
62348060|NCT01546844|EXPERIMENTAL|Care4Life|Text message and online interactive component to help patients with self-management.
61961898|NCT01049308||Heart Failure|veteran population with documented heart failure
61961899|NCT01738321||Cardiac patients|Patients undergoing cardiac surgery
61961900|NCT01738321||Non-cardiac patients|Patients undergoing any surgery other than cardiac surgery
61961901|NCT00525330|EXPERIMENTAL|KRP-104 120 mg QD|
61961902|NCT00525330|EXPERIMENTAL|KRP-104 60 mg BID|
61961903|NCT00525330|PLACEBO_COMPARATOR|Placebo|
62143869|NCT00866619|EXPERIMENTAL|Menjugate Comparator [6-12W] Group|Male or female children between and including 6 to 12 weeks of age \[6-12W\], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
62348061|NCT01546844|NO_INTERVENTION|Standard of Care|Patients enrolled in this arm will receive their normal standard of care from their physician for treatment of type II Diabetes Mellitus.
61961904|NCT02567916|EXPERIMENTAL|FRESOFOL MCT|To compare the incidence and intensity of pain on injection that is caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol) .
62143870|NCT06326788|EXPERIMENTAL|Short Duration Moderate Intensity Soleus Push-ups (Group A)|Moderate physical activity involving weighted soleus push-ups performed till patient MHR is achieved.
61961905|NCT02567916|ACTIVE_COMPARATOR|Propofol|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol).
61961906|NCT04476069|EXPERIMENTAL|Ibuprofen|30 minutes before extraction, once/day orally
61961907|NCT04476069|PLACEBO_COMPARATOR|Placebo|30 minutes before extraction, once/day orally
61961908|NCT01811654|NO_INTERVENTION|Standard Care|Patients in this group will receive treatment per standard care. Standard Care is defined as consisting of physical therapy, activity modification (relative rest), and/or oral analgesic therapy. A specific physical therapy (PT) protocol will be implemented.
61961909|NCT01811654|ACTIVE_COMPARATOR|Intra-Articular Hyaluronic Acid-Euflexxa|Patients assigned to this group will receive treatment per standard care AND three (3) consecutive weekly injections of intra-articular hyaluronan (Euflexxa). Oral analgesics will be used at the lowest dose and for the shortest time possible to treat PFPS symptoms.
61961910|NCT04144244|EXPERIMENTAL|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips will be used when preparing sperm of male partner and IUI will be made with separated sperm
62143871|NCT06326788|EXPERIMENTAL|Sustained Soleus Push-ups (Group B)|sustained soleus push-ups will be performed for up to 270 min.
62143872|NCT01918176|EXPERIMENTAL|Fixed sequence crossover|All the subjects will undergo the treatment of Palbociclib alone first and then treatment of Palbociclib and Rabeprazole.
62143873|NCT01366742||HPV Cohort|Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.
62143874|NCT03838549|EXPERIMENTAL|implant for breast reconstruction|20 patients female with genetic risk for breast cancer and who ask for prophylactic mastectomy. They will have a prophylactic mastectomy with immediate breast reconstruction
62143875|NCT06479889|EXPERIMENTAL|Counseling + Lock provision|Guardians of patients admitted to the behavioral health team who identify as firearm owners will be provided lethal means counseling and offered up to 3 secure storage devices of their choosing.
62143876|NCT05134103|EXPERIMENTAL|Mindbeacon TAI-CBT for Depression group|Participants randomized to this condition will receive immediate Therapist-Guided Internet-CBT for Depression for 12 weeks.
62143877|NCT05134103|OTHER|Waitlist Control Group|Participants randomized to this condition will remain on the waitlist for 12 weeks before crossing over and receiving Therapist-Guided Internet-CBT for Depression for 12 weeks.
62143878|NCT02988713|EXPERIMENTAL|Spinal cord stimulation|Spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
62505992|NCT05675358|EXPERIMENTAL|virtual reality|In the study, Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used, and the Epic Roller Coasters train game, an application that would attract the attention of children, was determined by the researchers. The virtual reality application was started 2 minutes before the procedure and continued until the procedure was completed.
62505993|NCT05675358|NO_INTERVENTION|control|The child in the control group did not receive any additional intervention.
61961911|NCT04144244|ACTIVE_COMPARATOR|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and IUI will be made with separated sperm
61961912|NCT04915430|ACTIVE_COMPARATOR|Supervised training regimen|"This training regimen consisted of 3 phases: the 1st focused on restoring motion, the 2nd on strengthening of the rotator cuff muscles, and the 3rd on strengthening of the scapular muscles. Stretching completed every training session.~* Motion training consisted of 6 exercises.~  * Postural training: shoulder shrugs and shoulder retraction exercises.~ * Glenohumeral training: pendulum exercises, and active assisted flexion, abduction and external rotation.~* Strengthening of the rotator cuff: side lying external rotation, internal rotation and scaption.~* Strengthening of the scapular muscles: press-up, push-up with a plus, serratus anterior supine punch, standing rowing (low row), and seated rowing (high row).~* Training sessions ended with 4 stretches: anterior shoulder stretch, posterior shoulder stretch, inferior capsular stretch, sleepers stretch.~Exercises were performed 3 times a week, with progression after the 1st week, and thereafter every 2nd week."
62143879|NCT03578965|NO_INTERVENTION|Arm A: No antibiotic prophylaxis prior to skin incision|-Women randomized to no antibiotic prophylaxis will not receive any antibiotics prior to skin incision.
62143880|NCT03578965|EXPERIMENTAL|Arm B: Antibiotic prophylaxis prior to skin incision|-Women randomized to prophylactic antibiotics will receive a cefazolin as per ACOG guidelines.
62505994|NCT06353308|PLACEBO_COMPARATOR|General Sexual Health intervention|Participants will receive their general online sexual health education programming.
62505995|NCT06353308|EXPERIMENTAL|Feminist Sexual Health Intervention|Participants will receive online feminist sexual health program.
62505996|NCT04596397|ACTIVE_COMPARATOR|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
61961913|NCT04915430|ACTIVE_COMPARATOR|Home training regimen|"The program consisted of the following:~* 1 motion exercise: upper trapezius relaxation~* 3 strengthening exercises: serratus anterior strengthening exercise, humeral external rotation with the arm at the side of the body, and humeral external rotation with a rubber band and the arm at 90 degrees abduction.~* 2 stretching exercises: posterior shoulder and pectoralis minor stretching, Exercises were performed daily, with weekly progression."
61961914|NCT01609374|EXPERIMENTAL|M6-C Artificial Cervical Disc|
61961915|NCT01609374|ACTIVE_COMPARATOR|Anterior Cervical Discectomy and Fusion|
61961916|NCT06301685|EXPERIMENTAL|Routine therapy+Stellate ganglion block|"The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.~Based on the invention above, the patients were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
61961917|NCT06301685|PLACEBO_COMPARATOR|Routine therapy+Placebo|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy and placebo injection.
61961918|NCT03434275|EXPERIMENTAL|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
61961919|NCT03434275|PLACEBO_COMPARATOR|IV Placebo|IV Placebo every 24 hours
61961920|NCT00929318|ACTIVE_COMPARATOR|benign|patients after surgery because of a benign disease
61961921|NCT00929318|ACTIVE_COMPARATOR|DTC|Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
61961922|NCT03528772|ACTIVE_COMPARATOR|Minoxidil|Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
61961923|NCT03528772|ACTIVE_COMPARATOR|Glyceryl trinitrate|Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
61961924|NCT05923437|EXPERIMENTAL|Experimental: Interventions Group|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiological approach, simultaneously with the mother's supply."
61961925|NCT05923437|NO_INTERVENTION|Control Group|Breast milk will be given to newborns in the control group according to the clinical routine and infants will be followed up for 3 days.
61961926|NCT01506713|EXPERIMENTAL|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
61961927|NCT01506713|ACTIVE_COMPARATOR|Plavix|Clopidogrel Tablet 75 mg
61961928|NCT00101595|EXPERIMENTAL|1|
61961929|NCT00948701|EXPERIMENTAL|Phone-based PA program (RTR Plus)|"The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials. RTR volunteers or coaches will be asked to contact participants by telephone once a week for 12 weeks. The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers."
62348062|NCT06253013|EXPERIMENTAL|Full study intervention|"In addition to the standard of care at the institutions which includes virtual pulmonary rehabilitation, remote clinical monitoring and integrated care, patients will have the option to use the following interventions:~* FitBit wearable device with continuous monitoring for oxygen saturation and respiratory rate for 90 days~* Hyfe cough monitoring smartwatch with continuous monitoring for 90 days~* Home spirometer used once daily for 90 days~* Audio recordings on a tablet once daily for 90 days"
62348063|NCT05875376|EXPERIMENTAL|ASD couple|Either one of the couple has ASD diagnosis, including couples who are married or in romantic relationship.
62505997|NCT04596397|EXPERIMENTAL|Induction of labour with oral misoprostol, outpatient setting|These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.
61961930|NCT00948701|ACTIVE_COMPARATOR|Standard RTR services (RTR)|RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
61961931|NCT03346278|NO_INTERVENTION|No Text Message Intervention|Participants will receive usual care of information on CR and clinical referral to CR.
61961932|NCT03346278|EXPERIMENTAL|Text Message Intervention|Participants randomized to the intervention will receive usual care plus a text messaging intervention.
61961933|NCT01506674||criticall ill patients|
61961934|NCT03711812|ACTIVE_COMPARATOR|Serratus Anterior Plane Catheter|
61961935|NCT03711812|PLACEBO_COMPARATOR|Thoracic Epidural|
61961936|NCT03435861|EXPERIMENTAL|VX-745|In the present study, VX-745 will be given at the dosage of 40 mg twice a day (1 tab. of 40 mg, twice), orally for 12 weeks
61961937|NCT03435861|PLACEBO_COMPARATOR|placebo|In the present study, placebo will be given twice a day (1 tab. , twice), orally for 12 weeks
61961938|NCT06021145|EXPERIMENTAL|Empagliflozin 2.5 mg daily|Empagliflozin is a sodium/glucose cotransporter 2 inhibitor (SGLT2i) that inhibits glucose reabsorption in the kidney. In this study, a capsule of empagliflozin 2.5 mg will be taken daily in conjunction with the participant's personal automated insulin delivery system for 26 weeks.
61961939|NCT06021145|ACTIVE_COMPARATOR|Placebo|As a control, a placebo capsule will be taken daily in conjunction with the participant's personal automated insulin delivery system for 26 weeks.
61961940|NCT03275454|EXPERIMENTAL|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 intravenous (IV) infusion and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 every 2 weeks for approximately 21 weeks in Part A (based on time to complete 11 doses of study drug). There will be a 9-week safety follow-up/washout period after administration of the last dose of study drug in Part A. Participants who have been shown to benefit from BIVV009 treatment during Part A, will receive BIVV009 (based on weight) biweekly for up to 52 weeks of BIVV009 after Last Patient In (LPI) in part B.
61961941|NCT01775085|EXPERIMENTAL|Meaning-Centered Group for Breast Cancer Survivors (MCG-BCS)|
61961942|NCT01775085|ACTIVE_COMPARATOR|Discussion Group (DG)|
61961943|NCT02684916|EXPERIMENTAL|Chiropractic treatment|Visit with active treatment.
62505998|NCT03795389|EXPERIMENTAL|3.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).
61961944|NCT02684916|PLACEBO_COMPARATOR|Placebo|Visit without active treatment.
61961945|NCT02551978|EXPERIMENTAL|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
61961946|NCT02551978|NO_INTERVENTION|Control|Children in the same primary school, aged between 9 and 12 years do receive basic information during the study phase.
61961947|NCT06342466|EXPERIMENTAL|BPd|BPd regimen (Bortezomib, pomalidomide, and dexamethasone) will be applied every 28 days until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of six cycles.
61961948|NCT06124560|EXPERIMENTAL|Reference group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
61961949|NCT06124560|EXPERIMENTAL|Test group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
62143881|NCT02350400|EXPERIMENTAL|DEBIRI|For unilobar disease, two treatments will be planned, separated by four weeks. For bilobar disease, there will be four treatments planned, alternating between right and left lobe, separated by 2 weeks duration.
61961950|NCT01331915|EXPERIMENTAL|Theravac|Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
61961951|NCT05746871|EXPERIMENTAL|GroupA_Agilik first|This arm will be assessed at T0, then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and will perform T1 evaluations, and then it will repeat the evaluations after other 5 weeks (T2) during which they performed they standard care
61961952|NCT05746871|EXPERIMENTAL|GroupB_standard care first|This arm will be assessed at T0, then it will continue with their standard care and will perform T1 evaluation after 5 weeks, and then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and the final evaluation (T2)
61961953|NCT04176978|EXPERIMENTAL|T2T + statin|Patient in this arm will receive treat-to-target strategy with rousavastin 20mg
61961954|NCT04176978|ACTIVE_COMPARATOR|T2T only|Patient in this arm will receive treat-to-target strategy only.
61961955|NCT05808972|ACTIVE_COMPARATOR|Sodium chloride 0.9% (SC) arm|"The SC arm receives insulin therapy via an electric syringe (Actrapid HM ®, Novorapide®) (1 ml = 100 IU) - take 0.5 ml (= 40 IU) and complete to 50 ml with SC to obtain a solution of 1 ml = 1 IU. -Infusion rate = 0.1 IU/kg/h.~In parallel, and on an insulin-independent route, 0.9% chloride saline is started on the basis of 3 L/ 24 hours per day if capillary glyceamia\>2,5 g/l . Blood samples were taken for glycemia, arterial Blood gas, electrolytes, lactate at baseline, 6, 12, 24 and 48 hours later."
61961956|NCT05808972|ACTIVE_COMPARATOR|Ringer lactate (RL) arm|"The SC arm receives insulin therapy via an electric syringe (Actrapid HM ®, Novorapide®) (1 ml = 100 IU) - take 0.5 ml (= 40 IU) and complete to 50 ml with SC to obtain a solution of 1 ml = 1 IU. -Infusion rate = 0.1 IU/kg/h.~In parallel, and on an insulin-independent route, Ringer lactate is started on the basis of 3 L/ 24 hours per day if capillary glyceamia\>2,5 g/l . Blood samples were taken for glycemia, arterial Blood gas, electrolytes, lactate at baseline, 6, 12, 24 and 48 hours later."
61961957|NCT06300372|EXPERIMENTAL|Group A=M-TAPA block group|M-TAPA plane block will be performed and standard postoperative pain management protocols will be applied.
62704507|NCT00843882|EXPERIMENTAL|Arm B (lenalidomide, epoetin alfa)|Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly. Patients undergo bone marrow biopsy at screening and during follow-up. Patients undergo blood specimen collection on study.
61961958|NCT06300372|ACTIVE_COMPARATOR|Group B = control group|Only standard postoperative pain management protocols will be applied. No plane blocks will be applied
61961959|NCT02885012|EXPERIMENTAL|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
62348064|NCT04031053||Intensive Pharmacokinetic Group|After receiving the first dose of ITZ, a single blood sample will be collected 12-hours post-dose. On Day 7, the blood will be collected for intensive PK study. After 7 days of combined ITZ + EFV, a blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. An identical set of intensive PK blood samples will be drawn 2 weeks after initiating the EFV based regimen.
61961960|NCT02885012|EXPERIMENTAL|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
61961961|NCT06110780|ACTIVE_COMPARATOR|Acupuncture group|"The conductor of the study, an acupuncturist experienced in electroacupuncture, will apply electroacupuncture to the PC 6, LU7, LU2 points for 30 minutes on the day before surgery and on the day of surgery.~The placement of the needles will be applied to a depth of 1-2 cm, depending on the thickness of the local tissues, according to Traditional Chinese Medicine standards.~The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best within the range of 0.5 mA to 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
61961962|NCT06110780|NO_INTERVENTION|Control group|Control group
61961963|NCT03064451|EXPERIMENTAL|Intervention|cartofinder guided ablation followed by PVI
62143882|NCT04727294||MGUS, SMM, MM Patients or their Caregivers|"Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile.~The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility.~Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete."
62143883|NCT01054287|EXPERIMENTAL|Falls prevention|
62143884|NCT01054287|PLACEBO_COMPARATOR|Usual care|
62348065|NCT04031053||Trough Level Group|On Days 7 and 14, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. After initiating an EFV based regimen, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose on Days 7 and 14.
62348066|NCT05061797|ACTIVE_COMPARATOR|Active Study Product|An energy beverage formulated to improve the thermogenic (calorie burning) impact in humans via caffeine and ingredients for overall metabolic wellness.
62704508|NCT00644228|ACTIVE_COMPARATOR|Arm I (dexamethasone and lenalidomide)|Patients receive dexamethasone PO QD on days 1, 8, 15, and 22 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62704509|NCT00644228|EXPERIMENTAL|Arm II (dexamethasone, lenalidomide, bortezomib)|Patients receive dexamethasone PO QD on days 1, 2, 4, 5, 8, 9, 11, and 12; lenalidomide PO QD on days 1-14; and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
61961964|NCT00877253|EXPERIMENTAL|Dose Level One|
61961965|NCT00877253|EXPERIMENTAL|Dose Level Two|
61961966|NCT00877253|EXPERIMENTAL|Dose Level Three|
61961967|NCT00795314|ACTIVE_COMPARATOR|1|Propofol-fentanyl combined anesthesia
61961968|NCT00795314|EXPERIMENTAL|2|Propofol-butorphanol combined anesthesia
61961969|NCT01604837||Pelvic malignancy group|those with diagnosis of gynecologic or urologic malignancy
62704510|NCT02610465||1|Computed Tomography (CT) images
61961970|NCT01604837||Pelvic chronic disease group|those with chronic pelvic pain with constitutional cause e.g. endometriosis
61961971|NCT01130142|ACTIVE_COMPARATOR|Arm 1 (Phase 2)|IPI-926 in combination with gemcitabine
61961972|NCT01130142|PLACEBO_COMPARATOR|Arm 2 (Phase 2)|Placebo in combination with gemcitabine
61961973|NCT06557070|EXPERIMENTAL|Emotional Freedom Technique (EFT) experimental group|A total of 8 sessions of Emotional Freedom Technique (EFT) will be applied to the experimental group, once a week. First, the experimental group was informed about premenstrual syndrome and EFT face to face and EFT application was taught. EFT application was performed every week for 2 cycles. During the application, plans were made to be face-to-face, online, in a group or individually. The posttest was repeated after the application was completed.
61961974|NCT06557070|NO_INTERVENTION|The control group.|The control group was first given a pre-test, then given information about premenstrual syndrome face to face, no intervention was made, they were asked not to use painkillers, a post-test was performed at the end of 2 cycles, and EFT was taught to the students who wanted it.
61961975|NCT01175252||Gastroenteritis Cohort|All children suffering with gastroenteritis
61961976|NCT01663532|EXPERIMENTAL|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks
61961977|NCT01663532|PLACEBO_COMPARATOR|Placebo|Matching placebo
61961978|NCT03594721|EXPERIMENTAL|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
61961979|NCT03594721|EXPERIMENTAL|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
62704511|NCT04106349||1st line|
62704512|NCT04106349||2nd line|
62704513|NCT04106349||later lines|
61961980|NCT03454776|ACTIVE_COMPARATOR|Unloader One brace|Patients receiving an active brace, Unloader One with active straps facilitating unloading of affected knee compartment
61961981|NCT03454776|PLACEBO_COMPARATOR|Placebo brace|Patients receiving a dummy, lookalike or placebo brace without active straps that facilitate unloading of the affected knee compartment
61961982|NCT02868775||Interstitial cystitis/bladder pain syndrome|These are the patients that will be evaluated in this study.
61961983|NCT03478332|ACTIVE_COMPARATOR|Treatment group|The aim of the arm is to test if the addition of Yangxinshi pills to the conventional coronary heart disease medicine will improve the exercise tolerance of the coronary heart disease
61961984|NCT03478332|PLACEBO_COMPARATOR|Control group|The patients of the control group are treated with conventional coronary heart disease medicine plus the placebos-Yangxinshi simulant
61961985|NCT00899054|EXPERIMENTAL|P276-00 plus Radiation|"P276-00:~Level 1:100 mg/m2/day x 5 q 3 weeks, level 2:140 mg/m2/day x 5 q 3 weeks, level 3: 185 mg/m2/day x 5 q 3 weeks.~External beam radiotherapy (EBRT):~2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 2 cycles (6 weeks)followed by upto 10 additional Gy if required"
61961986|NCT05704452||Patient group|who diagnosed with dementia
61961987|NCT05704452||Control group|who diagnosed as healthy (don't have dementia)
61961988|NCT03303924|EXPERIMENTAL|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
61961989|NCT04036344|NO_INTERVENTION|Control|Control participants receive treatment for a facial skin cancer with Mohs micrographic surgery (MMS), however, do not receive a peer mentor. Participants complete 3 online Skin Cancer Index (SCI) surveys at enrollment, 1 week follow-up, and 3 month follow-up.
62143885|NCT00507767|EXPERIMENTAL|Treatment (dasatinib)|Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62704514|NCT01273168|EXPERIMENTAL|1|Z-endoxifen will be administered orally once a day in 28-day cycles
62704515|NCT05877963|EXPERIMENTAL|Ublituximab|Participants will receive a modified regimen of ublituximab intravenous (IV) including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) IV infusion at Week 24.
62704516|NCT05574062|EXPERIMENTAL|Treatment Arm|AHCL therapy (780G system in Auto Mode with G4S sensor in the study phase and 780G BLE 2.0 system in Auto Mode with DS5 sensor in the continuation phase)
62704517|NCT05574062|ACTIVE_COMPARATOR|Control Arm|Predictive low-glucose suspend (780G system in Manual Mode with G4S sensor) in the study phase and AHCL therapy (780G system in Auto Mode with G4S sensor) in the continuation phase
62704518|NCT01498263||Alzheimers related dementias (family)|Enrollment was open to family members of persons diagnosed with Alzheimers (/related dementia) in specific communities around Memphis, TN.
61961990|NCT04036344|EXPERIMENTAL|Mentee - Preoperative Consult|Mentees are enrolled at preoperative consultation visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
61961991|NCT04036344|EXPERIMENTAL|Mentee - Same Day Surgery|Mentees are enrolled at same day surgery visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
62505999|NCT03795389|EXPERIMENTAL|5.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
62506000|NCT03795389|EXPERIMENTAL|8.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
62506001|NCT00706719|EXPERIMENTAL|25 mg Androxal no wash out|1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
62506002|NCT00706719|ACTIVE_COMPARATOR|Testim 1% (topical testosterone)|Testim 1% Gel applied topically for 6 months
62506003|NCT00706719|EXPERIMENTAL|25 mg Androxal wash out|1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
61961992|NCT03118258|EXPERIMENTAL|Pap smear|'Pap smear' arm: women are invited to participate in a preventive consultation. This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
61961993|NCT03118258|EXPERIMENTAL|Self-collected vaginal swab for HPV testing + pap smear triage|"'Self-collected vaginal swab for HPV testing + pap smear triage' arm : women are invited to participate in a preventive consultation. This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
62506004|NCT04271072||Study|"Parturients that underwent cesarean delivery and is POSITIVE for the composite outcome of either:~* perinatal depression (Edinburgh postnatal depression scale \>=10 during pregnancy or within 3 months after delivery), and/or~* persistent pain (pain score \>=3 at pelvic or lower abdominal areas at 3 months after delivery)"
62506005|NCT04271072||Control|"Parturients that underwent cesarean delivery and is NEGATIVE for the composite outcome of both:~* perinatal depression (Edinburgh postnatal depression scale \>=10 during pregnancy or within 3 months after delivery), AND~* persistent pain (pain score \>=3 at pelvic or lower abdominal areas at 3 months after delivery)"
62506006|NCT03690167|ACTIVE_COMPARATOR|Concentrated Growth Factor (CGF)|Participants with impacted lower third molar
62506007|NCT03690167|ACTIVE_COMPARATOR|Advanced Platelet Rich Fibrin (A-PRF)|Participants with impacted lower third molar
62506008|NCT03690167|SHAM_COMPARATOR|Control|Participants with impacted lower third molar
62506009|NCT00202839|EXPERIMENTAL|24-Week Treatment|Genotype 1 hepatitis C virus \[HCV\] subjects treated for a total of 24 weeks, during the pilot treatment program (immediately before randomization)
62506010|NCT00202839|ACTIVE_COMPARATOR|48-Week Treatment|Genotype 1 HCV subjects treated for a total of 48 weeks: 24 weeks during the pilot treatment program (immediately before randomization) plus 24 weeks during the extended treatment program (immediately after randomization)
62506011|NCT04458558|EXPERIMENTAL|Medical abortion patients|Oral mifepristone 200 mg followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone).
62506012|NCT05762887|EXPERIMENTAL|Probiotic group|"In addition to the usual medication treatment for bipolar disorder, following the main international guidelines for the treatment of bipolar disorder, subjects will receive food supplementation with a probiotic formulation, twice daily, with food. We will use Pendulum Therapeutics' Glucose Control, probiotic formulation patented in the United States.~Probiotic Ingredients: Clostridium butyricum WB-STR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WB-STR-0001, and Bifidobacterium infantis.~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
62506013|NCT05762887|PLACEBO_COMPARATOR|Placebo Group|"In addition to the usual medication treatment for bipolar disorder, following the main international guidelines for the treatment of bipolar disorder, the subjects will receive food supplementation with a placebo formulation, twice daily, with food We will use Pendulum Therapeutics' placebo formulation that contains:~Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
62506014|NCT00459823|EXPERIMENTAL|1|
62704519|NCT01498263||Inherited inflammatory condition (family)|Enrollment open to family members of persons diagnosed with inherited inflammatory conditions. Participation at NIH or remote (internet/phone); request referral of family for remote participation.
61961994|NCT03187106|EXPERIMENTAL|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for a total of 6 doses; 500 mg metronidazole per oral every 8 hours for a total of 6 doses
61961995|NCT03187106|PLACEBO_COMPARATOR|Placebo / standard of care|Placebo pills per oral every 8 hours for a total of 6 doses
61961996|NCT05457764|EXPERIMENTAL|Virtual Reality|Participants use Virtual reality headsets as medium of erotica to produce their sperm sample
62143886|NCT06212661||CGRP inhibitor|"* Ubrogepant (Ubrelvy™)~* Rimegepant (Nurtec®)~* Atogepant (Qulipta™)~* Eptinezumab (Vyepti®)~* Fremanezumab (Ajovy®)~* Galcanezumab (Emgality®)~* Erenumab (Aimovig®) dosage and duration according to provider's clinical decision."
62348067|NCT05061797|PLACEBO_COMPARATOR|Placebo|A carbonated soft-drink with the same appearance, aroma, and flavor as the active study product
62348068|NCT00608452||1|
62348069|NCT01064219|EXPERIMENTAL|intrauterine hCG|intrauterine injection of 100 hCG followed by endometrial biopsy
62348070|NCT00514436|NO_INTERVENTION|Usual care|Usual care consisted of referral back to primary care provider after index hospitalization
62348071|NCT00514436|EXPERIMENTAL|Behavioral|Asthma coaching, inperson contact followed by telephone contact
62348072|NCT03123055|EXPERIMENTAL|B-701 (vofatamab)|B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
62348073|NCT03123055|EXPERIMENTAL|B-701 (vofatamab) plus pembrolizumab|B-701 (vofatamab, 25 mg/kg \[or the recommended Phase 2 dose if different than 25 mg/kg\]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
61961997|NCT05457764|NO_INTERVENTION|No Virtual Reality|Participants did not use Virtual reality headsets as medium of erotica to produce their sperm sample. They used a computer screen to display erotica.
62506015|NCT04101695|ACTIVE_COMPARATOR|sham tDCS- washout period- anodal tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds. At least 7 days of washout period is in between two tDCS. For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA."
61961998|NCT02155062|EXPERIMENTAL|Whole grain rye|3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)
61961999|NCT02155062|EXPERIMENTAL|Whole grain wheat|3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)
61962000|NCT02155062|PLACEBO_COMPARATOR|Refined cereal|No intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)
61962001|NCT05125757|EXPERIMENTAL|intervention group|The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
61962002|NCT05125757|ACTIVE_COMPARATOR|control group|The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities
62348074|NCT01240408|EXPERIMENTAL|Treatment group 1|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
62506016|NCT04101695|ACTIVE_COMPARATOR|anodal tDCS- washout period- sham tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA. At least 7 days of washout period is in between two tDCS. For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds."
62506017|NCT02075034|EXPERIMENTAL|560 mg morning/280 mg afternoon|Two 280 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule of rigosertib will be taken in the afternoon.
62348075|NCT01240408|EXPERIMENTAL|Treatment group 2|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
62348076|NCT02327533||Patients with Aggressive Periodontitis|The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria and was defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.(Lang et al., 1999)
62348077|NCT02327533||Controls|Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
62348078|NCT03943888|EXPERIMENTAL|Sugammadex 2mg|Administer 2mg/kg of sugammadex 15 minutes after rocuronium administration
62348079|NCT03943888|EXPERIMENTAL|Sugammadex 4mg|Administer 4mg/kg of sugammadex 15 minutes after rocuronium administration
62348080|NCT03943888|EXPERIMENTAL|Sugammadex 8mg|Administer 8mg/kg of sugammadex 15 minutes after rocuronium administration
62348081|NCT03943888|ACTIVE_COMPARATOR|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) 15 minutes after rocuronium administration
62348082|NCT04092816|EXPERIMENTAL|FAMILY|Patient-co-parent dyads will participate in the FAMILY intervention in-person.
62348083|NCT03325556|PLACEBO_COMPARATOR|Placebo|
62348084|NCT03325556|EXPERIMENTAL|Drug - Pimavanserin|
62348085|NCT05072665|EXPERIMENTAL|PATIENT WITH Irritable Bowel Syndrome|"2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. after the fluorescein injection.~A first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped"
62506018|NCT02075034|EXPERIMENTAL|420 mg morning and afternon|One 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the afternoon.
62506019|NCT02075034|EXPERIMENTAL|280 mg TID|One 280 mg capsule of rigosertib will be taken in the morning, one 280 mg capsule of rigosertib will be taken at mid-day, and one 280 mg capsule of rigosertib will be taken in the afternoon.
61962003|NCT00232232|NO_INTERVENTION|Control|No fish oil
61962004|NCT00232232|EXPERIMENTAL|Fish oil|Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
61962005|NCT02878746|EXPERIMENTAL|Robotic mirror therapy|For 30 min per day for two weeks (10 sessions)
61962006|NCT02878746|ACTIVE_COMPARATOR|Conventional mirror therapy|For 30 min per day for two weeks (10 sessions)
61962007|NCT02079220|EXPERIMENTAL|Arm A|"Arm A (every 2 week schedule) Dosage and dosage regimen for all study periods~* Capecitabine: will be administered 1,000 mg/m2 orally twice a day on Days 1 - 7 of each cycle, repeating every 14 days.~* Oxaliplatin: will be administered 85 mg/m2 IV on Day 1 of each cycle, repeating every 14 days.~* Ziv-aflibercept: will be administered 4 mg/kg IV on Day 1 of each cycle, repeating every 14 days."
61962008|NCT02079220|EXPERIMENTAL|Arm B|"Arm B (every 3 week schedule):~Dosage and dosage regimen for all study periods~* Capecitabine: will be administered 850 mg/m2 orally twice a day on Days 1 - 14 of each cycle, repeating every 21 days.~* Oxaliplatin: will be administered 130 mg/m2 IV on Day 1 of each cycle, repeating every 21 days.~* Ziv-aflibercept: will be administered 6 mg/kg IV on Day 1 of each cycle, repeating every 21 days."
61962009|NCT02491203|NO_INTERVENTION|Usual care|All study participants in the control group will receive a 4-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
62143887|NCT06212661||BoNTA extracranial muscle injections|Botolinum toxin A (Botox) Injection into extracranial muscles to treat migraine. Dosage and duration according to provider's clinical decision
62348086|NCT05003063|ACTIVE_COMPARATOR|Donepezil|5mg Donepezil will be administered in pill form.
62348087|NCT05003063|PLACEBO_COMPARATOR|Placebo|5mg placebo will be administered in pill form.
62348088|NCT00738205||1|
62348089|NCT00738205||2|
61962010|NCT02491203|EXPERIMENTAL|Telerehabilitation system|Participants in the experimental group will receive four weeks written home exercise program provided by a clinician, i.e. usual care discharge home program plus virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and the program adapted to ensure it remains at an appropriate level for the patient.
61962011|NCT04115839|EXPERIMENTAL|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
61962012|NCT04115839|EXPERIMENTAL|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 16 weeks.
61962013|NCT04115839|PLACEBO_COMPARATOR|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
62704520|NCT01498263||Inherited metabolic conditions (family)|Enrolls family members of persons diagnosed with inborn errors of metabolism / mitochondrial disorders. Study at NIH or remote (internet/phone); request family-referrals for remote participation.
61962014|NCT04115839|EXPERIMENTAL|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 44 weeks.
61962015|NCT04115839|EXPERIMENTAL|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 44 weeks.
61962016|NCT03153969|EXPERIMENTAL|SHOFU Beautifil II LS|Composite: SHOFU Beautifil II LS, Bonding Agent: SHOFU BeautiBond
61962017|NCT03153969|ACTIVE_COMPARATOR|3M/ESPE Filtek Supreme|Composite: 3M/ESPE Filtek Supreme, Bonding Agent: 3M/ESPE Scotchbond Universal
62704521|NCT01498263||Inherited neurodegenerative disorders (family)|Open to family members of persons diagnosed with genetically-defined neurodegenerative conditions. Study at NIH or (internet/phone); request referral of family members for remote participation.
61962018|NCT04394260||LGBT Caregivers Participating in a Focus Group|LGBT caregivers attending a focus group after watching the videos of the remote learning Savvy Caregiver Program. The focus group will guide modification of the Savvy Caregiver Program to meet the needs of LGBT caregivers of PLWD.
62506020|NCT04313426|EXPERIMENTAL|Integrative Yoga Therapy|Self managed Yoga based practices were included in one to one sessions for 6-sessions.
62506021|NCT00523289|ACTIVE_COMPARATOR|B|Arm number B corresponds to the Bupivacaine group.
62506022|NCT00523289|ACTIVE_COMPARATOR|R|Arm number R corresponds to the Ropivacaine group.
62704522|NCT01498263||Typically developing (family) = Healthy Volunteers|Open to parents of typically-developing child/ren \<18yrs (\*when age-matched child is full-time resident of parent's home). Study at NIH; request family-referrals for remote participation.
62704523|NCT01498263||Undiagnosed conditions (family)|Enrollment open to family members referred in from the Undiagnosed Disease Network. Participation at NIH or remote (internet/phone); request referral of family members for remote participation
62704524|NCT06406465|EXPERIMENTAL|Arm 1|Belinostat at 400 mg/m\^2/day plus Cisplatin plus Etoposide
62704525|NCT06406465|EXPERIMENTAL|Arm 2|Belinostat at 600 mg/m\^2/day plus Cisplatin plus Etoposide
61962019|NCT01439269|NO_INTERVENTION|Phase 1: Standard Care|Mothers are given infant care instruction as part of standard care
61962020|NCT01439269|EXPERIMENTAL|Phase 1: Facilitated infant care|Family Nurture Intervention (FNI)
61962021|NCT01439269|ACTIVE_COMPARATOR|Phase 2: Effectiveness|All participants receiving FNI
61962022|NCT00662012|EXPERIMENTAL|Sodium Stibogluconate (SSG) 20 mg/kg|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
62348090|NCT02602171|EXPERIMENTAL|dereverberation condition|Oldenburger Sentence test, localization test
62506023|NCT01510860|ACTIVE_COMPARATOR|Ursodeoxycholic acid (UDCA)250 mg|UDCA 250 mg capsule
61962023|NCT06265012|EXPERIMENTAL|Group A, Low Dose PHV01|Group A (10 subjects) PHV01 @ 10\^5 pfu/dose
61962024|NCT06265012|EXPERIMENTAL|Group B, Medium Dose PHV01|Group B (10 subjects) PHV01 @ 10\^6 pfu/dose
61962025|NCT06265012|EXPERIMENTAL|Group C, Hjigh Dose PHV01|Group C (10 subjects) PHV01 @ 10\^7 pfu/dose
61962026|NCT06265012|PLACEBO_COMPARATOR|Group D, Placebo|Group D (6 subjects) Placebo
61962027|NCT01833013|OTHER|endometriosis cohort|females suffer from endometriosis
61962028|NCT03547180|ACTIVE_COMPARATOR|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
61962029|NCT03547180|ACTIVE_COMPARATOR|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
62348091|NCT02602171|EXPERIMENTAL|reverberation condition|Oldenburger Sentence test, localization test
62506024|NCT01510860|EXPERIMENTAL|Ursodeoxycholic acid (UDCA)500 mg|UDCA 500 mg tablet
62506025|NCT02491996|EXPERIMENTAL|DTIG|Outpatients who treated by DTIG at Outpatient Unit for Gambling Disorder of Kurihama Medical and Addiction Center
62506026|NCT01961687|OTHER|Resorbable Mesh|Phasix Mesh
62506027|NCT02225106|EXPERIMENTAL|Open label methylphenidate treatment|Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily.
62506028|NCT03090490|EXPERIMENTAL|Intervention group|Antipsychotic treatment discontinuation (DT)
62704526|NCT02912949|EXPERIMENTAL|Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
62704527|NCT02912949|EXPERIMENTAL|Part 2 NSCLC cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
62506029|NCT03090490|ACTIVE_COMPARATOR|Control group|Maintenance antipsychotic treatment (MT)
62506030|NCT03527680|EXPERIMENTAL|Lactobacillus rhamnosus|received daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus
62506031|NCT03527680|PLACEBO_COMPARATOR|Placebo|received one placebo capsule per day Infant formula after meal for 28 days
62506032|NCT06024317|EXPERIMENTAL|Early onset|"20 clusters will be assigned to the early onset arm. A cross-sectional cohort and two longitudinal cohorts will be enrolled from each cluster.~Both longitudinal cohorts will receive all components of the Chanjo Kwa Wakati intervention."
61962030|NCT03547180|OTHER|In-vivo exposure therapy|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
61962031|NCT03185767|OTHER|SLE group|
62506033|NCT06024317|EXPERIMENTAL|Delayed onset|"20 clusters will be assigned to the delayed onset arm. A cross-sectional cohort and two longitudinal cohorts will be enrolled from each cluster.~The second longitudinal cohort will receive all components of the Chanjo Kwa Wakati intervention."
62506034|NCT00638833|ACTIVE_COMPARATOR|A|Memantine 30 mg/day
62506035|NCT00638833|PLACEBO_COMPARATOR|B|Placebo
62506036|NCT04526652|ACTIVE_COMPARATOR|Dexmedetomidine|Intranasal dexmedetomidine 1mcg/kg
61962032|NCT03185767|OTHER|control group|
61962033|NCT04362982|EXPERIMENTAL|ADHD|In the first part of the clinical trials, ADHD cohorts are going to undergo a neuropsychological assessement. Moreover, they will interact with the serious game twice (30-45 minutes/each time). In the second part, participants will interact with game two or three times per week (30-45 minutes/each time). Finally, a neuropsychological assessment will be administered following the procedures of the first one.
61962034|NCT04362982|ACTIVE_COMPARATOR|non-ADHD|Non-ADHD group will follow the same procedures as the experimental one.
61962035|NCT01701557|ACTIVE_COMPARATOR|slow fluid rate|bolus 10 ml/kg of NS followed by 1.25 times maintenance rate
61962036|NCT01701557|ACTIVE_COMPARATOR|Fast fluid rate|bolus 20 ml/kg of NS followed by 1.5 times maintenance rate
61962037|NCT02654730|EXPERIMENTAL|G6PD deficient 0.25 mg/kg PQ + DHAP|
61962038|NCT02654730|EXPERIMENTAL|G6PD deficient 0.4 mg/kg PQ + DHAP|
61962039|NCT02654730|ACTIVE_COMPARATOR|G6PD deficient DHAP only|
61962040|NCT02654730|ACTIVE_COMPARATOR|G6PD normal 0.25 mg/kg PQ + DHAP|
61962041|NCT02654730|ACTIVE_COMPARATOR|G6PD normal 0.4 mg/kg PQ + DHAP|
61962042|NCT05044390||lung transplantation|Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.
62143888|NCT04932018|EXPERIMENTAL|Interventional|The intervention group will participate in a round table educational session with a study facilitator/mentor farmer and occupational health nurse plus receive an invitation to participate in an interactive virtual community providing ongoing resources and support from community farmers and agriculture experts.
62143889|NCT04932018|SHAM_COMPARATOR|Attention Control|The second group (attention control) will receive an invitation to participate in the virtual community without mentor interaction.
62506037|NCT04526652|PLACEBO_COMPARATOR|Placebo|Intranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine)
62506038|NCT05612139||JTIN treated patients|Pediatric patients, older than 18 months, suffering from osteogenesis imperfecta treated with JTIN telescopic nail
62506039|NCT02510261|EXPERIMENTAL|Prior Placebo Group of Study 004|Participants who received placebo and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 milligrams per kilogram (mg/kg) patisiran intravenously (IV) once every 3 weeks (Q3W) up to 65.5 months.
62506040|NCT02510261|EXPERIMENTAL|Prior Patisiran Group of Study 004|Participants who received patisiran and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 66.9 months.
62506041|NCT02510261|EXPERIMENTAL|Prior Patisiran Group of Study 003|Participants who received patisiran and completed parent study ALN-TTR02-003 (NCT01961921) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 61.4 months.
62506042|NCT00206596|EXPERIMENTAL|Arm 1|
62506043|NCT00206596|PLACEBO_COMPARATOR|Arm 2|
62506044|NCT02371993|EXPERIMENTAL|Choline 650 mg twice daily|See above
62506045|NCT02371993|PLACEBO_COMPARATOR|Placebo|See above
62506046|NCT06001801|ACTIVE_COMPARATOR|Diabetes Prevention Program (DPP) (usual care)|
62506047|NCT06001801|EXPERIMENTAL|DPP plus the INSPIRA intervention|This arm will include the DPP plus additional interventions.
62506048|NCT04126343|EXPERIMENTAL|Padsevonil|Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.
61962043|NCT00263601|EXPERIMENTAL|Allergovit 6-grasses immunotherapy|Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
61962044|NCT00263601|PLACEBO_COMPARATOR|Placebo|Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
61962045|NCT01099982||Advanced Heart Failure Therapy Group|Patients diagnosed with end stage heart failure undergoing either VAD implantation or heart transplantation.
62143890|NCT01026805||Hysteroscopic Morcellator|11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.
62506049|NCT04126343|PLACEBO_COMPARATOR|Placebo|Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.
62506050|NCT04126343|ACTIVE_COMPARATOR|Moxifloxacin|Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.
62506051|NCT05996692||Patients who walked regularly for exercise|"Walking for exercise was explored according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.~According to this criterion, the patients were divided into 2 groups as those who walked regularly for exercise and those who did not walk regularly for exercise."
62704528|NCT02912949|EXPERIMENTAL|Part 2 Solid tumour (basket) harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
61962046|NCT01099982||Normal Hearts Group|Control samples will be obtained from individuals undergoing other types of cardiac surgery during which it is routine to discard some tissue intraoperatively.
62704529|NCT04685200||Controls|90 controls to collect epidemiological data as well as blood samples, nasal swabs, salivary samples and stool samples from family members and cohabitants of subjects affected with PSC.
62704530|NCT04685200||PSC Pariticipants|40 patients with PSC diagnosed by standard clinical, biochemical, or imaging features (including up to 30 with a known diagnosis of IBD)
62704531|NCT06375512|EXPERIMENTAL|Arm 1: Dose A|Participants will receive placebo by intramuscular (IM) injection on Day 0 followed with IN001 by IM injection on Day 56.
62704532|NCT06375512|EXPERIMENTAL|Arm 2: Dose B|Participants will receive IN001 by IM injection on Day 0 and Day 56.
62704533|NCT06375512|EXPERIMENTAL|Arm 3: Dose C|Participants will receive IN001 by IM injection on Day 0 and Day 56.
62704534|NCT06375512|EXPERIMENTAL|Arm 4: Dose D|Participants will receive IN001 by IM injection on Day 0 and Day 56.
62704535|NCT06375512|ACTIVE_COMPARATOR|Arm 5: Shingrix|Participants will receive Shingrix by IM injection on Day 0 and Day 56.
61962047|NCT04654117|NO_INTERVENTION|Baseline|Following completing the online tutorial, each agency will have a baseline lasting 3-6 weeks (this will be staggered by agency).
61962048|NCT04654117|EXPERIMENTAL|Treatment (Consultation)|Consultation will be conducted in 4-week phases that correspond to the three consultation components. The phases will occur in a randomized order. During a given phase, no components of any other phases will be provided. Feedback phase. Consultees will submit 5-minute clips of session recordings of their Project ImPACT session with their enrolled family for feedback. Oral feedback will be provided by the consultant and peers. Case support phase. The consultant will lead the group in problem-solving common barriers that providers experience with their cases. Skill rehearsal phase. The consultant will lead skill rehearsal practices in which providers role play elements of a Project ImPACT session.
61962049|NCT04654117|NO_INTERVENTION|Follow Up|During the follow-up period, consultation will not occur, and providers will continue implementing Project ImPACT with their cases. Eight weeks post-consultation, providers will submit a recorded Project ImPACT session with their enrolled family. Providers and caregivers will complete a final online questionnaire.
61962050|NCT03633695|EXPERIMENTAL|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye. The AcuFocus IC-8 IOL implanted in the second eye.
62143891|NCT06510140||Post-operative delirium (POD) arm (experimental group)|Patients who present a post-operative delirium according to the 3D-CAM within 48h
61962051|NCT03633695|ACTIVE_COMPARATOR|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted.
61962052|NCT02091934|ACTIVE_COMPARATOR|Wavefront-guided PRK|Wavefront-guided PRK
61962053|NCT02091934|ACTIVE_COMPARATOR|Wavefront-optimized PRK|Wavefront-optimized PRK
61962054|NCT01126853|EXPERIMENTAL|Vaccination|Receipt of up to 3 series of double dose combination hepatitis A/B vaccine (Twinrix)
62143892|NCT06510140||No Post-operative delirium (POD) arm (control group)|Patients who do not present a post-operative delirium according to the 3D-CAM within 48h
62143893|NCT05277285|NO_INTERVENTION|Standard Treatment|The standard treatment includes the application of mechanical ventilation and / or support with the administration of inotropes and / or extracorporeal oxygenation (ECMO) and the intravenous administration of fluids and dexamethasone. The administration of any other immunosuppressive therapy, including tocilizumab and / or antimicrobials at the discretion of the therapists, is permitted.
62143894|NCT05277285|EXPERIMENTAL|One intravenous 12.5 gr STS - Treatment Group 1|Patients will receive standard treatment and one intravenous (iv)12.5 gr STS in 60 minutes continuous intravenous infusion. STS is dissolved in a final volume of 100ml N/S 0.9% w/v,
62143895|NCT05277285|EXPERIMENTAL|Three intravenous doses of 12.5 gr STS - Treatment Group 2|Patients will receive standard treatment and three intravenous doses of 12.5 g STS. STS is dissolved in a final volume of 100ml N/S 0.9% w/v. Each dose will be given in 60 minutes of continuous intravenous infusion with 48 hours intervals between each dose.
62143896|NCT00792337|ACTIVE_COMPARATOR|simvastatin|simvastatin in combination with budesonide
62704536|NCT04728893|EXPERIMENTAL|Nemtabrutinib|Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.
62704537|NCT05644951|EXPERIMENTAL|Hot AXIOS system|Hot AXIOS system (20 mm diameter stent)
62704538|NCT00013559||Family|Parents and/or siblings of patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
62704539|NCT00013559||Patients|Patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
61962055|NCT04004715|EXPERIMENTAL|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
61962056|NCT04004715|ACTIVE_COMPARATOR|Whey Protein|commercially available whey protein isolate
61962057|NCT04004715|ACTIVE_COMPARATOR|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
61962058|NCT03967652||cancer|Patients with definitively diagnosed of solid tumors
61962059|NCT03967652||Benign disease|Patients with definitively diagnosed of benign disease or precancerous lesion
61962060|NCT03967652||Normal|Healthy volunteers
61962061|NCT03859752|EXPERIMENTAL|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
62704540|NCT00001403||Proteus Syndrome|Patients with Proteus syndrome (PS) and other overgrowth disorders hypothesized to be in the AKT/PI3K pathway
62704541|NCT05749822|PLACEBO_COMPARATOR|Placebo-UDCA|1 tablet/ day and UDCA 13-15mg/kg/day for 12 months
62704542|NCT05749822|EXPERIMENTAL|Fenofibrate-UDCA|Fenofibrate 200 mg/day and UDCA 13-15mg/kg/day for 12 months
62704543|NCT06448299|ACTIVE_COMPARATOR|TAPB|
62704544|NCT06448299|ACTIVE_COMPARATOR|ESPB|
62704545|NCT05726864|EXPERIMENTAL|Phase 1A: ELI-002 7P (Low Peptide dose)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (1.4mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
62704546|NCT05726864|EXPERIMENTAL|Phase 1A: ELI-002 7P (High Peptide dose)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (4.9mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
62506052|NCT05996692||Patients who did not walk regularly for exercise|"Walking for exercise was explored according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.~According to this criterion, the patients were divided into 2 groups as those who walked regularly for exercise and those who did not walk regularly for exercise."
62506053|NCT04184206|ACTIVE_COMPARATOR|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness influence
61962062|NCT05142943|EXPERIMENTAL|Visual Illusion (VI and therapeutic exercise program (EP)|"the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes. Then a physical exercise program for the upper extremities will be carried out:~* General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~* Gross mobility and coordination: ball games.~* Fine mobility and coordination: writing tasks, puzzles, abacus ...~* Strength exercises: shoulder, elbow, wrist, fingers.~* Stretching."
61962063|NCT05142943|SHAM_COMPARATOR|VI sham and EP|the configuration of the work table will be the same as in real IV, although videos of landscapes will be projected on them without any type of human or animal movement appearing on them. This program will last 10 minutes. Afterwards, a physical exercise program for the upper extremities will be carried out, detailed in Arm I.
62704547|NCT05726864|EXPERIMENTAL|Phase 1B: ELI-002 7P|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
62704548|NCT05726864|EXPERIMENTAL|Phase 2 randomized: ELI-002 7P|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
61962064|NCT05142943|EXPERIMENTAL|VI|only the visual illusion program will be carried out, detailed in Arm I.
62506054|NCT04184206|ACTIVE_COMPARATOR|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness influence
61962065|NCT05142943|SHAM_COMPARATOR|VI sham|
61962066|NCT05367648|EXPERIMENTAL|Elio (supplement under investigation)|3g of Elio administered orally daily with the first meal of the day for a 17 day period
62506055|NCT04184206|ACTIVE_COMPARATOR|attention training intervention 3|14-day smartphone-based audio-guided intervention without mindfulness emphasis
62506056|NCT04703855|EXPERIMENTAL|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
62704549|NCT04101344|EXPERIMENTAL|Fiber-blend|All participants will receive a two fiber-blend snack and then a four fiber-blend snack. Stool, blood, and urine will be monitored for changes throughout the study.
62704550|NCT06101095|EXPERIMENTAL|Dupilumab|Subcutaneous injection (SC) as per protocol
62704551|NCT06101095|PLACEBO_COMPARATOR|Placebo|SC injection as per protocol
61962067|NCT05367648|PLACEBO_COMPARATOR|Place|3g of SMCC administered orally daily with the first meal of the day for a 17 day period
61962068|NCT04985097|ACTIVE_COMPARATOR|Experimental group|Half an hour of active visual training per day for a period of 20 consecutive days with the Optictrain software
61962069|NCT04985097|SHAM_COMPARATOR|Control group|Half an hour of using a videogame without specific stimuli to improve visual performance (Fun Kid Racing 3.53 for Android) per day for a period of 20 consecutive days
61962070|NCT00975650|EXPERIMENTAL|Test 8.0, Ref 5.0, Test 14.0, Test 11.0|Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;
61962071|NCT00975650|EXPERIMENTAL|Test 11.0, Test 8.0, Ref 5.0, Test 14.0|Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
61962072|NCT00975650|EXPERIMENTAL|Test 14.0, Test 11.0, Test 8.0, Ref 5.0|Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;
62143897|NCT00792337|PLACEBO_COMPARATOR|B1-6-12|Budesonide in combination with B1-6-12
62143898|NCT02195856|ACTIVE_COMPARATOR|Diseased condition|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
62143899|NCT02195856|PLACEBO_COMPARATOR|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
62506057|NCT02434263|EXPERIMENTAL|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
62506058|NCT00804024||ClearWay™ RX|
62506059|NCT00835939|ACTIVE_COMPARATOR|25% Dextrose and 1% Lidocaine|
62506060|NCT00835939|PLACEBO_COMPARATOR|Lidocaine|
62506061|NCT01661634|EXPERIMENTAL|Ularitide|Ularitide, lyophilizate for i.v. infusion, 15 ng/kg BW/min, for 48 hours
62506062|NCT01661634|PLACEBO_COMPARATOR|Placebo|Placebo lyophilizate for i.v. infusion
62506063|NCT02821949||Patients|Patients with Non Small Cells Lung Cancer PCT dosage
62506064|NCT04314544|EXPERIMENTAL|Arm A|
62506065|NCT04314544|PLACEBO_COMPARATOR|Arm B|
62506066|NCT02512055|EXPERIMENTAL|Group 1|Pediatric patients undergoing repeat radiotherapy session under ketamine sedation
62506067|NCT01007279|ACTIVE_COMPARATOR|CLOPIDOGREL|
62506068|NCT01007279|EXPERIMENTAL|ROSUVASTATIN|
61962073|NCT00975650|EXPERIMENTAL|Ref 5.0, Test 14.0, Test 11.0, Test 8.0|Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
61962074|NCT04255108||Men/Women who meet the inclusion/exclusion criteria|
61962075|NCT04445311|EXPERIMENTAL|Ivermectin group|group that will receive ivermectin plus standard of care ttt
62506069|NCT00984516|EXPERIMENTAL|Intradermal Juvidex|
62506070|NCT00984516|PLACEBO_COMPARATOR|Placebo (vehicle)|
62506071|NCT06021054|EXPERIMENTAL|Veligrotug (VRDN-001)10 mg/kg|Drug: 5 IV Infusions of veligrotug (VRDN-001)10 mg/kg
61962076|NCT04445311|NO_INTERVENTION|Control group|group that will receive standard of care ttt
61962077|NCT01753271|EXPERIMENTAL|Thoracic Mobilization|thoracic mobilization in addition to shoulder mobilization plus exercise
62506072|NCT06021054|EXPERIMENTAL|Placebo Drug|Placebo Drug: 5 IV Infusions of placebo
62506073|NCT01401335|OTHER|Trauma counseling|
62506074|NCT01027767||Surgery/Radiation Arm|Patients that have had surgery along with radiation therapy
61962078|NCT01753271|ACTIVE_COMPARATOR|exercise only|shoulder mobilization plus exercise alone
61962079|NCT05504564||Control group|healthy child
61962080|NCT05504564||Experimental group|parents with language disorder
61962081|NCT00386178|EXPERIMENTAL|1|Vitamin E supplement rich in gamma tocopherol
61962082|NCT03478202|EXPERIMENTAL|Open Label RELEASE Supplement|
61962083|NCT04200664||Siderosis (iSS) group|participants with a known diagnosis of infratentorial superficial siderosis (defined using standardised radiological criteria) confirmed by a consultant neurologist with expertise in this condition at University College London Hospitals National Health Service (NHS) Foundation Trust
61962084|NCT04200664||Age-related hearing loss (ARHL) group|participants with age-related hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
61962085|NCT04200664||Control group|participants with no known or previously reported hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
61962086|NCT04985864|EXPERIMENTAL|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
61962087|NCT04985864|ACTIVE_COMPARATOR|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
61962088|NCT01270776|EXPERIMENTAL|Aqueous Chlorhexidine|The group received skin antisepsis using 2% aqueous chlorhexidine solution.
61962089|NCT01270776|ACTIVE_COMPARATOR|2% Chlorhexidine 70% isopropyl alcohol|The group will receive skin antisepsis with 2% chlorhexidine solution in alcohol.
61962090|NCT04829396|EXPERIMENTAL|Fibre mixture|"Dietary supplement. A mixture of fibres will be administered consisting of 10g of acacia gum powder and 3g of carrot powder.~The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day."
61962091|NCT04829396|PLACEBO_COMPARATOR|Placebo for Fibre mixture|A placebo of the mixture of fibres will be administered.
62143900|NCT05469165|EXPERIMENTAL|Cyproheptadine 4 Mg Oral Tablet|Participants will receive cyproheptadine 4mg tablet orally three times a day for three months, with a daily increase of 4mg/dose if the previous dose was well tolerated, up to 0.5 mg/kg/day.
62506075|NCT01027767||Surgery Arm|Patients that have had surgery of a benign lesion.
62506076|NCT00688298|EXPERIMENTAL|Arm 1|Female patients Greater than or 18 years of age, diagnosed with Stress Urinary Incontinence (SUI).
62506077|NCT03224520|EXPERIMENTAL|Fully enhanced|Peer recruitment and recommender CTHC
62506078|NCT03224520|EXPERIMENTAL|Recommender CTHC only|Recommender CTHC and standard online recruitment
62506079|NCT03224520|EXPERIMENTAL|Peer recruitment only|Peer recruitment and standard CTHC
62506080|NCT03224520|EXPERIMENTAL|Standard|Standard online recruitment and standard CTHC
62506081|NCT01503463|NO_INTERVENTION|Usual Care|Patients in the control group receive usual care delivered by their primary care physicians and cardiologists. Usual care consists of regular visits to the specialist or primary care clinics every time a medication change is required, or a medical examination is needed.
62506082|NCT01503463|EXPERIMENTAL|Home telemonitoring of patients with CHF|
62506083|NCT00808509|ACTIVE_COMPARATOR|Adalimumab + MTX|Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
62506084|NCT00808509|EXPERIMENTAL|Methotrexate|Participants discontinued adalimumab and continued to receive methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. Participants with a significant increase in RA disease activity were re-instituted to adalimumab 40 mg every other week (rescue arm). After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
62506085|NCT02931292||Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
62506086|NCT01199120|EXPERIMENTAL|Omega 3|
62506087|NCT02900482||case group|Patients with a history of congenital hip dislocation
62506088|NCT02900482||control group|Patients with no history of congenital hip dislocation
62506089|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
62506090|NCT04300023|NO_INTERVENTION|Solo Cycling Control Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location. Participants will be provided with exercise recommendations, but will receive only data recording calls every 2-weeks. \[will crossover and complete the cycling intervention following the initial 6-months\]
62539240|NCT01724086|EXPERIMENTAL|Panel 4 - Arm 1|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (30 mg once daily)
61962092|NCT01581255||Conventional lung protective ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the conventional lung protective ventilation arm of the OSCILLATE trial.
62506091|NCT04300023|EXPERIMENTAL|Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
62506092|NCT01886937|EXPERIMENTAL|37.5 mg Phentermine daily for 7 days|"In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.~Other names for phentermine:~adipex ionamin"
62506093|NCT01886937|PLACEBO_COMPARATOR|Placebo (for phentermine 37.5mg)|In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days.
62506094|NCT02376660|EXPERIMENTAL|Oats|70 grams oats
62506095|NCT02376660|PLACEBO_COMPARATOR|usual diet and exercise|usual diet and exercise
62506096|NCT00406016|EXPERIMENTAL|1|
62506097|NCT06132048|EXPERIMENTAL|MuCopilot - Summative evaluation|Performance of digital tests and questionnaire from MuCopilot, during the visit.
62506098|NCT01042873|OTHER|Intravenous dobutamine|3 hours infusion of dobutamine
62506099|NCT05954819|EXPERIMENTAL|Planned patient education|"Pre-test data will be obtained by using the Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale. The participants will be individual education on myocardial infarction and diabetes by researcher. One month later, the posttest data will be obtained using Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale."
62506100|NCT05954819|NO_INTERVENTION|Routine patient education|"Pre-test data will be obtained by using Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale. No attempt will be made to participants by the researcher. Participants will undergo discharge training routinely administered by bedside nurses at the hospital. One month later, the posttest data will be obtained using Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale."
62506101|NCT00810628|EXPERIMENTAL|1|All subjects in same investigative group with same CBT intervention.
62348092|NCT03896113|EXPERIMENTAL|Celecoxib|Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery will receive celecoxib 400 mg twice a day, for 15 days before the curative surgery for their endometrial cancer. The patients will undergo an endometrial biopsy at the inclusion and during the surgery.
62506102|NCT05933473|ACTIVE_COMPARATOR|LM-LAD (Crossover stenting (CO))|Crossover stenting (CO) from the LM into the LAD, using standard provisional bifurcation techniques and proximal stent optimization (POT), where post dilatation was typically performed.
62506103|NCT05933473|ACTIVE_COMPARATOR|ostial LAD (Ostial stenting(OS))|Ostial stenting of the LAD (OS) with no cross-over back to the LM.
62506104|NCT06326528||SGLT2 group|First group will receive SGLT2 (Dapaglifozin or Empagliflozin) inhibitors one month before surgery and three months after surgery.
61962093|NCT01581255||High frequency oscillation ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the high frequency oscillation ventilation arm of the OSCILLATE trial.
62348093|NCT06285110||People living with HIV|People living with HIV and on a Dolutegravir-based ART regimen, and experiencing treatment failure.
62506105|NCT04941131|EXPERIMENTAL|chlorhexidine digluconate mouthwash|
62506106|NCT04941131|EXPERIMENTAL|chlorhexidine digluconate lozenges|
62506107|NCT04941131|EXPERIMENTAL|povidone iodine mouthwash|
62506108|NCT04941131|NO_INTERVENTION|tap water|
61962094|NCT00982137|EXPERIMENTAL|ChimeriVax™-JE then STAMARIL®|Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
61962095|NCT00982137|EXPERIMENTAL|STAMARIL® then ChimeriVax™-JE|Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
61962096|NCT00982137|EXPERIMENTAL|ChimeriVax™-JE and STAMARIL®, then Diluent|Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
61962097|NCT00982137|EXPERIMENTAL|Diluent then ChimeriVax™-JE and STAMARIL®|Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
62348094|NCT04742920|OTHER|MMA embolization group|MMA embolization procedure with Onyx™ in addition to standard (surgical/conservative) management
62348095|NCT04742920|OTHER|Control group|Standard (surgical/conservative) Management alone
62348096|NCT01825655|ACTIVE_COMPARATOR|Cetirizine|zyrtec 10mg, oral, one time
62348097|NCT01825655|PLACEBO_COMPARATOR|Sugar pill|Placebo, one pill, one time
62348098|NCT02300428||1-year cohort|"Patients with at least 1 prescription of any oral iron preparation in the last 2 years and who have at least 1 year of follow up data post-prescription.~It is anticipated that ca. 123,000 patients in CPRD fulfil this criteria."
62348099|NCT02300428||10-year cohort|"All pre-menopausal women (18-45 years old) with at least 1 prescription of one ferrous iron salt (i.e. sulphate, fumarate and gluconate) since January 2000.~It is anticipated that ca. 299,000 patients in CPRD fulfil this criteria."
62348100|NCT01450956|EXPERIMENTAL|Sevoflurane|Patients will receive 2% sevoflurane via oxygenator during CPB
62506109|NCT00673764|EXPERIMENTAL|Systane Ultra|Systane Ultra Lubricant Eye Drops
62506110|NCT00673764|ACTIVE_COMPARATOR|Optive|Optive Lubricant Eye Drops
62506111|NCT03574337|ACTIVE_COMPARATOR|Sugammadex|Patient's will receive sugammadex at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight and TOF ratio by the pharmacy. It will be a one time dose at the end of the case
62506112|NCT03574337|ACTIVE_COMPARATOR|Neostigmine/glycopyrrolate|Patient's will receive neostigmine/glycopyrrolate at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight (50mcg/kg of neostigmine with an equivalent volume to volume ratio of glycopyrrolate). It will be a one time dose at the end of the case
62506113|NCT03574337|NO_INTERVENTION|No reversal administered|No reversal administered at the end of the case
62506114|NCT05148078|EXPERIMENTAL|General Anesthesia Decrease use : PROMISE|To decrease the total number of pediatric patients who require general anesthesia through the use of PROMISE
62506115|NCT02812771|EXPERIMENTAL|Efinaconazole|Efinaconazole
62506116|NCT01020526|EXPERIMENTAL|Pregabalin|
62506117|NCT02179593|OTHER|2-Segment SARPE|Maxilla expansion using one sagittal section of the maxilla.
62348101|NCT01450956|NO_INTERVENTION|Control|Patients will receive only oxygen and air through oxygenator
62506118|NCT02179593|OTHER|3-Segment SARPE|Maxilla Expansion using two parasagittal section of the maxilla.
62506119|NCT06146855|EXPERIMENTAL|Tunneling with amnion membrane|
62506120|NCT06146855|ACTIVE_COMPARATOR|Tunneling with De-epithelialized Free Gingival Graft|
61962098|NCT00766337|EXPERIMENTAL|Dose Group 1|
62143901|NCT05469165|PLACEBO_COMPARATOR|Placebo|Participants will receive a matched placebo orally three times a day for 3 months. Daily titration similar to the treatment arm.
62348102|NCT00600028|EXPERIMENTAL|Experimental: Thalidomide, then placebo|Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
62348103|NCT00600028|EXPERIMENTAL|Experimental: Placebo, then Thalidomide|Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.
62348104|NCT01659333||Peritoneal dialysis, hypervolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
62348105|NCT01659333||Peritoneal dialysis, normovolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
62348106|NCT02159261||Cohort 1|Female patients ≥ 18 years old requiring contraception.
62348107|NCT03272217|EXPERIMENTAL|Arm A - Atezolizumab + Bevacizumab|Patients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
61962099|NCT00766337|EXPERIMENTAL|Dose Group 2|
61962100|NCT00766337|PLACEBO_COMPARATOR|Dose Group 3|
62143902|NCT00509756|ACTIVE_COMPARATOR|1|Drug: FXR-450
62348108|NCT02691221|OTHER|Participants with previous suicide attempt or ideation|Participants will complete daily tasks assigned for completion through a downloaded application on their mobile device and completing six 2-hour long outcome assessment sessions including rater-lead scales over the course of six months.
62348109|NCT01736254|EXPERIMENTAL|Gemfibrozil|Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1
62348110|NCT01736254|EXPERIMENTAL|Evacetrapib|Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)
62348111|NCT01736254|EXPERIMENTAL|Evacetrapib + Gemfibrozil|Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
62348112|NCT02069236|NO_INTERVENTION|G6PD Testing|All subjects receive G6PD test
62348113|NCT05821348|EXPERIMENTAL|cases|acting from 2 months up to the first year of life, with age postmenstrual \> 40 weeks, hospitalized, with symptoms of GER or GERD and undergoing 24-hour esophageal MII-pH. Saliva samples will be collected during the execution of the MII-pH of the esophagus 24 hours, at defined time points, at least 2 hours after the last meal, so as to study the circadian variations of their composition.
62348114|NCT05821348|NO_INTERVENTION|controls|healthy infants from whom it will be taken a single saliva sample during a health assessment.
62348115|NCT02581865|PLACEBO_COMPARATOR|Placebo|Placebo administered once daily for 8 weeks
62348116|NCT02581865|EXPERIMENTAL|Dose Group 1|Fixed dose administered once daily for 8 weeks
62348117|NCT02581865|EXPERIMENTAL|Dose Group 2|Fixed dose administered once daily for 8 weeks
62348118|NCT05093998|EXPERIMENTAL|Group 1.|AV5080 at a daily dose of 160 mg
62348119|NCT05093998|PLACEBO_COMPARATOR|Group 2.|Placebo
62348120|NCT04518982|EXPERIMENTAL|The experimental group|
62348121|NCT04518982|PLACEBO_COMPARATOR|The control group|
62506121|NCT06313060|EXPERIMENTAL|Intervention group|200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
62506122|NCT06313060|NO_INTERVENTION|Control group|will not receive any type of medication or drink
62506123|NCT04248517|EXPERIMENTAL|mHealth intervention group|participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
62143903|NCT00509756|PLACEBO_COMPARATOR|2|Placebo
62143904|NCT04404894||Prolaris tested patients with Prostate Cancer|Recently diagnosed patients with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites who have undergone Prolaris testing.
62143905|NCT00831948||Mitochondrial disease|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques
62143906|NCT03259568|EXPERIMENTAL|Dose-response TMS - Intensity = 20%RMT|"Four levels of TMS intensity (here, 20% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
62348122|NCT03989752|EXPERIMENTAL|Wearable robotic exoskeleton-assisted walking program|Total of 34 training sessions (60 min/session) during 16 weeks (1-3 session/week). Session intensity will be individualized and safely progressed thereafter (standing time, number of steps) to maintain a moderate-to-vigorous intensity (Borg rate of perceived exertion ≥12/20).
62348123|NCT01959399|EXPERIMENTAL|ASP015K + rosuvastatin|
62506124|NCT04248517|NO_INTERVENTION|Treatment as Usual group|participants will undergo their routine treatment.
62506125|NCT01921231|EXPERIMENTAL|Hyperbaric prilocaine 1%|Solution for injection. Intradural use. In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%). Administer 3 mL of syringe contains in two minutes.
62506126|NCT01921231|ACTIVE_COMPARATOR|Hyperbaric Bupivacaine 0.5%|Solution for injection. Intradural use. Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
61962101|NCT02206048|EXPERIMENTAL|High-Resolution Microendoscopy (HRME)|Before participant's cold knife cone biopsy (CKC), topical application of 0.01% proflavine solution applied to cervix. HRME probe applied to cervix and high-resolution images obtained. Participant undergoes cervical biopsies of any abnormal areas noted with colposcopy and/or HRME. Immediately following the CKC, the removed surgical specimen evaluated. Proflavine reapplied to surgical specimen and repeat evaluation with HRME performed and high-resolution images obtained.
61962102|NCT01224860|EXPERIMENTAL|Telmisartan|
61962103|NCT01224860|EXPERIMENTAL|Losartan|
61962104|NCT05636683|EXPERIMENTAL|Periodontitis treated with Root surface debridement|Immediately after inclusion in the study, the patient's examination with saliva sampling will be conducted as follows: At a base line visit (Zero time visit), subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
61962105|NCT02755519||Primary Aldosteronism|"1. Those with hypertension, and with or without hypoglycemia;~2. Those with PAC/PRC≥42.95 pg·mL-1/µIU·mL-1"
61962106|NCT02755519||Non-Primary Aldosteronism|"1. Those with Primary Hypertension;~2. Those with adrenal diseases except for Primary Aldosteronism"
61962107|NCT01633853|EXPERIMENTAL|Vitamin D2 Treatment|Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
62348124|NCT06005298|NO_INTERVENTION|AUDIT <8|Participants whose audit score is less than eight are assigned to this arm. AUDIT is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, dependence, and experience of alcohol-related harm. AUDIT \<8 is non-hazardous.
62506127|NCT01450241|EXPERIMENTAL|Early antibiotic discontinuation|Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
62506128|NCT01450241|OTHER|Usual practice|Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
62506129|NCT01121588|EXPERIMENTAL|Crizotinib|
62704552|NCT00182858||1|Participants will be 18 years or older that are Healthy Volunteers or have been identified by the investigator and/or physician to have a condition of interest for exploratory studies related to the participant s illness or other feature that offers the possibility of creating information that leads to scientifically useful and important studies.
62704553|NCT00001465||LAM|Patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research
62704554|NCT04972201||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected.
61962108|NCT01633853|ACTIVE_COMPARATOR|1,25(OH)2 Vitamin D3|Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
61962109|NCT01310621|NO_INTERVENTION|No Lavage|Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward. The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
61962110|NCT01310621|EXPERIMENTAL|Surfactant Lavage|The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds. Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine. The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube. Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by \> 5% of the prelavage value. The same shall be resumed once prelavage oxygen saturation has been restored. The infant's bed will now be moved back to horizontal position. Once the neonate is STABLE, suctioning will be again repeated. The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
61962111|NCT00003499|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
61962112|NCT01303107|ACTIVE_COMPARATOR|bupivacaine S50:R50|3 ml subarachnoid block
62143907|NCT03259568|EXPERIMENTAL|Dose-response TMS - Intensity = 40%RMT|"Four levels of TMS intensity (here, 40% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
62348125|NCT06005298|EXPERIMENTAL|AUDIT >8 + SBIRT|This is an experimental arm, and AUDIT \>8 is hazardous. The goal is to make connections on the impact of the SBIRT intervention on PrEP engagement and alcohol use among the participants to create a full picture of the impact of the intervention on groups exhibiting different types of alcohol use.
62348126|NCT06005298|NO_INTERVENTION|AUDIT > 8 NO SBIRT|This is NOT an experimental arm, despite an AUDIT score \> 8.
62348127|NCT04346693|ACTIVE_COMPARATOR|group 1|80 patients with moderate and critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). Standard therapy is prescribed recommended by the Ministry of Health of the Russian Federation.
62506130|NCT02246764|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
62506131|NCT02246764|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
62506132|NCT02246764|ACTIVE_COMPARATOR|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
62506133|NCT06436287||Cases|Diagnosed with a movement disorder
61962113|NCT01303107|EXPERIMENTAL|bupivacaine S75:R25|3 ml for subarachnoid block
61962114|NCT04073654|ACTIVE_COMPARATOR|SA Implants|Dental implant with sandblasted and Acid-etched (SA) surface
61962115|NCT04073654|EXPERIMENTAL|SOI Implants|Same dental implant with sandblasted and Acid-etched surface modified with pH buffering agent
61962116|NCT06201702|EXPERIMENTAL|Experimental group|Participants in the intervention group will first be pre-tested by filling out the data collection tools, and then they will be informed about 3 mL of pomegranate supplementation three times a day for 10 days during 2 menstrual cycles (between 7 days before and 3 days after the estimated onset of menstruation). The test will be repeated at the end of the 2nd month after the intervention
61962117|NCT06201702|NO_INTERVENTION|Control group|Participants in the control group will be pre-tested and post-tested after 2 menstrual cycles and at the end of menstrual bleeding. This group will not receive any intervention.
61962118|NCT02034669|EXPERIMENTAL|Treatment with ADSCs transplantation|4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous
61962119|NCT02034669|NO_INTERVENTION|Treatment without ADSCs transplantation|Only intervention: laminectomy
61962120|NCT00089154|EXPERIMENTAL|Treatment (apolizumab)|Patients receive apolizumab IV over 2-4 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity.
61962121|NCT03059602||Knee group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total knee arthroplasty.
61962122|NCT03059602||Hip group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total hip arthroplasty.
61962123|NCT03059602||Spine group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing Cervical/Thoracic Lumbar Spine Surgery (Discectomy, Foraminotomy, Laminectomy, Fusion, Nerve Root Decompression)
61962124|NCT02587715|EXPERIMENTAL|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
61962125|NCT03031314|ACTIVE_COMPARATOR|Standard suture|standard suture used (monocryl)
61962126|NCT03031314|ACTIVE_COMPARATOR|Barbed suture|barbed suture used (Quill suture, Surgical Specialties)
61962127|NCT01748669|EXPERIMENTAL|Patients of palmer arsenical keratosis|One soft capsule of garlic oil (10 mg) daily for 12 weeks
62506134|NCT06436287||Control|Healthy controls
62704555|NCT04972201||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected.
61962128|NCT01748669|ACTIVE_COMPARATOR|Arsenic exposed controls|One soft capsule of garlic oil (10 mg) daily for 12 weeks
61962129|NCT01748669|ACTIVE_COMPARATOR|Heathy volunteers|One soft capsule of garlic oil (10 mg) daily for 12 weeks
61962130|NCT06364098|EXPERIMENTAL|intrauterine misoprostol group (Group A)|96 women receiving 400 mcg intrauterine misoprostol + IV oxytocin.
61962131|NCT06364098|ACTIVE_COMPARATOR|sublingual misoprostol group (Group B)|: 96 women receiving 400 mcg sublingual misoprostol + IV oxytocin.
61962132|NCT02268344|ACTIVE_COMPARATOR|Grass SD9 Stimulator|Brief intraoperative electrical stimulation of the spinal accessory nerve (ESSAN) continuously at 20 Hz, 10-15V for 60 minutes immediately following neck dissection.
61962133|NCT02268344|NO_INTERVENTION|No Stimulation|No stimulation will be performed in this group, and patients will simply have the neck dissection as planned. No sham stimulation is required, as all outcome measures are performed by individuals not present in the operating room, and therefore, blinded to the treatment arm.
61962134|NCT01435200|EXPERIMENTAL|Intravenous iron|Iron sucrose 200 mg intravenous infusion in 15 minutes
61962135|NCT01435200|PLACEBO_COMPARATOR|Oral iron|Ferrous fumarate 200 mg oral three times a day
61962136|NCT04344392|OTHER|Dysphagic hemiplegic patients|Dysphagic patients with hemiplegia as assessed by clinical examination
61962137|NCT04344392|OTHER|Control|Volunteers which do not have an active swallowing dysfunction.
62348128|NCT04346693|EXPERIMENTAL|group 2|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days).
62143908|NCT03259568|EXPERIMENTAL|Dose-response TMS - Intensity = 80%RMT|"Four levels of TMS intensity (here, 80% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
62506135|NCT01129739|EXPERIMENTAL|Human umbilical cord-derived MSCs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle
62506136|NCT01129739|ACTIVE_COMPARATOR|cyclosporine A (CsA)|CsA at a dose of 5 mg CsA/kg
62506137|NCT04599621||patients with unstable angina|This group included patients with frequent anginal attacks, with a burdened history and comorbid conditions.
62506138|NCT00496028|EXPERIMENTAL|1|AZD0530 + Paclitaxel
62506139|NCT00496028|EXPERIMENTAL|2|AZD0530 + Carboplatin
61962138|NCT04730284|EXPERIMENTAL|Health supplements|One arm only
61962139|NCT03305575|EXPERIMENTAL|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
61962140|NCT03305575|ACTIVE_COMPARATOR|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
61962141|NCT06131177|EXPERIMENTAL|Treatment|Patients are treated with supplementary protein drink
61962142|NCT06131177|NO_INTERVENTION|SOC (standard of Care)|Patient are provided normal hospital diet or meal
61962143|NCT03473977|EXPERIMENTAL|Benralizumab|Subcutaneous dose of 30 mg of Benralizumab every 4 weeks
61962144|NCT03473977|PLACEBO_COMPARATOR|Placebo|Subcutaneous dose of Placebo every 4 weeks
61962145|NCT01882491|PLACEBO_COMPARATOR|Placebo|
62348129|NCT04346693|EXPERIMENTAL|group 3|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
62348130|NCT04346693|EXPERIMENTAL|group 4|80 patients with moderate to critical severity of the disease with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular administration of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days) in conjunction with inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
62348131|NCT00039741|EXPERIMENTAL|PI/1K|Two NRTIs plus a PI with a regimen change recommended at when viral load reaches 1000 copies/ml or higher
62348132|NCT00039741|EXPERIMENTAL|NNRTI/1K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 1,000 copies/ml or higher
62348133|NCT00039741|EXPERIMENTAL|PI/30K|2 NRTIs plus 1 PI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
62348134|NCT00039741|EXPERIMENTAL|NNRTI/30K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
62348135|NCT04230798|NO_INTERVENTION|Control|This group did not perform any specific exercise program nor injury prevention program. They continued their normal training routine
62348136|NCT04230798|EXPERIMENTAL|Prevention program|This group performed two sessions per week of the injury prevention program. The program included strength training, plyometrics and core stability training.
62348137|NCT00413335|ACTIVE_COMPARATOR|1|Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
62348138|NCT00413335|PLACEBO_COMPARATOR|2|Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
62348139|NCT00795353||1. Amevive Exposure|Canadian subjects with moderate to severe chronic plaque psoriasis
62348140|NCT05232019||Infertile females|No less than 20 years old who were attending our clinical center for the first time were enlisted
62348141|NCT01079286|EXPERIMENTAL|nelfinavir and temsirolimus|dose escalation
62506140|NCT00496028|EXPERIMENTAL|3|AZD0530 + Carboplatin + Paclitaxel
62506141|NCT02518217|ACTIVE_COMPARATOR|Apps Only|
62506142|NCT02518217|EXPERIMENTAL|ShapeUp Empower|
62704556|NCT06484088|EXPERIMENTAL|Frustration task|The experimental manipulation for this study is the frustration task. The frustration task is designed to elicit the emotional state of frustrative non-reward (FNR). During the task, participants are asked to use button press (left or right) to alternately press one of the two doors displayed on the monitor. The task has two non-frustration blocks (Block 1 and 2) and one frustration block (Block 3). During the non-frustration blocks, participants earn money for correct press on a fixed schedule. During the frustrative block, participants will not always receive reward for correct press.
62704557|NCT06019182||Affected|Individuals who have MEHMO syndrome or eIF2-pathway related conditions 1-week of age or older.
61962146|NCT01882491|EXPERIMENTAL|gevokizumab|
61962147|NCT00887978|PLACEBO_COMPARATOR|Placebo|Identical placebo tablets to UT-15C, doses were titrated in the same manner
62348142|NCT05415345|EXPERIMENTAL|Group A|Participants in this arm will be simultaneously administrated with HPV and HEV vaccine. The immunization schedule is 0,1,6 months.
62348143|NCT05415345|ACTIVE_COMPARATOR|Group B|Participants in this arm will be administrated with HPV vaccine. The immunization schedule is 0,1,6 months.
61962148|NCT00887978|EXPERIMENTAL|UT-15C SR|Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.
62348144|NCT05415345|ACTIVE_COMPARATOR|Group C|Participants in this arm will be administrated with HEV vaccine. The immunization schedule is 0,1,6 months.
62348145|NCT02999880|EXPERIMENTAL|Polychromatic layering (Control):|Using and mixing different composite shades, opalescents and intensives.
62348146|NCT02999880|NO_INTERVENTION|Dual-shade layering (Intervention):|Only two composite resin material shades the opaque dentin composite and enamel shade composite.
62348147|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
62506143|NCT02518217|EXPERIMENTAL|ShapeUp Empower + Incentives|
62506144|NCT05783856|PLACEBO_COMPARATOR|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline.~The routine treatment regimen at the Bac Ninh Center for Disease Control depends on the type of pathogen tested using multiplex real time PCR assay on day 0, as follows:~Oral administrative medication based on the results of STIs pathogen detection test, antibiotic Clinidamycin (Withus Clinidamycin®) or/and the antifungal drug Itraconazole (Miduc®) are prescribed for 7 days to treat pathogenic bacteria or/and fungi infections, respectively.~Vaginal suppository medication: Canvey®, which contains Metronidazole and Chloramphenicol, is only prescribed for further 7 days in the event that oral treatments of Clindamycin and Itraconazole have been unsuccessful."
62704558|NCT06019182||Carrier|EIF2S3-variant carrier individuals 1-month of age or older.
62704559|NCT06019182||Unaffected Non-carrier|Unaffected individuals 1 month of age or older who are 1st degree relative of an affected individual
61962149|NCT02367183|EXPERIMENTAL|GED-0301 160mg QD 12 WK|GED-0301 160 mg once daily (QD) for 12 weeks
61962150|NCT02367183|EXPERIMENTAL|GED-0301 160 mg QD 8 WK|GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
61962151|NCT02367183|EXPERIMENTAL|GED-0301 160 mg QD 4 WK|GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
61962152|NCT03890601||Biological APS|50 Asymptomatic patients with aPL antibodies and prolonged APTT
61962153|NCT03890601||Obstetrical APS|50 patients with Obstetrical aPL syndrome
61962154|NCT03890601||Thrombosis APS|APS with a personal history of venous or arterial thrombosis (50 patients)
61962155|NCT04673162|EXPERIMENTAL|A SOC plus MP|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Methylprednisolone 1gr daily iv on days 1,2,3
61962156|NCT04673162|ACTIVE_COMPARATOR|B SOC plus Pb|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Placebo
61962157|NCT05415839|ACTIVE_COMPARATOR|Pulsed dye laser|Laser device
61962158|NCT05415839|ACTIVE_COMPARATOR|Fractional CO2|Laser Device
61962159|NCT01952405|EXPERIMENTAL|Dialectical behavior therapy|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
61962160|NCT01952405|PLACEBO_COMPARATOR|alternative psychotherapy|The therapists of the alternative psychotherapy in the comparison group are asked to provide the type and dose of therapy that they believed is most suited to the patient, with a minimum of 1 scheduled individual session per week. Ancillary treatment could be prescribed as needed. Case management strategies are also available in the comparison group (alternative psychotherapy group). No restrictions are placed on ancillary pharmacotherapy in either condition.
61962161|NCT06464068|EXPERIMENTAL|DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE|"All drugs will be administered intravenously. Induction treatment will be administered on a 21-day cycle for four cycles and will consist of:~* etoposide 80-100 mg/m² (administered on days 1-3 of each 21-day cycle);~* investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m² (administered on day 1 of each cycle);~* durvalumab 1500 mg every 3 weeks in combination with chemotherapy (induction phase) followed by maintenance phase with durvalumab 1500 mg every 4 weeks. Patients will continue treatment until disease progression per investigator assessment, unacceptable toxicity, or other discontinuation criteria were met for a maximum of 24 months. Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months."
61962162|NCT05832398|EXPERIMENTAL|Organoid guided chemotherapy|Patients will receive sensitive chemotherapy in organoid drug test once every two weeks for 6 cycles as adjuvant chemotherapy
61962163|NCT05832398|ACTIVE_COMPARATOR|FOLFOX regimen|Patients will receive FOLFOX regimen once every two weeks for 6 cycles as adjuvant chemotherapy
61962164|NCT03539081|EXPERIMENTAL|Subjects with RLS|"Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Subject will have received the standard of care intervention of epidural spinal cord stimulation for pain."
61962165|NCT03539081|OTHER|Subjects without RLS|"Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Subject will have received the standard of care intervention of epidural spinal cord stimulation for pain."
61962166|NCT03539081|OTHER|Continous BP Monitoring|"This arm consists of subjects from arm Subjects with RLS, Subjects without RLS, and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only.~Subject will have received the standard of care intervention of epidural spinal cord stimulation for pain."
61962167|NCT01243892||Cohort 1: IGHD participants|Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid \[DNA\] origin) (recombinant human growth hormone \[rhGH\]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
61962168|NCT01243892||Cohort 2: ISS participants|Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
61962169|NCT05630209|EXPERIMENTAL|Blood Brain Barrier Disruption (BBBD)|Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG
61962170|NCT06501833|EXPERIMENTAL|FIFA 11+ kids program group|
62143909|NCT03259568|EXPERIMENTAL|Dose-response TMS - Intensity = 120%RMT|"Four levels of TMS intensity (here, 120% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
62704560|NCT00044304|EXPERIMENTAL|Imatinib|open label imatinib mesylate treatment
62348148|NCT01610076|NO_INTERVENTION|No Video - Control|"This group does not watch the 10 minute code status video before having the knowledge base video administered."
62348149|NCT01610076|EXPERIMENTAL|Code Status Video|"This group views a 10 minute video about code status prior to knowledge base survey administration"
62539241|NCT01724086|EXPERIMENTAL|Panel 4 - Arm 2|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (60 mg once daily)
62704561|NCT00044304|EXPERIMENTAL|Ruxolitinib|open label ruxolitinib treatment
61962171|NCT06501833|ACTIVE_COMPARATOR|Regular training group|
61962172|NCT01694472|EXPERIMENTAL|MAGE-A4 TCR Gene-Modified T Cells|
61962173|NCT00026663||1/Patients with cancer|Cancer patients providing tissue for research studies
61962174|NCT00026663||2/Normal Volunteers|normal volunteers providing samples for research studies
61962175|NCT00814970|EXPERIMENTAL|Complete SE Vascular Stent System|COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.
61962176|NCT01154764|EXPERIMENTAL|Group 1|Period 1: CG100649 will be administered alone on Day 1 -After washout period- Period 2: The combination of CG100649 and ketoconazole tabs together on Day 1 followed by ketoconzzole tabs
62506145|NCT05783856|EXPERIMENTAL|X-secret|"X-secret group receives the routine treatment and uses NaCl 0.9% plus B. subtilis, B. clausii, and B. coagulans at 5 billion CFU/5 mL (LiveSpo®️ X-secret).~The routine treatment regimen at the Bac Ninh Center for Disease Control depends on the type of pathogen tested using multiplex real time PCR assay on day 0, as follows:~Oral administrative medication based on the results of STIs pathogen detection test, antibiotic Clinidamycin (Withus Clinidamycin®) or/and the antifungal drug Itraconazole (Miduc®) are prescribed for 7 days to treat pathogenic bacteria or/and fungi infections, respectively.~Vaginal suppository medication: Canvey®, which contains Metronidazole and Chloramphenicol, is only prescribed for further 7 days in the event that oral treatments of Clindamycin and Itraconazole have been unsuccessful."
62506146|NCT06059417|OTHER|Foam-tape/Control|"One of the participants upper extremity (arm) was used for intervention and the same participants other arm was used as the control in this study.~There was only 1 research arm in this study and all study participants were in it."
62506147|NCT03860207|EXPERIMENTAL|Hu3F8-BsAb|Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.
62506148|NCT00388934|EXPERIMENTAL|Drug eluting stent (Cypher)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Cypher)
62506149|NCT00388934|EXPERIMENTAL|Drug eluting stent (Taxus)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Taxus)
62506150|NCT02010294||Children hospitalized for invasive GAS infection|Children hospitalized for invasive GAS infection
62506151|NCT02010294||Children with non-invasive infection|Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
62506152|NCT05709769||Training Group|A primary cohort of eligible patients from the cancer center of Zhejiang Provincial People's Hospital is used for developing the radiomics-based nomogram prediction model. In the training cohort, a sample size of 88 was required to accept the hypothesis that the prediction accuracy of the radiomics-based nomogram model was greater than 45% with 90% power and to reject the hypothesis that the prediction accuracy rate was less than 30% with an α error of 5%. Initially, we planned to enroll 77 patients in the first stage. If 27 or more prediction accuracy rates were observed, we planned to continue to the second stage for a total of 88 patients for the analysis. Considering some deviant cases, the preplanned accrual number was set to 100 patients in the training cohort.
62506153|NCT05709769||Validation Group|An independent cohort of eligible patients is used for external validation. we are planning to enroll an additional 50 patients to further validate this radiomics-based nomogram prediction model.
61962177|NCT01154764|EXPERIMENTAL|Group 2|"Period 1: The combination of CG100649 and ketoconazole tabs will be administered together on Day 1, followed by ketoconazole tabs for 4 days, for a total of 5 days.~-After washout period- Period 2: CG100649 alone"
61962178|NCT05083572|EXPERIMENTAL|Group A (Lavage and Vivomixx)|Colonic lavage, followed by Vivomixx treatment
61962179|NCT05083572|EXPERIMENTAL|Group B (Lavage and Placebo)|Colonic lavage, followed by Placebo treatment
61962180|NCT05083572|EXPERIMENTAL|Group C (Vivomixx)|No colonic lavage, only Vivomixx treatment
61962181|NCT05083572|EXPERIMENTAL|Group D (Rifaximin and Vivomixx)|Rifaximin, followed by Vivomixx treatment
61962182|NCT03867292|EXPERIMENTAL|Myofascial|The subjects that include the experimental group will receive an intervention through myofascial therapy of crossed hands and electrotherapy
61962183|NCT03867292|ACTIVE_COMPARATOR|Electrotherapy|The subjects that are included in the experimental group will receive an intervention through electrotherapy
61962184|NCT06046391|EXPERIMENTAL|LP-003 dose 1|Eligible patients randomized to this arm received LP-003 subcutaneously for 8 weeks
61962185|NCT06046391|EXPERIMENTAL|LP-003 dose 2|Eligible patients randomized to this arm received LP-003 subcutaneously for 8 weeks
61962186|NCT06046391|PLACEBO_COMPARATOR|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 8 weeks
61962187|NCT02220205|ACTIVE_COMPARATOR|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
62143910|NCT03807596|ACTIVE_COMPARATOR|SRP group|Chronic periodontitis patients with type 2 diabetes mellitus recieved Periodontal treatment in the form of scaling \& root planing (SRP) alone.
62348150|NCT02071264|OTHER|HIV/STI intervention|This study implements a socio-behavioral intervention in Metro Manila, the Philippines, using a community-based participatory approach with 1-2 psychosocial and health education training workshops for the establishment managers and their workers, including street sex workers, focusing on HIV/AIDS risk reduction information, condom use, and condom negotiation skill-building. Participants participate in dream-building activities to explore personal goals and goals for their organization of peers. The interventions are directed at organizational behavior change and social influence modeling through training peers and managers. The participants receive information on STIs along with standard care, held on a day convenient to the participants and at a neutral location.
62506154|NCT03769831|EXPERIMENTAL|SHR2285|Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
62506155|NCT03769831|EXPERIMENTAL|Placebo|Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.
62539242|NCT03052010|OTHER|PrEP for HIV-1 uninfected partners and ART for HIV-1 infected|Integrated PrEP as a bridge to ART HIV-1 prevention strategy
62539243|NCT06369597|EXPERIMENTAL|Robotic telesurgery|Patients with liver cancer, renal cancer, rectal cancer will be treated by telesurgery.
61962188|NCT02220205|PLACEBO_COMPARATOR|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
62143911|NCT03807596|EXPERIMENTAL|Hyaluronic acid & SRP group|Chronic periodontitis \& type 2 diabetes mellitus patients received Periodontal treatment in the form of scaling \& root planing (SRP) with the adjunctive use of hyaluronic acid.
62143912|NCT00875706|OTHER|Training Feasibility|"4 sites will receive the training intervention to determine the feasibility of the train-the trainer approach.~The educational intervention is included in this arm."
61962189|NCT00064337|EXPERIMENTAL|Treatment|"MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70.~Mobilization and SC Collection:~MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis.~Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection).~Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion \>/= 3.5 x 10\^6 CD34+ cells/kg IV Day 0.~Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year."
62348151|NCT02118857||Omnivore, vegetarian and vegan subjects.|These subjecs followed the diet from at least two years.
62348152|NCT01589510||Lumigan® 0.01%|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
62348153|NCT04268472|EXPERIMENTAL|TR Sequence|In first Intervention period subjects was administered test medecine (GP30101) and in seconde Intervention period subjects was administered reference medecine (Prezista)
62348154|NCT04268472|EXPERIMENTAL|RT Sequence|In first Intervention period subjects was administered reference medecine (Prezista) and in seconde Intervention period subjects was administered test medecine (GP30101)
62348155|NCT01481909|PLACEBO_COMPARATOR|Sugar Pill|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
62348156|NCT01481909|ACTIVE_COMPARATOR|Rupafin|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
62348157|NCT03402152|EXPERIMENTAL|NRX-101 vs. Placebo|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral placebo and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
62348158|NCT03402152|EXPERIMENTAL|NRX-101 vs. lurasidone HCl|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral lurasidone and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
62348159|NCT03859492|EXPERIMENTAL|Intermediate or high-risk breast cancer subjects|Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)
62348160|NCT03849976||Experimental group|Patients accompanied to the operating room by a stretcher bearer trained in therapeutic communication
62348161|NCT03849976||Control group|Patients accompanied to the operating room by a stretcher bearer not trained in therapeutic communication
62348162|NCT06047899|EXPERIMENTAL|Intervention|In the intervention phase we will administer 500 mg luteolin (2x250 mg capsules, e.g. every morning and evening) per day formulated for oral administration for 14.5 days.
62348163|NCT06047899|PLACEBO_COMPARATOR|Placebo|Placebo control intervention consists of identical looking placebo capsules containing mannitol formulated for oral administration to be taken twice daily (e.g. every morning and evening) for 14.5 days.
62348164|NCT00797524||DR|Diabetic Retinopathy
62348165|NCT00797524||ARMD|Age-Related Macular Degeneration
62348166|NCT00797524||ME|Macular Edema
62348167|NCT05457348|EXPERIMENTAL|Group A:experimental group|those who receive planned incisions
62348168|NCT05457348|ACTIVE_COMPARATOR|Group B:Controlled group|the patients who were operated by conventional phacoemulsification
62348169|NCT03263156|EXPERIMENTAL|Intervention group|The intervention will involve two face-to-face consultation sessions and one follow-up phone call with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
62704562|NCT02115282|EXPERIMENTAL|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI at baseline, at the end of cycle 3, every 3 cycles, at treatment discontinuation, and during follow-up, collection of blood samples at baseline and day 15 of cycle 1, and collection of archived tissue at baseline.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
61962190|NCT04925362|OTHER|Patients|Patients with histologically confirmed NAFLD
62348170|NCT03263156|NO_INTERVENTION|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
62539244|NCT06369597|ACTIVE_COMPARATOR|Laparoscopic surgery|Patients with liver cancer, renal cancer, rectal cancer will be treated by laparoscopic surgery.
62539245|NCT05953090|EXPERIMENTAL|Feasibility|
62539246|NCT01758588|NO_INTERVENTION|Observation arm|Subjects will be monitored closely for disease progression, however will receive no intervention.
62348171|NCT04970394||Intervention|"The principal investigator reviews the medical notes of all individuals they consult over a period of three years to check if they are non responders. If confirmed as non responder, they receive a three-step verbal intervention:~1. Your cervical cancer screening is now overdue.~2. The test is easy to perform and saves thousands of lives from cervical cancer every year.~3. Should we book an appointment for cervical screening now so that you make sure you have it done?~   Those who are seen face-to-face receive a fourth intervention:~4. An appointment slip is given to the patient to hand to the receptionist. This includes the patient's name and the comment, book an appointment with practice nurse for cervical screening."
62348172|NCT04970394||Control|The control group receives standard unstructured reminders regarding their overdue status from any of the 6 other clinicians during appointments and / or reminder letters from the administration team.
62348173|NCT01771458|ACTIVE_COMPARATOR|Standard chemotherapy|Treatment choice is based on Investigator decision.
62348174|NCT01771458|EXPERIMENTAL|Personalized treatment|"Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)~Elligible therapies in this trial are :~Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
62348175|NCT01224587|EXPERIMENTAL|1|D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition
62348176|NCT01224587|EXPERIMENTAL|2|D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition
62348177|NCT01224587|EXPERIMENTAL|3|D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition
62348178|NCT01224587|EXPERIMENTAL|4|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition
62348179|NCT01224587|EXPERIMENTAL|5|D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition
62348180|NCT01224587|EXPERIMENTAL|6|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition
62348181|NCT04404010|ACTIVE_COMPARATOR|Immersive Virtual Reality|"Participants randomized to the immersive virtual reality (iVR) study arm, considered the intervention group will receive training on completion of a reverse shoulder arthroplasty using an iVR simulator (PrecisionOS Technology)."
62348182|NCT04404010|OTHER|Surgical Video|"Participants randomized to the standard video study arm, considered the control group will receive training on completion of reverse shoulder arthroplasty using a technical surgical instructional video."
62348183|NCT00718107||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
62348184|NCT05126745||Patients who had an epidural placed for labour|Patients who had an epidural placed for labour may take part. Study procedures will take place after delivery and prior to removal of the epidural catheter.
62348185|NCT04613505||Phase 1: Instrument Development|Parents will be asked to participate in a semi-structured interview with one of the researchers that will explore their attitudes toward day of surgery consent. Particular attention will be given to a) study designs, b) previous research experience, and c) previous medical experiences.
62348186|NCT04613505||Phase 2: Questionnaire Adaptation|Parents will be given approximately 5 minutes to review a questionnaire we developed using participant responses in Phase 1. After reviewing the questionnaire, participants will be asked to participate in a semi-structured interview with one of the investigators.
62348187|NCT04613505||Phase 3: Questionnaire Application & Development of Day of surgery consent Table of Guidelines|Participants will be asked to complete the questionnaire developed in Phase 2.
62348188|NCT04613505||Phase 4: Table of Guidelines Refinement|Participants will be given approximately 5 minutes to review the table of guidelines developed in Phase 3. After reviewing the guidelines, participants will be asked to participate in a semi-structured interview with one of the investigators.
62348189|NCT06241417||renal recovery|Renal recovery was defined as not satisfied by AKI criteria which was defined by KDIGO.
62348190|NCT06241417||non renal recovery|Non renal recovery was defined by presenting at least KDIGO Stage 1 criteria or death.
62348191|NCT06223438||Cognitively normal (CN)|"Participants must have an MMSE score of ≥26 and meet clinical criteria for cognitively normal based on National Institute of Aging (NIA) criteria verified in medical records or clinical assessment at first visit;~● Based on the judgment of the site PI, no evidence of functional decline based on the Functional Activities Questionnaire (FAQ) or equivalent assessment;"
62348192|NCT06223438||Mild Cognitive Impairment (MCI) with known amyloid status.|"Cognitive concern, reflecting a change in cognition reported by the participant, informant (family member, caregiver), or clinician;~* Participants must have an MMSE score of ≥24 and meet clinical criteria for MCI based on National Institute of Aging (NIA) criteria and verified through medical records or clinical evaluation at first visit;~* Based on the judgment of the site PI, minimal to mild functional impairment but with preservation of independence in functional abilities based on the Functional Activities Questionnaire (FAQ) or equivalent assessment;"
62348193|NCT00293423|EXPERIMENTAL|Phase 1: Vaccine|Patients received 25 micrograms of HSPPC-96 bi-weekly or weekly for the first 4 vaccinations followed by biweekly injections.
62348194|NCT00293423|EXPERIMENTAL|Phase 2: Vaccine|Treatment consisted of 25 mcg of HSPPC-96 weekly for at least 4 weeks, followed by biweekly injections (pending vaccine availability) for up to 52 weeks from the date of surgical resection.
62506156|NCT02803086||1|To date, around 700 patients, who were treated with Radiotherapy for Prostate Cancer, have been enrolled. 34% of them underwent radiotherapy with radical intent, whereas the others were post-prostatectomy patients (29% adjuvant, 37% salvage). Various techniques of irradiation were used (1% 3DCRT, 6% SF-IMRT, 52% VMAT, 41% Tomotherapy) in conventional (42%, 1.7-2.0 Gy/fr.) and hypofractionated (58%, 2.1-2.7 Gy/fr.) settings. EQD2(alpha/beta=3) to prescribed PTV ranged between 64 and 93 Gy. Limph nodes were treated in the 98% of cases.
62506157|NCT03164109|EXPERIMENTAL|GC4419 IV|
62506158|NCT03164109|PLACEBO_COMPARATOR|Placebo|
62506159|NCT03164109|ACTIVE_COMPARATOR|Oral moxifloxacin|
62506160|NCT03901157|EXPERIMENTAL|Active yogurt|Contains 120 g yogurt + 60 g oil-gel particles (containing 6 g oil) + 24 g water
62506161|NCT03901157|ACTIVE_COMPARATOR|Control yogurt|Contains 120 g yogurt + 54 g empty gel particles + 6 g oil in 24 g water
62348195|NCT03741725|EXPERIMENTAL|Pay-it-forward|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
62348196|NCT03741725|EXPERIMENTAL|Pay-what-you-want|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
62348197|NCT03741725|NO_INTERVENTION|Standard of care|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing at the standard patient price.
62348198|NCT01539785|ACTIVE_COMPARATOR|Secondary cytoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction.
62348199|NCT01539785|EXPERIMENTAL|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique.
62348200|NCT03689062|ACTIVE_COMPARATOR|conservative group|patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .
62348201|NCT03689062|EXPERIMENTAL|active group|Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.
62348202|NCT02758223|EXPERIMENTAL|Treatment|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
62348203|NCT06356948|ACTIVE_COMPARATOR|Rapid-rate administration of TXA|This group will be administered tranexamic acid over 1 minute
62348204|NCT06356948|ACTIVE_COMPARATOR|Slow-rate administration of TXA|This group will be administered tranexamic acid over 10 minutes
62348205|NCT05308758|EXPERIMENTAL|GameHIIT intervention group|In the GameHIIT group, a specially designed game-based training program with HIIT in nature will be delivered to the participants for 8 weeks.
62348206|NCT05308758|ACTIVE_COMPARATOR|GameSE intervention group|In the GameSAE group, participants will attend a tailor-made game-based exercise training program. Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week.
62348207|NCT05308758|NO_INTERVENTION|Control group|No intervention.
62348208|NCT06045949||living donor liver transplantation in children|
62348209|NCT01244191|EXPERIMENTAL|Tivantinib and erlotinib|Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day
62348210|NCT01244191|ACTIVE_COMPARATOR|Placebo and erlotinib|Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day
62348211|NCT03514069|EXPERIMENTAL|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
62348212|NCT03514069|EXPERIMENTAL|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
62704563|NCT02115282|PLACEBO_COMPARATOR|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI at baseline, at the end of cycle 3, every 3 cycles, at treatment discontinuation, and during follow-up, collection of blood samples at baseline and day 15 of cycle 1, and collection of archived tissue at baseline.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
62704564|NCT00055172||Non-sibling relative|18 years of age or older
62704565|NCT00055172||Patients (index cases)|Patients (index cases), 6 months of age or older
62143913|NCT00875706|OTHER|Data Collection - Survey|Survey data collection tools will be piloted to assess feasibility of survey administration and development of the survey for future studies. This tools were piloted in sites where the educational intervention was administered.
62348213|NCT05796882|EXPERIMENTAL|WFPBD Group|The participants in this group follow a Whole Food Plant-Based Diet for 8 weeks
62348214|NCT05796882|ACTIVE_COMPARATOR|Nutritional Standard Care Group|The participants in this group receive a nutritional consultation every month with dietetic guidance and recommendations about a healthy lifestyle, duration 8 weeks
62348215|NCT06499727|ACTIVE_COMPARATOR|WOMEN - ACETAZOLAMIDE oral capsule|Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
62348216|NCT06499727|ACTIVE_COMPARATOR|MEN - ACETAZOLAMIDE oral capsule|Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
62348217|NCT06499727|PLACEBO_COMPARATOR|WOMEN - PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
62348218|NCT06499727|PLACEBO_COMPARATOR|MEN - PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m.
62539247|NCT01758588|EXPERIMENTAL|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 50 micrograms once a week for up to 3 years.
62704566|NCT00055172||Siblings|Siblings, 6 months of age or older
62704567|NCT03996291|EXPERIMENTAL|SAR442168|"SAR442168 : Experimental - Part A: Double-blind period of continued treatment with the respective SAR442168 dose administered in the DRI15928 study until selection of Phase 3 dose.~Part B: Open-label period of a single-group treatment with SAR442168 selected Phase 3 dose of 60 mg. All participants will be switched to this 60 mg dose."
62704568|NCT04370795|ACTIVE_COMPARATOR|Group 1|Patients will be treated with Total Body Irradiation (TBI)
62704569|NCT04370795|ACTIVE_COMPARATOR|Group 2|Patients will not be treated with Total Body Irradiation (TBI)
61962191|NCT03391180|EXPERIMENTAL|ICON Remineralization|Firstly, Conditioning of the WSL surface by 15% HCL gel (Icon-Etch, DNG) and subsequent application of the drying solution (Icon-Dry, DMG), Numbers of additional etching intervals have been determined by visual assessment after each of the etch/dry intervals to achieve individual, customized intensities of WSL surface conditioning.
61962192|NCT03391180|ACTIVE_COMPARATOR|CPP-ACPF|Participants in group 2 (CPP-ACPF) were treated with applying a pea sized amount of ACC-ACPF plus on a gloved finger of the examiner and rubbed the surface of the labial tooth for 4 minutes with advising the patient to avoid drinking and eating for the next 30 minutes of application.
61962193|NCT05392244||active group|Active PNS was defined as a serum albumin concentration of \<2.5 g/dL and a urinary protein excretion of \>40 mg/m2 per hour with high cholesterol levels.
61962194|NCT05392244||partial remission group|Partial remission PNS was defined as symptoms between active group and complete remission group.
61962195|NCT05392244||complete remission group|PNS in remission was defined as no proteinuria using the colorimetric qualitative test and a urinary protein/creatinine ratio of \<0.2 on a random urine sample.
61962196|NCT02033616|EXPERIMENTAL|AVOVA-1|Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells. AVOVA-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
61962197|NCT02033616|PLACEBO_COMPARATOR|MC|Autologous monocytes will serve as the control arm. MC is admixed with GM-CSF as an adjuvant, prior to injection.
61962198|NCT01465997|EXPERIMENTAL|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
62348219|NCT01071096|ACTIVE_COMPARATOR|OnabotulinumtoxinA|Minimum dose of 155 international units (U) OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
62704570|NCT05328154|OTHER|Bisphosphonates (zoledronic acid, Aclasta® 5 mg) alone|Bisphosphonates are considered as the gold standard of treatment for osteoporosis. Zoledronic acid, Aclasta® 5 mg will be administered intravenously according to standard management criteria in order to obtain an homogeneous population.
62704571|NCT05328154|ACTIVE_COMPARATOR|bisphosphonates (zoledronic acid, Aclasta® 5 mg) associated with magnesium (MAG 2®, 100 mg)|In addition to bisphosphonates, patients in this group will take a 3-month treatment of magnesium (magnesium carbonate, MAG 2® 100 mg), 2 tablets of 100 mg/day, during the 3 months preceding the 1-year visit.
62704572|NCT05657405||Affected|Individuals with known or suspect genetic conditions
62704573|NCT05657405||Family member|Family members of individuals with known or suspected genetic conditions
62704574|NCT03294460|EXPERIMENTAL|1|Alcohol self-administration (IV ethanol for sessions 1 and oral for session 2)
62704575|NCT04069468||TheraSphere®|"Patients with HCC, iCC and mCRC will be treated. TheraSphere is administered in the liver through the hepatic artery. Treatment will be performed according to the Instructions for Use (IFU). Activity of administered TheraSphere is tailored in order to deliver an absorbed dose of 80 to150 gray (Gy) to the liver. Lung dose (D) will be calculated from the following formula: D=A\*(1-S)\*50/1. D=Planned dose absorbed by treated volume(Gy), A=Activity injected with microspheres (gigabequerel \[GBq\]), S=Percentage of pulmonary shunt, 1 assuming that the lung mass=1 kilograms \[kg\]). Number of treatments is up to Investigator's discretion while taking into account the cumulative dose to the liver and lung."
62704576|NCT06161558|EXPERIMENTAL|A|Erlotinib with lenvatinib combination
62348220|NCT01071096|PLACEBO_COMPARATOR|Saline|155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
62348221|NCT02535832|PLACEBO_COMPARATOR|Placebo|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the placebo arm. Participants will take matching placebo throughout the 15 weeks of treatment.
62348222|NCT02535832|ACTIVE_COMPARATOR|Pioglitazone|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
62704577|NCT06161558|EXPERIMENTAL|B|Erlotinib with axitinib combination
62704578|NCT00055055||Healthy Volunteers|A healthy individual who has not used any NSAIDS, with no infectious disease, or severe trauma within 8 weeks of enrollment, doesn't have a first degree relatives with RA, SLE, SSc or IIM
61962199|NCT01465997|ACTIVE_COMPARATOR|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)
61962200|NCT02641808|EXPERIMENTAL|follicular flushing group|Monofollicular IVF therapy with follicular flushing up to five times after aspiration of the follicule at the time to the oocyte pick-up
61962201|NCT02641808|ACTIVE_COMPARATOR|aspiration group|Monofollicular IVF therapy with aspiration only at the time of the oozyte pick-up
61962202|NCT03707782||Individuals with immune deficiencies|aged 18 years or older and have an immune deficiency
62539248|NCT04840537|ACTIVE_COMPARATOR|cytological brushing followed by cholangioscopy in case of failure|
62704579|NCT00055055||Parent of Proband|Biological mother or father of the proband who is willing to enroll in the study
62704580|NCT00055055||Primary Unaffected Dizygous Twin|Dizygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
62704581|NCT00055055||Primary Unaffected Monozygous Twin|Monozygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
62704582|NCT00055055||Primary Unaffected Non-twin Sibling|Sibling of the same biological parents, same gender, within 5 years of age of the proband who does not meet criteria for one of the rheumatic diseases
62704583|NCT00055055||Proband|Proband should have documented evidence that he/she meets criteria for adult and juvenile forms of systemic rheumatic disorders
62704584|NCT06238622|EXPERIMENTAL|BI 1015550 treatment group|
62704585|NCT06287762||Centralized|Visits are conducted at the NIH clinical center. All participants are ambulatory.
62704586|NCT06287762||Decentralized|Visits are conducted via telehealth.
62704587|NCT01132937||Healthy Controls|Accrual Ceiling: 20. Healthy, uninjured, subjects are used to match to those suspected of head injury. 10 subjects have been enrolled to date in the PET arm
62348223|NCT02990455|EXPERIMENTAL|Reduced Nicotine Cigarette - Moderate|Nicotine Research Cigarette Drug Supply Program Category Codes NRC600 and NRC601 (menthol); each cigarette contains 0.8mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
62348224|NCT02990455|EXPERIMENTAL|Reduced Nicotine Cigarette - Low|Nicotine Research Cigarette Drug Supply Program Category Codes NRC102 and NRC103 (menthol); each cigarette contains 0.03mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
62348225|NCT00742807|EXPERIMENTAL|1|Administration of low dose of alfentanil hydrochloride before paracervical block
62348226|NCT00742807|ACTIVE_COMPARATOR|2|Administration of alfentanil hydrochloride dose after paracervical block
62348227|NCT06437145|ACTIVE_COMPARATOR|High intensity interval training (HIIT)|The high-intensity interval training session consists of 5-min warm-up and 5-min cool-down periods. The main part has 7 cycles. Each cycle consists of 1.5 min of 80-90% of HRpeak and 3 min of 65-70% of HRpeak.
62348228|NCT06437145|ACTIVE_COMPARATOR|Moderate intensity continuous training (MICT)|The moderate-intensity continuous training session consists of 5 min warm-up and 3-min cool down period. The main part consists of 32 min of 75% of HRpeak.
62704588|NCT01132937||Suspected of Head Injury|Accrual Ceiling: 1000. Subjects enrolled with 48hrs of suspected head injury in emergency department of local hospitals, Suburban Hospital Center or Washington Hospital Center
62704589|NCT06052618|EXPERIMENTAL|Arm 1|Treatment with pacritinib
62348229|NCT05533255|EXPERIMENTAL|Preheated Resin Composites|Preheated resin composite is placed on the noncarious cervical lesion of a canine/ first premolar/ second premolar/ first molar on either one quadrant of the maxillary arch.
62704590|NCT06322940|EXPERIMENTAL|2-3 servings of regular-fat milk|Milk
61962203|NCT03707782||Family members|aged 18 years or older and are related to a person who has an immune deficiency
62348230|NCT05533255|ACTIVE_COMPARATOR|Conventional Resin Composites|Conventional resin composite is placed on the noncarious cervical lesion of a canine/ first premolar/ second premolar/ first molar on the other quadrant of the maxillary arch.
62704591|NCT06322940|EXPERIMENTAL|2-3 servings of regular-fat yogurt|Yogurt
62704592|NCT06322940|EXPERIMENTAL|2-3 servings of regular-fat cheese|Cheese
62704593|NCT06557772|EXPERIMENTAL|Amlitelimab dose 1 + Gluten-free product (GFP)|Amlitelimab SC as per protocol + GFP
61962204|NCT05089721||Anesthesiologist|
61962205|NCT05089721||Obstetricians|
61962206|NCT04968301||hip developmental dysplasia group|patients with developmental dysplasia of hip
61962207|NCT04968301||femoroacetabular impingement group|patients with femoroacetabular impingement
61962208|NCT04968301||control group|healthy volunteers
61962209|NCT00743340|EXPERIMENTAL|Emtricitabine|Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
62348231|NCT03052439|ACTIVE_COMPARATOR|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
62348232|NCT03052439|ACTIVE_COMPARATOR|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
62348233|NCT03052439|ACTIVE_COMPARATOR|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
62348234|NCT03052439|ACTIVE_COMPARATOR|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
62539249|NCT04840537|EXPERIMENTAL|cholangioscopy from the start|
62704594|NCT06557772|EXPERIMENTAL|Amlitelimab dose 2 + GFP|Amlitelimab SC as per protocol + GFP
62704595|NCT06557772|EXPERIMENTAL|Amlitelimab dose 3 + GFP|Amlitelimab SC as per protocol + GFP
62704596|NCT06557772|EXPERIMENTAL|Amlitelimab dose 1 + SIGE|Amlitelimab SC as per protocol + SIGE
62704597|NCT06557772|PLACEBO_COMPARATOR|Placebo + GFP|Placebo SC as per protocol + GFP
62704598|NCT06557772|PLACEBO_COMPARATOR|Placebo + SIGE|Placebo SC as per protocol + SIGE
62704599|NCT05968430|EXPERIMENTAL|Open-Label Arm|lorundrostat once daily for 36 or 48 weeks depending on when the subject enrolled
62704600|NCT05968430|EXPERIMENTAL|RTW Substudy|"lorundrostat or placebo once daily for 4 weeks starting at week 12, in the double-blind randomized treatment withdrawal substudy~Optional for subjects from the MLS-101-301 parent study only"
62704601|NCT05968430|EXPERIMENTAL|Optional Continuation Period|lorundrostat once daily from weeks 36 or 48 until marketing authorization or early termination of the trial by the sponsor
62704602|NCT06161545|EXPERIMENTAL|Arm 1|N-803 + pembrolizumab
62704603|NCT06161545|EXPERIMENTAL|Arm 2|N-803 + pembrolizumab + PD-L1 t-haNK cells
62704604|NCT06567847|ACTIVE_COMPARATOR|Neurocognitive Enriched Exercise|Individuals with a diagnosis of lateral ankle instability who underwent supervised neurocognitive enriched exercise under the guidance of a physiotherapist for 8 weeks, 2 days a week.
62704605|NCT06567847|ACTIVE_COMPARATOR|Multimodal Exercise|Individuals with a diagnosis of lateral ankle instability who underwent supervised routine exercise under the guidance of a physiotherapist for 8 weeks, 2 days a week.
61962210|NCT02947503|ACTIVE_COMPARATOR|Metformin on top of usual care|"Metformin TEVA 850 mg (1-3 times daily) added to usual care from start of the diagnosis GDM.~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: metformin TEVA 850 mg (1-3 times daily) on top of usual care."
61962211|NCT02947503|NO_INTERVENTION|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: usual care."
61962212|NCT01415284|EXPERIMENTAL|Hydroxyethylstarch 130/0.4|
61962213|NCT05416593|PLACEBO_COMPARATOR|General exercise prescription (FITT)|Exercise group; control; general exercise prescription
61962214|NCT05416593|EXPERIMENTAL|Affective regulation (AFFECT)|Exercise group; experimental; general exercise prescription plus affective response and preferences regulation
61962215|NCT01530061|EXPERIMENTAL|Preschool Children age 4-6 years|Preschool children participate in eating either an egg breakfast or a bagel breakfast.
61962216|NCT01530061|EXPERIMENTAL|Teenagers 14-17 years of age|Teenagers participate in eating either an egg breakfast or a bagel breakfast.
61962217|NCT04776200||Ballet Groups|It was invited the individuals, who were ongoing for at least 3 months in classical ballet dance activity in the dance studio, between December 2019 and March 2020.
61962218|NCT04776200||Control Groups|It was invited the individuals, who have just registered for classical ballet dance activity.
61962219|NCT05884996|EXPERIMENTAL|PNF training|kabat training with elastic bands for 8 weeks 2 times a week before swimming training. 3 series of 10-15 repetitions will be performed
61962220|NCT05884996|NO_INTERVENTION|Control group|swimming training 2 times a week
61962221|NCT05217147||Patient group|60 patients with laryngeal carcinoma
61962222|NCT05217147||Control group|20 healthy age- and sex- matched controls
61962223|NCT03539536|EXPERIMENTAL|Telisotuzumab vedotin|Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.
62348235|NCT03052439|ACTIVE_COMPARATOR|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
62348236|NCT00505895|EXPERIMENTAL|Fludarabine + Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m\^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).~Melphalan 140 mg/m\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 IV infused starting on day -5."
62348237|NCT00505895|EXPERIMENTAL|Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m\^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).~Lower-Dose Melphalan 100 mg/m\^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\^2 intravenous infused starting on day -5."
62348238|NCT02697630|EXPERIMENTAL|Pembrolizumab and Entinostat|
62348239|NCT05997186|OTHER|Surgery|Oral cavity and oropharyngeal defect reconstruction
61962224|NCT04010487||Endometrial carcinoma arising in adenomyosis|Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
61962225|NCT04010487||Adenomyosis without malignancy|Patients pathologically diagnosed with adenomyosis
61962226|NCT05914298||HME group|"204 children and adult patients with HME, admitted to our Hospital for diagnosis and treatment.~the patients will be stratified by age in four subgroups:~* subgroup I (0-7 Years)~* subgroup II (8-12 Years)~* subgroup III (13-18 Years)~* subgroup IV (\>18 Years)"
61962227|NCT05914298||healty control group|204 children and adult voluntary healty controls will be stratified in the same manner and matched with the population in study in order to assess normal and pathologic growth.
61962228|NCT06091267|EXPERIMENTAL|ASTX727 and IV Decitabine|Cycle1：ASTX727 tablets, oral, 1 tablet/day for 5 days；Cycle2：IV Decitabine, 20 mg/m\^2, is administered for 1 hour at a time for 5 days；≥ Cycle 3：ASTX727 tablets, oral, 1 tablet/day for 5 days
62704606|NCT04431024||Cancer patients|Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS
62704607|NCT04431024||Relatives of cancer patients|First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)
61962229|NCT06091267|ACTIVE_COMPARATOR|IV Decitabine and ASTX727|Cycle1：IV Decitabine, 20 mg/m\^2, is administered for 1 hour at a time for 5 days； Cycle2：ASTX727 tablets, oral, 1 tablet/day for 5 days；≥ Cycle 3：ASTX727 tablets, oral, 1 tablet/day for 5 days
61962230|NCT06091267|EXPERIMENTAL|ASTX727|ASTX727 tablets, oral, 1 tablet/day for 5 days；
61962231|NCT01850875|EXPERIMENTAL|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
61962232|NCT01850875|NO_INTERVENTION|Treatment as usual (control group)|treatment as usual
61962233|NCT00662805||Salmeterol/Fluticasone propionate (50/500 μg)|Open label, 6 visits, single arm study
61962234|NCT04819074||Patients with unruptured brain aneurysms|"We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.~No intervention."
61962235|NCT04061213||Patients with symptomatic severe aortic stenosis|Elderly patients referred for TAVR evaluation
61962236|NCT01352910|EXPERIMENTAL|effective rTMS|
61962237|NCT01352910|SHAM_COMPARATOR|Sham rTMS|
61962238|NCT00934310||Ambulatory Surgical Patients 1|"The nature of the operating room time out for ambulatory surgical patients will be examined before implementation of the World Health Organization's Surgical Safety Checklist."
61962239|NCT00934310||Ambulatory Surgical Patients 2|"The nature of the operating room time out for ambulatory surgical patients will be examined after implementation of the World Health Organization's Surgical Safety Checklist.Ambulatory surgical patients"
61962240|NCT04031391|EXPERIMENTAL|physical activity group|
61962241|NCT04031391|NO_INTERVENTION|Control group|
61962242|NCT01235351|ACTIVE_COMPARATOR|Clopidogrel - for CYP2C19*2 carriers|Clopidogrel for CYP2C19\*2 gene carriers
61962243|NCT01235351|ACTIVE_COMPARATOR|Clopidogrel - for CYP2C19*2 non-carriers|Clopidogrel for CYP2C19\*2 gene NON-carriers
61962244|NCT01929460|OTHER|Drug (Standard group)|"Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.~Ciprofloxacin 500mg by mouth twice a day for three days."
61962245|NCT01929460|PLACEBO_COMPARATOR|Intervention group|"Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration~Oral Placebo, one cap twice a day for three days."
61962246|NCT03119584|ACTIVE_COMPARATOR|1)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
61962247|NCT03119584|ACTIVE_COMPARATOR|2)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
62348240|NCT03919968|EXPERIMENTAL|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
62348241|NCT03919968|ACTIVE_COMPARATOR|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
62348242|NCT05576480|EXPERIMENTAL|SCRT sequential Penpulimab in combination with CAPEOX|"* Short-course radiotherapy (SCRT) + one dose of immunotherapy in week 1：Radiotherapy once daily at 5Gy, D1-D5 (5×5Gy); Penpulimab, 200mg, intravenous for 60±5min, D6 or D7.~* Rest at week 2, 4 cycles of chemotherapy (CAPEOX) + immunotherapy from week 3 in cycles of 3 weeks: Capecitabine, 1000 mg/m2 orally, administered twice daily, D1-D14 per cycle; Oxaliplatin, 135 mg/m2, intravenous \>2h, administered every cycle D1; Penpulimab, 200 mg, administered intravenously for 60 ± 5 min every cycle D1.~* Clinical re-staging assessment at the end of neoadjuvant therapy allows for a watch-and-wait strategy if cCR is achieved. If any residual lesions remained, radical rectal cancer surgery would be performed at least 2 weeks after the last dose of capecitabine. Whether post-operative adjuvant treatment is performed and the option of post-operative adjuvant treatment is decided by the investigator."
62506162|NCT01363011|EXPERIMENTAL|E/C/F/TDF (Cohort 1)|"Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country."
62506163|NCT01363011|EXPERIMENTAL|COBI+PI+2 NRTI (Cohort 2)|"Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country."
62506164|NCT05122351|EXPERIMENTAL|Group of Bupivacaine infiltration at the Quadratus Lumborum muscle|Patients will receive Quadratus Lumborum Block by infiltration of Bupivacaine as post operative analgesia in Open Inguinal Hernia surgery
62704608|NCT06312137|EXPERIMENTAL|Pembrolizumab + Sacituzumab tirumotecan|Participants will receive pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by sacituzumab tirumotecan 4 mg/kg IV infusion every 2 weeks (Q2W) for up to 20 doses (\~40 weeks) with pembrolizumab monotherapy 200 mg IV infusion every 6 weeks (Q6W) for up to 7 cycles (\~42 weeks).
62704609|NCT06312137|ACTIVE_COMPARATOR|Pembrolizumab|Participants will receive pembrolizumab 200 mg intravenous (IV) infusion Q3W for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by pembrolizumab monotherapy 200 mg IV infusion Q6W for up to 7 cycles (\~42 weeks).
62704610|NCT06052631||Healthy controls|Healthy participants
61962248|NCT02102906|EXPERIMENTAL|TMS treatment|Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
62348243|NCT00502320|EXPERIMENTAL|Ramelteon|8 mg
62348244|NCT00502320|PLACEBO_COMPARATOR|Placebo|
61962249|NCT05769439||NTS iT2D-dTwin case-co-twin-control cohort|The twin pairs discordant for incident type 2 diabetes (iT2D) \[17 monozygotic (MZ) and 20 dizygotic twin pairs (DZ)\] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iT2D while his co-twin did not or develop iT2D at least one year later.
62143914|NCT00875706|OTHER|Data Collection - Interview|Interview data collection tools will be piloted to assess feasibility of interview administration and development of the interview protocol for future studies. This tools were piloted in sites where the educational intervention was administered.
62348245|NCT02133742|EXPERIMENTAL|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
62348246|NCT05739760|EXPERIMENTAL|"Families assigned the Cuddle and Calm booklet"|A poem about emotional expression in times of upset
62348247|NCT05739760|EXPERIMENTAL|"Families assigned the Health and Safety booklet"|A poem about health and safety with tips on topics such as first aid and injury prevention
62348248|NCT04521335|EXPERIMENTAL|Treatment: all patients|disulfiram and copper gluconate in combination
62348249|NCT02833220||Healthy volunteers|"* Healthy adults between the ages of 18-65 are eligible.~* Participants will receive non-invasive brain stimulation by way of single-pulse transcranial magnetic stimulation to the motor cortex"
62348250|NCT02289274|EXPERIMENTAL|NVP-1203|NVP-1203
62348251|NCT02289274|ACTIVE_COMPARATOR|Eperisone SR tab. + and Airtal tab.|Eperisone HCl and aceclofenac
61962250|NCT05769439||NTS iOB-dTwin case-co-twin-control cohort|The twin pairs discordant for incident obesity (iOB) \[11 monozygotic (MZ) and 15 dizygotic twin pairs (DZ)\] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iOB while his co-twin did not or develop iOB at least one year later.
62348252|NCT05497895|EXPERIMENTAL|Group I (SRP and TQ gel)|In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application
61962251|NCT04080401|EXPERIMENTAL|Fun-Knee Mobile Application|Participants will use a mobile application paired to a knee sleeve with embedded inclinometer sensors. The sensor system will compute knee movement, and feed towards game-based rehabilitation exercises for Total Knee Arthroplasty rehabilitation. game-based and supported on mobile device running on Android or Inter-network Operating System platforms. The mobile apps is able to capture the angle and position data from the two inclinometers on smart knee sleeve.
62506165|NCT05122351|EXPERIMENTAL|Group of paracetamol injection|Patients will receive post operative 1 gm paracetamol injection as analgesia in Open Inguinal Hernia surgery
62506166|NCT02523794|EXPERIMENTAL|Electro-kinetically Modified Water|Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months
62506167|NCT02523794|PLACEBO_COMPARATOR|Placebo|Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months
62506168|NCT03978416|NO_INTERVENTION|Focus groups|"Information on practical and cultural barriers and promoters of successful weight management will be collected through focus groups. This will include include food access, dietary patterns, physical activity, time and financial constraints, and additional psychosocial and cultural factors.~A total of 30 participants will be recruited for the focus groups."
62506169|NCT03978416|EXPERIMENTAL|Pilot behavioral intervention|A prototype bilingual English-Spanish lifestyle intervention for weight reduction will be created. The prototype will then be iteratively refined during a series of short-term tests with 5 participants per test (two tests lasting 4 weeks, followed by a final test lasting 12 weeks) of intervention delivery.
62506170|NCT04583696|EXPERIMENTAL|Walnut Consumption of Healthy Volunteers|
62704611|NCT06052631||PIEZO2 Deficiency Syndrome (PDS)|Participants with a diagnosis of PIEZO2 Deficiency Syndrome; an inherited mutation in the PIEZO2 gene
61962252|NCT04080401|ACTIVE_COMPARATOR|Conventional Exercise Brochures|Participants will be guided to do their Total Knee Arthroplasty rehabilitation exercises using conventional, paper-based exercise brochures.
61962253|NCT05501301||Immune tolerance cohort|"Patients that are enrolled into this cohort will receive IS minimization if virus infection or side effects of IS was found. The strategy of IS minimization will follow the Clinical guidelines for pediatric liver transplantation in China(2015). Blood test and liver biopsy will be conducted to monitor liver function and intrahepatic pathological conditions. If IS is ceased for more than one year without liver dysfunction or signs of acute rejection in liver biopsy, immune tolerance was considered reached."
62348253|NCT05497895|PLACEBO_COMPARATOR|Group II (SRP and Placebo)|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
62348254|NCT05497895|ACTIVE_COMPARATOR|Group III (Only SRP and one stage prophylaxis)|The Group III patients will be subjected to one-stage oral prophylaxis.
62348255|NCT00517335||1|Women who are healthy controls
62348256|NCT00517335||2|Women who have recovered from bulimia
62704612|NCT04402788|ACTIVE_COMPARATOR|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.
62348257|NCT00517335||3|Women who have recovered from anorexia
62348258|NCT02486211|PLACEBO_COMPARATOR|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
62348259|NCT02486211|EXPERIMENTAL|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
62348260|NCT05186909|EXPERIMENTAL|CM310 300mg Q2W|CM310 is injected subcutaneously (SC) with a loading dose of 600 mg at the first dose, and then 300 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
62348261|NCT05186909|EXPERIMENTAL|CM310 150mg Q2W|CM310 is injected subcutaneously (SC) with a loading dose of 300 mg at the first dose, and then 150 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
62506171|NCT01505361|EXPERIMENTAL|Probiotic|Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)
62506172|NCT01505361|PLACEBO_COMPARATOR|Placebo|Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)
62506173|NCT04645940|EXPERIMENTAL|Fed/Fasted|fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
62506174|NCT04645940|EXPERIMENTAL|Fasted/Fed|fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
62506175|NCT04836351|EXPERIMENTAL|Concentrated rehabilitation|3+ 1-2 day concentrated rehabilitation for patients with persistent symptoms post COVID-19.
62506176|NCT00668096|PLACEBO_COMPARATOR|Arm 2|
62704613|NCT04402788|EXPERIMENTAL|Arm II (atezolizumab, radiation therapy)|Patients receive atezolizumab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy QD on days 1-5 during weeks 1-5 only. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.
62704614|NCT05382559|EXPERIMENTAL|ASP3082 Dose Escalation (Monotherapy Part 1)|Participants will receive ASP3082 in a 21-day cycle.
62704615|NCT05382559|EXPERIMENTAL|ASP3082 Dose Expansion (Monotherapy Part 2)|Participants will receive ASP3082 with dose level(s) selected from dose escalation (part 1) in a 21-day cycle.
61962254|NCT01749137|EXPERIMENTAL|Setmelanotide|Participants received 1 milligram (mg) setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.
62348262|NCT05186909|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 12 doses.
62348263|NCT04242238|EXPERIMENTAL|Advanced High-grade Sarcoma|Dose Escalation: Up to 18 pts with locally advanced or metastatic high-grade sarcomas Dose Expansion: 10 pts per each diagnosis - undifferentiated pleomorphic sarcoma or myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated liposarcoma
62348264|NCT04644549||Subjects with CLN6 Batten disease|
62348265|NCT04644549||Subjects with juvenile CLN3 Batten disease|
62348266|NCT05456152|EXPERIMENTAL|Sublingual zolpidem|1 sublingual tablet (5mg) 30 minutes before bed time during 60 days.
62348267|NCT05304000|ACTIVE_COMPARATOR|Mindfulness Meditation|5 minutes a day of mindfulness meditation practice for 28 days (passive attention to breath) delivered remotely through a video link.
62348268|NCT05304000|EXPERIMENTAL|Cyclic Sighing Breathing|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of slow inhales until lungs felt full then one more inhale to maximally fill the lungs, followed up a slow exhale. Repeat this cycle for 5 minutes.
62348269|NCT05304000|EXPERIMENTAL|Box Breathing|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of equal duration of inhale, hold, exhale, hold cycles. The duration of the cycle is determined by the participant's comfort level with holding. (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold). Repeat this cycle for 5 minutes.
62348270|NCT05304000|EXPERIMENTAL|Cyclic Hyperventilation with Retention|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of 30 breaths (inhale deeply through the nose and exhale passively through the mouth) and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds. Repeat this cycle for 5 minutes.
62348271|NCT01330563|EXPERIMENTAL|CKD-501|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
62348272|NCT01330563|EXPERIMENTAL|ketoconazole|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
62704616|NCT05382559|EXPERIMENTAL|ASP3082 + Cetuximab Dose Escalation (Combination Therapy Part 1)|Participants will receive ASP3082 in a 21-day cycle. Cetuximab will be administered weekly.
61962255|NCT01749137|PLACEBO_COMPARATOR|Placebo|Participants received placebo matching setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.
61962256|NCT02467868|EXPERIMENTAL|MYL-1401H|MYL-1401H
61962257|NCT02467868|ACTIVE_COMPARATOR|Neulasta|Neulasta
61962258|NCT00653744|EXPERIMENTAL|1|Rosuvastatin
61962259|NCT00653744|ACTIVE_COMPARATOR|2|Atorvastatin
61962260|NCT06431087|EXPERIMENTAL|"Mindfulnes Healthy Under Stress Stress Management Program"|Participants will have two-hour sessions for 8 weeks.
61962261|NCT00471328|EXPERIMENTAL|Nilotinib|400mg twice daily in core and extension phases of the study.
61962262|NCT00471328|ACTIVE_COMPARATOR|Control/cross-over to Nilotinib|"In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm.~Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression."
61962263|NCT04177160|EXPERIMENTAL|SCD subjects|Patients were diagnosed with subjective cognition decline and referred by neurologists.
62348273|NCT05657704|NO_INTERVENTION|Tramadol|Patients treated with Tramadol, 100 mg every 8 hours according to clinical practice for the treatment of postoperative pain.
62506177|NCT00668096|EXPERIMENTAL|Arm 1|
62506178|NCT05187741|EXPERIMENTAL|Daily message group|This group would be receiving text messages intended to improve treatment adherence and text reminders for appointments to improve care retention.
61962264|NCT04177160|EXPERIMENTAL|Healthy controls|Voluntary healthy elderly recruited from the community.
61962265|NCT03240302|ACTIVE_COMPARATOR|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte using a standard ICSI petri dish.
61962266|NCT03240302|ACTIVE_COMPARATOR|PICSI Procedure|The PICSI procedure is based on a selection of mature spermatozoa with CD44 receptors and their injection into the oocyte using the PICSI petri dish that has been coated with hyaluronic acid on its bottom.
61962267|NCT02559921|EXPERIMENTAL|rhRIG（20 IU/kg）only|Subjects received rhRIG（20 IU/kg） on day 0
61962268|NCT02559921|EXPERIMENTAL|rhRIG（40 IU/kg）only|Subjects received rhRIG（40 IU/kg） on day 0
62348274|NCT05657704|NO_INTERVENTION|Dexketoprofen|Patients treated with Dexketoprofen 25 mg every 8 hours according to clinical practice for the treatment of postoperative pain.
62348275|NCT05657704|EXPERIMENTAL|Experimental Group|"The patients in this group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype.~Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours"
62506179|NCT05187741|NO_INTERVENTION|Control group|This group would be just observed through the same period as the intervention group but the participants will only receive the standard care provide by the clinic.
62704617|NCT05382559|EXPERIMENTAL|ASP3082 + Cetuximab Dose Expansion (Combination Therapy Part 2)|Participants will receive ASP3082 or ASP3082 + Cetuximab with dose level(s) selected from dose escalation (part 1) in a 21-day cycle. Cetuximab will be administered weekly.
62704618|NCT05382559|EXPERIMENTAL|ASP3082 China Safety Cohort|Participants will receive ASP3082 with dose level selected from dose escalation (Monotherapy part 1) in a 21-day cycle.
62704619|NCT05382559|EXPERIMENTAL|Treatment naive PDAC cohort ASP3082 + FOLFIRINOX|Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with FOLFIRINOX (leucovorin \[LV\]/fluorouracil \[5-FU\]/irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.
62704620|NCT05382559|EXPERIMENTAL|Treatment naive PDAC cohort ASP3082 + Nab-Paclitaxel + Gemcitabine|Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with Nab-P + GEM (nanoparticle albumin-bound-paclitaxel plus gemcitabine) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.
62704621|NCT06344130|EXPERIMENTAL|1/Arm 1|Fraction size escalation of 3 planned re-irradiation dose levels.
62704622|NCT06344130|EXPERIMENTAL|2/Arm 2|MTD of re-irradiation dose.
62704623|NCT06312176|EXPERIMENTAL|Arm A: Sacituzumab tirumotecan|Participants receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation.
62704624|NCT06312176|EXPERIMENTAL|Arm B:Pembrolizumab + Sacituzumab tirumotecan|Participants receive 4 mg/kg of sacituzumab tirumotecan Q2W via IV infusion until progressive disease or discontinuation PLUS 400 mg of pembrolizumab once every 6 weeks (Q6W) via IV infusion for up to 18 administrations (up to \~2 years).
62348276|NCT04958304||Moderna COVID-19 Vaccine in Pregnant Women|The Moderna COVID-19 Vaccine Pregnancy Registry will collect primary data from pregnant women who have received the Moderna COVID-19 vaccine and their healthcare providers (HCPs).
62348277|NCT05688319|EXPERIMENTAL|experimental group|The participants in the experimental group were divided into five groups of eight participants each according to the number of days they visited the center. The training was conducted face to face in the meeting room of the special education and rehabilitation center. Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks . The duration of each training session was 60-90 minutes. The weekly training sessions for all the experimental groups were completed on the same day.
62348278|NCT05688319|NO_INTERVENTION|control group|The control group did not receive any training, and there was no interaction between the experimental group and the control group during the training period.
62704625|NCT06312176|ACTIVE_COMPARATOR|Arm C: Treatment of Physician's Choice (TPC)|At the physician's discretion, participants receive chemotherapy of 80 mg/m\^2 of paclitaxel once every week (Q1W) via IV infusion OR 90 mg/m\^2 of paclitaxel once every 4 weeks (Q4W) via IV infusion OR 100 mg/m\^2 of nab-paclitaxel Q4W via IV infusion OR 1000 mg/m\^2 of capecitabine every 3 weeks (Q3W) orally OR 50 mg/m\^2 of liposomal doxorubicin once every 4 weeks (Q4W) via IV infusion, until progressive disease or discontinuation.
62704626|NCT06517654|ACTIVE_COMPARATOR|Group 1: EMG-Biofeedback|In this group, pelvic floor strengthening training will be conducted with EMG-Biofeedback 2 days a week, and patients will follow a home exercise program 5 days a week. The Neurotrac® Simplex device will be used for EMG-Biofeedback. The EMG reference electrode will be placed on the patient's forearm, while two adhesive electrodes will be placed on the perineal muscles. Patients will contract and relax their pelvic floor muscles at 5-second intervals, guided by visual and auditory stimuli on the device or computer screen. Sessions will last 25 minutes, twice a week, for 8 weeks in a clinical environment. Treatment will include visual imagery for better engagement. Scores (%), and the lowest and highest EMG values (mV) will be recorded. Home exercises will be demonstrated by a physiotherapist, to be practiced 5 days a week. Patients will be instructed to report any pain during exercises to the physiotherapist.
62704627|NCT06517654|ACTIVE_COMPARATOR|Group 2: Rebound Therapy|In this group, rebound therapy will be performed on a trampoline, along with pelvic floor strengthening training, twice a week. Patients will also follow the home exercise program given to the first group, practicing it 5 days a week. For rebound therapy, a trampoline-based exercise program targeting pelvic floor muscles will be conducted in a clinical setting for 8 weeks, 2 days a week, with 20-minute sessions. Proper breathing patterns will be taught before starting. During rest periods, O2 saturation and maximum heart rate will be monitored. Maximum heart rate will be calculated (HRmax = 208 - 0.7 × age), and exercises will pause if it exceeds 80%. Patients will contract pelvic floor muscles during exercises, with posture corrections provided as needed. Exercise intensity will be progressively increased for adaptation. Home exercises will be demonstrated by a physiotherapist, to be practiced 5 days a week. Patients must report any pain during exercises to the physiotherapist.
62704628|NCT06517654|ACTIVE_COMPARATOR|Group 3: Home Exercise Group|Home exercise program will be taught to patients in a practical way with the physiotherapist and patients will be asked to practice at home 5 days a week. If the patient feels any pain during the exercises, they will be informed that they must report the situation to the physiotherapist.
62704629|NCT04616326|EXPERIMENTAL|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
61962269|NCT02559921|ACTIVE_COMPARATOR|HRIG（20 IU/kg）only|Subjects received HRIG（20 IU/kg）on day 0
61962270|NCT02559921|EXPERIMENTAL|rhRIG（20 IU/kg）+ vaccine|Subjects received rhRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
62348279|NCT05956587|EXPERIMENTAL|Study treatment|Participants received SI-B003 and BL-B01D1+SI-B003 in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
62348280|NCT03287245|EXPERIMENTAL|Idasanutlin|Two cohorts of ruxolitinib-naïve and ruxolitinib-resitant or intolerant participants will be enrolled to receive idasanutlin once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years).
62348281|NCT02952703|ACTIVE_COMPARATOR|First Breath|brief pre-natal smoking cessation counseling
62348282|NCT02952703|EXPERIMENTAL|Striving to Quit|Additional pre-natal counseling (in-person and telephonic); post delivery counseling (in-person and telephonic) and incentives
62704630|NCT04616326|PLACEBO_COMPARATOR|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
62143915|NCT06227988||patients with liver disease who undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
62704631|NCT06354257|EXPERIMENTAL|Study Group|Participants will receive Ethinyl Estradiol (EE) and Levonorgestrel (LNG) on Day 1 followed by GSK3036656 dose level (DL) 1 on Day 4, then GSK3036656 DL 2 daily from Day 5 to Day 14, followed by EE/LNG + GSK3036656 DL 2 on Day 15 and then GSK3036656 DL 2 daily from Day 16 to Day 17. Participants will be followed-up until Day 18 inclusive.
62704632|NCT04267848|ACTIVE_COMPARATOR|Arm A (platinum doublet, observation)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then undergo observation.~Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial.~(CLOSED AS OF UPDATE #7)"
62704633|NCT04267848|EXPERIMENTAL|Arm B (platinum doublet, sequential pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens\* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.~Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial."
62348283|NCT03862742||Patients admitted to the hospital|We will recruit patient volunteers from the Scripps Green Hospital and Scripps Memorial Hospital inpatient teaching services.
62704634|NCT04267848|EXPERIMENTAL|Arm C (platinum doublet, combination pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens\* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.~Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo a MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial."
62704635|NCT06373731|EXPERIMENTAL|Elamipretide|Subjects will receive once daily subcutaneous doses of 40mg elamipretide for 96 weeks
62704636|NCT06373731|PLACEBO_COMPARATOR|Placebo|Subjects will receive once daily subcutaneous doses of placebo for 96 weeks
62704637|NCT05715125|PLACEBO_COMPARATOR|Placebo|
62704638|NCT05715125|EXPERIMENTAL|VTX958 Dose A|
62704639|NCT05715125|EXPERIMENTAL|VTX958 Dose B|
62704640|NCT05102019|EXPERIMENTAL|Arm 1 (treatment arm):Implantation of the Reducer device|
62704641|NCT05102019|SHAM_COMPARATOR|Arm 2 (sham-control arm): Control (no device implantation)|
62704642|NCT05102019|OTHER|Arm 3 (unblinded, non-randomized): Single Arm Registry|
62704643|NCT04444921|ACTIVE_COMPARATOR|Arm A (carboplatin, paclitaxel)|Patients receive paclitaxel IV on days 1, 8, and 15 of each cycle, and carboplatin IV on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62348284|NCT00380276|OTHER|Open Label Arm|Treatment is open-label
62704644|NCT04444921|EXPERIMENTAL|Arm B (carboplatin, paclitaxel, nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 of cycle 1 and then on day 1 only of subsequent cycles, paclitaxel IV on days 1, 8, and 15 of each cycle, and carboplatin on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles for carboplatin and paclitaxel, and up to 2 years for nivolumab in the absence of disease progression or unacceptable toxicity.
62704645|NCT06203834|PLACEBO_COMPARATOR|placebo|Placebo 200g, without any ingredients of inulin fiber. Eat 200g for once, and once a day.
62704646|NCT06203834|EXPERIMENTAL|I-Fiber Pearl|I-Fiber Pearl 200g, with inulin fiber. Eat 200g for once, and once a day.
62704647|NCT04971109|ACTIVE_COMPARATOR|TPOXX|Treatment Group 1: An oral dose of 600 mg (3 x 200 mg capsules)TPOXX
62704648|NCT04971109|PLACEBO_COMPARATOR|TPOXX Placebo|Treatment Group 2: An oral dose of placebo (3 capsules identical to TPOXX)
61962271|NCT02559921|EXPERIMENTAL|rhRIG（40 IU/kg）+ vaccine|Subjects received rhRIG（40 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
61962272|NCT02559921|EXPERIMENTAL|HRIG（20 IU/kg）+ vaccine|Subjects received HRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
62348285|NCT03563456|EXPERIMENTAL|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
62348286|NCT03563456|ACTIVE_COMPARATOR|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
62704649|NCT06274632|EXPERIMENTAL|ADELANTE|Participants will receive 5, individualized problem solving sessions delivered by a community health worker over 6 months. The intervention content is framed around a bi-lingual film about HIV.
61962273|NCT02559921|PLACEBO_COMPARATOR|placebo + vaccine|Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
62348287|NCT05931913|EXPERIMENTAL|ERP+iTBS|Participants will receive two weeks (10 sessions) of intermittent theta burst stimulation (iTBS; a form of TMS) targeting the dorsolateral prefrontal cortex (dlPFC), followed immediately by Exposure Plus Response Prevention (ERP).
62348288|NCT05931913|EXPERIMENTAL|ERP+cTBS|Participants will receive two weeks (10 sessions) of continuous theta burst stimulation (cTBS; a form of TMS) targeting the presupplementary motor area (pSMA), followed immediately by Exposure Plus Response Prevention (ERP).
62348289|NCT05931913|ACTIVE_COMPARATOR|ERP+Sham|"Participants will receive two weeks (10 sessions) of sham (fake) TMS, followed immediately by Exposure Plus Response Prevention (ERP)."
62348290|NCT00234208|EXPERIMENTAL|Medical thoracoscopy|
62348291|NCT00234208|ACTIVE_COMPARATOR|Simple chest tube drainage|
62348292|NCT06371339|OTHER|Patients with hyperthyroidism treated and monitored according to the standard practices.|
62348293|NCT01705964|EXPERIMENTAL|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
62348294|NCT01705964|SHAM_COMPARATOR|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
62348295|NCT05293574|EXPERIMENTAL|norethisterone acetate group|". In the norethisterone acetate group, the women will receive of norethisterone acetate 5 mg twice daily and are counseled about how to take norethisterone acetate and informed of possible side effects. They also receive a diary card for recording norethisterone acetate intake to be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography.~If there is no remission occurred another month of Norethisterone acetate will be given ."
62348296|NCT05293574|NO_INTERVENTION|expectant managment group|
62348297|NCT02823678||Pancreatectomy|Patients scheduled to undergo a pancreatectomy
62348298|NCT00141557|EXPERIMENTAL|1|
62348299|NCT00141557|ACTIVE_COMPARATOR|2|
62348300|NCT05591794|EXPERIMENTAL|Study group|The women in the study group will be asked to walk for 30 minutes/5 days or 50 minutes/3 days a week while performing a diet program for eight weeks and aerobic and resistance exercise program 3 days a week.
62348301|NCT05591794|ACTIVE_COMPARATOR|Control group|The women in the control group will be asked to walk for 30 minutes/5 days or 50 minutes/3 days a week while performing a diet program.
62348302|NCT05061394||Second division football players|Players competing in the third best league in Denmark
62348303|NCT05061394||"Danmarkserien football players"|Players competing in the fourth best league in Denmark
62348304|NCT00676793|EXPERIMENTAL|Polyphenon E|This is a single arm study comparing changes within patients before and after receiving the experimental drug Polyphenon E for the duration of the study, between recruitment and surgery for breast cancer.
62348305|NCT03276013|EXPERIMENTAL|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
62348306|NCT04599049|OTHER|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
62348307|NCT03513250|EXPERIMENTAL|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
62506180|NCT04380545|EXPERIMENTAL|Treatment (fluorouracil, interferon alpha 2b, nivolumab)|Patients receive fluorouracil IV continuously on days 1-7 and 15-21 and recombinant interferon alpha 2b-like protein SC on days 1, 3, 5, 15, 17, and 19. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 3, patients receive nivolumab IV over 30 minutes on day 1, fluorouracil IV continuously on days 1-7 and 15-21, and recombinant interferon alpha 2b-like protein interferon alpha 2b SC on days 1, 3, 5, 15, 17, and 19. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62506181|NCT03088852|ACTIVE_COMPARATOR|Experimental group|After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
62506182|NCT03088852|NO_INTERVENTION|Control group|control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
62506183|NCT01877902||Pemetrexed 500 mg/m 2|
62506184|NCT05494502|EXPERIMENTAL|Erector spinae plane block group|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
62506185|NCT05494502|SHAM_COMPARATOR|Control group|General anesthesia alone.
62506186|NCT06474481|EXPERIMENTAL|Treatment arm|"Induction: Zanubrutinib and G-CHOP 4-6cycles~Maintenance: Zanubrutinib and Obinutuzumab 1 year"
62506187|NCT01249014|NO_INTERVENTION|Control|No peri-operative warming.
62506188|NCT01249014|EXPERIMENTAL|Warmed fluids|Patients will receive warmed i.v. fluids administered pre- and intra-operatively.
62506189|NCT01249014|EXPERIMENTAL|Warmed fluids and warm air|Patients will receive warmed i.v. fluids administered pre- and intra-operatively, and warmed air blown into a blanket covering the body intra-operatively.
62506190|NCT01839695|EXPERIMENTAL|Valiant Mona LSA Stent Graft System|TEVAR procedure using Medtronic Stent Graft
62704650|NCT06274632|NO_INTERVENTION|Enhanced Care Condition|Participants in the enhanced care control group will receive 5 locator phone calls confirming contact information at the same interval as CHW sessions in the ADELANTE group. They will be offered routine HIV health promotion materials as is available in the clinic. If a participant requests support for navigation or case management, they will be encouraged to contact their HIV team
62704651|NCT05268276|EXPERIMENTAL|study group|"the study group will recelve adesigned protocol of care that entails three interventions as the following1) Application of ice gel pad on perineal trauma for the first 24 hours post partum 2) Performance of pelvic floor exercises (Kegel exercises) from six hours till one week postpartum 3) Application of warm compresses after 48 hours and through the first week postpartum.~The investigator will perform demonstration and then redemonstration by the women on each intervention will be done. A designed booklet (developed previously) that explains each intervention will be given to each woman."
62704652|NCT05268276|NO_INTERVENTION|control group|The control group will receive the routine hospital care only
62704653|NCT06429956|EXPERIMENTAL|Order 1 (mindful emotion awareness + cognitive flexibility)|Participants will receive 6 therapy sessions starting with 3 sessions of mindful emotion awareness followed by 3 sessions of cognitive flexibility. Each session will have a duration of approximately 1 hour. Treatment will follow the UP manual by Barlow et al. (2018).
61962274|NCT04254705|OTHER|Subjects with CF and R334W mutation|Subjects with CF and R334W mutation
62704654|NCT06429956|EXPERIMENTAL|Order 2 (cognitive flexibility + mindful emotion awareness)|Participants will receive 6 therapy sessions starting with 3 sessions of cognitive flexibility followed by 3 sessions of mindful emotion awareness. Each session will have a duration of approximately 1 hour. Treatment will follow the UP manual by Barlow et al. (2018).
61962275|NCT02837601|OTHER|LOW AIS Pressure AirSeal®|AIS with an insufflation pressure target of 9mmHg ±1mmHg
61962276|NCT02837601|OTHER|HIGH AIS Pressure AirSeal®|AIS with an insufflation pressure target of 15mmHg ±1mm
62348308|NCT03513250|PLACEBO_COMPARATOR|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
62348309|NCT05729425||Observational (microvessel ultrasound imaging)|Patients undergo microvessel ultrasound imaging on study.
62704655|NCT06500702|EXPERIMENTAL|Frexalimab|Frexalimab active dose
62704656|NCT06500702|EXPERIMENTAL|SAR442970|SAR442970 active dose
62704657|NCT06500702|EXPERIMENTAL|Rilzabrutinib|Rilzabrutinib active dose
61962277|NCT03640130|EXPERIMENTAL|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
61962278|NCT05767645|EXPERIMENTAL|Mistral device|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
61962279|NCT02008201|EXPERIMENTAL|Vitamin D dose 1|Vitamin D dose 1
61962280|NCT02008201|EXPERIMENTAL|Vitamin D dose 2|Vitamin D dose 2
61962281|NCT02008201|EXPERIMENTAL|Vitamin D dose 3|Vitamin D dose 3
61962282|NCT02008201|NO_INTERVENTION|observational|No dose
61962283|NCT06088732|EXPERIMENTAL|Session 1|Exercise (30 min on bicycle ergometer at 60% peak power output) and a single oral dose 800mg of ibuprofen
61962284|NCT06088732|ACTIVE_COMPARATOR|Session 2|Exercise (30 min on bicycle ergometer at 60% peak power output) and matching placebo
62348310|NCT05972044|EXPERIMENTAL|Solriamfetol 150 mg|Up to 6 weeks
62704658|NCT06500702|PLACEBO_COMPARATOR|Placebo|Matching placebo
62704659|NCT06445023|EXPERIMENTAL|barzolvolimab 150 mg|barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks
61962285|NCT06088732|ACTIVE_COMPARATOR|Session 3|30 minutes rest (sitting in chair) and a single oral dose 800mg of ibuprofen
61962286|NCT06088732|PLACEBO_COMPARATOR|Session 4|30 minutes rest (sitting in chair) and matching placebo
61962287|NCT01385566|ACTIVE_COMPARATOR|Full Dose Subcutaneous|Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
61962288|NCT01385566|EXPERIMENTAL|1/3 Dose Subcutaneous|Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
62348311|NCT05972044|EXPERIMENTAL|Solriamfetol 300 mg|Up to 6 weeks
62348312|NCT05972044|PLACEBO_COMPARATOR|Placebo|Up to 6 weeks
62348313|NCT00694629|ACTIVE_COMPARATOR|1|rifampin, isoniazid, pyrazinamide, ethambutol
62348314|NCT00694629|EXPERIMENTAL|2|rifapentine 10 mg/kg, isoniazid, pyrazinamide, ethambutol
62348315|NCT00694629|EXPERIMENTAL|3|rifapentine 15 mg/kg, isoniazid, pyrazinamide, ethambutol
62348316|NCT00694629|EXPERIMENTAL|4|rifapentine 20 mg/kg, isoniazid, pyrazinamide, ethambutol
62348317|NCT01889628|OTHER|Chinese ethnicity|Three nutritional formulae (Isocal, Protinex and Diasip) and liquid glucose
62704660|NCT06445023|EXPERIMENTAL|barzolvolimab 300 mg|barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks
62704661|NCT06445023|EXPERIMENTAL|Placebo then barzolvolimab 150 mg|Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.
62704662|NCT06445023|EXPERIMENTAL|Placebo then barzolvolimab 300 mg|Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.
62704663|NCT06504394|EXPERIMENTAL|Pembrolizumab Coformulated With Hyaluronidase|Participants with rrCHL and rrPMBCL receive pembrolizumab coformulated with hyaluronidase subcutaneous (SC) injection on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (approximately 2 years) until documented disease progression per investigator assessment.
62704664|NCT02286089|EXPERIMENTAL|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
62704665|NCT05604547|OTHER|1|Single-arm study
62348318|NCT01889628|OTHER|Malay ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
62539250|NCT00999427|EXPERIMENTAL|A|The randomly selected group of subjects who will receive the intervention. The radiologist performing the transrectal prostate biopsy on these subjects will have a gauze soaked with Povidone-iodine over his/her index finger, and will insert this into the rectum. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin to the other. This will be allowed to dry for 2 minutes before proceeding with the biopsy.
62704666|NCT02473445|EXPERIMENTAL|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
62348319|NCT01889628|OTHER|Indian Ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
62348320|NCT00318565|EXPERIMENTAL|Navistar ThermoCool Catheter|
62348321|NCT03428685|ACTIVE_COMPARATOR|Intervention group|
62348322|NCT03428685|PLACEBO_COMPARATOR|Placebo group|
62348323|NCT00537264|EXPERIMENTAL|Computer|Health-related quality of life questionnaires will be administered using a computerised multimedia touchscreen system.
62348324|NCT00537264|EXPERIMENTAL|Interviewer|Health-related quality of life questionnaire will be administered via face-to-face interviews.
62348325|NCT03495817|EXPERIMENTAL|ATI-50002 Topical Solution|"This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia.~Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks."
62348326|NCT05552118|EXPERIMENTAL|Cochlear™ Remote care|Is composed of Cochlear™ Remote Check and Cochlear™ Remote Assist.
62348327|NCT05552118|ACTIVE_COMPARATOR|Standard of care|Routine In-clinic care
62348328|NCT03728712||Never smokers|Participants with no history of cigarette smoking
62348329|NCT03728712||Active smokers|Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
62348330|NCT02488525|EXPERIMENTAL|Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
62348331|NCT02488525|NO_INTERVENTION|Control|The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®
62704667|NCT04459468||HCC for Lipiodol TACE, denovo ablation, or Y90 radioembolization|These patients will receive standard of care Lipiodol TACE, denovo ablation, or Y90 radioembolization treatment. No research intervention is planned.
62704668|NCT04459468||Healthy controls|Healthy controls from public database
62704669|NCT04459468||HCC patients|HCC patients will be used for biomarker validation.
62704670|NCT06589440|EXPERIMENTAL|MSS-CRC subject with no active liver metastases|
62704671|NCT06589440|EXPERIMENTAL|MSS-CRC subject with active liver metastases|
62704672|NCT03717753|NO_INTERVENTION|Before Group|We plan to have 70 patients studied prior to initiation of a pathway.
62704673|NCT03717753|EXPERIMENTAL|After Group|We plan to have 70 patients studied after initiation of a pathway.
62348332|NCT01830816|EXPERIMENTAL|Normal Renal Function: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
62348333|NCT01830816|EXPERIMENTAL|Severe Renal Impairment: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
62348334|NCT01830816|EXPERIMENTAL|End-stage Renal Disease: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
62348335|NCT01654042|NO_INTERVENTION|Standard interval between PT testing|Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
62348336|NCT01654042|EXPERIMENTAL|Prolonged interval between PT testing|Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
62348337|NCT01811355|ACTIVE_COMPARATOR|Mexiletine|Mexiletine, capsule, 150mg, PO BID, 14 days
62348338|NCT01811355|PLACEBO_COMPARATOR|Placebo|Placebo, capsule, PO BID, 14 days
62348339|NCT01853436|EXPERIMENTAL|Single stage reconstructions|as defined for use in the Experimental arm
62348340|NCT01853436|OTHER|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
62348341|NCT05101395||Patients with Gastritis|Patients who underwent sleeve gastrectomy and the histopathology result of resected gastric specimen showed the presence of gastritis in it.
62348342|NCT03235817|EXPERIMENTAL|Spontaneous ventilation|
62348343|NCT03235817|EXPERIMENTAL|Pressure support ventilation|
62348344|NCT03235817|ACTIVE_COMPARATOR|Pressure control ventilation|
62539251|NCT00999427|NO_INTERVENTION|B|The randomly selected group of subjects who will receive the standard of care biopsy without any added intervention.
62539252|NCT01279083|EXPERIMENTAL|Concentration 1|
62539253|NCT01279083|EXPERIMENTAL|Concentration 2|
62539254|NCT01279083|EXPERIMENTAL|Concentration 3|
62704674|NCT06652503|EXPERIMENTAL|Intervention Group|The coaching program will consist of (6) free, 60 minute online coaching sessions. You will be assigned the same coach for the 6 weeks. You can coordinate schedule day/time preferences as the sessions will be done through HIPAA Zoom. Everyone in the study will get the same coaching topics in the same order.
62704675|NCT06652503|NO_INTERVENTION|Waitlist Group|Waitlist, no intervention group
62704676|NCT03988621|EXPERIMENTAL|Intervention|Caregivers randomized to the intervention ViCCY received 10 sessions of virtual health coaching by trained health coaches over 6 months with content based on the theoretical framework (the Transactional Model of Stress and Coping) and prior research. In addition, they received the same health information as that provided to the caregivers in the control arm. Sessions were provided through tablets. We helped caregivers gain the knowledge and skills needed to achieve self-identified health goals through self-care using motivational interviewing. We focused on identifying personal values, solving problems, and transforming goals into action. ViCCY was standardized in a treatment manual. Because stress does not affect all people equally, the intervention was tailored to individual appraisals and the factors most likely to influence demand and perceived burden.
62704677|NCT03988621|NO_INTERVENTION|Control|The control group received Health Information (HI) delivered through the internet.
62348345|NCT01396239|EXPERIMENTAL|AVI-4658 (Eteplirsen)|"1. 50 mg/kg eteplirsen for 28 weeks~2. 30 mg/kg eteplirsen for 28 weeks"
62704678|NCT03484819|EXPERIMENTAL|Treatment (copanlisib hydrochloride, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62704679|NCT06592703|EXPERIMENTAL|Patient|repeated allogenic ASCs IT injections
62348346|NCT01396239|PLACEBO_COMPARATOR|Placebo / Delayed Treatment|"3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.~3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks."
62348347|NCT05743751|ACTIVE_COMPARATOR|Hypothermic machine perfusion|After organ acquisition, the donor kidney was trimmed, and then the donor kidney was connected to the cryoperfusion machine (lifeport, which has been used in routine clinical practice in our hospital) for continuous low temperature mechanical perfusion (\<8 ℃). The perfusion solution was extracted for proteomic study at 10 min after perfusion and at the end of perfusion.
62704680|NCT04592211|EXPERIMENTAL|olaparib+pembrolizumab+paclitaxel|olaparib+pembrolizumab+paclitaxel
62348348|NCT05743751|EXPERIMENTAL|Normothermic machine perfusion|After conventional UW perfusion is obtained, the marginal donor kidney is immediately perfused without ischemia at normal temperature. The perfusion time is at least 4 hours (so as to repair the marginal donor kidney). The perfusion solution is as above, and the perfusion solution is loaded into the device authorized in Europe (XVIVO - KidneyAssist ®）， Connect the transplanted renal artery with the device. Take 5ml perfusion solution in advance before perfusion, 5ml perfusion solution every 30min after perfusion, take perfusion solution at the end of perfusion (blood gas analysis for each perfusion solution, and finally perfusion solution for culture), and measure urine volume every hour. After perfusion, the transplanted kidney was disconnected from the perfusion device, and the donor kidney was perfused again with 2L HTK solution, followed by routine transplantation.
62348349|NCT00789191|EXPERIMENTAL|Comb|Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
62348350|NCT00789191|ACTIVE_COMPARATOR|Sita|Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment
62348351|NCT00003077|EXPERIMENTAL|Omega-3 fatty acid|"Patients receive omega-3 fatty acids orally in two equal doses with/after breakfast and lunch for 4 months or until weight loss is observed.~Dose is escalated in cohorts of two patients, although dose escalation is allowed in individual patients. Patients are evaluated for cachexia response every 2 weeks, and tumor response every 4 weeks for a maximum of 4 months. If no response of cachexia or tumor after a 2 month period, patients will be discontinued from study. Patients will be followed for survival post-treatment."
62348352|NCT04090437|ACTIVE_COMPARATOR|Group1 - PVI first step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~* PVI as first step~* Remap to assess any change in activation~* Ablate all rotors (API) in LA until SR or DCCV~* Deployment of RA CTI line and demonstration of bidirectional block"
62348353|NCT04090437|ACTIVE_COMPARATOR|Group2 - PVI last step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~* Ablate all rotors (API) in LA until SR or DCCV~* Remap to assess any change in activation~* PVI as last step even when SR achieved earlier~* Deployment of RA CTI line and demonstration of bidirectional block"
62539255|NCT01279083|EXPERIMENTAL|Concentration 4|
62539256|NCT01279083|PLACEBO_COMPARATOR|Vehicle Solution|
62704681|NCT06602453|EXPERIMENTAL|Part 1: GDC-8264|Participants will receive GDC-8264 as per a pre-defined dosing regimen in Part 1.
62704682|NCT06602453|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive GDC-8264 matching placebo as per a pre-defined dosing regimen in Part 1.
62704683|NCT06602453|EXPERIMENTAL|Part 2: GDC-8264|Participants will receive GDC-8264 as per a pre-defined dosing regimen in Part 2.
62704684|NCT06602453|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive GDC-8264 matching placebo as per a pre-defined dosing regimen in Part 1.
62704685|NCT06586112|EXPERIMENTAL|ESK-001|ESK-001 administered as an oral tablet
62704686|NCT06586112|PLACEBO_COMPARATOR|Placebo|Matching oral placebo
62704687|NCT06586112|ACTIVE_COMPARATOR|Apremilast|Apremilast administered as an oral capsule
62704688|NCT06591455|EXPERIMENTAL|fenofibrate|fenofibrate 200mg/day
62704689|NCT06591455|ACTIVE_COMPARATOR|UDCA|UDCA 13-15mg/kg/day
62704690|NCT05698745||Cohort A (preclinical IBD)|asymptomatic patients with a new diagnosis of IBD during the colorectal cancer screening programme meeting all inclusion and none of the exclusion criteria (n=350).
62704691|NCT05698745||Cohort B (control)|new-onset symptomatic IBD (n=80) - patients with a symptomatic debut of IBD in the last 3 months, naïve to immunosuppressants and biologic agents.
61962289|NCT01385566|EXPERIMENTAL|Full Dose Intradermal|Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
62506191|NCT00981799|EXPERIMENTAL|Nelarabine Dose Level 1|The study will begin at Dose Level 1 at 480 mg/m2 Nelarabine (75% of single agent maximum tolerated dose) and 330 mg/m2 Cyclophospamide and will escalate to the next Dose Level if the maximum tolerated dose (MTD) is not exceeded. The first 3 patients will be enrolled into Dose Level 1. If 0/3 experiences dose limiting toxicity (DLT) at a given dose level, then the dose is escalated to the next higher level and 3 more patients are enrolled. If 1/3 experiences DLT at current dose, the up to 3 more patients are accrued at the same dose level. If 2 or more DLTs are observed in a 3-patient or 6-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to 3 additional patients will be enrolled at the next lower dose level (unless 6 patients have already been treated at that prior dose). If the MTD is exceeded at Dose Level 0, the study will be closed.
61962290|NCT01385566|EXPERIMENTAL|1/3 Dose Intradermal|Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
61962291|NCT01385566|EXPERIMENTAL|1/10 Dose Intradermal|Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
61962292|NCT01385566|EXPERIMENTAL|1/27 Dose Intradermal|Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
61962293|NCT04388189|EXPERIMENTAL|Duloxetine|Duloxetine 60 mg daily for 8 weeks
61962294|NCT04388189|ACTIVE_COMPARATOR|Bupropion|Bupropion 150-450 mg daily for 8 weeks
62506192|NCT00981799|EXPERIMENTAL|Nelarabine Dose Level 2|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 330 mg/m2 Cyclophosphamide.
61962295|NCT03922503|EXPERIMENTAL|Advanced- platelets rich fibrin with DFDBA|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
62348354|NCT05541484|OTHER|Group A: Usual care followed by usual care plus dapagliflozin|10 persons with T1D will check capillary beta hydroxybutyrate (BOHB) and concomitant breath acetone (BrAce) 2 - 3 times daily for 2 weeks during usual care, then undergo an insulin withdrawal visit. Subsequently, the Group A patients will repeat the paired measurements of BOHB and BrAce, 2 - 3 times daily for 2 weeks during usual care plus treatment with the SGLT2i dapagliflozin, 10 mg taken orally daily, followed by an insulin withdrawal visit.
62348355|NCT05541484|OTHER|Group B: Usual care plus dapagliflozin followed by usual care|10 persons with T1D will check capillary beta hydroxybutyrate (BOHB) and concomitant breath acetone (BrAce) 2 - 3 times daily for 2 weeks during usual care plus treatment with the SGLT2i dapagliflozin, 10 mg taken orally daily, then undergo an insulin withdrawal visit. Subsequently, the Group B patients will repeat the paired measurements of BOHB and BrAce, 2 - 3 times daily during usual care alone followed by an insulin withdrawal visit.
62348356|NCT00556192|ACTIVE_COMPARATOR|1|Rituximab
62348357|NCT00556192|ACTIVE_COMPARATOR|2|Rituximab + Cyclophosphamide
62348358|NCT00556192|ACTIVE_COMPARATOR|3|Cyclophosphamide
62348359|NCT03347812||Endovascular Aortic Repair|Patients with aortic arch lesions who only received endovascular treatment, including chimney / fenestration / branch stent-grafts technique and combination of these techniques, would be assigned to this group.
62348360|NCT03347812||Total Arch Replacement|Patients with aortic arch lesions who only received traditional open surgery for total aortic arch replacement, would be assigned to this group.
62348361|NCT01108562|PLACEBO_COMPARATOR|Control Group|Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
62348362|NCT01108562|EXPERIMENTAL|Lidocaine Group|Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
62348363|NCT02853032|ACTIVE_COMPARATOR|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
62348364|NCT02853032|PLACEBO_COMPARATOR|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
62348365|NCT06530238|EXPERIMENTAL|Group (A)|Russian current
62506193|NCT00981799|EXPERIMENTAL|Nelarabine Dose Level 3|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 400 mg/m2 Cyclophosphamide
62506194|NCT00981799|EXPERIMENTAL|Nelarabine Dose Level 0|Patients in this arm will be administered Nelarabine 325 mg/m2 (50% of single agent MTD) and 330 mg/2 Cyclophosphamide. Patients will only enter this arm if the MTD at Dose Level 1 has been exceeded. If the MTD is exceeded at Dose Level 0, the study will be closed.
62506195|NCT04810169||Smart inhaler|Children with smart inhaler
62506196|NCT01563458|EXPERIMENTAL|High dose|
62506197|NCT01563458|EXPERIMENTAL|Low dose|
62506198|NCT01563458|PLACEBO_COMPARATOR|Placebo|
62506199|NCT04688372||Inpatient encounters with COVID-19 present-on-admission|See Study description above
62539257|NCT01279083|ACTIVE_COMPARATOR|Timolol Maleate Ophthalmic Solution|
62704692|NCT05698745||Cohort C (control)|healthy controls (n=20): patients with a normal screening colonoscopy, with no signs of IBD after a detailed evaluation of the ileum and colon, will be included.
62704693|NCT06603246|EXPERIMENTAL|GDC-6988|Participants in cohort 1 will receive low dose GDC-6988 twice a day (BID) on Day 1 followed by high dose BID on Day 2. Participants in cohort 2 will receive high dose GDC-6988 BID for 14 days. Participants in Cohorts 3 and 4 will receive low dose GDC-6988 BID for 14-days.
62704694|NCT06660355|EXPERIMENTAL|Ruxolitinib Treatment Arm|Ruxolitinib is administered as 10 mg orally twice daily in 28-day cycles.
62704695|NCT06660355|ACTIVE_COMPARATOR|Prednisone Treatment Arm|Prednisone will be started at 1mg/kg/day based on patient current body weight in kilograms.
62704696|NCT06661304|EXPERIMENTAL|BRE|
62704697|NCT06661304|ACTIVE_COMPARATOR|Control|
62704698|NCT06660667|EXPERIMENTAL|Part I - SAR402663 open-label (OL)|Participants will receive a single dose of SAR402663 on Day 1. Multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants.
62704699|NCT06660667|EXPERIMENTAL|Part II - SAR402663 Dose A|Participants will receive a single dose of SAR402663 on Day 1.
62704700|NCT06660667|EXPERIMENTAL|Part II - SAR402663 Dose B|Participants will receive a single dose of SAR402663 on Day 1.
62704701|NCT06587204|OTHER|Control Group|Participants in this group will be receiving the standard of care for up to 3 months.
62704702|NCT06587204|EXPERIMENTAL|Decentralized Group|Participants in this group will be receiving the decentralized intervention for up to 3 months.
62704703|NCT06587204|EXPERIMENTAL|Digital Literacy Navigation Group|Participants in this group will be receiving the Digital Literacy Navigation intervention for up to 3 months.
62704704|NCT06587204|EXPERIMENTAL|Social Care Navigation Group|Participants in this group will be receiving the Social Care Navigation intervention for up to 3 months.
62704705|NCT06660342||Exposed Cohort|Pregnant women who are exposed to vonoprazan during pregnancy.
62704706|NCT06660342||Unexposed Cohort|Pregnant women who are not exposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.
62704707|NCT06662383|EXPERIMENTAL|Retatrutide|Participants will receive retatrutide administered subcutaneously (SC)
62704708|NCT06662383|ACTIVE_COMPARATOR|Tirzepatide|Participants will receive tirzepatide administered SC
62704709|NCT06606847|EXPERIMENTAL|Arm 1|durvalumab plus oleclumab as an IV infusions
62704710|NCT06603818|EXPERIMENTAL|Arm 1|Atezolizumab and tiragolumab IV every 3 weeks cycle plus SBRT on Days 1, 3, and 5 of Cycle 1
62704711|NCT06663072|EXPERIMENTAL|Safety-Run In|Safety and tolerability data of the combination treatment from the first 6 patients who complete at least 28 days of safety follow-up after the first dose of combination treatment. If no significant safety issues are identified the study will proceed to Arm 2 (dose expansion).
62704712|NCT06663072|EXPERIMENTAL|Dose-Expansion|Stage 2 will enroll an additional 13 patients for dose expansion. Fulvestrant and 177Lu-DOTATATE will be given at doses 500 mg IM and 7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV.
62704713|NCT06065345|EXPERIMENTAL|BRight DCB|Single arm study. All subjects will be treated with the BRight DCB
62704714|NCT03604991|EXPERIMENTAL|Arm A (carboplatin, paclitaxel, radiation therapy)|Patients receive carboplatin IV and paclitaxel IV once weekly and undergo radiation therapy QD (Monday-Friday) beginning on day 1 of each cycle. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or PET scan during screening and follow-up and undergo collection of blood samples throughout the trial.
62704715|NCT03604991|EXPERIMENTAL|Arm B (carboplatin, paclitaxel, radiation therapy, nivolumab)|Patients receive carboplatin, paclitaxel, and radiation therapy as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or PET scan during screening and follow-up and undergo collection of blood samples throughout the trial.
62704716|NCT03604991|EXPERIMENTAL|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan and collection of blood samples throughout the trial.
62704717|NCT03604991|EXPERIMENTAL|Arm D (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm C and receive ipilimumab IV over 90 minutes on day 1 of cycles 1 and 4 and day 15 of cycles 2 and 5. Treatment repeats every 4 weeks for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan and collection of blood samples throughout the trial.
62704718|NCT06608849||Comparators|Comparators without medical history of acute infection by SARS-CoV-2.
62704719|NCT06608849||Participants with NO dysfunction|Patients fully recovered by acute COVID-19 who did not present any acute organ injury during acute infection by SARS-CoV-2.
62704720|NCT06608849||Participants with Dysfunctions|Patients who presented signs of lung, heart, and kidney dysfunction during acute infection by SARS-CoV-2.
62704721|NCT04823689|SHAM_COMPARATOR|Dorsal decubitus|The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.
62704722|NCT04823689|EXPERIMENTAL|Ventral decubitus|The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula.
62704723|NCT06589804|ACTIVE_COMPARATOR|Arm 1 (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT or MRI throughout the trial and optionally undergo blood sample collection on study and at disease progression or end of treatment.
62506200|NCT06193187|EXPERIMENTAL|Sequence 1: TRTR|According to the randomization table, subjects will be randomly assigned to the Sequence 1: Test (T)-Reference (R)-Test (T)-Reference (R) for Period 1,2,3 and 4, respectively. The washout period between doses will be at least 7 days.
62506201|NCT06193187|EXPERIMENTAL|Sequence 2: RTRT|According to the randomization table, subjects will be randomly assigned to the Sequence 2: Reference (R)-Test (T)-Reference (R)-Test (T) for Period 1,2,3 and 4, respectively. The washout period between doses will be at least 7 days.
62506202|NCT04035382|EXPERIMENTAL|Labor Induction|Induction of labor between 39 0/7 to 39 6/7 weeks. Cervical ripening and induction method will be left to the managing clinician. However, combination method of cervical ripening with prostaglandin or oxytocin and Foley catheter, followed by oxytocin infusion and amniotomy will be encouraged.
62506203|NCT01782287|EXPERIMENTAL|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
62506204|NCT01782287|ACTIVE_COMPARATOR|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
62506205|NCT06136416|EXPERIMENTAL|Patients with Non-dystrophic myotonias|
62506206|NCT03716635|EXPERIMENTAL|cryotherapy|2.5c cold saline as a final flush after chemicomechanical debridement
62506207|NCT03716635|OTHER|normal saline|room temperature saline is used as a final flush after chemicomechanical preparation
62143916|NCT06227988||patients with liver disease who do not undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
62143917|NCT03154775|EXPERIMENTAL|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
62506208|NCT02244424|EXPERIMENTAL|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
62506209|NCT02244424|NO_INTERVENTION|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
62506210|NCT04087317|EXPERIMENTAL|Fixed time interval group.|Patients received oral 1-gram paracetamol and 400 milligram ibuprofen every 6 hours, in the first 24 hours postpartum. After 24 hours postpartum and until discharge, they will receive analgesics at maternal request. At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
62506211|NCT04087317|EXPERIMENTAL|'On-demand' group.|Patients received oral 1-gram paracetamol and 400 milligram ibuprofen at maternal request. At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
62506212|NCT06441903||Adults with no history of pectoralis major|
62506213|NCT01540292|EXPERIMENTAL|MSC|Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.
62506214|NCT02036801||ARDS|Patients with ARDS (according to the Berlin Definition criteria) in mechanical ventilation
62506215|NCT02036801||Healthy control|Patients with healthy lung supported with mechanical ventilation for clinical purposes
62506216|NCT00224484|EXPERIMENTAL|GD2-AS04 GROUP|Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
61962296|NCT03922503|ACTIVE_COMPARATOR|Collagen membrane and DFDBA|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
61962297|NCT02031354|EXPERIMENTAL|Lysine Chloride|
62143918|NCT05655000|EXPERIMENTAL|Neonatal thymus transplantation|Supermicrosurgical technique for neonatal thymus transplantation into the subject's radial forearm. The donor will be a neonate subject to corrective heart surgery via sternotomy requiring routinary partial thymectomy.
62143919|NCT03736980|EXPERIMENTAL|Psilocybin Group 1|Group 1: randomized, placebo-controlled, double-blind, cross-over design
62348366|NCT06530238|ACTIVE_COMPARATOR|Group (B)|Exercise
62506217|NCT00224484|ACTIVE_COMPARATOR|HAVRIX GROUP|Female subjects aged 10-17 years, who received 3 doses of Havrix, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
62704724|NCT06589804|EXPERIMENTAL|Arm 2 (cetuximab, pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day -14 prior to cycle 1 and then on days 1, 15 and 29 of each cycle and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT or MRI throughout the trial and optionally undergo blood sample collection on study and at disease progression or end of treatment.
62704725|NCT06592768|PLACEBO_COMPARATOR|Placebo|
62143920|NCT03736980|EXPERIMENTAL|Psilocybin Group 2|Group 2: randomized, placebo-controlled, double-blind, cross-over design
62348367|NCT04437173|EXPERIMENTAL|Virtual Reality Arm|Patients undergo interventional pain procedure with virtual reality distraction
62348368|NCT04437173|NO_INTERVENTION|No Intervention Arm|Patients undergo interventional pain procedure without virtual reality distraction
62348369|NCT01503580|EXPERIMENTAL|antimuscarinic drug|
62348370|NCT02521298|ACTIVE_COMPARATOR|Strength Training + Placebo|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Placebo: Ultrasound-guided subcutaneous injection of 2 ml isotonic saline over the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
62348371|NCT02521298|EXPERIMENTAL|Strength Training + Cortico-Steroid Inj.|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Cortico-Steroid Injection: Ultrasound-guided injection of 1 ml depomedrol 40 mg/ml + 1 ml lidocaine 10 mg/ml deep to the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
62348372|NCT02521298|EXPERIMENTAL|Strength Training + Dry Needling|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Dry Needling: Ultrasound-guided penetration of the proximal part of the common extensor tendon origin is repeated 10 times using a 0,8 mm needle, followed by subcutaneous injection of 2 ml isotonic saline superficial to the tendon. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
62348373|NCT04343209||Individuals with confirmed or suspected cardiovascular disease|Individuals in this group will undergo myocardial perfusion imaging, utilizing Ammonia N-13 PET imaging agent. Each individual will receive two intravenous injections of Ammonia N-13 in accordance with site imaging protocol.
62348374|NCT02146248|EXPERIMENTAL|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
62348375|NCT03617029|EXPERIMENTAL|Microcoil|Needle localization for deep-seated lung nodules with microcoil placement
62348376|NCT03617029|ACTIVE_COMPARATOR|Contrast|Needle localization for deep-seated lung nodules with contrast injection
62348377|NCT01947959||Rivaroxaban|Patients who have been prescribed Rivaroxaban for the first time
62348378|NCT01947959||Standard of care|Patients who have been prescribed Standard of care for the first time
62348379|NCT03117530|EXPERIMENTAL|Minocycline|
62348380|NCT00562653||1|infective endocarditis patients before treatment
62348381|NCT00562653||2|infective endocarditis treatment after treatment
62348382|NCT00562653||3|control
62348383|NCT04297826|EXPERIMENTAL|Harvest for Health|The study is a gardening intervention among 150 older cancer survivors and individuals living with chronic disease (cardiovascular disease and diabetes) in the states of Alabama and Mississippi. This program focuses on 15 counties where a Community Health Advisor training program is in place (Bullock, Calhoun, Dallas Madison, Marengo, Monroe, Sumter, Talladega, Walker Counties in Alabama and Boliver, Granada, Humphrey, Panola, Sunflower, and Yazoo Counties in Mississippi). Participants are paired with Cooperative Extension certified Master Gardeners to plant a vegetable garden at their place of residence (the intervention). Baseline, midpoint, and 1 year follow up will occur. Previous pilot work provides an established relationship with the Cooperative Extension as well as training mechanisms for the Master Gardeners.
62348384|NCT01793519|ACTIVE_COMPARATOR|Anti-tumor necrosis factor agent|Anti-TNF agent - etanercept, infliximab, adalimumab - administered parentally at standard dosage and frequencies
62348385|NCT01793519|PLACEBO_COMPARATOR|Placebo|Administered appropriately to active comparator
62348386|NCT02658344|EXPERIMENTAL|Jointstem|Autologous Adipose Tissue derived MSCs
62348387|NCT02658344|PLACEBO_COMPARATOR|Saline solution|Sodium chloride
62348388|NCT05393076|EXPERIMENTAL|Cohort 1 (Moderate hepatic impairment participants)|Eligible participants to receive single dose of linerixibat.
62348389|NCT05393076|EXPERIMENTAL|Cohort 2 (Matched healthy control participants)|Eligible participants to receive single dose of linerixibat
62704726|NCT06592768|EXPERIMENTAL|Briquilimab|
62704727|NCT06606990|EXPERIMENTAL|Treatment (pidnarulex)|Patients receive pidnarulex IV over 60 minutes on days 1 and 8 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, biopsy, and collection of blood samples throughout the trial. Patients may undergo ECHO at screening and then as clinically indicated.
62143921|NCT03736980|EXPERIMENTAL|Psilocybin Group 3|Group 3: randomized, placebo-controlled, double-blind, cross-over design
62143922|NCT03736980|EXPERIMENTAL|Psilocybin Group 4|Group 4: randomized, placebo-controlled, double-blind, matched group design
62704728|NCT06661122||mHSPC patients|Adult male patients with a diagnosis of low-volume metastasis HSPC (hormone-sensitive prostate cancer) whom the decision for treatment with darolutamide in combination with docetaxel and ADT has been made by the physician or a delegate.
62704729|NCT06591468|EXPERIMENTAL|Prednisone|Combination therapy of UDCA (13-15 mg/kg/day) and prednisone. Prednisone 30-40 mg/day, at 7am in the morning, gradually reduced after 1 month (5mg every 7-14 days) to 5-10 mg for maintenance treatment
62704730|NCT06591468|ACTIVE_COMPARATOR|UDCA|UDCA (13-15 mg/kg/day)
62704731|NCT06660732|EXPERIMENTAL|Rilonacept+Standard therapy|
62704732|NCT06660732|NO_INTERVENTION|Standard therapy|
62704733|NCT06609330|EXPERIMENTAL|2-week wait time group|This group is randomized to a 2-week wait time prior to treatment with CART
62704734|NCT06609330|EXPERIMENTAL|3-week wait time group|This group is randomized to a 3-week wait time prior to treatment with CART
62704735|NCT06609330|EXPERIMENTAL|4-week wait time group|This group is randomized to a 4-week wait time prior to treatment with CART
62704736|NCT04170374||Patients who initiated HIV treatment|
62704737|NCT04170374||Service providers at study facilities|
62704738|NCT06669572|EXPERIMENTAL|Treatment arm|"Treatment consists of lenvatinib (20 mg orally once daily) in combination with pembrolizumab (200 mg IV every 3 weeks).~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks."
62506218|NCT00224484|PLACEBO_COMPARATOR|SALINE GROUP|Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
62506219|NCT02001051|OTHER|Operative Arm|operative arm
62506220|NCT02001051|OTHER|Delayed Operative Arm|delayed operative arm
62704739|NCT06669416|NO_INTERVENTION|Control/Usual Care|Chemotherapy infusion clinics deliver infusion services based on the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) Chemotherapy Administration Safety Standards (2020) including standard toxicity screening and providing standard chemotherapy patient education with general information for managing nausea and other gastrointestinal side effects and nutrition tips. Usual care patients will be supplemented with a single-item question to evaluate taste alteration severity and to gather information about what they are doing and their diet intake.
62506221|NCT06163417||O group|conventional Kasai portoenterostomy
62506222|NCT06163417||L group|laparoscopic Kasai portoenterostomy
62506223|NCT04573296|EXPERIMENTAL|Participants using Vitadio|Participants in the intervention arm undergo a 6-month digitally administered behavioral change program Vitadio focused on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and one-on-one remote coaching. In addition, they undergo regular face-to-face medical assessment.
62539258|NCT04102280|OTHER|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
62539259|NCT02485119|EXPERIMENTAL|BAY94-9343|"Cohort 1: Safety, tolerability and PK of 4.5 mg/kg dose given Q3W. Proceeding to Cohort 2 or not will be decided based on both safety variables during Cycle 1 (21 days) of 3 to 6 subjects in Cohort 1 and PK obtained from Cycle 1 (at least Day 1 to Day 5).~Cohort 2: Safety, tolerability and PK of 6.5 mg/kg dose given Q3W. Whether recruitment will be continued up to 9 subjects for Cohort 2 or not will be decided based on safety variables during Cycle 1 (21 days) of the first 3 subjects in Cohort 2. The safety and tolerability of 6.5 mg/kg will be assessed based on the data of 9 subjects during Cycle 1 in Cohort 2, and considering long term toxicity, the safety and tolerability of BAY94-9343 will be assessed all safety data by the end of 3 cycles in Cohort 2."
62539260|NCT02459535|ACTIVE_COMPARATOR|Glucose only|oral ingestion of 54 g Glucose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
62539261|NCT02459535|ACTIVE_COMPARATOR|Glucose + Saccharin|oral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
62539262|NCT02459535|ACTIVE_COMPARATOR|Saccharin only|oral ingestion of 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
62539263|NCT02459535|ACTIVE_COMPARATOR|Glucose + Aspartame|oral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
62539264|NCT02459535|ACTIVE_COMPARATOR|Aspartame only|oral ingestion of 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
62539265|NCT02459535|ACTIVE_COMPARATOR|Glucose + Sucralose|oral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
62539266|NCT02459535|ACTIVE_COMPARATOR|Sucralose only|oral ingestion of 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
62539267|NCT02529644|ACTIVE_COMPARATOR|Comparison (Standard Information Arm)|The comparison/standard information churches will receive standard multilevel HIV education information that is similar in type to those provided to the intervention churches. These churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. These churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
62539268|NCT02529644|EXPERIMENTAL|Intervention|Taking It to the Pews (TIPS) will be delivered through church-based multilevel (community, church-wide, ministry group, interpersonal/individual) activities by trained church leaders using religiously/ culturally-tailored study materials packaged in a TIPS HIV Tool Kit and following a scripted, study implementation manual.
62539269|NCT05138991|EXPERIMENTAL|Screening (echo, CMR, Tonometry-based system)|Patients undergo a one time assessment of cardiac function by echo, CMR, and the Tonometry-based system system in the clinic over 4-6 hours, and will be asked to perform their home-based measurements within 1-5 days of the clinical assessment, allowing us to directly compare measurements obtained by survivors to those by research personnel. Patients also complete questionnaires at baseline.
62704740|NCT06669416|EXPERIMENTAL|Treatment - TA Self-monitoring and Self-management|The nurse-led intervention involves using a valid/reliable TA assessment tool (Chemotherapy-induced Taste Alterations Scale (CiTAS) and teaching the patient to use the assessments and the evidence-based Patient Education Sheet to select assessment-driven interventions to manage TA symptoms. Data is collected about the specific actions prescribed in the teaching tool to identify which interventions were used and their overall impact.
62704741|NCT06658301|EXPERIMENTAL|plyometric push up exercises|The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.
61962298|NCT04370405|EXPERIMENTAL|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
62348390|NCT01788982|EXPERIMENTAL|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
62704742|NCT06658301|EXPERIMENTAL|swiss ball push up exercises|The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
62704743|NCT04758533|EXPERIMENTAL|AloCELYVIR|Patients will received weekly infusion of AloCELYVIR during 8 weeks.
62704744|NCT04526665|EXPERIMENTAL|Elafibranor 80mg double-blind|Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
62704745|NCT04526665|PLACEBO_COMPARATOR|Placebo|Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
62348391|NCT01788982|PLACEBO_COMPARATOR|Placebo|Placebo should be administered orally at a dose of 200 mg twice daily. Cross-over to nintedanib is allowed after progression.
61962299|NCT03669172|EXPERIMENTAL|NK cells infusion|NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor
61962300|NCT02600572|EXPERIMENTAL|Isometric exercise|Subjects performing the isometric exercises intervention
61962301|NCT02600572|EXPERIMENTAL|Eccentric exercise|Subjects performing the eccentric exercises intervention
61962302|NCT01827605|EXPERIMENTAL|Arm A RIT|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures.
62143923|NCT03087890|ACTIVE_COMPARATOR|Cotrimoxazole|Patients in the Cotrimoxazole study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme.
62348392|NCT01249534||Patients after gastroesophageal cancer surgery|
62348393|NCT03344848|EXPERIMENTAL|Single Arm|Implanted with the Orion Visual Cortical Prosthesis System
62348394|NCT02085057||anorexia nervosa|Diagnosis of anorexia nervosa
62348395|NCT02085057||obsessive-compulsive disorder|Diagnosis of obsessive-compulsive disorder
62348396|NCT02085057||healthy control|No psychiatric diagnoses
61962303|NCT01827605|EXPERIMENTAL|ARM B ASCT|BEAM conditioning regimen (or in alternative FEAM regimen with fotemustine to replace BCNU) and reinfusion of CD34+ cells of ≥ 2x106/Kg CD34+ day 0 (optimal dose to reinfuse 4x106/Kg CD34+). G-CSF 5 mcg/Kg from day 2 until ANC\>1500/mmc. Patients who failed mobilization will directly proceed to rituximab maintenance
61962304|NCT04770662|OTHER|research group|patients who are willing to participate in the study
61962305|NCT05953493||GKS1|Patients with a Glasgow coma scale between 9 and 12
61962306|NCT05953493||GKS2|Patients with a Glasgow coma scale between 13 and 15
62348397|NCT02085057||sisters|Sisters of those enrolled with a diagnosis of anorexia nervosa
62348398|NCT05942729||Patients with hypokinetic cardiomyopathy.|The first arm includes patients with hypokinetic cardiomyopathy for whom echocardiographic data do not readily distinguish between a cause related to coronary artery disease or related to primary myocardial dysfunction, requiring invasive intervention, i.e., coronary angiography.
62348399|NCT05942729||Patients with left ventricular hypertrophy related to hypertension/infiltrative myocardial disease|The second arm includes patients with left ventricular hypertrophy, whose aetiology may be various and whose workup is particularly extensive and expensive.
62348400|NCT03529123|EXPERIMENTAL|Tested Drug|Insulin glargine/lixisenatide fixed ratio combination (FRC)
61962307|NCT03894553|EXPERIMENTAL|FUS Mesencephalotomy|Subjects will receive unilateral stereotactic focused ultrasound mesencephalotomy using the ExAblate Neuro device for severe, opioid-resistant pain associated with head and neck cancer.
62348401|NCT03529123|ACTIVE_COMPARATOR|Control Drug|Insulin glargine (Lantus®)
62348402|NCT04990661|EXPERIMENTAL|Intervention group (massage group)|intradialytic massage for lower extremity was applied to the intervention group in three sessions a week and a total of six sessions for two weeks
62348403|NCT04990661|NO_INTERVENTION|Control group|not administered except nursing interventions in the HD unit.
62348404|NCT01527019|EXPERIMENTAL|Cephalosporin oral suspension|130 research subjects on cephalosporin oral suspension (test) 400 mg once daily
62348405|NCT01527019|EXPERIMENTAL|Cephalosporin capsules|130 research subjects on cephalosporin capsules (test) 400 mg once daily
62348406|NCT01527019|ACTIVE_COMPARATOR|Norfloxacin|130 research subjects on norfloxacin (test) 400 mg twice daily
62506224|NCT04573296|ACTIVE_COMPARATOR|Participants assigned to conventional high-intensity lifestyle intervention program|Participants in the control group undergo a 6-month high-intensity lifestyle intervention program consisting of of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator. In addition, they undergo regular face-to-face medical assessment.
62506225|NCT02555319|EXPERIMENTAL|Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
62506226|NCT06077461|EXPERIMENTAL|Experimental:mandala painting|Patients in this group will be subjected to mandala painting.
62704746|NCT04526665|EXPERIMENTAL|Elafibranor 80mg open label|Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
62704747|NCT05432804|ACTIVE_COMPARATOR|Group I (temozolomide)|Patients receive temozolomide PO on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the study and blood sample collection while on study.
62704748|NCT05432804|EXPERIMENTAL|Group II (temozolomide, selinexor)|Patients receive temozolomide PO on days 1-5 of each cycle and selinexor PO on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the study and blood sample collection while on study.
61962308|NCT01998529|EXPERIMENTAL|Cisplatin|After cytoreductive surgery, possible pneumonectomy, and possible diaphragm resection, the chest cavity will be closed in layers, leaving inflow and outflow chest tubes in place. Catheters connected to an extracorporeal perfusion circuit. Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C). In order to limit the systemic toxicity of cisplatin, amifostine administered intravenously over 15 minutes beginning 30 minutes after cisplatin perfusion. Patient response to amifostine continuously monitored by anesthesiologist. Infusion may be stopped and/or restarted based on blood pressure.
61962309|NCT01815593|EXPERIMENTAL|Enhanced External Counterpulsation|Men with erectile dysfunction receive Enhanced External Counterpulsation treatment
61962310|NCT01815593|NO_INTERVENTION|Control|Men with erectile dysfunction without Enhanced External Counterpulsation treatment
61962311|NCT03618498|OTHER|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
61962312|NCT03120416|EXPERIMENTAL|Resistance exercise training program|Eight exercises will be used to include large upper and lower body muscle groups. The baseline 1 repetition maximum (RM) will be used to set initial training loads. All exercise sessions will be performed under the supervision of an exercise physiologist. Vital signs and body weight will be recorded before each session. The workload during training will be adjusted to reflect 80% of the most recent 1 RM (approximately 8-12 RM set). In addition, patients' workloads will be progressively increased if the patients can lift the weight more than 12 repetitions. Participants will perform three sets of 8-12 repetitions on each machine per session.
61962313|NCT03120416|NO_INTERVENTION|Control|Participants randomized to the control group will be offered an educational brochure regarding exercise published by the NKF.
61962314|NCT04597788|EXPERIMENTAL|Protein supplemented very low calorie diet program|The lifestyle intervention using protein supplemented very low calorie meals will be implemented with individual counseling sessions for 12 months. Initial intensive weight loss stage will be delivered during the first 4 month period with total meal replacement to partial meal replacement using protein supplemented very low calorie meals. During the weight loss maintenance stage, regular intermittent very low calorie meal replacement one week per month will be delivered for the entire period. Mobile counseling will be offered to help patients achieve weight loss as well as weight loss maintenance.
61962315|NCT04597788|ACTIVE_COMPARATOR|Conventional low calorie diet program|The conventional low calorie diet program will be offered to participants assigned to control group using educational material and individual counseling sessions for 12 months. Mobile counseling will be also offered for weight loss and weight loss maintenance.
61962316|NCT05512845||Double factor group|"Patients treated with full arch implant supported prostheses based on the All-on-four® concept. All implants were placed using the double factor computer assisted surgery technique, which involves combination of the static and dynamic computer assisted surgery protocols."
61962317|NCT03319914||ST-003 Observational|Calciphylaxis patients who participated in the ST-001 CALISTA
62348407|NCT03833817|EXPERIMENTAL|Patient intervention arm|This intervention arm contains the patients from this single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
62506227|NCT06077461|NO_INTERVENTION|Control|Patients in this group will not be subjected to mandala painting.
61962318|NCT02420392|EXPERIMENTAL|Dapagliflozin treatment|Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
61962319|NCT02420392|NO_INTERVENTION|Normal glucose tolerance|Test incretin sensitivity in subjects with normal glucose tolerance
62506228|NCT06533657|EXPERIMENTAL|Trichomylin®|Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
62506229|NCT05746117|EXPERIMENTAL|Continuous Blood Pressure Monitoring (CBPM)|Participants will wear the Aktiia Bracelet for 6-months and potentially receive blood pressure medication titrations during the 6-month period.
62506230|NCT05746117|ACTIVE_COMPARATOR|Home Blood Pressure Monitoring (HBPM)|Participants will receive an upper arm cuff and standard hypertension care from their primary care physician.
62506231|NCT00455962|ACTIVE_COMPARATOR|African American women 18-35 yo|intervention: estradiol steroid infusion and progesterone steroid infusion
62704749|NCT04585958|EXPERIMENTAL|Treatment (trastuzumab deruxtecan, olaparib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21 or days 8-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients taking olaparib BID on days 1-21 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, and 15 of cycle 1, day 1 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after cycle 4 and then at treatment end. Patients taking olaparib BID on days 8-14 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, 9, and 15 of cycle 1, days 1 and 8 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after that, and at treatment end. Patients undergo biopsy at baseline, and then on day 3 or day 10 of cycle 1. Patients also undergo echocardiography and CT throughout the trial.
62506232|NCT00455962|ACTIVE_COMPARATOR|Caucasian women 18-35 yo|intervention: estradiol steroid infusion intervention: progesterone steroid infusion
62506233|NCT04228978|EXPERIMENTAL|Weight loss + exercise (WL+EX)|Weight loss + home based walking exercise (WL+EX)
61962320|NCT01874613|EXPERIMENTAL|Skull bone reconstruction|Patients with skull bone defect
62506234|NCT04228978|ACTIVE_COMPARATOR|Exercise alone (EX)|Home based walking exercise (EX)
62506235|NCT00490503||MRI + MRS|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to start systemic chemotherapy.
62506236|NCT05644756|OTHER|Measurement Based Care Implementation|Four community mental health clinics located in Washington state will receive trainings on how to implement Measurement Based Care (MBC) in their clinics. We are creating implementation plans to improve therapists' use of measurement-based care.
62506237|NCT02050035|EXPERIMENTAL|CKD Aerobic Exercise Training|Chronic Kidney Disease participants randomly allocated to the CKD Exercise arm will receive 12 weeks of Aerobic Exercise Training three times per week.
62506238|NCT02050035|NO_INTERVENTION|CKD Control|Chronic Kidney Disease participants allocated to the the CKD Control arm will receive their standard routine care over a 12 week period.
62704750|NCT06596694|EXPERIMENTAL|Patritumab deruxtecan|Participants receive patritumab deruxtecan intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.
61962321|NCT01874613|EXPERIMENTAL|Orbital floor defect|Patients with orbital floor defect
61962322|NCT02335866|EXPERIMENTAL|Test groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
61962323|NCT02335866|ACTIVE_COMPARATOR|Control groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
61962324|NCT01559597|ACTIVE_COMPARATOR|Cold chain|Group vaccinated with tetanus toxoid vaccine kept in cold chain
61962325|NCT01559597|EXPERIMENTAL|CTC|Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain
61962326|NCT02968901|EXPERIMENTAL|bitherapy|Macitentan and tadalafil
61962327|NCT02319993|EXPERIMENTAL|TIAN WANG BU XIN DAN|"Drug:TIAN WANG BU XIN DAN CONCENRATED GRANULES CHUANG SONG ZONG"
61962328|NCT02319993|EXPERIMENTAL|Suan Tzao Ren Tang|"Drug:Suan Tzao Ren Tang Granula Subtilae CHUANG SONG ZONG"
61962329|NCT02319993|PLACEBO_COMPARATOR|Placebo|Drug:1/10 TIAN WANG BU XIN DAN
61962330|NCT04629352|EXPERIMENTAL|Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)|Each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For the Verum-tDCS condition, 2-mA of constant current will be delivered for 20 minutes, with additional ramp-up and ramp-down of 30 seconds each.
61962331|NCT04629352|PLACEBO_COMPARATOR|Sham Accelerated Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Sham-tDCS, no current will be delivered beyond the initial ramp-up time.
61962332|NCT00495183|EXPERIMENTAL|1|caffeine + placebo
61962333|NCT00495183|EXPERIMENTAL|2|caffeine + biperiden
61962334|NCT00495183|PLACEBO_COMPARATOR|3|Placebo+placebo
61962335|NCT00787852|EXPERIMENTAL|Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*"
61962336|NCT00787852|EXPERIMENTAL|Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*"
61962337|NCT03346785|EXPERIMENTAL|Food Photography|Participants will engage in food photography on their smart phones while eating
62506239|NCT02050035|NO_INTERVENTION|Healthy Control|Healthy participants will act as comparators, they will undergo baseline testing only and will not receive an intervention.
62506240|NCT01604369|EXPERIMENTAL|Cryoablation|
62506241|NCT03259789|ACTIVE_COMPARATOR|Bexagliflozin tablets, 20 mg; Double-Blind|
62506242|NCT03259789|PLACEBO_COMPARATOR|Bexagliflozin tablets, Placebo; Double Blind|
62506243|NCT03259789|EXPERIMENTAL|Bexagliflozin Tablets, 20 mg; High Glycemic Group|
62506244|NCT05965817|EXPERIMENTAL|Patients with colorectal liver metastases receiving SGM-101 and ICG|In total 10 patients will be included who are scheduled for resection of colorectal liver metastases and receive SGM-101 and ICG
62506245|NCT03186716|EXPERIMENTAL|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
62506246|NCT03186716|PLACEBO_COMPARATOR|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
62506247|NCT03936933|EXPERIMENTAL|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
62506248|NCT03936933|ACTIVE_COMPARATOR|ZOLADEX® 3.6mg Injection.|3.6 mg, Subcutaneously at every 28 days
62704751|NCT01286766|ACTIVE_COMPARATOR|DCS|DCS: docetaxel with cisplatin with TS-1
62704752|NCT01286766|ACTIVE_COMPARATOR|DCF|DCF : docetaxel with cisplatin with 5-FU
62704753|NCT05505942|EXPERIMENTAL|Lifestyle Physical Activity (LPA)|The LPA arm will receive 7 LPA sessions with a trained interventionist to assist in adding LPA to the participant's routine.
61962338|NCT03346785|EXPERIMENTAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
61962339|NCT03346785|EXPERIMENTAL|No Phone Use|Participants will not use their smart phones while eating
61962340|NCT05113420||Per os+topical solution(1)|
61962341|NCT05113420||Per os+topical solution(2)|
61962342|NCT05113420||Per os only|
61962343|NCT05113420||Topical solution only|
61962344|NCT03132220|ACTIVE_COMPARATOR|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
61962345|NCT03132220|EXPERIMENTAL|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
61962346|NCT01603355|EXPERIMENTAL|Tocilizumab|
61962347|NCT06505317|EXPERIMENTAL|Clinical Site 1|Randomized to start AI-based PAD screening interventionat week 13.
61962348|NCT06505317|EXPERIMENTAL|Clinical Site 2|Randomized to start AI-based PAD screening intervention at Week 26.
61962349|NCT06505317|EXPERIMENTAL|Clinical Site 3|Randomized to start AI-based PAD screening intervention at Week 39.
61962350|NCT03325283|EXPERIMENTAL|Protembo device treatment|Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
61962351|NCT03837197|EXPERIMENTAL|Kidney-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.
61962352|NCT03837197|NO_INTERVENTION|Kidney-Static Cold Storage|Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
61962353|NCT03837197|EXPERIMENTAL|Liver-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.
61962354|NCT03837197|NO_INTERVENTION|Liver-Static Cold Storage|Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
61962355|NCT03759574||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilisation
61962356|NCT03759574||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure \> 20 mmHg and/or diastolic pressure \> 10 mmHg) during mobilisation
61962357|NCT03808545|ACTIVE_COMPARATOR|BIPAMS|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
61962358|NCT03808545|EXPERIMENTAL|BIPAMS + Diet|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.
61962359|NCT01308060|EXPERIMENTAL|Botulinum Toxin type A|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
61962360|NCT01308060|PLACEBO_COMPARATOR|Placebo|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
61962361|NCT03273595|PLACEBO_COMPARATOR|Control|
61962362|NCT03273595|EXPERIMENTAL|Experimental group|
61962363|NCT02036294|OTHER|Usual Care|Usual Care: Standard healthcare services will be received. Study participants in this arm will not receive any additional study interventions.
61962364|NCT02036294|EXPERIMENTAL|BREATHE program|Study participants randomized to this arm will be offered the BREATHE program an integrated multifaceted intervention that includes comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
61962365|NCT00381485|EXPERIMENTAL|MF/F MDI 400/10 mcg BID|"Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
61962366|NCT00381485|EXPERIMENTAL|MF/F MDI 200/10 mcg BID|"Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
61962367|NCT00381485|ACTIVE_COMPARATOR|MF MDI 400 mcg BID|"Mometasone Furoate 400 mcg taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
62143924|NCT03087890|PLACEBO_COMPARATOR|Placebo|Participants in the Placebo arm will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo
62143925|NCT02680262|EXPERIMENTAL|Intervention group 1|HPV self-sampling kit mailed directly
61962368|NCT02933047|ACTIVE_COMPARATOR|Outpatient LH|Patients in the intervention group are discharged within 6 to 8 hours after total laparoscopic hysterectomy.
61962369|NCT02933047|PLACEBO_COMPARATOR|Inpatient LH|Patients in the control group follow regular hospitalization and are discharged within 24 hours after total laparoscopic hysterectomy.
61962370|NCT00790985|EXPERIMENTAL|flavocoxid 500 mg|flavonoid mixture
61962371|NCT00790985|ACTIVE_COMPARATOR|naproxen|nonsteroidal anti-inflammatory drug
62143926|NCT02680262|EXPERIMENTAL|Intervention group 2|HPV self-sampling kit on demand
62143927|NCT02680262|EXPERIMENTAL|Intervention group 3|second reminder
61962372|NCT02656784|EXPERIMENTAL|Trial-Based Cognitive Therapy (TBCT)|"Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach, based on the work of Franz Kafka The Trial and developed by Professor Irismar Reis de Oliveira at Federal University of Bahia, Brazil. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All individuals in the group will be submitted to MRI"
61962373|NCT02656784|EXPERIMENTAL|Behavioral Therapy (ERP)|The Behavioral Therapy is an intervention of first choice for treatment of OCD , which employs the technique of Exposure and Response Prevention (ERP) , considered the gold standard to the disorder. The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All individuals in the group will be submitted to MRI
61962374|NCT02656784|NO_INTERVENTION|Control Group|The control group consisted of individuals without OCD, matched with the experimental group in terms of gender,age and education. In this group are not included in individuals in psychotherapeutic care and with a history of neurological or psychiatric disorder; however, all them will be submitted to MRI .
61962375|NCT00946699|EXPERIMENTAL|1|MEDI-551
61962376|NCT00946699|EXPERIMENTAL|2|MEDI-551
61962377|NCT00946699|EXPERIMENTAL|3|MEWDI-551
61962378|NCT00946699|EXPERIMENTAL|4|MEDI-551
61962379|NCT00946699|EXPERIMENTAL|5|MEDI-551
61962380|NCT00946699|PLACEBO_COMPARATOR|6|Placebo
61962381|NCT03801486||Experimental (SCF40)|At the experimental data collection visits participants consumed 255g of pasta made with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
62348408|NCT03833817|EXPERIMENTAL|Caregiver (of patient) intervention arm|This intervention arm contains the caregivers of patients from this single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
62348409|NCT04090905||Unselected cohort|Consecutive adult patients who were referred for acute abdominal surgery. Patients underwent standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
62348410|NCT04090905||Subgroup with Holter monitoring|Consecutive adult patients who were referred for acute abdominal surgery in the time interval 7 AM to 11 PM. Holter monitoring was applied on top of standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
62348411|NCT06017648|EXPERIMENTAL|Experimental: Group 1 - Non Invasive Ultrasound (FUBA5200)|Treatment with the Focused Ultrasound Fat Reduction device (FUBA5200) 4 times in total, once every two weeks
62348412|NCT06017648|ACTIVE_COMPARATOR|Active comparator: Group 2 - Non Invasive Ultrasound (Contour I V3)|Treatment with the focused ultrasound fat reduction device (Contour I V3) 4 times in total, once every two weeks
62348413|NCT02521688||Group I (PTD + CP)|include ten mothers exhibiting spontaneous preterm delivery with moderate to severe chronic periodontitis +incisional biopsy from placenta and GCF sample
62348414|NCT02521688||Group II (TD + CP)|include ten mothers exhibiting spontaneous term delivery with moderate to severe chronic periodontitis+incisional biopsy from placenta and GCF sample
62348415|NCT02521688||Group III (PTD + HP)|include tenmothersexhibiting spontaneous preterm delivery with healthy periodontium +incisional biopsy from placenta and GCF sample
62348416|NCT02521688||Group IV (TD + HP)|ten mothersexhibiting spontaneous term delivery with healthy periodontium(Armitage GC. 1999)+ incisional biopsy from placenta and GCF sample
62348417|NCT06079866|OTHER|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Participants will be randomized as to the order they will trial Mask A and Mask B. This arm will first use the Oran Park mask for 7 days and then use the Evora Mask for 7 days.
62348418|NCT06079866|OTHER|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Participants will be randomized as to the order they will trial Mask A and Mask B. This arm will first use the Evora mask for 7 days and then use the Oran Park mask for 7 days.
62348419|NCT06461312|EXPERIMENTAL|enrolled patients|Enrolled patients underwent pulsed radiofrequency of the pudendal nerve combined with ganglion impar block after pudendal nerve diagnostic block
61962382|NCT03801486||Control (SEM100)|At the control data collection visits participants consumed 255g of pasta made with 100% semolina flour (SEM100) with butter.
61962383|NCT01881360|EXPERIMENTAL|Gluten-free diet|
62348420|NCT05331456|OTHER|Alveolar cleft repair using autologous bone from the mandibular symphysis|Control group
62348421|NCT05331456|OTHER|Alveolar cleft repair using a biphasic clacium phosphate putty|Study group
62348422|NCT05020093|EXPERIMENTAL|Injection molding|cavity design, packing technique, bonding technique
61962384|NCT01881360|ACTIVE_COMPARATOR|Hypocaloric diet|
61962385|NCT02628652|EXPERIMENTAL|Gluco-Galacto-Oligosaccharide (GOS)|Subjects randomized to this treatment arm will ingest GOS once per day for a total of 14 days. One level of GOS will be taken during Phase I and 2 levels of GOS will be taken during Phase II.
61962386|NCT02628652|EXPERIMENTAL|Gluco-Oligosaccharide (GLOS)|Subjects randomized to this treatment arm will ingest GLOS once per day for a total of 14 days. One level of GLOS will be taken during Phase I and 2 levels of GLOS will be taken during Phase II.
61962387|NCT02628652|ACTIVE_COMPARATOR|FructoOligosaccharide (FOS)|Subjects randomized to this treatment arm will ingest FOS once per day for a total of 14 days. One level of FOS will be taken during Phase I and 2 levels of FOS will be taken during Phase II.
61962388|NCT01317160|NO_INTERVENTION|Routine care: Plaster Cast Treatment|Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
61962389|NCT01317160|EXPERIMENTAL|Intermittent pneumatic compression (IPC)|Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.
61962390|NCT02204397|EXPERIMENTAL|INGAP Peptide, Ustekinumab|INGAP Peptide, Ustekinumab subcutaneous
61962391|NCT01572558|ACTIVE_COMPARATOR|Appendectomy|Standard surgical treatment, appendectomy
61962392|NCT01572558|EXPERIMENTAL|Conservative, non-surgical treatment|Non-operative treatment with intravenous and oral antibiotics
61962393|NCT01835587|EXPERIMENTAL|CC-486|Dose of 150 mg, 200 mg, or 300 mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
61962394|NCT05886829|ACTIVE_COMPARATOR|Chlorpheniramine Malate (0.4%) Nasal Spray|Chlorpheniramine Malate (0.4%) Nasal Spray
61962395|NCT05886829|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo Nasal Spray
61962396|NCT02364479|EXPERIMENTAL|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week, Subcutaneous injection
61962397|NCT02364479|EXPERIMENTAL|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injectio, 25mg per week, Subcutaneous injection
62506249|NCT05778240|EXPERIMENTAL|Status quo bias and implementation intention bias|Participants' families in this arm were informed about prophylaxis program and provided a schedule additionally called two days before appointments (status quo bias) and were asked to plan the appointment day (implementation intention).
62506250|NCT05778240|EXPERIMENTAL|Availability bias and social norm|Participants' families in this arm were informed about prophylaxis program and provided a schedule and were received messages biweekly informing about benefits of program and adherence rate (availability bias and social norm).
62506251|NCT05778240|EXPERIMENTAL|Control|Participants' families in this arm were informed about prophylaxis program and provided a schedule
62506252|NCT05247268|EXPERIMENTAL|GnRHa+letrozole|Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group will be randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group. Patients who will be assigned to GnRHa+letrozole group will receive triprorelin acetate (intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses) plus letrozole (2.5mg oral daily and no more than 24 weeks). Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
62506253|NCT05247268|ACTIVE_COMPARATOR|MA/MPA|Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group were randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group.Patients assigned to MA/MPA group will receive MA/MPA (160 mg oral MA daily or 500 mg oral MPA daily).Then every 3 months, an hysteroscopy will be used to evaluate the endometrial condition, and the findings will be recorded.
62506254|NCT01956487|OTHER|Propafenone|Open label comparison of 2 formulations
62506255|NCT02425384|EXPERIMENTAL|Intervention Group|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and is linked to a motivational website. On the website, activity data from the activity meter can be viewed after uploading information from the meter to the website. The reward website allots points for participants based on the amount and intensity of physical activity. Points can be redeemed for rewards on the website, such as gift cards and digital badges.
62506256|NCT02425384|ACTIVE_COMPARATOR|Active Control|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and a copy of the game Dance Dance Revolution (DDR). The activity meter will upload data to a secure server but will not be linked to the motivational website used by the intervention group. DDR is a dancing video game in which players view arrows timed to music on a TV screen and gain points by stepping on the corresponding arrows on a floor mat. Players obtain points in the game by stepping on the correct arrows at the right time to the beat of the music. The points earned with DDR cannot be redeemed for rewards.
62506257|NCT02425384|PLACEBO_COMPARATOR|Passive Control|This group is provided with an activity meter and will be asked to carry it with them as they go about their normal daily activities. Like in the Active Control group, participants in the Passive Control group will not have access to the motivational website. For this group, the activity meter functions solely as a monitor to track their activity levels. No other product or intervention will be introduced to the control group.
62506258|NCT03700645|NO_INTERVENTION|PCI and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and receive standard medical treatment according to practice guidelines.
61962398|NCT02364479|PLACEBO_COMPARATOR|Placebo|Placebo, Subcutaneous injection per week
61962399|NCT05782491|EXPERIMENTAL|Treatment Arm|Patient in cardiogenic shock listed for Impella 5.5 placement who meets study inclusion criteria
61962400|NCT03149198|EXPERIMENTAL|Interventional group|Mat pilates exercises
61962401|NCT03149198|ACTIVE_COMPARATOR|Control group|Aquatic aerobic exercises
61962402|NCT06558565|ACTIVE_COMPARATOR|stromal vascular fraction side|stromal vascular fraction will be injected in one half of the frontal scalp
61962403|NCT06558565|ACTIVE_COMPARATOR|PRP side|PRP will be injected in the other half of frontal scalp
62506259|NCT03700645|ACTIVE_COMPARATOR|PCI, standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and in addition to standard medical treatment, receive treatment with allopurinol.
62506260|NCT03700645|NO_INTERVENTION|CABG and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and receive standard medical treatment according to practice guidelines.
61962404|NCT00848874|EXPERIMENTAL|PVGS User|
61962405|NCT01200602|EXPERIMENTAL|Arm A|Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
61962406|NCT01200602|ACTIVE_COMPARATOR|Arm B|Patients have clinical observation for weight loss and gain for 4 weeks.
61962407|NCT05466877|EXPERIMENTAL|MG-K10 Regimen 1|subcutaneous injection every 4 weeks (placebo injections at 2, 6, 10, 14 weeks to maintain blindness)
61962408|NCT05466877|EXPERIMENTAL|MG-K10 Regimen 2|subcutaneous injection every 2 weeks
61962409|NCT05466877|EXPERIMENTAL|MG-K10 Regimen 3|subcutaneous injection every 4 weeks (placebo injections at 2, 6, 10, 14 weeks to maintain blindness)
61962410|NCT05466877|PLACEBO_COMPARATOR|Placebo|subcutaneous injection every 2 weeks
61962411|NCT05686850|ACTIVE_COMPARATOR|High-Flow Oxygen|Patients assigned to the control group will be continuously treated by high-flow nasal oxygen during the 48 hours following randomization
61962412|NCT05686850|EXPERIMENTAL|NIV alternating with High-Flow Oxygen|Patients assigned to the intervention group will be treated with curative NIV alternating with high-flow nasal oxygen during the 48 hours following randomization
62704754|NCT05505942|ACTIVE_COMPARATOR|Fitbit Only|The Fitbit only arm will receive only brief check in phone calls and only related to assisting with any Fitbit functioning issues.
62704755|NCT05181748|EXPERIMENTAL|Experimental: Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intraovarian infusion during the mid-luteal phase, undergoing a subsequent stimulated fresh ET-ICSI cycle on the first month following PRP infusion
62704756|NCT05181748|NO_INTERVENTION|Control Group: Group of participants receiving standard protocol|Women presenting with POR undergoing a stimulated fresh ET-ICSI cycle
62704757|NCT06402825||Intervention|Children born from mothers who were allocated to the intervention group in the Obesity-Fertility study.
62704758|NCT06402825||Control|Children born from mothers who were allocated to the control group in the Obesity-Fertility study. Participants in the control group received standard care from the fertility clinic without delay.
62704759|NCT06017973|OTHER|Possible non-convulsive status epilepticus with ictal-interictal continuum EEG patterns|Patients with a possible non-convulsive status epilepticus, according to American Clinical Neurophysiology Criteria (ACNS) (2021).
62704760|NCT06017973|OTHER|Healthy control subjects|Healthy control subjects.
62704761|NCT06595940||Affected|Individuals with a condition that is expected to be caused by a genetic change
62704762|NCT06595940||Unaffected|Individuals who are first-degree relatives (parents, siblings, children) of affected individuals enrolled in this study
62704763|NCT05197855|EXPERIMENTAL|Technological innovations and CPAP|Patients will be equipped with 4 devices: a Dreem 3 Headband, a pulse oximeter, a continuous glucose sensor, and a pedometer. In parallel they will be equipped by the CPAP at home by Icadom.
62704764|NCT06592742|ACTIVE_COMPARATOR|Control group (PR alone)|The control group in this study will undergo a standard pulmonary rehabilitation (PR) program designed to improve lung function, physical endurance, and overall quality of life in patients with cystic fibrosis (CF). The intervention will last for 21 days, with participants attending daily sessions of structured PR. This group will not receive the progressive muscle relaxation (PMR) component.
62704765|NCT06592742|EXPERIMENTAL|Intervention group (PR + PMR)|The intervention group in this study will participate in the standard pulmonary rehabilitation (PR) program, similar to the control group, but with progressive muscle relaxation (PMR) sessions aimed at improving mental health, reducing anxiety, and enhancing sleep quality. This group will receive both physical and mental health interventions over the 21-day program to assess the combined impact of PR and PMR on quality of life, mental health, sleep quality, and physical endurance.
62704766|NCT05470777|EXPERIMENTAL|CD22/CD19 CAR T and auto-HSCT sandwich strategy as consolidation therapy for B-ALL|
62704767|NCT06617325|EXPERIMENTAL|Dapirolizumab pegol|Study participants will receive dapriolizumab pegol throughout the Treatment Period.
62704768|NCT06617325|PLACEBO_COMPARATOR|Placebo|Study participants will receive placebo throughout the Treatment Period.
62704769|NCT04548752|EXPERIMENTAL|Arm A (olaparib, pembrolizumab)|Patients receive olaparib PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 19, patients receive olaparib PO BID on days 1-42 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI, tumor biopsy and blood sample collection throughout the study.
62704770|NCT04548752|ACTIVE_COMPARATOR|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI, tumor biopsy and blood sample collection throughout the study.
62143928|NCT02329704||Density Gradient processing|"Semen portion processed using Density Gradient (80/40 %) Spin on 1200 r.p.m./20min Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
62143929|NCT02329704||Swimming down Processing|"Semen portion processed using swimming down (100 %) 30 min at room temperature processing for swim down Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
62143930|NCT05701059||Semi-Constrained Nuvasive Simplify|This group will be undergoing cervical arthroplasty with the Nuvasive Simplify artificial disc implant. The Nuvasive Simplify implements a three-piece design with two endplates and a semi-constrained mobile core.
62704771|NCT05347485|EXPERIMENTAL|Ciltacabtagene Autoleucel (Cilta-cel)|Eligible participants will receive bridging therapy (that is, anti-plasma cell directed treatment) based on participant's clinical status and timing of availability of cilta-cel (JNJ-68284528) along with lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] intravenous \[IV\] and fludarabine 30 mg/m\^2 IV daily, for 3 days). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants will receive a single IV infusion of cilta-cel (JNJ-68284528) at a total targeted dose of 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg).
62704772|NCT06676033|EXPERIMENTAL|epcoritamab|Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
62143931|NCT05701059||Unconstrained Biomet Zimmer Mobi-C|This group will be undergoing cervical arthroplasty with the Biomet Zimmer Mobi-C artificial disc implant. The Biomet Zimmer Mobi-C implements an unconstrained three piece design.
62348423|NCT05020093|ACTIVE_COMPARATOR|Incremental packing|cavity design, packing technique, bonding technique
62143932|NCT04681794|EXPERIMENTAL|MayoP4 Group|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, hopping/jumping, and movement-based mindfulness.
62143933|NCT04681794|NO_INTERVENTION|Control Group|No intervention
62348424|NCT04041908|EXPERIMENTAL|Experimental Product|Drink mix powder
62506261|NCT03700645|ACTIVE_COMPARATOR|CABG standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and in addition to standard medical treatment, receive treatment with allopurinol.
61962413|NCT00052689|EXPERIMENTAL|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
62704773|NCT00687115|OTHER|Overfeeding|an inpatient overfeeding arm in which obesity resistant individuals are prescribed a 150% increase in a weight maintenance calorie diet for 6 weeks which (by random assignment) is either low in protein (6%) content. Overfeeding or Overfeeding Low Pro or with normal (20%) protein content
62704774|NCT00687115|OTHER|Weight Loss|a weight loss arm in which obese individuals are placed on a 50% decrease from a weight maintenance calorie diet for 6 weeks which (by random assignment) is either a standard 50% decrease in energy intake with all macronutrients held at the same percentage (20% protein, 50% carbohydrate, 30% fat) or a 50% decrease in energy intake with the same absolute protein content (in grams) as the weight maintaining diet while on our clinical research unit then followed as outpatients monthly for 10 months
62704775|NCT00024622||Healthy volunteers|Healthy volunteers.
62704776|NCT00024622||Patients - Parkinsons|Patients with Parkinsons
61962414|NCT00052689|EXPERIMENTAL|Arm II|Patients receive bortezomib as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.
61962415|NCT03168854|EXPERIMENTAL|GAP Arm 1|10 subjects will receive 5 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 0, 4, 8, 12, and 20 for a maximum cumulative dose of 1000 GAP3KO bites per subject
62506262|NCT02176668|EXPERIMENTAL|Cohort1-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
62506263|NCT02176668|EXPERIMENTAL|Cohort1-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal
62506264|NCT02176668|EXPERIMENTAL|Cohort1-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
62506265|NCT02176668|EXPERIMENTAL|Cohort1-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
62506266|NCT02176668|EXPERIMENTAL|Cohort2-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
62506267|NCT02176668|EXPERIMENTAL|Cohort2-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
62506268|NCT02176668|EXPERIMENTAL|Cohort2-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
62506269|NCT02176668|EXPERIMENTAL|Cohort2-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
62506270|NCT02176668|EXPERIMENTAL|Cohort3-YH4808 OF 200|"(Partial cross over design)~1. 7 days repeat administration of YH4808 Old Formulation 200mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before dinner~2. 7 days repeat administration of YH4808 Old Formulation 200mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before bed"
62704777|NCT00024622||Patients - schizophrenia spectrum disorders|Patients - schizophrenia spectrum disorders
62506271|NCT02176668|EXPERIMENTAL|Cohort3-YH4808 OF 400|"(Partial cross over design)~1. 7 days repeat administration of YH4808 Old Formulation 400mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before dinner~2. 7 days repeat administration of YH4808 Old Formulation 400mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before bed"
62506272|NCT01483014|EXPERIMENTAL|imatinib|
62704778|NCT06455202|EXPERIMENTAL|barzolvolimab 150 mg|barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks
62704779|NCT06455202|EXPERIMENTAL|barzolvolimab 300 mg|barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks
62704780|NCT06455202|EXPERIMENTAL|Placebo then barzolvolimab 150 mg|Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.
62704781|NCT06455202|EXPERIMENTAL|Placebo then barzolvolimab 300 mg|Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.
62704782|NCT06676046||Patients diagnosed with rare primary lipid disorders.|Male and female participants with rare primary lipid disorders ages 10 and older.
61962416|NCT03168854|EXPERIMENTAL|GAP Arm 2|6 subjects will receive 3 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 8, 12, and 20 for a maximum cumulative dose of 600 GAP3KO bites per subject
61962417|NCT03168854|ACTIVE_COMPARATOR|Malaria-naive Infectivity Control Arm|6 healthy volunteers will receive challenge with wild type Plasmodium falciparum NF54 sporozoites through the bites of five infectious A. stephensi moquitoes using standard CHMI procedures
61962418|NCT02122250|EXPERIMENTAL|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
61962419|NCT02122250|ACTIVE_COMPARATOR|Static web-based materials|Static version of the interactive web-based materials
61962420|NCT03268902|EXPERIMENTAL|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
61962421|NCT03268902|EXPERIMENTAL|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
61962422|NCT03268902|EXPERIMENTAL|Nicotinamide only|Nicotinamide Placebo Placebo
61962423|NCT03268902|PLACEBO_COMPARATOR|No active treatment|Placebo Placebo Placebo
61962424|NCT06214338|EXPERIMENTAL|Low Dose|10 mg of β-alanine
61962425|NCT06214338|EXPERIMENTAL|High Dose|20 mg of β-alanine
61962426|NCT04390178|EXPERIMENTAL|Convalescent plasma treatment|All participants will receive a bag of convalescent plasma. The bag volume will be 180-200 ml. The first 10 patients will receive 1, 5, 10, 50 and 134 ml of plasma at 30 minute intervals while being closely monitored for adverse events, especially allergic reactions. The remaining twenty patients will receive the convalescent plasma as a slow infusion according to normal routines.
61962427|NCT04934397|EXPERIMENTAL|Study Infant Formula|Feed ad libitum during study period
61962428|NCT02771093|EXPERIMENTAL|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
61962429|NCT02771093|EXPERIMENTAL|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
61962430|NCT04521153|EXPERIMENTAL|Experimental group|Preoperative camrelizumab combined with apatinib mesylate (q2w, 2 cycles) → radical surgery → postoperative TACE treatment → sequential camrelizumab and apatinib mesylate (q3w, at least 6 cycles) (Note: Surgery within 2-4 weeks after the last administration of neoadjuvant therapy, postoperative TACE treatment at least 4 weeks after surgery, and camrelizumab combined with apatinib mesylate within 2 weeks after TACE treatment)
61962431|NCT04521153|ACTIVE_COMPARATOR|Control group|Radical surgery→postoperative TACE treatment
61962432|NCT04655898|EXPERIMENTAL|Administration of [14C]CC-90001|A single oral dose of \[14C\]CC-90001, containing approximately 100 μCi of radioactivity, will be administered on Day1 under fasted conditions.
62143934|NCT02379000|ACTIVE_COMPARATOR|Transpupillary therapy alone|Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid
62506273|NCT00627081|PLACEBO_COMPARATOR|1|general anesthesia and thoracic epidural administration of saline
62506274|NCT00627081|ACTIVE_COMPARATOR|2|general anesthesia and thoracic epidural administration of chirocaine
62506275|NCT04985955|EXPERIMENTAL|Candin + Tofacitinib|Participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9 percent (%) sodium chloride (NaCl) on the opposite forearm on Day 3 and oral dose of tofacitinib for 5 days.
62506276|NCT04985955|NO_INTERVENTION|Candin Challenge|All participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9% NaCl on the opposite forearm on Day 3.
62506277|NCT02938442|ACTIVE_COMPARATOR|Chemotherapy Only Arm|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
62506278|NCT02938442|EXPERIMENTAL|Chemo+Vaccine Arm|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
62506279|NCT03287687|ACTIVE_COMPARATOR|Air for insufflation|In this arm of patients, air which is currently used as standard of care will be used for insufflation
62704783|NCT05256290|EXPERIMENTAL|Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)|"* Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M).~* Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor~* Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)"
62704784|NCT05256290|EXPERIMENTAL|Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations|Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)
62704785|NCT05256290|EXPERIMENTAL|Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation|Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)
62704786|NCT05256290|EXPERIMENTAL|Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations|Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
62704787|NCT00923104||1/healthy volunteers|healthy volunteers
62704788|NCT00923104||2/patients|subjects with breast cancer, ductal carcinoma in situ, and adenocarcinoma of prostate
62704789|NCT01143454||1. Adult index cases and relatives|Enrolled with a known or suspected pathology that may be associated w/cardiovascular dysfunction or risk w/suspected atypical presentation, heritable disorder, or genetic predisposition.
62506280|NCT03287687|EXPERIMENTAL|Carbon dioxide gas for insufflation|in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy
62506281|NCT01010035||type 2 diabetes|patients with diagnosis of Type 2 diabetes mellitus
62506282|NCT01010035||Control|non type 2 diabetes mellitus
62506283|NCT05642169|EXPERIMENTAL|HIIT|Training program for 12 weeks with a frequency of 3 workouts per week.
62506284|NCT05642169|EXPERIMENTAL|HIIT+AF|They will develop the same training program as the HIIT group, and they will also have to perform 10,000 steps per day.
62506285|NCT05642169|PLACEBO_COMPARATOR|Control|They will not suffer any change in their lifestyle.
61962433|NCT02314702||Revision Total Hip Arthroplasty|Single study group previously implanted with a PROFEMUR® L Revision Femoral Stem
61962434|NCT02800681||Asperger syndrome|"1. Expert panel evaluation for identification of participants with typical symptoms~2. Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~3. Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~4. Other general interviewer ratings for assessing functioning and severity of psychopathology"
62506286|NCT01071850|EXPERIMENTAL|ASP1941 lowest dose|oral tablet
62506287|NCT01071850|EXPERIMENTAL|ASP1941 low dose|oral tablet
62506288|NCT01071850|EXPERIMENTAL|ASP1941 high dose|oral tablet
62506289|NCT01071850|EXPERIMENTAL|ASP1941 highest dose|oral tablet
62506290|NCT01071850|ACTIVE_COMPARATOR|Metformin|oral tablet
61962435|NCT02800681||Schizotypal disorder|"1. Expert panel evaluation for identification of participants with typical symptoms~2. Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~3. Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~4. Other general interviewer ratings for assessing functioning and severity of psychopathology"
61962436|NCT02032121|EXPERIMENTAL|Intervention procedures|All the procedures will be completed for every subject
61962437|NCT03949374|ACTIVE_COMPARATOR|10mg of the generic formulation (rosuvastatin, ROVASRO®)|Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
61962438|NCT03949374|ACTIVE_COMPARATOR|10mg of the reference formulation (rosuvastatin, CRESTOR®)|Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)
62143935|NCT02379000|ACTIVE_COMPARATOR|TTT+Triamcinolone Acetonide|transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.
62143936|NCT06692998|EXPERIMENTAL|HILT Group|Patients will receive pulsed laser therapy using the HIRO 3 device (ASA Laser, Arcugnano, Italy) five times a week for 3 weeks, one session per day for a total of 15 sessions. The HILT device offers pulsed emission (1064 nm), very high peak power (3 kW), high fluence (energy density 360-1780 mJ/cm2), short duration (120-150 μs), average power of 10.5 W, low frequency (10-40 Hz), duty cycle of approximately 0.1%, a 0.5 cm diameter probe and a spot size of 0.2 cm. A standard handpiece equipped with fixed spacers is used to maintain the same distance from the skin. The 3-stage treatment program is planned to be applied to the 1st CMC joint area in each session.
62143937|NCT06692998|ACTIVE_COMPARATOR|LLLT Group|The MLS Multiwave Locked System laser device will be used for the treatment (low level laser). The laser probe (1 cm in diameter) will be applied directly and perpendicularly and lightly in contact with the skin. LLLT for de quatrein will be applied twice per session. Once the probe will be held in contact with the skin (at the radial styloid) and the second time in scanning mode (approximately 1 inch long along the tendon sheath). The area to be treated will be divided into 1 cm square areas and the optimum anti-inflammatory dosage (3 J/cm) continuous output mode will be used
62143938|NCT01812226||experimental group|This group will consist of men and women who received a liver transplant for alcohol-related liver disease.
62143939|NCT01812226||control group|This group will consist of men and women who had a liver transplant for reasons that are not alcohol-related.
62143940|NCT04148170|ACTIVE_COMPARATOR|classic intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with metal probe and then intubation with bicanlicular silicon tube.
62143941|NCT04148170|ACTIVE_COMPARATOR|endodiathermy probe|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
62143942|NCT04009291|EXPERIMENTAL|TransCon PTH 15 mcg|TransCon PTH 15 mcg delivered once daily by subcutaneous injection
62143943|NCT04009291|EXPERIMENTAL|TransCon PTH 18 mcg|TransCon PTH 18 mcg delivered once daily by subcutaneous injection
62143944|NCT04009291|EXPERIMENTAL|TransCon PTH 21 mcg|TransCon PTH 21 mcg delivered once daily by subcutaneous injection
62143945|NCT04009291|PLACEBO_COMPARATOR|Placebo|Placebo mimicking 15, 18, or 21 mcg of TransCon PTH delivered once daily by subcutaneous injection
62506291|NCT01071850|PLACEBO_COMPARATOR|Placebo|oral tablet
62143946|NCT04009291|EXPERIMENTAL|Open-Label Extension Period|Subjects who complete the four-week blinded period are assigned to open-label treatment with TransCon PTH for up to 262 weeks, with up to an initial 14 weeks of TransCon PTH titration and standard of care optimization, followed by approximately 248 weeks of individualized dosing.
62143947|NCT02554006|OTHER|good clinical practice|all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
62143948|NCT02554006|EXPERIMENTAL|bundle group|patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
62348425|NCT00995670|EXPERIMENTAL|Sevoflurane and Glucose|"Endothelial function will be measured via forearm blood flow (FBF). Subjects may get I/R injury (ischemia) without glucose or sevoflurane (placebo); I/R with glucose only (glucose trial); I/R with sevoflurane only (sevo trial); I/R with glucose and sevoflurane (combo trial). Baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Glucose: 5% dextrose will be infused at 12 ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 1 hr to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent I/R injury.~Sevoflurane: 1 minimum alveolar concentration (MAC) for 20 min (after 1 hr glucose and before I/R) 26 volunteers were studied 67 times in this arm."
62704790|NCT01143454||2. Child index case and child relatives|Children over 1 year of age who is affected with diseases/disorders (index cases), or who is a relative of a person who is affected with diseases/disorders.
62506292|NCT02087891|NO_INTERVENTION|CTL|Wait-list control, no intervention. Intervention offered after week 16 and outcomes are collected.
62704791|NCT01143454||3. Healthy adult volunteers|Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.
62506293|NCT02087891|EXPERIMENTAL|Web-based stress management (WSM)|Subjects randomized to this group will receive access to the WSM program to complete on their own time.
62506294|NCT02087891|EXPERIMENTAL|WSMg1|Subjects randomized to this group will receive access to WSM with group support. They will meet once per week for 1 hour. Meeting will be led by one of their peers who is a non-expert facilitator.
61962439|NCT01815515|EXPERIMENTAL|18F-DCFBC|Participants with hormone-naive prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC) with metastatic lesions detected on conventional imaging modalities (contrast-enhanced computed tomography \[CECT\] and bone scintigraphy \[BS\]) undergo PET imaging with 18F-DCFBC radiotracer.
61962440|NCT00769470|ACTIVE_COMPARATOR|Arm I|Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61962441|NCT00769470|EXPERIMENTAL|Arm II|Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61962442|NCT00769470|EXPERIMENTAL|Arm III|Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61962443|NCT04942444|NO_INTERVENTION|Control Group|Patients from the control group kept on taking the same medical treatment that they received before randomization
61962444|NCT04942444|EXPERIMENTAL|Dry needling group|Besides maintaining their current medical treatment, patients from the experimental group received an additional weekly one-hour session of dry needling over the 18 tender points for a 6-week-period.
61962445|NCT05833854|EXPERIMENTAL|Virtual reality glasses group|The study group (n=25) will watch a video with virtual reality glasses during the intramuscular injection.
61962446|NCT05833854|EXPERIMENTAL|Manual pressure group|In the study group (n=25), pressure will be applied to the area to be injected for 10 seconds before the intramuscular injection procedure.
61962447|NCT05833854|NO_INTERVENTION|Control group|The control group (n=25) will not be subjected to any application other than intramuscular injection, which is routinely applied in pediatric emergency.
61962448|NCT06178939|ACTIVE_COMPARATOR|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
61962449|NCT06178939|EXPERIMENTAL|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
61962450|NCT02568800|EXPERIMENTAL|Prolonged Cefepime Infusion|Cefepime infusions should last 4 hours at least
61962451|NCT02568800|ACTIVE_COMPARATOR|Usual Cefepime Infusion|Cefepime infusion should last no more than 30 minutes
61962452|NCT01991769|EXPERIMENTAL|exercise diabetes type 2|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
61962453|NCT01991769|ACTIVE_COMPARATOR|exercise healthy volunteers|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
61962454|NCT06279962|EXPERIMENTAL|Experimental: V1: Woman with Major Depressive Disorder|Depicting a young woman with symptomatic major depressive disorder
61962455|NCT06279962|EXPERIMENTAL|Experimental: V2: Man with Major Depressive Disorder|Depicting a young man with symptomatic major depressive disorder
61962456|NCT06279962|EXPERIMENTAL|Experimental: V3: Man with Generalized Anxiety Disorder|Depicting a young man with symptomatic generalized anxiety disorder
62704792|NCT06132958|EXPERIMENTAL|Sacituzumab tirumotecan|Participants will receive 4 mg/kg of sacituzumab tirumotecan via intravenous (IV) infusion on Day 1 of each 14-day cycle. Additionally, participants receive diphenhydramine (or equivalent), a Histamine (H2 antagonist) of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
61962457|NCT06279962|EXPERIMENTAL|Experimental: V4: Woman with Generalized Anxiety Disorder|Depicting a young woman with symptomatic generalized anxiety disorder
61962458|NCT06279962|EXPERIMENTAL|Experimental: V5: Woman with Schizophrenia|Depicting a young woman with symptomatic schizophrenia
61962459|NCT06279962|EXPERIMENTAL|Experimental: V6: Man with Schizophrenia|Depicting a young man with symptomatic schizophrenia
61962460|NCT06279962|EXPERIMENTAL|Experimental: V7: Woman with Alcohol Use Disorder|Depicting a young woman with symptomatic alcohol use disorder
61962461|NCT06279962|EXPERIMENTAL|Experimental: V8: Man with Alcohol Use Disorder|Depicting a young man with symptomatic alcohol use disorder
61962462|NCT05009615|EXPERIMENTAL|Green coffee extract|Nutraceutical containing a decaffeinated green coffee extract rich in phenolic compounds (hydroxycinnamates). Participants received powdered sachets containing 300 mg of GC extract twice daily for 8 weeks
61962463|NCT05009615|EXPERIMENTAL|Beta-glucan|Nutraceutical containing a oat beta-glucan. Participants received powdered sachets containing 2.5 g of BG twice daily for 8 weeks
61962464|NCT05009615|EXPERIMENTAL|Green coffee + Beta-glucan|Nutraceutical containing both green coffee extract and beta-glucan. Participants received powdered sachets containing 2.5 g of BG plus 300 mg of GC extract twice daily for 8 weeks
61962465|NCT02401438||pregnant women with preterm delivery|5D LB and 2D ultrasounds will be done to pregnant women between 28 and 34 weeks planned for termination of pregnancy for obstetric or medical causes.
61962466|NCT06506708|NO_INTERVENTION|Usual care group|The gynecologist will proceed to administer the standard treatments to the control group. Moreover, assessors will emphasize healthy lifestyle benefits.
62348426|NCT00995670|EXPERIMENTAL|Vitamin C and Glucose|"To determine if vitamin C can restore the impairment of the endothelium (FBF) caused by the glucose (dextrose infusion). All subjects received glucose and I/R injury (ischemia), either with or without vitamin C. Control baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Vitamin C: 1 gm iv bolus injection 5 min before I/R injury 16 volunteers were studied 25 times in this arm."
62704793|NCT06132958|ACTIVE_COMPARATOR|Chemotherapy|Participants will receive 60 mg/m\^2 of doxorubicin by IV infusion on Day 1 of each 21-day cycle; or 80 mg/m\^2 of paclitaxel by IV infusion on Days 1, 8, and 15 of each 28-day cycle.
62704794|NCT03481829||Children|Children of mothers enrolled in the study
61962467|NCT06506708|EXPERIMENTAL|Experimental group|The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once session each two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing Swedish massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and relaxing music, and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
61962468|NCT00579228||1 Cardiovascular disease (CVD) in Participants without diabetes|Progression of cardiovascular disease (CVD) in participants without diabetes
61962469|NCT00579228||2 Cardiovascular disease (CVD) in participants with type 2 Diabetes|Progression of cardiovascular disease (CVD) in participants with type 2 Diabetes with good control
61962470|NCT00579228||3 Cardiovascular disease (CVD) in participants with type 1 diabetes|Progression of cardiovascular disease (CVD) in participants with type 1 diabetes with good control
62506295|NCT02087891|EXPERIMENTAL|WSMg2|Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
62704795|NCT03481829||Pregnant women and mothers|Pregnant women/mothers
62704796|NCT06225258|NO_INTERVENTION|Group C|Patients are treated according to the recommendations of the Surviving Sepsis Campaign.
62704797|NCT06225258|EXPERIMENTAL|Group Xn|Patients, who are admitted to the Intensive Care Unit (ICU) due to septic shock in the early, acute phase. Patients are treated according to the recommendations of the Surviving Sepsis Campaign and receive xanthohumol at a dose of 2 mg per kg body weight administered via nasogastric tube as supportive therapy.
62704798|NCT05206500|OTHER|Symptomatic Patients with low Colony Count|Patients with positive urinalysis, symptomatic, and Urine Culture Colony Count \<10,000 to be treated based on Next Generation Sequencing result.
62704799|NCT05139017|EXPERIMENTAL|ZV + R-GemOx (Part 1)|Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.
62704800|NCT05139017|EXPERIMENTAL|ZV + R-GemOx (Part 2)|Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
62704801|NCT05139017|ACTIVE_COMPARATOR|R-GemOx (active control for Part 2)|Participants will receive R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
62704802|NCT05139017|EXPERIMENTAL|ZV + BR (Part 2)|Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m\^2, given intravenously on Day 1 and Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2, of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
62704803|NCT05139017|ACTIVE_COMPARATOR|Bendamustine Rituximab (BR)|Participants will receive Rituximab 375 mg/m\^2, given intravenously on Day 1 Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
62704804|NCT05139017|EXPERIMENTAL|ZV + BR (Part 1)|Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.
62704805|NCT03782207||Cohort 1 (UC LOT2+later lines[LOT2+] & platinum eligible LOT1)|"Participants diagnosed with locally advanced or metastatic Urothelial Cancer previously treated with platinum-containing chemotherapy.~Enrollment is closed."
61962471|NCT05641324|EXPERIMENTAL|ANV419 single agent, dose 1, Q2W|
61962472|NCT05641324|EXPERIMENTAL|ANV419 single agent, dose 2, Q2W|
62704806|NCT03782207||Cohort 2 (NSCLC LOT2 plus later lines [LOT2+])|"Participants diagnosed with Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after prior chemotherapy. Participants with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumor mutations should also have received targeted therapy.~Enrollment closed."
62704807|NCT03782207||Cohort 3 (NSCLC LOT1 plus EGFR+/ALK+ LOT2+)|"EMA: Participants diagnosed with locally advanced/metastatic non-squamous NSCLC not previously treated. Participants with EGFR-activating mutations or ALK-positive tumor mutations should have received at least one line of targeted therapy.~FDA: for the treatment of adult participants with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Participants with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.~Enrollment is closed."
62704808|NCT03782207||Cohort 4 (ES-SCLC LOT1)|"Participants diagnosed with extensive stage (ES) small cell lung cancer (SCLC) not previously treated.~Enrollment is closed."
61962473|NCT05641324|EXPERIMENTAL|ANV419 Q2W + Lenalidomide plus low-dose dexamethasone|
61962474|NCT05641324|EXPERIMENTAL|ANV419 Q2W + Daratumumab|
61962475|NCT04051008|NO_INTERVENTION|Group 1 - Control|No intervention - participants will shop in-person as they usually would. Participants will receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
61962476|NCT04051008|EXPERIMENTAL|Group 2 - Online|Participants will utilize online grocery shopping (shopping at a local grocery store via an online platform). Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
62506296|NCT00707317||1|HIV infected individuals
62506297|NCT00707317||2|patients with chronic renal failure
62506298|NCT00707317||3|patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)
62506299|NCT00707317||4|patients with rheumatoid arthritis
62506300|NCT00707317||5|stem cell transplant recipients
62506301|NCT00707317||6|immunocompromised patients with confirmed tuberculosis
62506302|NCT00707317||7|immunocompetent controls with no known risk of exposure or tuberculosis
62506303|NCT06013345|ACTIVE_COMPARATOR|Arm P|Patients in arm P will be administered 2-3 mg midazolam IV before the beginning of the procedure, 5-10 mcg sufentanil IV and a loading dose of propofol 0,8-1,0 mg/kg in 2-5 minutes before the start of the ablation phase. During the procedure, boluses of 0,5 mg/kg propofol will be repeated as needed, in case of inappropriate analgosedation, boluses of midazolam and/or sufentanil can also 0be repeated.
62506304|NCT06013345|EXPERIMENTAL|Arm R|Patients in arm R will be administered 2,5 mg loading dose of remimazolam followed by continuous infusion at 0,5 mg/h/kg of ideal body weight (IBW, calculated using the Miller formula) and a dose of ketamine 1 mg/kg IBW 2-5 minutes before the beginning of the ablation phase. In case of inadequate sedation depth, a bolus of 2,5 mg remimazolam can be repeated as needed. If the patient shows signs of pain or discomfort, a single dose of ketamine - 0,5 mg/kg IBW - will be administered, followed by a bolus of 5-10 mcg sufentanil if needed. The continuous infusion will be terminated as the last ablation pulses are delivered.
62506305|NCT06013345|ACTIVE_COMPARATOR|Arm TIVA (Total Intravenous Anesthesia)|Patients randomised in arm TIVA will be administered light analgosedation with spontaneous ventilation for the first part of the procedure. The analgosedation will be induced and maintained with bolus of 5 mcg sufentanil IV and propofol infusion dosed by TCI system (the target plasma concentration for propofol 1-2 mcg/ml). Before the beginning of the ablation phase, general anesthesia will be induced with one bolus of 5-10 mcg sufentanil (the TCI target 3-7 mcg/ml for induction and 3-5 mcg/ml for the rest of the procedure), and a bolus of rocuronium 0,2-0,4 mg/kg IBW. Then, the airways will be secured with a laryngeal mask (LMA), the patient ventilated (0,4 - 0,45 FiO2, the target EtCO2 30 - 45 mmHg). After the last ablation pulse is delivered, infusion of propofol will be ceased and LMA extracted at the return of consciousness, muscle strength and sufficient spontaneous ventilation. If residual muscle relaxation occurs, sugammadex will be administered.
62506306|NCT05562453|EXPERIMENTAL|Investigational device|The investigational device (FlowOx2.0) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the commercial Pressure Chamber (and disposable parts). Subjects randomized to the investigational device arm will receive a Control Unit that generates intermittent negative pressure (INP) of - (minus) 40 mmHg.
62506307|NCT05562453|SHAM_COMPARATOR|Comparator|The investigational device (FlowOx2.0) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the commercial Pressure Chamber (and disposable parts). Subjects randomized to the comparator arm will receive a Control Unit that generates INP pulses of only - (minus) 10 mmHg.
62506308|NCT06535035|EXPERIMENTAL|Group1 laser therapy|Data collection, informed consent, a complete clinical and oral evaluation, as well as a radiological study with cone beam computed tomography (CBCT). A surgical intervention was performed with the placement of dental implants. In the experimental group, low-level laser therapy (LLLT) was applied immediately after the placement of the implants in a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA), voltage 100-240 V, 1.5 A, power 0.5 W, 10-20 J, for 10-30 seconds. It was applied to three points in the area: buccal side, palatal/lingual side, and occlusal side to stimulate the tissue.Pain and inflammation were evaluated using visual analog scales (VAS) from day 0 to 7 days postoperatively. Additionally, MDA levels were measured and the OHIP-14 questionnaire was used to assess oral health-related quality of life
62704809|NCT03782207||Cohort 5 (NSCLC LOT1)|Participants diagnosed with metastatic Non-Small Cell Lung cancer with high PD-L1 expression, previously untreated.
62704810|NCT03782207||Cohort 6 (HCC LOT1)|Participants diagnosed with unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
61962477|NCT04051008|EXPERIMENTAL|Group 3 - Default|The default intervention will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make recipes from the provided recipe cards, and that they can modify it as they like. Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
61962478|NCT03284944||Control (Before) Period|Use of standard-volume blood collection tubes (6 weeks)
61962479|NCT03284944||Intervention (After) Period|"Use of small-volume (soft-draw) blood collection tubes (6 weeks following 2-week washout period)"
61962480|NCT02941198|ACTIVE_COMPARATOR|Gynefix|The GyneFix® 200 IUD(frameless iud) is only 2 cm long. Its small surface area is 1/3 of that of the conventional T-shaped IUDs such as TCu380A
61962481|NCT02941198|ACTIVE_COMPARATOR|Cu T380a|conventional T-shaped IUDs (TCu380A)which has a frame will be placed into the uterus after placental extraction
61962482|NCT01780818|ACTIVE_COMPARATOR|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
61962483|NCT01780818|EXPERIMENTAL|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
61962484|NCT01780818|EXPERIMENTAL|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
62704811|NCT05320367|EXPERIMENTAL|CBD (Group 1)|"Group will receive four CBD doses (5 mg, 20 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence"
62143949|NCT06341959|EXPERIMENTAL|Intervention Group|The intervention group will be provided with tools to facilitate dental contact and will be informed about the importance of regular dental visits. Participants are given the opportunity to receive an oral examination. Afterwards, each participant will receive brochures with oral hygiene instructions to take home. Participants will receive information about any identified oral pathology. A referral letter for the dentist and a report for the general practitioner will also be prepared to increase social influence. If the participant doesn't have a dentist, the participant will receive a list of contact information for dentists in the area.
62143950|NCT06341959|NO_INTERVENTION|Control Group|In the control group, no oral examination will be performed. However, participants will be given a list of nearby dentists and flyers with oral hygiene instructions.
62143951|NCT02831699||Febrile Rash|
62539270|NCT06399653|ACTIVE_COMPARATOR|Active cervical transcutaneous vagus nerve stimulation|Participants will be assigned to active transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
62143952|NCT02831699||Household|
62143953|NCT02831699||Guillain-Barré prospective|
62143954|NCT02831699||Prior Guillain-Barré|
62143955|NCT03043443|PLACEBO_COMPARATOR|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
62143956|NCT03043443|ACTIVE_COMPARATOR|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
62539271|NCT06399653|PLACEBO_COMPARATOR|Sham cervical transcutaneous vagus nerve stimulation|Participants will be assigned to sham transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
62539272|NCT01239134|EXPERIMENTAL|TRX518|
62539273|NCT03996629|EXPERIMENTAL|Pharmacist-managed anticoagulation service|
62539274|NCT03996629|NO_INTERVENTION|Usual medical care|
62539275|NCT04773301|EXPERIMENTAL|LEVOBUPIVACAINE|Patients treated with Levobupivacaine Altan 7.5 mg / ml solution for injection and infusion
62539276|NCT04773301|EXPERIMENTAL|ROPIVACAINE|Patients treated with Ropivacaine Altan 2 mg / ml solution for infusion
62539277|NCT03485365|EXPERIMENTAL|Part A: Cohort 1: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
62539278|NCT03485365|EXPERIMENTAL|Part A: Cohort 2: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
62539279|NCT03485365|EXPERIMENTAL|Part A: Cohort 3: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
62539280|NCT03485365|EXPERIMENTAL|Part A: Cohort 4: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
62539281|NCT03485365|EXPERIMENTAL|Part A: Cohort 5: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
62539282|NCT03485365|EXPERIMENTAL|Part A: Cohort 6: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
62539283|NCT03485365|PLACEBO_COMPARATOR|Part A: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC or IV route.
62539284|NCT03485365|EXPERIMENTAL|Part B: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
62539285|NCT03485365|PLACEBO_COMPARATOR|Part B: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC route.
62539286|NCT05485987|EXPERIMENTAL|Vatiquinone|Participants will receive an oral solution (100 milligrams \[mg\]/milliliter \[mL\]) of vatiquinone (15 mg/kilogram \[kg\] if body weight \<13 kg and 200 mg if body weight ≥13 kg) 3 times a day (TID) for 72 weeks.
62539287|NCT02686138|EXPERIMENTAL|50mg BID|Tenapanor, 50mg BID (100mg total)
62539288|NCT02686138|PLACEBO_COMPARATOR|Placebo|Placebo
62539289|NCT02024113||Lung cancer|"Subjects with lung cancer detected by a computed tomography (CT)-scan and referred to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology with respect to radiological or clinical data.~Intervention: a fasted venous blood sample is taken before PET-scan"
62539290|NCT02024113||Control subjects|"The control group consists of subjects who were referred to the department Nuclear Medicine for an examination of the heart. This control group represents the average population, consists of healthy subjects and patients with non-cancer diseases and who did not undergo a PET/CT-scan.~Intervention: fasted venous blood sample"
62539291|NCT02418481|EXPERIMENTAL|Group A|DC-CIK cells will be used against tumor cells.
62539292|NCT02418481|EXPERIMENTAL|Group B|γδ T cells will be used against tumor cells.
62539293|NCT02418481|EXPERIMENTAL|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
62539294|NCT02111928||NovaTears®|
62539295|NCT02927366|EXPERIMENTAL|QCC374|Adult patients with pulmonary arterial hypertension (PAH) on QCC374. All patients were initiated at 0.03 mg BID (Day 1-3), and were up-titrated to next higher dose 0.06 mg BID (Day 4) and increased to 0.12 mg BID (Day 7-14).
62539296|NCT02927366|PLACEBO_COMPARATOR|Placebo|Adult patients with pulmonary arterial hypertension (PAH) on placebo matching to QCC374 doses (0.03 mg BID (Day 1-3), 0.06 mg BID (Day 4) and 0.12 mg BID (Day 7-14)).
62539297|NCT03058432|EXPERIMENTAL|Intensity-modulated Radiotherapy|Radiotherapy alone was given.
62539298|NCT03058432|ACTIVE_COMPARATOR|Concurrent chemoradiotherapy|Concurrent cisplatin-based radiotherapy was given.
62539299|NCT05787301||Patients with hearing loss after infection|Patients with hearing loss after infection
62539300|NCT05787301||Patients with hearing loss before infection|Patients with hearing loss before infection
62539301|NCT05787301||Healthy control|Healthy subjects who have never been infected with COVID-19 or diagnosed with hearing loss.
62539302|NCT02598687|OTHER|treatment|treatment arm: TH-302 pre-treatment day 4 and weekly during treatment. 5 x carboplatin and paclitaxel, radiotherapy: 23 x 1.8Gy HX4 scans day 1 and day 8,surgery 6-10 weeks after chemo-radiotherapy
62539303|NCT02388360|OTHER|topical prostaglandin analogs|
62539304|NCT01844232|EXPERIMENTAL|Arbaclofen Extended Release (ER) Tablets|Arbaclofen Extended Release Tablets, 20 mg/day, 30 mg/day or 40 mg/day
62348427|NCT00995670|EXPERIMENTAL|Statins and Glucose|"Volunteers ingested a 40 mg simvastatin (statin) pill for the two evenings prior to study day and the morning of the study to determine the effect of simvastatin on modulating the I/R injury during hyperglycemia (high glucose). Volunteers were studied with statin alone and with statin and glucose.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Statin: 40 mg of simvastatin 17 volunteers were studied 31 times in this arm."
62539305|NCT04937114|EXPERIMENTAL|Flap will be approximated using conventional, simple continuous suturing with barbed sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with unidirectional barbed sutures.
62704812|NCT05320367|EXPERIMENTAL|CBD (Group 2)|"Group will receive four CBD doses (5 mg, 20 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence"
62704813|NCT05320367|EXPERIMENTAL|CBD (Group 3)|"Group will receive four CBD doses (5 mg, 20 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62704814|NCT05320367|EXPERIMENTAL|CBD (Group 4)|"Group will receive four CBD doses (5 mg, 20 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62704815|NCT05320367|EXPERIMENTAL|CBD (Group 5)|"Group will receive four CBD doses (5 mg, 20 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
62704816|NCT05718817|EXPERIMENTAL|XEN1101 15 or 25 mg/day|XEN1101 15 or 25 mg/day
62704817|NCT05844137|EXPERIMENTAL|Evidence-based care of NAFLD in T2D|Intervention content will include: 1) NAFLD education; 2) diet/lifestyle support; 3) T2D medication management; and 4) clinically-indicated liver testing and care
62704818|NCT06013475||Apalutamide|
62348428|NCT03930420|ACTIVE_COMPARATOR|Standard|Local health department staff in the standard arm will receive Connect to Wellness intervention materials, multiple real-time training sessions delivered via webinar, access to a web-based platform that includes all intervention and training materials and has features allowing them to communicate with each other and with research staff, and a monthly group technical assistance call.
62348429|NCT03930420|EXPERIMENTAL|Enhanced|Local health department staff in the enhanced arm will receive all the Connect to Wellness intervention materials, training, and support as described for the standard arm. In addition, the participants in the enhanced arm can telephone research staff at will to receive additional technical assistance. Research staff will also contact participants monthly, if they do not request assistance proactively.
62348430|NCT05632224|ACTIVE_COMPARATOR|Aprepitant|Substance P inhibitor chemotherapeutic and also useable for prevention of postoperative nausea and vomiting
62348431|NCT05632224|ACTIVE_COMPARATOR|Granisetron|5- HT3( 5-hydroksitriptamine 3) antagonist drug for prevention of postoperative nausea and vomiting
62348432|NCT04585451||Chronic Pain Patients|
62348433|NCT04585451||Healthy Controls|
62348434|NCT00151125|EXPERIMENTAL|A|rhIL-11 (Interleukin-11, Neumega) 25 mcg/kg subcutaneously daily for 7 days
62348435|NCT00151125|EXPERIMENTAL|B|rhIL-11 (interleukin-11, Neumega) 50 mcg/kg subcutaneously daily for 7 days
62348436|NCT00151125|EXPERIMENTAL|C|rhIL-11 (Interleukin-11, Neumega) 10 mg/kg subcutaneously daily for 7 days
62348437|NCT01692912|ACTIVE_COMPARATOR|Intensive Care (IC)|Rheumatologists treating to target of DAS28\<2.6
62348438|NCT01692912|NO_INTERVENTION|Routine Care (RC)|Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28\<2.6)
62348439|NCT02855320|EXPERIMENTAL|PE (patient education)|Nurse-led self-management education intervention : The intervention group will benefit from the nurse intervention in addition to usual care : follow up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
62348440|NCT02855320|NO_INTERVENTION|Standard|The control group will be followed up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
62348441|NCT02993055|EXPERIMENTAL|Ulimorelin|Active
62348442|NCT02993055|PLACEBO_COMPARATOR|Placebo|Placebo
62348443|NCT02601443|EXPERIMENTAL|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.~Cervical pessary has been tried as a simple, non-invasive alternative that might replace the above invasive cervical stitch operation to prevent preterm birth."
62348444|NCT02601443|NO_INTERVENTION|Routine care (watch and wait)|
62348445|NCT05903937|EXPERIMENTAL|Autologous tumor infiltrating lymphocytes (TIL)|
62348446|NCT00059618|EXPERIMENTAL|Bortezomib|PS-341 (Bortezomib) 0.8-1.5 mg/m\^2 IV push + Carboplatin (AUC 5) IV on Day 1 of each cycle, then Bortezomib alone on Days 4, 8 and 11 in each 28 day cycle.
62704819|NCT06013475||Darolutamide|
62704820|NCT06013475||Enzalutamide|
62704821|NCT04659408|EXPERIMENTAL|Bactosan - oat bran|This group will receive Bactosan first, followed by oat bran.
62704822|NCT04659408|EXPERIMENTAL|Oat bran - Bactosan|This group will receive oat bran first, followed by Bactosan.
62704823|NCT04689828|EXPERIMENTAL|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used.
62704824|NCT04689828|ACTIVE_COMPARATOR|Androgen receptor-directed therapy (ARDT)|For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used.
62506309|NCT06535035|SHAM_COMPARATOR|group Sham|data collection, informed consent, a complete clinical and oral evaluation, as well as a radiological study with cone beam computed tomography (CBCT). Surgical intervention was performed with the placement of dental implants. In the group sham comparate p, low-level laser therapy (LLLT) was applied inactive . Pain and inflammation were evaluated using visual analog scales (VAS) from day 0 to 7 days postoperatively. Additionally, MDA levels were measured and the OHIP-14 questionnaire was used to assess oral health-related quality of life
62506310|NCT06615856||Patients referred for high-resolution oesophageal manometry and multi-channel impedance pH testing|Patients that have been referred for high-resolution oesophageal manometry and multi-channel intraluminal impedance-pH monitoring at the Gastrointestinal Physiology department at Leeds Teaching Hospitals between September 2024 - January 2025 (subject to change based on recruitment time).
61962485|NCT05466682|EXPERIMENTAL|RELAX|"Patients will receive Progressive Muscle Relaxation Therapy (PMR) via the RELAXaHEAD smart-phone app.~Patients will be asked to do the following:~* Week 1: 5 min deep breathing at least 5/7 days of the week~* Week 2: 5 min PMR session at least 5/7 days of the week~* Week 3: 15 min PMR session at least 5/7 days of the week~* Week 4: PMR at least 4 days a week~* Week 5: PMR at least 3 days a week~* Weeks 6-8: Use PMR when it is most helpful~Patients will be asked to track headache frequency, intensity, sleep, and acute medication use on the app. They will also receive written educational material about migraine."
61962486|NCT05466682|ACTIVE_COMPARATOR|Monitored Usual Care (MUC)|"Patients will be given a general education session consisting of basic migraine information. They will receive the RELAXaHEAD app but the Progressive Muscle Relaxation Therapy (PMR) function will be blocked.~Patients will be asked to track headache frequency, intensity, sleep, and acute medication use on the RELAXaHEAD app. They will also receive written educational material about migraine."
61962487|NCT02454296|ACTIVE_COMPARATOR|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
61962488|NCT02454296|SHAM_COMPARATOR|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
61962489|NCT03564314|EXPERIMENTAL|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
61962490|NCT03564314|NO_INTERVENTION|Control|Usual care provided to patients with AKI on surgical units.
61962491|NCT02640014|EXPERIMENTAL|Study 1: Milk OIT follow up|Follow up on patient with severe milk allergy how have participated to milk OIT.
61962492|NCT02640014|NO_INTERVENTION|Study 1: Follow up|Follow up on patient with severe milk allergy how have not participated to milk OIT.
61962493|NCT00655044||Type 1 and type 2 diabetes patients|
62348447|NCT02401243|EXPERIMENTAL|Cohort 1 (INSIGHT titration algorithm)|INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L
62506311|NCT02485158|EXPERIMENTAL|AMP, ALC, THC or Placebo 1|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
62704825|NCT06481319|EXPERIMENTAL|Infertility Patient Navigator Group|Participants in this group will receive assistance from the Infertility Patient Navigator (PN) to schedule and complete the infertility evaluation.
62704826|NCT06481319|NO_INTERVENTION|Historical Comparison Group|Age-matched controls selected from the electronic medical record database who received infertility evaluation without PN assistance.
61962494|NCT01102959|EXPERIMENTAL|Photographic Material|Photographic Educational Material on Carbohydrate Counting
62348448|NCT02401243|EXPERIMENTAL|Cohort 2 (EDITION titration algorithm)|INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L
62348449|NCT01766479|EXPERIMENTAL|Family Degree-relatives of pts. with CRC|Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day.
62704827|NCT04002947|EXPERIMENTAL|1|Acalabrutinib 100 mg orally twice a day for 14 days; Following window: patients with \> or = to 25% tumor reduction, treat with DA-EPOCH-R or R-CHOP + acalabrutinib 100mg orally twice a day for the first 10 days, for 6 cycles; whereas, patients with \<25% tumor reduction, treat with DA-EPOCH-R or R-CHOP alone for 6 cycles
62348450|NCT03260972|ACTIVE_COMPARATOR|Chloroprocaine arm|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
61962495|NCT02172924|ACTIVE_COMPARATOR|Early Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy.
61962496|NCT02172924|ACTIVE_COMPARATOR|Late Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy.
61962497|NCT03751111|EXPERIMENTAL|Naloxone|Naloxone at an sublingual dose of 40 mg daily will be given to each subject.
61962498|NCT03751111|PLACEBO_COMPARATOR|Placebo|Sublingual placebo will be given to each subject.
61962499|NCT06254430||Epidural analgesia|"The patients were fasted for 8 hours before the operation without premedication. The patient was taken to the operation room. In all cases, a vein on the back of the hand was cannulated for peripheral venous catheter was cannulated from the back of the hand. Standard monitoring was applied.~In the epidural group, 42 patients received a standard 18 G injection at the appropriate level between T8 and T10. The epidural space was entered by loss of resistance method with touchy needle. 15 µg in 3 mL saline The test dose was administered by administering epinephrine. Then the epidural catheter was inserted towards the cranium. was advanced five cm. Bupivacaine 0.25% was started as infusion through the catheter.~Since the mean arterial pressure dropped below 60 mm/hg in 5 patients, epidural infusion was stopped and inotropic treatment was started."
62348451|NCT03260972|PLACEBO_COMPARATOR|Normal saline arm|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
61962500|NCT06254430||Erector Spina Plan(ESP) Block|"Esp group included 28 patients in the preoperative operating theatre between T8 and T10 1 hour before the operation.~level, the USG (ultrasonography) probe is placed in the midline in the cephalocaudal direction and then the USG (ultrasonography) probe is placed approximately 3 cm laterally over the transverse processes and transverse with the erector spinae muscle 0.25 % bupivacaine 20 cc each in the fascial plane between the processes bilateral thoracic erector spina block and then 50 mg dexketoprofen before surgery implemented."
62348452|NCT02921763||Dydrogesterone|Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.
62348453|NCT02397603|ACTIVE_COMPARATOR|bupivacaine saline group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml normal saline perineurally in the paravertebral catheter
62348454|NCT02397603|ACTIVE_COMPARATOR|Dexmedetomidine- bupivacaine group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml (50 microgram) dexmedetomidine administered perineurally in the paravertebral catheter.
62704828|NCT06123312|EXPERIMENTAL|Single intervention arm: Tri-modality biopsy|Patients enrolled in this single arm will have lung nodules biopsied by Tri-modality (forceps biopsy, needle aspiration, and cryobiopsy)
62704829|NCT01861106|ACTIVE_COMPARATOR|Arm A|10/10 HLA Matched Related Donor or Unrelated Donor or 9/10 HLA with DQ mismatch Transplant
62704830|NCT01861106|ACTIVE_COMPARATOR|Arm B|9/10 or 8/10 HLA Match Related Donor or Unrelated Donor or Haploidentical Donor Transplant
62704831|NCT01861106|ACTIVE_COMPARATOR|Arm C (combined with Arm B per Amendment N)|Haploidentical Related Donor Transplant
62704832|NCT01861106|ACTIVE_COMPARATOR|Arm D (Deleted this arm per amendment I)|Umbilical Cord Blood Transplant
62704833|NCT01861106|NO_INTERVENTION|Arm E (Deleted this arm per amendment O)|Donor
62704834|NCT05719584|EXPERIMENTAL|hypopressive exercises|pelvic floor muscle exercises along with hypopressive exercises
62704835|NCT05719584|ACTIVE_COMPARATOR|pelvic floor muscle training|pelvic floor muscle exercises alone
62704836|NCT03878589|ACTIVE_COMPARATOR|Oxytocin Crossover Placebo Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 International Units of oxytocin (OT) twice a day at home, at 8-9 in the morning and again at 5-6 in the afternoon. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 International Units of placebo (P) twice a day will be self-administered.
62704837|NCT03878589|ACTIVE_COMPARATOR|Placebo Crossover Oxytocin Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 International Units of placebo (P) twice a day at home, at 8-9 in the morning and again at 5-6 in the afternoon. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 International Units of oxytocin (OT) twice a day will be self-administered.
61962501|NCT01983436|EXPERIMENTAL|Manual Lymphatic Drainage|"* 9 daily sessions of manual lymphatic drainage (except on Saturday/Sunday) starting at Day 1 after surgery.~* 4 more sessions (one every two days)."
61962502|NCT01983436|NO_INTERVENTION|Control|No session of manual lymphatic drainage
61962503|NCT04750330||Severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the Intensive Care Unit (ICU) during hospitalisation
62348455|NCT01076738||single group study|
62348456|NCT02976727|EXPERIMENTAL|GroupA (Vit-D pretreated AFL-PDT group )|Group A was treated with topical VitD-assisted AFL-PDT
62348457|NCT02976727|ACTIVE_COMPARATOR|GroupB (Conventional AFL PDT group )|Group B was treated with conventional AFL-PDT
62348458|NCT04284280|EXPERIMENTAL|Early Routine Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) when feeds of 150 ml/kg/day are reached (120Kcal/kg/day)
62348459|NCT04284280|ACTIVE_COMPARATOR|Selective Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) only for weight gain less than 15g/kg/day after full feeds of 180 ml/kg/day are achieved (120 Kcal/kg/day). If milk of any infant in the selective fortification group gets fortified the volume will be decreased to 150 ml/kg/day to keep the total caloric intake equal.
62348460|NCT02287402|EXPERIMENTAL|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
62348461|NCT02056717|EXPERIMENTAL|Dexamethasone group|
62348462|NCT02056717|PLACEBO_COMPARATOR|Control group|
62348463|NCT04649762||Control|Group 1 includes patients with anxiety consulting a doctor not practicing hypnosis
62348464|NCT04649762||TAC|Group 2 includes patients with anxiety consulting a doctor practicing hypnosis
62348465|NCT01094951|OTHER|ENGAGE|"In stage 1, study investigators will train Neighborhood House caseworkers to screen their clients for depressive symptoms.~In stage 2, study investigators will train Neighborhood House caseworkers to use the ENGAGE intervention in referring their clients to mental health services"
62348466|NCT03398746|EXPERIMENTAL|LOOP Technique|Placement of subcutaneous loop drain
62348467|NCT03398746|ACTIVE_COMPARATOR|Incision and Drainage|Standard Incision and Drainage Technique
62348468|NCT06480188|EXPERIMENTAL|Group A|GPi-DBS group
62348469|NCT06480188|EXPERIMENTAL|Group B|STN-DBS group
62348470|NCT03703271|ACTIVE_COMPARATOR|chemotherapy|Methotrexate 0.4mg/kg·d, im ,\*5d started at the first day of cycle, two weeks a cycle
62348471|NCT03703271|EXPERIMENTAL|study group|hysteroscopic repeat curettage
62348472|NCT00965406|PLACEBO_COMPARATOR|glucose insulin potassium (GIK)|Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
62348473|NCT00965406|EXPERIMENTAL|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
62704838|NCT01496599||Healthy Volunteers|Subjects without PD diagnosis
62704839|NCT01496599||Parkinsons Disease subjects|Subjects fitting the MSD Clinical Diagnostic Criteria for PD
62704840|NCT01496599||Prodromal Parkinson disease|Subjects fitting the MDS prodromal criteria for PD
62704841|NCT03687957|EXPERIMENTAL|Phase I: rhIL-7-hyFc|"* Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 7 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (\~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (\~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (\~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned~* The phase I part will begin with an Accelerated Phase with 1 patient per cohort at the first 2 doses (60 mcg/kg and 120 mcg/kg) followed by a standard 3+3 design on the remaining 4 dose levels"
62704842|NCT03687957|EXPERIMENTAL|Randomized Phase II: Placebo|-Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. Placebo will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (\~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (\~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (\~Week 37). A total of 4 doses of placebo injections are planned.
61962504|NCT04750330||Non-severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the hospital but NOT to the Intensive Care Unit (ICU) during hospitalisation
61962505|NCT04750330||Minor COVID-19|Patients, diagnosed with COVID-19, who were NOT admitted to the hospital and could recover at home
61962506|NCT06272760|EXPERIMENTAL|Tele-HABIT|Children in the experimental group are going to receive intensive bimanual activity-based occupational therapy, known as Home-Based HABIT (H-HABIT). This therapy is going to be administered remotely. Each session will last for 2 hours and was conducted 5 times a week. The total duration of this intervention is 3 weeks.
61962507|NCT06272760|ACTIVE_COMPARATOR|In-laboratory-HABIT|Children in the control group are going to receive bimanual activity-based tasks. These tasks are of the same intensity and duration as those are going to be administered to the experimental group. However, unlike the experimental group, the treatment for the control group is going to be conducted in a hospital setting. The duration of this intervention is also 3 weeks, with sessions lasting 2 hours each and occurring 5 times a week.
61962508|NCT01186510|EXPERIMENTAL|Lung perfusion|
61962509|NCT01186510|ACTIVE_COMPARATOR|no lung perfusion|
61962510|NCT00958750|ACTIVE_COMPARATOR|5% MTF|5% minoxidil topical foam used once daily
62143957|NCT03709849|EXPERIMENTAL|experimental group|Intervention, dosage and frequency: drug: Bushen Culuan Decoction 13g tid and Clomiphene Citrate Tablets placebo 50mg qd; Dosage form: Bushen Culuan Decoction is dissolved medicine and Clomiphene Citrate Tablets placebo is tablets; Duration: the medicine will be taken from 5th day of a menstrual cycle, Bushen Culuan Decoction is taken for 14 days while Clomiphene Citrate Tablets placebo being taken for 5 days. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
62348474|NCT00965406|NO_INTERVENTION|Control group|No intervention and patients were treated with updated international recommendations of acute coronary syndrome.
62348475|NCT05971953|ACTIVE_COMPARATOR|Muscle Energy Technique|Muscle Energy Technique
62348476|NCT05971953|OTHER|Conventional PT|Hot pack Ischemic compression
61962511|NCT00958750|ACTIVE_COMPARATOR|2% MTS|2% minoxidil topical solution twice daily use
61962512|NCT02392143|ACTIVE_COMPARATOR|Printed Education Material|Participants received printed education materials (PEM) sent by first class mail.
61962513|NCT02392143|ACTIVE_COMPARATOR|Academic Detailing|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices.
61962514|NCT02392143|ACTIVE_COMPARATOR|Academic Detailing+Telephone Education|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices and participants received tailored telephone education (TTE).
61962515|NCT04023604|ACTIVE_COMPARATOR|Controlled diet with beef raised without antibiotics|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in RWA (raised without antibiotics) systems for three weeks.
61962516|NCT04023604|EXPERIMENTAL|Controlled diet with beef produced in conventional systems|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in conventional systems for three weeks.
61962517|NCT01001377|ACTIVE_COMPARATOR|Cetuximab|"Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.~Participants were treated until disease progression, intolerability, withdrawal of consent, or death."
61962518|NCT01001377|EXPERIMENTAL|Panitumumab|Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
61962519|NCT04803370|OTHER|Control group|Standard treatment for COVID-19 (according to clinical guidelines for COVID-19).
61962520|NCT04803370|EXPERIMENTAL|Intervention group|Convalescent patient plasma 300 ml given in 2 consecutive days, plus standard treatment for COVID-19 (according to clinical guidelines).
61962521|NCT02248103|EXPERIMENTAL|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
61962522|NCT02248103|ACTIVE_COMPARATOR|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
62348477|NCT05474911|ACTIVE_COMPARATOR|Conventional care|
62704843|NCT03687957|EXPERIMENTAL|Randomized Phase II: rhIL-7-hyFc|Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (\~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (\~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (\~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned.
62704844|NCT03687957|EXPERIMENTAL|Phase II Expansion Arm: rhIL-7-hyFc|Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (\~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (\~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (\~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned.
62704845|NCT01200680||chordoma cohort|Chordoma patients
62348478|NCT05474911|EXPERIMENTAL|Negative pressure therapy|
62348479|NCT02729077||Increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry. Patients in this arm will be especially evaluated for hypoxemia and other complications.
62704846|NCT05993442|EXPERIMENTAL|Optimised kangaroo care|"The sites randomised in this group will adapt the study intervention consisting of:~Component 1: Skin-to-skin contact for optimised KC, describes the targeted level of early, repeated and sustained skin-to-skin contact (StSC) considered to represent optimised KC in a high-technology neonatal unit environment in which KC is already offered as part of routine care.~Component 2: Implementation Support aims to engage clinical staff in the neonatal unit who are involved in implementing StSC as part of optimised KC."
62704847|NCT05993442|NO_INTERVENTION|Standard of Care|The sites randomised in this group will follow the standard care, including KC and StSC sessions, treatment of severe infections/sepsis and infection prevention and control measures based on current routine local practice. Standard care in all participating NICUs already includes KC but without specific activities to ensure this is implemented according to international best practice recommendations.
62704848|NCT05559359|EXPERIMENTAL|Lebrikizumab (Cohort 1)|"Participants who are 6 years to \<18 years of age, 12 years to \<18 years of age who weigh \<40 kilogram (kg) or 6 years to \<12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS).~Dosing will be based on weight."
62348480|NCT02729077||Not increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry.
62348481|NCT04325945|EXPERIMENTAL|Laser acupuncture|808nm low level laser therapy
62348482|NCT04325945|SHAM_COMPARATOR|Sham laser acupuncture|no low level laser output but same device
62348483|NCT01590862|ACTIVE_COMPARATOR|Deep Brain Stimulation On|We will assess Reward Motivation behavior with Deep Brain Stimulation on.
62348484|NCT01590862|NO_INTERVENTION|Deep Brain Stimulation Off|We will assess Reward Motivation behavior with Deep Brain Stimulation off.
62348485|NCT04250012|EXPERIMENTAL|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 10-week internet-based acceptance and commitment therapy intervention with three remote meetings with a psychologist"
62348486|NCT04250012|ACTIVE_COMPARATOR|Psychoeducation|"Group Psychoeducation will receive a self-help booklet and a link to mobile wellness training program"
62348487|NCT02325817|EXPERIMENTAL|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
62348488|NCT02325817|ACTIVE_COMPARATOR|Uncoated balloon|Treat the side branch of bifurcation lesion with uncoated balloon
62348489|NCT00187629|EXPERIMENTAL|1|dietary phosphorus
62348490|NCT00187629|ACTIVE_COMPARATOR|2|other
62348491|NCT00691093||fesoterodine|
61962523|NCT01528904||Hyperthyroid pregnant women|hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination.
62348492|NCT04385147||ERCP|Patients who will have endoscopic retrograde cholangiopancreatography
62348493|NCT04385147||EUS|Patients who will have endoscopic ultrasound
62348494|NCT06105567|EXPERIMENTAL|Effect of Education on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress|Students who score over 110 on the premenstrual syndrome scale and meet the study criteria will be included in the experimental and control groups. Personal Information Form, PMS Scale, Premenstrual Eating Habits Form, Healthy Lifestyle Behaviors Scale, Emotional Eating Scale, Perceived Stress Scale and Visual Visual Pain Scale will be administered to the students in this group before the training. Premenstrual syndrome periods will be determined by creating a menstrual cycle calendar for the participants. Students will be trained with their first powerpoint presentation. Afterwards, brochures will be distributed. It will be applied according to the Philips 66 technique. 4 weeks after the first training, students will be given general reminder training online during pms periods. Survey forms will be filled out by the group 4 weeks after the second training.
62348495|NCT06105567|NO_INTERVENTION|control group|Students who score over 110 on the premenstrual syndrome scale and meet the study criteria will be included in the experimental and control groups. Students in this group will not receive training and will be administered the Personal Information Form, PMS Scale, Premenstrual Eating Habits Form, Healthy Lifestyle Behaviors Scale, Emotional Eating Scale, Perceived Stress Scale and Visual Vissual Pain Scale. Data will be collected by face-to-face research method. Survey forms will be filled out by the control group.
62506312|NCT02485158|EXPERIMENTAL|AMP, ALC, THC or Placebo 2|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
62506313|NCT02759549|EXPERIMENTAL|eSMART-MH|Participants undergoing radiation treatment for breast cancer will receive the Electronic Self-Management Resource Training for Mental Health (eSMART-MH) intervention.
61962524|NCT01528904||Hypothyroid pregnant women|hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
61962525|NCT01528904||Healthy pregnant women|uncomplicated pregnancies in healthy women, older then 35 years, directed for cordocentesis due to age, because of missed karyotyping in previous period of pregnancy
62506314|NCT02759549|OTHER|Theater Testing|Participants undergoing radiation treatment for breast cancer will participate in a theater testing workshop.
62506315|NCT04625673|ACTIVE_COMPARATOR|Group A|Group A will wear the OsciPulse device for the first 3 hours then switch to the standard IPC device for the second 3 hours.
62506316|NCT04625673|ACTIVE_COMPARATOR|Group B|Group B will wear the standard IPC device for the first 3 hours then switch to the OsciPulse device for the second 3 hours.
62704849|NCT05559359|EXPERIMENTAL|Lebrikizumab (Cohort 2)|"Participants who are 6 months to \<6 years of age, 2 years to \<6 years of age or 6 months to \<2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS.~Dosing will be based on weight."
62704850|NCT05559359|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching lebrikizumab by SC injections with a TCS.
62704851|NCT05947760|EXPERIMENTAL|IV Magnesium Sulfate adjuvant group|Participants in this group will receive standard-of-care procedures intraoperatively and postoperatively along with IV magnesium sulfate for pain control.
62704852|NCT05947760|NO_INTERVENTION|Control group|Participants in this group will receive standard-of-care procedures intraoperatively and post-operatively for pain control.
62704853|NCT06428396|EXPERIMENTAL|Belzutifan + Fulvestrant|Participants will receive belzutifan 120 mg orally once daily (QD) PLUS fulvestrant 500 mg via intramuscular (IM) injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter until progressive disease or discontinuation.
62704854|NCT06428396|ACTIVE_COMPARATOR|Everolimus + ET (fulvestrant or exemestane)|Participants will receive everolimus 10 mg orally QD PLUS investigator's choice of fulvestrant 500 mg via IM injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter OR exemestane 25 mg orally QD until progressive disease or discontinuation.
62704855|NCT03650114|EXPERIMENTAL|Ofatumumab|Subcutaneous injection
61962526|NCT01948947|EXPERIMENTAL|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
61962527|NCT01948947|SHAM_COMPARATOR|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
61962528|NCT04737083||clubfoot fetuses|
61962529|NCT06177730|ACTIVE_COMPARATOR|Pre-hospital ECPR Strategy|All patients will have high performance CPR at the scene throughout the resuscitation. If the patient is randomised to the Pre-hospital ECPR Strategy, this will be continued until the PACER team arrives. If return of spontaneous circulation (ROSC) has not been achieved at this point, ECPR will be implemented. The patient will be transported to The Alfred Hospital to receive ongoing care.
61962530|NCT06177730|NO_INTERVENTION|Conventional Cardiac Arrest Strategy|All patients will have high performance CPR at the scene throughout the resuscitation. If the patient has been randomised to the Conventional Cardiac Arrest Strategy and ROSC has not occurred after \>20 minutes, ongoing resuscitation will occur and the patient may be transported via AV to the nearest emergency cardiac catheterisation capable hospital where conventional resuscitation care will continue and Hospital based ECPR may be implemented if the patient meets local eligibility criteria. This is in line with current practice.
62506317|NCT04726189|ACTIVE_COMPARATOR|Standard care exercises|This is the currently used treatment in the nine weeks of immobilisation with an orthosis.
62506318|NCT04726189|EXPERIMENTAL|Early progressive strength exercise|This exercise program initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration.
62506319|NCT06004180|EXPERIMENTAL|Lu AF28996|Participants will receive ascending oral doses of Lu AF28996 OD for 14 days (Day 1 to Day 14). From Day 15, the participant will initiate down-titration of Lu AF28996 as per investigator's judgement.
62506320|NCT05532007|ACTIVE_COMPARATOR|Peanut Group|Peanuts: 2-3 ounces per day to replace 20% of daily energy intake
62506321|NCT05532007|ACTIVE_COMPARATOR|Control Group|Habitual diet abstain from eating peanuts
62506322|NCT03361124|PLACEBO_COMPARATOR|Control|Patient will receive standard post-partum Oxytocin (20 mU in 1 L LR) and 1 L LR over 8 hours following delivery.
62506323|NCT03361124|EXPERIMENTAL|Treatment|Patient will receive standard post-partum Oxytocin(20 mU in 1 L LR) an additional 20 mU Oxytocin in 1 L LR over 8 hours following delivery.
62506324|NCT06399861|ACTIVE_COMPARATOR|Incubator ambient relative humidity (RH) of 70%|Infants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving ambient relative humidity (RH) of 70% in the incubator.
62704856|NCT05267054|EXPERIMENTAL|Cohort 1|Participants with PD-L1 positive tumor cells will receive ociperlimab combined with tislelizumab
62704857|NCT05267054|EXPERIMENTAL|Cohort 2|Participants in the dose confirmation stage with PD-L1 negative tumor cells, and those in the dose expansion stage regardless of PD-L1 expression, will receive ociperlimab combined with rituximab
62704858|NCT04305054|EXPERIMENTAL|Pembrolizumab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62704859|NCT04305054|ACTIVE_COMPARATOR|Pembrolizumab|Participants will receive pembrolizumab IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
62506325|NCT06399861|EXPERIMENTAL|Incubator ambient relative humidity (RH) of 90%|Infants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving ambient relative humidity (RH) of 90% in the incubator.
62506326|NCT03768349|EXPERIMENTAL|PET/CT Ga-68 PSMA|Ga-68 labeled PSMA-11 (or PSMA-HBED-CC) PET/CT
62506327|NCT03768349|EXPERIMENTAL|PET/CT F-18 Labeled PSMA 1007|F-18 Labeled PSMA 1007 PET/CT
62348496|NCT02370940|EXPERIMENTAL|High Phytate Diet|The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
62704860|NCT04305054|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab|Participants will receive coformulation of pembrolizumab and quavonlimab (MK-1308A) IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
62704861|NCT04305054|EXPERIMENTAL|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive coformulation of pembrolizumab and quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62704862|NCT04305054|EXPERIMENTAL|Coformulation Favezelimab/Pembrolizumab|Participants will receive cofomulation of favezelimab + pembrolizumab (MK-4280A) IV at specified dose on specified days every 3 weeks (Q3W) for up to approximately 2 years
61962531|NCT02256189|OTHER|Sitagliptin first, then placebo|Sitagliptin treatment for four weeks, then washout for four weeks, then placebo for four weeks
62704863|NCT04305054|EXPERIMENTAL|Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA)|Participants will receive coformulation of favezelimab and pembrolizumab IV Q3W for up to 35 cycles, plus ATRA orally (for 3 days surrounding each infusion of MK-4280A, including Days 1, 2, and 3 of Cycle 1 and on Days -1, 1, and 2 of all subsequent cycles).
62704864|NCT04305054|EXPERIMENTAL|Coformulation Favezelimab/Pembrolizumab + Vibostolimab|Participants will receive coformulation of favezelimab and pembrolizumab (MK-4280A) IV and vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
62704865|NCT06534411|EXPERIMENTAL|CagriSema|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every 4 weeks in a 8-week dose escalation period until target dose of CagriSema is achieved and maintained for 52 weeks.
61962532|NCT02256189|OTHER|Placebo first, then sitagliptin|Placebo for four weeks, then washout for four weeks, then sitagliptin for four weeks
61962533|NCT05011539||Ovarian cancer|The patients with ovarian cancer
61962534|NCT05011539||Control group|
61962535|NCT02706340||Vaginal delivery|Women who have had a copper IUD placed within 10 minutes of a vaginal delivery of at least 34 weeks 0 days gestation.
61962536|NCT02706340||Cesarean delivery|Women who have had a copper IUD placed within 10 minutes of a cesarean delivery of at least 34 weeks 0 days gestation.
61962537|NCT01320904|PLACEBO_COMPARATOR|Closed Kinetic Chain and NMES placebo|"During the stimulation period the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.~We used a 10-channel electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings."
61962538|NCT01320904|OTHER|Closed Kinetic Chain Group|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
61962539|NCT03067961|EXPERIMENTAL|Wild type S. Typhi Quailes strain|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
62348497|NCT02370940|EXPERIMENTAL|Low Phytate Diet|The low phytate diet group was required to consume a low phytate diet for 8 weeks. They received foods similar to those for the high phytate diet group but which were made from refined wheat and white rice, eggs and cheese, and were instructed to avoid high phytate foods.
61962540|NCT03067961|EXPERIMENTAL|Quailes typhoid toxin knock-out|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
62348498|NCT05046678||Control|Periodontally healthy, non-smoking
62348499|NCT05046678||Smokers with periodontally healthy|Periodontally healthy, smoking
62506328|NCT00638040||1|The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
62506329|NCT04013698|EXPERIMENTAL|PEEP level 5 cmH2O to 15 cmH2O|
62506330|NCT04013698|EXPERIMENTAL|PEEP level 15 cmH2O to 5 cmH2O|
61962541|NCT06557837||Patients with sagittal imbalance|Patients that have pelvic incidence-lumbar lordosis deficit (PI-LL) greater than 10 or sagittal vertical axis (SVA) greater than 4 centimetres on X-ray imaging.
61962542|NCT06557837||Control group|Participants with normal pelvic incidence-lumbar lordosis deficit (PI-LL) and sagittal vertical axis (SVA) on X-ray imaging.
62704866|NCT06534411|EXPERIMENTAL|Tirzepatide|Participants will receive once-weekly s.c injections of tirzepatide at escalating dose in a 4-week dose escalating period and maintained up to 56 weeks.
62704867|NCT06481462||Intrathecal Morphine|A subarachnoid block will be performed by injecting morphine 100 mcg + 12.5 mg hyperbaric bupivacaine + 10 mcg fentanyl.
62704868|NCT06481462||Posterior Quadratus Lumborum Block|Patients scheduled for elective cesarean section under spinal anesthesia will receive bilateral ultrasound-guided posterior quadratus lumborum block.
62704869|NCT00026884||Family Members|Family members (related by blood) of patients who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder
62704870|NCT00026884||Patients|Patients with biopsy-proven malignant diseases; or patients suspected of having a malignant disease; or patients who have or who are suspected of having an inherited genitourinary malignant disorder
62704871|NCT03793166|ACTIVE_COMPARATOR|Arm A (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~TREATMENT:~Patients with iuPD with clinical instability receive cabozantinib PO daily on days 1-28. Treatment repeats every 28 days until further disease progression or unacceptable toxicity~Patients with iCR receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients with non-CR/non-PD with clinical stability receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan, MRI and blood and urine sample collection, and may also undergo a bone scan as clinically indicated throughout the study."
61962543|NCT01816204|EXPERIMENTAL|Therapist assisted online treatment (TAO)|Students assigned to treatment with weekly online modules and weekly 10-15 minute video conference with counselor.
61962544|NCT01816204|ACTIVE_COMPARATOR|face-to-face individual therapy|weekly individual 50 minute psychotherapy sessions.
61962545|NCT04849143|EXPERIMENTAL|Honey dressing group|A thin layer of honey will be applied to the wounds
61962546|NCT04849143|ACTIVE_COMPARATOR|Gel dressing group|A thin layer of gel will be applied to the wounds
61962547|NCT03385902|EXPERIMENTAL|optimal start dialysis group|The DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE reaching to 30-35, which defined as the optimal start time.
61962548|NCT03385902|ACTIVE_COMPARATOR|late start dialysis group|the DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE less than 30, which defined as late start time.
61962549|NCT01008488|ACTIVE_COMPARATOR|Antibiotic|
61962550|NCT01008488|NO_INTERVENTION|No antibiotic|
62348500|NCT05046678||Non-smokers with gingivitis|Gingivitis, non-smoking
62348501|NCT05046678||Smokers with gingivitis|Gingivitis, smoking
62348502|NCT05046678||Non-smokers with periodontitis|Periodontitis, non-smoking
62348503|NCT05046678||Smokers with periodontitis|Periodontitis, smoking
61962551|NCT02587260|ACTIVE_COMPARATOR|Sequence I|Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III
62348504|NCT05511818|PLACEBO_COMPARATOR|Placebo Control 1|Rest Product Form 1 - control
62348505|NCT05511818|PLACEBO_COMPARATOR|Placebo Control 2|Rest Product Form 2 - control
62348506|NCT05511818|PLACEBO_COMPARATOR|Placebo Control 3|Rest Product Form 3 - control
62348507|NCT05511818|EXPERIMENTAL|Active Product 1.1|Rest Product Form 1 - active product 1
62348508|NCT05511818|EXPERIMENTAL|Active Product 1.2|Rest Product Form 1 - active product 2
61962552|NCT02587260|ACTIVE_COMPARATOR|Sequence II|Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III
61962553|NCT02587260|ACTIVE_COMPARATOR|Sequence III|Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III
61962554|NCT02587260|ACTIVE_COMPARATOR|Sequence IV|Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III
62348509|NCT05511818|EXPERIMENTAL|Active Product 1.3|Rest Product Form 1 - active product 3
62348510|NCT05511818|EXPERIMENTAL|Active Product 1.4|Rest Product Form 1 - active product 4
62348511|NCT05511818|EXPERIMENTAL|Active Product 2.1|Rest Product Form 2 - active product 1
62348512|NCT05511818|EXPERIMENTAL|Active Product 2.2|Rest Product Form 2 - active product 2
62348513|NCT05511818|EXPERIMENTAL|Active Product 3.1|Rest Product Form 3 - active product 1
62348514|NCT05511818|EXPERIMENTAL|Active Product 3.2|Rest Product Form 3 - active product 2
61962555|NCT02587260|ACTIVE_COMPARATOR|Sequence V|Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III
61962556|NCT02587260|ACTIVE_COMPARATOR|Sequence VI|Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
61962557|NCT01251601||Raltegravir in Pregnancy|HIV positive pregnant women currently on raltegravir as part of combination antiretroviral therapy
61962558|NCT00803725|ACTIVE_COMPARATOR|1|Mepivicaine for spinal anesthesia
61962559|NCT00803725|EXPERIMENTAL|2|Mepivacaine with Fentanyl for spinal anesthesia
61962560|NCT00768157|EXPERIMENTAL|antiviral group|Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC)
62348515|NCT05511818|PLACEBO_COMPARATOR|Placebo Control 4|Rest Product Form 4 - control
62348516|NCT05511818|EXPERIMENTAL|Active Product 4|Rest Product Form 4 - active product 1
62348517|NCT01214941|PLACEBO_COMPARATOR|Placebo|
62348518|NCT01214941|ACTIVE_COMPARATOR|Ticlopidine|
62348519|NCT01214941|ACTIVE_COMPARATOR|Ticlopidine and itraconazole|
62348520|NCT03796234|EXPERIMENTAL|Dietary and physiotherapy|A multidisciplinary program was developed. 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
62348521|NCT03796234|EXPERIMENTAL|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
62348522|NCT01974986|PLACEBO_COMPARATOR|Placebo|Water with flavoring and non-nutritive sweetener.
62348523|NCT01974986|EXPERIMENTAL|High-Na low-CHO beverage|Beverage containing sodium concentration of 40 to 50 mEq/L and carbohydrate concentration between 310 and 350 mmol/L.
62348524|NCT01974986|EXPERIMENTAL|Low-Na high-CHO beverage|Beverage containing sodium concentration of 15 to 25 mEq/L and carbohydrate concentration between 120 and 160 mmol/L.
62348525|NCT03602261|ACTIVE_COMPARATOR|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
62348526|NCT03602261|ACTIVE_COMPARATOR|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
61962561|NCT00768157|ACTIVE_COMPARATOR|control group|Procedure/Surgery (radical resection of HBV-related HCC) without Drug of antiviral treatment - close observation without antiviral treatment
61962562|NCT04293120|EXPERIMENTAL|Training|Training 4 sessions over a one week time period of 180 catches/stops with a medicine ball.
61962563|NCT05540353|ACTIVE_COMPARATOR|Transvaginal photobiomodulation|"Participants will undergo active transvaginal photobiomodulation therapy per clinic protocol, using the SoLa Pelvic Therapy system. This includes 9 treatments, each lasting about 3-5 minutes. A sterile narrow vaginal probe is inserted into the vagina, the low-level laser is activated, and the probe is slowly moved along the vaginal walls for the indicated period of time, via a surface area power calculation based on the measured vaginal length at the beginning of the procedure. The 9 treatments must be completed in 3-4 weeks.~Intervention: Active SoLa Low-level laser therapy"
61962564|NCT05540353|SHAM_COMPARATOR|Sham treatment|"Participants will undergo sham transvaginal photobiomodulation therapy, following the same protocol as the active arm, without activation of the machine. This includes 9 treatments, lasting 3-5 minutes each. A sterile narrow vaginal probe is inserted into the vagina, the machine is NOT activated, and the inactive probe is slowly moved along the vaginal walls for 3-5 minutes. The 9 treatments must be completed in 3-4 weeks.~Intervention: Mock treatment with inactivated probe"
62704872|NCT03793166|EXPERIMENTAL|Arm B (nivolumab, cabozantinib)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~TREATMENT:~Patients with iuPD with clinical instability receive cabozantinib PO daily on days 1-28. Treatment repeats every 28 days until further disease progression or unacceptable toxicity.~Patients with iCR receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients with non-CR/non-PD rwith clinical stability eceive nivolumab IV over 30 minutes on day 1 and cabozantinib PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan, MRI and blood and urine sample collection, and may also undergo a bone scan as clinically indicated throughout the study."
62348527|NCT03602261|ACTIVE_COMPARATOR|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
61962565|NCT02541682|OTHER|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
61962566|NCT02541682|OTHER|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
61962567|NCT02541682|OTHER|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
61962568|NCT02541682|OTHER|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
61962569|NCT00465205|EXPERIMENTAL|I|
62704873|NCT02190266||Patients|Patients with confirmed refractory and/or disseminated coccidioidomycosis.
62704874|NCT03854474|EXPERIMENTAL|Treatment (tazemetostat, pembrolizumab)|Patients receive tazemetostat PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial and undergo collection of blood samples on study.
61962570|NCT00996307|EXPERIMENTAL|3.75_(50)MF59|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
62348528|NCT03602261|PLACEBO_COMPARATOR|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
62704875|NCT05024760|NO_INTERVENTION|Control|This arm will receive standard of care during dental implant insertion.
62348529|NCT02652312|ACTIVE_COMPARATOR|Group 'D'|"Dexmedetomidine group Patients received dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg over 10 minutes. A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour was infused.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
62348530|NCT02652312|PLACEBO_COMPARATOR|Group 'P'|"Placebo group Patients received similar volume of normal saline as the bolus and maintenance infusion as group D.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
62704876|NCT05024760|EXPERIMENTAL|Chlorhexidine|Chlorhexidine treatment.
62348531|NCT03894098|ACTIVE_COMPARATOR|Single shot regional popliteal and saphenous block|Standard of care traditional single shot popliteal / saphenous regional block for acute pain control after elective ankle surgery
62348532|NCT03894098|EXPERIMENTAL|High ankle block|High ankle block for acute pain control after elective ankle surgery
62348533|NCT03744182|EXPERIMENTAL|HM15211|
62348534|NCT03744182|PLACEBO_COMPARATOR|Placebo|
62704877|NCT05024760|EXPERIMENTAL|Hydrogen Peroxide|Hydrogen Peroxide treatment.
62704878|NCT06558123||Control|single level
61962571|NCT00996307|EXPERIMENTAL|7.5_(0)MF59|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
61962572|NCT00996307|EXPERIMENTAL|7.5_(50)MF59|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
61962573|NCT00996307|EXPERIMENTAL|15_(0)MF59|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
61962574|NCT00620867|EXPERIMENTAL|Ibuprofen|
61962575|NCT00620867|EXPERIMENTAL|Celecoxib|
61962576|NCT00620867|PLACEBO_COMPARATOR|placebo|
61962577|NCT01824953||atrophy-/Hp- group|Subjects without Helicobacter pylori infection and without atrophy
62704879|NCT06558123||study|two level
62704880|NCT00720785|EXPERIMENTAL|1|NK Cell Infusion (cell /kg pt wt)
62704881|NCT00720785|EXPERIMENTAL|2|1.3 mg/m2/dose administered as a 3 to 5 second bolusintravenous injection
62506331|NCT02497131|EXPERIMENTAL|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
62506332|NCT02620059|EXPERIMENTAL|Lifestyle Intervention|"Behavioral: Lifestyle Intervention These women will receive the Healthy Lifestyle Intervention. This intervention will have been delivered during 12 weeks, which will be Distance learning program (multimedia or internet). During the intervention (12 weeks) and follow up period, women will receive not only motivational messages through the Short Message System (SMS) but also a pedometer to record their steps.The intervention will focus on women increasing physical activity (walking) to 10'000 steps per day and receiving healthy eating guidelines.~This intervention curriculum will cover topics related to healthy eating, physical activity, and stress management during postpartum. General information about postpartum period will also be provided."
62506333|NCT02620059|NO_INTERVENTION|Control|These women will receive general information via pamphlet about postpartum period and tips for stress management.
61962578|NCT01824953||atrophy-/Hp+|Subjects with Helicobacter pylori infection and without atrophy
61962579|NCT01824953||atrophy+/Hp+|Subjects with Helicobacter pylori infection and with atrophy
62506334|NCT02360306|ACTIVE_COMPARATOR|Conventional EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the conventional EBUS scope rather than the hybrid EBUS scope. Subjects in this arm, like in the Hybrid EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
61962580|NCT01824953||atrophy+/Hp-|Subjects without Helicobacter pylori infection and with atrophy
62506335|NCT02360306|EXPERIMENTAL|Hybrid EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the hybrid EBUS scope rather than the conventional EBUS scope. Subjects in this arm, like in the conventional EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
62704882|NCT04085887|EXPERIMENTAL|Cohort 1-0.006 Panitumumab-IRDye800|Dose: 0.006 Panitumumab-IRDye800 (mg/kg)
61962581|NCT01481727|PLACEBO_COMPARATOR|cpap sham|non invasive mechanical ventilation type cpap sham manoeuver
62704883|NCT04085887|EXPERIMENTAL|Cohort 2-0.25 Panitumumab-IRDye800|Dose: 0.25 Panitumumab-IRDye800 (mg/kg)
61962582|NCT01481727|ACTIVE_COMPARATOR|high-intensity NIMV|Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (\>18cmH2O)
62704884|NCT04085887|EXPERIMENTAL|Cohort 3-0.50 Panitumumab-IRDye800|Dose: 0.50 Panitumumab-IRDye800 (mg/kg)
62704885|NCT04085887|EXPERIMENTAL|Cohort 4-1.0 Panitumumab-IRDye800|Dose: 1.0 (with max cap dose 50 mg) Panitumumab-IRDye800 (mg/kg)
62704886|NCT03602599||Healthy-controls Longitudinal Cohort|( Cohort HL ; approximate n=20) includes subjects who will participate in up to 4 study visits across 1 year.
62704887|NCT03602599||Healthy-controls Short-term Cohort|( Cohort HS ; approximate n=80) will participate in a single baseline visit.
62704888|NCT03602599||New Transplant Cohort|( Cohort NT ; approximate n=300) consists of patients who are scheduled to undergo allogeneic HSCT (under another protocol at the NIH).
61962583|NCT02025621|EXPERIMENTAL|Levosimendan|levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
62506336|NCT05824858|EXPERIMENTAL|LY3537982 (High-Fat Meal)|LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard high-fat meal) in the other study period.
62704889|NCT03602599||Prior Transplant Cohort|( Cohort PT ; approximate n=100) consists of patients who have already undergone allogeneic HSCT.
62704890|NCT05286879|OTHER|Patient Navigator|Navigators will assist linking study participants to appropriate community service providers
62704891|NCT05286879|OTHER|Mobile Health Unit|Study participants will be linked to a MHU within their community
62704892|NCT03916978|EXPERIMENTAL|Participants receiving PRP treatment|Menopausal women minimum 45 years of age, receiving ovarian PRP treatment.
62704893|NCT03916978|PLACEBO_COMPARATOR|Control Group: Participants receiving Platelet Free Plasma|Women in menopause, 45-55 years old, treated with autologous PFP intra ovarian infusion.
61962584|NCT02025621|PLACEBO_COMPARATOR|Placebo|placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
61962585|NCT03498027||Data Collection|
61962586|NCT06364943|NO_INTERVENTION|Dry eye patients|Collect clinical information and tear samples from patients with dry eye syndrome.
61962587|NCT06364943|OTHER|Non-Dry eye patients|Collect clinical information and tear samples from patients without dry eye syndrome.
61962588|NCT04531943||TGWSM Using Estrogen|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of only estrogen.
61962589|NCT04531943||TGWSM Using Estrogen plus Progesterone|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of estrogen and progesterone.
61962590|NCT04531943||Cisgender MSM|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of cisgender MSM.
61962591|NCT04531943||TGWSM Initiating Feminizing Hormone Therapy|Cohort 2 participants are in the longitudinal portion of the study and are TGWSM who are planning to initiate feminizing hormone therapy. Individuals in Cohort 2 will participate in study activities for 18 months.
62714964|NCT02807701|ACTIVE_COMPARATOR|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy Under general anesthesia, the patient is placed in a supine position with the legs abducted. Carbon dioxide pneumoperitoneum is established using an open technique through a 10-mm trocar over the umbilicus. A 30 telescope is inserted to examine the peritoneal cavity, liver, stomach, and mesentric vessels.Then 4 to 6 more trocars are inserted under direct vision in the epigastrium and upper quadrants~1. dissection~2. reconstruction"
61962592|NCT00729651|EXPERIMENTAL|1|Alendronate sodium/Cholecalciferol
61962593|NCT00729651|ACTIVE_COMPARATOR|2|Alendronate sodium
61962594|NCT01444560||Cutaneous Melanoma|
61962595|NCT01444560||Cutaneous Melanoma Metastases|
61962596|NCT01444560||Benign Melanocytic Nevi|
61962597|NCT00382252|EXPERIMENTAL|18F-FDG PET/CT + RFA|"18F-FDG PET/CT: I.V. injection of 5 to 15 mCi (185 to 555 MBq) of 18F-FDG. Capture time of 60 to 90 minutes. Acquisition of images: A whole body CT scan with normal breathing will be performed for attenuation correction with 5mm thick slices. A whole body PET acquisition of 6 or 7 steps will be done from the upper third of the thighs to the base of the skull. PETC/CT performed at inclusion, 1 month et 3 months after RFA.~RFA: Treatment procedure: the location under scanner allows to place the electrode in the center of the tumor. The treatment then lasts 15 to 20 minutes.~CT scanner: The CT examination will be performed in spiral acquisition without or after injection of contrast medium (70 ml at 2 or 3 ml/sec). On a 16-slice scanner, the examination is performed with 1.25 mm slices every 0.9. Constants generally used 120kV, 350 mA. Ct scanner performed at inclusion, 48H post-RFA, 1 month, 3 months, 6, 9 and 12 months after RFA."
61962598|NCT00954070||Case (subjects with NERD)|The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
61962599|NCT00954070||Control|Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases
61962600|NCT01295801||Linezolid+vitamin B6|
62506337|NCT05824858|EXPERIMENTAL|LY3537982 (Low-Fat Meal)|LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard low-fat meal) in the other study period.
62348535|NCT00405821|ACTIVE_COMPARATOR|Acyclovir 400mg tablet twice daily|
61962601|NCT01295801||Linezolid|
61962602|NCT01101503|EXPERIMENTAL|Intensive multifactorial group|Intensive multifactorial therapy group receive intensive blood glucose, blood pressure and blood lipids control.
62348536|NCT00405821|PLACEBO_COMPARATOR|Placebo tablet twice daily|
62506338|NCT03946917|EXPERIMENTAL|JS001/regorafenib|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with regorafenib tablet
62506339|NCT06110286||Mechanical photorefractive keratectomy|Laser photorefractive keratecyomy by Ex500 excimer laser after mannual removal of corneal epithelium
62506340|NCT06110286||Stream light trans-PRK|Laser photorefractive keratectomy by Ex500 excimer laser after removal of corneal epithelium by stream-light laser technique
61962603|NCT01101503|EXPERIMENTAL|conventional multifactorial therapy group|Conventional multifactorial therapy group receive conventional blood glucose, blood lipids and blood lipids control to the local targets.
61962604|NCT01307397|EXPERIMENTAL|Vemurafenib|Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
61962605|NCT05392296|EXPERIMENTAL|Power ball|experimental group getting the power ball training with conventional treatment
62506341|NCT04299217|ACTIVE_COMPARATOR|Mango Leaf Extract|300 mg Mangifera indica (mango) leaf extract standardized to ≥ 60% mangiferin (Zynamite®), plus carrier
62506342|NCT04299217|PLACEBO_COMPARATOR|Placebo|Carrier (placebo)
62506343|NCT03776578||Head and neck Cancer surgery not treatment and rehabilitation|The patients with oral cavity cancer who weren't treated by radical operation and free flap reconstruction,and can't provide them with preventive swallowing rehabilitation
62539306|NCT04937114|ACTIVE_COMPARATOR|Flap will be approximated using conventional, simple continuous suturing with conventional sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with conventional sutures.
61962606|NCT05392296|ACTIVE_COMPARATOR|Conventional|group will be control group getting the conventional treatment (isometric hand grip training exercises)
61962607|NCT06505434||Low myopia group|A low myopia group (0D to -6.0D)
61962608|NCT06505434||high myopia group|B high myopia group (-6.0 to -12.0D)
61962609|NCT06505434||ultra-high myopia group|C ultra-high myopia group (greater than -12.0D) group
61962610|NCT00714649|OTHER|I-1|"This is a phase I/II trial. PhaseI: The delay between the last administration of cetuximab and surgery will be progressively reduced. Five delay schedules are pre-defined before final administration of 3 preoperative doses of cetuximab with a 24-hour delay between the last dose of cetuximab and surgery. The cohort size is 3 patients per delay schedule, extended to 6 patients if one limiting toxicity is observed.~Phase II: will proceed if delay schedule V is safe. The patients included in delay schedule V of the Phase I part of the study will be involved in the phase II analysis. Recruitment of a total of 12 patients (3-6 of delay schedule V in phase I plus an additional 3-9 patients)."
61962611|NCT03756844|EXPERIMENTAL|Just Right Challenge Food Club Protocol|There was only one arm in this study. All participants received the Just Right Challenge Food Club Protocol and single subject (time series) data was collected.
61962612|NCT00215332||Training- CHARITE|Non-Randomized Training (TDR with CHARITE)
62348537|NCT02373241|ACTIVE_COMPARATOR|Standard Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to \<95th percentile
62348538|NCT02373241|EXPERIMENTAL|Experimental Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to \<75th percentile
62348539|NCT05424991|EXPERIMENTAL|comedy movie group|The anxiety level of the patients in the experimental group was measured. Afterwards, each patient watched a comedy movie for 25 minutes. Anxiety levels were re-measured 25 minutes after watching the comedy movie. Pain levels were measured after the anesthesia effect disappeared in the postoperative period. Afterwards, each patient watched a comedy movie for 25 minutes. Pain levels were re-measured 25 minutes after watching the comedy movie.
62539307|NCT01178216|EXPERIMENTAL|Rituxan|All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
61962613|NCT00215332||CHARITE|Randomized Subjects treated by Lumbar Total Disc Replacment with CHARITE
61962614|NCT00215332||Control|Randomized Subjects treated by ALIF with BAK cage
61962615|NCT02505204|EXPERIMENTAL|Clonidine|Will receive bilateral PVB with clonidine.
61962616|NCT02505204|PLACEBO_COMPARATOR|Placebo|Will receive bilateral PVB with placebo.
61962617|NCT06045897|EXPERIMENTAL|Major depressive disorder|Major depressive disorder as defined by DSM-5 classification
61962618|NCT06045897|EXPERIMENTAL|Autism spectrum disorder|Autism spectrum disorder as defined by DSM-5 classification
61962619|NCT06045897|EXPERIMENTAL|At risk mental state|At risk mental state as defined in the CAARMS
61962620|NCT06045897|EXPERIMENTAL|First episode psychosis|Any DSM-5 category associated with psychotic symptoms
61962621|NCT06045897|EXPERIMENTAL|Schizophrenia|Schizophrenia as defined by DSM-5 classification
61962622|NCT06045897|EXPERIMENTAL|Healthy controls|Healthy controls with no history of neurodevelopmental disorder or psychotic disorder in a first degree relative
61962623|NCT00894660|EXPERIMENTAL|Amodiaquine (Pfizer)|
61962624|NCT00894660|ACTIVE_COMPARATOR|Amodiaquine tablets (Arsuamoon-Guilin China)|
61962625|NCT05424367||NH Hispanic/Latino Adults|New Hampshire adults(at least 18 years of age) with cultural background in a Spanish-speaking Latin American country or territory surveyed between March 2021 - March 2022.
61962626|NCT00357968|EXPERIMENTAL|Prasugrel to Clopidogrel|One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
61962627|NCT00357968|ACTIVE_COMPARATOR|Clopidogrel to Prasugrel|One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
61962628|NCT04717609|ACTIVE_COMPARATOR|Partial Meniscectomy without Saphenous Nerve Block|Participants scheduled for partial meniscectomy will preoperatively receive 0.5% ropivacaine with epinephrine
61962629|NCT04717609|EXPERIMENTAL|Partial Meniscectomy with Saphenous Nerve Block|Participants scheduled for a partial meniscectomy will preoperatively receive a saphenous nerve block at the medial femoral condyle in addition to an injection of 0.5% ropivacaine with epinephrine
61962630|NCT00838396|EXPERIMENTAL|XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of XP19986 10, 20, 40 or 60 mg.
61962631|NCT00838396|PLACEBO_COMPARATOR|Placebo for XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of placebo.
61962632|NCT05052762|EXPERIMENTAL|Group A: Elastic resisted training for Gluteus Maximus strength.|bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped and weight-bearing hip extension are added.
61962633|NCT05052762|EXPERIMENTAL|Group B: Weight resisted training for Gluteus Maximus strength|Prone hip extension with knee flexion against weighted resistance
61962634|NCT06280170|NO_INTERVENTION|Services-as-usual (SAU)|During the services-as-usual (SAU) phase of this study, providers will deliver the routine case management services offered by Centerstone and report these services in the usual way they do.
61962635|NCT06280170|EXPERIMENTAL|Artificial Intelligence (AI)|Once randomized to start using the AI-based platform for documenting their services, providers will have access to the Eleos Health platform, a secure and HIPAA-compliant tool specifically designed for documenting behavioral health encounters. This AI-powered platform enables providers to complete progress notes more quickly. Providers will complete the progress notes on their phones, and these notes will be integrated into the client's electronic health records.
62539308|NCT01801631|EXPERIMENTAL|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
61962636|NCT00791960|ACTIVE_COMPARATOR|Dimenhydrinate|Dimenhydrinate
61962637|NCT00791960|PLACEBO_COMPARATOR|Placebo|Placebo
61962638|NCT00341406||Healthy volunteers|healthy, non-overweight or other medical conditions
61962639|NCT00341406||Patients overweight|Those who are generally healthy but overweight
61962640|NCT00341406||Patients with health conditions|Those with diabetes and cardiovascular disease.
61962641|NCT01652612|NO_INTERVENTION|Control|zero PEEP
61962642|NCT01652612|EXPERIMENTAL|OLV strategy: PEEP|1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery
61962643|NCT01652612|EXPERIMENTAL|OLV strategy: PEEP followed by AR|"1. alveolar recruitment strategy before one lung ventilation~2. 8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery"
61962644|NCT05230550||Participants with AGHD (only severe case)|Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. The decision to treat a patient with Sogroya® has been made at the treating physician's discretion and independently from the decision to include the patient in this study.
61962645|NCT00735410|EXPERIMENTAL|1|
61962646|NCT02818569|EXPERIMENTAL|Oral Dexmedetomidine, Then Placebo|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.
61962647|NCT02818569|EXPERIMENTAL|Placebo, Then Oral Dexmedetomidine|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .
61962648|NCT03103737|EXPERIMENTAL|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
61962649|NCT03103737|NO_INTERVENTION|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
61962650|NCT02272062|NO_INTERVENTION|Preferences Not Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, but these preferences will NOT be shared with the treating clinicians.
61962651|NCT02272062|EXPERIMENTAL|Preferences Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, and these preferences WILL be shared with the treating clinicians.
61962652|NCT02923960|ACTIVE_COMPARATOR|Standard ONS|liquid oral nutritional supplement
62704894|NCT03984448|ACTIVE_COMPARATOR|Arm 1 (R-CHOP, DA-EPOCH-R)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen consisting of rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study.~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen consisting of rituximab IV on day 1, doxorubicin hydrochloride IV on days 1-4, etoposide IV on days 1-4, vincristine sulfate IV on days 1-4, prednisone PO BID on days 1-5, and cyclophosphamide IV on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study"
62704895|NCT03984448|EXPERIMENTAL|Arm 2 (R-CHOP, DA-EPOCH-R, venetoclax)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study.~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study."
62704896|NCT01594723|EXPERIMENTAL|120 mg LY2784544|120 milligram (mg) administered orally once daily for 6 cycles (168 days)
61962653|NCT02923960|EXPERIMENTAL|Diabetes specific ONS 1|liquid oral nutritional supplement with novel carbohydrate blend
61962654|NCT02923960|ACTIVE_COMPARATOR|Diabetes specific ONS 2|liquid oral nutritional supplement with novel carbohydrate blend
61962655|NCT02615145||Genotype 1a (G1a) Participants|"Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
62348540|NCT05424991|NO_INTERVENTION|No treatment group|In the follow-up of the patient, no application was made other than clinical protocols. Anxiety scale was filled preoperatively, and anxiety level was evaluated again 25 minutes later. Pain level was evaluated in the postoperative period. Pain levels were evaluated again at the end of the same period with the experimental group without any intervention.
62704897|NCT05982964||back pain group|
62704898|NCT05982964||Healthy volunteers|
62704899|NCT02332668|EXPERIMENTAL|Melanoma|Participants aged 6 months to \<18 years with melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W). Enrollment of participants aged 6 months to \<12 years with melanoma was closed with Amendment 8. Enrollment of participants aged ≥12 years to ≤18 years with melanoma continues.
62704900|NCT02332668|EXPERIMENTAL|Solid Tumors and Other Lymphomas|Participants aged 6 months to \<18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed death-ligand 1 (PD-L1)-positive participants. PD-L1-negative participants may enroll if responses are observed. Enrollment of participants with solid tumors and other lymphomas was closed with Amendment 8.
62704901|NCT02332668|EXPERIMENTAL|rrcHL|Participants aged 3 years to \<18 years with rrcHL receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
62704902|NCT02332668|EXPERIMENTAL|MSI-H|Participants aged 6 months to \<18 years with microsatellite-instability-high (MSI-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
62704903|NCT02332668|EXPERIMENTAL|TMB-H|Participants aged 6 months to \<18 years with tumor-mutational burden-high ≥10 mutation/Mb (TMB-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
62704904|NCT02332668|EXPERIMENTAL|Adjuvant Melanoma|Participants aged 12 years to \<18 years with resected high-risk Stage IIB, IIC, III, or IV melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W).
61962656|NCT02615145||Genotype 1b (G1b) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 \[G4\]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
61962657|NCT02615145||Genotype 4 (G4) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
62348541|NCT02107430|EXPERIMENTAL|DCVAC/PCa arm post radiotherapy|Dendritic Cells DCVAC/PCa Experimental therapy post radiotherapy
62348542|NCT02107430|ACTIVE_COMPARATOR|Standard radiotherapy|Standard care
62704905|NCT03366116|EXPERIMENTAL|1|Aza-TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
62704906|NCT04421768|EXPERIMENTAL|systematic cervical exam training--retrospective measures|Effects of systematic cervical exam training on Labor and Delivery Care The total number of exams per hour of labor or triage stay and exam discrepancy between 2 examiners who performed exams less than 30 minutes apart will be compared between the 6 month time period before the unit wide training and 6 months after completing training
62704907|NCT04421768|EXPERIMENTAL|systematic cervical exam training--prospective measures|Effects of systematic cervical exam training on Labor and Delivery care Patient will be approached to obtain consent for them to have 2 cervical exams performed one after the other when an exam is clinically indicated. The discrepancy between the 2 examiners will be compared between the 6 month time period before the unit wide training and 6 months after completion of the training.
61962658|NCT00943059|EXPERIMENTAL|Acipimox|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
62348543|NCT03130023|EXPERIMENTAL|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
62704908|NCT03152773|EXPERIMENTAL|1|Open label
62704909|NCT02431845|EXPERIMENTAL|SSRIs treatment as usual OCD gruop|SSRIs treatment as usual fluoxetine 40\~80 mg dose equivalent (fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine)
62506344|NCT03776578||Head and neck Cancer surgery treatment and rehabilitation|Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, It is well accepted that pre-treatment swallow function is indicative of post-treatment status and is helpful in identifying patients with high risk of aspiration and dysphagia.Preventive swallowing rehabilitation including evaluation patient's swallowing function and propose rehabilitation and adaptive maneuver or change in food texture. The aim is to ensure safe swallowing and prevent deglutitive muscles from deconditioning. Investigators include patients with advanced oral cavity cancer who were treated by radical operation and free flap reconstruction, and provided them with preventive swallowing rehabilitation.Investigators then analyze the swallowing function, oral intake status, and nasogastric tube dependence rate and tracheostomy tube dependence rate.
62506345|NCT06338631||Adults with weight excess|
62506346|NCT02302937|ACTIVE_COMPARATOR|group A: Standard TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
62506347|NCT02302937|ACTIVE_COMPARATOR|Group B: LESS Port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port (12 to 15 mm transumbilical).
62506348|NCT05025631|EXPERIMENTAL|Fruquintinib dose-optimization|Fruquintinib was administered orally on 21 consecutive days in a 28-day treatment cycle. All patients were dose-optimized for the first cycle of fruquintinib - oral fruquintinib 3 mg/day in the first week; if tolerated, oral fruquintinib 4 mg/day in the second week; if still tolerated, then the dose was increased to 5 mg/day in the third week. From the second cycle, patients were given the maximum dose that they have tolerated in the first cycle.
62506349|NCT03844724|EXPERIMENTAL|Group A|subjects using the drug-eluting PTA balloon dilatation catheter
62506350|NCT03844724|ACTIVE_COMPARATOR|Group B|subjects using the peripheral balloon dilatation catheter
62506351|NCT03540849|EXPERIMENTAL|BV after allogeneic hematopoietic stem cell transplantation|
62506352|NCT03847363||general anesthesia|patients underwent general anesthesia
62348544|NCT04745195||Complement-mediated thrombotic microangiopathy|
62348545|NCT04745195||Thrombotic microangiopathty with normal complement regulation|
62704910|NCT02954874|EXPERIMENTAL|Arm I (observation)|Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment. Patients may also undergo collection of blood samples throughout the trial.
61962659|NCT00943059|PLACEBO_COMPARATOR|Cellulosum mycrocryst capsula|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
61962660|NCT01488929|EXPERIMENTAL|5 mg TC-5619|One tablet of 5 mg TC-5619 will be administered orally once a day.
61962661|NCT01488929|EXPERIMENTAL|50 mg TC-5619|One tablet of 50 mg TC-5619 will be administered orally once a day.
61962662|NCT01488929|PLACEBO_COMPARATOR|Placebo|One tablet of placebo will be administered orally once a day.
61962663|NCT01538043|ACTIVE_COMPARATOR|local mud packs and thermal-mineral bath|50 patients with primary knee OA will be treated with daily local mud packs and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
62348546|NCT00889070||1|Stage 1 (Pilot Study) All infants enrolled in the pilot stage and completing baseline screening will be evaluated as the analyzable set.
62348547|NCT03686865||dental implants|
62348548|NCT05022745|EXPERIMENTAL|ERAS group|Posterior lumbar interbody fusion Multimodal, multidisciplinary patient care.
62348549|NCT05022745|ACTIVE_COMPARATOR|Standard group|Posterior lumbar interbody fusion Standard treatment pre-, per-, and post-operative
62348550|NCT04093362|EXPERIMENTAL|TAS-120|TAS-120 tablets, oral; 21-day cycle
62348551|NCT04093362|ACTIVE_COMPARATOR|Cisplatin/Gemcitabine|"• On Days 1 and 8 of a 21-day cycle, patients will receive:~* Cisplatin 25 mg/m2 in 1000 mL 0.9% saline by intravenous (I.V.) infusion over 1 hour, followed by 500 mL 0.9% saline over 30 minutes; and~* Gemcitabine 1000 mg/m2 in 250-500 mL 0.9% saline by I.V. infusion over 30 minutes, beginning after completion of the cisplatin and saline infusions."
62506353|NCT03847363||general and epidural anesthesia|patients underwent general and epidural anesthesia
62506354|NCT03847363||general anesthesia combined with nerve block|patients underwent general anesthesia combined with nerve block
62506355|NCT01621906|EXPERIMENTAL|Cohort 1|Cohort 1 will include the first ten patients treated with WBRT concomitantly with sorafenib (on a separate phase I trial). We will perform a pilot study of serial FLT-PET imaging of the brain at baseline (\< 4 weeks prior to initiation of WBRT), up to 7-10 days post-WBRT and 10-12 weeks after WBRT in patients with metastatic breast cancer to the brain (N=20) treated with WBRT with or without sorafenib.
62506356|NCT01621906|EXPERIMENTAL|Cohort 2|Cohort 2 will include patients treated with standard WBRT alone. Patients in both these cohorts will also be assessed with standard non-invasive MRI in addition to \[18F\] FLT PET at baseline (\< 4 weeks of WBRT) and 10-12 weeks after completion of WBRT.
62506357|NCT02979691|ACTIVE_COMPARATOR|SIB-IMRT|SIB-IMRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday).
62506358|NCT02979691|EXPERIMENTAL|S1 based SIB-IMRT|S1 based SIB-IMRT receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday) followed by four cycles of S-1 (40-60mg, orally twice daily, d1-14, every 3 weeks) as an adjuvant chemotherapy.
62506359|NCT04552912|EXPERIMENTAL|Build Stamina Group|The Build StaMINA (Biobehavioral Self-Management INtervention using physical Activity) is a tailored evidence-based physical activity (PA) program designed to improve endurance, strength, and balance which are all areas of physical function, that adults with acute leukemia (AL) post-induction are known to have diminished capacity. The Build StaMINA program will be tailored to their current Physical Function, per assessment. The detailed PA prescription includes each exercise in the program as well as the frequency, number of repetitions each day and rate of perceived exertion (RPE) for each exercise. The repetitions and RPE are based on the participants' current Physical Function Assessment and will be assigned based on our evidence-based algorithm.
62506360|NCT04552912|NO_INTERVENTION|Attention-Control Group|Participants assigned to the attention control group will have a Physical Function Assessment at baseline after informed consent has been provided and prior to randomization. Participants will also be asked to complete questionnaires regarding at baseline, 6-weeks and 3 months. Those in the attention-control group will also receive a newsletter detailing the benefits of participating in regular PA as well as regular phone calls by study team to discuss general health and wellbeing at the same schedule as intervention group.
62506361|NCT06616805|EXPERIMENTAL|low-volume High Intensity Interval Training|Group (A): low-volume High Intensity Interval Training Patients in this group will undergo a warm-up at low intensity for 10 minutes, and then they will perform a single bout protocol that consisted of 1×4 min at 80-90% HRmax. Finally, a 5-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
62506362|NCT06616805|EXPERIMENTAL|Moderate Intensity Continuous Training|Group (B): Moderate Intensity Continuous Training Each session will start with a 10-minute warm-up at low intensity. Then they will walk on a treadmill for 30 min at moderate intensity corresponding to 65-75% of HR-max. Finally, a 5-min cool-down period will be permitted
62506363|NCT05911087|EXPERIMENTAL|Phase II group 1 :A single 25 μg dose mRNA vaccine SWIM816|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
62506364|NCT05911087|ACTIVE_COMPARATOR|PhaseII group 2:A single 25 μg dose mRNA vaccine SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Control Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
62704911|NCT02954874|EXPERIMENTAL|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Cycles repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment. Patients may also undergo collection of blood samples throughout the trial.
62704912|NCT06035874|ACTIVE_COMPARATOR|Bem group|Patient will get Bempedoic acid along with the standard of Care
62704913|NCT06035874|NO_INTERVENTION|Control Group|Patient will get the standard of Care as per routine practice
62704914|NCT04399941|EXPERIMENTAL|IVUS and venography group|Participants in the this group will receive venography/fistulogram, intravascular ultrasound (IVUS), and image processing.
62704915|NCT02583646||normal weight|Girls age 8-14 below 85% in respect to weight for their age group
62704916|NCT02583646||overweight|Girls age 8-14 at or above 85% in respect to weight for their age group
62704917|NCT05281562|NO_INTERVENTION|Standard of Care Group|Patients will receive standard of care wound treatment as determined by a treating physician.
62704918|NCT05281562|EXPERIMENTAL|Immunonutrition Supplementation Group|Patients will receive a 6 week daily oral supply of 1.68 grams Omega-3 fatty acids, 4.5 grams L-Arginine, and 500 mg Vitamin C.
61962664|NCT01538043|NO_INTERVENTION|regular routine ambulatory care|50 patients, the control group, will continue regular routine ambulatory care
61962665|NCT05954806||Patients With Hypnale Hypnale Bite receiving Antivenom|Patients With Hypnale Hypnale Bite receiving Antivenom for local or systemic signs of envenomation
61962666|NCT05954806||Patients With Hypnale Hypnale Bite not receiving Antivenom|Patients With Hypnale Hypnale Bite not receiving Antivenom for local or systemic signs of envenomation
61962667|NCT01162512|EXPERIMENTAL|Physical Activity|Participants will receive 7 weeks of weekly news letters and phone calls. The news letters and phone calls will include information about physical activity and ways to increase physical activity levels. This is in addition the standard medical care.
61962668|NCT01162512|NO_INTERVENTION|Standard Medical Care|Participants will receive standard medical care
62348552|NCT05872295|EXPERIMENTAL|Dose Escalation Cohort (Part 1)|Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62348553|NCT05872295|EXPERIMENTAL|Dose Expansion: HER2+ Breast Cancer Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62348554|NCT05872295|EXPERIMENTAL|Dose Expansion: HER2 Low Breast Cancer Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62348555|NCT05872295|EXPERIMENTAL|Dose Expansion: HER2+ Gastric Cancer or Gastro-esophageal Junction Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
61962669|NCT02577510|EXPERIMENTAL|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
62506365|NCT05911087|EXPERIMENTAL|Phase III group 1:A single 25 μg dose mRNA vaccine SWIM816|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
62704919|NCT05376111|EXPERIMENTAL|Venetclax combined with Azacitidine|T-cell acute lymphoblastic leukemia patients reveive venetoclax combined with azacitidine regimen treatment.
62704920|NCT03711734|EXPERIMENTAL|Acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally with electrostimulation at Shen men and Hypothalamus at 30 hz."
62704921|NCT03711734|NO_INTERVENTION|No acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will not have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally."
62704922|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders.
62348556|NCT05872295|EXPERIMENTAL|Dose Expansion: HER2 Low Gastric Cancer or Gastro-esophageal Junction Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62348557|NCT05872295|EXPERIMENTAL|Dose Expansion: HER2 Solid Tumor Cancer Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62348558|NCT02658201|OTHER|MRI group|Ultrafast MRI
62348559|NCT05508685|EXPERIMENTAL|HIIT and Cognitive Reassessment|The experimental group will receive high-intensity interval training associated with cognitive reassessment
62348560|NCT05508685|ACTIVE_COMPARATOR|HIIT Group|The HITT group will receive only the exercise without cognitive reassessment
62348561|NCT05508685|ACTIVE_COMPARATOR|Emotional regulation strategy group|This group will receive only cognitive reassessment strategy
62348562|NCT05508685|PLACEBO_COMPARATOR|Group No exercise and cognitive reassessment|This group will only be evaluated in pre and post, without intervention.
62348563|NCT00333619|EXPERIMENTAL|Nonpharmacological sleep intervention|The intervention will combine: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies.
62348564|NCT00333619|ACTIVE_COMPARATOR|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
62348565|NCT01326117|EXPERIMENTAL|tadalafil|
62506366|NCT05911087|ACTIVE_COMPARATOR|Phase III group 2:A single 30 μg dose mRNA Pfizer Bivalent vaccine|Intervention Name :Pfizer Bivalent Vaccine Type :Control Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.3μg; Dosage Level(s) :0.3ml;
61962670|NCT02577510|EXPERIMENTAL|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
61962671|NCT03225183||1|Framingham Heart Study participants
61962672|NCT05479071||SLE patients WITH cardiovascular disease|Relation of antibodies against LDL to disease activity in pt with cardiovascular disease
61962673|NCT05479071||SLE Patients without cardiovascular disease|Relation of antibodies against LDL to disease activity in pt without cardiovascular disease
62348566|NCT06372054||High-performance Italian Air Force Pilots|"The primary study cohort is represented by super-healthy high-performance Italian Air Force Pilots, aged between 26 and 38 years, in active flight service.~Intervention: not applicable"
62704923|NCT02270814|EXPERIMENTAL|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:~* nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by~* cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by~* cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle~* Cisplatin or carboplatin may be given at the discretion of the investigator.~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:~* nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle~* cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
62348567|NCT06372054||Italian Air Force ground staff|This cohort of Italian Air Force ground personnel will be used as a control group to compare data from the pilot cohort.
62348568|NCT02104999|OTHER|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
62348569|NCT00643604|EXPERIMENTAL|treprostinil sodium|all subjects had switched from IV epoprostenol to IV treprostinil sodium
62348570|NCT05977153|ACTIVE_COMPARATOR|Group 1: ARDSNet|Participants will receive standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol.
62348571|NCT05977153|EXPERIMENTAL|Group 2: Individualized PEEP (positive end expiratory pressure) Strategy|Participants will receive individualized PEEP (positive end-expiratory pressure).
62506367|NCT02676245|EXPERIMENTAL|Viewing NBS + DBS Educational Movies|Group A: pregnant women who will view the NBS and residual specimen movies and printed materials during one visit between 30 and 40 weeks gestation.
62506368|NCT02676245|EXPERIMENTAL|Viewing NBS Educational Movie only|Group B: pregnant women who will view the NBS movie only and printed materials at one visit between 30 and 40 weeks. The movies will be presented on a tablet PC.
62506369|NCT02676245|NO_INTERVENTION|No Educational Interventions|Control Group: pregnant women who will receive no experimental intervention during pregnancy or the postpartum period but will receive whatever information is routinely provided by their OB clinic and/or delivery center.
62506370|NCT02230111|EXPERIMENTAL|Energy restriction plus CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. They will be told that they are on a low-calorie diet and strategies to increase CDR will be used.
62506371|NCT02230111|EXPERIMENTAL|Energy restriction without CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. To have a condition of energy restriction without CDR, they will not be told that they are on a low-calorie diet and non-restrictive messages will be used.
62506372|NCT02672540|EXPERIMENTAL|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
62506373|NCT02672540|PLACEBO_COMPARATOR|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
62506374|NCT02607137|EXPERIMENTAL|Health Education|Health information related to physical activity
62506375|NCT03188601||Rambam|Approximately 40 patients in total.No intervention planned.
62506376|NCT03188601||Soroka|Approximately 10 patients in total.No intervention planned.
62506377|NCT03188601||Tel Aviv Souraski|Approximately 40 patients in total.No intervention planned.
62506378|NCT03188601||Jerusalem Hadassah|Approximately 50 patients in total. No intervention planned.
62506379|NCT01787110|NO_INTERVENTION|No oxygen|"For patients randomised to withholding oxygen treatment~* no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~* all patients receive standard acute coronary syndrome treatment including reperfusion strategies~* observation duration 12 hours"
62506380|NCT01787110|ACTIVE_COMPARATOR|Oxygen|"For patients randomised to oxygen therapy:~* 6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~* all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
62506381|NCT02926651|ACTIVE_COMPARATOR|Conventional Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
62506382|NCT02926651|ACTIVE_COMPARATOR|Conventional Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA (Tranexamic Acid) 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
62506383|NCT02926651|EXPERIMENTAL|Multi-Dose Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
62506384|NCT02926651|EXPERIMENTAL|Multi-Dose Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
61962674|NCT05926102|EXPERIMENTAL|Precision screening intervention|The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
61962675|NCT05926102|EXPERIMENTAL|Usual care|Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
61962676|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
61962677|NCT01239004|PLACEBO_COMPARATOR|Placebo|
61962678|NCT01239004|EXPERIMENTAL|Colesevelam|
62506385|NCT04157452||proximal ureteral stone patient|
62506386|NCT04187924|ACTIVE_COMPARATOR|Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage. Sputum will be collected during the session.
62506387|NCT04187924|ACTIVE_COMPARATOR|SIMEOX + Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage with the SIMEOX device. Sputum will be collected during the session.
62506388|NCT06461793|EXPERIMENTAL|Prostate cancer patient, candidate of definitive radiation treatment|A single institution with a single group, a phase II study, we plan to evaluate grade 1 or higher rectal bleeding within 3 years in high-risk prostate cancer patients who received biodegradable substance injection followed by curative radiotherapy in combination with hormone therapy.
61962679|NCT03122769|EXPERIMENTAL|11C-metformin|All participants allocated to the study will be included in this arm
61962680|NCT01314573|EXPERIMENTAL|Interval maximal exercise|Interval exercise involving repeated Wingate tests (30s durations of maximal exercise on a cycle ergometer).
61962681|NCT01314573|EXPERIMENTAL|Continuous maximal exercise|Continuous exercise of maximal exertion that has been work matched to an initial bout of interval exercise of 4 x 30s of maximal exercise. This exercise is performed on a cycle ergometer.
61962682|NCT01186354|EXPERIMENTAL|Receiving results via web-based program|participants will receive genetic risk results for Type 2 diabetes via a web-based program that they access on their own
62506389|NCT06192641|ACTIVE_COMPARATOR|Melatonin|Patients will receive 3 mg melatonin in capsule for 30 days. They will be instructed to ingest melatonin once a day, at night, one hour before bed.
62506390|NCT06192641|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo capsule composed of cellulose and indigestible fiber for 30 days. They will be instructed to ingest melatonin once a day, at night, one hour before bed.
62506391|NCT03209609|EXPERIMENTAL|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
62506392|NCT03209609|ACTIVE_COMPARATOR|Standard of care vein grafts|Coronary artery bypass vein grafts
62506393|NCT01359579|EXPERIMENTAL|Subjects with mild renal impairment|
62704924|NCT00324805|ACTIVE_COMPARATOR|Arm I (chemotherapy)|"Patients receive one of the following. For all, treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~REGIMEN 1: Vinorelbine ditartrate 30 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV over 60 minutes on day 1 REGIMEN 2: Docetaxel 75 mg/m2 IV and cisplastin 75 mg/m2 IV on day 1 REGIMEN 3: Gemcitabine hydrochloride 1200 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV on day 1 REGIMEN 4 (non-squamous histology only): Pemetrexed disodium 500mg/m2 IV and cisplatin 75 mg/m2 IV on day 1"
62704925|NCT00324805|EXPERIMENTAL|Arm II (chemotherapy, bevacizumab)|Patients receive chemotherapy as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 1 year.
62704926|NCT06429059|EXPERIMENTAL|Neuroinflammation|Study participants in this category are expected to have inflammation in their brains and spinal cords.
62704927|NCT06429059|EXPERIMENTAL|Oxidative Stress|"Study participants in this category are expected to have too many damaging free radical chemicals in their brains and spinal cords."
62506394|NCT01359579|EXPERIMENTAL|Subjects with moderate renal impairment|
62506395|NCT01359579|EXPERIMENTAL|Subjects with normal renal function|
62506396|NCT01359579|EXPERIMENTAL|Subjects with severe renal impairment|
62506397|NCT06152705|EXPERIMENTAL|fMRI guided iTBS targetting|The target selected is based on functional connectivity determined from the MRI scan.
62506398|NCT06152705|ACTIVE_COMPARATOR|Neuronavigation guided iTBS targetting|A technique for treatment location targeting, based on structural images of the brain using standard coordinates.
61962683|NCT02732119|EXPERIMENTAL|Cohort A|Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
62506399|NCT01011556|ACTIVE_COMPARATOR|20 mcg Subcutaneous Teriparatide|Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
62506400|NCT01011556|EXPERIMENTAL|30 mcg Transdermal Teriparatide|Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
62506401|NCT01011556|EXPERIMENTAL|50 mcg Transdermal Teriparatide|Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
62506402|NCT01011556|EXPERIMENTAL|80 mcg Transdermal Teriparatide|Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
62506403|NCT05895578|ACTIVE_COMPARATOR|Probiotic|2 Capsule daily containing approximately 1\*10E9 colony forming unit (CFU) of Lactobacillus CECT 9422 +1\*10E9 colony forming unit (CFU) of Bifidobacterium CECT 30257.
62506404|NCT05895578|ACTIVE_COMPARATOR|Probiotic + placebo|One capsule daily containing approximately 1\*10E9 colony forming unit (CFU) of Lactobacillus CECT 9422 +1\*10E9 colony forming unit (CFU) of Bifidobacterium CECT 30257 and 1 capsule of placebo supplement.
62704928|NCT06429059|EXPERIMENTAL|Impaired Autophagy and Axonal Transport|Study participants in this category are expected to have motor neurons that have trouble transporting materials up and down their length, and/or trouble with the turnover of damaged proteins and intracellular structures.
62506405|NCT05895578|PLACEBO_COMPARATOR|Placebo|Two capsules daily of Placebo supplement.
61962684|NCT02732119|EXPERIMENTAL|Cohort B|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
61962685|NCT02732119|EXPERIMENTAL|Cohort C|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
61962686|NCT02732119|EXPERIMENTAL|Group 1|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
61962687|NCT02732119|EXPERIMENTAL|Group 2|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
61962688|NCT02228460|EXPERIMENTAL|GZ/SAR402671|GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.
62506406|NCT02913820||snowfall >5cm/d|impact of snowfall and its correlation with acute myocardial infarctions is analyzed. Other precipitation (rainfall) changes in atmospheric pressure and temperature will be variables to be corrected for.
62506407|NCT04688047|EXPERIMENTAL|Experimental|Women aged 18 and over with urinary incontinence will be taken. A total of seven online interviews will be conducted with the women in the experimental group, one of which is pre-test, one is the last interview where the post-tests are applied, and five of which are motivational. Women in the experimental group were interviewed every 2 weeks and the women will be followed up by phone / mail every 2 weeks.
62506408|NCT04688047|NO_INTERVENTION|Control|Women aged 18 and over with urinary incontinence will be taken. A total of two online interviews will be conducted with women in the control group, one of which is a pre-test interview and one is a final interview where post-tests are applied.
62506409|NCT04380649|EXPERIMENTAL|ALS people with severe disability|
62506410|NCT05377606|ACTIVE_COMPARATOR|Silicone oil group|Primary pars plana vitrectomy will be performed and silicone oil will be used as the tamponading agent. For these patients, optical coherence tomography (OCT) and angiography (OCTA), along with microperimetry will be done 2 months after the primary surgery. Then they will be scheduled for silicone oil removal after 3 months from the time of primary surgery. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy (i.e. one month after the silicone oil removal).
62704929|NCT06429059|EXPERIMENTAL|Mitochondrial Dysfunction|Study participants in this category are expected to have motor neurons that are unable to produce normal amounts of energy.
62704930|NCT06356311|EXPERIMENTAL|Sacituzumab tirumotecan|Participants will receive sacituzumab tirumotecan at a dose of 4mg/kg by intravenous (IV) infusion on days 1, 15, and 29 of every 42-day cycle.
62506411|NCT05377606|ACTIVE_COMPARATOR|Sulfur hexafluoride (SF6) group|Primary pars plana vitrectomy will be performed and sulfur hexafluoride (SF6) will be used as the tamponading agent. For these patients, optical coherence tomography (OCT) and angiography (OCTA), along with microperimetry will be done 2 months and 4 months after the primary surgery.
62506412|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
62506413|NCT01236417|EXPERIMENTAL|Exercise|Subjects will be participating in a home-based flexibility and exercise program
62506414|NCT04944316|ACTIVE_COMPARATOR|Low-fat, vegan diet|For a 12-week period, participants will be asked to follow a low-fat, vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index \<70, using tables standardized to a value of 100 for glucose.
62506415|NCT04944316|ACTIVE_COMPARATOR|Portion-controlled diet|For a 12-week period, participants will be asked to follow a portion-controlled diet that is compliant with American Diabetes Association (ADA) guidelines. This diet will include individualized diet plans that reduce daily energy intake by 500-1,000 kcal for overweight (body mass index \> 25 kg/m2) participants and keep carbohydrate intake reasonably stable over time. It will derive 15-20% from protein, \<7% saturated fat, 60-70% carbohydrate and monounsaturated fats and ≤200 mg/day of cholesterol/day.
62506416|NCT03244982|ACTIVE_COMPARATOR|Full-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
62506417|NCT03244982|EXPERIMENTAL|Half-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
62506418|NCT00692315|EXPERIMENTAL|Methyl B12|Subcutaneous injection of 75 micrograms/Kg
62506419|NCT00692315|EXPERIMENTAL|Folinic Acid|400 micrograms orally twice a day
62506420|NCT04219787|EXPERIMENTAL|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
62506421|NCT04219787|ACTIVE_COMPARATOR|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
62506422|NCT03233451|EXPERIMENTAL|Interventional group|Subjects receive guided psycho-behavioral intervention once a week for 8 weeks. After 8 weeks, the subjects will receive monthly psychological counseling for 7 months.
62506423|NCT03233451|NO_INTERVENTION|control group|Subjects will receive usual care and be contacted as same frequent as the intervention group.
62506424|NCT05849688|ACTIVE_COMPARATOR|Designed Physical Therapy Program|Boys with Duchenne muscular dystrophy will receive the designed physical therapy program for 1 hour/ session.
62506425|NCT05849688|EXPERIMENTAL|Bicycle Ergometry Training|Boys with Duchenne muscular dystrophy will receive the designed physical therapy program for 1 hour/ session in addition to bicycle ergometry training for 20 min./ session
62506426|NCT03348488|NO_INTERVENTION|Standard ultrafiltration|standard ultrafiltration (fluid removal from the body by dialysis at the prescribed volume and rate) during a conventional treatment
62506427|NCT03348488|ACTIVE_COMPARATOR|High dose ultrafiltration|Intervention= Fixed rate high dose ultrafiltration (fluid removed from the body by dialysis) of 1 litre per hour over 1 hr instaed of standard ultrafiltration rate and volume.
62506428|NCT00891072|EXPERIMENTAL|Treatment|Patients receive oral R-(-)-gossypol acetic acid twice daily on days 1-3. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
61962689|NCT01794884|EXPERIMENTAL|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg)(volume ratio=1:5).Intravenous injection twice (24 hours、1 hour before operation).
62506429|NCT01607190||Patients with diabetic retinopathy.|
62506430|NCT06490406|EXPERIMENTAL|Experimental Group 1 (EG1)|"In addition to the usual training in communication skills, a systematic and digitalized guide will be used that included the health literacy practices qualified by Coleman et al. \[10\] as a training complement and self-assessment of its performance. They will also receive feedback from independent observers (according to the systematic guide)."
62506431|NCT06490406|NO_INTERVENTION|Control Group / Experimental Group 2 (CG / EG2)|"The CG will receive the usual training (consisting of two weekly meetings of two hours each with seven sessions whose main topics were social skills for clinical interviews: opening and closing of the clinical interviews, non-verbal communication, active listening, empathy, helping relationship, giving information about the nature of the disease and rationality of the therapeutic measures, health education, and negotiation). Furthermore, throughout the course, they will self-assess their performance using the opening video recording without systematic guidance and they will receive feedback about their communication practices during this first performance.~Thus, CG will receive the full intervention after being evaluated (post-test 1 assessment), becoming the delayed Experimental Group 2 (EG2)"
62506432|NCT05587257|EXPERIMENTAL|Group 1|six sessions of fractional carbon dioxide laser every 2 weeks will be done for 15 patients with alopecia areata followed immediately by topical application of minoxidil 5%
62506433|NCT05587257|EXPERIMENTAL|Group 2|six sessions of microneedling evry 2 weeks will be done for 15 patients with alopecia areata followed immediately by topical application of minoxidil 5%
62506434|NCT05587257|EXPERIMENTAL|Group 3|15 patient of alopecia areata that will be treated by topical nanominoxidil for 3 months.
62506435|NCT05587257|ACTIVE_COMPARATOR|Group 4|15 patient of alopecia areata that will be treated by topical minoxidil 5% for 3 months
62506436|NCT03485846|EXPERIMENTAL|Narlaprevir + Ritonavir + Daclatasvir|All of enrolled patients receive equal study therapy with Narlaprevir/Ritonavir/Daclatasvir daily for 12 weeks
61962690|NCT01794884|PLACEBO_COMPARATOR|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation).
61962691|NCT02744690|EXPERIMENTAL|MMC Injection|Intervention: At the intended surgical site and about 6mm from the limbus, 0.2ml of 0.2mg/ml of mitomycin-C (MMC) will be injected subconjunctivally before peritomy
61962692|NCT02744690|ACTIVE_COMPARATOR|MMC Sponge Application|Intervention: After peritomy, three half-sponges soaked in 0.2mg/ml mitomycin-C (MMC) will be placed posterior to the area of intended filtration. After 2 minutes, the sponges will be removed
62348572|NCT00881361|OTHER|Study cohort|Patients who plan to receive or have received neoadjuvant chemotherapy are eligible. Patients undergo examination for breast and axilla lymph adenopathy and then undergo ultrasound of the axillary nodes at baseline and after completion of neoadjuvant chemotherapy. Within 12 weeks of completing neoadjuvant chemotherapy, patients undergo a mastectomy or lumpectomy (per surgeon discretion) including both sentinel lymph node surgery and axillary lymph node dissection.
62506437|NCT02196064||Safety of the three-drug combination TDF/FTC/RPV|A total of 176 patients will be included in this study, as well as 352 patients naive for RPV who initiated any ART that does not include RPV, who will serve as control group.
62506438|NCT03630419|EXPERIMENTAL|Mito-Food Plan and Cellular Repair|Mito-Food Plan with adjunctive Cellular Repair Therapy
62506439|NCT02839798|EXPERIMENTAL|sTMS active|Treatment with the NEST Device
62506440|NCT05518032|EXPERIMENTAL|Treatment (pembrolizumab, autologous dendritic cells)|Patients receive pembrolizumab IV on days 8, 29, 50, and 71, and autologous dendritic cells intratumorally on days 1 and 8 in the absence of disease progression or unacceptable toxicity. Patients may also receive an autologous dendritic cells intratumorally on day 50.
62506441|NCT01397981|EXPERIMENTAL|Walking modification|Changing kinematics for walking
62506442|NCT06616649|EXPERIMENTAL|SCS Implantation|Participants will be screened on a weekly basis in the Pain Management Clinic
62506443|NCT00707421|PLACEBO_COMPARATOR|1|placebo, artificial tears
62506444|NCT00707421|ACTIVE_COMPARATOR|3|corticosteroid , CS
62506445|NCT00707421|ACTIVE_COMPARATOR|2|non-steroidal anti-inflammatory drug, NSAID
62506446|NCT06492564|EXPERIMENTAL|Dose 1|Low dose, expected to be approximately 10\^3 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
62506447|NCT06492564|EXPERIMENTAL|Dose 2|Medium dose, expected to be approximately 10\^4 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
62506448|NCT06492564|EXPERIMENTAL|Dose 3|High dose, expected to be approximately 10\^5 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
62506449|NCT03087786|EXPERIMENTAL|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
62506450|NCT03087786|ACTIVE_COMPARATOR|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
61962693|NCT05188911||mCRPC|Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 5mg prednisone bid. Patients would get medical or surgical castration.
61962694|NCT04645875|EXPERIMENTAL|Sit regimen|Participants will be instructed to restrict walking and standing to ≤1 h/day each (total ≤2 h/day ) and the remainder of the waking day will be seated apart from visiting the toilet.
61962695|NCT04645875|EXPERIMENTAL|SitLess regimen|Participants will be instructed to substitute a minimum of 5h/day of sitting with ≥2 h of light-intensity physical activity and ≥3 h of standing. Participants will be advised to rise from the seated position for 2-5 min every 30 min to engage in standing /light-intensity physical activities to interrupt their sitting.
61962696|NCT01943578||lung cancer patients|Non Small Cell Lung Cancer, Small Cell Lung Cancer
61962697|NCT05557981|EXPERIMENTAL|Trainees - treatment|"Residents and fellows paired with a faculty coach from the faculty - treatment arm to participate in up to 4 coaching meetings"
61962698|NCT05557981|NO_INTERVENTION|Trainees - control|Residents and fellows randomized to the control arm. They are not paired with a faculty coach and instead continue to receive standard mentorship as part of their training program.
61962699|NCT05557981|EXPERIMENTAL|Faculty - treatment|"Faculty members randomized to receive coaching training and are paired with a resident/fellow from the trainees - treatment arm to conduct up to 4 coaching sessions over the course of the academic year."
62348573|NCT06396572|EXPERIMENTAL|Immersive Virtual Reality|The Participants used Immersive Virtual Reality for learning and practice urinary catheterisation procedure
62506451|NCT00063882|EXPERIMENTAL|EBRT + Brachytherapy|External beam radiation therapy (EBRT) and transperineal interstitial permanent brachytherapy (100/110)
62506452|NCT00063882|ACTIVE_COMPARATOR|Brachytherapy Only|Transperineal interstitial permanent brachytherapy (125/145)
62506453|NCT00872326|EXPERIMENTAL|Autologous Bone Marrow Mononuclear Cells|Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells
62506454|NCT04431635|EXPERIMENTAL|Arm A: Copanlisib, Nivolumab & Rituximab|Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
62506455|NCT03070015|EXPERIMENTAL|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
62506456|NCT03070015|ACTIVE_COMPARATOR|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
62506457|NCT03239496|EXPERIMENTAL|Group A|3 doses IPV IM at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.
62506458|NCT03239496|EXPERIMENTAL|Group B|2 doses IPV IM at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.
62506459|NCT03239496|EXPERIMENTAL|Group C|3 doses f-IPV ID at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.
62506460|NCT03239496|EXPERIMENTAL|Group D|2 doses f-IPV ID at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.
62506461|NCT03964441||control|fetus with at least 2 ultrasound abnormalities and both parents
62506462|NCT03964441||comparison|fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling
62506463|NCT03964441||professional|obstetrician, midwife, geneticist, biologist
62506464|NCT05763849|EXPERIMENTAL|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance, food exposure, and body image exposure.
61962700|NCT05557981|NO_INTERVENTION|Faculty - control|Faculty members randomized to control arm. They are not paired with a trainee from this study and instead continue to provide mentorship as they typically would, as part of their role at an academic medical center
61962701|NCT04472195|EXPERIMENTAL|Experimental|The experimental group will review a pre-induction airway management plan for their upcoming case and undergo a scripted 10-minute RCDP session with an airway coach within 1 hour of patient intubation. The intubation approach (DL vs. video assisted DL) will be chosen by the primary case attending and communicated to the airway coach to simulate the planned laryngoscopy attempt. The experimental group will then proceed with their scheduled case with a member of the research team observing the laryngoscopy attempt(s) to capture data.
61962702|NCT04472195|NO_INTERVENTION|Control|The trainees in the control group will have no interventions by the research team, only observation of the intubation and documentation of the same details.
61962703|NCT04856371|EXPERIMENTAL|CYH33 + fulvestrant|Participants will receive CYH33 in combination with a standard fixed dose of fulvestrant 500 mg.
61962704|NCT04856371|EXPERIMENTAL|CYH33 + fulvestrant + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of fulvestrant (500 mg) and palbociclib (125 mg).
61962705|NCT04856371|EXPERIMENTAL|CYH33 + letrozole + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of letrozole (2.5 mg) and palbociclib (125 mg)
61962706|NCT01482000|EXPERIMENTAL|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
61962707|NCT01482000|ACTIVE_COMPARATOR|Control|The control group will get the usual care with some additional tests for the study.
62348574|NCT06396572|ACTIVE_COMPARATOR|Nursing clinical laboratory|The Participants used a traditional nursing clinical laboratory for face to face learning and practice urinary catheterisation procedure
62348575|NCT03534726||Patients|Patients with cardiomyopathy
62348576|NCT03534726||Normal subjects|No prior history of heart disease.
62348577|NCT03619291|EXPERIMENTAL|High-intensity functional training|all-out exercise
62348578|NCT03619291|ACTIVE_COMPARATOR|Aerobic exercise|walking
62348579|NCT03619291|SHAM_COMPARATOR|control|sitting
62348580|NCT03728140|EXPERIMENTAL|Self-spent Culture Medium|Changing embryo transfer solution with self-spent culture medium
62348581|NCT03728140|NO_INTERVENTION|New Culture Medium|embryo transfer with new culture medium in IVF-ET
62348582|NCT01812486|ACTIVE_COMPARATOR|control arm|NID2Gy = 50 Gy Swallowing apparatus: standard dose
62348583|NCT01812486|EXPERIMENTAL|Experimental de escalated arm|NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge
62348584|NCT04046341|EXPERIMENTAL|Behavioral Sleep Intervention|Parents attend 1-3 one-hour sessions at their primary care office or via telemedicine, where they receive sleep education and work with interventionists to develop strategies to help their child at bedtime.
62348585|NCT06123910|EXPERIMENTAL|Colostrum bovine|Subjets taking a colostrum supplement
62348586|NCT06123910|PLACEBO_COMPARATOR|Placebo|Subjets taking a commercial dairy product
62348587|NCT03968341|EXPERIMENTAL|intraocular antibiotic concentrations determination|"In the event that the patient develops unfavourably, the ophthalmologist include the patient in the trial.~The patient is reviewed at 48 hours after the introduction of probabilistic antibiotic therapy for clinical reassessment and the return of microbiological test results. Following this inclusion, the new samples will be taken when the patient passes through the operating room for the treatment of his pathology as part of the care. Ophthalmologists may have to adapt the patient's management (i.e. adjustment of antibiotic therapy) as part of their usual care routine. An anterior chamber puncture and a vitrectomy are performed. Eye fluids collected as part of the treatment are sent for analysis."
61962708|NCT05680597|EXPERIMENTAL|Supervised Tele-Rehabilitation Home Exercise|40 participants will have tele-rehabilitation virtually with a physical therapist for 60 minutes approximately three times per week for four weeks of intervention (12 visits). Participants will also be assessed for daily life mobility for seven days pre and post intervention with wearable sensors.
62348588|NCT03111264|EXPERIMENTAL|CHAMP group|Childcare centers randomly assigned the CHAMP group will receive an intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
62348589|NCT03111264|EXPERIMENTAL|CHAMP+ group|These childcare centers, also randomly assigned, will have the same intervention as the CHAMP group in addition to a parenting intervention that promotes wellness and healthy behaviors within families.
62348590|NCT03111264|NO_INTERVENTION|Control|This group will not receive theCHAMP intervention at the childcare center nor will this group receive the CHAMP+ parenting intervention.
62348591|NCT04449783||study patients|Patients undergoing elective cancer surgery, who will receive pre-operative screening including reporting symptoms and nose and throat swabbing 48 hours prior to surgery
62348592|NCT03106948|PLACEBO_COMPARATOR|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
62348593|NCT03106948|ACTIVE_COMPARATOR|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
62348594|NCT03106948|ACTIVE_COMPARATOR|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
61962709|NCT05680597|ACTIVE_COMPARATOR|Unsupervised Rehabilitation Home Exercise|40 participants will complete their home exercise Agility Boot Camp (ABC) program for 60 minutes approximately three times per week for four weeks of intervention (12 sessions). Participants will also be assessed for daily life mobility for seven days pre and post intervention with wearable sensors.
61962710|NCT01728064|PLACEBO_COMPARATOR|Placebo|Placebo capsules three times daily
61962711|NCT01728064|ACTIVE_COMPARATOR|EPI-743 400 mg|EPI-743 at a dose of 400 mg three times daily
61962712|NCT01728064|ACTIVE_COMPARATOR|EPI-743 200 mg|EPI-743 at a dose of 200 mg three times daily
61962713|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width \<4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
61962714|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width \<4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
61962715|NCT01201382|EXPERIMENTAL|IPT-AST|Interpersonal Psychotherapy-Adolescent Skills Training
61962716|NCT01201382|ACTIVE_COMPARATOR|Group Counseling|Group Counseling
61962717|NCT02381288|EXPERIMENTAL|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
61962718|NCT02381288|EXPERIMENTAL|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
61962719|NCT02381288|EXPERIMENTAL|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
61962720|NCT02381288|PLACEBO_COMPARATOR|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
62348595|NCT00771173|ACTIVE_COMPARATOR|Study Medication Group|Participants that are randomized to the phenazopyridine HCl group will receive the study medication (200 mg of phenzopyridine HCl orally) after leaving the operating room. We anticipate the first dose to be given after the patient has left the recovery area. We will continue use of study medication until it has been given up to 24 hours after the first VAS collection or catheter removal, whichever occurs first
61962721|NCT01473836|EXPERIMENTAL|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
61962722|NCT05081154|EXPERIMENTAL|Product usage order A B G C F D E|Subjects will use each of the 7 products (A B G C F D E) during an evaluation period, followed by a 4 hour Test Session
62348596|NCT00771173|PLACEBO_COMPARATOR|Placebo tablet Group|For participants randomized to the placebo group will follow the same dosing schedule for the study medication, although they will receive an inert placebo tablet.
62348597|NCT04408066|EXPERIMENTAL|Arm A:Suspected COVID-19 patients|Arm A: Suspected COVID-19 Patients - SARS-CoV-2 viral antigen test swab and blood sample for SARS-CoV-2 IgG/IgM
62348598|NCT04408066|EXPERIMENTAL|Arm B: Previously positive COVID-19 patients|Arm B: Previously Positive COVID-19 patients - SARS-CoV-2 IgG/IgM blood sample. Capillary fingerstick samples will additionally be collected in Stage 2.
62348599|NCT01623700||dual antiplatelet treatment 12 months after ACS event|
62348600|NCT01623700||dual antiplatelet treatment 6 months after ACS event|
62348601|NCT01623700||dual antiplatelet treatment 3 months after ACS event|
62348602|NCT03136770|EXPERIMENTAL|A|CK-30 600 mg -\> red ginseng extracts 2.94 g
62348603|NCT03136770|EXPERIMENTAL|B|red ginseng extracts 2.94 g -\> CK-30 600 mg
62348604|NCT03302208|ACTIVE_COMPARATOR|pregabalin group|
62348605|NCT03302208|PLACEBO_COMPARATOR|placebo group|
62348606|NCT05960110|EXPERIMENTAL|Test Group|Fluoride toothpaste and fluoride varnish
62348607|NCT05960110|SHAM_COMPARATOR|Control Group|Fluoride toothpaste
62348608|NCT03716518|EXPERIMENTAL|TCM group|Tonifying Spleen and Kidney Sequential Regimen(TSKSR) will be prescribed to the participants in each course of chemotherapy.
62348609|NCT03716518|PLACEBO_COMPARATOR|Placebo group|Placebo of Tonifying Spleen and Kidney Sequential Regimen(TSKSR)similar in color,smell and texture with TSKSR will be prescribed to participants in each course of chemotherapy.
62348610|NCT02209649|EXPERIMENTAL|Telmisartan and Lacidipine FDC, formulation A|
62348611|NCT02209649|EXPERIMENTAL|Telmisartan and Lacidipine FDC, formulation B|
62348612|NCT02209649|ACTIVE_COMPARATOR|Lacidipine and Telmisartan, mono|
62348613|NCT02420223|EXPERIMENTAL|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
62348614|NCT02420223|NO_INTERVENTION|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
62348615|NCT04975542|EXPERIMENTAL|Treatment Group|
61962723|NCT05081154|EXPERIMENTAL|Product usage order B C A D G E F|Subjects will use each of the 7 products (B C A D G E F) during an evaluation period, followed by a 4 hour Test Session
61962724|NCT05081154|EXPERIMENTAL|Product usage order C D B E A F G|Subjects will use each of the 7 products (C D B E A F G) during an evaluation period, followed by a 4 hour Test Session
61962725|NCT05081154|EXPERIMENTAL|Product usage order D E C F B G A|Subjects will use each of the 7 products (D E C F B G A) during an evaluation period, followed by a 4 hour Test Session
61962726|NCT05081154|EXPERIMENTAL|Product usage order E F D G C A B|Subjects will use each of the 7 products (E F D G C A B) during an evaluation period, followed by a 4 hour Test Session
61962727|NCT05081154|EXPERIMENTAL|Product usage order F G E A D B C|Subjects will use each of the 7 products (F G E A D B C) during an evaluation period, followed by a 4 hour Test Session
62348616|NCT04975542|SHAM_COMPARATOR|Sham Group|
62348617|NCT02967094|EXPERIMENTAL|A - mucolytic solution|Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
62348618|NCT02967094|NO_INTERVENTION|B - no intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
62348619|NCT02967094|PLACEBO_COMPARATOR|C - water|100 ml of water given 30 minutes prior to upper endoscopy.
62348620|NCT02674672|EXPERIMENTAL|VenaTech Retrievable arm|VenaTech Retrievable arm
62348621|NCT03508661|EXPERIMENTAL|SPIN-SSLED Program|13-session SPIN-SSLED Program
62348622|NCT06459622|EXPERIMENTAL|Sensitive to corticosteroids|Patients who are sensitive to corticosteroids have high serum IL-25
62348623|NCT06459622|EXPERIMENTAL|Non sensitive to corticosteroids|Patients who aren't sensitive to corticosteroids have low serum IL-25
62348624|NCT02517853|EXPERIMENTAL|Tibial nerve stimulation|Tibial nerve stimulation during 16 sessions
62348625|NCT02517853|SHAM_COMPARATOR|Sham comparator|Sham tibial nerve stimulation during 16 sessions
62348626|NCT00935337|EXPERIMENTAL|Mind-Body Bridging Program|Mind Body Bridging subjects will be accessed with questionnaires and medical history evaluations for the impact of MBBP over the past 6 months since undertaking the program.
62348627|NCT00935337|ACTIVE_COMPARATOR|Sleep Hygiene|Sleep Hygiene subjects will be accessed with questionnaires and medical history evaluations for the impact of SH over the past 6 months since undertaking the program.
62348628|NCT03472274|ACTIVE_COMPARATOR|Cisplatin-based neoadjuvant chemotherapy|"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:~Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin"
62348629|NCT03472274|EXPERIMENTAL|Durvalumab plus Tremelimumab|Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks
61962728|NCT05081154|EXPERIMENTAL|Product usage order G A F B E C D|Subjects will use each of the 7 products (G A F B E C D) during an evaluation period, followed by a 4 hour Test Session
61962729|NCT05081154|EXPERIMENTAL|Product usage order E D F C G B A|Subjects will use each of the 7 products (E D F C G B A) during an evaluation period, followed by a 4 hour Test Session
61962730|NCT05081154|EXPERIMENTAL|Product usage order F E G D A C B|Subjects will use each of the 7 products (F E G D A C B) during an evaluation period, followed by a 4 hour Test Session
61962731|NCT05081154|EXPERIMENTAL|Product usage order G F A E B D C|Subjects will use each of the 7 products (G F A E B D C) during an evaluation period, followed by a 4 hour Test Session
61962732|NCT05081154|EXPERIMENTAL|Product usage order A G B F C E D|Subjects will use each of the 7 products (A G B F C E D) during an evaluation period, followed by a 4 hour Test Session
61962733|NCT05081154|EXPERIMENTAL|Product usage order B A C G D F E|Subjects will use each of the 7 products (B A C G D F E) during an evaluation period, followed by a 4 hour Test Session
62704931|NCT06356311|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|TPC include either trifluridine-tipiracil (35 mg/m\^2 orally (PO) twice a day (BID) on days 1 to 5 and 8 to 12 of every 28-day cycle), irinotecan (150 mg/m\^2 IV on days 1 and 15 of every 28-day cycle), paclitaxel (80 mg/m\^2 IV on days 1, 8, and 15 of every 28-day cycle), or docetaxel (75 mg/m\^2 IV on day 1 of every 21-day cycle).
61962734|NCT05081154|EXPERIMENTAL|Product usage order C B D A E G F|Subjects will use each of the 7 products (C B D A E G F) during an evaluation period, followed by a 4 hour Test Session
61962735|NCT05081154|EXPERIMENTAL|Product usage order D C E B F A G|Subjects will use each of the 7 products (D C E B F A G) during an evaluation period, followed by a 4 hour Test Session
61962736|NCT03921671|EXPERIMENTAL|Ramucirumab +carboplatin+ paclitaxel|All patient will receive the combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with recurrent and / or metastatic thymic carcinoma or thymoma B3 with area of carcinoma, in the first line.
62348630|NCT04663139|EXPERIMENTAL|normal weight healthy adult volunteers receiving Xla1|one capsule Xla1 given once daily
62348631|NCT04663139|EXPERIMENTAL|overweight and class 1 obese adult patients receiving Xla1|one capsule Xla1 given once daily
62348632|NCT04663139|PLACEBO_COMPARATOR|overweight and class 1 obese adult patients receiving placebo|one capsule placebo given once daily
62348633|NCT01238406|EXPERIMENTAL|MD-logic Artificial Pancreas (MDLAP) system|Use of the closed loop MD-logic Artificial Pancreas(MDLAP)System
62348634|NCT01238406|ACTIVE_COMPARATOR|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
61962737|NCT04176757|EXPERIMENTAL|ZN-c5|
61962738|NCT05467280|EXPERIMENTAL|Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars, and challenges.
61962739|NCT05467280|NO_INTERVENTION|Control|They will not carry out any type of intervention, they will only be monitored during the 6 months
61962740|NCT02160574|ACTIVE_COMPARATOR|ZuraPrep|ZuraPrep will be compared statistically to ZuraPrep without IPA and both to the Positive Control (0.1% Sodium Lauryl Sulfate). The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.
61962741|NCT02760069|ACTIVE_COMPARATOR|Inhaled ISO + oral ondansetron|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
61962742|NCT02760069|EXPERIMENTAL|Inhaled ISO + oral placebo|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
61962743|NCT02760069|ACTIVE_COMPARATOR|Inhaled placebo + oral ondansetron|Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
61962744|NCT02626546||Major surgical procedures|All patients selected to follow up
61962745|NCT03129100|EXPERIMENTAL|Ixekizumab (IXE) 80Q4W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
61962746|NCT03129100|EXPERIMENTAL|Ixekizumab (IXE) 80Q2W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
61962747|NCT03129100|PLACEBO_COMPARATOR|Placebo|Participants received subcutaneous dose of placebo.
61962748|NCT01087645|EXPERIMENTAL|Trial part 1|
62348635|NCT01811901|ACTIVE_COMPARATOR|Intervention group (SITS-WATCH centers)|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
62348636|NCT01811901|NO_INTERVENTION|Control group (non SITS-WATCH centers in SITS registry)|Centres that do not use 15-item list of suggested interventions aiming to reduce DNT.
62348637|NCT01896908|EXPERIMENTAL|Intervention|Sodium restriction (1.6g sodium daily - 4g salt) combined with 800 ml of fluid intake
62348638|NCT01896908|NO_INTERVENTION|Control|Normal sodium diet (4g sodium daily - 10g salt) and free fluid intake
62348639|NCT05804448||High-altitude group|Parturient who are native to their resident altitude, i.e. residing at the altitude above 2500 m from sea level will receive spinal anesthesia for caesarean section.
62348640|NCT05804448||Low-altitude group|Parturient who are native to their resident altitude, i.e. residing at the altitude below 500 m from sea level will receive spinal anesthesia for caesarean section.
62704932|NCT05563220|EXPERIMENTAL|Phase 1b Arm A: elacestrant with alpelisib|Elacestrant Dihydrochloride 300 mg or 400 mg + Alpelisib 250 mg or 300 mg
62704933|NCT05563220|EXPERIMENTAL|Phase 1b Arm B: elacestrant with everolimus|Elacestrant Dihydrochloride 300 mg or 400 mg + Everolimus 5.0 mg, 7.5 mg or possibly 10 mg
62348641|NCT01546285|EXPERIMENTAL|Blood Pressure Reading|Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
62348642|NCT05454722|EXPERIMENTAL|Adex Gel|Dry Skin Emollient with Nicotinamide
62348643|NCT04105569|EXPERIMENTAL|Healthy Volunteers|Enrolled subjects will be included in an experimental gingivitis model (SIBO) for 21 days and use an acrylic stent fabricated before and dispensed at the baseline appointment
62348644|NCT00399594|EXPERIMENTAL|A|Targeted LV lead placement
62704934|NCT05563220|EXPERIMENTAL|Phase 1b Arm C: elacestrant with abemaciclib or ribociclib:|"Elacestrant Dihydrochloride 100 mg, 200 mg, 300 mg + Ribociclib 400 mg or possibly 600 mg~The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)"
61962749|NCT01087645|EXPERIMENTAL|Trial part 2|
61962750|NCT03733002|EXPERIMENTAL|AngongNiuhuang|Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
61962751|NCT03733002|PLACEBO_COMPARATOR|Placebo of AngongNiuhuang|Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
61962752|NCT04956367|EXPERIMENTAL|CO2 laser with PRP|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, PRP will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
61962753|NCT04956367|PLACEBO_COMPARATOR|CO2 laser with placebo|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, pNSS will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
61962754|NCT00904644||Salvage group|In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
61962755|NCT00904644||Switch group|In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
61962756|NCT02469922|EXPERIMENTAL|Positron emission tomography|Two additional PET Scan will be performed at 2 and 4 weeks for the first 30 patients. Then for the other patients only one additional PET-Scan will be performed
61962757|NCT05533684|NO_INTERVENTION|postoperative pain|Measuring postoperative pain using the visual analogue scale
61962758|NCT05533684|OTHER|total analgesic consumption|Recording the total amount of analgesia consumed by the patients
61962759|NCT04449575||Health care workers with hand eczema|Swabs will be taken from eczema lesions on dominating hand (if possible) and nostril
61962760|NCT04449575||controls (health care workers without hand eczema)|swabs will be taken from healthy skin on dominating hand and nostril
61962761|NCT00313157|ACTIVE_COMPARATOR|Metoprolol|Treatment with Metoprolol 100 mg x 1 for three weeks
62143958|NCT03709849|ACTIVE_COMPARATOR|control group|Intervention, dosage and frequency: drug: Clomiphene Citrate Tablets 50mg qd and Bushen Culuan Decoction placebo 13g tid; Dosage form: Clomiphene Citrate Tablets is tablet and Bushen Culuan Decoction placebo is dissolved medicine; Duration: the medicine will be taken from 5th day of a menstrual cycle, Clomiphene is taken for 5 days while Bushen Culuan Decoction placebo being taken for 14 days while. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
61962762|NCT00313157|ACTIVE_COMPARATOR|Diltiazem|Treatment with Diltiazem 360 mg x 1 for three weeks
62143959|NCT04169776|EXPERIMENTAL|Steroid Sensitive Frequently-Relapsing Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid sensitive frequently relapsing idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and the level of proteinuria before and while using taVNS therapy.
62348645|NCT00399594|ACTIVE_COMPARATOR|B|Usual LV lead placement
62704935|NCT05563220|EXPERIMENTAL|Phase 1b Arm D: elacestrant with either palbociclib, abemaciclib, or ribociclib (no prior CDK4/6i)|"Elacestrant Dihydrochloride 300 mg or 400 mg + Palbociclib 100 mg,125 mg OR The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)~Elacestrant 86 mg, 172 mg, 258 mg + Ribociclib 400 mg or possibly 600 mg"
62704936|NCT05563220|EXPERIMENTAL|Phase 1b Arm E:|Elacestrant Dihydrochloride 300 mg, 400 mg + Capivasertib 200 mg, 320 mg, 400 mg
61962763|NCT00313157|ACTIVE_COMPARATOR|Verapamil|Treatment with Verapamil 240 mg x 1 for three weeks
61962764|NCT00313157|ACTIVE_COMPARATOR|Carvedilol|Treatment with Carvedilol 25 mg x 1 for three weeks
61962765|NCT05863832|EXPERIMENTAL|Ciprodiazole|Ciprodiazole Tablets: (Ciprofloxacin 500 mg \& Metronidazole 500 mg), 1 tablet every 12 hours up to 15 days
61962766|NCT05863832|ACTIVE_COMPARATOR|Ciprofloxacin 500 mg Tablets & Metronidazole 500 mg tablets|"Ciprofloxacin 500 mg Tablets: 1 tablet every 12 hours up to 15 days~Metronidazole 500 mg tablets: 1 tablet every 8 hours up to 10 days"
61962767|NCT01716767|EXPERIMENTAL|Menthol|Biofreeze topical gel containing 3.5% menthol
61962768|NCT01716767|PLACEBO_COMPARATOR|Placebo|Topical gel containing a menthol scent, but no active menthol
61962769|NCT02893943|ACTIVE_COMPARATOR|Probiotics|1 capsule per day containing probiotics
61962770|NCT02893943|PLACEBO_COMPARATOR|Placebo|1 capsule per day without probiotics
61962771|NCT05949008|EXPERIMENTAL|Metformin Extended Release (ER) Oral Tablets|This is a 24-week, randomized, double-blinded, two arm parallel clinical trial comparing metformin ER vs. placebo in combination with a hypocaloric diet (-500 kcal/day). 150 individuals with obesity and increased waist circumference will be randomized to taking metformin ER with hypocaloric diet or placebo with hypocaloric diet. All patients will receive dietary and exercise counseling with the intent of reducing their average caloric intake by 500 kcal/day.
61962772|NCT05949008|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will be randomized to placebo with hypocaloric diet. All patients will receive dietary and exercise counseling with the intent of reducing their average caloric intake by 500 kcal/day.
61962773|NCT00646009|EXPERIMENTAL|1|budesonide/formoterol
61962774|NCT00646009|ACTIVE_COMPARATOR|2|fluticasone/salmeterol
61962775|NCT00646009|ACTIVE_COMPARATOR|3|albuterol
61962776|NCT02901990||GMT-low-level group|low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
61962777|NCT02901990||GMT-high-level group|high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
62348646|NCT01590394|EXPERIMENTAL|Pancreatic Cancer Patients|A large plastic biliary stent was placed in the bile duct.
62348647|NCT03602534||cases with variable acne severity scores|"* group will include 50 females~* Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)~* Assessment of body mass index (BMI)~* blood serum samples will be collected from all patients to do thyroid function test"
62348648|NCT03602534||healthy controls|"* group will include 29 females~* Assessment of body mass index (BMI)~* blood serum samples will be collected from all healthy controls to do thyroid function test"
62506465|NCT05763849|ACTIVE_COMPARATOR|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) focuses on parent-enforced contingencies, increasing value of eating, and decreasing the value of food avoidance.
62506466|NCT05582109|EXPERIMENTAL|Envafolimab, Lenvatinib Combined With TACE|Envafolimab, Lenvatinib Combined With TACE
62506467|NCT03305276||general population|the study is open to all population, (14-90 years, male/female) to verify the impact of lifestyles (mediterranean style) on intermediate and hard endpoint.
61962778|NCT02688205||Shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
61962779|NCT02688205||Without shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
61962780|NCT04030611||control group|Participants in the type 2 DM group were diagnosed with DM based on criteria recommended by the American Diabetes Association and required to have a fasting plasma glucose of ≥7mmol/L or an HbA1c of ≥6.5%, as measured on 2 separate occasions.
61962781|NCT04030611||diabetic retinopahty group|Participants in th ediabetic retinopahty group group were diagnosed according to the International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales.
61962782|NCT06243263|EXPERIMENTAL|Group BNAI+|"Randomization process will be used to preoperatively assign patient's left or right side to receive inferior alveolar nerve block. At the end of the surgery, each patient will receive an inferior alveolar nerve block with 2ml of bupivacaine 0.5% on one side ;the other side will not be injected. This arm include the group of fracture which will receive an inferior alveolar nerve block with bupivacaine.~All patient will receive during the postoperative period 1 gram of paracetamol each 8 hours."
61962783|NCT06243263|NO_INTERVENTION|Group BNAI-|"Randomization process will be used to preoperatively assign patient's left or right side to receive inferior alveolar nerve block. At the end of the surgery, each patient will receive an inferior alveolar nerve block with 2ml of bupivacaine 0.5% on one side ;the other side will not be injected. This arm include the group of fracture which will not receive an inferior alveolar nerve block with bupivacaine ( control group).~All patient will receive during the postoperative period 1 gram of paracetamol each 8 hours."
61962784|NCT02071121|PLACEBO_COMPARATOR|Placebo|Fasted participants will receive a single oral dose of placebo to BIIB061.
61962785|NCT02071121|EXPERIMENTAL|BIIB061 3 mg|Fasted participants will receive a single oral dose of BIIB061 3 mg.
61962786|NCT02071121|EXPERIMENTAL|BIIB061 10 mg|Fasted participants will receive a single oral dose of BIIB061 10 mg followed by a tracer amount of 14C-BIIB061 (at ≤ 500 nCi/participant; approximately 4 μg of BIIB061), administered by manual slow intravenous push injection at 4 hours postdose.
61962787|NCT02071121|EXPERIMENTAL|BIIB061 30 mg|Fasted participants will receive a single oral dose of BIIB061 30 mg. Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
61962788|NCT02071121|EXPERIMENTAL|BIIB061 60 mg|Fasted participants will receive a single oral dose of BIIB061 60 mg.
61962789|NCT02071121|EXPERIMENTAL|BIIB061 100 mg|Fasted participants will receive a single oral dose of BIIB061 100 mg.
61962790|NCT06091631|EXPERIMENTAL|Magnesium sulfate|will receive magnesium sulfate inhation
62348649|NCT00866892|ACTIVE_COMPARATOR|irrigation|
62348650|NCT00866892|EXPERIMENTAL|no irrigation|
62348651|NCT04765436|EXPERIMENTAL|PTX-COVID19-B|Participants, 45 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of PTX-COVID19-B vaccine in doses of 16 μg, 40 μg and 100 μg on Day 1, followed by a second dose on Day 28, respectively.
62348652|NCT04765436|PLACEBO_COMPARATOR|Placebo|Participants, 15 healthy adults 18 to 64 years of age, will receive 1 IM injection of matching placebo on Day 1, followed by a second dose on Day 28.
61962791|NCT06091631|NO_INTERVENTION|Control|Will receive distilled water vaporization
62348653|NCT05256082|ACTIVE_COMPARATOR|with mask (FFP2 mask or surgical mask)|Patient is Walking with mouth/nose-mask for 6 Minutes.
62348654|NCT05256082|PLACEBO_COMPARATOR|without mask|Patient is Walking without mouth/nose-mask for 6 Minutes.
62348655|NCT04419818||Left brain damaged patients|"A group of 20 left brain damaged (LBD) patients will perform:~* a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~* a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~* questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
62348656|NCT04419818||Right brain damaged patients|"A group of 20 right brain damaged (RBD) patients will perform:~* a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~* a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~* questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
62506468|NCT01043926|EXPERIMENTAL|Participants with Moderate Hepatic Insufficiency (Part I)|Participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
62506469|NCT01043926|EXPERIMENTAL|Healthy Participants (Part I)|Healthy participants matched to participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
62506470|NCT01043926|EXPERIMENTAL|Participants with Mild Hepatic Insufficiency (Part II)|Participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
62506471|NCT01043926|EXPERIMENTAL|Healthy Participants (Part II)|Healthy participants matched to participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
62506472|NCT03328429|OTHER|Marsupialization|Bartholin gland marsupialization will be done to all patients with Bartholin abscess.
62506473|NCT03328429|OTHER|Excision|Bartholin gland excision will be done to all patients with Bartholin abscess.
62506474|NCT00944684|EXPERIMENTAL|A|PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
62506475|NCT00944684|ACTIVE_COMPARATOR|B|PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
62704937|NCT01145196||Affected|Participants affected by Plaquenil induced retinal toxicity
61962792|NCT01528670||Skull Base|
61962793|NCT01528670||Lower GI|
61962794|NCT01528670||Prostate|
61962795|NCT01528670||Pelvic Region|
61962796|NCT01528670||Head-and-Neck|
62348657|NCT04419818||Healthy controls|"A group of 40 (20 young and 20 elderly) healthy controls (HC) will perform:~* a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~* a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria;~* questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
62348658|NCT04037917|EXPERIMENTAL|Synthetic Tissue Substitute|Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
62506476|NCT06377020|EXPERIMENTAL|PACT2|All participants will join a 16-week diabetes prevention program based on the PreventT2 curriculum. We have worked with stakeholders within the communities in rural Eastern Colorado to develop and refine the curriculum to offer 3 dietary strategies (daily caloric restriction, time restricted eating, and low carb diet) among which participants can choose.
62704938|NCT01145196||Unaffected|control participants without Plaquenil induced retinal toxicity
62704939|NCT05030428|EXPERIMENTAL|Inclisiran sodium|Subcutaneous injection
62704940|NCT05030428|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection
62704941|NCT06487442||Observational|No intervention, observation of postoperative pain scores and treatments
62704942|NCT05763719|ACTIVE_COMPARATOR|Rabbits for Resilience (RFR) + HIKA|Households randomly selected for RFR + HIKA will consent to one adolescent (age 10-14 years) to participate in RFR, a youth led animal husbandry economic empowerment intervention, where each youth is provided training and mentorship on raising rabbits. Once the adolescent builds the rabbit cage, the adolescent receives a loan of 2 rabbits to raise and breed, once the rabbit produces offspring, the adolescent repays the rabbit loan with 2 rabbits, one to repay the loan and one to repay the interest on the loan. The original rabbits and the remaining offspring are then for the adolescents to continue to raise, breed, sell, or eat with mentorship from the RFR team and other family members. Parents (mother and father) will consent to complete a 22 week couple's curriculum to increase gender equality (e.g. shared decision making, improved communication and reduced partner violence). The curriculum is delivered for 3 hours weekly by trained facilitators with 12 couples per group.
62704943|NCT05763719|ACTIVE_COMPARATOR|Rabbits for Resilience (RFR) only|Households randomly selected for RFR only will consent to one adolescent (age 10-14 years) to participate in RFR, a youth led animal husbandry economic empowerment intervention, where each youth is provided training and mentorship on raising rabbits. Once the adolescent builds the rabbit cage, the adolescent receives a loan of 2 rabbits to raise and breed, once the rabbit produces offspring, the adolescent repays the rabbit loan with 2 rabbits, one to repay the loan and one to repay the interest on the loan. The original rabbits and the remaining offspring are then for the adolescents to continue to raise, breed, sell, or eat with mentorship from the RFR team and other family members.
62348659|NCT00525408|EXPERIMENTAL|2|Docetaxel+Mw
62348660|NCT00525408|ACTIVE_COMPARATOR|1|Docetaxel
62348661|NCT04529434|EXPERIMENTAL|Arm 1|Households living in novel-design houses.
62348662|NCT04529434|OTHER|Arm 2|Households living in traditional African houses.
62506477|NCT05744401|EXPERIMENTAL|AL002 Dose 1|AL002 every 4 weeks
62704944|NCT05763719|ACTIVE_COMPARATOR|HIKA only|Households randomly selected for HIKA, parents (mother and father) will consent to complete a 22 week couple's curriculum to increase gender equality (e.g. shared decision making, improved communication and reduced partner violence). The curriculum is delivered for 3 hours weekly by trained facilitators with 12 couples per group.
61962797|NCT01528670||Upper GI|
61962798|NCT01528670||Brain|
61962799|NCT01528670||Other|
61962800|NCT03456050|EXPERIMENTAL|FRC group|This group will receive FRC exercise.
61962801|NCT03456050|EXPERIMENTAL|Conventional treatment|This group will receive conventional exercise.
61962802|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
61962803|NCT00279591|ACTIVE_COMPARATOR|Continuous Blood Pressure Monitoring|Patients received continuous blood pressure monitoring the entire time they were in med flight to the hospital.
61962804|NCT00279591|PLACEBO_COMPARATOR|Standard of care blood pressure monitoring|Patients received the normal standard of care for blood pressure monitoring during the course of the med flight to the hospital.
62143960|NCT04169776|EXPERIMENTAL|Steroid Resistant Idiopathic Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
62143961|NCT05162339||IBD patients|
62348663|NCT05225051|EXPERIMENTAL|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
62506478|NCT05744401|EXPERIMENTAL|AL002 Dose 2|AL002 every 4 weeks
62506479|NCT05744401|EXPERIMENTAL|AL002 Dose 3|AL002 every 4 weeks
62506480|NCT01388452|EXPERIMENTAL|Point of Care HIV RNA PCR|Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for point of care RNA PCR testing, number the sample, and transport it to the central laboratory for processing. Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an inpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end.
62704945|NCT03432286|EXPERIMENTAL|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
62704946|NCT03432286|PLACEBO_COMPARATOR|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
62704947|NCT03855995||Active surveillance (DTP sub-Group)|Children enrolled in the active surveillance (AS), \<18 months of age who were identified at any administration of DTP/HepB/Hib (usually given at 6, 10 and 14 weeks of age) or at hospitalisation before administration of 3rd dose of DTP/HepB/Hib and vaccinated with at least one dose of DTP/HepB/Hib; including both RTS,S/AS01E vaccinated and unvaccinated children (from exposed or unexposed clusters), living in the HDSS area are eligible for enrolment in the DTP sub-group of active surveillance.
62704948|NCT03855995||Active surveillance (Catch-up sub-Group)|Children enrolled in the active surveillance (AS), \<18 months of age who were identified at 1st RTS,S/AS01E dose administration and who either received all DTP/HepB/Hib doses before study start or received at least one dose of DTP/HepB/Hib and are older than the age corresponding to the 3rd DTP/HepB/Hib dose at study start; including only RTS,S/AS01E vaccinated children from exposed clusters who could not be recruited at the time of DTP/HepB/Hib administration because the study had not yet started, living in the HDSS area are eligible for enrolment in the Catch-up sub-group of active surveillance.
61962805|NCT02786797|EXPERIMENTAL|MBSR(BC) 6 Week Program|Participants who are randomized to MBSR(BC) program will receive of educational material; group practice of mindfulness meditation (MM) and homework assignments; and group processes related to the practice of MM and supportive group interaction. Participants who receive MBSR will receive training in (1) sitting meditation anchored to the breath; (2) body scan (observing body sensations from the toes to the head); (3) Gentle Yoga (postures and stretches that increase awareness and balance; and (4) walking meditation. Through this arm of the study the goal is to enhance executive cognition through training in self-regulation of attention and acceptance of experience.
61962806|NCT02786797|ACTIVE_COMPARATOR|BCES Education Support Program|Participants who are randomized to the BCES program will be scheduled for 6 weekly, 2-hour sessions. BCES compared to MBSR(BC) meets the following criteria: (1) professional contact and group support time matched equally to the MBSR(BC) program; and (2) the content or activities of the BCES program does not include meditation or attention, relaxation, yoga, body scan, or walking meditation. This program is as an active control condition that accounts for nonspecific effects related to attention from the leader and favorable outcome expectancy, the educational materials provided and supportive interaction between group members and is matched for homework activity time over the 6 months. This group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
61962807|NCT02786797|NO_INTERVENTION|Usual Care|Participants who are randomized to the Usual Care (UC) or control group will continue to receive standard post-treatment medical and nursing clinic visits that will not be modified by study participation. The UC participants will participate in their standard care appointments and will not be required to alter their UC regimen; however, they will be asked not to initiate a mindfulness program during the study period. The UC group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
61962808|NCT00963196|ACTIVE_COMPARATOR|One unsuccessful trial|Patients with one unsuccessful previous antidepressant trial
61962809|NCT00963196|ACTIVE_COMPARATOR|One successful trial|Patients with one previous successful antidepressant trial
62348664|NCT05225051|EXPERIMENTAL|symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)|symptomatic HD individuals with motor UHDRS \> 5 (Mutated Huntingtin)
62348665|NCT05225051|EXPERIMENTAL|human control cell lines, Unmutated Huntingtin|human control cell lines, Unmutated Huntingtin
62348666|NCT05386121|ACTIVE_COMPARATOR|Erector spinae plane block (ESPB) group|30 child will receive a preoperative unilateral single shot US-guided erector spinae plane block at the level of T9 vertebra in the lateral position after induction of general anesthesia, using 0.5 mL/kg of bupivacaine 0.125%
62704949|NCT03855995||Enhanced Hospitalisation Surveillance Group|Children at least 6 weeks and \<5 years of age, within the study areas in both exposed and unexposed clusters, not already enrolled in the active surveillance (because parents/ Legally Acceptable Representative (LARs) declined enrolment in active surveillance or because recruitment had been completed) or not eligible for active surveillance at the time of hospitalisation, living in the HDSS area are eligible for enrolment in the Enhanced Hospital Surveillance (EHS) group.
62704950|NCT04159259|EXPERIMENTAL|Diet intervention|All participants will stay weight stable while undergoing 3 phases of a dietary intervention
62348667|NCT05386121|ACTIVE_COMPARATOR|Quadratus lumborum block (QLB) group|30 child will receive a preoperative unilateral single shot US-guided quadratus lumborum block at the level of L2 spinous process in the lateral position after induction of general anesthesia, using 0.5 mL/kg of bupivacaine 0.125%
62704951|NCT05042505|ACTIVE_COMPARATOR|Dapa Group|Patients with diabetes mellitus will receive dapagliflozin 10 mg once daily. Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and/or metformin and/or sulfonylurea; maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
61962810|NCT00963196|ACTIVE_COMPARATOR|No previous trial|Patients with no prior antidepressant therapy
61962811|NCT01581814|ACTIVE_COMPARATOR|Metformin|31 subjects were randomized to receive 500 mg Metformin per 3/die
61962812|NCT01581814|ACTIVE_COMPARATOR|0.03 mg EE plus 3 mg of DRPS|
61962813|NCT01581814|ACTIVE_COMPARATOR|Metformin plus Yasmin|
62704952|NCT05042505|ACTIVE_COMPARATOR|Sita Group|Patients with diabetes mellitus will receive sitagliptin 100 mg once daily.Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and/or metformin and/or sulfonylurea; maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
62704953|NCT06502639|ACTIVE_COMPARATOR|conventional therapy|The control group will receive a designed conventional physical therapy program for the affected hand like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises.
62143962|NCT06455059|EXPERIMENTAL|vosoritide injection with vial and syringe|
62143963|NCT06455059|PLACEBO_COMPARATOR|Placebo injection with vial and syringe|
62143964|NCT04114019||Stress urinary incontinence|Women suffering from stress urinary incontinence
62143965|NCT02284607|EXPERIMENTAL|MHAA4549A higher dose|
62704954|NCT06502639|EXPERIMENTAL|conventional therapy along with theraplay program|The experimental group will receive Theraplay therapy or a program and different play-based activities like playing with wooden puzzles and playing with clay and blocks, special handshake claps high fives, making wraps, and bubble tennis in addition to designed conventional therapy.
61962814|NCT02881437|EXPERIMENTAL|IgHy10 (HyQvia)|"Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after IgHy10 (HyQvia) administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods:~* The first period is a one-week ramp-up period. The first administration of IgHy10 (HyQvia) will be with a one-week dose~* During the first three-month follow-up period, IgHy10 (HyQvia) will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).~* At the end of this first follow-up period, the dose of IgHy10 (HyQvia) will be increased for the next infusion to reach a 3-4 week equivalent dose."
61962815|NCT00567294|ACTIVE_COMPARATOR|A|Participants will receive mailed education materials on osteoporosis and medication use.
61962816|NCT00567294|EXPERIMENTAL|B|Participants will receive a telephone coaching program.
61962817|NCT00567294|EXPERIMENTAL|C|Participants will receive a telephone coaching program, and doctors of these participants will receive medication adherence alert notifications.
62348668|NCT05393921|NO_INTERVENTION|Patients receiving HoLEP surgery only|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for HoLEP to treat their urinary symptoms. No Botox injections will be given.
62348669|NCT05393921|EXPERIMENTAL|Patients receiving HoLEP surgery + Intravesical Botox Injections|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for HoLEP to treat their urinary symptoms. Botox injections will be given during the surgery.
61962818|NCT05956496|PLACEBO_COMPARATOR|Control Group: Acellular Dermal Matrix - Superficial cut (ADM-S)|A commonly used allograft material is the Acellular Dermal Matrix (ADM) which is harvested from human donor dermal tissues. Most commercially available ADM products are superficial cuts.
61962819|NCT05956496|ACTIVE_COMPARATOR|Test Group:Acellular Dermal Matrix - Deep cut (ADM-D)|The use of a deep cut ADM for root coverage gingival plastic procedures.
62348670|NCT03654755|EXPERIMENTAL|ASN002 40 mg|ASN002 40 mg
62348671|NCT03654755|EXPERIMENTAL|ASN002 60 mg|ASN002 60 mg
62348672|NCT03654755|EXPERIMENTAL|ASN002 80 mg|ASN002 80 mg
62348673|NCT02353039|EXPERIMENTAL|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
62348674|NCT02353039|EXPERIMENTAL|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
62348675|NCT02353039|EXPERIMENTAL|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
62348676|NCT02353039|PLACEBO_COMPARATOR|Placebo|Administer placebo t.i.d for 2 weeks.
62348677|NCT01841528|EXPERIMENTAL|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
62348678|NCT01841528|EXPERIMENTAL|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
61962820|NCT05741632|EXPERIMENTAL|Moxifloxacin|Subjects will receive 0.1 cc undiluted non preserved intracameral Moxifloxacin during cataract surgery.
61962821|NCT05741632|ACTIVE_COMPARATOR|Levofloxacin|Subjects will receive 0.1 cc undiluted non preserved intracameral Levofloxacin during cataract surgery.
61962822|NCT03947372|ACTIVE_COMPARATOR|OA (open Appendectomy)|Open Appendectomy
61962823|NCT03947372|EXPERIMENTAL|LA (Laparoscopic Appendectomy)|Laparoscopic Appendectomy
61962824|NCT03087669|EXPERIMENTAL|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
61962825|NCT03204903|EXPERIMENTAL|Laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using laser acupuncture during 3 sessions per week for 12 weeks.
61962826|NCT03204903|SHAM_COMPARATOR|Sham laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using sham laser acupuncture (without laser output) during 3 sessions per week for 12 weeks.
62348679|NCT02679443|NO_INTERVENTION|Delayed Arm|Participants are started on folate and vitamin B12 supplementation for 5-7 days prior to initiation of chemotherapy
62348680|NCT02679443|EXPERIMENTAL|Immediate Arm|Participants are started on folate and vitamin B12 supplementation simultaneously with chemotherapy (within 24 hours of initiation of chemotherapy)
62348681|NCT06189170|EXPERIMENTAL|Cohort 1|KP405_dose 1, single dose
62348682|NCT06189170|EXPERIMENTAL|Cohort 2|KP405_dose 2, single dose
62348683|NCT06189170|EXPERIMENTAL|Cohort 3|KP405_dose 3, single dose
62348684|NCT06189170|EXPERIMENTAL|Cohort 4|KP405_dose 4, single dose
62348685|NCT06189170|EXPERIMENTAL|Cohort 5|KP405_dose 5, single dose
62348686|NCT06189170|EXPERIMENTAL|Cohort 6|KP405_dose 6, single dose
62348687|NCT06189170|EXPERIMENTAL|Cohort 7|KP405_dose 1, multiple dose
61962827|NCT04736420||Warfarin|Reference group
61962828|NCT04736420||Rivaroxaban|Exposure group
61962829|NCT04966715|EXPERIMENTAL|Patients planned for complete cytoreductive surgery|Only one arm in the study. All patients operated for complete cytoreductive surgery and who signed informed consent form
62143966|NCT02284607|EXPERIMENTAL|MHAA4549A lower dose|
62143967|NCT02284607|PLACEBO_COMPARATOR|Placebo|
61962830|NCT04403477|NO_INTERVENTION|Standard treatment|Standard supportive treatment (Oxygen, Enoxaparine, antibiotic, fluid, immune modulator (Steroid) and or antiviral (favipiravir or ramdesivir or lopinavir + ritonavir)
61962831|NCT04403477|EXPERIMENTAL|Standard treatment + 200 ml plasma|Standard supportive treatment + 200 ml apheretic convalescent plasma single transfusion
61962832|NCT04403477|EXPERIMENTAL|Standard treatment + 400 ml plasma|Standard supportive treatment + 400 ml apheretic convalescent plasma single transfusion
61962833|NCT02923934|EXPERIMENTAL|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 3mg/kg every 2 weeks until progression (up to 48 total doses of nivolumab)
61962834|NCT05315128|ACTIVE_COMPARATOR|Intralesional methotrexate|Group A 30 patients received intralesional injection of MTX with an insulin syringe into the tumor at a dose ranging between 12.5 mg to 25 mg according to the tumor size every week until complete improvement or for a maximum of 8 sessions.
61962835|NCT05315128|ACTIVE_COMPARATOR|Intramuscular methotrexate|Group B 30 patients received systemic MTX (SC, or IM) was injected at a dose of 25 mg every week until clearance or for a maximum of 8 sessions.
61962836|NCT01296620|EXPERIMENTAL|Experimental 1|
61962837|NCT01296620|EXPERIMENTAL|Experimental 2|
61962838|NCT01296620|PLACEBO_COMPARATOR|Placebo|
61962839|NCT00902915|EXPERIMENTAL|Lenalidomide - Dexamethasone|
61962840|NCT04748120|ACTIVE_COMPARATOR|Operative management|Treatment with surgery
61962841|NCT04748120|ACTIVE_COMPARATOR|Non-operative management|Treatment with antibiotics
62704955|NCT03739827||1/Cohort 1|Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year)
61962842|NCT04833010|ACTIVE_COMPARATOR|No cloth face mask|Cross-over randomization. Participants randomized to this arm will not wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
61962843|NCT04833010|EXPERIMENTAL|Cloth face mask|Cross-over randomization. Participants randomized to this arm will wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
62143968|NCT04176952|EXPERIMENTAL|FOLFOX-A|"FOLFOX A arm (14-day cycle)~* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)~Patients will also receive daily G-CSF as primary prophylaxis against neutropenic events for all cycles. This should be given as per local policy for chemotherapy regimens given every 14 days e.g. it may be started on day 4 for 7 days (preparation and dose should be given as per local policy)."
62143969|NCT04176952|ACTIVE_COMPARATOR|Abraxane and Gemcitabine|"Nab-Paclitaxel + Gemcitabine (AG) arm (28-day cycle)~* nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
62143970|NCT03483649|EXPERIMENTAL|HLX04|
62143971|NCT03483649|ACTIVE_COMPARATOR|United States (US) Avastin®|
62143972|NCT03483649|ACTIVE_COMPARATOR|European Union (EU) Avastin®|
62704956|NCT03739827||2/Cohort 2|Relatives of subjects with a rare tumor who have a germline genetic variant that predispose to a rare solid tumor or a subject who has a germline genetic variant that predispose to a rare solid tumor
62704957|NCT03739827||3/Cohort 3|Relatives of subjects with a diagnosis of rare tumor that do NOT have known germline genetic variants that predispose to a rare solid tumor.
62348688|NCT06189170|EXPERIMENTAL|Cohort 8|KP405_dose 2, multiple dose
62704958|NCT03739827||4/ Cohort 4|Parents/guardians of children with a diagnosis of rare tumor participating in focus groups (if not enrolled in Cohorts 1, 2 or 3)
61962844|NCT01276132||Subjects who are designated to receive same-day PCI|
61962845|NCT01276132||Subjects who had been admitted to the hospital after their PCI|
61962846|NCT03281577|PLACEBO_COMPARATOR|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
61962847|NCT03281577|EXPERIMENTAL|TAK-954 0.1 mg|TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
61962848|NCT03281577|EXPERIMENTAL|TAK-954 0.3 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
61962849|NCT03281577|EXPERIMENTAL|TAK-954 1 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
61962850|NCT01927237|EXPERIMENTAL|HLR-first|"Patients in this arm will have the hypercapnia with low respiratory rate (HLR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, no additional changes will be made to the ventilator. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the EHR strategy per the cross-over design."
61962851|NCT01927237|EXPERIMENTAL|EHR-first|"Patients in this arm will have the eucapnia with high respiratory rate (EHR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, respiratory rate will be increased until PetCO2 returns to baseline or up to 35 breaths per minute, as limited by the National Heart Lung and Blood Institute (NHLBI) ARDS Network protocol. fraction of inspired oxygen inspired oxygen fraction and set tidal volume will be maintained. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the HLR strategy per the cross-over design."
62143973|NCT03483649|ACTIVE_COMPARATOR|China (CN) Avastin®|
62143974|NCT05276999|EXPERIMENTAL|Echocardiographic Screening of school age children|Echocardiographic screening of school age children in Tororo and Iganga districts in Uganda to measure the prevalence of RHD before and two years after the deployment of an integrated strep infection education and treatment package.
62143975|NCT05276999|EXPERIMENTAL|Healthcare worker knowledge|Health care worker representatives from 101 facilities (n=101) will participate in primary educational workshops in identifying and treating GAS pharyngitis.
62143976|NCT05276999|EXPERIMENTAL|Health seeking behavior in the community|To increase health seeking behavior for sore throat thorough a multifaceted community awareness campaign that includes school based education, VHT lead education, education of patients seeking evaluation of sore throat at HC, and public service announcements
62348689|NCT06189170|EXPERIMENTAL|Cohort 9|KP405_dose 3, multiple dose
62506481|NCT01388452|NO_INTERVENTION|Standard of Care|"Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for dried blood spot DNA PCR testing, number the sample, and transport it to the central laboratory for processing. If the patient is PD positive then the patient will be offered ART initiation prior to hospital discharge.~Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an outpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end."
62506482|NCT04214665|EXPERIMENTAL|Test/Reference|Single dose of test tablet in period I. Followed by single dose of reference tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
62506483|NCT04214665|EXPERIMENTAL|Reference/Test|Single dose of reference tablet in period I. Followed by single dose of test tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
62143977|NCT02434276|EXPERIMENTAL|Vaccine Dose Group 8 mcg dose|VAX2012Q, 8 mcg dose
62143978|NCT02434276|EXPERIMENTAL|Vaccine Dose Group 12 mcg dose|VAX2012Q, 12 mcg dose
62143979|NCT02434276|ACTIVE_COMPARATOR|Control|Fluzone Quadrivalent vaccine
62348690|NCT06189170|EXPERIMENTAL|Cohort 10|KP405_dose 4, multiple dose
62348691|NCT06189170|EXPERIMENTAL|Cohort 11|KP405_dose 5, multiple dose
62348692|NCT03302897|EXPERIMENTAL|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
62348693|NCT03302897|EXPERIMENTAL|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
62348694|NCT01992848|EXPERIMENTAL|All participants|"Venous blood sampling 4-day food diary~1 week UV Dosimeter Peripheral Quantitative Computed Tomography of the radius"
62348695|NCT00282568|EXPERIMENTAL|Tacrolimus Modified Release|Participants were enrolled into the study on their stable twice-daily (bid) dose of tacrolimus on Day 1 and continued to receive a stable bid dose of tacrolimus through Day 7. Participants then converted to Tacrolimus Modified Release (MR), administered once daily at an equivalent dose to the patient's previous stable total daily dose of tacrolimus. Participants who completed the 4-week pharmacokinetic treatment period with tacrolimus MR could continue receiving tacrolimus MR as part of the extended treatment period of the study. Dose adjustments were allowed in order to maintain tacrolimus trough concentrations within the target range of 5 to 15 ng/mL and for clinical reasons.
62506484|NCT03731728|EXPERIMENTAL|Group CBT plus TAU|"Participants enrolled in the group CBT plus TAU arm of the study will receive a 2-hour session of group CBT every week for 14 weeks in addition to being wait-listed to receive treatment as usual."
62506485|NCT03731728|EXPERIMENTAL|Group Exercise plus TAU|"Participants enrolled in the group exercise plus TAU arm of the study will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks in addition to being wait-listed to receive treatment as usual."
62506486|NCT03731728|NO_INTERVENTION|Wait-listing for TAU|"Participants enrolled in the wait-listing for treatment as usual or TAU arm of the study will be wait-listed to receive individual therapy or counselling from an Addiction and Mental Health therapist as per current standard protocol for managing patients with MDD at Addiction and Mental Health Clinics of Edmonton Zone."
62143980|NCT02208843|EXPERIMENTAL|Afatinib|Afatinib tablet once daily until progression
62348696|NCT00801853|EXPERIMENTAL|Aerovant 1|Aerovant 1mg bid
62348697|NCT00801853|EXPERIMENTAL|Aerovant 2|Aerovant 3mg bid
62348698|NCT00801853|EXPERIMENTAL|Aerovant 3|Aerovant 10mg bid
62348699|NCT00801853|PLACEBO_COMPARATOR|Placebo Control|Placebo Control
62348700|NCT04027101|EXPERIMENTAL|Experimental group|Oral baricitinib 4mg/day for 12 weeks. Then, at week 12, if PMR-AS≤10, patients will receive baricitinib 2 mg for 12 weeks. If PMR-AS ≤10, the patients will not receive any treatment until W24 At W24, if PMR-AS\>10, they will receive GCs according to the PMR-AS (PMR-AS\<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS\> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1 mg every week) or increased according to PMR-AS (PMR-AS \< 10: decrease, PMR-AS \> 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) according to investigator's opinion.
62143981|NCT04121715|ACTIVE_COMPARATOR|standard medication|"standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
62143982|NCT04121715|EXPERIMENTAL|standard medication+fastigial nucleus stimulation|"1. fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.~2. standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
62143983|NCT02282254|ACTIVE_COMPARATOR|Single-hormone closed-loop strategy|
62143984|NCT02282254|ACTIVE_COMPARATOR|Dual-hormone closed-loop strategy|
62143985|NCT02661958|EXPERIMENTAL|S6G5T-3|topical cream
62143986|NCT02661958|EXPERIMENTAL|S6G5T-1|topical cream
62143987|NCT02661958|ACTIVE_COMPARATOR|S6G5T-5|topical cream
62143988|NCT02661958|ACTIVE_COMPARATOR|S6G5T-7|topical cream
62143989|NCT02661958|ACTIVE_COMPARATOR|S6G5T-6|topical cream
62143990|NCT02661958|PLACEBO_COMPARATOR|S6G5T-8|topical cream
62143991|NCT03951259|EXPERIMENTAL|SM934 10mg|SM934 10mg（1 tablet）+Placebo（4 tablets）p.o. qd in combination with steroids
62143992|NCT03951259|EXPERIMENTAL|SM934 30mg|SM934 10mg（3 tablet）+ Placebo（2 tablets）p.o. qd in combination with steroids
62143993|NCT03951259|EXPERIMENTAL|SM934 50mg|SM934 10mg（5 tablet）p.o. qd in combination with steroids
62143994|NCT03951259|PLACEBO_COMPARATOR|Placebo|Placebo（5 tablets）p.o. qd in combination with steroids
61962852|NCT03244215|EXPERIMENTAL|The study group|"The intervention to be evaluated is the patient response and compliance to best medical treatment and prevention of recognized stroke risk factors and the recurrence of stroke and TIA in the study group and its relation to the incidence of blood biomarkers.~The Nurse practitioners at the stroke ward will withdraw blood and collect urine samples from all the subjects. All the subjects from the study group will have 2 follow up visits (1 month and at 1 year) at HGH and one telephonic follow up at 3 months. The blood samples will be used to monitor blood inflammatory biomarker levels. At the beginning of the study, all subjects will have an MRI scan to assess plaque volume (this MRI scan will be ordered as part of the standard of care as per the policies applied to all stroke patients). MRI scans will be repeated at one year to assess any progression or regression in the plaque volume of the subjects.~No drugs will be administered to the patients for the purpose of our study."
61962853|NCT03244215|OTHER|Control|The control group will have blood work done to assess their blood inflammatory biomarkers but not the corneal confocal imaging.
61962854|NCT05832385||radiation dose≤50Gy|rectal cancer with IMRT radiation dose≤50Gy
61962855|NCT05832385||radiation dose>50Gy|anal cancer with IMRT radiation dose\>50Gy
61962856|NCT01192516|EXPERIMENTAL|Arm 1|Tailored activity pacing
61962857|NCT01192516|EXPERIMENTAL|Arm 2|General activity pacing and symptom management (Occupational therapy)
61962858|NCT01192516|NO_INTERVENTION|Arm 3|Usual care group
61962859|NCT02079545|EXPERIMENTAL|Group 1|18 participants will receive a single intravenous (IV) infusion of 100 mg sirukumab
61962860|NCT02079545|EXPERIMENTAL|Group 2|18 participants will receive a single subcutaneous (SC) injection of 50 mg sirukumab using a Pre-filled Syringe (PFS) fitted with the UltraSafe Passive™ Delivery System (PFS-U)
61962861|NCT02079545|EXPERIMENTAL|Group 3|18 participants will receive a single SC injection of 50 mg sirukumab using the SmartJect™ Autoinjector (PFS-AI)
61962862|NCT02079545|EXPERIMENTAL|Group 4|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-U
61962863|NCT02079545|EXPERIMENTAL|Group 5|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-AI
61962864|NCT05027100|EXPERIMENTAL|exploratory research|Anlotinib 10mg QD with 2W stop 1W tiselizumab injection 200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
61962865|NCT02075710|EXPERIMENTAL|High sugar/meal feed|Diet high in simple sugar fed as two large meals daily
61962866|NCT02075710|EXPERIMENTAL|High sugar/nibble|Diet high in simple sugar fed as 8 small meals daily
61962867|NCT02075710|EXPERIMENTAL|High fat/meal feed|Diet high in fat fed as two large meals daily
61962868|NCT02075710|EXPERIMENTAL|High fat/nibble|Diet high in fat fed as 8 small meals daily
61962869|NCT02075710|EXPERIMENTAL|High sugar/3 meals a day|Diet high in simple sugar fed as 3 meals a day
61962870|NCT02075710|EXPERIMENTAL|High fat/ 3 meals a day|Diet high in fat fed as 3 meals a day
61962871|NCT01002027|ACTIVE_COMPARATOR|CBT-counselling with Nurse|CBT-counselling with Maternal Health Nurse, adjunctive to management by general medical practitioner
61962872|NCT01002027|ACTIVE_COMPARATOR|CBT-Counselling by Psychologist|CBT-counselling with Psychologist, adjunctive to management by general medical practitioner
61962873|NCT01002027|NO_INTERVENTION|Routine management|Ongoing management by general medical practitioner
61962874|NCT05279443|EXPERIMENTAL|yoga-based exercises|
61962875|NCT00522197|ACTIVE_COMPARATOR|ACAPHA|
61962876|NCT00522197|PLACEBO_COMPARATOR|Sugar Pill|
61962877|NCT01756547|EXPERIMENTAL|Potassium citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
61962878|NCT01756547|PLACEBO_COMPARATOR|Placebo|Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.
61962879|NCT00590005||Children with severe asthma|This group consists of children with severe asthma as defined per ATS workshop criteria (published in 2000).
61962880|NCT00590005||Children with non-severe asthma|This group includes children with asthma who do not meet the ATS criteria for severe asthma as outlined in the 2000 workshop report.
61962881|NCT02069717||Not applicable-observational study|Not applicable-observational study
62143995|NCT04748341|ACTIVE_COMPARATOR|Traditional Group|Group A will be taught through the two steps traditional method (2 lectures/week + 1 skill lab/week). First, learn through didactic Lectures and then practice skills on the Mannequins. The educational lecture content will be the same for both groups.
62348701|NCT04027101|PLACEBO_COMPARATOR|Control group|Oral placebo every day during 3 months (W12). Then, at week 12, if PMR-AS ≤10, placebo for 12 weeks. If PMR-AS ≤10, the patients do not receive any treatment until a flare. If PMR-AS\>10, they will receive GCs according to the PMR-AS (PMR-AS\<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS\> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1mg every week) or increased according to PMR-AS (PMR-AS \< 10: decrease, PMR-AS \> 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) and according to investigator's opinion.
61962882|NCT03425747|ACTIVE_COMPARATOR|Calcium Carbonate|Calcium Carbonate
61962883|NCT03425747|ACTIVE_COMPARATOR|calcium Citrate|Calcium Citrate
61962884|NCT02737293|EXPERIMENTAL|Control Diet|Menu based on the average American diet.
61962885|NCT02737293|EXPERIMENTAL|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
61962886|NCT02737293|EXPERIMENTAL|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
61962887|NCT05048784|EXPERIMENTAL|Treatment Sequence ABC|"Participants will be administered sotorasib dose A orally in the following order:~* Treatment A - as 3 tablets (test 1)~* Treatment B - as 8 tablets (reference)~* Treatment C - as 3 tablets (test 2)"
61962888|NCT05048784|EXPERIMENTAL|Treatment Sequence BAC|"Participants will be administered sotorasib dose A orally in the following order:~* Treatment B - as 8 tablets (reference)~* Treatment A - as 3 tablets (test 1)~* Treatment C - as 3 tablets (test 2)"
61962889|NCT05973500|EXPERIMENTAL|Mediterranean Diet|Mediterranean Diet for 42 Days
61962890|NCT06451094|EXPERIMENTAL|US therapy, paraffin therapy|Group 1, US therapy to the palmar region of the wrist, 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions and Paraffin therapy to the wrist area by dipping the hand 3 times into a paraffin bath and removing it, covering the entire wrist with paraffin, and waiting for 15 min (2 weeks, 5 times a week, for a total of 10 sessions).
61962891|NCT06451094|EXPERIMENTAL|TECAR therapy, paraffin therapy|Group 2, TECAR therapy to the palmar region of the wrist, 5 min capacitive (CAP) and 10 min resistive (RES), 3 days a week for 2 weeks, for a total of 6 sessions and Paraffin therapy to the wrist area by dipping the hand 3 times into a paraffin bath and removing it, covering the entire wrist with paraffin, and waiting for 15 min (2 weeks, 5 times a week, for a total of 10 sessions).
61962892|NCT03217175|ACTIVE_COMPARATOR|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
61962893|NCT03217175|PLACEBO_COMPARATOR|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
61962894|NCT04047745|ACTIVE_COMPARATOR|liposomal bupivacaine|
62506487|NCT05785806|EXPERIMENTAL|Skin to skin contact and co-parenting theory course|"1. Skin to skin contact and co-parenting theory course~2. Skin to skin contact instruction manual and co-parenting theory brochure~3. Daily face-to-face skin to skin contact guidance during hospitalization~4. Online punching skin to skin contact"
61962895|NCT04047745|ACTIVE_COMPARATOR|ropivacaine|
61962896|NCT05948397||Study Group|Female patients admitted to urology outpatient clinic with mixed urinary incontinence.
61962897|NCT03662490||patient|Patient who performed a High resolution oesophageal manometry (HRM) for the diagnosis of oesophageal motility disorder.
61962898|NCT05907512|EXPERIMENTAL|Drug group|
61962899|NCT04039698|EXPERIMENTAL|Telemedicine|Sofosbuvir 400mg and velpatasvir 100mg qd for 12 weeks Telemedicine support
61962900|NCT02457260|EXPERIMENTAL|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
61962901|NCT02457260|EXPERIMENTAL|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
62348702|NCT04111107|EXPERIMENTAL|Drug Administration Based on Next Gen Sequencing Report|Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.
62348703|NCT05733364|EXPERIMENTAL|Investigational Product (Capsules with B vitamins & taurine)|IP will be administered orally once daily in capsule form, ideally between conventional mealtimes (i.e., breakfast, lunch, supper).
62506488|NCT05785806|OTHER|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
62506489|NCT01957150|EXPERIMENTAL|Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD|Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
62506490|NCT01957150|EXPERIMENTAL|Vilanterol 25 mcg QD|Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
62506491|NCT02695979||Patients undergoing OLT|Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).
62506492|NCT02087917|PLACEBO_COMPARATOR|Placebo|
62506493|NCT02087917|ACTIVE_COMPARATOR|HS-25 5 MG|
62506494|NCT02087917|ACTIVE_COMPARATOR|HS-25 10 MG|
62506495|NCT02087917|ACTIVE_COMPARATOR|HS-25 20 MG|
62506496|NCT02087917|ACTIVE_COMPARATOR|HS-25 30 MG|
62506497|NCT00256529||I|All subjects presenting in with dysphagia will be in this cohort.
62506498|NCT05164835|EXPERIMENTAL|Experimental|
62506499|NCT00920114|EXPERIMENTAL|Lupus disease|
62506500|NCT00920114|ACTIVE_COMPARATOR|Healthy witnesses|
62506501|NCT00920114|ACTIVE_COMPARATOR|Healthy witnesses with an other auto-immune disease|
62506502|NCT03577886|EXPERIMENTAL|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
62506503|NCT03577886|PLACEBO_COMPARATOR|Placebo|Phosphate Buffer Diluent solution
62506504|NCT05907655||Adult patients with migraine|Diagnosis of migraine, by the ICHD-3 criteria. Age between 18 and 60 years. Female and males. Right-handed
62506505|NCT05907655||Healthy controls|Age between 18 and 60 years. Female and males. Right-handed
62506506|NCT01275976|ACTIVE_COMPARATOR|C1-esterase inhibitor|C1-esterase inhibitor, 100 U/kg bodyweight
62506507|NCT01275976|PLACEBO_COMPARATOR|Saline 0.9%|Saline 0.9%
62506508|NCT01269476|EXPERIMENTAL|SNX-001|
62506509|NCT01269476|PLACEBO_COMPARATOR|Placebo|
62506510|NCT03034161||Stage I Pressure Ulcer|Ten patients with a Stage I decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
62506511|NCT03034161||Stage II Pressure Ulcer|Ten patients with a Stage II decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
62506512|NCT03034161||Stage III Pressure Ulcer|Ten patients with a Stage III decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
62506513|NCT03034161||Stage IV Pressure Ulcer|Ten patients with a Stage IV decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
62506514|NCT02421016|EXPERIMENTAL|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
62506515|NCT02421016|ACTIVE_COMPARATOR|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
62506516|NCT04838119||Patients with a preoperative asymptomatic COVID screening test|
62506517|NCT02285348|OTHER|Ataxia Telangiectasia|20 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will get a lumbar puncture
62704959|NCT04074135|EXPERIMENTAL|1/ Arm 1|Study natural history of VHL pancreatic neuroendocrine tumors with yearly 68-Gallium DOTATATE PET/CT research scans.
61962902|NCT02457260|EXPERIMENTAL|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
61962903|NCT05174897|NO_INTERVENTION|Control Group|The child for whom an intravenous catheter will be applied will be placed on a stretcher and pain and fear will be evaluated before the procedure. Afterwards, an intravenous catheter will be applied. Pain and fear scores will be evaluated during and after the procedure.
61962904|NCT05174897|EXPERIMENTAL|Experimental group|The child to whom an intravenous catheter will be applied is placed on a stretcher. After evaluating the pain and fear score before the procedure, emotional liberation technique (EFT) is performed for 10 minutes. followed by an intravenous catheter. Pain and fear scores are evaluated during and after the procedure.
61962905|NCT02774525|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Outpatient substance-abuse treatment plus drug and alcohol screening plus brief support for personal goal setting
61962906|NCT02774525|EXPERIMENTAL|Contingency Management|Contingency management for drug and alcohol abstinence plus TAU
61962907|NCT02774525|EXPERIMENTAL|Parenting Intervention|Parenting intervention plus TAU
61962908|NCT02774525|EXPERIMENTAL|Parenting Intervention + Contingency Management|Parenting intervention plus contingency management for drug and alcohol abstinence plus TAU
61962909|NCT03695120|NO_INTERVENTION|Full Dose ACEI/ARB or Home Dose Group|This group will receive the full dose of ACEI/ARBs.
61962910|NCT03695120|ACTIVE_COMPARATOR|No ACEI/ARB Group|This group will not receive the full dose of ACEI/ARBs for the first 72 hours of hospitalization.
61962911|NCT05812456|ACTIVE_COMPARATOR|3m Metal Brackets|"3m Unitek Gemini Roth Stainless-Steel Brackets. it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are 0.018 slot and 0.022 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
61962912|NCT05812456|ACTIVE_COMPARATOR|American Orthodontics Metal Brackets|"American Orthodontics Mini Masters 0.022 Roth Stainless-Steel Brackets. it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are .18 slot and .22 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
62143996|NCT04748341|EXPERIMENTAL|Pedagogical Group|Group B will learn through the 5-step method \[ 2 lectures/week + video + 2skill lab/week (1 session under instructor + 1 session for skill maintenance)\], learn skill, see the video on resuscitation, practice on simulator, prove through practice, observe skill on clinical rotation and lastly maintain it through clinical supplemented with simulation.
62143997|NCT02980588|OTHER|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
62143998|NCT02223728|EXPERIMENTAL|Treatment Condition|Telehealth Lifestyle Program
62143999|NCT02223728|SHAM_COMPARATOR|Attention Control Condition|Health Education Program
62144000|NCT03221881|EXPERIMENTAL|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
62144001|NCT04218084|EXPERIMENTAL|Voxelotor|Voxelotor 1500mg or equivalent daily as a tablet, dispersible tablet, or as powder for oral suspension.
62348704|NCT05733364|PLACEBO_COMPARATOR|Microcrystalline cellulose placebo|Placebo will be administered orally once daily in identical capsule form as the IP, ideally between conventional mealtimes (i.e., breakfast, lunch, supper).
62348705|NCT04156828|EXPERIMENTAL|Treatment (copanlisib, R-GCD)|Patients receive copanlisib IV and gemcitabine IV on days 1 and 8, carboplatin IV and rituximab IV on day 1, and dexamethasone PO or IV 30-60 minutes prior to chemotherapy on day 1 and PO in AM or 30-60 minutes prior to chemotherapy on days 2-4. Patients also receive pegfilgrastim SC on day 8 or 9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
62144002|NCT04218084|PLACEBO_COMPARATOR|Placebo|Matching placebo.
62144003|NCT02629666|ACTIVE_COMPARATOR|Exercise Referral Scheme (ERS)|In the Exercise Referral Scheme (ERS) intervention participants will undergo a physical activity program of 16 weeks, with two sessions per week (60 minutes each session). Participants will be asked to perform the activity in a moderate to vigorous intensity (according to each individual's progression) during the central part of each session. Intensity will be estimated using the modified Borg Scale of Perceived Exertion (e.g. moderate intensity activity will be considered as a 4 to 6 and vigorous-intensity activity as a 7 to 9) or with training loads (i.e. ankle weights and dumbbells) corresponding to 70-80% of maximum, adjusted progressively during the training period. ERS programs will be based on a combination of aerobic, strength-based, balance and flexibility activities, with a specially trained PA specialist. These sessions will be always performed under the supervision of the same trainer. The PA intervention is adapted to the participants' functional status.
62348706|NCT04247815|EXPERIMENTAL|ATI-450 plus Methotrexate|ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate
62348707|NCT04247815|PLACEBO_COMPARATOR|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of Methotrexate
62348708|NCT05001061|ACTIVE_COMPARATOR|Sublingual Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive sublingual Misoprostol 800 micrograms every 4 hours up to five doses
61962913|NCT05812456|EXPERIMENTAL|Fanta Metal Brackets|"Fanta Firmax 0.022 Roth Stainless-Steel Brackets. Fanta is a Chinese Orthodontic bracket brand that started to spread.~it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are 0.018 slot and 0.022 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
61962914|NCT05812456|EXPERIMENTAL|Matt Orthodontics Metal Brackets|"Matt Orthodontics Pierre 0.022 Roth Metal Brackets. Matt is a Chinese Orthodontic bracket brand that started to spread.~it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are 0.018 slot and 0.022 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
61962915|NCT04802291|EXPERIMENTAL|Healthy HomeStyles|Online educational intervention addressing salient factors affecting school-age children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, irregular breakfast consumption, limited physical activity, and inadequate sleep as well as children's limited food preparation skills.
61962916|NCT04802291|ACTIVE_COMPARATOR|Safe HomeStyles|Online educational intervention addressing aspects of home safety issues, such as indoor air quality, mold \& moisture, hazardous household products, carbon monoxide, home safety, foodborne illness, and refrigerator temperatures.
61962917|NCT05742100||Group of patients treated with darvadstrocel|
62506518|NCT02285348|OTHER|Healthy Control|20 patients without inflammation, infection or any other pathology of the CNS, in that a lumbar puncture is indicated for either diagnostic or therapeutic reason (i.e. for the exclusion of a meningitis, subarachnoid hemorrhage or in therapeutic liquor drain in idiopathic intracranial hypertension)
62704960|NCT04074135|NO_INTERVENTION|2/ Arm 2|Study natural history of VHL pancreatic neuroendocrine tumors without research scans.
61962918|NCT00187369|OTHER|Caesarean Section|delivery by CS
62144004|NCT02629666|EXPERIMENTAL|ERS + Self-management Strategies|"Participants will undergo the aforementioned Physical Activity program plus 11 sessions of Self-Management Strategies (SMS).~SMS start with a face-to-face session in an indoor primary-care facility. The next 6 sessions are further implemented in a group format. SMS are aimed at increasing self-efficacy in reducing sedentary behaviour and at adopting/maintaining an active behaviour as complement to a standard physical activity program (ERS). SMS group sessions will be conducted during week 3 to 11 of the ERS, after the PA sessions (6 sessions: 3 once a week, 3 once every second week). There will be 4 telephone contacts during the adherence phase, at week 15, 20, 25 and 30."
62144005|NCT02629666|NO_INTERVENTION|Control group|Researchers will give to all participants during the first informative meeting (prior assessment) a written general booklet standardized across sites with WHO recommendation regarding PA regular practice for health. During the intervention, a health advice meeting with standardized topics about healthy lifestyle and feedback on some outcomes regarding their results will be held twice in the Primary Health Centre (at week 5, and at week 11). Researchers will send a letter or phone call prior to each follow up reminding the next assessment.
61962919|NCT00187369|OTHER|Vaginal Birth|delivery by VB
61962920|NCT02517567|OTHER|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
61962921|NCT02517567|OTHER|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
62144006|NCT05215249|NO_INTERVENTION|Standard of Care|Patient will receive conventional tubeless anesthesia
62144007|NCT05215249|EXPERIMENTAL|High Flow Oxygen Delivery|Patient will receive Transnasal humidified high-flow oxygen delivery (Optiflow)
62144008|NCT04295642|PLACEBO_COMPARATOR|Part 1|Will include 4 subjects (3 active + 1 placebo) that will receive a single 15mg dose with approximately 48 hours of confinement and a follow-up after 7 days.
62144009|NCT04295642|EXPERIMENTAL|Part 2|"2A: will include 14 subjects to complete 12 with 28 days of dosing with 7 days (+/-2) of follow-up, with at least 14 days of confinement.~-or- 2B: will include 20 subjects to complete 12 with 2 dosing days and 5 days of washout with 7 days (+/-2) of follow-up, with 4 days of confinement (may be increased up to 12 days at the investigators discretion)."
62144010|NCT02602548||Open Shoulder Surgery|Culture
62144011|NCT02602548||Arthroscopic Shoulder Surgery|Culture
62144012|NCT00084435|EXPERIMENTAL|chemoRT after surgery|chemoRT with cisplatin and docetaxel after surgery
62144013|NCT03510416|EXPERIMENTAL|apatinib combined with TACE|Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.
62506519|NCT02074267|EXPERIMENTAL|Carbatin|Carbatin is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days
62506520|NCT02074267|ACTIVE_COMPARATOR|Neurontin|Neurontin is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days
62506521|NCT00784030|OTHER|Polycystic Kidney Disease Patients|Patients who present with polycystic kidney disease (PKD)
62506522|NCT00784030|OTHER|Healthy Patients|
62704961|NCT06109311|EXPERIMENTAL|Orforglipron Dose 1|Participants will receive orforglipron orally.
62704962|NCT06109311|EXPERIMENTAL|Orforglipron Dose 2|Participants will receive orforglipron orally.
62704963|NCT06109311|EXPERIMENTAL|Orforglipron Dose 3|Participants will receive orforglipron orally.
62704964|NCT06109311|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally.
62704965|NCT02233868|EXPERIMENTAL|Phase I|PET scan with \[11C\]PBR28 followed by PET scan with FDG and MRI.
62704966|NCT02233868|EXPERIMENTAL|Phase II|After 3 weeks of abstinence or non-abstinence, PET scan with \[11C\]PBR28 followed by PET scan with FDG and MRI are repeated.
61962922|NCT02517567|OTHER|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
61962923|NCT02517567|OTHER|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
61962924|NCT03274128|ACTIVE_COMPARATOR|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
61962925|NCT03274128|NO_INTERVENTION|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
61962926|NCT00777608|EXPERIMENTAL|Donepezil 5-10 mg|There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
61962927|NCT00777608|PLACEBO_COMPARATOR|Placebo|There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
61962928|NCT03102372|EXPERIMENTAL|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
61962929|NCT03102372|PLACEBO_COMPARATOR|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
61962930|NCT02352350||Cardiac Arrest Patients|All adult patients with non traumatic cardiac arrest in Alachua County Florida will have blood lactate levels taken and neurological outcomes performed based on the Cerebral Performance Categories (CPC) Scale
61962931|NCT05378204|OTHER|Patients with breast cancer|Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
61962932|NCT04849598|EXPERIMENTAL|ESWT Order A and B|First Endurance Shuttle Walk Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2, the second Endurance Shuttle Walk Test using the prescribed constant flow oxygen therapy.
61962933|NCT04849598|EXPERIMENTAL|ESWT Order B and A|First Endurance Shuttle Walk Test using the prescribed constant flow oxygen therapy, the second Endurance Shuttle Walk Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2.
61962934|NCT04849598|EXPERIMENTAL|Stairs Order A and B|First Stair Walking Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2, the second Stair Walking Test using the prescribed constant flow oxygen therapy.
62144014|NCT01752959|ACTIVE_COMPARATOR|Remifentanyl|Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva
61962935|NCT04849598|EXPERIMENTAL|Stairs Order B and A|First Stair Walking Test using the prescribed constant flow oxygen therapy, the second Stair Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2.
61962936|NCT03888456|EXPERIMENTAL|study|participants will receive a single touch intervention based on osteopathic assessment and treatment
61962937|NCT03888456|SHAM_COMPARATOR|Control|participants will receive a single touch sham intervention mimicking the intervention
61962938|NCT05613595|ACTIVE_COMPARATOR|Positive Psychotherapy Group|In this phase of the study, the caregivers of CP having moderate to high scores on mental health issues on three scales (Depression, Burnout \& Caregiver burden) will receive positive Psychotherapy sessions for a period of four months, divided over different weekly sessions. For Psychotherapy treatment group participants will be given both counseling as well as Positive psychotherapy based interventions. . Each session will be based upon individual session and duration of the session will be 40 minutes. Before starting every session feedback will be taken about the previous session and home based assignments will also be discussed
61962939|NCT05613595|ACTIVE_COMPARATOR|Counseling Group|10 participants will be included in in control group (N=10), for control group caregivers will be given regular counseling as a part of treatment of their child (psychoeducation). Each session will be based upon individual session and duration of the session will be 40 minutes.
61962940|NCT04670848|EXPERIMENTAL|Patients suspected of suffering from sleep apnea|
61962941|NCT04670848|EXPERIMENTAL|Healthy volunteers|
61962942|NCT01455259|EXPERIMENTAL|AdCD40L|Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.
61962943|NCT03009578|EXPERIMENTAL|Intravenous iron|Women will receive iron sucrose (sacrofer ampules 100 mg/5ml) A patient's total body iron deficit will be calculated using the Ganzoni formula (total iron dose = \[body weight (kilogram)× (15-actual Hemoglobin)\] × 2.4 + 500 mg) then the total dose will be divided on 3 settings
61962944|NCT03009578|ACTIVE_COMPARATOR|Oral ferrous bis-glycinate|Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets
61962945|NCT05961085||Adductor Canal Catheter|Pre-operative adductor canal catheter placement
62144015|NCT01752959|EXPERIMENTAL|esmolol|Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion
62144016|NCT02185794|PLACEBO_COMPARATOR|Placebo (GT 1a, Cohort 1)|Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
62144017|NCT02185794|EXPERIMENTAL|Voxilaprevir 50 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
62348709|NCT05001061|ACTIVE_COMPARATOR|Vaginal Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive vaginal Misoprostol 800 micrograms every 4 hours up to five doses
62506523|NCT03208673|EXPERIMENTAL|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
61962946|NCT01872377|EXPERIMENTAL|Radiotherapy Boost|All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.
62704967|NCT05775497|EXPERIMENTAL|Weight Loss Program Only|Participants complete an online behavioral weight loss program.
62704968|NCT05775497|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss.
61962947|NCT03379805||Fontan-Kreutzer operated patients|Patients with a Fontan-Kreutzer circulation. No interventions are done. (The intervention is the operation done 15-20 years ago)
61962948|NCT03379805||Healthy Control subjects|Age, gender and weight matched control subjects
62506524|NCT05907408||Steatosis|Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation
62506525|NCT05907408||Steatohepatitis|Patients with non-alcoholic fatty liver disease presenting with steatosis and degree \>1 of liver fibrosis
62506526|NCT04532177|EXPERIMENTAL|Active|
62506527|NCT01242618|EXPERIMENTAL|engineered nasal cartilage graft|Biological intervention: autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold
61962949|NCT01604174|EXPERIMENTAL|Interactive Virtual Telerehabilitation|Rehabilitation by IVT
61962950|NCT01604174|ACTIVE_COMPARATOR|Standard rehabilitation care|Standard care rehabilitation after total knee arthroplasty
62348710|NCT00956215|ACTIVE_COMPARATOR|80mg of Aprepitant|Patients will be randomized to receive 80mg of Aprepitant with 50 ml of water no later than 30 minutes before induction of anesthesia.
62348711|NCT00956215|PLACEBO_COMPARATOR|80 mg of placebo|. Patients will be randomized to placebo with 50 ml of water no later than 30 minutes before induction of anesthesia.
62348712|NCT01894477|EXPERIMENTAL|Arm A|"Arm A: Treosulfan, Fludarabine Phosphate~Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2."
62348713|NCT01894477|EXPERIMENTAL|Arm B|"Arm B: Treosulfan, Fludarabine Phosphate, TBI~Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0"
62348714|NCT01811381|EXPERIMENTAL|Curcumin and aerobic exercise|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six to 12 months after the beginning of the study, subjects will take curcumin (4 capsules BID before meals, total 800 mg/day) and also participate in an aerobic yoga exercise program (Attendance at 2 classes of 1 hour duration \[or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient\] and 2 home practices of 30 minute duration per week).
62506528|NCT06350617|EXPERIMENTAL|Ipsilateral High-Frequency|"Patients with motor priority confirmed by TUG and TUG-Cog tests.~High-frequency (HF) rTMS over more affected primary motor cortex (M1) of lower extremity will be applied."
62506529|NCT06350617|ACTIVE_COMPARATOR|Bilateral High-Frequency1|"Patients with motor priority confirmed by TUG and TUG-Cog tests.~High-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied."
62506530|NCT06350617|EXPERIMENTAL|DLPFC High-Frequency|"Patients with cognitive priority confirmed by TUG and TUG-Cog tests.~High-frequency (HF) rTMS over Lt. dorsolateral prefrontal cortex (DLPFC) will be applied."
62506531|NCT06350617|ACTIVE_COMPARATOR|Bilateral High-Frequency2|"Patients with cognitive priority confirmed by TUG and TUG-Cog tests.~High-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied."
62506532|NCT00986219||Asthma Language between patients and physicians|
62506533|NCT05610449||Testing Done Simple Antigen test in Symptomatic Subjects (Nasal swab)|
62506534|NCT05610449||Testing Done Simple Antigen test in Asymptomatic Subjects (Nasal swab)|
62506535|NCT01595841|EXPERIMENTAL|Sirolimus|Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
61962951|NCT05850546|EXPERIMENTAL|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission. The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy is then discontinued.
61962952|NCT05850546|OTHER|Routine Therapy|The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy is then discontinued.
61962953|NCT06242951||Cystic fibrosis|Patients with cystic fibrosis
61962954|NCT06242951||Control|
61962955|NCT02937909|EXPERIMENTAL|Prospective Data|Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
62506536|NCT01595841|NO_INTERVENTION|Not taking Sirolimus|Participants will not change the standard of care.
62506537|NCT00277524||Overall|All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled.
62506538|NCT02344745|PLACEBO_COMPARATOR|Control|Distilled water
61962956|NCT02937909|NO_INTERVENTION|Historical data|Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .
61962957|NCT01294267|OTHER|Circulatory Support System|Percutaneous use of left ventricular assist device, Impella 2.5 Circulatory Support System to facilitate mapping and ablation of ongoing VT by maintaining near-normal hemodynamics, reducing myocardial workload and preservice organ perfusion.
61962958|NCT03415217|OTHER|Neighbourhood Team Development|Neighbourhood Team Development consisted of a 30-month standardised training and implementation plan to promote inter-professional team collaboration and enhanced resident centeredness.
61962959|NCT05368571|EXPERIMENTAL|CHOICES-TEEN|This is a four session session utilizing Motivational Interviewing (MI) and cognitive-behavioral approaches to enhance motivation for change in one or more primary behaviors: alcohol, marijuana, and condom/contraceptive use. The intervention is delivered by a trained master's level counselor and an Adolescent Medicine Specialist using one in-person session, and three Telehealth sessions.
61962960|NCT05368571|ACTIVE_COMPARATOR|Health and Life Skills Education|This four session life skills education program provides detailed information on time management, sleep, nutrition and exercise, and financial management. This program is delivered in person for the first session and then by Telehealth platform.
61962961|NCT05657834|EXPERIMENTAL|Treatment Arm 1|Single dose of TVB-2640, 50 mg, oral administration
61962962|NCT01169207||Unaffected|Individuals who do not have IBD
61962963|NCT01169207||Affected|Individuals with IBD
61962964|NCT03313791|EXPERIMENTAL|Whey protein concentrate|portion size that contains 25 g of protein, oral, single administration
61962965|NCT03313791|EXPERIMENTAL|Yoghurt|portion size that contains 25 g of protein, oral, single administration
62506539|NCT02344745|EXPERIMENTAL|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
62506540|NCT01997723|EXPERIMENTAL|OSA testing|Cross-over design, single group/arm Interventions: polysomnography with simultaneous portable monitoring and home portable monitoring administered to each participant in random order.
61962966|NCT03313791|EXPERIMENTAL|50%whey-50% casein (Standard)|portion size that contains 25 g of protein, oral, single administration
61962967|NCT03313791|EXPERIMENTAL|50%whey-50% casein (Alternative)|portion size that contains 25 g of protein, oral, single administration
61962968|NCT03313791|EXPERIMENTAL|Micellar Casein Isolate- WPH|portion size that contains 25 g of protein, oral, single administration
61962969|NCT03313791|EXPERIMENTAL|Micellar Casein Isolate - Na-caseinate|portion size that contains 25 g of protein, oral, single administration
61962970|NCT03313791|EXPERIMENTAL|Micellar Casein Isolate|portion size that contains 25 g of protein, oral, single administration
61962971|NCT03313791|EXPERIMENTAL|UHT milk|portion size that contains 25 g of protein, oral, single administration
61962972|NCT03313791|EXPERIMENTAL|Recombined milk|portion size that contains 25 g of protein, oral, single administration
61962973|NCT03313791|EXPERIMENTAL|Recombined 50% whey milk|portion size that contains 25 g of protein, oral, single administration
61962974|NCT03313791|EXPERIMENTAL|Ca-caseinate|portion size that contains 25 g of protein, oral, single administration
61962975|NCT03313791|EXPERIMENTAL|Milk protein isolate|portion size that contains 25 g of protein, oral, single administration
62506541|NCT03304782||Preterm birth|Data collected using Fitbit activity tracker from women with delivery prior to 37 weeks gestation
62506542|NCT03304782||Full-term birth|Data collected using Fitbit activity tracker from women with delivery after 37 weeks gestation
62506543|NCT01477099|EXPERIMENTAL|Toothbrushing with a manual brush|Toothbrushing with a manual brush
62506544|NCT01477099|NO_INTERVENTION|No toothbrushing|no toothbrushing
62506545|NCT01301482|EXPERIMENTAL|battlefield auricular acupuncture|
61962976|NCT00836485|EXPERIMENTAL|1|Ketotifen 4.0% Patch
61962977|NCT00836485|PLACEBO_COMPARATOR|2|Placebo Patch
61962978|NCT00836485|ACTIVE_COMPARATOR|3|Pataday(TM)
61962979|NCT00836485|PLACEBO_COMPARATOR|4|Placebo eye drops
61962980|NCT01063868|EXPERIMENTAL|001|Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 52 weeks
61962981|NCT01063868|ACTIVE_COMPARATOR|002|Oxycodone controlled release (CR) 20 30 40 50 mg twice daily for 52 weeks
61962982|NCT00682162|SHAM_COMPARATOR|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
61962983|NCT00682162|ACTIVE_COMPARATOR|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
61962984|NCT00486200|ACTIVE_COMPARATOR|1|Oral administration of active comparator
61962985|NCT00486200|PLACEBO_COMPARATOR|2|Oral administration of placebo
62506546|NCT01301482|NO_INTERVENTION|placebo|
62506547|NCT03895619|EXPERIMENTAL|Men living with HIV|Uptake of safer conception strategies among men living with HIV and/or their female partners
62704969|NCT05775497|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program + Body Image Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
62704970|NCT05775497|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss, (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (4) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
61962986|NCT00486200|EXPERIMENTAL|3|Dosing regimen 1
61962987|NCT00486200|EXPERIMENTAL|4|Dosing regimen 2
61962988|NCT00486200|EXPERIMENTAL|5|Dosing regimen 3
61962989|NCT00486200|EXPERIMENTAL|6|Dosing regimen 4
61962990|NCT03833245|NO_INTERVENTION|Control|The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.
61962991|NCT03833245|EXPERIMENTAL|Patient Navigation|The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
61962992|NCT03170401|ACTIVE_COMPARATOR|no protein supplementation|subjects receiving enteral nutrition without any protein supplementation
61962993|NCT03170401|EXPERIMENTAL|protein supplementation|subjects receiving enteral nutrition with additional protein supplementation
61962994|NCT02264197|EXPERIMENTAL|BIBX 245 CL - fed|after a light breakfast with 40 g fat
61962995|NCT02264197|ACTIVE_COMPARATOR|BIBX 245 CL - fasted|
61962996|NCT05318170||Women affected by gynecological cancer|Women affected by gynecological cancer (cervical, endometrial, ovarian and vulvar cancer)
61962997|NCT04593225|EXPERIMENTAL|TAU + multicomponent treatment VIRTUAL SFCAMINA|VIRTUAL SFCAMINA is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
61962998|NCT04593225|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
62506548|NCT02928978|EXPERIMENTAL|Ruxolitinib|Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
61962999|NCT04555291|EXPERIMENTAL|Drug Ropivacaïne 2 mg/ml|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
61963000|NCT04555291|PLACEBO_COMPARATOR|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
61963001|NCT01397084|OTHER|esomeprazole 20 mg|esomeprazole 20 mg
61963002|NCT05443789|EXPERIMENTAL|Proton pump inhibitor education|The general practices in this arm will receive the education visits about Proton pump inhibitor.
61963003|NCT05443789|PLACEBO_COMPARATOR|Other education|The general practices in this arm will receive an educational visit on another topic (asthma).
61963004|NCT00105469|EXPERIMENTAL|AzaSite|1.0% azithromycin in DuraSite
61963005|NCT00105469|ACTIVE_COMPARATOR|Tobramycin|0.3% tobramycin
62144018|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
62506549|NCT02928978|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
62506550|NCT06571500||Men and women with a family history of type 2 diabetes|
61963006|NCT02495298|EXPERIMENTAL|Treatment Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
61963007|NCT02495298|SHAM_COMPARATOR|Placebo Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Sham Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
62144019|NCT02185794|EXPERIMENTAL|Voxilaprevir 300 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
62506551|NCT06571500||Men and women without a family history of type 2 diabetes|
62704971|NCT05775497|EXPERIMENTAL|Weight Loss Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
61963008|NCT00127660|EXPERIMENTAL|Menu: calories=yes, value pricing=no|There were calories listed on the menu, but no value pricing was in place.
61963009|NCT00127660|EXPERIMENTAL|Menu: calories=yes, value pricing = yes|There were calories listed on the menu, AND value pricing was in place.
61963010|NCT00127660|EXPERIMENTAL|Menu: calories=no, value pricing = no|Calories were not listed on the menu, and value pricing was not in place.
61963011|NCT00127660|NO_INTERVENTION|Menu: calories=no, value pricing = yes|CONTROL CONDITION: calories were not listed on the menu, and value pricing WAS in place.
62144020|NCT02185794|PLACEBO_COMPARATOR|Placebo (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
62704972|NCT05775497|EXPERIMENTAL|Weight Loss Program + Coping with Stress Program + Social Support Program|Participants complete a (1) online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress \& stigma due to weight, sexual orientation, and gender \& its impact on weight loss, and (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
62704973|NCT05775497|EXPERIMENTAL|Weight Loss Program + Body Image Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
62506552|NCT02991560|EXPERIMENTAL|Kinesio tape (KT)|The KT group was taped 2 days a week for 4 weeks using the muscle and fascia correction techniques
62506553|NCT02991560|EXPERIMENTAL|Athletic taping (AT)|An athletic tape with adhesive backing was used (38 mm wide-Muller Protape-The Netherlands).
62506554|NCT04725591|ACTIVE_COMPARATOR|Diabeloop closed-loop glucose control session with the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and MEDISAFE WITH insulin pump.~Subjects are asked to declare their meals for 4 weeks.~A remote monitoring system is provided in closed-loop session."
61963012|NCT02007109||Nausea measurement by VAS and BARF|"All patients will be asked to rate their nausea on both the VAS and the BARF scales. For the nausea scales, the script would be: Have you thrown up or felt like you were going to throw up before? How did your tummy feel then? We call that feeling of being sick to the stomach as nausea.~For the BARF scale:These faces show children who feel no nausea at all, who feel a little bit nauseated, who feel even more nauseated, and these are children who have the most nausea it is possible to feel. (Point to the each face at the appropriate time). Which face is more like you feel right now? For the VAS scale: On this line the far left indicates No nausea and the far right Worst nausea ever. Can you show me on this line how much nausea you have right now?"
61963013|NCT03600545|EXPERIMENTAL|Active|4 weeks daily practice of the brain exercises
61963014|NCT03600545|NO_INTERVENTION|control|no brain exercises
62144021|NCT02185794|EXPERIMENTAL|Voxilaprevir 50 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
62506555|NCT04725591|EXPERIMENTAL|Diabeloop closed-loop glucose control session without the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and MEDISAFE WITH insulin pump.~Subjects are asked to not declare their meals for 4 weeks.~A remote monitoring system is provided in closed-loop session."
62506556|NCT02051595|OTHER|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
62506557|NCT05673993|EXPERIMENTAL|Telitacicept 80 mg|Subjects will be given subcutaneous Telitacicept 80 mg once a week for 48 weeks.
62506558|NCT05673993|EXPERIMENTAL|Telitacicept 160 mg|Subjects will be given subcutaneous Telitacicept 160 mg once a week for 48 weeks.
62506559|NCT05673993|PLACEBO_COMPARATOR|Placebo|Subjects will be given subcutaneous placebo once a week for 24-48 weeks. Subjects who are randomized to the placebo group are allowed to be transferred to either Telitacicept 80 mg or Telitacicept 160 mg after Week 24 by the investigator. Subjects and investigators are blinded throughout the study.
62704974|NCT05775497|EXPERIMENTAL|Weight Loss Program + Social Support Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
62704975|NCT04145115|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the study.
61963015|NCT02498314|EXPERIMENTAL|Grade I-II SZ mobilization|Grade I-IISZ hip traction in resting position
61963016|NCT02498314|EXPERIMENTAL|Grade II TZ mobilization|Grade IITZ hip traction in resting position
61963017|NCT02498314|EXPERIMENTAL|Grade III mobilization|Grade III hip traction in resting position
61963018|NCT01699282|EXPERIMENTAL|Group thorough VKA (antivitamin K)education|
61963019|NCT01699282|ACTIVE_COMPARATOR|control group|
61963020|NCT02171520|EXPERIMENTAL|Dabigatran etexilate generation I|
61963021|NCT02171520|ACTIVE_COMPARATOR|Dabigatran etexilate generation II|
61963022|NCT05256953|ACTIVE_COMPARATOR|Group ESP|bilateral ESPB (total of 40 ml, %0.25 bupivacaine) + IV morphine PCA
61963023|NCT05256953|ACTIVE_COMPARATOR|Group GA|only IV morphine PCA
62144022|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
62144023|NCT02185794|EXPERIMENTAL|Voxilaprevir 300 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
62144024|NCT02185794|PLACEBO_COMPARATOR|Placebo (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
61963024|NCT05799066|EXPERIMENTAL|Known RAPD|Participants with known RAPD will be administered the standard of care swinging light test and pupil measurements taken manually, then administered the light test using the VR HMD and ML.
61963025|NCT05799066|EXPERIMENTAL|No Known RAPD|Participants with no known RAPD will be administered the standard of care swinging light test and pupil measurements taken manually, then administered the light test using the VR HMD and ML.
61963026|NCT02551965|EXPERIMENTAL|Caregiver of cancer patient followed in geriatric oncology|caregiver of cancer patient with 70 years old or more, for which a treatment is planned, along with their long term evolution
62144025|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
61963027|NCT04189159|EXPERIMENTAL|PROMPT Treated|PROMPT treatment, twice a day, for 5 days a week, for 3 consecutive weeks
61963028|NCT04189159|NO_INTERVENTION|Control|Usual treatment
61963029|NCT05657444|EXPERIMENTAL|TNK group|
62144026|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg (GT 4, Cohort 4)|Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
62144027|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg (GT 1b, Cohort 5)|Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
62144028|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg Fed (GT 3a, Cohort 6)|Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
62506560|NCT03263793|EXPERIMENTAL|Behavioral vocal training|12-week vocal training program will use maximum vocal function exercises targeting vocal deficits specific to Parkinson Disease.
62506561|NCT06277050|EXPERIMENTAL|Maintenance Therapy with Toripalimab and Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
62506562|NCT06277050|ACTIVE_COMPARATOR|Maintenance Therapy with Capecitabine alone|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
61963030|NCT05657444|NO_INTERVENTION|control group|
61963031|NCT03558776|ACTIVE_COMPARATOR|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
61963032|NCT03558776|ACTIVE_COMPARATOR|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) \< 2.5 En% linoleic acid (n = 37)
61963033|NCT03558776|ACTIVE_COMPARATOR|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
61963034|NCT03558776|PLACEBO_COMPARATOR|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
61963035|NCT06229990|EXPERIMENTAL|Protocol based-furosemide stress test|Furosemide at 1.5 mg/kg intravenously
61963036|NCT06229990|NO_INTERVENTION|Standard care|Standard CRRT care without furosemide use during treatment.
61963037|NCT03779802|EXPERIMENTAL|CRT device|Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes
62144029|NCT02185794|EXPERIMENTAL|Voxilaprevir 600 mg (Cohorts 7-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
62144030|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
62144031|NCT02185794|EXPERIMENTAL|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.
62144032|NCT06700070|EXPERIMENTAL|PBA-0111|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at 1-2 days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of PBA-0111, as single agents. Each microdose is simultaneously injected in a columnar fashion through each of 8, or 5, (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node
62506563|NCT05080608||Nerve injury|This is an interview study of patients with injury to the median, ulnar or digital nerve or brachial plexus injury.
62506564|NCT05002881|ACTIVE_COMPARATOR|Moringa oleifera (E-HS-01)|One capsule to be taken stat
62506565|NCT05002881|PLACEBO_COMPARATOR|Placebo|One capsule to be taken stat
62506566|NCT02184741|PLACEBO_COMPARATOR|Placebo|Infusion of normal saline
62506567|NCT02184741|EXPERIMENTAL|GB-0998|Infusion of GB-0998 (Immunoglobulin)
61963038|NCT02741024|ACTIVE_COMPARATOR|Amodiaquine-Artesunate (ASAQ)|Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
61963039|NCT02741024|ACTIVE_COMPARATOR|Artemether-Lumefantrine (AL)|Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).
61963040|NCT04186520|EXPERIMENTAL|8/12 Day Production of CAR-T for NHL|"Phase 1: Determine safety of 2.5x10\^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at eight or 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
61963041|NCT04186520|EXPERIMENTAL|8/12 Day Production of CAR-T for CLL|"Phase 1: Determine safety of 2.5x10\^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with CLL. Patients will be enrolled in 3+3 fashion.~Phase 1b: The enrollment will cap at 24 subjects."
62506568|NCT00893451|ACTIVE_COMPARATOR|A|Vitamin D3 1600 IU orally twice daily
62506569|NCT00893451|PLACEBO_COMPARATOR|B|Placebo orally twice daily
62506570|NCT03497819|EXPERIMENTAL|CARTmeso/19 treatment arm|Patients with pancreatic cancer receiving CARTmeso and CART19 autologous cells via artery infusion or i.v. with cyclophosphamide precondition
62506571|NCT05044494||study group|non-prompt surgery after acute type a aortic dissection occurred
62506572|NCT05044494||control group|prompt surgery after acute type a aortic dissection occurred
62144033|NCT01217099|NO_INTERVENTION|methylprednisolone|methylprednisolone pulse azithromycin
62506573|NCT03907917|ACTIVE_COMPARATOR|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
62506574|NCT03907917|SHAM_COMPARATOR|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
62506575|NCT02904538|EXPERIMENTAL|Perineural group|1cc (4mg) of dexamethasone will be administrated in perineural injection. 2.5cc of isotonic saline solution will be administrated in systemic injection.
62506576|NCT02904538|EXPERIMENTAL|systemic group|1cc of isotonic saline will be administrated in perineural injection. 2.5cc (10mg) of dexamethasone will be administrated in systemic injection.
62506577|NCT02076776|ACTIVE_COMPARATOR|Repetitive Task Practice (RTP)|This group focuses on RTP.
62506578|NCT02076776|EXPERIMENTAL|Voluntary cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
62506579|NCT02076776|EXPERIMENTAL|Assisted cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
62506580|NCT06472180|EXPERIMENTAL|intervention- Glass ceramic sectional veneer|participants receive Glass ceramic sectional veneer covering only the area of defect
62506581|NCT06472180|ACTIVE_COMPARATOR|control-Glass ceramic laminate veneer|participants receive laminate veneers made of glass ceramics as it is well documented in the literatures as successful restoration modality
62506582|NCT05927779|EXPERIMENTAL|Dose escalation|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of TFX06 tablet.Safety Expansion: Additional patients will be enrolled to further evaluate the safety, tolerability and RP2D of TFX06 tablet.~Part B ,Dose Expansion, A cohort of patients will be enrolled to evaluate preliminary preliminary efficacy of the TFX06 tablet in RP2D in a group of patients with at least 6 months of standard endocrine therapy prior to disease progression."
62506583|NCT05521022|EXPERIMENTAL|Part 1 AT-02|Part 1 enrolling Healthy Volunteers (Randomised, Double-blind) Drug: AT-02 Dosage: 30mg to 1000mg Dosage Form \& Route of Admin: Solution for IV Infusion
62506584|NCT05521022|PLACEBO_COMPARATOR|Part 1 Placebo|Part 1 enrolling Healthy Volunteers (Randomised, Double-blind) Dosage Form \& Route of Admin: Normal Saline Solution for IV Infusion
62506585|NCT05521022|EXPERIMENTAL|Part 2 AT-02|Part 2 enrolling Systemic Amyloidosis Participants (Single-Arm, Open-label) Drug: AT-02 Dosage: 300mg to 4000mg Frequency: Single Dose Dosage Form \& Route of Admin: Solution for IV Infusion
61963042|NCT04186520|EXPERIMENTAL|8/12 Flexible Manufacturing with Mandated Cryopreservation|8/12 flexible manufacturing with mandated cryopreservation prior to infusion of LV20.19 CAR T-cells. The enrollment will cap at 24 subjects.
61963043|NCT04186520|EXPERIMENTAL|12-Day Production of Car-T Cells for NHL|"Phase 1: Determine safety of 2.5x10\^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
61963044|NCT04186520|EXPERIMENTAL|8/12 Day Production of CAR-T for Relapsed/Refractory Primary or Secondary CNS Lymphoma|"Phase 1: Determine safety of 2.5x106 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with primary/secondary central nervous system (CNS) lymphoma.~Phase 1b: Safety and efficacy will be evaluated in this study that will enroll 12 to 24 patients."
61963045|NCT04186520|EXPERIMENTAL|Phase 2 - Efficacy of CAR-20/19-T cells in MCL|Single-stage Phase II design with three-month CR as the target endpoint.
61963046|NCT06025097|EXPERIMENTAL|Single Treated Arm|Single arm study, Patients with SNHL and Tinnitus all were given same Composite solution consisting of (Methyl prednisone and Platelet rich plasma) via intr-atympanic route..
62348715|NCT01811381|PLACEBO_COMPARATOR|Placebo vs non-aerobic yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient\] and 2 home practices of 30 minute duration per week).
62348716|NCT01811381|ACTIVE_COMPARATOR|Placebo vs Aerobic Yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly aerobic yoga program (Attendance at 2 classes of 1 hour duration \[or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient\] and 2 home practices of 30 minute duration per week).
62348717|NCT01811381|ACTIVE_COMPARATOR|Curcumin vs non aerobic yoga|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Curcumin (4 capsules x BID, total 800 mg/day) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration \[or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient\] and 2 home practices of 30 minute duration per week).
62506586|NCT05521022|EXPERIMENTAL|Part 3 AT-02|Part 3 enrolling Systemic Amyloidosis Participants (Single-Arm, Open-label) Drug: AT-02 Dosage: Dose levels will be determined by the SRC. The starting dose in Part 3 will be determined by the SRC based on all available safety, tolerability, PK, and PD data from all prior cohorts Frequency: Multiple Doses Dosage Form \& Route of Admin: Solution for IV Infusion
62506587|NCT00442351|EXPERIMENTAL|Asmanex Twisthaler|
62506588|NCT00442351|PLACEBO_COMPARATOR|Placebo inhaler|
62506589|NCT01177163|OTHER|001|Placebo one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
62506590|NCT01177163|EXPERIMENTAL|002|JNJ 28431754 100 mg/placebo one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
62506591|NCT01177163|EXPERIMENTAL|003|JNJ 28431754 300 mg/placebo one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
62506592|NCT00678327|ACTIVE_COMPARATOR|Arm I|Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
61963047|NCT00752232|EXPERIMENTAL|ACC-001+QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
61963048|NCT00752232|EXPERIMENTAL|ACC-001|Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
61963049|NCT00752232|PLACEBO_COMPARATOR|QS-21|Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
61963050|NCT00752232|PLACEBO_COMPARATOR|PBS|Placebo, IM injection, Day 1, month 3, 6, 9, 12
62144034|NCT01217099|NO_INTERVENTION|azithromycin|azithromycin
62348718|NCT01608282|EXPERIMENTAL|OPEN Intervention Group|Intervention group participants will receive an email prompt to access the OPEN website every two weeks for the first three months, with a short message about the ongoing projects at the Arthritis Research Centre of Canada. The OPEN website will remain accessible throughout the study, but no further prompting emails will be sent after Month 3. In addition, they will receive an education pamphlet produced by The Arthritis Society containing information about osteoarthritis, physical activity and other treatments.
62348719|NCT01608282|NO_INTERVENTION|Control Group|Control group participants will receive, by email, the same Arthritis Society pamphlet as the Intervention group. Participants will also receive, by email, the same short message about the ongoing projects at the Arthritis Research Centre of Canada, every two weeks for the first three months (i.e. the same schedule as the intervention group receiving the prompting email so that the number of contacts is equal in both groups), but without the prompting to use the OPEN website.
62348720|NCT04229472|EXPERIMENTAL|Normal subject control group|High density mapping of left atrial voltages in patients with supraventricular tachycardia
62506593|NCT00678327|ACTIVE_COMPARATOR|Arm II|Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62506594|NCT00678327|EXPERIMENTAL|BEACOPP-14 chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62506595|NCT00678327|EXPERIMENTAL|BEACOPP-escalated chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62506596|NCT03085368|EXPERIMENTAL|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
61963051|NCT02634320|OTHER|Aripiprazole Lauroxil|Intramuscular (IM) injection
61963052|NCT01010490|EXPERIMENTAL|Torsional ultrasound|Torsional ultrasound with the INFINITI phacoemulsification system (Alcon Lab, USA)
61963053|NCT01010490|ACTIVE_COMPARATOR|Longitudinal ultrasound (INFINITI)|Longitudinal ultrasound with the INFINITI phacomachine (Alcon Lab, USA)
61963054|NCT01010490|ACTIVE_COMPARATOR|Longitudinal ultrasound (LEGACY)|Longitudinal ultrasound with the LEGACY phacomachine (Alcon Lab, USA)
61963055|NCT02305056|EXPERIMENTAL|C13 N15 Valine|Intervention C13 N15 Valine
61963056|NCT02891759|EXPERIMENTAL|Group A: Alloderm RTU|"* Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~* On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group A will receive Alloderm RTU~* A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
62144035|NCT03213028|OTHER|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
62144036|NCT02326506|EXPERIMENTAL|Pump speed variation|VA-ELS pump speed variations
62144037|NCT00223756|EXPERIMENTAL|Arm 1|interdisciplinary, outpatient blind rehabilitation
62144038|NCT00223756|NO_INTERVENTION|Arm 2|usual care
62144039|NCT04197791|EXPERIMENTAL|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular Electrical Stimulation will be applied to 18 patients with idiopathic pulmonary fibrosis. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
62144040|NCT04197791|EXPERIMENTAL|Core Stabilization Exercises|Core stabilization exercises will be applied to 18 patients with idiopathic pulmonary fibrosis. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
62348721|NCT04229472|EXPERIMENTAL|Atrial fibrillation group|High density mapping of left atrial voltages
62348722|NCT04229472|EXPERIMENTAL|AcQMap atrial fibrillation group|High density mapping of left atrial voltages and AcQMap propagation patterns alongside cardiac MRI
62348723|NCT01648829|ACTIVE_COMPARATOR|Atorvastatin|os, 20 mg, once per day, for 30 days
62348724|NCT01648829|ACTIVE_COMPARATOR|Pitavastatin|os, 4 mg, once per day, for 30 days
62348725|NCT01996891|OTHER|Anti-Inflammatory Diet First|For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
62144041|NCT04373967|EXPERIMENTAL|TQZ2451+metformin hydrochloride|TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
62144042|NCT04373967|ACTIVE_COMPARATOR|Victoza®+metformin hydrochloride|Victoza® (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
62348726|NCT01996891|OTHER|Anti-Inflammatory Diet Second|For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.
62348727|NCT03140423|ACTIVE_COMPARATOR|Arm 1: Routine Care (Mupirocin/CHG)|ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
62348728|NCT03140423|ACTIVE_COMPARATOR|Arm 2: Iodophor/CHG Decolonization|ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
62348729|NCT00761683||1|Patients diagnosed with endometriosis
62348730|NCT00709033|EXPERIMENTAL|autologous or syngeneic PBTLs and EBV-CTLs|The subject will be assigned a dose of CD19-CD28 chimeric receptor T cells at study entry.
62348731|NCT05301023|EXPERIMENTAL|Individual group|In the individual group, the participants receive individualized antibiotic therapy.
62348732|NCT05301023|ACTIVE_COMPARATOR|Standard group|In the standard group, the participants receive standard antibiotic therapy as defined by the national guideline.
62348733|NCT00050986|EXPERIMENTAL|Temozolomide and R115777|
62348734|NCT05806021|EXPERIMENTAL|Group A TA 40 mg|intra-articular injection of 40 mg of triamcinolone acetonide, which is the standard dose used
62348735|NCT05806021|ACTIVE_COMPARATOR|Group B TA 10 mg|intra-articular injection of 10 mg of triamcinolone acetonide
62348736|NCT05806021|ACTIVE_COMPARATOR|Group C TA 5 mg|intra-articular injection of 5 mg of triamcinolone acetonide
62348737|NCT05615766|EXPERIMENTAL|Device Intervention|The intervention group who will be undergoing rehabilitation using the robotic exoskeleton in addition to the assigned traditional rehabilitation programme on their dominant arm only.
62348738|NCT05615766|NO_INTERVENTION|Control|the matched control group will be the same subjects undergoing traditional rehabilitation only on their non-dominant arm.
62348739|NCT03987334|EXPERIMENTAL|Experimental Group (VRT)|Subjects in the experimental group (VRT) will undergo 30 minutes of motor control exercises using a virtual reality-based sensorimotor rehabilitation provided using the Virtual Reality Rehabilitation System (VRRS) of Khymeia Group. The equipment includes a computer workstation connected to a 6 degrees of freedom (DOF) motion-tracking system (Polhemus G4, Vermont, US), a high-resolution LCD displaying the virtual scenarios on a large screen and a software processing the motion data coming: from the receiver of the sensors end-effectors placed on the sternum and on the head through a helmet. The system has been found to reliably record head position and cervical range of motion among asymptomatic people as well as persistent neck pain patients. The VRRS allows the participant to perform the requested motor tasks, while the movement of the system's end-effector is simultaneously represented in a virtual scenario.
62348740|NCT03987334|ACTIVE_COMPARATOR|Control Group (CT)|Control group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
62144043|NCT01199991||Normative database|
62144044|NCT01152229||nuisance bleeding|
62144045|NCT01152229||alarming bleeding|
62144046|NCT01152229||maintenance therapy|
62144047|NCT04767815|EXPERIMENTAL|Sequence 1|"* Period 1: A (Fasting)~* Period 2: B (30 minutes after a High-fat meal)~* Period 3: C (2 hours after a High-fat meal)"
62348741|NCT03176173|EXPERIMENTAL|Immunotherapy plus Image-guided Radiation Therapy|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while continuing their prior treatment with the treating physician's choice of regular medical care immunotherapy.
62348742|NCT03176173|ACTIVE_COMPARATOR|Immunotherapy Alone (Regular Medical Care)|Patients who decline to undergo radiation therapy will continue their prior treatment with the treating physician's choice of regular medical care immunotherapy.
62144048|NCT04767815|EXPERIMENTAL|Sequence 2|"* Period 1: B (30 minutes after a High-fat meal)~* Period 2: C (2 hours after a High-fat meal)~* Period 3: A (Fasting)"
62348743|NCT02584465|ACTIVE_COMPARATOR|A-Tamoxifen|Tamoxifen 40mg/day 2 film-coated tablet containing 20 mg of Tamoxifen/day until progression
62348744|NCT02584465|EXPERIMENTAL|B-Regorafenib|Regorafenib 120mg/day 3 film-coated tablet containing 40 mg of Regorafenib/day, 3 weeks/4 until progression
62348745|NCT02394808|EXPERIMENTAL|Test Lens 1|senofilcon A (Approved contact lens material)
62348746|NCT02394808|ACTIVE_COMPARATOR|Test Lens 2|lotrafilcon B (Approved contact lens material)
62348747|NCT00213980|NO_INTERVENTION|Observation|Observation only for 12 months
62348748|NCT00213980|ACTIVE_COMPARATOR|Zoledronate|Zoledronate
62348749|NCT05510206|ACTIVE_COMPARATOR|Super elastic NiTi Group|0.014-inch super elastic nickel-titanium archwire (ortho Technology™ , west Columbia, USA) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks.
62348750|NCT05510206|EXPERIMENTAL|Smartarch Group|0.016-inch Smartarch archwir (Ormco™, USA) will be placed in mandibular arch at the day of bonding. Re-ligated every four weeks for 16 weeks.
62348751|NCT01292044|EXPERIMENTAL|The study population|The study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
62539309|NCT01801631|OTHER|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
62144049|NCT04767815|EXPERIMENTAL|Sequence 3|"* Period 1: C (2 hours after a High-fat meal)~* Period 2: A (Fasting)~* Period 3: B (30 minutes after a High-fat meal)"
62144050|NCT04767815|EXPERIMENTAL|Sequence 4|"* Period 1: A (Fasting)~* Period 2: C (2 hours after a High-fat meal)~* Period 3: B (30 minutes after a High-fat meal)"
62144051|NCT04767815|EXPERIMENTAL|Sequence 5|"* Period 1: C (2 hours after a High-fat meal)~* Period 2: B (30 minutes after a High-fat meal)~* Period 3: A (Fasting)"
62144052|NCT04767815|EXPERIMENTAL|Sequence 6|"* Period 1: B (30 minutes after a High-fat meal)~* Period 2: A (Fasting)~* Period 3: C (2 hours after a High-fat meal)"
62704976|NCT05228158||Tazemetostat|Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation will receive Tazemetostat 800 milligram (mg), tablet, orally, twice daily or as per physicians discretion in routine clinical practice. All the participants will be observed for up to Week 52 prospectively.
62704977|NCT06192758|EXPERIMENTAL|TheraSphere PCa Dose Escalation|"Participants will be treated in cohorts of three across three sequential dose levels:~* Dose Level 1 (or starting dose) = 175 Gy; however, a provisional lower dose level, Dose Level -1 = 150 Gy, may be utilized in case de-escalation is warranted at Dose Level 1.~* Dose Level 2 = 200 Gy~* Dose Level 3 = 225 Gy"
62704978|NCT06122701|ACTIVE_COMPARATOR|OCT1 deficient and wild type genotypes: 200 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
62704979|NCT06122701|ACTIVE_COMPARATOR|OCT1 deficient and wild type genotypes: 50 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
62704980|NCT06122701|ACTIVE_COMPARATOR|OCT1 deficient and wild type genotypes: 10 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
62704981|NCT06122701|ACTIVE_COMPARATOR|OCT1 deficient and wild type genotypes: 5 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
62704982|NCT04084288|EXPERIMENTAL|Postoperative Acupuncture|"Neuraxial anesthesia (spinal or combined spinal epidural (CSE) with up to 4cc mepivacaine 1.5%) and 2 blocks for postoperative pain (IPACK and adductor canal peripheral nerve blocks). Sedation will be provided. Tranexemic acid (TXA) will be dosed per surgeon request.~A certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed. If an epidural is placed, it may be redosed with lidocaine as needed (up to 100mg total) and will be removed prior to transfer to the recovery room.~A periarticular injection (PAI) will be placed by the surgeon during the surgery (timing at the discretion of the surgeon)"
62704983|NCT03584633|OTHER|Lymphedema|The subjects with lymphedema will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with Indocyanine Green Lymphography.
62704984|NCT04360018|ACTIVE_COMPARATOR|arm one|participants receive alcohol beverage
62704985|NCT04360018|PLACEBO_COMPARATOR|arm two|Placebo
62704986|NCT01631617|ACTIVE_COMPARATOR|1A/Cephalexin|Cephalexin + Placebo bleach
62704987|NCT01631617|ACTIVE_COMPARATOR|1B/TMP/SMX|TMP/SMZ DS 800 /160 orally every 12 hours for 14 days
62704988|NCT01631617|ACTIVE_COMPARATOR|1C/Doxycycline 100|Doxycycline 100 mg orally every 12 hours for 56 days
62704989|NCT01631617|ACTIVE_COMPARATOR|1D/Doxycycline 20|Doxycycline 20 mg orally every 12 hours for 56 days
62704990|NCT01631617|ACTIVE_COMPARATOR|2A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
62704991|NCT01631617|PLACEBO_COMPARATOR|2B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
62704992|NCT01631617|PLACEBO_COMPARATOR|2C/Placebo capsules + Dilute bleach|Placebo capsules + dilute bleach study bath liquid
62704993|NCT01631617|PLACEBO_COMPARATOR|2D/Placebo capsules + Placebo bleach|Placebo capsules + placebo study bath liquid
62704994|NCT01631617|ACTIVE_COMPARATOR|3A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
62704995|NCT01631617|PLACEBO_COMPARATOR|3B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
62704996|NCT01928394|EXPERIMENTAL|Arm N - Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62704997|NCT01928394|EXPERIMENTAL|Arm N-I, Level 1: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 1 mg/kg solution every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62704998|NCT01928394|EXPERIMENTAL|Arm N-I, Level 2: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62704999|NCT01928394|EXPERIMENTAL|Arm N-I, Level 2b: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously plus Ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62705000|NCT01928394|EXPERIMENTAL|Arm N-I, Level 2c: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62705001|NCT01928394|EXPERIMENTAL|Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks and cobimetinib 60mg once daily 21days on/7 days off until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
62705002|NCT04821089|EXPERIMENTAL|IPN10200 group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
62705003|NCT04821089|PLACEBO_COMPARATOR|Placebo group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
62705004|NCT04821089|ACTIVE_COMPARATOR|Dysport group (stage 1 / step 2 only)|
62705005|NCT03831958||Family member|Family member of survivor of pediatric Cushing disease
62705006|NCT03831958||Subjects|survivor of pediatric Cushing disease
62705007|NCT02460458||Type 3 Von Willebrand's Disease (VWD3)|Patients with diagnosis of Type 3 Von Willebrand's Disease
62705008|NCT06285318||Participants with Relapsed/Refractory Multiple Myeloma (RRMM): Teclistamab Cohort 1|Participants with RRMM who received at least one dose of teclistamab outside of clinical trials on or before 31 December 2022 will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.
61963057|NCT02891759|EXPERIMENTAL|Group B: Cortiva 1mm Allograft Dermis|"* Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~* On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group B will receive Cortiva 1mm Allograft Dermis~* A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
61963058|NCT05421624|EXPERIMENTAL|Amped-PD|6-week community-based, self-directed walking program that uses a novel digital therapeutic that delivers music-adaptive rhythmic auditory stimulation.
61963059|NCT05421624|ACTIVE_COMPARATOR|Active-Control|6-week community-based, self-directed walking program without using a novel digital therapeutic or any form of rhythmic auditory stimulation.
61963060|NCT04343547|EXPERIMENTAL|1|
61963061|NCT04343547|EXPERIMENTAL|2|
61963062|NCT04343547|EXPERIMENTAL|Experimental 3|
61963063|NCT03164252|ACTIVE_COMPARATOR|Grupo I- Lower laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 10 J / cm2 fluency, in the immediate period after surgical period of the third molar third molar extraction / impacted by the intraoral region
61963064|NCT03164252|ACTIVE_COMPARATOR|Grupo II- Greater laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 30J / cm2 fluency, in the immediate period after surgical of the third molar third molar extraction / impacted by the intraoral region
61963065|NCT03164252|PLACEBO_COMPARATOR|Grupo III- Laser sham|Application of laser sham, the handpiece of the device will be positioned intraorally and activated. However, the tip of the applicator will be covered by an opaque material that prevents radiation from passing through.
61963066|NCT01720121|NO_INTERVENTION|Control group|The control group received the guidelines orientation provide by nursing team
61963067|NCT01720121|EXPERIMENTAL|Guidelines printed group|The patient received the informative material in details about the cardiac catheterization provide by the researchers
61963068|NCT01720121|EXPERIMENTAL|Guidelines digital video disc group|Guidelines digital video disc group: The patient received the informative provide by digital video disc in details about the cardiac catheterization
61963069|NCT05349994|NO_INTERVENTION|Control|Standard amount of physical therapy at surgical wards in an urban hospital, corresponding to 1.75 physiotherapy employment on weekdays divided on four wards with a total of approx. 40-48 patients.
61963070|NCT05349994|EXPERIMENTAL|Intervention|Extended physiotherapy with an extra 0.5 employment on weekdays, leading to 1-2 physiotherapy session per day for the study participants in the intervention group.
62705009|NCT06285318||Participants with Relapsed/Refractory Multiple Myeloma (RRMM): Teclistamab Cohort 2|Participants with RRMM who received at least one dose of teclistamab outside of clinical trials from 01 January 2023 to 31 December 2024, inclusive will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.
61963071|NCT01236599|NO_INTERVENTION|traditional care|Preterm Infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off and wrapped up in a sterile preheated field
61963072|NCT01236599|EXPERIMENTAL|Polyethylene bag with previous drying|infants were placed under the radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off, and wrapped up in a polyethylene bag, leaving their faces discovered as well as the access at umbilical catheters or veined access.
61963073|NCT01236599|EXPERIMENTAL|Polyethylene bag without previous drying|Preterm infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel) and without previous body drying (only the head was dried), were wrapped up with the polyethylene bag, leaving their faces discovered as well as the access to umbilical catheters or veined access
61963074|NCT05157230|EXPERIMENTAL|exercise|volunteers in this group do shoulder/arm exercises after vaccine injection and fill in the pain diary
61963075|NCT05157230|NO_INTERVENTION|no-exercise|volunteers in this arm only completed the pain diary without any intervention
61963076|NCT05038189|EXPERIMENTAL|Ankylosing Spondylitis|Study group
61963077|NCT05038189|EXPERIMENTAL|Non-radiographic Axial Spondyloarthritis|Study group
61963078|NCT05038189|EXPERIMENTAL|Healthy individuals|Control group
61963079|NCT02950532||Cases|Retrospective radiological evaluation in cases presenting A3 or A4 TL burst fractures (AOSpine classification) between T11 to L2 with or without suspected PLC injury
61963080|NCT04006574|EXPERIMENTAL|core stabilization training|Patient with hip dysplasia aged between 20-60, non-operated
61963081|NCT04006574|ACTIVE_COMPARATOR|traditional physiotherapy and core stabilization|Patient with hip dysplasia aged between 20-60, non-operated
62705010|NCT06285318||Participants with RRMM: Talquetamab Cohort|Participants with RRMM who received at least one dose of talquetamab outside of clinical trials on or before 31 December 2023 will be enrolled in the study. The data available from the medical records of each enrolled participant will be collected to describe the use of talquetamab.
62144053|NCT01333449|EXPERIMENTAL|Single Arm|Decitabine 20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
62144054|NCT06268782|EXPERIMENTAL|The intervention group|All participants belonged to the intervention group. The participants were asked to answer for the pretest questionnaire before the intervention, then accomplish the six-week intervention, answer to the posttest questionnaire after the intervention and answer to the follow-up questionnaire six months after the intervention.
62705011|NCT01733316|EXPERIMENTAL|All Participants|"Cystagon® Phase: From Screening and during Months 1, 2, 3 participants receive their usual dose of Cystagon® every 6 hours (Q6H).~RP103 Phase: During Months 3.5, 4, 5, 6, 7 participants receive RP103 every 12 hours (Q12H).~Long Term Phase: On or after Month 7, for the remainder of study participants receive RP103 Q12H."
62705012|NCT03986021||At-risk girls|Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-\<15
62705013|NCT03986021||early post-menarche girls|Healthy, early post-menarchal girls age 8-\<15
62705014|NCT03986021||Healthy control women|Women age \>18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days
62705015|NCT03986021||late post-menarche girls|Late post-menarchal girls age 11-\<17.5 (gynecological age 2-5)
62705016|NCT03986021||pre-menarche girls|Healthy, pre-menarchal girls age 8-\<14.5
62705017|NCT03986021||Women with PCOS|Women diagnosed with PCOS \>18-34 at least 3-years post-menarchal with irregular menstrual cycles
62705018|NCT06060392|EXPERIMENTAL|Oral Semaglutide|Patient will receive oral semaglutide
62705019|NCT06060392|NO_INTERVENTION|Standard of care|Patient will receive standard of care
62705020|NCT02587403|ACTIVE_COMPARATOR|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
62705021|NCT02587403|ACTIVE_COMPARATOR|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
62705022|NCT06503497|EXPERIMENTAL|Chemotherapy Sequential NKG2D CAR-NK Cell|
62705023|NCT05886049|EXPERIMENTAL|Treatment (revumenib, daunorubicin, cytarabine)|See Detailed Description.
62705024|NCT01730131||Control Patients at Risk for PML|Participants with impaired immune function from any cause and considered at risk for PML
62705025|NCT01730131||Healthy Volunteers|Healthy volunteers without impaired immune function
62705026|NCT01730131||PML Patients|Participants with PML
62705027|NCT05455684|EXPERIMENTAL|Aticaprant|Participants will receive aticaprant tablets orally once daily for 42 days during double-blind treatment phase in addition to the current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy. Participants who will complete the double-blind treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study (67953964MDD3003).
62705028|NCT05455684|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally once daily for 42 days during double-blind treatment phase in addition to their current antidepressant (SSRI/SNRI) therapy. Participants who will complete the double-blind treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study (67953964MDD3003).
62705029|NCT05858034|OTHER|Activity Intervention|Customized selection of exercise and other community and online activity options to improve activity.
62705030|NCT05858034|OTHER|Nutrition Intervention|Development of a customized nutrition plan to address nutritional needs.
62705031|NCT06154252|EXPERIMENTAL|CABA-201|"DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with DM.~ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with ASyS.~IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with IMNM.~JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with JIIM."
62705032|NCT06145334|EXPERIMENTAL|Veterans Social|Peer-led weekly community-based social groups (16 weeks)
62705033|NCT05974280||Alofisel group (routine care)|The patient receives Alofisel injection as in routine care
62705034|NCT05974280||Autologous fat injection (routine care)|The back-up patient receives autologous fat stem cells injection as in routine care
62539310|NCT03928730|OTHER|Group I|Inflammatory swellings
62539311|NCT03928730|OTHER|Group II|Cystic swellings
62539312|NCT03928730|OTHER|Group III|Lymph node swellings
62539313|NCT03928730|OTHER|Group IV|Benign swellings
62705035|NCT06135792|EXPERIMENTAL|Arginine solution|Arginine treatment is performed outside the oral cavity (ex vivo) by immersing one side of a splint into a solution of arginine 1.5% (w/v). Treatment is performed 3 times a day for 30 min.
62705036|NCT06135792|PLACEBO_COMPARATOR|Placebo|Placebo treatment is performed outside the oral cavity (ex vivo) by immersing one side of a splint into distilled water. Treatment is performed 3 times a day for 30 min.
62705037|NCT06492616|EXPERIMENTAL|Elacestrant|Participants will receive 345 milligrams (mg) elacestrant once daily (QD) for 5 years
62705038|NCT06492616|EXPERIMENTAL|Standard of Care (SoC) Endocrine Therapy|"Participants will receive the SoC endocrine therapy that was used prior to randomization:~* AI (anastrozole 1 mg QD, letrozole 2.5 mg QD, or exemestane 25 mg QD); or~* Tamoxifen 20 mg QD"
62705039|NCT03825757|EXPERIMENTAL|Primaspan tablet 250 mg|Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
62705040|NCT03825757|PLACEBO_COMPARATOR|Placebo tablet|Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
62705041|NCT01621581|EXPERIMENTAL|Single Arm|AAV2-GDNF vector will be delivered to each patient
62705042|NCT01143519||FLT1 C-677T|SNP
62705043|NCT01143519||MDM2 rs2279744|SNP
62705044|NCT01143519||p53 rs1042522|SNP
62705045|NCT01143519||RMM1 rs1465952|SNP
62705046|NCT01143519||TLR8 rs3761624|SNP
62705047|NCT01674140|PLACEBO_COMPARATOR|Arm I|Patients receive an approved endocrine therapy comprising tamoxifen citrate\*, goserelin acetate\*\* or leuprolide acetate\*\*, or an aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
62705048|NCT01674140|EXPERIMENTAL|Arm II|Patients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
62705049|NCT01197378|EXPERIMENTAL|Cysteamine Bitartrate|Cysteamine bitartrate delayed-release capsules were administered twice daily for up to 96 months.
62705050|NCT05590351|EXPERIMENTAL|Intervention|m-health coaching application
62705051|NCT05590351|ACTIVE_COMPARATOR|Standard of care|Face to face counselling
62705052|NCT06390163|EXPERIMENTAL|Sensory-motor Integration Training|Patients in the study group will receive sensory-motor integration training for 60 minutes, 3 days a week for 8 weeks, in addition to their routine lives.
61963082|NCT02132091|EXPERIMENTAL|Intermittent Fasting|Intermittent Fasting
61963083|NCT02132091|EXPERIMENTAL|Intermittent Fasting + Antioxidants|Intermittent Fasting; 400 IU Vitamin E; 1000 mg Vitamin C
61963084|NCT02408315|PLACEBO_COMPARATOR|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
61963085|NCT02408315|PLACEBO_COMPARATOR|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
61963086|NCT00574132|EXPERIMENTAL|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
62506597|NCT03085368|EXPERIMENTAL|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
62705053|NCT06390163|NO_INTERVENTION|Standart Care|Patients in the control group will be asked to continue their routine lives and return for evaluation after 8 weeks. Individuals in the control group will be followed without any additional treatment or advice.
62705054|NCT03896750|ACTIVE_COMPARATOR|Part A Group 1A|6 healthy participants with normal renal function: Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR \> / = 90 mL/min) matched to Group 2 by race, gender, age (+/- 10 years, but between 18 to 85 years of age) and body mass index (BMI) (18 to 40 kg/m\^2) will receive a single oral dose of 200 mg pretomanid
62539314|NCT03928730|OTHER|Group V|Malignant swellings
62539315|NCT06232798|EXPERIMENTAL|A prospective, singlecenter, single-arm clinical study|
62705055|NCT03896750|EXPERIMENTAL|Part A Group 2|6 participants with severe renal impairment: Stage 4, Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR 15-29 mL/min), and End Stage Renal Disease (ESRD) not on dialysis: Stage 5, Modification of Diet in Renal Disease (MDRD) with estimated Glomerular Filtration Rate (eGFR \< 15 mL/min) matched to Group 1A will receive a single oral dose of 200 mg pretomanid
61963087|NCT00574132|PLACEBO_COMPARATOR|Placebo Control|infusion every 13 weeks for a total of 6 infusions.
62348752|NCT03700736|ACTIVE_COMPARATOR|Facebook|"Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via a private (secret) Facebook group. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. A study counselor will facilitate discussions about the topics posted in the Facebook group. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to download the MyFitnessPal app to track daily diet."
62506598|NCT03085368|ACTIVE_COMPARATOR|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
62506599|NCT03085368|ACTIVE_COMPARATOR|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
62506600|NCT02215668|NO_INTERVENTION|No physical exercise|Women are never subjected to any exercise prior to mammography.
62506601|NCT02215668|EXPERIMENTAL|Physical exercise (Upper limb)|Women will be subjected to physical exercise on upper limb prior to mammography.
61963088|NCT00574132|EXPERIMENTAL|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
61963089|NCT00637338|EXPERIMENTAL|PF-04603629|The dose range initially planned is 3 mg up to 70 mg, although the specific doses administered may be modified based on emerging study data.
61963090|NCT00637338|PLACEBO_COMPARATOR|Placebo|
61963091|NCT06217198|EXPERIMENTAL|Deprexis|Deprexis: an internet-delivered psychosocial treatment for depressive symptoms and related functional impairment.
61963092|NCT06217198|NO_INTERVENTION|Treatment-as-Usual|Access to standard non-study care
61963093|NCT03833115|EXPERIMENTAL|vaginal gel containing sodium lauryl sulfate|
62506602|NCT02215668|ACTIVE_COMPARATOR|Group 2|Women are subjected to physical exercise in the lower limbs prior to mammography
62506603|NCT02419573|ACTIVE_COMPARATOR|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
61963094|NCT01032005|PLACEBO_COMPARATOR|Fortified salt|Common table salt that has been fortified with iodine only
61963095|NCT01032005|EXPERIMENTAL|Double fortified salt|Common table salt that has been fortified with iron and well as the usual iodine
61963096|NCT01211327|EXPERIMENTAL|Cyclosporine A|Cyclosporine A (CsA) 2% eye drops
61963097|NCT01211327|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 0,1% eye drops
62506604|NCT02419573|ACTIVE_COMPARATOR|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
62506605|NCT00145613|OTHER|1|
62506606|NCT00549341|ACTIVE_COMPARATOR|1|
62506607|NCT00549341|PLACEBO_COMPARATOR|2|
62506608|NCT01805635||Children suspected of allergic diseases|Children suspected of allergic diseases No intervention
62506609|NCT00975390|EXPERIMENTAL|1|Carbohydrate ingestion
62506610|NCT00975390|EXPERIMENTAL|2|Carbohydrate and protein ingestion
62506611|NCT00975390|EXPERIMENTAL|3|Carbohydrate and caffeine ingestion
62506612|NCT03566238|EXPERIMENTAL|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
62506613|NCT03566238|EXPERIMENTAL|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
61963098|NCT00630981||Intervention group|"Combined psychotherapy and pharmacological treatment~Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.~Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered."
61963099|NCT03143894|ACTIVE_COMPARATOR|Active tDCS first|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
61963100|NCT03143894|SHAM_COMPARATOR|Sham tDCS first|Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.
61963101|NCT01180946|ACTIVE_COMPARATOR|Ergocalciferol|Weekly ergocalciferol for 16 weeks
61963102|NCT01180946|PLACEBO_COMPARATOR|Placebo|Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
61963103|NCT03938168||Pain patients|30 patients eligible for adhesiolysis because of chronic adhesion-related pain. Patients are recruited at the RadboudUMC, MUMC+ and Pantein hospital departments of surgery. These are patients with chronic pain after previous abdominal surgery who have been selected for operative treatment after evaluated with CineMRI. CineMRI is used to map adhesions. This technique has been established to provide insight in localization of adhesions in relation to the pain, and risk of bowel injury based on extensiveness of adhesions.
61963104|NCT03938168||Control group|The control group will comprise of 30 patients undergoing an abdominal reoperation during which adhesiolysis has to be performed for reasons other than chronic adhesion-related pain.
62506614|NCT03566238|PLACEBO_COMPARATOR|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
62506615|NCT00869687|OTHER|Poly-L-Lactic Acid Injection|
61963105|NCT05581420|ACTIVE_COMPARATOR|Oral iron|"Ferrous fumarate 200mg daily for 4 weeks.~Group A1 (Normal Hb at week 4):~Ferrous fumarate 100mg daily for 12 weeks~Group A2 (Abnormal Hb at week 4):~Ferrous fumarate 200mg daily for 8 weeks~Group A2 at week 12:~Normal Hb: ferrous fumarate 100 mg daily till week 16 Abnormal Hb: intervention failure. End of study."
61963106|NCT05581420|ACTIVE_COMPARATOR|IV Iron|Dosage based on iron formulation and instructions according to recommended guidelines (weight of patient)
62506616|NCT03814915||Study 1 - Prediabetes|"The primary objective of Study 1 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in non-diabetic high-risk participants.~Participants in Study 1 were recruited from existing prospective cohort studies in or around each of the following European cities: Malmö, Sweden (Malmö Diet and Cancer Study); Amsterdam, The Netherlands (Hoorn Study); Copenhagen, Denmark (Inter99); and Kuopio, Finland (METSIM). A clinically practicable screening tool (DIRECT-DETECT) was used to identify at-risk participants from existing cohort studies, who were then recruited into this new prospective cohort study (Study 1)."
62506617|NCT03814915||Study 2- Diabetic|The primary objective of Study 2 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in people who have recently been diagnosed with type 2 diabetes. Participants in Study 2 of DIRECT are recruited from or nearby each of the following European cities: Malmö, Sweden; Amsterdam, the Netherlands; Copenhagen, Denmark; Exeter, UK; Newcastle, UK; Dundee, UK. Potential participants are recruited through targeted searches of existing databases and research registers combined with person-to-person contact at educational clinics and through routine retinal screening programmes.
62506618|NCT06109857||Observational|Patients undergo blood and urine sample collection and have their medical records reviewed while on study.
62506619|NCT00688402|EXPERIMENTAL|1|IR Formulation 65 mg
62506620|NCT00688402|EXPERIMENTAL|2|IR Formulation 150 mg
62506621|NCT00688402|EXPERIMENTAL|3|MR formulation, 1h 65 mg
62506622|NCT00688402|EXPERIMENTAL|4|MR Formulation, 1h 150 mg
62506623|NCT00688402|EXPERIMENTAL|5|MR Formulation, 2h 150 mg
62506624|NCT02636829|EXPERIMENTAL|Multiple Sclerosis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
62506625|NCT02636829|EXPERIMENTAL|Rheumatoid Arthritis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
62506626|NCT05583877|EXPERIMENTAL|Intervention - Diabetes BOOST|Intervention group participants will complete a baseline survey, receive a referral to DSMT from the research team, a mailed welcome letter and self-care education sent via a series of personalized patient portal secure messages, text messages, and video call. They will be sent text messages with information about one of the American Association of Diabetes Educators 7 self-care behaviors and will receive encouragement to author their own self-management behavioral goals. Participants will also complete a telehealth training video call with research staff to review the functionality of their patient portal and refine diabetes-related goals. The participant will then be encouraged to send a patient portal message to their DSMT CDCES that includes their personalized goals prior to their scheduled DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
62506627|NCT05583877|ACTIVE_COMPARATOR|Usual Care|Comparison Group participants will complete a baseline survey, receive a DSMT referral request from research team to their primary care provider and a mailed welcome letter. The mailed letter will welcome the participant to the study and contain general information about diabetes self-care behaviors and goal setting. They will complete a DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
62506628|NCT06251960|EXPERIMENTAL|socket preservation with completely demineralized dentin graft.|
62506629|NCT06251960|EXPERIMENTAL|socket preservation with partially demineralized dentin graft.|
62506630|NCT04403399|EXPERIMENTAL|Varenicline then Placebo|Varenicline 0.5 mg BID orally for 3 weeks, followed by a 3-week washout period, then placebo BID orally for 3 weeks
62506631|NCT04403399|EXPERIMENTAL|Placebo then Varenicline|Placebo BID orally for 3 weeks, followed by a 3-week washout period, then Varenicline 0.5 mg BID orally for 3 weeks
62506632|NCT04643392||Patients with Lipedema|Participants who were diagnosed with upper extremity lipedema by a lymphologist.
62506633|NCT02951936|EXPERIMENTAL|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
62506634|NCT02951936|SHAM_COMPARATOR|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment
62506635|NCT05531851|EXPERIMENTAL|Experiment group.|İnstrument-assisted soft tissue mobilization will be applied after the delayed onset muscle soreness induction protocol
62506636|NCT05531851|NO_INTERVENTION|Control Group|Delayed onset muscle soreness generation protocol will be applied
62506637|NCT02558465||Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxavban administration group
62506638|NCT03993327|EXPERIMENTAL|Diagnostic (iodine I 124 monoclonal antibody M5A, PET scan)|Patients receive iodine I 124 monoclonal antibody M5A IV on day 0 and undergo PET scan on days 2 and 6.
62506639|NCT04413032|EXPERIMENTAL|Patients with MS|30 Patients with MS will use the DreaMS App over a study duration of 6 weeks.
62506640|NCT04413032|EXPERIMENTAL|Healthy Volunteers|30 Healthy Volunteers will use the DreaMS App over a study duration of 6 weeks.
62506641|NCT02321124|ACTIVE_COMPARATOR|intervention|we will apply connective tissue manipulation and life style advice.
62506642|NCT02321124|OTHER|control group|We will apply only life style advice.
62506643|NCT04691440|EXPERIMENTAL|HBOT|Hyperbaric oxygen breathing at 2.4 atm.abs for 90 minutes. The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
62348753|NCT03700736|ACTIVE_COMPARATOR|Traditional|Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
62348754|NCT02374034|EXPERIMENTAL|Treatment|Experimental group (n=20) completed a corrective exercise routine, as per the Egoscue Method, at least five days per week for two weeks.
62348755|NCT02374034|NO_INTERVENTION|Control|The control group maintained their current lifestyle for the two-week duration of the study.
62348756|NCT01911299|EXPERIMENTAL|Choline|Liquid glycerophosphocholine (GPC) supplement
62348757|NCT01911299|PLACEBO_COMPARATOR|Placebo|Liquid placebo supplement
62506644|NCT03224078||adult Emergency Department Patients|adult patients that were treated with any condition in one of the participating emergency departments in 2016 (n≈680.000 cases)
62506645|NCT03153826|OTHER|Patients|
62348758|NCT01352065|EXPERIMENTAL|BOSENTAN|
62348759|NCT01352065|EXPERIMENTAL|AMBRISENTAN|
62348760|NCT01352065|PLACEBO_COMPARATOR|PLACEBO|
62348761|NCT01682577|EXPERIMENTAL|Perindopril 4 mg tablets of PT Dexa Medica|"Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects."
62348762|NCT01682577|ACTIVE_COMPARATOR|Perindopril 4 mg tablets of Servier|"Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects."
62506646|NCT04938973|EXPERIMENTAL|NIF-Guided RAMIE using ICG Dye (Experimental Arm)|The patient will undergo NIF-guided RAMIE using ICG dye using the standard Ivor-Lewis approach. This will be a two-stage operation involving a first stage through a 5-port robotic approach through the abdomen to achieve a proximal gastrectomy and D2 nodal dissection. A feeding jejunostomy would not be inserted, as per the enhanced recovery pathway for esophagectomy. In addition, the vascularization of the conduit can be confirmed using the near-infrared camera of the robot with the ICG dye. The second stage of the operation will involve a 4-port robotic approach through the right chest to achieve thoracic nodal dissection, esophagectomy, and a hand-sewn anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein. During this second stage of the operation, NIF with ICG dye will be used to visualize the vascular supply of the gastric conduit, and assess the gastric conduit for any perfusions to potentially reduce anastomotic leaks.
62506647|NCT04938973|ACTIVE_COMPARATOR|Open Transthoracic Esophagectomy (OTE)|The patient will undergo OTE using the standard Ivor-Lewis approach. This is a two-stage operation involving a first stage through laparotomy, proximal gastrectomy, D2 nodal dissection, and insertion of feeding jejunostomy. The second stage of the operation will involve a right thoracotomy, thoracic nodal dissection, esophagectomy, and a stapled anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein.
62506648|NCT03629106|EXPERIMENTAL|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level \<20 ng/ml.
62506649|NCT03629106|EXPERIMENTAL|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
62506650|NCT04581876|EXPERIMENTAL|raltitrexed for injection + nab-paclitaxel|Patients receive raltitrexed 2mg/m2 (iv, 15min) and nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
62506651|NCT03882411|EXPERIMENTAL|Electronic shared decision making (eSDM) Tool|"In the pre-intervention period, patients in clinic clusters will receive usual care.~When a clinic cluster's randomly allotted intervention period arrives, coronary heart disease patients in that given clinic cluster will complete a web application, which delivers screening, behavioral activation and shared decision making (eSDM), and providers will receive education and a patient preference report generated from the application.~During both the pre and post intervention periods, patients will be assessed at baseline and 6 month follow up."
62506652|NCT04099641|EXPERIMENTAL|bavituximab and pembrolizumab|Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks
62506653|NCT00759278||1|Group of 30 women who are pregnant as subjects that take antihypertensive medication
62506654|NCT00759278||2|Group of 30 women who are pregnant and do not take antihypertensive medications as a control group
62506655|NCT05250206|EXPERIMENTAL|Myopia Control Lens|
62506656|NCT01215903|EXPERIMENTAL|Fish gelatin and omega-3|
62506657|NCT01215903|EXPERIMENTAL|Omega-3|
62506658|NCT02009709|ACTIVE_COMPARATOR|9 mW/cm2|CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
62506659|NCT02009709|ACTIVE_COMPARATOR|18 mW/cm2|CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution
62506660|NCT02596633|NO_INTERVENTION|Treatment as Usual|Participants carry on with their usual care
62506661|NCT02596633|ACTIVE_COMPARATOR|Intervention|ACT self help book with telephone support calls; Telephone-support Acceptance and Commitment therapy (ACT)
62506662|NCT05118477|EXPERIMENTAL|AMS group|Patients randomised to the intervention group will receive the AMS; this will be connected to the dashboard and the alerting system. Clinical staff will have access to the dashboard and alerted accordingly for the assigned patients.
62506663|NCT05118477|ACTIVE_COMPARATOR|Standard Care group|"Patients in the control group will also receive the AMS however this will not be connected to the ward dashboard and clinical staff will not be able to access these patient's continuous vital signs:~* Patient will not appear on the ward dashboard~* No alerting system will be given to staff"
62348763|NCT01824693|EXPERIMENTAL|Arm I (busulfan, cyclophosphamide, melphalan)|"CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.~TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
62506664|NCT00855764|EXPERIMENTAL|Paclitaxel|
62506665|NCT05555927|EXPERIMENTAL|active tDCS|tDCS devices (Neuroelectrics, Starstim 8, USA) are used. The anode and cathode electrodes are inserted in saline-soaked sponges with diameter of 3.2cm and then positioned over the left and right dorsolateral prefrontal cortex (DLPFC) using specific headgear. Each session uses a 2mA current and lasts 60 minutes. Ten sessions are daily performed.
62506666|NCT05555927|SHAM_COMPARATOR|sham tDCS|The anode and cathode electrodes are inserted in saline-soaked sponges with diameter of 3.2cm and then positioned over the left and right dorsolateral prefrontal cortex (DLPFC) using specific headgear. Each session uses a 2mA current and lasts 60 minutes. Ten sessions are daily performed. For sham, the current rapidly ramp up to 2mA over the first 30s and rapidly ramped down to 0mA over the next 30s automatically to allow participants to feel typical initial sensations of active tDCS.
62506667|NCT03336918||Bipolar Disorder I or II Depressed|DSM-V Bipolar I or II Depressed treated with lithium
62506668|NCT03336918||Healthy Controls|Healthy Controls with no psychiatric history
62506669|NCT05287399|EXPERIMENTAL|ASC61 200 mg 1|ASC61 200 mg orally once
62348764|NCT01824693|EXPERIMENTAL|Arm II (busulfan, fludarabine phosphate)|"CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.~TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
62506670|NCT05287399|EXPERIMENTAL|ASC61 200 mg 2|ASC61 200 mg orally twice daily
62705056|NCT03896750|ACTIVE_COMPARATOR|Part B Group 1B|6 healthy participants with Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR of \> / = 90 mL/min) matched to Group 3 by race, gender, age (+/- 10 years, but between 18 to 85 years of age) and body mass index (BMI) (18 to 40 kg/m\^2) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
62348765|NCT04925518|ACTIVE_COMPARATOR|Conventional Ventilation Mode|Patients mechanically ventilated with a conventional mechanical ventilation mode until steady state is achieved for several hours.
62506671|NCT05287399|EXPERIMENTAL|ASC61 300 mg|ASC61 300 mg orally twice daily
62506672|NCT05287399|EXPERIMENTAL|ASC61 400 mg|ASC61 400 mg orally twice daily
62506673|NCT05287399|EXPERIMENTAL|ASC61 600 mg|ASC61 600 mg orally twice daily
62506674|NCT00717782|EXPERIMENTAL|1|"Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland).~A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
62506675|NCT00717782|PLACEBO_COMPARATOR|2|"Patients in the placebo group received a 0·6-ml injection of saline.~A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
62506676|NCT05212441|EXPERIMENTAL|Group A (LED group)|This group includes 30 burned patients who will receive LED therapy in addition to their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
62506677|NCT05212441|ACTIVE_COMPARATOR|Group B (Control group)|This group includes 30 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
62506678|NCT00664287|EXPERIMENTAL|Group 1|Patients will remain on existing lipid-modifying therapy throughout the study. Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
62144055|NCT03715985|EXPERIMENTAL|NeoPepVac|Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
62506679|NCT00664287|PLACEBO_COMPARATOR|Group 2|Patients will remain on existing lipid-modifying therapy throughout the study. Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
62506680|NCT03245216|EXPERIMENTAL|aerobic exercise + motor skill practice|acute bout of aerobic exercise before motor learning
62506681|NCT03245216|ACTIVE_COMPARATOR|rest + motor skill practice|seated rest before motor learning
62506682|NCT06616038||heart failure patients (HFrEF and HFpEF) without atrial fibrillation|Will be enrolled 57 patients with heart failure patients (HFrEF and HFpEF) without atrial fibrillation
62506683|NCT06616038||heart failure patients (HFrEF and HFpEF) with atrial fibrillation|Will be enrolled 57 patients with heart failure patients (HFrEF and HFpEF) with atrial fibrillation
62506684|NCT05029934|ACTIVE_COMPARATOR|EndoClot group|patients who are being provided with EndoClot adhesive spray after polyp resection
62506685|NCT05029934|SHAM_COMPARATOR|Control group|no further prophylactic bleeding prevention after polyp resection
62506686|NCT00843830|EXPERIMENTAL|Treatment Arm|Participants will receive tumoral irradiation and dendritic cell vaccination.
62506687|NCT06028646|EXPERIMENTAL|Dynamic Airway CT scan (DA-CT)|All participants will have a DA-CT scan after flexible bronchoscopy has been performed.
62506688|NCT03729518|EXPERIMENTAL|Arm 1|All patients will have the volume treated and radiation dose delivered to the regional lymphatics decreased according to the characteristics of the primary site and involved lymph nodes. The high risk neck will receive 50 Gy instead of 60 Gy, and the treated volume of the contralateral low risk neck will be reduced and receive only 45 Gy.
62506689|NCT00513617|ACTIVE_COMPARATOR|Low Dose|0.05 g/kg/day Arginine
62506690|NCT00513617|ACTIVE_COMPARATOR|High Dose|0.10 g/kg/day Arginine
62506691|NCT00513617|PLACEBO_COMPARATOR|Placebo|No Arginine
62705057|NCT03896750|ACTIVE_COMPARATOR|Part B Group 1C|6 healthy participants: with Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR \> / = 90 mL/min) matched to Group 4 by race, gender, age (+/- 10 years, but between 18 to 85 years of age) and body mass index (BMI) (18 to 40 kg/m\^2) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
62348766|NCT04925518|EXPERIMENTAL|Closed Loop Ventilation Mode|Once steady state on the conventional mechanical ventilation mode is achieved for several hours, switch to closed loop ventilation mode for the remainder of the study period.
62506692|NCT05808166|EXPERIMENTAL|Pregnant participant receiving Hecolin®|"1 (N=1,104): Pregnant participants receiving Hecolin® (n=150 immunogenicity subset).~For Arm 1, pregnant participants will receive 2 doses of Hecolin® at a 4 weeks interval and the third dose will be administered postpartum, approximately 20 weeks after the second dose."
62705058|NCT03896750|EXPERIMENTAL|Part B Group 3|6 participants with mild renal impairment: Stage 2, Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR 60-89 mL/min) matched to Group 1B will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
62705059|NCT03896750|EXPERIMENTAL|Part B Group 4|6 participants with moderate renal impairment: Stage 3, Modification of Diet in Renal Disease (MDRD) estimated Glomerular Filtration Rate (eGFR = 30-59 mL/min) matched to Group 1C will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
62348767|NCT01261546|EXPERIMENTAL|Dexamethasone|"* Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
62348768|NCT01261546|PLACEBO_COMPARATOR|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
62348769|NCT05092295||TBI Patients|TBI participants 13 to 45 years of age, recruited from patients at a clinical research facility who present with head trauma. Clinical evaluation for the patient can be positive (target condition present) or negative (target condition absent) for mTBI. Enrollment is to occur within 2 weeks of the incident injury.
62348770|NCT05092295||Controls|Participants should not be part of the Intended Use Population. Subjects that present to the hospital, clinic or emergency department, either as a patient or non-patient, with no history of head trauma.
62348771|NCT03812588|PLACEBO_COMPARATOR|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
62348772|NCT03812588|PLACEBO_COMPARATOR|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
62348773|NCT03812588|ACTIVE_COMPARATOR|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
62348774|NCT03812588|ACTIVE_COMPARATOR|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
62348775|NCT04060576|EXPERIMENTAL|Group A treated with a 16-gauge needle|Group A is intervened on the gastrocnemius muscle with a 16-gauge needle.
62348776|NCT04060576|EXPERIMENTAL|Group B treated with a 25-gauge needle|Group B is intervened on the gastrocnemius muscle with a 25-gauge needle.
62348777|NCT04060576|EXPERIMENTAL|Group C treated with a 32-gauge needle|Group C is intervened on the gastrocnemius muscle with a 32-gauge needle.
62348778|NCT05534035|EXPERIMENTAL|PTX-COVID19-B|
62348779|NCT05534035|ACTIVE_COMPARATOR|Vaxzevria®|
62348780|NCT05421221|EXPERIMENTAL|olfactory training group|"12 weeks of olfactory traiing with Sniffin' sticks Duftquartett."
62348781|NCT05421221|NO_INTERVENTION|no olfactory training with natural history of the disease|natural history of the disease
62348782|NCT03332472|EXPERIMENTAL|Telemedicine group|Telematics visit in front of the conventional visit face to face
62348783|NCT03332472|PLACEBO_COMPARATOR|Conventional group|Group with conventional medical visit
62348784|NCT01790711|EXPERIMENTAL|FMT by endoscopy|Once, fresh or frozen bacteria
62506693|NCT05808166|PLACEBO_COMPARATOR|Pregnant participants receiving placebo|"Arm 2 (N=1,104): Pregnant participants receiving placebo (n= 150 immunogenicity subset).~For Arm 2, pregnant participants will receive 2 doses of placebo at a 4 weeks interval and the third dose will be administered postpartum, approximately 20 weeks after the second dose."
62506694|NCT05808166|ACTIVE_COMPARATOR|Non-Pregnant participants receiving Hecolin®|"Arm 3 (N=150): Non-Pregnant participants receiving Hecolin® (n= 150 immunogenicity subset).~For Arm 3, non-pregnant participants will receive Hecolin® at 0-1-6 months schedule."
62144056|NCT01503099||Active ITB|Patients with active intestinal tuberculosis (ITB)
62144057|NCT01503099||Controls India|Healthy subjects serving as controls
62144058|NCT01503099||CD India|Patients with active Crohn's Disease (CD) in India
62348785|NCT02604862|EXPERIMENTAL|FIB ONE administration|All participants in this clinical study will be dosed on one occasion with FIB ONE. The final dosage will be less than 100 µg.
62348786|NCT02604862|EXPERIMENTAL|AZD1236 administration|To quantify the change in mean FIB ONE fluorescence amplification gradient in the presence of AZD1236 in the fibroproliferative lung
62705060|NCT06454838||Children with pulmonary arterial hypertension|Pulmonary function (spirometer), respiratory muscle strength (mouth pressure device), upper extremity exercise capacity (Six minutes PegBoard Ring Test) and lower extremity exercise capacity (Six minutes walk test), muscle oxygenation ('Moxy' monitor device), dyspnea (modified Borg Scale), peripheral muscle strength (hand-held dynamometer), arterial stiffness (arteriograph), physical activity level (multi-sensor activity monitor) and static balance (balance system with computed) will be evaluated.
62348787|NCT00869388|EXPERIMENTAL|Arm 1|rBBX-01 1.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
62348788|NCT00869388|EXPERIMENTAL|Arm 2|rBBX-01 2.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
62348789|NCT00869388|EXPERIMENTAL|Arm 3|rBBX-01 4.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
62348790|NCT00869388|EXPERIMENTAL|Arm 4 (optional)|rBBX-01 8.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
62705061|NCT06454838||Age- and sex- matched healthy controls|Pulmonary function (spirometer), respiratory muscle strength (mouth pressure device), upper extremity exercise capacity (Six minutes PegBoard Ring Test) and lower extremity exercise capacity (Six minutes walk test), muscle oxygenation ('Moxy' monitor device), dyspnea (modified Borg Scale), peripheral muscle strength (hand-held dynamometer), arterial stiffness (arteriograph), physical activity level (multi-sensor activity monitor) and static balance (balance system with computed) will be evaluated.
62705062|NCT00862433|EXPERIMENTAL|Arm 1|Determine optimal fat content of meal for optimal absorption of vitamin E
62705063|NCT00862433|EXPERIMENTAL|Arm 2|Determine optimal dose of vitamin E.
62705064|NCT00862433|EXPERIMENTAL|Arm 3|Investigate the relationship between vitamin C status and vitamin E turnover
62705065|NCT00862433|EXPERIMENTAL|NAFLD sub-study|Investigate the relationship between fatty liver disease and vitamin E turnover.
62506695|NCT05062148|NO_INTERVENTION|Standard of Care|Subjects will follow the standard of care, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
62506696|NCT05062148|ACTIVE_COMPARATOR|Float-REST|Subjects will do Flotation Restricted Environmental Stimulation Therapy, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
62506697|NCT05062148|ACTIVE_COMPARATOR|Photobiomodulation|Subjects will do photobiomodulation, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
62506698|NCT03549455|EXPERIMENTAL|Exposure Therapy and Self Distancing|All subjects will have 2 introduction sessions and then receive Exposure therapy with Self-Distancing (2 weeks) following Exposure therapy without Self-Distancing (2 weeks) followed by 2 more weeks of Exposure therapy with Self-Distancing.
62506699|NCT03381196|EXPERIMENTAL|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
62506700|NCT03381196|PLACEBO_COMPARATOR|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
62348791|NCT01756872||Ovarian reserve study participants|Measurements of ovarian reserve for women attending the Oxford Fertility Unit having their first IVF/IVF-ICSI cycle.
62506701|NCT02546050|EXPERIMENTAL|Metformin|18 weeks study with intervention during week 6 to 12: the intervention consist of 500 mg of metformin once daily for week 7, then 500 mg twice daily week 8, 1000 mg + 500 mg daily week 9 and 1000 mg + 1000 mg daily for weeks 10-12.
62506702|NCT00774943|ACTIVE_COMPARATOR|AMG 557|
62506703|NCT00774943|PLACEBO_COMPARATOR|Placebo|
62348792|NCT02555657|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Qualified participants who receive first course of pembrolizumab but continue to experience disease progression may, at investigator's discretion, initiate a second course of pembrolizumab at 200 mg IV Q3W for up to 17 administrations (up to \~1 year).
62348793|NCT02555657|ACTIVE_COMPARATOR|Chemotherapy|Participants receive capecitabine, eribulin, gemcitabine, or vinorelbine as TPC in accordance with local regulations and guidelines.
62348794|NCT03562754|ACTIVE_COMPARATOR|Control|
62506704|NCT01567241|PLACEBO_COMPARATOR|Relaxation music|
62506705|NCT01567241|EXPERIMENTAL|Clinical hypnosis|
62705066|NCT04512716|EXPERIMENTAL|B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell Lym|Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma
62705067|NCT01581554||Patients with HBeAg negative chronic hepatitis B|Patients with HBeAg negative chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
62705068|NCT01581554||Patients with HBeAG positive chronic hepatitis B|Patients with HBeAg positive chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
62705069|NCT01629108||1|Healthy volunteers aged 5 to 80
62705070|NCT05172258|EXPERIMENTAL|Arm I (ipatasertib, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ipatasertib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, undergo collection of blood samples on study and during follow up, and undergo CT scans throughout the trial.
62348795|NCT03562754|EXPERIMENTAL|Prometheus System|
62348796|NCT06364761||Bag in the lens|Patients who underwent bag in the lens cataract surgery at least 3 months before inclusion in the University Hospital Brussels, Belgium.
62348797|NCT01381718|EXPERIMENTAL|Arm I|Participants receive modafinil orally (PO) once daily (QD) on days 1-42.
62348798|NCT01381718|PLACEBO_COMPARATOR|Arm II|Participants receive placebo PO QD on days 1-42.
62348799|NCT06372886||Preservation of portal/superior mesenteric vein|
62348800|NCT06372886||Resection of portal/superior mesenteric vein|
62348801|NCT05216068|OTHER|donated abandonment embryos|Embryos biopsies for PGT-A (by use of NGS platforms from our institute) will be used for the validation of our Lab QC.
62348802|NCT06521866|EXPERIMENTAL|Group A|"Group A (Left-sided wild-type):~Induction therapy (up to 24 weeks):~Toripalimab: 240 mg IV on Day 1, every 3 weeks Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Toripalimab: 240 mg IV on Day 1, every 3 weeks Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
62348803|NCT06521866|EXPERIMENTAL|Group B|"Group B (Left-sided wild-type):~One cycle of Toripalimab combined with Cetuximab and chemotherapy, followed by Stereotactic ablative radiotherapy（SABR: 25-60 Gy/5 Fx）, then continued Toripalimab combined with Cetuximab and chemotherapy."
62348804|NCT06521866|EXPERIMENTAL|Group C|"Group C (Right-sided or RAS-mutant): Induction therapy (up to 24 weeks):~Toripalimab: 240 mg IV on Day 1, every 3 weeks Bevacizumab: 5 mg/kg IV on Day 1 Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Toripalimab: 240 mg IV on Day 1, every 3 weeks Bevacizumab: 5 mg/kg IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
62348805|NCT06521866|EXPERIMENTAL|Group D|Group D (Right-sided or RAS-mutant): One cycle of Toripalimab combined with Bevacizumab and chemotherapy, followed by Stereotactic ablative radiotherapy（SABR: 25-60 Gy/5 Fx）, then continued Toripalimab combined with Bevacizumab and chemotherapy.
62348806|NCT03040765|ACTIVE_COMPARATOR|Denosumab|"Denosumab 60 MG/ML Prefilled Syringe~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)"
62348807|NCT03040765|ACTIVE_COMPARATOR|Zoledronic Acid|"Zoledronic Acid 5Mg/Bag 100Ml Inj~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year"
62348808|NCT03143556|EXPERIMENTAL|Magnetic Stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for magnetic stent group will receive magnetic stent and the removal of stent would be done by help of magnetic device.
62348809|NCT03143556|NO_INTERVENTION|Routine stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for routine stent would receive routine stent and the removal of stent would be done by cystoscopy
62348810|NCT03721237|EXPERIMENTAL|EBC-assisted|A nasogastric tube, equipped with esophageal and gastric balloons, will be inserted in each patient enrolled in the study. After definitive catheter positioning has been obtained, Esophageal ballon calibration will be run in volume-controlled ventilation, pressure support ventilation and sigh + pressure support ventilation.
62348811|NCT05896046|EXPERIMENTAL|Phase I/ II: SHR1701|Phase I: 30-150 mg/kg, IV over 30 minutes, every 3 weeks. Phase II: recommended dose from phase I trial, IV over 30 minutes, every 3 weeks.
62348812|NCT05896046|EXPERIMENTAL|Phase II: SHR2554+ SHR170|SHR2554: 350mg/day, PO, twice a day, every 3 weeks. SHR1701: recommended dose from phase I trial, IV over 30 minutes, every 3 weeks.
62348813|NCT02229110|ACTIVE_COMPARATOR|Signal|In addition to usual care, there will be an automatic signal in the electronic medical record (EMR) upon opening that will show the reader that the patient is currently not treated in the correct treatment setting and it simultaneously will give advice to which treatment allocation this patient should be transferred to.
62506706|NCT04542694|EXPERIMENTAL|Favipiravir (Areplivir)|"Arm 1 (n=100) receives the study drug Areplivir film-coated tablets:~on day 1 of therapy - 1600 mg (8 tablets) 2 times a day; on days 2-14 of treatment - 600 mg (3 tablets) 2 times a day. The drug is taken orally every 12 hours, swallowing whole tablet without chewing and washing down with a glass of water. The course of treatment is 14 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient."
61963107|NCT04206501|EXPERIMENTAL|ICM guided Medical Management Group|A pre-specified management regimen based on standard clinical practice will be provided to the study team in which medical management including medication dosing (focusing on beta-blockers and diuretics) will be monitored and modified using Cardiac Implantable Electronic Devices (CIED) and OptiVol Monitor data. Based on CIED and patient engagement data, the study team will adjust medications and dosages, and optimize activity/exercise steps.
62144059|NCT01503099||Active PTB|Patients with active pulmonary tuberculosis (PTB)
62348814|NCT02229110|NO_INTERVENTION|No signal|Patients receive usual care, consisting of 4 office visits yearly
62348815|NCT01925651|OTHER|Standard Risk - No bolus|No Bolus
62348816|NCT01925651|OTHER|Standard Risk - Alternate Bolus|Alternate 5mm Bolus
62348817|NCT01925651|OTHER|High Risk - Alternate Bolus|Alternate 5mm Bolus
62348818|NCT01925651|OTHER|High Risk - Continuous bolus|Continuous 5mm bolus
62348819|NCT01515280||Chronic cough|Patients taking part in supplementary study must be randomised to main study which includes a placebo arm and treatment arm
62348820|NCT02709928|EXPERIMENTAL|TD-0714|Capsule formulation
62348821|NCT02709928|PLACEBO_COMPARATOR|Placebo|Capsule formulation
62348822|NCT00703469|EXPERIMENTAL|1|
62348823|NCT00703469|PLACEBO_COMPARATOR|2|
62348824|NCT03277703|EXPERIMENTAL|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
61963108|NCT04206501|NO_INTERVENTION|Conventional Management Control Group|Non-study physicians will receive CIED/OptiVol data (as in usual care) and its use and the management strategy will be left to his/her discretion. To control for patient contact, patients in the conventional management group will have the same study visits as the interventional group and will include in-person device interrogation, and documentation of any medications changes.
61963109|NCT03129698|OTHER|Formerly Arm Label|Apatinib 250mg daily
61963110|NCT05779995|EXPERIMENTAL|C1-XW001|Low dose of XW001 once daily
61963111|NCT05779995|PLACEBO_COMPARATOR|C1-Placebo|Matched Placebo once daily
61963112|NCT05779995|EXPERIMENTAL|C2-XW001|Medium dose of XW001 once daily
61963113|NCT05779995|PLACEBO_COMPARATOR|C2-Placebo|Matched Placebo once daily
61963114|NCT05779995|EXPERIMENTAL|C3-XW001|High dose of XW001 once daily
61963115|NCT05779995|PLACEBO_COMPARATOR|C3-Placebo|Matched Placebo once daily
61963116|NCT03975608|EXPERIMENTAL|"Adaptation of CALM"|"This is the patient group that receives the intervention (IG), i.e., the psychotherapeutic treatment, i.e., the adapted version of the psychotherapeutic program Managing Cancer and Living Meaningfully (CALM) which was originally designed for patients with cancer."
61963117|NCT01850771|ACTIVE_COMPARATOR|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
61963118|NCT01850771|ACTIVE_COMPARATOR|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
61963119|NCT00496054|EXPERIMENTAL|RotaTeq™ Vaccine (V260)|Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.
61963120|NCT01312701||cancer patients|as described patietns with solid cancer about to be treated with anticancer therapies
61963121|NCT01312701||control group|normal populations who domated blood for further use
61963122|NCT02095574|EXPERIMENTAL|[14C]ABT-199|Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
61963123|NCT04614740|EXPERIMENTAL|VC004|1. Dose escalation stage: subjects in the 50 mg, 100 mg, 200 mg, and 300 mg dose groups took a single oral dose on the first day; starting from the fourth day, each group of subjects took the corresponding dose twice a day. 2. Dose expansion stage: subjects in the 100mg and 200mg dose groups took the corresponding dose twice a day on an empty stomach; 3. Phase II clinical trial stage: oral administration twice a day before meals, and the dosage is to be determined.
61963124|NCT03636061|ACTIVE_COMPARATOR|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL
61963125|NCT03636061|ACTIVE_COMPARATOR|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL
61963126|NCT03636061|ACTIVE_COMPARATOR|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL
61963127|NCT03636061|PLACEBO_COMPARATOR|Placebo|Placebo (vehicle) nasal spray
62348825|NCT03277703|ACTIVE_COMPARATOR|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
62506707|NCT04542694|ACTIVE_COMPARATOR|Standard of care|"Arm 2 (n=100) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health (but not Favipiravir) by decision of the investigator and taking into account the availability of drugs at the study site. Might include hydroxychloroquine (with or without azithromycin), chloroquine, lopinavir/ritonavir or other recommended schemes.~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
61963128|NCT03429686|EXPERIMENTAL|DRT Intervention|Intervention: Individual digital reminiscence therapy programme.
61963129|NCT06037395|EXPERIMENTAL|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
61963130|NCT06037395|ACTIVE_COMPARATOR|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
61963131|NCT04258722|EXPERIMENTAL|Trainee + Teleneonatologist|Trainee, teleneonatologist, nurse, and respiratory therapist will perform resuscitation
61963132|NCT04258722|ACTIVE_COMPARATOR|Trainee|Trainee, nurse, and respiratory therapist will perform resuscitation.
61963133|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
61963134|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
61963135|NCT03125317||The control group|no intervention
61963136|NCT03067168|ACTIVE_COMPARATOR|Bupivacaine Arm|The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
61963137|NCT03067168|PLACEBO_COMPARATOR|Placebo Arm|The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
61963138|NCT04932551||Physician|
61963139|NCT05832359|EXPERIMENTAL|Children diagnosed with childhood rheumatic disease|
61963140|NCT05832359|EXPERIMENTAL|Healthy children|
61963141|NCT02427022|EXPERIMENTAL|Online CTI Training|Services providers in this group received a novel online CTI training. The enhanced course combines depth of knowledge among trainers, skills-based and practical approaches to learning, new technologies, and opportunities for social networking. The course is divided the knowledge, skills, and tools associated with CTI into four two-week modules. The total instruction time for the course was 24 hours.
61963142|NCT02427022|ACTIVE_COMPARATOR|Face-to-Face CTI Training|Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
61963143|NCT05070299|EXPERIMENTAL|Psychosexual Educational Partners Program (PEPP)|Women and their partners will work through a three module workbook together, completing each module over a 2-week period (6 weeks total).
61963144|NCT03438344|EXPERIMENTAL|Arm I (CMV-MVA triplex vaccine)|Patients receive multi-antigen CMV-modified vaccinia Ankara vaccine via injection on days 28 and 56 post-HCT.
61963145|NCT03438344|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo via injection on days 28 and 56 post-HCT.
62705071|NCT05172258|ACTIVE_COMPARATOR|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, undergo collection of blood samples on study and during follow up, and undergo CT scans throughout the trial.
61963146|NCT00883805||Metal-on-Metal Articulations|Subjects will be people who have had metal-on-metal total hip arthroplasties
61963147|NCT00883805||Ceramic-on-Metal Articulations|Subjects will be people who have had ceramic-on-metal total hip arthroplasties
61963148|NCT03951402|EXPERIMENTAL|CG5503 PR 100 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 100 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 1 tablet CG5503 PR and 1 placebo-tablet, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin 400 mg.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
61963149|NCT03951402|EXPERIMENTAL|CG5503 PR 200 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 200 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
61963150|NCT03951402|PLACEBO_COMPARATOR|Placebo|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
61963151|NCT03951402|ACTIVE_COMPARATOR|Moxifloxacin 800 mg single dose|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); and 2 placebo-capsules, matching moxifloxacin on days 1 and 2; In the morning of Day 3, each participant received additionally 2 capsules each containing 1 tablet moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
61963152|NCT04584645|EXPERIMENTAL|cardiovascular disorders digital intervention arm (CVD-I)|Individuals with cardiovascular disease who receive a targeted digital intervention aimed at increasing influenza vaccination
61963153|NCT04584645|NO_INTERVENTION|cardiovascular disorders without digital intervention arm|Individuals with cardiovascular disease who receive no intervention
61963154|NCT01520012|EXPERIMENTAL|Sequence 1|
61963155|NCT01520012|EXPERIMENTAL|Sequence 2|
61963156|NCT01520012|EXPERIMENTAL|Sequence 3|
61963157|NCT01520012|EXPERIMENTAL|Sequence 4|
62348826|NCT03028584||Clinicians|"Observe up to N=10 clinicians. Observations will include:~1. Oncology history and care plan development by clinicians including use of EHR technology to develop care plans and methods used to secure necessary information for care plan creation~2. Provision and coordination of survivorship care occurring during care team meetings, discussions among clinicians, and survivor visits with clinicians, especially visits in which a care plan is provided to a survivor~3. Clinician seeking survivorship related information or resources through use of technology or discussion with other clinicians~4. Survivorship work or tasks performed by the clinician including adding, modifying or extracting information from the EHR and adding or modifying information in the care plan"
62348827|NCT03028584||Clinicians and Patients|"Surveys of N=30 breast cancer, colon cancer, and prostate cancer patients. Subjects will complete 1st survey electronically in-clinic. Subjects will either be e-mailed or mailed a survey at 4 weeks.~Survey of clinicians will be sent via e-mail."
62348828|NCT04527276|ACTIVE_COMPARATOR|Chlorhexidine|5 ml of 0,12 % Chlorhexidine (CHX) solution is applied to the intervention group for oral care
62705072|NCT00098475|ACTIVE_COMPARATOR|Arm I (lenalidomide, dexamethasone)|Patients receive lenalidomide PO QD on days 1-21 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20.
62705073|NCT00098475|EXPERIMENTAL|Arm II (lenalidomide, low-dose dexamethasone)|Patients receive lenalidomide and acetylsalicylic acid as in Arm I and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
61963158|NCT01520012|EXPERIMENTAL|Sequence 5|
61963159|NCT04469036|NO_INTERVENTION|Telephone consultation|Telephone consultation to a pediatric trauma specialist
61963160|NCT04469036|EXPERIMENTAL|Virtual Pediatric Trauma Center|The Virtual Pediatric Trauma Center (VPTC), uses live video, or telehealth, to bring the expertise of a Level I pediatric trauma center virtually to patients at a hospital emergency department.
61963161|NCT01829373|EXPERIMENTAL|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
61963162|NCT05010421|ACTIVE_COMPARATOR|Clobetasol Group|Treatment with clobetasol-0,05% over 3 months (month 1: daily, month 2: every other day, month 3: 3x per week)
61963163|NCT05010421|EXPERIMENTAL|Laser Group|3 applications every 14 days of a non-ablative CO2 laser treatment
62144060|NCT01503099||CD Norway|Patients with active Crohn's Disease (CD) in Norway
62348829|NCT04527276|NO_INTERVENTION|Placebo Group|Group of patients who received standard oral care
62506708|NCT03822273|EXPERIMENTAL|Traditional acupuncture (TA)|The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
62506709|NCT03822273|ACTIVE_COMPARATOR|Laser acupuncture (LA)|The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
62506710|NCT03822273|PLACEBO_COMPARATOR|Sham laser acupuncture (SLA)|The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
62506711|NCT03546647|EXPERIMENTAL|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
62705074|NCT00098475|ACTIVE_COMPARATOR|Arm III (thalidomide, dexamethasone)|Patients with no response after treatment on Arm I: Patients receive thalidomide PO QD on days 1-28 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20
61963164|NCT06036212|EXPERIMENTAL|Journey II UK Partial Knee Implant with Robotic Assisted Surgery|Robotically-assisted implant of the partial (unicompartmental) knee implant (Journey II UK)
61963165|NCT06036212|SHAM_COMPARATOR|Journey II UK Partial Knee Implant with Conventional, Manual Surgery|Implant of the partial (unicompartmental) knee implant (Journey II UK) with conventional, typical manual surgery
62144061|NCT01503099||Controls Norway|Healthy subjects serving as controls in Norway
62144062|NCT03705572|ACTIVE_COMPARATOR|Dietary Supplement: Phospholipid drink.|Participant in an intervention parallel group consumed a drink with added phospholipids (Lacprodan PL20).
62144063|NCT03705572|PLACEBO_COMPARATOR|Dietary Supplement: Placebo milk drink.|Participant in an intervention parallel group consumed a drink without added phospholipids.
62705075|NCT00098475|EXPERIMENTAL|Arm IV (thalidomide, low-dose dexamethasone)|Patients with no response after treatment on Arm II: Patients receive thalidomide as in arm III and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
62144064|NCT05538000|EXPERIMENTAL|Personalized support program|
62144065|NCT03871439|EXPERIMENTAL|PF-05221304 Formulation A|
62144066|NCT03871439|EXPERIMENTAL|PF-05221304 Formulation B|
62144067|NCT06372340|EXPERIMENTAL|Supervised and individualized pelvic floor muscle training|Subjects in the experimental group (EG) will accept individualized pelvic floor muscle training under the introduction of skilled clinicians.
62144068|NCT06372340|ACTIVE_COMPARATOR|Standard training program|Subjects in the control group(CG) will accept pelvic floor muscle training according to the handbook or oral guidance
62144069|NCT04484376||Other invasive candida infection|Patients with invasive candida infection due a Candida specie othr than Candida Auris.
62144070|NCT04484376||Candida Auris related invasive infection|Candida Auris related invasive candida infection.
62348830|NCT05336006|EXPERIMENTAL|High-intensity aerobic training with high protein diet - Group A|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
62348831|NCT05336006|PLACEBO_COMPARATOR|Control group - Group B|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
62348832|NCT00339885||AADM|Family and Population based individuals
62506712|NCT03546647|EXPERIMENTAL|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
62506713|NCT01104571|OTHER|Part 1: Control|No peri-operative therapy given
61963166|NCT05273918|EXPERIMENTAL|Therapy cognitivo-comportmental|"Each child will participate in a structured cognitive behavioral therapy program entitled better manage your anger and frustration. 15 workshops is planned."
61963167|NCT05273918|ACTIVE_COMPARATOR|Body mediation|Each child will participate in sports, artistic or fun activities involving the body (physical, emotional and communicative dimensions)
61963168|NCT06361485|EXPERIMENTAL|Lumbar Injection Arm|Lumbar Injections with 10cc's of Umbilical Cord Wharton's Jelly Allograft (BelloWJY)
61963169|NCT03748797|EXPERIMENTAL|Exercise group|8-week moderate intensity exercise training under supervision
61963170|NCT03748797|NO_INTERVENTION|Control group|No supervised exercise training given. Participants were advised to continue their routine daily activities and self exercises if they have
61963171|NCT02119481|EXPERIMENTAL|Mindfulness-based stress reduction|Mindfulness-based stress reduction training
61963172|NCT02119481|ACTIVE_COMPARATOR|Expressive writing condition|Expressive writing
61963173|NCT02119481|NO_INTERVENTION|Waiting-list control condition|Waiting list
61963174|NCT03677505|EXPERIMENTAL|KoMAC group|Orotracheal intubation with KoMAC videolaryngoscope
62144071|NCT03485287|EXPERIMENTAL|MDMA-assisted therapy|Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
62144072|NCT04559633|EXPERIMENTAL|Anxious school refusal|Adolescents with anxious shool refusal will beneficiate of cognitive and behavioral therapy (CBT) in order to help them to return back to school
62144073|NCT02106078|ACTIVE_COMPARATOR|Level 1|Moderated discussion board only
61963175|NCT03677505|ACTIVE_COMPARATOR|Macintosh group|Orotracheal intubation with Macintosh laryngoscope
62144074|NCT02106078|ACTIVE_COMPARATOR|Level 2|Moderated discussion board plus psychoeducation
62144075|NCT02106078|ACTIVE_COMPARATOR|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools
62144076|NCT06272591||Pregnant women with induction indication|Any pregnant woman, with a singleton pregnancy, giving birth at Saint-Etienne University Hospital, with an indication for induction of labour from 37SA will be included. The indications may be for a maternal pathology, a maternal wish or a foetal pathology.
62348833|NCT00339885||Action-LADA|Population based individuals
62348834|NCT00339885||D2D 2004|Population based individuals
62348835|NCT00339885||DIAGEN (Dresden Biobank)|Population based individuals
62348836|NCT00339885||FINRISK 1987|Population based individuals
62348837|NCT00339885||FINRISK 2002|Population based individuals; Test DNA
62348838|NCT00339885||Fusion 1|Affected-sib pair (ASP) families and elderly controls
62348839|NCT00339885||Fusion 2|275 Replication ASP Families; Trios
62348840|NCT00339885||Fusion 3|Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
62348841|NCT00339885||Fusion 4/5|Spouses, Offspring of FUSION 1 and 2 Families
62348842|NCT00339885||FUSION Finnish Groups|Family and Population based (including METSIM and DR's EXTRA): Tissue samples
62348843|NCT00339885||Health-2000|Population based individuals
62348844|NCT00339885||HUNT 2|Population based individuals
62506714|NCT01104571|EXPERIMENTAL|Part 1: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery.
61963176|NCT01625702|EXPERIMENTAL|cisplatin plus capecitabine|gastric cancer patients treated with capecitabine/cisplatin
62506715|NCT01104571|EXPERIMENTAL|Part 1: lapatinib|Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery
61963177|NCT01625702|EXPERIMENTAL|capecitabine plus paclitaxel|gastric cancer patients treated with capecitabine/paclitaxel
61963178|NCT02820753|NO_INTERVENTION|Enhanced Usual Care|"Patients who have not received the initial 6 weeks of text message reminders telling them to take their medicines; or did not complete at least 1 portal survey that asks them if they filled their medications, if they had any side effects or concerns; or did not receive either intervention will be considered as enhanced usual care.~Patients will only receive EHR tools (patient-friendly med-sheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles)."
61963179|NCT02820753|ACTIVE_COMPARATOR|Text or Portal|Participants who received EHR strategies as well as, the initial 6 weeks of SMS messaging continuously that remind them to take their medicines; or logged on to the patient portal and completed at least one survey will be considered as receiving the intervention.
61963180|NCT04313218||A|recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
61963181|NCT04313218||B|women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
61963182|NCT06502717|NO_INTERVENTION|Placebo|Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert or inactive ingredients. Participants may need to use a mobile app in order to participate in the trial.
61963183|NCT06502717|ACTIVE_COMPARATOR|Viome's Precision Nutrition Program (VPNP)|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
61963184|NCT03767816|EXPERIMENTAL|Group R : Rectus sheath block group|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision
61963185|NCT03767816|ACTIVE_COMPARATOR|Group RE: Rectus sheath block and erector spinae plane block|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision and ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml
61963186|NCT03962920|ACTIVE_COMPARATOR|Surgical treatment + antibiotics|Use antibiotic
61963187|NCT03962920|PLACEBO_COMPARATOR|surgical treatment + placebo|Use placebo
61963188|NCT02835404|EXPERIMENTAL|Concurrent radiochemotherapy Group|Concurrent radiochemotherapy with Nedaplatin Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f with 8mv-X rays (SSD) 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations; Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
61963189|NCT02835404|ACTIVE_COMPARATOR|Radiotherapy Group|patients received Radiotherapy only Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X Linear Accelerator SSD 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations.
61963190|NCT06441994|EXPERIMENTAL|Administration arm|
61963191|NCT05892471|EXPERIMENTAL|ciprofol|
61963192|NCT05892471|PLACEBO_COMPARATOR|propofol|
61963193|NCT00107471|EXPERIMENTAL|Dose Level I (0.5 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
61963194|NCT00107471|EXPERIMENTAL|Dose Level 2 (0.6 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)
61963195|NCT01780636|EXPERIMENTAL|Botulinum toxin (Botox) injection|All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.
61963196|NCT03695250|EXPERIMENTAL|Treatment (BMS-986205 and nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-14 and nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
61963197|NCT04690998|OTHER|Without treatment for SMA|Patient that will not take treatment for SMA during the two years of the study.
61963198|NCT04690998|OTHER|Under treatment for SMA|Patient that will take treatment for SMA during the two years of the study
62506716|NCT01104571|OTHER|Part 2: Control|No peri-operative therapy
62506717|NCT01104571|EXPERIMENTAL|Part 2: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery.
62705076|NCT05124769|EXPERIMENTAL|Pain Allow|Pain is allowed up to 5/10 during exercises, monitored by NPRS. Depending on tissue irritability and other factors such as ROM, the exercises may be performed in an isometric way, or dynamic.
61963199|NCT02624908|ACTIVE_COMPARATOR|canagliflozin|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
61963200|NCT02624908|PLACEBO_COMPARATOR|placebo|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
61963201|NCT04433377|EXPERIMENTAL|Suprascapular nerve block group|"Suprascapular nerve block will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the suprascapular fossa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 22 gauge 90-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
61963202|NCT04433377|EXPERIMENTAL|Subacromial injection group|"Subacromial injection will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the subacromial bursa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 21 gauge 38-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
62705077|NCT05124769|ACTIVE_COMPARATOR|Pain Avoid|Pain is not allowed during the exercises, and should be \<2/10, monitored by NPRS.
61963203|NCT06229197|EXPERIMENTAL|Billroth II with Braun Reconstruction|
61963204|NCT06229197|ACTIVE_COMPARATOR|Billroth II Reconstruction|
61963205|NCT00840450|EXPERIMENTAL|Paclitaxel + Imatinib Mesylate (Gleevec)|
61963206|NCT04235114|EXPERIMENTAL|Establish Imaging Time|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
61963207|NCT04235114|EXPERIMENTAL|Diagnostic Quality|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging once at the best time calculated from arm 1 participants. Vitals, blood sample and urine sample will be collected before imaging. Participants will be followed up for any adverse event until day 30 post administration
61963208|NCT04235114|EXPERIMENTAL|Establish Cold Dose|Participants will receive an i.v. injection of 1 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
61963209|NCT05339568||Platform follow-up cohort|This cohort will be managed and follow-up by patients' whole process follow-up platform. The patients can report the symptoms, get the reminder of the hospital visit, get the reminder of medicine taking, get the information of patients education.
61963210|NCT05339568||Routine follow-up cohort|This cohort will be managed and follow-up by the investigators or nurses. This cohort will take the routine follow-up and management way by the hospital.
61963211|NCT02671552|EXPERIMENTAL|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren protein-type A microspheres IV and then undergo contrast-enhanced ultrasound imaging the morning prior to cryosurgery and at 3-4 months post treatment during Magnetic Resonance Imaging (MRI) or computed tomography (CT) follow up.
61963212|NCT00160693|EXPERIMENTAL|Certolizumab Pegol|
61963213|NCT05872841|EXPERIMENTAL|Recombinant human adenovirus type 5 combined with TACE|"Recombinant human adenovirus type 5: The recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment. The recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with saline before administration.~TACE: Chemotherapeutic drugs were specifically oxaliplatin 85 mg/m2, calcium folinic acid 400 mg/m2, 5-fluorouracil 1200 mg/m2, and then superfluid iodinated oil bolus was given according to the intraoperative imaging tumor blood supply."
61963214|NCT01755013|EXPERIMENTAL|PDT Group|Subjects who receive Photodynamic therapy with plastic optic diffuser.
61963215|NCT00801632|EXPERIMENTAL|Kidney and Marrow Recipients|Combined kidney and bone marrow transplant
61963216|NCT00009698|EXPERIMENTAL|All patients|Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.
61963217|NCT04284410|EXPERIMENTAL|CLASP-PE arm|
61963218|NCT02534870|EXPERIMENTAL|ABT-450/r/ABT-267 + ABT-333|ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.
61963219|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
61963220|NCT03586180||Dr. Clowns|they will perform shows for children and parents
61963221|NCT04451239|OTHER|COVID-19 keratoconjunctivitis|cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
61963222|NCT01691781|EXPERIMENTAL|lisinopril|Lisinopril - open-label, 2.5-40mg daily
61963223|NCT02407353|EXPERIMENTAL|PF-06648671 High dose group|subjects receive a single oral dose of PF-06648671 at 300 mg
61963224|NCT02407353|EXPERIMENTAL|PF-06648671 Low dose group|Subjects receive a single oral dose of PF-06648671 lower than 300 mg dose
61963225|NCT02407353|PLACEBO_COMPARATOR|Placebo group|Subjects receive matching placebo
61963226|NCT02407353|EXPERIMENTAL|PF-06648671 Low dose group (2)|Optional arm. Subjects receive a single oral dose of PF-06648671 at second lower dose if 300 mg dose is not repeated in cohort 2
61963227|NCT02898337||Methadone-induced QTc interval prolongation|
61963228|NCT02898337||Methadone-treated patients, no QT interval prolongation|
61963229|NCT02954731|EXPERIMENTAL|UP-CBT|"The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is one of the most widely studied transdiagnostic manuals. Here, the investigators apply a group manual that has been modified from the published UP for individual therapy based on recommendations on group delivery from the UP Institute (personal communications) and integrations modifications necessary for the delivery in the Mental Health Service. Group UP-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions."
61963230|NCT02954731|ACTIVE_COMPARATOR|Standard-CBT|Group CBT following Danish versions of diagnosis specific manuals (Social Anxiety Disorder (SAD) Group; Depression (DEP) Group; Agoraphobia/Panic Disorder (Ag/PD) (standard-CBT). The original elements of psychoeducation, cognitive restructuring, and exposure/activity scheduling are present in the applied manuals. Standard-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions.
62144077|NCT00573105|EXPERIMENTAL|1|Laparoscopic Ventral hernia repair by heavy weight mesh
62144078|NCT00573105|EXPERIMENTAL|2|Laparoscopic Ventral hernia repair by lighter weight mesh
62144079|NCT01123174|EXPERIMENTAL|ALGOS group|Algorithm of case management over the 6 months following the suicidal gesture (systematic telephone contact, postcards and crisis card)
62144080|NCT01123174|NO_INTERVENTION|Control group|Treatment as usual (referral back to the general practitioner)
62144081|NCT00703391|EXPERIMENTAL|1|Active Treatment
62705078|NCT01875601|EXPERIMENTAL|A|NK cell infusion (dose escalation)
62705079|NCT01875601|EXPERIMENTAL|B|NK cell infusion + escalating doses of rhIL15
62705080|NCT06105918|EXPERIMENTAL|Treatment (EBRT, 177Lu-rhPSMA-10.1)|Patients undergo EBRT followed by 177Lu-rhPSMA-10.1 IV on study. Patients also receive rhPSMA-7.3 IV with PET/CT at screening and undergo SPECT-CT and collection of blood samples on study.
61963231|NCT05503394|EXPERIMENTAL|Peer support WeChat platform intervention group|Peer support WeChat platform intervention for primary caregivers of children with biliary atresia based on routine care during the postoperative period up to one month postoperatively
61963232|NCT05503394|OTHER|Routine nursing care group|Perform routine nursing care for primary caregivers of children with biliary atresia during the postoperative period up to one month postoperatively
61963233|NCT04740788||Monofocal IOL|Patients already implanted with a monofocal IOL
61963234|NCT06190691|EXPERIMENTAL|Pirtobrutinib (Mild Hepatic Impairment)|Pirtobrutinib administered orally.
61963235|NCT06190691|EXPERIMENTAL|Pirtobrutinib (Moderate Hepatic Impairment)|Pirtobrutinib administered orally.
61963236|NCT06190691|EXPERIMENTAL|Pirtobrutinib (Severe Hepatic Impairment)|Pirtobrutinib administered orally.
62144082|NCT00703391|PLACEBO_COMPARATOR|2|Placebo Treatment
62506718|NCT01104571|EXPERIMENTAL|Part 2: lapatinib-trastuzumab combination|Lapatinib 1000mg/day p.o. continuously for 28 days, in combination with trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery. Both drugs should start 11 days (+2 or -1 day) before the scheduled surgery.
61963237|NCT06190691|EXPERIMENTAL|Pirtobrutinib (Normal Hepatic Function)|Pirtobrutinib administered orally.
61963238|NCT05770856||Trauma related infection|
62144083|NCT04881305||Cases|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, with cognitive/emotional complaints.
62144084|NCT04881305||Controls|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, reporting no cognitive/emotional complaints.
62144085|NCT02441374|EXPERIMENTAL|Forced Use Therapy|Constriction (through the tubular mesh) of non paretic upper limb for a period of 12 and 24 hours, 5 days per week for 4 weeks.
62144086|NCT02441374|ACTIVE_COMPARATOR|Classical Kinesiotherapy|Rehabilitation of classical kinesiotherapy,at least 2 times a week for 4 weeks.
62144087|NCT05715632|EXPERIMENTAL|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of Carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical surgery for gastric cancer
62705081|NCT05508789|EXPERIMENTAL|Donanemab|Participants will receive donanemab intravenously (IV)
62705082|NCT05508789|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo IV
61963239|NCT00718835|ACTIVE_COMPARATOR|Contingent Voucher condition|Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
61963240|NCT00718835|PLACEBO_COMPARATOR|Noncontingent control condition|Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
61963241|NCT00121745|EXPERIMENTAL|1|
61963242|NCT00121745|EXPERIMENTAL|2|
61963243|NCT00121745|EXPERIMENTAL|3|
61963244|NCT00121745|EXPERIMENTAL|4|
61963245|NCT03012438|EXPERIMENTAL|NIRF imaging in thyroid surgery|"7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible.~After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR."
61963246|NCT03406572|EXPERIMENTAL|HFHO Group|Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH \< 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
62144088|NCT04675684|EXPERIMENTAL|Recovery-group|"The recovery group consists of:~1. Physical, mental and social health education, advice and feedback from a health investigator.~2. Daily self-monitoring about their mood and health in an app, Monsenso.~3. Intersectoral collaboration between 1) Mental Health Centre Copenhagen Rigshospitalet, IAOC 2) Centre for Research and Education in General Practice, University of Copenhagen 2) Centre for Social Medicine at Frederiksberg Hospital, 3) Competence Centre for Rehabilitation and Recovery, Mental Health Centre Ballerup, and 5) Private Practicing Psychiatrists."
62144089|NCT04675684|NO_INTERVENTION|Control-group|The control group consists of usual treatment at their General Practitioner and / or Private Practicing Psychiatrist.
62144090|NCT02879136|ACTIVE_COMPARATOR|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
62144091|NCT02879136|ACTIVE_COMPARATOR|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
62144092|NCT02879136|ACTIVE_COMPARATOR|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
62348845|NCT00339885||METSIM|Population based individuals
62348846|NCT00339885||Savitaipale|Population based individuals
62506719|NCT01115855|EXPERIMENTAL|Eplerenone arm|Add on standard heart failure therapy
62506720|NCT01115855|PLACEBO_COMPARATOR|Placebo arm|Add on standard heart failure therapy
62506721|NCT05352477|EXPERIMENTAL|Balneotherapy with thermal water|Daily balneotherapy with Acquabios thermal water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
62705083|NCT06082167|EXPERIMENTAL|Zanzalintinib + Pembrolizumab|Subjects with R/M HNSCC will receive zanzalintinib + pembrolizumab
62705084|NCT06082167|PLACEBO_COMPARATOR|Zanzalintinib-Matched Placebo + Pembrolizumab|Subjects with R/M HNSCC will receive zanzalintinib-matched placebo + pembrolizumab
62705085|NCT02610361|EXPERIMENTAL|BGB-283|
62144093|NCT03227510||HCC Cases (Group 1)|This group will include 63 subjects and the diagnoses will be based on clinical examination, laboratory tests such as (Liver Function tests, Alpha-fetoprotein , Ultrasound, and biopsy in some cases if possible (Depends on the patients and their financial issues).
62144094|NCT03227510||Chronic Liver Diseases (group 2)|This group will be including 31 patients, and the diagnoses will be based on laboratory such as (liver function tests, viral markers, AFP,) and by ultrasound findings (shrunken liver, coarse echo-pattern, attenuated hepatic vein and finding nodular surface)
62144095|NCT03227510||Healthy Volunteer (group 3)|"It will include 32 subjects that serve as control group.~These all patients and control groups will be subject the following parameters: Biochemical tests such as (Liver function tests, viral markers, serum AFP, CBC, Kidney functions and others) and circulating MicroRNAs levels of all these subjects."
62144096|NCT02565966|EXPERIMENTAL|Modified Atkins Diet (MAD)|
62144097|NCT02565966|NO_INTERVENTION|Normal Diet|Those patients in the normal diet (no intervention) group will also meet with the epilepsy center nutritionist to review the food diary and completion of this document, similar to those in the intervention (MAD) group. No dietary restrictions will be made in this group.
62506722|NCT05352477|PLACEBO_COMPARATOR|Balneotherapy with tap water|Daily balneotherapy with tap water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
62506723|NCT06026059||interview with the dietician|"Initially, parent(s) and child will be interviewed together, details of the dietary record, as well as the data needed to calculate the nutritional risk score will be obtained.~The interview will then be only with the child, he will be asked to determine, on his/her own, the portion of food he/she thinks he/she ate the previous evening, using the SEFI score.~Finally, one of the two parents will determine, on their own, the portion of food they think their child ate the previous evening, using the SEFI score."
62506724|NCT00877617||QOL Questionnaire|
62506725|NCT05527158|EXPERIMENTAL|Yi Jin Jing exercise|Yi Jin Jing exercise three times per week for 12 weeks. Each exercise lasts an hour and consists of three fundamental Yijinjing exercises.
62506726|NCT05527158|NO_INTERVENTION|Routine care|routine joint rehabilitation guidance, such as joint energy conservation and joint protection, basic daily activities without additional exercise.
62506727|NCT05511649||Post-MI NOAF with low AF burden|Patients with post-MI NOAF who had a AF burden\<10.87%. The cut-off value of AF burden of 10.87% was identified based on our previous work.
62506728|NCT05511649||Post-MI NOAF with high AF burden|Patients with post-MI NOAF who had a AF burden≥10.87%.
62506729|NCT05407818|EXPERIMENTAL|JNJ-63733657|Participants will receive a single dose of JNJ-63733657 as an intravenous (IV) infusion on Day 1.
62705086|NCT06011239|EXPERIMENTAL|Survey participants|All participants in the study will be in a single arm, divided by clinic.
62705087|NCT06011239|NO_INTERVENTION|Clinic Staff|"Project champions at each clinic who are helping to implement the project."
62144098|NCT02027259|EXPERIMENTAL|Group visits with behavioral activation|Group visits with behavioral activation (BA) will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
62144099|NCT02027259|NO_INTERVENTION|Standard group visits|Standard group visits will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
62144100|NCT02915783|EXPERIMENTAL|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
62705088|NCT06332534|EXPERIMENTAL|Period 1: Open Label Induction Phase (Dose A)|All participants in the open label induction phase of Period 1 will receive upadacitinib Dose A for 12 weeks based on body weight.
62705089|NCT06332534|EXPERIMENTAL|Period 1: Double-Blind Maintenance Phase (Dose B)|Clinical responders per PCDAI at the end of open label induction phase of Period 1 will be randomly assigned to receive Dose B or C for 52 weeks (oral solution dose will be based on body weight)
62144101|NCT00764166|EXPERIMENTAL|1|
62144102|NCT00764166|ACTIVE_COMPARATOR|2|
62506730|NCT02430207|EXPERIMENTAL|Femoral Vein|patients receiving temporary pacing via femoral vein
62506731|NCT02430207|EXPERIMENTAL|Subclavian Vein|patients receiving temporary pacing via subclavian vein
62705090|NCT06332534|EXPERIMENTAL|Period 1: Double-Blind Maintenance Phase (Dose C)|Clinical responders per PCDAI at the end of open label induction phase of Period 1 will be randomly assigned to receive either upadacitinib Dose C or B for 52 weeks (oral solution dose will be based on body weight)
62705091|NCT06332534|EXPERIMENTAL|Period 2: Open Label Long-Term Extension Phase Cohort 1|Participants receiving double-blind maintenance therapy with upadacitinib Dose B or upadacitinib Dose C daily in Period 1 who complete the Week 64 visit will receive upadacitinib Dose B daily for up to 156 weeks.
61963247|NCT03406572|ACTIVE_COMPARATOR|Standard O2 Group|NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. ABG will also be performed between one and two hours and NIV extended according to ABG result (i.e. extended if pH \< 7.30). Switch from NIV to oxygen will require the same predefined criteria as the HFHO group. In-between each NIV session, oxygen will be delivered using standard low flow O2 to reach the same targeted SpO2: 88% ≤SpO2 ≤ 92%. Similar criteria will be used to resume NIV
62144103|NCT01052935|NO_INTERVENTION|Arm 1|This is a phlebotomy study.
62144104|NCT02509858|ACTIVE_COMPARATOR|thyroxine in eythyroid diabetics|50 μg of thyroxine once daily, for 2 months.
62506732|NCT05607433|EXPERIMENTAL|Air Q ILA group|Air Q supraglottic device will be placed in the participants in this group .
62506733|NCT05607433|EXPERIMENTAL|Ambu AuraGain group|Ambu AuraGain supraglottic device will be placed in the participants in this group .
62506734|NCT05141630|EXPERIMENTAL|group with axillary sentinel or targeted lymph node biopsy alone|The patients with stage II to III breast cancer with biopsy-confirmed nodal metastases who convert to cN0 following NAC is recruited. Eligible patients are treated with axillary sentinel or targeted lymph node biopsy alone. Post-surgery radiation therapy will be administered at the discretion of the radiologist and the nodal radiotherapy must be conducted in patients with low nodal disease.
62506735|NCT04333381|ACTIVE_COMPARATOR|Common Practice|Patients included in the phase I will receive common practice.
62705092|NCT06332534|EXPERIMENTAL|Period 2: Open Label Long-Term Extension Phase Cohort 2|Participants who were receiving rescue therapy with open-label upadacitinib Dose C during maintenance phase in Period 1 and completed the Week 64 visit will continue to receive upadacitinib Dose C daily for up to 156 weeks.
61963248|NCT02944968|EXPERIMENTAL|Treatment group|Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
61963249|NCT01765088|ACTIVE_COMPARATOR|temozolomide|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles)
61963250|NCT01765088|EXPERIMENTAL|temozolomide +α-IFN|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m\^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles
61963251|NCT04692571|EXPERIMENTAL|Study B: Limb-Absent Subject|"Ten unilateral transradial limb-absent subjects will each participate in one, half-day experimental session. Subjects will be seated and prepared in test apparatus seat (16 electrodes on the affected side, hand-wrist on the able side secured to load cells). Subjects will complete the 1-DoF and 2-DoF dynamic (force-varying) contractions (40-s duration, 0.75 Hz bandlimited, uniform random target). With 2 DoF contraction trials, hand Opn-Cls will always be one of the dimensions. The subject will then be released from the cuff and their able side not further involved in the experiment. The force feedback triangle cursor on the computer screen will be deleted such that only the target remains. Subjects will then repeat 1-DoF and 2-DoF trials in which the affected side attempts to produce hand-wrist effort that mimic movement of the target (with no feedback provided)."
61963252|NCT04692571|EXPERIMENTAL|Study B: Able-bodied Subjects|Ten able-bodied subjects, the electrodes will be mounted on the dominant arm for the EMG-force and EMG-target tracking trials. In addition, the non-dominant arm will also be constrained and measured in a second load cell. This load cell will not be used for feedback during the experiment, but will compare (RMS error, off-line) the dominant vs. non-dominant forces. For EMG-target tracking, the dominant hand will remain in the wrist cuff (to prevent flailing during contractions), with the screen feedback disabled. These subjects will repeat the trials with the electrodes moved to the non-dominant side. EMG-force tracking will be repeated using mirrored contractions. The three training methods (EMG-force ipsilateral, EMG-force contralateral mirrored, EMG-target on the dominant side) will be contrasted to help understand the source of errors when training with limb-absent subjects.
61963253|NCT06081257|EXPERIMENTAL|experimental group|"KB-120 small molecule nutrients, taken orally once a day in one bag (30ml), and vitamin E100mg taken orally 2 times a day for a total of 3 menstrual cycles"
61963254|NCT06081257|ACTIVE_COMPARATOR|control group|Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
61963255|NCT01830972|EXPERIMENTAL|Crossover Participants|"Participants completing the 48-week study (UX001-CL201; NCT01517880) were enrolled into Part I of the study:~* Part I: participants continued on 6 g/day SA-ER for 12 weeks~* Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment 4 times per day \[QID\]) for 36 months~* Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~* Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
62705093|NCT06332534|EXPERIMENTAL|Period 2: Open Label Long-Term Extension Phase Cohort 3|Participants who did not achieve clinical response per PCDAI at Week 12 of Period 1 will receive an extended treatment with open-label upadacitinib Dose C daily for an additional 12 weeks. If they are responders after 12 weeks extended treatment, they will continue, otherwise they may be discontinued at the discretion of the investigator
61963256|NCT01830972|EXPERIMENTAL|Naïve Participants|"Treatment naïve participants with GNE myopathy were enrolled into Part II of the study:~* Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment QID) for 36 months~* Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~* Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
62705094|NCT01352975||Group 0|participants without AMD (no large drusen or advanced AMD in either eye)
62705095|NCT01352975||Group 1|participants with large drusen in study eye and no large drusen or advanced AMD or GA in fellow eye
62705096|NCT01352975||Group 2|participants with bilateral large drusen with or without retinal pigment epithelial hypo/hyperpigmentary changes
62705097|NCT01352975||Group 3|participants with large drusen in study eye and advanced AMD (CNV and GA) in fellow eye
61963257|NCT04255602|EXPERIMENTAL|low dose ticagrelor|After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation
61963258|NCT04255602|ACTIVE_COMPARATOR|standard dose ticagrelor|subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation
61963259|NCT00755092|ACTIVE_COMPARATOR|1|Doula for Nulliparous women
61963260|NCT00755092|ACTIVE_COMPARATOR|2|Doula for Multiparous women
61963261|NCT02555072|OTHER|naive children and adults for yellow fever vaccine|both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old
61963262|NCT02058667|EXPERIMENTAL|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
61963263|NCT01154855||Periodontitis|"Patients with severe periodontal disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning~1 per patient at 2nd visit lasting approximately 1 hour."
62144105|NCT02509858|ACTIVE_COMPARATOR|thyroxine in euthyroid healthy humans|50 μg of thyroxine once daily, for 2 months.
62705098|NCT01352975||Group 4|participants with findings of RPD
62705099|NCT06143514||Breast Milk Collection|Breast milk will be collected of participants with relapsing forms of multiple sclerosis (RMS) who are receiving BRIUMVI™ therapeutically for up to 24 hours to determine concentration of BRIUMVI™ in milk samples.
62705100|NCT05950191|EXPERIMENTAL|PermaNet Dual|long lasting insecticidal nets with chlorfenapyr-pyrethroid
62705101|NCT05950191|ACTIVE_COMPARATOR|PermaNet 3.0|long lasting insecticidal nets with PBO-pyrethroid
62705102|NCT05961436|ACTIVE_COMPARATOR|PENG block group|using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
62705103|NCT05961436|ACTIVE_COMPARATOR|FN block group|using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
62705104|NCT03814759|EXPERIMENTAL|SP+CCRT|S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks
62506736|NCT04333381|EXPERIMENTAL|Educational and organizational measures|Patients included in the phase II will be attended by emergency nurses that received the educational and organizational intervention.
62705105|NCT06333951|EXPERIMENTAL|Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A|Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 orally (PO) and carboplatin, paclitaxel, and pembrolizumab intravenously (IV)
62705106|NCT06333951|EXPERIMENTAL|Subprotocol A: NSCLC Arm B|Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 PO and carboplatin, pemetrexed, and pembrolizumab IV
62506737|NCT06125756|EXPERIMENTAL|KL001 injection solution|Subjects will be dosed with three different dose of KL001 injection solution at 2.5x10\^12 vg/kg to 1.0x10\^13 vg/kg.
62506738|NCT02510950|EXPERIMENTAL|Arm 1: Peptide/poly-ICLC|"* For all patients, concurrent chemoradiation with temozolomide will be given per standard of care and is outside the scope of this study as per standard of care.~* The long peptide + poly-ICLC will be given on Cycle 1 Day 1 of maintenance temozolomide.~* If the vaccine is not ready by this time, the first vaccination will begin on Day 1 of the next cycle of maintenance temozolomide.~* The peptide + poly-ICLC vaccine will be given again on Days 8, 15, and 22 of the first cycle, as a priming strategy.~* On all subsequent cycles, the peptide vaccine + poly-ICLC will be given on Day 22 (+/-3 days)."
62506739|NCT05487755|NO_INTERVENTION|control group|: (n=30) control group will receive traditional therapy blood glucose lowering agent +RAAS blockade ACEI or ARBs for six months.
62506740|NCT05487755|EXPERIMENTAL|Tadalafil group|:( n=30) will receive traditional therapy +tadalafil PO 20 mg every other day for six months
62506741|NCT05487755|EXPERIMENTAL|pentoxifylline group|:( n=30) will receive traditional therapy+ pentoxifylline PO 400 mg twice daily for six months.
62506742|NCT04080596|EXPERIMENTAL|Sequential arm|Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11.
62506743|NCT06495580|EXPERIMENTAL|Optic Nerve Stimulation|The most significant procedure will be using an anterograde microstimulator and provoke stimulations to the optic nerve as the surgery proceeds. During surgery, the optic nerve and chiasm will be stimulated and the response recorded in both eyes and occipital cortex via skin electrodes. These responses will be monitored at all times by the neuromonitorig team who will inform if changes in neural responses change. The use of microstimulator has been proven safe in other surgical approaches.
62506744|NCT06495580|NO_INTERVENTION|No Intervention|Patients receiving regular standard of care in endoscopic endonasal approaches within the same case series.
62506745|NCT06300827|EXPERIMENTAL|Experimental Group|Experimental Group: Structured digital-based training will be implemented.
62506746|NCT06300827|NO_INTERVENTION|Control Group|"Control Group: The nursing student will be expected to continue their daily life.~Nursing students who meet the inclusion criteria will be randomly assigned to the experimental group by a statistician."
62506747|NCT02320162|EXPERIMENTAL|Experiential learning|Oral health education using experiential learning (EL)
62506748|NCT02320162|PLACEBO_COMPARATOR|Traditional lecturing|Oral health education using traditional lecturing (TL)
62506749|NCT04296955|EXPERIMENTAL|Health communication intervention|Motivational interview as a new health communication intervention (one arm)
62506750|NCT04296955|NO_INTERVENTION|Standard care|Standard care
62506751|NCT01662362|OTHER|Testing Donor Specimens with ESA Chagas|Test blood donor specimens that are ABBOTT PRISM Chagas Repeatedly Reactive with ESA Chagas. Donors will be asked to return for a follow-up blood draw.
62506752|NCT03332251|EXPERIMENTAL|Posture Correction Girdle|The design of posture correction girdle will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure
62506753|NCT03332251|NO_INTERVENTION|Control|No treatment will be provided for control participants.
62506754|NCT04761471|EXPERIMENTAL|TI stimulation|Temporal interference (TI) stimulation is a type of low-intensity transcranial electrical stimulation with alternating current (tACS). In case of TI stimulation, 2 electric fields in kHz range are delivered to 4 electrodes, which are placed on the surface of the skull, to modulate neural oscillations.
62506755|NCT05368558|EXPERIMENTAL|Cariprazine|Participants will receive cariprazine Dose A daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.
62506756|NCT05368558|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.
62506757|NCT02343965|EXPERIMENTAL|Touch-massage group|Patient receive 3 sessions of touch-massage (the duration of a session of touch massage is 15 minutes) ,once a week, for 3 weeks
62705107|NCT06333951|EXPERIMENTAL|Subprotocol A: NSCLC Arm C|Participants with MTAP-deleted NSCLC will receive a combination of AMG 193 PO and pembrolizumab IV
62705108|NCT06333951|EXPERIMENTAL|Subprotocol B: NSCLC With KRasG12C Mutation|Participants with MTAP-deleted NSCLC and KRasG12C mutation will receive a combination of AMG 193 and sotorasib PO
62705109|NCT06333951|EXPERIMENTAL|Subprotocol C: NSCLC With Brain Metastases|Participants with MTAP-deleted NSCLC with brain metastases will receive AMG 193 PO
62144106|NCT02509858|PLACEBO_COMPARATOR|placebo in euthyroid diabetics|50 μg of placebo once daily, for 2 months.
62506758|NCT02343965|NO_INTERVENTION|without touch-massage group|
62506759|NCT06184594|EXPERIMENTAL|eNav intervention|Subjects assigned to this arm will receive a link to the eNav website.
62506760|NCT06184594|PLACEBO_COMPARATOR|Usual Care Group|Subjects assigned to this arm will not receive the link to the website and will receive standard clinical care.
62506761|NCT04228965|OTHER|Co-Use Group|Cannabis and tobacco co-use group.
62506762|NCT04228965|ACTIVE_COMPARATOR|Tobacco Only Group|Tobacco only group.
62506763|NCT01011335|EXPERIMENTAL|Active Vaccine|Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
62506764|NCT01011335|PLACEBO_COMPARATOR|Placebo with Alum|
62506765|NCT01011335|PLACEBO_COMPARATOR|Saline Placebo|
62506766|NCT00650273|EXPERIMENTAL|1|Azithromycin Tablets 600 mg
62506767|NCT00650273|ACTIVE_COMPARATOR|2|Zithromax® Tablets 600 mg
61963264|NCT01154855||Healthy patients|"Patients without periodontal (gum) disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning"
61963265|NCT05318053||2022 Cohort|"1. Successful completion of screening checklist to indicate one of the following conditions:~   1. recurring, long-standing fantasies that focus on kink, in areas such as: power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities. By fetish, we mean a type of sexual desire in which gratification depends on or is significantly increased by particular objects, clothing items, parts of the body, or types of persons.~  2. OR currently engaging, or have engaged in the past, in consensual kink activities such as power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities.~2. Age of majority in the legal jurisdiction (geographic location) where the survey is taken (usually age 18)~3. English-language proficiency sufficient to understand the study instruments~4. Completion of an electronically signed and dated informed consent form"
61963266|NCT05114798|EXPERIMENTAL|Time Restricted Eating (TRE)|During the active weight loss period, the TRE group will be instructed to eat ad libitum from 12:00pm - 8:00pm daily and fast from 8:00pm - 12:00pm. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.
61963267|NCT05114798|ACTIVE_COMPARATOR|Calorie Restriction (Cal-R)|Cal-R subjects will be instructed to restrict energy intake by 25% of their baseline total energy expenditure (TEE) daily. Subjects will meet with a study dietitian for a 60-min one-on-one session to develop individualized weight loss meal plans to help them adhere to their calorie restriction goal. Meal plans will include portion sizes and food lists that are consistent with their food preferences and prescribed calorie levels for weight loss. Food scales will be provided to help with food portioning. Cal-R subjects will meet with the dietitian every week throughout the weight loss period to review intervention adherence and modify the meal plans as needed. Subjects will be asked to maintain their baseline level of physical activity. At the beginning of the weight maintenance phase, total energy needs will be reassessed.
61963268|NCT05114798|NO_INTERVENTION|Control|Controls will be instructed to maintain their weight throughout the 12 m trial and to not change eating or physical activity habits. Controls will not receive dietary counseling. Controls will visit the research center every 3 months for outcome measurements.
61963269|NCT03565744|EXPERIMENTAL|Group 1 - B'N Fit POWER|Participants enrolling in B'N Fit POWER afterschool program will be assigned to Group 1.
61963270|NCT03565744|NO_INTERVENTION|Group 2 - Standard of Care|All other PS/MS-95 participants who completed the screening (approximately 50) will be in comparison Group 2
62705110|NCT01925196||C9ORF72|Participants with C9ORF72 mutation
62705111|NCT01927783||Group 1|Healthy Volunteer
62705112|NCT01927783||Group 2|Focus Group- Neighborhood and Physical Activity
62705113|NCT01927783||Group 3|Focus Group
62705114|NCT01927783||Group 4|Focus Group- Mobile App
61963271|NCT03565744|NO_INTERVENTION|Group 3 - Standard of Care|Participants at an additional school site completing the screening (approximately 100) will be in an additional comparison Group 3.
61963272|NCT06327347|ACTIVE_COMPARATOR|ARTIS SYMBIOSE|25 patients will be implanted bilaterally with Artis Symbiose IOLs (Cristalens Industrie, France) . The device is CE-marked and used according to the intended purpose.
62705115|NCT01927783||Group 5|Consent for Cooking Survey Focus Group
61963273|NCT06327347|ACTIVE_COMPARATOR|PANOPTIX|25 patients will be implanted bilaterally with AcrySof IQ PanOptix IOLs (Alcon, Switzerland).The device is CE-marked and used according to the intended purpose.
61963274|NCT01471236|EXPERIMENTAL|Agili-c bi-phasic implant|mini-arthrotomy
61963275|NCT02071914|EXPERIMENTAL|CT-P27 10mg/kg|CT-P27 will be administrated once in IV infusion.
61963276|NCT02071914|EXPERIMENTAL|CT-P27 20mg/kg|CT-P27 will be administrated once in IV infusion.
61963277|NCT02071914|PLACEBO_COMPARATOR|Placebo|Placebo will be administrated once in IV infusion.
61963278|NCT02793934||1st phase|"In the 1st phase of the study the staff of the medical organizations continue to work in the familiar old scheme, but using the set of scales."
62144107|NCT02158806|EXPERIMENTAL|Aspirin|150 mg capsule once daily for up to 24 weeks
62705116|NCT01927783||Group 6|Community Organization Survey focus Group
62705117|NCT05369611||SELF|1,668 current members of the SELF cohort: African American women between the ages of 23-35 at enrollment in SELF who have not previously withdrawn from SELF and are not known to have died.
62705118|NCT04623944|EXPERIMENTAL|NKX101 - CAR NK cell therapy|"All subjects in Part 1 will receive lymphodepletion with fludarabine/cyclophosphamide followed by 3 or 2 (Regimen A or B, respectively) weekly doses of NKX101.~Subjects in Part 2 will receive lymphodepletion with either fludarabine/cyclophosphamide or fludarabine/cytarabine (ara-C), or if the optional arm is opened, lymphodepletion with fludarabine/cyclophosphamide and decitabine, followed by 3 weekly doses of NKX101.~Part 2: unrelated off-the-shelf donor derived NKX101 will be used."
62705119|NCT05432427|EXPERIMENTAL|Group A, B, C, D, E, F, G|Scans
62705120|NCT04339738|EXPERIMENTAL|Arm I (nivolumab, paclitaxel)|Patients receive nivolumab IV over 30 minutes on day 1 and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood at baseline and on study, CT scan, spiral CT, or MRI, or FDG-PET scan throughout the trial.
62705121|NCT04339738|EXPERIMENTAL|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood at baseline and on study, CT scan, spiral CT, or MRI, or FDG-PET scan throughout the trial.
62705122|NCT04339738|EXPERIMENTAL|Arm III (nivolumab, cabozantinib S-malate)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood at baseline and on study, CT scan, spiral CT, or MRI, or FDG-PET scan throughout the trial.
61963279|NCT02793934||2nd phase|"In the 2nd phase, medical organizations will start to work on a new model with the implementation of problem-oriented multidisciplinary approach and the use of modern rehabilitation technologies. There is planning to use clearly defined criteria for transfer from stage to stage, developed by the professional community. When doctors will be trained program ICF-reader will have an opportunity to establish a rehabilitation diagnosis on the basis of the ICF, and the option for ICF assessment using rating scales."
62705123|NCT05980234||Longevity IT Oblique Liners|The Longevity IT Oblique liner was designed to provide variable joint anteversion and abduction.
61963280|NCT06418100|NO_INTERVENTION|The Control|The participants will have standardized anaesthesia management and receive postoperative rescue analgesia as morphine.
61963281|NCT06418100|EXPERIMENTAL|The rectointercostal fascial plane block|The participants will receive postoperative recto intercostal fascial plane block, with 20 ml 0,25 bupivacaine bilaterally.
61963282|NCT06293404|ACTIVE_COMPARATOR|Group F|the lateral decubitus position, Group F will keep the spinal cord flexed for 10 minutes,
61963283|NCT06293404|OTHER|Group N|the lateral decubitus position, Group N will keep the natural position of the spinal cord in lateral decubitus for 10 minutes,
61963284|NCT06239454|ACTIVE_COMPARATOR|empirical stimulation modes group (ESG)|empirical programming for the first 9 months' period, followed by any stimulation decided by the neurologists/neurosurgeons for the final 3 months.
61963285|NCT06239454|EXPERIMENTAL|interleaving stimulation modes group (ISG)|empirical stimulation for the first 3 months, followed by interleaving programming period for 6 months, and any stimulation decided by the neurologists/neurosurgeons for the final 3 months.
62144108|NCT02158806|PLACEBO_COMPARATOR|Inert capsule|Matching capsule once daily for up to 24 weeks
62144109|NCT02634307|EXPERIMENTAL|ALKS 8700|Oral capsules taken twice daily.
62348847|NCT00339885||UEF - Laakso|Monogenic disease individuals and family members
62348848|NCT06139861|EXPERIMENTAL|TranS-C|
62348849|NCT06139861|ACTIVE_COMPARATOR|Psychoeducation|
62348850|NCT05871021|EXPERIMENTAL|75 Gy with two cycles of bevacizumab|
62348851|NCT02312583|SHAM_COMPARATOR|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment.
62348852|NCT02312583|EXPERIMENTAL|iFightDepression online programme.|iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
62348853|NCT03209440|ACTIVE_COMPARATOR|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
62348854|NCT03209440|EXPERIMENTAL|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
62348855|NCT03209440|EXPERIMENTAL|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
62348856|NCT04007601|ACTIVE_COMPARATOR|Active tDCS|Remotely delivered active tDCS + cognitive training
62348857|NCT04007601|PLACEBO_COMPARATOR|Sham tDCS|Remotely delivered sham tDCS + cognitive training
62348858|NCT02892825|EXPERIMENTAL|music group|music listening
62348859|NCT02892825|ACTIVE_COMPARATOR|no music group|no music listening
62348860|NCT02767856|EXPERIMENTAL|Intense 12-hour IO-therapy Group|Participants wear 12-hour daily IO-therapy glasses for 4 weeks
62348861|NCT02767856|ACTIVE_COMPARATOR|Standard 4-hour IO-therapy Group|Participants wear 4-hour daily IO-therapy glasses for 12 weeks
62348862|NCT04406935|ACTIVE_COMPARATOR|475 KHz|NuEra device treatment using 475 KHz
62348863|NCT04406935|ACTIVE_COMPARATOR|1 MHz|Arm 2: NuEra device treatment using 1 MHz
62348864|NCT04406935|ACTIVE_COMPARATOR|2 MHz|NuEra device treatment using 2 MHz
62348865|NCT04929756||Fixation PRL|Visual feedback will be provided at the the preferred retinal locus (PRL) to train subjects to attend to a fixation location. Feedback consists of a gaze-contingent ring whose size varies depending on task performance. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Gaze behavior will be measured with an eye tracker.
62348866|NCT04929756||Smooth Pursuit PRL|Visual feedback will be provided to train subjects to attend to a PRL for smooth pursuit eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on a drifting target. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Smooth pursuit tracking behavior will be measured with an eye tracker.
62348867|NCT04929756||Saccade PRL|Visual feedback will be provided to train subjects to attend to a PRL for saccadic eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on an abruptly shifting dot. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Saccadic eye movement behavior will be measured with an eye tracker.
62348868|NCT04929756||Scotoma Awareness PRL|Subjects are often unaware of their scotomas because they are filled in with the surrounding background texture. The investigators will exploit this filling in to increase awareness of the scotoma by surrounding the scotoma with a visible disk that will be perceptually completed across the scotoma, rendering the scotoma visible. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Scotoma Awareness Disk at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
62348869|NCT04929756||Meta-Guidance PRL|Oculomotor control can be promoted in the location around our hands. The investigators will exploit this meta-guidance advantage by asking subjects to move their hand and their PRL to an on-screen target. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Hand Movement at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
62348870|NCT00992732|EXPERIMENTAL|HQK-1004 + Valganciclovir|
62348871|NCT03033251|ACTIVE_COMPARATOR|Non invasive ventilation|Patients will receive non invasive ventilation with setting decided by the attending physician.
62506768|NCT04522999|EXPERIMENTAL|Photobiomodulation|Valeda™ Light Delivery System
62705124|NCT05980234||Longevity IT Offset Liners|The Longevity IT Offset liner was designed to lateralize the center of rotation of the cup.
62705125|NCT05039515|EXPERIMENTAL|IPN60130 high dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
62705126|NCT05039515|EXPERIMENTAL|IPN60130 low dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
62705127|NCT05039515|PLACEBO_COMPARATOR|Placebo|Oral capsule, swallowed whole or sprinkled onto food, once daily
62705128|NCT04803201|EXPERIMENTAL|Arm A (duvelisib, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =\< 60 years old, and prednisone PO QD on days 1-5. Patients also receive duvelisib PO BID on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62705129|NCT04803201|EXPERIMENTAL|Arm B (CC-486, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =\< 60 years old, and prednisone PO QD on days 1-5. Patients also receive CC-486 PO QD on days -6 to 0 of cycle -1 and days 8-21 of cycles 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62705130|NCT04803201|ACTIVE_COMPARATOR|Arm C (CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =\< 60 years old, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62705131|NCT06019260||group 1|open surgical repair using suture button device method in acute acromioclavicular joint disruption
62705132|NCT06019260||group 2|arthroscopic assisted treatment of acute acromioclavicular joint disruption using suture button device
62705133|NCT04094298|EXPERIMENTAL|Treatment Group|Patients receiving the 32-unit injection of FX006.
62705134|NCT05651022|EXPERIMENTAL|Cohort -3|A single dose of Decoy20 at a dose of 0.75 x 10\^7 Killed Bacteria (KB)
62705135|NCT05651022|EXPERIMENTAL|Cohort -2|A single dose of Decoy20 at a dose of 1.5 x 10\^7 KB
62705136|NCT05651022|EXPERIMENTAL|Cohort -1|A single dose of Decoy20 at a dose of 3 x 10\^7 KB
62705137|NCT05651022|EXPERIMENTAL|Cohort 1|A single dose of Decoy20 at a dose of 7 x 10\^7 KB
62705138|NCT05651022|EXPERIMENTAL|Cohort 2|A single dose of Decoy20 at a dose of 20 x 10\^7 KB
61963286|NCT06158126||Prospective safety cohort of time and type of PrEP initiation|The cohort will include pregnant women assessed as being at substantial risk for HIV acquisition and eligible for PrEP per Malawi national PrEP guidelines at Bwaila District Hospital. All women meeting eligibility criteria will be consented and offered PrEP (if not already taking it). Women will have access to either CAB-LA or oral PrEP and will be given an opportunity to choose one option. We will group our women according to use of oral PrEP (FTC/TDF or TDF/3TC) versus injectable PrEP (CAB-LA), and according to PrEP use before or after pregnancy diagnosis and follow up in those groups. All women will be registered into the PrEP Pregnancy Registry as part of routine care.
61963287|NCT06313229|EXPERIMENTAL|Staged implant placement approach|the bone defect was grafted using bone plates buccally and palatally and the defect between plates was grafted by sticky allogenic bone graft. 6 months later the implant was placed in the grafted site.
61963288|NCT06313229|EXPERIMENTAL|Simultaneous implant placement approach|the bone defect was grafted using bone plates buccally and palatally and the defect between plates was grafted by sticky allogenic bone graft combined with simultaneous implant placement.
62348872|NCT03033251|ACTIVE_COMPARATOR|High Flow 50 L/min|High Flow Oxygen Cannula with a flow set at 50 L/min.
62348873|NCT03033251|ACTIVE_COMPARATOR|High Flow 30 L/min|High Flow Oxygen Cannula with a flow set at 30 L/min.
62348874|NCT00555906|EXPERIMENTAL|1|
62348875|NCT00592657||1|Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
62348876|NCT00592657||2|Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion
62506769|NCT05743634|EXPERIMENTAL|Treatment Group|Single injection with YY001 in glabellar lines
62506770|NCT05743634|ACTIVE_COMPARATOR|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
62506771|NCT05743634|PLACEBO_COMPARATOR|Placebo-Controlled Group|Single injection with placebo in glabellar lines
62506772|NCT05567887|EXPERIMENTAL|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
62705139|NCT05651022|EXPERIMENTAL|Cohort 3|A single dose of Decoy20 at a dose of 70 x 10\^7 KB
62705140|NCT05651022|EXPERIMENTAL|Cohort 4|A single dose of Decoy20 at a dose of 200 x 10\^7 KB
62705141|NCT06584656|EXPERIMENTAL|Aerobic exercise group|-Aerobic group. 30 min at 60-70% of the Maximal Heart Rate, moderate intensity on cycle.
62705142|NCT06584656|EXPERIMENTAL|Resistance exercise group|30 min at 4-6 RPE (OMNI-Resistance Exercise Scale of Perceived Exertion), 3 sets of 8 exercise/set, 40 sec/exercise. Moderate intensity using elastic bands and body weight.
62705143|NCT06584656|NO_INTERVENTION|Control|30 min seated watching a neutral documentary without cognitive engagement
62506773|NCT05118360|EXPERIMENTAL|Part 1-ASC41 2mg|ASC41 2mg for 52 weeks.
62506774|NCT05118360|PLACEBO_COMPARATOR|Part1-placebo|Matching placebo for 52 weeks.
62506775|NCT05118360|EXPERIMENTAL|Part 2-ASC41 4mg|ASC41 4 mg for 52 weeks.
62506776|NCT05118360|PLACEBO_COMPARATOR|Part2-placebo|Matching placebo for 52 weeks.
62506777|NCT05598034|EXPERIMENTAL|Left DLPFC tDCS|Participants randomized to this arm will receive tDCS at the left DLPFC brain region.
62705144|NCT04704674||0.5 - 5 years|Age bracket for infants/children up to age five years
62705145|NCT04704674||10 - 18 years|Age bracket for children 10 - 18 years
62705146|NCT04704674||19 + years|Age bracket for adults over 19 years
62705147|NCT04704674||5 - 10 years|Age bracket for children ages 5 - 10 years
62705148|NCT06232044|EXPERIMENTAL|Phase I (iberdomide, belantamab mafodotin, dexamethasone)|Patients receive iberdomide orally on days 1-21 and 29-49, belantamab mafodotin IV on day 1, and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo a bone marrow biopsy and aspiration and blood sample collection throughout trial.
62506778|NCT05598034|EXPERIMENTAL|Left DLPFC tDCS + task|Participants randomized to this arm will receive tDCS at the left DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
61963289|NCT03950115|EXPERIMENTAL|Group 1|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
61963290|NCT05386069|NO_INTERVENTION|Control Arm|Routine Care per Anesthiologist/cRNA
62506779|NCT05598034|EXPERIMENTAL|Right DLPFC tDCS|Participants randomized to this arm will receive tDCS at the right DLPFC brain region.
62506780|NCT05598034|EXPERIMENTAL|Right DLPFC tDCS + task|Participants randomized to this arm will receive tDCS at the right DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
62506781|NCT00791986|NO_INTERVENTION|control|The patients in this control group do not conduct any breathing training.
62506782|NCT00791986|EXPERIMENTAL|ULB|The patients conduct controlled slow breathing training using the WPTB device without inspiratory resistance.
62506783|NCT00791986|EXPERIMENTAL|LB|The patients breath in against resistance using WPTB device.
62506784|NCT05945810|EXPERIMENTAL|sequence A|In cycle 1, subjects in sequence A receive a 50-mg single dose of TLL-018 extended-release tablet on day 1, and once daily for 5 consecutive days from day 3 onwards. After a 3-day washout period, subjects enter the cycle 2 at day 11 when they receive a 20-mg single dose of TLL-018 immediate-release tablet on the morning and another dose 12 hours later at night. From day 13 onward, they continue to receive 20 mg TLL-018 immediate-release tablets twice daily for 5 consecutive days.
62506785|NCT05945810|EXPERIMENTAL|sequence B|In cycle 1, subjects in sequence B receive a 20-mg single dose of TLL-018 immediate-release tablet on the morning on day 1 and another dose 12 hours later at night. From day 3 onward, they continue to receive 20-mg TLL-018 immediate-release tablets twice daily for 5 consecutive days. After 3 days of washout, subjects receive a 50-mg single dose of TLL-018 extended-release tablet on day 11 In cycle 2, and once daily for 5 consecutive days from day 13 onwards.
62705149|NCT06232044|ACTIVE_COMPARATOR|Phase II, Arm I (belantamab mafodotin, dexamethasone)|Patients receive belantamab mafodotin IV on day 1 and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients who progress may cross over to Arm II. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo a bone marrow biopsy and aspiration and blood sample collection throughout trial.
62705150|NCT06232044|EXPERIMENTAL|Phase II, Arm II (iberdomide, belantamab mafodotin)|Patients receive iberdomide orally on days 1-21 and 29-49, belantamab mafodotin IV on day 1, and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo bone marrow biopsy and aspiration and blood sample collection throughout trial.
61963291|NCT05386069|ACTIVE_COMPARATOR|Treatment Arm|Patients to receive standard weight-based ketamine bolus (0.5 mg/kg) at start of procedure, withhold opioids in post-operative period unless rescue medications fail
61963292|NCT02340975|EXPERIMENTAL|Phase 1b-M20 mg/kg (Q4W) + T 1 mg/kg (Q4W) Fw M10 mg/kg (Q2W)|Participants in second-line therapy with gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive intravenous (IV) infusion of 20 mg/kg MEDI4736 every 4 weeks (Q4W) for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
62348877|NCT02115113|EXPERIMENTAL|Group A (Tacrolimus Elimination Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
62348878|NCT02115113|ACTIVE_COMPARATOR|Group B (Tacrolimus Minimization Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
62506786|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
62506787|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
62506788|NCT03838341||Included|The consecutive patients with atrial fibrillation assigned to totally thoracoscopic stand-alone left atrial appendage occlusion using AtriClip® for stroke prevention.
62506789|NCT02369549|ACTIVE_COMPARATOR|Micro-particle curcumin|"Three 30 mg capsules once daily, self-administered for 6 months.~Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s."
62705151|NCT02709161|EXPERIMENTAL|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
62506790|NCT02369549|PLACEBO_COMPARATOR|Placebo|"Three 30 mg capsules taken once daily, self-administered for 6 months.~Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape."
62506791|NCT02807441|NO_INTERVENTION|No aspirin|Patients will not be given any Acetylsalicylic acid in the perioperative period.
61963293|NCT02340975|EXPERIMENTAL|Phase 2 Arm A-(M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
61963294|NCT02340975|EXPERIMENTAL|Phase 2 Arm B-M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg MEDI4736 Q2W for 12 months (up to 26 doses).
61963295|NCT02340975|EXPERIMENTAL|Phase 2 Arm C-T10 mg/kg (Q4W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg tremelimumab Q4W for 7 doses and then Q12W for 2 doses for 12 months (for a total of up to 9 doses).
61963296|NCT02340975|EXPERIMENTAL|Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
61963297|NCT02340975|EXPERIMENTAL|Phase 2 Arm E-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second and third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma and a positive IFN-γ gene expression signature will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
61963298|NCT00309114|EXPERIMENTAL|Interventions for Experimental Arm|Bacterial Interference with Escherichia coli 83972. Each bladder inoculation contains the study organism, E. coli 83972, suspended as a clear solution in sterile physiological saline.
61963299|NCT00309114|PLACEBO_COMPARATOR|Interventions for Control Arm|Each bladder inoculation contains sterile physiological saline that does not contain the study organism.
61963300|NCT05831020|ACTIVE_COMPARATOR|Group A (VAC group)|For Group A, VAC dressing was placed to secure split thickness skin graft. Two sheets of sterilized VAC sponge that was cut to fit the wound contour were placed with a fenestrated tube between the two layers that was secured to the surrounding skin using tincture of benzoin spray and an adhesive dressing (OPSITE). The VAC was placed to intermittent -125 mmHg suction for 2 hours and then decompressed for next 2 hours.
61963301|NCT05831020|ACTIVE_COMPARATOR|Group B (Bolster dressing group)|For Group B, Bolster dressing was done to secure split thickness skin graft. The recipient site was bolstered with wet bulky cotton gauze dressing and wrapped with cotton bandage. 0.9% normal saline was used for moisture.
61963302|NCT05798832|ACTIVE_COMPARATOR|Active Comparator|The active control group was given traditional Basic Life Support, which already practiced in most schools.For the traditional BLS training group; basic life support was given a lesson in the classroom for 45 to 50 minutes, demonstrated on a model, and the training session was ended after a question and answer session. In terms of standardization of the trainings, the trainings were given by Derya ASLAN HUYAR.
62506792|NCT02807441|EXPERIMENTAL|Low-dose aspirin|Patients will be given low-dose Acetylsalicylic acid (81 mg) in the perioperative period.
62705152|NCT02709161|ACTIVE_COMPARATOR|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
62714965|NCT02807701|ACTIVE_COMPARATOR|Open pancreaticoduodenectomy|"Open pancreaticoduodenectomy Abdomen is opened from the Bilateral Subcostal incision. (Chevron's Incision) 2. Abdominal cavity is explored for metastasis especially in liver, base of mesentary, mesocolon and pelvis.~Dissection Reconstruction Pancreaticogastrostomy Hepaticojejunostomy is next- Done in single layer and can be performed in interrupted or continuous fashion.~Gastrojejunostomy is the final step of reconstruction."
62348879|NCT03406910||Seventh day Adventist adults|Seventh day Adventist adults recruited from the USA and Canada. Approximately 65% female and 35% male. Composed of participants with different dietary patterns and a wide variation in egg and meat intake ranging from non-consumptive to daily consumption.
62348880|NCT05998655|EXPERIMENTAL|experimental group|In the research, tele-nursing practices and counseling based on the theory of technological competence will be provided to the experimental group.
62348881|NCT05998655|NO_INTERVENTION|control group|No attempt will be made on individuals in the control group during the research process
62506793|NCT02807441|EXPERIMENTAL|High-dose aspirin|Patients will be given high-dose Acetylsalicylic acid (325 mg) in the perioperative period.
62506794|NCT04022031||Exposed group|Chinese patent medicine combined with western medicine routine
62506795|NCT04022031||Non-exposed group|Western medicine routine treatment
62506796|NCT02208752|ACTIVE_COMPARATOR|Exercises|exericises on motor control and strengthening exercises on the Rotator Cuff
62506797|NCT02208752|PLACEBO_COMPARATOR|Control group- No exercises|No exercises
62506798|NCT03124134|EXPERIMENTAL|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
62506799|NCT03124134|EXPERIMENTAL|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
62506800|NCT03124134|PLACEBO_COMPARATOR|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
62506801|NCT03124134|PLACEBO_COMPARATOR|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
62506802|NCT03124134|EXPERIMENTAL|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
62506803|NCT03124134|PLACEBO_COMPARATOR|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
61963303|NCT05798832|EXPERIMENTAL|experimental|Basic Life Support training with VR was given to the experimental group.For the VR BLS training group; The use of VR was introduced in the VR hall. The lexical meanings of the basic concepts of BLS were explained. The student received training on a scenario he chose in the training module, and then he was asked to perform the steps individually in the assessment mode. After the training was completed, a question-answer was made and the session was closed. In terms of standardization of the trainings, the trainings were made by Derya ASLAN HUYAR.
61963304|NCT03748888|EXPERIMENTAL|Exercise group|An antenatal physical activity (APA) programme will be designed for participants in the exercise group.
62705153|NCT05912608|ACTIVE_COMPARATOR|Conservative Type A Acute Aortic Dissection Repair (TAAAD-R)|All conservative TAAAD-R will be performed through a median sternotomy. The conservative TAAAD-R will include patients receiving valve-sparing root procedures and recipients of ascending aortic root sparing replacement if the intima separation extended into the sinuses resulting in commissural collapse.When necessary, the hemiarch technique will be used with a limited extension of the conservative procedure by resection of all the aortic tissue up to the left common carotid artery and which will be dictated according to the presentation of the lesion.
61963305|NCT03748888|NO_INTERVENTION|Control Group|Sedentary participants.
61963306|NCT01804465|EXPERIMENTAL|Immediate IpilimumabTreatment|Arm 1 (Immediate Treatment) Ipilimumab Q3wks x 4 started 1 day following the final dose of SipT.
61963307|NCT01804465|EXPERIMENTAL|Delayed IpilimumabTreatment|Arm 2 (Delayed Treatment) Ipilimumab Q3wks x 4 started 3 weeks following the final dose of SipT.
61963308|NCT02142101||GFR >60|5 patients with polycystic kidney disease with eGFR \> 60 ml/min.
61963309|NCT02142101||GFR 15-60|5 patients with polycystic kidney disease with eGFR between 15-60 ml/min.
62705154|NCT05912608|OTHER|Extensive Type A Acute Aortic Dissection Repair (TAAAD-R)|All extensive TAAAD-R will be performed through a median sternotomy.The extensive TAAAD-R will include patients receiving replacement of the aortic root and total arch replacement procedures (TARP)
62705155|NCT04426591|EXPERIMENTAL|Biotin labeled Red Blood Cells|Participants receiving a transfusion with biotin labeled RBCs. Samples will be taken for 12 weeks after the biotinylated transfusion. During this time participants will continue to receive regular monthly transfusions (non-biotinylated) as part of CTT.
61963310|NCT02142101||GFR <15|5 patients with polycystic kidney disease with eGFR \<15 ml/min.
61963311|NCT03428360|EXPERIMENTAL|Subjects with Epilepsy|Male or female subjects between the ages of 2 and 65 years who had an established diagnosis of epilepsy exhibited by motor seizures with clear alteration of awareness, and while on a regimen of anti-epileptic medication(s), still experienced bouts of seizures (frequent breakthrough seizures, eg, seizure clusters) and who, in the opinion of the Investigator, could need benzodiazepine intervention for seizure control at least 1 time a month on average. Subjects must have been on at least 1 concomitant anti-epileptic drug at screening.
61963312|NCT05037734|ACTIVE_COMPARATOR|Robotic-Assisted UKA|Randomized participant will receive UKA via the ROSA Partial Knee System.
61963313|NCT05037734|ACTIVE_COMPARATOR|Traditional/Conventional UKA|Randomized participant will receive the UKA via Conventional/Traditional UKA Methods.
61963314|NCT01959815||Scleroderma and diagnosed PAH|
61963315|NCT01959815||"Low risk scleroderma"|
61963316|NCT01959815||Healthy volunteers|
61963317|NCT01959815||"High risk scleroderma"|
61963318|NCT01206660|EXPERIMENTAL|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
61963319|NCT01206660|PLACEBO_COMPARATOR|placebo|Placebo administered to affected area twice a day for 28 days
61963320|NCT02468115|EXPERIMENTAL|VIS410|Single intravenous fixed dose of VIS410
61963321|NCT02468115|PLACEBO_COMPARATOR|Placebo|Single intravenous infusion of placebo
61963322|NCT05739097||non-anemic women|Pregnant women consecutively observed at Ob/Gyn Dept
62348882|NCT00503542|EXPERIMENTAL|Intervention|Patients primarily with itching or irritation are treated for candidal vaginitis. Patients primarily with vaginal odor are treated for bacterial vaginosis. Patients who did not fit either of the previous groups are treated for both candidal vaginitis and bacterial vaginosis.
62348883|NCT00503542|ACTIVE_COMPARATOR|Control|Patient are examined and a wet mount is prepared. If a definitive diagnosis is made patient is treated for the condition diagnosed. If no diagnosis is made the clinician has the option of either foregoing treatment (watchful waiting) or following the protocol in the experimental group
62348884|NCT01745601|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
61963323|NCT05739097||anemic women|Pregnant women at Ob/Gyn Dept
61963324|NCT05739097||bleeders|Pregnant women at Ob/Gyn Dept
61963325|NCT02486432|EXPERIMENTAL|Single arm Levodopa/Carbidopa|The intervention is dosing with Sinemet® which is an oral tablet containing Levodopa/Carbidopa. Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
61963326|NCT01257997||Healthy subjects|18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
61963327|NCT05787457||Tamil natives with Diabetes Type 2|Thirty Tamil natives (15 men, 15 women), representing general Tamil diabetic cohort.
61963328|NCT05787457||Swiss natives with Diabetes Type 2_matched|Thirty Swiss natives (15 men, 15 women) matching the Tamil cohort.
61963329|NCT05787457||Swiss natives with Diabetes Type 2_not matched|Thirty Swiss natives (15 men, 15 women), who are not matched to the Tamil cohort, representing general Swiss diabetic cohort.
61963330|NCT00492908|ACTIVE_COMPARATOR|Titanium Nitride Oxide Coated Stent|Stent
61963331|NCT00492908|ACTIVE_COMPARATOR|Zotarohlimus Eluting Stent|Stent
61963332|NCT04981769||Patients|Patients presenting to clinical sites for Covid-19 testing who are 2 years of age or older.
61963333|NCT05701527|EXPERIMENTAL|Part A-Cohort 1|Patients will be administered Dose 1 of EBC-129 as a monotherapy.
61963334|NCT05701527|EXPERIMENTAL|Part A-Cohort 2|Patients will be administered Dose 2 of EBC-129 as a monotherapy.
61963335|NCT05701527|EXPERIMENTAL|Part A-Cohort 3|Patients will be administered Dose 3 of EBC-129 as a monotherapy.
61963336|NCT05701527|EXPERIMENTAL|Part A-Cohort 4|Patients will be administered Dose 4 of EBC-129 as a monotherapy.
61963337|NCT05701527|EXPERIMENTAL|Part A-Cohort 5|Patients will be administered Dose 5 of EBC-129 as a monotherapy.
61963338|NCT05701527|EXPERIMENTAL|Part B|Patients will be administered three different dose levels of EBC-129 in combination with a fixed dose of pembrolizumab.
61963339|NCT05701527|EXPERIMENTAL|Part C|Patients will be administered the highest dose of EBC-129 as a monotherapy at the RP2D determined in Part A of the study.
61963340|NCT01073553|EXPERIMENTAL|Arm 1|
61963341|NCT01073553|ACTIVE_COMPARATOR|Arm 2|
61963342|NCT00413452|EXPERIMENTAL|50 mg|50 mg once weekly
61963343|NCT04256798|EXPERIMENTAL|Mouthwash and liberal oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.
61963344|NCT04256798|ACTIVE_COMPARATOR|No mouthwash and liberal oxygen during surgery|No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.
61963345|NCT04256798|EXPERIMENTAL|Mouthwash and restrictive oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.
62348885|NCT01745601|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
62348886|NCT00440895|EXPERIMENTAL|1 intracoronary + infusion|Bolus abciximab i.c. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
62348887|NCT00440895|ACTIVE_COMPARATOR|2 intravenous|Bolus abciximab i.v. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
62705156|NCT04858009|EXPERIMENTAL|Treatment (HIPEC)|Patients undergo HIPEC with nab-paclitaxel and cisplatin over 90 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with paclitaxel and cisplatin up to 5 times. Patients undergo CT scan, MRI or PET during screening.
62705157|NCT03952624||Control|FNS \<= 3
62705158|NCT03952624||Fatigued|FNS \>= 4
62705159|NCT00342732||non-diabetic volunteers|non-diabetic volunteers aged 18-65 who are healthy as determined by medical history, physical examination, and laboratory tests
62705160|NCT05230667|ACTIVE_COMPARATOR|PRP injection (PRP group) and physical therapy|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for 2 times in 2-week interval. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance. Physical therapy will be conducted for 8 weeks.
62705161|NCT05230667|ACTIVE_COMPARATOR|Corticosteroid injection (CS group) and physical therapy|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa) for 2 times in 2-week interval. The techniques of injection are the same as those used in the PRP injection. Physical therapy will be conducted for 8 weeks.
61963346|NCT04256798|ACTIVE_COMPARATOR|No mouthwash and restrictive oxygen during surgery|No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.
61963347|NCT03844646|EXPERIMENTAL|CGM plus dietitian|Intermittent use of a continuous glucose monitor (CGM) plus dietitian support
61963348|NCT03844646|OTHER|Dietitian only|Dietitian support only
61963349|NCT05677581||pregnancy and lactation period women|
61963350|NCT05677581||healthy women of childbearing age|
61963351|NCT04830774|OTHER|COVID-19 patients with new-onset AF|Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.
61963352|NCT01379040||Cystic Fibrosis Patients|Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
61963353|NCT01379040||Control|Healthy volunteers
62348888|NCT00440895|PLACEBO_COMPARATOR|3 Placebo|Bolus of placebo followed by 12 h infusion (placebo).
61963354|NCT03310021|EXPERIMENTAL|Cohort 1|Apixaban + low dose andexanet
61963355|NCT03310021|EXPERIMENTAL|Cohort 2|Rivaroxaban + high dose andexanet
61963356|NCT03310021|EXPERIMENTAL|Cohort 3|Edoxaban + high dose andexanet
61963357|NCT03310021|EXPERIMENTAL|Cohort 4|Edoxaban + high dose andexanet
61963358|NCT03310021|EXPERIMENTAL|Cohort 5|Apixaban + low dose andexanet
61963359|NCT03310021|EXPERIMENTAL|Cohort 6|Apixaban + high dose andexanet
61963360|NCT03310021|EXPERIMENTAL|Cohort 7|Edoxaban + low dose andexanet
61963361|NCT03310021|EXPERIMENTAL|Cohort 8|Apixaban + low dose andexanet
61963362|NCT03310021|EXPERIMENTAL|Cohort 9|Rivaroxaban + low dose andexanet
61963363|NCT03310021|EXPERIMENTAL|Cohort 10|Edoxaban + low dose andexanet
61963364|NCT04750148||Cancer|Individuals with an oncology disease will be included in the study.
61963365|NCT05803005||children with autism spectrum disorder|: 50 patients aged 3_18 years, equally sex distributed, who visit pediatric neurology outpatients clinic with autistic disorder at assiut university hospital will enrolled in this study and 50 controls . (According to DSM IV and ADT-R)
61963366|NCT04847492|ACTIVE_COMPARATOR|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy.
61963367|NCT04847492|EXPERIMENTAL|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy.
61963368|NCT02848651|EXPERIMENTAL|Atezolizumab|Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
61963369|NCT05450731|EXPERIMENTAL|cardiac rehabilitation intervention group|Participants assigned to the intervention group will participate in pre-post assessments and a 12-week supervised exercise based cardiac rehabilitation program at a designated local Pulse Heart Institute Cardiac Rehabilitation program.
61963370|NCT05450731|NO_INTERVENTION|control group|Participants assigned to the control group will participate in pre-post assessments and will maintain usual care and current activity levels.
62506804|NCT05721651|EXPERIMENTAL|Experimental|Fruquintinib+PD-1
62506805|NCT05860387||Suspicion of IPA at enrolment|Study subjects with suspicion of IPA at enrolment will be included in this study group.
62705162|NCT05230667|ACTIVE_COMPARATOR|Normal saline injection (NS group) and physical therapy|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml) for 2 times in 2-week interval . The techniques of injection are the same as those used in the PRP injection. Physical therapy will be conducted for 8 weeks.
62705163|NCT00001727||1|Subjects with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome.
62348889|NCT02307838|OTHER|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
62348890|NCT03184857|ACTIVE_COMPARATOR|two stage sinus lifting using bovine bone particles|Open maxillary sinus lifting will be done with sinus augmentation using bovine bone particles
62348891|NCT03184857|EXPERIMENTAL|two sage sinus lifting using Nano HA bone particles|Open maxillary sinus lifting will be done with sinus augmentation using Nano HA bone particles
62348892|NCT01204333|EXPERIMENTAL|Endovascular thrombolysis|
62348893|NCT01204333|ACTIVE_COMPARATOR|Standard treatment|
62348894|NCT02915107|EXPERIMENTAL|Biofreedom|Experimental: Biofreedom BioFreedom stent at index procedure
62348895|NCT02915107|ACTIVE_COMPARATOR|Orsiro|Active comparator: Orsiro Orsiro stent at index procedure
62348896|NCT06436729|EXPERIMENTAL|MINST with Splinting|Minimally Invasive Non-Surgical Therapy will be done along with splinting of mobile anterior teeth
62348897|NCT06436729|ACTIVE_COMPARATOR|MINST without Splinting|Minimally Invasive Non-Surgical Therapy will be done without splinting of mobile anterior teeth
62348898|NCT03216278|EXPERIMENTAL|Treatment A|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed
62348899|NCT03216278|ACTIVE_COMPARATOR|Treatment B|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed
62348900|NCT03216278|EXPERIMENTAL|Treatment C|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted
62348901|NCT03216278|ACTIVE_COMPARATOR|Treatment D|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted
62348902|NCT03216278|EXPERIMENTAL|Treatment E|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed
62348903|NCT03216278|ACTIVE_COMPARATOR|Treatment F|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed
62348904|NCT03216278|EXPERIMENTAL|Treatment G|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted
62348905|NCT03216278|ACTIVE_COMPARATOR|Treatment H|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted
62348906|NCT04968340|OTHER|• Group 1(conventional c s)|this arm will be exposed to the conventional method of cesserian section which entail introduction of the operator hand below the fetal head during its extraction
62348907|NCT04968340|OTHER|• Group2(EPO technique)|this group will be exposed to external pop out teqnique which entails support of lower uterine segment without introduction of the obstetrician hand into uterine incision
62348908|NCT04775472|EXPERIMENTAL|Early left atrial septostomy group|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation.
62348909|NCT04775472|ACTIVE_COMPARATOR|Conventional approach group|Conventional approach group will receive left atrial septostomy in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
62348910|NCT00185354|EXPERIMENTAL|Arm 1|
62348911|NCT00185354|ACTIVE_COMPARATOR|Arm 2|
62348912|NCT00828685|ACTIVE_COMPARATOR|Operative (CRPP)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized.
62348913|NCT00828685|ACTIVE_COMPARATOR|Operative (ORIF)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized
62348914|NCT04846348|EXPERIMENTAL|Skin Guard|"Skin cream combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base:~Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor"
62348915|NCT05751057|EXPERIMENTAL|NSTEMI patients|Patients will undergo CMR before ICA
62348916|NCT04699214|EXPERIMENTAL|Endostar combined with chemotherapy AI|"Endostar: Endostar 45mg/d, D1-5 iv, Q3W, that is, continuous intravenous pump injection for 120 hours for 5 consecutive days, one cycle. Endostar uses 15 medicines per cycle, 15 Endostar medicines and a Baxter pump per single cycle. Subjects buy and use them at their own expense every two cycles.~AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W."
62348917|NCT04699214|ACTIVE_COMPARATOR|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
62506806|NCT05860387||Probable or proven IPA at enrolment|Study subjects with probable or proven IPA at enrolment will be included in this study group.
62506807|NCT02251977|EXPERIMENTAL|Adjuvant Chemotherapy plus GM1|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
61963371|NCT02012075|EXPERIMENTAL|Extended-Release Carvedilol Sulfate|18-72mg/d,po
62506808|NCT02251977|PLACEBO_COMPARATOR|Adjuvant Chemotherapy plus placebo|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4).
62506809|NCT06613269|EXPERIMENTAL|NY104 and FDG guided RT combining systemic therapy|In this arm, patients will undergo baseline evaluation using both 68Ga-NY104 and 18F-FGD PET/CT. Metastatic lesions will be identified based on these two PET/CTs and all other imaging modalities available. The radiation field will be planned to cover as much metastasis as possible if not all. Systemic therapy will be delivered at the same time. The patients will be followed up for disease status.
62506810|NCT02423317|ACTIVE_COMPARATOR|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
62506811|NCT02423317|EXPERIMENTAL|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
62506812|NCT01636817|EXPERIMENTAL|60 mg|
62506813|NCT01636817|EXPERIMENTAL|120 mg|
62705164|NCT02466971|ACTIVE_COMPARATOR|Arm I (cisplatin, IMRT or RT, brachytherapy)|Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, 30, (and day 36 or 37 at the treating physician's discretion). Patients then undergo EBRT (either conventional RT or IMRT) QD 5 days a week for 25 fractions followed by LDR or HDR brachytherapy according to institution's standards. Treatment continues in the absence of disease progression or unacceptable toxicity.
62705165|NCT02466971|EXPERIMENTAL|Arm II (cisplatin, IMRT or RT, brachytherapy, triapine)|Patients receive cisplatin and undergo EBRT followed by brachytherapy as in Arm I. Patients also receive triapine IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Treatment continues in the absence of disease progression or unacceptable toxicity.
62705166|NCT05496036|EXPERIMENTAL|Pembrolizumab|Study participants will undergo a tumor tissue collection biopsy prior to treatment, followed by one dose of pembrolizumab 400mg, then undergo a curative intent resection of all remaining disease 3 weeks after the initial dose of pembrolizumab. Post-operatively, subjects will receive up to 1 year of pembrolizumab 400mg every 6 weeks.
62705167|NCT05652465|EXPERIMENTAL|Active|TMS
62348918|NCT04699214|PLACEBO_COMPARATOR|Observation group|"The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator.~Patients with no disease progression (local tumor recurrence, distant metastasis, or the appearance of new lesions of the same tumor subtype) and the adverse reactions can be tolerated, continue to use the drug for 6 cycles, and cannot receive other anti-tumor treatments. In the course of medication, if the disease progresses or the researcher believes that the patient is not suitable for continuing medication, the medication will end."
62348919|NCT01398267|EXPERIMENTAL|1|
62348920|NCT01398267|PLACEBO_COMPARATOR|2|
62348921|NCT05854251|EXPERIMENTAL|Experimental Intervention|Patients receive investigational product
62348922|NCT05854251|PLACEBO_COMPARATOR|Control Intervention|Patients receive placebo
62348923|NCT03700970|EXPERIMENTAL|TAP block with liposomal bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
62348924|NCT03700970|ACTIVE_COMPARATOR|TAP block with regular bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of 0.25% bupivacaine injected on each side.
62348925|NCT05507060|ACTIVE_COMPARATOR|Vibrating MESH nebulizer|Medication will be applied with Vibrating MESH nebulizer
62348926|NCT05507060|ACTIVE_COMPARATOR|Jet nebulizers|Medication will be applied with Jet nebulizers
62348927|NCT00505102|ACTIVE_COMPARATOR|A|
62348928|NCT01724112|EXPERIMENTAL|LY2940094|40 mg administered orally as 1 capsule QD for 8 weeks.
62348929|NCT01724112|PLACEBO_COMPARATOR|Placebo|Administered orally as 1 capsule QD for 8 weeks.
62348930|NCT05741086|EXPERIMENTAL|Evolocumab added to statin therapy|Evolocumab (140 mg every 2 weeks for 1 year) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management in both arms.
62506814|NCT01636817|EXPERIMENTAL|240 mg|
62506815|NCT01636817|PLACEBO_COMPARATOR|Placebo|
62348931|NCT05741086|ACTIVE_COMPARATOR|Statin therapy|Atorvastatin 20-40mg. Anti-platelet aggregation and risk factor management in both arms.
62506816|NCT05780450|EXPERIMENTAL|Treatment group|
62506817|NCT04629274|EXPERIMENTAL|Test of Imotopes® candidates on blood cells of patients with stabilized NMO|To test in vitro the binding of different Imotopes® to class II HLA antigens on PBMC isolated from patients presenting a diagnosed and stabilized neuromyelitis optica spectrum disorders, as well as their ability to generate a cytolytic response directed against the immune cells involved in the maintenance and triggering of the disease (i.e. non-cytolytic T cells recognising the same epitopes and antigen presenting cells (APC) presenting the same epitopes).
62506818|NCT01305876|EXPERIMENTAL|one group with yoga intervention|one group with yoga intervention
62705168|NCT06430801|EXPERIMENTAL|Study 1: High Dose Induction, High Dose Maintenance|Participants receive high dose intravenous (IV) tulisokibart, followed by a high dose subcutaneous (SC) tulisokibart regimen.
62705169|NCT06430801|EXPERIMENTAL|Study 1: High Dose Induction, Low Dose Maintenance|Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
62705170|NCT06430801|EXPERIMENTAL|Study 1: Low Dose Induction, Low Dose Maintenance|Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
62705171|NCT06430801|PLACEBO_COMPARATOR|Study 1: Placebo|Participants receive IV placebo, followed by an SC placebo regimen.
62506819|NCT03490409|EXPERIMENTAL|compression stocking|The intervention group will receive a thigh compression stocking, which is to be used for 24 hours a day for 14 days after surgery.
62144110|NCT02265107|EXPERIMENTAL|cardiac rehabilitation|We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
62348932|NCT01195831|EXPERIMENTAL|Xamiol® gel|Calcipotriol (as hydrate) 50mcg/g plus betamethasone 0.5mg/g (dipropionate)
62348933|NCT01195831|ACTIVE_COMPARATOR|Calcipotriol scalp solution|Calcipotriol (as hydrate) 50 mcg/ml
61963372|NCT02012075|ACTIVE_COMPARATOR|Sustained-release Metoprolol Succinate|11.875-190mg/d,po
61963373|NCT03500952|EXPERIMENTAL|Patient Decision Aid|Birth Control After Pregnancy patient decision aid and supporting document
62348934|NCT03077113|OTHER|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
62348935|NCT04897438|EXPERIMENTAL|Intervention|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. If absolute levels of dd-cfDNA are \> 50 copies/ml, the patients receive a kidney allograft biopsy. Additionally, kidney allograft biopsies are performed according to standard of care as determined by the treating physicians.
62348936|NCT04897438|NO_INTERVENTION|Control|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. These measurements are not used to guide kidney allograft biopsies. Those are performed according to standard of care as determined by the treating physicians.
62348937|NCT02466412|ACTIVE_COMPARATOR|CHTP 1.1 M then mCC|"Each subject will follow the below study design:~* Day -1 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of CHTP 1.1 M)~* Day 2 = Wash-out~* Day 3 = 2nd intervention (single product use of mCC)."
62348938|NCT02466412|ACTIVE_COMPARATOR|mCC then CHTP 1.1 M|"Each subject will follow the below study design:~* Day -1 = Wash-out (1 day)~* Day 1 = 1st intervention (single product use of mCC)~* Day 2 = Wash-out~* Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
62348939|NCT01392053|NO_INTERVENTION|Control group|Control Group (CG) that will receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group
62348940|NCT01392053|EXPERIMENTAL|Massage Group|Massage Group (GM):receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation
62348941|NCT01709981|EXPERIMENTAL|Colchicine|1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later
62348942|NCT01709981|PLACEBO_COMPARATOR|Placebo|Placebo 1-2 hours prior PCI, followed by placebo 1 hour later
62348943|NCT05057741|EXPERIMENTAL|Multimodal Prehabilitation|Multimodal prehabilitation: exercise, nutrition and relaxation
62348944|NCT05057741|NO_INTERVENTION|Standard of Care|Usual care group: advice of surgeons about self care
62348945|NCT05833971|EXPERIMENTAL|Experimental: cadonilimab (AK104) + chemotherapy|Drug: Cadonilimab+ chemotherapy，10mg/kg IV every 3 weeks (Q3W)，Other Name: AK104； Cisplatin，60-75mg/m2 IV every 3 weeks (Q3W)，Other Name: DDP；Albumin Paclitaxel，260mg/m2 IV every 3 weeks D1, 8(Q3W)，Other Name: Nab-PTX
62348946|NCT01697267|EXPERIMENTAL|Rituximab Maintenance|Rituximab maintenance: 1g at 4, 8, 12, 16 \& 20 months with standardised steroid taper
62348947|NCT01697267|ACTIVE_COMPARATOR|Azathioprine Maintenance|Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.
62348948|NCT03421574|EXPERIMENTAL|MR-Guided Focused Ultrasound|
62348949|NCT03945435||Normal Glucose Tolerance|Blood glucose level of less than 140 mg/dL at the 2 hour timepoint.
62348950|NCT03945435||Impaired Glucose Tolerance|Blood glucose level of greater or equal to 140 mg/dL at the 2 hour timepoint.
62348951|NCT01410877||Inhaler naive healthy volunteers|
62348952|NCT03053310||Primary (P) - group|"* Patients with a primary diagnosis~* Patients treated with curative intent (stage I-IVb)"
62506820|NCT03490409|NO_INTERVENTION|Conventional treatment|The control group will receive conventional treatment, a compression bandage placed at the end of surgery and removed on the night of the surgery.
62348953|NCT03053310||Relapse (R) - group|"* Patients with a recurrent (loco)regional tumour~* Patients treated with curative intent (stage I-IVb)"
62348954|NCT01286116|EXPERIMENTAL|Treatment|Parachute implant
62348955|NCT05875129|EXPERIMENTAL|Intervention arm|Participants (N=15) will will be provided with the VAVA prototype along with installation instructions to embed the VAVA within their homes. We provide them with a smart speaker running our intervention, a smart lamp, and a new router. They will be asked to trial the VAVA for a period of 2 weeks, a duration consistent with the primary stage of CBT-I treatment.
62348956|NCT05443451|EXPERIMENTAL|Transperineal Microwave needle ablation for symptomatic BPH|
62506821|NCT06331117|EXPERIMENTAL|Case group|Multiomics profiling of the RASopathies
62506822|NCT02985398|EXPERIMENTAL|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
61963374|NCT03500952|ACTIVE_COMPARATOR|Patient Information Leaflet|Postpartum Birth Control patient information leaflet
61963375|NCT05123261|EXPERIMENTAL|the mindfulness-based elder care (MBEC) therapy|The experimental group was offered eight 50-minute courses once a week.
62348957|NCT02861755|EXPERIMENTAL|Arm 1|The MARIGOLD positive emotions course plus a blend of enhancements to include: 5-minutes of weekly facilitator contact, online discussion board, or gamification through virtual flower badges.
62506823|NCT02238132||Chronic Obstructive Airways Disease|
62705172|NCT06430801|EXPERIMENTAL|Study 1: High Dose Extension|Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
61963376|NCT05123261|NO_INTERVENTION|the routine activities|The control group maintained routine activities.
62506824|NCT00735930|EXPERIMENTAL|Treatment (alvocidib, lenalidomide)|Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62506825|NCT04407832|ACTIVE_COMPARATOR|low dose PPI|40 mg esomeprazole IV for three days followed by esomeprazole 40 mg po daily for two months
62506826|NCT04407832|ACTIVE_COMPARATOR|high dose PPI|40 mg esomeprazole IV every 6 hr for 3 days followed by 40 mg po daily for two months
62705173|NCT06430801|EXPERIMENTAL|Study 1: Low Dose Extension|Participants receive a low dose SC tulisokibart and placebo regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
62705174|NCT06430801|EXPERIMENTAL|Study 2: High Dose Induction|Participants receive high dose IV tulisokibart.
61963377|NCT00576927|EXPERIMENTAL|Group1|SHI followed by Active Drug Ramelteon
61963378|NCT00576927|PLACEBO_COMPARATOR|Group 2|SHI Followed by Placebo
62144111|NCT03723031|ACTIVE_COMPARATOR|rectal misopristol|will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion.
62144112|NCT03723031|ACTIVE_COMPARATOR|intrauterine misopristol|will receive 400 microgram misoprostol inserted intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta.
62348958|NCT02861755|EXPERIMENTAL|Arm 2|Emotion reporting control condition. Reporting daily emotions for the same duration of the online emotions course.
62348959|NCT05425719|EXPERIMENTAL|eGFR ≥ 70 mL/min/1.73 m^2|Participants with eGFR ≥ 70 mL/min/1.73 m\^2 received one 130 mg dose of MB-102 and a transdermal sensor was placed on their chest. Blood samples and fluorescent measurements were collected over 12 hours.
62348960|NCT05425719|EXPERIMENTAL|eGFR < 70 mL/min/1.73 m^2|Participants with eGFR \< 70 mL/min/1.73 m\^2 received one 130 mg dose of MB-102 and a transdermal sensor was placed on their chest. Blood samples and fluorescent measurements were collected over 24 hours.
62348961|NCT02608229|EXPERIMENTAL|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"* Treatment will be given in a 28-day cycle.~* BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals).~* BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.~* Nab-paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.~* Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.~* Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
62705175|NCT06430801|EXPERIMENTAL|Study 2: Low Dose Induction|Participants receive low dose IV tulisokibart.
62705176|NCT06430801|PLACEBO_COMPARATOR|Study 2: Placebo|Participants receive IV placebo.
62705177|NCT06430801|EXPERIMENTAL|Study 2: High Dose Extension|Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
62705178|NCT06430801|EXPERIMENTAL|Study 2: Low Dose Extension|Participants receive a low dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
62705179|NCT02911077||AUD population|The participants/group were treatment-seeking AUD individuals admitted to the NIH CC 1SE Addictions Unit.
62705180|NCT06566534|NO_INTERVENTION|Passive Control|Patients randomized to this arm will receive no special communications, beyond what Geisinger sends out as standard practice.
62705181|NCT06566534|EXPERIMENTAL|Active Control|Patients will receive a simple message encouraging them to get a flu shot at their appointment.
62705182|NCT06566534|EXPERIMENTAL|Best Nudge|"Patients will receive the nudge found to be numerically most effective in the megastudy, including language that a flu vaccine is reserved for them at their upcoming appointment."
61963379|NCT02256852|EXPERIMENTAL|QBKPN SSI|Individualized maintenance dose administered subcutaneously for 12 weeks
61963380|NCT03202498|EXPERIMENTAL|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
61963381|NCT03202498|PLACEBO_COMPARATOR|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
62506827|NCT02095886|EXPERIMENTAL|Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)|BMS-955176 single dose by mouth as specified
62714966|NCT01638507|OTHER|Resolute Integrity|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
61963382|NCT03202498|EXPERIMENTAL|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
61963383|NCT03202498|PLACEBO_COMPARATOR|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
61963384|NCT02115893|ACTIVE_COMPARATOR|Sodium Nitrate|Dietary Supplement: Sodium nitrate 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
61963385|NCT02115893|PLACEBO_COMPARATOR|Sodium Cloride|Dietary Supplement: Sodium chloride 800 mg of sodium chloride added with water to get a 140 mL solution (Frisia Zout BV, Harlingen, The Netherlands)
61963386|NCT04949048|EXPERIMENTAL|Magneto PE Kit|Treatment with Magneto PE Kit
61963387|NCT03504475|EXPERIMENTAL|Paroxetine Hydrochloride Tablet|During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.
62144113|NCT03065400|EXPERIMENTAL|Pembolizumab|
62144114|NCT03567278|EXPERIMENTAL|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
62144115|NCT03072888|EXPERIMENTAL|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
62144116|NCT03072888|SHAM_COMPARATOR|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
62144117|NCT02040870|EXPERIMENTAL|LDK378|daily dosing, 28-day cycle patients
62506828|NCT02095886|EXPERIMENTAL|Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)|BMS-955176 single dose by mouth as specified
62506829|NCT02095886|EXPERIMENTAL|Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)|BMS-955176 single dose by mouth as specified
62506830|NCT02095886|EXPERIMENTAL|Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)|BMS-955176 single dose by mouth as specified
61963388|NCT03504475|ACTIVE_COMPARATOR|Paxil®|During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.
61963389|NCT01422317|EXPERIMENTAL|n-3 fatty acids|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each capsule containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters, in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
61963390|NCT01422317|ACTIVE_COMPARATOR|Corn Oil|Two gelatine capsules twice a day, each containing 1 gram of corn oil. Alpha-Tocopherol (4 mg) was added to each capsule.
61963391|NCT05209958||Group A|Patients with NLR level below 2
61963392|NCT05209958||Group B|Patients with NLR level equal to or above 2
62506831|NCT02095886|EXPERIMENTAL|Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)|BMS-955176 single dose by mouth as specified
62506832|NCT02095886|EXPERIMENTAL|Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)|BMS-955176 single dose by mouth as specified
62506833|NCT02095886|EXPERIMENTAL|Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)|BMS-955176 single dose by mouth as specified
62506834|NCT02095886|EXPERIMENTAL|Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)|BMS-955176 single dose by mouth as specified
62506835|NCT04285827|EXPERIMENTAL|CSL889 Cohort A1 (Dose 1)|CSL889 administered as a single IV infusion
62506836|NCT04285827|EXPERIMENTAL|CSL889 Cohort A2 (Dose 2)|CSL889 administered as a single IV infusion
62506837|NCT04285827|EXPERIMENTAL|CSL889 Cohort A3 (Dose 3)|CSL889 administered as a single IV infusion
62506838|NCT04285827|EXPERIMENTAL|CSL889 Cohort A4 (Dose 4)|CSL889 administered as a single IV infusion
62705183|NCT06566534|EXPERIMENTAL|Personalized Nudge|Patients will receive the nudge predicted to be most effective for them on the basis of the machine learning-derived treatment assignment trees.
62144118|NCT05127902||adolescent idiopathic scoliosis group|Female subjects aged 10 to 16 will be recruited if they are diagnosed with AIS by standard standing long X-ray examinations, with Cobb angle larger or equal to 15°, without prior treatment for their AIS and been cleared for physical activity by their doctors. Subjects were excluded if they had (i) Cobb angle larger or equal to 40°, (ii) scoliosis with any known aetiologies such as congenital, neuromuscular, metabolic, and skeletal dysplasia, (iii) known endocrine and connective tissue abnormalities, (iv) known heart condition or other diseases that could affect the safety of exercise, (v) eating disorders or gastrointestinal malabsorption disorders, and (vi) currently taking medications that affecting their bone or muscle metabolism. All subjects will be recruited in the community.
62506839|NCT04285827|EXPERIMENTAL|CSL889 Cohort A5 (Dose 5)|CSL889 administered as a single IV infusion
62506840|NCT04285827|EXPERIMENTAL|CSL889 Cohort A6 (Dose 6)|CSL889 administered as a single IV infusion
62705184|NCT06271317||Nissen sleeve gastrectomy|Nissen sleeve gastrectomy patients
62705185|NCT06271317||Sleeve gastrectomy with the data of PMSI|Sleeve gastrectomy with the data of PMSI
62506841|NCT04285827|EXPERIMENTAL|CSL889 Cohort B1 (low dose)|CSL889 administered as a single IV infusion
62506842|NCT04285827|EXPERIMENTAL|CSL889 Cohort B2 (high dose)|CSL889 administered as a single IV infusion
62506843|NCT05405049|ACTIVE_COMPARATOR|Group intraperitoneal instillation of local anesthetic + local anesthetic infiltration (IPLA+ LWI)|local anesthetic infiltration into all layers of the anterior abdominal wall and peritoneal instillation
62506844|NCT05405049|ACTIVE_COMPARATOR|Group morphine ( M )|intrathecal injection of morphine with local anesthesic
61963393|NCT01393704|ACTIVE_COMPARATOR|High Volume Dilute Vasopressin|20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
61963394|NCT01393704|ACTIVE_COMPARATOR|Low volume dilute vasopressin|20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
61963395|NCT00158158|PLACEBO_COMPARATOR|1|Usual care
61963396|NCT00158158|EXPERIMENTAL|2|Reduction in smoking
61963397|NCT03797599|EXPERIMENTAL|20 minutes of mindfulness practice|Two sessions a week for two weeks of: 5 minutes listening to audio book excerpts followed by 20 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
62506845|NCT06343363||Patients treated with either mitral TEER, tricuspid TEER or both|Patients treated with either mitral TEER, tricuspid TEER or both, at John Radcliffe Hospital, Oxford
62506846|NCT04476186|ACTIVE_COMPARATOR|treatment group|200 mg of oral acyclovir 5 timed per day for 5 days per week for maximum 1 month
62506847|NCT04476186|PLACEBO_COMPARATOR|controlled group|KOH 10 % solution local application with apiece of cotton 2 time per day maximum for 1 month
62506848|NCT06337513|EXPERIMENTAL|Intervention group|The intervention consists of a physiotherapist-coordinated (PT) interdisciplinary outpatient rehabilitation for 6-months.
62506849|NCT06337513|ACTIVE_COMPARATOR|Usual care (control group)|Both groups are offered standard care.
62506850|NCT06532409|EXPERIMENTAL|Oral Amoxicillin|Patients in this group will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
62506851|NCT06532409|EXPERIMENTAL|IV Ceftriaxone|Patients in this group will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
62506852|NCT00898768|OTHER|capsule endoscopy|capsule endoscopie at baseline and after 2 years
62705186|NCT02891603|EXPERIMENTAL|Phase 1, Level 1: Pacritinib with Sirolimus and Tacrolimus|"After standard of care allogenic hematopoietic cell transplantation, Pacritinib will be added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~100 mg Pacritinib will begin taken by mouth the day of the participant's transplant (Day 0) and will continue until 70 days after the transplant..~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
62705187|NCT02891603|EXPERIMENTAL|Phase 1, Level 2: Pacritinib with Sirolimus and Tacrolimus|"After standard of care allogenic hematopoietic cell transplantation, Pacritinib will be added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~100 mg Pacritinib will begin taken by mouth twice daily starting the day of the participant's transplant (Day 0) and continuing until 70 days after the transplant..~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
61963398|NCT03797599|ACTIVE_COMPARATOR|5 minutes of mindfulness practice|Two sessions a week for two weeks of: 20 minutes listening to audio book excerpts followed by 5 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
61963399|NCT03797599|PLACEBO_COMPARATOR|Audio book control|Two sessions a week for two weeks of: 25 minutes listening to audio book excerpts (with non mindfulness practice). Participants will be asked not to engage in formal mindfulness practice during the study.
61963400|NCT05475795|ACTIVE_COMPARATOR|Metapex group|Obturation of primary molars with calcium hydroxide and iodoform paste
61963401|NCT05475795|EXPERIMENTAL|Endoflas group|Obturation of primary molars with calcium hydroxide, eugenol and iodoform paste
62348962|NCT02608229|EXPERIMENTAL|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"* Treatment will be given in a 28-day cycle.~* First 2 patients enrolled: BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~* Remaining 6 patients enrolled: BVD-523 450 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 800 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~* Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
62348963|NCT03138018|ACTIVE_COMPARATOR|Standard instruction|
62348964|NCT03138018|EXPERIMENTAL|Reduced threat instruction|
62348965|NCT05545904|EXPERIMENTAL|Intervention arm|Participants randomized to the intervention arm will undergo a substance use screening and brief intervention delivered by the peer-mentors. Screening will be performed using the ASSIST-Y (28). The brief intervention will be delivered in a single session (20-30 minutes) using the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
62348966|NCT05545904|PLACEBO_COMPARATOR|Control arm|Participants assigned to the control arm will participate in a substance use education intervention. This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
62348967|NCT04526119|EXPERIMENTAL|Z-338|
62348968|NCT04526119|PLACEBO_COMPARATOR|Placebo|
62348969|NCT04091334|EXPERIMENTAL|Serial ultrasound group|"Will received standard care and monitoring and in addition, have focused ultrasound examination of the heart and the lungs done twice.~The investigator is supposed to titrate the treatment according to the findings on the ultrasound examinations."
62348970|NCT04091334|ACTIVE_COMPARATOR|Standard care group|Standard care and monitoring.
62348971|NCT03404271|PLACEBO_COMPARATOR|Normal Diet|Participants in the normal diet (ND) group will follow a traditional dietary pattern, consisting of eating breakfast and continuing to eat throughout the day until the evening. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
62348972|NCT03404271|EXPERIMENTAL|Time-Restricted Feeding|Participants in the time-restricted feeding (TRF) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
62348973|NCT03404271|EXPERIMENTAL|Time-Restricted Feeding plus HMB|Participants in the time-restricted feeding plus HMB (TRF+HMB) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive HMB capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
62506853|NCT04322357|NO_INTERVENTION|Daily Glucocorticoid (GC)|Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.
62506854|NCT04322357|ACTIVE_COMPARATOR|Twice weekly glucocorticoid with or without exercise|"Patients will be randomized to one of 2 groups:~* Twice weekly prednisone alone for 12 months~* Twice weekly prednisone for 6 months followed by twice weekly prednisone plus 6 months of structured, supervised and home-based exercise training."
62506855|NCT04322357|ACTIVE_COMPARATOR|Daily glucocorticoid with exercise|Patients on daily glucocorticoids will undergo 6 months of structured, supervised and home-based exercise training.
61963402|NCT02188251|EXPERIMENTAL|Activamp|Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks
61963403|NCT02188251|PLACEBO_COMPARATOR|Placebo|1 capsule taken twice daily for 12 weeks
61963404|NCT05786391|EXPERIMENTAL|Flat position with no Insufflation|
61963405|NCT05786391|EXPERIMENTAL|Trendelenburg position and Insufflation|insufflation to 15 mm Hg
61963406|NCT05786391|EXPERIMENTAL|Flat position and Insufflation|
61963407|NCT05786391|EXPERIMENTAL|Trendelenburg position with no Insufflation|
61963408|NCT00536198|EXPERIMENTAL|Sertraline|Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
61963409|NCT00536198|PLACEBO_COMPARATOR|Placebo|Participants will take similar looking placebo during the symptomatic period.
61963410|NCT04034485|EXPERIMENTAL|LIB003 (lerodalcibep)|300 mg SC Q4W
61963411|NCT04034485|ACTIVE_COMPARATOR|evolocumab|420 mg SC Q4W
61963412|NCT04606082|EXPERIMENTAL|Group 1|Granulocyte Colony Stimulated Factor was intrauterine injected once at ovum pick up day
61963413|NCT04606082|ACTIVE_COMPARATOR|Group 2|500 IU Human Chorionic Gonadotropins was injected intrauterine once at ovum pick up day
61963414|NCT03645369|EXPERIMENTAL|Mechano-Analgesia|The first SC heparin injections were applied from the right abdominal region using ShotBlocker®.
61963415|NCT03645369|EXPERIMENTAL|Cold Application|The second SC heparin injections were applied from the left abdominal region with an ice pack
61963416|NCT03645369|NO_INTERVENTION|Control|The second SC heparin injections were applied from the lower abdominal region without any additional application
61963417|NCT00657527|EXPERIMENTAL|1|Rosuvastatin
61963418|NCT00657527|NO_INTERVENTION|2|Diet
61963419|NCT02449655|EXPERIMENTAL|AZD5363 plus paclitaxel|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
61963420|NCT02449655|ACTIVE_COMPARATOR|AZD2014 plus paclitaxel|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
61963421|NCT04873505|EXPERIMENTAL|Troches|25 persons take one probiotic troche after each meal.
61963422|NCT04873505|PLACEBO_COMPARATOR|Troches do not contain probiotics|25 persons take one troche that does not contain probiotics after each meal.
61963423|NCT01405248|EXPERIMENTAL|Butylphthalide|Single center of the placebo control a double-blind randomized control study to evaluate Butylphthalide prevention stents restenosis effect
62144119|NCT05127902||Control group|Ten healthy female subjects with matched for age, height and weight will be recruited as control.
62144120|NCT02417285|EXPERIMENTAL|CC-122 in combination with Obinutuzumab|CC-122 will be administered orally QD starting on Day 1 for 5 consecutive days followed by 2 days off study drug every 7 days (5/7-day schedule) in each 28-day cycle in combination with Obinutuzumab administered as an intravenous (IV) infusion at a dose of 1000 mg on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8.
62144121|NCT03331536||Roux en Y Gastric Bypass Pre-menopausal|Pre-menopausal women undergoing Roux en Y Gastric Bypass
62144122|NCT03331536||Roux en Y Gastric Bypass Post-menopausal|Post-menopausal women undergoing Roux en Y Gastric Bypass
61963424|NCT01405248|PLACEBO_COMPARATOR|control|Placebo
61963425|NCT04673864|EXPERIMENTAL|Sequence 1|"Period 1: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 3: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
61963426|NCT04673864|EXPERIMENTAL|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 2: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 4: D012, D326, D337- A single oral dose of 3 tablets under fasting condition"
61963427|NCT06127953|OTHER|Unilateral Cleft Lip Patients|Study is intermediate cleft rhinoplasty that will be performed in the patients with nasal deformities after repair of unilateral cleft lip congenital anomaly
61963428|NCT00217594|EXPERIMENTAL|Alemtuzumab|Patients received a 1-mg test dose of alemtuzumab, and the following day, alemtuzumab was administered at 10 mg/dose intravenously for 10 days
61963429|NCT02268084|SHAM_COMPARATOR|Sham Stimulation|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
62144123|NCT03331536||Sleeve Gastrectomy Pre-menopausal|Pre-menopausal women undergoing Sleeve Gastrectomy
62144124|NCT03331536||Sleeve Gastrectomy Post-menopausal|Post-menopausal women undergoing Gastric Sleeve
62144125|NCT06466759|NO_INTERVENTION|VOLCANO - double lumen tube placement with direct laryngoscopy|Patients will receive double lumen tube placement with direct laryngoscopy
61963430|NCT02268084|ACTIVE_COMPARATOR|Active sTMS|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase) and 2 additional weeks for all subjects (open label) with Synchronized Transcranial Magnetic Stimulation (sTMS), using an active device.
61963431|NCT05777876|NO_INTERVENTION|non-TRD|Patients with first episode or relapse of untreated depression group are treated with escitalopram for 8 weeks, and if effective, they are included in the n-TRD group. If ineffective, Venlafaxine is used for full treatment for 8 weeks; if effective, the patients are included in the non-TRD group. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring.
62144126|NCT06466759|ACTIVE_COMPARATOR|VOLCANO - double lumen tube placement with videolaryngoscopy|Patients will receive double lumen tube placement with videolaryngoscopy
62714967|NCT05160701|NO_INTERVENTION|Usual Care|Usual Care: no intervention elements.
61963432|NCT05777876|EXPERIMENTAL|TRD Target stimulation A|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target A (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
62144127|NCT02725138|EXPERIMENTAL|Probiotic|subjects will be treated with probiotic containing Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
62144128|NCT02725138|PLACEBO_COMPARATOR|Placebo|subjects will be treated with placebo without Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
62144129|NCT01437410||EUS-FNA|
62144130|NCT00087256|PLACEBO_COMPARATOR|Arm 1: placebo|one placebo capsule taken orally twice a day for 3 years
62144131|NCT00087256|EXPERIMENTAL|Arm 2: celecoxib|one 400 mg capsule taken orally twice a day for 3 years
62144132|NCT04696016|EXPERIMENTAL|Skin conductance guided|Sufentanil is titrated by the intensive care team to maintain skin conductance in target
62144133|NCT04696016|ACTIVE_COMPARATOR|Standard care|Sufentanil is titrated at the discretion of the intensivist
61963433|NCT05777876|EXPERIMENTAL|TRD Target stimulation B|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target B (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
61963434|NCT05777876|EXPERIMENTAL|TRD Target stimulation C|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target C (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
61963435|NCT05777876|SHAM_COMPARATOR|TRD sham stimulation|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: sham stimulation for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 seconds, total wearing the instrument for 30 minutes)
62506856|NCT05787067|EXPERIMENTAL|Intervention group|"The web-based Insulin Guide mobile application prepared by the researcher was installed on the phones of the intervention group participants. They were asked to use this application for three months, at least three hours a week. Participants were followed up through the application. Participants who did not use the application were informed by SMS or phone and asked to use the application. Participants who did not use the application were excluded from the study. At the end of three months, the participants in the intervention groups were invited to the Endocrinology and Metabolic Diseases Outpatient Clinic for a post-test. Both groups were asked to practice again on the insulin injection model. Whether the application was correct, incomplete, or incorrect was recorded on the observation form by the diabetes nurse."
61963436|NCT05777876|EXPERIMENTAL|TRD closed-loop stimulation|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Patients receive closed-loop stimulation guided by EEG phase, and the stimulation target is the effective deep brain region target verified in this study. Regimen: stimulation for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit)
61963437|NCT05777876|EXPERIMENTAL|HC experimental stimulation|The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. HC will receive TIS intervention in the exercise area for one time, the stimulation scheme adopted 20 Hz and 2mA total current intensity, and each stimulation lasted for 30 minutes (15 seconds respectively for lead-in and withdrawal)
61963438|NCT05777876|SHAM_COMPARATOR|HC sham stimulation|The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Electrode placement, current intensity and intervention times are consistent with those of TIS regimen. 20 Hz, 2mA total current intensityis used, but only lasted for 30 seconds, and then the current is 0 for a total of 30 minutes.
61963439|NCT05777876|NO_INTERVENTION|HC observation|Collect data on healthy controls without stimulation. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring.
61963440|NCT05062798|EXPERIMENTAL|Control group (standart bottle)|After the surgery, standard bottle will be used for feeding
61963441|NCT05062798|EXPERIMENTAL|Experimental Group (squeezable bottle)|After the surgery, squeezable bottle will be used for feeding
62506857|NCT05787067|NO_INTERVENTION|control group|Control group participants were invited to the Endocrinology and Metabolic Diseases Polyclinic for the pre-test. They were asked to administer insulin injections using an insulin injection model. Whether the application was correct, incomplete or incorrect was recorded in the observation form by the diabetes nurse. No intervention was made to the participants. At the end of three months, the participants in the control group were invited to the Endocrinology and Metabolic Diseases Polyclinic for the final test. And they were asked to repeat the insulin injection model. Whether the application was correct, incomplete or incorrect was recorded in the observation form by the diabetes nurse.
61963442|NCT00971698||Sickle Cell Patients|Patients with homozygous Sickle Cell Anemia
61963443|NCT00971698||Sickle Cell Thalassemia|Patients with Sickle Cell Thalassemia
61963444|NCT00732017|EXPERIMENTAL|HVPC-|This group received standard physical therapy treatment and HVPC with negative polarity.
61963445|NCT00732017|ACTIVE_COMPARATOR|CG|The control group received only standard physical therapy treatment.
61963446|NCT00732017|EXPERIMENTAL|HVPC+|This group received standard physical therapy treatment and HVPC using active electrodes with positive polarity.
61963447|NCT04804475|ACTIVE_COMPARATOR|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
62506858|NCT01069224||RC tear|This study will include a consecutive series of patients who met the study inclusion criteria. Study group patients will be diagnosed RC tear on clinical examination and imaging findings (US and MRI) that will be verified at arthroscopy in order to complete the enrollment.
62506859|NCT01069224||Control group|Control group will include patients suffering from shoulder instability that scheduled for elective surgical repair.
62506860|NCT04382430|EXPERIMENTAL|US Guided Axillary venous access|Physician/ provider will perform 2 unassisted \& 10 solo Ultrasound (US) guided venous access and pocket creation cardiac device implant. First 2 device implant will be done to educate physicians about ultrasound guided venous access. Subsequent subject will be randomized to 2:1 in ultrasound vs. conventional technique.
62506861|NCT04382430|ACTIVE_COMPARATOR|Conventional technique|Physician/ provider will perform 5 cardiac device implant using conventional technique for venous access and pocket creation.
61963448|NCT04804475|NO_INTERVENTION|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
62506862|NCT06289829|OTHER|Remifentanil|Ambu Auragain inserted after general anesthesia induced with remimazolam and remifentanil
62506863|NCT03003364|EXPERIMENTAL|XCEL-UMC-BETA/placebo|Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)
62506864|NCT03003364|PLACEBO_COMPARATOR|Placebo/XCEL-UMC-BETA|Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)
62506865|NCT06185972|EXPERIMENTAL|Experimental: Treatment Arm|All biopsy confirmed breast cancer patients undergoing MRI-guided ultrasound-stimulated microbubble treatment plus radiation therapy
62506866|NCT00703976|ACTIVE_COMPARATOR|Cetuximab, Pemetrexed and Radiation therapy|"Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks"
62506867|NCT00703976|EXPERIMENTAL|Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab|"Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy."
62506868|NCT06616896|EXPERIMENTAL|Continued mode vibration intervention|
62506869|NCT06616896|EXPERIMENTAL|Pause mode vibration intervention|
61963449|NCT01118221|EXPERIMENTAL|Arm 1|enroll in pulmonary rehabilitation program
62506870|NCT04346940|EXPERIMENTAL|Study Group|The group to which the exercise protocol consisting of chair-based exercises will be applied.
62506871|NCT04346940|ACTIVE_COMPARATOR|Control Group|Group to be given an exercise brochure
62506872|NCT06261619|ACTIVE_COMPARATOR|Bag mask ventilation with Adult Sotair device|The anesthesia provider will manually bag ventilate with the Adult Sotair® device for 3 minutes with an average respiratory rate of 12 breaths per minute with a deep breath every 30 seconds.
62506873|NCT06261619|NO_INTERVENTION|Bag mask ventilation|The anesthesia provider will manually bag ventilate for 3 minutes with an average respiratory rate of 12 breaths per minute with a deep breath every 30 seconds.
62506874|NCT03738787|EXPERIMENTAL|Pancreatic duct occlusion|Patients considered at high risk for pancreatic fistula or oncological relapse due to introperative evaluation submitted to pancreatic duct occlusion with Neoprene-based glue.
62506875|NCT03738787|ACTIVE_COMPARATOR|Pancreato-Jejunal anastomosi|Patients considered at low risk for pancreatic fistula submitted to pancreato-jejunal anastomosis.
62506876|NCT03397953|EXPERIMENTAL|Vinorelbine monotherapy treatment|Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
62506877|NCT04093154|EXPERIMENTAL|Virtual Reality|Standard Care + VR VR applications introduced to the child or adolescent by the researcher before the procedure. Three VR applications were used in this study; riding a rollercoaster (Rilix VR), swimming with marine animals in underwater world (Ocean Rift) and exploring the forest though the eyes of woodland species (In the eyes of animal). Children/adolescent chose one of these three applications. When the child is ready for the procedure, the researcher started the application by wearing virtual glasses to the child/adolescent. VR intervention was started 2-3 min before the procedure and continued until the procedure was completed.
62506878|NCT04093154|NO_INTERVENTION|Control|Standart Care Control group children did not receive any distraction techniques.
62506879|NCT04380727||Almitrine|Administration of 4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, France), over 30-45 min followed by 12 mcg/kg/min infusion rate. Because of a shortage of drug store at national level, a protocol using continuous infusion was not considered. Some patients may receive the drug for 36 hours depending on availability..
62506880|NCT04380727||Control|To eliminate the eventuality of a spontaneous evolution of hypoxia, these patients were matched to control COVID-19 patients treated without almitrine (time control).
62506881|NCT05922488|EXPERIMENTAL|Umbilical cord milking|In the cesarean section or vaginal delivery, the obstetrician will gently grasp the uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
62144134|NCT02325466|PLACEBO_COMPARATOR|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
62144135|NCT02325466|ACTIVE_COMPARATOR|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
61963450|NCT01118221|NO_INTERVENTION|Arm 2|no structured exercise
61963451|NCT03660267|EXPERIMENTAL|coffee group|caffeine coffee
61963452|NCT03660267|EXPERIMENTAL|decaffeinete coffee group|decaffeinete coffee group
62506882|NCT05922488|EXPERIMENTAL|delayed cord clamping|In the cesarean section or vaginal delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord. Infants will be dried and will be given gentle tactile stimulation to promote the respiratory effort.
62506883|NCT01321697||Vulvar Cancer|
62506884|NCT01083238|EXPERIMENTAL|1|AZD5069 following a 10-hour fast
61963453|NCT03660267|EXPERIMENTAL|water group|
61963454|NCT00123396|EXPERIMENTAL|Arm 1|Test the effectiveness of the BioCASES teaching modules by way of a randomized controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for increasing and sustaining VA clinician knowledge, skills, and ability to respond to bioterrorism events.
62144136|NCT02325466|ACTIVE_COMPARATOR|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
62144137|NCT03609099|ACTIVE_COMPARATOR|Moxifloxacin|Active treatment to patients treated during the 5 previous days.
62144138|NCT03609099|EXPERIMENTAL|Placebo|Placebo treatment to patients treated during the 5 previous days.
62144139|NCT00162318|EXPERIMENTAL|A|
62144140|NCT02765126|ACTIVE_COMPARATOR|Group 1|Diphtheria-tetanus-acellular pertussis vaccine administered day 0, followed by seasonal influenza vaccination four weeks later. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week, 4 weeks, 4 weeks + 24 hours, 5 weeks, 8 weeks and 30 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
62705188|NCT02891603|EXPERIMENTAL|Phase 2: Pacritinib with Sirolimus and Tacrolimus|"After standard of care allogenic hematopoietic cell transplantation, Pacritinib will be added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~Patients will take Pacritinib at the MTD: 100 mg Pacritinib will begin taken by mouth twice daily starting the day of the participant's transplant (Day 0) and continuing until 70 days after the transplant..~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
62705189|NCT04164082|EXPERIMENTAL|Treatment (pembrolizumab, gemcitabine hydrochloride)|"INDUCTION: Patients receive pembrolizumab IV over 25-40 minutes on day 1 of cycles 1-4. Patients also receive gemcitabine hydrochloride intravesically on days 1, 8 and 15 of cycles 1 and 2. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 5, patients with no evidence of disease after induction receive pembrolizumab IV over 25-40 minutes and gemcitabine intravesically on day 1 of each cycle. Treatment repeats every 3 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity.~Additionally, patients with T1 tumors undergo a re-staging TURBT within 60 days of registration. Patients also undergo urine and blood sample collection, bladder biopsy, cystoscopy, CT and MRI throughout the study."
62705190|NCT06159764||Cardioneuroablation|Cardioneuroablation
62705191|NCT04269902|ACTIVE_COMPARATOR|Arm I (delayed V-O)|Treatment begins once 2018 IWCLL indications are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, collection of blood samples, and bone marrow aspiration and biopsy throughout the trial.
62705192|NCT04269902|EXPERIMENTAL|Arm II (early V-O)|Treatment begins as soon as eligibility criteria are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, collection of blood samples, and bone marrow aspiration and biopsy throughout the trial.
61963455|NCT04882540|EXPERIMENTAL|brivaracetam|This is a Single-Arm study with Single- and Multiple- Dose Periods. Study participants will receive a single dose of brivaracetam (BRV) on Day 1 and will then receive multiple doses of brivaracetam from Day 5-10.
61963456|NCT02380677|EXPERIMENTAL|Schedule 1 Cohort 1|CRLX301 7.5 mg/m2 IV given every 3 weeks
61963457|NCT02380677|EXPERIMENTAL|Schedule 1 Cohort 2|CRLX301 15 mg/m2 IV given every 3 weeks
61963458|NCT02380677|EXPERIMENTAL|Schedule 1 Cohort 3|CRLX301 30 mg/m2 IV given every 3 weeks
61963459|NCT02380677|EXPERIMENTAL|Schedule 1 Cohort 4|CRLX301 60 mg/m2 IV given every 3 weeks
61963460|NCT02380677|EXPERIMENTAL|Schedule 1 Cohort 5|CRLX301 75 mg/m2 IV given every 3 weeks
61963461|NCT02380677|EXPERIMENTAL|Schedule 1 Cohort 6|CRLX301 90 mg/m2 IV given every 3 weeks
62144141|NCT02765126|ACTIVE_COMPARATOR|Group 2|Seasonal influenza vaccine administered on day 0, to be offered DTP vaccine at week 26. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
62705193|NCT06004479||Pregnant|Adult females between 18-40 years old who have a confirmed pregnancy.
62705194|NCT06004479||Non-pregnant|Adult females between 18-40 years old who do not have a confirmed pregnancy.
62705195|NCT06340958|EXPERIMENTAL|CLE-100|1 oral tablet of CLE-100 once daily (in addition to current anti-depressant drug) for 4 weeks
62144142|NCT02765126|ACTIVE_COMPARATOR|Group 3|Seasonal influenza vaccine and DTP vaccine administered together on day 0. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
62506885|NCT01083238|EXPERIMENTAL|2|AZD5069 30 minutes after the start of a high fat meal
62506886|NCT02003781||cardiovascular disease|high risk cardiovascular disease patients and their relatives
62705196|NCT06340958|PLACEBO_COMPARATOR|Placebo|1 oral tablet of Placebo once daily (in addition to current anti-depressant drug) for 4 weeks.
62705197|NCT05967247|EXPERIMENTAL|MBSR|"The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practising audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate."
62714968|NCT05160701|ACTIVE_COMPARATOR|Existing Medherent|Group using the Medherent Device with no added intervention components.
62506887|NCT01314768|ACTIVE_COMPARATOR|Brief intervention|Behavioural brief intervention delivered by GP
61963462|NCT02380677|EXPERIMENTAL|Schedule 2 Cohort 1|CRLX301 25 mg/m2 IV given weekly
61963463|NCT02380677|EXPERIMENTAL|Schedule 2 Cohort 2|CRLX301 35 mg/m2 IV given weekly
61963464|NCT02380677|EXPERIMENTAL|Schedule 2 Cohort 3|CRLX301 45 mg/m2 IV given weekly
61963465|NCT02380677|EXPERIMENTAL|Schedule 2 Cohort 4|CRLX301 54 mg/m2 IV given weekly
61963466|NCT02380677|EXPERIMENTAL|Schedule 2 Cohort 5|CRLX301 54 mg/m2 given weekly for 3 weeks with 1 week off
61963467|NCT02380677|EXPERIMENTAL|Phase 2a expansion cohort|CRLX301 75mg/m2 IV given every 3 weeks
61963468|NCT00660023|EXPERIMENTAL|Mircera in Renal Anemia|Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.
61963469|NCT00612781|OTHER|A|
61963470|NCT00612781|OTHER|B|
61963471|NCT02439840||Light sedation|Light sedation is defined as RASS of +1 to -2.
62144143|NCT03690804|EXPERIMENTAL|newborn is above 28 weeks of gestational age|40 parent-newborn duos in which the newborn is above 28 weeks of gestational age and less than 3 months of life and hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France)
62506888|NCT01314768|PLACEBO_COMPARATOR|Business as usual|Business as usual according to individual GP
62506889|NCT01314768|OTHER|Chronic headache control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
62506890|NCT01314768|OTHER|Population control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
61963472|NCT02439840||Deep sedation|Deep sedation is defined as RASS of -3 to -5
61963473|NCT00403234|EXPERIMENTAL|BTDS 10|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
62506891|NCT04105114|EXPERIMENTAL|Complete Spinal Cord Injury - Gravity Neutral Stepping|Group 1 will begin with a 3-4-month preparation phase and up to 12 sessions in the gravity neutral device (GND) will occur. The training sessions in the GND will be used to obtain the optimal stimulation parameters. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. This will be done in the GND in the presence of stimulation. Afterwards, Intervention 2 will include the same training procedures with the addition of Buspirone or Placebo in a cross-over fashion halfway through this phase.
61963474|NCT00403234|EXPERIMENTAL|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
61963475|NCT00403234|EXPERIMENTAL|BTDS 30|Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
61963476|NCT00403234|PLACEBO_COMPARATOR|Placebo TDS|Placebo patches were similar to BTDS 10 and 20.
61963477|NCT03340532|PLACEBO_COMPARATOR|Sleep hygiene video|Participants will watch a sleep hygiene video
61963478|NCT03340532|EXPERIMENTAL|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
61963479|NCT03340532|EXPERIMENTAL|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
61963480|NCT05502757|EXPERIMENTAL|Provision of paper FV vouchers (VOUCHER) condition|Families in the VOUCHER condition will be provided 6, $15 paper vouchers ($90 total) for the purchase of fresh FV at a partnering Food City location in Knoxville, TN.
61963481|NCT05502757|EXPERIMENTAL|Home delivery of fresh FV (DELIVERY) condition|Families in the DELIVERY condition will be provided access to an online Food City account to purchase up to $90 fresh FV for home delivery, delivered by research staff at the time of their choosing.
61963482|NCT02742480||Dabigatran|300 patients treated with dabigatran under the habitual clinical practice.
62506892|NCT04105114|EXPERIMENTAL|Complete Spinal Cord Injury - Exoskeleton Assisted Stepping|Group 2 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours in the Ekso overground, in the presence of stimulation and Buspirone/placebo. The second phase will include the same training procedures except for the removal of Buspirone/placebo administration. The third phase will include sessions twice per week in the Ekso overground with stimulation and one day per week using a rolling walker with stimulation. The last phase will include 2 sessions per week using the rolling walker and one day per week in the Ekso, both in the presence of stimulation and Buspirone/placebo.
62506893|NCT04105114|EXPERIMENTAL|Incomplete Spinal Cord Injury - Overground Stepping|Group 3 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. The first hour will be done in the Ekso overground and the second hour will use the rolling walker overground, both in the presence of stimulation. Afterwards, the second phase will include the same training procedures with the addition of Buspirone/placebo.
62714969|NCT05160701|EXPERIMENTAL|New Medherent|Group using Medherent Device with added interventional components.
61963483|NCT02742480||Acenocoumarol|200 patients treated with acenocoumarol under the habitual clinical practice.
61963484|NCT01900704|EXPERIMENTAL|SER120 750 ng|SER120 750 ng
61963485|NCT01900704|EXPERIMENTAL|SER120 1500 ng|SER120 1500 ng
61963486|NCT01900704|PLACEBO_COMPARATOR|Placebo|Placebo
61963487|NCT00521014|EXPERIMENTAL|GM-CSF and Rituximab After Autologous Stem Cell Transplant|"GM-CSF: 250 mcg (flat dose) three times per week for 8 weeks, administered on alternate days. Thus, 24 doses of GM-CSF will be administered.~Rituximab: 375 mg/m2/week for 4 weeks, beginning within 3 days after the first dose of GM-CSF; rituximab. The second course of GM-CSF and rituximab will be administered approximately 22-26 weeks (day +154 to +182) after ASCT."
61963488|NCT02785432|SHAM_COMPARATOR|Sham low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 0 watts for a total of 0 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint. The contact head applicator will be used if soft tissue contact is tolerable. Otherwise, the non-contact head will be utilized.
62144144|NCT05018143|EXPERIMENTAL|STARS|The investigators will deliver an online intervention focused on safety planning (STARS). The intervention content includes life skills interactive modules across 14 domains, a goal tracker, referral to community resources, and scheduling of peer mentoring sessions.
62144145|NCT05018143|ACTIVE_COMPARATOR|Control Condition|The investigators will deliver an in-person therapeutic session where participants can develop an individualized safety plan for use during a suicidal crisis, focusing on adaptive coping, addressing barriers or ambivalence, and strengthening their self-efficacy.
62506894|NCT02965664|EXPERIMENTAL|PresbiDrops (CSF-1)|Participants self-administer PresbiDrops (CSF-1) , with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
62506895|NCT02965664|PLACEBO_COMPARATOR|Placebo|Participants self-administer Placebo, with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
62506896|NCT05344287||Typical American Diet|African American individuals who self-report adhering to a typical American diet prior to enrolling in the study.
62714970|NCT01843530|EXPERIMENTAL|Group 1|Cortisone, Clemastin + BERINERT
62506897|NCT05344287||Plant-Based Diet|African American individuals who self-report adhering to a plant-based diet prior to enrolling in the study.
61963489|NCT02785432|ACTIVE_COMPARATOR|Active low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. This equates to standard acceptable dosing of 6-10 j/cm2 over the larger area of treatment. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Areas for administration and contact will otherwise be consistent with the sham group.
61963490|NCT02193867|EXPERIMENTAL|Open-Label Sebelipase Alfa|All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (United Kingdom only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.
61963491|NCT03251300|EXPERIMENTAL|group A|daytime dosing of mirabegron
62506898|NCT03667859||Women undergoing Brachytherapy|Women with either uterine or cervical malignancy treated primarily by brachytherapy.
62506899|NCT03667859||Women undergoing Pelvic Radiation|Women with either uterine or cervical malignancy treated primarily by pelvic radiation.
62506900|NCT06021470|EXPERIMENTAL|Cognitive rehabilitation intervention arm|Five-week group-based and largely interactive format, with groups of four patients. Short presentations are delivered by the clinical neuropsychologist relating to psychoeducation and adjustment to stroke-related deficits in executive function, attention, and memory, respectively, and strategies addressing the activities and participation levels of functioning. Each session lasts approximately 2.5 hours, with a break in the middle. Tailored home activities are included for completion between group sessions to encourage self-efficacy and generalisation of skills and strategies. A member of the research team contacts all participants by telephone twice a week to assess engagement and reported self-efficacy in managing cognitive difficulties. In addition, a weekly text message is sent to all participants. In the proposed pilot RCT, for those receiving the intervention, the text message will contain tips on implementing compensatory strategies.
62506901|NCT06021470|NO_INTERVENTION|Usual care|"Those in the control group will be allocated to usual care from their multidisciplinary rehabilitation team in both acute and rehabilitation settings. Usual rehabilitation care is likely to vary across hospital settings (acute vs. rehabilitation). Information about type, dose, and amount of rehabilitation therapy will be captured from patients' medical charts in both the intervention and control arm of the study.~A member of the research team (RA) contacts all participants by telephone twice a week to assess engagement and reported self-efficacy in managing cognitive difficulties. In addition, a weekly text message is sent to all participants. For those in the wait-list control condition, the text message will contain a positive affirmation."
62506902|NCT05799716|EXPERIMENTAL|IVIG|
62506903|NCT05799716|NO_INTERVENTION|Sham|
62506904|NCT02588196|EXPERIMENTAL|treatment of dexamethasone group|
62506905|NCT01854255|EXPERIMENTAL|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
62506906|NCT05853809|ACTIVE_COMPARATOR|FeNO measurement|Anti inflammatory treatment guided by measurement of airway inflammation (FeNO).
62506907|NCT05853809|NO_INTERVENTION|Usual care|
61963492|NCT03251300|ACTIVE_COMPARATOR|group B|nighttime dosing of mirabegron
61963493|NCT06136793|EXPERIMENTAL|Experimental: Healthy HomeStyles|Online educational intervention
61963494|NCT06136793|ACTIVE_COMPARATOR|Active Comparator: Safe HomeStyles|Online educational intervention
61963495|NCT02817256|ACTIVE_COMPARATOR|Group A, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Ergocalciferol 300,000 IM - Every 3 months Oral Vitamin B12 tablets daily (500mcg) Calcium /D Tab 600-200mg Centrium -1 Tablet Daily~Mineral:~Iron preparation - Daily (47mg)"
61963496|NCT02817256|ACTIVE_COMPARATOR|Group B, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Centrium - 1 Tablet daily Ergocalciferol 50000 IU once every two weeks Vitamin B12 1000mcg IM every three months Calcium /D Tab 600-200mg~Minerals:~Iron preparation - Daily (47mg)"
61963497|NCT05168527|EXPERIMENTAL|experimental group|This is an opened single-arm phase 2 study， the study drug includes Fruquintinib combine with Paclitaxel Injection and Gemcitabine.
61963498|NCT01678911|PLACEBO_COMPARATOR|Placebo then Gralise|Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
62348974|NCT04938388|ACTIVE_COMPARATOR|Oral Semaglutide (OS) with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the OS dose will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the OS tablet whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
62506908|NCT05120687||Corticosteroid group|Patients in corticosteroid group will receive systemic corticosteroid. In case of severe, the patients may receive methylprednisolone (no more than 1 gram/day) followed by gradual taper of oral prednisone.
62714971|NCT01843530|PLACEBO_COMPARATOR|Group 2|Cortinsone, Clemastin + NaCl
62506909|NCT05120687||Corticosteroid + NCSIT group|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate or Adalimumab or other noncorticosteroid systemic immunomodulatory such as cyclophosphamide.
61963499|NCT01678911|ACTIVE_COMPARATOR|Gralise then Placebo|Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.
61963500|NCT00959764|EXPERIMENTAL|Oral calcitonin and placebo nasal spray|Intervention: Oral calcitonin tablet (along with placebo intranasal spray)
61963501|NCT00959764|ACTIVE_COMPARATOR|Intranasal calcitonin & oral placebo|Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).
62348975|NCT04938388|PLACEBO_COMPARATOR|Oral Semaglutide (OS) Placebo with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the Placebo will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the Placebo will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of Placebo will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the Placebo will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the matched OS Placebo whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
62348976|NCT02336139|EXPERIMENTAL|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination
62348977|NCT02827994|EXPERIMENTAL|Education and exercise|The intervention included neurophysiology of pain education and exercises.
62506910|NCT02111434|EXPERIMENTAL|testosterone|testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
62506911|NCT01015924|ACTIVE_COMPARATOR|Elastic Stable Intramedullary Nailing|Operative intervention with closed or open reduction and intramedullary stabilization of midshaft clavicle fractures
62506912|NCT01015924|ACTIVE_COMPARATOR|Plate osteosynthesis|Open reduction and plate fixation of midshaft clavicle fractures
62506913|NCT06421142|EXPERIMENTAL|MIBC diagnostic study-FAPI PET/MRI|suspected MIBC participants receive FAPI PET/MRI examination after entering the group.
62714972|NCT02375100|ACTIVE_COMPARATOR|Intrathecal bupivacaine&analgesics|Patients will be given standard care during perioperative period. They will undergo inguinal herniorraphy operation under spinal anesthesia (with 3ml of %0.5 hyperbaric bupivacaine intrathecally) and receive an parenteral pain regimen (acetaminophen for intravenous infusion in two doses routinely and intramuscular tramadol 50 mg when pain score is higher than 4) in postoperative period.
62348978|NCT02827994|NO_INTERVENTION|No intervention|This group received no intervention as participants were students that were not seeking treatment for their pain.
62348979|NCT01932281|EXPERIMENTAL|SierraSil|SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
62348980|NCT01932281|PLACEBO_COMPARATOR|Placebo|This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
62348981|NCT03668535|ACTIVE_COMPARATOR|Bladder Filling arm|Group A have triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
62348982|NCT03668535|ACTIVE_COMPARATOR|Bladder deflation arm|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
62348983|NCT00442676|EXPERIMENTAL|1|Celecoxib, 200 mg/day
62348984|NCT00442676|PLACEBO_COMPARATOR|2|Placebo
62348985|NCT01110772|EXPERIMENTAL|2-octyl cyanoacrylate|As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
62506914|NCT06421142|EXPERIMENTAL|MIBC diagnostic study-FDG PET/MRI|suspected MIBC participants receive FDG PET/MRI examination after entering the group.
61963502|NCT00959764|PLACEBO_COMPARATOR|Placebo: tablet & intranasal spray|Intervention: Both oral matching placebo tablets and matching intranasal placebo spray
61963503|NCT01024634|OTHER|African American Group|A group of young African American males and females
61963504|NCT01024634|OTHER|Caucasian Group|a group of young Caucasian men and women
61963505|NCT05295511|EXPERIMENTAL|Team Handball 1|Team handball group participants were instructed to perform one weekly 60-min recreational team handball training sessions for 16 weeks.
62348986|NCT01110772|ACTIVE_COMPARATOR|iodine povacrylex in isopropyl alcohol|Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
62506915|NCT06421142|ACTIVE_COMPARATOR|MIBC diagnostic study-MRI|suspected MIBC participants receive MRI examination after entering the group.
62506916|NCT06421142|EXPERIMENTAL|MIBC neoadjuvant evaluation study-FAPI PET/MRI|Patients diagnosed with MIBC receive FAPI PET/MRI examination before and after neoadjuvant therapy.
62506917|NCT06421142|EXPERIMENTAL|MIBC neoadjuvant evaluation study-FDG PET/MRI|Patients diagnosed with MIBC receive FDG PET/MRI examination before and after neoadjuvant therapy.
62506918|NCT06421142|ACTIVE_COMPARATOR|MIBC neoadjuvant evaluation study-MRI|Patients diagnosed with MIBC receive MRI examination before and after neoadjuvant therapy.
62506919|NCT00876720|EXPERIMENTAL|1|Combined frontal and temporal transcranial magnetic stimulation
62506920|NCT00876720|EXPERIMENTAL|2|Temporal transcranial magnetic stimulation
61963506|NCT05295511|EXPERIMENTAL|Team Handball 2|Team handball group participants were instructed to perform two weekly 60-min recreational team handball training sessions for 16 weeks.
62506921|NCT03215459||Cardiopulmonary Exercise Test|A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
62705198|NCT05967247|PLACEBO_COMPARATOR|waiting list|"The waiting list used only the Heart Care Life app for the first eight weeks, as self-management is an essential element of heart failure treatment (Tsami et al., 2023), following the situation-specific theory of heart failure self-management (the situation- specific theory of heart failure self-care:) (Riegel et al., 2022) and American heart failure guidelines (Heidenreich et al., 2022) design (Tsami et al., 2023; Vellone et al., 2020), mainly for Disease-related knowledge and self-management tools, built-in disease health education electronic audiobooks, diet sodium content calculator, diet water content calculator, activity step calculation, etc., to help research subjects self-manage the disease.~Measure T2 at week 8. From the ninth to the sixteenth week, use the Mindful Live app."
62705199|NCT00077909||Group 1|Patients with Infectious Pneumonia
62705200|NCT00077909||Group 2|Patients with Non-Infectious Pneumonia
61963507|NCT05295511|EXPERIMENTAL|Team Handball 3|Team handball group participants were instructed to perform three weekly 60-min recreational team handball training sessions for 16 weeks.
61963508|NCT05295511|NO_INTERVENTION|Control Group|The control group participants were instructed to keep their regular daily physical activity for 16 weeks.
61963509|NCT01772108|EXPERIMENTAL|MitraClip Device|Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
62348987|NCT06199622|EXPERIMENTAL|experimental group|Pregnant women in the intervention group will listen to 20 minutes of music consisting of classical western music - Beethoven moonlight sonata -, classical Turkish music - Nihavend and Buselik Maqam - for three days with a MP3 player with a good sound system and headphones.
62705201|NCT05322031|EXPERIMENTAL|Onset of depression|15 participants with onset of schizophrenia who, after a period of stabilization with aripiprazole in oral formulation, would begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole since no more than two weeks.
62705202|NCT03049475||Control|Healthy, between age 18-80, African/African decent
62705203|NCT03049475||Subjects in steady State|Steady state is defined as the period from at any time 8 weeks prior to or after a crisis and samples obtained during this time would be considered steady state samples .
61963510|NCT01772108|NO_INTERVENTION|Control|Subjects randomized to the Control group will receive optimal standard of care therapy alone.
61963511|NCT04370938|EXPERIMENTAL|Coping strategies video|Individuals will be asked to watch a 1 hour long video that discusses strategies helpful in coping with stress during the COVID-19 pandemic.
61963512|NCT04370938|NO_INTERVENTION|Control|No additional requests will be made of individuals in the control arm.
62348988|NCT06199622|NO_INTERVENTION|control group|Pregnant women in the control group did not receive 20 minutes of music for three days and routine care will continue.
62348989|NCT01102218|EXPERIMENTAL|erythropoietin plus pentoxifylline|
62348990|NCT01102218|ACTIVE_COMPARATOR|erythropoietin alone|
62348991|NCT02103036|EXPERIMENTAL|Core Stability Exercises|"Core Stability Exercises:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Core Stability Exercises (25-30 minutes)."
62348992|NCT02103036|EXPERIMENTAL|Traditional Back School|"Traditional Back School:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Traditional Back School (25-30 minutes)."
62348993|NCT05948852|EXPERIMENTAL|Group A: SADI-S|SINGLE ANASTOMOSE DUODENAL SWITCH
62348994|NCT05948852|ACTIVE_COMPARATOR|Group B: OAGB|SINGLE ANASTOMOSE GASTRIC BY-PASS
62348995|NCT03685045|EXPERIMENTAL|Campaign Days|All participants have the intervention of the campaign days which include hepatitis C screening, fibroscans and clinical assessments.
62348996|NCT04113148||Healthy volunteer|Physiological measurements from heel over 60 minute period
61963513|NCT00598832|EXPERIMENTAL|Adapalene lotion 0.1%|
61963514|NCT00598832|PLACEBO_COMPARATOR|Adapalene Lotion vehicle|
61963515|NCT00094744|ACTIVE_COMPARATOR|6hrs daily patching|6 hours per day of patching in the sound eye
61963516|NCT00094744|ACTIVE_COMPARATOR|Full-time daily patching|Patching of the sound eye all but one waking hour
61963517|NCT02294591|ACTIVE_COMPARATOR|NAC group|Receiving N-acetylcysteine as add-on treatment
61963518|NCT02294591|PLACEBO_COMPARATOR|Placebo group|Receiving placebo as add-on treatment
62348997|NCT04113148||At risk of Pressure Ulcer|Physiological measurements from heel over 60 minute period
62348998|NCT04113148||Confirmed Catefory I Pressure Ulcer|Physiological measurements from heel over 60 minute period
62348999|NCT04113148||Suspected Deep Tissue Injury|Physiological measurements from heel over 60 minute period
62349000|NCT03329599|EXPERIMENTAL|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
62349001|NCT03329599|NO_INTERVENTION|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
62349002|NCT05501288|EXPERIMENTAL|intervention group|receive oral HSBDG for 5 consecutive days
62349003|NCT05501288|OTHER|control group|receive compound pholcodine oral solution for 5 consecutive days
62506922|NCT02070354||Group 1|New clinic visit in GI Nutrition (prior to bariatric surgery).
62506923|NCT02070354||Group 2|1 month prior to bariatric surgery
62506924|NCT02070354||Group 3|6 months after bariatric surgery
62506925|NCT02070354||Group 4|12 months after bariatric surgery
62506926|NCT02070354||Group 5|24 months after bariatric surgery
62506927|NCT02070354||Group 6|≥ 36 months after bariatric surgery
62506928|NCT04968106|OTHER|Standard Arm A: treatment by neoadjuvant chemotherapy|Treatment by doxorubicin and ifosfamide followed by surgery
62506929|NCT04968106|EXPERIMENTAL|Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab|Treatment by doxorubicin, ifosfamide and retifanlimab followed by surgery
62506930|NCT02456987|EXPERIMENTAL|Intervention|Patients that qualify for the intervention will receive the Samsung Gear virtual reality experiences and will participate in a brief survey about their opinions and preferences once the experiences are completed.
61963519|NCT01927874|ACTIVE_COMPARATOR|Infiltration, analgesic effect|10ml 0.5% bupivacaine each side Block Injection of local anesthetic at pudendal nerve
62506931|NCT02456987|NO_INTERVENTION|Control|Age and sex matched control participants will be asked to answer a series of satisfaction questions after the study recruitment period is over. These individuals will have been inpatients during the same time as the intervention participants.
62349004|NCT01819506|EXPERIMENTAL|Targeted Task Practice|"Targeted task practice is defined as a therapy program aimed at patient-specific upper extremity motor impairment levels and systematically progressed to assure an ongoing just right match between task-difficulty and patient-ability. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length."
62349005|NCT01819506|ACTIVE_COMPARATOR|Non-Targeted Task Practice|Non-targeted task practice is a standard of care treatment consisting of task practice with no guidance from the measurement framework to systematically address specific upper extremity motor impairment levels or progress rehabilitation therapy. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length.
62349006|NCT01431729||mucositis|
62705204|NCT04164069|EXPERIMENTAL|Prevention (dasatinib, mFOLFOX, bevacizumab)|Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.
62705205|NCT02610426||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
62506932|NCT03346954|EXPERIMENTAL|Patients with Cushing's disease|Implementation of \[11C\]-Methionine PET/MRI
62506933|NCT06425367|EXPERIMENTAL|MHR SIR|rapid antibiotic susceptibility testing by diffusion on MHR-SIR (Mueller-Hinton Rapid-SIR) medium from the blood culture bottle. Antibiotic susceptibility test results are obtained 7 hours after blood culture positivity
62349007|NCT05717959|EXPERIMENTAL|intervention group|We conducted a once a week, 12-week-intervention of Oropharyngeal Exercises and Mandibular advancement device
62349008|NCT05717959|SHAM_COMPARATOR|control group|Mandibular advancement device
62506934|NCT06425367|ACTIVE_COMPARATOR|MH|Standard antibiotic susceptibility testing by diffusion on MH (Mueller-Hinton ) medium from the blood culture bottle Antibiotic susceptibility test results are obtained 24 hours after blood culture positivity
62506935|NCT01938352|EXPERIMENTAL|CR8020|CR8020 administered as a single 2-hour intravenous infusion
62506936|NCT01938352|PLACEBO_COMPARATOR|Placebo|Placebo administered as a single 2-hour intravenous infusion
62506937|NCT00754494|EXPERIMENTAL|Erlotinib Hydrochloride (25 mg)|Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
62506938|NCT00754494|EXPERIMENTAL|Erlotinib Hydrochloride (50 mg)|Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
62506939|NCT00754494|EXPERIMENTAL|Erlotinib Hydrochloride (100 mg)|Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
62506940|NCT01433887|EXPERIMENTAL|Genotype 6|Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
62349009|NCT01864824|EXPERIMENTAL|methyl donor|"Methyl donor is made up of:~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure."
62506941|NCT01433887|EXPERIMENTAL|Genotype 1|Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
62506942|NCT01433887|EXPERIMENTAL|Genotype 2/3|Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks
62506943|NCT02685696|EXPERIMENTAL|Alexis O Retractor|Group 1 received the Alexis-O-Retractor at thet time of first Caesarean Section
62506944|NCT02685696|ACTIVE_COMPARATOR|Metal Retractor|Group 2 received the traditional self retaining metal Retractor at thet time of first Caesarean Section
62506945|NCT01644149|EXPERIMENTAL|Stratis Jet Injector|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
62506946|NCT01644149|ACTIVE_COMPARATOR|Needle and Syringe|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
62506947|NCT05276687|EXPERIMENTAL|Diluted betadine|
62506948|NCT05276687|EXPERIMENTAL|Powdered vancomycin|
62506949|NCT05276687|NO_INTERVENTION|No intervention|
62506950|NCT05934838|EXPERIMENTAL|Tazemetostat and CAR T-Cell Therapy|Tazemetostat is being administered prior to, and following, standard of care CAR T cell therapy. The use of tazemetostat in this way is investigational.
62705206|NCT06397846|EXPERIMENTAL|Biological sample|Blood sample
62705207|NCT06407713|ACTIVE_COMPARATOR|intrinsic foot muscle training.|Intrinsic foot muscle training would be performed
61963520|NCT01927874|ACTIVE_COMPARATOR|Spinal block|10 mg of hyperbaric 0.5% bupivacaine Injection of anesthetic at subarachnoidal space
62705208|NCT06407713|ACTIVE_COMPARATOR|intrinsic foot muscle training with hip abductor muscle training|hip abductor muscle strengthening would be administered alongside intrinsic foot muscle training
61963521|NCT00886899|EXPERIMENTAL|BridgePoint Medical System|Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire
61963522|NCT06040060|ACTIVE_COMPARATOR|Preemptive Ketamine|Preemptive administration of Ketamine 0.5 mg/kgBB intravenously, given 10 minutes prior to incision
62506951|NCT01767727|OTHER|Surgical flap|Surgical flap is based on the dorsal branch of the digital artery, and is used for soft tissue coverageof multiple finger defects.
62705209|NCT06567548|ACTIVE_COMPARATOR|Control group|absorbable gelatin sponge
62705210|NCT06567548|ACTIVE_COMPARATOR|Platelet-rich fibrin (PRF) group|Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
61963523|NCT06040060|PLACEBO_COMPARATOR|Placebo|Placebo administration of 10 mL NaCl 0,9% intravenously, given 10 minutes prior to incision
61963524|NCT03636932|ACTIVE_COMPARATOR|N-acetylcysteine (NAC) group|
62144146|NCT06297057|EXPERIMENTAL|Neurophysiological Recordings|"Participants suitable for hdEEG, MEG, and MUSE recordings will first undergo a neuronavigation session, and then three identical neurophysiological data acquisition sessions, one for hdEEG, one for MEG, and one for MUSE.~The sessions will take place in three consecutive weeks, once a week, taking care that they are made at the same time of day for each participant. Finally, a structural magnetic resonance imaging (MRI) recording will be obtained for each participant.~Each neurophysiological data acquisition session will consist of 5 blocks: 4 eyes-open and eyes-closed resting-state blocks, and one passive auditory stimulation block.~The four blocks in the resting condition will be performed first, to avoid interference due to the passive acoustic task. The order of blocks 1 and 2, and consequently also blocks 3 and 4, representing the open-eye and closed-eye conditions will be counterbalanced between subjects and between different sessions for the same subject."
62705211|NCT06567548|EXPERIMENTAL|Albumin Platelet Rich- Fibrin (Alb-PRF) group:|Albumin Platelet-Rich Fibrin (Alb-PRF) is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
62144147|NCT04740944|EXPERIMENTAL|Intervention group|the intervention group was subjected to salutogenic approach-based interview consisting of 16 sessions twice a week.
62349010|NCT01864824|PLACEBO_COMPARATOR|placebo|placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
62349011|NCT05360823|EXPERIMENTAL|Birth Ball Group|In the active and transitional phases, during contractions, performing exercises on the birth ball (fully rotating the hip, moving to the right/left, coming back and forth, and slightly bouncing while sitting on the birth ball) (average 25 minutes). In order to monitor the condition of the fetus, exercises on the birth ball were performed by the pregnant woman during contractions while connected to NST.
62349012|NCT05360823|EXPERIMENTAL|Squatting Group|In the active and transitional phase, squatting position (squatting with feet shoulder-width apart by laying a clean sheet on the floor and getting support from a bed, chair or birth ball) during contractions (average 25 minutes). In order to monitor the condition of the fetus, the squatting position was used by the pregnant woman during contractions while connected to the NST.
62144148|NCT04740944|NO_INTERVENTION|Control group|The control group continued their routine activities and was interviewed face-to-face 5 times.
62144149|NCT03154736|EXPERIMENTAL|Interview|Individual interview an in a group interview. Socio-economic questionnaire
62349013|NCT05360823|NO_INTERVENTION|Control Group|Usual routine care of the service.
62349014|NCT05937217|EXPERIMENTAL|myofascial induction and direct scar release techniques group|They will receive myofascial induction therapy in the form of transverse sliding and cross hand therapy and direct scar release techniques in the form of stroking, circular movement, vertical point lifting , C and S grip techniques, and therapeutic ultrasound, 2 sessions per week for two weeks.
62349015|NCT05937217|EXPERIMENTAL|therapeutic ultrasound group|They will receive a therapeutic ultrasound, 2 sessions per week for two weeks.
62349016|NCT00977015|EXPERIMENTAL|Treatment A - PF-04764793|PF-04764793 using inhaler A
62506952|NCT05872464|EXPERIMENTAL|Artificial saliva containing cumin and ginger extract|Artificial saliva containing cumin and ginger extract in spray bottle
62506953|NCT05872464|PLACEBO_COMPARATOR|Placebo|Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
62705212|NCT05784246|EXPERIMENTAL|Mirikizumab Weight-Based Group 1|Experimental: Participants will receive mirikizumab weight-based dosing intravenously (IV) or subcutaneously (SC).
62144150|NCT04874649|EXPERIMENTAL|Balloon-blowing breathing|"1. Start by measuring the vital capacity using a balloon to determine. The width of the balloon diameter for each blow and used the value to make a balloon size control device to give to the sample group and parents to use it for home training.~2. Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks"
62506954|NCT01672047|EXPERIMENTAL|Treament|Intervention Vitamin D2
62705213|NCT05784246|EXPERIMENTAL|Mirikizumab Weight-Based Group 2|Experimental: Participants will receive mirikizumab weight-based dosing IV or SC.
62349017|NCT00977015|ACTIVE_COMPARATOR|Treatment B - PF-04764793|PF-04764793 using inhaler B
62506955|NCT01672047|NO_INTERVENTION|Control|Not take Vitamin D2
62506956|NCT00996437|PLACEBO_COMPARATOR|Saline Injection|Saline injection at baseline, 4 and 8 weeks
62506957|NCT00996437|ACTIVE_COMPARATOR|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
62506958|NCT02073136|EXPERIMENTAL|Phosphate modified diet|
62506959|NCT04238637|EXPERIMENTAL|Arm 1|Durvalumab
62506960|NCT04238637|EXPERIMENTAL|Arm 2|Durvalumab in combination with Tremelimumab
62705214|NCT05784246|EXPERIMENTAL|Mirikizumab Weight-Based Group 3|Experimental: Mirikizumab Participants will receive mirikizumab weight-based dosing IV or SC.
61963525|NCT03636932|PLACEBO_COMPARATOR|Placebo group|
61963526|NCT03657511|OTHER|Educational Interventions to Promote Tobacco Cessation|
61963527|NCT00552916|OTHER|1|Participants will be randomized to either an intervention arm where they will receive 'true' FES and the other control arm where they will receive 'false' FES. The sham group will receive 'false' FES.
61963528|NCT00552916|OTHER|2|The intervention group will receive 'true' FES
62349018|NCT01115075|EXPERIMENTAL|Dietitian|Recruitment of dietitians and senior level or graduate level dietetics students who are not restrained eaters. This group is skilled in identifying and accurately recording food than individuals not trained in dietetics.
61963529|NCT05136768|EXPERIMENTAL|Single arm|Sintilimab combined with platinum-based chemotherapy and SBRT
61963530|NCT01684007|EXPERIMENTAL|Bilateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 \[SV25T0\], bilateral implantation
61963531|NCT01684007|ACTIVE_COMPARATOR|Contralateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 \[SV25T0\] and AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, contralateral implantation
61963532|NCT01361152|EXPERIMENTAL|Fixed-bearing group|Fixed-bearing group
61963533|NCT01361152|EXPERIMENTAL|Mobile-bearing group|Mobile-bearing group
61963534|NCT05911516|EXPERIMENTAL|Pennisetum purpureum group|
62349019|NCT03094832|EXPERIMENTAL|Part A: Miransertib PROS/PS|During Cycles 1-3, participants with either PROS (phosphatidylinositol- 4,5-bisphosphate 3-kinase, catalytic subunit alpha \[PIK3CA\]-related Overgrowth Spectrum) or PS (Proteus syndrome) received miransertib 15 mg/m\^2 once daily (QD) (each cycle length = 28 days). From Cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m\^2 and then titrated to 35 mg/m\^2 orally QD at the investigator's discretion.
61963535|NCT05911516|PLACEBO_COMPARATOR|Placebo group|
61963536|NCT05114720|EXPERIMENTAL|standard adjuvant chemotherapy plus moxifloxacin|"Standard adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus antibiotic (moxifloxacin)~Other Name: docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, combined with cyclophosphamide 600 mg/m\^2, IV, days 1, followed by docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days"
62349020|NCT03094832|EXPERIMENTAL|Part B: Miransertib PROS (Cohort 1)|During Cycles 1-3, participants with PROS who have a measurable lesion by volumetric magnetic resonance imaging (MRI) received miransertib 15 mg/m\^2 QD (each cycle length = 28 days). From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m\^2 orally QD at the investigator's discretion.
62349021|NCT03094832|EXPERIMENTAL|Part B: Miransertib PS (Cohort 2)|During Cycles 1-3, participants with PS who have a measurable lesion by standardized digital photography received miransertib 15 mg/m\^2 QD (each cycle length = 28 days). From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m\^2 orally QD at the investigator's discretion.
62349022|NCT03094832|EXPERIMENTAL|Part B: Miransertib PROS/PS (Cohort 3)|During Cycles 1-3, participants with PROS or PS who do not meet all the eligibility criteria for Cohorts 1 or 2 received miransertib 15 mg/m\^2 QD (each cycle length = 28 days). From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m\^2 orally QD at the investigator's discretion.
62349023|NCT03094832|EXPERIMENTAL|Part B: Miransertib Compassionate Use/Expanded Access (Cohort 4)|During cycles 1-48 (each cycle length = 28 days) or until disease progression, unacceptable toxicity, or discontinuation, participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access continued to receive the current dose of miransertib (did not exceed 25 mg/m\^2).
62349024|NCT02204514||Surgery for external snapping hip|
62349025|NCT05118542|ACTIVE_COMPARATOR|PTU Group|Propylthiouracil (PTU) was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
62349026|NCT05118542|ACTIVE_COMPARATOR|Methimazole Group|Methimazole was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
62349027|NCT05572827|EXPERIMENTAL|Experimental|Breathing exercises will be taught to COVID-19 patients after intensive care.
62349028|NCT05572827|NO_INTERVENTION|Control|Breathing exercises will not be taught to COVID-19 patients after intensive care.
62349029|NCT00335998|EXPERIMENTAL|Treatment (triapine)|"Group 1: Patients undergo external-beam pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive 3-AP IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33 and cisplatin IV over 1½ hours on day 2, 9, 16, 23, and 30.~Group 2: Patients undergo external-beam pelvic radiotherapy and receive 3-AP as in group 1.~In both groups, patients undergo intracavitary or interstitial brachytherapy at least once weekly for 3-5 weeks during or after external-beam radiotherapy as per standard of care."
62349030|NCT05368129|EXPERIMENTAL|POT group|A total of 24 patients are assigned to POT group after randomization schedule.
61963537|NCT05114720|PLACEBO_COMPARATOR|standard adjuvant chemotherapy plus placebo|"Standard adjuvant chemotherapy (Docetaxel combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by docetaxel) plus placebo~Other Name: docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, combined with cyclophosphamide 600 mg/m\^2, IV, days 1, followed by docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days"
62349031|NCT05368129|ACTIVE_COMPARATOR|NCB group|A total of 24 patients are assigned to NCB group after randomization schedule.
62349032|NCT02142257||Gastric Bypass|Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.
61963538|NCT00095901|EXPERIMENTAL|Capecitabine|Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
61963539|NCT02379871|EXPERIMENTAL|Experimental Group|While lying in supine, subjects will receive a single posterior to anterior directed spinal manipulation to the mid-thoracic region (T4-5).
61963540|NCT02379871|SHAM_COMPARATOR|Sham Group|Sham group will procedures will be identical with the exception of the spinal manipulation intervention. Sham shall not receive the spinal manipulation intervention.
62506961|NCT01355302|EXPERIMENTAL|Phase Ib: Cohort 1 and 2 and 3|"Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine~Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine"
62506962|NCT01355302|ACTIVE_COMPARATOR|Phase II: Arm 1; E7050 + cisplatin+ capecitabine|Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine
62506963|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
62705215|NCT04280848|EXPERIMENTAL|Cohort A: UCPVax vaccine (patient with unmethylated MGMT status)|UCPVax
62705216|NCT04280848|EXPERIMENTAL|Cohort B: UCPVax vaccine + Temozolomide (patient with unmethylated or methylated MGMT status)|"UCPVax~+ Temozolomide according to standard of care"
62705217|NCT05064085|EXPERIMENTAL|Dose Level 1|Cemiplimab 350mg + Capecitabine 800 mg/m\^2
61963541|NCT02414750|EXPERIMENTAL|Treatment with BRAF/MEK inhibitor|"Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.~During the study biopsies and blood will be taken from the patients."
61963542|NCT03042624|EXPERIMENTAL|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
62705218|NCT05064085|EXPERIMENTAL|Dose Level 2|Cemiplimab 350mg + Capecitabine 1000 mg/m\^2
61963543|NCT03042624|PLACEBO_COMPARATOR|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
61963544|NCT05071469|NO_INTERVENTION|Control Group (CG)|Control group
62144151|NCT04874649|EXPERIMENTAL|Sustained maximal inspiration breathing|Participants sitting in a chair, back and head close to the wall. Inhale through their nose fully and hold for 3 seconds for a full breath, then slowly exhale through their mouth and hold for 1 second of exhalation, counted as 1 breathing cycle.Do this 3 times in a row for 1 set. Practice each time doing a total of 3 sets, with 1 minute rest between sets. Participants were required to complete breathing exercise 5 times per week for 8 weeks.
62705219|NCT05946070|EXPERIMENTAL|Intervention Group (ONKOSIS)|Patients in the intervention group will be instructed to use the mobile application. Patients in the experimental group will be able to access the application contents without restrictions and will be able to use the in-app messaging module as well as the risk factors, symptom findings, and intervention suggestions for symptom management.
62705220|NCT05946070|NO_INTERVENTION|Control group|Patients in the control group will receive standard care as is currently available at their clinical site. They will use demo version of the mobile application only for assessing symptom severity. In the demo version used by the control group patients, there is no in-app messaging module as well as information such as risk factors, symptoms and intervention recommendations for symptom management.
62705221|NCT04468607|EXPERIMENTAL|Dose-Escalation Stage|Participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD).
62705222|NCT04468607|EXPERIMENTAL|Dose-Expansion Stage|Once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial.
62714973|NCT02375100|EXPERIMENTAL|TAP Block with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive transversus abdominis plane block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
62714974|NCT02375100|EXPERIMENTAL|IlNB with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive Ilioinguinal nerve block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
62349033|NCT02142257||AspireAssist Aspiration Therapy|Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.
62144152|NCT06298266|EXPERIMENTAL|infusion of GPRC5D-CD19 CAR T injection|Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
62349034|NCT03569306|EXPERIMENTAL|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
61963545|NCT05071469|EXPERIMENTAL|Kinesiotaping Group (KG)|Experimental group
61963546|NCT05071469|EXPERIMENTAL|Mulligan Mobilization Technique Group (MG)|Experimental group (2)
61963547|NCT00280098|EXPERIMENTAL|single group|
61963548|NCT05013073|EXPERIMENTAL|Experimental Arm|All patients will be enrolled in a single arm and download the mobile application ASTHMAxcel ED to their smartphones.
62349035|NCT03569306|ACTIVE_COMPARATOR|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
62349036|NCT00735085|EXPERIMENTAL|SLV334|
62349037|NCT00735085|PLACEBO_COMPARATOR|Placebo|
62349038|NCT05491655|EXPERIMENTAL|High intensity His bundle pacing|"After implantation of the device there will be a 1-month run-in period that the device will be programmed to deliver His bundle pacing therapy during this period at 3.5V/1msec.~After one month these patients will continue to receive active pacing treatment with 3.5V/1msec."
62349039|NCT05491655|SHAM_COMPARATOR|Back up only ventricular pacing|"After implantation of the device there will be a 1-month run-in period that the device will be programmed to deliver His bundle pacing therapy during this period at 2V/1msec.~After one month these patients will receive back up only pacing (pacemaker programmed to VVI 30 bpm or AAI(R)-DDD(R) 50bpm) for 6 months."
62349040|NCT05914961||Control Group|Chemotherapy without immunotherapy
62349041|NCT05914961||Experimental Group|Chemotherapy in combination with immunotherapy
62349042|NCT04498572|EXPERIMENTAL|research group|active exercises and dry needling for the Gluteus medius muscle
62349043|NCT04498572|SHAM_COMPARATOR|control group|active exercises and sham dry needling for the Gluteus medius muscle
62349044|NCT01310218|OTHER|extended postoperative dressing|Bulky dressing for 2 weeks
62349045|NCT01310218|OTHER|short postoperative dressing|2 day bulky dressing followed by bandaid.
61963549|NCT05881447||RenalTWO screening cohort|Approximately 1200 patients seeking primary care in the Bagamoyo District Hospital and in two of its associated dispensaries are randomly selected to participate in the RenalTWO cohort study. This includes a longitudinal health check-up over three visits: at the date of enrolment, after a minimum of 90 days for confirmation, and finally after one full calendar year.
61963550|NCT03620240|EXPERIMENTAL|Sleep Education|Half of the participants are randomly assigned to the Sleep Education group. These participants will undergo 4 weekly class-based lesson, during which they are educated about sleep.
61963551|NCT03620240|NO_INTERVENTION|Control|Half of the participants are randomly assigned to the Control group. These participants undergo 4 weekly class-based lessons, during which they are educated about health-related topics, but not about sleep.
61963552|NCT01694030|EXPERIMENTAL|Neutral Condition|Participants in the neutral (control) condition of the attachment security priming experiment will be asked to spend time visualising neutral events (e.g., supermarket shopping)for 3-10 minutes at a time.
61963553|NCT01694030|EXPERIMENTAL|Secure condition|Participants in the attachment security priming condition will be asked to complete visualisation tasks where they think about a secure attachment figure for between 3 - 10 minutes.
61963554|NCT01841983|EXPERIMENTAL|Intervention|Be Well Work Well
62506964|NCT04640779|EXPERIMENTAL|Treatment (selinexor, choline salicylate)|Patients receive selinexor PO BIW on days 1, 3, 8, 10, 15, 17, 22, and 24, and choline salicylate PO TID on days 1-28. Patients undergoing pharmacokinetic analysis receive choline salicylate beginning on D3C1 and beginning on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patents who achieve \>= stable disease continue treatment for an additional 6 cycles (maximum of 12 cycles) at the discretion of the treating physician and patient.
62506965|NCT05838456|EXPERIMENTAL|Hospital 1 - 3 months with no Viz.AI software, then 12 months with Viz.AI software|
62506966|NCT05838456|EXPERIMENTAL|Hospital 2 - 6 months with no Viz.AI software, then 9 months with Viz.AI software|
61963555|NCT01841983|NO_INTERVENTION|Control|No intervention
61963556|NCT03912155||Patients|20 patients per presumed location of the epileptogenic zone (see experimental plan) for a total of 120 patients, including 30 minors. For patients, a MEG-EEG-SEEG examination during the SEEG exploration period.
61963557|NCT03912155||Controles|For the control population, 120 control subjects, including 30 minors, that is to say as many as patients. For control subjects, a MEG-EEG exam.
61963558|NCT01804621|EXPERIMENTAL|Exercise|Participant received health newsletter with targeted articles about exercise behavior.
62506967|NCT05838456|EXPERIMENTAL|Hospital 3 - 9 months with no Viz.AI software, then 6 months with Viz.AI software|
62506968|NCT05838456|EXPERIMENTAL|Hospital 4 - 12 months with no Viz.AI software, then 3 months with Viz.AI software|
62506969|NCT04826666||Groups/Cohorts|The Principal Investigator propose to conduct a retrospective observational cohort study of all consecutive adult patients who underwent a liver transplantation between July 2008 and January 2021 at the Centre hospitalier de l'Université de Montréal (CHUM).
62506970|NCT00595335|EXPERIMENTAL|Rituximab|Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion.
62506971|NCT00595335|PLACEBO_COMPARATOR|Placebo|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
62349046|NCT03986190|EXPERIMENTAL|Healthy Juntos Intervention Condition|Parent-adolescent dyads randomized to the Healthy Juntos intervention condition will access a program that includes didactic, behavioral, and positive parenting content from their smartphones for 8 weeks.
62506972|NCT04231487||Essential tremor|"This is not an intervention study.~Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days"
61963559|NCT01804621|EXPERIMENTAL|Fruit & Vegetable|Participant received health newsletter with targeted articles about fruit \& vegetable consumption.
61963560|NCT01804621|EXPERIMENTAL|Colorectal Cancer Screening|Participant received health newsletter with targeted articles about colorectal cancer screening.
61963561|NCT01804621|EXPERIMENTAL|Mammography|Participant received health newsletter with targeted articles about mammography screening.
62349047|NCT03986190|NO_INTERVENTION|Control Group|This group will receive a digital standard of care - a list of publicly available lifestyle apps and websites which they may access at their discretion.
62349048|NCT00503178|EXPERIMENTAL|Patients undergoing imaging guided radiotherapy.|
62349049|NCT03769324||Normal Eye Group|Normal eye receiving Osmolarity Test
62349050|NCT03769324||DED Group|Dry Eye Disease receiving Osmolarity Test
62349051|NCT04441736|ACTIVE_COMPARATOR|High flow nasal cannula|A device of high flow nasal cannula giving 60 litres / min flow
62349052|NCT04441736|PLACEBO_COMPARATOR|Conventional oxygen|Nasal cannula giving oxygen up to 10 litres / minute
62349053|NCT04441736|ACTIVE_COMPARATOR|Non invasive ventilation|non invasive ventilation with IPAP and EPAP
62349054|NCT01365377|EXPERIMENTAL|Booklet|Referent member of the family is designated to receive a written detailed information on Critical care.
62349055|NCT01365377|NO_INTERVENTION|No booklet|daily information to the family is given as usual.
62506973|NCT04231487||Parkinson's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days"
62349056|NCT04861558|ACTIVE_COMPARATOR|Standard HIPEC|Injection of oxaliplatin 460 mg/m2 and an intraoperational IV of 5-fluorouracil 400 mg/m2, and calcium folinate 60 mg/m2.
62506974|NCT04231487||Huntington's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days"
62506975|NCT04231487||Primary Focal Dystonia|"This is not an intervention study.~Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days"
62506976|NCT04231487||Spinocerebellar Ataxia|This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days
62506977|NCT04231487||Functional Movement Disorder|This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days
62506978|NCT04231487||Healthy Controls|"This is not an intervention study.~People with Healthy Controls"
62506979|NCT00851409|OTHER|Recombinant Human C1 Inhibitor|Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
62506980|NCT04224194|OTHER|Interventional, Single arm to evaluate autoinjector handling|To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who selfinject AVT02 (adalimumab) subcutaneously (SC).
62506981|NCT06503354||Participants|Healthy adults
61963562|NCT06238050||hospitalized patients suspected of chronic permanent ischemia realizing transcutaneous oxymetry|"hospitalized patients suspected of chronic permanent ischemia realizing transcutaneous oxymetry are enroled in the study.~The WIfI score is calculated at the inclusion."
61963563|NCT05490641|EXPERIMENTAL|Biofeedback Group|
61963564|NCT05490641|ACTIVE_COMPARATOR|Standard Care Group|
62506982|NCT00883935|EXPERIMENTAL|Sequence 2|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV 400mg q24h (treatment C) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
62506983|NCT00883935|EXPERIMENTAL|Sequence 1|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV/RTV 300/100mg q24h (treatment B) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
61963565|NCT04657120|EXPERIMENTAL|YEARS algorithm|Patients randomized to this arm will be evaluated according to the YEARS algorithm.
61963566|NCT04657120|ACTIVE_COMPARATOR|CTPA as single test|Patients randomized to this arm will undergo a contrast enhanced CTPA.
61963567|NCT00578812|EXPERIMENTAL|PCM Cervical Disc - Investigational|PCM Cervical Disc replacement at one level from C3 to T1
61963568|NCT00578812|ACTIVE_COMPARATOR|ACDF - Control Group|Anterior cervical discectomy and fusion (ACDF) at one level from C3 to T1
61963569|NCT02530593||Patients with colon cancer|All patients presenting with a newly diagnosed colon cancer regardless of tumour stage
61963570|NCT03743389|EXPERIMENTAL|12G pigtail catheter|
62349057|NCT04861558|EXPERIMENTAL|Intensified HIPEC+EPIC|"Injection of irinotecan 360 mg/m2 and 5-fluorouracil 24-hr EPIC 250-850 mg/m2 in combination with Oxaliplatin 360 mg/m2 and an intraoperational IV of 5-fluorouracil bolus 400 mg/m2 with calcium folinate 60mg/m2.~The EPIC treatment is given after the abdomen is completely sutured in the operating theater. The dose will be divided equally into 2 injections á 200ml each through two abdominal drains."
62349058|NCT02825147|EXPERIMENTAL|MESA|stage I/II: methotrexate 1000mg/m2,d1 dexamethasone 40mg,d2-d4 etoposide 100mg,d2-d4 pegaspargase 2500U/m2,d5 a cycle of every 21 days with totally 4 cycles Radiotherapy at least 50Gy in dose for the involved local focus is sandwiched after 2 cycles.
62349059|NCT02262884|ACTIVE_COMPARATOR|AIS @ 12mmHg pressure|SurgiQuest AirSeal Insufflation System (AIS) set at 12mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
62349060|NCT02262884|ACTIVE_COMPARATOR|AIS @ 15mmHg pressure|SurgiQuest AirSeal insufflation System (AIS) set at 15 mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
62506984|NCT01086345|EXPERIMENTAL|Arm I|Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
62506985|NCT05467826|EXPERIMENTAL|Arm 1|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
62506986|NCT05467826|EXPERIMENTAL|Arm 2|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
62506987|NCT03458143||ketamine 150 ng/ml|The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
62506988|NCT03458143||ketamine 200 ng/ml|The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
62714975|NCT00329043|EXPERIMENTAL|Sunitinib + Hormonal Ablation Before Prostatectomy|Sunitinib Malate 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles. LHRH Agonist intramuscular injection either monthly for 3 months or in a single 3-month dose. Radical prostatectomy after completion of Sunitinib and LHRH agonist.
61963571|NCT03743389|ACTIVE_COMPARATOR|16F chest tube|
61963572|NCT05738668||Anti-NMDAR encephalitis|Patients with well-characterized anti-NMDAR encephalitis.
61963573|NCT02173327|OTHER|Continuously Helm CPAP|Continuously helm CPAP for 6 hours
61963574|NCT02173327|OTHER|Intermittent Mask CPAP|Intermittent Mask CPAP for 10minuttes every 2 hours in a 18 hours period postoperative.
62714976|NCT01081158|EXPERIMENTAL|Treatment-naïve 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days."
61963575|NCT02648776||Estazolam|Exposure to sedative-hypnotic drugs; Patients who have taken estazolam for at least one week before the first date of enrollment
61963576|NCT02648776||Lorazepam|Exposure to sedative-hypnotic drugs; Patients who have taken lorazepam for at least one week before the first date of enrollment
61963577|NCT02648776||Diazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Diazepam for at least one week before the first date of enrollment
61963578|NCT02648776||Alprazolam|Exposure to sedative-hypnotic drugs; Patients who have taken Alprazolam for at least one week before the first date of enrollment
61963579|NCT02648776||Flunitrazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Flunitrazepam for at least one week before the first date of enrollment
61963580|NCT02648776||Zolpidem|Exposure to sedative-hypnotic drugs; Patients who have taken Zolpidem for at least one week before the first date of enrollment
61963581|NCT02648776||Zopiclone|Exposure to sedative-hypnotic drugs; Patients who have taken Zopiclone for at least one week before the first date of enrollment
61963582|NCT02648776||Control Group|Patients not taking any of the included or any other anxiety-hypnotic agents
62506989|NCT05321823|NO_INTERVENTION|Control|Two districts in Ife East Local County with an estimated screening population of 4,500 will be randomly selected to serve as the control community. The control arm will not receive iBE screening and clinical breast examinations by the community health nurses and nor get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community. All women for screening and diagnostic workup in the control community will be directed to the tertiary hospital to receive breast care.
62705223|NCT05675410|ACTIVE_COMPARATOR|Arm A (ABVD)|Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
61963583|NCT05342545|EXPERIMENTAL|Alert|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
62144153|NCT04441775||All patients for enrollment and analysis|Patients previously treated with RT for prostate cancer who are now being enrolled into this study for data analysis and incorporation into Artificial Intelligence (AI) models
62144154|NCT03098199|EXPERIMENTAL|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
62144155|NCT03098199|EXPERIMENTAL|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
62144156|NCT03098199|EXPERIMENTAL|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
62705224|NCT05675410|EXPERIMENTAL|Arm B (ABVD, brentuximab vedotin, nivolumab)|Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
61963584|NCT05342545|NO_INTERVENTION|No Alert|"Providers in the No Alert group will not receive any on-screen notification"
61963585|NCT03617445|ACTIVE_COMPARATOR|FMT oral capsules/ oral vancomycin placebo|FMT plus placebo vancomycin
61963586|NCT03617445|ACTIVE_COMPARATOR|Placebo FMT capsules/ Active oral vancomycin|Vancomycin plus FMT enema placebo
61963587|NCT02902198|PLACEBO_COMPARATOR|Placebo preoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
61963588|NCT02902198|PLACEBO_COMPARATOR|Placebo postoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
61963589|NCT02902198|ACTIVE_COMPARATOR|Glucose preoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
61963590|NCT02902198|ACTIVE_COMPARATOR|Glucose postoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
61963591|NCT02902198|ACTIVE_COMPARATOR|Monosodium glutamate preoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
61963592|NCT02902198|ACTIVE_COMPARATOR|Monosodium glutamate postoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
61963593|NCT02902198|ACTIVE_COMPARATOR|Quinine preoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
61963594|NCT02902198|ACTIVE_COMPARATOR|Quinine postoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
61963595|NCT01192854|EXPERIMENTAL|1|
61963596|NCT01192854|ACTIVE_COMPARATOR|2|
61963597|NCT01854710|OTHER|Treatment sequence ABC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
61963598|NCT01854710|OTHER|Treatment sequence ACB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
61963599|NCT01854710|OTHER|Treatment sequence BCA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
62144157|NCT03098199|EXPERIMENTAL|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
62144158|NCT04998552|EXPERIMENTAL|SBRT (Cyberknife)|5-10 Gy/fraction. Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
62144159|NCT04998552|ACTIVE_COMPARATOR|IMRT|1.2-3 Gy/fraction up to 40 fractions. 15 mins daily (M-F) for a total of 28 sessions (5.5 weeks).
62144160|NCT02436694|ACTIVE_COMPARATOR|Local Anesthetic ropivacaíne|Femoral nerve block with ropivacaine 0.375% and sciatic nerve block with ropivacaine 0.2%
62144161|NCT02436694|EXPERIMENTAL|Perineural Dexamethasone|Femoral nerve block with ropivacaine 0.375% and perineural dexamethasone and sciatic nerve block with ropivacaine 0.2% and perineural dexamethasone
62144162|NCT03301870|EXPERIMENTAL|ATx201 GEL, 2% - intact skin|ATx201 GEL, 2% applied intact skin
62349061|NCT02262884|ACTIVE_COMPARATOR|CIS @ 15mmHg pressure|Conventional Insufflation System (CIS) set at 15mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephectomy.
62705225|NCT05675410|EXPERIMENTAL|Arm C (ABVD, eBEACOPP or eBPDac, ISRT)|See Detailed Description.
62705226|NCT05675410|EXPERIMENTAL|Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)|Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
62705227|NCT05675410|EXPERIMENTAL|Arm E (ABVD, AVD)|Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
62705228|NCT05675410|EXPERIMENTAL|Arm F (ABVD, brentuximab vedotin, nivolumab)|Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
62705229|NCT05675410|EXPERIMENTAL|Arm G (ABVD, eBEACOPP or eBPDac, ISRT)|Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C.
62705230|NCT05675410|EXPERIMENTAL|Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)|Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm B.
62705231|NCT04980248|EXPERIMENTAL|ALXN1850|Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.
62705232|NCT00867269||Blood Relatives|Blood Relatives of ICL subjects
62705233|NCT00867269||Household Contacts|Household contacts of ICL subjects
62705234|NCT00867269||ICL Subjects|Patients with confirmed idiopathic CD4 lymphocytopenia
62705235|NCT00001539||healthy volunteers|healthy individuals who have never had Lyme disease
62705236|NCT00001539||Lyme arthritis|patients with suspected Lyme arthritis
62705237|NCT00001539||multiple sclerosis controls|patients diagnosed with multiple sclerosis who have never been diagnosed with Lyme disease
62705238|NCT00001539||OspA vaccine|patients who received two doses of the OspA vaccine
62705239|NCT00001539||PTLDS|presumed PTLDS
62705240|NCT00001539||PTLDS for screening|patients suspected of PTLDS for screening
62705241|NCT00001539||recovered controls|patients who were diagnosed with Lyme disease, treated, and fully recovered
62705242|NCT00001539||seropositive controls|patients who are seropositive for Lyme disease, but have no manifestations/symptoms and have never been treated for Lyme disease
62705243|NCT04136171|EXPERIMENTAL|Eplontersen|Eplontersen by subcutaneous injection once every 4 weeks
62705244|NCT04136171|PLACEBO_COMPARATOR|Placebo|Eplontersen-matching placebo by subcutaneous injection once every 4 weeks
61963600|NCT01854710|OTHER|Treatment sequence BAC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
62705245|NCT06408688|ACTIVE_COMPARATOR|Arm A: Immune checkpoint inhibitors plus Iscador® Qu|Patients randomized to Arm A will be treated with Immune checkpoint inhibitors plus Iscador® Qu.
62705246|NCT06408688|ACTIVE_COMPARATOR|Arm B: Immune checkpoint inhibitors|Patients randomized to Arm B will be treated with Immune checkpoint inhibitors only.
62705247|NCT06503159|EXPERIMENTAL|Mindfulness-based Stress Reduction (MBSR) Program|This protocol will use fMRI and in-person and technology-delivered mindfulness-based stress reduction (MBSR) training to elucidate neurobehavioral correlates of regular nicotine vaping in adolescents compared to non-vaping adolescents, and changes in these correlates after MBSR training.
62705248|NCT05199870||Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head|Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head to repair hip malfunction/disease/injury.
62705249|NCT06250608|EXPERIMENTAL|Acute ischemic stroke patients|
61963601|NCT01854710|OTHER|Treatment sequence CAB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
61963602|NCT01854710|OTHER|Treatment sequence CBA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
62144163|NCT03301870|EXPERIMENTAL|ATx201 GEL, 4% - intact skin|ATx201 GEL, 4% applied to intact skin
62705250|NCT06302816|EXPERIMENTAL|TUPLER exercises|
61963603|NCT06421493||Case group|Age \> 18 years Singleton pregnancy Live fetus at 11-13 weeks of gestation Pregnancies complicated by hypertensive disorders (HDP) and fetal growth restriction (FGR) Women with pregnancies complicated by HDP and a fetus with appropriate weight for gestational age (AGAf) Women with pregnancies complicated solely by early fetal growth restriction (before 34 weeks) Women with pregnancies complicated solely by late fetal growth restriction (after 34 weeks) Women identified as high-risk in first-trimester screening for preeclampsia Women identified as high-risk in first-trimester screening for fetal growth restriction
61963604|NCT06421493||Controls|Age \> 18 years Singleton pregnancy Feto vivo a 11-13 settimane di gravidanza Low-risk pregnancies in first-trimester screening for preeclampsia and fetal growth restriction, with physiological follow-up visits until delivery (homogeneous control sample)
61963605|NCT01786044|EXPERIMENTAL|MasterMed|MasterMed, an online interactive educational program
61963606|NCT01786044|PLACEBO_COMPARATOR|Usual care|Access to an online patient portal
61963607|NCT05506891|EXPERIMENTAL|Astragalus group|
61963608|NCT05506891|ACTIVE_COMPARATOR|Physical therapy group|
62349062|NCT01805102||maternal serum|measurement by immunoassay
62349063|NCT04424199||LBD patients R-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:~1. First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~2. Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
62349064|NCT04424199||LBD patients L-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:~1. First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~2. Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
62705251|NCT06302816|ACTIVE_COMPARATOR|SCOOP EXERCISES|
62705252|NCT03048331|EXPERIMENTAL|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
61963609|NCT03740945|PLACEBO_COMPARATOR|Placebo|Placebo vaginal ovule daily for 12 weeks
61963610|NCT03740945|EXPERIMENTAL|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
61963611|NCT04374721|EXPERIMENTAL|Patients with Adrenal Insufficiency|Patients with Adrenal Insufficiency established or newly diagnosed, under glucocorticoid replacement therapy.
62144164|NCT03301870|EXPERIMENTAL|ATx201 GEL, 2% - abraded skin|ATx201 GEL, 2% applied to abraded skin
62144165|NCT03301870|EXPERIMENTAL|ATx201 GEL, 4% - abraded skin|ATx201 GEL, 4% applied to abraded skin
62349065|NCT04424199||RBD patients R-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:~1. First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~2. Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
62705253|NCT03048331|NO_INTERVENTION|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
61963612|NCT04374721|EXPERIMENTAL|Patients with Cushing's Syndrome|patients with adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent Cushing's Syndrome diagnosis during active disease (new diagnosis or recidivating) at enrollment.
61963613|NCT04374721|EXPERIMENTAL|Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by Adrenal Insufficiency or Cushing's Syndrome.
61963614|NCT02771002||septic shock patients|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until normalisation of lactate sonographic assesment of perfusion of solid organs once within 24h after admission
61963615|NCT02771002||patients rewarming after cardiac surgery|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until extubation
61963616|NCT02771002||healthy volunteers|measurements of peripheral perfusion including capillary refill time and peripheral perfusion index in ambient temperature and after cooling of extremity
61963617|NCT04234178|ACTIVE_COMPARATOR|Dural puncture epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
61963618|NCT04234178|ACTIVE_COMPARATOR|Combined spinal-epidural with epidural volume extension|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
61963619|NCT05043506||Palbociclib + aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between September 1, 2016, and July 31, 2020.
61963620|NCT05043506||Aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated an aromatase inhibitor as first line therapy between January 1, 2010,, and July 31, 2020
61963621|NCT02967835|EXPERIMENTAL|Telepsychiatry Consult|One time tele-psychiatry consultation to provide treatment recommendations for patients primary care physician.
61963622|NCT01433614|ACTIVE_COMPARATOR|Epirubicin + paclitaxel (Taxol)|Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.
61963623|NCT01433614|ACTIVE_COMPARATOR|Paclitaxel + epirubicin + capecitabine|Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.
62144166|NCT03301870|PLACEBO_COMPARATOR|ATx201 GEL Placebo - intact skin|ATx201 GEL Placebo applied to intact skin
62144167|NCT03301870|PLACEBO_COMPARATOR|ATx201 GEL Placebo - abraded skin|ATx201 GEL Placebo applied to abraded skin
62506990|NCT05321823|EXPERIMENTAL|Intervention|Three districts in Ife North Local County with an estimated screening population (women 40-70 years) of 5,800 will be randomly selected to serve as the intervention community. Women in the intervention community will receive iBreast and clinical breast examinations by the community health nurses and get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community.
62506991|NCT02658786||Hepatitis B patients|Biopsy proven Hepatitis B virus infected cases will be followed for the period of 5 years
61963624|NCT02370160|EXPERIMENTAL|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
61963625|NCT00889460|PLACEBO_COMPARATOR|1|Placebo group
61963626|NCT00889460|EXPERIMENTAL|2|rBet v 1 tablets
61963627|NCT01282892||patients with NAFLD|
62506992|NCT02658786||Hepatitis C patients|Biopsy proven Hepatitis C virus infected cases will be followed for the period of 5 years
62506993|NCT02658786||Non Alcoholic Fatty liver Disease patients|Biopsy proven Non Alcoholic Fatty liver Disease patients cases will be followed for the period of 5 years
62506994|NCT00732524|ACTIVE_COMPARATOR|Glipizide arm|Glipizide XL is an insulin secretagogue and is an extended release tablet designed to provide a controlled rate of delivery. Glipizide XL was chosen because it is the most frequently used discharge oral medication in our ED. It has a quick onset of action within a few hours after oral ingestion, lasts for 24 hours and has a powerful glucose lowering effect. In addition, there are very few contraindications to Glipizide XL and there is published literature regarding their use in subjects with severe hyperglycemia
62506995|NCT00732524|ACTIVE_COMPARATOR|Glipizide + Glargine|Insulin Glargine is a recombinant human basal insulin analog. It was chosen since it is a non-peaking insulin with cover for 24 hours. It can be injected subcutaneously only once a day and has a low incidence of hypoglycemia
61963628|NCT01282892||excess of visceral fat|
61963629|NCT04157439|ACTIVE_COMPARATOR|Control Group|Hot fermentation, Sustain pressure on trigger point, Self-stretches
61963630|NCT04157439|EXPERIMENTAL|Experimental Group|Integrated Neuromuscular Inhibition Technique Post isometric stretch (MET) Strain counter strain
61963631|NCT04585386|EXPERIMENTAL|ATLAS|"Medical device named ATLAS which is an active corset (rigid lumbar restraint) and connected."
61963632|NCT04585386|ACTIVE_COMPARATOR|Standard lumbar support belt|Standard lumbar support belt : LombaSkin® or Lombogib®
61963633|NCT01804075|ACTIVE_COMPARATOR|methadone|"Methadone (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Methadone 8-12 0.05 mg/kg/dose \>=13 0.1 mg/kg/dose~1. Maximum dose of methadone will be 0.2 mg/kg/dose. (NeoFax)~2. Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 4 hours, until NAS scores are consistently \<8 for 48 hours.~3. If the maximum dose of methadone is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
61963634|NCT01804075|ACTIVE_COMPARATOR|morphine|"Morphine (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Morphine 8-12 0.05 mg/kg/dose \>=13 0.1 mg/kg/dose~1. Maximum dose of morphine will be 0.2 mg/kg/dose. (NeoFax)~2. Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 6 hours, until NAS scores are consistently \<8 for 48 hours.~3. If the maximum dose of morphine is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
61963635|NCT00850564|EXPERIMENTAL|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily
61963636|NCT05065632||Groupe 1|\[1-15\[
61963637|NCT05065632||Group 2|\[15- 30\[
61963638|NCT05065632||Group 3|\[30-45\[
61963639|NCT05065632||Group 4|\[45-60\[
62144168|NCT03301870|ACTIVE_COMPARATOR|Negative Irritant Control - intact skin|Negative (low) Irritant Control applied to intact skin
61963640|NCT05065632||Group 5|60+
62144169|NCT03301870|ACTIVE_COMPARATOR|Negative Irritant Control - abraded skin|Negative (low) Irritant Control applied to abraded skin
62144170|NCT03301870|ACTIVE_COMPARATOR|Positive Irritant Control - intact skin|Positive (high) Irritant Control applied to intact skin
62144171|NCT02785159|EXPERIMENTAL|IDP-118 Lotion|Lotion
62506996|NCT05050227|EXPERIMENTAL|cCBT Enhanced Collaborative Care|Participants in the intervention arm will receive computerized cognitive behavioral therapy (cCBT) supported by a depression care manager in addition to the usual care provided.
62506997|NCT05050227|ACTIVE_COMPARATOR|Usual Care|Participants in the usual care arm will receive the usual care provided as described below.
62506998|NCT00625924||1|autogenous tissue breast reconstruction
62506999|NCT00625924||2|tissue expander/implant breast reconstruction
62507000|NCT00625924||3|mastectomy alone
62507001|NCT05186779||Cohort A|Early Pregnancy Bleeding/Recurrent Pregnancy loss
62507002|NCT05186779||Cohort B|IVF/ART
61963641|NCT02198274|EXPERIMENTAL|BIBH 1|
61963642|NCT03534557||COPD|FEV1/FVC and FEV1/FEV6 will be compared within the same cohort of COPD patients
61963643|NCT00913497|ACTIVE_COMPARATOR|insulin glulisine|
61963644|NCT00913497|ACTIVE_COMPARATOR|insulin aspart|
61963645|NCT06021730|NO_INTERVENTION|Control|Patients received standard after visit procedure based on the provider
61963646|NCT06021730|EXPERIMENTAL|Standardized After Visit Instructions Only|The standardized after visit instructions (AVI) only group included patients receiving typed standardized AVI which included a text template that providers used to write customized AVI for the patient.
61963647|NCT06021730|ACTIVE_COMPARATOR|Standardized After Visit Instructions & Teach Back|The standardized AVI \& teach back (TB) group included standardized written AVI with the patient repeating to the provider which changes and future management had been agreed upon during the visit.
61963648|NCT00790023|EXPERIMENTAL|80 mcg Ciclesonide|80 mcg Ciclesonide once daily
61963649|NCT00790023|EXPERIMENTAL|160 mcg Ciclesonide|160 mcg Ciclesonide once daily
61963650|NCT00790023|PLACEBO_COMPARATOR|Placebo|Placebo once daily
61963651|NCT05740397|OTHER|Standard MAP|Control group: MAP values between 50-60 mmHg
62144172|NCT02785159|ACTIVE_COMPARATOR|Tazorac Cream|Cream
62507003|NCT06355830||intermediate AMD|Subjects over 55 years old with drusen secondary to intermediate AMD
62349066|NCT04424199||RBD patients L-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:~1. First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~2. Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
62349067|NCT04424199||HC R-PA|"A group of 10 healthy controls (HC) will attend two sessions:~1. First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.~2. Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
62349068|NCT04424199||HC L-PA|"A group of 10 healthy controls (HC) will attend two sessions:~1. First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.~2. Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
62507004|NCT04067193||old geriatric inpatients|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes)
62507005|NCT04067193||unformal caregivers|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes) by their relative
62507006|NCT04067193||professional caregivers|usability assessment after the possible use of the device (PARADE CONNECT shoes) by 40 hospitalzed old patients in the geriatrics ward
62507007|NCT04572204||Conservative group|
62507008|NCT04572204||interventional group|
62507009|NCT04234464|EXPERIMENTAL|A/B - Treatment with BDA MDI 160/180 followed by treatment with Placebo MDI|Subjects randomized to receive a single dose of BDA MDI 160/180 in treatment period 1, and a single dose of Placebo MDI in treatment period 2.
62349069|NCT01726413|EXPERIMENTAL|Test Arm|GRC17356 for daily administration
62349070|NCT01726413|PLACEBO_COMPARATOR|Placebo|Matching placebo for daily administration
62349071|NCT01700985|EXPERIMENTAL|122-0551|
62349072|NCT01700985|PLACEBO_COMPARATOR|Vehicle|
62349073|NCT00311558|EXPERIMENTAL|SSG & INF|1 arm study: SSG \& interferon
62349074|NCT02001675|EXPERIMENTAL|Volunteer healthy|
62349075|NCT00799500|EXPERIMENTAL|Weekly screening|Screening and treatment of bacterial vaginosis during pregnancy through self-administered weekly vaginal pH determination.
62349076|NCT00799500|NO_INTERVENTION|Observation|Usual care
62507010|NCT04234464|EXPERIMENTAL|B/A - Treatment with Placebo MDI followed by treatment with BDA MDI 160/180|Subjects randomized to receive a single dose of Placebo MDI in treatment period 1, and a single dose of BDA MDI 160/180 in treatment period 2.
62507011|NCT02608840|EXPERIMENTAL|MCI auditory stimulation|MCI patients receiving auditory stimulation during sleep (crossover arm 1)
62507012|NCT02608840|SHAM_COMPARATOR|MCI sham stimulation|Sham intervention: MCI patients sleeping with headphones but sounds not played (crossover arm 2)
62507013|NCT02608840|EXPERIMENTAL|Older adult auditory stimulation|healthy older adults receiving auditory stimulation during sleep (crossover arm 1)
62507014|NCT02608840|SHAM_COMPARATOR|older adult sham stimulation|Sham intervention: healthy older adults sleeping with headphones but sounds not played (crossover arm 2)
62507015|NCT04159194|ACTIVE_COMPARATOR|Normal CHO|
62507016|NCT04159194|EXPERIMENTAL|High CHO|
62507017|NCT00006102|EXPERIMENTAL|Arm I|"Patients with solid tumors are stratified according to tumor histology (neuroblastoma vs Ewing's sarcoma \[closed to accrual as of 5/19/03\]/peripheral primative neuroectodermal tumor \[PNET\] vs osteosarcoma \[closed to accrual as of 5/19/03\] vs rhabdomyosarcoma vs non-Hodgkin's lymphoma vs other solid tumors). Patients with CNS tumors are stratified according to tumor histology (medulloblastoma/PNET vs ependymoma vs brainstem glioma vs other CNS tumors).~Patients receive rebeccamycin analogue IV over 1 hour on day 1. Treatment continues every 21 days for a total of 16 courses in the absence of disease progression or unacceptable toxicity."
62507018|NCT04395599|EXPERIMENTAL|COVID19 patients undergoing visceral surgery|
62507019|NCT02614833|EXPERIMENTAL|Paclitaxel + IMP321 at the RPTD|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
62349077|NCT04504435|EXPERIMENTAL|Participants in Cohort 1|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with 20 milligram (mg) and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
62349078|NCT04504435|EXPERIMENTAL|Participants in Cohort 2|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with dose level (DL) 5 and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
62507020|NCT02614833|ACTIVE_COMPARATOR|Comparator: Paclitaxel + Placebo|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
62507021|NCT03932279||Stage IA-IIA cutaneous T cell lymphoma|
62507022|NCT03932279||Stage IIB and above cutaneous T cell lymphoma|
62507023|NCT03932279||CD30+ lymphoproliferative disorders|
62507024|NCT03932279||Plaque psoriasis with BSA>5% on routine phototherapy|
62144173|NCT02785159|ACTIVE_COMPARATOR|IDP 118 Vehicle Lotion|Lotion
62507025|NCT03932279||Moderate to severe atopic dermatitis on routine bleach bath|
61963652|NCT05740397|OTHER|High MAP|First Comparator group: MAP values between 70-80 mmHg
61963653|NCT05740397|OTHER|Patient-tailored MAP|"Second Comparator group: MAP comparable to the patient's pre-operative MAP. This one will be calculated by performing 3 blood pressure measurement in three different moments of the day before surgery (at 8 am, at 3 pm, and at 9 pm), and will be calculated using the standard formula Diastolic AP + 0,33 x (systolic AP - Diastolic AP). The preoperative MAP value obtained will be target during CPB, within a range of ± 10 mmHg"
61963654|NCT04964531||Adults|group of adults includes all patients aging 19 years or more
61963655|NCT04964531||children|group of children includes all patients aging less than 19 years
61963656|NCT02634671|OTHER|22Q11|24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
61963657|NCT02634671|OTHER|SCHIZOPHRENIA|24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
61963658|NCT01343498|EXPERIMENTAL|BEZ235|
61963659|NCT04809688|EXPERIMENTAL|Single arm|Single arm
61963660|NCT01126450|EXPERIMENTAL|Arm I|Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61963661|NCT01367002|ACTIVE_COMPARATOR|Carboplatin/Paclitaxel|Chemotherapy
61963662|NCT01367002|EXPERIMENTAL|Trastuzumab|Monoclonal antibody
61963663|NCT02616055|EXPERIMENTAL|50mg Daily|One 50mg tesevatinib tablet per day
61963664|NCT02616055|EXPERIMENTAL|100mg Daily|Two 50mg tesevatinib tablets per day
61963665|NCT02616055|EXPERIMENTAL|150mg M/Th|Three 50mg tesevatinib tablets every Monday and Thursday.
61963666|NCT02616055|EXPERIMENTAL|150mg MWF|Three 50mg tesevatinib tablets every Monday, Wednesday and Friday.
61963667|NCT04745429|EXPERIMENTAL|Intervention|19 people suffering from psoriasis were performing excersises for 10 weeks
61963668|NCT04745429|NO_INTERVENTION|Control|19 people suffeing from psoriasis that didn't train the exercises
61963669|NCT00670683||A|
62349079|NCT04504435|EXPERIMENTAL|Cohort 3: Participants receiving GSK3494245 (fasted then fed)|Participants will receive the selected dose level (DLX) of GSK3494245 in the fasted state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fed state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
62349080|NCT04504435|EXPERIMENTAL|Cohort 3: Participants receiving GSK3494245 (fed then fasted)|Participants will receive the DLX of GSK3494245 in the fed state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fasted state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
62144174|NCT02785159|ACTIVE_COMPARATOR|IDP-118 Vehicle Cream|Cream
61963670|NCT01111097|ACTIVE_COMPARATOR|Cohort 1|Subjects are given a dose of Dichloroacetate 4mg/kg twice a day for 30 days
61963671|NCT01111097|ACTIVE_COMPARATOR|Cohort 2|Subjects are given a dose of Dichloroacetate 12.5mg/kg twice a day for 30 days
61963672|NCT01427504|EXPERIMENTAL|Sequence 1a|Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.
62144175|NCT02604693||Chronic Beryllium Disease|Those that have been diagnosed with the disease. No interventions will be administered.
62144176|NCT02604693||Beryllium Sensitization|Those that have been diagnosed with beryllium sensitization and do not have chronic beryllium disease. No interventions will be administered.
62349081|NCT02702011|EXPERIMENTAL|empagliflozin low dose|
61963673|NCT01427504|EXPERIMENTAL|Sequence 1b|Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.
61963674|NCT01427504|EXPERIMENTAL|Sequence 2a|Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.
62144177|NCT02604693||normal controls|Those that do not have chronic beryllium disease or beryllium sensitization. No interventions will be administered
61963675|NCT01427504|EXPERIMENTAL|Sequence 2b|Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.
61963676|NCT01427504|EXPERIMENTAL|Sequence 3a|Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.
61963677|NCT01427504|EXPERIMENTAL|Sequence 3b|Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.
61963678|NCT02061982|EXPERIMENTAL|Caffeine|Instant coffee with or without caffeine will be provided
61963679|NCT02061982|PLACEBO_COMPARATOR|Coffee without caffeine|Coffee without caffeine
61963680|NCT03331003|EXPERIMENTAL|low level light therapy|1 group uses the investigational device on the left side, and the subjects will have half part receiving low level light therapy (red light-emitting diode and laser irradiation)
61963681|NCT03331003|PLACEBO_COMPARATOR|non-LLLT wavelength group group|the control device on the right side, other half with non-low-level laser therapy wavelength (white light-emitting diode light bulb coating with red paint to make the irradiating light close to the red).
61963682|NCT03485547|EXPERIMENTAL|Venetoclax|"* Venetoclax is administered on a daily basis orally.~* The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax."
61963683|NCT02387398|EXPERIMENTAL|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
61963684|NCT02387398|NO_INTERVENTION|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
62349082|NCT02702011|EXPERIMENTAL|empagliflozin medium dose|
62349083|NCT02702011|EXPERIMENTAL|empagliflozin high dose|
62349084|NCT02702011|PLACEBO_COMPARATOR|placebo|
62349085|NCT04048655|OTHER|Study group|Single arm and everyone gets the same treatment according the protocol
62349086|NCT04824417|ACTIVE_COMPARATOR|Control|Oral itraconazole
62349087|NCT04824417|EXPERIMENTAL|Intervention|Oral voriconazole
61963685|NCT06204146|EXPERIMENTAL|massage|massage was applied to the infants in the experimental group three times daily for 10 days,
61963686|NCT06204146|NO_INTERVENTION|control|the control group received the usual care
61963687|NCT02704117|EXPERIMENTAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.
61963688|NCT04413396||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
61963689|NCT02688140|EXPERIMENTAL|Arm A|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses."
61963690|NCT02688140|ACTIVE_COMPARATOR|Arm B (standard chemotherapy)|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7, oral tretinoin twice daily on day 1-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation I:~IDA 5 mg/m2 i.v. day 1-4 Ara-C 1000 mg/m2/3h i.v. day 1-4 ATRA 45 mg/m2 p.o. day 1-15~Consolidation II:~MTZ 10 mg/m2 i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Consolidation III:~IDA 12 mg/m2 i.v. day 1 Ara-C 150 mg/m2 every 8h i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Maintenance (duration 7 cycles = 2 years; one cycle lasts 106 days):~6-MP 50 mg/m2 p.o. Cycle 1-7: day 1-91 (followed by 15 days of ATRA on days 92-106)~MTX 15mg/m2 i.m./p.o. Cycle 1-7: once weekly for 91 days (followed by 15 days of ATRA on days 92-106)~ATRA 45 mg/m2 p.o. Cycle 1-6: day 92-106 Cycle 7: without ATRA Administration~(treatment break of 6-MP and MTX during ATRA administration)"
61963691|NCT03459547|EXPERIMENTAL|dental implant + PEEK (test)|Dental implant insertion, material polyetheretherketone
61963692|NCT03459547|ACTIVE_COMPARATOR|dental implant + Ti-5 (control)|Dental implant insertion, material titanium group 5
61963693|NCT03459547|ACTIVE_COMPARATOR|dental implant + zirconia (control)|dental implant insertion, material zirconia
61963694|NCT03459547|ACTIVE_COMPARATOR|dental implant + Ti-4 (control)|dental implant insertion, material titanium group 4
62507026|NCT03932279||Healthy controls|
62705254|NCT06254950|EXPERIMENTAL|TAK-279 Dose 1|TAK-279, capsules, orally at Dose 1 up to Week 12 followed by either Dose 1 or Dose 2 up to week 52 based on the response.
62705255|NCT06254950|EXPERIMENTAL|TAK-279 Dose 2|TAK-279, capsules, orally at Dose 2 up to Week 12 followed by either Dose 1 or Dose 2 up to week 52 based on the response.
62705256|NCT06254950|PLACEBO_COMPARATOR|Placebo|TAK-279 matching placebo capsules, orally, for 12 weeks followed by TAK-279 capsules, orally either Dose 1 or Dose 2 up to Week 52 based on the response.
61963695|NCT04029948|ACTIVE_COMPARATOR|laser ERBT|Laser En Bloc Resection Of bladder Tumor
61963696|NCT04029948|ACTIVE_COMPARATOR|electro-surgical ERBT|electro-surgical En Bloc Resection Of bladder Tumor
62144178|NCT03879538|ACTIVE_COMPARATOR|The nitrous oxide group|Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
62705257|NCT06346392|EXPERIMENTAL|AZD0901 arm 1|Participants in the AZD0901 arm 1 will receive AZD0901 dose level 1 intravenous infusion treatment.
62144179|NCT03879538|PLACEBO_COMPARATOR|The Control Group|Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
62144180|NCT03650543|EXPERIMENTAL|amoxicillin clarithromycin omeprazole 1|"This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days."
62349088|NCT01796639||kidney transplantation patients with living-donor grafts|
62705258|NCT06346392|EXPERIMENTAL|AZD0901 Arm 2|Participants in the AZD0901 arm 2 will receive AZD0901 dose level 2 intravenous infusion treatment.
62705259|NCT06346392|ACTIVE_COMPARATOR|Investigator's choice arm|Participants in the Investigator's choice arm will receive a regimen of Investigator's choice, including regionally accepted chemotherapies or targeted therapies.
62144181|NCT03650543|EXPERIMENTAL|amoxicillin clarithromycin omeprazole 2|"This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 \*1/\*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 \*1/\*2 or \*1/\*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 \*2/\*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner."
62144182|NCT03096470||anesthesia|The children were treated with closed reduction with anesthesia after prolonged traction
62144183|NCT03096470||No anesthesia|The children were treated with closed reduction with no anesthesia after prolonged traction
62507027|NCT00531362||Patients|All patients (acute or stable) presenting to a cardiovascular clinic and on aspirin.
62507028|NCT00757679|EXPERIMENTAL|Milnacipran|
62507029|NCT00757679|PLACEBO_COMPARATOR|Placebo|
62507030|NCT02823847|EXPERIMENTAL|Oral Screening|Participants given a screening interview at baseline. Carbon monoxide testing given to participants at baseline. Participants who want to stop smoking are given referral information for a tobacco cessation program. Participants undergo an oral examination using conventional light, and oral examination using a fluorescence light-based hand held device at baseline, and again two weeks later. Oral lesions still present after two weeks are biopsied. Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation.
62507031|NCT02203617|EXPERIMENTAL|educational baby books|books embedded with educational information (pediatric anticipatory guidance)
62705260|NCT05135390|EXPERIMENTAL|HSK21542|0.3 μg/kg
62705261|NCT05135390|EXPERIMENTAL|Placebo|Placebo
61963697|NCT04694417|EXPERIMENTAL|Compression stocking|Compression stockings are mainly used for the prevention and reduction of lower limb oedema or venous thrombosis. There are three compression classes used in health care. The compression stocking group of the study will receive CE-marked stockings within the compression class of 1 (25-40 mmHg compression). The correct size for the compression stockings will be defined by the reported circumference of the participant's ankle and calf. The participants will be given instructions to put the stockings on immediately after getting out of bed in the morning and to take them off before going to bed in the evening for the last four weeks of the study. Stockings within the mild compression class have no harmful effects on individuals when the exclusion criteria are considered. The participants will be instructed to communicate with a dedicated research assistant via e-mail or phone in case of any problems or questions.
61963698|NCT04694417|ACTIVE_COMPARATOR|Magnesium|"Magnesium is a mineral substance which regulates many biochemical reactions in the body, for example protein synthesis and the function of the muscles and nerves. It has a significant role in controlling blood sugar, blood pressure, energy generation and the formation of the bones. The recommended dietary allowance for magnesium is 420 mg for males and 320 mg for females over 50 years old. Dark green vegetables, leguminous plants, nuts, seeds and wholegrains are good sources of magnesium (11,12).~In the average Finnish diet, the recommendation is usually exceeded, and excessive amounts of magnesium in the body are extremely rare. The magnesium arm of the study will take oral tablets containing 620 mg of magnesium hydrochloride daily for the last four weeks of the study, which is equivalent to 250 mg of pure magnesium per day. The magnesium tablets for this study were manufactured and analysed by the Pharmia pharmaceutical company in Finland."
61963699|NCT04694417|PLACEBO_COMPARATOR|Placebo|The placebo tablets will consist of microcrystalline cellulose, magnesium stearate (anti-caking agent) and silicon dioxide. The placebo tablets were manufactured and analysed by the Pharmia pharmaceutical company in Finland. The placebo arm will receive placebo tablets to be taken daily for the last four weeks of the study. The participants will not know whether they are randomised into the magnesium arm or the placebo arm. The packaging and the appearance of the placebo and magnesium tablets are identical.
61963700|NCT04964310||APAP_DILI|"（①/②）+③+④：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU/L ④ liver impairment is caused by acetaminophen：Russel U-Calf Causality Assessment Method(RUCAM) causality score\>6"
62144184|NCT03987698|EXPERIMENTAL|Arm 1: CIK+PD-1i|"SHR-1210 \& CIK cells~SHR-1210,200mg/d,intravenous infusion,d1; CIK cells, 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W."
62144185|NCT03987698|ACTIVE_COMPARATOR|Arm 2: Control|SHR-1210,200mg/d,intravenous infusion,d1; Q3W.
62144186|NCT01971255|EXPERIMENTAL|High Titer (HAI > or = 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of ≥1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
62349089|NCT01923233|EXPERIMENTAL|Treatment|Intradermal AlloStim(TM) (1ml) on day 0 and 3 in same location Intradermal AlloStim(TM) (1ml) on day 7 and day 10 in same location Radiofrequency ablation on day 14 followed by intralesional AlloStim (3ml) Intralesional AlloStim(TM)(3ml) on day 17 in same ablated lesion Intravenous AlloStim(TM)(5ml) on days 21, 49 and 78
62349090|NCT03522883|PLACEBO_COMPARATOR|group control|the subjects will not take any type of nutrient intake
62507032|NCT02203617|ACTIVE_COMPARATOR|non-educational baby books|baby books given with same illustrations but no educational information
62507033|NCT02203617|NO_INTERVENTION|no books|not given any baby books
62705262|NCT05306938|EXPERIMENTAL|Intervention|Adolescents in this arm will receive the Adolescent Wellness Visit intervention.
62705263|NCT05306938|NO_INTERVENTION|Control|Adolescents in this arm will not receive the Adolescent Wellness Visit intervention.
62349091|NCT03522883|EXPERIMENTAL|experimental group 1|carbohydrate intake prior to exercise
62349092|NCT03522883|ACTIVE_COMPARATOR|experimental group 2|carbohydrate intake prior to exercise
62349093|NCT05387577|ACTIVE_COMPARATOR|Sublingual Estradiol|Sublingual estradiol administered for 8 weeks
62349094|NCT05387577|ACTIVE_COMPARATOR|Oral Estradiol|Oral estradiol administered for 8 weeks
62507034|NCT02882269|ACTIVE_COMPARATOR|Postoperative chemotherapy|Patients receive 6 months of chemotherapy after surgery.
62507035|NCT02882269|EXPERIMENTAL|Neoadjuvant chemotherapy|Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months.
62507036|NCT01192399|EXPERIMENTAL|Eculizumab|Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses
62507037|NCT02335957|OTHER|Intentional irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
62507038|NCT02335957|EXPERIMENTAL|Incidental irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
62507039|NCT05301686||Patients with Cyclop lesion|Patients with an anterior cruciate ligament reconstruction with a symptomatic Cyclop lesion leading to a arthroscopy within 2 years after primary surgery
62705264|NCT06442514|EXPERIMENTAL|PASS-IVR|An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls. Veterans in PASS-IVR will also be offered 12-weeks of pharmacotherapy (e.g., NRT patches and one of two rescue methods such as nicotine lozenge or gum or varenicline) via telemedicine consult. The NRT dose and delivery route will be tailored to the number of cigarettes smoked per day (using an established protocol).
62349095|NCT05387577|ACTIVE_COMPARATOR|Transdermal Estradiol|Transdermal estradiol administered for 8 weeks
62349096|NCT04934306||Patients without cleft|Patients without developmental speech disorder (including articulation disorder) or hearing impairment
62507040|NCT05301686||Patients without Cyclop lesion|Patients without no arthroscopy within 2 years after primary surgery
61963701|NCT04964310||APAP_NO-DILI（NDILI）|"（①/②）not（③/④）：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：ALT or AST ≥ 1000 IU/L④ liver impairment is caused by acetaminophen：RUCAM causality score\>6"
61963702|NCT02164760|EXPERIMENTAL|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
61963703|NCT02164760|NO_INTERVENTION|STSG alone|STSG alone
61963704|NCT06066944|EXPERIMENTAL|Group B|The experimental group will receive a Self-Thai Foot Massage on every alternate day for 15 days for 30 minutes.
61963705|NCT06066944|NO_INTERVENTION|Group A|Participants in the control group will continue with the standard treatment regimen prescribed by the physician at the diabetic clinic. Baseline data will be collected as conducted for the experimental group. After the completion of the study, if the intervention will prove effective, the Self-Thai foot massage will be taught to the control group.
61963706|NCT01437072||Total study population|
62507041|NCT05659329||Non-medicated Simplex HV|Retrospective observation of patients who have received a Triathlon Total Knee Replacement implanted with nonmedicated Simplex HV Bone Cement.
62705265|NCT06442514|OTHER|Treatment as Usual|Treatment as usual includes referral to the local smoking cessation clinic where Veterans may select a virtual individual or group based cognitive behavioral smoking cessation program with a trained psychology intern, postdoctoral fellow or staff psychologist. In conjunction, Veterans are encouraged but not required, by clinic staff, to connect with the VA Quitline and the VA's Annie text-messaging service to support their quit. Veterans are strongly encouraged to consider pharmacotherapy (e.g., NRT patches and one of two rescue methods such as nicotine lozenge or gum or varenicline). The NRT dose and delivery route will be tailored to the number of cigarettes smoked per day (using an established protocol - interested Veterans will be offered a telemedicine consult for this service
62705266|NCT00102544|EXPERIMENTAL|All cohorts (prostate biopsy percutaneous biopsy and ablation)|This study will consist of comparison of tracked imaging with near-simultaneous actual imaging .
62705267|NCT03314454|ACTIVE_COMPARATOR|Elevated Mental Status|Elevated score on Patient Health Questionnaire
62705268|NCT03314454|ACTIVE_COMPARATOR|Non-elevated depressed mood|Lower score on Patient Health Questionnaire
62705269|NCT03314454|ACTIVE_COMPARATOR|Social Drinking status|The social drinker group will be those who consume alcohol regularly but with infrequent heavy drinking days.
61963707|NCT03598556|EXPERIMENTAL|Vitamin D3 Supplementation Arm|This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
61963708|NCT03598556|PLACEBO_COMPARATOR|Placebo Arm|This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
61963709|NCT02539121|EXPERIMENTAL|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
62705270|NCT03314454|ACTIVE_COMPARATOR|Heavy drinker status|The heavy drinker group will be those who consume alcohol regularly with frequent heavy drinking days.
62705271|NCT02503722|EXPERIMENTAL|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61963710|NCT02539121|PLACEBO_COMPARATOR|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
61963711|NCT05950932|EXPERIMENTAL|Treatment-Placebo|This arm will assume firstly the supplement product (Melissa phytosome) and later the placebo.
62705272|NCT06052059|EXPERIMENTAL|Study 1: High Dose Induction, High Dose Maintenance|Participants receive high dose intravenous (IV) tulisokibart, followed by a high dose subcutaneous (SC) tulisokibart regimen.
62705273|NCT06052059|EXPERIMENTAL|Study 1: High Dose Induction, Low Dose Maintenance|Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
62705274|NCT06052059|EXPERIMENTAL|Study 1: Low Dose Induction, Low Dose Maintenance|Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
62705275|NCT06052059|PLACEBO_COMPARATOR|Study 1: Placebo|Participants receive IV placebo, followed by an SC placebo regimen.
61963712|NCT05950932|EXPERIMENTAL|Placebo-Treatment|This arm will assume firstly the placebo and later the supplement product (Melissa phytosome).
61963713|NCT01718275||Non-operative Group|Patients and caregivers who agree to receive non-operative management with antibiotics alone
61963714|NCT01718275||Surgery Group|Patients and caregivers who decide to undergo appendectomy that permit us to track their standard treatment course
61963715|NCT05211882|EXPERIMENTAL|Immediate|Participants in the intervention arm will start on the ENABLE program at point of randomization.
61963716|NCT05211882|EXPERIMENTAL|Wait-list (delayed)|Participants on wait-list will start ENABLE 6 months after randomization.
61963717|NCT04506372|EXPERIMENTAL|Intervention group|Perioperative withdrawal of ACEI/ARB.
61963718|NCT04506372|ACTIVE_COMPARATOR|Control group|Perioperative continuation of ACEI/ARB.
61963719|NCT06117657|EXPERIMENTAL|KL-HIV-Tri01 injection solution|Subjects will be dosed with three different dose of KL-HIV-Tri01 injection solution at 2.4x10\^11 vg/kg to 2.4x10\^12 vg/kg.
62349097|NCT04934306||Patients with a cleft|Patients with a hard and/or soft palate cleft and for whom the perceptual speech-language pathology evaluation revealed a velopharyngeal insufficiency
62349098|NCT02623296|EXPERIMENTAL|GLPG1205 and single CYP450 substrate cocktail dose|Daily GLPG1205 administration from Day 1 to Day 12 Single GLPG1205 co-administration on Day 13 with CYP450 substrate cocktail
61963720|NCT04425915|EXPERIMENTAL|Convalescent Plasma with Standard of Care|Two doses of 250 ml Convalescent plasma from recovered COVID-19 patients + Standard of Care will be given to severely sick COVID-19 patients in the treatment arm
61963721|NCT04425915|ACTIVE_COMPARATOR|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
61963722|NCT00738595|EXPERIMENTAL|1|EVT 302, 5 mg once Daily
61963723|NCT00738595|PLACEBO_COMPARATOR|2|Placebo once daily
61963724|NCT00738595|EXPERIMENTAL|3|EVT 302 plus open label Nicotine replacement
61963725|NCT00738595|ACTIVE_COMPARATOR|4|Placebo plus nicotine replacement therapy
61963726|NCT04951999|OTHER|Blood sampling|
61963727|NCT00959309|EXPERIMENTAL|Intervention|
62507042|NCT05659329||Gentamycin Simplex HV|Retrospective observation of patients who have received a Triathlon Total Knee Replacement implanted with Gentamycin Simplex HV Bone Cement.
62144187|NCT01971255|EXPERIMENTAL|Low Titer (HAI < 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of \<1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
62349099|NCT02623296|PLACEBO_COMPARATOR|Placebo and single CYP450 substrate cocktail dose|Daily Placebo administration from Day 1 to Day 12 Single Placebo co-administration on Day 13 with CYP450 substrate cocktail
62507043|NCT03588650|EXPERIMENTAL|HLX20, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 1, 3, 10 and 20 mg/kg, starting from 1 mg/kg.
62507044|NCT05509088|EXPERIMENTAL|high flow nasal cannula|will receive oxygen through high flow nasal cannula
62507045|NCT05509088|NO_INTERVENTION|oxygen mask|will receive oxygen through oxygen mask
62507046|NCT06073899|NO_INTERVENTION|Quiet Rest|Participants will sit quietly for two minutes, three times. Pressure pain threshold will be measured between each two-minute interval.
62144188|NCT01608685||Renal transplant recipients|Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent
62144189|NCT00317395|EXPERIMENTAL|Otamixaban Dose 1|dosage regimen 1
62507047|NCT06073899|EXPERIMENTAL|High Fatigue Exercise|"Participants will perform a leg extension exercise in a machine with weight equipment to 65% of their 1-repetition maximum. Participants will complete this exercise for three sets until they report the exercise is hard (8/10 on the OMNI perceived exertion scale)."
61963728|NCT00959309|ACTIVE_COMPARATOR|Control|
61963729|NCT03141476|OTHER|Cefuroxime 1,5g|BMI \<30kg/m\*m
61963730|NCT03141476|OTHER|Cefuroxime 3g|BMI 30-50kg/m\*m
61963731|NCT03141476|OTHER|Cefuroxime 4,5g|BMI \>50kg/m\*m
61963732|NCT02672878|EXPERIMENTAL|BVS implantation in patients with ISR|
61963733|NCT04592601|EXPERIMENTAL|S.L.I.M.M.S. Procedure|Prospective collection of data on the safety and efficacy of the S.L.I.M.M.S. Procedure
62144190|NCT00317395|EXPERIMENTAL|Otamixaban Dose 2|dosage regimen 2
61963734|NCT05184244||Participants with CP|Children with CP
61963735|NCT04278638|EXPERIMENTAL|with IORT|
61963736|NCT04278638|ACTIVE_COMPARATOR|without IORT|
61963737|NCT00819611|EXPERIMENTAL|Working memory training|
61963738|NCT00819611|SHAM_COMPARATOR|Control version of working memory training|
61963739|NCT01906502|EXPERIMENTAL|Device|Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
61963740|NCT00784498|ACTIVE_COMPARATOR|midazolam/ketamine|Patients with orthopedic injuries requiring painful manipulation
61963741|NCT00784498|ACTIVE_COMPARATOR|propofol|Patients with orthopedic injuries requiring painful manipulation
61963742|NCT03972332||Sensitised|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
62144191|NCT00317395|EXPERIMENTAL|Otamixaban Dose 3|dosage regimen 3
62144192|NCT00317395|EXPERIMENTAL|Otamixaban Dose 4|dosage regimen 4
62144193|NCT00317395|EXPERIMENTAL|Otamixaban Dose 5|dosage regimen 5
62144194|NCT00317395|ACTIVE_COMPARATOR|UFH/Eptifibatide|
62144195|NCT03292692|EXPERIMENTAL|OurRelationship|Online Intervention
62144196|NCT03292692|NO_INTERVENTION|Waitlist Control|2 month waiting period before couples can receive intervention
62349100|NCT01611272||1|Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
62349101|NCT00589147|ACTIVE_COMPARATOR|1|One study group will consist of patients treated with the modular cemented tibia.
62349102|NCT00589147|ACTIVE_COMPARATOR|2|Study arm will consist of patients that are treated with non-modular cemented tibia.
62349103|NCT00589147|ACTIVE_COMPARATOR|3|Study arm will consist of patients that are treated with non-modular uncemented tibia.
62349104|NCT02574858|EXPERIMENTAL|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (\~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (\~100 µM concentration).
62349105|NCT04179435|OTHER|Tourette syndrome|Patients with Tourette syndrome aged 13 - 18 y.o. Interventions : Brain scans, cognitive testing, TMS measures
62349106|NCT04179435|OTHER|Controls|Controls matched to Tourette syndrome group nterventions : Brain scans, cognitive testing, TMS measures
62349107|NCT03114566||Consenting healthy donor|Transplant and healthy HLA typed donors
62705276|NCT06052059|EXPERIMENTAL|Study 1: High Dose Extension|Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
62705277|NCT06052059|EXPERIMENTAL|Study 1: Low Dose Extension|Participants receive a low dose SC tulisokibart and placebo regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
62705278|NCT06052059|EXPERIMENTAL|Study 2: High Dose Induction|Participants receive high dose IV tulisokibart.
62705279|NCT06052059|EXPERIMENTAL|Study 2: Low Dose Induction|Participants receive low dose IV tulisokibart.
62705280|NCT06052059|PLACEBO_COMPARATOR|Study 2: Placebo|Participants receive IV placebo.
62705281|NCT06052059|EXPERIMENTAL|Study 2: High Dose Extension|Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
62705282|NCT06052059|EXPERIMENTAL|Study 2: Low Dose Extension|Participants receive a low dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
62705283|NCT05256225|ACTIVE_COMPARATOR|Arm I (paclitaxel, carboplatin)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.~Patients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment."
61963743|NCT03972332||Non-sensitised|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
62507048|NCT06073899|ACTIVE_COMPARATOR|Low Fatigue Exercise|"Participants will perform a leg extension exercise in a machine with weight equipment to 65% of their 1-repetition maximum. Participants will complete this exercise for three sets until they report the exercise is somewhat easy (4/10 on the OMNI perceived exertion scale)."
62705284|NCT05256225|EXPERIMENTAL|Arm II (paclitaxel, carboplatin, Herceptin Hylecta)|"Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.~MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment.~Patients undergo ECHO or MUGA and CT throughout the study. Additionally patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment."
62714977|NCT01081158|EXPERIMENTAL|Treatment-experienced: 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days"
62714978|NCT01081158|EXPERIMENTAL|Treatment-naïve: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
61963744|NCT05033860|EXPERIMENTAL|Intervention group|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and questionnaire surveys were conducted afterwards.
61963745|NCT05033860|NO_INTERVENTION|Control group|Questionnaire surveys were conducted without leaflets distribution.
61963746|NCT06058676||Patients with reduced cerebrovascular reserve|"Interventions:~Procedure: carotid artery stenting"
61963747|NCT06058676||Patients with sufficient cerebrovascular reserve|"Interventions:~Procedure: carotid artery stenting"
61963748|NCT04000490||patient with a chest pain|adult patient with a chest pain calling for urgency center
61963749|NCT05221515|EXPERIMENTAL|Intervention condition|Participants received both parent training and child-focussed treatment
62349108|NCT06060756||Patients with confirmed Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) diagnosis|Patients from site's pain unit with confirmed OSAHS diagnosis. OSAHS diagnosis will be made according to standard of care practice in the investigation site, through polysomnography and Epworth Sleepiness Scale (ESS).
62349109|NCT01205958|ACTIVE_COMPARATOR|medication(Zaltoprofen)|
62349110|NCT01205958|ACTIVE_COMPARATOR|Acupuncture|
62349111|NCT01205958|ACTIVE_COMPARATOR|Zalprofen plus Acupuncture|
62349112|NCT02183623|EXPERIMENTAL|BI 1356 BS and Simvastatin|
62507049|NCT06616363||60 POTS Postural Tachycardia Syndrome (POTS)|POTS patients will be current patients of the study practitioners within the autonomic, cardiology PM\&R clinics and autonomic laboratory. This cohort may receive a codified treatment plan within the following 7 treatment categories which are also standard of care procedures based on clinical recommendations: (1) salt, fluid and diet management; (2) exercise program with or without PT; (3) cognitive behavioral therapy or other counseling; (4) vagal stimulation forms like yoga, breathing exercises, relaxation, microauricular stimulation; (5) pharmacotherapy for pressure maintenance; (6) medications for pain and headache; (7) medications for the gastrointestinal issues.
61963750|NCT05221515|ACTIVE_COMPARATOR|Control condition|Participants received only parent training
62144197|NCT02075723|EXPERIMENTAL|Overfeeding + sleep restriction|overfeeding condition (130 % of energy requirements ) + 6 days of sleep restriction (4 hours per night)
62144198|NCT02075723|EXPERIMENTAL|Overfeeding + normal sleep duration|overfeeding condition (130 % of energy requirements ) + 6 days of normal sleep duration (8 hours per night)
62144199|NCT05925335|EXPERIMENTAL|Transcatheter mitral valve-in-valve implantation|
62349113|NCT04370964|OTHER|Family with young aged people|The family will be evaluated in two stages via the standardized situations LTP (parents and patient) and LFP (family) as well as self-assessments
62349114|NCT04457193||post-ablation Barrett's patients|The patients with known prior diagnosis of histologically-confirmed Barrett's esophagus with or without dysplasia who have documentation of complete remission of Barrett's esophagus by endoscopy and histology after endoscopic ablation
61963751|NCT03736616|EXPERIMENTAL|Cohort A: Transplant eligible|"Patients receive RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin area under curve (AUC) 5 IV d2, Etoposide (VP16) 100mg/m2 IV d1-3 \& Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~BEAM chemotherapy \& autoHSCT: BEAM given as Carmustine (BCNU) 300mg/m2 IV day -6 respective to stem cell infusion, VP16 200mg/m2 IV BID day -5 to day-2, Cytarabine (Ara-C) 200mg/m2 IV BID day -5 to day -2, and Melphalan 140mg/m2 IV day -1. Autologous hematopoietic stem cell infusion on day 0. Only patients with CR/PR after RICE acalabrutinib will undergo BEAM and autoHSCT~Maintenance therapy: Post autoHSCT patients will receive Acalabrutinib 100mg oral BID starting on day +30 for 12 consecutive months or until progression or intolerance if occurs within those 12 months."
61963752|NCT03736616|EXPERIMENTAL|Cohort B: Transplant ineligible|"Patients receive RICE chemoimmunotherapy + Acalabrutinib Salvage therapy: RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin AUC 5 IV d2, Etoposide 100mg/m2 IV d1-3. Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~Maintenance therapy: Patients will receive Acalabrutinib 100mg oral BID for 12 consecutive months or until progression or intolerance if occurs within those 12 months. Maintenance therapy will only be given to patients with stable disease or better response after 3 cycles of RICE+ acalabrutinib"
61963753|NCT01102504|EXPERIMENTAL|Tomato extract (Ateronon)|Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.
61963754|NCT01102504|PLACEBO_COMPARATOR|Placebo|Placebo
61963755|NCT05412745|EXPERIMENTAL|group A|class I pullulan based medical device containing Allium cepa \& HA
61963756|NCT05412745|ACTIVE_COMPARATOR|Group B|class I medical device silicone gel
61963757|NCT05281887||ischemic stroke|According to diagnostic criteria
61963758|NCT05281887||healthy control|without any retinal diseases
61963759|NCT04091854||HMS5552 treatment|
61963760|NCT03987529||Sevoflurane+Remifentanil|Using inhalent agent(Sevoflurane), continuous infusion of Remifentanil
62714979|NCT01081158|EXPERIMENTAL|Treatment-experienced: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
61963761|NCT03987529||Propofol+Remifentanil|Using continuous infusion of Propofol and Remifentanil
61963762|NCT01288105|EXPERIMENTAL|Optical Coherence Tomography|Patients enrolled in the study will undergo optical coherence tomography to evaluate the extent of stent strut coverage.
61963763|NCT04445545|EXPERIMENTAL|Experimental group 1 (HILT + stretching exercise)|The group will receive treatment of high-intensity laser therapy (HILT) with a total energy delivery of 1,060J divided into 3 phases will be achieved: phase 1, 500J; phase 2, 60J; phase 3, 500J. It will work with an average power of 3W and an energy density of 50J/cm2. At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
61963764|NCT04445545|SHAM_COMPARATOR|Experimental group 2 (Sham HILT + stretching exercise)|The group will receive a sham treatment of high-intensity laser therapy (HILT). At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
62144200|NCT03339466|EXPERIMENTAL|Experimental arm - Inspiratory Muscle Training|Single arm study. All subjects will perform 6-8 weeks of inspiratory muscle therapy with cardiopulmonary stress test (both standard and constant work rate) before and after intervention.
62144201|NCT03032198|EXPERIMENTAL|Imagio OA/US Scan|Imagio opto-acoustic gray-scale ultrasound scan
62144202|NCT06463145|PLACEBO_COMPARATOR|Placebo|Pill of Food grade Maltodextrin 12 . Once daily for three days.
62144203|NCT06463145|EXPERIMENTAL|Vanizem 50mg|Pill of Aframomum melegueta extract 50 mg with Food grade Maltodextrin 12 . Once daily for three days.
62144204|NCT06463145|EXPERIMENTAL|Vanizem 100mg|Pill of Aframomum melegueta extract 100 mg with Food grade Maltodextrin 12 . Once daily for three days.
62714980|NCT01079312|ACTIVE_COMPARATOR|Propofol infusion|Anaesthesiologist's managed intravenous infusion of propofol 10mg/ml
61963765|NCT04445545|ACTIVE_COMPARATOR|Experimental group 3 (US + stretching exercise)|The group will receive treatment of therapeutic ultrasound. The US parameters will be programmed with a frequency of 1MHz, the intensity of 1.5 W/cm2, the Duty cycle of 100%, an ERA of 5cm2, and a time of 6 minutes. At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
61963766|NCT02601469|EXPERIMENTAL|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
61963767|NCT00587054|EXPERIMENTAL|Transplant Patients|
61963768|NCT05369637|EXPERIMENTAL|Non-pharmacological Intervention|Participants in the intervention group will receive a multidomain non-pharmacological program, including cognitive training, physical exercise, nutrition education, psychoeducation, and diagnosis and correction of hearing impairment.
61963769|NCT05369637|NO_INTERVENTION|Control group|Control group will receive the usual standard of care provided to these clinical diseases.
61963770|NCT04481932|EXPERIMENTAL|Trastuzumab combined with Pyrotinib and chemotherapy|The dosage of the above drugs can be adjusted according to the adverse reactions of the subjects. The subject continued to use the drug until the full cycle or the disease progressed or the toxicity was intolerable or withdrawn, or the researcher judged that the medication must be terminated.
62144205|NCT06463145|EXPERIMENTAL|Vanizem 150mg|Pill of Aframomum melegueta extract 150 mg with Food grade Maltodextrin 12 . Once daily for three days.
62144206|NCT01484743||Patients with parastomal hernia repair|Patients registered in the Danish Ventral Hernia database
62144207|NCT02510573||sTBI group|The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
62144208|NCT03829553|EXPERIMENTAL|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will received 2.67 Gy for 16 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67 Gy for 4 fractions following breast conserving surgery
62714981|NCT01079312|ACTIVE_COMPARATOR|Patient-controlled sedation|self-administration of propofol and remifentanil mixture during ERCP
62507050|NCT06616363||40 Post-Infection cohort|Post-Infection participants will be identified through Best Practice Alerts through EPIC, and referrals from hospitalist and gastroenterology inpatient services. Post-Infection cohorts will be approached up to 6 weeks after they are released from the hospital, to ensure they are healthy enough to participate.
62507051|NCT06616363||20 healthy controls|Healthy control participants will be recruited from local communities using flyers, social media and using EPIC Best Practice Alerts.
62507052|NCT04747795|PLACEBO_COMPARATOR|standard care + placebo|The 'standard care' group will receive intermittent infusion of normal saline (3 ampoules of 5 ml 9mg/ml normal saline diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
62507053|NCT04747795|ACTIVE_COMPARATOR|standard care + Vitamin C|The 'standard care + Vitamin C' group will receive intermittent infusion of Vitamin C (3 ampoules of 500 mg/5ml Vitamin C diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
62507054|NCT04846647||Unexplained hypophosphatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
62507055|NCT02079337|ACTIVE_COMPARATOR|Deep NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during deep neuromuscular blockade and without neuromuscular blockade
62507056|NCT02079337|PLACEBO_COMPARATOR|No NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during no neuromuscular blockade and during deep neuromuscular blockade.
62507057|NCT05021484|ACTIVE_COMPARATOR|Felzartamab|9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
62507058|NCT05021484|PLACEBO_COMPARATOR|Placebo|9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
62507059|NCT02576717|EXPERIMENTAL|1 mg RPC1063 (Ozanimod) oral capsule|1 mg RPC1063 (Ozanimod) oral capsule daily
62507060|NCT01134627|EXPERIMENTAL|Minocycline group|
62507061|NCT01134627|PLACEBO_COMPARATOR|Placebo Group|
62507062|NCT03990480|ACTIVE_COMPARATOR|valsartan|Group I treated with valsartan (160 mg/d, n = 100)
61963771|NCT02531906|EXPERIMENTAL|Arm I (gabapentin)|"Patients receive gabapentin PO TID for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
61963772|NCT02531906|EXPERIMENTAL|Arm II (gabapentin, methadone, oxycodone)|"Patients receive gabapentin PO TID, methadone hydrochloride PO BID, and oxycodone hydrochloride PO Q8H PRN for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
61963773|NCT03555955|EXPERIMENTAL|Cohort 1|Normal renal function
61963774|NCT03555955|EXPERIMENTAL|Cohort 2|Moderate renal impairment
61963775|NCT03555955|EXPERIMENTAL|Cohort 3|Severe renal impairment
62144209|NCT03829553|ACTIVE_COMPARATOR|Conventional radiotherapy|Patients with an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
62144210|NCT02597699|ACTIVE_COMPARATOR|Arm 1: Sufentanil + Lidocaïne|"For patients randomized to arm 1, as in the current practice, we will inject Sufentanil intra-cordially at the dose of 1.5 μg / kg of the estimated fetal weight, then the Lidocaïne 1% bolus of 10 ml (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of fetal asystole, we will inject 100mg of Lidocaïne 1% in bolus of 10 ml. In the event of failure of the procedure, we will inject 10ml of KCL 10% intra-cordial if the cord is always accessible, if not intra-cardiac."
62507063|NCT03990480|ACTIVE_COMPARATOR|amlodipine|Group II amlodipine (10 mg/d, n = 100).
62507064|NCT03990480|NO_INTERVENTION|Control|30 healthy subjects are enrolled as control group (Group III).
62507065|NCT04924699|EXPERIMENTAL|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
62714982|NCT02373904|EXPERIMENTAL|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
62507066|NCT04924699|ACTIVE_COMPARATOR|Trastuzumab Emtansine for Injection|Trastuzumab Emtansine for Injection will be administrated via intravenous infusion of 3.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
62507067|NCT02370836|EXPERIMENTAL|Psycho-oncological education|One 60 minute psycho-oncological education session on late effects, fatigue and stress management.
62507068|NCT02370836|NO_INTERVENTION|Usual Care|Usual care includes completion of a symptom checklist by the nurse practitioner
62507069|NCT06302348|EXPERIMENTAL|Sepiapterin|Participants will receive age- and weight-adjusted doses of sepiapterin orally once daily for up to 6 years.
62507070|NCT02806687|EXPERIMENTAL|Gene Therapy product CYL-02|Two EUS-guided intratumor injections of CYL-02 at one month interval plus Gemcitabine (3 weeks/month) during two months followed by four months Gemcitabine alone (3 weeks/month) or until progression.
62507071|NCT02806687|ACTIVE_COMPARATOR|Standard of care|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
62714983|NCT02622035|EXPERIMENTAL|1|Gain frame; Anger
62714984|NCT02622035|EXPERIMENTAL|1b|high visual perceptual load high interactive
62714985|NCT02622035|EXPERIMENTAL|2|Gain frame; Fear
61963776|NCT01738360|EXPERIMENTAL|Arsenic trioxide|Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).
61963777|NCT02063620|ACTIVE_COMPARATOR|ketamine HCL|%0.5 Lidocaine+Ketamine HCL 0.8 mg/kg, total 40ml, single dose administration, 30 minute duration, total 200mg lidocaine
62714986|NCT02622035|EXPERIMENTAL|2b|high visual perceptual load
61963778|NCT02063620|NO_INTERVENTION|lidocaine+ serum physiologic|% 0.5 lidocaine+ serum physiologic, total 40ml, total 200 mg lidocaine, 30 minute duration, single dose administration,
61963779|NCT04718051|EXPERIMENTAL|Shen Pu Yang Gan Wan|Traditional Chinese Medicine
62507072|NCT04401111||Survivors of Intensive care unit patients|Survivors of severe COVID-19 pneumonia after intensive care unit
62507073|NCT03259685|ACTIVE_COMPARATOR|Regular beverages|Sugar sweetened soft drinks
62705285|NCT05256225|EXPERIMENTAL|Arm III (paclitaxel, carboplatin, Phesgo)|"Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.~MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment.~Patients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment."
62705286|NCT04811560|EXPERIMENTAL|Bleximenib|Participants in Phase 1 Part 1 (dose escalation) will receive bleximenib orally. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) have been identified. Participants in Phase 1 Part 2 (dose expansion) will receive bleximenib orally at the RP2D(s) determined in Part 1.
62705287|NCT03762733||Patient Relatives|Biological relatives (1st-3rd degree) of participants with histologically confirmed malignancy
62705288|NCT03762733||Patients|Participants with histologically confirmed malignancy
62705289|NCT04924075|EXPERIMENTAL|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
61963780|NCT04718051|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Comparator
61963781|NCT05468827|EXPERIMENTAL|interventional|lymphatic mapping by indocyanine green
61963782|NCT05845151|EXPERIMENTAL|LN Patients group|
62507074|NCT03259685|EXPERIMENTAL|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
61963783|NCT01595932|PLACEBO_COMPARATOR|placebo|
61963784|NCT01595932|EXPERIMENTAL|α-galactosidase|
62144211|NCT02597699|EXPERIMENTAL|Arm 2: Remifentanil + Lidocaïne|"For patients randomized to arm 2, we will inject 30 μg of intravenous Remifentanil (Ultiva®) followed by Xylocaine 1% in a 10 ml bolus (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of asystole, we will inject 100 mg of Lidocaïne 1% in bolus of 10 ml. In case of failure of the procedure, we will inject 10 ml of KCL 10% intra-cordial if the cord is still accessible, if not intra-cardiac."
62507075|NCT03259685|EXPERIMENTAL|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
61963785|NCT06076265||Single arm group|
61963786|NCT06037447||Standardized Group|Patients in this group will undergo standardized strategy during mitral repair surgeries, including subvalvular apparatus rehabilitation, leaflets repair and annuloplasty.
61963787|NCT06037447||Annuloplasty Group|Patients in this group will undergo annuloplasty only during mitral repair surgeries.
61963788|NCT05374434|ACTIVE_COMPARATOR|Conventional irrigation|Root canal cleaning will be performed by manual irrigation with sodium hypochlorite NaOCl solution.
62144212|NCT00689351|EXPERIMENTAL|1|13vPnC
62705290|NCT06016062|EXPERIMENTAL|Phase1-RC148 monotherapy|Participants will be allocated to one of the following dose groups:1.0, 3.0, 10.0, 20.0, and 30.0mg/kg, and receive a treatment of RC148 followed by 28 days of dose limited toxicity (DLT) observation period.
62144213|NCT00689351|ACTIVE_COMPARATOR|2|7vPnC
61963789|NCT05374434|EXPERIMENTAL|Inertial cavitation|Root canal cleaning will be performed by inertial cavitation-generating device.
62144214|NCT05585710|EXPERIMENTAL|Pulsed Lavage Washout|This cohort will undergo standard of care bilateral or unilateral mastectomies as determined by breast surgical oncologists and immediate standard of care breast reconstruction with tissue expander placement and pulsed lavage washout.
62144215|NCT05585710|ACTIVE_COMPARATOR|No Pulsed Lavage|This cohort will undergo standard of care bilateral or unilateral mastectomies as determined by breast surgical oncologists and immediate standard of care breast reconstruction with tissue expander placement.
62144216|NCT00872248|EXPERIMENTAL|1|Parturients received spinal anesthesia
61963790|NCT01055171|ACTIVE_COMPARATOR|Propranolol|Patients will receive Propranolol in this condition.
61963791|NCT01055171|PLACEBO_COMPARATOR|Placebo|Patient to receive placebo in this condition.
62507076|NCT01017094|EXPERIMENTAL|dry dressing|local application
62507077|NCT00508040|EXPERIMENTAL|A|To analyse the potential therapeutic effect of Interferon alpha2a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
62507078|NCT00508040|ACTIVE_COMPARATOR|B|
62507079|NCT03952988|EXPERIMENTAL|Probiotic|
62507080|NCT03952988|PLACEBO_COMPARATOR|Placebo|
62507081|NCT00813345|EXPERIMENTAL|A - Light therapy|Light therapy (1500 lux)
62507082|NCT00813345|PLACEBO_COMPARATOR|B - identical control lamp|identical control lamp
61963792|NCT04020965|NO_INTERVENTION|Control arm|This arm includes all households in villages randomized to the active control arm (double-sized) or passive control arm of the original trial. Village-level promoter visited households enrolled in the WASH Benefits Kenya study active control arm and strictly engaged in recording the child's MUAC and referring children identified as malnourished (MUAC\<11.5 cm) to health clinics, for two years. These visits were also conducted in all active comparator arms. Households in active control and active comparator villages which were not enrolled in the original study did not receive such visits.
61963793|NCT04020965|EXPERIMENTAL|Water Treatment|This arm includes all households in villages randomized in the original WASH Benefits trial to the water treatment arm, combined water treatment with handwashing and sanitation (WASH) arm, and combined WASH + nutrition arm. Village-level promoter visited households enrolled in the original trial to promote the interventions for approximately two years.
62507083|NCT05559463|EXPERIMENTAL|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
62507084|NCT00468871|EXPERIMENTAL|Fluocinolone acetonide|Intravitreal fluocinolone acetonide implant
62507085|NCT00468871|ACTIVE_COMPARATOR|Standard care|Standard of Care
62144217|NCT00872248|ACTIVE_COMPARATOR|2|Parturients received epidural anesthesia
62349115|NCT01802554|EXPERIMENTAL|Pleasant Events Program (PEP)|The Pleasant Events Program (PEP) is a Behavioral Activation (BA) treatment for depression. Participants receive 4 weekly sessions of face-to-face therapy (60 minutes each) to increase caregiver participation in pleasurable activities. Two additional phone sessions focus on continued behavioral activation for caregivers as well as problem-solving barriers to activation.
62507086|NCT03760016|ACTIVE_COMPARATOR|Moderate-Intensity Aerobic Training|
62507087|NCT03760016|EXPERIMENTAL|High-Intensity Interval Training|
62507088|NCT00388037|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62507089|NCT06236412|EXPERIMENTAL|Intervention arm 1: pregnant woman alone|"Breastfeeding education:~Breast milk features, contents, advantages, how to improve its quality, and quantity.~Pre-lacteal feeding: meaning, addressing misconceptions, to avoid any foods/fluids up to 6 months and its harmful effects Colostrum feeding: meaning, its contents, advantages and addressing related misconceptions Early initiation of breastfeeding: proper time to initiation of breastfeeding \& advantages for mother \& child Exclusive breastfeeding: meaning, advantages, how long to exclusively breastfed.~They will also receive iron suphate/folic acid supplementation as recommended practice, at least for 90 days (90+ days)"
62507090|NCT06236412|EXPERIMENTAL|Intervention arm 2: Pregnant woman with mother-in-law|"Breastfeeding education:~Breast milk features, contents, advantages, how to improve its quality, and quantity.~Pre-lacteal feeding: meaning, addressing misconceptions, to avoid any foods/fluids up to 6 months and its harmful effects Colostrum feeding: meaning, its contents, advantages and addressing related misconceptions Early initiation of breastfeeding: proper time to initiation of breastfeeding \& advantages for mother \& child Exclusive breastfeeding: meaning, advantages, how long to exclusively breastfed.~They will also receive iron suphate/folic acid supplementation as recommended practice, at least for 90 days (90+ days)"
62507091|NCT06236412|ACTIVE_COMPARATOR|Control arm: 'Pregnant woman in routine care'.|Pregnant women in this arm receive routine care, which includes existing community and health facility-based health care. The routine (standard) care at the community level includes those services given by the health extension workers such as hygiene (personal, food and environmental hygiene), and family health services such as antenatal care, postnatal care, immunization, breastfeeding, nutrition. In this trial, the control arm will receive counseling about antenatal care, health facility delivery, postnatal care, dietary intake (additional meal during pregnancy and after delivery), hygiene, and less deep information about breastfeeding practices such as on demand feeding day and night, exclusive breastfeeding, continuing breastfeeding for at least 24 months, to balance and make the frequency and duration with that of the intervention arm. They will also receive iron suphate/folic acid supplementation as recommended practice, at least for 90 days (90+ days)
62507092|NCT05318976|EXPERIMENTAL|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 23 weeks.
62507093|NCT05318976|PLACEBO_COMPARATOR|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 23 weeks.
62507094|NCT00398684|EXPERIMENTAL|1|One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
62507095|NCT00398684|EXPERIMENTAL|2|One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
62507096|NCT00398684|PLACEBO_COMPARATOR|3|One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
62507097|NCT01074645|NO_INTERVENTION|Placebo|Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
62705291|NCT06016062|EXPERIMENTAL|Phase2-Arm1 (NSCLC): RC148+docetaxel|RC148+docetaxel Combination Therapy： Participants receive RC148 (10mg/kg or 20mg/kg Q3W) in combination with docetaxel (75mg/m\^2 Q3W).
61963794|NCT04334031|EXPERIMENTAL|IMMINeNT cohort|
62349116|NCT01802554|ACTIVE_COMPARATOR|Information-Support (IS)|Participants in the Information-Support (IS) control condition were provided with a resource manual consisting of topics commonly covered in support groups or information packets provided by community agencies. Topics included problem-solving and communication skills, cognitive reframing and behavioral management, self-care help, caregiver fact sheets on a range of social and mental health issues, placement information, financial and legal issues, and lists of local organizations and community resources available. Each IS session allowed caregivers to select issue(s) from the resource manual to discuss. The therapist covered the material based on the caregivers' needs. When requested by the caregiver, supportive psychotherapy was also provided.
62349117|NCT06067282|EXPERIMENTAL|Experimental group|The experimental group used microteaching training to cultivate the teaching skills of university students majoring in physical education in China.
62349118|NCT06067282|ACTIVE_COMPARATOR|Control group|The control group trained the students' teaching skills by conventional training methods.
62714987|NCT02622035|EXPERIMENTAL|3|Loss frame; Anger
61963795|NCT03394326|EXPERIMENTAL|LOW-ED|In the LOW-ED condition each participant will consume at least 10 low-ED foods/day (ED ≤1.0 kcal/g) and no more than 2 high ED foods/day (ED ≥3.0 kcal/g). Foods with an ED \>1.0 kcal/g and \<3.0 kcal/g will be unlimited; however, lowering the overall ED of the diet will be encouraged.
62349119|NCT01091909|EXPERIMENTAL|post-extraction wound healing|53 individuals with diabetes and 29 controls, without diabetes, were followed for 60 days after dental extractions, and were examined after 3, 7, 21, and 60 postoperative days.
62349120|NCT06420596|OTHER|Control intervention|In the control group, patients receive conventional physiotherapy.
62349121|NCT06420596|EXPERIMENTAL|Study Intervention|In the interventional group, patients receive 12 weeks of a remote physiotherapy via Akina Cloud in addition to conventional physiotherapy (treatment according to FMH Switzerland guidelines). Patients are encouraged to complete at least three app-guided training sessions per week.
62144218|NCT05996315||Adults >18 years with distal end radius fracture|Adults \> 18 years with distal end radius fracture requiring closed reduction in Emergency Department
62144219|NCT04703907|EXPERIMENTAL|Intervention group|This group is constituted from patients who will receive the intervention first within 15 weeks
62144220|NCT04703907|NO_INTERVENTION|Waiting list|This group is constituted from patients who will receive the intervention after 15 weeks
62507098|NCT01074645|ACTIVE_COMPARATOR|Tenofovir disoproxil fumarate (TDF)|Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
62507099|NCT01622608|EXPERIMENTAL|Kiosk Users|
62507100|NCT01622608|NO_INTERVENTION|Non-Kiosk Users|
62507101|NCT04458467|ACTIVE_COMPARATOR|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout).
62507102|NCT04458467|EXPERIMENTAL|Automated Boluses|Patients will receive intermittent boluses of Ropivacaine 0.2% (8 mL automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
62507103|NCT01706718|PLACEBO_COMPARATOR|Control white bread|
62507104|NCT01706718|EXPERIMENTAL|Beetroot bread|
62507105|NCT06081140|EXPERIMENTAL|Supplementation|Participants were enrolled at baseline where all outcome measures were collected. Once baseline visit was complete, participants started with the supplementation of Hemp Oil Complex by Standard Process. After 10 days, outcome measures were collected.
62507106|NCT03460145|EXPERIMENTAL|Strip with Lavender Oil (Lx)|"Application of Nasal Strip with essential oil (Lavender), 20minutes before induction.~VAS- Anxiety scores pre and post inhalation."
62507107|NCT03460145|PLACEBO_COMPARATOR|Strip without Lavender Oil (Px)|Application of Nasal strip without essential oil, acting as placebo. VAS- Anxiety scores pre and post placebo.
62507108|NCT01069796|EXPERIMENTAL|Association bevacizumab paclitaxel capecitabine breast cancer|"* bevacizumab 10 mg/kg in IV, D1 and D15~* paclitaxel 80mg/m2 in IV, D1 to D8 and D15~* capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3"
61963796|NCT03394326|ACTIVE_COMPARATOR|STANDARD|In the STANDARD condition participants will consume the recommendations for calories, fruits, vegetables and whole grains based on age and sex corresponding with MyPlate. The daily caloric recommendations from MyPlate are for weight maintenance.
62144221|NCT03250793|EXPERIMENTAL|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
62349122|NCT01611350|EXPERIMENTAL|Health Marketing Message|Marketing message focused on health effects of cooking with wood on a three stone fire.
62349123|NCT01611350|EXPERIMENTAL|Savings Marketing Message|Marketing message focused on savings (both time and money) related to using an energy efficient cookstove.
62349124|NCT01611350|EXPERIMENTAL|Savings and Health Marketing Messages Combined|One group will receive both the savings and health marketing messages.
62349125|NCT01611350|EXPERIMENTAL|Novel Sales Offer|This group will receive a free trial and time payments when purchasing an energy efficient cookstove.
62349126|NCT01611350|EXPERIMENTAL|Early vs. Late Buyers|Of those who accept the Novel Sales Offer, half the buyers will randomly be selected to start their free trial within a few weeks of the sales meeting, while the other half- the late buyers- will start their free trial a within 2 months of the sales meeting.
62349127|NCT03799328|EXPERIMENTAL|multi-OIT|Low dose OIT with multiple allergens
62349128|NCT02003807||Diverticulitis patients (case)|Cases were the patients who admitted to hospital because of acute diverticulitis attack.
62349129|NCT02003807||Non-diverticulitis patients (control)|Controls were the patients who admitted to hospital due to non-gastrointestinal disorder.
62349130|NCT05844904||General|This research is an observational study. There's no control and experimental group.
62349131|NCT04806516|EXPERIMENTAL|Summit RC+S DBS Implant for OCD|All subjects will receive surgical implantation of RC+S DBS system with ECoG paddles
62507109|NCT00867412||Conventional staging|Staging with CT, mediastinoscopy and bronchoscopy
62507110|NCT00867412||Conventional staging and PET/CT|Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy
62507111|NCT05606952|ACTIVE_COMPARATOR|Group (C)|patients with BMI less than 35
62507112|NCT05606952|ACTIVE_COMPARATOR|Group (O)|patients with BMI more than 35
62507113|NCT04124029||Younger mild Traumatic Brain Injury|mTBI subjects aged 30-59 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the Test of Memory Malingering (TOMM) and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
62507114|NCT04124029||Older mild Traumatic Brain Injury|mTBI subjects aged 60- 90 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
62507115|NCT04124029||moderate Traumatic Brain Injury|TBI control subjects, age-, education- and sex-matched with mTBI subjects (aged 30-90) will be recruited who have a physician diagnosis of 1 or more moderate TBI episodes (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). Moderate TBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
62714988|NCT02622035|EXPERIMENTAL|3b|low visual perceptual load
62349132|NCT04806516|EXPERIMENTAL|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
62349133|NCT00658710|ACTIVE_COMPARATOR|1|patients who continue physical therapy sessions during two months.
62349134|NCT00658710|NO_INTERVENTION|2|patients who stop physical therapy sessions during two months
61963797|NCT02771912|EXPERIMENTAL|Propofol|"Infusion containing Propofol lipuro® 2% at a concentration of 2 mg/ml (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Propofol lipuro® 2 %).~Self administration of propofol via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution (0.25 mg/kg propofol) with a programmed lock-out period of 3 minutes.~Maximal dose of propofol : 1,25 mg/kg corresponding to 5mg/kg/h."
61963798|NCT02771912|PLACEBO_COMPARATOR|Intralipid|"Infusion containing Intralipid® (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Intralipid® 20%) to obtain an identical aspect to that of propofol infusion.~Self administration via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution with a programmed lock-out period of 3 minutes."
61963799|NCT04226001||Patients|Patients screened for carriers infected or colonized by emerging highly resistant bacteria.
61963800|NCT05746312|EXPERIMENTAL|Multiple-baseline study|All participants in this study received the same protocol. First, we had a baseline control period (no intervention) during which we assessed state anxiety levels every two minutes. Subsequently, we administered the intervention and continued to assess state anxiety at two minute intervals. Participants were randomized to baseline periods that varied in length (10,12,14, or 16 minutes of baseline).
61963801|NCT02325375||ALS newly diagnosed|
62144222|NCT02895659|ACTIVE_COMPARATOR|Ringer lactate|Fluid resuscitation will be performed with lactated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
62144223|NCT02895659|ACTIVE_COMPARATOR|Ringer acetate|Fluid resuscitation will be performed with acetated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
62144224|NCT03173625|EXPERIMENTAL|AC-076 sc administration - single ascending dose|On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
62507116|NCT04124029||Mild Cognitive Impairment (MCI)|MCI control subjects, age-, education- and sex-matched with older mTBI subjects (aged 60-90) will be recruited if they meet diagnostic criteria for MCI (without a history of TBI) based on the judgement of a behavioral neurologist following the 2011 MCI criteria. Specifically, subjects will test in the impaired range on one or more cognitive domains on neuropsychological testing and will not have impairments in function (i.e. will not meet diagnostic criteria for dementia). MCI subjects will be matched for their Montreal Cognitive Assessment (MoCA) score with older mTBI subjects. Of note, subjects with MCI may or may not meet diagnostic criteria for MCI due to AD. The intent of this control group is to recruit a broad range of MCI subjects without TBI as controls for subjects with cognitive impairment who have a history of mTBI.
62507117|NCT04124029||Younger Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with younger mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
62507118|NCT04124029||Older Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with older mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
62705292|NCT06016062|EXPERIMENTAL|Phase2-Arm 2 (Cervical): RC148+RC48|"RC148+RC48 Combination Therapy:~Participants receive RC148 (20mg/kg Q2W) in combination with RC48 (2.0mg/kg Q2W)."
62144225|NCT03173625|PLACEBO_COMPARATOR|Placebo|For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition
62144226|NCT03486509|EXPERIMENTAL|afatinib 40mg bid plus chemotherapy|afatinib 40mg bid po plus chemotherapy
62507119|NCT03566407|OTHER|Single Group|This is a prospective, longitudinal descriptive study of subjects with diagnosed Crohn's disease. Blood samples for measurement of protein biomarkers (serology), fresh whole blood for detection of gene polymorphisms, and stool samples for detection and assessment of microbiome and host DNA will be collected, and colonoscopy will be performed.
62507120|NCT00561171|EXPERIMENTAL|1|high dose
62507121|NCT00561171|EXPERIMENTAL|2|lower dose
62507122|NCT02151175|EXPERIMENTAL|LIFUP|
62507123|NCT05051878|EXPERIMENTAL|articulating paper occlusal adjustment|occlusal adjustments of implant supported prosthesis according to articulating paper occlusal analysis
62507124|NCT05051878|EXPERIMENTAL|T-scan occlusal analysis|occlusal adjustments of implant supported prosthesis according to T-scan occlusal analysis
62705293|NCT06016062|EXPERIMENTAL|Phase2-Arm 3 (Gastric cancer) : RC148+RC48|RC148+RC48 Combination Therapy: Participants receive RC148 (20mg/kg Q2W) in combination with RC48 (2.0mg/kg Q2W).
62705294|NCT06016062|EXPERIMENTAL|Phase2-Arm 4 (Lung Adenocarcinoma): RC148+RC88|RC148+RC88 Combination Therapy: Participants receive RC148 (20mg/kg Q3W) in combination with RC88 (2.0mg/kg Q3W).
62714989|NCT02622035|EXPERIMENTAL|4|Loss frame; Fear
61963802|NCT02325375||ALS treated|
61963803|NCT02325375||controls|
61963804|NCT03414814|EXPERIMENTAL|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
61963805|NCT04352647||female athletes over the age of 18|the presence or absence of urinary incontinence in female athletes is studied. In addition, the quality of life and other aspects are evaluated
61963806|NCT01365910|EXPERIMENTAL|Treatment (enzyme inhibitor)|Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61963807|NCT03570645|EXPERIMENTAL|dexmedetomidine group|thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine 100 ug every time
61963808|NCT03570645|EXPERIMENTAL|dexamethasone Group|thoracic paravertebral blocks using a combination of ropivacaine and dexamethasone 10 mg every time
61963809|NCT03570645|SHAM_COMPARATOR|control group|thoracic paravertebral blocks using only ropivacaine
61963810|NCT02067871|EXPERIMENTAL|Electrical stimulation|"* 18-32 min of pulsed current.~* stimulation frequency of 80Hz (hertz).~* pulse duration of 200μs (microseconds).~* stimulation intensity fixed near to maximal tolerated."
61963811|NCT02067871|EXPERIMENTAL|Laser Therapy|"* λ = 810 nm (nanometers)~* continuous wave~* 200 mW (milliwatts) output power~* low-level laser therapy dose of 4-6J (Joules) per point~* six points at the knee joint"
62507125|NCT04889391|EXPERIMENTAL|[14C]-Danicopan|Participants were administered a single oral dose of danicopan between 151 and 154 mg (nominal dose of 150 mg), providing approximately 100 μCi of \[14C\] radiolabel in the form of \[14C\]-danicopan.
62507126|NCT04448496|EXPERIMENTAL|Arms|Diabetic macular edema Dexamethasone 0.7mg is injected into the vitreous cavity. Center-involved macular edema secondary to diabetic retinopathy for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
62507127|NCT03300908|EXPERIMENTAL|Project ADHERE|Participants will receive a 3-session antiretroviral medication adherence and risk reduction intervention called Project ADHERE.
62507128|NCT03300908|ACTIVE_COMPARATOR|Control MACE|Participants will receive a one-session antiretroviral medication adherence intervention called MACE.
62507129|NCT06537232|EXPERIMENTAL|Delayed supplementation|Participants will consume greens-based supplement for 30 days after living their normal lives (free-living) for 30 days.
62507130|NCT06537232|EXPERIMENTAL|Immediate supplementation|Participant will consume greens-based supplement for 30 days after which they will crossover into a free-living/non-supplementation setting for 30 days.
62705295|NCT06016062|EXPERIMENTAL|Phase2-Arm 5 (Platinum-resistant Ovarian cancer) : RC148/Bevacizumab+RC88|"RC148+RC88 Combination Therapy: Participants receive RC148 (20mg/kg Q3W) in combination with RC88 (2.0mg/kg Q3W).~Bevacizumab+RC88 Combination Therapy: Participants receive Bevacizumab (15mg/kg Q3W) in combination with RC88 (2.0mg/kg Q3W)."
61963812|NCT02067871|EXPERIMENTAL|Combined Treatment|"Electrical Stimulation:~* 18-32 min of pulsed current,~* stimulation frequency of 80Hz (hertz).~* pulse duration of 200μs (microseconds).~* stimulation intensity fixed near to maximal tolerated.~and~Laser Therapy:~* λ = 810 nm (nanometers)~* continuous wave~* 200 mW (milliwatts) output power~* low-level laser therapy dose of 4-6J (Joules) per point.~* six points at the knee joint."
61963813|NCT03128554|EXPERIMENTAL|Intervention with Training and Materials|Clinics randomized to the intervention group will receive a one time, 2-hour Continuing Medical Education/Group Learning training session on the smoking reduction intervention model, along with provider and patient handouts.
61963814|NCT03128554|NO_INTERVENTION|Usual Care|Clinics randomized to the control group will not be exposed to the intervention program.
61963815|NCT04817865||Standard Pre-Procedural Urine Culture|This is a control cohort that follows standard pre-procedural protocol by implementing antibiotic prophylaxis and treatment regimens based on dipstick urine analysis (UA) followed by reflexed traditional urine culture and sensitivity (C\&S) methods performed before injection.
61963816|NCT04817865||Pre-Procedural M-PCR/P-AST|This is an experimental cohort that implements Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST) for pre-procedural UTI screening. The cohort follows an antibiotic treatment regimen based on the results of M-PCR/P-AST.
62144227|NCT03611556|EXPERIMENTAL|Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
62349135|NCT03902782|EXPERIMENTAL|ESP block|patients will receive an ultrasound guided ESP block (technique as described by Forero et al) under strict sterile conditions in the operating room area. After identifying the T5 transverse process (TP) and after infiltration of lidocaine 2% subcutaneously. A 22g 100mm block needle will be advanced under vision, in a cephalad to caudad direction, until the tip contacts the T5 TP. 20 ml of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be injected under the erector spinae muscle. A visible separation of the erector spinae muscle from the TP will be the sign of a successful block. A 20 ml syringe of Normal Saline will be given to the surgeon (unaware of the content) at the end of the surgery, for the intercostal nerve block as per standard present technique.
62349136|NCT03902782|SHAM_COMPARATOR|ESP sham block|patients will receive an ultrasound guided sham ESP block under strict sterile conditions in the operating room area as described above. 20 ml of Normal Saline will be injected under the erector spinae muscle. A 20 ml syringe of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be given to the surgeon (blinded to the content) at the end of the surgery for the intercostal nerve block.
62349137|NCT02038569|EXPERIMENTAL|LEO 80185 gel|
62507131|NCT04429841||D1 Gastrectomy|Patients are managed by radical gastrectomy with D1 lymphadenectomy
62507132|NCT04429841||D2 Gastrectomy|Patients are managed by radical gastrectomy with D2 lymphadenectomy
62507133|NCT01275157|EXPERIMENTAL|LY2452473|15 mg, containing 100 micro curies of 14C labeled LY2452473 taken once only
62507134|NCT06471491|EXPERIMENTAL|Lung protective ventilation group|PEEP was titrated individually in a sequential manner after mechanical ventilation. According to previous studies, PEEP was 5 cmH2O, inspiratory pressure was 20 cmH2O, and respiratory rate was set according to patient age. PEEP and inspiratory pressure were increased by 5 cmH2O every 30 seconds until PEEP was 15 cmH2O and inspiratory pressure 30 cmH2O. This was followed by a decreasing amplitude of 2 cmH2O to 3 cmH2O starting from 15 cmH2O, and each PEEP level was maintained for 4 to 5 respiratory cycles.The PEEP was at the lowest driving pressure was applied throughout the procedure. The PEEP level resulting in the lowest driving pressure was applied during surgery.
62705296|NCT06016062|EXPERIMENTAL|Phase2-Arm 6 (Platinum-sensitive Ovarian cancer): RC148+RC88|RC148+RC88 Combination Therapy: Participants receive RC148 (20mg/kg Q3W) in combination with RC88 (2.0mg/kg Q3W).
62705297|NCT06016062|EXPERIMENTAL|Phase2-Arm 7 (MSLN-expressing Cervical cancer): RC148+RC88|RC148+RC88 Combination Therapy: Participants receive RC148 (20mg/kg Q3W) in combination with RC88 (2.0mg/kg Q3W).
62736660|NCT02850224|EXPERIMENTAL|Motivational interviewing to elicit PCO in pediatrics|"Providers will be randomized into a patient-centered outcomes (PCO) education course or standard of care. The PCO education course will educate and test providers on patient-centered outcomes of interest and appropriate methods to deliver PCO care.~Providers randomized into the intervention arm will be required to take a brief, one-hour, webinar describing the background, problem, results from focus groups we conducted, and a training program on motivational interviewing. After completing the course, providers will be required to complete an evaluation."
62736661|NCT02850224|NO_INTERVENTION|No Intervention|Standard care
62736662|NCT01581229|EXPERIMENTAL|NPPV|
61963817|NCT02764515|EXPERIMENTAL|Kunxian capsule group|"Intervention:~Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo."
61963818|NCT02764515|ACTIVE_COMPARATOR|Methotrexate group|"Intervention:~Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks."
61963819|NCT03980002|EXPERIMENTAL|FCR/BR alternating with ibrutinib|FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
61963820|NCT00700661|EXPERIMENTAL|1|Drug
62349138|NCT02882815|OTHER|IrisFIT PFO Occluder|Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
62349139|NCT00936117|EXPERIMENTAL|Posaconazole|Posaconazole 200 mg (liquid) by mouth 3 times per day.
62349140|NCT03603834|EXPERIMENTAL|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
62349141|NCT04556656|EXPERIMENTAL|Pridopidine|45 mg pridopidine twice daily (BID)
62349142|NCT04556656|PLACEBO_COMPARATOR|Placebo|Matching placebo
62349143|NCT04686318||suspected acute pyelonephritis|All patients admitted to the emergency department with suspected acute pyelonephritis assessed by the receiving physician
62349144|NCT00126789|EXPERIMENTAL|ZR-02-01|ZR-02-01 matrix transdermal fentanyl patch
62349145|NCT02168803|EXPERIMENTAL|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
62349146|NCT02168803|EXPERIMENTAL|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
62349147|NCT02168803|EXPERIMENTAL|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
62349148|NCT02168803|EXPERIMENTAL|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
62349149|NCT06375980||patients who developed postoperative pulmonary complications|This cohort consists of patients who developed postoperative pulmonary complications (PPCs). The cohort of patients developing PPCs includes individuals who experienced postoperative hypoxia, atelectasis, bronchospasm, pulmonary infection, pulmonary infiltration, aspiration pneumonia, acute respiratory distress syndrome, pleural effusion, and pulmonary edema. PPCs were assessed using the European Perioperative Clinical Outcome framework.
62349150|NCT06375980||patients who did not develop postoperative pulmonary complications .|This cohort comprises patients who did not develop postoperative pulmonary complications (PPCs). The cohort of patients not developing PPCs includes individuals who did not exhibit significant pulmonary complications postoperatively.
62349151|NCT02181010|EXPERIMENTAL|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in low-income, urban, minority neighborhoods. Intervention components will occur at the policy level; food wholesaler level; small food retail outlet level; neighborhood level; household level.
62507135|NCT06471491|NO_INTERVENTION|Traditional mechanical ventilation group|In the traditional mechanical ventilation group, a fixed PEEP of 5 cm H2O was applied.
62507136|NCT04372784|ACTIVE_COMPARATOR|EGD with Balloon Dilatation|Esophagogastroduodenoscopy with balloon dilatation
62736663|NCT01581229|ACTIVE_COMPARATOR|Control|
61963821|NCT00700661|PLACEBO_COMPARATOR|2|Pbo
61963822|NCT03933345||People who use illicit opioids|The study will recruit an adult-age (18+) sample of 600 people who use illicit opioids (either heroin or prescription opioid analgesics without a doctor's prescription) in New York City using Respondent Driven Sampling.
61963823|NCT05130320||Asthma biologics|120 people receiving asthma biologics (monoclonal antibodies)
61963824|NCT05130320||Asthma inhalers|40 people receiving asthma inhalers
61963825|NCT05130320||Steroid tablets|40 people needing daily steroid tablets to control their asthma
61963826|NCT05130320||Healthy Control|50 age-matched healthy people
61963827|NCT01104350|EXPERIMENTAL|Radiotherapy and Concurrent Gemcitabine Chemotherapy|This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.
61963828|NCT04838613|EXPERIMENTAL|PET/CT imaging with [18F]CTT1057 followed by [68Ga]Ga-PSMA-11 or vice versa|"All eligible participants will be assigned to one of the following two PET/CT scan sequences at random in a 1:1 ratio:~* Sequence 1: \[18F\]CTT1057 on Day 1 (investigational imaging agent of interest) followed by \[68Ga\]Ga-PSMA-11 at least 14 days apart (as part of CTS if required, and for secondary endpoint)~* Sequence 2: \[68Ga\]Ga-PSMA-11 (as part of CTS if required, and for secondary endpoint) on Day 1 followed by \[18F\]CTT1057 (investigational imaging agent of interest) at least 14 days apart"
61963829|NCT04250883|EXPERIMENTAL|Experimental group: Low Impact laparoscopy|low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)
61963830|NCT04250883|ACTIVE_COMPARATOR|Control group: Standard laparoscopy|standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)
61963831|NCT05871645|EXPERIMENTAL|Jakarta Surgical Uterine Conservation (JSICA) technique|Cipto Mangunkusumo General Hospital's novel uterine preservation technique based on standard procedure
61963832|NCT05871645|ACTIVE_COMPARATOR|Standard Hysterectomy|Surgery to remove the uterus
62507137|NCT04372784|EXPERIMENTAL|EGD with Balloon Dilatation and Cryotherapy|Esophagogastroduodenoscopy with balloon dilatation and cryotherapy
62507138|NCT04619199|EXPERIMENTAL|Idiopathic Pulmonary Fibrosis|Blood sample were performed during the study for all patients.
62736664|NCT01700959|ACTIVE_COMPARATOR|Melatonin|Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime.
62736665|NCT01700959|PLACEBO_COMPARATOR|Placebo|Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime.
62736666|NCT04643587|EXPERIMENTAL|CSL787 (SAD dose 1)|Inhalation by mouth of a nebulized aerosol in healthy subjects
62507139|NCT01987726||Observational (NGS, FMI testing)|"PART I: Within 10 weeks of beginning a treatment regimen, tumor tissue samples, Blood Collection and CTCs(Circulating tumor cell)from patients are collected for NGS and FMI testing, respectively. Patients remain on current line of therapy until a change in treatment is warranted. The physician's treatment recommendation is documented prior to the release of the FMI results.~PART II: Physicians are furnished with FMI test results when patients become eligible for a change in therapy and new treatment recommendations are documented. Treatment is dependent on preferences of the physician, patient, and/or results of the FMI test."
61963833|NCT04908878|EXPERIMENTAL|Group I (pectoral nerve (PECS) block -transversus thoracic plane (TTP) block group)|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
62144228|NCT03611556|EXPERIMENTAL|Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
61963834|NCT04908878|EXPERIMENTAL|Group II (serratus anterior plane (SAP) block group)|Patients will receive US-guided SAP block after induction of general anesthesia.
61963835|NCT00439244|ACTIVE_COMPARATOR|Zoledronic acid plus teriparatide|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
62144229|NCT03611556|EXPERIMENTAL|Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX|Participants with 2L metastatic disease will receive IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m\^2 IV; folinic acid 400 mg/m\^2 IV; 5-FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
62144230|NCT03611556|EXPERIMENTAL|Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX|Participants with 2L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m\^2 IV; folinic acid 400 mg/m\^2 IV; 5-FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
62144231|NCT03611556|ACTIVE_COMPARATOR|Dose-expansion, Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
62349152|NCT02181010|NO_INTERVENTION|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
62349153|NCT00860418|ACTIVE_COMPARATOR|1|Standard asthma education delivered during 2 home visits by a nurse.
62507140|NCT00466843|EXPERIMENTAL|1|Participants will be treated with ATG
61963836|NCT00439244|EXPERIMENTAL|Zoledronic acid|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion.
61963837|NCT00439244|ACTIVE_COMPARATOR|Placebo zoledronic acid plus teriparatide|Placebo zoledronic acid 100 mL intravenous (i.v.) (once at randomization) plus teriparatide 20 μg (daily subcutaneous injections administered concurrently through 52 weeks). Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
61963838|NCT03801291|ACTIVE_COMPARATOR|Transvaginal repair|Repair of anterior rectocele via the vagina
61963839|NCT03801291|ACTIVE_COMPARATOR|Transperineal repair|Repair of anterior rectocele via the perineum
61963840|NCT05092724|NO_INTERVENTION|standard protocol of manaegement|
61963841|NCT05092724|ACTIVE_COMPARATOR|fetal blood|
61963842|NCT03322878|EXPERIMENTAL|Intravenous magnesium group (Group IV)|Group IV (n=30) will receive intravenous (IV) 20 ml magnesium SO4 (50 mg/ kg 10% MgSO4(magnesium sulphate) diluted in normal saline to a total volume of 20 ml(milliliter) ) and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg) .
61963843|NCT03322878|ACTIVE_COMPARATOR|Caudal magnesium group (Group CA)|Group CA (n=30) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% and 50 mg Magnesium SO4 diluted in normal saline with total volume of 1mL/kg).
62349154|NCT00860418|EXPERIMENTAL|2 PAAL|PAAL
62349155|NCT03444870|EXPERIMENTAL|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
62349156|NCT03444870|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as SC injections with gradual uptitration.
62349157|NCT04906993|EXPERIMENTAL|camrelizumab combined with famitinib malate|
62349158|NCT04906993|ACTIVE_COMPARATOR|platinum-based chemotherapy|
62507141|NCT06166264|EXPERIMENTAL|Progressive resistance training|
62736667|NCT04643587|EXPERIMENTAL|CSL787 (SAD dose 2)|Inhalation by mouth of a nebulized aerosol in healthy subjects
62736668|NCT04643587|EXPERIMENTAL|CSL787 (SAD dose 3)|Inhalation by mouth of a nebulized aerosol in healthy subjects
62736669|NCT04643587|EXPERIMENTAL|CSL787 (SAD dose 4)|Inhalation by mouth of a nebulized aerosol in healthy subjects
61963844|NCT03322878|PLACEBO_COMPARATOR|Placebo group (Group P)|Group P (n=30) ) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg).
61963845|NCT01057342|EXPERIMENTAL|Paclitaxel, Carboplatin, ASA404|
62507142|NCT06166264|EXPERIMENTAL|Control group|
62507143|NCT02668094|ACTIVE_COMPARATOR|Group L|Lidocaine 40mg was given intravenously before injection of propofol
62507144|NCT02668094|ACTIVE_COMPARATOR|Group LP|Pregabalin 75 mg was given orally 2 hour before surgery
62507145|NCT02668094|ACTIVE_COMPARATOR|Group HP|Pregabalin 150 mg was given orally 2 hour before surgery
62144232|NCT03611556|EXPERIMENTAL|Dose-expansion, Oleclumab 3000 mg + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
62144233|NCT03611556|EXPERIMENTAL|Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
62144234|NCT00797056|EXPERIMENTAL|G-CSF|
62144235|NCT00797056|PLACEBO_COMPARATOR|Placebo|
62144236|NCT04353050|NO_INTERVENTION|Cohort 1 (retrospective)|Only data from medical records and formalin-fixed paraffin-embedded tissue blocks will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
62144237|NCT04353050|NO_INTERVENTION|Cohort 2 (retrospective)|Only data from medical records, formalin-fixed paraffin-embedded tissue blocks and cytologic slides will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
62144238|NCT04353050|OTHER|Cohort 3 (prospective)|Patients with pigmented lesions on the skin or mucosa who are referred for excisional biopsy will be offered to apply investigated non-invasive adhesive system on their lesion just before the excisional biopsy. After biopsy cytological slides and FFPE tissue blocks will be prepared. All three types of obtained samples will be investigated separately (adhesive patches, cytologic slides and FFPE tissue blocks) for genetic markers whereas cytologic slides and FFPE tissue blocks will be processed also routinely and regular cytologic and histopathologic report will be generated.
62349159|NCT04262401|ACTIVE_COMPARATOR|Standard health coaching|Standard health coaching to increase health behaviors
62349160|NCT04262401|EXPERIMENTAL|Habit-focused health coaching|Health coaching enhanced with a focus on habit formation using a mobile application called Habit Design
62349161|NCT00208494|ACTIVE_COMPARATOR|A|Ceramic-on-metal total hip implant
62349162|NCT00208494|ACTIVE_COMPARATOR|B|Metal-on-metal total hip implant
62349163|NCT05291637||Medical management cohort|Patients who have undergone medical management stroke treatment from 1/01/2003 to 01/01/2022; this could include intravenous thrombolysis.
62349164|NCT05291637||EVT management cohort|Patients who have undergone EVT stroke treatment from 01/01/2015 to 01/01/2022
62349165|NCT04428359|EXPERIMENTAL|Measles, Mumps, Rubella vaccine|All Group A patients will receive intralesional MMR.
62349166|NCT04428359|EXPERIMENTAL|Vitamin D3|All Group B patients will receive intralesional Vitamin D3
62349167|NCT02379390|EXPERIMENTAL|Cabazitaxel|Participants received Cabazitaxel 25 mg/m\^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
62507146|NCT01075061|OTHER|healthy volunteers|healthy volunteers
62507147|NCT01075061|OTHER|Kallmann|Kallmann syndrome patients
62507148|NCT01075061|OTHER|Congenital Mirror Movement|patients with CMM
62507149|NCT05695391|EXPERIMENTAL|Coagulation Factor VIIa (Recombinant)|
62507150|NCT05486845|EXPERIMENTAL|adults|People who use the lower back pillow.
62507151|NCT00374049|EXPERIMENTAL|One|MUC1 vaccine in conjunction with GM-CSF and Poly-ICLC (Hiltonol)in Arm ONE
62507152|NCT06311006||Patients|adult patients for whom FMT for CDI is indicated and planned as part of the routine care (definition of CDI and recurrence according to European recommendations 2014 10)
62507153|NCT06311006||Stool donor|
62507154|NCT02785653|EXPERIMENTAL|sevoflurane and rocuronium|After induction of general anaesthesia, patients in the sevoflurane group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen with 2% inspired concentration of sevoflurane. After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
62507155|NCT02785653|ACTIVE_COMPARATOR|rocuronium|After induction of general anaesthesia, patients in the control group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen . After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
62507156|NCT00989209|ACTIVE_COMPARATOR|A: myofunctional prior to botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group A, botulinum toxin was applied after myofunctional therapy.
62507157|NCT00989209|ACTIVE_COMPARATOR|B: myofunctional after botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group B, botulinum toxin was applied before myofunctional therapy.
62507158|NCT04006938|EXPERIMENTAL|Single Bout ('S') - 30 minutes of moderate intensity cycling|Subjects will perform a single 30-minute bout of moderate intensity cycling before breakfast
62507159|NCT04006938|EXPERIMENTAL|Multiple Bout ('M')|Subjects will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
62507160|NCT02415387|EXPERIMENTAL|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
62507161|NCT02415387|PLACEBO_COMPARATOR|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
62705298|NCT02573493|EXPERIMENTAL|Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT|"* Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment~* If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)~* If \<PR, move directly to CRT if not surgical candidates.~* CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.~* It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
62705299|NCT02573493|EXPERIMENTAL|Arm 2: nab-Paclitaxel (A) + CRT|"* Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment~* If CR/PR, three more weeks of nab-paclitaxel followed by CRT~* If \<PR, move directly to CRT if not surgical candidates.~* CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m\^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m\^2 for seven additional doses concurrently with radiation therapy.~* It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
62705300|NCT02573493|EXPERIMENTAL|Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT|"* 6 weeks of nab-paclitaxel and cisplatin (days 1 \& 22) followed by primary tumor site assessment~* If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab~* If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab~* CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy~* Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study."
62144239|NCT04649645|ACTIVE_COMPARATOR|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
62144240|NCT04649645|ACTIVE_COMPARATOR|Intervention Arm (Arm B)|Participant switches to using C-F NDS.
62144241|NCT04649645|ACTIVE_COMPARATOR|Control Arm (Arm C)|Participant continues to not smoking or using of any nicotine/tobacco products.
62144242|NCT02399449|EXPERIMENTAL|Brand sodium ferric gluconate then Generic sodium ferric gluconate|Crossover trial. Each arm will receive Brand sodium ferric gluconate (single dose of 125mg) then Generic sodium ferric gluconate (single dose of 125mg)
62144243|NCT02399449|EXPERIMENTAL|Generic sodium ferric gluconate then Brand sodium ferric gluconate|Crossover trial. Each arm will receive Generic sodium ferric gluconate (single dose of 125mg) then Brand sodium ferric gluconate (single dose of 125mg)
62507162|NCT05945992|EXPERIMENTAL|Condition 1: emotions, self, mindfulness, resources|(1) emotion regulation, (2) self-acceptance, (3) mindfulness, (4) resource activation
62507163|NCT05945992|EXPERIMENTAL|Condition 2: emotions, self, mindfulness, conflict resolution|(1) emotion regulation, (2) self-acceptance, (3) mindfulness, (4) constructive conflict resolution
62507164|NCT05945992|EXPERIMENTAL|Condition 3: emotions, self, stress, resources|(1) emotion regulation, (2) self-acceptance, (3) stress management, (4) resource activation
62705301|NCT02194738|EXPERIMENTAL|A081105 Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
62736670|NCT04643587|EXPERIMENTAL|CSL787 (MAD dose 1)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
62144244|NCT01281657||Prescribed fingolimod 0.5 mg/day|
62144245|NCT04652869|EXPERIMENTAL|Mindfulness Training|Mindfulness training
62507165|NCT05945992|EXPERIMENTAL|Condition 4: emotions, self, stress, conflict resolution|(1) emotion regulation, (2) self-acceptance, (3) stress management, (4) constructive conflict resolution
62507166|NCT05945992|EXPERIMENTAL|Condition 5: emotions, communication, mindfulness, resources|(1) emotion regulation, (2) communication skills, (3) mindfulness, (4) resource activation
62507167|NCT05945992|EXPERIMENTAL|Condition 6: emotions, communication, mindfulness, conflict resolution|(1) emotion regulation, (2) communication skills, (3) mindfulness, (4) constructive conflict resolution
62507168|NCT05945992|EXPERIMENTAL|Condition 7: emotions, communication, stress, resources|(1) emotion regulation, (2) communication skills, (3) stress management, (4) resource activation
62507169|NCT05945992|EXPERIMENTAL|Condition 8: emotions, communication, stress, conflict resolution|(1) emotion regulation, (2) communication skills, (3) stress management, (4) constructive conflict resolution
62144246|NCT04652869|EXPERIMENTAL|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
62144247|NCT04652869|EXPERIMENTAL|Mindfulness + tDCS|Mindfulness training with transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
62144248|NCT05413993|ACTIVE_COMPARATOR|intra and extraoral application|The laser was applied for 60 seconds, in 2 intraoral points and 2 extraoral points.
62144249|NCT05413993|EXPERIMENTAL|extraoral application|The laser was applied only extraoral points
62144250|NCT04958720||Cohort 1|Resectable non-advanced cancer
62507170|NCT05945992|EXPERIMENTAL|Condition 9: group dynamics, self, mindfulness, resources|(1) social behavior in groups, (2), self-acceptance, (3) mindfulness, (4) resource activation
62507171|NCT05945992|EXPERIMENTAL|Condition 10: group dynamics, self, mindfulness, conflict resolution|(1) social behavior in groups, (2) self-acceptance, (3) mindfulness, (4) constructive conflict resolution
62507172|NCT05945992|EXPERIMENTAL|Condition 11: group dynamics, self, stress, resources|(1) social behavior in groups, (2) self-acceptance, (3) stress management, (4) resource activation
62507173|NCT05945992|EXPERIMENTAL|Condition 12: group dynamics, self, stress, conflict resolution|(1) social behavior in groups, (2) self-acceptance, (3) stress management, (4) constructive conflict resolution
62705302|NCT02194738|PLACEBO_COMPARATOR|A081105 Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
62705303|NCT02194738|EXPERIMENTAL|A081105 Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62705304|NCT02194738|ACTIVE_COMPARATOR|A081105 Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
62705305|NCT02194738|ACTIVE_COMPARATOR|A081801 Arm A (platinum doublet, observation)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then undergo observation."
62705306|NCT02194738|EXPERIMENTAL|A081801 Arm B (platinum doublet, sequential pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 17 cycles in the absence of disease progression or unacceptable toxicity."
62736671|NCT04643587|EXPERIMENTAL|CSL787 (MAD dose 2)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
61963846|NCT04869644|EXPERIMENTAL|Intervention: Behavioral Change Techniques to encourage Habit Formation|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps 5 days per week. Participants will be enrolled for a baseline period lasting 2 weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will be asked to generate a walking plan with the goal of walking an additional 2,000 steps above their baseline activity level on 5 days per week. This walking plan will include details about day of the week, time of day, and location of walking. Once participants have completed their walking plan, they will receive daily texts based on the 5 identified BCTs for the duration of the 10-week intervention. All BCTs will be delivered daily. The goal of the text messages will be to encourage habit formation for walking behavior.
61963847|NCT02480439|EXPERIMENTAL|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
61963848|NCT02480439|EXPERIMENTAL|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
61963849|NCT02480439|EXPERIMENTAL|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
61963850|NCT05577442|EXPERIMENTAL|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|for the HR+/HER2+MBC will be treated with Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy. Endocrine drug be determined by physician depend on the history.
61963851|NCT02804932|EXPERIMENTAL|Beetroot crystals (nitrate)|Participants will receive a nitrate rich beetroot powder (10g/day) for 8 weeks.
61963852|NCT02804932|PLACEBO_COMPARATOR|Placebo (beetroot powder, no nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 8 weeks.
62736672|NCT04643587|EXPERIMENTAL|CSL787 (MAD dose 3)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
61963853|NCT03719521|EXPERIMENTAL|Intervention Arm|"Community-based provision of an integrated package of services over a 24 month period.~For all those aged 16-24 years residing in the intervention clusters: HIV testing, Sexual and reproductive health services (condoms, menstrual hygiene management, contraception, syndromic sexually transmitted infection (STI) treatment, referral for voluntary medical male circumcision, cervical screening), General health information and counselling. For those who are aged 16-24 years and test HIV-positive (or known HIV positive) within the intervention clusters: ART initiation and community-based treatment, adherence support."
61963854|NCT03719521|ACTIVE_COMPARATOR|Control Arm|Routine existing services
62144251|NCT04958720||Cohort 2|Unresectable advanced cancer
62144252|NCT04559698|EXPERIMENTAL|immediate training group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the immediate training group will take part in the first 11-week course.
62144253|NCT04559698|EXPERIMENTAL|waitlist control group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the waitlist control group will take part in the second 11-week course.
62507174|NCT05945992|EXPERIMENTAL|Condition 13: group dynamics, communication, mindfulness, resources|(1) social behavior in groups, (2) communication skills, (3) mindfulness, (4) resource activation
62144254|NCT04069806|EXPERIMENTAL|Preoperative oral carbohydrate load|6 hours for solid food and 2 hours for liquids + oral carbohydrate preparation 2 hours prior to surgery.
62507175|NCT05945992|EXPERIMENTAL|Condition 14: group dynamics, communication, mindfulness, conflict resolution|(1) social behavior in groups, (2) communication skills, (3) mindfulness, (4) constructive conflict resolution
62507176|NCT05945992|EXPERIMENTAL|Condition 15: group dynamics, communication, stress, resources|(1) social behavior in groups, (2) communication skills, (3) stress management, (4) resource activation
62507177|NCT05945992|ACTIVE_COMPARATOR|Condition 16: group dynamics, communication, stress, conflict resolution|(1) social behavior in groups, (2) communication skills, (3) stress management, (4) constructive conflict resolution
62507178|NCT00348816|EXPERIMENTAL|Docetaxel (Single Arm)|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Prednisone 5mg twice a day Radical prostatectomy as standard of care Radiation therapy will be used as standard of care Post radiation Doxcetaxel
62736673|NCT04643587|PLACEBO_COMPARATOR|Placebo|Inhalation by mouth of a nebulized aerosol
62507179|NCT02244931|EXPERIMENTAL|Phase 1: Performance evaluation on ergometer|"The 3 devices are experimented in random order to compare them on performance using an ergometer wheelchair:~* Servomatic™ assisting device~* E.Motion© assisting device~* Standard manual Wheelchair"
62507180|NCT02244931|EXPERIMENTAL|Phase 2: Comparison of maneuverability|"The 3 devices are experimented in random order to compare them on maneuverability:~* Servomatic™ assisting device~* E.Motion© assisting device~* Standard manual Wheelchair"
62507181|NCT02244931|EXPERIMENTAL|Phase 3: Comparison of the autonomy|"The 3 devices are experimented in random order to compare them on the autonomy they afford to patients:~* Servomatic™ assisting device~* E.Motion© assisting device~* Standard manual Wheelchair"
62507182|NCT02492815||Population with condition and without condition|Participating in EAP
62507183|NCT02146976|EXPERIMENTAL|Propofol|introvenious infusion of propofol
62507184|NCT02146976|EXPERIMENTAL|Inhaled anaesthetic (Sevoflurane)|sevoflurane (1.0-1.3% Minimum Alveolar Concentration)
62507185|NCT00703131||1|Anal Fistula Plug
62507186|NCT00282581|PLACEBO_COMPARATOR|placebo|
62507187|NCT02838940|EXPERIMENTAL|cesarean in different indications|Women that are about to undergo an elective cesarean in different indications.
62507188|NCT02709629|EXPERIMENTAL|Individualized and adaptive computerised cognitive training|Training in this group is individualized using a computer algorithm which assigns tasks (from a pool of 33 training tasks) on the basis of cognitive strengths and weaknesses as determined by the training program. In addition, task difficulty is adaptive and responsive to performance level. Participants are able to see feedback on their progress each training session in the form of a session-score. A range of behavior change techniques are used throughout the training period (delivered via scheduled monitoring phone calls, and email contact with participants) to support the compliance and adherence of participants. These include a range of motivation and confidence building strategies, based on a theoretical framework. Participants are required to train for approx. 30 min., 3 times per week, for 8 weeks.
62507189|NCT02709629|ACTIVE_COMPARATOR|Active control|"Training in this group is generic, and tasks (from the same pool of 33 training tasks) are randomly selected by the training program. In addition, task difficulty is fixed, such that irrespective of performance, each time a participant is presented with a given task, the level of difficulty returns to the basic level. Participants in this arm do not receive feedback on their progress at the end of each training session. The same protocol of behavior change techniques is used in this intervention arm.~Participants are also required to train for approx. 30 min., 3 times per week, for 8 weeks."
62507190|NCT00744172|ACTIVE_COMPARATOR|I|laparoscopy
62144255|NCT04069806|NO_INTERVENTION|Standard preoperative fasting|6 hours for solid food and 2 hours for liquids.
62144256|NCT03560271|EXPERIMENTAL|Dose A|Cyclo-Z containing 23 mg zinc plus 6 mg CHP
62144257|NCT03560271|EXPERIMENTAL|Dose B|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
62144258|NCT03560271|PLACEBO_COMPARATOR|Dose C|Placebo
62144259|NCT03555812|EXPERIMENTAL|Healthy volunteers|"* a medical examination~* 10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
62507191|NCT00744172|ACTIVE_COMPARATOR|2|vaginal
62507192|NCT00744172|ACTIVE_COMPARATOR|3|abdominal
62507193|NCT00855127||Liver transplant recipients|
62507194|NCT05450991||Hirschsprung's Disease|Infants, children and adults cared for in Alder Hey Children's Hospital from the neonatal period onward with histologically confirmed Hirschsprung's disease.
62507195|NCT05450991||Anorectal Malformations|Infants, children and adults cared for in Alder Hey Children's Hospital from the neonatal period onward with an anorectal malformation.
62507196|NCT02000323|ACTIVE_COMPARATOR|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Standard enteral nutrition liquid regimen （Peptisorb Liquid）will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day."
62507197|NCT02000323|ACTIVE_COMPARATOR|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through Naso-gastro-Jejunal tube until 2 or more followed requirements were met mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day."
62507198|NCT05565261||Group 1: Complete Dentures|The group consists of patients using conventional complete dentures applied to edentulous patients.
62507199|NCT05565261||Group 2: Implant Supported Overdentures|The group consists of patients who use implant-supported overdentures after 2 dental implants have been surgically placed in edentulous patients and osseointegration has occurred.
62507200|NCT05758909||Patients receiving transfemoral (TF) TAVI|TF TAVI
62507201|NCT04200625||Semaglutide|Patients using standard of care weekly GLP-1A analog Semaglutide
62507202|NCT04200625||Dulaglutide|Patients using standard of care weekly GLP-1A analog Dulaglutide
62507203|NCT04200625||Metformin|Patients using standard of care daily Metformin.
62507204|NCT04194437|EXPERIMENTAL|OCS Preserved Livers|This is a single-arm trial of OCS preserved livers used for transplantation.
62507205|NCT02118168||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-002 and that received at least 3 immunizations and reached 48-weeks of follow-up."
62507206|NCT05677217||nab-paclitaxel plus gemcitabine-cisplatin|gemcitabine, 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 100 mg/m2, on days 1 and 8 of 21-day cycles
62507207|NCT06325280||Congenital heart disease|Participants aged 10-18 years who have congenital heart disease.
62144260|NCT03555812|EXPERIMENTAL|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:~* a medical examination~* 3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
62144261|NCT02718196|EXPERIMENTAL|Application Users|English-speaking parents of children ages 6-24 months who are interested in starting sleep training within the next month.
61963855|NCT01876160|EXPERIMENTAL|threshold of sensory perception|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of sensory perception was identified as the first sensation of increased current intensity and the threshold of motor response as the minimum muscle contraction detected.
61963856|NCT01876160|EXPERIMENTAL|threshold of motor response|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of motor response as the minimum muscle contraction detected.
61963857|NCT03935204|EXPERIMENTAL|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
61963858|NCT03935204|PLACEBO_COMPARATOR|Placebo|Participants in this arm would receive 1.0ml aluminium adjuvant.
61963859|NCT02452489|OTHER|Single point group (Zhongwan)|Patients will be acupuncture with Zhongwan(RN12).
61963860|NCT02452489|OTHER|Combination of He-Mu points group|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).
61963861|NCT02452489|OTHER|Control group|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.
61963862|NCT06175910|ACTIVE_COMPARATOR|percutaneous nephrolithotomy|60 patients were undergone percutaneous nephrolithotomy, three patients were lost in follow up and one case was excluded due to stricture urethra. So, the investigators analysed 56 patients
61963863|NCT06175910|ACTIVE_COMPARATOR|retrograde intrarenal surgery|60 patients were undergone retrograde intrarenal surgery, one patient was lost in follow up and one case was aborted due to narrow ureter \& DJ was applied. So, the investigators analysed 58 patients.
61963864|NCT03032705|EXPERIMENTAL|SonicFill™ 2|Composite: SonicFill™ 2; Bonding Agent: Optibond XRT
61963865|NCT03032705|ACTIVE_COMPARATOR|Filtek™ Supreme|Composite: Filtek™ Supreme Ultra Universal Restorative; Bonding Agent: Scotchbond™ Universal Adhesive
61963866|NCT05669495||No dementia, increased risk of dementia|"Meets criteria for No Dementia and one of the following (according to CCNA Criteria):~1. Cognitively Unimpaired~2. Cognitively Unimpaired plus Subjective Cognitive Impairment~3. Mild Cognitive Impairment (MCI)~AND Classified as being at increased risk of dementia based on at least one of the following:~1. First-degree family history of dementia~2. Self-Reported or documented current and/or history at midlife (45-60 years) of the following risk factors:~i. Hypertension ii. Hypercholesterolemia iii. Body Mass Index \> 30 kg/m2 iv. Physical Inactivity v. Insomnia vi. Vascular-metabolic risk"
61963867|NCT05032560|EXPERIMENTAL|25 mg single dose|Subject will receive a single oral dose of ABX464 25 mg or its matching placebo
62507208|NCT06325280||Heart transplant recipient|Participants aged 10-18 years who have recieved a heart transplant.
62507209|NCT06298214|NO_INTERVENTION|Usual Care|Subjects will see doctors as normal during first year postpartum with no assistance.
61963868|NCT05032560|EXPERIMENTAL|50 mg single dose|Subject will receive a single oral dose of ABX464 50 mg or its matching placebo
62507210|NCT06298214|EXPERIMENTAL|Her Health Program|Her Health is a patient navigation intervention delivered by community health workers across the first postpartum year. Her Health has two interspersed components: Navigation and Education. Her Health Navigation is delivered through weekly and monthly check-ins between participant and navigator. Her Health navigators will deliver historically informed and culturally competent education designed to promote self-efficacy and self-advocacy within the healthcare system.
61963869|NCT05032560|EXPERIMENTAL|25 mg multiple dose|Subject will receive a daily oral dose of ABX464 25 mg or its matching placebo for 28 days
61963870|NCT05032560|EXPERIMENTAL|50 mg mulptiple dose|Subject will receive a daily oral dose of ABX464 50 mg or its matching placebo for 28 days
61963871|NCT04767932|EXPERIMENTAL|control group|the control group will receive regular exercise training at same time.
61963872|NCT02007694|ACTIVE_COMPARATOR|VRET plus Yohimbine|Virtual Reality Exposure Therapy combined with the administration of yohimbine.
62349168|NCT02379390|ACTIVE_COMPARATOR|Abiraterone acetate or Enzalutamide|Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
62507211|NCT01723150|EXPERIMENTAL|Oral antibiotics|The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
62507212|NCT01723150|ACTIVE_COMPARATOR|Intravenous antibiotics|The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
62507213|NCT00588731|EXPERIMENTAL|Cannabidiol|
62507214|NCT00588731|PLACEBO_COMPARATOR|Placebo|
62507215|NCT03980210|EXPERIMENTAL|Hyperbaric oxygen therapy|"Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)~Five successive steps:~1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA"
62507216|NCT01675284|EXPERIMENTAL|Low Dosage AT-301|7.5 µg hemagglutinin (HA)
62507217|NCT01675284|EXPERIMENTAL|Middle Dosage AT-301|15 µg hemagglutinin (HA)
61963873|NCT02007694|ACTIVE_COMPARATOR|VRET plus propranolol|Virtual Reality Exposure Therapy combined with the administration of propranolol
61963874|NCT02007694|PLACEBO_COMPARATOR|VRET plus placebo|Virtual Reality Exposure Therapy combined with the administration of a non-active placebo pill
61963875|NCT02268604|EXPERIMENTAL|BIIB 722 CL|
61963876|NCT02268604|PLACEBO_COMPARATOR|Placebo|
61963877|NCT06153329|EXPERIMENTAL|THDB0206 injection|
61963878|NCT06153329|ACTIVE_COMPARATOR|Humalog®|
61963879|NCT06153329|ACTIVE_COMPARATOR|BC222insulin lispro injection|
62349169|NCT05078580|EXPERIMENTAL|Healthy participants|Iptacopan 200 mg single dose
62507218|NCT01675284|EXPERIMENTAL|High Dosage AT-301|30 µg hemagglutinin (HA)
62349170|NCT05078580|EXPERIMENTAL|Mild hepatic impairment patients|Iptacopan 200 mg single dose
62507219|NCT04079582|EXPERIMENTAL|Higher dialysate magnesium|
61963880|NCT05502601|NO_INTERVENTION|Control|The control group will be comprised by those who will not receive any specific oral care intervention. For ethical reasons, the control group will receive periodontal therapy at the Endo of the study (after 6 months). In those cases presenting periodontal disease progression in a single tooth, the patients will be treated and withdrawn from the study
61963881|NCT05502601|ACTIVE_COMPARATOR|Non-surgical periodontal treatment|"Periodontal treatment will be performed with scaling and root planning (SRP).SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (patient education and motivation to control plaque and calculus accumulation)"
61963882|NCT01233440|EXPERIMENTAL|Cohort 1|25 IU/kg dose
61963883|NCT01233440|EXPERIMENTAL|Cohort 2|50 IU/kg dose
61963884|NCT01233440|EXPERIMENTAL|Cohort 3|75 IU/kg dose
61963885|NCT04569266|OTHER|No specific exercise rehabilitation treatment|"After randomization, patients will not benefit from any specific exercise rehabilitation treatment until 6 months post-ICU. They will then be proposed to follow the treatment protocol if efficacy is demonstrated, once their follow-up in the study is completed."
61963886|NCT04569266|EXPERIMENTAL|specific exercise rehabilitation treatment|"Patients will receive a prescription for exercise rehabilitation, at the rate of 2 sessions of approximately 1 hour each per week for 10 weeks.~Continuous endurance training will start at 60-70% of the patient's maximum power. For patients who are unable to maintain continuous re-training, interval training sequences (30 seconds of effort followed by 30 seconds of rest) may be offered.~Initially, the effort will be 15 minutes, then gradually increase to reach an exercise duration of 40 minutes or 45-60 minutes for endurance or interval training respectively.~The power can be adjusted as the patient progresses to reach the target heart rate and dyspnea at 4-6 on the BORG scale.~All patients will be offered lower limb and upper limb strengthening exercises. Each exercise will consist of 3-4 sets of 6-12 repetitions."
61963887|NCT01074112||Abdominal Trauma|Patients with mechanism of injury that could produce abdominal bleeding
61963888|NCT01074112||Female Abdominal Pain|Female patients of child bearing age complaining of abdominal pain
62144262|NCT00600353|EXPERIMENTAL|Melphalan, dexamethasone, aprepitant, palonosetron|"Group A: Subjects with Multiple Myeloma~* Conditioning regimen, over a 7 day period, includes:~* Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion~Group B: Subjects with Lymphoma~* Conditioning regimen, over a 7 day period, includes: (BEAC)~* BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant"
62705307|NCT02194738|EXPERIMENTAL|A081801 Arm C (platinum doublet, combination pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice and pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 13 cycles in the absence of disease progression or unacceptable toxicity."
62705308|NCT02194738|EXPERIMENTAL|E4512 Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
61963889|NCT01074112||Difficult Vascular Access|Patients whom vascular access is needed but difficult
61963890|NCT01074112||Abdominal Aortic Anuerysm|Patients who complain of or are suspected of having an abdominal aortic aneurysm
61963891|NCT01074112||Pulseless Electrical Activity|Patients whom are in cardiac arrest and no pulse can be determined yet they show an electrical rhythm on the monitor
61963892|NCT01074112||Kidney Stones (Hydronephrosis)|Patients who complain of flank pain
61963893|NCT01074112||Plueral Effusion|Patients with a history of renal or hepatic problems and complain of difficulty breathing of an unknown etiology
61963894|NCT01074112||ETT placement|field intubated patients who need another means of verifying tube placement
61963895|NCT01074112||Transcutaneous Pacing|Patients who are being externally paced and need a method of determining mechanical capture
61963896|NCT01074112||Paramedic Discretion|Patients in whom the paramedic feels that an ultrasound study would provide useful data in their treatment
61963897|NCT04502589|ACTIVE_COMPARATOR|perampanel by itself|
61963898|NCT04502589|ACTIVE_COMPARATOR|Perapanel with Disulfiram|
61963899|NCT03766581|PLACEBO_COMPARATOR|BMS-986177 Placebo|Specified Dose on Specified Days
61963900|NCT03766581|EXPERIMENTAL|Dose 1: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
62349171|NCT05078580|EXPERIMENTAL|Moderate hepatic impairment patients|Iptacopan 200 mg single dose
62349172|NCT05078580|EXPERIMENTAL|Severe hepatic impairment patients|Iptacopan 200 mg single dose
61963901|NCT03766581|EXPERIMENTAL|Dose 2: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
61963902|NCT03766581|EXPERIMENTAL|Dose 3: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
61963903|NCT03766581|EXPERIMENTAL|Dose 4: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
61963904|NCT03766581|EXPERIMENTAL|Dose 5: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
61963905|NCT03766581|EXPERIMENTAL|Dose 6: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
61963906|NCT03766581|EXPERIMENTAL|Dose 7: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
61963907|NCT01308775|ACTIVE_COMPARATOR|SIS.NET, Routine Follow up|
61963908|NCT06498999|EXPERIMENTAL|Experimental Group: Individual Setting|4-STEP-Training Program in 1-1 Setting
61963909|NCT06498999|EXPERIMENTAL|Experimental Group: Group Setting|4-STEP-Training Program in Group Setting
61963910|NCT06498999|NO_INTERVENTION|Control Group|No Intervention
61963911|NCT00628784|EXPERIMENTAL|Group 1|Specialized intestinal metaplasia (Barrett's esophagus) documented via endoscopic esophageal biopsy, with standard surveillance biopsies (four-quadrant biopsies obtained every 2-cm the entire length of the specialized intestinal metaplasia in the esophagus) performed within the past two years prior to study enrollment. Biopsies show either low grade dysplasia, indeterminate for dysplasia, or no dysplasia.
61963912|NCT00628784|EXPERIMENTAL|Group 2|Diagnosis of Barrett's esophagus and high grade dysplasia or intramucosal carcinoma. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). Endoscopic ultrasound\* (EUS) demonstrating no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa (T1).
61963913|NCT00628784|EXPERIMENTAL|Group 3|Diagnosis of esophageal carcinoma (T1smN0 or T2N0 via EUS). Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement).
61963914|NCT00628784|EXPERIMENTAL|Group 4|Diagnosis of severe dysplasia within esophageal squamous mucosa on pathology review. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). EUS with no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa.
61963915|NCT04443270|EXPERIMENTAL|Chloroquine phosphate prophylactic group|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
61963916|NCT04443270|NO_INTERVENTION|Control group|Health personnel who want to be included voluntary in the study and meet the inclusion criteria without Chloroquine use.
62507220|NCT04079582|ACTIVE_COMPARATOR|Lower dialysate magnesium|
61963917|NCT05770791|ACTIVE_COMPARATOR|Group A|Group A Obese Grade I
62507221|NCT06615804|EXPERIMENTAL|Treatment resistant depression group|"Participants will be treated with transcranial magnetic stimulation (TMS) using the MagVenture™ MagProX100™ device. The treatment includes 20 sessions over 4 weeks, delivering 18000 pulses in total. The stimulation targets the left dorsolateral prefrontal cortex, with parameters set to achieve optimal therapeutic effects without inducing adverse side effects. Motor threshold measurements are conducted prior to the initiation of treatment and adjusted weekly to maintain consistent treatment intensity.~Comprehensive ophthalmologic examinations will be performed on all participants both before and after the completion of the TMS treatment. These examinations will include assessments of retinal nerve fiber layer, macula, and choroidal thickness using spectral-domain optical coherence tomography equipped with an enhanced depth imaging mode. The patient health questionnaire and Hamilton Depression Rating Scale will be conducted to evaluate changes in the severity of depressive symptoms."
62705309|NCT02194738|ACTIVE_COMPARATOR|E4512 Arm B (observation)|Patients undergo observation.
62705310|NCT02194738|EXPERIMENTAL|EA5142 Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET/CT throughout the trial and blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated.
62705311|NCT02194738|ACTIVE_COMPARATOR|EA5142 Arm II (observation)|Patients are followed serially with CT and/or PET/CT imaging for up to 1 year and then during follow-up. Patients also undergo blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.
61963918|NCT05770791|ACTIVE_COMPARATOR|Group B|Group B Obese Grade I
61963919|NCT02315001|ACTIVE_COMPARATOR|Liraglutide|"Week 1 Run-In Phase = 0.6 mg (0.1 ml) Liraglutide once daily via subcutaneous injection~Week 2 Low-Dose Phase = 1.2 mg (0.2 ml) Liraglutide once daily via subcutaneous injection~Week 3 High-Dose Phase = 1.8 mg (0.3 ml) Liraglutide once daily via subcutaneous injection"
61963920|NCT02315001|PLACEBO_COMPARATOR|Saline Placebo|"Week 1 Run-In Phase = 0.1 ml normal saline once daily via subcutaneous injection~Week 2 Low-Dose Phase = 0.2 ml normal saline once daily via subcutaneous injection~Week 3 High-Dose Phase = 0.3 ml normal saline once daily via subcutaneous injection"
61963921|NCT04344925||Aerosol-reducing Mask|The participant will be placed on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
61963922|NCT04344925||Standard Mask|The patient will be placed on BIPAP using the standard mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
61963923|NCT01606436|EXPERIMENTAL|400 mg LY2140023|400 milligrams (mg) LY2140023 (5 x 80 mg tablets) administered orally as a single dose during 1 of 3 treatment periods separated by 2-day washout periods.
62705312|NCT00005909||Alkaptonuria|Patients with confirmed or suspected alkaptonuria
61963924|NCT01606436|PLACEBO_COMPARATOR|Placebo|Placebo tablets (5) matching LY2140023 administered orally as a single dose during 1 of 3 treatment periods separated by 2-day washout periods.
61963925|NCT01606436|OTHER|400 mg Moxifloxacin|Positive control, unblinded 400 milligrams (mg) moxifloxacin (1 x 400 mg tablet) administered orally as a single dose during 1 of 3 treatment periods separated by 2-day washout periods.
61963926|NCT05693896|EXPERIMENTAL|Centering Appetite Intervention, Then Attention- Control Group|Participants randomized to the attention-control group will participate remotely via a smartphone app and online lessons. The intervention will build participants' self-efficacy to reduce binge eating and to assist them in preventing weight gain.
61963927|NCT05693896|NO_INTERVENTION|Attention- Control Group, Then Centering Appetite Intervention|Participants randomized to the centering appetite intervention group will receive weekly psychoeducation emails about general wellness topics, discussion of binge eating, diet, and physical activity.
61963928|NCT06259266|EXPERIMENTAL|valce arm|"Two strategies are compared in a parallel plan : a valve arm  (implementation of TEGO ® valve associated with interdialytic saline locks) and a control arm ( standard care )."
62349173|NCT05191355||subjects with familial hypercholesterolemia|blood test
62349174|NCT05191355||healthy subjects|blood test
62705313|NCT06113237||Retrospective Pregnancy|Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is no longer pregnant at the time of study enrollment.
62349175|NCT01653002||Lung cancer with lymph node involvement|
62349176|NCT05227482|ACTIVE_COMPARATOR|Standard dosimetric approach for 90Y activity calculation|The radionuclide activity to be injected is calculated with standard dosimetric approach such as body surface area (BSA) method or Medical Internal Radiation Dose (MIRD) monocompartmental method.
62507222|NCT00346164|EXPERIMENTAL|Arm A: No adjuvant treatment|Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
62507223|NCT00346164|EXPERIMENTAL|Arm B: Low risk; adjuvant radiotherapy|Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
62507224|NCT00346164|EXPERIMENTAL|Arm C: Intermediate & High risk; adjuvant chemoradiotherapy|High risk \[metastatic, resected, incompletely resected, or unresected disease\] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
62507225|NCT00346164|EXPERIMENTAL|Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy|High risk \[metastatic, resected, incompletely resected, or unresected disease\] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
62507226|NCT05220891||Crystalloid group|"Group( 1)Patients will be randomly assigned to be treated with crystalloid (n=30). They will receive an intravenous infusion of saline at a constant rate utilizing a pump infusion device (170 mL of 3.5% saline solution per liter of ascites removed at 999 mL/h). The amount of liquid infused and rate of infusion was selected based on previous studies (Sola-vera et al.,2003) Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
62507227|NCT05220891||Colloid group|"Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
62507228|NCT03297619|EXPERIMENTAL|ACT self-help book condition|Participants in this condition will be assigned to read The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness by Fleming and Kocovski (2013), a self-help book based on acceptance and commitment therapy.
62507229|NCT03297619|ACTIVE_COMPARATOR|CBT self-help book condition|Participants in this condition will be assigned to read The Shyness and Social Anxiety Workbook by Antony and Swinson (2008), a self-help book based on cognitive-behavioral therapy for social anxiety.
62507230|NCT02377388|ACTIVE_COMPARATOR|treatment: DPP4 -i|"Use of DPP4-i :~sitagliptin 50 mg (if glomerular filtration rate-GFR \<50 ml/min at randomization) or 100 mg (if GFR\>50 ml/min at randomization),during 30 days,once-daily(OD)~OR~saxagliptin 2,5 mg (if glomerular filtration rate-GFR \<50 ml/min at randomization) or 5 mg (if GFR\>50 ml/min at randomization),during 30 days,once-daily(OD)"
62507231|NCT02377388|PLACEBO_COMPARATOR|control|placebo tablets identical to active comparator,administered according to GFR at randomization,during 30 days,OD
62507232|NCT01522079|EXPERIMENTAL|Air stacking|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position.
62507233|NCT05386056|EXPERIMENTAL|Experimental: Pembrolizumab plus photodynamic therapy (PDT)|"Interventions:~* Drug: Pembrolizumab~* Drug: sinoporphyrin sodium (DVDMS)~* Photodynamic therapy (PDT)"
62705314|NCT06113237||Prospective Pregnancy|Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is pregnant at the time of study enrollment.
62705315|NCT05390268|EXPERIMENTAL|digital tic training|The active treatment including apps released for every session
61963929|NCT06259266|OTHER|control arm|"Two strategies are compared in a parallel plan : a valve arm  (implementation of TEGO ® valve associated with interdialytic saline locks) and a control arm ( standard care )."
62349177|NCT05227482|EXPERIMENTAL|Personalized voxel-based dosimetric method for 90Y activity calculation|The radionuclide activity to be injected is calculated with voxel-based approach based on pre-treatment simulation with the injection of 99mTc-MAA and the acquisition of SPECT/CT images.
62349178|NCT02201355|EXPERIMENTAL|chemoradiation|Hypofractionated, PET-directed, Intensity Modulated Radiotherapy Concurrent with Weekly Cisplatin Chemotherapy
61963930|NCT05948696||Horticultural participants|Inpatients with chronic schizophrenia who attend to a horticultural group therapeutic program.
62349179|NCT03149926||Patients with Borderline Personality Disorder|
62349180|NCT03149926||Healthy controls|
62349181|NCT03169049|EXPERIMENTAL|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
62349182|NCT03169049|SHAM_COMPARATOR|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
62349183|NCT02152358|ACTIVE_COMPARATOR|Ganciclovir|Patients with a positive CMV PCR
62349184|NCT02152358|PLACEBO_COMPARATOR|Ganciclovir placebo|Patients with a positive CMV PCR
62349185|NCT02152358|ACTIVE_COMPARATOR|Aciclovir|Patients with a PCR positive for HSV
62349186|NCT02152358|PLACEBO_COMPARATOR|Aciclovir placebo|Patients with a positive PCR for HSV
62705316|NCT05390268|ACTIVE_COMPARATOR|digital tic learner|The control arm including apps released in the first session
62705317|NCT06407687|EXPERIMENTAL|Electric dry needling|Group A will receive Electrical Dry Needling along with conventional physiotherapy. The parameters for Electro dry needling will be needles of 30×0.25 mm, 50×0.25 mm sizes Frequency 80-100 Hz, Duration 10-30 minutes and intensity as tolerated.
61963931|NCT05544916|EXPERIMENTAL|XC221|Patients will take 1 tablet of XC221, tablets, 100 mg twice daily, in the morning (between 7:00 and 11:00 a.m.) and in the evening (between 7:00 and 11:00 p.m.), for 5 days.
61963932|NCT05544916|PLACEBO_COMPARATOR|Placebo|Patients will take 1 placebo pill orally twice a day, in the morning (between 7:00 and 11:00 a.m.) and in the evening (between 7:00 and 11:00 p.m.), for 5 days.
61963933|NCT00292266|EXPERIMENTAL|Rebif®|
62507234|NCT05643716|EXPERIMENTAL|Aerobic Exercise|During this single session, participants will walk on a treadmill at a moderate-vigorous intensity (65-75% age-predicted HRmax) for 20 minutes. While walking on the treadmill, participants will also watch a 20-minute video clip to match the control condition. Exercise intensity will be continuously monitored using a Polar OH1 heart rate monitor, which will be strapped to the participant's chest prior to starting the exercise session. Age-predicted HRmax will be calculated for each participant using the following formula: (HRmax = 220 - Age). Subjective units of distress related to their perceived exercise intensity will be measured in 3-minute intervals. Following the exercise session, participants will rest until their heart rate returns to within 10% of their resting heart rate (approximately 5 minutes) before starting the post-assessments.
62349187|NCT02941289|EXPERIMENTAL|Alzheimer's patient|Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26) according to DSM IV diagnosis criteria
62349188|NCT02941289|ACTIVE_COMPARATOR|Control patient|patient with MMSE score equal or \> 27
62507235|NCT05643716|NO_INTERVENTION|Silent Sitting|Participants will be guided by a research assistant through a single silent sitting session, which will serve as a time-matched control. During the sitting session, participants will watch a 20-minute video clip while sitting silently. Similar to the aerobic exercise group, participants' heart rate will be continuously monitored via a Polar OH1 heart rate monitor. Following the sitting session, participants will rest for 5 minutes to match the exercise group before starting the post-assessments.
62507236|NCT03274037|EXPERIMENTAL|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
62349189|NCT02046954||Study group|Patients monitored with hemodynamically focussed transesophageal echocardiography (placement within 12 hours of ICU admission)
62349190|NCT02046954||Control Group|Patients receiving conventional monitoring (e.g. transpulmonary thermodilution)
62507237|NCT01392326|EXPERIMENTAL|Group 1|Secukinumab (75mg)
62507238|NCT01392326|EXPERIMENTAL|Group 2|Secukinumab (150 mg)
62507239|NCT01392326|PLACEBO_COMPARATOR|Group 3|
62507240|NCT05902468|NO_INTERVENTION|Group 1|44 diabetic patients receiving dual treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin)
62507241|NCT05902468|ACTIVE_COMPARATOR|Group 2|44 diabetic patients who will receive ursodeoxycholic acid 500 mg orally twice daily in addition to dual treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin)
62507242|NCT01071031|EXPERIMENTAL|Group 1|Low Dose HIV-v with water for injection
62507243|NCT01071031|EXPERIMENTAL|Group 2|Low Dose HIV-v with adjuvant
62507244|NCT01071031|EXPERIMENTAL|Group 3|High Dose HIV-v with water for injection
61963934|NCT00292266|ACTIVE_COMPARATOR|Avonex®|
61963935|NCT06472063||upfront D2 gastrectomy (S)|patients submitted to upfront D2 gastrectomy
62507245|NCT01071031|EXPERIMENTAL|Group 4|High Dose HIV-v with adjuvant
62705318|NCT06407687|ACTIVE_COMPARATOR|Dry needling|Group B will receive Dry Needling along with conventional Physiotherapy in which parameters will be dry needles will be 30×0.25 and 50×0.25 mm sizes.
61963936|NCT06472063||pre- or perioperative treatment and D2 gastrectomy (NAC)|patients who underwent pre- or perioperative treatment and D2 gastrectomy
61963937|NCT01190774|EXPERIMENTAL|Dentist behaviour|Patient completes the MDAS which is handed to receptionist who then gives the information to the dentist with patient knowledge
61963938|NCT01190774|EXPERIMENTAL|Dentist behaviour and patient expectancy|Patient completes the MDAS and hands to the dentist
61963939|NCT03009188||Pedigree of the family with ARS|Nine members of the same family with ARS
62349191|NCT05578482|ACTIVE_COMPARATOR|Dicillin & Elocon|20 of the participating patients are randomized to the active arm where systemic dicloxacillin and elocon creme (mometasone furoate 0.1%) is received.
62349192|NCT05578482|PLACEBO_COMPARATOR|Placebo & Elocon|20 of the participating patients are randomized to the placebo arm where placebo and elocon creme (mometasone furoate 0.1%) is received.
62349193|NCT01921634|OTHER|Standard analysis|Standard pathological analysis currently used.
62507246|NCT01071031|PLACEBO_COMPARATOR|Group 5|Control group: adjuvant only or water for injection only
62705319|NCT06193070|EXPERIMENTAL|Supportive Care (escape room game)|Patients play the virtual misinformation escape room game consisting of 5 puzzles and a final task over 30-45 minutes on study.
62705320|NCT04997902|EXPERIMENTAL|PIK3CA-dependent (Cohort 1)|Adult participants with R/M HNSCC whose tumors harbor PI3KCA (activating) mutations and/or amplifications
62705321|NCT04997902|EXPERIMENTAL|HRAS-dependent (Cohort 2)|Adult participants with R/M HNSCC whose tumors have increased HRAS dependency, defined as HRAS overexpression
61963940|NCT01080534|ACTIVE_COMPARATOR|Prograf® Capsule 5 mg|
61963941|NCT01080534|EXPERIMENTAL|Tacrolimus Capsule 5 mg|
61963942|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
61963943|NCT01717261|EXPERIMENTAL|Single Pre-Operative Radiation Therapy|
62349194|NCT01921634|OTHER|Modified Pathologic Analysis|After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.
62349195|NCT02776956|EXPERIMENTAL|atorvastatin group|atrial fibrillation in atorvastatin group will orally receive atorvastatin before and after operation.
62349196|NCT02776956|OTHER|non-atorvastatin group|atrial fibrillation in non-atorvastatin group will not receive atorvastatin before and after operation..
61963944|NCT01299792||one arm; neurogenic bladder dysfunction|evaluation of the clinical utility of bladder wall thickness as a diagnostic tool in patients with spinal cord injury
61963945|NCT01238432||Inpatient population|Children with asthma who are admitted to the hospital with an exacerbation.
62705322|NCT04626635|EXPERIMENTAL|Dose Escalation|Variety of mixed advanced solid tumor types
62705323|NCT04626635|EXPERIMENTAL|Dose Expansion A|Triple Negative Breast Cancer (TNBC)
62705324|NCT04626635|EXPERIMENTAL|Dose Expansion B|Cutaneous Squamous Cell Carcinoma (CSCC)
62705325|NCT04626635|EXPERIMENTAL|Dose Expansion C|Non-Small Cell Lung Cancer (NSCLC)
62705326|NCT04626635|EXPERIMENTAL|Dose Expansion D|Head and Neck Squamous Cell Carcinoma (HNSCC)
62705327|NCT04626635|EXPERIMENTAL|Dose Expansion E|Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases
61963946|NCT01238432||Outpatient population|Children with asthma who have not been admitted to the hospital with an exacerbation.
61963947|NCT01238432||Healthy controls|Children without asthma or any other chronic condition.
61963948|NCT00386945|OTHER|1|Non-Experiment Intervention consisting of an intervention based on the Clinical Practice Guideline: Treating Tobacco Use and Dependence and modified for use in chiropractic settings.
61963949|NCT04580667||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from normal tissues shortly after the start of radiotherapy provides an early indication of patients at high risk of radiation-related toxicity. Blood specimens for RadTox test will be collected: (a) prior to radiotherapy (T0); (b) after the 2nd but before the 4th radiotherapy dose during week 1 (T1); (c) on Week 2 during radiotherapy (T2); and (d) 3 months after completion of radiotherapy (T3).
61963950|NCT00808977|EXPERIMENTAL|Dersalazine|
62349197|NCT00795509||Tolterodine tartrate.|Patients taking Tolterodine tartrate.
62349198|NCT04929613|EXPERIMENTAL|Mindfulness-Based Resilience Training|Designed to train participants in a number of experiential exercises evoking qualities of mindfulness: mental focus, sustained attention and personal and situational awareness. These exercises include versions of the body scan (body awareness exercise), sitting meditation, mindful movement, walking meditation, eating meditation, mindful martial arts exercises and other elements of mindfulness.
62349199|NCT06205394||GROUP 1 (focus group)|Cancer survivors participate in a focus group on study.
62349200|NCT06205394||GROUP 2 (interview)|Breast cancer clinicians undergo a semi-structured interview on study.
62705328|NCT04626635|EXPERIMENTAL|Dose Expansion F|MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases)
62507247|NCT00074750|EXPERIMENTAL|DTGM|Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion, three times /week (M,W,F) for two consecutive weeks. In absence of defined grade 3/4 nonhematological toxicities in the first 0/3 or 1/6 patients, the dose will be escalated by 1 mcg/kg/day for the next patient cohort.
62705329|NCT04626635|EXPERIMENTAL|Dose Expansion G|Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI)
62705330|NCT04626635|EXPERIMENTAL|Dose Expansion H|EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy
62705331|NCT04626635|EXPERIMENTAL|Dose Expansion I|Third-line (3L) MSS-CRC with Active Liver Metastases
62705332|NCT04626635|EXPERIMENTAL|Dose Expansion J|3L MSS-CRC without Active Liver Metastases
62705333|NCT02154035||Group 1|HIV-infected patients on ART with suppressed viral loads, defined as \<40 copies per ml over a period of 10-18 months.
62705334|NCT02154035||Group 2|HIV-infected patients on ART with suppressed viral loads, defined as \<40 copies per ml over a period of 10-18 months.
62705335|NCT02133196|EXPERIMENTAL|1/High-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus high-dose Aldesleukin
62705336|NCT02133196|EXPERIMENTAL|2/Low-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus low-dose Aldesleukin
62705337|NCT06491745|ACTIVE_COMPARATOR|ESWT+PT+corticosteroid injection, ESWT group|ESWT group. Patients in the ESWT group will receive ESWT, physical therapy, and both shoulder joint (glenohumeral joint, GHJ) and SASD bursa injection for 2 times in a 2-week interval. 3ml triamcinolone (1ml triamcinolone= 10mg) will be added to 3ml 1% xylocaine to make 6ml injectate. Among them, 4ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. After withdrawing the needle to subcutaneous layer, another 2ml injectate will be injected into the SASD bursa of the affected shoulder under US guidance.
62705338|NCT06491745|ACTIVE_COMPARATOR|Sham ESWT+PT+corticosteroid injection, SHAM group.|SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.
61963951|NCT00808977|ACTIVE_COMPARATOR|Mesalazine|
61963952|NCT00808977|PLACEBO_COMPARATOR|Placebo|
61963953|NCT01467167||Baseline|Baseline group in which patients are anesthetized without the use of Smart Pilot View, according to common practice.
61963954|NCT01467167||Smart Pilot View Group|Study group in which patients are anesthetized with the use of Smart Pilot View.
61963955|NCT04547569|EXPERIMENTAL|Adaptation to altered auditory feedback|fMRI measurement of brain activity during speech production under altered auditory feedback
61963956|NCT04547569|EXPERIMENTAL|Speech production|fMRI measurement of brain activity during normal speech production
61963957|NCT04547569|EXPERIMENTAL|Vibrotactile discrimination|fMRI measurement of brain activity during a vibrotactile discrimination task
61963958|NCT02761278|ACTIVE_COMPARATOR|HOXA10 and HOXA11 Expression Before Polypectomy|A biopsy will taken in infertility patients with endometrial polyp before polypectomy
62705339|NCT06280820||Participants with heart condition|Heart Failure
62736674|NCT06155006||Adults with risk factors for hepatitis C virus|All persons over 18 years of age who are treated in the included health care institutions (IPS) and who are users of hospitalization, emergency, outpatient, and any other hospital care services.
61963959|NCT02761278|ACTIVE_COMPARATOR|HOXA10 and HOXA11 Expression After Polypectomy|A biopsy will taken in infertility patients with endometrial polyp 1-3 months after polypectomy
61963960|NCT01207869|EXPERIMENTAL|Mesenchymal stem cells|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
61963961|NCT01207869|PLACEBO_COMPARATOR|Control|Normal saline
61963962|NCT00789022||1|40 subjects in a First Psychotic Episode
61963963|NCT00789022||2|20 First Degree relatives
61963964|NCT00789022||3|20 Healthy subjects
61963965|NCT04089384|OTHER|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
62705340|NCT06020508||Group 1|Attending anesthesiologists who are trained in epidural placement will perform neuraxial procedures (CSEs, Epidural, Spinals through an epidural needle) utilizing loss of resistance with saline in conjunction with the Lumoptik BrightPoint Epidural Device. The Lumoptik device will be connected between a standard commercially available 17G or 18G, 3.5-inch epidural needle and a saline filled loss of resistance syringe. The anesthesiologist will view the Lumoptik BrightPoint visual display in real time as the epidural procedures are performed. The LOR epidural procedure using haptic feedback will be used as the primary confirmation of correct needle placement in the epidural space. Graphic and color circle information from the Lumoptik visual display will be used as a secondary confirmation of epidural placement.
62705341|NCT05642195|EXPERIMENTAL|1/ Vaccine with Montanide Adjuvant|H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant without or with N-803 (Phase I component to determine H1299 cell lysate dose)
61963966|NCT04089384|ACTIVE_COMPARATOR|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
61963967|NCT04089384|PLACEBO_COMPARATOR|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment
61963968|NCT05452070|EXPERIMENTAL|HArmonyCa Lidocaine Injectable Gel|Participants will receive HArmonyCa Lidocaine Injectable Gel on Day 1 and followed for up to 25 months. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of HArmonyCa Lidocaine injectable gel during the follow-up duration period.
61963969|NCT05452070|OTHER|Control Group|Participants will be followed for 3 months. Participants can opt to receive HArmonyCa Lidocaine Injectable Gel after 3 months and followed for up to 25 months.
61963970|NCT04813198|ACTIVE_COMPARATOR|TIPSTART|Following baseline testing, the study orientation and randomization, the TIPSTART group will engage in 5.5 hours (30 minutes, on 11 separate occasions, over 10 weeks) of training delivered through Zoom and supported by instructional and communication apps, and that is further supervised by our TIPSTART study navigators who will provide motivational support and detailed lifestyle behavioral prescriptions (150 to 300 minutes per week of aerobic and strength training, with mental practice of material discussed each week). Participants will also be asked to complete approximately 3 total hours of repeated testing that occurs online via surveys and face-to-face interviews for the 12-week study.
61963971|NCT04813198|NO_INTERVENTION|Wait-list Control|Following baseline testing, the study orientation and randomization, the wait-list control group will be asked to continue living life as usual until their delayed TIPSTART program is initiated. Participants will be asked to complete repeated online surveys and face-to-face interviews during the first 12 weeks, concurrently, with participants assigned to the TIPSTART intervention.
61963972|NCT02028065|EXPERIMENTAL|Sugammadex 4 mg/kg|Administration of 3 single IV doses of sugammadex 4 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
62144263|NCT06157645|NO_INTERVENTION|Group A|"1. Good preparation of the patient preoperative~2. Performing an opening in the skin surrounding the stoma 3-4 mm from the muco-cutaneous junctions.~3. Separate the bowel loop away from its attachment to the abdomen wall.~4. Cut out a rim of 0.3-0.4 cm of scarred bowel edges exposes healthful tissue.~5. Avoid any spillage or soiling~6. Closing of bowel defect can be made by double layer of 3-0 vicryl interrupted.~7. Once the tissue is of poor quality for simply closing, we expand the incision in the abdomen wall and resect a section. An end-to-end anastomosis is created using the conventional 2-layers suture method.~8. Reduction of the bowel into the abdomen are carried out.~9. irrigation the surgical field with a dilute anti-biotics or antiseptics and closure of the defect by continuous sutures using vicryl or prolene sutures~10. Closure of the wound"
62349201|NCT02469532||Atherectomy|"Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR\>2.4) post-atherectomy revascularization procedures."
62349202|NCT02469532||Angioplasty|"Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR\>2.4) post-angioplasty revascularization procedures."
62349203|NCT01868776|EXPERIMENTAL|buffered lidocaine|4% lidocaine with 1:100,000 epinephrine/0.18 mEq/mL sodium bicarbonate.
61963973|NCT02028065|EXPERIMENTAL|Sugammadex 16 mg/kg|Administration of 3 single IV doses of sugammadex 16 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
61963974|NCT02028065|PLACEBO_COMPARATOR|Placebo|Administration of 3 single IV doses of placebo, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
61963975|NCT00499577|EXPERIMENTAL|Group 1 (HLA-A2 positive)|Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
61963976|NCT00499577|EXPERIMENTAL|Group 2|Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
61963977|NCT00499577|EXPERIMENTAL|Second group 1|On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
61963978|NCT00499577|EXPERIMENTAL|Second group 2|On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
61963979|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.~Patients will recieve treatment as per standard of care."
61963980|NCT00601458|ACTIVE_COMPARATOR|Arm 1: Pregabalin 300 mg|
61963981|NCT00601458|ACTIVE_COMPARATOR|Arm 2: naproxen sodium 550 mg|
61963982|NCT00601458|PLACEBO_COMPARATOR|Arm 3: Placebo|
61963983|NCT06368544|EXPERIMENTAL|Gait intervention group|On the basis of routine standardized rehabilitation procedures, in Early gait intervention training under the condition of weight loss
61963984|NCT06368544|NO_INTERVENTION|Standardized rehabilitation control group|Only standardized rehabilitation training
61963985|NCT01144286|PLACEBO_COMPARATOR|placebo|placebo pessary, single dose
61963986|NCT01144286|EXPERIMENTAL|Arasertaconazole nitrate 150 mg|Arasertaconazole nitrate 150 mg pessary, single dose
61963987|NCT01144286|EXPERIMENTAL|arasertaconazole nitrate 300 mg|Arasertaconazole nitrate 300 mg pessary, single dose
61963988|NCT01144286|EXPERIMENTAL|arasertaconazole 600 mg|Arasertaconazole nitrate 600 mg pessary, single dose
61963989|NCT02421432|EXPERIMENTAL|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
62507248|NCT06429514|EXPERIMENTAL|Ganoderma lucidum spore powder|Oral administration of Ganoderma lucidum spore powder 4g per day ( 1 bag at a time, 2 times a day, 2g / bag ) for 90 days
61963990|NCT02426437|OTHER|Early Pulmonary Rehabilitation (EPR)|Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
61963991|NCT02426437|OTHER|Late Pulmonary Rehabilitation (LPR)|Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
61963992|NCT02426437|OTHER|Usual Care|Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
62144264|NCT06157645|EXPERIMENTAL|Group B|"1. Good preparation of the patient preoperative~2. Performing an opening in the skin surrounding the stoma 3-4 mm from the muco-cutaneous junctions.~3. Separate the bowel loop away from its attachment to the abdomen wall.~4. Cut out a rim of 0.3-0.4 cm of scarred bowel edges exposes healthful tissue.~5. Avoid any spillage or soiling~6. Closing of bowel defect can be made by double layer of 3-0 vicryl interrupted.~7. Once the tissue is of poor quality for simply closing, we expand the incision in the abdomen wall and resect a section. An end-to-end anastomosis is created using the conventional 2-layers suture method.~8. Reduction of the bowel into the abdomen are carried out.~9. irrigation the surgical field with a dilute anti-biotics or antiseptics and closure of the defect by continuous sutures using vicryl or prolene sutures~10. mesh is simply fixed over the defect as a tension-free patch (onlay)~11. Closure of the wound"
62144265|NCT05123079|EXPERIMENTAL|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fasted (Without Food)|Oral Dose
62144266|NCT05123079|EXPERIMENTAL|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fed (With food)|Oral Dose
62507249|NCT06429514|PLACEBO_COMPARATOR|placebo|Oral ' placebo ' 4g per day ( 1 bag at a time, 2 times a day, 2g / bag ) for 90 days.
62705342|NCT05642195|EXPERIMENTAL|2/ Vaccine with Montanide Adjuvant and N-803|H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant with N-803 (H1299 cell lysate at dose determined in Phase I)
61963993|NCT01747798|EXPERIMENTAL|Treatment (auranofin)|Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61963994|NCT06349031|ACTIVE_COMPARATOR|Polyethylene glycol (PEG) 3350 +Electrolytes ARM|\[PEG 33500+Electrolyte\] will be administered at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as passage of clear liquid stool and no palpable abdominal fecolith
61963995|NCT06349031|EXPERIMENTAL|Polyethylene glycol (PEG) 4000 ARM|PEG 4000 will be administered at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
61963996|NCT00380497|EXPERIMENTAL|Pico-Salax|
61963997|NCT00380497|ACTIVE_COMPARATOR|PEGlyte|
61963998|NCT03803397|EXPERIMENTAL|PV-001-DC alone|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells
61963999|NCT01928017||Hematooncology patients|No intervention
61964000|NCT01007812|OTHER|Lotrafilcon B / Comfilcon A|Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week, followed by Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week.
61964001|NCT01007812|OTHER|Comfilcon A / Lotrafilcon B|Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week, followed by Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week.
61964002|NCT04703335|EXPERIMENTAL|Non-inferiority and Persistence|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution).
61964003|NCT03203304|EXPERIMENTAL|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
62144267|NCT05123079|EXPERIMENTAL|Single Oral Dose of 25 mg administered as 2 x 7.5 and 2 x 5.0 mg tablets, Fasted (Without Food)|Oral Dose
62507250|NCT05305131|EXPERIMENTAL|Induction cisplatin and gemcitabine|Each treatment cycle is 3 weeks. All patients would receive 3 cycles of induction chemotherapy as part of the study, and would then be considered for subsequent concurrent chemoradiotherapy at the investigator's discretion. Cross over is not allowed.
62705343|NCT00450788||Golestan Cohort|Cohort of adults from Golestan region in Iran
62705344|NCT05382299|EXPERIMENTAL|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle.
62507251|NCT05305131|EXPERIMENTAL|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab|Each treatment cycle is 3 weeks. All patients would receive 3 cycles of induction chemotherapy as part of the study, and would then be considered for subsequent concurrent chemoradiotherapy at the investigator's discretion. Cross over is not allowed.
62507252|NCT02147587|EXPERIMENTAL|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
62507253|NCT02147587|PLACEBO_COMPARATOR|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
62507254|NCT05331391|EXPERIMENTAL|Brief mobile SMART Exercise Support Program|Patients will receive a brief SMART Exercise individual session with instant messages and telephone coaching for exercise habit formation and maintenance.
62507255|NCT05331391|PLACEBO_COMPARATOR|General Hygiene Information (GHI)|Patients will receive an individual session, instant messages and telephone coaching regarding general hygiene information.
62507256|NCT00810862|EXPERIMENTAL|Pimecrolimus|Pimecrolimus 1% cream
62507257|NCT00810862|PLACEBO_COMPARATOR|2|Placebo cream over affected study area
62507258|NCT02668042|EXPERIMENTAL|liveness tissue skin|
62507259|NCT01944384|EXPERIMENTAL|aldactone|aldactone 25 mg for 6 months
62507260|NCT01944384|NO_INTERVENTION|without aldactone|
62507261|NCT04233138|EXPERIMENTAL|Intervention|The intervention group will have immediate access to the SUPPORT platform.
62507262|NCT03514186|EXPERIMENTAL|Intensive Comprehensive Aphasia Program|60 hours of comprehensive speech and language therapy applied intensively, 4 hours per day, 5 days a week for three weeks.
62507263|NCT03514186|ACTIVE_COMPARATOR|Distributed Comprehensive Aphasia Tx|60 hours of comprehensive speech and language therapy distributed over 15 weeks (i.e. two 2-hour visits per week).
62507264|NCT03747185|EXPERIMENTAL|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
62507265|NCT03747185|ACTIVE_COMPARATOR|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
62507266|NCT02220595|EXPERIMENTAL|Carotid stenting|Carotid artery stenting for treatment of carotid artery stenosis
62507267|NCT02220595|ACTIVE_COMPARATOR|Carotid endarterectomy|Carotid artery endarterectomy for treatment of carotid artery stenosis
62507268|NCT01676129|EXPERIMENTAL|Nocipoint Therapy|"Nocipoint therapy (NT) follows rules of TENS stimulation in each session, all within the general FDA guidelines of TENS uses. The key points of Nocipoint Therapy include the following:~* The stimulation pads are located at the skin surface location of the nociceptors of the muscle/tissue in pain (i.e., Nocipoint)~* The intensity is set to induce C-fiber response during the stimulation~* The duration of stimulation (about 1.5-4 minutes for each tissue stimulation)~* Stimulations for different tissues (muscles, ligaments) are sequenced such that later stimulations will not cause re-injury of previously treated tissues.~* Patient are instructed not to use the newly recovered muscle/tissue too much for an estimated rest period depending on his/her age."
62507269|NCT01676129|ACTIVE_COMPARATOR|Physical Therapy|"Patients in this group will be treated with comprehensive physical therapy program including typical electrical stimulation using a standard transcutaneous electrical nerve stimulation (TENS) device, manual myofascial release and postural correction exercise.~The application of TENS will follow general physical therapy guidelines, especially for TMD. Manual myofacial release will be applied on orofacial muscles and neck muscles.~TENS will serve both as a part of the standard of care and as placebo, as the same TENS device is used in both arms."
62144268|NCT03528291||Cardiogenic shock treated with medical treatment|Patients with cardiogenic shock treated only by medical treatment
62144269|NCT03528291||Cardiogenic shock treated with transient circulatory support|Patients where transient circulatory support was implanted: veno-arterial extracorporeal circulatory life support (ECLS), Impella
62144270|NCT00336505|ACTIVE_COMPARATOR|Clarithromycin|
62144271|NCT00336505|EXPERIMENTAL|Cethromycin|
62144272|NCT04627896|EXPERIMENTAL|Katty focal therapy|Patients fulfilling inclusion criteria undergo focal treatment with Trinity-guided Katty device
62349204|NCT01868776|ACTIVE_COMPARATOR|nonbuffered lidocaine|4% lidocaine with 1:100,000 epinephrine
62507270|NCT05657106|EXPERIMENTAL|Syringe Service Program Plus a Harm Reduction Kiosk Intervention|The intervention to be implemented in the intervention county involves enhancing its existing SSP model with a KyOSK. The intervention county SSP operates identically to the comparison county. As in the comparison county, a card reader will be installed in the intervention county SSP at the beginning of the study to provide objective data on visits and supply access. The KyOSK will resemble a vending machine. The KyOSK will include harm reduction, wound care, hygiene, and other supplies; offer overdose education and other content; a sharps container with a device to obtain data on syringe disposal; and an innovative call-back feature for care navigation by recovery coaches. While the KyOSK is operating, the intervention county will operate its traditional SSP 40 hours/week.
62507271|NCT05657106|NO_INTERVENTION|Syringe Service Program|The comparison county SSP operates in the local health department and provides syringes, cookers/cottons, naloxone, wound care kits, condoms and lubricant, snacks, drinks, and sharps containers. A peer support specialist is present for consultation with clients upon request during SSP hours. The SSP will expand it hours from 3 hours/week to 40 hours/week at the same time the intervention county receives its KyOSK, to be comparable. SSP clients who enroll in the study will receive a swipe card linked to their SSP client identification. Card readers will be installed in the SSP for clients to swipe upon entry. Staff will provide clients with the same menu of supplies as those in the KyOSK and the same supply/time interval limits will be imposed. SSP clients will receive a resource guide.
62507272|NCT05927142|EXPERIMENTAL|Durvalumab and rintatolimod combination therapy|"1500mg Durvalumab administered via IV infusion once every first day of a 28 day cycle for a total of maximum 12 cycles (12 infusions in total).~200-400mg Rintatolimod administered via IV infusion twice per week for a total of 6 weeks (12 infusions in total)."
62507273|NCT03206567|ACTIVE_COMPARATOR|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
62507274|NCT03206567|PLACEBO_COMPARATOR|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
62705345|NCT05382299|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization from 1 of the 3 allowed regimens:~* Paclitaxel 90 mg/m\^2 on Days 1, 8, and 15 of a 28-day cycle~* Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of a 28-day cycle~* Gemcitabine 1000 mg/m\^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of a 21-day cycle"
62705346|NCT04847063|EXPERIMENTAL|1/ HIPEC: Oxaliplatin Randomized treatment assignment|HIPEC with intraperitoneal oxaliplatin and IV 5-FU, randomly assigned
61964004|NCT03203304|EXPERIMENTAL|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
61964005|NCT02649465|ACTIVE_COMPARATOR|SGLT2 inhibitor|N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
61964006|NCT02649465|ACTIVE_COMPARATOR|Sulfonylurea|N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.
61964007|NCT02039492|EXPERIMENTAL|A|Denervation
62144273|NCT04419779|ACTIVE_COMPARATOR|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with inadequately controlled type 2 diabetes.
62507275|NCT00739973|PLACEBO_COMPARATOR|Placebo|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
62507276|NCT00739973|EXPERIMENTAL|Aliskiren 150 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
62144274|NCT04419779|SHAM_COMPARATOR|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with inadequately controlled type 2 diabetes.
62507277|NCT00739973|EXPERIMENTAL|Aliskiren 300 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
62507278|NCT00739973|EXPERIMENTAL|Amlodipine 5 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
62507279|NCT00739973|EXPERIMENTAL|Amlodipine 10 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
62705347|NCT04847063|EXPERIMENTAL|2/ HIPEC: Mitomycin C Randomized treatment assignment|HIPEC with intraperitoneal mitomycin C, randomly assigned
62705348|NCT04847063|EXPERIMENTAL|3/ HIPEC: Cisplatin, Doxorubicin Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and doxorubicin, in addition to IV sodium thiosulfate, randomly assigned
62705349|NCT04847063|EXPERIMENTAL|4/ HIPEC: Cisplatin, Mitomycin C Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and mitomycin C, in addition to IV sodium thiosulfate, randomly assigned
62705350|NCT04977466||Group #1 / Pregnant Female NIH Participants|Female NIH study participants.
62705351|NCT04977466||Group #2 / Male and Female Partners|Male or female partners of women who participated in NIH intramural clinical trials and that became pregnant.
62705352|NCT04977466||Group #3 / Pregnant Female Partners of Male or Female NIH Clinical Trial Partici|Female partners of NIH intramural clinical trial participants who became pregnant while their partner was or within 1 year after the last day of intervention after their partner was on a study.
62705353|NCT04977466||Group #4 / Neonate or Offspring of a Pregnant Female Participant or Pregnant Fe|Offspring from birth to 12 months of age and born to female participants / female partners.
62705354|NCT01812694|ACTIVE_COMPARATOR|Enhanced Standard Care|Standard prenatal care plus education
62705355|NCT01812694|EXPERIMENTAL|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
62705356|NCT05696717|ACTIVE_COMPARATOR|Ampreloxetine (Open Label)|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 12 weeks.
61964008|NCT02039492|ACTIVE_COMPARATOR|B|Treatment with aldactone
62705357|NCT05696717|PLACEBO_COMPARATOR|Ampreloxetine (Randomized Withdrawal)|After completing the open label, participants are randomized to either ampreloxetine or placebo receiving a single, oral, daily dose of active drug or placebo for a further 8 weeks.
61964009|NCT05447715|OTHER|Fruquintinib sequential BEV+FOLFIRI|
62144275|NCT03340415|NO_INTERVENTION|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
62144276|NCT03340415|EXPERIMENTAL|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
62144277|NCT03905512|EXPERIMENTAL|SEL-212|Intravenous (IV) infusion of SEL-212 every 28 days for up to 6 infusions
62144278|NCT03905512|ACTIVE_COMPARATOR|KRYSTEXXA|IV infusion of KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for up to 12 infusions
62507280|NCT00739973|EXPERIMENTAL|Aliskiren/amlodipine 150/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
62507281|NCT00739973|EXPERIMENTAL|Aliskiren/amlodipine 150/10 mg tablet|150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
62507282|NCT00739973|EXPERIMENTAL|Aliskiren/amlodipine 300/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
62507283|NCT00739973|EXPERIMENTAL|Aliskiren/amlodipine 300/10 mg tablet|300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
62507284|NCT00611325|EXPERIMENTAL|EIAED|Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
62507285|NCT00611325|EXPERIMENTAL|Non-EIAED|Patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 1.7 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
62507286|NCT06222593|EXPERIMENTAL|Bicalutamide in combination with Sunitinib|Bicalutamide 50mg once a day (QD) in combination with sunitinib 37.5mg, 25mg or 50mg QD (2 weeks ON, 1 week OFF). Four or more 21 day-long cycles.
62507287|NCT04813562|EXPERIMENTAL|Middle-dose vaccine (18-59 years)|Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
62507288|NCT04813562|EXPERIMENTAL|High-dose vaccine (18-59 years)|Two doses of High-dose vaccine at the schedule of day 0, 28, 56
62507289|NCT04813562|EXPERIMENTAL|Middle-dose vaccine (60-85 years)|Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
62507290|NCT04813562|EXPERIMENTAL|High-dose vaccine (60-85 years)|Two doses of High-dose experimental vaccine at the schedule of day 0, 28, 56
62507291|NCT04813562|PLACEBO_COMPARATOR|Middle-dose placebo (18-59 years)|Three doses of middle-dose placebo at the schedule of day 0, 28, 56
62507292|NCT04813562|PLACEBO_COMPARATOR|High-dose placebo (18-59 years)|Two doses of High-dose placebo at the schedule of day 0, 28, 56
62507293|NCT04813562|PLACEBO_COMPARATOR|Middle-dose placebo (60-85 years)|Three doses of middle-dose placebo at the schedule of day 0, 28, 56
62507294|NCT04813562|PLACEBO_COMPARATOR|High-dose placebo (60-85 years)|Two doses of High-dose placebo at the schedule of day 0, 28, 56
62507295|NCT06613061|EXPERIMENTAL|Experimental (breathing exercise)|"The researcher has a breathing exercise certificate. In our study, the breathing exercise application consists of three stages: box breathing, sigh breathing and diaphragm breathing.~Patients will be asked to continue the breathing exercise application for 2 weeks and will be reminded to do the breathing exercises. Box and sigh breathing will be done 3 times a day (morning, noon and evening) every day for 2 weeks. Diaphragm breathing exercise will be applied for 2 minutes in the first week and 4 minutes in the second week."
62507296|NCT06613061|NO_INTERVENTION|Control|The control group will receive standard care. No intervention will be applied to these patients during the follow-up period, only data collection forms will be applied. Data collection forms will be collected in the same time period as the intervention group.
62705358|NCT05696717|ACTIVE_COMPARATOR|Long-Term Extension Period|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 104 weeks.
62144279|NCT05460910|EXPERIMENTAL|core stability exercise, treadmill|core stability exercises and treadmill training
62144280|NCT05460910|EXPERIMENTAL|core stability exercises|core stability exercises without treadmill training
62507297|NCT00136760|EXPERIMENTAL|1|Contingent reinforcement plus bupropion
62507298|NCT00136760|EXPERIMENTAL|2|Contingent reinforcement plus placebo
62507299|NCT00136760|EXPERIMENTAL|3|Non-contingent reinforcement plus bupropion
62507300|NCT00136760|PLACEBO_COMPARATOR|4|Non-contingent reinforcement plus placebo
62507301|NCT05942976||group 1: axial spondyloarthritis|SpA patients identified according to the Assessment of Spondyloarthritis classification criteria
62507302|NCT05942976||group 2: Rheumatoid arthritis|RA patients identified according to the 2010 American College of Rheumatology/Europan Leage Against Rheumatism classification criteria
62507303|NCT05942976||group:3 Healthy Control|healthy controls with no history of rheumatic diseases
62705359|NCT06507748|OTHER|1/Feasibility and longitudinal assessments|Evaluation with the AlgometRx device and patient- and observer-reported outcome measures
61964010|NCT05447715|OTHER|BEV+FOLFIRI sequential fruquintinib|
62144281|NCT00427440|EXPERIMENTAL|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
62144282|NCT00427440|EXPERIMENTAL|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
62144283|NCT02956109|ACTIVE_COMPARATOR|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 10 mg finerenone tablet fasting
62144284|NCT02956109|EXPERIMENTAL|Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting|Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting
62705360|NCT06469944|ACTIVE_COMPARATOR|Pembrolizumab plus Chemotherapy|Participants will receive pembrolizumab 400 mg via intravenous (IV) injection on day 1 of every 6 week cycle for up to 18 cycles (up to \~2 years) AND investigator's choice of CAPOX chemotherapy (capecitabine 1000 mg/m\^2 orally twice daily for 14 days every 3 weeks (Q3W) and oxaliplatin 130 mg/m\^2 via IV infusion Q3W) OR mFOLFOX6 chemotherapy (oxaliplatin 85 mg/m\^2 via IV infusion Q3W; 5-FU 400 mg/\^2 via bolus IV plus 2400 mg/m\^2 continuous IV once every 2 weeks (Q2W); and leucovorin 400 mg/m\^2 via IV infusion Q2W OR levoleucovorin 200 mg/m\^2 Q2W).
62705361|NCT06469944|EXPERIMENTAL|Pembrolizumab plus Sacituzumab Tirumotecan plus Chemotherapy|Participants will receive sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 of each 6 week cycle until discontinuation, pembrolizumab 400 mg via IV injection on day 1 of every 6 week cycle for up to 18 cycles (up to \~2 years) AND investigator's choice of capecitabine 1000 mg/m\^2 orally twice daily for 14 days Q3W OR 5-FU 400 mg/\^2 via bolus IV plus 2400 mg/m\^2 continuous IV once Q2W.
62705362|NCT05333458|EXPERIMENTAL|Arm I (atezolizumab, selienexor)|Patients receive atezolizumab IV over 30-60 minutes on day 8 of cycle 1, and then on day 1 of subsequent cycles. Patients also receive selinexor PO QW on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy at baseline, cycle 1 day 8 and cycle 3 day 1, CT and MRI at baseline, end of cycle 2, and every 2 cycles thereafter, and collection of blood samples throughout the study.
62705363|NCT05333458|EXPERIMENTAL|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I. Patients also undergo biopsy at baseline and cycle 3 day 1, CT and MRI at baseline, end of cycle 2, and every 2 cycles thereafter, and collection of blood samples throughout the study.
62705364|NCT01568658||Affected probands|Affected probands over age 4 weeks and onwards with known or suspected inherited neurological disorders of childhood onset
62705365|NCT01568658||Healthy volunteers|Healthy volunteers will be recruited for the imaging procedures in order to establish baseline and age-range matched data on the healthy, maturing muscle, spinal cord volume and dynamic breathing
62705366|NCT01568658||Single patient on Idebenone|Single patient on IND expanded access of Idebenone
62705367|NCT01568658||Unaffected family members|Families of affected probands with known or suspected inherited neurological disorders of childhood onset
62705368|NCT05601544|EXPERIMENTAL|Sphere TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence.
62705369|NCT05601544|EXPERIMENTAL|Sphere CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence.
62705370|NCT05601544|EXPERIMENTAL|Multifocal TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence.
62705371|NCT05601544|EXPERIMENTAL|Multifocal CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence.
62705372|NCT05601544|EXPERIMENTAL|Toric TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence.
62705373|NCT05601544|EXPERIMENTAL|Toric CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence.
62705374|NCT04577755|EXPERIMENTAL|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with CR or PR continue pomalidomide for an additional 12 cycles with the option to continue thereafter in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray imaging throughout the trial. Patients may undergo CT as clinically indicated. Patients also undergo blood sample collection and may optionally undergo tissue biopsy during screening and on the trial.
61964011|NCT04258384||Patient|The study included individuals whose native language is Turkish, who are literate, over the age of 18, diagnosed with rheumatoid arthritis, without cognitive impairment and communication problems, and who want to participate in the study.
62349205|NCT02293902|EXPERIMENTAL|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either tender joint count \[TJC\] or swollen joint count \[SJC\], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
62349206|NCT02293902|EXPERIMENTAL|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
61964012|NCT05517044|EXPERIMENTAL|Preacclimatization group|The participants assigned to the preacclimatization group will undergo a defined preacclimatization program by sleeping in a nitrogen concentration tent prior to an expedition to high altitude.
62144285|NCT02956109|EXPERIMENTAL|Pediatric formulation: 1.25 mg Finerenone ODT_Fasting|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting
61964013|NCT05517044|NO_INTERVENTION|Control group|The participants assigned to the control group sleep in their regular environment without use of a nitrogen concentration tent prior to an expedition to a high altitude expedition.
61964014|NCT04073589|EXPERIMENTAL|Treatment A|Single SC injection of Dose A
61964015|NCT04073589|EXPERIMENTAL|Treatment B|Single SC injection of Dose B
61964016|NCT04073589|EXPERIMENTAL|Treatment C|Single SC injection of Dose C
62144286|NCT02956109|EXPERIMENTAL|Pediatric formulation: 1.25 mg Finerenone ODT_Fed|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast
62507304|NCT04475276|PLACEBO_COMPARATOR|Placebo|Life style modification with the placebo will be given for 12 weeks
62507305|NCT04475276|EXPERIMENTAL|Alphalipoic acid|Life style modification with Alpha lipoic acid in a dose of 600mg twice daily will be prescribed orally for 12 weeks
62507306|NCT03643926|EXPERIMENTAL|Arthroscopic Brostrom|
62507307|NCT03643926|ACTIVE_COMPARATOR|Open Brostrom|
62507308|NCT05042440|EXPERIMENTAL|efanesoctocog alfa (BIVV001)|Each participant will be sequentially dosed with three single intravenous (IV) doses of first rFVIII (Advate®), second Polyethylene Glycol (PEG)-rFVIII (Adynovi® or Adynovate®), and lastly, BIVV001
62507309|NCT02136238|ACTIVE_COMPARATOR|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
62507310|NCT02136238|ACTIVE_COMPARATOR|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
62507311|NCT02136238|NO_INTERVENTION|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
62507312|NCT04679142||Adult patients starting a treatment with Baclocur®|Baclofen(Baclocur®) 10mg, 20mg, 30mg, 40mg.
62507313|NCT00862537||Active Resonator magnetic field therapy|Administration of active magnetic fields with the Resonator Device
62507314|NCT00521482|ACTIVE_COMPARATOR|A|Temozolomide 75 mg/m2 daily for 21 days during each 28-day cycle until tumor progression.
62507315|NCT00521482|EXPERIMENTAL|B|Temozolomide 200 mg/m2 for 5 days during each 28-day cycle plus Thalidomide 100 mg for 2 weeks, thereafter 200 mg daily continuously until tumor progression.
62507316|NCT00193973|ACTIVE_COMPARATOR|1|
62507317|NCT03700827|EXPERIMENTAL|Resistance Training Group|Resistance training will consist of 3 whole body circuits per week for 3 weeks lasting approximately 1 hour per session. All major muscle groups will be involved (leg press, bent-over-row, bench press, back squat, dumbbell jump squats, dead-lifts, and weighted abdominal crunches). Each participant will go through each circuit three times with 30 seconds between each exercise and 2 minutes between each set.
62507318|NCT03700827|EXPERIMENTAL|Aerobic Training Group|Aerobic interval training will consist of 3 sessions/week for 3 weeks for approximately 45-50 minutes per session depending on exercise energy expenditure. There will be two periods of intervals. The first period will be 3 minutes of high-intensity activity and the second period will be reduced to moderate-intensity for 2 minutes. The speed/incline will change depending on the participants perception or Borg's rating of perceived exertion. Intensity will be measured using Lactate levels after each session.
62507319|NCT03700827|NO_INTERVENTION|Control Group|The control group must attend sessions but will not exercise.
62705375|NCT04241835|EXPERIMENTAL|Open label Tazemetostat|"Part 1:~Participants will receive a single oral 800 mg dose on day 1, and twice daily from day 5 to day 14. Participants will return to the clinical study unit on an out-patient basis from day 15 to day 18. A single oral 800 mg dose of tazemetostat will be administered on day 15.~Part 2:~Will begin on day 19 and participants continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles."
62144287|NCT03497052||Group 1|Oocytes and embryos will be cultured in GEMS single step medium (in vitro culture in medium 1)
62507320|NCT05507034||Breast cancer|Breast cancer patients following over time during cancer treatment
62507321|NCT03261024|ACTIVE_COMPARATOR|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
62507322|NCT03261024|ACTIVE_COMPARATOR|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
62507323|NCT03739216||Open label|Open label registry study of patients treated with the ClariFix device for chronic rhinitis.
62507324|NCT04030013|ACTIVE_COMPARATOR|Group education for 2 years|Patients who will receive structured diabetes education in groups , Group 1
62507325|NCT04030013|ACTIVE_COMPARATOR|One to one education for 2 years|Patients who will receive one to one structured diabetes education, Group 2
62507326|NCT04030013|NO_INTERVENTION|Control group without structured education|Patients who will not receive structured diabetes education, Group 3
62507327|NCT00440609|ACTIVE_COMPARATOR|0.5mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
62507328|NCT00440609|ACTIVE_COMPARATOR|1.0 mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
62507329|NCT05247333|EXPERIMENTAL|Patients presenting with minor ailments or requesting a non-prescription product.|"Community pharmacists working with agreed protocols with primary care physicians respond to all type of patients presenting with minor ailments or requesting a non-prescription product.~Following this consultation, patients are followed up after ten days."
61964017|NCT04073589|EXPERIMENTAL|Treatment D|Single SC injection of Dose D
62144288|NCT03497052||Group 2|Oocytes and embryos will be cultured in IRVINE single step medium (in vitro culture in medium 2)
62144289|NCT06698328|ACTIVE_COMPARATOR|Active Vagus Nerve Stimulation|This active vagus nerve stimulation uses electrodes on the ear to be administered twice daily, seven days per week, for four weeks at-home.
62507330|NCT00476593|EXPERIMENTAL|Diclofenac|Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
62507331|NCT00476593|EXPERIMENTAL|Dexamethasone|Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
62507332|NCT06462131|EXPERIMENTAL|CaGCBT with TAU|In this group, CaGCBT-SUD along with TAU will be provided.
62507333|NCT06462131|ACTIVE_COMPARATOR|CBTAG with TAU and with caregivers|In this group, CaGCBT-SUD along with TAU will be provided. Moreover caregivers will be provided psychoeducation
61964018|NCT04922437||Enterocystoplasty (EC)|Patients who had an implantation of the catheterizable continent channel by seromuscular plicature on the anterior wall of the bladder augmentation.
62507334|NCT06462131|NO_INTERVENTION|No intervention only TAU|Treatment as usual
62507335|NCT01709812|OTHER|1 standard care|standard care
62507336|NCT01709812|EXPERIMENTAL|2 individualized PSP|individualized patient support program
62507337|NCT04783194|ACTIVE_COMPARATOR|Dexamethasone + bupivacaine in bilateral TiPVB in lumbar spine surgery|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
62507338|NCT04783194|ACTIVE_COMPARATOR|Bupivacaine in bilateral TiPVB in lumbar spine surgery|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
62507339|NCT01575262|EXPERIMENTAL|Incentive|Participants use their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of physical activity = 1 point; capped at 30 points per day) over the 12-week intervention period. Points are redeemed for rewards (extrinsic motivation) at week 6 and week 12.
62705376|NCT04813055||Therapeutic EUS|Procedures involving Linear Echoendoscopes to create a communication between the gastrointestinal tract and a target organ (biliary tree, pancreatic duct, fluid collection, gallbladder, downstream gastrointestinal tract) through plastic or metal stents.
61964019|NCT04922437||Detrusor (D)|Patients who had an implantation of the catheterizable continent channel in the detruosr of their native bladder (Lich-Gregoir or Cohen).
61964020|NCT01932112|OTHER|adenosine arm|single arm study
61964021|NCT01512277|EXPERIMENTAL|3 administrations of 100 µg of rSh28GST|Adult volunteers (n=8) receive 100μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0, D28, and D150.
61964022|NCT01512277|EXPERIMENTAL|2 administrations of 300 µg of rSh28GST|Adult volunteers (n=8) receive 300μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0 and D28.
62144290|NCT06698328|SHAM_COMPARATOR|Sham Stimulation|This sham nerve stimulation uses electrodes on the ear to be administered twice daily, seven days per week, for four weeks at-home.
62507340|NCT01575262|ACTIVE_COMPARATOR|No Incentive|Participants used their PAL card to self-monitor their physical activity levels (intrinsic motivation) over the 12-week intervention period but do not collect points or earn rewards.
62507341|NCT06600750||Patients who underwent radiocephalic arteriovenous fistula due to advanced chronic kidney disease|Patients who underwent radiocephalic arteriovenous fistula due to advanced chronic kidney disease
62507342|NCT06167473|EXPERIMENTAL|low-dose stem cell group (1×10^6cells/kg per infusion)|Peripheral intravenous infusion of low-dose stem cells
62705377|NCT04813055||Controls|Patients eligible for T-EUS procedures, but undergoing alternative surgical interventions, percutaneous interventions (e.g. Percutaneous Biliary Drainage) or non-EUS based endoscopic procedures (e.g. enteral stenting)
62705378|NCT03994796|EXPERIMENTAL|Arm I (CDK gene mutation)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61964023|NCT01512277|PLACEBO_COMPARATOR|Placebo|Adult volunteers (n=8) receive aluminium hydroxide (Alum) alone at D0 and D28.
61964024|NCT03529851|EXPERIMENTAL|PRO intervention|Patients included will weekly fill in a 12 item questionaire via the internet during the 3 week study period.
61964025|NCT02879305|EXPERIMENTAL|Daprodustat|Participants will receive oral daprodustat once daily.
61964026|NCT02879305|ACTIVE_COMPARATOR|rhEPO|Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).
61964027|NCT03848117|ACTIVE_COMPARATOR|(DTF massage & Mill's manipulation)(Group 1)|For any given subject in group 1, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in 1st group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
62507343|NCT06167473|EXPERIMENTAL|medium-high-dose stem cell group (3×10^6cells/kg per infusion)|Peripheral intravenous infusion of medium-high-dose stem cells
62507344|NCT05992987||CSU group|Adult patients complaining of chronic spontaneous urticaria (CSU)
62507345|NCT05992987||Control group|A group of age and sex-matched healthy controls (blood donors).
61964028|NCT03848117|ACTIVE_COMPARATOR|( Taping & MWM) (Group 2).|For any given subject in group 2, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
61964029|NCT03706105|EXPERIMENTAL|Intervention - Cardiac Rehabilitation|
62507346|NCT01102452|PLACEBO_COMPARATOR|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
62507347|NCT01102452|EXPERIMENTAL|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
61964030|NCT01611649|EXPERIMENTAL|Dairy lipids and plant oils|
61964031|NCT01611649|EXPERIMENTAL|Plant oils|
61964032|NCT01611649|EXPERIMENTAL|Dairy lipids and plant oils, DHA+ARA|DHA: docosahexaenoic acid, ARA: arachidonic acid
61964033|NCT01611649|NO_INTERVENTION|Human milk|
61964034|NCT04007081|EXPERIMENTAL|Participants with Xerostomia|Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration
61964035|NCT02536196|EXPERIMENTAL|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
62144291|NCT02161458|EXPERIMENTAL|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
62507348|NCT04686994|EXPERIMENTAL|ASC41|ASC41 two tablets, once daily, from Day 1 to Day 28.
62507349|NCT04686994|PLACEBO_COMPARATOR|ASC41 placebo|ASC41 placebo two tablets, once daily, from Day 1 to Day 28.
62507350|NCT01453153|ACTIVE_COMPARATOR|Gemcitabine|Gemcitabine + Placebo
62507351|NCT01453153|EXPERIMENTAL|PEGPH20|PEGPH20+Gemcitabine
62507352|NCT00672776|EXPERIMENTAL|1|paroxetine
62507353|NCT00672776|PLACEBO_COMPARATOR|2|placebo
61964036|NCT02536196|ACTIVE_COMPARATOR|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
61964037|NCT04101461|ACTIVE_COMPARATOR|Group I: 27 mg elemental iron|will receive PharaFerro27; Devart Lab Company, Egypt; once daily starting at 12 -14 weeks until 37-38 weeks
61964038|NCT04101461|ACTIVE_COMPARATOR|Group II: 54 mg elemental iron|will receive two tablets of PharaFerro27; Devart Lab Company, Egypt; daily starting at 12 -14 weeks until 37-38 weeks
61964039|NCT00965042|EXPERIMENTAL|Ceftobiprole|Ceftobiprole 500 mg by 2 hour intravenous infusion every 8 hours for 7 days
62144292|NCT02161458|PLACEBO_COMPARATOR|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
61964040|NCT05868200|EXPERIMENTAL|Capitano zenzero toothpaste|Participants will be given the test interventions, Capitano zenzero toothpaste, and will be asked to brushing teeth with this product for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing.
61964041|NCT05868200|ACTIVE_COMPARATOR|Colgate total toothpaste|Participants will be given the test interventions, Colgate total toothpaste, and will be asked to brushing teeth with this product for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing.
62144293|NCT02161458|EXPERIMENTAL|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
62507354|NCT01332721|EXPERIMENTAL|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
62507355|NCT04880226|OTHER|Healthy Volunteers|Imaging of healthy volunteers would performed to optimize image parameters (contrast, SNR) prior to clinical imaging of actual patients receiving treatment.
62507356|NCT04880226|EXPERIMENTAL|Patients receiving MRI-guided procedures|As described in the study protocol this imaging would be performed to evaluate a given sequence for potential benefit during MR-guided interventions.
62507357|NCT05371639|EXPERIMENTAL|Tian Ma Bian Chun Zhi Gan group|Tian Ma Bian Chun Zhi Gan tablets
62507358|NCT05371639|PLACEBO_COMPARATOR|Placebo group|placebo identified to Tian Ma Bian Chun Zhi Gan tablets
62507359|NCT04046549|EXPERIMENTAL|Belatacept+VIB4920|Participants will be admitted to the transplant center for the administration of VIB4920 and belatacept (with Thymoglobulin and corticosteroids) and will be discharged on Day 3/4 at the discretion of the investigator. Participants will return to the study center to receive study drugs (VIB4920 and /or belatacept) weekly for 2 visits, then every 2 weeks for 5 visits, and then monthly for 9 visits for safety monitoring.
62705379|NCT03994796|EXPERIMENTAL|Arm II (PI3K gene mutation)|Patients receive PI3K inhibitor paxalisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62705380|NCT03994796|EXPERIMENTAL|Arm III (NTRK/ROS1 gene mutation)|Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61964042|NCT04932278|ACTIVE_COMPARATOR|Usual Care Group|Participants in this group will receive routine care for the management and treatment of concussions
61964043|NCT04932278|EXPERIMENTAL|OMT Group|Participants who are randomized into the OMT group will receive OMT in addition to their usual care.
61964044|NCT00706823|EXPERIMENTAL|i-gel-SGA|Patients who received i-gel supraglottic device (i-gel airway) for intubation
61964045|NCT00706823|ACTIVE_COMPARATOR|LMA-Unique|Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation
61964046|NCT06177587||Assesment of platelet biomarkers in acute coronary syndromes - low level of parameters|Blood is collected within the first 24 hours from hospital admission and after 72 hours following hospital admission. The level of selected biomarkers is measured.
61964047|NCT06177587||Assesment of platelet biomarkers in acute coronary syndromes - high level of parameters|Blood is collected within the first 24 hours from hospital admission and after 72 hours following hospital admission. The level of selected biomarkers is measured.
61964048|NCT04418453||Integration of telemedicine in primary care settings for MOUD|Primary care providers may refer OUD patients to receive telemedicine for MOUD
61964049|NCT04847362|EXPERIMENTAL|Experimental|The mothers in this group will be given telehealth training for 4 weeks.
61964050|NCT04847362|NO_INTERVENTION|Control|Mothers in this group will not be given telehealth education, they will receive care within the scope of routine care.
62705381|NCT03994796|EXPERIMENTAL|Arm IV (KRAS G12C mutation)|Patients receive adagrasib (MRTX849) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61964051|NCT02487602|ACTIVE_COMPARATOR|A|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
61964052|NCT02487602|ACTIVE_COMPARATOR|B|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
61964053|NCT02487602|PLACEBO_COMPARATOR|C|Placebo capsules 30 minutes before a standard radiolabeled lunch.
61964054|NCT02487602|EXPERIMENTAL|D|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a radiolabeled water.
62144294|NCT02161458|EXPERIMENTAL|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
62144295|NCT02167451|EXPERIMENTAL|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
62144296|NCT03067857|EXPERIMENTAL|Stem Cells|Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
62144297|NCT06061900|EXPERIMENTAL|Participants who receive group exercise intervention|Intervention will include a warm-up, restive exercises with dumbbells, interval training, game or dancing, and cool down. Intervention sessions will run for 30-45 minutes, 2-3 times a week, for 8 weeks. Participants will also participate in pre and post-testing.
62144298|NCT06061900|NO_INTERVENTION|Participants who do not receive group exercise intervention|Participants will participate in pre and post-testing.
62144299|NCT02108171|ACTIVE_COMPARATOR|dexmedetomidine|intranasal dexmedetomidine
62349207|NCT02293902|PLACEBO_COMPARATOR|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
62349208|NCT02293902|PLACEBO_COMPARATOR|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
62349209|NCT00570531|EXPERIMENTAL|Bevacizumab|
62349210|NCT03935607||Normal amniotic fluid index|Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.
62705382|NCT02523014|EXPERIMENTAL|Arm A (vismodegib)|Patients receive vismodegib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018)
62349211|NCT03935607||Oligohydramnios|Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.
62705383|NCT02523014|EXPERIMENTAL|Arm B (FAK inhibitor GSK2256098)|Patients receive FAK inhibitor GSK2256098 PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017)
62705384|NCT02523014|EXPERIMENTAL|Arm C (capivasertib)|Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity.
61964055|NCT02487602|EXPERIMENTAL|E|Up to 5 Gelesis100 and/or placebo capsules 10 minutes before a radiolabeled meal.
61964056|NCT03416530|EXPERIMENTAL|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
61964057|NCT03416530|EXPERIMENTAL|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
61964058|NCT03416530|EXPERIMENTAL|Midline Glioma Biopsy|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.
61964059|NCT03416530|EXPERIMENTAL|H3 K27M CSF Biopsy|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory), have completed at least one line of prior therapy, must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF), and must be scheduled to undergo sedated MRIs.
61964060|NCT03416530|EXPERIMENTAL|Liquid ONC201 in relapsed/refractory H3 K27M glioma|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
61964061|NCT03416530|EXPERIMENTAL|Dose Expansion Cohort in relapsed/refractory H3 K27M glioma|Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
62349212|NCT01274455|EXPERIMENTAL|Therapy|
62349213|NCT03442348|EXPERIMENTAL|Omega 3 fatty acid supplements|Participants in this arm (N\>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
62507360|NCT06318871|EXPERIMENTAL|Dose Level 0: CIML NK + low dose IL-2|"Participants will be enrolled in a staggered fashion into a 3+3 dose de-escalation design per protocol to establish a maximum tolerated dose (MTD) of CIML NK Cells. Dose will start at Dose Level 0.~* Baseline visit.~* Day -7: Apheresis for autologous NK cell collection.~* Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol.~* Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital.~* Days 1 through 8: Low dose IL-2 every other day~* Day 28 and then ever 2-3 months: CT/MRI/PET~* In-clinic visit every 3 months with CT, MRI, or PET scan.~* End of Treatment: in-clinic visit~* Follow Up: every 4 months in-clinic, by telephone, or remotely.~* If 2 or more out of 5 participants experience dose-limiting toxicities (DLTs), subsequent dose will be de-escalated to Dose Level -1."
62705385|NCT02523014|EXPERIMENTAL|Arm D (abemaciclib)|Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62705386|NCT06575296|EXPERIMENTAL|Treatment (revumenib)|Starting 50-150 days after alloHCT, patients receive revumenib PO QD or every 12 hours on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo bone marrow biopsy during screening and may undergo ECHO during screening and as clinically indicated. Patients also undergo bone marrow aspiration and collection of blood samples throughout the trial.
62705387|NCT01264055||1|Adults with idiopathic bronchiectasis
62144300|NCT02108171|PLACEBO_COMPARATOR|placebo|intranasal saline
62349214|NCT03442348|ACTIVE_COMPARATOR|Inulin fibre|The participants in the control arm (N\>32) will be asked to take 20 g of fibre (inulin fibre) per day for a period of 6 weeks.
62705388|NCT06454461|EXPERIMENTAL|A|upadacitinib after autologous non-cultured epidermal cell suspension transplantation
62705389|NCT06454461|NO_INTERVENTION|B|autologous non-cultured epidermal cell suspension transplantation
62705390|NCT06075667|EXPERIMENTAL|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC).
62705391|NCT06075667|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62349215|NCT03224481|EXPERIMENTAL|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
62705392|NCT04628767|EXPERIMENTAL|Arm A (durvalumab, chemotherapy)|Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.
62705393|NCT04628767|ACTIVE_COMPARATOR|Arm B (chemotherapy)|Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.
62705394|NCT04628767|EXPERIMENTAL|Arm C (durvalumab, gemcitabine hydrochloride)|Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.
62705395|NCT06534008|EXPERIMENTAL|12-week Exercise Intervention|In this single-arm study, every participant will be enrolled in the 12-week distance-based exercise intervention. All participants will receive an exercise regimen and the necessary materials to complete and measure their exercise. All participants will receive weekly online heath coaching.
62705396|NCT05440786|EXPERIMENTAL|Abemaciclib + Irinotecan +Temozolomide|Abemaciclib given orally in combination with irinotecan given IV and temozolomide given orally.
62705397|NCT05440786|EXPERIMENTAL|Irinotecan +Temozolomide|Irinotecan given IV and temozolomide orally.
62705398|NCT06172296|ACTIVE_COMPARATOR|Arm A (SOC treatment)|See detailed description
62705399|NCT06172296|EXPERIMENTAL|Arm B (Dinutuximab in induction)|See detailed description
62705400|NCT06498596||Control|Healthy volunteer
62705401|NCT06498596||Patient|cerebral palsy (CP)
62705402|NCT05044845||Hemophilia B patients|Patients ≥12 years of age with a diagnosis of moderate (FIX ≥1% and ≤2%) or severe (\<1%) hemophilia B
62705403|NCT05044845||Parents or Caregivers|Parents or caregivers to patients with hemophilia 12-17 years of age
62144301|NCT03176056|EXPERIMENTAL|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate \<=90g/day
62144302|NCT03176056|ACTIVE_COMPARATOR|Calori restricted diet|Traditional diabetic diet
62144303|NCT01263132|EXPERIMENTAL|F0434|
62705404|NCT05044845||Healthcare Workers|Doctors, nurses, social workers, pharmacists and educators who participate in the care of hemophilia B patients
62144304|NCT01263132|ACTIVE_COMPARATOR|Gabapentin|
62144305|NCT02444845||Study Population|Hypertensive and diabetic patients who meet eligibility criteria will be enrolled and evaluated for the presence of anemia secondary to CKD. The first visit will capture medical history including risk factors for CKD; laboratory assessments will be performed at the second and third visits to evaluate glomerular filtration rate (eGFR) and anemia profile, respectively. Participants who are not diagnosted with CKD based upon the second visit will not return for the third visit.
62507361|NCT06318871|EXPERIMENTAL|Dose Level -1: CIML NK + low dose IL-2|"Participants will complete:~* Baseline visit.~* Day -7: Apheresis for autologous NK cell collection.~* Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol.~* Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital.~* Days 1 to 8: low dose IL-2 every other day~* Day 28 and then ever 2-3 months: CT/MRI/PET~* In-clinic visit every 3 months with CT, MRI, or PET scan.~* End of Treatment: in-clinic visit~* Follow Up: every 4 months in-clinic, by phone, or remotely.~* If 1 or less DLTs are observed, this will be the maximum tolerated dose. If 2 or more DLTs are observed, accrual will stop."
62507362|NCT06490887||Degenerative Disc Disease patients undergoing spine surgery|Collection of blood. Collection of nucleous pulposus, annulus fibrosus and cartilaginous endplate biopsies that would be considered as waste material after surgery.
62507363|NCT06490887||Subjects undergoing plastic surgery|Collection of adipose tissue that would be considered as waste material after surgery.
62507364|NCT06490887||Pregnant female subjects|Collection of amnion of human term placenta (38-40 weeks of gestation) within 6 hours of birth.
62507365|NCT03756883|EXPERIMENTAL|Test|Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg
62507366|NCT03756883|ACTIVE_COMPARATOR|Reference|ADVAIR DISKUS® 100/50 (fluticasone propionate and salmeterol) Inhalation Powder
62507367|NCT03756883|PLACEBO_COMPARATOR|Placebo|Placebo
62507368|NCT03684681|OTHER|Peer Navigator|Current standard of care
62507369|NCT03684681|OTHER|Social Worker|Current standard of care
62507370|NCT05922631|EXPERIMENTAL|APRV group|In APRV group, ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
62507371|NCT05922631|PLACEBO_COMPARATOR|LTV group|The ARDSnet method was used for LTV group mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
62705405|NCT06003985||Control|The control group will be comprised of patients who are not currently taking any GLP-1 agonist medications. Controls will receive the ultrasound exam to assess stomach contents.
62705406|NCT06003985||GLP-1 agonist intake|The GLP-1 agonist intake group will be comprised of patients who are currently taking any GLP-1 agonist medications. This group will receive the ultrasound exam to assess stomach contents.
61964062|NCT03416530|EXPERIMENTAL|ONC201 given on two consecutive days of each week|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.
61964063|NCT02435784|ACTIVE_COMPARATOR|2-COM group|Patients will use the Two-Way Communication Checklist (2-COM) once in a psychiatric consultation.
61964064|NCT02435784|PLACEBO_COMPARATOR|TAU group|Treatment as usual (TAU) group.
61964065|NCT01888679|EXPERIMENTAL|head movement|head movement in extension, flexion, right and left rotation
62144306|NCT06124170||Total knee arthroplasty (TKA)|Total knee arthroplasty
62507372|NCT00412204|ACTIVE_COMPARATOR|1|Tiotropium
61964066|NCT01217814|PLACEBO_COMPARATOR|Placebo|Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
62507373|NCT00412204|PLACEBO_COMPARATOR|2|Placebo
62705407|NCT05974644||Asymptomatic carriers|
62705408|NCT05974644||Patients with cardiac hereditary transthyretin amyloidosis (hATTR)|
61964067|NCT01217814|ACTIVE_COMPARATOR|Golimumab 50 mg|Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
61964068|NCT01217814|EXPERIMENTAL|Sarilumab 150 mg|Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.
62144307|NCT06124170||Unicompartmental knee arthroplasty (UKA)|Unicompartmental knee arthroplasty
62144308|NCT06124170||High tibial osteotomy (HTO)|High tibial osteotomy
62507374|NCT04372719|EXPERIMENTAL|H3N2 10EXP5 TCID50/mL|A/Belgium/4217/2015 (H3N2) (SGS Code: SGS 421-7), Wild-type, influenza A (H3N2) human challenge strain
62507375|NCT02330952|EXPERIMENTAL|Prednisone|
62507376|NCT02330952|PLACEBO_COMPARATOR|Placebo|
62507377|NCT02427087|ACTIVE_COMPARATOR|Continuous Aerobic training|Aerobic training continuous (n=19 patients) carry a protocol continuous aerobic training twice a week for 24 weeks and the session will last 60 minutes/2 days/week with recommendation for healthy diet.
62507378|NCT02427087|ACTIVE_COMPARATOR|Healthy diet|Diet group (n=21 patients) only recommendation for healthy diet.
62507379|NCT02390310|ACTIVE_COMPARATOR|Phase 1 - 7 Day Removal|Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
62507380|NCT02390310|ACTIVE_COMPARATOR|Phase 1 - Delayed Removal|Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
62705409|NCT06021353|OTHER|UV fs-Laser|First surgical eye randomly assigned to the UV fs-Laser with the second surgical eye (fellow eye) assigned to the IR fs-Laser for the purpose of corneal flap creation during LASIK surgery
62705410|NCT06021353|OTHER|IR fs-Laser|First surgical eye randomly assigned to the IR fs-Laser with the second surgical eye (fellow eye) assigned to the UV fs-Laser for the purpose of corneal flap creation during LASIK surgery
62144309|NCT06509581|EXPERIMENTAL|Beta thalassemia patiens with oxidative stress and taking iron chelators receiving vitamin E|Beta thalassemia patiens with oxidative stress and taking iron chelators(desferoxamine,deferiprone or deferasirox) receiving vitamin E in dose 400 mg daily for 12 months
62507381|NCT02390310|ACTIVE_COMPARATOR|Phase 2 - Topical Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
62507382|NCT02390310|ACTIVE_COMPARATOR|Phase 2 - Injectable Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.
62507383|NCT04888949|EXPERIMENTAL|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
62507384|NCT04888949|PLACEBO_COMPARATOR|Placebo|Saline
62507385|NCT03230734|EXPERIMENTAL|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
61964069|NCT00438984|EXPERIMENTAL|Treatment (chemotherapy, immunosuppressive, lymphocytes)|"All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.~COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.~COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5."
62705411|NCT06340451|ACTIVE_COMPARATOR|iovera° system treatment|
62705412|NCT06340451|SHAM_COMPARATOR|sham iovera° system treatment|
61964070|NCT01028144|EXPERIMENTAL|ACT Program|Motivational and Behavioral Skills Physical activity after-school program
61964071|NCT01028144|ACTIVE_COMPARATOR|General Health|General health education after-school program
61964072|NCT00833885|OTHER|1|Control
62144310|NCT06509581|PLACEBO_COMPARATOR|Beta thalassemia patiens with oxidative stress and taking iron chelators receiving placebo|B thalassemia patiens with oxidative stress and taking iron chelators(desferoxamine,deferiprone or deferasirox) receiving placebo for 12 months
62144311|NCT04112810|EXPERIMENTAL|Tildrakizumab|Tildrakizumab (IluymaTM) is a humanized monoclonal antibody that specifically binds to the IL-23p19 subunit of IL-23 to neutralize its function.
62144312|NCT04318483||Angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
62705413|NCT03538600||Healthy Volunteers|healthy volunteers
62705414|NCT02610413||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
62144313|NCT04318483||Without angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
62144314|NCT01164488|EXPERIMENTAL|1|
62144315|NCT05775432||Heart transplantation group|Patients with heart failure of different etiologies undergoing heart transplant.
62144316|NCT05775432||Control group|Individuals whose hearts are donated.
62705415|NCT06393595||CHD + CHF|Coronary Heart Disease with overt Chronic Heart Failure (200 participants)
62144317|NCT01064466|EXPERIMENTAL|ETOPOSIDE - Usual|"* Etoposide Injection~* Chemotherapy~* Etoposide Injection~* Usual Approach Group"
62144318|NCT01064466|EXPERIMENTAL|ETOPOSIDE - Study|"* Etoposide Capsule~* Chemotherapy~* Etoposide Capsule~* Study Approach Group"
62144319|NCT00681837||1|children from 0 to 17 years old
62144320|NCT04806100|EXPERIMENTAL|Compliant, NoCDO, Stiff|Participants will be tested while wearing a moderate stiffness device (Compliant), then while wearing no brace (NoCDO), then while wearing a stiff device (Stiff).
62507386|NCT03230734|EXPERIMENTAL|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
62507387|NCT04270006|EXPERIMENTAL|Exosomes|
62705416|NCT06393595||CHD|Coronary Heart Disease without Chronic Heart Failure (70 participants)
62705417|NCT06393595||NICMP +CHF|Non-Ischemic Cardiomyopathies with overt Chronic Heart Failure (50 participants)
62705418|NCT06393595||VCMP+CHF|Valvular Cardiomyopathies with overt Chronic Heart Failure (40 participants)
62705419|NCT06386419|EXPERIMENTAL|inclisiran|300 mg inclisiran sodium equivalent to 284 mg inclisiran administered as a single SC injection
62705420|NCT06016842|EXPERIMENTAL|Elafibranor 80 mg|Participants will take 1 tablet of elafibranor 80 mg per day orally before breakfast with a glass of water at approximately the same time each morning.
62705421|NCT06016842|PLACEBO_COMPARATOR|Placebo|Participants will take 1 placebo tablet per day orally (matching the 80 mg elafibranor sized tablet) before breakfast with a glass of water at approximately the same time each morning.
62705422|NCT06153966|EXPERIMENTAL|ION717 + Placebo, Regimen 1|Participants will receive multiple doses of study drug (ION717 and placebo) during the 30-week double-blind treatment period; the order of doses is blinded. Participants will then receive multiple doses of ION717 during the 70-week open-label extension period.
61964073|NCT00833885|OTHER|2|Masks
61964074|NCT00833885|OTHER|3|Masks and Hygiene
61964075|NCT02134795|EXPERIMENTAL|TNM (trade name), a form of brainstem stimulation|ThermoNeuroModulation (TNM) device with a standardized active neuromodulation waveform will be used for all patients. The device will be used twice for \~19 minutes each time. There will be a gap of roughly 1 hour between the two device applications.
61964076|NCT00495339|EXPERIMENTAL|1|Levofloxacin
62144321|NCT04806100|EXPERIMENTAL|Compliant, Stiff, NoCDO|Participants will be tested while wearing a moderate stiffness device (Compliant), then while wearing a stiff device (Stiff), then while wearing no brace (NoCDO).
62144322|NCT04806100|EXPERIMENTAL|NoCDO, Compliant, Stiff|Participants will be tested while wearing no brace (NoCDO), then a moderate stiffness device (Compliant), then while wearing a stiff device (Stiff).
62144323|NCT04806100|EXPERIMENTAL|NoCDO, Stiff, Compliant|Participants will be tested while wearing no brace (NoCDO), then while wearing a stiff device (Stiff), then while wearing a moderate stiffness device (Compliant).
62144324|NCT04806100|EXPERIMENTAL|Stiff, Compliant, NoCDO|Participants will be tested while wearing a stiff device (Stiff), then while wearing a moderate stiffness device (Compliant), then while wearing no brace (NoCDO).
62144325|NCT04806100|EXPERIMENTAL|Stiff, NoCDO, Compliant|Participants will be tested while wearing a stiff device (Stiff), then while wearing no brace (NoCDO), then while wearing a moderate stiffness device (Compliant).
62144326|NCT04815720|EXPERIMENTAL|pepinemab + pembrolizumab|Pepinemab will be administered at 20 mg/kg (with possible dose modifications to 15 mg/kg or 10 mg/kg, if the initial 20 mg/kg dose of pepinemab is determined not to be well tolerated) in combination with a fixed dose of 200 mg pembrolizumab, administered in separate IV infusions, Q3W.
62144327|NCT04012970|EXPERIMENTAL|A - Intervention then control|Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
62705423|NCT06153966|EXPERIMENTAL|ION717 + Placebo, Regimen 2|Participants will receive multiple doses of study drug (ION717 and placebo) during the 30-week double-blind treatment period; the order of doses is blinded. Participants will then receive multiple doses of ION717 during the 70-week open-label extension period.
62705424|NCT00086567||patients|Patients in first remission from treatment of FIGO stage III/IV primary peritoneal, fallopian tube, or epithelial ovarian carcinoma
61964077|NCT05341193|EXPERIMENTAL|low risk|Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab every 3 weeks for a maximum of 1 year after radiotherapy.
62507388|NCT01978652|EXPERIMENTAL|Peginterferon Beta-1a administered to Japanese participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
61964078|NCT05341193|EXPERIMENTAL|high risk|Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab and bevacizumab every 3 weeks for a maximum of 1 year after radiotherapy.
61964079|NCT01342302|OTHER|Couples Intervention|Single arm study design
61964080|NCT03385005|ACTIVE_COMPARATOR|Healthy Volunteers|This arm consists of healthy volunteers receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
62507389|NCT01978652|EXPERIMENTAL|Peginterferon Beta-1a administered to Caucasian participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
62507390|NCT05725902|EXPERIMENTAL|Etavopivat|Single-arm, open-label
62507391|NCT03314363|OTHER|all patients|Classic CRRT with citrate predilution
62507392|NCT03788915|ACTIVE_COMPARATOR|Online dietician lifestyle counseling|Online dietetic lifestyle counseling
62507393|NCT03788915|PLACEBO_COMPARATOR|Usual care|Usual care
62507394|NCT01118117|EXPERIMENTAL|Misago™ Self-Expanding Stent System|
62507395|NCT03908528|EXPERIMENTAL|Chemotherapy plus Placebo for six Months|• Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus Placebo.
62507396|NCT03908528|EXPERIMENTAL|Chemotherapy plus alpha lipoic acid for six Months|• Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks in addition to oral 600 mg alpha lipoic acid (ALA) once daily.
62507397|NCT04210349|EXPERIMENTAL|Group A: 6 to 35 months, previously unvaccinated, step 1|Participants will receive two injections of SP Shz QIV 0.5 mL at Day 0 and Day 28
62507398|NCT04210349|EXPERIMENTAL|Group 1: 6 to 35 months, step 2|Participants will receive one injection of SP Shz QIV 0.25 mL or SP Shz QIV 0.5 mL at Day 0 or SP Shz TIV1 0.25 mL or SP Shz TIV2 0.25 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
61964081|NCT03385005|ACTIVE_COMPARATOR|Spinal Cord Injury Participants|This arm consists of spinal cord injury participants receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
61964082|NCT01310101|EXPERIMENTAL|Ofatumumab plus dexamethasone|
61964083|NCT02509247|EXPERIMENTAL|Telemonitoring group|Patients allocated to the telemonitoring group started with wireless telemonitoring after the titration period, i.e. in the beginning of habituation phase of CPAP treatment.
61964084|NCT02509247|NO_INTERVENTION|Usual care group|Patients were followed-up during the habituation phase according to hospital's standard procedure.
62507399|NCT04210349|EXPERIMENTAL|Group 2: 3 to 8 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62507400|NCT04210349|EXPERIMENTAL|Group 3: 9 to 17 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
62507401|NCT04210349|EXPERIMENTAL|Group 4: 18 to 60 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
61964085|NCT02399826|OTHER|Standard of Care|Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice offloading, reassessment weekly at office visit
62507402|NCT04210349|EXPERIMENTAL|Group 5: >=61 years|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
62507403|NCT03529565||Ancillary-Correlative (biospecimen collection)|Participants undergo collection of blood samples for histamine level analysis via ELISA.
62507404|NCT02593344|EXPERIMENTAL|endopat|measure of endothelial function with endopat
61964086|NCT02399826|EXPERIMENTAL|Amniotic Membrane / Amnioband|Application of Amnioband with dressing application, to be changed weekly following surgical debridement. Patient will practice offloading. If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
61964087|NCT00725569|ACTIVE_COMPARATOR|A|Bellis perennis and Staphysagria (C6)
61964088|NCT00725569|ACTIVE_COMPARATOR|B|Bellis perennis and Staphysagria (C30)
61964089|NCT00725569|PLACEBO_COMPARATOR|C|Placebo Remedy
61964090|NCT03478358|EXPERIMENTAL|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
61964091|NCT03478358|EXPERIMENTAL|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
62349216|NCT03224481|NO_INTERVENTION|Control group|Participants in the control group will not receive additional reminders.
62349217|NCT01536106|EXPERIMENTAL|Treatment|Implantation of bone marrow derived mononuclear cells
62349218|NCT01536106|PLACEBO_COMPARATOR|Placebo Control|Infusion of autologous peripheral blood
62349219|NCT01989182|EXPERIMENTAL|Treatment with Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
62349220|NCT01989182|ACTIVE_COMPARATOR|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
62349221|NCT06145152|EXPERIMENTAL|Adaptive|Subjects in the Adaptive group will get updated and adjusted training programs based on daily readiness level
62507405|NCT04874896|ACTIVE_COMPARATOR|Control|Patients of this branch will not have autotransplantation of gut microbiota in capsules and will follow their usual post-transplant treatment
62507406|NCT04874896|ACTIVE_COMPARATOR|Microbiota autotransplantation|Patients in this branch will receive autotransplantation of intestinal microbiota in capsules for 6 months post-transplantation
62507407|NCT05628441||CADe system|All patients included in the study will undergo the endoscopic procedure according to standard clinical care and the study protocol. The CADe system will run in the back, not interfering with care.
62507408|NCT04455971||OM Group|People who participate in the practice of orgasmic meditation (OM)
62507409|NCT02865941|EXPERIMENTAL|5 milk analysis|"1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.~2. Routine fortifier will be added to breast milk batches.~3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
62507410|NCT02865941|EXPERIMENTAL|1 milk analysis|"1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.~2. Routine fortifier will be added to breast milk batches.~3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
62507411|NCT00931463|ACTIVE_COMPARATOR|Ritonavir-boosted lopinavir and 2N(t)RTI|This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
62507412|NCT00931463|EXPERIMENTAL|Ritonavir-boosted lopinavir and raltegravir|This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.
61964092|NCT03478358|EXPERIMENTAL|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
61964093|NCT03478358|EXPERIMENTAL|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
61964094|NCT03478358|EXPERIMENTAL|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7 GBq (100 mCi) of 177LuDOTA-TATE and amino acids (lysine and arginine).
61964095|NCT03478358|EXPERIMENTAL|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7 GBq (100 mCi) of 177LuDOTA-TATE without amino acids (lysine and arginine).
61964096|NCT03958851||patients with lupus nephritis|Lupus nephritis is diagnosed by either the presence of proteinuria (\>0.5 g/day), active urinary sediment (with red blood cell, granular, tubular and/or mixed casts), or an unexplained rise in serum creatinine in patients with systemic lupus.
61964097|NCT03958851||systemic lupus patients without lupus nephritis|The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997).these group will be taken as a control group
61964098|NCT03958851||healthy individuals|a group of age and sex matched healthy individuals will be taken as a control group.
61964099|NCT05229380||saccharin test|"The patients with SPT less than 20 minutes are considered to have a normally functioning ET.~The patients with SPT between 20- 45 minutes are considered to have a partial dysfunction of ET .~The patients with SPT more than 45 minutes are considered to have a gross dysfunction of the ET ."
62144328|NCT04012970|EXPERIMENTAL|B - Control then intervention|Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.
61964100|NCT05229380||methylene blue test|"The patients with methylene blue clearance time less than 10 minutes are considered to have a normally functioning ET.~The patients with methylene blue clearance time between10 to 20 minutes are considered to have a partial dysfunction of ET.~The patients with methylene blue clearance time more than 20 minutes are considered to have a gross dysfunction of the ET ."
61964101|NCT00036738|EXPERIMENTAL|Treatment (allogeneic nonmyeloablative HSCT)|See Detailed Description
62144329|NCT00570999|EXPERIMENTAL|Arm A|Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
62144330|NCT00570999|PLACEBO_COMPARATOR|Arm B|Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
62144331|NCT00570505|EXPERIMENTAL|LapBand|All subjects who receive the LAP-BAND System.
62144332|NCT05785728|EXPERIMENTAL|DB-1202 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 1 on Day 1 of each cycle Q3W
62144333|NCT05785728|EXPERIMENTAL|DB-1202 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 2 on Day 1 of each cycle Q3W
62144334|NCT05785728|EXPERIMENTAL|DB-1202 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 3 on Day 1 of each cycle Q3W
62144335|NCT05785728|EXPERIMENTAL|DB-1202 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 4 on Day 1 of each cycle Q3W
62144336|NCT05785728|EXPERIMENTAL|DB-1202 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 5 on Day 1 of each cycle Q3W
62507413|NCT01869426|ACTIVE_COMPARATOR|VSL#3 drops|31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.
62507414|NCT01869426|PLACEBO_COMPARATOR|VSL#3 drops placebo|31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.
62507415|NCT00921284|PLACEBO_COMPARATOR|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
62507416|NCT00921284|EXPERIMENTAL|dexmedetomidine|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine
62507417|NCT03775941||Cross-Sectional Lifespan Connectomics Study|
62736675|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
62507418|NCT00682552|EXPERIMENTAL|1|"A cervico-vaginal cervical smear will be realized before every colposcopique examination.~A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized."
62507419|NCT00537199|OTHER|OraTest + Visual Exam|OraTest dye
62507420|NCT02875041|EXPERIMENTAL|Transcranial Magnetic Stimulation (TMS) MAGSTIM Rapid2 Therapy|TMS is a non-invasive device that employs the use of a magnet on the scalp to measure and potentially modulate cortical excitability. The use of TMS for Parkinson's treatment is experimental.
62507421|NCT02875041|ACTIVE_COMPARATOR|MAGSTIM Rapid2 Therapy System|MAGSTIM Rapid2 Therapy System has been FDA cleared for the treatment of refractory depression.
62507422|NCT01469507|EXPERIMENTAL|V0220|
62507423|NCT01469507|ACTIVE_COMPARATOR|Hyaluronan|
62507424|NCT05436132|EXPERIMENTAL|VR/AR group|Home care workers (HCW)HCWs in the VR/AR group received 2.5 hours of VR and AR training. VR offered learners the standard oral care procedures under different physical and oral health conditions in elderly people and AR simulation training for the manual Bass brushing technique.
62507425|NCT05436132|PLACEBO_COMPARATOR|Control group|The home care workers in the control group received 2.5 hours of traditional teaching methods for oral care.
62507426|NCT02409940|EXPERIMENTAL|Autologus Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
62507427|NCT02409940|ACTIVE_COMPARATOR|Allogeniec Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
62507428|NCT02409940|NO_INTERVENTION|Control without Mesenchymal Stem Cells|This group would get no stem cell infusion.
62507429|NCT03400917|EXPERIMENTAL|AV-GBM-1|Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
61964102|NCT02925494|EXPERIMENTAL|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
61964103|NCT02925494|EXPERIMENTAL|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
62144337|NCT05785728|EXPERIMENTAL|DB-1202 Dose Level 6|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 6 on Day 1 of each cycle Q3W
61964104|NCT03275012|EXPERIMENTAL|Group 1|Gabapentin + Morphine
61964105|NCT03275012|PLACEBO_COMPARATOR|Group 2|Placebo + Morphine
62144338|NCT05785728|EXPERIMENTAL|DB-1202 Dose Expansion 1|Enrolled Subjects with locally advanced or metastatic primary thyroid cancers with pathology of epithelial tumors that originated from thyroid follicular cells will be enrolled regardless of PD-L1 expression will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
61964106|NCT03607162|NO_INTERVENTION|Usual care|Local usual management of FWS (pragmatic approach)
62144339|NCT05785728|EXPERIMENTAL|DB-1202 Dose Expansion 2|Enrolled Subjects in selected solid malignant tumors can be added will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
62144340|NCT05785728|EXPERIMENTAL|DB-1202 Dose Expansion 3|Enrolled Subjects in selected solid malignant tumors can be added will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
62144341|NCT03041090|EXPERIMENTAL|Static Imaging participants|"This arm of the study assessed participants' static PET/CT images. These were the standard of care images acquired after their standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (Lucerno Device Identity Document (LD ID), Lucerno Device 1 (LD1), Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
62349222|NCT06145152|ACTIVE_COMPARATOR|Static|Subjects in the Static group will get the same inital training program as the Adaptive group but will not get updated and adjusted training programs based on daily readiness level
62349223|NCT00779324|EXPERIMENTAL|Amantadine|Amantadine 100 mg every morning and Noon
62349224|NCT00779324|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62507430|NCT00755378|EXPERIMENTAL|1|
62507431|NCT00755378|PLACEBO_COMPARATOR|2|
62507432|NCT02663882|EXPERIMENTAL|smoking-related self control task|self control practice - smoking related task
62507433|NCT02663882|ACTIVE_COMPARATOR|Non-smoking-related self control task|self control practice - non-smoking related task
62507434|NCT05505305|EXPERIMENTAL|Time-restricted eating and high-intensity interval training|Seven weeks of time-restricted eating and high-intensity interval training with digital follow-up.
62507435|NCT05505305|NO_INTERVENTION|Control|No intervention nor digital follow-up for seven weeks.
61964107|NCT03607162|EXPERIMENTAL|DIAFEVER algorithm|New DIAFEVER sequential algorithm PCT rapid test-based will be applied
61964108|NCT02720471|ACTIVE_COMPARATOR|Locoregional anesthesia|Classical locoregional analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh will be performed in patients of this arm
61964109|NCT02720471|EXPERIMENTAL|Peroperative infiltration|Peroperative infiltration of local anesthetics (IAL) will be performed in patients of this arm
61964110|NCT03689478|EXPERIMENTAL|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
62507436|NCT05678738|EXPERIMENTAL|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
62507437|NCT05678738|ACTIVE_COMPARATOR|Exercise-Heat Stress + Antioxidant Berry Supplementation|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress. Participants who opt-in may be randomly assigned to receive bioactive (antioxidant berry supplement) ingredient in addition to repeated bouts of exercise-heat stress.
62507438|NCT05678738|PLACEBO_COMPARATOR|Exercise-Heat Stress + Placebo (Non-juice) Supplementation|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress. Participants who opt-in may be randomly assigned to receive placebo (non-juice) ingredient in addition to repeated bouts of exercise-heat stress.
61964111|NCT01182987|ACTIVE_COMPARATOR|Dementia care management|Patients and family caregivers will be offered dementia care management, which includes detailed comprehensive assessment, education, counseling, referrals to community agencies, collaboration with medical providers and frequent telephone follow-up
61964112|NCT01182987|NO_INTERVENTION|Usual care|Patients and care family care givers will receive usual support and medical care offered by the health plan.
62349225|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
62349226|NCT02616185|EXPERIMENTAL|Dose Escalation|PF-06753512
62507439|NCT04004845||Pregnant women|We are including only women who are age 18 or over, who have a single baby (not twins), with the baby's head down, and are between 36 weeks 6 days and 42 weeks 0 days of pregnancy.
62736676|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
61964113|NCT06162936||Inflammatory bowel disease patients|Pediatric patients (under 18 years of age) diagnosed with IBD
61964114|NCT06162936||Healthy controls|Healthy chidren (no chronic disease)
62349227|NCT04508725|EXPERIMENTAL|Tyrosine kinase (TKI) inhibitor plus immune checkpoint inhibitor (ICI)|Patients are planned to be treated with vascular endothelial growth factor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
62349228|NCT04508725|EXPERIMENTAL|Non-ICI therapy|Patients are planned to be treated with non-ICI therapy
62349229|NCT01230749|EXPERIMENTAL|JNJ-41443532 250 mg|Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
62349230|NCT01230749|EXPERIMENTAL|JNJ-41443532 1000 mg|Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
62349231|NCT01230749|ACTIVE_COMPARATOR|Pioglitazone|Participants will receive pioglitazone 30 mg in morning for 28 days.
62349232|NCT01230749|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.
62349233|NCT06194981||3-4 months CapOx/SOX|"Adjuvant CapOx/SOX 3-4 months after curative surgery:~CapOx: Oxaliplatin: 130 mg/m²/day (day 1) , Capecitabine: 1,000 mg/m², bid (day 1-14), q3W, total 3-4 months (4-6 cycles); SOX: Oxaliplatin: 130 mg/m2/day(day 1) , S-1: 40-60 mg, bid (day 1-14), q3W, total 3-4 months (4-6 cycles)"
62349234|NCT06194981||5-6 months CapOx/SOX|"Adjuvant CapOx/SOX 5-6 months after curative surgery:~CapOx: Oxaliplatin: 130 mg/m²/day (day 1) , Capecitabine: 1,000 mg/m², bid (day 1-14), q3W, total 5-6 months (7-8 cycles); SOX: Oxaliplatin: 130 mg/m2/day(day 1) , S-1: 40-60 mg, bid (day 1-14), q3W, total 5-6 months (7-8 cycles)"
62349235|NCT02712177||Coadministration B_RV246|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).
62349236|NCT02712177||Coadministration B_RV234|Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..
62349237|NCT02712177||Coadministration B_MMRV12|Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.
62349238|NCT02712177||Separate administration B246_RV357|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.
62349239|NCT02712177||Separate administration B12_MMRV13|Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.
62349240|NCT02712177||Routine vaccines only at 2, 3 and 4 months of age (RV234)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.
62349241|NCT02712177||Routine vaccines only at 2, 4 and 6 months of age.(RV246)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.
62349242|NCT00617656|ACTIVE_COMPARATOR|A: Control|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
61964115|NCT05311618|EXPERIMENTAL|NGM438 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
61964116|NCT05311618|EXPERIMENTAL|NGM438 Combination Dose Finding with pembrolizumab ( KEYTRUDA ® )|Part 1b NGM438 plus pembrolizumab ( KEYTRUDA ® )
61964117|NCT05311618|EXPERIMENTAL|Biopsy Cohort with NGM438 Monotherapy Followed by Combination Therapy with Pembrolizumab(KEYTRUDA ®)|Part 1C NGM438 followed by NGM438 plus pembrolizumab ( KEYTRUDA ® )
62349243|NCT00617656|EXPERIMENTAL|B1: Experimental group B1|Low RAP expression and any levels of BRCA1 expression: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
62349244|NCT00617656|EXPERIMENTAL|B2: Experimental group B2|Intermediate or high RAP expression and low or intermediate BRCA1 expression: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
62349245|NCT00617656|EXPERIMENTAL|B3: Experimental group B3|Intermediate or high RAP expression and high BRCA1 expression: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
62349246|NCT01088269||AF|Hypertensive patients in AF
61964118|NCT01836770||Transforaminal Epidural Steroid Injection|Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.
61964119|NCT06488235||obese adolescents over 12 years of age and their parents|"Children who have started an educational care program between 2017 and 2022 at one of the four participating centers and have stopped the educational care program early.~Child over 12 years of age at the time of the focus group."
61964120|NCT05538702|EXPERIMENTAL|Heated tobacco product with bland taste unit|Nicotine content: 0,5 mg
61964121|NCT05538702|EXPERIMENTAL|Heated tobacco product with menthol taste unit|Nicotine content: 0,5 mg
61964122|NCT05538702|EXPERIMENTAL|Conventional cigarette|Nicotine content: 0,5 mg
61964123|NCT05538702|PLACEBO_COMPARATOR|Heated tobacco product turned off with a bland taste unit|Placebo device
61964124|NCT04167644||Unfavorable outcome|80 patients with poor outcome were classified according to mRS score after discharge (mRS range from 3 up to 6).
62705425|NCT05987241|ACTIVE_COMPARATOR|Cohort A, Arm I (nivolumab)|Patients in Cohort A, Arm I receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of tissue during screening and collection of blood throughout the trial. Patients also undergo CT or MRI scans throughout the trial.
62705426|NCT05987241|EXPERIMENTAL|Cohort A, Arm II (nivolumab, relatlimab)|Patients in Cohort A, Arm II receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of tissue during screening and collection of blood throughout the trial. Patients also undergo CT or MRI scans throughout the trial.
62705427|NCT05987241|ACTIVE_COMPARATOR|Cohort B, Arm III (nivolumab)|Patients in Cohort B, Arm III receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of tissue during screening and collection of blood throughout the trial. Patients also undergo CT or MRI scans throughout the trial.
62705428|NCT05987241|EXPERIMENTAL|Cohort B, Arm IV (ctDNA surveillance, nivolumab)|Patients in Cohort B, Arm IV undergo ctDNA surveillance consisting of collection of tissue and blood during screening and collection of blood only on study and during follow up. Patients who convert to ctDNA(+) during surveillance then receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans throughout the trial.
62705429|NCT00067054||1|Sample collection only
61964125|NCT04167644||Favorable outcome|70 patients with better outcome were classified according to mRS score after discharge (mRS range from 0 up to 2) .
61964126|NCT00824239|ACTIVE_COMPARATOR|1. Intermittent sedation|
61964127|NCT00824239|ACTIVE_COMPARATOR|2. Daily interruption of sedation|
61964128|NCT04525417|OTHER|hospital healthcare workers|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
62144342|NCT03041090|EXPERIMENTAL|Dynamic image participants|"This arm of the study assessed participants' dynamic PET/CT images. These were the study related images of and around the injection site acquired during the participants' standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (LD ID, LD1, Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
62144343|NCT02018549|EXPERIMENTAL|Placebo|Inhalation through Chiesi NEXThaler DPI containing Placebo Dry Powder. Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
62349247|NCT01088269||Non-AF|Hypertensive Patients
61964129|NCT04525417|OTHER|private health professionals|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
61964130|NCT04997161|EXPERIMENTAL|SZC arm with enhanced dietary advice|Participants will continue taking Sodium Zirconium Cyclosilicate (SZC), which can be titrated up or down to maintain S-K+ in the range 3.5-5.5 mmol/L; participants will also receive enhanced nutritional advice to consume fruit and vegetables. Advice will be provided by dietitians at study visits and by Noom app between visits.
61964131|NCT04997161|OTHER|SoC arm with standard dietary advice|SZC will be withdrawn and participants will receive SoC as per site practice, including dietary K+ restriction. Dietary advice will be given by dietitians at study visits and by Noom app between study visits.
61964132|NCT01009632|EXPERIMENTAL|Voice rest|
61964133|NCT01009632|EXPERIMENTAL|Resonant voice exercise|
61964134|NCT01009632|EXPERIMENTAL|Spontaneous speech|
61964135|NCT04495348||Open-label arm|Participants are switched to doravirine and then switched back to INSTI-based therapy.
61964136|NCT04700709|EXPERIMENTAL|RaparoBell® Tablet|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
62349248|NCT01668186||Patients diagnosed with a peroxisomal disorder|Collection of medical records and images (ultrasounds, X-rays, MRIs, CT scans, ophthalmic images), Next-generation panel, Drug screening, and Consultation
62349249|NCT02160886|EXPERIMENTAL|Child-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the children themselves, using the Swedish version of the Perceived Efficacy and Goal Setting System (PEGS).~A PEGS interview will be performed with the children. The children identifies tasks they find difficult to perform and prioritize three tasks, they want to perform better, as goals for intervention."
62349250|NCT02160886|EXPERIMENTAL|Parent-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the parents using the Canadian Occupational Performance Measure (COPM).~Using the COPM interview technique, the parents are encouraged to talk about an ordinary day to identify occupational performance issues their child is not able to perform. Identified performance issues are rated for importance and the parents selects the three most important issues as goals for intervention."
62349251|NCT04115618|EXPERIMENTAL|SIB|Simultaneous integrated boost intensity-modulated chemoradiotherapy
62349252|NCT06402968||designated clevidipine hospitals|
62349253|NCT06402968||designated non-clevidipine hospitals|
62349254|NCT01623141||Patients with CRPS|18 patients with unilateral CPRS of the upper limb were included to the study
62349255|NCT01623141||Patients with limb pain of other origin|17 patients with unilateral upper limb pain of other origin served as control group
62349256|NCT01623141||Healthy subjects|18 healthy subjects were included to establish reference data for the pressure pain thresholds
62349257|NCT00493974|ACTIVE_COMPARATOR|Zileuton|Zileuton (Zyflo, 600 mg 4 times a day)
62349258|NCT00493974|PLACEBO_COMPARATOR|Placebo|Placebo
62507440|NCT04584996||Pancreatic cancer|Patients being evaluated at MDT for suspected Pancreatic Ductal Adenocarcinoma (PDAC), via radiological test (e.g. endoscopic ultrasound (EUS), endoscopic retrograde cholangiography (ERCP), cross-sectional imaging), serum tumour marker (i.e. CA 19-9), or other diagnostic procedure
62507441|NCT04584996||Control|Patients diagnosed and/or due to undergo surgery for benign pathology (e.g. gallstones, chronic pancreatitis, etc); or patients with a diagnosis of a pre-malignant lesion (e.g. pancreatic intraductal papillary mucinous neoplasm); Pancreatic Neuroendocrine Tumour, or a Biliary Tract Cancer (i.e. cholangiocarcinoma; gallbladder cancer; ampullary cancer)
62507442|NCT06616883|EXPERIMENTAL|Experimental: Sequence A|
62507443|NCT06616883|EXPERIMENTAL|Experimental: Sequence B|
62507444|NCT01235715|ACTIVE_COMPARATOR|Evicel|Evicel is a fibrin sealant used for hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical. It has been shown to stop bleeding in 2 minutes or less. Evicel is a combination of a biologic activated component containing human fibrinogen and topical thrombin that functions on wet, actively bleeding tissue. It is a bioresorbable and biocompatible agent.
62507445|NCT01235715|NO_INTERVENTION|no evicel|Patients will receive standard treatment for bleeding as practiced at the Hospital for Special Surgery.
62507446|NCT02123420|OTHER|Implant outcome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the right molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
62705430|NCT00923065||Consults|Individuals being seen as a consult.
62705431|NCT00923065||Donors|Donors of cellular products.
62705432|NCT00923065||Genetic Follow-Up|Individuals with a known/suspected germline genomic research incidental pathogenic or likely pathogenic variant, and/or who require CLIA confirmation.
62705433|NCT00923065||Patients|Individuals being enrolled for the treatment or follow-up of their disease.
62705434|NCT04530799||IAPA+|Influenza patients who develop IAPA during ICU admission
62705435|NCT04530799||IAPA-|Influenza patients admitted to the ICU not developing IAPA
61964137|NCT04700709|ACTIVE_COMPARATOR|Mycophenolate Mofetil Tablet/Capsule|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
61964138|NCT06281990|NO_INTERVENTION|Control group|The control group received standard care.
61964139|NCT06281990|EXPERIMENTAL|Intervention group|1:Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.
62349259|NCT00866515|EXPERIMENTAL|Active|Ketoconazole 400mg OD days 1-6
62349260|NCT00866515|PLACEBO_COMPARATOR|Placebo|Placebo OD for 1 to 6 days
62349261|NCT00971425|EXPERIMENTAL|Placebo-Pandemrix-Fluarix Group|Subjects received one dose of placebo intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21, and 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day 42.
62349262|NCT00971425|EXPERIMENTAL|Fluarix-Pandemrix-Placebo Group|Subjects received 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid of the non-dominant arm at Day 0 and 21, and 1 dose of placebo intramuscularly in the deltoid of the non-dominant arm at Day 42.
62349263|NCT01974726|OTHER|affected, intact tympanic membranes|History of middle-ear disease, ears with no holes/perforations/patent tympanostomy tubes in eardrum
62349264|NCT01974726|OTHER|affected, non-intact tympanic membranes|History of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
62349265|NCT01974726|OTHER|controls, intact tympanic membranes|No history of middle-ear disease, ears with no hole/perforation/patent tympanostomy tube in eardrum
62349266|NCT01974726|OTHER|controls, non-intact tympanic membranes|No history of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
62349267|NCT05010993||Czech healthy people|Czech healthy men and women will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test.
62349268|NCT01969669|EXPERIMENTAL|Arm A (ABT-199 and ketoconazole)|
62349269|NCT02107651||NOAC|Patients admitted for GI bleeding while in treatment with NOAC
62349270|NCT05699317|EXPERIMENTAL|Intervention|
62349271|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
62349272|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
62349273|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
62349274|NCT01287481|EXPERIMENTAL|Stress and Emotions|Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
62349275|NCT01287481|ACTIVE_COMPARATOR|Thoughts and Behaviors|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
62349276|NCT01287481|ACTIVE_COMPARATOR|Brain and Body|Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
62349277|NCT01718626|ACTIVE_COMPARATOR|S1+Docetaxel|
62349278|NCT01718626|EXPERIMENTAL|S1+Docetaxel followed by S1|
62349279|NCT06429423|EXPERIMENTAL|Exhaustion disorder (ED)|Patients with diagnosed exhaustion disorder (F43.8A in Swedish ICD-10).
62507447|NCT02123420|OTHER|Implant outome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the left molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
62507448|NCT00603564|ACTIVE_COMPARATOR|1|CPAP delivered by a helmet
62349280|NCT06429423|ACTIVE_COMPARATOR|Control group|Age- and sex-matched healthy control participants.
62705436|NCT00001529||Group 1|Healthy volunteers
62349281|NCT03070561|EXPERIMENTAL|Sublingual film with peanut extract|
62349282|NCT04107558|EXPERIMENTAL|Painful stimuli with Hypnosis and Virtual Reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes. This session takes place under hypnosis
62349283|NCT04107558|NO_INTERVENTION|Painful stimuli without Hypnosis and Virtual reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes.
62507449|NCT00603564|NO_INTERVENTION|2|O2 administration via a conventional Venturi mask
62507450|NCT04676880|EXPERIMENTAL|Intervention arm - Left atrial appendage occlusion (with Watchman FLX or Amplatzer Amulet device)|Patients randomized to the intervention arm will receive left atrial appendage occlusion. In order to prevent device-related thrombus, they will use dual antiplatelet therapy (acetylsalicylzuur + clopidogrel) for three months and single antiplatelet therapy (acetylsalicylzuur) until at least 12 months after the procedure.
62507451|NCT04676880|NO_INTERVENTION|Control arm - no or usual care|The patients in the control arm will stay on optimal treatment as decided by the referring physician (antiplatelet therapy or nothing).
62705437|NCT03937661|EXPERIMENTAL|Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period.
62705438|NCT03937661|PLACEBO_COMPARATOR|Control Group: participants receiving Platelet Free Plasma|Women presenting with POR, treated with autologous PFP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period
62144344|NCT04165772|EXPERIMENTAL|Cohort 1|Patients with clinical Stage II or Stage III MRI-staged, MSI-H or dMMR, solid tumors will receive up to 6 months (9, 21-day cycles) of PD-1 blockade followed by radiological and surgical restaging of the tumor. If subject exhibits complete clinical response, non-operative management will be followed. If a complete clinical response is not reached after 6 months of PD-1 blockade, the participant will proceed with standard chemoradiation. After completing chemoradiation participant will be assessed for response if complete CR is not obtained then the participant will proceed with disease specific surgical resection or standard of care therapy.
62144345|NCT04165772|OTHER|Cohort 2|The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory
62144346|NCT04598594|EXPERIMENTAL|Nicotine patch|
62144347|NCT04598594|PLACEBO_COMPARATOR|Placebo patch|
62349284|NCT02816372|EXPERIMENTAL|Tidal volume 4 ml/kg Predicted Body Weight (PBW)|
62349285|NCT04972734|EXPERIMENTAL|NEC|premature newborns developing a NEC
62349286|NCT04972734|ACTIVE_COMPARATOR|Healthy control|premature newborns without NEC
62349287|NCT04173871|EXPERIMENTAL|Intervention|Intervention group
62349288|NCT04173871|NO_INTERVENTION|Control|Control group
62349289|NCT00571792||methodologies to identify characteristics of non-smokers with normal lung function|Imaging, genomic and proteomic methodologies to identify characteristics of individuals with normal lung function who do not smoke
62349290|NCT00571792||methodologies to identify characteristics of smokers but do not demonstrate symptoms of COPD|Imaging, genomic and proteomic methodologies to identify characteristics of individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
62349291|NCT00571792||methodologies to identify characteristics of smokers that demonstrate symptoms of COPD|Imaging, genomic and proteomic methodologies to identify characteristics of individuals who smoke that demonstrate symptoms of COPD
62349292|NCT00593840|EXPERIMENTAL|Intensity modulated radiation therapy (IMRT)|-This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume.
62349293|NCT02922192||Rheumatoid arthritis (RA)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
62349294|NCT02922192||Inflammatory bowel disease (IBD)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
62349295|NCT02922192||Psoriatic conditions|Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
62349296|NCT05452876|EXPERIMENTAL|ABCp|The patient sees MD that follows ABCp, patient then enrolls in ABCp intervention based on MD's categorization of low back pain.
62349297|NCT05452876|ACTIVE_COMPARATOR|Usual Care|"The patient receives usual care at the clinical site."
62349298|NCT06435182|EXPERIMENTAL|OT202 conc.0.5% group|Administered three times daily (morning, afternoon, and evening), with 1-2 drops each time, instilled into the conjunctival sac.
62507452|NCT06208423|ACTIVE_COMPARATOR|GPT-4|Group will be given access to GPT-4
62507453|NCT06208423|NO_INTERVENTION|Usual Resources|Group will not be given access to GPT-4 but will be encouraged to use any resources they wish besides large language models (UpToDate, Dynamed, google, etc).
62705439|NCT04595760||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
62705440|NCT00713492|EXPERIMENTAL|1|Alcohol
62705441|NCT04629248|EXPERIMENTAL|Open Label Treatment: Obinutuzumab|Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).
62705442|NCT04629248|ACTIVE_COMPARATOR|Open Label Treatment: Tacrolimus|Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).
62507454|NCT06010745|ACTIVE_COMPARATOR|Active capsules|Dietary ingredient standardized to deliver 10 mg of biotin and 10 mg of silicon per serving (1 capsule/serving).
62507455|NCT06010745|PLACEBO_COMPARATOR|Placebo capsules|The placebo comparator contains only inert ingredients (1 capsule/serving)
62736677|NCT01301053|OTHER|Current UVA intensive care insulin protocol without brakes|Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days and uses the current UVA intensive care insulin for insulin management for 12 hours.
61964140|NCT03971214|EXPERIMENTAL|PD-1 inhibitor JS-001 consolidation for SCLC|The extensive-stage SCLC patients will receive PD-1 inhibitor JS-001 treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
62144348|NCT06509867|EXPERIMENTAL|Platelet rich fibrin|de-epithelialized subepithelial gingival grafts+ L-Platelet Rich Fibrin + Coronally advanced flap
62507456|NCT06010745|OTHER|open label|Open-label arm that will involve men who only receive the active dietary ingredient capsules. This arm will run in parallel with the blinded study conducted in women.
62507457|NCT05306197|EXPERIMENTAL|Gaze-Contingent Feedback Training (toward threat)|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
62507458|NCT05306197|ACTIVE_COMPARATOR|Active Comparator: RT-Based Attention Bias Modification (toward threat)|"A dot-probe task of 160 trials. Trials begins with a fixation cross (+), on which the participant is asked to focus (500ms). Then two face stimuli (one angry one neutral) are presented above and below the fixation cross (500ms). After the stimuli disappear, a target probe (right- or left-pointing arrowhead) appears in place of one of the face stimuli. The participant is asked to indicate which target probe was presented using a predetermined key. The target probe will remain on the screen until response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the threat location (angry face). Thus, over multiple trials, learning is expected to occurs such that the threatening face predicts the location of the target probe, thereby achieving the desired change in attention pattern."
62507459|NCT05306197|PLACEBO_COMPARATOR|Non-Contingent Feedback Training|This condition is also based on the eye-tracking task (see Experimental Arm) with a fundamental change - The music chosen by the soldier will play continuously without any reinforcement for looking at threat or neutral faces.
62736678|NCT01301053|ACTIVE_COMPARATOR|Current UVA intensive care insulin protocol with brakes|"Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days. Uses the current UVA intensive care insulin protocol for insulin management for 12 hours with the addition of brakes that reduce insulin administration based on continuous glucose monitoring data between hourly reference glucose data."
62349299|NCT06435182|EXPERIMENTAL|OT202 conc. 0.1% group|Administered three times daily (morning, afternoon, and evening), with 1-2 drops each time, instilled into the conjunctival sac.
62349300|NCT06435182|EXPERIMENTAL|Placebo group|Administered three times daily (morning, afternoon, and evening), with 1-2 drops each time, instilled into the conjunctival sac.
61964141|NCT01562418|EXPERIMENTAL|Ergonomic consulting|Ergonomic consulting without biofeedback
62144349|NCT06509867|ACTIVE_COMPARATOR|de-epithelialized gingival grafts|de-epithelialized gingival grafts + coronally advanced flap
62349301|NCT00131677|ACTIVE_COMPARATOR|active immediate|participants in this arm start study product immediately upon enrollment
62349302|NCT00131677|PLACEBO_COMPARATOR|placebo immediate|participants in this arm start study product immediately upon enrollment
62349303|NCT00131677|ACTIVE_COMPARATOR|active delayed|persons in this arm start study product 9 months after enrollment
62349304|NCT00131677|PLACEBO_COMPARATOR|placebo delayed|participants in this arm start study product nine months after enrollment
62349305|NCT03483766|NO_INTERVENTION|Baseline before robotic functional rehabilitation|Baseline spinal cord MRI scan
61964142|NCT01562418|EXPERIMENTAL|Ergonomic consulting with biofeedback|Ergonomic intervention with biofeedback
61964143|NCT01562418|NO_INTERVENTION|general instructions|general instructions with no intervention
61964144|NCT00230607|EXPERIMENTAL|Fabrazyme|Mothers with Fabry disease who received commercially available Fabrazyme intravenous infusion as part of the standard of care while lactating/pregnant and their infants who were breastfed while the mothers were receiving Fabrazyme were enrolled in this study.
61964145|NCT00542854||MP3|4 different brands of MP3 players will be tested at 3 distances from pacemakers and ICDs.
61964146|NCT02790528|EXPERIMENTAL|Atorvastatin|20mg QD
61964147|NCT02790528|PLACEBO_COMPARATOR|Placebo|
61964148|NCT03917914|ACTIVE_COMPARATOR|Bisoprolol|1.25, 2.5 or 5mg of bisoprolol daily
61964149|NCT03917914|PLACEBO_COMPARATOR|Placebo|1.25, 2.5 or 5mg of matched placebo daily
61964150|NCT04009343|ACTIVE_COMPARATOR|Artemether-lumefantrine|Standard 6-dose regimen
62144350|NCT00978588|EXPERIMENTAL|HES 130/0.4|
62144351|NCT00978588|ACTIVE_COMPARATOR|5% albumin|
62144352|NCT01925144|EXPERIMENTAL|Baricitinib|Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
62144353|NCT01925144|EXPERIMENTAL|Baricitinib + Omeprazole|Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
62144354|NCT04487249|EXPERIMENTAL|Vision Therapy|Participants will receive 20 consecutive weeks of office-based vision therapy with home therapy.
62507460|NCT05040126|ACTIVE_COMPARATOR|Arm 1 - 26 weeks of BDQ +Pa + LZD (600mg)|"26 wks. of BDQ +Pa + LZD (600mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in Arm1.~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
61964151|NCT04009343|EXPERIMENTAL|Dihydroartemisinin-piperaquine|Standard 3-dose regimen
61964152|NCT04675645|OTHER|HU-Go app intervention arm|Participants will use HU-Go app intervention arm for a total of 12 weeks.
62349306|NCT03483766|EXPERIMENTAL|post rehabilitation|Those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.
62349307|NCT05100069||Brigatinib Tablets|Brigatinib 90 milligrams (mg), tablet, orally, once daily for up to 7 days, followed by 180 mg, tablets, once daily for 51 weeks. Participants received interventions as part of routine medical care.
62349308|NCT00003476|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62349309|NCT00795964|EXPERIMENTAL|1|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
62349310|NCT00795964|ACTIVE_COMPARATOR|2|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
62349311|NCT04078334|EXPERIMENTAL|Group 1|PATH Tool : Prescription of exercise programs at discharge
62349312|NCT04078334|EXPERIMENTAL|Group 2|PATH 2.0 Tool : Prescription of exercise programs during hospitalization and discharge
62349313|NCT04078334|EXPERIMENTAL|Group 3|MATCH tool: Prescription of physical exercise programs during hospitalization
62349314|NCT04078334|NO_INTERVENTION|Group 4|Control group: Usual care by the clinical teams
62349315|NCT02173392|EXPERIMENTAL|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
62349316|NCT02173392|EXPERIMENTAL|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
62349317|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss as well as 3, 4, 5 and 6 years post loss.
62349318|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) as well as 3, 4, 5 and 6 years post loss.
62349319|NCT05137730|EXPERIMENTAL|Part I: Sequence AB|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation A) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation B) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
62349320|NCT05137730|EXPERIMENTAL|Part I: Sequence BA|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation B) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation A) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
62349321|NCT05137730|EXPERIMENTAL|Part II: Sequence CDEF|Participants will receive a single SC injection of 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 1 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 2 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 3 followed 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
62349322|NCT05137730|EXPERIMENTAL|Part II: Sequence DFCE|Participants will receive a single SC injection of 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 1 followed by 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 2 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 3 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
62349323|NCT05137730|EXPERIMENTAL|Part II: Sequence ECFD|Participants will receive a single SC injection of 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 1 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 2 followed by 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 3 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
62349324|NCT05137730|EXPERIMENTAL|Part II: Sequence FEDC|Participants will receive a single SC injection of 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 1 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 2 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 3 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
62349325|NCT03601208|EXPERIMENTAL|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
62349326|NCT04365647||1|Patient's in whom there is increase in tumor size after craniotomy
62349327|NCT04365647||2|Patient's in whom there was either no increase in tumor size or decrease in tumor size after craniotomy
62349328|NCT01013168|EXPERIMENTAL|OncoSorb® column|
62349329|NCT04569695|EXPERIMENTAL|Part 1: Cohort A: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 once daily (QD) on Day 1 followed by washout period of 4 days and then Dose 1 of JNJ-70033093 QD from Days 5 to 12.
62349330|NCT04569695|EXPERIMENTAL|Part 1: Cohort B: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 twice daily (BID) from Days 1 to 8.
62349331|NCT04569695|EXPERIMENTAL|Part 1: Cohort C: JNJ-70033093|Participants will receive Dose 2 of JNJ-70033093 BID from Days 1 to 8.
62507461|NCT05040126|EXPERIMENTAL|Arm 2 - 9 weeks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg)|"9 wks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 2 and ½ tablet of 600 mg once daily in CP of Arm 2 .~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
62507462|NCT05040126|EXPERIMENTAL|Arm 3 -13 weeks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg)|"13 wks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 3 and ½ tablet of 600 mg once daily in CP of Arm 3.~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
62507463|NCT02339090|EXPERIMENTAL|Somavaratan|Participants will receive somavaratan 3.5 milligrams (mg)/kilogram (kg) subcutaneous (SC) bolus injection twice monthly for 12 months.
62507464|NCT02339090|ACTIVE_COMPARATOR|rhGH|Participants will receive commercially available rhGH (genotropin) 34 micrograms (μg)/kg once daily SC bolus injection for 12 months.
61964153|NCT03772691|EXPERIMENTAL|lateral suspension|All operations will be performed with patient in loyd davies position, sterilization of the perineum then sterilization of the vagina
62507465|NCT03519282|EXPERIMENTAL|Test Multifocal Toric Lens|comfilcon A multifocal toric lens
62507466|NCT03519282|ACTIVE_COMPARATOR|omafilcon A Multifocal Toric Lens|Control multifocal toric lens
62507467|NCT06173596|EXPERIMENTAL|Part 1|During Part 1, Period 1, participants will receive a single dose of ALXN2080 on the morning of Day 1. In Part 1, Period 2, participants will receive a dose of itraconazole orally once daily on the morning of Day 1 to Day 13. On the morning of Day 5, participants will be given a single dose of ALXN2080 co-administered with itraconazole.
62507468|NCT06173596|EXPERIMENTAL|Part 2 (Optional)|During Part 2, Period 1, participants will receive a single dose of ALXN2080 on the morning of Day 1. In Part 2, Period 2, participants will receive a single loading dose of fluconazole, followed by a dose of fluconazole qd on the morning of Day 2 to Day 10. On the morning of Day 4, participants will be given a single dose of ALXN2080 co-administered with fluconazole.
62507469|NCT06173596|EXPERIMENTAL|Part 3|During Part 3, Period 1 participants will receive a single dose of ALXN2080 on the morning of Day 1. In Part 3, Period 2, participants will receive a dose of carbamazepine bid on the morning and evening of Day 1 to Day 3, followed by a dose of carbamazepine bid on the morning and evening of Day 4 to Day 6 and a dose of carbamazepine bid on the morning and evening of Day 7 to Day 23. On the morning of Day 19, participants will be given a single dose of ALXN2080 co-administered with carbamazepine.
62507470|NCT02999984|EXPERIMENTAL|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
62507471|NCT00958802|PLACEBO_COMPARATOR|Arm A|Chondrocyte culture with FBS medium
62507472|NCT00958802|EXPERIMENTAL|Arm B|Chondrocyte culture with PRP
62507473|NCT05294835|EXPERIMENTAL|Ketamine Infusion|subanesthetic ketamine infusion (0.5mg/kg) over 2-3 weeks
62507474|NCT02142231|PLACEBO_COMPARATOR|Laser Acupuncture|Subjects and Therapists are blinded. Instead of a real Laser Acupuncture device (able to elicit physiologic responses) them is given a sham-laser device only radiating non-energetic red LED-light. Without palpation, therapists treat the acupoint Heart 7, on both wrists, each for 1 minute, with additional 18 minutes of resting time after.
62507475|NCT02142231|ACTIVE_COMPARATOR|Acupuncture|Acupuncture at the acupoint Heart 7, on both wrists, each for 1 minute, eliciting a deqi-response, additional stimulation and total needle-in time of 20 minutes (2 minutes treatment and 18 minutes of resting time)
62507476|NCT05270486||Group A|group A undergoing TELD (transforaminal endoscopic lumbar discectomy) with electromagnetic navigation system
62507477|NCT05270486||Group B|group B undergoing TELD with X-ray fluoroscopy (gold standard)
62349332|NCT04569695|EXPERIMENTAL|Part 2: Cohort D: JNJ-70033093|Participants will receive Dose 3 of JNJ-70033093 QD on Day 1 followed by washout period of 4 days and then Dose 3 of JNJ-70033093 BID from Days 5 to 12 in Cohort D. Dose escalation to Part 2: Cohort D will occur only after the safety and tolerability data of the Part 1 are assessed.
62507478|NCT00487929|EXPERIMENTAL|CPAP|Continuous positive airway pressure
62507479|NCT00487929|SHAM_COMPARATOR|Sham CPAP|Sham nasal continuous positive airway pressure
62507480|NCT05234814|ACTIVE_COMPARATOR|Control group|The control group was given the Traditional Chinese Medicine auricular acupuncture point buried seeds therapy.
62507481|NCT05234814|EXPERIMENTAL|Observation group|The observation group was given the auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.
62507482|NCT04657250|EXPERIMENTAL|Smoking cessation + quitline linkage text messages|Text messaging for smoking cessation + text messages with proactive linkage to quitline
62144355|NCT04487249|NO_INTERVENTION|Observation|Participants will receive no treatment for IXT is received during the study unless one of the deterioration criteria is met.
62349333|NCT01090219|EXPERIMENTAL|two differents meshes|Heavy-weight versus low-weight polypropylene meshes
62349334|NCT03323996||Health Professionals|Health Professionals attending a training in therapeutic education
62349335|NCT03323996||Patients|Patients of the health Professionals recruited for the study
62349336|NCT03371342|EXPERIMENTAL|MEDITOXIN|
61964154|NCT03772691|ACTIVE_COMPARATOR|sacropexy|Our ﬁrst passage is the peritoneum incision overlying the sacral promontory (L5-S1) to expose the anterior longitudinal ligament, which is the anchorage point of the mesh on the sacrum. We create a tunnel under the peritoneum on the right side through the cul-de-sac of Douglas till reach the cervix or vaginal cuff (after hysterectomy).
62507483|NCT04657250|PLACEBO_COMPARATOR|Passive quitline referral|Single text message with contact information for the Quitline
62507484|NCT01048463|PLACEBO_COMPARATOR|EN|The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.
62507485|NCT01048463|EXPERIMENTAL|ENLDEPA|The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
62507486|NCT01048463|EXPERIMENTAL|ENHDPEA|The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
62507487|NCT00472953|EXPERIMENTAL|A|
62507488|NCT00472953|ACTIVE_COMPARATOR|B|
62507489|NCT02429375|EXPERIMENTAL|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35)|Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
62507490|NCT01879631||mild to moderate keratoconus cases|keratoconus with a central corneal thickness (CCT) over 400µm, poor corrected visual acuity (≤0.4 at Snellen visual acuity charts), contact lens intolerance, no apical scarring, no ocular or systemic problem other than keratoconus
62507491|NCT05968963|EXPERIMENTAL|Mindfulness-based Music Therapy (MBMT)|Participants will be in the MBMT group for 5 months.
62507492|NCT05968963|EXPERIMENTAL|Mindfulness Meditation (MM)|Participants will be in the MM group for 5 months.
62705443|NCT05646355|EXPERIMENTAL|Proactive Screening Outreach|"Participants will receive a letter from their clinic explaining CRC screening options (fecal immunochemical test (FIT) vs colonoscopy) including a FIT kit with completion and return instructions. The letter will also include information for navigation to a screening colonoscopy instead of FIT testing, if deemed to be the participant's preference.~Approximately 10-14 days after mailing the FIT kit, participants who have not completed screening will receive a telephone call (with voice message left) and text message, querying whether the FIT kit was received and reminding the participant to complete the test or request a new kit, if needed.~If the FIT kit has not been submitted after about two weeks from the reminder call/text message, the study team will mail a final letter to the participant on behalf of the clinic, reminding them to complete and return the FIT kit."
62705444|NCT05646355|ACTIVE_COMPARATOR|Usual Care|Individuals in the usual care group will not be approached or notified of their enrollment in the study.
62705445|NCT04531917|EXPERIMENTAL|Pain Neuroscience Education + Behavioural Graded Activity|Patients allocated to the intervention group will receive a 12-week treatment program that consists of 6 sessions, in which 'Pain Neuroscience Education' and 'Behavioural Graded Activity' will be integrated.
62705446|NCT04531917|ACTIVE_COMPARATOR|Usual care|"Patients allocated to the control group will receive an information leaflet from Kom op tegen kanker regarding Pain in and after cancer."
62736679|NCT01234480|EXPERIMENTAL|Participants with Cervical Disease|Participants positive for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
62736680|NCT01234480|EXPERIMENTAL|Participants without Cervical Disease|Participants negative for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
62144356|NCT01278030|NO_INTERVENTION|Control group|Patients will be implanted according to the standard of care with the LV lead in the traditional LV lead position.
62736681|NCT04052750|NO_INTERVENTION|The control group|Patients in this group only received medications without daily text message reminder
62736682|NCT04052750|EXPERIMENTAL|The intervention group|Patients in this group received a daily short message service (SMS) reminder when medications were prescribed
61964155|NCT00802139|EXPERIMENTAL|venoferrum group|
61964156|NCT00802139|ACTIVE_COMPARATOR|Bolgre group|
62144357|NCT01278030|EXPERIMENTAL|3D echo-guided LV lead placement group|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.
62144358|NCT05208034|NO_INTERVENTION|single-dose group|Women in single-dose group were administered a single-dose of intramuscular methotrexate as 50 mg/m2 on day-zero (the start of treatment).
62144359|NCT05208034|EXPERIMENTAL|two-dose group|Women allocated to two-dose group were administered intramuscular methotrexate as 50mg/m2 at day-zero and 7 while measurement of β-hCG was ordered at day-14.
62144360|NCT05825274|EXPERIMENTAL|Refractory Epilepsy Group|50 patients with at least they have 3 crisis per week They Receive Cathodal tDCS We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
62144361|NCT05825274|PLACEBO_COMPARATOR|Placebo Patients|50 patients with at least they have 3 crisis per week that receive SHAM They Not Receive Cathodal tDCS. We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
62507493|NCT05701618|EXPERIMENTAL|Psychologically Informed Education|is arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with atraumatic lower extremity injuries.
62507494|NCT05701618|PLACEBO_COMPARATOR|Control Education|This arm will provide education of basic leg anatomy and will not address maladaptive psychological behaviors.
62507495|NCT03844828|EXPERIMENTAL|POD FT IOL Implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT and POD F.
62507496|NCT01897168||No grouping|
61964157|NCT05858710|EXPERIMENTAL|IV DPPG2-TSL-DOX|"DPPG2-TSL-DOX (20 or 40 or 50 mg/m\^2) + regional hyperthermia (RHT)~3 dose levels are planned in this study: dose level 1 will be receiving 20 mg/m\^2 DPPG2-TSL-DOX dose level 2 will be receiving 40 mg/m\^2 DPPG2-TSL-DOX dose level 3 will be receiving 50 mg/m\^2 DPPG2-TSL-DOX~Participants are to be treated with DPPG2-TSL-DOX infusion over 30 minutes and RHT every three weeks (one cycle = 21 days), receiving up to 6 cycles in total:~* In the first cycle (cycle 1), DPPG2-TSL-DOX application will be performed without RHT in all participants for safety precaution.~* In cycles 2-6, DPPG2-TSL-DOX will be applied in parallel with RHT. Dexrazoxane as cardioprotectant will be provided for participants overcoming a cumulative dose of 300 mg/m\^2 DOX."
61964158|NCT01654029|NO_INTERVENTION|Control group receiving usual care|Usual care consists of speech language therapy for some patients. Most care is focused on swallowing assessments.
61964159|NCT01654029|EXPERIMENTAL|PCCI Intervention|The Patient-Centred Communication Intervention consists of 1) development of a communication care plan; 2)a workshop for staff focused on communication and behavioural management strategies,: and 3) implementing a staff support system.
61964160|NCT03018821|ACTIVE_COMPARATOR|Standard CMF|"Standard Chinese medical formulas (CMF) for the corresponding TCM syndromes, plus an anti-virus treatment of western drugs (such as Entecavir or Tenofovir).~1. Yinchengao Decoction plus Ganlu Detoxification Pill for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~2. Chaihu Shugan San for the TCM syndrome: Liver depression and qi stagnation~3. Xiaoyao powder for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~4. Yiguan Decoction for the TCM syndrome: Yin deficiency of liver and kidney~5. Fuzilizhong Decoction plus Jinkui Shenqi Bolus for the TCM syndrome: Yang deficiency of spleen and kidney~6. Ge Xia Zhu Yu Decoction for the TCM syndrome: Internal blood stasis"
61964161|NCT03018821|EXPERIMENTAL|Advanced CMF|"Advanced TCM formulas for corresponding TCM syndromes provided by famous TCM doctors who were national wide known in China, plus an anti-virus western drugs (such as Entecavir or Tenofovir).~1. Taohong Huazhuo Decoction for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~2. Soothe the liver and regulate qi Decoction for the TCM syndrome: Liver depression and qi stagnation~3. Supplemented Ganbi Decoction for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~4. Supplemented Zimu Dan for the TCM syndrome: Yin deficiency of liver and kidney~5. Guifu Erxian Decoction for the TCM syndrome: Yang deficiency of spleen and kidney~6. Supplemented Ganji Decoction for the TCM syndrome: Internal blood stasis"
61964162|NCT03018821|EXPERIMENTAL|Pure Entecavir or Tenofovir|Use an anti-virus western drug alone (such as Entecavir or Tenofovir).
62144362|NCT02733159|EXPERIMENTAL|Pembrolizumab|Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
62349337|NCT03371342|ACTIVE_COMPARATOR|BOTOX|
61964163|NCT01612481|ACTIVE_COMPARATOR|chest radiography|clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
61964164|NCT01612481|ACTIVE_COMPARATOR|chest CT|clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year
61964165|NCT06113744|EXPERIMENTAL|Low-dose test vaccine, 1 dose|
61964166|NCT06113744|EXPERIMENTAL|Mid-dose test vaccine, 1 dose|
61964167|NCT06113744|EXPERIMENTAL|High-dose test vaccine, 1 dose|
61964168|NCT06113744|PLACEBO_COMPARATOR|Placebo, 1 dose|
61964169|NCT06113744|EXPERIMENTAL|Low-dose test vaccine, 2 dose|
61964170|NCT06113744|EXPERIMENTAL|Mid-dose test vaccine, 2 dose|
61964171|NCT06113744|EXPERIMENTAL|High-dose test vaccine, 2 dose|
61964172|NCT06113744|PLACEBO_COMPARATOR|Placebo, 2 doses|
61964173|NCT06113744|ACTIVE_COMPARATOR|Active control vaccine, 2 doses|
61964174|NCT04464889|EXPERIMENTAL|MDG1021|Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
61964175|NCT00757887|EXPERIMENTAL|EHMI8|Previously protected volunteers, N=10
61964176|NCT00757887|ACTIVE_COMPARATOR|control|5 malaria-naive volunteers
61964177|NCT03450746||Healthy patients for orthopaedic surgery|Standard general anaesthesia and ventilation with FiO2 0.50 for at least 45 minutes following the standard settings in our department.
61964178|NCT00650260|EXPERIMENTAL|vH2 System Group|The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
61964179|NCT00650260|ACTIVE_COMPARATOR|Control Group|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
62144363|NCT01681485||NSCL cancer patients|Surgery, chemotherapy and/or radiation therapy
62144364|NCT04016207||Guanfacin regular treatment|
62144365|NCT05202366||Treatment group|Only one treatment group (CGB-400 Topical Gel) will be used for analysis
62349338|NCT01566058|EXPERIMENTAL|With BB Box|"The mothers in this arm of the study will have access to a BB Box video system to maintain contact with their premature baby."
62349339|NCT01566058|ACTIVE_COMPARATOR|Without BB Box|"The mothers in this arm of the study will not have access to a BB Box video system to maintain contact with their premature baby. (Standard care)"
62349340|NCT02140619|ACTIVE_COMPARATOR|multiple health education interventions|The group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular text message during 1 year after discharge.
62507497|NCT06080659|EXPERIMENTAL|DCS+|Patient with subjective cognitive decline, prodromal condition of Alzheimer's disease
61964180|NCT01461603|ACTIVE_COMPARATOR|Amino acids|Amino acids compared to saline
61964181|NCT01461603|ACTIVE_COMPARATOR|3hydroxybutyrat (3OHB)|Ketone body, 3OHB compared to saline
61964182|NCT04755127|ACTIVE_COMPARATOR|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
61964183|NCT04755127|EXPERIMENTAL|arthroscopic synovectomy|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
61964184|NCT04954703|EXPERIMENTAL|Muscle energy technique of gluteus maximus and tensor fascia lata|INTERVENTIONAL GROUP (muscle energy technique of gluteus maximus and tensor fascia lata)
61964185|NCT04954703|ACTIVE_COMPARATOR|Myofascial release of iliotibial band|CONTROL GROUP(Myofascial release of iliotibial band)
61964186|NCT02085317|OTHER|Lepromatous Patients|Composed of patients with lepromatous Leprosy acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
61964187|NCT02085317|OTHER|Healthy Patients|Composed of patients without any disease acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
61964188|NCT00272467|EXPERIMENTAL|Rebamipide|"1. Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) Rebamipide 100mg, t.i.d. (before breakfast, evening, before bed).~2. Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
61964189|NCT00272467|ACTIVE_COMPARATOR|Omeprazole|"1. Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) omeprazole 20mg, once daily (before breakfast)~2. Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
61964190|NCT04073498|EXPERIMENTAL|Part 1a - Cohort 1|A single IV infusion of 0.0003 mg/kg SerpinPC in healthy subjects.
61964191|NCT04073498|EXPERIMENTAL|Part 1a - Cohort 2|A single IV infusion of 0.001 mg/kg SerpinPC in healthy subjects.
61964192|NCT04073498|EXPERIMENTAL|Part 1a - Cohort 3|A single IV infusion of 0.003 mg/kg SerpinPC in healthy subjects.
61964193|NCT04073498|EXPERIMENTAL|Part 1a - Cohort 4|A single IV infusion of 0.01 mg/kg SerpinPC in healthy subjects.
61964194|NCT04073498|EXPERIMENTAL|Part 1a - Cohort 5|A single SC dose of 0.03 mg/kg SerpinPC and a single SC dose of placebo in healthy subjects.
61964195|NCT04073498|EXPERIMENTAL|Part 1b - Cohort 6|A single SC dose of 0.1 mg/kg SerpinPC and a single SC dose of placebo in patients.
61964196|NCT04073498|EXPERIMENTAL|Part 1b - Cohort 7|A single SC dose of 0.3 mg/kg SerpinPC and a single SC dose of placebo in patients.
61964197|NCT04073498|EXPERIMENTAL|Part 1b - Cohort 8|A single SC dose of 0.6 mg/kg SerpinPC and a single SC dose of placebo in patients.
61964198|NCT04073498|EXPERIMENTAL|Part 1b - Cohort 9|Two single SC doses of 0.6 mg/kg SerpinPC in patients.
61964199|NCT04073498|EXPERIMENTAL|Part 2|Up to 3 SC doses may be selected for Part 2 and each patient will be assigned a single SerpinPC dose level (and placebo). The dose for Part 2 will be determined from ongoing review of the Part 1 data. The dose in Part will not exceed 1.2 mg/kg, or the highest dose deemed safe from Part 1b.
61964200|NCT04073498|EXPERIMENTAL|Part 3|A single flat SC dose of SerpinPC will be administered every 4 weeks for 48 weeks for patients who have completed Week 24 of Part 2. The dose level will be chosen after reviewing Part 2 data and will not exceed maximum dose level in Part 2.
62144366|NCT02324790|EXPERIMENTAL|Treatment|Treated with iNAP® Sleep Therapy System on the treatment PSG night.
62144367|NCT02343666|EXPERIMENTAL|Treatment (gene modified HPSC)|See Detailed Description.
62144368|NCT05132049|EXPERIMENTAL|Sequence A|
61964201|NCT04073498|EXPERIMENTAL|Part 4|SC doses of 1.2 mg/kg SerpinPC will be administered every 2 weeks for 24 weeks for patients who have completed Week 48 of Part 3.
61964202|NCT04073498|EXPERIMENTAL|Part 5|SC doses of 1.2 mg/kg SerpinPC will be administered every 2 weeks for 52 weeks for patients who have completed Week 24 of Part 4.
61964203|NCT04073498|EXPERIMENTAL|Part 6|A single flat SC dose of 60mg SerpinPC will be administered every 2 weeks for 52 weeks for patients who have completed Week 52 of Part 5.
61964204|NCT02579720||Group 1: Pollinex® Quattro Patients|Patients treated with Pollinex® Quattro
61964205|NCT02579720||Group 2: Control Patients|Patients who decided to use only anti-allergic drugs during the grass pollen season
61964206|NCT03142087|ACTIVE_COMPARATOR|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
61964207|NCT03142087|ACTIVE_COMPARATOR|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
61964208|NCT00280631|EXPERIMENTAL|1|Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
62144369|NCT05132049|EXPERIMENTAL|Sequence B|
62144370|NCT04318691||acute respiratory failure group|60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure
62144371|NCT04318691||vascular surgery control group|10 control patients admitted to the ICU after a planned vascular surgery
61964209|NCT05950490||Group A|Cerebrospinal fluid IL-10 was normal
62144372|NCT04318691||Healthy volunteers group|10 healthy subjects.
62144373|NCT01596231|PLACEBO_COMPARATOR|Placebo|This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
62144374|NCT01596231|ACTIVE_COMPARATOR|Kudzu|Kudzu 2mg
62144375|NCT03239704|EXPERIMENTAL|Telemedicine Follow-Up and Telemedicine Monitoring|
62144376|NCT03239704|ACTIVE_COMPARATOR|Minimal Intervention|
62144377|NCT04440800||Study participants|All patients will receive the intervention
62144378|NCT03066921|PLACEBO_COMPARATOR|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
62349341|NCT02140619|PLACEBO_COMPARATOR|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, text message and Digital Video Disc (DVD)
62349342|NCT05409768|EXPERIMENTAL|Short axis, out of plane approach|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein with a short axis out of the plane method
62144379|NCT03066921|EXPERIMENTAL|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
62349343|NCT05409768|EXPERIMENTAL|Short axis, anteroposterior in plane approach|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein with an anteroposterior short axis in-plane method
62349344|NCT00684112|EXPERIMENTAL|Gabapentin|Single dose preoperative gabapentin
62349345|NCT00684112|PLACEBO_COMPARATOR|Placebo Control|Single dose preoperative placebo control
62349346|NCT02683018|ACTIVE_COMPARATOR|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 Smoked Cannabis High CBD/low THC cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
62349347|NCT02683018|PLACEBO_COMPARATOR|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
62705447|NCT04224493|EXPERIMENTAL|Tazemetostat + R2 arm|"Stage 1 (Phase 1b): This phase is now completed.~* Tazemetostat was escalated from a starting dose of 400 mg PO twice daily to 600 mg PO twice daily to 800 mg PO twice daily in 28-day cycles.~* Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~* Lenalidomide 20 mg or 10 mg (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administred PO QD on days 1 to 21 for 12 cycles.~Stage 2:~* Tazemetostat 800 mg administered PO twice daily in continuous 28-day cycles.~* Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~* Lenalidomide 20 mg or 10 mg (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), PO QD on days 1 to 21 for 12 cycles.~Maintenance Therapy (Stages 1 and 2):~Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
62705448|NCT04224493|PLACEBO_COMPARATOR|Placebo + R2 Arm|"Stage 2:~* Placebo administered PO twice daily in continuous 28-day cycles.~* Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~* Lenalidomide 20 mg or 10 mg (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.~Maintenance Therapy (Stage 2):~Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy. During maintenance, placebo will be continued until disease progression or unacceptable toxicity, or participant withdraws consent."
61964210|NCT05950490||Group B|Cerebrospinal fluid IL-10 was normal or elevated
62507498|NCT06080659|EXPERIMENTAL|TCL-MA|Patient with mild neurocognitive disorder linked to Alzheimer's disease
61964211|NCT02063360|EXPERIMENTAL|Cohort 1: BMS-663068+DRV/RTV|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
61964212|NCT02063360|EXPERIMENTAL|Cohort 2: BMS-663068+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
61964213|NCT02063360|EXPERIMENTAL|Cohort 3: BMS-663068+DRV/RTV+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
61964214|NCT03910062||VA ECMO|Patients under VA-ECMO with a femoral reperfusion cannula.
61964215|NCT01802931|ACTIVE_COMPARATOR|Session 1 or Session 2|Single dose sessions without ketoconazole co-administration
61964216|NCT01802931|ACTIVE_COMPARATOR|Co-dose Session|Single dose session with ketoconazole co-administration
61964217|NCT03802136||high concentration of biomarkers|the patients with biomarkers level over the normal max value
61964218|NCT03802136||low concentration of biomarkers|the patients with biomarkers level below the normal max value
62144380|NCT04147637|EXPERIMENTAL|FSL-M|FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
62144381|NCT04147637|ACTIVE_COMPARATOR|FSL-A|FreeStyle Libre alone
62144382|NCT00360269|EXPERIMENTAL|Active|Atomoxetine plus Motivational Enhancement Therapy
62144383|NCT00360269|PLACEBO_COMPARATOR|Placebo|Placebo plus Motivational Enhancement Therapy
62349348|NCT05507970|EXPERIMENTAL|Part 1 Single Ascending Dose Cohort A|100 mg MMV367 or placebo, oral solution, fasted,
62349349|NCT05507970|EXPERIMENTAL|Part 1 Single Ascending Dose Cohort B|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
62349350|NCT05507970|EXPERIMENTAL|Part 1 Single Ascending Dose Cohort C|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
62349351|NCT05507970|EXPERIMENTAL|Part 1 Single Ascending Dose Cohort D|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
62507499|NCT06080659|EXPERIMENTAL|MPdn|early-stage or de novo Parkinson's disease patients with no cognitive deficits
62507500|NCT06080659|EXPERIMENTAL|TCL-MP|Patient with mild neurocognitive disorder linked to Parkinson's disease
62507501|NCT06080659|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers
62507502|NCT03223909|EXPERIMENTAL|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
61964219|NCT02503735|OTHER|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|10 patients with hepatitis C (HCV) and HCV-associated CKD that will receive 12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)
61964220|NCT03487068|OTHER|Patients with NAFLD|
62144384|NCT01529632|EXPERIMENTAL|QVA149|QVA149 plus placebo once daily for 28 days.
62144385|NCT01529632|ACTIVE_COMPARATOR|QAB149 + NVA237|Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.
62705449|NCT05195281|EXPERIMENTAL|Repetition of EUS-FNA or FNB for RNA extraction|
62507503|NCT03223909|ACTIVE_COMPARATOR|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.~1 drop every 4 hours for 90 days."
62507504|NCT03223909|ACTIVE_COMPARATOR|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.~1 drop every 4 hours for 90 days."
62507505|NCT04438850|EXPERIMENTAL|I_600|ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo
62507506|NCT04438850|EXPERIMENTAL|I_1200|ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
62507507|NCT04438850|PLACEBO_COMPARATOR|Placebo|placebo
62507508|NCT01472926|EXPERIMENTAL|Tenecteplase 0.25 mg/kg|Intravenous tenecteplase 0.25 mg/kg (single bolus, maximum 25 mg)
62705450|NCT06337318|EXPERIMENTAL|Arm I (Rituximab, rituximab and hyaluronidase)|Patients receive rituximab IV on day 1 of cycle 1 and receive rituximab and hyaluronidase SC on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.
62705451|NCT06337318|EXPERIMENTAL|Arm II (Mosunetuzumab)|Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.
62349352|NCT05507970|EXPERIMENTAL|Part 1 Single Ascending Dose Cohort E (optional)|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
62349353|NCT05507970|EXPERIMENTAL|Part 2 Food Effect|Open label, 2-period cross-over, randomized, food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV367 determined to be safe in Part 1.
62349354|NCT05507970|EXPERIMENTAL|Part 3 Multiple Dose Cohort A|"Double-blinded, randomised, placebo-controlled, multiple-dose study.~Intervention: MMV367 or placebo, oral solution, fasted. Once daily for 3 days."
62349355|NCT05507970|EXPERIMENTAL|Part 3 Multiple Dose Cohort B (optional)|"Multiple ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted. Once daily for 3 days."
62349356|NCT05507970|EXPERIMENTAL|Part 3 Multiple Dose Cohort C (optional)|"Multiple ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted. Once daily for 3 days."
62349357|NCT02797639|EXPERIMENTAL|Co-PID|Eight collaborative consultation meetings between occupational therapist to each teacher in purpose of enhancing participation of students in class
62349358|NCT02797639|ACTIVE_COMPARATOR|In-service|Three in- service meetings to all homeroom teachers together, in purpose of enhancing participation of students in class
62349359|NCT02000648||Patients diagnosed with chronic rhinitis or chronic urticaria|Patients diagnosed with chronic rhinitis/urticaria and followed-up at Allergy Clinics, Chulalongkorn University
62349360|NCT05137886|EXPERIMENTAL|PD-1 inhibitor combined with decitabine followed by ASCT|Patients will receive salvage treatment of PD-1 inhibitor Tislelizumab combined with decitabine for four cycles, If PR or CR was obtained after salvage treatment, patients will receive GBM (gemcitabine, bulsufan and melphalan) conditioning regimen followed by ASCT. High-risk patients will receive PD-1 inhibitor for 1 year after ASCT as maintenance therapy.
62349361|NCT02825433||Patients receiving procedural sedation|The investigators collected ventilation data for each breath (respiratory rate, tidal volume, and end-tidal CO2) for all patients receiving procedural sedation for endoscopy.
62349362|NCT05275452||School age children aged 9-13 years|
62349363|NCT05275452||Women of reproductive age aged 18-44 years|
62349364|NCT02325687|EXPERIMENTAL|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
62507509|NCT01472926|ACTIVE_COMPARATOR|Alteplase 0.9 mg/kg|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
62507510|NCT00749411|EXPERIMENTAL|Arm 1|
62507511|NCT00749411|PLACEBO_COMPARATOR|Arm 2|
62507512|NCT03417830|EXPERIMENTAL|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
62507513|NCT03417830|EXPERIMENTAL|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
62507514|NCT03427476|EXPERIMENTAL|Metastatic RCC (> 3 lesions)|Patients with metastatic renal cell carcinoma and planned biopsy of a metastatic lesion (N = 5)
62507515|NCT03427476|EXPERIMENTAL|RCC patients with primary lesions > 7 mm in diameter|Cohort B: Patients with evidence of primary renal cell carcinoma and lesions \> 7 cm (may also have metastatic disease) (N = 5)
62507516|NCT01940302|EXPERIMENTAL|LEHEL multi-nutrients supplement|75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
62507517|NCT01940302|NO_INTERVENTION|Control|Received only oral hypoglycemic agents.
62507518|NCT04003818|EXPERIMENTAL|Teicoplanin|teicoplanin, administered orally 100-200 mg, twice a day
62507519|NCT04122781|EXPERIMENTAL|with novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation and novel K-wire fixation devices
62507520|NCT04122781|ACTIVE_COMPARATOR|without novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation
62507521|NCT02563418|EXPERIMENTAL|Patient with Huntington's disease|
62507522|NCT00436917|EXPERIMENTAL|zoledronic acid|4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.
62705452|NCT05663801|ACTIVE_COMPARATOR|Group A (control group )|Patients will be given 30 mL of 0.25% bupivacaine hydrochloride in pectoral nerve block .
62507523|NCT04451928||Preterm delivery|Pregnant women who give birth before 37th gestational week
62705453|NCT05663801|ACTIVE_COMPARATOR|Group B ( Ketamine group)|Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) in pectoral nerve block .
61964221|NCT01362205|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine titrated to achieve predefined goals on selected components of the MINDS score using the minimum amount of medication possible. Blinded study medication will be started at a rate determined by the MINDS score. The maximum infusion rate is 1.4 μg/kg per hour. Uncontrolled SAWS/D symptoms, will be treated with open label lorazepam according to the MINDS score algorithm. Persistent SAWS/D symptoms despite maximum infusion rate of study medication treatment limiting symptoms while receiving higher infusion rates of study medication, ancillary therapies will be administered according to the MINDS score algorithm, at the discretion of the treating physician.
61964222|NCT01362205|PLACEBO_COMPARATOR|Placebo|Blinded placebo study drug administration in equal volume per hour as active study medication arm.
61964223|NCT02250170|EXPERIMENTAL|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
62144386|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
62349365|NCT02325687|EXPERIMENTAL|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
62144387|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
62144388|NCT06510673|EXPERIMENTAL|Shockwave therapy|Shockwave therapy for calcaneal spur
62144389|NCT06510673|EXPERIMENTAL|High-power LASER therapy|High-power LASER therapy for calcaneal spur
62144390|NCT06510673|SHAM_COMPARATOR|Control|cold application with receive 6 sessions of sham LASER therapy.
62144391|NCT06510673|EXPERIMENTAL|Platelet rich plasma|Platelet-rich plasma injection for the heel
62144392|NCT01113736|EXPERIMENTAL|Human Peritoneal Membrane: AlloMEM™|For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
62144393|NCT03389789|EXPERIMENTAL|Oral glucose solution + maternal holding|Infants will receive 2 mL of oral glucose solution two minutes before the heel-prick and will be held in the mothers' lap (maternal relationship) throughout the painful procedure.
62144394|NCT03389789|EXPERIMENTAL|Breastfeeding|Infants will be breastfed two minutes before the heel-prick and throughout the painful procedure.
62144395|NCT03389789|ACTIVE_COMPARATOR|Oral glucose solution|Infants will receive 2 mL of oral glucose solution given two minutes before the heel-prick on a changing table.
62349366|NCT02325687|EXPERIMENTAL|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score \<3 are considered to have minimal risk for OSA and will be included in the control group.~Intervention: Lumbar Puncture (Standard-of-Care)"
62507524|NCT04451928||Term delivery|Pregnant women who will give birth 37th and after gestational week
62507525|NCT02457819|EXPERIMENTAL|Dasotraline|Dasotraline 2, 4, 6 mg
61964224|NCT04884477||COVID-19 with previous anti-CD20 therapy and Convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy and who received Convalescent plasma in addition to standard treatment for COVID-19
61964225|NCT04884477||COVID-19 with previous anti-CD20 therapy and no convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy treated with standard COVID-19 treatment and who did not receive Convalescent plasma treatment for COVID-19
61964226|NCT02139111|PLACEBO_COMPARATOR|Placebo|Placebo Arm
61964227|NCT02139111|ACTIVE_COMPARATOR|PRC-063 25 mg and Placebo|PRC-063 25 mg and placebo capsule by mouth once daily
61964228|NCT02139111|ACTIVE_COMPARATOR|PRC-063 45 mg and Placebo|PRC-063 45 mg and placebo capsule by mouth once daily
61964229|NCT02139111|ACTIVE_COMPARATOR|PRC-063 70 mg and Placebo|PRC-063 70 mg and placebo capsule by mouth once daily
61964230|NCT02139111|ACTIVE_COMPARATOR|PRC-063 85 mg and Placebo|PRC-063 85 mg and placebo capsule by mouth once daily
61964231|NCT03036696||Pregnant Mothers Interview|(1) 18 years old or over, (2) between 28-38 weeks of pregnancy, (3) lives in Gainesville, Florida, and (4) are committed to exclusively breastfeeding through 6 months.
61964232|NCT03036696||Breastfeeding Mothers Interview|(1) 18 years old or over, (2) actively breastfeeding infant less than 12 months of age, and (3) lives in Gainesville, Florida.
61964233|NCT00763672|OTHER|A|sFlt-1 status known
61964234|NCT00763672|OTHER|B|sFlt-1 status unknown
62144396|NCT03389789|ACTIVE_COMPARATOR|Oral expressed breastmilk|Infants will receive 2 mL of expressed breastmilk given two minutes before the heel-prick on a changing table.
62144397|NCT05192382|EXPERIMENTAL|Paltusotine|
62144398|NCT05192382|PLACEBO_COMPARATOR|Placebo|
62144399|NCT02322424||Patients who undergo pancreaticoduodenectomy|
62144400|NCT03078205|NO_INTERVENTION|The control group|No Intervention
62144401|NCT03078205|EXPERIMENTAL|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
62144402|NCT03078205|EXPERIMENTAL|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
62144403|NCT00914641|OTHER|Apixaban Cross-over|
62736683|NCT02297711|EXPERIMENTAL|Total ExtraPeritoneal|Total ExtraPeritoneal (TEP) technique in general anesthesiacanal from behind
62705454|NCT05663801|ACTIVE_COMPARATOR|Group C (Magnesium sulfate group)|Patients will be given 30 mL 0.25% bupivacaine hydrochloride plus magnesium sulfate ( 28 ml bupivacaine 0.25% plus 2ml magnesium sulfate (50%) in pectoral nerve block
61964235|NCT05329974|EXPERIMENTAL|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
61964236|NCT00830362|ACTIVE_COMPARATOR|Propranolol 40mg|
61964237|NCT00830362|PLACEBO_COMPARATOR|Placebo|
62349367|NCT04490317||Acute CO poisoning|A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin \>5% (\>10% in smokers).
62349368|NCT00553553|ACTIVE_COMPARATOR|1|IV morphine group
62349369|NCT00553553|EXPERIMENTAL|2|Remifentanil-intrathecal morphine group
62349370|NCT01958879|EXPERIMENTAL|ringer with corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups .In this group patients received 1mg dexamethasone after finishing the irrigation .
62349371|NCT01958879|PLACEBO_COMPARATOR|Ringer with out corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups
62349372|NCT03623334|EXPERIMENTAL|Dose Level A: IGRT 3.33Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks
61964238|NCT01839851||Asthma|Treatment with any inhaled corticosteroid
62349373|NCT03623334|EXPERIMENTAL|Dose Level B: IGRT 3.67Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks
62349374|NCT03623334|EXPERIMENTAL|Dose Level C: IGRT 4.00Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 60 Gy) which is given over the course of about 3 weeks
62349375|NCT04084249|EXPERIMENTAL|ctDNA guided surveillance|ctDNA analysis will be performed every 4 months postoperatively (4, 8, 12, 16, 20 and 24). At time of first positive ctDNA, patients undergo a whole-body FDG-PET/CT-scan for radiological assessment and a colonoscopy. If the initial assessment is without evidence of recurrence, patients will be offered high-intensive radiological surveillance with FDG-PET/CT-scans every 3 months, until recurrence detection or 21 months has passed. At baseline and months 12, 18, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C). At every FDG-PET/CT-scans the patients also complete the questionnaire.
61964239|NCT01839851||Allergic rhinitis|Treatment with any intranasal glucocorticoid
61964240|NCT01839851||Asthma and allergic rhinitis|Inhaled corticosteroid + intranasal glucocorticoid
61964241|NCT06145061||POI patients|POI patients:1.meet the diagnostic criteria for POI:POI diagnostic criteria refer to the 2016 European Society for Reproductive Medicine POI guidelines:Age \< 40 years; Oligomenorrhea or amenorrhea for at least 4 months; Two measurements (on day 2-4 of the menstrual cycle, at least 4 weeks apart)Follicle Stimulating Hormone（FSH） \> 25 IU/L and meet the above three requirements.2.18 years old ≤ age \< 40 years old, gender female; 3.They are conscious and able to communicate normally.4.Provide recent transvaginal ultrasound or pelvic color Doppler ultrasound examination report to determine the menstrual cycle.5.Those who understand and are willing to comply with the study protocol and sign the informed consent form.
61964242|NCT06145061||healthy subjects|Healthy subjects:1.Healthy subjects who can provide physical examination report within the past 1 year and have routine physical examination by the investigator, and confirm that they have no serious underlying diseases such as reproductive system, urinary system, blood, endocrine system and nervous system;2.Currently no symptoms of oligomenorrhea or amenorrhea;3.18 years ≤ age \< 40 years, female;4.Those who understand and are willing to comply with the study protocol and sign the informed consent form.
61964243|NCT05251090|EXPERIMENTAL|Arm 1|Subjects(up to 12 years of age) received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW107 in the second period.
61964244|NCT01167894|EXPERIMENTAL|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
62349376|NCT04084249|NO_INTERVENTION|Standard Danish follow-up program|Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At baseline and months 12, 18, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).
62705455|NCT06531083|EXPERIMENTAL|Prospective Surveillance for Trismus and Early Physical Therapy Intervention|Weekly monitoring of mouth opening and jaw function. Early intervention if the participant presents with 5% or greater reduction in mouth opening compared to pre-treatment measures. Early intervention will comprise: physical therapy, home exercises and use of a jaw stretching device.
62705456|NCT00028080||Lyme Disease|Participants who have been diagnosed with or are strongly suspected to have Lyme disease.
62736684|NCT02297711|ACTIVE_COMPARATOR|Open minimal suture repair|Open minimal repair (OMR) technique in local or spinal anesthesia
61964245|NCT01167894|ACTIVE_COMPARATOR|Zocor|Zocor® 80 mg tablets of Merck \& Co. Inc., USA
61964246|NCT04528381|OTHER|Laparoscopy|Diagnostic and therapeutic laparoscopy
61964247|NCT06378476|EXPERIMENTAL|CHW + TIC|Patients in this arm will receive 6 months of support from a community health worker as well as primary care from a clinic where clinicians and staff have undergone trauma-informed care training.
61964248|NCT06378476|EXPERIMENTAL|TIC only|Patients in this arm will receive primary care from a clinic where clinicians and staff have undergone trauma-informed care training.
61964249|NCT06378476|NO_INTERVENTION|Usual Care|Patients in this arm will receive usual care.
61964250|NCT04815161|OTHER|Pilloxa pillbox|Patients receiving the Pilloxa pillbox for drug administration
61964251|NCT02205112|EXPERIMENTAL|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL, intravenous administration, once daily for 7\~14 days
61964252|NCT02205112|ACTIVE_COMPARATOR|Levofloxacin 500mg|Levofloxacin: 500mg/100mL, intravenous administration, once daily for 7\~14 days
61964253|NCT02052583|EXPERIMENTAL|34°C|therapeutic hypothermia at 34 ° C
61964254|NCT02052583|EXPERIMENTAL|32°C|therapeutic hypothermia at 32 ° C
61964255|NCT03765905||PCOS diagnosis area|The study group consisted of 40 reproductive age women between 18th and 35th years old women who were PCOS diagnosis (according to the 2003 Rotherdam criteria)
61964256|NCT03765905||PCOS is not diagnosed|Forty patients who did not have any complaints between the ages of 18-35 who applied to the gynecology policlinic as a control group but who had no PCOS orany other systemic problems and were similar in terms of age group and body mass index were included in the study after being approved for participation in the study
61964257|NCT05349175|EXPERIMENTAL|Cohort A|Receives AIR device feedback beginning immediately after training
61964258|NCT05349175|EXPERIMENTAL|Cohort B|Receives AIR device feedback beginning 2 months after training
61964259|NCT05349175|EXPERIMENTAL|Cohort C|Receives AIR device feedback beginning 4 months after training
61964260|NCT04211623|ACTIVE_COMPARATOR|Constraint induced movement therapy group|Constrained on more affected side for three hours.
62144404|NCT01961609|EXPERIMENTAL|Secukinumab (AIN457) 300 mg|Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 \& 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.
62144405|NCT01961609|EXPERIMENTAL|Secukinumab (AIN457) 150 mg|Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 \& 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg.
61964261|NCT04211623|ACTIVE_COMPARATOR|Bimanual activities group; BIM training|Set of bimanual activities performed.
61964262|NCT04462445|EXPERIMENTAL|pazopanib|Pazopanib 800 mg (2x400mg ) taken orally daily as per clinical practice
61964263|NCT04277416||Entrada Hip System|All orthopaedic patients that are scheduled to undergo primary total hip arthroplasty using the Entrada™ Hip System within 12 weeks will be screened for the following eligibility criteria.
61964264|NCT05715034|EXPERIMENTAL|Compassionate Care|Single-session, self-guided web-based intervention (\~45 minutes) hosted on Qualtrics with animated videos, audio-guided exercises, graphics, text-based material, and interactive questions. This intervention is designed to teach participants about mindfulness and self-compassion.
61964265|NCT05715034|ACTIVE_COMPARATOR|Relaxing with Nature|Single-session self-guided web-based intervention (\~30 to 45 minutes) hosted on Qualtrics with videos (real-life images), text-based material, and questions. Each video includes a sequence of pleasant nature photos (shown about 6 seconds each) with relaxing music in the background.
61964266|NCT03771677|ACTIVE_COMPARATOR|Active Comparator:NAs group|"Active Comparator:nucleotide analogues(NAs)~patients continue to use NAs"
61964267|NCT03771677|EXPERIMENTAL|Experimental:PEG-IFN group|"Experimental: peg-interferon alfa-2a~patients use peg-interferon α-2a and nucleotide analogues(NAs)"
62144406|NCT02356055|EXPERIMENTAL|Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 3 hours/day, 5 days/week for 2 weeks. Participants will choose functional goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. For the intensive protocol, each hour of training will focus on 1 of 3 identified goals and will include 50 minutes of intervention and a 10 minute break."
62144407|NCT02356055|ACTIVE_COMPARATOR|Less-Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 1 hour/day, 2 days/week for 2 weeks. Participants will choose goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. In the less-intensive protocol, each of the 3 ADL goals will be practiced as many times as possible within 20 minutes of the scheduled hour."
62349377|NCT02982486|EXPERIMENTAL|Nivolumab and ipilimumab|Nivolumab 240 mg IV every 2 weeks plus Ipilimumab 1 mg/m2 IV every 6 weeks
62349378|NCT01963754|EXPERIMENTAL|Subepriosteal Articaine|Administer Subperiosteal 1:100.000 Articaine 4% epinephrine, buccal and lingually, for Dental Implants in Posterior mandible
61964268|NCT00996645|NO_INTERVENTION|Feedback report only|This arm will receive performance feedback reports but no worksheet to facilitate goal-setting and action plans.
61964269|NCT00996645|EXPERIMENTAL|Goal-Setting Worksheet|This arm will receive a theory-informed worksheet to facilitate the development of goals and action plans in response to the performance feedback reports.
61964270|NCT05529303|EXPERIMENTAL|Intervention group|The intervention group determined by the randomization method will be given the 'Feminine Identity Improvement Program', based on cognitive behavioral and expressive techniques, which is structured to be 90-120 minutes once a week for 10 weeks. The program to be applied to the intervention group has been created by the researcher in line with the literature review and the necessary expert opinions were obtained.
61964271|NCT05529303|NO_INTERVENTION|Control group|No intervention will be applied to the control group during the study.
61964272|NCT02272595||Arm A - Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
61964273|NCT02272595||Arm B - Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
61964274|NCT00627120|EXPERIMENTAL|1|1mg dose group
61964275|NCT00627120|EXPERIMENTAL|2|10mg dose group
61964276|NCT00627120|EXPERIMENTAL|3|100mg dose group
61964277|NCT00627120|EXPERIMENTAL|4|200mg dose group
61964278|NCT00627120|EXPERIMENTAL|5|400mg dose group
61964279|NCT00627120|EXPERIMENTAL|6|800mg dose group
61964280|NCT02662296|EXPERIMENTAL|Treatment (ibrutinib or idelalisib)|Patients receive ibrutinib PO QD on days 1-28 or idelalisib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61964281|NCT00064116|ACTIVE_COMPARATOR|Arm A: CHOP-21|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
61964282|NCT00064116|ACTIVE_COMPARATOR|Arm B: CHOP-21 + Rituximab|Rituximab 375 mg/m² i.v. day 1\* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
62144408|NCT01847768|EXPERIMENTAL|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
62349379|NCT01963754|ACTIVE_COMPARATOR|Loco-regional Articaine|Administer Loco-regional 1:100.000 articaine 4% epinephrine, for Dental Implants in Posterior Mandible
61964283|NCT06083272||Study population|"The study population is comprised of two subgroups;~1. Adult patients admitted to the Emergency Ward (EW). Patients are recruited after the treatment and examination in EW are finished and the patient is waiting for transfer to a hospital ward.~2. If there is a prolonged period of waiting time for a control blood sample, chest CT or any other examination which usually incurs significant waiting time in the EW. This will be evaluated by a specialist in emergency medicine based on the premise that the inclusion in the study will not delay or interfere with these examinations."
61964284|NCT04191720|NO_INTERVENTION|Control group|The control group, or usual care group, will receive occupational therapy standard of care. Occupational therapy standard of care provide training, education, and therapeutic activities including relaxation strategies. These coping mechanisms are aimed at reducing the impact of anxiety on a patient's performance and participation in necessary and meaningful activities of daily living, refeeding and medical stabilization. Specifically, these interventions will include diaphragmatic and yogic breathing exercises, mindfulness-based cognitive therapy (MBCT) education and exercises, therapeutic restorative yoga activities, occupational therapy group participation, aromatherapy, identifying and promoting engagement in meaningful leisure activities, client-centered sensory diets to provide patients with consistent preferred sensory experiences, and individualized checklists and schedules to grade the self-initiation of effective coping strategies.
61964285|NCT04191720|EXPERIMENTAL|Weighted blanket group|In the weighted blanket intervention group, patients will receive usual occupational therapy care in addition to a weighted blanket. The patient will be given an appropriately weighted blanket, within 1 lb +/- of 10% of body weight as measured on day of admission. Further, the occupational therapy will provide education to the patient on the use of the weighted blanket. Patients will be free to use the weighted blanket at their discretion, however, during meals, over the shoulders or head, and during ambulation, weighted blanket use will not be permitted.
61964286|NCT05013593|EXPERIMENTAL|Symptomatic RCE|Bladder symptomatic group receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
62144409|NCT01847768|ACTIVE_COMPARATOR|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
62144410|NCT01632956||in-person support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
62349380|NCT00709917||A|
62349381|NCT01059396|EXPERIMENTAL|Propranolol|
62349382|NCT01059396|EXPERIMENTAL|carvedilol|
62349383|NCT01059396|PLACEBO_COMPARATOR|Placebo|
62507526|NCT00574067|EXPERIMENTAL|Buprenorphine+OTP|Buprenorphine and counseling in prison and continued at opioid treatment program (OTP) upon release.
61964287|NCT05013593|EXPERIMENTAL|Healthy RCE|Healthy group without bladder symptoms receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
62349384|NCT05883085|OTHER|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
62507527|NCT00574067|EXPERIMENTAL|Buprenorphine+CHC|Buprenorphine and counseling in prison and continued at a community health center (CHC) upon release.
62507528|NCT00574067|ACTIVE_COMPARATOR|Counseling + OTP|Counseling only in prison and Buprenorphine upon release at a opioid treatment program (OTP)
62507529|NCT00574067|ACTIVE_COMPARATOR|Counseling + CHC|Counseling only in prisons and Buprenorphine upon release at a community health center (CHC)
61964288|NCT05013593|PLACEBO_COMPARATOR|Symptomatic PL|Bladder symptomatic group receiving placebo
61964289|NCT05013593|PLACEBO_COMPARATOR|Healthy PL|Healthy group without bladder symptoms receiving placebo
61964290|NCT00461045|EXPERIMENTAL|MRZ 0.5 mg/m^2|Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
61964291|NCT06280937|NO_INTERVENTION|Control Group|In this group, participants will go on their daily activities. No additional intervention will be applied to the participants in this group.
61964292|NCT06280937|EXPERIMENTAL|Study Group|In this group, participants will wear a tie during one office working day
61964293|NCT00719420|EXPERIMENTAL|1|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid for 14 days (with or without omeprazole 20 mg bid)
61964294|NCT00719420|ACTIVE_COMPARATOR|2|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
61964295|NCT04271137|OTHER|Orbital fractues|Orbital fractures
61964296|NCT00353262|EXPERIMENTAL|1|
61964297|NCT01085747||Plastic stent|
61964298|NCT01085747||Covered SEMS|
61964299|NCT02888886|EXPERIMENTAL|COPD|
61964300|NCT03910023|ACTIVE_COMPARATOR|Control group|The control group will perform home exercises alone
61964301|NCT03910023|EXPERIMENTAL|Spa group|The spa group will be proposed an additional spa treatment
61964302|NCT04953000||All Participants|Male participants with severe or moderate hemophilia A who have been treated with FVIII concentrate octocog alfa (Advate) during at least 12 months prior to the study enrollment, who started octocog alfa treatment in 2021 or currently being treated with octocog alfa will be observed in this study.
61964303|NCT05536986||Observation group of newly oligodendroglioma patients with high-level psychological stress|The patients had high threshold levels of perceived psychological stress, fear, anxiety, and depression as assessed by psychologists
61964304|NCT05536986||Observation group of newly oligodendroglioma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
61964305|NCT03304743||Post-menopausal women|A cohort of 124 consecutive post-menopausal women that performed a DXA scan within the previous 12 months
61964306|NCT05037708|EXPERIMENTAL|Group 1|Group 1 receives treatment A for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B was applied to group 1.
62144411|NCT01632956||virtual support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
62144412|NCT01276743||T1DM|Children and adolescents with T1DM
62144413|NCT01276743||Unaffected Population|Population not known to be affected by T1DM
61964307|NCT05037708|ACTIVE_COMPARATOR|Group 2|Group 2 receives treatment B for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A was applied to group 2 .
61964308|NCT06451978|EXPERIMENTAL|Intervention group|Participants will receive the intervention first. Caregivers will attend a one-off training session on how to deliver the intervention. Then the participants will follow the sessions in the intervention manual (8 sessions weekly).
61964309|NCT06451978|ACTIVE_COMPARATOR|Waitlist-control group|Participants will receive the intervention after the intervention group has finished the intervention. Caregivers will attend a one-off training session on how to deliver the intervention. Then the participants will follow the sessions in the intervention manual (8 sessions weekly).
61964310|NCT03053544|EXPERIMENTAL|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
61964311|NCT02835924|ACTIVE_COMPARATOR|Arm A|160 mg/day 3w on/1w off
61964312|NCT02835924|EXPERIMENTAL|Arm B|120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
61964313|NCT02835924|EXPERIMENTAL|Arm C|160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
61964314|NCT02026739|EXPERIMENTAL|low supplemental oxygen concentration|The group in which low supplemental oxygen concentration of 40% will be performed during minimally invasive esophagectomy.
61964315|NCT02026739|ACTIVE_COMPARATOR|high supplemental oxygen concentration (conventional)|The group in which high supplemental oxygen concentration (onventional) of 80% will be performed during minimally invasive esophagectomy.
62144414|NCT00391170|EXPERIMENTAL|Dexamethasone oral rinse in stem cell transplant participants|Dexamethasone 0.01% (0.5mg/5 mL) oral rinse solution in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
61964316|NCT04767373|EXPERIMENTAL|Clesrovimab|Participants receive a single intramuscular (IM) administration of clesrovimab on Day 1.
61964317|NCT04767373|PLACEBO_COMPARATOR|Placebo|Participants receive a single IM administration of placebo on Day 1.
61964318|NCT05226715|EXPERIMENTAL|Intervention|Received a bilateral, lower extremity manipulation series
61964319|NCT05226715|NO_INTERVENTION|Control|30 seconds of lying supine on a chiropractic bench (control) without manual manipulation
61964320|NCT00491075|EXPERIMENTAL|Pemetrexed + Gemcitabine|Pemetrexed 500 mg/m\^2 intravenous (IV) and Gemcitabine 1500 mg/m\^2 IV on Day 1.
61964321|NCT03642405||Methylphenidate-Group|The group is examined before and after intake of Methylphenidate
62144415|NCT00391170|PLACEBO_COMPARATOR|Placebo oral rinse in stem cell transplant participants|Placebo oral rinse in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
62144416|NCT04103099|OTHER|HLNatural Immune Cohort|Observational one arm virtual study of HLNatural Immune supplement
61964322|NCT03642405||Methylphenidate and know QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
61964323|NCT03642405||Methylphenidate and non-QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
61964324|NCT01468012|EXPERIMENTAL|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
62705457|NCT03811002|EXPERIMENTAL|Arm I (chemotherapy, radiation therapy)|Patients receive etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D-CRT or IMRT BID for approximately 3 weeks or QD for approximately 6-7 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood specimen collection throughout the trial.
61964325|NCT01468012|PLACEBO_COMPARATOR|Placebo|placebo
61964326|NCT03497208|EXPERIMENTAL|Microneedling+cell susp+phototherapy|Experiment is about the use of abrasion technic with dermaroller, equipped with a 0,25mm needle, applied on a vitiligo lesion. After that, a transplant with non cultured cell suspension (melanocytes and keratinocytes) will be applied to pacient 's skin scalp.
61964327|NCT03497208|ACTIVE_COMPARATOR|Microneedling and phototherapy|Technique involves only the abrasion with dermaroller equipped with 0,25mm on the lesion of vitiligo.
61964328|NCT01730469|EXPERIMENTAL|AT1001 150 mg|Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
61964329|NCT00838890|ACTIVE_COMPARATOR|Cdc7-inhibitor (A)|
61964330|NCT00838890|ACTIVE_COMPARATOR|Cdc7-inhibitor (B)|
62705458|NCT03811002|ACTIVE_COMPARATOR|Arm II (chemotherapy, radiation therapy, atezolizumab)|Patients receive treatment as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients undergo blood specimen collection throughout the trial.
62705459|NCT04920890|EXPERIMENTAL|Patients receiving radiofrequency treatment with manual therapy.|Patients without previous pathology of any kind who have passed the Covid19 and have olfactory and gustatory sequelae; who will receive radiofrequency treatment with manual therapy.
61964331|NCT03995121||Schizophrenia and other psychotic disorders|For each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
61964332|NCT03995121||Cannabis Use Disorder|For each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
62705460|NCT06554912|EXPERIMENTAL|Lymphatic Decompression|Pre-procedural evaluation : CT with contrast injected in the right arm, baseline heart failure questionaries and assessments Study intervention : Transvenous retrograde access of the thoracic duct, hemodynamic measures, measurement of central venous and thoracic duct pressures, lymphovenous junction stenting, fluid sampling Follow-up evaluation : phone calls on days 2 and 7 to assess adverse events and in-person consultations including adverse events, heart failure questionaries and assessments at 1, 3, and 6 months
62705461|NCT05388669|EXPERIMENTAL|Arm A: Lazertinib with Amivantamab SC-CF|Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase.
62736685|NCT01076205||Adalimumab|Adults with moderate to severe active rheumatoid arthritis (RA) who initiated adalimumab therapy during routine clinical care.
61964333|NCT03995121||Healthy Control|For each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
61964334|NCT00552721|EXPERIMENTAL|A|Physical therapy with strength training.
61964335|NCT00552721|ACTIVE_COMPARATOR|B|Physical therapy without strength training.
61964336|NCT03962010|EXPERIMENTAL|Dose level 1|
61964337|NCT03962010|EXPERIMENTAL|Dose level 2|
61964338|NCT03962010|EXPERIMENTAL|Dose level 3|
61964339|NCT03962010|EXPERIMENTAL|Dose level 4|
61964340|NCT03962010|PLACEBO_COMPARATOR|Placebo|
61964341|NCT03962010|ACTIVE_COMPARATOR|Dulaglutide|
61964342|NCT05059210|NO_INTERVENTION|Control|Coach McLungs not yet implemented in practice
61964343|NCT05059210|ACTIVE_COMPARATOR|Intervention|Coach McLungs Implemented in Practice
61964344|NCT05725967||Primary Obesity Endoscopic Procedures|Primary endoscopic procedures for treatment of obesity.
61964345|NCT05725967||Endoscopic Revision of Bariatric Surgical Procedures|Endoscopic revision of post-bariatric surgical complications.
61964346|NCT05725967||Bariatric Surgery Procedures|Bariatric surgical procedures.
61964347|NCT03167840|EXPERIMENTAL|Physical training alone (PT)|Physical Training (flexibility, endurance, strengthening, and balance training) for 60-90 minutes 3x/week over 12 weeks of moderate intensity.
61964348|NCT03167840|EXPERIMENTAL|Cognitive training alone (CT)|Cognitive training with a focus on orientation, memory, attention and executive functioning for 60-90 minutes per session, once per week for 12 weeks.
61964349|NCT03167840|EXPERIMENTAL|Physical and cognitive training (PACT)|Integrated cognitive training in physical exercise for 60-90 minutes per session, 3x/week over 12 weeks.
61964350|NCT03167840|NO_INTERVENTION|Wait-list group (WG)|The control group on wait-list. They will be instructed to go on with their usual activities and will receive the intervention, combined physical and cognitive training, at a later date.
61964351|NCT02339272||NOA|Infertile males with non obstructive azoospermia
61964352|NCT02339272||OA|Post-vasectomized patients with proven fertility before vasectomy
62507530|NCT03270592|OTHER|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
61964353|NCT05090059|EXPERIMENTAL|Lower limb myofascial trigger points f-ESWT group|3 total sessions, one per week, of focused extracorporeal shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ (millijoule)/mm2 administered on 3 or 4 myofascial points (identified based on Fascial Manipulation principles), 1500 shocks per point.
61964354|NCT05090059|ACTIVE_COMPARATOR|Plantar fascia insertion f-ESWT group|3 total sessions, one per week, of focused extracorporeal shockwave treatment, with a frequency of 5 Hz, an energy flux density of 0.32 mJ(millijoule)/mm2, for a total of 2000 shocks administered on the area of the painful heel on the medial calcaneal tubercle.
61964355|NCT05512572|EXPERIMENTAL|Experimental group|Receiving IPL-MGD treatment.
61964356|NCT05512572|ACTIVE_COMPARATOR|Control group|Another set of age, sex and diagnosis matched consecutive cases of chalazion, who received conservative treatment or excision with curettage but without IPL-MGX treatment as a control (Non-IPL group).
61964357|NCT03978520|PLACEBO_COMPARATOR|Elsubrutinib placebo/upadacitinib placebo|Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks
61964358|NCT03978520|EXPERIMENTAL|ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg)|60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
62144417|NCT05123859||age groups|"* A total of 30 participants in the 25- to 34-year age group~* A total of 45 participants in the 35- to 44-year age group~* A total of 50 participants in the 45- to 54-year age group~* A total of 50 participants in the 55- to 64-year age group~* A total of 45 participants in the 65- to 74-year age group~* A total of 30 participants in the 75- to 85-year age group"
62507531|NCT00075686|EXPERIMENTAL|gemcitabine hydrochloride + IMC-C225|Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
62507532|NCT00075686|EXPERIMENTAL|gemcitabine hydrochloride alone|gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
62507533|NCT01501968|ACTIVE_COMPARATOR|Colistin|Colistimethate sodium 2.5-5mg/kg iv
62507534|NCT01501968|EXPERIMENTAL|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv and ascorbic acid 2 grams iv every 12 hours
62705462|NCT05388669|EXPERIMENTAL|Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion|Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase.
62705463|NCT06470243|ACTIVE_COMPARATOR|Arm 1 (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 60 minutes on day 1 of each cycle and prednisone PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, CT, PET, or MRI throughout the trial and chest x-ray before randomization.
62705464|NCT06470243|EXPERIMENTAL|Arm 2 (cabazitaxel, carboplatin, prednisone)|Patients receive cabazitaxel and carboplatin IV over 60 minutes on day 1 of each cycle and prednisone PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, CT, PET, or MRI throughout the trial and chest x-ray before randomization.
62705465|NCT06431763|EXPERIMENTAL|Inclisiran|Inclisiran treatment on top of background treatment (high intensity statin with/without ezetimibe)
61964359|NCT03978520|EXPERIMENTAL|Elsubrutinib placebo/upadacitinib 30 mg|Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
61964360|NCT03978520|EXPERIMENTAL|ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg)|60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks
61964361|NCT03978520|EXPERIMENTAL|Elsubrutinib 60 mg/upadacitinib placebo|60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks
62705466|NCT06431763|ACTIVE_COMPARATOR|Bempedoic acid (BPA)|BPA treatment on top of background treatment (high intensity statin with/without ezetimibe)
61964362|NCT05473702||Cardiac health subjects|"Subjects over 18 years of age. Subject should satisfy any one of the following:~* Healthy subject with no pre-existing conditions.~* Subject with prehypertension~* Subject with hypertension~* Subject undergoing dialysis"
61964363|NCT01709916||Glaucoma patients|Glaucoma patients treated with eye drops to lower the IOP.
61964364|NCT03608449|ACTIVE_COMPARATOR|study group|after monitoring treatment outcomes for 4 weeks, treatment plan or psychotherpist will be changed according to scoring by the director of department.
61964365|NCT03608449|PLACEBO_COMPARATOR|control group|treatment as usual. treatment counitunes as usual without depending on monitoring treatment outcomes.
61964366|NCT02221193|EXPERIMENTAL|site specific vs panoral disinfection|
61964367|NCT02737098|ACTIVE_COMPARATOR|Standard Implementation|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
61964368|NCT02737098|ACTIVE_COMPARATOR|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
62144418|NCT01727570|NO_INTERVENTION|Nutrition Counselling|Patients will be asked to fill out a three day record of all food and drink consumed. Patients will be given an appointment with the nutritionist approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of their diet
62144419|NCT01727570|ACTIVE_COMPARATOR|Nutrition Supplementation|Patients will be asked to fill out a three day record of all food and drink consumed. An appointment with the nutritionist will be given approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of the diet. Patients will also be given a supply of nutritional supplements to take orally (by mouth) every day. These supplements include a whey protein isolate (Immunocal®, Immunotec Inc), omega-3 fatty acids from fish oil, and vitamins/minerals.
62144420|NCT06181656||Group 1|30 participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer. This group will be subdivided into Group 1A, which will comprise 15 participants treated with proton therapy, and Group 1B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
62144421|NCT06181656||Group 2|30 participants currently receiving, planning to receive, or recently completed chemoradiation for hepatocellular carcinoma. This group will be subdivided into Group 2A, which will comprise 15 participants treated with proton therapy, and Group 2B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
62144422|NCT06181656||Group 3|20 Healthy Volunteers.
62144423|NCT03840096|EXPERIMENTAL|Quadriceps NMES using Breg Flex|
62144424|NCT03840096|NO_INTERVENTION|Control|
62349385|NCT04826458|EXPERIMENTAL|A. electronic diary (TreC-Onco)|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
62349386|NCT04826458|OTHER|B. paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
62349387|NCT03853512|EXPERIMENTAL|Women_Inguinal side BAY207543|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
62349388|NCT03853512|ACTIVE_COMPARATOR|Women_Inguinal side Vaseline|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
62349389|NCT01603030|EXPERIMENTAL|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
62349390|NCT01603030|ACTIVE_COMPARATOR|moxifloxacin 0,5% + Prednisolone 1%|1 drop of each bottle, BID, 15 days
62349391|NCT01492296|ACTIVE_COMPARATOR|conventional fasting|patients were evaluated after fasting for 8 hours
62144425|NCT06475079||Group (A):|Body mass index \< 25
62144426|NCT06475079||Group (B):|Body mass index \> 25
62144427|NCT06699589|PLACEBO_COMPARATOR|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
62349392|NCT01492296|EXPERIMENTAL|Short fasting|patients who were evaluated with endoscopy after fasting for two hours
62349393|NCT05055570||Hypoxemia group|oxygenation index (OI)≤200
62705467|NCT03685721||HbAS|HbAS genotype, of African American descent;Between 18 and 80 years of age
62705468|NCT03685721||Healthy control|African American descent;Between 18 and 80 years of age
61964369|NCT03677531|EXPERIMENTAL|Other (radiation therapy, videos)|Participants undergo daily radiation therapy and watch videos/movies of their choice during treatments.
61964370|NCT05433792|EXPERIMENTAL|Myolens CN|Subjects' will be allocated to Myolens CN study arm in a 1:1:1 ratio.
61964371|NCT05433792|EXPERIMENTAL|Myolens CF|Subjects' will be allocated to Myolens CF study arm in a 1:1:1 ratio.
61964372|NCT05433792|ACTIVE_COMPARATOR|MiSight®|Subjects' will be allocated to MiSight® study arm in a 1:1:1 ratio.
62507535|NCT00544817|EXPERIMENTAL|Combination Therapy|"In the combined modality portion of the study, patients were administered:~Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily~Patients took a four week break before beginning follow-up systemic therapy:~Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
62507536|NCT01911104|EXPERIMENTAL|Exercise|10 weeks of aerobic exercise
61964373|NCT00828347|OTHER|1.0 μg/day Alfacalcidol|Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
62349394|NCT05055570||Non-hypoxemia group|oxygenation index (OI)\>200
62349395|NCT04432506|EXPERIMENTAL|Treatment (cyclophosphamide, fludarabine, axi-cel, anakinra)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra SC on days 0-6 in the absence of disease progression or unacceptable toxicity.
62349396|NCT03717363|ACTIVE_COMPARATOR|Control group|Educational talk: an educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
62349397|NCT03717363|EXPERIMENTAL|Interventional group|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
62349398|NCT00592670|EXPERIMENTAL|1|Baseline measures followed by a randomized 6 weeks treatment of Prozac.
62349399|NCT00592670|PLACEBO_COMPARATOR|2|Baseline followed by a 6 week randomized treatment of placebo.
62349400|NCT02919735|EXPERIMENTAL|CG 428 cutaneous solution|Herbal Medicinal Product, topical use by spray on the scalp
62349401|NCT02919735|PLACEBO_COMPARATOR|Placebo cutaneous solution|Placebo, topical use by spray on the scalp
62349402|NCT01016548|EXPERIMENTAL|Two doses of vaccine|Second dose is given 21 days after the initial dose. The same dose and route of administration are used.
62349403|NCT01016548|ACTIVE_COMPARATOR|One dose of vaccine|Given at baseline only.
62507537|NCT01911104|NO_INTERVENTION|Active Control|Young athletes as a trained control
61964374|NCT00828347|OTHER|0.25 μg/day Alfacalcidol|Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months
62349404|NCT04718324|EXPERIMENTAL|e-PROMS|Patients allocated to the e-PROMS arm will fill an online version of PROMS and then respond to the e-PREMS questionnaire.
62349405|NCT04718324|ACTIVE_COMPARATOR|p-PROMS|Patients allocated to the p-PROMS arm will fill in PROMS in paper form (p-PROMS) and then respond to the p-PREMS questionnaire.
62349406|NCT02913742|EXPERIMENTAL|monitoring by depth electrode|Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive a QOLIE-31-P questionnaire, in addition to standard post-operative care.
61964375|NCT01984177||cocaine-dependent (CD)|cocaine-dependent individuals
61964376|NCT01984177||healthy control (HC)|healthy age and sex-matched individuals who do not use cocaine
61964377|NCT03809143|EXPERIMENTAL|Depot buprenorphine arm|All participants will receive monthly injections of depot buprenorphine (RBP-6000, Sublocade)
62144428|NCT06699589|EXPERIMENTAL|Intervention|School population with the Old SCHOOL Hip-Hop program.
62144429|NCT05017454|EXPERIMENTAL|sodium valproate group|Group 1 will be treated with the optimized sodium valproate-loaded nanospanlastic dispersion, twice daily on the affected areas of the scalp for 3 months
62144430|NCT05017454|ACTIVE_COMPARATOR|topical steroid group|Group 2 will be treated with the marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
62349407|NCT04521634||Acute Stroke + Diabetes|People who have experienced and acute stroke and also have diabetes
62349408|NCT04521634||Acute stroke|People without diabetes who have experienced and acute stroke
62349409|NCT02905903|OTHER|Trichloroacetic Acid|Intervention-Apply 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study. Comparisons will be made using Investigators Global Assessment scoring of hyperpigmentation and erythema, colorimetry, photography, and biopsies
62349410|NCT05521464|ACTIVE_COMPARATOR|Group 1|Cast by Plaster of Paris
62349411|NCT05521464|EXPERIMENTAL|Group 2|Robert Jones bandage
62349412|NCT05597917|ACTIVE_COMPARATOR|Arm 1: Standard chemotherapy with trabectidin (in-label)|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
62507538|NCT00641199|ACTIVE_COMPARATOR|1|Jarrow-Dophilus EPS
62507539|NCT00641199|PLACEBO_COMPARATOR|2|Placebo
62507540|NCT05554289|EXPERIMENTAL|Experimental group|Conventional Treatment + Depression Auxiliary Intervention Treatment Software.A software used to treat depression, used frequently once a day.
62507541|NCT05554289|PLACEBO_COMPARATOR|control group|Conventional treatment + auxiliary intervention treatment software for depression (placebo software)
62507542|NCT04819854|EXPERIMENTAL|EP395|EP395 in ascending doses. Orally, once daily.
62507543|NCT04819854|PLACEBO_COMPARATOR|Placebo|Placebo, weight matched in ascending doses. Orally, once daily.
62507544|NCT01451476||Healthy females aged >=18|Healthy female volunteers of skin type I or II
62705469|NCT03685721||SCD|HbSS, HbSC, HbSbeta-thal has sickle cell disease and is of African American descent;Between 18 and 80 years of age
62507545|NCT02644798||ARDS patients|Adult ARDS (according to Berlin definition) patients were enrolled in the trial. The diagnostic criteria included (a) within one week of a known clinical insult or new or worsening respiratory symptoms; (b) chest imaging showing that bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules; (c) respiratory failure not fully explained by cardiac failure or fluid overload; and (d) arterial partial pressure of oxygen / fraction of inspiration oxygen (PaO2/FiO2 ratio, P/F ratio) less than or equal to 300 mmHg.
62507546|NCT03562949|EXPERIMENTAL|Test Product|Test Product, 40 mcg, 2 x daily
62507547|NCT03562949|ACTIVE_COMPARATOR|Reference Product|Reference Product, 40 mcg, 2 x daily
62507548|NCT03562949|PLACEBO_COMPARATOR|Placebo|Placebo Product 2 x daily
62507549|NCT02369120|ACTIVE_COMPARATOR|Normal care by GP|"Control group: Will follow conventional treatment provided by the family physician in primary care. This treatment is based on the clinical guidelines of the Institut Català de la Salut (http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf)."
62705470|NCT02867592|EXPERIMENTAL|Treatment (cabozantinib s-malate)|Patients receive cabozantinib-s-malate orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61964378|NCT01525485||Electrical Stimulation|Participants will have a dedicated visit with a pelvic floor physical therapist during which instructions on usage and technique for the Minnova unit will be given. The electrical parameters selected will be: 10 Hertz frequency, 5-second on/10=second off cycle, and a pulse width of 0.4 milliseconds. The bipolar square will be delivered over a range that varies from 0 to 100 milliamps, depending on the maximum current intensity comfortably tolerated by the patient. The participant will perform each treatment session for 20 minutes twice daily for 8 weeks. Participants will be asked to keep a log recording the dates, times, and duration of each treatment session.
61964379|NCT01525485||Interstim device|Participants assigned to the sacral neuromodulation group will undergo InterStim device placement by one of the three Urogynecologists at OUHSC using a staged implant technique according to manufacturer's specifications.
61964380|NCT06358365|EXPERIMENTAL|adult patients undergoing regular hemodialysis|This study will be a crossover study with one center and an open label design. Patients who sign the informed consent form and meet the inclusion and exclusion criteria will undergo a 2-hour acclimatization period to verify their ability to adhere to the AquaPass procedure. Once enrolled, patients will undergo a 3-week observation period where they will continue with their regular hemodialysis treatment with no changes. Study endpoint parameters will be assessed during this observation period and used as a control group. After the observation period, patients will undergo the AquaPass procedure 2-3 times a week for 4 weeks. Study assessments will be conducted at the beginning of each week during the patient's dialysis session.
61964381|NCT00590720|EXPERIMENTAL|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
61964382|NCT00590720|PLACEBO_COMPARATOR|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
61964383|NCT05658146|EXPERIMENTAL|Sequence 1|
61964384|NCT05658146|EXPERIMENTAL|Sequence 2|
62144431|NCT06322368|EXPERIMENTAL|Myofunctional and respiratory training|Patients with chronic stroke receiving an exercise training program for the muscles around the face, mouth, and tongue and a respiratory training focused on inspiratory and expiratory muscle strengthening.
62144432|NCT06322368|ACTIVE_COMPARATOR|Range of motion and stimulation exercises|Standard treatment focused mainly on range of motion, such as opening and closing the mouth and stimulation exercises
62507550|NCT02369120|EXPERIMENTAL|Educational intervention using a website|This group of subjects will be given access to our web-site in where they will find information related to CLBP. This information will be provided in different formats: explanatory video by the author, animated video about the neurophysiology of pain, written format using metaphors, and FAQs. All this information will be based on the information provided by the subjects on QUAL. The aim of this educational intervention is to change patient´s misbeliefs about CLBP with the last outcome of reducing pain intensity, improving function, and reducing disability.
62507551|NCT06074263|EXPERIMENTAL|Steroid|Dexamethasone 8mg
62705471|NCT06439225|ACTIVE_COMPARATOR|Docetaxel|
62705472|NCT06439225|EXPERIMENTAL|Carboplatin + Docetaxel|
62705473|NCT04717375|EXPERIMENTAL|SAR444881 Dose Escalation (Sub-Part 1A)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 will be administered intravenously (IV), every 2 weeks (Q2W)."
62144433|NCT02408913|EXPERIMENTAL|Group 2|MVA-EbolaZ 1x10(8) PFU
62705474|NCT04717375|EXPERIMENTAL|SAR444881 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W)."
62705475|NCT04717375|EXPERIMENTAL|SAR444881 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W)."
62144434|NCT02408913|EXPERIMENTAL|Group 3|cAd3-EBO 2x10(11) PU followed by MVAEbolaZ 1x10(8) PFU at 8 weeks
62144435|NCT02408913|EXPERIMENTAL|Group1|MVA-EbolaZ 1x10(7) PFU
62144436|NCT02408913|EXPERIMENTAL|Groups 4 to 7|MVA-EbolaZ 1x10(8) PFU administered in VRC 208 to participants who received cAd3-EBO or cAd3-EBOZ in VRC 207.
62144437|NCT03247595|ACTIVE_COMPARATOR|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
62144438|NCT03247595|EXPERIMENTAL|Magnesium Citrate Capsules|36 Magnesium citrate capsules
62507552|NCT06074263|PLACEBO_COMPARATOR|Placebo|Placebo
62507553|NCT06215131|ACTIVE_COMPARATOR|In-person dietary weight loss counseling|The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.
62507554|NCT06215131|EXPERIMENTAL|Virtual reality dietary weight loss counseling|The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
62507555|NCT02330744|EXPERIMENTAL|Approach-positive AAT|Computerized AAT procedure designed to increase automatic approach responses for positive social cues.
61964385|NCT05658146|EXPERIMENTAL|Sequence 3|
61964386|NCT05658146|EXPERIMENTAL|Sequence 4|
61964387|NCT05658146|EXPERIMENTAL|Sequence 5|
61964388|NCT05658146|EXPERIMENTAL|Sequence 6|
61964389|NCT04743297|ACTIVE_COMPARATOR|Propess Vaginal Delivery System|Propess - Prostaglandin E2 Vaginal Delivery System. Slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
61964390|NCT04743297|ACTIVE_COMPARATOR|Prostin Tablet|Prostaglandin E2 Vaginal Tablet 3 mg dinoprostone
61964391|NCT05272020|OTHER|TAVI|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment
61964392|NCT05272020|OTHER|AVR|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment, Myocardial + aortic valve biopsy
61964393|NCT04435132|EXPERIMENTAL|PCNL with the aid of the robotic device|Patients will undergo prone PCNL under fluoroscopic guidance and with the aid of the robotic device.
61964394|NCT00350909|EXPERIMENTAL|1|One arm was a 2-session brief intervention with both sessions involving only the adolescent. Each session was a 60 minute individual session with the counselor.
62144439|NCT03444415|EXPERIMENTAL|Motivational interviewing in groups|The Intervention is performed at Primary Care Centers by health professionals (General Practitioners, Nurses, Pediatricians and Midwives), during pregnancy and the first 2 years of the child. Researchers will be trained in motivational interviewing and group dynamics. Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children. They intend to encourage the shift towards healthy lifestyles to parents on issues related to diet, physical activity and smoking habit, encourage breastfeeding and increase their knowledge and self-efficacy to promote healthy habits regarding diet, physical activity and sleep habits of their children.
62144440|NCT03444415|OTHER|Control Group|"Control Group: Usual Care as established in the Programa Integral de Atención a la Mujer (Comprehensive Program of Woman Assistance) and the Programa de Atención al Niño Sano (Well Child Program) in the Servicio Murciano de Salud.~Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits."
62507556|NCT02330744|PLACEBO_COMPARATOR|Control AAT|Computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
62144441|NCT01354574|EXPERIMENTAL|High Glycemic Index meals|Three days of run-in diet with meals containing high glycemic index carbohydrates followed by test day with breakfast meal containing high glycemic index carbohydrates.
62144442|NCT01354574|EXPERIMENTAL|Low Glycemic Index meals|Three days of run-in diet with meals containing low glycemic index carbohydrates followed by test day with breakfast meal containing low glycemic index carbohydrates.
62144443|NCT01583166|ACTIVE_COMPARATOR|Bupivacaine + epinephrine|
62507557|NCT05952453|EXPERIMENTAL|Carbo/taxol/pembro followed by maintenance of olaparib/pembro post-surgery|neoadjuvant carbo/taxol/pembro followed by maintenance olaparib/pembro post- surgery
62507558|NCT02244073|EXPERIMENTAL|Individualized blood glucose target|Maintain blood glucose in individualized target based on glycated hemoglobin level (A1c); Blood glucose level is maintained bellow 1.59 × A1c - 1.59 (mmol/l).
62144444|NCT01583166|PLACEBO_COMPARATOR|Saline + epinephrine|
62507559|NCT02244073|ACTIVE_COMPARATOR|Conventional blood glucose target|Maintain blood glucose bellow 10 mmol/l.
62507560|NCT04296201|EXPERIMENTAL|Treatment in the face area|5 female subjects will receive treatment in the face area
62705476|NCT04717375|EXPERIMENTAL|SAR444881 Dose Optimization (Sub-Part 2A)|SAR444881 Dose Optimization in combination with pembrolizumab/carboplatin/pemetrexed, pembrolizumab, or cetuximab. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
61964395|NCT00350909|ACTIVE_COMPARATOR|2|The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
61964396|NCT00850668|ACTIVE_COMPARATOR|EMP-123|Participants who are not allergic to peanuts will receive four escalating doses of study product on a weekly basis
61964397|NCT00850668|EXPERIMENTAL|EMP-123 in Peanut Allergics|Participants who are allergic to peanuts will receive weekly dose escalation of the study product for 10 weeks followed by administration every 2 weeks for 6 weeks
61964398|NCT02302820|ACTIVE_COMPARATOR|Make Your Wishes Known|"A Decision Aid that uses interactions, videos, vignettes.~A formatted Advance Directive; saved data that may be revisited to produce a revised Advance Directive"
61964399|NCT02302820|ACTIVE_COMPARATOR|Mayo Clinic-Advance Health Care Planning|"Not an online decision aid~Written instructions, worksheets, and Advance Directive to complete"
61964400|NCT02302820|ACTIVE_COMPARATOR|Mydirectives.com|"Online decision aid that uses interactions, videos, and vignettes.~An electronically stored Advance Directive that may be printed."
62507561|NCT04296201|EXPERIMENTAL|Treatment in the buttocks area|5 female subjects will receive treatment in the buttocks area
61964401|NCT02302820|ACTIVE_COMPARATOR|Prepare|"An online decision aid that uses interactions, videos and vignettes.~A printed summary useful for transposing values and treatment wishes into an Advance Directive; a list of action steps."
61964402|NCT01502098|ACTIVE_COMPARATOR|Early passive motion|Pendulum exercises starting on the first postoperative day. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises were not permitted until four weeks after surgery.
62144445|NCT04275167|EXPERIMENTAL|Feasibility of TCE|Feasibility is measured by the number of participants that we have successfully deployed the Tethered capsule device in.
62144446|NCT04275167|EXPERIMENTAL|Feasibility of TNE and Microbiome Brushing|Feasibility is measured by the number of participants that we have successfully deployed the TNE device and collected brush samples in.
62144447|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
62507562|NCT04296201|EXPERIMENTAL|Treatment in the abdominal region|5 male subjects will receive treatment in the abdominal region
62507563|NCT01140737|EXPERIMENTAL|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily.
62507564|NCT06263140||1. Patients diagnosed with drug-induced severe non-immediate cutaneous reactions|Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptom (DRESS), acute generalized exanthematous pustulosis (AGEP)
62507565|NCT06263140||2. Patients diagnosed with drug-induced non-severe non-immediate cutaneous reactions|Maculopapular exanthem (MPE), fixed drug eruption (FDE)
62507566|NCT06263140||3. Subjects who tolerated drugs potentially causing severe non-immediate cutaneous reactions|Studied drug groups matched patients in group 1
62507567|NCT06263140||4. Subjects who tolerated drugs potentially causing non-severe non-immediate cutaneous reactions|Studied drug groups matched patients in group 2
62507568|NCT05025280||hearing loss|According to the audiological test results, individuals with a pure tone average of more than 25 dB in the better ear and with less than 10 dB difference between the air-bone conduction thresholds
62507569|NCT05025280||normal hearing|According to the audiological test results, individuals with a pure tone average of 25 dB or less in both ears and with less than 10 dB difference between the air-bone conduction thresholds
62349413|NCT05597917|EXPERIMENTAL|Arm 2: tTF-NGR added to standard trabectedin|Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
62349414|NCT03506100|OTHER|water walking in spirometric values|Experimental: practice swimming complemented with water walking
62349415|NCT06100484||Healthy group|Pregnant women above 20 weeks of pregnancy with no hypertensive disorders with pregnancy
62349416|NCT06100484||Diseased group|Pregnant women above 20 weeks of pregnancy with gestational hypertension or pre-eclampsia
62349417|NCT01714297|ACTIVE_COMPARATOR|dalteparin 5000IU s.c.|5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
62349418|NCT01714297|PLACEBO_COMPARATOR|saline|Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
62349419|NCT04269655|EXPERIMENTAL|Intervention CB CGM|On CB CGM patients, CGM data will also be transmitted from the bedside smartphone to the Digital Dashboard. The Digital Dashboard will integrate CGM data for CB CGM's participants for presentation via two views: (1) Real-Time Management and (2) Clinical Optimization. Telemetry technicians to conduct site-based monitoring, and the Diabetes APN will conduct remote management of patients at the site from a central, Scripps Diabetes Hub, per below. (Note, as CGMs are not FDA-approved for in-hospital glucose management, CB CGM participants will also have their glucose monitored via the hospital's standard POC testing protocol described for UC).
62349420|NCT04269655|NO_INTERVENTION|Usual Care|For UC, CGM data will be blinded to the care team and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours for patients who are not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring: UC (and intervention) participants' glucose levels will be managed using the glucose management protocol and the Diabetes APN will assess UC participants' POC data documented in the EMR from the previous 24-48 hours and make recommendations for changes to the basal/bolus regimen to improve glucose management.
62349421|NCT02308176|EXPERIMENTAL|intervention group|health advice and app installation in patient's mobile
62349422|NCT02308176|PLACEBO_COMPARATOR|control group|health advice
62349423|NCT06123000|ACTIVE_COMPARATOR|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
62349424|NCT06123000|EXPERIMENTAL|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed
62507570|NCT05883397|ACTIVE_COMPARATOR|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA (atmospheres), with five-minute air brakes every 20 minutes.
62507571|NCT05883397|ACTIVE_COMPARATOR|HBOT + hippocampal training|"Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.~Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session."
62507572|NCT01960868|EXPERIMENTAL|patients|
62507573|NCT01960868|OTHER|control group|
62507574|NCT02333188|EXPERIMENTAL|Treatment (FOLFIRABRAX)|Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation IV over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
62507575|NCT00661921|ACTIVE_COMPARATOR|40 mg AMG 108 Q2W|
62507576|NCT00661921|ACTIVE_COMPARATOR|150 mg AMG 108 Q2W|
62507577|NCT00661921|ACTIVE_COMPARATOR|75 mg AMG 108 Q2W|
62507578|NCT00661921|PLACEBO_COMPARATOR|Placebo Q2W|
62144448|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
62705477|NCT04717375|EXPERIMENTAL|SAR444881 Dose Expansion (Sub-Part 2B)|The indication for this monotherapy cohort is cholangiocarcinoma. Enrollment will be opened based on emerging data from the dose-escalation phase and combination optimization data.
62705478|NCT04731376|EXPERIMENTAL|Arm I (testosterone cypionate)|Patients with low testosterone levels receive testosterone cypionate IM QW for 3 months.
62705479|NCT04731376|ACTIVE_COMPARATOR|Arm II (best practice)|Patients with normal testosterone levels receive standard peri-operative care.
62705480|NCT05332769||Infertile women have IVF/ICSI cycle|All Vietnamese infertile women who have IVF/ICSI cycle with at least 8 follicles ≥ 10 mm on ultrasonography at induced ovulation date agreed to freeze-all day 5-6 embryos at IVFMD and IVFMD PN will be enrolled in the study.
62705481|NCT06041503|EXPERIMENTAL|Arm 1|Treatment with enfortumab vedotin
62705482|NCT06041503|EXPERIMENTAL|Arm 2|Treatment with enfortumab vedotin and pembrolizumab
62705483|NCT02108041||Physicians that interact with the black/High SES avatar patien|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American.
61964403|NCT01502098|NO_INTERVENTION|Immobilization|Immobilization with sling during a month. Pendulum exercises starting on the fourth postoperative week. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises.
61964404|NCT01410786|ACTIVE_COMPARATOR|Conventional Oxford instrumentation|Patients who receive an Oxford Partial Knee with Conventional instrumentation.
61964405|NCT01410786|EXPERIMENTAL|Signature Guides Oxford|Patients who receive an Oxford Partial Knee with Signature Custom Guides
61964406|NCT00694785|EXPERIMENTAL|Group NT3|Patients will receive a total dose of approximately 1.7 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL
61964407|NCT00694785|EXPERIMENTAL|Group T3|Patients will receive a total dose of approximately 1.4 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
61964408|NCT00694785|EXPERIMENTAL|Group NT6|Patients will receive a total dose of approximately 3.9 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL.
62144449|NCT02542943|EXPERIMENTAL|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
62349425|NCT00642018|ACTIVE_COMPARATOR|A: Docetaxel|Standard of care (SOC) docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel therapy
62349426|NCT00642018|EXPERIMENTAL|B: LY2181308 + Docetaxel|LY2181308 administered with docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel
62349427|NCT04609995|NO_INTERVENTION|No financial incentive|No financial incentives will be provided for completing a PrEP evaluation
62349428|NCT04609995|ACTIVE_COMPARATOR|Fixed incentive|A fixed incentive ($25 Amazon.com gift card) will be provided for completing a PrEP evaluation
62349429|NCT04609995|ACTIVE_COMPARATOR|Lottery incentive|An entry into a lottery for a 20% chance to win a $100 Amazon.com gift card will be provided for completing a PrEP evaluation
62349430|NCT04557163|EXPERIMENTAL|Subjects receiving TS-142 and itraconazole|Eligible subjects will receive a single dose of 5 mg TS-142 on Day 1. Subjects will also receive twice-a-day of 200 mg itraconazole on Day 3 and an once-daily single dose of 200 mg itraconazole from Day 4 to Day 7 and single dose of 1 mg TS-142 on Day 6.
62349431|NCT04682353|EXPERIMENTAL|Group 1 - 120 mg/0.4 mL|
62349432|NCT04682353|EXPERIMENTAL|Group 2 - 180 mg/0.6 mL|
62349433|NCT04682353|EXPERIMENTAL|Group 3 - 240 mg/0.8 mL|
62349434|NCT04682353|ACTIVE_COMPARATOR|Group 4 - 104 mg/0.65 mL|
62349435|NCT01866761||Periodontitis, Lifestyle-related disease|
62507579|NCT03359837|EXPERIMENTAL|Glargine based therapy|Once daily glargine plus prandial oral anti-hyperglycemic drugs
62507580|NCT03359837|ACTIVE_COMPARATOR|Premixed insulin|Twice daily premixed insulin
62705484|NCT02108041||Physicians that interact with the black/Low SES avatar patient|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American.
62705485|NCT02108041||Physicians that interact with the white race/high SES avatar|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian.
62705486|NCT02108041||Physicians that interact with the white race/low SES avatar p|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian.
62705487|NCT02543996||Affected or unaffected cohorts (including genetic carriers or non-carriers as|Affected or unaffected cohorts (including genetic carriers or non-carriers as reference biospecimens)
62705488|NCT00442195||1|Healthy Volunteers
61964409|NCT00694785|EXPERIMENTAL|Group T6|Patients will receive a total dose of approximately 3.1 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
61964410|NCT04071132||Participants diagnosed with PTSD|
61964411|NCT04071132||Non-PTSD participants|
61964412|NCT05540405|EXPERIMENTAL|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
61964413|NCT05540405|EXPERIMENTAL|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
61964414|NCT05540405|PLACEBO_COMPARATOR|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
62144450|NCT02542943|EXPERIMENTAL|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
62144451|NCT02542943|PLACEBO_COMPARATOR|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
62507581|NCT06617078|OTHER|Long-Term Oxygen therapy (LTOT) then High Flow Nasal Therapy (HFNT)|2 weeks of LTOT then 2 weeks of LTOT+HFNT
62507582|NCT06617078|OTHER|High Flow Nasal Therapy (HFNT) then Long-Term Oxygen therapy (LTOT)|2 weeks of LTOT+HFNT then 2 weeks of LTOT
62705489|NCT02196181|EXPERIMENTAL|Arm I (continuous dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-56 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT scans in week 1 of cycle 2 and at off treatment follow up prior to progression. Additionally, patients undergo blood sample collection, ECHO or MUGA on study.
61964415|NCT04564729|EXPERIMENTAL|Decision Aid|The shared decision aid (SDA) includes factual information about the World Health Organization pain ladder, the 0-10 numeric rating score pain scale, pharmacologic pain management options, opioid medication benefits and risks and predicted post-discharge opioid requirements based on previous modeling in total knee arthroplasty patients. Subjects in the decision aid group will view the decision aid and have the opportunity to participate in shared decision-making for their discharge opioid prescriptions.
61964416|NCT04564729|NO_INTERVENTION|Control|Subjects in the control group will undergo standard care and discharge practices. Baseline pain and psychosocial factors will be documented as well as postoperative pain and analgesic consumption.
61964417|NCT02840097|EXPERIMENTAL|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
61964418|NCT02840097|EXPERIMENTAL|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
61964419|NCT02840097|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
61964420|NCT03181334|ACTIVE_COMPARATOR|Branch I|"Condition 1: (Standard Intervention)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation letter to complete free colorectal cancer (CRC) screening."
61964421|NCT03181334|EXPERIMENTAL|Branch II and Branch III|"Condition 2: (Time Guideline)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal cancer (CRC) screening within a specified time frame:~Branch II - Brief Time (1-week)~Branch III - Extended Time (3-weeks)"
61964422|NCT03181334|EXPERIMENTAL|Branch IV and Branch V|"Condition 3: (Time Guideline + Incentive)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal (CRC) screening within a specified time frame with a monetary incentive:~Branch IV - High Incentive~Branch V - Low Incentive"
62349436|NCT03585699|ACTIVE_COMPARATOR|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
62349437|NCT03585699|ACTIVE_COMPARATOR|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
62349438|NCT01117012|EXPERIMENTAL|VX-770|VX-770 (ivacaftor) 150 milligram (mg) tablet orally twice daily (q12h).
62349439|NCT04393350|EXPERIMENTAL|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62507583|NCT03670732|ACTIVE_COMPARATOR|CPAP first|The intervention is application of continuous positive airway pressure (CPAP). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
62705490|NCT02196181|EXPERIMENTAL|Arm II (intermittent dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT scans in week 1 of cycle 2 and at off treatment follow up prior to progression. Additionally, patients undergo blood sample collection, ECHO or MUGA on study.
62705491|NCT06020716|EXPERIMENTAL|AMIC 1: Arm A|In AMIC 1, 90 children will be randomly be assigned 1:1 to receive either amoxicillin-clavulanate syrup or placebo (Arm A and B) for 14 days. AMIC 1 Arm A will receive 14 days amoxicillin-clavulanate syrup.
62705492|NCT06020716|PLACEBO_COMPARATOR|AMIC 1: Arm B|In AMIC 1, 90 children will be randomly be assigned 1:1 to receive either amoxicillin-clavulanate syrup or placebo (arm A and B) for 14 days. AMIC 1 Arm B will receive 14 days placebo syrup.
61964423|NCT01246401|ACTIVE_COMPARATOR|Extended-Release Naltrexone|Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
61964424|NCT01246401|PLACEBO_COMPARATOR|Placebo|Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release
62507584|NCT03670732|ACTIVE_COMPARATOR|NIPPV first|The intervention is application of nasal intermittent positive pressure ventilation (NIPPV). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
62507585|NCT00779402|EXPERIMENTAL|Sipuleucel-T|Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
62507586|NCT00779402|PLACEBO_COMPARATOR|Control|Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions.
61964425|NCT05416502||Passage Observed|Enrolled patients whose stone and ureter diameters are obtained and their stone passage was successful during the follow-up.
61964426|NCT05416502||Passage Not Observed|Enrolled patients whose stone and ureter diameters are obtained and their stone passage was not successful during the follow-up.
61964427|NCT03961581|EXPERIMENTAL|car|Children who will use cars to go from the double-door entrance of the block to the operative room.
62507587|NCT03439631|ACTIVE_COMPARATOR|Tiered OR Satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
62349440|NCT02465346|EXPERIMENTAL|MSU-based stroke management|The Mobile Stroke Unit (MSU) and the conventional emergency medical Service (EMS) will meet at the emergency site. The patient's medical history, the physical examination will directly be performed by a physician. Laboratory tests will be analyzed by a point of care laboratory. CT will be performed. After performance of the acute stroke diagnostic work-up the patients and, if indicated thrombolysis, the patient will be transported according to the diagnostic results: Stroke due to large vessel occlusion or to intracranial hemorrhage-\> Neurovascular centre; Stroke without large vessel occlusion or without hemorrhage-\> primary hospital with regional stroke unit.
62507588|NCT03439631|OTHER|Status Qou OR satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
62507589|NCT04674683|EXPERIMENTAL|Test Arm|HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days
62507590|NCT04674683|PLACEBO_COMPARATOR|Control Arm|Placebo oral BIW + nivolumab IV at specific doses on specific days
62507591|NCT00471991|ACTIVE_COMPARATOR|Arm 1|
62507592|NCT00471991|EXPERIMENTAL|Arm 2|
62507593|NCT06234748|EXPERIMENTAL|Treatment Arm|Patients will initially receive a single prescription of 70 Gy to PTVhigh in 35 fractions with RT given once daily, 5 days a week along with weekly platinum (standard therapy). All fields must be treated daily. On days when chemotherapy is given, it will be administered prior to RT. Prescription to high risk PTV will be 70Gy in 35 fractions and to PTV2 will be 56Gy in 35 fractions.
62507594|NCT05540379|ACTIVE_COMPARATOR|Group A: Ob/Gyn physicians|It is about 51 participants whom had performed less than 50 diagnostic hysteroscopies and hysteroscopic polypectomy.
62507595|NCT05540379|ACTIVE_COMPARATOR|Group B: Ob/Gyn physicians|It is about 51 participants whom had performed at least 50 diagnostic hysteroscopies and hysteroscopic polypectomy.
62507596|NCT01847365|EXPERIMENTAL|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
62507597|NCT00493064|EXPERIMENTAL|Prospective active treatment|Niacin 500mg TID PO for treatment of retinal vein occlusions.
62349441|NCT02465346|ACTIVE_COMPARATOR|Control stroke management|After performing patient's medical history, physical examination (reassessment of the extended Face Arm Speech Time score) and glucose testing by the (stroke trained) emergency personnel, the patient will be transported according to current best clinical practice and relevant guidelines to the next stroke unit or neurovascular centre. The hospital stroke team will be prenotified by the EMS. According to the patients needs the patient might be further transferred.
62349442|NCT00418379|EXPERIMENTAL|300 IR (4M)|300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
62349443|NCT00418379|EXPERIMENTAL|300 IR (2M)|300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
62349444|NCT00418379|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62349445|NCT00377429|EXPERIMENTAL|catumaxomab|
62507598|NCT06617208|EXPERIMENTAL|Neuropixel probe recording|Cortical electrophysiology using the Neuropixel probe is performed to record brain activity in the peritumoral cortex
62507599|NCT04569786|EXPERIMENTAL|V590 5.00x10^5 pfu (Panel A)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel A) will receive a single dose of V590 5.00x10\^5 pfu or placebo on Day 1.
62507600|NCT04569786|EXPERIMENTAL|V590 2.40x10^6 pfu (Panel B)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel B) will receive a single dose of 2.40x10\^6 pfu or placebo on Day 1.
62507601|NCT04569786|EXPERIMENTAL|V590 1.15x10^7 pfu (Panel C)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel C) will receive a single dose of 1.15x10\^7 pfu or placebo on Day 1.
62705493|NCT06020716|EXPERIMENTAL|AMIC 2: Arm C|In AMIC 2, 210 children will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup (arm C and D). AMIC 2 Arm C will receive 14 days amoxicillin-clavulanate syrup and 14 days placebo.
62705494|NCT06020716|EXPERIMENTAL|AMIC 2: Arm D|In AMIC 2, 210 children will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup (arm C and D). AMIC 2 Arm D will receive 28 days amoxicillin-clavulanate syrup.
62705495|NCT06407934|EXPERIMENTAL|Amlitelimab dose 1|Subcutaneous injection as per protocol
62705496|NCT06407934|EXPERIMENTAL|Amlitelimab dose 2|Subcutaneous injection as per protocol
62705497|NCT06407934|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection as per protocol
61964428|NCT03961581|NO_INTERVENTION|bed|Children who will use bed to go from the double-door entrance of the block to the operative room.
62349446|NCT01673191|EXPERIMENTAL|OZURDEX intraocular implant|OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
62349447|NCT01673191|ACTIVE_COMPARATOR|Steroid plus NSAID eye drop combination therapy|NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
62349448|NCT02925663|EXPERIMENTAL|EFI-E|10-session web-based modules to teach about executive functioning with videoconferencing with a therapist
62507602|NCT04569786|EXPERIMENTAL|V590 5.55x10^7 pfu (Panel D)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel D) will receive a single dose of V590 5.55x10\^7 pfu or placebo on Day 1.
62507603|NCT04569786|EXPERIMENTAL|Part 2: 5.00x10^5 pfu (Panel E)|Participants in this ≥ 55 years old SARS CoV-2 seronegative cohort (Panel E) will receive a single dose of V590 5.00x10\^5 pfu or placebo on Day 1.
62507604|NCT04569786|EXPERIMENTAL|Part 2: 2.40x10^6 pfu (Panel F)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel F) will receive a single dose of 2.40x10\^6 pfu or placebo on Day 1.
62507605|NCT04569786|EXPERIMENTAL|Part 2: 1.15x10^7 pfu (Panel G)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel G) will receive a single dose of V590 1.15x10\^7 pfu or placebo on Day 1
62507606|NCT04569786|EXPERIMENTAL|Part 2: 5.55x10^7 pfu (Panel H)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel H) will receive a single dose of V590 5.55x10\^7 pfu or placebo on Day 1.
62507607|NCT04569786|EXPERIMENTAL|Part 3: 5.55x10^7 pfu (Panel I)|Participants in this 18 to 54-year-old SARS-CoV-2 seropositive cohort (Panel I) will receive a single dose of V590 5.55x10\^7 pfu or placebo on Day 1.
62507608|NCT04580849|EXPERIMENTAL|telerehabilitation with dance (Parkinson's)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
62507609|NCT04580849|ACTIVE_COMPARATOR|telerehabilitation with dance (Healthy controls)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
62507610|NCT05265299|EXPERIMENTAL|Sequence 1|"* Week 1-2: aspirin 81mg~* Week 5-6: aspirin 162mg~* Week 9-10: aspirin 325mg"
62507611|NCT05265299|EXPERIMENTAL|Sequence 2|"* Week 1-2: aspirin 162mg~* Week 5-6: aspirin 81mg~* Week 9-10: aspirin 325mg"
62507612|NCT05265299|EXPERIMENTAL|Sequence 3|"* Week 1-2: aspirin 325mg~* Week 5-6: aspirin 81mg~* Week 9-10: aspirin 162mg"
61964429|NCT06318195|EXPERIMENTAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) for three weeks with therapist support.
61964430|NCT03216889|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6 weeks of CBT-I.
61964431|NCT03216889|ACTIVE_COMPARATOR|Control|6 weeks of stretching and thinking games.
61964432|NCT02532491|ACTIVE_COMPARATOR|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
61964433|NCT02532491|ACTIVE_COMPARATOR|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
62349449|NCT03171311|ACTIVE_COMPARATOR|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
62349450|NCT03171311|EXPERIMENTAL|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
61964434|NCT05119452|OTHER|Assisted monitoring|In the Assisted monitoring arm, C-reactive protein and musculoskeletal ultrasound information will be made available to the clinical assessors who, at each time-point will use this information, along with information from the clinical examination, to identify patients experiencing recurrence of inflammation which will then be counted as subclinical flare according to predefined criteria.
61964435|NCT05119452|OTHER|Clinical monitoring|In the Clinical monitoring arm, the results of C-reactive protein and musculoskeletal ultrasound information will be recorded but will not be made available to the clinical assessor who at each time-point will make the decision on whether the patient is experiencing or has experienced a clinical flare according to predefined criteria based on information from the clinical examination.
61964436|NCT02810197|EXPERIMENTAL|Exposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
61964437|NCT02810197|EXPERIMENTAL|unexposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
61964438|NCT00880828|EXPERIMENTAL|A|FIR cervical collar plus Acetaminophen
61964439|NCT00880828|ACTIVE_COMPARATOR|B|Conservative cervical collar plus Acetaminophen
61964440|NCT00880828|PLACEBO_COMPARATOR|C|Acetaminophen only
61964441|NCT04719871||with posterior vitreous detachment|patient with stage 3 or more of posterior vitreous detachment on optical coherence tomography
61964442|NCT04719871||without posterior vitreous detachment|patient with stage 2 or less of posterior vitreous detachment on optical coherence tomography
61964443|NCT01888237|ACTIVE_COMPARATOR|Sequential therapy (ST)|10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
61964444|NCT01888237|EXPERIMENTAL|High dose PPI triple therapy(TT)|10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days
61964445|NCT00713050|EXPERIMENTAL|Experimental|Computer-based Aphasia therapy
61964446|NCT00713050|ACTIVE_COMPARATOR|Control|Control Arm - Healthy subjects.
61964447|NCT04460638||Covid+ hospitalization group|Patients hospitalized with SARS-CoV2 infection
61964448|NCT04460638||Covid+ outpatient group|Patients or caregivers followed on an outpatient basis for an SARS-CoV2 infection
61964449|NCT04460638||Covid- group|Caregivers not infected with an SARS-CoV2
61964450|NCT04460638||Non-SARS pathology group|Individuals not infected with SARS-CoV2 but with another acute and/or infectious non-SARS pathology
61964451|NCT02310568|EXPERIMENTAL|PF 06372865 2.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
62349451|NCT03655574|EXPERIMENTAL|Motivational + Family Check-up (MET+FCU)|"The MET individual session covers three constructs; 1) intentions to use marijuana; 2) normative beliefs about peer substance use; and 3) attitudes towards peer substance use. These same three constructs are also addressed with respect to truancy. In addition, motivation to abstain from substance use is discussed.~The FCU session with teens and parents/caregivers begins by collecting self-report measures and conducting a videotaped Family Assessment Task (FAsTask) to assess parent-teen interactions. The FAsTask is the basis of FCU feedback. There are four specific phases of the feedback session: 1) Self-assessment, 2) Support and clarification, 3) Feedback, and, 4) Action plan."
62349452|NCT03655574|PLACEBO_COMPARATOR|Psychoeducation|An interventionist will review a set of educational materials with the parents regarding teen marijuana use, effects of marijuana on the brain, body and behavior, risks associated with marijuana use, how to tell if a teen is engaging in marijuana use or truancy, and parenting skills. A comparable set of materials will be reviewed with the adolescent.
62507613|NCT05265299|EXPERIMENTAL|Sequence 4|"* Week 1-2: aspirin 325mg~* Week 5-6: aspirin 162mg~* Week 9-10: aspirin 81mg"
62507614|NCT05265299|EXPERIMENTAL|Sequence 5|"* Week 1-2: aspirin 162mg~* Week 5-6: aspirin 325mg~* Week 9-10: aspirin 81mg"
62507615|NCT05265299|EXPERIMENTAL|Sequence 6|"* Week 1-2: aspirin 81mg~* Week 5-6: aspirin 325mg~* Week 9-10: aspirin 162mg"
62507616|NCT01367717|ACTIVE_COMPARATOR|Creatine Monohydrate|Each of the 25 subjects took Creatine Monohydrate.
62507617|NCT01367717|ACTIVE_COMPARATOR|Creatine Ethyl Ester|Each of the 25 subjects took Creatine Ethyl Ester.
62507618|NCT04231409|ACTIVE_COMPARATOR|WaveWriter Settings|WaveWriter Programming
62507619|NCT04231409|ACTIVE_COMPARATOR|Conventional Settings|Conventional Programming
62507620|NCT05010824|EXPERIMENTAL|Intervention group|The intervention will involve three consultation sessions and four follow-up phone calls with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
62144452|NCT04463394|EXPERIMENTAL|Vasopressin|Participants undergoing cardiac catheterization
62507621|NCT05010824|NO_INTERVENTION|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
62507622|NCT04823507||Concussion patients treated with Photobiomodulation|"* Patients between the ages of 15-65 years clinically diagnosed with a mild Traumatic Brain Injury by a health professional and currently not undergoing any treatment during a 1 year period from January 2018 to December 2018.~* Documentation of the history of a qualifying mild Traumatic Brain Injury within 3 months of traumatic incident and/or diagnosis with persistent symptomatology after 3 months. For reference, International Classification of Diseases, Tenth Revision (ICD-10) clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol4."
62507623|NCT03618329|ACTIVE_COMPARATOR|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
62507624|NCT03618329|NO_INTERVENTION|No Prehabilitation|Not: exercise, nutrition and anxiety reduction in the preoperative period
62507625|NCT06616090|EXPERIMENTAL|Nurse implementation|This arm will receive nurse implemented attachment-based parenting modules in addition to routine well-child check up
62507626|NCT06616090|NO_INTERVENTION|No intervention|This arm will receive routine well-child check up
62507627|NCT05498493|EXPERIMENTAL|Cognitive Rehabilitation|Active Group participants will receive nine 1.5-h sessions of virtual (via Zoom platform) group-based training, three individual virtual 1-h training sessions, and approximately 20 h of home practice and CCT over 12 weeks.
62507628|NCT05498493|ACTIVE_COMPARATOR|Brain Health Education Program|The control group format will be twelve 1.5 or 1 h virtual sessions over 12 weeks, in addition to 20 h of home practice of a computerized control program (e.g., consisting of publicly available computer games such as sudoku and crossword puzzles).
62507629|NCT01471834|EXPERIMENTAL|Device and Medical Management|Participants will be implanted with the BAROSTIM NEO System and will continue to receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association \[AHA\] / American College of Cardiology \[ACC\] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
62349453|NCT02017613|EXPERIMENTAL|Single arm|RP6530 administered orally
62144453|NCT03104530||Brown crabmeat consumers|Those habitually consuming 40 grams or more of brown crab meat each week.
62144454|NCT03104530||Control|Those consuming less than 40 grams of brown crabmeat a year, or no brown crabmeat.
62349454|NCT04198233|EXPERIMENTAL|Diazepam group|Rectal Diazepam suppository
62349455|NCT04198233|PLACEBO_COMPARATOR|Placebo group|Placebo suppository
62507630|NCT05886257|EXPERIMENTAL|Candonilimab Plus Bevacizumab|Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week
62507631|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
62507632|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
62349456|NCT04758858|ACTIVE_COMPARATOR|VLCHF (Very Low CHO High Fat) Diet|10% of energy from CHO, 15% proteins, and 75% lipids
62507633|NCT02191566|EXPERIMENTAL|S-1/Oxaliplatin|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months; Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
62144455|NCT01427413||Hyper1|Only patients who achieved hyperstimulation pathology after external administration of gonadotrophin during IVF treatment
62144456|NCT03395600|ACTIVE_COMPARATOR|0.1%bupivacaine+10µg sufentanyl|Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
62144457|NCT03395600|ACTIVE_COMPARATOR|0.125%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
62144458|NCT03395600|ACTIVE_COMPARATOR|0.1%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
62507634|NCT02638519|OTHER|Healthy Volunteers|Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
62507635|NCT02638519|OTHER|Alzheimer's Disease Participants|Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
62144459|NCT02124356||Emergency High-risk Abdominal Surgery|
62144460|NCT01375699|EXPERIMENTAL|Sildenafil + doxorubicin|"Patients receive sildenafil citrate PO QD\* beginning at least 2 days prior to scheduled first dose of doxorubicin hydrochloride and continuing until 2 weeks after last scheduled dose of doxorubicin hydrochloride. Patients also receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.~NOTE: \*Patients receive sildenafil citrate PO TID on days that doxorubicin hydrochloride is also administered."
62349457|NCT04758858|ACTIVE_COMPARATOR|Low-CHO Diet|30% of energy from CHO, 15% proteins and 55% lipids
62349458|NCT04758858|PLACEBO_COMPARATOR|Control Diet|50% of energy from CHO, 15% proteins and 35% lipids
62349459|NCT03345433|EXPERIMENTAL|interactive group drumming sessions|Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.
62349460|NCT01156207|EXPERIMENTAL|Aliskiren|
62349461|NCT01156207|PLACEBO_COMPARATOR|placebo|
62507636|NCT05899920|ACTIVE_COMPARATOR|Controlled arterial hypertension|"Controlled arterial hypertension according the results of 24-hour blood pressure monitoring.~Blood samples will be taken for pharmacokinetics and pharmacogenetics"
62507637|NCT05899920|EXPERIMENTAL|Uncontrolled arterial hypertension|"Uncontrolled arterial hypertension according the results of 24-hour blood pressure monitoring.~Blood samples will be taken for pharmacokinetics and pharmacogenetics"
62507638|NCT00268892|EXPERIMENTAL|Degarelix 240/240@40(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (40 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (40 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
62705498|NCT06459726|ACTIVE_COMPARATOR|shi style mobilisation|In this group patient will receive Shi style cervical mobilization SCM including three crucial steps soothing tendon step, mobilization step and dredging collateral step 6 sessions over 2 weeks for 20 minutes.
61964452|NCT02310568|EXPERIMENTAL|PF 06372865 7.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
61964453|NCT02310568|EXPERIMENTAL|Placebo then PF 06372865 2.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
61964454|NCT02310568|EXPERIMENTAL|Placebo then PF 06372865 7.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
62144461|NCT01375699|ACTIVE_COMPARATOR|Doxorubicin-based chemotherapy|Patients receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
61964455|NCT02310568|PLACEBO_COMPARATOR|Placebo followed by placebo.|Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
61964456|NCT01622504|EXPERIMENTAL|Test Product Dose 1|
61964457|NCT01622504|EXPERIMENTAL|Test Product Dose 2|
62144462|NCT05646407|EXPERIMENTAL|Exercise training with Fan-to-face|Participants randomized to the fan-to-face group will perform supervised exercise training with a basic, portable fan (Honeywell HT-900 Turbo Force Air Circulator). The fan will be placed to the front of the treadmill with airflow directed toward the area of the face innervated by the second and third branches of the trigeminal nerve. The airflow speed will be chosen by each participant so that it is most comfortable to them. An anemometer will measure the airflow from the fan.
62144463|NCT05646407|NO_INTERVENTION|Exercise training with no fan|Participants randomized to the no fan group will perform supervised exercise training with no fan. The exercise duration and intensity titration will follow the same format as the experimental group.
62144464|NCT04929600|EXPERIMENTAL|Experimental|One pill of sacubitril/valsartan (200mg tablet) + one pill of matching placebo of amlodipine daily. If possible, dosage titration should be conducted.
62144465|NCT04929600|ACTIVE_COMPARATOR|Comparator|One pill of amlodipine (5mg tablet) + one pill of matching placebo of sacubitril/valsartan daily. If possible, dosage titration should be conducted.
62349462|NCT00922350|EXPERIMENTAL|heliox|The patients in this group underwent nebulization with heliox carried by the trunk erect
62507639|NCT00268892|EXPERIMENTAL|Degarelix 240/240@60(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
62507640|NCT00268892|EXPERIMENTAL|Degarelix 240/240@60(1-4-7-10)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 4, 7, 10) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
62507641|NCT01634412|EXPERIMENTAL|SL TNX-102 at pH 3.5|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5
62507642|NCT01634412|EXPERIMENTAL|SL TNX-102 at pH 7.1|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1
62349463|NCT00922350|EXPERIMENTAL|heliox+posture|The patients in this group carried out the mist carried by heliox and the trunk tilted forward
62507643|NCT01634412|ACTIVE_COMPARATOR|Cyclobenzaprine tablets|5 mg cyclobenzaprine tablet once
62507644|NCT01634412|ACTIVE_COMPARATOR|Cyclobenzaprine IV|2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4
62507645|NCT00607295|EXPERIMENTAL|1|Clino-san 2ml vaginal application 3 times per week for 12 weeks
62736686|NCT05815095||Routine practice (control)|In this group, a health professional will assess the infant's neurodevelopmental characteristics through routine practice evaluations, such as motor skills, vocalizations, babbling, and social interactions
61964458|NCT01622504|ACTIVE_COMPARATOR|Comparator Product|
61964459|NCT02787668|EXPERIMENTAL|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat.
61964460|NCT02787668|ACTIVE_COMPARATOR|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
61964461|NCT03378232|PLACEBO_COMPARATOR|Placebo Olive Oil|Placebo supplement with olive oil
61964462|NCT03378232|EXPERIMENTAL|High EPA Supplement|Supplements providing up to 3g per day of Omega-3, with increased EPA
61964463|NCT03378232|EXPERIMENTAL|High DHA Supplement|Supplements providing up to 3g per day of Omega-3, with increased DHA
61964464|NCT05574699|ACTIVE_COMPARATOR|Social Risk Score and Closed Loop Referral|Patients in intervention arm will have a social risk score available through the CDS tool, which the provider can review and decide whether the patient needs more assessment. If the patient is identified as with high social needs based on the risk score in the CDS tool, the providers will refer the patient to social workers/ care managers for further in-depth assessment of the participants social needs at HCC. HCC will reach out to the patients over the phone and will perform an in-depth assessment of the patients social needs. If any social needs are identified and patient agrees to address those needs HCC staff will refer the patient to CBOs.
61964465|NCT05574699|ACTIVE_COMPARATOR|Control|Patients randomized into the control arm will be provided with the standard-of-care screening, assessment, and addressing social needs in the clinic setting. This would not include any automated mechanism of pre-collected data in the EHR. Currently providers on an ad-hoc basis apply a series of needs-assessment tools including one available within JHHS-EHR. Patients in the control arm that are identified as someone with social needs will then be referred to appropriate services through current standard-of-care mechanisms, this may include a sheet of various educational resources, or a list of organizations that can address the identified social need.
61964466|NCT03937297|EXPERIMENTAL|Arm 1|Six Arts intervention
61964467|NCT03937297|EXPERIMENTAL|Arm 2|Cognitive Stimulation Therapy (CST)
62507646|NCT00607295|PLACEBO_COMPARATOR|2|placebo 2ml vaginal application 3 times per week for 12 weeks
61964468|NCT03937297|ACTIVE_COMPARATOR|Arm 3|Usual care (control group)
61964469|NCT04433221|EXPERIMENTAL|Multiple sarcoma-specific CAR-T cells|Patients who have confirmed surface antigens including GD2, PSMA, Her2, CD276 or other markers
61964470|NCT05935293|EXPERIMENTAL|Dexmedetomidine|"Patients in the dexmedetomidine group will receive intraoperative dexmedetomidine initiated in the operating room, before anesthetic induction.~Bolus of 0.6/mcg/Kg 15 mins before induction, followed by a continuous infusion of 0.4 mcg/kg/h during the per-operative period until transfer to intensive care and then 0.1 mcg/kg/h continued for additional 24 hours."
61964471|NCT05935293|PLACEBO_COMPARATOR|Control|"Patients in the control group will receive intraoperative sodium chloride 0.9% initiated in the operating room, before anesthetic induction.~IV administration rate will be weight adapted and similar to that of Dexmedetomidine group in volume (mL) and time (minutes) Bolus of 0.6/mcg/Kg 15 mins before induction, followed by a continuous infusion of 0.4 mcg/kg/h during the per-operative period until transfer to intensive care and then 0.1 mcg/kg/h continued for additional 24 hours."
61964472|NCT06071130|EXPERIMENTAL|Experiment 4A & 4B|Participants will attend for 3 sessions/week for 8 weeks. Instructors will conduct classes and maintain participant attendance records. Exercise components include flexibility, aerobics, strengthening, and physical activity logs. Classes begin and end with 10-minute warmups and cool downs. Participants are taught low-impact aerobic routines to maximize self-efficacy for physical activity maintenance after the program. This will include fitness walking that will progress from each participant's maximum capacity to the goal of 20 minutes of sustained walking. Participants will be instructed on how to gauge their exercise intensity and physical exertion. The strengthening focus of the program will improve independent functioning by targeting lower extremity strength with a graded, task-specific approach. Resistance will be progressively increased over the course of the program by adding weight. At the end of each exercise session, participants will log physical activity.
61964473|NCT03103568|EXPERIMENTAL|Arm A - CYP substrates|"In Arm A of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances tolbutamide, metoprolol and chlorzoxazone will be investigated. These substances are metabolized by CYP2C9, CYP2D6 and CYP2E, respectively.~A cocktail of the substances tolbutamide, metoprolol and chlorzoxazone will be given as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic serum concentrations level is reached. Serum and urine concentrations of nitisinone will then be investigated for 24 hours, followed by giving the substances tolbutamide, metoprolol and chlorzoxazone as a single dose together with nitisinone to investigate the PK during interaction."
61964474|NCT03103568|EXPERIMENTAL|Arm B - OAT substrates|"In Arm B of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances furosemide in the blood, which is transported by the transporter proteins OAT 1 and OAT 3, will be investigated.~Furosemide will be given intravenously as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic dose is reached. Furosemide will then be given as a single dose together with nitisinone to investigate the PK during interaction."
61964475|NCT04303832|EXPERIMENTAL|eye exercise group|This group made different types of eye exercises beside the traditional treatment of strabismus which is eye glasses
61964476|NCT04303832|SHAM_COMPARATOR|control group|This group had traditional treatment of strabismus which is eye glasses
61964477|NCT01384136||High risk pregnancy|
61964478|NCT01384136||"|Control - Normal low risk pregnancies"|
61964479|NCT06074068|EXPERIMENTAL|Fathers for Change|Defining features of F4C include: 1) focus on the fathering role to facilitate engagement, 2) focus on RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 60 minutes per week over 18 weeks.
61964480|NCT06074068|ACTIVE_COMPARATOR|Duluth BIP|The BIP is a psychoeducational intervention that will be delivered in 60- minute individual weekly sessions over 18 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including video vignettes and role plays to teach anger management skills.
61964481|NCT00923247|EXPERIMENTAL|Phase 1 - vandetanib and bortezomib|Patients will be treated with vandetanib and bortezomib to find the maximally tolerated dose
61964482|NCT00923247|ACTIVE_COMPARATOR|Phase 2 B - vandetanib alone|Patients will be treated with vandetanib alone.
62349464|NCT00922350|EXPERIMENTAL|oxygen+posture|The patients in this group carried out the mist carried by oxygen and the trunk tilted forward
62349465|NCT00922350|ACTIVE_COMPARATOR|oxygen|The patients in this group carried out the mist carried by the oxygen and the trunk upright
62507647|NCT04751474|EXPERIMENTAL|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
62507648|NCT04751474|NO_INTERVENTION|Control group|The control group did not receive any intervention.
62736687|NCT05815095||Use of PREAUT Grid (intervention)|In this group, a health professional will assess the infant's neurodevelopmental characteristics using the PREAUT grid
62736688|NCT06474000|ACTIVE_COMPARATOR|Oxytocin induction group|Participants in the oxytocin induction group received oxytocin induction during labour. The ALPS-Neo form was completed between 1-40 minutes after delivery, based on observation before, during and after the drying process, the first injection process and the blood glucose measurement procedures.
62705499|NCT06459726|ACTIVE_COMPARATOR|SNAGS|"Patient will receive sustained natural apophyseal glides as described by brian mulligan. Patient position will be upright sitting when therapist will apply a sustained passive assesory glide while patient moves actively through available physiological range of motion in the direction in which symptoms are produced(25).~the headache SNAG technique will be performed with the patient sitting on a chair in the erect posture. The therapist will handle C2 spinous process with the middle phalanx of one hand. With the other hand, he will perform ventral gliding on C2 for 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Patient will be asked to report dizziness or any other symptom after procedure. If patient reports symptom then angle of application is changed to ensure symptom free treatment in all patients. Number of repetitions are increased gradually from 6 to 10 and end physiological movement is maintained for 10seconds"
62736689|NCT06474000|ACTIVE_COMPARATOR|Control group|Participants in the control group did not receive oxytocin induction during labour. The ALPS-Neo form was completed between 1-40 minutes after delivery, based on observation before, during and after the drying process, the first injection procedure and the blood glucose measurement procedures.
61964483|NCT00923247|ACTIVE_COMPARATOR|Phase 2 A - vandetanib and bortezomib at the MTD|Patients will be treated with vandetanib and bortezomib at the maximally tolerated dose (MTD) of the Phase I study
62144466|NCT04037020||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa.
62349466|NCT05121909|EXPERIMENTAL|Prototype 1 Mouthwash|Participants will brush their teeth using Colgate (registered \[R\]) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Prototype 1 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62349467|NCT05121909|EXPERIMENTAL|Prototype 2 Mouthwash|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 2 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62349468|NCT05121909|EXPERIMENTAL|Prototype 3 Mouthwash|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 3 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62349469|NCT05121909|ACTIVE_COMPARATOR|Listerine (R) Cool Mint (R) Antiseptic Mouthwash (Positive Control)|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Antiseptic Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62349470|NCT05121909|ACTIVE_COMPARATOR|5 Percent (%) Hydroalcohol Mouthwash (Negative Control)|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the 5% Hydroalcohol Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
62349471|NCT04011748|EXPERIMENTAL|Hair regrowth by SCE|AA subjects will receive Stem Cell Educator therapy. Hair regrowth will be evaluated during six-month follow-up studies.
62349472|NCT04011748|EXPERIMENTAL|Minoxidil therapy|Control subjects will receive treatment with topical 5% minoxidil
62349473|NCT03831308||Breast cancer new diagnosis|group will include volunteer women, diagnosed with breast cancer, in any stage, aged 18y or more; at least 100 patients will be recruited in medical oncology appointments; all subjects should be periodically submitted to non-invasive evaluation tests - that is, clinical test/clinical and physical assessment to collect information on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
62349474|NCT01889888|EXPERIMENTAL|ADRC injection|
62349475|NCT02083393||Patients with acute lung injury|Patients with sepsis induced acute lung injury
62349476|NCT02083393||Postsurgery patients|Postsurgery patients without acute lung injury and sepsis
62349477|NCT01430572|EXPERIMENTAL|Pazopanib + Everolimus|Pazopanib 200 mg and Everolimus 5.0 mg oral dosing every other day (except for lead in 5 days of Cycle 1 where both drugs administered daily).
61964484|NCT02073552|ACTIVE_COMPARATOR|High volume|"* Two 5 mg bisacodyl tablets It is a stimulant laxative with local action.~* Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate."
62349478|NCT03685526|EXPERIMENTAL|Interventional arm|Patients will be treated with Cinenses Lung Volume Reduction Reverser System.
62144467|NCT03466983|EXPERIMENTAL|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
62349479|NCT03201887|EXPERIMENTAL|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
62349480|NCT03201887|EXPERIMENTAL|Sub-optimal effort Chronic pain|Sub-optimal effort
62349481|NCT03201887|NO_INTERVENTION|Traumatic Brain Injury|optimal effort
62349482|NCT03201887|NO_INTERVENTION|Chronic pain|optimal effort
62349483|NCT04493957|EXPERIMENTAL|educational intervention|"Patients and caregivers included in the ACCOMPAGNE Education Program group will benefit from seven group workshops spread over three half-days (once a week over 3 consecutive weeks), animated in pairs, each lasting approximately one and a half hours. and using educational pedagogical methods."
62349484|NCT04493957|ACTIVE_COMPARATOR|Control group|"Patients and caregivers included in the Control group will receive the usual recommendations for driving, issued by their referring doctor in memory consultation during the diagnostic announcement process or during the follow-up of their illness."
62349485|NCT03604068|ACTIVE_COMPARATOR|Active Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.
62349486|NCT03604068|SHAM_COMPARATOR|Control Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.
62349487|NCT04781569||Patients with S. aureus infection|
62349488|NCT04781569||healthy participants|
62349489|NCT01019772|EXPERIMENTAL|LBVH0101|
62349490|NCT01019772|ACTIVE_COMPARATOR|Hiberix|
62144468|NCT03466983|ACTIVE_COMPARATOR|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
61964485|NCT02073552|EXPERIMENTAL|Low volume|"* Two 5 mg bisacodyl tablets, taken in the same way as for the high volume group.~* Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid."
61964486|NCT03346915|EXPERIMENTAL|Subjects receiving WoW and BNI|The behavioral intervention (WoW and BNI) will supplement the subject's standard of care by incorporating interactive messaging, reminders, patient education, and enhanced provider communication.
62507649|NCT02564848|EXPERIMENTAL|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and hormonal therapy.
62705500|NCT03478956|EXPERIMENTAL|Etrolizumab Q4W|Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
61964487|NCT03294902||Critical Limb Ischaemia (CLI) Group with tibial arterial dis|Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels. The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
61964488|NCT03294902||Peripheral Artery Disease (PAD) Group with SFA disease|Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
61964489|NCT03294902||PAD-free group (Healthy Volunteer Group)|Up to 20 subjects with no clinical diagnosis of peripheral vascular disease.
61964490|NCT01908374|ACTIVE_COMPARATOR|DHA-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish oil in triglyceride form (12 capsules/d providing 575 mg/d EPA; 1843 mg/d DHA; 259 mg/d n-3 DPA)
61964491|NCT01908374|EXPERIMENTAL|Phospholipid-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish roe high in EPA/DHA phospholipids \[(12 capsules/d providing 628 mg/d EPA; 1810 mg/d DHA; 137 mg/d n-3 docosapentaenoic acid (DPA)\]
61964492|NCT02101060|EXPERIMENTAL|exercise|16-week progressive aerobic and resistance exercise training
61964493|NCT02101060|NO_INTERVENTION|control|usual care controls
61964494|NCT04936256||Bilateral implantation of the Clareon monofocal IOL|Clareon monofocal intraocular lens (IOL)
61964495|NCT00461162|EXPERIMENTAL|1: i-DSMP|Internet Dyspnea Self-management Program (i-DSMP)
61964496|NCT00461162|EXPERIMENTAL|2: f-DSMP|Face-to-Face Dyspnea Self-management Program (f-DSMP)
61964497|NCT00461162|ACTIVE_COMPARATOR|3: AC|Attention Control (AC)
61964498|NCT00198939|ACTIVE_COMPARATOR|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
61964499|NCT00198939|EXPERIMENTAL|Conitive Behavorial Therapy|The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
61964500|NCT00198939|EXPERIMENTAL|Family Therapy|Participants assigned to the Family Therapy arm received a family-centered intervention to support targeted adolescent behavior change. The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases.
61964501|NCT00198939|EXPERIMENTAL|Intergrated Family and Cognitve Behavioral Therapy|Participants assigned to the IFCBT arm received the Cognitive Behavioral Therapy and Family Therapy intervention components.
61964502|NCT01234298|EXPERIMENTAL|SPD489 Low-Dose|
61964503|NCT01234298|EXPERIMENTAL|SPD489 High-Dose|
61964504|NCT01234298|PLACEBO_COMPARATOR|Placebo|
61964505|NCT04943315|EXPERIMENTAL|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia crowns
61964506|NCT04943315|ACTIVE_COMPARATOR|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic crowns
61964507|NCT06504849|EXPERIMENTAL|Intervention group|Intervention group will receive personalised brief LSM messages (according to their unhealthy behaviours and preferences, screened during the baseline measurement) using instant messaging applications with an active self-BP monitor for 3 months. Chat-based support will also be given to the participants as an extension of the LSM messages.
61964508|NCT06504849|OTHER|Control group|The control group will receive a flyer with brief pre-HTN information, which is distributed during the recruitment phase, as well as brief pre-HTN messages via instant messaging applications.
62144469|NCT04845386||TOF Cuff on arm and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
62507650|NCT03302572|EXPERIMENTAL|Brief information group|Patients will be given brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
62507651|NCT03302572|NO_INTERVENTION|Control group|"Patients who fall into a control group will only be attended to their reason for visiting and will be asked for the necessary data to obtain the independent variables if they do not appear in their history. If the patient in this group wants the information, he will be excluded from the study because he refuses to participate."
61964509|NCT01083368|EXPERIMENTAL|Arm 1: Combination of temsirolimus and AVASTIN|Patients receive temsirolimus IV over 30-60 minutes once weekly and bevacizumab IV over 30-90 minutes once every two weeks . Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
61964510|NCT00490295||newborn cardiac surgical study group|
61964511|NCT03101683|EXPERIMENTAL|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
61964512|NCT06011057||threatened miscarriage Group|"This group will include 50 pregnant women presenting with vaginal bleeding and/or abdominal cramps concerning for possible miscarriage in the first trimester. Inclusion criteria will be gestational age between 6-14 weeks by last menstrual period and/or ultrasound dating, and clinical signs/symptoms suggestive of threatened miscarriage including:~Vaginal bleeding Abdominal cramps/pain Closed cervical os on exam Women with confirmed fetal demise on ultrasound will be excluded. Participants in this group will undergo blood testing to measure C reactive protein (CRP) level and fetal ultrasound to assess parameters like crown-rump length, heartbeat, yolk sac size, and embryonic motion. This group will provide data to assess C reactive protein (CRP) and ultrasound findings in women with threatened first trimester miscarriage."
62144470|NCT04845386||TOF Cuff on lower leg and TOF Scan on adductor pollicis|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
62144471|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on toe|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
62349491|NCT04716153|EXPERIMENTAL|Interventional|"Patients in the interventional arm will follow a multifactorial sensory rehabilitation program focused on smell and taste that integrates several non-drug interventions, which are part of the current recommendations: program of workshops at the technical center, hydration of the mucous membranes with daily (3 times a day) liposomal sprays (LipoSaliva® and LipoNasal) between V0 and V1, presentation of visual dishes.~The workshops will take place at the frequency of one session of 2 hours per week and will last for 3 weeks. Each session will accommodate a minimum of 2 participants. The program will include 3 workshops on olfactory rehabilitation and taste rehabilitation.~Exercises (taking up the themes discussed) will be carried out at home between 2 workshops."
62349492|NCT04716153|OTHER|Control|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified.~Patients in the control group will be able to benefit from the rehabilitation workshops if they wish at the end of the study."
62349493|NCT06281405|EXPERIMENTAL|Immunochemotherapy group|The patients will receive 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W\&W option can be applied to patients achieving cCR.
62349494|NCT06281405|EXPERIMENTAL|Radiation plus immunochemotherapy group|The patients will receive short-course radiotherapy (25Gy/5Fx), followed by 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W\&W option can be applied to patients achieving cCR.
62349495|NCT01208571|EXPERIMENTAL|Lifestyle counseling|
62349496|NCT01208571|NO_INTERVENTION|Treatment as usual|
62349497|NCT05701488|EXPERIMENTAL|Durvalumab + Tremelimumab (Arm A)|"-Participants will be randomized into the treatment group in a 1:1 ratio and will receive interventions as outlined:~Neoadjuvant Treatment:~* Cycle 1:~  * Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab and Tremelimumab~ * Day 28 of 28 Day cycle: Pre-determined dose of Durvalumab~* Participants will undergo surgery on day 49 of Cycle 1. Surgery will be performed per institutional standard of care.~Adjuvant Treatment:~--Cycles 1 (28 days postoperatively) - 13:~---Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab"
62349498|NCT05701488|EXPERIMENTAL|Durvalumab + Tremelimumab + SIRT (Arm B)|"-Participants will be randomized into the treatment group in a 1:1 ratio and will receive interventions as outlined:~Neoadjuvant Treatment:~* Cycle 1:~  * Day 3 of 28 Day Cycle: Pre-determined dose of Durvalumab and Tremelimumab~ * Day 31 of 28 Day Cycle: Pre-determined dose of Durvalumab~ * Day 1 of 28 Day Cycle: Yttrium-90~* Participants will undergo surgery on Day 52 of Cycle 1. Surgery will be performed per institutional standard of care.~Adjuvant Treatment:~--Cycles 1 (28 days postoperatively) - 13:~---Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab"
62349499|NCT00475540|ACTIVE_COMPARATOR|Prolift mesh|vaginal prolapse repair with mesh
62349500|NCT00475540|ACTIVE_COMPARATOR|Prolapse repair without mesh|vaginal prolapse repair without mesh
62349501|NCT03944070|ACTIVE_COMPARATOR|Intensive Treatment|The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
62349502|NCT03944070|ACTIVE_COMPARATOR|Standard Treatment|The participants will continue their preoperative treat and extend protocol .
62349503|NCT05161637|EXPERIMENTAL|TLC590 490mg|TLC590 490mg (20mL)
62349504|NCT05161637|EXPERIMENTAL|TLC590 588mg|TLC590 588mg (24mL)
62349505|NCT05161637|ACTIVE_COMPARATOR|Bupivacaine 75mg|Bupivacaine HCl 75mg (30mL)
62349506|NCT05161637|ACTIVE_COMPARATOR|Ropivacaine|Ropivacaine HCl 150mg (30mL) (Part 1)
62349507|NCT05161637|PLACEBO_COMPARATOR|Normal saline|Normal Saline 0.9% (20mL or 24mL)
62349508|NCT03179579|EXPERIMENTAL|Experimental group|"1. HIPEC with paclitaxel 135 mg/m\^2+HIPEC with cisplatin 75 mg/m\^2±HIPEC with Raltitrexed 3 mg/m\^2 intraperitoneally in succession~2. 2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m\^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m\^2, d1, IV, every 3 weeks~3. Cytoreductive surgery~4. HIPEC with paclitaxel 135 mg/m\^2+HIPEC with cisplatin 75 mg/m\^2±HIPEC with Raltitrexed 3 mg/m\^2 intraperitoneally in succession~5. 4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m\^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m\^2, d1, IV, every 3 weeks"
62349509|NCT03179579|ACTIVE_COMPARATOR|Control group|"1. 3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m\^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m\^2, d1, IV, every 3 weeks~2. Cytoreductive surgery~3. 4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m\^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m\^2, d1, IV, every 3 weeks"
62507652|NCT06616818|PLACEBO_COMPARATOR|STANDARD|Nutrition counseling only as part of standard of care
62507653|NCT06616818|ACTIVE_COMPARATOR|DASH diet toolkit arm|A group of participants receiving DASH diet intervention
61964513|NCT06011057||Control Group|"The control group will include 50 low-risk pregnant women matched to the threatened miscarriage group based on gestational age. Inclusion criteria are normal pregnancy dating, no vaginal bleeding/cramping, normal prior ultrasounds, and no history of pregnancy complications. Controls will undergo the same CRP blood testing and fetal ultrasounds as the threatened miscarriage group. This will provide comparative normal pregnancy CRP and ultrasound data. Matching controls on demographics and gestation will allow analysis of differences in CRP and ultrasound parameters between groups to determine predictors of pregnancy viability.~Copy Retry"
61964514|NCT03761524|EXPERIMENTAL|Customized V plate fixation|Computed tomography (CT) scan of the Facial bones (Axial cuts, DICOM file, Gantry tilt zero and minimal thickness of 1mm )is taken for the patients and a customized V pattern plate
62349510|NCT03945734|EXPERIMENTAL|Expressive Helping|Participants complete four 20-minute writing/voice-recording sessions spaced one week apart. During the first week, the instructions will explain that cancer patients and survivors benefit from learning about other cancer survivors' experiences. They are told that the first three weeks of writing/voice-recording (writing/talking about their stress and coping at Week 1, deepest emotions about cancer at Week 2, self-affirmation and benefit finding at Week 3) are exercises designed to help them think about their cancer experiences and to prepare them to write/record the narrative they would share on Week 4. During Week 4, they are asked to write/record a narrative as if they are speaking to another Chinese person with cancer, adding advice and encouragements, and reminded that their writing/recording would be shared with other Chinese American cancer patients and survivors.
62349511|NCT01755312|EXPERIMENTAL|medication reminder|medication reminder
62349512|NCT01755312|PLACEBO_COMPARATOR|Placebo|Placebo
62349513|NCT02835677|EXPERIMENTAL|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
62349514|NCT01233700|EXPERIMENTAL|Motivational Interviewing|Subjects will receive two, individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on assisting subjects to delineate their reasons for or against proceeding with living organ donation and assisting subjects to resolve any lingering concerns about their decisions regarding donation.
62349515|NCT01233700|ACTIVE_COMPARATOR|Enhanced Standard Care|Subjects will receive two individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on providing educational information to subjects regarding healthy lifestyle issues (healthy eating, diet, exercise, quitting smoking).
62349516|NCT01233700|NO_INTERVENTION|Standard Care|Subjects will receive the standard care and education provided by the Living Donor Program at their medical center.
62349517|NCT00631540|EXPERIMENTAL|1|renal artery stenting
62349518|NCT05671926||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
62349519|NCT05671926||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
62349520|NCT04904965|EXPERIMENTAL|Propofol Group 1|Patients will receive induction of anesthesia with Propofol at a rate of 2.0 mg/kg/hr.
62349521|NCT04904965|EXPERIMENTAL|Propofol Group 2|Patients will receive induction of anesthesia with Propofol at a rate of 4.0 mg/kg/hr.
62349522|NCT04904965|EXPERIMENTAL|Propofol Group 3|Patients will receive induction of anesthesia with Propofol at a rate of 6.0 mg/kg/hr.
62349523|NCT04904965|EXPERIMENTAL|Propofol Group 4|Patients will receive induction of anesthesia with Propofol at a rate of 8.0 mg/kg/hr.
62507654|NCT03608306|EXPERIMENTAL|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
61964515|NCT03761524|ACTIVE_COMPARATOR|Conventional miniplates fixation|Conventional superior-inferior miniplates fixation of mandibular angle fixation
61964516|NCT00712127|EXPERIMENTAL|Diet and Exercise|Diet and Exercise for Class II and Class III Obesity
62349524|NCT03679429||Control group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
62349525|NCT03679429||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined by using the NBI function of the scope.
62349526|NCT05706649|EXPERIMENTAL|Plant-based diet|Subjects will receive a handbook on plant-based diet including recipe recommendations. They will follow a strict plant-based diet for 21 day.
62349527|NCT02986685|EXPERIMENTAL|trimebutine maleate + rabeprazole|trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily
62507655|NCT03608306|ACTIVE_COMPARATOR|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
62507656|NCT01017939|EXPERIMENTAL|Group A: abiraterone + prednisone + dextromethorphan|Group A will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP2D6 using 2 single doses of dextromethorphan hydrobromide as a probe drug.
62507657|NCT01017939|EXPERIMENTAL|Group B: abiraterone + prednisone + theophylline|Group B will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP1A2 using 2 single doses of theophylline as a probe drug.
62507658|NCT04729608|EXPERIMENTAL|Batiraxcept+PAC|Combination of batiraxcept and PAC
62507659|NCT04729608|PLACEBO_COMPARATOR|Placebo+PAC|Placebo-controlled arm with PAC
62507660|NCT04366180|EXPERIMENTAL|Probiotic|Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10\^9 cfu/day).
62507661|NCT04366180|PLACEBO_COMPARATOR|Control|Control group who will receive a daily placebo capsule consisting of maltodextrin
62507662|NCT01212549|ACTIVE_COMPARATOR|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 weeks imiquimod
62507663|NCT01212549|ACTIVE_COMPARATOR|Cryoimmunotherapy|Cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 5 weeks imiquimod
62507664|NCT04829760|EXPERIMENTAL|Psyllium|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to at least 8 ounces (240 mL) of cold water or a beverage that is typically consumed. Participants will ingest the intervention each morning and evening for eight weeks.
62507665|NCT04829760|EXPERIMENTAL|Coarse wheat bran|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to a food they normally eat.
62705501|NCT03478956|EXPERIMENTAL|Etrolizumab Q8W|Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
62705502|NCT03762590|EXPERIMENTAL|Doxy.me plus Color Genomics Arm (Arm 1)|"* Participants in this arm will receive genetic education through an online platform called Doxy.me~* The Doxy.me session will consist of two parts: 1) a pre-recorded genetic education video 2) a live interactive video conferencing session with a GENERATE genetic counselor~* After completing the Doxy.me session and post intervention questionnaires, participants will be directed to the Color Genomics study portal where they may elect to review Color Genomics' genetic education content or proceed directly to order genetic testing~* Intervention is Doxy.me genetic education +/- genetic education via Color Genomics website"
62705503|NCT03762590|EXPERIMENTAL|Color Genomics Only Arm (Arm 2)|"* Participants in this arm will access genetic education on the Color Genomics website which includes both written information and an educational video~* After accessing the Color Genomics website, participants may elect to review educational content or proceed directly to order genetic testing~* Intervention is genetic education via Color Genomics website"
62144472|NCT04845386||TOF Scan on adductor pollicis and TOF Cuff on arm|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
62144473|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
62349528|NCT02986685|OTHER|rabeprazole|rabeprazole 20mg once daily
62349529|NCT05128682|OTHER|Urodynamic testing with and without pudendal nerve stimulation|"The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the dose and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject."
62349530|NCT03086681|EXPERIMENTAL|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
61964517|NCT00712127|EXPERIMENTAL|Diet and Exercise-Delayed|Diet and Exercise-Delayed for 6 months for Class II and Class III Obesity
61964518|NCT00712127|NO_INTERVENTION|Control|Normal weight, overweight and Class I obesity
62349531|NCT03086681|ACTIVE_COMPARATOR|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
62349532|NCT02451202|EXPERIMENTAL|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
62507666|NCT04829760|PLACEBO_COMPARATOR|Maltodextrin|Volume equivalent to the psyllium. Participants will be instructed to divide the daily dose into 2 doses and ingest by adding the product to a food or to 8 ounces (240 mL) of a beverage that is typically consumed.
62507667|NCT05423093|EXPERIMENTAL|Intervention delivery|Participants will receive a 45-60 minute single-session video group psychoeducational intervention delivered by clinic staff.
62507668|NCT01272089|EXPERIMENTAL|Pataday|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once daily for one week
62507669|NCT06612034||Healthcare professionals for prostate cancer|Healthcare professionals actively engaged in prostate cancer treatment, including urologists, uro-oncologists, medical oncologists, and radiation oncologists
62507670|NCT05201638|EXPERIMENTAL|IMU-838|"IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.~Formulation:~Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning."
62507671|NCT05201638|PLACEBO_COMPARATOR|Placebo|Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.
62507672|NCT00606138|EXPERIMENTAL|Anti-VEGF injection|Intravitreal injection of 0.5-mg dose of ranibizumab
61964519|NCT00430690||1|Cocaine dependent subjects
61964520|NCT00430690||2|Healthy controls
61964521|NCT00430690||3|Siblings of cocaine dependent subjects
61964522|NCT02599129|EXPERIMENTAL|Secukinumab|300 mg subcutaneous injections
61964523|NCT02599129|PLACEBO_COMPARATOR|Placebo|matching placebo subcutaneous injections
61964524|NCT01138553|EXPERIMENTAL|Mifepristone|
61964525|NCT01064713|EXPERIMENTAL|Tesetaxel|Therapy initiated at a flat dose of 40 mg for subjects in Cohort A and at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.
61964526|NCT02812160|ACTIVE_COMPARATOR|Spatz3 Adjustable Balloon|Spatz3 Adjustable Balloon with Dietary and exercise counselling
62507673|NCT00606138|ACTIVE_COMPARATOR|PRP Laser|Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
62507674|NCT04752488|EXPERIMENTAL|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
62507675|NCT04752488|ACTIVE_COMPARATOR|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
62507676|NCT02413294|EXPERIMENTAL|Bright Light Intervention|Before the bright light intervention is initiated (and during the intervention), participants will wear two wrist bands which measure sleep quality and activity levels- the Fitbit and actigraphy watches. These will be worn for two weeks to assess individuals' baseline levels of sleep quality and will continue to be worn during the intervention. Following the baseline period, the re-timer glasses will be introduced and worn for a period of 30 to 50 minutes a day for two weeks.
62507677|NCT02165514|EXPERIMENTAL|Lunar iDXA (DEXA) scan|Spinal scans taken by DEXA scanner
62507678|NCT01718730||Mild depression|Subjects with mild, but clinically significant depression
62507679|NCT01718730||Moderate to Severe MDD|Subjects with moderate to severe major depressive disorder who have not yet initiated treatment with an SSRI
61964527|NCT02812160|NO_INTERVENTION|Control|Dietary and Exercise counselling
61964528|NCT03585257|EXPERIMENTAL|IV albumin|25% IV albutein (albumin) formulation will be infused 1.0g/kg IV over one hour weekly for 5 weeks
62705504|NCT03926130|PLACEBO_COMPARATOR|Placebo|Participants received Placebo intravenously (IV) or subcutaneously (SC) every 4 weeks (Q4W). Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study. Nonresponse is defined as failing to achieve at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) and be no worse than baseline.
62705505|NCT03926130|EXPERIMENTAL|300 mg Mirikizumab|Participants received 900 milligrams (mg) Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W
61964529|NCT03585257|PLACEBO_COMPARATOR|Placebo|Normal saline will be infused 1.0g/kg IV over one hour weekly for 5 weeks
61964530|NCT00818818|EXPERIMENTAL|Meglumine antimoniate|Treated with 5mg/kg/d of pentavalent antimony (meglumine antimoniate) intravenously for 20 consecutive days.
61964531|NCT05798091|EXPERIMENTAL|Supportive-expressive group therapy|An intervention is based on the evidence-based supportive-expressive approach that was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
61964532|NCT05798091|ACTIVE_COMPARATOR|Treatment as usual|Standard care for impatiens with limb loss at St. John's Rehab - Sunnybrook Health Sciences Centre. Patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed.
62144474|NCT01535898||Pts having an MRI|This is a technology assessment protocol. The study is designed to assess the utility of the technology using a limited number of participants.
62507680|NCT01718730||MDD with response to SSRI|Subjects with moderate to severe major depressive disorder that has responded to an SSRI
62507681|NCT01718730||MDD without response to SSRI|Subjects with moderate to severe major depressive disorder which has not responded to treatment with an SSRI
62507682|NCT05412524|EXPERIMENTAL|Reading|Mother and, if desired, mother's partner will read to infant for at least 15 minutes per week, but will be encouraged to read to infant as much as possible. Saliva will be collected from infants and parents for OXTRm assay at pre-specified time points, and at these time point parents will also complete standardized questionnaires including PSS-NICU, PROMIS depression, and PROMIS anxiety to assess parental mood and stress. Reading time will be measured with a reading log provided to the parents, as well as with a commercially-available LENA device to measure word count.
62507683|NCT00932217|ACTIVE_COMPARATOR|filgrastim|patients mobilized with filgrastim
62507684|NCT00932217|ACTIVE_COMPARATOR|lenograstim|patients mobilized with lenograstim
62507685|NCT01196117|PLACEBO_COMPARATOR|14 days of Placebo therapy, then CPAP|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
62507686|NCT01196117|ACTIVE_COMPARATOR|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
62507687|NCT06471309|EXPERIMENTAL|Bilateral stimulation group|On the basis of routine treatment and routine swallowing rehabilitation training, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side
62507688|NCT06471309|EXPERIMENTAL|Unilateral stimulation group|On the basis of routine treatment and routine swallowing rehabilitation training, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side
62507689|NCT06471309|SHAM_COMPARATOR|Sham stimulation group|On the basis of routine treatment and routine swallowing rehabilitation training, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side
62507690|NCT06678646|EXPERIMENTAL|Ultrasound guided surgery|Percutaneous Ultrasound-Guided Release of the Lacertus Fibrosus for Median Nerve Entrapment at the Elbow
62507691|NCT06428695|EXPERIMENTAL|dietary self-monitoring tool education session|access the impact of a one-hour dietary self-monitoring tool education session for participants in a calorie-restricted weight management program on their knowledge of the use of the tool to help them adhere to a calorie-restricted weight management program
62507692|NCT01901172|EXPERIMENTAL|Extension|
62507693|NCT01901172|EXPERIMENTAL|Part 1: Drug-drug interaction|
62507694|NCT01901172|EXPERIMENTAL|Part 2: Relative bioavailability|
62705506|NCT03926130|ACTIVE_COMPARATOR|90 mg Ustekinumab|Participants received 6 mg/kg Ustekinumab IV for one dose, then 90 mg SC every 8 weeks (Q8W)
62705507|NCT03926130|EXPERIMENTAL|300 mg Mirikizumab (Adolescents)|Participants received open label 900 mg Mirikizumab IV for 3 doses, then 300 mg SC Q4W
62705508|NCT05621291|EXPERIMENTAL|1/Intervention|Systematic, frequent monitoring intervention to risk stratify pts for risk of relapse postCART
61964533|NCT04763304|ACTIVE_COMPARATOR|PPE-G (gown) followed by PPE-C (coverall)|"Placement of PPE-G (personal protective equipment including a gown for body protection) fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning."
61964534|NCT04763304|ACTIVE_COMPARATOR|PPE-C (coverall) followed by PPE-G (gown)|"Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-G (personal protective equipment including a gown for body protection), fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning."
61964535|NCT00621985|EXPERIMENTAL|Experimental|Experimental therapy with nocturnal dexamethasone.
61964536|NCT02482506|OTHER|SG-WLP|Self-guided weight loss program
61964537|NCT02482506|ACTIVE_COMPARATOR|MF-WLP|Moving Forward Weight Loss Program
61964538|NCT02990910|OTHER|Individualized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS\<=6 and Aldrete score\>9.
61964539|NCT02990910|OTHER|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS\<=6 and Aldrete score\>9.
61964540|NCT03919799|EXPERIMENTAL|Belumosudil QD/Belumosudil QD|Participants received belumosudil 200 mg tablet, QD orally for 28 weeks during the DB period. After completion of DB period, participants entered open-label extension (OLE) period and continued to receive belumosudil 200 mg tablet QD orally for 24 weeks in OLE period (i.e., up to Week 52).
62144475|NCT06375759|EXPERIMENTAL|Subarachnoid-Subarachnoid (S-S) Bypass|After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long. The total length of the tube was equal to the distance between the cephalic and caudal ends of the normal dissected arachnoid mater, along with approximately 4 cm of extra tubing.
62144476|NCT06375759|ACTIVE_COMPARATOR|Intradural Adhesion Lysis|The dura is opened sharply, exposing the spinal cord. After microsurgical dissection adhesion, the dura is sewn closed with a dural graft.
62144477|NCT01401218||thoracic aortic surgery group|patients who underwent thoracic aortic surgery
62144478|NCT06332326|EXPERIMENTAL|VR+VAGUS GROUP|VR+VAGUS GROUP (n=20): PATIENTS USED NON-INVASIVE VAGUS NERVE STIMULATION IN ADDITION TO VESTIBULAR REHABILITATION
62144479|NCT06332326|ACTIVE_COMPARATOR|VR GROUP|VR GROUP (n=20) : PATİENTS UNDERGOİNG VESTİBULAR REHABİLİTATİON
62144480|NCT05237999|EXPERIMENTAL|Intervention: KopOpOuders-PTSD|KopOpOuders-PTSD is a blended care (i.e., partially online and partially in person) intervention that addresses the enhancing of protective factors within the family setting (reducing negative parental self-perceptions; parent-child interaction quality, social support, child adaptive functioning/coping, and child understanding of the parent's illness) from a combination of transdiagnostic and PTSD-specific perspectives. It consists of 8 sessions (5 online self-help modules, 3 in-person sessions with a professional) to be completed in a maximum period of 9 weeks.
62144481|NCT05237999|NO_INTERVENTION|Control: No intervention|The control group receives no parenting intervention during their participation.
62144482|NCT02911961|EXPERIMENTAL|Acetaminophen|Subjects will take extra strength acetaminophen (4g/day) for the three days prior to the embolization procedure.
62507695|NCT01901172|EXPERIMENTAL|Part 3: Food effect|
62507696|NCT02323802|EXPERIMENTAL|educational group intervention|"The group educational food intervention: it provides the delivery of information leaflet and inclusion in groups on a weekly basis for the first 3 meetings, and then, there are other 2 meetings on the third and sixth month by the AMI.~The meetings will cover education to self-nutrition, physical activity and learning techniques for stimulus control and management of high-risk situations."
62507697|NCT02323802|ACTIVE_COMPARATOR|prescriptive diet|An objectives food scheme elaborated for each patients will provide the reduction in caloric intake (equivalent to 500-600 calories in deficit if compared to the estimated daily requirement, based on the RDAs) and a reduced intake of lipids, which does not exceed 30% of total calories introduced, with a contribution of saturated fat no more than 7-9% .
62507698|NCT05397795|EXPERIMENTAL|Group(A)|subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly.
62507699|NCT05397795|EXPERIMENTAL|Group(B)|subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) intramuscular injection in addition to the GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
62507700|NCT01618630|EXPERIMENTAL|EAA Supplementation + Exercise Training|Drink an amino acid supplementation during exercise training.
62507701|NCT01618630|PLACEBO_COMPARATOR|Placebo + Exercise Training|Drink a placebo supplementation during exercise training.
62705509|NCT04241276|ACTIVE_COMPARATOR|Gemcitabine + nab-paclitaxel|Patients will receive Gemcitabine and nab-Paclitaxel in 28 day cycles until disease progression.
62705510|NCT04241276|EXPERIMENTAL|Gemcitabine + nab-paclitaxel + ATRA|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
62705511|NCT00012545||Healthy Pregnant Volunteers|Pregnant women whose babies are at risk for sickle cell anemia will be identified and referred to the NIH Research Coordinator for evaluation and entry into the study
61964541|NCT03919799|EXPERIMENTAL|Belumosudil BID/Belumosudil BID|Participants received belumosudil 200 mg tablet BID orally, for 28 weeks during the DB period. After completion of DB period, participants entered OLE period and continued to receive belumosudil 200 mg tablet BID orally for 24 weeks in OLE period (i.e., up to Week 52).
61964542|NCT03919799|PLACEBO_COMPARATOR|DB Period: Placebo|Participants received placebo (matched to belumosudil) tablet, orally for 28 weeks during the DB period.
62705512|NCT06079359|EXPERIMENTAL|ALXN1850|Starting at Day 1 of the Randomized Evaluation Period, the ALXN1850 group will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once every 2 weeks (q2w) via SC injection, for 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.
62705513|NCT06079359|PLACEBO_COMPARATOR|Placebo|Starting at Day 1 during the Randomized Evaluation Period, participants will receive placebo q2w for a total of 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.
62144483|NCT02911961|NO_INTERVENTION|Observational - No Acetaminophen|Subjects will take no acetaminophen containing products prior to the embolization procedure.
62349533|NCT02451202|ACTIVE_COMPARATOR|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (\< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections\]will be administered at least reappearance of T2."
62349534|NCT04169854|EXPERIMENTAL|Lidocaine Patch|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked Lidocaine 5% patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
62349535|NCT04169854|PLACEBO_COMPARATOR|Placebo|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked placebo patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
62349536|NCT06259864|ACTIVE_COMPARATOR|Neurodevelopmental treatment program group|NDT aims to bring the child to the maximum level of independence possible within the limits of age and ability. Treatment sessions are planned for a certain functional result, and the patient's active participation as much as possible is requested. As the child fulfills postural and motor requirements, the physical therapist provides less assistance and less guidance. Positionings supported by auxiliary materials, appropriate hand contacts, correct ways to hold the child, tonus regulation, family education, environmental regulations and goal-oriented quality movement approaches; These are some of the methods used by the NDT approach, which is based on facilitation, stimulation and communication. Neurodevelopmental treatment physiotherapy session for 2 days in a week, over 8 week.
62705514|NCT00001372||1|Longitudinal cohort study with affected SLE patients
62705515|NCT00001372||2|Patient relatives
62144484|NCT02022865||periodontitis patients|according to american academy of periodontology classification of periodontal diagnosis.
62349537|NCT06259864|EXPERIMENTAL|Mollii Suit method group|The Exopulse Mollii Suit is designed to restore normality and healthy balance of muscle groups in the body. The suite uses one of several different forms of neuromodulation, based on gently stimulating the affected muscle groups with electrical signals. This approach has been shown to help resynchronize muscle signals that have been disrupted due to spasticity and muscle groups that may have stopped working together. 58 electrodes embedded in the suit send mild and imperceptible impulses to both tense and spastic muscles and the weakened muscles that balance them. These stimulations not only relax tense muscles and reactivate weak ones, but also restore the natural balance of the group and help the body move as it should. Children will wear the outfit twice a week for 8 weeks and each session will last 60 minutes. During this practice, children will also receive NDT twice a week.
62349538|NCT04430946|EXPERIMENTAL|Lean patients with type 1 diabetes|Test meal consumed within 10 minutes
62349539|NCT04430946|EXPERIMENTAL|Obese patients with type 1 diabetes|Test meal consumed within 10 minutes
62349540|NCT04430946|ACTIVE_COMPARATOR|Lean healthy control subjects|Test meal consumed within 10 minutes
62349541|NCT04430946|ACTIVE_COMPARATOR|Obese healthy control subjects|Test meal consumed within 10 minutes
62349542|NCT04011124|EXPERIMENTAL|Rifampicin + Fluzoparib|
62349543|NCT02452801|EXPERIMENTAL|ALKS 5461|Sublingual tablet
62349544|NCT00661102|EXPERIMENTAL|1|
62349545|NCT00661102|ACTIVE_COMPARATOR|2|
62349546|NCT00661102|PLACEBO_COMPARATOR|3|
62144485|NCT02022865||healthy periodontium|according to american academy of periodontology classification of periodontal diagnosis.
62144486|NCT04346875|EXPERIMENTAL|Regularly changing group|Participants will undergo dressing every 3 days by the senior wound care nurse
62144487|NCT04346875|ACTIVE_COMPARATOR|Non-changing group|Participants will not be subject to dressing change.
62349547|NCT01089829||CKD Stage 4|eGFR \<30
62349548|NCT01089829||CKD Stage 5|Receiving Haemodialysis or Peritoneal dialysis therapy
62349549|NCT01017328||surgery with general anesthesia|
62349550|NCT05693870|EXPERIMENTAL|Group I (B&L)|13 Band and loop (B\&L) appliance were included in group one
62349551|NCT05693870|EXPERIMENTAL|Group II (Ssb&l)|13 Single-sided Band and loop (SsB\&L) appliance were included in group two
62349552|NCT05693870|EXPERIMENTAL|Group III (DBW)|13 Direct Bonded Wire (DBW) appliance were included in group three
62705516|NCT00001372||3|Unrelated healthy volunteers
62705517|NCT05662241|EXPERIMENTAL|ZB012|Obexelimab administered as an SC injection.
62349553|NCT05693870|EXPERIMENTAL|Group IV(T&L)|13 Tube and Loop (T\&L) appliance were included in group four
62705518|NCT05662241|PLACEBO_COMPARATOR|Placebo|Placebo administered as an SC injection.
62705519|NCT05300035|ACTIVE_COMPARATOR|bNAbs|ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).
62705520|NCT05300035|PLACEBO_COMPARATOR|Placebo|ART plus placebo (saline solution) at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).
62144488|NCT03421301|EXPERIMENTAL|1. Dietary portfolio (DP)|the dietary portfolio was given daily in the breakfast and dinner for 2.5 months
62144489|NCT03421301|PLACEBO_COMPARATOR|2. placebo (P)|the placebo (P) was based was given daily in the breakfast and dinner for 2.5 months
61964543|NCT03919799|EXPERIMENTAL|OLE Period: Placebo/Belumosudil QD|Participants who had received placebo in the DB period were entered and re-randomized into OLE period and received belumosudil 200 mg tablet QD orally for 24 weeks (i.e., up to Week 52) in the OLE period.
61964544|NCT03919799|EXPERIMENTAL|OLE Period: Placebo/Belumosudil BID|Participants who had received placebo in the DB period were entered and re-randomized into OLE period and received belumosudil 200 mg tablet BID orally for 24 weeks (i.e., up to Week 52) in the OLE period.
61964545|NCT03849196|EXPERIMENTAL|2L PEG-Asc|2L PEG-Asc for bowel preparation
62144490|NCT03170882|ACTIVE_COMPARATOR|Pomalidomide 4 mg + Dexamethasone 40 mg|Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.
62144491|NCT03170882|EXPERIMENTAL|Ixazomib 4 mg + Dexamethasone 20 mg|Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.
62507702|NCT06384794|ACTIVE_COMPARATOR|SWIM-UP|Half of the sample from the same patient will be processed by the capacitation technique routinely used in the clinic, swim-up: this is a sperm capacitation technique in which the motile spermatozoa in the seminal sample, after centrifugation and incubation, move to the top of the medium. In this way, spermatozoa with good progressive motility will remain in the supernatant.
62507703|NCT06384794|EXPERIMENTAL|ZYMOT|Half of the semen sample will be processed through the ZyMōt® Sperm Separation Device sperm separation chip: This chip based on microfluidic properties will help us to separate and recover the semen sample with an improvement in the quality of the spermatozoa, the capacitated spermatozoa with better motility will be selected.
62507704|NCT03480672|EXPERIMENTAL|Pembrolizumab + aRCH|Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
62507705|NCT03480672|ACTIVE_COMPARATOR|aRCH|adjuvant radio-chemotherapy (aRCH)
62507706|NCT05647616|EXPERIMENTAL|Strengthening exercises|The participants in this group will be given instructions to follow a resistance exercises to strengthen the peroneus longs muscle.
62507707|NCT05647616|NO_INTERVENTION|Control|Participants in this group will be given no treatment.
62507708|NCT04244799|EXPERIMENTAL|Behavioral nudges|Schools randomized to this arm will receive the behavioral nudges intervention and the Philippines Department of Education national WASH in Schools (WinS) policy.
62349554|NCT05479305|EXPERIMENTAL|Intervention/Treatment|The Valiant Captivia physician fenestrated stent graft for the treatment of aneurysms/penetrating ulcers, Type B aortic dissections or residual dissection after Type A repair, of the aortic arch and the descending thoracic aorta which are candidates for revascularisation of all three supra-aortic vessels (BT, LCCA, LSA)
62507709|NCT04244799|ACTIVE_COMPARATOR|Control group|Schools in the control group will not receive handwashing nudges but will receive DepEd's national WASH in Schools (WinS) policy.
62507710|NCT02451150|EXPERIMENTAL|Azilsartan 5 mg|Weight \<50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
61964546|NCT03849196|ACTIVE_COMPARATOR|1L PEG-Asc & 'Bisacodyl 10Mg Suppository|1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation
61964547|NCT04299490|EXPERIMENTAL|Sleep Continuity Disruption|The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.
61964548|NCT04299490|EXPERIMENTAL|Sleep Fragmentation|The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.
61964549|NCT04299490|ACTIVE_COMPARATOR|Undisturbed Sleep|An 8-hour period of undisturbed sleep is permitted on each night.
61964550|NCT03229278|EXPERIMENTAL|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
62349555|NCT05064332|EXPERIMENTAL|OC only|Subjects will receive a single dose of an oral contraceptive during the first period of the study
62349556|NCT05064332|EXPERIMENTAL|PF-06650833 + OC|Subjects will receive PF-06650833 every day for 11 days and a single dose of an oral contraceptive on day 10.
62507711|NCT02451150|EXPERIMENTAL|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
62507712|NCT02483338|OTHER|Children surgery|
62507713|NCT02087176|EXPERIMENTAL|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
62507714|NCT02087176|PLACEBO_COMPARATOR|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
62507715|NCT02675959|EXPERIMENTAL|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
62507716|NCT01301924|ACTIVE_COMPARATOR|High dose|High dose: 20 days of 20 mg/kg/day meglumine antimoniate
62507717|NCT01301924|EXPERIMENTAL|Low dose|Low dose: 30 days of 5 mg/kg/day meglumine antimoniate
62507718|NCT04785131|EXPERIMENTAL|Prune group|Oral contraceptive users will consume 50 grams prunes daily.
62507719|NCT04785131|NO_INTERVENTION|Oral contraceptive users|Oral contraceptive users will be monitored throughout the study period.
62507720|NCT04785131|NO_INTERVENTION|Non oral contraceptive users|Non oral contraceptive users will be monitored throughout the study period.
61964551|NCT04869332|ACTIVE_COMPARATOR|three-screw group|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck
61964552|NCT04869332|EXPERIMENTAL|four-screw group|the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
61964553|NCT03923712|NO_INTERVENTION|Control Group|Participants randomly assigned to control group will be instructed to maintain their normal life habits with respect to physical activity and diet. During the 5 months of intervention participants from this group will receive at least one call from the researchers to be interested in their health status and inform them about the next evaluation appointment, as well as, an objectively evaluation of the main behaviours in the middle of intervention. Investigators will inform about the relevance of attending the full process and respecting the condition and rule as control. Participants from the control group will be freely offered the possibility to get involve in a similar intervention protocol at the end of the study in order to benefit from the potential positive effect of exercise.
61964554|NCT03923712|EXPERIMENTAL|Supervised exercise programme|5 months of supervised physical exercise program. The individualized and progressive Health periodization model will be applied establishing an initial individualizing period, as well as identifying any need or adaptation to apply during the exercise program. The physical exercise program will be applied in a period of progressive increase whose initial objective will be to reach the volume and intensity established by the international recommendations of physical activity (http://www.health.gov/paguidelines/) for this population. Briefly, a volume of 150 min/week of moderate-vigorous physical activity (60% -85% reserve heart rate) spread over a maximum of 5 days and including force work 2-3 days/week. The training load will progressively increase with a wave and flexible periodization.
61964555|NCT01354756||bariatric population|obese patients in whom a bariatric surgery is planified
62705521|NCT05836584|EXPERIMENTAL|Arm A (chemotherapy, atezolizumab)|"NEOADJUVANT THERAPY: Patients receive physician's choice of chemotherapy regimen consisting of FLOT or mFOLFOX or CAPOX in addition to atezolizumab IV on study.~SURGERY: Patients undergo surgery with lymphadenectomy on study.~ADJUVANT THERAPY: Patients receive FLOT, mFOLFOX, or CAPOX and atezolizumab IV as in neoadjuvant therapy and then receive atezolizumab IV alone.~Patients also undergo CT or MRI throughout the trial. Patients may optionally undergo PET/CT and/or collection of blood samples throughout the trial. Patients may also undergo ECHO throughout the trial as clinically indicated."
62705522|NCT05836584|EXPERIMENTAL|Arm B (atezolizumab)|"NEOADJUVANT THERAPY: Patients receive atezolizumab IV on study.~SURGERY: Patients undergo surgery with lymphadenectomy on study.~ADJUVANT THERAPY: Patients receive atezolizumab IV on study.~Patients also undergo CT or MRI throughout the trial. Patients may optionally undergo PET/CT and/or collection of blood samples throughout the trial. Patients may also undergo ECHO throughout the trial as clinically indicated."
62705523|NCT04633252|EXPERIMENTAL|1/Dose Escalation|Docetaxel plus M9241 dose escalation with optional prednisone and ADT as part of SOC
62705524|NCT04633252|EXPERIMENTAL|2/Safety Run-in (no longer applies; removed before enrollment)|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
61964556|NCT01867424|ACTIVE_COMPARATOR|Participants with Advanced Disease|Advanced disease: who have failed hormone therapy and who have sufficient tissue from a soft tissue or metastatic bone lesion (measuring 1.5cm in diameter at computed tomography (CT) or magnetic resonance imaging (MRI) scan) available for organic anion-transporting polypeptide 1B3 (OATP1B3) immunohistochemistry (IHC) or must have a soft tissue or metastatic bone lesion that can be biopsied and be willing to undergo percutaneous biopsy to obtain tissue for OATP1B3 expression.
61964557|NCT01867424|ACTIVE_COMPARATOR|Participants with Localized Disease|Localized disease: must have image guided biopsy confirmed prostate cancer and sufficient tissue available for OATP1B3 IHC.
61964558|NCT03090178|EXPERIMENTAL|Patients|"Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~* sleep diary~* Pruritus~* dermatology life quality index"
61964559|NCT03090178|ACTIVE_COMPARATOR|Healthy Volunteers|"Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~* sleep diary~* Pruritus~* dermatology life quality index"
61964560|NCT03984253||Severe Asthma|All patients with severe asthma who will be treated in the participating centers should be continuously enrolled in the register.
61964561|NCT04826432|EXPERIMENTAL|Pasireotide|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
61964562|NCT04826432|PLACEBO_COMPARATOR|Placebo|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
62144492|NCT00336791|EXPERIMENTAL|Paclitaxel + Additional FAC/FEC|"12 weekly Paclitaxel treatments 80 mg/m\^2 by vein (IVPB) over 1 hour + 4 additional FAC or FEC combination chemotherapy treatments; FAC or FEC treatments given once every 3 weeks.~FAC Chemotherapy: 5-Fluorouracil 500 mg/m\^2 intravenous (IV) day 1 \& 4 + Doxorubicin 50 mg/m\^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m\^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m\^2 IV day 1 + Epirubicin 100 mg/m\^2 IV day 1 + Cyclophosphamide 500 mg/m\^2 IV day 1."
62144493|NCT00336791|ACTIVE_COMPARATOR|FAC/FEC|"6 courses FAC or FEC Combination Chemotherapy~FAC Chemotherapy: 5-Fluorouracil 500 mg/m\^2 intravenous (IV) day 1 \& 4 + Doxorubicin 50 mg/m\^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m\^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m\^2 IV day 1 + Epirubicin 100 mg/m\^2 IV day 1 + Cyclophosphamide 500 mg/m\^2 IV day 1."
62144494|NCT03094546|EXPERIMENTAL|Polyamine supplementation|Intervention: Dietary Supplement (Polyamine supplementation): 750 mg wheat germ extract
62705525|NCT04633252|EXPERIMENTAL|3/mCSPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
61964563|NCT03694821|EXPERIMENTAL|Ketorolac|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
62144495|NCT03094546|PLACEBO_COMPARATOR|Placebo|Intervention: Dietary Supplement Placebo: 750 mg cellulose
62144496|NCT01793779|PLACEBO_COMPARATOR|Control|Placebo supplement given prior to exercise and two times per day following exercise
62507721|NCT03755089|ACTIVE_COMPARATOR|Oral Phenazopyridine|Patients randomized to the oral phenzopyridine arm will receive 200mg phenazopyridine to take by mouth 1-2 hours before their scheduled procedure.
62507722|NCT03755089|ACTIVE_COMPARATOR|Intravesical Lidocaine|Patients randomized to the intravesical lidocaine arm will have the bladder back-filled with 30mL 2% lidocaine for the 20 minutes immediately preceding their procedure.
61964564|NCT03694821|ACTIVE_COMPARATOR|Corticosteroid|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
61964565|NCT03694821|ACTIVE_COMPARATOR|Hyaluronic Acid|One knee injection of Hylan G-F 20 (Synvisc-One)
61964566|NCT02301572||Aggressive onset MS|Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
61964567|NCT01211002|ACTIVE_COMPARATOR|radiotherapy combined with EP|the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
61964568|NCT01211002|EXPERIMENTAL|adiotherapy / EP /recombinant human endostatin|recombinant human endostatin: The number of courses is 3 \~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.
61964569|NCT01923493|ACTIVE_COMPARATOR|no intervention waiting list|Patients in the no intervention waiting list group will not receive a study intervention.
61964570|NCT01923493|EXPERIMENTAL|tuina|tuina treatment
61964571|NCT03444961|EXPERIMENTAL|CAREN system training|CAREN training
61964572|NCT03781596|EXPERIMENTAL|Fluticasone and omeprazole|These patients will be prescribed swallowed fluticasone and omeprazole to be taken together for the 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
61964573|NCT03781596|PLACEBO_COMPARATOR|Fluticasone and placebo|These patients will be prescribed swallowed fluticasone and a placebo medication that appears identical to omeprazole to be taken together for an 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
61964574|NCT03798483|EXPERIMENTAL|Individualized exercise|Participants after a lateral kneecap dislocation will be enrolled into an individualized exercise intervention supervised by a physiotherapist
62507723|NCT06616662||LIFT|
62507724|NCT06616662||MAF|
61964575|NCT06261385|EXPERIMENTAL|Intervention group|In the intervention group, in addition to routine counselling (15-30 minutes), they will classify their identity with our screening tool (developed in Phase 2) and then apply the counselling protocol for the participants (5-10 minutes). After the counselling session, the personalized e-messages will be sent to the participants by our research staff for 4 weeks.
61964576|NCT06261385|NO_INTERVENTION|Control Group|In the control group, the routine smoking cessation counselling, including generic advice on preventing smoking relapse, will be retained, and no e-messages will be sent.
61964577|NCT02421523|EXPERIMENTAL|Aim 2 Exercise group|The 10 subjects randomized to the experimental group will participate in an isometric exercise strengthening intervention of the knee extensor and knee flexor muscles in both legs with a frequency of \~three times/week for 12 weeks.
62507725|NCT05462314||Gastrointestinal Malignancies (pancreatic, colorectal, gastroesophageal, and hepatobiliary)|Individuals with a gastrointestinal malignancy including pancreatic, colorectal, gastroesophageal, or hepatobiliary malignancies.
62507726|NCT04329416|OTHER|Predicted depth of insertion|The predicted insertion depth of the DLT was calculated using the formula \[0.249 x (BH) 0.916\] before induction of anesthesia using an application on the smartphone
62507727|NCT05850884||group A|• One hundred stool samples will be collected from patients with intestinal cancer admitted to Sohag Hospital.
61964578|NCT02421523|ACTIVE_COMPARATOR|Aim 2 Control group|The 10 subjects randomized to the control group will not participate in any exercise program during the 12 weeks and will be instructed to continue with their normal activities.
61964579|NCT02421523|EXPERIMENTAL|Aim 1 Exercise Dosing|In order to implement a pilot home exercise intervention, the dose response and safety of this intervention must first be determined. We will enroll 12 boys with DMD for this aim and testing will be performed on the right leg.
61964580|NCT02459353|EXPERIMENTAL|dapagliflozin 10mg|a group which treated with dapagliflozin 10mg plus basal insulin therapy
61964581|NCT02459353|PLACEBO_COMPARATOR|placebo 10mg|a group which treated with dapagliflozin placebo plus basal insulin therapy
61964582|NCT03648541|EXPERIMENTAL|Spesolimab IV infusion|Spesolimab IV infusion
61964583|NCT03648541|EXPERIMENTAL|Spesolimab SC solution for injection|Spesolimab SC solution for injection
62144497|NCT01793779|EXPERIMENTAL|cold water immersion|Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
62144498|NCT01793779|EXPERIMENTAL|HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
62144499|NCT01793779|EXPERIMENTAL|cold water immersion group + HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
62144500|NCT01669356|EXPERIMENTAL|PN supplement|Parenteral supplement with enteral nutrition for patients after esophagectomy
62507728|NCT05850884||group B|one hundred stool samples will be collected from the control group of patients who attended outpatient clinics
62507729|NCT01010815||UC group|clinically and microscopically confirmed UC patients between the age of 19 and 75 years
62507730|NCT01010815||Control group|normal healthy controls
62705526|NCT04633252|EXPERIMENTAL|4/mCRPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
62705527|NCT05746442|ACTIVE_COMPARATOR|Standard Care Group|Participants will receive brief advice and education materials to quit smoking along with brief weekly assessments to be completed on a smartphone. They will also receive a 8 week supply of of nicotine replacement therapy in the form of nicotine patches.
61964584|NCT05867745||Lead nurse for Transition/Regional Nurse Advisors|The Lead Nurse and RNAs will be interviewed using telephone or online via Zoom. The interviews will be recorded using a Dictaphone rather than being saved via Zoom. Recordings will then be saved on the University's secure, password protected SharePoint for the study. Only the research team, and the designated transcriber, will have access to interview data. At the start of the project, interviews have been conducted in a PPI format to explore in depth the programme, expectations of how it should work and its implementation in order for the research team to devise the study. For the purposes of the research, interviews will be undertaken at one year, two years, and at the end of the programme to further explore implementation of the programme, including what works well, challenges encountered and their perceptions of the impact the programme has on families' experiences.
61964585|NCT05867745||Young people|"Young people aged 12 to 25 years will be invited to participate. Young people will be asked to complete surveys at baseline, six months to one year and 18 months.~Survey: Online surveys (Qualtrics) will be used to collect data from young people participating in the case studies. Young people will be asked to provide basic demographic details: age, gender, health condition, and type of service they attend (children's/young person's/adults') and length of time since transfer to adult services (if already transitioned).~Letter/email/video to a friend: Young people will also be asked to write a 'letter/email to a friend' to describe their experiences. This will be completed online with the survey. They will be invited to write a letter/email or record a video about a recent clinic appointment/encounter with a health professional."
61964586|NCT05867745||Parents|"Case study: Parents/carers will be invited to participate alongside young people. We will aim transition (including preparation, transfer and within adult services). Survey: Parents/carers of young people participating in the case study will be invited to complete an online survey (Qualtrics). Basic demographic details will be requested about the parent: age and gender; and their child: age, gender, health condition, and type of service they attend (children's/young person's/adults'), length of time since transfer to adult services (if already transitioned).~Letter/email/video about their experiences: Parents will also be asked to complete a written task/video. They will be asked to describe their experiences relating to the shift in responsibility towards their child as the primary partner in their own healthcare, how their child is moving (or has moved) towards greater independence and competence in self-management."
61976130|NCT05402592|EXPERIMENTAL|Carbonhydrate-rich drink|Patients will be given 800 ml of carbohydrate-containing beverage until 24:00 at night before the surgery by the blind caregiver, and 400 ml of carbohydrate-containing beverage in the morning 2-3 hours before the surgery.Blood samples for plasma glucose, plasma cortisol, and serum insulin levels will be drawn just before the morning dose, 40 minutes and 90 minutes after ingestion of the beverage, and during anesthesia induction. Gastric volume and pH will be evaluated within the first 10 minutes intraoperatively. Vital signs will be evaluated before, during and after surgery. To evaluate the biochemical parameters, blood samples will be taken again preoperatively and at the 6th and 24th hours postoperatively. Postoperative subjective well-being findings of the patients will be evaluated. The SF-36 quality of life scale will be applied to evaluate the quality of life of the patients on the 30th day after surgery.
62144501|NCT01669356|ACTIVE_COMPARATOR|EN alone|Enteral nutrition alone for patients after esophagectomy
62144502|NCT02318810|ACTIVE_COMPARATOR|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
62705528|NCT05746442|EXPERIMENTAL|Automated Messaging Treatment Group|Participants will receive brief advice and education materials to quit smoking, along with brief weekly assessments and an interactive phone-based treatment program delivered on a smartphone. They will also receive a 8 week supply of of nicotine replacement therapy in the form of nicotine patches.
62705529|NCT05826652|ACTIVE_COMPARATOR|subcostal transversus abdominis plane block|At the end of the operation, a right-sided subcostal transversus abdominis plane block will be applied to the patients by ultrasound aided. While applying the subcostal transabdominal plan block, %2,5 Marcaine 20 ml will be given between the transverse and rectus abdominis muscle immediately next to the linea semilunaris. Patient-controlled analgesia devices with Tramadol will be prepared for postoperative analgesia. Rest and coughing pains, nausea and total PCA consumption will be recorded10 minutes, 30 minutes, 1, 3, 6, 24 hours postoperatively. Verbal Numerical Rating Scala (0 = no pain; 10 = the most severe pain you can imagine) for pain and Categorical Scoring Method (0 = none; 1 = less; 2 = too; 3 = too much) for nausea will be used. Complications such as infection, bleeding, and subcutaneous emphysema will be recorded.
62144503|NCT02318810|ACTIVE_COMPARATOR|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
62705530|NCT05826652|ACTIVE_COMPARATOR|Multiple injection subcostal transversus abdominis plane block|At the end of the operation, a right-sided subcostal transversus abdominis plane block will be applied to the patients by ultrasound aided. patients received %2,5 Marcaine 5 ml between the transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volumes lateral to this point near the subcostal margin. Patient-controlled analgesia devices with Tramadol will be prepared for postoperative analgesia. Rest and coughing pains, nausea and total PCA consumption will be recorded10 minutes, 30 minutes, 1, 3, 6, 24 hours postoperatively. Verbal Numerical Rating Scala (0 = no pain; 10 = the most severe pain you can imagine) for pain and Categorical Scoring Method (0 = none; 1 = less; 2 = too; 3 = too much) for nausea will be used. Complications such as infection, bleeding, and subcutaneous emphysema will be recorded.
62705531|NCT03223610|EXPERIMENTAL|Arm 1: Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
62705532|NCT03223610|EXPERIMENTAL|Arm 2: Dose Escalation|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
62705533|NCT03223610|EXPERIMENTAL|Arm 3: Dose Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
62705534|NCT03223610|EXPERIMENTAL|Arm 4: Dose Expansion|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
62144504|NCT02318810|ACTIVE_COMPARATOR|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
62144505|NCT02318810|PLACEBO_COMPARATOR|Placebo|Patients receive saline
62144506|NCT06510569|EXPERIMENTAL|Clear aligner therapy|U lab aligners
62144507|NCT06510569|EXPERIMENTAL|Fixed orthodontic treatment|Oromo bracket
62705535|NCT05879484|EXPERIMENTAL|Arm 1|Pembrolizumab + de-escalating doses of valemetostat
62705536|NCT05879484|EXPERIMENTAL|Arm 2|RP2D of valemetostat in combination with pembrolizumab
61964587|NCT05867745||Transition champions/key professionals|Transition champions and key professionals in participating Trusts who are involved in the care of young people included in the case studies will be identified by the RNAs. We will aim to involve staff from various professional roles. They will be invited to complete an online survey (using Qualtrics) during the first year and one at the end of the second year, towards the end of the project. The surveys will explore their views on the implementation of the programme, experiences of building/making changes to a transition service, including what works well, challenges encountered and their perceptions of the impact the programme has on families' experiences. One professional from each case study site will be interviewed via Zoom/telephone to explore these aspects more in-depth at the same time points as the surveys. Ideally, we will aim to interview the same professionals at both time points. Data access and storage for will be the same as for the Lead Nurse/RNA interviews.
61964588|NCT01308671|ACTIVE_COMPARATOR|varenicline|On 3 day after received clopidogrel 75mg/day, Varenicline group will be administered with varenicline 0.5mg Qd,after 3 days, 0.5mg Bid,after 7days,1mg Bid .And received counseling and psychosocial support.
61964589|NCT01308671|OTHER|Blank|Blank group will be only administered with Counseling and psychosocial support,beside antiplatelet etc.conventional therapy for 14 days.
61964590|NCT00717132|EXPERIMENTAL|Individual Behavioral Modification|Individual behavioral weight control treatment; parent and child are treated separately for 15 total sessions.
61964591|NCT00717132|ACTIVE_COMPARATOR|Family-based Behavioral Modification|Family-based behavioral weight control treatment; parent and child are treated together for 15 total sessions.
61964592|NCT06334783|EXPERIMENTAL|TILs|Biological: TILs Drug: IL-2
61964593|NCT04828252|EXPERIMENTAL|808nm|The wavelength of this experimental group was 808nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
61964594|NCT04828252|ACTIVE_COMPARATOR|660nm|The wavelength of this experimental group was 660nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
61964595|NCT04828252|PLACEBO_COMPARATOR|Control|The wavelength of control group, total power: 0.0072W, 15 minutes a session, 3 times a week for 8 weeks
61964596|NCT05353023||ICU ADMISSION|All patients admitted in a French intensive care unit over a 7-year period (2013 to 2019) using the French National Uniform Hospital Discharge Database (PMSI)
61964597|NCT00003746|ACTIVE_COMPARATOR|CDA day|CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
62507731|NCT02654587|EXPERIMENTAL|OSE2101|OSE2101 was administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit of OSE2101. OSE2101 dose was 5 mg of peptides (0.5 mg for each peptide).
62507732|NCT02654587|ACTIVE_COMPARATOR|Docetaxel or Pemetrexed|"Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.~Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.~Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal."
62507733|NCT00489099|EXPERIMENTAL|V232 Modified Process Hepatitis B Vaccine: Lot A|Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
62507734|NCT00489099|EXPERIMENTAL|V232 Modified Process Hepatitis B Vaccine: Lot B|Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
62507735|NCT00489099|EXPERIMENTAL|V232 Modified Process Hepatitis B Vaccine: Lot C|Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
61964598|NCT00003746|ACTIVE_COMPARATOR|CDA week|CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
61964599|NCT03716089||Group A (Study group)|Group for laparoscopic resection of GIST with unfavorable group (Unfavorable group)
61964600|NCT03716089||Group B (Control group)|Group for laparoscopic resection of GIST with favorable group (favorable group)
62507736|NCT00489099|ACTIVE_COMPARATOR|V232 Current Process Hepatitis B Vaccine|Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
61964601|NCT01280175|EXPERIMENTAL|pMDI + charcoal block|BDP/formoterol 100/6 µg pMDI with charcoal ingestion
61964602|NCT01280175|EXPERIMENTAL|pMDI + Aerochamber Plus|BDP/formoterol 100/6 µg with Aerochamber Plus
61964603|NCT01280175|ACTIVE_COMPARATOR|pMDI|BDP/formoterol 100/g µg pMDI
61964604|NCT06333145|EXPERIMENTAL|normal group|BMI: ≥18.5 and \<24
61964605|NCT06333145|EXPERIMENTAL|overweight group|BMI: ≥24 and \<30
61964606|NCT06333145|EXPERIMENTAL|obese group|BMI: ≥30
61964607|NCT03918083|OTHER|5-pronged wellness approach|30-day assessment of daily exercise, mindfulness, sleep, social connectedness, and nutrition
61964608|NCT01357733|OTHER|Interim FDG PET/CT|Single arm study with diagnostic imaging study as the intervention.
61964609|NCT01966900|ACTIVE_COMPARATOR|Group A|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 6; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
61964610|NCT01966900|ACTIVE_COMPARATOR|Group B|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 12; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
61964611|NCT00657098||Observation|
61964612|NCT04458974|EXPERIMENTAL|Experimental group (Exp)|Active tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation)
61964613|NCT04458974|SHAM_COMPARATOR|Sham-tDCS (Sham)|Sham tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation
61964614|NCT04458974|OTHER|Control group (Control)|Conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation) without tDCS.
61964615|NCT02737657||Cohort 1|Participants who are already receiving Canagliflozin and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as the part of study.
61964616|NCT02737657||Cohort 2|Participants who are already receiving any sulphonylurea and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as a part of study.
61964617|NCT01132092||Normal hearing (experimental 1)|76 Normal hearing subjects, male and female, adults, , evaluated by new device
61964618|NCT01132092||Normal hearing (experimental 2)|15 Normal hearing subjects, male and female, adults, , evaluated by new device
61964619|NCT01132092||Hearing loss (experimental 3)|15 hearing loss subjects, male and female, adults, evaluated by new device
61964620|NCT01132092||Gold standard 1|15 Normal hearing subjects, male and female, adults, evaluated by gold standard device
61964621|NCT01132092||Gold Standard 2|15 hearing loss subjects, male and female, adults, evaluated by gold standard device
61964622|NCT06170723|EXPERIMENTAL|Part 1: BMS-986368 - Fasted|
61964623|NCT06170723|EXPERIMENTAL|Part 1: Itraconazole - Fasted|
61964624|NCT06170723|EXPERIMENTAL|Part 1: BMS-986368 with Itraconazole - Fasted|
61964625|NCT06170723|EXPERIMENTAL|Part 2: BMS-986368 - Fasted|
61964626|NCT06170723|EXPERIMENTAL|Part 2: BMS-986368 - Fed|
61964627|NCT06170723|EXPERIMENTAL|Part 2: Famotidine, followed by BMS-986368 - Fasted|
61964628|NCT06379178|ACTIVE_COMPARATOR|Oral Care 2 Hours|Oral colostrum application is done every 2 hours
61964629|NCT06379178|ACTIVE_COMPARATOR|Oral care 4 Hours|Oral colostrum application is done every 4 hours
61964630|NCT04781998|EXPERIMENTAL|liraglutide 3 mg (Saxenda®) once-daily|
61964631|NCT04250103||patient|patients who receive home health care
61964632|NCT04250103||caregiver|caregivers who take care of patients with home health care
61964633|NCT05109156||This is an observational study|This is an observational study
61964634|NCT02777801|EXPERIMENTAL|Prophylactic Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the initiation of chemotherapy till 6 months after the end of chemotherapy.
61964635|NCT02777801|ACTIVE_COMPARATOR|Preemptive Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the time that the DNA copies of hepatitis B virus are more than 100 IU/ml till 6 months after the end of chemotherapy.
62349557|NCT04631068|ACTIVE_COMPARATOR|Santen xact Mono-EDoF ME4 Intraocular Lens (IOL)|"The Monofocal Extended Depth of Focus (Mono-EDoF) posterior chamber foldable intraocular lens is ultraviolet and blue-light absorbing designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens. The diffractive technology of the IOL allows most of the light to converge in one focal point thereby providing high quality of distance vision and continuous focus to intermediate vision while minimizing the effects of unwanted visual disturbances. The visual quality is expected to be similar to monofocal IOLs.~Surgery to implant the Mono-EDoF ME4 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
61964636|NCT04488068|EXPERIMENTAL|Magnetic Stimulation|Patients will be subjected to TPMS.
61964637|NCT04488068|NO_INTERVENTION|Sham TPMS|Patients will be subjected to sham TPMS
61964638|NCT00663169|EXPERIMENTAL|Canakinumab|Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.
62507737|NCT06617039|ACTIVE_COMPARATOR|Ciprofol group (C group)|Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
62507738|NCT06617039|EXPERIMENTAL|The group of remifentanil 0.5ug/kg combined with ciprofol(R group)|R group will be started with remifentanil 0.5ug/kg and ciprofol 0.2-0.4 mg/kg.
62507739|NCT06617039|EXPERIMENTAL|The group of esketamine 0.3mg/kg combined with ciprofol(E1 group)|E1 group will be started with esketamine 0.3mg/kg and ciprofol 0.2-0.4 mg/kg.
62507740|NCT06617039|EXPERIMENTAL|The group of esketamine 0.5mg/kg combined with ciprofol(E2 group)|E2 group will be started with esketamine 0.5mg/kg and ciprofol 0.2-0.4 mg/kg.
61964639|NCT00663169|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.
61964640|NCT02550249|EXPERIMENTAL|Nivolumab|Nivolumab 3 mg every 2 weeks
61964641|NCT02906059|EXPERIMENTAL|AZD1775 & Irinotecan|"Group AZD1775 (study drug); Irinotecan (chemotherapy)~1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks~3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks"
61964642|NCT05477810|EXPERIMENTAL|Treatment A (CHILD-IVITAB) before Treatment B (STROMECTOL)|"A single oral dose of 12 mg CHILD-IVITAB administered as four ODTs of 3 mg (given in the fasted state in the morning).~A single oral dose of 12 mg STROMECTOL administered as four tablets of 3 mg (given in the fasted state in the morning).~The wash-out period between doses will be at least 7 days."
61964643|NCT05477810|ACTIVE_COMPARATOR|Treatment B (STROMECTOL) before Treatment A (CHILD-IVITAB)|"A single oral dose of 12 mg STROMECTOL administered as four tablets of 3 mg (given in the fasted state in the morning).~A single oral dose of 12 mg CHILD-IVITAB administered as four ODTs of 3 mg (given in the fasted state in the morning).~The wash-out period between doses will be at least 7 days."
61964644|NCT03609632|EXPERIMENTAL|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
61964645|NCT00895167|EXPERIMENTAL|curcumin|every subject receives 12 g of oral curcumin
61964646|NCT01126476|ACTIVE_COMPARATOR|small volume strata|12 in small volume strata
61964647|NCT01126476|ACTIVE_COMPARATOR|large volume strata|12 in large volume strata
61964648|NCT01354977|EXPERIMENTAL|Resveratrol|Each participant will receive a 28 days' supply of resveratrol capsules on day 0.
61964649|NCT03824613||Endometrial cancer patients|
61964650|NCT03824613||Control group|Patients without cancer
61964651|NCT05655962|EXPERIMENTAL|STARS center|Centers in the southeast region of Sweden working according to STARS.
61964652|NCT05655962|NO_INTERVENTION|Control center|Centers in the southeast region of Sweden not working according to STARS.
61964653|NCT05084521|EXPERIMENTAL|Famotidine|Suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
61964654|NCT01230905|OTHER|MPI nuclear scan|Nuclear MPI for CAD for prostate cancer subjects undergoing treatment and development of normal comparison.
61964655|NCT05888766||Episodic migraine patients|20 patients with episodic migraine (\<15 attacks/month) will be recruited from a specialized headache Clinic (headache clinic of the Sapienza University of Rome, Latina).
61964656|NCT06370650|ACTIVE_COMPARATOR|Narrow band UVB|
61964657|NCT06370650|ACTIVE_COMPARATOR|Platelet rich plasma plus narrow band UVB|
61964658|NCT03792581|ACTIVE_COMPARATOR|EV1000 monitor|MAP management will be done as usual ( adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
61964659|NCT03792581|EXPERIMENTAL|EV1000 monitor + closed-loop system|fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
61964660|NCT03761277|OTHER|Intrathecal Therapy|Enrolled subjects who successfully wean from all systemic opioids and have a successful intrathecal trial, proceed to the intervention phase. This includes implantation with a SynchroMed™ II infusion system in the intrathecal space for targeted drug delivery of preservative-free morphine sulfate (PFMS).
61964661|NCT01194180|EXPERIMENTAL|Group A|"BCG-naive subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
61964662|NCT01194180|EXPERIMENTAL|Group B|"BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
61964663|NCT01194180|EXPERIMENTAL|Group C|"BCG-experienced subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
61964664|NCT01194180|EXPERIMENTAL|Group D|"BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
61964665|NCT03467191|EXPERIMENTAL|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
61964666|NCT03467191|PLACEBO_COMPARATOR|Placebo Beverage|
61964667|NCT04847947|EXPERIMENTAL|Interventional group|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks.
61964668|NCT04847947|PLACEBO_COMPARATOR|Control Group|Oral capsule Placebo once daily and Calcium Lactate 500 mg once daily for 12 weeks.
61964669|NCT06237660||Aim 1|"To test the proposed panel of simple bedside tests below, to see how accurately they corelate with lower airway infection or inflammation.~The aim is correlate the results from the bronchoscopy with the panel of test proposed, and evaluate if these simple bedside tests can pick up the same level of infection or inflammation and obtain the same results, as the bronchoscopy, which is a much more invasive test, but the only method available at present to get this information."
61964670|NCT06237660||Aim 2|The aim is to test how acceptable these bedside tests are to parents and children, and if they reflect the child's symptoms, symptoms control and medication use.
61964671|NCT06237660||Aim 3|"Small proof-of-concept study. This is for a feasibility trial of using the proposed tests and deciding the treatment of their wheeze, based on the results of the tests. Children with evidence of allergen sensitisation +/- blood eosinophilia (\>0.3x109/L) will be prescribed regular inhaled corticosteroids. Children who are non-atopic (non-atopic is defined as blood eosinophil of \<0.3x109/L + no evidence of allergen sensitisation) with positive bacterial detection in sputum, will be prescribed four weeks of targeted antibiotics. Children who are non-atopic with no bacteria detected in sputum, will be prescribed only be prescribed short acting bronchodilators as required. All medications will be prescribed, as per the British National Formulary for Children, based on age and weight.~The aims of this preliminary study are to understand whether parents will agree to be part of such an interventional trial. This will help the research team when designing a future larger clinical trial."
61964672|NCT03940404||experiment|The patients whose treatment strategy containing anlotinib.
62507741|NCT06412211||SLN resected patients|Patients with breast cancer underwent sentinel lymph node biopsy
61964673|NCT00660309|EXPERIMENTAL|Aliskiren|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received aliskiren 300 mg tablets orally once a day for 14 days.
61964674|NCT00660309|ACTIVE_COMPARATOR|Irbesartan|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received irbesartan 300 mg tablets orally once a day for 14 days.
61964675|NCT03296358|NO_INTERVENTION|Control group|Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
61964676|NCT03296358|EXPERIMENTAL|Experiment 1|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
61964677|NCT03296358|EXPERIMENTAL|Experiment 2|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2\*2 po pc as home medication
61964678|NCT02554357|EXPERIMENTAL|Exparel block in arthroscopic surgery|Evaluation of Exparel block in arthroscopic shoulder surgery.
61964679|NCT02554357|EXPERIMENTAL|Bupivacaine block in shoulder surgery|Evaluation of Bupivacaine block in shoulder surgery.
61964680|NCT03320954|EXPERIMENTAL|Anomia treatment|Phase 2 portion of the research during which participants with acquired brain injury will perform intervention activities.
61964681|NCT03847662||Community Based Production and Access of Complimentary Foods|"Nine communes were randomly selected with the cluster inclusion criteria as having high levels of; agricultural production, childhood under-nutrition and food security. This was carried out in the three rural mountainous provinces of Lao Cai, Lai Chau, and Ha Giang. In each of these provinces, one district and three subsequent communes were selected, for a total of 9 communes. The districts of Bat Xat, Tam Duong, and Vi Xuyen were selected in Lao Cai, Lai Chau and Ha Giang province respectively. This second stage district sampling selected sites with similar characteristic of population density, area, number of women of reproductive age(15-35y), percentage of children(\<2y), income primarily from agricultural production, poverty and climate data.~Changes were observed on food security and nutritional status with exposure to community based self reported purchasing local agricultural products and access to locally produced fortified complimentary foods."
61964682|NCT01803373|EXPERIMENTAL|Treatment Sequence ABC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
62144508|NCT06274203|EXPERIMENTAL|Oral vitamin D3|Monthly oral vitamin D3 dose (100,000 IU,150,000 IU, and 200,000 IU)
62507742|NCT01739413|ACTIVE_COMPARATOR|General Anesthesia|Patients will receive general anesthesia alone followed by intravenous morphine for postoperative pain control. This techniques is safe and is standard procedure for colorectal surgery.
61964683|NCT01803373|EXPERIMENTAL|Treatment Sequence ACB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
61964684|NCT01803373|EXPERIMENTAL|Treatment Sequence BAC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
61964685|NCT01803373|EXPERIMENTAL|Treatment Sequence BCA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
61964686|NCT01803373|EXPERIMENTAL|Treatment Sequence CBA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
61964687|NCT01803373|EXPERIMENTAL|Treatment Sequence CAB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
62349558|NCT04631068|PLACEBO_COMPARATOR|J&J TECNIS ZCB00 Intraocular Lens (IOL)|"The TECNIS 1-Piece Intraocular Lens (IOL), Model ZCB00, is a standard monofocal ultraviolet light absorbing posterior chamber IOL, which is designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens.~Surgery to implant the TECNIS ZCB00 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
62349559|NCT00502632|EXPERIMENTAL|1|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
61964688|NCT04188327|SHAM_COMPARATOR|Control group(Group I)|Patients will receive sham stellate ganglion block weekly for three times
61964689|NCT04188327|EXPERIMENTAL|Stellate Ganglion block group (Group II)|Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg
61964690|NCT02495168|EXPERIMENTAL|Generic Budesonide/Formoterol Fumarate Dihydrate|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
61964691|NCT02495168|ACTIVE_COMPARATOR|Symbicort (Budesonide/Formoterol Fumarate Dihydrate)|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
61964692|NCT02495168|PLACEBO_COMPARATOR|Placebo|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.
62507743|NCT01739413|EXPERIMENTAL|Epidural Anesthesia|Patients will receive general anesthesia plus epidural anesthesia followed by epidural analgesia for postoperative pain control. This techniques is safe and standard procedure for colorectal surgery.
62507744|NCT03309917|EXPERIMENTAL|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:~* MAP set at 80-85 mmHg for 5 min.~* MAP set at 70-75 mmHg for 5 min.~* MAP set at 60-65 mmHg for 5 min.~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
62507745|NCT00982501|EXPERIMENTAL|WS® 1442 900 mg|
61964693|NCT04359654|EXPERIMENTAL|Dornase alfa treatment|Best available care and nebulised dornase alfa \[2.5 mg BID\] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure
61964694|NCT04359654|NO_INTERVENTION|Best available care|Best available standard of care
61964695|NCT00681005|ACTIVE_COMPARATOR|Rabeprazole|Rabeprazole 1 # qd
61964696|NCT00681005|ACTIVE_COMPARATOR|pantoprazole|Pantoprazole 1# qd
61964697|NCT03752294|ACTIVE_COMPARATOR|Dabigatran|Participants will receive 150mg dabigatran daily for a total of 9-months.
61964698|NCT03752294|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo daily for a total of 9-months.
61964699|NCT03752294|ACTIVE_COMPARATOR|Open Label|All study participants are assigned to receive 150mg dabigatran daily for a total of 12 months (study month 9 through month 21)
61964700|NCT00436683|EXPERIMENTAL|1|Dose titration on active
61964701|NCT00436683|ACTIVE_COMPARATOR|2|Dose titration
61964702|NCT02350153||Patients with verified Cushing's Disease|Patients with verified Cushing's Disease
61964703|NCT05184218|EXPERIMENTAL|Sentinel|In the Sentinel Cohort, healthy volunteers will be randomized to receive intranasal and intraoral administration of 1 mg of IGM 6268 or placebo once per day for 5 days.
61964704|NCT05184218|EXPERIMENTAL|Cohort 1|In Cohort 1, healthy volunteers will be randomized to receive intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo once per day for 5 days.
62349560|NCT00502632|PLACEBO_COMPARATOR|2|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days"
62349561|NCT05424549|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%)|
62507746|NCT00982501|EXPERIMENTAL|WS® 1442 1800 mg|
62507747|NCT00982501|ACTIVE_COMPARATOR|Nordic walking training 2x30 min|
62507748|NCT00982501|ACTIVE_COMPARATOR|Nordic walking training 4x45 min|
62507749|NCT01226537|ACTIVE_COMPARATOR|Diabetes Mellitus type 1 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
62507750|NCT01226537|PLACEBO_COMPARATOR|Diabetes mellitus type 1 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
62507751|NCT01226537|ACTIVE_COMPARATOR|Diabetes type 2 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
62507752|NCT01226537|PLACEBO_COMPARATOR|Diabetes type 2 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
62507753|NCT05445609|EXPERIMENTAL|Treatment ((vidutolimod, nivolumab)|Patients receive vidutolimod SC on days 1 and 7 of cycle 1, IT on day 14 of cycle 1 and days 1 and 14 of cycle 2, and then SC on day 1 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 14 of cycle 2 and on day 1 of subsequent cycles. Cycles of nivolumab repeat every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Cycles of vidutolimod repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
62507754|NCT06361095|SHAM_COMPARATOR|Sham Attention Bias Modification|Sham and traditional ABM interventions will be identical in all respects with one critical exception. For sham ABM, after stimuli offset the target will appear with equal probability (50%) in the location of the neutral or the dysphoric stimulus.
62507755|NCT06361095|ACTIVE_COMPARATOR|Traditional Attention Bias Modification|This ABM variant is a web-based program delivered to participants via a computer. It presents pairs of stimuli to the right and left visual fields from two stimulus categories: sad or neutral facial expressions from the Pictures of Facial Affect (POFA) collection and dysphoric or neutral scenes from or from the International Affective Picture System (IAPS) collection.
62507756|NCT06361095|EXPERIMENTAL|Gamified Attention Bias Modification|This ABM variant will be completed on participants' mobile devices (iOS or Android). During app use, they will be presented with sad-happy stimulus pairs followed by target probes (tracing a path) always appearing at the happy stimulus location.
62349562|NCT05424549|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution|
62349563|NCT04154696|EXPERIMENTAL|Normothermic perfusion of a graft|
62507757|NCT03068949|ACTIVE_COMPARATOR|FluBlok|FluBlok 0.5 mL given IM X1
62507758|NCT03068949|ACTIVE_COMPARATOR|Fluzone|Fluzone 0.5 mL given IM X1
62507759|NCT03068949|ACTIVE_COMPARATOR|FluCelVax|FluCelVax 0.5 mL given IM X 1
62507760|NCT03068949|ACTIVE_COMPARATOR|Fluzone HD|Fluzone HD 0.5 mL given IM X1
62507761|NCT04922450|EXPERIMENTAL|Camrelizumab，albumin paclitaxel and cisplatin.|Participants will be given intravenous administration of Camrelizumab (200mg)，Albumin Paclitaxel(260mg/m²) and Cisplatin（80mg/m²）,After completing three times every three weeks of neoadjuvant therapy, The Participants will undergo surgery and Postoperative intensity modulated chemotherapy. The duration of treatment will till death, or unacceptable toxicity show up.
62507762|NCT04047953|EXPERIMENTAL|Conversion Therapy|Paclitaxel (albumin-bound) +S-1+Oxaliplatin
62507763|NCT01955512|PLACEBO_COMPARATOR|Placebo|Arm given placebo
62507764|NCT01955512|EXPERIMENTAL|Clopidogrel|Group given clopidogrel
61964705|NCT05184218|EXPERIMENTAL|Cohort 2|In Cohort 2, healthy volunteers will be randomized to receive intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once per day for 5 days.
62144509|NCT01825720|EXPERIMENTAL|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
62144510|NCT01825720|ACTIVE_COMPARATOR|normal saline group|same rate of normal saline
62349564|NCT03715959|EXPERIMENTAL|Diagnostic (nipple aspiration fluid)|Participants and healthy volunteers undergo collection of nipple aspirate fluid from both breasts.
62507765|NCT03307486||Gestational diabetes|Women diagnosed with GDM according to the IADPSG criteria, either by abnormal fasting plasma glucose or by abnormal oral glucose tolerance test.
62507766|NCT05762484|EXPERIMENTAL|Intervention group, laser hair removal therapy|Patients will undergo 6 monthly laser hair removal treatments with de Nd:YAG laser. After 6 months, a 6 follow up will start, using clindamycin 1% lotion if needed.
62507767|NCT05762484|ACTIVE_COMPARATOR|Control group, clindamycin 1% lotion if needed, standard care|Patients will use clindamycin 1% lotion of needed for 1 year.
62507768|NCT05388812|EXPERIMENTAL|Individual Placement and Support|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
62705537|NCT04089865|EXPERIMENTAL|Oral Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1950 mg of oral TXA in the pre-operative area.
62349565|NCT02331524|NO_INTERVENTION|Control/Usual Care|Usual care only
62349566|NCT02331524|EXPERIMENTAL|Activity Feedback and Encouragement|Weekly Feedback about daily activity using the FitBit Zip
62349567|NCT02331524|EXPERIMENTAL|Health Coaching/Home Exercise|Weekly contact from physical therapist to develop and progress home exercise program and by health coach for goal setting and support
62349568|NCT04354064||Healthy Donor Samples|"* Donation of blood and/or urine samples as often as bi-monthly and as many as 24 times in total~* These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise."
61964706|NCT05184218|EXPERIMENTAL|Cohort 3|In Cohort 3, healthy volunteers will be randomized to receive intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice per day for 5 days.
62507769|NCT05388812|ACTIVE_COMPARATOR|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
62705538|NCT04089865|ACTIVE_COMPARATOR|Intravenous (IV) Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1 g of intravenous (IV) TXA upon transfer to the operating room.
62705539|NCT05477420|EXPERIMENTAL|Experimental group|"Participants in the experimental group will be expected use the decision aid developed in this study. They will be assessed at two different time points:~(1) before intervention (T0) and (2) post-intervention (T1)."
62705540|NCT05477420|NO_INTERVENTION|Attention control group|"The control group participants will be asked to search information related to Depression and therapies for Depression online. They will be assessed at two different time points:~(1) at baseline (T0) and (2) after searching for information (T1)."
62705541|NCT01498276||General population|Members of the general population
62705542|NCT01498276||Members of under-resourced communities|Participants recruited from under-resourced communities in the Washington, DC area AND in the Southeastern US
62705543|NCT01572506|ACTIVE_COMPARATOR|Group 1|Age 70 and older with unexplained anemia
62705544|NCT01572506|ACTIVE_COMPARATOR|Group 2|Age 70 and older with iron deficient anemia
62705545|NCT01572506|ACTIVE_COMPARATOR|Group 3|Age 70 and older without anemia
62705546|NCT01572506|ACTIVE_COMPARATOR|Group 4|Age 18 - 50 without anemia
62705547|NCT00071526||Diabetes Type I|Subjects with Type I diabetes mellitus
62705548|NCT00071526||Diabetes Type II|Subjects with Type II diabetes mellitus
62705549|NCT00071526||Healthy Volunteers|Healthy Volunteers
62705550|NCT05247905|EXPERIMENTAL|Arm I (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62705551|NCT05247905|EXPERIMENTAL|Arm II (capecitabin, temozolomide)|Patients receive capecitabine PO BID days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62705552|NCT04858334|EXPERIMENTAL|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans or CT/MRI and collection of blood throughout the study.
62705553|NCT04858334|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans or CT/MRI and collection of blood throughout the study.
62705554|NCT05295030|ACTIVE_COMPARATOR|Breast Milk-Fed Group|The infants will be breastfed during the study.
62705555|NCT05295030|EXPERIMENTAL|Breast Milk Simulated Formula Group|Kieember Infant formula, Ruibuen®: Infants will be fed Kieember infant formula(Phase I) from baseline (1 month old) to 3 month old.
62705556|NCT05295030|EXPERIMENTAL|Traditional Formula Group|Yashili Infant formula, Ruibuen®: Infants will be fed Yashili infant formula (Phase I) from baseline (1 month old) to 3 month old.
62705557|NCT04558983||Retinitis Pigmentosa|Patients with Retinitis Pigmentosa
62705558|NCT05232929|EXPERIMENTAL|Risdiplam|Participants will receive risdiplam prescribed based on clinician judgment, as per the Evrysdi® USPI.
61964707|NCT05184218|EXPERIMENTAL|Cohort 4|In Cohort 4, mild-moderate Covid patients will be randomized to receive intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once per day for 5 days.
62144511|NCT04284085|EXPERIMENTAL|Intervention group|There will be psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
62144512|NCT04284085|NO_INTERVENTION|Control group|They will receive a fact sheet on suicide and also tips on how to increase suicidal ideation.
62705559|NCT00001721||Patients|Patients diagnosed with SLOS
62705560|NCT04660539|EXPERIMENTAL|Satralizumab Treatment|Participants will receive satralizumab subcutaneously (SC) every 4 weeks (Q4W)
62705561|NCT06108687|EXPERIMENTAL|Experiment|"In cold water applications, 50 cc bottles with plastic spray heads will be used. New materials will be used for each patient. Interventions will be carried out by the researcher and. Cold water kept in the refrigerator at +4 degrees will be placed in 50 cc spray bottles for the experimental group and will be sprayed orally to the patients 3 times an hour in the postoperative period. The spray will be applied to the patient's mouth, upper palate, top of the tongue, right inner cheek, and left inner cheek.~Patients will be given approximately 0.5 mL of water via spray in each application."
62705562|NCT06108687|NO_INTERVENTION|Control|Spray application will not be applied to patients in the control group.
62705563|NCT04802161|EXPERIMENTAL|Arm A (daunorubicin and cytarabine liposome, pomalidomide)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 and then pomalidomide PO QD beginning between days 21-30 for 14 days in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial."
61964708|NCT05184218|EXPERIMENTAL|Cohort 5|In Cohort 5, mild-moderate Covid patients will be randomized to receive one intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice per day for 5 days.
61964709|NCT05184218|EXPERIMENTAL|Ph1b Expansion|In the Ph1b expansion cohort, mild-moderate Covid patients will be randomized to receive one intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once or twice per day for 5 days. This cohort may be opened per Sponsor's discretion based on initial safety and activity.
61964710|NCT01914198||Sleep study|Patients who are having a sleep study done at NCH to diagnose sleep apnea.
61964711|NCT04043260|EXPERIMENTAL|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 3 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
61964712|NCT02670837|EXPERIMENTAL|Graft from HCT donor|Cells are harvested from a donor using Cellutome, then transferred via Adaptic dressing to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
61964713|NCT02670837|EXPERIMENTAL|Self donor from intact skin patch|Cells are harvested from the subject using Cellutome, then transferred via Adaptic dressing to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
61964714|NCT03332654||Multiple sclerosis|Prevalence and risk factor of stress urinary incontinence in women with multiple sclerosis and included in the database over 15 years from December 1999 to June 2014, who had undergone a urodynamic test
61964715|NCT01484197|EXPERIMENTAL|75 µg Indacaterol (LB) + Placebo (PoS)|75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
61964716|NCT01484197|EXPERIMENTAL|75 µg Indacaterol (PoS) + Placebo (LB)|75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
61964717|NCT01484197|EXPERIMENTAL|37.5 µg Indacaterol (PoS) + Placebo (LB)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
61964718|NCT01484197|EXPERIMENTAL|Placebo (LB) and Placebo (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
61964719|NCT01953263|EXPERIMENTAL|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
61964720|NCT02637739|EXPERIMENTAL|Pregnancy of unknown location|pregnant women of at least 5 weeks by last menstrual period and transvaginal ultrasound did not revealed intra-uterine pregnancy or ectopic pregnancy Intervention: hysteroscope
61964721|NCT02866552|PLACEBO_COMPARATOR|PLACEBO|Patients will receive an injection of placebo
62349569|NCT04354064||Samples from Repository and Banking Studies|"* Healthy prostate and/or blood and/or urine samples from Genitourinary Repository~* Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies~* Tissue and/or blood samples from Esophageal Repository~* Tissue and/or blood samples from Genitourinary Repository~* Tissue and/or plasma from Sarcoma Tissue Bank~* Tissue and/or plasma from Breast Cancer Bank~* Tissue, plasma, and/or urine from GI Tissue and Blood Bank~* Tissue, blood, and/or urine from Solid Tumor Bank~* Tissue, blood, and/or urine from Lung Cancer Bank~* Tissue and/or blood from Skin Cancer Bank~* Tissue and/or blood from Pediatric Neurosurgery Tissue Bank"
62349570|NCT03726333|ACTIVE_COMPARATOR|Group A1 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
62349571|NCT03726333|ACTIVE_COMPARATOR|Group A2 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
62349572|NCT03726333|EXPERIMENTAL|Group B mild hepatic impairment|continued daily administration of lorlatinib in patients with mild hepatic impairment
62349573|NCT03726333|EXPERIMENTAL|Group C moderate hepatic impairment|continued daily administration of lorlatinib in patients with moderate hepatic impairment
62349574|NCT03726333|EXPERIMENTAL|Group D severe hepatic impairment|continued daily administration of lorlatinib in patients with severe hepatic impairment
62349575|NCT01469572|EXPERIMENTAL|Sir-sphere radioembolization|Everolimus, Pasireotide and Sir-sphere radioembolization
62349576|NCT01480479|EXPERIMENTAL|Rindopepimut/GM-CSF plus Temozolomide|
62349577|NCT01480479|ACTIVE_COMPARATOR|KLH plus Temozolomide|
62349578|NCT01654523|OTHER|Treatment arm|Open trial with no randomization
62349579|NCT02007954|EXPERIMENTAL|DEBDOX|
62349580|NCT05602012|EXPERIMENTAL|Mindfulness Based Cognitive Counseling|The intervention was conducted in two groups with 25 participants/12-13 for each groups and two researchers per group. The program which consisted of eight sessions in total, was held once a week and each session lasted approximately 90-120 minutes.
62349581|NCT05602012|NO_INTERVENTION|No Intervention|Participants will not be given an intervention until after they have completed the study. Data collection tools were applied to the students simultaneously with the intervention group, and after the follow-up test of the intervention group, a single-session information meeting will be held by the researchers for the students in the control group.
62349582|NCT00304915|EXPERIMENTAL|Arm 1: Collaborative Care Intervention|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.
62349583|NCT00304915|NO_INTERVENTION|Arm 2: Usual Care|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.
62349584|NCT03248947|OTHER|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
62349585|NCT00862121|EXPERIMENTAL|Mesalazine|Mesalazine (Mesalamine) 2 g sachet; 6 g daily
62349586|NCT00862121|PLACEBO_COMPARATOR|Placebo|Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily
62705564|NCT04802161|ACTIVE_COMPARATOR|Arm B (daunorubicin and cytarabine liposome)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial."
62507770|NCT04959851||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are initiating or currently ongoing vedolizumab intravenous induction treatment or maintenance intravenous treatment in accordance with the current Summary of Product Characteristics (SmPC) along with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.
62507771|NCT03705949|ACTIVE_COMPARATOR|Study group|Sodium Hyaluronate 0.1% drops
62507772|NCT03705949|ACTIVE_COMPARATOR|Control group|Sodium Hyaluronate 0.2% drops
62507773|NCT00784134|EXPERIMENTAL|Alteplase|administration of alteplase via the intraventricular catheter
62705565|NCT05017012|EXPERIMENTAL|Pembrolizumab Conc1 [dose 1]/Berahyaluronidase alfa|Participants receive pembrolizumab (+) berahyaluronidase alfa (pembrolizumab Conc1 \[dose 1\] + berahyaluronidase alfa) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab intravenously (IV) on Day 1 of Cycles 2 and 4 to 18, with or without background standard of care (SOC) chemotherapy as appropriate for the indication. A cycle is 42 days.
61964722|NCT02866552|EXPERIMENTAL|DRUG : Stromal Vascular Fraction|Patients will receive an injection of Stromal Vascular Fraction injection
61964723|NCT04019574|EXPERIMENTAL|CR845 0.5 mcg/kg IV (Therapeutic Dose)|
62349587|NCT06190743||Study Group|Adult individuals who voluntarily wish to participate in prevention events organized by participating centers
62349588|NCT04172337|NO_INTERVENTION|No labeling Control|Arm 1 was the Control condition, which did not display FOP labels on any products.
62349589|NCT04172337|EXPERIMENTAL|HCS-only|Arm 2 (termed HCS-only) displayed the HCS on eligible products, crossed referenced via the Health Promotion Board's HCS database (https://www.hpb.gov.sg/food-beverage/healthier-choice-symbol). Out of the 4,177 products available on NUSMart, 311 (7·45%) carried the HCS. This was comprised of 150 foods and 161 beverages.
62349590|NCT04172337|EXPERIMENTAL|HCS+PAE|Arm 3 displayed the HCS on eligible products as in Arm 2 and the PAE label on all products (termed HCS+PAE). PAE was calculated as the minutes required to burn off the calories of a single serving for a 73 kg person jogging at 8 km per hour.
62349591|NCT06191965|EXPERIMENTAL|MitoQ|20 mg 2 capsules once daily for 12 weeks (total daily dose 40 mg)
62349592|NCT06191965|PLACEBO_COMPARATOR|Placebo|2 capsules (identical in appearance to MitoQ capsules) once daily for 12 weeks
62349593|NCT02219841||No intervention group|Receive general life-style advice and information on heart healthy diet Undergo catheter ablation for AFib
62349594|NCT02219841||Life-style intervention|patients will receive personilized low-calorie diet menu and undergo supervised exercise in the cardiac rehabilitation facility for 3 months before ablation with an aim of loosing \>10% of body weight. They will continue diet and exercise for 1 year following ablation procedure Will receive catheter ablation for AFib
62349595|NCT00828334|EXPERIMENTAL|Transcatheter PDA Coil|Transcatheter occlusion of Patent Ductus Arteriosus (PDA) with the flex and medium Nit-Occlud PDA.
62349596|NCT01098825||District VI AAP clinicians|
62349597|NCT00120289|EXPERIMENTAL|Combination Therapy|Extended release niacin plus simvastatin
62349598|NCT00120289|ACTIVE_COMPARATOR|Monotherapy|Simvastatin alone
62349599|NCT04008108|EXPERIMENTAL|Patient with urinary incontinence|Patient with urinary incontinence
62349600|NCT01525355||EUS prior to ERCP|
62507774|NCT00784134|PLACEBO_COMPARATOR|Saline Placebo|1 ml of normal saline administered via the intraventricular catheter
62539316|NCT03706014|EXPERIMENTAL|SIBS Program|The program condition includes 12 weekly 90-minute afterschool group sessions for siblings. Sessions are structured as psycho-educational groups and include social interactional activities, role-playing, discussion, and didactic presentation. The focus is on sibling relationship skills, cognitions, and activities. During a total of 3 family nights, parents attend with their children. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children. Family Nights promote parents' understanding of sibling relationships, review concepts, provide strategies for parental support of siblings, and teach parents skills for dealing with sibling problems. Family Nights include dinner and last 2 hours.
62705566|NCT05017012|EXPERIMENTAL|Pembrolizumab Conc2 [dose 1]/Berahyaluronidase alfa|Participants receive pembrolizumab (+) berahyaluronidase alfa (pembrolizumab Conc2 \[dose 1\] + Berahyaluronidase alfa) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab IV on Day 1 of Cycles 2 and 4 to 18, with or without background SOC chemotherapy as appropriate for the indication. A cycle is 42 days.
62705567|NCT05017012|EXPERIMENTAL|Pembrolizumab Conc1 [dose 1]/Berahyaluronidase alfa + SOC Chemotherapy|Participants in Japan receive pembrolizumab (+) berahyaluronidase alfa (pembrolizumab Conc1 \[dose 1\] + berahyaluronidase alfa) SC on Day 1 of Cycle 1, with background SOC chemotherapy, and then receive 400 mg pembrolizumab IV on Day 1 of Cycles 2 to 18, with background SOC chemotherapy. A cycle is 42 days.
61964724|NCT04019574|EXPERIMENTAL|CR845 3 mcg/kg IV (Supratherapeutic Dose)|
61964725|NCT04019574|PLACEBO_COMPARATOR|Placebo IV|
61964726|NCT04019574|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|
61964727|NCT03878628|EXPERIMENTAL|Adipose tissue-derived mesenchymal stem cells|Approximately 11 million ASCs in a 0.5 ml suspension
61964728|NCT00023504|ACTIVE_COMPARATOR|Pneumococcal Vaccine|To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
61964729|NCT00023504|ACTIVE_COMPARATOR|Rabies Vaccine|To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.
62705568|NCT05017012|EXPERIMENTAL|Pembrolizumab Conc1 [dose 2]/Berahyaluronidase alfa|Participants receive pembrolizumab (+) berahyaluronidase alfa (pembrolizumab Conc1 \[dose 2\] + berahyaluronidase alfa) SC on Day 1 of Cycles 1 to 35 without background standard of care (SOC) chemotherapy. A cycle is 21 days.
62705569|NCT04569591|EXPERIMENTAL|1|patients aged 8 or older with Cushing's Disease who are surgical candidates for resection of ACTH producing pituitary adenoma within 12 weeks of PET imaging
62705570|NCT04388839|EXPERIMENTAL|Arm A - First Strike|Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
62705571|NCT04388839|EXPERIMENTAL|Arm B - Second Strike - Maintenance|Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
62705572|NCT04388839|EXPERIMENTAL|Arm C - Adaptive Therapy|Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
62705573|NCT04388839|ACTIVE_COMPARATOR|Arm - D Conventional Therapy|Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
62705574|NCT04025554|EXPERIMENTAL|1/Active treatment|Patients with MS will be assigned to the same intervention
62705575|NCT00814827||Group 1|Patients with nontuberculous mycobacteria (NTM) alone.
62705576|NCT00814827||Group 2|Patients with non-NTM opportunistic infection, either with or without concurrent NTM infection.
62705577|NCT00814827||Group 3|Patients with pulmonary mycobacterium tuberculosis (MTB).
62705578|NCT00814827||Group 4|Patients with disseminated mycobacterium tuberculosis (MTB).
62705579|NCT00814827||Group 5|Blood Specimen Donors.
62705580|NCT03261089||Unresponsive patients post-cardiac arrest|As early as possible post-resuscitation, patients should undergo a detailed neurologic examination, comprised of a thorough assessment for consciousness and detailed cranial nerve function and motor response assessments. Neurologic assessment scores such as the Full Outline of Unresponsiveness, Glasgow Coma Scale (GCS), and Pittsburgh Cardiac Arrest Category Score will be also be used. On the first assessment (day of cardiac arrest), the PCAC score should be assigned only on the basis of the best neurologic exam in the first 6 hours after ROSC. Patients that are sedated or intubated will have the verbal score of GCS be estimated by a derivation of motor and eye scores. The presence of potential confounders, including core body temperature, medications, and/or intoxicants, as well as metabolic derangements should be noted.
62705581|NCT06571994|EXPERIMENTAL|Low Plastic Intervention Group|30 participants randomly assigned to the intervention group will consume low PAC food, employ low risk PAC food preparation practices, and use low PAC personal care and cleaning products.
62705582|NCT06571994|NO_INTERVENTION|Control Group|30 participants randomly assigned to the control group will not receive the intervention nor expected to change behaviour.
62705583|NCT06422143|EXPERIMENTAL|Maintenance Arm 1: Pembrolizumab + sac-TMT|During the Induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin area under the curve (AUC) 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 100 mg/m2 weekly for 4 cycles. During the Maintenance phase, participants receive sac-TMT 4 mg/kg infusion every 2 weeks (q2w) after receipt of an antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), and dexamethasone (or equivalent) until discontinuation criteria is met for sac-TMT; and pembrolizumab 400 mg every 6 weeks (q6w) for 96 weeks.
62705584|NCT06422143|ACTIVE_COMPARATOR|Maintenance Arm 2: Pembrolizumab Monotherapy|During the induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin AUC 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 100 mg/m2 weekly for 4 cycles. During the Maintenance phase, participants receive pembrolizumab 400 mg q6w for 96 weeks.
62705585|NCT04500613|ACTIVE_COMPARATOR|ESPB with Bupivacaine and Dexamethasone|12 pediatric spinal fusion surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.25% bupivacaine with 2mg preservative free dexamethasone with a maximum of 30 mL total per side, depending on the patient's weight.
62705586|NCT04500613|PLACEBO_COMPARATOR|No ESPB|12 pediatric spinal fusion surgery patients will be randomized to not receive an intraoperative ultrasound-guided bilateral ESPB. These patients will still receive the standard anesthesia regimen during and after surgery.
62705587|NCT04545736|EXPERIMENTAL|Metformin|Oral administration of metformin
62705588|NCT06043817|EXPERIMENTAL|Part 1: Dose Escalation|
62705589|NCT06043817|EXPERIMENTAL|Part 2: RP2D Selection|
62705590|NCT06043817|EXPERIMENTAL|Part 3: Dose Expansion|
61964730|NCT00869154|ACTIVE_COMPARATOR|Primary care follow up|Multidisciplinary examination and follow up by the family doctor.
62705591|NCT06460389||Insertion of an extended depth of focus intraocular lens with digital assistance|Participants that underwent uncomplicated IOL implantation of an extended depth of focus intraocular lens with digital assistance
61964731|NCT00869154|EXPERIMENTAL|Multidisciplinary follow up|Multidisciplinary examination and follow up by a multidisciplinary outpatient team.
61964732|NCT00041483|ACTIVE_COMPARATOR|Anecortave and Sham PDT|
62705592|NCT06460389||Insertion of an extended depth of focus intraocular lens without digital assistance|Participants that underwent uncomplicated IOL implantation of an extended depth of focus intraocular lens without digital assistance
62705593|NCT06406699|EXPERIMENTAL|Pain Reprocessing Therapy|Participants will participate in once weekly telehealth group pain reprocessing therapy. Sessions will last approximately 1 hour in length. Group size will be approximately 10 individuals.
61964733|NCT00041483|ACTIVE_COMPARATOR|PDT and Sham Anecortave Acetate|
61964734|NCT04648553|EXPERIMENTAL|Task-Based Grounding|Participating parents will be provided with three 50-minute Task Based Grounding sessions using a standardized manual over 6 weeks.
61964735|NCT04648553|SHAM_COMPARATOR|Connected Care (Enhanced treatment as usual)|"Participating parents will be provided with two sessions and one phone check-in call over 6 weeks. They will work with a care navigator to assess their child's needs, find them an appropriate referral for care, and help problem solve barriers to finding a therapist."
61964736|NCT04381598|EXPERIMENTAL|stevia rebaudiana bertoni|Randomly in all subjects one quadrant will be allotted as test site for placing stevia gel in the gingival sulcus having probing depth ≥ 5mm after performing thorough scaling and root planing.
61964737|NCT04381598|PLACEBO_COMPARATOR|placebo|Other quadrant will be allotted as a control site for placing placebo in the gingival sulcus having PD≥ 5mm after performing thorough scaling and root planing.
61964738|NCT01603004||everolimus, sunitinib or traditional chemotherapy|A total of 30 patients with well differentiated pancreatic NETs who have known liver metastases and who are planned to initiate therapy with either targeted (everolimus or sunitinib) or traditional cytotoxic chemotherapy will be recruited for this study. We plan to recruit approximately 10 patients for each therapy (everolimus, sunitinib, cytotoxic chemotherapy). Evidence of metastatic disease will be determined at the discretion of the oncologist based on available imaging, surgical and pathologic evidence.
61964739|NCT04383405|EXPERIMENTAL|Sequential Preparotory Approach|
61964740|NCT04383405|ACTIVE_COMPARATOR|Conventional|
61964741|NCT05801250|EXPERIMENTAL|AI platform|"All the patients in these group were asked to scan a QR code using smartphone to follow the WeChat public account.The WeChat public account can automatically push clear written instructions for bowel preparation. Including dietary advice ，how to consume the laxatives and remind patients to upload pictures.Patients will receive a reminder to upload stool images from the WeChat public account. After uploading their images, the patients received an evaluation result of pass or not pass .~For patients who received results of not pass, the system displayed tips instructing the patients to drink more water, or walk to improve the bowel preparation quality."
61964742|NCT05801250|NO_INTERVENTION|Manual guidance|A leaflet with clear written instructions on how to consume the laxatives was given to patients in these group.
61964743|NCT02314416|ACTIVE_COMPARATOR|Standard Treatment|Patients in the Control Arm will receive collagen matrix for wound coverage and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
61964744|NCT02314416|EXPERIMENTAL|Amniotic Stem Cells and Collagen Matrix|Patients will receive amniotic stem cells(NuCel) embedded in collagen matrix for wound coverage, and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
61964745|NCT06241534|EXPERIMENTAL|Recordings Group|Cardiac rehabilitation supplemented by relaxation-therapeutic recordings
61964746|NCT06241534|EXPERIMENTAL|VR Group|Cardiac rehabilitation supplemented by VR therapy
61964747|NCT06241534|ACTIVE_COMPARATOR|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
61964748|NCT04604223|EXPERIMENTAL|Pioglitazone|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total.
61964749|NCT04604223|PLACEBO_COMPARATOR|Placebo|Placebo tablets at 45 mg/day will be given for 10 days, after 10 days, the tablets will be reduced to 30 mg/day. The treatment will be continued for 4 weeks (28 days) total.
61964750|NCT02233647|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
62507775|NCT06617377|EXPERIMENTAL|anoxo-ischemic coma patients|"Standard multimodal prognostication procedure will be followed, including the collection of standard predictors:~i) clinical examination and behavioral data (Day 1, 3 and 7 after inclusion): Glasgow Coma Scale - GCS, Full Outline of UnResponsiveness - FOUR,Coma Recovery Scale Revised - CRS-R; and standardized brainstem reflex testing (FOUR, Glasgow-Liège score); ii) severity stratification scoring (Day 1 after inclusion): Cardiac Arrest Hospital Prognosis - CAHP, Out-of-Hospital Cardiac Arrest - OHCA, iii) laboratory findings (Day 1) : NSE blood level iv) electrophysiological assessments (once between Day 1 and Day 15 after inclusion): standard EEG following current guidelines and using ACNS classification; v) standard neuroimaging (once between Day 1 and Day 15 after inclusion): standard brain CT or MRI data (T1, T2\*, SWI, DWI, FLAIR).~An advanced wholebrain sMRI/fMRI/contrast-enhanced MRI scan will be acquired (between Day 1 and Day 7 after inclusion)."
62507776|NCT04314843|EXPERIMENTAL|Lenzilumab and Axicabtagene Ciloleucel|Phase 1: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab and axicabtagene ciloleucel on Day 0 to determine a recommended Phase 2 dose (RP2D) of lenzilumab. Phase 2: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab, at the RP2D, and axicabtagene ciloleucel on Day 0.
61964751|NCT02233647|EXPERIMENTAL|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.~Placebo will be administered acutely during low dose phendimetrazine maintenance."
62144513|NCT00895245|EXPERIMENTAL|Arm I|"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients also undergo radiotherapy once daily 5 days a week for up to 7 weeks.~Patients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients then receive oral dexamethasone on days 2-4. Patients with no emesis or requirement for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.~Patients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion."
62144514|NCT01676454||Vasopressin levels.|"Cohort will consist of subjects with a minor injury or injuries defined as:~1. no episodes of systolic blood pressure \< 90 mmHg between occurrence of injury and admission;~2. no blood transfusion requirement;~3. base deficit \< 5 mEq/L;~4. no requirement for mechanical ventilation other than transiently during orthopedic surgery."
62144515|NCT05011955|EXPERIMENTAL|Mindfulness, compassion and intercare based Intervention|Four week, one hour peer week, online group intervention plus home work based on mindfulness, compassion and intercare based programs.
62507777|NCT03553563|EXPERIMENTAL|Group1|Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
62507778|NCT03553563|EXPERIMENTAL|Group2|Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
62507779|NCT03553563|EXPERIMENTAL|Group3|D961H 10 mg once-daily (32 or 52 weeks)
61964752|NCT02233647|EXPERIMENTAL|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
61964753|NCT02233647|EXPERIMENTAL|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.~Placebo will be administered acutely during high dose phendimetrazine maintenance."
61964754|NCT05809401|EXPERIMENTAL|PRAGMACOM|An experimental treatment for pragmatic disorders characterized by activities that focus on conversational rules and on understanding figurative language. The treatment is already tested on Schizophrenic patients.
62507780|NCT03553563|EXPERIMENTAL|Group4|D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)
61964755|NCT05809401|ACTIVE_COMPARATOR|Standard Neuropsychological Treatment|The standard treatment for neuropsychological disorders is administered to RHD, and TBI patients in the IRCCS San Camillo Hospital, which consists mostly of attentional training.
61964756|NCT02090244|NO_INTERVENTION|Control|Standard care postoperatively.
61964757|NCT02090244|EXPERIMENTAL|Teriparatide|One injection daily for 4 weeks
61964758|NCT01897402|EXPERIMENTAL|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
61964759|NCT01897402|ACTIVE_COMPARATOR|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
61964760|NCT02612727|EXPERIMENTAL|Filtered-sunlight phototherapy|Infants will receive \>= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
61964761|NCT02612727|ACTIVE_COMPARATOR|Intensive phototherapy|Infants will receive \>= four hours per day of intensive phototherapy for 1 to 10 days.
61964762|NCT02709733|EXPERIMENTAL|VR Motivation Training|Weekly training sessions with a VR motivation treatment 1 hour per week for 8 weeks.
62507781|NCT01524029||Breast Cancer Screening Patients|Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
62507782|NCT01524029||Diagnostic Patients|Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
62507783|NCT06227910|EXPERIMENTAL|Double-blind Induction Phase: Vedolizumab + Upadacitinib|Participants will receive vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, 6 and 10 along with upadacitinib 45 mg, orally, once daily (QD) for 12 weeks.
62507784|NCT06227910|PLACEBO_COMPARATOR|Double-blind Induction Phase: Vedolizumab + Placebo|Participants will receive vedolizumab IV 300 mg infusion, at Weeks 0, 2, 6 and 10 along with upadacitinib matched placebo, orally, QD for 12 weeks.
62507785|NCT06227910|EXPERIMENTAL|Main Study Maintenance Phase: Vedolizumab Monotherapy|Participants who achieve a CDAI reduction of \>=70 points from baseline at Week 12 will receive vedolizumab 300 mg IV infusion (monotherapy), every 8 weeks (Q8W) starting at Week 14 to 52. The Q8W vedolizumab monotherapy may be escalated to Q4W at the investigator's discretion.
62507786|NCT02080507|ACTIVE_COMPARATOR|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
61964763|NCT06159530|EXPERIMENTAL|PEEK framework veneered with nanocomposite resin(visio-lign)|patients recieved 4 implants according to All on 4 concept then peek framework was delivered and veneered with nano-composite resin (visio-lign) as an occlusal material
61964764|NCT06159530|EXPERIMENTAL|PEEK framework veneered with zirconia crowns|patients recieved 4 implants according to All on 4 concept then peek framework was delivered and veneered with zirconia crowns as an occlusal material
61964765|NCT00349440|ACTIVE_COMPARATOR|1|
61964766|NCT00349440|PLACEBO_COMPARATOR|2|
61964767|NCT00957775|ACTIVE_COMPARATOR|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, self-help groups) provided at the treatment site.
61964768|NCT00957775|EXPERIMENTAL|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
61964769|NCT05685966||Infertile couples from the research center who visited for fertility disorders|Infertile couples infected or not infected with COVID-19 were included.This is an observational study with no interventions.
61964770|NCT01510691||Epiretinal membrane|
61964771|NCT01510691||diabetic macular edema|
61964772|NCT01510691||vein occlusion|
61964773|NCT00765050|EXPERIMENTAL|CD133+ cells|CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs.
61964774|NCT01878838|ACTIVE_COMPARATOR|Catalys Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
61964775|NCT01878838|ACTIVE_COMPARATOR|LenSx Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.
61964776|NCT03766932||Blood culture candida positive group|
61964777|NCT03766932||Tracheal aspiration candida culture positive group|
61964778|NCT03766932||Urine candida culture positive group|
61964779|NCT03766932||Other aseptic humoral candida positive group|
61964780|NCT05169047|ACTIVE_COMPARATOR|Best Medical Treatment|
61964781|NCT05169047|ACTIVE_COMPARATOR|Subthreshold Spinal Cord Stimulation|
61964782|NCT00580190|ACTIVE_COMPARATOR|1|
61964783|NCT00580190|PLACEBO_COMPARATOR|2|
61964784|NCT00580190|EXPERIMENTAL|3|
61964785|NCT04943497||ribociclib + AI/fulvestrant|Patients administered ribociclib + AI/fulvestrant by prescription AI: Aromatase inhibitor
61964786|NCT04943497||aplelicib + fulvestrant|Patients administered aplelicib + fulvestrant by prescription
61964787|NCT04943497||mono endocrine therapy|Patients administered mono endocrine therapy by prescription
61964788|NCT04943497||chemotherapy|Patients administered chemotherapy by prescription
61964789|NCT03370601|OTHER|Optimisation strategy|increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
61964790|NCT03370601|OTHER|Addition strategy|same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
62705594|NCT06393374|EXPERIMENTAL|Pembrolizumab + sacituzumab tirumotecan|Participants receive pembrolizumab every 6 weeks (q6w) in combination with sacituzumab tirumotecan every 2 weeks (q2w) for 24 weeks. In addition, participants receive an antihistamine, an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to sacituzumab tirumotecan infusions.
62705595|NCT06393374|ACTIVE_COMPARATOR|Treatment of Physician's Choice|Participants receive pembrolizumab q6w or pembrolizumab q6w in combination with capecitabine (twice daily \[BID\] on Days 1 to 14 and 22 to 35 every 42 days x 4 \[2 weeks 1, 1 week off\]) for 24 weeks.
62705596|NCT06565793||Non Complex PCI|The objective of this study is to examine the efficacy of percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES) in patients diagnosed with ST-Elevation Myocardial Infarction (STEMI) or Non-ST-Elevation Myocardial Infarction (NSTEMI).
62507787|NCT02080507|SHAM_COMPARATOR|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
62507788|NCT00670033|EXPERIMENTAL|Travoprost new formulation|Travoprost ophthalmic solution (new formulation), 1 of 3 dose levels, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
62507789|NCT00670033|ACTIVE_COMPARATOR|TRAVATAN|Travoprost ophthalmic solution 0.004%, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
62705597|NCT06565793||Complex PCI|"This study focuses on patients diagnosed with either STEMI or NSTEMI who have undergone complex percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).The following criteria were used to distinguish between complex and very complex angioplasty cases:~The following procedures have been identified as complex or very complex:~* Unprotected Left Coronary Common Trunk Angioplasty (UT-PCI)~* Angioplasty with Rotablator Rotary Atherectomy (ARota-PCI)~* Angioplasty of Chronic Coronary Occlusion (CCO-PCI)"
62705598|NCT05417594|EXPERIMENTAL|Module 1 Part A: Dose escalation|Participants with advanced/relapsed ovarian, breast, pancreatic, or prostate cancer who are deemed suitable for a PARPi will receive AZD9574 monotherapy at escalating cohorts.
62705599|NCT05417594|EXPERIMENTAL|Module 1 Part B: Dose expansion|Participants with breast cancer who are PARPi naive at doses determined in dose-escalation.
62705600|NCT05417594|EXPERIMENTAL|Module 2 Part A: Dose escalation|Participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 and TMZ at escalating cohorts.
62705601|NCT05417594|EXPERIMENTAL|Module 3 Panel 1: AZD9574 monotherapy (Sweden only)|Participants with advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm.
62705602|NCT05417594|EXPERIMENTAL|Module 3 Panel 2: AZD9574 + TMZ (Sweden only)|Participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 and TMZ at escalating cohorts.
61964791|NCT06460220|EXPERIMENTAL|Safe Alternatives for Teens and Youth - Parent (SAFETY-P) + Treatment as Usual (TAU)|"Phase 2 will include pilot testing of the SAFETY-P asynchronous parent intervention module with a nonrandomized case series of 10 families receiving services in CATC. Participants will be provided with the SAFETY-P modules and complete follow-up measures after one month.~Phase 3 will include an RCT with N = 30 youth and parents, with half randomized to SAFETY-P + treatment as usual (TAU). Participants will complete measures at baseline, 1 month, and 3 months."
62349601|NCT02098941||Topiramate|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs.
62349602|NCT02098941||Levetiracetam|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs.
62349603|NCT02098941||Oxcarbazepine|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs.
62507790|NCT00670033|PLACEBO_COMPARATOR|Vehicle|Inactive ingredients, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
62705603|NCT05417594|EXPERIMENTAL|Module 3 Panel 3: AZD9574 monotherapy (Sweden only)|Participants with breast cancer (without BM).
62705604|NCT05417594|EXPERIMENTAL|Module 4 Part A: Dose escalation (AZD9574 + T-DXdat)|Participants with advanced, unresectable, or metastatic solid tumours that are HER2-positive will receive a combination of AZD9574 and T-DXdat at escalating cohorts.
61964792|NCT06460220|OTHER|Treatment As Usual (TAU)|Phase 3 will include an RCT with N = 30 youth and parents, with half randomized treatment as usual (TAU). Participants will complete measures at baseline, 1 month, and 3 months.
62507791|NCT00831233|EXPERIMENTAL|Degarelix 240 mg/80 mg|Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
62507792|NCT00831233|ACTIVE_COMPARATOR|Goserelin (3.6 mg) + bicalutamide (50 mg)|Goserelin (3.6 mg) + bicalutamide (50 mg)
62507793|NCT02932917|EXPERIMENTAL|MapMySmoke|All patients in the study will use the MapMySmoke app to document their smoking and craving behavior
62507794|NCT03642067|EXPERIMENTAL|Cohort A/B: Nivolumab and Relatlimab|480mg/160mg (co-administered)
62507795|NCT03642067|EXPERIMENTAL|Cohort C: Nivolumab and Relatlimab|480mg/ 960mg or 480mg/480mg (sequential administration)
62507796|NCT03642067|EXPERIMENTAL|Cohort C: Nivolumab and Relatlimab (co-administration)|480mg/160mg (co-administration)
62507797|NCT04021355|EXPERIMENTAL|Early Sodium|Early sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for 9 days and in addition will take 2 g of sodium in the form of salt tablets with breakfast each day.
62507798|NCT04021355|EXPERIMENTAL|Late Sodium|Late sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for the next 9 days and in addition will take 2 g of sodium with dinner each day.
62507799|NCT01494103|EXPERIMENTAL|iCaspase9-transduced T cells|"The 5 dose levels are:~1. 1 x 10\^4 T cells/kg~2. 1 x 10\^5 T cells/kg~3. 5 x 10\^5 T cells/kg~4. 1 x 10\^6 T cells/kg~5. 5 x 10\^6 T cells/kg~AP1903 will be administered if there is development of Grade 1 or greater GvHD."
62507800|NCT02173652|EXPERIMENTAL|BI 1356, high dose|Treatment A: 7 days of BI 1356 treatment given once daily
62507801|NCT02173652|ACTIVE_COMPARATOR|BI 1356, low dose|Treatment B: 7 days of BI 1356 treatment given twice daily
62705605|NCT05417594|EXPERIMENTAL|Module 5 Part A : Dose escalation (AZD9574 + Dato-DXd)|Participants with advanced, unresectable, or metastatic solid tumours in different types of cancers will receive a combination of AZD9574 and Dato-DXd at escalating cohorts.
62705606|NCT06104605|EXPERIMENTAL|Implementation|Implementation will be deployed at the CHC, PCP, and patient level.
62705607|NCT06104605|NO_INTERVENTION|Standard of care|Usual patient care without deployment of intervention.
62705608|NCT05304377|EXPERIMENTAL|Phase 1a Dose Escalation|ELVN-001 administered in 3+3 dose escalation
61964793|NCT02083952|EXPERIMENTAL|swaddle blanket|
61964794|NCT02537197|EXPERIMENTAL|Treatment Group|Regular Naltrexone dosing (approximately 12 weeks): Initially, participants will be given seven 25mg oral naltrexone (ReVia, Generic Health, or similar) half tablets at intake (days 1-7). The Full dosing regimen will begin if no toxicity issues are present and consists of fourteen 50mg tablets (two per day; 100mg). If required, dosages can be stepped up or down. If adverse symptoms persist (or if gambling symptoms escalates), the participant will be removed from the study and given alternative treatments. Participants will receive the following week's medication at each Calgary Opioid Dependence Program visit. Pill counts will be made at each visit. Physicians will monitor the progress of participants from intake and adjust dosages up or down to control gambling behaviour.
61964795|NCT04972695||Glaucoma|People with diagnosis of Primary Open Angle Glaucoma (POAG)
61964796|NCT04972695||Ocular Hypertension / glaucoma suspect|People with diagnosis of Ocular Hypertension or POAG suspicion
61964797|NCT02034214|EXPERIMENTAL|Full Intervention|Life skills education vocational counseling Economic livelihoods reproductive health services social support
61964798|NCT02034214|ACTIVE_COMPARATOR|Education and health services alone|Life skills education Reproductive health services
61964799|NCT04059978|ACTIVE_COMPARATOR|CBD + Remifentanil|CBD 1600 mg p.o. + Remifentanil 0.1 µg/kg/min i.v. for 30 min
62507802|NCT01191476|ACTIVE_COMPARATOR|Sevoflurane|Subjects received sevoflurane, a inhalational (volatile) anesthetic, which was administered for induction and maintenance of general anesthesia. Inhalational induction was induced via vital capacity induction at 8% and maintained at 0.8-1.5 minimum alveolar concentration (MAC).
62507803|NCT01191476|ACTIVE_COMPARATOR|Propofol|Subjects received propofol, an intravenous (IV) anesthetic, which was administered for induction and maintenance of general anesthesia.
61964800|NCT04059978|PLACEBO_COMPARATOR|Placebo + Remifentanil|Placebo p.o + Remifentanil 0.1 µg/kg/min i.v. for 30 min
62144516|NCT05011955|ACTIVE_COMPARATOR|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work based on psychoeducation about stress, anxiety, selfcare and effective communication.
62705609|NCT05304377|EXPERIMENTAL|Phase 1b Dose Expansion at recommended dose level 1|ELVN-001 administered at the recommended dose in CML without T315I mutations
62705610|NCT05304377|EXPERIMENTAL|Phase 1b Dose Expansion at recommended dose level 2|ELVN-001 administered at a different recommended dose in CML without T315I mutations
62705611|NCT05304377|EXPERIMENTAL|Phase 1b expansion arm in T315I mutated CML|ELVN-001 administered at the recommended dose for CML with T315I mutation
62705612|NCT06444360|EXPERIMENTAL|IMPACT Group|A multifaceted training and implementation strategy across sites and formats will be used. Participants who report stimulant use in the context of condomless anal sex (CAS), will be randomized using a 2:1 allocation ratio with two-thirds being allocated to the IMPACT intervention. The participants in this arm participate in 10 sessions (approximately 50 minutes each) delivered over the course of approximately 10 weeks.
61964801|NCT03328312|ACTIVE_COMPARATOR|Sugammadex|For reversal of rocuronium neuromuscular- block we will use Sugammadex
61964802|NCT03328312|PLACEBO_COMPARATOR|neostigmine+atropine|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.
61964803|NCT03328312|EXPERIMENTAL|neostigmine+atropine+sugammadex|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.
61964804|NCT03759847|EXPERIMENTAL|Vanguard|Participants in this arm will use the fluid intake app and take a survey to test the fluid intake monitoring app for both safety and design issues.
62144517|NCT05011955|OTHER|General curricular intervention|All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.
62144518|NCT00880074|EXPERIMENTAL|Diagnostic (fluorine F-18 fluorothymidine PET)|Patients undergo fluorine F-18 fluorothymidine PET at baseline, at day 6-8 of course 1, day 20 of course 2, and prior to day 1 of course 3.
62144519|NCT05219526|EXPERIMENTAL|Subject BGMS measurement|Blood glucose measurement using BGMS
62144520|NCT04251923|EXPERIMENTAL|vagianl prolapse surgery accompanied with TVT sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need. Patient who falls in Group will undergo mid urethral sling with tension free vaginal tape (TVT) using TVT mid urethral sling.
62144521|NCT04251923|NO_INTERVENTION|vaginal prolapse surgery not accompanied with sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need.
62144522|NCT04755504|EXPERIMENTAL|EEG evaluation|All patients will be evaluated during 1 night by standard polysomnography and additionally EEG will be evaluated by 2 electrodes behind each ear connected to a recording device (Sensor Dot)
62705613|NCT06444360|ACTIVE_COMPARATOR|Enhanced Standard of Care (eSOC) Control Group|The comparison arm will receive the same 2 HIV sexual risk reduction (RR) intervention sessions and referrals to substance use and mental health treatment, per SOC.
62705614|NCT00340132||Adult volunteers|Volunteers aged 18-55 who are healthy as determined by medical history, physical examination, and laboratory tests
62507804|NCT01191476|ACTIVE_COMPARATOR|Propofol Induction and Sevoflurane Maintenance|Subjects received a bolus dose of propofol of 1.5 mg/kg administered for IV induction followed by sevoflurane at 0.8-1.5 MAC for maintenance anesthesia.
62507805|NCT06184867|EXPERIMENTAL|Relational Agent (RA)|RA participants will be provided with access to Alex, the RA. After completing the RA, RA participants can proceed directly to GT.
62705615|NCT03912428|OTHER|Single arm|all groups get the same studies
62705616|NCT06439602|EXPERIMENTAL|AR882 50 mg|AR882 50 mg taken once daily for 12 months
61964805|NCT03081065|EXPERIMENTAL|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
61964806|NCT03081065|EXPERIMENTAL|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
61964807|NCT03081065|NO_INTERVENTION|Control|Usual care
61964808|NCT04021940|EXPERIMENTAL|Dose adjusted ULOD|dose adjusted ULOD using 60J/cm3 applied to the larger ovary. The number of punctures (Np) per ovary will be calculated according to the following formula: Np = 60 J/cm3 divided by 30 W x 4 s.
61964809|NCT04021940|ACTIVE_COMPARATOR|Fixed dose ULOD|600 J for the larger ovary will be delivered through four punctures, each for 4 s and 40 W
61964810|NCT06417294|EXPERIMENTAL|3D model group|Received a explanation combined with 3D printed model
61964811|NCT06417294|ACTIVE_COMPARATOR|traditional education group|Received a regular education
61964812|NCT06384768|EXPERIMENTAL|Intervention|The arm that which was given an online video training
61964813|NCT06384768|NO_INTERVENTION|Control|No intervention was applied
61964814|NCT00739674|ACTIVE_COMPARATOR|Losartan-Based Regimen Alone (L Group)|Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.
61964815|NCT00739674|EXPERIMENTAL|Diet Management and Losartan-Based Regimen (DML Group)|Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.
61964816|NCT06402110|EXPERIMENTAL|Femoral Triangle Block (FTB) Group|Patients will receive femoral triangle block (FTB) at the end of surgery.
61964817|NCT06402110|EXPERIMENTAL|Adductor Canal Block (ACB) Group|Patients will receive adductor canal block (ACB) at the end of surgery.
61964818|NCT03780907|EXPERIMENTAL|E2007 1 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
61964819|NCT03780907|EXPERIMENTAL|E2007 2 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
61964820|NCT03780907|PLACEBO_COMPARATOR|Placebo|Tablet, once daily to be taken in the morning, one hour before breakfast, with a glass of water.
61964821|NCT01950507|EXPERIMENTAL|Cohort 1|subjects may be on fluconazole or micafungin at study entry or be on no antifungal prophylaxis.
61964822|NCT01950507|EXPERIMENTAL|Cohort 2|subjects are on voriconazole at study entry. Voriconazole will continue throughout days O to 7.
61964823|NCT01950507|EXPERIMENTAL|Cohort 3|subjects are on fluconazole at study entry. Fluconazole will continue throughout days O to 7.
61964824|NCT04374032|EXPERIMENTAL|ENKORTEN|
61964825|NCT04374032|OTHER|The standard of care treatment|The usual therapeutically established protocol for the treatment of patients with moderate to severe COVID-19 infection
61964826|NCT01895569|EXPERIMENTAL|Type 2 diabetic patients|Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin \> 6.5%, and \< 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.
61964827|NCT02014597|EXPERIMENTAL|Normal - No glaucoma|HOCD
61964828|NCT02014597|EXPERIMENTAL|Glaucoma|HOCD
61964829|NCT03744611|EXPERIMENTAL|Cortex Eucommiae(CE)|CE capsule administered orally twice daily for 12 weeks.
61964830|NCT03744611|PLACEBO_COMPARATOR|Placebo|Placebo capsule administered orally twice daily for 12 weeks.
61964831|NCT04832360|EXPERIMENTAL|Control (CTL)|Participants do not receive financial incentive intervention
61964832|NCT04832360|EXPERIMENTAL|Single Target (ST)|One member of each dyadic-smoking couple will receive financial incentive intervention
62507806|NCT06184867|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|EUC participants will be sent a clinical letter informing them of their increased risk of hereditary cancer, availability of GC and GT services, and contact information to schedule an appointment with a genetic counselor at the LIFE Center.
62507807|NCT00610324|EXPERIMENTAL|1|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
61964833|NCT04832360|EXPERIMENTAL|Dyadic Target (DT)|Both members of each dyadic-smoking couple will receive financial incentive intervention
61964834|NCT06201559|EXPERIMENTAL|Sequence TRTR|Participants will be administered with test (T) intervention \[Albendazole Indian Pharmacopoeia (IP) 400 mg\] in Period 1, reference (R) intervention (Albendazole Tablets 400 mg) in Period 2, T intervention in Period 3 and R intervention in Period 4.
61964835|NCT06201559|EXPERIMENTAL|Sequence RTRT|Participants will be administered with reference (R) intervention in Period 1, test (T) intervention in Period 2, R intervention in Period 3 and T intervention in Period 4.
61964836|NCT03393637|EXPERIMENTAL|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
62144523|NCT02594709|EXPERIMENTAL|ONSM Multisession Radiosurgery|Multisession Radiosurgery
61964837|NCT03393637|NO_INTERVENTION|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
61964838|NCT03004027|EXPERIMENTAL|Enhanced|self help leaflet enhanced with implementation intentions
61964839|NCT03004027|ACTIVE_COMPARATOR|Standard|self help leaflet standard (without implementation intentions)
61964840|NCT03004027|NO_INTERVENTION|Waiting list control|Baseline measures administered only. self help intervention will be made available once the study has finished.
61964841|NCT04448483|EXPERIMENTAL|Group A|Patients belonging to group A will start intervention I, immediately after baseline. We will recruit about 25 for group A (randomization will take into account the two to one study design) in order to have about 20 patients in Group A that will complete the study.
61964842|NCT04448483|EXPERIMENTAL|Group B|Patients belonging to group B will follow an observation period (max. 3 months) before starting intervention I. We will recruit about 15 patients for group B (randomization will take into account the two to one study design) in order to have about 10 patients in Group B that will complete the study.
61964843|NCT00458198|EXPERIMENTAL|1|Participants will receive integrated behavioral therapy
61964844|NCT00458198|ACTIVE_COMPARATOR|2|Participants will receive integrated behavioral therapy after a 12-week waitlist period
61964845|NCT04656691|EXPERIMENTAL|Participants with COVID-19|Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.
61964846|NCT00851500|EXPERIMENTAL|low dose K-604|
61964847|NCT00851500|EXPERIMENTAL|high dose K-604|
62507808|NCT00610324|ACTIVE_COMPARATOR|2|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
62507809|NCT00508027|OTHER|Simvastatin, Dose Escalation|There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
62144524|NCT01703546|EXPERIMENTAL|LAGB & LGCP|"All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB \& LGCP).~The percent of Excess Body Weight Loss will be monitored at all post op visits."
62144525|NCT03183349|EXPERIMENTAL|platelet rich fibrin|immediate implant grafting
62144526|NCT03183349|ACTIVE_COMPARATOR|deprotienized bovine bone (tutogen)|immediate implant grafting
62349604|NCT05244499|EXPERIMENTAL|Evidence-based leadership training|The training course will take 6 months. It is divided into seven online modules. Participants join the course based on pre-structured schedule. The progress of the training course will follow specific steps to improve participants' evidence-based leadership competencies. First, each participant identifies one leadership problem on daily practice. Second, organisational data will be collected and analysed to increase the understanding of the key problem. Third, scientific literature will be searched, identified and critically appraised to find solutions. Fourth, the views of stakeholders (patients, clinicians, family members, etc.) are considered together with ethical implications. And last, all sources of information are critically appraised, new solution will be designed and implemented into the practice, and evaluated in real world context. Each module includes specific learning material. Trained tutors are responsible for mentoring each module.
62349605|NCT05244499|ACTIVE_COMPARATOR|Conventional training|The participants will join a training course with the same structure, topics, and timing as the experimental group. However, training in this group is based on independent learning methods. The participants have access to the separate learning platform, which includes reading material to be read independently. No group discussions with peers, self-reflection, assignments, or support from tutors will be offered.
62349606|NCT00839423|PLACEBO_COMPARATOR|Placebo|
62349607|NCT00839423|EXPERIMENTAL|Vortioxetine (Lu AA21004) 5 mg|
62349608|NCT00839423|EXPERIMENTAL|Vortioxetine (Lu AA21004) 10 mg|
62349609|NCT00839423|OTHER|Venlafaxine XL 225 mg|Active Reference
62349610|NCT02030613|OTHER|Single arm: etanercept|Patients treated with etanercept for JIA
62349611|NCT01722812|OTHER|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion on left body side), Cromoglicate (on a lesion on right body side)
62349612|NCT01722812|OTHER|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion on right body side), Cromoglicate (on a lesion on left body side)
62349613|NCT04715256|EXPERIMENTAL|KCNQ1 mutated subjects|"This arm includes :~* KCNQ1-mutated subjects with long QT Romano-Ward syndrome~* KCNQ1-mutated subjects without phenotypic expression of the Romano-Ward syndrome~* family relatives of a KCNQ1-mutated enrolled subject, carrying the KCNQ1 family mutation"
62349614|NCT04715256|SHAM_COMPARATOR|Healthy subjects|Healthy subjects will be matched to KCNQ1 subjects. The matching factors will be age per decade (18-28 years, \> 28-38 years, \> 38-48 years), gender and body mass index (BMI: ≤ 24.9 kg/m2; 25-29.9 kg/m2; \> 30 kg/m2).
62349615|NCT01213069||all 5000 subjects|this is a purely descriptive study with one group
62705617|NCT06439602|EXPERIMENTAL|AR882 75 mg|AR882 75 mg taken once daily for 12 months
61964848|NCT00851500|PLACEBO_COMPARATOR|placebo|
61964849|NCT05132920|EXPERIMENTAL|Experimental arm|3 x 8 mg (2 ml) dexamethasone daily for days 1-7 and 1 x 8 mg (2 ml) dexamethasone daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients
62507810|NCT01783652|EXPERIMENTAL|Intervention group|Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.
62507811|NCT01783652|NO_INTERVENTION|Control group|Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.
62507812|NCT01047891|EXPERIMENTAL|Experimental|
62705618|NCT06439602|PLACEBO_COMPARATOR|Placebo|AR882 matching placebo taken once daily for 12 months
62705619|NCT02070549|EXPERIMENTAL|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61964850|NCT05132920|PLACEBO_COMPARATOR|Control arm|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients
61964851|NCT03942848|EXPERIMENTAL|intrathecal Ziconotide followed by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
62144527|NCT06427239|EXPERIMENTAL|Dose Escalation 300mg|For HRS-4642 in combination with Adebrelimab, for advanced or metastatic pancreatic ductal adenocarcinoma.
62349616|NCT04511442||Bariatric surgery|Women with obesity, with a bariatric surgery
62349617|NCT04511442||Control|Women with obesity, without a bariatric surgery
62349618|NCT00797485|ACTIVE_COMPARATOR|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62349619|NCT00797485|EXPERIMENTAL|Arm II|Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62349620|NCT05510609|OTHER|Thyroidectomy|Patients set for total thyroidectomy incl. functional total thyroidectomies.
62705620|NCT05536804|EXPERIMENTAL|Tirzepatide|Tirzepatide administered subcutaneously (SC)
62705621|NCT05536804|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62507813|NCT04751045|ACTIVE_COMPARATOR|Percutaneous Liver biopsy|"Technique: The preprocedure time out protocol will be completed prior to initiation of the procedure. The patient will be positioned supine and right hepatic lobe was localized with ultrasound. Conscious sedation with Versed and fentanyl will be initiated and the patient's vital signs were monitored by an independent trained observer during the procedure.~After placing a mark on the skin overlying the right upper quadrant, the skin was then prepped and draped in the usual sterile fashion. Maximum sterile barrier technique used at the procedure. Under direct sonographic guidance, a 15 gauge percutaneous liver biopsy needle will be used with a 2 cm throw was advanced into the right hepatic lobe. The biopsy samples will be obtained and submitted to pathology."
62705622|NCT00018057|EXPERIMENTAL|Active|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
62705623|NCT00018057|PLACEBO_COMPARATOR|Control|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
62705624|NCT04252235|SHAM_COMPARATOR|Sham air purifier|Participants will receive a sham air purifier that will be installed in the bedroom and living room. These purifiers will make a noise, but will not filter the air.
62349621|NCT04074824||Necrotizing enterocolitis|Neonates diagnosed with NEC based on the Modified Bell criteria for NEC including clinical, radiological and Laboratory findings.
62349622|NCT04074824||Non-NEC|Neonates diagnosed with other conditions including low birthweight, prematurity, infection, metabolic, cardiovascular, CNS, respiratory or gastrointestinal problems.
62349623|NCT06335498||Wear AFGen1 for at least 7 days|Wear AFGen1 for 7 to 10 days. ECG co-measurement with 12 lead device at start and periodic measurements of ECG with AFGen1 during wear period
62349624|NCT06335498||Misplacement Study Group|Wear AFGen1 device in misplaced position compared to wearing device in standard position as directed by instructions for use
62349625|NCT02333591|ACTIVE_COMPARATOR|GlucagonLikePeptide-1 (7-36)|"GLP-1 (7-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (7-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min.~A DPP-IV inhibitor - Januvia 100 mg is given the evening before and ½ an hour before the infusion is started."
62349626|NCT02333591|ACTIVE_COMPARATOR|GlucagonLikePeptide-1 (9-36)|GLP-1 (9-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (9-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min
62349627|NCT02333591|PLACEBO_COMPARATOR|NaCl|Saline is infused with a flow rate of 240 ml/h for 10 min and then reduced to 86 ml/h for 2½ hours.
62349628|NCT00012896|OTHER|Arm 1|
62349629|NCT00790179|ACTIVE_COMPARATOR|PCA;active comparator|Patients with intravenous PCA hydromorphone alone
62349630|NCT00790179|ACTIVE_COMPARATOR|CFB|Patients with a continuous femoral block (CFB) + PCA hydromorphone
62349631|NCT00790179|ACTIVE_COMPARATOR|CLPB|Patients with a continuous lumbar plexus block + PCA hydromorphone
62349632|NCT03558191|EXPERIMENTAL|SHR-1210 Injection|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes, once every 2 weeks .
62349633|NCT03722914|ACTIVE_COMPARATOR|benzonatate soft capsules group|
62349634|NCT03722914|PLACEBO_COMPARATOR|control group|
62349635|NCT03633565|ACTIVE_COMPARATOR|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
62349636|NCT03633565|ACTIVE_COMPARATOR|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
62349637|NCT03633565|EXPERIMENTAL|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
62349638|NCT05200156|EXPERIMENTAL|Choline supplement group|Phosphatidyl choline tablets at a dose of 1200 mg twice per day plus conventional management for 12 weeks
62349639|NCT05200156|NO_INTERVENTION|Control group|conventional management only for 12 weeks
62349640|NCT05057143|EXPERIMENTAL|Replacement of a defect in the chest wall with an individual implant|A patient with a tumor lesion of the chest wall undergoes СT scan with a step width of less than 1 mm, then engineers design an individual model to replace the defect. Using a 3D printer, a model is made based on the patient's anthropometric data.
62349641|NCT05057143|ACTIVE_COMPARATOR|Replacement of a defect in the chest wall with titanium plates|The use of standard titanium plates to replace the chest defect. These plates must be modeled and modified using special equipment intraoperatively, based on the characteristics of the defect after resection.
62349642|NCT02556424|ACTIVE_COMPARATOR|Reference Drug|Intravitreal implant of 700μg of dexamethasone (Ozurdex®)
62349643|NCT02556424|EXPERIMENTAL|Tested Drug|Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)
62349644|NCT00233818|OTHER|1|
62349645|NCT00453843|EXPERIMENTAL|proximal to distal training|
62349646|NCT00453843|EXPERIMENTAL|distal to proximal|
62349647|NCT00453843|EXPERIMENTAL|proximal and distal on alternate days|
62349648|NCT00453843|EXPERIMENTAL|proximal and distal same day|
62349649|NCT04441879|EXPERIMENTAL|Blended intervention|Women will receive a blended intervention (integrating face-to-face and online sessions) for the treatment of postpartum depression.
62349650|NCT04441879|ACTIVE_COMPARATOR|Control (online intervention)|Women will receive an online intervention (Be a Mom program).
62349651|NCT00721318||1|Patients diagnosed with rheumatoid arthritis
62349652|NCT00721318||2|Population controls to the subjects of group 1
62349653|NCT03517306||Beijing|No interventions
62349654|NCT03517306||Ningxia|No interventions
62705625|NCT04252235|EXPERIMENTAL|True air purifier|Participants will receive a HEPA air purifier in the bedroom and living room.
62705626|NCT03299049|EXPERIMENTAL|Subjects in group 1 receiving study treatment once in 4 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q4W via intramuscular (IM) route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
61964852|NCT03942848|PLACEBO_COMPARATOR|intrathecal Ziconotide preceded by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
61964853|NCT03566316|EXPERIMENTAL|Telmisartan/Amlodipine+Rosuvastatin|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
61964854|NCT03566316|ACTIVE_COMPARATOR|Telmisartan/Amlodipine|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
61964855|NCT03566316|ACTIVE_COMPARATOR|Telmisartan +Rosuvastatin|Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.
61964856|NCT01937559|EXPERIMENTAL|Topical Tranexamic acid (TXA)|Tranexamic acid (TXA) applied topically
61964857|NCT01937559|PLACEBO_COMPARATOR|Saline|Normal saline
61964858|NCT01937559|ACTIVE_COMPARATOR|Tranexamic acid (TXA)|Tranexamic acid (TXA) administered intravenously
61964859|NCT05195814||Effectiveness of tofacitinib|Participants receiving tofacitinib will be included to assess the effectiveness of tofacitinib overall and stratified by key variables of interest
61964860|NCT02834507|PLACEBO_COMPARATOR|Placebo|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
61964861|NCT02834507|EXPERIMENTAL|Nebicapone 75 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
62705627|NCT03299049|EXPERIMENTAL|Subjects in group 1 receiving study treatment once in 8 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q8W via IM route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
62705628|NCT03299049|EXPERIMENTAL|Subjects in group 2 receiving study treatment once in 4 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to continue CAB LA plus RPV LA Q4W administration via IM route.
61964862|NCT02834507|EXPERIMENTAL|Nebicapone 150 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
62144528|NCT06427239|EXPERIMENTAL|Dose Escalation 400mg|For HRS-4642 in combination with Adebrelimab, for advanced or metastatic pancreatic ductal adenocarcinoma.
62144529|NCT06427239|EXPERIMENTAL|Dose Escalation 500mg|For HRS-4642 in combination with Adebrelimab, for advanced or metastatic pancreatic ductal adenocarcinoma.
62144530|NCT02631655|OTHER|device 18FDOPA|impact of device 18F-FDOPA PET on treatment decisions
62349655|NCT03517306||Wenzhou|No interventions
62349656|NCT03517306||Changzhou|No interventions
62705629|NCT03299049|EXPERIMENTAL|Subjects in group 2 receiving study treatment once in 8 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
62705630|NCT00980538|EXPERIMENTAL|Etravirine|Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
61964863|NCT02834507|ACTIVE_COMPARATOR|Entacapone 200 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
61964864|NCT01546181||Controls|subjects older than 10 years old, with no know ocular or general disease
61964865|NCT01546181||Age-related macular degeneration|
61964866|NCT01546181||inherited retinal dystrophies|
61964867|NCT01546181||retinal trauma|
61964868|NCT01546181||toxic retinopathies|
61964869|NCT01546181||arterial hypertensive patients|
61964870|NCT01546181||diabetic patients|
61964871|NCT01546181||inflammatory diseases|
61964872|NCT02364752|EXPERIMENTAL|Healthy|Part 1: Blood is obtained from healthy participants on 3 consecutive days, and participants undergo Cardiac Magnetic Resonance Imaging (CMR) and two-dimensional speckle tracking echocardiography (2DSTE) on one of those 3 days.
61964873|NCT02364752|EXPERIMENTAL|Mild/moderate heart failure (HF)|Part 1: Blood is obtained from participants with mild/moderate HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
62144531|NCT05958966|EXPERIMENTAL|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
62144532|NCT05958966|EXPERIMENTAL|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
62144533|NCT05958966|EXPERIMENTAL|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
62349657|NCT01907841|EXPERIMENTAL|Ischemic Preconditioning|IPC (4 x 5 minute cycles @ 220 mmHg) with 5 min reperfusion between trials.
62349658|NCT01907841|PLACEBO_COMPARATOR|Ischemic Preconditioning Placebo|Placebo (4 x 5 minute cycles @ 20mmHg) with 5 minutes between each cycle
62349659|NCT00627835|EXPERIMENTAL|Treatment Group 1: Cohort 1|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
62705631|NCT06320743|ACTIVE_COMPARATOR|Group LFA|NIRS probe will be attached to the inner surface of the forearm and cerebral right-left frontotemporal region and the values will be noted. Standard ASA monitoring and induction will be performed. Fresh gas flow will be 4 lt/min, 50% oxygen/air mixture, sevoflurane vaporizer will be turned on at 4%, continue for 10 minutes and then fresh gas flow will be reduced to 0.8 lt/min, sevoflurane the MAK value will be adjusted to be between 0.9-1.1. Alarm limits appropriate to the patient's weight will be determined for all patients, the lower limit of inspired O2 will be set as 30%, the upper limit of inspired CO2 will be set as 5mmHg. If the inspired O2 value drops below 30%, the pulse oximeter peripheral SpO2 drops below 97, and the NIRS values drop by 20%, the oxygen concentration will be increased by 10%. The sevoflurane vaporizer will be turned off 10 minutes before the end of the operation. When the extubation criteria are met, the patient will be extubated.
61964874|NCT02364752|EXPERIMENTAL|Severe HF|Part 1: Blood is obtained from participants with severe HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
61964875|NCT04633694|EXPERIMENTAL|Insect protein|The participants are are given insect protein
62144534|NCT05958966|EXPERIMENTAL|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
61964876|NCT04633694|EXPERIMENTAL|Pea protein|The participants are are given pea protein
61964877|NCT04633694|EXPERIMENTAL|Whey protein|The participants are are given whey protein
62144535|NCT05958966|NO_INTERVENTION|No e-liquid|Participants do not receive an e-cigarette e-liquid to self-administer.
62144536|NCT04658667|EXPERIMENTAL|Full dose IHV01 and A244|Participants will receive a full dose of IHV01 (approximately 300μg) and A244 (approximately 300μg).
62144537|NCT04658667|EXPERIMENTAL|Fractional dose IHV01 and A244|Participants will receive a fractional dose of IHV01 (approximately 60μg) and A244 (approximately 60μg).
62144538|NCT04658667|EXPERIMENTAL|Full dose IHV01 and A244 + ALFQ|Participants will receive a full dose of IHV01 (approximately 300μg) and A244 (approximately 300μg) plus ALFQ (approximately 0.5mL).
62349660|NCT00627835|EXPERIMENTAL|Treatment Group 1: sorafenib and radiation: Cohort 2|Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
62349661|NCT00627835|EXPERIMENTAL|Treatment Group 2: Cohort 3|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
62349662|NCT00627835|EXPERIMENTAL|Treatment Group 2: Cohort 4|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
62349663|NCT00627835|EXPERIMENTAL|Treatment Group 2:Cohort 5|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
62349664|NCT03838445|EXPERIMENTAL|Therapy: V-Wave Shunt|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation.
62349665|NCT06224972||Observational group|The study is observational study - one group.
62349666|NCT00201981|ACTIVE_COMPARATOR|1|rebamipide 1%
62349667|NCT00201981|ACTIVE_COMPARATOR|2|Rebamipide 2%
62349668|NCT00201981|NO_INTERVENTION|3|placebo
62349669|NCT06481657|EXPERIMENTAL|The experimental group will train with oxygen goggles in the aerobic part of the training|"pon admission of the patients to the Cardiac Rehabilitation Center in Laniado, a cardiologist's evaluation was performed to check inclusion and exclusion criteria for the study. As usual, the participants were asked to come with the results of the echocardiogram in the effort they made as part of the health services in the community. At this point, the doctor or physiotherapist asked those who met the inclusion criteria to participate in the study. After a detailed explanation of the study and what was required in it, those interested in participating were asked to give their written consent and were randomly divided into one of two groups (with oxygen O2 and a control group). The two groups We trained with oxygen goggles in all aerobic efforts throughout the training program, the O2 group trained with an oxygen supplement of 5 liters/minute and the control group trained without oxygen enrichment with room air flow (placebo)."
62349670|NCT06481657|PLACEBO_COMPARATOR|The control group will train with oxygen goggles without oxygen enrichment (placebo).|"pon admission of the patients to the Cardiac Rehabilitation Center in Laniado, a cardiologist's evaluation was performed to check inclusion and exclusion criteria for the study. As usual, the participants were asked to come with the results of the echocardiogram in the effort they made as part of the health services in the community. At this point, the doctor or physiotherapist asked those who met the inclusion criteria to participate in the study. After a detailed explanation of the study and what was required in it, those interested in participating were asked to give their written consent and were randomly divided into one of two groups (with oxygen O2 and a control group). The two groups We trained with oxygen goggles in all aerobic efforts throughout the training program, the O2 group trained with an oxygen supplement of 5 liters/minute and the control group trained without oxygen enrichment with room air flow (placebo)."
62349671|NCT00080886|OTHER|Arm 1|"Participants receive rituximab IV over approximately 3-4 hours once weekly for 2 weeks followed 1 week later by hematopoietic stem cell or bone marrow harvest.~Participants then receive a third dose of rituximab IV over approximately 3-4 hours on day -7 or -6. Patients also receive high-dose chemotherapy comprising carmustine IV on day -6, cytarabine IV and etoposide IV twice daily on days -5 to -2, and melphalan IV on day -1. Participants undergo autologous hematopoietic stem cell transplantation on day 0. Participants who have less than a complete remission at day 100 post-transplantation receive 4 additional doses of rituximab IV over approximately 3-4 hours once weekly for 4 weeks. Participants are followed at day 100, at 1 year, and then annually thereafter."
62349672|NCT02741219|PLACEBO_COMPARATOR|Control Group|Parturients in this group receive 20ml intravenous normal saline immediately after delivery. Their patient controlled analgesia (PCA) protocol after surgery consists of 100 mcg sufentanil diluted into 100ml and administer at a background infusion of 1ml/h,and a bolus of 2ml, with a lock-out of 8min.
62349673|NCT02741219|EXPERIMENTAL|Dex Group|Parturients in this group receive 0.5mcg/kg intravenous dexmedetomidine diluted to 20ml with normal saline. Their PCA protocol after surgery is 100mcg sufentanil and 300mcg dexmedetomidine diluted to 100ml in saline, with the continuous infusion of 1ml/h, and a bolus of 2 ml, with a lock-out of 8min.
62349674|NCT03766230||peribulbar anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using peribulbar anesthesia
62507814|NCT04751045|ACTIVE_COMPARATOR|Endoscopic ultrasound guided liver biopsy|Procedure details: patients will be screened preoperatively to assess cardiovascular health prior to undergoing procedure as this is standard of care. Patients will follow all standard preoperative instructions prior to anesthesia. Upon undergoing general anesthesia, a videoendoscope will be introduced into the esophagus under direct vision. Once endoscope is in position near the liver, a 19-gauge sharkcore needle will be used to puncture the left lobe with a 3 accentuation and another pass from right lobe with 4 accentuation. Doppler study will be used to interrogate for any significant doppler signals in needle path. Post procedure, patients will be provided instructions to avoid NSAIDs for 4 days and perform lightweight activity for 4 days. Patients will be observed for bleeding and significant abdominal pain postoperatively
62507815|NCT02443324|EXPERIMENTAL|Cohort A|Participants with gastroesophageal junction (GEJ) cancer \[Second-Third Line (L)\] received 8 milligrams per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 for every 3 weeks (Q3W) of a 21-day cycle.
62507816|NCT02443324|EXPERIMENTAL|Cohort A1|Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
62507817|NCT02443324|EXPERIMENTAL|Cohort A2|Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
61964878|NCT05348070||Operated Non-Ruptured Endometrioma Group|It consists of patients who were found to have endometrioma in their clinical follow-ups and decided to operate as a result of the evaluations. The patients were operated under elective conditions.
62349675|NCT03766230||topical anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using topical anesthesia
62507818|NCT02443324|EXPERIMENTAL|Cohort B|Participants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
62507819|NCT02443324|EXPERIMENTAL|Cohort C|Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
62507820|NCT02443324|EXPERIMENTAL|Cohort D|Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
62507821|NCT02443324|EXPERIMENTAL|Cohort E|Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
62507822|NCT06535503||Patients with STEMI & Cardiogenic Shock|Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization treated at SKMC \& SSMC, Abu Dhbai
62507823|NCT02555982|EXPERIMENTAL|EXPERIMENTAL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
62507824|NCT02555982|OTHER|CONTROL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
62507825|NCT04431414||Group 1|Persons that are positive for SARS-CoV-2 and are asymptomatic
62507826|NCT04431414||Group 2|Persons that are positive for SARS-CoV-2 with recent onset of mild symptoms (not hospitalized)
62507827|NCT04431414||Group 3|Persons that are positive for SARS-CoV-2 and are symptomatic hospitalized patients
62507828|NCT06207630|ACTIVE_COMPARATOR|Standard dressing group|Use dry dressing, made with sterile compresses, then a glued dressing
62507829|NCT06207630|EXPERIMENTAL|NPWT 3/7d dressing group|Use of a PICO® dressing
62507830|NCT06207630|EXPERIMENTAL|NPWT 7d dressing group|Use of a PREVENA® dressing
62507831|NCT01891552||Tacetux|DEBIRI+ CETUXIMAB ADMINISTRATION
62507832|NCT01891552||DEBIRI|only DEBIRI treatment
62507833|NCT05418634||Pediatric Emergency Department (PED)|"PED: Patients presenting with unexplained impaired consciousness or active SE:~To investigate the role of pocEEG in the PED, we will collect all pocEEG tracings of all children with unexplained impaired consciousness or active SE, for whom written consent has been obtained. We will document the interpretation of the respective pocEEGs by the PEM physician and compare it to the interpretation of the neuropediatrician on call. The research team will also perform a post-hoc analysis."
62507834|NCT05418634||Epilepsy Clinic|CLINIC: Patients with either suspected epilepsy or established diagnosis of epilepsy will be recruited for simultaneous recording of cEEG and pocEEG in the epilepsy outpatient clinic will help define and investigate the limitations of pocEEG.
62507835|NCT01501110|ACTIVE_COMPARATOR|n-acetylcysteine|intra-venous infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours.
62507836|NCT01501110|NO_INTERVENTION|no intervention|No intervention
62507837|NCT06172855|EXPERIMENTAL|Premature ejaculation|Adult male with primary premature ejaculation. They will receive electroacupuncture at ST36 to treat premature ejaculation.
62507838|NCT04420624|EXPERIMENTAL|Colchicine|colchicine and standard therapy
62705632|NCT06320743|ACTIVE_COMPARATOR|Group HFA|NIRS probe will be attached to the inner surface of the forearm and cerebral right-left frontotemporal region and the values will be noted. Standard ASA monitoring and induction will be performed.Fresh gas flow will be 3lt/min, 50% oxygen/air mixture, and the sevoflurane vaporizer will be turned on at 3%, sevoflurane the MAK value will be adjusted to be between 0.9-1.1. The sevoflurane vaporizer will be turned off the end of the operation. When the extubation criteria are met, the patient will be extubated.
62705633|NCT04570956|EXPERIMENTAL|Oral Tamoxifen 10 mg/day|Oral Tamoxifen 10 mg/day
62349676|NCT03766230||peribulbar anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using peribulbar anesthesia
62349677|NCT03766230||topical anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using topical anesthesia
62349678|NCT03766230||peribulbar anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using peribulbar anesthesia
62349679|NCT03766230||topical anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using topical anesthesia
62507839|NCT04420624|NO_INTERVENTION|Comparator|standard therapy
62507840|NCT06416852|EXPERIMENTAL|18F-Alfatide and 18F-FDG Injection|The study is designed as a self-controlled trial, in which participants will be injected and scanned with two drugs.
62507841|NCT00426530|EXPERIMENTAL|RAD001 Daily Schedule|5mg or 10mg
62507842|NCT00426530|EXPERIMENTAL|RAD001 Weekly Schedule|30mg
62507843|NCT03014986||Patients who receive HCV treatment|HSCT patients with HCV who are receiving (or has recently received) HCV treatment
62507844|NCT03014986||Patients who do not receive HCV treatment|HSCT patients with HCV who have not received treatment
62507845|NCT01658917||Primary|Patients greater than or equal to 18 years of age who have premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis
61964879|NCT05348070||Operated Ruptured Endometrioma Group|Rupture of endometrioma, which is a rare gynecological emergency. This group consists of endometrioma patients requiring urgent/subacute operation such as acute abdominal pain, hemodynamic instability, intra-abdominal bleeding. The patients were operated after completing the necessary preparations
62349680|NCT03766230||peribulbar anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using peribulbar anesthesia
62349681|NCT03766230||topical anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using topical anesthesia
62507846|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
62507847|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
62507848|NCT02004184|EXPERIMENTAL|maintenance pemetrexed|maintenance pemetrexed immediately after induction chemotherapy
62507849|NCT02004184|ACTIVE_COMPARATOR|pemetrexed at progression|observation and pemetrexed therapy at disease progression
62705634|NCT04570956|EXPERIMENTAL|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day|"Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day~+oral placebo"
62705635|NCT04570956|EXPERIMENTAL|Control|Oral and gel placebo
62705636|NCT06170788|EXPERIMENTAL|Pembrolizumab + Sacituzumab tirumotecan|Participants receive sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle + 400 mg Pembrolizumab every 6 weeks (q6w) via IV infusion on Day 1 of each 6-week cycle for 18 cycles. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
62705637|NCT06170788|ACTIVE_COMPARATOR|Pembrolizumab|Participants receive 400 mg Pembrolizumab via IV infusion q6w on Day 1 of each 6-week cycle for 18 cycles
62349682|NCT03766230||peribulbar anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using peribulbar anesthesia
62349683|NCT03766230||topical anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using topical anesthesia
62349684|NCT04433728||Adults Phenylketonuric|Adults patients screened in neonatal period for PKU and treated
62349685|NCT02950012|EXPERIMENTAL|OPTI-BIOME™ Bacillus subtilis MB40|
62507850|NCT00775528|EXPERIMENTAL|A|
62705638|NCT00046202||normal subjects|subjects in whom no disorder of cholesterol is suspected related to affected individuals
62705639|NCT00046202||subjects suspected of cholesterol disorder|subjects in whom a disorder of cholesterol metabolism is suspected
62705640|NCT06044935|EXPERIMENTAL|Men with overweight or obesity|To investigate whether NR supplementation augments the sleeping energy expenditure and fat oxidation rate during the ketogenic diet in men and women with overweight and obesity
62349686|NCT02950012|PLACEBO_COMPARATOR|Placebo|
62349687|NCT05079763|EXPERIMENTAL|Experimental arm|Application of bacterial cellulose-monolaurin hydrogel in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
62349688|NCT05079763|PLACEBO_COMPARATOR|Placebo Arm|Application of placebo cream in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
62349689|NCT00270998|EXPERIMENTAL|Intravaginal Pessary|Pessary restores continence by stabilization of the proximal urethra and urethrovesical junction, facilitating pressure transmission to the proximal urethra.
62349690|NCT00270998|EXPERIMENTAL|Behavioral Therapy|Pelvic floor muscle training and exercise which includes strong contraction of the pelvic floor muscles to prevent incontinence by occluding the urethra and regular practice can improve pelvic muscle support.
62349691|NCT00270998|EXPERIMENTAL|Pessary combined with behavioral therapy|Combination of the explanations above.
62349692|NCT04328233|EXPERIMENTAL|Time-Restricted Eating|
62507851|NCT06475625|EXPERIMENTAL|Normal or mild renal dysfunction|eGFR ≥ 60 ml·min - 1·1.73㎡
62507852|NCT06475625|EXPERIMENTAL|Moderate renal dysfunction|30≤ eGFR\< 60 ml·min - 1·1.73㎡
62507853|NCT06475625|EXPERIMENTAL|Severe renal dysfunction|eGFR \< 30 ml·min -1·1.73㎡
62507854|NCT05398835|EXPERIMENTAL|Intervention|Online interventions promoting home-based HIV self-testing
62507855|NCT01560884|ACTIVE_COMPARATOR|Group B|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
62507856|NCT01560884|ACTIVE_COMPARATOR|Group C|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
62507857|NCT01560884|ACTIVE_COMPARATOR|Group D|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
62507858|NCT01560884|ACTIVE_COMPARATOR|Group A|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
62507859|NCT01961258||Sever asthmatics in the comminity|Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
62507860|NCT00571389||Cancer Cohort|The first cohort of patients to be enrolled for this study will be adults (males and females) with histological proven solid tumors of any stage, seen for routine cancer care at participating community cancer clinic sites. Patients on clinical trials with experimental study drugs will be allowed to participate in this observational prospective study.
61964880|NCT01619982|ACTIVE_COMPARATOR|Cefazolin 25 mg/kg body weight and vancomycin|"All infants \< 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children.~Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight"
62144539|NCT04658667|EXPERIMENTAL|Fractional dose IHV01 and A244 + ALFQ|Participants will receive a fractional dose of IHV01 (approximately 60μg) and A244 (approximately 60μg) plus ALFQ (approximately 0.5mL).
62349693|NCT04231955|EXPERIMENTAL|pain rating scales|"patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10, on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end and on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
62507861|NCT00571389||Healthy Volunteer Cohort|Healthy volunteers make up the second, smaller study population for this observational biospecimen laboratory study. Healthy volunteers serve primarily to aid in the proficiency, quality control and/or optimization of study procedures, experimental design assay development, and for device/equipment validation.
62507862|NCT00571389||COVID-19 Disease Cohort|Due to the COVID-19 pandemic and the consequent amendment to aid in the research response, study subjects with COVID-19 disease may participate in all aspects of this protocol, but depending on their disease state, infection timeline, and age, participation may be limited to only one component, procedure, and/or type of biospecimen collection. Age is a very important criteria, as pediatric subjects (5-17 years old) will only be eligible to participate in minimally invasive biospecimen collection procedures.
62507863|NCT03288402|EXPERIMENTAL|ongoing fasted|ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
62507864|NCT03288402|EXPERIMENTAL|intake of caffeine containing beverages|10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
62349694|NCT04066530|EXPERIMENTAL|AD-203|
62349695|NCT04066530|ACTIVE_COMPARATOR|Mucosta tab.|
62349696|NCT01933256|EXPERIMENTAL|600mg HIP2B|600mg HIP2B
62349697|NCT01933256|PLACEBO_COMPARATOR|Placebo|Placebo
62349698|NCT01933256|EXPERIMENTAL|400mg HIP2B|400mg HIP2B
62349699|NCT00671216|EXPERIMENTAL|Period 1|Subjects will receive first placebo, then GSK233705, GW642444 and combination of GSK233705 and GW642444
62349700|NCT00671216|EXPERIMENTAL|Period 2|Subjects will receive first combination of GSK233705 and GW642444, then placebo, GSK233705 and GW642444
62349701|NCT00671216|EXPERIMENTAL|Period 3|Subjects will receive first GSK233705, then GW642444, combination of GSK233705 and GW642444 and later placebo
62507865|NCT03288402|EXPERIMENTAL|intake of 5 item English breakfast|10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
62507866|NCT04689893|EXPERIMENTAL|68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT scan|Patients of Tumor-induced osteomalacia PET/CT imaging: The patients were subcutaneously injected with 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and underwent PET/CT scan 20\~40min after the injection in two consecutive days.
62507867|NCT05924867|EXPERIMENTAL|Intervention group|"The wounds of participants in the postoperative incision infection group and ulcer infection group will be given plasma activated saline irrigation (100 ml plasma activated saline for every 10 cm2 wound), drainage, and wet compress. The wounds of participants in the fat liquefaction group will be uniformly rinsed with plasma saline for 5-10 min to clean the incision, then drained and suction with negative pressure.~The researchers will determine the dressing change time according to the size of the patient's wound and the number of secretions, starting every day or every other day, and waiting for the incision to be fresh or less secretions at an interval of 2-3 days."
62507868|NCT05924867|ACTIVE_COMPARATOR|Control group|"The wounds of participants in the postoperative incision infection group and ulcer infection group will receive routine dressing change treatment, namely cleaning with chlorhexidine disinfectant (100 ml chlorhexidine disinfectant for every 10 cm2 wound area), drainage, bandaging. The wounds of participants in the fat liquefaction group will be receive conventional treatment, namely negative pressure sputum aspiration.~The researchers will determine the dressing change time according to the size of the patient's wound and the number of secretions, starting every day or every other day, and waiting for the incision to be fresh or less secretions at an interval of 2-3 days."
61964881|NCT01619982|OTHER|Cefazolin only 30mg/kg body weight|All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections
61964882|NCT04910802|EXPERIMENTAL|HPV-vaccination|Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.
62349702|NCT00671216|EXPERIMENTAL|Period 4|Subjects will receive first GW642444, then combination of GSK233705 and GW642444, placebo, and later GSK233705
62349703|NCT06524596|EXPERIMENTAL|the butorphanol group|0.02 mg/kg of tartaric acid butorphanol intravenously 30 minutes prior to anaesthesia induction.
62349704|NCT06524596|PLACEBO_COMPARATOR|the control group|0.02 mg/kg of normal saline intravenously 30 minutes prior to anaesthesia induction.
62349705|NCT05486936||study arm|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists. The plans which pass the on-line verification will then be de-identified and transferred to RapidPlan configuration workspace for RNI model training and verification.All enrolled patients will be regularly followed up during and after RT. Acute and late toxicity will be documented as well as tumor control endpoints.
62349706|NCT01661868|ACTIVE_COMPARATOR|PARP Inhibitor Naive|Patients with no prior PARP inhibitor treatment
61964883|NCT04243967|EXPERIMENTAL|MUSIC THERAPY|
61964884|NCT04243967|EXPERIMENTAL|CONTROL|
61964885|NCT06033794|EXPERIMENTAL|Laparoscopic No. 253 lymph node dissection and preserving the LCA under fluorescence guidance.|Preoperatively, indoycine green fluorescent dye was injected into the anus to trace the No. 253 lymph nodes, and intraoperatively, arterial branching of the mesentery was performed by intravenous injection of fluorescent dye to preserve the left colic artery.
61964886|NCT06033794|ACTIVE_COMPARATOR|Performing laparoscopic No. 253 lymph node dissection and preserving the LCA.|Conventional laparoscopic approach for dissection of the No. 253 lymph nodes and preservation of the left colic artery.
62705641|NCT06044935|EXPERIMENTAL|MODY2 Patients|To measure changes in sleeping energy expenditure and fat oxidation rate after transitioning from a baseline diet to an isocaloric ketogenic diet similar to our previous study in men
62705642|NCT06044935|EXPERIMENTAL|Women with overweight or obesity|To investigate whether NR supplementation augments the sleeping energy expenditure and fat oxidation rate during the ketogenic diet in men and women with overweight and obesity
62705643|NCT00071786||Group 1|All study participants fall into one group for this observational family study regardless of diagnosis.
61964887|NCT04813445|EXPERIMENTAL|Xingnaojing injection|"Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.~Interventions:~Drug: Xingnaojing injection Other: Standard care"
61964888|NCT04813445|NO_INTERVENTION|Standard care|"Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care"
62705644|NCT06208306|EXPERIMENTAL|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
62705645|NCT06208306|EXPERIMENTAL|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
62705646|NCT01581580|OTHER|treatment arm|patients with Parkinson's Disease, dysonia, and essential tremor
62705647|NCT02594202||1|Adults (= 18 years of age) with biopsy-proven or suspected prostate cancer
62705648|NCT05652478|ACTIVE_COMPARATOR|Dolutegravir|50mg one tablet orally once daily for 8 days.
61964889|NCT05890846|EXPERIMENTAL|DLPFC group|Active iTBS will be delivered to the cognitive control network at left DLPFC.
62144540|NCT04658667|PLACEBO_COMPARATOR|Placebo|Normal saline will serve as a placebo for the trial. All placebo injection volumes will match the study vaccine injection volumes for the group in which a participant has been randomized.
62144541|NCT03020498|OTHER|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
62144542|NCT03020498|OTHER|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
62144543|NCT03020498|OTHER|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
62144544|NCT03605732|EXPERIMENTAL|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
62144545|NCT03605732|ACTIVE_COMPARATOR|Patient education|Patients will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
62705649|NCT05652478|ACTIVE_COMPARATOR|Tenofovir alafenamide|25mg one tablet orally once a day for 8 days.
62507869|NCT03785145|EXPERIMENTAL|MT10109L|MT10109L will be injected into the LCL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
62705650|NCT06328036|EXPERIMENTAL|GROUP A (neoadjuvant atezolizumab, tiragolumab)|Patients receive atezolizumab IV over 60 minutes and tiragolumab IV over 20-75 minutes and 14-19 days later, undergo surgical resection. Following surgery, patients may receive tiragolumab IV and atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
62705651|NCT06328036|EXPERIMENTAL|GROUP B (neoadjuvant tiragolumab)|Patients receive tiragolumab IV over 20-75 minutes and 14-19 days later, undergo surgical resection. Following surgery, patients may receive tiragolumab IV and atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
61964890|NCT05890846|SHAM_COMPARATOR|Sham group|Sham iTBS will be delivered to the cognitive control network at left DLPFC.
61964891|NCT04232384|ACTIVE_COMPARATOR|Standard paracentesis group (SPG)|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography-guided (in cases the ascites is not clinically detectable).
61964892|NCT04232384|EXPERIMENTAL|Rollover paracentesis group (ROG)|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
61964893|NCT00528658|EXPERIMENTAL|1|
61964894|NCT00528658|EXPERIMENTAL|2|
61964895|NCT00528658|EXPERIMENTAL|3|
61964896|NCT05519410|EXPERIMENTAL|Sintilimab Combined With Lenvatinib|Pre-operation: 2-3 cycles;
61964897|NCT05519410|ACTIVE_COMPARATOR|HAIC|Pre-operation: HAIC-FOLFOX 2-3 cycles;
61964898|NCT02755558|EXPERIMENTAL|Low energy density, small portion|Low milk energy density and small portion size
61964899|NCT02755558|EXPERIMENTAL|Low energy density, large portion|Low milk energy density and large portion size
62349707|NCT01661868|ACTIVE_COMPARATOR|Prior PARP Inhibitor|Patients previously treated with a PARP inhibitor other than olaparib
62705652|NCT06328036|EXPERIMENTAL|GROUP C (neoadjuvant atezolizumab)|Patients receive atezolizumab IV over 60 minutes and 14-19 days later, undergo surgical resection. Following surgery patients may receive atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
62705653|NCT06328036|ACTIVE_COMPARATOR|GROUP D (no neoadjuvant drug)|Patients undergo surgical resection on study. Following surgery patients may receive atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
61964900|NCT02755558|EXPERIMENTAL|High energy density, small portion|High milk energy density and small portion size
61964901|NCT02755558|EXPERIMENTAL|High energy density, large portion|High milk energy density and large portion size
61964902|NCT06506201|EXPERIMENTAL|direct anterior approach with navigation assistance|Patients treated surgically with total hip arthroplasty (direct anterior approach) with navigation assistance.
61964903|NCT06506201|ACTIVE_COMPARATOR|direct anterior approach without navigation assistance|Patients treated surgically with total hip arthroplasty (direct anterior approach) without navigation assistance.
61964904|NCT06506201|EXPERIMENTAL|lateral direct approach with navigation assistance|Patients treated surgically with total hip arthroplasty (lateral direct approach) with navigation assistance.
62144546|NCT02676011|ACTIVE_COMPARATOR|Group A|Intramuscular (IM) atropine (0.01 mg/kg) (1 ml) 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
62144547|NCT02676011|ACTIVE_COMPARATOR|Group B|1 ml normal saline IM 30 minutes before induction of anesthesia, intravenously (IV) atropine (0.01 mg/kg) in 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
62349708|NCT01188096|EXPERIMENTAL|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly intramuscular injection (IM). The first 2 doses will be administered in the clinic under supervision.
62507870|NCT03785145|PLACEBO_COMPARATOR|Placebo|Placebo will be injected into the LCL: initial double-blind treatment on Day 1.
62705654|NCT01174108|EXPERIMENTAL|1|Target doses: CD34+ cells 8 x 106/kg; CD3+ cells 2 x 107/kg
62705655|NCT01174108|NO_INTERVENTION|2|Donor
62349709|NCT04145869|EXPERIMENTAL|Fluorescent cholangiography|Intraoperative fluorescent cholangiography using an intravenous injection of 5mg Indocyanine green
62705656|NCT02146170||Single group|Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET
62705657|NCT06575153|EXPERIMENTAL|Part 1 (SAD) Cohort 1 - Dose Level 1|3 mg/kg of ART5803 IV infusion over approximately 90 minutes (±60 minutes)
62705658|NCT06575153|EXPERIMENTAL|Part 1 (SAD) Cohort 2- Dose Level 2|10 mg/kg of ART5803 IV infusion over approximately 90 minutes (±60 minutes)
62705659|NCT06575153|EXPERIMENTAL|Cohort 3 (SAD)/Cohort A (MAD) - Dose Level 3|30 mg/kg of ART5803 IV infusion over approximately 90 minutes (±60 minutes)
62705660|NCT06575153|EXPERIMENTAL|Cohort 4 (SAD)/Cohort B (MAD) - Dose Level 4|60 mg/kg of ART5803 IV infusion over approximately 90 minutes (±60 minutes)v
62507871|NCT00437190|ACTIVE_COMPARATOR|Anterior Cervical Discectomy Fusion|
62705661|NCT06575153|EXPERIMENTAL|Cohort 5 (SAD)/Cohort C (MAD) - Dose Level 5|100 mg/kg of ART5803 IV infusion over approximately 90 minutes (±60 minutes)
62705662|NCT06575153|NO_INTERVENTION|Placebo|0.9% normal saline IV infusion over approximately 90 minutes (±60 minutes)
62705663|NCT01851447||Fragile Sarcolemmal Muscular Dystrophy|patients with early adulthood or late onset of a genetic disorder FSMD (LGMD 2B-F, I, L, MM, BMD and MMD3)
62705664|NCT01976715||HIV-1|Subjects (greater than or equal to 18 years) with human immunodeficiency virus type 1 (HIV-1) who have documented virologic failure.
62507872|NCT00437190|EXPERIMENTAL|BRYAN Cervical Disc Prosthesis|BRYAN Cervical Disc Prosthesis is a cervical intervertebral disc prosthesis designed to provide for motion like the normal cervical functional spinal unit.
62507873|NCT05246696||Patient group|
62705665|NCT03519945|EXPERIMENTAL|Mirikizumab|Mirikizumab administered subcutaneously (SC).
62705666|NCT05965700|EXPERIMENTAL|NVG-291 for Injection|Injected under the skin (subcutaneous).
62705667|NCT05965700|PLACEBO_COMPARATOR|Placebo|Injected under the skin (subcutaneous).
62705668|NCT06220669|EXPERIMENTAL|LY3541860 Phase 2a Dose Level 1|LY3541860 will be given intravenously (IV)
62705669|NCT06220669|EXPERIMENTAL|LY3541860 Phase 2a Dose Level 2|LY3541860 will be given IV.
62705670|NCT06220669|PLACEBO_COMPARATOR|Placebo Phase 2a|Placebo will be given IV.
61964905|NCT06506201|ACTIVE_COMPARATOR|lateral direct approach without navigation assistance|Patients treated surgically with total hip arthroplasty (lateral direct approach) without navigation assistance.
61964906|NCT06506201|EXPERIMENTAL|postero-lateral approach with navigation assistance|Patients treated surgically with total hip arthroplasty (postero-lateral approach) with navigation assistance.
61964907|NCT06506201|ACTIVE_COMPARATOR|postero-lateral approach without navigation assistance|Patients treated surgically with total hip arthroplasty (postero-lateral approach) without navigation assistance.
61964908|NCT01065090||training|one group will receive resistance training and one group the normal physiotherapeutic treatment
61964909|NCT01065090||physiotherapy|one group will receive resistance training and one group the normal physiotherapeutic treatment
61964910|NCT03876444|EXPERIMENTAL|Intervention arm|Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day
62705671|NCT06220669|EXPERIMENTAL|LY3541860 Phase 2b Dose Level 3|LY3541860 will be given IV.
62705672|NCT06220669|EXPERIMENTAL|LY3541860 Phase 2b Dose Level 4|LY3541860 will be given IV.
62705673|NCT06220669|PLACEBO_COMPARATOR|Placebo Phase 2b|Placebo will be given IV.
62705674|NCT03746431|EXPERIMENTAL|[225Ac]-FPI-1434 Single-Dose Escalation|
62705675|NCT03746431|EXPERIMENTAL|[225Ac]-FPI-1434 Multi-Dose Escalation|\[225Ac\]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
62705676|NCT03746431|EXPERIMENTAL|FPI-1175 Cold Antibody|
61964911|NCT03876444|ACTIVE_COMPARATOR|Control|Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day
61964912|NCT00434330|EXPERIMENTAL|Cohort 1, Q4W, SC, No Transition|
61964913|NCT00434330|EXPERIMENTAL|Cohort 2, Q4W, IV, No Transition|
61964914|NCT00434330|EXPERIMENTAL|Cohort 3, Q4W, SC, Transition|
61964915|NCT00434330|EXPERIMENTAL|Cohort 4, Q4W, IV, Transition|
61964916|NCT00434330|EXPERIMENTAL|Cohort 5, Q4W, SC, Transition|
61964917|NCT00434330|EXPERIMENTAL|Cohort 6, Q4W, IV, Transition|
62144548|NCT02676011|ACTIVE_COMPARATOR|Group C|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and 1mg/kg atropine mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
62144549|NCT02676011|PLACEBO_COMPARATOR|Group D|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
62144550|NCT05106621||Surgical Patients|
62144551|NCT01711294|ACTIVE_COMPARATOR|19 G Flex Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
62144552|NCT01711294|ACTIVE_COMPARATOR|22 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
62144553|NCT01711294|ACTIVE_COMPARATOR|19 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
62349710|NCT04145869|ACTIVE_COMPARATOR|X-ray cholangiography|Intraoperative X-ray cholangiography using an intraductal (cystic duct) injection of Iohexol
62349711|NCT01033487|PLACEBO_COMPARATOR|Placebo|
62349712|NCT01033487|ACTIVE_COMPARATOR|active comparator|
62705677|NCT03746431|EXPERIMENTAL|[225Ac]-FPI-1434 Multi-Dose|Phase 2 Tumour Cohort - Head \& Neck Squamous Cell Carcinoma (HNSCC), Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative, Adrenocortical Carcinoma (ACC), Uveal Melanoma, \[225Ac\]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
62705678|NCT00001594||Children with OI|Children with OI
61964918|NCT02150317|ACTIVE_COMPARATOR|TACE+Sorafenib|TACE followed by Sorafenib
61964919|NCT02150317|EXPERIMENTAL|TACE|TACE alone
61964920|NCT06432920|EXPERIMENTAL|ResWave|In-phase Chest Wall Vibration worn and active during constant work rate exercise testing.
61964921|NCT06432920|PLACEBO_COMPARATOR|Control|In-phase Chest Wall Vibration worn and inactive (off) during constant work rate exercise testing.
61964922|NCT00763568|EXPERIMENTAL|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
61964923|NCT03715010|ACTIVE_COMPARATOR|Brain Chain Amino Acid (BCAA)|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
62144554|NCT06327282||Intervention group|Anesthesia nurses carried out pain-related knowledge education.
62144555|NCT06327282||Blank group|Patients who did not receive any knowledge education.
62144556|NCT04809623|EXPERIMENTAL|Edecesertib|Participants continuing their standard of care therapy will receive edecesertib at a dose of 115 mg orally once daily for up to 4 weeks.
62144557|NCT04809623|EXPERIMENTAL|Placebo|Participants continuing their standard of care therapy will receive placebo to match edecesertib orally once daily for up to 4 weeks.
62144558|NCT03412266|OTHER|RIC regimen|"Low- and intermediate MDS patients without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
61964924|NCT03715010|PLACEBO_COMPARATOR|Placebo|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
61964925|NCT02223091|EXPERIMENTAL|Consultation by a trained physician|The physicians of this group receive a free consultation training program on skills regarding consultations on complementary medicine for breast-cancer patients. The training was developed by a multi-professional team and is comprised of three parts: (1) online-training, (2) on-site-training, and (3) consultation manual. Each of the physicians will counsel 10 patients. The patients in this group therefore receive a consultation by a trained physician.
62144559|NCT04609735|EXPERIMENTAL|Experimental: Electric DN, Manual therapy, exercise and US|Dry needling, manual therapy, exercise and ultrasound
62349713|NCT01033487|EXPERIMENTAL|PF-03635659|
61964926|NCT02223091|ACTIVE_COMPARATOR|Consultation by an untrained physician|The physicians of the control arm receive no training. Each will counsel 10 patients. The patients in this group therefore receive a consultation by an untrained physician.
61964927|NCT02617745|EXPERIMENTAL|Stupp protocol|Blood assessment of the platelet level every week during the radiotherapy phase and every cycle during the chemotherapy
61964928|NCT01441206|OTHER|rifampin|Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.
62349714|NCT04801394|EXPERIMENTAL|Mesh Group|Patient with large incisional hernia treated with FLaPp® mesh as neoperineium
62349715|NCT05535309||Occurrence of coagulation disorder|"1. All inpatients who used cefoperazone sulbactam sodium during hospitalization；~2. Hospital stay ≥ 48h;~3. Age ≥ 18 years old;~4. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and platelet (PLT) were detected twice or more during hospitalization"
62507874|NCT02293473|EXPERIMENTAL|Protocol Group|"Using multimodal monitoring to optimise the patients' haemodynamic status, namely, the use of LiDCO Rapid, BIS-Bispectral Index Monitor and INVOS-Cerebral Oxygenation Monitor monitors to assess and fine tune the patient, as described in the study protocol in detail."
62705679|NCT00065676|EXPERIMENTAL|1 gram quercetin|1 gram quercetin with 6 hour OGTT
62705680|NCT00065676|EXPERIMENTAL|2 grams quercetin|2 gram quercetin with 6 hour OGTT
62705681|NCT00065676|EXPERIMENTAL|placebo|placebo with 6 hour OGTT
61964929|NCT01441206|NO_INTERVENTION|rifampin per standard of care|Cohort 2: Receiving rifampin per standard of care
61964930|NCT06052605|EXPERIMENTAL|HAP-E Epilepsy Participants|
61964931|NCT04579705|EXPERIMENTAL|Group I (Brushed-1 minute)|Surgical hand scrubbing will be performed in 1 minute using a brush.
61964932|NCT04579705|NO_INTERVENTION|Group II (Brushless-1 minute)|Surgical hand scrubbing will be performed in 1 minute without using a brush.
61964933|NCT04579705|EXPERIMENTAL|Group III (Brushed-2 minutes)|Surgical hand scrubbing will be performed in 2 minute using a brush.
61964934|NCT04579705|NO_INTERVENTION|Group IV (Brushless-2 minutes)|Surgical hand scrubbing will be performed in 2 minute without using a brush.
61964935|NCT00783003|EXPERIMENTAL|Long acting muscarinic receptor antagonist (LAMA)|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
61964936|NCT00783003|EXPERIMENTAL|Long acting Beta 2 agonist (LABA)|Inhaled Long Acting Beta 2 agonist (LABA) which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
61964937|NCT00783003|EXPERIMENTAL|LAMA with LABA|Inhaled Long Acting Muscarinic receptor Antagonist (LAMA) and a inhaled Long Acting Beta 2 Agonist (LABA), both in development for treatment of Chronic Obstructive Pulmonary Disease and taken in combination.
61964938|NCT00783003|PLACEBO_COMPARATOR|Placebo|Matching placebo, no intervention.
61964939|NCT00990236|ACTIVE_COMPARATOR|Enoxaparin 30 mg BID|standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
61964940|NCT00990236|EXPERIMENTAL|Enoxaparin dose adjusted based on TEG|enoxaparin dose modified based on TEG results
61964941|NCT06014034|EXPERIMENTAL|Study group|Programmed Weaning From Noninvasive Mechanical Ventilation
61964942|NCT06014034|NO_INTERVENTION|Control group|this is the traditional withdrawal unit (the attending physician will decide the NIV regimen according to the condition).
61964943|NCT02716571|OTHER|Healthy Donors|Healthy Donors will given white blood cell and plasma
61964944|NCT05410561|EXPERIMENTAL|TeleTx intervention|The evidence-based manualized psychosocial program is via telehealth and uses adaptations of cognitive behavioral therapy and motivational interviewing.
61964945|NCT05410561|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|EUC will include brief psychoeducation about AUD and resources for treatment.
61964946|NCT01525537|EXPERIMENTAL|SPI guided arm|sufentanil was adjusted to SPI level
61964947|NCT01525537|ACTIVE_COMPARATOR|Standard practise|Sufentanil was given at standard practise
61964948|NCT01286298|EXPERIMENTAL|Laser gingivectomy|
61964949|NCT05930912||Participant Case|The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.
61964950|NCT01206608|ACTIVE_COMPARATOR|Low-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
61964951|NCT01206608|ACTIVE_COMPARATOR|Mid-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
61964952|NCT01022632|ACTIVE_COMPARATOR|Fluoxetine|Fluoxetine : 20 mg Once a day in morning after taking food for 6 weeks
62349716|NCT05535309||No coagulation disorder|"1. Inpatients who did not use cefoperazone sulbactam sodium during hospitalization;~2. Hospital stay ≥ 48h;~3. Age ≥ 18 years old;~4. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and platelet (PLT) were detected twice or more during hospitalization"
62507875|NCT02293473|ACTIVE_COMPARATOR|Control Group|Using current standard of care
62507876|NCT06467578|OTHER|Breezing Portable Indirect Calorimeter|Use Breezing to assess RMR once a week for six weeks
61964953|NCT01022632|EXPERIMENTAL|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
61964954|NCT01022632|EXPERIMENTAL|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
61964955|NCT05061771|ACTIVE_COMPARATOR|nomacopan (rVA576)|"PART A:~High dose nomacopan (standard complement ablating doses on Day 1 followed by 45 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd~or~Low dose nomacopan (standard complement ablating doses on Day 1 followed by 15 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS~PART B:~Nomacopan (standard complement ablating doses on Day 1 followed by to be confirmed mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd"
61964956|NCT05061771|PLACEBO_COMPARATOR|Placebo|"PART A:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 45mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~or~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 15mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~PART B:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of active dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd"
61964957|NCT03242057|EXPERIMENTAL|NI-NAVA|"* Wait to meet extubation criteria within 14 days postnatal age~* Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion~* Randomize to either NIPPV or NI-NAVA, 1:1 randomization~* PI will not be blinded to the intervention (not feasible)~* If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.~* ABG or CBG to be obtained at 4 hrs. post extubation~* NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
61976131|NCT05395806|EXPERIMENTAL|Health App|"This group will have access to a gamified App to help them to control their cardiovascular risk factors and to improve their adherence to medication therapy.~Half of the participants will be allocated to the App group. They will be stratified by age and cardiovascular risk level according to national standards based on the Framingham risk factors level."
62507877|NCT02067767|EXPERIMENTAL|Abacavir/Lamivudine/Dolutegravir|Patients switched from their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG.
61964958|NCT03242057|ACTIVE_COMPARATOR|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age~* Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion~* Randomize to either NIPPV or NI-NAVA, 1:1 randomization~* PI will not be blinded to the intervention (not feasible)~* ABG or CBG to be obtained at 4 hrs. post extubation~* NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
61964959|NCT04717115||Genetic diagnosis|
61964960|NCT01700777|EXPERIMENTAL|Intensive rehab group|"A group of children will beneficiate of HABIT-ILE treatment in an intensive way (camp) for 90h."
61964961|NCT01700777|ACTIVE_COMPARATOR|Regular treatment group|A group of children with hemiplegic cerebral palsy will beneficiate from conventional training at a regular frequency (1 to 6 hours / week) for 90hours.
61964962|NCT02300688|EXPERIMENTAL|Arm 1|Period 1 (Treatment A) - Wash out - Period 2 (Treatment B)
61964963|NCT02300688|EXPERIMENTAL|Arm 2|Period 1 (Treatment B) - Wash out - Period 2 (Treatment A)
61964964|NCT02892071|ACTIVE_COMPARATOR|22% TCA peel|22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
61964965|NCT02892071|ACTIVE_COMPARATOR|CO2 laser|CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
62144560|NCT04609735|ACTIVE_COMPARATOR|Active comparator: Manual therapy, exercise and ultrasound|Active comparator: Manual therapy, exercise and ultrasound
62144561|NCT00028548|EXPERIMENTAL|XK469|
62507878|NCT03573817|EXPERIMENTAL|Period 1: Revefenacin + Formoterol (Sequential)|Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
62507879|NCT03573817|EXPERIMENTAL|Period 2: Revefenacin + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
62507880|NCT03573817|PLACEBO_COMPARATOR|Period 1: Placebo + Formoterol (Sequential)|Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
62507881|NCT03573817|PLACEBO_COMPARATOR|Period 2: Placebo + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
62507882|NCT02504814|EXPERIMENTAL|ventilatory effects|measuring mean airway pressure, breathing volumes and decrease in hypercapnia
62507883|NCT02725424|ACTIVE_COMPARATOR|Her2 Positive with SOX|Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA \<1.25m2) ,100mg/day (BSA ≥1.25m2, \<1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
62507884|NCT02725424|EXPERIMENTAL|Her2 Positive with SOXT|Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA \<1.25m2) ,100mg/day (BSA ≥1.25m2, \<1.5 m2), 120mg/day (BSA ≥1.5m2), trastuzumab 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1, every 3 weeks.
61964966|NCT02892071|ACTIVE_COMPARATOR|Qs-NdYAG laser|Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.
61964967|NCT03462264|NO_INTERVENTION|Control Group / Group 1|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic.
62144562|NCT04196309|EXPERIMENTAL|Tinzaparin group|LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)
61964968|NCT03462264|EXPERIMENTAL|Group 2|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a pre-formatted diary for them to fill out.
61964969|NCT03462264|EXPERIMENTAL|Group 3|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a link to download the free ScolioGold App on to their mobile from the clinic.
61964970|NCT02198742|ACTIVE_COMPARATOR|Miller blade|Subjects must have \>500 intubations in order to participate in this study. There is no placebo group, and each subject wil be his or her own control.
61964971|NCT02198742|ACTIVE_COMPARATOR|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable. There is no placebo group, and each subject wil be his or her own control.
62144563|NCT04196309|NO_INTERVENTION|Control group|No intervention
62507885|NCT02725424|ACTIVE_COMPARATOR|Her2 Negative with SOX|Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA \<1.25m2) ,100mg/day (BSA ≥1.25m2, \<1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
61964972|NCT02198742|ACTIVE_COMPARATOR|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacterer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
61964973|NCT02893514|PLACEBO_COMPARATOR|Screening Only (SO)|
61964974|NCT02893514|EXPERIMENTAL|Substance Use Screening and Intervention Tool (SUSIT)|
62144564|NCT00595959|EXPERIMENTAL|Laser Treatment|CLiRpath Photoablation Atherectomy System
62144565|NCT00536120|EXPERIMENTAL|Tysabri Plus Vaccinations|Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin \[KLH\] and tetanus diphtheria toxoid \[Td\], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
62144566|NCT00536120|OTHER|Vaccinations Only|Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH. They do not receive any treatment for their MS and remain in the study through Month 2.
61964975|NCT03793738|ACTIVE_COMPARATOR|anterior component separation|The anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath.
61964976|NCT03793738|ACTIVE_COMPARATOR|posterior component separation|The posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles.
61964977|NCT01121237||CKD5, renal anaemia, haemodialysis|CKD5, renal anaemia, haemodialysis receiving recombinant human erythropoietin alfa (biosimilar)
61964978|NCT01325298|ACTIVE_COMPARATOR|20 Minute UV-X Light Treatment Duration|"20 Minute UV-X Light Treatment Duration~Note: UV-X is the trademark of Peschke GmbH"
61964979|NCT01325298|ACTIVE_COMPARATOR|30 Minute UV-X Light Treatment Duration|30 Minute UV-X Light Treatment Duration
61964980|NCT06501638|EXPERIMENTAL|Memantine|Take Memantine Hydrochloride for intervention
61964981|NCT06501638|PLACEBO_COMPARATOR|Placebo|Take placebo for intervention
61964982|NCT04773483|ACTIVE_COMPARATOR|Quorn Food products|
61964983|NCT04773483|ACTIVE_COMPARATOR|Meat/fish products|
61964984|NCT01218568|EXPERIMENTAL|Rifaximin plus lactulose|
62144567|NCT02888821|EXPERIMENTAL|CLS-FUERTE|Families will receive the CLS-FUERTE intervention in the fall of the 2016-2017 school year. CLS-FUERTE includes caretaker, child and teacher components implemented during a 6 week period. All content of group sessions will be derived from the manualized CLS-FUERTE treatment protocol developed by the PI and study staff.
62144568|NCT02888821|OTHER|Business as Usual (BAU) Waitlist Control|Families will receive school services as usual while on a waitlist to receive CLS-FUERTE in the spring of the 2016-2017 school year.
62144569|NCT05671445|EXPERIMENTAL|CM326|CM326 injection, subcutaneous (SC)
62144570|NCT00089791|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously once every 6 months for 3 years.
62144571|NCT00089791|EXPERIMENTAL|Denosumab 60 mg Q6M|Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
62507886|NCT02725424|EXPERIMENTAL|Her2 Negative with DOS|Docetaxel 60 mg/m2, ivgtt, d1; Oxaliplatin 100 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA \<1.25m2) , 100mg/day (BSA ≥1.25m2, \<1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
62507887|NCT06132152|ACTIVE_COMPARATOR|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
61964985|NCT01218568|ACTIVE_COMPARATOR|lactulose|30-60ml/day
61964986|NCT02634229||Diabetic family members|(i) probands negative for GCK/MODY2 , HNF1A/MODY3 genes and HNF4A/MODY1; (ii) dominant inheritance of diabetes (three consecutive affected generations, or two generations with at least 2 diabetic patients in a generation); (iii) Diagnosis of diabetes before age 40 years in at least 3 diabetic family members; (iv) negative testing for anti-GAD and IA2-antibodies; and (v) body mass index \< 30 kg/m2 (to avoid inclusion of patients with insulin-resistant type 2 diabetes).
61964987|NCT02634229||Healthy relatives|Healthy subjects whose relationship is relevant for genetic analysis and necessary for the validation step (family cosegregation study)
61964988|NCT03556150|EXPERIMENTAL|Manual Therapy protocol|Massages, mobilisation and stretching techniques in the most painful joint
61964989|NCT03556150|ACTIVE_COMPARATOR|Effleurage|Superficial massage in the most painful joint.
61964990|NCT00869453||1|Healthy volunteers
61964991|NCT03630952|EXPERIMENTAL|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
61964992|NCT03630952|EXPERIMENTAL|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
61964993|NCT03630952|ACTIVE_COMPARATOR|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
61964994|NCT03818828|EXPERIMENTAL|TTAX01|TTAX01 will be applied directly to the wound surface and fixed with sterile adhesive strips, plus a secondary foam dressing held in place by multi-layer compression bandaging. A single layer of the test article should cover the entire open surface of the wound. TTAX01 may overlap onto adjacent healthy tissue and must be fenestrated prior to or after fixture. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case product will be withheld; or, if the test article has been accidentally dislodged within 1-week post application, it may be replaced at the subsequent treatment visit.
61964995|NCT02275221||Hepatitis B and C|Hepatitis B and C
61964996|NCT04804878||Biospeciman Repository and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
61964997|NCT01532414|EXPERIMENTAL|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
62144572|NCT06015256|OTHER|Severe uncontrolled asthma in exacerbation|
62144573|NCT06015256|OTHER|Severe uncontrolled asthma excluding exacerbation|
62144574|NCT06015256|OTHER|Severe controlled asthma|
62144575|NCT06015256|OTHER|Healthy volunteers (control group)|
62144576|NCT00728104||1|The General Questionnaire: help to understand which characteristics of CVS patients are associated with both beneficial and harmful effects of these treatments
62144577|NCT00728104||2|The Co-Enzyme Q10 Questionnaire: to be completed by individuals who ever taken co-enzyme Q10
62144578|NCT00728104||3|The L-Carnitine Questionnaire: to be completed by individuals who have ever taken L-carnitine
62705682|NCT04204941|EXPERIMENTAL|Phase 1b: Open-label Tazemetostat and Phase 3: Tazemetostat + Doxorubicin Arm|"Phase 1b: On cycle 1 day -1, participants will receive a single morning dose of tazemetostat at the assigned dose level. Participants will receive doxorubicin 75 mg/m2 intravenously (IV) on day 1 of each cycle for up to 6 cycles.~Tazemetostat will be escalated from a starting dose of 400 mg twice daily PO to 600 mg twice daily PO to 800 mg twice daily.~Phase 3:~Tazemetostat (800 mg) administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
62705683|NCT04204941|PLACEBO_COMPARATOR|Phase 3: Placebo + Doxorubicin Arm|"Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond.~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
62705684|NCT05772520|EXPERIMENTAL|Cohort 2|TLL018 tables, 20 mg 1piece,BID
62705685|NCT05772520|EXPERIMENTAL|Cohort 3|TLL018 tables, 40 mg 1piece,BID
61964998|NCT01532414|EXPERIMENTAL|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
61964999|NCT01532414|PLACEBO_COMPARATOR|Placebo|Placebo oral capsules taken one time daily
61965000|NCT02563444|EXPERIMENTAL|Ultrasound fusion guiding system|
62507888|NCT06132152|ACTIVE_COMPARATOR|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
62507889|NCT05777824|NO_INTERVENTION|low-risk and PCR|Observation
62507890|NCT05777824|EXPERIMENTAL|low-risk and MPR|immunotherapy maintenance
62705686|NCT05772520|EXPERIMENTAL|Cohort 4|placebo, 1piece,BID
62705687|NCT04394858|EXPERIMENTAL|Arm I (temozolomide, olaparib)|Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
62705688|NCT04394858|ACTIVE_COMPARATOR|Arm II (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
62705689|NCT04115163|EXPERIMENTAL|Treatment (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62705690|NCT02625428|EXPERIMENTAL|For Cause|For cause biopsies to evaluate a recent rise in serum creatinine.
62705691|NCT02625428|EXPERIMENTAL|Surveillance|Surveillance biopsies done after transplant mostly looking for subclinical rejection.
62705692|NCT02958865|EXPERIMENTAL|PF-06651600 Drug Dose Level 1|Delivered orally for 8 weeks
62705693|NCT02958865|EXPERIMENTAL|PF-06651600 Drug Dose Level 2|Delivered orally for 8 weeks
62705694|NCT02958865|EXPERIMENTAL|PF-06651600 Drug Dose Level 3|Delivered orally for 8 weeks.
61965001|NCT00837811|EXPERIMENTAL|LY2127399|
61965002|NCT03692442||immunotherapy effective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
61965003|NCT03692442||immunotherapy ineffective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
61965004|NCT03971058|ACTIVE_COMPARATOR|young individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
61965005|NCT03971058|ACTIVE_COMPARATOR|elderly individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
62705695|NCT02958865|PLACEBO_COMPARATOR|PF-06651600 Placebo|Delivered orally for 8 weeks.
61965006|NCT03253497|ACTIVE_COMPARATOR|Chlorhexidine- benzidamine|before 15 minute anesthesia induction Chlorhexidine-benzidamine spray will be administrated to oropharynx
62507891|NCT05777824|EXPERIMENTAL|low-risk and IPR|postoperative radiotherapy (50 Gy) and immunotherapy maintenance
62705696|NCT02958865|EXPERIMENTAL|PF-06700841 Drug Dose Level 1|Delivered orally for 8 weeks
62705697|NCT02958865|EXPERIMENTAL|PF-06700841 Drug Dose Level 2|Delivered orally for 8 weeks.
62705698|NCT02958865|EXPERIMENTAL|PF-06700841 Drug Dose Level 3|Delivered orally for 8 weeks.
62705699|NCT02958865|PLACEBO_COMPARATOR|PF-06700841 Placebo|Delivered orally for 8 weeks.
62705700|NCT02958865|EXPERIMENTAL|PF-06651600 Drug Dose Level 4|Delivered orally for 24 weeks.
62705701|NCT02958865|EXPERIMENTAL|PF-06700841 Drug Dose Level 4|Delivered orally for 24 weeks.
62705702|NCT02415556|EXPERIMENTAL|Type 2 Diabetes Mellitus - Insulin|40 IU of regular human insulin once daily over 24 weeks
62705703|NCT02415556|PLACEBO_COMPARATOR|Type 2 Diabetes Mellitus - Placebo|Intranasal sterile saline once daily over 24 weeks
62705704|NCT02415556|EXPERIMENTAL|Control - Insulin|40 IU of regular human insulin once daily over 24 weeks
62705705|NCT02415556|PLACEBO_COMPARATOR|Control - Placebo|Intranasal sterile saline once daily over 24 weeks
62705706|NCT05199753|EXPERIMENTAL|LM-108 Dose Escalation|
61965007|NCT03253497|NO_INTERVENTION|Control|before 15 minute normal salin will be administrated to oropharynx
61965008|NCT03808493|EXPERIMENTAL|Study 1, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
61965009|NCT03808493|EXPERIMENTAL|Study 1, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
62144579|NCT00728104||4|The Amitriptyline Questionnaire: to be completed by individuals who have ever taken amitriptyline
62705707|NCT05199753|EXPERIMENTAL|LM-108 Dose Expansion|
62705708|NCT05199753|EXPERIMENTAL|LM-108 combination dose escalation|
62705709|NCT05199753|EXPERIMENTAL|LM-108 combination dose expansion|
62705710|NCT05687370|ACTIVE_COMPARATOR|Modified dynamic needle tip positioning technique|In Modified dynamic needle tip positioning technique, short-axis in-plane is used, needle tip was dynamic guided by ultrasound that added two developing lines on the ultrasonic probe.
62705711|NCT05687370|ACTIVE_COMPARATOR|Long-axis in-plane technique|
62705712|NCT05325684|EXPERIMENTAL|PD-L1 rechallenge|
61965010|NCT03808493|EXPERIMENTAL|Study 2, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
61965011|NCT03808493|EXPERIMENTAL|Study 2, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
61965012|NCT01129648|PLACEBO_COMPARATOR|BCX4208 placebo + Allopurinol placebo|Administered daily for 21 days.
61965013|NCT01129648|ACTIVE_COMPARATOR|BCX4208 placebo + Allopurinol 100mg|Administered daily for 21 days.
61965014|NCT01129648|ACTIVE_COMPARATOR|BCX4208 placebo + Allopurinol 200 mg|Administered daily for 21 days.
61965015|NCT01129648|ACTIVE_COMPARATOR|BCX4208 Placebo + Allopurinol 300 mg|Administered daily for 21 days.
61965016|NCT01129648|EXPERIMENTAL|BCX4208 20 mg + Allopurinol Placebo|Administered daily for 21 days.
61965017|NCT01129648|EXPERIMENTAL|BCX4208 20 mg + Allopurinol 100 mg|Administered daily for 21 days.
61965018|NCT01129648|EXPERIMENTAL|BCX4208 20 mg + Allopurinol 200 mg|Administered daily for 21 days.
61965019|NCT01129648|EXPERIMENTAL|BCX4208 20 mg + Allopurinol 300 mg|Administered daily for 21 days.
61965020|NCT01129648|EXPERIMENTAL|BCX4208 40 mg + Allopurinol placebo|Administered daily for 21 days.
61965021|NCT01129648|EXPERIMENTAL|BCX4208 40 mg + Allopurinol 100 mg|Administered daily for 21 days.
61965022|NCT01129648|EXPERIMENTAL|BCX4208 40 mg + Allopurinol 200 mg|Administered daily for 21 days.
61965023|NCT01129648|EXPERIMENTAL|BCX4208 40 mg + Allopurinol 300 mg|Administered daily for 21 days.
61965024|NCT01129648|EXPERIMENTAL|BCX4208 80 mg + Allopurinol Placebo|Administered daily for 21 days.
61965025|NCT01129648|EXPERIMENTAL|BCX4208 80 mg + Allopurinol 100 mg|Administered daily for 21 days.
62705713|NCT02357303|PLACEBO_COMPARATOR|Placebo|Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
62705714|NCT02357303|ACTIVE_COMPARATOR|Simethicone|Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
62705715|NCT02357303|ACTIVE_COMPARATOR|Simethicone plus N-acetylcysteine|Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
61965026|NCT01129648|EXPERIMENTAL|BCX4208 80 mg + Allopurinol 200 mg|Administered daily for 21 days.
61965027|NCT01129648|EXPERIMENTAL|BCX4208 80 mg + Allopurinol 300 mg|Administered daily for 21 days.
61965028|NCT01931124|EXPERIMENTAL|High Intensity Training|training at high intensities ranging from 85-95% of maximal heart rate
61965029|NCT01931124|EXPERIMENTAL|Moderate Intensity Training|training at intensities of 65-75% of maximal heart rate
61965030|NCT04938232|EXPERIMENTAL|Disease Progression after previous therapy|"Participants will receive Ipilimumab alone and depending on response will receive either a maintenance course of Ipilimumab or a course of Nivolumab and Ipilimumab in combination followed by a maintenance course of Ipilimumab. Patients who have progressive disease after fewer than 4 cycles of ipilimumab are also eligible to proceed to combination therapy with nivolumab and ipilimumab, if they are clinically stable.~* Ipilimumab Monotherapy: Every 3 weeks for 4 study cycles~* Complete Response/Partial Response: Maintenance Ipilimumab every 12 weeks for 8 cycles~* Stable or Progressive Disease Response: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles, followed by Maintenance Ipilimumab every 12 weeks for 7 cycles"
61965031|NCT01120678||Neonates assessed for sepsis.|
61965032|NCT00855920|ACTIVE_COMPARATOR|Placebo (for Rilonacept) and Indomethacin|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 with Indomethacin orally thrice a day (TID) for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
61965033|NCT00855920|ACTIVE_COMPARATOR|Rilonacept and Indomethacin|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
62507892|NCT05777824|EXPERIMENTAL|high-risk and PCR|postoperative radiotherapy (50 Gy) and immunotherapy maintenance
62705716|NCT03551093|EXPERIMENTAL|Study Population|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
62705717|NCT05503277|ACTIVE_COMPARATOR|Superglottic airway device LTSD|measuring seal pressure
62705718|NCT05503277|ACTIVE_COMPARATOR|Superglottic airway device i-gel|measuring seal pressure
62705719|NCT04078867||DeVega|The DeVega repair is performed when the patient had minimal annular dilation and lower severity of pulmonary hypertension
62705720|NCT04078867||MC3 ring|MC3 ring annuloplasty is performed in patients with severe tricuspid annular dilation and severe pulmonary hypertension
62705721|NCT03419182|ACTIVE_COMPARATOR|RCT - ORIF|A patient in this study arm consents to randomization and receives RCT - ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation.
61965034|NCT00855920|ACTIVE_COMPARATOR|Rilonacept and Placebo (for Indomethacin)|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Placebo (for Indomethacin) orally TID for 12 days.
61965035|NCT04049396|EXPERIMENTAL|Berberine|Berberine (6.25 g/day)
61965036|NCT04049396|NO_INTERVENTION|Control|No intervention
61965037|NCT03527277|EXPERIMENTAL|Naturally-sweetened orange juice|Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
61965038|NCT03527277|ACTIVE_COMPARATOR|Sugar-sweetened beverage|Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
61965039|NCT02984748||Cochlear Implant Recipients|
61965040|NCT05740644|EXPERIMENTAL|Blood Loss and Saline Infusion|
61965041|NCT02383277|EXPERIMENTAL|Stretching and Exercise|This group undergo a session of stretching aiming flexibility of the rib cage and later at an exercise test with constant load up to the limit of tolerance for exercise bike
61965042|NCT02383277|SHAM_COMPARATOR|Control and Exercise|This group will carry out the exercise test with constant load up to the limit of tolerance for exercise bike after a period of rest under the same environmental conditions and the experimental group time. During this time the therapist will place their hands but not performing the stretch.
61965043|NCT04522362|SHAM_COMPARATOR|Control task-|The Control Task was implemented to ensure the specificity of the psychological stress effects had on study outcomes. Therefore, the Control Task had a similar procedure and the same duration of the TSST, lacking except for only the psychologically stressful component. The control task consisted of (a) Participants had a 5-min a preparation section and anticipation phase (5 min ), (b) a reading task where they had to. Then, all participants had to be read a simple text in a low voice (5 min), and (c) an arithmetic section where they were asked to perform an easy mathematical calculation (5 mins).
61965044|NCT04522362|EXPERIMENTAL|Experimental Task- Trier Social Stress Task|"The Trier Social Stress Task (TSST) is a standardized, 15-minute laboratory task designed to induce psychological stress in laboratory settings (Kirschbaum, Pirke, \& Hellhammer, 1993). The TSST consists of three continuously successive phases: (a) an anticipation period (5 min); (b) a free speech task (5 min); and (c) a mental arithmetic task (5 min). As is standard in the TSST procedure, participants were told by a research staff member that they would provide a brief speech about their dream job in front of a critical audience. At the end of the speech, a member of the audience instructed the participant to conduct serial subtractions as accurately and quickly as possible."
61965045|NCT00484874|EXPERIMENTAL|A Single Dose of I-131 Tositumomab|I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
61965046|NCT03340701|OTHER|Vaginal Progesterone|micronized progesterone vaginal suppository 200mg
61965047|NCT04165447|NO_INTERVENTION|No labeling Control|Arm 1 was the Control condition, which did not display the label on any products.
61965048|NCT04165447|EXPERIMENTAL|Within-category labeling|Arm 2 displayed the label on the 20% of products that were lowest in calories per serving within each product category (termed Within-category Labeling, WC).
61965049|NCT04165447|EXPERIMENTAL|Across-category labeling|Arm 3 displayed the label on the 20% of all products that were lowest in calories per serving (termed Across-category Labeling, AC).
61965050|NCT03089450|EXPERIMENTAL|CGBIO stent (DES)|The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
61965051|NCT03089450|ACTIVE_COMPARATOR|Biomatrix flex(DES)|The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
61965052|NCT00772343|PLACEBO_COMPARATOR|Placebo Vaccine|0.9% Normal saline
61965053|NCT00772343|EXPERIMENTAL|Low dose|Low dose vaccine with adjuvant
61965054|NCT00772343|EXPERIMENTAL|High dose 1|High-dose vaccine with adjuvant
61965055|NCT00772343|EXPERIMENTAL|High dose 2|High-dose vaccine without adjuvant
61965056|NCT03751488|EXPERIMENTAL|LY03010 351mg|LY03010 at 351 mg
61965057|NCT03751488|EXPERIMENTAL|LY03010 156 mg|LY03010 at 156 mg
61965058|NCT03751488|EXPERIMENTAL|LY03010 117mg|LY03010 at 117mg
61965059|NCT03751488|ACTIVE_COMPARATOR|INVEGA SUSTENNA|INVEGA SUSTENNA 156mg
61965060|NCT05545696|SHAM_COMPARATOR|AI on scanning|The lower jaw of the participants was scanned with ''AI on'' scanning in line with recommended scanning protocol, and the IOS software automatically recorded the obtained data.
61965061|NCT05545696|ACTIVE_COMPARATOR|AI off scanning|The lower jaw of the participants was scanned with ''AI off'' scanning in line with recommended scanning protocol, and the IOS software automatically recorded the obtained data.
62349717|NCT00003157|EXPERIMENTAL|radiation + gemcitabine + cisplatin|Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
62349718|NCT04055987|EXPERIMENTAL|Congenitally deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of consonant-vowel-consonant (CVC) combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
62507893|NCT05777824|EXPERIMENTAL|high-risk and MPR|postoperative radiotherapy (60 Gy) and immunotherapy maintenance
61965062|NCT02823431|ACTIVE_COMPARATOR|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
62507894|NCT05777824|EXPERIMENTAL|high-risk and IPR|postoperative concurrent chemoradiotherapy (60 Gy) and immunotherapy maintenance
61965063|NCT02823431|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
61965064|NCT04412720|EXPERIMENTAL|Aerobic and Breathing Exercises|The experimental intervention will be aerobic and breathing exercises.
61965065|NCT04412720|ACTIVE_COMPARATOR|Aerobic and Stretching Exercises|The active comparative intervention will be aerobic and stretching exercises.
61965066|NCT04013334|EXPERIMENTAL|MTG201 plus Nivolumab|Single arm, open-label, patients receive both MTG201 and nivolumab
61965067|NCT04922008|EXPERIMENTAL|IRIS-C|
61965068|NCT04922008|EXPERIMENTAL|IRIS-D|
61965069|NCT01574131|PLACEBO_COMPARATOR|Sugar pill|pill
61965070|NCT01574131|ACTIVE_COMPARATOR|Fenofibrate|ppar-alpha agonist
62705722|NCT03419182|ACTIVE_COMPARATOR|RCT - (THA) + ORIF|A patient in this study arm consents to randomization and receives RCT - (THA) + ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
62705723|NCT03419182|NO_INTERVENTION|OBS - ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation.
62705724|NCT03419182|NO_INTERVENTION|OBS (THA) + ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
62705725|NCT05284643|EXPERIMENTAL|Cohort A: sMRI-Guided RT at 35 Gy in 10 fractions|"Participants will receive a total dose of 3500 centigrays (cGY) (35Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 350 cGy (3.5 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
62705726|NCT05284643|EXPERIMENTAL|Cohort B: sMRI-Guided RT at 40 Gy in 10 fractions|"Participants will receive a total dose of 4000 cGY (40Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 400 cGy (4 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
62705727|NCT02104193|EXPERIMENTAL|simvastatin|they will receive simvastatin in addition to radiation therapy
62705728|NCT02104193|ACTIVE_COMPARATOR|control|they will receive radiation therapy only
62705729|NCT01888016|EXPERIMENTAL|fascial manipulation|
61965071|NCT04231357|EXPERIMENTAL|Platelet rich plasma (PRP)|3 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
61965072|NCT04231357|ACTIVE_COMPARATOR|control|needle tenotomy with lidocaine
61965073|NCT04426968|EXPERIMENTAL|Hepalatide 2.1mg+Pegylated Interferon|"Hepalatide 2.1mg s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
62144580|NCT05827185|EXPERIMENTAL|Ergonomic modifications group (EMG)|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
61965074|NCT04426968|EXPERIMENTAL|Hepalatide 4.2mg+Pegylated Interferon|"Hepalatide 4.2mg s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
61965075|NCT04426968|EXPERIMENTAL|Hepalatide 6.3mg+Pegylated Interferon|"Hepalatide 6.3mg s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
61965076|NCT04426968|ACTIVE_COMPARATOR|placebo+Pegylated Interferon|"Hepalatide placebo s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
61965077|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
61965078|NCT03858114|EXPERIMENTAL|Mild-to-moderate physical activity|Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
61965079|NCT03858114|ACTIVE_COMPARATOR|Cultural group program|Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
61965080|NCT05368688||Cancer-free|Have confirmed colorectal cancer-free and Polyp-free colon using colonoscopy
61965081|NCT05368688||Pre-cancerous|Have benign or precancerous polyps, including tubulovillous or villous adenomas, using colonoscopy
61965082|NCT05368688||Colorectal cancer stage I|"Have confirmed TNM staging of colorectal cancer~The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor.~The N refers to the number of nearby lymph nodes that have cancer. The M refers to whether the cancer has metastasized. This means that the cancer has spread from the primary tumor to other parts of the body."
61965083|NCT05368688||Colorectal cancer stage II|"Have confirmed TNM staging of colorectal cancer~The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor.~The N refers to the number of nearby lymph nodes that have cancer. The M refers to whether the cancer has metastasized. This means that the cancer has spread from the primary tumor to other parts of the body."
61965084|NCT05368688||Colorectal cancer stage III|Have confirmed TNM staging of colorectal cancer
62349719|NCT04055987|EXPERIMENTAL|Adventitiously deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of CVC combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
62705730|NCT01888016|ACTIVE_COMPARATOR|standard treatment|
62507895|NCT03965728|EXPERIMENTAL|BAY1830839 arm|Period 1: Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, single dose. Period 2: Dose 1, Dose 2 and Dose 3, once daily over 10 days. Dose 4 and Dose 5, twice daily over 10 days. Dose 6, single dose on Day 1, three times daily (TID) for 9 days (Days 2-10).
62507896|NCT03965728|PLACEBO_COMPARATOR|Placebo arm|Placebo tablets matching BAY1830839
62507897|NCT04094740|EXPERIMENTAL|Needle-free Jet Injector|Subjects will be instructed to use a needle-free syringe to inject insulin during the study period. The dosage and frequency of insulin are determined by the responsible physician according to the patient's condition.
62507898|NCT04094740|NO_INTERVENTION|Conventional Insulin Pen|Patients allocated to the control group will be instructed to use conventional insulin pens to inject insulin. Except for the syringe, all of them are the same as the experimental group.
62507899|NCT04094740|NO_INTERVENTION|Routine Care|Subjects can receive the education provided by health-care professionals and training in the outpatient department and inpatient departments.
62507900|NCT04500132|EXPERIMENTAL|EC-18 Arm|EC-18 QD
62507901|NCT04500132|PLACEBO_COMPARATOR|Placebo Arm|Placebo EC-18 QD
62507902|NCT04936919|EXPERIMENTAL|Treatment Arm|Subjects in the treatment arm will receive broadband light treatment
62507903|NCT01884402||Pegasys, injection subcutaneous|HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin
62507904|NCT01813071|EXPERIMENTAL|Part A (Adults): Cohort A1|One oral dose of \~3x10\^4 cfu WRSS1(10 participants) or placebo (3 participants)
61965085|NCT04921371|OTHER|Healthy Reference Group|Participants who are identified as healthy will be a comparison group. This group will participate in the examinations and plaque sampling only and will not receive a prophylaxis or product.
62144581|NCT05827185|EXPERIMENTAL|Physiotherapy group (PTG)|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. If any participant reported any new red flag signs or showed no signs for manipulation, such as no pain or musculoskeletal dysfunction, then the procedure was not performed.
62507905|NCT01813071|EXPERIMENTAL|Part A (Adults): Cohort A2|Three oral doses of \~3x10\^5 cfu WRSS1(10 participants) or placebo (3 participants)
62507906|NCT01813071|EXPERIMENTAL|Part A (Adults): Cohort A3|Three oral doses of \~3x10\^6 cfu WRSS1(10 participants) or placebo (3 participants)
62507907|NCT01813071|EXPERIMENTAL|Part B (Children): Cohort B1|One oral dose of \~3x10\^3 cfu WRSS1(12 participants) or placebo (4 participants)
62507908|NCT01813071|EXPERIMENTAL|Part B (Children): Cohort B2|Three oral doses of \~3x10\^4 cfu WRSS1(12 participants) or placebo (4 participants)
62507909|NCT01813071|EXPERIMENTAL|Part B (Children): Cohort B3|Three oral doses of \~3x10\^5 cfu WRSS1(12 participants) or placebo (4 participants)
62507910|NCT01813071|EXPERIMENTAL|Part B (Children): Cohort B4|Three oral doses of \~3x10\^6 cfu WRSS1(12 participants) or placebo (4 participants)
62507911|NCT01935479|EXPERIMENTAL|AK159 SD 1|Single administration of AK159 dose level 1
62507912|NCT01935479|EXPERIMENTAL|AK159 SD 2|Single administration of AK159 dose level 2
61965086|NCT04921371|EXPERIMENTAL|5% Hydroalcohol Mouthrinse (Negative control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 milliliter (mL) of 5 percent (%) Hydroalcohol Mouthrinse twice daily (morning and evening) up to 6 weeks.
61965087|NCT04921371|EXPERIMENTAL|Listerine® Cool Mint® (Positive control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept curve winter series Toothbrush will rinse mouth for 30 seconds with 20 mL of Listerine® Cool Mint® twice daily (morning and evening) up to 6 weeks.
62507913|NCT01935479|EXPERIMENTAL|AK159 SD 3|Single administration of AK159 dose level 3
62507914|NCT01935479|EXPERIMENTAL|AK159 SD 4|Single administration of AK159 dose level 4
62507915|NCT01935479|ACTIVE_COMPARATOR|MN-10-T SD|Single administration of teriparatide acetate
62507916|NCT01935479|EXPERIMENTAL|AK159 MD 1|Multiple administration of AK159 dose level 1
62507917|NCT01935479|EXPERIMENTAL|AK159 MD 2|Multiple administration of AK159 dose level 2
62507918|NCT01935479|EXPERIMENTAL|AK159 MD 3|Multiple administration of AK159 dose level 3
62507919|NCT01935479|EXPERIMENTAL|AK159 MD 4|Multiple administration of AK159 dose level 4
61965088|NCT04921371|EXPERIMENTAL|Mouthrinse Prototype 1|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 1 twice daily (morning and evening) up to 6 weeks.
61965089|NCT04921371|EXPERIMENTAL|Mouthrinse Prototype 2|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 2 twice daily (morning and evening) up to 6 weeks.
61965090|NCT03571815|EXPERIMENTAL|fluoride varnish application|intervention; fluoride varnish application (with 5% Sodium fluoride varnish application on teeth)
62507920|NCT01935479|ACTIVE_COMPARATOR|MN-10-T MD|Multiple administration of MN-10-T
62507921|NCT01935479|PLACEBO_COMPARATOR|Placebo MD|Multiple administration of placebo AK159
62507922|NCT03766217|EXPERIMENTAL|Mesenchymal stem cells associated with biomaterials|Mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials. The stem cells will be obtained by enzimatic digestion in GMP laboratory and will be seed into the biomaterial (hydroxyapatite/collagen).
62507923|NCT03766217|ACTIVE_COMPARATOR|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest. The prepare of the receptor area will be the same in both arms and will follow current recommendations.
62507924|NCT02996019|EXPERIMENTAL|Part 1: Etrolizumab AI|Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
62507925|NCT02996019|ACTIVE_COMPARATOR|Part 1: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
62507926|NCT02996019|EXPERIMENTAL|Part 2: Etrolizumab AI|Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
62507927|NCT02996019|ACTIVE_COMPARATOR|Part 2: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
62507928|NCT03979833||1|Individuals currently living, over the age of 18 years and known carriers of a pathogenic variant in the VHL gene.
62705731|NCT03795142|EXPERIMENTAL|single intravenous dose; BGB149|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
62705732|NCT03795142|PLACEBO_COMPARATOR|single intravenous dose; placebo|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
61965091|NCT03571815|PLACEBO_COMPARATOR|control group|application of water on teeth in the control group
61965092|NCT04974385|EXPERIMENTAL|Liposomal Bupivacaine|Experimental group will receive ISNB with admixed LB (10 mL) and 0.5% bupivacaine (10 mL) total of 20 mL.
61965093|NCT04974385|ACTIVE_COMPARATOR|Non-liposomal Bupivacaine|Comparator group will receive ISNB with 20 mL of 0.5% non-liposomal bupivacaine
61965094|NCT02720991|EXPERIMENTAL|Mifepristone and sublingual misoprostol|200 mg mifepristone and 400 ug sublingual misoprostol
61965095|NCT03495362|EXPERIMENTAL|Intervention group|"Ingredients: yeast beta-glucan, and capsule shell Capsule, per capsule with 500mg insoluble beta-glucan, twice a day, 1 capsule each time.~The intervention period is about 3 months."
61965096|NCT03495362|PLACEBO_COMPARATOR|Placebo group|Ingredients: starch, and capsule shell Capsule, per capsule with 500mg starch, twice a day, 1 capsule each time. The intervention period is about 3 months.
62705733|NCT06639178|EXPERIMENTAL|DECLARAN cream|Patients will apply of DECLARAN cream is the investigational product based on NAC and urea
62705734|NCT04169763|EXPERIMENTAL|Treatment (nelfinavir, cisplatin, EBRT)|Patients receive nelfinavir PO BID for up to 8 weeks. Starting week 2, patients also receive cisplatin IV over 60-90 minutes once weekly during weeks 2-8. Patients undergo EBRT for 5 consecutive days between weeks 2-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
61965097|NCT04775875|EXPERIMENTAL|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the caudate. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
61965098|NCT05516602|EXPERIMENTAL|Peer Support|Standard health worker counselling during clinic visits plus peer support over the weekends.
61965099|NCT05516602|NO_INTERVENTION|Standard|Standard health worker counselling during clinic visits.
61965100|NCT05004766|EXPERIMENTAL|virtual reality apply|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
61965101|NCT05004766|NO_INTERVENTION|control condition|Each patient participated in the control condition, during which he or she performed RAGT with no distraction for the same amount of time spent doing therapy in VR.
61965102|NCT06140784|SHAM_COMPARATOR|0.76% Sodium Monofluorophosphate Dentifrice|
61965103|NCT06140784|ACTIVE_COMPARATOR|Marketed 0.454% Stannous Fluoride plus Arginine Dentifrice|
61965104|NCT06140784|ACTIVE_COMPARATOR|Marketed 0.454% Stannous Fluoride Dentifrice|
61965105|NCT06140784|ACTIVE_COMPARATOR|0.454% Stannous Fluoride Dentifrice|
61965106|NCT05989984|EXPERIMENTAL|ODF Iron Supplement|ODF iron supplement contains 30 mg of elemental iron (corresponding to 120 mg of ferric pyrophosphate) and 400 μg of folic acid.
61965107|NCT05989984|ACTIVE_COMPARATOR|Iron Supplement in Capsule|Iron supplement in capsule contains 30 mg of elemental iron (corresponding to 120 mg of ferric pyrophosphate) and 70 mg of vitamin C.
61965108|NCT04343261|EXPERIMENTAL|COVID-19 patients treated with convalescent plasma|Severely ill COVID-19 patients treated with convalescent plasma
61965109|NCT04416178||Parents of children with SCD|Parent of child with HbSS, HbS/ β0thalassemia, or HbSC aged 12 months to 18 years at study initiation
61965110|NCT04416178||Adolescents with SCD|Patient aged 13-18 with HbSS, HbS/ β0thalassemia, or HbSC
62705735|NCT00856557|EXPERIMENTAL|Seminar and Practicum|Seminar and practicum that occurs over 4 week period for internal medicine residents, designed to provide a systematic approach to identifying and addressing contextual factors essential to planning patient care.
61965111|NCT00806390|ACTIVE_COMPARATOR|Metoprolol|Receiving metoprolol
61965112|NCT00806390|NO_INTERVENTION|Control|Not receiving metoprolol
61965113|NCT01216306|EXPERIMENTAL|Television reduction curriculum|Students are taught the television reduction curriculum during the school day and parents are invited to attend after-school meetings to discuss reducing their children's television viewing.
61965114|NCT01216306|NO_INTERVENTION|Control|Students will be taught the standard preschool curriculum.
62507929|NCT03677219|NO_INTERVENTION|Control|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, and do not view an educational video.
62507930|NCT03677219|EXPERIMENTAL|Video|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, then view a 2 minute educational video and respond to a second survey.
62507931|NCT05235425|ACTIVE_COMPARATOR|Standard NDPP|12-month long, calorie-restricted NDPP
62507932|NCT05235425|EXPERIMENTAL|Very low-carbohydrate diet (VLCD)|VLCD is an adaptation of the standard NDPP curriculum, which preserves all features with the exception of altered dietary advice.
62705736|NCT00856557|NO_INTERVENTION|No intervention|No educational intervention.
62705737|NCT02216526|EXPERIMENTAL|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
61976132|NCT05395806|ACTIVE_COMPARATOR|Usual Care|This group will not have access to the gamified App and will receive their usual care at the primary care clinic. In addition, they will receive extra information on cardiovascular risk factors control. Both groups will have the same access to clinical checks and medications at the clinic.
62705738|NCT02216526|EXPERIMENTAL|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
62349720|NCT03173612|EXPERIMENTAL|AML-CAMS-2016 trial|AML-CAMS-2016 regimen includes risk-stratified therapy and the use of Dasatinib in CBF-AML.The induction regimen includes MAE (etoposide 150mg/㎡/d d1-5, cytarabine 200mg/㎡/d d6-12 , mitoxantrone 5 mg/㎡/d d6-10), CAG (aclacinomycin 6mg/㎡/d d1-8, Ara-C 10mg/㎡ q12h d1-14 , G-CSF 200ug/㎡/d d1-14),IAE (idarubicin 8 mg/㎡/d d1-3, Ara-C 500mg/㎡/d d1-3 d8-10, VP-16 200mg/㎡/d d8-10).Consolidation regimen includes IA (Ara-C 1g/㎡ q12h d1-4, IDA 10mg/㎡/d d1), MA (Ara-C 1g/㎡ q12h d1-4, MTZ 5mg/㎡/d d1-3), IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5), MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6). Dasatinib (60-80mg/㎡) is used in CBF-AML as a part of consolidation therapy.
62349721|NCT04565600|EXPERIMENTAL|Etoricoxib|Prophylactic etoricoxib (60 mg) was administered orally at each course of docetaxel-containing chemotherapy, which started from the day of chemotherapy and was performed once per day for 8 days (day 1-8).
62705739|NCT02216526|NO_INTERVENTION|Standard skin care|Usual skin care routine of the nursing home resident
62705740|NCT04547556|EXPERIMENTAL|Intervention|Diagnostic intervention
62349722|NCT04565600|NO_INTERVENTION|Control|No prophylactic regimen was given.
62349723|NCT04863937|EXPERIMENTAL|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
62705741|NCT04547556|NO_INTERVENTION|Standard of Care|Standard of care testing
62705742|NCT03643081|EXPERIMENTAL|"use of camera Fluobeam"|
62705743|NCT03643081|NO_INTERVENTION|"Without use of the camera Fluobeam"|
62705744|NCT05493410|EXPERIMENTAL|TREATMENT GROUP (TG)|Pulmonary rehabilitation protocol consisting of muscle strengthening, aerobic training, and IMT using the POWERbreathe Classic Medic® device - será comparado with the CONTROL GROUP (CG), which will not undergo IMT.
62705745|NCT05493410|ACTIVE_COMPARATOR|CONTROL GROUP (CG)|Pulmonary rehabilitation protocol consisting of muscle strengthening and aerobic training.
62705746|NCT05533840||Age under 18|Participants under the age of 18
62705747|NCT05533840||Age 18-30|Participants aged 18-30
62705748|NCT05533840||Age 31-40|Participants aged 31-40
62705749|NCT05533840||Age 41-50|Participants aged 41-50
62705750|NCT05533840||Age 51-60|Participants aged 51-60
62349724|NCT01303432|EXPERIMENTAL|Mobilee yogurt|Subjects eating daily on yogurt supplemented with Mobilee
62349725|NCT01303432|PLACEBO_COMPARATOR|Placebo yogurt|Subjects receiving daily a standard yogurt
62349726|NCT00387270|EXPERIMENTAL|A|Dimebon
62349727|NCT04367441|EXPERIMENTAL|608|8mg, 20mg, 40mg, 80mg, 120mg, 160mg, 200mg
62705751|NCT05533840||Age ≥61|Participants aged ≥61
62705752|NCT04474132|OTHER|single group|binary: positive or negative result
62705753|NCT03213067||Mitochondrial Disease Patients|"* Male and Females \>18 years at the time of screening~* Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A\>G mutation.~* Capacity to provide informed consent taken before any study related activities.~* Ability and willingness to adhere to the protocol, including all appointments.~* Ability to read and converse in English."
62705754|NCT03213067||Healthy Control Group|"* Male and Females \>18 years at the time of screening~* Capacity to provide informed consent taken before any study related activities.~* Ability and willingness to adhere to the protocol, including all appointments.~* Ability to read and converse in English."
62705755|NCT02164110|EXPERIMENTAL|Euvichol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
62705756|NCT02164110|ACTIVE_COMPARATOR|Shanchol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
62349728|NCT04367441|PLACEBO_COMPARATOR|Placebo|20mg, 40mg, 80mg, 120mg, 160mg, 200mg
62349729|NCT03852914|EXPERIMENTAL|Experimental: Sodium Hyaluronate 2%|Each patient will receive a single injection of SH2%
62705757|NCT02339051|EXPERIMENTAL|One leg jumping|Study subjects will jump on one leg on repeated occasions (incremental daily repetitions) for a period of three months. The same leg will be used for jumping throughout the study. The other leg will serve as control.
62705758|NCT02867137||Mild TBI patients|
62705759|NCT02308514|ACTIVE_COMPARATOR|conservative care|this group of patients will receive the conservative care: myofascial point release and radial head mobilisation
62705760|NCT02308514|EXPERIMENTAL|cryostimulation|this group of patients will receive the conservative care :myofascial point release and radial haed mobilisation and the cryostimulation (30-40 second of cold air application (-70 celsius degree) in order to lower skin temperature around the lateral epicondyle at 4 celsius degree.
62705761|NCT04183348|EXPERIMENTAL|Group A|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
62349730|NCT00884715|EXPERIMENTAL|1 implant|117 mg Octreotide implant
62349731|NCT00884715|EXPERIMENTAL|2 implants|234 mg Octreotide implant
62349732|NCT02463136|EXPERIMENTAL|Behaviour and brain training|fMRI-based neurofeedback
62349733|NCT01541267|ACTIVE_COMPARATOR|C - A - B|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
62349734|NCT01541267|ACTIVE_COMPARATOR|B - A - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
62705762|NCT04183348|EXPERIMENTAL|Group B|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
62705763|NCT03849261|EXPERIMENTAL|Group 1|"* Period 1: D635~* Period 2: CKD-387"
62705764|NCT03849261|EXPERIMENTAL|Group 2|"* Period 1: CKD-387~* Period 2: D635"
61976133|NCT02190357|EXPERIMENTAL|rifaximin|400 mg bid,orally
61976134|NCT02190357|NO_INTERVENTION|controlled group|no intervention
61976135|NCT02818322|EXPERIMENTAL|telemedical monitoring ( T)|Home care by a nurse trained in the management of diabetic foot lesions with transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion every week
61965115|NCT02860013|ACTIVE_COMPARATOR|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling heart failure in general. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
61965116|NCT02860013|NO_INTERVENTION|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with heart failure are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). Heart failure patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing heart failure. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in heart failure and definitely not on call
61965117|NCT00692081|EXPERIMENTAL|A|8 group sessions social competence training (CBT)
61965118|NCT00692081|ACTIVE_COMPARATOR|B|special vocational training as usual
61965119|NCT05614830|EXPERIMENTAL|Intervention group|
61965120|NCT05614830|ACTIVE_COMPARATOR|Control group|Usual physical therapy protocol 4 sessions, two sessions per week each session will include a group of therapeutic exercises
61965121|NCT01801891|ACTIVE_COMPARATOR|Control group|Patients randomised to the control group will, in addition to their routine compression bandaging, be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The stimulators given to the control group will be set to provide minimal stimulation resulting in no visible muscular contraction.
61965122|NCT01801891|EXPERIMENTAL|VASGARD stimulator|Patients randomised to this group, in addition to their routine treatment with compression bandaging, will be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The intervention group stimulators will be capable of causing muscular contraction with a maximum force ranging from 30-40% of voluntary contractions.
61965123|NCT06201377|EXPERIMENTAL|Suture with chlorhexidine|At the end of the surgical procedure, the flap will be sutured with an absorbable suture coated with chlorhexidine diacetate (NOVOSYN CHLORHEXIDINE)
61965124|NCT06201377|ACTIVE_COMPARATOR|Suture without chlorhexidine|At the end of the surgical procedure, the flap will be sutured with an absorbable suture coated without chlorhexidine diacetate (NOVOSYN)
61965125|NCT02927431|EXPERIMENTAL|Danirixin 15 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
61965126|NCT02927431|EXPERIMENTAL|Danirixin 50 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
61965127|NCT02927431|PLACEBO_COMPARATOR|Placebo of danirixin IV plus 75 mg oseltamivir|Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
61965128|NCT00813735|EXPERIMENTAL|Eszopiclone|Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg
61965129|NCT00813735|PLACEBO_COMPARATOR|Placebo|Drug: Placebo, Drug: Escitalopram 10mg or 20mg
62144582|NCT05827185|EXPERIMENTAL|Ergonomic modifications combined with physiotherapy group (EPG)|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. If any participant reported any new red flag signs or showed no signs for manipulation, such as no pain or musculoskeletal dysfunction, then the procedure was not performed."
62349735|NCT01541267|ACTIVE_COMPARATOR|A - B - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
62705765|NCT06042946||iscm_resection|-Adult patients admitted to one of the participating centres and treated for ISCM between 2017 and 2023 by resection of the ISCM with or without adjuvant radiotherapy
62705766|NCT06042946||iscm_radiotherapy|-Adult patients admitted to one of the participating centres and treated for ISCM between 2017 and 2023 by radiotherapy without resection of the ISCM
61965130|NCT00281255|EXPERIMENTAL|allopurinol|
61965131|NCT00281255|PLACEBO_COMPARATOR|placebo|
61965132|NCT03849898||Mandibular Fracture|"Elderly patients of \> 60 years who present a mandibular fracture~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice"
61965133|NCT01385215|PLACEBO_COMPARATOR|Placebo|
62349736|NCT01839201|ACTIVE_COMPARATOR|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
61965134|NCT01385215|PLACEBO_COMPARATOR|Nasal Aerosol Immunization|
61965135|NCT01385215|PLACEBO_COMPARATOR|Nasal Droplet Immunization|
61965136|NCT01385215|PLACEBO_COMPARATOR|Intramuscular Immunization|
61976136|NCT02818322|ACTIVE_COMPARATOR|classic monitoring|Home care by a nurse trained in the management of diabetic foot lesions without transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion
62349737|NCT01839201|ACTIVE_COMPARATOR|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
62349738|NCT01839201|ACTIVE_COMPARATOR|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
62507933|NCT00785096||Patients|Patients who admit for a minor or major surgical intervention
62507934|NCT00785096||Nurses|Medical staff of the University Hospital of Zurich
62705767|NCT03728335|EXPERIMENTAL|Treatment (enasidenib mesylate)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62507935|NCT00785096||Physicians|Medical staff of the University Hospital of Zurich and other institutions
61965137|NCT00309569|EXPERIMENTAL|A (pre- + postoperative chemotherapy)|3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil) followed by surgery. Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
61965138|NCT00309569|EXPERIMENTAL|B (conventional postoperative chemotherapy)|Surgery followed by 3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil). Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
61965139|NCT05927493||Upper gastrointestinal bleeding|Patients with upper gastrointestinal bleeding hospitalized after ED visit
61965140|NCT03100032|EXPERIMENTAL|NVD-001|Autologous osteogenic cells in ECM with DBM
62507936|NCT05110131|ACTIVE_COMPARATOR|Needle-first|Participants affiliated to this arm will undergo ENB-guided biopsy with needle aspiration first, followed by forceps biopsy
62507937|NCT05110131|ACTIVE_COMPARATOR|Forceps-first|Participants affiliated to this arm will undergo ENB-guided biopsy with forceps first, followed by needle aspiration.
62507938|NCT04529395|EXPERIMENTAL|Aromatherapy group|
62507939|NCT04529395|ACTIVE_COMPARATOR|Control group|
61965141|NCT03100032|ACTIVE_COMPARATOR|Standard of Care|Best standard of care in surgical practice
61965142|NCT01115634|EXPERIMENTAL|Fibroblast|Injection of autologous cultured fibroblast
61965143|NCT03911804|EXPERIMENTAL|Bolus group|
61965144|NCT03911804|ACTIVE_COMPARATOR|Infusion group|
61965145|NCT01880840|ACTIVE_COMPARATOR|Astepro 0.15% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
62349739|NCT00434499|ACTIVE_COMPARATOR|placebo first|placebo first then crossover to EGCG
61965146|NCT01880840|ACTIVE_COMPARATOR|Astepro 0.1% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
61976137|NCT05251909|EXPERIMENTAL|Benralizumab|This arm is a subcutaneous dose of Benralizumab
62349740|NCT00434499|ACTIVE_COMPARATOR|EGCG first|EGCG first then crossover to placebo
62349741|NCT03865459|EXPERIMENTAL|Video group|The video group watched relaxing video with a ceiling mounted television during the whole cystoscopy.
62349742|NCT03865459|NO_INTERVENTION|Control group|The control group received the standard treatment from a surgical technician who works in the cystoscopy during the whole procedure.The control group didn't watch relaxing video during the procedure.
62349743|NCT05164679|EXPERIMENTAL|MMT|Intervention group performing multimodal training (MMT) 1-2 hours weekly
62349744|NCT05164679|NO_INTERVENTION|CON|Sedentary control group
62349745|NCT02005224|OTHER|LCHF diet and a bout of exercise|LCHF diet for 3 weeks, where E% 70 fat, E% 20-25 proteins and 20g or less carbohydrates. Oral glucose tolerance test on the morning of day 21 followed by a bout of exercise in the afternoon (indoor bicycle, 60min at 75% HFpeak). The following morning (day 22) a new oral glucose tolerance test. Oral glucose tolerance test results from pre-tests used to determine the effect of LCHF and a bout of exercise on insulin sensitivity.
62349746|NCT02410096|ACTIVE_COMPARATOR|Oil supplementation verum|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach ones daily 1190 mg of middle-chain and polyunsaturated fatty acids for four weeks. Before and after supplementation an exercise challenge in a cold chamber will be performed.
62349747|NCT02410096|PLACEBO_COMPARATOR|Oil supplementation placebo|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach placebo for four weeks. Before and after placebo treatment an exercise challenge in a cold chamber will be performed.
62349748|NCT00861679|OTHER|HSCT from matched family or unrelated donors(MD)|HSCT from matched family or unrelated donors(MD) to matched related donors.
62349749|NCT02483689|PLACEBO_COMPARATOR|Saline|Patient will be given saline with a maximum of 30 cc either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
62349750|NCT02483689|EXPERIMENTAL|Local|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
62349751|NCT05565976|EXPERIMENTAL|Dapagliflozin|10mg PO q24h for 12 months plus standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.
62349752|NCT05565976|ACTIVE_COMPARATOR|Standard treatment|Standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.
62349753|NCT02535078|EXPERIMENTAL|Phase 2: Tebentafusp SC Monotherapy|Tebentafusp (IMCgp100) (single agent) subcutaneous (SC) injection
62349754|NCT03450915|EXPERIMENTAL|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
62349755|NCT03450915|PLACEBO_COMPARATOR|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
62349756|NCT03116308|EXPERIMENTAL|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
62349757|NCT02098460|PLACEBO_COMPARATOR|Probucol,Cilostazol|Atorvastatin + Probucol-placebo + Cilostazol-placebo
62349758|NCT02098460|PLACEBO_COMPARATOR|Cilostazol|Atorvastatin + Probucol+ Cilostazol-placebo
62349759|NCT02098460|ACTIVE_COMPARATOR|Probucol, Cilostazol|Atorvastatin + Probucol + Cilostazol
62349760|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
62349761|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
62349762|NCT04065191|EXPERIMENTAL|High-intensity interval training|High-intensity interval training
62349763|NCT00634335||sk|professional Israeli bicyclists
62349764|NCT04529421||Students, Higher Education Institution 1|All first, second, and third year students at Higher Education Institution 1 who agree to take part in study.
62349765|NCT04529421||Students, Higher Education Institution 2|All first, second, and third year students at Higher Education Institution 2 who agree to take part in study.
62507940|NCT00699530||Hyperprolactinemia|Patients recently diagnosed with hyperprolactinemia
62349766|NCT04529421||Students, Higher Education Institution 3|All first, second, and third year students at Higher Education Institution 3 who agree to take part in study.
61965147|NCT00599924|EXPERIMENTAL|Single arm|"SU011248 \[sunitinib\] in combination with FOLFOX; FOLFOX is a chemotherapy regimen that combines oxaliplatin and leucovorin with bolus and infusion 5-FU. The modified FOLFOX 6 (mFOLFOX6) regimen is one of several different regimens of FOLFOX used in clinic, according to different dosages of the 4 drugs. mFOLFOX6 was administered every 2 weeks on Days 1 and 2 of each cycle.~25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in three different dosing regimens: schedule 2/2 (2 weeks on, 2 weeks off), schedule 4/2 (4 weeks on, 2 weeks off), and continuous daily dosing (every day); FOLFOX will be administered every 2 weeks, using the modified FOLFOX 6 (mFOLFOX6) regimen, consisting of: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 as a 2-hr IV infusion; 5-FU 400 mg/m2 IV bolus, followed by - 5-FU 2400 mg/m2 as a 46-hr IV infusion"
61965148|NCT01464099|ACTIVE_COMPARATOR|Insulin aspart 100U/mL|
61965149|NCT01464099|EXPERIMENTAL|Insulin aspart 200U/mL|
61965150|NCT00533195|ACTIVE_COMPARATOR|0|5-MOP photochemotherapy. Intake of Geralen capsules (1.2 mg/kg) 2 hours before irradiation. Determination of the minimal phototoxic dose (MPD) and Geralen serum level prior to treatment. Start with 70 % of the MPD, no dose increments in the first treatment week. From the second week increments of the UVA dose by 20 % in the absence of an erythemal reaction, respectively by 10 % in cases of a barely perceptible erythemal response. Increments of the UVA dose at the earliest 96 hours after the last increments. Treatment frequency 3 x week for 5 weeks (=15 exposures). No maintenance therapy except emollients.
61965151|NCT00533195|EXPERIMENTAL|1|UVA1 phototherapy. Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability. No maintenance therapy except emollients.
62349767|NCT04529421||Students, Higher Education Institution 4|All first, second, and third year students at Higher Education Institution 4 who agree to take part in study.
62349768|NCT04529421||Students, Higher Education Institution 5|All first, second, and third year students atHigher Education Institution 5 who agree to take part in study.
62349769|NCT04529421||Students, Higher Education Institution 6|All first, second, and third year students at Higher Education Institution 6 who agree to take part in study.
62349770|NCT04529421||Students, Higher Education Institution 7|All first, second, and third year students at Higher Education Institution 7 who agree to take part in study.
62349771|NCT04529421||Students, Higher Education Institution 8|All first, second, and third year students at Higher Education Institution 8 who agree to take part in study.
62349772|NCT04529421||Students, Higher Education Institution 9|All first, second, and third year students at Higher Education Institution 9 who agree to take part in study.
62349773|NCT04529421||Students, Higher Education Institution 10|All first, second, and third year students at Higher Education Institution 10 who agree to take part in study.
62349774|NCT04529421||Students, Higher Education Institution 11|All first, second, and third year students at Higher Education Institution 11 who agree to take part in study.
62349775|NCT04529421||Students, Higher Education Institution 12|All first, second, and third year students at Higher Education Institution 12 who agree to take part in study.
62349776|NCT04529421||Students, Higher Education Institution 13|All first, second, and third year students at Higher Education Institution 13 who agree to take part in study.
62349777|NCT04529421||Students, Higher Education Institution 14|All first, second, and third year students at Higer Education Institution 14 who agree to take part in the study.
62349778|NCT00022152|EXPERIMENTAL|vinorelbine|"Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and then after completion of the second course.~Patients are followed every 3 months for 5 years."
62349779|NCT02199613|EXPERIMENTAL|Treatment simplification|Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food
62349780|NCT06446206|EXPERIMENTAL|Experimental arm|
62349781|NCT04015440|EXPERIMENTAL|HBMT|
62349782|NCT04015440|PLACEBO_COMPARATOR|Placebo|
62349783|NCT02781350|PLACEBO_COMPARATOR|High fat high carbohydrate (HFHC) meal|Subjects will consume a HFHC meal. HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
62349784|NCT02781350|EXPERIMENTAL|HFHC meal plus Fiber|HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). Subjects will also receive FiberOne Original cereal 14 grams (half cup) before and after the HFHC meal. 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
62349785|NCT02288611|PLACEBO_COMPARATOR|Maltodextrin/Dextrose mix|"Twenty-two healthy human individuals were randomly assigned to consume a control (maltodextrin-dextrose, 40.2g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.~P.S. placebo is called control in this study, where the bioactive comparator is a fruit."
62349786|NCT02288611|ACTIVE_COMPARATOR|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume date fruits (approx. 50g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
62349787|NCT04948463|EXPERIMENTAL|Early Stopping|Stopping empiric FN antibiotics after resolution of fever for 48 hours, irrespective of absolute neutrophil count (ANC)
62349788|NCT04948463|ACTIVE_COMPARATOR|Standard of care|Continuing empiric FN antibiotics until resolution of fever for 48 hours and recovery of ANC as defined by the treating clinician but usually to ≥200-500/mm3
62507941|NCT05556226|EXPERIMENTAL|ABBV-154 Dose A|Participants will receive subcutaneous dose of ABBV-154 Dose Formulation A.
62507942|NCT05556226|EXPERIMENTAL|ABBV-154 Dose B|Participants will receive subcutaneous dose of ABBV-154 Dose Formulation B.
62507943|NCT03404401|EXPERIMENTAL|BLI4700 Bowel Preparation|
61965152|NCT01500694|EXPERIMENTAL|Extended-release Guanfacine HCl|
61965153|NCT02664753|EXPERIMENTAL|L-Carnitine group|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Intervention: 56 days of weight-adjusted L-Carnitine treatment"
61965154|NCT02664753|PLACEBO_COMPARATOR|Placebo then open group|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Intervention: 10 days of intravenous placebo (isotonic saline)"
61965155|NCT00062374|EXPERIMENTAL|Treatment (preoperative chemotherapy)|"Neoadjuvant chemotherapy: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1, 8, 22, and 29. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Within 4 weeks after completion of neoadjuvant chemotherapy, patients undergo radical subtotal or total gastrectomy with lymph node dissection."
61965156|NCT04429139|EXPERIMENTAL|PDT treatment group|All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.
61965157|NCT04512404||hypercholesterolemia|"3-hydroxy-3-methylglutaric acid coenzyme A (HMG Co-A) reductase inhibitor Types of drug, dosage and frequency is according to the treating physician. This is an observational study.~Duration of treatment: 3-5 months"
61965158|NCT01288066|OTHER|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system.
61965159|NCT01288066|OTHER|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system.
61965160|NCT01803204|EXPERIMENTAL|Booklet - Preoperative Educational|This group received the booklet in the preoperative consult, they will monitoring during the postoperative phase
62144583|NCT05827185|SHAM_COMPARATOR|Control group (CNG)|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
62144584|NCT06140875|EXPERIMENTAL|Experimental|"Radiochemotherapy (RCT) and maintenance chemotherapy (CT) according to Stupp et al. 2005 combined with radiofrequency electromagnetic field treatment.~The standard therapy involves gross- or subtotal tumor resection if feasible (alternatively biopsy only) followed by RCT (60 Gy over six weeks) with concomitant CT (temozolomide 75mg/m2) on all days, followed by maintenance CT (temozolomide150-200 mg/m2) on d1-5 for six cycles every 28 days.~The trial intervention includes radiofrequency electromagnetic field treatment for 60 minutes three times a week during RCT and twice a week during d1-5 of maintenance CT, resulting in a total number of 30 radiofrequency electromagnetic field treatment therapy sessions."
62507944|NCT03404401|ACTIVE_COMPARATOR|FDA Approved Bowel Preparation|
62507945|NCT04012073|EXPERIMENTAL|IPERPEEP|"End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial.~PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O.~In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting.~* RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP.~* RI\<0.5 will lead to the setting of the lower PEEP value.~* In case of RI≥0.5 and \<1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics."
62144585|NCT03868878|EXPERIMENTAL|Capoeira training group|The experimental protocol for Capoeira program lasted 12 weeks and was performed twice a week with duration of 60 minutes each with warm-up, basic movements in the modality, and 20 minutes with theoretical instructions related to Capoeira and musicality.
62144586|NCT03868878|SHAM_COMPARATOR|Control group|While the Capoeira group performed the entire class, the Control group performed only the final part (20 minutes) with musicality - singing and touch of typical instruments - and theoretical instructions related to Capoeira.
62705768|NCT02333448||patients with suspected invasive candidiasis|
61965161|NCT01803204|NO_INTERVENTION|Control|This group don't received booklet, they will be monitored during the postoperative period to control
61965162|NCT04047940|EXPERIMENTAL|LY900020 Formulation 1|LY900020 Formulation 1 administered orally
62144587|NCT02085772|EXPERIMENTAL|Patients with pre-conceptional obesity|
62714990|NCT06622005|EXPERIMENTAL|Treatment|Patients receive SX-682 PO BID on days 1-21 of each cycle. Patients also receive daratumumab-hyaluronidase SC once weekly on cycles 1 and 2 and once every 2 weeks on cycles 3-6 and carfilzomib IV on days 1, 8 and 15 and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with sustained response after 6 cycles may continue to receive SX-682 PO BID on days 1-21, daratumumab-hyaluronidase SC on day 1, carfilzomib IV on days 1, 8, and 15 and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, BM aspiration, ECHO and PET/CT or MRI on study.
61965163|NCT04047940|EXPERIMENTAL|LY900020 Formulation 2|LY900020 Formulation 2 administered orally
62144588|NCT02481804|EXPERIMENTAL|Dietary intervention|There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
62144589|NCT03929198|EXPERIMENTAL|Intervention|The intervention group participated in a 6-week Pritikin diet, exercise program, and behavioral modification.
62144590|NCT03929198|NO_INTERVENTION|Control|This group did not receive any intervention.
62144591|NCT00831506|EXPERIMENTAL|A|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
61965164|NCT04047940|EXPERIMENTAL|LY900020 Formulation 3|LY900020 Formulation 3 administered orally
62507946|NCT04012073|ACTIVE_COMPARATOR|EXPRESS|PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O
62507947|NCT04377906|EXPERIMENTAL|High Protein-Fiber and Exercise|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day and exercise : aerobic and resistance training for 5x/week, 45 minute each sesion
62507948|NCT04377906|EXPERIMENTAL|High Protein-Fiber|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day
62507949|NCT04377906|EXPERIMENTAL|Exercise|aerobic and resistance training for 5x/week, 45 minute each sesion
62507950|NCT04377906|NO_INTERVENTION|control|regular diet
62714991|NCT00102661|EXPERIMENTAL|CAMPATH-1H|15 mg infused daily for continuous infusion x 7 days; starting day 10, CAMPATH-1H 30 mg subcutaneously three times weekly for 11 additional weeks.
61965165|NCT04047940|ACTIVE_COMPARATOR|Reference Drugs|Metformin XR, atorvastatin, and valsartan administered orally
61965166|NCT05979701|NO_INTERVENTION|Theoretical education|
61965167|NCT05979701|EXPERIMENTAL|Theoretical education PLUS simulation training|
61965168|NCT01350414||Alair Group|Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)
61965169|NCT03490097|EXPERIMENTAL|Group I|low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg daily for 12 weeks.
61965170|NCT03490097|ACTIVE_COMPARATOR|Group II|sofosbuvir plus daclatasvir
61965171|NCT03116893|EXPERIMENTAL|Reference Treatment|BI 685509 given alone, fasted
61965172|NCT03116893|EXPERIMENTAL|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
62144592|NCT00831506|EXPERIMENTAL|B|digoxin once daily (0.125 mg QD) plus Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
62507951|NCT06617390||AGA Cohort|NSCLC participants with AGA that received second-line or above therapies treatment.
62507952|NCT06617390||Non-AGA Cohort|NSCLC participants with non-AGA that received second-line or above therapies treatment.
62507953|NCT03284502|EXPERIMENTAL|Stage 1|Dose-escalation
62507954|NCT03284502|EXPERIMENTAL|Stage 1b|Dose-escalation
62507955|NCT03284502|EXPERIMENTAL|Stage 2 (Cohort I and II)|Dose-expansion
62507956|NCT03284502|EXPERIMENTAL|Stage 2 (Cohort III)|Dose-expansion
62507957|NCT03635502||Stroke Group|
62507958|NCT03635502||Healthy Group|
61965173|NCT03116893|EXPERIMENTAL|Treatment 2|BI 685509, given together with itraconazole, fasted
61965174|NCT03116893|EXPERIMENTAL|Treatment 3|BI 685509, given together with rifampicin, fasted
61965175|NCT04658498|EXPERIMENTAL|Usual Care (UC)|Intermittent spontaneous breathing periods
62507959|NCT00698087|EXPERIMENTAL|Group A|
62507960|NCT00698087|ACTIVE_COMPARATOR|Group B|
61965176|NCT04658498|EXPERIMENTAL|UC + High-intensity inspiratory muscle training (HI-IMT)|
61965177|NCT04658498|EXPERIMENTAL|UC + Low-intensity inspiratory muscle training (LI-IMT) (sham IMT)|
61965178|NCT05764759|EXPERIMENTAL|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
61965179|NCT05764759|ACTIVE_COMPARATOR|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
61965180|NCT00595530|EXPERIMENTAL|Ketamine|This group will receive ketamine
61965181|NCT03239288|PLACEBO_COMPARATOR|Control digestible carbohydrate|Control baked breakfast bar
61965182|NCT03239288|EXPERIMENTAL|Test resistant starch type 4|Test baked breakfast bar
61965183|NCT02333877|EXPERIMENTAL|Skinlink|applying Skinlink on simple laceration (length \< 5cm)
61965184|NCT02333877|OTHER|Nylon|applying conventional suture using nylon on simple laceration (length \< 5cm)
61965185|NCT06093698|EXPERIMENTAL|single arm|A-337dosage: 0.05, 0.15, 0.3, 0.6, 0.9, 1.2, 1.5 μg/kg/d
61965186|NCT05134012|EXPERIMENTAL|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|All participants with suspected CAD will receive two doses of \[15-O\]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).
61965187|NCT06497933||Paroxysmal atrial fibrillation patients|patients with paroxysmal atrial fibrillation undergoing first time catheter ablation using the pentaspline PFA catheter
62507961|NCT00698087|EXPERIMENTAL|Group C|
62507962|NCT00939627|PLACEBO_COMPARATOR|Arm I (cetuximab and placebo)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21.
62507963|NCT00939627|EXPERIMENTAL|Arm II (cetuximab and sorafenib tosylate)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate twice daily on days 1-21.
62507964|NCT01118026|EXPERIMENTAL|ABVD +/- BEACOPP + radiation|"Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles.~Patients undergo a PET scan following two cycles of ABVD. If the PET scan is negative, then the patient will receive four more cycles of ABVD (a total of 6 cycles of ABVD). If the PET scan is positive, then the patient receives four cycles of escalated BEACOPP for 21 days (a total of 4 cycles).~3-6 weeks after BEACOPP therapy, patients receive radiation therapy for 5 days per week (a total of 3.5 weeks).~All patients will be followed for a maximum of ten years."
62507965|NCT03201978|EXPERIMENTAL|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm\^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm\^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm\^2 gently tape stripped skin area in period 3.
62507966|NCT03201978|PLACEBO_COMPARATOR|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm\^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm\^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm\^2 gently tape stripped skin area in period 3.
62705769|NCT05313581|ACTIVE_COMPARATOR|START NOW as web-based group training guided by a facilitator|"In condition 1, participants will be required to attend weekly sessions of the group training (period of 9 weeks; 3 double sessions;4 to12 participants) guided by a facilitator, either face-to-face or via videoconferencing. Facilitation will be provided either by a staff member (caretaker) of the institution who has received a 1.5 days training in START NOW (face-to-face setting), or by a member of the START NOW facilitator team of Universitäre Psychiatrische Kliniken (UPK) Basel (videoconference setting). All participants will have access to the START NOW Web application (WebApp) during the entire intervention and follow-up phase to complete additional exercises or review content.~Institutions randomized to group training guided by a facilitator condition will receive the complete pretraining (12 hours à 3 blocks: Theoretical Background; WebApp and Facilitator Material; Running Sessions) with individual coaching. Supervision will be provided twice during the intervention phase."
61965188|NCT06497933||Persistent atrial fibrillation patients|patients with persistent atrial fibrillation undergoing first time catheter ablation using the pentaspline PFA catheter
61965189|NCT06497933||Long-standing persistent atrial fibrillation patients|patients with long-standing persistent atrial fibrillation undergoing first time catheter ablation using the pentaspline PFA catheter
61965190|NCT02941978|EXPERIMENTAL|Subject on Motivational Interview|"1. Motivational Interview - Baseline: At hospital discharge, patients assigned to the intervention group will be contacted in person by a study physician for an interactive session and will be given an educational leaflet. Both methods will aim to educate them about the risk for stroke and the importance of adherence to OAC medication. The leaflet will also provide some basic information on how to take OAC medication (doses, food interactions, skipping doses, etc.) and will describe the main clinical manifestations of side effects.~2. Motivational Interview - Follow-up: Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview at 1 week, 2 months, 6 months and 1 year after discharge. The delegated study personnel will assess whether an intervention is required and provide specific support tailored to the needs of the patient, aiming to improve adherence to OAC."
61965191|NCT02941978|ACTIVE_COMPARATOR|Subject Control|Patients assigned to the control group will receive usual treatment and will be contacted via telephone for a pre-specified interview at 1 year after discharge for outcome assessment.
61965192|NCT03763214|EXPERIMENTAL|Stenting with PTFE-coated stent (HILZO)|The bile duct is stented with a PTFE-coated stent by duodenoscopy to allow bile duct flow
61965193|NCT03763214|ACTIVE_COMPARATOR|Stenting standard silicone coated stent|The bile duct is stented with a standard silicone-coated stent by duodenoscopy to allow bile duct flow
61965194|NCT00510120|EXPERIMENTAL|1|Participants will receive collaborative problem solving.
61965195|NCT00510120|ACTIVE_COMPARATOR|2|Participants will receive parent management training.
62705770|NCT05313581|ACTIVE_COMPARATOR|START NOW as web-based pure self-help training|Participants in condition 2 will use the START NOW web-based pure self-help training. Using the same session contents as in the group training guided by a facilitator, sessions have been adjusted so that participants can complete them individually and participants receive one session each week (session 1+2, 9+10 and 11+12 as double sessions). Institutions randomized to pure self-help training will receive the first block of the pretraining and the material from the second block (facilitator training material) prior to interventions start.
62714992|NCT03634956|EXPERIMENTAL|Group I.IONM in thyroid surgery|Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.
61965196|NCT00510120|ACTIVE_COMPARATOR|3|Participants assigned to waitlist control will receive one of the two treatments after a 10-weeks waitlist period.
61965197|NCT06505616|ACTIVE_COMPARATOR|Asymmetric cellulose triacetate (ATA™) membrane (Solacea™, Nipro, Osaka, Japan)|Patients were dialyzed with an asymmetric cellulose triacetate (ATA™) membrane (Solacea™, Nipro, Osaka, Japan). Non synthetic membrane, cellulose membrane.
61965198|NCT06505616|ACTIVE_COMPARATOR|Synthetic haemodialysers membranes|Synthetic haemodialysis membranes habitual used in the hospitals included in the study: FXCorDiax 800™ (Fresenius MC),Polyflux 210H™ (Baxter),Revaclear 400™ (Baxter),Eliseo 19H™ (Nipro)
61965199|NCT04280133|EXPERIMENTAL|Educational Video Tool|Patients randomized to the intervention arm will watch a 3-minute video educational tool about CAR-T cell therapy prior to admission for CAR-T cell therapy.
62144593|NCT04873206||Functional/ Cyclical Endometrial group.|cases of normal endometrium will be obtained from hystrectomy specimens done for causes other than hyperplasia or adenocarcinoma, for example; uterine fibroids, uterine prolapse.
62507967|NCT01257581|EXPERIMENTAL|Creatine 30gm|"Creatine will be taken as a powder mixed into food or liquid twice a day. Volunteers in this arm will take a total of 30gm of creatine per day for 38 weeks. Volunteers will also take placebo capsules twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Creatine is a nutritional supplement and is not approved by the U.S. Food and Drug Administration (FDA) for treating ALS."
61965200|NCT04280133|NO_INTERVENTION|Standard Care|Patients randomized to the control arm will receive usual care per the treating team. Any questions regarding CAR-T cell therapy will be directed to the patient's medical team
61965201|NCT04822454|EXPERIMENTAL|Night shift shadowing program|Medical students who participated in a night shift shadowing program prior to their first official night shifts
61965202|NCT04822454|NO_INTERVENTION|No night shift shadowing program|Medical students who did not participate in the night shift shadowing program prior to their first official night shifts
61976138|NCT05251909|PLACEBO_COMPARATOR|Placebo|This arm is a subcutaneous dose of Placebo
62144594|NCT04873206||Hyperplastic Endometrial group.|cases of endometrial hyperplasia obtained by D\&C or hystrectomy will be stained by H\&E stain and categorized into typical or atypical hyperplasia.
62144595|NCT04873206||Primary Endometrial Adenocarcinoma group.|cases of primary endometrial adenocarcinoma obtained by D\&C or hystrectomy operations
62144596|NCT00647400|EXPERIMENTAL|Adalimumab 40 mg every other week|
62144597|NCT00647400|EXPERIMENTAL|Adalimumab 80 mg every other week|
62144598|NCT03035942|EXPERIMENTAL|D Group|Dexamethasone 8 mg
62144599|NCT03035942|EXPERIMENTAL|O group|Ondansetron 4 mg
62705771|NCT05313581|NO_INTERVENTION|Treatment as usual (TAU)|Participants in condition 3 will not receive any health promotion services during the skills training or follow-up period beyond what is offered at their respective institution. They will also be excluded from any group trainings similar to START NOW. For ethical reasons and to increase study-related commitment, they will be provided with the web-based pure self-help training after completion of the study. Institution staff will receive the first block of the pretraining and material from the second block after the end of the intervention. Supervision for participating caretakers and facilitators will not be provided during the intervention phase.
62144600|NCT03035942|PLACEBO_COMPARATOR|S group|Normal saline (5 mL total volume)
62705772|NCT02487511|ACTIVE_COMPARATOR|14 days|14 days treatment regimen
62705773|NCT02487511|NO_INTERVENTION|7 days|7 days treatment regimen
62705774|NCT00005830|EXPERIMENTAL|Treatment (doxorubicin, cisplatin, radiation therapy)|Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
62705775|NCT05150626|EXPERIMENTAL|Sequence A administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg under fasted condition, following a low-fat meal and a standard meal.
62705776|NCT05150626|EXPERIMENTAL|Sequence B administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg following a low-fat meal and standard meal, under fasted condition.
62705777|NCT05150626|EXPERIMENTAL|Sequence C administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg following a standard meal, under fasted condition, following a low-fat meal.
62705778|NCT04695990|EXPERIMENTAL|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given Wenyang Huoxue Decoction, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
62705779|NCT04695990|PLACEBO_COMPARATOR|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
62705780|NCT00085527|EXPERIMENTAL|depsipeptide|Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.
62705781|NCT06545006|EXPERIMENTAL|Quick Release Strengthening|The rugby player participants will do 10 sessions of 40 minutes of muscle strengthening at a rate of 2 to 3 sessions per week. 20 minutes of isometric strengthening and 20 minutes of Quick release strengthening
62705782|NCT06545006|SHAM_COMPARATOR|Stroboscopic Glasses Tasks|The rugby player participants will do 10 sessions of 40 minutes of muscle strengthening at a rate of 2 to 3 sessions per week. 20 minutes of exercises with a rugby ball while wearing stroboscopic glasses.
62705783|NCT01722669|EXPERIMENTAL|Quercetin|Single dose of quercetin with or without ascorbic acid
62705784|NCT01722669|ACTIVE_COMPARATOR|Isoquercetin|Single dose of isoquercetin with or without ascorbic acid
62144601|NCT00266656|EXPERIMENTAL|Experimental 1 Control|"No drug administration in B9R-US-GDFG (NCT00406926).~Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given."
62144602|NCT00266656|EXPERIMENTAL|Experimental 2 Humatrope|Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
62144603|NCT02697968|EXPERIMENTAL|Electroacupuncture|
62144604|NCT03636854|EXPERIMENTAL|Concentric Exercises|2 different concentric exercises will be done 3 times a week for 8 weeks.
62705785|NCT06387342|EXPERIMENTAL|Namodenoson 25 mg|namodenoson capsule, 25 mg, administered orally, twice daily for consecutive 28-day cycles
62705786|NCT03525847|ACTIVE_COMPARATOR|contrast enhanced FNA endosonography|First passage in the solid pancreatic tumor using FNA endosonography then with the contrast enhanced FNA endosonography
62705787|NCT03525847|ACTIVE_COMPARATOR|FNA standard endosonography|First passage in the solid pancreatic tumor using contrast enhanced FNA endosonography then with the FNA endosonography
62705788|NCT02482311|EXPERIMENTAL|AZD1775|"Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle.~This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types."
62705789|NCT03271515|NO_INTERVENTION|conventional therapy|patients accept conventional radioactive and chemical therapy.
61965203|NCT02331914||Gastro-intestinal stromal tumors|"A bio-databank consisting of TKI drug level and serum for analysis of mutations in circulating tumor DNA will be set up. This bio-databank will be used to study whether changes in the amount of the primary KIT mutation is an early predictor of treatment response and/of failure. Moreover, secondary TKI resistant mutations in circulating tumor DNA will be assessed.~To be able to assess those mutations, a tumor biopsy will be performed at the time of radiologic progressive disease. Vena puncture for blood collection will be performed at routine out patient visits."
61965204|NCT04147130|EXPERIMENTAL|MultiPAP Plus intervention|Complex intervention with general practitioners and patients
62144605|NCT03636854|EXPERIMENTAL|Eccentric Exercises|2 different eccentric exercises will be done 3 times a week for 8 weeks.
62144606|NCT02705976|ACTIVE_COMPARATOR|self-managing warfarin|self-managing warfarin patients who are educated in dosing warfarin to achieve target INR value
62144607|NCT02705976|EXPERIMENTAL|algorithm-suggested warfarin dosing|algorithm-suggested warfarin dosing, where the participants are provided with a dosage suggestion of their warfarin dosage (calculated dose) to achieve target INR
62144608|NCT00974805|EXPERIMENTAL|Seretide 500 Accuhaler|Seretide 500 Accuhaler one inhalation BD
62144609|NCT03400579|EXPERIMENTAL|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
62144610|NCT06690242|EXPERIMENTAL|MT1013 dose regimen 1|MT1013 injection dose regimen 1 administered intravenously (IV) three times per week for 26 weeks.
61965205|NCT04147130|ACTIVE_COMPARATOR|Usual care|Patients will recieve the usual clinical care
61965206|NCT01375647|EXPERIMENTAL|Rotarix + No IPV|Randomized to receive rotarix vaccine but no IPV boost
61965207|NCT01375647|EXPERIMENTAL|Rotarix + with IPV boost|Randomized to receive both rotarix vaccine and IPV boost
61965208|NCT01375647|NO_INTERVENTION|No Rotarix + No IPV|Randomized to receive neither rotarix vaccine nor IPV boost
61965209|NCT01375647|EXPERIMENTAL|No Rotarix + with IPV boost|Randomized to receive no rotarix vaccine but to receive IPV boost
61965210|NCT00048555|EXPERIMENTAL|1|
61965211|NCT05000476|OTHER|Nurse Education and Environmental Regulation|Clinical nurses will be given training on delirium risks, diagnosis, prevention and management. In order to implement the interventions, environmental arrangements will be made in the intensive care units in the light of the training given, and the nurses will record which attempts are made during the day with the daily follow-up form.
62705790|NCT03271515|EXPERIMENTAL|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
61965212|NCT05000476|EXPERIMENTAL|Eye mask and earplugs|"Patients will be monitored for 3 days starting from their hospitalization.~Along with the regulations, each patient will be assisted by the intensive care nurses for 3 days between 23:00 p.m. - 06:00 a.m. for the use of eye mask and earplugs."
62705791|NCT06167239|EXPERIMENTAL|Threshold inspiratory muscle trainer|Training of the inspiratory muscles by threshold inspiratory muscle trainer.
62705792|NCT06167239|EXPERIMENTAL|Ventilator pressure setting inspiratory muscle training|Training of the inspiratory muscles by ventilator pressure setting.
62705793|NCT06167239|NO_INTERVENTION|Traditional treatment|Only prescribed medical treatment programme
62705794|NCT06092437|EXPERIMENTAL|Tailored, Urine sodium guided, intensified diuretic strategy|
62705795|NCT06092437|ACTIVE_COMPARATOR|Usual care|
61965213|NCT05000476|NO_INTERVENTION|Control|With the adjustments made, theywill receive the usual care for 3 days.
61965214|NCT05246761||Cesarean section group|In the cesarean section group, all the pregnant women had only one prior cesarean section.
61965215|NCT05246761||Non-cesarean section group|In the non-cesarean section group, all the pregnant women are primipara，and never had a cesarean section.
61965216|NCT04659304|ACTIVE_COMPARATOR|Cohort 1|Single Intravenous (IV) dose of Allocetra-OTS with 5x10\^9 cells
61965217|NCT04659304|ACTIVE_COMPARATOR|Cohort 2|Single Intravenous (IV) dose of Allocetra-OTS with 10x10\^9 cells
61965218|NCT04659304|ACTIVE_COMPARATOR|Cohort 3|Two IV doses of Allocetra-OTS with 10x10\^9 cells in each dose
62144611|NCT06690242|EXPERIMENTAL|MT1013 dose regimen 2|MT1013 injection dose regimen 2 administered intravenously (IV) three times per week for 26 weeks.
62144612|NCT06690242|ACTIVE_COMPARATOR|Etelcalcetide|Etelcalcetide injection administered intravenously (IV) three times per week for 26 weeks.
62705796|NCT00538850|EXPERIMENTAL|Fentanyl sublingual spray|Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.
62705797|NCT04218981|EXPERIMENTAL|Schizophrenia group|"1. Schizophrenia was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~2. MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~3. Choose one of the antipsychotics drugs treatment( olanzapine, risperidone, aminosulpiride) according to the patient's condition"
62705798|NCT04218981|EXPERIMENTAL|Bipolar disorder group|"1. Bipolar disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~2. MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~3. Choose one of the mood stabilizer drugs treatment( lithium, valproate) according to the patient's condition"
62705799|NCT04218981|EXPERIMENTAL|Major depressive disorder group|"1. Major depressive disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~2. MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~3. Choose paroxetine treatment"
62705800|NCT04218981|NO_INTERVENTION|Healthy controls|MRI scan at baseline and no drugs treatment
62705801|NCT03896191||Stable, satisfied primary TKR|Participants who have a stable TKR (as assessed by the surgical team) and are satisfied with their knee replacement (as assessed by a questionnaire).
62705802|NCT03896191||Unstable, dissatisfied primary TKR|Participants who are dissatisfied with their TKR, with instability (including instability due to aseptic loosening) and consequently awaiting revision TKR.
62705803|NCT05766605|EXPERIMENTAL|the test group|The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results. Precise transarterial chemoembolization at 1-month intervals for 2 months after surgery.
62705804|NCT05766605|ACTIVE_COMPARATOR|the control group|The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization with Doxorubicin. Empirical transarterial chemoembolization at 1-month intervals for 2 months after surgery.
61965219|NCT06505369|EXPERIMENTAL|Induction with Dara -VRd + Consolidation with Talquetamab and Teclistamab as monotherapy in sequence|Induction with Daratumumab-VRd; Consolidation part I with Talquetamab; Consolidation part II with Teclistamab.
61965220|NCT01831193|ACTIVE_COMPARATOR|Diabetic|
61965221|NCT01831193|ACTIVE_COMPARATOR|Non-diabetic|
61965222|NCT05239923|EXPERIMENTAL|generation of neutralizing antibody for unvaccinated participants|participants received vaccine 1 capsule of 1×10\^10 CFU of B. subtilis spore at day 0, 14, and 28 respectively.
61965223|NCT00325728|EXPERIMENTAL|Ramelteon 8 mg QD|
61965224|NCT00325728|PLACEBO_COMPARATOR|Placebo|
61965225|NCT00786682|EXPERIMENTAL|Docetaxel and Hydroxychloroquine|"Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle~Drug: hydroxychloroquine 200 mg twice daily~A cycle is defined as an interval of 21 days."
61965226|NCT00208091|EXPERIMENTAL|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
62144613|NCT06690242|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously (IV) three times per week for 26 weeks;
62144614|NCT05325099|EXPERIMENTAL|AKI patient with azacitidine treatment|azacitidine (subcutaneous injection)
61965227|NCT05169749|OTHER|Control-Service Nurse Group|Patient education lasting 20-30 minutes was provided by the nurse who gives care in the surgical inpatient floor before the surgery. The nurse provided the patient's admission to the postoperative surgical inpatient floor and follow-up.
62507968|NCT01257581|EXPERIMENTAL|Tamoxifen 40mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 40mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
62144615|NCT05325099|PLACEBO_COMPARATOR|AKI patient with placebo treatment|Placebo drug (subcutaneous injection)
61965228|NCT05169749|EXPERIMENTAL|Experimental-Nursing Visiting Group|The nursing visit was done by the operating room nurse who will be involved in the patient's surgery, and the patient education lasted 20-30 minutes. The nurse, who carried out the nursing visit, welcomed the patient in the operating room, was next to the patient before anesthesia, and followed the patient to the recovery room after surgery.
61965229|NCT00018200|EXPERIMENTAL|Arm 1|Desipramine, low, middle or high exposure
61965230|NCT00018200|EXPERIMENTAL|Arm 2|Fluoxetine, low, middle, or high exposure
61965231|NCT00018200|PLACEBO_COMPARATOR|Arm 3|Benztropine .125-.5mg daily
61965232|NCT00333814|ACTIVE_COMPARATOR|1|Dexamethasone 350 µg
61965233|NCT00333814|ACTIVE_COMPARATOR|2|Dexamethasone 700 µg
61965234|NCT00333814|SHAM_COMPARATOR|3|Sham
61965235|NCT00705653|EXPERIMENTAL|PG-11047|
62144616|NCT06341946|OTHER|endoscopic third ventriculostomy|endoscopic third ventriculostomy in patients with malfunctioning ventriculoperitoneal shunt
62144617|NCT02725372|EXPERIMENTAL|Inhaled Nitric Oxide 75mcg/KgIBW/Hr|"Part 1:~15Mcg/kg IBW/hr during Run-in Period dose titrated to Inhaled Nitric Oxide / 75mcg/KgIBW/Hr upon randomization to treatment arm.~Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment (Open Label Treatment - All Subjects)"
62144618|NCT02725372|PLACEBO_COMPARATOR|Placebo|"Part 1:~Placebo dose setting 15mcg/kg IBW/hr Run In Period / Placebo dose setting 75 mcg/kg IBW/hr treatment period"
62507969|NCT01257581|EXPERIMENTAL|Tamoxifen 80mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 80mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
62507970|NCT06117943||Pregnant women|Pregnant women who smoke personally or are passively exposed to cigarette smoke
62144619|NCT06440213|ACTIVE_COMPARATOR|PeptiControl™ (Low - Dose 435 mg/day)|6 capsules, 30 minutes prior to lunch every day for 6 days
62144620|NCT06440213|ACTIVE_COMPARATOR|PeptiControl™ (Mid - Dose 870 mg/day)|6 capsules, 30 minutes prior to lunch every day for 6 days
62144621|NCT06440213|ACTIVE_COMPARATOR|PeptiControl™ (High - Dose 2610 mg/day)|6 capsules, 30 minutes prior to lunch every day for 6 days
62144622|NCT06440213|PLACEBO_COMPARATOR|Placebo Microcrystalline Cellulose|6 capsules, 30 minutes prior to lunch every day for 6 days
62144623|NCT02136654|EXPERIMENTAL|Culturally tailored diabetes program|"Culturally tailored diabetes program~* culturally tailored diabetes education~* lifestyle counselling~* medication adherence counseling~* peer supporter~* communication training~* family member involvement"
62144624|NCT02136654|NO_INTERVENTION|Usual Care|Usual Care includes continuing to visit primary care physician for ongoing diabetes management Printed diabetes education materials.
62507971|NCT00992563|EXPERIMENTAL|AL-39324 Concentration Level A|AL-39324 ophthalmic suspension, single intravitreal injection
62507972|NCT00992563|EXPERIMENTAL|AL-39324 Concentration Level B|AL-39324 ophthalmic suspension, single intravitreal injection
62507973|NCT00992563|EXPERIMENTAL|AL-39324 Concentration Level C|AL-39324 ophthalmic suspension, single intravitreal injection
62507974|NCT00992563|EXPERIMENTAL|AL-39324 Concentration Level D|AL-39324 ophthalmic suspension, single intravitreal injection
62144625|NCT04886466|EXPERIMENTAL|The trunk movement coordinated and legs coordination during walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in post-stroke patients (study group).
62507975|NCT00992563|EXPERIMENTAL|AL-39324 Concentration Level E|AL-39324 ophthalmic suspension, single intravitreal injection
62507976|NCT00992563|ACTIVE_COMPARATOR|Lucentis|Ranibizumab 10 mg/mL solution, single intravitreal injection
62507977|NCT01765517|EXPERIMENTAL|Probiotics|Probitoics
62507978|NCT01765517|PLACEBO_COMPARATOR|Placebo|Placebo
62507979|NCT04102345|EXPERIMENTAL|Lavender|1-2 drops of Lavender (essential oil) in approximately 120 ml of distilled water is added to a diffuser 10 minutes before light out. The diffuser runs for approximately 2 hours before automatically being shut off. A low mist option is used on the diffuser.
61965236|NCT00897104|EXPERIMENTAL|1|Rizatriptan
61965237|NCT00897104|EXPERIMENTAL|2|Sumatriptan
61965238|NCT00897104|PLACEBO_COMPARATOR|3|Placebo
62144626|NCT04886466|EXPERIMENTAL|The coordinated movement of the trunk and legs during fast walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in patients with back pain syndrome, but without neurological deficits (control group).
61965239|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
61965240|NCT02556814|EXPERIMENTAL|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
61965241|NCT02556814|ACTIVE_COMPARATOR|Placebo and dexamethasone|Oral administration of placebo tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
61965242|NCT02697812|EXPERIMENTAL|slow sternal retraction|sternal retraction (which is required for exposure of the heart during coronary artery bypass graft surgery) will be performed gradually over 15 minutes
61965243|NCT02697812|NO_INTERVENTION|standard sternal retraction|sternal retraction will be performed as per standard practice (sternum opened rapidly over 30 sec.)
61965244|NCT03269383|SHAM_COMPARATOR|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
62507980|NCT04102345|ACTIVE_COMPARATOR|Zolpidem|Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.
62705805|NCT05693376||Intervention group|Subjects who meet the following inclusion criteria: 1) Severe aortic stenosis. 2) Age \> 65 years for male and \>70 years for female. 3) Increased left ventricular wall thickness ≥14 mm. 4) Blood pressure ≤ 140/90 mmHg and at least 1 major or ≥ 2 minor criteria. Major criteria: a) Carpal tunnel syndrom; b) Non-traumatic rupture of the biceps tendon; c) NT-proBNP \> 1000 pg/ml; d) hs Troponin value above the 99th percentile without dynamic changes (≤ 20%). Minor criteria: a) Diastolic dysfunction (at least grade 2, E' \< 10 cm/s); b) Sinus bradycardia/AV block/pacemaker; c) Atrial fibrillation.
62705806|NCT05693376||Control group|Subjects who meet the following inclusion criteria: 1) Severe aortic stenosis. 2) Age \> 65 years for male and \>70 years for female. 3) Increased left ventricular wall thickness ≥14 mm. 4) Blood pressure ≤ 140/90 mmHg.
62705807|NCT03485157|EXPERIMENTAL|Micronized dHACM|Injection of micronized dHACM
62507981|NCT03634410||Employed|people aged +50 and currently employed
62507982|NCT03634410||Unemployed|people aged +50 and currently unemployed
62507983|NCT03634410||Early retirement|people aged +50 and currently on early retirement
62507984|NCT03634410||Disability pension|people aged +50 and currently on disability pension
62705808|NCT03485157|PLACEBO_COMPARATOR|Saline|Injection of 0.9% Sodium Chloride Injection, USP
62705809|NCT01006148|EXPERIMENTAL|Bone substitute|Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.
62705810|NCT04162834|EXPERIMENTAL|Papaverine group|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
62705811|NCT04162834|ACTIVE_COMPARATOR|Normal saline group|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
61965245|NCT03269383|EXPERIMENTAL|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
61965246|NCT03069807|EXPERIMENTAL|Intervention|Participants with LTBI will be treated in the Community/Primary Care.
62507985|NCT02388698|EXPERIMENTAL|Cervical Swab, PET-CT and plasma HPV|Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
62507986|NCT00217724|EXPERIMENTAL|Glutamine Arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral glutamine three times daily for 4 days.
62507987|NCT00217724|PLACEBO_COMPARATOR|Placebo arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral placebo three times daily for 4 days.
62507988|NCT03609242|EXPERIMENTAL|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
62507989|NCT03609242|NO_INTERVENTION|Control|Arm 2 will receive standard of care
62507990|NCT04733248|ACTIVE_COMPARATOR|Kinesiotaping group|Hot pack, Tens, stretching exercises, Kinesiotaping (I-O) and Home plan
62507991|NCT04733248|EXPERIMENTAL|stretching group|Hot pack, Tens, stretching exercises and Home plan
62507992|NCT03534908||NAFLD group|those with NAFLD
62507993|NCT03534908||Control group|those without NAFLD
62507994|NCT02807779|EXPERIMENTAL|Dexamethasone|Participants randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
62507995|NCT02807779|ACTIVE_COMPARATOR|Drug Coated Balloon|Participants randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.
62507996|NCT02807779|ACTIVE_COMPARATOR|Plain Balloon Angioplasty|Participants randomized to the Plain Balloon Angioplasty will receive balloon angioplasty (POBA) only. They will not receive adventital dexamethasone or paclitaxel.
62705812|NCT05478278|EXPERIMENTAL|Part 1: Treatment A (IP at Therapeutic Dose)|A single therapeutic dose of psilocybin.
61965247|NCT03069807|ACTIVE_COMPARATOR|Control|Participants with LTBI will be treated in the Hospital/TB Clinic
61965248|NCT02031107|ACTIVE_COMPARATOR|cTBS|A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver continuous bursts of bipolar magnetic pulses exerting an inhibition on the underlying brain tissue (cTBS). The stimulation coil will be placed over the unaffected primary motor cortex. The stimulation protocol implies 200 bursts, each consisting of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. Two stimulation trains of 30 s, separated by 15 min, will be applied 3 times per week for 3 weeks and will be immediately followed by physical therapy.
61965249|NCT02031107|ACTIVE_COMPARATOR|cathodal tDCS|A stimulator (NeuroConn GmbH, Illmenau, Germany) will deliver cathodal transcranial direct current stimulation (tDCS) of the unaffected motor cortex. The anode will be placed over the contralateral supraorbital region. Stimulation will be performed for 25 min, 3 times per week for 3 weeks during upper extremity treatment sessions.
61965250|NCT02031107|SHAM_COMPARATOR|sham stimulation|This group will receive the same stimulation protocol as used for the active groups except that sham stimuli will be applied. Half of the patients receive sham cTBS, the other half sham tDCS.
61965251|NCT01191398|PLACEBO_COMPARATOR|Placebo and Ketamine|Normal Saline 0.9% will act as a placebo. Two ml of normal saline 0.9% will be administered intravenously 30 minutes prior to the administration of the ketamine.
62507997|NCT03745417|EXPERIMENTAL|UCMSCs group|Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks.
62507998|NCT04812574|EXPERIMENTAL|Hypertonic Saline (10%) Injection|Periurethral hypertonic saline (10%) injection was performed in female patients with Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.
62507999|NCT05099523|PLACEBO_COMPARATOR|group I|50%Fio2
62508000|NCT05099523|ACTIVE_COMPARATOR|group II|30%Fio2
62508001|NCT06617117|EXPERIMENTAL|Moderate-intensity combined exercise|A one-hour exercise session of moderate-intensity structured as follows: a warm-up (10 min), aerobic exercise (20 min), followed by a circuit resistance exercise (20 min), concluded with passive stretching cool down (10 min).
61965252|NCT01191398|ACTIVE_COMPARATOR|Atropine and Ketamine|Atropine will be administered as a single dose of 0.01 mg/kg, with a minimum of dosage of 0.1 mg and a maximum dosage of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
61965253|NCT01191398|ACTIVE_COMPARATOR|Glycopyrrolate and Ketamine|Glycopyrrolate will be administered as a single dose of 0.01 mg/kg, with no minimum dosage and a maximum dose of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
62144627|NCT06152900|EXPERIMENTAL|Treatment Arm|All subjects enrolled in the study will be placed into the treatment arm of the study, to be treated by the Accufit device.
62144628|NCT03294967|ACTIVE_COMPARATOR|Caffeine|To determine the effect of caffeine on ocular circulation in high myopes by consuming 200 mg caffeine capsule
62144629|NCT03294967|PLACEBO_COMPARATOR|Vitamin E|To determine the effect of caffeine on ocular circulation in high myopes by consuming and 200 International Unit vitamin E control capsule, as control
62144630|NCT04571437|ACTIVE_COMPARATOR|Chemo endocrine treatment (A)|Letrozole 2.5mg PO daily + Capecitabine 500mg/m2 bid PO continously
62349789|NCT05200052|ACTIVE_COMPARATOR|Colchicine 0.5 mg oral tablet|100 patients presented with anterior Myocardial infarction undergoing primary Percutaneous coronary intervention will receive colchicine tablet 1mg loading dose and colchicine 0.5 mg maintance dose for 6 months and will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
62705813|NCT05478278|EXPERIMENTAL|Part 1: Treatment B (IP at Supratherapeutic Dose)|A single supratherapeutic dose of psilocybin.
62508002|NCT06617117|EXPERIMENTAL|High-intensity combined exercise|A one-hour exercise session of high-intensity structured as follows: a warm-up (10 min), aerobic exercise (20 min), followed by a circuit resistance exercise (20 min), concluded with passive stretching cool down (10 min).
62705814|NCT05478278|PLACEBO_COMPARATOR|Part 1: Treatment C (Placebo - Negative Control)|A single dose of placebo-to-match psilocybin MCC capsules.
62705815|NCT05478278|ACTIVE_COMPARATOR|Part 1: Treatment D (Placebo - Positive Control)|A single 400 mg dose of moxifloxacin.
62705816|NCT05478278|EXPERIMENTAL|Part 2: IP at Therapeutic Dose (Fasted Conditions)|A single therapeutic dose of psilocybin administered under fasted conditions.
62705817|NCT05478278|EXPERIMENTAL|Part 2: IP at Therapeutic Dose (Fed Conditions)|A single therapeutic dose of psilocybin under fed conditions.
62705818|NCT00622726|EXPERIMENTAL|Bevacizumab for ROP|Intravitreal Bevacizumab Therapy is the Experimental Arm of this Study
62705819|NCT00622726|ACTIVE_COMPARATOR|Conventional Laser for ROP|Conventional Laser to the Peripheral Retina is the Control Arm of this Study
62705820|NCT03503409|EXPERIMENTAL|AG-120|Subjects enrolled will receive continuous 28-day cycles of AG-120 - 500 mg. AG-120 will be dispensed on Day 1 of each treatment cycle
62705821|NCT00862940|EXPERIMENTAL|Memantine|
62144631|NCT04571437|ACTIVE_COMPARATOR|Endocrine treatment only (B)|Letrozole 2.5mg PO daily
62144632|NCT04127552||Patients with non-functioning adrenal adenoma|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels lower than 50 nmol/L
62144633|NCT04127552||Patients with pACS receiving conservative management|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving conservative management
62144634|NCT04127552||Patients with pACS receiving adrenalectomy|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving adrenalectomy according to the 2016 European Society of Endocrinology guidelines
62705822|NCT00862940|PLACEBO_COMPARATOR|Placebo|
62705823|NCT03527784|ACTIVE_COMPARATOR|Parietene Macro|Parietene Macro is a macroporous synthetic mesh.
62705824|NCT03527784|ACTIVE_COMPARATOR|Parietex Parastomal|Parietex Parastomal is a synthetic mesh with resorbable collagen lining to prevent attachments.
62705825|NCT03527784|ACTIVE_COMPARATOR|Dynamesh IPST|Dynamesh IPST is synthetic mesh with central tube to accommodate bowel tightly designed to prevent and treat parastomal hernia.
62705826|NCT01203345|ACTIVE_COMPARATOR|Immune globulin|Lyophilized human immune globulin product
62705827|NCT01203345|PLACEBO_COMPARATOR|Albumin solution|
62705828|NCT04595435||Cohort A- Preoperative Prospective|Subjects are eligible to receive IORT and have agreed to participate in the study prior to any intervention.
62705829|NCT04595435||Cohort B- Postoperative Prospective|Subjects who have had IORT performed within the previous 6 month who agree to participate.
62705830|NCT04542928|PLACEBO_COMPARATOR|routine care|The controlled group will receive routine functional treatment activities, a facial cleansing instruction and five facial cleansing videos.
62705831|NCT04542928|EXPERIMENTAL|experimental group|experimental group is required to receive a nurse leading 50- minute face care group every two weeks
62705832|NCT00934921|EXPERIMENTAL|Ondansetron|Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
61965254|NCT00482612|EXPERIMENTAL|Esmirtazapine 1.5 mg|Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
61965255|NCT00482612|EXPERIMENTAL|Esmirtazapine 3.0 mg|Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
61965256|NCT00482612|EXPERIMENTAL|Esmirtazapine 4.5 mg|Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
61965257|NCT00482612|PLACEBO_COMPARATOR|Placebo|Placebo to esmirtazapine
61965258|NCT01118702|ACTIVE_COMPARATOR|001|Concerta one 54mg tablet once
61965259|NCT01118702|ACTIVE_COMPARATOR|002|Ritalin-SR 3-20mg tablets once
61965260|NCT01118702|ACTIVE_COMPARATOR|003|Novo-Methylphenidate ER-C one 54mg tablet once
61976139|NCT05369455|EXPERIMENTAL|group 1|group of ultrasound guided Erector spine plane block:
62144635|NCT04127552||Healthy controls|Patients without adrenal masses
62705833|NCT00934921|ACTIVE_COMPARATOR|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in second period
62705834|NCT00614224|EXPERIMENTAL|A|Treadmill training group (TAEX)
62705835|NCT00614224|ACTIVE_COMPARATOR|B|Attention control group (CON)
62705836|NCT03787654|EXPERIMENTAL|electroacupuncture group|Acupoints of bilateral Zhongliao (BL33), Huiyang (BL35) and Sanyinjiao (SP6) are stimulated by Huatuo Brand disposable needles and SDZ-V electronic apparatus.
62705837|NCT03787654|SHAM_COMPARATOR|sham electroacupuncture group|Sham acupoints 1 cun(≈15mm) horizontally outwardly lateral to BL33 and BL35, and 0.5 cun(≈10mm) horizontally behind SP6 are stimulated superficially with a small electricity current by needles of 0.30×40mm size and SDZ-V electronic apparatus.
61965261|NCT02496611|PLACEBO_COMPARATOR|Weight Loss Maintenance without Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve ≥5% BMI reduction. A selection of these participants are then randomized to receive treatment with placebo.
61965262|NCT02496611|ACTIVE_COMPARATOR|Weight Loss Maintenance with Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve a \>/= 5% BMI reduction. A selection of these participants are then randomized to receive treatment with GLP-1RA.
61965263|NCT05564936|EXPERIMENTAL|MG patients|MG patients will perform 3 in-clinic visits and use the ME\&MG app at-home during 12 months
61965264|NCT05564936|OTHER|Healthy volunteers|Healthy volunteers will perform one in-clinic visit and will use the app at-home once
62705838|NCT03787654|ACTIVE_COMPARATOR|Solifenacin group|subjects will orally take Solifenacin 5-10mg per day.
62705839|NCT01088685|EXPERIMENTAL|Experimental Blister Patch|Experimental Hydrogel Blister patch
62705840|NCT01088685|ACTIVE_COMPARATOR|Marketed Pflaster|Scholls Blasen Pflaster
62705841|NCT04962854||Monoblock Cup|53 patients received a monoblock cup (RM Pressfit vitamys®)
62705842|NCT04962854||Modular Cup|64 patients received a modular cup (ANA.NOVA® Implantec)
62705843|NCT01655277|EXPERIMENTAL|Adductor Canal block first|This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
62705844|NCT01655277|EXPERIMENTAL|Femoral nerve block first|This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
61965265|NCT04446520|EXPERIMENTAL|autogenic drainage and traditional physiotherapy|autogenic drainage technique plus traditional physiotherapy (localized breathing exercise, diaphragmatic breathing and splinted coughing)
61965266|NCT04446520|ACTIVE_COMPARATOR|traditional physiotherapy|traditional physiotherapy (localized breathing exercise, diaphragmatic breathing, and splinted coughing)
61965267|NCT02332850|EXPERIMENTAL|Arm I (20 mg dexamethasone, isatuximab, carfilzomib)|"20 mg dexamethasone IV given on days 1, 8, 15, 22 (pre- SAR650984 and carfilzomib), then dexamethasone 4 IV or PO mg Day 2, 9, 16.~All patients will receive a fixed dose of Isatuximab (SAR650984) according to their assigned dose cohort. Patients receive isatuximab IV over 4-6 hours on days 1 and 15 of every cycle for the starting cohort, and days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Carfilzomib IV will be administered over 10 minutes on days 1, 2, 8, 9, 15, and 16 . Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment after 8 courses if clinical benefit is present at the investigator's discretion (carfilzomib may be switched to days 1, 2, 15, and 16 after 8 cycles per investigator discretion)."
61965268|NCT02332850|EXPERIMENTAL|Arm II (40 mg dexamethasone, isatuximab, carfilzomib)|"40 mg dexamethasone IV given on Days 1, 8, 15 and 22 (use as premed to isatuximab).~All patients will receive a fixed dose of Isatuximab (SAR650984) according to the assigned dose. Patients receive isatuximab IV over 4-6 hours on day 1, 3-4 hours on Day 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycle (patients may be eligible for rapid siatuximab given over 75 minutes), and carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
61965269|NCT02270957|ACTIVE_COMPARATOR|Abatacept|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
61965270|NCT02270957|PLACEBO_COMPARATOR|Placebo|Patients receive placebo instead of Abatacept in a double blind fashion. Otherwise participation is the same, including that at the time of treatment failure they may elect any standard of care treatment and/or to begin taking open label abatacept but this rescue will define non-response in the primary endpoint at six months.
61965271|NCT04098198||Participants with an Inborn Error of Metabolism|Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years
61965272|NCT05951673|EXPERIMENTAL|Treatment 1 - Receives Safe Space based life skills training program|Adolescent girls in this group receive a safe space-based life skills training program within their school.
61965273|NCT05951673|EXPERIMENTAL|Treatment 2 - Recieves Safe Space based life skills training program + digital literacy training|Adolescent girls in this group receive a safe space-based life skills training program and a digital literacy training program within their school.
61965274|NCT05951673|NO_INTERVENTION|Control - No intervention|Adolescent girls in this group receive neither the safe space-based life skills training program nor the digital literacy training program.
61965275|NCT00352560|ACTIVE_COMPARATOR|A|
61965276|NCT00352560|PLACEBO_COMPARATOR|B|
61976140|NCT05369455|ACTIVE_COMPARATOR|group 2|group of ultrasound guided Caudal block:
62705845|NCT06537388||EBUS_cohort|All patients who underwent EBUS between January 1st 2019 and december 31st 2019 or January 1st 2023 and december 31st 2023 at Erasme University Hospital
62705846|NCT05815888||Living donor nephrectomy patients|Patients who are scheduled for donor nephrectomy, and who will be operated in lateral position using laparoscopic techniques
62714993|NCT06070662||Suspected coronary microvascular disease confirmed at angiography (expected n=8)|Individuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. Those with confirmed coronary microvascular disease will complete an MRI scan as part of this pilot study and their CT scan will undergo additional analysis.
61965277|NCT05017766||A) Urinary tract infection|Processing of residual urine for proteomic, metabolomic and transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH) analysis, flow cytometry analysis (FACS), immunophenotyping. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties (Highly sensitive mass spectrometry, whole genome sequencing), expression of virulence factors, genomic alterations of bacterial species, metabolism, surface molecule expression, gene expression levels, cytokine levels, immune cell biology, antibiotic concentration (chromatography/mass spectrometry). Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included. First, a pilot study from randomly selected patients within each bacterial species group (n=50, each) is done.
61965278|NCT05017766||B) Pneumonia|Processing of residual samples (tracheal secretion, bronchioalveolar lavage (BAL)) for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
61965279|NCT05017766||C) Deep-seated infections|Processing of intraoperative material residual samples for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
62508003|NCT02031237||Stereotactic Radiosurgery (SRS)|"Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series."
61965280|NCT05017766||D) Controls for A), B) and C)|Control samples result from patients with a suspected infection (infection sites A), B) or C), in which no microbiological confirmed infection has been diagnosed. Storage at biobank
61965281|NCT05017766||E) Clinical controls for A), B) and C) without obtained samples|For clinical controls, clinical characteristics of patients with detection of target pathogens in their routine samples (but which could not be included for sample analysis in this study) will be assessed.
61976141|NCT04563793||Superion™ IDS|All patients to receive IDS for the treatment of their moderate Lumbar Spinal Stenosis Symptoms.
61976142|NCT04384666|EXPERIMENTAL|LY03003|LY03003 28 mg
62144636|NCT01746966||Rheumatoid Arthritis|20 patients age of 20-60 with Rheumatoid Arthritis according to ARA 1987 revised criteria and disease activity Disease Activity Score (DAS) 3-5
62349790|NCT05200052|NO_INTERVENTION|Standard anti ischemic treatment|100 patients presented with anterior myocardial infarction undergoing primary percutaneous coronary intervention will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
62349791|NCT05891691|EXPERIMENTAL|Intervention Group|In addition to the training program prepared by the classroom teacher, the initiative group will receive a program that includes music activities, yoga postures accompanied by stories, breathing techniques and massage exercises, 2 days a week, 30 minutes a day for 6 weeks.
62349792|NCT05891691|NO_INTERVENTION|Control Group|The teachers will continue their education within the program they have prepared.
62349793|NCT01902862|EXPERIMENTAL|Bortezomib plus rituximab|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3. Rituximab will be administered as intravenous infusion as 375 mg per m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
62349794|NCT01633671||Suspected APE|Post-surgical patients with clinically suspected acute pulmonary embolism
62705847|NCT03386773|EXPERIMENTAL|Intervention|Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
62349795|NCT00866268|EXPERIMENTAL|Low suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter.
61976143|NCT04384666|ACTIVE_COMPARATOR|Neupro 4Mg/24Hr Transdermal Patch|Neupro 4 mg / 24 Hr. Transdermal Patch
62349796|NCT00866268|ACTIVE_COMPARATOR|High suction drainage|The standard DRENOFAST® system was used in the control group, and the initial negative pressure was 700 mmHg.
62349797|NCT01159509||Infants ages -13 years that had HPS in infancy|
62349798|NCT05366192|EXPERIMENTAL|Paxlovid stage 1 group|Subjects in stage 1 will be treated with nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
62144637|NCT01746966||Healthy controls participants|Healthy controls age of 20-60 according to conclusion of preventive medicine department
62349799|NCT05366192|EXPERIMENTAL|Paxlovid stage 2 group|In stage 2, subjects will be treated with nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
61976144|NCT02528656|EXPERIMENTAL|Pectus Excavatum|Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.
61965282|NCT05017766||F) Cohort with analysis whether the application of Article (Art) 34 HFV can avoid a bias|Since part of the data and samples in this study are collected with the representative consent of the ethics committees, it is investigated whether the application of Art. 34 HFV prevents selection bias with respect to the study population. For this purpose, differences between the actual study population using Art. 34 HFV and the study population with provided research consent will be descriptively investigated in terms of the prevalence of multi-resistant germs and other available population characteristics.
61965283|NCT03068481|EXPERIMENTAL|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
62705848|NCT03386773|ACTIVE_COMPARATOR|Control|Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
61965284|NCT03068481|EXPERIMENTAL|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
61965285|NCT03068481|PLACEBO_COMPARATOR|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
61965286|NCT03068481|EXPERIMENTAL|Patient part -Single dose|Single oral dose of KDT-3594
61965287|NCT03068481|EXPERIMENTAL|Patient part -Multiple dose|Multiple oral doses of KDT-3594
61965288|NCT06066658|NO_INTERVENTION|Standard care|Standard care for Help with Breathlessness including medication, cognitive and behavioural strategies
62705849|NCT03509402|EXPERIMENTAL|Short implants|A full-arch screw-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6mm)
62705850|NCT03509402|ACTIVE_COMPARATOR|Long implants|A full-arch srew-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
62705851|NCT02092129||Acromegaly|Patients with acromegaly who have received surgical treatment
62705852|NCT00460213|EXPERIMENTAL|Valsartan|
62705853|NCT04193735||CIPO (case)|MRI scan of gastrointestinal content and activity
61965289|NCT06066658|EXPERIMENTAL|CES|8 weeks of 60 minutes a day 100microA a day with four week follow-up with standard care for help with breathlessness
61965290|NCT06077591|EXPERIMENTAL|Patient-Derived Tumor Organoids (PDO) Guided Therapy|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
61965291|NCT04876924|EXPERIMENTAL|BBP-711 for SAD|A single dose of BBP-711 will be administered orally.
62705854|NCT04193735||Chronic constipation (control)|MRI scan of gastrointestinal content and activity
62705855|NCT03249818|OTHER|HITT Device|HITT device to scan eyes of participants 3 times (30 seconds each) at time of admittance to hospital for diagnosed traumatic brain injury. If patient is still in hospital 2 weeks post-enrollment, a second set of 3 tests will be performed
62144638|NCT01939249|ACTIVE_COMPARATOR|Abbott Laboratories Xience|Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES).
62705856|NCT05775250|EXPERIMENTAL|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
62705857|NCT05775250|ACTIVE_COMPARATOR|fluoride varnish|5% NaF fluoride varnish, it will be administrated once.
62705858|NCT05892341|ACTIVE_COMPARATOR|AQUACEL® Ag+ Extra™|AQUACEL® Ag+ Extra™ is approved, needle-bonded nonwoven fabric layered and stitch-bonded wound dressing
61965292|NCT04876924|PLACEBO_COMPARATOR|Placebo for SAD|A single dose of matching placebo will be administered orally.
61965293|NCT04876924|EXPERIMENTAL|BBP-711 for MAD|A dose of BBP-711 will be administered orally for multiple days.
61965294|NCT04876924|PLACEBO_COMPARATOR|Placebo for MAD|A dose of matching placebo will be administered orally for multiple days.
61965295|NCT04876924|EXPERIMENTAL|BBP-711 for SAD Food Effect|A single dose of BBP-711 will be administered orally.
61965296|NCT04876924|PLACEBO_COMPARATOR|Placebo for SAD Food Effect|A single dose of matching placebo will be administered orally.
61965297|NCT00728598||1|Proliferative diabetic retinopathy, active.
62349800|NCT05708924|EXPERIMENTAL|IP FT538 monotherapy|Level -1: IP FT538 monotherapy 5 x 10\^7 cells/dose Level 1: IP FT538 monotherapy 1 x 10\^8 cells/dose Level 2: IP FT538 monotherapy 3 x 10\^8 cells/dose Level 3: IP FT538 monotherapy 1 x 10\^9 cells/dose Level 4: IP FT538 monotherapy 1.5 x 10\^9 cells/dose
62349801|NCT05708924|EXPERIMENTAL|IP FT538 + Enoblituzumab|Level 5: IP FT538 at the safe dose (MTD-1) + Enoblituzumab Level 6: IP FT538 at the highest dose (MTD) + Enoblituzumab
62349802|NCT01175213|EXPERIMENTAL|SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety)|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)
62705859|NCT05892341|ACTIVE_COMPARATOR|Cutimed® Sorbact®|Cutimed® Sorbact® is approved, bacterial and fungi binding wound dressing
62705860|NCT03197519|EXPERIMENTAL|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
61965298|NCT00728598||2|Proliferative diabetic retinopathy, quiescent.
61965299|NCT00728598||3|Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
61976145|NCT02528656|EXPERIMENTAL|Pectus Carinatum|Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.
62144639|NCT01939249|EXPERIMENTAL|Biotronik Orsiro|Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro
62144640|NCT00770874|EXPERIMENTAL|1|S-1 + Cisplatin (arm A)
62144641|NCT00770874|ACTIVE_COMPARATOR|2|Cisplatin (arm B)
62144642|NCT03156738|EXPERIMENTAL|Dose 1|MT-2990 or Placebo
62144643|NCT03156738|EXPERIMENTAL|Dose 2|MT-2990 or Placebo
62144644|NCT03156738|EXPERIMENTAL|Dose 3|MT-2990 or Placebo
62144645|NCT03156738|EXPERIMENTAL|Dose 4|MT-2990 or Placebo
62508004|NCT02031237||Whole Brain Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series."
62508005|NCT02031237||Stereotactic Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series."
62508006|NCT02571803|EXPERIMENTAL|Dietary And Lifestyle Counseling|Patients receiving strict dietary counseling (implementation of the DASH diet) and lifestyle changes support atop of optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
62508007|NCT02571803|ACTIVE_COMPARATOR|Optimal Medical Treatment|Patients receiving optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
62508008|NCT06133309|EXPERIMENTAL|Depressive patients|Patients suffering from depressive disorder and treated with Esketamine between 2 days and 3 months prior to the study.
62508009|NCT03721627|EXPERIMENTAL|Treatment group|Ledipasvir/sofosbuvir fixed dose combination tablet (90 mg ledipasvir, 400 mg sofosbuvir) once daily for 12 weeks for those 12-18 years, Wt 35 kg or more and half the dose (45 mg ledipasvir, 200 mg sofosbuvir) once daily for 12 weeks for those 6-11 years, Wt Less than 35 kg.
62508010|NCT01764867|ACTIVE_COMPARATOR|Algorithm Guided Treatment (AGT)|Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
62508011|NCT01764867|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement.
62349803|NCT01175213|EXPERIMENTAL|SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)
62508012|NCT02339415|ACTIVE_COMPARATOR|Treatment|Edoxaban 30mg daily
62508013|NCT02339415|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62508014|NCT02370459|NO_INTERVENTION|control|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive no AFIX consultation.
62508015|NCT02370459|EXPERIMENTAL|AFIX in-person consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive an in-person AFIX consultation. Consultations will be delivered by state health department staff.
62508016|NCT02370459|EXPERIMENTAL|AFIX webinar consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90. Clinics randomly assigned to this arm will receive an AFIX consultation via interactive webinar. Consultations will be delivered by state health department staff.
62508017|NCT01417351|PLACEBO_COMPARATOR|400 IU Vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
62705861|NCT03197519|OTHER|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
61965300|NCT02759432|EXPERIMENTAL|Intervention|Participants in the intervention group will complete a 4-week school-based high-intensity interval exercise training programme. The intervention will take place twice per week, and comprise of 6-8 repetitions of 45 s maximal effort exercise (boxing, running, soccer and basketball drills), each interspersed with 90-s rest. Participants will be encouraged to work maximally during the 45-s repetitions.
62508018|NCT01417351|EXPERIMENTAL|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
62508019|NCT04372134|ACTIVE_COMPARATOR|real rTMS group|motor incomplete traumatic SCI patients receiving real repetitive transcranial magnetic stimulation therapy
62508020|NCT04372134|SHAM_COMPARATOR|sham r TMS|motor incomplete traumatic SCI patients receiving sham repetitive transcranial magnetic stimulation therapy
62508021|NCT01139294|NO_INTERVENTION|standard IV therapy|control arm of the study
62508022|NCT01139294|EXPERIMENTAL|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours
62508023|NCT02452528|EXPERIMENTAL|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
62705862|NCT05294887|EXPERIMENTAL|bisoprolol first, diltiazem second|Crossover Design: bisoprolol first, diltiazem second, placebo third
62705863|NCT05294887|EXPERIMENTAL|bisoprolol first, placebo second|Crossover Design: bisoprolol first, placebo second, diltiazem third
61965301|NCT02759432|NO_INTERVENTION|Control|Participants in the control group will be instructed not to change their lifestyle, dietary or physical activity habits during the intervention period, and maintain their normal school physical education routine
61965302|NCT00795106|ACTIVE_COMPARATOR|Capsaicin patch|Patches will contain capsaicin 0.1% (500 mcg)
61965303|NCT00795106|PLACEBO_COMPARATOR|Placebo patch|Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing.
62508024|NCT02452528|PLACEBO_COMPARATOR|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
62508025|NCT06453525||C-mac|Intubation performed with a C-Mac videolaryngoscope
62144646|NCT03156738|EXPERIMENTAL|Dose 5|MT-2990 or Placebo
62349804|NCT01175213|EXPERIMENTAL|IV treatment with IGSC, 10% only|Partial efficacy (trough levels of immunoglobulin G \[IgG\] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603
62349805|NCT02214485|EXPERIMENTAL|integrated care (IC)|Subjects will receive such care twice weekly for 12 weeks.
62508026|NCT06453525||MacGrath|Intubation performed with a MacGrath videolaryngoscope
62144647|NCT05856682|ACTIVE_COMPARATOR|Pre-incision TAP (PITAP) and Rectus Sheath block|Pre-incision TAP block and Rectus sheath block will be performed after induction of anesthesia, just after prep and drape by Blind double pop technique by Anesthetist/Anesthesia trainee.Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be Immediate right subcostal region , 3 cm medially to mid axillary line The intervention and the control group will receive TAP block and rectus sheath block with Rupivacaine (3mg/kg). 1 ampule is of 10 ml and consists of 50mg /10ml, maximum dose will be 300mg. will use a of minimum volume of solution 50ml which will be made by 3 ampules of Rupivacaine and it will be diluted to a total of 20ml of injectate( distilled water )which is then divided between the four rectus block sites (5ml each) and one TAP block site(30ml ).
62144648|NCT05856682|ACTIVE_COMPARATOR|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee.Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be Immediate right subcostal region , 3 cm medially to mid axillary line The intervention and the control group will receive TAP block and rectus sheath block with Rupivacaine (3mg/kg). 1 ampule is of 10 ml and consists of 50mg /10ml, maximum dose will be 300mg. will use a of minimum volume of solution 50ml which will be made by 3 ampules of Rupivacaine and it will be diluted to a total of 20ml of injectate( distilled water )which is then divided between the four rectus block sites (5ml each) and one TAP block site(30ml each).
62349806|NCT02214485|EXPERIMENTAL|lower extremity strength training (LEST)|Subjects will receive training twice weekly for 12 weeks
61965304|NCT01489488|EXPERIMENTAL|Arm 1|
61965305|NCT01489488|EXPERIMENTAL|Arm 2|
62144649|NCT05387018||Observation group (hyperbaric oxygen + routine rehabilitation treatment)|
62144650|NCT05387018||control group (routine rehabilitation treatment)|
62144651|NCT02342652|EXPERIMENTAL|ASLAN003|Substance: ASLAN003 Administration route: Oral. Dosage form: Hard gelatine 50 mg capsules. Frequency: 100 mg (2 capsules) once daily for 14 consecutive days
62144652|NCT02342652|PLACEBO_COMPARATOR|Matched Placebo|Substance: Placebo Administration route: Oral Dosage form: Hard gelatine capsules Frequency: 2 capsules once daily for 14 consecutive days
62144653|NCT06238830||GROUP M|In patients undergoing elective Laparoscopic Cholecystectomy Surgery, after routine anesthesia induction, a magnesium loading dose of 30 mg/kg will be administered intravenously. Subsequently, a magnesium infusion will be initiated at a rate of 10 mg/kg/hour. Afterward, in the supine position, necessary field preparation and ultrasound (USG) setup will be conducted to administer the External Oblique Intercostal Plane (EOIP) block.The procedure will be applied unilaterally. After desufflation, patients will receive 50 mg dexketoprofen as standard analgesia administered intravenously as a non-steroidal anti-inflammatory drug (NSAID).
62349807|NCT04331990|ACTIVE_COMPARATOR|Standard Physical Therapy|Control group for the study. Intervention in the form of warm-up and strengthening, stretching and neuromuscular control exercises.
62349808|NCT04331990|EXPERIMENTAL|Intermittent Mechanical Traction|Standard care in addition to intermittent mechanical distraction of the knee joint.
62705864|NCT05294887|EXPERIMENTAL|diltiazem first, bisoprolol second|Crossover Design: diltiazem first, bisoprolol second, placebo third
62508027|NCT06453525||Airtraq|Intubation performed with an Airtraq videolaryngoscope
62508028|NCT03190772|EXPERIMENTAL|Positive placebo group|Participants receive a placebo nasal spray. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
62508029|NCT03190772|PLACEBO_COMPARATOR|Placebo control group|Participants receive a placebo nasal spray and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
62508030|NCT03190772|OTHER|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
62508031|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
62705865|NCT05294887|EXPERIMENTAL|diltiazem first, placebo second|Crossover Design: diltiazem first, placebo second, bisoprolol third
61965306|NCT01489488|EXPERIMENTAL|Arm 3|
61965307|NCT01489488|EXPERIMENTAL|Arm 4|
61965308|NCT01489488|EXPERIMENTAL|Arm 5|
61965309|NCT03637114|EXPERIMENTAL|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
61965310|NCT03637114|EXPERIMENTAL|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
62705866|NCT05294887|EXPERIMENTAL|placebo first, bisoprolol second|Crossover Design: placebo first, bisoprolol second, diltiazem third
62508032|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
62705867|NCT05294887|EXPERIMENTAL|placebo first, diltiazem second|Crossover Design: placebo first, diltiazem second, bisoprolol third
62705868|NCT04616898|ACTIVE_COMPARATOR|Diode Laser Treatment Only|Group 1: Patient 1- Laser Only This patient will present 20+, 14, 7, and 1 days prior to his/her scheduled abdominoplasty. Between 20 and 30 days prior, the patient will receive the first laser treatment on the 20+ day site 1. 14 days prior, the patient will receive laser treatment on the 14 day site 2. 7 days prior, the patient will receive laser treatment on the 7 day site 3. 1 day prior to the scheduled abdominoplasty, the patient will receive laser treatment on the 24 hour site 4.
62705869|NCT04616898|ACTIVE_COMPARATOR|Diode Laser and RadioFrequency Treatment|This patient will present 14 days and 7 days prior to his/her scheduled abdominoplasty. 14 days prior, the patient will be treated at site 1 with the laser and radiofrequency and site 3 with the laser only. 7 days prior, the patient will be treated at site 2 with the laser and radiofrequency and site 4 with the laser only.
62714994|NCT06070662||Suspected coronary microvascular disease not confirmed at angiography (expected n=4)|Individuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. If this is not confirmed coronary microvascular disease they will not undergo any further investigations as part of this research study.
61965311|NCT01369797|NO_INTERVENTION|reference|"reference group, where every patient will benefit: of the same GGA at home as those of the  specific intervention  group. The GGA results will not be supplied to the family practioner."
61965312|NCT01369797|EXPERIMENTAL|specific intervention|"specific intervention group, where every patient will benefit: of an GGA at home. According to the frailties or the detected morbidity, a specific plan of intervention will be established for the person. all the preventive actions will be coordinated by UPSAV."
61965313|NCT02573350|EXPERIMENTAL|Delamanid 100 mg BID + OBR|Participants received Delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) along with at least 4 additional anti-TB medications per optimized background regimen (OBR) from Week 0 to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment.
61965314|NCT02573350|EXPERIMENTAL|Delamanid 200 mg BID + OBR|Participants received Delamanid 200 mg (4x50 mg tablets), orally, BID along with at least 4 additional anti-TB medications per OBR up to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment. A participant might have been titrated to Delamanid 200 mg BID after an initial hospitalization of 2 weeks. Participants were grouped according to the longest duration of Delamanid dose administered during the study.
62144654|NCT06238830||GROUP K|"As part of standard analgesia, 50 mg dexketoprofen, administered intravenously as a non-steroidal anti-inflammatory drug (NSAID), will be applied, and these patients will be considered as the control group.~All patients will undergo general anesthesia induction with 1 µg/kg fentanyl, 2-3 mg/kg propofol, and 0.6 mg/kg rocuronium bromide. During anesthesia maintenance, a mixture of 50% O2 and air will be administered, and sevoflurane will be used at a minimum alveolar concentration of 0.8 (with a target MAC value of 0.8-1.2). Additionally, remifentanil will be administered at a rate of 0.01-0.2 mcg/kg/min. The remifentanil dose range will be increased if the patient\&#39;s Nociceptive Level (NOL) value remains elevated for 2 minutes when it exceeds 25. BIS monitoring will be performed for all patients, and the BIS value will be maintained between 40-50."
62144655|NCT06250868||Normal cornea|
61965315|NCT05471778|EXPERIMENTAL|comedy movie group|Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the comedy group on the first evening after surgery. 25-minute comedy film was watched. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
62144656|NCT00849485|EXPERIMENTAL|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra® 750 mg Tablet (reference) dosed in second period
62144657|NCT00849485|ACTIVE_COMPARATOR|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
62349809|NCT04331990|EXPERIMENTAL|Continuous Mechanical Traction|Standard care in addition to continuous mechanical distraction of the knee joint
62349810|NCT05572307||POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
62349811|NCT05572307||non-POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
62349812|NCT05572307||CPSP group|Patients were divided into CPSP group and non-CPSP group according to the occurrence of postoperative chronic pain
62349813|NCT05572307||non-CSP group|Patients were divided into CPSP group and non-CPSP group according to the occurrence of postoperative chronic pain
62349814|NCT06511440||Healthy group|Subject without eye disease
62349815|NCT01164865|EXPERIMENTAL|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
62349816|NCT01164865|ACTIVE_COMPARATOR|Clear Care|Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
62349817|NCT01486173||Premature infants with a GA < 32 Weeks|
62349818|NCT01486173||New born with a GA > 37Weeks|
62349819|NCT01626989|ACTIVE_COMPARATOR|BiPAP auto SV Advanced|BiPAP auto SV Advanced
62349820|NCT01626989|EXPERIMENTAL|BiPAP auto SV 4|Auto Servo Ventilation Device
62349821|NCT02236741||users of anti-parkinsonian drugs|
62508033|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
62508034|NCT05247931||CASE|patients experiencing a recurrent stroke while on ASA therapy
62508035|NCT05247931||CONTROL|ASA-naïve patients experiencing a first atherothrombotic stroke
62508036|NCT01696136|ACTIVE_COMPARATOR|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
62508037|NCT01696136|ACTIVE_COMPARATOR|AF-Ablation with single-tip electrode|Regular AF-ablation with a regular single-tip ablation catheter
62508038|NCT03334968||Patient group|Acute ischemic stroke patients
61965316|NCT05471778|EXPERIMENTAL|Music group|Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the music group on the first evening after surgery. 25 minutes of music (nature sound) was played. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
61965317|NCT05471778|NO_INTERVENTION|Control group|In the follow-up of the patient, no application was made other than clinical protocols. Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the control group on the first evening after surgery. No intervention was made. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
61965318|NCT02529345|EXPERIMENTAL|RoadSaver stent|patient treated with the RoadSaver stent of Terumo
61965319|NCT00826215|EXPERIMENTAL|1|Electroacupuncture treatment
61965320|NCT00826215|SHAM_COMPARATOR|2|Sham laser acupuncture
61965321|NCT03555591||Trelagliptin 100 mg|Trelagliptin 100 mg tablet, orally, once weekly for up to 36 months. Participants received interventions as part of routine medical care.
61965322|NCT00413127|EXPERIMENTAL|1|Lidocaine i.v
61965323|NCT00413127|ACTIVE_COMPARATOR|2|intraoperatively lidocaine epidural postoperatively lidocaine i.v.
62705870|NCT04616898|ACTIVE_COMPARATOR|Multiple Diode Treatments|These patients will present for three treatments, each four weeks apart, with the abdominoplasty scheduled four weeks following the last laser treatment. These patients will receive laser treatment every four weeks for twelve weeks on the sites labelled Multiple Tx below (sites 1 and 2) on Days -90, -60, and -30 prior to abdominoplasty. At the final treatment (Day -30), two additional diodes will be placed on the sites labelled Single Tx below (sites 3 and 4). 4 diodes total will be used at this visit. Four weeks following this last treatment, the scheduled abdominoplasty will be performed and the pannus containing the treated tissue will be excised.
62705871|NCT04425239|ACTIVE_COMPARATOR|CONTINUOUS ARM:|Patients will receive Panitumumab plus FOLFIRI until progressive disease, unacceptable toxicity or informed consent withdrawal.
62349822|NCT04268095|EXPERIMENTAL|No dressing change|Patients do not change dressing from procedure to first clinic followup after 14 days.
62349823|NCT04268095|EXPERIMENTAL|Ambulatory dressing change|Patients change dressing by an ambulatory nurse (not associated with the study) 2 times a week from surgery to first clinic followup after 14 days
62705872|NCT04425239|EXPERIMENTAL|INTERMITTENT ARM:|Patients will have a treatment free interval until progressive disease (PD), when they will receive up to 8 cycles of Panitumumab plus FOLFIRI. In the presence of complete or partial response, or stable disease, non-progressing patients will undergo again to treatment free interval until PD, when they will restart treatment. Treatment cycling will continue till any PD on treatment.
62705873|NCT05466383|ACTIVE_COMPARATOR|recommend exercise - perference exercise|
62705874|NCT05466383|ACTIVE_COMPARATOR|recommend exercise - perference brace|
62705875|NCT05466383|NO_INTERVENTION|recommend exercise - perference observation|
62705876|NCT05466383|ACTIVE_COMPARATOR|recommend brace - perference brace|
61965324|NCT00413127|ACTIVE_COMPARATOR|3|intraoperatively lidocaine i.v. postoperatively lidocaine epidural
62349824|NCT04268095|EXPERIMENTAL|No dressing|Patients take off dressing at post operative day 1 and clean it 3 times per day as instructed.
62349825|NCT05423002|PLACEBO_COMPARATOR|Control|Dim light condition as a baseline
61965325|NCT00413127|ACTIVE_COMPARATOR|4|lidocaine epidural
62349826|NCT05423002|ACTIVE_COMPARATOR|Modulation|Flickering light will be added sinusoidally onto the background light.
61965326|NCT00413127|PLACEBO_COMPARATOR|5|placebo i.v.
61965327|NCT03487276|PLACEBO_COMPARATOR|Cohort 1|Placebo
61965328|NCT03487276|EXPERIMENTAL|Cohort 2|Minimum Dose IFX-1 (400 mg Q4W)
61965329|NCT03487276|EXPERIMENTAL|Cohort 3|Low dose IFX-1 (800 mg Q4W)
61965330|NCT03487276|EXPERIMENTAL|Cohort 4|Medium Dose IFX-1 (800 mg Q2W)
61965331|NCT03487276|EXPERIMENTAL|Cohort 5|High Dose IFX-1 (1200 mg Q2W)
61965332|NCT05864872|EXPERIMENTAL|Ultrasound group|after blockage of the principal four nerves of the brachial plexus, the needle was redirected, and between 1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected (or less volume if the nerves appeared during the injection), in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
61965333|NCT05864872|ACTIVE_COMPARATOR|conventional group|after blockage of the principal four nerves of the brachial plexus, 3 to 6 mL of bupivacaine (at the discretion of the anesthesiologist) was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior to complete needle withdrawal
61965334|NCT05350111|OTHER|group supported through group education and telemedicine tools|the group of this pilot study will be compared to conventional obesity clinic
61965335|NCT00928603|EXPERIMENTAL|cryotherapy|Focal Cryotherapy of localized tumor of prostate after spatial definition by in-house extended perineal core biopsy using a template biopsy strategy under local or general anesthesia
61965336|NCT05924620|EXPERIMENTAL|Patients with PA using finerenone|Patients with PA divided into this group need to take finerenone for 60 days (20mg qd)
61965337|NCT05924620|NO_INTERVENTION|Patients with PA using spironolactone|Patients with PA divided into this group need to take spironolactone for 60 days (20mg qd)
61965338|NCT02376088||GA1|subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
62349827|NCT05423002|SHAM_COMPARATOR|Background|Constant light with maximum half irradiance (50%) of all primaries.
62349828|NCT02995122|EXPERIMENTAL|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62705877|NCT05466383|ACTIVE_COMPARATOR|recommend brace - perference exercise|
62705878|NCT05466383|NO_INTERVENTION|recommend brace - perference observation|
62705879|NCT00498628|EXPERIMENTAL|1|Quetiapine fumarate plus medical management
62705880|NCT00498628|PLACEBO_COMPARATOR|2|Medical management plus placebo comparator
62705881|NCT01180127|ACTIVE_COMPARATOR|exercise, dietary intervention|aerobic training and flavanol containing food product for 12 weeks
61965339|NCT02376088||GA2|subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
61965340|NCT02376088||GA3|subjects from coastal areas who were under Methimazole treatment and with a normal TH level
61965341|NCT02376088||GB1|subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
61965342|NCT02376088||GB2|subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
61965343|NCT02376088||GB3|subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
61965344|NCT02376088||NC|age-matched healthy checkup subjects
62705882|NCT01180127|ACTIVE_COMPARATOR|no exercise, dietary intervention|wait list control plus flavanol containing food product for 12 weeks
62705883|NCT01180127|ACTIVE_COMPARATOR|exercise, food product lacking flavanol|aerobic training plus food product without flavanol for 12 weeks
62705884|NCT01180127|PLACEBO_COMPARATOR|wait list control food additive without flavanol|wait list control plus food product without flavanol for 12 weeks
62705885|NCT05062421||Cases 1|Patients treated with JAK-type kinase inhibitors.
62705886|NCT05062421||Cases 2|Patients treated with monoclonal antibodies against TNF.
61965345|NCT03006497|NO_INTERVENTION|Control|The control group will not participate in any exercise program. However, at the end, home based exercises and special advice will be given to the participants.
61965346|NCT03006497|EXPERIMENTAL|Intervention|The intervention group will participate in an exercise program based on motor learning principles for 4 weeks/3 sessions per week, for a total of 12 sessions of 30-45 minutes each.
61965347|NCT02195440|EXPERIMENTAL|PRI-724|"3 cohorts (PRI-724: 10, 40, 160 mg/m2/day), 6 cycles (1 cycle: 1-week continuous i.v. administration+1-week observation period)~\*Cycle 2 will not be started until plasma drug concentrations of PRI-724 and C-82 on Days 1 and 2 in Cycle 1 are confirmed.~Cohort 1: 10 mg/m2/day (6 subjects) Cohort 2: 40 mg/m2/day (6 subjects) Cohort 3: 160 mg/m2/day (6 subjects) One cycle consists of 1-week continuous i.v. administration of PRI-724 followed by a 1-week observation period. The tolerability and safety after 6 cycles will be confirmed."
61965348|NCT00622245|EXPERIMENTAL|Lu AA34893: 4 mg|
62705887|NCT05062421||Cases 3|Patients treated with soluble receptor against TNF.
62705888|NCT05062421||Cases 4|Patients treated with FAME group biosimilars.
62705889|NCT05062421||Cases 5|Patients treated with rituximab.
62705890|NCT05062421||Cases 6|Patients treated with abatacept.
62705891|NCT05062421||Cases 7|Patients treated with drugs that block the IL6.
62705892|NCT02340195|EXPERIMENTAL|Idalopirdine (Lu AE58054) 60 mg (Group A)|8 patients with severe renal impairment and not on dialysis
62705893|NCT02340195|EXPERIMENTAL|Idalopirdine (Lu AE58054) 60 mg (Group B)|8 healthy subjects
61965349|NCT00622245|EXPERIMENTAL|Lu AA34893: 12 mg|
61965350|NCT00622245|EXPERIMENTAL|Lu AA34893: 18 mg|
61965351|NCT00622245|OTHER|Quetiapine fumarate|Active reference 300 mg
62144658|NCT02661932|EXPERIMENTAL|Letrozole associated COS|"Breast cancer patients undergo fertility preservation with letrozole associated COS for oocyte collection.~Letrozole is administered orally (5mg/day) during the entire stimulation protocol until ovulation triggering."
62349829|NCT06315855|EXPERIMENTAL|Telehealth Intervention (THI) arm|"The THI is a 6-month intervention. Participants randomized to THI arm will engage in 6,1-hour virtual sessions with trained study personnel. Modules contain a 1) participant check-in, 2) content designed to build oral health literacy and self-efficacy, 3) and goal-setting.~Coaches will use a facilitation guide, layered with motivational interviewing to conduct telehealth sessions. Participants will also receive biweekly text messages aligned with module content. Post-intervention follow-up will occur at 6- and 12-month post-randomization."
62705894|NCT02340195|EXPERIMENTAL|Idalopirdine (Lu AE58054) 60 mg (Group C)|"Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with moderate renal impairment"
61965352|NCT00622245|PLACEBO_COMPARATOR|Placebo|
61965353|NCT04219943|EXPERIMENTAL|Conservative Treatment for Impacted Femoral Neck Fracture|Conservative Treatment for Impacted Femoral Neck Fracture
61965354|NCT05086406|NO_INTERVENTION|In-Office Visit Group|This control group will undergo standard in-office pre-operative counseling visit.
62144659|NCT03365232|EXPERIMENTAL|non custom base attachment|
62144660|NCT03365232|ACTIVE_COMPARATOR|custom base attachment|
62144661|NCT00569439|EXPERIMENTAL|D5|5% Dextrose Solution in Normal Saline
62144662|NCT00569439|EXPERIMENTAL|D10|
62144663|NCT00569439|PLACEBO_COMPARATOR|NS|
62705895|NCT02340195|EXPERIMENTAL|Idalopirdine (Lu AE58054) 60 mg (Group D)|"Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with mild renal impairment"
62705896|NCT06341335|EXPERIMENTAL|Cadonilimab in combination with pulocimab and paclitaxel|Cadonilimab (AK104) in combination with pulocimab (AK109) and paclitaxel, iv, every 3 weeks
62705897|NCT06341335|ACTIVE_COMPARATOR|Placebo in combination with paclitaxel|Placebo in combination with Paclitaxel, iv, every 3 weeks
62705898|NCT03470025|EXPERIMENTAL|Psychological Intervention|A weekly combined face to face \& telephone-based PI (F-TPI); Psychological Intervention and medical therapy
62705899|NCT03470025|EXPERIMENTAL|A telephone-based PI (TPI)|Psychological Intervention - A telephone-based PI (TPI); Psychological Intervention and medical therapy
62705900|NCT03470025|NO_INTERVENTION|Optimal medical therapy|Patients will receive optimal medical therapy
62705901|NCT04165837|EXPERIMENTAL|Active|
62705902|NCT04165837|PLACEBO_COMPARATOR|Placebo|
62705903|NCT01331655|EXPERIMENTAL|Arm 1|
62705904|NCT01331655|EXPERIMENTAL|Arm 2|
62705905|NCT01331655|ACTIVE_COMPARATOR|Arm 3|
62705906|NCT03822611|EXPERIMENTAL|Targeted Subsidy|In these communities, households identified as vulnerable receive a voucher for a free latrine sub-structure (slab + pit lining), redeemable with local sanitation suppliers.
62705907|NCT03822611|NO_INTERVENTION|No subsidy|In these communities, no household receives a voucher.
62705908|NCT06179264|EXPERIMENTAL|Treatment|Following random assignment to the condition after completing baseline assessment, participants will be instructed to complete the ACT Guide for Chronic Health Conditions program over the next 6 weeks.
62144664|NCT03622710|EXPERIMENTAL|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
62144665|NCT03622710|ACTIVE_COMPARATOR|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
62349830|NCT06315855|NO_INTERVENTION|Usual Care (UC) arm|This group will receive biweekly text messages on general health behaviors as a retention strategy. This arm will receive no other outside interventions. The Dental Resource directory will be provided to all participants.
62508039|NCT03334968||Control group|Those served as control group
62508040|NCT03134430|PLACEBO_COMPARATOR|Normal saline|equal volume of normal saline as treatment group
62705909|NCT06179264|NO_INTERVENTION|Waitlist Control|Following random assignment to the condition after completing baseline assessment, participants will be instructed to wait to receive the intervention after a period of 10 weeks (this accounts for the 6 weeks that treatment condition participants are given to complete the program, plus the 4 interim between post-assessment and follow-up.
62705910|NCT01055951|EXPERIMENTAL|Solo MicroPump|
62705911|NCT03364504|EXPERIMENTAL|PXE patients|urine collection and culture of renal cells
62705912|NCT00304161|ACTIVE_COMPARATOR|Atomoxetine|Participants will receive 40-80mgs of atomoxetine orally once daily.
62705913|NCT00304161|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.
62705914|NCT05096130|NO_INTERVENTION|Control Group - No intervention|The control group will not participate in any intervention for the duration of the study. In addition, the participants will be instructed to follow their usual daily schedule for 6 months. Changes in health, medication, or habits will be discussed by the investigators' team and reassess the continuation or the termination of the investigated participant.
62705915|NCT05096130|EXPERIMENTAL|Lifestyle Medicine Strategies Groupo|The LSM (LifeStyle Medicine) group, will receive a 6-month lifestyle change intervention targeting the correction of diet, improving physical activity and exercise levels, reducing stress levels, and improving sleep hygiene by LSM registered professionals.
62349831|NCT03779893|ACTIVE_COMPARATOR|conventional group|Conventional resin based Pits \& fissures sealant 3M™ Clinpro™ Sealant is administrated
62349832|NCT03779893|EXPERIMENTAL|bioactive group|Bioactive Pits \& fissures sealant BioCoat® by Premier®.
62349833|NCT03008733|ACTIVE_COMPARATOR|NMMCB|patient with Neuropathies with Motrices Multifocal Conduction Block
62349834|NCT03008733|ACTIVE_COMPARATOR|PICD|patient with Inflammatory demyelinating polyneuropathy Chronicle
62349835|NCT03008733|ACTIVE_COMPARATOR|anti MAG|patient with neuropathy antibody Anti-MAG
62349836|NCT03008733|PLACEBO_COMPARATOR|healthy|healthy patient
62349837|NCT04713579||Premature infants|Infants born prematurely requiring a stoma for condition such as necrotizing enterocolitis (NEC) or spontaneous intestinal perforation (SIP).
62349838|NCT04713579||Term Infants|Infants born closer to term requiring a stoma e.g. for congenital causes of bowel obstruction such as intestinal atresia, gastroschisis or meconium ileus
62349839|NCT02405650||CRIC VAP cohort|"If eligible, the participant will have additional testing at regular annual CRIC Visit. The following will occur:~* abdominal and pelvic Magnetic Resonance Imaging (MRI) scan~* 400 meter walk test for physical fitness"
62349840|NCT03017846|EXPERIMENTAL|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
62349841|NCT00566449|EXPERIMENTAL|001|JNJ-31001074 10 mg daily for 4 weeks
62349842|NCT00566449|PLACEBO_COMPARATOR|003|Placebo one dose daily for 4 weeks
62349843|NCT00566449|EXPERIMENTAL|002|JNJ-31001074 30 mg daily for 4 weeks
61965355|NCT05086406|EXPERIMENTAL|Virtual Visit Group|This study group will receive pre-operative counseling via video, created by the Department of Gynecology at Cleveland Clinic Florida, followed by a virtual visit with a gynecologic surgery provider.
61965356|NCT02148198|ACTIVE_COMPARATOR|1g NWT-03, then placebo|7 days 1g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
61965357|NCT02148198|PLACEBO_COMPARATOR|placebo, then 1g NWT-03|7 days placebo, followed by 7days 1g NWT-03, separated by a 5-day wash-out period
61965358|NCT02148198|ACTIVE_COMPARATOR|2g NWT-03, then placebo|7 days 2g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
62349844|NCT05710965|ACTIVE_COMPARATOR|FRx-001|FRx-001 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and scheduled assistive messaging.
62349845|NCT05710965|ACTIVE_COMPARATOR|FRx-003|FRx-003 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and may include periodic assistive messaging.
62349846|NCT05710965|ACTIVE_COMPARATOR|FRx-004|FRx-004 is a wearable digital intervention that displays periodic therapeutic assistive messaging.
62508041|NCT03134430|ACTIVE_COMPARATOR|peripheral Nerve block|0.35% ropivacaine and 0.5% lidocaine in normal saline
62508042|NCT06616961|EXPERIMENTAL|Semaglutide|This study features a single treatment arm where participants receive semaglutide (Fitaro) for weight management. Administered subcutaneously once weekly, the treatment begins at 0.25 mg and escalates to a maximum of 2.4 mg over 16 weeks based on individual response and tolerance. Participants include overweight or obese adults aged 18 and older, with or without Type 2 Diabetes Mellitus (T2DM). The primary focus is to assess the efficacy and safety of semaglutide in achieving significant weight loss, while also evaluating its impact on metabolic parameters like body mass index (BMI), waist circumference, blood glucose levels, and overall quality of life. Alongside medication, participants will receive lifestyle counseling to encourage dietary adjustments and increased physical activity. Regular follow-up assessments will be conducted to monitor weight loss progress, metabolic health, and any treatment-related adverse events throughout the study duration.
62508043|NCT04791488|EXPERIMENTAL|Healthy individuals|
62508044|NCT04791488|EXPERIMENTAL|Decompression sickness patients|
62508045|NCT04351347|EXPERIMENTAL|Ivermectin|Ivermectin alone in larger doses
62508046|NCT04351347|NO_INTERVENTION|Standard treatment|Standard of care treatment
61965359|NCT02148198|PLACEBO_COMPARATOR|placebo, then 2g NWT-03|7 days placebo, followed by 7days 2g NWT-03, separated by a 5-day wash-out period
61965360|NCT02148198|ACTIVE_COMPARATOR|5g NWT-03, then placebo|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
62508047|NCT04614584|EXPERIMENTAL|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
62508048|NCT04614584|PLACEBO_COMPARATOR|Placebo|Placebo 30 mg PO Daily x 4 days
62508049|NCT03214302|NO_INTERVENTION|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA \> 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
61965361|NCT02148198|PLACEBO_COMPARATOR|placebo, then 5g NWT-03|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
61965362|NCT03871712|EXPERIMENTAL|Motivational Interview (MI)|In the MI arm, a NAV case worker will meet the participants after the baseline assessment (electronic questionnaires) and randomisation and conduct the MI. The NAV case-worker will either meet (or call) again after a few weeks (anticipated 2-4 weeks) and conduct another MI.
61965363|NCT03871712|ACTIVE_COMPARATOR|Stratified vocational advice intervention (SVAI)|A trained physiotherapist will call the participants after the baseline assessment and randomisation. The SVAI intervention will be stratified due to the participants risk of long term sick leave estimated by the Orebro Screening Questionnaire and The Keele STarT MSK Tool. The low/moderate risk group will receive 1-2 phone calls, and the high risk group will be followed up 2-4 times. The follow-up can include face to face Meetings bewteen the Physical therapist and the participant, and also the employer and general practitioner when needed. The intervention will include an assessment of the participants obstacles for returning to work and help to develop and implement an action plan to overcome obstacles. The physical therapists' will cooperate with other health care providers and employer when needed.
61965364|NCT03871712|NO_INTERVENTION|Usual follow-up|This arm will be the control group receiving usual NAV follow-up. The other two groups will also receive usual NAV follow-up additionally to the interventions.
61965365|NCT04829903|ACTIVE_COMPARATOR|Group DUL|Group taking Dulaglutide injections
61965366|NCT04829903|PLACEBO_COMPARATOR|Group LIR|Group taking Liraglutide injections
62508050|NCT03214302|EXPERIMENTAL|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA \> 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
62705916|NCT01058746|ACTIVE_COMPARATOR|pts undergoing pancreatic resection Restrictive arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from 8am to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. After randomization occurs, those patients randomized to the Restricted Arm will continue to receive Normosol or equivalent solution at 6ml/kg/operative hour.
62705917|NCT01058746|ACTIVE_COMPARATOR|pts undergoing pancreatic resection Liberal arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from midnight to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. Those patients randomized to the Liberal Arm will receive an additional Normosol bolus or equivalent solution equal to (another) 1.5 ml/kg/fasted hour IV (to bring the total to 2 ml/kg/fasted hour) plus an additional bolus of Normosol or equivalent solution 6ml/kg/operative hour to bring the hourly rate to 12ml/kg/operative hour with a maximum of 1000 ml/operative hour.
61965367|NCT03679936||Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
61965368|NCT03679936||Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
62144666|NCT02448069|EXPERIMENTAL|Argatroban treatment|Intravenous Argatroban delivered at 100mcg/kg bolus, then 12-hour infusion initiated at 3mcg/kg/min.
62144667|NCT03642834|EXPERIMENTAL|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
62144668|NCT02727205|EXPERIMENTAL|Single Arm|One-half (½) of the test patch and one-half (½) of the reference patch (Rotigotine Transdermal System) was applied daily to the same site for each product over a 21 day period followed by a 14 day rest phase and a 48 hour challenge phase.
62508051|NCT04661449|EXPERIMENTAL|Lifestyle Intervention|every 3 months within 1 year.
62705918|NCT05538728|ACTIVE_COMPARATOR|8ml|Device: Sculptra current label dilution for treatment of wrinkles in the decolletage area
62705919|NCT05538728|ACTIVE_COMPARATOR|17ml|Experimental: PLLA new dilution volume for treatment of wrinkles in the decolletage area
62705920|NCT06247137|ACTIVE_COMPARATOR|Dietary supplement|
62705921|NCT06247137|PLACEBO_COMPARATOR|Placebo|
62508052|NCT04661449|NO_INTERVENTION|control group|Regular follow-up every 6 months within 1 year.
62508053|NCT02775578|EXPERIMENTAL|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
62705922|NCT02179034|PLACEBO_COMPARATOR|Tobacco Flavor|In this arm, subjects will receive tobacco flavor- without nicotine (placebo). Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
61965369|NCT03679936||Multiple primary lung cancer group|PET/CT dynamic scan,needle biopsy and gene detection
61965370|NCT03679936||Intrapulmonary metastases group|PET/CT dynamic scan,needle biopsy and gene detection
61965371|NCT05846945|ACTIVE_COMPARATOR|IMT group|Training by inspiratory muscle device plus chest physiotherapy
61965372|NCT05846945|ACTIVE_COMPARATOR|TS group|Adjusting trigger sensitivity of the mechanical ventilator to the lowest pressure tolerated plus chest physiotherapy
61965373|NCT05846945|SHAM_COMPARATOR|PT group|Routine chest physiotherapy
61965374|NCT01506128||HPV|Premenopausal women with HSIL in Pap test or high-risk HPV
61965375|NCT00313378|EXPERIMENTAL|ketamine|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
62144669|NCT03543059||exposure group|exposed to some factors
62144670|NCT03543059||control group|not exposed to some factors
62349847|NCT05269641|EXPERIMENTAL|Almonds|Daily consumption of almonds.
62144671|NCT05912374|ACTIVE_COMPARATOR|Control arm with standard intervention|Participants will complete a 4-week CHRP-BB standard intervention
62349848|NCT05269641|PLACEBO_COMPARATOR|Control Snack|Daily non-nut snack will be consumed.
62508054|NCT02775578|EXPERIMENTAL|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
61965376|NCT00313378|OTHER|placebo|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
61965377|NCT02490228|OTHER|surgical group|transurethral resection of urethral caruncle
62705923|NCT02179034|ACTIVE_COMPARATOR|Low Dose Nicotine|In this arm, subjects will receive a low dose of nicotine (6 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
62705924|NCT02179034|ACTIVE_COMPARATOR|High Dose Nicotine|In this arm, subjects will receive a high dose of nicotine (12 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
61965378|NCT02683161|OTHER|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
62705925|NCT05391555|EXPERIMENTAL|Noninteractive, then Interactive|Participants undergo the infusion under noninteractive conditions, followed by a second drug infusion under interactive conditions.
62705926|NCT05391555|EXPERIMENTAL|Interactive, then Noninteractive|Participants undergo the infusion under interactive conditions, followed by a second drug infusion under noninteractive conditions.
61965379|NCT01221571|EXPERIMENTAL|AFM13|IV (intravenous) infusion, dose escalation
62144672|NCT05912374|EXPERIMENTAL|Experimental arm with enhanced intervention|Participants will complete a 4-week CHRP-BB intervention enhanced with included cognitive dysfunction accommodation strategies.
62144673|NCT01584596|EXPERIMENTAL|Adapted Diet and Physical Activity|Adapted diet and physical activity guidelines sessions
62705927|NCT03224845|EXPERIMENTAL|Cognitive behavioural skills training|
62705928|NCT03224845|NO_INTERVENTION|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
62144674|NCT01584596|ACTIVE_COMPARATOR|Adapted Diet|Adapted dietary guidelines sessions
61965380|NCT02638545|EXPERIMENTAL|dexmedetomidine|
62349849|NCT05568498|EXPERIMENTAL|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5\*10\^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10\^9 CFU/gram) per day.
62349850|NCT05568498|PLACEBO_COMPARATOR|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
62349851|NCT03288324|EXPERIMENTAL|Tofacitinib Arm|open-label study
62508055|NCT02775578|EXPERIMENTAL|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
62705929|NCT04883944|EXPERIMENTAL|Intervention group|All the enrolled infants will receive the heel stick procedure with the maternal involvement after mother will be trained on the application of the non-pharmacological techniques during the performance of the procedure.
62705930|NCT04883944|ACTIVE_COMPARATOR|Standard care|All the enrolled infants will receive the heel stick procedure according to local protocol without the maternal involvement. The non-pharmacological techniques will be performed by a second nurse not involved in the heel stick procedure itself.
62705931|NCT01280331|EXPERIMENTAL|Q8003 12 mg/8 mg|Combination
62705932|NCT01280331|ACTIVE_COMPARATOR|Morphine sulfate 24 mg|Single component
62705933|NCT01280331|ACTIVE_COMPARATOR|Oxycodone HCl 16 mg|Single component
61965381|NCT04286321|EXPERIMENTAL|Zero hard-boiled egg|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
61965382|NCT04286321|EXPERIMENTAL|Two egg whites|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two egg whites (0 g fat) prior to the 72-h pharmacokinetics trial.
61965383|NCT04286321|EXPERIMENTAL|Two hard-boiled eggs|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two whole eggs (9.6 g fat) prior to the 72-h pharmacokinetics trial.
61965384|NCT04286321|EXPERIMENTAL|Vegetable oil|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with vegetable oil (9.6 g fat) prior to the 72-h pharmacokinetics trial.
61965385|NCT04897308|ACTIVE_COMPARATOR|Suprascapular nerve block|This group will include will under go suprascapularnerve block as following :10 ml of .5% bupivacaine and 2 ml of methylpradnisolon 40mg/ml
61965386|NCT04897308|ACTIVE_COMPARATOR|Hydrodilatation of shoulder capsule|This group will undergo intraarticular hydrodilatation by injection of :first lidocaine10ml%followed by 1ml of methylprednisolon 40mg/ml and finally 20ml of .9 % sodium chloride slowly in the gleno humeral joint
61965387|NCT04897308|ACTIVE_COMPARATOR|Hydrodilatation of shoulder interval|This group will undergo interval hydrodilatation by injection of :first mepivacaine 10ml folowed by 20ml of sterile water slowly in the shoulder interval
62144675|NCT01018550|EXPERIMENTAL|AMG 853|
62144676|NCT01018550|PLACEBO_COMPARATOR|Placebo|
62144677|NCT02506452|ACTIVE_COMPARATOR|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading device
62144678|NCT02506452|ACTIVE_COMPARATOR|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading device
62144679|NCT03620955||Risk stratification|Risk stratification based on cytogenetic and molecular and MRD level after three courses of chemo therapy.
62144680|NCT04559074|EXPERIMENTAL|Interventional|Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
62144681|NCT04559074|NO_INTERVENTION|Observational|This group will record blood pressure readings and data on a daily basis for a total of 3 months. They will not take any medication. They will be reviewed on a monthly basis in consultations.
61965388|NCT01576263||Total knee arthroplasty|25 consecutive patients diagnosed for total knee arthroplasty.
61965389|NCT01576263||Total hip arthroplasty|27 patients diagnosed for total hip arthroplasty.
61965390|NCT00822991|ACTIVE_COMPARATOR|Group of CE-US|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
61965391|NCT00822991|ACTIVE_COMPARATOR|Group of B-mode US|screening by conventional B-mode US every 3-5 months
61965392|NCT05420077|EXPERIMENTAL|RVM-V001 10 µg|RVM-V001-10 µg administered as a single dose of by intramuscular injection on Day 1
61965393|NCT05420077|EXPERIMENTAL|RVM-V001 30 µg|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1
61965394|NCT05420077|EXPERIMENTAL|RVM-V001 60 µg|RVM-V001-60 µg administered as a single dose of by intramuscular injection on Day 1
61965395|NCT03903705|EXPERIMENTAL|VEGFR cohort:|Fruquintinib
61965396|NCT03944460|ACTIVE_COMPARATOR|Contraloid 4 mg|4 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965397|NCT03944460|ACTIVE_COMPARATOR|Contraloid 12 mg|12 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965398|NCT03944460|ACTIVE_COMPARATOR|Contraloid 36 mg|36 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965399|NCT03944460|ACTIVE_COMPARATOR|Contraloid 108 mg|108 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965400|NCT03944460|ACTIVE_COMPARATOR|Contraloid 320 mg|320 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965401|NCT03944460|PLACEBO_COMPARATOR|Placebo (for Contraloid) 4 mg|4 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965402|NCT03944460|PLACEBO_COMPARATOR|Placebo (for Contraloid) 12 mg|12 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965403|NCT03944460|PLACEBO_COMPARATOR|Placebo (for Contraloid) 36 mg|36 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965404|NCT03944460|PLACEBO_COMPARATOR|Placebo (for Contraloid) 108 mg|108 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
61965405|NCT03944460|PLACEBO_COMPARATOR|Placebo (for Contraloid) 320 mg|320 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
62349852|NCT02518100|EXPERIMENTAL|VSP 3-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 3-lead (NEHB) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
61965406|NCT03393624||Cases: patients with dark circles|Patients who believe they have periorbicular hyperchromia and have a confirmatory physical examination performed by a dermatologist.
61965407|NCT03393624||Controls: patients without dark circles|Patients who believe that they do not have periorbicular hyperchromia under their eyes and have physical examination that excludes dark circles carried out by a dermatologist.
61965408|NCT00187486|EXPERIMENTAL|Temodar plus Tarceva plus Radiation Therapy|Single arm phase-2 experimental treatment of newly diagnosed patients with Glioblastoma with Temodar plus Tarceva plus Radiation Therapy
61965409|NCT00471068|EXPERIMENTAL|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
61965410|NCT00471068|ACTIVE_COMPARATOR|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
61965411|NCT03013478|NO_INTERVENTION|Standard treatment as usual (TAU)|Treatment normally offered at this primary care clinic
61965412|NCT03013478|ACTIVE_COMPARATOR|TAU plus CBT4CBT program|Treatment normally offered at this clinic PLUS 8 weeks of CBT4CBT computerized therapy.
61965413|NCT04812964|ACTIVE_COMPARATOR|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
61965414|NCT04812964|ACTIVE_COMPARATOR|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
61965415|NCT05623098||Dietary fiber was not added to enteral nutrition preparation|Dietary fiber was not added to enteral nutrition preparation
61965416|NCT05623098||Dietary fiber was added to enteral nutrition preparation|Dietary fiber was added to enteral nutrition preparation
61965417|NCT00664872|EXPERIMENTAL|case management|
61965418|NCT02466178||Serene RF System|Percutaneous delivery of radiofrequency (RF) energy to create a temporary conduction block to the corrugator and/or procerus muscles.
61965419|NCT01991210|EXPERIMENTAL|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
61965420|NCT01991210|ACTIVE_COMPARATOR|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
61965421|NCT01828281|ACTIVE_COMPARATOR|Therapeutic CPAP|Therapeutic CPAP
61965422|NCT01828281|SHAM_COMPARATOR|control|subtherapeutic CPAP using 4 cm water
61965423|NCT03812094|ACTIVE_COMPARATOR|Basic Bladder advice|Basic bladder advice as given from a pre-specified document, study nurse
62349853|NCT02518100|EXPERIMENTAL|VSP 1-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration. The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 1-lead (PAL) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
61965424|NCT03812094|ACTIVE_COMPARATOR|Alarm|Alarm Enurad 400
61965425|NCT03812094|NO_INTERVENTION|No treatment|No treatment during study period.
62349854|NCT06049615|EXPERIMENTAL|CLAAS|Subjects to be implanted with the CLAAS device.
62349855|NCT04285944|ACTIVE_COMPARATOR|Study|
62349856|NCT04285944|NO_INTERVENTION|Control|
62705934|NCT00410683|EXPERIMENTAL|Radiotherapy|Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
61965426|NCT06024356||Experimental|long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks). Thymalfasin was started on the first day of neoadjuvant chemoradiotherapy, 1.6 mg subcutaneously twice a week until the end of the last neoadjuvant treatment.
61965427|NCT06024356||Control|long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks).
61965428|NCT02835820|EXPERIMENTAL|Ketogenic Diet Group|Ketogenic meals (3 meals/day, 7 days/week x 12 weeks) prepared and delivered to participants.
62705935|NCT00410683|ACTIVE_COMPARATOR|No radiotherapy|Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
62705936|NCT06080555|EXPERIMENTAL|Test product-Ferric carboxymaltose Injection provided by SichuanHuiyuPharma|
62705937|NCT06080555|ACTIVE_COMPARATOR|Reference product-marketed by Vifor France|
62705938|NCT04281667|EXPERIMENTAL|Mechanical Bowel Preparation and Oral Antibiotics|Mechanical Bowel Preparation and Oral Antibiotics
62705939|NCT04281667|ACTIVE_COMPARATOR|Mechanical Bowel Preparation Only|Mechanical Bowel Preparation Only
62705940|NCT02444754||Health services research (surveys, questionnaires)|Patients complete survey items across a number of domains (patient characteristics, access to health care, perceived quality of care, clinical trial knowledge and attitudes, and cancer related health needs). Patients also complete questionnaires to obtain demographics information including age, education, race and ethnicity, marital status, employment status, insurance coverage, and income, as well as health status/indicators. Cancer-related characteristics, including diagnosis, stage, time since diagnosis, and treatments received are obtained self-report and patients' medical records.
62705941|NCT06424639|EXPERIMENTAL|Luspatercept combined with cyclosporine|Administered Luspatercept (1.0 mg/kg, subcutaneous injection every 3 weeks), and Cyclosporine (3-5mg/kg/day) adjusted according to hematological parameters, for at least 6 months to evaluate efficacy. Effective patients will continue to receive Cyclosporine treatment for at least 1.5 years, followed by a gradual reduction in dosage.
61965429|NCT02835820|NO_INTERVENTION|Patient Choice Diet|Control.
61965430|NCT05945524|EXPERIMENTAL|Analysis of bone marrow|Analysis of bone marrow in patients initiated treatment by Teclistamab for 18 cycles
61965431|NCT02312661|EXPERIMENTAL|Carboplatin / paclitaxel /metformin|Three-weekly cycles of carboplatin/paclitaxel chemotherapy in combination with metformin treatment
61965432|NCT00540826||A|A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
61965433|NCT00540826||B|B: ADHD-patients receiving stimulants
61965434|NCT03032146|EXPERIMENTAL|participation in cardiac rehabilitation|Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.
61965435|NCT03032146|NO_INTERVENTION|control|Patients who chose not to participate in the rehabilitation program, despite being offered the option.
61965436|NCT05099874|EXPERIMENTAL|EndeavorRx|Children will be asked to begin attentional control training at home within two weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).
61965437|NCT01996501|EXPERIMENTAL|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
61965438|NCT01655472|ACTIVE_COMPARATOR|healthy parents|
61965439|NCT01655472|ACTIVE_COMPARATOR|schizophrenic parents|
61965440|NCT03075540|OTHER|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
62144682|NCT04255225|EXPERIMENTAL|10-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
62144683|NCT04255225|EXPERIMENTAL|20-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
62714995|NCT06070662||Multivessel coronary artery disease (n=12)|Individuals with multivessel coronary artery disease, diagnosed based on CT and MRI scans completed as part of the main research study and confirmed at angiography.
61965441|NCT05494333||2|NO INTERVENTION
61965442|NCT04144205|EXPERIMENTAL|Fraction of inspired oxygen setting change|
61965443|NCT01177592|EXPERIMENTAL|Guided Therapy|Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19\*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
61965444|NCT01177592|NO_INTERVENTION|Standard Therapy|Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.
61965445|NCT01942330|NO_INTERVENTION|Traditional Laparoscopic-Assisted Colectomy|
61965446|NCT01942330|EXPERIMENTAL|Transvaginal Laparoscopic-Assisted Colectomy|Laparoscopic-Assisted Natural Orifice Surgery
61965447|NCT01822431||Patients with type 1 diabetes mellitus|Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring
61965448|NCT01822431||Healthy controls|Autonomic function tests, Pupillometry, Holter monitoring
61965449|NCT01513473|EXPERIMENTAL|Insulin Degludec + Insulin Aspart|
62144684|NCT04255225|EXPERIMENTAL|30-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
62144685|NCT05885620|ACTIVE_COMPARATOR|regular|"components of interventions:~1. short vibration and short audio signal,~2. textual greeting,~3. textual prompt,~4. picture~5. short vibration"
62705942|NCT06424639|EXPERIMENTAL|cyclosporine|Give cyclosporine 3-5mg/kg/day, adjust the dose based on the blood count, and administer it for at least 6 months to evaluate the efficacy. If effective, the patient will continue to receive cyclosporine treatment for at least 1.5 years, followed by a gradual reduction in dosage.
62705943|NCT06505460|EXPERIMENTAL|real tDCS|In transcranial direct current stimulation, the constant current of 2.0 mA was applied to each site for up to 20 minutes.
61965450|NCT01513473|EXPERIMENTAL|Insulin Detemir +Insulin Aspart|
61965451|NCT02299700||Autism Spectrum Disorder (ASD) Participants (6-9 years)|Participants with ASD aged 6 to 9 years will be observed for the usability of the Janssen Autism Knowledge Engine (JAKE) personal healthcare record (pHR) and biosensors in stage 1 and stage 2 (at laboratory sites).
61965452|NCT02299700||ASD Participants (13-17 years)|Participants with ASD aged 13 to 17 years will be observed for the usability of the JAKE pHR and biosensors in stage 1 and stage 2 (at laboratory sites).
61965453|NCT02299700||ASD Participants (3 or greater than 3 years)|Participants with ASD aged 3 or greater than 3 years will be observed for the usability of the JAKE pHR and biosensors in stage 2 (at clinical sites).
61965454|NCT02074111||Intracranial atherosclerotic stroke|
61965455|NCT02074111||Moyamoya disease|
61965456|NCT02074111||Healthy controls|
61965457|NCT06115213|EXPERIMENTAL|Patient screening|Single group, no masking, receiving the intervention
61965458|NCT06104670|EXPERIMENTAL|Experimental: Synaquell Male Group|Male youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
61965459|NCT06104670|PLACEBO_COMPARATOR|Placebo Comparator: Placebo Male Group|Male youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
62144686|NCT05885620|ACTIVE_COMPARATOR|intense|"components of interventions:~1. long vibration and long audio signal,~2. textual greeting,~3. textual prompt and speech output,~4. animation~5. long vibration"
61965460|NCT06104670|EXPERIMENTAL|Experimental: Synaquell Female Group|Female youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
61965461|NCT06104670|PLACEBO_COMPARATOR|Placebo Comparator: Placebo Female Group|Female youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
61965462|NCT05130398|EXPERIMENTAL|the rVSVΔG-ZEBOV-GP vaccine|Participants of the experimental arm will receive a single intramuscular dose of ≥7.8 x 107 pfu of the rVSVΔG-ZEBOV-GP vaccine. In total, 80 participants will receive the experimental vaccine: 40 participants aged 6-12 years and 40 aged 1-5 years.
61965463|NCT05130398|ACTIVE_COMPARATOR|The Chikenpox or Varicella (Varilix) vaccine|The control arm consists of the chickenpox vaccine. Forty children will receive a single subcutaneous dose of Varilix, the active comparator vaccine, 20 aged 6-12 years and 20 aged 1-5 years
61965464|NCT05130398|EXPERIMENTAL|Fibre and equilibrate diet|Participants were assigned to receive two meals daily ( breakfast and lunch) for 21 days. About 30 children are randomly assigned to fibre and equilibrate diet.
61965465|NCT05130398|EXPERIMENTAL|Active detection and treatment of pathogens according to standard of care|The following pathogens: P. falciparum, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, intestinal protozoa, BG+, BG- colonies and pathogens, SARS-CoV2 are actively detected and treated according to the standard of care every month. About 30 children are randomly assigned to this arm.
61965466|NCT05130398|EXPERIMENTAL|Diet plus Active detection and treatment of pathogens according to standard of care|Participants were assigned to receive two meals daily ( breakfast and lunch) for 21 days and concomitantly assigned to active detection of P. falciparum, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, intestinal protozoa, BG+, BG- colonies and pathogens, SARS-CoV2 every month. About 30 children are assigned to receive combined interventions
61965467|NCT05130398|PLACEBO_COMPARATOR|No diet and no pathogen detection|About 30 children received no diet and no active detection of pathogens
62144687|NCT03383848|EXPERIMENTAL|Experimental Software Group|Subjects in the experimental group will be provided with free access to the medication management software online, which will be able to be accessed on the SmartPhone/SmartDevice and home tablet(s) or computer(s) of their choice, through any browser. They will also be provided with links to the surveys to be filled out in the REDCap secure web application throughout the study.
62144688|NCT03383848|NO_INTERVENTION|Control Group|Subjects in the control group will receive standard of care, and will receive emails with links to the surveys to be filled out in the REDCap secure web application throughout the study.
62705944|NCT06505460|SHAM_COMPARATOR|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
62705945|NCT01238887|PLACEBO_COMPARATOR|microcrystalline cellulose|
62705946|NCT01238887|ACTIVE_COMPARATOR|Hydroxycitric acid|2800 mg divided in three doses per day
62705947|NCT01238887|ACTIVE_COMPARATOR|Hydroxycitric Acid|5400 mg divided into three doses per day
62705948|NCT00223145|EXPERIMENTAL|Arm 1|Androgen blockade for 6 months + Radiotherapy 70 Gy
62705949|NCT00223145|EXPERIMENTAL|Arm 2|Androgen blockade for 6 months + Radiotherapy 76 Gy
62705950|NCT00223145|ACTIVE_COMPARATOR|Arm 3|Radiotherapy alone with 76 Gy
62714996|NCT05874726||Bariatric Surgery Patients|Subjects who have had bariatric surgery for obesity - primary and revision. Bariatric surgical procedures include laparoscopic adjustable gastric banding (LAGB), laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), bilio-pancreatic diversion (BPD) with or without duodenal switch (BPD-DS).
62705951|NCT02448381|ACTIVE_COMPARATOR|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
62705952|NCT02448381|PLACEBO_COMPARATOR|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
62705953|NCT04417985|EXPERIMENTAL|18F-FDG PET/CT with MRI and blood sampling|"The enrolled subjects received 18F-FDG PET/CT and MRI before, during, and after the primary definitive treatment.~The blood sample was collected on the same day of PET/CT scan."
62705954|NCT05342168|EXPERIMENTAL|Histology|Specimen samples from the tradition pinch esophageal biopsy and the supernatant sample obtained from the mesh sponge (Cytosponge TM) will each be fixed and stained. The eosinophil count per high power field for the mesh sponge sample and the traditional biopsy sample will be compared for each subject.
62705955|NCT04881084|EXPERIMENTAL|Digital storytelling group (Group 1)|Participants will be randomly assigned to the digital storytelling group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six digital storytelling videos which will be assessed using a between-subjects design.
61965468|NCT01262053|EXPERIMENTAL|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated.
62144689|NCT01855165|EXPERIMENTAL|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
62144690|NCT01855165|NO_INTERVENTION|General advice|
62144691|NCT06199115|NO_INTERVENTION|Control|Patients will not receive any intervention during their oxaliplatin chemotherapy cycles.
61965469|NCT01262053|EXPERIMENTAL|Active Intervention|The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders.
61965470|NCT01262053|ACTIVE_COMPARATOR|Control|Parallel control with no intervention
61965471|NCT05276401|EXPERIMENTAL|Active|Dosage Form: Topical Antimicrobial Gel; Dosage: 5% Gel, 10% Gel; Frequency: BID for 28 days
61965472|NCT05276401|PLACEBO_COMPARATOR|Placebo|Dosage Form: Topical Gel; Dosage: Placebo; Frequency: BID for 28 days
61965473|NCT03673332|EXPERIMENTAL|treatment including immune checkpoint inhibitors|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
61965474|NCT01864811|EXPERIMENTAL|Baby-CIMT|The infants will be prevented from using the preferred hand while the other hand will be trained using amusing and easily handled toys.
61965475|NCT01864811|EXPERIMENTAL|baby-massage|The infants will receive baby massage
61965476|NCT02253251||Family Registry|For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
61965477|NCT02253251||KRAS-variant BRCA negative Breast Cancer|Women with breast cancer who are BRCA negative will be tested for the KRAS-variant, to determine the associations as well as the prevalence.
61965478|NCT02253251||Double primary breast cancer|Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
61965479|NCT02253251||Autoimmunity|We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
61965480|NCT04212650|EXPERIMENTAL|Losartan|12.5mg Losartan capsules, oral administration, twice daily (25mg total per day), taken for 30 consecutive days starting on the evening of the second post-surgery day.
61965481|NCT04212650|PLACEBO_COMPARATOR|Placebo|Appearance-matched placebo capsules, oral administration, twice daily, taken for 30 consecutive days starting on the evening of the second post-surgery day.
61965482|NCT04249583|EXPERIMENTAL|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
61965483|NCT04249583|PLACEBO_COMPARATOR|Placebo|A buffered solution; Mode of administration: intramuscular injection
61965484|NCT03984097|EXPERIMENTAL|Treatment Phase: TAK-079 and LenDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with lenalidomide, orally, once daily for 21 days and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until progressive disease (PD) or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are greater than (\>) 75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
61976146|NCT05611203|EXPERIMENTAL|Oropharyngeal swab only including the posterior oropharyngeal wall|An Oropharyngeal swab is performed with the collection of specimens from the posterior oropharyngeal wall only
61976147|NCT05611203|EXPERIMENTAL|Oropharyngeal swab including the posterior oropharyngeal wall and both palatine tonsils|An Oropharyngeal swab is performed with the collection of specimens from the posterior oropharyngeal wall and both palatine tonsils
61976148|NCT00079118|EXPERIMENTAL|docetaxel + irinotecan|"Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.~Patients are followed every 2 months until disease progression and then every 6 months thereafter."
61976149|NCT06336850|EXPERIMENTAL|Treatment|Patients undergoing Endoscopic-Ultrasound Guided liver biopsies and Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurements
61976150|NCT03444519|EXPERIMENTAL|Mannitol A|in this group, Mannitol (1.0g/kg) is given just after the induction of general anesthesia
61976151|NCT03444519|ACTIVE_COMPARATOR|Mannitol B|in this group, Mannitol (1.0g/kg) is given at the time of skin incision
61976152|NCT03792867|EXPERIMENTAL|Radical Resection and HIPEC|
62705956|NCT04881084|ACTIVE_COMPARATOR|Social marketing/fundraising group (Group 2)|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
61965485|NCT03984097|EXPERIMENTAL|Treatment Phase: TAK-079 and VRd|TAK-079 subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with bortezomib, subcutaneously, once on Days 1, 8, and 15, for a maximum of 8 cycles, lenalidomide, orally, once daily for 21 days, and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until PD or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are \>75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
61965486|NCT03984097|EXPERIMENTAL|Safety Extension Phase: TAK-079 and, if applicable, backbone therapy (LenDex, VRd, or PomDex)|TAK-079 dosing and, if applicable, backbone therapy will be administered as per the schedule outlined in the parent study.
61965487|NCT03241251||parents children pediatric cancer|Screening questionnaire psychosocial risk factors
61965488|NCT02654522|EXPERIMENTAL|Filler|Each subject will have one product in one forearm and another product in the other. Products: JUVEDERM Ultra Plus (24 mg/mL of HA) and VOLUMA (20 mg/mL of HA). Subjects will be randomized as to which forearm will receive which product. In one forearm, subject will receive four injections of the assigned HA filler (0.2mL). HA injections will be placed along a line from the wrist to the antecubital fossa. The initial 0.2mL HA injection will be placed in the deep dermis 5 cm from the wrist and the subsequent three 0.2mL HA injections will be place in 5 cm increments in the deep dermis along the line noted above. Same process will be used on the contralateral forearm using the other HA filler.1-3 hours post injection, these 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
61965489|NCT02654522|NO_INTERVENTION|Scale Validation|"One forearm of one of three subjects will be randomized to the scale control forearm. The opposite forearm of this subject as well as the forearms of the two remaining subjects will receive treatment in this study. The forearm that has been designated as the scale control forearm will be injected with VOLUMA in a straight line into the mid-dermis in the following manner: 0.05ml of VOLUMA will be injected 5 cm proximal to the wrist, 0.1ml of VOLUMA will be injected 10 cm proximal to the wrist, 0.15ml of VOLUMA will be injected 15 cm proximal to the wrist and 0.2ml of VOLUMA will be injected 20 cm proximal to the wrist. The remaining randomized forearms (the non-injected forearm from the subject above and the forearms from the two additional subjects) will be injected in a similar fashion to the control forearm as noted above; however, the dose at each location will be randomized. Control subject will receive no Hylenex until after pertinent data is collected for the study."
61965490|NCT02516345|ACTIVE_COMPARATOR|Child-based Incentive (CBI)|"Children earn rewards each week (with the week beginning on Monday and ending on Sunday) that they log 10,000 daily steps on the Fitbit according to the schedule below and their matched parent logs at least 2,000 steps on ≥4 of 7 days each week (regardless of which 4 of the 7 days they wear it). Incentives are tied, in addition to child's activity, to parent's Fitbit wear so that the investigators are better able to capture parent's activity in this arm.~Step Targets for Children in CBI arm:~* Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~* Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~* Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
61965491|NCT02516345|EXPERIMENTAL|Family-based Incentive (FBI)|"Children earn rewards each week that they log daily steps on the Fitbit according to the schedule below but only if their matched parent also logs 10,000 steps according to the schedule below. Otherwise, children earn no incentive for that week.~Step targets for children and parents in FBI arm:~* Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~* Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~* Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
61965492|NCT01293357|EXPERIMENTAL|Patches|
61965493|NCT05000060|EXPERIMENTAL|1 week restart|Restart of mono or dual antiplatelet therapy one week post injury in TICrH patients
61965494|NCT05000060|ACTIVE_COMPARATOR|3 week restart|Usual Care for restart of mono or dual antiplatelet therapy after TICrH at clinician's discretion
61965495|NCT02015871|EXPERIMENTAL|Degarelix|
61965496|NCT02204800||Small clear cell renal tumors (Wild Type)|No specific chromatin remodeling gene (CRG) alteration
62144692|NCT06199115|EXPERIMENTAL|Experimental|Patients will receive three photobiomodulation sessions per week during their oxaliplatin chemotherapy cycles
62144693|NCT01963598|EXPERIMENTAL|Group 1|Dosing regimen 1
62144694|NCT01963598|EXPERIMENTAL|Group 2|Dosing regimen 2
62144695|NCT01963598|EXPERIMENTAL|Group 3|Dosing regimen 3
62144696|NCT01963598|EXPERIMENTAL|Group 4|Dosing regimen 4
62144697|NCT04569188|EXPERIMENTAL|convalescent plasma|Cohort of elderly patients treated with convalescent plasma
62508056|NCT02617641|EXPERIMENTAL|TAVIEenM@RCHE intervention|The experimental group will receive a web-based tailored nursing intervention. Between 3 and 4 sessions of 15 to 25 minutes each are completed within 4 weeks. A booster session is delivered at 8 weeks post randomization.
62349857|NCT01779713||Vasospastic patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) and developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
62508057|NCT02617641|ACTIVE_COMPARATOR|Publicly available websites|The control group will receive hyperlinks to four publicly available websites and one online booklet on the topic of walking.
62508058|NCT00931996|EXPERIMENTAL|Antipsychotic|Antipsychotic
62508059|NCT02419833|EXPERIMENTAL|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
62508060|NCT02419833|ACTIVE_COMPARATOR|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and within 2-72 hours of admission
62705957|NCT02957838|EXPERIMENTAL|Non-diabetics|Non-diabetic volunteers with HbA1c \< 6.5%. Subjects will be treated with C18:0 supplementation or mock.
62705958|NCT02957838|EXPERIMENTAL|Type 2 Diabetics|Type 2 Diabetes according to common definitions, but we exclude insulin-treated Type 2 diabetics because nutritional intervention is more difficult/risky. Subjects will be treated with C18:0 supplementation or mock.
62705959|NCT06564792|EXPERIMENTAL|Contingency management arm|Participants are offered once weekly contingency management in clinic to support reduced stimulant use and HIV medication adherence.
62705960|NCT02551185|EXPERIMENTAL|ACY-241 in combination with Paclitaxel|
61965497|NCT02204800||Small clear cell renal tumors (Mutant)|Specific chromatin remodeling gene (CRG) alteration
61965498|NCT04806724|EXPERIMENTAL|Program #1|Participants attend 5 sessions (1.5 hours each) consisting of education and skills training to address cancer-related reproductive and sexual health concerns. Sessions occur via videoconference.
61965499|NCT04806724|ACTIVE_COMPARATOR|Program #2|Participants attend 4 sessions (1.5 hours each) consisting of education and skills training to address cancer-related concerns. Sessions occur via videoconference.
62144698|NCT03442777|EXPERIMENTAL|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings~* Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~* Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith \& Nephew (Allevyn® brand)."
62508061|NCT04615312|EXPERIMENTAL|a CDK4 / 6 inhibitor and a MEK inhibitor|Participants will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment
62705961|NCT03254810|EXPERIMENTAL|SYN060|a single 0.57 mg/kg dose of SYN060
62144699|NCT03442777|EXPERIMENTAL|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings~* Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~* Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
62705962|NCT03254810|ACTIVE_COMPARATOR|Adalimumab North American source|a single 0.57 mg/kg dose of adalimumab from North American source
61965500|NCT05995743||Cases: Children with sickle cell disease|Children aged 6 to 17 years with a confirmed diagnosis of sickle cell disease (i.e., homozygous HbS/S or heterozygous HbS/C mutations)
62144700|NCT03442777|NO_INTERVENTION|Study Arm 3 (standard of care)|"* Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~* No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
62349858|NCT01779713||Control patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) not developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
62349859|NCT02119026|ACTIVE_COMPARATOR|A: XELIRI + BEV Followed by XELOX + BEV|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
62349860|NCT02119026|ACTIVE_COMPARATOR|B: XELOX + BEV followed by XELIRI + BEV|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)~Arm B:~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
62508062|NCT03160586|ACTIVE_COMPARATOR|Stutter|Children who stuttering
62508063|NCT03160586|ACTIVE_COMPARATOR|Control|Children who non stuttering
62508064|NCT02218307|ACTIVE_COMPARATOR|Mupirocin|topical antibiotic
62508065|NCT02218307|PLACEBO_COMPARATOR|Placebo|Placebo control for mupirocin
62508066|NCT05816200|EXPERIMENTAL|Grupo TENS|Participants with burning mouth underwent to transcutaneous electrical nerve stimulation
62508067|NCT05816200|ACTIVE_COMPARATOR|Grupo LLLT|Participants with burning mouth underwent low-level laser therapy
62705963|NCT03254810|ACTIVE_COMPARATOR|Adalimumab European source|a single 0.57 mg/kg dose of adalimumab from European source
62705964|NCT06134882|EXPERIMENTAL|Abstinence reinforcement|Participants earn incentives for submission of salivary drug toxicology video selfies that show test results consistent with the goals of treatment. Goals are abstinence-based (i.e., relate to which tested substances should be negative on the test given the medications that the particular participant has been prescribed). Incentives are also provided for attendance at treatment-related appointments and for completion of self-paced cognitive behavior therapy modules available via the smartphone app.
61965501|NCT05995743||Controls: Healthy children referred for a non-severe functional symptom linked to exercise|Children aged 6 to 17 years with a completely normal check-up, including physical examination, ECG, echocardiography, and spirometry. Children with any chronic disease, medical condition, or medical treatment and those requiring any further specialized medical consultation were not eligible.
61965502|NCT02784808||Biologic DMARDs|Participants who received biologic DMARDs as per standard of care were included in this arm.
61965503|NCT02784808||Non-biological DMARDs|Participants who received non-biologic DMARDs as per standard of care were included in this arm.
61965504|NCT03247530|PLACEBO_COMPARATOR|Placebo|Placebo, qd, oral capsule
61965505|NCT03247530|EXPERIMENTAL|100mg SPN-812|100mg SPN-812, qd, oral capsule
61965506|NCT03247530|EXPERIMENTAL|200mg SPN-812|200mg SPN-812, qd, oral capsule
62508068|NCT05814133|EXPERIMENTAL|Lithotripsy|Ureteroscopy with lithotripsy using the Thulium Fiber Laser
62508069|NCT06256835|EXPERIMENTAL|The experimental group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
62508070|NCT06256835|ACTIVE_COMPARATOR|The control group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
62508071|NCT02598245|ACTIVE_COMPARATOR|TOT 8/4|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
62705965|NCT06134882|SHAM_COMPARATOR|Sample-contingent control|Identical to the experimental group except that incentives are available only for submission of selfie-videos that show test results, without regard to the results of the salivary drug toxicology test. Similarly, incentives are not provided for appointments or completion of wellness modules.
62705966|NCT06163339|EXPERIMENTAL|CFI + Usual Care|About half of participants who are allocated to a person who works with the CFI during the trial.
62705967|NCT06163339|NO_INTERVENTION|Usual Care|About half of participants who are allocated to a person who do not work with the CFI during the trial (i.e., usual care).
62705968|NCT04537650||COVID-19 Ventilated|Participants who were diagnosed with COVID-19 prior to October, 2021 who required hospitalization in an ICU with mechanical ventilation during their illness.
62705969|NCT04537650||COVID-19 Non-Ventilated|Participants who were diagnosed with COVID-19 prior to October, 2021 who did not require mechanical ventilation during their illness.
62705970|NCT05428644|ACTIVE_COMPARATOR|reflexology hand massage group|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
62705971|NCT05428644|PLACEBO_COMPARATOR|placebo hand massage group|In addition to the standard nursing care of the hospital, individuals in the placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
62349861|NCT00804843|EXPERIMENTAL|Statin 80 mg + Niacin extended-release (ER)|Participants in Russia and Brasil will receive 80 mg Simvastatin + niacin. All other participants will receive 80 mg Atorvastatin + niacin.
62349862|NCT00804843|ACTIVE_COMPARATOR|Statin 10 mg|Participants in Russia and Brasil will receive 10 mg Simvastatin. All other participants will receive 10 mg Atorvastatin.
62349863|NCT03153020||Cohort of patients with stroke or transient ischemic attack|The cohort will be constituted of all consecutive patients admitted for a stroke or transient ischemic attack by the Rhône's emergency medical help service (SAMU), or in one of the emergency unit or stroke unit of the Rhône area, and presenting a symptom-onset (the last time the patient was seen without deficit) less than 24 hours.
62349864|NCT03487406|PLACEBO_COMPARATOR|Placebo Ticagrelor & placebo Aspirin|Placebo Ticagrelor 90 mg- one tablet, twice daily. Placebo Aspirin 75 mg- one tablet, once a day.
61965507|NCT06294860||Hormone replacement therapy with rhGH|Each subject will be treated with hormone replacement therapy with rhGH with a dose of 0.025-0.035 mg/kg body weight per day (or 0.7-1.0 mg/ m2 body surface area per day) for a period of 6 months.
62349865|NCT03487406|ACTIVE_COMPARATOR|Aspirin & Placebo Ticagrelor|Aspirin 75mg - one tablet, once a day. Placebo Ticagrelor 90 mg- one tablet, twice daily.
62349866|NCT03487406|ACTIVE_COMPARATOR|Placebo Aspirin & Ticagrelor|Placebo Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
62349867|NCT03487406|EXPERIMENTAL|Aspirin & Ticagrelor|Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
62349868|NCT04372342|EXPERIMENTAL|nalbuphine|
62349869|NCT04372342|PLACEBO_COMPARATOR|remifentanil|
62349870|NCT00985296||Ragweed+ Dust Mite+ CAC w/ DM|
62349871|NCT00985296||Ragweed + Dust Mite + CAC w/Saline|
62349872|NCT00985296||Ragweed + Dust Mite - CAC|
62349873|NCT04077736|EXPERIMENTAL|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
62508072|NCT02598245|EXPERIMENTAL|TOT 6/3|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
62508073|NCT02803931|EXPERIMENTAL|Cardiogoniometry|Every patient in the study will have a cardiogoniometry recording performed by the Cardiologic Explorer whilst an inpatient on the ward. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI. The researcher interpreting the cardiogoniometry recording will be blind to the results of the ECG and the coronary angiography,
62508074|NCT02803931|ACTIVE_COMPARATOR|12-lead ECG|For every patient in the study, copies of their 12-lead ECGs performed during their admission will be taken for interpretation by an independent cardiologist. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.The researcher interpreting the ECG recordings will be blind to the results of the cardiogoniometry and the coronary angiography,
62508075|NCT05288166|EXPERIMENTAL|Abemaciclib + Abiraterone + Prednisone/Prednisolone|Abemaciclib plus (+) abiraterone + prednisone/prednisolone administered orally.
62508076|NCT05288166|ACTIVE_COMPARATOR|Placebo + Abiraterone + Prednisone/Prednisolone|Placebo + abiraterone + prednisone/prednisolone administered orally.
62508077|NCT03166124|EXPERIMENTAL|Elderly Adults LY900014|Single, subcutaneous (SC) 15-U dose of LY900014 in the elderly adult group.
62508078|NCT03166124|ACTIVE_COMPARATOR|Elderly Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in in the elderly adult group.
62508079|NCT03166124|EXPERIMENTAL|Younger Adults LY900014|Single, SC 15-U dose of LY900014 in the younger adult group.
62508080|NCT03166124|ACTIVE_COMPARATOR|Younger Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in the younger adult group.
62508081|NCT04231123|EXPERIMENTAL|PENG group|PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine
62508082|NCT04231123|PLACEBO_COMPARATOR|Placebo group|PENG block with 20 ml of 0,9% saline
62508083|NCT05119660|EXPERIMENTAL|Patient Arm|"In a 2x2 factorial double-blind design, we will randomize a sample of adolescents (13-18 years) with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
62508084|NCT05119660|EXPERIMENTAL|Healthy Control Arm|"Control Arm: A sample of healthy young adults (18-25 years) will receive an individualized theta-gamma parameters protocol of iTBS to the left DLPFC.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
62508085|NCT02846883|ACTIVE_COMPARATOR|Intravenous infusion of 1 million allogenic MSCs/kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. Subjects will be discharged 2 hours post-infusion if no signs of complications.
62705972|NCT02490189|EXPERIMENTAL|Mindfulness-Based Intervention|Participants in the mindfulness-based intervention arm will receive 12 weekly sessions of 2 to 2.5 hours duration. The intervention will be delivered in a group format. Participants will be assigned weekly homework.
62705973|NCT02490189|ACTIVE_COMPARATOR|Cognitive Behavior Group Therapy|Participants in the cognitive behavior group therapy arm will receive 12 weekly sessions of 2 to 2.5 hours in duration. Participants will be assigned weekly homework.
62705974|NCT04123704|EXPERIMENTAL|Sitravatinib|Sitravatinib 100 mg daily
61965508|NCT03323931|ACTIVE_COMPARATOR|(1) standard therapy|Standard therapy based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the therapist reinforces the adaptive behavior of the child.
62349874|NCT00604435|ACTIVE_COMPARATOR|chemotherapy|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
62349875|NCT00604435|EXPERIMENTAL|chemotherapy plus endostatin|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin
62349876|NCT03972826|OTHER|1|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
62349877|NCT02823041|EXPERIMENTAL|Cognitive Training & Exercise|This arm involves a combination of systematic computerized cognitive training plus 150 minutes per week of aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as Individual Placement and Support.
62349878|NCT02823041|ACTIVE_COMPARATOR|Cognitive Training|This arm includes the same systematic computerized cognitive training as the experimental condition, but without the additional aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as and Individual Placement and Support.
62349879|NCT03351569|EXPERIMENTAL|Immunoglobulin|Intravenous immunoglobulin 25 grams (five 100 ml bottles, 5g/100ml), in 3 hours, once a month for one year.
62349880|NCT03351569|PLACEBO_COMPARATOR|Saline solution|Intravenous saline solution 500 ml (five 100 ml bottles), in 3 hours, once a month for one year.
62349881|NCT03933514||GAgP parents|Parents diagnosed with Generalized Aggressive Periodontitis
62349882|NCT03933514||GAgP children|Children from parents diagnosed with Generalized Aggressive Periodontitis
62349883|NCT03933514||Health parents|Parents diagnosed as periodontally healthy
62349884|NCT03933514||Health children|children from parents diagnosed as periodontally healthy
62349885|NCT02783144|EXPERIMENTAL|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, 4 mg of Dexamethasone are added to 20 ml of 0,375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
62349886|NCT02783144|PLACEBO_COMPARATOR|TAP Block and Saline|After general anesthesia and before the beginning of surgery, 2 ml of saline are added to 20 ml of 0.375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
62349887|NCT02783144|ACTIVE_COMPARATOR|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, 20 ml of 0,375% Levobupivacaine are used in Ultrasound-guided Tranversus Abdominis Plain Block. In this group 4 mg of dexamethasone are injected intravenously.
62349888|NCT01927393|EXPERIMENTAL|Arm I (PCPI)|Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.
62349889|NCT01927393|ACTIVE_COMPARATOR|Arm II (standard care plus attention control)|Patients receive standard care plus attention comprising two telephone contacts.
62349890|NCT04485234||All patients|All lesions undergo assessment with coronary pressure sensor and either Doppler velocity or coronary thermodilution
62349891|NCT05913479|EXPERIMENTAL|Mucogyne treatment|"3 planned visits for each eligible patient:~* Screening/Baseline visit: V0 at Day 0. Patient receive a box of Mucogyne Gel.~* Phone call: V1 phone call at Day 10 ± 3~* End-of-study visit: V2 at Day 35 ± 3"
61976153|NCT01980914|EXPERIMENTAL|Type 2 diabetes group|Patients over age 70 who have had type 2 diabetes for at least 5 years and are being treated with insulin. All patients will have a BMI of between 20 and 35 Kg/M2, and an A1C between 7 and 8.5 %.
62349892|NCT01790009|ACTIVE_COMPARATOR|Flavanol Rich drink|Flavanol-rich drink containing 800 mg/75 Kg of Body Weight (BW)
62349893|NCT01790009|ACTIVE_COMPARATOR|Flavanol rich drink|Flavanol Intervention drink 400 mg/75 Kg BW
62349894|NCT01790009|ACTIVE_COMPARATOR|Acetaminophen|2 tabletsx500 mg
62705975|NCT04336826|EXPERIMENTAL|Ataluren|Participants will receive ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 24 weeks.
62705976|NCT05374616||Individuals with TANGO2 deficiency|Individuals with TANGO2 deficiency known to have disease causing variants in TANGO2
62705977|NCT03140111|OTHER|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
62705978|NCT03140111|OTHER|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
62705979|NCT04726501|EXPERIMENTAL|Low risk group|Ann Arbor stage IA or IIA without bulky disease.
62705980|NCT04726501|EXPERIMENTAL|Intermediate risk group|Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulk disease, and IA or IIA with bulk disease
62705981|NCT04726501|EXPERIMENTAL|High risk group|Ann Arbor stages III or IV with B symptoms
62705982|NCT06249464|EXPERIMENTAL|Stellate Ganglion Block group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
62705983|NCT06249464|ACTIVE_COMPARATOR|Routine treatment group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
62705984|NCT02150746||Pancreatic Cancer CTC|Peripheral/Central Venous Blood Draw Peritoneal Wash
62705985|NCT03984240|EXPERIMENTAL|Brain eloquent area glioma group|The brain eloquent area glioma will be diagnosed by MRI scan.
62705986|NCT03984240|ACTIVE_COMPARATOR|control group|Healthy volunteers without intracranial diseases.
62705987|NCT04633330|EXPERIMENTAL|Study Arm|AHCC®capsules, 5 capsules \* 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
62705988|NCT04633330|PLACEBO_COMPARATOR|Control Arm|Simulation of AHCC®capsules, 5 capsules \* 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
62705989|NCT02665091|EXPERIMENTAL|Peer Education Group|Group was self compared after the intervention
62705990|NCT05162248||Microsatellite instability|Immunohistochemical analysis was performed for Microsatellite Instability (MSI) status of colorectal tumors tissue.
62705991|NCT04629430|EXPERIMENTAL|Prebiotic diet|2 servings a day of pre-biotics every day from start of conditioning regimen for HSCT through 100 days following HSCT
62705992|NCT00666263|EXPERIMENTAL|IGIV, 10% Then Placebo|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle)."
62705993|NCT00666263|EXPERIMENTAL|Placebo Then IGIV, 10%|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)"
62705994|NCT00954447|EXPERIMENTAL|Linagliptin|patient receives a tablet with intended final marketed dose
62705995|NCT00954447|PLACEBO_COMPARATOR|Placebo|patient receives a tablet identical to those containing Linagliptin
62705996|NCT01259011|NO_INTERVENTION|control|Written information on advance directives and the patient's right to have an advance directive is provided to every patient on the first day of dialysis treatment by a social worker at the clinic. A social worker documents whether the patient has an advance directive, a surrogate decision maker, and/or a Do-Not-Resuscitate (DNR) Order on a Comprehensive Interdisciplinary Assessment form. The social worker encourages patients to complete an advance directive and addresses their questions about life-sustaining treatment options. If completed, the advance directive is placed in the medical record.
62508086|NCT02846883|ACTIVE_COMPARATOR|Intravenous infusion of 3 million allogeneic MSCs/kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. Subjects will be discharged 2 hours post-infusion if no signs of complications.
61976154|NCT02694874|EXPERIMENTAL|Rosiglitazone|Participants will receive rosiglitazone 0.045mg/kg/dose twice daily dosing, for 4 days
61976155|NCT02694874|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (grounded placebo powder) at a dose of 0.045mg/kg/dose twice daily for 4 days
62508087|NCT02846883|PLACEBO_COMPARATOR|Intravenous infusion of Plasmalyte A (placebo)|In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. Subjects will be discharged 2 hours post-infusion if no signs of complications.
61965509|NCT03323931|EXPERIMENTAL|(2) robot--enhanced intervention|A treatment developed on the same principles as standard therapy, based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the robotic agent reinforces the adaptive behaviors of the child, under the supervision of the therapist.
62508088|NCT03442569|EXPERIMENTAL|Open-label, single arm, Phase II|Nivolumab and ipilimumab with panitumumab
62508089|NCT03823287|EXPERIMENTAL|Faricimab|
62508090|NCT03823287|ACTIVE_COMPARATOR|Aflibercept|
62508091|NCT04805619|EXPERIMENTAL|Arm 1|Patients with long or very long lesions (≥ 30 mm) in native coronary arteries.
62508092|NCT00271024|EXPERIMENTAL|Male Naltrexone|50 mg Naltrexone tablet
62508093|NCT00271024|EXPERIMENTAL|Female Naltrexone|Females receiving either naltrexone (50 mg)
62508094|NCT00271024|PLACEBO_COMPARATOR|Male Placebo|Males receiving Placebo (sugar pill)
62705997|NCT01259011|EXPERIMENTAL|SPIRIT intervention|The SPIRIT intervention is a two-session, 1½ hour-long, structured intervention that is composed of six steps (assessing representations, identifying and exploring gaps and concerns, creating conditions for conceptual change, introducing replacement information, summarizing, and setting goals and planning), presented to both patient and surrogate by a trained nurse interventionist in a face-to-face interview format based on the representational approach.
62705998|NCT05858814|EXPERIMENTAL|RC1012 injection (allo-DNT Cells)|The trial is divided into two parts: Part A is a dose escalation trial with two dose groups (1.0×10\^8 cells/kg, 1.5×10\^8 cells/kg at day 0, day 28 and day 56), with 6-12 patients planned to be enrolled. Part B is a dose-expansion randomized controlled trial in which 40-60 patients will receive RC1012 infusions at RP2D dose levels.
61965510|NCT00935597|EXPERIMENTAL|Group 1|Patients with Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion
62349895|NCT02664207|EXPERIMENTAL|Fetal Surgery in Women with ex|"Fetal myelomeningocele repair surgery will be offered to pregnant women meeting the criteria for surgery (as set by the MOMS trial) with the exception of the following:~* a BMI greater than 35 (but less than or equal to 40 kg/m2)~* (minor) Fetal structural abnormality~* (well-controlled) Diabetes~* Previous preterm delivery (followed by a full term delivery)~* Maternal red cell alloimmunization (must NOT be associated with fetal disease, OR fetus must have negative red cell antigen status as determined by amniocentesis).~Intervention: Open Fetal Repair of Myelomeningocele"
62349896|NCT01462448||Phantom Limb Pain|Subjects will have lower or upper extremity amputation(s) that have resulted in the presence of phantom limb pain.
62349897|NCT01462448||No Phantom Limb Pain|Subjects in the group will have a lower or upper extremity amputation(s) without the presence of phantom limb sensation.
62349898|NCT03036449||A|Group A: Phase 1: Observations (Baseline rate of errors); Phase 2: Main Educational program; Phase 3: Observations; Phase 4: Maintenance Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
62349899|NCT03036449||B|Group B: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: Main Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
62349900|NCT03036449||C|Group C: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: No intervention; Phase 5: Observations (Baseline rate of errors); Phase 6: Main educational program; Phase 7: Observations; Phase 8: Maintenance educational program; Phase 9: Observations.
62349901|NCT00013481|OTHER|1|
62349902|NCT04014270|EXPERIMENTAL|Self modulated functional electrical stimulation (SM-FES)|Patients will receive self-modulated functional electrical stimulation SM-FES
62349903|NCT04014270|ACTIVE_COMPARATOR|Standard care (SC)|Patients will receive standard care, dose matched to the experimental group therapy
62508095|NCT00271024|PLACEBO_COMPARATOR|Female Placebo|Females receiving placebo (sugar pill)
62508096|NCT00929981||Oral Methylprednisolone|
62508097|NCT06276699|PLACEBO_COMPARATOR|1.Isometric exercise|
62508098|NCT06276699|EXPERIMENTAL|2. Combined conservative treatment|
62508099|NCT01698593|ACTIVE_COMPARATOR|Ring Finger Nerve Block|
62508100|NCT01338662||Group A-1|"* study enroll number 3n+1 (N=0,1,2...)~* initial treatment- amantadine~* add levodopa when the patient become to need further treatment."
62508101|NCT01338662||Group A-2|"* study enroll number 3n+2 (N=0,1,2...)~* initial treatment: amantadine~* add dopamine agonist when the patient become to need further treatment."
62508102|NCT01338662||Group B|"* study enroll number 3n+3 (N=0,1,2...)~* initial treatment: dopamine agonist~* add levodopa when the patient become to need further treatment. but cannot use amantadine"
62705999|NCT03641196|NO_INTERVENTION|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
62706000|NCT03641196|ACTIVE_COMPARATOR|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
61965511|NCT00935597|EXPERIMENTAL|Group 2|Patients with greater than Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion in conjunction with donor lymphocyte infusion (DLI)
61965512|NCT03752632|EXPERIMENTAL|Veinplicity with tourniquet (treatment)|Veinplicity with tourniquet
61965513|NCT03752632|ACTIVE_COMPARATOR|Tourniquet (control)|Control: Tourniquet
62508103|NCT00375791|EXPERIMENTAL|Perifosine daily|Patients will take three 50 mg tablets of perifosine daily at bedtime with food. Patients will be examined every three weeks. If patients have no progression it is allowed to receive 8 cycles of perifosine
62508104|NCT00375791|EXPERIMENTAL|Perifosine daily + Dexa twice per week|Patients will take three 50 mg tablets of perifosine daily at bedtime with food until progression. If progressive disease is confirmed by a second measurement at least one week later the patient will receive a combination of 20 mg twice per week dexamethasone (dexa) and 150 mg perifosine daily at bedtime.
61965514|NCT04834076||Cancer patients|50 cancer patients referred to the Oncology Department, Faculty of medicine, Sohag University.
62508105|NCT05694130|PLACEBO_COMPARATOR|Prednisolone monotherapy|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
62508106|NCT05694130|EXPERIMENTAL|Prednisolone plus Tacrolimus|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Oral tacrolimus 1-2mg twice daily for 12 weeks.
62706001|NCT03641196|ACTIVE_COMPARATOR|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
62706002|NCT02141009|OTHER|Prevnar 13|Prevnar 13, 1 administration of 1 single dose (0.5mL)
62706003|NCT01696643|EXPERIMENTAL|CB-5945|0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
62706004|NCT01696643|PLACEBO_COMPARATOR|Placebo|Placebo, administered orally, BID for 52 weeks
62706005|NCT00518180|EXPERIMENTAL|MenACWY + Tdap + HPV|Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
61965515|NCT04834076||Healthy controls|50 healthy controls will be recruited in the study.
61965516|NCT03762421|EXPERIMENTAL|Psychosocial skills development workshops based on PM plus|A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
62144701|NCT04829552||Control group: low dose group.|patients treated with subcutaneous low molecular weight heparin 40 mg once daily or unfractionated heparin 5000 IU twice or three times daily for at least 5 days.
61965517|NCT03762421|ACTIVE_COMPARATOR|Control Arm|The control group will receive 5 routine training induction sessions.
62349904|NCT00695708|EXPERIMENTAL|BFT|20 schizophrenic patients
61965518|NCT03535844|EXPERIMENTAL|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
61965519|NCT03535844|ACTIVE_COMPARATOR|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
61976156|NCT02422628||EGFR mutation postive|Blood samples every 3 months till disease progression or intolerable due to side effect.
61976157|NCT02422628||EGFR mutation wild type|Blood samples before treatment once.
62349905|NCT00695708|ACTIVE_COMPARATOR|CP|19 schizophrenic patients
62349906|NCT00695708|NO_INTERVENTION|HCG|20 healthy age and sex matched subjects
62349907|NCT02293993|EXPERIMENTAL|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
62349908|NCT02293993|EXPERIMENTAL|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
62349909|NCT02293993|EXPERIMENTAL|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
62349910|NCT02293993|EXPERIMENTAL|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
62349911|NCT03519672||Participants with cTTP - adolescents|Adolescents aged 12 to 17 years
62349912|NCT03519672||Participants with cTTP - adults|Adults aged ≥18 years
62349913|NCT03579992|EXPERIMENTAL|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
62349914|NCT03579992|EXPERIMENTAL|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
62349915|NCT03579992|EXPERIMENTAL|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
62349916|NCT01602237||Bakery workers|
62349917|NCT02700295||Orthokeratology contact lens group|
62349918|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity \& evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
62349919|NCT05713578|EXPERIMENTAL|apantamide+docetaxel+ADT|The dosage is adjusted according to the adverse reaction (according to the instructions).Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally;ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator;The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles. It is up to the researcher to decide whether to use prednisone or prednisolone.
62349920|NCT05713578|ACTIVE_COMPARATOR|apantamide+ADT treatment|Patients were treated with apantamide and ADT after enrollment. The patient received each drug treatment according to the instructions. The dosage is adjusted according to the adverse reaction (according to the instructions)Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally;ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT used in each research center are determined by the investigator.
62706006|NCT00518180|EXPERIMENTAL|MenACWY →Tdap → HPV|Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
62706007|NCT00518180|EXPERIMENTAL|Tdap →MenACWY → HPV|Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8
62706008|NCT05714982|EXPERIMENTAL|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills.
62706009|NCT05714982|EXPERIMENTAL|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills.
61965520|NCT00331682|EXPERIMENTAL|Treatment (docetaxel and alvocidib)|Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62706010|NCT05714982|OTHER|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills.
62706011|NCT03119220|OTHER|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
62706012|NCT03119220|OTHER|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
62706013|NCT02796456||Normal weight women|BMI between 18.5 and 25 kg/m2 and without gestational diabetes
62706014|NCT02796456||Obese women without gestational diabetes|BMI more than 30 kg/m2 and without gestational diabetes
62144702|NCT04829552||Study group: high dose group.|Patients treated with subcutaneous low molecular weight heparin 1 mg/kg twice daily or 1.5 mg/kg daily or a continuous intravenous infusion of unfractionated heparin for at least 5 days.
62144703|NCT01003366|EXPERIMENTAL|bevel down|approaching the IJV with the needle bevel facing down
62349921|NCT01762306|EXPERIMENTAL|Diclofenac Potassium|Diclofenac Potassium 50 mg PO 1 hour prior to fractional curettage
62706015|NCT02796456||Obese women with gestational diabetes|BMI more than 30 kg/m2 and with gestational diabetes
62349922|NCT01762306|PLACEBO_COMPARATOR|Folic Acid|Folic acid 5 mg PO 1 hour prior to fractional curettage
62349923|NCT05789849|EXPERIMENTAL|Blood Pressure Collection|This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
62349924|NCT01074658||severe aortic valve stenosis|elderly patients with severe aortic valve stenosis requiring treatment
62349925|NCT00975429|EXPERIMENTAL|WST11 - 4mg (TOOKAD® Soluble)|4mg/kg Treatment with WST11-mediated VTP
62508107|NCT05454358|EXPERIMENTAL|Letrozole|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
62706016|NCT02188966|EXPERIMENTAL|Geographical Information System|Availability of Geographical Information System data from ambulances destined for the Emergency Department of Regional Hospital Horsens.
62706017|NCT06263699||Patients with diagnosed Dupuytren's disease|Range of motion measurement of the MCP and PIP joints in digits 4 and 5
62706018|NCT06254625|EXPERIMENTAL|Fecal microbiome transplantation|25-30 capsules are ingested with apple juice or coca cola light, and the patient is observed for 30-60 minutes before they are allowed to go home. The capsules are to be ingested within 4 hours of thawing. Each transplant, comprising 25-30 capsules, contain 50 g of feces originating from one donor.
62706019|NCT06254625|PLACEBO_COMPARATOR|Placebo|The placebo group receives 25-30 placebo capsules.
62706020|NCT02540421||Case|Recurrent lesions
62706021|NCT02540421||Control|Absence of lesions
62706022|NCT06391268|EXPERIMENTAL|The group to whichEmotional freedom technique (EFT) EFT was applied by the researcher|"Emotional Freedom Technique (EFT) works on cognitive and energetic levels. While ensuring that the individual is conscious and aware of a disturbing symptom or discomfort, selected acupuncture points are touched at the same time, creating a cognitive transition and energetic release.~1-The group to which EFT was applied by the researcher"
61965521|NCT01259908||Laparoscopic vs open Ygraft|Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
61976158|NCT02422628||Healthy Volunteers|Blood samples once.
62144704|NCT01003366|ACTIVE_COMPARATOR|bevel up|approaching the IJV with the needle bevel facing up
62144705|NCT01869049||ITP patients accepted splenectomy|
62144706|NCT01869049||Trauma with spleen rupture underwent splenectomy|
62349926|NCT00975429|EXPERIMENTAL|WST11 - 6mg|6mg/kg Treatment with WST11-mediated VTP
62349927|NCT01127295|OTHER|Tamoxifen, Anastrozole, letrozole, Exemestane|Current hormonotherapy treatment in hormono dependent breast cancer
62349928|NCT01184846|EXPERIMENTAL|IgPro10|10% liquid formulation of human immunoglobulin (IgPro10). IgPro10 will be administered by IV infusion as one induction dose of 2 g/kg body weight (bw), followed by seven 3-weekly maintenance doses of 1 g/kg bw.
62349929|NCT03728504|EXPERIMENTAL|ASN002 40 mg|40 mg ASN002
62349930|NCT03728504|EXPERIMENTAL|ASN002 80 mg|80 mg ASN002
62508108|NCT05454358|NO_INTERVENTION|Observation|Observation alone without any other therapy after postoperative adjuvant therapy
62508109|NCT03858023|EXPERIMENTAL|Hippotherapy|Children in hippotherapy arm will participate in hippotherapy (30 min/sessions, twice a week, 15 weeks)
62508110|NCT03858023|NO_INTERVENTION|Control|Children in control group will not receive hippotherapy
62508111|NCT03886649|EXPERIMENTAL|Copanlisib + Venetoclax|Phase Ib -\> dose escalation with 2 expansion cohorts
62706023|NCT06391268|EXPERIMENTAL|Emotional freedom technique (EFT) for fibromyalgia -2-The group that applies EFT to itself|"Emotional Freedom Technique (EFT) works on cognitive and energetic levels. While ensuring that the individual is conscious and aware of a disturbing symptom or discomfort, selected acupuncture points are touched at the same time, creating a cognitive transition and energetic release.~2-The group that applies EFT to itself"
62706024|NCT06391268|NO_INTERVENTION|Emotional freedom technique (EFT) for fibromyalgia -3-Control group without EFT:|3-Control group without EFT: Pain, problem-stress, comfort and fibromyalgia scales were applied in 3 interviews.
62706025|NCT00690339|EXPERIMENTAL|1|Augmentation
62706026|NCT00690339|EXPERIMENTAL|2|Reconstruction
62706027|NCT00690339|EXPERIMENTAL|3|Revision-augmentation
62706028|NCT00690339|EXPERIMENTAL|4|Revision-reconstruction
62706029|NCT01811420|EXPERIMENTAL|CHEMOMECHANICAL CARIES REMOVAL|Dental caries removal using papain based gel
62706030|NCT01811420|ACTIVE_COMPARATOR|conventional method|Dental caries removal using rotatory instrument
62706031|NCT02422108|EXPERIMENTAL|intervention|Denosumab (Prolia) 60 mg s.c.
62706032|NCT01151267|OTHER|Control Arm|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.
62706033|NCT01151267|ACTIVE_COMPARATOR|HSH Group|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
61965522|NCT02385513|ACTIVE_COMPARATOR|6 + 10 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
61965523|NCT02385513|ACTIVE_COMPARATOR|6 + 14 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule
61965524|NCT02498184|EXPERIMENTAL|real acupuncture|traditional chinese acupuncture
61965525|NCT02498184|SHAM_COMPARATOR|sham acupuncture|non effective acupuncture
61965526|NCT02926365|EXPERIMENTAL|ICBT|Therapist-supported internet-delivered CBT
61965527|NCT05021991|EXPERIMENTAL|Regimen 1|"Double-blind Part: Oral dosing, once daily in the morning with titration over 56 days to 100 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 14 days of 100 mg~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning over 43 days: 100 mg PRAX-944~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 469 days~Crossover Part: Following double-blind lead-in/open-label: 1:1 randomization to placebo or stable dose of PRAX-944 for 21 days followed by cross-over to either placebo or PRAX-944 oral dosing, once daily in the morning with titration over 7 days (3 days at 20 mg, 4 days at 40 mg) to 60 mg (14 days) before returning to open-label part."
61965528|NCT05021991|EXPERIMENTAL|Regimen 2|"Double-blind Part: Oral dosing, once daily in the morning with titration over 56 days to 60 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 28 days of 60 mg~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning with titration over 43 days to 100 mg PRAX-944: 7 days of 80 mg, 36 days of 100 mg~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 469 days~Crossover Part: Following double-blind lead-in/open-label: 1:1 randomization to placebo or stable dose of PRAX-944 for 21 days followed by cross-over to either placebo or PRAX-944 oral dosing, once daily in the morning with titration over 7 days (3 days at 20 mg, 4 days at 40 mg) to 60 mg (14 days) before returning to open-label part."
62706034|NCT00833690|PLACEBO_COMPARATOR|[A:]|Placebo to produce no urate elevation
61976159|NCT02155179||Good prognosis|Sperm samples \>15mill/ml \>30% progresive sperms
61976160|NCT02155179||bad prognosis|Sperm samples \<5mill/ml \<5% progresive sperms
62706035|NCT00833690|EXPERIMENTAL|[B:]|"Inosine to produce a mild urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL"
62349931|NCT03728504|PLACEBO_COMPARATOR|Placebo oral tablet|Matching placebo for ASN002 doses
62349932|NCT03312868|EXPERIMENTAL|Prospective Arm|Prospective arm with patients being treated with SBRT
62706036|NCT00833690|EXPERIMENTAL|[C.]|"Inosine to produce a moderate urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL"
62706037|NCT05152602||Unilateral ESP block group|The group who underwent laparoscopic cholecystectomy and underwent unilateral ESP block for postoperative analgesia.
62706038|NCT05152602||Bilateral ESP block group|The group who underwent laparoscopic cholecystectomy and underwent bilateral ESP block for postoperative analgesia.
62706039|NCT05152602||Control group|The group that underwent laparoscopic cholecystectomy and underwent 1mg/kg tramadol and 50mg dexketoprofen for postoperative pain.
62706040|NCT03324841||MI Profiling|Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.
62706041|NCT02648945|ACTIVE_COMPARATOR|high intensity exercise|"high intensity exercise on a treadmill according to Balke's Protocol.~high intensity of exercises for each group of 15 participants were set at 80-85% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
62714997|NCT05874726||Endoscopic Metabolic and Bariatric Therapies|Subjects who have had endoscopic bariatric therapies for obesity - primary and revision. Bariatric endoscopic procedures include ablation techniques, intragastric balloons, submucosal tunneling procedures (PSAM, GEM, G-POEM), tissue plication platforms (POSE, ROSE), endoluminal sleeves and endoscopic suturing devices (ESG).
62508112|NCT00277160|EXPERIMENTAL|Treatment Group 1 (Primary Prophylaxis)|Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
62706042|NCT02648945|ACTIVE_COMPARATOR|low intensity exercise|"low intensity exercise on a treadmill according to Balke's Protocol. low intensity of exercises for each group of 15 participants were set at 50-55% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
62508113|NCT00277160|ACTIVE_COMPARATOR|Treatment Group 2 (Secondary Prophylaxis)|Per Investigator's discretion
62508114|NCT05332054||Patients who received a Caribou-sponsored allogeneic CAR-T therapy|in a Caribou-sponsored clinical study, a special access program, or as part of an IIT
62508115|NCT06605625||Patients with Cancer|Patients with cancer who are clinically indicated to receive influenza, recombinant shingles and/or SARS-CoV2 vaccine
62508116|NCT04782752|EXPERIMENTAL|Experimental: Radiation|"Patients will be differentiated into 4 groups:~1. Patients with end-stage interstitial lung disease (ILD) and suspected stage I (up to 4 cm) primary lung cancer~2. Patients with end-stage lung disease other than ILD (e.g. emphysema/COPD, cystic fibrosis and pulmonary hypertension) and suspected stage I (up to 4 cm) primary lung cancer~3. Patients with multifocal primary lung cancer (e.g. multifocal adenocarcinoma) in the absence of nodal metastasis and distant metastasis.~4. Patients with isolated pulmonary metastasis in the absence of other sites of malignancy (primary and metastatic).~For this study, different doses will be used for each different group depending on their tumour size. The first 3 patients will start with a dose of 4 Gy, for the ILD group, or 8 Gy, for the non ILD group. The doses are then increased incrementally until the dose limiting toxicity is reached."
62508117|NCT04159181|EXPERIMENTAL|Day A|After an overnight fast participants will receive an oral solution of lactulose (20g lactulose/200mL water).
62508118|NCT04159181|EXPERIMENTAL|Day B|After an overnight fast participants will drink 200mL of water
62508119|NCT04159181|EXPERIMENTAL|Day C|After an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).
62706043|NCT05296161|NO_INTERVENTION|Standard interval dosing|The standard group will receive ocrelizumab every 24 weeks following the current label.
62706044|NCT05296161|EXPERIMENTAL|Personalized B cell tailored ocrelizumab treatment|The personalized group will start with B cell measurements 24 weeks after the last infusion (baseline). The infusion interval will never be shorter than 24 weeks. The personalized group will start the study with a possible extension of the interval. The infusion will be postponed as long as CD19 B cell count stays below 10 cells/µL (determined every 4 weeks). When CD19 B cell count exceeds or is equal to 10 cells/µL, ocrelizumab infusion will be scheduled within two weeks
62706045|NCT04233021|EXPERIMENTAL|Osimertinib|Osimertinib 80 mg/d
62706046|NCT04015388||Diabetes Mellitus / Hyperglycemia|iPro Continuous Glucose Monitoring on subjects with blood sugar value \>140 mg/dL upon admission to the intensive care unit or who have been diagnosed with type 1 or type 2 diabetes or have glycosylated hemoglobin A1C (HbA1C) values \> 6.5% prior to admission.
61965529|NCT05021991|PLACEBO_COMPARATOR|Regimen 3|"Double-blind Part: Oral dosing, once daily in the morning: 56 days of placebo~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning with titration over 43 days to 100 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 14 days of 100 mg~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 469 days~Crossover Part: Following double-blind lead-in/open-label: 1:1 randomization to placebo or stable dose of PRAX-944 for 21 days followed by cross-over to either placebo or PRAX-944 oral dosing, once daily in the morning with titration over 7 days (3 days at 20 mg, 4 days at 40 mg) to 60 mg (14 days) before returning to open-label part."
61965530|NCT03916120||Postoperative Analgesic Failure|
61965531|NCT03916120||Postoperative Analgesic Success|
61965532|NCT06217055|EXPERIMENTAL|remimazolam based MAC group|remimazolam based monitored anesthesia care
62144707|NCT05307952|EXPERIMENTAL|Fitting and Training Intervention|"All participants will undergo the full set of diagnostic visits and both Fitting and Training interventions.~The Fitting Intervention is an adjustment of their processors' MAPs based on their error pattern.~The Training Intervention is a personalized training via an app focusing on their most frequent errors."
62508120|NCT02152462|OTHER|Exergaming|Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
62508121|NCT02152462|NO_INTERVENTION|Control|Control Group: After baseline testing the control group will be asked to maintain their current daily activities for the duration of the study. The control group will have the option to exercise at the Wii Fit stations following their completion of the study. They will receive the same measures as the exercise group.
62508122|NCT04904055||Value-based Formulary Beneficiaries|enrolled in the value-based formulary
62508123|NCT04904055||Standard Formulary Beneficiaries|enrolled in a standard (i.e., non-value-based formulary)
62508124|NCT05633238|EXPERIMENTAL|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
62508125|NCT00761176|NO_INTERVENTION|Standard of Care|Standard of Care will be utilized without the device.
62508126|NCT00761176|OTHER|The Provant Therapy System|Thirty minutes, twice daily treatment
62508127|NCT01483625|EXPERIMENTAL|tiotropium 18mcg|active
62508128|NCT01483625|PLACEBO_COMPARATOR|Placebo|placebo
62508129|NCT00108576|PLACEBO_COMPARATOR|Arm 1|Look-a-like placebo
61965533|NCT06217055|ACTIVE_COMPARATOR|inhalation general anesthesia group|general anesthesia with sevoflurane
61965534|NCT02591589|EXPERIMENTAL|Normoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For normoxic oxygenation FiO2 will be set at 0.35 (35%) ideally to maintain PaO2 above 70mmHg (or saturations greater than or equal to 92%), and titrated up if need be to prevent potentially injurious hypoxemia (saturations below 92%). During cardiopulmonary bypass, blended air/ oxygen mixture will be titrated to arterial blood gas analysis with maintenance of PaO2 between 100mmHg and 150mmHg.
61965535|NCT02591589|ACTIVE_COMPARATOR|Hyperoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
61965536|NCT05399056|NO_INTERVENTION|Enhanced usual care|Enhanced usual care describes a process in which automated surveillance is used to identify individuals experiencing a COPD exacerbation. This is followed by direct outreach - either through in-person visits while a patient is hospitalized, or by mail and telephone in the outpatient setting, to facilitate referral to PR. Subjects randomized to this arm will be given a pamphlet describing the benefits of PR.
61965537|NCT05399056|ACTIVE_COMPARATOR|Enhanced usual care + Storytelling|Subjects randomized to the eUC + Storytelling intervention will view the video narrative(s) of one or more individuals with COPD who has overcome similar barriers and has attended a program of PR. Subjects will be shown the first chapter of the story immediately after randomization and will receive email and/or text messages to prompt viewing of subsequent chapters at 2 weeks, 1 month, 2 months, 3 months and 5 months. Emails and text messages will include a link to a REDCap document that contains a set of embedded video clips representing the next chapter in each storyteller's narrative.
62706047|NCT02501421|ACTIVE_COMPARATOR|TB/FLU-04L|Live recombinant influenza vectored tuberculosis vaccine
62706048|NCT02501421|PLACEBO_COMPARATOR|Placebo|Buffer
62706049|NCT01296308||type 2 diabetics with neuropathy|
62706050|NCT01777477|EXPERIMENTAL|Chloroquin in addition to Gemcitabine|Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle.
62706051|NCT01939145|ACTIVE_COMPARATOR|Normal Saline|The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
61965538|NCT05399056|ACTIVE_COMPARATOR|Enhanced usual care + Peer support|Subjects randomized to the eUC + Peer support intervention will be matched with a peer coach of the same gender, race, and approximate age. For those enrolled during a hospitalization, coaches will be instructed to attempt the initial phone contact prior to the patient's discharge; for patients enrolled after an ED visit or outpatient exacerbation, coaches will be instructed to contact the patients within 72 hours of randomization. Peer coaches will be asked to complete at least one call each week during months 1-2, biweekly calls during months 3-4, and monthly calls during months 5-6. Coaches will be asked to follow a conversation guide, provided during the initial training, to structure phone conversations with their paired patient.
61965539|NCT05227027|EXPERIMENTAL|Education plus game module|Participants receive an educational intervention through the Smoke Free application with the embedded game module. Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
61965540|NCT05227027|ACTIVE_COMPARATOR|Education module only|Participants receive an educational intervention through the Smoke Free application only (core app only). Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
61965541|NCT02980601|EXPERIMENTAL|Integra and a Split Thickness Skin Graft (STSG)|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
61965542|NCT02980601|ACTIVE_COMPARATOR|Split Thickness Skin Graft (STSG)|reconstruction as dictated by the protocol. They will either receive 1) a 0
61965543|NCT02927522|PLACEBO_COMPARATOR|Control|Placebo was administrated
61965544|NCT02927522|EXPERIMENTAL|Donepezil|Donepezil (5mg/ day for 7 days) was administrated
61965545|NCT05412511|EXPERIMENTAL|Training|Participants in this arm will perform seven medicine ball training exercises (acute bout per exercise) at two different conditions \[Throwing a ball (TB) and no Throwing a ball (NTB)\].
61965546|NCT05412511|NO_INTERVENTION|Control|Participants in this arm will receive no intervention.
61965547|NCT03890172||study group|in this group the investigators will be managing diabetic wounds with platelet rich plasma treatment.
62144708|NCT03773497|OTHER|Common snack combination|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of a combination of common snack foods (pretzels, potato chips, and popcorn).
62706052|NCT01939145|ACTIVE_COMPARATOR|Prontosan|The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
62706053|NCT04196621|ACTIVE_COMPARATOR|High viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, high viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
62706054|NCT04196621|ACTIVE_COMPARATOR|Low viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, low viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
62706055|NCT01459627|ACTIVE_COMPARATOR|6 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.
62706056|NCT01459627|ACTIVE_COMPARATOR|12 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study
62706057|NCT04118660||Thoracic Disease|Thoracic Diseases (which includes but not limited to the following: thoracic neoplasms (masses/nodules) malignant or benign, interstitial lung diseases (ILD), chronic obstructive pulmonary disease (COPD), thoracic infections, thoracic malignancies metastatic to other organs, other cancers metastatic to the thoracic cavity.
62706058|NCT05442697|EXPERIMENTAL|Mild-to-moderate Knee OA PEMF Treatment|Patients with Mild-to-moderate Knee OA will accept PEMF treatment
62706059|NCT05442697|PLACEBO_COMPARATOR|Mild-to-moderate Knee OA Placebo Treatment|Patients with Mild-to-moderate Knee OA will accept placebo treatment
62706060|NCT00925275|EXPERIMENTAL|Dosimetric|
62508130|NCT00108576|EXPERIMENTAL|Arm 2|Divalproex
62508131|NCT00656968|ACTIVE_COMPARATOR|10-day concomitant therapy|esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
62508132|NCT00656968|EXPERIMENTAL|10-day sequential therapy|esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
62508133|NCT06677788|ACTIVE_COMPARATOR|Roflumilast group (n=31)|Arm Description: Roflumilast group (n=31) which received roflumilast 500 μg once daily for three months. Patients were assessed at baseline and after intervention through liver stiffness measurement (LSM) using fibro-scan and through evaluation of serum levels of tumor necrosis factor -alpha (TNF-α), Malondialdehyde (MDA), transforming growth factor-beta 1 (TGF-ß1). In addition, liver enzymes, lipid panel, fasting blood glucose and fasting insulin level with subsequent calculation of homeostatic model assessment for Insulin resistance (HOMA-IR) were also assessed.
62706061|NCT04023019||Group 1: ITI with Nuwiq, octanate, or wilate|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery and for prophylaxis.
62706062|NCT04023019||Group 2: ITI with Nuwiq, octanate, or wilate with emicizumab|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate, in combination with emicizumab prophylaxis. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery.
62706063|NCT04023019||Group 3: Prophylaxis with emicizumab, aPCC, or rFVIIa|Participants receiving routine prophylaxis with emicizumab, aPCC, or rFVIIa without immune tolerance induction. On-demand aPCC/rFVIIa can be used as needed to treat bleeding episodes or during surgery.
62706064|NCT06306183|EXPERIMENTAL|Acetaminophen and Vitamin C with Naproxen rescue|"900 mg vitamin C taken orally twice a day Extended-release acetaminophen 650 mg two pills every eight hours regularly~Naproxen 500 mg as a rescue medication"
62706065|NCT06306183|PLACEBO_COMPARATOR|Acetaminophen and Placebo with Naproxen rescue|"Placebo taken orally twice a day Extended-release acetaminophen 650 mg two pills every eight hours regularly~Naproxen 500 mg as a rescue medication"
62706066|NCT02460276|EXPERIMENTAL|Lenalidomide, ibrutinib and rituximab.|
62706067|NCT06563557|ACTIVE_COMPARATOR|Epidural group|
62706068|NCT06563557|EXPERIMENTAL|Paravertebral group|
62706069|NCT05803785|EXPERIMENTAL|BBC1501 1.25ug|Cohort 1; open-label, non-randomized, single administration
62706070|NCT05803785|EXPERIMENTAL|BBC1501 2.5ug|Cohort 2; open-label, non-randomized, single administration
62706071|NCT05803785|EXPERIMENTAL|BBC1501 5ug|Cohort 3; open-label, non-randomized, single administration
62706072|NCT01342666|EXPERIMENTAL|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
62706073|NCT01342666|PLACEBO_COMPARATOR|Cucumber consumption|Daily consumption of 300g of cucumber.
62508134|NCT06677788|ACTIVE_COMPARATOR|Vitamin E group or control group (n=24)|vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily. Patients were assessed at baseline and after intervention through liver stiffness measurement (LSM) using fibro-scan and through evaluation of serum levels of tumor necrosis factor -alpha (TNF-α), Malondialdehyde (MDA), transforming growth factor-beta 1 (TGF-ß1). In addition, liver enzymes, lipid panel, fasting blood glucose and fasting insulin level with subsequent calculation of homeostatic model assessment for Insulin resistance (HOMA-IR) were also assessed.
62706074|NCT06635785|EXPERIMENTAL|AI-081|AI-081 will be given by IV infusion in designated dose, q3w.
62706075|NCT05010473|EXPERIMENTAL|Neurotypical Human Participants|Native speakers of Chinese and native speakers of English
62706076|NCT00674102|EXPERIMENTAL|ASA404|
62706077|NCT04313582|EXPERIMENTAL|SmartPrompt|
61965548|NCT03890172||control group|In this group patients will receive the standard treatment in form of debridement and dressing twice weekly
62508135|NCT06307041|OTHER|Test (HA group)|One side is HA gel impregnated dental floss usage
62706078|NCT04750083|EXPERIMENTAL|phase II|Thirty-sixty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W for another 31 cycles.
62706079|NCT04750083|EXPERIMENTAL|phase III-experimental|Three hundred and twenty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W for another 31 cycles.
62706080|NCT04750083|EXPERIMENTAL|phase III-control|Three hundred and twenty participants will receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W for another 31 cycles.
62706081|NCT02071615|EXPERIMENTAL|Methylphenidate and placebo|Placebo or Methylphenidate 20 mg tablet given once by mouth
62706082|NCT02071615|EXPERIMENTAL|modafinil and placebo|placebo or modafinil 200mg tablet given once by mouth
62706083|NCT02071615|EXPERIMENTAL|caffein and placebo|placebo or caffein 200mg tablet given once by mouth
62706084|NCT02735200|EXPERIMENTAL|Topical Vitamin D3 application|Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
62706085|NCT02735200|ACTIVE_COMPARATOR|Aloe vera gel Application|Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days
62706086|NCT03531255|EXPERIMENTAL|1,080 mg pegcetacoplan administered subcutaneously|1,080mg pegcetacoplan administered subcutaneously twice weekly or every three days.
61965549|NCT06508632|EXPERIMENTAL|Experimantal group|Individual mandala activity will be carried out in all sample groups after admission to the clinic where they come to receive outpatient chemotherapy and when they start taking medication.
62508136|NCT06307041|OTHER|Control Group|One side is dental floss usage
62714998|NCT05874726||Medical Management|Subjects who follow lifestyle modification and/or anti-obesity medications for treatment of obesity with no previous surgical intervention for obesity. Medical therapies include weight loss diets or anti-obesity medications.
62714999|NCT05722015|EXPERIMENTAL|Arm 1 (MK-3475A + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive MK 3475A SC in combination with platinum doublet chemotherapy.
61965550|NCT06508632|NO_INTERVENTION|Control Group|In this study, the control group will receive standard care.
62706087|NCT00557440|EXPERIMENTAL|Ind/M - FP/Salm - Pbo|"In Treatment Period 1 (Days 1 \& 2) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 \& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 \& 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
62706088|NCT00557440|EXPERIMENTAL|FP/Salm - Pbo - Ind/M|"In Treatment Period 1 (Days 1 \& 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 \& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 \& 16) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
62706089|NCT00557440|EXPERIMENTAL|Pbo - Ind/M - FP/Salm|"In Treatment Period 1 (Days 1 \& 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 \& 9) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 \& 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
61965551|NCT01679860|EXPERIMENTAL|Clin A|Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years
61965552|NCT01679860|EXPERIMENTAL|Clin B|Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged \> 60 ≤ 75 years
61965553|NCT02852538|EXPERIMENTAL|NEW FED TR for Anorexia|NEW FED TR
61965554|NCT03296241|EXPERIMENTAL|Laser|One session of non-ablative Er:YAG laser (2940 nm) treatment of the vaginal wall, introitus and vestibule.
62508137|NCT00402025|EXPERIMENTAL|Talimogene Laherparepvec|Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
62508138|NCT01151319|EXPERIMENTAL|Stage 1.|The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).
62508139|NCT01151319|EXPERIMENTAL|Stage 2|The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.
61965555|NCT03296241|SHAM_COMPARATOR|Sham control|The sham control group was treated with the same procedure but with zero intensity settings - without receiving therapeutic irradiation (placebo).
61965556|NCT04937491||Healthy volunteers|Adult healthy volunteers (students). Intervention 1: Intake of water (2% of body weight) Intervention 2: Intake of sports drink (2% of body weight) Intervention 3: Intake of soya saus (salt): 10 ml (equal to 8 g salt) Intervention 4: Intake of 90 g sugar (jelly figures)
61965557|NCT01778218|EXPERIMENTAL|99mTc-EC-DG|99mTc-EC-DG injection followed by SPECT imaging during a cardiac rest study (Visit 1) and an exercise/regadenoson study (Visit 2)
61965558|NCT05665478|ACTIVE_COMPARATOR|model intervention group|The model was used for prediction to guide the later dosing regimen
61965559|NCT05665478|NO_INTERVENTION|Non-intervention group|In the non-intervention group, the doctor chose the treatment plan.
62508140|NCT01151319|EXPERIMENTAL|Stage 3|Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
62508141|NCT01151319|EXPERIMENTAL|Stage 4|Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).
62508142|NCT01151319|PLACEBO_COMPARATOR|Stage 2 Placebo|Time-course matched to vaccinations (n=2)
62508143|NCT01151319|PLACEBO_COMPARATOR|Stage 3 placebo|Time-course matched to vaccinations (n=2)
61965560|NCT06281600|PLACEBO_COMPARATOR|Placebo control arm|Maltodextrin will be given as a white powder placebo for 4 weeks.
61965561|NCT06281600|EXPERIMENTAL|HMO intervention arm|HMOs will be given as a white powder for 4 weeks.
61965562|NCT01890356|EXPERIMENTAL|Transcranial electrical stimulation|
61965563|NCT04810312|EXPERIMENTAL|Intervention group|Back extensor strengthening with oral protein supplementation
61965564|NCT04834284||Helicopter Emergency Medical Services (HEMS)|Patients transported to the comprehensive stroke centre at least in some part by a HEMS unit
61965565|NCT04834284||Ground Emergency Medical Services (GEMS)|Patients transported to the comprehensive stroke centre solely by an ambulance
61965566|NCT04381403|EXPERIMENTAL|Bio-descaling D-Tart toothpaste|Bio-descaling D -Tart is a bio-descaler toothpaste that is manufactured at Du-Var laboratories (1460 Graham Bell, Boucherville, Québec, Canada J4B 6H5)
61965567|NCT04381403|ACTIVE_COMPARATOR|Crest®|anti-tartar toothpaste, Complete Whitening plus Scope, tartar control produced by Procter \& Gamble, Cincinnati, OH),
62508144|NCT01151319|PLACEBO_COMPARATOR|Stage 4 placebo|Time-course matched to vaccinations (n=2)
61965568|NCT02396485|EXPERIMENTAL|Early Feeding Arm|Patients will be started on regular diet within 6 hrs postoperative.
62508145|NCT04325854||Ectopic pregnancy population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all ART procedures (both I and II level) performed between 2009 and 2018.
61965569|NCT02396485|NO_INTERVENTION|Late Feeding Group|Patients will be remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs as standard postoperative protocol in the investigators' institution.
62508146|NCT06614751|EXPERIMENTAL|Part 1, Dose escalation|Monotherapy, dose escalation to definite MTD or RDE.
62508147|NCT06614751|EXPERIMENTAL|Module 1 Part 2, Dose optimizing|Dose optimizing by 2 dose level after dose escalation to definite RP2D
61965570|NCT05077722|EXPERIMENTAL|AI Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy (PCIT) will wear a Garmin smartwatch that will provided targeted messages during tantrums picked up by the Garmin devices that will instruct them on how to deescalate their child.
62508148|NCT06614751|EXPERIMENTAL|Module 2 Part 2, Dose expansion|To evaluate safety and efficacy of DAT-2645 tablet in solid tumor under RP2D dosage
61965571|NCT05077722|SHAM_COMPARATOR|Sham Biometric - Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy will wear Garmin smartwatch and will receive only random messages throughout the day with various relaxation strategies such as reminders to practice deep breathing with their child.
62508149|NCT05430841|EXPERIMENTAL|18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
61965572|NCT04147208|EXPERIMENTAL|Combination group|Subjects will receive 96 weeks of GLS4+RTV+ETV.
61965573|NCT04147208|ACTIVE_COMPARATOR|Entecavir monotherapy|Subjects received 96 weeks of entecavir treatment
61965574|NCT05765604|EXPERIMENTAL|test group|low dose and high dose, only one dose at day 0
61965575|NCT05765604|ACTIVE_COMPARATOR|control group|one dose at day 0
62144709|NCT03773497|OTHER|Cheese broccoli|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli.
62144710|NCT03773497|OTHER|Cheese broccoli with Daikon radish powder|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder.
62144711|NCT03773497|OTHER|Uncooked broccoli with ranch-type dip|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of uncooked, freeze-dried broccoli with ranch-type dip.
62144712|NCT02906137|EXPERIMENTAL|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:~* 15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~* 15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~* 10 subjects will have both a gastroscopy and a coloscopy"
62144713|NCT02906137|OTHER|Uninfected-controls|"40 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:~* 10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~* 10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~* 20 subjects will have both a gastroscopy and a coloscopy"
62349933|NCT03115112|ACTIVE_COMPARATOR|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
62349934|NCT03115112|ACTIVE_COMPARATOR|Sitagliptin|Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
62349935|NCT05911464|EXPERIMENTAL|HS-10386|Participants will receive HS-10386 once daily. The duration of each treatment cycle is 21 days.
62349936|NCT05435742|EXPERIMENTAL|SON-080 Dose Level 1|20 µg SON-080 SC administration TIW
62349937|NCT05435742|EXPERIMENTAL|SON-080 Dose Level 2|60 µg SON-080 SC administration TIW
62349938|NCT05435742|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo 20 µg SON-080 SC administration TIW
62349939|NCT01512147|OTHER|Isoflurane, Propofol, Dexmedetomidine|Our trial will examine the changes in latency and amplitude of SSEP and changes in amplitude and morphology of MEP while using different anesthetic combinations including isoflurane, proposal and dexmedetomidine. Monitoring teams will document any changes throughout the surgery and communicate with the team about those changes. The design of the study will be a prospective AB design.
62349940|NCT03480958|ACTIVE_COMPARATOR|ESP group|Erector Spinae Plane Block administered group
62349941|NCT03480958|ACTIVE_COMPARATOR|TPVB group|Thoracic Paravertebral Block administered group
62349942|NCT03480958|OTHER|Control Group|No regional anesthesia technique will be applied to control group; but will be provided with iv PCA
62349943|NCT04387318|EXPERIMENTAL|Multimodal training|"IMT + NMES + Pulmonary Rehabilitation~IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
62508150|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 1|3 patients dosed at 0.01 mg/kg until MTD determined
62508151|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 2|4 patients dosed at 0.02 mg/kg until MTD determined
62508152|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 3|4 patients dosed at 0.04 mg/kg until MTD determined
61965576|NCT00888368|EXPERIMENTAL|Transpatellar Approach|
61965577|NCT00888368|ACTIVE_COMPARATOR|Suprapatellar Approach|
61965578|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
61965579|NCT00696722|EXPERIMENTAL|1|Placebo treatment first, atazanavir treatment second
61965580|NCT00696722|EXPERIMENTAL|2|Atazanavir treatment first, placebo treatment second
62508153|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 4|4 patients dosed at 0.08 mg/kg until MTD determined
61965581|NCT00820690||Clinical stage III|Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)
61965582|NCT05459675|EXPERIMENTAL|Very low-calorie diet|Patients in the very low-calorie diet group will be prescribed a very low-calorie diet (meal replacement) for 12 weeks, then the patients will be monitored up to 1 year
61965583|NCT05459675|EXPERIMENTAL|Bariatric surgery|Patients in the bariatric surgery group will be undergone bariatric surgery LRYGB and will be follow-up according the current guideline
61965584|NCT05240053|ACTIVE_COMPARATOR|group (1)|Group 1: included 25 patients who were subjected to enhance recovery program after laparoscopic colorectal surgery .
62706090|NCT00164281|EXPERIMENTAL|Continuous vs limited isoniazid|The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).
62706091|NCT01027676|EXPERIMENTAL|study arm|single arm Gefitinib plus vorinostat
62706092|NCT03624725|ACTIVE_COMPARATOR|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
62706093|NCT03624725|NO_INTERVENTION|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
62706094|NCT04748237|EXPERIMENTAL|Coronary computed tomopraphic angiography|"Patients randomized to strategy including early CCTA will receive standard care according to responsible physician and referred to a CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days. Local scanning protocols can be used on ≥64-slice multi-detector CT scanners able to perform ECG-gated coronary angiography.~The coronary angiography will be classified as normal (or near normal) or as having atherosclerosis (CAD). The report will also classify each vessel (left main, prox LAD, mid or distal LAD, LCX and RCA regarding degree of stenosis (no stenosis, 0-49%, ≥50%, or not possible to estimate because of calcification or technical reason).~The result will be presented to the responsible physician as soon as possible and who will plan further care of the patients."
61965585|NCT05240053|NO_INTERVENTION|group (2)|Group 2: included 25 patients who were subjected to traditional way
61965586|NCT00109798|EXPERIMENTAL|Temozolomide, Topotecan|Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
61965587|NCT02374801|EXPERIMENTAL|Treatment|"This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON (AV+VV)."
61965588|NCT00462267|NO_INTERVENTION|Usual care|
61965589|NCT00462267|EXPERIMENTAL|Enriched lifestyle intervention|
61965590|NCT04650360|EXPERIMENTAL|Postoperative Intervention Educational Program|The intervention group will receive an educational program during admission. The health educational program will consist of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics will be addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls
61965591|NCT04650360|NO_INTERVENTION|Control|The patients in the control group will not receive any educational program. These patients will be treated according to routine protocols
62349944|NCT04387318|EXPERIMENTAL|IMT + Pulmonary Rehabilitation|"IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
62349945|NCT04387318|EXPERIMENTAL|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
62349946|NCT04387318|PLACEBO_COMPARATOR|Pulmonary Rehabilitation|Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise.
61965592|NCT02161367|EXPERIMENTAL|Simethicone, OVOL|Patients in the intervention arm will receive, in a blinded fashion, 160mg of simethicone orally four times a day for the first five postoperative days. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
61965593|NCT02161367|PLACEBO_COMPARATOR|Oral Suspending Vehicle, Ora-Plus|Patients in the control arm will receive, in a blinded fashion, 160mg of the placebo orally four times a day for the first five postoperative days. The placebo will be prepared by pharmacy to be identical to the test drug formulation except for being pharmacologically inert. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
61965594|NCT05502185||healthy volunteers|no intervention
61965595|NCT05502185||Atopic Dermatitis patients|no intervention
61965596|NCT01818921|PLACEBO_COMPARATOR|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.
62349947|NCT01121003|OTHER|Low fructose diet/no exercise|
62349948|NCT01121003|EXPERIMENTAL|high fructose diet/no exercise|
62349949|NCT01121003|EXPERIMENTAL|high fructose diet+exercise|
62706095|NCT04748237|NO_INTERVENTION|No Coronary computed tomopraphic angiography|"Patients randomized to a strategy not including early CCTA will receive further care (including examinations) according to responsible physician but not include early CCTA. These patients will often undergo a non-invasive functional test, such as Exercise-ECG, stress echocardiography or nuclear imaging according to local routines, but not always.~Regardless of diagnostic strategy, the responsible physician is encouraged to initiate secondary prevention measures if the investigations indicate signs of CAD, including medication with aspirin and statins."
62706096|NCT01602484|EXPERIMENTAL|Splint Pack|Group of post-op patients who have splint applied from prepared Plaster-of-Paris splint pack
62508154|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 5|3 patients dosed at 0.12 mg/kg until MTD determined
62508155|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 6|4 patients dosed at 0.18 mg/kg until MTD determined
62508156|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 7|5 patients dosed at 0.27 mg/kg until MTD determined
62706097|NCT01602484|ACTIVE_COMPARATOR|Bulk Supplies|Group of post-op patients who have splint applied from bulk supplies
62706098|NCT05486507|EXPERIMENTAL|Montmorency tart cherry juice|
62706099|NCT05486507|PLACEBO_COMPARATOR|Placebo|
62706100|NCT04743648|EXPERIMENTAL|Intervention Group|After determining the experimental and control groups, pre-tests were performed.The program was applied to students in the experimental group.The program was implemented for six weeks based on the theme of innovative thinking.The program developed a training program based on the Tyler Taba model. This model, which is often used in developing educational programs, includes all the necessary steps to teach and accept a new concept. In the ITDP training program, an interactive educational content has been created in which knowledge will be transformed into behavior.In the training, subjects were taught in units, workshops were held, seminars were given. Post-tests were applied at the end of the training.
62706101|NCT04743648|NO_INTERVENTION|Control Group I|Pre-test and post-tests were applied to the non-intervention group
62706102|NCT04743648|NO_INTERVENTION|Control Group II|Pre-test and post-tests were applied to the non-intervention group
62706103|NCT05646082|EXPERIMENTAL|Open Label|
62706104|NCT01577316|EXPERIMENTAL|Pregnant Woman|Pregnant Woman
62706105|NCT01577316|EXPERIMENTAL|Nonpregnant women|2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
62706106|NCT04152239||Study group|Study group includes consecutive patients with suspected small bowel pathology based on clinical presentation, small bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic enteroscopy. Patients fulfilling the inclusion criteria and without exclusion criteria would undergo MSE per study protocol.
62706107|NCT01409408|ACTIVE_COMPARATOR|Aliskiren|
62706108|NCT01409408|ACTIVE_COMPARATOR|Amlodipine|
62706109|NCT03144401|ACTIVE_COMPARATOR|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
62706110|NCT03144401|ACTIVE_COMPARATOR|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
62706111|NCT02882347|EXPERIMENTAL|somatostatin group|The investigators administrate somatostatin at a rate of 3.5ug/kg/hour to PHLF patients (prothrombin time \< 50% and serum total bilirubin \> 2.9mg/dl after liver resection) until recovery from liver failure.
62706112|NCT06417060|EXPERIMENTAL|Caudal block|Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
62508157|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 8|7 patients dosed at 0.40 mg/kg until MTD determined
62706113|NCT06417060|SHAM_COMPARATOR|Dorsal Penile Block Anesthesia|Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
62706114|NCT05136755|EXPERIMENTAL|NMDAE|An NMDA enhancer
62706115|NCT05136755|PLACEBO_COMPARATOR|Placebo|Placebo
62706116|NCT02988908|EXPERIMENTAL|Drug: Donepezil|"Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
62706117|NCT02988908|PLACEBO_COMPARATOR|Placebo (Control)|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
62706118|NCT03457792||Abatacept for Rheumatoid Arthritis (RA)|Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept
61965597|NCT01818921|EXPERIMENTAL|1.2 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
61965598|NCT01818921|EXPERIMENTAL|1.8 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
62706119|NCT04717401|EXPERIMENTAL|Strain-counterstrain Group A|Strain Counterstrain (SCS) is a passive positional technique which aims to relieve musculoskeletal pain and dysfunction by indirect manipulation .
62715000|NCT05722015|ACTIVE_COMPARATOR|Arm 2 (Pembrolizumab + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive Pembrolizumab IV in combination with platinum doublet chemotherapy.
62715001|NCT06678542|EXPERIMENTAL|Treatment sequence T-R|
61965599|NCT03186560|ACTIVE_COMPARATOR|Group A: Arterial Leg Ulcer|Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
61965600|NCT03186560|ACTIVE_COMPARATOR|Group B: Mixed Leg Ulcer|only to be done once Arterial leg ulcers show change in flux ABPI of \<0.8-0.6
61965601|NCT03186560|ACTIVE_COMPARATOR|Group C: Diabetic Foot Ulcer - neuropathic|On clinical inspection present as neuropathic
62508158|NCT02561234|EXPERIMENTAL|AEB1102 Dose Escalation Cohort 9|7 patients dosed at 0.33 mg/kg until MTD determined MTD determined at 0.33 mg/kg
62508159|NCT02561234|EXPERIMENTAL|AEB1102 Expansion|Uveal: 11 patients dosed at 0.33 mg/kg Cutaneous Melanoma: 11 dosed at 0.33 mg/kg SCLC: 13 patients dosed at 0.33 mg/kg
61965602|NCT03186560|ACTIVE_COMPARATOR|Group D: Diabetic Foot Ulcer - neuroischemic|On clinical inspection present as neuroischemic
61965603|NCT02292602|EXPERIMENTAL|Family-Based Weight Control Intervention|Families will receive the FBWC
62508160|NCT01398202|ACTIVE_COMPARATOR|Vitamin D3 (20 microgram/day)|
62508161|NCT01398202|ACTIVE_COMPARATOR|25-hydroxyvitamin D (7 microgram/day)|
62508162|NCT01398202|ACTIVE_COMPARATOR|25-hydroxyvitamin D3 (20 micogram/day)|
62508163|NCT01398202|PLACEBO_COMPARATOR|Placebo|
62508164|NCT01435824|ACTIVE_COMPARATOR|Water as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml water and orally administered in a fasting state.
61965604|NCT02292602|NO_INTERVENTION|Control|Families will continue with standard of care at WIC
62508165|NCT01435824|EXPERIMENTAL|Human milk as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml human milk and orally administered in a fasting state.
62144714|NCT04348357|ACTIVE_COMPARATOR|Traditional Visit|Patients come to the office for a traditional postoperative visit
62706120|NCT04717401|EXPERIMENTAL|Muscle Energy Technique Group B|MET is a gentle manual therapy for the restricted mobility of the spine and extremities and is an active procedure in which the corrective force is regulated by the patient, not the clinician. This technique requires the patient to perform voluntary muscle contractions of varying intensity, in a specific direction, while the clinician uses a counter-force that does not allow movement to occur The physiological mechanism underlying SCS is unknown though. It has hypothesized that muscle tone inhibition occurs by stimulation of the target muscle's Golgi tendon organ by physical approximation of muscle origin and insertion.
62706121|NCT01793389|ACTIVE_COMPARATOR|Subepithelial connective tissue graft|Soft tissue harvested from palatum of the subjects.
62706122|NCT01793389|EXPERIMENTAL|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
62508166|NCT04472858|EXPERIMENTAL|Cholangiocarcinoma|Cholangiocarcinoma
62706123|NCT02525198|PLACEBO_COMPARATOR|Placebo|Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
62706124|NCT02525198|EXPERIMENTAL|fatty acid/flavonoid blend|Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
62706125|NCT01186276|PLACEBO_COMPARATOR|Corn Starch|Corn starch will serve as the control arm.
62706126|NCT01186276|EXPERIMENTAL|Fiber|Fiber will serve as the intervention.
62706127|NCT03477812||Healthy children|Healthy children 7-14 years of age.
62706128|NCT03477812||Nocturnal enuresis with polyuria|Children with nocturnal enuresis and polyuria aged 7-14 years.
62706129|NCT03477812||Nocturnal enuresis without polyuria|Children without nocturnal enuresis and polyuria aged 7-14 years.
61965605|NCT04249674||Patient under a CYP2D6 inhibitor and under Tramadol|
61965606|NCT04249674||Patient not under a CYP2D6 inhibitor but under Tramadol|
61965607|NCT04360915|EXPERIMENTAL|ASK120067 in fast condition|Take ASK120067 tablets orally once in the first day at 160mg in fast condition.
62144715|NCT04348357|EXPERIMENTAL|Tele-medicine|Patients receive postoperative care via telemedicine
62144716|NCT02441569|EXPERIMENTAL|Common factors intervention|Children and parents in this arm will be cared for by a provider who has received brief training in common factors patient engagement skills (the intervention) for use in addition to standard anxiety-related advice. Thus this arm will receive common factors engagement training for provider.
62508167|NCT04472858|EXPERIMENTAL|Squamous cell carcinoma of the head and neck|Squamous cell carcinoma of the head and neck（HNSCC）
62144717|NCT02441569|ACTIVE_COMPARATOR|Control|Children and parents in this arm will be cared for by a provider who is able to offer standard pediatric anxiety-related advice (the control intervention). Families will receive standard pediatric advice for childhood anxiety.
62144718|NCT03709797|EXPERIMENTAL|Experimental group|Experimental group will receive dry needling treatment.
62349950|NCT04782804|ACTIVE_COMPARATOR|Capecitabine|Capecitabine as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
62508168|NCT04472858|EXPERIMENTAL|Endometrial cancer|Endometrial cancer
62706130|NCT06563856|EXPERIMENTAL|Cohort 1: TEPEZZA Dose A SubQ|Participants will receive Dose A of TEPEZZA administered SubQ.
61965608|NCT04360915|EXPERIMENTAL|ASK120067 in fed condition|Take ASK120067 tablets orally once in the first day at 160mg in fed condition.
61965609|NCT04119882||Positive for ischaemia|Blood test for 121 patients with confirmed cardiac ischemic event
61965610|NCT04119882||Negative for ischaemia|Blood test for 283 patients with no cardiac ischemic event
62706131|NCT06563856|EXPERIMENTAL|Cohort 2: TEPEZZA Dose B SubQ|Participants will receive Dose B of TEPEZZA administered SubQ.
62706132|NCT06563856|EXPERIMENTAL|Cohort 3: TEPEZZA Dose B Intravenously (IV)|Participants will receive Dose B of TEPEZZA administered IV.
62706133|NCT06563856|EXPERIMENTAL|Cohort 4: TEPEZZA Dose B and EDP SubQ|Participants will receive coadministered doses of TEPEZZA Dose B and EDP SubQ.
62706134|NCT03116126|ACTIVE_COMPARATOR|Guanfacine|
62706135|NCT03116126|PLACEBO_COMPARATOR|Placebo|
62706136|NCT05755581|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy group|Patients in this arm will receive neoadjuvant chemotherapy as usual
62706137|NCT05755581|ACTIVE_COMPARATOR|Neoadjuvant endocrine therapy group|Patients in this group will receive neoadjuvant endocrine therapy
62706138|NCT04744103|EXPERIMENTAL|TCA peal|Patients will have their actinic cheilitis treated with a TCA peal.
61965611|NCT06372223|EXPERIMENTAL|Group A|
61965612|NCT06372223|EXPERIMENTAL|Group B|
61965613|NCT04047394|EXPERIMENTAL|PEGylated recombinant candida urate oxidase|Participants will be administered with 2mg, 3mg, 4.5mg, 6mg, 8mg, 10mg once by Intravenous injection. Subjects will be followed for 56 days.
62144719|NCT03709797|SHAM_COMPARATOR|Control group|Control group will receive sham dry needling treatment.
62144720|NCT04913506|ACTIVE_COMPARATOR|Group Mirror|Along with conventional rehabilitation techniques, patients will be given ROM exercises in all directions, in front of the real mirror, by the practitioner on the healthy upper extremity for 30 minutes.
62144721|NCT04913506|ACTIVE_COMPARATOR|Group NMES|Along with conventional rehabilitation techniques, NMES will be applied to the hemiplegic arm for 30 minutes by the practitioner while the patients are sitting in a chair.
62706139|NCT02502552||Inflammatory Bowel Disease|Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen
62706140|NCT05851963|EXPERIMENTAL|Group using sonic toothbrush|Patients will be asked to use a sonic toothbrush for 24 months
62706141|NCT05851963|EXPERIMENTAL|Group using hydrosonic toothbrush|Patients will be asked to use a hydrosonic toothbrush for 24 months
62706142|NCT05851963|PLACEBO_COMPARATOR|Group using manual toothbrush|Patients will be asked to use a manual toothbrush for 24 months
62706143|NCT05851963|EXPERIMENTAL|Group using manual toothbrush with 5460 strands|Patients will be asked to use a manual toothbrush with 5460 strands for 24 months
61965614|NCT01709162|EXPERIMENTAL|Ipilimumab, 3 mg/kg|Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
61965615|NCT01709162|ACTIVE_COMPARATOR|Chemotherapy|Participants received the investigator's choice of chemotherapy, administered per package instructions.
62508169|NCT04158635|EXPERIMENTAL|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 1-9|"Patients receive bosentan PO BID on days 8-21 of cycle 1 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
61965616|NCT03937310||Surgical intervention for non-union|The investigation group will consist of cases undergoing surgical intervention for non-union
62706144|NCT02783833|EXPERIMENTAL|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
61965617|NCT03937310||Acute fracture fixation|The control group will consist of cases undergoing acute fracture fixation
61965618|NCT06123845|EXPERIMENTAL|CPAP 8|Upon arrival of the infant on the neonatal resuscitation trolley, start the normal standard procedures required by international protocols (e.g., drying, temperature control measures, placement of pulse-oximeter sensor to the right hand or wrist, etc.). Immediately start CPAP application with mask and T-piece: the CPAP level will be set at 8 cmH2O. Perform gentle tactile stimulation if the child is not breathing in appropriately. Place the pulse-oximeter sensor on the right hand then connect it to the oxymeter previously turned on. Assess breathing and HR for 30 seconds. Perform the next step of the flow-chart of resuscitation in the delivery room according to the Neonatal Resuscitation Program guidelines. If positive pressure ventilation (PPV) is required (in case of persistent bradycardia or apnea), maintain PEEP at 8 cm H2O and an initial PIP of 25 cm H2O. The CPAP level will be reduced to 6 cm H2O after 15 minutes of life, then the recording will be discontinued.
61965619|NCT06123845|ACTIVE_COMPARATOR|CPAP 5|Upon arrival of the infant on the neonatal resuscitation trolley, start the normal standard procedures required by international protocols (e.g., drying, temperature control measures, placement of pulse-oximeter sensor to the right hand or wrist, etc.). Immediately start CPAP application with mask and T-piece: the CPAP level will be set at 5 cmH2O. Perform gentle tactile stimulation if the child is not breathing in appropriately. Place the pulse-oximeter sensor on the right hand then connect it to the oxymeter previously turned on. Assess breathing and HR for 30 seconds. Perform the next step of the flow-chart of resuscitation in the delivery room according to the Neonatal Resuscitation Program guidelines. If positive pressure ventilation (PPV) is required (in case of persistent bradycardia or apnea), maintain PEEP at 5 cm H2O and an initial PIP of 25 cm H2O. The CPAP level will be raised to 6 cm H2O after 15 minutes of life, then the recording will be discontinued.
61965620|NCT05641753|EXPERIMENTAL|4-Week LDL-Cholesterol (LDL-C)-Reduction Treatment|"Treatment consists of: Evolocumab (140 mg; 2 injections, one administered at baseline visit and another self-administered 2 weeks later), and; Atorvastatin (up to 80mg dose; 1 tab per day for 30 days, starting at baseline visit post-assessment). Participants with statin intolerance will be provided with a 1-month supply of ezetimibe 10 mg to replace Evolocumab and Atorvastatin.~* Additional procedures: Blood draws.~* Optional procedures: Glycocalyx testing, PET/CT, or Endothelial Cell Collection."
62349951|NCT04782804|EXPERIMENTAL|Capecitabine+PD-1 Antibody（Tislelizumab）|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery. PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
61965621|NCT03982368|EXPERIMENTAL|rhNGF 20 μg/ml TID|One drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
62349952|NCT05508399||PD-1 group|Patients who are qualified for receiving anti-PD-1 antibody combined with chemotherapy neoadjuvant therapy
61965622|NCT03982368|EXPERIMENTAL|rhNGF 20 μg/ml BID + vehicle OD|One drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily (BID) plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (OD) (every 6-8 hours)
61965623|NCT03982368|PLACEBO_COMPARATOR|Vehicle TID|Vehicle eye one drop will be instilled in both eyes three times daily (every 6-8 hours)
61965624|NCT01575769|EXPERIMENTAL|1|
62349953|NCT01175421||Patients undergoing sleep study|
62349954|NCT06144242|EXPERIMENTAL|Feedback on RTD metric|An e-mail will be sent to the clinicians in the experimental arm every two months describing their performance on the RTD metric and making a comparison to how their peers have performed. The e-mail will also direct clinicians to visit a dashboard to review their practice in greater depth.
62349955|NCT06144242|NO_INTERVENTION|No feedback on RTD metric|Any clinician assigned to the control arm will not receive the above-mentioned e-mails.
62349956|NCT01155596|NO_INTERVENTION|Control group|Base on positive pressure ventilation with intubation and mechanical ventilator, weaning processes will undergo by Pulmonologists.
62349957|NCT01155596|EXPERIMENTAL|Experimental group|Experimental group is weaning with the support of negative pressure ventilator.
62706145|NCT02783833|EXPERIMENTAL|MMV390048 dose to be determined mg|MMV390048 dose to be determined mg, tablets, single dose
62706146|NCT00688740|EXPERIMENTAL|TAC (Docetaxel)|docetaxel (75 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment
62706147|NCT00688740|ACTIVE_COMPARATOR|FAC (5-fluorouracil)|5-fluorouracil (500 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment
62706148|NCT01003223|EXPERIMENTAL|PKM modeling with graphical report|
61965625|NCT03464305|EXPERIMENTAL|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
62349958|NCT00098020|EXPERIMENTAL|Isotretinoin|Subjects will be treated with Isotretinoin.
62349959|NCT01252641|EXPERIMENTAL|SB-728-T|Subjects will receive one intravenous infusion of SB-728-T
62349960|NCT04917497||Levosimendan Treated Group|All patients consecutively admitted to the medical ICU of the University Hospital Zurich aged over 18 years, with an underlying cardiogenic shock, receiving Levosimendan.
62349961|NCT01373424||Cervical dystonia|People diagnosed with cervical dystonia
62349962|NCT01373424||Laryngeal dystonia|People diagnosed with laryngeal dystonia
62715002|NCT06678542|EXPERIMENTAL|Treatment sequence R-T|
61965626|NCT03464305|PLACEBO_COMPARATOR|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
61965627|NCT03010514||case|
62349963|NCT01373424||Other voice disorders|People diagnosed with a voice disorder other than laryngeal dystonia - enrollment for this group is complete
62349964|NCT01373424||Craniofacial dystonia|People diagnosed with craniofacial dystonia (including blepharospasm, meige syndrome, and oromandibular dystonia)
62349965|NCT01373424||Limb dystonia|People diagnosed with limb dystonia
62508170|NCT04158635|EXPERIMENTAL|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 10-12|"Patients receive bosentan PO BID on days -7 to 21 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62508171|NCT04158635|EXPERIMENTAL|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 13-21|"Patients receive bosentan PO BID on days 1-21 of cycle 1 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62508172|NCT05931276|ACTIVE_COMPARATOR|Metoprolol Succinate|"Depending on baseline type and dose of beta blocker:~* 25 mg once daily (12.5 mg once daily if \> NYHA class II)~* 50 mg (or 25 mg) once daily~* 100 mg (or 50 mg) once daily~* 200 mg (or 100 mg titrated to 200 mg) once daily"
62508173|NCT05931276|ACTIVE_COMPARATOR|Carvedilol|"Depending on baseline type and dose of beta blocker:~* 3.125 mg twice daily~* 6.25 mg twice daily~* 12.5 mg twice daily~* 25 mg twice daily (may titrate to 5 0mg twice daily if \> 85 kg)"
62508174|NCT02917252|ACTIVE_COMPARATOR|Intervention|Subjects drink 3-hydroxybuturate
62508175|NCT02917252|PLACEBO_COMPARATOR|Placebo|Subjects drink saline
62508176|NCT05612087||gastrointestinal post acute COVID-19 syndrome|newly developped functional dyspepsia or irritable bowel syndrome after COVID-19 infection
62508177|NCT06616064|EXPERIMENTAL|Experimental|
62508178|NCT06616064|OTHER|Control|
62508179|NCT03321474|EXPERIMENTAL|modified gull wing preparation|Gullwing preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation
62508180|NCT03321474|ACTIVE_COMPARATOR|conventional preparation|"In conventional preparation of veneer it circumvents the contact areas and extends palatally in the incisal third of the tooth only. The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines placed facially to the proximal contacts~Gull wing (dog leg) preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. This preparation design helps to hide the restoration margin when viewed from an angle, especially in discoloration.~The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
62508181|NCT03743090||CABG with ECC|Group of patients for whom CABG was performed under ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
62508182|NCT03743090||CABG without ECC|Group of patients for whom CABG was performed without ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
62508183|NCT01034852||Surgical ablation|Patients undergoing surgical ablation for Atrial Fibrillation that have failed one or more previous attempts at catheter ablation for Atrial Fibrillation
62508184|NCT00337974|EXPERIMENTAL|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
62508185|NCT00337974|ACTIVE_COMPARATOR|Active Control|Educational DVDs
62706149|NCT05743309|EXPERIMENTAL|Telemedicine Practices|In this study, telemedicine practices stand for video call sessions used for contraceptive counseling services.
62706150|NCT05743309|NO_INTERVENTION|Routine Contraceptive Counseling Services|Participants in the control group received only routine contraceptive counseling services provided by primary health care settings.
61965628|NCT03010514||control|
62349966|NCT01373424||All other isolated dystonias|People diagnosed with any isolated dystonia not listed in descriptions of other cohorts
62349967|NCT01373424||Myoclonus dystonia|People diagnosed with myoclonus dystonia
62508186|NCT00337974|NO_INTERVENTION|No Contact Control|
62508187|NCT00982631|EXPERIMENTAL|temsirolimus/PLD|temsirolimus (Torisel) with pegylated liposomal doxorubicin (PLD,Doxil,Caelyx);a dose escalating study in a 3+3 design
62706151|NCT01416337|EXPERIMENTAL|Treatments A & B|Single 2 mg GSK1120212 oral tablet, fasted Single IV dose of 5 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK1120212 Both doses are given together.
61976161|NCT03518073|PLACEBO_COMPARATOR|Placebo|Participants received intravenous (IV) infusion of placebo once every four weeks (Q4W) for 100 weeks.
61976162|NCT03518073|EXPERIMENTAL|Zagotenemab 1400 mg|Participants received IV infusion of 1400 milligram (mg) zagotenemab Q4W for 100 weeks.
61976163|NCT03518073|EXPERIMENTAL|Zagotenemab 5600 mg|Participants received IV infusion of 5600 mg zagotenemab Q4W for 100 weeks.
62349968|NCT01373424||Dopa-responsive dystonia|People diagnosed with dopa-responsive dystonia
62349969|NCT02521623|EXPERIMENTAL|Surgimend|Patients randomized to this arm will receive SurgiMend® Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
62349970|NCT02521623|ACTIVE_COMPARATOR|Strattice|Patients randomized to this arm will receive Strattice™ Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
62349971|NCT03992209|OTHER|Standard handwashing by anesthesia provider|Anesthesia provider will conduct patient care per their usual standard practice in the operating room.
62706152|NCT02850341|EXPERIMENTAL|Intervention group|Patients receive a pedometer and instructions how to raise their physical activity
61976164|NCT03541824|EXPERIMENTAL|Body Acceptance Program|The Body Acceptance Program (BAP) is the active condition. Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
62349972|NCT03992209|ACTIVE_COMPARATOR|Protocolized hand washing by anesthesia provider|Anesthesia provider will conduct patient care using a personal hand washing device to optimize hand washing and captures hand washing events in real time.
62508188|NCT04473716|EXPERIMENTAL|Neoadjuvant therapy with Toripalimab, Paclitaxcel and Cisplatin|Pre-operative neoadjuvant therapy will be used with the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of paclitaxcel and cisplatin in patients with locally advanced OSCC. After inductive therapy, the patients will receive radical surgery and post-operative radiotherapy/chemoradiotherapy.
62508189|NCT00551616|EXPERIMENTAL|CDB-2914|
61965629|NCT04410211|ACTIVE_COMPARATOR|Group S (inhalational Sevoflurane sedation)|"The inhalational anaesthetic agent and oxygen will be delivered via an anaesthetic circuit with a vaporizer (Sevotec 3, Ohmeda, Streeton UK) with a nasal mask.~Patients who are allocated for Sevoflurane will be given initial oxygen flow of 8L/min and then Sevoflurane was introduced at a concentration of 0.2% and was increased stepwise by 02% for every 30s up to a maximum of 1.0 minimum alveolar concentration (MAC; 2.05% end tidal). Patient's deepest sedation was recorded and adjusted to achieve optimal Observer's Assessment of Alertness/ Sedation Scale (OAAS) score of 3.~Inadequate or over sedation was treated by reducing or increasing the Sevoflurane concentration dial by 0.2 - 0.6% until the desired effect is reached.~Full vital signs monitoring are done for every participant"
62508190|NCT00551616|ACTIVE_COMPARATOR|Levonorgestrel|
62508191|NCT05025852||Metformin exposed in utero|Offspring of mothers who were exposed to metformin during pregnancy in the MiTy trial.
62508192|NCT05025852||Placebo exposed in utero|Offspring of mothers who were not exposed to metformin during pregnancy in the MiTy trial.
62508193|NCT02139618|EXPERIMENTAL|Methyl Aminolevulinate (MAL)|1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
62508194|NCT02139618|PLACEBO_COMPARATOR|Placebo|1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
61976165|NCT03541824|NO_INTERVENTION|Waitlist control|Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
61976166|NCT02144389|ACTIVE_COMPARATOR|Praziquantel (PZQ)|A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
62508195|NCT02580084|ACTIVE_COMPARATOR|aorta femoral bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
62508196|NCT02580084|EXPERIMENTAL|hybrid intervention|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
62508197|NCT05345782|ACTIVE_COMPARATOR|Laparoscopic Hypo gastric Neural Plexus Block|laparoscopy for diagnosis of the causes of chronic pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the sacral promontory then30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) are injected.
62508198|NCT05345782|ACTIVE_COMPARATOR|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block|laparoscopy for diagnosis and conventional surgical treatment of the causes of pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the promontory followed by 30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) then injecting 5 ml ( 2.5 marcaine+1ml betamethasone +1.5 ml normal saline) 2 cm away from the cervix at the uterosacral ligament on each sides.
62508199|NCT03939949|EXPERIMENTAL|High Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions (all including questions about pain) twice daily for six days.
62508200|NCT03939949|EXPERIMENTAL|Low Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (some related to pain) twice daily for six days.
62508201|NCT03939949|ACTIVE_COMPARATOR|Active control|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (none about pain) twice daily for six days.
62508202|NCT04541420||Eribulin|Eribulin 1.4mg/m2 d1,8 iv q3w
62508203|NCT06387979||Observational|Patients undergo tissue sample collection and DESI-MS during standard of care surgery and have their medical records reviewed on study. Patients also undergo MRI per standard of care on study.
62508204|NCT02770144|EXPERIMENTAL|Financial Coaching & Social Services Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
62508205|NCT02770144|ACTIVE_COMPARATOR|Access to Referrals to Social Services|Enrollment provides access to referrals to social services to meet basic needs.
62508206|NCT01337726|ACTIVE_COMPARATOR|Illness Management Only|
62508207|NCT01337726|EXPERIMENTAL|Combined Psychotherapy & Illness Management|
62508208|NCT05645211||Group 1: Healthy children|"140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.~Inclusion Criteria:~1. Ambulatory male and female children aged 5-17 years~2. Normal weight at birth~3. Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.~Exclusion Criteria:~1. Genetic defects, chronic illnesses.~2. Current prescription medication use~3. Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry."
62706153|NCT02850341|NO_INTERVENTION|Control group|Patients receive treatment-as-usual
62715003|NCT06716255||Group 1|Patients receiving the buffered form of ASA
61976167|NCT02144389|EXPERIMENTAL|Arachidonic acid (ARA)|A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
61965630|NCT04410211|ACTIVE_COMPARATOR|Group M (Intravenous Midazolam sedation)|"Patients who are allocated for Midazolam will be given the similar nasal mask delivering 8L/min oxygen. However, Sevoflurane will not be introduced to these patients.~Midazolam is titrated slowly to achieve OAAS score of 3 but no more than 2.5mg is to be given within 2 minutes period to patients selected to be in Midazolam group.~Inadequate sedation is treated by giving slow titration of the medication based on the unblinded observer's judgement. Over sedation is treated by withholding the midazolam and continuing oxygen supplementation until the patient returned to the desired sedation level. No other sedative agents are allowed to be given to the patient or else patient will be excluded from this study."
61965631|NCT04579185|EXPERIMENTAL|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
61965632|NCT04711447|OTHER|no-tape, experimental KT, sham KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both an experimental-KT (E-KT) and sham-KT (S-KT) condition.
61976168|NCT02144389|EXPERIMENTAL|PZQ + ARA|A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.
62144722|NCT04913506|ACTIVE_COMPARATOR|Group Mirror+NMES|In addition to conventional rehabilitation techniques, patients will be given ROM exercises for 30 minutes in all directions in front of the real mirror to the healthy extremity, which the practitioner will synchronize with visual or auditory stimuli, and NMES treatment for 30 minutes to the paretic upper extremity.
62508209|NCT05645211||Group 2: Children with GH deficiency|"16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature.~They will be representative of the diverse racial and ethnic mix of our hospital's patient population.~GH deficiency:~Inclusion Criteria:~1. Ambulatory male and female children aged 5-9 years who are prepubertal~2. Normal weight at birth~3. Growth failure~4. Peak GH response to 2 GH stimulation tests \< 10 ng/ml~5. Normal renal and liver function~Exclusion criteria:~1. Multiple pituitary hormone deficiencies,~2. GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.~3. History of diabetes or malignancy~4. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry."
62508210|NCT05645211||Group 3: Children with short stature|"Idiopathic Short Stature:~Inclusion Criteria:~1. Ambulatory male and female children aged 5-9 years who are prepubertal~2. Normal weight at birth~3. Height \>2.25 SD below mean for age~4. Peak GH response to 2 stimulation tests \>10 ng/ml or normal IGF-1 and IGFBP-3 levels~5. No prior supplemental growth hormone exposure~6. Normal renal and liver function~Exclusion criteria:~1. Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.~2. History of diabetes or malignancy~3. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry."
62349973|NCT02196987||Urination, urethral catheterisation|Act of urination during urethral catheterisation in males
62349974|NCT02196987||Lie, catheterisation, urethra|Urethral catheterisation without medical professional guidance
62508211|NCT05986136|ACTIVE_COMPARATOR|control group|Control group ( Mesalamine group, n =30 ) who will receive 1 g mesalamine three times daily for 6 months
62349975|NCT06118164|EXPERIMENTAL|experimental group -pursing- lip breathing combined with aerobic walking exercise|"For the pursed-lip breathing combined with aerobic walking exercise group (experimental group), subjects were taught to coordinate their breathing with their walking. They were instructed to inhale for two steps and exhale with pursed lips for four to five steps. Initially, they were allowed to walk at a pace that felt comfortable to them, and then gradually increase their walking speed until they reached the target aerobic heart rate, calculated using the formula: (220 - age) × 55-65% of maximum heart rate.~During the walking exercise, a pulse oximeter was used to monitor their heart rate and blood oxygen saturation. Training sessions were conducted daily from the first day after surgery until the fifth day, with three sessions each day, and each session lasting for 15 minutes."
62349976|NCT06118164|ACTIVE_COMPARATOR|Control group 1-pursed-lip breathing|"For the group receiving single pursing- lip breathing training (control group 1), subjects were taught to perform deep inhalation through the nose (counting mentally from 1 to 2) while in a seated or standing position. They were then instructed to purse their lips and exhale slowly and steadily (counting mentally from 1 to 4).~During the walking exercise, a pulse oximeter was used to monitor their heart rate and blood oxygen saturation. Training sessions were conducted daily from the first day after surgery until the fifth day, with three sessions each day, and each session lasting for 15 minutes."
62349977|NCT06118164|ACTIVE_COMPARATOR|Control group 2 -aerobic walking exercise|"For the single aerobic walking exercise group (control group 2), subjects were taught to start with their own acceptable stride and pace and then gradually increase their walking speed until they reached the target aerobic heart rate. Pulse oximeters were used to monitor their heart rate and blood oxygen saturation levels during the process.~During the walking exercise, a pulse oximeter was used to monitor their heart rate and blood oxygen saturation. Training sessions were conducted daily from the first day after surgery until the fifth day, with three sessions each day, and each session lasting for 15 minutes."
62508212|NCT05986136|ACTIVE_COMPARATOR|Dapagliflozin group|Patients will receive 1 g mesalamine three times daily plus dapagliflozin 10 mg once daily for 6 months
62508213|NCT02710591|EXPERIMENTAL|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
62508214|NCT05744700|ACTIVE_COMPARATOR|Inulinase|Total 2,000 INU inulinase per day for 28 days
62508215|NCT05744700|PLACEBO_COMPARATOR|Placebo|Maltodextrin for 28 days
62715004|NCT06716255||Group 2|Patients receiving the enteric-coated form of ASA
62715005|NCT06033625||Cd-TKR|Bicompartmental cemented cruciate retaining Total knee replacement
62508216|NCT03715686|EXPERIMENTAL|Wire localization|Intervention: procedure: wire localization
62706154|NCT01891929|EXPERIMENTAL|RECOS|The RECOS program (COgnitive REmediation for Schizophrenia) was designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 6 main cognitive functions (selective attention; verbal memory; visuo-spatiale attention and memory, working memory, reasoning, and speed of execution) which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS is determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participates in the module corresponding to his/her most altered cognitive area.
62706155|NCT01891929|ACTIVE_COMPARATOR|TAU (Treatment as Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
62715006|NCT06033625||Cs-TKR|Bicompartmental cementless cruciate retaining Total knee replacement
61965633|NCT04711447|OTHER|no-tape, sham KT, experimental KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both a sham-KT (S-KT) condition and experimental-KT (E-KT).
61965634|NCT03041597|EXPERIMENTAL|Immediate loading|
61965635|NCT03041597|ACTIVE_COMPARATOR|delayed loading|
61965636|NCT00016016|EXPERIMENTAL|Treatment (flavopiridol, cytarabine, mitoxantrone)|Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
61965637|NCT00597181|ACTIVE_COMPARATOR|1|Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
61965638|NCT00597181|ACTIVE_COMPARATOR|2|Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes
61965639|NCT01421108|EXPERIMENTAL|Loss-framed messages|
61965640|NCT01421108|EXPERIMENTAL|gain-framed messages|"Adolescents will randomly assign to three groups: gain-framed message , loss-framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images (6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
61965641|NCT06313814|OTHER|before and after result comparison|we will see if there is an effect after the intervention. we will measure the before and after signs.
61965642|NCT06348602|ACTIVE_COMPARATOR|Topical cyclosporine|"Topical cyclosporine ophthalmic solution 0.1%, with a dosage of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months.~Composition: Each ml contains Cyclosporine A 0.1% w/v (1 mg/ml) in a sterile aqueous vehicle q.s."
61965643|NCT06348602|EXPERIMENTAL|Topical tacrolimus|Topical tacrolimus ophthalmic ointment 0.03%, with a dosage of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months Composition: Each gram contains Tacrolimus 0.03% w/w (0.3 mg/g) in a sterile ointment base q.s.
61965644|NCT06284174|PLACEBO_COMPARATOR|control group|Before wound closure, patients will undergo 0.9% normal saline irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
61965645|NCT06284174|EXPERIMENTAL|povidone-iodine group|Before wound closure, patients will undergo 3.5% povidone-iodine solutions for soaking the wound for three minutes followed by rinsing with copious saline.
62144723|NCT02624830|EXPERIMENTAL|Drug, Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to intravenous glucagon have been tested.
62144724|NCT05292118||Coronary Artery Disease (CAD)|
62144725|NCT01385800|PLACEBO_COMPARATOR|Placebo|Intradermal injection, 1 x 8 administrations 2 weeks apart
62144726|NCT01385800|EXPERIMENTAL|ToleroMune Grass Dose 1|Intradermal injection 1 x 8 administrations 2 weeks apart
62349978|NCT01676857||CP/CPPS group|The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
62349979|NCT01676857||Control group|Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
62349980|NCT01151540|EXPERIMENTAL|Rufinamide|Ralfinamide was administered orally twice daily after breakfast and dinner. Participants on placebo in Study 304 were titrated over to rufinamide within 2 weeks during the Conversion Period. As a general rule, the dose of rufinamide at the end of the Conversion Period was maintained throughout the Maintenance Period.
62349981|NCT04141553|ACTIVE_COMPARATOR|Diltiazem IV push|In the standard IV push group, diltiazem will be administered at a dose of 0.25 mg/kg, to a max dose of 25 mg, over 2 minutes. At time 0, these participants will also receive 30 mg of immediate release oral diltiazem. After 15 minutes, if adequate rate control of \<110 BPM has not been achieved, an additional dose 0.35 mg/kg to a max dose of 35 mg will be administered. In order to maintain the blind, the control group will also receive 50 mL of 0.9% NS IV over 20 minutes.
62349982|NCT04141553|ACTIVE_COMPARATOR|Diltiazem IV Slow Infusion|In the slow infusion group, 50 mg of diltiazem will be diluted in 50 mL of 0.9% NS and infused over 20 minutes. Similar the other group, these participants will also receive 30 mg of immediate release oral diltiazem. In order to maintain the blind, this slow infusion group will receive the equivalent volume of IV 0.9% NS over 2 minutes as a placebo.
62349983|NCT04879654|EXPERIMENTAL|endonasal endoscopic surgery with adjuvant therapy|endonasal endoscopic surgery followed by Toripalimab,radiotherapy and/or chemotherapy
61965646|NCT06284174|EXPERIMENTAL|CHG group|Before wound closure, patients will undergo 0.05% chlorhexidine gluconate (CHG) solution for soaking the wound for three minutes followed by rinsing with copious saline.
61965647|NCT05576870|EXPERIMENTAL|Plant based toddler nutrition|Plant based toddler nutrition based on almond and buckwheat drink
61965648|NCT05576870|ACTIVE_COMPARATOR|Dairy based toddler nutrition|Commercially available dairy based toddler nutrition drink
61965649|NCT01990404|ACTIVE_COMPARATOR|Premixed 50% nitrous oxide and oxygen|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. Premixed 50% nitrous oxide and oxygen is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN \<3/10.
61965650|NCT01990404|PLACEBO_COMPARATOR|Medical air|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN \<3/10.
61965651|NCT01462097|EXPERIMENTAL|Aerobic exercise|12 months of treadmill walking and strength training exercise. Exercise is gradually progressed in walking speed and time on the treadmill based on the individual's tolerance, abilities, and safety. For months 1-6 exercise will take place 3 times per week at the research center. For months 6-12 exercise will take place 2 times per week at the center and 1 time per week at home.
61965652|NCT01462097|ACTIVE_COMPARATOR|Health Education|12 months of Health education sessions which will cover topics important to older adults (safe travel, age-appropriate preventative screenings, resources for reliable health information, and topics relevant to chronic kidney disease). For months 1-6 classes will take place 1 time per week. For months 6-12 classes will take place 1 time per month.
61965653|NCT00426907|EXPERIMENTAL|1|Full postoperative weightbearing
61965654|NCT00426907|ACTIVE_COMPARATOR|2|Partial weightbearing 6 weeks postoperative
62508217|NCT05044728|EXPERIMENTAL|Neoadjuvant Chemotherapy Immunotherapy stage|Patients with locally advanced non-small cell lung cancer and locally advanced thoracic esophageal squamous cell carcinoma who met the entry and discharge criteria will be enrolled. After detecting the functional subsets of peripheral CD8-positive T cells, the group was randomly stratified 1:1, respectively. Group A received immunotherapy 24 hours after chemotherapy, and group B received chemotherapy 24 hours after immunotherapy.
62508218|NCT05386394|EXPERIMENTAL|Active tDCS + Language Therapy first|Active tDCS will be applied at the beginning of 45 minutes language therapy session and will last for 20 minutes.
61965655|NCT06295250|ACTIVE_COMPARATOR|Depression Treatment (DT)|Participants in the control group will receive a 6 month manualized group based psychotherapy treatment..
61965656|NCT06295250|EXPERIMENTAL|Integrated Intervention|"The experimental arm includes 2 elements:~1. A poverty alleviation intervention~2. The psychotherapy intervention described above."
61965657|NCT02155608|EXPERIMENTAL|Active eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
61965658|NCT02155608|SHAM_COMPARATOR|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
62349984|NCT03509987|OTHER|hb analysis with Hemacue|Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
62349985|NCT04653857||High-level athlete who had a recent COVID 19 infection, symptomatic or not|High-level athlete who had a recent COVID 19 infection, symptomatic or not
62349986|NCT03846219|EXPERIMENTAL|IMU-838 (30 mg/day)|"IMU-838 tablet containing 15 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 30 mg consists of 2 tablets IMU-838.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 9.5 years for the main trial)."
62349987|NCT03846219|EXPERIMENTAL|IMU-838 (45 mg/day)|"Tablet containing 22.5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 45 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838."
62508219|NCT05386394|SHAM_COMPARATOR|Sham tDCS + Language Therapy first|Sham tDCS will be applied at the beginning of 45 minutes language therapy session.
61965659|NCT04026308|NO_INTERVENTION|Written Safety Plan|Participants will complete a traditional written suicide safety plan.
61965660|NCT04026308|EXPERIMENTAL|Electronic Safety Plan|Participants will complete a suicide safety plan in the Safety Net app using a tablet.
61965661|NCT02622308|EXPERIMENTAL|single-case design|"The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design)."
61965662|NCT04743739|ACTIVE_COMPARATOR|Rituximab monotherapy|Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to the CD19+ B cells count.
61965663|NCT04743739|EXPERIMENTAL|Rituximab combined with cyclosporine|"Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to CD19+ B cells count.~cyclosporine (CsA) will be started at a dose of 3mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Doses of CsA will be adjusted according to the blood levels of CsA. CsA will be tapered after 6 months and discontinued over a 3 month period."
61965664|NCT04324073|EXPERIMENTAL|SARILUMAB|Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1).
61965665|NCT04324073|NO_INTERVENTION|Standard of care|best standard of care
61965666|NCT02647203|EXPERIMENTAL|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
61965667|NCT02647203|ACTIVE_COMPARATOR|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
61965668|NCT04497688|EXPERIMENTAL|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®) 48 hours after the end of chemotherapy, 6mg for patients with body weight≥45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
61965669|NCT02810860|OTHER|Open Label|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
61965670|NCT03312270|EXPERIMENTAL|Multimodality information Comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
61965671|NCT02754245||JPS|study sample at JPS included for analysis
61965672|NCT02754245||BUMC Dallas|study sample at Baylor University Medical Center Dallas included for analysis
61965673|NCT02754245||BUMC at Gardin|study sample at Baylor University Medical Center Gardin included for analysis
61965674|NCT02754245||BUMC Waxahachie|study sample at Baylor University Medical Center Waxahachie included for analysis
61965675|NCT02754245||BUMC Carrolton|study sample at Baylor University Medical Center Carrolton included for analysis
61965676|NCT02754245||BUMC McKinney|study sample at Baylor University Medical Center McKinney included for analysis
61965677|NCT03672747|ACTIVE_COMPARATOR|Anodal Brain Stimulation|Participants will receive anodal stimulation using high-definition tDCS
61965678|NCT03672747|ACTIVE_COMPARATOR|Cathodal Brain Stimulation|Participants will receive cathodal stimulation using high-definition tDCS
62349988|NCT03846219|PLACEBO_COMPARATOR|Placebo|"Tablet containing no active ingredient. The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Once-daily oral dose consists of 2 active compound-free tablets.~Duration: until the end of the main treatment period (24 weeks). The placebo is not applicable in the optional extended treatment period, in which participants who were receiving placebo in the main treatment period were re-randomized to IMU-838 for the extended treatment period."
62508220|NCT02098070||Knee Pain Population|Participants who have responded to the questionnaire with self-reported pain.
62508221|NCT02098070||Non-Knee Pain Population|Participants who have responded to the questionnaire, no self-reported pain.
62508222|NCT04305873||EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test \<93%
62508223|NCT04305873||Non-EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test \>95%
62715007|NCT06719245|OTHER|Standard Neurectomy (control)|Standard Neurectomy during amputation (control)
61965679|NCT03672747|SHAM_COMPARATOR|Sham Brain Stimulation (Placebo)|Participants will receive sham stimulation (placebo) using high-definition tDCS
62349989|NCT03846219|EXPERIMENTAL|IMU-838 (10 mg/day) - Cohort 2|"Cohort 2 sub-trial: additional sub-trial with a small double-blind, placebo-controlled, randomized, parallel-group assessment of a low IMU-838 dose (i.e. 10 mg/day) to provide additional data for pharmacodynamic modelling.~Tablet containing 5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 10 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 8.5 years for the cohort 2 sub-trial)."
61965680|NCT00646776|ACTIVE_COMPARATOR|A|
61965681|NCT00646776|ACTIVE_COMPARATOR|B|
61965682|NCT00001265||Healthy Volunteers|Patients with no disease
61965683|NCT00001265||Patients with muscle disease|Patients with known or suspected Idiopathic Inflammatory myopathies (IIM)
61965684|NCT02055716|PLACEBO_COMPARATOR|alpha-cyclodextrin|A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
61965685|NCT02055716|EXPERIMENTAL|Sulforadex|100mg or 300mg size 00 acid resistant HPMC capsules
61965686|NCT05758051|OTHER|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
61965687|NCT00823368||Arbaclofen followed by Placebo|
61965688|NCT00823368||Placebo followed by Arbaclofen|
61965689|NCT04937673|EXPERIMENTAL|Camrelizumab+ Paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
62349990|NCT02677220|EXPERIMENTAL|Surgical|Subjects to be implanted with the CI532 cochlear implant in one ear
62508224|NCT04305873||Intermediate EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test of 93-95%
62715008|NCT06719245|OTHER|Targeted Muscle Reinnervation (intervention)|Targeted Muscle Reinnervation (TMR) during amputation (intervention)
62715009|NCT01191151||Orthopedic injury, osteoarthritis|All eligible patients receiving orthopedic, sports medicine, arthroscopy and related surgery or nonoperative treatment
61965690|NCT04937673|EXPERIMENTAL|Camrelizumab+ Albumin bound paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
61965691|NCT04383795||Graves' disease patients|First diagnosed Graves' disease patients volunteered for stool collection
61965692|NCT03667924|EXPERIMENTAL|PorchLight Project Intervention Group|Participants in the intervention group will receive home-based support and respite services from PorchLight Project trained Senior Companion volunteers of the Lutheran Social Services of Minnesota.
61965693|NCT01437722|EXPERIMENTAL|1% SPL7013 Gel|
61965694|NCT01437722|EXPERIMENTAL|3% SPL7013 Gel|
61965695|NCT01437722|PLACEBO_COMPARATOR|placebo gel|
61965696|NCT01153347|EXPERIMENTAL|SSRI/Serotonin/SNRI+ TC-5214 0.5 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.5 mg BID
61965697|NCT01153347|EXPERIMENTAL|SSRI/Serotonin/SNRI + TC-5214 2 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 2 mg BID
61965698|NCT01153347|EXPERIMENTAL|SSRI/Serotonin/SNRI + TC-5214 4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
61965699|NCT01153347|PLACEBO_COMPARATOR|SSRI/Serotonin/SNRI + Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
61965700|NCT02460302|EXPERIMENTAL|Vaginal Progesterone|"In the experimental arm, the participants will be randomized (1:1 allocation) to receive a vaginal progesterone suppository (100mg) as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the drug three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
61965701|NCT02460302|PLACEBO_COMPARATOR|Placebo Comparator|"In the placebo arm, the participants will be randomized (1:1 allocation) to receive a vaginal suppository (100mg) containing hard fat without any active hormonal ingredient as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the placebo three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
61965702|NCT02474459|ACTIVE_COMPARATOR|iPad-based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be performed using an iPad-based decision support system. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
61965703|NCT02474459|ACTIVE_COMPARATOR|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
62508225|NCT03965624|EXPERIMENTAL|Ixazomib|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, in combination with dexamethasone 20 mg weekly. The investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see below) or de-escalation in case of response and severe adverse events.
62508226|NCT03523845||Test group|Test group (patients diagnosed with early apical peri-implantitis diagnosed)
62508227|NCT03523845||Control group|Control group (patients whose implants had not developed any inflammatory/infectious process and were osseointegrated)
61965704|NCT00253045|EXPERIMENTAL|Motivational group|Group counseling using motivational interviewing
61965705|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
61965706|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
61965707|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
62349991|NCT05958758|EXPERIMENTAL|Single arm|Group administered Psilocybin-assisted therapy
62349992|NCT02800720|EXPERIMENTAL|Meditation Awareness Training|"Target Intervention Arm:~8-week meditation intervention"
62508228|NCT03800225|EXPERIMENTAL|Repair|Anterior cruciate ligament repair with internal brace after anterior ligament rupture.
62715010|NCT04896801|EXPERIMENTAL|MR-guided prostate stereotactic body radiotherapy|Patients will receive MR-guided RT in 5 fractions over 7 days (daily excluding weekend, i.e. start on Wednesday or Thursday, until Tuesday or Wednesday respectively the week after).
61965708|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
62144727|NCT01385800|EXPERIMENTAL|ToleroMune Grass Dose 2|Intradermal injection 1 x 8 administrations 2 weeks apart
62144728|NCT01385800|EXPERIMENTAL|ToleroMune Grass Dose 3|Intradermal injection 1 x 8 administrations 2 weeks apart
62144729|NCT02767999|EXPERIMENTAL|Fluoxetine|One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI
62144730|NCT02767999|PLACEBO_COMPARATOR|Placebo|The other group will take a cellulose placebo per day from D0 to D90 and have fMRI
62144731|NCT01958385|ACTIVE_COMPARATOR|Treatment group|The treatment of obese patients with the placement of g-Cath EZ suture anchors along with Diet and Exercise
62144732|NCT01958385|SHAM_COMPARATOR|Sham Group|The treatment of obese patients with the sham procedure along with Diet and Exercise
62144733|NCT03543904|EXPERIMENTAL|Pre-operative physiotherapy education|Pre-operative education regarding post-operative physiotherapy intervention and post-operative physiotherapy intervention in children with abdominal surgery
62349993|NCT02800720|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy for Groups|"Active Comparator Arm:~8-week CBT-based intervention"
62349994|NCT00718666|EXPERIMENTAL|Group A|Subjects who were previously vaccinated with one dose of GSK134612 at 12 months of age.
62349995|NCT00718666|EXPERIMENTAL|Group B|Subjects who were previously vaccinated with two doses of GSK134612, one each at 9 and 12 months of age.
62349996|NCT00718666|EXPERIMENTAL|Group C|Subjects aged 5-6 years not previously administered meningococcal vaccine.
62349997|NCT05883007|EXPERIMENTAL|Dose-optimized BNCT with borofalan(10B)|
62349998|NCT04238676|EXPERIMENTAL|PP353|
62508229|NCT03800225|ACTIVE_COMPARATOR|Patella tendon graft|The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture.
62508230|NCT00124462|OTHER|Realignment to Placebo|Realigning knee brace and custom orthodic- A valgus brace, customized functional orthotic for neutral foot position and motion control footwear.
61965709|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
61965710|NCT00704054|EXPERIMENTAL|1|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
61965711|NCT02412475|EXPERIMENTAL|Treatment Plan - 2 treatment courses|Drug Method Used to Give Drug Days Cytarabine IT 0 or -1 Decitabine IV over 1 hour 1-5 Vorinostat PO 1-5 Fludarabine IV over 30 minutes 6-10 Cytarabine IV over 3 hours 6-10 Filgrastim (G-CSF) IV or SQ 5-12 Sorafenib PO 11-28
61965712|NCT00905697||Living donor lung transplantation|Living lung transplantation donors
61965713|NCT01504035|EXPERIMENTAL|Hemostatic putty plus Lidocaine (Orthostat-L)|
61965714|NCT01504035|ACTIVE_COMPARATOR|Hemostatic putty (Orthostat)|
61965715|NCT01876030|EXPERIMENTAL|FES|All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
61965716|NCT01876030|NO_INTERVENTION|Conventional|Treated with regular gait re-education with or without AFO fitting. All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the AFO will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
61965717|NCT05144321||All pregnant women delivering a twin pregnancy|All pregnant women delivering a twin pregnancy
61965718|NCT03358121||Diabetics without hypoglycemia awareness|Diabetic patients without impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
61965719|NCT03358121||Diabetics with hypoglycemia awareness|Diabetic patients with impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
61965720|NCT02324062||Pathogenic group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a mutation in a gene not commonly tested for prior to the advent of multiplex panel testing. This excludes BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH unless a patient tested positive for one of these 9 genes but did not meet clinical criteria for the underlying syndrome (n = 124). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
61965721|NCT02324062||VUS group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a variant of unknown significance of any gene of any nonBRCA (BRCA1 and BRCA2) or non-Lynch syndrome gene (MLH1, MSH2, MSH6, PMS2 and EPCAM).~Target accrual is 100. These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
61965722|NCT02324062||Negative Group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients who test negative for all the genes tested. Target goal is 50 for Stanford (100 for the study). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
61965723|NCT02324062||No follow-up intervention group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~All other participants who do not meet any of the above criteria or fall into one of these groups after the target goal is met for that group."
61965724|NCT06408025|EXPERIMENTAL|Syrenity App|The Syrenity App is a mental health app that has been designed to help improve mental health and well-being. The content on the app was created using cognitive-behavioral therapy principles. It uses both active and passive interventions. Active interventions are interventions where the user engages with the app in a back and forth dialogue (e.g., a conversation about restructuring unhelpful thoughts). Passive interventions meanwhile consist of text or videos that the user can read or watch and do not require dialogue with the app.
62144734|NCT03543904|EXPERIMENTAL|Post-OP PT without Pre-OP education|Post-operative physiotherapy intervention without pre-operative education in children with abdominal surgery
62144735|NCT00714402||a|children with proven of probable invasive bacterial infections
62144736|NCT01667003||Orsiro DES|
62144737|NCT04266496|OTHER|<2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention~* Complete a 3 day Frequency Volume chart~* Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
62144738|NCT04266496|OTHER|=> 2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention~* Complete a 3 day Frequency Volume chart and collection of the urine of the last day and night to complete osmolality and sodium testing.~* Measuring the circumference off the lower limbs just after awakining and before falling asleep~* Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
62144739|NCT02066155|EXPERIMENTAL|Parish nurse|On-going support provided by parish nurse
62144740|NCT02066155|EXPERIMENTAL|Peer support|On-going support provided by a person with diabetes
62144741|NCT02066155|NO_INTERVENTION|Control group|No on-going support provided
62349999|NCT04238676|PLACEBO_COMPARATOR|Sham injection|
62350000|NCT06035588|ACTIVE_COMPARATOR|Daily whitening|Volunteers should whiten daily with a whitening tray from 15 to 25 and 35 to 45 for 2 hours. This procedure will last 3 weeks.
62350001|NCT06035588|EXPERIMENTAL|Alternate whitening|Volunteers will bleach for 3 weeks with 16% carbamide peroxide, alternating one rest day for each placement day. They will wear a whitening tray from 15 to 25 and from 35 to 45 for 2 hours.
61965725|NCT06408025|NO_INTERVENTION|Waiting list control|Those assigned to the waiting list control condition will complete weekly surveys as those assigned to the intervention group but will not have access to the Syrenity platform until after the the 6-week trial period.
61965726|NCT05732688|EXPERIMENTAL|Pharmacoscopy|Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds
61965727|NCT00788021||Tacrolimus|Recipients of deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
61965728|NCT00788021||Sirolimus|Recipients of deceased or living donor renal transplants maintained on immunosuppressive regimen using sirolimus
61965729|NCT00788021||Healthy controls|Age, race and gender-matched individuals not on immunosuppressive regimens. Whenever possible an transplant recipient's donor may be recruited to serve as healthy control
61965730|NCT04366102|EXPERIMENTAL|Group A|Multisensory stimulation and soft tissue therapy
61965731|NCT04366102|EXPERIMENTAL|Group B|Routine Hospital care
61965732|NCT04758169|EXPERIMENTAL|Enhanced Homestead Food Production|Participant in this arm will receive the Helen Keller's EHFP model which involves homestead food production, nutrition and WASH education and gender transformative sessions (intervention group). Participants will also receive interventions related to parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH and basic life-skill trainings.
61965733|NCT04758169|EXPERIMENTAL|Control|Participants in this arm will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings. This particular arm will not receive any homestead food production intervention over the course of the implementation.
61965734|NCT06361030|EXPERIMENTAL|Experimental Group|After 4-6 cycles of induction therapy with gemcitabine and nab-paclitaxel plus surufatinib, if become operable, the therapy will be continued for another 6 months after surgery; if not operable, the therapy will be also continued as long as no PD during induction therapy. If PD occurs, it will enter second-line therapy.
61965735|NCT02205632|OTHER|High myopic patients with lacker craks|
61965736|NCT02205632|OTHER|High myopic patients without lacker cracks|
61965737|NCT03229850|OTHER|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
61965738|NCT03229850|OTHER|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
61965739|NCT06229340|EXPERIMENTAL|Group 1|Leflunomide
61965740|NCT06229340|EXPERIMENTAL|Group 2|Combination of MEK Inhibitor and Hydroxychloroquine ( Plaquenil)
61965741|NCT06229340|NO_INTERVENTION|historical control group|standard therapy
62144742|NCT06216704||Cystic Fibrosis|"This group will be 36 adolescents, ages 13-20 years old, who have been diagnosed with cystic fibrosis.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
62715011|NCT06340763||JETi Hydrodynamic Thrombectomy System|Subject was treated or is expected to be treated with the JETi Hydrodynamic Thrombectomy System.
61965742|NCT03057431|PLACEBO_COMPARATOR|Placebo|Once daily for 3 years
62144743|NCT06216704||Control|"Controls will be matched for age, Tanner staging, BMI percentile, and ancestry.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
62144744|NCT03067337|EXPERIMENTAL|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
62144745|NCT03067337|EXPERIMENTAL|Zirconia crowns (Group B)|Groups that received Zirconia crowns
62715012|NCT04855370|EXPERIMENTAL|Patients diagnosed with Pulmonary Embolism|Patients requiring intensive care unit (ICU) level care with a confirmed diagnosis of pulmonary embolism (PE) by computed tomography (CT) angiogram or endobronchial ultrasound (EBUS) prior to or within 4 hours of initiation of any PE therapy or intervention.
61965743|NCT03057431|EXPERIMENTAL|12.5 mg hydrochlorothiazide|Once daily for 3 years
61965744|NCT03057431|EXPERIMENTAL|25.0 mg hydrochlorothiazide|Once daily for 3 years
61965745|NCT03057431|EXPERIMENTAL|50.0 mg hydrochlorothiazide|Once daily for 3 years
61965746|NCT04688853|EXPERIMENTAL|Single Arm, Open label|"This is a single arm, open-label, multicenter phase I study with a dose escalation and an expansion segment.~For the Dose escalation segment, 3-9 patients per dose cohort will receive:~* Dose level 1: Low~* Dose level 2: Medium~* Dose level 3: High~For the expansion segment, additional patients may be enrolled until a maximum of 20 patients have received the recommended dose"
61965747|NCT00569478|ACTIVE_COMPARATOR|1|rehabilitation
61965748|NCT00569478|NO_INTERVENTION|2|controls
61965749|NCT05848960|ACTIVE_COMPARATOR|Mediterranean diet|Mediterranean diet
61965750|NCT05848960|EXPERIMENTAL|Mediterranean diet plus hypercaloric, hyperproteic oral supplement|Mediterranean diet plus hypercaloric, hyperproteic oral supplement
61965751|NCT05612789|EXPERIMENTAL|Cohort A (Prehab)|Pre-frail and frail subjects will attend at least twice weekly exercise sessions with a physical therapist and be given an exercise program to complete at home prior to admission for HCT. Patients enrolled in this cohort can continue on to Cohort B.
61965752|NCT05612789|EXPERIMENTAL|Cohort B (Rehab)|All patients 60 years and older upon discharge from their initial hospital stay for HCT will attend at least weekly exercise sessions with a physical therapist and be given an exercise program to complete at home with sessions continued through Day +100 after HCT.
61965753|NCT01761890||CML patients|
61965754|NCT05304273|ACTIVE_COMPARATOR|Mifepristone|"Participants with 1st trimester miscarriage will receive oral 200mg mifepristone .~After 48 hours of mifepristone, 800 micro gm misoprostol will be given vaginally for expulsion of product of conception (standard care)."
61965755|NCT05304273|EXPERIMENTAL|Letrozole|"Participants with 1st trimester miscarriage will receive 10mg letrozole orally for three consecutive days.~This is to be followed by tablet misoprostol 800 micro gm vaginally for expulsion of product of conception (standard care)."
61965756|NCT04669600|EXPERIMENTAL|SAR445088|Participants received SAR445088 (BIVV020).
61965757|NCT02222974|EXPERIMENTAL|BIIR 561 CL|
61965758|NCT02222974|PLACEBO_COMPARATOR|Placebo|
61965759|NCT04617509|EXPERIMENTAL|Part I GS-248 Formulation A|Formulation A given in fasting state.
62144746|NCT06543797|EXPERIMENTAL|Stroke patients|
61965760|NCT04617509|ACTIVE_COMPARATOR|Part I GS-248 Formulation B|Formulation B given in fasting state.
61965761|NCT04617509|OTHER|Part II GS-248 Formulation A or B|Formulation A or B given in fed condition
61965762|NCT06485882|EXPERIMENTAL|Intervention group|Intervention Group Procedure Children in the intervention group, who met the inclusion criteria for the study and agreed to participate, were informed about the training they were to receive. Teachers were also informed about the self-care and social competence scales they were to administer to the children.
61965763|NCT06485882|NO_INTERVENTION|Control group|"The self-care and social competence skills of the children in the control group were assessed at the beginning of the study together with the intervention group. To this end, pretests of the Self-Care Skills Assessment Scale for 3- to 6-Year-Old Children, and the Social Competence and Behavior Evaluation - 30 Scale were filled out by the teachers, while the parents were asked to fill out the Demographic Assessment Form.~Posttest: The children in the control group received no extra self-care or social competence training besides that provided by the teachers for one week as part of the regular curriculum. For the posttest of this group, the Self-Care Skills Assessment Scale for 3- to 6-Year-Old Children was used, as well as the Social Competence and Behavior Evaluation-30 Scale, both of which were filled out by the teachers at the end of the fourth month. No other assessments were carried out in the intervening months."
61965764|NCT02279420|OTHER|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
61965765|NCT04347044|EXPERIMENTAL|Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up plus Pulmonary rehabiltation
61965766|NCT04347044|ACTIVE_COMPARATOR|Non-Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up
61965767|NCT02300532||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg
61965768|NCT01833520|EXPERIMENTAL|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.~Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II."
61965769|NCT01743053|OTHER|Control: Standard Care|The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).
62144747|NCT04459572|OTHER|Sepsis and sepstic shock|The study consists patients and healty-control group. Patients divided into 3 groups based on severity: sepsis, severe sepsis and septic shock
62350002|NCT05511025|EXPERIMENTAL|Cohort 1|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC
62350003|NCT05511025|EXPERIMENTAL|Cohort 2|Participants will receive a single dose of AZD6234 via an SC injection and matching volume of the placebo as a solution via SC injection
62350004|NCT05511025|EXPERIMENTAL|Cohort 3|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
62350005|NCT05511025|EXPERIMENTAL|Cohort 4|Participants will receive single ascending doses of AZD6234 via IV injection and matching volumes of the placebo as a solution via IV injection
62350006|NCT05511025|EXPERIMENTAL|Cohort 5|One dose level for SC administration is planned to be investigated for Japanese participants only
62350007|NCT05511025|EXPERIMENTAL|Cohort 6|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
62350008|NCT05511025|EXPERIMENTAL|Cohort 7|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
62350009|NCT05511025|EXPERIMENTAL|Cohort 8|Participants will receive AZD6234 via SC injection and matching volumes of placebo as a solution via SC injection
62508231|NCT00124462|OTHER|Placebo to Realignment|Non realigning knee brace and flat orthodic- A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
62706156|NCT03094052|EXPERIMENTAL|Treatment (Neratinib)|Patients will receive up to 240mg neratinib to be taken continuously in 21-day cycles once a day for up to 55 weeks on study with no rest between cycles unless related to toxicity. Patients will receive Neratinib and may also be prescribed standard of care maintenance adjuvant trastuzumab (duration of maintenance trastuzumab is at the discretion of the treating physician), for up to 55 weeks. If applicable, after the completion of trastuzumab maintenance therapy (determined by treating physician), neratinib may continue as monotherapy to complete a maximum of 55 weeks.
62706157|NCT03682965|EXPERIMENTAL|Intra-lymphatic allergenic extract|A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
61965770|NCT01743053|EXPERIMENTAL|ReCell|The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).
62144748|NCT05899699|EXPERIMENTAL|DAP/FLU ME|Acne vulgaris patients treated with the optimized topical combination ME contain DAP-FLU.
62144749|NCT05899699|ACTIVE_COMPARATOR|Adapalene .1% gel|Acne vulgaris patients treated with standard therapy of Adapalene.
62144750|NCT04363112|OTHER|study with just one arm|"All of participants are in this arm. Mini Kid II and CBCL score are administered between day 3 and 7. Moreover, salivary test will be remove to evaluate cortisol secretion, 4 time per day during 2 consecutive days.~Psychologic aftercare will be propose if children have psychologic troubles (results of Mini Kid II)"
62144751|NCT01779700|ACTIVE_COMPARATOR|Fingolimod|0.5mg of fingolimod, oral administration, daily, for 8 weeks.
62144752|NCT01779700|PLACEBO_COMPARATOR|placebo|placebo, oral administration, daily, for 8 weeks.
62144753|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
61965771|NCT06231160||Systematic Therapy Combined With Microwave Ablation|Perform microwave ablation for patients with pancreatic cancer, and then conduct chemotherapy according to the guidelines two to three weeks later
61965772|NCT06231160||Systematic Therapy|Using the same chemotherapy method as the experimental group
61965773|NCT01949506|OTHER|Stereotactic Body Radiation Therapy|Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with \> 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for \>5 fraction treatment schedules.
62706158|NCT03682965|PLACEBO_COMPARATOR|Intra-lymphatic placebo|Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
61965774|NCT05699239|EXPERIMENTAL|10 mg bid|Patients receive TS-172 10 mg bid.
61965775|NCT05699239|EXPERIMENTAL|30 mg bid|Patients receive TS-172 30 mg bid.
61965776|NCT05699239|EXPERIMENTAL|60 mg bid|Patients receive TS-172 60 mg bid.
61965777|NCT05699239|EXPERIMENTAL|20 mg tid|Patients receive TS-172 20 mg tid.
62508232|NCT01885351|EXPERIMENTAL|Phase II: MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
62706159|NCT05370092|ACTIVE_COMPARATOR|Control group|"Patients assigned to this group will receive a session of manual therapy and therapeutic exercise. The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).~The therapeutic exercise session participants will perform 2 exercises for 4 weeks 3 days per week. The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase. Each exercise will be performed in 3 series of 15 repetitions, with 1 minute rest between series, the exercise session will follow the TM and will last approximately 15-20 minutes."
62715013|NCT06637462|EXPERIMENTAL|Participants with Rectal Cancer|Participants will be diagnosed with rectal cancer and will be undergoing standard-of-care neoadjuvant therapy.
62715014|NCT05261711|EXPERIMENTAL|AB1|AB1 is the investigational product in this study taken orally, once daily, for 8 weeks. This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.
61965778|NCT05699239|PLACEBO_COMPARATOR|Placebo|Patients receive placebo.
61965779|NCT05813015|EXPERIMENTAL|DS-S group|All patients pathologically confirmed pTNM stage III, will receive 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy till 1 year postoperation.
62350010|NCT05378022|PLACEBO_COMPARATOR|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~* Oral administrative drugs: antipyretic paracetamol (Efferegant®); expectorant Carbocysteine (Carbothiol®); antiviral Oseltamivir phosphate (Tamiflu®); antibiotics e.g. cefotaxim (Goldcefo®), Amoxicillin / clavulanic acid (Augmentin®) based on the results of antibiotic susceptibility test.~* Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
62715015|NCT06176248|ACTIVE_COMPARATOR|Block and arthrodistension|
62715016|NCT06176248|PLACEBO_COMPARATOR|Placebo and arthrodistension|
61965780|NCT04023851||Adolescent patient|"* Participant between the ages of 15-18~* Participants who are taking antiepileptic drug for seizure control"
61965781|NCT04023851||Parents with epilepsy children|"* Participants who have child with epilepsy (ages of 1-15)~* Participants' child who are taking antiepileptic drug for seizure control"
61965782|NCT06072729|EXPERIMENTAL|Magnesuuim Sulphate|"After the initial assessment, the cannula will be removed from the site (if present) the cannulation site will be cleaned with normal saline. A mixture of 100mg magnesium sulfate and glycerin will be applied to a gauze pad (2 × 2). This gauze pad placed on the site of phlebitis induced by peripheral intravenous catheter (PIVC). This will be done three times a day for three consecutive days"
61965783|NCT06072729|EXPERIMENTAL|Cold compression|"After the initial assessment, the cannula will be removed from the site (if present) and the area will be cleaned with normal saline. A gauze pad (2 × 2) soaked in cold water with a temperature below 15 °C will be applied to the phlebitis site for 20 minutes. This will be done three times a day for three consecutive days. The cold water will be stored in the refrigerator in the respective wards one day prior to the dressing. It will be taken from the refrigerator just before the dressing and applied within one minute. After 20 minutes of application, the gauze pad for cold compress will be removed from the phlebitis site. From 1st to 3rd Day daily assessment done through VIP scale, will be conducted in both Group A (magnesium sulphate group) and Group B (cold compression group)"
61965784|NCT03582540|ACTIVE_COMPARATOR|early double-guidewire technique (DGT)|First arm: early double-guidewire technique The early arm attempts biliary cannulation using the DGT immediately once the guidewire is inserted in the pancreatic duct in cases of difficult biliary cannulation.
62144754|NCT01847456|EXPERIMENTAL|insulin nasal spray|160 Units of human insulin as nasal spray
62144755|NCT01847456|PLACEBO_COMPARATOR|Placebo nasal spray|Nasalspray containing placebo solution
62144756|NCT02431741|EXPERIMENTAL|Mepilex Transfer Ag|Non controlled investigation
62350011|NCT05378022|EXPERIMENTAL|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®); expectorant Carbocysteine (Carbothiol®); antiviral Oseltamivir phosphate (Tamiflu®); antibiotics e.g. cefotaxime (Goldcefo®), Amoxicillin / clavulanic acid (Augmentin®) based on the results of antibiotic susceptibility test.~- Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
62508233|NCT01885351|EXPERIMENTAL|Phase II: MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers"
62706160|NCT05370092|EXPERIMENTAL|Intervention group|"Participants in this group will receive 4 sessions (once a week during their respective treatment session) of percutaneous electrolysis guided by MUSCULO-SKELETAL ECOGRAPHY, by a physiotherapist with extensive clinical experience in this therapeutic approach. The technique will be applied using a specifically developed and medically certified device (EPI Advanced Medicine®, Barcelona, Spain. EPI®). The galvanic current will be applied using acupuncture needles. In the present study, a 0.30\*25 mm needle (Agupunt, Barcelona, Spain) will be used, with an intensity of 2 mA for a total of 3-5 seconds and 3-5 impacts on the liquid content (TTP tenosynovitis) and 2 mA for a total of 3 seconds and 2-3 impacts if in the tendon (intrasubstance). The technique shall be applied under ultrasound guidance.~The needle shall be introduced at an angle of 80° in a short-axis cross-section to the skin, with the tip of the needle directed towards the posterior tibial tendon."
62706161|NCT05303883|EXPERIMENTAL|Pediatric constraint induced therapy|Constrained induced therapy for children with hemiplegic cerebral palsy. Three hours of therapy per day, for five days a week, for four weeks.
62706162|NCT03747692|EXPERIMENTAL|study group|patient put in dorsal postion , insertion of a speculum , sterilization of the cervix then intracervical injection of 5 ml mepicaine hydrochloride a local anasthetic as Carbocaine3%54 mg at site 3 and 9 using a 10 cm syringe
62706163|NCT03747692|PLACEBO_COMPARATOR|control group|patient receives one tablet of NSAIDs (diclofenac sodium 50 mg )15 minutes before procedure then 5 ml of normal saline will be injected intracervical using 10 cm syringe then wait for 5 minutes before the procedure
62706164|NCT02515318|EXPERIMENTAL|Physiotherapy program|Patients with COPD are included in this group. They will receive a physiotherapy program during the hospitalization due to acute exacerbation of COPD, additionally to the standard medical treatment
62706165|NCT02515318|ACTIVE_COMPARATOR|Control group|Patients with COPD are included in this group. They will receive the medical standard treatment during the hospitalization due to acute exacerbation of COPD.
61965785|NCT03582540|ACTIVE_COMPARATOR|delayed double-guidewire technique (DGT)|In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
62144757|NCT01519557|EXPERIMENTAL|DAR-100A|DAR-0100A is a dopamine D1 full agonist, the active component of the racemic mixture DAR-0100
62706166|NCT06308224|EXPERIMENTAL|Group A (Modified-Otago Exercises)|"Participants will engage in Modified-Otago exercises for 30 minutes of moderate-intensity exercise at least three times weekly for 12 weeks.~1. Walking for 15 minutes~2. Strengthening exercises for 10 minutes~3. Balance exercises 20 minutes"
62706167|NCT06308224|EXPERIMENTAL|Group B (Tai Chi Exercises)|"Participants of the Tai Chi qigong group will participate in a 30-minute exercise class three times a week for 12 weeks.~1. Warm-up exercises for 10 minutes~2. Tai Chi Exercises for 30 minutes~3. Cool-down exercises for 5 minutes"
62706168|NCT00711373|EXPERIMENTAL|Unilateral and Bilateral Amputees|
61965786|NCT05990114|EXPERIMENTAL|intervention group|The structured caregiver support program is a psychosocial training program developed to improve caregivers' burden of care, psychological well-being and resilience.This training program will be applied to the intervention group.
61965787|NCT05990114|NO_INTERVENTION|control group|No intervention will be applied to the control group.
62144758|NCT01519557|PLACEBO_COMPARATOR|Placebo|Intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
62350012|NCT05161182|EXPERIMENTAL|High fat, low carbohydrate diet|
62706169|NCT06479356|EXPERIMENTAL|Relma-cel|Efficacy, safety and PK of Relma-cel will be evaluated in 1 x 10\^8 CAR+T cells dose level
62706170|NCT01069757|EXPERIMENTAL|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
61965788|NCT05062382|EXPERIMENTAL|Complementary feeding program|Promotion of eggs.
61965789|NCT05062382|NO_INTERVENTION|Comparison|Comparison arm with no program
62144759|NCT05420584|EXPERIMENTAL|experimental arm|
62144760|NCT04163432|EXPERIMENTAL|Arm A: Chemo-Immuno|ArmA receives chemotherapy on D1 and immunotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
62144761|NCT04163432|EXPERIMENTAL|Arm B: Immuno-Chemo|ArmB receives immunotherapy on D1 and chemotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
62144762|NCT02113826|EXPERIMENTAL|Pazopanib|Pazopanib 800mg po qd until disease progression
62144763|NCT01501825|ACTIVE_COMPARATOR|single channel|Single Channel with a coil placed over the left PFC (10 Hz).
61965790|NCT04766398|ACTIVE_COMPARATOR|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
61965791|NCT04766398|PLACEBO_COMPARATOR|Placebo|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
61965792|NCT01846416|EXPERIMENTAL|Atezolizumab (MPDL3280): 1L Participants|Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
61965793|NCT01846416|EXPERIMENTAL|Atezolizumab (MPDL3280): 2L+ Participants|Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
61965794|NCT01846416|EXPERIMENTAL|Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants|Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
62144764|NCT01501825|EXPERIMENTAL|four channels|"Four channels:~1. 10 Hz over the left PFC.~2. 1 Hz over the right PFC.~3. 10 Hz over the left parietal cortex.~4. 1 Hz over the right parietal cortex."
62144765|NCT01240785|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
62144766|NCT01240785|ACTIVE_COMPARATOR|insulin|NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
62144767|NCT02721407|EXPERIMENTAL|Anti-CD22 CAR-T|Administrated with CD22.CAR-T cells on day 0,1,2 in the lympho-depleted patients
62706171|NCT05267496|OTHER|Conventional rehabilitation|Patients will receive conventional pulmonary rehabilitation
62706172|NCT05267496|EXPERIMENTAL|AEROBIKA|Patients will receive conventional pulmonary rehabilitation in addition to an oscillating positive expiratory pressure device
62706173|NCT02902614|EXPERIMENTAL|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from opposite side to the 2nd polar body or from vegetal pole.
62706174|NCT02902614|EXPERIMENTAL|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from and side around the 2nd polar body and not the vegetal pole.
62706175|NCT05638828|EXPERIMENTAL|Cell injection|
61965795|NCT00138203|EXPERIMENTAL|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61965796|NCT05447637||Individuals who meet NCCN Testing Criteria|
61965797|NCT05447637||Individuals who do not meet NCCN Testing Criteria|
61965798|NCT02397278|ACTIVE_COMPARATOR|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
61965799|NCT02397278|NO_INTERVENTION|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
61965800|NCT04658277|ACTIVE_COMPARATOR|Treatment|Patients will be given one tab of Clarithromycin 250mg daily.
62706176|NCT06563635||etanercept|psoriasis patients receiving etanercept therapy
62706177|NCT06563635||infliximab|psoriasis patients receiving infliximab therapy
62706178|NCT06563635||adalimumab|psoriasis patients receiving adalimumab therapy
62706179|NCT03358082|ACTIVE_COMPARATOR|Tacrolimus group|Tacrolimus 0.03% ointment twice daily for 6 months
62706180|NCT03358082|ACTIVE_COMPARATOR|Hydrocortisone group|hydrocortisone acetate 1% ointment twice daily for 6 months
62706181|NCT06489002|EXPERIMENTAL|Intervention Arm|Intervention health centers will receive implementation support when they crossover from Control to Intervention.
61965801|NCT04658277|PLACEBO_COMPARATOR|usual care|Patients will receive usual medical care
61965802|NCT04160897||ETV cohort|CHB patients with entecavir naive treatment
61965803|NCT04160897||TDF cohort|CHB patients with naive tenofovir disopropyl naive treatment
62144768|NCT01556594|EXPERIMENTAL|Nasal Glucagon 1 mg|Nasal glucagon (NG) administered as single dose of 1 milligram (mg).
62144769|NCT01556594|EXPERIMENTAL|Nasal Glucagon 2 mg|NG administered as single dose of 2 mg.
62144770|NCT01556594|ACTIVE_COMPARATOR|SC Glucagon|Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.
62144771|NCT01556594|EXPERIMENTAL|Nasal Glucagon 3 mg|NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).
62144772|NCT00148122|EXPERIMENTAL|Arm 1|Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, \&15)
62144773|NCT05328258|EXPERIMENTAL|Arm A: Triptorelin|"Triptorelin given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.~The dose is ether 11.25 mg triptorelin given for subjects having at least 3 months gonadotoxic treatment, OR 3.75 mg for subjects during one-month of gonadotoxic treatment"
62144774|NCT05328258|PLACEBO_COMPARATOR|Arm B: Placebo|"Placebo, 0.9% sodium chloride, given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.~The dose will be provided both as one injection compensating for 3 months' effect and one injection compensating for 1 month' effect to maintain the study blind."
62706182|NCT06489002|NO_INTERVENTION|Control Arm|Control health centers will not receive an intervention prior to crossover to Intervention.
62706183|NCT03594708|PLACEBO_COMPARATOR|Placebo|placebo consisting of rice starch, light olive oil, and vegetable oil
62706184|NCT03594708|ACTIVE_COMPARATOR|Supplement|active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc
62706185|NCT02892370|EXPERIMENTAL|SHR0302 fasted to fed|SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast
62706186|NCT02892370|EXPERIMENTAL|SHR0302 fed to fasted|SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting
62706187|NCT02996929|EXPERIMENTAL|Study group|Subjects who are scheduled for CIED lead extraction with the LC system
62350013|NCT05161182|EXPERIMENTAL|Low fat, high carbohydrate diet|
62706188|NCT01342055|EXPERIMENTAL|Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg|
62706189|NCT01342055|EXPERIMENTAL|Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg|
62706190|NCT01342055|EXPERIMENTAL|Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg|
62706191|NCT01342055|EXPERIMENTAL|Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg|
62350014|NCT00836277|EXPERIMENTAL|Irinotecan plus panitumumab|"Irinotecan 100 mg/m2 IV Day 1 and Day 8~+ Panitumumab 9mg/kg IV Day 1 Cycle = 21 days"
62350015|NCT00870818|EXPERIMENTAL|Double-blind Herold Regimen|Patients who had been assigned to Herold Regimen in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
62350016|NCT00870818|EXPERIMENTAL|Double-blind 33.3% Herold Regimen|Patients who had been assigned to 33.3% Herold Regimen in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
62350017|NCT00870818|EXPERIMENTAL|Double-blind Curtailed Herold Regimen|Patients who had been assigned to Curtailed Herold Regimen in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
62350018|NCT00870818|PLACEBO_COMPARATOR|Double-blind Placebo|Patients who had been assigned to Placebo in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
62350019|NCT00870818|EXPERIMENTAL|Open-label Herold Regimen|Patients who had been assigned to Herold Regimen in Segment 1 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
62350020|NCT03844503|PLACEBO_COMPARATOR|Cereal Bar no fiber|Cereal bar without fiber
62350021|NCT03844503|ACTIVE_COMPARATOR|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
62350022|NCT03844503|ACTIVE_COMPARATOR|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
62706192|NCT01342055|EXPERIMENTAL|Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg|
62706193|NCT01342055|EXPERIMENTAL|Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg|
62706194|NCT05207384|ACTIVE_COMPARATOR|Ozone (O2-O3) group|Ultrasound (US)-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
62706195|NCT05207384|OTHER|Corticosteroid group|US-guided injection will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
62706196|NCT05687344|EXPERIMENTAL|Intervention arm|Intervention group - intensive postpartum BP control with Nifedipine initiation at SBP≥140 mmHg or DBP≥90 mmHg and maintaining BP at \<140/90 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.
62706197|NCT05687344|ACTIVE_COMPARATOR|Active control arm|Active control group - a group of usual care that follows ACOG recommendations with Nifedipine initiation at SBP≥150 mmHg or DBP≥100 mm Hg and maintaining BP at \<150/100 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.
62706198|NCT02816814|ACTIVE_COMPARATOR|Love Diet|Overweight females (BMI \> 25) in menopause
62706199|NCT02816814|EXPERIMENTAL|LωVE diet|Overweight females (BMI \> 25) in menopause
62706200|NCT05526729||Beovu|Patients prescribed with Beovu for diabetic macular edema
62706201|NCT03058952|EXPERIMENTAL|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
62350023|NCT02440295||Lower Extremity Amputations|"All patients \>= 18 years of age requiring Below Knee Amputation (BKA) or Above Knee Amputation (AKA) cared for by the Spectrum Health vascular surgery service will be assessed for eligibility.~Subjects with a history of allergies to iodides or iodinated contrast agents, pregnant or nursing women, subjects who are unable to provide consent, and prisoners will be excluded. Eighteen subjects will be enrolled in the pilot study. No special population subjects will be enrolled."
62350024|NCT04485117|ACTIVE_COMPARATOR|Sevoflurane Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane anesthesia under BIS monitoring.
62144775|NCT01402518||Per-oral endoscopic myotomy|
62350025|NCT04485117|ACTIVE_COMPARATOR|Propofol Group|Laryngeal mask airway is inserted and anesthesia is maintained with propofol infusion under BIS monitoring.
62350026|NCT03807232||pbARDS|Burn patients who developed post-burn ARDS
62350027|NCT03807232||No pbARDS|Burn patients without development of post-burn ARDS
62350028|NCT03170557|ACTIVE_COMPARATOR|Traditional chinese acupuncture|Traditional chinese acupuncture. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
62706202|NCT03058952|ACTIVE_COMPARATOR|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
62706203|NCT03817580|EXPERIMENTAL|Project X 26ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 26ml volume. Single use.
61965804|NCT03926169|EXPERIMENTAL|Risankizumab 180 mg|In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
61965805|NCT03926169|EXPERIMENTAL|Risankizumab 360 mg|In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
61965806|NCT03926169|PLACEBO_COMPARATOR|Placebo|In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
61965807|NCT03926169|EXPERIMENTAL|Risankizumab 180 mg / Risankizumab 360 mg|"In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg every 8 weeks (q8w) at Weeks 20, 28, 36, 44, 52, and 60."
61965808|NCT03926169|EXPERIMENTAL|Risankizumab 360 mg / Risankizumab 360 mg|"In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60."
61965809|NCT03926169|PLACEBO_COMPARATOR|Placebo / Risankizumab 360 mg|"In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded risankizumab 360 mg at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60."
61965810|NCT03269864|ACTIVE_COMPARATOR|pedicled perforator flaps|"Once the perforator is identified, the flap will be designed around the perforator or perforators according to the location and size of the defect.~A tourniquet is inflated without prior exsanguination. This maneuver facilitates identification of perforators as they remain filled with the blood.~An exploratory incision along the margin of flap is made keeping the position of marked perforator in mind. The incision is made through the skin, subcutaneous tissue, deep fascia (sub-fascial approach) and the perforator vessel is directly visualized. The incision is initially always made from one side of the flap only to properly identify the perforator.~Careful and meticulous dissection is done in a blunt way isolating the perforator.~After deflation of the tourniquet, hemostasis is performed."
61965811|NCT03269864|ACTIVE_COMPARATOR|free perforator flaps|"A two-team approach is used for microvascular free tissue transfer. The first team starts exploring the limb for the recipient vessel. The second team simultaneously begins elevating the perforator flap and its vascular pedicle.~Microvascular anastomosis will be carried out under operating microscope for one artery and one or two accompanying veins."
61965812|NCT02323113|EXPERIMENTAL|Phase 1b: TAK-659|TAK-659 tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage of TAK-659 may increase in 20 mg increments using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
61965813|NCT02323113|EXPERIMENTAL|Phase 2: TAK-659|TAK-659, tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage for this phase will be determined from results of Phase 1b MTD/RP2D.
61965814|NCT05753423||Egyptian mothers-children pairs|Egyptian mothers-children pairs attending the Faculty of Dentistry, Ain Shams University will be recruited.
61965815|NCT02254252|ACTIVE_COMPARATOR|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
61965816|NCT02254252|ACTIVE_COMPARATOR|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
61965817|NCT01140243|EXPERIMENTAL|test product|Dietary supplement
61965818|NCT01140243|ACTIVE_COMPARATOR|standart|Dietary supplement
61965819|NCT05109689|EXPERIMENTAL|ACT-P|ACT-P is a cognitive behavioral program based on acceptance and commitment therapy, and it has been modified for use in the prison setting.
61965820|NCT05109689|ACTIVE_COMPARATOR|T4C|Thinking for Change (T4C) is an evidence-based cognitive behavioral program focused on changing criminal thinking.
61965821|NCT04083053|EXPERIMENTAL|Perianal Exam First|Perianal exam that is a part of anal cancer screening will be performed prior to the intraanal portion of the exam (high-resolution anoscopy with biopsy).
61965822|NCT04083053|EXPERIMENTAL|Perianal Exam Last|Perianal exam that is a part of anal cancer screening will be performed after the intraanal portion of the exam (high-resolution anoscopy with biopsy).
61965823|NCT05745584|EXPERIMENTAL|Experimental|8 weeks of mirabegron treatment==\> 8 weeks of anticholinergics treatment
61965824|NCT03647033|NO_INTERVENTION|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
61965825|NCT03647033|EXPERIMENTAL|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
61965826|NCT05975944|EXPERIMENTAL|dose-escalation part of phase Ib clinical trial|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
61965827|NCT06304194|OTHER|Patients with suspected diagnostic onco-hematologic/immunologic disease|"All patients with suspected diagnostic onco-hematologic, onco-immunologic, and hematologic disease at onset or relapse.~Patients undergo several procedures to complete the diagnostic process and eventually the staging of the disease"
61965828|NCT02301052|PLACEBO_COMPARATOR|placebo|placebo topical cream 2 cc twice daily for 3 weeks
62350029|NCT03170557|SHAM_COMPARATOR|Aspecific needle skin stimulation|Aspecific needle skin stimulation. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
62706204|NCT03817580|EXPERIMENTAL|Project X 5.1ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 5.1ml volume. Single use.
62706205|NCT03817580|ACTIVE_COMPARATOR|Prevantics Maxi Swabstick|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. 5.1ml volume. Single use.
62715017|NCT05024474|EXPERIMENTAL|Intervention: inspiratory muscle training + physical exercise|Inspiratory muscle training (IMT) twice a day for 8 weeks combined with a physical exercise program at least two times a week for 8 weeks.
62715018|NCT05024474|ACTIVE_COMPARATOR|Active control: physical exercise|A physical exercise program at least two times a week for 8 weeks.
62706206|NCT05242939|EXPERIMENTAL|The Group of Cartoons|The cartoons that are suitable for the child's age and gender will be watched. The child will be asked which cartoon he would like to watch. The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher. Due to the COVID-19 pandemic, cartoons will be watched on the parent's phone. Parents who do not have an internet connection will also be provided with internet access by the researcher. The child will watch cartoons on their parent's phone.
62706207|NCT05242939|EXPERIMENTAL|The Group of Game|723 / 5.000 Çeviri sonuçları The group whose video games will be played will be told to choose the game they want before the process. Due to the COVID-19 pandemic, video games will be played on the parent's phone. Parents who do not have an internet connection will also be provided with internet access by the researcher. The child will play the video game on their parent's phone.
62706208|NCT05242939|NO_INTERVENTION|Rutin Care Group|In the control group, the institution's routine nebula application will be performed and no intervention will be made. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
61965829|NCT02301052|ACTIVE_COMPARATOR|Anti-hemorrhoid topical cream drug|Anti hemorrhoid topical cream as a standard drug 2 cc twice daily for 3 week
61965830|NCT02301052|ACTIVE_COMPARATOR|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
62706209|NCT00648414|EXPERIMENTAL|1|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
61965831|NCT02301494|EXPERIMENTAL|Fluocinonide (Vanos) cream 0.1%|Fluocinonide (Vanos) cream 0.1% will be applied as currently approved by the FDA for treatment of corticosteroid responsive disorders of the skin. Treatment will continue for 4 months with a follow up at 6 and 12 months.
62508234|NCT01885351|NO_INTERVENTION|Phase II: Usual Care|The IPHR will be programmed so that where the IPHR-CRCS would normally present patients, who based on their demographics and health conditions, with content advising them to seek CRCS and links to third-party sites, they would instead be randomized to receive the usual care (IPHR-CRCS).
62508235|NCT03527004||General Population|Survey on use of tobacco products in the general population of adults living in Italy.
62706210|NCT00648414|EXPERIMENTAL|2|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
62706211|NCT00648414|EXPERIMENTAL|3|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
62706212|NCT00648414|EXPERIMENTAL|4|Duragesic 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
62706213|NCT00648414|EXPERIMENTAL|5|Duragesic 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
62706214|NCT00648414|EXPERIMENTAL|6|Duragesic 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
61965832|NCT02301494|EXPERIMENTAL|3.75% Imiquimod (Zyclara) Cream|3.75% Imiquimod (Zyclara) Cream will be used as currently labeled by the FDA for treatment of actinic keratoses. Treatment will continue for 4 months with follow up at 6 and 12 months.
61965833|NCT00871702|EXPERIMENTAL|Donor lymphocyte infusion|CD34-TK75 transduced T lymphocytes from donors matched at a 5/6 or 6/6 antigen level at a dose of 1.0 x 105 cells/kg recipient weight.
62144776|NCT04056754|EXPERIMENTAL|Abiraterone acetate group|Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
62706215|NCT06454656|EXPERIMENTAL|Intervention|"Participants will undergo 30 hours of therapy over 6 weeks in format of their choosing.~A minimum of 24 hours must be completed in clinic with the rest made up of home program."
62706216|NCT05452473|EXPERIMENTAL|CDSS-assisted screening endoscopy|Participants will be tested for CDSS-assisted screening upper gastrointestinal endoscopy
62706217|NCT05452473|PLACEBO_COMPARATOR|Conventional routine screening endoscopy|Participants will be tested for Conventional routine screening upper gastrointestinal endoscopy
62706218|NCT01204957|EXPERIMENTAL|Arm 1 Seaweed and Soy Protein|Arm 1 5 g/d Seaweed for 6 wk, then 5 g/d Seaweed and Soy Protein for 1 wk
62706219|NCT01204957|EXPERIMENTAL|Arm 2 Placebo and soy protein|Arm 2 5 g/d Placebo for 6 wk, then 5 g/d Placebo and Soy Protein for 1 wk
62706220|NCT01972659|ACTIVE_COMPARATOR|sugammadex and placebo|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
62706221|NCT01972659|EXPERIMENTAL|sugammadex and magnesium sulphate|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
62706222|NCT00629603|EXPERIMENTAL|cytokine polymorphisms, HCV infection|Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease
61965834|NCT01104506|ACTIVE_COMPARATOR|Painless plexus|Patient with a painless avulsion of brachial plexus
61965835|NCT01104506|ACTIVE_COMPARATOR|Healthy|Healthy volunteers
61965836|NCT01104506|EXPERIMENTAL|Painful plexus|Patient with a painful avulsion of brachial plexus
62144777|NCT04056754|PLACEBO_COMPARATOR|Placebo group|Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
62144778|NCT05957770||cases|rheumatoid arthritis patients
62144779|NCT05957770||control|healthy subjects
62144780|NCT05377476|EXPERIMENTAL|Motor Imagery Group|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation. Patients will be trained 3 days a week for 6 weeks.
62508236|NCT03527004||IQOS Users|Survey on use of tobacco products in adult current IQOS Users (at the time of survey) living in Italy who are registered in the Italy IQOS User Database and agreed to be contacted for research purposes at the time of registration.
62706223|NCT00238394|EXPERIMENTAL|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing disease progression within 5 years after completion of study treatment may receive additional courses of study treatment.
61965837|NCT00299975|EXPERIMENTAL|MaZiRenWan (MZRW) Low dose|MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
61965838|NCT00299975|EXPERIMENTAL|MaZiRenWan (MZRW) Median dose|MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
61965839|NCT00299975|EXPERIMENTAL|MaZiRenWan (MZRW) High dose|MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
61965840|NCT01929798|EXPERIMENTAL|Optimized basal/bolus with artificial pancreas|Portable artificial pancreas with optimization
61965841|NCT01929798|NO_INTERVENTION|Nominal basal/bolus treatment|Portable artificial pancreas without optimization.
61965842|NCT04079101|EXPERIMENTAL|BIIB104 0.15 mg|Participants will receive multiple oral doses of BIIB104 0.15 mg capsules twice daily (BID) for 9 days, with an additional dose occurring in the morning on Day 10.
61965843|NCT04079101|EXPERIMENTAL|BIIB104 0.5 mg|Participants will receive multiple oral doses of BIIB104 0.5 mg capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
61965844|NCT04079101|EXPERIMENTAL|Placebo|Participants will receive multiple oral doses of placebo-matched BIIB104 capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
61965845|NCT03098550|EXPERIMENTAL|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
61965846|NCT03098550|EXPERIMENTAL|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
61965847|NCT01673867|EXPERIMENTAL|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
61965848|NCT01673867|ACTIVE_COMPARATOR|Arm B: Docetaxel|Docetaxel 75 mg/m\^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
61965849|NCT00577681||1|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who have no history of CVD
61965850|NCT00577681||2|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who experienced a major CVD event during the study, analyzed along with 2 matched controls
61965851|NCT00577681||3|Participants from the SMART study who have no previous use of ART or have taken ART but not done so within 6 months prior to study entry; allows for a comparison of immediate ART versus deferred ART
62508237|NCT05637476|ACTIVE_COMPARATOR|Group A (Active control group)|Group A (number=20): which is the control group with medial tibial stress syndrome, they will receive a selected physical therapy exercise program.
62706224|NCT05006495|EXPERIMENTAL|C3 laminectomy with C4-6 laminoplasty|Cervical myelopathy patients who underwent C3 laminectomy with laminoplasty.
61965852|NCT01053416|NO_INTERVENTION|observation|
62144781|NCT05377476|EXPERIMENTAL|Action Observation Group|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation. Patients will be trained 3 days a week for 6 weeks.
62144782|NCT05377476|OTHER|Control Group|Individuals included in this group will receive only 40 minutes of standard rehabilitation. Patients will be trained 3 days a week for 6 weeks.
62706225|NCT05006495|ACTIVE_COMPARATOR|C3-6 laminoplasty|Cervical myelopathy patients who underwent C3-6 laminoplasty.
62706226|NCT01777867||Healthy Volunteers|Subjects in this arm were healthy volunteers. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
62706227|NCT01777867||Non-erosive reflux disease with reflux|Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
62715019|NCT05622578|OTHER|scleroderma with pain|systemic sclerosis (SSc) with chronic pain
61965853|NCT01053416|EXPERIMENTAL|Yag laser iridotomy|the enrolled eyes will undergo an iridotomy performed by using a Yag-laser
61965854|NCT04779840||period 2011|
61965855|NCT04779840||period 2018|
62715020|NCT05622578|OTHER|scleroderma without pain|systemic sclerosis patients without chronic pain
61965856|NCT02052674|EXPERIMENTAL|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
61965857|NCT02052674|ACTIVE_COMPARATOR|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
61965858|NCT05083962|ACTIVE_COMPARATOR|Healthy Lifestyle Program Intervention Arm|
61965859|NCT05083962|NO_INTERVENTION|Waitlist Control Group|
61965860|NCT05228288|ACTIVE_COMPARATOR|CDL|Conventional direct laryngoscopy using a Macintosh blade
61965861|NCT05228288|EXPERIMENTAL|M-VAL|Video assisted laryngoscopy with a Macintosh-shaped blade
61965862|NCT05228288|EXPERIMENTAL|H-VAL|Video assisted laryngoscopy with a hyper-angulated blade
62508238|NCT05637476|EXPERIMENTAL|Group B (Experimental group)|Group B (number=20): which is the experimental group with Medial tibial stress syndrome, they will receive the same physical therapy exercise program as group A in addition to, functional strength training of hip abductors.
62144783|NCT05235685|ACTIVE_COMPARATOR|Patients with COPD|Patients with COPD will only exercise under medical air (for between-group comparison: COPD vs COPD-HF)
62508239|NCT03655275|ACTIVE_COMPARATOR|Group(A): PRP|PRP prolotherapy injections with 2.5ml of PRP at an interval of 2 weeks. Intraticular and pericapsular
61965863|NCT02704715|OTHER|general anesthesia,orbital operation|"1. diagnosed as orbital disease and ocular tumor~2. over 16 years old~3. orbital operation under general anesthesia"
61965864|NCT03729089|EXPERIMENTAL|Modified Biophysical Profile scan|Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea.
61965865|NCT03729089|NO_INTERVENTION|Current standard of care|The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy.
61965866|NCT06502535|EXPERIMENTAL|Inulin (15 g)|Participants will receive 15 g inulin in powder form once daily for 4 weeks.
61965867|NCT06502535|EXPERIMENTAL|Inulin (15 g) and potassium nitrate (1300 mg)|Participants will receive 15 g inulin in powder form once daily for 4 weeks and 1300 mg potassium nitrate in powder form once daily for 4 weeks.
61965868|NCT04244721|SHAM_COMPARATOR|a group of children receiving the usual therapy (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
61965869|NCT04244721|EXPERIMENTAL|a group of children receiving TAU plus the PACT intervention.|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
61965870|NCT06049940|EXPERIMENTAL|Experimental Group|630 Participants (including 30 subjects in phaseⅠ, 600 subjects in phase Ⅲ ) will receive one dose of experimental vaccine or control vaccine.
61965871|NCT06049940|ACTIVE_COMPARATOR|Control Group|630 Participants (including 30 subjects in phaseⅠ, 600 subjects in phase Ⅲ ) will receive one dose of experimental vaccine or control vaccine.
62144784|NCT05235685|EXPERIMENTAL|Patients with COPD-HF overlap|Patients with COPD-HF overlap will first exercise under medical air (for between-group comparison: COPD vs COPD-HF); Patients with COPD-HF overlap will then exercise under intervention (hyperoxia, for within-group comparison: medical air vs intervention trial)
62144785|NCT02011360|OTHER|Low carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein. This will be administered over 72 hour hospital stay.
62508240|NCT03655275|ACTIVE_COMPARATOR|Group (B): saline|Saline prolotherapy injections with 2.5ml of saline at an interval of 2 weeks.intrarticular and pericapsular
62508241|NCT04638270|EXPERIMENTAL|anti-CD19 FasT CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.~3×10\^5 /KG 6×10\^5 /KG 1×10\^6/KG"
62706228|NCT01777867||Non-erosive reflux disease without reflux|Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn). Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
61965872|NCT01837615|EXPERIMENTAL|Photopill treatment|
61965873|NCT01874054|EXPERIMENTAL|Brentuximab Vedotin + Bendamustine|Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
62144786|NCT02011360|OTHER|Low Fat diet|Low fat diet: 65%carb; 15%fat; 20% protein. This will be administered over a 72 hour hospital stay.
61965874|NCT03667261|ACTIVE_COMPARATOR|cover screw|extraction of hopeless mandibular molars followed by immediate implants that will be covered using cover screw
61965875|NCT03667261|EXPERIMENTAL|sealing socket abutment|extraction of hopeless mandibular molars followed by immediate implants that will be covered using sealing socket abutment
61965876|NCT05806788|EXPERIMENTAL|BESTOW behavioral intervention|The intervention will utilize behavioral-based strategies to reduce BE and improve health behaviors, with content including strategies to improve body image, regulation of eating behaviors, and integration of physical activity with an emphasis on body function, health, and longevity.
61965877|NCT06433869|EXPERIMENTAL|Group A|Treat the malignant ascites by local intraperitoneal injection of PD-1 inhibitor and bevacizumab
61965878|NCT06433869|EXPERIMENTAL|Group B|Treat the malignant ascites by local intraperitoneal injection of PD-1 inhibitor and rmhTNF-NC
62144787|NCT01696500|EXPERIMENTAL|NPB-01|
62508242|NCT03443791|EXPERIMENTAL|women enrolled|pregnant women enrolled in trial
62508243|NCT03443791|OTHER|newborns of female study participants|newborns will be tested to determine if virus is present.
62508244|NCT02537509|ACTIVE_COMPARATOR|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
62508245|NCT02537509|PLACEBO_COMPARATOR|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
62508246|NCT01143649|EXPERIMENTAL|active tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday).
62706229|NCT04669067|EXPERIMENTAL|Phase 1b - Dose Level 1|KRT-232 240mg QD, orally administered on days 1 through 7 of each 28-day cycle in combination with TL-895 150mg BID continuously for each 28-day cycle.
61965879|NCT06433869|EXPERIMENTAL|Group C|Treat the malignant ascites by local intraperitoneal injection of PD-1 inhibitor, rmhTNF-NC and bevacizumab
62144788|NCT03774849|EXPERIMENTAL|Picoway™ 532nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 532nm fractional handpiece
62144789|NCT03774849|EXPERIMENTAL|PicoWay™ 730nm wavelength|PicoWay™ 730nm wavelength. Subjects will receive up to four study treatments with the PicoWay™ 730nm wavelength.
62144790|NCT03774849|EXPERIMENTAL|PicoWay ™1064nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 1064nm fractional handpiece
62350030|NCT02802878|EXPERIMENTAL|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
62508247|NCT01143649|EXPERIMENTAL|active tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT)
62508248|NCT01143649|EXPERIMENTAL|tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one session of treatment with active tACS (in which the order in which they receive either sham or active transcranial alternating current stimulation (tACS) stimulation will be randomized).
62508249|NCT01143649|SHAM_COMPARATOR|sham tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday). For the sham session, tDCS is turned off after 30seconds.
62508250|NCT01143649|SHAM_COMPARATOR|sham tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT). The sham stimulation consists of 30 seconds of stimulation at the beginning of the 40 min of treatment.
62706230|NCT04669067|EXPERIMENTAL|Phase 1b - Dose Level 2|KRT-232 300mg QD, orally administered on days 1 through 7 of each 28-day cycle in combination with TL-895 150mg BID continuously for each 28-day cycle.
62706231|NCT04669067|EXPERIMENTAL|Phase 1b - Dose Level 3|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 150 mg BID continuously for the first 28-day cycle~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 150 mg BID continuously for each 28-day cycle."
62350031|NCT02802878|ACTIVE_COMPARATOR|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
62350032|NCT05297656|EXPERIMENTAL|Experimental Group|"A total of 8 sessions of graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~All patients will also receive home exercise therapy including stretching of the trapezius muscle and posture exercises"
62350033|NCT05297656|SHAM_COMPARATOR|Sham Comparator Group|"A total of 8 sessions of sham graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~Sham graston massage is not a deep tissue massage, but will be performed with the device superficially, without applying pressure and mobilization.~All patients will also receive home exercises."
62350034|NCT05297656|OTHER|Control group|The volunteers in the control group will be only given home exercise therapy including stretching of the trapezius muscle and posture exercises
62350035|NCT00305747|EXPERIMENTAL|BR-DIM|BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.
62350036|NCT02531464|EXPERIMENTAL|Experimental: supportive care|Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
62508251|NCT01143649|SHAM_COMPARATOR|sham tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one day of treatment with sham tACS. All participants received active and sham stimulation in a randomized order.
62508252|NCT05105659||B thalassemia Major patients|
62508253|NCT05105659||B thalassemia Intermedia patients|
62508254|NCT05105659||Healthy Controls|
62706232|NCT04669067|EXPERIMENTAL|Phase 1b - Dose Level 4|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 300 mg BID continuously for the first 28-day cycle.~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 300 mg BID continuously for each 28-day cycle."
62706233|NCT04669067|EXPERIMENTAL|Phase 1b - Dose Level 5|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 450 mg BID continuously for the first 28-day cycle.~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 450 mg BID continuously for each 28-day cycle."
62706234|NCT04669067|EXPERIMENTAL|Phase 2 - Dose Expansion|Dose expansion of the recommended phase 2 dose of TL-895 in combination with KRT-232 as determined in Phase 1b.
62508255|NCT00782561|EXPERIMENTAL|FG-3019|FG-3019 5 mg/kg
62508256|NCT05996406|EXPERIMENTAL|Ven-D|Venetoclax combined with dexamethasone
62706235|NCT03895372|EXPERIMENTAL|PF-06826647 Drug Dose Level 1|Delivered orally for 16 weeks during the Investigational Treatment Period
62706236|NCT03895372|EXPERIMENTAL|PF-06826647 Placebo|Delivered orally for 16 weeks during the Investigational Treatment Period
62706237|NCT03895372|EXPERIMENTAL|PF-06826647 Drug Dose Level 2|Delivered orally for 16 weeks during the Investigational Treatment Period
62508257|NCT04944472||group I|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group I, project participants will only be presented with video publications on each of the declared topics (8 in total)."
62508258|NCT04944472||group II|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group II - only text publications (total 8)."
62706238|NCT03895372|EXPERIMENTAL|PF-06826647 Drug Dose Level 3|Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
62706239|NCT03895372|EXPERIMENTAL|PF-06826647 Drug Dose Level 4|Delivered orally for 16 weeks then for 24 weeks in Extension Period.
61965880|NCT05085652||hypotensive COVID19 patients|Neuraxial anesthesia-related hypotension was based on a single episode of deﬁned hypotension from the time of local anesthetic injection until 15 min after delivery of the newborn. And hypotension was deﬁned as systolic blood pressure \<80% of baseline or \<90 mmHg and was treated with an intravenous bolus of ephedrine 5 mg, additional bolus of Ringer Lactates and colloid infusion hydroxyethyl starch solution.
61965881|NCT05085652||non-hypotensive COVID19 patients|from the time of local anesthetic injection until 15 min after delivery of the newborn no hypotension was seen. systolic blood pressure \> 80% of baseline or \>90 mmHg. no medical treatment needed.
62144791|NCT01640340|EXPERIMENTAL|Arm I (palonosetron hydrochloride)|Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.
62350037|NCT02531464|NO_INTERVENTION|Control: usual care|In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) . The PNO screens patients for distress and assesses their needs. She does a bio-psycho-social comprehensive evaluation and may provide help and information. She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory. However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them. If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
62350038|NCT06333392|ACTIVE_COMPARATOR|Conventional colonoscopy (CO2) group|this groups receives conventional colonoscopy with CO2 withdrawal
62350039|NCT06333392|EXPERIMENTAL|Total underwater colonoscopy (TUC) group|This group receives total underwater colonoscopy
62350040|NCT04256304|EXPERIMENTAL|Intervention group|"Personalized Health Engagement Plan group~1. First face-to-face session (Motivational interviewing) + Pre-tests~   * Patient Health Engagement Scale~  * Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~  * The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus~2. Phone call coaching~3. A set of personalized home-based exercises~4. Second face-to-face session (Motivational interviewing) + Post-tests"
62350041|NCT04256304|NO_INTERVENTION|Control group|"1. First meeting (Pre-tests)~   * Patient Health Engagement Scale~  * Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~  * The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus~2. Second meeting (Post-tests)~   * Patient Health Engagement Scale~  * Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~  * The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus"
62350042|NCT00980421|EXPERIMENTAL|IT|Iron Tablet group (12.5 mg/d) + Placebo Biscuit
62350043|NCT00980421|EXPERIMENTAL|IZ|Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
62350044|NCT00980421|EXPERIMENTAL|IB|Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
62350045|NCT00980421|PLACEBO_COMPARATOR|CO|Placebo Tablet + Placebo Biscuit
62350046|NCT05838209|PLACEBO_COMPARATOR|Control|Scaling and root planing + saline solution gel (control) will be adminster at probing depth \> 5mm.
62350047|NCT05838209|ACTIVE_COMPARATOR|Test|Scaling and root planing + Ozone Oil will be adminster at probing depth \> 5mm.
62350048|NCT00823524|EXPERIMENTAL|donor NK cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
62350049|NCT05596786|EXPERIMENTAL|Rituximab|
62508259|NCT04944472||group III|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group III - first text publications, and then video publications (16 in total)."
62508260|NCT04944472||group IV|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group IV - first video publications, and then text publications (16 in total)."
62508261|NCT06473402|EXPERIMENTAL|Muscle Energy Technique|Patients received anterior and posterior innominate muscle energy techniques. The anterior technique had the patient lying on their back with their leg on the diagonal shoulder. The clinician flexed the knee and hip, placed their hand on the back thigh, and instructed the patient to push, resulting in hip extension. After eight seconds, the patient inhaled and exhaled. The clinician then increased hip flexion and pushed against a new barrier. The posterior technique was performed with the patient lying on their side in the modified sims position. The clinician held the leg with their caudal hand and placed the hypothenar edge of their cranial hand on the right SIPS. They then extended the leg in their caudal hand and had the patient pull it towards themselves, applying equal counterforce. After eight seconds, the patient inhaled and exhaled. The clinician then extended the leg and pushed it towards a new barrier.
62350050|NCT05596786|PLACEBO_COMPARATOR|Placebo|
62350051|NCT01707368||all eligible patients|Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
62706240|NCT04958057|NO_INTERVENTION|Routine prenatal care|Routine prenatal care: All women participating in the study will receive routine prenatal care by their obstetric provider, consisting of 1 prenatal visit a month up to 28 weeks of gestation, 1 prenatal visit every 2 weeks during 28-36 weeks and weekly visits during 36-40 weeks.
62706241|NCT04958057|EXPERIMENTAL|SAIL intervention|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
62706242|NCT03369158|EXPERIMENTAL|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
62508262|NCT06473402|EXPERIMENTAL|Massage Gun|A percussion massage device was used in the study. Massage application was applied to the Hamstring muscle, adhering to optimal standards. During the application, a wide round head, which is the most preferred by clinical professionals, was used and 30 Hz, which is considered as the average application speed, was used. The application was applied for a total of 6 minutes, 2 minutes for each part of the muscle. Applications have been made many times on every part of the muscle, from the starting point to the ending point.
62508263|NCT01396382|EXPERIMENTAL|68Ga-DOTATATE PET|Patients will receive a 68Ga-DOTATATE PET scans
61965882|NCT05173402||The experimental group|The experimental group included 26 patients - orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw.
61965883|NCT05173402||The comparison group|The comparison group included 20 patients - orthopedic treatment was performed using a face mask.
61965884|NCT02353104|EXPERIMENTAL|Onion-Pumpkin Extract|Take two capsules, twice daily before breakfast and dinner
61965885|NCT03903848|EXPERIMENTAL|Exercise session|One session of physical exercise
61965886|NCT05127473|EXPERIMENTAL|Dose level 1|All participants will receive a single dose of Mim8
61965887|NCT05127473|EXPERIMENTAL|Dose level 2|All participants will receive a single dose of Mim8
61965888|NCT05127473|EXPERIMENTAL|Dose level 3|All participants will receive a single dose of Mim8
62350052|NCT03129204|EXPERIMENTAL|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
61965889|NCT05127473|EXPERIMENTAL|Dose level 4|All participants will receive a single dose of Mim8
62350053|NCT03129204|NO_INTERVENTION|Control Group|The control group will not receive the SAF-T intervention.
62350054|NCT02067416|ACTIVE_COMPARATOR|taxane-based chemotherapy|physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
62350055|NCT02067416|ACTIVE_COMPARATOR|anthacycline based chemotherapy|Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
62350056|NCT00405652|EXPERIMENTAL|Enteric-coated Mycophenolate sodium|Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
62350057|NCT01943318||Alcohol|"Alcoholic Liver Cirrhosis~Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement."
62350058|NCT01943318||Hepatitis B virus|Hepatitis B virus (HBV) Liver Cirrhosis
62350059|NCT01943318||Hepatitis C virus|Hepatitis C virus (HCV) Liver Cirrhosis
61965890|NCT05127473|EXPERIMENTAL|Dose level 5|All participants will receive a single dose of Mim8
61965891|NCT05127473|EXPERIMENTAL|Dose level 6|All participants will receive a single dose of Mim8
61965892|NCT05127473|EXPERIMENTAL|Dose level 7|All participants will receive a single dose of Mim8
62350060|NCT01943318||Autoimmune|Autoimmune Cirrhosis
61965893|NCT05127473|EXPERIMENTAL|Dose level 8|All participants will receive a single dose of Mim8
61965894|NCT05127473|EXPERIMENTAL|Dose level 9|All participants will receive a single dose of Mim8
61965895|NCT05127473|EXPERIMENTAL|Dose level 10|All participants will receive a single dose of Mim8
61965896|NCT05127473|EXPERIMENTAL|Dose level 11|All participants will receive a single dose of Mim8
61965897|NCT05127473|EXPERIMENTAL|Dose level 12|All participants will receive a single dose of Mim8
61965898|NCT05333978|EXPERIMENTAL|Imaging of Inflammatory region|"Inflammatory regions of patients scheduled for standard of care clinical visits will be imaged using the MSOT device before and after 4 weeks of treatment.~The temperature of their skin prior to and after MSOT imaging will also be measured."
61965899|NCT00160485|EXPERIMENTAL|1|Glyburide,gestational diabetes, maternal complications, neonatal complications
61965900|NCT00160485|ACTIVE_COMPARATOR|2|Insulin, gestational diabetes, maternal complications, neonatal outcomes
62350061|NCT01943318||Biliary|Primary or secondary biliary cirrhosis
62350062|NCT01943318||Toxic|Medication related cirrhosis
62350063|NCT01943318||Others|Hepatic venous pressure gradient (HVPG) measurement
62350064|NCT04335604|EXPERIMENTAL|JPI-547|
62350065|NCT02331615|EXPERIMENTAL|Right|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Right hemisphere anodal stimulation of the dorso lateral frontal area (F3), left hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of 1.5 mA (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
62350066|NCT02331615|EXPERIMENTAL|left|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
62508264|NCT03358095|NO_INTERVENTION|Early surgery|Patients in this group proceed to pancreatic resection within 2 week of recruitment.
62508265|NCT03358095|ACTIVE_COMPARATOR|Preoperative biliary drainage|Endoscopic retrograde cholangiopancreatography (ERCP) is used to place an endoprosthesis to the biliary ducts to drain biliary stasis, and the patients proceed to pancreatic resection within 6 weeks of recruitment.
61965901|NCT01995032|EXPERIMENTAL|750 mg metformin and 7.5 g L-citrulline daily p.o.|7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks
61965902|NCT01995032|PLACEBO_COMPARATOR|Placebo|metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks
61965903|NCT04783480|ACTIVE_COMPARATOR|Birthly plus standard of care|Women will receive a code to sign up for childbirth education classes through the Birthly platform. They will also participate in childbirth education at their own discretion.
61965904|NCT04783480|PLACEBO_COMPARATOR|Standard of Care|Women will not receive a code for the 3 Birthly courses. They will participate in childbirth education at their own discretion.
61965905|NCT03817307|EXPERIMENTAL|USPIO enhanced-MRI|The contrast agent ferumoxtran-10 will be administered intravenously under constant medical supervision 24-36 hours before performing a T2\* weighted MRI scan (prior to surgery).
61965906|NCT02947997||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
61965907|NCT06270498|ACTIVE_COMPARATOR|Sucrosomial iron|
61965908|NCT06270498|PLACEBO_COMPARATOR|Placebo|
61965909|NCT04388800|EXPERIMENTAL|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist."
61965910|NCT04388800|EXPERIMENTAL|app-based cognitive behavioral intervention|"App-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist"
61965911|NCT04388800|NO_INTERVENTION|Wait-list control group|No intervention will be provided when the experimental group is receiving services, but the access to the app-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
61965912|NCT01377090||SSc DU-history subgroup|Systemic sclerosis patients with history of digital ulcers
61965913|NCT01377090||SSc with No-DU-history subgroup|Systemic sclerosis patients with no history of digital ulcers
61965914|NCT06258356|EXPERIMENTAL|patients receiving Remimazolam|
61965915|NCT06258356|PLACEBO_COMPARATOR|patients without Remimazolam|
62706243|NCT03369158|ACTIVE_COMPARATOR|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
61965916|NCT02559193||No treatment.|Data collection only trial design.
61965917|NCT01261104||Hearing impaired elderly|
61965918|NCT01261104||Hearing impaired adults|
61965919|NCT04068714||Endovascular repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through endovascular repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
61965920|NCT04068714||Open repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through open repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
61965921|NCT01433991|EXPERIMENTAL|Phase 1B|Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.
61965922|NCT01433991|EXPERIMENTAL|Phase 2 Cohort 1 Arm A:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.
61965923|NCT01433991|EXPERIMENTAL|Phase 2 Cohort 1 Arm B:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1\*4 mg capsule + 2\*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).
61965924|NCT01433991|EXPERIMENTAL|Phase 2 Cohort 2 Arm C:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.
61965925|NCT01433991|EXPERIMENTAL|Phase 2 Cohort 2 Arm D:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.
61965926|NCT03879707|EXPERIMENTAL|Experimental|Melatonin and magnesium for 14 days
61965927|NCT03879707|PLACEBO_COMPARATOR|Control|Placebo for 14 days
61965928|NCT01938677|EXPERIMENTAL|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
61965929|NCT01938677|NO_INTERVENTION|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
62144792|NCT01640340|EXPERIMENTAL|Arm II (ondansetron)|Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.
62706244|NCT06063655|EXPERIMENTAL|Water, Hydration Multiplier, Sugar-Free|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: water, Liquid IV Hydration Multiplier, and Liquid IV Sugar-Free Hydration Multiplier."
62144793|NCT04565652|EXPERIMENTAL|ICD Defibrillation|Detection of ICD shock during elective ICD implant using the investigational device
62715021|NCT06635551|EXPERIMENTAL|Catheter-related thrombosis in oncologic patients after major surgery|Cancer patients who will receive central venous catheter
62715022|NCT06635551|ACTIVE_COMPARATOR|Catheter-related thrombosis in non-oncologic patients after major surgery|Patients without known cancer who will receive a central venous catheter
61965930|NCT03909256|EXPERIMENTAL|NUTRI-HAB|"The intervention group participates in a targeted rehabilitation program 'NUTRI-HAB' with a focus on eating problem after treatment for head and neck cancer. The program comprises:~* a five day residential stay with patient education~* a two day follow-up residential stay after 3 months~* two telephone consultations with clinical dietitian between the two residential stays."
62144794|NCT03269500||malnourished older people|The hospitalized elderly with swallowing and/or Mastication problems.
62706245|NCT06063655|EXPERIMENTAL|Water, Sugar-Free, Hydration Multiplier|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: water, Liquid IV Sugar-Free Hydration Multiplier, and Liquid IV Hydration Multiplier."
62706246|NCT06063655|EXPERIMENTAL|Hydration Multiplier, Sugar-Free, Water|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Hydration Multiplier, Liquid IV Sugar-Free Hydration Multiplier, and water."
62706247|NCT06063655|EXPERIMENTAL|Hydration Multiplier, Water, Sugar-Free|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Hydration Multiplier, water, and Liquid IV Sugar-Free Hydration Multiplier."
62706248|NCT06063655|EXPERIMENTAL|Sugar-Free, Water, Hydration Multiplier|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Sugar-Free Hydration Multiplier, water, and Liquid IV Hydration Multiplier."
62706249|NCT06063655|EXPERIMENTAL|Sugar-Free, Hydration Multiplier, Water|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Sugar-Free Hydration Multiplier, Liquid IV Hydration Multiplier, and water."
62706250|NCT04604431|EXPERIMENTAL|Intervention (CDS Tool Integrated)|Pediatric clinicians in this arm will receive the iREACH CDS tool and education on the PPA Guidelines to support adherence to the Guidelines.
62706251|NCT04604431|NO_INTERVENTION|Control (No CDS Tool Integrated)|No study procedures will be implemented in the control practices, and their pediatric clinicians will not receive extra PPA Guidelines education, nor will any EHR modifications be made in their practices to support adherence to PPA Guidelines.
62706252|NCT03371212|ACTIVE_COMPARATOR|Conventional Cohort|Patients in this group will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.
62706253|NCT03371212|EXPERIMENTAL|Modular Dual Mobility Cohort|Patients in this group will receive a Taperloc femoral stem, inner ceramic femoral head (28mm), mobile polyethylene bearing, cobalt alloy liner, and G7 acetabular shell.
62706254|NCT06059950|EXPERIMENTAL|Mindfulness Flow Program|Mindfulness flow program, with 11 sessions conducted via Zoom video meeting and one in-person session of sport-specific session.
61965931|NCT03909256|NO_INTERVENTION|Control group|"The control group receives no intervention other than usual care in the study period.~After 3 months, the control group will be offered participation in the same residential rehabilitation program as the intervention group parcitipated in."
61965932|NCT04412369||Study group|Patients with COVID-19 and cardiac Troponin elevation
61965933|NCT02870582|EXPERIMENTAL|Donafenib|Donafenib 300mg bid on 1-21 days of each 28 days cycle.
61965934|NCT02870582|PLACEBO_COMPARATOR|Placebo|Placebo 300mg bid on 1-21days of each 28 days cycle.
61965935|NCT04342897|EXPERIMENTAL|LY3127804|Participants received 20 milligrams (mg) per kilogram (kg) of LY3127804 as an intravenous (IV) infusion on Days 1 and 15.
61965936|NCT04342897|PLACEBO_COMPARATOR|Placebo|Participants received 20 mg/kg of Placebo as an IV infusion on Days 1 and 15.
61965937|NCT05731895|EXPERIMENTAL|Arm 1: Participants with mild hepatic impairment (Child-Pugh A)|
61965938|NCT05731895|EXPERIMENTAL|Arm 2: Participants with moderate hepatic impairment (Child-Pugh B)|
61965939|NCT05731895|EXPERIMENTAL|Arm 3: Participants with normal hepatic function individually matched to participants of Arm 1|
61965940|NCT05731895|EXPERIMENTAL|Arm 4: Participants with normal hepatic function individually matched to participants of Arm 2|
61965941|NCT03150615|EXPERIMENTAL|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
62144795|NCT05097638||Cured pulmonary Tuberculosis patients|6 months after a completed course of anti-tuberculosis therapy
62144796|NCT04958837|EXPERIMENTAL|FIFA 11+ with dynamic core stability training|Participants in this group will undergo FIFA 11+ protocol along with additional Core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge will be given. Each exercise plan will be progressively increased.
62144797|NCT04958837|ACTIVE_COMPARATOR|FIFA 11+ protocol|Participants in this group will undergo traditional FIFA 11+ protocol which consists of slow paced running exercises, strength, plyometric \& Balance exercises and high speed running with planting/cutting
62144798|NCT02829398|EXPERIMENTAL|Patients with subarachnoid hemorrhage|Patients with subarachnoid hemorrhage will have CerebroSpinal fluid and plasma sample.
61965942|NCT03150615|PLACEBO_COMPARATOR|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
61965943|NCT03150615|OTHER|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
61965944|NCT01783301|ACTIVE_COMPARATOR|Antral follicle count|"Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide~* AFC \< 6 on both ovary: 375 IU FSH~* 6\<AFC \<=15 on both ovary: 225 IU FSH~* AFC\> 15 on both ovary: 150 IU FSH"
61965945|NCT01783301|ACTIVE_COMPARATOR|Anti-Mullerian Hormone|"Start dose of FSH based on AMH guide~* AMH \< 5 pmol/L or \< 0.7ng/ml: 375 IU FSH~* AMH 5 to \< 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH~* AMH ≥ 15 pmol/L or \> 2.1ng/ml: 150 IU FSH"
61965946|NCT01931904||Trabeculectomy or Tube Shunt Patients|46 glaucoma patients undergoing trabeculectomy or tube shunt surgery to lower IOP
61965947|NCT03047694|EXPERIMENTAL|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
61965948|NCT03047694|ACTIVE_COMPARATOR|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
61965949|NCT01936103|ACTIVE_COMPARATOR|standard group|patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .
61965950|NCT01936103|EXPERIMENTAL|intensive group|patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .
61965951|NCT04655391|EXPERIMENTAL|Chapter 1 (glasdegib, decitabine, venetoclax)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD on days 1-28,decitabine IV over 1 hour on days 1-5, and venetoclax PO QD on days 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
61965952|NCT04655391|EXPERIMENTAL|Chapter 2 (glasdegib, gilteritinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and gilteritinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
61965953|NCT04655391|EXPERIMENTAL|Chapter 3 (glasdegib, bosutinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and bosutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
61965954|NCT04655391|EXPERIMENTAL|Chapter 4 (glasdegib, ivosidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
61965955|NCT04655391|EXPERIMENTAL|Chapter 5 (glasdegib, enasidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and enasidenib PO QD on days 1-28 .Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
61965956|NCT05252117|EXPERIMENTAL|Articaine 4%|With the patient in the lithotomy position, asepsis of the thighs, vulva and vagina will be performed with aqueous chlorhexidine; insertion of vaginal speculum; puncture in the uterine cervix, at the 12h point, injecting 1.8 ml of articaine. After a latency of five minutes, the procedure to insert the IUD will start with clamping the cervix at 12 hours with the Pozzi clamp, followed by rectification of the uterus and hysterometry with the hysterometer. After confirming the hysterometry, the IUD will be inserted with its own applicator and the excess wire will be cut.
61965957|NCT05252117|EXPERIMENTAL|Mepivacaíne 3%|With the patient in the lithotomy position, asepsis of the thighs, vulva and vagina will be performed with aqueous chlorhexidine; insertion of vaginal speculum; puncture in the uterine cervix, at the 12h point, injecting 1.8 ml of Mepivacaine. After a latency of five minutes, the procedure to insert the IUD will start with clamping the cervix at 12 hours with the Pozzi clamp, followed by rectification of the uterus and hysterometry with the hysterometer. After confirming the hysterometry, the IUD will be inserted with its own applicator and the excess wire will be cut.
61965958|NCT02734940|ACTIVE_COMPARATOR|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
62144799|NCT02829398|ACTIVE_COMPARATOR|Control subjects|healthy controls from a previous study with a CerebroSpinal fluid and plasma sample
62144800|NCT05188066||Normal, pathological IVG|We will use placenta and fetal memebranes collected from first trimester termination of pregnancy. This will constitute group IVG.
62144801|NCT05188066||Normal and pathological term|We will also use the same specimens collected from third trimester pregnancies . We will call this group normal and pathological..... à finaliser
62144802|NCT01087437|EXPERIMENTAL|gastrolith calcium treatment|
62706255|NCT01121757|EXPERIMENTAL|Azacitidine followed by Lenalidomide|"Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.~Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1."
62144803|NCT05103891|EXPERIMENTAL|Binimetinib 15 mg / Binimetinib 45 mg|2 periods
62144804|NCT05103891|EXPERIMENTAL|Binimetinib 45 mg / Binimetinib 15 mg|2 periods
62144805|NCT00201045|EXPERIMENTAL|Intervention|Intervention patients receive care from a clinical pharmacist to improve blood pressure.
62706256|NCT01121757|EXPERIMENTAL|Lenalidomide followed by Azacitidine|"Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.~Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a."
62706257|NCT05329220|EXPERIMENTAL|ABNCoV2 100μg single dose|ABNCoV2 100μg single dose
61965959|NCT02734940|EXPERIMENTAL|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to \<250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
61965960|NCT01384760|ACTIVE_COMPARATOR|Lifestyle modification program|"At the 1st session, the dietitian carried out a complete behavioral assessment, with emphasis on patient's current eating and lifestyle patterns, specific eating-related behaviors, knowledge of risks associated with current eating patterns, and concerns and feelings about specific lifestyle changes. In the subsequent follow up visit, the dietitian reviewed the 7-day food diaries to ensure nutritional adequacy and treatment compliance, and also offered recommendations for controlling caloric intake.~Patients were encouraged to see an exercise instructor who designed an individualized suitable exercise regime with cardiovascular and resistance exercises for the patients to perform at home. Subjects were encouraged to perform 30-minute aerobic exercise 2-3 times a week."
61965961|NCT01384760|PLACEBO_COMPARATOR|Simple lifestyle advice|Subjects in control group received simple lifestyle advice from a clinician at baseline and month 6. This was a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects were encouraged to perform regular 30-minute exercise 2 to 3 times per week. This was to resemble routine clinical practice.
61965962|NCT01325636|EXPERIMENTAL|CD4 and CD8 T cell|Injection of specific CD4 and CD8 T cell
61965963|NCT03725098|EXPERIMENTAL|HEMOBLAST Bellows (Hemostatic Device)|Bleeding sites will be treated with HEMOBLAST Bellows per its approved Indications for Use
61965964|NCT03725098|ACTIVE_COMPARATOR|FLOSEAL (Hemostatic Device)|Bleeding sites will be treated with FLOSEAL per its approved Indications for Use
61965965|NCT01328925|EXPERIMENTAL|Nitazoxanide Oral Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml
61965966|NCT01328925|PLACEBO_COMPARATOR|Placebo Oral Suspension|Placebo Oral Suspension
61965967|NCT06278467||Patients with chronic low back pain|Consecutive patients over the age of 60, diagnosed with CBP, who have been suffering from low back pain for at least 6 months (n=57 )
61965968|NCT06278467||Healtyh control|Healthy control with compatible sociodemographic characteristics (n=50)
61965969|NCT02817191|EXPERIMENTAL|Hylo-Comod|The patients used Hylo-Comod eye drop after phaco+IOL in this group.
61965970|NCT02817191|EXPERIMENTAL|Tears Naturale Forte|The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.
62706258|NCT05329220|ACTIVE_COMPARATOR|Comirnaty|Comirnaty
61965971|NCT05849389|EXPERIMENTAL|Vosoritide treatment arm|Vosoritide will be administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
61965972|NCT04799431|EXPERIMENTAL|Neoantigen Vaccine with Poly-ICLC adjuvant and Retifanlimab|All participants receive this intervention.
61965973|NCT03982628||Sepsis|Adults admitted to a mixed medical/surgical ICU for sepsis with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
61965974|NCT03982628||Trauma|Adults admitted to a mixed medical/surgical ICU for trauma (without sepsis) with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
61965975|NCT02343627|EXPERIMENTAL|NVXT Solution|NVXT Solution once daily for 60 days
61965976|NCT02343627|PLACEBO_COMPARATOR|Vehicle of test product|Vehicle of test product, once daily for 60 days
61965977|NCT01456247|EXPERIMENTAL|TAK-438 10 mg QD|
61965978|NCT01456247|EXPERIMENTAL|TAK-438 20 mg QD|
61965979|NCT01456247|ACTIVE_COMPARATOR|AG-1749 15 mg QD|
61965980|NCT04889456|NO_INTERVENTION|Surgical variations laparoscopic right hemicolectomy|
61965981|NCT04889456|ACTIVE_COMPARATOR|Implementing standardised laparoscopic right hemicolectomy with proctoring|
61965982|NCT04889456|ACTIVE_COMPARATOR|Implementing standardised laparoscopic right hemicolectomy without proctoring|
61965983|NCT02695498|EXPERIMENTAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a standardized course in mindfulness mediation and yoga.
61965984|NCT02695498|EXPERIMENTAL|Migraine/stress Education|This course will educate participants about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
62706259|NCT04746755|EXPERIMENTAL|Experimental: Lower back pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced lower back pain; the subjects selection was corroborated by a physiotherapist.
62715023|NCT04332783|EXPERIMENTAL|Healthy Typical Adults|Observers including radiologists and non-radiologists will be asked to participate in computer based tasks in which they visually search for, detect, localize, and categorize tumors in x-ray images.
61965985|NCT01382823|EXPERIMENTAL|Femtosecond Laser|
61965986|NCT00023764|EXPERIMENTAL|Arm I|Patients receive an infusion of bortezomib (dose of 1.8 mg/m2) over 3-5 seconds once weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response lasting at least 6 months may receive retreatment.
61965987|NCT04074460|ACTIVE_COMPARATOR|Propofol (TIVA)|Propofol-based total intravenous anaesthesia
61965988|NCT04074460|ACTIVE_COMPARATOR|Volatile|Volatile-based (isoflurane, sevoflurane or desflurane) general anaesthesia
61965989|NCT00056316|EXPERIMENTAL|Behavioral Skills Training|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
61965990|NCT00056316|ACTIVE_COMPARATOR|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
61965991|NCT04172506|EXPERIMENTAL|AK105|AK105 200 mg, every 2 weeks
61965992|NCT04813406|EXPERIMENTAL|Anlotinib + Sintilimab|
61965993|NCT04134013|EXPERIMENTAL|Nutrition and Chiropractic|LBP chiropractic adjustment per protocol and 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
62508266|NCT01978769||Preadolescents with ADHD|preadolescents with prior diagnosis of ADHD and without any other psychiatric or neurological diagnosis.
62508267|NCT01978769||Preadolescents with out any diagnosis|Preadolescents with out any diagnosis
62508268|NCT02241694||survey|
62508269|NCT03330314|EXPERIMENTAL|Part 1|Intravenous (IV) infusion
62508270|NCT03330314|EXPERIMENTAL|Part 2: Cohort A|Intravenous (IV) infusion (Dose A)
62508271|NCT03330314|EXPERIMENTAL|Part 2: Cohort B|Intravenous (IV) infusion (Dose B)
62508272|NCT03330314|EXPERIMENTAL|Part 2: Cohort C|Intravenous (IV) infusion (Dose C)
62706260|NCT04746755|EXPERIMENTAL|Experimental: Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the heels of their feet; the subjects selection was corroborated by a physiotherapist.
62706261|NCT04746755|EXPERIMENTAL|Experimental: Knee to Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced Knee to Heel pain; the subjects selection was corroborated by a physiotherapist.
62706262|NCT04746755|EXPERIMENTAL|Experimental: Arch pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the arch of their feet; the subjects selection was corroborated by a physiotherapist.
62706263|NCT03560388|NO_INTERVENTION|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
62706264|NCT03560388|EXPERIMENTAL|Touch/relaxation|Touch/relaxation treatment (pre-operative)
62706265|NCT03560388|EXPERIMENTAL|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
61965994|NCT04134013|ACTIVE_COMPARATOR|Chiropractic Adjustment ONLY|LBP chiropractic adjustment per protocol
62706266|NCT00867607|EXPERIMENTAL|MRX-6 (2%)|
62706267|NCT00867607|EXPERIMENTAL|MRX-6 (1%)|
61965995|NCT03861975|EXPERIMENTAL|Breast Cancer-Related Lymphedema Measurements|Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.
61965996|NCT03836937|EXPERIMENTAL|Obeticholic acid|Patients diagnosed as NAFLD with raised ALT will be treated with both life style modification and Obeticholic acid. Obeticholic acid will be given as 10 mg twice daily. Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
61965997|NCT03836937|NO_INTERVENTION|Lifestyle modification|Patients diagnosed as NAFLD with raised ALT will be given only life style modification.Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
62706268|NCT00867607|EXPERIMENTAL|MRX-6 (0.2%)|
62508273|NCT05070390|EXPERIMENTAL|Panel A - Moderate Renal Impairment (RI)|Single dose of enlicitide chloride 10 mg
62508274|NCT05070390|EXPERIMENTAL|Panel B - Healthy Controls|Single dose of enlicitide chloride 10 mg
62508275|NCT06375369|NO_INTERVENTION|Pre-implementation|Subjects undergoing tracheostomy procedure before the implementation of DECIDE-T
62508276|NCT06375369|ACTIVE_COMPARATOR|Post-implementation/Intervention|Subjects undergoing tracheostomy procedure after the implementation of DECIDE-T
62508277|NCT02281682|ACTIVE_COMPARATOR|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
62508278|NCT02281682|ACTIVE_COMPARATOR|5-Fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
62508279|NCT02281682|ACTIVE_COMPARATOR|Ingenol mebutate 0.015%|during 3 (consecutive) days once daily. Prior to treatment: curettage
62508280|NCT02281682|ACTIVE_COMPARATOR|MAL-PDT|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
62508281|NCT02190279|EXPERIMENTAL|Suspected Localized Prostate Cancer|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
62508282|NCT02190279|EXPERIMENTAL|Biochemical Recurrence|Patients with biochemical prostate cancer relapse after definitive treatment
62508283|NCT02190279|EXPERIMENTAL|Known Metastatic Disease|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
62508284|NCT04414137||Eosinophilic pneumonia on daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia
62508285|NCT01974076|ACTIVE_COMPARATOR|Active tDCS|
62508286|NCT01974076|SHAM_COMPARATOR|Sham tDCS|
62508287|NCT04868864||Moderate to severe COVID-19 infection|COVID-19 patients with radiographic changes on CXR or CT which had not resolved or had persistent hypoxia due to COVID-19 at the time of discharge will be enrolled. All participants will undergo a LDCT and PFT.
62508288|NCT04868864||Persistent LDCT or PFT abnormalities|Participants with abnormalities on LDCT and or PFT will be invited to continue with a follow-up sub-study. This will involve follow up with repeated LDCT and PFT at subsequent time points to monitor and manage the abnormalities detected until the abnormalities fully resolve or to the last time point at 9 months of the study.
62508289|NCT02997137|ACTIVE_COMPARATOR|BOT-01|Dietary supplement: specific amino acid composition with micronutrients
62508290|NCT02997137|PLACEBO_COMPARATOR|Placebo|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties
62508291|NCT03934749||standard mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV using Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
62706269|NCT00867607|ACTIVE_COMPARATOR|Steroid|
62706270|NCT04772794|ACTIVE_COMPARATOR|hyperoxygenation group|Intraoperative administration of a mixture of 80% oxygen and 20% air
62508292|NCT03934749||Lowenstein mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV without Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
62508293|NCT06285240|EXPERIMENTAL|MK-1167 Panel A|Participants receive 6 mg MK-1167 oral loading doses QD Days 1 to 7, followed by 3 mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also receive 10 mg oral Donepezil on Days -3 to 21.
62508294|NCT06285240|PLACEBO_COMPARATOR|Placebo Panel A|Participants receive placebo to MK-1167 oral QD from Days 1 to 21. Participants also receive 10 mg oral Donepezil QD on Days -3 to 21
62508295|NCT06285240|EXPERIMENTAL|MK-1167 Panel B|Participants receive 6 mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10 mg oral Donepezil on Days -3 to 31.
62508296|NCT06285240|PLACEBO_COMPARATOR|Placebo Panel B|Participants receive placebo to MK-1167 oral QD from Days 1 to 31. Participants also receive 10 mg oral Donepezil QD on Days -3 to 31.
62508297|NCT06227377|EXPERIMENTAL|Part 1a: QTX3034 monotherapy dose-escalation|QTX3034 will be administered at protocol defined dose based on cohort assignment
62508298|NCT06227377|EXPERIMENTAL|Part 1b: QTX3034 combination with cetuximab dose-escalation|QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
62508299|NCT06227377|EXPERIMENTAL|Part 2: QTX3034 monotherapy dose-expansion|QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
62508300|NCT06227377|EXPERIMENTAL|Part 3: QTX3034 combination with cetuximab dose-expansion|QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
62706271|NCT04772794|PLACEBO_COMPARATOR|control group|intraoperative administration of 30% oxygen and 70% air
61965998|NCT04980040||Nesina® Tablet|Participants with a diagnosis of Type 2 Diabetes who took Nesina® tablet (alogliptin), as prescribed by the physician, are observed in this study.
61965999|NCT01779401|ACTIVE_COMPARATOR|Clopidogrel + Aspirit|A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
62350067|NCT02331615|SHAM_COMPARATOR|sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
62508301|NCT02129309|EXPERIMENTAL|Systemic Apelin infusion|"Study 2a - Haemodynamic studies to investigate the response to systemic infusions of 3 apelin agonists in healthy volunteers~Study 2b - Haemodynamic studies to investigate the response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures"
62508302|NCT02129309|EXPERIMENTAL|Apelin infusion - forearm|"Study 1a - A validation dose study of 3 apelin agonists using forearm plethysmography to evaluate changes in forearm blood flow: performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.~Study 1b- A validation dose study of apelin receptor antagonist using forearm plethysmography to evaluate changes in forearm blood flow, in healthy volunteers and COPD patients with elevated pulmonary artery pressures."
62508303|NCT03259191|OTHER|completely circumferential ARMS|
62706272|NCT01262105|NO_INTERVENTION|No device|
62706273|NCT01262105|EXPERIMENTAL|Device deployed|
62706274|NCT01058850|EXPERIMENTAL|Rindopepimut (EGFRvIII Vaccine, CDX-110)|
61966000|NCT01779401|ACTIVE_COMPARATOR|Clopidogrel + Aspirin|B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
62706275|NCT06242795|EXPERIMENTAL|Single arm treatment group with 7% HS|All study participants will receive 7% HS by nebulizer twice a day for two weeks as part of airway clearance.
61966001|NCT01779401|ACTIVE_COMPARATOR|Clopidogrel + Aspirin + Cilostazol|C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd
62350068|NCT05314881|EXPERIMENTAL|SLE patients|
62350069|NCT01476748|ACTIVE_COMPARATOR|Ethicon Xcel Trocars|Ethicon Xcel trocars will be used in this arm with Laprostop device
62508304|NCT03259191|OTHER|semi-circumferential ARMS|
62508305|NCT05924334|EXPERIMENTAL|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
62706276|NCT04035226||Relapsed/refractory Multiple Myeloma|Patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody treatment will be observed.
62706277|NCT02305186|EXPERIMENTAL|Neodjuvant CRT + Pembrolizumab|Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
62706278|NCT02305186|ACTIVE_COMPARATOR|Neoadjuvant CRT|Standard neoadjuvant chemoradiation treatment (CRT) alone
62350070|NCT01476748|ACTIVE_COMPARATOR|Covidien Veraport Trocars|Covidien Veraport Trocars will be used in this arm with the Laprostop device
62350071|NCT01476748|ACTIVE_COMPARATOR|Storz Reusable Trocars|Storz Reusable Trocars will be used in this arm with the Laprostop device
62350072|NCT03685552|EXPERIMENTAL|Prog: Purify-2|All subjects will be participating in a diet life style modification program (High Phytopro dietary program) ( a modified Mediterranean style low glycemic load food plan) and will be receiving a supportive nutritional supplements over a 4 week period.
62350073|NCT03240718|EXPERIMENTAL|Laser treated HSc scar|Co2 laser treatment
62350074|NCT03240718|NO_INTERVENTION|Control scar|Standard care
62706279|NCT02001168|EXPERIMENTAL|Pemetrexed &Cis-platinum|Pemetrexed d1＋Cis-platinum , d1, 21 d as a cycle.
62706280|NCT02001168|EXPERIMENTAL|Pemetrexed & Cis-platinum & rh-Endostatin|Pemetrexed d1＋Cis-platinum , d1； rh-Endostatin d1-14; 21 d as a cycle.
62706281|NCT02001168|EXPERIMENTAL|Docetaxel & Cis-platinum|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
61966002|NCT02945683|ACTIVE_COMPARATOR|Reuterin D3|Patients should take 10 drops once a day during meals for 3 months
61966003|NCT02945683|PLACEBO_COMPARATOR|Placebo|Patients should take 10 drops once a day during meals for 3 months
61966004|NCT05933395|EXPERIMENTAL|Arm A- neratinib and fulvestrant|"Participants with a qualifying ERBB2 (HER2) mutation will be assigned to Treatment Arm A and given the combination of neratinib and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Neratinib will initially be administered orally in 3 tablets (total dose of 120 mg) taken 1 time per day with food on Cycle 1 Days 1-7, in combination with fulvestrant starting on Cycle 1 Day 1 as described above. The dose of neratinib will be increased to 4 tablets (total dose of 160 mg) taken 1 time per day with food on Cycle 1 Days 8-14, and then increased further to 6 tablets (240 mg) taken once daily with food thereafter."
61966005|NCT05933395|EXPERIMENTAL|Arm B- alpelisib and fulvestrant|"If a participant does not have a qualifying ERBB2 (HER2) mutation, but they have a qualifying PIK3CA mutation, the subject will be assigned to Treatment Arm B and given the combination of alpelisib and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Alpelisib will be administered orally in 2 tablets (total dose of 300 mg) taken 1 time per day with food, in combination with fulvestrant as described above."
61966006|NCT05933395|EXPERIMENTAL|Arm C- everolimus and fulvestrant|"If a subject does not have a qualifying ERBB2 or PIK3CA mutation, but they have a qualifying mutation/alteration in AKT1, MTOR, or PTEN, the subject will be assigned to Treatment Arm C and given the combination of everolimus and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Everolimus will be administered orally in 1 tablet (10 mg per tablet) taken 1 time per day, in combination with fulvestrant as described above."
61966007|NCT05933395|EXPERIMENTAL|Arm D- abemaciclib and fulvestrant|"If a participant does not have a qualifying mutation/alteration for Arms A/B/C, and the participant does not have mutation or loss of RB1, the subject will be assigned to Treatment Arm D and given the combination of abemaciclib and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Abemaciclib will be administered orally in 1 tablet (150 mg) taken 2 times per day, in combination with fulvestrant as described above."
61966008|NCT01740193|ACTIVE_COMPARATOR|TAP Block|
61966009|NCT01740193|ACTIVE_COMPARATOR|Ilioinguinal/iliohypogastric blockade|
61966010|NCT06245135|EXPERIMENTAL|TIME at Home|TIME at Home is a virtual, group, task-oriented exercise program targeting balance and mobility. A community organization delivers two 1.5-hour sessions per week, for 8 weeks using Zoom.
61966011|NCT06245135|NO_INTERVENTION|Waitlist|Individuals in the waitlist control group will receive the TIME at Home program following the final 5-month evaluation.
61966012|NCT01548651|PLACEBO_COMPARATOR|Placebo|Placebo 5 mg orally daily for 6 months
61966013|NCT01548651|EXPERIMENTAL|Saxagliptin|Saxagliptin 5 mg orally daily for 6 months
61966014|NCT00572702|ACTIVE_COMPARATOR|A|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with Amreich-Richter procedure; it will be set randomly
61966015|NCT00572702|ACTIVE_COMPARATOR|B|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with total Prolift procedure; it will be set randomly
61966016|NCT05786820|ACTIVE_COMPARATOR|Pycnogenol Group|Professional mechanical plaque removal + Pycnogenol capsule
61966017|NCT05786820|PLACEBO_COMPARATOR|Placebo Group|Professional mechanical plaque removal + placebo capsule
62144806|NCT00201045|NO_INTERVENTION|Control|Control patients receive usual care and do not have a clinical pharmacist included in their care.
62508306|NCT05924334|EXPERIMENTAL|placebo control|The same intervention procedure will be performed with the Reiki Group. Only the placebo group practitioner does not have a Reiki Master certificate. In other words, despite the apparent reiki applied, there will be no energy flow in its real meaning.
62508307|NCT02095340|EXPERIMENTAL|Positive Training|
62508308|NCT02095340|SHAM_COMPARATOR|Neutral Training|
62508309|NCT03862534|EXPERIMENTAL|CAF|After the restoration of the enamel patients were treated with a CAF
62144807|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
62144808|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
62144809|NCT03507244|EXPERIMENTAL|Group 1,Intra-pemetrexed, radiotherapy|The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5-8 times, 4-7 weeks in total) and radiotherapy. Radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on magnetic resonance imaging, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40-50 Gy.
62508310|NCT03862534|EXPERIMENTAL|CAF + CTG|After the restoration of the enamel patients were treated with a CAF + CTG
62508311|NCT05049811|EXPERIMENTAL|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
62508312|NCT05049811|SHAM_COMPARATOR|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
62508313|NCT02464241||normal control|normal control
62706282|NCT02001168|EXPERIMENTAL|Docetaxel & Cis-platinum & rh-Endostatin|Docetaxel ＋ Cis-platinum ＋ rh-Endostatin，21 d as a cycle.
62706283|NCT05601882|EXPERIMENTAL|Upadacitinib|Participants will receive upadacitinib dose A daily in period 1. Eligible participants will receive upadacitinib dose B daily in period 2.
61966018|NCT04984720|EXPERIMENTAL|Smart phone based digital app arm|Digital smartphone application which tracks migraine and to offers pill reminders for medication adherence and community blog and disease related educational material for migraineurs will be given to the patients
61966019|NCT04984720|ACTIVE_COMPARATOR|Paper and pen diary arm|Clinic based education and traditional paper-pen diary will be administered in tracking headache parameters
61966020|NCT01528488|EXPERIMENTAL|EVOZAC|EVOZAC should be sprayed to the skin of the total face three times per day.
62508314|NCT02464241||patients|patients with optic or macular pathology or amblyopia
62508315|NCT05598879||Breast cancer|Patients with breast cancer who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
62508316|NCT05598879||Hematological malignancies|Patients with lymphomas, leukemias, multiple myeloma, and AL amyloidosis who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
62706284|NCT05601882|EXPERIMENTAL|Dupilumab followed by Upadacitinib|Participants will receive dupilumab as per its label in period 1. Eligible participants will receive upadacitinib dose A in period 2.
61966021|NCT01528488|PLACEBO_COMPARATOR|Physiological saline|Physiological saline should be sprayed to the total face three times per day.
62508317|NCT05598879||Immune check point inhibitors|Patients with any type of cancer treated with immune check point inhibitors who present for initial cardio-oncology consultation. Clinical follow for 18 months
62508318|NCT02845726||Patients with temporary ureteral stent|Assessment of patients transiently undergoing ureteral stenting.
62508319|NCT02719704|EXPERIMENTAL|"MEXA-SE"|Intervention on physical fitness, eating habits and body image
62706285|NCT00895921|ACTIVE_COMPARATOR|Aripiprazole|Participants will receive an injection of aripiprazole during the tracer-clamp study.
62706286|NCT00895921|ACTIVE_COMPARATOR|Olanzapine|Participants will receive an injection of olanzapine during the tracer-clamp study.
62144810|NCT05118100||Protect Bond|Restoration placed using Clearfil Protect Bond adhesive (Kuraray Noritake, Osaka, Japan) , which contains the antibacterial monomer MDPB (12-Methacryloyloxydodecylpyridiniumbromide)
62144811|NCT05118100||SE Bond|Restoration placed using Clearfil SEBond adhesive (Kuraray Noritake, Osaka, Japan)
62144812|NCT04439825|ACTIVE_COMPARATOR|Botox|
62144813|NCT04439825|PLACEBO_COMPARATOR|Placebo|
62144814|NCT00286325|EXPERIMENTAL|Treatment Rituximab|Open label study all subjects treated with rituximab
62144815|NCT00359203|PLACEBO_COMPARATOR|Dual chamber pacemaker|Dual chamber pacemaker programmed ODO (switched OFF)
62144816|NCT00359203|ACTIVE_COMPARATOR|Dual chamber pacemeker|Medtronic dual chamber pacemaker programmed ON and with Rate Drope Response programmed ON
62144817|NCT05686499|ACTIVE_COMPARATOR|High Fidelity (HF) Arm|The HF simulator will be Limbs and Things Colonoscopy Training Model product KKM40.
62144818|NCT05686499|EXPERIMENTAL|Low Fidelity (LF) Arm|The LF simulator will be made in Nigeria, based on low fidelity models that have been published in the literature
62144819|NCT05037305|OTHER|Intervention arm|All individuals in the Intervention arm will undergo pharmacogenetic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenomic assay used at Vanderbilt University Medical Center. Upon completion of the testing, they will be provided a link to an educational video about pharmacogenetic testing and results. Surveys will be performed before and after the pharmacogenetic testing.
62508320|NCT02719704|NO_INTERVENTION|Control|School of the control group carried out one semester with the regular and traditional activities. The control school had three physical educations lessons per week, similar of experimental schools.
62144820|NCT05037305|OTHER|Delayed intervention arm|All individuals in the Delayed intervention arm will undergo pharmacogenetic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenomic assay used at Vanderbilt University Medical Center. Surveys will be performed before and after the pharmacogenetic testing. Upon completion of the first follow up survey, they will be provided a link to an educational video about pharmacogenetic testing and results. A second follow up survey will then be completed.
62144821|NCT01590134|NO_INTERVENTION|Control|"Following randomisation,to no active intervention, blood and urine samples will be collected at 6 stated intervals over a 48 hour period~Total number of participants in arm = 6"
62144822|NCT01590134|ACTIVE_COMPARATOR|Iron control|"Following randomisation, on each of two consecutive mornings, the participant will receive a single dose of ferrous sulphate 200mg. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Total number of participants in arm = 6"
62508321|NCT02719704|EXPERIMENTAL|"Espelho, espelho meu"|School-based intervention on body image
62508322|NCT00515034|EXPERIMENTAL|001|Doripenem 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
62508323|NCT00515034|ACTIVE_COMPARATOR|002|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
62706287|NCT04995341|EXPERIMENTAL|Cohort 1: Functional and structural outcomes in children after bedside OCT imaging in infancy|80 pediatric participants who were previously enrolled in BabySTEPS1 from July 22, 2016 - December 30, 2020 will be enrolled for follow-up neurodevelopmental testing, visual acuity, visual function testing and investigational retinal imaging
62706288|NCT04995341|EXPERIMENTAL|Cohort 2: Test of bedside OCT imaging data to predict RW-ROP or ROP progression|250 infants at risk for retinopathy of prematurity: 132 will be enrolled and have investigational bedside OCT retinal imaging, and their data will be combined with that from 118 infants who had similar imaging in BabySTEPS1 for analysis of the total group versus the indirect ophthalmoscopic clinical exam data.
62706289|NCT04995341|EXPERIMENTAL|Cohort 3: Comparison of ROP imaging with investigational OCT versus retinal camera|102 infants, who are a sub-group of the 132 enrolled in Cohort 2, will also have imaging with a conventional, commercially available, retinal camera system to compare utility, stress, and prediction and documentation of referral-warranted ROP between the camera images and those from investigational OCT.
62715024|NCT06715358|ACTIVE_COMPARATOR|Reintervention|Implement the SI! Program environment intervention from 2nd grade throughout the whole Elementary Education (5 years) and with two classroom interventions: one at 2nd grade and a reintervention at 5th grade.
61966022|NCT06241872|EXPERIMENTAL|Dry needling group (study group)|For patients in this group, dry needling will be performed once a week for three weeks on trigger points described as pain points in the Copeman nodule, gluteus medius, gluteus maximus, and iliotibial band muscles, guided by ultrasound. Patients will be instructed to perform daily stretching exercises outlined in the home program and mark their daily use of paracetamol on the provided schedule if needed. They will refrain from using NSAIDs or steroids during this period.
61966023|NCT06241872|SHAM_COMPARATOR|Sham dry needling group (control group)|For the patients in this group, dry needling will be performed once a week for three weeks on trigger points described as pain points in the Copeman nodule, gluteus medius, gluteus maximus, and iliotibial band muscles, guided by ultrasound. However, the needles will not penetrate beyond the subcutaneous fatty tissue. Patients will be instructed to perform daily stretching exercises outlined in the home program and mark their daily use of paracetamol on the provided schedule if needed. They will refrain from using NSAIDs or steroids during this period.
61966024|NCT00824512|EXPERIMENTAL|EGb 761® 120 mg|
61966025|NCT00824512|PLACEBO_COMPARATOR|Placebo|
61966026|NCT03954925|ACTIVE_COMPARATOR|Anatomic anterior cruciate ligament with short hamstring|Anatomic anterior cruciate ligament with short hamstring graft
61966027|NCT03954925|ACTIVE_COMPARATOR|Anatomic anterior cruciate ligament with standard hamstring|Anatomic anterior cruciate ligament with standard hamstring graft
62508324|NCT00515034|EXPERIMENTAL|003|Doripenem 1 gram infused over 4 hours at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
62508325|NCT00515034|ACTIVE_COMPARATOR|004|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
62508326|NCT06483087|EXPERIMENTAL|the intervention group|\[\*\]Arm Description: The Animated Education Program (AEP) and usual care interventions provided for children randomly assigned to the experimental group during the day before receiving a CC procedure. The Animated Education Program (AEP) was developed to prepare children for cardiac catheterization (CC) by improving their knowledge of CC procedures and helping them become familiar with such procedures in all phases. It will be presented as an AEP for eight minutes; it was uploaded on the researcher's laptop and was presented individually to children in their rooms.
62706290|NCT04995341|EXPERIMENTAL|Cohort 4: Adult and pediatric participants enrolled for imaging during system development|12 awake healthy adult controls and 12 pediatric participants undergoing examination under anesthesia in the operating room will be imaged with the investigational bedside OCT for the purpose of technological development.
62706291|NCT06565052|EXPERIMENTAL|Group A: Prehabilitation Program|"Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:~* In-clinic baseline visit with assessments~* Virtual exercise sessions 3 days per week for 4 weeks.~* IMN supplementation and daily multivitamin starting at 4 weeks of the preoperative phase.~* Resection surgery per standard of care~* In-clinic 30 day postoperative visit."
62706292|NCT06565052|NO_INTERVENTION|Group B: Usual Care|"Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:~* In-clinic baseline visit with assessments~* Resection surgery per standard of care~* In-clinic 30 day postoperative visit~* After completion of the study period, participants will be offered exercise equipment with an exercise instruction booklet."
62706293|NCT05744479|EXPERIMENTAL|Metformin (Oral)|50 participants will be administered oral metformin titrated to a maximum dose of 2000mg/day for 24 weeks.
62706294|NCT05744479|PLACEBO_COMPARATOR|Placebo|50 participants will be administered an identical oral placebo for 24 weeks.
62706295|NCT06337448|EXPERIMENTAL|Light-emitting diode|The LED application protocol will be carried out with external use equipment model Antares, from the company IBRAMED (Amparo, São Paulo, Brazil), with a cluster G2 applicator. The power will be 450mW/cm2 and dose 5J/cm2 for 2 minutes and 13 seconds (automatic programming) in 450nm waves (blue wavelength). The treatment consists of eight sessions, carried out daily, except on weekends. The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, in the presence of only a physiotherapist specializing in women's health, who will apply the light.
62706296|NCT02037529|EXPERIMENTAL|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62144823|NCT01590134|EXPERIMENTAL|Dietary supplement|"Following randomisation, on each of two consecutive mornings, the participant will receive the experimental dietary iron supplement. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Toal participants in arm = 6"
62508327|NCT06483087|NO_INTERVENTION|Control group|Provide brief procedural instructions, such as time for fasting, and the need to increase the fluid intake post cardiac catheterization. However, no written or animated materials are used to provide health education for children before undergoing the CC procedure.
62508328|NCT04083859|EXPERIMENTAL|mPATH-Lung|Participants randomized to the mPATH arm will complete a self-survey and a brief video decision aid, and then invites them to estimate their personal risks and benefits of screening by completing 8 survey items needed to calculate their predicted risk of developing lung cancer based on the validated Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Model 2012.
61966028|NCT02066246|SHAM_COMPARATOR|Olympus UHI-3|patients are treated with the Olympus UHI-3-CO2-insufflation and trocar system
61966029|NCT02066246|ACTIVE_COMPARATOR|AirSeal|patients are treated with the AirSeal-CO2-insufflator and trocar-system
61966030|NCT04388709|EXPERIMENTAL|Peginterferon lambda-1a|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
62144824|NCT01788371|NO_INTERVENTION|No antiviral arm|provide standard of care to mothers and standard immunoprophylaxis to their infants
62144825|NCT01788371|EXPERIMENTAL|Lamivudine|lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
62144826|NCT01788371|EXPERIMENTAL|Telbivudine|Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
62508329|NCT04083859|PLACEBO_COMPARATOR|Usual care (CONTROL)|Participants randomized to the control arm will see an animated video about exercise for lung health based on recommendations from the European Lung Foundation. They will not be offered the opportunity to estimate their predicted benefits and harms of screening or to request a lung cancer screening visit.
62508330|NCT01033578|NO_INTERVENTION|Control|Receive hepatectomy and thrombectomy alone, no postoperative adjuvant treatments
62706297|NCT02037529|EXPERIMENTAL|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62706298|NCT02298725|EXPERIMENTAL|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans. All foods and beverages will be provided to enrolled subjects during the intervention period.
62706299|NCT02298725|EXPERIMENTAL|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet plan will be closely aligned with the NHANES What We Eat In America report. All foods and beverages will be provided to enrolled subjects during the intervention period."
62706300|NCT05762354||Scoliosis Group|Adolescent Idıopathic Scoliosis
62706301|NCT01936831|EXPERIMENTAL|Group 1: 5mg Cohort|Group 1 participants had an M. tuberculosis strain with an inhA mutation only. 5 mg cohort received Isoniazid 5 mg/kg daily plus vitamin B6 \>=25 mg daily for 7 days
62706302|NCT01936831|EXPERIMENTAL|Group 1: 10mg Cohort|Group 1 participants had an M. tuberculosis strain with an inhA mutation only. 10 mg cohort received Isoniazid 10 mg/kg daily plus vitamin B6 \>=25 mg daily for 7 days
62706303|NCT01936831|EXPERIMENTAL|Group 1: 15mg Cohort|Group 1 participants had an M. tuberculosis strain with an inhA mutation only. 15 mg cohort received Isoniazid 15 mg/kg daily plus vitamin B6 \>=25 mg daily for 7 days
62706304|NCT01936831|ACTIVE_COMPARATOR|Group 2: 5mg Cohort|Group 2 participants had an M. tuberculosis strain with neither inhA nor katG mutations. All Group 2 participants received Isoniazid 5 mg/kg daily plus vitamin B6 \>=25 mg daily for 7 days
62706305|NCT01936831|EXPERIMENTAL|Group 3: 15mg Cohort|Group 3 participants had an M. tuberculosis strain with a katG mutation with or without an inhA mutation. 15mg cohort received Isoniazid 15 mg/kg daily plus vitamin B6 \>=25 mg daily for 7 days
62706306|NCT01936831|EXPERIMENTAL|Group 3: 20mg Cohort|Group 3 participants had an M. tuberculosis strain with a katG mutation with or without an inhA mutation. 20mg cohort received Isoniazid 20 mg/kg daily plus vitamin B6 \>=25 mg daily for 7 days
62706307|NCT01626742|PLACEBO_COMPARATOR|Ready to drink flavored beverage|
62706308|NCT01626742|EXPERIMENTAL|Ready to drink flavored beverage w/ AN 777|
62706309|NCT02234193|ACTIVE_COMPARATOR|Micro biopsies 2mm x control|2 mm diameter micro biopsies will be performed on all subjects.
62706310|NCT02234193|ACTIVE_COMPARATOR|Micro biopsies 1mm x control|1 mm diameter micro biopsies will be performed on all subjects.
62706311|NCT02234193|ACTIVE_COMPARATOR|Micro biopsies 0.8 mm x control|0.8 mm diameter micro biopsies will be performed on all subjects.
62706312|NCT02234193|ACTIVE_COMPARATOR|Micro biopsies 0.6 mm x control|0.6 mm diameter micro biopsies will be performed on all subjects.
62706313|NCT02234193|ACTIVE_COMPARATOR|Micro biopsies 0.5 mm x control|0.5 mm diameter micro biopsies will be performed on all subjects.
62706314|NCT02234193|ACTIVE_COMPARATOR|Micro biopsies 0.40 mm x control|0.4 mm diameter micro biopsies will be performed on all subjects.
62706315|NCT02234193|ACTIVE_COMPARATOR|Micro biopsies 0.20 mm x control|0.2 mm diameter micro biopsies will be performed on all subjects.
62706316|NCT03798210|PLACEBO_COMPARATOR|Placebo|Look and taste-alike placebo tablets in white plastic vials.
62706317|NCT03798210|EXPERIMENTAL|Lactobacillus reuter's|Lactobacillus reuteri tablets in white plastic vials.
61966031|NCT04388709|NO_INTERVENTION|Best supportive care|Best supportive care
62144827|NCT02414594|EXPERIMENTAL|IONIS-APO(a)-LRx|Drug: IONIS-APO(a)-LRx
62144828|NCT02414594|PLACEBO_COMPARATOR|Placebo (Normal Saline)|Drug: Sterile Normal Saline (0.9% NaCl)
62144829|NCT04179565|ACTIVE_COMPARATOR|Immediate intervention|The immediate education (IE) group will receive the intervention, Healthy Children, Healthy Families: Parents Making a Difference! in period 1. In period 2, IE will receive no education and will be followed longitudinally for periods 2 and 3.
62144830|NCT04179565|ACTIVE_COMPARATOR|Delayed intervention|The delayed education (DE) group will serve as controls in period 1, receiving no intervention. In period 2, the treatments will cross over, so DE will receive the Healthy Children, Healthy Families: Parents Making a Difference! intervention.
62144831|NCT05143125|EXPERIMENTAL|Treatment group|Decitabine combined with NK cell infusion as post-remission therapy
62508331|NCT01033578|EXPERIMENTAL|PVIC Group|Portal Vein Infusion Chemotherapy (PVIC): 5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) was continuously infused into portal vein through tube by a infusion pump implanted in operation. Treatment started 2 weeks after the operation and was repeated every 4 weeks for six cycles.
61966032|NCT05312723||Rhinitis allergy|Patients with rhinitis symptoms and positive skin pric test to one or more allergens.
61966033|NCT05312723||Non-rhinitis allergy|Patients with rhinitis symptoms and negative skin pric test to one or more allergens.
61966034|NCT06175091|ACTIVE_COMPARATOR|control group|Usual management, i.e. alarm management left to the discretion of the nurse caring for the patient.
61966035|NCT06175091|EXPERIMENTAL|intervention group|restrictive alarm strategy
61966036|NCT06007885|EXPERIMENTAL|Community-based activity program|Engagement in 8-week community-based activity program.
62508332|NCT01033578|EXPERIMENTAL|TACE Group|Transcatheter Arterial Chemoembolization (TACE): 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
62706318|NCT05587127|EXPERIMENTAL|Cognitive Behavioral Therapy|Subjects will receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder.
62706319|NCT05587127|NO_INTERVENTION|Usual Care|In the usual care condition, participants will be allowed to continue with treatment they are already receiving at the time of randomization, and we will collect detailed data on the nature of these interventions. Participants will be allowed to pursue non study treatments in this condition.
62706320|NCT04312802||Observational|Single arm observational study
62706321|NCT04466891|EXPERIMENTAL|ZW25 (Zanidatamab) Monotherapy|
62706322|NCT04388826|EXPERIMENTAL|Veru-111 18 mg|Veru-111 18mg capsules
62706323|NCT04388826|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62706324|NCT02769793|EXPERIMENTAL|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
62706325|NCT02769793|ACTIVE_COMPARATOR|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
62706326|NCT05884125|EXPERIMENTAL|Brief Electrical Stimulation Therapy|Single, 10 minute dose of electrical stimulation delivered to the injured nerve during surgical intervention.
62706327|NCT05884125|NO_INTERVENTION|Standard of Care|Surgical intervention for repair of peripheral nerve injury.
62706328|NCT04767321|EXPERIMENTAL|LTX-109 treatment|Nasal application of LTX-109 gel 3% (w/w), 250 mikroliters in each nostril, 4 times in one day, every two hours.
61966037|NCT03475537|EXPERIMENTAL|the treatment of transcranial direct current stimulation|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
62144832|NCT04711291|NO_INTERVENTION|Remain on IR-Tac prescribed doses every 12 hours|Patient will remain in Tacrolimus IR-Tac Arm and will complete medication adherence questionnaire monthly. They will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus Trough levels and change in tacrolimus dose levels during their routine follow up.
62144833|NCT04711291|ACTIVE_COMPARATOR|Convert to Envarsus XR once daily|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR and will complete medication adherence questionnaire. However, patients in this group will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
62144834|NCT04711291|EXPERIMENTAL|Convert to Envarsus XR once daily combined with TransMedAx app use|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR, will receive notification by scanning a QR code through TransMedAx application and will complete medication adherence questionnaire. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
62144835|NCT00986752|ACTIVE_COMPARATOR|Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
62144836|NCT00986752|EXPERIMENTAL|Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
62350075|NCT04950192||Prospective Observational|Prospective observational subjects undergoing planned cardiac procedures utilizing image guidance
62706329|NCT04767321|EXPERIMENTAL|Placebo|Nasal application of placebo, 250 mikroliters in each nostril, 4 times in one day, every two hours.
62706330|NCT01661283|EXPERIMENTAL|Arm A|All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days
62706331|NCT04982796|EXPERIMENTAL|Psilocybin-enhanced psychotherapy|Psilocybin will be administered twice (25mg \& 30mg two weeks apart) in addition to a 6-week psychotherapy protocol while admitted to a residential rehabilitation treatment program.
61966038|NCT01649661||premenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
61966039|NCT01649661||postmenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
61966040|NCT03608592|EXPERIMENTAL|UCMSCs group|Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min.
62144837|NCT00986752|EXPERIMENTAL|Atherectomy|The third randomization arm is Atherectomy.
62350076|NCT05670431||4th-grade students of a dentistry faculty|
62350077|NCT05670431||5th-grade students of a dentistry faculty|
62350078|NCT05670431||Dentists|
62350079|NCT05670431||Specialist dentists|
62350080|NCT05670431||Laypeople|
62706332|NCT04982796|OTHER|Treatment-as-Usual|Treatment-as-usual while admitted to a residential rehabilitation treatment program.
62706333|NCT01659502|EXPERIMENTAL|TL-118 alone or with pancreas cancer chemotherapy|
62706334|NCT02105129|EXPERIMENTAL|HMPL-523|Single/Multiple Ascending Dose. oral administration, a single dose of 5, 20, 50, 100, 200 and 300 mg (Part A) and multiple dose of HMPL-523 at dose level based on result of Part A
62706335|NCT02105129|PLACEBO_COMPARATOR|Placebo|Placebo: oral administration
62706336|NCT03326908|OTHER|Normal conditions of light exposure|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCTs will be produced under the same lighting conditions (photopic).~* At baseline~* 20 minutes after baseline~* 25 minutes after baseline~* 45 minutes after baseline~* 60 minutes after baseline"
62706337|NCT03326908|OTHER|Light variations|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCT will be performed:~* at baseline, in a room with photopic artificial lighting (400 lux)~* after a period of adaptation to the dark (20 minutes in the dark: 0 lux)~* after 5 min of retinal glare, obtained by means of a projection of light of 1000 lux on the fundus of eye~* 15 minutes after this period of retinal glare, in photopic artificial lighting~* 30 minutes after the period of retinal glare, in photopic artificial lighting"
62706338|NCT06467409|PLACEBO_COMPARATOR|Placebo|
62706339|NCT06467409|ACTIVE_COMPARATOR|morphine hydrochloride injection|
62706340|NCT06467409|EXPERIMENTAL|LPM3480392 injection group 1|
62706341|NCT06467409|EXPERIMENTAL|LPM3480392 injection group 2|
62706342|NCT06467409|EXPERIMENTAL|LPM3480392 injection group 3|
62706343|NCT06467409|EXPERIMENTAL|LPM3480392 injection group4|
61966041|NCT05174260||hypotension developing group|Pregnant women who underwent elective C/S under spinal anesthesia with systolic arterial pressure below 90 mmHg or with hypotension symptoms such as dizziness, nausea and vomiting during the procedure.
61966042|NCT05174260||group without hypotension|Pregnant women who underwent elective cesarean section under spinal anesthesia whose systolic arterial pressure did not fall below 90 mmHg or did not have any symptoms of hypotension during the procedure.
61966043|NCT03779724|EXPERIMENTAL|isokinetic exercise|The isokinetic dynamometer (Biodex Multijoint Pro 3) was used for isokinetic exercises. The isokinetic exercise program was implemented over eight weeks, twice a week on non-consecutive days under the supervision of a doctor. The number of repetitions undertaken by the patients over the program were as follows: first week 5 at 60°/s and 10 at 180°/s, second week 10 at 60°/s and 15 at 180°/s, third week 15 at 60°/s and 20 at 180°/s, fourth week 20 at 60°/s and 30 at 180°/s, and in the last four weeks 20 at 60°/s and 40 at 180°/s angular velocities. Each block of 10 repetitions were performed as a set.
61966044|NCT03779724|ACTIVE_COMPARATOR|home exercise|The patients undertook lower extremity strengthening and balance exercises three times a week for eight weeks without supervision. They started with three repetitions, which was gradually increased to 10-15. The patients were called two times a week to inquire about exercise continuity and encouraged to undertake the recommended exercises.
61966045|NCT05667545|ACTIVE_COMPARATOR|Negative control group (A1)|A1: cavities will be sealed directly by restorative material (conventional glass ionomer) without any treatment.
61966046|NCT05667545|ACTIVE_COMPARATOR|Treatment group (A2)|A2: cavities will be treated by Self-Assembling peptide P11-4 then sealed by conventional glass ionomer.
61966047|NCT01121822|EXPERIMENTAL|Group 1|Participants at age 18 to 59 years
61966048|NCT01121822|EXPERIMENTAL|Group 2|Participants at age 60 years or older
62144838|NCT02260973|ACTIVE_COMPARATOR|Omega-3|re esterified TG omega-3
62508333|NCT01033578|EXPERIMENTAL|PVIC+TACE Group|Combination of PVIC and TACE. PVIC started 2 weeks after operation and TACE started 6 weeks after operation. Both PVIC and TACE were repeated at 8 weeks intervals for 3 cycles.
62508334|NCT01491633|EXPERIMENTAL|Dasatinib|Dasatinib 140 mg by mouth each day
61966049|NCT01635946|EXPERIMENTAL|Isavuconazole and atorvastatin|Atorvastatin on Days 1 and 12, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 15
62508335|NCT05494216|ACTIVE_COMPARATOR|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Individual bound sperm selection is done followed y ICSI
62508336|NCT05494216|ACTIVE_COMPARATOR|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for ICSI.
62508337|NCT03658863|ACTIVE_COMPARATOR|Endoscopy first|Endoscopic ultrasound is used to evaluate bile ducts. If stones in extrahepatic bile ducts are seen ERCP and stone evacuation is performed during the same anaesthesia. Laparoscopic cholecystectomy is performed after endoscopic procedures in two days.
62508338|NCT03658863|ACTIVE_COMPARATOR|Cholecystectomy first|Laparoscopic cholecystectomy with intraoperative cholangiography is performed. If stones are found postoperative ERCP with stone evacuation is applied (during cholecystectomy if common bile duct is completely blocked or as soon as possible).
62508339|NCT04027257|EXPERIMENTAL|STAR|Receive 15-week STAR intervention immediately after pretest.
62508340|NCT04027257|NO_INTERVENTION|Waitlist Control|No intervention for the 15 weeks after pretest.
62508341|NCT04017559|EXPERIMENTAL|Intervention cohort|All participants were entered into the intervention cohort to receive the Motivational Interviewing intervention
61976169|NCT03267498|EXPERIMENTAL|Nivolumab + chemoradiation|Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62144839|NCT02260973|PLACEBO_COMPARATOR|Safflower Oil|vegetable oil
62144840|NCT00776139|EXPERIMENTAL|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
62144841|NCT00776139|EXPERIMENTAL|2|Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
62508342|NCT03968926||Vasoplegic ECMO|All patients during VA-ECMO support for cardiogenic shock who presented, within 48 hours after implantation, a vasoplegia defined by a norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2
62508343|NCT04628845|PLACEBO_COMPARATOR|SRP and endontic treatment without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals without using laser 940nm.
62508344|NCT04628845|ACTIVE_COMPARATOR|SRP and endodontic treatment with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
62508345|NCT04490226|EXPERIMENTAL|fasting, active|36 hours fasting, PAL 1.6
62508346|NCT04490226|EXPERIMENTAL|ketogenic diet, active|24 hours of ketogenic diet (liquid meals), PAL 1.6
62508347|NCT04490226|EXPERIMENTAL|exogeneous ketone bodies, active|24 hours of ketone body supplements (Beta-Hydroxybutyrate as Ca-Mg-salt) additional to a normal diet (liquid meals), PAL 1.6
62508348|NCT04490226|EXPERIMENTAL|fasting, inactive|36 hours fasting, PAL 1.3
62508349|NCT02856087|PLACEBO_COMPARATOR|group LR|low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
62508350|NCT02856087|ACTIVE_COMPARATOR|group HR|High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
61976170|NCT05810623|EXPERIMENTAL|SI Chemotherapy|Patients randomized to the experimental arm will receive a SI within 24h after diagnostic URS. In case of multiple diagnostic URS during the follow-up (including 2nd look for incomplete ablation, non-diagnostic first URS or UTUC recurrence) patients randomized to the interventional arm will receive a SI after each diagnostic URS for 2 years after the day of first diagnostic URS.
61976171|NCT05810623|NO_INTERVENTION|Observation|Patient randomized to the observational arm will be treated and followed according to institutional own standards.
61966050|NCT06150313|EXPERIMENTAL|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|MISC-T is an adaptation of MISC for trainers. The trainer is the figure who trains a caregiver to enable him/her to interact with higher quality (i.e., with more MISC components). MISC for trainers is commonly administered to groups of 6-20 trainees, either face to face or using videoconference, and consists of 8 hours of theory about MISC principles and 12 hours of practice using video feedback. Video feedback is the core component of MISC training, which aims to transfer more competency than knowledge, using ecological practice. This means using video recordings of daily interactions with a significant child and watching them together (supervisor and trainee) to enable the trainee to realize the consequences of MISC components. MISC for trainers was adapted to be administered to groups of 6-12 teachers using 4 x 2-hours theoretical sessions (8h) and 11 x 1.5-hours of practice using video-feedback.
62508351|NCT02856087|EXPERIMENTAL|group HR-N|remifentanil infusion at 4ng/ml of Ce with naloxone infusion
62508352|NCT04838379|PLACEBO_COMPARATOR|group Bupivacaine|will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline, 10 minutes before skin incision
62508353|NCT04838379|ACTIVE_COMPARATOR|group bupivacaine&dex|will include 30 patients: each one will receive 2.5mg/kg of 0.25% bupivacaine plus 1 µ/kg of dexmedetomidine diluted in a 20 mL syringe of normal saline, 10 minutes before skin incision
62508354|NCT04838379|ACTIVE_COMPARATOR|Group bupivacaine & dexamethasone|will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine plus dexamethasone (0.3 mg/kg) diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
62508355|NCT01546922|ACTIVE_COMPARATOR|First low dose HC followed by high dose HC|First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
62508356|NCT01546922|ACTIVE_COMPARATOR|First high dose HC followed by low dose HC|First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight
62508357|NCT06078540|EXPERIMENTAL|USeeBP|Participants will be asked to use the USeeBP mHealth app alongside participating in UCM-RPM program as part of their routine care.
61966051|NCT06150313|EXPERIMENTAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This MISC version (MISC-SA) aims to transference the MISC training to wider communities by diminishing the cost of the teaching and learning. By implementing the MISC lessons in an online platform, thus allowing self-learning, the new Self-Administered version of MISC allows to obtain MISC training in 25 weekly sessions distributed across 7 months (approximately, a scholar course). In contrast to MISC-T, this version allows the simultaneous self-training of a high number of participants with very low intervention of a supervisor, which diminishes the cost. As MISC-T, MISC-SA keeps the core component of MISC trainings (video-feedback) by fostering participants to record interactions and then visualize them using guided reflection.
61966052|NCT06150313|ACTIVE_COMPARATOR|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R)|Teachers usually do not get training to improve the quality of the interactions. However, to avoid using a Waiting-List or a Placebo control group, a last version of MISC training was designed but, this time, without the core MISC component: video-feedback. MISC-Readings provides the theoretical knowledge of MISC but lacks practice and reflection of MISC components by watching once own video recorded interactions with a significant child. MISC-Readings substitutes all the practice time of the other versions (video-feedback) by readings, that is, theoretical knowledge. This assimilates this version to the 'intellectual' or more theoretical format of teachers' common training, even when it is referred to social-emotional learning.
61966053|NCT01025791|EXPERIMENTAL|Panel A, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
61966054|NCT01025791|EXPERIMENTAL|Panel A, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
61966055|NCT01025791|EXPERIMENTAL|Panel A, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.
62508358|NCT02361814|EXPERIMENTAL|Amniotic membrane allograft group|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
62508359|NCT01098110|EXPERIMENTAL|Asenapine 5 mg BID|Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.
62508360|NCT01098110|EXPERIMENTAL|Asenapine 10 mg BID|Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.
62508361|NCT01098110|PLACEBO_COMPARATOR|Placebo BID|Participants received matching placebo BID for 6 weeks.
62508362|NCT00267163|EXPERIMENTAL|1.|
62508363|NCT00267163|PLACEBO_COMPARATOR|2.|
62508364|NCT02023008|EXPERIMENTAL|Supportive care (internet-based integral yoga intervention)|Participants undergo 12 sessions of cancer-adapted integral yoga classes using an internet-based videoconferencing platform. Integral yoga includes postures, deep relaxation, breathing practices and meditation to create a profound experience of peace and well-being. Participants take part in study classes from home (or other location that is convenient for the participant and that allows them to access the internet-based classes) with two-way interaction with group instructors and members alike over 75 minutes twice weekly for 6 weeks during radiation therapy. Participants are encouraged to complete additional yoga practice sessions outside of the twice weekly study sessions.
62508365|NCT04502498||60 patients with local advanced bladder cancer|Local advanced bladder cancer patients candidate for radical cystectomy
62508366|NCT01121107|EXPERIMENTAL|Left Atrial Pressure Monitoring System|Left Atrial Pressure (LAP) Monitoring System
62508367|NCT01121107|ACTIVE_COMPARATOR|Patient Advisor Module|Patient Advisory Module
62508368|NCT00275275|EXPERIMENTAL|1|Conversion factor of Mirapex to Requip 24-Hour of 1:3. This was a switch study in which the conversion factor was being investigated to assist in the conversion from Mirapex to Requip PR. In this group, the dose of Requip PR was 3 times the dose of Mirapex.
62508369|NCT00275275|EXPERIMENTAL|2|Conversion factor of Mirapex to Requip 24-Hour of 1:4
62508370|NCT00275275|EXPERIMENTAL|3|Conversion factor of Mirapex to Requip 24-Hour of 1:5
62144842|NCT04903080|EXPERIMENTAL|Treatment (HER2 CAR T cells), Phase I Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0. Treatment repeats every 8 to 12 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
62508371|NCT05478187|EXPERIMENTAL|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
62508372|NCT05478187|ACTIVE_COMPARATOR|Control Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of traditional visual cues consisting of stripes on the floor
62508373|NCT05429697|EXPERIMENTAL|Pembrolizumab+SMT-NK inj.|"Experimental:~Pembrolizumab + SMT-NK inj. Participants will be randomized to receive 200 mg pembrolizumab followed by 3\*10\^6cells/kg SMT-NK inj.~Interventions:~Drug: SMT-NK inj. Drug: Pembrolizumab"
62508374|NCT05429697|PLACEBO_COMPARATOR|Pembrolizumab|"Placebo Comparator: Pembrolizumb Participants will be randomized to receive 200 mg pembrolizumab.~Intervention:~Drug: Pembrolizumab"
62508375|NCT05290337|EXPERIMENTAL|ZR-CHOP|
62706344|NCT05057507||Atrial fibrillation patients undergoing radiofrequency catheter ablation|Up to 115 patients undergoing radiofrequency catheter ablation will be enrolled.
62706345|NCT04085250|EXPERIMENTAL|Nivolumab Consolidation|Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
62706346|NCT04085250|ACTIVE_COMPARATOR|Observation|Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
62706347|NCT04179344||Integrated e-healthcare services (IeHS) web-based app|This usability study is conducted under 3 steps: IeHS simulation, user experience survey using SUS questionnaire, and qualitative study through the in-depth interview.
62706348|NCT04243486|EXPERIMENTAL|UHE-105 Shampoo|UHE-105 Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
62706349|NCT04243486|PLACEBO_COMPARATOR|Vehicle Shampoo|Vehicle Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
62706350|NCT05775445||Group 1 (significant CAD, low risk factors)|"1. Evidence of significant CAD~   a. Coronary angiogram or CT coronary angiogram with documented stenosis \>=50% in left main or \>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)~   AND all of the following~2. Age \</= 45 for males and \</= 50 for females~3. Absence of diabetes mellitus~4. Absence of tobacco use~5. No prior CVA or PAD"
62715025|NCT06715358|ACTIVE_COMPARATOR|Late intervention|Implement the SI! Program environment intervention from 5th grade throughout the rest of the Elementary Education (2 years) with only one classroom intervention at 5th grade.
62715026|NCT03364153|EXPERIMENTAL|avacincaptad pegol|Participants will receive avacincaptad pegol monthly for up to 17 Months.
61966056|NCT01025791|EXPERIMENTAL|Panel A, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
62350081|NCT03624764|EXPERIMENTAL|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
62350082|NCT03624764|ACTIVE_COMPARATOR|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
62350083|NCT04591496|EXPERIMENTAL|SmartFeeding4Kids|SmartFeeding4Kids: information about children's healthy diet and effective parental feeding practices, with a behavioral intervention (5 sessions plus 2 brief booster sessions online intervention)
62350084|NCT04591496|ACTIVE_COMPARATOR|SmartFeeding4Kids Health|Psychoeducational condition: information about children's healthy diet and effective parental feeding practices (5 sessions plus 2 brief booster sessions online intervention)
62350085|NCT05475912|EXPERIMENTAL|group A, Conventional Pysical Therapy treatment|group A will be given, Electrotherapy Modalities treatment:Hot pack - 20 min,Transcutaneous Electrical Nerve Stimulator - 30 min and will perfome Active Exercises including;Knee to chest exercise,Hamstring stretch, Pelvic bridging,Pelvic tilt, Lumbar rotation stretch exercise.(1set with10 reps of each excercise) Home exercise plan \& precautions; Perform above mentioned active exercises, 3 sessions per day (1sets x 10 reps) will also be given to Group A.
62350086|NCT05475912|EXPERIMENTAL|Group B, Talocrural joint manipulation and Conventional Physical Therapy treatment|group Bwill be given, Talocrural Joint Manipulation with Electrotherapy Modalities treatment:Hot pack - 20 min,Transcutaneous Electrical Nerve Stimulator - 30 min and will perfome Active Exercises including;Knee to chest exercise,Hamstring stretch, Pelvic bridging,Pelvic tilt, Lumbar rotation stretch exercise.(1set with10 reps of each excercise) Home exercise plan \& precautions; Perform above mentioned active exercises, 3 sessions per day (1sets x 10 reps) will also be given to Group B.
62350087|NCT00680953|EXPERIMENTAL|1|Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
62350088|NCT00680953|PLACEBO_COMPARATOR|2|Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
62350089|NCT00680953|ACTIVE_COMPARATOR|3|Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
62350090|NCT00453180|EXPERIMENTAL|1|Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.
62350091|NCT00453180|PLACEBO_COMPARATOR|2|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
62350092|NCT06377722|EXPERIMENTAL|Treatment with cabozantinib prior to cytoreductive nephrectomy|To evaluate the efficacy of preoperative cabozantinib treatment as measured by the radiological response rate prior to NC in patients with advanced or metastatic renal cell cancer candidates for NC.
62350093|NCT06187311|EXPERIMENTAL|Rivaroxaban 15mg|Subjects eligible for this clinical trial will be randomly assigned to Group 1 (15 mg of rivaroxaban) or Group 2 (20 mg of rivaroxaban) at baseline visits in a 1:1 ratio.
61966057|NCT01025791|EXPERIMENTAL|Panel B, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.
61966058|NCT01025791|EXPERIMENTAL|Panel B, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
61966059|NCT01025791|EXPERIMENTAL|Panel B, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
61966060|NCT01025791|EXPERIMENTAL|Panel B, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.
61966061|NCT01025791|EXPERIMENTAL|Panel C, Mild/Moderate Hypertension, Sequence 1|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
61966062|NCT01025791|EXPERIMENTAL|Panel C, Mild/Moderate Hypertension, Sequence 2|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
61966063|NCT01025791|EXPERIMENTAL|Panel C, Mild/Moderate Hypertension, Sequence 3|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
62508376|NCT05930431|EXPERIMENTAL|Physical activity variety intervention|Participants in the variety condition will be sent the link to their condition's website via email. The variety website will contain nine distinct high intensity interval training (HIIT) videos. The videos will be 30-minutes containing a five-minute warm-up, 20-minute workout, and a five-minute cool down. The website will emphasize the importance of having variety in one's physical activity routine. This will include reminders to have variety in selected workouts and the benefits associated with doing so. This emphasis will be supported through the counseling sessions provided to participants in the variety condition.
62715027|NCT03364153|SHAM_COMPARATOR|Sham|Participants will receive a matching sham monthly for up to 17 Months.
61966064|NCT01025791|EXPERIMENTAL|Panel C, Mild/Moderate Hypertension, Sequence 4|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
61966065|NCT01025791|EXPERIMENTAL|Panel C, Mild/Moderate Hypertension, Sequence 5|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
61966066|NCT01025791|PLACEBO_COMPARATOR|Panel C, Mild/Moderate Hypertension, Sequence 6|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na
61966067|NCT00825591|ACTIVE_COMPARATOR|1|Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.
61966068|NCT00825591|PLACEBO_COMPARATOR|2|
61966069|NCT04235478|EXPERIMENTAL|Cervical interlaminar epidural steroid injecion|Floroscopy-guided cervical interlaminar epidural steroid injecion will be applied to the patients with cervical radiculopathy related neck and arm pain
61966070|NCT04654130|EXPERIMENTAL|Neurofeedback (NFB)|Participants in the NFB condition will complete 19 weekly sessions of NFB from home with research staff supervision (via videoconferencing), and pre-, post- and 3-month follow-up assessments.
61966071|NCT04654130|NO_INTERVENTION|Wait List|Participants in the Wait List condition will receive no NFB for approximately 31 weeks, and will be asked to complete pre-, post- and 3-month follow-up assessments. After study completion, they will be offered the same 19 weeks of NFB.
62350094|NCT06187311|EXPERIMENTAL|Rivaroxaban 20mg|Subjects eligible for this clinical trial will be randomly assigned to Group 1 (15 mg of rivaroxaban) or Group 2 (20 mg of rivaroxaban) at baseline visits in a 1:1 ratio.
62350095|NCT00856258|PLACEBO_COMPARATOR|Cohort 1|Cohort 1 completed.
62350096|NCT00856258|PLACEBO_COMPARATOR|Cohort 2|Cohort 2 not studied
62350097|NCT00856258|PLACEBO_COMPARATOR|Cohort 3|Cohort 3 not studied
62350098|NCT00856258|PLACEBO_COMPARATOR|Cohort 4|Cohort 4 not studied
62350099|NCT03659760|EXPERIMENTAL|Group Isolated|Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)
62350100|NCT03659760|NO_INTERVENTION|Group Disrupted|Group Disrupted (Group I) (exposed to ambient light and noise)
62350101|NCT00920036|EXPERIMENTAL|Arm 1|Eight subjects were trained to utilize a handheld biofeedback device
62350102|NCT00920036|NO_INTERVENTION|Arm 2|usual care
62350103|NCT02714504|NO_INTERVENTION|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
62350104|NCT02714504|EXPERIMENTAL|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
62350105|NCT02992834|ACTIVE_COMPARATOR|IL-2 pre-treated CD19 cells|Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
62350106|NCT02992834|ACTIVE_COMPARATOR|IL-7/IL-15 pre-treated CD19 cells|Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
62350107|NCT02850952|EXPERIMENTAL|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
62350108|NCT01993615|ACTIVE_COMPARATOR|Arthroscopic Surgery|Arthroscopic surgery at the femoroacetabular joint, followed by a standardized post-operative rehabilitation protocol in physical therapy.
62350109|NCT01993615|ACTIVE_COMPARATOR|Physical Therapy|An impairment-based supervised in-clinic physical therapy program.
62706351|NCT05775445||Group 2 (minor CAD, high risk factors)|"1. No evidence of significant CAD~   a. Coronary angiogram or CT coronary angiogram with \<50% stenosis in major blood vessel/branch~2. No prior history of clinical CAD, PAD or CVA~   with one of the~3. Age \>65 with~   1. Diabetes mellitus \>5years; or~  2. End Stage Renal Failure (ESRF), regardless of duration or~  3. Framingham risk score \> 10%~4. Diabetes \>10 years~5. End Stage Renal Failure (ESRF) \> 5 years~6. Age \>80"
62508377|NCT05930431|ACTIVE_COMPARATOR|Physical activity consistency comparison condition|Upon the completion of randomization, participants in the consistency condition will be sent the link to their condition's website via email. The consistency website will contain one HIIT video. The video will be 30-minutes and include a five-minute warm-up, 20-minute workout, and a five-minute cool down. The website will emphasize the importance of having consistency in one's physical activity routine. This will include reminders to be consistent in workouts and the benefits associated with doing so (Guiney \& Machado, 2013). This emphasis will be supported through the counseling sessions provided to participants in the consistency condition.
62706352|NCT05775445||Group 3 (signifcant CAD, high risk factors)|"1. Evidence of significant CAD with one of the following:~1. age\>65~2. Diabetes mellitus~3. End Stage Renal Failure (ESRF)~4. Framingham risk score \>10%"
62706353|NCT05775445||Group 4 Control group|"1. No evidence of significant CAD and all of the following:~1. Age \<55 for males, \<65 for females~2. Absence of diabetes mellitus~3. Absence of CKD~4. Absence of tobacco use"
62706354|NCT02666560|ACTIVE_COMPARATOR|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
62706355|NCT02666560|EXPERIMENTAL|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
61966072|NCT02596308|EXPERIMENTAL|15µg vaccine|15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
61966073|NCT02596308|EXPERIMENTAL|30µg vaccine|30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
62706356|NCT01645202|ACTIVE_COMPARATOR|TAVI with Edwards Sapien XT valve|
62706357|NCT01645202|ACTIVE_COMPARATOR|TAVI with Medtronic CoreValve|
62706358|NCT04149743|NO_INTERVENTION|Randomized Standard of Care|Standard of Care
62706359|NCT04149743|ACTIVE_COMPARATOR|Randomized Standard of Care with HEMOTAG|Standard of Care with HEMOTAG
62706360|NCT04794933|ACTIVE_COMPARATOR|Conventional therapy (CT)|Cold pack (15 minutes); pulsed ultrasound therapy (1 watt/cm², 3 MHz, 1:2 pulsed mode; 3 minutes); transcutaneous electrical nerve stimulation (60-120 Hz; 20 minutes) and exercises (20 minutes). The exercises included stretching, strengthening and posture exercises.
62706361|NCT04794933|EXPERIMENTAL|CT+ PNF in extremity pattern|PNF in the extremity pattern, were instructed to actively move through the PNF flexion-abduction-external rotation diagonal pattern for 10 repetitions with manual facilitation and the treatment was performed within the range in which pain did not occur. Rhythmic stabilization and repeated contractions were applied from the PNF techniques.
62706362|NCT04794933|EXPERIMENTAL|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|PNF in scapula and upper trunk patterns in addition to PNF in the extremity pattern. The scapular pattern application was performed by positioning the affected extremity in a relaxed position above the stable side in the side-lying position. Rhythmic stabilization and repeated contractions were applied from the anterior-elevation position in the direction of posterior-depression. Extension, lateral flexion and rotation to the affected side were performed in the trunk patterns in rhythmic stabilization and repeated contractions.
61966074|NCT05238441|EXPERIMENTAL|SCTV01E and SCTV01E|SCTV01E on D0 and D180
61966075|NCT05238441|ACTIVE_COMPARATOR|Comirnaty and SCTV01E|Comirnaty on D0 and SCTV01E on D180
62706363|NCT04694911||Health Services Research (focus group, interview, OOCAT)|"FOCUS GROUP: Patients participate in focus group session over 60-90 minutes.~COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT.~FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference."
62706364|NCT00861887|ACTIVE_COMPARATOR|Vancomycin|Vancomycin 125 mg every 6 hours x 4 weeks
62706365|NCT00861887|PLACEBO_COMPARATOR|Placebo|Vancomycin 125 mg every 6 hours x 2 weeks, followed by placebo every 6 hours x 2 weeks
61966076|NCT05238441|ACTIVE_COMPARATOR|Comirnaty and Comirnaty|Comirnaty on D0 and D180
62508378|NCT05230602|EXPERIMENTAL|Study Group|The participants will fill the study scales and will be instructed to eat the tzabar fruit twice a day for two weeks
62706366|NCT01974284|EXPERIMENTAL|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
62706367|NCT06564753|PLACEBO_COMPARATOR|Placebo Comparator: NA-931(Placebo)|Placebo Comparator: NA-931(Placebo) Placebo
61966077|NCT02016053||cirrhosis with baseline renal function|500 patients of cirrhosis with normal baseline renal function will be enrolled.
61966078|NCT02016053||Cirrhosis with Acute Kidney Injury (AKI).|Cirrhotics patients who present with AKI (Acute Kidney Injury) will be enrolled.
61966079|NCT00911053|NO_INTERVENTION|Baseline|
61966080|NCT00911053|EXPERIMENTAL|Melatonin|Subjects will be administered melatonin.
61966081|NCT00911053|EXPERIMENTAL|Light|
61966082|NCT00911053|EXPERIMENTAL|Regular Sleep Schedule|
61966083|NCT00911053|NO_INTERVENTION|Longitudinal Monitoring|Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
62144843|NCT04903080|EXPERIMENTAL|Treatment (HER2 CAR T cells), Surgical Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0 followed by surgical tumor resection 4-6 weeks following HER2 CAR T cell infusion. Treatment repeats every 8 to 15 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
62508379|NCT05230602|NO_INTERVENTION|Control Group|The participants will fill the study scales and will be instructed not to change their diet for two weeks
62508380|NCT06200584|NO_INTERVENTION|control|normal healthy individuals
62508381|NCT06200584|EXPERIMENTAL|psychotic patients|treatment given
61966084|NCT02088047|EXPERIMENTAL|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
61966085|NCT02088047|NO_INTERVENTION|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
62508382|NCT03653026|EXPERIMENTAL|Upadacitinib 45 mg|Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period.
62508383|NCT03653026|PLACEBO_COMPARATOR|Placebo|Participants received placebo matching to upadacitinib once daily for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period.
62508384|NCT04251858|EXPERIMENTAL|Athletes with oral problems|Athletes with periodontal diseases or gingivitis
62508385|NCT04251858|NO_INTERVENTION|Athletes without oral problems|Athletes diagnosed without oral problems
62350110|NCT03200093|EXPERIMENTAL|Oral vancomycin|"Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.~Taken by mouth once daily for:~1. If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.~2. If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days."
62508386|NCT04612530|ACTIVE_COMPARATOR|Arm A: Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will start with the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
62508387|NCT04612530|EXPERIMENTAL|Arm B: IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will first receive (an incomplete) IRE of the primary pancreatic tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
62706368|NCT06564753|EXPERIMENTAL|Experimental: NA-931 - daily orally (Dose #1)|Experimental: NA-931 - daily orally (Dose #1) NA-931 is a peptide quadruple receptor agonist of Insulin-like Growth Hormone 1 (IGF-1), Glucagon-Like Peptide 1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon Receptor
62350111|NCT03200093|PLACEBO_COMPARATOR|Placebo arm|"Ora-Sweet 5 mL~Taken by mouth once daily for:~1. If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.~2. If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days."
62508388|NCT04612530|EXPERIMENTAL|Arm C: CpG + IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), a toll-like receptor ligand (CpG) will be administered into the primary pancreatic tumor. A week later, the patient will receive (an incomplete) IRE of the primary tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
62508389|NCT04307472|NO_INTERVENTION|Control|Control arm will receive no intervention.
62508390|NCT04307472|EXPERIMENTAL|Clinician nudge|"The clinician nudge using an active choice intervention in the electronic health record will be delivered to the clinician during the patient's visit. This will be through a Best Practice Advisory that describes the guideline criteria for which the patient is eligible for statin therapy, provides pre-selected options for a statin with alternative options.~The clinician nudge using monthly peer comparison messages will be sent as an inbox message through the electronic health record. Clinicians will be told what percent of their eligible patients have been prescribed a statin and how that compares to peer clinicians at Penn Medicine."
62508391|NCT04307472|EXPERIMENTAL|Patient nudge|The patient nudge will be a text message. Patients with a visit scheduled with their primary care clinician will be identified and sent this text 72 hours before their scheduled visit. The text will remind them of the visit, inform them of their eligibility for a statin, describe the benefits and risks of statin therapy, and ask the patient to discuss statin therapy with their primary care clinician during the visit.
62508392|NCT04307472|EXPERIMENTAL|Clinician Nudge and Patient Nudge|The clinician nudge and patient nudge will be implemented.
62508393|NCT01765751|ACTIVE_COMPARATOR|Manual Cervical Distraction High Force|Manual Cervical Distraction forces will be limited to greater than 50N in the high force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
62508394|NCT01765751|ACTIVE_COMPARATOR|Manual Cervical Distraction Medium Force|Manual Cervical Distraction forces will be limited to between 20N-50N in the medium force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
62508395|NCT01765751|SHAM_COMPARATOR|Manual Cervical Distraction Low Force|Manual Cervical Distraction forces will be limited to less than 20N in the low force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
62508396|NCT01376206||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
62508397|NCT00699244|EXPERIMENTAL|Peripheral placement of local anesthesia|to receive ultrasound guided peripheral placement of local anesthetic
62508398|NCT00699244|ACTIVE_COMPARATOR|Central placement of local anesthesia|to receive central placement of local anesthetic
62508399|NCT06404541|ACTIVE_COMPARATOR|Group A|20 eyes received single dose unit Dexathalm containing: actives: In 1ml: Dexamethason 1mg and Netilimicin 3mg, without preservatives 5 times per day.
61966086|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
62706369|NCT06564753|EXPERIMENTAL|Experimental: NA-931 - daily orally (Dose #2)|Experimental: NA-931 - daily orally (Dose #2) NA-931 is a peptide quadruple receptor agonist of Insulin-like Growth Hormone 1 (IGF-1), Glucagon-Like Peptide 1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon Receptor
61966087|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
61966088|NCT01927367|OTHER|Clinical Decision Support System for AF|Providers randomized to use the Clinical Decision Support System (CDSS, a web-based tool).
61966089|NCT01927367|NO_INTERVENTION|Usual Care|Usual Care - providers are not eligible to access / use the CDSS.
62706370|NCT06564753|EXPERIMENTAL|Experimental: NA-931 - daily orally (Dose #3)|Experimental: NA-931 - daily orally (Dose #3) NA-931 is a peptide quadruple receptor agonist of Insulin-like Growth Hormone 1 (IGF-1), Glucagon-Like Peptide 1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon Receptor
62706371|NCT06564753|EXPERIMENTAL|Experimental: NA-931 - daily orally (Dose #4)|Experimental: NA-931 - daily orally (Dose #4) NA-931 is a peptide quadruple receptor agonist of Insulin-like Growth Hormone 1 (IGF-1), Glucagon-Like Peptide 1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon Receptor
62706372|NCT03561311|EXPERIMENTAL|Remote ischemic conditioning group|
62706373|NCT03561311|SHAM_COMPARATOR|Sham remote ischemic conditioning group|
62706374|NCT05789251|EXPERIMENTAL|Standardized breakfast to replace in fine oral induced hyperglycemia test|Standardized breakfast to replace in fine oral induced hyperglycemia test
62706375|NCT01333436|EXPERIMENTAL|Diabetic participants|Diabetic participants with normal to moderately high LDL-C
62706376|NCT01333436|EXPERIMENTAL|Nondiabetic participants|Non-diabetic participants with normal to moderately high LDL-C
62706377|NCT03455686|EXPERIMENTAL|Patients with and without lung disease|All enrolled patients will undergo pulmonary function testing, questionnaires, 1H MRI, static ventilation and/or diffusion-weighted hyperpolarized 129Xe MRI and sputum induction at one or more timepoints over five years.
62706378|NCT05539482|EXPERIMENTAL|Community-Based Health Education Group|The collaborators will design the Community-based education approach (based on the core intervention package). Collaborators will be required to submit a brief standardized proposal to the academic investigators for review and approval, to ensure that all intervention programs have the same core intervention content and can be implemented appropriately. Collaborators will be able to use any reasonable strategies, such as social media platforms, information technology, posters, leaflets, and videos, to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.
62715028|NCT01621178|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
61966090|NCT03733834||SD therapy|SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
61966091|NCT03733834||NSD therapy|Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
62144844|NCT06510985|EXPERIMENTAL|Monitoring with high/low-intensity stimulation|The cross-over design includes one group which starts with high-intensity stimulation (n = 40) and another group, who starts with low-intensity stimulation (n = 40). The first group receives at first high-intensity for 6 weeks, followed by a low-intensity stimulation phase for 6 weeks. To control for placebo effects, other forty individuals start with the 6-week low-intensity stimulation phase followed by 6 weeks of high-intensity tVNS stimulation phase.
62508400|NCT06404541|ACTIVE_COMPARATOR|Group B|20 eyes received regular Tobradex eye drops containing actives: In 1 ml: tobramycin 3 mg and dexamethasone 1 mg, preservative: 0.1mg of BAK per ml 5 times per day.
62508401|NCT06404541|ACTIVE_COMPARATOR|Group C|20 eyes received Dexathalm multi-dose containing actives: In 1ml: Dexamethasone 1mg and Netilimicin 3mg, preservatives: 0.05mg of BAK per ml 5 times per day.
61966092|NCT02658929|EXPERIMENTAL|bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy
61966093|NCT05695898|EXPERIMENTAL|Phase 1b: Dose Escalation (Cohort 1)|Participants will receive 0.3 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 \& 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
61966094|NCT05695898|EXPERIMENTAL|Phase 1b: Dose Escalation (Cohort 2)|After the safety and tolerability for cohort 1 has been evaluated, participants will receive 1 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 \& 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
62144845|NCT06510985|EXPERIMENTAL|Monitoring without stimulation|"Another group of patients is included as a control group (n = 40) undergoing 'treatment as usual' for Long/Post Covid. This group of participants receive the same monitoring throughout their participation during 12 weeks as the Stimulation-Group. As there is no standardized treatment protocol for Long/Post Covid, 'treatment as usual' implies a supportive approach.~This group of participants have the option to receive taVNS stimulation after participating in the study."
62144846|NCT04555668|EXPERIMENTAL|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch
62144847|NCT04555668|ACTIVE_COMPARATOR|Hamstring Stretch Program|Hamstring Stretch Program and Knee -flexor eccentric training
62350112|NCT03978104|EXPERIMENTAL|Okara biscuits|Subjects will consume their habitual diet with daily okara biscuit consumption accounting to 20 grams/ day of dry okara powder for 21 days.
62508402|NCT02367287||Sampling strata|Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.
62508403|NCT02604576|EXPERIMENTAL|Group 1|FDC Bromopride 10 mg and Simethicone 80 mg
62350113|NCT03978104|EXPERIMENTAL|Bio-okara biscuits|Subjects will consume their habitual diet with daily bio-okara biscuit consumption accounting to 20 grams/ day of dry bio-okara powder for 21 days.
62508404|NCT02604576|ACTIVE_COMPARATOR|Group 2|Bromopride 10 mg (Digesan ® - Sanofi Aventis)
62508405|NCT05488886|EXPERIMENTAL|A: Whole Aronia Berry Powder|
62508406|NCT05488886|EXPERIMENTAL|B: Aronia Berry Extract|
61966095|NCT05695898|EXPERIMENTAL|Phase 1b: Dose Escalation (Cohort 3)|After the safety and tolerability for cohort 2 has been evaluated, participants will receive 3 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 \& 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
62350114|NCT03978104|EXPERIMENTAL|Control biscuits|Subjects will consume their habitual diet with daily control biscuit consumption for 21 days.
62508407|NCT05488886|EXPERIMENTAL|C: Phospholipid-Polyphenol|
62508408|NCT05488886|EXPERIMENTAL|D: Low-Polyphenol Control|
62508409|NCT04174716|EXPERIMENTAL|IDX-1197|Patient will be receive IDX-1197HCl once daily for 28 continuous days
62508410|NCT05854706|EXPERIMENTAL|Active arm|Prolonged iTBS sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks
62508411|NCT05854706|SHAM_COMPARATOR|Sham arm|Sham stimulation sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks
62508412|NCT04977596||Group PNETs|The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018
62508413|NCT04977596||Group PDAC|Patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015.
62508414|NCT01431443|EXPERIMENTAL|Dark chocolate|
62508415|NCT01431443|PLACEBO_COMPARATOR|Placebo chocolate|Placebo intervention
62508416|NCT04913519|EXPERIMENTAL|SAD Cohorts 1 -3 TDM-105795 topical solution|Single dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01%
62508417|NCT04913519|PLACEBO_COMPARATOR|Placebo for TDM-105795 topical solution|Single dose administration of Placebo forTDM-105795 Topical Solution
62508418|NCT02138981|ACTIVE_COMPARATOR|Immediate Resection|patients received immediate surgical hepatic resection
62706379|NCT05539482|ACTIVE_COMPARATOR|Health Information Sharing Group|The collaborators will design the community-based education approach and deliver health information to the participants. Researchers will provide some information, while collaborators need to self-collect the rest. Collaborators also need to submit a proposal to ensure the feasibility of intervention programs and the accuracy of health information. Collaborators can use any reasonable strategies to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.
62508419|NCT02138981|EXPERIMENTAL|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
62508420|NCT00478049|ACTIVE_COMPARATOR|1|Docetaxel
62706380|NCT01047540|EXPERIMENTAL|Dose regimen 1|
62706381|NCT01047540|EXPERIMENTAL|Dose regimen 2|
62350115|NCT02494778|EXPERIMENTAL|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
62508421|NCT00478049|EXPERIMENTAL|2|Gefitinib
62508422|NCT02340689||Genetic testing|Genetic Analysis
62508423|NCT01684059||Single group|Single group: each participant receive same intervention (zinc sulfate) throughout study (non-randomized)
62508424|NCT04675775|EXPERIMENTAL|Medically-tailored meals|Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than or equal to 2000 milligrams a day).
62508425|NCT01473147|ACTIVE_COMPARATOR|GLP-1|
62706382|NCT01047540|EXPERIMENTAL|Dose regimen 3|
62706383|NCT01047540|EXPERIMENTAL|Dose regimen 4|
62508426|NCT01473147|PLACEBO_COMPARATOR|Normal saline|
62508427|NCT02317250|EXPERIMENTAL|prompt amyloid imaging, delayed FDG-PET|Subject's managing physicians will be given the results of amyloid imaging scans immediately. FDG-PET results will be released two years after scanning.
62508428|NCT02317250|EXPERIMENTAL|prompt FDG-PET, delayed amyloid imaging|Subject's managing physicians will be given the results of FDG-PET scans immediately. Amyloid imaging results will be released two years after scanning.
62508429|NCT02317250|EXPERIMENTAL|prompt FDG-PET, prompt amyloid imaging|Both FDG-PET and amyloid imaging scan results will be made immediately available to the managing physician.
62508430|NCT02317250|ACTIVE_COMPARATOR|delayed FDG-PET, delayed amyloid imaging|Neither FDG-PET nor amyloid imaging scan results will be released to the managing physician for 2 years.
62508431|NCT03777345|ACTIVE_COMPARATOR|cobalt-chromium framework partial dentures|It's the gold standard biocompatible metal alloy used in thin sections, provide high strength and stiffness ,conduct heat and cold for a more natural experience, and is resistant to corrosion but their disadvantages include esthetic issues with metal display, oral galvanism, adverse tissue reactions,and osteolysis of abutment teeth.
62508432|NCT03777345|EXPERIMENTAL|PEEK framework partial dentures|It's a promising polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
62508433|NCT04815850||Patients on haemodialysis|Patients receiving haemodialysis
62706384|NCT01047540|PLACEBO_COMPARATOR|Placebo|
62508434|NCT04815850||Healthy controls|Participants with no chronic kidney disease or history of immunosuppression
61966096|NCT01423058|EXPERIMENTAL|Momelotinib|
62144848|NCT00307216|EXPERIMENTAL|1|Participants will receive Graduated Recovery Intervention Program plus treatment as usual
62508435|NCT01955044|EXPERIMENTAL|"high dose LCPUFA"|"the high dose LCPUFA supplement is a drop that will be administered to ELBW infants."
62508436|NCT01955044|EXPERIMENTAL|"low dose LCPUFA"|"the low dose LCPUFA supplement is a drop that will be administered to ELBW infants."
62508437|NCT01955044|PLACEBO_COMPARATOR|placebo|"the placebo is a drop that will be administered to ELBW infants."
62508438|NCT00628979|OTHER|1|CBT
62508439|NCT00475917|EXPERIMENTAL|1|
62508440|NCT04421976|PLACEBO_COMPARATOR|Conventional PEEP|PEEP = 5 cmH2O
62508441|NCT04421976|EXPERIMENTAL|Driving pressure (DP) guided-PEEP|PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
62508442|NCT01446224||Subjects who experience cardiac ischemia|Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident
62508443|NCT01446224||Subjects who do not experience cardiac ischemia|Subjects who do not experience cardiac ischemia
62508444|NCT01446224||Subjects who experience Torsades de Pointes|Subjects who experience Torsades de Pointes
62508445|NCT01446224||Subjects who do not experience Torsades de Pointes|Subjects who do not experience Torsades de Pointes
62508446|NCT03371329|EXPERIMENTAL|Group 1 MSC dose .5 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10\^6/kg for 3 participants.
62508447|NCT03371329|EXPERIMENTAL|Group 2 MSC dose 1 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10\^6/kg for next 3 participants.
62508448|NCT03371329|EXPERIMENTAL|Group 3 MSC dose 2 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10\^6/kg for next 3 participants.
62508449|NCT03371329|EXPERIMENTAL|Group 4 MSC dose 0.5 x 10^6/kg I|Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10\^6/kg for final 3 participants.
61966097|NCT01654536|EXPERIMENTAL|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg
62508450|NCT04252287|EXPERIMENTAL|Canagliflozin 100 mg|Participants will be administered 100 milligram (mg) immediate-release, over-encapsulated tablets (as a capsule) orally once daily for 12 weeks.
62508451|NCT04252287|PLACEBO_COMPARATOR|Placebo|Participants will be administered matching placebo capsules orally once daily for 12 weeks.
62508452|NCT03877341|ACTIVE_COMPARATOR|PLF|posterolateral fusion
62508453|NCT03877341|ACTIVE_COMPARATOR|PLIF|posterior lumbar interbody fusion
62508454|NCT01950676|NO_INTERVENTION|Control|Individuals in the control group will not use the smart phone application
62508455|NCT01950676|EXPERIMENTAL|Intervention|Individuals in the intervention group will use the smart phone application in insulin titration
62508456|NCT02235714||Tetraplegia|Individuals with chronic tetraplegia
61966098|NCT01654536|ACTIVE_COMPARATOR|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg
61966099|NCT03183076|ACTIVE_COMPARATOR|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
61966100|NCT03183076|ACTIVE_COMPARATOR|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
62144849|NCT00307216|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual
62508457|NCT02235714||Asthma|Individuals with mild asthma
62144850|NCT02695199|EXPERIMENTAL|laparoscopic varicocelectomy|laparoscopic Doppler ultrasound assisted laparoscopic varicocelectomy group
62144851|NCT02695199|SHAM_COMPARATOR|microscopic varicocelectomy|conventional Microscopic Subinguinal varicocelectomy group
62508458|NCT02235714||Able-bodied controls|Age matched able-bodied (AB) controls with no history of lung disease
62508459|NCT00865007|EXPERIMENTAL|Monotherapy group|Lopinavir/ritonavir (LPV/r).
62508460|NCT00865007|ACTIVE_COMPARATOR|Triple arm|Lopinavir/ritonavir (LPV/r)+ ABC/3TC
62508461|NCT00686244|EXPERIMENTAL|Training Group|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
62508462|NCT00686244|NO_INTERVENTION|Control Group|No guided training. Exercise optional after detailed consulting and handing over an information dossier for adequate physical activity.
62508463|NCT03839277|ACTIVE_COMPARATOR|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
62508464|NCT03839277|NO_INTERVENTION|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
62508465|NCT04906330||PPHM-0000-21|50-70 year old female patients, without a personal history of oncological pathology, who attend for gynecological and mammographic control.
62508466|NCT05282108||Carcemia group|The cohort treated with Carcemia
62508467|NCT05282108||Glivec Group|The cohort treated with Glivec
62508468|NCT05863559|EXPERIMENTAL|Treatment|After completing baseline data collection, families randomized to the intervention group will receive the 4-session prototype over a period of up to 6 weeks. This will allow for illness, family vacations, school holidays, and scheduling conflicts. After completing session 4, the family will proceed to post assessment. The investigators have successfully used this approach in previous interventions. It is anticipated each session will take \~1.5 hrs to complete (online phase - \~30 minutes; home phase - \~1 hr). The parent and child will each be assigned a password with which to login to the online phase. Parents and children will be asked to keep their password private. Each will need to login at the same time to view each new online session. The session can be viewed by parent or child separately or together after the initial viewing.
62508469|NCT05863559|NO_INTERVENTION|Wait-list control|Families randomized to this group will receive the intervention after the dyad completes both baseline and post intervention data collection.
62508470|NCT05685524||Cancer group|Patients aged 18 years or older with high suspicion of cancer diagnosed by endoscopy, other imaging tests, pathological examinations, etc. The cancer types include liver cancer, head and neck squamous cell carcinoma, esophageal cancer, pancreatic cancer, ovarian cancer, colorectal cancer, bladder cancer, cervical cancer, lung cancer and stomach cancer.
62508471|NCT05685524||Non-cancer group|Composed by healthy individuals and patients with non-cancerous diseases including hemorrhoids, enteritis, gastritis, tuberculosis and other non-cancerous diseases.
62508472|NCT01520883||DEcisional conflict|
62508473|NCT01897623|OTHER|ultrasound of aorta|
62508474|NCT06617000|EXPERIMENTAL|SCG101|
62508475|NCT03322020|EXPERIMENTAL|CK 18 Gy|Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions
62508476|NCT03322020|EXPERIMENTAL|CK 21 Gy|Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions
62508477|NCT01221831|EXPERIMENTAL|estetrol dose 1 / P1|
62508478|NCT01221831|EXPERIMENTAL|estetrol dose 1 / P2|
62508479|NCT01221831|ACTIVE_COMPARATOR|estradiol valerate/dienogest pill|
62350116|NCT02750267|EXPERIMENTAL|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
62350117|NCT02750267|EXPERIMENTAL|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
62350118|NCT04779632|OTHER|Crossover study: Fish Oil --> Safflower Oil|4 weeks of fish oil supplementation followed by 4 weeks of safflower oil supplementation
62508480|NCT01221831|EXPERIMENTAL|estetrol dose 2 / P1|
62508481|NCT01221831|EXPERIMENTAL|estetrol dose 2 / P2|
62508482|NCT05265065|ACTIVE_COMPARATOR|AstraZeneca (ChAdOx1-S, or Vaxzevria®) - Standard Pfizer-BioNTech booster group|Previously received two doses of AstraZeneca as primary COVID-19 vaccine
62508483|NCT05265065|EXPERIMENTAL|AstraZeneca (ChAdOx1-S, or Vaxzevria®) - Fractional Pfizer-BioNTech booster group|"Previously received two doses of AstraZeneca as primary COVID-19 vaccine~."
62508484|NCT05265065|ACTIVE_COMPARATOR|Sinopharm (BBIBP-CorV®)- Standard Pfizer-BioNTech booster group|Previously received two doses of Sinopharm as primary COVID-19 vaccine
62508485|NCT05265065|EXPERIMENTAL|Sinopharm (BBIBP-CorV®)- Fractional Pfizer-BioNTech booster group|Previously received two doses of Sinopharm as primary COVID-19 vaccine
62706385|NCT05809947|EXPERIMENTAL|Growth hormone/somatropin|Somatropin over two weeks (33.3 ug/kg/day in the first week, 50 ug/kg/day in the second week)
62350119|NCT04779632|OTHER|Crossover study: Safflower Oil --> Fish Oil|4 weeks of safflower oil supplementation followed by 4 weeks of fish oil supplementation
62350120|NCT04736329|ACTIVE_COMPARATOR|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of their heart failure therapy.
62706386|NCT05809947|PLACEBO_COMPARATOR|Placebo|Injections of placebo/saline over two weeks
62706387|NCT02018211|EXPERIMENTAL|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
62706388|NCT03735914|EXPERIMENTAL|neuralgic patients|MRI experimentation
61966101|NCT00751270|EXPERIMENTAL|A|Arm A for unresectable malignant glioma was closed due to poor accrual.
62144852|NCT04707807||Nightshift workers|
62350121|NCT04736329|NO_INTERVENTION|Enalapril|Enalapril (2.5 up to 20mg ) for RAAS inhibition, as part of their heart failure therapy.
62350122|NCT06048653|EXPERIMENTAL|control group|The control group (GI) will receive a computer based cognitive rehabilitation program (Rehacom system)
62350123|NCT06048653|EXPERIMENTAL|study group|The study group (GII) will receive a computer based cognitive rehabilitation program (Rehacom system) in addition to Vagus nerve stimulation.
62508486|NCT05265065|ACTIVE_COMPARATOR|Sputnik V (Gam-COVID-Vac®)- Standard Pfizer-BioNTech booster group|Previously received two doses of Sputnik as primary COVID-19 vaccine
62508487|NCT05265065|EXPERIMENTAL|Sputnik V (Gam-COVID-Vac®)- Fractional Pfizer-BioNTech booster group|Previously received two doses of Sputnik as primary COVID-19 vaccine
62508488|NCT06449755|OTHER|Elastic Nail|Percutaneous antegrade elastic nail fixation
62508489|NCT06449755|OTHER|Screw|Percutaneous retrograde screw fixation
62508490|NCT04615533||Frail older adults, assessment|Frail older adults, assessment Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinetti Blance and Gait Scale
62508491|NCT04077242|ACTIVE_COMPARATOR|"Parryscope-group"|"In these patients, Fallopian tube patency is assessed using the Parryscope technique. A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed."
62508492|NCT04077242|ACTIVE_COMPARATOR|"Tubal flow-group"|"In these patients, Fallopian tube patency is assessed using the flow technique. a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
62508493|NCT01168687|EXPERIMENTAL|Group A|Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
62706389|NCT05970328||Arrhythmia Participant|Non-critical adult (21 years and older) participants that are suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour Holter monitor.
62144853|NCT04707807||Non-nightshift workers|
62144854|NCT01138384|EXPERIMENTAL|Foretinib and Lapatinib|Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1.
62144855|NCT01524497|ACTIVE_COMPARATOR|Trazodone|
62144856|NCT01524497|PLACEBO_COMPARATOR|Placebo|
62144857|NCT01661972|EXPERIMENTAL|Phase 1: Capecitabine and Aflibercept|A standard 3+3 dose escalation format will be used. Capecitabine will start at 850mg/m2 to be given on days 1-14 and off days 15-21. If tolerated, the dose will then be escalated to 1000mg/m2 for the next cohort, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
62144858|NCT01661972|EXPERIMENTAL|Phase 2: Capecitabine and Aflibercept|Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single, Phase 2 arm
62144859|NCT04284878||A|patients with inflammatory bowel disease
62508494|NCT01168687|EXPERIMENTAL|Group B|Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
62508495|NCT05069233||UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
62508496|NCT04418531|EXPERIMENTAL|Experimental antibodies (immunoglobulins) infusion|Anti-coronavirus obtained with double-filtration plasmapheresis (DFPP) from convalescent patients
62508497|NCT03034434||Patients after vaginal delivery|Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery.
62508498|NCT00745719|EXPERIMENTAL|1|surgical total parathyroidectomy with forearm autografting
62144860|NCT04284878||B|healthy subjects
62144861|NCT05749237|ACTIVE_COMPARATOR|Active group|children older than 10 years with a diagnosis of allergic asthma respiratory and relaxation exercises
62144862|NCT05749237|PLACEBO_COMPARATOR|Placebo group|children older than 10 years with a diagnosis of allergic asthma only relaxation exercises
62144863|NCT03398668|ACTIVE_COMPARATOR|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
62144864|NCT03398668|SHAM_COMPARATOR|Sham Comparator: Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
62144865|NCT03031743||rotavirus (Rotarix TM) vaccination|Infants who received rotavirus vaccination (Rotarix TM) at 6 and 10 weeks, 10 and 14 weeks or 6,10, and 14 weeks. This is a nested study and infants received the vaccination in the overarching study: The Immunogenicity of ROtavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine (clinicaltrials.gov: NCT01199874)
62350124|NCT02780479|EXPERIMENTAL|Dexamethasone|Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
62508499|NCT05892484|EXPERIMENTAL|Thermal Imaging|Participants will receive thermal imaging in addition to their routine x-ray for comparison.
62508500|NCT05892484|OTHER|X-ray|Routine x-ray is what the active comparator is being evaluated against.
62508501|NCT06474299|ACTIVE_COMPARATOR|Varenicline, Dual Focused, 1 session|
62508502|NCT06474299|ACTIVE_COMPARATOR|Varenicline, Dual Focused, 4 sessions|
62508503|NCT06474299|ACTIVE_COMPARATOR|Varenicline, Smoking Focused, 1 session|
62508504|NCT06474299|ACTIVE_COMPARATOR|Varenicline, Smoking Focused, 4 sessions|
62508505|NCT06474299|ACTIVE_COMPARATOR|Nicotine Patches, Dual Focused, 1 session|
62144866|NCT04580004|EXPERIMENTAL|Medication Optimization Group|Patients randomized to the medication optimization group will receive an evidence-based medication recommendation intervention.
62706390|NCT04342247||androgen deficient|
62706391|NCT04342247||healthy|
62508506|NCT06474299|ACTIVE_COMPARATOR|Nicotine Patches, Dual Focused, 4 sessions|
62508507|NCT06474299|ACTIVE_COMPARATOR|Nicotine Patches, Smoking Focused, 1 session|
62508508|NCT06474299|ACTIVE_COMPARATOR|Nicotine Patches, Smoking Focused, 4 sessions|
62508509|NCT02853175||Patients with both CF and ABPA|"Patients with both cystic fibrosis and allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
62508510|NCT02853175||Patients with CF and no ABPA|"Patients with both cystic fibrosis and no allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
62508511|NCT06422494|ACTIVE_COMPARATOR|Participants without type 1 diabetes|The participants without type 1 diabetes
62508512|NCT06422494|ACTIVE_COMPARATOR|Participants with type 1 diabetes|Participants with type 1 diabetes
62508513|NCT04980495|EXPERIMENTAL|efgartigimod IV - I|Patients receiving efgartigimod IV treatment (Continuous regimen: efgartigimod 10 mg/kg q2w)
62508514|NCT04980495|EXPERIMENTAL|efgartigimod IV - II|Patients receiving efgartigimod IV treatment (Cyclic regimen: efgartigimod 10 mg/kg q7d for a total of 4 infusions per TP for 2 TPs with a fixed 4-week IP between each TP)
62508515|NCT01731886|ACTIVE_COMPARATOR|Arm A|Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by steam cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
62715029|NCT01621178|EXPERIMENTAL|0.75 mg Dulaglutide|0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
62715030|NCT01621178|EXPERIMENTAL|1.5 mg Dulaglutide|1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
62715031|NCT03959085|EXPERIMENTAL|Arm I (HR-FAV B-ALL)|See detailed description for Arm I
61966102|NCT00751270|EXPERIMENTAL|B|Arm B for resectable malignant glioma completed the Phase I accrual and long term follow up continues. A follow on study at dose level 3 was opened as a Phase 2a study (see BrTK02).
61966103|NCT00089245|EXPERIMENTAL|Radiolabeled Monoclonal Antibody Therapy|This is a Phase I trial designed to evaluate the Maximally Tolerated Dose (MTD) of intrathecal 131I-8H9. In order to find the MTD, a dose escalation scheme will be employed with patients entering in cohorts of 3 at each dose level from 10 mCi to 60 mCi and a cohort of 6 at each dose level from 70 mCi to 100 mCi.
61966104|NCT02319889|EXPERIMENTAL|Treatment (SBRT, carboplatin, Abraxane)|Patients undergo Stereotactic Body Radiotherapy every other day for up to 14 days for a total of 5 fractions. After a break period of about 30 days, patients will then start chemotherapy. Patients will receive carboplatin IV over 30-40 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
61966105|NCT06012825||Physical Activity (PA) Round 1|All enrollees will have the opportunity to attend virtual PA sessions.
61966106|NCT06012825||Physical Activity Round 2|This second cohort is the 2nd round of intervention, which allows participants to enroll for another round, and/or newly recruited patients will have the opportunity to participate.
61966107|NCT03379532|ACTIVE_COMPARATOR|BCI-NMES|Electrical stimulation of paretic upper limb is triggered contigent to voluntary motor cortex activation of the patient, as detected by the brain-computer interface.
61966108|NCT03379532|SHAM_COMPARATOR|Sham-NMES|Electrical stimulation of paretic upper limb is applied independently of motor cortex activation of the patient by using a prerecorded session of another patient.
61966109|NCT03647397|EXPERIMENTAL|PECO|All pediatric patients admitted for respiratory distress will have the intervention of Photo Electrochemical Oxidation (PECO) for Air Purification.
61966110|NCT01288495|EXPERIMENTAL|L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
61966111|NCT01288495|PLACEBO_COMPARATOR|Placebo|Subjects will consume the placebo prior to eating fructose-containing foods.
61966112|NCT04691505||Methotrexate|Reference group
61966113|NCT04691505||Hydroxychloroquine|Exposure group
61966114|NCT04450368||Cases with Air Trapping|20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC \[FRC/TLC\])
61966115|NCT04450368||Cases without Air Trapping|20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC \[FRC/TLC\])
61966116|NCT04450368||Healthy Controls|Non COPD patients and non-smokers
61966117|NCT05015608|EXPERIMENTAL|Savolitinib + Osimertinib|Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks)
61966118|NCT05015608|ACTIVE_COMPARATOR|Pemetrexed combined with platinum|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
61966119|NCT01440660||Leaking Phenotype|Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.
61966120|NCT01440660||Ischemic Phenotype|Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate \>= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.
61966121|NCT05123768||Patients with cerebral palsy|In Slovenia, all children with cerebral palsy born in 1996 or later are included in the Slovenian National Registry of Cerebral Palsy. All patients from the Registry will be invited to participate in the study.
61966122|NCT02943278|PLACEBO_COMPARATOR|Sleep Hygiene Group|Participants assigned to the sleep hygiene group you have 1 session with a clinician to learn about different things they can do to improve their sleep.
61966123|NCT02943278|ACTIVE_COMPARATOR|Intensive Sleep Retraining Group|Participants assigned to this group will spend just over 1 day at our sleep lab, starting around your usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake the participant up after a few minutes if they fall asleep.
62144867|NCT04580004|NO_INTERVENTION|Control Group|Patients in the control group will receive the same intervention, delayed 2 weeks after the intervention group. During those initial 2 weeks they will act as a control.
62715032|NCT03959085|ACTIVE_COMPARATOR|Arm II (HR B-ALL CONTROL)|See detailed description for Arm II.
61966124|NCT05908513|ACTIVE_COMPARATOR|NAC treatment|N-acetylcysteine capsule, 600mg/day, oral, 5 years
61966125|NCT05908513|PLACEBO_COMPARATOR|Placebo|Similar chemical structure of NAC but without function
62715033|NCT03959085|EXPERIMENTAL|Arm III (HR B-ALL EXPERIMENTAL)|See detailed description for Arm III.
62715034|NCT03959085|EXPERIMENTAL|Arm IV (MPAL)|See detailed description for Arm IV.
61966126|NCT03902574|EXPERIMENTAL|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
61966127|NCT03902574|EXPERIMENTAL|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
61966128|NCT03902574|EXPERIMENTAL|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
61966129|NCT04772911||Strata A: One-time OCT Measurements|The indication for Strata A is that some participants will elect not to undergo laser treatment, particularly if they have been extensively treated with laser previously, or have a light pink vascular stain that has been stable.
61966130|NCT04772911||Strata B: Serial OCT Measurements|Participants will have serial OCT measurements of their vascular stain performed prior to the start of standard of care laser treatment. OCT will be performed prior to each standard of care laser treatment if the participant has elected to have standard of care laser treatment as treatment of their vascular stain at the time of enrollment.
62144868|NCT02226159|ACTIVE_COMPARATOR|Lidocaine|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
62144869|NCT02226159|EXPERIMENTAL|Lidocaine with Dexamethasone|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
62715035|NCT03959085|EXPERIMENTAL|ARM V (B-LLY)|See detailed description for Arm V.
62715036|NCT04461639||Damoctocog alfa pegol|Participants with hemophilia A received damoctocog alfa pegol as prophylaxis treatment prescribed by the physician as part of normal clinical practice.
62706392|NCT05765474|EXPERIMENTAL|Training with Practice Variable|All participants will practice a motor task (the Scooping Task) for 2 consecutive days. Each day of training, participants will complete 50 trials (10 blocks of 5 trials each) with their more affected arm and 20 trials (10 blocks of 2 trials each) with their less affected arm. One trial of the task will involve using a spoon to scoop beans, one at a time, from one cup to another while seated at a table. Participants will be asked to complete as many scoops as possible from the cup closest to them to the cup farthest from them within 30 seconds in an anterior-posterior direction. One successful repetition occurs when at least one bean is transferred. The number of successful repetitions within a 30 second trial is then counted. Training for the experimental group will include the practice variable of interest.
62706393|NCT05765474|OTHER|Training without Practice Variable|All participants will practice a motor task (the Scooping Task) for 2 consecutive days. Each day of training, participants will complete 50 trials (10 blocks of 5 trials each) with their more affected arm and 20 trials (10 blocks of 2 trials each) with their less affected arm. One trial of the task will involve using a spoon to scoop beans, one at a time, from one cup to another while seated at a table. Participants will be asked to complete as many scoops as possible from the cup closest to them to the cup farthest from them within 30 seconds in an anterior-posterior direction. One successful repetition occurs when at least one bean is transferred. The number of successful repetitions within a 30 second trial is then counted. Training for the control group will not include the practice variable of interest.
62706394|NCT06227949|NO_INTERVENTION|Control|subcutaneous injection of Gonal-F (FSH)
62706395|NCT06227949|EXPERIMENTAL|Intervention|subcutaneous injection of Luveris in addition to Gonal-F (FSH)
62706396|NCT02884453|EXPERIMENTAL|ibrutinib|ibrutinib delivered orally at a dose of 560mg once daily continuously on a 4 weekly cycle until disease progression or unacceptable toxicity occurs.
62706397|NCT00668759|EXPERIMENTAL|1|"Vernakalant Injection:~In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes."
62706398|NCT00668759|ACTIVE_COMPARATOR|2|"Amiodarone Injection:~In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF."
62706399|NCT02743962|ACTIVE_COMPARATOR|Usual physiotherapy treatment group|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome: dietary advice regarding fluid and fibre intake, advice regarding bladder retraining and 15 minutes manual intra-vaginal pelvic floor muscle myofascial release and gentle stretching each week for 6 weeks. They will be instructed to briefly contract and then fully relax their pelvic floor muscles independently (clothed, in a seated or lying position) for 5 minutes daily.
62706400|NCT02743962|EXPERIMENTAL|Therapeutic Wand group|This group will receive the standard specialist physiotherapy intervention for bladder pain syndrome for 6 weeks, but will also be provided with an intra-vaginal therapeutic wand and taught how to use it. They will then be asked to use the therapeutic wand at home twice a week to release and relax their pelvic floor muscles for 5 minutes.
62706401|NCT00681070|ACTIVE_COMPARATOR|Arm1: Non-absorbable sutures|use of non-absorbable sutures in facial laceration in this arm
62706402|NCT00681070|ACTIVE_COMPARATOR|Arm 2: Absorbable sutures|use of absorbable sutures in this arm
62706403|NCT00615888|ACTIVE_COMPARATOR|A|Traditional management including preoperative bowel washout, patient controlled analgesia (PCA), delayed start of enteral feeding
62706404|NCT00615888|EXPERIMENTAL|B|Fast track management including no bowel washout, patient controlled epidural anesthesia, early enteral feeding
62706405|NCT04329767||IRIS Arm|Utilize the CT scan along with the IRIS 3D model preoperatively and intraoperatively
61966131|NCT04772911||Strata C: Laser SOC without OCT|Participants will have serial evaluation with standard of care laser treatment without use of OCT.
62144870|NCT00109031|ACTIVE_COMPARATOR|Palifermin 60 µg/kg for 3 days|Palifermin 60 µg/kg plus placebo to match the total volume equivalent to a 180 µg/kg dose on the 3 days prior to fractionated total body irradiation (fTBI) and palifermin 60 µg/kg on Days 0, 1 and 2 after peripheral blood progenitor cell transplantation (PBPC). Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
62706406|NCT04329767||CT Arm|Utilize only the standard 2D CT scan preoperatively and intraoperatively
62706407|NCT03107845|ACTIVE_COMPARATOR|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
61966132|NCT03506178|EXPERIMENTAL|Obstructive sleep apnea patients|
61966133|NCT03506178|OTHER|Healthy controls|
61966134|NCT02612324|EXPERIMENTAL|Pono Choices|Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program for Middle School Youth in Hawaii. The program includes 9.5 hours of scripted lessons or modules.
61966135|NCT02612324|ACTIVE_COMPARATOR|Business as Usual|Middle school sexual health content or programs chosen by control group schools.
61966136|NCT02299297|EXPERIMENTAL|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
61966137|NCT06373627|EXPERIMENTAL|Hypnosis|Hypnosis + MEOPA + direct intravenous Ketamine (0.3 mg/kg) In the event of insufficient analgesia or failure of hypnosis, a 2nd dose of ketamine (0.3 mg/kg) may be administered.
61966138|NCT06373627|ACTIVE_COMPARATOR|Conventional sedation-analgesia|MEOPA + direct intravenous Ketamine (0.5 mg/kg) + direct intravenous Midazolam (50 µg/kg) In accordance with current service protocol.
61966139|NCT01240720|EXPERIMENTAL|I131-F16SIP|"Phase I: Multicentre, open-label, two-step singlearm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-F16SIP, given at the RD of 55.5 mCi/m2, as determined in phase I."
61966140|NCT03403660|EXPERIMENTAL|non white coat rounding|The postpartum physician rounding in this group will be performed wearing white coat.
62508516|NCT01731886|ACTIVE_COMPARATOR|Arm B|Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
62508517|NCT01343875||surgery, biceps tear|
62508518|NCT01058928||Group ID 7.5|Patients with a tracheal tube ID (internal diameter) 7.5 mm
62508519|NCT01058928||Group ID 8.0|Patients with a tracheal tube ID 8.0 mm
62508520|NCT02878408|OTHER|acute Bipolar disorder|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
62508521|NCT02878408|OTHER|acute Schizophrenia|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
62508522|NCT02878408|OTHER|stable Bipolar disorder|blood sampling and data collection (only one visit)
62508523|NCT02878408|OTHER|stable Schizophrenia|blood sampling and data collection (only one visit)
62508524|NCT02878408|OTHER|healthy control|blood sampling and data collection (only one visit)
62508525|NCT02878408|OTHER|TOC|blood sampling and data collection (only one visit)
62508526|NCT00338130|ACTIVE_COMPARATOR|1|Temozolomide
62508527|NCT00338130|EXPERIMENTAL|2|AZD6244
62508528|NCT04999696|EXPERIMENTAL|Laparoscopic radical hysterectomy|
62508529|NCT04999696|ACTIVE_COMPARATOR|Laparotomic radical hysterectomy|
62508530|NCT03290313|EXPERIMENTAL|shu gan yi yang capsule|4 capsules / time, 3 times / day, taking 8 weeks
62508531|NCT03290313|PLACEBO_COMPARATOR|shu gan yi yang capsule capsule simulation agent|4 capsules / time, 3 times / day, taking 8 weeks
62508532|NCT04360408|EXPERIMENTAL|Intervention|Participant of the cluster randomised to the intervention group will receive both the usual care from their healthcare providers and EVEREST delivered by the researcher who is a nurse.
62508533|NCT04360408|NO_INTERVENTION|Control|Participants of the cluster randomised to the control group will receive usual care (standard care with no formalised, structured or tailored interventional to reduce symptom/s) from their healthcare providers
62508534|NCT01997684|EXPERIMENTAL|Colonic Stenting with Elective Surgery|"In the experimental group, the patients will undergo colonic stenting within 24 h of inclusion. For this study, the WallFlex ™ Colonic Stent (Boston Scientific, Natick, MA) will be employed.~Candidates for elective surgery, after clinical success of colonic stenting, will be preferably operated on 5-14 days after inclusion, and no later than 4 weeks. Type and extent of the elective surgery will be selected by the surgeon.~In this group, unplanned emergency surgery will be indicated in case of technical failure of colonic stenting, iatrogenic morbidity, or clinical failure.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
62508535|NCT01997684|ACTIVE_COMPARATOR|Emergency Surgery|"In the comparator group, patients will be undergo emergency surgery. Surgical options including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
62508536|NCT02354807|EXPERIMENTAL|Experimental group|Subjects that undergo both cold exposure and one-time dose of 100mg of Mirabegron drug
62508537|NCT01290237|EXPERIMENTAL|Vancomycin loading dose|Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
62508538|NCT01290237|ACTIVE_COMPARATOR|Control|No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.
62508539|NCT05310708|EXPERIMENTAL|Validation Study of a patch-based PSG system|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
62706408|NCT03107845|EXPERIMENTAL|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
61966141|NCT03403660|PLACEBO_COMPARATOR|White coat rounding|The postpartum physician rounding in this group will be performed not wearing white coat.
61966142|NCT01485237||Severe H1N1 pneumonia in adult patients|Severe adult H1N1 pneumonia patients undergoing antiviral and oxygen therapy, mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO, HFO)in Winnipeg
61966143|NCT01485237||Severe pneumonia in adults not H1N1|Patients admitted to the hospital and/or ICU with viral pneumonia, bacterial pneumonia, septic shock, ARDS in Winnipeg
62144871|NCT00109031|EXPERIMENTAL|Palifermin 180 μg/kg on Day -1|Palifermin 180 μg/kg on Day -1 and matched placebo on Days -2 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
62144872|NCT00109031|EXPERIMENTAL|Palifermin 180 μg/kg on Day -2|Palifermin 180 μg/kg on Day -2 and placebo on Days -1 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
62508540|NCT02900053|ACTIVE_COMPARATOR|Arm 1|Cerebral modulation using tDCS (transcranial Direct-Current Stimulation) associated with repetitive traumatic exposure using a personal traumatic script
62706409|NCT03107845|EXPERIMENTAL|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
62508541|NCT02900053|PLACEBO_COMPARATOR|Arm 2|Placebo cerebral modulation using sham-tDCS associated with repetitive traumatic exposure using a personal traumatic script
62508542|NCT04051216|EXPERIMENTAL|Supportive Care|Caregivers receive the Roadmap information system loaded on an Apple iPad® for use during the inpatient hospitalization of CART therapy. The Roadmap information system consists of 5 modules personalized to the CART patient: laboratory studies, medications, clinical trial enrollment, healthcare providers, and criteria for discharge. Patients wear an activity monitoring device on days 0-100. Patients wear the device as long as they can each day to monitor physical activity level, sleep/wake patterns, skin temperature, heart rate and respiratory rate.
62508543|NCT00894517|EXPERIMENTAL|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
62508544|NCT00894517|PLACEBO_COMPARATOR|Placebo (saline)|Placebo (saline) injected into the prostate on Day 1.
62350125|NCT02780479|ACTIVE_COMPARATOR|Prednisone|Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
62350126|NCT00442767|ACTIVE_COMPARATOR|Rapid acting Insulin therapy - before meal|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal
62350127|NCT00442767|EXPERIMENTAL|Pre-meal Pramlintide and Post-meal Insulin therapy|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
62350128|NCT00818207|OTHER|Full Smoking Cessation Treatment Coverage (100%)|A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
62350129|NCT00818207|OTHER|No Smoking Cessation Treatment Coverage (0%)|Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.
62350130|NCT03911778||Sacrospinofixation|Patients with apical symptomatic prolapse ≥ II in the POP-Q classification and for whom sacrospinofixation with posterior isthmic BSC Mesh is planned
62350131|NCT03636568|EXPERIMENTAL|Fluid restricted|Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh \> 100kg)
62350132|NCT03636568|NO_INTERVENTION|Non Fluid Restricted|No fluid restriction
62350133|NCT01829217|EXPERIMENTAL|Sunitinib|42 day cycle, taken orally every day for the first 28 days followed by 14 days off
62350134|NCT01181102|EXPERIMENTAL|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
62350135|NCT01181102|ACTIVE_COMPARATOR|enoxaparin sodium|enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
62350136|NCT02190617|ACTIVE_COMPARATOR|Enhanced Clinic+ Unified Management Plan|"Patients in study arm will receive:~* Enhanced Clinic Intervention~* Enhanced Health Plan~* Unified Management Plan"
62350137|NCT02190617|ACTIVE_COMPARATOR|CHW Home Visit Only|"Patients in study arm will receive:~* CHW Home Visit~* Usual clinic care with enhanced health plan"
62350138|NCT02190617|ACTIVE_COMPARATOR|Enhanced Clinic+ Unified Plan+ CHW|"Patients in study arm will receive:~* CHW Home Visit~* Enhanced Clinic intervention~* Enhanced health plan~* Unified asthma management plan"
62350139|NCT02190617|NO_INTERVENTION|Usual Care|-Usual clinic care with enhanced healthplan
62144873|NCT00109031|EXPERIMENTAL|Palifermin 180 μg/kg on Day -3|Palifermin 180 μg/kg on Day -3 and placebo on Days -1 and -2 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
61966144|NCT05104229|ACTIVE_COMPARATOR|Standard of Care|standard VTE chemoprophylaxis
62144874|NCT05522309|EXPERIMENTAL|Dose Escalation and Dose Expansion|ET0111 will be administered orally once daily in 21 days treatment cycles.
62144875|NCT04913532|EXPERIMENTAL|Hypofractionation with SIB|Hypofractionation with SIB
62144876|NCT01087710|EXPERIMENTAL|novel nutritional formula|
62144877|NCT01087710|ACTIVE_COMPARATOR|Control nutritional product|1 8oz serving per day for 12 weeks
62350140|NCT04239079||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
62350141|NCT04239079||AD/aMCI and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Alzheimer's disease or Amnestic Mild Cognitive Impairment (aMCI)
62350142|NCT03587571|ACTIVE_COMPARATOR|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
62350143|NCT03587571|NO_INTERVENTION|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
62350144|NCT02072382|EXPERIMENTAL|Metformin|Metformin 850 mg twice a day for eight weeks versus Placebo
62350145|NCT03701646||arterial line|Pediatric patients admitted to the ICU with a medically indicated arterial line.
62350146|NCT03701646||cardiac output|Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
62350147|NCT02027415|EXPERIMENTAL|Beet Orange|Beet juice will be given prior to the first car ride and orange juice will be given prior to the second car ride.
62350148|NCT02027415|EXPERIMENTAL|Orange Beet|Orange juice will be given before the first car ride and beet juice will be given before the second car ride.
62350149|NCT04092998|EXPERIMENTAL|Thermocautery VS scalpel circumcision|Thermocautery circumcision in comparison to circumcision with traditional scalpel
62350150|NCT01333306|EXPERIMENTAL|tDCS and cognitive training|
61966145|NCT05104229|EXPERIMENTAL|Aspirin|Aspirin VTE chemoprophylaxis
61966146|NCT04084665|EXPERIMENTAL|Intervention|Guselkumab 200mg q4 weekly
61966147|NCT02837016|EXPERIMENTAL|Experimental 1|Wearable biofeedback device + Relaxation Training
61966148|NCT02837016|ACTIVE_COMPARATOR|Experimental 2|Relaxation Training only
61966149|NCT00812864|EXPERIMENTAL|Capecitabine|
62350151|NCT03074149||Idiopathic Pulmonary Fibrosis (IPF) patients with less than 6 months diagnosis|
62350152|NCT03074149||Idiopathic Pulmonary Fibrosis (IPF) patients with equal or more than 6 months diagnosis|
62350153|NCT06202001|EXPERIMENTAL|Irinotecan, TAS-102 plus Bevacizumab arm|This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
62350154|NCT01707329|ACTIVE_COMPARATOR|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
62350155|NCT01707329|EXPERIMENTAL|Icotinib+Chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
62508545|NCT00637091|EXPERIMENTAL|EGFR expression|Patients' accrual will be adjusted by EGFR expression (positive vs. negative)
62508546|NCT01734135|NO_INTERVENTION|Usual Care|Usual care
61966150|NCT02771054|EXPERIMENTAL|TAF/emtricitabine (FTC)|All 20 patients will switch their nucleoside backbone, either ABC/3TC or TDF/FTC to TAF/FTC
61966151|NCT00723983|ACTIVE_COMPARATOR|Period 1|Subject dosed with oral sumatriptan succinate during an acute migraine attack.
61966152|NCT00723983|ACTIVE_COMPARATOR|Period 2|Subject dosed with oral sumatriptan during a non-migraine period.
61966153|NCT00723983|EXPERIMENTAL|Period 3 and Period 6|Subject dosed with NP101 during an acute migraine attack.
61966154|NCT00723983|EXPERIMENTAL|Period 4 and Period 5|Subject dosed with NP101 study patch during a non-migraine period.
62144878|NCT05478096|EXPERIMENTAL|We-based intervention for procrastination|GetStarted is a guided e-health application, based on cognitive-behavioral therapy (CBT). It comprises 5 main and 4 optional modules that are delivered weekly via computer, laptop, tablet, or mobile phone. Every week a trained e-coach will provide feedback on the progress of the program and the exercises via e-mail. The main modules are (1) psycho-education about procrastination (2) getting insight into one's own procrastination behavior, (3) uncovering unhelpful thoughts underlying procrastination and (4) replacing these unhelpful thoughts with helpful ones. Each module takes approximately 40 minutes to complete and participants will receive provide asynchronous written personalized feedback from their e-coaches within 48 hours (counting workdays only) after session completion.
62144879|NCT05478096|NO_INTERVENTION|Wait list|Participants in the waiting list condition will receive no treatment for four weeks post-randomization. Following this, they can start the program if they choose to do so.
62350156|NCT05517356|EXPERIMENTAL|Malperfusion Cohort|"Patients presenting to hospital with ATAAD meeting criteria for malperfusion syndrome which includes both components:~1. Radiographic findings reveal occlusion of the corresponding arteries (including either coronary artery, either carotid artery, celiac trunk, superior mesenteric artery or either iliac artery).~2. Clinical features of end organ ischemia (abnormal left ventricular wall motion, disorder of consciousness or paralysis, abdominal pain, distended abdomen, pulselessness, loss of sensory or motor function of the lower extremities) OR Laboratory findings suggestive of end organ ischemia (elevated troponin, elevated creatine kinase, lactic acidosis, elevated myoglobin)."
62350157|NCT02277522|EXPERIMENTAL|RNA autologous T cells (anti CD19 CAR T cells)|
62350158|NCT05575284||Robot-assisted urological surgery|Patients with programmed robot-assisted urological surgery
62350159|NCT01241019|EXPERIMENTAL|Topiramate|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate
62350160|NCT01241019|NO_INTERVENTION|Control|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia
62350161|NCT06071637|ACTIVE_COMPARATOR|Group A - single emission|"The application will be carried out with the DMC device, with a power of 100mW, with a beam area of 0.09842 cm² in each optical fiber.~Extraoral: A gallium and aluminum arsiade diode with emission of radiation in the infrared region of the electromagnetic spectrum (808 nm). An energy of 4J/point were determined, which will be applied punctually, with a distance between points of a maximum of 1cm, for 40s per point, totaling 9 points per region; Intraoral: An indium gallium aluminum phosphide diode with emission of radiation in the red region of the electromagnetic spectrum (660 nm). An energy of 1J/point were determined, which will be applied punctually, with a distance between points of a maximum of 1cm, for 10s per point, totaling 9 points per region ."
62508547|NCT01734135|EXPERIMENTAL|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
62508548|NCT04553835|EXPERIMENTAL|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).
62508549|NCT04553835|ACTIVE_COMPARATOR|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
62508550|NCT04553835|EXPERIMENTAL|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.
62508551|NCT04553835|ACTIVE_COMPARATOR|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
62715037|NCT05770596|EXPERIMENTAL|Vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
61966155|NCT01191801|EXPERIMENTAL|Group A: vosaroxin + cytarabine|vosaroxin (short IV infusion within 10 minutes) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
61966156|NCT01191801|PLACEBO_COMPARATOR|Group B: placebo + cytarabine|placebo (short IV infusion within 10 minutes and volume matched to vosaroxin) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
61966157|NCT03116971|EXPERIMENTAL|M3814 PiC with Etoposide and Cisplatin|Participants received M3814 100 milligram (mg) powder in capsule (PiC) orally once daily in combination with Etoposide 100 mg/m\^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 milligram per square meter (mg/m\^2) over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until progressive disease (PD).
61966158|NCT03116971|EXPERIMENTAL|M3814 (HME Tablet + PiC) with Etoposide and Cisplatin|Participants received M3814 100 mg hot melt extrusion (HME) tablet orally 5 days prior to Day 1 and M3814 100 mg PiC, orally once daily from Day 1 in combination with Etoposide 100 mg/m\^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 mg/m\^2 over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until PD.
61966159|NCT01220375|EXPERIMENTAL|1|Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell release from bone marrow and HSC movement into the peripheral circulation.
61966160|NCT00775424|EXPERIMENTAL|PENNVAX-B alone|PENNVAX-B alone
61966161|NCT00775424|EXPERIMENTAL|PENNVAX-B+IL12|PENNVAX-B+IL12
62144880|NCT01329406|EXPERIMENTAL|Milnacipran|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
61966162|NCT00775424|EXPERIMENTAL|PENNVAX-B+IL15|PENNVAX-B+IL15
61966163|NCT00775424|PLACEBO_COMPARATOR|PLACEBO|PLACEBO
62508552|NCT05659134|ACTIVE_COMPARATOR|Alfredson group (A)|"Participants allocated to the Alfredson exercise program were instructed to exercise twice a day on both legs for 12 months. They performed concentric calf rises (CR) on both legs up and eccentric CR on one leg down.~The protocol contained 15 repetitions and 3 sets on each leg with extended and flexed knee. One session contained 45 reps in the flexed position and 45 reps in the extended position, the total daily number of reps was 180. At the start, the exercises were performed with body weight. Participants could progress by adding the 5, 10 and 15 kg, if they met the criteria. The criteria for adding weight was at least one week of training at the same weight and no disabling pain during or after the exercise during the week."
62508553|NCT05659134|ACTIVE_COMPARATOR|Silbernagel group (B)|"Participants allocated to the Silbernagel exercise program were instructed to exercise every day with exception of the first week (every other day) for 12 months. The protocol contained 4 phases, which were based on a variety of CR exercises.~The protocol contained concentric and eccentric CR on both legs, CR on one leg, CR in sitting, CR on the step, CR without step, quick rebound CR, CR with added weight and hops on the forefoot.~The daily number of reps for 1st phase was 135, for the 2nd phase was 240, for the 3rd phase was 255 and for the 4th phase was 150. It's performed with body weight, added weight and plyometric loading progressively through all phases (maximal added weight is 15 kilos). To progress to the next phase participant needs to reach pain intensity during and after exercise under 5 from the 10 on the visual analogue scale, morning stiffness should not increase as well as pain during the week."
62508554|NCT05767216|OTHER|Down syndrome children|Two pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
62508555|NCT00703560||1|HIV and HCV genotype 1 coinfected (any race)
62508556|NCT00703560||2|HCV genotype 1 (any race)
62508557|NCT04565496|EXPERIMENTAL|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
62706410|NCT05847166|ACTIVE_COMPARATOR|Cohort A - lymph node assessment in intermediate risk group|The patients will undergo \[99mTc\]Tc-PSMA-T4 semiWB- SPECT/CT as an additional modality to contrast-enhanced (CE) multiparametric MRI (according to PI-RADS 2.1 protocol) with additional chest and abdominal CE computed tomography and \[99mTc\]Tc-MDP bone scan in unfavorable risk prostate cancer patients
61966164|NCT04008615||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test.~For the purpose of this study, patients will be offered to participate in an additional exercise session in which they will repeat the same procedure (two 6-minute stepper test) but but monitoring cardiopulmonary parameters and gaz exchanges using a face mask, a pneumotachograph and a gaz analyser (indirect calorimetry)."
61966165|NCT06230887|EXPERIMENTAL|Building Spiritual Strength|Spiritually integrated group intervention for moral injury.
62508558|NCT04313010|EXPERIMENTAL|Regenerative endodontics therapy with PRF|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. Only the apex 1/3 of the root canal need to be filled with blood. PRF was injected into the root canal to a level below the CEJ, then wait for 10-15min to coagulate.
62508559|NCT04313010|ACTIVE_COMPARATOR|Regenerative endodontics therapy with BC|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. The adequate blood need to be full with canal space and below the CEJ, then wait for 10-15min to coagulate.
62508560|NCT03110796|EXPERIMENTAL|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
62508561|NCT03110796|EXPERIMENTAL|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
62508562|NCT03110796|PLACEBO_COMPARATOR|No LU3103209|Dressing without LU3103209
62508563|NCT02498535|EXPERIMENTAL|Nitric oxide gas at 160 ppm|Nitric oxide gas at 160 ppm inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days. Total dose of 2400 ppm hours.
62508564|NCT02498535|PLACEBO_COMPARATOR|Breathing 20.3% oxygen|Breathing 20.3% oxygen inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days.. 100% nitrogen will be injected into the breathing circuit (instead of 99.5% nitrogen and 0.5% NO).
61966166|NCT06230887|ACTIVE_COMPARATOR|Present Centered Group Therapy|Coping strategies group intervention addressing broad spectrum trauma symptoms
62508565|NCT04632524|ACTIVE_COMPARATOR|MgSO4|Group (Mg So4) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery.
62508566|NCT04632524|PLACEBO_COMPARATOR|Placebo|Group (P) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse
62508567|NCT00810602|EXPERIMENTAL|Vorinostat prophylaxis|Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
62508568|NCT06532968|SHAM_COMPARATOR|Control group|General spinal system
62715038|NCT05770596|PLACEBO_COMPARATOR|Placebo group|patients in this group will receive placebo tablets with the same manner.1 hour before surgery and for 50 days starting from the 2nd postoperative day.
61966167|NCT06194565|EXPERIMENTAL|99mTc-ABH2 SPECT/CT|The patients will be injected with 5.55 to 7.4 MBq per kilogram body weight of 99mTc-ABH2 in one dose intravenously and undergo SPECT/CT scan 1h to 2h later.
62144881|NCT01329406|PLACEBO_COMPARATOR|Placebo|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
61966168|NCT05360381|EXPERIMENTAL|Phase 1a dose-escalation stage|"Phase 1a uses the 3+3 design, to investigate the safety and determine the MTD of HLX35. Seven dose levels of 0.015 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg are planned for dose finding. Enrollment will continue until a maximum of 42 patients are enrolled"
62144882|NCT01627314|EXPERIMENTAL|ProHema-CB with MAC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with myeloablative conditioning regimen (MAC)
62350162|NCT06071637|EXPERIMENTAL|Group B - double emission|"The application will be carried out with the DMC device, with a power of 100mW, with a beam area of 0.09842 cm² in each optical fiber.~Extraoral: An indium gallium aluminum phosphide diode and gallium aluminum arsiade with double radiation emission simultaneously in the red and infrared region of the electromagnetic spectrum (660 nm/808nm). An energy of 4J/point were determined, which will be applied punctually, with a maximum distance between points of 1cm, for 20s per point, totaling 9 points per region; Intraoral: An indium gallium aluminum phosphide diode and gallium aluminum arsiade with double radiation emission simultaneously in the red and infrared region of the electromagnetic spectrum (660nm/808nm). An energy of 1J / point (0.5J in the red and 0.5 in the infrared) were determined, which will be applied punctually, with a distance between points of no maximum 1cm, for 5s per point, totaling 9 points per region."
62350163|NCT05871229|EXPERIMENTAL|Study group|Lumoral and standard treatment
62350164|NCT05871229|OTHER|Control group|Standard treatment only
62350165|NCT05516693|EXPERIMENTAL|Intervention group (MOG)|Patients in the experimental group (MOG) will undergo a myofunctional training protocol.
62350166|NCT05516693|NO_INTERVENTION|Control group (COG)|Patients in the control group (COG) will not undergo any intervention, being only evaluated at the beginning and at the end of the protocol.
62350167|NCT05941169|EXPERIMENTAL|Cytoreductive Nephrectomy|Cytoreductive Nephrectomy within 6 months to 1 year after start systemic therapy for metastatic Renal Cell Carcinoma
62350168|NCT05941169|NO_INTERVENTION|Standard of Care|Standard of Care for metastatic Renal Cell Carcinoma
62350169|NCT02060318||Infliximab|35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
62350170|NCT02060318||Healthy controls|12 healthy controls without Crohn's Disease.
62350171|NCT00370890|EXPERIMENTAL|A|Adjuvant chemotherapy and then clinical follow-up and surveillance
62350172|NCT00370890|NO_INTERVENTION|B|Clinical follow-up and surveillance only
62350173|NCT04354779||AUVA HCW|health care workers in Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA)
62350174|NCT06252766|EXPERIMENTAL|Experiment (Clown)|During this process, the clown will continue to distract the children by playing games and blowing foam balloons. During the procedure, the child's pain and anxiety score will be evaluated by both the researcher, the parent, and the child. After the procedure is completed, children will be taken out of the blood collection room and taken to the waiting area in the next room, and after being allowed to rest for 1-2 minutes, surveys will be administered to the children.
62350175|NCT06252766|NO_INTERVENTION|Control|Blood collection will be routine and surveys will be administered 1-2 minutes after the end of the procedure to determine the level of pain and anxiety during the procedure.
62350176|NCT02541448|ACTIVE_COMPARATOR|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
62350177|NCT02541448|ACTIVE_COMPARATOR|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
62706411|NCT05847166|ACTIVE_COMPARATOR|Cohort B - general assessment (bone and lymph nodes) in high and very high-risk group|The patients will undergo \[99mTc\]TcPSMA-T4 semi-WB- SPECT/CT and CE multiparametric MRI (according to PI-RADS 2.1 protocol), and chest and abdomen CE computed tomography, and skeletal scintigraphy (\[99mTc\]Tc-MDP bone scan).
62350178|NCT03963713|EXPERIMENTAL|Stereotactic radiotherapy|"In this study, the metastases were treated with Stereotactic radiotherapy（SBRT）.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).~Stereotactic radiotherapy"
62508569|NCT06532968|EXPERIMENTAL|LMC group|General spinal system with ORION spinal lamina cover
62508570|NCT01965626|ACTIVE_COMPARATOR|Oseltamivir Combining HD-DXM|"Oseltamivir 75 mg twice per day, 10consecutive days~HD-DXM (orally at 40 mg daily for 4d )"
62706412|NCT05847166|ACTIVE_COMPARATOR|Cohort C - recurrent disease after definitive treatment (radiotherapy or surgery)|The patients will undergo \[99mTc\]TcPSMA-T4 semiWB- SPECT/CT and the second confirmatory imaging modality or biopsy in the case of evidence on progressive disease (PSA persistence/recurrence or radiographic evidence of metastatic disease or clinical symptoms suggesting metastatic disease).
61966169|NCT05360381|EXPERIMENTAL|Phase 1b dose-expansion stage|Patients with sqNSCLC (EGFR H score≥200) will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX35. Phase 1b dose expansion will include 15-20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
62144883|NCT01627314|EXPERIMENTAL|ProHema-CB with RIC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with reduced intensity conditioning regimen (RIC)
62350179|NCT03963713|EXPERIMENTAL|Conventionally-fractionated image- guided Intensity modulated|In this study, the metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
62350180|NCT05778019||Case Scenarios|No personal patient information is shared. The circulated case scenarios within the network will be constructed cases from the clinical practice, to serve representatively
62350181|NCT05754697|EXPERIMENTAL|instrument assisted soft tissue mobilization in addition to traditional treatment|study group
62350182|NCT05754697|EXPERIMENTAL|positional release technique in addition to traditional treatment|study group
62350183|NCT05754697|ACTIVE_COMPARATOR|traditional treatment|control group
62350184|NCT04981977|EXPERIMENTAL|Care Transitions Intervention|Patient participants in this arm will receive the Care Transition Intervention.
62350185|NCT04981977|EXPERIMENTAL|Care Transition Intervention and Peer Support|Patient participants in this arm will receive the Care Transition Intervention.
62508571|NCT01965626|ACTIVE_COMPARATOR|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
62715039|NCT02259816|ACTIVE_COMPARATOR|Telmisartan|
62508572|NCT01636934|EXPERIMENTAL|Minocycline|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Minocycline 100 mg capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
61966170|NCT04391127|EXPERIMENTAL|Hospitalized patients with COVID-19 QTc < 500 mseg|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc \< 500 ms could be randomized to hydroxychloroquine, ivermectin or placebo.
62508573|NCT01636934|PLACEBO_COMPARATOR|Placebo|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
62508574|NCT00913796|EXPERIMENTAL|Postassium citrate|Aim: correction of metabolic acidosis
62508575|NCT00913796|ACTIVE_COMPARATOR|Potassium chloride|Potassium chloride is given to compensate for any possible effects of potassium in potassium citrate (primary treatment).
62508576|NCT04244006|EXPERIMENTAL|Dupilumab|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of Dupilumab 300 mg (syringe of 2 mL for subcutaneous administration).
62508577|NCT04244006|PLACEBO_COMPARATOR|Placebo|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of placebo (syringe of 2 mL for subcutaneous administration)..
62508578|NCT01497119|EXPERIMENTAL|JNJ-39758979, 300 mg|
62508579|NCT01497119|EXPERIMENTAL|JNJ-39758979, 100 mg|
62508580|NCT01497119|PLACEBO_COMPARATOR|Placebo|
62508581|NCT06618300||Yttrium-90 (Y90) radioembolization|Patients with small Hepatocellular Carcinoma undergoing Yttrium-90 (Y90) radioembolization.
62508582|NCT05528302|EXPERIMENTAL|Tech-CBT intervention|Participants allocated to the Tech-CBT intervention group will attend six telehealth videoconferencing sessions - 1 session per week over 6 weeks. Each session will last between 60 to 90 minutes and will be facilitated by a trained therapist. During each session, the participant will learn and practice different psychotherapy techniques. The participant will be encouraged to practice these skills between sessions with the technology provided, either on their own or with the help of their support person.
62508583|NCT05528302|NO_INTERVENTION|Control|Participants allocated to the Control group will receive usual care (i.e., no treatment for anxiety) and a mid-point check-in phone call/video call/email (depending on their preference) from the study team approximately 3 weeks after completing the initial questionnaires. This mid-point check-in is to identify whether there have been any changes to their usual care.
61966171|NCT04391127|EXPERIMENTAL|Hospitalized patients with COVID-19 infection with QTc >500ms|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc \> 500 ms could be randomized to ivermectin or placebo.
61966172|NCT02860169|EXPERIMENTAL|Participants with cold and flu|Eligible participants with cold and flu were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
62144884|NCT01627314|PLACEBO_COMPARATOR|Control Arm with MAC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with myeloablative conditioning regimen
62144885|NCT01627314|PLACEBO_COMPARATOR|Control Arm with RIC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with reduced intensity conditioning regimen
62508584|NCT04649489||Arm A (experimental arm)|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle
62508585|NCT04649489||Arm B (control arm)|atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle
62508586|NCT02896543||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attacks. They will all undergo coronary angiography.The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had obvious blood system diseases,severe liver dysfunction, severe renal insufficiency,severe heart failure (NYHA class 3 and 4), acute or chronic infectious diseases, disease of immune system, asthma, malignant tumor, other advanced disease are excluded.
62508587|NCT02896543||Control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are enrolled as Control group.
62508588|NCT02056067|EXPERIMENTAL|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
62508589|NCT02056067|ACTIVE_COMPARATOR|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
62508590|NCT04514497|EXPERIMENTAL|Cohort I (elimusertib, irinotecan)|Patients receive elimusertib PO BID on days 1 and 2 and irinotecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
62144886|NCT03466970||IgG4 patient|20 samples of IgG4 patients
62144887|NCT03466970||healthy donors|20 healthy donors
62144888|NCT04843449|EXPERIMENTAL|Inhibitor group|"1. ASC40 50mg, once daily on the 1st and 11th days before meal;~2. Itraconazole 200mg, once daily from the 6th day to the 15th day."
62350186|NCT04981977|OTHER|Usual Care|Patient participants in this arm will receive the usual discharge/transition care provided by the hospital.
62508591|NCT04514497|EXPERIMENTAL|Cohort II (elimusertib, irinotecan)|Patients receive elimusertib PO QD on days 2, 3, 9, 10, 16, and 17 of cycle 1 and 2, and on days 2, 3, 9, and 10 of each cycle thereafter. Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 of cycle 1 and 2, and on days 1 and 8 of each cycle thereafter. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
61966173|NCT02860169|PLACEBO_COMPARATOR|Healthy participants|Eligible healthy participants were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
62350187|NCT03495453|ACTIVE_COMPARATOR|CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy (OAS)|OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB)
62350188|NCT03495453|ACTIVE_COMPARATOR|Medtronic's Hawkone Directional Atherectomy system (DAS)|DAS (using the Hawkone device) followed by DCB
62350189|NCT01478893|EXPERIMENTAL|SEL-068|
62350190|NCT01478893|PLACEBO_COMPARATOR|Saline|
62350191|NCT04257084|ACTIVE_COMPARATOR|CE-NBI|High definition chromoendoscopy with target biopsy, at 1st surveillance colonoscopy during the trial High definition NBI with target biopsy, at 2nd surveillance colonoscopy during the trial
62350192|NCT04257084|ACTIVE_COMPARATOR|NBI-CE|High definition NBI with target biopsy, at 1st surveillance colonoscopy during the trial High definition chromoendoscopy with target biopsy, at 2nd surveillance colonoscopy during the trial
62350193|NCT01473329|EXPERIMENTAL|Structured Diabetes education|The intervention group received a structured DSME course. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
62350194|NCT03185104|EXPERIMENTAL|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
62350195|NCT03185104|PLACEBO_COMPARATOR|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
62350196|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
62350197|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
62350198|NCT02334670||CrAg(+) and CM(+)|Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
62706413|NCT00833521|EXPERIMENTAL|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
62706414|NCT00833521|ACTIVE_COMPARATOR|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
61966174|NCT01004627|NO_INTERVENTION|Control group - selective duplex|Patients will receive a duplex ultrasound only if specifically requested following physical examination.
61966175|NCT01004627|EXPERIMENTAL|Obligatory Duplex scan|Patients will receive a duplex ultrasound regardless of clinical findings. Arterial and venous duplex ultrasound examination
62144889|NCT04843449|EXPERIMENTAL|Inducer group|"1. ASC40 50mg, once daily on the 1st and 19th days before meal;~2. Rifampicin 600mg, once daily from the 6th day to the 19th day."
62144890|NCT04067609|EXPERIMENTAL|patients receiving dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
62144891|NCT04067609|PLACEBO_COMPARATOR|placebo|100mL of normal saline (placebo) immediately upon the subjects' arrival to the Post Anesthesia Care Unit (PACU) after leaving the operating room from their scheduled c-section
62144892|NCT03692845|OTHER|O-TLIF group|Spinal fusion ,Transforaminal lumbar interbody fusion procedure will be performed through open surgery.
62144893|NCT03692845|OTHER|MI-TLIF group|Spinal fusion,Transforaminal lumbar interbody fusion procedure will be performed through minimally invasive surgery using a tubular retractor.
62144894|NCT05659394|OTHER|Standard Wound Care Alone|Patients receiving gold standard compression therapy for venous or mixed etiology ulcers
62350199|NCT02334670||CrAg(+) and CM(-)|Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 \>200 cells/µL for at least 6 months.
62706415|NCT01998477|EXPERIMENTAL|TIVc|flu vaccine
62350200|NCT02334670||CrAg negative|Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines
62706416|NCT01998477|ACTIVE_COMPARATOR|TIV|flu vaccine
62706417|NCT05751109||ipack+adductor canal block|The 40 patients received ACB + IPACK (Group 1, n = 40),. All patients were evaluated with VAS score for pain recorded at 1h, 8 h, postoperative day (POD) 1 and 3. month after the surgery. The secondary outcome measures assessed were movement time and discharge time.
62715040|NCT02259816|EXPERIMENTAL|Telmisartan and amlodipine|
61966176|NCT03827733||AD patients|Participants who are diagnosed with AD.
61966177|NCT03827733||Partners of the AD patients|Partners of AD patients who live together with the AD patients.
62144895|NCT05659394|OTHER|Standard Wound Care plus IPC|Patients receiving gold standard compression therapy plus IPC (WoundExpress)
62144896|NCT01276275||Exposure Group 1|First time users of ticagrelor
62144897|NCT01276275||Exposure Group 2|First time users of clopidogrel
62144898|NCT01276275||Exposure Group 3|First time users of prasugrel
62350201|NCT05782582|EXPERIMENTAL|Package investigation|"1. Resting ECG,~2. Evaluation of risk according to PTP-table.~3. Echocardiography,~4. Exercise stress bicycle test (secondarily drug provocation) with injection of isotope for myocardial scintigraphy,~5. Scanning for myocardial perfusion~6. CAC-scoring with CT"
62350202|NCT05782582|ACTIVE_COMPARATOR|Standard investigation|"1. Resting ECG~2. Evaluation of risk according to PTP-table.~3. Echocardiography.~4. Exercise stress bicycle test.~If judged to be needed according to clinical indication sequentially completed by:~Echocardiography, Exercise stress bicycle test (secondarily drug provocation) with injection of isotope for myocardial scintigraphy and/or Coronary CTA. In addition, cardiac examinations done with other modalities chosen on clinical grounds will be examined in the study.~,"
62350203|NCT01729572|EXPERIMENTAL|Experimental: Tele-medicine monitoring|Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
62350204|NCT01729572|NO_INTERVENTION|No Intervention: Control Rutine out-patient treatment|routine out-patient treatment will be given to the control group
62350205|NCT02330107|EXPERIMENTAL|Treatment arm 1|"Subjects will receive MAT and placebo LA. The magnetic pellets will be applied to the six selected acupoints as detected by an acupoint finder. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during treatment."
62350206|NCT02330107|EXPERIMENTAL|Treatment arm 2|Subjects will receive a combined approach that includes the use of MAT and LA. A laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use (King et al., 1990; Round et al., 2013). This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection.
62350207|NCT02330107|PLACEBO_COMPARATOR|Treatment arm 3|"Subjects will serve as a placebo control and will receive LA at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plasters centred with a small portion of Junci Medulla (mimicking the MAT treatment)."
62350208|NCT04799353|EXPERIMENTAL|Group 1: Placebo SC + Placebo IV|Participants will receive Subcutaneous (SC) Placebo, followed by Intravenous (IV) Placebo.
62350209|NCT04799353|EXPERIMENTAL|Group 2: Budigalimab (SC) + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
62350210|NCT04799353|EXPERIMENTAL|Group 3: Budigalimab SC + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
62350211|NCT04799353|EXPERIMENTAL|Group 4: Placebo SC + Budigalimab IV|Participants will receive Subcutaneous (SC) Placebo, followed by IV Budigalimab.
62508592|NCT04514497|EXPERIMENTAL|Cohort III (elimusertib, topotecan)|Patients receive elimusertib PO QD on days 2 and 5 and topotecan IV over 30 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
62508593|NCT00864799|ACTIVE_COMPARATOR|Vaginal misoprostol|"Women allocated to the vaginal misoprostol management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 4 hours by 400 mcg vaginal misoprostol, the latter repeated every 4 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
62144899|NCT04701372||Obsessive-Compulsive Disorder|adults, adolescents, and children with obsessive-compulsive disorder
62144900|NCT03251456|EXPERIMENTAL|Tertiary care|
62144901|NCT03251456|ACTIVE_COMPARATOR|Usual care|
62144902|NCT01579032||CKD patients|
62350212|NCT01853098|EXPERIMENTAL|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
62350213|NCT01796262|PLACEBO_COMPARATOR|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
62350214|NCT01796262|ACTIVE_COMPARATOR|docosahexaenoic acid|DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
62350215|NCT03015558|EXPERIMENTAL|patients|
62350216|NCT03015558|ACTIVE_COMPARATOR|healthy subjects|
62350217|NCT00089271|EXPERIMENTAL|Treatment (alvespimycin hydrochloride)|Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61966178|NCT03827733||Elderly participants with normal cognition|Community dwelling elderly with normal cognition and with AD.
62144903|NCT03673605|EXPERIMENTAL|Rivaroxaban|
62144904|NCT03673605|ACTIVE_COMPARATOR|Warfarin|
62144905|NCT01360918|ACTIVE_COMPARATOR|Usual care|
62144906|NCT01360918|ACTIVE_COMPARATOR|Pulmonary vein isolation|
62144907|NCT04338178|EXPERIMENTAL|Experimental intervention|Standard outpatient program, with additional group sessions integrating the experimental intervention : Cognitive Remediation Therapy (CRT), Emotional Skills Training (EST), and Cognitive Behavioral Therapy focused on craving and food addiction (CBT), delivered once a week during 10 weeks.
62144908|NCT04338178|ACTIVE_COMPARATOR|Standard intervention|Standard outpatient program, with additional group sessions integrating control intervention : multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches, delivered once a week during 10 weeks.
62144909|NCT05732727|EXPERIMENTAL|Experimental group|Antihypertensive algorithm based on diuretics agents : the clinicians will adjust the drug therapy according to the antihypertensive algorithm based on diuretics agents.
62706418|NCT05751109||epidural analgesia|The 40 patients received combine spinal epidural (Group 2, n = 40),. All patients were evaluated with VAS score for pain recorded at 1h, 8 h, postoperative day (POD) 1 and 3. month after the surgery. The secondary outcome measures assessed were movement time and discharge time.
61966179|NCT01402544|OTHER|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year
62144910|NCT05732727|ACTIVE_COMPARATOR|Control group|Standard of care : the clinicians will adapt the antihypertensive strategy according to his own standard of care which can be pharmacological or non-pharmacological therapies.
62508594|NCT00864799|ACTIVE_COMPARATOR|Oral misoprostol|"Women allocated to the standard management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg misoprostol orally, the latter repeated every 3-hours to a maximum of 4 oral doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
62508595|NCT00864799|ACTIVE_COMPARATOR|Sublingual misoprostol|"Women allocated to the sublingual misoprostol protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg sublingual misoprostol, the latter repeated every 3 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
62508596|NCT00968019||Presillion stent|Patients treated with the Presillion stent in up to two de novo coronary artery lesions
62706419|NCT01533623|OTHER|mandibular advancement device treatment|Patients diagnosed with sleep-disordered breathing that receive treatment with a titratable, duobloc mandibular advancement devices
62706420|NCT01404234|EXPERIMENTAL|Open-label AZLI|Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
62706421|NCT01013571|EXPERIMENTAL|1|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
62706422|NCT01013571|EXPERIMENTAL|2|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
62706423|NCT00529048||T2DM|T2DM patients (WHO-criteria)
62706424|NCT00529048||CTRL|Healthy control subjects matched individually to the cases.
61966180|NCT06204913|EXPERIMENTAL|Left, black, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon only design, and height that is 100% of size of the menu text height.
62144911|NCT02591056|EXPERIMENTAL|Erchonia Verju Laser + Green PRESS 8|All subjects receive 12 combination treatments over 6 weeks (two per week) with the Erchonia® Verju™ Laser and the Green PRESS 8 devices simultaneously.
62350218|NCT06138327|EXPERIMENTAL|BMN 255 Investigational drug arm|Oral administration of BMN 255 at a dose of 100mg per day for 7 days in Treatment Period 1 or 2
62350219|NCT06138327|PLACEBO_COMPARATOR|Placebo Comparative drug arm|Oral administration of Placebo at a dose of 100mg per day for 7 days in Treatment Period 1 or 2
62350220|NCT00834886|ACTIVE_COMPARATOR|Combination|Bright light 10.000 lux + melatonin 3 mg
62350221|NCT00834886|ACTIVE_COMPARATOR|Melatonin|Melatonin 3 mg + placebo red light 400 lux
62350222|NCT00834886|ACTIVE_COMPARATOR|Bright light|Bright light 10.000 lux + placebo capsule 3 mg rice flour
62350223|NCT00834886|PLACEBO_COMPARATOR|Placebo|Placebo Red light 400 lux + placebo capsule 3 mg rice flour
62350224|NCT00176124|NO_INTERVENTION|1|storage and transfusion of autologous whole blood without leukocyte depletion : Control group
62350225|NCT00176124|EXPERIMENTAL|2|storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
62350226|NCT04072185|EXPERIMENTAL|Physical activity group|
62350227|NCT04072185|NO_INTERVENTION|Control group|
62350228|NCT02431130|EXPERIMENTAL|Low-fidelty instructor driven simulation training|participants receive simulation training
62350229|NCT02431130|NO_INTERVENTION|No simulation training|
62350230|NCT04172311|EXPERIMENTAL|Modified Atkins Diet|"Modified Atkins Diet administration~1. Carbohydrates will be restricted to 10 grams per day.~2. Recipes will be provided to be prepared from easy home available foods, to have 2.5 gram per meal. Along with this, a list of carbohydrate free foods will be provided.~3. Fats intake will be actively encouraged. Protein intake will be unrestricted.~4. Medications will be changed to carbohydrate free preparations.~5. A multivitamin and calcium supplementation will be added."
62350231|NCT04172311|ACTIVE_COMPARATOR|Levetiracetam|Levetiracetam will be started at a dose of 10 mg/kg/day in two divided doses and increased to 20 mg/kg/day after 1 week. Syrups will be used in children younger than 5 years of age, and tablets will be used in children \> 5 years of age. Further dose titration will be done as per the seizure control, in 10 mg/kg/day increments in 2 weekly intervals, to a maximum of 60mg/kg/day.
62350232|NCT03589820|ACTIVE_COMPARATOR|Artificial liver support system group|30 patients will receive treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine.
62350233|NCT03589820|NO_INTERVENTION|Control group|30 patients will receive treatment of internal medicine.
62350234|NCT02013128|EXPERIMENTAL|Ublituximab + ibrutinib|Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib: Fixed oral daily dose
62350235|NCT02290964|NO_INTERVENTION|Control group|After general anesthesia is applied, surgery is performed. Whenever transfusion is indicated, the patients will received allogenic blood transfusion
62350236|NCT02290964|ACTIVE_COMPARATOR|ANH group|After general anesthesia is applied, blood from patients in this group were withdrawn. the volume of blood withdrawn was determined based on Gross equation. The blood obtained was then stored in the operating room at temperature between 23 - 25 Celsius degree, and given back to the patient whenever transfusion is indicated.
62350237|NCT04142216|EXPERIMENTAL|Chewing gum group|The patients will be asked to chew on a regular chewing gum for three months.
62350238|NCT04142216|NO_INTERVENTION|Control group|The patients will not chewing gum during three months.
62508597|NCT06615908|EXPERIMENTAL|High dose (25mg)|High Dose (25mg) PEX010 (Oral Psilocybin), 25mg; single dose (20 participants) administered 24hrs prior to first BrainACT session
62508598|NCT06615908|ACTIVE_COMPARATOR|Low dose (1mg)|Low Dose (1mg) PEX010 (Oral Psilocybin), 1mg; single dose (20 participants)administered 24hrs prior to first BrainACT session
62508599|NCT01253928|ACTIVE_COMPARATOR|Pioglitazone 45mg per day|Pioglitazone 45mg qd will be added to the current treatment
62508600|NCT01253928|PLACEBO_COMPARATOR|placebo|placebo qd will be added to current treatment
62508601|NCT01939431||Advanced|advanced stage podoconiosis
62508602|NCT01939431||Control|non-podoconiosis controls
62508603|NCT01939431||Early|early stage podoconiosis
62508604|NCT02983032|EXPERIMENTAL|Brief behavioural treatment for insomnia (BBTI)|A behavioural therapy for improving symptoms of insomnia in older adults focussing on sleep-related behaviour such as napping and when a person gets up and goes to bed.
62508605|NCT02910414|EXPERIMENTAL|Treated with Peregrine System Kit|The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.
62508606|NCT02910414|SHAM_COMPARATOR|Renal Angiography Only (Sham Procedure)|The sham control group will only have diagnostic renal angiography performed. There will be no insertion of the Peregrine Catheter and no alcohol infusion (i.e. no renal denervation).
62508607|NCT02283190|EXPERIMENTAL|Ewwinase|Six doses of Erwinase given three times weekly (Monday-Wednesday-Friday) for two weeks. Possible dose levels used are 20.000 IU/m2/day, 25,000IU/m2/day, and 30,000IU/m2/day.
62508608|NCT05299567|ACTIVE_COMPARATOR|azitrhomycin|Group1 Azitrhomycin 250 or 500 mg in capsuls tree days a week for 6 months if the patiens are less or more than 40 kg respectively Exposure
62508609|NCT05299567|PLACEBO_COMPARATOR|Placebo|Group 2 placebo Not exposure Placebo in capsuls tree days a week for 6 months
62508610|NCT02407067|ACTIVE_COMPARATOR|Voice Amplifier|Participant will be fit with a voice amplifier (ChatterVox) and it will be used during speech testing and during regular conversations over a one week period.
62508611|NCT02407067|EXPERIMENTAL|Personal Communication System|Participant will be fit with a personal communication system (Easy Listener FM system) and it will be used during speech testing and during regular conversations over a one week period.
62508612|NCT00503230|ACTIVE_COMPARATOR|Standard Care Intervention (SCI)|
62508613|NCT00503230|ACTIVE_COMPARATOR|Culturally Tailored Intervention (CTI)|
62508614|NCT01826916|EXPERIMENTAL|5mg/m2 DX-88 IV|5mg/m2 DX-88 (ecallantide)administered intravenously
62350239|NCT02203669|ACTIVE_COMPARATOR|Structured In-Office Therapy|Structured In-Office Therapy: Study subjects will receive structured, therapist-supervised occupational/physical therapy twice per week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Patients in this arm will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These patients will also receive exercise and stretching handouts to use at home between therapy visits. Will complete the DASH at week 1 and week 4.
62508615|NCT01826916|EXPERIMENTAL|10mg/m2 DX-88 IV|10mg/m2 DX-88(ecallantide)administered intravenously
62508616|NCT01826916|EXPERIMENTAL|20mg/m2 DX-88 IV|20mg/m2 DX-88 (ecallantide) administered intravenously
62706425|NCT04113889|ACTIVE_COMPARATOR|Combination therapy group|Arm 1: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)
62706426|NCT04113889|PLACEBO_COMPARATOR|Standard therapy group|Arm 2: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Placebo
62706427|NCT00883597||Controls|Patients with ileostomy.
62706428|NCT00883597||Standard Sepsis Treatment|Patients with ileostomy and sepsis
62350240|NCT02203669|NO_INTERVENTION|No therapy|Study subjects in this arm will not receive post-operative occupational /physical therapy. Will complete the DASH at week 1 and week 4.
62508617|NCT01826916|EXPERIMENTAL|30 mg DX-88 SC|30mg DX-88(ecallantide)administered subcutaneously
62706429|NCT03378960|OTHER|omeprazole|omeprazole 20 mg
62706430|NCT05482022|EXPERIMENTAL|speaking valve|Respiratory physical therapy treatments conducted using a speaking valve for 2 weeks (at least 8 treatments).
62706431|NCT05482022|OTHER|control|Respiratory physical therapy treatments conducted without using a speaking valve .
62715041|NCT05942716|EXPERIMENTAL|Tourette disorder|25 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.
62508618|NCT04403763|PLACEBO_COMPARATOR|Placebo Dose|Administered as single drop in one or both eyes
62508619|NCT04403763|EXPERIMENTAL|Cohort 1: AGN-241622 Dose 1 (Low Dose)|Administered as single drop in one eye
62508620|NCT04403763|EXPERIMENTAL|Cohort 2: AGN-241622 Dose 2 (Medium Dose)|Administered as single drop in one eye
62508621|NCT04403763|EXPERIMENTAL|Cohort 3: AGN-241622 Dose 3 (High Dose)|Administered as single drop in one eye
62508622|NCT04403763|EXPERIMENTAL|Cohort 4: AGN-241622 Dose 1 (Low Dose)|Administered as a single drop in each eye
62715042|NCT05986929||Staff on the neurology and geriatric units|Staff that will participate in the electronic survey (N=100) and focus group (N=6-8)
62508623|NCT04403763|EXPERIMENTAL|Cohort 5: AGN-241622 Dose 2 (Medium Dose)|Administered as single drop in each eye
62508624|NCT04403763|EXPERIMENTAL|Cohort 6: AGN-241622 Dose 3 (High Dose)|Administered as single drop in each eye
62508625|NCT06259877||Individuals with stroke over the age of 18|
62508626|NCT06259877||Healthy individuals over the age of 18|
62508627|NCT02539784|EXPERIMENTAL|Spinal Cord Stimulation|
62508628|NCT03782480|ACTIVE_COMPARATOR|Intrarosa|Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
62508629|NCT03782480|PLACEBO_COMPARATOR|Placebo|Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
62508630|NCT01546519|EXPERIMENTAL|1|Control cohort with normal renal and normal hepatic function
62508631|NCT01546519|EXPERIMENTAL|2|Severe renal impairment and normal hepatic function
62508632|NCT01546519|EXPERIMENTAL|3|Mild hepatic impairment and normal renal function
62508633|NCT01546519|EXPERIMENTAL|4|Moderate hepatic impairment and normal renal function
62350241|NCT02203669|ACTIVE_COMPARATOR|Home Therapy|Home Therapy: Study subjects will receive a handout of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist to complete independently at home for four (4) weeks. Will complete the DASH at week 1 and week 4.
62508634|NCT01546519|EXPERIMENTAL|5|Severe hepatic impairment and normal renal function
62508635|NCT02122614|EXPERIMENTAL|Experimental group|
62508636|NCT02122614|ACTIVE_COMPARATOR|Control group|
62508637|NCT02228109|EXPERIMENTAL|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
62508638|NCT02228109|EXPERIMENTAL|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
62508639|NCT02228109|EXPERIMENTAL|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
62508640|NCT05987072|EXPERIMENTAL|Arm 1|This only arm will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
62508641|NCT02247518|OTHER|Group1: Treatment A + Treatment B, PO|Treatment A : Tadarafil 5mg\*1t/day for 5days, Treatment B : Tadarafil 5mg\*1t/day and Tamsulosin 0.2mg\*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
62508642|NCT02247518|OTHER|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg\*1t for 5days, Treatment B : Tamsulosin 0.2mg\*1t/day and Tadalafil 5mg\*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
62508643|NCT05915364||HF patients|Adult subjects with all forms of HF will be recruited
62508644|NCT01845116|OTHER|Single Arm|Single Omegaven® Intervention Arm
62508645|NCT01774630|EXPERIMENTAL|Nilotinib|300 mg/twice a day
62508646|NCT05824494|EXPERIMENTAL|Cadonilimab plus nab-paclitaxel|"Drug: Cadonilimab 10mg/kg,every 3 weeks,IV infusion~Drug: Nab paclitaxel~≤260mg/m2,every 3 weeks,IV infusion"
62508647|NCT02842684|EXPERIMENTAL|Traumacad software|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise . The recent TraumaCad system ( Brainlab® ) allows adjustment of the scales for each patient and the virtual positioning of implants to simulate the response to the return of geometric hip parameters
62350242|NCT04861519||adult subjects who underwent a clinically indicated invasive coronary angiography|adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.
62350243|NCT03697486|EXPERIMENTAL|High Protein|(40,6% protein)
62350244|NCT03697486|EXPERIMENTAL|Moderate Protein|(23.5% protein)
62350245|NCT03697486|EXPERIMENTAL|Low Protein|(12.4% protein)
62350246|NCT04190212|EXPERIMENTAL|High-intensity interval training|Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
62350247|NCT04190212|NO_INTERVENTION|Standard care|Participants will not participate in on-site supervised exercise sessions.
62350248|NCT05568056|EXPERIMENTAL|ASD-EXP and NT-EXP|Autistic children and Neurotypical children who receive intervention between pre and post testing
62350249|NCT05568056|NO_INTERVENTION|ASD-WLC and NT|Autistic children who receive intervention only after their pre and post testing and Neurotypical children who do not receive any intervention
62350250|NCT03842748||Retrospective study group|200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
62350251|NCT03842748||Prospective observational study group|100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
62350252|NCT04401397|EXPERIMENTAL|Early mobilization group|Immediately after ICU extubation, enrolled patients will receive an intensive 30-45 minutes, implemented twice a day early mobilization protocol containing psychological empowerment, detailed informative education of patients and close relatives, close monitoring of the recovery course, frequent parameter protocol configuration, high intensity active progressive pulmonary and musculoskeletal exercises and mobility techniques, close monitoring for early identification and measures for prevention and treatment of complications.
62350253|NCT04401397|ACTIVE_COMPARATOR|Standard care group|Enrolled patients will receive the standard hospital mobilization protocol after their admission to the ward, containing standardized basic pulmonary and mobilization techniques of 15 minutes, once a day.
62350254|NCT05273658|PLACEBO_COMPARATOR|Placebo|Placebo cannabis and placebo alcohol
62350255|NCT05273658|EXPERIMENTAL|Cannabis, No alcohol|18.16% THC, placebo alcohol
62508648|NCT02842684|NO_INTERVENTION|without digital planning|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise
62508649|NCT05483387|EXPERIMENTAL|HBS 2 Resorb Mg|Study arm treated with the HBS 2 Resorb Mg.
62508650|NCT03225014|ACTIVE_COMPARATOR|Physical Therapy|
62508651|NCT03225014|ACTIVE_COMPARATOR|ARP Wave Therapy|
62508652|NCT06087718|EXPERIMENTAL|Maastro applicator in combination with chemoradiotherapy|The intervention is similar to the treatment of arm B of the published OPERA trial, however the endoluminal boost will be given using the Maastro applicator instead of a CXRT device.
62508653|NCT04958252|EXPERIMENTAL|Part A: BI 1569912 low dose|
62508654|NCT04958252|EXPERIMENTAL|Part A: BI 1569912 lower medium dose|
62508655|NCT04958252|EXPERIMENTAL|Part A: BI 1569912 higher medium dose|
62508656|NCT04958252|EXPERIMENTAL|Part A: BI 1569912 high dose|
62350256|NCT05273658|EXPERIMENTAL|Cannabis, Low dose alcohol|18.16% THC, .07 breath alcohol concentration
62350257|NCT05273658|EXPERIMENTAL|Placebo cannabis, High dose alcohol|\<.1% THC, .10 Breath alcohol concentration
62350258|NCT05273658|EXPERIMENTAL|Placebo cannabis, Low dose alcohol|\<.1% THC, .07 breath alcohol concentration
62350259|NCT02220946|ACTIVE_COMPARATOR|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. Each patient received a 20 minute session once a week for total 8 sessions
62350260|NCT02220946|PLACEBO_COMPARATOR|plasebo|sham electrical stimulation
62350261|NCT03685487||patients with failures of decolonization S. aureus|patients with failures of decolonization S. aureus in their nose
62350262|NCT03410927|EXPERIMENTAL|TAS0728|Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)
62350263|NCT04839536|ACTIVE_COMPARATOR|Target controlled infusion (TCI) propofol|For TCI propofol group, all patients will receive nasal CPAP mask and nasal breathing with oxygen of 3 litre/min. We will utilize the Schneider model to target effect-site (Cet) starting from 0.5 mcg/ml and with a gradual 0.5mcg/ml increment every 30s until OAAS score of 3 is achieved. For any patients with OAAS score \< 3, Cet will be decreased by a decremental 0.5 mcg/ml. The deepest level of sedation will be recorded.
62350264|NCT04839536|EXPERIMENTAL|Sevoflurane sedation|Patients randomised to this arm will be given time to familiarise with the nasal continuous positive airway pressure (CPAP) mask and nasal breathing with oxygen 3 litre/min via a Bain anaesthetic circuit before the introduction of sevoflurane. Once the patient starts to adapt to nasal CPAP mask, sevoflurane will be delivered, starting with a concentration of 0.2% and increase stepwise by 0.2% every 30s until sedation score of OAAS of 3 is achieved. Anaesthetist in charge will assess and maintain sedation endpoint to OAAS 3. If patient is over sedated, sevoflurane concentration will be reduced by 0.2% until OAAS 3. The deepest level of sedation will be recorded.
62350265|NCT04649619|OTHER|Single-arm-study|Prospective clinical trial with intentional sample selection that aims to describe the results of the gastric Bypass surgery modified by De Melo, for the purpose of endoscopic access to the excluded remaining stomach, as well as to monitor the clinical conditions of comorbidities and the quality of life of the patient.
62350266|NCT01428999|EXPERIMENTAL|probiotics|1 pack bid use for 3 weeks
62350267|NCT01428999|PLACEBO_COMPARATOR|Placebo|placebo 1pack bid for 3 weeks
62350268|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
62350269|NCT00807300|ACTIVE_COMPARATOR|brachytherapy|
62350270|NCT00807300|OTHER|TACE|transarterial chemoembolization
62350271|NCT02726529|EXPERIMENTAL|Brighter Bites|Children of families in the intervention group will also receive the Coordinated Approach to Child Health (CATCH) school-based curriculum in addition to families receiving fresh fruits and vegetables to take home from school once a week along with nutrition education for 8 weeks in Fall and 8 weeks in Spring semesters of the school year.
62350272|NCT02726529|ACTIVE_COMPARATOR|Comparison|
62350273|NCT04311801|EXPERIMENTAL|OCT Arm|Each patient underwent OCT examinations.
62350274|NCT01225978||GeneInsight Clinic (GIC)|The Group/Cohort in this study are geneticists, physicians, and genetic counselors who are using the GeneInsight Clinic (previously known as Patient Genome Explorer) to receive and store genetic test reports and variant update information.
62350275|NCT03783728||Untreated Latent Tuberculosis Infection|Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
62350276|NCT01030380|EXPERIMENTAL|Slendertone Face NMES|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
62350277|NCT01030380|NO_INTERVENTION|Control Group: No NMES|Control Group: No NMES over the course of 12 weeks.
62706432|NCT05784012|EXPERIMENTAL|Cohort A|"Three stages:~Neoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until 48 hours prior to the start of definitive radiotherapy (day 0).~Concurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday) with concurrent Cisplatin at a dose of 100 mg/m2 intravenously on day 1 of week 1, week 4 and week 7.~Maintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily at a dose of 200 or 300 mg in cycles of 21 days."
62350278|NCT00560222|ACTIVE_COMPARATOR|A|This group will receive daily lactoferrin supplementation
62350279|NCT00560222|PLACEBO_COMPARATOR|B|placebo
62350280|NCT03789890|EXPERIMENTAL|Healthy men|Healthy male adults from Germany receiving BAY1902607 during study period 1 (length = 6 days) and BAY1902607 + Itraconazole during study period 2 (length = 15 days), separated by a washout phase.
62350281|NCT00967109|ACTIVE_COMPARATOR|Allowed drop in hemoglobin to 4,5-5,5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
62350282|NCT00967109|EXPERIMENTAL|Allowed drop in hemoglobin to 5,5-6,5 mmol/L|Transfusion with red blood cells to level between 5.5-6.5 mmol/L
62350283|NCT01011036|OTHER|1|
62350284|NCT01011036|OTHER|2|
62350285|NCT01011036|OTHER|3|
62508657|NCT04958252|EXPERIMENTAL|Part B: BI 1569912 low dose|
62508658|NCT04958252|EXPERIMENTAL|Part B: BI 1569912 high dose|
62508659|NCT04958252|EXPERIMENTAL|Part C: BI 1569912|
62508660|NCT04958252|PLACEBO_COMPARATOR|Placebo|
62508661|NCT04927325|OTHER|central line with a reddened exit site|A standardized set of photos will be taken of 10 central lines with an erythema at exit site (visible to the naked eye)
62508662|NCT04927325|OTHER|Control Group: central line without a reddened exit site|A standardized set of photos will be taken of 10 newly inserted CVC (as a control over time to evaluate the in-patient redness and the impact of irritation of a CVC)
61966181|NCT06204913|EXPERIMENTAL|Left, black, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon plus text design, and height that is 100% of size of the menu text height.
61966182|NCT06204913|EXPERIMENTAL|Left, black, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, boxed icon design, and height that is 100% of size of the menu text height.
61966183|NCT06204913|EXPERIMENTAL|Right, black, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon only design, and height that is 100% of size of the menu text height.
61966184|NCT06204913|EXPERIMENTAL|Right, black, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon plus text design, and height that is 100% of size of the menu text height.
61966185|NCT06204913|EXPERIMENTAL|Right, black, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, boxed icon design, and height that is 100% of size of the menu text height.
61966186|NCT06204913|EXPERIMENTAL|Left, red, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon only design, and height that is 100% of size of the menu text height.
61966187|NCT06204913|EXPERIMENTAL|Left, red, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon plus text design, and height that is 100% of size of the menu text height.
61966188|NCT06204913|EXPERIMENTAL|Left, red, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, boxed icon design, and height that is 100% of size of the menu text height.
61966189|NCT06204913|EXPERIMENTAL|Right, red, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon only design, and height that is 100% of size of the menu text height.
61966190|NCT06204913|EXPERIMENTAL|Right, red, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon plus text design, and height that is 100% of size of the menu text height.
61966191|NCT06204913|EXPERIMENTAL|Right, red, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, boxed icon design, and height that is 100% of size of the menu text height.
62350286|NCT03833375|NO_INTERVENTION|Usual Care (n=20)|Control: general information about TBI from Center for Disease Control (CDC)/about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
62350287|NCT03833375|EXPERIMENTAL|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
62350288|NCT04721977|EXPERIMENTAL|Tucatinib + Trastuzumab + Capecitabine|Participants will receive tucatinib plus trastuzumab plus capecitabine. Tucatinib 300 mg will be administered orally twice daily (BID). Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose thereafter, will be administered intravenously (IV) on Day 1 of each 21-day cycle. Capecitabine 1000 mg/m\^2 will be administered orally BID on Days 1-14 of each 21-day cycle. Tucatinib, trastuzumab and capecitabine treatment will continue until unacceptable toxicity, disease progression, death, withdrawal of consent or study closure.
62350289|NCT04074278||development groups|The development groups included 150 patients derived from outpatients in Peking University First Hospital, between March 1st, 2014 and November 26th 2014.
62508663|NCT02618226||Optic nerve ultrasound|Optic nerve sheath diameter (ONSD) measurement will be performed in subjects with concomitant measurement of Intracranial Pressure (ICP) from an invasive ICP monitor. The operator measuring ONSD will be blinded to concomitant ICP.
62508664|NCT01841541|EXPERIMENTAL|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
62508665|NCT01841541|NO_INTERVENTION|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
62508666|NCT05389709||Pharmacy based survey|Patients receive a questionnaire to fill out and return it the Contract Research Organization (CRO) or, alternatively to the pharmacy.
62706433|NCT05784012|EXPERIMENTAL|Cohort B|"Three stages:~Neoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until the start of definitive radiotherapy (day 0).~Concurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday). Niraparib is to be given once daily on a continous basis (200 to 300 mg), from w1 d1 until end of w10 in cycles of 21 days.~Maintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily on a continous basis at a dose of 200 or 300 mg in cycles of 21 days."
62706434|NCT01995097|EXPERIMENTAL|SGR + Support Messages|scheduled gradual reduction text messages for first 3-5 weeks of participation; support text messages through 35th week of pregnancy
62706435|NCT01995097|ACTIVE_COMPARATOR|Support Messages Only|support text messages through 35th week of pregnancy
62706436|NCT00851084|ACTIVE_COMPARATOR|mFOLFOX6 only|modified FOLFOX6 chemotherapy regimen
62706437|NCT00851084|EXPERIMENTAL|mFOLFOX6 + aflibercept|modified FOLFOX6 chemotherapy regimen in combination with aflibercept
62706438|NCT04696029|EXPERIMENTAL|Difluoromethylornithine (DFMO)|study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study.
61966192|NCT06204913|EXPERIMENTAL|Left, black, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon only design, and height that is 150% of size of the menu text height.
61966193|NCT06204913|EXPERIMENTAL|Left, black, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon plus text design, and height that is 150% of size of the menu text height.
61966194|NCT06204913|EXPERIMENTAL|Right, black, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon only design, and height that is 150% of size of the menu text height.
61966195|NCT06204913|EXPERIMENTAL|Right, black, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon plus text design, and height that is 150% of size of the menu text height.
61966196|NCT06204913|EXPERIMENTAL|Left, red, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon only design, and height that is 150% of size of the menu text height.
62508667|NCT05735626|EXPERIMENTAL|Piperine 150μM + tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA (NeuroConn, Germany) with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of piperine (150μM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or piperine + tDCS randomly in the first or second day depending on the randomization."
62706439|NCT03674281|EXPERIMENTAL|Sensor Augmented Pump (SAP)-Closed-Loop Control (CLC)|"SAP: Subjects will be utilizing their own insulin pumps (without automated insulin delivery) plus Dexcom G6 CGM to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period.~CLC with Control-IQ plus CGM: Following SAP, subjects will be utilizing the Tandem t:slim X2 with Control-IQ along with a Dexcom G6 continuous glucose monitor to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period."
61966197|NCT06204913|EXPERIMENTAL|Left, red, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon plus text design, and height that is 150% of size of the menu text height.
61966198|NCT06204913|EXPERIMENTAL|Right, red, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon only design, and height that is 150% of size of the menu text height.
61966199|NCT06204913|EXPERIMENTAL|Right, red, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon plus text design, and height that is 150% of size of the menu text height.
61966200|NCT06204913|EXPERIMENTAL|Left, red, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, boxed icon design, and height that is 150% of size of the menu text height.
61966201|NCT06204913|EXPERIMENTAL|Left, black, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, boxed icon design, and height that is 150% of size of the menu text height.
61966202|NCT06204913|EXPERIMENTAL|Right, red, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, boxed icon design, and height that is 150% of size of the menu text height.
61966203|NCT06204913|EXPERIMENTAL|Right, black, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, boxed icon design, and height that is 150% of size of the menu text height.
61966204|NCT04983654|EXPERIMENTAL|Patients with limb ulcer|Patients with sickle cell disease and suffering from limb ulcer
61966205|NCT04983654|EXPERIMENTAL|Patients without limb ulcer|Patients with sickle cell disease without any limb ulcer
61966206|NCT00954434|EXPERIMENTAL|red wine|intervention: dietary supplement intake of red wine on a daily basis, 1 glass/day for women, 2 for men
61966207|NCT00954434|NO_INTERVENTION|total abstention from alcohol|
62350290|NCT04074278||validation groups|The validation groups included 150 patients derived from outpatients in Peking University First Hospital, between November 27th 2014 and December 1st, 2015.
62350291|NCT01794728||Elderly inpatients with heart failure|A single cohort group of elderly patients hospitalized for heart failure.
62350292|NCT02862548|EXPERIMENTAL|TAF|TAF 25 mg once daily for 48 weeks
62350293|NCT02862548|ACTIVE_COMPARATOR|TDF-Containing Regimens|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
62706440|NCT02435030||NP-C Patients|NPC type 1 or 2 patients aged 2-18 years
62706441|NCT04243148|EXPERIMENTAL|Multifactorial intervention|Frail and pre-frail patients will receive multifactorial intervention consisting of home exercise, BCAA supplements and a multispecies probiotic for 12 months.
62350294|NCT02862548|EXPERIMENTAL|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF 25 mg once daily for an additional 144 weeks.
62350295|NCT02401802|EXPERIMENTAL|Low-residue diet|The experimental group will receive 4 days of low-residue diet Laxative 4 liters polyethylene glycol 4000 in split fashion.
62706442|NCT04243148|EXPERIMENTAL|Control group|Frail and pre-frail patients will be followed but will not receive any specific intervention.
61966208|NCT02498860|EXPERIMENTAL|Pemebit plus Cisplatin|Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles
61966209|NCT03192254|ACTIVE_COMPARATOR|Self-Monitoring Control|Daily tracking of fruit and vegetable consumption
61966210|NCT03192254|EXPERIMENTAL|Daily Incentives|Incentives for fruit and vegetable consumption delivered daily
61966211|NCT03192254|EXPERIMENTAL|Delayed Lump Sum Incentives|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
61966212|NCT01250405|ACTIVE_COMPARATOR|Cinacalcet|
62144912|NCT00838994|EXPERIMENTAL|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
61966213|NCT01250405|PLACEBO_COMPARATOR|Placebo|
61966214|NCT04802460|EXPERIMENTAL|virtual reality|Patients assigned to the VR group will be engaged with the VR using a publicly available VR set. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
61966215|NCT04802460|NO_INTERVENTION|control arm|Patients in the control arm will undergo standard of care office hysteroscopy. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
61966216|NCT05288075|EXPERIMENTAL|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant A|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant A in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
61966217|NCT05288075|EXPERIMENTAL|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant B|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant B in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
61966218|NCT05288075|EXPERIMENTAL|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant C|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant C in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
61966219|NCT05288075|ACTIVE_COMPARATOR|Ultibro® Breezhaler® 85/43 µg inhalation powder, hard capsule|Each subject will receive 2 capsules of Ultibro® Breezhaler® (=Indacaterol/glycopyrronium) as a single dose in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
61966220|NCT02847156|OTHER|cystic fibrosis infants|1 year follow-up in CF infants
61966221|NCT00982878|EXPERIMENTAL|Maraviroc|
61966222|NCT04105153||TKI-treated advanced EGFR+ NSCLC|Patients with advanced EGFR-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors
62144913|NCT00838994|ACTIVE_COMPARATOR|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Deltoideus \[in the middle of the line insertion of Binao LI 14 and acromion\], Forearm \[1 inch laterally of the middle point between Shaohai HE3 and Shenmen HE7\], Upper arm \[1 inch laterally of Tianfu LU 3\] and Lower leg \[0.5 inch dorsally of Xuanzhong GB39\]. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
62144914|NCT00838994|PLACEBO_COMPARATOR|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
62350296|NCT02401802|ACTIVE_COMPARATOR|Usual care|"The control group will receive 3 days of low-residue diet followed by 24 hours of liquid diet.~Laxative 4 liters polyethylene glycol 4000 in split fashion."
62350297|NCT02746354|EXPERIMENTAL|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
62350298|NCT02746354|NO_INTERVENTION|Usual care|
62350299|NCT03811886|EXPERIMENTAL|Phase I: Natalizumab|"Traditional 3+3 design escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed a maximum dose of 300mg~Phase II treatment to continue if the participant has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS as defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If the participant has progressive disease after 6 cycles, they will be removed from the study."
62706443|NCT01901692|EXPERIMENTAL|TACE+External beam RT|Transarterial chemoembolization plus external beam radiation therapy
62706444|NCT01901692|ACTIVE_COMPARATOR|Sorafenib|Sorafenib 800 mg/day orally
62706445|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
61966223|NCT03780855|EXPERIMENTAL|nerve scaffold group|the experimental group of cases with peripheral sensory nerve injuries will be treated with nerve scaffold.
61966224|NCT03780855|NO_INTERVENTION|non-nerve scaffold group|the control group of cases will be treated without nerve scaffold.
61966225|NCT00878774|EXPERIMENTAL|Cohort 1|ToleroMune Ragweed, subjects to receive either active or placebo comparator
62706446|NCT04533945|OTHER|FreeStyle Libre Device|Inpatients admitted to the medical-surgical units that are eligible for the trial will have the FreeStyle Libre device will be placed by the inpatient diabetes team at the discharge and glucose log will be obtained in 2 weeks followed by Hba1c in 3 months.
61966226|NCT00878774|EXPERIMENTAL|Cohort 2|ToleroMune Ragweed or placebo comparator
61966227|NCT00878774|EXPERIMENTAL|Cohort 3|ToleroMune Ragweed or placebo comparator
61966228|NCT00878774|EXPERIMENTAL|Cohort 4|ToleroMune Ragweed or placebo comparator
61966229|NCT00878774|EXPERIMENTAL|Cohort 5|ToleroMune Ragweed or placebo comparator
61966230|NCT05765240|EXPERIMENTAL|Group 1|Hyaluronic acid gel will be applied to the extraction site of the patients in group 1 immediately after the extraction.
61966231|NCT05765240|EXPERIMENTAL|Group 2|"Alveolar socket in group 2, will ve irradiated with an energy dose of J/cm2, 20mW/670 nm potency and 4 for 7 minutes immediately after extraction.~It will be irradiated with an energy dose of J/cm2."
61966232|NCT05765240|NO_INTERVENTION|Control Group|
61966233|NCT01482884|EXPERIMENTAL|1|tralokinumab (CAT-354) sc injection
61966234|NCT01482884|PLACEBO_COMPARATOR|2|placebo sc injection
61966235|NCT05444192|ACTIVE_COMPARATOR|insoles manufactured from foam-box cast|Both arms are currently standard treatment within the NHS GGC Orthotic Department. There are no experimental interventions in the study.
61966236|NCT05444192|ACTIVE_COMPARATOR|insoles manufactured from direct 3D scan|Both arms are currently standard treatment within the NHS GGC Orthotic Department. There are no experimental interventions in the study.
61966237|NCT05955729|EXPERIMENTAL|Nap group|The experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
61966238|NCT05955729|ACTIVE_COMPARATOR|Control group|The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
61966239|NCT02048891|ACTIVE_COMPARATOR|hCG trigger|Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
61966240|NCT02048891|EXPERIMENTAL|GnRH agonist trigger|ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
61966241|NCT04885361|EXPERIMENTAL|Arm 1 injection|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
61966242|NCT04885361|EXPERIMENTAL|Arm 2 injections separated by 21 days|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
61966243|NCT05145530|ACTIVE_COMPARATOR|Group C|selective anterior cervical discectomy and fusion (ACDF)
61966244|NCT05145530|EXPERIMENTAL|Group SNRB|US-guided selective nerve root block (SNRB) then selective anterior cervical discectomy and fusion (ACDF)
62706447|NCT01272427|EXPERIMENTAL|noncaloric beverage|noncaloric sweetened beverage administered 30 min prior to mealtime
62706448|NCT01272427|EXPERIMENTAL|noncaloric beverage (60 min)|noncaloric sweetened beverage administered 60 min prior to mealtime
61966245|NCT02010775|ACTIVE_COMPARATOR|BOTOX® 24U|Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
61966246|NCT02010775|ACTIVE_COMPARATOR|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
61966247|NCT02010775|ACTIVE_COMPARATOR|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
61966248|NCT02010775|ACTIVE_COMPARATOR|BOTOX® 96U|Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
61966249|NCT02010775|PLACEBO_COMPARATOR|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
61966250|NCT03907358||cataract in old age|
61966251|NCT03907358||cataract in young age|
61966252|NCT03906123|EXPERIMENTAL|NBP|DL-3-n-butylphthalide (NBP), soft capsule, 200mg Tid, po, for 48 weeks.
61966253|NCT03906123|PLACEBO_COMPARATOR|Placebos|Placebo, soft capsule, 200mg Tid, po, for 48 weeks.
62706449|NCT01272427|EXPERIMENTAL|glucose beverage|glucose beverage administered 30 min prior to mealtime
61966254|NCT00618072|PLACEBO_COMPARATOR|A: Study diet|EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
62706450|NCT01272427|EXPERIMENTAL|glucose beverage (60 min)|glucose beverage administered 60 min prior to mealtime
61966255|NCT00618072|ACTIVE_COMPARATOR|B: Study diet plus Metformin|"Metformin and Rosiglitazone Placebo~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
61966256|NCT00618072|ACTIVE_COMPARATOR|C: Study diet plus metformin and avandia|"Metformin and Rosiglitazone~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
61966257|NCT06040125|EXPERIMENTAL|Exercise Group|Participants will partake in a 16-week supervised exercise program.
61966258|NCT06040125|EXPERIMENTAL|Attention Control Group|Participants will continue with their normal daily activities.
61966259|NCT05501730||Pre-Quantra|Patients undergoing cardiac surgery prior to the introduction of the Quantra.
62706451|NCT01272427|EXPERIMENTAL|whey protein beverage|whey protein beverage administered 30 min prior to mealtime
62706452|NCT01272427|EXPERIMENTAL|whey protein beverage (60 min)|whey protein beverage administered 60 min prior to mealtime
61966260|NCT05501730||Post-Quantra|Patients undergoing cardiac surgery after the introduction of the Quantra.
61966261|NCT00563979|ACTIVE_COMPARATOR|1|VitaluxPlus®
61966262|NCT00563979|ACTIVE_COMPARATOR|2|Omega 3
61966263|NCT01847794|EXPERIMENTAL|chemotheropy|
62144915|NCT03352713|EXPERIMENTAL|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
61966264|NCT01695902|EXPERIMENTAL|Levosert-20|Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
61966265|NCT01695902|ACTIVE_COMPARATOR|Mirena®|Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
61966266|NCT00615498||Surgical cases|Subjects who are undergoing bariatric surgery
61966267|NCT00615498||Controls|Subjects who qualify for bariatric surgery but do not undergo the procedure
61966268|NCT05376124||original therapy|ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
61966269|NCT05376124||rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
61966270|NCT01203605||In-patient adult non-cardiac surgery|Consecutive patients admitted to participating centres undergoing elective and non-elective non-cardiac surgery commencing during the seven day study period with a planned overnight stay. All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible.
61966271|NCT05023772|EXPERIMENTAL|Experimental Treatment of Laser Interstitial Thermal Ablation Therapy and Stereotactic Radiosurgery|Patients will undergo laser interstitial thermal ablation and CT guided stereotactic radiosurgery via intensity-modulated radiation therapy on different dates within a one to fourteen day window. The order of treatment is at the treating physicians discretion.
61966272|NCT03767504|EXPERIMENTAL|Musclin|Thymol based dietary supplement
61966273|NCT02948972|EXPERIMENTAL|complete surgery|Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery
62706453|NCT05434468|EXPERIMENTAL|Sustained neutral apophyseal glides group|Sustained neutral apophyseal glides will apply on this group.
62706454|NCT05434468|EXPERIMENTAL|Gong mobilization|mobilization technique
61966274|NCT02948972|ACTIVE_COMPARATOR|In vitro fertilization without surgery|IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.
62144916|NCT00042926|EXPERIMENTAL|Radiolymphoscintigraphy + surgery|"Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H\&E) staining. If negative by H\&E, lymph nodes are further analyzed by immunohistochemistry.~Patients are followed at 30 days."
62144917|NCT01469585|ACTIVE_COMPARATOR|Sub-antimicrobial doxycycline|Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.
62144918|NCT01469585|NO_INTERVENTION|Continuous Oral Contraceptive Pill|Women will take only the continuous oral contraceptive.
62706455|NCT05204121|EXPERIMENTAL|Elpida 40 mg once weekly|elsulfavirine 40mg orally once weekly for 8 weeks
62706456|NCT05204121|EXPERIMENTAL|Elpida 80 mg once weekly|elsulfavirine 80mg orally once weekly for 8 weeks
61966275|NCT01876797|OTHER|ticagrelor-prasugrel|in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.
61966276|NCT05511909|EXPERIMENTAL|opioid stepwise taper + buspirone|up to 45mg/day buspirone during the opioid stepwise taper
62144919|NCT02298166|PLACEBO_COMPARATOR|Standard arm|chemotherapy (MC) in combination with placebo
62144920|NCT02298166|EXPERIMENTAL|Experimental arm|chemotherapy (MC) in combination with crenolanib
62706457|NCT05204121|EXPERIMENTAL|Elpida 160 mg once weekly|elsulfavirine 160mg orally once weekly for 8 weeks
62706458|NCT05691920|ACTIVE_COMPARATOR|Block group|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
62706459|NCT05691920|ACTIVE_COMPARATOR|Opioid group|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
62706460|NCT01721720||Participants with and without ADHD|Participants with and without ADHD
62706461|NCT04770207|EXPERIMENTAL|Group 1: DC-Beads loading with Chemodrug/IL2/PD1/CTLA4 antibodies|Intra-tumor injection of above drugs for patients with previous treatment with PDL1 antibody and relapsed.
61966277|NCT05511909|ACTIVE_COMPARATOR|opioid stepwise taper + lofexidine|up to 2.16mg/day lofexidine during the opioid stepwise taper
61966278|NCT05511909|PLACEBO_COMPARATOR|opioid stepwise taper + placebo|placebo during the opioid stepwise taper
62706462|NCT04770207|EXPERIMENTAL|Group 2: DC-Beads loading with Chemodrug/IL2/PDL1/CTLA4 antibodies|Intra-tumor injection of above drugs for patients with previous treatment with PD1 antibody and relapsed.
61966279|NCT05268900|PLACEBO_COMPARATOR|Volume control ventilation group|Patients' lungs will be ventilated with volume control ventilation mode
61966280|NCT05268900|ACTIVE_COMPARATOR|Pressure control ventilation-volume guaranteed group|patients' lungs will be ventilated with Pressure control ventilation-volume guaranteed mode
62144921|NCT04813991|EXPERIMENTAL|Arm 1 - Ibuprofen Breakthrough|600 mg Ibuprofen for breakthrough pain.
62144922|NCT04813991|ACTIVE_COMPARATOR|Arm 2 - Oxycodone Breakthrough|5 mg of Oxycodone for breakthrough pain.
62144923|NCT03140670|EXPERIMENTAL|Single Arm|
62144924|NCT00895596|EXPERIMENTAL|LB80380 30mg|LB80380 30mg
62706463|NCT04770207|EXPERIMENTAL|Group 3: DC-Beads loading with Chemodrug/IL2/PD1/PDL1/CTLA4 antibodies|Intra-tumor injection of above drugs for patients with previous heavily treated with PD1/PDL1/CTLA4 antibodies and relapsed.
62144925|NCT00895596|EXPERIMENTAL|LB80380 60mg|LB80380 60mg
62144926|NCT00895596|EXPERIMENTAL|LB80380 90mg,|LB80380 90mg
62144927|NCT00895596|EXPERIMENTAL|LB80380 150mg|LB80380 150mg
62144928|NCT00895596|EXPERIMENTAL|LB80380 240mg|LB80380 240mg
62706464|NCT06288438|EXPERIMENTAL|Multicomponent Telerehabilitation Intervention (Group 1)|Veterans randomized to the MCTR group will complete the 24-week study intervention consisting of the Active (weeks 1-6), Transition (weeks 7-12), and Sustainability (weeks 13-24) phases. Participants will receive a total of 16 individual sessions (6 integrated, 4 high-intensity rehabilitation, and 6 self-management intervention sessions).
62350300|NCT00649441|EXPERIMENTAL|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
62350301|NCT00649441|ACTIVE_COMPARATOR|2|Accuretic™ Tablets 20 mg/25 mg
62706465|NCT06288438|OTHER|Education Control (Group 2)|This group will not receive any exercise intervention but will complete 16 sessions with research staff through videoconferencing. These visits will consist of standardized Health Status Update and education sessions on general health topics.
62706466|NCT04893733|EXPERIMENTAL|Vitamin B complex|Randomized patients with AKI to this arm will received during 5 consecutive days IV Vitamin B complex each 12 hours. They will also received the Institution standard of care for AKI.
62706467|NCT04893733|PLACEBO_COMPARATOR|Placebo|Randomized patients with AKI to this arm will received during 5 consecutive days IV placebo each 12 hours. They will also received the Institution standard of care for AKI.
62706468|NCT01350076|ACTIVE_COMPARATOR|control group|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
62706469|NCT01350076|EXPERIMENTAL|study group|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
62706470|NCT00978848||Women seeking emergency contraception|Women seeking emergency contraception
62706471|NCT00978848||Women seeking urine pregnancy testing|Women seeking urine pregnancy testing
62706472|NCT05334836|ACTIVE_COMPARATOR|Pancreatic cystic lesion subjects|Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm
62706473|NCT05334836|ACTIVE_COMPARATOR|Healthy subjects|Healthy subjects
62706474|NCT00567580|ACTIVE_COMPARATOR|PBRT Alone|Prostate bed radiotherapy (PBRT) begins within 6 weeks (+/- 2 weeks) after registration.
62706475|NCT00567580|EXPERIMENTAL|PBRT + STAD|Prostate bed radiotherapy (PBRT) and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before radiotherapy (RT), and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
62706476|NCT00567580|EXPERIMENTAL|PLNRT + PBRT + STADT|Pelvic lymph node radiotherapy (PLNRT), prostate bed radiotherapy (PBRT), and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before RT, and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
62706477|NCT01101126|EXPERIMENTAL|Disease Management|Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
62706478|NCT01101126|ACTIVE_COMPARATOR|Unual care|Care delivered by the primary practitioner with the advice of a consultant pulmonologist
62706479|NCT03005886|EXPERIMENTAL|AMI+CP:|"GCF sampling,periodontal examination,phase I therapy:~Patients, who met the AMI diagnostic criteria with chronic periodontitis. Baseline periodontal examination of AMI patients and 24-48h GCF sampling was carried out in their hospital bed under sufficient illumination using artificial light. Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology. Mucoperiosteal flap operation was performed in cases where needed."
62706480|NCT03005886|ACTIVE_COMPARATOR|Chronic Periodontitis (CP)|"GCF sampling,periodontal examination,phase I therapy:~Systemically healthy chronic periodontitis patients.Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology.Mucoperiosteal flap operation was performed in cases where needed."
62706481|NCT03005886|SHAM_COMPARATOR|Healthy controls|clinically healthy individuals not having any periodontal and systemic diseases history.Comprehensive medical and periodontal examination to confirm that they did not have systemic and periodontal diseases
62706482|NCT05023109|EXPERIMENTAL|GP+PD-1+Tight|"Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
62706483|NCT00517790|EXPERIMENTAL|ABT-869 0.25 mg/kg|Approximately half of the subjects were randomized to receive the high dose
61966281|NCT00607009|EXPERIMENTAL|Intervention|ALIVE - received emails about chosen behavioral intervention path - physical activity, fruits/vegetables or fats/sugars
62144929|NCT02790632|EXPERIMENTAL|EG-1962 Group|"* 1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg~* Up to 21 days of placebo capsules/tablets"
62706484|NCT00517790|EXPERIMENTAL|ABT-869 0.10 mg/kg|Approximately half of the subjects were randomized to receive the Low Dose
62715043|NCT00900497|EXPERIMENTAL|White Blood Cells/Granulocytes|Fresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors
62715044|NCT03278548|EXPERIMENTAL|Volulyte 6%|Volulyte 6% solution for infusion
61966282|NCT00607009|NO_INTERVENTION|Control|no intervention
61966283|NCT05018299|PLACEBO_COMPARATOR|FB704A placebo|placebo
61966284|NCT05018299|EXPERIMENTAL|FB704A|Anti-IL6 antibody
61966285|NCT01304654||ALI/ARDS oncologic patients|Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
62144930|NCT02790632|ACTIVE_COMPARATOR|Enteral Nimodipine Group|"* 1 dose of intraventricular normal saline~* Up to 21 days of oral nimodipine capsules/tablets"
61966286|NCT03501316|ACTIVE_COMPARATOR|Hand Instrumentation|Root surface debridement using hand instruments.
62144931|NCT01650051|PLACEBO_COMPARATOR|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|
62144932|NCT01650051|EXPERIMENTAL|Phenazopyridine Hydrochloride Tables, USP 200 mg|
61966287|NCT03501316|ACTIVE_COMPARATOR|Ultrasonic Instrumentation|Root surface debridement using ultrasonic scaler.
61966288|NCT05181683|EXPERIMENTAL|Co-formulated casirivimab+imdevimab SC|Randomized 1:1
61966289|NCT05181683|EXPERIMENTAL|Co-formulated casirivimab+imdevimab IV|Randomized 1:1
61966290|NCT03519646|EXPERIMENTAL|Experimental Case_Eiglustat|Besides regular ERT, patients also need to take Eiglustat for 24 months.
61966291|NCT06365398|ACTIVE_COMPARATOR|Regular-dose group|3000\~5000 Units of normal heparin was injected via the sheath tube in the systemic heparinization (Regular-dose) group. Half a dose of normal heparin is added after the imaging session has lasted more than half an hour.
61966292|NCT06365398|EXPERIMENTAL|Micro-dose group|Micro-dose group is performed with two bags of 500 milliliter(ml) saline with 2500 Units of heparin were used to make a 5000 Units per liter heparin saline, which was used to infuse anticoagulation.
61966293|NCT06365398|EXPERIMENTAL|heparinization group|No heparinization is performed with no additional heparin is administered by a sheath or arterial route in the third group.
61966294|NCT05699499|EXPERIMENTAL|KeryFlex|Patients 18 years and older presenting with retronychia and/or lichens planus of the toenails and/or fingernails to the Weill Cornell Medicine, Department of Dermatology, specialized nail clinic.
61966295|NCT04993092|EXPERIMENTAL|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
61966296|NCT04993092|ACTIVE_COMPARATOR|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
61966297|NCT02170298|PLACEBO_COMPARATOR|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.~Drug: Placebo"
61966298|NCT02170298|EXPERIMENTAL|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.~Drug: Lisdexamfetamine"
62706485|NCT02467270|EXPERIMENTAL|Cohort A: Ponatinib 45 mg|Ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
62706486|NCT02467270|EXPERIMENTAL|Cohort B: Ponatinib 30 mg|Ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
61966299|NCT05373368|EXPERIMENTAL|home residents|multi purpose activities were performed for home residents
61966300|NCT05373368|EXPERIMENTAL|nursing home residents|multi purpose activities were performed for nursing home residents
61966301|NCT01515709||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of COPD
61966302|NCT04473924|EXPERIMENTAL|Body surface area-based mycophenolate dosing|Intervention group will receive mycophenolate mofetil 750 mg/m\^2/day divided into twice daily dosing.
62706487|NCT02467270|EXPERIMENTAL|Cohort C: Ponatinib 15 mg|Participants received ponatinib 15 mg orally once daily up to data cut-off: 31 May 2020 in each 28 day Cycle.
62706488|NCT06170684||complete remission|
61966303|NCT04473924|ACTIVE_COMPARATOR|Standard (fixed) dosing|Active comparator group will receive standard fixed dosing of mycophenolate mofetil 1000 mg twice daily.
62144933|NCT04404465||Control Group|Participants undergoing electrophysiologic (EP) study or ablation for supraventricular tachycardia (SVT) with no history of AF and does not meet criteria of At Risk Group or AF Group
62350302|NCT04465123|EXPERIMENTAL|Furosemide with spironolactone or hydrochlorothiazide|"IV furosemide dosage will be adjusted according to the protocol as follows. Level 1: previous oral furosemide dose ≤80 mg/day; furosemide 80 mg IV bolus every 6 hours Level 2: previous oral furosemide dose 81-160 mg/day; furosemide 160 mg IV bolus every 6 hours Level 3: previous oral furosemide dose \>160 mg/day; furosemide 250 mg IV bolus every 6 hours Furosemide dosage will be adjusted to keep urine output between 3,000 and 5,000 ml/day and \>600 ml during 6 hours after furosemide administration.~If the urine output \<3,000 ml/day or \<600 ml per 6 hours, furosemide dosage will be increase 1-level up per protocol above.~If the urine output \>5,000 ml/day, furosemide dosage will be reduced 1-level down per protocol above.~Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels."
62350303|NCT04465123|ACTIVE_COMPARATOR|Furosemide with placebo|"IV furosemide dosage will be adjusted according to the pre-defined protocol as shown in the experimental group.~Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels."
61966304|NCT04070274|EXPERIMENTAL|New surgery platform for calcaneal surgery|"The lateral position surgical platform for calcaneus surgery is designed with a bottom board, mats in front and at back of calf and thigh, and two sizes of cover plates, using tunnel principle according to physiological curve of lower limbs."
62350304|NCT04571918|EXPERIMENTAL|Group A: Biodegradable spacer|Intervention group
62706489|NCT06170684||non-complete remission|
62706490|NCT01910155|EXPERIMENTAL|Test|Ciprofloxacin/Dexamethasone
62706491|NCT01910155|ACTIVE_COMPARATOR|Reference|Ciprodex (R)
62706492|NCT01910155|PLACEBO_COMPARATOR|Placebo|Placebo
62715045|NCT03278548|ACTIVE_COMPARATOR|Ionolyte|Ionolyte solution for infusion
61966305|NCT04070274|EXPERIMENTAL|Traditional lateral platform|"The traditional lateral position makes the surgery platform bread-shaped arch surface by using medical mats and putting lower limbs superimpose on each other"
61966306|NCT05346471|OTHER|Acute posterior fossa lesions|Subjects will receive additional multimodal infratentorial neuromonitoring
61966307|NCT01516554|EXPERIMENTAL|Testosterone undecanoate|
61966308|NCT01516554|PLACEBO_COMPARATOR|Sugar pill|
61966309|NCT04128176|EXPERIMENTAL|Rituximab combined with Omalizumab|All patients will receive daily doxycycline, nicotinamide, and high-potency topical steroids. Additionally, all patients will receive rituximab combined with omalizumab.
61966310|NCT04388618||covid19 positive patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested positive
61966311|NCT04388618||covid19 negative patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested negative
61966312|NCT00817024|EXPERIMENTAL|Xuefu Zhuyu Capsules|
61966313|NCT00817024|ACTIVE_COMPARATOR|Sheng Mai Capsules|
61966314|NCT00817024|PLACEBO_COMPARATOR|Placebo|
61966315|NCT03639298|EXPERIMENTAL|training|children submitted to the Intendu training with motion based cognitive video games software
61966316|NCT03639298|NO_INTERVENTION|no training|children not submitted to the training, entering the study as a control group
61966317|NCT01380275|EXPERIMENTAL|Docetaxel and Irinotecan (DI)|"Combination chemotherapy of Docetaxel and Irinotecan (DI) in recurrent or refractory bone and soft tissue sarcomas.~Docetaxel and Irinotecan (DI) have different biologic targets, mode of action and mechanism of resistance. Preclinical studies have demonstrated an additive or synergistic effect of irinotecan and taxanes when used in combination in human.~Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1 Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8 Therapy consists of 3-week cycles comprising weekly treatment for 2 weeks (docetaxel on D1 and irinotecan on D1 and D8) followed by 1-week rest, and will be continued in the absence of disease progression or unacceptable toxicity."
61966318|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
61966319|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
61966320|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
61966321|NCT05711953|EXPERIMENTAL|Egyfil Pain Lotion|Interventional study on Egyil 50mL will be topically administered ad libitum for three days.
61966322|NCT02151591|EXPERIMENTAL|Integrated Counseling for Tobacco and Alcohol (INT)|Integrated counseling for smoking and alcohol entails weekly counseling for 12-weeks targeting both behaviors. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
61966323|NCT02151591|OTHER|Standard Care for Primary Presenting Concern (SC)|Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
61966324|NCT06227845|EXPERIMENTAL|Intervention|10 infants born by CS to screening negative mothers receive an oral maternal fecal transplant (from their own mother) containing 0.35mg/kg of maternal fecal content at the age of 2-7 days of age.
61966325|NCT06227845|NO_INTERVENTION|Control|12 infants born by CS (8 to screening negative mothers and 4 to screening positive mothers in case of Blastocystis hominis or Dientamoeba fragilis).
61966326|NCT06227845|NO_INTERVENTION|Comparison|Infants born vaginally to mothers with screening negative or mild pathogene findings (Blastocystis hominis or Dientamoeba fragilis)
61966327|NCT05237531|EXPERIMENTAL|Experimental Arm|"Patients in the experimental arm will receive standardized preoperative education in the form of a brief video, interactive quiz, and written handout.~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects."
61966328|NCT05237531|ACTIVE_COMPARATOR|Control Arm|"Patients in the control arm will receive education per the provider's preference (current standard of care).~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects."
61966329|NCT03069547|ACTIVE_COMPARATOR|Quadriceps Exercise program|The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
61966330|NCT03069547|ACTIVE_COMPARATOR|Hip Exercise program|The Hip Exercise (HE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
61966331|NCT00545194|ACTIVE_COMPARATOR|A|sustained release preparation of prostaglandin E2
61966332|NCT00545194|ACTIVE_COMPARATOR|B|short-acting (instant-released) preparation of prostaglandin E2
61966333|NCT04866030||NostraData Database|All prescriptions for Intuniv available in the NostraData database in Austrialia will be analyzed in this study.
61966334|NCT04866030||Physician Survey|Physician will collect medical record data of 100 participants who have been prescribed Intuniv at least once during the study period to treat participants with ADHD.
61966335|NCT01874132|EXPERIMENTAL|Aerobic exercise training|Dose response
62144934|NCT04404465||At Risk Group|"Participants with no prior diagnosis of AF and have:~1. two or more of the following criteria:~   * Age \>65 years of age~  * A diagnosis of hypertension~  * A diagnosis of diabetes~  * A diagnosis of sleep apnea~  * A body mass index (BMI) ≥30~  * Stable heart failure (HF) with preserved or reduced ejection fraction (New York Heart Association Class I, II or III)~  * Chronic kidney disease (CKD) not requiring dialysis~   AND/ OR~2. More than 5% premature atrial complex (PAC) burden on ambulatory ECG monitoring (e.g. holter, ZioPatch, Lifewatch, etc.)"
62144935|NCT04404465||AF Group|Participants who have a history of non-valvular AF or Atrial Flutter (AFL) documented on ECG or ambulatory monitoring within 1 year of enrollment
61966336|NCT01874132|EXPERIMENTAL|Aerobic and resistance exercise training|Dose response
61966337|NCT01874132|NO_INTERVENTION|Control|Non-exercising control group
61966338|NCT04802278||Babies born to mothers convalescent from antenatal COVID-19|
61966339|NCT04802278||Babies born to healthy mothers|
61966340|NCT04802278||Vaccinated mothers|Lactating mothers who received COVID-19 vaccination
61966341|NCT04556695||Questionnaire survey|An initial online questionnaire, based on the International Sedentary Assessment Tool (ISAT), will be distributed to General Practice Specialty Trainees (GPSTs) and General Practitioners (GPs) throughout Northern Ireland.
62144936|NCT06317623||UTD A1, low risk group|A group of fetuses and children with less severe dilation of the urinary tract in second or third trimester of pregnancy
62144937|NCT06317623||UTD A2-3, high risk group|A group of fetuses and children with severe dilation of the urinary tract in second or third trimester of pregnancy
62144938|NCT01787032|EXPERIMENTAL|Period 3: BI 113608+Voriconazole|tablets with 240 ml water
62144939|NCT01787032|EXPERIMENTAL|Period 2: BI 113608+Ketoconazole|tablets with 240 ml water
61966342|NCT04556695||Accelerometer study|A purposive sample of questionnaire respondents will be asked to participate in the accelerometer study. This purposive sample will be based on responses to the online questionnaire. The aim will be to obtain a varied sample, based on questionnaire responses, by selecting individuals with a range of demographic characteristics and self-reported levels of sedentary behaviour. Some participants will also be asked to complete a further online survey, while wearing the accelerometer, regarding their health, wellbeing, burnout and fatigue.
61966343|NCT04556695||Semi-structured interview study|A purposive sample comprising participants of the accelerometer study will be asked to participate in semi-structured interviews. This purposive sample will be based on the accelerometer data. The aim will be to obtain a varied sample, based on accelerometer data, by selecting individuals with a range of different levels of sedentary behaviour, demographic and workplace characteristics. The final number of participants will depend on the saturation of information.
61966344|NCT02635945|EXPERIMENTAL|PBF-680 10 mg|2 capsules: PBF-680, 5 mg capsules for oral administration (excipient: 76 mg microcrystalline cellulose).
61966345|NCT02635945|PLACEBO_COMPARATOR|Placebo|2 capsules: Placebo to PBF-680, as 95.12 mg microcrystalline cellulose capsules.
61966346|NCT02024815|EXPERIMENTAL|External Beam radiotherapy|Single 8 Gy fraction
61966347|NCT02024815|ACTIVE_COMPARATOR|3 Gy x 10 fractions|External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction.
61966348|NCT03489824|EXPERIMENTAL|modified-WIM colonoscopy in RLP|Modified-water immersion method colonoscopy is performed to patients with right-lateral starting position (RLP). Patients will lie in the right lateral position with both hips and knees flexed at the beginning and change the position into supine and at last left-lateral position when it is needed.
61966349|NCT03489824|ACTIVE_COMPARATOR|modified-WIM colonoscopy in LLP|Modified-water immersion method (WIM) colonoscopy is performed to patients with left-lateral starting position (LLP). Patients will lie in the left lateral position with right hip and knee flexed and left leg straight at the beginning and change the position into supine and at last right lateral position when it is needed.
61966350|NCT01993654||Nevus|
62144940|NCT01787032|EXPERIMENTAL|Period 1: BI 113608|tablets with 240 ml water
62144941|NCT00780741|ACTIVE_COMPARATOR|Immediate Office Probing|Probing to be performed in the office setting using topical anesthesia and infant restraint. Probing to be performed either the same day as randomization or within two weeks.
62706493|NCT03663582|EXPERIMENTAL|Teduglutide 0.05 mg|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
62706494|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
62706495|NCT05482295|EXPERIMENTAL|Hepatitis B vaccine lot 1|3 doses Recombinant Hepatitis B new Bulk vaccine lot 1
62706496|NCT05482295|EXPERIMENTAL|Hepatitis B vaccine lot 2|3 doses Recombinant Hepatitis B new Bulk vaccine lot 2
61966351|NCT01993654||Racial Melanosis|
62144942|NCT00780741|ACTIVE_COMPARATOR|Deferred Facility Probing|Probing to be performed in a surgical facility under general anesthesia within four weeks after completion of the 26-week visit if any of the clinical signs persist.
62144943|NCT01874366|EXPERIMENTAL|P11187|"* Part I: Step wise dose escalation in subsequent cohorts and will be based upon the review of safety and tolerability results of the preceding cohort~* Part II: Step wise dose escalation in the multiple dosing for 14 consecutive days after review of the safety and tolerability of the preceding cohorts~* Part III: Study drug will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 7-10 days"
61966352|NCT01993654||Primary Acquired Melanosis|
61966353|NCT01993654||Malignant Melanoma|
61966354|NCT01993654||Normal|
61966355|NCT06304220|ACTIVE_COMPARATOR|Group DSG: Desogestrel|Desogestrel Cerazet® 75 mg/day orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).
62144944|NCT01874366|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
62144945|NCT04329598|EXPERIMENTAL|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
62144946|NCT04329598|EXPERIMENTAL|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
62144947|NCT00815100|PLACEBO_COMPARATOR|Placebo|
62144948|NCT00815100|ACTIVE_COMPARATOR|Ivabradine|
62144949|NCT06368999|EXPERIMENTAL|heatlhcare workers|
61966356|NCT06304220|ACTIVE_COMPARATOR|Group MPA: Medroxyprogesterone|Medroxyprogesterone acetate Progevera® 10 mg/day orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).
61966357|NCT01302093|EXPERIMENTAL|Experimental Tablet|A single 100 mg dose of an experimental Racecadotril Film-Coated Tablet (FCT)
61966358|NCT01302093|ACTIVE_COMPARATOR|Marketed Capsule|A single 100 mg dose of a marketed Racecadotril capsule
62706497|NCT05482295|EXPERIMENTAL|Hepatitis B vaccine lot 3|3 doses Recombinant Hepatitis B new Bulk vaccine lot 3
62706498|NCT05482295|ACTIVE_COMPARATOR|Active Control: Hepatitis B vaccine (registered)|3 doses Recombinant Hepatitis B vaccine (registered)
61966359|NCT02495441||Dribbling group|Any woman who presents with alleged leakage of amniotic fluid. They will under go rapid Immunoassay Tests for the Detection of PROM
61966360|NCT01183156|ACTIVE_COMPARATOR|Re-invitation letter|
61966361|NCT01183156|ACTIVE_COMPARATOR|Educational Meeting|
61966362|NCT00111345|EXPERIMENTAL|1|Daunoxome, standard risk
61966363|NCT00111345|ACTIVE_COMPARATOR|2|Idarubicin, standard risk
61966364|NCT00111345|EXPERIMENTAL|3|Daunoxome, high-risk, 2-CDA
61966365|NCT00111345|ACTIVE_COMPARATOR|4|Idarubicin, high-risk, nothing
61966366|NCT00847860|EXPERIMENTAL|1|Cilostazol
62144950|NCT03403036|EXPERIMENTAL|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
62706499|NCT05120804|ACTIVE_COMPARATOR|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
61966367|NCT00847860|ACTIVE_COMPARATOR|2|Asprin
61966368|NCT03671460|EXPERIMENTAL|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
61966369|NCT01224431|EXPERIMENTAL|Buffered lidocaine J-tip|Needleless injection of buffered lidocaine prior to lumbar puncture versus placebo (Normal saline)
61966370|NCT01224431|PLACEBO_COMPARATOR|Normal saline J-tip|Needleless injection of normal saline (placebo) prior to lumbar puncture versus use of buffered lidocaine
61966371|NCT03777878|ACTIVE_COMPARATOR|Carbetocin plus placebo to TA and placebo to oxytocin|100 μg carbetocin ampoule or separate placebo ampoule was diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby plus two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion
61966372|NCT03777878|ACTIVE_COMPARATOR|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1gm TA in 100ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
62144951|NCT02142725|EXPERIMENTAL|LT-02|LT-02 0.8g four times daily
61966373|NCT03777878|ACTIVE_COMPARATOR|oxytocin plus placebo to TA and placebo to carbetocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
61966374|NCT03462082|NO_INTERVENTION|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
61966375|NCT03462082|EXPERIMENTAL|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
61966376|NCT03462082|EXPERIMENTAL|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
61966377|NCT03292588|EXPERIMENTAL|Mepolizumab|Intervention: Mepolizumab plus guidelines-based standard of care asthma treatment.
61966378|NCT03292588|PLACEBO_COMPARATOR|Placebo|Intervention: Placebo for mepolizumab plus guidelines-based standard of care asthma treatment.
61966379|NCT03674749|ACTIVE_COMPARATOR|Hyperbaric Oxygen|Hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks
61966380|NCT03674749|EXPERIMENTAL|Meditation with Hyperbaric Oxygen|Meditation session combined with each hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks,
61966381|NCT06504901||CapeOX+PD-1+IL-2+rhG-CSF|Tislelizumab 200mg ivd D1 + Interleukin 2 100IU HD,QOD d1-d14+rhG-CSF 5mcg/kg HD, QD d1-d14 +CapeOX (Capecitabine: 1000mg/m2 bid po, d1-d14；Oxaliplatin 130mg/m2 ivd, d1) 6 cycles
61966382|NCT02038023|OTHER|IV iron|Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.
61966383|NCT03550898|OTHER|Dynamic ultrasonography|Dynamic ultrasonography was performed in all patients who underwent urodynamics, simultaneously.
61966384|NCT01943890|EXPERIMENTAL|Physiotherapy and hypertonic saline|Chest physiotherapy integrated with inhalation of hypertonic saline
61966385|NCT00808366|EXPERIMENTAL|RV4104A ointment|
61966386|NCT00808366|ACTIVE_COMPARATOR|bifonazole-urea ointment|
61966387|NCT04216771|EXPERIMENTAL|IDA with ID Cytarabine|
61966388|NCT04216771|ACTIVE_COMPARATOR|ID Cytarabine|
62144952|NCT02142725|EXPERIMENTAL|B: LT-02|LT-02 1.6g twice daily
62144953|NCT02142725|PLACEBO_COMPARATOR|Placebo|LT-02 Placebo
61966389|NCT00902408|EXPERIMENTAL|Lutein|Lutein enriched eggs
61966390|NCT00902408|PLACEBO_COMPARATOR|Placebo|Non enriched
61966391|NCT01658072|EXPERIMENTAL|Peri-Articular Injection|
61966392|NCT01658072|ACTIVE_COMPARATOR|Epidural Patient Controlled Analgesia (Epidural PCA)|
61966393|NCT04897932|ACTIVE_COMPARATOR|Adult nocturia|Use of device over 28 days
61966394|NCT04897932|ACTIVE_COMPARATOR|Adult urge urinary incontinence|Use of device over 28 days
61966395|NCT04897932|ACTIVE_COMPARATOR|Adult frequency urinary incontinence|Use of device over 28 days
61966396|NCT04897932|ACTIVE_COMPARATOR|Adult functional incontinence|Use of device over 28 days
61966397|NCT00948129|ACTIVE_COMPARATOR|Group I (standard care)|Participants undergo standard of care smoking cessation intervention consisting of brief advice to quit smoking, NRT, and self-help written materials.
61966398|NCT00948129|EXPERIMENTAL|Group II (enhanced care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number and supportive text messages daily for 12 weeks.
61966399|NCT00948129|EXPERIMENTAL|Group III (intensive care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number, supportive text messages daily for 12 weeks, and a smoking cessation telephone call over 15 minutes weekly for 12 weeks.
61966400|NCT01129609||Participants with Successful Secondary Endovascular Treatment|
61966401|NCT02116907|EXPERIMENTAL|Perampanel|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
61966402|NCT02132130|EXPERIMENTAL|CGF166 dose 20 uL|single dose volume #1
61966403|NCT02132130|EXPERIMENTAL|CGF166 dose 30 and 40 uL|single dose volume #2
61966404|NCT02132130|EXPERIMENTAL|CGF166 dose 40 uL|single dose volume #3
61966405|NCT02132130|EXPERIMENTAL|CGF166 dose 60 uL|single dose volume #4
61966406|NCT02132130|EXPERIMENTAL|CFG166 dose 30 uL|Single dose volume #5
62144954|NCT01211106|EXPERIMENTAL|Arm 1: Integrated Conditions|Motivational enhancement therapy for addiction is combined with Prolonged exposure therapy for PTSD from the beginning of treatment. Both are delivered by the same provider throughout treatment.
62144955|NCT01211106|EXPERIMENTAL|Arm 2 Sequential therapy|Motivational enhancement therapy for addiction is delivered in the first 4 weeks and only after the addiction is addressed is the Prolonged exposure therapy for PTSD started.
62350305|NCT04571918|ACTIVE_COMPARATOR|Group B: control group|Control group
61966407|NCT03519425|NO_INTERVENTION|Group 1 (Standard of care)|"Participants will be directed to the clinic waiting area to be seen by facility health workers who will direct all further care without any further input from the study team. Available to facility health workers will be:~* Routine HIV testing and counselling, provided by Facility HIV Testers using a rapid fingerprick kit-based algorithm.~* Routine TB screening, with both sputum smear microscopy and Xpert MTB/Rif testing available onsite.~* Routine linkage to the onsite HIV clinic, where patients are registered and assessed for initiation onto antiretroviral therapy by facility HIV Care Clinic health workers. Malawi guidelines recommend universal treatment for HIV. HIV Care Clinic health workers will additionally have access to TB screening tests as described above.~* Routine linkage to the onsite TB clinic, where patients are registered and initiated onto anti-TB treatment. Malawi guidelines recommend universal HIV testing for all patients with confirmed TB."
61966408|NCT03519425|ACTIVE_COMPARATOR|Group 2 (Optimised HIV screening and linkage to care)|"Participants will be directed to the study room located in a separate building. After identity validation participants will be offered a supervised HIV self-testing intervention. Participants will be given brief pre-test instructions and will be asked to self-test in a private area using the OraQuick 1/2 (OraSure Technologies) oral fluid HIV kit. Participants will be supported to read their HIV test result by study Research Assistants, and provided with confirmatory HIV testing by the trained Research Assistants.~* HIV-positive participants will be supported by Research Assistants to register at the onsite HIV care clinic, and all further care (including TB screening) will be directed by facility health workers without any further study input.~* HIV-negative participants will be referred to the clinic waiting area (with a copy of their HIV test results) to be seen by the facility health workers who will direct all further investigations without further study input."
61966409|NCT03519425|ACTIVE_COMPARATOR|Group 3 (Optimised HIV and TB screening and linkage to care)|"Participants will be directed to the Study Room. After identity validation, they will be offered the HIV self-testing and linkage intervention as described above for Group 2. Additionally, they will be offered a TB screening intervention comprising of:~* A digital chest x-ray using the study MinXray unit.~* Chest x-rays will be immediately classified by the CAD4TB software running on the MinXray unit laptop as either high probability of TB, or low probability of TB.~* Participants whose chest x-rays have a low probability of TB will be referred to facility health workers (at either the onsite HIV care clinic if HIV-positive, or the clinic waiting area), with copies of their results for further routine care, and without further study input.~* Participants whose chest x-ray x-ray show a high probability of TB will submit a single spot sputum sample for Xpert testing (done in the clinic). Those with confirmed TB will be linked to register at the onsite TB clinic."
61966410|NCT05405205|EXPERIMENTAL|synbiotic|synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)
62706500|NCT05120804|EXPERIMENTAL|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus brief and structured counseling on family functioning
61966411|NCT05405205|EXPERIMENTAL|probiotic|probiotic consisting of the identical three different strains of Lactobacillus fermentum
61966412|NCT05405205|PLACEBO_COMPARATOR|placebo|microcrystalline cellulose
61966413|NCT05409456|EXPERIMENTAL|mild aerobic exercise|group A was given mild aerobic exercise on treadmill with warm up exercise
61966414|NCT05409456|EXPERIMENTAL|moderate aerobic exercise|group B was moderate aerobic on treadmill with warm up exercise
61966415|NCT06289998|ACTIVE_COMPARATOR|Tamibarotene Group|
61966416|NCT06289998|PLACEBO_COMPARATOR|Placebo Group|
61966417|NCT03795987|EXPERIMENTAL|Open Label Treatment Arm|Intervention with NightWare Therapeutic System
61966418|NCT04011267|EXPERIMENTAL|Intervention Group|Patients in the intervention group will perform foot-related exercises described in the SOPeD software three times/week at home via web-software. In the follow-up period, patients will follow the same schedule set by the project till the end of the study.
61966419|NCT04011267|NO_INTERVENTION|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
61966420|NCT05677724||Group 1|HBV DNA(\>20000IU/mL)
61966421|NCT05677724||Group 2|HBV DNA(\>2000IU/mL)
62144956|NCT01573338|EXPERIMENTAL|Arm 1|BAY1000394 will be administered in combination with chemotherapy (etoposide and cisplatin or carboplatin) for up to 6 cycles. BAY1000394 will continue beyond Cycle 6 of chemotherapy. Type of chemotherapy for each patient will be decided by the investigator case by case.
62706501|NCT03714516|EXPERIMENTAL|Online psychological intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
61966422|NCT05677724||Group 3|HBV DNA(10-2000IU/mL)
62350306|NCT01444313|OTHER|nelfilcon A OD / narafilcon A OS|Soft contact lens without UV protection worn on the right eye (OD) and soft contact lens with UV protection worn on the left eye (OS).
62350307|NCT01444313|OTHER|narafilcon A OD / nelfilcon A OS|Soft contact lens with UV protection worn on the right eye (OD) and soft contact lens without UV protection worn on the left eye (OS).
62706502|NCT00242606|ACTIVE_COMPARATOR|1|Levetiracetam 2000mg/day
62706503|NCT00242606|ACTIVE_COMPARATOR|2|Lamotrigine
62706504|NCT02101255|EXPERIMENTAL|Curodont Repair|Application on Day 0 and Day 360
62706505|NCT02101255|ACTIVE_COMPARATOR|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
62706506|NCT00883155|EXPERIMENTAL|1|Bupropion HCl 100 mg Tablets (Invamed Inc.)
62706507|NCT00883155|ACTIVE_COMPARATOR|2|Wellbutrin 100 mg Tablets (Glaxo Wellcome)
62715046|NCT06717698|EXPERIMENTAL|Dosing scheme a: NNC0519-0130|Participants will receive once-weekly subcutaneous (s.c) injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.
62715047|NCT06717698|PLACEBO_COMPARATOR|Dosing scheme a: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.
62715048|NCT06717698|EXPERIMENTAL|Dosing scheme b: NNC0519-0130|Participants will receive once-weekly s.c injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.
61966423|NCT05677724||Group 4|HBV DNA(=\<10IU/mL)
61966424|NCT05677724||Group 5|HBV DNA(0 IU/mL)
61966425|NCT00203996|NO_INTERVENTION|Aim 1: Placebo|One of the 3 treatment arms in Aim 1: Placebo. No subjects were randomized to this arm.
61966426|NCT00203996|EXPERIMENTAL|Aim 1: Pioglitazone|One of the 3 treatment arms in Aim 1: Pioglitazone. No subjects were randomized to this arm.
61966427|NCT00203996|EXPERIMENTAL|Aim 1: Leuprolide + Estrogen/Progestin|One of the 3 treatment arms in Aim 1: depot leuprolide plus estrogen/progestin replacement. No subjects were randomized to this arm.
61966428|NCT00203996|EXPERIMENTAL|Aim 2: PCOS + SDB|One of the 2 study groups in Aim 2: Women with polycystic ovary syndrome (PCOS) and sleep disordered breathing (SDB) were treated with 8 weeks of continuous positive airway pressure (CPAP).
61966429|NCT00203996|EXPERIMENTAL|Aim 2: Matched Controls|One of the 2 study groups in Aim 2: Women who were of similar age to those in the PCOS+SDB group were treated with 8 weeks of continuous positive airway pressure (CPAP). The recruitment of control subjects for this protocol was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria. As a consequence, the sample size of control subjects was insufficient to allow for any meaningful conclusions to be drawn. Statistical analyses were not possible due to insufficient sample size.
62144957|NCT04406532|EXPERIMENTAL|PT-Pal|Participants randomized to the 14-day intervention arm will receive exercise instructions via PT-Pal. The Pt-Pal is a mobile health technology used to facilitate communication between the Care Team and patients, by allowing the team to send from their web-portal, exercise routines, surveys and educational material to the patient's mobile device. The PT-Pal app then captures the patient activity adherence, and reports those results back to the team including a graphical summary about patients' condition and activity. Clinicians can send/receive HIPAA-secure messages with patients. The app was designed to work with intermittent data connectivity typically found in mobile networks by switching between store-and-forward and real-time mode of connectivity to ensure data delivery.
62144958|NCT04406532|ACTIVE_COMPARATOR|Self-guided exercises|Participants randomized to the 14-day control arm will be instructed by research staff on how to use the exercise manual provided at the time of their screening.
62508668|NCT05735626|EXPERIMENTAL|Piperine 1mM+ tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of piperine (1 mM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or piperine + tDCS randomly in the first or second day depending on the randomization."
62508669|NCT05735626|EXPERIMENTAL|Capsaicin 10μM + tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of capsaicin (10 μM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or capsaicin + tDCS randomly in the first or second day depending on the randomization."
62508670|NCT06092190||Group A|
62508671|NCT06092190||Group B|
62508672|NCT06573970|EXPERIMENTAL|active atomoxetine|Active ATX (40mg capsules) will be prepared. Initial dose is 40mg, titrated to 80mg if tolerable in one week.
62706508|NCT04217434|EXPERIMENTAL|Group 300µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 300 µm fibre length will be used in continuous contact mode at a power setting of 1.5 to 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
62508673|NCT06573970|PLACEBO_COMPARATOR|Placebo|placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
62508674|NCT02551679|ACTIVE_COMPARATOR|ACP-01|Injection into lower extremity
62508675|NCT02551679|PLACEBO_COMPARATOR|Placebo|Injection into lower extremity
62508676|NCT05247073|OTHER|Patients of controlled group with routine closure of the episiotomy|The vagina will be stitched using a continuous locking stitch and the perineal muscles and skin are repaired using approximately three or four individual stitches, each needing to be knotted separately to prevent them from dislodging.
62715049|NCT06717698|PLACEBO_COMPARATOR|Dosing scheme b: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.
61966430|NCT00203996|EXPERIMENTAL|Aim 3: REM frag - SWS supp - Baseline|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Slow wave sleep (SWS) suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
61966431|NCT00203996|EXPERIMENTAL|Aim 3: REM frag - Baseline - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
61966432|NCT00203996|EXPERIMENTAL|Aim 3: Baseline - REM frag - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
61966433|NCT00203996|EXPERIMENTAL|Aim 3: SWS supp - REM frag - Baseline|"Each subject was assessed under three experimental conditions in the following order.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
61966434|NCT00203996|EXPERIMENTAL|Aim 3: Baseline - SWS supp - REM frag|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed."
61966435|NCT00090480|EXPERIMENTAL|Vaccine group|
61966436|NCT04967443|ACTIVE_COMPARATOR|Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site|One 2 mg capsule manufactured at the current site, Barceloneta
62350308|NCT06364644|EXPERIMENTAL|Community Champions|"Participants assigned to the Community Champions group will undergo a six-month behavioral intervention. This intervention involves bi-weekly problem-solving training sessions (DECIDE) conducted in groups of 6-10 individuals, along with support from community health workers. Additionally, participants will receive a YMCA membership to exercise with a professional health coach."
62350309|NCT06364644|ACTIVE_COMPARATOR|Homegrown Heroes|"Participants assigned to the Homegrown Heroes will receive a YMCA membership for exercise and a monthly newsletters for 6 months that include education about diabetes self-management, healthy lifestyle and heart failure prevention ."
62350310|NCT05930990|EXPERIMENTAL|Mamas in Harmony (and usual care)|Mamas in Harmony is a 1 hour face to face intervention for mothers and their infants, delivered in groups of 10-12 mother-infant dyads, every week for 8 weeks. Mothers and infants also receive usual postnatal care from health and social care services.
62350311|NCT05930990|NO_INTERVENTION|Control (usual care only)|Mothers and infants receive usual postnatal care from health and social care services.
62350312|NCT02991066||Patients|patients with de novo acute promyelocytic leukemia with hemorrhage.
62350313|NCT02991066||Control|healthy volunteers.
62350314|NCT06366295|EXPERIMENTAL|Subgingival mechanotherapy with perioscopy|Scaling and root planing using ultrasonic scaler and curettes, under the control of a perioscope, enabling real-time, magnified imaging of the root surface.
62350315|NCT06366295|ACTIVE_COMPARATOR|Classical subgingival mechanotherapy|Scaling and root planing using ultrasonic scaler and curettes.
62350316|NCT00980785|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62350317|NCT00980785|EXPERIMENTAL|Active|Ramipril 5mg/day
62350318|NCT04856956|EXPERIMENTAL|Intervention (Use of diagnostic decision support software)|Trainee or nurse practitioner sees patient and uses diagnostic decision support software in developing their differential diagnosis and plan
62350319|NCT04856956|NO_INTERVENTION|Control (Current process)|Trainee or nurse practitioner sees patient but doesn't use diagnostic decision support software in developing their differential diagnosis and plan
62350320|NCT05362331|EXPERIMENTAL|Companion for CAR-T Web Application (CC)|Enrolled participants and caregivers will receive access to the CC web application during the participants Chimeric Antigen Receptor T-cell (CAR-T) therapy. Key components include (1) educational videos and materials, (2) appointment calendars and 'Appointment Companion' features to prepare for clinical appointments, and (3) tools to assist with vital sign and neurological monitoring at home.
62508677|NCT05247073|ACTIVE_COMPARATOR|Patients of study group with Mostafa Maged technique for closure of the episiotomy|The vagina will be stitched with the Mostafa Maged technique, The Mostafa Maged four-stitch technique uses absorbable vicryl threads with round needles 75 mm. The technique will prevent dead space formation, Good and tight hemostasis of the episiotomy strong approximation of the two edges of the episiotomy.
61966437|NCT04967443|EXPERIMENTAL|Prazosin HCL 2 mg capsule Ascoli site|One 2 mg capsule manufactured at the proposed site (Ascoli)
62144959|NCT03069209|EXPERIMENTAL|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
62350321|NCT02389686|NO_INTERVENTION|Without Radiotherapy|Patients just accept nipple-sparing mastectomy (NSM) without radiotherapy.
62350322|NCT02389686|EXPERIMENTAL|Intraoperative Radiotherapy|Followed by nipple-sparing mastectomy (NSM),INTRABEAM IORT was carried out with a single dose of 16 Gy for nipple-areola complex (NAC).
62350323|NCT04266106|PLACEBO_COMPARATOR|Placebo Comparator|
62350324|NCT04266106|EXPERIMENTAL|probiotic|
62350325|NCT05071144||Pediatric Spine Deformity Patients|Standard of care surgery using robotics coupled with navigation
62350326|NCT05414370|ACTIVE_COMPARATOR|Liquid medical oxygen|Liquid medical oxygen will be administered using high-flow nasal cannula delivery system.
62350327|NCT05414370|PLACEBO_COMPARATOR|Synthetic medical air|Synthetic medical air will be administered using high-flow nasal cannula delivery system.
62350328|NCT01477515||End stage renal disease patient|
62508678|NCT04227041|EXPERIMENTAL|HER2 positive metastatic colorectal cancer|
62350329|NCT01477515||Matched controls|
62350330|NCT01900756|ACTIVE_COMPARATOR|Behavioral|"1. Pre-appointment phone text~2. In-clinic educational video~3. Patient report card~4. Post-clinic phone text~5. Outpatient stroke registry"
62350331|NCT01900756|NO_INTERVENTION|Standard care|Routine and customary management.
62350332|NCT02858973|EXPERIMENTAL|Q203|Q203 tablets
62350333|NCT02858973|PLACEBO_COMPARATOR|Placebo|Placebo tablets
61966438|NCT04967443|EXPERIMENTAL|Prazosin HCL 1 mg capsule Ascoli site|Two 1 mg capsule manufactured at the proposed site, Ascoli
61966439|NCT04967443|ACTIVE_COMPARATOR|Prazosin HCL 5 mg capsule Barceloneta site|One 5 mg capsule manufactured at the current site, Barceloneta
61966440|NCT04967443|ACTIVE_COMPARATOR|Prazosin HCL 1 x 5 mg capsule Ascoli site|One 5 mg capsule manufactured at the proposed site, Ascoli
61966441|NCT00812578|ACTIVE_COMPARATOR|Cholecalciferol|
61966442|NCT00812578|PLACEBO_COMPARATOR|Placebo pill|
61966443|NCT02868320|EXPERIMENTAL|Intervention group|This group received a diabetes instruction booklet in addition to daily educational SMS messages and weekly reminders
61966444|NCT02868320|ACTIVE_COMPARATOR|Control group|This group only received a diabetes instruction booklet
61966445|NCT05837819|ACTIVE_COMPARATOR|Active Lighting Intervention|Lighting intervention designed to effect the circadian system then will receive the control lighting intervention.
61966446|NCT05837819|PLACEBO_COMPARATOR|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
62706509|NCT04217434|EXPERIMENTAL|Group 300µm in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes, 300 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 - 3 W. Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
62706510|NCT04217434|EXPERIMENTAL|Group 400µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
62706511|NCT04217434|EXPERIMENTAL|Group 400µm in pulsed contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 t 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
62706512|NCT00388609|EXPERIMENTAL|T|5 mg (ST) to 50 mg (LT)
61966447|NCT06171763|EXPERIMENTAL|Telehome care|"For patients/caregivers assigned to the tele-homecare group, before discharge, instruction on the use of the TytoCareTM system was provided by healthcare personnel trained in the use of the system. Subsequently, each patient give the device they used until the scheduled post-discharge clinical assessment. A parent/caregiver was invited to participate for each pediatric patient.~Every 24 hours, the patient was assessed remotely in synchronous teleconsultation by medical staff; during tele-visit, the physician performed the complete routine procedure, including medical history and physical examination with user friendly medical device and completed the data collection sheet.~At 72 hours after discharge, an in-person clinical assessment was scheduled for outcome evaluation. In particular, during the visit, the complete resolution of the disease state was assessed through the post-discharge objective examination."
61966448|NCT06171763|NO_INTERVENTION|Standard care|"Patients remained hospitalized for the continuation of the treatment. Every 24 hours, the patient was assessed in person by medical staff; the traditional physical examination involved assessment of the clinical parameters using standard equipment such as a digital thermometer, conventional stethoscope, and otoscope and completed the same data collection sheet.~After 72 hours of hospital observation, an in-person clinical examination was conducted to evaluate the outcome. In particular, during the visit, the complete resolution of the disease state was assessed through the post-discharge objective examination."
61966449|NCT00740831|EXPERIMENTAL|A (PGL4001 5 mg)|Drug: PGL4001 5mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
62350334|NCT02405806|EXPERIMENTAL|low carbohydrate food|"The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.~Intervention: Food: Low carbohydrate food"
62350335|NCT02405806|ACTIVE_COMPARATOR|standard food|The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food
62350336|NCT04717778|EXPERIMENTAL|pH milk|Group of children who were given the different types of milk and only the pH was measured
62350337|NCT01946919||cinepazide|Inpatient using the cinepazide in department of neurology
62350338|NCT02720653||Appropriate Medical Therapy|Patients will self-select continued, non-standardized, appropriate medical management of symptoms associated with chronic sinusitis.
62350339|NCT02720653||Endoscopic Sinus Surgery|Patients will self-select endoscopic sinus surgery for symptoms associated with chronic sinusitis.
62508679|NCT01104090|EXPERIMENTAL|C-MAC direct laryngoscopy, then C-MAC indirect laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and then using C-MAC with indirect laryngoscopy.
61966450|NCT00740831|EXPERIMENTAL|B (PGL4001 10mg)|Drug: PGL4001 10 mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
61966451|NCT00740831|ACTIVE_COMPARATOR|C (GnRH-agonist)|PGL4001 matching placebo (oral tablets) and leuprorelin 3.75 mg (intramuscular injection)
62144960|NCT06055491|EXPERIMENTAL|Vitamin D3 injection|1.0mL Vitamin D3 injection at ilsilateral deltoid muscle and extensor muscle strengthening exercise with counter force brace in lateral epicondylitis of elbow
61966452|NCT05554094|EXPERIMENTAL|Psilocybin-assisted therapy|Participants will receive two doses of psilocybin, approximately 2 weeks apart, in conjunction with preparatory and post-psilocybin therapy sessions
62350340|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
62350341|NCT02475850|OTHER|Fall prevention standard of care|"An evidence-based patient-centered intervention that will combine elements of a multifactorial, risk factor-based, standardly-tailored fall prevention strategy developed at Yale, practice guidelines offered by the CDC's STEADI toolbox and the joint American Geriatrics Society/British Geriatrics Society guidelines, and ACOVE practice change approach"
62706513|NCT00388609|EXPERIMENTAL|U|10 mg (ST) to 50 mg (LT)
62706514|NCT00388609|EXPERIMENTAL|V|25 mg (ST) to 50 mg (LT)
62144961|NCT06055491|PLACEBO_COMPARATOR|Saline injection|1.0mL saline injection at ilsilateral deltoid muscle and extensor muscle strengthening exercise with counter force brace in lateral epicondylitis of elbow
62350342|NCT02475850|OTHER|Control|Usual fall prevention care
62350343|NCT04965506|EXPERIMENTAL|IBI362 low dose|Participants receive low dose IBI362 by subcutaneous (SC) injection once a week.
62350344|NCT04965506|EXPERIMENTAL|IBI362 moderate dose|Participants receive medium dose IBI362 by subcutaneous (SC) injection once a week.
62350345|NCT04965506|ACTIVE_COMPARATOR|Dulaglutide|Participants receive Dulaglutide 1.5mg by subcutaneous (SC) injection once a week.
62350346|NCT04965506|EXPERIMENTAL|IBI362 high dose|Participants receive high dose IBI362 by subcutaneous (SC) injection once a week.
62350347|NCT04965506|PLACEBO_COMPARATOR|placebo|Participants receive placebo by subcutaneous (SC) injection once a week.
62350348|NCT02322411|ACTIVE_COMPARATOR|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
62350349|NCT02322411|EXPERIMENTAL|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
62350350|NCT03841487||Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI).
62508680|NCT01104090|EXPERIMENTAL|C-MAC indirect laryngoscopy, then C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with indirect laryngoscopy first and then using C_MAC with direct laryngoscopy.
62508681|NCT05889013||Nasal Nitric Oxide|Participants who are referred by his/her clinician for nasal NO testing and meet the inclusion and exclusion criteria will undergo testing. Clinical information regarding prior diagnostic testing will be collected at time of enrollment. Participants that have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry
62508682|NCT05369091|NO_INTERVENTION|Placebo|Atraumatic Extraction Only (placement of gelatin sponge mixed with normal saline without SIMVASTATIN).
62706515|NCT00388609|EXPERIMENTAL|W|50 mg (ST and LT)
61966453|NCT04997811|EXPERIMENTAL|VBaP|Combination of sodium valproate, bezafibrate, medroxyprogesterone
61966454|NCT04997811|EXPERIMENTAL|Danzol|Single agent
61966455|NCT05545215||Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
61966456|NCT02601690||Blood Sampling|Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.
61966457|NCT06254404|ACTIVE_COMPARATOR|Low dose of Protamine|
61966458|NCT06254404|EXPERIMENTAL|Normal dose of protamine|
61966459|NCT00907777|EXPERIMENTAL|Pn Group|Subjects receiving GSK 1024850A vaccine.
62144962|NCT05302115||S-ICD|
62144963|NCT04085952|EXPERIMENTAL|anterior colporrhaphy with dermal graft|Patients randomized to this arm underwent anterior colporrhaphy with dermal graft augmentation (ARUCS) during their surgery for pelvic organ prolapse.
62706516|NCT00388609|EXPERIMENTAL|X|25 mg/d (X1 wk), 5 mg/d (X11 wks) (ST) to 50 mg (LT)
62706517|NCT00388609|EXPERIMENTAL|Z|"Open label: 50 mg/d (X 4 wks) 100 mg/wk (X8 wks) (ST) to 50 mg (LT)~Once daily (x 4 weeks), once daily (x 8 weeks)"
62706518|NCT00388609|PLACEBO_COMPARATOR|Y|0 mg (ST and LT)
62706519|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
62706520|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
62706521|NCT02106832|EXPERIMENTAL|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
62715050|NCT06717698|EXPERIMENTAL|Dosing scheme c: NNC0519-0130|Participants will receive once-weekly s.c injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.
61966460|NCT00907777|ACTIVE_COMPARATOR|Prev Group|Subjects receiving Prevenar™ vaccine.
61966461|NCT06139432|EXPERIMENTAL|Active transcranial Direct Current Stimulation|Active transcranial Direct Current Stimulation (tDCS): Stimulation of 2mA for 20 minutes
61966462|NCT06139432|SHAM_COMPARATOR|Sham transcranial Direct Current Stimulation|Sham transcranial Direct Current Stimulation (tDCS): Effective stimulation of 2.5 mA for 30 seconds, then the stimulation stops. The complete session lasts 20 minutes, with 19 minutes and 30 seconds without stimulation.
61966463|NCT03932110|OTHER|psoriasis vulgaris,|patients who have only psoriasis vulgaris
61966464|NCT03932110|OTHER|psoriatic arthritis|patients who have psoriatic arthritis
62350351|NCT03841487||PCI alone|In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
62350352|NCT03790384|NO_INTERVENTION|Bacillus Calmette-Guérin|Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
62350353|NCT03790384|EXPERIMENTAL|Mytomicin and Bacillus Calmette-Guérin|Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
62350354|NCT01406652|ACTIVE_COMPARATOR|One-stage bursectomy|Bursectomy with debridement and primary closure of the wound during one surgical intervention
62350355|NCT01406652|EXPERIMENTAL|Two-stage bursectomy|Bursectomy with debridement and left open. Wound closure in a second step and in a second surgery.
62350356|NCT03404635||Apixaban for VTE|
62350357|NCT03404635||Rivaroxaban for VTE|
62350358|NCT05613842|EXPERIMENTAL|Male patients with hormone sensitive disease|who demonstrate rising PSA levels (\>0.2ng/ml) following definitive therapy and a negative 68Ga-PSMA-11 PET scan (defined as SUV max \< 3);
62350359|NCT05613842|EXPERIMENTAL|Male patients with metastatic castration resistant prostate cancer|being considered for 177Lu-PSMA-617 therapy with known metastatic disease on conventional imaging and sites with low PSMA expression on 68Ga-PSMA-11 PET scan (defined as SUV max \<10) in the presence of disease volume of \> 1cm.
62350360|NCT04291976|EXPERIMENTAL|back-to-back HDWLE|Similar to single-pass HDWLE, with a second segmental inspection after the first examination in the same session. Equipment is similar to 1.
62350361|NCT04291976|ACTIVE_COMPARATOR|single-pass HDWLE|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
61966465|NCT03932110|OTHER|healthy control|healthy people
61966466|NCT05806814|EXPERIMENTAL|Extended course of Sipuleucel-T treatment|
61966467|NCT02885753|EXPERIMENTAL|Experimental arm FOLFOX with oxaliplatin intraarterial + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intraarterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
61966468|NCT02885753|ACTIVE_COMPARATOR|Reference arm FOLFOX with oxaliplatin intravenous + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
61966469|NCT02885753|EXPERIMENTAL|Experimental arm mFOLFIRINOX with oxaliplatin intraarterial + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intraarterially Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
61966470|NCT02885753|ACTIVE_COMPARATOR|Reference arm mFOLFIRINOX with oxaliplatin intravenous + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intravenously Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
61966471|NCT02279381|EXPERIMENTAL|Intervention group A|"1. Essential Neonatal Care~2. Kangaroo mother Care~3. Application of 4% Chlorhexidine~4. Education and counseling for mothers and care providers"
62350362|NCT04291976|ACTIVE_COMPARATOR|Chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or 0.3% indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two arms.
62350363|NCT06305221|EXPERIMENTAL|Opioid-free group|
62350364|NCT06305221|ACTIVE_COMPARATOR|Opioid group|
61966472|NCT02279381|EXPERIMENTAL|Intervention group B|"1. Essential Neonatal Care~2. Application of 4% Chlorhexidine~3. Education and counseling for mothers and care providers"
61966473|NCT02279381|ACTIVE_COMPARATOR|Control group|"1. Essential Neonatal Care~2. Education and counseling for mothers and care providers"
61966474|NCT05079139|OTHER|surgical technique of Musset|
62350365|NCT01770899|EXPERIMENTAL|Montelukast|Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
62350366|NCT01770899|PLACEBO_COMPARATOR|Placebo|One placebo capsule given every 24h
62350367|NCT03353532||Cohort|Adult patients with SSI after any surgical procedure.
62350368|NCT03353532||Case-Control|"Cases: Patients establishing S. aureus SSI Controls: Patients from the same center who did not undergo S. aureus SSI, matched by the following criteria~* Type of procedure~* Age~* ASA score~* BMI~* Duration of procedure (as percentile for this procedure)~* Diabetes~* Sex"
62350369|NCT04825288|ACTIVE_COMPARATOR|Arm 1|"XB2001 + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 1 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: XB2001 MTD as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-Fluorouracil 2400mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
62350370|NCT04825288|PLACEBO_COMPARATOR|Arm 2|"Placebo + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 2 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: Placebo as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
62706522|NCT02106832|EXPERIMENTAL|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
62350371|NCT01167218||verify now assay|subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
62350372|NCT04093687|EXPERIMENTAL|Intervention Arm|"The intervention will consist of one training session, focusing on technical and non-technical aspects identified in the study Phase I (according to the evaluation questionnaire). The training will be conducted by a team consisting of (i) supervisors (researchers) and (ii) teachers experienced in the previous trial (Train-Colonoscopy-Leaders course - TCL; this methodology has already been evaluated (citation)). There will be 7 trainees per session: 1 under-, 4 average and 2 overperformers.~The training session will be divided into two parts: theoretical and practical. During the first, theoretical part of the training, the body of research on the phenomenon of colonoscopy pain will be presented. The second, practical part of the training, will consist of a one-day session of 7 colonoscopies.~Each average and underperforming endoscopist who underwent training in the randomized phase will receive a written, customized feedback on his/her performance during the training session."
62350373|NCT04093687|NO_INTERVENTION|Control Arm|The endoscopists in the control arm will not be informed about participation in the study and will receive only tailored feedback on adjusted painful colonoscopy rate (practice as usual). They will receive a reminder, that dedicated report on painful colonoscopy rate is provided in the Polish Colonoscopy Screening Program database and they will be monitored for endpoints through Polish Colonoscopy Screening Program database.
62350374|NCT03736629|PLACEBO_COMPARATOR|Placebo|8 weeks of placebo capsule once daily by mouth
62350375|NCT03736629|ACTIVE_COMPARATOR|Azithromycin|8 weeks of Azithromycin (250 mg) capsule once daily by mouth
61966475|NCT06056713|EXPERIMENTAL|Experimental Interventions|Hand massage should be done for 10 minutes, 5 minutes for each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
61966476|NCT06056713|NO_INTERVENTION|Control Group|The control group did not receive any intervention during the study period.
61966477|NCT02563405|ACTIVE_COMPARATOR|doxazosin|To observe the effects of doxazosin (4 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
62350376|NCT03736629|NO_INTERVENTION|Non-asthmatic controls|Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given.
61966478|NCT02563405|ACTIVE_COMPARATOR|nifedipine|To observe the effects of nifedipine (30 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
61966479|NCT05984160|ACTIVE_COMPARATOR|Paragastric neural block|Patients who were operated for sleeve gastrectomy were included in the study. Afterwards, they were divided into two groups. While pragastric neural block was applied to one group, no intervention was made to the other group.
62350377|NCT02680587|NO_INTERVENTION|Observational (no SBRT)|Men with oligometastatic prostate cancer lesions randomized to observation
62706523|NCT02106832|PLACEBO_COMPARATOR|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
61966480|NCT05984160|NO_INTERVENTION|Control|Control grup
61966481|NCT05784350|ACTIVE_COMPARATOR|Intravenous fluid bolus|
61966482|NCT05784350|ACTIVE_COMPARATOR|Intravenous Ondansetron|
61966483|NCT05784350|NO_INTERVENTION|No intervention|
61966484|NCT06141395||Patients with an infection|Patients with high suspicion of infection with at least one sign of the quick Sequential Organ Failure Assessment (qSOFA) score
61966485|NCT05170841|ACTIVE_COMPARATOR|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase film coated tablets (administered as one tablet)
62350378|NCT02680587|EXPERIMENTAL|SBRT|Men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
62350379|NCT00370877|ACTIVE_COMPARATOR|Standard care for post-partum hemorrhage|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
62350380|NCT00370877|EXPERIMENTAL|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
61966486|NCT05170841|ACTIVE_COMPARATOR|Tramadol Hydrochloride 100 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase (administered as 2 capsules of Tramadol 50 mg)
61966487|NCT05170841|PLACEBO_COMPARATOR|Placebo and Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo film-coated tablets matching Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg MULTIPLE DOSE PHASE: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg film coated tablets (administered as one tablet)"
61966488|NCT05170841|PLACEBO_COMPARATOR|Placebo and Tramadol Hydrochloride 100 mg|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo capsules matching active comparator (administered as 2 capsules of Tramadol 50 mg) MULTIPLE DOSE PHASE: Tramadol Hydrochloride 100 mg (administered as 2 capsules of Tramadol 50 mg)"
61966489|NCT03308877|EXPERIMENTAL|Brief Motivational Intervention (BMI)|
62706524|NCT02106832|PLACEBO_COMPARATOR|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
61966490|NCT03308877|ACTIVE_COMPARATOR|Standard Care (SC)|
61966491|NCT02918175|OTHER|mHealth Intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.
62350381|NCT01815580|ACTIVE_COMPARATOR|Immediate ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at enrollment.
62508683|NCT05369091|EXPERIMENTAL|Simvastatin|Atraumatic Extraction and administration of SIMVASTATIN (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket.
62508684|NCT04491695|EXPERIMENTAL|Tirofiban+Oral antiplatelet therapy|Patients will receive Tirofiban in the first 72 hours and bridge to oral antiplatelet therapy thereafter.
62508685|NCT04491695|ACTIVE_COMPARATOR|Oral antiplatelet therapy|Patients will receive oral antiplatelet therapy alone.
62508686|NCT05952089|EXPERIMENTAL|Danicamtiv + Midazolam|
62508687|NCT02851732|NO_INTERVENTION|Control|"Clusters randomized to the control group will keep their usual practice standards. Patient screening will be performed at the outpatient clinics and primary care centers. Both groups must complete the following forms: Admission, 06 months, and 12 months. Data collection will be performed from medical records by an independent professional not involved in patient care. Furthermore, study coordinator and data collectors from the sites, when asked, must provide appropriate documents for adjudication purposes."
62508688|NCT02851732|EXPERIMENTAL|Intervention|Educational multifaceted intervention can increase the evidence based prescriptions. If this is the case, this tool package may be offered as a quality improvement intervention for all hospitals. Health care professionals from each institution one being a physician (acting as a local leader) and the other being a research nurse (acting as a case manager) must attend the training course for high cardiovascular risk patients that will take place at HCor.
62508689|NCT06397222|EXPERIMENTAL|Sin-Bev-SIRT|Sintilimab, Bevacizumab plus SIRT
62508690|NCT01333202|EXPERIMENTAL|Fresh lime|Those who were randomly assigned to receive fresh lime were instructed to use it every time they began to crave cigarettes and as often as they needed. Fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible. All participants in this group had to report the number of fresh lime slices used per day in the self-report card.
62508691|NCT01333202|ACTIVE_COMPARATOR|Nicotine gum|"The dosage of nicotine gum used in this group was primarily based on the participants' FTND scores. Those with FTND score of 4 or above were given 4-mg nicotine gum. The 2-mg gum was assigned only to light smokers. Appropriate gum use by chew and park technique was instructed to all subjects in this group. They were advised to use the gum whenever they began to crave a cigarette but not to exceed more than 20 pieces per day. All participants in this group also had to report the total number pieces of gum used per day in the self-report card. Like the lime use group, phone calls were also made every 2-3 days during the initial month of study to remind them of technique and record keeping."
62508692|NCT01076556|EXPERIMENTAL|Treatment (rituximab, cyclophosphamide, alvocidib)|Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).
62508693|NCT02588079|EXPERIMENTAL|Internet-based cognitive behavioral therapy|The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
62508694|NCT02588079|NO_INTERVENTION|Wait list|Participants are not offered any active controlled psychological interventions but have free access to dental health services, which could involve exposure and other behavioral strategies applied by dental staff.
62508695|NCT00576303|EXPERIMENTAL|RO0503821 (C.E.R.A.), 1x/4weeks|Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator \[C.E.R.A\]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of\<8000, 8000-16000, or \>16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks
62350382|NCT01815580|PLACEBO_COMPARATOR|Deferred ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at 24 weeks.
62508696|NCT03493321|EXPERIMENTAL|PRF with MTA|PRF with MTA with PRF with Theracal as intervention
62508697|NCT02073006|ACTIVE_COMPARATOR|Natural Fibre Supplement|2 doses per day for 4 weeks
61966492|NCT02918175|NO_INTERVENTION|No intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.
61966493|NCT04402931|OTHER|Transcatheter Valve-in-Valve Intervention|Transcatheter Valve-in-Valve Intervention
62350383|NCT05915936||laparoscopic ventral mesh rectopexy|correction of rectal prolapse through laparoscopic ventral mesh rectopexy
62350384|NCT05915936||perineal stapler resection|correction of rectal prolapse through perineal stapler resection
62350385|NCT05200455|EXPERIMENTAL|Microelectrodes|Patients who qualify for this study will be implanted with standard electrodes as well as microelectrodes for their intracranial seizure monitoring.
62350386|NCT01729650|EXPERIMENTAL|Physical and diet educational group|group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
62508698|NCT02073006|PLACEBO_COMPARATOR|Placebo|2 doses per day for 4 weeks
62539317|NCT03706014|PLACEBO_COMPARATOR|Contact-Equivalent Attention Control|The Contact-Equivalent Attention Control condition includes 12 weekly 90-minute afterschool group sessions for siblings led by two co-leaders. Students work on educational games and activities. Groups begin with an icebreaker and continue with games and projects. This condition also includes 3 family nights, where parents attend with their children. Activities of the Family Nights include children showing their parents the activities they have been engaging in during the sessions. Family Nights include dinner and last 2 hours. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children; during this part, parents will break out with one group leader, and siblings will work with the other group leader.
62539318|NCT02875652|EXPERIMENTAL|Blood sampling|
61966494|NCT04402931|OTHER|Redo Surgery|Surgical Mitral valve replacement
62350387|NCT01729650|NO_INTERVENTION|Usual clinical care|
61966495|NCT02775162|EXPERIMENTAL|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
61966496|NCT02775162|OTHER|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
61966497|NCT05590013|ACTIVE_COMPARATOR|Pectointercostal and ESP|Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the 30 patients under general anaesthesia in Group block . Sevoflurane+remifentanil and O2/air combination will perform to the all patients during the surgery. Totally bupivacaine %0.25 2.5 mg/kg will use for blocks and 1 ml epinephrin will add to the each local anesthetic solutions in each side.10 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery.
61966498|NCT05590013|PLACEBO_COMPARATOR|Control Group|Block will not perform to the control group.
61966499|NCT00897260|EXPERIMENTAL|1|
61966500|NCT03767530|EXPERIMENTAL|Mibo Thermoflo (thermal device)|3 sessions at 2 weeks interval (basal, week 2, week 4)of 11 minutes per eye of thermal therapy with Mibo Thermoflo.
61966501|NCT03767530|ACTIVE_COMPARATOR|Warm compresses and eyelid massage|2 times per day, 11 minutes per eye.
61966502|NCT05776420|EXPERIMENTAL|Food voucher|
61966503|NCT05776420|NO_INTERVENTION|Control|
62350388|NCT03372603|EXPERIMENTAL|Treatment Sequence AB|Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
62350389|NCT03372603|EXPERIMENTAL|Treatment Sequence BA|Subjects will receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days).
62350390|NCT00707343|EXPERIMENTAL|All patients|All participants enrolled.
62539319|NCT04349943|EXPERIMENTAL|inflammatory bowel disease|According to the patient's disease condition, tube feeding time, internal and surgical diagnosis and treatment plan, standard step-based nutrition treatment was carried out for the patients with adaptive signs of nutrition treatment, and dynamic nutrition evaluation and efficacy evaluation were carried out.
61966504|NCT02532972|EXPERIMENTAL|Cochlear Implant surgery|All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
62350391|NCT05065307|EXPERIMENTAL|Video game in Virtual reality|The study subject will be playing a video game during the venipuncture, in virtual reality
62539320|NCT01505153|EXPERIMENTAL|pbi-shRNA STMN1 LP|pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
61966505|NCT03633682|EXPERIMENTAL|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
61966506|NCT03633682|OTHER|No Engagement Support|Participants in this group will receive no text message support.
61966507|NCT03205033|ACTIVE_COMPARATOR|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
61966508|NCT03205033|PLACEBO_COMPARATOR|Placebo|Placebo Oral Capsules, once a day at bedtime
61966509|NCT01129479|ACTIVE_COMPARATOR|Galantamine|
61966510|NCT01129479|PLACEBO_COMPARATOR|Placebo|
61966511|NCT03793777|PLACEBO_COMPARATOR|placebo|microcrystalline cellulose supplementation
61966512|NCT03793777|EXPERIMENTAL|Aronia|aronia melanocarpa supplementation
61966513|NCT02027896|EXPERIMENTAL|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
61966514|NCT02027896|NO_INTERVENTION|Standard surgical care|Surgical hip fracture repair according to the standard timing.
61966515|NCT00553644|EXPERIMENTAL|Treatment (bortezomib, lenalidomide)|Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
62539321|NCT06175988||Visceral Adiposity|No intervention to be adminstrated. Participants will be considered based on their visceral adiposity (ctageorial and continous). Visceral adiposity index is computed with BMI, waist circumference, triglyceridemia, HDL-cholesterol levels, and biological sex.
62715051|NCT06717698|PLACEBO_COMPARATOR|Dosing scheme c: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.
61966516|NCT04846621|OTHER|group Nicorandil|women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours
61966517|NCT04846621|OTHER|group Nifedipine|Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours
61966518|NCT01842074|EXPERIMENTAL|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
61966519|NCT05989763|EXPERIMENTAL|Transcutaneous Electrical Acustimulation (TEA)|
61966520|NCT05989763|SHAM_COMPARATOR|Sham-TEA|
61966521|NCT00560859|ACTIVE_COMPARATOR|Early AT Surgery|There will be removal of tonsils and adenoids that will be performed within 4 weeks of the baseline visit.
61966522|NCT00560859|OTHER|Watchful Waiting|Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
61966523|NCT05825521|EXPERIMENTAL|Patients with hydrocephalus|Age \> 55, Ventricular dilation: Evans Index \> 0.3; Patients with cognitive impairment, and gait disturbances and/or urinary incontinence or a combination of these three symptoms; Absence of other neurological diseases that could cause ventriculomegaly, information and non-opposition.
61966524|NCT05825521|ACTIVE_COMPARATOR|Controls|Age ≥ 55; No ventricular dilation: Evans Index \< 0.3; Individuals who have no neurological or psychiatric disease; No neurological deficit. No history of neurosurgery or head trauma; signed informed consent; affiliation to a social security scheme.
61966525|NCT02292277||NSTEMI patients|Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
61966526|NCT02292277||SCAD controls|Patients with stable coronary artery disease (SCAD) planned for elective angiography. If PCI is to be performed and if the responsible physician decides to administrate a loading dose of 180 mg ticagrelor, written informed consent will be obtained before loading dose and blood sampling.
61966527|NCT05531760||DMEK-operated eyes without graft detachment|Eyes operated with DMEK without graft detachment
61966528|NCT05531760||DMEK-operated with graft detachment|Eyes operated with DMEK with graft detachment
61966529|NCT02384889|EXPERIMENTAL|Difluoromethylornithine|Subjects may be given daily dose of DFMO
61966530|NCT02384889|PLACEBO_COMPARATOR|Placebo|Subjects may be given daily dose of placebo
61966531|NCT00963547|EXPERIMENTAL|Pt. 1: MK-2206 45mg, QOD + Trastuzumab|Participants in Part 1 (Pt. 1) receive MK-2206 45 mg every other day (QOD), taken orally. In combination with MK-2206, trastuzumab is administered by intravenous (IV) infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg every 3 weeks (q3wk).
61966532|NCT00963547|EXPERIMENTAL|Pt. 1: MK-2206 60mg, QOD + Trastuzumab|Participants in Pt. 1 receive MK-2206 60 mg QOD, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
61966533|NCT00963547|EXPERIMENTAL|Pt. 1: MK-2206 135mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 135 mg once weekly (QW), taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
61966534|NCT00963547|EXPERIMENTAL|Pt. 1: MK-2206 200mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 200 mg QW, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
61966535|NCT00963547|EXPERIMENTAL|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 500mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the maximum tolerated dose defined in Part 1 (Pt. 1 MTD). MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 500 mg taken orally once daily (QD).
61966536|NCT00963547|EXPERIMENTAL|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 750mg, QD|Participants in Pt. 2 receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 750 mg taken orally QD.
61966537|NCT00963547|EXPERIMENTAL|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 1000mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 1000 mg taken orally QD.
62350392|NCT05065307|ACTIVE_COMPARATOR|Video game on a tablet|The study subject will be playing a video game during the venipuncture, on a tablet
62350393|NCT01873443|EXPERIMENTAL|Rituximab, MTX, folic acid|
62350394|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
62350395|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
62350396|NCT03453918|EXPERIMENTAL|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
62350397|NCT03453918|EXPERIMENTAL|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
62350398|NCT05494749|EXPERIMENTAL|Test group|
62350399|NCT05494749|ACTIVE_COMPARATOR|Control|
62350400|NCT03181477|OTHER|radiotherapy + chimiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
62706525|NCT06420700||Combined gastric mucosal ablation with endoscopic sleeve gastroplasty|All patients included in the multi-site, prospective registry will undergo the combined gastric mucosal ablation with endoscopic sleeve gastroplasty procedure, regardless of their participation in the research study.
61966538|NCT02888444|ACTIVE_COMPARATOR|Varenicline plus behavioural support|12 weeks extended treatment with varenicline, plus relapse prevention-orientated behavioural support
61966539|NCT02888444|PLACEBO_COMPARATOR|Placebo plus behavioural support|12 weeks extended treatment with placebo, plus relapse prevention-orientated behavioural support
61966540|NCT02013739||Patients with chronic heart failure|other
61966541|NCT02013739||Healthy volontiers|other
61966542|NCT02689388|ACTIVE_COMPARATOR|General Anesthesia with nerve block|Femoral Nerve Block
62350401|NCT02671461|EXPERIMENTAL|BMS-986141 0.8mg|BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)
62350402|NCT02671461|EXPERIMENTAL|BMS-986141 4.8mg|BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)
62350403|NCT02671461|PLACEBO_COMPARATOR|Placebo|Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)
62350404|NCT02887859|EXPERIMENTAL|HAV Treatment|Human Acellular Vessel (HAV)
62350405|NCT06015412||Grade 1 osteoarthritis|disease stages 1 according to the Kellgren-Lawrence radiographic classification system
62350406|NCT06015412||Grade 2 osteoarthritis|disease stages 2 according to the Kellgren-Lawrence radiographic classification system
62350407|NCT06015412||Grade 3 osteoarthritis|disease stages 3 according to the Kellgren-Lawrence radiographic classification system
62350408|NCT06015412||Grade 4 osteoarthritis|disease stages 4 according to the Kellgren-Lawrence radiographic classification system
62350409|NCT02335112|EXPERIMENTAL|Group A|irreversible electroporation with voltage in level A for Unresectable Head and Neck Neoplasms
61966543|NCT02689388|NO_INTERVENTION|General Anesthesia no nerve block|No femoral Nerve Block
61966544|NCT05508581|OTHER|Varicose veins|Ablation of varicose veins by microwaves
61966545|NCT01918085|OTHER|Peristomal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from the Peristomal skin
61966546|NCT01918085|OTHER|Pre-stripped abdominal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from healthy abdominal skin
61966547|NCT02197845|EXPERIMENTAL|Phase I: Recruitment into Specialty Care|Participants in the Phase I Experimental Arm are enrolled into SCD specialty care. PN's will contact patient up to 3 times to assure patients have had an initial visit by 3 months time.
61966548|NCT02197845|EXPERIMENTAL|Phase II: Patient Navigator Arm|Participants in the Phase II Experimental Arm follow routine clinical care and are assigned a Patient Navigator. A specially trained (SCD specefic)PN will work with participants for one year. Participants will be contacted by their Navigator weekly for the first 6 months, then biweekly for the second 6 months.
61966549|NCT02197845|NO_INTERVENTION|Phase II: Passenger Arm|No Intervention. Participants in the Phase II Passenger Arm follow routine clinical care.
61966550|NCT00320411|EXPERIMENTAL|Lapatinb|Lapatinib 1500mg QD
61966551|NCT03710538|NO_INTERVENTION|[Placebo + Sedentary]|1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
61966552|NCT03710538|EXPERIMENTAL|[Snack effect + Sedentary]|2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
62706526|NCT04509258|PLACEBO_COMPARATOR|control group|this group will have the standard and routine therapy of treatment of acute Aluminium Phosphide poisoning immediately after admission according to PCCA guidelines
62706527|NCT04509258|ACTIVE_COMPARATOR|N- acetyl cysteine grouo|N-acetyl cysteine will be given at dose of 300mg/kg/d IV in the first day then 150 mg/kg/d IV in addition to standard of care according to PCCA guidelines
61966553|NCT03710538|EXPERIMENTAL|[Placebo + Exercise]|3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
61966554|NCT03710538|EXPERIMENTAL|[Snack + Exercise]|4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
62144964|NCT04085952|ACTIVE_COMPARATOR|anterior colporrhaphy suture based|Patients randomized to this arm underwent anterior colporrhaphy with suture based repair (native tissue) during their surgery for pelvic organ prolapse. This is and was the most common practice for anterior colporrhaphy.
62144965|NCT01326455|OTHER|Terumo Control|
62144966|NCT01326455|ACTIVE_COMPARATOR|Terumo Fast Release|
62350410|NCT02335112|EXPERIMENTAL|Group B|irreversible electroporation with voltage in level B for Unresectable Head and Neck Neoplasms
62350411|NCT02335112|EXPERIMENTAL|Group C|irreversible electroporation with voltage in level C for Unresectable Head and Neck Neoplasms
62706528|NCT04509258|ACTIVE_COMPARATOR|Acetyl L-carnitine group|Acetyl L-carnitine will be given at dose of 50 mg/kg IV once to be followed by additional doses of 15 mg/kg IV q4hr infused over 30 min. standard of care according to PCCA guidelines will also be provided
62706529|NCT04509258|ACTIVE_COMPARATOR|Medicated paraffin oil group|Gastric decontamination with sodium bicarbonate (NaHCO3; 44 mEq, orally) and medicated paraffin oil (200 mL) will be administered in addition to standard of care according to PCCA guidelines
62706530|NCT05006664|EXPERIMENTAL|Brentuximab Vedotin (Adcetris) in Combination with CHEP|Single arm, open label, Brentuximab Vedotin (Adcetris) in Combination with CHEP
62706531|NCT04448379|EXPERIMENTAL|Dose Escalation Cohort|"Two dose levels of JMT101 combined with afatinib or osimertinib will be tested according to the 3 + 3 dose-escalation design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
62706532|NCT04448379|EXPERIMENTAL|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
62706533|NCT05819957|EXPERIMENTAL|Experimental patients|MSA patients included in the therapeutic education program
62706534|NCT03699202|EXPERIMENTAL|100mg AK0529 Arm|Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
62706535|NCT03699202|EXPERIMENTAL|200mg AK0529 Arm|Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.
61966555|NCT05316142|ACTIVE_COMPARATOR|AGV with intraoperation MMC|Patients with neovascular glaucoma undergoing shunt implant surgery with MMC during surgery. This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world. First, MMC at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed. The shunt is fixed and then the shunt tube is inserted into the eye and fixed with nylon 10.0 thread. The conjunctiva is also swabbed with 8.0 vicryl sutures. After the operation, patients undergo regular examinations according to a specific protocol to evaluate the effectiveness as well as possible complications.
62144967|NCT01326455|ACTIVE_COMPARATOR|Clo-Sur P.A.D.|
62144968|NCT05089487|EXPERIMENTAL|High altitude 2500 m above sea level|
62144969|NCT05089487|ACTIVE_COMPARATOR|Low altitude 470 m above sea level|
62144970|NCT01705756|PLACEBO_COMPARATOR|Vehicle|•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
62350412|NCT04080869|EXPERIMENTAL|retinyl palmitate ethosomes arm|All patients will be instructed to apply a thin film of the new formula on one side of the face
62350413|NCT04080869|ACTIVE_COMPARATOR|tretinoin arm|All patients will be instructed to apply a thin film of topical retinoid cream on the other side of the face
62350414|NCT04671342|EXPERIMENTAL|Validation Arm|Participants will wear the DreamKit device (test device) while instrumented with polysomnography sensors (gold standard).
62350415|NCT05205278|EXPERIMENTAL|training group|Group 1 (n=21) was the training group and, in addition to the routine volleyball training programmes, an 8-week (3 days/week) progressive core stability training programme was applied.
62350416|NCT05205278|NO_INTERVENTION|control group|Group 2 (n=21) was the control group, and they only engaged in routine volleyball training: no core stability training was given.
62706536|NCT03699202|EXPERIMENTAL|300mg AK0529 Arm|Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.
62706537|NCT03699202|PLACEBO_COMPARATOR|Placebo Arm|Patients randomised into this arm will be orally administered with placebo q.d. for five days.
62706538|NCT02898038|EXPERIMENTAL|Experimental|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PARIS for a period of 9 days.
62144971|NCT01705756|EXPERIMENTAL|Kineret (Anakinra)|Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
62144972|NCT03650166|ACTIVE_COMPARATOR|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
62350417|NCT06312046|EXPERIMENTAL|Balance training intervention group|The program HiBalance-MS is based on scientifically well-established principles of exercise training and postural control. It will be conducted as a progressive individually adjusted group training to challenge the specific balance deficit of every participant. To ensure highly challenging exercises, each task is individually adjusted, e.g., by altering the base of support, increasing speed, restricting vision and varying grade of multitasking. Daily variation in capacity will be rated before each training session and participants will at the end of each session rate the challenging level. The training will be performed in the clinic, at Karolinska University Hospital, for an hour, twice a week for 10 weeks, as a group intervention including 6 to 8 participants and facilitated by two physiotherapists/trainers.
62350418|NCT06312046|NO_INTERVENTION|No intervention control group|Participants in the control group are encouraged to maintain their normal physical activities and are not restricted from participation in ongoing rehabilitation programs.
62350419|NCT01097148|ACTIVE_COMPARATOR|Atracurium, TBW|Dose of atracurium 0.5 mg/kg based on total body weight
62350420|NCT01097148|ACTIVE_COMPARATOR|Atracurium IBW|dose 0.5 mg/kg based on ideal body weight
62350421|NCT00917085|NO_INTERVENTION|Control group|Control infants received the same standard care as infants who were not in the study. Infants were kept warm in incubators or warmer beds and were wrapped in blankets when held by their mothers. Hospital staff was responsible for providing standard care.
62350422|NCT00917085|EXPERIMENTAL|Skin-to-Skin group|
62350423|NCT02261883|ACTIVE_COMPARATOR|IV Remodulin|The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.
62706539|NCT02786056|EXPERIMENTAL|Lung MRI examination|
62706540|NCT00629928|EXPERIMENTAL|1|20mg capsule once daily
62706541|NCT00629928|EXPERIMENTAL|2|40mg capsule daily
62706542|NCT00629928|PLACEBO_COMPARATOR|3|
62706543|NCT04470414||Recovered COVID-19 patients|Patients recovered from COVID-19 infection within three months before the start of the study.
62144973|NCT03650166|EXPERIMENTAL|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
62350424|NCT02261883|PLACEBO_COMPARATOR|Placebo|The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.
62706544|NCT03855904|EXPERIMENTAL|TC-325|The intervention (experimental) arm patients are treated initially with TC-325 alone. Treatment failure for TC-325 is defined as endoscopists cannot achieve hemostasis with 1 syringe (20gm) of TC-325.
62706545|NCT03855904|ACTIVE_COMPARATOR|Traditional treatment (Control group)|Control group patients initially receive usual standard of (traditional) endoscopic treatment (SET) as defined by injection therapy with another modality or sole/combination use of thermal or mechanical modalities. Crossovers to either treatment arm are permitted if immediate haemostasis does not achieved with standard endoscopic or TC-325 application.Treatment failure of SET is defined as endoscopists cannot achieve hemostasis by selected SET.
62706546|NCT04848194|OTHER|All patients|All patients with psoriasis recruted by dermatological departement.
62350425|NCT00089479|EXPERIMENTAL|1|
62350426|NCT00089479|ACTIVE_COMPARATOR|2|
62350427|NCT00927264|EXPERIMENTAL|Behavioral|"Motivational Interviewing Intervention Plus Education~Caregivers will receive a home-based motivational interviewing intervention for ETS reduction plus an educational program for ETS reduction."
62350428|NCT00927264|ACTIVE_COMPARATOR|Education Only|Caregivers will receive only educational program for ETS reduction.
62350429|NCT01061736|EXPERIMENTAL|Part A: SAR 100 mg qw|Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
62350430|NCT01061736|EXPERIMENTAL|Part A: SAR 150 mg qw|Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
62144974|NCT02916576|EXPERIMENTAL|Blood glucose measurement|
62350431|NCT01061736|EXPERIMENTAL|Part A: SAR 100 mg q2w|Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
62706547|NCT04380142|EXPERIMENTAL|ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)|After an open-label LD/CD Stabilization Period, participants will receive double-blind ABBV-951 by continuous subcutaneous infusion (CSCI) and oral placebo for LD/CD for 12 weeks
62706548|NCT04380142|ACTIVE_COMPARATOR|Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951|After an open-label LD/CD Stabilization Period, participants will receive double-blind oral LD/CD and CSCI of placebo for ABBV-951 for 12 weeks
62706549|NCT00601744||Patient|Diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
62706550|NCT00601744||Family Member/Friend|Family member or close friend of a patient with a diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
62715052|NCT06717698|EXPERIMENTAL|Dosing scheme d: NNC0519-0130|Participants will receive once-weekly s.c injections of NNC0519-0130 following a fixed dose escalation until the maintenance dose is reached.
61966556|NCT05316142|ACTIVE_COMPARATOR|AGV with intraoperation MMC and postoperation 5FU|Patients with neovascular glaucoma undergoing shunt implant surgery with MMC during and 5FU after surgery .This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world. First, 5FU at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed. The shunt is fixed and then the shunt tube is inserted into the eye and fixed with nylon 10.0 thread. The conjunctiva is also swabbed with 8.0 vicryl sutures. After the operation, patients undergo regular examinations according to a specific protocol to evaluate the effectiveness as well as possible complications. Also in the first, third and fifth weeks, 5FU injections are given as a subconjugate with a volume of 0.1 ml containing 5 mg of the drug.
62706551|NCT00060125|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
61966557|NCT05773963|OTHER|At V0, as per clinical practice, only 1 of the IPs products can be assigned to the enrolled subject|At V0, as per clinical practice, only 1 of the IPs products can be assigned to the enrolled subject
61966558|NCT04229394|EXPERIMENTAL|2ccPA|"Only day 1 Intra-articular injection can be given under direct ultrasound guidance; the only one strength for 2ccPA injection vial is 2,400 μg (1.2 mL per vial).~IP name: 2-carba-cyclic phosphatidic acid (2ccPA)"
61966559|NCT04229394|PLACEBO_COMPARATOR|Placebo|Only day 1 Intra-articular injection can be given under direct ultrasound guidance; placebo
61966560|NCT02321644|EXPERIMENTAL|CC-90001|"Part 1: All subjects will receive the following doses of CC-90001 in the fixed sequence below:~Treatment A: 60 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment B: 160 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment C: 400 mg of CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days"
61966561|NCT02321644|EXPERIMENTAL|CC-90001 2 X 100mg fasted|Treatment D: 2 x 100 mg CC-90001 as Active-Ingredient-in-Capsule, single oral dose administered under fasted conditions.
61966562|NCT02321644|EXPERIMENTAL|CC-90001 1 X 200mg fasted|Treatment E: 1 x 200 mg CC-90001 \[formulated tablet(s)\] single oral dose administered under fasted conditions
61966563|NCT02321644|EXPERIMENTAL|CC-90001 1 X 200mg fed|Treatment F: 1 x 200 mg CC-90001 \[formulated tablet(s)\] single oral dose administered under fed conditions (standard high fat breakfast).
62350432|NCT01061736|EXPERIMENTAL|Part A: SAR 150 mg q2w|Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
62350433|NCT01061736|EXPERIMENTAL|Part A: SAR 200 mg q2w|Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
62350434|NCT01061736|PLACEBO_COMPARATOR|Part A: Placebo qw|Placebo (for sarilumab) qw on top of MTX for 12 weeks.
62350435|NCT01061736|EXPERIMENTAL|Part B Cohort 1: Non-selected Doses|Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
61966564|NCT04072302|EXPERIMENTAL|KAF156 800 mg pre-challenge|Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
61966565|NCT04072302|PLACEBO_COMPARATOR|Placebo 800 mg pre-challenge|Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
62144975|NCT04967118|EXPERIMENTAL|Skin-to-skin contact|Neonates will be placed ventral skin-to-skin position with their mother at least thirty minutes prior the heel lance to give time to calm down following transfer. Skin-to-skin positioning will be taken account comfortable position as possible for mother and the baby, easy to access heel for blood sample and interference minimizing during video recording and continuous NIRS, ECG and oxygen saturation measurement. Skin-to-skin contact will be continued for approximately fifteen minutes after completion of blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
62350436|NCT01061736|EXPERIMENTAL|Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
62350437|NCT01061736|EXPERIMENTAL|Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
62350438|NCT01061736|EXPERIMENTAL|Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)|Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
62350439|NCT01957852||FloSeal +|Routine use of Floseal during cytoreductive and HIPEC surgery
62350440|NCT01957852||FloSeal -|FloSeal not used during CRS and HIPEC procedure
62350441|NCT05808842|ACTIVE_COMPARATOR|Group A CeraVe|Subjects will be given a skincare regimen consisting of CeraVe products to be applied to the face and neck following laser treatment.
62350442|NCT05808842|SHAM_COMPARATOR|Group B Calecim|Subjects will be given a skincare regimen consisting of CeraVe products and Calecim products to be applied to the face and neck following laser treatment.
62350443|NCT04162535|EXPERIMENTAL|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
62350444|NCT04162535|EXPERIMENTAL|Total intravenous anesthesia|Patients will receive a general anesthesia with Propofol as anesthetic agent
62350445|NCT04162535|EXPERIMENTAL|Total intravenous anesthesia and Lidocaine|Patients will receive a general anesthesia with Propofol as anesthetic agent and will also receive a fully lidocaine infusion according to the lidocaine protocol
62350446|NCT04162535|NO_INTERVENTION|Placebo|10 presumed healthy volunteers that have donated 10 ml of venous blood for serum comparison
62706552|NCT00718185||A|Patients receiving sildenafil as standard of care
62706553|NCT01972126||AMI patients with LVEF 36% - 50%|Acute myocardial infarction patients with left ventricular ejection fraction between 36% and 50%
62706554|NCT03685942|EXPERIMENTAL|active light therapy|Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment
62715053|NCT06717698|PLACEBO_COMPARATOR|Dosing scheme d: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly.
61966566|NCT04072302|EXPERIMENTAL|KAF156 800 mg post-challenge|Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966567|NCT04072302|PLACEBO_COMPARATOR|Placebo 800 mg post-challenge|Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966568|NCT04072302|EXPERIMENTAL|KAF156 300 mg post-challenge|Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966569|NCT04072302|PLACEBO_COMPARATOR|Placebo 300 mg post-challenge|Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966570|NCT04072302|EXPERIMENTAL|KAF156 100 mg post-challenge|Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
62144976|NCT04967118|EXPERIMENTAL|Mother's heartbeats as sound and vibration|Neonates will be placed in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The platform on which the mother's heartbeat will be played will be placed under mattress of the incubator or crib. The playing of the mother's recorded heartbeats will be started thirty minutes prior the heel lance and will be continued during and fifteen minutes after the blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
61966571|NCT04072302|PLACEBO_COMPARATOR|Placebo 100 mg post-challenge|Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966572|NCT04072302|EXPERIMENTAL|KAF156 20 mg post-challenge|Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966573|NCT04072302|PLACEBO_COMPARATOR|Placebo 20 mg post-challenge|Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966574|NCT04072302|EXPERIMENTAL|KAF156 50 mg post-challenge|Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966575|NCT04072302|PLACEBO_COMPARATOR|Placebo 50 mg post-challenge|Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
61966576|NCT01695265|EXPERIMENTAL|Exercie oronasal breathing (ONB)|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
61966577|NCT01695265|EXPERIMENTAL|Exercie nasal breathing through the FB|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
61966578|NCT06504043|EXPERIMENTAL|Experimental: cohort low dose HST101|HST101 single SC administration of 150 mg or placebo;
61966579|NCT06504043|EXPERIMENTAL|Experimental: cohort high dose HST101|HST101 single SC administration of 300 mg or placebo.
61966580|NCT02028624|EXPERIMENTAL|Face-to-face|Patients received face-to-face nutrition counseling.
61966581|NCT02028624|EXPERIMENTAL|Telephone|Patients received telephone nutrition counseling.
61966582|NCT02028624|NO_INTERVENTION|Minimum Intervention|Patients in this group received no further lifestyle-related counseling and contact until the 6-month evaluation.
61966583|NCT05079529|EXPERIMENTAL|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|This group will receive capsule contains 180 mg of β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma lucidum which will be taken 3 times daily for 90 days
62350447|NCT05647018|ACTIVE_COMPARATOR|Deferred stenting in STEMI patients with high thrombus burden undergoing primary PCI|
61966584|NCT05079529|PLACEBO_COMPARATOR|Placebo Group|This group will receive empty capsule which will be taken 3 times daily for 90 days
61966585|NCT02618889|ACTIVE_COMPARATOR|CBT plus botox|Participants will be randomized to receive BoNT (onabotulinumtoxinA). Patients will undergo study assessments four weeks later. We will inject a total of 250 units of onabotulinumtoxinA, as the average optimal dose in cervical dystonia,11 using a 100:1 dilution with normal saline. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral \[leg and arm, respectively\]; 200 + 200 units, if involvement is symmetric).
61966586|NCT02618889|PLACEBO_COMPARATOR|CBT plus placebo|Participants will be randomized to receive normal saline (placebo). We will inject a total of 250 units of normal saline, as this is the average optimal dose of onabotulinumtoxinA in cervical dystonia. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral \[leg and arm, respectively\]; 200 + 200 units, if involvement is symmetric).
61966587|NCT03631472|EXPERIMENTAL|RheOx Treatment|RheOx Treatment (i.e., Bronchial Rheoplasty)
61966588|NCT04819646|EXPERIMENTAL|Inflammation|Marine Lipid Oil concentrate softgel and dietary supplement capsule
61966589|NCT04770012|PLACEBO_COMPARATOR|placebo|
62350448|NCT05647018|ACTIVE_COMPARATOR|Non-deferred stenting in STEMI patients with high thrombus burden undergoing primary PCI|
61966590|NCT04770012|ACTIVE_COMPARATOR|clopidogrel|
61966591|NCT04770012|ACTIVE_COMPARATOR|aspirin|
61966592|NCT02554448|EXPERIMENTAL|Circulating Tumor Cells|Use ISET system to test the number of CTCs from patients before and during treatment.
62539322|NCT05381714||Patients|Post-COVID-19 Functional Status (Post-COVID-19 Functional Status Scale), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), physical activity level (International Physical Activity Questionnaire), fatigue (Modified Borg Scale), shortness of breath (Modified Borg Scale) will be evaluated.
61966593|NCT02692703|EXPERIMENTAL|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
61966594|NCT00553514|EXPERIMENTAL|AS900672-Enriched 10 mcg|
61966595|NCT00553514|EXPERIMENTAL|AS900672-Enriched 20 mcg|
61966596|NCT00553514|EXPERIMENTAL|AS900672-Enriched 30 mcg|
61966597|NCT00553514|EXPERIMENTAL|AS900672-Enriched 40 mcg|
62350449|NCT00485589|PLACEBO_COMPARATOR|Placebo|Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
62706555|NCT03685942|PLACEBO_COMPARATOR|placebo light therapy|People receive usual treatment and use a placebo light therapy device (175 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.
61966598|NCT00553514|ACTIVE_COMPARATOR|Follitropin alfa 75 IU|
61966599|NCT02521610|PLACEBO_COMPARATOR|Placebo|Healthy volunteers will receive the placebo equivalent to RG7625 as oral capsules once or twice daily for 8 days. Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin purified protein derivative \[PPD\], Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
61966600|NCT02521610|EXPERIMENTAL|RG7625|Participants will undergo a series of Screening visits prior to treatment and 7- to 14-day follow-up. Healthy volunteers will be enrolled in up to 4 cohorts and will receive RG7625 as oral capsules once or twice daily for 8 days. The first cohort is planned to receive 100 milligrams (mg) on Day 1, followed by 100 mg twice daily on Days 3 to 9. Subsequent dose and frequency decisions will be based upon observations in previous cohort(s). Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin PPD, Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
61966601|NCT02931968||Monolithic zirconia prosthesis|Subjects previously treated with at least one arch (maxilla/mandible) of dental implants restored with a full-arch monolithic zirconia implant supported fixed dental prosthesis will be recalled for clinical and radiographic examination.
61966602|NCT03623802|EXPERIMENTAL|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
61966603|NCT03623802|EXPERIMENTAL|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
61966604|NCT02798185||Former NFL Players|120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
61966605|NCT02798185||Former College Football Players|60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
61966606|NCT02798185||Control Group|60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.
61966607|NCT03790488|EXPERIMENTAL|JTX-4014|Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
61966608|NCT03750604|ACTIVE_COMPARATOR|patients with OAB|"Patients were asked to fill (OABSS) for more accurate evaluation of bothersome degree. Waist Circumference is evaluated. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to CT detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL"
62144977|NCT04967118|ACTIVE_COMPARATOR|30% oral glucose|Neonates will be placed on in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The neonates will be given a 30% oral glucose solution two minutes prior the heel lance
62144978|NCT06117215||women of reproductive age|women of reproductive age
62144979|NCT05689073|EXPERIMENTAL|Conversational AI system|
62350450|NCT00485589|EXPERIMENTAL|Ocrelizumab 200 mg|Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
62350451|NCT00485589|EXPERIMENTAL|Ocrelizumab 500 mg|Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
62350452|NCT02155361|ACTIVE_COMPARATOR|Topical Citrullus colocynthis fruit oil|Topical Citrullus colocynthis fruit oil (1%) 1 cc twice daily
62350453|NCT02155361|PLACEBO_COMPARATOR|Placebo (Vehicle)|Topical vehicle oil 1 cc twice daily
62350454|NCT02790333|EXPERIMENTAL|Tri-Staple reloads|Tri-Staple reloads were used for pancreatic stump texture
62350455|NCT02790333|ACTIVE_COMPARATOR|traditional reloads|the traditional reloads were used for pancreatic stump texture
62350456|NCT00979680|ACTIVE_COMPARATOR|High-dose Radiotherapy|
62350457|NCT00979680|ACTIVE_COMPARATOR|Chemo-radiotherapy|
62706556|NCT00793520|EXPERIMENTAL|1|Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
62706557|NCT00793520|EXPERIMENTAL|2|Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
62144980|NCT05689073|ACTIVE_COMPARATOR|Educational brochure|
62706558|NCT06363760||All participants|All participants who complete or discontinue one of the parent studies (EM-SCD-301-001 or EDIT-301-BThal-001)
62715054|NCT06717698|ACTIVE_COMPARATOR|Dosing scheme e: Semaglutide|Participants will receive once-weekly s.c injections of semaglutide with a dose escalation done until maintenance dose is reached.
62144981|NCT01995214|EXPERIMENTAL|P|Anesthesia maintenance with propofol+remifentanil
62508699|NCT05269992|EXPERIMENTAL|Real food products|The study products are 1) a 1kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed; 2) a 1.5kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed, and 3) a 1.5kcal/ml oral nutritional supplement provided in a 200ml ready to drink format. This study is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period aiming to recruit 60 in paediatric patients. During the intervention period, patients will receive one of the three study products (or more if deemed appropriate) for 28 days as a sole source of nutrition or alongside any additional routine nutritional management as required. As such, randomisation was not deemed suitable for this study. The appropriate study product and volume prescribed will be recommended by the investigating dietitian/nurse and agreed with the patient/parent/carer based on their clinical and nutritional requirements.
62508700|NCT06617494||Chronic Temporomandibular disorder (TMD) pain group|
62508701|NCT06617494||Age- and sex-matched pain-free controls|
62350458|NCT02600000|EXPERIMENTAL|Sympathetic myocardial activity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the modulation of sympathetic myocardial activity of patients with HF
62350459|NCT02600000|EXPERIMENTAL|Maximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the maximal functional capacity of patients with HF
62350460|NCT02600000|EXPERIMENTAL|submaximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the submaximal functional capacity of patients with HF
62350461|NCT02600000|EXPERIMENTAL|Thickness and mobility of the diaphragm after IMT|Assess the impact of Inspiratory Muscle Training in combination with a cardiac rehabilitation program on the thickness and mobility of the diaphragm in patients with heart failure.
62350462|NCT01283997|PLACEBO_COMPARATOR|Placebo Group|1 dose on first day of induction therapy, then every 12 hours for 10 weeks.
62350463|NCT01283997|EXPERIMENTAL|Minocycline Group|200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks.
62350464|NCT04240171||dapagliflozin|Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.
62350465|NCT04240171||glimepiride|Group 2 (n=30): are the patients who are prescribed glimepiride
62350466|NCT01887782|EXPERIMENTAL|HFL rTMS|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks
62350467|NCT01887782|ACTIVE_COMPARATOR|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks
62350468|NCT00892957|EXPERIMENTAL|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr will be applied to the study suture line.
62350469|NCT00892957|ACTIVE_COMPARATOR|Manual compression with surgical gauze pads|Dry gauze pads will be positioned to cover the complete study suture line.
62350470|NCT05780593|EXPERIMENTAL|Intervention Group A|Manual mobilization of lumbosacral spine along with passive stretching of the hip abductors and 01 minute of inclined board standing for 03 times a day.
62350471|NCT05780593|EXPERIMENTAL|Intervention Group B|Routine medications(if any) along with 01 minute of inclined board standing for 03 times a day.
62350472|NCT03095053|ACTIVE_COMPARATOR|PGT-A group|Next Generation sequencing preimplantation genetic testing for aneuploidy
62508702|NCT04735107|EXPERIMENTAL|Reinforcement|Low anterior resection + mucosa flap reinforcement + vacuum sponge endoluminal drainage
62508703|NCT01258088|ACTIVE_COMPARATOR|Cohort 1: AN2728 Ointment|
62350473|NCT03095053|NO_INTERVENTION|Morphology group|morphological assessment of blastocyst by light microscope
62350474|NCT02983058|OTHER|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
62350475|NCT03216083|EXPERIMENTAL|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
62350476|NCT03216083|PLACEBO_COMPARATOR|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
62350477|NCT02827279|OTHER|Patients|Mesure of emotional induction by eye tracking on Patient with Pervasive Developmental Disorders (PDD)
62350478|NCT02827279|OTHER|Healthy volunteers|Mesure of emotional induction by eye tracking on People without disorders
62350479|NCT04046445|EXPERIMENTAL|Cohort 1a|6 patients with stage IV CRC who failed SoC therapies
62350480|NCT04046445|EXPERIMENTAL|Cohort 1b|6 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
62350481|NCT04046445|EXPERIMENTAL|Cohort 2a|5 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
62508704|NCT01258088|PLACEBO_COMPARATOR|Cohort 1: AN2728 Vehicle|
62508705|NCT01258088|ACTIVE_COMPARATOR|Cohort 3: AN2728 Ointment|
62508706|NCT01258088|PLACEBO_COMPARATOR|Cohort 3: AN2728 Vehicle|
62508707|NCT03558620|EXPERIMENTAL|Group 1O2|A fitting mask is held by one hand -\> one hand with an endoscopic bite block -\> held by two hands
62144982|NCT01995214|EXPERIMENTAL|S|Anesthesia maintenance with sevoflurane+remifentanil
62350482|NCT04046445|EXPERIMENTAL|Cohort 2b|15 patients with stage IV MSS/MMRp CRC with liver-limited disease
62350483|NCT04046445|EXPERIMENTAL|Cohort 2c|19 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
62350484|NCT04046445|EXPERIMENTAL|Cohort 3|6 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
62350485|NCT04046445|EXPERIMENTAL|Cohort 4a|24 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
62350486|NCT04046445|EXPERIMENTAL|Cohort 4b|15 patients with stage IV MSS/MMRp CRC with liver-limited disease
62508708|NCT03558620|EXPERIMENTAL|Group 12O|A fitting mask is held by one hand -\> held by two hands-\> one hand with an endoscopic bite block
62508709|NCT03558620|EXPERIMENTAL|Group O12|A fitting mask is held by one hand with an endoscopic bite block-\>by one hand -\> by two hands
62508710|NCT03558620|EXPERIMENTAL|Group O21|A fitting mask is held by one hand with an endoscopic bite block -\> by two hands-\> one hand
62508711|NCT03558620|EXPERIMENTAL|Group 21O|A fitting mask is held by two hands -\> one hand -\> one hand with an endoscopic bite block
62508712|NCT03558620|EXPERIMENTAL|Group 2O1|A fitting mask is held by two hands -\>one hand with an endoscopic bite block-\> by one hand
62508713|NCT02409329|EXPERIMENTAL|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
62508714|NCT02409329|EXPERIMENTAL|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
62706559|NCT06551649|EXPERIMENTAL|Patients diagnosed with amyotrophic lateral sclerosis|Amyotrophic lateral sclerosis patients will be recruited to obtain venous blood draw and skin biopsy, to optimize a three-dimensional cellular model of multiple sclerosis in which determine the neuroprotective and anti-inflammatory/immunomodulatory effects of the human amniotic mesenchymal stromal cell secretome.
62706560|NCT06551649|EXPERIMENTAL|Patients diagnosed with multiple sclerosis|Multiple sclerosis patients will be recruited to obtain venous blood draw and skin biopsy, to optimize a three-dimensional cellular model of multiple sclerosis in which determine the neuroprotective and anti-inflammatory/immunomodulatory effects of the human amniotic mesenchymal stromal cell secretome.
62706561|NCT06551649|ACTIVE_COMPARATOR|Healthy volunteers, patients' unaffected spouses|Spouses of patients will be enrolled as healthy controls, matching their age and male-to-female ratio for both conditions, to obtain venous blood draw and skin biopsy, in order to develop a control model against which to evaluate the preclinical efficacy of the human amniotic mesenchymal stromal cell secretome.
62706562|NCT04641832|EXPERIMENTAL|Chronic cannabis use and subconcussive head impacts|"Group: Chronic cannabis users Criteria: self-reported chronic THC use (average use once per week but not dependent). Urine cannabis test must show positive.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
62706563|NCT04641832|ACTIVE_COMPARATOR|Non-cannabis use and subconcussive head impacts|"Group: Non cannabis users Criteria: self-reported none THC use. Urine cannabis test must show negative.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
62706564|NCT01781988|EXPERIMENTAL|A.individual therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
62706565|NCT01781988|EXPERIMENTAL|B. non-individualized therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
61966609|NCT03750604|PLACEBO_COMPARATOR|normal variants healthy without symptoms|"WC is evaluated crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL. And in males:VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL"
62350487|NCT01797991|ACTIVE_COMPARATOR|Group A (dexamethasone per os)|"* Dexamethasone 20 mg per os 12 hours and 6 hours before paclitaxel (form: opaque white capsules)~* Matching placebo for dexamethasone IV (NaCl 0,9%) 30 minutes before paclitaxel"
62350488|NCT01797991|EXPERIMENTAL|Group B (dexamethasone IV)|"* Dexamethasone 20 mg IV 30 minutes before paclitaxel~* Matching placebo for dexamethasone per os (lactose capsule) 12 hours and 6 hours before paclitaxel (form: opaque white capsules)"
62350489|NCT01379924|EXPERIMENTAL|Young Parents Program plus Parenting/Life Skills modules|In addition to receiving standard medical and social services for young parents and their children, patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
62350490|NCT01379924|ACTIVE_COMPARATOR|Young Parents Program usual care|Patients receive regular standard of care without modules.
62350491|NCT02873364|ACTIVE_COMPARATOR|Vitamin D3 (Low dose)|Daily 600 unites of vitamin D + Cetirizine 10mg twice a day
62350492|NCT02873364|EXPERIMENTAL|Vitamin D3 (High dose)|Daily 4000 unites vitamin D + Cetirizine 10mg twice a day
62350493|NCT05454930|NO_INTERVENTION|Typical Commute|Participants spend two hours in automobile, on heavily trafficked roadways, without active filtration of air pollutants
61966610|NCT05679232|EXPERIMENTAL|Hydrogel coating|cementless revision hip arthroplasty with hydrogel coating applied on orthopaedic implants' surfaces
61966611|NCT05679232|SHAM_COMPARATOR|Control|cementless revision hip arthroplasty
62350494|NCT05454930|OTHER|Typical Commute, Filtered Air|Participants spend two hours in automobile, on heavily trafficked roadways, with active filtration of air pollutants
62350495|NCT03807076|OTHER|GIP-A|Infusion of GIP-A alone as a study tool.
62350496|NCT03807076|PLACEBO_COMPARATOR|Placebo|Saline
62350497|NCT06325306|NO_INTERVENTION|Control Group|Participants in this arm receive no specific intervention. They are on a waiting list for the 'Citoyen en mouvement pour ma santé' program, allowing for natural observation of their health progression without targeted physical literacy interventions. This group serves as a baseline to compare the effects of the adapted physical activity (APA) programs with and without physical literacy components.
61966612|NCT02164812|EXPERIMENTAL|Moxifloxacin, Placebo, Efavirenz|Moxifloxacin, Placebo, Efavirenz single dose as specified
62508715|NCT02409329|ACTIVE_COMPARATOR|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
62508716|NCT06121258|EXPERIMENTAL|Video website access|Participants will gain access to the educational video website in order to watch the series.
62508717|NCT00909571|EXPERIMENTAL|1. FK506E high dose group|
62508718|NCT00909571|EXPERIMENTAL|2. FK506E low dose group|
62508719|NCT02666391|EXPERIMENTAL|UCMSCs|Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)
61966613|NCT04412824|ACTIVE_COMPARATOR|Alcohol Beverage Cues|Participants will complete an MRI with alcohol beverage visual cues and oral alcohol session.
62350498|NCT06325306|EXPERIMENTAL|Traditional APA Group|This group engages in a standard adapted physical activity program, focusing on improving physical fitness and mobility. The intervention is designed for chronic disease management, emphasizing regular physical exercises without an explicit incorporation of physical literacy principles. The same APA educator supervises all sessions to maintain consistency in the delivery of physical activity interventions.
62350499|NCT06325306|EXPERIMENTAL|APA+PL Group|Participants in this arm participate in an adapted physical activity program enriched with physical literacy elements. The intervention aims to enhance physical activity engagement through increased motivation, confidence, knowledge, and understanding. This arm explores the added benefits of integrating physical literacy into traditional APA programs for chronic disease patients.
61966614|NCT04412824|PLACEBO_COMPARATOR|Non-Alcoholic Beverage Cues|Participants will complete an MRI with non-alcoholic beverage cues and oral alcohol session.
61966615|NCT04425161||VO2 ≥15 %|This group is classified based on increased oxygen consumption (VO2) ≥15 % by volume expansion in fluid responders
62508720|NCT02666391|NO_INTERVENTION|controls|Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion
62508721|NCT02382367|EXPERIMENTAL|Pulmonary emphysema|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
61966616|NCT04425161||VO2 <15 %|This group is classified based on increased oxygen consumption (VO2) \< 15 % by volume expansion in fluid responders
61966617|NCT02697032|EXPERIMENTAL|Patients|At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.
61966618|NCT00002942|ACTIVE_COMPARATOR|Peripheral Blood Progenitor Cells|
62350500|NCT00650598|ACTIVE_COMPARATOR|Arm 1|
62350501|NCT00650598|ACTIVE_COMPARATOR|Arm 2|
62350502|NCT03111017|EXPERIMENTAL|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
62508722|NCT03746106|ACTIVE_COMPARATOR|Thiamine only|5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
62508723|NCT03746106|EXPERIMENTAL|Trimethporim + thiamine combination|5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
62508724|NCT03746106|EXPERIMENTAL|Metformin + thiamine combination|5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.
62508725|NCT02994290|EXPERIMENTAL|receive inpatient HPV vaccine|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
61966619|NCT00002942|EXPERIMENTAL|Autologous Bone Marrow Collection|
61966620|NCT05861921|EXPERIMENTAL|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Intervention will be the delivery of Lithium Di-silicate resin bonded fixed partial denture as final prosthetic restorative material for replacing missing upper anterior tooth.
61966621|NCT05861921|ACTIVE_COMPARATOR|Single-retainer Zirconia Resin Bonded Fixed Partial Denture|Comparator will be the delivery of Zirconia resin bonded fixed partial denture as final prosthetic restorative material for replacing missing upper anterior tooth.
61966622|NCT01224067|ACTIVE_COMPARATOR|Quetiapine|Quetiapine (dosage 50mg to 300mg + sertraline)Experimental
61966623|NCT01224067|PLACEBO_COMPARATOR|Placebo|Participant will receive placebo for 8 weeks.
61966624|NCT03810898|EXPERIMENTAL|Phase 1 (a & b)|"Radioligand \[¹¹C\]CHDI-00485180-R and/or Radioligand \[¹¹C\]CHDI-00485626/ 6 Stage II HDGECs and 6 young (\< 35) HCs/ Imaging- MRI and PET/~Both radioligands administered- 1x each/ Optional CSF collection for HDGECs"
61966625|NCT03810898|EXPERIMENTAL|Phase 2a|"Per Radioligand- Radioligand \[¹¹C\]CHDI-00485180-R or Radioligand \[¹¹C\]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
61966626|NCT03810898|EXPERIMENTAL|Phase 2b|"Per Radioligand- Radioligand \[¹¹C\]CHDI-00485180-R or Radioligand \[¹¹C\]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x -HCs/"
61966627|NCT03810898|EXPERIMENTAL|Phase 2c|"Per Radioligand- Radioligand \[¹¹C\]CHDI-00485180-R or Radioligand \[¹¹C\]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
61966628|NCT04255524|EXPERIMENTAL|Group 1/Control|Spherical equivalent: -2.00～+2.00 D
61966629|NCT04255524|EXPERIMENTAL|Group 1/Myopia|Spherical equivalent: -3.00～-6.00 D
62508726|NCT02994290|EXPERIMENTAL|decline the inpatient dose|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
62508727|NCT02997722|EXPERIMENTAL|Ketamine infusion|Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.
62508728|NCT02997722|PLACEBO_COMPARATOR|Normal Saline infusion|Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.
62706566|NCT03222570|EXPERIMENTAL|IPT-A - possible augment with addl IPT-A|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, the dose of IPT-A will be increased by scheduling sessions twice per week for 4 weeks (16 sessions total).
61966630|NCT04255524|EXPERIMENTAL|Group 3/High|Spherical equivalent: -6.00～-10.00 D
61966631|NCT04255524|EXPERIMENTAL|Group 4/Super High|Spherical equivalent: \<-10.00
61966632|NCT01923220|EXPERIMENTAL|HO/02/02|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
61966633|NCT01923220|SHAM_COMPARATOR|Aloe Vera Jel|To be applied topically
61966634|NCT04605484|EXPERIMENTAL|Posoleucel|Arm 1: Regimen A
61966635|NCT04605484|EXPERIMENTAL|Posoleucel and Placebo|Arm 2: Regimen B
61966636|NCT04605484|PLACEBO_COMPARATOR|Placebo|Arm 3: Regimen A
61966637|NCT01903187|EXPERIMENTAL|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
62508729|NCT01293370||vocational rehabilitation|Admitted and discharged psychiatric patients receiving vocational rehabilitation
62508730|NCT02363439|EXPERIMENTAL|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
62508731|NCT05095649|EXPERIMENTAL|Regulatory T-cell enriched infusion|The doses of Regulatory T-cell enriched infusion will be 2x10\^6 cells/kg
62508732|NCT06276530|ACTIVE_COMPARATOR|Thoracotomy|The patients in this group will have a major lung resection through a conventional postero-lateral thoracotomy.
62508733|NCT06276530|ACTIVE_COMPARATOR|RATS (robotic-assisted thoracoscopic surgery)|The patients in this group will have a major lung resection through a minimally invasive approach by RATS.
61966638|NCT01903187|ACTIVE_COMPARATOR|Sham procedure|Sham procedure
61966639|NCT03769454|EXPERIMENTAL|PP-001 verum - cohort 1|PP-001 verum - cohort 1
61966640|NCT03769454|PLACEBO_COMPARATOR|Placebo - cohort 1|Placebo - cohort 1
61966641|NCT03769454|EXPERIMENTAL|PP-001 verum - cohort 2|PP-001 verum - cohort 2
62508734|NCT03241316||district-level representative rural survey|Approximately 4,800 adults in 60 villages across Thailand and Lao PDR to study health and antimicrobial resistance (AMR)-related behaviour in breadth.
62508735|NCT03241316||village-level social network census|Approximately 4,800 adults across 6 villages in rural Thailand and Lao PDR that are exposed to AMR awareness activities to study health behaviour within social networks.
62508736|NCT01758341|EXPERIMENTAL|Malignant biliary obstruction|All patients who underwent endoscopic radiofrequency ablation with the HabibTM EndoHBP as a treatment for malignant biliary obstruction in Austria between November 2010 and December 2012.
62508737|NCT01470417|ACTIVE_COMPARATOR|Chemotherapy|Individuals with low risk disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
62706567|NCT03222570|EXPERIMENTAL|IPT-A - possible augment with SSRI|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, treatment will be augmented by adding a selective serotonin reuptake inhibitor (SSRI).
62706568|NCT03222570|ACTIVE_COMPARATOR|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI.
61966642|NCT03769454|PLACEBO_COMPARATOR|Placebo - cohort 2|Placebo - cohort 2
61966643|NCT03769454|EXPERIMENTAL|PP-001 verum - cohort 3|PP-001 verum - cohort 3
61966644|NCT03769454|PLACEBO_COMPARATOR|Placebo - cohort 3|Placebo - cohort 3
61966645|NCT03769454|EXPERIMENTAL|PP-001 verum - cohort 4|PP-001 verum - cohort 4
61966646|NCT03769454|PLACEBO_COMPARATOR|Placebo - cohort 4|Placebo - cohort 4
61966647|NCT04608526||Group 1|Patients without deep dentin caries / apical rarefying osteitis
61966648|NCT04608526||Group 2|Patients with deep dentin caries / apical rarefying osteitis on the right or left sides
61966649|NCT04608526||Group 3|Patients with deep dentin caries / apical rarefying osteitis on either the right and left side
61966650|NCT04475653|ACTIVE_COMPARATOR|Group coaching|Performing physical activities with Activity tracker, coaching included
61966651|NCT04475653|ACTIVE_COMPARATOR|Group Independant|Performing physical activities with Activity tracker, coaching NOT included
61966652|NCT04475653|OTHER|Controls|Controls from former study (see Study description)
61966653|NCT00368355|EXPERIMENTAL|CLINIMACS Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
61966654|NCT00368355|EXPERIMENTAL|ISOLEX Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
61966655|NCT05325554|EXPERIMENTAL|Research Group|multi-mode rehabilitation
61966656|NCT05325554|NO_INTERVENTION|control group|control group
61966657|NCT05035953|EXPERIMENTAL|Edaravone|Edaravone Dexborneol injection
61966658|NCT05035953|PLACEBO_COMPARATOR|Placebo|Edaravone Dexborneol matching injection
62350503|NCT03111017|NO_INTERVENTION|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
62350504|NCT01257321||post tonsillectomy|children
62508738|NCT01470417|ACTIVE_COMPARATOR|Chemotherapy and ChemoRadiotherapy|Individuals with high-risk disease or borderline resectable disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
62508739|NCT06345963|EXPERIMENTAL|Active rTMS|Participants in this group will receive active H-coil delivered rTMS.
62508740|NCT05480306|EXPERIMENTAL|Treatment|DKN-01 + FOLFIRI or FOLFOX + bevacizumab
62508741|NCT05480306|ACTIVE_COMPARATOR|Control|FOLFIRI or FOLFOX + bevacizumab
62350505|NCT05277233||Early-onset preeclampsia|Defined as preeclampsia that develops before 34 weeks of gestation
62508742|NCT00468949||1|Patients undergoing excision surgery for their dupuytren's contracture
62508743|NCT00468949||2|Patients not undergoing surgery for their excision surgery
62508744|NCT01533649|EXPERIMENTAL|A/R intervention|The A/R intervention will accommodate 10 study subjects who will participate in an epilepsy-specific counseling intervention.
62350506|NCT05277233||Late-onset preeclampsia|Defined as preeclampsia that develops after 34 weeks of gestation
62350507|NCT05277233||Control|Healthy pregnancies, matched to early and late-onset cases
62508745|NCT01533649|EXPERIMENTAL|Relaxation|The relaxation group will accommodate 10 study subjects who will participate in a condition unspecific supportive relaxation intervention.
62508746|NCT01533649|NO_INTERVENTION|Usual care|10 Potential study subjects who are not interested in participating in either intervention will be asked to provide data as a usual care control group.
62706569|NCT03192436|ACTIVE_COMPARATOR|Real Ultrasound|The subjects will receive real ultrasound intervention.
62706570|NCT03192436|SHAM_COMPARATOR|Sham Ultrasound|The subjects will receive sham ultrasound intervention.
62706571|NCT06442982|EXPERIMENTAL|Insole wearing group|"Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined."
62706572|NCT04940169|EXPERIMENTAL|quadriceps tendon autograft|Ramdomized half of the patient underwent quadriceps graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
61966659|NCT05205005|EXPERIMENTAL|Dietary supplementation of glycocalyx precursors (DSGP)|Participants will daily ingest 3,712mg (i.e., six capsules) of DSGP for eight weeks. DSGP, commercially available as Endocalyx (Microvascular Health Solutions LLC, Alpine, UT), include glucosamine sulfate, fucoidan, superoxide dismutase, and high molecular weight hyaluronan.
61966660|NCT05205005|PLACEBO_COMPARATOR|Placebo|Participants will daily ingest 6 capsules daily of placebo
61966661|NCT03036046|EXPERIMENTAL|F901318 with fluconazole low dose|safety assessment
61966662|NCT03036046|EXPERIMENTAL|F901318 with fluconazole high dose|safety assessment
61966663|NCT03036046|EXPERIMENTAL|F901318 with posaconazole|safety assessment
61966664|NCT05192681|EXPERIMENTAL|Tislelizumab arm|Tislelizumab: 200 mg, intravenous infusion, administered on the 1st day of each cycle, every 3 weeks Docetaxel: 60-75mg/m2 administered on the 1st day of each cycle, every 3 weeks Treatment until the disease progresses or intolerable side effects appear.
62350508|NCT01613547|ACTIVE_COMPARATOR|Routine antibiotic prescription|Routine antibiotic prescription with amoxicillin (80 mg/kg/day for 7 days)
62350509|NCT01613547|PLACEBO_COMPARATOR|No routine antibiotic prescription|
62350510|NCT03428841||Patients with dural puncture at epidural|Patients who sustained an accidental dural puncture during the epidural procedure.
62350511|NCT03428841||Patients with no dural puncture|Patients with no dural puncture during epidural procedure, to serve as a control group.
62350512|NCT04019795|SHAM_COMPARATOR|Non-Active REVIAN (Sham) Cap 100|Sham (Control) Group
62350513|NCT04019795|EXPERIMENTAL|Active REVIAN Cap 101|(625 nm and 660 nm)
62350514|NCT04019795|EXPERIMENTAL|Active REVIAN Cap 102|(425 nm)
62350515|NCT04019795|EXPERIMENTAL|Active REVIAN Cap 103|(425 nm, 625 nm and 660 nm)
62350516|NCT03050216|EXPERIMENTAL|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide~ALT-803 Activation of Donor NK Cells~ALT-803 to Facilitate NK Cell Survival and Expansion"
62350517|NCT00436293|EXPERIMENTAL|1|Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
62350518|NCT00436293|ACTIVE_COMPARATOR|2|Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
62350519|NCT05823168||patients with seizures|patients with traumatic brain injury
62706573|NCT04940169|EXPERIMENTAL|hamstring tendon autograft|Ramdomized half of the patient underwent hamstring graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
62350520|NCT05823168||patients without seizures|patients with traumatic brain injury
62350521|NCT00983359|EXPERIMENTAL|Treatment (conformal stereotactic radiation therapy)|Patients undergo conformal stereotatic radiation
62350522|NCT05267197||3D Telemedicine|Clinical consultation conducted with 3D Telemedicine
62350523|NCT05267197||2D Telemedicine|Clinical consultation conducted with 2D Telemedicine
62508747|NCT03571659||two subthreshold parameters|5% and 15% duty cycle (DC)
62508748|NCT03571659||standard ETDRS|early treatment of diabetic retinopathy study
62508749|NCT02741154|EXPERIMENTAL|aromataze group|patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection
62508750|NCT02741154|ACTIVE_COMPARATOR|classic group|same protocol for induction without aromataze inhibitor
62508751|NCT02347319|EXPERIMENTAL|Pennel|This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.
62508752|NCT02347319|ACTIVE_COMPARATOR|Legalon|This group will treated with Silymarin 140mg for 12 weeks.
62508753|NCT02347319|PLACEBO_COMPARATOR|Placebo|This group will treated with Placebo for 12 weeks.
61966665|NCT00759031|PLACEBO_COMPARATOR|A - Marketed fluoride toothpaste|
61966666|NCT00759031|ACTIVE_COMPARATOR|B -Triclosan/NaF/CoPolymer toothpaste|
61966667|NCT02076698|EXPERIMENTAL|AN-DBS|Deep Brain Stimulation of the Anterior Nucleus of the thalamus
62508754|NCT00668447|EXPERIMENTAL|1|Soy protein and isoflavone tablets
61966668|NCT02076698|ACTIVE_COMPARATOR|Usual treatment|Usual treatment of epilepsy including vagus nerve stimulation (VNS)
61966669|NCT01380171||Cleft lip/palate|Patients who have had surgical intervention for cleft lip/palate since 1998 at Children's Healthcare of Atlanta at the Center for Craniofacial Disorders
61966670|NCT02146898|ACTIVE_COMPARATOR|Lateral|patient placed in the lateral postion for spinal anesthesia
61966671|NCT02146898|ACTIVE_COMPARATOR|Sitting|patient placed in the sitting position for spinal anestheisa, then supine
61966672|NCT02146898|ACTIVE_COMPARATOR|Recline|patient placed in the sitting position for spinal anesthesia administration. After spinal placed, the patient turned to a 30-degree upperbody tilt, followed by a slow recline to supine over 5 minutes
61966673|NCT03825315|EXPERIMENTAL|DAXI 80 U|LOW Dose Group
61966674|NCT03825315|EXPERIMENTAL|DAXI 120 U|HIGH Dose Group
61966675|NCT03825315|PLACEBO_COMPARATOR|Placebo|Placebo Group.
62350524|NCT03661450||PICU-Patients|Pediatric patients admitted after 01.08.2018
62350525|NCT04141592||Healthy Control|non-obese individuals without fatty liver disease
62350526|NCT04141592||Obese wihtout non-alcoholic steatohepatitis|Body mass index greater than 30 without liver histological evidence of non-alcoholic fatty liver disease
62350527|NCT04141592||Obese Non-alcoholic steatohepatitis|Body mass index greater than 30 with liver histological evidence of non-alcoholic fatty liver disease
62350528|NCT05535101|EXPERIMENTAL|theta burst stimulation|Those participants to receive 1-3 sessions in a single day at an interval of 15 minutes(at least), and 5 high-frequency iTBS sessions per week in total four weeks. Each session: 600-900 pulses with 120-100% resting motor threshold.
62508755|NCT00668447|ACTIVE_COMPARATOR|2|Soy protein and placebo tablets
61966676|NCT02135302|EXPERIMENTAL|Impaired hepatic function|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each hepatically impaired subject.
62350529|NCT05535101|SHAM_COMPARATOR|Sham arm|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
62350530|NCT04197986|EXPERIMENTAL|Infigratinib 125 mg|Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
62350531|NCT04197986|PLACEBO_COMPARATOR|Placebo|Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
61966677|NCT02135302|EXPERIMENTAL|Healthy subjects|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each healthy subject.
62350532|NCT03620812|EXPERIMENTAL|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
62350533|NCT03620812|ACTIVE_COMPARATOR|soy protein|
62350534|NCT03620812|PLACEBO_COMPARATOR|no protein|
62350535|NCT05379894||group (1 ) Modified Supine|Modified Supine position PNL
62350536|NCT05379894||group (2) prone|Prone position PNL
62508756|NCT00668447|ACTIVE_COMPARATOR|3|control protein and Isoflavone tablets
62508757|NCT00668447|PLACEBO_COMPARATOR|4|control protein and placebo tablets
61966678|NCT05503615|OTHER|Control Group|Which leg of the individuals will be applied will be determined by the coin toss. After the money shot, the right leg will be applied when the writing comes, and the left leg will be applied when the tour comes. The leg to be applied includes the treatment group of the individuals; the other leg (the leg without application) will form the control group of individuals.
61966679|NCT05503615|EXPERIMENTAL|IASTM Treatment Group|Which leg of the individuals will be applied will be determined by the coin toss. After the money shot, the right leg will be applied when the writing comes, and the left leg will be applied when the tour comes. The leg to be applied includes the treatment group of the individuals; the other leg (the leg without application) will form the control group of individuals.
61966680|NCT02397785|EXPERIMENTAL|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
61966681|NCT02397785|SHAM_COMPARATOR|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
61966682|NCT04669639|EXPERIMENTAL|The block group (a)|Patients were randomized in a 1:1 :1ratio, group (a) will receive SSN. The nerve blocks The procedure will be performed after induction of anaesthesia and endotracheal intubation.
61966683|NCT04669639|EXPERIMENTAL|The block group (b)|Patients were randomized in a 1:1:1 ratio. group (b) will receive the Erector spinae plane block. The procedure will be performed after induction of anesthesia and endotracheal intubation.
62508758|NCT03791294|EXPERIMENTAL|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
62508759|NCT03791294|NO_INTERVENTION|Control|No treatment
62706574|NCT04815447||CCS group|Patients under 25 were recruited in the pediatric CPET laboratory of Montpellier University Hospital after a regular paediatric cardiology outpatient visit.
62706575|NCT04815447||Control|The control group consisted in children referred for a non-severe functional symptom linked to exercise (murmur, palpitation, or dyspnoea) or for a medical sports certificate. These children were classified in the control group only after a completely normal check-up, including physical examination, electrocardiogram, echocardiography, and spirometry.
62706576|NCT01290991|OTHER|Bone Graft|Single Arm.. Augment Bone Graft for Osteochondral Defects
62706577|NCT04373200|EXPERIMENTAL|COVID-19 patients with associated ARDS|
61966684|NCT04669639|PLACEBO_COMPARATOR|control group|Patients were randomized in a 1:1:1 ratio. this group will receive general anesthesia (GA) only
62706578|NCT04373200|ACTIVE_COMPARATOR|COVID-19 patients without associated ARDS|
62706579|NCT04373200|ACTIVE_COMPARATOR|Patients with ARDS from other causes|
62350537|NCT04503811||Frail Older People|The first phase of the data collection process will include one to one interviews with up to twenty (20) frail older people. The pre-selected inclusion criteria for this category of participants include; older people (aged 65 years and over); individuals diagnosed with frailty and receiving (part of their) care services at the Day Hospital; the capacity to give free and fully informed consent; ability to use the English language, as well as judgement by the clinical staff and/or nominated manager that the potential participant can take part in an in-depth interview.
62350538|NCT04503811||Day Hospital Staff|The second phase of the data collection process will entail one to one interviews with up to ten (10) Staff at the Day Hospital. The study will include staff that routinely work with frail older people at the Day Hospital including nurses (registered and unregistered), doctors, physiotherapists, occupational therapists and therapy assistants that can give free and fully informed consent. Furthermore, the study will include both part-time and full-time staff with a minimum of six months of work experience with frail older people.
62350539|NCT03188432|EXPERIMENTAL|Treatment - Carboplatin, CRS, HIPEC|Beginning 4-8 weeks after completion of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 90 minutes immediately following CRS.
62350540|NCT01626053|NO_INTERVENTION|control group|
62350541|NCT01626053|EXPERIMENTAL|lifestyle counseling|These participant received the ASMART interventions.
62350542|NCT03027141|ACTIVE_COMPARATOR|Pre-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI)
62350543|NCT03027141|EXPERIMENTAL|Post-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI). Patients for whom a pre-transplant fMRI was obtained will undergo functional MRI scanning at three-points post-transplant (approximately 2 and 4 months +/- 2 months post-operation and again at 1 year +/- 3 months post-transplant).
62350544|NCT01767012|ACTIVE_COMPARATOR|Polylens EC-Y10-PAL (uncoated)|hydrophobic acrylic IOL (no coating) implantation during cataract surgery
62350545|NCT01767012|ACTIVE_COMPARATOR|Polylens EC-Y10H-PAL (coated)|hydrophobic acrylic heparin-coated IOL implantation during cataract surgery
62350546|NCT02832596|NO_INTERVENTION|Control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
62350547|NCT02832596|ACTIVE_COMPARATOR|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
62350548|NCT04871542||Observational (biospecimen collection, questionnaire)|Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients will have the option of providing blood samples at several time points during the study.
62350549|NCT04637971|EXPERIMENTAL|Coaching|The present intervention is a structured, group-based coaching program that is facilitating an active process of change through the identification of achievable personal goals, the formulation of action plans, the provision of constructive feedback, and progressive monitoring of goal attainment.
62706580|NCT02625779|ACTIVE_COMPARATOR|Valproate and Placebo|Valproate: 300mg/day for 8 weeks Placebo: for 8 weeks
62350550|NCT04637971|ACTIVE_COMPARATOR|Self-help tips plus telephone support|Self-help tips including stress coping methods. Our project staff will contact the subject to encourage her to make use of the tips we sent her.
62508760|NCT02696941|EXPERIMENTAL|Metformin|Participants with insulin resistance who have not yet started any diabetic medication will be recruited and will be prescribed metformin at standard clinical doses.
62508761|NCT02696941|EXPERIMENTAL|SGLT2|Participants with poorly controlled type 2 Diabetes (T2DM) who have been recommended to start an SGLT2 inhibitor will be recruited.
62508762|NCT03379155|EXPERIMENTAL|Active Group|Internet-based self-help
62706581|NCT02625779|EXPERIMENTAL|Valproate and Cytidine-containing Drug|Valproate: 300mg/day for 8 weeks Cytidine-containing Drug: 2g/day for 8 weeks
61966685|NCT05490329|NO_INTERVENTION|Standard of Care (Control)|Research staff will provide COVID vaccine materials from the Centers for Disease Control (CDC) to those participants in the Standard of Care (SOC) arm.
62508763|NCT03379155|NO_INTERVENTION|Waiting List Group|
62706582|NCT02625779|EXPERIMENTAL|Valproate and Creatine-containing Drug|Valproate: 300mg/day for 8 weeks Creatine-containing Drug: 3g/day for the first week 5g/day for week 2-8
62706583|NCT01389687|EXPERIMENTAL|Study Group|
62706584|NCT05298930|EXPERIMENTAL|Physical activity intervention|"The intervention will take place during the whole isolation phase and will consist of an APA program defined at inclusion, integrating supervised sessions with an APA teacher, as well as unsupervised sessions. The program will be individualized according to the patient's age, physical condition and PA preferences. The sessions will also be adapted to the biological, psychological and social parameters of the patients.~The intervention will be carried out during the entire hospitalization period and for a maximum of 3 months. An connected bike will be installed in the patient's room for the duration of the hospitalization."
62706585|NCT05839925||Ankylosing spondylitis group|The patients were selected on a randomized form among the patients with a diagnosis of AS according to the modified New York criteria who referred to Istanbul Physical Medicine Rehabilitation Training and Research Hospital.
62144983|NCT02169414|EXPERIMENTAL|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
61966686|NCT05490329|EXPERIMENTAL|TT-C Intervention|Research staff will provide access to the TT-COVID app for one-month, which will provide knowledge about the COVID-19 vaccine, address mis-information, and include multi-media digital stories from study participant's peers.
61966687|NCT01922128|ACTIVE_COMPARATOR|Drug, MC-1101|One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days.
61966688|NCT01922128|PLACEBO_COMPARATOR|Placebo|One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient.
61966689|NCT01101646|EXPERIMENTAL|001|rabeprazole sodium four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
61966690|NCT01101646|EXPERIMENTAL|002|rabeprazole sodium two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
61966691|NCT01101646|EXPERIMENTAL|003|rabeprazole sodium four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
61966692|NCT04011761|ACTIVE_COMPARATOR|Experimental Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
61966693|NCT04011761|NO_INTERVENTION|Control Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the control arm will receive treatment prescribed by pediatricians.
62144984|NCT02169414|EXPERIMENTAL|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
62508764|NCT04157478|EXPERIMENTAL|Radiation therapy, Temozolomide and anlotinib|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
62706586|NCT05839925||Healthy volunteers|Healthy volunteers between the ages of 18-75 were selected randomly.
62350551|NCT00979017|EXPERIMENTAL|Avastin in combination with temozolomide and irinotecan|Avastin 10 mg/kg every 14 days. Temozolomide 200 mg/m2 daily x 5 days in a 28-day cycle. Irinotecan dose depends on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). EIAED 340 mg/m2 every other week and no EIAED 125 mg/m2 every other week. Irinotecan dose also depends on if the patient has the UGT 1A1 polymorphism (7/7). If so, they do not metabolize the irinotecan normally, so these patients will start out at a two dose level reduction. EIAED starting dose will be 275 mg/m2 and no EIAED starting dose will be 75 mg/ m2.
61966694|NCT03918720|EXPERIMENTAL|Trekkers|
62144985|NCT02169414|EXPERIMENTAL|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
62350552|NCT02395653|EXPERIMENTAL|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
62350553|NCT02362542|EXPERIMENTAL|Sham tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
62350554|NCT02362542|EXPERIMENTAL|Real tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
62508765|NCT04157478|ACTIVE_COMPARATOR|Radiation therapy and temozolomide|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).
62508766|NCT05115617||Pregnant individuals|Pregnant individuals who have previously received one-dose of COVID-19 vaccine, or who are planning to receive a COVID-19 vaccine in pregnancy.
62508767|NCT05811221|ACTIVE_COMPARATOR|single group|give esketamine 0.75 mg/kg at the time of induction
61966695|NCT03918720|NO_INTERVENTION|Controls|
61966696|NCT01083745||IVF patients - 1|Poor responders
61966697|NCT01083745||IVF patients - 2|Good responders
61966698|NCT05611398||Lactate Level Under 2 mmol/L|Patients with a lactate level below 2
61966699|NCT05611398||Lactate Level Over 2 mmol/L|Patients with a lactate level above 2
61966700|NCT00102726|ACTIVE_COMPARATOR|Arm 1|SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.
61966701|NCT00102726|ACTIVE_COMPARATOR|Arm 2|SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.
61966702|NCT00102726|ACTIVE_COMPARATOR|Arm 3|SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.
61966703|NCT00102726|PLACEBO_COMPARATOR|Placebo Arm|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
61966704|NCT06049498|EXPERIMENTAL|Mongolian Medicine ZhenBao Pills group|Experimental group
61966705|NCT06049498|PLACEBO_COMPARATOR|Mongolian Medicine ZhenBao Pills Placebo-controlled group|Placebo-controlled group
61966706|NCT01828957|EXPERIMENTAL|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10\^7 cells/kg)
61966707|NCT01828957|PLACEBO_COMPARATOR|normal saline|A single intratracheal administration of normal saline
61966708|NCT04849455|EXPERIMENTAL|Active Treatment|This group will receive a continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 120 minutes with 2ml/hr continuous infusion (14mls total every 2 hours per catheter)
62144986|NCT02169414|PLACEBO_COMPARATOR|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
62144987|NCT04349319|OTHER|Digital preoperative planning|To use digital preoperative planning software
62144988|NCT01989104||Children|6-12 years of age
62508768|NCT05811221|EXPERIMENTAL|intermittent group|give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
62706587|NCT01296165||Travellers visiting India|People that are older than 18 years and planning to visit India for a period of at least 5 days will be approached by the personal at the travel clinics to participate in the study. Informed consent will be obtained prior to enrolling subjects.
61966709|NCT04849455|PLACEBO_COMPARATOR|Placebo|This group will receive a superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
61966710|NCT06436508|EXPERIMENTAL|Early mobilization|"This group is mobilized in the intensive care unit by the institutional physiotherapist with the assistance of specialized personnel. Mobilization is carried out according to the Early Mobilization Protocol (EMP)~Early mobilization protocol:~* Step 1 - Day 1: Bed rest, elevation of the head end to 30°~* Step 2 - Day 2: Bed rest, elevation of the head end to 60°~* Step 3 - Day 3: Bed rest, elevation of the head end to 80°~* Step 4 - Day 4: Sitting on the edge of the bed~* Step 5 - Day 5: Sitting in a chair, standing up~* Step 6 - Day 6: Walking with or without assistance~* Step 7 - Day 7: Walking with or without assistance from today"
61966711|NCT06436508|ACTIVE_COMPARATOR|Standard bed rest|No early mobilization
61966712|NCT05627960|EXPERIMENTAL|AG-01 treated group phase 1A|For dose escalation, subjects will be treated with increasing doses of AG01 from 1 mg/kg to 8 mg/kg. The duration of each treatment cycle is 28 days with two infusions of AG01 every 14 days.
61966713|NCT05627960|EXPERIMENTAL|AG-01 1B triple negative breast cancer treated group|"TNBC is defined as ER and/or PR \< 1% by IHC, HER2 \<3+ by IHC and/or FISH negative, subjects must have received 1 or more standard of care (SOC) therapies for metastatic TNBC.~If PD(L)1-positive, must have received a combination of chemotherapy and a PD (L)-1 agent (Pembrolizumab), unless not a candidate for these therapies If gBRCA 1 or 2 mutation is present, must have received SOC therapies including a PARPi, unless not a candidate for these therapies.~Sacituzumab Govitecan ADC is FDA approved for treatment of advanced TNBC, prior exposure to this therapy does not preclude eligibility in the current study."
61966714|NCT05627960|EXPERIMENTAL|AG-01 1B Hormone-resistant breast cancer|Hormone-resistant breast cancer is defined as, ER and/or PR \>1%, HER2 \<3+ by IHC and/or FISH negative, received 1 or more hormonal (HT) therapies or HT/CD4/6 kinase inhibitor or HT/MTOR inhibitor for treatment of metastatic breast cancer. If the tumor has known PIK3CA mutation, HT/Alpelisib combination should be considered unless not a candidate for this therapy.
61966715|NCT05627960|EXPERIMENTAL|AG-01 1B NSCLC|Subjects with metastatic/recurrent NSCLCA failed 2 or more SOC therapies, including platinum-based chemotherapy and an anti-PD (L) -1 agent (sequentially or consecutively), Subjects with sensitizing mutations/alterations/rearrangements are eligible if received 1 or more SOC agent/s targeting these mutations unless not a candidate for these therapies.
62706588|NCT05072899|EXPERIMENTAL|25 patient with chronic shoulder pain injected with platelet rich plasm|patients with chronic shoulder pain injected with platelet rich plasm ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
61966716|NCT05627960|EXPERIMENTAL|AG-01-1B mesothelioma|Subjects with mesothelioma who received at least 1 SOC therapy for metastatic/recurrent mesothelioma per NCCN guidelines or not a candidate for SOC therapy.
61966717|NCT04121377|EXPERIMENTAL|Resistance exercise program|Early resistance exercise sessions and home program
61966718|NCT02063022|ACTIVE_COMPARATOR|Standard treatment (as per ISG SSG III protocol)|"Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).~It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
61966719|NCT02063022|EXPERIMENTAL|Intensified treatment|Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response
61966720|NCT02875756|EXPERIMENTAL|10 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
61966721|NCT02875756|ACTIVE_COMPARATOR|20 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
61966722|NCT01661296|ACTIVE_COMPARATOR|Sodium stibogluconate|Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
61966723|NCT01661296|ACTIVE_COMPARATOR|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
62144989|NCT01989104||Adolescents|13-17 years of age
62706589|NCT05072899|EXPERIMENTAL|25 patient with chronic shoulder pain injected with Hyaluronic acid|patients with chronic shoulder pain injected with Hyaluronic acid ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
62144990|NCT01989104||Young adults|18-20 years of age
62508769|NCT00897286||Tumor/Tissue Sample|Tumor material collected prospectively from a clinically well characterized patient cohort
62706590|NCT01144650|PLACEBO_COMPARATOR|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
62706591|NCT01144650|EXPERIMENTAL|Dapsone|Patients will receive either a single total dose of 250 mg IV and oral dosage
61966724|NCT01125384|NO_INTERVENTION|nurse swabbing|
61966725|NCT01125384|EXPERIMENTAL|"accurate swabbing by a physician"|
61966726|NCT00404677|PLACEBO_COMPARATOR|Standard|Methacholine challenges are performed using the standardized two minute tidal breathing method
61966727|NCT00404677|ACTIVE_COMPARATOR|Modified|Five deep inhalation maneouvers are incorporated into the standardized methacholine challenge
62144991|NCT02390206||Botulinum toxin type A (BoNT-A) injection Naïve|Subjects naïve to BoNT-A treatment. Investigators follow their individual injection protocol for treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines).
62144992|NCT01084525|EXPERIMENTAL|OTO-104 (steroid) 3 mg|
62144993|NCT01084525|PLACEBO_COMPARATOR|Placebo|
62144994|NCT01084525|EXPERIMENTAL|OTO-104 (steroid) 12 mg|The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
62350555|NCT01207388|EXPERIMENTAL|Blinatumomab|Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
62508770|NCT06616727|EXPERIMENTAL|SNC109 CART|After the screening and evaluation, SNC-109 CAR-T Cells will be infusion.
61966728|NCT06359470|EXPERIMENTAL|positioning|the supine position, then from the oblique position after 10 minutes, and finally from the oblique position again after 48 hours
61966729|NCT04548570||approximation of both recti group|
61966730|NCT04548570||non approximation of both recti group|
61966731|NCT00691015|EXPERIMENTAL|Chemotherapy or chemotherapy + total body irradiation|"Standard of care (SOC) chemotherapy or ( SOC) chemotherapy + total body irradiation (TBI) of one of the following regimens:~Regimen I: Patients receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV;anti-thymocyte globulin IV.~Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV; anti-thymocyte globulin IV.~Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV; anti-thymocyte globulin IV.~Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI; anti-thymocyte globulin IV."
61966732|NCT02097576|ACTIVE_COMPARATOR|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
61966733|NCT02097576|ACTIVE_COMPARATOR|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
61966734|NCT00160251|ACTIVE_COMPARATOR|Arm 1A: PegIntron (PEG) + Ribavirin (RBV)|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is undetected, PEG + RBV will continue for another 36 weeks.
62508771|NCT02457611|EXPERIMENTAL|LDV/SOF|LDV/SOF FDC for 6 weeks
62508772|NCT04649697|EXPERIMENTAL|Rebamipide|The enrolled subjects will be treated with Rebamipide in mucoadhesive gel for 2 weeks or until complete healing.
62508773|NCT04649697|EXPERIMENTAL|Nanoparticulated Rebamipide|The enrolled subjects will be treated with nanoparticulated Rebamipide in mucoadhesive gel for 2 weeks or until complete healing.
61966735|NCT00160251|ACTIVE_COMPARATOR|Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is detectable, BOC 400 mg TID will be added for 36 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
61966736|NCT00160251|EXPERIMENTAL|Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
61966737|NCT00160251|EXPERIMENTAL|Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
61966738|NCT00160251|EXPERIMENTAL|Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
61966739|NCT00160251|EXPERIMENTAL|Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
62144995|NCT01052766|EXPERIMENTAL|PET/CT and BH PET/CT|In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
62144996|NCT00464893|ACTIVE_COMPARATOR|catumaxomab arm|Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
62508774|NCT04649697|ACTIVE_COMPARATOR|Clobetasol|The enrolled subjects will be treated with Clobetasol in mucoadhesive gel for 2 weeks or until complete healing.
62508775|NCT01665651|PLACEBO_COMPARATOR|kidney Yin deficiency with placebo|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules placebo treatment besides basic treatment.
62706592|NCT03841409||Bupivacaine dosage in ESP block|The pharmacokinetics of bupivacaine 0.5% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following an ESP block will be determined by the collection of blood samples at predetermined time points.
62508776|NCT01665651|PLACEBO_COMPARATOR|kidney Yang deficiency with placebo|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules placebo treatment besides basic treatment.
62508777|NCT01665651|EXPERIMENTAL|kidney Yin deficiency with Zuogui|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules treatment besides basic treatment.
62706593|NCT05737979||Women undergoing IVF|Women undergoing an antagonist in vitro fertilization cycle using Rekovelle and Menopur for stimulation
62706594|NCT05189678||frailty group|Modified Frailty index score greater than or equal to 0.21
62706595|NCT05189678||non-frailty group|Modified Frailty index score is less than 0.21
62706596|NCT04284111||Children with myopia|"A total of 1,000 children from 8 hospitals in China is required to undergo ophthalmic examinations and complete questionnaires at baseline and~1yr after wearing ortho-k lenses."
62144997|NCT03937609|OTHER|Standard dosing|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The control group will continue with 5 mg/kg IFX at week 2 and 6, followed by every 8 weeks.
62144998|NCT03937609|EXPERIMENTAL|Intervention group|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The intervention group will receive model based dosing of infliximab with 5mg/kg at various timepoints based on the dashboard model.
62706597|NCT02421757|EXPERIMENTAL|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
62508778|NCT01665651|EXPERIMENTAL|kidney Yang deficiency with Yougui|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules treatment besides basic treatment.
62508779|NCT05391659|ACTIVE_COMPARATOR|current workflow in Flanders|patient visits ophthalmologist
62508780|NCT05391659|ACTIVE_COMPARATOR|AI-only workflow|patient is imaged, images are interpreted by DR AI tool, only referrable cases identified by DR AI tool will visit ophthalmologist
62508781|NCT05391659|ACTIVE_COMPARATOR|AI-human workflow|patient is imaged, images are interpreted by DR AI tool, referrable cases identified by DR AI tool will be remotely graded by a human, only the high risk patients will visit ophthalmologist
62508782|NCT06038396|EXPERIMENTAL|Part A-Arm 1|Part A will follow the standard 3+3 dose escalation design, 3\~6 participants will be allocated to the first dose group of RC118, and receive a treatment of RC118-ADC (1.0mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
62508783|NCT06038396|EXPERIMENTAL|Part A-Arm 2|Part A will follow the standard 3+3 dose escalation design, 3\~6 participants will be allocated to the second dose group of RC118, and receive a treatment of RC118-ADC (1.5mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
62706598|NCT02421757|PLACEBO_COMPARATOR|Sham Device|Sham Device
62706599|NCT01644435|OTHER|Study arm A|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
62706600|NCT01644435|OTHER|Study arm B|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring.
62706601|NCT06559449||Weekend surgery|Patients undergoing surgery during weekend or national holiday
62706602|NCT06559449||Weekday group|Patients waiting in hospital during weekend and undergoing surgery during a weekday
62706603|NCT00817609|EXPERIMENTAL|A|
62706604|NCT00817609|PLACEBO_COMPARATOR|B|
62706605|NCT06508619|EXPERIMENTAL|Patients receiving blood pressure lowering medication (uptitration) as standard of care|
62144999|NCT03212885|EXPERIMENTAL|1|STN Monopolar Stimulation
62706606|NCT01329133|ACTIVE_COMPARATOR|DBS of subthalamic nucleus|
62508784|NCT06038396|EXPERIMENTAL|Part A-Arm 3|Part A will follow the standard 3+3 dose escalation design, 3\~6 participants will be allocated to the Thrid dose group of RC118, and receive a treatment of RC118-ADC (2.0mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
62508785|NCT06038396|EXPERIMENTAL|Part A-Arm 4|Part A will follow the standard 3+3 dose escalation design, 3\~6 participants will be allocated to the last dose group of RC118, and receive a treatment of RC118-ADC (2.5mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
62508786|NCT06038396|EXPERIMENTAL|Part B-Arm 1|Part B-Arm 1 will include approximately 20 patients with gastric cancer (including gastric esophageal junction). This subject group will receive RC118-ADC and Toripalimab (3.0mg/kg) Day 1 of every 14-day cycle. The starting dose of RC118-ADC for expansion will be derived from the RP2D determined during Part A.
62706607|NCT01329133|ACTIVE_COMPARATOR|DBS of ventral striatum|
62706608|NCT05594186|ACTIVE_COMPARATOR|Tranexamic acid|Patients in group A, received Tranexamic acid 1300 mg (2 tablets of 650 mg) three times daily for 5 days starting from the first day of menses for 12 months.
62145000|NCT03212885|EXPERIMENTAL|2|rZI + STN stimulation
62145001|NCT06323369|EXPERIMENTAL|Neoadjuvant Tislelizumab + Chemotherapy (Arm A)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1、2、3（Cycle length: 21 days）：Tislelizumab(IV) , dose= 200mg, day=1; Cisplatin(IV) , dose=75 mg/m2, or Carboplatin(IV) , AUC=5, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Following surgical resection, lymph node positive participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Lymph node negative participants receive 200 mg Tislelizumab Q3W as adjuvant therapy."
62350556|NCT06182930|EXPERIMENTAL|Experimental|Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.
62706609|NCT05594186|ACTIVE_COMPARATOR|Combined oral contraceptive pill|Patients in group B, received combined oral contraceptive pill (OCP) once daily for 21 days (Desogestrel 150 micrograms/ Ethinylestradiol 30 micrograms, tablets), starting from the first day of menses, then to have a one-week pill free period to allow for a withdrawal bleed, and that was repeated for 12 cycles.
62706610|NCT05594186|ACTIVE_COMPARATOR|Tranexamic acid plus Combined oral contraceptive pill|Patients in group C, received a combination of Tranexamic acid 1300 mg three times daily for 5 days, and a combined oral contraceptive pill once daily for 21 days (Desogestrel 150 micrograms/ Ethinylestradiol 30 micrograms, tablets), both starting from the first day of menses for 12 consecutive cycles.
62706611|NCT05594186|ACTIVE_COMPARATOR|Levonorgestrel-releasing intrauterine system|Patients in group D, had the levonorgestrel-releasing intrauterine system inserted into the uterine cavity. The insertion was done by a skilled gynecologist as an outpatient procedure without anesthesia.
62706612|NCT04277260||Full term delivery|In the cooperative obstetric hospital, 30 cases of full-term delivery healthy mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
62706613|NCT04277260||Preterm delivery(35-37 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(35-37 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
62706614|NCT04277260||Preterm delivery(32-35 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
61966740|NCT00160251|EXPERIMENTAL|Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
61966741|NCT00160251|EXPERIMENTAL|Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800|By first protocol amendment to P03659, this non-randomized arm is added. A single dose of PEG is given first, followed 1 week later by PEG + BOC 800 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
62706615|NCT04277260||Preterm delivery(28-32 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(28-32 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
61966742|NCT00160251|EXPERIMENTAL|Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800|By second protocol amendment to P03659, participants from all arms except Arm 1A will be rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.
61966743|NCT00888862|EXPERIMENTAL|A|Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
61966744|NCT01717560|EXPERIMENTAL|Collaborative multidisciplinary integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
62706616|NCT03558217|EXPERIMENTAL|Collared Femoral Implant|Participants will have the Corail collared femoral implant used during their surgery.
62706617|NCT03558217|ACTIVE_COMPARATOR|Collarless Femoral Implant|Participants will have the Corail collarless femoral implant used during their surgery.
62706618|NCT05524233|EXPERIMENTAL|Transcranial Direct Stimulation|Subjects will receive an active electrical stimulation device (tDCS) to use up to 20 minutes daily for 4 weeks. To deliver tDCS subjects will place a strap around their forehead area.
62706619|NCT04856280|EXPERIMENTAL|The kinesiological taping (KT) group (n=15)|6 sessions of taping was applied to the kinesiological taping group, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended. Using the KT ligament technique, it was applied to the supra pubic region with 100% tension in order to reduce contraction in the uterus
62706620|NCT04856280|ACTIVE_COMPARATOR|The aerobic exercise (AE) group (n=15)|"In the AE group, walking and climbing stairs were given during the menstrual cycle, 45 minutes session per day, 3 days a week over 3 weeks. The exercise protocol consists of 5 minute warm up, 35 min AE and 5 minute cool-down exercises. Warm-up and cool-down exercises include an active range of motion (ROM) exercises for upper and lower extremity. Aerobic exercise includes 30 min of moderate walking and climbing stairs. The aerobic exercise was performed in accordance with the definition of moderate-intensity exercise of the World Health Organization; It was given to the participants that during moderate exercise, the individual should walk with a tempo in a way that he can speak but cannot sing"
62706621|NCT04856280|NO_INTERVENTION|The control group (n=15)|No intervention was applied to the control group.
62706622|NCT02666053|EXPERIMENTAL|Treatment A|Single BMS-663068 tablet under fasted conditions
61966745|NCT03740061||Antwerp|
61966746|NCT03740061||Barcelona|
61966747|NCT03740061||Istanbul|
61966748|NCT03740061||Oldenburg|
61966749|NCT03740061||Krakow|
62706623|NCT02666053|EXPERIMENTAL|Treatment B|Single BMS-663068 tablet with a high fat meal
62706624|NCT02666053|EXPERIMENTAL|Treatment C|Single BMS-663068 tablet after a single famotidine tablet under fasted conditions
62706625|NCT01769027|ACTIVE_COMPARATOR|SSRI+AB|Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ). Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
62706626|NCT01769027|PLACEBO_COMPARATOR|SSRI+placebo|Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
62706627|NCT04446052|PLACEBO_COMPARATOR|Placebo|
62706628|NCT04446052|ACTIVE_COMPARATOR|GM-CSF priming|
61966750|NCT03740061||Bialystok|
61966751|NCT03740061||Rome|
61966752|NCT03740061||Madrid|
61966753|NCT03740061||Leuven|
61966754|NCT02959931|EXPERIMENTAL|High potassium meal|In this arm individuals will be provided with a breakfast meal that provides \~2400 mg of dietary potassium.
61966755|NCT02959931|ACTIVE_COMPARATOR|Low potassium meal|In this arm individuals will be provided with a breakfast meal that provides \~540 mg of dietary potassium.
61966756|NCT01651195|ACTIVE_COMPARATOR|Probiotic tablet (military recruits)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
61966757|NCT01651195|PLACEBO_COMPARATOR|Placebo tablet (military recruits)|Crystalline cellulose 2 x 2, 3 weeks
61966758|NCT01651195|ACTIVE_COMPARATOR|Probiotic tablet (reserve officer candidates)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
61966759|NCT01651195|PLACEBO_COMPARATOR|Placebo tablet (reserve officer candidates)|Crystalline cellulose 2 x 2, 3 weeks
61966760|NCT04943185|OTHER|Ab interno technique|Ab Interno is traditional method of stent XEN implantation, where the device will injected through a small corneal incision that closes with the preloaded XEN injector.
61966761|NCT04943185|OTHER|Ab externo technique|The ab externo approach does this without any incision, less invasive, and the implant is directly injected through the conjunctiva into the anterior chamber of the eye. Both methods create a new way out through the subconjunctival space, which is the traditional target of trabeculectomy.
61966762|NCT06350825|EXPERIMENTAL|Local treatment group|Triplet or doublet therapy followed by cytoreductive prostatectomy or brachytherapy
61966763|NCT06350825|ACTIVE_COMPARATOR|SOC group|Triplet or doublet therapy (ie. docetaxel/abiraterone, apalutamide，Rezvilutamide，darolutamide，enzalutamide)
61966764|NCT02789150|EXPERIMENTAL|MAP 65-70|Goal MAP of 65-70
61966765|NCT02789150|ACTIVE_COMPARATOR|MAP greater than or equal to 85|MAP greater than or equal to 85
61966766|NCT06131034|EXPERIMENTAL|Music group|
61966767|NCT06131034|NO_INTERVENTION|Control group|
61966768|NCT04294576|EXPERIMENTAL|Arm 1; BJ-001|Phase 1a Part 1, Part 2, and Part 4: dose escalation for BJ-001 as single agent
62350557|NCT06182930|NO_INTERVENTION|Control|They will receive routine home health care follow-up.
62508787|NCT06038396|EXPERIMENTAL|Part B-Arm 2|Part B-Arm 1 will include approximately 20 patients with pancreatic cancer and other solid tumors. This subject group will receive RC118-ADC and Toripalimab (3.0mg/kg) Day 1 of every 14-day cycle. The starting dose of RC118-ADC for expansion will be derived from the RP2D determined during Part A.
62145002|NCT06323369|ACTIVE_COMPARATOR|Up-front Surgery (Arm B)|Following surgical resection, lymph node positive participants receive chemoradiotherapy as adjuvant therapy. Lymph node negative participants receive follow-up.
62350558|NCT01798017|EXPERIMENTAL|Mifepristone-misoprostol|Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol
62706629|NCT04544280|EXPERIMENTAL|Intervention|
62706630|NCT04943861|ACTIVE_COMPARATOR|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
62706631|NCT04943861|OTHER|Usual Care|There is no peer navigation within usual care.
61966769|NCT04294576|EXPERIMENTAL|Arm 2; BJ-001 and pembrolizumab|"Phase 1a Part 3 and Part 5: dose escalation for BJ-001 in combination with Pembrolizumab~Phase 1b: expansion cohorts for the combination of BJ-001 and pembrolizumab"
62350559|NCT05796804|ACTIVE_COMPARATOR|ERECTOR SPINAE PLANE BLOCK|ultrasound guided block at L4
62350560|NCT05796804|ACTIVE_COMPARATOR|PERICAPSULARE NERVE GROUP AND LATERAL FEMORAL CUTANEOUS NERVE BLOCK|ultrasound guided block below the ileo-psoas muscle tendon, above the ilio-pectineous eminence and ultrasound guided block of lateral femoral cutaneous nerve
62508788|NCT01557582|OTHER|Right ventrical volumn comparison|Single arm study comparing Ventripoint Medical System (VMS) right ventricle volume measurement to gold standard cardiac Magnetic Resonance Imaging (cMRI) measurement in patients with Pulmonary Arterial Hypertension.
62350561|NCT00321269|ACTIVE_COMPARATOR|Single Illness Managment|This intervention includes standard disease self-management coaching for heart failure and helps patients set goals for fluid management, restricted salt-intake, and medication adherence.
62508789|NCT05931120|EXPERIMENTAL|Dry needling|dry needling with multimodal physical therapy approach containing hurdler stretch and extended triangular pose
62508790|NCT05931120|EXPERIMENTAL|IASTM|IASTM with multimodal physical therapy approach containing hurdler stretch and extended triangular pose
62508791|NCT06446388|EXPERIMENTAL|QLS31905 + oxaliplatin + capecitabine|Gastric/gastroesophageal junction cancer participants will be treated with QLS31905 at doses determined by the phase I study in combination with oxaliplatin and capecitabine.
62508792|NCT06446388|EXPERIMENTAL|QL1706 + oxaliplatin + capecitabine|Gastric/gastroesophageal junction cancer participants will be treated with QL1706 in combination with oxaliplatin and capecitabine.
62508793|NCT06446388|EXPERIMENTAL|QLS31905 + oxaliplatin + capecitabine + QL1706|Gastric/gastroesophageal junction cancer participants will be treated with QLS31905 at doses determined by the phase I study in combination with oxaliplatin and capecitabine+ QL1706.
62350562|NCT00321269|EXPERIMENTAL|Comorbid Illness Management|This intervention includes the same self-management coaching found in the comparator arm, but also includes discussion of ways to cope and manage mood.
62508794|NCT06446388|EXPERIMENTAL|QLS31905 + gemcitabine+cisplatin|Biliary tract cancer will be treated with QLS31905 at doses determined by the phase I study in combination with gemcitabine and cisplatin.
62508795|NCT06446388|EXPERIMENTAL|QL1706 + gemcitabine+cisplatin|Biliary tract cancer will be treated with QL1706 in combination with gemcitabine and cisplatin.
62508796|NCT06446388|EXPERIMENTAL|QLS31905 + gemcitabine+cisplatin+ QL1706|Biliary tract cancer will be treated with QLS31905 at doses determined by the phase I study in combination with gemcitabine and cisplatin+ QL1706.
62508797|NCT06446388|EXPERIMENTAL|QLS31905 + standard chemotherapy|Other solid tumor participants will be treated with QLS31905 at doses determined by the phase I study in combination with standard chemotherapy recommended by guidelines.
62508798|NCT06446388|EXPERIMENTAL|QL1706 + standard chemotherapy|Other solid tumor participants will be treated with QL1706 in combination with standard chemotherapy recommended by guidelines.
62706632|NCT01160406||ischemic stroke, no atrial fibrillation|Patients who have suffered ischemic stroke or transient ischemic attack without known atrial fibrillation
62706633|NCT00744744||Survey|
62706634|NCT06490159||Patients with peripheral neuropathy of paclitaxel in second-line chemotherapy for gastric cancer|A panel of microRNA, whose expression level is tested exosomal microRNA from blood sample before second-line chemotherapy with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
62706635|NCT06490159||Patients without peripheral neuropathy of paclitaxel in second-line chemotherapy for gastric cancer|A panel of microRNA, whose expression level is tested exosomal microRNA from blood sample before second-line chemotherapy with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
62706636|NCT05450562|EXPERIMENTAL|SAR444200 - Dose Escalation Phase (Part 1A)|SAR444200 will be administered as intravenous injection as monotherapy in participants with GPC3+ solid tumors over a 21-day cycle
61966770|NCT01020227|EXPERIMENTAL|Integrative Therapies|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
62706637|NCT05450562|EXPERIMENTAL|SAR444200 - Dose Expansion Phase (Part 2A)|SAR444200 will be administered as intravenous injection in participants with GPC3+ NSCLC over a 21-day cycle
61966771|NCT01020227|NO_INTERVENTION|Standard Care|Patients were given no intervention but were contacted at 6 weeks and 6 months for data collection purposes
61966772|NCT00909051||Group 1|
61966773|NCT02715674|PLACEBO_COMPARATOR|control group|take 4lt/min oxygen with Plasti-med oxygen therapy mask
61966774|NCT02715674|ACTIVE_COMPARATOR|IS group|in postoperatively, patients will carry out Plasti-med TRIFLO 5 min per hour for 6 hours.
61966775|NCT02715674|ACTIVE_COMPARATOR|CPAP group|in postoperatively, patients will carry out 10 cmH2O noninvasive continuous positive airway pressure with BIPAP VISION 5 min per hour for 6 hours.
61966776|NCT03817177|PLACEBO_COMPARATOR|nasal prong|conventional nasal prong application after the surgery in postanesthetic care unit (PACU)
61966777|NCT03817177|EXPERIMENTAL|high flow nasal cannula oxygenation|high flow nasal cannula application after the surgery in postanesthetic care unit (PACU)
61966778|NCT01927224|EXPERIMENTAL|Nifurtimox (Group 1)|Descriptive pharmacokinetic group
61966779|NCT01927224|EXPERIMENTAL|Nifurtimox (Group 2)|The assessment of bioequivalence of the two formulation (30mg vs.120mg)
62508799|NCT06446388|EXPERIMENTAL|QLS31905 + standard chemotherapy + QL1706|Other solid tumor participants will be treated with QLS31905 at doses determined by the phase I study in combination with standard chemotherapy and QL1706.
62508800|NCT04540718|NO_INTERVENTION|Control|Participants in this group continues with their sedentary behavior
62508801|NCT04540718|ACTIVE_COMPARATOR|Exercise only|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and will sit in the exercise laboratory for 15 minutes whilst the experimental group uses the sauna.
62508802|NCT04540718|EXPERIMENTAL|Exercise and sauna|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and incorporates sauna bathing (heat therapy) immediately after exercise.
62706638|NCT05450562|EXPERIMENTAL|SAR444200 and Atezolizumab combination therapy - Dose Escalation Phase (Part 1B)|SAR444200 in combination with atezolizumab will be administered as intravenous injection in participants with GPC3+ solid tumors over a 21-day cycle
62706639|NCT04312022|EXPERIMENTAL|Berry extract intake, then Placebo|Participants received a single dose of berry extract supplement (hawthorn berry extract, tart cherry extract, and bromelain). After a washout period of 2 weeks, they then received a single dose of the placebo (flour capsule).
62706640|NCT04312022|PLACEBO_COMPARATOR|Placebo intake, then Berry extract intake|Participants received a single dose of placebo (flour capsule). After a washout period of 2 weeks, they then received a single dose of berry extract supplement (hawthorn berry extract, tart cherry extract, and bromelain).
62706641|NCT04163757|PLACEBO_COMPARATOR|placebo|
62706642|NCT04163757|ACTIVE_COMPARATOR|crocin|
62706643|NCT06450743|OTHER|Derivation Cohort|Adult and pediatric patients who have routinely performed the lymphocyte immunophenotyping test, including also the enumeration of NKT-like cells, to exclude an immunological impairment during the period from May 2019 to March 2020 (for adults) and from May 2019 to August 2021 (for pediatric patients).
61966780|NCT02687945|ACTIVE_COMPARATOR|Outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of outpatient physiotherapy with 2-3 weekly sessions
61966781|NCT02687945|ACTIVE_COMPARATOR|No outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of self-guided physiotherapy exercises
61966782|NCT00000105||Arm A: Intracel KLH|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
61966783|NCT00000105||Arm B: Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
61966784|NCT00000105||Arm C: Biosyn KLH with Montanide ISA51|Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
61966785|NCT06112262|EXPERIMENTAL|Heparin and Hirudin|Anticoagulant in Hemodialysis
61966786|NCT06373991|EXPERIMENTAL|ATHENA CAR-T Arm|A conditioning chemotherapy regimen will be administered followed by investigational treatment of ATHENA CAR-T
61966787|NCT01872988|ACTIVE_COMPARATOR|Tenofovir treatment|Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
61966788|NCT01872988|PLACEBO_COMPARATOR|Placebo|Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
61966789|NCT02387060|EXPERIMENTAL|H-Bupivacaine 11.5 mg + fentanyl 25 mcg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75% plus fentanyl 25 mcg.
62145003|NCT02761499||Total Hip Arthroplasty|The United Hip System consist of several components, and for this clinical evaluation it includes the U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem.
62508803|NCT03711916|EXPERIMENTAL|Breast flap creation with PlasmaBlade|During participant's scheduled bilateral mastectomy, breast flap on one breast will be created using low thermal dissection device (PlasmaBlade) on one breast and standard Bovie cautery in the contralateral breast.
62508804|NCT03711916|NO_INTERVENTION|Breast flap creation with Bovie Cautery|During participant's scheduled bilateral mastectomy, breast flap will be created using standard Bovie cautery on the breast contralateral to the one that was created using PlasmaBlade.
62706644|NCT06450743|OTHER|Validation Cohort|Healthy adult blood donors in order to validate the obtained results.
62706645|NCT06204783||Cohort A: Transaortic Valve Implantation (TAVI)|Elective TAVI with biventricular PV loop monitoring (throughout the procedure)
61966790|NCT02387060|ACTIVE_COMPARATOR|H-Bupivacaine 11.5 mg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75%
61966791|NCT04758780|EXPERIMENTAL|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
61966792|NCT04821921||Patients with diabetes mellitus|Approximately 750 patients with diabetes mellitus from 3 GP practices specialized on diabetes treatment
61966793|NCT00767637|EXPERIMENTAL|Arm 1|
61966794|NCT02116296|OTHER|LIfestyle counseling|
61966795|NCT05743946|EXPERIMENTAL|Trikafta|Participants with NCFBE and one known CFTR mutation and/or mildly elevated sweat chloride measurements (i.e., 30-60 mEq/L) receiving Trikafta for four weeks.
61966796|NCT05182489|EXPERIMENTAL|Medtronic Adaptix™ titanium implants|This arm will use Medtronic Adaptix™ titanium implants supplemented with a pedicle screw system. Both cages will be used in conjunction with a 50:50 mixture of autograft: allograft using milled local autograft bone and GRAFTON™ DBM DBF (no iliac crest autograft will be utilized).
61966797|NCT05182489|ACTIVE_COMPARATOR|Medtronic CAPSTONE® PEEK cage|This arm will use Medtronic CAPSTONE® PEEK cage supplemented with a pedicle screw system. Both cages will be used in conjunction with a 50:50 mixture of autograft: allograft using milled local autograft bone and GRAFTON™ DBM DBF (no iliac crest autograft will be utilized).
61966798|NCT05931861|EXPERIMENTAL|T2769|One drop in each eye, from 3 to 6 times daily, at any time but only when patients are wearing their contact lenses.
61966799|NCT05163444|EXPERIMENTAL|Rolling can|Gait analysis with rolling cane
61966800|NCT05163444|ACTIVE_COMPARATOR|Quadripod can|Gait analysis with quadripod cane
61966801|NCT02837575|EXPERIMENTAL|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses
62706646|NCT06204783||Cohort B: Mitral Transcatheter Edge-to-Edge Repair (mitral TEER)|Elective mitral TEER with biventricular PV loop monitoring (throughout the procedure)
61966802|NCT02837575|PLACEBO_COMPARATOR|Phosphate-buffered saline, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 4 doses
61966803|NCT03158116|EXPERIMENTAL|Treatment|All participants will be receiving the study drug
61966804|NCT06381882||Patients|Adult patients with resectable pancreatic or periampullary presumed (pre)malignancy
61966805|NCT02396615|ACTIVE_COMPARATOR|Active|Satin pineapple. Active juice with fibre and ginseng
61966806|NCT02396615|PLACEBO_COMPARATOR|Control|SATIN pineapple control. Control juice - normal juice prpoducts without added active ingredients
61966807|NCT05562128|EXPERIMENTAL|Active forest therapy|
61966808|NCT05562128|ACTIVE_COMPARATOR|Passive forest therapy|
61966809|NCT05562128|NO_INTERVENTION|Waiting list|
61966810|NCT00717691|EXPERIMENTAL|1|Immediate fitting with dynamic splinting following diagnosis of hallux limitus.
62706647|NCT06204783||Cohort C: Tricuspid Transcatheter Edge-to-Edge Repair (tricuspid TEER)|Elective tricuspid TEER with biventricular PV loop monitoring (throughout the procedure)
62706648|NCT01959932|EXPERIMENTAL|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
61966811|NCT00717691|NO_INTERVENTION|2|Control arm; patients only treated with standard of care following diagnosis of hallux limitus.
61966812|NCT00645060|EXPERIMENTAL|Y-90-DOTA-M5A anti-CEA antibody|
61966813|NCT00254904|EXPERIMENTAL|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
61966814|NCT00254904|ACTIVE_COMPARATOR|B|Standard of Care chemotherapy
61966815|NCT02837198|EXPERIMENTAL|Uric acid-overproduction Type|FYU-981
61966816|NCT02837198|EXPERIMENTAL|Uric acid- underexcretion Type|FYU-981
61966817|NCT02837198|EXPERIMENTAL|Uric acid-overproduction Type (combination)|FYU-981 , Topiroxostat
61966818|NCT02837198|EXPERIMENTAL|Uric acid- underexcretion Type2|FYU-981
61966819|NCT05392010||ventilated critically ill patients|All consecutive adult patients (≥ 18 years old) who are admitted to the ICU and require invasive mechanical ventilation (endotracheal tube or tracheostomy) longer than 12 hours. 2. Adult patients admitted to the ICU and require advanced respiratory support (high flow oxygen nasal cannula \[HFONC\], or noninvasive ventilation \[NIV\] BIPAP or CPAP with oronasal, nasal, helmet or facial mask) with acute respiratory failure defined as PaO2/ fraction of inspired oxygen (FiO2), \[PaO2/FiO2\] ratio \<300, or the pulse oximetric saturation (SpO2/FiO2 ) ratio \< 315 for more than 1 hour.
61966820|NCT04870593|EXPERIMENTAL|Community receives buddy and gossip treatment, individual informed directly (arm (1))|"(i) Individual elder given vaccination information.~(ii) Individual elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated.~(iii) Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders and to encourage their communities to use the buddy system to get elders vaccinated."
61966821|NCT04870593|EXPERIMENTAL|Community receives buddy and gossip treatment, individual not informed directly (arm (2))|Individual elder lives in community with elders in arm (1).
61966822|NCT04870593|EXPERIMENTAL|Community receives gossip treatment, individual informed directly (arm (3))|"(i) Individual elder given vaccination information.~(ii) Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders."
62145004|NCT05850624|EXPERIMENTAL|ice massage|ice massage to hoku point for labor pain for 20 minutes
62706649|NCT01959932|SHAM_COMPARATOR|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
61966823|NCT04870593|EXPERIMENTAL|Community receives gossip treatment, individual not informed directly (arm (4))|Individual elder lives in community with elders in arm (3).
61966824|NCT04870593|EXPERIMENTAL|Community receives buddy treatment, individual informed directly (arm (5))|"(i) Individual elder given vaccination information.~(ii) Individual elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
61966825|NCT04870593|EXPERIMENTAL|Community receives buddy treatment, individual not informed directly (arm (6))|Individual elder lives in community with elders in arm (5).
61966826|NCT04870593|EXPERIMENTAL|Community receives information, individual informed directly (arm (7))|Individual elder given vaccination information.
61966827|NCT04870593|EXPERIMENTAL|Community receives information, individual not informed directly (arm (8))|Individual elder lives in community with elders in arm (7).
61966828|NCT01152242|ACTIVE_COMPARATOR|Part 1|Part I of the trial
61966829|NCT01152242|ACTIVE_COMPARATOR|Part 2|Part II of the trial
62145005|NCT05850624|EXPERIMENTAL|virtual animation|watching virtual animation for 20 minutes for labor pain
62145006|NCT05850624|NO_INTERVENTION|Control Group|receiving standart care
62706650|NCT01959932|ACTIVE_COMPARATOR|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
62706651|NCT05678465|EXPERIMENTAL|FIXATION|"Lightweight macroporous mesh at least 15x10cm will be placed in preperitoneal space and fixated with use of histoacryl glue.~Mesh - B Braun® Optilene Mesh® or BD® SoftMesh® Glue - Histoacryl® LapFix"
62706652|NCT05678465|EXPERIMENTAL|NON-FIXATION|"Standard, 3-D, anatomical mesh will be placed in preperitoneal space without the use of fixating materials.~Mesh - BD® 3D Max® Mesh or Medtronic® Dextile Anatomical Mesh®"
62508805|NCT01902030||Proven/Probable IA Patients|Case Population
62508806|NCT01902030||possible/No IA Patients|Control population
61966830|NCT06229353||Under-immunized Emergency Department adult patients|"Adults attending the Emergency Department who are aged 18-45, without previous HPV vaccination history and without previously known infection from HPV high-risk strain, and in good functional capacity.~Eligible participants will receive Gardasil 9 (HPV) vaccination if interested."
61966831|NCT03276156|EXPERIMENTAL|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
61966832|NCT02673437||Rivaroxaban group|Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
61966833|NCT02673437||Alternative dual antiplatelet therapy|Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
61966834|NCT05404295|ACTIVE_COMPARATOR|Umbilical cord blood platelel lysate group|A Umbilical cord blood platelel lysate gel will be applied in diabetic foot ulcer every three days for one month.
61966835|NCT05404295|PLACEBO_COMPARATOR|Control group|The control group will receive the clinical standard of care; removable of any necrotic, hyperkeratotic and infected tissue, cleansing of the wound with normal saline and covering of the ulcer with dressing with normal saline and then with a few layers of sterile gauze, and non-compressible bandage.
61966836|NCT02157467|EXPERIMENTAL|Arm 1: NGMN/EE + BMS-955176|"Cycle 1- Active Ortho Cyclen QD on Days 1 to 21. Inert Ortho Cyclen tablets on Days 22 to 28~Cycle 2- Active Ortho Cyclen QD alone on Days 29 to 39 (11 days), followed by concomitant administration of active Ortho Cyclen QD + BMS-955176 80 mg QD on Days 40 to 49 (10 days)"
61966837|NCT01145040||Partition 1|Overt primary hypothyroidism
61966838|NCT01145040||Partition 2|"Hypothyroidism with full dose levothyroxine substitution therapy (more than 1.75 µg per kg of body mass)"
61966839|NCT01145040||Partition 3|Overt primary hyperthyroidism
61966840|NCT00003170|EXPERIMENTAL|glutamine|Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
61966841|NCT00003170|PLACEBO_COMPARATOR|placebo|Beginning the first or second day of radiotherapy, patients receive placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
61966842|NCT02603614|EXPERIMENTAL|Cenderitide-Placebo|"Infusion Period A: Cenderitide Infusion Period B: Placebo~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
62350563|NCT05096702||Tafenoquine (TQ)|Patients aged ≥16 years, G6PD activity ≥ 6.1 IU/gHb, not pregnant or breastfeeding, will receive single-dose TQ in addition to standard blood schizonticidal drug.
62706653|NCT06184802|EXPERIMENTAL|Experimental Group (EG)|"The group consists of 50 patients diagnosed with autism spectrum disorder, randomly assigned.~The patients underwent treatment as usual (TAU) integrated with the use of multisensory room, in a 1:1 ratio. All the exercises have been customized by the therapists according to the individual treatment needs, adapting the level of difficulty to the patient's abilities.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
62706654|NCT06184802|ACTIVE_COMPARATOR|Control Group (CG)|"The group consists of 50 patients diagnosed with autism spectrum disorder randomly assigned.~The patients underwent TAU, consisting in standard neuro-psychomotor training. The treatment was tailored according to each child's goals need and preferences.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
62706655|NCT01855984|EXPERIMENTAL|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
62706656|NCT01855984|PLACEBO_COMPARATOR|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
62706657|NCT04836533|EXPERIMENTAL|Computerized Cognitive Training|Those assigned to the computerized cognitive training arm prior to antidepressant trial enrollment will receive computerized cognitive training that includes games that scale in difficulty.
62706658|NCT04836533|ACTIVE_COMPARATOR|Solitaire Training|Those assigned to the solitaire training arm prior to antidepressant trial enrollment will receive computerized solitaire games.
62706659|NCT04836533|EXPERIMENTAL|Open-label antidepressant treatment|Those assigned to receive open-label antidepressant treatment will begin with 10 mg of escitalopram. If the participant cannot tolerate or has an adverse reaction to escitalopram, duloxetine will be offered instead.
62706660|NCT04836533|PLACEBO_COMPARATOR|Placebo-controlled antidepressant treatment|Those assigned to the placebo-controlled group will be told that they have a 50/50 chance of receiving either escitalopram or placebo.
62715055|NCT06026865|EXPERIMENTAL|S-adenosylmethionine (SAMe)|Participants randomized to SAMe Group will receive S-adenosyl-L-methionine 1200 mg/daily (as 2400mg SAMe disulfate tosylate) in tablets in two divided doses (800mg in the morning and 400mg midday) over the period of 6 months. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.
61966843|NCT02603614|EXPERIMENTAL|Placebo-Cenderitide|"Infusion Period A: Placebo Infusion Period B: Cenderitide~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
61966844|NCT01880398||Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
61966845|NCT05895747|EXPERIMENTAL|Low Dose 5-hydroxytryptophan and Creatine Monohydrate|5-HTP 100mg PO BID plus creatine 5g PO Qday
61966846|NCT05895747|EXPERIMENTAL|High Dose 5-hydroxytryptophan and Creatine Monohydrate|5-HTP 200mg PO BID plus creatine 10mg PO Qday
61966847|NCT05895747|PLACEBO_COMPARATOR|Double Placebo|Creatine-matched placebo and 5-HTP-matched placebo
62508807|NCT02495532|ACTIVE_COMPARATOR|Colon Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
61966848|NCT03576924|ACTIVE_COMPARATOR|MICT|Continuous exercise for 30 minutes per session at 60-70% of heart rate max for five times per week, consistent with physical activity guidelines that advocate 150 minutes per week of moderate activity.
61966849|NCT03576924|ACTIVE_COMPARATOR|HIIT|Five repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods; 3-min warm-up and 2-min cool-down, making the total session duration 15 minutes for five times/week, equated to match the guidelines of 75 min of vigorous exercise per week.
61966850|NCT03576924|EXPERIMENTAL|CHOICE|Participants will be introduced to HIIT and MICT during sessions 1 and 2 of the 4-week intervention in a counterbalanced randomized order, and will thereafter self-select one of the two exercise types for remaining sessions. Exercise will be matched to the parallel imposed conditions.
61966851|NCT02114814|EXPERIMENTAL|Intervention group|Diabetes self-management and family support
61966852|NCT02114814|ACTIVE_COMPARATOR|Attention control group|General health information
62145007|NCT03686839|EXPERIMENTAL|SMR neurofeedback training to MCI|"Sensorimotor rhythm neurofeedback protocol consisted of 20 individual sessions, twice a week, during 11 weeks maximum. For each subject MCI, NF was planned and conducted by a neuropsychologist experienced in neurophysiology and neurofeedback. Each session lasted 1h10-15min and was conducted as follows:~1. Preparation and installation of the electrodes, verification of the impedance, adjustment of the calibration and thresholds (15 minutes).~2. NF training (tasks and video described below) (45 minutes).~3. Feedback and debriefing about the session (15 minutes)."
62350564|NCT05096702||Daily primaquine (PQ) for 7 days|Patients aged ≥ 6 months, with G6PD activity between 4.1 and 6.0 IU/gHb, not pregnant or breastfeeding for \< 1 month, will receive daily PQ in addition to standard blood schizonticidal drug.
62508808|NCT02495532|ACTIVE_COMPARATOR|Rectal Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
62508809|NCT04674982|EXPERIMENTAL|Vibration Group|In the vibration group, a vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz) was applied to the middle/side area through which the sural nerve passes immediately below the knee of the extremity from which heel blood was to be collected approximately 30 seconds prior to commencement of the heel lance procedure. The vibration was continued throughout the heel lance procedure unless there was redness, swelling, bruising or a change in the skin integrity in the area to which the vibration was applied, and the vibration was stopped once the procedure was over.
62508810|NCT04674982|NO_INTERVENTION|Control Group|No interventions were made on the newborns in the control group during the heel lance procedure.
62508811|NCT06214559|EXPERIMENTAL|Serum VERRUPRO|To be applied twice a day
62508812|NCT03766139|EXPERIMENTAL|SUPERCELL GLUE(STEM CELLS AND PRFM)|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites .
62508813|NCT03766139|ACTIVE_COMPARATOR|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites
62508814|NCT04661592|EXPERIMENTAL|Control|Neurologically healthy individuals will be recruited for the longitudinal study
62715056|NCT06026865|PLACEBO_COMPARATOR|Placebo|Patients in Placebo Group will receive a placebo of identical appearance, smell and taste, with the same schedule. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg.In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.
62145008|NCT04700202||Retrospective Cohort|Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
62508815|NCT03592329|EXPERIMENTAL|active tVNS + SRT A|active tVNS and Stress Reduction Training A
62508816|NCT03592329|EXPERIMENTAL|active tVNS + SRT B|active tVNS and Stress Reduction Training B
61966853|NCT05557799|ACTIVE_COMPARATOR|Photobiomodulation group|Participants in this group will receive photobiomodulation with a vaginal diode laser and its introit.
62145009|NCT02954289|OTHER|Dietary intervention|Dietary intervention
61966854|NCT05557799|PLACEBO_COMPARATOR|Placebo group|Participants in this group will receive simulated photobiomodulation, with the laser device turned off.
61966855|NCT02260700|EXPERIMENTAL|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
62145010|NCT01860300|EXPERIMENTAL|Antibiotic|Amoxicillin-Potassium Clavulanate Combination
62145011|NCT01860300|PLACEBO_COMPARATOR|Placebo|Placebo
62350565|NCT05096702||Weekly primaquine for 8 weeks|Patients aged ≥ 6 months, with G6PD activity ≤ 4.0 IU/gHb, not pregnant or breastfeeding for \< 1 month, will receive weekly once-a-week PQ for eight weeks in addition to standard blood schizonticidal drug.
62350566|NCT04191603|ACTIVE_COMPARATOR|MONOPOLAR HOOC|COLPOTOMY WITH USAGE MONOPOLAR HOOC
62350567|NCT04191603|ACTIVE_COMPARATOR|PLASMAKINETIK BIPOLAR SPATULA|COLPOTOMY WITH USAGE MONOPOLAR HOOC
62508817|NCT03592329|OTHER|sham tVNS + SRT A|sham stimulation and Stress Reduction Training A
62508818|NCT03592329|OTHER|sham tVNS + SRT B|sham tVNS and Stress Reduction Training B
62508819|NCT04763278|EXPERIMENTAL|Prosthesis|Patient is temporarily fit with Point Digit partial hand prosthetic system
62508820|NCT00249015|EXPERIMENTAL|1|Combined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
61966856|NCT02260700|EXPERIMENTAL|Sequence 2 (ACB)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
61966857|NCT02260700|EXPERIMENTAL|Sequence 3 (BAC)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed by Treatment A (single oral dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
61966858|NCT02260700|EXPERIMENTAL|Sequence 4 (BCA)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed byTreatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
62145012|NCT04255498|EXPERIMENTAL|Etanercept|50 MG/ML Prefilled Syringe (once a week for 4 weeks)
62145013|NCT04255498|EXPERIMENTAL|Mifepristone|(300 mg once a day for 7 days) will follow the etanercept.
62350568|NCT03742115|EXPERIMENTAL|Etoposide standard group|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
62350569|NCT03742115|EXPERIMENTAL|Etoposide reduction group|Etoposide 150 mg/m2 once a week; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
62350570|NCT03742115|ACTIVE_COMPARATOR|Corticosteroid group|dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering, with or without IvIG (0.5 g/kg IV, once every 4 weeks)
62350571|NCT06215456|NO_INTERVENTION|Control|The control group will be treated according to local protocol. Unless contra-indicated, patients experiencing moderate to severe anxiety before undergoing ICA may receive preprocedural oxazepam (10 mg, oral) at the day care unit and diazepam (5 mg, intravenous) before arterial puncture at the catheterization room at nurses and physicians discretion. In patients planned for coronary function testing, benzodiazepines are withheld per protocol.
61966859|NCT02260700|EXPERIMENTAL|Sequence 5 (CAB)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
62145014|NCT01855399|EXPERIMENTAL|Peer Coaching + Decision Aid|All participants will be assigned to one of up to 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants in the TEC arm will be scheduled for an initial visit with their coach to review the decision aid, which has incorporated their personal baseline data.
61966860|NCT02260700|EXPERIMENTAL|Sequence 6 (CBA)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
62145015|NCT01855399|ACTIVE_COMPARATOR|Peer Coaching Alone|Participants randomized to the 'print materials' group will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches in both arms will call their assigned peers once a week to provide support for their action steps.
62145016|NCT03775252|EXPERIMENTAL|Ketogenic diet|Group of patients treated with ketogenic diet after the first neurophysiological screening.
62350572|NCT06215456|ACTIVE_COMPARATOR|Virtual Reality therapy|The VR intervention group will receive two sessions of VRH in addition to standard care. Before starting the first guided session in this study, patients can use VR during the waiting time using SyncVR Relax \& Distract (SyncVR Medical, Utrecht, The Netherlands). Subsequently, the first session of VRH is administered at the day-care unit 20 minutes prior to the procedure. After the first session patients is transported to the catheterization room, where the treatment team have the possibility to introduce themselves to the patients. The second session of VRH is administered during arterial access puncture in the catheterization room, starting 5 minutes prior to puncture and terminating when the diagnostic or guiding coronary catheter is in position. The rest of the procedure will be continued without VR.
62350573|NCT04047121||Truven Health MarketScan|The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.
62350574|NCT05768425||Dementia with Lewy Bodies (DLB)|Mild cognitive impairment (MCI) to moderate dementia with probable DLB No other severe neurological or psychiatric diseases. No alcohol or drug abuse.
62350575|NCT05768425||Alzheimers disease (AD)|MCI to moderate dementia with probable AD. No other severe neurological or psychiatric diseases. No alcohol or drug abuse.
62350576|NCT05768425||Healthy Controls (HC)|Young healthy controls under the age of 40.
62508821|NCT00249015|ACTIVE_COMPARATOR|2|Moderate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
62508822|NCT00249015|EXPERIMENTAL|3|High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
61966861|NCT04432896|EXPERIMENTAL|New dietary protocol|Exclusion of food containing nickel (duration: 4 weeks) + gradual weekly reintroduction of food containing nickel (duration: 4 weeks) under the supervision of a trained dietician who monitors symptoms related to systemic nickel allergy syndrome.
61966862|NCT04432896|ACTIVE_COMPARATOR|Traditional dietary protocol|Exclusion of foods containing nickel without monitoring for symptoms related to systemic nickel allergy syndrome by a trained dietician.
61966863|NCT03910842|EXPERIMENTAL|CD19-TriCAR-T/NK（SILK）|CD19-TriCAR-T/SILK cells will be administered intravenously
61966864|NCT02617628|ACTIVE_COMPARATOR|Before Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
61966865|NCT02617628|ACTIVE_COMPARATOR|After Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
61966866|NCT01113983|EXPERIMENTAL|TAVI - TF and TA approach|Transcatheter aortic valve implantation and transfemoral/ transapical approach
61966867|NCT03258021||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
62145017|NCT03128099|EXPERIMENTAL|Low dose VR social skills training|In the low dose condition, participants play the video game for one hour per session. This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
62350577|NCT06460597|EXPERIMENTAL|Papworth Technique|The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
62350578|NCT06460597|ACTIVE_COMPARATOR|Pranayama|Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
62508823|NCT04328870|ACTIVE_COMPARATOR|oxytocin and spinal anesthesia|spinal anesthesia combined with intravenous oxytocin infusion
62508824|NCT04328870|ACTIVE_COMPARATOR|general anesthsia|general anesthesia alone
62508825|NCT04425122||Esophageal cancer|Patients with esophageal cancer (SCC)
62508826|NCT04425122||Non-cancer group|Non-cancer patients scheduled for upper endoscopy
62508827|NCT02833207|EXPERIMENTAL|EDD Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
62508828|NCT02833207|EXPERIMENTAL|EDD Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
62706661|NCT04164277|EXPERIMENTAL|Intervention|"The 16-week intervention includes three components:~1. Caregiver Component. Facebook-based program including four new habit-formation tasks/week, and 3 face-to-face or virtual caregiver meetings: MSU research staff will lead the meetings at Head Start centers (weeks 1, 8, \& 16) to connect caregivers to each other, offer health information, and discuss behavioral change strategies.~2. Caregiver-Preschooler Learning. Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent privately to each caregiver , and caregivers will be asked to respond to the letters.~3. Center-based Preschooler Component. Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators."
62706662|NCT04164277|NO_INTERVENTION|Control|Control group will receive usual Head Start activities during intervention period. After post-intervention data collection, each control caregiver will receive all intervention supplies and a mini program including a face-to-face or virtual caregiver meeting and 1-week preschooler program. The caregiver meeting will cover contents on alternative cooking ingredients, food labels, and portion sizes.
61966868|NCT01530568|ACTIVE_COMPARATOR|Smear|Routine microbiology based diagnostics for TB
61966869|NCT01530568|EXPERIMENTAL|GeneXpert|Arm that will receive the Xpert test
61966870|NCT04540601|ACTIVE_COMPARATOR|Cancer patients, randomized A|Patients in high-dose antiresorptives with bone metastases
61966871|NCT04540601|NO_INTERVENTION|Cancer patients, randomized B|Drug Holiday as standard operation procedure
61966872|NCT04217876||Clinically suspected infarct-like acute myocarditis|Diagnosis of infarct-like AM was based on five criteria: (a) history of flu-like symptoms within 8 weeks prior admission; (b) new onset of symptoms such as fatigue/breathlessness, chest pain, mild dyspnea, and/or palpitation; (c) ischemic ECG pattern (ST-segment elevation and/or T-wave anomalies); (d) increase of inflammatory markers (non-high- sensitivity CRP \> 8 mg/L and/or white blood cell count \> 11.000/mm3) and cardiac enzymes; and (e) preserved global systolic function (EF \> 50%). We excluded patients with New York Heart Association (NYHA) functional heart classifications II-IV, LVEF \< 50% and those patients with electrocardiographic evidence of bradyarrhythmias (≥second-degree atrioventricular block) or tachyarrhythmias (ventricular or supraventricular arrhythmias).
61966873|NCT05283668|EXPERIMENTAL|(LASER WITH I-PRF)|Eight sites that were treated with laser method for gingival depigmentation, followed by intra-mucosal field injection of I-PRF
61966874|NCT05283668|ACTIVE_COMPARATOR|(LASER WITHOUT I-PRF)|Eight sites that were treated with laser technique for gingival depigmentation only
61966875|NCT00612690|EXPERIMENTAL|Links to Learning|Participants received the community mental health consultation model program.
61966876|NCT00612690|ACTIVE_COMPARATOR|Services as Usual|Participants received treatment as usual and referrals.
62145018|NCT03128099|EXPERIMENTAL|High dose Low dose VR social skills training|In the high dose condition, participants play the same video game twice per session (it takes them two hours). This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
61966877|NCT04310501||CKD Patients|"Patients (n=150) with CKD (Stages 1-5 pre-dialysis, undergoing dialysis, kidney transplantation) who fulfil the inclusion criteria from the Nephrology Dept and Renal Transplant Unit of the University Hospital of Ioannina.~Sixty patients will be selected for the pilot study which will include blood and urine tests and specific polymorphism analysis (pharmacogenetic tests)"
61966878|NCT02622321|EXPERIMENTAL|Arm A: 1.5 mg/kg Emicizumab QW|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
61966879|NCT02622321|ACTIVE_COMPARATOR|Arm B (Control): No Prophylaxis, Then Emicizumab|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
61966880|NCT02622321|EXPERIMENTAL|Arm C: 1.5 mg/kg Emicizumab QW|Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
61966881|NCT02622321|EXPERIMENTAL|Arm D: 1.5 mg/kg Emicizumab QW|Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
62508829|NCT02833207|EXPERIMENTAL|ROV Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
62706663|NCT02445209|ACTIVE_COMPARATOR|EOX|"Epirubicin 50mg/m2 IV on day 1; Oxaliplatin 130mg/m2 IV on day 1; Capecitabine 625mg/m2/day PO BID days 1-21; Cycled every 21 days. Cycled every 3 weeks for a maximum of 8 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 8 cycles of EOX chemotherapy, could be rechallenged with the same regimen."
62706664|NCT02445209|ACTIVE_COMPARATOR|mDCF|"Docetaxel 40 mg/m2 IV od day 1; Leucovorin 400 mg/m2 IV on day 1; 5fluorouracyl 400 mg/m2 IV on day 1; 5fluorouracil 1000 mg/m2/d IV continuous infusion days 1-2; Cisplatin 40 mg/m2 IV on day 3; Cycled every 2 weeks for a maximum of 12 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 12 cycles of mDCF chemotherapy, could be rechallenged with the same regimen"
62706665|NCT01461460|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|
61966882|NCT02495805|ACTIVE_COMPARATOR|adductor canal block (ACB)|Subjects randomized to this groups receive a continuous proximal adductor canal block (ACB) during surgery.
61966883|NCT02495805|ACTIVE_COMPARATOR|femoral nerve block (FNB)|Subjects randomized to this groups receive a continuous femoral nerve block (FNB) during surgery.
61966884|NCT04522960|EXPERIMENTAL|Patients with dementia or mild cognitive impairment due to AD|Dementia or MCI due to AD according to NIA-AA research criteria.
61966885|NCT04522960|ACTIVE_COMPARATOR|Healthy volunteers|Age-and-gender matched healthy controls.
61966886|NCT05144360|EXPERIMENTAL|Atenas association|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Atenas, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan + amlodipine placebo, oral."
61966887|NCT05144360|ACTIVE_COMPARATOR|Empagliflozin + telmisartan + amlodipine|"The patient must take 3 tablets once a day, as follows:~1 tablet Atenas placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan + amlodipine, oral."
61966888|NCT01682057|EXPERIMENTAL|Group A|ROX Anastomic Coupler System (ACS) + continuing standard antihypertensive medications
61966889|NCT00869674|NO_INTERVENTION|Routine pathologic method|Half of each sentinal lymph node will have rountine pathologic examination as normal practice.
61966890|NCT00869674|EXPERIMENTAL|GeneSearch BLN Assay|Half of each sentinal lymph node will have GeneSearch BLN testing.
61966891|NCT05510804|EXPERIMENTAL|ALISA (therapist-assisted digital self-help intervention)|structured app-based self-help programme with scheduled therapist assistance
61966892|NCT05510804|ACTIVE_COMPARATOR|TAU (supportive therapist contacts)|low-frequency supportive therapist contacts
61966893|NCT00600483|EXPERIMENTAL|gentamicin Group|Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy
61966894|NCT00600483|NO_INTERVENTION|Control Group|Standard of care, ie, insertion of no gentamicin-collagen sponge.
62706666|NCT01461460|EXPERIMENTAL|TR-701 FA 1200 mg|
62706667|NCT01461460|EXPERIMENTAL|TR-701 FA 200 mg plus Placebo|
62706668|NCT01461460|PLACEBO_COMPARATOR|Placebo|
62706669|NCT00078260|EXPERIMENTAL|A|
62706670|NCT00078260|EXPERIMENTAL|B|
62706671|NCT02400684||Deep endometriosis|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.
62706672|NCT02400684||Deep endometriosis and endométriomas|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.
62706673|NCT04980560||VAC cohort|Subjects who will take COVID-19 vaccines
62706674|NCT04980560||CON cohort|Subjects who are COVID-19 survivors
62706675|NCT06564116|EXPERIMENTAL|Test Group|Thiomersal-free hepatitis E vaccine
62706676|NCT06564116|ACTIVE_COMPARATOR|Control Group|Licensed hepatitis E vaccine
61966895|NCT03468153|EXPERIMENTAL|CAR-T cell therapy|Patient-derived dual specificity CD19 and CD22 CAR-T
61966896|NCT02877420|EXPERIMENTAL|Non-Technical Skills Training Curriculum|This group will receive 4 hours of small-group and hands-on sessions and 1 hour of didactic NTS sessions. Participants will watch a video that demonstrates ideal endoscopic performance. They will use the E-NTS Checklist during the integrated scenario training. This checklist targets NTS. The group will be given 7 hours of expert-assisted instruction on the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (6 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist who will demonstrate techniques, answer questions and provide individualized performance feedback with a focus on NTS. The last three hours on the high fidelity simulator will be an integrated scenario (IG) featuring standardized patient (SP) and standardized nurse (SN). Feedback will be given after each IG by the instructor, SP and SN. Participants can view the E-NTS Checklist before and after each case.
61966897|NCT02877420|ACTIVE_COMPARATOR|Conventional Simulation Training Group|This group will receive 4 hours of small-group and hands-on sessions on colonoscopy theory from an expert endoscopist. The core curriculum is designed on the basis of the American Society for Gastrointestinal Endoscopy colonoscopy curriculum and an endoscopic training textbook. This curriculum has been shown to be effective when compared to self-regulated learning on the simulator. The sessions will be interlaced with eight hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and on the high-fidelity VR simulator (7 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist. The expert will demonstrate techniques, answer questions and provide feedback on global performance. Feedback, in the form of performance metrics, will be provided by the simulator upon completion/failure of each module.
62706677|NCT06563921|EXPERIMENTAL|Experimental: probiotics supplementation + physical exercise program|Behavioral: physical exercise program in the form of a resistance/hypertrophy-oriented resistance program Dietary Supplement: probiotics supplementation
61966898|NCT05448053|EXPERIMENTAL|Ilizarov device|Ilizarov fixation in open type III pediatric tibial shaft fractures
61966899|NCT01526798|EXPERIMENTAL|Therlite hemodialysis|
61966900|NCT01526798|ACTIVE_COMPARATOR|Control group hfHDF|Control group hfHDF
61966901|NCT02573298|ACTIVE_COMPARATOR|Ice|patients randomized to receive local ice on inflamed joint
61966902|NCT02573298|ACTIVE_COMPARATOR|Cold gas|patients randomized to receive cold gas on inflamed joint
61966903|NCT05024591||same as study population|Use of AI-based CADe/x by breast radiologists
61966904|NCT03501069|EXPERIMENTAL|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
61966905|NCT03501069|EXPERIMENTAL|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
61966906|NCT03501069|EXPERIMENTAL|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
61966907|NCT03501069|EXPERIMENTAL|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
61966908|NCT03501069|EXPERIMENTAL|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
61966909|NCT03501069|EXPERIMENTAL|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
62145019|NCT03128099|NO_INTERVENTION|Healthy Control Participants|23 healthy control participants were recruited and consented to yield baseline comparison data. These participants did not undergo VR training. Only baseline comparison data were collected.
62145020|NCT01606098|ACTIVE_COMPARATOR|Systemic treatment|First-line fluoropyrimidine-based chemotherapy with bevacizumab initiated within 4 weeks of randomization, followed by salvage therapy upon progression at the discretion of the local investigator. Surgery of primary tumour will be performed only when indicated by local signs or symptoms.
62145021|NCT01606098|EXPERIMENTAL|Surgery followed by systemic treatment|Surgery within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy upon progression at the discretion of the local investigator
62145022|NCT03547154|EXPERIMENTAL|Pegylated interferon alfa-2b|Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
62145023|NCT03547154|ACTIVE_COMPARATOR|Interferon alfa-2b|Participants received interferon alfa-2b (Intron\^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m\^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
62508830|NCT02833207|EXPERIMENTAL|ROV Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
62706678|NCT06563921|ACTIVE_COMPARATOR|Active Comparator: resistance/hypertrophy-oriented resistance program|resistance/hypertrophy-oriented resistance program
62508831|NCT01397955||Group 1|Drug (incl. Placebo)
62508832|NCT01953887|EXPERIMENTAL|1 combination tablet EC905|
62706679|NCT06563921|PLACEBO_COMPARATOR|Placebo|Supplementation with placebo
61966910|NCT01550302|NO_INTERVENTION|Controls|Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
61966911|NCT01550302|ACTIVE_COMPARATOR|Superficial Cervical Plexus Block|Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.
61966912|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
61966913|NCT00023634|EXPERIMENTAL|EGFR vaccine with GMCSF|EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
61966914|NCT00023634|EXPERIMENTAL|EGFR vaccine with KLH|EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m
61966915|NCT03158376|EXPERIMENTAL|gabapentin group|"* the day before surgery : gabapentin 400 mg orally~* preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution~* postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
61966916|NCT03158376|PLACEBO_COMPARATOR|placebo group|"* The day before surgery: 1 placebo capsule orally~* preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine~* postoperative day 1 to 10: 1 placebo capsule x 3"
61966917|NCT01479699|PLACEBO_COMPARATOR|Placebo capsule|Four placebo capsules containing safflower oil only
61966918|NCT01479699|ACTIVE_COMPARATOR|Olive leaf extract capsule|Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
61966919|NCT02820272|EXPERIMENTAL|NPWT with cold water|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change.
61966920|NCT02820272|ACTIVE_COMPARATOR|NPWT with normal saline room temp|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change.
61966921|NCT02820272|PLACEBO_COMPARATOR|NPWT without other intervention|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was no injection of any liquids into sponge before dressing change.
61966922|NCT02302027|EXPERIMENTAL|platinium IRC9LXO2AWQ|Normobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
61966923|NCT01335984|EXPERIMENTAL|Telemonitoring group|The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
61966924|NCT01335984|EXPERIMENTAL|Telemonitoring & Telemedicine group|The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring \& Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
62350579|NCT02527148|ACTIVE_COMPARATOR|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
61966925|NCT01335984|OTHER|Control group|The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)
61966926|NCT03492346||LGMD2E Subject Population|"Individuals:~* Confirmed LGMD2E diagnosis by genetic testing or~* Suspected of having LGMD type 2E due to symptoms and a diagnosed family member or a member of a community with a large population of one of these two types"
61966927|NCT04077645|EXPERIMENTAL|Sun salutations|Sun salutations, breathing exercises, and relaxation, at a low to moderate intensity, for 30 minutes.
61966928|NCT04077645|ACTIVE_COMPARATOR|Aerobic exercise|Walking on a treadmill at low to moderate intensity for 30 minutes.
62145024|NCT04305496|EXPERIMENTAL|Capivasertib + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
62145025|NCT04305496|PLACEBO_COMPARATOR|Placebo + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
62350580|NCT02527148|ACTIVE_COMPARATOR|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
62350581|NCT01668030|EXPERIMENTAL|Bacitracin on left, Enzymatic agent on right|Subjects were randomized to receive enzymatic agent on right side of face and bacitracin on left.
62350582|NCT01668030|EXPERIMENTAL|Bacitractin on right, enzymatic agent on left|Subjects were randomized to receive enzymatic agent on left side of face and bacitracin on right.
62706680|NCT06563921|ACTIVE_COMPARATOR|Active Comparator: probiotics supplementation|Supplementation with probiotics
61966929|NCT04077645|OTHER|Seated rest (attentional control)|Watching educational videos for 30 minutes.
61966930|NCT06076616|EXPERIMENTAL|Prehabilitation/rehabilitation|Patients in this arm follow a lifestyle counseling programme starting from diagnosis up to 6 months postoperatively.
62508833|NCT01953887|EXPERIMENTAL|2: solifenacin|
62508834|NCT01953887|EXPERIMENTAL|3: tamsulosin|
61966931|NCT06076616|NO_INTERVENTION|Usual care|Patients in this arm follow usual care.
61966932|NCT01985867|EXPERIMENTAL|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 8×10\^8 colony forming units (CFU), twice daily, orally for 4 weeks
61966933|NCT01985867|PLACEBO_COMPARATOR|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
61966934|NCT03048968|EXPERIMENTAL|study group1: elderly adults|Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS
61966935|NCT03048968|EXPERIMENTAL|study group2: stroke patients|Sit-to-stand movement and treadmill gait with GEMS and without GEMS
61966936|NCT01574625||Mosaic prosthetic heart valve|All patients who were enrolled and implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany) during the previous Mosaic PMA study and who agree to participate in this long-term follow-up study by informed consent.
61966937|NCT02152033|EXPERIMENTAL|Home-based Continuing Care|The components of Home-based Continuing Care (HCC) include brief parent training, brief Young Adult (YA) orientation and recovery planning, telephone-based continuing care (TCC) and home-based contingency management. Both parent and YA participants will attend sessions with a family specialist.
61966938|NCT02152033|OTHER|Services as Usual|YAs completing residential care usually are referred to continuing outpatient services and/or self-help groups.
61966939|NCT04857905|OTHER|Microsurgical Resection of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after counseling~-\> Patients who after counseling decide for microsurgical resection of their brain metastasis"
62350583|NCT03414554||HCV patients receiving DAAs|Patients with HCV-related liver cirrhosis (eligible for treatment) who will recieve DAAs therapy with one year follow up.markers: miR121, miR122, miR124will be assessed in both groups before and after DAAs
61966940|NCT04857905|OTHER|Radiosurgery of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after study counseling~-\> Patients who after counseling decide for dose-staged radiosurgical treatment of their brain metastasis"
61966941|NCT04138654|EXPERIMENTAL|Normal nitrite levels|Processed meat products enriched with natural compounds will contain normal nitrite levels.
61966942|NCT04138654|EXPERIMENTAL|Reduced nitrite levels|Processed meat products enriched with natural compounds will contain reduced nitrite levels
61966943|NCT01340898|EXPERIMENTAL|Nimenrix 3+1 Group|Subjects, male and female, received 4 doses of Nimenrix™ vaccine (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
61966944|NCT01340898|EXPERIMENTAL|Nimenrix 1+1 Group|Subjects, male and female, received 2 doses of Nimenrix™ vaccine (1 dose at 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
62508835|NCT05472155|EXPERIMENTAL|Oropharyngeal suctioning with a bulb syringe|Newborn infants who have obvious obstruction to spontaneous breathing or who require positive pressure ventilation immediately after birth will be suctioned with a bulb syringe
61966945|NCT01340898|EXPERIMENTAL|Nimenrix Control Group|Subjects, male and female, received 1 dose of Nimenrix™ at 15-18 months of age and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
61966946|NCT02393508|ACTIVE_COMPARATOR|Fresh Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are less than or equal to 7 days of age from the time of donation.
61966947|NCT02393508|ACTIVE_COMPARATOR|Aged Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are greater than 21 days and up to a maximum of 42 days of age from the time of donation.
61966948|NCT03789344|EXPERIMENTAL|Acupuncture treatment|
61966949|NCT03789344|ACTIVE_COMPARATOR|Psychotherapy|
61966950|NCT03789344|PLACEBO_COMPARATOR|blank control|
61966951|NCT03928574||Ultrasound-Guided|Ultrasound-Guided Plane Block
61966952|NCT03928574||Conventional|Conventional Block
61966953|NCT03092609|EXPERIMENTAL|Attention Bias Modification|
61966954|NCT03092609|ACTIVE_COMPARATOR|Attention Control|
62508836|NCT05472155|ACTIVE_COMPARATOR|Oropharyngeal suctioning with a suction catheter|Newborn infants who have obvious obstruction to spontaneous breathing or who require positive pressure ventilation immediately after birth will be suctioned with a suction catheter
62508837|NCT02582788|ACTIVE_COMPARATOR|Bleach|Patients will use bleach added to their baths twice a week.
62508838|NCT02582788|ACTIVE_COMPARATOR|Vinegar|Patients will use vinegar (dilute acetic acid) added to their baths twice a week.
62508839|NCT03882073|EXPERIMENTAL|Intervention group|Modified amputation procedure
62508840|NCT03882073|ACTIVE_COMPARATOR|Control group|Standard amputation procedure
61966955|NCT04440202|ACTIVE_COMPARATOR|Conventional sea bream group|This arm will consume 2 portions (each 200 g cooked) of conventional fish (sea bream) fillet per week for a 1-month period.
61966956|NCT04440202|EXPERIMENTAL|Enriched sea bream group|This arm will consume 2 portions (each 200 g cooked) of fish fillet bred with bioactive lipids from olive oil by-products per week for a 1-month period.
61966957|NCT00878085|EXPERIMENTAL|1|Robot Therapy with activities of daily living (ADLs)
61966958|NCT00878085|ACTIVE_COMPARATOR|2|Standard Occupational Therapy
61966959|NCT00666627|ACTIVE_COMPARATOR|1|Ibandronate
61966960|NCT00666627|ACTIVE_COMPARATOR|2|Risedronate
61966961|NCT00666627|ACTIVE_COMPARATOR|3|Alendronate 70mg once weekly
61966962|NCT00666627|NO_INTERVENTION|4|Young women control group
61966963|NCT00563381|ACTIVE_COMPARATOR|Tiotropium + Placebo|patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
61966964|NCT00563381|ACTIVE_COMPARATOR|Salmeterol + Placebo|patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
61966965|NCT02322034|EXPERIMENTAL|Interval Training|Hospital outpatient-based regimen (3 times/week for 24 weeks) exercise program will be performed by cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
61966966|NCT02322034|NO_INTERVENTION|Controls|CHF patients allocated to the control group (no intervention) will undergo biochemical and hormonal sampling, Doppler-echocardiography, cardiopulmonary exercise stress testing at study enrollment and at 24-week follow-up.
61966967|NCT05924204|EXPERIMENTAL|G1 TREATMENT GROUP|In the Treatment group the FMB with 4 J of energy by point
61966968|NCT05924204|SHAM_COMPARATOR|G2 SHAM GROUP|In the Sham group, the the device will be turned off
61966969|NCT04016285|EXPERIMENTAL|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
61966970|NCT04016285|ACTIVE_COMPARATOR|Standard of Care: Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
61966971|NCT03063567|OTHER|one month trial of Nasal Mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
61966972|NCT03063567|OTHER|One month trial of Oronasal mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
61966973|NCT03063567|OTHER|One month trial of Nasal pillows|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
61966974|NCT04610840|ACTIVE_COMPARATOR|Direct puncture|Direct puncture of the caliceal system performed under ultrasound or Xray control
62145026|NCT03683641|ACTIVE_COMPARATOR|Shock Wave group|Applying shock wave to patient's Achilles tendon insertion
62350584|NCT03945032|EXPERIMENTAL|8 parents of a childhood cancer survivor|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
62706681|NCT03226041|EXPERIMENTAL|retroperitoneoscopic urologic surgery|All included patients will undergo retroperitoneoscopic renal or adrenal surgery with the transcutaneous carbon dioxide monitor.
61966975|NCT04610840|ACTIVE_COMPARATOR|Non-direct puncture|Puncture of the caliceal system performed under ultrasound or Xray control and retrograde contrast
61966976|NCT06236178|ACTIVE_COMPARATOR|Autologous Blood Injection Mixed With Local Anesthetic|Autologous Blood Injection group were administered 1ml of autologous venous blood mixed with 2ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
61966977|NCT06236178|ACTIVE_COMPARATOR|Corticosteroid Injection Mixed With Local Anesthetic|Corticosteroid Injection category were given 1ml of 40 mg methylprednisolone acetate(Prednol-L 40mg,Mustafa Nevzat,Turkey) mixed with 2ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
61966978|NCT06236178|ACTIVE_COMPARATOR|Combined Injection Mixed With Local Anesthetic|Combined Injection group received a mixture containing 1ml each of autologous venous blood and 40mg methylprednisolone acetate(Prednol-L 40mg,Mustafa Nevzat,Turkey), along with 1ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
62508841|NCT02915926|ACTIVE_COMPARATOR|OT|standard OT
61966979|NCT02364973||PET-MRI|Patients with chronic inflammatory bowel disease who are treated at Turku University hospital outpatient clinic or ward
61966980|NCT06094569||Endovascular therapy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.
61966981|NCT06094569||Best medical management|Patients enrolled in this group received the best medical management.
62508842|NCT02915926|EXPERIMENTAL|OT+OPC|occupational performance coaching
62508843|NCT05601778|EXPERIMENTAL|HSK31858 20mg|multiple oral doses: 20mg/d for 24w
62508844|NCT05601778|EXPERIMENTAL|HSK31858 40mg|multiple oral doses: 20mg/d for 24w
62508845|NCT05601778|PLACEBO_COMPARATOR|placebo|multiple oral doses for 24w
62508846|NCT05872334|EXPERIMENTAL|Monofix|In patients who underwent laparoscopic colorectal cancer surgery, the fascial closure of the midline incision was performed using a running suture type with Monofix, one of the barbed sutures.
62508847|NCT05872334|NO_INTERVENTION|Control group|In patients who underwent laparoscopic colorectal cancer surgery, the fascial closure of the midline incision was performed using an interrupted suture type with PDS-II, one of the monofilament sutures.
62508848|NCT01118845|EXPERIMENTAL|SyB L-0501|
62508849|NCT06196944|OTHER|Augmentative Alternative Communication|Traditional treatment
62145027|NCT03683641|SHAM_COMPARATOR|Sham Control group|Applying sham shock wave to patient's Achilles tendon insertion
62145028|NCT03735849|NO_INTERVENTION|Pre-treatment|Biopsy collected but was not randomized to any treatment group
62145029|NCT03735849|EXPERIMENTAL|Group 1: VRC07-523LS|Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
62145030|NCT03735849|EXPERIMENTAL|Group 2: VRC07-523LS|Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
62145031|NCT01030315|EXPERIMENTAL|Cohort 1|The lowest dose level of HM10760A
62508850|NCT06196944|OTHER|Augmentative Alternative Communication Device|3 sessions per week for 40 minutes
62508851|NCT03633552|EXPERIMENTAL|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
62706682|NCT01535482|EXPERIMENTAL|Cognitive Therapy|A cognitive therapy protocol specifically designed to target suicidal ideation in older adults.
62706683|NCT01535482|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced usual care consists of the usual care that individuals receive for suicide prevention, plus assessment and referral services provided by project staff, and weekly phone calls provided by study therapists.
62706684|NCT00995787|EXPERIMENTAL|AZD1656|
61966982|NCT01125683|EXPERIMENTAL|1|2,5 mg once daily
62706685|NCT00995787|PLACEBO_COMPARATOR|Placebo|
62706686|NCT01073969|PLACEBO_COMPARATOR|Control cereal|grain-based ready to eat cereal that does not contain active wheat bran extract
61966983|NCT01125683|ACTIVE_COMPARATOR|2|single dose of 5 mg
61966984|NCT01125683|PLACEBO_COMPARATOR|3|
61966985|NCT01125683|EXPERIMENTAL|4|60 mg once daily
61966986|NCT01125683|EXPERIMENTAL|5|60 mg three times daily
61966987|NCT00940225|EXPERIMENTAL|Lead-in Stage - cabozantinib (XL184)|Open Label, cabozantinib, 100 mg, po QD for 12 weeks.
62350585|NCT02586077|EXPERIMENTAL|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
62508852|NCT03633552|ACTIVE_COMPARATOR|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
61966988|NCT00940225|EXPERIMENTAL|Randomized Stage - cabozantinib (XL184)|Blinded, cabozantinib, 100 mg, po QD until disease progression.
61966989|NCT00940225|PLACEBO_COMPARATOR|Randomized Stage - placebo|Blinded, placebo, 100 mg, po QD until disease progression.
61966990|NCT00940225|EXPERIMENTAL|Open-Label Extension - cabozantinib (XL184)|Open Label, cabozantinib, for subjects that were on placebo during the randomized stage, 100 mg, po QD until disease progression or unacceptable toxicity.
61966991|NCT00940225|EXPERIMENTAL|Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg|Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.
61966992|NCT00940225|EXPERIMENTAL|Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg|Open Label, cabozantinib, 39.4, po QD until disease progression or unacceptable toxicity.
61966993|NCT00940225|EXPERIMENTAL|A. Non-Randomized Expansion (NRE) Cohort - Ovarian|Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.
61966994|NCT01213745|EXPERIMENTAL|Intervention|
61966995|NCT01213745|EXPERIMENTAL|Attention|
61966996|NCT01213745|ACTIVE_COMPARATOR|Control|
61966997|NCT02759328|EXPERIMENTAL|Xbox Kinect™ training group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program plus 60 minutes/day, 5 days/week, 4 weeks (20 sessions) Xbox Kinect™ upper extremity training. Two games both of which require using upper extremities, were chosen and each game was played for 30 minutes per session.
62350586|NCT01736306||Volunteers|Volunteer milk donors
62706687|NCT01073969|ACTIVE_COMPARATOR|low dose|grain-based ready to eat cereal containing a low dose of wheat bran extract
62706688|NCT01073969|ACTIVE_COMPARATOR|High dose|grain-based ready to eat cereal that contains a high dose of wheat bran extract
61966998|NCT02759328|ACTIVE_COMPARATOR|Conventional rehabilitation group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program only. The treatment protocol was individualized according to the goals which were determined depending on each patient's needs and functional level.
61966999|NCT01461902||Pediatric Traumatic Brain Injury|Children from 5 days to 15 years of age who have been admitted to the hospital with a traumatic brain injury.
61967000|NCT01725334|EXPERIMENTAL|Nucleus Accumbens/Ventral Striatum (NAcc/VS) Stimulation|The first 3 patients will have the DBS device target the NAcc/VS, which has been found to be hypoactive in patients with primarily negative symptoms.
61967001|NCT01725334|EXPERIMENTAL|Ventral Tegmental Area (VTA) Stimulation|For 3 patients, the DBS device will target the VTA, which has been found to be hypoactive in patients with primarily negative symptoms.
61967002|NCT03928600|EXPERIMENTAL|Combined method induction group|"* 25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)~* After 4 hours of last misoprostol initiate oxytocin.~* Cervical Foley will be removed after 12h of placement or when fails out."
62350587|NCT00792701|EXPERIMENTAL|Arm II|Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62508853|NCT05202288|ACTIVE_COMPARATOR|Single vaccination|"The control arm (vaccination alone) will serve as a comparator of vaccine response.~r-VSV-ZEBOV vaccine will be administered at inclusion (D0)"
62508854|NCT05202288|EXPERIMENTAL|Simoultaneous vaccination|Mabs and r-VSV-ZEBOV vaccine will be administered the same day, at inclusion (D0), one hours appart
62706689|NCT01596920|ACTIVE_COMPARATOR|Grafix®|
61967003|NCT03928600|PLACEBO_COMPARATOR|Current department guidelines group|"* Following current department guidelines, as usual, with the method considered more suitable.~* If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.~* If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place."
62145032|NCT01030315|EXPERIMENTAL|Cohort 2|Second dose level of HM10760A
62508855|NCT05202288|EXPERIMENTAL|Early vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 3 weeks later
62508856|NCT05202288|EXPERIMENTAL|Intermediate vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 6 weeks later
62508857|NCT05202288|EXPERIMENTAL|Late vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 12 weeks later
62706690|NCT01596920|PLACEBO_COMPARATOR|Control (non-adherent dressing)|
62706691|NCT02279056|EXPERIMENTAL|Self-help book|A self-help book for insomnia (written in Norwegian). Earlier proven to be effective among insomnia patients (without OSA co-morbidity).
62706692|NCT02279056|PLACEBO_COMPARATOR|Sleep hygiene advice|A sheet of paper with sleep hygiene advice.
62706693|NCT05019209|EXPERIMENTAL|Exposure to saline-dissolved house dust mite allergen and allergen-free air|Subjects are blinded to the sequence of interventions in the allergen challenge chamber (ACC). Overall, subjects will be in the ACC 4 times during the study. Of those, exposure to allergen-free air and HDM is allocated in a 2:2 ratio.
62706694|NCT04902872|EXPERIMENTAL|Phase 1 Schedule B Dose Escalation (Daily Dosing x 3)|CBX-12 administered on a daily x 3, 3 week schedule
62706695|NCT04902872|EXPERIMENTAL|Phase 1 Schedule C Dose Escalation (Once Weekly Dosing )|CBX-12 administered once weekly, 4 week schedule
61967004|NCT02824874|EXPERIMENTAL|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Duvie Tab. 0.5mg)\*1T/day for 5 days, QD, PO~Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)\*1T/day for 5 dyas, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
61967005|NCT02824874|EXPERIMENTAL|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)\*1T/day for 5 dyas, QD, PO~Period 2: Treatment A(Duvie Tab. 0.5mg)\*1T/day for 5 days, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
62706696|NCT04902872|EXPERIMENTAL|Phase 2 Ovarian Cancer Expansion Cohort|CBX-12 administered TBD
62706697|NCT04902872|EXPERIMENTAL|Phase 2 Metastatic Breast Expansion Cohort|CBX-12 administered TBD
61967006|NCT05137106|EXPERIMENTAL|Active Dry Needling|Active dry needling (ADN). Intramuscular insertion Intervention/treatment. All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm JEMCO acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
61967007|NCT05137106|SHAM_COMPARATOR|Sham Dry needling|Sham dry needling (SDN). All participants in this group received one session of SDN with a 25 mm X 0.22 mm JEMCO acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
61967008|NCT01217840|EXPERIMENTAL|vitamin D|"Subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop (Sanofi-Aventis)), given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments.~Intervention: Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks"
61967009|NCT01217840|PLACEBO_COMPARATOR|Placebo|Subjects were assigned to receive two observed doses of placebo, given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks
62706698|NCT04902872|EXPERIMENTAL|Phase 1 Schedule A Dose Escalation (Daily Dosing x 5)|CBX-12 administered on a daily x 5, 3 week schedule
61967010|NCT00700960||A|
61967011|NCT02454400|OTHER|Pre-surgery physiotherapy|Twice a week, in 9 weeks
61967012|NCT02454400|OTHER|Waiting-list|Standard information by the orthopedic surgeon
62145033|NCT01030315|EXPERIMENTAL|Cohort 3|Third dose level of HM10760A
62350588|NCT03809221|EXPERIMENTAL|early follicular phase down-regulation|Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle. If complete pituitary down-regulation is achieved after 28-42 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours after pre-ovulatory hCG injection transvaginally under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
62350589|NCT03809221|ACTIVE_COMPARATOR|luteal phase down-regulation|Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle. If complete pituitary down-regulation is achieved after 14-21 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and the serum hormone level and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours later under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
62350590|NCT03454906||L Hemoglobin|L Hemoglobin: consistently low all 6 months with low hemoglobin levels
62706699|NCT04902872|EXPERIMENTAL|Phase 1 Modified Schedule B Dose Escalation (Once Every 3 weeks)|CBX-12 administered once every 3 weeks
62706700|NCT04038879||Mitral/Aortic Regurgitation|Subjects identified with mitral or aortic regurgitation will be asked to undergo testing with trans thoracic echocardiogram, stress echocardiography, and cardiac MRI with and without contrast. In addition, patients will be asked to answer the KCC and EQ5DL questionnaires.
62706701|NCT05041829|EXPERIMENTAL|lowsodium|Participants in this arm will be guided to have low dietary sodium intake of \<2.3 g/day (\<100 mmol/day) for 4 weeks.
62706702|NCT05041829|ACTIVE_COMPARATOR|highsodium|Participants in this arm will be guided to have low dietary sodium intake of ≥4 - \<6 g/day (≥174 - \<261 mmo/day) for 4 weeks.
61967013|NCT02254993|EXPERIMENTAL|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
61967014|NCT02254993|EXPERIMENTAL|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
61967015|NCT02254993|EXPERIMENTAL|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
61967016|NCT02254993|EXPERIMENTAL|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
61967017|NCT02254993|EXPERIMENTAL|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
61967018|NCT02254993|EXPERIMENTAL|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
61967019|NCT02254993|EXPERIMENTAL|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
62145034|NCT01030315|EXPERIMENTAL|Cohort 4|Fourth dose level of HM10760A
62145035|NCT01030315|EXPERIMENTAL|Cohort 5|The highest dose level of HM10760A
62145036|NCT00894218|ACTIVE_COMPARATOR|Conventional arthroplasty|Total hip or knee conventional arthroplasty
62145037|NCT00894218|EXPERIMENTAL|Mini-invasive arthroplasty|Total hip or knee mini-invasive arthroplasty
62145038|NCT00894218|EXPERIMENTAL|Mini-invasive and computer-assisted arthroplasty|Mini-invasive and computer-assisted total hip or knee arthroplasty
62508858|NCT01456429|EXPERIMENTAL|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
62508859|NCT05422313||56 patients with RA.|Patients age is \> 20 years old.
62706703|NCT05755750|EXPERIMENTAL|Intratendinous genipin injection|"Genipin was administrated intratendinously under sonographic guidance. For lesions up to 3 cm in length, two separate 0.2 ml injections of genipin solution were administered into the region of transition from degenerated to normal tendon tissue. One injection was given at the proximal end of the lesion and the other at the distal end.~For lesions longer than 3 cm, an additional 0.2 ml injection was used for every additional 3 cm of lesion length. In the illustrated example, the 6 cm lesion required a total of three injections, and therefore one additional injection was given in the middle of the lesion between the distal and proximal injections.~Genipin treatment solution contained 100 mM genipin and 20% of the solvent dimethyl sulfoxidee in phosphate buffered saline. Instead of one administration of a relatively large volume, several individual administrations of 0.2 ml were performed depending on lesion size ."
62706704|NCT04225767|EXPERIMENTAL|Calcium electroporation treatment|Experimental treatment with calcium electroporation for malignant cutaneous and subcutaneous tumours
62706705|NCT01276951|PLACEBO_COMPARATOR|Placebo|
62350591|NCT03454906||T Hemoglobin|T Hemoglobin; consistently within the target range all 6 months with target-range hemoglobin levels
62350592|NCT03454906||H Hemoglobin|H Hemoglobin: consistently high all 6 months with high hemoglobin levels
61967020|NCT02254993|EXPERIMENTAL|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
61967021|NCT02254993|EXPERIMENTAL|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
62145039|NCT03735459|EXPERIMENTAL|Patient reminder|"Patient Oriented SCORAD (PO-SCORAD): Assess severity of eczema.~Adherence Questionnaire (AQ): Assess adherence to eczema treatment plan provided to them by their healthcare provider.~Family Dermatology Life Quality Index (FDLQI): Assess impact of the participant's eczema on the family's quality of life.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 1, 2, and 4: Participants will complete PO-SCORAD and AQ.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
62350593|NCT03454906||LAL Hemoglobin|LAL Hemoglobin: low amplitude fluctuation with low hemoglobin; all 6 months with low or target range hemoglobin levels
62350594|NCT03454906||LAH Hemoglobin|LAH Hemoglobin: low-amplitude fluctuation with high hemoglobin levels 6 months with target-range or high hemoglobin levels)
62350595|NCT03454906||HA Hemoglobin|HA Hemoglobin ; high-amplitude fluctuation low, target-range, and high hemoglobin levels within the 6 month period
62145040|NCT03735459|NO_INTERVENTION|No patient reminder/control|"Participants in arm 2 are not sent text messages, and will not be asked to complete questionnaires 1, 2, and 4 weeks post enrollment. Participants will be asked to complete questionnaires during enrollment and 6 weeks post enrollment.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
62145041|NCT01396629||single group|the intra ocular lenses will be loaded in the cartridge.
62145042|NCT01179802|EXPERIMENTAL|1|single event of a prolonged strenuous endurance exercise (mountain marathon)
62508860|NCT05422313||: 30 age-matched Healthy|Individual must be without a prior history of chronic inflammation or any form of arthritis. - .
62508861|NCT05196100|EXPERIMENTAL|Confidence socket|Participants to receive a confidence socket system
62508862|NCT00116480|EXPERIMENTAL|Misoprostol|three tablets of active misoprostol (600 mcg) given sublingually
62508863|NCT00116480|PLACEBO_COMPARATOR|Placebo|three tablets resembling misoprostol given sublingually
62508864|NCT02568709|ACTIVE_COMPARATOR|Interventional|40 IU Oxytocin
62145043|NCT00647335||1|Women with diagnosis of PCOS
62350596|NCT05197140|ACTIVE_COMPARATOR|4 ounce beef patty|Subjects consume one beef patty of 4 ounces of cooked meat.
62706706|NCT01276951|ACTIVE_COMPARATOR|6,5g Dose Group|
62706707|NCT01276951|ACTIVE_COMPARATOR|12g Dose Group|
62706708|NCT01276951|ACTIVE_COMPARATOR|25g Dose Group|
62706709|NCT01276951|ACTIVE_COMPARATOR|50g Dose Group|
62706710|NCT00940147||1|patients with OAC, Score finding
62706711|NCT00940147||2|patients without OAC, Score finding
62706712|NCT05606107|ACTIVE_COMPARATOR|Glucocorticoid group|
62706713|NCT05606107|EXPERIMENTAL|Tofacitinib group|
62706714|NCT03940755||Critical Illness Survivors|Those intensive care unit(ICU) patients who survive from critical illness.
62350597|NCT05197140|EXPERIMENTAL|4 ounce vegetarian burger|Subjects consume one patty of 4 ounces of cooked vegetarian product.
62350598|NCT05197140|EXPERIMENTAL|2x 4 ounce vegetarian burger|Subjects consume two patties of 4 ounces of cooked vegetarian product.
62350599|NCT05399849|EXPERIMENTAL|Mindfulness Intervention|All participants will be enrolled in the mindfulness intervention arm to complete the six-week mindfulness intervention.
62350600|NCT01630759|EXPERIMENTAL|Telemonitoring|The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
62350601|NCT01630759|ACTIVE_COMPARATOR|Control group|Control group will consist of usual care and review at clinic.
62508865|NCT02568709|PLACEBO_COMPARATOR|Saline Nasal Spray|Placebo Comparator
62508866|NCT05335850|EXPERIMENTAL|Intervention Group|Breathing and Wellness Webinar: a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
62706715|NCT05965219|EXPERIMENTAL|Part A: Emraclidine Followed by Itraconazole + Emraclidine|Participants will receive a single oral dose of emraclidine 10 milligrams (mg) on Day 1 in Treatment Period (TP) 1 followed by itraconazole 200 mg, orally, twice daily (BID) on Day 1 and once daily (QD) from Days 2 to 14, with a single oral dose of emraclidine 10 mg co-administered on Day 5 in TP 2.
62706716|NCT05965219|EXPERIMENTAL|Part B: Emraclidine Followed by Carbamazepine + Emraclidine|Participants will receive a single oral dose of emraclidine 30 mg on Day 1 in TP 1 followed by carbamazepine 100 mg BID from Days 1 to 3, 200 mg BID from Days 4 to 6, and 300 mg BID from Days 7 to 19, orally, with a single oral dose of emraclidine 30 mg on Day 16 in TP 2.
62706717|NCT05965219|EXPERIMENTAL|Part C: Metformin Followed by Emraclidine + Metformin|Participants will receive a single oral dose of metformin 850 mg on Day 1 in TP 1 followed by emraclidine 30 mg, orally, QD for Days 1 to 10, with a single oral dose of metformin 850 mg co-administered on Day 8 in TP 2.
62706718|NCT05790447|EXPERIMENTAL|Intervention group|"A treatment cycle includes:~Loading dose with thymalfasin was administrated based on the absolute number of T lymphocytes.~Radiotherapy (5 or 8Gy three fractions)was administrated to a metastatic lesion GM-CSF 200ug was subcutaneous injected for seven days from the first day of radiotherapy PD-1/L1 inhibitor was intravenous injected within one week after radiotherapy"
62508867|NCT05335850|ACTIVE_COMPARATOR|Waitlisted Control Group|This group will be asked to wait for 6 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
62706719|NCT06249919|EXPERIMENTAL|Group A|NS101 15mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
62706720|NCT06249919|EXPERIMENTAL|Group B|NS101 30mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
62706721|NCT06249919|ACTIVE_COMPARATOR|Cohort A|NS101 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients
62706722|NCT06249919|PLACEBO_COMPARATOR|Cohort B|Placebo 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients
61967022|NCT02254993|EXPERIMENTAL|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
61967023|NCT02254993|EXPERIMENTAL|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
61967024|NCT04658953|EXPERIMENTAL|Ultrasound-guided infiltration|The patient is positioned in the prone position with a block under his stomach. After disinfection of the lumbosacral region with alcoholic chlorhexidine 0.5%, the investigators position the convex probe of the ultrasound machine in the transverse plane. Once the spine has been located, the investigators look for the spinous processes of the lower lumbar vertebrae L4 and L5 with the mark on the cranial side and the side opposite the mark on the side of the sacrum. The latter is visualized as a continuous hyperechoic line. Then, the probe is tilted 90 ° to be in a transverse plane. A 22G needle is introduced in a transverse axis starting from the laterality by inserting it in the direction of the median bone contacts of the lower lumbar vertebrae L3, L4 and L5. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels).
62706723|NCT06030635|EXPERIMENTAL|CPMX1|Compartment compressibility measurement using the CPMX1 device
62706724|NCT01008826|EXPERIMENTAL|glucoraphanin-rich broccoli extract|
62706725|NCT01008826|EXPERIMENTAL|sulforaphane-rich broccoli extract|
62706726|NCT06145412|EXPERIMENTAL|Xevinapant in Combination with Post-Operative Cisplatin and Radiotherapy|The study will consist of three phases: 2) concurrent radiation, cisplatin, and xevinapant, and 3) adjuvant xevinapant. Concurrent Chemoradiation Subjects will undergo FDG PET/CT simulation and standard radiation treatment planning. FDG PET/CT (Simulation or diagnostic) will also be utilized to rule out distant metastases. Subjects who meet criteria for the treatment phase will undergo standard of care adjuvant radiation (60-70 Gy administered in 2 Gy fractions) with concurrent cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks), and xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles) Adjuvant Phase After completion of concurrent chemoradiation, patients will undergo an additional 3 cycles of xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3- cycles)
62706727|NCT03212729|ACTIVE_COMPARATOR|Control Group|CONVENTIONAL ENDODONTIC TREATMENT
62706728|NCT03212729|EXPERIMENTAL|Test Group|CONVENTIONAL ENDODONTIC TREATMENT ASSOCIATED WITH ANTIMICROBIAL PHOTODYNAMIC THERAPY
62706729|NCT04754464|ACTIVE_COMPARATOR|synbiotic|synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)
62706730|NCT04754464|PLACEBO_COMPARATOR|microcrystalline cellulose|microcrystalline cellulose
62706731|NCT06547606|EXPERIMENTAL|Resistive Inspiratory Muscle Training|Participants in this group will perform resistive inspiratory muscle training, designed to strengthen respiratory muscles and improve lung function. Training involves inhaling through a device that provides resistance, performed five days a week for four weeks.
62145044|NCT03413826|EXPERIMENTAL|6 Days per week|This group will exercise 6 days per week and expend 3,000 kcal per week for 12 weeks
62145045|NCT03413826|EXPERIMENTAL|2 Days per week|This group will exercise 2 days per week and expend 3,000 kcal per week for 12 weeks
62145046|NCT03413826|NO_INTERVENTION|control|This group will remain sedentary for 12 weeks
62508868|NCT05790707|EXPERIMENTAL|Atrial fibrillation + antiarrhythmic drugs|"The ablation can be done with different sources of energy (radiofrequency, cryoballoon or pulsed field ablation). Different sets of lesions can be performed but the cornerstone is pulmonary vein isolation which will be mandatory.~Antiarrhythmic drugs management will be at the operator discretion. Some operators may stop antiarrhythmic drugs after atrial fibrillation ablation."
62539323|NCT05381714||Control|Respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), physical activity level (International Physical Activity Questionnaire), fatigue (Modified Borg Scale), shortness of breath (Modified Borg Scale) will be evaluated.
62145047|NCT01493128||stable sinus rhythm|
62145048|NCT01493128||permanent atrial fibrillation|
62508869|NCT05790707|ACTIVE_COMPARATOR|Antiarrhythmic drugs alone|"Antiarrhythmic drugs available available are amiodarone, flecainide, propafenone, sotalol.~If not previously started, patients randomized to antiarrhythmic drugs arm should start antiarrhythmic drugs therapy within 1 week of randomization.~Apart from these recommendations, antiarrhythmic drugs management will be at the operator discretion."
62508870|NCT03222986||Sepsis with organ failure|Patients have organ failure
62508871|NCT03222986||Sepsis without organ failure|Patients have no organ failure
62508872|NCT02432118|EXPERIMENTAL|Diagnostic (radiofrequency-guided localization)|Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
62508873|NCT04239482|EXPERIMENTAL|L-arginine + Nitrate/Nitrite|Subjects will receive 1 L-arginine tablet per day and drink 35 mL of beetroot juice for 8 weeks.
62706732|NCT06547606|ACTIVE_COMPARATOR|Usual Care|Participants in this group will receive conservative respiratory physiotherapy, which includes standard techniques aimed at maintaining respiratory function and managing symptoms.
61967025|NCT04658953|EXPERIMENTAL|Fluoroscopy-guided infiltration|"The patient is positioned in the prone position with a block under his stomach. The lumbosacral region is disinfected with alcoholic chlorhexidine 0.5%.~The C-shaped arm of a X-ray fluoroscopy is positioned around the patient in an antero-posterior view tilted ¾ in order to free the classic view called scotty dogs . The puncture point is determined by the positioning of the needle in so-called tunnel vision. The needle is thus brought to the bone contact corresponding to the eye of the scotty dog in tunnel vision, an area corresponding to the passage of the lumbar median branch. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels)."
62350602|NCT05100433|EXPERIMENTAL|Microbiological analysis of root canals after endodontic procedures|Bacterial levels and activity in root canal samples after chemomechanical procedures and ultrasonic irrigation.
62350603|NCT03941691|EXPERIMENTAL|Treatment Group|Experimental group is allocated to use novel fully degradable ventricular septal defect closure system manufactured by Shanghai shape memory alloy materials co. LTD.
62350604|NCT03941691|ACTIVE_COMPARATOR|Control Group|Control Group is allocated to use Interposition conveying device for ventricular septal defect closure produced by Shanghai shape memory alloy material co. LTD.
62350605|NCT06026007|EXPERIMENTAL|Control group|patient in this group received advice only for edema relief
62350606|NCT06026007|EXPERIMENTAL|Circulatory exercise group|patient in this group received advice in addition to circulatory exercise for edema relief
62350607|NCT06026007|EXPERIMENTAL|Acupressure group|patient in this group received advice in addition to acupressure for edema relief
62350608|NCT01369849|EXPERIMENTAL|Treatment (Akt inhibitor MK2206, bendamustine, rituximab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22 (days 1, 8, 15, 22, and 29 of course 1); rituximab IV on day 1 (day 8 of course 1); and bendamustine hydrochloride IV over 30-60 minutes on days 1-2 (days 8-9 of course 1). Treatment repeats every 28 days (35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease progression or unacceptable toxicity.
62706733|NCT01842659|EXPERIMENTAL|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
62706734|NCT05931731|EXPERIMENTAL|Mechanical interference|the patients will receive mechanical interference and conventional treatment three times a week for four weeks
62706735|NCT05931731|EXPERIMENTAL|Neural mobilization|the patients will receive neural mobilization and conventional treatment three times a week for four weeks
62350609|NCT05231993|ACTIVE_COMPARATOR|Active comparator|"1. All women ages \<41, women ages ≥41 with TZ1 and TZ2, and women ages ≥41 with a desire for further childbearing Clinical management and follow-up according to the national screening guidelines published in 2017 (same as for the comparator group, see below).~2. Women with TZ3 and women ages ≥41 with no desire for further childbearing a. Referral to (diagnostic) excision. The depth of the diagnostic excision will be clinically determined in the trial. It should be with the intent to treat but no so extensive that the risk for side effects increases.~The excision should include a cervical abrasion and endometrial sampling."
62350610|NCT05231993|PLACEBO_COMPARATOR|Placebo comparator|"Clinical management and follow-up according to the national screening guidelines published in 2017:~1. Colposcopy with biopsy within 3 months, endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
62350611|NCT00305604|ACTIVE_COMPARATOR|1|sitagliptin
62350612|NCT00305604|PLACEBO_COMPARATOR|2|Placebo
62350613|NCT01932658|EXPERIMENTAL|Hematopoietic stem cell transplantation|Lymphoablation followed by autologous hematopoietic stem cell transplantation rescue.
62350614|NCT01700361||No treatment|This is an observational study. Women in this study are not receiving any treatments.
62350615|NCT01122030|EXPERIMENTAL|Cohort 1|In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
62706736|NCT05931731|ACTIVE_COMPARATOR|conventional treatment|the patients will receive conventional treatment only three times a week for four weeks
62715057|NCT04708535||Bariatric Cohort|For consenting subjects who are undergoing bariatric surgery, a visceral fat sample will be taken during surgery. In addition to the fat sample, insulin resistance will be measured and determined by a modification of the insulin suppression test.
62145049|NCT01493128||paroxysmal atrial fibrillation|
62350616|NCT01122030|EXPERIMENTAL|Cohort 2|In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
62508874|NCT04239482|PLACEBO_COMPARATOR|Placebo|Subjects will receive 1 cellulose tablet per day and drink 35 mL of nitrate/nitrite depleted beetroot juice for 8 weeks.
62508875|NCT06472544|EXPERIMENTAL|Culturally Grounded Intervention|One week of meetings to describe Blackfeet history, culture, traditions, and cerimonies. One additional week of visiting Blackfeet sacred sites.
62715058|NCT04979598||Acute unilateral vestibular deafferentiation|Patients suffering from acute dizziness due to a unilateral vestibular deafferentiation.
62715059|NCT06105866||Patients without Cardiac Disease|Patients between the ages of 18-75 with sinus rhythm, and without valvular disease, pulmonary hypertension, acute myocardial infarction, dilated, and hypertrophic cardiomyopathy will be included in the study.
61967026|NCT06244472|EXPERIMENTAL|Healthy subjects|Healthy volunteers aged between 18 and 70 years, without neurological or psychiatric or sleep disorders
62350617|NCT01122030|EXPERIMENTAL|Cohort 3|In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
62508876|NCT02488824|EXPERIMENTAL|Warm Temperature Exposure in Tetraplegia|Subjects are persons with higher-level spinal cord injury, levels C3 to T4, and ASIA Impairment Scale (AIS) level A and B, ages 18-68 years. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
62508877|NCT02488824|ACTIVE_COMPARATOR|Warm Temperature Exposure in Able-Bodied|Subjects are able-bodied controls matched with participants with tetraplegia for age and gender. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
61967027|NCT06244472|EXPERIMENTAL|Subjects with concussion|Male athletes volunteers with concussion aged between 18 and 40 years, without neurological or psychiatric or sleep disorders other than cerebral concussion.
61967028|NCT02183194|EXPERIMENTAL|Lutonix Paclitaxel Drug Coated Balloon|
62508878|NCT02170831|EXPERIMENTAL|BIBR 1048 MS low dose|
62508879|NCT02170831|EXPERIMENTAL|BIBR 1048 MS medium dose 1|
62508880|NCT02170831|EXPERIMENTAL|BIBR 1048 MS medium dose 2|
62508881|NCT02170831|EXPERIMENTAL|BIBR 1048 MS high dose|
62508882|NCT02170831|PLACEBO_COMPARATOR|BIBR 1048 Placebo|
62715060|NCT00034216||Healthy Volunteers|Healthy volunteers 18 years of age and older
62350618|NCT01122030|EXPERIMENTAL|Cohort 4|In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
62350619|NCT01122030|EXPERIMENTAL|Cohort 5|In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
62350620|NCT01122030|EXPERIMENTAL|Cohort 6|In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
62350621|NCT04702048|EXPERIMENTAL|Aflibercept injection|Intravitreal injection of Aflibercept
62508883|NCT02953678|EXPERIMENTAL|Ruxolitinib in combination with corticosteroids|Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
61967029|NCT01008007|EXPERIMENTAL|A|Viusid in combination with the conventional treatment for acute fever of viral etiology
61967030|NCT01008007|ACTIVE_COMPARATOR|B|Conventional treatment for acute fever of viral etiology
62350622|NCT04702048|PLACEBO_COMPARATOR|Sham injection|Empty syringe with no needle
62350623|NCT02487277|EXPERIMENTAL|Combination therapy with 1 week Run-In|"PEGPH20: 3ug/kg on Days 1 and 4~1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m\^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m\^2 on Days 1, 8, 15"
62350624|NCT02487277|EXPERIMENTAL|Combination therapy alone|"1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m\^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m\^2 on Days 1, 8, 15"
62350625|NCT04291872|EXPERIMENTAL|Non-Heated Arm|Proximal cavities were restored with Equia Forte (GC Corporation, Europe) according to manufacturer's orders.
62508884|NCT01858350|OTHER|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
62508885|NCT01858350|OTHER|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
62508886|NCT01858350|NO_INTERVENTION|No intervention|
62508887|NCT01858350|OTHER|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
62508888|NCT02487082|OTHER|Group A|Run-In Phase: Placebo. Phase 1 \& Phase 2: Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) for 10 weeks Wash-Out Phase: no active or placebo medication. Note: Dosage of study drug varies with age/weight. Younger children (\<12 years or \< 80 lbs. weight start at a lower dose of donepezil (1.25 mg/night) and increase to 2.5 mg/night after one week. Older children (\>= 12 years or \>= 80 lbs weight) start at 3 mg donepezil and increase to 5 mg after one week. The dose of melatonin remains stable at 3 mg throughout for both groups.
61967031|NCT02030392|EXPERIMENTAL|Intervention group|"IG participation in the cognitive-behavioral program Stop the pain with Happy Pingu. The program compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each)."
61967032|NCT02030392|ACTIVE_COMPARATOR|Active control group|CG participation in an information and education control group (physical well-being, health and gastrointestinal tract). The program of the control group compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each).
61967033|NCT02322398||Group A|Patients who had been stimulated with a starting dose of 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio.
61967034|NCT02322398||Group B|Patients who had been stimulated with a starting dose of 150-300 IU/d hMG.
62508889|NCT02487082|OTHER|Group B|Run-In Phase: Placebo. Phase 1: Placebo. Phase 2: Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 5 weeks Wash-out Phase: no active or placebo medication. Note: Dosage of study drug varies with age/weight. Younger children (\<12 years or \< 80 lbs. weight start at a lower dose of donepezil (1.25 mg/night) and increase to 2.5 mg/night after one week. Older children (\>= 12 years or \>= 80 lbs weight) start at 3 mg donepezil and increase to 5 mg after one week. The dose of melatonin remains stable at 3 mg throughout for both groups.
62508890|NCT04489186|EXPERIMENTAL|All subjects|Single arm feasibility study with a wearable device intervention for cardiorespiratory and activity monitoring in subjects with cystic fibrosis.
62508891|NCT05621187|OTHER|All patients|
62715061|NCT00034216||Participants|Participants with cancer 18 years of age and older
62715062|NCT06007677|EXPERIMENTAL|Dose Regimen 1 (Arm A): STAR-0215|Participants will receive STAR-0215 every 3 months.
62715063|NCT06007677|EXPERIMENTAL|Dose Regimen 2 (Arm B): STAR-0215|Participants will receive STAR-0215 every 6 months.
62706737|NCT06293183|EXPERIMENTAL|Intervention group|After the purpose and method of the research are explained, a written informed consent form will be obtained and the Patient Introduction Form will be filled out. Mobile phone usage skills of patients undergoing hemodialysis treatment will be evaluated using the Digital Literacy Scale. Individuals in the initiative group will be given individual training on how to use the application through the application demo. Individuals in the initiative group will be given consultancy by the researcher while downloading the application and logging in with their username. Questionnaires and scale forms will be applied to the patients in the control group on the 0th day, the 14th day, and at the 1st, 2nd and 3rd months. Laboratory values and intradialytic weight information will be obtained from patient files.
62706738|NCT06293183|NO_INTERVENTION|Control group|After the purpose and method of the research are explained, a written informed consent form will be obtained and the Patient Introduction Form will be filled out. No intervention will be made to the participants in this group. Questionnaires and scale forms will be applied to the patients in the control group on the 0th day, 14th day, 1st, 2nd and 3rd months. Laboratory values and intradialytic weight information will be obtained from patient files.
62706739|NCT01567722||HIV-positive diffuse large B-cell lymphoma cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.
62706740|NCT01567722||HIV-positive lung cancer cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
62706741|NCT01567722||HIV-positive cervical cancer cases|Tissue specimen collection from HIV positive patients with a diagnosis of cervical cancer
62706742|NCT03089294|ACTIVE_COMPARATOR|Group A|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)
62706743|NCT03089294|ACTIVE_COMPARATOR|Group B|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)
62350626|NCT04291872|EXPERIMENTAL|Heated Arm|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
61967035|NCT01929915|ACTIVE_COMPARATOR|Epidural patient controlled analgesia|Epidural patient controlled analgesia
61967036|NCT01929915|SHAM_COMPARATOR|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia for post operative pain control
62145050|NCT04274790||Metastatic colon cancer|Patient with metastatic colon cancer operated on and followed up at the Centre Leon Berard for liver metastasis.
62350627|NCT06001840|EXPERIMENTAL|Experimental: Exclusive cigarette smokers|Exclusive cigarette smokers will be recruited and will be exposed to all of the conditions described in the intervention section.
62706744|NCT03089294|ACTIVE_COMPARATOR|Group C|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)
62706745|NCT03089294|ACTIVE_COMPARATOR|Group D|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)
62706746|NCT05036135|EXPERIMENTAL|AV-101 10 mg|
62706747|NCT05036135|EXPERIMENTAL|AV-101 35 mg|
62350628|NCT06001840|EXPERIMENTAL|Experimental: Dual cigarette/ nicotine vaping product users|Dual cigarette and nicotine vaping product users will be recruited and will be exposed to all of the conditions described in the intervention section
62350629|NCT02779881||Healthy controls|Healthy controls
62706748|NCT05036135|EXPERIMENTAL|AV-101 70 mg|
62706749|NCT05036135|PLACEBO_COMPARATOR|Placebo|
62706750|NCT04509388|PLACEBO_COMPARATOR|Commercially Available Sports Drink A|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes
62706751|NCT04509388|EXPERIMENTAL|Commercially Available Sports Drink B|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes.
62706752|NCT04509388|EXPERIMENTAL|Commercially Available Sports Drink A with added Amino Acids|The same as sports drink A above (a commercially available sports water, with small amounts of flavouring, sweetener and electrolytes), but with the addition of a small amount of amino acids (\~0.7 g/100 ml).
62706753|NCT04899687|EXPERIMENTAL|Group A: fluoxetine then fluoxetine plus dextromethorphan|Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.
62350630|NCT02779881||Children at diagnosis of cow's milk allergy|Children at diagnosis of cow's milk allergy
61967037|NCT06387095|ACTIVE_COMPARATOR|1. control group|control group. block will not be applied to this group and the patient's analgesia needs will be provided with patient-controlled analgesia devices.
61967038|NCT06387095|ACTIVE_COMPARATOR|2. superficial parasternal plane block group|superficial parasternal plane block group. superficial paraasternal plane block will be applied to this group. it will be applied to the parasternal region with ultrasound after the patient is intubated. patient-controlled analgesia devices will be used for additional postoperative pain needs.
61967039|NCT06387095|ACTIVE_COMPARATOR|3. deep parasternal plane block group|deep parasternal plane block group. deep paraasternal plane block will be applied to this group. it will be applied to the parasternal region with ultrasound after the patient is intubated. patient-controlled analgesia devices will be used for additional postoperative pain needs.
62145051|NCT02446275|EXPERIMENTAL|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression.
62145052|NCT02446275|EXPERIMENTAL|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid.
62145053|NCT01784107|EXPERIMENTAL|Belotecan and Ifosfamide|
62145054|NCT02622698|PLACEBO_COMPARATOR|Control|The patients in the control group did not receive any supplementation, and were directed to follow the dietary guidelines of their surgeon.
62350631|NCT02779881||Subjects outgrown cow's milk allergy with formula+probiotic|Tolerant with extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG
62350632|NCT02779881||Subjects outgrown cow's milk allergy assuming other formulas|Subjects tolerant with other formulas
62706754|NCT04899687|EXPERIMENTAL|Group B: fluoxetine plus dextromethorphan then fluoxetine|Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.
62706755|NCT02740270|EXPERIMENTAL|Arm A|
62706756|NCT02740270|EXPERIMENTAL|Arm B|
62706757|NCT01636284|EXPERIMENTAL|JX-594 recombinant vaccina GM-CSF|JX-594 recombinant vaccina GM-CSF
62706758|NCT01072084||Patients with food allergy|
62706759|NCT01072084||Healthy subjects|
62706760|NCT01681914||Anemia|Ambulatory, HIV-infected adult patients with hemoglobin \<10 g/dL will be evaluated and managed in accordance with Mozambique's new anemia guideline for non-physician clinicians. The basic steps recommended by the guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral blood smear) and treat if indicated; evaluate for adverse drug reactions and manage per Mozambican national guidelines; consider nutritional deficiencies and intestinal parasites; evaluate response to therapy at \<=1 month.
62539324|NCT03240835||CCRT±NACT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
62706761|NCT01681914||Fever or History of Fever|Ambulatory, HIV-infected adult patients with measured axillary temperature \>=37.5 C or history of fever within the past 24 hours will be evaluated and managed in accordance with Mozambique's new fever guideline for non-physician clinicians. The basic steps of the fever guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral smear) and treat if indicated; treat any other cause of fever identified through history and physical examination; re-evaluate at next scheduled clinical visit (sooner if worse or if not improving within 48 hours of initiating treatment). Although blood cultures are seldom performed in Mozambican health centers, venipuncture specimens will also be cultured for bacterial pathogens at the first study visit.
62706762|NCT01681914||Anemia and Fever/History of Fever|Patients who meet eligibility criteria for both the anemia and fever arms will be evaluated and managed using both the new Mozambican anemia guideline and the new Mozambican fever guideline, as above.
62706763|NCT03552016|EXPERIMENTAL|200 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 200 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
62706764|NCT03552016|EXPERIMENTAL|400 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 400 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
62706765|NCT03552016|PLACEBO_COMPARATOR|0 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 0 mg oral riboflavin (placebo) each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
62706766|NCT01481610|EXPERIMENTAL|Lumiracoxib group|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.
62706767|NCT01481610|ACTIVE_COMPARATOR|Diclofenac group|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
62706768|NCT01993082|EXPERIMENTAL|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
62706769|NCT01993082|NO_INTERVENTION|Activity Maintenance Group|Participants randomized into the waitlist control group receive no aerobic training. Wait-list control participants will receive monthly check-in phone calls to establish that they have not significantly increased activity engagement. Participants in this group will receive a free gym membership at the end of the study, monthly phone calls with a fitness coach support provider for 6 months, and 2 coaching text messages per week.
62706770|NCT01676233|EXPERIMENTAL|Sequence 1|Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal
62350633|NCT00821665|EXPERIMENTAL|Sucrose|Sucrose
62350634|NCT00821665|PLACEBO_COMPARATOR|Water|Water
62350635|NCT02103452|EXPERIMENTAL|ovarian endometrioma|Ovarian and endometrial samples
62706771|NCT01676233|EXPERIMENTAL|Sequence 2|Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal
62706772|NCT04570202|NO_INTERVENTION|Usual Care|Subject from this group are screened positive for psychological distress but they will only receive standard of care.
62350636|NCT02103452|EXPERIMENTAL|normal ovary|Ovarian and endometrial samples
62145055|NCT02622698|EXPERIMENTAL|Treatment|Patients were instructed to consume one ounce (containing 16 grams of protein) of the supplement three times daily. No other modifications were made to the patient's diet. Patients were provided with a total of 60 doses, which would last 20 days if they consumed each dose as instructed.
62350637|NCT05340322|EXPERIMENTAL|HPV+ Pap smear|Visualization of cervix and if abnormalities are present treat with SOC thermocoagulation.
62350638|NCT02675179|EXPERIMENTAL|EOS + Spiral CT pelvimetry|Women with an indication of pelvimetry will be included in this study. They will be their own control because they will benefit from the two methods of diagnosis : EOS new technique, and spiral CT (usual technique).
62350639|NCT00838006|EXPERIMENTAL|Biofeedback training|Heart rate variability biofeedback training and iPod with Breath Pacer app
62350640|NCT00838006|EXPERIMENTAL|Cognitive bias modification training|Cognitive bias modification training and iPod with cognitive bias training app
62350641|NCT00838006|SHAM_COMPARATOR|Control Group|No additional resilience training and iPod with no resilience training apps
62350642|NCT02727660|EXPERIMENTAL|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
62539325|NCT01026987|EXPERIMENTAL|Related Donors: G-CSF & AMD3100|G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.
62539326|NCT01026987|OTHER|Recipient|Stem Cell Infusion on Day 0
62145056|NCT01802619|PLACEBO_COMPARATOR|inhaled nitrogen|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, pure nitrogen (placebo) is mixed with pure O2 or air. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the NO is delivered through the inspiratory limb of the anesthetic or ventilator circuit.
62350643|NCT02727660|EXPERIMENTAL|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
62350644|NCT02727660|EXPERIMENTAL|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
62350645|NCT06283173|EXPERIMENTAL|Collagen wound dressing with positive and negative controls|Application of test dressing, 0.5% sodium lauryl sulfate in distilled water, and distilled water on areas of the back or upper arm.
62508892|NCT05415124|EXPERIMENTAL|HemoPIll group|Participants who have scheduled endoscopies will be given the HemoPill acute capsule and the HemoPill Receiver will be activated (connected to the HemPill). Approximately 20 to 60 minutes after HemoPill acute capsule ingestion, the endoscopy will start. The attending physician will proceed with the endoscopic intervention in accordance with clinical practice and NYU protocols, which is a standard procedure. In the case bleeding pathologies are found, these will be endoscopically treated as per clinical standard.For later evaluation of the HemoPill acute measurement, a statistical correlation of the obtained data from the HemoPill Acute measurement with the endoscopic findings will be performed. The HemoPill acute capsule travels through and leaves the body naturally
62508893|NCT03723278||Healthy individuals|Young, male and healthy volunteers without any significant disease
62508894|NCT03327350||WATCHMAN transplantation|This group will receive WATCHMAN device implantation.Device implantation included concomitant antithrombotic medication to facilitate device endothelialization: warfarin and aspirin for 45 days. To assess for device stability, peridevice leaks, and device-related thrombus, transesophageal echo (TEE) imaging was performed at 45 days, 6 months, and 12 months. When the 45-day TEE revealed minimal residual peridevice flow (jet width ≤5 mm) and no device-related thrombus, warfarin will be stopped and replaced by clopidogrel, 75 mg daily, until the 6-month visit, after which only aspirin was continued. If an adequate seal is not obtained or a thrombus is detected, patients continue taking warfarin until an adequate seal is attained or thrombus is resolved before transitioning to aspirin.
62508895|NCT03327350||Oral anticoagulant therapy|"This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).~For patients taking warfarin, international normalized ratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Follow-up visits occurred twice annually after the first year, with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected."
62508896|NCT01779388|OTHER|Bronchoscopy guided by fluoroscopy|Bronchoscopy guided by fluoroscopy followed by ENG
62508897|NCT01779388|EXPERIMENTAL|Bronchoscopy guided by electromagnetic navigation|Bronchoscopy guided by ENG followed by fluoroscopy
62508898|NCT04862962||Group A: Rosuvastatin /Ezetimibe fixed dose (TREZETE®)|Rosuvastatin /Ezetimibe fixed dose (TREZETE®) Pharmaceutical Form: Tablets Dosage: 10 mg / 10 mg or 20 mg / 10 mg Administration way: Oral
62508899|NCT03345758||ECMO mode,outcome|ECMO mode includes VV-ECMO and VA-ECMO, outcome includes survive condition , physical and mental health, cognitive function and social adaptation
62508900|NCT04114942|EXPERIMENTAL|Constant Coach|Randomized to have coach during didactic training and internship.
62508901|NCT04114942|EXPERIMENTAL|Internship Only Coach|Randomized to have coach during internship only.
62508902|NCT04114942|EXPERIMENTAL|Never Coach|Randomized to never have coach.
62508903|NCT03297294|EXPERIMENTAL|EMA401|During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
62508904|NCT03297294|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
62706773|NCT04570202|EXPERIMENTAL|Eye Movement Desensitization & Reprocessing Group|Subject from this group are screened positive for psychological distress. They will receive 12 sessions of Eye Movement Desensitization \& Reprocessing therapy by a trained therapist over three months in addition to standard of care.
62145057|NCT01802619|EXPERIMENTAL|inhaled nitric oxide|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, 800 ppm NO gas is mixed with pure O2 or air to obtain a final concentration of 80 ppm NO. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the gas is delivered through the inspiratory limb of the anesthetic or ventilator circuit. NO, NO2 and O2 and methemoglobin levels are monitored by an unblinded observer.
62350646|NCT04280887|EXPERIMENTAL|Intervention|Participants will wear the device for the specified test period (3 months)
62350647|NCT03443609|OTHER|68Ga-HBED-CC-PSMA PET / CT|"Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the patient and lesion level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria)."
62539327|NCT01914861||Men/Women, 21-65, following exposure to a traumatice event|
62539328|NCT05337371||Philips ePatch® 2.0|Patients who are discharged from the hospital with ECG patch (Philips ePatch® 2.0).
62539329|NCT04197817|ACTIVE_COMPARATOR|JS002|JS002, Subcutaneous or intravenous injection
62539330|NCT04197817|PLACEBO_COMPARATOR|Placebo,|Placebo,Subcutaneous or intravenous injection
62706774|NCT03006055|EXPERIMENTAL|MBC Group|metastatic breast cancer Age：18-75 ECOG:0-2
62706775|NCT03006055|EXPERIMENTAL|Control Group|benign breast tumour Age：18-75 ECOG:0-2
62706776|NCT02551783|EXPERIMENTAL|Urethroplasty with buccal mucosa graft|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the dorsal wall of the urethra.
62706777|NCT02551783|ACTIVE_COMPARATOR|Ventral Buccal|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
62706778|NCT00502918||1|
62145058|NCT02433444||Patients receiving ERCP|Patients receiving Endoscopic retrograde cholangiopancreatography (ERCP) at Cedars-Sinai Medical Center.
62145059|NCT04181385|EXPERIMENTAL|Olanzapine|Olanzapine, 10mg, oral, single dose
61967040|NCT00276744|EXPERIMENTAL|Arm 1|"PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.~Capecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks~PART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration."
61967041|NCT01034865||HCC PTS|Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
61967042|NCT01034865||LD|Patients with chronic liver disease without evidence of HCC
62145060|NCT04181385|EXPERIMENTAL|Olanzapine plus bromocriptine|Olanzapine, 10mg, oral, single dose Bromocriptine, 5mg, oral, single dose
62145061|NCT04181385|PLACEBO_COMPARATOR|Placebo|Placebo, oral, single dose
62350648|NCT01848639|ACTIVE_COMPARATOR|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
62508905|NCT06615947|ACTIVE_COMPARATOR|Traditional Gait Rehabilitation training (tRHB|"Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions."
62508906|NCT06615947|EXPERIMENTAL|Robot Gait training (RAGT):|"RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern."
62508907|NCT06616480|EXPERIMENTAL|BenQ Materials DSFNC1 lenses|BenQ Materials contact lens wears for daily disposable
62508908|NCT06616480|ACTIVE_COMPARATOR|Visco SiHy Color lens|
62508909|NCT02827396|EXPERIMENTAL|Psycho-social intervention|Experimental group: The intervention group will get Psycho social Training Intervention which will be developed during the third phase of the study.
62508910|NCT02827396|NO_INTERVENTION|TAU intervention|Wait-list (controlled) group: The waiting list (control) group will continue getting the general health education (TAU) that is done at disability clinics in the existing sites.
62508911|NCT06015113|EXPERIMENTAL|Label 1|tale Disitamab Vedotin with pyrotinib or neratinib
62508912|NCT06029582|EXPERIMENTAL|Virtual Reality headset|Individuals will wear the Virtual Reality Headset that produce a calming scenario
62508913|NCT06029582|NO_INTERVENTION|controls|no headset
62350649|NCT01848639|PLACEBO_COMPARATOR|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
62350650|NCT05396313||Zhongshan Hospital cohort|Patients receiving CIED implantation at Zhongshan Hospital
62350651|NCT05396313||Fuwai Hospital cohort|Patients receiving CIED implantation at Fuwai Hospital
62350652|NCT05396313||Shanghai Chest Hospital cohort|Patients receiving CIED implantation at Shanghai Chest Hospital
62350653|NCT03922035|EXPERIMENTAL|Arm I (CBM588)|Patients receive standard peri-/post-transplant supportive care and CBM588 PO BID from day of admission to day 28 in the absence of disease progression or unacceptable toxicity.
62508914|NCT03753776|PLACEBO_COMPARATOR|Radium bromatum placebo group|Placebo group will receive placebo pills of Radium bromatum during radiotherapy
62508915|NCT03753776|EXPERIMENTAL|Radium bromatum group|Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy
62508916|NCT03753776|PLACEBO_COMPARATOR|Radium bromatum/Apis mellifica/Belladonna placebo group|Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis
62508917|NCT03753776|EXPERIMENTAL|Radium bromatum/Apis mellifica/Belladonna group|Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis
62508918|NCT04305990|EXPERIMENTAL|Demand-driven delivery followed by free-flow delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a demand-driven delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
61967043|NCT01384253|EXPERIMENTAL|Phase I: Dose escalation|In preparation for the study, patients screened and eligible will have a peritoneal catheter placed and the evening prior to the injection of the labeled antibody will receive furosemide. Herceptin will be administered IV followed by a single IP infusion of ²¹²Pb-TCMC-Trastuzumab. Serial sampling of blood, urine, and dosimetry will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antitumor effects.
61967044|NCT04358120|OTHER|Hyaluronic Acid Combined With Chondroitin Sulfate|The treatment consists of 3 intra articular injections of Hyaluronic Acid With Chondroitin Sulfate administered one per week for 3 consecutive weeks: the 1st at Visit 1 (Week 0), the 2nd at Visit 2 (Week 1) and the 3rd at Visit 3 (Week 2)
61967045|NCT00688753|EXPERIMENTAL|RAD001|two 5 mg tablets of everolimus orally, once daily
62508919|NCT04305990|EXPERIMENTAL|Free-flow delivery followed by demand-driven delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
62706779|NCT02446002|EXPERIMENTAL|Lofexidine + Naltrexone|
61967046|NCT02579408||LDLT donor|Donors of living donor-related liver transplantation
61967047|NCT05642208|EXPERIMENTAL|Experimental Group|"Injections will be spaced as :~* Every 3 weeks between M0 and M4,~* Every 4 weeks between M4 and M8 (if ADCT\<7 and IGA ≤ 2, AD assessed as controlled by the investigator and stable amount of local treatment used),~* Then every 5 weeks until the end of the clinical trial (M12) (if ADCT\<7 and IGA ≤ 2, AD assessed as controlled by the investigator and stable amount of local treatment used).~In case of ADCT≥7 or IGA \> 2 or disease assessed as uncontrolled by the investigator, the injection interval treatment will be step up to the previous interval.~The treatment is administered subcutaneously and can be delivered in pen or syringe for subcutaneous injection.~The dosage is usually :~* 300 mg per injection for adults and adolescents (12-17 years) weighing more than 60 kg~* 200 mg per injection for adolescents (12-17 years) weighing less than 60 kg."
61967048|NCT05642208|NO_INTERVENTION|Control group|"in this group the interval between injections is maintained every 2 weeks (14 days) throughout the clinical trial.~The treatment is administered subcutaneously and can be delivered in pen or syringe for subcutaneous injection.~Treatment will be prescribed in the control group according to the marketing authorization dosage (see paragraph 5.1). The dosage is usually :~* 300 mg every 14 days for adults and adolescents (12-17 years) weighing more than 60 kg~* 200 mg every 14 days for adolescents (12-17 years) weighing less than 60 kg."
61967049|NCT00688974||Roux-en-Y gastric bypass|Patients with class 3 obesity and type 2 diabetes submitted to Roux-en-Y gastric bypass
62350654|NCT03922035|ACTIVE_COMPARATOR|Arm II (standard of care)|Patients receive standard peri-/post-transplant supportive care.
62350655|NCT00997178|EXPERIMENTAL|Non-surgical periodontal therapy|Non-surgical periodontal therapy consisted of scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
62350656|NCT00997178|OTHER|Delayed non-surgical periodontal therapy|No periodontal treatment for 6 months
62350657|NCT06138028|EXPERIMENTAL|Combined chemo-immuno-irradiation|TP regimen plus PD-1 inhibitor for 4 cycles then irradiation and PD-1 inhibitor maintenance therapy for 13 cycles.
62350658|NCT05355428|EXPERIMENTAL|recruited patients|recruited patients will be required to feed 3 hours prior to planned procedure start with their normal method of taking breast milk (from the breast, or expressed into a bottle).
62350659|NCT01661920|EXPERIMENTAL|INTERVENTION GROUP|Patients with diagnosis of CAP with shorten treatment, defined as 5 days antibiotic treatment.
62350660|NCT01661920|ACTIVE_COMPARATOR|CONTROL GROUP|Patients with diagnosis of CAP which antibiotic treatment duration will be not modified by their doctors.
62350661|NCT01047748|ACTIVE_COMPARATOR|intra-fetal injection|Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
62350662|NCT01047748|ACTIVE_COMPARATOR|intra-amniotic injection|Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion
62350663|NCT04196205|EXPERIMENTAL|Anti-CD19 CAR-T|Anti-CD19 CAR-T
62350664|NCT01153477|NO_INTERVENTION|TAU|This group is the control group by which we are comparing our intervention. This group will not receive an intervention from us but will continue to be treated at the Intensive Outpatient facility from which we recruited them.
62350665|NCT01153477|EXPERIMENTAL|Counseling (TMAC-E)|This telephone based intervention includes six factors to improve our extended treatment model: Incentive component; Patient choice; Provision of cell phones to those who need them; Social support and community resources; Positive recovery factors; and Outreach following dropout.
62350666|NCT05096013|EXPERIMENTAL|individual nutrition therapy|Individualized nutrition therapy: Specialists in nutritional counseling determine the patient's individual energy and protein needs and create targeted individual measures to achieve them. Measures can include, for example, adjustments to the menu, food enrichment or supplementation. The measures are discussed with the patients on an ongoing basis and adjusted as necessary.
62508920|NCT05804435|EXPERIMENTAL|iNod™ System|Subjects with a qualifying lung lesion will have a standard of care Transbronchial Needle Aspiration using the the iNod™ System
62706780|NCT02321475||Psycho-emotional symptoms, added to cognitive disorders|Patients of middle age and younger with psycho-emotional symptoms, added to cognitive disorders.
62706781|NCT05949593|EXPERIMENTAL|LBS-008, Tinlarebant|
62706782|NCT05949593|PLACEBO_COMPARATOR|Placebo|
62706783|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.~A second blood draw will be collected at 12 months."
62706784|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.~Diagnostic information will be collected to confirm the final diagnosis."
62706785|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.~Subject will be enrolled and provide a blood sample."
61967050|NCT00688974||Adjustable gastric banding|Patients with class 3 obesity and type 2 diabetes submitted to adjustable gastric banding
61967051|NCT00688974||Healthy controls|Non-obese, non-diabetic adults
61967052|NCT04094363|EXPERIMENTAL|Product usage order ABCD|Subjects will use each of the 4 products (ABCD) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
61967053|NCT04094363|EXPERIMENTAL|Product usage order BDAC|Subjects will use each of the 4 products (BDAC) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
62508921|NCT06609434|NO_INTERVENTION|systemic therapy|This arm includes patients with intrahepatic recurrence of colorectal cancer liver metastases who underwent systemic therapy.
62508922|NCT06609434|EXPERIMENTAL|systemic therapy combined with radiofrequency ablation|This arm includes patients with intrahepatic recurrence of colorectal cancer liver metastases who underwent systemic therapy combined with radiofrequency ablation.
62508923|NCT05802446|EXPERIMENTAL|Active feedback|"Group receiving real neurofeedback (NFB) (activity of the emotional brain network)"
62508924|NCT05802446|SHAM_COMPARATOR|Sham feedback|"Group receiving sham NFB (activity from brain regions not implicated in emotion processing) to control for a potential placebo effect."
62508925|NCT04374799|ACTIVE_COMPARATOR|Low dose heparin|heparin (25 IU/Kg -maximal dose 3,000 IU)
62508926|NCT04374799|ACTIVE_COMPARATOR|High dose heparin|heparin 50 IU/kg -maximal dose 5,000 IU
61967054|NCT04094363|EXPERIMENTAL|Product usage order CADB|Subjects will use each of the 4 products (CADB) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
62145062|NCT01331408|EXPERIMENTAL|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks
62350667|NCT05096013|NO_INTERVENTION|usual care|Usual care: Participants in the control group receive a standardized food fortification of the soups with fat and protein, as well as an energy- and protein-rich dessert. No additional advice or adjustments are made by the iNT.
62508927|NCT04374799|PLACEBO_COMPARATOR|Placebo|Normal saline 0.9%.
62508928|NCT04512326||Total or subtotal colectomy|Total or subtotal colectomy with ileorectal or ileosigmoid anastomosis
62508929|NCT04116151|EXPERIMENTAL|Intervention group|Local administration of the Alantel (R) cream on the affected skin
62508930|NCT04116151|PLACEBO_COMPARATOR|Control group|Local administration of the Placebo cream on the affected skin
62508931|NCT01254461|EXPERIMENTAL|A|
62508932|NCT01254461|EXPERIMENTAL|B|
62508933|NCT06615934|EXPERIMENTAL|Aerobic and resistance exercise|respiratory physiotherapy + aerobic and resistance exercise therapy
61967055|NCT04094363|EXPERIMENTAL|Product usage order DCBA|Subjects will use each of the 4 products (DCBA) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
61967056|NCT03981263|OTHER|MEAVANTI + Standard protheses|The patients will benefit from the experimental prothesis (MEAVANTI), after a wash-out period of 15 days, they will benefit from the standard non-adherent prothesis.
61967057|NCT03981263|OTHER|Standard + MEAVANTI protheses|The patients will benefit from the standard non-adherent prothesis, after a wash-out period of 15 days, they will benefit from the experimental prothesis (MEAVANTI).
61967058|NCT04221009|EXPERIMENTAL|Intervention (single arm)|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
62145063|NCT03794219|EXPERIMENTAL|Kinesio tape plus NSAID|Kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions in addition to 750 mg/day oral naproxen.
62145064|NCT03794219|ACTIVE_COMPARATOR|NSAID|750 mg/day oral naproxen is administered for 10 days.
62145065|NCT03803150|EXPERIMENTAL|PRA approach|PRA extends downward in curvilinear fashion in cervicomastoid skin crease
62145066|NCT03803150|ACTIVE_COMPARATOR|RT approach|RT begins 5mm below the ear lobe and continues 3 to 3.5cm inferiorly.
62350668|NCT03582735|EXPERIMENTAL|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
62508934|NCT06615934|ACTIVE_COMPARATOR|Respiratory physiotherapy|respiratory physiotherapy alone
62508935|NCT01100450|EXPERIMENTAL|Resistance Training|
62508936|NCT02219308|EXPERIMENTAL|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
62508937|NCT02219308|SHAM_COMPARATOR|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
62508938|NCT02045524|EXPERIMENTAL|Injection location1|Single dose IM injection
62508939|NCT02045524|EXPERIMENTAL|Injection location 2|Single dose IM Injection
62508940|NCT05164913||Control group|No general anesthesia between 0-3 years old or 0-5 years old
62508941|NCT05164913||Single anesthesia group|Only once general anesthesia between 0-3 years old or 0-5 years old
62508942|NCT05164913||Multiple anesthesia group|More than once general anesthesia between 0-3 years old or 0-5 years old
62508943|NCT06534931|EXPERIMENTAL|Manipulation|Those in the intervention group received a high velocity low amplitude manipulation to the mid-thoracic spine provided by a licensed chiropractor.
62508944|NCT06534931|SHAM_COMPARATOR|Sham|Those in the control group received a validated sham manipulation to the mid-thoracic spine. The sham manipulation was done so that there was minimal downward force applied to the spine.
62715064|NCT06007677|EXPERIMENTAL|Dose Regimen 1 (Arm C): STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
62715065|NCT06007677|EXPERIMENTAL|Dose Regimen 3 (Arm D): STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
62715066|NCT06717464|EXPERIMENTAL|Capecitabine therapy group|
62706786|NCT00027599|EXPERIMENTAL|Arm I|Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.
62706787|NCT01006733|EXPERIMENTAL|Target INR 1.8 and Pharmacogenetic|The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
62706788|NCT01006733|EXPERIMENTAL|Target INR 2.5 and Pharmacogenetic|The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
62706789|NCT01006733|EXPERIMENTAL|Target INR 1.8 and Clinical|The target INR is 1.8. Warfarin initiation is via clinical dosing.
62706790|NCT01006733|NO_INTERVENTION|Target INR 2.5 and Clinical|The target INR is 2.5. Warfarin initiation is via clinical dosing.
62706791|NCT02143882|EXPERIMENTAL|LAIV|All children will receive LAIV, currently available as the marketed product Fluenz
62706792|NCT00637351||Group A|Subjects with diagnosed pneumonia \& positive culture of streptococcus pneumoniae
62706793|NCT00637351||Group B|Subjects with diagnosed pneumonia \& positive culture of non-typable haemophilus influenzae
62706794|NCT01006395|ACTIVE_COMPARATOR|zoledronic acid|intervention
62706795|NCT01006395|PLACEBO_COMPARATOR|Placebo|
62706796|NCT02595515|EXPERIMENTAL|Chiropractic treatment|Manipulation and/or mobilisation. Intervention: Procedure: Chiropractic treatment.
61976172|NCT04447144||COVID-19 mild severity|"Definition of mild cases according to MOH:~1. Age \< 60~2. Temperature \<38.5~3. arterial oxygen saturation (SaO2) \>92%~4. Heart Rate \<110~5. Respiratory Rate \<25 /min.~6. Neutrophil / lymphocyte ratio on complete blood count (CBC) \< 3.1~7. No co-morbidities that necessitates hospital admission: Pregnancy, severe uncontrolled Diabetes, Chronic lung disease, Chronic kidney disease, Chronic liver disease, Serious heart diseases (arrythmia, Ischemic heart disease, uncontrolled hypertension), immunocompromised: prolonged use of corticosteroids and other immunosuppressive drugs/ organ transplantation/ HIV/ Immunodeficiency, Obesity (BMI \> 40)"
62145067|NCT03003104|EXPERIMENTAL|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks
62350669|NCT03582735|NO_INTERVENTION|Control|No intervention according to current practice.
62350670|NCT01225367||pulmonary doppler|
62350671|NCT01492699|EXPERIMENTAL|PRX-03140|PRX-03140 for the treatment of PTSD
62706797|NCT02595515|PLACEBO_COMPARATOR|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
62706798|NCT05557396|ACTIVE_COMPARATOR|NEX (Control group)|"Nose-ear-xiphoid measurement method (NEX), (n=31)~The distance between the patient's nose tip and earlobe will be measured first, then the distance between the earlobe and the xiphoid (NEX method) Marking will be made on the nasogastric tube according to the length obtained from the measurement, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the nasogastric tube placement procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded."
62706799|NCT05557396|EXPERIMENTAL|CoNEX|Corrected nose-earlobe-xiphoid measurement method (CoNEX), (n=31) The distance between the patient's nose tip and earlobe will be measured first, and then the distance between the earlobe and the xiphoid, The nasogastric tube length to be applied to the patient will be determined according to the formula (NEX x 0.38696) + 36.37 cm, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the nasogastric tube placement procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded.
62706800|NCT05557396|EXPERIMENTAL|XEN+10|"Xiphoid-earlobe-nose+10 cm (XEN+10), (n=31)~The distance between the patient's xiphoid and earlobe will be measured first, and then the distance between the earlobe and the tip of the nose will be measured and 10 cm will be added to the obtained measurement, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the nasogastric tube placement procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded."
62715067|NCT06717464|EXPERIMENTAL|Toripalimab combined with capecitabine therapy group|
62715068|NCT06578182|EXPERIMENTAL|Colchicine|
62715069|NCT06578182|PLACEBO_COMPARATOR|Placebo|
62736690|NCT03835182|ACTIVE_COMPARATOR|Ultrasound group|Thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The ultrasound group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and ultrasound 1MHz frequency (ten minutes) applied to the lower back, abdominal and lower back muscle strengthening exercises.
62350672|NCT06048926|EXPERIMENTAL|Experimental group: carrelizumab in combination with concurrent chemoradiotherapy|Study drugs were administered intravenously on the first day of each cycle. Administered sequentially: carrelizumab, 200mg/time, paclitaxel, 50mg/m2, cisplatin, 25mg/m2, chemotherapy once a week, a total of 5 doses, carrelizumab every three weeks until PD or intolerable, up to 2 years, simultaneous radiotherapy at the first dose, the total dose of radiotherapy is 50.4Gy, completed in 28 divided doses, 1.8Gy each time, 5 times a week.
62350673|NCT06048926|PLACEBO_COMPARATOR|Control group: placebo-resistant in combination with chemoradiotherapy|"Placebo: 200 mg intravenously given with Q3W until PD or intolerable, carrelizumab/placebo for up to 2 years.~Paclitaxel: 50mg/m2, iv, D1, 8, 15, 22, 29, once a week, a total of 5 times. cisplatin: 25mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 doses. Radiotherapy: total dose of 50.4 Gy, completed in 28 divided doses of 1.8 Gy each time, 5 times a week."
62350674|NCT03748277|EXPERIMENTAL|Minimally invasive fusion|Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
62350675|NCT03748277|ACTIVE_COMPARATOR|Open Fusion|Bilateral decompression, open fusion + screw fixation
62350676|NCT03634878|EXPERIMENTAL|Perineal ultrasound to visualize the strips and their position|
62350677|NCT00049218|EXPERIMENTAL|Vaccine Administration|"• Phase I: Beginning 9 weeks after completion of chemotherapy, patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC) on days 1, 14, and 28. Patients without PD may undergo repeat leukapheresis on day 49. Patients receive vaccine SC again on days 56, 84, and 112 in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of autologous dendritic cell-adenovirus p53 vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~• Phase II: Patients receive autologous dendritic cell-adenovirus p53 vaccine at the MTD determined in phase I."
62350678|NCT04731623|EXPERIMENTAL|ION904|Single ascending dose of ION904 will be administered by SC injection on Day 1.
62508945|NCT00925756|EXPERIMENTAL|Maraviroc 150 mg, 300 mg, or 600 mg twice daily|"This was a single arm study where Maraviroc was added for 24 weeks.~Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:~150 mg twice daily with strong CYP3A4 inhibitors, including:~* Protease inhibitors (except tipranavir/ ritonavir)~* Delavirdine~* ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin~* Darunavir/r + etravirine~  300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:~* Tipranavir/ ritonavir~* Nevirapine~* All NRTIs~* Enfuvirtide~  600 mg twice daily with strong CYP3A4 inducers, including:~* Efavirenz, etravirine~* rifampin"
62508946|NCT00707447|PLACEBO_COMPARATOR|1/Control|Control group received written information about diabetes risks with instructions about healthy eating and increasing physical exercise
62508947|NCT00707447|EXPERIMENTAL|2/PREDIAS|Intervention consists of a group programme (PREDIAS) aiming at modification of lifestyle
62508948|NCT05041114|OTHER|Single|Implantation of motor neuroprosthesis medical device.
62508949|NCT03669016|EXPERIMENTAL|Face-to-face group-based mindfulness|8 weeks training.
62508950|NCT03669016|EXPERIMENTAL|Internet-based mindfulness|8 weeks training.
62508951|NCT03669016|NO_INTERVENTION|Waiting-list control group|No training during the study.
62508952|NCT04778306|ACTIVE_COMPARATOR|Trans Oral Laser Surgery (Group 1)|In TOLS, the tumor tissue was removed en bloc and in one piece. The removed specimen was marked on a card with the help of pins. Permanent surgical margins were taken from the anterior, posterior, superior, inferior and deep areas of the tumor area.
62508953|NCT04778306|ACTIVE_COMPARATOR|Radiotherapy (Group 2).|. In RT; the head was routinely stabilized with the help of a thermoplastic mask and subsequently covered the primary area with a size varying from 4x4 cm to 6x6 cm. Total 63-70 Gy radiotherapy was applied 2.0-2.3 Gy/ day,5 days a week, for 6-7 weeks.
62508954|NCT00401245|ACTIVE_COMPARATOR|A|
62508955|NCT00401245|ACTIVE_COMPARATOR|B|
62508956|NCT00401245|ACTIVE_COMPARATOR|C|
62508957|NCT00401245|ACTIVE_COMPARATOR|D|
62508958|NCT00401245|ACTIVE_COMPARATOR|E|
62508959|NCT00401245|ACTIVE_COMPARATOR|F|
62508960|NCT00401245|ACTIVE_COMPARATOR|G|
62508961|NCT00401245|PLACEBO_COMPARATOR|H|
62508962|NCT05997940|ACTIVE_COMPARATOR|PENG|PENG block performed before spinal anesthesia
62508963|NCT05997940|NO_INTERVENTION|Control|
62350679|NCT04731623|PLACEBO_COMPARATOR|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection on Day 1.
62508964|NCT02210052|EXPERIMENTAL|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
62508965|NCT05601076|EXPERIMENTAL|The drainage tube in the experimental group was fixed with the triple-buffer system|
62508966|NCT05601076|ACTIVE_COMPARATOR|that in the control group was fixed using the conventional lifting platform method|
62508967|NCT05433259|EXPERIMENTAL|CRT type lens|Subjects fitted with CRT type lenses
62508968|NCT05433259|EXPERIMENTAL|VST type lens|Subjects fitted with VST type lenses
62508969|NCT02060045|EXPERIMENTAL|bundle implementation|The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
62508970|NCT03253094|ACTIVE_COMPARATOR|Fluconazole|150 mg/day for 1 day
62508971|NCT03253094|EXPERIMENTAL|Ibrexafungerp 750mg|750mg QD for 1 day only
62508972|NCT03253094|EXPERIMENTAL|Ibrexafungerp 300mg|300mg BID for 1 day only
62508973|NCT03253094|EXPERIMENTAL|Ibrexafungerp 450mg|450mg BID for 1 day only
62508974|NCT03253094|EXPERIMENTAL|Ibrexafungerp 150mg|150mg BID for 3 days
62508975|NCT03253094|EXPERIMENTAL|Ibrexafungerp 300mg D1-D3|300mg BID for 3 days
62508976|NCT05409521|EXPERIMENTAL|Tape Group|Kinesio taping will be applied on thoracic region
62508977|NCT05409521|PLACEBO_COMPARATOR|Placebo Group|Placebo taping will be applied on arm region
62508978|NCT00715091|EXPERIMENTAL|1|continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
62508979|NCT00715091|ACTIVE_COMPARATOR|2|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
62508980|NCT01758133||Mothers exposed to medical clowns|Mothers of premature infants who have been exposed to medical clown activities
62508981|NCT01758133||Mothers not exposed to medical clown activity|
62508982|NCT03936218|EXPERIMENTAL|Inj. Goserelin (Test) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
62508983|NCT03936218|ACTIVE_COMPARATOR|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
62508984|NCT01144403|EXPERIMENTAL|Rituximab|Rituximab, 375 milligram per meter square (mg/m\^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).
62508985|NCT05976724|EXPERIMENTAL|Mobilization with movement|Mobilization with movement technique and traditional physiotherapy will be applied to the intervention group. Also patients will receive a traditional therapy program consisting of Conventional TENS and stretching and strengthening exercises.
62508986|NCT05976724|ACTIVE_COMPARATOR|Control group|Patients will receive a traditional therapy program consisting of Conventional TENS and stretching and strengthening exercises.
62508987|NCT02397213|PLACEBO_COMPARATOR|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
62508988|NCT02397213|ACTIVE_COMPARATOR|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection.
62508989|NCT01525654|ACTIVE_COMPARATOR|Partners|Patients who are matched with support partners and have a billing diagnosis of RA (714.0) or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) or the Patient-Centered Outcomes Initiative (PACO)
62508990|NCT01525654|NO_INTERVENTION|Controls|Controls will be BRASS patients who continue to receive regular care without being matched with a peer support partner.
62508991|NCT04499378||SARS-CoV-2|Patients with a positive SARS-CoV-2 PCR test upon admission to the emergency department.
62508992|NCT04499378||H1N1 influenza|Patients with a positive Influenza H1N1 PCR test upon admission to the emergency department.
62508993|NCT06224855|EXPERIMENTAL|Experimental|Dose Escalation DXC006, Cohort Expansion DXC006
61976173|NCT04447144||COVID-19 moderate severity|Any patient not fulfilling the above mild criteria is considered having moderate disease as well as any positive pulmonary imaging findings
62145068|NCT03003104|PLACEBO_COMPARATOR|Vehicle Control|Topical Gel vehicle applied to the face twice daily for 12 weeks
62145069|NCT01934036|EXPERIMENTAL|Obex, a nutritional supplement|Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
62145070|NCT01934036|PLACEBO_COMPARATOR|Placebo|Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
62508994|NCT01913795|ACTIVE_COMPARATOR|Environmental Intervention|4 classroom air purifiers and school integrated pest management environmental intervention
62715070|NCT06093464|EXPERIMENTAL|Group A- Natural Compound A to Natural Compound B to Natural Compound C|"* Cycle 1 (4 weeks): use diffused Natural Compound A (essential oil) in a diffuser every night when sleeping~* Cycle 2 (4 weeks): will not use compounds/diffuser (wash-out period)~* Cycle 3 (4 weeks): use diffused Natural Compound B (essential oil) in a diffuser every night when sleeping~* Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~* Cycle 3 (4 weeks): use diffused Natural Compound C (control) in a diffuser every night when sleeping~* Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~There will be 3 natural compounds; the intervention compounds essential oils and are commercially available and there is a control compound (water). They will be used as intended with diffusers."
62145071|NCT06346652|ACTIVE_COMPARATOR|Control Group|Routine Physical Therapy
62145072|NCT06346652|EXPERIMENTAL|Interventional Group|Routine Physical Therapy + PNF + Core Strengthening
62508995|NCT01913795|PLACEBO_COMPARATOR|Sham and Control|4 sham air purifiers and no school integrated pest management environmental intervention
62508996|NCT01913795|PLACEBO_COMPARATOR|Active Air Purifier and Control|4 air purifiers and no school integrated pest management environmental intervention
62508997|NCT01913795|SHAM_COMPARATOR|Sham and Integrated Pest Management|4 classroom sham air purifiers and school integrated pest management
62508998|NCT06617676|EXPERIMENTAL|TTNS - two times per week|Participants will receive transcutaneous tibial nerve stimulation for 30 minutes with a frequency of 12 Hz, pulse width of 300 microseconds, and to an intensity of the participant's tolerance under the motor threshold. This group will receive treatment two times per week.
62508999|NCT06617676|EXPERIMENTAL|TTNS - four times per week|Participants will receive transcutaneous tibial nerve stimulation for 30 minutes with a frequency of 12 Hz, pulse width of 300 microseconds, and to an intensity of the participant's tolerance under the motor threshold. This group will receive treatment four times per week.
62509000|NCT06617676|NO_INTERVENTION|No treatment group|Treatment will be deferred after 12 weeks.
62509001|NCT00122447|ACTIVE_COMPARATOR|Anti-inflammatory agent|Aspirin (ASA)
62509002|NCT00122447|ACTIVE_COMPARATOR|Angiotensin receptor blocker (ARB)|Olmesartan (ARB)
62509003|NCT00122447|ACTIVE_COMPARATOR|Antioxidant|Alpha lipoic acid (ALA)
62509004|NCT00122447|PLACEBO_COMPARATOR|Placebo|Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day
62509005|NCT03899649||IRE Cohort|Patients who received SOC and received IRE
62509006|NCT03899649||SOC Cohort|Patients who received SOC and did not receive IRE
61976174|NCT01074957|ACTIVE_COMPARATOR|Incentive Spirometry|Incentive Spirometry group (IS) was oriented to take a deep breathing through Voldyne 5000TM (Sherwood Medical; St Loius, MO, USA) from Functional Residual Capacity (FRC) to Total Lung Capacity (TLC).
61976175|NCT01074957|ACTIVE_COMPARATOR|Exercise group|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
61976176|NCT01074957|ACTIVE_COMPARATOR|Breath-Stacking|Breath-Stacking group (BS) performed successive inspiratory efforts using a facial mask adapted to an unidirectional valve
62509007|NCT02506218|EXPERIMENTAL|10 + 20 g protein consumption|10 g breakfast followed by the consumption of a 20g whey protein shake
62509008|NCT02506218|ACTIVE_COMPARATOR|30 g protein breakfast|
62509009|NCT02506218|ACTIVE_COMPARATOR|10 g protein breakfast|
62509010|NCT06590376|EXPERIMENTAL|Experimental Intervention group (Group receiving midwifery care based on Swanson Care Theory)|After randomization of the women who were allocated to the clinic, they were informed about the research and their consent was obtained; then, the Women's Introductory Information Form, General Well-Being Scale, Perinatal Bereavement Scale, and the Male Introductory Information Form were completed by their husbands. The intervention group (n=38) received midwifery care based on Swanson Care Theory in addition to routine care in accordance with clinical procedures. The control group (n=38) received only routine care in accordance with the clinical procedures. For the participants in the intervention group, a practitioner's guide based on the Swanson Care Theory consisting of the stages of 'Knowing, ' 'Being together,' 'Meeting the needs,' 'Empowering' and 'Maintaining faith' was created. In this guideline, eight interviews were conducted, four face-to-face in the clinic and four by telephone after discharge. In the first interview, immediately after the woman was admitted to the clinic
62509011|NCT06590376|NO_INTERVENTION|Control group|"The women and their husbands who were assigned to this group in a randomised controlled trial were interviewed after admission to the clinic and given detailed information about the study and a consent form was filled out. Women's Introductory Information Form and General Well-Being Scale Short Form, Perinatal Bereavement Scale Short Version and Male Introductory Information Form were filled out for their husbands.~During the study period, women in this group received routine midwifery care and counselling in accordance with hospital and clinical procedures. Clinical procedures included physiological care such as bleeding control and monitoring of vital signs during termination of pregnancy. No care procedures other than physiological care were applied.~On the thirtieth day after the woman was discharged from the clinic, the General Well-Being Scale and Perinatal Bereavement Scale were completed by telephone interview method."
62509012|NCT02253069|EXPERIMENTAL|PHMB-based antiseptic|Applying Prontosan antiseptic solution to tie-over dressings
62509013|NCT02253069|PLACEBO_COMPARATOR|Control|Applying water to tie-over dressings
62509014|NCT01790113|ACTIVE_COMPARATOR|Univer™ II|Univers™ II Total Shoulder Replacement
62509015|NCT01790113|EXPERIMENTAL|Eclipse™|Eclipse™ Total Shoulder Replacement
62509016|NCT03692091|ACTIVE_COMPARATOR|Anterior portal|Injection in to subacromial space from anterior portal
62509017|NCT03692091|ACTIVE_COMPARATOR|Lateral portal|Injection in to subacromial space from lateral portal
61967059|NCT02499302|EXPERIMENTAL|Mental training|"The intervention consists of one introductory session (patients and their parents/next-of-kin), followed by 9 individual therapy sessions (one each week) of 1.5 hours duration and related home-work, combining elements from cognitive behavioural therapy and music therapy: Important elements of the mental training program are:~* Psychoeducation: Theories of CFS/ME pathophysiology and treatment rationale~* Relaxation: Bodily stress reduction, mindfulness~* Visualization: Contact with positive emotions, techniques of worrying reduction~* Experiences: Behavioral 'experiments' (individually adjusted), 'trick into action'~* Cognitive challenges: Challenging thoughts about disease process, stimulus and outcome expectancies, prognosis"
62509018|NCT00783887||1|Patients with suspected or confirmed primary ciliary dyskinesia after ciliary investigations who accepted to participate to the genetic studies
62509019|NCT00727077||IntronA/Rebetol|Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites
61967060|NCT02499302|NO_INTERVENTION|Routine follow-up|Routine follow-up by the general practitioner, which is normal approach to chronic fatigue following acute EBV infection.
61967061|NCT03537105|EXPERIMENTAL|Sclerodermic patients|Sclerodermic patients presenting cutaneous fibrosis
61967062|NCT05261256||Participants treated for pediatric cancer|This group includes children, adolescents and young adults treated for pediatric cancer who received anthracyclines and/or chest radiation during treatment.
61967063|NCT05261256||Healthy control subjects|This group includes healthy children, adolescents and young adults without a history of pediatric cancer as age-and gender-matched control subjects.
61967064|NCT04490538||Critically ill patients|Critically ill patients hospitalised at the intensive care unit indicated to echocardiographic examination.
61967065|NCT02171923||Remitted depressed patients|Formerly depressed patients in remission for 6 months or more
61967066|NCT02171923||healthy controls|healthy subjects with no history of mental disorders
61967067|NCT01336764|EXPERIMENTAL|Active|individual coping self-statements and stimulus guided paced breathing.
61967068|NCT01336764|SHAM_COMPARATOR|Control|Coping self statements and breathing retraining will be replaced with undirected passive behaviors such as listening to music.
62509020|NCT04474093|ACTIVE_COMPARATOR|Zirconium-reinforced glass ceramics (ZRGC)|12 posterior single tooth crowns made from monolithic zirconium-reinforced glass ceramics(ZRGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
62509021|NCT04474093|ACTIVE_COMPARATOR|Lithium disilicate glass ceramics (LGC)|Group 2: 12 posterior single tooth crowns made from monolithic lithium disilicate glass ceramics(LGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
61967069|NCT03908697|EXPERIMENTAL|Single cohort|All 20 participants will use ClearBlue and Mira monitors on first morning urine
61967070|NCT00959621|ACTIVE_COMPARATOR|ASA|The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.
61967071|NCT00959621|ACTIVE_COMPARATOR|Klexane|Clexane (enoxaparine) 40 mg sc
61967072|NCT00959621|ACTIVE_COMPARATOR|Aspirin and Enoxaparine|
61967073|NCT04478955||normal|no make up
61967074|NCT04478955||eyeliner only|three days a week at least for 6 months
61967075|NCT04478955||mascara only|three days a week at least for 6 months
62509022|NCT04474093|ACTIVE_COMPARATOR|Resin infiltrated glass ceramics (RIGC)|12 posterior single tooth crowns made from monolithic resin infiltrated glass ceramics(RIGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
62509023|NCT06312423|EXPERIMENTAL|Group 1 - 20 mg|Four volunteers will be enrolled (no more than one per day and only after verifying that the preceding volunteer did not show any significant adverse effects) who will be administered the initial dose level (1 x 20 mg of IMT504).
62509024|NCT06312423|EXPERIMENTAL|Group 2 - 60 mg|If no toxicity is detected and there is good tolerance, another 4 patients will be enrolled (no more than one per day and only after verifying that the preceding one did not show significant adverse effects) who will receive treatment with the next dose level (3 x 20 mg of IMT504, one application per day for 3 consecutive days).
62509025|NCT06312423|EXPERIMENTAL|Group 3 - 100 mg|If no toxicity is detected and there is good tolerance, another 4 patients will be enrolled (no more than one per day and only after verifying that the preceding one did not show significant adverse effects) who will receive treatment with the next dose level (5 x 20 mg of IMT504, one application per day for 5 consecutive days).
62509026|NCT01363063|EXPERIMENTAL|Ketorolac tromethamine (Part A)|
62509027|NCT01363063|EXPERIMENTAL|Ketorolac tromethamine (Part B)|
62509028|NCT05116137|EXPERIMENTAL|Exercise Intervention|12-week circuit-based resistance exercise
62509029|NCT05116137|NO_INTERVENTION|Wait-list Control|Standard of care wait-list control group
62509030|NCT00869440|EXPERIMENTAL|1: Remimazolam (CNS 7056) 0.10 mg/kg|Remimazolam (CNS 7056) 0.10 mg/kg iv
62509031|NCT00869440|EXPERIMENTAL|2: Remimazolam (CNS 7056) 0.15 mg/kg|Remimazolam (CNS 7056) 0.15 mg/kg iv
62509032|NCT00869440|EXPERIMENTAL|3: Remimazolam (CNS 7056) 0.20 mg/kg|Remimazolam (CNS 7056) 0.20 mg/kg iv
62509033|NCT00869440|EXPERIMENTAL|4: Midazolam 0.075 mg/kg|Midazolam 0.075 mg/kg iv
62509034|NCT04034355|EXPERIMENTAL|PledOx (5 µmol/kg)|Calmangafodipir 5 µmol/kg
62509035|NCT04034355|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride in 20 mL vials
62509036|NCT04039048|EXPERIMENTAL|ctDCS during Balance training|
62509037|NCT04039048|SHAM_COMPARATOR|ctDCS sham during Balance training|
62509038|NCT04204031|OTHER|Presentation of the adherence record|"Following a first observation period of 15 days, participants whose actual time of use will be less than prescribed will be offered an intervention which will consist of a presentation of the adherence record. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.~Only participants with an actual time of use less than prescribed will be offered this intervention and will continue the monitoring over a period of 15 additional days."
62509039|NCT02733627|EXPERIMENTAL|BI 1467335 10 mg (low dose)|
62509040|NCT02733627|EXPERIMENTAL|BI 1467335 15 mg (medium dose)|
62509041|NCT02733627|EXPERIMENTAL|BI 1467335 20 mg (high dose)|
62509042|NCT02733627|PLACEBO_COMPARATOR|Placebo|
61967076|NCT04478955||eyeliner and mascara|three days a week at least for 6 months
61976177|NCT04831203|EXPERIMENTAL|Protein-hydrolysate|Dietary supplement: an egg-protein hydrolysate (NWT-03) Study volunteers will receive a daily powder of 5 g of protein hydrolysate to mix with 200 mL of water for 36 weeks.
61976178|NCT04831203|PLACEBO_COMPARATOR|Control|Control: 5 g of maltodextrin powder mixed with 250 mL of water for 36 weeks.
62145073|NCT05678725|ACTIVE_COMPARATOR|Transcranial Alternating Current Stimulation|the alternating current stimulation lasted 20 mins and was delivered at 2mA (peak to peak) at 20Hz during the Simple Reaction Task(SRT), targeting the primary motor cortex. EEG should be acquired before and after the stimulation session.
62509043|NCT02394691|ACTIVE_COMPARATOR|anodal stimulation|Patients receive an anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
62509044|NCT02394691|PLACEBO_COMPARATOR|sham stimulation|Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
62509045|NCT03956589|EXPERIMENTAL|Orkambi open-label arm|Open-label study: all subjects will receive Orkambi during 3 months.
62509046|NCT06353191||Observational|Patients undergo blood sample collection and have their medical records reviewed on study.
61976179|NCT02733367|EXPERIMENTAL|Infacort|Infacort® granules
61976180|NCT01967251|EXPERIMENTAL|Udenafil 25 mg|Udenafil 25 mg, tablets, orally, once daily for 12 weeks.
62509047|NCT02401841||Sugammadex|Patients treated with Sugammadex
62509048|NCT02401841||Neostigmine|Patients treated with Neostigmine
62509049|NCT03068884|SHAM_COMPARATOR|Tdcs sham|
62509050|NCT03068884|PLACEBO_COMPARATOR|Placebo|
62509051|NCT03068884|EXPERIMENTAL|Tdcs cathodal|
62509052|NCT03068884|EXPERIMENTAL|Tyrosine|
62509053|NCT02044250|ACTIVE_COMPARATOR|Clopidogrel|Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
62509054|NCT02044250|PLACEBO_COMPARATOR|Aspirin|Antiplatelet monotherapy : Aspirin 100\~200mg P.O. daily
62509055|NCT02718287|EXPERIMENTAL|Treatment:|Home visiting with PCCSF
62706801|NCT05557396|EXPERIMENTAL|GWNUF|"Gender-weight-nose-umblikus-head flat (GWNUF), (n=31)~The patient's body weight will be measured without clothes on, When the patient is in the supine position, the distance between the tip of the nose and the umbilicus will be measured, The length of the nasogastric tube to be applied to the patient according to the formula 29.38 + (4.53 x gender) + (0.34 x distance between the tip of the nose and the umbilicus) - (0.06 x patient weight), (gender = 1 for male patient, 0 for female patient) to be determined, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the insertion procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded."
62706802|NCT05557396|EXPERIMENTAL|EXU-NE|The distance between the patient's xiphoid and earlobe will be measured first (Measurement 1), (n=31) The distance between the patient's xiphoid and the midline of the umbilicus will be measured (Measurement 2), The two obtained measurement values will be added (Measurement 1 + Measurement 2), The distance between the patient's nose tip and earlobe will be measured (Measurement 3), Measurement 3 value will be subtracted from the sum of Measurement 1 and Measurement 2 values, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the insertion procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded.
62706803|NCT04581811|EXPERIMENTAL|Prolonged Proning Arm|Patients will receive 24 hours in the prone position followed by 8 hours in the supine position for the duration of the study
62509056|NCT02718287|EXPERIMENTAL|Control|Home visiting no PCCSF
62509057|NCT06368752|EXPERIMENTAL|GIP[3-30]NH2 infusion|GIP\[3-30\]NH2 intravenous infusion (800 pmol/kg/min)
62706804|NCT04581811|ACTIVE_COMPARATOR|Traditional Proning Arm|Patients will receive standard 16 hour prone positioning followed by 8 hours in the supine position for the duration of the study
62706805|NCT05701826|EXPERIMENTAL|Treatment group A1|HRS3797 for injection
62509058|NCT06368752|PLACEBO_COMPARATOR|Saline infusion|Saline intravenous infusion (0,5 % human serum albumin)
62706806|NCT05701826|EXPERIMENTAL|Treatment group A2|HRS3797 for injection
62350680|NCT06299579|EXPERIMENTAL|GD-11 for injection test group|"GD-11 for injection, freeze-dried powder, 80mg, 160mg/dose Before the test drug is used, from the specification of 100 ml saline infusion bag, use a sterile syringe to extract about 15 ml saline into the test drug, by the oscillator or artificial vibration for about 5min, completely dissolved and then injected back to the administration of the infusion bag with a sterile syringe, gently shaking and mixing, and then intravenously titrated for 30min ± 10min.~The first dose should be completed as soon as possible after randomization; the second dose should not be less than 6 hours from the start of the first dose, but not more than 12 + 1h; each subsequent dose interval of 12 ± 1h (calculated using the fixed time of administration as the baseline point and each dose should not be less than 6 hours from the start of the last dose); 10 consecutive days of treatment, a total of 20 times."
62509059|NCT00867048|EXPERIMENTAL|Early ART|Initiate ART immediately following randomization
62706807|NCT05701826|EXPERIMENTAL|Treatment group B1|HRS3797 for injection
62509060|NCT00867048|ACTIVE_COMPARATOR|Deferred ART|Defer ART until the CD4+ count declines to \<350 cells/cu mm or AIDS develops
62509061|NCT06099990|EXPERIMENTAL|dalpiciclib+ abiraterone+ prednisone|
62706808|NCT05701826|EXPERIMENTAL|Treatment group B2|HRS3797 for injection
62706809|NCT05701826|EXPERIMENTAL|Treatment group C1|HRS3797 for injection
62706810|NCT05701826|EXPERIMENTAL|Treatment group C2|HRS3797 for injection
61976181|NCT01967251|EXPERIMENTAL|Udenafil 50 mg|Udenafil 50 mg, tablets, orally, once daily for 12 weeks.
61976182|NCT01967251|EXPERIMENTAL|Udenafil 75 mg|Udenafil 75 mg, tablets, orally, once daily for 12 weeks.
62145074|NCT05678725|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|the direct current stimulation lasted 20 minutes and was delivered at 2mA during the SRT, targeting at the primary motor cortex. EEG should be acquired before and after the stimulation session.
62509062|NCT06099990|PLACEBO_COMPARATOR|placebo+abirarerone+prenisone|
62509063|NCT05943041|EXPERIMENTAL|GB104: Dose level 1|Dose escalation cohort includes patients with CRC who completed curative colectomy and planned therapy. 3 to 6 patients will be enrolled per escalating dose levels.
62509064|NCT05943041|EXPERIMENTAL|GB104: Dose level 2|Dose escalation cohort includes patients with CRC who completed curative colectomy and planned therapy. 3 to 6 patients will be enrolled per escalating dose levels.
62509065|NCT05943041|EXPERIMENTAL|GB104: Dose level 3|Dose escalation cohort includes patients with CRC who completed curative colectomy and planned therapy. 3 to 6 patients will be enrolled per escalating dose levels.
62509066|NCT02850172|EXPERIMENTAL|Walk, eat, & breathe group|"Participants in the experimental group will receive Walk, Eat, \& Breathe at initiation of CCRT and ends before curative surgery."
62509067|NCT02850172|NO_INTERVENTION|Control group|Participants in the control group received usual care.
62509068|NCT02776553|EXPERIMENTAL|Active (physical training program)|physical activity + behavioral therapy + nutritional intervention
62509069|NCT02776553|ACTIVE_COMPARATOR|Control|nutritional intervention
62509070|NCT06603181|EXPERIMENTAL|Group A|Conventional Treatment Patients in this group will be given activity modification and home exercise program training, including stretching and eccentric strengthening exercises. Patients will be asked to perform the exercise treatment in 3 sets of 10 repetitions. Additionally, a splint will be recommended to rest the arm.
62509071|NCT06603181|EXPERIMENTAL|GroupB|Conventional Treatment and Phonophoresis Patients in this group will receive phonophoresis treatment in addition to a home exercise program and splint. A US device (Intelect 2776 Combo; Chattanoga Group, Inc, Chattanoga, TN) will be used for phonophoresis. The gel containing 10% naproxen will be mixed with aquasonic us gel to better deliver the drug through the body. Continuous mode at 1watt/cm2 1mhz frequency will be applied around the lateral epicondyle for 5 minutes. Sessions will be applied 5 sessions per week for 2 weeks.
62706811|NCT04862312|EXPERIMENTAL|VideoDine|Use of video chat to eat a meal with a dining partner.
61967077|NCT06298110|EXPERIMENTAL|PRP group|on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
61967078|NCT06298110|NO_INTERVENTION|Control group|the patients received no topical treatment in the subcutaneous tissue or the skin before closure during surgery
61967079|NCT05518539||The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
61967080|NCT06498401|EXPERIMENTAL|intervention group|The intervention group will receive the gut microbiota targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly healthy diet guidance for the same duration. The intervention will span three months, followed by a three-month follow up period.
61967081|NCT06498401|NO_INTERVENTION|control group|The control group will continue routine follow-up and health education practices.
61967082|NCT06373302||Exercise Therapy|Patients who are advised by their clinician to undertake exercise therapy as their treatment for peripheral arterial disease
61967083|NCT06373302||Angioplasty|Patients undergoing angioplasty for treatment of peripheral arterial disease, as advised by their clinician.
61967084|NCT01202474|EXPERIMENTAL|insulin glulisine and insulin glargine|insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)
61967085|NCT04109794|ACTIVE_COMPARATOR|E-CTG|Envelope connective tissue graft
61967086|NCT04109794|ACTIVE_COMPARATOR|SCAF|Semilunar connective tissue graft
61967087|NCT03321123|EXPERIMENTAL|CRA treatment|"The drug for this trial is autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1). The dose is 2x10e6 \~2x10e7 MB-CART19.1/kg.~A leukapheresis for the patient will be performed for MB-CART19.1 generation. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells."
61967088|NCT06501066|EXPERIMENTAL|Phase I Treatment Arm|umbilical cord mesenchymal stem cells, 100×10\^6 cells/subject, single treatment by intravenous infusion in phase I.
61967089|NCT06501066|EXPERIMENTAL|Phase II Treatment Arm|umbilical cord mesenchymal stem cells, 100×10\^6 cells/subject, single treatment by intravenous infusion in phase II.
61967090|NCT06501066|PLACEBO_COMPARATOR|Phase II Placebo Arm|Peripheral IV infusion of placebo at baseline.
61967091|NCT01293721|NO_INTERVENTION|control|
61967092|NCT01293721|EXPERIMENTAL|Treatment|Receive vibration therapy
61967093|NCT04763798|EXPERIMENTAL|Dominant|All subjects will receive the three stretching techniques on dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will be one week. Stretching exercises will be perform in a random order. A random-number generator will be used for randomization
61967094|NCT04763798|ACTIVE_COMPARATOR|Non dominant|All subjects will receive the three stretching techniques on non dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will bé one week. Stretching exercises will be perform in a random order. A random-number generator will bé used for randomization
61967095|NCT02966028|EXPERIMENTAL|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
61967096|NCT02966028|EXPERIMENTAL|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
61967097|NCT02966028|PLACEBO_COMPARATOR|Matching Placebo|Placebo arm: 2 vials of physiological saline
61967098|NCT04885972|EXPERIMENTAL|Resiniferatoxin|7.5 mcg, 10 mcg, 12.5 mcg, 15 mcg, or 20 mcg in 5 mL injected once intra-articularly
61967099|NCT04885972|ACTIVE_COMPARATOR|Zilretta|32 mg in 5 mL injected once intra-articularly
61967100|NCT04885972|PLACEBO_COMPARATOR|Placebo|5 mL injected once intra-articularly
61967101|NCT05300620|EXPERIMENTAL|Original Shoe Liner|This condition will be administered by inserting the original liner in the shoe and have the participants run with this shoe condition.
61967102|NCT05300620|EXPERIMENTAL|Custom Foot Orthotic made out of Ethyl Vinyl Acetate material|This condition will be administered by inserting a custom EVA orthotic in the shoe and have the participants run with this shoe condition.
61967103|NCT05300620|EXPERIMENTAL|Custom Foot Orthotic made of thermoplastic poly-urethane material|This condition will be administered by inserting a custom TPU orthotic in the shoe and have the participants run with this shoe condition.
61967104|NCT05300620|EXPERIMENTAL|Hybrid - Orthotic made of EVA and TPU material|This condition will be administered by inserting a custom EVA/TPU orthotic in the shoe and have the participants run with this shoe condition.
61967105|NCT03547869|EXPERIMENTAL|Active tDCS|Active tDCS
61967106|NCT03547869|SHAM_COMPARATOR|Sham tDCS|Sham tDCS
61967107|NCT00848081|PLACEBO_COMPARATOR|Placebo|
61967108|NCT00848081|EXPERIMENTAL|Tadalafil|
61967109|NCT00664391|EXPERIMENTAL|1|
61967110|NCT00075010|EXPERIMENTAL|Decitabine + Valproic acid|Decitabine 15 mg/m\^2 by vein over 1 hour times 10 days
61967111|NCT03254004|EXPERIMENTAL|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
61967112|NCT02781493|EXPERIMENTAL|Prucalopride group|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
61967113|NCT02781493|PLACEBO_COMPARATOR|Placebo group|2 mg Placebo plus 2 L Polyethylene Glycol regimen
61967114|NCT03032315|EXPERIMENTAL|TAH(80/10/12.5) tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide(80/10/12.5) tablet
62706812|NCT05901272|OTHER|Implementation strategy bundle 1|Local clinical champion and learning collaborative.
61967115|NCT03032315|ACTIVE_COMPARATOR|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
61967116|NCT00694993|EXPERIMENTAL|Subjects receiving GSK1004723 + placebo in cohort I and II|Eligible subjects will receive GSK1004723 nasal spray with single doses of 50 micrograms, 100 micrograms, 200 micrograms, 500 micrograms and 1000 micrograms. Subjects will also receive placebo nasal spray.
61967117|NCT00694993|EXPERIMENTAL|Subjects receiving GSK1004723 200 micrograms in cohort III|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 200 micrograms given once daily for 14 days.
61967118|NCT00694993|EXPERIMENTAL|Subjects receiving placebo in cohort III|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
62509072|NCT06603181|EXPERIMENTAL|Group C|Conventional Treatment and Ekstrakorporeal shock wave therapy Patients in this group will receive ESWT treatment in addition to a home exercise program and splint. ESWT; With the MODUS ESWT system, 2 sessions per week will be applied to the lateral epicondyle (2.4 bar intensity, 15 Hz frequency, 1500 pulses) for 2 weeks (Modus ESWT® RadialShockwaveTherapy).
62509073|NCT00965016|SHAM_COMPARATOR|No Hypothermia, No intervention, ECMO|No hypothermia used during ECPR
62706813|NCT05901272|OTHER|Implementation strategy bundle 2|Local clinical champion, learning collaborative, and external facilitation.
61967119|NCT00694993|EXPERIMENTAL|Subjects receiving GSK1004723 1000 micrograms in cohort IV|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 1000 micrograms given once daily for 14 days.
62706814|NCT00966459|OTHER|1|
62706815|NCT06289374||The LABS study (Bioresource 2: Longitudinal)|200 patients following oesophagogastric cancer resection recruited into BIORESOURCE 1. Following surgery at 3 months, 6 months, 1 year and 2 years: saliva, urine, blood, breath and quality of life questionnaires will be collected.
61967120|NCT00694993|EXPERIMENTAL|Subjects receiving placebo in cohort IV|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
61967121|NCT02992106|OTHER|Normal weight during pregnancy|"Offspring of 156 women with a normal weight during their pregnancy recruited by Bogaerts et al, in 3 belgian hospitals. Results of maternal data published in 2013. Now the children will be recruited. This group wil function as a control group.~All participating children will undergo the same examinations:~* Parental questionnaires~* Blood sample~* Urine sample~* Anthropometric measurements~* Abdominal ultrasound (fat mass)~* EndoPAT"
61967122|NCT02992106|OTHER|Obese mothers without intervention|"This subgroup will be compiled of the offspring of women recruited in two different studies. First of all there is the offspring of 65 women from the cohort that was recruited by Guelinckx et al, data published in 2010. This population was recruited in the University hospital of Leuven as control group for women receiving lifestyle interventions during pregnancy. Secondly there are children of 63 women from the cohort of Bogaerts et al of 2013 that had a BMI \> 29 kg/m² during their singleton pregnancy.~All participating children will undergo the same examinations:~* Parental questionnaires~* Blood sample~* Urine sample~* Anthropometric measurements~* Abdominal ultrasound (fat mass)~* EndoPAT"
61967123|NCT02992106|OTHER|Obese mothers & lifestyle intervention|"This one will also be a composition of study subjects of two different study cohorts. Firstly there are children of about 100 Belgian women that were included in the DALI cohort, a European randomized controlled trial. All of them underwent a lifestyle intervention during pregnancy, concerning diet and/ or exercise. Secondly there is the offspring of the other subgroup of the cohort recruited by Guelinckx et al. 130 women were divided into 2 groups which underwent lifestyle interventions during pregnancy.~All participating children will undergo the same examinations:~* Parental questionnaires~* Blood sample~* Urine sample~* Anthropometric measurements~* Abdominal ultrasound (fat mass)~* EndoPAT"
61976183|NCT01967251|PLACEBO_COMPARATOR|Placebo|Udenafil placebo-matching tablets, orally, once daily for 12 weeks.
61976184|NCT01876342|EXPERIMENTAL|Open repair|Open minimal repair (OMR) of Sportsman's hernia using 2-0 continuous sutures
61976185|NCT01876342|ACTIVE_COMPARATOR|Endoscopic TEP repair|Totally Endoscopic extraperitoneal repair (TEP)using lightweight mesh
61976186|NCT06314568||Patients with vaginal cancer|Patients affected by vaginal cancer
62145075|NCT05678725|SHAM_COMPARATOR|Sham Group with No Actual Stimulation|the procedure of this protocol lasted 20 minutes and was delivered at 0mA during the SRT. EEG should be acquired before and after the stimulation session.
62509074|NCT00965016|ACTIVE_COMPARATOR|Hypothermia, intervention, ECMO|Hypothermia + intervention
62509075|NCT00965016|ACTIVE_COMPARATOR|Hypothermia, no intervention, ECMO|Hypothermia without intervention after ECMO
62509076|NCT01396421|EXPERIMENTAL|OPC-34712 [Brexpiprazole] High Dose|Higher Dose, tablet, once daily, for six weeks
62509077|NCT01396421|EXPERIMENTAL|OPC-34712 [Brexpiprazole] Middle Dose|Middle Dose, tablet, once daily, for six weeks
62706816|NCT04965584||Active Crohn's disease group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited, and patients with CDAI score ≥ 150 were included in this group.
62706817|NCT04965584||Crohn's disease remission group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological features and histological features were recruited, and patients with CDAI score \< 150 were included in this group.
62706818|NCT04965584||Healthy control group|Normal healthy people were randomly recruited as the control group
62509078|NCT01396421|EXPERIMENTAL|OPC-34712 [Brexpiprazole] Low Dose|Lower Dose, tablet, once daily, for six weeks
62509079|NCT01396421|PLACEBO_COMPARATOR|Placebo|Placebo, once daily, for six weeks
62509080|NCT03203772|EXPERIMENTAL|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
62509081|NCT00949195||COPD patients|COPD patients with severe obstruction performed the tests.
62509082|NCT00949195||Healthy subjects|Age-matched healthy subjects performed the same test also.
62706819|NCT04856878|EXPERIMENTAL|Intervention|Standard of care (SOC) + single-dose intravenous vancomycin 15mg/kg
62706820|NCT04856878|NO_INTERVENTION|Control|Standard of care (SOC)
62706821|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
62509083|NCT05624528|EXPERIMENTAL|Tolcapone|100mg of tolcapone twice daily for two weeks, then 200mg tolcapone twice daily for the remaining six weeks.
62706822|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
62706823|NCT02143284|EXPERIMENTAL|Endoscopy exploratory single arm|Exploratory single arm, the system will be used in otherwise standard procedures, and will be reviewed in terms of performance, usability, ease of use and safety.
61967124|NCT02992106|OTHER|History of bariatric surgery|"The PABAS cohort (Pregnancy After Bariatric Surgery) provides children of 49 women who underwent bariatric surgery before their singleton pregnancy. The women were included in five Flemish hospitals before 15 weeks of pregnancy. Furthermore we will recruit the offspring of 200 women that are recruited in the ongoing AURORA cohort (bAriatric sUrgery Registration in women Of Reproductive Age). Women in this cohort are recruited from the start of their process undergoing bariatric surgery and are followed until after their pregnancy.~All participating children will undergo the same examinations:~* Parental questionnaires~* Blood sample~* Urine sample~* Anthropometric measurements~* Abdominal ultrasound (fat mass)~* EndoPAT"
61967125|NCT05131646||Cohort 2 (Low-mid Dose) Extension|Subjects who were administered by suprachoroidal injection 0.10 mg CLS-AX in cohort 2 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
62350681|NCT06299579|PLACEBO_COMPARATOR|Placebo control group|"Placebo, freeze-dried powder, 80mg, 160mg/dose Before the test drug is used, from the specification of 100 ml saline infusion bag, use a sterile syringe to extract about 15 ml saline into the test drug, by the oscillator or artificial vibration for about 5min, completely dissolved and then injected back to the administration of the infusion bag with a sterile syringe, gently shaking and mixing, and then intravenously titrated for 30min ± 10min.~The first dose should be completed as soon as possible after randomization; the second dose should not be less than 6 hours from the start of the first dose, but not more than 12 + 1h; each subsequent dose interval of 12 ± 1h (calculated using the fixed time of administration as the baseline point and each dose should not be less than 6 hours from the start of the last dose); 10 consecutive days of treatment, a total of 20 times."
62350682|NCT04084340|EXPERIMENTAL|Anodal tDCS + Exercises therapies|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA"
62350683|NCT04084340|SHAM_COMPARATOR|Sham tDCS + Exercises therapies|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA"
62350684|NCT00438893|OTHER|A portfolio of cholesterol-lowering foods|Dietary advice to consume a dietary portfolio of cholesterol-lowering foods
62350685|NCT05367219|EXPERIMENTAL|Air sterilizer|The invesitigators will monitore smoke and try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the experimental group.
62350686|NCT05367219|NO_INTERVENTION|Control|The control group was monitored for smoke during the endoscopic gastrointestinal surgery without any intervention.
62350687|NCT01862432|EXPERIMENTAL|immediate skin-to-skin|
62350688|NCT01862432|NO_INTERVENTION|control|
62350689|NCT01564667|EXPERIMENTAL|Attention Bias Modification Treatment|Attention bias modification training using a computerized spatial attention task (dot-probe) designed to alter threat-bias attention patterns away from threat.
62350690|NCT01564667|ACTIVE_COMPARATOR|Attentional Control Training|Attention control training using a computerized spatial attention taks (dot-probe) counter balances training toward and away from threat.
62350691|NCT00735670|EXPERIMENTAL|Venlafaxine|Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder. The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week. While this was the standard protocol, study drug tapering was individualized based on side effects and the clinical judgment of the prescriber.
62350692|NCT00735670|PLACEBO_COMPARATOR|Placebo|Placebo capsules were compounded by filling a matching gelatin capsule with lactose. Titration up and down followed the same schedule as the treatment group.
62350693|NCT05698121|EXPERIMENTAL|Intervention|The intervention group will use an eHealth application during the waiting period before cardiac rehabilitation starts.
62350694|NCT05698121|NO_INTERVENTION|Control|The control group will go through the usual waiting period before the start of cardiac rehabilitation.
62350695|NCT01877824|EXPERIMENTAL|Fast-track training|A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
62350696|NCT01877824|NO_INTERVENTION|Control|Follows the existing training program without intervention. Video recording of the trainee performing a open groin hernia repair and a laparoscopic cholecystectomy procedure at start end end of first training year.
62350697|NCT04968964|EXPERIMENTAL|Cohort 1: Scheduled to receive first line therapy|"* Scheduled to receive 1st line therapy with endocrine therapy + any FDA-approved CDK 4/6 inhibitor~* Serum samples (analyzed using DiviTum® TKa) at Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months. Treating physician will evaluate the patient \& review any updated results of the institutional standard of care monitoring tests. Following receipt of DiviTum® TKa value, the treating physician will review the preceding locked Study Care Plan and record any changes"
62509084|NCT05624528|PLACEBO_COMPARATOR|Placebo|100mg of placebo twice daily for two weeks, then 200mg of placebo twice daily for the remaining six weeks.
62509085|NCT02018094|ACTIVE_COMPARATOR|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
62706824|NCT05332704|EXPERIMENTAL|Part A, Active|
62706825|NCT05332704|PLACEBO_COMPARATOR|Part A, Placebo|
62706826|NCT05332704|EXPERIMENTAL|Part B, Active|
62706827|NCT05332704|PLACEBO_COMPARATOR|Part B, Placebo|
62706828|NCT05332704|EXPERIMENTAL|Part C, Active|
62706829|NCT05332704|PLACEBO_COMPARATOR|Part C, Placebo|
62350698|NCT04968964|EXPERIMENTAL|Cohort 2: Currently receiving first line therapy|"* 1st line therapy with endocrine therapy + any FDA-approved CDK 4/6 inhibitor for ≤ 24 months with stable disease~* Serum samples (analyzed using DiviTum® TKa) at Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months. Treating physician will evaluate the patient \& review any updated results of the institutional standard of care monitoring tests. Following receipt of DiviTum® TKa value, the treating physician will review the preceding locked Study Care Plan and record any changes"
62706830|NCT05458531||Patients with an inflammatory disease taking immune-suppressing medication|Aged 18 years and over, able to give consent, diagnosed with one of the above inflammatory conditions and currently treated with one of the following immune-suppressing treatments for six months or longer: methotrexate, azathioprine, 5-acetyl salicylates, sulfasalazine, mycophenolate mofetil, leflunomide or biologics.
62706831|NCT05458531||Healthcare professionals|Consultants, general practitioners (GPs), nurse specialists, practice nurses and pharmacists with experience of prescribing and monitoring long-term immune-suppressing treatments for the above inflammatory diseases
62706832|NCT01021800|EXPERIMENTAL|Cell infusion|
62706833|NCT05114928||Progression Group (P-group)|Eyes that showed progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 7 eyes).
62706834|NCT05114928||No Progression Group (NP-group)|Eyes that showed no progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 11 eyes).
62706835|NCT01511302|EXPERIMENTAL|RNS60-BD 0.25|RNS60 in combination with Budesonide 0.25mg/2ml concentration
62706836|NCT01511302|EXPERIMENTAL|RNS60-BD 0.5|RNS60 in combination with Budesonide 0.5mg/2ml concentration
62706837|NCT01511302|PLACEBO_COMPARATOR|NS-BD 0.5|Normal Saline control (NS) in combination with Budesonide 0.5mg/2ml concentration
62706838|NCT01649193||Chronic Respiratory Disease|Any patient with a chronic respiratory disease referred for pulmonary rehabilitation
61967126|NCT05131646||Cohort 3 (High-mid Dose) Extension|Subjects who were administered by suprachoroidal injection 0.50 mg CLS-AX in cohort 3 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
61967127|NCT05131646||Cohort 4 (High Dose) Extension|Subjects who were administered by suprachoroidal injection 1.0 mg CLS-AX in cohort 4 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
61967128|NCT01919723|ACTIVE_COMPARATOR|Ticagrelor and Eptifibatide bolus|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
62350699|NCT04968964|EXPERIMENTAL|Medical Oncologists|-Will be completing the Study Care Forms at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months.
61967129|NCT01919723|ACTIVE_COMPARATOR|Ticagrelor & Eptifibatide bolus+infusion|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
61967130|NCT04236830|EXPERIMENTAL|Silver diamine fluoride/ potassium iodide group|Riva Star Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia
62350700|NCT02252237||Children with glucocorticoids|Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic
62350701|NCT01915108|NO_INTERVENTION|group R0|remifentanil Ce of 0 ng/ml
62350702|NCT01915108|ACTIVE_COMPARATOR|group R0.5|remifentanil Ce of 0.5 ng/ml
62350703|NCT01915108|ACTIVE_COMPARATOR|group R1.0|remifentanil Ce of 1.0 ng/ml
62350704|NCT01915108|ACTIVE_COMPARATOR|group R1.5|remifentanil Ce of 1.5 ng/ml
62350705|NCT05518799|OTHER|Patients with prostate cancer|
62350706|NCT05518799|OTHER|Male patients with other types of solid tumours|
62350707|NCT01975246|EXPERIMENTAL|Telmisartan+amlodipine+HCTZ|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
62350708|NCT01975246|ACTIVE_COMPARATOR|Telmisartan+amlodipine|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
62350709|NCT02102984|ACTIVE_COMPARATOR|covered stents|endoscopic placement of covered biliary stents
62350710|NCT02102984|ACTIVE_COMPARATOR|uncovered biliary stents|endoscopic placement of uncovered biliary stents
62350711|NCT01178346|EXPERIMENTAL|NicVAX|Experimental vaccine
62350712|NCT01178346|PLACEBO_COMPARATOR|Placebo|Placebo vaccine
62350713|NCT01440907|EXPERIMENTAL|Intervention Group|Those age 65 or older who are discharged from Maimonides Medical Center to home during the study period and enrolled in the Care Coordination Program
62706839|NCT06505226|EXPERIMENTAL|In person with live music|Cohort 1 will be guided through in-person meditation. Participants in all cohorts will be asked to attend one of the weekly sessions offered twice a week for the entirety of the 8 weeks for at least 1 hour. Participants will also be given access and asked to listen to virtual music-backed mindfulness guided meditations to listen to between in- person sessions.
62706840|NCT06505226|EXPERIMENTAL|In person with headphones|Cohort 2 (also in-person) will experience this same meditation as Cohort 1 concurrently through headphones (in a space separate from Cohort 1). Participants in all cohorts will be asked to attend one of the weekly sessions offered twice a week for the entirety of the 8 weeks for at least 1 hour. Participants will also be given access and asked to listen to virtual music-backed mindfulness guided meditations to listen to between in- person sessions.
61967131|NCT04236830|EXPERIMENTAL|Silver diamine fluoride group|Advantage arrest TM, Elevate Oral Care, USA
62706841|NCT06505226|EXPERIMENTAL|Virtual participation|Cohort 3 will be participating virtually by following along to the guided meditation via a password-protected Zoom room. Participants in all cohorts will be asked to attend one of the weekly sessions offered twice a week for the entirety of the 8 weeks for at least 1 hour. Participants will also be given access and asked to listen to virtual music-backed mindfulness guided meditations to listen to between in- person sessions.
62706842|NCT04658485|ACTIVE_COMPARATOR|Active tDCS|
62706843|NCT04658485|PLACEBO_COMPARATOR|Sham tDCS|
62706844|NCT00642291|EXPERIMENTAL|1|Treatment naive pediatric patients (Group 1: ages 3 to 24 months)were to receive emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if \>=7 to \<15kg; 10/2.5 mg/kg BID if \>=15 to \<=40 kg)
61967132|NCT04236830|ACTIVE_COMPARATOR|Resin modified glass ionomer cement group|Riva light cure, SDI, Bayswater, Australia
61967133|NCT01513161|ACTIVE_COMPARATOR|TRK-820 5μg|Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days
61967134|NCT01513161|ACTIVE_COMPARATOR|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg capsule \& one placebo capsule)by oral route once daily for 14 days
61967135|NCT01513161|PLACEBO_COMPARATOR|Placebo|Taking Placebo(two placebo capsule) by oral route once daily for 14 days
61967136|NCT02108353|ACTIVE_COMPARATOR|Melatonin 2mg|The study medication will be compared to placebo control.
61967137|NCT02108353|PLACEBO_COMPARATOR|Placebo|The study medication will be compared to placebo control.
61967138|NCT01009125|EXPERIMENTAL|$2 cash incentive|
61967139|NCT01009125|EXPERIMENTAL|$5 cash incentive|
61967140|NCT05577481|SHAM_COMPARATOR|functional MRI-guided iTBS(sham group)|The stimulating site of the left DLPFC is targeted based on functional MRI, where the most negative functional connectivity with the left pgACC. The MNI coordinate is (-10, 42, 6).
61967141|NCT05577481|EXPERIMENTAL|functional MRI-guided iTBS (pgACC-DLPFC)|The stimulating site of the left DLPFC is targeted based on functional MRI, where the most negative functional connectivity with the left pgACC. The MNI coordinate is (-10, 42, 6).
62350714|NCT01440907|NO_INTERVENTION|Control Group|Those age 65 or older who are discharged from Maimonides Medical Center to home
61967142|NCT01265277||at home|Infants 0-3 months who will stay at home with a parent
61967143|NCT01265277||child care|Infant 0-3 months who will attend a licensed child care center
61967144|NCT01958008|EXPERIMENTAL|BI 113608 low dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
62350715|NCT00906867||Vocal cord dysfunction|Patients with suspicion of VCD
62350716|NCT02241928|EXPERIMENTAL|Stem Cell|Bone marrow mononuclear cell transplantation
62350717|NCT05317013|EXPERIMENTAL|Group A - 100 mg CBD|100 mg CBD per day
62350718|NCT05317013|EXPERIMENTAL|Group B - 300 mg CBD|300 mg CBD per day
62350719|NCT05317013|PLACEBO_COMPARATOR|Group C - Placebo|Placebo
62706845|NCT00642291|EXPERIMENTAL|2|Treatment naive or experienced pediatric patients (Group 2: ages 7 to 12 years; Group 3: ages 13-17 years) received emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
61967145|NCT01958008|EXPERIMENTAL|BI 113608 medium dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
62145076|NCT00005799|EXPERIMENTAL|Treatment (chemotherapy, TBI, HSCT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO BID on days 0-40 with taper to day 96. Patients with mixed chimerism, persistent or progressive disease, and no evidence of graft-versus-host disease and who have been off immunosuppression for at least 2 weeks undergo DLI over 30 minutes. DLI may be repeated every 65 days for up to 3 doses."
62350720|NCT03593863|NO_INTERVENTION|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
62350721|NCT03593863|EXPERIMENTAL|Intervention Group|Physical Education (PE) Programme
62706846|NCT02196350|EXPERIMENTAL|Intervention A: Diet|Intervention A: One week of very low calorie diet, 12 weeks of low calorie diet; exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen).
62706847|NCT02196350|EXPERIMENTAL|Intervention B: Exercise|"Intervention B: Combination of strength and endurance training, 3 x per week 60 minutes according to the Exercise Program Diabetes (Beweegprogramma Diabetes).~Healthy isocaloric diet."
62706848|NCT02196350|EXPERIMENTAL|Intervention C: Diet and Exercise|"Intervention C: one week very low calorie diet, followed by 12 weeks healthy isocaloric diet.~One week exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen) followed by 12 weeks strength and endurance training (3 x per week 60 minutes) according to the Exercise Program Diabetes (Beweegprogramma Diabetes)"
61967146|NCT01958008|EXPERIMENTAL|BI 113608 high dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
61967147|NCT00488176|ACTIVE_COMPARATOR|1|monteluksat sodium
61967148|NCT00488176|ACTIVE_COMPARATOR|2|cetirizine
61967149|NCT00488176|ACTIVE_COMPARATOR|3|montelukast sodium and cetirizine
61967150|NCT00488176|PLACEBO_COMPARATOR|4|placebo
61967151|NCT01980368|EXPERIMENTAL|Group I (Tai Chi Easy)|Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.
61967152|NCT01980368|ACTIVE_COMPARATOR|Group II (educational control)|Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.
61967153|NCT00622791||CABG group|Patients undergoing coronary artery bypass graft with cardiopulmonary bypass
61967154|NCT00622791||OPCAB group|Patients undergoing off-pump coronary artery bypass graft
61967155|NCT02509156|EXPERIMENTAL|Allo-MSCs|Target dose of 100 million allo-MSCs
61967156|NCT02509156|PLACEBO_COMPARATOR|Placebo|Buminate solution
61967157|NCT02266121|ACTIVE_COMPARATOR|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks"
62145077|NCT04417075|EXPERIMENTAL|Impacto|This is the mobile app to be developed and evaluated in this project.
62350722|NCT04943172|EXPERIMENTAL|VenoValve|Subjects who receive VenoValve implant
62350723|NCT04776421||ileostomy group|
62350724|NCT05859048|ACTIVE_COMPARATOR|Investigational arm guided by NT-proBNP result|NT-proBNP drawn and if level elevated (\>125 pg/ml) a study visit with artificial intelligence (AI) echocardiogram, electrocardiogram (ECG), and heart failure (HF) focused examination conducted
62350725|NCT05859048|NO_INTERVENTION|Routine care arm|Participants will be remotely monitored for number of heart failure events
62350726|NCT02814695|NO_INTERVENTION|Control|First fraction was control, 0.1ml of liquefied semen mixed with 0.1ml Ham's F10 medium and incubated at 37o C for 30 minutes.
61967158|NCT02266121|PLACEBO_COMPARATOR|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
61967159|NCT04580953|EXPERIMENTAL|Treatment with CardiaCareTM RR2|
61967160|NCT05833191|EXPERIMENTAL|Auricular vagus stimulation|Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid.
61967161|NCT05833191|EXPERIMENTAL|Tibial Nerve Stimulation|Transcutaneous tibial nerve stimulation (TTNS) is reported to be beneficial for fecal and urinary incontinence. A review of the literature showed that there are very few studies using TTNS that have been shown to be effective for constipation.
61967162|NCT04620993||Group 1: pregnant women with pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy and have pelvic girdle pain.
61967163|NCT04620993||Group 2:pregnant women without pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy but have not pelvic girdle pain.
61967164|NCT04620993||Group 3: healthy women|This group will consist of healthy women who have not been pregnant.
61967165|NCT05240456|EXPERIMENTAL|Intervention|This arm will receive standard behavioral therapy plus Mirabegron with adjusted-dose regimen (25-50 mg), patients of 20-40 kg will receive 25-50 mg once a day; patients \>40 kg will receive 50 mg once a day, for three months.
61967166|NCT05240456|ACTIVE_COMPARATOR|Control|This arm will receive will receive standard behavioral therapy plus Solifenacin with a daily dosage of (2.5-10 mg/kg), for three months.
61967167|NCT06054698|EXPERIMENTAL|HRS9531 injection|
62706849|NCT02196350|NO_INTERVENTION|Control - Historical data|Historical data from the GPs Information System from 60 newly diagnosed type 2 diabetes patients in the last five years will be used as control.
62706850|NCT05957627|EXPERIMENTAL|Saleem's intervention|Early tenotomies and serial casting were used in Saleem's technique to reduce foot deforming forces. It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia.The foot is placed in a serial cast close to its natural anatomical position following tenotomies at first visit. children are evaluated after 1 week.This technique necessitates 4 to 5 casts on average. DB shoes were advised when the foot casting was finished, and a 6-month follow-up with the patient was conducted.
61967168|NCT06054698|PLACEBO_COMPARATOR|HRS9531 injection Placebo|
61967169|NCT00844389|ACTIVE_COMPARATOR|NIR light|Group of patients stimulated with near to infrared light daily stimulation
61967170|NCT00844389|PLACEBO_COMPARATOR|Green light|Group of patients stimulated with green light.
62350727|NCT02814695|EXPERIMENTAL|Vit E supplementation|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
62350728|NCT02814695|EXPERIMENTAL|Yeast supplementation|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) Yeast extraction and incubated at 37o C for 30 minutes.
62350729|NCT02814695|EXPERIMENTAL|Vit C supplementation|fractions (Vit. C. 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02, 0.04, 0.06 mg/ml) Vitamin C respectively and incubated at 37o C for 30 minutes.
61967171|NCT03971370|EXPERIMENTAL|Experimental 1|
61967172|NCT03971370|EXPERIMENTAL|Experimental 2|
61967173|NCT03971370|ACTIVE_COMPARATOR|Positive Control|
61967174|NCT03789318|ACTIVE_COMPARATOR|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (CA-008 5 mg): the surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
61967175|NCT03789318|PLACEBO_COMPARATOR|Placebo for Cohort 1|"Cohort 1:~Placebo comparator is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
61967176|NCT03789318|ACTIVE_COMPARATOR|CA-008 10 mg (0.1 mg/mL)|Cohort 2 (CA-008 10 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
62350730|NCT02272283|ACTIVE_COMPARATOR|Angio-guided PCI|"Patients allocated to angio-guided PCI are having Percutaneous Coronary Intervention (PCI) with stent implantation guided by routine angiography alone.~Documentary (comparator) intravascular imaging with Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) is performed. The PCI-operator is blinded to the image aquisitions, and the analysis is performed offline later."
62509086|NCT02018094|ACTIVE_COMPARATOR|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
62706851|NCT01474109|ACTIVE_COMPARATOR|macitentan 3mg|macitentan 3mg tablet once daily
62706852|NCT01474109|ACTIVE_COMPARATOR|macitentan 10mg|macitentan 10mg tablet once daily
62706853|NCT01474109|PLACEBO_COMPARATOR|placebo|matching placebo once daily
61967177|NCT03789318|ACTIVE_COMPARATOR|CA-008 15 mg (0.15 mg/mL)|Cohort 3 (CA-008 15 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
61967178|NCT03789318|PLACEBO_COMPARATOR|Placebo for Cohorts 2 and 3|"Cohorts 2 \& 3:~Placebo comparator in each cohort is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
62509087|NCT02018094|ACTIVE_COMPARATOR|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
62509088|NCT02018094|ACTIVE_COMPARATOR|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
61967179|NCT00468182||1|MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
61967180|NCT00468182||2|MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
61967181|NCT06347835|EXPERIMENTAL|symbiotic and whey protein intervention|This group received dietary guidance, symbiotic and whey protein intervention for 12 weeks
61967182|NCT06347835|EXPERIMENTAL|whey protein intervention|This group received dietary guidance and whey protein intervention for 12 weeks
62509089|NCT06616376|EXPERIMENTAL|Experimental Group|AES was redressed within the 21st day after the operation
62509090|NCT06616376|NO_INTERVENTION|Control Group|The AES was dressed within the 10st day after the operation remained in the patient until the sutures
62509091|NCT06439199||Azacytidine and Venetoclax|"40 patients treated with Azacytidine and Venetoclax +/- another molecule according to the following schedule:~* Azacytidine 75 mg/m² D1 to D7 SC~* Venetoclax: 400 mg/day orally in 1 dose between 14 and 28 days per cycle. The cycles will be 28 days long and will be carried out until relapse or death. Cytokine assays will be carried out on D1, D8, D15 and D22 of each cycle for 2 cycles."
62706854|NCT01198626|EXPERIMENTAL|JNJ-32729463|
61967183|NCT06347835|PLACEBO_COMPARATOR|control|This group received dietary guidance and maltodextrin for 12 weeks
61967184|NCT05578391|EXPERIMENTAL|Convalescent plasma|
61967185|NCT05578391|NO_INTERVENTION|Conventional treatment|
61967186|NCT01606514|EXPERIMENTAL|Child, Parenting, & Parent Web-Intervention|Bounce Back Now Child, Parenting, \& Parent Psychoeducation \& Self-Help Web-Intervention.
62509092|NCT06439199||Azacytidine|"20 patients treated with Azacytidine +/- another molecule according to the following schedule:~• Azacytidine 75 mg/m² D1 to D7 SC The cycles will be 28 days long and will be carried out until relapse or death. The cytokine assays will be carried out on D1, D8, D15 and D22 of each cycle for 3 cycles.~The duration of follow-up for a patient is 12 months from day 1 of the first cycle."
62509093|NCT05647707|NO_INTERVENTION|Conventional Group|"This group will comprise 36 patients who will receive conventional supportive treatment for the management of acute CO poisoning that include the following:~* Airway: maintaining clear patent airways.~* Breathing:~* High-flow normobaric oxygen (NBO)~* Hyperbaric oxygen (HBO) (if indicated).~* Mechanical ventilation ( if required).~* Circulation: intravenous fluids, and treatment of arrhythmias according to ECG abnormalities."
62509094|NCT05647707|EXPERIMENTAL|L-Carnitine Group|The 36 patients will receive conventional supportive care as in the conventional group in addition to IV L-carnitine.
62509095|NCT00414349|EXPERIMENTAL|1|
62509096|NCT00414349|ACTIVE_COMPARATOR|2|
62509097|NCT00414349|EXPERIMENTAL|3|
62509098|NCT05972018|EXPERIMENTAL|RSB LB/B|Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS) (30mL per side)
62509099|NCT05972018|ACTIVE_COMPARATOR|RSB/RSC Ropivacaine|"Rectus Sheath Block: Total 60mL of 0.2% ropivacaine (3 vials) (30mL per side)~+ Rectus Sheath Catheter intermittent hourly boluses of 0.2% ropivacaine 10mL/hr per side"
62509100|NCT04385095|ACTIVE_COMPARATOR|SNG001|inhalation using the I-neb device.
62706855|NCT01198626|ACTIVE_COMPARATOR|moxifloxacin|
61967187|NCT01606514|EXPERIMENTAL|Child & Parenting Web-Intervention|Bounce Back Now Child \& Parenting Psychoeducation and Self-Help Web-Intervention.
61967188|NCT01606514|NO_INTERVENTION|Child & Parent Web-based Assessment|Bounce Back Now Web-Based Symptom Assessment
61967189|NCT01748032|OTHER|Alternative Uses Training|In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
61967190|NCT01748032|OTHER|Word Association Training|In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.
61967191|NCT00804791|ACTIVE_COMPARATOR|Systane|One drop dispensed into each eye
61967192|NCT00804791|ACTIVE_COMPARATOR|Unisol|One drop dispensed into each eye
62509101|NCT04385095|PLACEBO_COMPARATOR|Placebo|inhalation using the I-neb device.
62509102|NCT00697970|EXPERIMENTAL|Group A|
62509103|NCT00697970|EXPERIMENTAL|Group B|
62706856|NCT01198626|EXPERIMENTAL|JNJ-32729463 Open-Label|subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
61967193|NCT01353326|ACTIVE_COMPARATOR|Cementless Hip Resurfacing|Patients randomized into the Cementless Hip Resurfacing Group will have their hip resurfaced with the cementless Cormet / Corin Hip Resurfacing System.
61967194|NCT01353326|ACTIVE_COMPARATOR|Cemented Hip Resurfacing|Patients randomized into the Cemented Hip Resurfacing Group will have their hip resurfaced with the cemented Conserve Plus Total Resurfacing Hip System.
61967195|NCT04104945|EXPERIMENTAL|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
61967196|NCT03861351|EXPERIMENTAL|Mini WELL Toric Ready intraocular lens|
62509104|NCT00697970|EXPERIMENTAL|Group C|
62509105|NCT00697970|EXPERIMENTAL|Group D|
62509106|NCT00697970|EXPERIMENTAL|Group E|
62509107|NCT00697970|ACTIVE_COMPARATOR|Group F|
62509108|NCT02400476|EXPERIMENTAL|Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
62509109|NCT02400476|EXPERIMENTAL|Budesonide and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
62706857|NCT02690142|EXPERIMENTAL|ABY-035 i.v.|Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
62706858|NCT02690142|EXPERIMENTAL|ABY-035 s.c.|Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.
62706859|NCT02690142|EXPERIMENTAL|ABY-035 i.v. in psoriasis patients|Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.
62706860|NCT02690142|EXPERIMENTAL|ABY-035 s.c. in psoriasis patients|Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections
61967197|NCT02037269||All participants|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
61967198|NCT04949477|ACTIVE_COMPARATOR|Group (D)|The patient will receive intranasal dexmedetomidine.
61967199|NCT04949477|ACTIVE_COMPARATOR|Group (P)|The patient will receive paracetamol orally.
61967200|NCT01276353|EXPERIMENTAL|1|
61967201|NCT01276353|ACTIVE_COMPARATOR|2|
61967202|NCT01332474||JCP|treatment of Equinus Foot due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older
61967203|NCT02584673|EXPERIMENTAL|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
61967204|NCT02584673|NO_INTERVENTION|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
62509110|NCT02400476|EXPERIMENTAL|Colestipol and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
62706861|NCT03372616||All participants|Aortic blood pressure, LV filling pressrue, and LV volume will be measured in all participants. Meanwhile, echocardiography and non-invasive aortic blood presure measurement will be performed. Three devices will be used in non-invasive aortic blood presure measurement, including Sphygmocor (AtCor Medical, Australia), PulsePen (DiaTecne SRL, Italy), and Mobil-O-Graph (IEM, Germany). In conclusion, all participants will receive invasive and non-invasive left ventricular diastolic function assessment, together with invasive and non-invasive aortic blood pressure assessment.
62706862|NCT03474276|ACTIVE_COMPARATOR|Control group|"Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).~200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old."
62706863|NCT03474276|ACTIVE_COMPARATOR|Azythromycin|Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.
62706864|NCT03474276|ACTIVE_COMPARATOR|Prebiotic|Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)
61967205|NCT04203238|EXPERIMENTAL|Potatoes Lean Meat (PLM)|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
61967206|NCT04203238|EXPERIMENTAL|Lean Meat Pulses (LMP)|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
61967207|NCT05209984|EXPERIMENTAL|Experimental drug (Sibutramine IR 15mg / Topiramate XR 75mg)|ADF1 Group Eurofarma drug association of sibutramine IR 15mg / topiramate XR 75mg
61967208|NCT05209984|EXPERIMENTAL|Experimental drug (Sibutramine IR 15mg / Topiramate XR 100mg)|ADF2 Group Eurofarma drug association of sibutramine IR 15mg (Sibus®) Topiramate XR 100mg from Eurofarma Laboratórios S.A..
61967209|NCT05209984|ACTIVE_COMPARATOR|Sibus (Sibutramine 15mg)|SIB Group Sibutramine 15mg
62706865|NCT00062764|EXPERIMENTAL|Pioglitazone|
61967210|NCT05209984|PLACEBO_COMPARATOR|Placebo Group|Placebo Group
61967211|NCT02324569|EXPERIMENTAL|Treatment Group I|One tablet of SYR-472 100 mg orally once weekly before breakfast
61967212|NCT02324569|EXPERIMENTAL|Treatment Group II|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
62706866|NCT02146378||Vyndaqel|
62706867|NCT03207347|EXPERIMENTAL|Cohort A|This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.
62706868|NCT03207347|EXPERIMENTAL|Cohort B|This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).
62706869|NCT00763828|EXPERIMENTAL|ThermoSuit-Induced Patient Cooling|The Life Recovery Systems ThermoSuit System will be used to cool STEMI patients under conditions of conscious sedation.
61967213|NCT01516385||spinal cord injury|
61967214|NCT01516385||other neurological conditions|
61967215|NCT01327898|EXPERIMENTAL|1|empowerment theory-based small group discussion
61967216|NCT01327898|ACTIVE_COMPARATOR|2|single session individual resilience counseling
61967217|NCT02314897|EXPERIMENTAL|LV pacing|Left ventricular pacing lead implanted via coronary sinus
61967218|NCT02314897|ACTIVE_COMPARATOR|RV pacing|Conventional right ventricular pacing lead.
61967219|NCT00935753|EXPERIMENTAL|Kuvan|10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
61967220|NCT00615758|EXPERIMENTAL|1|Tarceva
61967221|NCT03445104|EXPERIMENTAL|Huperzine A|Huperzine A will be provided in the form of a single capsule for oral ingestion.
61967222|NCT03445104|PLACEBO_COMPARATOR|Rice Flour|Placebo will be provided in the form of a single capsule for oral ingestion.
61967223|NCT03124875|EXPERIMENTAL|Treatment|Treated with the LimFlow System
61967224|NCT05284149|ACTIVE_COMPARATOR|H.S. Supplement|Patients taking Hirsutella Sinensis Nutrient Supplements
61967225|NCT05284149|PLACEBO_COMPARATOR|Placebo|Patients taking placebo
61967226|NCT04623138||Garmin Study Device Group|Individuals who are randomly assigned to receive the Garmin vívosmart® 4
61967227|NCT04623138||Empatica Study Device Group|Individuals who are randomly assigned to receive the Empatica E4
61967228|NCT04862000||Endometriosis or adenomyosis|participants suffering pelvic endometriosis, endometrioma, deep infiltrating endometriosis or adenomyosis
61967229|NCT01764321||Certolizumab Pegol treatment|Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
61967230|NCT01764321||Other Tumor Necrosis Factor TNF inhibitor treatment|Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
61967231|NCT02954237||AMPLATZER™ Cardiac Plug|Subjects who were implanted with AMPLATZER™ Cardiac Plug will be included in this arm.
61967232|NCT03548103|EXPERIMENTAL|Green Tea Extract|Green Tea Extract 500 mg per capsule
61967233|NCT03548103|PLACEBO_COMPARATOR|Placebo|Identical Placebo capsule
61967234|NCT05549570|EXPERIMENTAL|Reference group|Thirty minutes after the start of the breakfast, a single dose of the Reference formulation was administered with approximately 240 mL of water at ambient temperature
61967235|NCT05549570|EXPERIMENTAL|Test group|Thirty minutes after the start of the breakfast, a single dose of the Test formulation was administered with approximately 240 mL of water at ambient temperature
61967236|NCT01417273|ACTIVE_COMPARATOR|vitamin A, multiple sclerosis,|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A for 6 months and 10000 IU/day for next 6 months
61967237|NCT01417273|PLACEBO_COMPARATOR|placebo/Multiple Sclerosis|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
61967238|NCT03748147|ACTIVE_COMPARATOR|Control|Standard of care, misoprostol 25 mcg po every four hours
61967239|NCT03748147|EXPERIMENTAL|Intervention|Misoprostol 50 mcg po every four hours
61967240|NCT04367636|ACTIVE_COMPARATOR|Active Comparator: PSE + OCAT-sham|Psycho-education video + an active placebo training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected scrambled sentences task with online contingent feedback.
61967241|NCT04367636|EXPERIMENTAL|Experimental: PSE + OCAT|Psycho-education video + an attention training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback.
61967242|NCT04913402||Consultation|Patient who were administered sufentanil in acute trauma by paramedics after phone call consultation with medical doctor.
61967243|NCT04913402||Competency|Patient who were administered sufentanil in acute trauma by paramedics with competence to administer sufentanil without any consultation with medical doctor.
61967244|NCT00119054|OTHER|Arm 1|
61967245|NCT02662491|EXPERIMENTAL|vitamin D and calcium|daily oral vitamin D(3) (2000 IU) and calcium (600 mg) for 6 months
61967246|NCT02662491|EXPERIMENTAL|Calcium supplement|daily oral calcium (600 mg) for 6 months
61967247|NCT02662491|EXPERIMENTAL|vitamin D supplement|daily oral vitamin D(3) (2000 IU) for 6 months
61967248|NCT02662491|PLACEBO_COMPARATOR|Placebo|daily placebo tablet for 6 months
61967249|NCT01654341|NO_INTERVENTION|Usual Care Group|Subjects undergo usual standard of care
61967250|NCT01654341|EXPERIMENTAL|Intervention Group|Intervention with exercise, dietary and educational programs
61967251|NCT06290726||living donor liver transplantations with anti-HBc (+) grafts|No intervention(s) had been administered.
61967252|NCT06290726||living donor liver transplantations with anti-HBc (-) grafts|No intervention(s) had been administered.
61967253|NCT02851758|EXPERIMENTAL|Autologous mitochondria injection|All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).
61967254|NCT02603094|EXPERIMENTAL|clear fluids until premedication|allowed to drink until premedication, aprox 30 minutes before anaesthesia induction. Fasting for solids and non-clear fluids is six hours.
61967255|NCT02603094|ACTIVE_COMPARATOR|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction clear fluid Ingestion. Fasting for solids and non-clear fluids is six hours.
61967256|NCT02904330|EXPERIMENTAL|Single dose|The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.
62509111|NCT02400476|EXPERIMENTAL|Colestipol with Loperamide as needed|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
61967257|NCT04014712|EXPERIMENTAL|acute BH4/Tetrahydrobiopterin treatment|Oral supplement, Pill, 10 mg/kg of body weight
61967258|NCT04014712|PLACEBO_COMPARATOR|Placebo|Oral supplement, Pill, Placebo pill with inert excipient
61967259|NCT00751751|EXPERIMENTAL|1|oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks
61967260|NCT00751751|ACTIVE_COMPARATOR|2|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.
61967261|NCT04851314|ACTIVE_COMPARATOR|ICU certified ventilator|Participants assigned to receive ventilation with the ICU certified ventilator
61967262|NCT04851314|ACTIVE_COMPARATOR|Non-ICU certified ventilator|Participants assigned to receive ventilation with the Non-ICU certified ventilator
61967263|NCT05385731|EXPERIMENTAL|Nordic Walking (NWG)|"The Nordic Walk program consists of 3 moments:~warm-up, walk, and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion."
61967264|NCT05385731|ACTIVE_COMPARATOR|Free walking (FWG)|"The free walking program consists of 3 moments:~warm-up, walk, and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.~Intervention administered:~24 sessions will be held twice a week, with each session taking an average of 60 minutes."
61967265|NCT05385731|NO_INTERVENTION|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
61976187|NCT03231033|EXPERIMENTAL|Pioglitazone|Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
61976188|NCT00143403|EXPERIMENTAL|1|
61976189|NCT00143403|ACTIVE_COMPARATOR|2|
62509112|NCT02400476|EXPERIMENTAL|Neratinib Dose Escalation 1|120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
61967266|NCT01089062|OTHER|Treatment A, then Treatment B, then Treatment C|"The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
61967267|NCT01089062|OTHER|Treatment A, then Treatment C, then Treatment B|"The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
61967268|NCT01089062|OTHER|Treatment B, then Treatment A, then Treatment C|"The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
61967269|NCT01089062|OTHER|Treatment B, then Treatment C, then Treatment A|"The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
61967270|NCT01089062|OTHER|Treatment C, then Treatment A, then Treatment B|"The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
61967271|NCT01089062|OTHER|Treatment C, then Treatment B, then Treatment A|"The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
61967272|NCT05407402|EXPERIMENTAL|laughter yoga|laughter yoga
61967273|NCT05407402|EXPERIMENTAL|funny videos,|funny videos,
61967274|NCT05407402|NO_INTERVENTION|control|control group. routine nursing care will be applied.
61967275|NCT05385536||Guidance clinical pathway|Sites will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification.
61967276|NCT05385536||Traditional clinical pathway|Sites will employ their current standard clinical care practices for suspected UTI, including Standard Urine Culture (SUC), Urine Analysis (UA), and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.
61967277|NCT01664533||Erlotinib|Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg.
61967278|NCT03954236|EXPERIMENTAL|topical ruxolitinib BID to left side of face/body|And topical moisturizer BID to right side of face/body.
61967279|NCT03954236|EXPERIMENTAL|topical ruxolitinib BID to right side of face/body|And topical moisturizer BID to left side of face/body.
61967280|NCT02108470|NO_INTERVENTION|Dental consultation without OHQoL assessment|Dentist performs consultation in the traditional method
61967281|NCT02108470|EXPERIMENTAL|Dental consultation using OHIP|Dental consultation using OHIP incorporating OHRQoL issues.
61967282|NCT01975753|ACTIVE_COMPARATOR|Intravenous morphine|one bolus of intravenous morphine
61967283|NCT01975753|EXPERIMENTAL|nebulized morphine|"one nebulized bolus of morphine"
61967284|NCT01975753|ACTIVE_COMPARATOR|fentanyl|"one nebulized bolus of fentanyl"
61967285|NCT03920579|EXPERIMENTAL|Sequence 1|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: D326, D337, D013(3 tabs, once)
61967286|NCT03920579|EXPERIMENTAL|Sequence 2|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 2(1 tab, once)
61967287|NCT03920579|EXPERIMENTAL|Sequence 3|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 1(1 tab, once)
61967288|NCT03920579|EXPERIMENTAL|Sequence 4|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: D326, D337, D013
62509113|NCT02400476|EXPERIMENTAL|Neratinib Dose Escalation 2|160 mg neratinib for the first 2 weeks, followed by 200 mg neratinib for the next 2 weeks, followed by 240 mg neratinib thereafter (C2D1 to End of treatment. Loperamide will be administered on an as-needed basis only.
62509114|NCT00955721|EXPERIMENTAL|Phase 1: GEMOX + Sorafenib|"Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib.~* Gemcitabine: 1000 or 750 mg/m2, IV, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~* Oxaliplatin: 100 or 75 mg/m2, IV, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~* Sorafenib: 200 mg, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
62706870|NCT06304415||Working General Population|Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken.
62706871|NCT05938686|EXPERIMENTAL|Interventional Group|Home_Based Digital Mindful Dance Program for 12 weeks
62706872|NCT05938686|NO_INTERVENTION|Control Group|Routine care for 12 weeks.
62706873|NCT06281418|PLACEBO_COMPARATOR|Control arm|2 ml IP normal saline (0.9 % NaCl)
62706874|NCT06281418|EXPERIMENTAL|Intervention arm|2ml IP granisetron (1 mg/mL)
61967289|NCT03920579|EXPERIMENTAL|Sequence 5|Period 1: D326, D337, D013(3 tabs, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: CKD-386 formulation 2(1 tab, once)
61967290|NCT03920579|EXPERIMENTAL|Sequence 6|Period 1: D326, D337, D013 (3 tabs, once)/ Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: CKD-386 formulation 1(1 tab, once)
61967291|NCT01564420||Intrathecal morphine|Patients were randomized for general anesthesia, and allocated in the control group and morphine intrathecal group.
61967292|NCT01564420||Control group|
61967293|NCT06531057||cross sectional|The population of the study consisted of 236 patients who underwent cholecystectomy, appendectomy, hernia surgery and bariatric surgery in the general surgery clinic of the specified hospital on the dates of data collection. Among these patients, 152 patients who met the sampling criteria and volunteered to participate in the study were included in the sample.
61967294|NCT03956732|EXPERIMENTAL|High protein yoghurt and vitamin D supplement|Subjects will receive high protein yoghurt and vitamin D tablets.
61967295|NCT03956732|EXPERIMENTAL|High protein yoghurt and placebo supplement|Subjects will receive high protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
61967296|NCT03956732|EXPERIMENTAL|Medium protein yoghurt and vitamin D supplement|Subjects will receive medium protein yoghurt and vitamin D tablets.
61967297|NCT03956732|PLACEBO_COMPARATOR|Medium protein yoghurt and placebo supplement|Subjects will receive medium protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
61967298|NCT04561193||Retrospective Cohort|Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test.
61967299|NCT02970422||Quartile 1 [Mild]|
61967300|NCT02970422||Quartile 2 [Moderate]|
61967301|NCT02970422||Quartile 3 [Severe]|
61967302|NCT02970422||Quartile 4 [Very Severe]|
61967303|NCT01850524|PLACEBO_COMPARATOR|Placebo + LenDex|Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib matching placebo capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).
61967304|NCT01850524|ACTIVE_COMPARATOR|Active Comparator: Ixazomib + LenDex|Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).
61967305|NCT05551039||Physicians treating patients with mCRC|Physicians provide case histories of mCRC patients
61967306|NCT04812691|EXPERIMENTAL|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in 1 x 10\^8 CAR+T cells dose level
61967307|NCT00821353|ACTIVE_COMPARATOR|RFCA|
61967308|NCT00821353|ACTIVE_COMPARATOR|Drug|
61967309|NCT05870020|EXPERIMENTAL|Adults with dystono-diskinetic syndrome treated by depp brain stimulation in the unit.|
62706875|NCT01259258|ACTIVE_COMPARATOR|varicocelectomy with dye|subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation
61967310|NCT02034110|EXPERIMENTAL|Dabrafenib + Trametinib|Subjects received Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib was administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib was administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects took their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle was 28 days in duration. Subjects continued treatment until an unacceptable toxicity, disease progression, or death occurs.
61967311|NCT03530098|NO_INTERVENTION|Control (Without-AI)|This is the control arm where no intervention is provided; represents current standard of care.
61967312|NCT03530098|EXPERIMENTAL|Experiment (With-AI)|"This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final."
61967313|NCT03846596||Evaluated|An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
62706876|NCT01259258|ACTIVE_COMPARATOR|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
61967314|NCT00952679|EXPERIMENTAL|experimental arm|
61967315|NCT04143321|EXPERIMENTAL|empagliflozin|following a two-week washout and complete SAQ and exercise tolerance test patients gave 25 mg empagloflozin and therafter SAQ and ETT was done
61967316|NCT04143321|PLACEBO_COMPARATOR|No drug|following a two-week washout and complete SAQ and exercise tolerance test patients gave placebo and therafter SAQ and ETT was done
61967317|NCT00709683||A|
61967318|NCT00634894|EXPERIMENTAL|Femara|
61967319|NCT00634894|PLACEBO_COMPARATOR|Placebo|
61976190|NCT01051050|OTHER|Mandatory use of surgery wiki|Mandatory participation in journal club wiki which will include adding to and reviewing the information posted on the wiki. Contribution to the wiki will be required at least once during the study period.
61976191|NCT01051050|OTHER|Voluntary use of surgery wiki|Voluntary participation in the journal club wiki
61976192|NCT04431648|EXPERIMENTAL|MRg-FUS MB Treatment|Patients with head and neck cancer will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
61967320|NCT02956577||T2|Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).
61967321|NCT02956577||T1|Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.
61967322|NCT02956577||Non-diabetic subjects|Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.
61967323|NCT06382584||Anti XA|adults treated with direct oral factor Xa inhibitors undergoing Femoral head fracture surgery
61967324|NCT02020330|ACTIVE_COMPARATOR|AL3days|Artemether-lumefantrine 3 days
61967325|NCT02020330|EXPERIMENTAL|AL5days|Artemether-lumefantrine 5 days
61967326|NCT00003325|OTHER|Sentinenal lymph node mapping|Sentinenal lymph node mapping
61967327|NCT03585998|EXPERIMENTAL|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide/Cisplatin) with durvalumab, and followed by consolidation durvalumab
61967328|NCT04166916|ACTIVE_COMPARATOR|Slow waves enhancing acoustic stimulation|During non-rapid eye movement (NREM) sleep, acoustic stimuli will be played to increase slow wave amplitude.
61967329|NCT04166916|SHAM_COMPARATOR|SHAM: no application of acoustic stimuli|During NREM sleep no acoustic stimuli will be played.
61967330|NCT04166916|ACTIVE_COMPARATOR|Slow waves decreasing acoustic stimulation|During NREM sleep acoustic stimuli will be played to decrease/modulate slow waves amplitude in a dose-dependent way (e.g. less pronounced than arm 1).
61967331|NCT00387023|EXPERIMENTAL|Zevalin + Rituximab|Rituximab 250 mg/m\^2 intravenous (IV) over 4-6 hours for 2 weeks, + Zevalin 5 millicurie (mCi)/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
62509115|NCT00955721|EXPERIMENTAL|Phase 2 - RPTD GEMOX + Sorafenib|"Recommended Phase Two Dose (RPTD) of Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib:~* Gemcitabine: Recommended Phase II Dose determined from Phase I, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~* Oxaliplatin: Recommended Phase II Dose determined from Phase I, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~* Sorafenib: Recommended Phase II Dose determined from Phase I, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
61967332|NCT01103791|EXPERIMENTAL|Cohort 1|Docetaxel-PNP 20mg/m2
61967333|NCT01103791|EXPERIMENTAL|Cohort 2|Docetaxel-PNP 35mg/m2
62706877|NCT06518304|OTHER|GentleWave|Featuring a handpiece CleanFlow technology, optimizes the delivery of irrigants: initially, a 3% NaOCl solution for 3 or 5 minutes, followed by a water rinse for 15 or 30 seconds, an 8% EDTA solution for 2 minutes, and a final distilled water rinse for 15 or 30 seconds. These solutions penetrate and eliminate necrotic tissue, debris, biofilm and bacteria, leaving the dentin intact and preserving the tooth structure. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices that extend into the maxillary sinus.
61967334|NCT01103791|EXPERIMENTAL|Cohort 3|Docetaxel-PNP 45mg/m2
61967335|NCT01103791|EXPERIMENTAL|Cohort 4|Docetaxel-PNP 60mg/m2
61967336|NCT01103791|EXPERIMENTAL|Cohort 5|Docetaxel-PNP 75mg/m2
62706878|NCT06518304|OTHER|Control group|Conventional Syringe Irrigation (CSI), which delivers irrigants (NaOCl, EDTA) through a needle-syringe system. After local anesthesia, the tooth will be isolated with a rubber dam. The pulp chamber will be accessed using ultrasound, eliminating all cavities, restorations with microfiltration or creating access through metal crowns. All canals will be cleaned and shaped with rotary files until at least a canal size of 20.6 or 25.04 is achieved within 0.5 to 1 mm of the apical end. Between each file, 6% NaOCl will be used to disinfect and clean the waste channels. Each canal will then be soaked in 17% EDTA for 1 minute, rinsed with 6% NaOCl, and finally subjected to a final saline rinse. The canals will be filled with root canal sealant and gutta-percha.
61967337|NCT01103791|EXPERIMENTAL|Cohort 6|Docetaxel-PNP 90mg/m2
62145078|NCT04417075|ACTIVE_COMPARATOR|Dejar de Fumar Asistente|This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto.
62145079|NCT02114515|OTHER|Usual Care|"Hospital usual care~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge."
62509116|NCT01117467|EXPERIMENTAL|Solo|Students will perform their simulation scenario solo and receive feedback within the group
62509117|NCT01117467|EXPERIMENTAL|Paired|Students will be paired with one of their peers for this simulation scenario
62509118|NCT04963608||non-interventional study|Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
62509119|NCT02593487|EXPERIMENTAL|Rosuvastatin 10mg/d group|rosuvastatin 10mg table by mouth, qd
62509120|NCT02593487|ACTIVE_COMPARATOR|Rosuvastatin 20mg/d group|rosuvastatin 20mg table by mouth, qd
62509121|NCT06369506|ACTIVE_COMPARATOR|Gingival Phenotype Classification 1|According to the GT of the point corresponding to the GT of the gingival sulcus base
62509122|NCT06369506|ACTIVE_COMPARATOR|Gingival Phenotype Classification 2|According to the average GT of three points
61967338|NCT04860453|EXPERIMENTAL|Affected participants with 5 or more discordant cancers - WES|"Affected individuals with a family history of 5 or more discordant cancers in unilateral descent with a 3-generation pedigree will receive SOC CLIA/CAP multicancer panel (DNA collected via blood draw or punch biopsy) to examine monogenic variant diagnostic yield. Eligible participants (families with no mutations and at least 2 affected and 1 non-affected family members) may move forward with WES.~Any identified monogenic variants of interest will be sent to an industry partner with CLIA/CAP certification for validation. A 6-month follow-up visit will take place during which variants will be discussed and participants who underwent gHFI variant counting (those who were not considered a gene candidate) will have results explained. Appropriate genetic counselling, recurrence risk, and additional clinical referrals will be made as necessary"
61967339|NCT04860453|ACTIVE_COMPARATOR|SOC genetic counseling (routine clinical care)|"Affected individuals (cancer) with a family history suggestive of a known hereditary syndrome or meeting NCCN criteria for germline testing will receive SOC CLIA/CAP multicancer panel in order to examine monogenic variant diagnostic yield (retrospective data)~This arm would also include prospective participants from the 5 or more discordant cancers group who DID have a variant identified and therefore did not move on to WES."
61967340|NCT00964860|NO_INTERVENTION|Brushing Only|Brushing Only with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice
61967341|NCT00964860|EXPERIMENTAL|Brushing + Flossing|Brushing with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice, plus flossing with Glide floss
61967342|NCT00171730|EXPERIMENTAL|Pasireotide s.c. Overall|Participants received pasireotide as a daily subcutaneous (s.c) injection, every 12 hours at 9:00 AM and 9:00 PM at the dose at which the biochemical control was achieved (either 200, 400, or 600 microgram (μg)) for as long as the participant benefited from the treatment, and there were no safety or tolerability concerns (median duration of 22.7 months).
61967343|NCT00494078|ACTIVE_COMPARATOR|1|Patients randomised to this arm are treated with intensive insulin therapy guided by the continuous glucose monitoring system.
61967344|NCT00494078|ACTIVE_COMPARATOR|2|intensive insulin therapy guided by an algorithm
61967345|NCT04254471|EXPERIMENTAL|Dose escalation (AL3810 + carboplatin + etoposide)|Phase II:Participants will receive AL3810 orally in combination with carboplatin and etoposide during the Cycles 1-4 . AL3810 dose escalated form 5mg to 10mg step-up to determine the recommended dose of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
61967346|NCT04254471|EXPERIMENTAL|AL3810+ carboplatin + etoposide|Phase III:Participants will receive AL3810(recommended dose will be determined by safety monitoring committee (SMC) in Phase II) orally in combination with carboplatin and etoposide during the Cycles 1-4. Thereafter, participants will receive maintenance AL3810 until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
61967347|NCT04254471|PLACEBO_COMPARATOR|Placebo+ carboplatin + etoposide|Phase III:Participants will receive placebo orally in combination with carboplatin and etoposide during the induction Cycles 1-4. Thereafter, participants will receive maintenance placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
61967348|NCT01785550||Control Group|No intervention to be performed.
62350731|NCT02272283|EXPERIMENTAL|OCT-guided PCI|"After obtaining an angiographic optimal result, patients allocated to OCT-guided PCI have guiding Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) performed. Online image interpretation is performed by a dedicated OCT-analyst and the PCI-operator. If the OCT reveals; 1) under expansion of the stent with a minimal stent area (MSA) \<90% of the distal/proximal reference vessel lumen area and/or; 2) significant acute incomplete stent apposition (defined as more than or equal to 3 stent struts detached \>140 microns from the underlying vessel wall), and/or; 3) edge dissection(s) causing significant reduction in minimal lumen area(s) (MLA \<4 mm2) and/or, 4) significant residual stenosis (MLA \<4 mm2) at the proximal and/or distal reference segment(s), additional intervention is encouraged. The degree of optimization based upon OCT findings is left to the judgement of the PCI-operator."
62509123|NCT05967871|EXPERIMENTAL|Fecal Microbiota Transpant|Participants will receive a Fecal Microbiota transplant Infusion via participants' existing enteral feeding tubes or via elective upper endoscopy (with infusion into the duodenum). Most patients with SBS at MCH and HSC have an existing enteral feeding tube (gastrostomy or jejunostomy tube).
62509124|NCT04440722||Transgender individuals|All transgender individuals referred to center of gender identity Odense
61967349|NCT01785550||Ultrasound Group|All will receive nerve and muscle ultrasound.
61967350|NCT04479423|EXPERIMENTAL|Soda water|400ml soda water was drunk to obtain good vision before undergoing MCE examination.
62350732|NCT02607332|EXPERIMENTAL|Paclitaxel|paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
62509125|NCT00330460|ACTIVE_COMPARATOR|Alendronate|Subjects in this arm will receive active ALN and placebo denosumab
62509126|NCT00330460|EXPERIMENTAL|Denosumab|Subjects in this arm will receive active denosumab and placbo ALN
62509127|NCT04760587||study group|smart devices in adolescent
62509128|NCT05390125||4B ward staff|Multidisciplinary staff members from a surgical ward in Cork University Hospital.
62509129|NCT05390125||Cedar ward staff|Multidisciplinary staff members from the Cedar ward in University Hospital Waterford with a similar case mix of patients to ward 4B in CUH.
62509130|NCT01566526||Patients Previously Treated with OZURDEX®|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
62509131|NCT02997878|EXPERIMENTAL|PSC patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
61967351|NCT04479423|NO_INTERVENTION|water|900ml clear water(100 ml water of simethicone solution was not included) was drunk to obtain good vision before undergoing MCE examination.
62350733|NCT06042842||group 1|healthy control
62509132|NCT02997878|EXPERIMENTAL|AIH patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
62509133|NCT02013531|EXPERIMENTAL|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
62509134|NCT06469619|NO_INTERVENTION|Control group|Standard care and rehabilitation.
61967352|NCT01906008|EXPERIMENTAL|Minocycline|Group 2 receives minocycline 200 mg orally for the first dose, then 100 mg orally every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
61967353|NCT01906008|PLACEBO_COMPARATOR|Placebo|Group 1 receives a placebo 200 mg orally for the first day of chemotherapy, then 100 mg doses every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
61967354|NCT00112320|ACTIVE_COMPARATOR|1|Standard PVR
61967355|NCT00112320|EXPERIMENTAL|2|PVR plus RV remodeling
61967356|NCT02699645|EXPERIMENTAL|Triple Pill (active treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
61967357|NCT02699645|PLACEBO_COMPARATOR|Placebo|Matched placebo
61967358|NCT04648956||Knee/Hip osteoarthritis|Patients referred for physical therapy rehabilitation
61967359|NCT06428669|NO_INTERVENTION|No nitropaste group|Participants get standard of care chest masculinizing surgery utilizing double incision and free nipple grafting surgery. They will get standard dressing applied, which includes Xeroform bolster over the nipple grafts + Tegederm over the bolster and surgical site and instructed not to remove the dressing until they come to clinic on POD5 for bolster take down.
61967360|NCT06428669|EXPERIMENTAL|Nitropaste group|Participants get standard of care chest masculinizing surgery utilizing double incision and free nipple grafting surgery. They will then get 2 packets of nitropaste applied (1 on each chest) around the free nipple graft and surgical sites. They will then get standard dressing applied, which includes Xeroform bolster over the nipple grafts + Tegederm over the bolster and surgical site and instructed not to remove the dressing until they come to clinic on POD5 for bolster take down.
62509135|NCT06469619|EXPERIMENTAL|Music group|Standard care and rehabilitation and music listening one hour a day during 4 weeks.
61967361|NCT01202396||ulcerative colitis patients with a pouch|"* ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis~* comparing patients with versus those without pouchitis~* no intervention"
61967362|NCT06372002|EXPERIMENTAL|Cognitive Stimulation Therapy|Participants assigned to the intervention group will undergo 14 CST sessions, twice a week, for 7 weeks, in addition to continuing their standard care. Participants will then receive the CST Maintenance program, which consists of 24 sessions, once a week for 24 weeks, in addition to continuing their standard care.
61967363|NCT06372002|NO_INTERVENTION|Control|Participants in the control group will maintain their standard care, participating in those activities previously assigned in their individual care plan.
62145080|NCT02114515|EXPERIMENTAL|Usual Care + PArTNER|"Navigator intervention: (Community health worker, peer-led telephone support line, usual care)~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge.~Community health worker: The community health worker provides social support, literacy appropriate education, and acts as a conduit between the patient and the patient's medical team~Peer-led telephone support line: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team."
62509136|NCT04048031|ACTIVE_COMPARATOR|Nutrafol Supplement Capsules|"NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal."
62509137|NCT04048031|PLACEBO_COMPARATOR|Placebo Capsules|The placebo capsules contain no active ingredients. Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
62539331|NCT00834496||1|"Our experience with the use of Sirolimus is delineated below. About 15% to 20% of our patients are currently switched to Sirolimus.Indications for conversion from calcinurin inhibitors (CNIs) to Sirolimus more than 90 days post liver transplantation include:~* CNI renal toxicity.~* Hepatic fibrosis on biopsy.~* CNI neurologic toxicity.~* Post transplant diabetes. Any of the above 4 indications makes a patient a candidate for conversion from CNIs to Sirolimus at or \> 90 days after liver transplantation."
62539332|NCT05199090|ACTIVE_COMPARATOR|MBL949 Arm 1|MBL949 one 3 mg dose followed by two doses of 6 mg followed by five doses of 4.5 mg
62539333|NCT05199090|ACTIVE_COMPARATOR|MBL949 Arm 2|MBL949 two 3 mg doses followed by six doses of 4.5 mg
61967364|NCT04541862||Critically ill patients|
61967365|NCT02418026|NO_INTERVENTION|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
61967366|NCT02418026|EXPERIMENTAL|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
61967367|NCT03516994|EXPERIMENTAL|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
61967368|NCT03516994|ACTIVE_COMPARATOR|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
61967369|NCT02385552||Experienced endoscopists|All of the experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rate every 3 months
62145081|NCT01972906|EXPERIMENTAL|Moxibustion treatment group|Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
62350734|NCT06042842||group 2|patient with hepatic cell carcinoma
62350735|NCT06042842||group 3|patient with non malignant liver diseased
61967370|NCT04448288|EXPERIMENTAL|Hamstring Group|Pretest-posttest experimental design. Subjects participated in three experimental trials on three different days. On day-I for static-stretching for 2 minutes (SS2), day-II for 4 minutes (SS4), and day-III for 8 minutes (SS8). Testing was conducted before (pre), immediately after (post), and at 10 and 20 min post stretching. MVCF was measured using strain gauze as main outcome measure. The SS trials involved varied repetitions of 30-s static-stretches and 20-s relax period. MVC force was assessed.
61967371|NCT02047890|EXPERIMENTAL|BAY1000394|Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).
61967372|NCT01584102|EXPERIMENTAL|Group 1|
61967373|NCT01584102|ACTIVE_COMPARATOR|Group 2|
61967374|NCT01087190|EXPERIMENTAL|INH treatment group|"* randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)~* INH 300 mg po qd for 9 months"
61967375|NCT01087190|NO_INTERVENTION|Control group|"* randomly allocated to control group in renal transplant recipients with ELISPOT (+)~* no treatment"
61967376|NCT01087190|NO_INTERVENTION|Observation group|"* allocated to observation group in renal transplant recipients with ELISPOT (-)~* no treatment"
61967377|NCT00697762|PLACEBO_COMPARATOR|003|Placebo tablet twice daily for 12 weeks
61967378|NCT00697762|EXPERIMENTAL|002|RWJ-333369 200 mg tablet twice daily for 12 weeks
61967379|NCT00697762|EXPERIMENTAL|001|RWJ-333369 100 mg tablet twice daily for 12 weeks
61967380|NCT00673465|EXPERIMENTAL|Treatment sequence 1: SCH 497079 → Placebo → Metformin|Participants received SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks followed by metformin daily for 4 weeks.
61967381|NCT00673465|EXPERIMENTAL|Treatment sequence 2: Placebo → Metformin → SCH 497079|Participants received placebo daily for 4 weeks followed by metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
62145082|NCT01972906|ACTIVE_COMPARATOR|Medicine control group|Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea
62145083|NCT00927706|EXPERIMENTAL|Immediate intervention|Subjects and their caregivers randomized to this arm receive the intervention immediately after baseline data is collected.
62145084|NCT00927706|EXPERIMENTAL|Delayed Intervention|Subjects and their caregivers who are randomized to this group will receive the intervention after baseline measurements are administered twice (6 weeks apart).
62145085|NCT00540111|OTHER|1|"Study of intervention, prospective,uncontrolled Group Number: 1~Group Type:Other - the subjects of group were compared the initial moment (M0 - moment without soluble fiber supplementation)with the others two moments: M1 (one month after soluble fiber supplementation) and M2 (four months after soluble fiber supplementation).~Group Description - HIV-positive individuals with hypertriglyceridemia (serum levels ≥ 200 to ≤ 500 mg/dL),who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study.~Intervention:Received 20g/day of soluble fiber® (partially hydrolyzed guar gum) for 4 months at pre-established times."
62145086|NCT05474313|EXPERIMENTAL|PrEP-3D|Use of Alto Pharmacy, PrEP-3D mobile app and home laboratory testing.
62145087|NCT05474313|OTHER|Control Arm|Participants in the control arm will receive standard of care PREP navigation.
62145088|NCT05266300||Retrospective|Historic group. Patients treated in the historic control group did not receive DPYD-genotype before treatment with fluorouracil, capecitabine, tegafur. They received standard start doses of 5-FU, capecitabine, tegafur.
62539334|NCT05199090|ACTIVE_COMPARATOR|MBL949 Arm 3|MBL949 one 12 mg dose followed by seven doses of 4.5 mg
61967382|NCT00673465|EXPERIMENTAL|Treatment sequence 3: Metformin → SCH 497079 → Placebo|Participants received metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks.
61967383|NCT00673465|EXPERIMENTAL|Treatment sequence 4: SCH 497079 → Metformin → Placebo|Participants received SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks followed by placebo daily for 4 weeks.
61967384|NCT00673465|EXPERIMENTAL|Treatment sequence 5: Placebo → SCH 49709 → Metformin|Participants received placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks.
61967385|NCT00673465|EXPERIMENTAL|Treatment sequence 6: Metformin → Placebo → SCH 497079|Participants received metformin daily for 4 weeks followed by placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
61967386|NCT00716885||CHF|"Informed consented participants are recruited among all patients admitted to the OLVG hospital.~Inclusion criteria:~* Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy~* Dyspnoe NYHA class III and IV~* Optimal and constant heart failure treatment according to the ESC guidelines~Exclusion criteria:~* Renal failure (creatinine \>1.70 mg/dl)~* Signs of infection or inflammation"
61967387|NCT00716885||Control|The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.
61967388|NCT05231395|EXPERIMENTAL|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
61967389|NCT05231395|SHAM_COMPARATOR|Control Group|Control group will be given breathing exercises as a home program for 8 weeks.
61967390|NCT02362217|EXPERIMENTAL|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10\^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10\^8 pfu at week 8.~Subjects: 8 healthy volunteers."
61967391|NCT02362217|EXPERIMENTAL|Group 2|"Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10\^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10\^8 pfu at week 8.~Subjects: 8 healthy volunteers."
61967392|NCT02362217|EXPERIMENTAL|Group 3|"Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10\^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10\^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10\^8 pfu and 1 dose MVA.HIVconsv 1 x 10\^8 pfu at week 8.~Subjects: 16 healthy volunteers."
62350736|NCT01975077|EXPERIMENTAL|A- 4mg QD|arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
62539335|NCT05199090|ACTIVE_COMPARATOR|MBL949 Arm 4|MBL949 one 1.5 mg dose followed by seven doses of 2.2 mg
62539336|NCT05199090|ACTIVE_COMPARATOR|MBL949 Arm 5|MBL949 one 3 mg dose followed by two doses of 6 mg followed by five doses of 7.5 mg
62539337|NCT05199090|PLACEBO_COMPARATOR|Placebo|Placebo to MBL949
61967393|NCT04953780|EXPERIMENTAL|Calaspargase pegol-mknl dose level 1|"Induction Phase (It usually lasts 29 days):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~* The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.~* A single cycle of consolidation may last between 4-8 weeks in duration."
61967394|NCT04953780|EXPERIMENTAL|Calaspargase pegol-mknl dose level 2|"Induction Phase (It usually lasts 29 days):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~* The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine(every 21 days ( per cycle).~* A single cycle of consolidation may last between 4-8 weeks in duration."
61967395|NCT04953780|EXPERIMENTAL|Calaspargase pegol-mknl dose level 3|"Induction Phase (It usually lasts 29 days):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High- dose Cytarabine.~* The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.~* A single cycle of consolidation may last between 4-8 weeks in duration."
61976193|NCT06473766|EXPERIMENTAL|Feasibility of RF data to compare RF data in ovarian masses|"To evaluate the feasibility of RF data in patients with ovarian masses with solid ultrasound morphology~1. To compare RF data in benign and malignant ovarian masses with ultrasound solid morphology. Histology will be the reference standard.~2. To compare RF data in primary invasive and metastases to the ovary.~3. To describe the reliability of RF data between different images of the same solid ovarian tumor."
61976194|NCT03970954|EXPERIMENTAL|1|Low-dose IL-2
62350737|NCT01975077|EXPERIMENTAL|B- 5mg once daily, 3wks on/1wk off|arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent
62350738|NCT05052528|EXPERIMENTAL|Dose level 1 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily and cyclophosphamide IV over 60 minutes daily on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
62350739|NCT05052528|EXPERIMENTAL|Dose level 2 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
62350740|NCT05052528|EXPERIMENTAL|Dose level 3 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -3 to -5 and cyclophosphamide IV over 60 minutes daily on day -5. Patients also receive CD19 CAR T cells IV on day 0.
62509138|NCT04048031|OTHER|Open Label 6 month Extension|"During the 6 month open label extension all 70 subjects will receive NUTRAFOL's Synergen Complex Plus® which is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for the six month extension with a substantial meal."
62509139|NCT00919178|EXPERIMENTAL|1|Participants will receive a single immunization for Dengue virus serotype 4 (DEN4)
62350741|NCT05052528|EXPERIMENTAL|Dose level 4 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on day -5. Patients also receive CD19 CAR T cells IV on day 0.
62509140|NCT00919178|PLACEBO_COMPARATOR|2|Participants will receive a single immunization in the form of placebo resembling vaccine for DEN 4
62509141|NCT05093881|EXPERIMENTAL|Cellgram-LC|Patients with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.
62509142|NCT06295094|EXPERIMENTAL|Pressurized intraperitoneal chemotherapy (PIPAC)|"In the intervention arm, conventional pressurized intraperitoneal chemotherapy (PIPAC) with cisplatin (10.5 mg/m2 body surface in 150ml saline) and doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through Medical Device Regulation (MDR) class IIb the CE-certified nebuliser by certified PIPAC surgeons directly after the completion of the minimally invasive gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is administered through a CE-certified nebulizer according to the manufacturer's manual and followed by 30 minutes of simple diffusion. The carbondioxide is evacuated through a closed system, and the abdominal wall is closed according to local surgical standards.~The same procedure is repeated, incorporating the same compounds and dose regimens six to eight weeks postoperatively and before the start of the adjuvant part of the perioperative systemic chemotherapy."
62509143|NCT06295094|NO_INTERVENTION|Standard|In the control arm, patients will undergo minimally invasive D2 gastrectomy
62350742|NCT05052528|EXPERIMENTAL|Dose level 5 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -5 to -1 and cyclophosphamide IV over 60 minutes daily on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
62350743|NCT05052528|EXPERIMENTAL|Dose level 6 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -1, and cyclophosphamide IV over 60 minutes on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
62706879|NCT04844333|EXPERIMENTAL|Extubation under deep anesthesia|When the patient is in sedation or anesthesia state, including no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the endotracheal tube is removed.
61967396|NCT04953780|EXPERIMENTAL|Calaspargase pegol-mknl dose level 4|"Induction Phase (It usually lasts 29 days):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~* The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~* The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~* The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine per cycle.~* A single cycle of consolidation may last between 4-8 weeks in duration."
61967397|NCT01491334||Asymptomatic|Asymptomatic women presenting at various ages without prolapse condition.
61967398|NCT01491334||Symptomatic|Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
61967399|NCT03764501|ACTIVE_COMPARATOR|Image fusion group (Image fusion)|Use image fusion system during surgery (Image fusion, ZedTrauma, LEXI Co., Ltd.)
61967400|NCT03764501|NO_INTERVENTION|Control group (ZedTrauma)|only use 3D preoperative planning (Zed Trauma, LEXI Co., Ltd.)
61967401|NCT06166303||Previous Cesarean Section|Subjects with one or more previous cesarean sections
61967402|NCT06166303||No Cesarean|Subjects scheduled for an elective or urgent cesarean, but no history of previous cesarean section
61967403|NCT06166355|EXPERIMENTAL|Cognitive-behavioral therapy plus VR-based body exposure and Attentional Bias Modification Training.|In this group, five sessions of VRE will be added to the usual CBT, as in the other experimental group, but, in addition, at the beginning of each of the exposure sessions, the training aimed at reducing the attentional bias will be carried out. The training will be developed through the visual selection of geometric figures that fit approximately with specific parts of the body. Each of these figures can have different colors. Specifically, the patient must detect and identify the figures that will appear in different parts of the avatar's body. In half of the trials, the shape of the figure must be discriminated and in the remaining 50%, the discrimination will be based on color. Throughout the training, the geometric figures will appear on weight-related body parts in 45% of the trials, and in another 45% of the trials, it will appear on non-weight-related body parts. In the remaining trials (10%), the test will appear on one of three neutral stimuli located next to the avatar.
61967404|NCT06166355|EXPERIMENTAL|Cognitive-behavioral therapy for anorexia and VR-based body exposure:|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, five sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions until a healthy BMI value is reached.
61967405|NCT06166355|ACTIVE_COMPARATOR|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the center in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
61967406|NCT00651794|ACTIVE_COMPARATOR|Control (NRP Curriculum with LFT and no team training)|Standard Neonatal Resuscitation Program (NRP) curriculum with no team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
61967407|NCT00651794|EXPERIMENTAL|NRP with LFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
61967408|NCT00651794|EXPERIMENTAL|NRP with HFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitations using high-fidelity simulators for high-fidelity training (HFT)
61967409|NCT06204744|EXPERIMENTAL|Home-based GRASP program|
61967410|NCT06204744|ACTIVE_COMPARATOR|Conventional occupational therapy home program|
61967411|NCT03146715|ACTIVE_COMPARATOR|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
62350744|NCT01777971||Patients with cirrhosis|Male and female subjects who have cirrhosis of the liver and diuretic-resistant ascites (based on International Ascites Clib criteria) and have been evaluated and approved to have a large-volume paracentesis as part of standard of care treatment.
61967412|NCT03146715|PLACEBO_COMPARATOR|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
61967413|NCT06219512|EXPERIMENTAL|CPET exercise prescription group|Formulate exercise prescription of cardiopulmonary exercise test (CPET) according to the principle of FITT \[frequency, intensity, time and type\]
61967414|NCT06219512|EXPERIMENTAL|6MWT exercise prescription group|Exercise prescription is set according to the recommendation of the Chinese expert consensus on the application of clinical norms of six-minute walking test
61967415|NCT06219512|ACTIVE_COMPARATOR|Regular exercise group|Carry out regular exercise as usual
61967416|NCT04742296|ACTIVE_COMPARATOR|Treatment group of low level laser therapy|
61967417|NCT04742296|PLACEBO_COMPARATOR|Sham group of low level laser therapy|
62350745|NCT00960258|EXPERIMENTAL|Arm 1|
62350746|NCT01511432|EXPERIMENTAL|Part A|Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.
62350747|NCT01511432|EXPERIMENTAL|Part B|Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state
62350748|NCT01737658|OTHER|Exercise Program upon enrollment|Subject will receive exercise intervention immediately upon enrollment to study
61967418|NCT01487551|EXPERIMENTAL|paquinimod|
61967419|NCT06507891|EXPERIMENTAL|TQ-A3334 tablets|TQ-A3334 tablets administered orally on day 1, 8, 15 in 21-day cycle.
61967420|NCT06507891|EXPERIMENTAL|TQ-A3334 tablets + Anlotinib capsules|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
61967421|NCT02727751|EXPERIMENTAL|50mg BID|Tenapanor, 50 mg BID (100 mg total)
61967422|NCT02573311|EXPERIMENTAL|men|
61967423|NCT03517956|EXPERIMENTAL|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.~Dose expansion (urothelial cancer):~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
61967424|NCT03287661|EXPERIMENTAL|Treatment Condition|An Online 8-week Acceptance-based Behavioural Therapy for chronic pain.
61967425|NCT03287661|NO_INTERVENTION|Wait-list Control Condition|Wait-list Control group (8-weeks)
62706880|NCT04844333|NO_INTERVENTION|Awake extubation|When the patient is in awake state, including bispectral index \>70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, the cough and swallowing reflex are obvious and the circulation is stable, the endotracheal tube is removed.
61967426|NCT00791245||1|DeNovo NT
61967427|NCT04572932|ACTIVE_COMPARATOR|group 1:Probiotic arm|first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks
61967428|NCT04572932|ACTIVE_COMPARATOR|Group 2:Placcebo arm|the second group received only itopridehcl 50mg by the same dose for four weeks.
61967429|NCT03700671|EXPERIMENTAL|High intensity interval training|HIIT was set at \> 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
61967430|NCT03700671|ACTIVE_COMPARATOR|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.
62350749|NCT01737658|OTHER|Exercise Program 6 months after enrollment|Subject will be enrolled into study and then receive exercise intervention 6 months after enrollment.
62350750|NCT03581929|EXPERIMENTAL|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
62350751|NCT03581929|PLACEBO_COMPARATOR|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
62350752|NCT04410757||Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply POCUS examinations in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
62706881|NCT05815602|EXPERIMENTAL|Ebastine verum and duspatalin placebo|
62706882|NCT05815602|ACTIVE_COMPARATOR|Duspatalin verum and ebastine placebo|
61967431|NCT05506085||Deep Brain Stimulation|Voice outcomes and Magnetic resonance imaging will be compared pre- and post-DBS (Deep brain stimulation) in patients with laryngeal dystonia and adductor laryngeal dystonia. The evaluators will be masked for analyzing the voice outcomes pre-and post-DBS
62706883|NCT00789555|EXPERIMENTAL|PATANASE|Olopatadine hydrochloride 0.6% nasal spray (PATANASE), two sprays in each nostril twice a day (morning and evening) for up to 12 months
61967432|NCT01244425|EXPERIMENTAL|FS VH S/D 500 s-apr|Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
61967433|NCT01244425|ACTIVE_COMPARATOR|Manual compression - Control|A dry surgical gauze swab will be used to apply by hand an even light pressure onto the oozing resection surface of the liver. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
61967434|NCT01773785|EXPERIMENTAL|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
61967435|NCT01366690|EXPERIMENTAL|Peer Support|Peer supporter assigned to participant.
61967436|NCT01366690|NO_INTERVENTION|Standard of Care|No peer assigned. Current standard of care.
61967437|NCT03707860||head and neck radiotherapy patients|(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.
61967438|NCT02445092|EXPERIMENTAL|Catheter prewashing|"Intervention: prewashing the catheter before IUI.~450 patients randomly included in this group will have their insemination catheter prewashed with the same media used to wash the sperm, prior to performing the insemination using the washed catheter."
61967439|NCT02445092|NO_INTERVENTION|Control group|450 patients randomly assigned in this group will have their insemination performed routinely, without washing the insemination catheter..
61967440|NCT04220684|EXPERIMENTAL|Conditioning Regimen|Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2g/ m2/day (days -6 to day -2)
61967441|NCT04220684|EXPERIMENTAL|Induction|Six doses of third-party-donor mbIL-21 expanded (KDS-1001) cells given thrice weekly for two weeks. Days may vary and KDS-1001 can be given from days 0 to 21
62350753|NCT04410757||No Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply routine bedside examination techniques in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
62350754|NCT01106742|EXPERIMENTAL|AndoSan, UC|AndoSan as a supplement to 10 UC patents
62350755|NCT01106742|EXPERIMENTAL|AndoSan, CD|AndoSan as a supplement to 10 CD patients.
62706884|NCT00789555|PLACEBO_COMPARATOR|Patanase Vehicle, pH 3.7|Olopatadine nasal spray vehicle, pH 3.7, two sprays in each nostril twice a day (morning and evening) for up to 12 months
62706885|NCT00789555|PLACEBO_COMPARATOR|Patanase Vehicle, pH 7.0|Olopatadine nasal spray vehicle, pH 7.0, two sprays in each nostril twice a day (morning and evening) for up to 12 months
61967442|NCT03725280||Transgender men I|Transgender men after testosterone treatment
61967443|NCT03725280||Transgender men II|Transgender men before testosterone treatment
61967444|NCT03725280||IVF- PCOS|IVF- PCOS patients with high testosterone levels
61967445|NCT03725280||Egg donors|IVF- egg donors patients
61967446|NCT03425123|EXPERIMENTAL|REP Group|All participants in this single arm study will receive Regenerative Endodontic Procedure (REP). It regenerates the root tip on recently erupted permanent teeth that did not complete root development due to pulp infection and necrosis by allowing cells to migrate from the surrounding periapical tissue and enter the pulp space. Cells contained within the intentional bleeding create at the root tip help in root completion as well as increasing the thickness of the canal walls over up to two years following the procedure.
61967447|NCT02760199|EXPERIMENTAL|89Zr-AMG211 and 89Zr-AMG211 PET|
61967448|NCT00284050|EXPERIMENTAL|Ranibizumab 0.3 mg|Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
61967449|NCT00284050|EXPERIMENTAL|Ranibizumab 0.5 mg|Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
61967450|NCT00284050|SHAM_COMPARATOR|Sham injection|Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
61967451|NCT00674544|NO_INTERVENTION|Control group|No intervention, regular kindergarten program
61967452|NCT00674544|EXPERIMENTAL|Intervention group|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
61967453|NCT02098759|EXPERIMENTAL|epilepsy early diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
61976195|NCT02953314|EXPERIMENTAL|Part A|"Participants weighing \<25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days.~Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days."
62145089|NCT05266300||Prospective|"Participants enrolled in the prospective group will give a blood sample for immediate DPYD genotyping. Once the results from these tests are in, the treating oncologist have immediate access to the participant's genetic test results and can make dosing decisions/changes to the participant's chemotherapy prescription. The recommended starting doses for 5-FU, capecitabine, tegafur are.~No DPYD-gene variant = normal starting dose (100%)~1 DPYD-gene variant (heterozygous) = Reduced starting dose (50%) Homozygous for 1 DPYD variant or compound heterozygous (\>1 variants) = Treatment with 5-FU, capecitabine, tegafur is not recommended ."
62145090|NCT03372252|EXPERIMENTAL|Successful weaning|Patients extubated after the success of the breathing test in spontaneous ventilation under artificial nose and always extubated after seven days.
62350756|NCT02773394||Group 1|Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.
62350757|NCT04961918|EXPERIMENTAL|Treatment Group|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
62350758|NCT00895648|EXPERIMENTAL|Alimta plus Cisplatin|
62350759|NCT04178135|EXPERIMENTAL|rLH supplementation from day 1 of stimulation|rLH supplementation from day 1 of stimulation
62350760|NCT04178135|ACTIVE_COMPARATOR|rLH supplementation from day 6 of stimulation|rLH supplementation from day 6 of stimulation
62350761|NCT02800486|EXPERIMENTAL|Intra-arterial Cetuximab with Re-Irradiation|Mannitol 20% 12.5ml over two minutes for blood brain barrier (BBB) disruption followed by Cetuximab administered intra-arterially for three doses at a dose of 250 mg/m2 combined with hypofractionated re-irradiation
62350762|NCT00976248|EXPERIMENTAL|RAD001|RAD001, oral, 10 mg, daily
62350763|NCT05479721||LITMUS Imaging Study Group|Patients within the European NAFLD Registry who have also consented to participate in the LITMUS Imaging study
62509144|NCT01883791|EXPERIMENTAL|SBIRT|The SBIRT condition will include the WHO's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and its accompanying brief intervention that uses motivational interviewing techniques to provide feedback, emphasize personal responsibility, give advice, provide a menu of options, convey empathy, and promote self-efficacy.
62350764|NCT03002103|EXPERIMENTAL|ET+P+G|
62350765|NCT03002103|ACTIVE_COMPARATOR|Control|
62509145|NCT01883791|OTHER|Health Education|The control group will receive a Health Education (HE) session, informational brochures and a contact information for addiction treatment sites that we will develop with Ventura County. The session will be administered in an individual format for 30-minutes and will address general health, wellness and lifestyle topics.
62509146|NCT00660088||1|10 gram x 7 days, then 20 gram x 7 days active ingredient of original formulation
62509147|NCT00660088||2|20 grams x 14 days active ingredient of original formulation
62706886|NCT02786407|ACTIVE_COMPARATOR|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose,dextran and gelatin.
61967454|NCT02098759|EXPERIMENTAL|standard epilepsy diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
61967455|NCT00811798|EXPERIMENTAL|Cervarix Group|
61967456|NCT05403905|EXPERIMENTAL|non-surgical treatment|The patient who was diagnosed with complete rupture of the ACL in the Institute of Sports Medicine of the Third Hospital of Peking University was informed by the doctor that there is a chance that the ACL may grow back after 6 weeks of strict bracing.
61967457|NCT05403905|ACTIVE_COMPARATOR|surgical treatment|"The patient who was diagnosed with complete rupture of the ACL in the Institute of Sports Medicine of the Third Hospital of Peking University was informed by the doctor that there is a chance that after 6 weeks of strict brace immobilization, the ACL may grow back without surgery. However, the choice was still made for immediate ACL reconstruction.~This group of patients underwent anterior cruciate ligament reconstruction surgery in the Third Hospital of Peking University."
61967458|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
61967459|NCT06140927|EXPERIMENTAL|Ketamine|"All subjects will be in a single arm. Patients will serve as their own control.~Patients will receive general anesthesia in the usual fashion for the indicated procedures. This anesthetic will be standardized between patients. All patients participating in the study will have neuromonitoring as part of their spine surgery as standard care. Baseline motor-evoked potential data will then be collected. Then study drug Ketamine will be administered as following:~* Step 1: 0.1 mg/kg bolus over 30 sec followed by infusion of 3mcg/kg/min (0.18 mg/kg/hr)~* Step 2: 0.3 mg/kg bolus over 30 sec followed by infusion of 15mcg/kg/min (0.9mg/kg/hr)~* Step 3: 0.85 mg/kg bolus over 30 sec followed by infusion at 50mcg/kg/min (3mg/kg/hr)~Motor Evoked Potentials will be collected for 5 times at minutes 2, 4, 6, 8, 10 after drug step."
61967460|NCT02376361|ACTIVE_COMPARATOR|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
61967461|NCT02376361|NO_INTERVENTION|Control Group|Control group will receive standard monitoring (standard care).
61967462|NCT04208789||Positive Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Positive Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
61967463|NCT04208789||Negative Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Negative Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
61967464|NCT03577691|EXPERIMENTAL|Training for use of web based Decision Aid|Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
61967465|NCT03577691|PLACEBO_COMPARATOR|No training for use of web based Decision Aid|Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
61967466|NCT04080414|EXPERIMENTAL|Home-based high-intensity interval training|
61967467|NCT04080414|ACTIVE_COMPARATOR|Home-based moderate-intensity continuous exercise|
62350766|NCT02849249|ACTIVE_COMPARATOR|One day schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in one day schedule. The maintenance dose (0.5 mL) is reached in one day.
62350767|NCT02849249|ACTIVE_COMPARATOR|Rapid schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in a rapid Schedule.The initation phase includes 3 weekly increasing doses till the maintenance dose of 0.5 mL is reached.
61967468|NCT03640845|EXPERIMENTAL|experimental group|Patient living in nursing homes a tele-expertise will be performed
61967469|NCT03640845|NO_INTERVENTION|control group|Patient living in nursing homes will performed a normal care.
62350768|NCT02823600|OTHER|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
61967470|NCT01745172|EXPERIMENTAL|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
62350769|NCT05605977|NO_INTERVENTION|Control group|regular early intervention
62509148|NCT00660088||3|10 grams x 7 days; then 20 grams x 7 days of low protein formulation
62509149|NCT00660088||4|20 grams x 14 days of low protein formulation
61967471|NCT04350489||Control|Periodontally healthy group
61967472|NCT04350489||Periodontitis|Patients with periodontitis
62350770|NCT05605977|EXPERIMENTAL|Traditional visual-motor training program|traditional visual-motor training program plus regular early intervention
62350771|NCT05605977|EXPERIMENTAL|Computerized visual-motor training program|computerized visual-motor training program plus regular early intervention
62509150|NCT00660088||5|10 grams x 7 days; then 20 grams x 7 days of high protein formulation
62509151|NCT00660088||6|20 grams x 14 days of high protein formulation
62509152|NCT00934596|EXPERIMENTAL|Lund de-airing|Lund de-airing technique
62509153|NCT00934596|ACTIVE_COMPARATOR|Carbon-dioxide insufflation|carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner
62509154|NCT03211039|OTHER|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
61967473|NCT00691418|ACTIVE_COMPARATOR|1|600 mg per day of docosahexaenoic acid (DHA)
61967474|NCT00691418|PLACEBO_COMPARATOR|2|Placebo
61967475|NCT01259505|EXPERIMENTAL|Safety|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
61967476|NCT01050426|ACTIVE_COMPARATOR|Group 1|UFT/LV + RT
61967477|NCT01050426|ACTIVE_COMPARATOR|Group 2|UFT/LV + RT + Cetuximab
61967478|NCT00468325|ACTIVE_COMPARATOR|Multi-slice Computed Tomography|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to a multi-slice computed tomography arm where they will receive a CT scan of their heart.
61967479|NCT00468325|ACTIVE_COMPARATOR|Standard of Care|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to the Standard of Care arm and receive rest-stress nuclear myocardial perfusion imaging test.
61967480|NCT06093295|EXPERIMENTAL|Left Dorsolateral Prefrontal Cortex (experimental)|This is the experimental condition where participants will receive theta burst stimulation to the left dorsolateral prefrontal cortex.
61967481|NCT06093295|PLACEBO_COMPARATOR|Vertex (control)|This is the control condition where participants will receive theta burst stimulation to the vertex.
61967482|NCT06334510||Approval consistency study|A total of 1050 recipients aged 18-59 years were enrolled in this study. Blood samples were collected before and 30 days after vaccination. Hemagglutination inhibition (HI) antibody to influenza virus was detected in the serum of all recipients to evaluate the inter-batch consistency of the vaccine.
61967483|NCT06334510||Safety and immunogenicity in a larger vaccination cohort aged 3 years and older|3850 recipients were enrolled in an open trial: safety observation after vaccination, follow-up for adverse events (AE) 30 minutes and 0-30 days after vaccination, and SAEs for 6 months after vaccination.
62350772|NCT04690257|EXPERIMENTAL|TICK-B group as Intervention group|"Experimental: TICK-B group~-Pediatric patients received TICK-B as a distraction in the TICK-B group"
61967484|NCT02468414|EXPERIMENTAL|MDGN201 TARGTEPO secreting EPO|MDGN201 TARGTEPO secreting EPO
61967485|NCT01652898|ACTIVE_COMPARATOR|Esmolol hydrochloride|Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
62509155|NCT03211039|OTHER|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
62509156|NCT05259904|EXPERIMENTAL|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 0a/1. Washout period of 4 to 6 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
62509157|NCT05259904|PLACEBO_COMPARATOR|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 0a/. Washout period of 4 to 6 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
61967486|NCT01652898|ACTIVE_COMPARATOR|ONO LDL50|ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
61967487|NCT01652898|EXPERIMENTAL|AOP LDLA202|AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
61967488|NCT01705639|EXPERIMENTAL|Melatonin|melatonin 4mg od for 3 months
62350773|NCT04690257|NO_INTERVENTION|Standard care provided group as control group|-Pediatric patients received standard care (routine care) in the control group.
62350774|NCT01606735|EXPERIMENTAL|Dose 1|
62350775|NCT01606735|EXPERIMENTAL|Dose 2|
62350776|NCT01606735|EXPERIMENTAL|Dose 3|
62509158|NCT02399631|EXPERIMENTAL|ERAS group|early recovery program with no preoperative mechanical bowel preparation, early diet initiation, and prevention of postoperative ileus after elective laparoscopic colon cancer surgery
62509159|NCT02399631|NO_INTERVENTION|Congrol group|Traditional, conventional perioperative treatment
62509160|NCT01010750|ACTIVE_COMPARATOR|LDX + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
61967489|NCT02740764|EXPERIMENTAL|Optimization of drug prescribing|The group with optimization program will have: (i) a medical history of the drug prescribing; (ii) analysis and pharmaceutical recommendations and (iii) preparation of a management plan. Notices will be sent only to referring physicians in this experimental group.
61967490|NCT02740764|NO_INTERVENTION|No intervention|This group will receive the current management of patients in geriatric or memory consultation, during which the intervention of a clinician pharmacist is not provided. There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital, but the recommendations will not be transmitted to the referring physicians of patients.
61967491|NCT02807532||atrial fibrillation group|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
61967492|NCT02807532||non-atrial fibrillation group|Patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
62509161|NCT01010750|ACTIVE_COMPARATOR|MAS-IR + LDX Placebo|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
62509162|NCT01010750|PLACEBO_COMPARATOR|Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
62509163|NCT06368557|EXPERIMENTAL|iCBT with planned feedback|Participants in this iCBT condition will receive written feedback from their therapist on assignments weekly. The participants will also be able to contact their assigned therapist through messages within the program and receive asynchronous support if needed. Participant depression and suicidality will also be continuously monitored using weekly questionnaires.
62539338|NCT05187130|EXPERIMENTAL|Intervention|Mindfulness-based breathing and music therapy
62539339|NCT05187130|NO_INTERVENTION|Control|No intervention has been made
62539340|NCT00858481|PLACEBO_COMPARATOR|1|Vehicle control
62539341|NCT00858481|ACTIVE_COMPARATOR|2|0.5% Spinosad creme rinse
62539342|NCT00858481|ACTIVE_COMPARATOR|3|1.0% Spinosad Creme Rinse
61967493|NCT05589922||Patients with abnormal modified Schober index|This group will include the patients with Ankylosing Spondylitis who have modified Schober index smaller than 5 cm
61967494|NCT05589922||Patients with normal modified Schober index|This group will include the patients with Ankylosing Spondylitis who have modified Schober index bigger than 5 cm
61967495|NCT03763253|ACTIVE_COMPARATOR|Control Arm: Standard of Care (SOC)|"Standard of Care (SOC) treatment as determined by treating physician (positive control) (androgen deprivation with or without docetaxel chemotherapy or other systemic standard of care treatment including but not limited to Abiraterone or Enzalutamide).~Radiotherapy to the prostate in this arm is defined as cytoreductive (for symptom control) in high volume (\>/=4) metastases or to mirror current accepted local radiotherapy dose regimens for men with low volume metastases (\<4 metastases).~Metastases directed therapy will not be permitted in the control arm. Palliative radiotherapy for symptom control or for prevention of fracture will be permitted as standard clinical practice."
61967496|NCT03763253|ACTIVE_COMPARATOR|Intervention Arm 1: Minimally Invasive Ablative Therapy (MIAT)|"MIAT to prostate in form of cryotherapy or high intensity focused ultrasound (HIFU), in addition to SOC systemic treatment. No local prostate radiotherapy will be given as part of this intervention. Radiotherapy can be given subsequently for palliative reasons.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
61967497|NCT03763253|ACTIVE_COMPARATOR|Intervention Arm 2: Radical Therapy|"Radical therapy in form of prostatectomy (any approach) or external beam radiotherapy (radical dose) in addition to SOC systemic treatment. Modality based on physician and patient preference and patient co-morbidities.~For patients undergoing radical prostatectomy no local prostate radiotherapy will be given as part of the intervention. Radiotherapy can be given subsequently for palliative reasons.~Radical radiotherapy doses in this arm will be higher than SOC.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
61967498|NCT06406283|EXPERIMENTAL|High-Intensity Functional Training (HIFT) Group|
61967499|NCT06406283|EXPERIMENTAL|Mindfulness Group|
61967500|NCT06406283|EXPERIMENTAL|Qigong Group|
61967501|NCT05453656|OTHER|exercise|live and on demand exercise sessions on the Kidney BEAM-KIDS platform
61967502|NCT03053323|EXPERIMENTAL|Lifestyle Intervention|
61967503|NCT05666492|EXPERIMENTAL|Less than 12 months PRP- Test|Patients randomized into the less than 12 months PRP arm will receive 3 doses of topical PRP each month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
62145091|NCT03372252|EXPERIMENTAL|Failure to wean|Patients who failed the breathing test in spontaneous ventilation under artificial nose and not extubated or patients extubated after the success of the weaning test in spontaneous ventilation under artificial nose but reintubated within seven days.
62145092|NCT05093894|ACTIVE_COMPARATOR|Group 1: Microlyte will be cut into strips and placed on the surgical incision|Microlyte will be cut into strips and placed on the surgical incision
62145093|NCT05093894|NO_INTERVENTION|Group 2: Nothing will be placed on the surgical incision|Nothing will be placed on the surgical incision
62350777|NCT02052934|EXPERIMENTAL|Cohort 1|Three sublingual (SL) doses of dMLT, 1 microgram (mcg), on Days 1, 15 and 29, 8 subjects
62706887|NCT02786407|PLACEBO_COMPARATOR|Placebo|The placebo does not include botulinum toxin A ,but include sucrose,dextran and gelatin.
62145094|NCT04320966||Acquired Anemia|Otherwise healthy individuals with hemoglobin below 10.5 g/dl or hematocrit below 32
62145095|NCT04320966||Control|Age and sex matched individuals with hemoglobin in the upper quartile of normal
62145096|NCT02707952|EXPERIMENTAL|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) for 8 weeks in HCV genotype(GT)1 -infected, DAA treatment-naïve participants without cirrhosis.
62145097|NCT02707952|ACTIVE_COMPARATOR|Arm B|Ombitasvir (25 mg)/paritaprevir (150 mg)/ritonavir (100mg) (OBV/PTV/r) QD for 12 weeks in HCV GT1 infected, DAA treatment-naïve participants without cirrhosis.
62145098|NCT02707952|EXPERIMENTAL|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120mg) QD for 12 weeks in HCV GT1- or GT2-infected participants with compensated cirrhosis, HCV GT3-, 4-, 5- and 6-infected participants (with compensated cirrhosis or without cirrhosis), HCV GT1- and GT2-infected participants who had failed prior DAA treatments (with compensated cirrhosis or without cirrhosis), and HCV GT1- or GT2-infected participants with severe renal impairment and compensated cirrhosis.
62145099|NCT02707952|EXPERIMENTAL|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in GT1- or GT2-infected participants with severe renal impairment and without cirrhosis.
62145100|NCT03450642||Observation|Patients presenting with right Iliac Fosse pain
62145101|NCT00853528|EXPERIMENTAL|Single-fraction radiosurgery; 16 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 16 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
62145102|NCT00853528|EXPERIMENTAL|Hypo-fractionated radiosurgery; 21 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 21 Gray
62350778|NCT02052934|EXPERIMENTAL|Cohort 2|Three SL doses of dMLT, 5 mcg, on Days 1, 15 and 29, 8 subjects
62350779|NCT02052934|EXPERIMENTAL|Cohort 3|Three SL doses of dMLT, 25 mcg, on Days 1, 15 and 29, 11 subjects
62539343|NCT00858481|ACTIVE_COMPARATOR|4|2.0% Spinosad Creme Rinse
62145103|NCT00853528|EXPERIMENTAL|Single-fraction radiosurgery; 18 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 18 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
62350780|NCT02052934|EXPERIMENTAL|Cohort 4|Three SL doses of dMLT, 50 mcg, on Days 1, 15 and 29, 11 subjects
62350781|NCT02052934|EXPERIMENTAL|Cohort 5a|Three SL doses of dMLT,25 mcg on Days 1, 15 and 29, 13 subjects.
61967504|NCT05666492|PLACEBO_COMPARATOR|Less than 12 months placebo- control|Patients randomized into the less than 12 months placebo arm will receive saline topically every month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
61967505|NCT05666492|EXPERIMENTAL|More than 12 months PRP- Test|Patients randomized into more than 12 months PRP arm will receive 3 doses of topical PRP each month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
61967506|NCT05666492|PLACEBO_COMPARATOR|More than 12 months Placebo- Control|Patients randomized into the less than 12 months placebo arm will receive saline topically every month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
61967507|NCT05870540|EXPERIMENTAL|Low dose|Active placebo comparator
61967508|NCT05870540|EXPERIMENTAL|Medium dose|
61967509|NCT05870540|EXPERIMENTAL|High dose|
61967510|NCT00718224|EXPERIMENTAL|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given 8 hours after surgery~To maintain the blind, placebo for Enoxaparin sodium:~* 12 and 24 hours after surgery, then once daily if no SRI~* 12 hours after surgery only if SRI"
61967511|NCT00718224|ACTIVE_COMPARATOR|Enoxaparin|"Enoxaparin sodium 30 mg twice daily (20 mg once daily if Severe Renal Impairment \[SRI\]) for 7-10 days with an initial dose given 12 hours after surgery~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
61967512|NCT06355154|NO_INTERVENTION|The Standard of Care diet|(a diet that includes at least 175 grams of carbohydrates per day or more/ \>40% CHO, SCD)
61967513|NCT06355154|EXPERIMENTAL|The moderate carbohydrate diet|(a diet with 120 grams of carbohydrates and customized according to pregnancy requirements/ \<40% CHO, MCD)
61967514|NCT01463553|NO_INTERVENTION|wedge resection|
61967515|NCT01463553|EXPERIMENTAL|Wedge resection and pleurodosis|
61967516|NCT04152161|EXPERIMENTAL|Bacille Calmette Guerin (BCG) group|
61967517|NCT04152161|PLACEBO_COMPARATOR|Placebo group|
61967518|NCT04567225|EXPERIMENTAL|Early Glargine|All consecutive adult patients getting admitted to Medical ICU and meet the inclusion criteria and accepted to receive insulin glargine early as per the protocol. They will receive insulin glargine 0.4 unit/kg within 4 hours from initiating the IV Insulin Infusion, as per the Cleveland Clinic DKA protocol.
62145104|NCT00853528|EXPERIMENTAL|Single-fraction radiosurgery; 20 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 20 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
62145105|NCT00853528|EXPERIMENTAL|Hypo-fractionated radiosurgery; 24 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 24 Gray
62350782|NCT02052934|EXPERIMENTAL|Cohort 5b|Three oral doses of dMLT, 25 mcg on Days 1, 15and 29, 13 subjects
62539344|NCT04751929|EXPERIMENTAL|Biomarker-Unselected Abemaciclib Monotherapy (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~* Monotherapy : Participants will receive Abemaciclib orally 2x daily"
61967519|NCT04567225|ACTIVE_COMPARATOR|Standard practice (Late Glargine)|Retrospective, prespecified and matched sample of consecutive adults who admitted to the same Medical ICU with a diagnosis of DKA in the period between January 1st 2019 till the Institutional Review Board (IRB) approval date and didn't receive basal insulin before Anion Gap closure.
61967520|NCT01291173|EXPERIMENTAL|SPD489 30 mg|
61967521|NCT01291173|EXPERIMENTAL|SPD489 50 mg|
61967522|NCT01291173|EXPERIMENTAL|SPD489 70 mg|
61967523|NCT01291173|PLACEBO_COMPARATOR|Placebo|
61967524|NCT01953198||All study participants|A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
61967525|NCT03466697|OTHER|Healthy subjects|All subjects will be injected twice for each visit (normal saline or glucose)
61967526|NCT01631578|EXPERIMENTAL|Injection of mitochondrial concentrate|A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
61967527|NCT01631578|ACTIVE_COMPARATOR|Control|ICSI will be performed conventionally.
61967528|NCT02224040|EXPERIMENTAL|Ceftriaxone I.V|The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
61967529|NCT02224040|EXPERIMENTAL|Ceftriaxone I.V+Azithromycin P.O|The participants in this arm will receive the following drugs and dosages: adult: 2 g intravenous ceftriaxone and 500 mg oral azithromycin once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day and oral 20 mg/kg azithromycin suspension once a day. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
61967530|NCT02224040|EXPERIMENTAL|Azithromycin P.O|The participants in this arm will receive the following drug and dosage: adult: azithromycin oral 500 mg once a day. Pediatric: oral 20 mg/kg azithromycin suspension once a day (maximum dose 1000 mg/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
61967531|NCT02224040|EXPERIMENTAL|Azithromycin P.O+Cefixime P.O|The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
61967532|NCT01456468|EXPERIMENTAL|UDCA + ATRA|This is a single-arm study. All subjects will take UDCA and ATRA.
61967533|NCT02269241|EXPERIMENTAL|LF111 (drospirenone)|single treatment arm receives LF111
61967534|NCT03410550|EXPERIMENTAL|Exoskeleton Training|Twenty men with complete and incomplete SCI will be enrolled in the trial.
61967535|NCT03579732||Long-term users|Adults using low-dose aspirin for \> 3 years
61967536|NCT03579732||Episodic users|Adults using low-dose aspirin inconsistently, or consistently but \< 3 years
61967537|NCT03579732||Former users|Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
62509164|NCT06368557|EXPERIMENTAL|iCBT with on-demand feedback|Participants in the on-demand iCBT condition will not receive any planned contact with the therapist. However, the participants will be able to contact the therapist through messages within the program and receive asynchronous support if needed. The therapist will also be monitoring the participants' answers on questionnaires and assignments to ensure progress. Participant depression and suicidality will also be continuously monitored using weekly questionnaires.
62706888|NCT01416350|ACTIVE_COMPARATOR|Part A - randomized, open-label parallel group|Part A is a randomized, open-label parallel group study evaluating PK/PD of a single azithromycin dose of 250 or 1000 mg. Data from Part A will be used to assess the dose resulting in induction/inhibition of various ex vivo biomarkers relative to a 250 mg dose of azithromycin (the clinical dose used in treatment of neutrophil-induced inflammatory conditions). This information will guide the range of doses to be studied in a FTIH study of a new chemical entity.
62706889|NCT01416350|ACTIVE_COMPARATOR|Part B - repeat dose group|Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
62706890|NCT00640003|EXPERIMENTAL|1|
62706891|NCT00640003|EXPERIMENTAL|2|
61967538|NCT03579732||Non-consumers|Adults who did not use low-dose aspirin
62706892|NCT01891955|ACTIVE_COMPARATOR|Diet A|Healthy diet with grains and dairy
62706893|NCT01891955|ACTIVE_COMPARATOR|Diet B|Healthy diet without grains and dairy
62706894|NCT02552225|EXPERIMENTAL|amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
61967539|NCT00922181|EXPERIMENTAL|MWA|Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
62706895|NCT02552225|PLACEBO_COMPARATOR|placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
62706896|NCT03350945|ACTIVE_COMPARATOR|Device:Titanium Clips|Device: Tumor localization. Preoperative endoscopic localization with titanium clips
61967540|NCT00922181|ACTIVE_COMPARATOR|RFA|Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
62706897|NCT03350945|ACTIVE_COMPARATOR|Device:Intra-operative Endoscopy|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using intra-operative endoscopy detection.
62706898|NCT03350945|EXPERIMENTAL|Device:Carbon Nanoparticles|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using carbon nanoparticles.
62706899|NCT01937065||No treatment|
61967541|NCT00692341|EXPERIMENTAL|Hepatic Function - Mild Impairment|Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)
61967542|NCT00692341|EXPERIMENTAL|Hepatic Function - Moderate Impairment|Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)
61967543|NCT00692341|EXPERIMENTAL|Hepatic Function - Normal|"Group 1~1) subjects with normal hepatic function"
61967544|NCT02254486|EXPERIMENTAL|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
62706900|NCT04600284|EXPERIMENTAL|Sequence 1|Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102
62706901|NCT04600284|EXPERIMENTAL|Sequence 2|Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102
62706902|NCT04600284|EXPERIMENTAL|Sequence 3|Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102
62706903|NCT04600284|EXPERIMENTAL|Sequence 4|Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101
62706904|NCT04600284|EXPERIMENTAL|Sequence 5|Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102
62706905|NCT04600284|EXPERIMENTAL|Sequence 6|Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101
62706906|NCT02518529|EXPERIMENTAL|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
62706907|NCT02897336|EXPERIMENTAL|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
61967545|NCT02254486|ACTIVE_COMPARATOR|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
61967546|NCT06221293||Group 1|the first group consists of patients with increased abdominal pressure, signs of multi-organ failure with a fatal outcome
61967547|NCT06221293||Group 2|the second group consists of patients with increased abdominal pressure, signs of multi-organ failure without death
61967548|NCT03440021|EXPERIMENTAL|High-dosage (60mg) ORM-12741|6 x 10 mg ORM-12741 immediate release capsules in a single dose
61967549|NCT03440021|EXPERIMENTAL|Low-dosage (10mg) ORM-12741|1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose
61967550|NCT03440021|PLACEBO_COMPARATOR|Placebo|6 x placebo capsules in a single dose
61967551|NCT02707874|ACTIVE_COMPARATOR|CI 0.2% ropivacaine|"Patients in Group Continuous Infusion (CI) will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
61976196|NCT02953314|EXPERIMENTAL|Part B|"Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks.~Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks."
61976197|NCT05595356|EXPERIMENTAL|Active tDCS|Participants will receive 30 daily sessions of tDCS. Each session lasts 20 minutes, and delivers a current of 2mA.
62706908|NCT02897336|ACTIVE_COMPARATOR|interlaminar|interlaminar epidural corticosteroid injection
61967552|NCT02707874|ACTIVE_COMPARATOR|PIB 0.2% ropivacaine|"Patients in Group programmed intermittent boluses (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
61967553|NCT02128178|ACTIVE_COMPARATOR|ENOXAPARIN 2 HOURS BEFORE|Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter
61967554|NCT02128178|ACTIVE_COMPARATOR|Enoxaparin 40 mg 12 hours before|Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter
61967555|NCT02280785|EXPERIMENTAL|Brentuximab vedotin|"Brentuximab vedotin administered in 250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.~In the absence of infusion toxicities, the infusion rate for all patients must be calculated in order to achieve a 30-minute (approximate) infusion period.~Brentuximab Vedotin is dosed at 1.8mg/kg (capped at 100kg of body weight). Dosing is based on patients' weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥ 10% change in weight from baseline. Actual weight will be used except for patients weighing greater than 100 kg; dose will be calculated based on 100 kg for these individuals. The dose will be rounded to the nearest whole number of milligrams."
61967556|NCT01535053|EXPERIMENTAL|Arm I (dactinomcin)|Patients receive dactinomycin IV over 15 minutes on day 1.
61967557|NCT01535053|ACTIVE_COMPARATOR|Arm II (leucovorin calcium and methotrexate)|Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
61967558|NCT01947205|ACTIVE_COMPARATOR|paracetamol|Duration
61967559|NCT01947205|ACTIVE_COMPARATOR|without drug|Control group
61967560|NCT01947205|ACTIVE_COMPARATOR|dexketoprofen trometamol|Study group
61967561|NCT01947205|ACTIVE_COMPARATOR|two puff xylocain administration on cervical surface|Study group
61967562|NCT01947205|ACTIVE_COMPARATOR|paracervical block with ultracaine|study group
62509165|NCT06368557|NO_INTERVENTION|waitlist control|A waitlist control is included to compare the treatment conditions to a no-treatment condition and serves as a control for the effects of time and assessment on efficacy. Participants in the waitlist condition will be instructed to wait 14 weeks. After the 14-week period, participants will be offered iCBT treatment with planned therapist feedback and with elective modules. If participants do not wish to receive the iCBT treatment, they will receive help in finding another relevant treatment if needed.
62509166|NCT00655278|EXPERIMENTAL|1|T2000 at 600-1000 mg daily
62706909|NCT00794430|EXPERIMENTAL|V3381|V3381: titrated from 100 mg bid to maximum 400 mg bid over 4 weeks followed by maintenance phase at highest tolerated dose. Total duration of treatment 13 weeks.
62706910|NCT00794430|PLACEBO_COMPARATOR|Placebo|Placebo to match V3381, 100 mg, given according to the same regimen.
62145106|NCT00853528|EXPERIMENTAL|Hypo-fractionated radiosurgery; 27 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 27 Gray
62350783|NCT00821145|ACTIVE_COMPARATOR|1|50 patients operated using a conventional open surgery to exclude an abdominal aortic aneurysm
62509167|NCT06120634|ACTIVE_COMPARATOR|Open surgical method|In this group, the participants were circumcised using the open method. A total of 304 patients were enrolled in this group.
62509168|NCT06120634|ACTIVE_COMPARATOR|Plastibell method|A total of 304 patients were enrolled in this group and underwent the process of circumcision by the Plastibell method.
62509169|NCT02274948|ACTIVE_COMPARATOR|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
62706911|NCT00243035|EXPERIMENTAL|Treatment (bortezomib, tipifarnib)|"Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD."
62706912|NCT03017001|EXPERIMENTAL|CHO (carbohydrate) group|Patients received a 8h preoperative fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g) and no infusion of intraoperative w-3-PUFA
61967563|NCT05380804||Patients with primary Sjögren's syndrome|Cutaneous silent period measurement was performed in patients with the primary Sjögren's syndrome classified according to the 2016 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) criteria.
61967564|NCT05380804||Healthy population|Cutaneous silent period measurement was also performed in healthy population.
61967565|NCT00412659|ACTIVE_COMPARATOR|Midline excision|Midline excision for pilonidal sinus disease.
61967566|NCT00412659|ACTIVE_COMPARATOR|Karydakis|Karydakis operation for pilonidal sinus disease.
62350784|NCT00821145|EXPERIMENTAL|2|50 patients operated using a total laparoscopic aortic aneurysm resection
62706913|NCT03017001|EXPERIMENTAL|W-3 PUFA group|Patients received preoperative fast for solids but allowed to drink 200 mL of water until 2h before anesthesia, and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
62350785|NCT00821145|ACTIVE_COMPARATOR|3|25 patients using a laparoscopic approach for AAA resection with a stapled proximal anastomosis
62350786|NCT04868370||Multiple Sclerosis (MS)|
62350787|NCT04868370||Healthy Subject|
61967567|NCT01965275|EXPERIMENTAL|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
61967568|NCT03742934|EXPERIMENTAL|Formula group|short peptide formula prior to capsule endoscopy
61967569|NCT03742934|OTHER|Control group|regular liquid diet
61967570|NCT05763550|EXPERIMENTAL|HSK16149 20mg BID|
61967571|NCT05763550|EXPERIMENTAL|HSK16149 40mg BID|
61967572|NCT05763550|ACTIVE_COMPARATOR|Pregabalin 150mg BID|
61967573|NCT02980445|NO_INTERVENTION|Control|
61967574|NCT02980445|EXPERIMENTAL|Outdoor Activity 1|40min outdoor time in total.
61967575|NCT02980445|EXPERIMENTAL|Outdoor Activity 2|80min outdoor time in total
61967576|NCT00793598|EXPERIMENTAL|Brincidofovir|"Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows:~* 20 mg BCV once weekly (QW) on Days 0, 7, and 14; or~* 10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28."
61967577|NCT00793598|PLACEBO_COMPARATOR|Placebo|"Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28."
62706914|NCT03017001|EXPERIMENTAL|CHO plus intravenous w3-PUFA group|Patients received a 8h fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g), and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
62706915|NCT03017001|NO_INTERVENTION|Control|Patients received preoperative fast for solids for 8h but allowed to drink 200 mL of water until 2h before anesthesia; and no infusion of intraoperative intravenous w-3-PUFA
62706916|NCT04806152|EXPERIMENTAL|Sarcopenia and combined-modality high intensity supervised exercise training|Participants were given Treadmill exercise training, lower extremity progressive resistance training using a Cybex leg press machine, and a 1-hour adaptive physical activity (APA) programme in which participants were required to walk for 12 minutes through an obstacle course in which they must clear 10 cm high boards, climb 3 steps and walk sideways through hula-hoops placed on the floor all the while dual-tasking i.e. waving at strategically placed signs, conversing while walking and picking up objects. Participants also performed exercises at the parallel bars which included weight-shifting from leg to leg and half-squatting; they were also guided through seated upper- and lower-limb stretching exercises for range of motion and trunk mobility. All exercise sessions were supervised by physiotherapists. For two of the weekdays on which participants did not attend supervised training, they were asked to walk for 30 minutes at home and perform the APA exercises described above.
61967578|NCT02562053|ACTIVE_COMPARATOR|Fluoxetine|Women will receive daily oral fluoxetine 20 mg in addition to an oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation.
61967579|NCT02562053|ACTIVE_COMPARATOR|Combined oral contraceptives and fluoxetine|Women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily.
61967580|NCT02562053|PLACEBO_COMPARATOR|Placebo|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
61967581|NCT04648631|EXPERIMENTAL|ABWG|The participants in this group will be receiving the ABWG daily for 4 consecutive weeks.
61967582|NCT01931852|EXPERIMENTAL|CMR-guided care|Participants in this group will receive a cardiac MRI
61967583|NCT01931852|ACTIVE_COMPARATOR|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
61967584|NCT06306040|EXPERIMENTAL|• Group N (Nalbuphine group n=35 )|administrate nalbuphine 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery (injected once) dose
61967585|NCT06306040|EXPERIMENTAL|• Group M (Magnesium sulfate group n=35 )|administrate magnesium sulfate once 30 mg/kg Magnesium sulphate diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery
61967586|NCT06306040|EXPERIMENTAL|Group C (Control group n=35 ):|administrate 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery
61967587|NCT02966990|OTHER|hand orthosis patients|Patients using hand orthosis for better hand function
61967588|NCT01327105|EXPERIMENTAL|TVU|
61967589|NCT05387031||patients with symptomatic stricturing Crohn's disease|The decision to start ustekinumab was at the discretion of the treating physician. The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician.
61967590|NCT04891874|EXPERIMENTAL|SBRT group|Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.
61967591|NCT04891874|NO_INTERVENTION|Surgery alone group|Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.
61967592|NCT01414855|EXPERIMENTAL|obinutuzumab + CHOP|Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.
61967593|NCT02505997|EXPERIMENTAL|Midazolam/Delafloxacin|Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.
61967594|NCT05755048|EXPERIMENTAL|FS-1502|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
61967595|NCT05755048|ACTIVE_COMPARATOR|Trastuzumab Emtansine (T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
62350788|NCT05810844|EXPERIMENTAL|Motor Relearning Program (MRP)|
62145107|NCT04798534|EXPERIMENTAL|Intervention group|CHW in the intervention arm will receive intervention through a combination of in-person training sessions and internet support. MMT patients in the intervention arm can use a specially designed online platform to communicate with their CHW.
62145108|NCT04798534|NO_INTERVENTION|Control group|The control group CHW will perform business as usual. Both control group CHW and MMT patients do not have access to the online platform.
62509170|NCT02274948|PLACEBO_COMPARATOR|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
62509171|NCT04934852|EXPERIMENTAL|ephedrine (4mg)|
62509172|NCT04934852|EXPERIMENTAL|ephedrine (8mg)|
62509173|NCT04934852|EXPERIMENTAL|ephedrine (12mg)|
62145109|NCT03211988|OTHER|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
62145110|NCT01767688|EXPERIMENTAL|Moderate Hepatic Impairment Group|
62509174|NCT01714739|EXPERIMENTAL|Part 1|Dose Escalation and Initial Signal Detection in Multiple Solid Tumors - Nivolumab with Lirilumab
62509175|NCT01714739|EXPERIMENTAL|Part 2 and 3: Cohort Expansion|In platinum-refractory recurrent or metastatic SCCHN - Nivolumab with or without Lirilumab
62509176|NCT01714739|EXPERIMENTAL|Part 4: Cohort Expansion|Additional Signal Detection in Solid Tumors - Nivolumab with Lirilumab (Study Part 4 Removed; No Subjects Enrolled)
62706917|NCT04806152|ACTIVE_COMPARATOR|Sarcopenia and 'usual care' unsupervised exercise|Participants were required to do 5-12 chair rises and also 30-minutes walking 5 days per week. Upper limb and trunk flexibility exercises were also taught.
62706918|NCT00675883||Prospective|500 patients who will be enrolled in the MS Alliance program will be consented to participate in this study.
62706919|NCT00675883||Retrospective|500 patient chart reviews will be completed for patients who were enrolled in the MS Alliance program between two (2) to three (3) years ago.
61967596|NCT03342105|EXPERIMENTAL|Cettum (Electrical moxibustion)|The patients in this group will receive Cettum (Electrical moxibustion) treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
61967597|NCT03342105|ACTIVE_COMPARATOR|Acupuncture|The patients in this group will receive acupuncture treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
62145111|NCT01767688|EXPERIMENTAL|Healthy Matched Control Group|
62145112|NCT03246750|EXPERIMENTAL|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
62145113|NCT05162352|EXPERIMENTAL|Donafenib+sintilimab|Donafenib combined with sitilimab.
62145114|NCT04877756|EXPERIMENTAL|Arm A 2.0 mg/cm OLX10010 biweekly|Arm A- half the scar treated with 2.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
62706920|NCT03651206|EXPERIMENTAL|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
62706921|NCT03651206|EXPERIMENTAL|Arm B - Niraparib + TSR-042 (Dostarlimab)|"Niraparib, 200 mg or 300 mg, daily dose~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
61967598|NCT02889965||Radiologically Isolated Syndromes (RIS)|
61967599|NCT02889965||Clinically Isolated Syndromes (RIS)|
62145115|NCT04877756|EXPERIMENTAL|Arm B 5.0 mg/cm OLX10010 biweekly|Arm B- half the scar treated with 5.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
62509177|NCT01714739|EXPERIMENTAL|Part 5 and 6|Safety Lead-In and Additional Signal Detection in Solid Tumors -- Nivolumab Plus Ipilimumab with Lirilumab (Study Part 6 Removed; No Subjects Enrolled)
62509178|NCT06083415|EXPERIMENTAL|6 to 8 years old girls, presenting with a breast flare-up|Girls aged 6 to 8 years old with breast flare (isolated or not) and scheduled for pediatric day hospital stay
62509179|NCT03088878|EXPERIMENTAL|Part 1|Cirmtuzumab followed by Cirmtuzumab plus ibrutinib
62509180|NCT03088878|EXPERIMENTAL|Part 2|Cirmtuzumab plus ibrutinib
62509181|NCT03088878|EXPERIMENTAL|Part 3 - Arm A|Cirmtuzumab plus ibrutinib
62509182|NCT03088878|ACTIVE_COMPARATOR|Part 3 - Arm B|Ibrutinib only
62509183|NCT05719337||Hypertensive heart disease group|Systolic blood pressure exceeded 140 mmHg and/or diastolic blood pressure exceeded 90 mmHg, or a history of systemic hypertension in the absence of other cardiac or systemic disease was described as hypertension.
62509184|NCT05719337||Hypertrophic cardiomyopathy group|Wall thickness≥15 mm in the absence of other causes of hypertrophy in a non-dilated left ventricle (LV) defines HCM. End diastolic wall thickness≥13 mm can be diagnostic if there is a family history of HCM or a known disease-causing genetic mutation.
61967600|NCT02889965||Primary progressive MS (PPMS)|
61967601|NCT01934114||Under Treatment|Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
62145116|NCT04877756|EXPERIMENTAL|Arm C 2.0 mg/cm OLX10010 weekly|Arm C- half the scar treated with 2.0 mg/cm of OLX10010 weekly, other half treated with OLX Placebo
62145117|NCT00388726|EXPERIMENTAL|1|
62145118|NCT00388726|ACTIVE_COMPARATOR|2|
62145119|NCT01307254||Non alcoholic fatty liver disease|
62145120|NCT01307254||control|
62145121|NCT01688505||Visit-to-visit BP variability|The highest, intermediate, and the lowest visit-to-visit BP variability (Tertile grouping)
62145122|NCT04365959||covid-19 pneumonia related patients|This study will be conducted on all patients admitted to the Infectious Diseases and UTIR units of the S. Gerardo Hospital in Monza with the diagnosis of related COVID pneumonia requiring oxygen support or CPAP.
62509185|NCT05719337||Cardiac amyloidosis group|Clinical diagnosis of cardiac amyloidosis confirmed by blood tests or tissue biopsy.
62509186|NCT05719337||Fabry disease group|Clinical diagnosis of Fabray disease confirmed by blood biomarkers or genetic testing.
62509187|NCT06396507|ACTIVE_COMPARATOR|Arm P1|"Permethrin 5% solution~Participants randomly assigned to this group will apply the solution once, leave it on for ≥ 8 hours, rinse it, then reapply it the same way on day 8."
62145123|NCT04888052|EXPERIMENTAL|Group 1|
62509188|NCT06396507|EXPERIMENTAL|Arm P2|"Permethrin 5% solution~Participants randomly assigned to this group will apply the solution on days one, two, and three -for ≥ 8 hours each day- then rinse it (without rinsing in between these days) and reapply it on days eight, nine, and ten then rinse it."
61967602|NCT01934114||Normal Cohort|Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
61967603|NCT01594879|EXPERIMENTAL|Endometrial cancer, LNG-IUS with MPA|
61967604|NCT00585728|OTHER|1|CT virtual proctoscopy
61967605|NCT02546804|EXPERIMENTAL|HOT SALT WATER|3% HOT SALT WATER , 25ml used for rinsing for 60 sec, twice daily for 60 days.
61967606|NCT02546804|EXPERIMENTAL|POTASSIUM PERMANGANATE|0.01% POTASSIUM PERMANGANATE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
61967607|NCT02546804|ACTIVE_COMPARATOR|CHLORHEXIDINE|0.2% CHLORHEXIDINE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
61967608|NCT03330730|EXPERIMENTAL|Experimental|"Patients with oncological follow up and home-care service package IsereADOM:~Objects connected to patients' home (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer) with graduated protocol for medical platform support.~Digital linkbook (different from the medical file) accessible to the patient and the standard care actors.~Referent sentinel: a field actor to coordinate the care. Preferred contact of the patient outside the center Motivational coaching: 1 to 2 axes to be defined by the investigator among the following axes (physical activity, nutrition and hydration, drug compliance, medical follow-up, chronic and moral pain, acceptance of the disease and treatments)."
61967609|NCT03330730|NO_INTERVENTION|Control|Patients with oncological follow up only
61967610|NCT01359397|ACTIVE_COMPARATOR|Herceptin -|
61967611|NCT01359397|EXPERIMENTAL|Herceptin +|
62145124|NCT06186349||non-significant hyperbilirubinemia|including 500 cases of non-significant hyperbilirubinemia ( TSB / TCB \< 205umol / L )
62145125|NCT06186349||significant hyperbilirubinemia|500 cases of significant hyperbilirubinemia ( 205umol / L ≤ TSB / TCB \< 342umol / L )
62145126|NCT06186349||severe hyperbilirubinemia|500 cases of severe hyperbilirubinemia ( TSB / TCB ≥ 342umol / L )
62145127|NCT06186349||Extremely severe hyperbilirubinemia|500 cases ( TSB / TCB ≥ 428umol / L )
62145128|NCT02699099|EXPERIMENTAL|Coad group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
62350789|NCT05810844|EXPERIMENTAL|Neuro Development Treatment (NDT)|
62350790|NCT03627494|EXPERIMENTAL|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350791|NCT03627494|EXPERIMENTAL|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350792|NCT03627494|EXPERIMENTAL|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350793|NCT03627494|EXPERIMENTAL|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350794|NCT03627494|EXPERIMENTAL|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350795|NCT03627494|EXPERIMENTAL|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62509189|NCT06396507|EXPERIMENTAL|Arm P3|"Permethrin 5% solution~Participants randomly assigned to this group will apply the solution on days one, two, and three -for ≥ 8 hours each day- then rinse it (without rinsing in between these days). They will reapply it on day eight and rinse it after ≥ 8 hours."
62706922|NCT03651206|ACTIVE_COMPARATOR|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
62706923|NCT03573674|EXPERIMENTAL|Cognitive ergonomics Intervention|
61967612|NCT01634360|EXPERIMENTAL|Perampanel (1-4 mg)|Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204), and dosed placebo or perampanel. Subjects started this open-label extension study on perampanel 1 mg once daily for two weeks, followed by 2 mg once daily for two weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
62145129|NCT02699099|EXPERIMENTAL|RTS,S group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
62509190|NCT06396507|EXPERIMENTAL|Arm P4|"Permethrin 5% solution~Participants assigned to this group will apply the solution on the first two days in the first week (for ≥ 8 hours each day with rinsing in between these days) and reapply it on day eight and rinse it after ≥ 8 hours."
62509191|NCT06396507|EXPERIMENTAL|Arm S|"Sulfur 10%+ vaseline 90 % ointment~Participants assigned to this group will apply the ointment for three consecutive days (for ≥ 8 hours each day and without rinsing in between these days)."
62509192|NCT06494800||pathologically proved lung cancer patient|"All the pathologically proved lung cancer patients by true cut needle biobsy are enrolled in the study.~the true cute needle biobsy procedure performed by two interventional radiologists and a pathologist. TCNB was guided by the use of a 16-detector CT device after local anesthesia is done and done either by ultrasound guidance or CT guidance."
62509193|NCT05190523|EXPERIMENTAL|ASC42 tablets of 5mg|ASC42 tablets 5mg for 12 weeks
62509194|NCT05190523|EXPERIMENTAL|ASC42 tablets of 10mg|ASC42 tablets 10mg for 12 weeks
62509195|NCT05190523|EXPERIMENTAL|ASC42 tablets of 15mg|ASC42 tablets 15mg for 12 weeks
62509196|NCT05190523|PLACEBO_COMPARATOR|Placebo|Placebo for 12 weeks
62509197|NCT00991510|EXPERIMENTAL|Reference/Test/Test|"The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
62509198|NCT00991510|EXPERIMENTAL|Test/Reference/Reference|"The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
62509199|NCT05994248|EXPERIMENTAL|Non-Absorbable Synthetic Mesh|Subjects randomized to the non-absorbable synthetic mesh arm will undergo the procedure (umbilical hernia repair) to receive Marlex mesh.
62509200|NCT05994248|ACTIVE_COMPARATOR|Absorbable Synthetic Mesh|Subjects randomized to the absorbable synthetic mesh arm will undergo the procedure (umbilical hernia repair) to receive Enform mesh.
62509201|NCT05296876||carotid endarterectomy|Patients who are treated with CEA under SSPC evaluation
62706924|NCT03573674|ACTIVE_COMPARATOR|Stress management Intervention|
61967613|NCT02516683||Shigella sonnei-exposed cohort|Shigella sonnei infection - A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
62509202|NCT05244018|ACTIVE_COMPARATOR|Group 1(Treatment group)|
62706925|NCT03573674|NO_INTERVENTION|Passive control|"Passive Control groups receive no intervention at all."
61967614|NCT02516683||control cohort|A control cohort of age and sex-matched, non-infected 105 contemporary hospital employees.
61967615|NCT01466855|EXPERIMENTAL|Treatment of Retinoblastoma|Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
61967616|NCT01204853|EXPERIMENTAL|Sitaxentan treatment|
61967617|NCT03875885|OTHER|CONNECT Intervention Group - Group A|A web-based intervention (CONNECT) to empower and connect caregivers of newly diagnosed cancer patients to supportive care resources A randomized pilot study will be conducted to assess feasibility and acceptability and obtain data on caregiver and patient outcomes. CONNECT e-tool, re-education and optional referral (2 weeks post CONNECT e-tool). Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
61967618|NCT03875885|OTHER|CONNECT Comparison Group - Group B|Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
61967619|NCT01096901|ACTIVE_COMPARATOR|Comprehensive behavioral weight loss|The group will be implemented to induce a 6% weight loss over 3 months. The lessons will follow protocols from the Look AHEAD trial and Diabetes Prevention Program. This behavioral program has been shown to promote long-term weight loss and a reduction in diabetes and cardiovascular risk factors, and is based on the social cognitive theory.
62706926|NCT02724839|EXPERIMENTAL|Biweekly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place biweekly.
62706927|NCT02724839|EXPERIMENTAL|Monthly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place monthly.
61967620|NCT01096901|NO_INTERVENTION|Education and Support Control group|Participants in this group will receive support and education about healthy eating and activity with lessons based on the Look AHEAD support and education control condition. Participants will attend monthly closed group meetings and meetings will be designed to promote retention but not weight loss.
61967621|NCT04851249||Adult participants operated for Hallux Valgus deformity|All adult participants accepted for hallux valgus corrective surgery at ostfold hospital trust (ØHT) is asked to participate in the study. The goal is to include 200-250 participants.
61967622|NCT01073891|ACTIVE_COMPARATOR|Arm 1|
61967623|NCT01073891|EXPERIMENTAL|Arm 2|
61967624|NCT01073891|EXPERIMENTAL|Arm 3|
62509203|NCT05244018|ACTIVE_COMPARATOR|Group 2(Control group)|
62509204|NCT02918331|EXPERIMENTAL|Daratumumab with Lenalidomide and dexamethasone|"Daratumumab (16 milligram per kilogram \[mg/kg\]) will be administered by intravenous \[IV\] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle."
62509205|NCT01530308|ACTIVE_COMPARATOR|Investigational medicinal product|Haloperidol 1 mg twice daily at 12am and 20pm
62706928|NCT02724839|EXPERIMENTAL|Weekly|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place weekly.
62706929|NCT03620396|EXPERIMENTAL|Experimental: Interventional|Group A patients consists of Gingivitis patients whose serum is collected at base line and treated with Scaling and root planing and after three months serum is collected for assessment of Trefoil factor 3.
62509206|NCT01530308|PLACEBO_COMPARATOR|Placebo group|Placebo 1 mg twice daily at 12am and 20pm
62509207|NCT03185182|EXPERIMENTAL|experimental group|"185 megabecquerel (MBq) of Ioflupane I-123 (DaTSCAN) will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.The images from the DaTSCAN investigation will be analyzed and anatomically compared to CT-scan from the same the patient. Any adverse effects during the study will be reported.~This is a exploratory open single arm trial, including a small number of patients with suspected disseminated renal cell carcinoma."
62509208|NCT03997786|ACTIVE_COMPARATOR|Part A|Part A is a DOSE FINDING COMPONENT: OPEN LABEL PK lead-in and safety component
62509209|NCT03997786|EXPERIMENTAL|Part B Part 1: Placebo and active comparator controlled study|
62509210|NCT03997786|EXPERIMENTAL|Part B-1 and B-2: Randomized withdrawal and retreatment after relapse|
61967625|NCT03553667|ACTIVE_COMPARATOR|Standard group|Adult patients, Creatinine clearance \>= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
61967626|NCT03553667|EXPERIMENTAL|ClearSight|Adult patients, Creatinine clearance \>= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
61967627|NCT02033694||Participants With 2 Years Follow up|Participants with NIRS-IVUS imaging at baseline and assigned to follow up for Non-Index Culprit Lesion related Major Adverse Cardiac Events (NC-MACE) for 2 years
61967628|NCT05524155|EXPERIMENTAL|Sintilimab Combined With Regorafenib and HAIC|Sintilimab Combined With Regorafenib and HAIC
61967629|NCT00000383|EXPERIMENTAL|Trauma-Focused CBT|Trauma -Focused CBT provides 12 sessions (45 minutes child, 45 minutes parent) of CBT treatment. This includes therapist-directed trauma-focused skills training, exposure, parenting, conjoint parent-child sessions, and safety component provided to child and parent.
61967630|NCT00000383|ACTIVE_COMPARATOR|Child Centered Therapy|Child Centered Therapy provides 12 sessions (45 minutes child, 45 minutes parent) of supportive interventions. This includes client-directed activities focused on the needs and interests of the child or parent, respectively.
61967631|NCT03388879|EXPERIMENTAL|Circular frame external fixator|A Taylor Spatial Frame should consist of 2 rings with 4 half pins/K-wire attached to each ring. If possible 3, not hydroxyapatite-coated, half pins and one K-wire should be attached to each ring. The half pins/K-wire should be spread in distance and direction for optimum stability.
62350796|NCT03627494|EXPERIMENTAL|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350797|NCT03627494|EXPERIMENTAL|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
61967632|NCT03388879|ACTIVE_COMPARATOR|Intramedullary nail|Nailing technique according to Karladani and Styf published technique (ref: Karladani AH, Styf J. Percutaneous intramedullary nailing of tibial shaft fratures: a new approach for prevention of anterior knee pain. Injury, Int. J. Care Injury 32 (2001) 736-39)
62350798|NCT03627494|EXPERIMENTAL|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350799|NCT03627494|EXPERIMENTAL|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
62350800|NCT03627494|PLACEBO_COMPARATOR|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
62350801|NCT03627494|EXPERIMENTAL|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62509211|NCT03997786|NO_INTERVENTION|Part B 3: Efficacy and Safety Follow-up|
62509212|NCT03997786|EXPERIMENTAL|Part C: LTE|
62509213|NCT05723198|EXPERIMENTAL|Baricitinib High Dose|Participants will receive baricitinib high dose orally.
62509214|NCT05723198|EXPERIMENTAL|Baricitinib Low Dose|Participants will receive baricitinib low dose orally.
62509215|NCT05723198|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo
62509216|NCT01063959|OTHER|Safety|Chart review will evaluate the safety of the two procedures, incidence of complications operatively, hospital stay, and 6-week post-operative periods.
62509217|NCT01063959|EXPERIMENTAL|Weight Loss|Chart review will evaluate weight loss in subjects during the operative, 6-week post-operative, and follow-up of at least 18 months.
62509218|NCT01063959|OTHER|Insurance versus Private Pay|An insurance company issues an insurance policy to cover specific complications from the gastric bypass or the sleeve gastrectomy surgery which allows the surgeon to offer a fixed price to the patient. Comparison of surgical complications in subjects paying by insurance versus paying personally for the gastric bypass operation.
62509219|NCT00186823|OTHER|1|
62509220|NCT02153684||Mild COPD, symptomatic|Smokers fitting GOLD 1B criteria for COPD
62509221|NCT02153684||Mild COPD, asymptomatic|Smokers fitting GOLD 1A criteria for COPD
62509222|NCT02153684||Symptomatic smokers, at risk for COPD|Smokers who do not meet spirometric criteria for COPD
62509223|NCT02153684||Healthy, non-smoking controls|Non-smokers, matched to smoking groups for age (\>40 yrs of age) and gender
62509224|NCT06153160|EXPERIMENTAL|Patients with HemaShock device|"12 patients in cardiac arrest will receive HemaShock device during resuscitation.~All other interventions will be made following guidelines."
62509225|NCT06153160|NO_INTERVENTION|Patients with-out HemaShock device|"12 patients in cardiac arrest will not receive HemaShock device during resuscitation.~All other interventions will be made following guidelines."
62509226|NCT00611884|EXPERIMENTAL|SIBA (D)|
62509227|NCT00611884|EXPERIMENTAL|SIBA (E)|
62509228|NCT00611884|EXPERIMENTAL|SIBA (D) M, W, F|
62509229|NCT00611884|ACTIVE_COMPARATOR|IGlar|
62509230|NCT02563769|EXPERIMENTAL|Clavulanic Acid (CLAV) 250mg; CLAV 500mg then Placebo (PBO)|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo
62509231|NCT02563769|EXPERIMENTAL|CLAV 250mg; PBO; then CLAV 500mg|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg
62509232|NCT02563769|EXPERIMENTAL|PBO; CLAV 250mg; then CLAV 500mg|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg
62509233|NCT00004079|EXPERIMENTAL|Treatment (SarCNU)|"Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SarCNU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
62509234|NCT06319079|EXPERIMENTAL|Super 1.000 Mamá|Breastfeeding mothers who breastfeed their children during the first four months postpartum will receive a fortified powder milk product formulated and designed specifically for this population.
62509235|NCT06319079|SHAM_COMPARATOR|Leche comercial|Breastfeeding mothers who breastfeed their children during the first four months postpartum will receive commercial powder milk.
62509236|NCT06357780|EXPERIMENTAL|Close-loop synchronization controller|30 minutes period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during NIV mode.
62509237|NCT06357780|ACTIVE_COMPARATOR|Conventional|30 minutes period where the synchronization of pressure support of patient effort during NIV mode will be manually set.
61967633|NCT02554487|EXPERIMENTAL|sSDB ASV+|sSDB ASV+: Patients with an AHI \> 20/h assessed during the first night of stroke that are randomized to ASV treatment (AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)).
62350802|NCT03627494|EXPERIMENTAL|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
62350803|NCT04697862|EXPERIMENTAL|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
62350804|NCT04697862|EXPERIMENTAL|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62350805|NCT02861872||IP Patients|women, aged younger than 70 years, who will receive standard IP chemotherapy for advanced epithelial ovarian cancer, who are in an adequate physical and biochemical state to receive chemotherapy will be studied.
62350806|NCT05053126|EXPERIMENTAL|Lyrica 300 mg|Single Dose
62350807|NCT05053126|EXPERIMENTAL|Lyrica 450 mg|Single Dose
62509238|NCT01998243|EXPERIMENTAL|IGB group A|the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)
62509239|NCT01998243|PLACEBO_COMPARATOR|control group B|the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)
62509240|NCT04030663|ACTIVE_COMPARATOR|papaverine|
62509241|NCT04030663|ACTIVE_COMPARATOR|nitroglycerine|
62509242|NCT04030663|PLACEBO_COMPARATOR|xlyocaine|
62509243|NCT04915911||adult patients with Crohn's disease|multi-center cross-sectional study
62509244|NCT02771106||vision dysfunction|This group are subjects with mild TBI who have been diagnosed with profound oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist. These subjects will undergo neuro vision rehabilitation.
62509245|NCT02771106||control|This group are subjects with mild TBI who have no oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist
62509246|NCT03059485|EXPERIMENTAL|DC/AML Vaccine|- Patients will be vaccinated with DC/AML Fusion Vaccine
62509247|NCT03059485|EXPERIMENTAL|Observation|- Patients will be monitored with routine labs and bone marrow biopsies
62509248|NCT04719611|EXPERIMENTAL|Healthy Women|Healthy women between the ages of 18-40 years will be given a probiotic supplement to evaluate the detection and persistence of the strains in biological samples.
61967634|NCT02554487|NO_INTERVENTION|sSDB ASV-|sSDB ASV-: Patients with an AHI \> 20 no ASV treatment.
62350808|NCT05053126|EXPERIMENTAL|Lyrica 300mg with Oxycodone 20 mg|Single Dose
62350809|NCT05053126|EXPERIMENTAL|Lyrica 450 mg with Oxycodone 20 mg|Single Dose
62350810|NCT05053126|ACTIVE_COMPARATOR|Oxycodone 20 mg|Single Dose
62509249|NCT01629576|NO_INTERVENTION|control group|
62509250|NCT01629576|EXPERIMENTAL|low reward|economic incentive
62509251|NCT01629576|EXPERIMENTAL|high reward|economic incentive
62509252|NCT01754987|EXPERIMENTAL|Ascorbic Acid + Sorafenib|"Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate~Dosage:~Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
62509253|NCT01754987|OTHER|Sorafenib alone|Sorafenib: taken daily (oral)
62509254|NCT04814459|EXPERIMENTAL|HOP-UP-PT Program|HOP-UP-PT Program group will participate in the 7-month HOP-UP-PT program
62509255|NCT04814459|NO_INTERVENTION|Normal Level of Activity|Normal Level of Activity group will be instructed to continue their normal level of activity throughout the 7-months after which they will be offered the opportunity to receive the HOP-UP-PT program
62509256|NCT00908557|EXPERIMENTAL|1|Patients receiving an information and consent form that has been modified using the LISYCOM methods.
62509257|NCT00908557|ACTIVE_COMPARATOR|2|Patients receiving a standard information and consent form.
62509258|NCT05276505|NO_INTERVENTION|Control Group - Standardized care|"Standardized nursing care applications~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
62509259|NCT05276505|EXPERIMENTAL|Experimental Group- Lavender Aromatherapy Tablet|"Before 20 minutes from breast biopsy. Lavender aromatherapy tablets. A small (approximately 1x 0.5 inch), rectangular, absorbent tablet containing 2 ml of lavender essential oil (10) was adhered to the patient's shoulder level in the waiting room.~Patients were asked to inhale the aromatherapy tablet for 20 minutes before the procedure.~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
61967635|NCT02554487|NO_INTERVENTION|no SDB|no SDB: Stroke patients without SDB (AHI \< 5 / h) serve as a control group to observe the evolution of the lesion volume and stroke outcome without the additional burden of SDB.
62350811|NCT05053126|PLACEBO_COMPARATOR|Placebo|Single Dose
62350812|NCT00715312|EXPERIMENTAL|A|
62350813|NCT05317702|EXPERIMENTAL|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
62350814|NCT00393068|EXPERIMENTAL|Treatment|"Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).~Surgery will be performed approximately 12-14 weeks after beginning this combined treatment."
62350815|NCT05380349|EXPERIMENTAL|Personalized Combination Drug Therapy for Cancer Stem Cells|Administer combinations of up to 3 FDA approved drugs from a panel of compounds selected based on high throughput screening
62350816|NCT03061045|EXPERIMENTAL|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
62350817|NCT03703687|EXPERIMENTAL|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
62350818|NCT02681185|EXPERIMENTAL|Interventional Group|The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
62350819|NCT02681185|ACTIVE_COMPARATOR|Standard of Care|The recruited participants will receive the standard of diabetes care as offered by the services in their community.
62350820|NCT05220241|OTHER|Case : patient with 1st episode of COVID-19 and persistence of neurocognitive complaint|Patient with a 1st episode of COVID-19 in the 12 months preceding inclusion and presenting persistence of neurocognitive complaint beyond 4 weeks
62350821|NCT05220241|OTHER|Control : Patient with a 1st episode of COVID-19 cured and without neurocognitive complaint|Patient with a cured 1st episode of COVID-19 (without persisting symptoms beyond 4 weeks) in the 12 months preceding inclusion and without neurocognitive complaint
62350822|NCT03686696|NO_INTERVENTION|No Beta blocker and no ACEI/ARB|No Beta blocker and no ACEI/ARB
62350823|NCT03686696|EXPERIMENTAL|Beta blocker and ACEI/ARB|Beta blocker and either ACE inhibitor or Angiotensin receptor blocker
62350824|NCT03686696|EXPERIMENTAL|Beta blocker alone|Beta blocker alone
62350825|NCT03686696|EXPERIMENTAL|ACEI/ARB alone|Either ACE inhibitor or Angiotensin receptor blocker alone
62350826|NCT05979233|ACTIVE_COMPARATOR|staged managment|ERCP then interval laparoscopic cholecystectomy
62350827|NCT05979233|EXPERIMENTAL|one session ERCP then LC|one session ERCP then LC
62350828|NCT05979233|EXPERIMENTAL|one session LC then ERCP|one session LC then ERCP
62509260|NCT05276505|EXPERIMENTAL|Experimental Group- Lavender-Mint Aromatherapy Tablet|"Before 20 minutes from breast biopsy. Lavender-Mint aromatherapy tablets. A small (approximately 1x 0.5 inch), rectangular, absorbent tablet containing 2 ml of lavender essential oil (10) was adhered to the patient's shoulder level in the waiting room.~Patients were asked to inhale the aromatherapy tablet for 20 minutes before the procedure.~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
62509261|NCT06616623|EXPERIMENTAL|Treatment (vismodegib, atezolizumab)|Patients receive vismodegib PO daily on days 1-28 and atezolizumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and blood sample collection throughout the study. Some patients undergo tissue sample collection during screening and on study.
62509262|NCT02965872||Healthy individuals|
62509263|NCT03187496|EXPERIMENTAL|Single Arm|
62509264|NCT01620723|EXPERIMENTAL|New breastfeeding programme|"The breastfeeding programme consists of four core elements:~1. breastfeeding is a parental task~2. skin to skin contact during the first three days~3. frequent breastfeeding at least 8 times a day~4. good positioning, preferable in a laid back position~Moreover communication was supposed to enhance breastfeeding self-efficacy, using Banduras theory of self-efficacy"
62509265|NCT01620723|ACTIVE_COMPARATOR|Treatment as usual|Breastfeeding counselling uses the national handbook of breastfeeding as reference
61967636|NCT03081260|OTHER|Patellar resurfacing|Patellar resurfacing during the total knee prosthesis Anatomic surgery
61967637|NCT03081260|OTHER|Patellar non-resurfacing|Patellar non-resurfacing during the total knee prosthesis Anatomic surgery
62350829|NCT03329417|ACTIVE_COMPARATOR|Traditional occupational therapy|The program includes 30 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
61967638|NCT02786446|ACTIVE_COMPARATOR|Lidocaine gel|20 grams Lidocaine gel 2 % will be applied to corresponding lumber area of the patients 30 minutes before undergoing ESWL for renal stone.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
61967639|NCT02786446|ACTIVE_COMPARATOR|Naproxen Sodium|Oral Naproxen sodium 550 mg will given to patients 45 minutes before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
62145130|NCT02699099|EXPERIMENTAL|Control group|Children randomized received Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. These children received SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
62350830|NCT03329417|ACTIVE_COMPARATOR|Mirror therapy using a mirror box|The program includes 30 minutes of mirror therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
62350831|NCT03329417|EXPERIMENTAL|Virtual reality based mirror therapy|The program includes 30 minutes treatment session of virtual reality mirror therapy, followed by 20 minutes of motor task specific training in each treatment session.
62350832|NCT01486004|EXPERIMENTAL|001|35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total) + 150 mg capsule once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle
62350833|NCT04462536|PLACEBO_COMPARATOR|Placebo|Vehicle only
62350834|NCT04462536|EXPERIMENTAL|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
62350835|NCT02162121|EXPERIMENTAL|Stimulating catheter|"After Spinal Anesthesia (Levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15 ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
62350836|NCT02162121|ACTIVE_COMPARATOR|Non-stimulating catheter|"After Spinal Anesthesia (levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with non-stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
62350837|NCT03210220|EXPERIMENTAL|pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
62350838|NCT03210220|NO_INTERVENTION|control group|There is no block.
62350839|NCT01788280|EXPERIMENTAL|All participants|All enrolled participants
62350840|NCT05536193|EXPERIMENTAL|Topical Metformin Emulgel and salicylic acid|
62350841|NCT04004377||acoustic neuroma monitored radiologically|patient with an acoustic neuroma (vestibular schwannoma) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, monitoring by radiology
62350842|NCT04004377||acoustic neuroma whose treatment is surgical|patient with an acoustic neuroma (vestibular schwannoma or) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, resection surgery planified
62350843|NCT04480931|EXPERIMENTAL|mHealth Intervention Group|This group will be provided with the mobile health app (including introductory videos on how to use its features).
62350844|NCT04480931|SHAM_COMPARATOR|Control Group|This group will receive an educational brochure about physical activity during pregnancy.
62350845|NCT02637024|EXPERIMENTAL|APBI: 30 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy
62350846|NCT02637024|EXPERIMENTAL|APBI: 27.5 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy
62350847|NCT02814864|EXPERIMENTAL|Mesenchymal Stromal Cell (MSC)|Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale\>2)
62350848|NCT04374279|ACTIVE_COMPARATOR|Standard of care and bicalutamide|Randomized participants receive bicalutamide 150mg oral for 7 days, plus standard of care
62145131|NCT02113449|EXPERIMENTAL|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
62145132|NCT02714777||Pediatric population from 4 to 8 years-old|Description of the Autonomic nervous system activity (parasympathetic activity)
62145133|NCT04126577||Patients with suspected peritonitis|Secondary peritonitis, sepsis and endotoxemia
62145134|NCT00718120|EXPERIMENTAL|Fluviral Adult Group|Subjects aged between 18 and 60 years received a single dose of Fluviral® vaccine.
62350849|NCT04374279|NO_INTERVENTION|Standard of care only|Randomized participants receive standard of care only.
62145135|NCT00718120|EXPERIMENTAL|Fluviral Elderly Group|Subjects aged more than 60 years received a single dose of Fluviral® vaccine.
62145136|NCT02326220|EXPERIMENTAL|Placebo Q2W (Double Blind Period)|Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
62145137|NCT02326220|EXPERIMENTAL|Alirocumab 150 mg Q2W (Double Blind Period)|Alirocumab 150 mg SC injection Q2W up to Week 16.
62350850|NCT02080286|ACTIVE_COMPARATOR|Prism adaptation + anodal tDCS|"Participants will receive 1 milliamp (mA) anodal tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
62350851|NCT02080286|PLACEBO_COMPARATOR|Prism Adaptation + Sham tDCS|"Participants will receive Sham tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
61967640|NCT02786446|ACTIVE_COMPARATOR|Lidocaine Gel and Naproxen Sodium|Oral Naproxen sodium 55o mg and locally applied 2 % lidocaine gel to patients before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
61967641|NCT03405129|ACTIVE_COMPARATOR|Factoid Group|The Factoid group will receive a smartphone app that delivers 2 factual messages per day
61967642|NCT03405129|EXPERIMENTAL|Phoenix Group|The Phoenix group will receive a smartphone app that includes multiple components that vary based upon the participant's smoking cessation stage
61967643|NCT03405129|EXPERIMENTAL|Phoenix + NRT Group|"The Phoenix + (Nicotine Replacement Therapy) NRT group will receive a smartphone app that is identical to the Phoenix group, with one additional feature. Participants will be able to click an Order Nicotine Patches and Gum button to order NRT."
62350852|NCT02080286|PLACEBO_COMPARATOR|Prism adaptation + no tDCS|"Participants will receive no tDCS at all but will undergo a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
62350853|NCT00168064|ACTIVE_COMPARATOR|1 (PG - NM (MCH) 0.02%)|PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
61967644|NCT02551757|EXPERIMENTAL|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
61967645|NCT02551757|SHAM_COMPARATOR|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
61967646|NCT06135350|EXPERIMENTAL|Treatment arm|
61967647|NCT06135350|PLACEBO_COMPARATOR|Placebo arm|
62350854|NCT00168064|ACTIVE_COMPARATOR|2 (AP - MCH(NM) 0.02%)|AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF
62350855|NCT01943422|EXPERIMENTAL|Vemurafenib + IFNα-2b (10 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)~* IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~* Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
62350856|NCT01943422|EXPERIMENTAL|Vemurafenib + IFNα-2b(15 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)~* IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~* Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
61967648|NCT04107194|EXPERIMENTAL|Tailored therapy|"1. Clarithromycin-sensitive strain (10 day-therapy):~   Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~2. Clarithromycin-resistant and tetracycline-sensitive strain (10 day-therapy):~   Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)~3. Clarithromycin- and tetracycline-resistant and levofloxacin-sensitive strain (10 day- therapy):~   Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Levofloxacin 500 mg bid (tablet)~4. Clarithromycin-, tetracycline- and levofloxacin-resistant strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Rifabutin 150 mg bid (tablet)"
61967649|NCT04107194|ACTIVE_COMPARATOR|Empiric therapy|"Either one of the two following 10-day regimens (according to physician's decision):~1. Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~2. Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)"
61967650|NCT05182138|PLACEBO_COMPARATOR|Unfortified potato plus placebo|Volunteers given potato with no fortified zinc and a placebo
61967651|NCT05182138|ACTIVE_COMPARATOR|Zinc Biofortified potato plus placebo|Volunteers given potato biofortified with zinc and a placebo
62350857|NCT01943422|EXPERIMENTAL|Vemurafenib + IFNα-2b (20 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)~* IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~* Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
62350858|NCT02683304|EXPERIMENTAL|The study population|The study population consists of consecutive headache patients (visual analogue scale \> 3) presenting at the emergency department of the Nîmes University Hospital
62350859|NCT06192953|EXPERIMENTAL|Stimulated group|5 sessions per week for 6 weeks maximum of reeducation with Functional Proprioceptive Stimulation
62706930|NCT03620396|EXPERIMENTAL|Experimental Interventional|Group B patients consists of Periodontitis patients whose serum is collected at base line and treated with Scaling and Root Planing and after three months serum is collected for assessment of Trefoil factor 3.
61967652|NCT05182138|ACTIVE_COMPARATOR|Unfortified potato plus zinc supplement|Volunteers given potato with no fortified zinc and a zinc supplement
62145138|NCT02326220|EXPERIMENTAL|Alirocumab 150 Q2W (Open Label Treatment Period)|Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
62145139|NCT04755972|ACTIVE_COMPARATOR|N-acetylcysteine|Inhalation of 5 ml-s of N-acetylcysteine every 12 hours.
61967653|NCT03020160|EXPERIMENTAL|Emicizumab: PK Run-in Cohort|Participants received emicizumab subcutaneously (SC) at a dose of 6 mg/kg once every 4 weeks, with no loading dose, for at least 24 weeks.
62509266|NCT02283671|EXPERIMENTAL|Tolerogenic dendritic cells|"Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.~Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.~The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level."
62509267|NCT04134026|EXPERIMENTAL|HIF-PHI|HIF-PHI will be dosed orally three times a week.
61967654|NCT03020160|EXPERIMENTAL|Emicizumab: Expansion Cohort|Participants received emicizumab subcutaneously (SC) at a loading dose of 3 mg/kg once every week for the first 4 weeks followed by a maintenance dose of 6 mg/kg emicizumab SC once every 4 weeks for at least 24 weeks.
61967655|NCT01851616|ACTIVE_COMPARATOR|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
61967656|NCT01851616|ACTIVE_COMPARATOR|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
61967657|NCT01250275|EXPERIMENTAL|Acute Phase: traditional canola oil|Participants will receive banana bread containing traditional canola oil once weekly during the 5-week schedule
61967658|NCT01250275|ACTIVE_COMPARATOR|Acute Phase: high oleic canola oil|Participants will receive banana bread containing high oleic canola oil once weekly during the 5-week schedule
62145140|NCT04755972|ACTIVE_COMPARATOR|Hypertonic saline|Inhalation of 5 ml-s of 5% sodium chloride every 12 hours.
62350860|NCT06192953|NO_INTERVENTION|Simulated group|5 sessions per week for 6 weeks maximum with the device of Functional Proprioceptive Stimulation settled but not activated
62350861|NCT00949910|EXPERIMENTAL|Erlotinib|Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.
62350862|NCT03746808|PLACEBO_COMPARATOR|EMA only|Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are receiving shelter-based treatment.
62350863|NCT03746808|ACTIVE_COMPARATOR|EMA + App/Treatment Messages|Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
62350864|NCT04315493|EXPERIMENTAL|A|
62350865|NCT04315493|EXPERIMENTAL|B|
62350866|NCT02861053|EXPERIMENTAL|chronic quiet inflammatory bowel disease patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with regular and moderate physical activity
62350867|NCT02861053|SHAM_COMPARATOR|chronic quiet inflammatory bowel disease Patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with no regular and moderate physical activity more than usual
62350868|NCT04673604|PLACEBO_COMPARATOR|Triple preservative-free therapy with placebo in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use placebo (artificial tears) in the evening (21:00) for 6 months. At the end of this period patients will be crossed over to the other therapy (cyclosporine 0.1% in the evening)
62350869|NCT04673604|ACTIVE_COMPARATOR|Triple preservative-free therapy with cyclosporine 0.1% in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use cyclosporine 0.1% drops in the evening (21:00) for 6 months. At the end of this period all patients will be crossed over to the other therapy (placebo in the evening)
62509268|NCT04134026|ACTIVE_COMPARATOR|Epoetin alfa|Epoetin alfa wull be disoensed per the package insert or the country-specific product labeling.
62509269|NCT03081728|EXPERIMENTAL|block|will be given block and continuous infusion with bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
62509270|NCT03081728|EXPERIMENTAL|control|IV analgesia only with diclofenac and paracetamol
62509271|NCT01607177|EXPERIMENTAL|Text message group|Patients randomised to this group will receive daily text message reminders used to motivate them to exercise in the preoperative period. They will also receive an exercise information sheet to complement the text messages.
62509272|NCT01607177|NO_INTERVENTION|No text message group|Patients randomised to this group will receive standardised exercise advice but will not receive the text message reminders or the exercise information sheet.
62509273|NCT01611207|EXPERIMENTAL|Negative Pressure Wound Therapy|Used therapy systems
62509274|NCT01611207|ACTIVE_COMPARATOR|Standard Conventional Wound Therapy|Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
62509275|NCT06617533||Experimental: PCF practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the PCF model.
62509276|NCT06617533||No Intervention: Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the PCF practices and whose outcomes will be compared to those of the PCF practices.
61967659|NCT01250275|ACTIVE_COMPARATOR|Acute Phase: soybean oil|Participants will receive banana bread containing soybean oil once weekly during the 5-week schedule
61967660|NCT01250275|ACTIVE_COMPARATOR|Acute Phase: high linoleic safflower oil|Participants will receive banana bread containing high linoleic safflower oil once weekly during the 5-week schedule
61967661|NCT01250275|ACTIVE_COMPARATOR|Acute Phase: coconut oil|Participants will receive banana bread containing coconut oil once weekly during the 5-week schedule
61967662|NCT01250275|EXPERIMENTAL|Chronic Phase: traditional canola oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing traditional canola oil for a total of 8 weeks
61967663|NCT01250275|ACTIVE_COMPARATOR|Chronic Phase: safflower oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing an oil mixture representing the typical western diet for a total of 8 weeks
62145141|NCT04755972|ACTIVE_COMPARATOR|Bicarbonate|Inhalation of 5 ml-s 8.4% sodium bicarbonate every 12 hours.
62145142|NCT04755972|NO_INTERVENTION|Control group|No preventive inhalation.
62706931|NCT01726764|EXPERIMENTAL|Metformin|"7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.~Minimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
61967664|NCT02346630|ACTIVE_COMPARATOR|Levodopa / Carbidopa + Armeo|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
61967665|NCT02346630|PLACEBO_COMPARATOR|Placebo + Armeo|Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
61967666|NCT02350790|ACTIVE_COMPARATOR|Robotic ablation|Half of the patients in the study will be randomized to robotic ablation of endometriosis with the argon beam coagulator (ABC).
61967667|NCT02350790|ACTIVE_COMPARATOR|Robotic Excision|Half of the patients in the study will be randomized to robotic excision of endometriosis.
61967668|NCT05571540|EXPERIMENTAL|U-CAR-T Cells (LstCAR019)|Subjects who meet the enrollment conditions will receive intravenous infusion of U-CAR-T Cells (LstCAR019) after lymphodepletion.
61967669|NCT01853761|EXPERIMENTAL|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
62145143|NCT05966272|EXPERIMENTAL|Treatment group A|HRS9531 injection dose level 1
62350870|NCT04157647|ACTIVE_COMPARATOR|CytoSorb|Patients assigned to this arm group will receive hemadsorption witbhCytoSorb during the surgery and in the next 24 hours after surgery.
62350871|NCT04157647|SHAM_COMPARATOR|Control|Patients assigned to this arm group will undergo to a normal CPB without the use of any hemoadsorption system.
62350872|NCT02604615|EXPERIMENTAL|Capecitabine-oxaliplatin 2 cycles|oxaliplatin：65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
62350873|NCT02604615|ACTIVE_COMPARATOR|Capecitabine-oxaliplatin 4 cycles|oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
62350874|NCT05364229|EXPERIMENTAL|MR-guided Tumour Boost with SBRT|MR-guided radiotherapy boost to MRI visible tumour
62350875|NCT04800120|ACTIVE_COMPARATOR|Study Group|Identified COVID 19 patients receiving the intervention of Hyperbaric Oxygen Therapy
62350876|NCT04800120|NO_INTERVENTION|Control Group|Historical control of COVID 19 patients who were previously treated and did not receiving Hyperbaric Oxygen Therapy
62350877|NCT01066884|EXPERIMENTAL|1|
62350878|NCT02990819|OTHER|Reduced intensity regimen|Conditioning regimen is dependent on patient diagnosis and age. Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care reduced intensity conditioning will include Busulfan, Fludarabine, Thiotepa followed by stem cell infusion.
62350879|NCT02990819|OTHER|Myeloablative regimen|"Conditioning regimen is dependent on patient diagnosis and age. Patients with chronic granulomatous disease or Wiskott-Aldrich syndrome will receive cyclophosphamide in lieu of thiotepa to ensure engraftment.~Myeloablative regimen with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care myeloablative regimen will include Busulfan, Fludarabine, Thiotepa, or Cyclophosphamide followed by stem cell infusion."
62509277|NCT01566279|OTHER|everolimus|All patients in first part will receive everolimus 10mg q.d.
62509278|NCT05867524|EXPERIMENTAL|High IL-6 c-aAb|Individuals with top percentile IL-6 c-aAb
62509279|NCT05867524|EXPERIMENTAL|Low IL-6 c-aAb|Individually matched controls with low IL-6 c-aAb
62706932|NCT03707821|EXPERIMENTAL|senofilcon A TEST Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.
61967670|NCT01853761|EXPERIMENTAL|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
62350880|NCT02990819|OTHER|Immunotherapy|Conditioning regimen is dependent on patient diagnosis and age. Severe combined immunodeficiency (SCID) patients will be conditioned with immunotherapy only followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Immunotherapy regimen will include anti-thymocyte globulin followed by stem cell infusion.
62350881|NCT05931185|EXPERIMENTAL|Low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|participant will receive low frequency transcutaneous electrical stimulation and therapeutic Ultrasound as a treatment
62350882|NCT05931185|ACTIVE_COMPARATOR|Therapeutic Ultrasound|patients will receive therapeutic ultrasound as a treatment
61967671|NCT01853761|EXPERIMENTAL|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
61967672|NCT01853761|EXPERIMENTAL|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
62145144|NCT05966272|EXPERIMENTAL|Treatment group B|HRS9531 injection dose level 2
62145145|NCT05966272|EXPERIMENTAL|Treatment group C|HRS9531 injection dose level 3
62145146|NCT05966272|EXPERIMENTAL|Treatment group D|HRS9531 injection dose level 4
62350883|NCT05931185|ACTIVE_COMPARATOR|Low frequency transcutaneous electrical stimulation|participant will receive low frequency transcutaneous electrical stimulation
62350884|NCT03914495|PLACEBO_COMPARATOR|Placebo|Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.
62509280|NCT00823381|EXPERIMENTAL|Resveratrol|
62509281|NCT00823381|PLACEBO_COMPARATOR|Placebo|
62706933|NCT03707821|ACTIVE_COMPARATOR|senofilcon A CONTROL Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.
62509282|NCT00823381|ACTIVE_COMPARATOR|Calorie Restriction|
62509283|NCT00604084|EXPERIMENTAL|Ivermectin|Non-pregnant, non-breastfeeding, taller than 90cm and 5 years or older
62706934|NCT04013178|EXPERIMENTAL|Accentuated eccentric loading + electromyostimulation|This group will undertake a supervised 12-week intervention involving accentuated eccentric loading and electromyostimulation of the knee extensors, dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
61967673|NCT01853761|PLACEBO_COMPARATOR|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
61967674|NCT06364449||AVF-wrist|
61967675|NCT06364449||AVF-elbow|
61967676|NCT06364449||AVG-forearm|
61967677|NCT06364449||AVG-elbow|
61967678|NCT06410820|ACTIVE_COMPARATOR|Ultrasound method group|The ultrasound-assisted technique will be used for spinal anesthesia performance.
61967679|NCT06410820|EXPERIMENTAL|Landmark method group|Land-mark assisted technique will be used for spinal anesthesia performance.
61967680|NCT04472130||Early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset less than 5 years
61967681|NCT04472130||Non-early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset more than 5 years
61967682|NCT04472130||Multiple System Atrophy|100 patients with Multiple System Atrophy based on Second consensus statement on the diagnosis of MSA
62145147|NCT05966272|PLACEBO_COMPARATOR|Treatment group E|HRS9531 injection Placebo dose level 1
62145148|NCT05966272|PLACEBO_COMPARATOR|Treatment group F|HRS9531 injection Placebo dose level 2
62145149|NCT05966272|PLACEBO_COMPARATOR|Treatment group G|HRS9531 injection Placebo dose level 3
62350885|NCT03914495|ACTIVE_COMPARATOR|Inulin|Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
62145150|NCT05966272|PLACEBO_COMPARATOR|Treatment group H|HRS9531 injection Placebo dose level 4
62145151|NCT06028308|EXPERIMENTAL|Sound 1|A sound will be played while moving the head
62145152|NCT06028308|EXPERIMENTAL|Sound 2|A sound (different from Sound 1) will be played while moving the head
62145153|NCT06028308|NO_INTERVENTION|No Sound|No sound will be played while moving the head
62145154|NCT01634165|EXPERIMENTAL|0.3 U/kg LY2963016|Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
62350886|NCT03039920|ACTIVE_COMPARATOR|Electronic cigarette with or without nicotine|Electronic cigarette assisted cessation program
62350887|NCT03039920|ACTIVE_COMPARATOR|Smoker control|Conventional cigarette smoking continuation
62509284|NCT00604084|EXPERIMENTAL|Permethrin|Pregnant, breastfeeding, children under 90cm or under 5 years old
62509285|NCT00860743|NO_INTERVENTION|Arm 1|"We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep."
62509286|NCT00860743|EXPERIMENTAL|ANTIOXIDANT COCKTAIL|We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
62509287|NCT02061176|EXPERIMENTAL|Transanal Haemorrhoidal Dearterialization|Patients randomised to Transanal Haemorrhoidal Dearterialization.
62509288|NCT02061176|ACTIVE_COMPARATOR|Open Haemorrhoidectomy|Patients randomised to Open Haemorrhoidectomy
61967683|NCT04472130||Progressive Supranuclear Palsy|100 patients with Progressive Supranuclear Palsy based on Clinical research criteria for diagnosis of PSP
61967684|NCT04472130||Alzheimer's Disease|100 patients with Alzheimer's Disease by Diagnostic and Statistical Manual of Mental disorder, Fifth edition (DSM-5) criteria
61967685|NCT04472130||Motor Neuron Disease|200 patients with Motor Neuron Diseases by revised El Escorial criteria or Awaji ALS criteria
61967686|NCT04472130||Small Vessel Disease|200 patients with cerebral Small Vessel Diseases
61967687|NCT04472130||Frontotemporal Dementia|100 patients with Frontotemporal Dementia by International consensus criteria for behavioral variant FTD (FTDC) or Primary Progressive Aphasia by Gorno-Tempini
61967688|NCT04472130||Healthy Control|200 age and sex matched healthy controls
61967689|NCT03972553|OTHER|Sugarbaker|For the Sugarbaker group, the bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
61967690|NCT03972553|OTHER|Keyhole|For the Keyhole group the stoma will be taken down and rematured through a cruciate incision (keyhole)
61967691|NCT02021240|ACTIVE_COMPARATOR|Ketamine|Single dose of intravenous ketamine 0.5mg/kg before incision
61967692|NCT02021240|ACTIVE_COMPARATOR|Dexamethasone|Single dose of intravenous dexamethasone 8mg before incision
61967693|NCT02021240|PLACEBO_COMPARATOR|Normal saline|Single dose of intravenous normal saline before incision
61967694|NCT02911753|EXPERIMENTAL|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
62145155|NCT01634165|EXPERIMENTAL|0.3 U/kg Lantus|Single 0.3 U/kg subcutaneous dose of Lantus
62145156|NCT01634165|EXPERIMENTAL|0.6 U/kg LY2963016|Single 0.6 U/kg subcutaneous dose of LY2963016
62145157|NCT01634165|EXPERIMENTAL|0.6 U/kg Lantus|Single 0.6 U/kg subcutaneous dose of Lantus
62350888|NCT03071003|EXPERIMENTAL|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
62509289|NCT01730560|EXPERIMENTAL|Arm 1:Treatment A|Treatment A (active) followed by treatment B (neutral)
62509290|NCT01730560|EXPERIMENTAL|Arm 2: Treatment B|Treatment B (neutral) followed by treatment A (active)
62509291|NCT00094094|EXPERIMENTAL|Axitinib|AG-013736 is a vascular endothelial growth factor \[VEGF\] inhibitor
62509292|NCT02642237|EXPERIMENTAL|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
62509293|NCT02642237|PLACEBO_COMPARATOR|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
62509294|NCT06614608|EXPERIMENTAL|5% ASKC200|A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.
62509295|NCT06614608|EXPERIMENTAL|1% ASKC200|A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.
62509296|NCT01182662|EXPERIMENTAL|Human umbilical cord-derived MSCs and cyclosporin|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months
62509297|NCT01182662|ACTIVE_COMPARATOR|cyclosporine A|cyclosporine A at a dose of 5 mg CsA/kg
62706935|NCT04013178|ACTIVE_COMPARATOR|Traditional resistance training|This group with undertake a supervised 12-week intervention involving volume matched dynamic resistance training of the knee extensors, and dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
62706936|NCT03342560|EXPERIMENTAL|30 Patients with known liver biopsy results|Patients with chronic liver disease with known biopsy results
62706937|NCT00710099|EXPERIMENTAL|1|
62706938|NCT00710099|ACTIVE_COMPARATOR|2|SNP iontophoresis
62706939|NCT00718432|ACTIVE_COMPARATOR|UC group|Usual care with education
62706940|NCT00718432|EXPERIMENTAL|ENIC group (IC group in 2009 study)|Exercise and nutritional integrated care
62509298|NCT05546268|EXPERIMENTAL|Phase 1 Dose Escalation|Patients with NSCLC, SCLC, high-grade neuroendocrine cancer of any primary site, any solid tumors with L-MYC or N-MYC amplification, or DLBCL
62706941|NCT00718432|EXPERIMENTAL|PSTIC group (IC group in 2009 study)|Problem solving therapy integrated care
62706942|NCT06388629|EXPERIMENTAL|Single Arm|Single arm of the study that receives treatment with the subject device.
62706943|NCT01923922|OTHER|CT Perfusion|Participants with suspected Glioblastoma Multiforme undergo CT perfusion prior to surgery or biopsy.
62706944|NCT00719368||pain-free control|Pain-free controls from previous prospective study (KF 01294867), operated \>2 years previously
62706945|NCT00719368||Pain Patients|Patients with persistent postherniotomy pain lasting \>1 year and pain related impaired daily function
62706946|NCT04186832|ACTIVE_COMPARATOR|Group I (pedometer)|Patients wear a pedometer for step count monitoring over 6 weeks.
62509299|NCT05546268|EXPERIMENTAL|Phase 2 Expansion - NSCLC|Patients with NSCLC with high or low L-MYC or N-MYC expression
62509300|NCT05546268|EXPERIMENTAL|Phase 2 Expansion - SCLC|Patients with SCLC
62509301|NCT05546268|EXPERIMENTAL|Phase 2 Expansion - L-MYC or N-MYC amplified solid tumors|Patients with L-MYC or N-MYC amplified solid tumors
62509302|NCT05546268|EXPERIMENTAL|Phase 2 Expansion - HR-positive, HER2-negative breast cancer|Patients with HR-positive, HER2-negative breast cancer in combination with fulvestrant
62706947|NCT04186832|EXPERIMENTAL|Group II (FitBit)|Patients wear a FitBit for step count monitoring over 6 weeks.
62509303|NCT05546268|EXPERIMENTAL|Phase 2 Expansion - Prostate Cancer|Patients with prostate cancer in combination with enzalutamide
62509304|NCT01588535|ACTIVE_COMPARATOR|benzocaine solution|ear drops
62509305|NCT01588535|PLACEBO_COMPARATOR|Placebo|ear drops
62509306|NCT02378051|EXPERIMENTAL|Staying Strong with Schools Intervention|The Staying Strong with Schools Intervention includes: (a) a training of all school professionals, and (b) a year-long training and supervision of the school guidance counselor (RSL), by a Liaison-Trainer (LT).
62509307|NCT02378051|PLACEBO_COMPARATOR|Waitlist Control|The waitlist control schools will receive an educational pamphlet outlining resources useful to support military-connected children to be distributed to all educators at the beginning of the Year 1. They will then receive the Staying Strong with Schools Intervention in Year 2.
62509308|NCT04487899||Instructors group|Group of flight instructors at the reactor school.
62509309|NCT04487899||Students group|Group of students at the reactor school.
62509310|NCT03002480|OTHER|Severe Hemophilia A subjects w/ inhibitors|Males age 4-70 years diagnosed with severe hemophilia A with inhibitors who are currently treated with prophylaxis or on-demand treatment will be enrolled.
62509311|NCT06616259|EXPERIMENTAL|Arm A|mCapOX (Capecitabine+Oxaliplatin) plus Cetuximab
62509312|NCT06616259|ACTIVE_COMPARATOR|Arm B|mFOLFOX6 (Fluorouracil+Leucovorin+Oxaliplatin) plus Cetuximab
62509313|NCT02629250|PLACEBO_COMPARATOR|SV maximization|Goal-directed fluid therapy with stroke volume maximization. Device: The Volume-View system from Edwards Co.
62509314|NCT02629250|EXPERIMENTAL|supernormal DO2|"Goal-directed fluid therapy with stroke volume maximization and supernormal oxygen delivery.~Device: The Volume-View system from Edwards Co."
62509315|NCT00190580|EXPERIMENTAL|1|
62706948|NCT05678140|EXPERIMENTAL|soft tissue mobilization+conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
62706949|NCT05678140|PLACEBO_COMPARATOR|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area.
62706950|NCT02437318|EXPERIMENTAL|fulvestrant + alpelisib|Alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
62509316|NCT00190580|EXPERIMENTAL|2|
62509317|NCT01705431|EXPERIMENTAL|Support for students with EBD|
62509318|NCT01705431|NO_INTERVENTION|Control|Participants continue with services as usual
62509319|NCT02380313|EXPERIMENTAL|Afuresertib 125 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 125mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
62509320|NCT02380313|EXPERIMENTAL|Afuresertib 150 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 150 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
62509321|NCT02380313|EXPERIMENTAL|Afuresertib 175 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 175 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
62509322|NCT02380313|EXPERIMENTAL|Afuresertib 200 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 200 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
62509323|NCT02380313|EXPERIMENTAL|Afuresertib 125 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 125mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
62706951|NCT02437318|PLACEBO_COMPARATOR|fulvestrant + placebo|Placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
62706952|NCT04778202||first group (control group)|25 normal health control women apparently healthy. blood samples will be obtained after getting informed consent
61967695|NCT02911753|EXPERIMENTAL|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
61967696|NCT02911753|PLACEBO_COMPARATOR|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
61967697|NCT01943331||patients admitted to ICU|
61967698|NCT04943094||TURBT alone|Patients treated with TURBT without adjuvant instillation therapy
61967699|NCT04943094||TURBT and mitomycin C|Patients treated with TURBT followed by six adjuvant instillations with mitomycin C
61967700|NCT04943094||TURBT and bacillus Calmette-Guerin|Patients treated with TURBT followed by six adjuvant instillations with BCG
61967701|NCT01929434|ACTIVE_COMPARATOR|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
61967702|NCT01929434|NO_INTERVENTION|control|Patients receive no professional treatment in hospital or rehabilitation centre.
61967703|NCT01929434|EXPERIMENTAL|stem cell injection|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
62509324|NCT02380313|EXPERIMENTAL|Afuresertib 150 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 150mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
62509325|NCT02380313|EXPERIMENTAL|Afuresertib 100 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 100 mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
62509326|NCT02380313|EXPERIMENTAL|RP2D of Afuresertib + enzalutamide 160 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to plus enzalutamide 160 mg once daily.
62509327|NCT02380313|EXPERIMENTAL|Afuresertib RP2D + abiraterone 1000 mg + prednisone 5 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations.
62706953|NCT04778202||Second group (breast cancer patient group)|25 female patients referred to radiology departement at South Egypt Cancer Institute or Assiut University Hospital diagnosed as breast cancer patients as evidenced by clinical examination , mammography and histopathology
62706954|NCT01300637|ACTIVE_COMPARATOR|metformin|metformin intervention group
62706955|NCT01300637|PLACEBO_COMPARATOR|placebo|placebo-controlled
62706956|NCT06639789|EXPERIMENTAL|Vitamin B12 (B12)|Subjects in this group will intake 1 mg/day of vitamin B12 three days before the tests.
61967704|NCT01324765|EXPERIMENTAL|TARGET|12-session affect regulation therapy for PTSD
61967705|NCT01324765|ACTIVE_COMPARATOR|SGT|12 session supportive group therapy
61967706|NCT06211478|EXPERIMENTAL|cases who are taking vitamin E|gaucher disease patients with oxidative stress and vitamin E defeciency taking vitamin E treatment (weigh below 20 kg dose will be 200mg daily and whose weight above 20 kg dose will be 400mg daily for duration 6 months )
61967707|NCT06211478|NO_INTERVENTION|controls who are not taking vitamin E treatment|gaucher disease patients with oxidative stress and vitamin E defeciency not taking vitamin E treatment but take the standard of care which is enzyme replacement therapy
61967708|NCT01777100|EXPERIMENTAL|sufentanil|Anesthetic induction with IV sufentanil at 0.5 mcg.kg-1 and analgesic maintenance with IV remifentanil at 0.1 to 0.3 mcg.kg-1.min-1 on demand target-controlled infusion
61967709|NCT01777100|NO_INTERVENTION|remifentanil|Anesthetic induction with target-controlled infusion IV remifentanil at 0.5 mcg.kg-1.min-1 in 5 minutes followed by analgesic maintenance on demand of IV target-controlled infusion remifentanil at 0.1 to 0.3 mcg.kg-1.min-1.
61967710|NCT00479609|PLACEBO_COMPARATOR|1|Placebo gel
61967711|NCT00479609|ACTIVE_COMPARATOR|2|Transdermal testostrone therapy
62509328|NCT02380313|EXPERIMENTAL|Afuresertib RP2D + abiraterone + prednisone in PK cohort|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations
62509329|NCT06135376|ACTIVE_COMPARATOR|Control groups with single intervention|The control groups will each receive a single intervention which will be selected at random.
61967712|NCT01760707|EXPERIMENTAL|Exercise Training|aerobic exercise training
61967713|NCT01760707|ACTIVE_COMPARATOR|Control|
61967714|NCT01880385|EXPERIMENTAL|bevacizumab, inflammatory breast cancer|Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2
61967715|NCT01448278|EXPERIMENTAL|All-inside technique|
61967716|NCT01448278|ACTIVE_COMPARATOR|Classical technique|
61967717|NCT03932227|OTHER|Cardioskin-Holter|Subjects in the randomized group A, start by wear the Cardioskin during 24h, and after wear the Holter during 24h.
62509330|NCT06135376|EXPERIMENTAL|Experimental group with 4 interventions|"2 Primary Health Care Centers (PHCCs) will receive the comprehensive multi-component intervention, which consists of four elements:~1. Option for deferred prescription fulfilment.~2. Education of staff regarding appropriate uses of antibiotics.~3. algorithm-driven decision support tool.~4. Feedback on individual and group performance. The training will be repeated at monthly intervals over the 6-month intervention period."
62509331|NCT00483548|EXPERIMENTAL|Ziprasidone|Active treatment, double-blind, randomized treatment arm
62509332|NCT00483548|PLACEBO_COMPARATOR|Placebo|Inactive, placebo treatment, double-blind, randomized arm
62509333|NCT04768634|NO_INTERVENTION|Observation|Patients will be observed for arrhythmias and treated if they occur.
61967718|NCT03932227|OTHER|Holter-Cardioskin|Subjects in the randomized group B, start by wear the Holter during 24h, and after wear the Cardioskin during 24h.
61967719|NCT03198117|EXPERIMENTAL|Huaier Granule|Huaier Granule
61967720|NCT03198117|PLACEBO_COMPARATOR|placebo|placebo
61967721|NCT03198117|NO_INTERVENTION|No-treatment Control|patients refused any treatment
61967722|NCT01997632|ACTIVE_COMPARATOR|control vaccine: Imovax Polio®|
61967723|NCT01997632|EXPERIMENTAL|investigational vaccine|
62509334|NCT04768634|EXPERIMENTAL|Testing|Patients will undergo provocative electrophysiology testing, and antiarrhythmic medication considered if arrhythmias can be induced.
62509335|NCT05083377||Patients who have been prescribed clozapine during 2018|Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.
62509336|NCT02752802|ACTIVE_COMPARATOR|Treatment|The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
62509337|NCT02752802|ACTIVE_COMPARATOR|Control|The control group will include standard of care for diagnostic coronary angiograms.
61967724|NCT03423381|EXPERIMENTAL|Cereal product 1|Cereal based müsli no. 1, made from typical Swedish cereals. All experimental products have different types and amounts of dietary fibre (df). The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
61967725|NCT03423381|EXPERIMENTAL|Cereal product 2|Cereal based muesli no. 2 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
61967726|NCT03423381|EXPERIMENTAL|Cereal product 3|Cereal based muesli no.3 made from typical Swedish cereals. All experimental products have different types and amounts of df.The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
61967727|NCT03423381|EXPERIMENTAL|Cereal product 4|Cereal based muesli no. 4 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
62350889|NCT03071003|EXPERIMENTAL|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
62350890|NCT03071003|EXPERIMENTAL|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
62706957|NCT06639789|PLACEBO_COMPARATOR|PLACEBO (PLA)|Subjects in this group will intake 200 mg/day of microcrystalline cellulose three days before the tests.
61967728|NCT03423381|EXPERIMENTAL|Cereal product 5|Cereal based muesli no. 5 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
61967729|NCT03423381|PLACEBO_COMPARATOR|Control product|A cereal based product with low concentrations of df. The control portion is consumed as a single evening meal prior to determinations of test variables in the morning.
61967730|NCT02994979|EXPERIMENTAL|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
61967731|NCT02994979|SHAM_COMPARATOR|Usual care group|Usual care plus a sham visit from the intervention CNA
61967732|NCT04800705||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
61967733|NCT04800705||Control group|The study population will be consisted of 70 women with POI as the study group and 70 patients with normal healthy women as the control group. A volunteer group of healthy women who will be visited the gynaecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
61967734|NCT00193154|EXPERIMENTAL|OSI-774 & bevacizumab|OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.
61967735|NCT03863249|ACTIVE_COMPARATOR|The exCELLigence system|"1. Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~2. The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~3. The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~4. The adjunctive antibiotics selected by 'the exCELLingence' system will be started at the second SRP visit."
62706958|NCT02302287|EXPERIMENTAL|Group A|"1. Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~2. Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~3. Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day~4. Mediterranean diet and ketoacids for 6 months"
62706959|NCT02302287|EXPERIMENTAL|Group B|"1. Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~2. Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day;~3. Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~4. Mediterranean diet and ketoacids for 6 months"
62706960|NCT02302287|OTHER|Group control|Free diet: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day
62706961|NCT03281213||Female|
62706962|NCT03281213||Male|
62706963|NCT02167776|EXPERIMENTAL|Church-based teaching|Teaching about male circumcision provided to church leaders in addition to standard teaching available from Ministry of Health.
61976198|NCT05595356|SHAM_COMPARATOR|Sham tDCS|Participants will receive 30 daily sessions of sham tDCS. Each session lasts 20 minutes, and the sham programming delivers 3 ramps of 30 seconds of active current, the first in the first minute of the session, the second after 10 minutes and the third at the last minute of the session.
61976199|NCT00729989|NO_INTERVENTION|1|
61976200|NCT00729989|EXPERIMENTAL|2|
61976201|NCT00498602|EXPERIMENTAL|1|ACC-001
62145158|NCT02455557|EXPERIMENTAL|Treatment (SurVaxM, temozolomide)|Patients receive the first priming dose of SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC within 7-28 days after completion of chemoradiation. Treatment repeats every 2 weeks for a total of 4 doses in the vaccine priming phase and then every 12 weeks during the adjuvant phase in the absence of disease progression or unacceptable toxicity. Patients also receive standard adjuvant temozolomide PO or IV on days 1-5. Treatment repeats every 28 days for 6 courses or more (at the discretion of the investigator) in the absence of disease progression or unacceptable toxicity. Patients may then receive maintenance SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC every 12 weeks in the absence of disease progression or unacceptable toxicity.
62145159|NCT03938272|EXPERIMENTAL|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes Strain HC-1
62145160|NCT04497545|EXPERIMENTAL|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual therapy and 30 minutes of therapy on the Luna EMG device.
62145161|NCT04497545|OTHER|Control Group|A four-week rehabilitation program (Monday to Friday) involving one hour of individual therapy and 30 minutes on lower limb rotor
62539345|NCT04751929|EXPERIMENTAL|Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~* Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
62706964|NCT02167776|NO_INTERVENTION|No church-based teaching|Standard of care. Teaching about male circumcision provided by Ministry of Health.
62706965|NCT03952845|EXPERIMENTAL|Intranasal Capsaicin|Separate patients will be given escalating doses of intranasal capsaicinoid spray
61976202|NCT00498602|OTHER|2|QS-21
62706966|NCT05819359|EXPERIMENTAL|BIA 28-6156 10 mg|Participants will be randomized to receive BIA 28-6156 10 mg during the Treatment Period.
62706967|NCT05819359|EXPERIMENTAL|BIA 28-6156 60 mg|Participants will be randomized to receive BIA 28-6156 60 mg during the Treatment Period.
62706968|NCT05819359|PLACEBO_COMPARATOR|Placebo|Placebo
61967736|NCT03863249|ACTIVE_COMPARATOR|Origen|"1. Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~2. The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~3. The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~4. The adjunctive antibiotics agents selected by 'Origen' laboratories analysis will be started at the second SRP visit."
61967737|NCT03863249|ACTIVE_COMPARATOR|Echevarne|"1. Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~2. The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~3. The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~4. The adjunctive antibiotics agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit."
61967738|NCT00666029|ACTIVE_COMPARATOR|Atorvastatin|Active arm atorvastatin 40 mg. o.d.
62350891|NCT06528210|EXPERIMENTAL|Treatment (Pembrolizumab, ADT, radiotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 51 weeks in the absence of disease progression or unacceptable toxicity. Patients receive standard of care ADT with GNRH agonist (leuprolide, goserelin, triptorelin) or GNRH antagonist (relugolix, degarelix) for a total of 24 months, bicalutamide PO QD for 6 months or up to 24 months per the discretion of the treating physician and radiation therapy per standard of care. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo bone scan and/or CT scan/MRI during screening and prostate biopsy and blood sample collection throughout the study.
62350892|NCT01270100|EXPERIMENTAL|Recovery management intervention|
62350893|NCT05793216|EXPERIMENTAL|Classroom interventions|Students within five classrooms will engage in prescribed vestibular activities embedded within learning curricula to determine the impact of the intervention on learning outcomes, particularly memory, sequencing, attention, and ordinance related outcomes.
62350894|NCT04324138|EXPERIMENTAL|Experimental group|Jianpi Qinghua granules, 3 times a day and 1 hour after a meal
62350895|NCT04324138|SHAM_COMPARATOR|Control group|Jianpi Qinghua placebo granules(inclued 5% of experimental drug),3 times a day and 1 hour after a meal
62350896|NCT06229587|EXPERIMENTAL|furlow with buccinator arm|
62350897|NCT01788150|EXPERIMENTAL|Svelte Drug-Eluting Coronary Stent|Coronary Stenting
61967739|NCT00666029|PLACEBO_COMPARATOR|Placebo|Placebo arm dummy pill
61967740|NCT01554553|EXPERIMENTAL|Posterior crural repair|
61967741|NCT01554553|NO_INTERVENTION|No posteriorcrural repair|
62350898|NCT01788150|ACTIVE_COMPARATOR|Medtronic Resolute Integrity Drug-Eluting Stent|Coronary Stenting
62350899|NCT04137419|EXPERIMENTAL|ProlacSan|Patient will get ProlacSan lozenges after nonsurgical treatment of periodontitis.
62350900|NCT04137419|PLACEBO_COMPARATOR|Placebo|Patients will get placebo lozenges after nonsurgical periodontal treatment
62350901|NCT01504048|EXPERIMENTAL|Chromoendoscopy|
62350902|NCT00749268|ACTIVE_COMPARATOR|A|
62509338|NCT03084809|EXPERIMENTAL|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
62706969|NCT06431880|EXPERIMENTAL|External oblique intercostal plane block|Patients will receive external oblique intercostal plane block.
62706970|NCT06431880|EXPERIMENTAL|Thoracic paravertebral block|Patients will receive thoracic paravertebral block.
62145162|NCT01179100|PLACEBO_COMPARATOR|Normal Saline|Normal Saline: Calculated and adjusted to match loading dose and infusion rate of lidocaine equivalent adjusted for weight.
62145163|NCT01179100|ACTIVE_COMPARATOR|Lidocaine|
62350903|NCT00749268|ACTIVE_COMPARATOR|B|
62706971|NCT06026098|EXPERIMENTAL|Case Report with Artificial Intelligence|Medical students, resident physicians, or attending physicians report rare cases with using Artificial Intelligence.
62350904|NCT02667379|OTHER|Diagnostic skin testing|Diagnostic skin testing with cat dander samples on volar forearms.
62350905|NCT04045574|EXPERIMENTAL|DAMP1 :|Single arm trial comparing a conventional technique with an experimental one, within the same patient.
62350906|NCT00307242|ACTIVE_COMPARATOR|Direct switch to Adefovir Dipivoxil from Lamivudine|
62706972|NCT06026098|NO_INTERVENTION|Case Report without Artificial Intelligence|Medical students, resident physicians, or attending physicians report rare cases without using Artificial Intelligence.
62706973|NCT05558904|EXPERIMENTAL|Diagnostic (Me-4FDG PET/CT)|Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
62706974|NCT01737905|EXPERIMENTAL|Arm T|Experimental arm utilizing Epinephrine HFA-MDI (E004)
62706975|NCT01737905|PLACEBO_COMPARATOR|Arm P|Placebo comparator arm utilizing Placebo-HFA
62706976|NCT06060535|ACTIVE_COMPARATOR|Usual Care|Usual care suicide prevention pathway
62706977|NCT06060535|EXPERIMENTAL|Intervention|Implementation of the suicide risk model
62706978|NCT05438147|ACTIVE_COMPARATOR|CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis
62706979|NCT05438147|SHAM_COMPARATOR|Care-as-Usual control in Patients with Multiple Sclerosis|Randomized controlled Study to Evaluate Care-as-Usual control in Patients with Multiple Sclerosis
62509339|NCT03084809|EXPERIMENTAL|FOLFOX4|"FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
61967742|NCT03591198|EXPERIMENTAL|Qigong Training|
62706980|NCT05438147|ACTIVE_COMPARATOR|CT-100 DiNaMo (Study App) in Patients with Breast or Lung Cancer|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with with Breast or Lung Cancer
62145164|NCT00361907|ACTIVE_COMPARATOR|2|Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
62145165|NCT00361907|PLACEBO_COMPARATOR|1|Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy
62145166|NCT04810832|EXPERIMENTAL|Whole group|"The whole group undergo the two phases of the study:~* 1/ They listen successively the 3 oddball paradigms in the department of neurophysiology : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice~* 2/ They listen successively the same 3 oddball paradigms in the neurosurgical department, during their intractable epilepsy presurgical evaluation : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice"
62350907|NCT00307242|ACTIVE_COMPARATOR|Overlapping Lamivudine and Adefovir Dipivoxil for 3 months followed by ADV monotherapy|
62350908|NCT01641991|EXPERIMENTAL|Arm B: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
62350909|NCT01641991|EXPERIMENTAL|Arm C: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 14, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
62350910|NCT01641991|EXPERIMENTAL|Arm D: 0.25mL BioThrax®|BioThrax® 0.25mL subcutaneously on Days 0,14, and 28,and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
62350911|NCT01641991|EXPERIMENTAL|Arm A: 0.50mL BioThrax®|BioThrax® 0.50 ml subcutaneously on Days 0, 14, and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
62350912|NCT03108209|EXPERIMENTAL|single arm|Signle arm study. Every subjects apply Photoderm Max lait SPF50+ and Photoderm stick SPF50+
62350913|NCT03729934|NO_INTERVENTION|Control|This arm receives no treatment control.
62145167|NCT01840722|NO_INTERVENTION|NIDA Standard HIV Education|NIDA Standard HIV Education Participants in this condition will be given HIV education using NIDA standard pre and post-test counseling, HIV and HCV rapid testing, and an information packet on existing community drug abuse and HIV/HCV resources
62350914|NCT03729934|EXPERIMENTAL|Ketone Ester|This arm receives 25 g ketone ester.
62350915|NCT03729934|EXPERIMENTAL|Ketone Salt|This arm receives 25 g ketone salt.
62350916|NCT00891163|EXPERIMENTAL|Synera|
62350917|NCT00891163|PLACEBO_COMPARATOR|Placebo|
62350918|NCT03437317|EXPERIMENTAL|Active - MEG|Participants completed 1 session of 8 Perceptual Retraining blocks following an instructional presentation.
62509340|NCT04938986|EXPERIMENTAL|IMMUNOSCORE®|
62509341|NCT00003531|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62350919|NCT03437317|SHAM_COMPARATOR|Control - MEG|Participants completed 1 session of 8 blocks of Gender Discrimination Task.
61967743|NCT03591198|ACTIVE_COMPARATOR|Cognitive Training|
61967744|NCT03471650|EXPERIMENTAL|18F-DCFPyL Injection|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
62350920|NCT03437317|EXPERIMENTAL|Active - 3 Behavior/EEG|Participants completed 3 sessions of Perceptual Retraining following an instructional presentation. The first session included 6 blocks of perceptual training, and the second session included 12 blocks of perceptual training. No perceptual training was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
61967745|NCT04647578||Child with IBD|
61967746|NCT04647578||Healthy child witnesses|
61976203|NCT00498602|OTHER|3|Diluent: Phosphate Buffered Saline
62350921|NCT03437317|EXPERIMENTAL|Active - 1 Behavior/MEG|Participants completed 1 session of 6 Perceptual Retraining blocks following an instructional presentation.
62350922|NCT03437317|SHAM_COMPARATOR|Control - 3 Behavior/MEG|Participants completed 3 sessions of a Gender Discrimination Task. The first session included 6 blocks of gender discrimination task, and the second session included 12 blocks of the gender discrimination task. No gender discrimination task was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
62350923|NCT03948126||travel medicine|Healthy adults originating from Sub-Saharan Africa, South America and the Caribbean and attending a travel medicine and international vaccination consultation in France.
62350924|NCT02381548|EXPERIMENTAL|Treatment (belinostat, WEE1 inhibitor AZD1775)|Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
62350925|NCT04006080|EXPERIMENTAL|Vedolizumab|
62350926|NCT04712266|ACTIVE_COMPARATOR|Insulin IV|calculated insulin rate
62350927|NCT04712266|EXPERIMENTAL|Insulin and Glucagon IV|calculated molar ratio insulin:glucagon
61967747|NCT01083576|ACTIVE_COMPARATOR|Paromomycin Alone Treatment|Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days
61967748|NCT01083576|ACTIVE_COMPARATOR|WR 279,396|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days
62706981|NCT05438147|SHAM_COMPARATOR|Care-as-Usual control in Patients with Breast or Lung Cancer|Randomized Controlled Study to Evaluate Care-as-Usual control in Patients with with Breast or Lung Cancer
62706982|NCT05438147|ACTIVE_COMPARATOR|CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment
61967749|NCT02650362|EXPERIMENTAL|spinal cord stimulation|
61967750|NCT01447602|EXPERIMENTAL|Interpersonal psychotherapy (IPT-A)|Interpersonal psychotherapy for depressed adolescents which focuses on identifying problematic relationships connected to onset or maintenance of depression and suicidal behavior. The treatment teaches skills such as communication and problem-solving to the adolescent and parents.
61967751|NCT03181581|EXPERIMENTAL|High grade gliomas stage 1 ACF|In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
61967752|NCT03181581|EXPERIMENTAL|Low-high grade gliomas stage 2 ACF|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
61967753|NCT03181581|ACTIVE_COMPARATOR|High grade gliomas stage 1 control|In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
61967754|NCT03181581|ACTIVE_COMPARATOR|Low-high grade gliomas stage 2 control|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma
61967755|NCT04464369|PLACEBO_COMPARATOR|Placebo|Placebo t.i.d.
61967756|NCT04464369|ACTIVE_COMPARATOR|Itopride|Itopride co 100 mg t.i.d.
61967757|NCT04632108|EXPERIMENTAL|ASKB589 Injection|Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.
62350928|NCT02223429|EXPERIMENTAL|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
62350929|NCT02223429|EXPERIMENTAL|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
62350930|NCT02826993|EXPERIMENTAL|CCE in incomplete Colonoscopies|Patients in which colonoscopy is not possible are invited for CT colonography and those patients are examined by Camera Capsule Endoscopy the day before the CT colonography and the two different examinations are compared.
62706983|NCT05438147|SHAM_COMPARATOR|Care-as-Usual in Patients with Mild Cognitive Impairment|Randomized Controlled Study to Evaluate Care-as-Usual in Patients with Mild Cognitive Impairment
62706984|NCT00808873|EXPERIMENTAL|1|brief education and 6 follow-up visits
61967758|NCT00592384|PLACEBO_COMPARATOR|placebo|identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
61967759|NCT00592384|EXPERIMENTAL|venlafaxine XR|venlafaxine XR 37.5 - 300 mg/day for 12 weeks
61967760|NCT01750450||Elective left heart cath|Patients undergoing elective left heart catheterization will be consented for this study
61967761|NCT03352622|ACTIVE_COMPARATOR|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness
61967762|NCT03352622|ACTIVE_COMPARATOR|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
61967763|NCT01283360|PLACEBO_COMPARATOR|HEC Placebo Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
61976204|NCT00498602|EXPERIMENTAL|4|ACC-001
62145168|NCT01840722|EXPERIMENTAL|MI-based HIV Risk Reduction|MI-based HIV Risk Reduction -- In addition to what is received in the HIV-Ed group, participants in this condition will also receive a CDC evidence-based brief intervention for high-risk women focused on an individualized plan for enhancing motivation to reduce risk behaviors and to use health and behavioral health services in the community.
62706985|NCT00808873|NO_INTERVENTION|2|treatment-as-usual
62706986|NCT00928668|EXPERIMENTAL|Olodaterol (BI1744) Low|Single dosing of low dose Olodaterol inhaled orally from Respimat Device
62706987|NCT00928668|EXPERIMENTAL|Olodaterol (BI1744) Medium Low|Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device
62706988|NCT00928668|EXPERIMENTAL|Olodaterol (BI1744) Medium High|Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device
62706989|NCT00928668|EXPERIMENTAL|Olodaterol (BI 1744) High|Single dosing of high dose Olodaterol inhaled orally from Respimat Device
62706990|NCT00928668|PLACEBO_COMPARATOR|Placebo|Single dosing of Olodaterol placebo inhaled orally from Respimat Device
62706991|NCT03093714|EXPERIMENTAL|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
62706992|NCT03093714|EXPERIMENTAL|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
62706993|NCT03093714|EXPERIMENTAL|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
62706994|NCT03093714|PLACEBO_COMPARATOR|Placebo|Multiple dose placebo as repeat doses in CF subjects
62706995|NCT01731782|ACTIVE_COMPARATOR|bupivacaine|bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
61967764|NCT01283360|ACTIVE_COMPARATOR|Tenofovir 1% Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
61967765|NCT05118503|ACTIVE_COMPARATOR|Customized education app|A customized URL-based platform will present brief education videos addressing a patients stroke etiology, risk factors, stroke prevention medications, and post-stroke lifestyle issues. This URL will be made available to the patient and caregiver.
61967766|NCT05118503|PLACEBO_COMPARATOR|Standard of care discharge education|Standard discharge education is performed by the bedside nurse at the time of hospital discharge.
61967767|NCT03198234|EXPERIMENTAL|Cohort 1|Participants will receive 1 X 10\^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
61967768|NCT03198234|EXPERIMENTAL|Cohort 2|Participants will receive 3 X 10\^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
61967769|NCT03198234|EXPERIMENTAL|Cohort 3|Participants will receive 9 X 10\^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
62706996|NCT01731782|PLACEBO_COMPARATOR|normal saline|Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
61967770|NCT00439660|EXPERIMENTAL|rotavirus vaccine 116E 1 X 10(4)|vaccine dose of 1 X 10(4) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
61967771|NCT00439660|EXPERIMENTAL|rotavirus vaccine 116E 1 X 10(5)|vaccine dose of 1 X 10(5) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
61967772|NCT02710565|OTHER|Cohort|"Participants who are scheduled to have an endo bronchial ultrasound (EBUS) trans bronchial needle aspiration (TBNA) will provide additional samples. These samples will then be sent to Imperial College London to see whether a cell line can be grown.~If growth is successful then the samples will be returned to our pathology department to see if grading is possible and then to compare these results with the previous diagnostic samples.~The cell line samples will not be used for patient diagnosis."
61967773|NCT02557620|EXPERIMENTAL|semaglutide OD + placebo semaglutide OW|
61967774|NCT02557620|PLACEBO_COMPARATOR|placebo semaglutide OW + placebo semaglutide OD|
61967775|NCT02557620|EXPERIMENTAL|semaglutide OW + placebo semaglutide OD|
61967776|NCT04847505|EXPERIMENTAL|Neuroendocrine cancer patients|"All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician.~Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed."
62706997|NCT03360994|EXPERIMENTAL|WATChmAN|Patients randomized to the WATChmAN Active Surveillance arm will receive their active surveillance testicular cancer care via an online virtual clinic. Importantly, patients will follow the same surveillance schedule as patients in the standard of care arm. However, patients in the WATChmAN arm will be able to see their upcoming tests and virtual appointments online, request requisitions to perform their required testing at outside institutions, and indicate any concerns for physicians to review during the virtual visit.
61967777|NCT05834660|EXPERIMENTAL|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
61967778|NCT01525368||cognitive intervention group|
61967779|NCT01525368||active control group|
61967780|NCT05071456|EXPERIMENTAL|Atopic dermatitis patients|
61967781|NCT05071456|EXPERIMENTAL|Patient with oily acne skin|
61967782|NCT05071456|ACTIVE_COMPARATOR|Control group of patient without facial dermatosis|
61967783|NCT02782975|EXPERIMENTAL|aducanumab IV|Infusion of aducanumab over approximately 1 hour
61967784|NCT02782975|EXPERIMENTAL|aducanumab SC|Subcutaneously via injection
61967785|NCT01458652|EXPERIMENTAL|Lifestyle counseling|"Drug:Kremezin~Other Names:AST-120~Kremezin is an oral adsorbent, 9g/day in treatment arm"
61967786|NCT01432080|NO_INTERVENTION|Standard of Care|Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
61967787|NCT01432080|EXPERIMENTAL|SAMS|Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).
61967788|NCT01448811|EXPERIMENTAL|AEP monitoring|
61967789|NCT01448811|ACTIVE_COMPARATOR|RSS monitoring|
62706998|NCT03360994|ACTIVE_COMPARATOR|Standard of Care|Patients randomized to the standard of care arm (in-person active surveillance) will follow the current active surveillance protocol in place at Princess Margaret Cancer Centre's Multidisciplinary Testicular Cancer Clinic. This protocol involves the same schedule of testing as the WATChmAN arm, but will require patients to come into the clinic to receive their test results (as in current practice).
62706999|NCT05577156||Patients|
61967790|NCT04988646|EXPERIMENTAL|Acyclovir Tablet|Participants received Acyclovir Tablet 200 mg or 400 mg with 240 mL of water
61967791|NCT04988646|ACTIVE_COMPARATOR|Zovirax® Tablet|Participants received Zovirax® Tablet 200 mg or 2x200 mg with 240 mL of water
61967792|NCT04376372||TD_lefthanders|Typical developing lefthanded children and adolescents Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
61967793|NCT04376372||F_lefthanders|Forced left handed NBPP children Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
61967794|NCT03682445|ACTIVE_COMPARATOR|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
61967795|NCT03682445|ACTIVE_COMPARATOR|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
61967796|NCT03682445|NO_INTERVENTION|Control group|The participants in the control group will make stretching exercise at home
61967797|NCT01925053|PLACEBO_COMPARATOR|Ref meal|"The reference meal (REF) is based on WHO dietary guidelines for protein, fat and carbohydrate. It comprises everyday modern ingredients such as white rice."
61967798|NCT01925053|ACTIVE_COMPARATOR|PAL meal|Palaeolithic meal (PAL) is based on WHO dietary guidelines for protein, fat and carbohydrate but only uses ingredients that would have been available in Palaeolithic times (e.g. no cereals or dairy).
61967799|NCT03766633||Living liver donors|This is a group of living liver donors that underwent a CT prior to donating their partial liver to a recipient.
61967800|NCT03224572|EXPERIMENTAL|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
61967801|NCT03224572|PLACEBO_COMPARATOR|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
61967802|NCT01572220|OTHER|stress echocardiography|Comparative effectiveness
61967803|NCT01572220|OTHER|Myocardial SPECT|CER
61967804|NCT06436872|EXPERIMENTAL|intervention group|Caregivers in the study group were given 45 minutes of training and a booklet in line with the training booklet prepared according to daily life activities aimed at improving the patient's quality of life and reducing the caregiver's care burden. The caregivers in the study group were given the researcher's contact number and were able to reach the researcher whenever they needed.
61967805|NCT06436872|NO_INTERVENTION|Control Group|Patients in the control group underwent standard procedure; No information, training booklet or contact number was provided. The Caregiver Information Form was administered by the researcher in a face-to-face meeting with the caregiver. The Patient Introduction Form was filled out by the researcher from the patients' files. Multidimensional Quality of Life Scale was administered by the researcher. The Caregiving Burden Scale was introduced to the caregiver by the researcher and filled in by the caregiver himself. The Caregiver Tracking Form, prepared to track the patient and the caregiver, was applied to the caregiver by the researcher in order to determine the caregiver's zero point.
62350931|NCT06119451|EXPERIMENTAL|Interventional Group|Participants who will be given both educational video and traditional music therapy 3 times a week for 4 weeks in a row. This group will get Maslach Burnout Inventory, Heart Rate Variability, IgA, T cell regulator, cortisol, and endorphine score evaluated before, in the middle, right after finishing intervention, and 2 weeks after intervention.
62707000|NCT03534492|EXPERIMENTAL|Durvalumab plus Olaparib|Durvalumab 1500 mg every 4 weeks for up to a maximum of 2 months (up to 2 doses/cycles) plus Olaparib 300 mg b.i.d. up to 56 days (2 cycles of 28 days each cycle).
61967806|NCT01411904|EXPERIMENTAL|MagProbe (TM)|"Patients whose bone marrow aspirates are exposed to the MagProbe and CD34 nanoparticles.~Leukemia patients~* MagProbe (TM)~* Diagnosed or suspected leukemia~Non-leukemia patients~* MagProbe (TM)~* Requiring bone marrow biopsy"
61967807|NCT04199611|EXPERIMENTAL|Integrated Therapy Group|Both liposuction and psychological therapy are delivered to the participants in this group.
61967808|NCT04199611|ACTIVE_COMPARATOR|Liposuction Group|This group experiences only liposuction and do self-help care after the liposuction.
61967809|NCT04199611|ACTIVE_COMPARATOR|Psychological Therapy Group|This group experiences only cognitive behavioral therapy (CBT; psychological therapy) during the intervention period.
61967810|NCT04199611|NO_INTERVENTION|Self-help Group|This group do not receive any interventions and do self-help care.
61967811|NCT01790256|ACTIVE_COMPARATOR|Cereve Sleep System at 14-16 degrees C.|Active
61967812|NCT01790256|ACTIVE_COMPARATOR|Cereve Sleep System at 30 degrees C|Active
61967813|NCT01640223|EXPERIMENTAL|D-3 sensor|patients will be equiped with 2 Dexcom sensors 3 days before hospitalization
61967814|NCT01640223|EXPERIMENTAL|D-1 sensor|patients will be equiped with 2 Dexcom sensors one day before hospitalization
61967815|NCT04346602||patients with COVID-2019|Patients with COVID-2019 would be observed.
61967816|NCT04933656|EXPERIMENTAL|50g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
61967817|NCT04933656|EXPERIMENTAL|90g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
61967818|NCT04933656|EXPERIMENTAL|130g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
61967819|NCT04933656|EXPERIMENTAL|170g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
61967820|NCT01474057|EXPERIMENTAL|DESTRESS-PC|A brief, nurse-assisted, Internet-based online self-management tool for PTSD (DESTRESS-PC), based on empirically valid cognitive-behavioral therapy (CBT) strategies and designed for implementation in a primary care setting. DESTRESS-PC stands for DElivery of Self-TRaining and Education for Stressful Situations for Primary Care.
62350932|NCT06119451|NO_INTERVENTION|Control group|Participants who will be given only educational video. This group will get Maslach Burnout Inventory, Heart Rate Variability, IgA, T cell regulator, cortisol, and endorphine score evaluated before, in the middle, right after finishing intervention, and 2 weeks after intervention.
62707001|NCT00415636|EXPERIMENTAL|LY2603618 40 mg/m^2 (4.5-hour infusion)|LY2603618 40 milligrams per square meter (mg/m\^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed.
61967821|NCT01474057|ACTIVE_COMPARATOR|OUC|Optimized Usual Care (OUC) for PTSD--usual PTSD treatment offered within the primary care setting, optimized by training PC providers in PTSD identification and treatment and providing basic care management including phone check-ins to monitor symptoms and feedback to providers.
61967822|NCT04412408|EXPERIMENTAL|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
61967823|NCT03471130|EXPERIMENTAL|Low dose MT-8554 or placebo to match|Low dose MT-8554
61967824|NCT03471130|EXPERIMENTAL|High dose MT-8554 or placebo to match|High dose MT-8554
61967825|NCT05438056|EXPERIMENTAL|providing training to mothers of premature babies with a mobile application|providing training with mobile application to mothers discharged home with their premature babies +standard education prior to discharge
62707002|NCT00415636|EXPERIMENTAL|LY2603618 40 mg/m^2 (1-hour infusion)|Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m\^2 \[4.5-hour infusion\]), the LY2603618 40 mg/m\^2 dose in Cohort 2 (LY2603618 40 mg/m\^2 \[1-hour infusion\]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed.
62707003|NCT00415636|EXPERIMENTAL|LY2603618 70 mg/m^2|Beginning with Cohort 3 (LY2603618 70 mg/m\^2), dose modifications were allowed. LY2603618 70 mg/m\^2 was administered over the course of 1 hour.
62707004|NCT00415636|EXPERIMENTAL|LY2603618 105 mg/m^2|Cohort 4: LY2603618 105 mg/m\^2 administered over the duration of 1 hour.
62707005|NCT00415636|EXPERIMENTAL|LY2603618 150 mg/m^2|Cohort 5: LY2603618 150 mg/m\^2 administered over the duration of 1 hour.
61967826|NCT05438056|NO_INTERVENTION|standard education prior to discharge control group; standard education prior to discharge|standard education prior to discharge
61967827|NCT04404374|ACTIVE_COMPARATOR|A-PRF|Advanced Platelet-Rich Fibrin
61967828|NCT04404374|ACTIVE_COMPARATOR|EMD|Enamel Matrix Derivatives
61967829|NCT00989378||control|normal healthy men and women
62350933|NCT06436625|ACTIVE_COMPARATOR|Outpatient Pulmonary Rehabilitation|The intervention group will receive 6 weeks of outpatient pulmonary rehabilitation in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
62350934|NCT06436625|NO_INTERVENTION|Control|The control group receives no pulmonary rehabilitation since this is standard of care.
62350935|NCT04753138|EXPERIMENTAL|SBO with calcium silicate sealer|The teeth will be obturated with the single cone technique and BC sealer
62707006|NCT00415636|EXPERIMENTAL|LY2603618 195 mg/m^2|Cohort 6: LY2603618 195 mg/m\^2 administered over the duration of 1 hour.
62707007|NCT04868422|EXPERIMENTAL|Telemonitoring|After CPAP titration, patients will be followed with telemonitoring device attached to the fixed pressure CPAP device
61967830|NCT03983291|EXPERIMENTAL|FaReWell Depression|Physiotherapeutic exercises for the relaxation of facial muscles associated with the expression of negative emotions and for the activation and strengthening of facial muscles associated with the expression of positive emotions 15 minutes daily
61967831|NCT03983291|PLACEBO_COMPARATOR|Resting exercise|Resting 15 minutes daily
61967832|NCT03856164|ACTIVE_COMPARATOR|Tranexamic acid|Tranexamic Acid for intravenous administration.
61967833|NCT03856164|PLACEBO_COMPARATOR|Placebo|Normal saline for intravenous administration.
61967834|NCT02235480|EXPERIMENTAL|Tazarotene Gel|once daily
61967835|NCT02235480|PLACEBO_COMPARATOR|Placebo Gel|once daily
61967836|NCT04691453|ACTIVE_COMPARATOR|QM-C Hysterectomy|QM-C Hysterectomy
61967837|NCT04691453|EXPERIMENTAL|QM-B Hysterectomy|QM-B Hysterectomy
61967838|NCT02850029||critically ill patients|Critically ill patients admitted in intensive care units and receiving one of the following aminoglycosides: gentamicin, tobramycin and amikacin as part of their usual care.
61967839|NCT05499312|EXPERIMENTAL|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
61967840|NCT05499312|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
61967841|NCT04978740|EXPERIMENTAL|Participants affected by cutaneous and systemic mastocytosis|Participants affected by cutaneous and systemic mastocytosis with or without eye disabilities
61967842|NCT03347877|EXPERIMENTAL|autologous bone-periosteal graft|The patients in experimental group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteo-periosteal cylinder graft transplantation.
62350936|NCT04753138|ACTIVE_COMPARATOR|WVC with resin based sealer|The teeth will be obturated with warm vertical compaction and AH+ sealer
62350937|NCT00988260|EXPERIMENTAL|Ganirelix 0.125 mg|
62350938|NCT00988260|EXPERIMENTAL|Ganirelix 0.25 mg|
62350939|NCT00988260|EXPERIMENTAL|Ganirelix 0.5 mg|
62350940|NCT05893667||High levels of inflammatory scores|
62350941|NCT05893667||Low levels of inflammatory scores|
62350942|NCT04457128|EXPERIMENTAL|Secular Image|Secular Image
62350943|NCT04457128|EXPERIMENTAL|Non-secular image|non-secular images
62350944|NCT04457128|EXPERIMENTAL|Secular message|secular messages
62350945|NCT04457128|EXPERIMENTAL|Non-secular message|non-secular messages
62350946|NCT00587769|EXPERIMENTAL|Bupropion SR & Varenicline|All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.
62707008|NCT04868422|NO_INTERVENTION|Usual care|Patients with fixed pressure CPAP will be followed according to routine protocol without telemonitoring
62707009|NCT00475098|ACTIVE_COMPARATOR|A|
62707010|NCT00475098|EXPERIMENTAL|B|
62350947|NCT03219567|EXPERIMENTAL|Normals|Normal subjects will be imaged with the OCT system to ensure the imaging range of the system.
62350948|NCT03219567|EXPERIMENTAL|Patients with a history of cataract surgery or high myopia|Subjects will be imaged with both the OCT system and MRI. Reconstructions of the eye from each modality will then be compared.
62350949|NCT04503941|EXPERIMENTAL|Active Comparator|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
62350950|NCT04503941|PLACEBO_COMPARATOR|The control group|False Needle treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
62350951|NCT04438252|EXPERIMENTAL|Cariescan pro|device for early caries detection
62350952|NCT04438252|EXPERIMENTAL|ICDAS II|Index for caries detection
62350953|NCT04564066|EXPERIMENTAL|efgartigimod IV|intravenous infusions of efgartigimod
62509342|NCT04733209|EXPERIMENTAL|Mobilization with movement|"Mobilization with movement technique and traditional physiotherapy were applied to the intervention group. For mobilization with movement technique, the patient was asked to actively flex and extend the wrist with the forearm in neutral in a sitting position on a treatment table, and the pain was asked. The painful side was determined according to the patient's statement.~In a patient whose painful side was flexion, the wrist joint was shifted manually (with the help of the web space of both hands of the therapist) to the lateral and medial at the same time while the patient actively flexed the wrist. The treatment was done 3 times a week for 4 weeks."
62350954|NCT04564066|EXPERIMENTAL|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
62350955|NCT04765748||TAAA patients with Cytosorb|Patients suffering from a TAAA larger than 55mm
62350956|NCT04765748||TAAA patients without Cytosorb|Patients suffering from a TAAA larger than 55mm
62350957|NCT00489034||Index Participants|HIV-infected females, ages 13- 23 years, recruited from ATN sites in New York, Chicago, Miami, Los Angeles, and New Orleans will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic and/or gender interviewing.
62539346|NCT04751929|EXPERIMENTAL|CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle"
62707011|NCT04687930|ACTIVE_COMPARATOR|Active genicular nerve block group|group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).
62350958|NCT00489034||Network Participants|Closest friends of index participants s and parents/guardians of index participants who know the index participant's HIV status will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic interviewing.
62350959|NCT05573529|EXPERIMENTAL|Edof IOL vs. multifocal IOL I|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive Edof IOL one (I) vs. multifocal IOL one (I).
62350960|NCT05573529|EXPERIMENTAL|Edof IOL vs. multifocal IOL II|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm two (II) participants will receive Edof IOL one (I) vs. multifocal IOL two (II).
62350961|NCT03297216|ACTIVE_COMPARATOR|250 mg 17P|weekly intramuscular injection of 250mg 17P
62350962|NCT03297216|PLACEBO_COMPARATOR|Placebo|weekly intramuscular injection of indistinguishable placebo
62350963|NCT02483702|EXPERIMENTAL|Patients under 4 months Receive Irradiated Blood|Patients under 4 months of age will receive irradiated blood products, as per hospital protocol. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
62350964|NCT02483702|EXPERIMENTAL|Patients Over 4 Months Recieve Non-Irradiated Blood|Patients over 4 months of age will receive non-irradiated blood products. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
62350965|NCT00517283|EXPERIMENTAL|Sequence 1|Exenatide 5 mcg - Exentatide 10 mcg - Placebo
62350966|NCT00517283|EXPERIMENTAL|Sequence 2|Exenatide 10 mcg - Placebo - Exenatide 5 mcg
62350967|NCT00517283|EXPERIMENTAL|Sequence 3|Placebo - Exenatide 5 mcg - Exenatide 10 mcg
62350968|NCT03714347|ACTIVE_COMPARATOR|Group Control|routine monitoring will be applied to this group
62350969|NCT03714347|ACTIVE_COMPARATOR|Group Oxygen|cerebral oxygen monitoring is applied to this group
62350970|NCT03015025||Stable treatment with acenocoumarol|Patients in stable anticoagulant treatment with acenocoumarol for auricular fibrillation, venous thromboembolic disease and/or cardiac valve replacement.
62350971|NCT00489372|PLACEBO_COMPARATOR|Arm I (placebo)|Participants receive oral placebo on day 1.
62350972|NCT00489372|EXPERIMENTAL|Arm II (Se-methyl-seleno-L-cysteine)|Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.
62350973|NCT06386172|EXPERIMENTAL|Intervention|Centers which have been randomized to recieve the intervention with CKD clinical decision support triggers will be administered via ALMA
62350974|NCT06386172|NO_INTERVENTION|Care as usual|Centers which have been randomized to no intervention and receive only prior/general clinical decision support triggers currently available in the ALMA platform. They do not receive the specific clinical decision support triggers for CKD.
62350975|NCT00920478|ACTIVE_COMPARATOR|Control Group|Inflammatory disease activity assessed using DAS28
62350976|NCT00920478|EXPERIMENTAL|Ultrasound Group|Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)
62350977|NCT00944788|EXPERIMENTAL|qi-gong|
62350978|NCT00944788|NO_INTERVENTION|Usual care|
61967843|NCT03347877|ACTIVE_COMPARATOR|autologous osteochondral graft|The patients in control group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteochondral graft transplantation.
61967844|NCT01033591|EXPERIMENTAL|Exercise|Supervised exercise + Optimized treatment according to the European Society of Cardiology guidelines
62707012|NCT04687930|OTHER|intra-articular steroid injection group|while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.
61967845|NCT01033591|OTHER|Control|Optimized treatment according to the European Society of Cardiology guidelines
61967846|NCT03256877||All participants|Patients with haematuria.
61967847|NCT05284214|EXPERIMENTAL|Sargramostim daily: 14 of 21 days|Sargramostim administered by subcutaneous (SC) injection for 14 consecutive days every 3 weeks, for up to 12 weeks, given in combination with an ipilimumab-containing regimen.
61967848|NCT05284214|EXPERIMENTAL|Sargramostim daily: 5 of 7 days|Sargramostim given by SC injection for 5 consecutive days every week, for up to 12 weeks, given in combination with an ipilimumab-containing regimen for a total of 12 weeks.
61967849|NCT03364023||Acute Ischemic Stroke Patients|Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device
61967850|NCT04081168|ACTIVE_COMPARATOR|Stereotactic Body Radiotherapy|Patients included will undergo Stereotactic Body Radiotherapy (SBRT) of hepatic metastases.
61967851|NCT04081168|ACTIVE_COMPARATOR|Microwave Ablation|Patients included will undergo Microwave Ablation (MWA) of hepatic metastases.
62350979|NCT02486367|ACTIVE_COMPARATOR|Standard care/clopidogrel|300mg load followed by 75mg daily.
62350980|NCT02486367|EXPERIMENTAL|Ticagrelor|180mg load followed by 90mg twice daily for 30 days.
62350981|NCT02034552|EXPERIMENTAL|Radium-223 dichloride (Xofigo, BAY88-8223)|
62350982|NCT02034552|EXPERIMENTAL|Radium-223 with abiraterone&prednisone|
62350983|NCT02034552|EXPERIMENTAL|Radium-223 with enzalutamide|
62350984|NCT04655209|EXPERIMENTAL|M1-Seq group|
62350985|NCT04655209|EXPERIMENTAL|PMC-Seq group|
62707013|NCT01358162|EXPERIMENTAL|SQ109|300 mg of SQ109, orally, given daily for 14 consecutive days
61967852|NCT02101476|ACTIVE_COMPARATOR|Percocet|Oxycodone/APAP (acetaminophen)
61967853|NCT02101476|ACTIVE_COMPARATOR|Xartemis|
61967854|NCT03851068|EXPERIMENTAL|Tria Aortic Valve|Patients receiving the Foldax Tria Aortic Valve
61967855|NCT00660998|EXPERIMENTAL|Arm 1|
61967856|NCT00660998|PLACEBO_COMPARATOR|Arm 2|
61967857|NCT01661621|EXPERIMENTAL|Group 1|Antimuscarinics (Detrusitol 4 mg QD)
61967858|NCT01661621|EXPERIMENTAL|Group 2|α-blockers (Doxazosin 4 mg QD)
62350986|NCT04655209|SHAM_COMPARATOR|MT with sham tDCS|
62350987|NCT04791033||Adenomyosis|Patients with adenomyosis
62350988|NCT04791033||Other benign gynecological conditions|Patients with other benign gynecological conditions (i.e: myomas, endometriosis).
61967859|NCT03234686|EXPERIMENTAL|Deferiprone|Patients will orally receive the equivalent 15 mg/kg of 600mg delayed release Deferiprone tablets twice daily.
61967860|NCT03234686|PLACEBO_COMPARATOR|Placebo|Patients will receive matching placebo tablets designed to mimic the experimental treatment, twice daily
61967861|NCT00039832|EXPERIMENTAL|1|CT
61967862|NCT00039832|EXPERIMENTAL|2|MRI
61967863|NCT01856413|EXPERIMENTAL|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
62350989|NCT03685370|ACTIVE_COMPARATOR|LOS group|Patients randomized to recieve epidural catheter placement with LOS technique, without any Rx control
62350990|NCT03685370|EXPERIMENTAL|X-ray group|Patients randomized for X-ray placement of epidural catheter
62350991|NCT05815680|EXPERIMENTAL|warfarin+atorvastatin+IBI362|
62350992|NCT05815680|EXPERIMENTAL|metformin+digoxin+IBI362|
62350993|NCT04945213|EXPERIMENTAL|Biperiden|Drug: Biperiden 5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
62350994|NCT04945213|PLACEBO_COMPARATOR|Placebo|"Placebo~1 mL of sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 mL of 0,9% saline - every 6 hours for 10 consecutive days - IV"
62350995|NCT02836483|EXPERIMENTAL|Group 1|LCB01-0371 800mg, QD
62350996|NCT02836483|EXPERIMENTAL|Group 2|LCB01-0371 400mg, BID
62350997|NCT02836483|EXPERIMENTAL|Group 3|LCB01-0371 800mg, BID
62707014|NCT01358162|PLACEBO_COMPARATOR|Placebo|Placebo given orally, daily for 14 consecutive days
62707015|NCT05151926|EXPERIMENTAL|Full weight-bearing|Full immediate weight-bearing postoperatively
62707016|NCT05151926|ACTIVE_COMPARATOR|Partial-weight bearing|Partial weight-bearing for the first 6 weeks postoperatively.
61967864|NCT01355341|EXPERIMENTAL|HERBMED PLUS|Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
61967865|NCT03571152|EXPERIMENTAL|Educational videos|Subjects allocated in this arms will receive the educational videos.
61967866|NCT03554746|EXPERIMENTAL|GC group|It mainly involve core stability exercise, stretching exercise and gluteal control training. All of above will be arranged 3 times a week for a total 6 weeks.
61967867|NCT03554746|EXPERIMENTAL|CG group|It involve core stability exercise and stretching exercise. All of above will be arranged 3 times a week for a total 6 weeks.
61967868|NCT04140591|PLACEBO_COMPARATOR|Proton-pump inhibitor|PPI: Pariet EC 20 mg/QDAC
62350998|NCT02836483|ACTIVE_COMPARATOR|Group 4|Tubes 3\~5Tablet, QD
62350999|NCT02836483|ACTIVE_COMPARATOR|Group 5|Zyvox 600mg, BID
62351000|NCT02836483|EXPERIMENTAL|Group 6|LCB01-0371 1200mg, QD
62351001|NCT00347412|EXPERIMENTAL|Group A: NOV-002 plus Chemotherapy|NOV-002 in combination with Paclitaxel and Carboplatin
61967869|NCT04140591|ACTIVE_COMPARATOR|Propranolol+Proton-pump inhibitor|"Propranolol:~Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)~PPI: Pariet EC 20 mg/QDAC"
61967870|NCT01492244||Patients with knee pain and a known diagnosis|
61967871|NCT04155060||DM group , non-DM group|Septic patients were divided into the DM group and non-DM group, based on their comorbidity
62351002|NCT00347412|ACTIVE_COMPARATOR|Group B: Chemotherapy Alone|Paclitaxel and Carboplatin
61967872|NCT04155060||high lactate group,low lactate group|high lactate group (lactate \> 2 mmol/L) and low lactate group (lactate ≤ 2 mmol/L), according to the admission lactate level.
61967873|NCT01235247|EXPERIMENTAL|reminders, no reminder|
61967874|NCT01260636|EXPERIMENTAL|MultiHance contrast agent|MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)
61967875|NCT01260636|ACTIVE_COMPARATOR|Magnevist|Magnevist administered at a dose of 0.2 mmol/kg
61967876|NCT01612936|EXPERIMENTAL|Allergic asthmatic, allergic nonasthmatic|Adults who are allergic asthmatics or allergic non-asthmatics will receive segmental allergen challenge to the lung
61967877|NCT05798169|EXPERIMENTAL|Intervention Group|Group of participants receiving resistance training during hospitalisation
61967878|NCT05798169|SHAM_COMPARATOR|Control Group|Group of participants receiving sham training during hospitalisation
61967879|NCT03095014|EXPERIMENTAL|Cesarean Myomectomy|Myomectomy plus Cesarean section
61967880|NCT03095014|ACTIVE_COMPARATOR|Cesarean section|Cesarean section only
61967881|NCT03006991||good efficacy|using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
62707017|NCT05014984|ACTIVE_COMPARATOR|Telephone Delivered MOVE!|During the baseline visit, Veterans randomized to the control arm will receive only the standard information about MOVE!, diet, and physical activity delivered by the same lay educators. They will not learn the WOOP technique nor receive telephone follow up as detailed below. While we considered having an attention control with the same amount of contact, we decided that the study would be more pragmatic and findings would be more relevant to real-world practice if the control arm followed standard patient education and referral strategies. Data collection during study visits will be at the same timepoints in both arms.
61967882|NCT03006991||poor efficacy|patients can not reach effective outcome.
61967883|NCT03907553||Health and Anemia|"individuals belonging to the Health and Anemia'' prospective population-based observational study (2003-2013) of all elderly residents (\>65 years) in the municipality of Biella"
61967884|NCT03907553||Monzino|"individuals belonging to the Monzino Over 80 trial"
61967885|NCT01479517|EXPERIMENTAL|Kovacaine Mist 0.1 mL x 4 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
61967886|NCT01479517|EXPERIMENTAL|Kovacaine Mist 0.2 mL x 2 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
62351003|NCT04159077|EXPERIMENTAL|Tamsulosin Hydrochloride (HCL)|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of tamsulosin HCL to be started 3 days prior to their date of surgery.
62351004|NCT04159077|PLACEBO_COMPARATOR|Placebo|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of placebo to be started 3 days prior to their date of surgery.
62351005|NCT03241238|OTHER|Regular Brownie|Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
62351006|NCT03241238|OTHER|Psyllium Brownie|For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
61967887|NCT01479517|EXPERIMENTAL|Kovacaine Mist, 0.2 mL x 1 spray|Total dose: 6 mg tetracaine/0.1 mg oxymetazoline
61967888|NCT01502059|EXPERIMENTAL|Pilates Group|This group keep their usual treatment and did a Pilates treatment twice a week (one hour each class) during 90 days.
61967889|NCT01502059|NO_INTERVENTION|Control Groups|This group keep their usual treatment and can do the Pilates training after the end of the study.
61967890|NCT01554150|EXPERIMENTAL|Method of Levels Cognitive Therapy (MOL)|Participants in this arm will be able to receive therapy over a 3 month period. They will be able to schedule sessions with a therapist as and when they need them.
61967891|NCT01554150|NO_INTERVENTION|Contact Service|The Contact Service arm is effectively a waiting list control. Participants assigned this arm will remain on the service's waiting list during the 3 months of the therapy phase. These participants will have access to a 'Contact Service' provided by the study therapist, where they are able to contact him if they want further information about the study or their treatment options.
61967892|NCT01823185|ACTIVE_COMPARATOR|Clopidogrel|CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
61967893|NCT01823185|EXPERIMENTAL|Ticagrelor or prasugrel|Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
61967894|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
61967895|NCT02057406|ACTIVE_COMPARATOR|2:1 EPA/DHA|400/200 EPA/DHA fish oil 2 grams
61967896|NCT02057406|ACTIVE_COMPARATOR|High EPA|Almost pure EPA 2 grams
61967897|NCT02057406|PLACEBO_COMPARATOR|Placebo|Matched placebo corn oil capsules
61967898|NCT02602496|EXPERIMENTAL|Control|3 servings of refined grains per day.
61967899|NCT02602496|EXPERIMENTAL|Fruits and Vegetables|5 servings of fruits and vegetable per day.
61967900|NCT02602496|EXPERIMENTAL|Whole Grain|3 servings of whole grains per day.
61967901|NCT04235985|OTHER|All time points|
61967902|NCT05127434|EXPERIMENTAL|mRNA-1345|Single injection of mRNA-1345 on Day 1.
61967903|NCT05127434|EXPERIMENTAL|Placebo|Single injection of mRNA-1345 matching-placebo on Day 1.
61967904|NCT05127434|EXPERIMENTAL|mRNA-1345 BD|Single injection of mRNA-1345 on BD Day 1.
61967905|NCT04962204|ACTIVE_COMPARATOR|Virtual visitation group|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
61967906|NCT04962204|NO_INTERVENTION|Control group|Phone interview between physicians-caregivers once a day
62509343|NCT04733209|ACTIVE_COMPARATOR|Conventional|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the transverse carpal ligament in the wrist with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; tendon-nerve gliding exercises, night splint, stretching and strengthening exercises applied. The treatment was done 3 times a week for 4 weeks.
62509344|NCT06495190|EXPERIMENTAL|Blueberry + walking|Blueberry intake combined with walking exercise.
61967907|NCT03284827|EXPERIMENTAL|NOAC|60 mg once daily
61967908|NCT03284827|ACTIVE_COMPARATOR|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD)
62509345|NCT06495190|EXPERIMENTAL|Blueberry + stretching|Blueberry intake combined with stretching exercise.
62509346|NCT06495190|ACTIVE_COMPARATOR|Placebo + walking|Placebo intake combined with walking exercise.
61967909|NCT00958152|EXPERIMENTAL|Cohort 1|
62145169|NCT03915678|EXPERIMENTAL|Population 1: Pancreatic cancer|Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
62509347|NCT06495190|ACTIVE_COMPARATOR|Placebo + stretching|Placebo intake combined with stretching exercise.
62509348|NCT03710902|EXPERIMENTAL|Intervention|
62509349|NCT03710902|NO_INTERVENTION|Control|Standard diagnostic work-up, follow-up, and treatment of hypertension.
62509350|NCT03105934|EXPERIMENTAL|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
62509351|NCT00700817|EXPERIMENTAL|Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg|Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
62509352|NCT00700817|EXPERIMENTAL|Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg|Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
62509353|NCT00700817|ACTIVE_COMPARATOR|Sita -> Sita|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).
62509354|NCT00700817|EXPERIMENTAL|Sita -> Sita -> Lira 1.2 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.
62509355|NCT00700817|EXPERIMENTAL|Sita -> Sita -> Lira 1.8 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.
62509356|NCT02419924|EXPERIMENTAL|Experimental|Pelvic floor support device to treat refractory constipation.
62707018|NCT05014984|EXPERIMENTAL|Mental Contrasting with Implementation Intentions (WOOP) plus MOVE!|At the baseline visit, a lay educator will teach the WOOP technique in-person using protocols adapted from our prior work.12 After, to support WOOP practice, the lay educator will schedule and provide 3 follow-up telephone check-ins with the Veteran. This arm will also receive telephone-delivered MOVE!
62351007|NCT03241238|OTHER|β-glucan Brownie|For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later
62351008|NCT05690971|EXPERIMENTAL|Horizons mobile app|"Participants randomly assigned to the Horizons group, will use the Horizons app over an eight-week period in addition to receiving usual care from transplant team.~Participants will complete study questionnaires at the time of enrollment (baseline) and at eight and sixteen weeks after enrollment"
62509357|NCT03536494|EXPERIMENTAL|Mirabegron intervention|Review the use of mirabegron and its discontinuation
62707019|NCT06055283|EXPERIMENTAL|Training group|Aerobic exercise training on moderate intensity.
62145170|NCT03915678|EXPERIMENTAL|Population 2: Virus-associated tumors|Participants with virus-associated tumors will be treated with Atezolizumab combined with BDB001 and radiotherapy.
62509358|NCT03536494|NO_INTERVENTION|Control group|Usual care
62539347|NCT04751929|EXPERIMENTAL|CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
62707020|NCT06055283|NO_INTERVENTION|Control group|Monitoring.
62707021|NCT02693756|NO_INTERVENTION|Control|Participants will be allowed to perform all usual activities but should refrain from performing the motor imagery exercises.
62145171|NCT03915678|EXPERIMENTAL|Population 3: anti-PD-1/L1 refractory non-small lung cancer|Participants with anti-PD-1/L1 refractory non-small lung cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
61967910|NCT00958152|EXPERIMENTAL|Cohort 2|
61967911|NCT00958152|EXPERIMENTAL|Cohort 3|
61967912|NCT05885204||Sun Yat-sen Memorial Hospital|
61967913|NCT05885204||Renji Hospital, Shanghai Jiaotong University School of Medicine|
61967914|NCT05885204||The Third Medical Centre of Chinese PLA General Hospital|
61967915|NCT05885204||The First Affiliated Hospital of Nanchang University|
61967916|NCT05885204||Peking University Third Hospital|
62145172|NCT03915678|EXPERIMENTAL|Population 4: Soft-tissue sarcoma|Participants with soft-tissue sarcoma will be treated with Atezolizumab combined with BDB001 and radiotherapy.
61967917|NCT05885204||The Second Xiangya Hospital, Central South University|
62707022|NCT02693756|EXPERIMENTAL|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
61967918|NCT05885204||Zhongda Hospital Southeast University|
61967919|NCT05885204||The First Hospital of Jilin University|
62509359|NCT05674799|EXPERIMENTAL|Healthy Lifestyle|"Women in the Healthy Lifestyle group will be invited to attend the online NDPP-NextGen class which will cover how to eat healthy, be active, and lose weight before getting pregnant. The classes will be led by a trained Lifestyle Coach. Each class lasts about 1 hour. Classes initially meet about once a week (for the first 6 months), then twice a month (for the next 3 months), and then once a month (for the last 3 months). Classes will meet virtually through video-conference. Lifestyle coaches will also call participants in between classes to discuss how participants are doing, answer questions, and provide reminders for upcoming classes. Prior to the first class, women will also participate in a pre-session designed to increase NDPP engagement via discussion of diabetes risks and treatment options (i.e., clarify relevance) and motivational interviewing to resolve barriers."
62509360|NCT05674799|NO_INTERVENTION|Healthy Women|Women in the Healthy Women group get a packet of information standardly given in OB clinics about how to be healthy before, during and after pregnancy.
62707023|NCT04064905|EXPERIMENTAL|mRNA-1893|
62707024|NCT04064905|PLACEBO_COMPARATOR|Placebo|0.9% sodium chloride
62707025|NCT06075784|EXPERIMENTAL|Reiki|The intervention will be applied to the reiki group to be applied in the application laboratory of the midwifery department of the faculty of health sciences. Reiki therapy will be applied by a practitioner with a Reiki application certificate in the application laboratory for 30 minutes while the participants lie down with their eyes closed. 4 sessions of reiki application will be applied to the intervention group for a month. Reiki application will start from the time of menstruation, the first pain scores and comfort conditions will be recorded. Menstruation and general comfort after 4 sessions will be recorded. Any medication and side effects during menstruation with the last reiki application will be recorded by the research team member.
61967920|NCT05885204||Second Hospital of Dalian Medical University|
61967921|NCT05885204||Gansu Provincial Hospital|
61967922|NCT02056340|ACTIVE_COMPARATOR|Atorvastatin|Patients will be administered study medication (atorvastatin 40 mg) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
61967923|NCT02056340|PLACEBO_COMPARATOR|Placebo|Patients will be administered study medication (matched placebo) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
61967924|NCT01754610||Families participating in SFCR|Families who have experienced multiple traumas and high stress related to poverty
61967925|NCT02547649|EXPERIMENTAL|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
61967926|NCT02547649|EXPERIMENTAL|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
61967927|NCT02547649|ACTIVE_COMPARATOR|Prevnar 13®|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1
61967928|NCT05157984||Retrospective cohort|Any patient of the physicians listed in this study who has undergone the ZPOEM procedure to treat ZD at Methodist Health System
61967929|NCT05157984||Prospective cohort|Any patient of the physicians listed in this study who has undergone the ZPOEM procedure to treat ZD at Methodist Health System and has agreed to be follow-up post-procedure.
61967930|NCT05954013|EXPERIMENTAL|PD_Pal intervention|Participants with Parkinson's disease receive usual care from their established neurology and/or home care team + the PD_Pal intervention.
61967931|NCT05954013|NO_INTERVENTION|Control group|Participants with Parkinson's disease receive usual care from their established neurology and/or home care team.
61967932|NCT00671697|EXPERIMENTAL|Dose Level 1 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
61967933|NCT00671697|EXPERIMENTAL|Dose Level 2 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
61967934|NCT00671697|EXPERIMENTAL|Dose Level 3 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
61967935|NCT02582502|EXPERIMENTAL|Treatment|This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
61967936|NCT02582502|OTHER|Wait list Treatment|This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
61967937|NCT03768960|EXPERIMENTAL|Daratumumab|Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.
61967938|NCT01444118|EXPERIMENTAL|EGF Vaccine|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
61967939|NCT01444118|NO_INTERVENTION|Best Supportive Care|Patients in this arm will receive best supportive care
61967940|NCT03583489|PLACEBO_COMPARATOR|Placebo|
62509361|NCT02306837|EXPERIMENTAL|Consolidation chemo|Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
62509362|NCT05022407||Cohort 1 (SARS-CoV-2 uninfected)|Participants who test negative on the SARS-CoV-2 rapid test and are not considered at risk of COVID-19 or who have a negative RNA-PCR SARS-CoV-2 test result at baseline.
61967941|NCT03583489|EXPERIMENTAL|APD421|
61967942|NCT03583489|EXPERIMENTAL|APD421 + ondansetron|
61967943|NCT03724955|EXPERIMENTAL|Treatment Group|The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
61967944|NCT03724955|PLACEBO_COMPARATOR|Placebo Group|The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
61967945|NCT05028478|EXPERIMENTAL|Single Arm|"Four planned CN202 dose level of 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg~Subjects will receive CN202 by intravenous infusion (IV) on Day 1 of each cycle (once every 2 weeks) for up to 24 months"
62145173|NCT03915678|EXPERIMENTAL|Population 5: anti-PD-1/L1 refractory bladder cancer|Participants with anti-PD-1/L1 refractory bladder cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
62145174|NCT03915678|EXPERIMENTAL|Population 6: Triple negative breast cancer|Participants with triple negative breast cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
62145175|NCT03480815|ACTIVE_COMPARATOR|TLA device|These patients will be withdrawal of omalizumab treatment and receive nocturnal temperature controlled laminar flow device at nighttime for 12 months.
62509363|NCT05022407||Cohort 2 (SARS-CoV-2 infected)|Participants who test positive on RNA-PCR SARS-CoV-2.
62509364|NCT05022407||Cohort 3 (SARS-CoV-2 exposed)|Participants who have a positive SARS-CoV-2 rapid test result and are not considered to be at risk of active COVID-19 infection or have a negative RNA-PCR SARS-CoV-2 test.
62736691|NCT03835182|ACTIVE_COMPARATOR|Short wave diathermy group|The short wave diathermy group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The short wave diathermy group will be treated with a hotpack (20minutes), transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and short wave diathermy at a frequency of 27.12MHz (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
61976205|NCT04406961|ACTIVE_COMPARATOR|Standard sphincterotomy.|"Standard retrograde sphincterotomy is performed on 750 patients using a standard sphincterotome. After deep bile duct cannulation, the standard sphincterotome, the Erlangen pull-type model, retrogradely cuts all layers of the wall of the duodenum and sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve insert standard sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis."
62145176|NCT03480815|PLACEBO_COMPARATOR|None device|These patients will be withdrawal of omalizumab treatment and do not receive TLA device for 12 months.
62351009|NCT05690971|ACTIVE_COMPARATOR|Usual Care|"Participant in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.~Participants will complete study questionnaires at the time of enrollment (baseline) nad at eight and sixteen weeks after enrollment"
62351010|NCT01810549|ACTIVE_COMPARATOR|Anakinra|Anakinra 100mg. Every subject will receive one subcutaneous injection of study drug once during the study, a total of one injection.
62351011|NCT01810549|PLACEBO_COMPARATOR|Placebo|Every study participant will receive a single subcutaneous injection of Placebo once during the study, a total of one injection.
62145177|NCT04659382|EXPERIMENTAL|Single arm|XELOX + bevacizumab + atezolizumab + SIRT (Therasphere)
62351012|NCT01905670|EXPERIMENTAL|Implant|Implant of the WiCS-LV system
62351013|NCT03036111|SHAM_COMPARATOR|Hemorrhoidectomy|Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
62351014|NCT03036111|ACTIVE_COMPARATOR|trimebutine|Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
62351015|NCT00716638|EXPERIMENTAL|Treatment group 1|Trauma-focused Cognitive Behavior Therapy (TF-CBT)
62351016|NCT00716638|EXPERIMENTAL|Treatment group 2|Eye Movement Desensitization and Reprocessing (EMDR)
62351017|NCT02516150|EXPERIMENTAL|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
62351018|NCT02516150|ACTIVE_COMPARATOR|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
62351019|NCT05489120|NO_INTERVENTION|COMPARATOR|Follow-up of the CKD patient according to current practice i.e. low protein diet.
62351020|NCT05489120|EXPERIMENTAL|FLAVIS|Follow-up of the CKD patient according to the current practice i.e. low protein diet with the addition of of low-protein products (FLAVIS).
62351021|NCT00965146|EXPERIMENTAL|Scorpio® CR Total Knee System|Scorpio® CR Total Knee System Study Device
62351022|NCT02449408||Overweight or Obese|Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
62351023|NCT02449408||Premature or Small for Gestational Age|Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
62351024|NCT03427450||Healthy Volunteers (Controls)|A control population of healthy volunteers (HVs) consisting of women with no prior/current history of cancer and no known history of breast disease (the information obtained from the HVs may be 'self-reports', as complete medical records may not be available at the enrolling site for these control subjects), and with a broadly similar age range to the cancer patient study population. All eligible and consenting subjects will have blood draw.
62509365|NCT05022407||Cohort 4 ( Vaccinated)|Participants who declare having received at least one dose of COVID-19 vaccine (verbally or by showing vaccination card) at inclusion (for HCW or PLHIV) or at any follow-up visit (PLHIV) will be followed in this cohort.
62509366|NCT03431064||Surgical patients less than 18 years old|Patients less than 18 years old having surgery with general anesthesia at Boston Children's Hospital
62509367|NCT02136303|PLACEBO_COMPARATOR|S1-Placebo|placebo capsule with all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
62509368|NCT02136303|EXPERIMENTAL|S1-1L|capsule containing 1 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
61967946|NCT02187185|ACTIVE_COMPARATOR|Sonicare Elite-Flexcare|Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
62736692|NCT03835182|OTHER|Control group|The control group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The control group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
62145178|NCT02541318|EXPERIMENTAL|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
62351025|NCT03427450||MBC Patients (Cancers)|Women with either newly diagnosed metastatic breast cancer who are about to start a new line of therapy of any type for the treatment and/or management of their disease or those with currently progressive or recurrent disease (as determined by any means) will be eligible for enrollment into the cancer population. All eligible and consenting subjects will have blood draw.
62351026|NCT03475901|EXPERIMENTAL|Virtualy Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
62351027|NCT01530282|EXPERIMENTAL|measurement of respiratory mechanics|Invasive method: two catheters will be inserted to measure reference respiratory mechanics Non_invasive method: airway pressure measured during a 150-200 ms occlusion at the beginning of inspiration.
62351028|NCT04552431|PLACEBO_COMPARATOR|Placebo|Men assigned to placebo
62351029|NCT04552431|EXPERIMENTAL|Ciprofloxacin alone|Men assigned to Ciprofloxacin alone
62351030|NCT04552431|EXPERIMENTAL|Tamsulosin alone|Men assigned to Tamsulosin alone
62351031|NCT04552431|EXPERIMENTAL|Combination of ciprofloxacin and tamsulosin|Men assigned to a combination of ciprofloxacin and tamsulosin
62351032|NCT04580212|EXPERIMENTAL|Intervention arm|This arm received the poultry hygiene intervention.
62351033|NCT04580212|NO_INTERVENTION|Control arm|This arm received no intervention.
62351034|NCT03255265||Acute rejection|
62351035|NCT03255265||No acute rejection|
62351036|NCT05766436|ACTIVE_COMPARATOR|group D|will receive placebo ODF and nebulized dexmedetomidine (Precedex™ rxlist)
62351037|NCT05766436|ACTIVE_COMPARATOR|group M|will receive placebo nebulizer and ODF melatonin (metacyst ™ nerhadou)
62351038|NCT05766436|PLACEBO_COMPARATOR|group C|will receive placebo ODF and placebo 0.9% normal saline nebulizer
62351039|NCT04378699|EXPERIMENTAL|SMR Sensory Motor Rhythm (12-15 Hz)|3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region
62351040|NCT04378699|EXPERIMENTAL|the alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
62351041|NCT03557515|EXPERIMENTAL|CBT Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional CBT telephonic sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
62351042|NCT03557515|EXPERIMENTAL|Metta-Meditation Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional Metta-meditation sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
62351043|NCT01758926||Inflammatory bowel disease|Patients previously diagnosed as having IBD
62351044|NCT01758926||Health control|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
62351045|NCT01929265|EXPERIMENTAL|Rituximab - Bendamustine (RB)|"1 arm: Rituximab - Bendamustine (RB)~1 arm for all patients"
62351046|NCT04126031|EXPERIMENTAL|Part A, Cohorts 1-3|Single dose pharmacokinetics. This arm will include three age cohorts.
62351047|NCT04126031|EXPERIMENTAL|Part B, Cohorts 1-3|Multi-dose pharmacokinetics. This arm will include three age cohorts.
62351048|NCT00141037|ACTIVE_COMPARATOR|Steroid-Based Immunosuppression|Subjects will receive prednisone immunosuppression (10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing \<40kg and 1.5 mg/kg/day in subjects weighing \>40 kg) and proceed with a prednisone taper according to the trial's protocol.
62351049|NCT00141037|EXPERIMENTAL|Steroid-Free Immunosuppression|Subjects will receive extended daclizumab induction until the sixth month post-transplant (2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11 and months 4, 5, and 6).
62351050|NCT05109702|OTHER|Placebo Run-in|Participants self-administered placebo ocular drops, twice daily (BID) in both eyes for 14 days in the Placebo Run-in Period.
62351051|NCT05109702|EXPERIMENTAL|0.25% Tanfanercept Ophthalmic Solution|Participants self-administered tanfanercept 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks in Treatment Period.
62351052|NCT05109702|PLACEBO_COMPARATOR|Placebo|Participants self-administered tanfanercept placebo (vehicle solution) solution as topical ophthalmic drops, BID for up to 8 weeks in Treatment Period.
62351053|NCT00003828|EXPERIMENTAL|vinorelbine|vinorelbine 30 mg/m2/week IV bolus over approximately 6-10 minutes
62351054|NCT00967733|ACTIVE_COMPARATOR|High ALA-Low Linoleic|
62351055|NCT00967733|PLACEBO_COMPARATOR|Low ALA-Low Linoleic|
62351056|NCT00967733|ACTIVE_COMPARATOR|High ALA-High Linoleic|
62736693|NCT00399568|EXPERIMENTAL|IV acetaminophen 1 g/100 mL solution|
62736694|NCT00399568|PLACEBO_COMPARATOR|IV Placebo 100 mL solution|
61967947|NCT02187185|ACTIVE_COMPARATOR|Manual Toothbrush|Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
61967948|NCT00440219|EXPERIMENTAL|Prednisone group|Prednisone 50 mg daily for 10 days immediately pre-op
61967949|NCT00440219|PLACEBO_COMPARATOR|Placebo group|Placebo pill for 10 days immediately pre-operative
62509369|NCT02136303|EXPERIMENTAL|S1-2L|capsule containing 2 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
62509370|NCT02136303|EXPERIMENTAL|S1-5L|capsule containing 5 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
62509371|NCT02136303|EXPERIMENTAL|S2-Kale_extract|
62509372|NCT02136303|EXPERIMENTAL|S2-Kale_purée|
62509373|NCT02136303|PLACEBO_COMPARATOR|S3-Placebo|
61967950|NCT01658670|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC) exercise group|The EUC group is provided paid access to the exercise facility and has access to regular facility staff for the 18 month study period.
61967951|NCT01658670|EXPERIMENTAL|HEART Camp (HC) Intervention group|The HC intervention group will be provided paid access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
61967952|NCT05104320|EXPERIMENTAL|MICS-CABG|Patients undergoing MICS-CABG.
61967953|NCT05104320|ACTIVE_COMPARATOR|sternotomy CABG|Patients undergoing thoracotomy OPCABG.
61967954|NCT05937204|EXPERIMENTAL|one group pre- test post- test|
61967955|NCT04103853|EXPERIMENTAL|Proxalutamide|"Stage one - Dose climbing:~Each dose cohort will assess toxicity within the 35 days following the first dose of GT0918.~Stage two- the expansion cohort :~30 patients will be enrolled to the 200mg cohort . 15 patients will be enrolled to the 300mg cohort."
62145179|NCT02541318|OTHER|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
62351057|NCT00967733|PLACEBO_COMPARATOR|Low ALA-High Linoleic|
62351058|NCT03718702|EXPERIMENTAL|Intervention group|ePain will be accessible by the intervention group.
62351059|NCT03718702|NO_INTERVENTION|Control group|No intervention will be applied to control group and they can download an educational pamphlet only.
62351060|NCT04605939|EXPERIMENTAL|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated lievr fibrosis for 68Ga-DOTA-FAPI PET/MR imaging.
61967956|NCT03421028|ACTIVE_COMPARATOR|Control group|Patients with masticatory muscle pain treated with occlusal splint, physiotherapy and counseling
61967957|NCT03421028|EXPERIMENTAL|Experimental group 1|Patients diagnosed with masticatory muscle pain treated with 4 meetings of EMG-biofeedback assisted training
62351061|NCT05081596|EXPERIMENTAL|Problem Adaptation Therapy for Pain (PATH-Pain)|Problem Adaptation Therapy-PAIN (PATH-PAIN) is an emotion regulation intervention aimes to reduce stress and decrease depression and disability.
62351062|NCT05081596|NO_INTERVENTION|Attention Control Usual Care|Usual Care involves the continued medical attention and treatment provided by the subject's physician and other medical professionals in primary care. This may include medical intervention or referrals to specialists to address issues of depression, pain or memory difficulties. Subjects will also be asked to meet with a study research assistant for structured interviews and educational sessions consisting of general questions regarding health habits and other non-medical topics unrelated to cognitive impairment, pain, and depression. Additionally, subjects will receive an educational booklet on pain and depression.
62351063|NCT03771404|OTHER|Operable (stages I-IIIA) NSCLC|For Operable (stages I-IIIA) NSCLC Patients, blood sampling and tissue samples of the primary tumor as well as the regional involved lymph nodes and, in selected patients, from biopsies from metastasis
62509374|NCT02136303|EXPERIMENTAL|S3-AMD-Patients|
62509375|NCT02136303|EXPERIMENTAL|S3-non-AMD|
62509376|NCT02136303|PLACEBO_COMPARATOR|S1-Placebo-Tagetes|capsule containing all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
62509377|NCT02136303|EXPERIMENTAL|S1-1L-Tagetes|capsule containing 1 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
62509378|NCT02136303|EXPERIMENTAL|S1-2L-Tagetes|capsule containing 2 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
62509379|NCT02136303|EXPERIMENTAL|S1-5L-Tagetes|capsule containing 5 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
62509380|NCT02136303|EXPERIMENTAL|S1-10L-Tagetes|capsule containing 10 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
62509381|NCT05501808|EXPERIMENTAL|Enamic group|patient in this group received a restoration with enamic material
62509382|NCT05501808|ACTIVE_COMPARATOR|Cerasmart group|patient in this group received a restoration with Cerasmart material
62509383|NCT03550534|EXPERIMENTAL|Calcium Carbonate|Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks
62509384|NCT03550534|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks
62509385|NCT04057248|EXPERIMENTAL|Digital platform and CDE coaching intervention for patients with type 2 Diabetes|"Patients provided with digital platform and connected devices. They undergo digital and human (CDE) intervention based on patient captured clinical data.~Clinical parameters (HbA1C, weight, lipids profile, etc.) before and after intervention is assessed."
62509386|NCT04126954||Cinacalcet|Patients with primary or secondary hyperPTH resulting from phosphocalcic pathology treated by cinacalcet
62509387|NCT00670241|ACTIVE_COMPARATOR|1|
62509388|NCT00670241|ACTIVE_COMPARATOR|2|
62509389|NCT00670241|PLACEBO_COMPARATOR|3|
62145180|NCT03292406|EXPERIMENTAL|CD11301 Gel 0.06%|Participants applied 0.06% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
62351064|NCT04029324|ACTIVE_COMPARATOR|Immediate implant placement|Implants are placed immediately after extraction
62351065|NCT04029324|PLACEBO_COMPARATOR|Early implant placement|Implants are placed 4-8 weeks after extraction
62351066|NCT05133544|ACTIVE_COMPARATOR|Endocuff- AI assisted colonoscopy|Endocuff (Olympus, Hong Kong) and AI assisted colonoscopy will be used
62509390|NCT06217796|OTHER|Open Label Treatment|Single metered spray
62707026|NCT06075784|PLACEBO_COMPARATOR|Placebo reiki|Placebo Reiki will be applied to the participants in the group in the application laboratory of the midwifery department of the faculty of health sciences. The practice will be carried out in the application laboratory for 30 minutes, with the participants sitting with their eyes closed. Reiki life energy will not be transferred to participants in the placebo reiki group. Since the participants' eyes are closed, they will not know that there is a transfer. Placebo Reiki application will be performed in the laboratory 4 times during a month. Placebo application will start from the time of menstruation, and the first pain scores and comfort conditions will be recorded. After 4 sessions, menstruation and general comfort will be recorded. Any medication and side effects during menstruation with the last application will be recorded by the research team member.
62707027|NCT01463033|ACTIVE_COMPARATOR|Levetiracetam|66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
62707028|NCT01463033|NO_INTERVENTION|No Intervention Control|60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.
62707029|NCT02494414||French prospective cohort of cardiac arrest survivors|Outcome of cardiac arrest survivors: prospective cohort of Ile-de-France
61967958|NCT03421028|EXPERIMENTAL|Experimental group 2|Patients diagnosed with masticatory muscle pain treated with 8 meetings of EMG-biofeedback
61967959|NCT06440395||Small Steps for Big Changes: Diabetes Prevention Program|Diabetes Prevention Program (one-treatment group) The diabetes prevention program is a 4-week program that will introduce participants to a regular healthy behaviours that includes exercise and simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 24 months after the program has concluded.
62145181|NCT03292406|EXPERIMENTAL|CD11301 Gel 0.03%|Participants applied 0.03% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
62351067|NCT05133544|ACTIVE_COMPARATOR|AI-assisted colonoscopy|AI assisted colonoscopy will be used
62351068|NCT05133544|NO_INTERVENTION|Conventional colonoscopy|Conventional colonoscopy will be used without AI or Endocuff.
62351069|NCT02766595|OTHER|hyperventilation|Non-drug: performing hyperventilation while sitting up during routine EEG
62351070|NCT01203787|ACTIVE_COMPARATOR|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24
62509391|NCT05344716|EXPERIMENTAL|Laser|Intraurethral and vaginal laser treatment
62509392|NCT00724620|EXPERIMENTAL|Early Responders (ER)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have responded to therapy at Treatment Week 12 (ie, who are Early Responders defined by HCV-RNA\[-\] at Treatment Week 12) will continue the combined treatment for a total of 48 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
62509393|NCT00724620|EXPERIMENTAL|Slow Responders (SR): Decrease in viral load >=2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have a slow response to therapy at Treatment Week 12 (ie, Slow Responders who are not HCV-RNA\[-\] at Treatment Week 12 but decrease \>=2 log) will continue the combined treatment for a total of 72 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
62509394|NCT00724620|EXPERIMENTAL|Nonresponders (NR): Decrease in viral load <2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have not responded to therapy at Treatment Week 12 (ie, Nonresponders who are not HCV-RNA\[-\] at Week 12 of Treatment and/or have a decrease in viral load \<2 log) will stop treatment at Treatment Week 12.
62707030|NCT03901040|OTHER|obese patient|we will perform endoscopic ultrasound botulinum toxin (100 IU)injection to gastric antrum of obese patient with BMI more than 30 will
62736695|NCT01541007|ACTIVE_COMPARATOR|Standard Cabazitaxel Schedule|Cabazitaxel 25 mg/m2 every three weeks
62736696|NCT01541007|EXPERIMENTAL|Weekly cabazitaxel schedule|cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
62145182|NCT03292406|EXPERIMENTAL|Placebo|Participants applied placebo gel during cycle one followed by 0.03% CD11301 gel topically during cycle two once daily, 3 to 5 times per week, for 24 weeks.
62539348|NCT03903211|EXPERIMENTAL|Cognitively normal individuals|Cognitively normal individualswill receive a single IV injection of \[18F\]PI-2620.
61967960|NCT02853110|EXPERIMENTAL|Hypo-FLAME|External beam radiotherapy, 5 additional MRI scans, blood sampling
62145183|NCT04726657|ACTIVE_COMPARATOR|Premixed Insulin|Premixed Human Insulin
62145184|NCT04726657|ACTIVE_COMPARATOR|Premixed insulin|Premixed Insulin Analog
62145185|NCT04653688|EXPERIMENTAL|Parkinsonian syndromes patients|
62145186|NCT04653688|SHAM_COMPARATOR|healthy subjects|
62351071|NCT01203787|EXPERIMENTAL|Sorafenib Ramp-Up Regimen|200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
62351072|NCT00031499|EXPERIMENTAL|Azithromycin|Azithromycin 2.0 gram single oral dose.
62351073|NCT00031499|ACTIVE_COMPARATOR|Benzathine Penicillin|Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.
61967961|NCT02677467||Spontaneous epistaxis|A participant enroll if their age is over 18 with spontaneous epistaxis and their cause of visiting ER is spontaneous epistaxis. Exclusion criteria is that they needs immediately treatment for hypertensive urgency. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
61967962|NCT02677467||Bleeding of wound|A participant enroll if their age is over 18 with bleeding of wound and their cause of visiting ER is to bleed on wound. Exclusion criteria is that their wounds' condition is serious or their pain is much severe. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
61967963|NCT04771260||Case study #1|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967964|NCT04771260||Case study #2|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967965|NCT04771260||Case study #3|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967966|NCT04771260||Case study #4|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967967|NCT04771260||Case study #5|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967968|NCT04771260||Case study #6|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967969|NCT04771260||Case study #7|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967970|NCT04771260||Case study #8|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967971|NCT04771260||Case study #9|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967972|NCT04771260||Case study #10|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
61967973|NCT01139619||1|Inoperable non small cell lung cancer patients. Diagnosed between 2010-05-31 and 2009-06-01.
61967974|NCT05776199|EXPERIMENTAL|Ischemic Compression group|IC group with conservative technique in trigger points in levator scapulae muscle
61967975|NCT05776199|ACTIVE_COMPARATOR|Dry needling group|Dry needling group with invasive technique in trigger points in levator scapulae muscle
61967976|NCT03383198|ACTIVE_COMPARATOR|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
61967977|NCT03383198|ACTIVE_COMPARATOR|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
61967978|NCT01784458||intra-abdominal hypertension(IAH)|IAH group : patients developing IAH non-IAH group : patients without IAH
62509395|NCT02630290|PLACEBO_COMPARATOR|Ropivacaine|After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.
61967979|NCT04338698|ACTIVE_COMPARATOR|Control Intervention|Hydroxychloroquine
62145187|NCT02176577|EXPERIMENTAL|Product 0405|Topically Active Investigational Product 0405
61967980|NCT04338698|EXPERIMENTAL|Comparator 1|Azithromycin
61967981|NCT04338698|EXPERIMENTAL|Comparator 2|Oseltamivir
61967982|NCT04338698|EXPERIMENTAL|Comparator 3|Hydroxychloroquine + Azithromycin
62351074|NCT00796042|ACTIVE_COMPARATOR|1|Usual Care
61967983|NCT04338698|EXPERIMENTAL|Comparator 4|Hydroxychloroquine + Oseltamivir
61967984|NCT04338698|EXPERIMENTAL|Comparator 5|Oseltamivir + Azithromycin
61967985|NCT04338698|EXPERIMENTAL|Comparator 6|Hydroxyquinine + Oseltamivir + Azithromycin
61967986|NCT04338698|NO_INTERVENTION|Observational Cohort|Non-consenting to randomization
62145188|NCT04565717|EXPERIMENTAL|Part A: ALN-HSD|Participants will be administered a single dose of ALN-HSD.
62145189|NCT04565717|PLACEBO_COMPARATOR|Part A: Placebo|Participants will be administered a single dose of ALN-HSD-matching placebo.
62145190|NCT04565717|EXPERIMENTAL|Part B: ALN-HSD|Participants will be administered multiple doses of ALN-HSD.
62145191|NCT04565717|PLACEBO_COMPARATOR|Part B: Placebo|Participants will be administered multiple doses of ALN-HSD-matching placebo.
62145192|NCT04565717|EXPERIMENTAL|Part C: ALN-HSD|Participants will be administered multiple doses of ALN-HSD.
62145193|NCT00553332|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62351075|NCT00796042|EXPERIMENTAL|2|Individualized, Community-based, Pressure management and Mobility program:
62351076|NCT05034458|EXPERIMENTAL|Diet|Patients will do biologic treatment according to international guidelines and will do Crohns Disease Exclusion Diet( modulen- phase one ant two CDED) for 12 weeks.They will be monitored periodically by interview and physical examination by physician and nutritionist, laboratory, fecal calprotectin.
62351077|NCT05034458|NO_INTERVENTION|Control|Patients with normal treatment( biologic treatment indicated for CD)
62351078|NCT00606736||patients|subjects with right ventricular outflow tract arrhythmia
62351079|NCT00606736||control|subjects ,age match,healthy
62351080|NCT04766151|EXPERIMENTAL|Transdermal glyceryl trinitrate patches|
62351081|NCT04766151|PLACEBO_COMPARATOR|Transdermal placebo patches|
62509396|NCT02630290|EXPERIMENTAL|Ropivacaine + Dexmedetomidine|After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.
62509397|NCT04010916|ACTIVE_COMPARATOR|Group Pre = preoperatively before inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
62509398|NCT04010916|ACTIVE_COMPARATOR|Group Pre-T = preoperatively after inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
62539349|NCT03903211|EXPERIMENTAL|Subjects with Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment will receive a single IV injection of \[18F\]PI-2620.
62736697|NCT04660552|EXPERIMENTAL|CognilumTM|During the study participants will be wearing the photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
61967987|NCT04119492|EXPERIMENTAL|CO-OP Treatment Group|Participants in the treatment group will receive occupational therapy once weekly for 10 weeks using the published protocol for the CO-OP approach.
61967988|NCT04119492|NO_INTERVENTION|Waitlist Control Group|Participants in the waitlist control group not receive CO-OP intervention during this time. They will receive their CO-OP intervention 12 weeks after their baseline assessment.
62351082|NCT03428802|EXPERIMENTAL|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants with disease progression may continue pembrolizumab for up to 1 year.
62351083|NCT02279355||pressure ulcer group|Patient who developing pressure ulcer categorized as stage more than II after surgery
62351084|NCT02279355||Control group|Patients has identical values on the matching factors such as age, sex and surgical procedures of control group
62351085|NCT02928926||Thrombolysis|Acute ischaemic stroke patients who receive intravenous thrombolysis
62351086|NCT02928926||non thrombolysis|Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
62351087|NCT03499587||Obese pregnant women|BMI \>30 with early OB visit medical records accessible
62351088|NCT03499587||Normal weight pregnant women|BMI 18.5-25 with early OB visit medical records accessible.
62351089|NCT04907318||ANKORIS|Cataract surgery performed with POD26PAYT
62351090|NCT04907318||FINEVISION TORIC|Cataract surgery performed with POD26PAYFT
62351091|NCT01769469||Subjects Enrolled in ATN 110 or ATN 113|A subset of 100 participants who are enrolled in the ATN 110 or ATN 113 study will be recruited for participation in this study. There is no treatment or intervention for this study; however, all subjects will be on daily coformulated tenofovir/emtricitabine (TDF/FTC (Truvada®)) as part of the ATN 110 or ATN 113 study.
62351092|NCT02022956|EXPERIMENTAL|Open-Label Lorcaserin (BELVIQ)|
62351093|NCT05557669|EXPERIMENTAL|Investigation Group|Patients undergoing laparoscopic cholecystectomy for cholelithiasis
62351094|NCT05557669|NO_INTERVENTION|Control group|Patients with gallstone disease who are not planned for laparoscopic cholecystectomy in upcoming 3 months
62351095|NCT04861948|EXPERIMENTAL|Cohort A|
62351096|NCT04861948|EXPERIMENTAL|Cohort B|
62351097|NCT04861948|EXPERIMENTAL|Cohort C|
62351098|NCT04861948|EXPERIMENTAL|Cohort D|
61967989|NCT01786798|OTHER|Transvaginal sonography|
61967990|NCT01925677|EXPERIMENTAL|da Vinci® Single-Site™|Robotic-assisted single-incision laparoscopic nephrectomy.
61976206|NCT04406961|ACTIVE_COMPARATOR|Antegrade sphincterotomy. ASD.|750 patients underwent a new antegrade sphincterotomy using the new sphincterotome design developed by Dr. Dovbenko (ASD). After deep bile duct cannulation, the new design of sphincterotome, antegradely cuts only circular muscle layer of the sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve cannulation new design sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis.
62351099|NCT02067741|EXPERIMENTAL|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
62351100|NCT02067741|EXPERIMENTAL|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
62351101|NCT04771143|EXPERIMENTAL|AFQ056|Experimental study drug
62351102|NCT04771143|PLACEBO_COMPARATOR|Placebo|Matching placebo
62351103|NCT00388323|EXPERIMENTAL|1|
62351104|NCT06207695|EXPERIMENTAL|Brief Psychosocial Intervention|The group was leaded by two psychologists trained on trauma and disaster psychology, and group intervention. Each groups lasted 2.50 hours.
62351105|NCT00905619||Control|No kidney disease
62351106|NCT00905619||PreHD kidney disease|Kidney disease stage 4 or below
62351107|NCT00905619||Hemodialysis|Kidney disease receiving hemodialysis
62351108|NCT04522791|EXPERIMENTAL|RFB+VSOP (MCI)|"For home-based RFB+VSOP: The investigators will instruct subjects to do 10-minutes of app- guided paced breathing at RF daily; for select days, there will be VSOP training immediately following RFB.~A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions."
62351109|NCT04522791|ACTIVE_COMPARATOR|IR+VSOP (MCI)|The control IR strategy will be used, set-up of which will be the same as the RFB + VSOP intervention group with IR replacing RFB. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
62707031|NCT05903079|PLACEBO_COMPARATOR|Respondres placebo effect|"Braço: Comparador de placebo: responde ao efeito placebo Intervenção: 'Estimulação Transcraniana por Corrente Contínua - tDCS~Os pacientes receberão tratamento de estimulação tDCS córtex pré-frontal dorso lateral De acordo com o sistema 10-20 EEG, o ânodo será colocado no F3 esquerdo e o cátodo no F4 contralateral.~A estimulação placebo utiliza uma corrente de 2 miliamperes durante os primeiros minutos, nos 10 min e nos 19 minutos."
62707032|NCT05903079|ACTIVE_COMPARATOR|No Respondres placebo effect|"Braço: Comparador de placebo: responde ao efeito placebo Intervenção: 'Estimulação Transcraniana por Corrente Contínua - tDCS~Os pacientes receberão tratamento de estimulação tDCS córtex pré-frontal dorso lateral De acordo com o sistema 10-20 EEG, o ânodo será colocado no F3 esquerdo e o cátodo no F4 contralateral.~A estimulação placebo utiliza uma corrente de 2 miliamperes durante os primeiros minutos, nos 10 min e nos 19 minutos"
62539350|NCT03903211|EXPERIMENTAL|Subjects with Alzheimer Disease|Alzheimer Disease Subjects with Alzheimer Disease will receive a single IV injection of \[18F\]PI-2620.
62707033|NCT03947957|OTHER|collection of expectoration, stools and blood|
62707034|NCT04513236|NO_INTERVENTION|Control|No Airtime Incentive was given for completing the survey
62707035|NCT04513236|EXPERIMENTAL|Pre-survey incentive|0.1X incentive before the survey, 1X afterwards
62707036|NCT04513236|EXPERIMENTAL|Post-survey incentive|1X incentive after the survey
62707037|NCT03537703|EXPERIMENTAL|Active tDCS + Auditory Training|Cathodal tDCS plus concurrent active auditory training exercise
62707038|NCT03537703|ACTIVE_COMPARATOR|Active tDCS + Control Condition|Cathodal tDCS plus concurrent control condition
62707039|NCT03537703|ACTIVE_COMPARATOR|Sham tDCS + Auditory Training|Sham tDCS plus concurrent active auditory training exercise
62707040|NCT06164054|EXPERIMENTAL|Virtual Reality Rehabilitation Therapy|Experimental group.
62707041|NCT06164054|ACTIVE_COMPARATOR|Traditional Therapy|Control group.
62707042|NCT04870983||SAE group|SAE was defined as cerebral dysfunction in the presence of sepsis or septic shock and the absence of any of the exclusion criteria. For patients undergoing sedation during the ICU stay, the GCS scores were evaluated before sedation; for patients who have been sedated prior to ICU admission, the assumed GCS scores, i.e., the scores measured before any administration of sedative/relaxant drug were used for analysing; for postoperative patients, the GCS scores measured before surgery was used. The CAM-ICU was assessed daily by the nurse or the physician in charge of the patient during the ICU stay. For patients who were sedated, spontaneous awakening trials were performed daily; the longest evaluate time after withdrawal of sedation was 24 h during the trials. In this evaluation period, patients should be awake to evaluate their consciousness, and they were diagnosed of SAE if the patients were not awake.
62707043|NCT04870983||non-SAE group|The patient was diagnosed with sepsis or septic shock but could not be diagnosed with SAE
62707044|NCT04390282|EXPERIMENTAL|Application-based support system Lifepod®PAD|Patients in the experimental group will be introduced to and use Lifepod®PAD, a web-based application designed to support adherence to lifestyle advice and medication for three months. Lifepod®PAD is built as a two-side system. One side is the patient interface, the web-based application, accessible through a smartphone or tablet. The patients can log information about their lifestyle, symptoms and medication and review their data in relation to recommended targets. They get positive feedback, recommendations about healthy behaviours and receive notifications as short messages depending on their individual health status. The other side is the medical interface managed by the health care professionals. All information the patient is reporting into the app can be accessed by the treating nurse and the system ranks the patients, thus gives high priority to patients who have the greatest needs.
62707045|NCT04390282|NO_INTERVENTION|Life style advice according to usual practice|Patients in the control group will receive usual care meaning advice about lifestyle changes and medication from the physician at the visit in the vascular open clinic.
62707046|NCT04902612|EXPERIMENTAL|HM242-Solution|
62707047|NCT04902612|ACTIVE_COMPARATOR|Saline|
61976207|NCT05733624|EXPERIMENTAL|SCAI-001 0.01%|Cyclosporine 0.01%
61976208|NCT05733624|EXPERIMENTAL|SCAI-001 0.02%|Cyclosporine 0.02%
62539351|NCT03624686||healthy volunteer|
62539352|NCT03624686||luekemia patient|
62707048|NCT04798677|EXPERIMENTAL|Influenza vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Influenza vaccine followed by 30 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
62707049|NCT04798677|PLACEBO_COMPARATOR|Influenza vaccine + placebo|Influenza vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
62707050|NCT04798677|EXPERIMENTAL|Covid-19 vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Covid-19 vaccine followed by 35 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
62707051|NCT04798677|PLACEBO_COMPARATOR|Covid-19 vaccine + placebo|Covid-19 vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
62707052|NCT05459662|PLACEBO_COMPARATOR|Oat based porridge|Oat based porridge prepared with 64g of oat, 200ml of milk and 10 g of honey by the participant and consumed orally daily for 14 days as breakfast replacement
62707053|NCT05459662|ACTIVE_COMPARATOR|Enriched plant-based meal|Enriched plant-based meal pots (400 g) mixed with 25g of seeds and nuts consumed orally daily for 14 days as breakfast replacement
62707054|NCT02692573|EXPERIMENTAL|prone|Prone positioned after delivery
62707055|NCT02692573|ACTIVE_COMPARATOR|supine|Supine positioned after delivery
62707056|NCT04271293||Patients with PEG and oral anticoagulan treatment|Patients with PEG and indication for treatment with long-term oral anticoagulant therapy due to non valvular atrial fibrillation (FNAV), according to the current guidelines.
62707057|NCT01931644||Health Condition|Collect blood and other optional biospecimens from participants with a diagnosed health condition
62707058|NCT01931644||Healthy Control|Collect blood and other optional biospecimens from participants that have not been diagnosed with a health condition
62707059|NCT04747301|OTHER|Double-balloon catheter group|Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA).
62509399|NCT04010916|ACTIVE_COMPARATOR|Group Post = Postoperatively group|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
62509400|NCT04490473|OTHER|volunteer group|Only volunteer participants will be included in the research. Survey forms will be sent to individuals online. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
62509401|NCT05470322|EXPERIMENTAL|Laser Treatment|The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject to target HS scarring.
62509402|NCT02540837|EXPERIMENTAL|Bupivacaine|Obturator nerve block
62509403|NCT02540837|PLACEBO_COMPARATOR|Saline|Saline is injected as a placebo
62509404|NCT06372925|EXPERIMENTAL|Inclisiran and atorvastatin|Inclisiran 284mg SC (at D1,D90,D270)+ 20mg atorvastatin PO
62509405|NCT06372925|ACTIVE_COMPARATOR|atorvastatin|20mg atorvastatin PO
62509406|NCT04235257|EXPERIMENTAL|Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
62509407|NCT04235257|EXPERIMENTAL|Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
61967991|NCT05371743||ITP patients|"Patients will be recruited from the internal department- hematology unit outpatient clinic of El Minia University Hospital in collaboration with the clinical pathology department of El Minia University Hospital and the biochemistry department of Minia and Sohag University. Exclusion criteria:~1. Secondary causes of ITP as systemic lupus erythematous (SLE), viral infections (HIV, hepatitis B or C infections)~2. Other underlying medical diseases that may cause thrombocytopenia as:~   * malignancy~  * megaloblastic anemia~  * aplastic anemia~  * lymphoproliferative disorders~  * liver disease~  * renal impairment~  * pregnancy~3. Organomegally and/or lymphadenopathy.~4. Recent history of vaccination.~5. Recent evidence of bacterial infection."
62351110|NCT04522791|PLACEBO_COMPARATOR|IR only (MCI)|Participants randomized to this condition will receive weekly in-person check-in visits, and perform daily 10-minute IR, so that the number of treatment contacts (though not duration) will be equivalent. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
62351111|NCT04522791|OTHER|RFB+VSOP (HC)|"this is a new healthy control intervention arm used for testing adherence related items.~For home-based RFB+VSOP: The investigators will instruct subjects to do 10-minutes of app- guided paced breathing at RF daily; for select days, there will be VSOP training immediately following RFB.~A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions."
62351112|NCT06147713|EXPERIMENTAL|Intervention|The subjects will be examined during the drug-off period with the vibrotactile foot device off and on at different patterns. The tests will be carried out during the onsite clinical visits on the day of initial enrollment and two weeks after home wearing.
62351113|NCT03345940|ACTIVE_COMPARATOR|Fingolimod 0.5 mg/day|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
62351114|NCT03345940|ACTIVE_COMPARATOR|Dimethyl Fumarate 240 mg twice daily|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
62351115|NCT01596530|ACTIVE_COMPARATOR|AZD8931|AZD8931
62351116|NCT01596530|PLACEBO_COMPARATOR|Placebo|Placebo
62509408|NCT05468372|ACTIVE_COMPARATOR|Amphotericin B arm (standard of care)|Intravenous liposomal amphotericin B \[5 mg/kg per day\] for at least 4 weeks followed by maintenance therapy. Maintenance therapy (after four weeks of treatment initiation) will be continued for at least 12 weeks or longer as decided by the treating physician. The maintenance therapy will be posaconazole. However, if therapeutic drug monitoring is not possible or the participants opt to use isavuconazole or amphotericin, the same will be permitted and noted
62509409|NCT05468372|EXPERIMENTAL|Posaconazole arm|Combination of liposomal amphotericin B (5 mg/kg per day) and posaconazole for first 7 days followed by oral posaconazole only (for induction as well as maintenance therapy). The first four weeks of therapy will be called induction therapy
62509410|NCT05628181|NO_INTERVENTION|No educational tool|This arm will collect data on total standardized daily dosage of the medication classes contributing to CNS polyRx from the Electronic Medical Record (EMR).
62509411|NCT05628181|EXPERIMENTAL|Educational nudge intervention|Participants will be mailed the educational tool in the form of a brochure.
62509412|NCT05290779|ACTIVE_COMPARATOR|ultrasound|selective lumbar nerve root steroid injection under ultrasound guidance.
61967992|NCT05371743||normal individuals|Blood samples will be taken from normal individuals.
62509413|NCT05290779|SHAM_COMPARATOR|fluoroscopy|selective lumbar nerve root steroid injection under fluoroscopy guidance.
62509414|NCT03008837|EXPERIMENTAL|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
62539353|NCT00999323||coronary artery disease|patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
61967993|NCT05042167|EXPERIMENTAL|High-load resistance exercise|Subjects in high-load trial performed 3 sets per exercise, 8 repetitions with load of 70%-1RM with 90 sec of rest between sets, followed by a fourth set to voluntary failure.
61967994|NCT05042167|NO_INTERVENTION|Sedentary control|Subjects in control trial stayed sedentary during the period.
61976209|NCT05733624|ACTIVE_COMPARATOR|Restasis|Cyclosporine 0.05%
62707060|NCT04747301|OTHER|Vaginal insertion Prostaglandin E2 group|Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).
62509415|NCT03008837|ACTIVE_COMPARATOR|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
62509416|NCT05307133|OTHER|Pre menopausal women undergoing sleeve gastreexctomy for morbid obesity|After the indication for sleeve gastrectomy has been retained by the multidisciplinary committee eligible patients will be contacted and offered to participate in the BARIAXYTOCINE study. At the time of the first outpatient visit (V1), body densitometry and blood sample for estradiol, leptin and oxytocin will be done. Patients will undergo surgery within one month and 6 months after surgery they will undergo the same work-up (V2).
62509417|NCT04514016||HIV positive participants with positive COVID-19 results|Participants in this group will have a RT-PCR and Coronavirus Disease (COVID) -19 specific antibody testing at baseline, 1 month and 3 month visits.
62509418|NCT04514016||HIV positive participants with negative COVID-19 results|Participants in this group will have a RT-PCR and COVID-19 specific antibody testing at baseline only.
62509419|NCT02632175|EXPERIMENTAL|Subjects receiving Adalimumab|Subjects receiving Adalimumab up to 288 weeks
62509420|NCT00538655|EXPERIMENTAL|modafinil|
62509421|NCT02754284|EXPERIMENTAL|Autologous fat transplantation|
62509422|NCT02754284|EXPERIMENTAL|Functional collagen scaffold transplantation|
62509423|NCT06043622|EXPERIMENTAL|healthy subject vascular density|
62509424|NCT00151216|EXPERIMENTAL|Group A-Severe Stages of LINCL|"Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al.~All subjects will receive 3x10\^12 particle units of the AAV2CUhCLN2 vector."
62707061|NCT06028750|ACTIVE_COMPARATOR|Freehand|Nobel Replace Conical Connection® placed freehand
62351117|NCT03625141|EXPERIMENTAL|Cohort 1- cobimetinib and atezolizumab|Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
62351118|NCT03625141|EXPERIMENTAL|Cohort 2 - cobimetinib, atezolizumab and vemurafenib|Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
62351119|NCT05418569|ACTIVE_COMPARATOR|Intervention Arm - Use of the new smartphone application for T1DM|"The use of the locally designed smartphone application for T1DM for 6 months, which contained the following domains:~* Type 1 DM self-management information and decision-making algorithm~* Carbohydrate counting information on local food in Hong Kong~* DM day-to-day troubleshooting psychosocial scenarios~* Game-based interactive tools for DM knowledge enhancement~* Usage tracking for each domain of the smartphone application~* Individual participant identification and access code (known to research assistant)"
62351120|NCT05418569|PLACEBO_COMPARATOR|Control Arm - Standard diabetic education|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic information for both adult and pediatric population (that encompasses both information for type 1 and type 2 DM)
62351121|NCT00737685|EXPERIMENTAL|Fludarabine|
62509425|NCT00151216|EXPERIMENTAL|Group B-Moderate Stages of LINCL|"Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease.~All subjects will receive 3x10\^12 particle units of the AAV2CUhCLN2 vector."
62509426|NCT04282655|ACTIVE_COMPARATOR|Control|Standard method of warming breast milk in a hot water bath prior to feeding.
62509427|NCT04282655|EXPERIMENTAL|Treatment Guardian Milk Warmer (Medela TM)|External continuous milk warmer that heats milk within the tubing just posterior to the feeding tube to provide milk at body temperature for feeding infusion.
62509428|NCT02025088|ACTIVE_COMPARATOR|Laser|In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
62509429|NCT02025088|ACTIVE_COMPARATOR|Microneedling|"In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
61976210|NCT03940664||neovascular group|patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
62509430|NCT03783988|OTHER|Open uncontrolled pharmacokinetic study|Single armed - All subjects receive one dose of topical combination gel containing TRIAC and DHEA
62509431|NCT06443255|ACTIVE_COMPARATOR|Cocaine|2 mL 4% cocaine hydrochloride
62509432|NCT06443255|ACTIVE_COMPARATOR|Xylometazoline and lidocaine|1.5 mL of 4% lidocaine and 0.5 mL 0.1% xylometazoline
62509433|NCT06443255|PLACEBO_COMPARATOR|Saline|2 ml of 0,9% saline solution
62509434|NCT01561794|EXPERIMENTAL|Ciprofloxacin|
62509435|NCT04598360|EXPERIMENTAL|Experimental: Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of cardiac surgery patients are studied before and during heart-lung-machine procedure using LC-MS / MS
62707062|NCT06028750|EXPERIMENTAL|X-Guide guided surgery system (X-Nav Technologies®, Pennsylvania, USA)|Nobel Replace Conical Connection® placed using the X-Guide guided surgery system (X-Nav Technologies®, Pennsylvania, USA)
62707063|NCT04927221|EXPERIMENTAL|DC371739 20mg Dose MAD|Orally administered DC371739 tablets QD afer meal
62707064|NCT04927221|PLACEBO_COMPARATOR|DC371739 Placebo MAD|Placebo orally administered
62736698|NCT04660552|PLACEBO_COMPARATOR|Placebo condition|During the study participants will be wearing the photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
62707065|NCT05569317|EXPERIMENTAL|primary nursing|"The intervention group with patients who are cared with primary nursing (process-responsible nursing; PP) after elective thoracic and/or cardiovascular surgery are on the intervention ICU. Patients are assigned to the intervention group if they stay for at least 3 days on the ICU. PP take on~* the responsibility of the nursing process~* the daily care according to the individual patient case~* direct communication with all professional groups involved in care~* responsibility for the quality of care of the assigned patients over a fixed period of at least 14 and a maximum of 50 days - after that the primary nurse will change.~In this way, PP also take on the nursing anamnesis as well as the planning, implementation and evaluation of the nursing care. The nursing care ratio is at least 1:2"
62707066|NCT05569317|NO_INTERVENTION|standard care|The control group with patients who are cared for according to the principle of standard care (area care or room care) is located on another ICU. There is no PP responsible for the target group and the allocation of nursing staff to patients is redefined at the start of each shift. The nursing care ratio is at least 1:2.
62707067|NCT02327169|EXPERIMENTAL|MLN2480 + MLN0128|Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
62707068|NCT02327169|EXPERIMENTAL|MLN2480 + Alisertib|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
62707069|NCT02327169|EXPERIMENTAL|MLN2480 + Paclitaxel|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m\^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m\^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
62707070|NCT02327169|EXPERIMENTAL|MLN2480 + Cetuximab|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m\^2 (cycle 1 Day 1), then at 250 mg/m\^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
62707071|NCT02327169|EXPERIMENTAL|ML2480 + Irinotecan|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m\^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
62707072|NCT02327169|EXPERIMENTAL|MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)|Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
62707073|NCT00600340|ACTIVE_COMPARATOR|A Bev+Pac|Bevacizumab plus Paclitaxel
62707074|NCT00600340|ACTIVE_COMPARATOR|B Bev+Cap|Bevacizumab plus Capecitabine
62707075|NCT05159050|EXPERIMENTAL|Intraperitoneal paclitaxel-loaded tumor penetrating microparticles (TPM)|Paclitaxel-loaded tumor penetrating microparticles (TPM), dose escalation starting at 50 mg/m\^2 instilled in the peritoneal cavity at study start and again 6-8 weeks after the first TPM treatment.
62707076|NCT02675400|ACTIVE_COMPARATOR|Medication Arm|Vyvanse Arm: 3-week open-label titration beginning at 20 mg Vyvanse (a class II drug), and be increased weekly during the titration period until an optimal response is obtained and then continue for 5 weeks. Optimal response is defined as a clinician Clinical Global Impression-Improvement score (CGI-I) ≤ 2 with minimal associated adverse events. Fathers will remain on optimal dose through the course of the study. In cases of poor tolerability or loss of efficacy the dose can be changed. If an optimal response is not achieved a trial with a long acting methylphenidate will be initiated based upon the Texas algorithm for stimulant medication. The study physician will be available by phone 24 hours/day; participants will be instructed to call with any safety concerns.
62707077|NCT02675400|ACTIVE_COMPARATOR|Behavioral Parent Training Arm|"Behavioral Parent Training (BPT) Arm: Fathers in the BPT group will receive weekly parent training sessions based on the Barkley manual, Defiant Children, Third Edition. The child participants will also come to several sessions at the clinician's and supervisor's discretion."
62707078|NCT01651988|ACTIVE_COMPARATOR|Ketofol 1:1|1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.
61967995|NCT06113809|EXPERIMENTAL|Combination of Palbociclib with Pembrolizumab|Palbociclib given for 2 weeks following a pre-treatment ultrasound guided biopsy used to establish an immunological baseline of the tumor microenvironment. After the conclusion of palbociclib therapy, a post-treatment biopsy will be performed to assess the impact of palbociclib on the tumor microenvironment; pembrolizumab will be started the same day as the second biopsy. After 2 doses of pembrolizumab, a third (optional) biopsy could be performed.
61967996|NCT05786885|EXPERIMENTAL|Intervention Group|Microneedling will be done with application of topical vitamin C paste for depigmentation
61967997|NCT05786885|ACTIVE_COMPARATOR|Control Group|Gingival depigmentation will be done by vitamin C injection only.
62539354|NCT06632392|EXPERIMENTAL|Theory and simulation training|I. Interview: Before theoretical and simulation training II. Interview: After theoretical and simulation training III. Interview: Four weeks later
61967998|NCT04625309|EXPERIMENTAL|Sport|This group will be made up of subjects with a spinal cord injury that are actively participating in adaptive sports teams.
61967999|NCT04625309|NO_INTERVENTION|No sport|This group will be made up of subjects with a spinal cord injury that are not actively participating in any sports team.
61968000|NCT02471430|EXPERIMENTAL|Arm A|Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.
62145194|NCT05453630|EXPERIMENTAL|Patient Navigation Intervention|Patients randomized to this arm will receive language-concordant patient navigation from a trained navigator, over the phone and via text and email, to assist patients to complete colonoscopy to screen for colorectal cancer.
62145195|NCT05453630|OTHER|Usual Care Control|Participants randomized to this arm will receive an educational brochure about the importance of colonoscopy to screen for colorectal cancer.
62145196|NCT04382313|PLACEBO_COMPARATOR|the adequate hydration group guided by Vigileo|The hydration speed is adjusted according to SVV or SV by Vigileo
62509436|NCT02137382|EXPERIMENTAL|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to \<10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
62509437|NCT02137382|EXPERIMENTAL|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to \<10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
62509438|NCT02194023|PLACEBO_COMPARATOR|Placebo (PCB)|Placebo mouthrinse: physiological saline solution (0.9% w/w solution of NaCl in deionized water)
62509439|NCT02194023|EXPERIMENTAL|0.12%NF|0.12% Chlorhexidine digluconate new formulation
61968001|NCT02471430|EXPERIMENTAL|Arm B|Participants in Arm B will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a, a 15 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.
61968002|NCT02471430|EXPERIMENTAL|Arm C|Participants in Arm C will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0.The dose of pegylated IFN-alpha2a will be 180 mcg.
62509440|NCT02194023|EXPERIMENTAL|0.03%NF|0.03% Chlorhexidine digluconate new formulation
62145197|NCT04382313|NO_INTERVENTION|the control group|The routine hydration regimen is adopted, perioperative saline ≤500 ml hydration
62145198|NCT03295409|EXPERIMENTAL|Experimental: Standard self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will...~* think about the things I value about myself~* remember things that I have succeeded in~* think about what I stand for~* think about things that are important to me~If...___________________________________________________________________"
62145199|NCT03295409|EXPERIMENTAL|Experimental: Familial self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will...~* think about the things my family and I value about ourselves~* remember things that my family and I have succeeded in~* think about what my family and I stand for~* think about things that are important to my family and me~If...__________________________________________________________________"
62509441|NCT02194023|ACTIVE_COMPARATOR|PAT (Perio-Aid Treatment)|Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)
62509442|NCT03071913||Observational (biospecimen collection)|As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.
62509443|NCT02127073|EXPERIMENTAL|Oxytocin|Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
62509444|NCT05471609|EXPERIMENTAL|levodopa/carbidopa oral formulation A|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 100mg CD/100mg LD and inner sachet contains 0mg CD /300mg LD.
62509445|NCT05471609|EXPERIMENTAL|levodopa/carbidopa oral formulation B|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 100mg CD/0mg LD and inner sachet contains 0mg CD /400mg LD.
62509446|NCT05471609|EXPERIMENTAL|levodopa/carbidopa oral formulation C|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 50mg CD/200mg LD and inner sachet contains 50mg CD /200mg LD.
62509447|NCT00368316|EXPERIMENTAL|S. sonnei conjugate vaccine|Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
62509448|NCT00368316|EXPERIMENTAL|S. flexneri 2a conjugate vaccine|Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa
62145200|NCT03295409|NO_INTERVENTION|Control|Participants are asked to complete a questionnaire.
62145201|NCT00808496|EXPERIMENTAL|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline.
62145202|NCT00808496|ACTIVE_COMPARATOR|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists.
62145203|NCT00808496|PLACEBO_COMPARATOR|Standard of Care|Diagnostic imaging results (MRI or radiography) reported to upon requisition.
61968003|NCT01410032|ACTIVE_COMPARATOR|Plate fixation|Reconstruction plate
61968004|NCT01410032|ACTIVE_COMPARATOR|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
62509449|NCT00798681|EXPERIMENTAL|1|Patients will receive RTU TPN with olive-oil as the primary source of lipids
62509450|NCT00798681|ACTIVE_COMPARATOR|2|CNF parenteral nutrition made with olive oil as the primary source of lipids
62509451|NCT00798681|ACTIVE_COMPARATOR|3|CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
62509452|NCT01297322|ACTIVE_COMPARATOR|Manual compression|Using manual compression to reach hemostasis
62509453|NCT01297322|EXPERIMENTAL|VASCADE™ Vascular Closure System|The Cardiva VASCADETM Vascular Closure System (VCS) is indicated for the percutaneous closure of common femoral artery access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular catheterization procedures utilizing 6 Fr or 7 Fr procedural sheaths.
62509454|NCT03474029|EXPERIMENTAL|6 weeks of daily rifapentine (6wP)|Rifapentine daily for 6 weeks: 600 mg of Rifapentine (RPT) given once daily for 6 weeks
62509455|NCT03474029|ACTIVE_COMPARATOR|12-16 week rifamycin-based regimen|"A 12-16 week rifamycin-based regimen available at the participant's site:~Rifapentine and Isoniazid weekly for 12 weeks (3HP) or Rifampin and Isoniazid daily for 12 weeks (3HR) or Rifampin daily for 16 weeks (4R)"
62145204|NCT00343083|EXPERIMENTAL|Cetuximab comparison for Head and Neck Cancer|"To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).~Both chemotherapy and radiation will be given on a weekly basis (see interventions for details)."
62351122|NCT04902534|EXPERIMENTAL|Naoqingzhiming Tablets|"Naoqingzhiming Tablets, specification:500mg(contains echinacoside 180mg) Single dose ascending. Qualified subjects will enter 6 dose groups in order from low to high: 180mg, 360mg, 720mg, 1080mg, 1620mg and 2160mg, with increasing dose design The first group (180mg) is a pre-experiment. Two subjects were selected and all received the test drug.~Groups 2 to 6 received the experimental drug in 8 patients per group. Multi-dose ascending was divided into two groups: 360mg and 720mg. 10 subjects in each group received the test drug 3 times a day for 14 consecutive days."
62509456|NCT02959008||normal|Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.
62509457|NCT02959008||hypertension|"Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.~Hypertension group will measure TOI and BP."
62509458|NCT02722252||Embryoscope group|
62509459|NCT02722252||Embryo culture without incorporated camera group|
62509460|NCT03630094|EXPERIMENTAL|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
62509461|NCT02853864|PLACEBO_COMPARATOR|Propofol and 0.0 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
62509462|NCT02853864|EXPERIMENTAL|Propofol and 0.4 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
62509463|NCT02853864|EXPERIMENTAL|Propofol and 0.6 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
61968005|NCT05601284|EXPERIMENTAL|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
61968006|NCT05601284|ACTIVE_COMPARATOR|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
61968007|NCT01939743|EXPERIMENTAL|diclofenac suppository plus lidocaine gel|Intervention Drug with local anaesthetic
62509464|NCT02853864|EXPERIMENTAL|Propofol and 0.8 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
62509465|NCT03016741|OTHER|Arm I (abiraterone acetate, prednisone)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive abiraterone acetate PO and prednisone PO BID in the absence of disease progression or unacceptable toxicity. Patients then undergo cognitive assessment comprising of neuro-cognitive tests and assessments of overall quality of life, fatigue, pain, and symptoms at baseline, 3, 6, and 12 months. Patients also undergo MRI program for 40 minutes comprising of DTI, fMRI, ASL MRI, MPRAGE MRI, FLAIR MRI, and BOLD MRI at baseline and 3 months.
61968008|NCT01939743|OTHER|Lidocaine gel only|Used as local aneaethetic as a part of institutional prostate biopsy protocol
61968009|NCT05760833|ACTIVE_COMPARATOR|Pulmonary vein isolation|Ablation of the pulmonary veins.
61968010|NCT05760833|ACTIVE_COMPARATOR|atrioventricular node ablation.|Ablation of the atrioventricular node.
61968011|NCT00289471||Cognitive Screening|Cognitive screening
61968012|NCT00873223|EXPERIMENTAL|A|
62509466|NCT03016741|OTHER|Arm II (enzalutamide)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo cognitive assessment and MRI program as in Arm I.
62707079|NCT01651988|EXPERIMENTAL|Ketofol 1:2|2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.
62707080|NCT04448951||sepsis/septic shock|target population
61968013|NCT02905552||Case group|Patient developing a first episode of infection since diagnosis of high-risk MDS (index case)
61968014|NCT02905552||Control group|"Patient with no infection since diagnosis of MDS~Patient will be paired to index case by:~* Hospital site~* Age~* Sexe Control patient is eligible if he has been seen in consultation within 15days before or after date of first infection of index case If matching fails, control patient can be found in another site and/or within 30days before or after date of first infection of index case"
61968015|NCT03649750|EXPERIMENTAL|Treatment A: Mucinex® 600 mg (fast)|Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
61968016|NCT03649750|EXPERIMENTAL|Treatment B: Mucinex® 600 mg (fed)|Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
61968017|NCT01029626|OTHER|Endoscopy|If the Glasgow-Blatchford score is zero, the endoscopy is delayed as an outpatient
61968018|NCT02863029|OTHER|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
61968019|NCT05485376|EXPERIMENTAL|Early Pulmonary Artery Catheter|If you are in the experimental group a PAC will be placed within 6 hours of randomization and within 24 hours of presentation with ADHF-CS.
61968020|NCT05485376|NO_INTERVENTION|No or delayed Pulmonary Artery Catheter|If you are in the control group, a PAC will not be placed during hospitalization or may be placed 48 hours after randomization into the study. Placement of a PAC within 48 hours is only permitted for emergencies.
61968021|NCT03232021|PLACEBO_COMPARATOR|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
61968022|NCT03232021|EXPERIMENTAL|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
61968023|NCT03232021|EXPERIMENTAL|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
61968024|NCT05343351|EXPERIMENTAL|Out of Plane arm|The patient group who was injected using the ultrasound-guided out of plane injection method.
62707081|NCT04448951||non-septic critically ill|demographically-matched control group
61968025|NCT05343351|EXPERIMENTAL|In Plane arm|The group of patients who were injected using the ultrasound-guided in-plane injection method.
61968026|NCT02231723|EXPERIMENTAL|A: BBI608 in combination with Gemcitabine and nab-Paclitaxel|
61968027|NCT02231723|EXPERIMENTAL|B: BBI608 in combination with modified FOLFIRINOX|
62351123|NCT04902534|PLACEBO_COMPARATOR|placebo (without active ingredients echinoside)|Placebo Tablets, specification: 500mg(without echinoside) Single dose. Groups 2 to 6 received the placebo in 2 patients per group. Multi-dose ascending. Two people in each group received placebo 3 times a day for 14 consecutive days.
62351124|NCT06338072||Adult women of childbearing age using a loop system.|Adult women of childbearing age using the Minimed 780G loop system. Sixty-nine women of reproductive age will be recruited to assess variations in glycemic control across different stages of the menstrual cycle. Additionally, a subset of these women (n = 50) will wear a wearable device to collect temperature, photoplethysmography, and accelerometry data.
62509467|NCT03223454|EXPERIMENTAL|biological amnion loaded with hAECs|Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
62707082|NCT04448951||healthy control|control group
62707083|NCT03680521|EXPERIMENTAL|Sitravatinib and nivolumab|Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.
62707084|NCT04885621||underserved patients with diabetes mellitus|patients with type 2 diabetes mellitus living in underserved, financially challenged areas of Southwest Virginia who are poorly controlled
61968028|NCT02231723|EXPERIMENTAL|C: BBI608 in combination with FOLFIRI|
61968029|NCT02231723|EXPERIMENTAL|D: BBI608 in combination with MM-398, 5-FU and leucovorin|
62707085|NCT03755193|ACTIVE_COMPARATOR|SERM plus ELD|To examine the effects of SERM plus ELD in osteoporosis patients
62707086|NCT03755193|ACTIVE_COMPARATOR|BP plus ELD|To examine the effects of BP plus ELD in osteoporosis patients
61968030|NCT03867006|NO_INTERVENTION|control group|Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).
61976211|NCT03940664||non-neovascular group|patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.
62707087|NCT03755193|ACTIVE_COMPARATOR|ELD alone|To examine the effects of ELD alone in osteoporosis patients
62707088|NCT04253600|OTHER|MRI Acquisition|This does not refer to any group intervention. At-risk and control children will take part in a natural-sleep MRI protocol.
61976212|NCT05319145|ACTIVE_COMPARATOR|Control group|Treatment as usual. Mainly based on standard physical rehabilitation.
62707089|NCT05405270||Primary cHSIL|Women with a first diagnosis of cHSIL (e.g. CIN 2 or CIN 3) who prefer treatment with imiquimod.
62707090|NCT05405270||Recurrent/residual cHSIL (rrcHSIL)|Women who were treated for cHSIL before, but who have a residual or recurrent lesion and prefer treatment with imiquimod.
62707091|NCT05405270||CIN 2 observational group|Women with primary CIN 2 who prefer expectant management to await the potential of spontaneous regression.
62707092|NCT02006927|EXPERIMENTAL|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
62351125|NCT06338072||Adult men under 50 years old using a closed loop system.|A control group of 50 men will wear a wearable device to collect temperature, photoplethysmography, and accelerometry data.
62351126|NCT02879916|PLACEBO_COMPARATOR|Placebo|NaCl 0.9% 3ml perineural stellate ganglion injection
62351127|NCT02879916|ACTIVE_COMPARATOR|Stellate ganglion block|Levobupivacaine 3ml perineural stellate ganglion injection
62509468|NCT03223454|PLACEBO_COMPARATOR|biological amnion|Biological amnion is placed into uterine cavity immediately after TCRA.
62509469|NCT03223454|EXPERIMENTAL|intravenous infusion of hAECs|intravenous infusion of 100 million hAECs immediately after TCRA
62509470|NCT03223454|EXPERIMENTAL|intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity immediately after TCRA.
62707093|NCT04618094|EXPERIMENTAL|High intensity interval group|
62707094|NCT04618094|ACTIVE_COMPARATOR|Moderate continous intensity group|
62707095|NCT04618094|NO_INTERVENTION|non-exercising group|
62707096|NCT01969214|EXPERIMENTAL|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water,to be taken orally~1 tablet, 3 times a day"
62707097|NCT06569862|EXPERIMENTAL|Postoperative day 1 dressing|After removing the dressing on day 1, no dressing change by a nurse is required.
61968031|NCT03867006|EXPERIMENTAL|protein group|Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
62509471|NCT03223454|EXPERIMENTAL|hydrogel loaded with hAECs|Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
62707098|NCT06569862|OTHER|Postoperative day 6+/-1 dressing|Daily dressing changes should be performed according to standard nursing procedures until postoperative day 6 (+/-1)
62707099|NCT06594705|EXPERIMENTAL|TAVR in LVAD Patients|"Transcatheter Aortic Valve Replacement (TAVR)~TAVR in patients with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR)"
62707100|NCT01155050|ACTIVE_COMPARATOR|Tele-health Home Monitoring|Participants will use the tele-health monitoring equipment to measure daily weight.
62707101|NCT01155050|NO_INTERVENTION|Self-Directed Group|Participants will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss.
62707102|NCT01155050|ACTIVE_COMPARATOR|TrestleTree Telephone Coaching|Participants will speak to Trestletree health coaches for 15 to 60 minutes each session. During these sessions, the coaches will identify the participant's stage of change and intervene accordingly. The telephone calls will be centered on weight loss.
62707103|NCT01155050|ACTIVE_COMPARATOR|Home monitoring + telephone coach|System to track stage of change in weight loss.
62707104|NCT05433142|EXPERIMENTAL|Dose Escalation and Expansion|"Dose Escalation (Part A): Part A will establish the dosing schedule for XmAb819 administered IV and the dosing schedule of XmAb819 administered SC in subjects with ccRCC. The dosing schedule includes the priming dose, step-up priming dose(s), the minimum safe and biologically active dose.~Dose Expansion (Part B): Part B-1 may administer XmAb819 IV, and Part B-2 may administer XmAb819 SC."
62351128|NCT01874249|EXPERIMENTAL|Electronic detailed information|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.
62351129|NCT01874249|EXPERIMENTAL|NAFLD Score|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.
62351130|NCT01874249|EXPERIMENTAL|NAFLD Score plus Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.
62351131|NCT01874249|EXPERIMENTAL|Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.
62351132|NCT01874249|NO_INTERVENTION|Standard of care|Standard of care for patients with diagnosis of fatty liver by ultrasound.
62351133|NCT06088407|EXPERIMENTAL|With tranexamic acid|"Patient undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intraoperatively.~The patients received intravenous 1 gram tranexamic acid in 100ml normal saline 30 minutes before skin incision and a second dose of intravenous 1 gram tranexamic acid in 100 ml of normal saline during wound closure."
62509472|NCT03669575|EXPERIMENTAL|omega 7 - placebo|Receiving the active first then switch to the placebo after three weeks
62509473|NCT03669575|ACTIVE_COMPARATOR|placebo - omega 7|Receiving the placebo first then switch to the active after three weeks
62707105|NCT06032182|EXPERIMENTAL|Intervention|15 sessions of the combined cognitive remediation training and social recovery therapy intervention.
62351134|NCT06088407|NO_INTERVENTION|Without tranexamic acid|Patient undergoing surgery for elbow fracture-dislocation randomized to be treated without tranexamic acid intraoperatively
62509474|NCT00846859|EXPERIMENTAL|varenicline|
62509475|NCT00846859|PLACEBO_COMPARATOR|placebo|
62509476|NCT01404052|EXPERIMENTAL|Active tDCS + transcranial ultrasound|Subjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
62509477|NCT01404052|SHAM_COMPARATOR|Sham tDCS + transcranial ultrasound|Subjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
62509478|NCT00504478|EXPERIMENTAL|1|8-weeks of high complex carbohydrate diet
62707106|NCT06032182|ACTIVE_COMPARATOR|Control|15 sessions of social recovery therapy alone.
62707107|NCT02935764|EXPERIMENTAL|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
62509479|NCT00504478|EXPERIMENTAL|2|omega-3 fatty acids supplements
62509480|NCT00062101|EXPERIMENTAL|Group I (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib once daily and oral celecoxib twice daily.
62707108|NCT02935764|ACTIVE_COMPARATOR|IRINOTECAN|irinotecan
62707109|NCT06547931||Duffy null neutropenic subjects|Pediatric patients sent to our laboratory for anti-neutrophil antibodies evaluation in the suspicion of immune neutropenia
61968032|NCT03867006|EXPERIMENTAL|protein and carbohydrates group|Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
61968033|NCT02341885||One Group|This is an observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
61968034|NCT05496257|ACTIVE_COMPARATOR|Group I (control): Calcium hydroxide cement|Pulp capping material
61968035|NCT05496257|ACTIVE_COMPARATOR|Group 2: Premixed bioceramic putty|Pulp capping material
61968036|NCT04745754|EXPERIMENTAL|Intervention Condition|The trial will test the efficacy of an embedded primary care provider (PCP) model (experimental condition) in which PCPs are trained in survivorship and then embedded within an oncology practice to care for low-risk, early stage breast and colorectal cancer survivors who will be transitioned at 6-36 months post-treatment for comprehensive survivorship care.
61968037|NCT04745754|NO_INTERVENTION|Control Condition|Usual care for breast and colorectal cancer survivors (oncology-led model).
61968038|NCT02533739|EXPERIMENTAL|Patient group|This group will consist of vestibular patients and/or participants with vertigo.
61968039|NCT02533739|SHAM_COMPARATOR|Control group|This group will consist of participants without vestibular/vertigo impairments.
61968040|NCT05739955|EXPERIMENTAL|Sani24|Application of a 24-hour continuously acting quaternary ammonium salt disinfectant: Sani24 (PDI Healthcare Inc.) by study team
61968041|NCT05739955|EXPERIMENTAL|Standard EPA-registered disinfectant|Application of standard EPA-registered disinfectant by study team
61968042|NCT05739955|ACTIVE_COMPARATOR|Control|Routine disinfection completed by hospital staff
61968043|NCT04571138|EXPERIMENTAL|SCRI-CAR22v2|Patients will receive SCRI-CAR22v2 in either Phase I or Phase II
62509481|NCT00062101|EXPERIMENTAL|Group II (erlotinib hydrochloride)|Patients receive erlotinib as in group 1.
61968044|NCT05730751||Group F|The patients will receive 2.5 ml of hyperbaric bupivacaine 0.5 % and 25 µg fentanyl \[6\].
61968045|NCT05730751||Group C|The patients will receive 2.5 ml of hyperbaric bupivacaine 0.5 %
61968046|NCT02373215|EXPERIMENTAL|Cohort 1 - Groups 1-3|HD patients dosing up to 180mg BID
62509482|NCT05934487|EXPERIMENTAL|Randomized Arm- Treatment Arm|"All subjects will receive the Cordella Sensor.~Clinicians will manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy."
62509483|NCT05934487|EXPERIMENTAL|Randomized Arm- Active Control Arm|"All subjects will receive the Cordella Sensor.~Clinicians will manage subjects using the subjects daily data trends (BP, weight, HR, SpO2 symptoms) according to Guideline Directed Medical Therapy."
61968047|NCT02373215|EXPERIMENTAL|Cohort 1 - Group 4|HD patients dosing up to 240mg BID
62509484|NCT05934487|EXPERIMENTAL|Randomized Arm- Crossover Arm|"All subjects will receive the Cordella Sensor.~At least 12 months following implant and following an adjudicated HFH, subjects in the Active Control Arm can qualify to crossover to the Crossover Arm and both patients and clinicians would then be unmasked to PAP. Clinicians will then manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy."
62509485|NCT05934487|EXPERIMENTAL|Single Arm- Clinician-Directed Patient Self-Management Arm|"All subjects will receive the Cordella Sensor.~Subjects will self-manage their Loop diuretics per protocol specific Clinician-Directed Patient Self-Management Treatment Guidelines and Clinicians will manage the patients according to Guideline-Directed Medical Therapy."
61968048|NCT02373215|EXPERIMENTAL|Cohort 2|Healthy patients dosing up to 180mg BID
61968049|NCT03951844|EXPERIMENTAL|Experimental group|Each participant is evaluated while wearing or not wearing the device.
61968050|NCT02698839|EXPERIMENTAL|BuMA Supreme group|This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.
61968051|NCT02698839|ACTIVE_COMPARATOR|BuMA™ group|This group contains 220 subjects.
61968052|NCT05976750||AONDA contact lenses|Lotrafilcon A contact lenses worn daily and removed at night for cleaning and disinfection as instructed by the eye care professional
61968053|NCT05976750||PV2 contact lenses|Balafilcon A contact lenses worn daily and removed at night for cleaning and disinfection as instructed by the eye care professional
61968054|NCT04631081|ACTIVE_COMPARATOR|Occlusive dressing group|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film according. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing
61968055|NCT04631081|ACTIVE_COMPARATOR|Surgical group|In surgical group, coverage with a bipedicled palmar island flap will be performed ambulatory, either on admission if patients are directly oriented to the Hand Surgery department, or within 48h of initial visit for patients addressed from the Emergency department. The flap group will be evaluated on admission, at 48h, and 6 weeks.
61968056|NCT01044862|ACTIVE_COMPARATOR|Aromatase Inhibitors (AI)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
61968057|NCT01044862|ACTIVE_COMPARATOR|Clomiphene Citrate (CC)|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
61968058|NCT01044862|ACTIVE_COMPARATOR|Follicle Stimulating Hormone (FSH)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
61968059|NCT03097094|ACTIVE_COMPARATOR|Male dog|Male dog extract used for skin prick test and conjunctival provocation
61968060|NCT03097094|ACTIVE_COMPARATOR|Female dog|Female dog extract used for skin prick test and conjunctival provocation
61968061|NCT03063372|EXPERIMENTAL|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
61968062|NCT03063372|PLACEBO_COMPARATOR|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
62707110|NCT01194596|EXPERIMENTAL|Spirometry and lifestyle counseling|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
62707111|NCT01194596|NO_INTERVENTION|Lifestyle counseling|No intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
62707112|NCT01139151|EXPERIMENTAL|Group 1 - 3 Day Thiarabine|Thiarabine 3 days in a row in each cycle.
62707113|NCT01139151|EXPERIMENTAL|Group 2 - 5 Day Thiarabine|Thiarabine 5 days a row in each cycle.
62707114|NCT04809337|EXPERIMENTAL|Stabilization Exercise Group|
62509486|NCT05934487|EXPERIMENTAL|Single Arm- Clinician Management Arm|"All subjects will receive the Cordella Sensor.~Clinicians will manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy."
62509487|NCT06616545||Glycogen Storage Disease Type III|
62509488|NCT06616220|ACTIVE_COMPARATOR|DEXAMETHASONE|0.2% ropivacaine + 0.1mg/kg Dexamethasone for erector spinae plane block
62509489|NCT06616220|PLACEBO_COMPARATOR|CONTROL|0.2% ropivacaine for erector spinae plane block
62509490|NCT03242616|EXPERIMENTAL|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)~  1. Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th.... cycle after then.)~ 2. Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose~ 3. Dexa 4mg po bid on D0-2"
62509491|NCT03242616|ACTIVE_COMPARATOR|Vinorelbine|Vinorelbine (25 mg/m2, day 1 \& 8)
62509492|NCT03365999|ACTIVE_COMPARATOR|Oral Tranexamic Acid|"Tranexamic acid will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid tablets are 650 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
61968063|NCT04252456|OTHER|standard chemotherapy for advanced colorectal cancer|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.
62351135|NCT06299813|EXPERIMENTAL|Bentelan|The experimental treatment will consist of the active ingredient betamethasone, specifically using the medication Bentelan 0.5mg® effervescent tablets. A single dose of betamethasone will be administered according to the weight categories (0.5 mg if the patient's weight is greater than 5 and less than or equal to 7; 1 mg if the patient's weight is greater than 7 and less than or equal to 12; 1.5mg if the patient's weight is greater than 12 and less than or equal to 17; 2.0 mg if the patient's weight is greater than 17 and less than or equal to 22; 2.5 mg if the patient's weight is greater than 22 and less than or equal to 27.)
62509493|NCT03365999|EXPERIMENTAL|Oral Aminocaproic Acid|"Aminocaproic acid will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic acid tablets are 500 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 3 grams (6 tablets) divided between the 3 administrations (1 gram each, ie 2 tablets of 500 mg) will be administered."
62509494|NCT02717078|EXPERIMENTAL|LoBAG Diet|Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks.
62707115|NCT04809337|EXPERIMENTAL|Therapeutic Exercise Group|
62707116|NCT05119816|EXPERIMENTAL|music therapy group|Patients receive an individual intervention of receptive music therapy during biopsy
62509495|NCT02717078|ACTIVE_COMPARATOR|Control Diet|Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks.
61968064|NCT06431490|EXPERIMENTAL|TQB2102 for injection|Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, 6/8 cycles.
61968065|NCT02490332|EXPERIMENTAL|Ventilation tube treatment|Ventilation tube insertion in the tympanic membrane
62509496|NCT06484985|EXPERIMENTAL|AXT-1003|Dose Escalation: Level 1 (Starting Dose) Oral AXT-1003 5 mg BID; Level 2 Oral AXT-1003 10mg BID; Level 3 Oral AXT-1003 15mg BID ; Level 4 Oral AXT-1003 20mg BID; Level 5 Oral AXT-1003 25mg BID; Level 6 Oral AXT-1003 30mg BID; Level 7 Oral AXT-1003 35mg BID; Level 8 Oral AXT-1003 40mg BID Dose Expansion: 1 or 2 cohorts at the dose levels selected from dose escalation part
62509497|NCT06402682||Right approach|
62509498|NCT06402682||Left approach|
62509499|NCT01331577|EXPERIMENTAL|Cognitive behavioural Intervention|
62509500|NCT01331577|EXPERIMENTAL|Integrative Kinesiology Intervention|
62509501|NCT01331577|NO_INTERVENTION|Waiting-List control group|
62707117|NCT05119816|NO_INTERVENTION|Control group|Patients receive standard care
62707118|NCT05568862||spinal cord injury|patient with spinal cord injury
62707119|NCT05568862||no spinal cord injury|patient without spinal cord injury
62707120|NCT01135966|ACTIVE_COMPARATOR|Conventional training|
62707121|NCT01135966|EXPERIMENTAL|Whole body vibration training|
61968066|NCT02490332|NO_INTERVENTION|Conservative treatment|Conventional treatment
61968067|NCT05205044||Recurrent pregnancy loss|
61968068|NCT05205044||Healthy|
61968069|NCT02465216|EXPERIMENTAL|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
62707122|NCT00922857|EXPERIMENTAL|Respiratory rehabilitation|
62707123|NCT03808571||Study group|Pregnancies complicated with intrauterine growth restricted fetuses
62707124|NCT03808571||Control group|Healthy pregnancies
62707125|NCT01823055|EXPERIMENTAL|Surgery|Transvaginal suture capturing mesh device
62707126|NCT04436744|EXPERIMENTAL|Giredestrant + Palbociclib|
62707127|NCT04436744|ACTIVE_COMPARATOR|Anastrozole + Palbociclib|
61968070|NCT02465216|EXPERIMENTAL|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
61968071|NCT02465216|EXPERIMENTAL|2 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
61968072|NCT02465216|PLACEBO_COMPARATOR|Placebo|Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
61968073|NCT02465216|EXPERIMENTAL|2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
62509502|NCT01067716|EXPERIMENTAL|Refractive Error|
62707128|NCT04311450|EXPERIMENTAL|Behavioral Weight Loss|Behavioral: Participants randomized assigned to this arm will received 12 weeks of Behavioral Weight Loss (BWL) counseling.
61968074|NCT01676844|EXPERIMENTAL|Oral thin film therapy|One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
61968075|NCT01676844|ACTIVE_COMPARATOR|Standard therapy|Standard oral phosphate supplementation as per NHS Greater Glasgow and Clyde Guidelines. An oral solution containing potassium acid phosphate (1 mmol/mL) will be administered at a dosage of 0.5 mM/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Standard therapy will continue until the participant has received treatment for 14 consecutive days.
61968076|NCT02589756|EXPERIMENTAL|The fatty fish group|Participants will eat fatty fish and avoiding nuts)
61968077|NCT02589756|EXPERIMENTAL|The nut group|Participants who will avoid fatty fish
61968078|NCT02589756|PLACEBO_COMPARATOR|The control group|Participants who will avoid both fatty fish and nuts
61968079|NCT06146452||Pediatric palliative care|pediatric palliative care patients hospitalized in the Pediatric Palliative Care Clinic
61968080|NCT04953377|EXPERIMENTAL|Intervention|PFMT educational intervention including a 120 min workshop and 8 weeks of self training
61968081|NCT02747095|EXPERIMENTAL|Spectral CT image|Interventions: IQon Spectral CT
61968082|NCT04983264|EXPERIMENTAL|Single-dose Period (Part A)|Refer to Study Description
61968083|NCT04983264|EXPERIMENTAL|Multiple Ascending-dose Period (Part B and Part C)|Refer to Study Description
61968084|NCT01598324||escitalopram responders no augmentation|Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
61968085|NCT01598324||Ziprasidone augmentation|Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
61968086|NCT01598324||Placebo augmentation|Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.
61968087|NCT06167512||polytrauma patients|polytrauma patients
61968088|NCT06167512||healthy volunteers|healthy volunteers
61968089|NCT03578861|EXPERIMENTAL|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
61968090|NCT01218230|ACTIVE_COMPARATOR|Intravitreal Pegaptanib|
62351136|NCT06299813|PLACEBO_COMPARATOR|Placebo|The placebo used in the study will consist of 100 ml of purified water (PPI BBU). The water will be administered in an identical manner to the medication and, like the medication, will be odorless, tasteless, and visually indistinguishable, making it unrecognizable to parents. Regarding the patient population, the study population will primarily consist of infants and preschool-aged children, an age group where the palatability of the medication is perceived to be similar to that of water.
61968091|NCT00965718|EXPERIMENTAL|Immuncell-LC group|Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
61968092|NCT01849224|EXPERIMENTAL|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
61968093|NCT01849224|NO_INTERVENTION|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
61968094|NCT01948622|ACTIVE_COMPARATOR|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
61968095|NCT01948622|PLACEBO_COMPARATOR|placebo|500 mg of starch (2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
61968096|NCT06020378||Hydroxychloroquine treatment group|The Hydroxychloroquine treatment group was defined as having exposure to Hydroxychloroquine during pregnancy.
61968097|NCT06020378||Hydroxychloroquine nontreatment group|The Hydroxychloroquine nontreatment group was defined as having no exposure to Hydroxychloroquine during pregnancy.
61968098|NCT06268626||EIN/EC BIOPSY RESULT|Vaginal DNA, microbiome, pH, and saliva samples sequenced. Participation ends here.
61968099|NCT06268626||EH BIOPSY RESULT|Vaginal DNA, microbiome, pH, and saliva samples sequenced. All invited to move on to Part B and samples sequenced for 6 additional months.
62351137|NCT04433819||Cushing syndrome|Male and female patients diagnosed as Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
62351138|NCT04433819||Controls|Healthy controls matched for age, gender, and body mass index
62351139|NCT01663844|EXPERIMENTAL|(Study 1) ICBT for insomnia and depression|
62351140|NCT01663844|ACTIVE_COMPARATOR|(Study 1) ICBT for depr. plus placebo insomnia intervention|
61968100|NCT06268626||NEGATIVE BIOPSY RESULT|"Control for natural and spontaneous changes in vaginal DNA, microbiome, pH, and saliva samples sequenced.~Random subset selected to move on to Part B and samples sequenced for 6 additional months."
61968101|NCT04887051|EXPERIMENTAL|telerehabilitation|pre-post telerehabilltation
61968102|NCT06240975|OTHER|Theragun Technique|Theragun is a handheld percussive therapy device that can be used for massage and muscle relaxation. Use the Theragun for a designated duration per session, such as 5-10 minutes for 6 weeks
61968103|NCT06240975|OTHER|Dry Needling Technique|Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues, and muscle without the use of an anesthetic. Hold each stretch for an adequate duration (typically 15-30 seconds) to allow for muscle relaxation
61968104|NCT06463327|EXPERIMENTAL|Dose Escalation|"Drug product: TCB008 Administration route: Intravenous infusion~Proposed Dose Limits (DL) for dose escalation:~* Cohort 1: 1.5 mL IV TCB008 (3.6×107 to 6.9×107 cells)~* Cohort 2: up to 5 mL IV TCB008 (12.0×107 to 23.0×107 cells)~* Cohort 3: up to 18 mL IV TCB008 (43.2×107 to 82.8×107 cells)~The DL for the dose expansion will be based on the recommended dose for expansion determined in the dose escalation part of the study~Dosing is intended to be fixed (i.e., not weight-based or body surface area-based).~In both the dose escalation and dose expansion parts of the study, participants may be reinfused with TCB008 up to 3 times following initial infusion, if deemed appropriate by the investigator (or designee) based on review of available safety data and confirmation of disease status.~In the case that TCB008 is reinfused each dose will be administered 29 days apart."
61968105|NCT01114178||claudicants|patients referred for a treadmill test
61968106|NCT03348033|EXPERIMENTAL|Chronic Myeloid Leukemia + NK cell|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m\^2. Four hours later Cytarabine administrated by vein at 2 g/m\^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total.~NK Cell infusion on Days 0 to 14 for 6 doses total."
61968107|NCT05846932|EXPERIMENTAL|Occupational Therapy Integrating Horses|10 weeks of occupational therapy focused on self-regulation skills, provided while participants are riding horses
61968108|NCT05846932|ACTIVE_COMPARATOR|Occupational Therapy in a Clinic|10 weeks of occupational therapy focused on self-regulation skills, provided in a traditional clinic environment
61968109|NCT04323787||COVID19 test positive/pending or high clinical suspicion|COVID19 test positive/pending/high clinical suspicion- patient admitted to hospital
61968110|NCT00938639|EXPERIMENTAL|CSL425 (15 mcg)|15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
61968111|NCT00938639|EXPERIMENTAL|CSL425 (30 mcg)|30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
61968112|NCT01177917|EXPERIMENTAL|Cow milk-based infant formula with prebiotic blend|
61968113|NCT01177917|PLACEBO_COMPARATOR|Marketed Cow milk-based infant formula|
61968114|NCT05588232|EXPERIMENTAL|Patient with virtual reality|The virtual reality sedation-analgesia solution developed by Deepsen combines 3D environment content with medical hypnosis techniques. The technology includes a wearable visual headset that contains head movement sensors, enabling patient interaction in the virtual environment, as well as isolating headphones.
61968115|NCT05588232|ACTIVE_COMPARATOR|Patient with pharmacological sedation|
61968116|NCT00679302|PLACEBO_COMPARATOR|placebo group|Maalox and bitter mixture
61968117|NCT00679302|ACTIVE_COMPARATOR|antibiotic group|Trimethoprim-sulfamethoxazole suspension
61968118|NCT02669433|EXPERIMENTAL|RVT-101 35 mg|RVT-101 35 mg once daily
61968119|NCT02669433|EXPERIMENTAL|RVT-101 70 mg|RVT-101 70 mg once daily
61968120|NCT02669433|PLACEBO_COMPARATOR|Placebo|Placebo
61968121|NCT05779098||Extensive hepatectomy|
61968122|NCT04091568||Awake fibre-optic intubation|Awake fibre-optic intubation
61968123|NCT04091568||Asleep fibre-optic intubation|Asleep fibre-optic intubation
61968124|NCT04441021||Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
61968125|NCT02589184|EXPERIMENTAL|hypergravity WITH isometric load|Patient performing rehabilitation exercises under hypergravity as well as loaded isometric squats
61968126|NCT02589184|EXPERIMENTAL|hypergravity WITHOUT isometric load|Patient performing rehabilitation exercises under hypergravity
61968127|NCT02589184|EXPERIMENTAL|normal gravity WITH isometric load|Patient performing rehabilitation exercises under normal gravity as well as loaded isometric squats
61968128|NCT02589184|ACTIVE_COMPARATOR|normal gravity WITHOUT isometric load|Patient performing rehabilitation exercises under normal gravity
61968129|NCT03598985||Patients with CAI|"Patients referred with a confirmed diagnosis of CAI, with a Cumberland Ankle Instability tool score lower than 27 points. Patients should have had a recurrent sprain within the previous year.~Patients will have their balance assessed using the Myankle smartphone application simultaneously with Biodex balance system assessment."
61968130|NCT03598985||Healthy participants|"Healthy participants who are not complaining of pain and have not be exposed to trauma, injury or undergone surgery for the lower quadrant of the body.~Participants will have their balance assessed using the MyAnkle smartphone application simultaneously with Biodex balance system assessment."
61968131|NCT03648268|ACTIVE_COMPARATOR|Active DLPFC rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC at 80% of active motor threshold.
61968132|NCT03648268|SHAM_COMPARATOR|Sham DLPFC rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC
61968133|NCT03648268|ACTIVE_COMPARATOR|Active cerebellum rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum at 100% of active motor threshold.
61968134|NCT03648268|SHAM_COMPARATOR|Sham cerebellum rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum
61968135|NCT01793649|EXPERIMENTAL|Cross-Over Sequence 1|85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)
61968136|NCT01793649|EXPERIMENTAL|Cross-Over Sequence 2|2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)
61968137|NCT06141109|EXPERIMENTAL|MB07133+Sintilimab|"The test is divided into 2 stages： fist stage is dose escalation：Sintilimab 200mg，MB07133 injection is divided into three dosage groups: 600mg/m2/day, 1200mg/m2/day, and 1800mg/m2/day.~second stage Dose expansion：Sintilimab 200mg+MB07133 1800mg/m2/day"
61968138|NCT01813591|EXPERIMENTAL|H.P. Acthar Gel 80IU|H.P. Acthar Gel of 80IU (1.0 ml)
61968139|NCT01813591|EXPERIMENTAL|H.P. Acthar Gel 40IU|H.P. Acthar Gel of 40IU (0.5 mL)
61968140|NCT02743559|ACTIVE_COMPARATOR|Vitamin D group|Children born to mothers who received vitamin D during pregnancy will undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform(LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
61968141|NCT02743559|PLACEBO_COMPARATOR|Placebo group|Children born to mothers who received placebo during pregnancy will also undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform (LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
61968142|NCT04134468|EXPERIMENTAL|Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine|Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days.
61968143|NCT02922556|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training (Moodify) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
61968144|NCT02922556|ACTIVE_COMPARATOR|Active Comparator|Commercially available computerized training (Games) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
61968145|NCT01442493|EXPERIMENTAL|Patient-Centered Methadone Treatment|Patient-Centered Methadone Treatment alters the rules and staff roles in methadone treatment as usual in an attempt to increase treatment retention and improve patient outcomes.
61968146|NCT01442493|ACTIVE_COMPARATOR|Methadone Treatment as Usual|Methadone treatment provided as usual in the U.S.
61968147|NCT03018704|PLACEBO_COMPARATOR|Placebo|a placebo control arm
61968148|NCT03018704|EXPERIMENTAL|Topiramate|Topiramate an FDA approved anticonvulsant has been shown effective in the treatment of alcohol use disorder but there is no data supporting use in minority patients. The medication was dosed orally twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
61968149|NCT01693653|ACTIVE_COMPARATOR|Tocilizumab|tocilizumab infusion every 4 weeks over 3 months
61968150|NCT01693653|PLACEBO_COMPARATOR|Placebo|placebo infusion 0.9% sodium chloride every 4 weeks over 3 months
61968151|NCT01950650||Patients with diabetes|
61968152|NCT01950650||Physicians|
61968153|NCT05230771|EXPERIMENTAL|Palliative surgery after translational therapy|After randomization, patients received palliative surgery after translational therapy
61968154|NCT05230771|ACTIVE_COMPARATOR|Chemotherapy alone|After randomization, patients received chemotherapy alone
61968155|NCT03954756|EXPERIMENTAL|apatinib and PD-1|Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect
62351141|NCT01663844|EXPERIMENTAL|(Study 2) ICBT for insomnia with added support|
62509503|NCT00760526|ACTIVE_COMPARATOR|1|continuous glucose monitoring
61968156|NCT04693884|EXPERIMENTAL|High THC, Smoked|
62145205|NCT04905784|ACTIVE_COMPARATOR|Control group: Usual brushing.|Usual motivation to brush teeth in the clinic (KAI brushing technique) in addition to brushing teeth by the parents.
62351142|NCT01663844|ACTIVE_COMPARATOR|(Study 2) ICBT for insomnia with regular level of support|
62351143|NCT04344262|ACTIVE_COMPARATOR|control (C) group|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
62509504|NCT00760526|ACTIVE_COMPARATOR|2|Standard glucose monitoring with a home glucose meter
62509505|NCT04954859|EXPERIMENTAL|Not-on-NA participants|Participants rolling over from study 209668 who have not received nucleos(t)ide analogue (NA) therapy during the parent study and remain off NAs will be included in this arm. Participants will be followed up for 33 months. Participants maintaining either functional cure (FC) or a partial response off NA treatment at Month 33 will be eligible to be followed up for an additional 2 years. No study treatment will be administered in this study.
61968157|NCT04693884|EXPERIMENTAL|High THC, Vaporized|
61968158|NCT04693884|EXPERIMENTAL|High CBD, Smoked|
61968159|NCT04693884|EXPERIMENTAL|High CBD, Vaporized|
61968160|NCT01082991|OTHER|prevention|
61968161|NCT01115725||Gonal-f® prefilled pen|
61968162|NCT01539694|EXPERIMENTAL|LD118033 contact lens|Investigational LD118033 multifocal low add soft contact lenses, to be worn on a daily wear basis.
61968163|NCT01539694|ACTIVE_COMPARATOR|PureVision multifocal contact lens|PureVision multifocal low add soft contact lens, to be worn on a daily wear basis.
61968164|NCT06042452|EXPERIMENTAL|Genetic|Participants will have their DNA tested and this data alongside lifestyle data will personalize the information they receive
61968165|NCT03383172|EXPERIMENTAL|ICPS with internal school facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by the early educator of the class, who is part of the school personnel.This internal facilitator will be trained in the program. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
62145206|NCT04905784|EXPERIMENTAL|Test group: Differential learning group.|Use of differential learning of tooth brushing at home, including children and parents.
62351144|NCT04344262|EXPERIMENTAL|minimal dose (M) group|"Intubating dose of muscle relaxant will be 0.2 mg/kg will be injected~boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal."
62145207|NCT02191540|EXPERIMENTAL|Abnoba Viscum F 20mg|
62145208|NCT00729898||A|
62145209|NCT05535959|EXPERIMENTAL|Sequence 1|Participants will receive a single dose of reference FDC tablet of VX-121/TEZ/D-IVA in dosing period 1, followed by a single dose of test FDC tablet of VX-121/TEZ/D-IVA in dosing period 2. A washout period of 14 days will be maintained between the 2 dosing periods.
62351145|NCT04904003|EXPERIMENTAL|Experienced LLA - intervention|Experienced lower-limb amputees that complete a 4-week semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
62351146|NCT04904003|EXPERIMENTAL|Experienced LLA - controls|Experienced lower-limb amputees that will be tested with a 4-week interval. No intervention. This group will be matched to the group of experienced lower-limb amputees.
62509506|NCT04954859|EXPERIMENTAL|On-NA participants|Participants rolling over from studies 209668, 209348, 212602, 202009, 219288, and 217023 who entered the parent study on stable NA therapy and remained on NA therapy for the duration of the treatment and follow-up periods in the parent study will be included in this arm. NA cessation will occur at 3 months in 206882 for eligible and willing participants. Participants will be followed up for 33 months. Participants rolling over from studies 209668 and 209348 who stopped NA treatment and are maintaining either FC or a partial response at Month 33, and remaining off NA treatment, will be eligible to be followed up for an additional 2 years. No study treatment will be administered in this study.
62509507|NCT04954859|EXPERIMENTAL|NA-cessated participants|Participants rolling over from studies 202009 and 219288 who have stopped NA treatment during the parent study will be included in this arm. Participants will be followed up for 33 months. No study treatment will be administered in this study.
62707129|NCT04311450|NO_INTERVENTION|Waitlist Control|Waitlist Control: Participants assigned to this arm will attend follow-up visits to control for the effect of time. Following completion of post-treatment assessment participants in the waitlist control group will be offered an abbreviated BWL treatment.
62707130|NCT02578901|ACTIVE_COMPARATOR|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
61968166|NCT03383172|ACTIVE_COMPARATOR|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
61968167|NCT03383172|NO_INTERVENTION|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
61968168|NCT01911871||thalassemia|patients affected with thalassemia
62145210|NCT05535959|EXPERIMENTAL|Sequence 2|Participants will receive a single dose of test FDC tablet of VX-121/TEZ/D-IVA in dosing period 1, followed by a single dose of reference FDC tablet of VX-121/TEZ/D-IVA in dosing period 2. A washout period of 14 days will be maintained between the 2 dosing periods.
62145211|NCT02978183|ACTIVE_COMPARATOR|Group 1|1X ST266 dosed 4 times a day for 8 days
62145212|NCT02978183|PLACEBO_COMPARATOR|Group 2|Placebo dosed 4 times a day for 8 days
62351147|NCT04904003|EXPERIMENTAL|New LLA learning to use prosthesis|New lower-limb amputees that complete a 8-11 weeks semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
62351148|NCT05987345|EXPERIMENTAL|PEF treatment|All of participants who signed the Informed Consent Form(ICF) and meet all of inclusion and exclusion criterial will be enrolled to experimental arm. PEF treatment on Day 1, followed by anti PD-1 on Day 7 and then routinely.
61968169|NCT01911871||sickle cell disease|patients affected with sickle cell disease
61968170|NCT01911871||myelodysplasia|patients affected with myelodysplasia
61968171|NCT06129071|EXPERIMENTAL|US block of maxillar nerve|"Extraoral ultrasound-guided block of the maxillary nerve will be performed using an ultrasound device. After visualisation of the pterygomandibular space, of the maxillary artery and the mandibular nerve next to it, at a depth of 2-4 cm, the detection of the maxillary artery is confirmed by Color Doppler. A needle enters between the coronoid and condylar processes, using the out of plane technique, near the maxillary artery, and after negative aspiration, local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL)."
62145213|NCT02541305|ACTIVE_COMPARATOR|Cotrol|No propioceptive program.
62145214|NCT02541305|EXPERIMENTAL|Experimental|Propioceptive program
62145215|NCT02930317|EXPERIMENTAL|Pharmacokinetic parameters|Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
62351149|NCT03539913|ACTIVE_COMPARATOR|Saccharomyces boulardii|Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
62351150|NCT03539913|ACTIVE_COMPARATOR|Bacillus clausii|Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
62351151|NCT03384108|EXPERIMENTAL|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
62351152|NCT03384108|PLACEBO_COMPARATOR|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
62351153|NCT05855681|EXPERIMENTAL|experimental group|patients will receive strengthening exercise for hip rotators and ankle muscles in addition to quadriceps strengthening . stretching exercise for hamstring and calf muscle also will be received
62351154|NCT05855681|OTHER|control group|patients will receive strengthening exercises for quadriceps and stretching exercise for hamstring and calf muscle.
62351155|NCT05599698|EXPERIMENTAL|chemotherapy|chemotherapy
62351156|NCT02592395|EXPERIMENTAL|Electrochemotherapy with FOLFIRINOX|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with FOLFIRINOX . The schedule of administration of FOLFIRINOX will be administered as per standard of care.
61968172|NCT03634462|EXPERIMENTAL|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
61968173|NCT03634462|EXPERIMENTAL|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
61968174|NCT02329353|EXPERIMENTAL|Smoker group|30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
61968175|NCT02329353|EXPERIMENTAL|Non-smoker|30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
61968176|NCT05466526|EXPERIMENTAL|The participants who received HFDS|All participants in the arm were suffering from primary open-angle glaucoma and were indicated for surgery due to either progression of field defect and raised intraocular pressure above 21 mmHg in spite of maximum medical treatment or for patients who were not compliant patient to their medical treatment.
61968177|NCT02316808|PLACEBO_COMPARATOR|Placebo smoothie|
61968178|NCT02316808|EXPERIMENTAL|Plant stanol ester smoothie|
61968179|NCT05408949|EXPERIMENTAL|SEP+FR|- Single exercises program (SEP) is considered to be harmless, valid and has a valuable prescription as initial rehabilitation program. studies showed an immediate analgesic relief and increase in muscle strength after preforming single heavy-load isometric training program
61968180|NCT05408949|ACTIVE_COMPARATOR|SSMP+ETL+HSR+FR Group|"* The Shoulder Symptom Modification Procedure (SSMP) consists of applying several mechanical techniques and applied when the patient moves or performs a specific activity. This procedure is designed to address the symptoms and improve range of motion by identifying mechanical changes.~* Heavy slow resistance (HSR) training is an alternative from traditional exercise physiotherapy, by emphasizing on heavy weights and slow repetition. HSR training includes repetitive gradual and slow contraction of the muscle during concentric, isometric and eccentric phases against a heavy weight~* Early controlled and progressive tendon loading (EPTL) in rehabilitation practice is suggested to show a high and definite impact on healing and recovery of the tendon"
61968181|NCT01102400|EXPERIMENTAL|1|
61968182|NCT05924295|EXPERIMENTAL|C8 Ketone Supplement|360mg/kg of supplement will be given on a singular testing day.
61968183|NCT02035878|ACTIVE_COMPARATOR|Probiotics|400mg probiotic capsule taken once daily for ten weeks
61968184|NCT02035878|PLACEBO_COMPARATOR|Placebo (rice flour)|400mg placebo capsule containing rice flour taken once daily for ten weeks
61968185|NCT02246660|ACTIVE_COMPARATOR|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
61968186|NCT02246660|ACTIVE_COMPARATOR|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
61968187|NCT02246660|PLACEBO_COMPARATOR|Placebo|Placebo will be taken orally for 6 months.
61968188|NCT02433483|EXPERIMENTAL|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).~Interventions:~* Cycle 1: cytarabine, HPC-A donor infusion~* Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
61968189|NCT04899921|EXPERIMENTAL|Ipilimumab + Nivolumab + Troriluzole [Phase I dose level 1]|Phase I dose level 1 participants received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously (IV) on day 1 of each 21-day cycle and the original starting troriluzole dose of 140 mg orally in the morning as well as 280 mg orally in the evening every day of each 21-day cycle. Participants were treated until disease progression or unacceptable toxicity.
61968190|NCT04899921|EXPERIMENTAL|Ipilimumab + Nivolumab + Troriluzole [Phase II]|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Troriluzole self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Troriluzole self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
61968191|NCT04899921|EXPERIMENTAL|Ipilimumab + Nivolumab + Placebo [Phase II]|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Placebo self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Placebo self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
61968192|NCT04899921|EXPERIMENTAL|Ipilimumab + Nivolumab + Troriluzole [Phase I dose level 2]|Phase I dose level 2 participants received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously (IV) on day 1 of each 21-day cycle and troriluzole 140 mg twice per day orally. Participants were treated until disease progression or unacceptable toxicity.
61968193|NCT04899921|EXPERIMENTAL|Ipilimumab + Nivolumab + Troriluzole [Phase I dose level 3]|Phase I dose level 3 participants received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously (IV) on day 1 of each 21-day cycle and troriluzole 140 mg/day orally. Participants were treated until disease progression or unacceptable toxicity.
62145216|NCT02930317|EXPERIMENTAL|On-demand treatment|On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
62145217|NCT00856687|EXPERIMENTAL|PF-03893787|
62707131|NCT02578901|PLACEBO_COMPARATOR|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
61968194|NCT03975790||Truven Health MarketScan Research Database|Compare treatment patterns including dosing, concomitant medication use, adherence, persistence, and switching among tofacitinb+MTX patients who withdraw MTX vs. persist with MTX or experience interrupted MTX
61968195|NCT03503955|EXPERIMENTAL|study group|fine motor skills activities and Leap-Motion virtual reality games
61968196|NCT03503955|EXPERIMENTAL|control group|fine motor skills activities
61968197|NCT03873233|ACTIVE_COMPARATOR|Volume Controlled Ventilation|Volume Controlled Ventilation with Aisys Carestation ventilator and normal endotracheal tube'
61968198|NCT03873233|ACTIVE_COMPARATOR|Flow Controlled Ventilation|Flow Controlled Ventilation with Evone ventilator and Tritube
61968199|NCT05029440|EXPERIMENTAL|Electromagnetic and Exercise Group|Pulsed Electromagnetic Field (PEMF) PEMF was administered to the whole body using a 1.8×0.6m mat Exercise Program Exercise program to facilitate bone health
61968200|NCT05029440|ACTIVE_COMPARATOR|Laser and Exercise Group|Pulsed High Intensity Laser Therapy (HILT) HILT was administered to lumbar region and femoral head using Exercise Program Exercise program to facilitate bone health
62509508|NCT03559335||Patients after colorectal cancer surgery|
61968201|NCT05029440|ACTIVE_COMPARATOR|Exercise Group|Exercise Program Exercise program to facilitate bone health
61968202|NCT04532164|EXPERIMENTAL|Photoallergic reaction test|During the Induction Phase, participants received Butenafine HCl 1% on the treated irradiated skin test site followed by UV irradiation and on the treated non-irradiated skin test site without UV radiation, two times per week for three consecutive weeks. After 10 days of Rest Phase, during the Challenge Phase, participants received same procedure on the two virgin sites (treated sites) as in Induction Phase, and two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Test sites were evaluated at 24, 48, and 72 hours after irradiation using the same grading scale used during Induction Phase.
61968203|NCT03893799|EXPERIMENTAL|Cohort 1, Healthy Volunteers|Dose A, single dose
61968204|NCT03893799|EXPERIMENTAL|Cohort 2, Healthy Volunteers|Dose B, single dose
61968205|NCT03893799|EXPERIMENTAL|Cohort 3, Healthy Volunteers|Dose C, single dose
61968206|NCT03893799|EXPERIMENTAL|Cohort 4, Subjects with CKD Stage 3|Dose D, single dose
61968207|NCT03893799|EXPERIMENTAL|Cohort 5, Subjects with CKD Stage 3|Dose E, single dose
61968208|NCT03893799|EXPERIMENTAL|Cohort 6, Subjects with CKD Stage 4|Dose F, single dose
61968209|NCT03893799|EXPERIMENTAL|Cohort 7, Subjects with CKD Stage 4|Dose G, single dose
62509509|NCT00890331|ACTIVE_COMPARATOR|Diabetes Education|
62509510|NCT00890331|EXPERIMENTAL|TeamWork CS Sessions|
61968210|NCT03893799|EXPERIMENTAL|Cohort 8, Subjects with CKD Stage 3 or 4|Dose H, single dose
61968211|NCT03893799|EXPERIMENTAL|Cohort 9, Subjects with CKD Stage 3 or 4|Dose I, single dose
61968212|NCT01622790|EXPERIMENTAL|Arm 1|33 subjects will receive a single dose of each of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 1followed by dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
61968213|NCT01622790|EXPERIMENTAL|Arm 2|33 subjects will receive dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 1 followed by a single dose of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
61968214|NCT00684307|EXPERIMENTAL|1|AZD0837 450 mg
61968215|NCT00684307|EXPERIMENTAL|2|AZD0837 200 mg
61968216|NCT00684307|EXPERIMENTAL|3|AZD0837 300 mg
61968217|NCT00684307|EXPERIMENTAL|4|AZD0837 150 mg
61968218|NCT00684307|ACTIVE_COMPARATOR|5|Vitamin-K antagonist at INR 2-3
61968219|NCT05010577|EXPERIMENTAL|BX004-A|Participants will be randomized to receive standard dose of nebulized bacteriophage
61968220|NCT05010577|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive nebulized placebo
61968221|NCT03291054|EXPERIMENTAL|Epacadostat and pembrolizumab|Subjects will receive epacadostat and pembrolizumab
61968222|NCT03973385|EXPERIMENTAL|cryotherapy group|cryotherapy by vapocoolant spray is applied on skin for 4 to 10 seconds ( or up to skin whitening) to 15 centimeters distance with sweeping action before ABG
61968223|NCT03973385|PLACEBO_COMPARATOR|control group|water spray is applied on skin for 4 to 10 seconds to centimeters distance with sweeping action before ABG
62145218|NCT00856687|PLACEBO_COMPARATOR|Placebo|
62145219|NCT00856687|ACTIVE_COMPARATOR|Montelukast|
62509511|NCT02188992||Cohort 1|Patients with sepsis syndrome, without criteria for severe sepsis/septic shock. These patients are recruited from the emergency department.
62509512|NCT02188992||Cohort 2|Patients with community acquired sepsis syndrome REQUIRING critical care admission due to severity of sepsis. These patients are recruited from the critical care areas (ICU/HDU).
62509513|NCT02188992||Cohort 3|Patients without sepsis syndrome. Age and gender matched to cohort 1, and recruited from Emergency Department.
62509514|NCT00885677|ACTIVE_COMPARATOR|Study Group|Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
62509515|NCT00885677|NO_INTERVENTION|Control Group|Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.
62509516|NCT05255952|EXPERIMENTAL|Patients|"3 cycles of electrical stimualtions will be done at the end of cardiac surgery, before end of surgery (patient closure), under anaesthesia.~Cardiac outcomes will be monitored"
62509517|NCT01010789|EXPERIMENTAL|Armodafinil|Flexible dose 150-250mg/day
62509518|NCT01010789|PLACEBO_COMPARATOR|Mathing Placebo|
62509519|NCT05985694|PLACEBO_COMPARATOR|Cohort 1 Placebo|Formulation buffer
62509520|NCT05985694|EXPERIMENTAL|Cohort 1 Low dose|Formulation buffer + 10 μg LTh(αK)
62509521|NCT05985694|PLACEBO_COMPARATOR|Cohort 2 Placebo|Formulation buffer
61968224|NCT06102759||Adebrelimab, Fruquintinib combined with paclitaxel|Fruquintinib 4mg d1-14, q3w Paclitaxel 150mg/m2, d1, q3w / Albumin paclitaxel 125mg/m2, d1, d8, q3w PD-L1 antibody (Adebrelimab) 20 mg/kg, d1, q3w
61968225|NCT02908555||no intervention|Descriptive study without groups
62707132|NCT04821167|OTHER|Laparoscopic orchiopexy for intra-canalicular (emergent or peeping) testis|This is a prospective study conducted on male children with intermittent palpable (peeping) UDT to evaluate the safety and efficiency of laparoscopic orchiopexy of intra-canalicular (emergent or peeping) testis.
62707133|NCT05629871|EXPERIMENTAL|Single arm|Alzheimer
62707134|NCT03146260|EXPERIMENTAL|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
62707135|NCT03146260|EXPERIMENTAL|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
62707136|NCT00785720|EXPERIMENTAL|1|Dermacyd PH_DETINBACK (Lactic Acid)
62707137|NCT02767076|ACTIVE_COMPARATOR|Conventional|conventional paramedian spinal anesthesia
61968226|NCT05083442|ACTIVE_COMPARATOR|Group 1 - LLLT|Subject receive Laser treatments and Lifestyle Modifications
61968227|NCT05083442|SHAM_COMPARATOR|Group 2 - SHAM|Subject receives Sham Laser treatments and Lifestyle Modifications
61968228|NCT06173921|EXPERIMENTAL|Robotic system|implant placement by robotic surgery
61968229|NCT06173921|ACTIVE_COMPARATOR|Static system|implant placement by static navigation surgery
61968230|NCT05798429|EXPERIMENTAL|experimental group|
61968231|NCT05798429|NO_INTERVENTION|control group|
61968232|NCT04258397|ACTIVE_COMPARATOR|Experimental, pirfenidone|"Pirfenidone 267 mg capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
61968233|NCT04258397|PLACEBO_COMPARATOR|Placebo, pirfenidone|"Pirfenidone placebo capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
62707138|NCT02767076|EXPERIMENTAL|Ultrasound|ultrasound guided paramedian spinal anesthesia
62707139|NCT03899415|EXPERIMENTAL|TCR-Redirected T Cells|HBV antigen specific TCR redirected T cells
61968234|NCT05271695||The patients with type 2 diabetes|"* Patients with a diagnosis of Type 2 Diabetes Mellitus and HbA1c ≤ 7%~* Patients using or not using oral antidiabetic drugs~* Patients who inject insulin once or twice a day or repeated insulin injections"
62707140|NCT00966108||Healthy subjects|
62707141|NCT00966108||Glaucoma patients|
62707142|NCT04942002|PLACEBO_COMPARATOR|Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution
62707143|NCT04942002|EXPERIMENTAL|Standard treatment + intervention|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + retrobulbar injection of 2 cc (40 mg/mL) to methylprednisolone acetate
62707144|NCT00647088||aortic stenosis|various age and disease severity
62707145|NCT00647088||Controls|Controls free of valvular disease
62707146|NCT04648020|PLACEBO_COMPARATOR|Placebo|Placebo Mucoadhesive Buccal Tablet given daily during chemoradiotherapy
62707147|NCT04648020|EXPERIMENTAL|Clonidine HCl Mucoadhesive Buccal Tablet (MBT)|Clonidine HCl MBT given daily during chemoradiotherapy
62707148|NCT01891279|EXPERIMENTAL|elemental formula, Elecare®|Babies will receive elemental formula, Elecare®, if breast milk is not available.
62707149|NCT01891279|EXPERIMENTAL|part hydrolyzed formula, Pregestimil®|Babies will receive partially hydrolyzed formula, Pregestimil®, if breast milk is not available.
61968235|NCT05271695||The healthy controls|"* Patients diagnosed with Type I Diabetes Mellitus,~* Patients with HbA1c \> 7%~* Those with gestational diabetes,~* Breastfeeding diabetics,~* Patients with renal dysfunction,~* Patients with acute and chronic infection status"
62707150|NCT02558166||Patients with shock|"Critically ill patients admitted to the intensive care unit (ICU)~* with shock due sepsis/SIRS, cardiac failure or hemorrhage~* age \> 18 years,~* noradrenalin support~* \< 24 hours of ICU admission~* Signed informed consent"
62707151|NCT02558166||Patients without shock|"Critically ill patients admitted to the intensive care unit (ICU)~* without shock, without vasopressor support and without fluid dependent circulation~* age \> 18 years~* \< 24 hours of ICU admission~* Signed informed consent"
62707152|NCT06165055||MIH-affected participants (study group )|The Study Arm comprises individuals aged 8-13 with Molar-Incisor Hypomineralization (MIH) in at least one permanent molar.
62707153|NCT06165055||Systemically healthy controls (control group )|Systemically healthy individuals without MIH.
61968236|NCT03905603|EXPERIMENTAL|ACTH (Cosyntropin), rhCG (Ovidrel)|ACTH (Cosyntropin) administered 250 mcg IV; rhCG (Ovidrel) administered 250 mcg IV
61968237|NCT01962805|EXPERIMENTAL|Proellex Schedule A|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
61968238|NCT01962805|EXPERIMENTAL|Proellex Schedule B|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
61968239|NCT01533025|ACTIVE_COMPARATOR|bone-tendon Achilles allograft group|the group which underwent anterior cruciate ligament reconstruction using bone-tendon Achilles allograft
61968240|NCT01533025|ACTIVE_COMPARATOR|free tendon Achilles allogarft group|the group which underwent anterior cruciate ligament reconstruction using free tendon Achilles allograft
61968241|NCT06232811||Preterm|preterm infants with gestational age \<34 weeks
61968242|NCT06232811||Term|term infants with gestational age \>37 weeks
61968243|NCT01624389|EXPERIMENTAL|F18-AV45|
61968244|NCT03498300|EXPERIMENTAL|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
61968245|NCT03498300|NO_INTERVENTION|Active comparator|dT vaccine as standard protocol
61968246|NCT02233816|EXPERIMENTAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
61968247|NCT02233816|EXPERIMENTAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
61968248|NCT02233816|EXPERIMENTAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
61968249|NCT02233816|PLACEBO_COMPARATOR|Placebo|A single dose of Placebo
61968250|NCT06040372|EXPERIMENTAL|LB54640|"5 mg, 25 mg and 200 mg strengths~Subjects will be administered once daily and duration vary per each cohorts.~Single Ascending Dose (SAD) cohorts : 1 day~* SAD 1 10mg~* SAD 2 25mg~* SAD 3 50mg (Food effect cohort)~* SAD 4 100mg~* SAD 5 200mg~* SAD 6 400mg~healthy Multiple Ascending Dose (MAD) cohorts: 28days~* MAD 1 10mg~* MAD 2 25mg~* MAD 3 50mg~* MAD 4 100mg~* MAD 5 200mg~* MAD 6 400mg~* MAD 7 600mg"
62707154|NCT05383742|EXPERIMENTAL|Arm A|RIF 35 mg/kg + INH 15 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 2 weeks, followed by RIF 35 mg/kg + INH 10 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 6 weeks, and then RIF 35 mg/kg and INH 10 mg/kg for 16 weeks, for a total of 24 weeks of study treatment.
62707155|NCT05383742|ACTIVE_COMPARATOR|Arm B|WHO SOC: RIF 10 mg/kg + INH 5 mg/kg + ethambutol (EMB) 20 mg/kg + PZA 25 mg/kg for 8 weeks, followed by RIF 10 mg/kg and INH 5 mg/kg for 28 weeks, for a total of 36 weeks of study treatment. Up to 15 mg/kg or a maximum of 900 mg daily of oral RIF will be permitted in this arm at clinician's discretion.
61968251|NCT06040372|PLACEBO_COMPARATOR|Placebo|matching placebo
61968252|NCT01788332|ACTIVE_COMPARATOR|Olaparib|3 100mg tablets to be administered twice a day with approximately 240ml of water.
61968253|NCT01788332|PLACEBO_COMPARATOR|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water.
62707156|NCT01786122|EXPERIMENTAL|Exercise group|supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
61968254|NCT02432014|OTHER|PMTO-PTC Group clinic-based|PMTO-PTC = Oregon Parent Management Training program, Parenting Through Change groups provided at a clinic.
61968255|NCT02432014|OTHER|PMTO Individual home-based|PMTO = Oregon Parent Management Training program, delivered individually in the home.
61968256|NCT02432014|OTHER|PMTO Individual clinic-based|PMTO = Oregon Parent Management Training program, delivered individually at a clinic.
61968257|NCT02432014|OTHER|Services as Usual|Usual child-centered services (i.e. therapy) provided by the agencies at a clinic.
61968258|NCT01636804||Quicksite and Quickflex|Patients who have received the leads affected by the medical product advisory
61968259|NCT03432754|EXPERIMENTAL|Mindfulness-Based Attention Training|Four weekly group mindfulness attention training sessions of a 1.5-hour duration. Participants provided with audio recordings, readings, and homework assignments consisting of various mindfulness practices.
61968260|NCT03432754|ACTIVE_COMPARATOR|Lifestyle Education Group|Four weekly group lifestyle education sessions of a 1.5-hour duration. Homework consisting of reading, diet monitoring, stretching/toning exercises, and brainstorming new healthy living techniques/ideas.
61968261|NCT04366453|OTHER|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
61968262|NCT04187014|ACTIVE_COMPARATOR|Tranexamic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid are 650 mg each. The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
61968263|NCT04187014|EXPERIMENTAL|Aminocaproic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic tablets are 1000 mg each.The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 6 grams (6 tablets) divided between the 3 administrations (2 gram each, ie 2 tablets of 1000 mg) will be administered."
61968264|NCT01573975|EXPERIMENTAL|Seq-Metronidazole|10-day sequential therapy with metronidazole
61968265|NCT01573975|EXPERIMENTAL|Seq-Tetracycline|10-day sequential therapy with tetracycline.
62707157|NCT01786122|NO_INTERVENTION|control group|Pharmacological treatment and selfcare encouragement.
62707158|NCT02894398|EXPERIMENTAL|Palbociclib+AI or Fulvestrant|Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
62707159|NCT02447692|ACTIVE_COMPARATOR|PSV ventilation strategy|The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
62707160|NCT02447692|ACTIVE_COMPARATOR|PAV+ ventilation strategy|The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
61968266|NCT01573975|ACTIVE_COMPARATOR|Control|10-day standard triple therapy.
61968267|NCT05850572|EXPERIMENTAL|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
62707161|NCT01195974|EXPERIMENTAL|Period 1|YASMIN + 200 mg GSK2248761 or Placebo
61976213|NCT05319145|EXPERIMENTAL|Intervention group|Based on the results of the CGA, a tailored multidisciplinary intervention will be proposed, focused on a multicomponent physical exercise program with nutritional recommendations.
62707162|NCT01195974|EXPERIMENTAL|Period 2|YASMIN + 200 mg GSK2248761 or Placebo
62707163|NCT01195974|OTHER|Run In Period|YASMIN
62707164|NCT00799565|EXPERIMENTAL|1|Subject with a Mitral Valvular Prolapse
62707165|NCT00799565|EXPERIMENTAL|2|Healthy Volunteers
62707166|NCT01295047|ACTIVE_COMPARATOR|ATENOLOL|ATENOLOL 75MG FOR 4 WEEKS
62707167|NCT01295047|ACTIVE_COMPARATOR|VERAPAMIL|240MG VERAPAML FOR 4 WEEKS
62707168|NCT01295047|ACTIVE_COMPARATOR|PERINDOPRIL|4MG PERINDOPRIL FOR 4 WEEKS
61968268|NCT05850572|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
61968269|NCT02839070|EXPERIMENTAL|Regular Schedule|Participant will be on a regular sleep/wake schedule
61968270|NCT02839070|EXPERIMENTAL|Irregular Schedule|Participant will be on an irregular sleep/wake schedule
61968271|NCT04814134|EXPERIMENTAL|CPNS Therapy|Treatment with CPNS system: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
61968272|NCT04814134|OTHER|Standard of Care|Available standard treatment
61968273|NCT03176251|ACTIVE_COMPARATOR|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
61968274|NCT03176251|EXPERIMENTAL|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
61968275|NCT04677374|PLACEBO_COMPARATOR|Standard of care|Participants in this arm will be offered Standard of Care (SOC) referral process for voluntary medical male circumcision (VMMC) services
61968276|NCT04677374|EXPERIMENTAL|Block 1 (intensified health education)|Participants in this arm will be offered intensified health education
61968277|NCT04677374|EXPERIMENTAL|Block 2 (intensified health education and SMS/telephonic tracing)|Participants in this arm will be offered intensified health education and SMS/telephonic tracing
61968278|NCT04677374|EXPERIMENTAL|Block 3 (intensified health education, SMS/telephonic tracing and transport reimbursement)|Participants in this arm will be offered intensified health education, SMS/telephonic tracing and transport reimbursement
61968279|NCT03369405||Periodontally healthy patients|Patients that have no history of periodontal treatment and that have been scheduled for routine prophylaxis appointments in the predoctoral clinics at the School of Dental Medicine, University at Buffalo.
61968280|NCT03369405||Periodontitis, group 1|Patients that have been referred from the pre-doctoral dental clinics to the Postgraduate Periodontics clinic for advanced periodontal disease. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths \> 4 mm more likely to be prevalent.
62351157|NCT04509323|EXPERIMENTAL|Experimental：Huperzine A for Injection+Basic treatment|Huperzine A for Injection: Dissolve each bottle with 2ml sterile water for injection and inject into muscle, the course of treatment is 14 days； Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
62509522|NCT05985694|EXPERIMENTAL|Cohort 2 High dose|Formulation buffer + 20 μg LTh(αK)
62509523|NCT03151564|EXPERIMENTAL|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
62351158|NCT04509323|NO_INTERVENTION|Control：Basic treatment|Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
62509524|NCT03151564|EXPERIMENTAL|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
62509525|NCT03151564|EXPERIMENTAL|Deep Learning Image Reconstruction (DLIR)|DLIR is available in both single (SE) and dual/multi energy (DE) CT scanning modes. DLIR SECT and DLIR DECT reconstructions have yet to be compared.
62509526|NCT00962884|EXPERIMENTAL|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
62509527|NCT00962884|SHAM_COMPARATOR|Sham Device|Breathing device similar to active Res-Q-Gard device but with one-way resistance valve removed.
62509528|NCT02860819|EXPERIMENTAL|Gemcitabine, Carboplatin, Veliparib|Gemcitabine 800mg/m2 day 1 and 8 every 3 weeks; Carboplatin AUC = 4, day 1, every 3 weeks, Veliparib 250mg bid day continuously.
62509529|NCT01035476|EXPERIMENTAL|Data Card Report|Patients receive detailed reports of acceptance and adherence, with linked recommendations to optimize NIPPV.
62509530|NCT01035476|NO_INTERVENTION|Standard NIPPV Care|Patients receive routine monitoring and care related to NIPPV.
62509531|NCT01699919|ACTIVE_COMPARATOR|intravenous lignocaine|Intravenous lignocaine will be given as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr throughout surgery and till one hour post surgery.
62707169|NCT01731145|EXPERIMENTAL|SNUMAP assessment|Uses SNUMAP motion sensing system to quantify tremor symptom.
62707170|NCT01302886|EXPERIMENTAL|BHQ880|
62509532|NCT01699919|PLACEBO_COMPARATOR|normal saline|Normal saline will be given as a bolus at the time of intubation and saline infusion given to patients in the control group during the surgery and till one hour post surgery.
62509533|NCT03509571|EXPERIMENTAL|Ketogenic Diet Group|Ketogenic diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that included ≈72% total energy as fat, ≈25% as protein, and ≈3% as carbohydrate during enteral feeding and ≈65% total energy as fat, ≈27% as protein, and ≈8% as carbohydrate and fiber during solid feeding. Patients will start receiving ketogenic diet within the 72 hours injury, after completing their baseline measurements.
62509534|NCT03509571|OTHER|Standard Diet Group|Patients will start to receive standard hospital diet within 72 hours of injury after completing their baseline measurements. Standard diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
61968281|NCT03369405||Periodontitis, group 2|Patients referred to a faculty practice periodontist over the course of his clinical career due to chronic periodontitis that could not be treated by the referring general dentist. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths \> 4 mm more likely to be prevalent.
61968282|NCT04635943|ACTIVE_COMPARATOR|Ivermectin|Participants on this arm will receive orally one (1) daily dose of ivermectin 300 mcg/kg for three (3) consecutive days, starting at the enrolment visit.
61968283|NCT04635943|PLACEBO_COMPARATOR|Placebo|Participants on this arm will receive orally one (1) daily dose of placebo for three (3) consecutive days, starting at the enrolment visit.
61968284|NCT02091544||Lifestyle intervention|lifestyle intervention
61968285|NCT05606497||Early-onset FGR|
61968286|NCT03780283|EXPERIMENTAL|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
62707171|NCT02133573|EXPERIMENTAL|Progesterone|Vaginal gel, 90mg twice a day (BID)
61968287|NCT03780283|NO_INTERVENTION|placebo|observation
61968288|NCT02390895|EXPERIMENTAL|Minimally-invasive endoscopic repair|endoscopic repair of myelomeningocele before 26 SA
61968289|NCT01658891|EXPERIMENTAL|CHF 1535 50/6 µg|
62509535|NCT02419235|PLACEBO_COMPARATOR|20% Ethanol|Ten drops of unmedicated 20% ethanol must be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
62707172|NCT02133573|PLACEBO_COMPARATOR|Vaginal Lubricant|Vaginal twice a day (BID)
62707173|NCT03229538|EXPERIMENTAL|Methylprednisolone Arm|IV Methylprednisolone
62707174|NCT03229538|PLACEBO_COMPARATOR|Placebo Arm|IV Isotonic Saline
62707175|NCT03869112|EXPERIMENTAL|Physical activity intervention|Physical activity group will be given a FitBit device to monitor their PA, especially steps count Step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home based intervention.
62707176|NCT03869112|EXPERIMENTAL|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
62707177|NCT03869112|NO_INTERVENTION|Usual care|Usual care group will have the standard follow up care by rehabilitation clinic without being in any physical intervention.
62707178|NCT04908293|EXPERIMENTAL|Trial Group|Use of New Biorepair Advanced Sensitive toothpaste for home oral care.
62707179|NCT04908293|ACTIVE_COMPARATOR|Control Group|Use of Colgate toothpaste for home oral care.
62707180|NCT02279927|EXPERIMENTAL|Low energy high frequency|Ureteroscopy with laser settings of low energy \& high frequency with aim of stone dusting
61968290|NCT01658891|ACTIVE_COMPARATOR|beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|
61968291|NCT04118166|EXPERIMENTAL|Ipilimumab/nivolumab + cryotherapy|1 mg/kg with nivolumab 3 mg/kg every 3 weeks x 4 doses. (One cycle of treatment is 3 weeks). Cryotherapy (cryoablation) will be performed between investigational agent treatment Cycles 1 and 2
61968292|NCT05078008|PLACEBO_COMPARATOR|Group 1 - Physiotherapy modalities|
62351159|NCT00629525|EXPERIMENTAL|RAD001|RAD001 at a dose of 10 mg PO daily
62351160|NCT01371448||Patients prescribed PAXIL for long-term use|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
61968293|NCT05078008|EXPERIMENTAL|Group 2 - Physiotherapy modalities + Balneotherapy modalities|
61968294|NCT05352334|EXPERIMENTAL|High Intensity Interval Training|
61968295|NCT05352334|EXPERIMENTAL|Aerobic Exercise|
61968296|NCT00235898|EXPERIMENTAL|1|CoFactor, 5-FU
61968297|NCT00235898|ACTIVE_COMPARATOR|2|Leucovorin, 5-FU
61968298|NCT04818398|EXPERIMENTAL|DS-6016a dose level 1|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
61968299|NCT04818398|EXPERIMENTAL|DS-6016a dose level 2|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
61968300|NCT04818398|EXPERIMENTAL|DS-6016a dose level 3|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
62351161|NCT01954888|ACTIVE_COMPARATOR|Blind technique|Stellate ganglion block using the anterior paratracheal approach using surface landmarks.
62351162|NCT01954888|ACTIVE_COMPARATOR|Ultrasound-guided technique|Stellate ganglion block using the ultrasound-guided lateral approach at the sixth cervical vertebral level.
62351163|NCT05720767|EXPERIMENTAL|Part A - Itraconazole|HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 400 mg (combination of 2 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 10) in Part A. Itraconazole will be supplied as 100 mg capsules and will be administered as doses of 200 mg (2 × 100 mg) PO BID on Day 6 and 200 mg PO QD on Days 7 to 14 in Part A.
62351164|NCT05720767|EXPERIMENTAL|Part B - Rifampin|HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 700 mg (combination of 4 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 13) in Part B. Rifampin will be supplied as 300 mg capsules and will be administered as doses of 600 mg (2 × 300 mg) PO QD on Days 6 to 17 in Part B.
62351165|NCT03164785|EXPERIMENTAL|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
61968301|NCT04818398|EXPERIMENTAL|DS-6016a dose level 4|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
61968302|NCT04818398|EXPERIMENTAL|DS-6016a dose level 5|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
61968303|NCT04818398|EXPERIMENTAL|DS-6016a dose level 6|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
61968304|NCT04818398|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
61968305|NCT01675271|ACTIVE_COMPARATOR|individual exercise|individualized exercise program
61968306|NCT01675271|ACTIVE_COMPARATOR|general exercise|general exercise program
61968307|NCT01675271|NO_INTERVENTION|control|No exercise and dietary counselling
61968308|NCT05229601|EXPERIMENTAL|HFB301001|Participants will receive HFB301001 via intravenous infusions
61968309|NCT00634530|OTHER|I, Intervention|
61968310|NCT06508216|EXPERIMENTAL|Module 1 of part 2 : Datopotamab Deruxtecan (Dato-DXd) Monotherapy|Patients will receive Datopotamab Deruxtecan 6mg/kg every 21 days until progression or until unacceptable toxicity
61968311|NCT06508216|EXPERIMENTAL|Module 2 of part 2 : Datopotamab Deruxtecan (Dato-DXd) + Durvalumab|Patients will receive Datopotamab Deruxtecan 6mg/kg and durvalumab 1120mg every 21 days until progression or until unacceptable toxicity
61968312|NCT02048787|EXPERIMENTAL|Moderate renal impairment group|Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group
61968313|NCT02048787|EXPERIMENTAL|Severe renal impairment group|Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group
61968314|NCT02048787|EXPERIMENTAL|Matching healthy control group|Subjects with normal renal function defined as eGFR ≥ 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.
61968315|NCT00892762|EXPERIMENTAL|Travoprost APS|Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
61968316|NCT00892762|ACTIVE_COMPARATOR|XALATAN|Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
61968317|NCT05307419|ACTIVE_COMPARATOR|Rectal suction biopsy first|Children randomised for pahtological evaluation of rectal suction biopsy tissue first.
62707181|NCT02279927|ACTIVE_COMPARATOR|High energy low frequency|Ureteroscopy with laser settings of low energy high frequency with aim of stone fragmentation and basket extraction of fragments
61968318|NCT05307419|ACTIVE_COMPARATOR|Full thickness biopsy first|Children randomised for pathological evaluation of full thickness biopsy tissue first.
61968319|NCT00944489||1|Patients with diagnosis of essential hypertension under the criteria established by the Joint National Committee VII (9) and those patients under pharmacological treatment with the same therapeutic regime during at least the last 6 months.
61968320|NCT03940612|EXPERIMENTAL|STP4 (product with probiotics)|Dietary Supplement: STP4
61968321|NCT03940612|EXPERIMENTAL|Placebo (product without probiotics)|Dietary Supplement: Placebo
62707182|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
61968322|NCT01307007|EXPERIMENTAL|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
61968323|NCT01307007|ACTIVE_COMPARATOR|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
61968324|NCT06386250|ACTIVE_COMPARATOR|Group A|In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
61968325|NCT06386250|ACTIVE_COMPARATOR|Group B|In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
61968326|NCT06386250|EXPERIMENTAL|Group C|In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
61968327|NCT02876354|EXPERIMENTAL|Menaquinone 360|All patients in the study will be assigned to receive menaquinone 360 μg /d for 4 weeks.
61968328|NCT01053884|OTHER|Anidulafungin, safety, antifungal drug|single arm study
61968329|NCT02152696|ACTIVE_COMPARATOR|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
61968330|NCT02152696|ACTIVE_COMPARATOR|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
61968331|NCT02152696|ACTIVE_COMPARATOR|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
61968332|NCT00890006|EXPERIMENTAL|MRI + CBCT in prostate cancer|
61968333|NCT00516438|EXPERIMENTAL|1|Topotecan + KU-0059436
61968334|NCT05557604|NO_INTERVENTION|arm 1|SBRT alone 38 GY in 4 fractions
61968335|NCT05557604|EXPERIMENTAL|arm 2|SBRT along with short course (6 months) androgen deprivation (STAD)
61968336|NCT04461678|EXPERIMENTAL|Screening population and ASCUS referral population|"The screening population: Two cervical cytology samples will be collected from each subject. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks. In case of visible lesions under colposcopy, a biopsy of tissues at the site of the lesion will be performed; in case of no visible lesions, randombiopsy and/or ECC will be performed. Patients with histopathological results ≥ CIN2 will completed the study.~ASCUS referral population: Female subjects with an ASCUS cytology result will be recalled undergo colposcopy, the remaining samples for cytology test collected prior to enrollment will be used for BD Onclarity Assay HPV test."
61968337|NCT02056314|ACTIVE_COMPARATOR|brochure|The participants will be given a brochure that describes problem gambling and recommends methods of staying in control of gambling such as coping skills.
61968338|NCT02056314|EXPERIMENTAL|electronic tutorial|The participants will be given an electronic tutorial that will explain how to stay in control of their gambling including information about coping skills, warning signs, and information about myths related to gambling.
61968339|NCT03608501|EXPERIMENTAL|Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.
61968340|NCT01516697|OTHER|Control|The patients in Group A will serve as controls and will receive standard monitoring in addition to continuous measurement of SV and CO. The physicians will not know the CO and SV and will manage the patients in a standard fashion.
61968341|NCT01516697|EXPERIMENTAL|experimental|The patients in Group B will receive the same monitoring as those in Group A. But the physicians will know instantaneously the CO and SV in real time and will manage the patients accordingly.
61968342|NCT06507007||Group 1|Individuals with TS and SNHL
61968343|NCT06507007||Group 2|Individuals with TS without SNHL
61968344|NCT06507007||Group 3|Healthy age matched controls without TS and without SNHL
61968345|NCT05258175|EXPERIMENTAL|Kinesio taping muscle facilitation technique along with standardized physiotherapy protocol|"On the diaphragmatic muscle, muscle facilitation technique will be applied from proximal to distal with 10-15% tension when the participant is standing and exhaled out and the body is in extension. The base of the tape will be about 1 inch below the xiphoid area.~Then the one tail of tape applied with 10% tension on the rib cage with maximum deep inspiration followed by expiration and the other tail of tape will be applied to the subcostal area in forward bending position while taking deep breath with arms adduct and being crossed.~The tape will be changed on every fifth day and assessment will be done at baseline and 2nd week of intervention Total number of sessions: 3"
61968346|NCT05258175|ACTIVE_COMPARATOR|Standardized physiotherapy protocol|"Pursed lip breathing exercise: Patient instructed to breathe through nose and inspiration should be slowly and expiration is done through mouth by pursing the lips slowly such that if flame is held in front, then the flame should be bended but not blow off. 3 sets a day for 15 days.~Diaphragmatic breathing exercise: Patient sitting comfortably, with knees bent and shoulders, head and neck relaxed. Patient will be instructed to place one hand on upper chest and the other just below your rib cage. Breathe in slowly through nose so that stomach moves out against your hand. 3 sets a day for 15 days.~Deep breathing exercise: Patient instructed to take slow and deep breaths, inhaling through the nose and exhaling through the mouth. Participant is asked to place their hand on their abdomen and expand their abdomen to lift their hand during inhalation. 3 sets a day for 15 days."
62707183|NCT02501447|EXPERIMENTAL|Guided audio-visual relaxation group|The guided relaxation (GR) intervention included a single 12-min GR video clip we administered to subjects at the baseline visit to determine the immediate effects of GR on stress and pain. The GR intervention also included six video clips, which ranged from 2 to 20 minutes in length to determine the short-term (2-week) effects of GR on stress and pain.
61968347|NCT02283697|EXPERIMENTAL|Dietary Counseling|Apart from standard care, an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
61968348|NCT02283697|OTHER|Control: Standard Care|A standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
61968349|NCT04051723|EXPERIMENTAL|The dexamethasone plus ropivacaine group|Patients in the dexamethasone plus ropivacaine group will receive a peri-incisional scalp infiltration with 0.025% dexamethasone and 0.2% ropivacaine and normal saline miscible liquids.
61968350|NCT04051723|ACTIVE_COMPARATOR|The ropivacaine group|Patients in the ropivacaine group will receive a peri-incisional scalp infiltration with 0.2% ropivacaine and normal saline miscible liquids.
61968351|NCT01652703|PLACEBO_COMPARATOR|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
61968352|NCT01652703|PLACEBO_COMPARATOR|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
61968353|NCT01652703|EXPERIMENTAL|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
61968354|NCT01652703|EXPERIMENTAL|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
61968355|NCT01652703|EXPERIMENTAL|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
61968356|NCT01652703|EXPERIMENTAL|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
61968357|NCT00338234||Cardiac surgery|Successive cardiac surgery patients
61968358|NCT00338234||Surgical ICU|Successive patients admitted to the surgical ICU for more than 7 days, and experiencing anemia
61968359|NCT00583778|ACTIVE_COMPARATOR|Levalbuterol|levalbuterol 1.25 mg every 20 minutes for 3 doses plus placebo (saline)
61968360|NCT00583778|EXPERIMENTAL|Levalbuterol plus ipratropium|ipratropium 0.5 mg nebulized every 20 minutes for 3 doses added to levalbuterol 1.25 mg every 20 minutes for 3 doses
62707184|NCT02501447|NO_INTERVENTION|Attention Control group|For the attention control group, subjects engaged in a 12-min computer-based discussion about their sickle cell disease (SCD) experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses were captured via the microphone so that Data Collectors were not involved in this discussion process, and it was equivalent to the guided relation activity.
61976214|NCT03855098|OTHER|Fruit and Vegetable biomarkers|Each participant will consume the test foods over different weeks
61968361|NCT06501482|EXPERIMENTAL|Postoperative FOLFIRI group|Irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion over 46 h biweekly. For a total of 12 cycles of perioperative chemotherapy including the preoperative chemotherapy
61968362|NCT06501482|NO_INTERVENTION|No treatment group (control group)|No treatment
61968363|NCT02829450||PD|"Patients with CHF and chronic renal disease which started the treatment with peritoneal ultrafiltration.~The patients will be follow up every 3 months for assesment of symptoms, QOL questionary, routine blood and urine tests and also for assesment of residual renal function and peritoneal membrane function: monitoring of clinical symptoms of fluid overload, hospital admissions, UF rate, peritoneal membrane damage parameters (cell-free DNA in peritoneal effluent, peritoneal equilibration test) and residual renal function markers (eGFR creatinine or cystatin C based , KT/V, urinary markers) at the start of the treatment, each 3 months during the treatment and at each change of prescription. Complications of all kinds will be recorded."
62509536|NCT02419235|EXPERIMENTAL|Homoeopathic complex|Ten drops of 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrum muriaticum 6cH and Scutellaria lateriflora 6cH will be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
62509537|NCT02498249|EXPERIMENTAL|Experimental: low level laser therapy (LLLT)|"For the LLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the LLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 18 J"
62509538|NCT02498249|PLACEBO_COMPARATOR|Experimental: Placebo low level laser therapy (PLLLT)|"For the PLLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the PLLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 0 J"
62509539|NCT06617130|ACTIVE_COMPARATOR|corn soy bean flour porridge with added indespensable amino acids|"Children in the intervention arm will receive corn-soy blended flour porridge mixed with IAA. The CSB flour will be packed in 1kg packets while the IAA will be packed in small plastic bags. Parent/caretakers will be taught how to prepare complementary porridge and will be provided utensils to estimate amounts of porridge to give to the child. Pre-weighed IAA will be provided so that mothers can mix the IAA to the prepared CSB porridge.~The amount of porridge to be given to the child is estimated at 75g cooked porridge or 5 tablespoons of porridge. Likuni porridge is estimated to provide 403kcal per 100g when prepared using a standard recipe (Malawi Food and Nutrient Database). Based on the age range of the participating children we aim to provide an average of 250-302 kcal per child per day."
61968364|NCT02829450||Control|Patients with CHF and chronic renal disease which preferred to continue their regular treatment or choose other then peritoneal ultrafiltration type of renal replacement therapy (data from medical records): clinical symptoms of fluid overload, hospital admissions, urine volume,residual renal function markers (eGFR creatinine)
61968365|NCT00754260|EXPERIMENTAL|Caffiene reduction group|Caffeine reduction group Intervention is to counseling to reduce caffeine intake
62509540|NCT06617130|OTHER|Corn soy bean flour porridge|"Children in the control arm children will receive corn-soy blended flour porridge only. The CSB flour will be packed in 1kg packets. Parent/caretakers will be taught how to prepare complementary porridge and will be provided utensils to estimate amounts of porridge to give to the child.~The amount of porridge to be given to the child is estimated at 75g cooked porridge or 5 tablespoons of porridge. Likuni porridge is estimated to provide 403kcal per 100g when prepared using a standard recipe (Malawi Food and Nutrient Database). Based on the age range of the participating children we aim to provide an average of 250-302 kcal per child per day."
62707185|NCT04316416|ACTIVE_COMPARATOR|T7 Bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging T7 (7th thoracal vertebrae ) transverse process accompanied by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
61968366|NCT00754260|NO_INTERVENTION|No caffeine reduction group|No Caffeine reduction group Intervention is to not counsel regarding caffeine intake
61968367|NCT02528071||Patients|ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death
61968368|NCT02528071||Control|Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT
61968369|NCT05712928|EXPERIMENTAL|Dance/movement therapy|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove).
61968370|NCT01539057|EXPERIMENTAL|Intravenous Fibrinogen|Fibrinogen will be administered until an expected plasmatic value of 2.9 g / L is achieved.
61968371|NCT01539057|PLACEBO_COMPARATOR|Saline Serum|the same dose in volume of saline dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of saline dilution
61968372|NCT05577260|EXPERIMENTAL|Group D(dexemedetomidine group)|Patients receive 20 mL isobaric bupivacaine 0.25% + 1μg/kg Dexmedetomidine completed to 5ml with normal saline.
61968373|NCT05577260|EXPERIMENTAL|Group M: (magnesuim sulphate group)|Patients received 20ml isobaric bupivacaine 0.25% + 5 ml (500 mg) magnesium sulphate
61968374|NCT02548650|EXPERIMENTAL|Patients with diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
61968375|NCT02548650|ACTIVE_COMPARATOR|Patients without diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
61968376|NCT06036771|EXPERIMENTAL|Voice-activated Intelligent Personal Assistant (VIPA) intervention|"IG participants will receive~1. The developed VIPA user protocol~2. 30-minute training session on day 1~3. Weekly technical tele-support~Dosage of the intervention: PWP are encouraged to perform 10 voice commands/ day during the 8-week intervention period, self-reported usage will be documented by participants in a progress note."
61968377|NCT06036771|NO_INTERVENTION|Usual care, no intervention provided|CG participants will be placed under usual care, no intervention will be provided and PWP will continue their daily life during the intervention period
61968378|NCT02088255|ACTIVE_COMPARATOR|Static surface|The subjects will do the walking training with partial body weight support on static surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
61968379|NCT02088255|ACTIVE_COMPARATOR|dynamic surface|The subjects will do the walking training with partial body weight support on dynamic surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
61968380|NCT03776383|ACTIVE_COMPARATOR|Antibiotic use feedback letter 1|Antibiotic use feedback letter 1 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic prescribing for acute respiratory conditions
61968381|NCT03776383|ACTIVE_COMPARATOR|Antibiotic use feedback letter 2|Antibiotic use feedback letter 2 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic durations for common infections
61968382|NCT03776383|NO_INTERVENTION|Control|Controls will not receive a letter
61968383|NCT01025752|EXPERIMENTAL|Arm 1|Ten session IVR-based cognitive behavior therapy intervention for chronic low back pain
61968384|NCT01025752|ACTIVE_COMPARATOR|Arm 2|Ten session face to face cognitive behavior therapy for chronic low back pain
61968385|NCT00759811|EXPERIMENTAL|Methotrexate|Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
62351166|NCT03164785|NO_INTERVENTION|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
62509541|NCT04746079|EXPERIMENTAL|Positive Imagery Therapy|"Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy below:~Relax and close your eyes. Take deep breaths in through your nose and out through your mouth as you listen to the sound of my voice. (Three second pause.) I want you to picture yourself lying on a towel on a soft sandy beach. (Three second pause.) You can see a palm trees swaying in the wind beneath a bright blue sky with a few white puffy clouds. (Three second pause.) You can feel the sand between your toes, the warm sunlight on your skin and a cool breeze. (Three second pause) You can smell coconut lotion in the breeze. (Three second pause.) You can hear the sound of waves gently crashing on the beach and seagulls crying in the distance. \*\*End of vignette\*\*"
62707186|NCT04316416|ACTIVE_COMPARATOR|T9 bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging transverse process T9 (9th thoracal vertebrae) by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
61968386|NCT00759811|PLACEBO_COMPARATOR|Placebo|Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
61968387|NCT04355845|EXPERIMENTAL|Sumatriptan and PF-06651600 DDI|In Period 1, participants will receive a single oral 25 mg dose of sumatriptan on Day 1 in the morning. In Period 2 on Day 1, participants will receive a single oral 25 mg dose of sumatriptan and a single 400 mg oral dose of PF-06651600 in the morning. In Period 3 participants will receive a single 400 mg oral dose of PF-06651600 in the evening of Day 1, and then a single oral 25 mg dose of sumatriptan in the morning of Day 2.
61968388|NCT02768012|ACTIVE_COMPARATOR|mindfulness-based cognitive therapy|The practice of mindfulness will be followed plus the basics of cognitive therapy given in small group format.
61968389|NCT02768012|NO_INTERVENTION|waitlist|Women diagnosed with AISD randomised to wait list will receive no active treatment during the trial period.
61968390|NCT05328193|ACTIVE_COMPARATOR|Teaching Kitchen Outreach|All participants (both the intervention and control condition) will receive to 11 weekly short (about 2-3 minutes) Teaching Kitchen Outreach (TKO) videos. Recipe specific groceries will be delivered to participants' homes by a third party grocery delivery company, or will be available for pickup at a central location(s). These recipes reflect foods that can be purchased with SNAP and WIC and include tested meals and snacks that were developed and evaluated in person in Parks and Recreation after-school programming.
61968391|NCT05328193|EXPERIMENTAL|Healthier Families, COVID Edition|Those randomized to the intervention condition will also receive a 12-weekly health coach via a virtual platform (such as Zoom, FaceTime, or What's App) to provide an adapted version of the previously tested Healthier Families program. Adaptations include: shortening each session to 30 minutes and delivering the programming via a virtual platform. The health coach will provide the Healthier Families modules either to individual child-parent pairs.
62351167|NCT02850497|ACTIVE_COMPARATOR|CRE8 stent|Treatment with CRE8 stent implantation and evaluated with optical coherence tomography at 6 months
62351168|NCT02850497|ACTIVE_COMPARATOR|Biomatrix stent|Treatment with Biomatrix stent implantation and evaluated with optical coherence tomography at 6 months
62351169|NCT02850497|ACTIVE_COMPARATOR|patients treated with Xience stent|Treatment with Xience stent implantation and evaluated with optical coherence tomography at 6 months
61968392|NCT00637481|EXPERIMENTAL|Arm I (lower dose atorvastatin calcium)|Participants receive oral atorvastatin once daily for 3 months.
61968393|NCT00637481|EXPERIMENTAL|Arm II (atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm I) once daily for 3 months.
61968394|NCT00637481|EXPERIMENTAL|Arm III (higher dose atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm II) once daily for 3 months.
61968395|NCT00637481|OTHER|Arm IV (no intervention)|Participants do not receive treatment. Participants undergo blood sample collection and fine needle aspiration of breast tissue at baseline and at 3 months for correlative biomarker studies.
61968396|NCT01338766|EXPERIMENTAL|Surgery|Decompression using the iO-Flex® system
61968397|NCT00107445|EXPERIMENTAL|Treatment (EF5)|Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
61968398|NCT01868750|ACTIVE_COMPARATOR|Vitamin D (Calcitriol)|Calcitriol, 1.0ug twice daily for 7 days prior to surgery
61968399|NCT01868750|PLACEBO_COMPARATOR|Control|Placebo pill taken twice daily for 7 days prior to surgery
61968400|NCT01045720|PLACEBO_COMPARATOR|Placebo Comparator|
61968401|NCT01045720|EXPERIMENTAL|ChinesMed|
61968402|NCT02200289||Mother-infant pairs|Mother-infant pairs from the GRAPHS birth cohort study
61968403|NCT06158594|NO_INTERVENTION|Control|Children in this group will not receive a voucher to attend a pre-existing summer program
61968404|NCT06158594|EXPERIMENTAL|4-week voucher|Children in this group will receive a voucher to attend 4-weeks of a pre-existing summer program
61968405|NCT06158594|EXPERIMENTAL|6-week voucher|Children in this group will receive a voucher to attend 6-weeks of a pre-existing summer program
61968406|NCT06158594|EXPERIMENTAL|8-week voucher|Children in this group will receive a voucher to attend 8-weeks of a pre-existing summer program
61968407|NCT06507319|EXPERIMENTAL|Direct bone anchored pull distal slider|The appliance will be cemented on the maxillary first molars and two miniscrews will be placed in their positions. The appliance will be activated by closed coil spring, which apply 300g force.
62509542|NCT04746079|NO_INTERVENTION|Control|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds with no positive imagery therapy.
61968408|NCT06507319|EXPERIMENTAL|Indirect bone anchored dual force distalizer.|The appliance will be cemented on the teeth and two miniscrews will be placed in their positions. Activated by compressing the NiTi open coil spring from the buccal and palatal sides.
61968409|NCT03611764|EXPERIMENTAL|Arm 1: Body Scan|"* The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes~* Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.~* Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den"
61968410|NCT02458820|NO_INTERVENTION|Usual Care|Patients will be recorded and interpreted as per standard of care. If a seizure is noted by the neurology service, the standard seizure treatment protocol will be used by the clinical team.
61968411|NCT02458820|EXPERIMENTAL|DSA EEG + Usual Care|Patients will undergo at least hourly interpretation of DSA by the ICU bedside care provider. If the bedside care provider is concerned that there is a seizure on DSA they will contact the EEG tech on call for confirmation. If a seizure is confirmed by neurology, the standard seizure treatment protocol will be used by the clinical team.
61968412|NCT03281486|EXPERIMENTAL|HA formulation Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
61968413|NCT03281486|PLACEBO_COMPARATOR|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
61968414|NCT00839150||1|Diabetic patients without diabetic retinopathy : No intervention
61968415|NCT00839150||2|Sex and age-matched control subjects : No intervention
61968416|NCT02326571||spontaneous intracerebral hemorrhage|
61968417|NCT01508650|ACTIVE_COMPARATOR|No intervention|Usual care control group
61968418|NCT01508650|ACTIVE_COMPARATOR|Active Comparator|Multi domain rehabilitation intervention
61968419|NCT06013670|EXPERIMENTAL|Endoscopy+NSBBs treatment group|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure\>90mmHg and heart rate\>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
61968420|NCT06013670|EXPERIMENTAL|TIPS treatment group|Patients receives TIPS for the prevention of variceal bleeding
61968421|NCT01935271|EXPERIMENTAL|Muscle Armor Supplement|Treatment with a commercially available over the counter nutritional supplement
61968422|NCT01935271|PLACEBO_COMPARATOR|Placebo|Sugar-based placebo drink mix
61968423|NCT02045134|PLACEBO_COMPARATOR|Placebo|Soluble corn flour not rich in anthocyanins
61968424|NCT02045134|ACTIVE_COMPARATOR|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
62509543|NCT06614699||the colorectal cancer group|Abdominal fat and muscle area were calculated based on abdominal CT of colorectal cancer patients.
62509544|NCT04135729||Personal trainer (PT)|Cross-sectional study on mental health symptoms in personal trainers
62509545|NCT04135729||Group instructors (GI)|Cross-sectional study on mental health symptoms in group instructors
61968425|NCT04887714|EXPERIMENTAL|Mask|cloth mask wearing
61968426|NCT04887714|NO_INTERVENTION|control|control, without mask.
61968427|NCT02309697||Full Term|Children born at full term on or after Jan 1, 2011
62707187|NCT04316416|PLACEBO_COMPARATOR|Control group|Postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard pain follow-up and monitorization will be performed. No block will be performed in this group.
62707188|NCT01291589|EXPERIMENTAL|Cognitive-behavioral counseling|
62707189|NCT04756453|NO_INTERVENTION|Standard|Standard endoscopic submucosal dissection
61968428|NCT02309697||PreTerm|Children born preterm on or after Jan 1, 2011
61968429|NCT03478267||Fetal heart rate 110-130 bpm|Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.
61968430|NCT03478267||Fetal heart rate 140-160 bpm|Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.
62707190|NCT04756453|ACTIVE_COMPARATOR|Interventional|Mandatory use of the clip-traction device
61968431|NCT06376799||French adult patients followed in the context of a oncological disease,|French-speaking adult patients willing to participate in this study. Patients being treated for oncological disease, in a curative, palliative, or remission phase.
61968432|NCT03988985|EXPERIMENTAL|PATIENT-GP-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
61968433|NCT03988985|ACTIVE_COMPARATOR|GP-FEEDBACK|Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
61968434|NCT03988985|NO_INTERVENTION|NO-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.
61968435|NCT06476561||Elderly Participants in Iraq|This study group consists of community-dwelling elderly individuals aged 60 and above residing in Najaf, Iraq. The participants are healthy and do not have severe physical or mental health conditions. They are evaluated to understand how sociodemographic, psychological, and quality of life factors influence their dual-task performance, which includes both cognitive and motor functions. The study aims to provide insights into factors affecting their ability to perform dual tasks, contributing to the development of targeted interventions and policies for improving the quality of life and care for Iraq's aging population.
62707191|NCT03144284||dental interns|dental interns in pediatric dentistry department, faculty of dentistry, Cairo University.
61968436|NCT01681225|EXPERIMENTAL|EPVent|"The overall goals for the EPVent group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration \[Ptpexp\]. Fraction of inspired oxygen \[FiO2\] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target."
62351170|NCT01771536|ACTIVE_COMPARATOR|PCI Choice decision|Decision Aid intervention is provided to clinician to share with patient
62707192|NCT05165472|EXPERIMENTAL|Intervention|Real transcranial magnetic stimulation applied
62707193|NCT05165472|SHAM_COMPARATOR|Sahm-control|Sham transcranial magnetic stimulation applied
62351171|NCT01771536|NO_INTERVENTION|Usual Care|
62509546|NCT04135729||Combined instructors (PT + GI)|Cross-sectional study on mental health symptoms in personal trainers
62509547|NCT00734942|EXPERIMENTAL|1|intervention group
62509548|NCT00734942|NO_INTERVENTION|2|waiting group
62707194|NCT01693367|ACTIVE_COMPARATOR|DLS 5.0 (Dynamic Locking Screws)|ORIF with DLS 5.0 (Dynamic Locking Screws)
62351172|NCT05929885|EXPERIMENTAL|Low Dose OXIRI (LD-OXIRI)|Low Dose OXIRI (LD-OXIRI) regimen comprises Metronomic Oxaliplatin (O) and Metronomic Capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of Irinotecan (IRI).
62351173|NCT01480037||Elderly|Individuals between 60 and 70 years-old
62539355|NCT06632392|OTHER|Standart Theory training|I. Interview: Before theoretical and simulation training II. Interview: After theoretical training III. Interview: Four weeks later
62707195|NCT01693367|ACTIVE_COMPARATOR|SLS (Standard locking screw)|ORIF with SLS (Standard locking screw)
62707196|NCT00773188|EXPERIMENTAL|1|
62707197|NCT03164161|ACTIVE_COMPARATOR|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
62707198|NCT03164161|ACTIVE_COMPARATOR|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
62707199|NCT03164161|ACTIVE_COMPARATOR|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
62707200|NCT03164161|NO_INTERVENTION|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
62707201|NCT02878382|OTHER|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
62707202|NCT02878382|OTHER|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
61968437|NCT01681225|ACTIVE_COMPARATOR|Control|The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure \[PEEP\] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements, and instead will follow an empiric high PEEP mechanical ventilation strategy. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level specified in a study table.
61968438|NCT02234089||Degarelix|
61968439|NCT02234089||LHRH agonist|
61968440|NCT04938804|EXPERIMENTAL|Screening group|
61968441|NCT05187715|EXPERIMENTAL|Simvastatin with Standard Medical Treatment|Simvastatin 40mg OD plus standard treatment plus standard treatment (excluding Pentoxiphylline)
61968442|NCT05187715|ACTIVE_COMPARATOR|Placebo with Standard Medical Treatment|Matched placebo plus standard treatment (excluding Pentoxiphylline)
61968443|NCT02399501|EXPERIMENTAL|uterine lesion ultrasound, hysteroscopy|evaluation of female with proved uterine lesion by two dimensional ultrasound, three dimensional ultrasound, saline sonohysterography and hysteroscopy
61968444|NCT06158789|EXPERIMENTAL|Focused ultrasound treatment group|
61968445|NCT04233645|EXPERIMENTAL|Study Group|The group will be given a standard scripted verbal and identical written instructions plus the study group will be shown a 5-minute educational video (available at https://youtu.be/rvYfDc-Yfus ) which depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
61968446|NCT04233645|ACTIVE_COMPARATOR|Usual Care Group|The group will be given a standard scripted verbal and identical written instructions as per usual care.
61968447|NCT03576976|ACTIVE_COMPARATOR|Clinic-based Cognitive Remediation|Clinic-based cognitive remediation is the current standard of care in NY State outpatient programs. It consists of twice weekly group-based and clinician-led sessions.
61968448|NCT03576976|EXPERIMENTAL|Hybrid Cognitive Remediation|Hybrid cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
61968449|NCT04540224||Luminal A|Breast cancer patients with Luminal A phenotype
61968450|NCT04540224||Luminal B|Breast cancer patients with Luminal B phenotype
61968451|NCT04540224||Triple Negative|Breast cancer patients with Triple negative phenotype
61968452|NCT04540224||Control|Healthy volunteers
61968453|NCT03355651|ACTIVE_COMPARATOR|PROGEN Group|PROGEN + Standard Rehabilitation + ACL reconstruction
61968454|NCT03355651|NO_INTERVENTION|Control Group|Standard Rehabilitation + ACL reconstruction
61968455|NCT02013791|OTHER|Stage 1 Cohort 1|Vehicle administered to study eye and Sham administered to non-study eye on Day 1.
61968456|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 2|Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1.
61968457|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 3|Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1.
61968458|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 4|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1.
61968459|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 5A|Cyclosporine New Ophthalmic Formulation Dose D administered to the study eye and vehicle administered to the non-study eye on Day 1.
61968460|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 6A|Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1.
61968461|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 6B|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1.
61968462|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 6C|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
61968463|NCT02013791|EXPERIMENTAL|Stage 1 Cohort 6D|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
61968464|NCT02733939|EXPERIMENTAL|Technology intervention|Patients randomized in the intervention group will receive a technical home monitoring kit for 12 months. The kits will be composed of a control unit and a set of sensors that immediately notify caregivers, through their phones, of any potential risks for the person with dementia. The kit will have home leaving sensors, bed occupancy sensors, smoke and water leak sensors, automatic lights, and other interactive functions. These devices will be connected to a single-board microcontroller that will transmit alarm messages to the caregivers in case of need.
61968465|NCT02733939|NO_INTERVENTION|Usual care|"Patients receiving usual care, as provided to people with dementia in Southern Sweden can vary. In the target area, people with dementia usually receive comparable pharmaceutical treatment depending on the dementia type, as prescribed by a general practitioner or a specialist at a memory clinic. The social worker from the Municipality (Biståndshandläggaren) where the person resides, together with the district nurse, have a meaningful role in tailoring the care plan by mediating access to other care services such as respite care homes, home help and (dementia) nurse home visits. Use of such services depends on the specific needs of the person with dementia, which can also be unrelated to dementia, but rather dependent upon concomitant health and social issues."
61968466|NCT01116011|EXPERIMENTAL|AZD7268|
61968467|NCT01116011|PLACEBO_COMPARATOR|Placebo|
61968468|NCT02455232|EXPERIMENTAL|hemiplegic patient|muscle participation in upper limb spasticity
61968469|NCT00652405|EXPERIMENTAL|treatment A|four weeks of white wine consumption (25g alcohol/day; \~2.5 standard drinks)
61968470|NCT00652405|PLACEBO_COMPARATOR|Treatment B|Four weeks of water
61968471|NCT02694510|ACTIVE_COMPARATOR|Light-protection|Light-protection of TPN solutions. TPN bags and infusion sets will be protected from light by aluminum foils throughout the study period.
61968472|NCT02694510|ACTIVE_COMPARATOR|Light-exposure|TPN bags and infusion sets will be exposed to light throughout the study period.
61968473|NCT04940351|EXPERIMENTAL|GROUP - A: PIEZOCISION GROUP|This group will receive piezocision using piezotome inbetween the roots of mandibular anteriors after the placement of initial arch wire.
61968474|NCT04940351|EXPERIMENTAL|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive Micro-Osteoperforation using orthodontic mini-implants and mini-implant screw driver after the placement of initial arch wire.
61968475|NCT00616395||no grouping|IDE used for outcome measurement not for an intervention.
61968476|NCT04939402|OTHER|General|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
61968477|NCT00298051|NO_INTERVENTION|Early umbilical cord clamping (control)|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
61968478|NCT00298051|EXPERIMENTAL|Delayed umbilical cord clamping|Umbilical cord was clamped at 2 minutes after delivery of the infant's shoulder's with the infant held at the level of the mother's uterus.
61968479|NCT00504933|EXPERIMENTAL|A|Bilastine
61968480|NCT00504933|ACTIVE_COMPARATOR|B|Cetirizine
61968481|NCT00504933|PLACEBO_COMPARATOR|C|Placebo
62707203|NCT04361279|EXPERIMENTAL|SIBP-02|"Biological: SIBP-02, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.~Treatment cycle: 6 cycles, each cycle is 3 weeks."
61968482|NCT03547687|EXPERIMENTAL|Electrical Stimulation Treatment|Patient will receive electrical stimulation to the quadriceps muscle groups on both lower extremities simultaneously for 45 minutes at a time, for a total of 5 treatments each week (Mon-Sun), for up to 14 days or until ICU discharge, whichever comes first.
61968483|NCT00191789|EXPERIMENTAL|Gemcitabine+Doxorubicin+Cisplatin+Surgery|"Gemcitabine: 1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).~Doxorubicin: 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m\^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision."
61968484|NCT03418415|EXPERIMENTAL|Renal denervation|Procedure: Renal denervation
61968485|NCT00905398|EXPERIMENTAL|nilotinib|single arm study
61968486|NCT04693234|OTHER|Tislelizumab and Ociperlimab (BGB-A1217) Combination (Cohort 1)|Participants will receive tislelizumab 200 milligrams (mg) on Day 1 followed by the administration of ociperlimab (BGB-A1217) 900 mg of each 21-day cycle.
61968487|NCT04693234|OTHER|Tislelizumab Monotherapy (Cohort 2)|Tislelizumab 200 mg will be administered on Day 1 of each 21-day cycle
61968488|NCT02475746|EXPERIMENTAL|PF-06372865 treatment arm|treatment arm includes two treatment periods, a single dose of PF-06372865 (period 1) followed by 8-days itraconazole with a single dose of PF-06372865 co-administered on Day 4
61968489|NCT03655691|PLACEBO_COMPARATOR|Vehicle|Vehicle / Placebo formulation
61968490|NCT03655691|EXPERIMENTAL|Dose 1|lower dose of ET-01
61968491|NCT03655691|EXPERIMENTAL|Dose 2|higher dose of ET-01
61968492|NCT04957693|EXPERIMENTAL|treatment arm|vegan diet and lifestyle change
62145220|NCT04862598|NO_INTERVENTION|Control|The patient will be positioned on the operating table and have routine monitoring attached (ECG, blood pressure, O2 saturations, end tidal carbon dioxide monitoring (ETCO2). A surgical safety time out will be performed. The patient will receive routine operative and nursing care. The study team member will record highest and lowest heart rate and blood pressure as well as lowest O2 saturation and the total intra-operative dose of fentanyl and midazolam administered to the patient. At the end of the procedure, the patient is assisted into a wheelchair and will return to the recovery area. After 15 minutes of recovery, a member of the study team will give them the post-operative questionnaires which will consist of answering how anxious they felt during the procedure and the 11 question Iowa Satisfaction with Anesthesia scale (ISAS). The patient will then be free to leave once they have met the standard discharge criteria.
62351174|NCT01480037||Long-lived|Individuals above 85 years-old
62509549|NCT04387071|EXPERIMENTAL|Treatment (CMP-001, INCAGN01949)|Patients receive CMP-001 SC on day 1 of weeks 1 and 2 and IT on day 1 of weeks 3-6 in the absence of disease progression or unacceptable toxicity. Patients also receive INCAGN01949 IT on day 1 of weeks 3-6 in the absence of disease progression or unacceptable toxicity.
62509550|NCT03998319|EXPERIMENTAL|Tenecteplase (1/3 systemic weight based dose)|Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/3 of the weight based dose, and administered by intracoronary infusion over 3 minutes.
61968493|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
61968494|NCT02382393|EXPERIMENTAL|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) and then a third party validated assessment battery.
62351175|NCT01480037||Young|Individuals between 20 and 30 years-old
62351176|NCT00889395|NO_INTERVENTION|Home visit|Patients will have monthly home visits during which health educational talks will be given
62351177|NCT00444080|ACTIVE_COMPARATOR|Control Arm|Subjects undergoing trabeculectomy with the use of Mitomycin C
62351178|NCT00444080|EXPERIMENTAL|Treatment Arm|Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C
61968495|NCT02382393|EXPERIMENTAL|Computerized Assessment, BPT|Participants will take a third party validated assessment battery and then the Brain Performance Test (BPT).
61968496|NCT03716024|EXPERIMENTAL|PTK 0796|
61968497|NCT03716024|ACTIVE_COMPARATOR|Linezolid|
61968498|NCT05650398||Patients with exclusion|"Evaluation of the tactile sensitivity of the excluded finger using different tests: Static and dynamic two-points discrimination tests, the Semmes-Weinstein monofilament test, grating orientation task and the bar test inspired by the study of Louw et al.~Realization of the same tests on the controllateral healthy finger."
62351179|NCT00950976|EXPERIMENTAL|Citrulline|
62351180|NCT00950976|PLACEBO_COMPARATOR|lemonade|Equal volume and flavor to citrulline.
62351181|NCT02016469|EXPERIMENTAL|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days
62351182|NCT02016469|ACTIVE_COMPARATOR|single fecal microbiota transplantation|300ml Bacterial suspension (from 60g fresh stool )given for the first day
62351183|NCT02016469|ACTIVE_COMPARATOR|give pectin 20g/d|pure give pectin 20g/d for five days
61968499|NCT05650398||Control|"Evaluation of the tactile sensitivity of the finger using different tests: Static and dynamic two-points discrimination tests, the Semmes-Weinstein monofilament test, grating orientation task and the bar test inspired by the study of Louw et al.~Realization of the same tests on the controllateral finger."
61968500|NCT04150393|EXPERIMENTAL|MaaT033 treatment|A Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule
61968501|NCT05299281|OTHER|Glaucoma patients|Patients were enrolled from outpatient clinic with glaucoma during the period between January 2020 and July 2021
61968502|NCT01580618|PLACEBO_COMPARATOR|Normal Saline|Loculated pleural effusion infused with normal saline twice a day for three days.
61968503|NCT01580618|ACTIVE_COMPARATOR|TNKase|Loculated pleural effusion infused with TNK twice a day for three days.
61968504|NCT04689633|ACTIVE_COMPARATOR|Quadratus lumborum block|received bilateral ultrasound-guided Quadratus lumborum block using 20 ml bupivacaine 0.25% on each side
61968505|NCT04689633|ACTIVE_COMPARATOR|Erector spinae block|received bilateral ultrasound-guided erector spinae block using 20 ml bupivacaine 0.25% on each side
61968506|NCT04689633|NO_INTERVENTION|Control|didn't received any block
61968507|NCT00639054||Newly diagnosed patients|Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
61968508|NCT00639054||Relapse patients|Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
61968509|NCT00639054||Healthy controls|Healthy blood and bone marrow donors. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) for genetic analyses serving to compare normal bone marrow with bone marrow from multiple myeloma patients.
61968510|NCT02460614|EXPERIMENTAL|Rhinopharyngeal clearance + 0.9% saline|The retrograde rhinopharyngeal clearance (RRC) is based on the inspiratory reflex that follows a slow and prolonged expiration (passive exhalation technique performed using a slow thoracic-abdominal compression that begins at the end of a spontaneous exhalation and continues until the expiratory reserve volume). At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver. The instillation of saline (0.9%) preceded this step, resulting in the inhalation of the substance during the forced inspiration, contributing to the nasopharyngeal clearance.
62539356|NCT00700297|ACTIVE_COMPARATOR|Colchicine|Patients who received Colchicine and went on placebo after 4 months
62707204|NCT04361279|ACTIVE_COMPARATOR|Rituximab|"Biological: Rituximab, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.~Treatment cycle: 6 cycles, each cycle is 3 weeks."
61968511|NCT02460614|ACTIVE_COMPARATOR|Aspiration + 0.9% saline|Nasopharyngeal aspiration consisted in the introduction of a catheter that, by using negative pressure (vacuum), promotes the suction of secretion from the airways. In order to do that, a sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient. The saline instillation of 0.9% was used for humidification before the procedure.
61968512|NCT06048445||Biliary Drainage Stent group|placement of Biliary Drainage Stent in pediatric liver transplantation
61968513|NCT06048445||no Biliary Drainage Stent group|no placement of Biliary Drainage Stent in pediatric liver transplantation
61968514|NCT00691821|ACTIVE_COMPARATOR|1|Standard Dressings
61968515|NCT00691821|EXPERIMENTAL|2|Negative Pressure Wound Therapy
61968516|NCT03021122|EXPERIMENTAL|Arm A (PedAMINES™ / Conventional Method)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of PedAMINES™ first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of a Conventional Method.
61968517|NCT03021122|ACTIVE_COMPARATOR|Arm B (Conventional Method / PedAMINES™)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of a Conventional Method first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of PedAMINES™.
61968518|NCT03272074|EXPERIMENTAL|Egg Group (Group A)|Participants will consume one large egg per day for 12 weeks
61968519|NCT03272074|ACTIVE_COMPARATOR|Egg White Group (Group B)|Participants will consume equivalent amounts of egg whites for 12 weeks
61968520|NCT03749070|ACTIVE_COMPARATOR|Silymarin|Patients will receive 2 capsules containing a total of 700mg of silymarin, 8mg of vitamin E and 50mg of phosphatidylcholine, in addition to the excipient, which should be ingested daily for 12 weeks.
61968521|NCT03749070|PLACEBO_COMPARATOR|Placebo|Patients will also receive similarly 2 capsules per day, but without the bioactive principle tested (silymarin). Therefore, the capsules in the control group will contain only 700 mg of maltodextrin, a neutral food component derived from starch, in addition to the excipient and the same amount of vitamin E and phosphatidylcholine to balance the two groups.
61968522|NCT03052725|EXPERIMENTAL|reslizumab 110 mg|Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.
61968523|NCT06311201|ACTIVE_COMPARATOR|Abdominal belt|It consisted of 25 postpartum women who wore abdominal belt for 8 weeks.
61968524|NCT06311201|EXPERIMENTAL|Abdominal belt + Pilates exercises|It consisted of 25 postpartum women who followed Pilates training program, 3 times/week for 1 hour the session in addition to wearing abdominal belt, for 8 weeks
61968525|NCT04044235|EXPERIMENTAL|PrEP Cohort|AGYW HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.
61968526|NCT04044235|NO_INTERVENTION|HIV Incidence|HIV Incidence Cohort: In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence.
61968527|NCT02144051|EXPERIMENTAL|AZD5312|"AZD5312 will be given intravenously (IV) as an infusion, over one hour. For the purpose of planning, each 4 week period (28 days) will be called a Cycle. AZD5312 will initially be administered 4 times within the first 11 days, (on Days \[1, 4, 8 and 11\]± 2), with no dosing on sequential days. Patients will receive weekly treatments on Days 15 and 22 to complete Cycle~1. During the subsequent cycles, patients will receive weekly treatment on Days 1, 8, 15 and 22 (±2)."
61968528|NCT04827160||COVID-19|Patients with COVID-19
61968529|NCT04061915|EXPERIMENTAL|Infographic Intervention|Participants in the intervention arm will view an HIV self-testing infographic.
61968530|NCT04061915|ACTIVE_COMPARATOR|Control|Participants in the control arm will read paper-based HIV self-testing instructions.
61968531|NCT01499745|ACTIVE_COMPARATOR|Exercise Training at Pulmonary Rehabilitation Program|Exercise Training at Pulmonary Rehabilitation Program 2 weekly sessions of 60 min for 12 weeks
61968532|NCT01499745|PLACEBO_COMPARATOR|Standard Treatment for IPF|Continue for normal live with standard treatment
61968533|NCT02407821|ACTIVE_COMPARATOR|Escitalopram|
61968534|NCT02407821|PLACEBO_COMPARATOR|Placebo|
62351184|NCT02156401||Cohort 1: Suspect of Pulmonary Embolism (PE)|
62351185|NCT02156401||Cohort 2: Suspect of Deep Vein Thrombosis (DVT)|
62351186|NCT02156401||Cohort 3: Incidental Venous Thromboembolism (VTE)|
62509551|NCT03998319|PLACEBO_COMPARATOR|Sterile Water for injection (WFI)|Water for injection will be prepared to 20mL over an equivalent time period to the reconstitution time of the experimental arm, in order to maintain the blind, and administered by intracoronary infusion over 3 minutes.
62509552|NCT00778882|EXPERIMENTAL|VM106|
62707205|NCT03499756|EXPERIMENTAL|Couple-based interpersonal psychotherapy|The intervention consists of three weekly 2-hour antenatal sessions and two 30-minute telephone follow-up sessions delivered within four weeks postpartum.
62351187|NCT03467295||Surgically treated group|Surgical removal of intracerebral CMs by craniotomy with or without following stereotactic radiosurgery.
62351188|NCT03467295||Conservatively treated group|Observation with the best medicine administration and supportive treatment are performed.
62509553|NCT02148224||healthy without diabetes|
62509554|NCT04272489|EXPERIMENTAL|Adaptive Control|The adaptive control system updates the pattern recognition control algorithm by incorporating new EMG data each instance the prosthetic user recalibrates their device.
62509555|NCT04272489|ACTIVE_COMPARATOR|Non-Adaptive Control|The conventional, non-adaptive control systems resets the pattern recognition control algorithm by deleting old EMG data each instance the prosthetic user recalibrate their device.
62509556|NCT06494280|ACTIVE_COMPARATOR|study group|Epidural analgesia will be maintained by receiving programmed intermittent 10ml bolus of 0.1% Bupivacaine and 2microgram\\ml Fentanyl every one hour, until the delivery is completed, and lacerations are sutured.
62509557|NCT06494280|ACTIVE_COMPARATOR|control group|Epidural analgesia will be maintained by receiving 10ml\\h continuous infusion of 0.1% Bupivacaine and 2microgram\\ml Fentanyl until the delivery is completed, and lacerations are sutured.
62509558|NCT00793117|EXPERIMENTAL|1|poly vinil chloride packing
62509559|NCT01099631|EXPERIMENTAL|Salmonella typhimurium 10 to the 5th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
62509560|NCT01099631|EXPERIMENTAL|Salmonella typhimurium 10 to the 6th -- Level 2|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
62509561|NCT01099631|EXPERIMENTAL|Salmonella typhimurium 10 to the 7th -- Level 3|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
61968535|NCT03171415|EXPERIMENTAL|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):~1. 40mg RZL-012 -administered at 8 sites~2. 80mg RZL-012 - administered at 16 sites~3. 120mg RZL-012 - administered at 24 sites~4. 180mg RZL-012 - administered at 36 sited"
61968536|NCT03171415|PLACEBO_COMPARATOR|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-36 sites (0.1mL per site)
61968537|NCT00602953||Healthy volunteers|Normal weight and normal glucose tolerance.
62509562|NCT01099631|EXPERIMENTAL|Salmonella typhimurium 10 to the 8th - Level 4|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
61968538|NCT00602953||Pre-diabetes|Impaired fasting glucose of impaired glucose tolerance.
61968539|NCT00602953||Overweight|Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
61968540|NCT00602953||Type 2 diabetes|Patients with type 2 diabetes.
61968541|NCT00602953||Type 1 diabetes|Patients with type 1 diabetes.
61968542|NCT02870296|NO_INTERVENTION|Control|The control group will receive usual care; no interventions will be administered.
61968543|NCT02870296|EXPERIMENTAL|Intervention|Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
61968544|NCT00063973|EXPERIMENTAL|Treatment (cilengitide)|"Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of cilengitide until the MTD is determined. The MTD is defined as the dose at which 25% of patients are expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are accrued and treated at that dose level for a total of 12 patients at the MTD."
62509563|NCT01099631|EXPERIMENTAL|Salmonella typhimurium 10 to the 9th - Level 5|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
62707206|NCT03499756|NO_INTERVENTION|Control|The control group will receive the standard prenatal and postnatal care.
62707207|NCT05140421|EXPERIMENTAL|Early Implementation|This arm will receive D2S intervention components during Period 1 (Early Implementation) as well as throughout Period 2 of the stepped-wedge trial.
61968545|NCT05743270|EXPERIMENTAL|LA Cohort: RP3 in combination with CCRT followed by nivolumab in Locally Advanced SCCHN|RP3 will be administered via direct intratumoral injection or via CT, ultrasound, or laryngoscopy guided intratumoral injection into superficial, subcutaneous (SC), or nodal lesions and into deeper lesions, including visceral lesions.
61968546|NCT05743270|ACTIVE_COMPARATOR|LA Cohort: concurrent chemoradiation therapy in Patients With Locoregionally Advanced SCCHN|standard-of-care CCRT (defined as intensity-modulated radiation therapy \[IMRT\] and cisplatin
61968547|NCT05743270|EXPERIMENTAL|R/M Cohort:RP3 in combination with carboplatin, paclitaxel and then nivolumab in R/M SCCHN|RP3 will be administered via direct intratumoral injection or via CT, ultrasound, or laryngoscopy guided intratumoral injection into superficial, subcutaneous (SC), or nodal lesions and into deeper lesions, including visceral lesions.
61968548|NCT03483051|EXPERIMENTAL|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
61968549|NCT03483051|SHAM_COMPARATOR|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
61968550|NCT02603419|EXPERIMENTAL|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
61968551|NCT02603419|EXPERIMENTAL|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
61968552|NCT02603419|EXPERIMENTAL|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
61968553|NCT02603419|EXPERIMENTAL|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
61968554|NCT02603419|EXPERIMENTAL|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
61968555|NCT02603419|EXPERIMENTAL|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
61968556|NCT04372030|OTHER|General population|There is only one arm wishing to participate
61968557|NCT04912050||Tablo Hemodialysis System|Hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours on the Tablo Hemodialysis System
61968558|NCT00680862||Group 1|VA employees
61968559|NCT02373202|EXPERIMENTAL|Sarilumab 150 mg q2w + DMARDs|Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
61968560|NCT02373202|EXPERIMENTAL|Sarilumab 200 mg q2w + DMARDs|Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
61968561|NCT02373202|EXPERIMENTAL|Sarilumab 150 mg q2w|Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
61968562|NCT02373202|EXPERIMENTAL|Sarilumab 200 mg q2w|Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
61968563|NCT00530764|EXPERIMENTAL|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
61968564|NCT00530764|EXPERIMENTAL|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
61968565|NCT00530764|EXPERIMENTAL|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
61968566|NCT00530764|NO_INTERVENTION|Placebo|Range of 1-16 sprays per day of placebo spray.
61968567|NCT02016560|EXPERIMENTAL|Exploratory Cognitively Healthy Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
61968568|NCT02016560|EXPERIMENTAL|Exploratory MCI Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
62509564|NCT01099631|EXPERIMENTAL|Salmonella typhimurium 10 to the 10th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
61968569|NCT02016560|EXPERIMENTAL|Exploratory AD Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
61968570|NCT02016560|EXPERIMENTAL|Confirmatory Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.
61968571|NCT06013865|OTHER|Empagliflozin|Open Label, Empagliflozin 12.5 mg QD
61968572|NCT03804047|EXPERIMENTAL|Kinesio Tape (KTG)|Participants allocated into the KTG will receive a single time application of the kinesio tape flexible tape (Kinesio® Tex, Albuquerque, NM, USA) in the upper-body (i.e., back part of the trunk) and in the lower-body (i.e., legs and ankle) according to standardized procedures (https://kinesiotaping.com/how-to/). The tape is latex-free and wearable for weeks without causing skin irritation (i.e., hypoallergenic); and safe for populations ranging from pediatric to geriatric. The tape will be applied by a Physical Therapist with experience in tape application. Tape application will be conducted in a private room with a complete structure for the procedure.
61968573|NCT03804047|SHAM_COMPARATOR|Sham Tape (STG)|Participants allocated into the STG will receive a single time application of an inflexible tape (i.e., sham tape) in the same body segments as the intervention condition. Tape application will be conducted in a private room with a complete structure for the procedure.
61968574|NCT05218460|EXPERIMENTAL|All subjects will have an MRI examination|
61968575|NCT04697524|EXPERIMENTAL|Phase 1: Supportive care (GMV)|Participants will take a baseline assessment to collect socio-demographic information and complete a series of patient-reported outcome assessments (PROs) prior to their first group medical visit (GMV). The GMV intervention will take place over four weekly sessions conducted virtually. At the completion of all four weekly GMV sessions, participants will be asked to complete an exit survey. Participants in phase one will not be contacted or followed after the exit survey.
61968576|NCT04697524|EXPERIMENTAL|Phase 2: Refined GMV|Up to three new cohorts of participants are recruited to assess the acceptability and feasibility of the refined intervention based on the results from the Phase 1 group
62539357|NCT00700297|PLACEBO_COMPARATOR|Placebo|Patients who received placebo and went on Colchicine after 4 months
61968577|NCT02314611||PROFEMUR® Gladiator HA Coated Stem|Single study group previously implanted with a primary PROFEMUR® Gladiator HA Coated Modular Femoral Stem (HA = Hydroxyapatite)
61968578|NCT02272491|EXPERIMENTAL|ZrO2|"1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
61968579|NCT02272491|ACTIVE_COMPARATOR|PFM crown|Straumann Gold Abutment RN Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
61968580|NCT02285790|EXPERIMENTAL|RCM-OSS procedure|The Vivascope 1500 will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed for intended use only and interpreted on the Vivascope workstation by two investigators independently at both study locations. The investigators will be blinded to the results of the reference standard. After RCM imaging subjects will receive OSS surgical excision according to subtype. Clinically suspected primary BCCs that are not confirmed by RCM will also receive surgical treatment with a margin of 3mm.
61968581|NCT02285790|ACTIVE_COMPARATOR|Standard of care procedure|Clinical suspected primary BCCs, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most elevated part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. HE stained sections of the punch biopsies will be evaluated by an experienced board certified pathologist. Subjects will receive surgical excision according to subtype within 6 weeks after punch biopsy has been performed. Clinically suspected new primary BCCs that are not confirmed by punch biopsy will also receive surgical treatment with a margin of 3mm.
61968582|NCT04998474|EXPERIMENTAL|FRAME-001 personalized vaccine|"Prospective, single arm, multi center, open-label, phase II clinical trial.~Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs."
61968583|NCT01408004|EXPERIMENTAL|Alternating regimen|In the experimental arm (Arm A) alternating treatment will consist of 8 weeks of Pazopanib 800 mg qd alternated by 8 weeks of Everolimus 10 mg qd until first progression(PD per RECIST 1.1)followed thereafter by Pazopanib (when PD after 8 weeks of Everolimus)or Everolimus (when PD after 8 weeks of Pazopanib) monotherapy until second progression.
61968584|NCT01408004|ACTIVE_COMPARATOR|Sequential treatment|The comparative arm (Arm B) will be the standard regimen of Pazopanib (800 mg qd continuously) until progression, followed thereafter by Everolimus (10 mg qd continuously) until progression.
61968585|NCT04276792|EXPERIMENTAL|Horizontal implementation approach|The Horizontal implementation approach of the O-TLM intervention is accompanied by facilitated collaboration between Criminal Justice and Community Behavioral Health systems. Direct involvement of stakeholders with differing perspectives and buy-in from agency leadership and policymakers are key elements. The Horizontal approach involves first developing a prototype (including how to modify existing practices, overcome implementation barriers, and manage roles and responsibilities) that are tested and refined before being rolled out systematically to other units within an agency.
61968586|NCT04276792|ACTIVE_COMPARATOR|Vertical implementation approach|The Vertical implementation approach of the O-TLM intervention relies on the traditional criminal justice system's typical use of a hierarchical structure and the use of a top-down implementation approach (i.e., administrative orders) for directing change. Top-down regulatory and policy changes are viewed as vital levers for driving system change.
61968587|NCT02669732|EXPERIMENTAL|DS-8500a 75 mg once daily (QD)|tablets, orally, once daily for up to 28 days
61968588|NCT02669732|PLACEBO_COMPARATOR|Placebo|tablets, orally, once daily for up to 28 days
61968589|NCT06302504|EXPERIMENTAL|Nature-based mindfulness program|The program will include mindfulness exercises, including body scan, mindful stretching, mindful sitting, and befriending exercise. At least one of the four sessions will be conducted in retreat center in nature area.
61968590|NCT03724760|EXPERIMENTAL|Feedback|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve feedback regrding the number of steps taken by them at two time points.
62351189|NCT05715944|EXPERIMENTAL|AZD 1222|"AZD1222 vaccine~Dose Formulation:~10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6~Current/Former names/alias(es):ChAdOx1 nCoV-19"
62509565|NCT05116787|EXPERIMENTAL|BCX9930 monotherapy|"In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions~In Part 2, all participants receive open-label BCX9930 monotherapy"
62509566|NCT05116787|PLACEBO_COMPARATOR|Placebo|In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions
62509567|NCT00466895|EXPERIMENTAL|Stratum 1 Acute Leukemias|Patients must have a diagnosis of Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia(ALL)according to the WHO (World Health Organization) classification.
62539358|NCT06633328|EXPERIMENTAL|Treatment Group|Aplastic Anemia
61968591|NCT03724760|NO_INTERVENTION|Control|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve no feedback regrding the number of steps taken by them.
61968592|NCT04554667|EXPERIMENTAL|Exercise Intervention|Single exercise arm
61968593|NCT03729960|OTHER|LENA|Lena device with Fitbit and Cocooncam being optional
61968594|NCT06384040||PRP responder|response to treatment will be established in the presence of \>40% improvement of pain and/or motility
61968595|NCT06384040||PRP non responder|response to treatment will be established in the presence of \<40% improvement of pain and/or motility
61968596|NCT03329950|EXPERIMENTAL|CDX-1140|Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.
62351190|NCT06055127|EXPERIMENTAL|osseodensifiction internal sinus lift / sticky bone graft material|Osseodensifiction compacts bone and simultaneously autografts it into the osteotomy walls and apex instead of removing it. The use of a Densah® drill bit at high speed counterclockwise, without a cutting edge and with a steady irrigation causes the formation of a layer of strong dense bone along the walls of the base of the osteotomy preparation.
62509568|NCT00466895|EXPERIMENTAL|Stratum 2 Chronic lymphocytic leukemia|Patients must have diagnosis of B-Cell, Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Leukemia (SLL) (including Waldenstrom's Macroglobulinemia) requiring therapy (see eligibility criteria for definition of this) and have previously received treatment with one or more prior chemotherapy regimens.
62509569|NCT06616246|ACTIVE_COMPARATOR|Nurse Coach|HealthyLifetime program is administered by an experienced nurse coach.
62509570|NCT06616246|EXPERIMENTAL|Health worker coach|HealthyLifetime program is administered by a community health worker
62509571|NCT01275560|EXPERIMENTAL|Metronidazole|3 intakes per day during 10 days
62509572|NCT01275560|ACTIVE_COMPARATOR|Carbosylane|3 intakes per daysduring 10 days
62509573|NCT04576715|EXPERIMENTAL|TEaM Intervention Group|Dedicated Provider Education plus Information Technology Support. The IT support includes addition of an eMR concussion screening, followed by an alert to the provider, followed by a structured assessment / evaluation template.
62707208|NCT05140421|ACTIVE_COMPARATOR|Delayed Implementation|This arm will receive no D2S intervention components during Period 1 (Early Implementation), but will then receive all D2S intervention components in Period 2, starting 12 months later.
61968597|NCT03329950|EXPERIMENTAL|CDX-1140 and CDX-301|Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.
61968598|NCT03329950|EXPERIMENTAL|CDX-1140 and pembrolizumab|Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
61968599|NCT03329950|EXPERIMENTAL|CDX-1140 and chemotherapy|Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.
61968600|NCT03145350|ACTIVE_COMPARATOR|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
61968601|NCT03145350|ACTIVE_COMPARATOR|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (\~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
62509574|NCT04576715|ACTIVE_COMPARATOR|Control Group|Standard medical protocol for the management of mTBI in children. This group will not receive interventional Provider Training on the TEaM concussion evaluation examination and utilization of the eMR template.
62707209|NCT01090596|ACTIVE_COMPARATOR|Naproxen-Treated|
61968602|NCT02813564|EXPERIMENTAL|Training group|This group of children will receive the software based intervention program (CAVINS) and will train at home during the training phase.
61968603|NCT02813564|NO_INTERVENTION|Control group|This group of children will play video-games-as-usual and return in about 3 weeks for their next assessment appointment.
61968604|NCT02813564|EXPERIMENTAL|fMRI-training group|"This sub-group of children from the Training group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and train on CAVINS (the intervention) during the training phase."
61968605|NCT02813564|NO_INTERVENTION|fMRI-Control group|"This sub-group of children from the Control group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and play video-games-as-usual until their next assessment appointment (after about 3 weeks)."
62707210|NCT01090596|PLACEBO_COMPARATOR|placebo|
62707211|NCT01150357|EXPERIMENTAL|Low Dose Aliskiren|Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than \< 50 kg received 6.25 mg; ≥50 kg and \< 80 kg received 12.5 mg and ≥ 80 kg and ≤ 150 kg received 25 mg of aliskiren.
62707212|NCT01150357|EXPERIMENTAL|Mid dose|Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to \< 50 kg received 37.5 mg; ≥50 kg and \< 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.
62351191|NCT06055127|ACTIVE_COMPARATOR|piezoelectric internal sinus lift / sticky bone graft material|The piezoelectric surgical sets comprise various inserts from osteotomies to diamond-cutting inserts. The hydropneumatics pressure of the saline solution irrigation is subjected to the piezoelectric cavitation pushing the Schneiderian membrane upwards resulting in its' detachment and floating
62351192|NCT00166517|EXPERIMENTAL|1|RotaTeq
62509575|NCT05477719|EXPERIMENTAL|Compression stockings - No Compression|The patient will wear specific compression stockings in the first phase, and no compression in the second phase of the study
62509576|NCT05477719|EXPERIMENTAL|No Compression - Compression stockings|The patient won't wear anything in the first phase, and specific compression stockings in the second phase of the study
62509577|NCT02404077||Clonidine|Patients who received clonidine following prolonged dexmedetomidine infusions
62509578|NCT01619579|EXPERIMENTAL|Treatment|Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
62509579|NCT01022684||Healthy patients|
62707213|NCT01150357|EXPERIMENTAL|High dose|Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to \< 50 kg received 150 mg; ≥50 kg and \< 80 kg received 300 mg and ≥ 80 kg and ≤ 150 kg received 600 mg of aliskiren.
62707214|NCT04970914|EXPERIMENTAL|Anlotinib+Penpulimab|
62707215|NCT02083757||Resp|Fluid responsiveness is defined as a change of stroke volume stroke volume ≥ 10% after 250 ml rapid saline infusion in 10 minutes.
62707216|NCT02083757||Nonresp|Fluid responsiveness is defined as a change of stroke volume stroke volume \< 10% after 250 ml rapid saline infusion in 10 minutes.
62707217|NCT01170663|EXPERIMENTAL|Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel|Ramucirumab (IMC-1211B) DP and Paclitaxel
62707218|NCT01170663|PLACEBO_COMPARATOR|Placebo and Paclitaxel|Placebo and Paclitaxel
62707219|NCT04103450|EXPERIMENTAL|Vibegron|Participants will receive 75 milligrams (mg) vibegron orally once daily (QD).
62351193|NCT00166517|PLACEBO_COMPARATOR|2|Placebo
62509580|NCT01745952|EXPERIMENTAL|figure-of-eight active rTMS coil|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
62509581|NCT01745952|EXPERIMENTAL|round active rTMS coil|rTMS is administered using the round active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
62707220|NCT04555759|EXPERIMENTAL|Patient with spinal cord injuries|
61968606|NCT05845684|EXPERIMENTAL|trial group|The physiotherapy group will receive a 10-minute massage in 30-minute sessions, 3 days a week for 1 month, oral and intraoral tactile stimulations, and non-nutritive sucking exercises to stimulate sucking. Positioning will be done for 15 minutes for mobilization purposes.
62707221|NCT03758183||two-stage algorithm|Prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)
61968607|NCT05845684|OTHER|control group|In the control group, daily standard care practices will be performed.
61968608|NCT03030508||Group cap|Patients receiving capecitabine chemotherapy after operation
61968609|NCT04010708||IOMUM|Pregnant women
61968610|NCT00068497|EXPERIMENTAL|Treatment (gefitinib)|Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
61968611|NCT01148784|ACTIVE_COMPARATOR|Quadrupled Hamstring Allograft|
61968612|NCT01148784|ACTIVE_COMPARATOR|Doubled Tibialis Anterior Allograft|
62351194|NCT04759677|ACTIVE_COMPARATOR|the situation where the accelerometer is placed on the wrist during active video games playing|In one session the accelerometer will place on the dominant wrist Individuals will instructed not to remove and instruct them to wear the device during the session.
62351195|NCT04759677|ACTIVE_COMPARATOR|the situation where the accelerometer is placed on the hip during active video games playing|"In one session the accelerometer will place on a flexible belt by attaching to the hip area at the intersection of the dominant wrist and axillary line.~Individuals will instructed not to remove and instruct them to wear the device during the session."
62509582|NCT01745952|SHAM_COMPARATOR|sham rTMS coil (figure-of-eight)|rTMS is administered using the figure-of-eight sham coil, over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
61968613|NCT01892293|EXPERIMENTAL|Autologous genetically modified T cells|Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
62707222|NCT03758183||one-stage algorithm|total knee arthroplasty (TKA)
61968614|NCT05471622|EXPERIMENTAL|Intervention|The lead case manager and covering provider on the inpatient care team for participants in this group will receive a message from the research team identifying their patient as appropriate for home palliative care and will be asked to refer their patient for these services.
62736699|NCT05281237|EXPERIMENTAL|AVECURE FLEXIBLE MICROWAVE ABLATION PROBE FOR LUNG NODULES|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~* Ablation Procedure- MWA will be used to treat solitary pulmonary nodules up to 3cm.~* CT scan will then be performed to evaluate the radiological changes 2 - 4 weeks after the ablation procedure.~* Surgery will be performed to remove the lung nodule and the tissue will be evaluated by pathology."
62509583|NCT02268539|ACTIVE_COMPARATOR|Ablation at 20 watt / 30 seconds|Participants randomised to 20 watt ablation for 30 seconds
61968615|NCT05471622|NO_INTERVENTION|Usual Care|Participants in this group will receive usual care upon discharge from the hospital. Their clinical team will not be notified that they are appropriate for home palliative care services, but they may still be referred for those services if their clinicians feel their patient will benefit.
61968616|NCT02170051|EXPERIMENTAL|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
61968617|NCT02170051|ACTIVE_COMPARATOR|Goal-focused supportive contact|Goal-focused supportive contact
61968618|NCT01605877|EXPERIMENTAL|SN6AD2|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 \[SV25T0\], bilateral implantation
61968619|NCT04013139||CKD Stage 3|CKD patients with GFR between 30-60cc/min
61968620|NCT04013139||CKD Stage 4|CKD Patients with GFR 15-30 cc/min
61968621|NCT02375113|EXPERIMENTAL|Intervention|Soy supplementation: Isoflavones 160 mg/day + 25 gram soy protein / day
61968622|NCT02375113|PLACEBO_COMPARATOR|Control|Placebo capsules + 25 gram whey protein / day
61968623|NCT01150864|ACTIVE_COMPARATOR|Passive Humidifier|The Passive Humidifier (HME)will changed every 24 hours
61968624|NCT01150864|ACTIVE_COMPARATOR|Active-Passive humidifier|The Active-Passive Humidifier will be changed every 24 hours
61968625|NCT01150864|ACTIVE_COMPARATOR|Hot Water Humidifier|Hot water humidifier will be set at 36-37 °C
61968626|NCT04341389|ACTIVE_COMPARATOR|Arm 1|1×10\^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
61968627|NCT04341389|ACTIVE_COMPARATOR|Arm 2|5×10\^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
61968628|NCT04341389|PLACEBO_COMPARATOR|Arm 3|Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
61968629|NCT03554824||Pre-Transfer Adolescents aged 10-16 years|
61968630|NCT03554824||Post-Transfer Young Adults aged 16-25 years|
62351196|NCT00871091|EXPERIMENTAL|1|CAD/CAM group, customized archwires
62351197|NCT00871091|ACTIVE_COMPARATOR|2|prefabricated archwires (superelastic)
62351198|NCT00871091|ACTIVE_COMPARATOR|3|prefabricated archwires with manual adjustments
62509584|NCT02268539|ACTIVE_COMPARATOR|Ablation at 20 watt /45 seconds|20 watt ablation for 45 seconds
62509585|NCT02268539|ACTIVE_COMPARATOR|Ablation at 25 watt / 30 seconds|25 watt ablation for 30 seconds
62509586|NCT02268539|ACTIVE_COMPARATOR|iAblation at 25 watt / 45 seconds|25 watt ablation for 45 seconds
62509587|NCT05402306|EXPERIMENTAL|Treatment group|A two-week intensive group treatment with MCT mainly focusing on attention training. The participants will be allocated into treatment in groups of six. Group sessions will be conducted two times a day for approximately 60 minutes.
62509588|NCT05402306|NO_INTERVENTION|Waitlist control group|Cohorts of 12 included patients will be randomly assigned to active treatment or waitlist for two weeks. The waitlist patients will receive the same treatment immediately after four-week waiting period.
62509589|NCT03130348|EXPERIMENTAL|Treatment (ibrutinib, bortezomib, dexamethasone)|Patients receive ibrutinib PO QD on days 1-28. After 3 courses, patients who achieve partial response repeat treatment every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve partial response after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4, patients who do not achieve partial response also receive bortezomib SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
62509590|NCT02284347|EXPERIMENTAL|NuVent™|Revision patients treated with NuVent™
62509591|NCT02105155|EXPERIMENTAL|Conversion at day 7 ± 3|Conversion from Prograf to Advagraf at D7 ± 3
62509592|NCT02105155|ACTIVE_COMPARATOR|Conversion at day 90±5|Conversion from Prograf to Advagraf at 90±5
62509593|NCT05176379|EXPERIMENTAL|fluconazole|fluconazole tablet/pill 150 mg, single acute dose
62509594|NCT05176379|PLACEBO_COMPARATOR|Placebo|250 mg pill microcrystalline Cellulose, single acute dose
62509595|NCT05367765|EXPERIMENTAL|Flumatinib mesylate tablets|
62509596|NCT05367765|ACTIVE_COMPARATOR|Imatinib mesylate tablets|
62509597|NCT01719887|ACTIVE_COMPARATOR|Conservative treatment|Conservative treatment with functional brace and physiotherapy.
62509598|NCT01719887|EXPERIMENTAL|Operative treatment|Operative treatment with open reduction and internal fixation with 4,5mm locking compression plate. Physiotherapy at 3 and 9 wks.
62707223|NCT05014152|EXPERIMENTAL|Single group|"This study is specially designed according to its age range and customized/non-customized range, and meets the requirements of ISO 80601-2-56 test population (table). Comply with the age range and population requirements of ISO 80601-2-56, as well as clinical and subject trials, including news to the population over five years old, and hopefuls must account for at least 30% of the total and less than 50% of the total.~Each subject uses Q-temp-w1 to measure axillary temperature and obtains 3 temperature values, and at the same time uses a reference body temperature patch (Omron thermometer MC-171W) to measure the other side axillary temperature, and 1 is measured Temperature value data. Perform clinical efficacy analysis based on the measurement results. The main evaluation indicators of the trial include clinical bias, limits of agreement, and clinical repeatability."
62509599|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
61968631|NCT03554824||Parents/Guardians of Pre-Transfer Patients|
62707224|NCT05802901|ACTIVE_COMPARATOR|Spinal manipulation|Spinal manipulation of the lumbar spine only group.
62707225|NCT05802901|ACTIVE_COMPARATOR|Dry needling|Dry needling of the symptomatic side of the lumbar spine only group.
62707226|NCT05802901|ACTIVE_COMPARATOR|Spinal manipulation and dry needling|Combination of spinal manipulation and dry needling of the lumbar spine group
61968632|NCT04186039|EXPERIMENTAL|Congenital diaphragmatic and parietal malformations|Patients with fetal magnetic resonance imaging as part of their usual medical care, for fetal / placental indications of diaphragmatic hernia, omphalocele or gastroschisis.
61968633|NCT01443988|ACTIVE_COMPARATOR|iStent|Implantation of two iStent devices
62509600|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
62509601|NCT01706861|OTHER|Celotres|Celotres following surgical removal of earlobe keloid.
62509602|NCT00455026|PLACEBO_COMPARATOR|1|0 ng/ml target effect site concentration remifentanil
62509603|NCT00455026|ACTIVE_COMPARATOR|2|2 ng/ml target concentration remifentanil
62509604|NCT00455026|ACTIVE_COMPARATOR|3|4 ng/ml target effect site concentration remifentanil
62509605|NCT06072157|EXPERIMENTAL|Part A - Single Ascending Dose (SAD) Intravenous Cohorts|Part A: Healthy adult participants will receive a single intravenous infusion of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 5 cohorts evaluated.
62509606|NCT06072157|EXPERIMENTAL|Part B - Multiple Ascending Dose (MAD) Intravenous Cohorts|Part B: Healthy adult participants will receive multiple intravenous infusions of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 3 cohorts evaluated.
62509607|NCT06072157|EXPERIMENTAL|Part C - Multiple Dose Intravenous Cohort|Part C: Adults with Chronic Spontaneous Urticaria will receive multiple intravenous infusions of AK006 or matching placebo.
62509608|NCT06072157|EXPERIMENTAL|Part D - Single Ascending Dose (SAD) Subcutaneous Cohorts|Part D: Healthy adult participants will receive a single subcutaneous injection of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 2 cohorts evaluated.
62509609|NCT01682642|ACTIVE_COMPARATOR|Zoladex|After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
61968634|NCT01443988|ACTIVE_COMPARATOR|Drug|Travoprost drops
61968635|NCT03938389|ACTIVE_COMPARATOR|Valsartan|Valsartan 160 mg twice daily for 26 weeks
61968636|NCT03938389|EXPERIMENTAL|Sacubitril/Valsartan|Sacubitril/Valsartan (97/103 mg) twice daily for 26 weeks
61968637|NCT03938389|PLACEBO_COMPARATOR|Placebo|placebo (+/- amlodipine 2.5-5 mg twice daily if high blood pressure)
61968638|NCT01965496|EXPERIMENTAL|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 14 weeks
61968639|NCT01965496|EXPERIMENTAL|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 200 microgram qw for the 10 weeks.
62509610|NCT01682642|NO_INTERVENTION|vaporization only|Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.
62509611|NCT02721706|EXPERIMENTAL|CIPA screening tool|Patients are evaluated by CIPA nutritional screening tool
62509612|NCT02721706|NO_INTERVENTION|usual hospital clinical care|Patients are not subject of CIPA screening tool, and continue the usual hospital clinical care
62509613|NCT03143387|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
62509614|NCT03143387|EXPERIMENTAL|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
61968640|NCT01965496|EXPERIMENTAL|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 300 microgram qw for the 10 weeks.
61968641|NCT05853198|OTHER|PDAC patients|PDAC patients as described in the inclusion criteria
62509615|NCT05239533|EXPERIMENTAL|Safety lead-in Phase: Participants with Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. The protocol will start with a safety-lead in phase using a 3+3 design to establish the maximal tolerated dose (MTD) of 177Lu-labeled-girentuximab in combination with standard-dose nivolumab. The initial starting dose of 177Lu-labeled-girentuximab is 1804 MBq/m2 which is 75% of the single agent dose established in prior studies and will proceed as shown in the schema below. Once the MTD is established, a Simon two-stage optimal design will commence. 10 patients will be enrolled in the first stage and if no responses are observed, the study will be terminated. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
61968642|NCT05495906|ACTIVE_COMPARATOR|Routine schedule|Three doses of 9vHPV vaccine at the routine dosing schedule of 0/2/6 months
61968643|NCT05495906|EXPERIMENTAL|Extended schedule|Two doses of 9vHPV vaccine at an expanded dosing schedule of 0/6 months with a third dose given at month 12
61968644|NCT02893878||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in approximately 10 volunteer practices.
61968645|NCT02893878||Vaccinated_Non GSK Group|Volunteered subjects who received Non-GSK influenza vaccination in approximately 10 volunteer practices.
61968646|NCT02893878||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or Non-GSK not known) in approximately 10 volunteer practices.
61968647|NCT05604118|EXPERIMENTAL|Aspirin supplemented|
61968648|NCT05604118|NO_INTERVENTION|Off aspirin|
61968649|NCT02669381|OTHER|Experimental: phenylalanine intake|Dietary supplement: phenylalanine intake
61968650|NCT01497691|OTHER|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol.
61968651|NCT01497691|SHAM_COMPARATOR|Sham NIPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. The pressure settings will be fixed at a positive end-expiratory pressure (PEEP) of 5-8 cm H2O.
61968652|NCT01497691|ACTIVE_COMPARATOR|BiPAP|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. Settings will be adjusted based on the age and clinical presentation of the child.
62351199|NCT02013089|EXPERIMENTAL|Erlotinib or Gefitinib|Erlotinib 150 mg tablet or Gefitinib 250 mg tablet by mouth every day
62509616|NCT05239533|EXPERIMENTAL|Phase 2 Participants|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
62509617|NCT02591563||Healthy children|6-36 months of age who will have the following study procedures: Venipuncture, Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis
62509618|NCT01556282|EXPERIMENTAL|Therasphere|
62509619|NCT03998709|OTHER|Elevation of fasting FFA and Glucose|People with normal fasting glucose and normal fasting FFA (normal fasting glucose / normal glucose tolerance - NFG / NGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive intralipid and dextrose to raise fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
62707227|NCT01695603|NO_INTERVENTION|Standard mode of controlled ventilation|Each brain injured patient will be ventilated during two hours with a standard mode of controlled ventilation.
61968653|NCT04488484|OTHER|Arm|"Serology test results~The Paris Saint- Joseph Hospital Group staff was submitted to a 2 times serology test: the 1st took place between April, 20th to May, 12th and the second, between May, 26th to June, 12th. The employees presenting positive antibodies titers to SARS-CoV-2 will be contacted and asked for a 12 month follow-up study organized by the Occupational Health Team and the team of COVID-19 Serology referents appointed to carry out and coordinate the procedure. Each enrolled member will receive a letter with containing an information letter describing the study with a written consent form and a questionnaire enabling the data to be collected individually on the COVID-19 infection."
61968654|NCT01266954|EXPERIMENTAL|Stage 1|Three to six patients on a medium dose of GSK2141795 for four weeks
61968655|NCT01266954|EXPERIMENTAL|Stage 2|Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks
61968656|NCT03130361|EXPERIMENTAL|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
61968657|NCT04676282||Survey 1 Statin - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm.
61968658|NCT04676282||Survey 1 Stain - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may lack benefit.
61968659|NCT04676282||Survey 1 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
62351200|NCT02013089|EXPERIMENTAL|Everolimus|Everolimus 10 mg orally once daily every day
62351201|NCT02013089|EXPERIMENTAL|Imatinib|Imatinib 400 mg tablet orally per day
62351202|NCT02013089|EXPERIMENTAL|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day
62351203|NCT02013089|EXPERIMENTAL|Vandetanib|Vandetanib 300 mg orally once daily
62707228|NCT01695603|EXPERIMENTAL|Intellivent arm|Each brain injured patient will be ventilated during two hours with an automated mode of ventilation, the Intellivent mode.
62707229|NCT00312286|EXPERIMENTAL|1|
62707230|NCT00312286|EXPERIMENTAL|2|
61968660|NCT04676282||Survey 1 PPI - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm.
62707231|NCT00312286|EXPERIMENTAL|3|
62707232|NCT00312286|EXPERIMENTAL|4|
61968661|NCT04676282||Survey 1 PPI - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may lack benefit.
61968662|NCT04676282||Survey 1 PPI - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm and lack benefit.
61968663|NCT04676282||Survey 2 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
61968664|NCT04676282||Survey 2 Statin - Cardiologist|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin previously started by a cardiologist.
62707233|NCT00312286|EXPERIMENTAL|5|
62707234|NCT00312286|EXPERIMENTAL|6|
61968665|NCT04676282||Survey 2 Statin - Daughter Preference|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's adult daughter prefers for her to continue the medication.
61968666|NCT04676282||Survey 2 Statin - Husband Stroke|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's husband previously had a stroke after he stopped his statin.
61968667|NCT04676282||Survey 2 Statin - Flier|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient saw an educational flier about strokes in the waiting room.
62707235|NCT00312286|EXPERIMENTAL|7|
62707236|NCT00312286|PLACEBO_COMPARATOR|8|
61968668|NCT04676282||Survey 2 Statin - Difficulty Maintaining Lifestyle Changes|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient recognizes that they have had difficulty exercising and eating healthier foods.
62351204|NCT02013089|NO_INTERVENTION|Control|No intervention was performed for patients without any gene alternation or without any available target agents
62351205|NCT00788697|OTHER|Patients who received SonoVue|"Patients with at least 1 target lesion requiring work-up for characterization to undergo~* Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~* SonoVue-enhanced ultrasound of the target lesion (CE-US): procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~* Truth standard"
62351206|NCT04711759|EXPERIMENTAL|Sequence A: High flow nasal cannula - Standard oxygen therapy|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of standard oxygen therapy.
62351207|NCT04711759|EXPERIMENTAL|Sequence B: Standard oxygen therapy - High flow nasal cannula|Once participants are extubated they will receive one hour of standard oxygen therapy followed by one hour of high flow nasal cannula.
62707237|NCT00312286|PLACEBO_COMPARATOR|9|
62707238|NCT00312286|PLACEBO_COMPARATOR|10|
62707239|NCT00312286|PLACEBO_COMPARATOR|11|
61968669|NCT06166160|EXPERIMENTAL|SDR FLOW + bulk fill flowable|in class II cavities of primary molars
61968670|NCT06166160|ACTIVE_COMPARATOR|high-viscosity glass ionomer cement (EQUIA Forte)|in class II cavities of primary molars
61968671|NCT00187876|ACTIVE_COMPARATOR|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts.
62707240|NCT04399421||Conventional pedicle screw fixation|Patients undergoing conventional pedicle screw fixation without the use of bone cement.
62707241|NCT04399421||Cement-augmented pedicle screw fixation|Patients undergoing pedicle screw fixation augmented with bone cement.
62707242|NCT06564805|ACTIVE_COMPARATOR|intralesional Triamcinolone|Triamcinolone acetonide will be administered intralesionally at a concentration of 4 mg/mL. The solution will be injected in 0.1 mL doses, spaced 1 cm apart. The maximum total dose per session will be limited to 3 mL
62707243|NCT06564805|EXPERIMENTAL|Candida albicans antigen|Single subcutaneous administration of 0.1 mL of Candida albicans antigen into one of the alopecic patches
62707244|NCT04267445||Embolization patients|"Single center, open label, pilot study. Eligible patients will undergo transarterial embolization of the prostatic vasculature. Each patient will undergo a single embolization procedure.~After completion of treatment in the first 2 patients and a review of follow-up assessments after 7 days, subsequent patients will be enrolled if no safety concerns have arisen in the first 2 patients.~Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.~Magnetic resonance imaging (MRI) and CEUS is used to assess changes in prostate volume and in central gland enhancement characteristics using 3D volume assessment software."
62707245|NCT01270529|EXPERIMENTAL|CKD Stages 1-4|
62707246|NCT01270529|EXPERIMENTAL|ESRD on Dialysis|
62707247|NCT01270529|EXPERIMENTAL|Kidney Transplant recipients|
62707248|NCT02946996|EXPERIMENTAL|OPC|Subjects will take one OPC capsule at the same time each morning and evening, approximately 12 hours apart during weeks 1-12.
62707249|NCT00953628|ACTIVE_COMPARATOR|o Group A=uHCG ovul trig|HCG for triggering
61968672|NCT00187876|EXPERIMENTAL|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
61968673|NCT04823650||Ages 3-5|COHORT A and B
61968674|NCT04823650||Ages 6-11|COHORT A and B
62509620|NCT03998709|OTHER|Lowering of fasting FFA and glucose|People with elevated fasting glucose and elevated fasting FFA (Impaired fasting glucose / impaired glucose tolerance - IFG / IGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive insulin to lower fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
62509621|NCT05453786|EXPERIMENTAL|Sequence A|Period 1: SID1903-R1, SID1903-R2 / Period 2: SID1903
62509622|NCT05453786|EXPERIMENTAL|Sequence B|- Period 1: SID1903 / Period 2: SID1903-R1, SID1903-R2
62509623|NCT06020482||A-OE|women with ovarian endometriosis (study group)
62509624|NCT06020482||A-PE|women with peitoneal endometriosis (study group)
62509625|NCT06020482||A-DE|women with deep infiltrating endometriosis (study group)
61968675|NCT04823650||Ages 12-17|COHORT A and B
62351208|NCT00810095|EXPERIMENTAL|Treatment Arm|
62509626|NCT06020482||B|women without endometriosis
62509627|NCT00640263|EXPERIMENTAL|1|infant peri-exposure prophylaxis with lopinavir/ritonavir
62707250|NCT00953628|EXPERIMENTAL|o Group B=recHCG ovul trig|recombinant HCG for triggering
61968676|NCT00859053|ACTIVE_COMPARATOR|BMS-790052 in Child-Pugh A|
61968677|NCT00859053|ACTIVE_COMPARATOR|BMS-790052 in Child-Pugh B|
62351209|NCT05514106|EXPERIMENTAL|Myocardial 123I-MIBG scintigraphy imaging|Subjects with with normal neurologic functioning, REM sleep without atonia, RBD, parkinsonism, cognitive impairment, or some combination of these will undergo myocardial 123I-MIBG scintigraphy imaging
62509628|NCT00640263|ACTIVE_COMPARATOR|2|infant peri-exposure prophylaxis with lamivudine
62509629|NCT03321526|EXPERIMENTAL|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2\*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
62509630|NCT03321526|ACTIVE_COMPARATOR|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2\*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
62509631|NCT04570176|EXPERIMENTAL|Urologic tumor group|patients with adrenal adenoma, muscle-invasive bladder cancer or renal cell carcinoma are included in the experiment.
62509632|NCT00746291|EXPERIMENTAL|A|Traumatic brain injury
62509633|NCT00746291|EXPERIMENTAL|B|Cerebral palsy
62509634|NCT00746291|EXPERIMENTAL|C|Controls
62509635|NCT00813826|EXPERIMENTAL|SLC022|300mg TID
61968678|NCT00859053|ACTIVE_COMPARATOR|BMS-790052 in Child-Pugh C|
61968679|NCT00859053|ACTIVE_COMPARATOR|BMS-790052 in Healthy Subjects|
61968680|NCT05918692|EXPERIMENTAL|Escalation Phase|BMF-500 taken twice daily by participants who are not receiving drugs that inhibit CYP3A4 activity or who are receiving necessary azole antifungals that are moderate or strong CYP3A4 inhibitors excluding other moderate or strong CYP3A4 inhibitors.
61968681|NCT05918692|EXPERIMENTAL|Expansion Phase|BMF-500 taken twice daily by participants who are not receiving drugs that inhibit CYP3A4 activity or who are receiving necessary azole antifungals that are moderate or strong CYP3A4 inhibitors excluding other moderate or strong CYP3A4 inhibitors.
61968682|NCT00849641||1|patients with decompensated liver cirrhosis admitted to the medical ICU
61968683|NCT00849641||2|critically ill patients without liver cirrhosis, matched to group 1
61968684|NCT00849641||3|healthy control group
61968685|NCT00863603|NO_INTERVENTION|1|No exposure to supplemental oxygen
62351210|NCT04828369||EUS group|Patients who received EUS-guided coil embolization combined with endoscopic cyanoacrylate injection
62351211|NCT04828369||BRTO group|Patients who received balloon-occluded retrograde transvenous obliteration (BRTO)
62509636|NCT00813826|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule
62509637|NCT00114231|EXPERIMENTAL|Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)|"Patients undergo high-dose external beam radiotherapy once daily and receive capecitabine PO BID on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive oxaliplatin IV over 2 hours on days 1, 8, 22, and 29.~Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo local excision of the tumor. Patients with T3 disease or positive resection margins after local excision undergo radical resection of the rectum and receive additional chemotherapy and/or radiotherapy at the discretion of the physician."
62509638|NCT01553201|EXPERIMENTAL|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
62707251|NCT01128478|OTHER|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
62707252|NCT01128478|NO_INTERVENTION|Nil-per-mouth regimen|Conventional management
62707253|NCT02815163|NO_INTERVENTION|comparison group|The CG received no extra care; they could receive the usual routine care for THR in the unit as they had before participation in the study. The routine care included oral instruction by nurses follow by the handout. Also, a brochure was provided of the structure of hip, the risk factors of THR, care before and after THR, complications, care of discharge, and demonstration of rehabilitation with pictures) of THR designed by researchers in this study. Five orthopedics health care experts independently reviewed and rated each item in the brochure on a five-point Likert-type scale in terms of relevance, representativeness, specificity, and clarity.
62707254|NCT02815163|EXPERIMENTAL|Empowerment education group|"The 5 times total, 12-week EE intervention was aimed to empower older patients with THR to develop their own self-management program to meet their needs. This empowerment education intervention based on 6 empowerment components: Partnership, listening, dialogue, reflection, action, feedback and 5-step empowerment strategies: motivating patients self-awareness, assessing the causes of the problem, goal setting, individual self-care plan development, and checking whether goals or plans have been achieved who modified from Freire's 3-stage methodology. The difference between this program and the other health educations for patients with THR are that this program encourages them to explore their needs and worries, their own ability and power to meet their needs, and their capacity to seek and use their social support and resources etc."
62707255|NCT02428829|EXPERIMENTAL|Intervention|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
62707256|NCT02428829|ACTIVE_COMPARATOR|Control|Control group will receive standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively
62707257|NCT02051192|EXPERIMENTAL|Parent-Led Exposure Therapy (PLET)|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
61968686|NCT00863603|OTHER|Oxygen, treatment, supplement|6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement
61968687|NCT01129960|EXPERIMENTAL|Eslicarbazepine acetate 800 mg once daily (QD)|
61968688|NCT01129960|EXPERIMENTAL|Eslicarbazepine acetate 1200 mg QD|
61968689|NCT01129960|EXPERIMENTAL|Eslicarbazepine acetate 1600 mg QD|
62509639|NCT01553201|PLACEBO_COMPARATOR|Placebo|Saline, 4cc, one time intramuscular administration
62509640|NCT03543709||Behcet and fibromyalgia|Women with Behcet's disease with fibromyalgia
62509641|NCT03543709||Behcet|Women with Behcet's disease without fibromyalgia
61968690|NCT01129960|PLACEBO_COMPARATOR|Placebo|
61968691|NCT03932721|ACTIVE_COMPARATOR|Evolocumabe|Patients with T2DM treated with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure) AND evolocumab (anti-PCsk9).
61968692|NCT03932721|NO_INTERVENTION|Control|Patients with T2DM treated exclusive with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure).
61968693|NCT02165774|ACTIVE_COMPARATOR|sacral neuromodulation ON|active sacral neuromodulation (neuromodulator ON)
61968694|NCT02165774|PLACEBO_COMPARATOR|sacral neuromodulation OFF|placebo sacral neuromodulation (neuromodulator OFF)
61968695|NCT01648946|ACTIVE_COMPARATOR|Liberal Transfusion Strategy|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
61968696|NCT01648946|ACTIVE_COMPARATOR|Restrictive Transfusion Strategy|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
61968697|NCT02273024|EXPERIMENTAL|Exercise|Individuals will participate in weekly supervised and unsupervised exercise sessions prior to HSCT, during hospitalization and till 100 days from HSCT. Exercise will consist of endurance and resistance exercise 3-5 days a week.
61968698|NCT02273024|NO_INTERVENTION|Usual Care|Usual care will have continue with standard of care treatment without any specific exercise instruction or guidance other than what is provided by the patient education team at the cancer centre.
62509642|NCT04591652|EXPERIMENTAL|99mTc-MIRC208 SPECT/CT scan|The cancer patients will be injected with14.8 MBq/kg body weight, and 2h later, SPECT/CT scan will be performed.
62509643|NCT01745354|EXPERIMENTAL|SD-101 + Combined with Local Radiation|
62509644|NCT06035276|OTHER|Healthy subjects|
62509645|NCT06035276|OTHER|COPD patients|
62509646|NCT02788513|EXPERIMENTAL|BI 425809 dose 1|
61968699|NCT01414010|ACTIVE_COMPARATOR|Prebiotic|
61968700|NCT01414010|ACTIVE_COMPARATOR|Probiotic|
61968701|NCT01414010|ACTIVE_COMPARATOR|Antibiotic|
61968702|NCT01414010|NO_INTERVENTION|Control|Control group, no intervention given.
61976215|NCT01850550|NO_INTERVENTION|Control|"Participants in the control condition will be given written information at the baseline visit from the NIH website Aim for a Healthy Weight to provide a basic understanding of weight loss and access to basic online resources, but will not participate in group weight loss sessions with peer leaders."
61976216|NCT01850550|EXPERIMENTAL|Weight Loss Groups|Participants in this arm will receive peer-led facilitation within groups using an adaptation of the Diabetes Prevention Program.
62509647|NCT02788513|EXPERIMENTAL|BI 425809 dose 2|
62509648|NCT02788513|EXPERIMENTAL|BI 425809 dose 3|
62509649|NCT02788513|EXPERIMENTAL|BI 425809 dose 4|
62509650|NCT02788513|PLACEBO_COMPARATOR|Placebo|
62509651|NCT04454528|ACTIVE_COMPARATOR|Arm 1|Arm 1 will receive radiotherapy on day -14 and pembrolizumab on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
61968703|NCT04445324|EXPERIMENTAL|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
61968704|NCT04445324|ACTIVE_COMPARATOR|Control Group (pharmacotherapy and/or psychotherapy N=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
61968705|NCT03673553||Association of people with fibromyalgia|Control group included people affiliated to the FM Patient Association of Terres de l'Ebre, Spain.
61968706|NCT03673553||Multimodal treatment of patients with FM|The intervention group was made up of patients from the specialist FM Unit in the Hospital of Lleida, Spain.
61968707|NCT06089525||Open reduction and internal fixation (ORIF)|Patient has underwent ORIF to repair a pilon fracture.
61968708|NCT06089525||Primary arthrodesis (PA; ankle fusion)|Patient has underwent PA/ankle fusion to repair a pilon fracture.
61968709|NCT05999045||choir member|a person who sings in a choir
61968710|NCT05960266|ACTIVE_COMPARATOR|Subcutaneous immunotherapy|"Subcutaneous injection of grass-rye pollen allergen extract and micro-crystalline tyrosine.~Single dose of 2000 U allergen in 0.5 ml. Dosage form: aqueous suspension."
61968711|NCT05960266|EXPERIMENTAL|Intralymphatic immunotherapy|"Subcutaneous injection of grass-rye pollen allergen extract and micro-crystalline tyrosine.~Single dose of 400 U allergen in 0.1 ml. Dosage form: aqueous suspension."
62509652|NCT04454528|ACTIVE_COMPARATOR|Arm 2|Arm 2 will receive pembrolizumab on day -14 and radiotherapy on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
62509653|NCT04454528|OTHER|Arm 4 (Historical Controls)|Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.
61968712|NCT04610268|EXPERIMENTAL|tDCS group|The anode of tDCS is placed on the occipital lobe and the cathode on the frontal lobe, or the anode of tDCS is placed on the left temporal lobe and the cathode on the right temporal lobe.
61968713|NCT05014763|ACTIVE_COMPARATOR|CTG from deep palate|The connective tissue graft harvested from the deep palate during flap elevation for implant placement
61968714|NCT05014763|EXPERIMENTAL|CTG from tuberosity|The connective tissue graft harvested from the tuberosity
61968715|NCT01120301|EXPERIMENTAL|Transcranial Laser Therapy|
61968716|NCT01120301|SHAM_COMPARATOR|Sham control procedure|
61968717|NCT02547454||CKD participants treated with Mircera|Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.
61968718|NCT05723237|EXPERIMENTAL|Experiment|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
61968719|NCT05723237|NO_INTERVENTION|Control Group|No application will be made to the control group (n=60).
61968720|NCT02632474|EXPERIMENTAL|Low-dose|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
61968721|NCT03806140|ACTIVE_COMPARATOR|Intervention group|Receive daily text messages
61968722|NCT03806140|NO_INTERVENTION|Control group|No text messages, only written educational materials
61968723|NCT01538420|EXPERIMENTAL|GLPG0492 oral solution|Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
61968724|NCT01538420|PLACEBO_COMPARATOR|Placebo|Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
61968725|NCT02090569|EXPERIMENTAL|Functional micro-Doppler sonography|
61968726|NCT05647954|EXPERIMENTAL|HX008 Plus Transcatheter Arterial Chemoembolization(TACE)|
61968727|NCT05647954|ACTIVE_COMPARATOR|Temozolomide Plus Transcatheter Arterial Chemoembolization (TACE)|
61968728|NCT05647954|ACTIVE_COMPARATOR|Pembrolizumab|
61968729|NCT00785733||1|Moderate and severe asthma patients stabilized on Symbicort SMART
62509654|NCT00255151|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62509655|NCT00255151|EXPERIMENTAL|Dexlansoprazole MR 90 mg QD|
61968730|NCT01439191|EXPERIMENTAL|combination agent group|
61968731|NCT01439191|EXPERIMENTAL|single agent group|In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
61968732|NCT01569789|ACTIVE_COMPARATOR|Ear Stimulation|Comparing cytokine levels pre and post stimulation of the nerve in the ear
62509656|NCT00255151|PLACEBO_COMPARATOR|Placebo|
61968733|NCT01569789|PLACEBO_COMPARATOR|Calf Stimulation|Comparing cytokine levels pre and post stimulation of the placebo area on the calf
61968734|NCT00720434|EXPERIMENTAL|A|500 mg BID
61968735|NCT00720434|EXPERIMENTAL|B|300 mg BID
61968736|NCT00720434|EXPERIMENTAL|C|200 mg BID
61968737|NCT00720434|PLACEBO_COMPARATOR|D|Placebo
62509657|NCT06176625|NO_INTERVENTION|Delirium & Sensory Loss|The observational portion of the study, during which participants are screened for delirium. Consented individuals also complete bedside hearing and vision screenings, and provide information regarding care on patient satisfaction questionnaires.
61968738|NCT05582746|OTHER|COVID-19 mHealth Intervention|We are using a pre-post study design, given the low risk of the educational intervention and expected benefit.
61968739|NCT00725023|EXPERIMENTAL|1|Treatment: TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
61968740|NCT00725023|OTHER|2|Treatment: Dummy TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
61968741|NCT01624454|ACTIVE_COMPARATOR|large volume|bowel cleansing with PEG
61968742|NCT01624454|ACTIVE_COMPARATOR|Osmotic|
61968743|NCT03048565|NO_INTERVENTION|Usual care|No intervention
62145221|NCT04862598|EXPERIMENTAL|VR Group|The patient wears the VR headset after being positioned on the table and the surgical time out has been completed. The VR scene and accompanying music will continue until the end of the procedure or until the patient wishes for it to be removed. The patient will receive standard operative and nursing care. The study team member will record the intra-operative vitals as detailed in the control group procedure. At the end of the procedure, the patient will be moved to recovery and will receive standard care. At 15 minutes, they will be provided with the anxiety questionnaire and the ISAS. Additional questions will be asked; their level of VR immersion and if they would like to receive the VR technology again if they were to undergo another procedure in the future. They will then be free to leave once they have met the standard discharge criteria.
62145222|NCT02586467|EXPERIMENTAL|Gain-Framed|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products).
62509658|NCT06176625|NO_INTERVENTION|Baseline Delirium Prevalence|This arm of the interventional portion of the study will be used as baseline comparison data to determine whether implementation of the intervention impacted delirium outcomes. Baseline data collection will be collected for each of the units prior to implementation of the intervention.
62509659|NCT06176625|ACTIVE_COMPARATOR|Communication Signage|For patients who report a little or moderate trouble hearing following the implementation of the intervention, a pink sign will be posted to prompt use of effective communication strategies by nursing staff.
61968744|NCT03048565|EXPERIMENTAL|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
61968745|NCT01331798|EXPERIMENTAL|Test: TissuGlu Adhesive|Patients received the TissuGlu Adhesive Treatment
61968746|NCT01331798|ACTIVE_COMPARATOR|Control|Control Arm received no TissuGlu- Standard of Care received.
61968747|NCT06243809|EXPERIMENTAL|Linagliptin 5 mg, Then Trajenta 5 mg|Participants first received Linagliptin 5 mg tablet 1 tablet (Test product) in a fasting state. After a washout period of 1 week, they then received Trajecta 5 mg tablet (Reference product) in a fasting state.
61968748|NCT06243809|ACTIVE_COMPARATOR|Trajenta 5 mg, Then Linagliptin 5 mg|Participants first received Trajenta 5 mg tablet 1 tablet (Reference product) in a fasting state. After a washout period of 1 week, they then recieved Linagliptin 5 mg tablet (Test product) in a fasting state
62145223|NCT02586467|EXPERIMENTAL|Loss-Framed|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products).
62145224|NCT02586467|EXPERIMENTAL|Self-Regulatory Efficacy|Participants receive messages that provide them with tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.)
62509660|NCT06176625|ACTIVE_COMPARATOR|Amplifier|For patients who report a lot of trouble hearing following the implementation of the intervention, a blue sign will be posted to prompt nursing staff to remind patient to make use of amplifier provided as part of the study.
61968749|NCT05722483|EXPERIMENTAL|Virtual Intensive Outpatient Program|Participants will be treated in a 4 week program involving daily psychotherapy groups, weekly individual therapy and medication management, as well as daily breathalyzer monitoring.
61968750|NCT01174303|EXPERIMENTAL|IDegAsp - BIAsp|
61968751|NCT01174303|EXPERIMENTAL|BIAsp - IDegAsp|
61968752|NCT01918930|EXPERIMENTAL|MGA271|MGA271 (administered in main study CP-MGA271-01)
61968753|NCT03459248|EXPERIMENTAL|Dual therapy|Patients will receive 10 mg metoclopramide with 4mg ondansetron before induction of general anesthesia
61968754|NCT03459248|ACTIVE_COMPARATOR|Monotherapy|Patients will receive 10 mg metoclopramide before induction of general anesthesia.
61968755|NCT02255604|ACTIVE_COMPARATOR|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
61968756|NCT02255604|PLACEBO_COMPARATOR|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
61968757|NCT02255604|SHAM_COMPARATOR|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
61968758|NCT05397821||Radboudumc recipients|NTX performed with a refluxing technique
62509661|NCT01225055|EXPERIMENTAL|Teriparatide|Teriparatide alone with sham vibration
62509662|NCT01225055|EXPERIMENTAL|Vibration|Vibration alone with placebo-teriparatide
62509663|NCT01225055|EXPERIMENTAL|Teriparatide and vibration|Teriparatide with vibration applied in conjuction
62509664|NCT05123781|EXPERIMENTAL|Treatment A|Test Product Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
62509665|NCT05123781|ACTIVE_COMPARATOR|Treatment B|Reference Product Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
61968759|NCT05397821||Winsconsin recipients|NTX performed with a non-refluxing technique
62145225|NCT02586467|EXPERIMENTAL|Gain-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
62351212|NCT02297737|EXPERIMENTAL|Tai Chi|A manual consisting of 8 movements learned over a period of 12 weeks will be used to teach participants in the Tai Chi condition. Classes will include around 5-6 subjects, each class lasting one hour, including a 10-minute warm-up and cool-down, and meet twice per week. Patients will be told to practice Tai Chi three times/week at home. After 12 weeks of training patients will be told to practice at home five times/week for 8 more weeks, until the 8-week follow-up visit. Subjects will be asked to rate their perceived exertion/work intensity during each session using the Borg's perceived exertion scale and asked to increase the size of their movements to reach 12-13 (moderate difficulty), which consistently matches with 65-70% of HR max.
62351213|NCT02297737|ACTIVE_COMPARATOR|Health Education|Participants in the Health Education condition will also meet for one hour, twice per week for 12 weeks for a total of 24 hours. Sessions will be highly structured and will emphasize key concepts in the presentations. Medical and allied health experts will provide twelve didactic videotaped presentations on a series of health-related themes and a group leader will be present to answer questions. Themes will include: Epidemiology of Cardiovascular Disease, Patient/Physician Communication, Medication Adherence, Nutrition and Exercise, The Nature and Structure of Sleep, and Navigating the Health Care System.
62351214|NCT00614653|EXPERIMENTAL|Bevacizumab, Erlotinib + Capecitabine|Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.
62351215|NCT02491398||First-line|Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.
62351216|NCT02491398||Second-line|CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.
62351217|NCT05035095|EXPERIMENTAL|Oral semaglutide|Participants will receive once daily semaglutide tables in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68)
62351218|NCT05035095|PLACEBO_COMPARATOR|Oral semaglutide placebo|All participants are given once daily dose for 68 weeks
62351219|NCT00574457|OTHER|All subjects that meet the inclusion criteria invited|
62351220|NCT00289744|EXPERIMENTAL|Twinrix Group|Subjects who received 2 doses (at Day 0 and Month 6) of Twinrix in the primary study (208127/076)
62351221|NCT00289744|EXPERIMENTAL|Engerix-B Additional Dose (Adult)|Subjects aged 16 years and above who received an additional dose of EngerixTM-B (adult dose).
62351222|NCT00289744|EXPERIMENTAL|Engerix-B Additional Dose (Pediatric)|Subjects under the age of 16 years who received an additional dose of EngerixTM-B (pediatric dose).
62351223|NCT00502528|PLACEBO_COMPARATOR|1|Placebo
62351224|NCT00502528|ACTIVE_COMPARATOR|2|BQ-123
61968760|NCT03415191|EXPERIMENTAL|Ketamine Group|Five minutes before thoracotomy incision, Ketamine Group received a bolus dose of ketamine 1 mg/kg intravenously
61968761|NCT03415191|PLACEBO_COMPARATOR|Placebo Group|Five minutes before thoracotomy incision, Placebo Group received a bolus dose of normal saline 1 mg/kg intravenously
61968762|NCT02263989|EXPERIMENTAL|Telmisartan film coated tablet|
61968763|NCT02263989|ACTIVE_COMPARATOR|Telmisartan conventional tablet|
61968764|NCT02115789||Survey Group|Adult male or female volunteers.
62145226|NCT02586467|EXPERIMENTAL|Loss-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
62145227|NCT03742622|EXPERIMENTAL|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions
61968765|NCT00144963|EXPERIMENTAL|VSLI|Vincristine Sulfate Liposomes Injection (VSLI)
62351225|NCT04320290|EXPERIMENTAL|Treatment with Direct Acting Antiviral for HCV|8 weeks of treatment with HCV Direct Acting Antiviral tablet
62351226|NCT04977154||Trainers|
62351227|NCT05563714|EXPERIMENTAL|Clinician Notification with Nurse Facilitation (CNNF)|
62351228|NCT05563714|OTHER|Wait List Control (Usual care)|
62351229|NCT04732819|NO_INTERVENTION|Usual care|Facilities in the 'usual care' arm will be offered electronic messaging and education regarding the COVID-19 vaccine. This material stems from the Centers for Disease Control and Prevention (CDC) and AMDA - The Society for Post-Acute and Long-Term Care Medicine (AMDA) resources and represents a suggested approach to reduce vaccine hesitancy in staff and residents/proxies (e.g., legally authorized representatives, powers of attorney). This electronic quality improvement (QI) material will be developed as part of a QI initiative and disseminated by the American Health Care Association (AHCA) to the SNF chains and using social media.
62351230|NCT04732819|EXPERIMENTAL|High touch|Facilities in the 'high touch' arm will receive the same electronic messaging and educational material as in the 'usual care' arm but will receive an additional high touch multi-pronged behavioral intervention.
62351231|NCT05406557|ACTIVE_COMPARATOR|Partial pulpotomy|Removal of superficial 2-3 mm of pulp tissue from entire pulp chamber
61976217|NCT01705652|EXPERIMENTAL|Nexrutine Surgery Group|Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
61976218|NCT01705652|EXPERIMENTAL|Nexrutine Radiation Group|Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
62351232|NCT05406557|ACTIVE_COMPARATOR|Miniature pulpotomy|Removal of superficial 2-3 mm of pulp tissue from only affected pulp horn
62351233|NCT02437487|EXPERIMENTAL|SER-109|SER 109 (1 × 108 SporQs)
62351234|NCT02437487|PLACEBO_COMPARATOR|Placebo|Placebo
62351235|NCT03334474||young|18-35 years old
62351236|NCT03334474||middle|35-65 years old
61968766|NCT04720820|EXPERIMENTAL|Early Supported Discharge (ESD) Group|Patients in the ESD group will be discharged to home as soon as the acute medical treatment is finished. The patients will follow a pre-planned ESD program which consists of home-based rehabilitation (at least 30 minutes of physical therapy and 30 minutes of occupational therapy per week) offered by therapists. The ESD team will also provide social/medical services as needed. The ESD program will be provided till 1 months after discharge point.
61968767|NCT04720820|ACTIVE_COMPARATOR|Conventional Rehabilitation (CR) Group|The patients in CR group will be provided with inpatient rehabilitation after the acute medical treatment is finished. The length of inpatient rehabilitation may depend on the hospital's current program. Patients will be provided with outpatient based rehabilitation program if needed after discharge.
61968768|NCT04446546||Cold Stored Allograft Vascular Access|
61968769|NCT04770350|EXPERIMENTAL|Experimental|Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
61968770|NCT04405947|OTHER|deltopectoral|deltopectoral surgical approach
61968771|NCT04405947|OTHER|antero-superior|antero-superior approach
61968772|NCT03341949|EXPERIMENTAL|Patient with chronic kidney disease|Determination of the Cluster of Differentiation 146 (CD146)
61968773|NCT04575922|EXPERIMENTAL|Nivolumab+Ipilimumab+Radiation Therapy (RT)|"Study cycles are 6 weeks long, participants will receive:~Cycle 1: Nivolumab every 2 weeks during cycle, Ipilimumab 1x on Day 1 of cycle, and Radiation Therapy every other weekday or 2 days for a total of 3 treatments during week 1 of Cycle 1 only.~Cycles 2-4: Nivolumab every 2 weeks during each cycle, Ipilimumab 1x on Day 1 of each cycle~Cycles 5-Disease Progression: Nivolumab every 2 weeks during each cycle"
61968774|NCT02059486|EXPERIMENTAL|Teen Choice|The curriculum provides comprehensive sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress. The curriculum can be delivered in different formats that range in length from 6 to 12 weeks.
61968775|NCT02059486|NO_INTERVENTION|Control|Business as usual school health curriuclum
61968776|NCT01995825|EXPERIMENTAL|Brand lamotrigine then Generic lamotrigine|Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.
61968777|NCT01995825|EXPERIMENTAL|Generic lamotrigine then Brand lamotrigine|Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.
61968778|NCT04465331||patients with knee arthrosis|Painful Knee Osteoarthritis with presence of osteophytes on radiography
61968779|NCT00487773|ACTIVE_COMPARATOR|1|budesonide
62145228|NCT05606900|EXPERIMENTAL|Experiment group|Twenty volunteer patients between the ages of 18-65 who applied to the addiction polyclinic and were diagnosed with alcohol use disorder (AUD) constitute the sample of the experimental group. In addition to the standard alcohol addiction treatment (TAU) applied in the addiction polyclinic, the patients in the experimental group will be given addiction-focused eye movements, desensitization and reprocessing (AF-EMDR) psychotherapy. AF-EMDR consists of 3 sessions, with a total duration of 3 weeks. Each session will last between 1 and 1 and a half hours, depending on individual differences. Psychotherapy sessions will be conducted as face-to-face and individual sessions. TAU includes the medical treatment for AUD and motivational interviews if necessary, administered by the psychiatrist in the addiction polyclinic, where the research is conducted. Structured psychotherapy is not used in TAU practice.
62351237|NCT03334474||aged|65-85 years old
62351238|NCT05491044|EXPERIMENTAL|orelabrutinib|CLL/SLL patients who are slowly responding to ibrutinib are switched to orelabrutinib.
62351239|NCT03615118|EXPERIMENTAL|Intervention|Patients randomized to the intervention group will receive the AniMóvil intervention, including: the Sentirse Mejor manual that patients can refer to for information about CBT and skill practice, weekly IVR depression symptom assessments and psychoeducational messages, daily SMS mood monitoring and CBT reinforcement messages, and CHW telephone CBT sessions in the event of elevated PHQ-9 scores during the study. CHWs will use information from patients' IVR/SMS monitoring to support intervention-group patients' depression self-management under close supervision from their mental health specialist supervisor. Intervention patients will be part of a 'stepped' intervention based on the severity of their depression upon entry into the program and assessment throughout the intervention.
62539359|NCT02187692|NO_INTERVENTION|TAU|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
61968780|NCT00487773|ACTIVE_COMPARATOR|2|D3 vitamin
61968781|NCT00487773|ACTIVE_COMPARATOR|3|montelukast sodium
61968782|NCT00487773|ACTIVE_COMPARATOR|4|salbutamol
61968783|NCT04082312||Group 1|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + with KDIGO stage 3 AKI
61968784|NCT04082312||Group 2|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + without KDIGO stage 3 AKI and alive at D10
61968785|NCT04082312||Group 3|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + died before D10 without KDIGO stage 3 AKI
61968786|NCT02311582|EXPERIMENTAL|Phase I: MK-3475 + MLA|-In the phase I portion of this study, MK-3475 will be given every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.
61976219|NCT00662610|EXPERIMENTAL|naproxcinod 375 mg - 750 mg -1125 mg bid|dose escalating
61976220|NCT00662610|ACTIVE_COMPARATOR|naproxen 250 mg -500 mg -750 mg bid|dose escalating
61968787|NCT02311582|EXPERIMENTAL|Phase II: MK-3475 Only (Arm B)|"* In the phase II portion of this study, MK-3475 will be given every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no debulking)~* The phase II dose was determined during the Phase I portion of the study. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~* Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~* For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will only be performed when clinically warranted."
61968788|NCT02311582|EXPERIMENTAL|Phase II: MK-3475 + MLA (Arm A)|"* In the phase II portion of this study, MK-3475 will be given every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no debulking).~* The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~* Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~  --For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~* MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
62509666|NCT04061577|EXPERIMENTAL|Stimulation arm|"Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers:~Tier 1 - 1 mA, and Tier 2- 2 mA: Consist of a single stimulation cycle (20min) after the endovascular procedure (EVT) in patients with TICI\<2c,3 and negative immediate post-EVT CT scan for definitive evidence of ICH.~Tier 3 - 1 mA and Tier 4- 2mA consist of 2 treatment cycles after the EVT in patients with TICI\<2c and 3, and negative immediate post-EVT CT scan for definitive evidence of ICH.~Tier 5 - 1 mA and tier 6- 2 mA consist of 3 treatment cycles. The first cycle will be up to 20 min cycle, after initial imaging and prior to arterial puncture, the second and third cycles after EVT in patients with TICI\<2c and 3 and negative immediate post-EVT CT scan for definitive evidence of ICH."
62509667|NCT04061577|SHAM_COMPARATOR|Sham arm|Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without delivery of electrical stimulation.
62509668|NCT06216860|EXPERIMENTAL|Interventional group / Laughter yoga|"The data of the pre-intervention study will be recorded with Personal Information Form, Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory.~The application will be done for 8 weeks, 1 day a week. Post-intervention data will be collected with Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory and Post Laughter Yoga Evaluation Form."
61968789|NCT02311582|EXPERIMENTAL|Phase II (after amendment #12): MK-3475 + MLA|"* After amendment 12, all patients will be enrolled in this arm~* MK-3475 will be given every 3 weeks no more than 1 week after MLA~* The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~* Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~* For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~* MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
61968790|NCT05493527|EXPERIMENTAL|noninvasive high frequency oscillatory ventilation (NHFOV)|After documenting parental consent, the ventilated infants eligible for extubation were randomly assigned to NHFOV as post extubation noninvasive respiratory support
61968791|NCT05493527|ACTIVE_COMPARATOR|noninvasive positive pressure ventilation (NIPPV)|After documenting parental consent, the ventilated infants eligible for extubation were randomly assigned to NIPPV as post extubation noninvasive respiratory support
61968792|NCT04942691|NO_INTERVENTION|non-exercise group (control group)|The control group not performed physical activity for a total of 20-weeks.
61968793|NCT04942691|EXPERIMENTAL|exercise group|The exercise group performed SuperJump® training that will be performed for three times a week, each session lasting 60 minutes for a total of 20-weeks.
61968794|NCT06249191|EXPERIMENTAL|Treatment (Mosunetuzumab and EPOCH)|Patients receive mosunetuzumab IV, over 2-4 hours, on day 1, 8 and 15 of cycle 1 and day 1 of subsequent cycles. Patients receive etoposide IV, doxorubicin IV, and vincristine IV on days 1-4, cyclophosphamide IV, over 2 hours, on day 5 and prednisone PO BID on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles. Patients undergo bone marrow aspiration and biopsy, tumor biopsy and may undergo echocardiography or MUGA at screening and PET scan, CT scan or MRI and blood sample collection throughout the study.
62351240|NCT03615118|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced usual care patients will receive usual care, including the Sentirse Mejor manual developed by the research team in conjunction with local Ministries of Mental Health and tailored by the study team, emphasizing CBT principles, and daily SMS messages asking participants to report their mood on a 1 to 9 scale. Enhanced usual care group patients who report mood scores of 1 or 2 (worst scores) for at least 3 days per week and 3 consecutive weeks will be called by the Community health worker and referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression. Enhanced usual care patients will be part of a 'stepped' program based on the severity of their depression upon entry into the program and assessment throughout the intervention.
62351241|NCT04270487|EXPERIMENTAL|IBS diet|The simple IBS diet is a diet based on the Low FODMAPs diet and the NICE (National Institute of Health and Care Excellence) IBS diet. Patients will be aid to follow the diet with a mobile app.
62351242|NCT04270487|ACTIVE_COMPARATOR|Otilonium bromide|Otilonium bromide is a a frequently used musculotropic spasmolytic. The dosis used will be 40 mg t.i.d.
62351243|NCT04818528|EXPERIMENTAL|Constraint Induced Movement Therapy and Routine Physical Therapy|Patients received constrained induced movement therapy and routine physical therapy for up to 6 hrs/day, 5 days/week for 4 weeks.
62351244|NCT04818528|ACTIVE_COMPARATOR|Routine Physical Therapy|Patients received routine physical therapy for 5 days/week for 4 weeks.
62351245|NCT03165942|EXPERIMENTAL|Alcoholic Beverage|Participants will complete an MRI and oral alcohol session.
61968795|NCT00241813|ACTIVE_COMPARATOR|Health Education Control Program (CTL)|Health Education Control Program (CTL)
62707258|NCT02051192|ACTIVE_COMPARATOR|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
61968796|NCT00241813|EXPERIMENTAL|Mindfulness Meditation|Mindfulness Meditation (MM) Program
61968797|NCT00241813|EXPERIMENTAL|Lifeskills|Lifeskills Program (LP)
61968798|NCT00241813|EXPERIMENTAL|MM plus LP|Mindfulness Meditation (MM) Program plus Lifeskills Program (LP)
61968799|NCT03782272|EXPERIMENTAL|AA-ORS|Those receiving enterade oral re-hydration solution with amino acids
61968800|NCT03782272|PLACEBO_COMPARATOR|Placebo|Those receiving placebo solution without amino acids or rehydration salts
61968801|NCT05135897||Patients, depression, ECT|Patients in major depressive episode undergoing ECT
61968802|NCT05135897||Patients, depression, TMS|Patients in major depressive episode undergoing TMS
61968803|NCT05135897||Healthy|Healthy controls who do not receive ECT nor TMS but otherwise the same assessments.
61968804|NCT01366521|EXPERIMENTAL|Mepolizumab 250 mg subcutaneous (SC)|250 mg subcutaneous (SC)
61968805|NCT01366521|EXPERIMENTAL|Mepolizumab 125 mg subcutaneous (SC)|125 mg subcutaneous (SC)
61968806|NCT01366521|EXPERIMENTAL|Mepolizumab 12.5 mg subcutaneous (SC)|12.5 mg subcutaneous (SC)
61968807|NCT01366521|EXPERIMENTAL|Mepolizimab 75 mg intravenously (I.V.)|75 mg intravenously (I.V.)
62351246|NCT03165942|PLACEBO_COMPARATOR|Non-Alcoholic Beverage|Participants will complete an MRI and oral non-alcoholic session.
62351247|NCT01025687|EXPERIMENTAL|glucose beverage|
62509669|NCT06216860|NO_INTERVENTION|Control group|"The control group did not take part in the laughter yoga program. As a pre-test, the data of the study will be recorded with Personal Information Form, Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory. As the post-test, 8 weeks after the pre-test, the data of the study will be collected with the Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory."
62707259|NCT01055028|EXPERIMENTAL|Regimen A / Treatment 1|"Participants were to receive paclitaxel 200 mg/m² intravenously over 3 hours every 21 days followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
61968808|NCT03766555|EXPERIMENTAL|Microwave Ablation|Microwave ablation (MWA) will be performed in patients randomized to this arm.
61968809|NCT03766555|ACTIVE_COMPARATOR|Liver Resection|Liver resection will be performed in patients randomized to this arm.
61968810|NCT01709890||Airway catheter during sedation|
61968811|NCT04876274|EXPERIMENTAL|Intervention group|Patients in the intervention group received Taipei Medical University (TMU) line-oriented video education and care in addition to usual care
61968812|NCT04876274|NO_INTERVENTION|Control group|Patients in the control group received usual care
61968813|NCT02503553|EXPERIMENTAL|Decision aid|"Option grid for cerebral aneurysm treatment~Patients will receive an option grid during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded."
61968814|NCT02503553|PLACEBO_COMPARATOR|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
61968815|NCT05798650|EXPERIMENTAL|instagram user images of attractive smiles|the experimental group had 60 instagram user images of attractive smiles. The first author shortlisted 100 pictures with a hashtag #smile from Instagram. The photographs were of people with full attractive smile and well aligned teeth. These pictures were chosen from public profiles on Instagram. The photographs had an equal proportion of celebrity and non-celebrity faces and the age group was also similar to the people participating in the study (18-35 years).
61968816|NCT05798650|PLACEBO_COMPARATOR|instagram images of nature|the control group had 60 appearance- neutral Instagram images of nature. The neutral images for the control group were chosen with a hashtag nature on Instagram. These images only had nature and no people in them.
61968817|NCT00524784|EXPERIMENTAL|A|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses
61968818|NCT06074211|EXPERIMENTAL|Safe Sleep Education|The intervention group will receive safe sleep education via the Safety in Seconds mobile app.
62351248|NCT01025687|EXPERIMENTAL|noncaloric beverage with TV|
61968819|NCT06074211|ACTIVE_COMPARATOR|Car seat safety|The attention matched control group will receive car seat safety education via the Safety in Seconds mobile app.
61968820|NCT01085591|EXPERIMENTAL|CB-183,315, 125 mg|125 milligrams (mg) CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
62351249|NCT01025687|EXPERIMENTAL|glucose beverage with TV|
61968821|NCT01085591|EXPERIMENTAL|CB-183,315, 250 mg|250 mg CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
61968822|NCT01085591|ACTIVE_COMPARATOR|Vancomycin, 125 mg|125 mg vancomycin administered orally four times a day for 10 days.
61968823|NCT02248155||RLS patients|
62351250|NCT01025687|EXPERIMENTAL|noncaloric beverage|
62351251|NCT01220986||Right hepatectomy|Intervals from inflow division.
62351252|NCT02472795|EXPERIMENTAL|Cenerimod 0.5 mg (Part A)|Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
62351253|NCT02472795|EXPERIMENTAL|Cenerimod 1 mg (Part A)|Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
62351254|NCT02472795|EXPERIMENTAL|Cenerimod 2 mg (Part A)|Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
61968824|NCT02883153|EXPERIMENTAL|Zirconium-89 girentuximab PET/CT|A Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq).
61968825|NCT05812898|SHAM_COMPARATOR|control group|The control group received selective exercises therapy in the form of strengthening and stretching exercises for selective muscles of hip and knee
61968826|NCT05812898|EXPERIMENTAL|study group|The study group received selective exercises therapy in the form of strengthening and stretching exercises for selective muscles of hip and knee, plus myofascial release technique of the deep front line.
61968827|NCT02141243|EXPERIMENTAL|Group A|"All participants will receive both the lingual frenotomy and sham procedure. Group A infants will receive lingual frenotomy for intervention #1 and a sham procedure for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (\~5 minutes).~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and a laser, (iLaseTM 940 ± 15 nm) or scissors, will be used to release its attachment to the level of the periosteum."
61968828|NCT02141243|EXPERIMENTAL|Group B|"All participating infants will receive both the lingual frenotomy and sham procedure. Group B infants will receive the sham procedure for intervention #1 and a lingual frenotomy for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (\~5 minutes).~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and an iLaseTM 940 ± 15 nm laser used to release its attachment to the level of the periosteum."
61968829|NCT01339429|EXPERIMENTAL|simplified Negative Pressure Wound Therapy|The simplified Negative Pressure device will be placed on subjects selected from the hospital ward and meeting the eligibility criteria.
61968830|NCT04661085||Patients with a suspected infection|Acutely admitted patients from the emergency department across 3 sites who have a suspected infection.
61968831|NCT02067169||CMV infection|allograft recipient with active CMV infection
61968832|NCT05236010|ACTIVE_COMPARATOR|Active rTMS with Attention Process Training|Subjects in this arm will receive active rTMS and then complete the assigned Attention Process Training battery immediately following active rTMS.
61968833|NCT05236010|SHAM_COMPARATOR|Sham rTMS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training immediately following sham rTMS.
61968834|NCT05236010|ACTIVE_COMPARATOR|Active HD-tDCS with Attention Process Training|Subjects in this arm will receive active HD-tDCS and complete the assigned Attention Process Training battery during active HD-tDCS.
61968835|NCT05236010|SHAM_COMPARATOR|Sham HD-tDCS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training during sham HD-tDCS.
61968836|NCT04506021||Bicarbonate Ringer's Solution|"According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution.~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
61968837|NCT04506021||Other Crystalloid|"According to the choices of patients' immediate family members, patients will be divided into Other Crystalloid.~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
61968838|NCT01108302|NO_INTERVENTION|PPH Treatment only|Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject
61968839|NCT01108302|EXPERIMENTAL|Oxytocin in Uniject|Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery
62145229|NCT05606900|NO_INTERVENTION|Control group|The sample of the control group consists of 20 volunteer patients between the ages of 18-65 who applied to the addiction polyclinic and were diagnosed with alcohol use disorder (AUD). Patients in the control group will be given standard treatment of alcohol use disorder (TAU). The duration and dosage of TAU are regulated by the psychiatrist in the polyclinic specific to the patient. During the duration of AF-EMDR to the experimental group, patients in the control group will be on the waiting list and will not receive AF-EMDR intervention. If AF-EMDR intervention is concluded as beneficial for the patients in the experimental group after the analysis of the final measurements (1-month follow-up measurements), the same AF-EMDR intervention will be applied to the patients in the control group.
62145230|NCT01240590|EXPERIMENTAL|Ph I Level -1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 8 mg/m(2) Crolibulin
62145231|NCT01240590|ACTIVE_COMPARATOR|Ph I Level 1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
62145232|NCT01240590|ACTIVE_COMPARATOR|Ph I Level 2: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
62145233|NCT01240590|ACTIVE_COMPARATOR|Ph II Level 3: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 20 mg/m(2) Crolibulin
62145234|NCT01240590|ACTIVE_COMPARATOR|Ph II Level 4: Cisplatin|100mg/m(2) Cisplatin
62145235|NCT00846222|EXPERIMENTAL|Mild theraputic hypothermia|
62351255|NCT02472795|EXPERIMENTAL|Cenerimod 4 mg (Part B)|Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
62351256|NCT02472795|PLACEBO_COMPARATOR|Matching placebo (Part A and B)|Capsules of matching placebo taken orally once daily for 12 weeks.
62509670|NCT06616142|ACTIVE_COMPARATOR|Aldosterone producing adenoma|Patients diagnosed with an aldosterone producing adenoma
62351257|NCT03805555|ACTIVE_COMPARATOR|Radiofrequency ablation|Best radiofrequency ablation
62351258|NCT03805555|EXPERIMENTAL|Cryoballoon ablation|Best cryoballoon ablation
62351259|NCT03618342||PCOS|PCOS women
62351260|NCT03618342||Healthy controls|Healthy control women
62351261|NCT02128594|EXPERIMENTAL|Standard of Care|Standard of care
62509671|NCT06616142|ACTIVE_COMPARATOR|Bilateral adrenal hyperplasia|Patients diagnosed with bilateral adrenal hyperplasia
61968840|NCT02657174|EXPERIMENTAL|G1- experimental active comparator group|G1 - (Experimental) 40 third molars surgeries will be performed in a conventional manner. At the end of surgery low level laser in auricular acupuncture points will be applied for prevention of inflammation and pain in a split-mouth design.
61968841|NCT02657174|PLACEBO_COMPARATOR|G2- control group|G2 - (Control) 40 third molars surgeries will be performed in the conventional manner, identically to the G1. At the end of surgery low level laser device off in auricular acupuncture points will be applied. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1, with split-mouth design.
61968842|NCT01655615|EXPERIMENTAL|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
61968843|NCT03923855|EXPERIMENTAL|BTL-899 Therapy Arm|
61968844|NCT03938532|ACTIVE_COMPARATOR|Control Arm|Infant will receive pressure regulated breaths, 40-60 breaths/min, PiP of 20-24cm of water as recommended by 2017 Neonatal Resuscitation Program (NRP) guidelines. Reading of the TV will be blinded from the providers as in routine clinical situations
61968845|NCT03938532|EXPERIMENTAL|Intervention Arm|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
61968846|NCT03210168|EXPERIMENTAL|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
61968847|NCT02127879|EXPERIMENTAL|Transcranial Magnetic Stimulation|Active Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
62509672|NCT03923231||Children <5 years|Children under the age of 5 years who are receiving atazanavir as part of clinical care
61968848|NCT02127879|SHAM_COMPARATOR|Transcranial Magnetic Stimulation with sham coil|Sham coil Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
61968849|NCT05884723|EXPERIMENTAL|Ketogenic Diet Arm|Participants in this group will be counselled by a registered dietician and then undergo a 4-week preoperative well formulated ketogenic diet. They will record all nutritional uptake during the diet using an app called Cronometer and provide weekly summary reports to the study team.
61968850|NCT05884723|NO_INTERVENTION|Control Arm|Participants in this group will be counselled by a registered dietician and then undergo a 4-week standard of care diet, as recommended by Canada's Food Guide. They will record all nutritional uptake during the diet using an app called Cronometer and provide weekly summary reports to the study team.
61968851|NCT02393768||patients|patients with documented atherosclerosis on a CCTA
61968852|NCT02393768||controls|patients without atherosclerosis on a CCTA
61968853|NCT01353053||Tacrolimus, Everolimus|Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.
61968854|NCT03151837|EXPERIMENTAL|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
61968855|NCT03151837|PLACEBO_COMPARATOR|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
62509673|NCT03923231||Children 6-11|Children aged 6-11 years who are receiving atazanavir as part of clinical care
61968856|NCT01593215|ACTIVE_COMPARATOR|Placebo first then yohimbine|placebo first, then yohimbine
61968857|NCT01593215|ACTIVE_COMPARATOR|Yohimbine first then placebo|Yohimbine first then placebo
61968858|NCT00300937|EXPERIMENTAL|A|
62509674|NCT03923231||Adolescents 12-17|Adolescents aged 12-17 years who are receiving atazanavir as part of clinical care
61968859|NCT02536040|EXPERIMENTAL|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
61968860|NCT02536040|PLACEBO_COMPARATOR|Water|Topical application of fluoride free water to active cavity
61968861|NCT03630172|EXPERIMENTAL|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
61968862|NCT03630172|SHAM_COMPARATOR|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
61968863|NCT05292846|EXPERIMENTAL|Uninterruped direct-acting oral anticoagulation|Uninterrupted direct-acting oral anticoagulation in patients undergoing trans-radial percutaneous coronary procedures
62351262|NCT01244958|ACTIVE_COMPARATOR|Rituximab 1000 mg|Administration of 1000 mg Rituximab in Part I, followed by either re-treatment with 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
62351263|NCT01244958|PLACEBO_COMPARATOR|Placebo|Administration of Placebo in Part I followed by re-treatment with either 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
62509675|NCT03923231||Pregnant women|Women who are at least 20 weeks gestation, who are receiving atazanavir as part of clinical care
62509676|NCT03923231||BMI < 18.5|Adults with a BMI of \<18.5 kg/m2 who are receiving atazanavir as part of clinical care
62509677|NCT03923231||BMI >30|Adults with a BMI of \>30 kg/m2 who are receiving atazanavir as part of clinical care
62509678|NCT01021631|ACTIVE_COMPARATOR|Liberal Transfusion Strategy|Liberal Group - transfusion when hematocrit is lower than 30%
62509679|NCT01021631|ACTIVE_COMPARATOR|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hematocrit is lower than 24%
62509680|NCT00810173|EXPERIMENTAL|1|This group received call phone support to incentive the increase of the number of steps during 6 weeks
62509681|NCT00810173|NO_INTERVENTION|2|This group just received a pedometer to register the number of steps for 6 weeks but this group don´t received a phone call.
61968864|NCT04880525|EXPERIMENTAL|Study Group|The study group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). In addition to pilates, the women in the SG followed a personalized weight loss diet. In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
62509682|NCT03167502|ACTIVE_COMPARATOR|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
61968865|NCT04880525|NO_INTERVENTION|Control Group|The control group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). Individuals in the CG received no dietary or nutritional intervention. On any diet, the status of women in the CG was frequently questioned.
61968866|NCT05944874|EXPERIMENTAL|HD- TDCS (inhibition)|Patients will perform a session (inhibition) of HD-TDCS of twenty minutes with intensity of 3 milliamps in the left temporal cortex. Before and after each session, patients will perform the six-minute walk test. Heart rate variability (HRV) will be evaluated throughout the protocol through Holter (3-channel). At the end, the perception of exertion and the level of dyspnea of the patient, distance covered and blood pressure will be evaluated.
61968867|NCT05944874|EXPERIMENTAL|HD- TDCS (stimulation)|Patients will perform a session (stimulation) of HD-TDCS of twenty minutes with intensity of 3 milliamps in the left temporal cortex. Before and after each session, patients will perform the six-minute walk test. Heart rate variability (HRV) will be evaluated throughout the protocol through Holter (3-channel). At the end, the perception of exertion and the level of dyspnea of the patient, distance covered and blood pressure will be evaluated.
62509683|NCT03167502|EXPERIMENTAL|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
62509684|NCT05195177|EXPERIMENTAL|Study group|
62509685|NCT06214754|ACTIVE_COMPARATOR|Intravascular high-pressure cutting balloon catheter|
62509686|NCT06214754|ACTIVE_COMPARATOR|Boston Scientific Corporation|
62509687|NCT06617780||Patients with a distal radius fracture|Dorsally displaced distal radius fractures reduced to an acceptable position in patients aged 18-65 years.
62509688|NCT05545618||CCTA imaging with 18F-FDG-PET/CT assessment|Group of patients with 18F-FDG-PET/CT imaging and Coronary Computed Tomographic Angiography within 90 days
62509689|NCT06365684|EXPERIMENTAL|Potassium enriched diet|Patients with chronic kidney disease stage 3b to 4 will be treated for 6 weeks with a potassium enriched diet (adding +40mmol/day in the form of fruits/vegetables/nuts)
62509690|NCT06365684|NO_INTERVENTION|Regular diet|Patients with chronic kidney disease stage 3b to 4 will followed for 6 weeks, during their regular diet
62509691|NCT03092882|EXPERIMENTAL|Intervention|Diabetes Self-Management Program
62509692|NCT03092882|NO_INTERVENTION|Control|
61968868|NCT05944874|EXPERIMENTAL|HD- TDCS (shan)|Patients will perform a twenty-minute session (SHAN) of HD-TDCS with an intensity of 3 milliamps in the left temporal cortex. Before and after each session, patients will perform the six-minute walk test. Heart rate variability (HRV) will be evaluated throughout the protocol through Holter (3-channel). At the end, the perception of exertion and the level of dyspnea of the patient, distance covered and blood pressure will be evaluated.
61968869|NCT03582124|EXPERIMENTAL|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
61968870|NCT00878033||1|Diabetic Dialysis Patients
61968871|NCT00878033||2|Non-Diabetic Dialysis Patients
62351264|NCT01419015|EXPERIMENTAL|TAVI-TF Approach|Transcatheter aortic valve implantation and transfemoral approach. SAPIEN XT NovaFlex delivery system will be used.
62509693|NCT02104817|EXPERIMENTAL|EPANOVA|Epanova + statin, once daily
62509694|NCT02104817|ACTIVE_COMPARATOR|Corn oil|Corn oil + Statin
62509695|NCT05184699|ACTIVE_COMPARATOR|Food supplement Endocalyx|Thirty patients with psoriatic disease will randomized to receive 4 capsules a day of the food supplement Endocalyx for 4 months
62509696|NCT05184699|PLACEBO_COMPARATOR|Placebo|Thirty patients with psoriatic disease will randomized to receive 4 capsules a day of the placebo for 4 months
62509697|NCT02278458|EXPERIMENTAL|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
61968872|NCT00878033||3|Healthy Controls
61968873|NCT06066554|ACTIVE_COMPARATOR|14 early mycosis fungoids patients|Puva (psoralin and uva) Measure nlrp1 and nlrp3 and il18
61968874|NCT06066554|ACTIVE_COMPARATOR|8 mycosis fungoids patients|Puva (psoralin and uva) and methotrexate Measure nlrp1 and nlrp3 and il18
62509698|NCT00988208|EXPERIMENTAL|Docetaxel, Prednisone, Lenalidomide (DPL)|25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
62707260|NCT01055028|EXPERIMENTAL|Regimen B / Treatment 2|"Patients were to receive paclitaxel 90 mg/m² weekly x 3 of a 28-day cycle followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
62707261|NCT05458739||Treatment Group|The removed specimen (as part of BCS) is scanned with the ClearCoast MR System.
62509699|NCT00988208|EXPERIMENTAL|Docetaxel and Prednisone (DP)|Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
62509700|NCT02874014|EXPERIMENTAL|Hypofractionation Proton beam therapy|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
61968875|NCT06066554|ACTIVE_COMPARATOR|Eight mycosis fungoids patients|Puva (psoralin and uva)and retinoids (acetritin) Measure nlrp1 and nlrp3 and il18
61968876|NCT06066554|NO_INTERVENTION|Controls|Measure nlrp1 and nlrp3 and il18
61968877|NCT05673512|ACTIVE_COMPARATOR|IAH0968+ CAPEOX|IAH0968+ CAPEOX in HER2 positive metastatic colorectal cancer patient
61968878|NCT05673512|ACTIVE_COMPARATOR|CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
61968879|NCT02790398|EXPERIMENTAL|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol.
61968880|NCT02790398|ACTIVE_COMPARATOR|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol that includes a component aimed at the regulation of PA.
62509701|NCT01220609|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62509702|NCT04373629|EXPERIMENTAL|attention modulation|
62707262|NCT05458739||Historical Group|Historical data of patients undergone BCS, under the same eligibility criteria and performed by the same study surgeons, thus minimizing inter-groups and inter-surgeon variability and bias, will serve as a control group for the comparison of the complete resection rate.
62707263|NCT03896633|ACTIVE_COMPARATOR|Azopt 1% ophthalmic suspension|Ophthalmic suspension
62707264|NCT03896633|EXPERIMENTAL|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
62707265|NCT05523908|EXPERIMENTAL|High-dose hypofraction Arm|Patients in this arm (High-dose hypofraction Arm) would receive high-dose fractionated radiotherapy with 60Gy/15f.
61968881|NCT01053221|EXPERIMENTAL|MPA monotherapy|Subjects will discontinue calcineurin inhibitor (cyclosporine or tacrolimus) and remain on MPA (mycophenolate mofetil or mycophenolate sodium) monotherapy
61968882|NCT01053221|ACTIVE_COMPARATOR|Control: MPA and CNI|Subjects will continue with their current immunosuppressive regimen of MPA (mycophenolate mofetil or mycophenolate sodium) and calcineurin inhibitor (cyclosporine or tacrolimus)
61968883|NCT06072170|EXPERIMENTAL|Cohort 1, 1 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
62509703|NCT04373629|EXPERIMENTAL|perceptual modulation|
62509704|NCT04373629|EXPERIMENTAL|naturalistic viewing|
62509705|NCT03764735|PLACEBO_COMPARATOR|SkQ1 Vehicle|SkQ1 (Vehicle)
61968884|NCT06072170|EXPERIMENTAL|Cohort 2, 2 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
61968885|NCT06072170|EXPERIMENTAL|Cohort 3, 4 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
61968886|NCT06072170|EXPERIMENTAL|Cohort 4, 6 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
61968887|NCT06072170|EXPERIMENTAL|Cohort 5, 8 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
62707266|NCT05523908|EXPERIMENTAL|Low-dose hypofraction Arm (Standard BED)|Patients in this arm (Low-dose hypofraction Arm) would receive high-dose fractionated radiotherapy with 48Gy/12f.
62707267|NCT05504499|EXPERIMENTAL|Single Arm|A Prospective, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain A Prospective, Observational, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
62707268|NCT03556891|EXPERIMENTAL|eCoin Tibial Nerve Stimulation|
62351265|NCT05610917|EXPERIMENTAL|case group,|Patients in case group will be treated with CBRM program
62509706|NCT03764735|ACTIVE_COMPARATOR|Low Dose - SkQ1|Low-dose ophthalmic solution
62707269|NCT02587910|PLACEBO_COMPARATOR|Non-invasive arm|Participants in this arm, who fit the inclusion criteria and have a GERD Q score of 3 or more, will be randomized to receive either Melanole, a herbal derived melanin, 300 mg, 2 capsules three times a day or placebo for 10 days.To assess the symptomatic improvement, GERD Q score will be calculated on day 0 (before administration of the product) and then on days 11 and 30 having taken the product for 10 days.
62707270|NCT02587910|PLACEBO_COMPARATOR|Invasive arm|Participants in this arm will undergo a 24-hour pH monitoring before administration of Melanole, the herbal melanin or placebo. They will then be randomized to receive either Melanole or placebo for 10 days. pH metry will be repeated between days 7 and 10 from the study product or placebo.
62707271|NCT04781491|EXPERIMENTAL|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Subjects receive a 90-minute Forest Therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
61968888|NCT06072170|PLACEBO_COMPARATOR|Placebo|A total of 2 subjects per cohort will receive an oral single dose administration of placebo
61968889|NCT02501473|EXPERIMENTAL|Part 1: Local Radiation + G100 5μg/tumor|Part 1: Local radiation and G100 \[glucopyranosyl lipid A stable emulsion, GLA-SE\] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks.
61968890|NCT02501473|EXPERIMENTAL|Part 1: Local Radiation + G100 10μg/tumor|Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
61968891|NCT02501473|EXPERIMENTAL|Part 2: Local Radiation + G100 10μg/tumor|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
62351266|NCT05610917|OTHER|control group|the control group patients will be treated routinely as usual.
62509707|NCT03764735|ACTIVE_COMPARATOR|High Dose - SkQ1|High-dose ophthalmic solution
62509708|NCT04474431|OTHER|Patients admitted in the ICU of hospital of Rouen|Patients admitted in the intensive care unit (ICU) of the teaching hospital of Rouen.
62509709|NCT05856513|EXPERIMENTAL|Child-Pugh A|8 participants with mild hepatic impairment (Child-Pugh A) will be given 600mg of ZSP1273.
62509710|NCT05856513|EXPERIMENTAL|Child-Pugh B|8 participants with moderate hepatic impairment (Child-Pugh B) will be given 600mg of ZSP1273.
62509711|NCT05856513|EXPERIMENTAL|Normal hepatic function|8 participants with normal hepatic function will be given 600mg of ZSP1273.
62509712|NCT05181800||FIRMAGON® Cohort|
62509713|NCT04973098|EXPERIMENTAL|5 dose levels each with or without lymphocyte clearance were tentatively determined.|CT0181 Cells were transfused after lymphocyte clearance with fludarabine and cyclophosphamide or without lymphocyte clearance.
62707272|NCT04781491|NO_INTERVENTION|Waiting list|Subjects don't receive any therapy but are offered the same treatment after trial is finished.
62707273|NCT00687076|EXPERIMENTAL|1|Participants will receive standard of medical care and treatment with intensive lipid modification using a statin plus Ezetimibe and Niaspan.
61968892|NCT02501473|EXPERIMENTAL|Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.
61968893|NCT02501473|EXPERIMENTAL|Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors|Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors \[injectable lymphoma mass(es) ≥ 4 cm in total size\] for up to 8 weeks.
61968894|NCT02501473|EXPERIMENTAL|Part 3: Local Radiation + G100 20μg/tumor|Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks.
61968895|NCT02501473|EXPERIMENTAL|Part 4: G100 20μg/tumor and pembrolizumab 200mg|Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.
61968896|NCT02501473|EXPERIMENTAL|Part 5: G100 + Rituximab 375mg/m^2|Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m\^2 on Day 0 and then QW for up to 3 weeks.
61968897|NCT03684395||DOACs (Direct Oral Anticoagulants)|
61968898|NCT03684395||Standard of care|
61968899|NCT06198868||Operable group|Early-stage patients with radical surgery or operable patients with neoadjuvant treatment
61968900|NCT06198868||Inoperable group|Advanced-stage patients receive non-surgery therapies.
62509714|NCT05945667|ACTIVE_COMPARATOR|Monural|3000 mg of fosfomycin trometamol per sachet
61968901|NCT01479673|NO_INTERVENTION|Control group|"Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the liberal  regimen, i.e. according to local practice."
61968902|NCT01479673|EXPERIMENTAL|Indirect Calorimetry|Study group: Indirect Calorimetry (IC) Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry measurement of Resting Energy Expenditure (REE).
61968903|NCT05894928|EXPERIMENTAL|LOXO-783 alone|Single dose of LOXO-783 administered orally.
62351267|NCT04430283|EXPERIMENTAL|FDY-5301 Low Dose (1 mg/kg)|FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.
62351268|NCT04430283|EXPERIMENTAL|FDY-5301 High Dose (2 mg/kg)|FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.
62351269|NCT04430283|PLACEBO_COMPARATOR|Placebo|"Placebo will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.~Other Names:~Saline"
62351270|NCT02063282||Clostridium difficile carriers|
62351271|NCT02063282||Clostridium difficile non carriers|
62351272|NCT02768324||sepsis with diarrhea|
62351273|NCT02768324||sepsis without diarrhea|
62351274|NCT01930929||Bariatric surgery operated patients|All patients who have operated in the Central and North Denmark Region 2006-2011
62351275|NCT01928082|EXPERIMENTAL|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
61968904|NCT05894928|EXPERIMENTAL|LOXO-783 + Cholestyramine 1 hour post dose|Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 1 hour.
61968905|NCT05894928|EXPERIMENTAL|LOXO-783 + Cholestyramine 4 hours post dose|Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 4 hours.
61968906|NCT03750799|EXPERIMENTAL|Experimental group|Whole body vibration was applied on the right lower extremity.
61968907|NCT03750799|SHAM_COMPARATOR|Sham group|Unlike the experimental group, sham vibration was applied to the control group.
61968908|NCT05967156|EXPERIMENTAL|Empagliflozin|Heart failure dialysis patients will be treated with Empagliflozin
61968909|NCT03731611|ACTIVE_COMPARATOR|Group A|umbilical cord milking will be done for preterm infants \<34 gestational age without placental insufficiency
61968910|NCT03731611|ACTIVE_COMPARATOR|Group B|umbilical cord milking will be done for preterm infant \<34 gestational age with placental insufficiency
61968911|NCT03731611|NO_INTERVENTION|Group C|Immediate cord clamping for preterm infants \<34 gestational age with placental insufficiency
61968912|NCT05812612||COVID-19 infection in patients with autoimmune liver disease|To study the incidence of COVID-19 infection, COVID-19, disease degree and prognosis in patients with autoimmune liver disease treated with different drugs, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
61968913|NCT05615012|EXPERIMENTAL|Part 1: Rosuvastatin + BMS-986322|
61968914|NCT05615012|EXPERIMENTAL|Part 2: Metformin + BMS-986322 + Glucose|
61968915|NCT05615012|EXPERIMENTAL|Part 3: Methotrexate + BMS-986322 + Leucovorin|
61968916|NCT01087398|EXPERIMENTAL|Intervention|
61968917|NCT03508921|EXPERIMENTAL|Periprocedural Antibiotics Only|Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
62351276|NCT03994393|ACTIVE_COMPARATOR|Cohort 1|Participants with no evidence of T790M
62351277|NCT03994393|ACTIVE_COMPARATOR|Cohort 2|Participants with evidence of T790M
62351278|NCT01524237|EXPERIMENTAL|10 mg LY2140023 + ketamine|Single oral dose of 10 mg LY2140023 followed by intravenous (IV) ketamine during one of the crossover periods
62351279|NCT01524237|EXPERIMENTAL|20 mg LY2979165 + ketamine|Single oral dose of 20 mg LY2979165 followed by IV ketamine during one of the crossover periods
62351280|NCT01524237|EXPERIMENTAL|40 mg LY2140023 + ketamine|Single oral dose of 40 mg LY2140023 followed by IV ketamine during one of the crossover periods
62351281|NCT01524237|EXPERIMENTAL|60 mg LY2979165 + ketamine|Single oral dose of 60 mg LY2979165 followed by IV ketamine during one of the crossover periods
62509715|NCT05945667|EXPERIMENTAL|UroNext + Monural|3000 mg of fosfomycin trometamol per sachet 500 mg of Qcran, 2000 mg of D-mannose, 5 mcg of vitamin D3 per sachet
61968918|NCT03508921|EXPERIMENTAL|Extended Antibiotics|Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.
61968919|NCT04401189||Breast cancer patients|
61968920|NCT04401189||Healthy controls|
61968921|NCT05650216|EXPERIMENTAL|Immunotherapy combined with Chemoradiotherapy|"A:Chemotherapy: nab-paclitaxel (80mg/m2), carboplatin (AUC=2)，on day 1,8,15,22,29;~B:Immunotherapy: camrelizumab (200mg)，IV on days 5 and 26;~C:Radiotherapy: Primary lesion and adjacent lymph nodes: 41.4Gy, 1.8Gy/23f; Abscopal lymph node 2Gy, 0.5Gy/4f.~D:Ivor-Lewis or McKeown esophagectomy~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
61968922|NCT04039815|EXPERIMENTAL|ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group|"patients in study group, so called ABC (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days"
61968923|NCT04039815|PLACEBO_COMPARATOR|normal saline group|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
61968924|NCT03651921|NO_INTERVENTION|Usual care|Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).
61968925|NCT03651921|EXPERIMENTAL|Usual care and CTS-BC-CH|CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.
61968926|NCT00136656|ACTIVE_COMPARATOR|1|cefixime antibiotic treatment by oral route
61968927|NCT00136656|SHAM_COMPARATOR|2|ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days
61968928|NCT01776333|NO_INTERVENTION|usual care|
61968929|NCT01776333|EXPERIMENTAL|video arm|video decision aid intervention
61968930|NCT04097002|EXPERIMENTAL|Phase I, Part A, Cohort 1|"Single dose-escalation of ORCA-010, Dose Cohort 1: 1x10\*11 viral particles.~Single dose of ORCA-010 will be administered for the first subject only and all relevant safety data for this subject will be reviewed by the DSMB prior to enrolling additional subjects.~After the DSMB review, subjects will be enrolled in groups of three (including the first subject) and assessed for safety and Dose-Limiting Toxicity (DLT) after a single dose of ORCA-010.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
61968931|NCT04097002|EXPERIMENTAL|Phase I, Part A, Cohort 2|"Single dose-escalation of ORCA-010, Dose Cohort 2: 5x10\*11 viral particles.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
61968932|NCT04097002|EXPERIMENTAL|Phase I, Part A, Cohort 3|"Single dose-escalation of ORCA-010, Dose Cohort 3: 1.5x10\*12 viral particles.~Group of 3 subjects.~Dose will be considered as the Maximum Tolerated Dose based on safety and toxicity results from the 3 treated subjects."
61968933|NCT04097002|EXPERIMENTAL|Phase IIa, Part B, Cohort 4|"Two dose administration of ORCA-010 seperated by 2 weeks, Dose Cohort 4: The Maximum Tolerated Dose depending on Phase I/ Part A results.~Group of 12 subjects."
61968934|NCT02332278|EXPERIMENTAL|Early feeding|Early feeding (fluid diet), four hours after cesarean section.
61968935|NCT02332278|ACTIVE_COMPARATOR|Late feeding|Late feeding (fluid diet) 12 hours after cesarean section.
61968936|NCT04298892||hematologic disorder or malignancy|
61968937|NCT03740711|EXPERIMENTAL|Early LA venting|When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
61968938|NCT03740711|ACTIVE_COMPARATOR|Conventional LA venting|When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
62509716|NCT04184999|EXPERIMENTAL|Intracameral dexamethasone 9% + postoperative topical prednisolone acetate|dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively
61968939|NCT05634304|EXPERIMENTAL|The mobile app self-management (mSM) program focusing on patients' needs in OA patients|An individualized mobile app self-management (mSM) program for managing OA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their OA situations.
61968940|NCT05634304|NO_INTERVENTION|Control group for mSM program|The control group will receive with the usual care only and follow-up 6 months.
61968941|NCT00720837|EXPERIMENTAL|Laser Interstitial Thermal Therapy|Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
61968942|NCT04757064|EXPERIMENTAL|Standard Rehabilitation Group|"Standard Rehabilitation Group: will receive the standard protocol of king Hussein hospital 6 weeks post-operative which is:~Start aggressive knee flexion exercises and increase the extensor strength. Consider CPM/dynasplint if flexion \<60_ MUA contraindicated.~Examination under anesthesia can be done to assess the cause of limited knee flexion. Surgical release is indicated if knee flexion is \< 60 degrees at six months after surgery."
61968943|NCT04757064|EXPERIMENTAL|Supervised Rehabilitation Group|Supervised Rehabilitation Group: will receive supervised rehabilitation program 1 session / week for 45 minutes-1 hour.
61968944|NCT01414283|EXPERIMENTAL|Arm 1|
61968945|NCT00378196|EXPERIMENTAL|A|0.3 mg/0.05 ml dose of ranibizumab
62509717|NCT04184999|ACTIVE_COMPARATOR|postoperative topical prednisolone acetate|topical ophthalmic prednisolone acetate for 3 weeks post-operatively
61968946|NCT00378196|EXPERIMENTAL|B|0.5 mg /0.05 ml dose of ranibizumab
61968947|NCT02670083|PLACEBO_COMPARATOR|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
62351282|NCT01524237|EXPERIMENTAL|160 mg LY2140023 + ketamine|Single oral dose of 160 mg of LY2140023 followed by IV ketamine during one of the crossover periods
61968948|NCT02670083|EXPERIMENTAL|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
61968949|NCT04403971|EXPERIMENTAL|0.12% chlorhexidine|Participants will be randomized to Chlorhexidine solution group, applied twice a day by care givers.
61968950|NCT04403971|SHAM_COMPARATOR|Listerine|Participants will be randomized to Listerine solution group, applied twice a day by care givers.
61968951|NCT04403971|PLACEBO_COMPARATOR|Normal saline|Participants will be randomized to Normal saline group, applied twice a day by care givers.
61968952|NCT05914714|EXPERIMENTAL|treatment arm|
61968953|NCT00642941|EXPERIMENTAL|Cohort 1: Ewings Sarcoma Primary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
61968954|NCT00642941|EXPERIMENTAL|Cohort 2: Ewings Sarcoma Secondary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
62351283|NCT01524237|PLACEBO_COMPARATOR|Placebo capsules + ketamine|Single oral dose of placebo capsules followed by IV ketamine during one of the crossover periods
62351284|NCT01524237|PLACEBO_COMPARATOR|Placebo tablets + ketamine|Single oral dose of placebo tablets followed by IV ketamine during one of the crossover periods
62351285|NCT03213483|ACTIVE_COMPARATOR|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
62351286|NCT03213483|EXPERIMENTAL|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
62509718|NCT01687829||ILM-on group|patients were scheduled to undergo macular hole surgery without internal limiting membrane (ILM) peeling
62509719|NCT01687829||ILM-off group|patients were scheduled to undergo macular hole surgery with internal limiting membrane (ILM) peeling
62509720|NCT00003098|EXPERIMENTAL|fat reduction increased fiber|Patients are randomized to dietary fat reduction with increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
62509721|NCT00003098|EXPERIMENTAL|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
62707274|NCT00687076|ACTIVE_COMPARATOR|2|Participants will receive standard of medical care and treatment with standard lipid modifying medications plus placebo Ezetimibe and placebo Niaspan.
62707275|NCT05513963|EXPERIMENTAL|Treatment|Participants will complete a Clairity session between their regular therapy visits. The Clairity interview is between 4-11 minutes where a clinical research coordinator will ask participants questions about hope, secrets, anger, fear, and emotional pain.
62351287|NCT02305875|EXPERIMENTAL|MCN scoring|Scoring of the mcn nerve's position in the axillary sheat using MRI
62707276|NCT05513963|NO_INTERVENTION|Control|Participants will submit demographics and medical records and will only complete standard of care.
61968955|NCT00642941|EXPERIMENTAL|Cohort 3: Ewings Sarcoma Expanded Cohort|Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
61968956|NCT00642941|EXPERIMENTAL|Cohort 4: Osteosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
61968957|NCT00642941|EXPERIMENTAL|Cohort 5: Synovial Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
61968958|NCT00642941|EXPERIMENTAL|Cohort 6: Rhabdomyosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
62351288|NCT04950140|EXPERIMENTAL|Robot Assisted Laparoscopic|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
62351289|NCT04950140|ACTIVE_COMPARATOR|Conventional Laparoscopic Surgery|Conventional Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
62351290|NCT04344379|ACTIVE_COMPARATOR|Arm Title : hydroxychloroquine|
61968959|NCT00642941|EXPERIMENTAL|Cohort 7a: Alveolar Soft Part Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
61968960|NCT00642941|EXPERIMENTAL|Cohort 7b: Desmoplastic Small Round Cell Tumors.|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
61968961|NCT00642941|EXPERIMENTAL|Cohort 7c: Extraskeletal Myxoid Chondrosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
61968962|NCT00642941|EXPERIMENTAL|Cohort 7d: Clear Cell Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
61968963|NCT00642941|EXPERIMENTAL|Cohort 7e: Myxoid Liposarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
61968964|NCT00642941|EXPERIMENTAL|Cohort 8: Diagnosis Not Specified|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
61968965|NCT01442675|EXPERIMENTAL|Meningococcal vaccine Group|Participants must have received Menactra vaccine 4 to 6 years prior to enrollment
61968966|NCT02174120|EXPERIMENTAL|Group A|During maintenance of anesthesia, etomidate was give by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml to keep bispectral index between 40 to 60.
61968967|NCT02174120|EXPERIMENTAL|Group B|During maintenance of anesthesia, Propofol was give by target controlled infusion, the effect-site concentration is 2 to 4 micrograms/ml to keep bispectral index between 40 to 60.
61968968|NCT02174120|EXPERIMENTAL|Group C|During maintenance of anesthesia, etomidate will be given by target controlled infusion for 2 h first, and then propofol will be given by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml and 2 to 4 micrograms/ml, respectively. Bispectral index should be kept between 40 to 60.
61968969|NCT04161989|OTHER|Group I (omega-3 fatty acids group)|received omega 3 (Omega 3 plus, SEDICO, Egypt); once daily from 28-30 weeks till delivery. The omega 3 plus capsule contains 1000 mg Fish Oil plus 100 mg Wheat Germ Oil is a natural source of Vitamin E.
61968970|NCT04161989|OTHER|Group II (vaginal progesterone plus omega-3 group)|received vaginal progesterone (Prontogest 400 mg vaginal suppository, Marcyrl Pharmaceutical Industries, Egypt) and omega 3 once daily from 28-30 weeks till delivery.
61968971|NCT04024020||Individuals with insomnia|Men and women with chronic insomnia (\>5 years duration)
61968972|NCT04024020||Good sleepers|Men and women with a longstanding pattern of good sleep
61968973|NCT00881582|EXPERIMENTAL|Pegylated interferon alfa-2a plus ribavarin|Pegylated interferon alfa-2a plus ribavarin for 48 weeks
61968974|NCT05037591|PLACEBO_COMPARATOR|placebo A|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968975|NCT05037591|PLACEBO_COMPARATOR|placebo B|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968976|NCT05037591|PLACEBO_COMPARATOR|placebo C|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968977|NCT05037591|PLACEBO_COMPARATOR|placebo D|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968978|NCT05037591|PLACEBO_COMPARATOR|placebo E|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
62145236|NCT06417372||experimental group|"1. any gender, age 18-60 years old;~2. patients with a confirmed diagnosis of glioma (primary tumor or metastatic tumor) by imaging or biopsy;~3. patients who can tolerate the surgery by preoperative evaluation; the expected volume of tumor specimen to be resected intraoperatively is more than 1cm3;~4. subjects who voluntarily enroll in the study, sign the informed consent form, and have a good adherence to the study and cooperate with the follow-up visits;~5. patients with expected survival of not less than 12 months as judged by clinician; and 6. patients who are not in the clinical trial. The expected survival period, as judged by the clinician, is not less than 12 months."
62145237|NCT00620854|EXPERIMENTAL|rsCTA|Oral Tablet
61968979|NCT05037591|PLACEBO_COMPARATOR|placebo F|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968980|NCT05037591|PLACEBO_COMPARATOR|placebo G|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968981|NCT05037591|PLACEBO_COMPARATOR|placebo H|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
62145238|NCT00620854|EXPERIMENTAL|rsCTB|Oral Tablet
62145239|NCT00620854|ACTIVE_COMPARATOR|Fortical|Nasal Spray
62145240|NCT00524797|ACTIVE_COMPARATOR|Main|50 patients will receive Profonycia 5 gr/day PO for 7 days
62145241|NCT06148636|EXPERIMENTAL|-1 Dose Level|"This dose level is used if the starting dose level is deemed to have unacceptable toxicity.~Participants are prescribed \[212Pb\] VMT-α-NET with the total radiation dose to kidneys not to exceed 200 cGy."
62145242|NCT06148636|EXPERIMENTAL|Cohort 1|This is the starting dose level for participants. Participants are prescribed \[212Pb\] VMT-α-NET with the total radiation dose to kidneys not to exceed 350 cGy.
62351291|NCT04344379|PLACEBO_COMPARATOR|Placebo of hydroxychloroquine|
62351292|NCT04344379|ACTIVE_COMPARATOR|azythromycin|
61968982|NCT05037591|PLACEBO_COMPARATOR|placebo I|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968983|NCT05037591|PLACEBO_COMPARATOR|placebo J|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968984|NCT05037591|PLACEBO_COMPARATOR|placebo K|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968985|NCT05037591|PLACEBO_COMPARATOR|placebo L|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968986|NCT05037591|PLACEBO_COMPARATOR|placebo M|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968987|NCT05037591|PLACEBO_COMPARATOR|placebo N|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968988|NCT05037591|PLACEBO_COMPARATOR|placebo O|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968989|NCT05037591|PLACEBO_COMPARATOR|placebo P|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968990|NCT05037591|PLACEBO_COMPARATOR|placebo Q|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968991|NCT05037591|PLACEBO_COMPARATOR|placebo R|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968992|NCT05037591|PLACEBO_COMPARATOR|placebo S|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968993|NCT05037591|PLACEBO_COMPARATOR|placebo T|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
61968994|NCT05037591|EXPERIMENTAL|sea grape extract A|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61968995|NCT05037591|EXPERIMENTAL|sea grape extract B|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61968996|NCT05037591|EXPERIMENTAL|sea grape extract C|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61968997|NCT05037591|EXPERIMENTAL|sea grape extract D|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61968998|NCT05037591|EXPERIMENTAL|sea grape extract E|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61968999|NCT05037591|EXPERIMENTAL|sea grape extract F|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
62145243|NCT06148636|EXPERIMENTAL|Cohort 2|If the participants from Cohort 1 tolerate therapy, new participants are enrolled and are prescribed \[212Pb\] VMT-α-NET with the total radiation dose to kidneys not to exceed 600 cGy.
62145244|NCT06148636|EXPERIMENTAL|Cohort 3|If the participants from Cohort 2 tolerate therapy, new participants are enrolled and are prescribed \[212Pb\] VMT-α-NET with the total radiation dose to kidneys not to exceed 810 cGy.
62707277|NCT00760552|ACTIVE_COMPARATOR|Arm 1|VA patients with uncontrolled HTN.
61969000|NCT05037591|EXPERIMENTAL|sea grape extract G|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969001|NCT05037591|EXPERIMENTAL|sea grape extract H|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969002|NCT05037591|EXPERIMENTAL|sea grape extract I|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969003|NCT05037591|EXPERIMENTAL|sea grape extract J|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
62145245|NCT06148636|EXPERIMENTAL|Cohort 4|If the participants from Cohort 3 tolerate therapy, new participants are enrolled and are prescribed \[212Pb\] VMT-α-NET with the total radiation dose to kidneys not to exceed 1050 cGy.
62145246|NCT01227746||Tumor biopsies|
62351293|NCT02080156|NO_INTERVENTION|no-CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
62707278|NCT00760552|ACTIVE_COMPARATOR|Arm 2|VA patients with uncontrolled HTN.
61969004|NCT05037591|EXPERIMENTAL|sea grape extract K|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969005|NCT05037591|EXPERIMENTAL|sea grape extract L|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969006|NCT05037591|EXPERIMENTAL|sea grape extract M|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969007|NCT05037591|EXPERIMENTAL|sea grape extract N|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969008|NCT05037591|EXPERIMENTAL|sea grape extract O|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969009|NCT05037591|EXPERIMENTAL|sea grape extract P|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969010|NCT05037591|EXPERIMENTAL|sea grape extract Q|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969011|NCT05037591|EXPERIMENTAL|sea grape extract R|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969012|NCT05037591|EXPERIMENTAL|sea grape extract S|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969013|NCT05037591|EXPERIMENTAL|sea grape extract T|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
61969014|NCT02275871|EXPERIMENTAL|MRI and CESM|High risk patients will get standard of care screening MRI and study CESM on the same day.
61969015|NCT02209389||Positive OctavaPink|Following a positive OctavaPink result, an MRI is performed and any additional testing (required by the MRI).
61969016|NCT02209389||Negative OctavaPink - control|"For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and recalled for an MRI and any additional testing (required by the MRI).~MRI won't be performed to all negative OctavaPink results. Only one negative control will be assigned to each OctavaPink positive result."
61969017|NCT03145285|EXPERIMENTAL|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.~Treatment with single agent Abiraterone Acetate (AA) until progression"
61976221|NCT05800795|ACTIVE_COMPARATOR|laser group|Healing abutments have been treated by Er:YAG laser. The laser-machine (with a wavelength of 2.940 nm) was used with settings of 100 mJ/pulse (12.7 J/cm₂) and 10 Hz. The healing abutments' surface was thoroughly decontaminated by the fiber tip in a semicircular contact mode with copious water irrigation.
61969018|NCT03145285|EXPERIMENTAL|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
61969019|NCT06304753|EXPERIMENTAL|Remote Monitoring|"Patients with chronic heart failure with low ejection fraction who was hospitalized due to decompensation of their condition. Their condition should be stabilized and blood pressure and renal function (Potassium level and eGFR) should be sufficient for titration of drugs. They should also have a smartphone with internet access.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses."
61969020|NCT06304753|NO_INTERVENTION|Usual Care|"Patients with chronic heart failure with low ejection fraction who was hospitalized due to decompensation of their condition. Their condition should be stabilized and blood pressure and renal function (Potassium level and eGFR) should be sufficient for titration of drugs. They should also have a smartphone with internet access.~Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards"
61969021|NCT03668912|EXPERIMENTAL|Guided participation group|
61969022|NCT03668912|NO_INTERVENTION|Usual care group|
61969023|NCT02319746|EXPERIMENTAL|Experimental group|The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.
61969024|NCT02319746|ACTIVE_COMPARATOR|Control group|The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.
61969025|NCT01255657|EXPERIMENTAL|ABT-806 Arm|
61969026|NCT02259868|EXPERIMENTAL|Group A|randomized sequence of current low dose formulation (3 tablets) and high dose (1 tablet) BILR 355 BS 1B formulation, separated by 14-day washout
62145247|NCT02751710|EXPERIMENTAL|Whole-body FDG PET-CT alone|
62145248|NCT02751710|NO_INTERVENTION|Conventional breast cancer staging|Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen \& pelvis
62145249|NCT02183272|ACTIVE_COMPARATOR|Intranasal Ketamine|0.2 mg / kg dose of intranasal ketamine for treatment of suicidality will be given in two separate doses on the day of admission to the hospital.
62145250|NCT02183272|PLACEBO_COMPARATOR|Intranasal Saline Placebo|0.2 mg / kg dose saline intranasal will be given in two separate doses on the day of hospital admission.
62145251|NCT01885559|PLACEBO_COMPARATOR|ACE-I + placebo|Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg
62145252|NCT01885559|ACTIVE_COMPARATOR|ACE-I + ARB|Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
62145253|NCT02323945|ACTIVE_COMPARATOR|AIH/Walk|Subjects with chronic, motor-incomplete SCI receive acute intermittent hypoxia (AIH) with walking practice, then AIH with strength practice and compare their efficacy on enhancing strength and/or walking performance.
62145254|NCT02323945|ACTIVE_COMPARATOR|AIH/Strength|Subjects with chronic, motor-incomplete SCI receive AIH with strength practice, then AIH with walking practice and compare their efficacy on enhancing strength and/or walking performance.
62145255|NCT02590198||ANAES algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
62707279|NCT02429960|OTHER|Analgesia monitoring|Remifentanil is increased step-by-step according to the study protocol. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli consisting of the intracutaneous pain model and tetanic stimulation for the time period of 30 s with 80 milliampere, 50 Hz are applied. All stimulations are accompanied by the measurement of the analgesic monitoring-devices (PhysioDoloris®, SPI® and AlgiScan®). Moreover the investigators measure and inspect changes in heart rate and blood pressure as well as occurrence of defensive movements of the patients.
62707280|NCT00730327|EXPERIMENTAL|BIB®|Receives BioEnterics® Intragastric Balloon Intervention as well as diet and exercise counseling with the Behavioral Modification Intervention.
62707281|NCT00730327|OTHER|Control|Control arm receives the Behavioral modification intervention only.
61969027|NCT02259868|EXPERIMENTAL|Group B|randomized sequence of BILR 355 BS (JM) + SDS formulation low dose (2 tablets) ,BILR 355 BS (HM) + SDS formulation low dose (2 tablets), BILR 355 BS high dose 1B formulation (4 low dose tablets), separated by 14-day washout
61969028|NCT02259868|EXPERIMENTAL|Group C|randomized sequence of BILR 355 BS (JM) + SDS formulation high dose (4 tablets) , BILR 355 BS (JM) + SDS formulation mid dose (3 tablets), BILR 355 BS (HM) + SDS formulation high dose (4 tablets), separated by 14-day washout
61969029|NCT02259868|EXPERIMENTAL|Group D|randomized sequence of BILR 355 BS Suspension high dose, BILR 355 BS Suspension low dose, current low dose BILR 355 BS 1B formulation (3 tablets) separated by 14-day washout
61976222|NCT05800795|ACTIVE_COMPARATOR|plasma group|"Healing abutments have been sprayed with an atmospheric pressure plasma device (Piezobrush® PZ2)~, by using active gas, low-temperature plasma treatment under irradiation at 0.2 MPa for a total of 80 seconds at 10 mm (20 seconds per each surface)"
61976223|NCT05800795|NO_INTERVENTION|control group|Healing abutments were installed as they came from industry and received no further treatment.
61976224|NCT03502408|EXPERIMENTAL|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
62351294|NCT02080156|EXPERIMENTAL|CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
61969030|NCT04728074|EXPERIMENTAL|Intervention|"The ENtering Employment and SUstaining Work (ENESUW) program consists of 6 main topics which are; self-awareness, occupational self-awareness, taking responsibility, teamwork and labor division, problem identification and problem solving. The entire program adopts a very plain and easy to understand method of information transmission in order to facilitate lossless comprehension and strengthen the trust relationship between the therapists and the participants.~The ENESUW program took 8 weeks in total with twice weekly sessions, making up a total of 16 structured group sessions. The group format enabled the participants to learn through meaningful peer interactions and group activities which were supportive of the main learning goals (i.e. group work, labor division and taking responsibility) of the program. The twice weekly sessions were 45 minutes long in order to keep the participants attentive and active throughout the program."
61969031|NCT04728074|ACTIVE_COMPARATOR|control|The control group also consisted of individuals with ID. They received face to face, individual vocational based occupational therapy approaches, which were twice a week for 8 weeks (approximately 40-45 minutes)
61969032|NCT05695443|EXPERIMENTAL|Motivational Interviewing|Prisoners in this group are subjected to a MI-based conversation lasting up to 30 minutes aiming at improving oral health and oral health related behavior
61969033|NCT05695443|NO_INTERVENTION|Control group|Prisoners in this group do not receive the MI-based intervention
61969034|NCT00071513|EXPERIMENTAL|CAST-T/HSTS|The CAST-T/HSTS condition combined the Brief Intervention and 12 school based small group sessions which taught skills to enhance personal control (to manage depression, anger, stress), self-esteem, decision making and interpersonal communications. HSTS skills groups were held in the spring of 8th grade with 4 one-on-one booster sessions delivered to the students as 9th graders by HSTP leaders; parents also participated in 4 sessions. HSTS objectives are: 1) to increase the acquisition of coping skills competencies by teaching and practicing strategies taught; 2) to increase social support resources by building a supportive network; 3) to increase the youth's engagement in positive social activities; and 4) to motivate parents to increase their support via parent educational sessions.
62509722|NCT05103709|EXPERIMENTAL|MULTI-FORTIFIED|The product to be evaluated is bread made from wheat flour fortified according to Peruvian national standards \[Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)\] and a previtamin mix \[Vitamin A (240 ug), Vitamin b12 (0.72 ug), zinc (5.25 mg) per daily serving\]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
62509723|NCT05103709|ACTIVE_COMPARATOR|FORTIFIED|The active comparator is bread fortified according to Peruvian national standards \[Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)\]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
62707282|NCT00738127|EXPERIMENTAL|1|Group I (treatment with our technique) Eighteen patients (18 wrists) were available for long-term follow-up at an average of 47.8 months after surgery. There were 11 men and seven women. Their mean age at the time of surgery was 35.4 years (range, 22 to 56 years). The dominant hand was involved in 12 patients and the nondominant hand, in six.
62707283|NCT00738127|EXPERIMENTAL|2|Group II (treatment with Inoue et al.'s technique) Fifteen patients (15 wrists) were evaluated at an average of 51 months. Nine patients were men and 6 were women. The mean age of the group at the time of surgery was 37.5 years (range, 24 to 58 years). The dominant hand was involved in 10 and nondominant hand, in seven.
62707284|NCT02733757|NO_INTERVENTION|Sub-Tenon's group control|2% Lidocaine without epinephrine
62707285|NCT02733757|EXPERIMENTAL|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
61969035|NCT00071513|ACTIVE_COMPARATOR|Brief Intervention|Brief Intervention: After each youth and parent completed baseline questionnaires the youth participated in a 1 on 1 standardized clinical follow-up with a trained clinician (blind to study condition) to review areas of concern, based on questionnaire responses including stressors at school, home, and with peers, level of support available and how to access support. The teen and clinician then planned a feedback call to parents, allowing teens to shape requests for support from parents as well as understand exactly what information would be shared with parents. Feedback call to parents reviewed concerns and made recommendations for services as needed. A similar procedure was followed after each assessment for all participants who indicated a risk of clinical depression or self-harm.
61969036|NCT03090113|EXPERIMENTAL|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
61969037|NCT03090113|PLACEBO_COMPARATOR|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
61969038|NCT02156596|ACTIVE_COMPARATOR|Intravenous NSAI|patients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
61969039|NCT02156596|EXPERIMENTAL|Nebulised Morphine|patients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
61969040|NCT01543698|EXPERIMENTAL|dual combination|LGX818 QD and MEK162 BID
61969041|NCT01543698|EXPERIMENTAL|triple combination|LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.
62707286|NCT02733757|NO_INTERVENTION|Peribulbar group control|2% Lidocaine without epinephrine
61969042|NCT01184794|PLACEBO_COMPARATOR|Saline|Placebo solution
61969043|NCT01184794|EXPERIMENTAL|levobupivacaine, analgesia|Active drug
61969044|NCT00603889|EXPERIMENTAL|Na-ASP-2 Hookworm Antigen Skin Test|All participants will have the same number of concentrations of the Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
61969045|NCT01476371|EXPERIMENTAL|Mindfulness-based group treatment|8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
61969046|NCT01476371|NO_INTERVENTION|Treatment as usual|Treatment as usual (including individual CBT and medication)
61969047|NCT01133483|EXPERIMENTAL|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
62509724|NCT05103709|NO_INTERVENTION|CONTROL|The control group will be followed for 120 days. No product will be provided.
62509725|NCT02674386|OTHER|Cohort 1|long-term observational study of subjects from tanezumab parent study
62707287|NCT02733757|EXPERIMENTAL|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
62707288|NCT02972307||caregiver|dyad of caregiver and the wheelchair user to whom they provide care
61969048|NCT01133483|ACTIVE_COMPARATOR|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
61969049|NCT01648101|EXPERIMENTAL|Retigabine 900mg|900mg total daily dose
61969050|NCT01648101|EXPERIMENTAL|Retigabine 600mg|600mg total daily dose
61969051|NCT01648101|PLACEBO_COMPARATOR|Placebo|Placebo
61969052|NCT02823301|EXPERIMENTAL|VAMOS group|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
61969053|NCT02823301|NO_INTERVENTION|Control group|Group that will not receive the VAMOS program as intervention.
61969054|NCT02480023|EXPERIMENTAL|healthcare|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
62351295|NCT02021825|OTHER|MITO, annual relapse rate, safety|For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
62351296|NCT00373490|EXPERIMENTAL|Vorinostat 600 mg|600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
62351297|NCT00373490|EXPERIMENTAL|Vorinostat 400 mg|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
62351298|NCT06175442||Nasogastric tube only (I)|Nasogastric intubation only will be the only method of intestinal decompression both intra- and postoperatively.
62351299|NCT06175442||Short nasointestinal tube (IIA)|Intraoperative intestinal decompression will be performed by placing the tube behind the ligament of Treitz and expressing the contents in the proximal direction or by total nasointestinal intubation with subsequent intraopertional tube withdrawal. Postoperative decompression will consist of the tube behind the ligament of Treitz.
62351300|NCT06175442||Long nasointestinal tube intraoperative (IIB)|Total intraoperative intubation of the small intestine followed by replacement with a nasogastric tube.
62351301|NCT06175442||Long nasointestinal tube postoperative (IIC)|Total intraoperative intubation of the small intestine with a long tube, which will persist in the postoperative period
62351302|NCT04261452|OTHER|COPD|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
62351303|NCT04261452|OTHER|Overlap|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
62351304|NCT03801356|OTHER|Selective Nerve Root Block|Patient will receive a Selective Nerve Root Block injection at the target level prior to surgical intervention.
62351305|NCT03396978|EXPERIMENTAL|GnRHag|Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.
62351306|NCT03607474||Couple (Patients and caregivers)|"Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.~Questionnaires of life quality for patients Questionnaires of life quality for caregivers"
62351307|NCT01989754|EXPERIMENTAL|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
62351308|NCT01989754|PLACEBO_COMPARATOR|Placebo|Each patient will receive placebo (inactive medication) once daily.
62351309|NCT00772694|EXPERIMENTAL|sorafenib|drug
62351310|NCT00685841|EXPERIMENTAL|A|Arformoterol 50 mcg QD and placebo MDI
62351311|NCT00685841|EXPERIMENTAL|B|Arformoterol 25 mcg BID and placebo MDI
61969055|NCT03974945||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-60 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
61969056|NCT02593474|OTHER|Detoxification / induction|The detoxification / induction procedure consists of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection. Participants then receive a second injection 4 weeks after the first.
61969057|NCT01295502|EXPERIMENTAL|Treatment (radiation, cisplatin, paclitaxel, carboplatin)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
61969058|NCT03674996|EXPERIMENTAL|Same day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 12 hours after the surgery.
61969059|NCT03674996|EXPERIMENTAL|Next-day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 24 hours after the surgery.
61969060|NCT03674996|OTHER|2-days discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 48 hours after the surgery.
61969061|NCT01660698|PLACEBO_COMPARATOR|Placebo|maltodextrin powder
61969062|NCT01660698|ACTIVE_COMPARATOR|Probiotic|probiotic blended in maltodextrin
61969063|NCT05737303|EXPERIMENTAL|Nab-Paclitaxel/carboplatin for systemic therapy after surgery|Nab-Paclitaxel/carboplatin q3 weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles
61969064|NCT05737303|ACTIVE_COMPARATOR|Paclitaxel/carboplatin for systemic therapy|"Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve） 2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
62707289|NCT04476784|OTHER|LID018869, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
61969065|NCT01871532|EXPERIMENTAL|Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
61969066|NCT01871532|ACTIVE_COMPARATOR|Standard Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
61969067|NCT00121602|ACTIVE_COMPARATOR|Roller bottle|
61969068|NCT00121602|EXPERIMENTAL|Serum free|
61969069|NCT04988724|EXPERIMENTAL|Intervention|Intervention group that receive 30 min exercise training twice weekly in 20 weeks
61969070|NCT01733602|EXPERIMENTAL|active tDCS and cognitive training|Transcranial direct current stimulation combined with cognitive training
61969071|NCT01733602|ACTIVE_COMPARATOR|sham tDCD and cognitive training|Sham transcranial direct current stimulation combined with cognitive training
61969072|NCT01247740|EXPERIMENTAL|1|three chamber bag for parenteral nutrition containing lipids, glucose, amino acids and electrolytes
61969073|NCT01247740|ACTIVE_COMPARATOR|2|compounded monobag including lipids, glucose, amino acids and electrolytes
61969074|NCT00493324|EXPERIMENTAL|1|
61969075|NCT02236195|EXPERIMENTAL|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
61969076|NCT04842266||Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis|Patients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. Patient-reported outcome surveys will be administered pre-operatively, as well as at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years after surgery.
61969077|NCT04842266||Pelvic fragility fracture in a geriatric patients (age 65 or older)|Patients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. Patient-reported outcome surveys will be administered pre-operatively, as well as at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years after surgery.
62351312|NCT00685841|EXPERIMENTAL|C|Arformoterol 15 mcg BID and placebo MDI
62509726|NCT03605524|OTHER|Sensory training|"Sensory (Olfactory or visual) training will be done at home for 12 weeks.~The effect of the training will be evaluated using an experimental protocol includes (i) clinical and psychometric evaluations, (ii) the study of olfactory perception using Sniffin' Sticks Test and (iii) the study of the emotional perception using the subjective Sense'n Feel method and the objective measurement of the spontaneous pupillary dilatation."
61969078|NCT04225611|EXPERIMENTAL|Dexamethasone|Therapeutic Contact Lens Drug Delivery System (TCL-DDS) of Dexamethasone, up to 300 μg per day with a total release of 1,100 μg over 7 days
61976225|NCT05339594||NeuraGen Nerve Guide|Integra NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
62351313|NCT00685841|ACTIVE_COMPARATOR|D|Salmeterol MDI 42 mcg BID and placebo inhalation solution
62351314|NCT00685841|PLACEBO_COMPARATOR|E|Placebo BID MDI and inhalation solution
62351315|NCT00901381|EXPERIMENTAL|G-CSF|
62351316|NCT00901381|NO_INTERVENTION|Control|
62351317|NCT00476996|EXPERIMENTAL|Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
62351318|NCT00476996|EXPERIMENTAL|Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
62509727|NCT01338714|EXPERIMENTAL|A foumula|Compound Herbal Formula (RHD-1)
61969079|NCT01899300|EXPERIMENTAL|Metal Stent|The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.
61969080|NCT01993147|OTHER|Dual Task Paradigm|This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
61969081|NCT04581161|EXPERIMENTAL|Life2000® Ventilator|Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device.
61969082|NCT04581161|NO_INTERVENTION|Control Group|Subjects in the control group will be identified from the population of patients previously admitted to the study site with COVID-19 infection who required non-invasive oxygen therapy with HFNC but were not treated with NIV therapy. Subject data will be collected retrospectively from the medical record.
61969083|NCT05286281|EXPERIMENTAL|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
61969084|NCT02637752|ACTIVE_COMPARATOR|Lifestyle counseling|Intervention: Lifestyle counseling or nutrition/physical counselling
61969085|NCT02637752|NO_INTERVENTION|No Intervention|To ensure that both groups benefited equally from the study, the control group received the counselling and the handouts at the end of the study.
61969086|NCT04606173|EXPERIMENTAL|Standard Practice plus TEACH|Primary care teamlets will receive standard organizational education and support regarding suicide prevention and also engage in Team Education for Adopting Changes in Healthcare (TEACH) huddles.
61969087|NCT04606173|NO_INTERVENTION|Standard Practice|Standard Practice condition will involve the current evidence-based support included in web-based provider-trainings and electronic medical record reminders/templates that are standard within an organization
61969088|NCT05243862|EXPERIMENTAL|PolyPEPI1018 plus Atezolizumab|Participants receive every 3 weeks PolyPEPI1018 CRC Vaccine (Emulsified solution, 0.2 mg/peptide, 6 peptides total, and Montanide™ ISA51VG adjuvant), by SC injection in combination with Atezolizumab (Injectable solution,1200mg/20mL) by IV injection.
61969089|NCT02337257|ACTIVE_COMPARATOR|cholecalciferol|Subjects will take 4000 IU per day for 30 days
61969090|NCT02337257|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo everyday for 30 days
61969091|NCT03809117|EXPERIMENTAL|Experimental|Gastrointestinal Polymerase Chain Reaction test performed and results communicated to treatment provider. Followed by usual care per treating physician.
61969092|NCT03809117|ACTIVE_COMPARATOR|Control|Gastrointestinal Polymerase Chain Reaction test performed at the conclusion of the study. Clinician will not be informed of results. Usual Care performed per treating physician.
61969093|NCT06335914|EXPERIMENTAL|PSMA and FDG PET Imaging|Participants advanced prostate cancer will undergo PSMA and FDG PET prior to starting their standard of care treatment and during treatment.
61969094|NCT00643227|EXPERIMENTAL|1|
61969095|NCT00643227|EXPERIMENTAL|2|
61969096|NCT05833347||2-8 Years Paediatric Patients|"During the preoperative evaluation, demographic data and airway physical examination results (Mallampati score) of the patients will be recorded. Patients who have received preoperative sedation will be positioned supine on the operating table, and ultrasound-guided measurements of soft tissue distances will be taken using a linear probe with a frequency range of 6-13 Hz. The distance between the hyoid bone and skin (DSHB), distance between the vocal cord anterior commissure and skin (DSAC), and distance between the epiglottis and skin (DSE) will be measured. The A/E (Anterior Commissura/Epiglottis) ratio will be calculated after measurements.~After standard monitoring and anesthesia induction, difficult laryngoscopy will be evaluated using the Modified Cormack Lehane Score, which grades the visibility of vocal cords and glottic structures. A grade of 3 or 4 on this scale will be considered as difficult laryngoscopy and recorded as such."
62145256|NCT02590198||PCT algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
62509728|NCT01338714|PLACEBO_COMPARATOR|B formula|dilute Compound Herbal Formula
62509729|NCT03667495||Relapse|Patients who suffered colorectal cancer or adenoma relapse after curative surgery
61969097|NCT01378078|SHAM_COMPARATOR|sham|patients receive sham tDCS stimulation
61969098|NCT01378078|ACTIVE_COMPARATOR|active|active transcranial direct current stimulation
61969099|NCT03079908|EXPERIMENTAL|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
61969100|NCT03079908|ACTIVE_COMPARATOR|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
61969101|NCT03079908|PLACEBO_COMPARATOR|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
61969102|NCT04907656|EXPERIMENTAL|dCBT Condition|The dCBT used in this study (Daylight) was selected due to its noted efficacy in treating GAD. 25 interventions will be provided in four modules, with an average duration of 20 minutes. Sessions are unlocked weekly, and completion of an initial assessment drives an algorithm to personalize the program. Individuals may progress through treatment at a slower pace than weekly sessions; 10 weeks is allowed for treatment completion. Treatment is based on principles of applied relaxation, stimulus control, cognitive restructuring, and imaginal exposure. Participants schedule a time for each session and receive prompts if they miss the appointment. All interventions are aided by the use of an animated therapist.
61976226|NCT05339594||NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
62145257|NCT05208294|EXPERIMENTAL|High expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a sulpiride 400mg-capsule (note that the dose is presumably too high to produce antidepressant effects).
62145258|NCT05208294|EXPERIMENTAL|High expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a placebo capsule.
62509730|NCT03667495||Remission|Patients who get remission after curative surgery
62509731|NCT00504803|EXPERIMENTAL|1|MSC co-infusion with either HLA-mismatched PBSC or cord blood
62509732|NCT04329299||Blood Biomarkers Analyses|15 ml of blood sample will be obtained from each study participant, for blood-based biomarkers analyses.
61969103|NCT04907656|NO_INTERVENTION|Waitlist (control) Condition|Participants allocated to the waitlist (control) condition will not receive an active intervention during the study. Participants will still complete all scheduled study assessments. They will receive access to the dCBT after completion of all study assessments.
61969104|NCT01897220||University Hospital Patients|Consecutive patients with cardiovascular disease(s) undergoing non-cardiac surgery
61969105|NCT03998189|EXPERIMENTAL|Female Participants|45 female patients will be screened to participate.
61969106|NCT03998189|EXPERIMENTAL|Male Participants|45 male patients will be screened to participate
61969107|NCT00672867|EXPERIMENTAL|1|Clevudine
61969108|NCT00672867|ACTIVE_COMPARATOR|2|Adefovir
62145259|NCT05208294|EXPERIMENTAL|Low expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, while participants actually receive a sulpiride capsule (400 mg).
62145260|NCT05208294|EXPERIMENTAL|Low expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, and participants actually receive a placebo capsule.
62351319|NCT00476996|PLACEBO_COMPARATOR|Placebo x 2 IV + Non-Biologic DMARD Therapy|Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
62351320|NCT03520439|EXPERIMENTAL|study group|mifepristone tablets ，10mg，One tablet daily, oral treatment
62351321|NCT03520439|PLACEBO_COMPARATOR|control group|placebo，10mg，One tablet daily, oral treatment
62351322|NCT03120637|EXPERIMENTAL|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
62351323|NCT03120637|NO_INTERVENTION|Standard Treatment|
61969109|NCT05732454|EXPERIMENTAL|etrasimod|2 mg, oral tablet, once daily
61969110|NCT05732454|PLACEBO_COMPARATOR|Placebo (Part 1 DB period only)|Oral sham comparator
61969111|NCT02231060||AIE after Cardiac Arrest|Male and female patients with AIE following CA.
61969112|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
62351324|NCT05221788|EXPERIMENTAL|GDHT(goal-directed hemodynamic therapy)|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If stroke volume (SV) increased \>10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but MAP \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate (HR) more than 20% above baseline), plasma was administered until urine output and/or heart rate returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
62351325|NCT05221788|NO_INTERVENTION|control|Continuous infusion of compounded sodium lactate 5-7 ml/kg/h was allowed to receive colloidal solution, norepinephrine and dobutamine at the discretion of the anesthesiologist.
62351326|NCT06315244|EXPERIMENTAL|%5 Dextrose Injection Group|Participants in this arm will receive an ultrasound-guided injection of 5% dextrose solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve. The intervention aims to alleviate symptoms of chronic coccydynia by reducing nerve entrapment. Participants will continue their existing physical therapy/medical treatment regimen throughout the study.
62351327|NCT06315244|PLACEBO_COMPARATOR|Placebo Injection Group|Participants in this arm will receive an ultrasound-guided injection of a placebo solution (saline) into the same anatomical region as the experimental group. This arm serves as a control to evaluate the efficacy of the dextrose injection in treating chronic coccydynia symptoms. Participants will continue their existing physical therapy/medical treatment regimen throughout the study.
62351328|NCT04632407|EXPERIMENTAL|"Flax milk"|"A total of 30 women will receive flax (FLX) milk on a daily basis for a total of 4 months. The FLX milk will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3."
62351329|NCT04632407|EXPERIMENTAL|"Oat fibre milk"|"A total of 30 women will receive the oat fiber milk on a daily basis for a total of 4 months. The oat fibre milk will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water."
62351330|NCT02742857|EXPERIMENTAL|Treatment Group|
62351331|NCT05296837|EXPERIMENTAL|40mg of oral doxycycline|Arm A will receive submicrobial dose doxycycline (40mg) administered as 20mg twice a day for 8 weeks
62351332|NCT05296837|ACTIVE_COMPARATOR|100mg of oral doxycycline|Arm B will receive 200mg of oral doxycycline administered as 100mg twice a day for 8 weeks
62351333|NCT05296837|PLACEBO_COMPARATOR|Placebo|Arm C will receive a placebo twice a day for 8 weeks
62351334|NCT05238987|EXPERIMENTAL|Healthy men (before-and-after (pre-post) study)|Partcipants will undergo a 75g oral glucose tolerance test (OGTT) to document baseline insulin secretion kinetics. One week later, OGTT will be repeated after administering a single dose of ferrous sulphate (120 mg of elemental iron) 2 hours prior to the test.
62351335|NCT00467714|NO_INTERVENTION|1|2.5 cm Cartilage as columella strut
62351336|NCT03159819|EXPERIMENTAL|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
62351337|NCT01193816|EXPERIMENTAL|loxapine|loxapine
62351338|NCT01193816|PLACEBO_COMPARATOR|Placebo|Placebo
62351339|NCT02452177|EXPERIMENTAL|Vitamin D|Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.
62351340|NCT02452177|PLACEBO_COMPARATOR|Placebo|
62351341|NCT01557764|EXPERIMENTAL|Treatment (enzyme inhibitor and monoclonal antibody)|Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
61969113|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
61969114|NCT03180723|EXPERIMENTAL|study group|Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)
61969115|NCT03180723|ACTIVE_COMPARATOR|control group|Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.
61969116|NCT01491412||Acute psychotic episode in schizophrenia|Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
61969117|NCT02051608|PLACEBO_COMPARATOR|Part 1 (Double Blind treatment): Placebo|Participants received matching placebo by subcutaneous (SC) injection every 4 weeks (Q4W) up to 100 weeks during Part 1 of the study.
61969118|NCT02051608|EXPERIMENTAL|Part 1 (Double Blind treatment): Gantenerumab|Participants received 105 mg Gantenerumab by SC injection Q4W for 24 weeks and if eligible 225 mg SC injection Q4W from weeks 28-100 during Part 1 of the study.
61969119|NCT02051608|PLACEBO_COMPARATOR|Part 2 (Open-Label Extension [OLE] treatment): Placebo switched to Gantenerumab Up to 1200 mg|Participants who had received Placebo in Part 1, received Gantenerumab at doses up to 1200 mg by SC injection Q4W for up to 2 years. Additionally, participants were given the option to continue receiving open-label gantenerumab treatment for 3 years.
61969120|NCT02051608|EXPERIMENTAL|Part 2 (OLE treatment): Gantenerumab up to 1200 mg|Participants who had received Gantenerumab in Part 1, received treatment at doses up to 1200 mg by SC injection Q4W for up to 2 years. Additionally, participants were given the option to continue receiving open-label gantenerumab treatment for 3 years.
61969121|NCT04078113|EXPERIMENTAL|Experimental group|Every patient will be subjected to a measured stimulus with a power selected in phase 1 (X mA) and pupillary dilatation will be measured by pupillometry. In those patients showing pupillary size variation over the limit for insufficient analgesia estimated in phase 1 for tracheal suction, additional analgesia will be provided before tracheal suction. In those patients without pain detected by pupillometry, additional anlagesia won´t be provided. In both cases Pupillometry, BPS and ESCID will be measured during tracheal suction to determine whether the patient is in pain or not.
61969122|NCT04078113|NO_INTERVENTION|Control group|"Before tracheal suction and due to medical decision, analgesia following current clinical practice would be administered prophylactically.~Pupillometry, BPS and ESCID will be measured during tracheal suction to determinate whether the patient is in pain or not."
61969123|NCT01954550|EXPERIMENTAL|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
61969124|NCT01954550|SHAM_COMPARATOR|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
61969125|NCT01596868|ACTIVE_COMPARATOR|Gemcitabine and Cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT..
61969126|NCT01596868|ACTIVE_COMPARATOR|docetaxel and cisplatin|Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
62707290|NCT04476784|OTHER|Biofinity, then LID018869|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
62707291|NCT01071161|EXPERIMENTAL|Azithromycin|
62707292|NCT01071161|PLACEBO_COMPARATOR|Placebo|
61969127|NCT01975545|ACTIVE_COMPARATOR|Fluor varnish|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
61969128|NCT01975545|EXPERIMENTAL|Fluor varnish with nanoparticles|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
61969129|NCT04848545||Live-born sons (with and without testicular cancer diagnosis) from a Danish pregnancy Cohort|"Pregnancy cohort: Biological samples from 128,702 of pregnant women were stored for research purposes in the Danish National Biobank, in the period from 1976-2004.~Present study: live-born sons (with/without testicular cancer ascertained via data linkage in the Danish Cancer Registry)"
61969130|NCT03737721|EXPERIMENTAL|Avelumab and Radical radiotherapy|Single-arm combining Avelumab with radical radiotherapy.
62351342|NCT02299713|SHAM_COMPARATOR|placebo/sham acupuncture|There are different types of controls used in acupuncture trials. We used the control described as sham and by some as minimal acupuncture. This group had the same schedule as the electro-acupuncture group. Sham acupuncture was administered, with the same duration and frequency and by the same specialist who performed the non-sham acupuncture. Retractable needles were placed into small adhesive cylinders, so that the needles were supported but did not perforate the skin. The acupuncturist placed the needles at the same points as the non-sham group and used the same pairs of electrodes to simulate the electrical connection.
62707293|NCT03820076|EXPERIMENTAL|dose 1|AZT-04
62707294|NCT03820076|EXPERIMENTAL|dose 2|AZT-04
62707295|NCT03820076|EXPERIMENTAL|dose 3|AZT-04
62509733|NCT04830917|EXPERIMENTAL|Treatment with Kinesiotape and Oval 8|
62509734|NCT04830917|EXPERIMENTAL|Treatment with quick cast|
62509735|NCT04144426|EXPERIMENTAL|Normal diet then modified diet|Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM. Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.
62707296|NCT04473560||Catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with catheter-directed thrombectomy along with anticoagulation therapy
62707297|NCT04473560||No catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with anticoagulation therapy alone
62707298|NCT02083367||Hepatic Encephalopathy Group|Disease Group
61969131|NCT06311968|EXPERIMENTAL|Study arm|Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
61969132|NCT03647982|EXPERIMENTAL|botulinum toxin 1U|
61969133|NCT03647982|EXPERIMENTAL|botulinum toxin 3U(25U/1ml)|
61969134|NCT03647982|EXPERIMENTAL|botulinum toxin 5U|
61969135|NCT03647982|EXPERIMENTAL|botulinum toxin 10U|
61969136|NCT03647982|EXPERIMENTAL|botulinum toxin 3U(50U/1ml)|
61969137|NCT03647982|EXPERIMENTAL|botulinum toxin 3U(12.5U/1ml)|
62351343|NCT02299713|ACTIVE_COMPARATOR|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat knee pain. The points selected were local points St 34, St 35, St 36,Liv 8, Sp 10. One distal point St 44.A total of six needles were inserted into each leg by the acupuncturist (the out come measures were not specifically targeted to whether the patient had one or both knees involved). All patients belonging to this group experienced a De Qi sensation, which is a tingling and numbness sensation upon needling of specific points.
62707299|NCT02083367||Control Group|Healthy Group
62707300|NCT03426527|PLACEBO_COMPARATOR|Levobupivacaine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine General anesthesia
62509736|NCT04144426|EXPERIMENTAL|Modified diet then normal diet.|Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM.
62707301|NCT03426527|ACTIVE_COMPARATOR|Levobupivacaine-Dexmedetomidine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine-dexmedetomidine General anesthesia
62707302|NCT05772871|EXPERIMENTAL|Prednisone, Huaiqihuang granule, and Levamisole placebo|In this group, patients will take Prednisone, Huaiqihuang granule, and Levamisole placebo.
62351344|NCT05991557|EXPERIMENTAL|treatment arm|peroneus longus autograft
62351345|NCT06528899||Emergency Physiotherapy (E-PT)|Subcohort of patients receiving a referral + Emergency Physiotherapy (E-PT) during their visit to Emergency Department
62707303|NCT05772871|PLACEBO_COMPARATOR|Prednisone, Levamisole, and Huaiqihuang granule placebo|In this group, patients will take Prednisone, Levamisole, and Huaiqihuang granule placebo.
62707304|NCT01605097|EXPERIMENTAL|HDR interstitial brachytherapy|HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion
62707305|NCT02789982|EXPERIMENTAL|Reconsolidation blockade|β-adrenergic blocker propranolol 1 mg / kg to each of the 6 treatment sessions
62707306|NCT02789982|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual like SSRIs, psychotherapy, ...
62707307|NCT03735355|EXPERIMENTAL|Balloon dilation|TTS balloon dilation
62707308|NCT03735355|ACTIVE_COMPARATOR|Surgery|Resection of the fibrostenotic area
62351346|NCT06528899||control (CTL)|Subcohort of patients receiving a referral + but no Emergency Physiotherapy (E-PT) during their visit to Emergency Department
62707309|NCT02128776|ACTIVE_COMPARATOR|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
62707310|NCT02128776|ACTIVE_COMPARATOR|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
62707311|NCT04389697|EXPERIMENTAL|Intervention arm|Clear fluids and food up to up to 1 hour before the procedure
62707312|NCT04389697|NO_INTERVENTION|Control arm|Fasting for solids for up to 6 hours and fluids up to 2 hours before the procedure
61969138|NCT00816985|EXPERIMENTAL|Liposuction + Questionnaires|Liposuction, followed by Quality of Life Questionnaires and extended follow-up period.
61969139|NCT03303534|EXPERIMENTAL|PCR|pre-operative protein calorie restricted (PCR) group. participants randomized to this arm will consume scandishake diet (strawberry, caramel, banana cream, vanilla) mixed with almond milk for three days inpatient prior to planned elective carotid endarterectomy. Water is ad libitum for this cohort. Nutritionists will prepare shakes so participants will achieve 30% calorie restriction and severe protein restriction during the three days on the diet.
62351347|NCT01125657|EXPERIMENTAL|formualation-A to -B sequence group|
62707313|NCT01397253|NO_INTERVENTION|(Usual) MedTrak system of PCP notification|MedTrak, the information system used by the University of Pittsburgh Medical Center (UPMC), currently notifies PCPs when patients are admitted and discharged from the hospital.
62351348|NCT01125657|EXPERIMENTAL|formulation-B to -A sequence group|
62351349|NCT06195293|EXPERIMENTAL|Anti-cancer Neoantigen Polypeptide Vaccine|Anti-cancer neoantigen polypeptide vaccine will be produced to treat advanced solid tumors.
62351350|NCT01042951|ACTIVE_COMPARATOR|ShanChol Cholera Vaccine|
62707314|NCT01397253|EXPERIMENTAL|Automated communication tools|An enhanced version of MedTrak (the present system of PCP notification). Electronic medical record links will be developed and used to allow automated communication with the PCP.
61969140|NCT03303534|NO_INTERVENTION|control regular diet|participants in this cohort are randomized to the control group and will have no dietary restriction three days in patient prior to planned elective carotid endarterectomy
61969141|NCT05152589||gestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of gestational diabetes in the peritanotogy clinic
61969142|NCT05152589||pregestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of pregestational diabetes in the peritanotogy clinic
62351351|NCT01042951|PLACEBO_COMPARATOR|Placebo|
62351352|NCT00875303|PLACEBO_COMPARATOR|Control|Routine primary care.
62509737|NCT02092337|EXPERIMENTAL|computer assisted speech training|computer assisted speech training
62509738|NCT03676647||Diagnostic (biospecimen collection)|Previously collected FNA aspiration specimen samples are analyzed via DDMS assay. Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS assay.
62707315|NCT01263210|ACTIVE_COMPARATOR|Pneumococcal vaccine|Half of the children were randomized to receive heptavalent pneumococcal conjugate vaccine (before this vaccine was included in the national immunization programme).
62509739|NCT02343354|EXPERIMENTAL|Nutrition/physical activity intervention|There will be five in-person group sessions (3 to 4 weeks appart) with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website, telephone calls and phone applications.
62509740|NCT01230892|ACTIVE_COMPARATOR|Nebivolol|
62509741|NCT01230892|ACTIVE_COMPARATOR|Atenolol|
62509742|NCT02999451|EXPERIMENTAL|snare group|snare-assisted POEM
62509743|NCT02999451|ACTIVE_COMPARATOR|conventional group|knife-assisted POEM
62351353|NCT00875303|EXPERIMENTAL|Multimedia intervention|
62509744|NCT00528268|EXPERIMENTAL|Cohort 1|Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies
62509745|NCT00528268|EXPERIMENTAL|Cohort 2|Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies
62509746|NCT00111566|ACTIVE_COMPARATOR|18 Hour infusion|
62509747|NCT00111566|EXPERIMENTAL|4 hour infusion|
62509748|NCT06097845|EXPERIMENTAL|Transcranial Ultrasound|Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices currently used in routine clinical practice.
61969143|NCT05152589||non diabetic mother|Hearing tests of babies whose mothers do not have gestational or pregestational diabetes
61969144|NCT02006745|OTHER|Ribavirin|ARM 1: PEG-IFN and weight-based ribavirin (RBV)
62351354|NCT06183632||Healthy donor|All healthy volunteers are eligible to donate according to EFS criteria.
62351355|NCT04235439|EXPERIMENTAL|Gan & Lee Insulin Lispro Injection|Insulin lispro, 3 mL cartridge in prefilled pen, 100 units/mL (U-100)
62351356|NCT04235439|ACTIVE_COMPARATOR|EU - approved Humalog ®|Insulin lispro (product approved and marketed in the EU), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
62351357|NCT04235439|ACTIVE_COMPARATOR|US - licensed Humalog ®|Insulin lispro (product approved and marketed in the US), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
62351358|NCT01360853|EXPERIMENTAL|Arm A: Combination|Arm A: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle, + ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
62351359|NCT01360853|ACTIVE_COMPARATOR|Arm B: Gemcitabine only|Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
62351360|NCT04623463|OTHER|Exercise intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
62351361|NCT00141856|OTHER|1|
62351362|NCT00992186|EXPERIMENTAL|Carlumab|
62351363|NCT00970268|EXPERIMENTAL|1|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
62509749|NCT06070805||Non-depression group|The Hamilton Rating Scale for Depression (HAMD) will be applied to assess the depressive status of all enrolled patients. This scale consists of 24 survey items, each with a score of 0-4. Patients will be assigned to the nondepression group if their HAMD score was \<8.
62509750|NCT06070805||Depression group|Patients will be assigned to the depression group if their score was ≥8.
62509751|NCT00983606||1|32 to 35 WGA Infants less than six months of age by RSV season peak.
62509752|NCT06609538|ACTIVE_COMPARATOR|Control Group with Propofol|Receives standard preoperative instructions and propofol infusion.
62509753|NCT06609538|EXPERIMENTAL|Suggestion Group with Propofol|Receives positive preoperative suggestions and propofol infusion.
62509754|NCT06609538|ACTIVE_COMPARATOR|Control Group with Ketamine|Receives standard preoperative instructions and ketamine infusion.
62509755|NCT06609538|EXPERIMENTAL|Suggestion Group with Ketamine|Receives positive preoperative suggestions and ketamine infusion.
61969145|NCT02006745|OTHER|Telaprevir|ARM 2: PEG-IFN and weight-based RBV plus telaprevir (TPV)
62351364|NCT00970268|EXPERIMENTAL|2|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
62351365|NCT04995900|EXPERIMENTAL|Intervention|Intervention period with active Heart Matters education delivered
62351366|NCT04995900|NO_INTERVENTION|Control|Control period with no Heart Matters education delivered.
62351367|NCT02943265|EXPERIMENTAL|Complex Care Survivors|Patients eligible for the study who will receive Care Coordination Strategies.
62351368|NCT02227849|EXPERIMENTAL|Canagliflozin (TA-7284) ＋GLP-1 analogue|
62351369|NCT05752786|EXPERIMENTAL|"Eat Less Meat challenge"|"Participants take part in the Eat Less Meat challenge"
62351370|NCT05752786|OTHER|"Eat Less Meat challenge later"|"Participants take part in the Eat Less Meat challenge 4 months after the participants in the experimental arm, i.e., after all measures completion"
62509756|NCT01353846|ACTIVE_COMPARATOR|Natural cycle|
62509757|NCT01353846|ACTIVE_COMPARATOR|Artificial cycle|"Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.~Natural micronized progesterone, 400 mg/12 hours vaginal administration"
62509758|NCT02052791|EXPERIMENTAL|nusinersen|
62509759|NCT01789957|EXPERIMENTAL|Open-label AC2993|
62707316|NCT01263210|NO_INTERVENTION|Control|Half of the children were randomized to no vaccination and functioned as controls.
62509760|NCT01304381|EXPERIMENTAL|Integrated care|Multidisciplinary approach and collaboration between specialist palliative and heart failure (HF) caregivers in a shared structured person-centred and identity-promoting homecare
62509761|NCT01304381|NO_INTERVENTION|control|Usual care is performed for the control group
62707317|NCT03296982||Blood Sample|Blood will be sampled by direct venipuncture on 8 occasions.
61969146|NCT03659812|EXPERIMENTAL|MACS is applied to the sperm sample|Previous to the AID technique, the sperm sample undergoes capacitation through Percoll density gradient and MACS
62509762|NCT02288494||hypoalbuminemia|The primary purpose was to describe the acid base balance of ICU patients with severe hypoalbuminemia using Stewart's approach for acid base disorders, before and after an human albumin perfusion
62509763|NCT02241135|EXPERIMENTAL|80 µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
62509764|NCT02241135|EXPERIMENTAL|160µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
62509765|NCT02241135|EXPERIMENTAL|80 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
62509766|NCT02241135|EXPERIMENTAL|160 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
62509767|NCT02241135|EXPERIMENTAL|320 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
62509768|NCT02241135|EXPERIMENTAL|640 µg CV7201 mRNA long|Vaccination by injection on days 0, 28.
62351371|NCT05905757|EXPERIMENTAL|Group T|"Group T (Adjuvant tramadol): Bilateral subcostal TAP block was performed using solutions prepared by adding 0.250% bupivacaine + 40 mL adjuvant 1.5mg/kg (maximum 100 mg) tramadol.~Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), HR, SpO2 values were recorded.~Demographic data of the patients \[age, weight, height, body mass index (BMI), smoking use\] and operation times were recorded.~All patients were administered 1000 mg parol IV as standard analgesic before extubation.~The patients were followed up for side effects (such as nausea-vomiting, chills, itching and desaturation) including drug allergies.The patients were evaluated at 0, 3 and 6 hours after the operation with a 0-10 verbal rating scale visual analog scale (VAS) and the data were recorded. In all groups, VAS˃ 4 value was evaluated in favor of analgesic need and 50 mg Dexketoprofen IV bolus was administered in accordance with conventional treatment."
62509769|NCT02241135|EXPERIMENTAL|200 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
62509770|NCT02241135|EXPERIMENTAL|400 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
62509771|NCT06163092||Observational study|Women with recurrent miscarriage would be invited to do endometrial sampling (ES) procedure. The ES will be conducted precisely 7 days after LH surge. It will be obtained using a Pipelle sampler as an outpatient procedure.
62509772|NCT03399578|EXPERIMENTAL|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 MERS, 5 x 10\^9 vp through intramuscular route.
62509773|NCT03399578|EXPERIMENTAL|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp through intramuscular route.
62509774|NCT03399578|EXPERIMENTAL|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 MERS, 5 x 10\^10 vp through intramuscular route.
62509775|NCT03399578|EXPERIMENTAL|Group 4|Group 4 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10\^10 vp at week 26. Both administrations will be given through intramuscular route.
61969147|NCT03659812|NO_INTERVENTION|MACS is not applied to the sperm sample|Previous to the AID technique, MACS only undergoes capacitation through Percoll density gradient, but not MACS technique
62509776|NCT03399578|EXPERIMENTAL|Group 5|Group 5 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10\^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10\^10 vp at week 4. Both administrations will be given through intramuscular route.
62509777|NCT01332786|EXPERIMENTAL|Tigecycline|
62509778|NCT05687682|EXPERIMENTAL|Level -1|0.1 mg/kg
62509779|NCT05687682|EXPERIMENTAL|Level 1|0.3 mg/kg (Starting Dose)
62509780|NCT05687682|EXPERIMENTAL|Level 2|1 mg/kg
62509781|NCT05687682|EXPERIMENTAL|Level 3|3 mg/kg
61969148|NCT01731392|EXPERIMENTAL|Milk with Bifidobacteria|duration of the treatment is 5 months
61969149|NCT01731392|ACTIVE_COMPARATOR|Milk with non replicating lactobacilli|duration of the treatment is 5 months
61969150|NCT01731392|PLACEBO_COMPARATOR|Semi skimmed milk|duration of the treatment is 5 months
61969151|NCT04416594||Factor XIII deficiency|Patients admitted to hospital with FXIII levels below 70% during their hospital stay
61969152|NCT03290898|ACTIVE_COMPARATOR|Training group|"Supervised High intensity interval training (HIIT) 3 times a week for 6 months.~Training session:~10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)"
62509782|NCT05687682|EXPERIMENTAL|Level 4|6 mg/kg
62509783|NCT05687682|EXPERIMENTAL|Level 5|10 mg/kg
62509784|NCT05687682|EXPERIMENTAL|Level 6|15 mg/kg
62509785|NCT05332834|EXPERIMENTAL|Drug SM17|Peripheral intravenous injection
62509786|NCT05332834|PLACEBO_COMPARATOR|Drug Placebo|Peripheral intravenous injection
62509787|NCT06258161||Adult spinal deformity surgery patients|Adults diagnosed with spinal deformity and who are undergoing spinal realignment fusion surgery.
62509788|NCT06258161||Asymptomatic adult controls|Adults with no history of spinal deformity or previous spinal fusions.
62509789|NCT02678871|OTHER|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
62509790|NCT00605917||Sertraline hydrochloride.|The patients of Panic disorder taking Sertraline hydrochloride.
62509791|NCT03401554|ACTIVE_COMPARATOR|collagen membrane group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with collagen membrane
62509792|NCT03401554|EXPERIMENTAL|titanium mesh group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with titanium mesh
62509793|NCT04430127||Colorectal adenocarcinoma|patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal DECT for initial staging
62509794|NCT02247050|EXPERIMENTAL|Commitment invitation at time 1|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 2 months and then cross over to the intervention period for 6 months."
62509795|NCT02247050|EXPERIMENTAL|Commitment invitation at time 2|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 3 months and then cross over to the intervention period for 5 months."
62707318|NCT04462575|EXPERIMENTAL|Onlay bone block covered using collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block) covered by collagen membrane, stabilized by resorbable suture and fixed by tacs.
62509796|NCT02247050|EXPERIMENTAL|Commitment invitation at time 3|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 4 months and then cross over to the intervention period for 4 months."
62707319|NCT04462575|ACTIVE_COMPARATOR|Onlay bone block without collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block).
62707320|NCT03283241|ACTIVE_COMPARATOR|Zolidd One ExHex|Coated titanium implant
61969153|NCT03290898|NO_INTERVENTION|Control group|Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).
62145261|NCT01934322|EXPERIMENTAL|Case Management|"Furnish specific assistance and to provide referrals for the patients:~* If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~* If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~* If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~* In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
62351372|NCT05905757|EXPERIMENTAL|Group D|"Group D (adjuvant dexmedetomidine): Bilateral subcostal TAP block was performed using solutions prepared by adding 0.250% bupivacaine + 0.5 mcg/kg and (maximum 50 mcg) dexmedetomidine.~All patients were administered 1000 mg parol IV as standard analgesic before extubation.~The patients were followed up for side effects (such as nausea-vomiting, chills, itching and desaturation) including drug allergies.~The patients were evaluated at 0, 3 and 6 hours after the operation with a 0-10 verbal rating scale visual analog scale (VAS) and the data were recorded. VAS 0-2: no pain, 3-4: mild pain, 5-6: moderate pain, 7-8: severe pain, 9-10: excruciating pain. Additional analgesic requirement in the postoperative period was calculated by measuring VAS\>4 values. In all groups, VAS˃ 4 value was evaluated in favor of analgesic need and 50 mg Dexketoprofen IV bolus was administered in accordance with conventional treatment."
62351373|NCT05460650|EXPERIMENTAL|Receives app|All women in the study will receive access to the app.
62351374|NCT02924818|EXPERIMENTAL|Chronic Obstructive Pulmonary disease (COPD)|
62351375|NCT02924818|EXPERIMENTAL|Cystic Fibrosis (CF)|
62351376|NCT02924818|EXPERIMENTAL|bronchiectasis|
62351377|NCT02924818|EXPERIMENTAL|Interstitial lung disease (ILD)|
62351378|NCT02924818|EXPERIMENTAL|controls|
62351379|NCT04228562|NO_INTERVENTION|Non-modifiable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
62351380|NCT04228562|EXPERIMENTAL|Non-modifiable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
62509797|NCT02247050|EXPERIMENTAL|Commitment invitation at time 4|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 5 months and then cross over to the intervention period for 3 months."
62509798|NCT02247050|EXPERIMENTAL|Commitment invitation at time 5|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 6 months and then cross over to the intervention period for 2 months."
62707321|NCT03283241|SHAM_COMPARATOR|One ExHex|Uncoated titanium implant
62707322|NCT02232360|EXPERIMENTAL|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
62707323|NCT02232360|ACTIVE_COMPARATOR|Rosuvastatin alone|Rosuvastatin 10 mg per day
62707324|NCT02551588||Valvular aortic stenosis surgery|"Patients with symptomatic AVS had indication for surgery. They were proposed to have per procedure cardiac biopsy.~They were followed when possible one year after surgery."
62707325|NCT02551588||Valvular aortic stenosis without surgery|These patients with asymptomatic AVS had no indication for surgery. They were followed when possible one year after inclusion.
62707326|NCT02551588||Control subject|Patients without history of cardiac infarction, primary or secondary myocardiopathy or of radiotherapy or chemotherapy.
62707327|NCT03454035|EXPERIMENTAL|Open-label, single arm Phase I|Ulixertinib added to palbociclib
62707328|NCT00529295|EXPERIMENTAL|1|Titrated oral misoprostol
62707329|NCT00529295|ACTIVE_COMPARATOR|2|Vaginal misoprostol
62707330|NCT05454865|EXPERIMENTAL|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack (15 ml) oral use twice daily for two cycles (1 cycle = 3 wks)
61976227|NCT04841902|EXPERIMENTAL|Life Style Intervention Manual (Supervised)|Supervised Exercises with Life Style Intervention Manual (Dietary \& Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of alternating light to moderate intensity aerobic exercises including warm up and rest interval
61969154|NCT05022108|EXPERIMENTAL|Antihistamine test|The forearm was sensitized at four points (A, B, C and D). Point A: positive control sensitized with a drop of histamine at a concentration of 10 mg / Ml. Point B: histamine was applied and immediately after, the alpha bisabolol gel with a concentration of 0.5%. Point C: histamine and gel with 2.5% alpha-bisabolol were applied. Point D was sensitized with a drop of histamine and 5.0% alpha-bisabolol gel. The test reading at each point occurred 15 minutes after the procedure.
61969155|NCT03262818|EXPERIMENTAL|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"* Transvaginal ultrasound (US) prior to surgery~* Immediately after the transvaginal US, US/PAI imaging will be performed~* Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
62707331|NCT05454865|PLACEBO_COMPARATOR|Placebo group|Mimic Tea 1 pack (15ml) oral use twice daily in the first cycle, using Jin Si Herbal Tea in the 2nd cycle
62707332|NCT05074914|EXPERIMENTAL|Adenocarcinoma of the oesophagus|curative oesophagectomy
62707333|NCT05074914|NO_INTERVENTION|Barrett's oesophagus|Weight stable patient under survelliance with Barrett's oespophagus
61969156|NCT04144946||Healthy control group (CTRL)|Sports active individuals with no history of patellar tendinopathy.
61969157|NCT04144946||Early tendinopathy group (ET)|Sports active individuals with clinical signs of early tendinopathy and debut of symptoms within 90 days.
62707334|NCT03320005|ACTIVE_COMPARATOR|ResistanceTraining Group|The RT program has the following features: 05 classes performing two weekly sessions; day shift; sessions with maximum duration of 1 (one) hour; 02 series; 08 to 12 repetitions; interval between sets of 01 to 02 minutes; exercises: bench press, seated leg press 45°, pull forward, Earth, rowing standing calf standing, power lifting, abdominal and development.
62707335|NCT03320005|NO_INTERVENTION|Non training group|sedentary elderly
62707336|NCT03842397|EXPERIMENTAL|Implanted Patients|Implantation of Kephalios Device 1
62707337|NCT04033692||JuggerKnot Mini Soft Anchors|Patients who have been implanted with the JuggerKnot Mini Soft Anchor who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc
61969158|NCT04144946||Chronic tendinopathy group (CT)|Sports active individuals with clinical signs of tendinopathy and duration of symptoms \>90 days.
61969159|NCT05147116|EXPERIMENTAL|Hypoxia - 15% O2|Participants will sleep in a tent for 10 nights.
61969160|NCT05147116|SHAM_COMPARATOR|Sham - room air 21% 02|Participants will sleep in a tent for 10 nights.
61969161|NCT05208255|EXPERIMENTAL|Exercise Group1|"The telerehabilitation-based neurocognitive exercise group~6 weeks, 2 sessions per week Session duration: 60 minutes"
61969162|NCT05208255|EXPERIMENTAL|Exercise Group2|"The telerehabilitation-based neurocognitive exercise+motor imagery training group~6 weeks, 2 sessions per week Session duration: 60 minutes (45 minutes-neurocognitive exercise; 15 minutes-motor imagery training)"
61969163|NCT05208255|ACTIVE_COMPARATOR|Control Group|"The medication group - Participants who voluntarily participated in the study but did not want to participate in exercise groups.~6 weeks of medication use"
61969164|NCT00275990|EXPERIMENTAL|thrombectomy before stenting|thrombectomy before stenting
61969165|NCT00275990|ACTIVE_COMPARATOR|directing stenting alone|directing stenting alone
61969166|NCT04351321|EXPERIMENTAL|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed for the treatment of patients assigned to this group.
62145262|NCT01934322|NO_INTERVENTION|Control|Patients randomized to control group (usual care) will receive standard emergency care by physicians (resident or attending physician) and nurses, without the case manager been involved. Nevertheless, the mobile team will take contact with each patient of the control group, giving them short information through a flyer (flyer) which will underline the existence of the mobile team, its addresses and telephone numbers.
62145263|NCT05674981|EXPERIMENTAL|Probiotic group|Subjects received two probiotic sachets per day
62145264|NCT05674981|PLACEBO_COMPARATOR|Placebo group|Subjects received two placebo sachets per day
62145265|NCT05433441|NO_INTERVENTION|Standard care|
62707338|NCT04028830|EXPERIMENTAL|Arm 1|Medical representative presentation with the help internet tool for decision ANTIBIOCLIC
62707339|NCT04028830|EXPERIMENTAL|Arm 2|Medical representative presentation without presentation of the internet tool for decision support
62707340|NCT04028830|NO_INTERVENTION|Arm 3|Usual practice without intervention regarding the prescription of antibiotics
62707341|NCT06564584|EXPERIMENTAL|TLC-2716 Dose 1|Oral dose of TLC-2716 Dose 1
62707342|NCT06564584|EXPERIMENTAL|TLC-2716 Dose 2|Oral dose of TLC-2716 Dose 2
62707343|NCT06564584|PLACEBO_COMPARATOR|Placebo|Oral dose of placebo-to-match
62707344|NCT05554679|ACTIVE_COMPARATOR|group A|obese pregnant women who take metformin
62707345|NCT05554679|NO_INTERVENTION|group B|obese pregnant women who take no metformin
62707346|NCT03379974|EXPERIMENTAL|ARM A: DDAVP followed by exercise|"1. Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing \<50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~2. Intervention #2: Exercise intervention"
61969167|NCT04351321|ACTIVE_COMPARATOR|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-assisted total gastrectomy will be performed for the treatment of patients assigned to this group.
61969168|NCT02363517|NO_INTERVENTION|Group A|"Primary (n=40) and secondary (n=100) participants will receive supportive care only (includes a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84).~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
62707347|NCT03379974|ACTIVE_COMPARATOR|ARM B: DDAVP alone|"1. Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing \<50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~2. Intervention #2: no further intervention (rest)"
62707348|NCT03379974|EXPERIMENTAL|ARM C: Exercise intervention|"1. Intervention #1: Exercise intervention~2. Intervention #2: no further intervention (rest)"
61969169|NCT02363517|ACTIVE_COMPARATOR|Group B|"Primary participants (n=40) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Secondary participants (n=100) will receive supportive care only.~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
62145266|NCT05433441|EXPERIMENTAL|ESPark Intervention|Under medical prescription and in addition to medical and physiotherapy care, the ESPark will intervene in an ecological way with Parkinson's patients in order to rehabilitate them, maintain their autonomy in their daily life and their social life with the aim of improving the quality of life of the patient and his main caregiver. Beyond a rehabilitative intervention in the home, the ESPark's mission would also be to optimize the patient's living environment and possibly help with the implementation of the necessary aids in the continuity of medical care.
62145267|NCT03371316|EXPERIMENTAL|Hemicraniectomy Surgery with Viashield|All patients requiring a hemicraniectomy surgery will receive the anti-adhesion barrier of amnion patch.
62145268|NCT02773862|EXPERIMENTAL|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an invasive monitoring device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 48 hours, continuously depending on the patient's clinical condition.
62509799|NCT02247050|EXPERIMENTAL|Commitment invitation at time 6|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 7 months and then cross over to the intervention period for 1 month."
62509800|NCT04065061|EXPERIMENTAL|Experimental|Erinacine A-enriched Hericium Erinaceus Mycelia dietary supplement from week 0 to week 49.
62509801|NCT04065061|PLACEBO_COMPARATOR|Placebo|Placebo dietary supplement from week 0 to week 49.
62707349|NCT03379974|EXPERIMENTAL|ARM D: Exercise followed by DDAVP|"1. Intervention #1: Exercise intervention~2. Intervention #2: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing \<50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
62707350|NCT03958331|ACTIVE_COMPARATOR|Control Group|Automated reminders and individualized adherence feedback reports
62707351|NCT03958331|EXPERIMENTAL|Treatment Group|Automated reminders and individualized adherence feedback reports with social norms comparisons
62145269|NCT02142595|EXPERIMENTAL|dexmeditomidine group D|The sedative solution was prepared as a 10µg /ml dexmedetomidine in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
62145270|NCT02142595|EXPERIMENTAL|Midazolam group M|The sedative solution was prepared as a 0.375mg/ml midazolam or normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
62145271|NCT02142595|NO_INTERVENTION|group control|normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
62145272|NCT06176014|OTHER|(PEKK fixed hybrid prostheses|5 implants were placed in mandibular arch by surgical guide and after 3 months the prostheses was constructed by using digital workflow
62145273|NCT06176014|OTHER|PFM fixed hybrid prostheses|5 implants were placed in mandibular arch by surgical guide and after 3 months the prostheses was constructed by using digital workflow until making wax pattern the casting was made.
62145274|NCT02052687|EXPERIMENTAL|Part 1: LFX453/placebo|once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
62145275|NCT02052687|EXPERIMENTAL|Part 2 groupA: LFX453/placebo|once daily: LFX453 cream 1 / Placebo 1
62707352|NCT00457626|EXPERIMENTAL|Valsartan Open Label|Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.
62145276|NCT02052687|EXPERIMENTAL|Part 2 groupB: LFX453/placebo|once daily: LFX453 cream 2 / Placebo 2
62145277|NCT02052687|EXPERIMENTAL|Part 2 groupC: LFX453/LFX453|once daily: LFX453 cream 1 / LFX453 cream 2
62145278|NCT02052687|OTHER|Part 2 groupD: Imiquimod|once daily: imiquimod cream
62509802|NCT02082249|EXPERIMENTAL|ABT-SLV187|up to 6 years
62509803|NCT02990806|EXPERIMENTAL|Stages 1, 2 and 3: NI-071 Group|Participants received intravenous (IV) infusion of NI-071 at a dose of 3 milligrams/kilograms (mg/kg) at Weeks 0, 2, 6, 14 during stage 1 and at Weeks 22, 30, 38, 46, and 54 during stage 2. Participants were followed up to Week 62 (Stage 3).
62509804|NCT02990806|EXPERIMENTAL|Stage 1: Remicade-US Group|Participants received IV infusion of Remicade-US (infliximab) at a dose of 3 mg/kg at Weeks 0, 2, 6, 14 during stage 1.
62707353|NCT04991948|EXPERIMENTAL|CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab|
62707354|NCT02568657|ACTIVE_COMPARATOR|Celox group|Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
62509805|NCT02990806|EXPERIMENTAL|Stage 2 and Stage 3: Remicade US to Remicade-US Group|Participants who received Remicade US during stage 1; were re-randomized during stage 2 to continue Remicade-US dose 3 mg/kg from Week 22 through Week 54 with every 8 weeks dosing intervals. Participants were followed up to Week 62 (Stage 3).
62509806|NCT02990806|EXPERIMENTAL|Stage 2 and Stage 3: Remicade US to Switch Group|Participants who received Remicade US during stage 1; were re-randomized during stage 2 and received IV infusion of NI-071 at Week 22 followed by Remicade-US at Week 30, followed by NI-071 at Weeks 38, 46, and 54. Participants were followed up to week 62 (Stage 3).
61969170|NCT02363517|ACTIVE_COMPARATOR|Group C|Primary (n=40) and secondary participants with chronic HCV infection (approx. n=50%\*100) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.
61969171|NCT01849380|EXPERIMENTAL|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
62145279|NCT02052687|EXPERIMENTAL|Part 3: LFX453/placebo|twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
62351381|NCT04228562|EXPERIMENTAL|Non-modifiable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
62509807|NCT03353311||Enhanced Recovery After Surgery|"Patients undergoing elective colorectal surgical resection for benign/malignant disease.~A multidisciplinary validated approach based on 24 items including Preadmission information, education and counselling Preoperative optimization (increasing exercise, stop smoking and alcohol consumption should 4 weeks before surgery) No preoperative bowel preparation Use of preoperative carbohydrate drinks Pre-anesthetic medication Prophylaxis against thromboembolism Antimicrobial prophylaxis and skin preparation Standard anesthetic protocol for rapid awakening PONV Mini-invasive surgery No nasogastric dreinage Prevention of intraoperative hypothermia Perioperative fluid management No drains in the peritoneal cavity after colonic anastomosis Early remouval of urinary drainage (24-48 hrs) Prevention of postoperative ileus (including use of postoperative laxatives) Postoperative analgesia Perioperative nutritional care Postoperative control of glucose Early mobilization Auditing"
62509808|NCT01937819|EXPERIMENTAL|SMART arm|Using SMARTPHONE application for self judging bowel preparation
62509809|NCT01937819|NO_INTERVENTION|Conventional arm|Non-using SMARTPHONE application for bowel preparation
62509810|NCT00872924|EXPERIMENTAL|1|sumatriptan succinate 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan) of OHM laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA).
62509811|NCT00872924|ACTIVE_COMPARATOR|2|IMITREX® 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan)
62509812|NCT03112148|EXPERIMENTAL|Treatment A|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fed state.
62509813|NCT03112148|EXPERIMENTAL|Treatment B:|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fed state.
62509814|NCT03112148|EXPERIMENTAL|Treatment C|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fasted state.
62351382|NCT04228562|EXPERIMENTAL|Non-modifiable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
62509815|NCT03112148|EXPERIMENTAL|Treatment D|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fasted state.
62509816|NCT03112148|EXPERIMENTAL|Treatment E|Single oral 10 mg dose of tofacitinib MR-MODERATE administered in the fasted state
62509817|NCT03112148|EXPERIMENTAL|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state
62509818|NCT06068777|NO_INTERVENTION|Control group|with no interference before dental anesthesia and extraction
61969172|NCT01849380|ACTIVE_COMPARATOR|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
62145280|NCT00513071|EXPERIMENTAL|Treatment (saracatinib)|Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62509819|NCT06068777|ACTIVE_COMPARATOR|Rosemary group|children inhaled two drops of rosemary oil for 3 minutes before the procedures of dental anesthesia and extraction of a primary molar,
62509820|NCT06068777|ACTIVE_COMPARATOR|Lemongrass group|children inhaled two drops of lemongrass oil, for 3 minutes before the procedure of dental anesthesia and extraction of a primary molar
62509821|NCT00117741|EXPERIMENTAL|Dialectical Behavior Therapy|Participants receive standard dialectical behavior therapy and suboxone
62509822|NCT00117741|ACTIVE_COMPARATOR|Drug Counseling|Participants receive standard individual and group counseling and suboxone.
62509823|NCT04783116|EXPERIMENTAL|Plant stanols (3g/day)|Consumption of plant stanol chews
62509824|NCT04783116|PLACEBO_COMPARATOR|Control|Consumption of placebo chews (without plant stanols)
62509825|NCT00353652|ACTIVE_COMPARATOR|Study#1: chlorthalidone (CTD) first then spironolactone (SP)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months of chlorthalidone first (12.5-25 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with spironolactone (25-75 mg/d)without washout period for 3 months. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
61969173|NCT02611557|OTHER|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
61969174|NCT01112241|EXPERIMENTAL|albuterol-tiotropium|At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide \[Spiriva®\] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).
62509826|NCT00353652|ACTIVE_COMPARATOR|Study #1: spironolactone (SP) first, then chlorthalidone (CTD)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months spironolactone first (25-75 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with chlorthalidone(12.5-25 mg/d) without washout period. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
62509827|NCT00353652|ACTIVE_COMPARATOR|Study# 2 CTD alone 1st, CTD+ SP 2nd, CTD+IR 3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dosespironolactone (SP) 25 mg daily for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
62509828|NCT00353652|ACTIVE_COMPARATOR|Study# 2 CTD alone 1st, CTD+IR 2nd, CTD+SP3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, followed by fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
62509829|NCT00353652|ACTIVE_COMPARATOR|Study# 2 CTD+SP1st, CTD alone 2nd, CTD+IR 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
62509830|NCT00353652|ACTIVE_COMPARATOR|Study# 2 CTD+SP1st, CTD+IR 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, then fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
62509831|NCT00353652|ACTIVE_COMPARATOR|Study# 2 CTD+IR 1st, CTD alone 2nd, CTD+SP 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
62509832|NCT00353652|ACTIVE_COMPARATOR|Study# 2 CTD+IR 1st, CTD+SP 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, followed by fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
62509833|NCT01380249|EXPERIMENTAL|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12 mg, 2.24 mg, 3.5 mg and 14 mg, 28 mg and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or the patient is refractory to it.
62509834|NCT00108082|EXPERIMENTAL|Carvedilol CR|Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study. (In the protocol, carvedilol CR was referred to as carvedilol modified-release \[MR\].)
62509835|NCT00108082|EXPERIMENTAL|Atenolol|Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
62509836|NCT00108082|EXPERIMENTAL|Lisinopril|Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
62509837|NCT02605252|EXPERIMENTAL|CHB patients|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg \<1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks.
62145281|NCT04348669|EXPERIMENTAL|Tele-yoga|This is a single group study with all subjects included in this single arm. All subjects will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
62509838|NCT03378414|EXPERIMENTAL|Intravenous infusion group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
62509839|NCT03378414|EXPERIMENTAL|Intrathecal injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
62145282|NCT05038215|EXPERIMENTAL|multifactor intervention|The experimental group will receive adherence promotion techniques in addition to routine care.
62351383|NCT04800471|ACTIVE_COMPARATOR|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
62351384|NCT04800471|PLACEBO_COMPARATOR|Point of Care Glucose Group|Participants in this group will be monitored by point of care glucose values
62351385|NCT05399030|EXPERIMENTAL|ICP-332|Single ascending doses of ICP-332 tablet; Multiple ascending doses of ICP-332 tablet
62351386|NCT05399030|PLACEBO_COMPARATOR|Placebo|Single ascending doses of placebo; Multiple ascending doses of placebo
62351387|NCT03532880|EXPERIMENTAL|Participants with Small Cell Lung Cancer|
62351388|NCT01357980|EXPERIMENTAL|Dysport 750 U (15 injection sites)|
62351389|NCT01357980|PLACEBO_COMPARATOR|Placebo (15 injection sites)|
62351390|NCT01357980|EXPERIMENTAL|Dysport 750 U (30 injection sites)|
62351391|NCT01357980|PLACEBO_COMPARATOR|Placebo (30 injection sites)|
62351392|NCT01419080||Peripheral Arterial Disease (PAD) patients|Patients with new onset or exacerbation of peripheral artery (PA) symptoms.
62351393|NCT03411707||Mutiple screening test group|
62351394|NCT04740333||Group A- Normal ICU admission blood glucose level|Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).
62351395|NCT04740333||Group B- High ICU admission blood glucose level|Patients with admission blood glucose level higher than 180 mg / dL.
62707355|NCT02568657|ACTIVE_COMPARATOR|Bakri balloon group|Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
62707356|NCT04069988|NO_INTERVENTION|Control group|The control group (CG) received routine care and was required to physical activity for thirty minutes
62707357|NCT04069988|EXPERIMENTAL|Baduanjin program|The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks ; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
62707358|NCT04626934|ACTIVE_COMPARATOR|control group|Patients in the control group will recieve conventional occupational therapy treatment: 3 weeks of all together 12 sessions, 45 minutes each.
62707359|NCT04626934|EXPERIMENTAL|Intervention group|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
62707360|NCT00420186|EXPERIMENTAL|1|
62707361|NCT04697927||MSK Patients|Patients include those undergoing cancer screening and treatment as well as cancer survivors that received COVID-related care. Both adult and pediatric patients will be included.
62707362|NCT04697927||Household Members (identified by MSK Patient)|Individuals over the age of 18 (i.e., individuals currently living in the same household as the MSK enrollee).
62707363|NCT02873728|EXPERIMENTAL|RIC|In the study group, a blood pressure cuff will be inflated to 50 mmHg above systolic blood pressure while the performing investigator examines the radial pulse to ensure complete blood flow obstruction. Ischemia will be performed for 3 cycles of 5 min each and 10 min resting between cycles.
62707364|NCT02873728|SHAM_COMPARATOR|Control|In the control group, a blood pressure cuff will be inflated to 10 mmHg (Sham procedure) for 3 cycles of 5 min each and 10 min resting between cycles.
62707365|NCT01734902|EXPERIMENTAL|1 Hyoscine butylbromide|drops, oral administration with 240 mL water
62707366|NCT01734902|EXPERIMENTAL|2 Hyoscine butylbromide|sugar coated tablets, oral administration with 240 mL water
62707367|NCT06544460|EXPERIMENTAL|Recurrent Ovarian Cancer After PARPi Therapy|After treated with PARP inhibitors, patients have recurrent ovarian cancer and need a surgery.
62707368|NCT05826509|ACTIVE_COMPARATOR|Control arm|
62509840|NCT03378414|NO_INTERVENTION|Control groups|No intervention
62539360|NCT02187692|EXPERIMENTAL|MCT|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
62707369|NCT05826509|EXPERIMENTAL|Experimental arm|
62707370|NCT00841815|EXPERIMENTAL|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
62707371|NCT00841815|ACTIVE_COMPARATOR|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
62707372|NCT02092714||Ancillary-correlative (molecular analysis)|Previously collected tissue samples are analyzed via mutational sequencing and immunohistochemistry.
62707373|NCT04272801|EXPERIMENTAL|Pre-operative endocrine therapy|All participants enrolled to the study will receive 3 months of pre-operative endocrine therapy (e.g. tamoxifen or aromatase inhibitors (AIs) such as letrozole, anastrozole, or exemestane). The choice and dose of endocrine therapy will be at the discretion of the treating medical oncologist.
62707374|NCT03859219|EXPERIMENTAL|Dose 1 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
62707375|NCT03859219|EXPERIMENTAL|Dose 2 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
62707376|NCT03859219|EXPERIMENTAL|Dose 3 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
62707377|NCT03859219|EXPERIMENTAL|Dose 1 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
62707378|NCT03859219|EXPERIMENTAL|Dose 2 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
62707379|NCT03859219|EXPERIMENTAL|Dose 3 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
62707380|NCT03859219|EXPERIMENTAL|Dose 2 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
62707381|NCT03859219|EXPERIMENTAL|Dose 3 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
61969175|NCT04359550|EXPERIMENTAL|treatment group|ZKAB001 injection 10mg/kg once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
62351396|NCT02890043|EXPERIMENTAL|Robot|Intervention: Surgery: robot-assisted spine surgery, device: TiRobot surgery system
62351397|NCT02890043|ACTIVE_COMPARATOR|Free-hand|Intervention: Surgery: free-hand surgery
62539361|NCT04035915|EXPERIMENTAL|Limited driving pressure ventilation|
62539362|NCT04035915|EXPERIMENTAL|Conventional mechanical ventilation strategies|
62707382|NCT03859219|PLACEBO_COMPARATOR|Placebo in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
62539363|NCT04522817|EXPERIMENTAL|CLBS119 Active Treatment|Single administration of CLBS119
61969176|NCT04359550|PLACEBO_COMPARATOR|control group|placebo will given in the same way for once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
61969177|NCT04216095|ACTIVE_COMPARATOR|Electroconvulsive Therapy (ECT)|Right unilateral (RUL, N=15), or Bitemporal (BT, N=15) ECT
61969178|NCT04216095|ACTIVE_COMPARATOR|Magnetic Seizure Therapy (MST)|High-dose magnetic seizure therapy (HD-MST)
62351398|NCT01828918|OTHER|early recurrence|find the postoperative early relapse out
62351399|NCT04794946|EXPERIMENTAL|Liver Cirrhosis|Evidence of liver cirrhosis established during the clinical investigations and/or hospital stay, as evidenced by clinical, endoscopic, radiological and/or histological criteria.
61969179|NCT03773081|OTHER|Magmaris implantation|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice.
61969180|NCT01904591|EXPERIMENTAL|Selenium and Vitamin E|single arm, all subjects receive both vitamins for 1 year from time zero.
61969181|NCT04250870|ACTIVE_COMPARATOR|Nursing Home Residents|Nursing home residents (n=59) were evaluated in five different nursing homes.
61969182|NCT04250870|ACTIVE_COMPARATOR|Community-Dwelling Elderly|The community-dwelling elderly people (n=59) were selected from two different municipalities of the city.
62351400|NCT04794946|ACTIVE_COMPARATOR|Non Liver Cirrhosis (Healthy Control)|No major respiratory, cardiac comorbid illnesses or malignancy or immunosuppressed state
62351401|NCT00424294|ACTIVE_COMPARATOR|Celecoxib|Celecoxib with placebo therapy.
62351402|NCT00424294|OTHER|Methotrexate|Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
62351403|NCT00424294|EXPERIMENTAL|CP-195,543|CP-195,543 and Celecoxib dual therapy.
62351404|NCT01530555|EXPERIMENTAL|Treatment arm|"1. Rabbit ATG, Thymoglobuline (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months, with later tailing according to individual patient response. Aim to maintain trough whole blood CSA levels between 150 and 250 ng/ml."
62351405|NCT03201848|EXPERIMENTAL|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
62539364|NCT00386633|OTHER|1|Lower dosage: 10E7_TCID50
62539365|NCT00386633|ACTIVE_COMPARATOR|2|10E8_TCID50
61969183|NCT04803825|EXPERIMENTAL|Heavy Slow Exercise|One dedicated physiotherapist will supervise and instruct the exercise program on an individual basis. If the patient doesn't have access to a dumbbell, it will be offered free rental from the physiotherapy ward. Follow-up on the exercises will be scheduled as needed and tele rehabilitation will be offered as an option. Additionally to HSR exercises, participants will be instructed to perform daily stretches of the forearm.
61969184|NCT04803825|ACTIVE_COMPARATOR|Extracorporeal Shock wave therapy|The patients will receive rESWT (SwissDolodClast/EMS) once a week for three sessions. The treatment will be given by a physiotherapist trained in using rESWT. The rESWT is given on the ECRB tendon insertion area.
62539366|NCT03769714|ACTIVE_COMPARATOR|Saline Solution for Injection|Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
61969185|NCT04803825|ACTIVE_COMPARATOR|Information and advice|The information and advice group are given a single face-to-face session with a physiotherapist, lasting up to 60 minutes.
62539367|NCT03769714|EXPERIMENTAL|Exparel|Group B (study, n=26) to receive 20ml of liposomal bupivacaine (EXPAREL) into the stroma of the cervix at the 4 and 8 o'clock positions (innervation insertion points of the cervix).
62539368|NCT04463797|EXPERIMENTAL|Square-stepping exercise group|Square-stepping exercise
62539369|NCT04463797|ACTIVE_COMPARATOR|Control group|Whole-body stretching and upper extremity strengthening
62539370|NCT03047330|EXPERIMENTAL|Study arm|Participants completed 2 nights of unfragmented sleep followed by 3 nights of experimentally-fragmented sleep during high estradiol (E2) phase of their menstrual cycle (Sleep Block 1). A subset of participants repeated these procedures in an experimentally-induced low-E2 state (Sleep Block 2).
62539371|NCT00013091|OTHER|Arm 1|
62539372|NCT04132700|EXPERIMENTAL|ICU Patients|Patients admitted to the ICU will be monitored using the Q-NRG for up to 30 mins.
62539373|NCT00767624|OTHER|antidepressant + desensitization|Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
62539374|NCT00767624|OTHER|antidepressant + cognitive behavioral|Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
62539375|NCT01507766|EXPERIMENTAL|Early enteral nutrition|The enteral nutrition was started within 48h after admission
62539376|NCT01507766|ACTIVE_COMPARATOR|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
62539377|NCT00324727|EXPERIMENTAL|Arm I|"Patients undergo an isolated hepatic arterial infusion of melphalan over 30 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response undergo 2 additional courses~in the absence of ongoing or increasing toxicity."
62539378|NCT00324727|ACTIVE_COMPARATOR|Arm II|"Patients receive the best alternative therapy comprising supportive care, systemic or regional chemotherapy, hepatic artery (chemo)-embolization, or any other appropriate therapy at the National Cancer Institute or therapy at the discretion of their physician.~Patients may cross over to arm I if they have evidence of disease progression."
62539379|NCT03680612|EXPERIMENTAL|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg
62539380|NCT03680612|ACTIVE_COMPARATOR|cefepime monotherapy|cefepime 1 g or cefepime 2 g
62539381|NCT03812549|EXPERIMENTAL|Sintilimab Combined with SBRT and LDRT|"Part A-Dose escalation cohort. DOSE LEVEL: Stereotactic body radiation therapy (SBRT) dose at 30 Gy/3f + Low Dose Radiotherapy (LDRT) dose from 2 Gy to 10Gy + anti-PD-1 inhibitor 200mg.~Part-B - Expansion cohort. SBRT dose at 30 Gy/3f + LDRT + anti-PD-1 inhibitor 200mg, LDRT dose at MTD determined in Part A ."
62539382|NCT04610879|ACTIVE_COMPARATOR|Carbamazepine plus sleep intervention|
62539383|NCT04610879|ACTIVE_COMPARATOR|Carbamazepine plus standard care|
62539384|NCT04610879|ACTIVE_COMPARATOR|Levetiracetam plus sleep intervention|
62145283|NCT05038215|ACTIVE_COMPARATOR|Control|The control group will receive routine care
62509841|NCT01832402|EXPERIMENTAL|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD). FPNS administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of FPNS. Participant will rest for 30 minutes after walk test. FPNS administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. FPNS administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
62509842|NCT01832402|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of placebo nasal spray. Participant will rest for 30 minutes after walk test. Placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
62509843|NCT03889834|EXPERIMENTAL|Autotransfusion: blood stored at 4 ° C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days
62509844|NCT03889834|EXPERIMENTAL|Autotransfusion: blood stored at -80°C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days
62509845|NCT03889834|OTHER|Controls not transfused|no transfusion
62509846|NCT02956616|EXPERIMENTAL|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
62509847|NCT02956616|ACTIVE_COMPARATOR|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
62509848|NCT02277431|EXPERIMENTAL|Probiotic dietary supplement|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
62509849|NCT02277431|PLACEBO_COMPARATOR|Placebo|The placebo capsules utilized in this study will be indistinguishable from the probiotic dietary supplement capsules as they will be identical in appearance, odor, weight, and taste. Furthermore, the same sunflower oil matrix will be in both the probiotic dietary supplement and placebo. The only difference between the dietary supplement and placebo capsules will be the probiotic bacteria.
62509850|NCT02851719|EXPERIMENTAL|BF group|24 outpatient sessions of the PFMT (twice a week) using manometric-based BF equipment and daily home PFMT exercises.
62509851|NCT02851719|ACTIVE_COMPARATOR|PFMT group|24 outpatient sessions (twice a week) of PFMT without BF and daily home PFMT exercises.
62509852|NCT02341521|EXPERIMENTAL|OC000459 50 mg|OC000459 50 mg daily for 8 days
62707383|NCT03859219|PLACEBO_COMPARATOR|Placebo in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
61969186|NCT02395380|EXPERIMENTAL|C-reactive protein dosage|
61969187|NCT03086889|EXPERIMENTAL|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
62351406|NCT03201848|PLACEBO_COMPARATOR|Placebo|Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
62351407|NCT02807844|EXPERIMENTAL|Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W
62351408|NCT02807844|EXPERIMENTAL|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W
61969188|NCT03086889|OTHER|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
61969189|NCT05626257||Xolair|patients who prescribed with Xolair according to the current label information in Korea.
62145284|NCT00623337|EXPERIMENTAL|Newhints|Home visits
62145285|NCT00623337|NO_INTERVENTION|Control|Community based surveillance volunteers will continue with current duties eg urging attendance at immunisation clinics and child health weeks
62351409|NCT02807844|EXPERIMENTAL|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W
62351410|NCT02807844|EXPERIMENTAL|Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W
62351411|NCT02807844|EXPERIMENTAL|Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W
62351412|NCT02807844|EXPERIMENTAL|Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W
62351413|NCT02807844|EXPERIMENTAL|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)
62351414|NCT02807844|EXPERIMENTAL|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)
62351415|NCT02807844|EXPERIMENTAL|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)
61969190|NCT01411774|ACTIVE_COMPARATOR|Cognitive-behavioral therapy plus pill placebo|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with pill placebo taken 1 hour before the session.
61969191|NCT01411774|EXPERIMENTAL|Cognitive-behavioral Therapy plus d-cycloserine|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with d-cycloserine taken 1 hour before the session.
61969192|NCT04918433|ACTIVE_COMPARATOR|TRANSEVERSUS THORACIS MUSCLE PLANE BLOCK (TTPB)|After induction of anaesthesia, ultrasound guided transverses thoracis muscle plane block will be done using 0.25% bupivacaine
62707384|NCT03859219|PLACEBO_COMPARATOR|Placebo in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
61969193|NCT04918433|ACTIVE_COMPARATOR|PECTO-INTERCOSTAL FACIAL PLANE BLOCK (PIFB)|After induction of anaesthesia, ultrasound guided pectointercostal facial plane block will be done using 0.25% bupivacaine
62707385|NCT05900752|ACTIVE_COMPARATOR|QiMeiYan Probiotics|"1.5g/ sachet, containing the following ingredients:~* Bifidobacterium animalis subsp. lactis V9~* Lactobacillus casei Zhang~* Lactobacillus plantarum P-9~* Lactobacillus plantarum CCFM1143~* Xylo-oligosaccharide~* Maltodextrin~* Resistant Dextrin~* Blueberry powder"
61969194|NCT01084746|ACTIVE_COMPARATOR|PC-based tailored intervention|
61969195|NCT01084746|ACTIVE_COMPARATOR|Printed educational materials|
61969196|NCT01084746|NO_INTERVENTION|No patient intervention|Patients will not receive a patient-directed intervention.
62351416|NCT02807844|EXPERIMENTAL|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)
62351417|NCT04939870||PREDIALYSIS GROUP|(n = 48) - patients in the pre-dialysis period (stage G3b-G4 CKD) with moderate or severe decrease in eGFR (eGFR 44-29 ml / min / 1.73 m2),
62509853|NCT06469762|PLACEBO_COMPARATOR|Placebo|Individuals in this condition will receive treatment using plastic cups with two 2 mm holes drilled in either side of them, for all three treatment sessions.
61969197|NCT01104493|EXPERIMENTAL|1|Single dose of monovalent vaccine
61969198|NCT01104493|PLACEBO_COMPARATOR|2|Placebo
61969199|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
61969200|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
61969201|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
62351418|NCT04939870||END-STAGE RENAL DISEASE GROUP|patients with ESRD (n=78) - (eGFR \<15 ml/min /1.73 m2) undergoing renal replacement therapy. Depending on the method of renal replacement therapy used, two subgroups are distinguished: PD subgroup (n=35) including patients treated by peritoneal dialysis. In this subgroup, initially, due to the treatment technique, two groups were separated, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique, and a group of patients (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), HD subgroup (n = 43) including patients treated with repeated hemodialysis. Hemodialysis procedures were performed in each patient three times a week, via an arteriovenous fistula from own or artificial vessels. The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers. The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min.
62509854|NCT06469762|EXPERIMENTAL|Intervention|Individuals in this condition will receive treatment using regular plastic cups, for all three treatment sessions.
62539385|NCT04610879|ACTIVE_COMPARATOR|Levetiracetam plus standard care|
62539386|NCT04610879|ACTIVE_COMPARATOR|No AED plus sleep intervention|
62539387|NCT04610879|NO_INTERVENTION|No AED plus standard care|
62539388|NCT00400595|EXPERIMENTAL|1|Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
62539389|NCT00400595|ACTIVE_COMPARATOR|2|Mupirocin
61969202|NCT03935100|EXPERIMENTAL|Treatment Group|All visible diverticula clipped during index colonoscopy
61969203|NCT03935100|PLACEBO_COMPARATOR|Control Group|5 clips fired at random into colon lumen. No diverticula closed.
61976228|NCT04841902|EXPERIMENTAL|Life Style Intervention Manual (Home Based)|Home Based- Life Style Intervention Manual (Exercise, Dietary \& Educational Component for 16 weeks. Subject will be asked to maintain a regular exercise and dietary diary to ensure adherence to the program
62539390|NCT06232330|EXPERIMENTAL|Group A|TOA and conventional therapy
62539391|NCT06232330|EXPERIMENTAL|Group B|PNF and conventional therapy
62539392|NCT03813615|EXPERIMENTAL|"Pilot Proof-of-Concept"|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear (breast, prostate, and endometrial) or non-linear (lung) dosing schedule for a minimum of 2 weeks.
62539393|NCT03813615|EXPERIMENTAL|Phase 1a: Dose-Finding / Escalation|Individualized, progressive aerobic training consisting of treadmill walking ranging from a total of 90 mins/wk to 450 mins/wk delivered over 3 to 7 sessions/wk following a linear or non-linear dosing schedule for a minimum of 2 weeks. If a patient is temporarily unable to complete supervised sessions as a result of unforeseen circumstances, patients may be assigned low intensity unsupervised training sessions per EP/PI discretion.
62539394|NCT01381666|EXPERIMENTAL|INS316|inhalation via nebulizer given for 2 doses for 60 minutes each
62539395|NCT01381666|PLACEBO_COMPARATOR|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
62539396|NCT04869215|EXPERIMENTAL|EverVita Pro consumed at breakfast followed by an ad lib meal|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include EverVita Pro bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
61969204|NCT03688165||Treadmill-based Robotic Gait Training|The Treadmill-based Robotic Gait Training (TRGT) period will last 20 sessions, 3-5 days/week for at least 400' of exercise totally. The parameters to be respected for the robotic training will be the following for all patients: 0.9 km / h starting speed up to a maximum of 2.5 km / h; weight support not exceeding 40-45% of the body weight at the beginning and gradual progressive reduction depending on the case; for Lokomat: maximum assistance required at the start of treatment and gradual decrease during the treatment. The TRGT will always be associated with the traditional gait rehabilitation, and will be part of the Individual Rehabilitation Project which normally includes 3 hours of rehabilitation treatments for patients in the subacute phase, 60' of treatment for those in chronic phase.
61969205|NCT03688165||Traditional Over-ground Gait Training|"The Traditional Over-ground Gait Training (TOGT) period will last 20 sessions, 3-5 days / week for a total time that corresponds to the same total time of traditional overground gait training, or at least 400' totally at the end of the period.~By Traditional Therapy we mean any technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids."
61969206|NCT02176330|ACTIVE_COMPARATOR|Usual care|ePAQ-PF followed by a face to face consultation.
61969207|NCT02176330|EXPERIMENTAL|Virtual Clinic|ePAQ-PF followed by a telephone consultation.
61969208|NCT02917304|EXPERIMENTAL|GC3110A vaccine group|Participants administered a single dose of GC3110A(Quadrivalent Influenza Vaccine).
62707386|NCT05900752|PLACEBO_COMPARATOR|Placebo product|"1.5g/sachet, containing the following ingredients:~* Maltodextrin~* Blueberry powder"
62707387|NCT01015950|EXPERIMENTAL|Pumpy'Sup|Lipid-based nutrient supplement
62707388|NCT01015950|EXPERIMENTAL|SCSB|Processed, fortified, cereal-based food blend (SCSB for malnourished children)
62707389|NCT01015950|EXPERIMENTAL|Misola|Locally processed, fortified food blend (Misola)
62707390|NCT01015950|ACTIVE_COMPARATOR|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, oil) and a multiple micronutrient powder (Mix-Me) are provided to simulate the currently recommended enhanced home-prepared rehabilitation food mixture (farines enrchies) according to the national Mali CMAM protocol."
61969209|NCT02642289|EXPERIMENTAL|Probiotic1: Lactobacillus acidophilus|Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)
61969210|NCT02642289|PLACEBO_COMPARATOR|Placebo|Inactivate substance
61969211|NCT02642289|EXPERIMENTAL|Probiotic2: Lactobacillus Rhamnosus GG ®|Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)
61969212|NCT05377983|EXPERIMENTAL|the intervention group|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes. Pain intensity and vital signs will be evaluated and recorded before each application and in the first five minutes after the application.
61969213|NCT05377983|NO_INTERVENTION|the control group|The control group will only receive routine care.
61969214|NCT03731780|EXPERIMENTAL|Personalized Treatment|Intervention by (standard preventive measures + targeting individual caries risk factors)
61969215|NCT03731780|EXPERIMENTAL|Chlorhexidine and Rremineralization|Intervention is (chlorhexidine + Remineralizing agent + standard preventive measures)
61969216|NCT03731780|ACTIVE_COMPARATOR|Control|standard preventative measures (tooth brushing, fluoride tooth paste, interdental cleaning)
61969217|NCT00830596|ACTIVE_COMPARATOR|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
61969218|NCT00830596|ACTIVE_COMPARATOR|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
62509855|NCT04241133|EXPERIMENTAL|Experimental Group|A 12 week pilot trial will be conducted at two rural food pantries in Montana with 40 low-income adults to measure within-participant changes over time. The study will provide the initial investigation of the extent to which UP3 will improve overall dietary quality as measured by the Healthy Eating Index-2015 (HEI) compared to baseline. Psychosocial factors will be measured to understand changes in knowledge, attitudes, and perceptions about processed foods. Data on biomarkers of health (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to assess the feasibility of measuring potential short-term health effects of UP3.
62707391|NCT03732755|EXPERIMENTAL|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
61969219|NCT00830596|PLACEBO_COMPARATOR|Sham Intervention|Light effleurage and a sham mechanically-assisted chiropractic treatment for 2 weeks followed by full spine manipulation for 4 weeks
61969220|NCT00467571|EXPERIMENTAL|I|Drug: lansoprazole, clarithromycin, amoxycillin
61969221|NCT00875251||term infants body composition|Term infants from 2 days of life to 7 days of life without IUGR
61969222|NCT00875251||preterm infants body composition|very low birth weight infants before discharge
61969223|NCT03656328|EXPERIMENTAL|Lactobacillus Reuteri 4659|This Arm received standard antibiotic therapy, consisting of ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for seven days, with supplementation with the probiotic L. reuteri 4659 twice a day for 10 days
61969224|NCT03656328|PLACEBO_COMPARATOR|Placebo|This arm received the same standard antibiotic therapy and a matching placebo for the same periods.
61969225|NCT05117320|EXPERIMENTAL|AI support|
61969226|NCT05117320|NO_INTERVENTION|Non-AI support|
61969227|NCT05112432|ACTIVE_COMPARATOR|Treatment as Usual|Participants will be treated as usual and will not complete cognitive training or use the Personalized Real-Time Motivational Enhancement App. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
61969228|NCT05112432|EXPERIMENTAL|Cognitive Training plus Personalized Real-Time Intervention for Motivational Enhancement App (PRIME)|The Mobile Intervention. 20 hours of training consisting of 10 hours of cognitive training exercises plus 10 hours of social cognitive training exercises will be delivered over the course of 12 weeks in addition to PRIME. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
61969229|NCT05741320||public|Subjects older than 16 years of age and not working in any health sector will be included in the study.
61969230|NCT04368767|NO_INTERVENTION|Usual Care: Incubator|The infant will remain in the incubator and stress biomarkers will be collected per protocol
61969231|NCT04368767|EXPERIMENTAL|Intervention: Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, 30 minutes after feeding. SSC will usually occur in the afternoon between 11:30-12:30 pm or 14:30-15:30pm. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. The room will be monitored to maintain a temperature of 72-77 degrees Fahrenheit during SSC. Stress biomarkers will be collected per protocol.
61969232|NCT05993468||TMC - group 1|TMC - group 1 was a closed group treated at a specialized outpatient facility for adult clients with CPTSD and complex dissociative disorders. Group 1 was led by two clinical psychologists
62351419|NCT04939870||CARDIOLOGY GROUP|• CARD group (n = 37) - patients with at least one history of cardiovascular events, admitted to hospital for elective angiography, without any signs of impaired kidney function. The studies in this group were to show the changes that occur as a result of diseases of the cardiovascular system and the functioning of the kidneys.
62351420|NCT04939870||HEALTHY VOLUNTEERS|Healthy volunteers, (n = 32) - it was composed of healthy people, with no evidence of impairment in renal function and cardiovascular function in the history and at the time of enrollment in the study.
62509856|NCT04241133|NO_INTERVENTION|Control Group|20 separate participants from a different food pantry will be enrolled into a control group. The control group will be assessed at baseline and 12 weeks for dietary intake, height, weight, waist circumference, food security, demographics, and psychosocial factors.
62509857|NCT04260321||AI|Artificial intelligence colonoscopy
62351421|NCT02938767||peritoneal dialysis patients|37 peritoneal dialysis patients followed at the Istanbul Medical Faculty from October 1994 to October 2011
62509858|NCT04260321||Control|White light colonoscopy
62509859|NCT02994394|EXPERIMENTAL|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
61969233|NCT05993468||TMC - group 2|TMC - group 2 was connected to specialized mental health services, but the intervention itself was carried out at a community centre. The community centre has collaborated with the District Psychiatric Centre (DPS) for many years, hosting an TMC group open to anyone attending the community centre in addition to clients connected to the DPS. This open concept was continued through the study intervention, but only clients connected to the DPS were included in the study.
61969234|NCT03274505||Stroke patients|Patients seen by a rehabilitation physician at a routine 3 months' post-stroke examination
62509860|NCT02994394|EXPERIMENTAL|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
61969235|NCT03274505||TIA patients|"Patients seen by a stroke specialist at the SOS TIA examination"
61969236|NCT01102751||Vitamin D deficient females|(n =18, mean age 29.1±9.9 yrs)
61969237|NCT01102751||vitamin D sufficient healthy females|(control group; n = 19, mean age 28.5±5.2 yrs)
61969238|NCT01102751||genetically-determined hypophosphatemic rahitis|(n=13, mean age 26.5±15.1 yrs)
62351422|NCT02938767||renal transplant recipients|20 renal transplant recipients followed at the Istanbul Medical Faculty from October 1994 to October 2011 setted as the control group
62509861|NCT02994394|EXPERIMENTAL|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
62509862|NCT02994394|EXPERIMENTAL|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
62509863|NCT02994394|EXPERIMENTAL|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
62509864|NCT02994394|EXPERIMENTAL|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
62509865|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
61969239|NCT04459091|EXPERIMENTAL|Amino essential acids|oral supplementation with a mixture of amino essential acids 8 gr die in two administrations for six weeks
61969240|NCT04459091|PLACEBO_COMPARATOR|Placebo|placebo consisting in isocaloric product containing maltodextrins in two administrations for six weeks
61976229|NCT04841902|PLACEBO_COMPARATOR|Control|Age matched Control Group followed for 16 weeks with General Advise to stay healthy and active
61976230|NCT05241067|PLACEBO_COMPARATOR|Normal saline|Placebo (Dose: equal volume saline) + Standard of care
61976231|NCT05241067|ACTIVE_COMPARATOR|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
62509866|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
62509867|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
62707392|NCT01895192|OTHER|Fertile men|Assessment of sperm morphology by high magnification with interference contrast microscopy.
61976232|NCT05966168|EXPERIMENTAL|Micra AV Exercise Testing|All participants will have Micra AV 2.0 implanted then undergo exercise testing while wearing Holter Monitor
62351423|NCT02679495|ACTIVE_COMPARATOR|Lifestyle intervention|A better lifestyle that are supposed to prevent gastric cancer occurrence are advised to patients. Measures includes dietary change and cessation of smoking and alcohol abuse. Behavioural and cognitive strategies from investigators are performed to patients to ensure adherence to established intervention.
62351424|NCT02679495|NO_INTERVENTION|No intervention|No meassures are taken to change life style of enrolled patients.
62351425|NCT01383642||individuals age >=70|
62351426|NCT02849626|EXPERIMENTAL|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
62351427|NCT03351439|ACTIVE_COMPARATOR|Group 1|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily x 3 weeks
62509868|NCT01961752|PLACEBO_COMPARATOR|Control group|
62509869|NCT01961752|EXPERIMENTAL|Bupivacaine only group|
62509870|NCT01961752|ACTIVE_COMPARATOR|Bupivacaine with triamcinolone group|
62509871|NCT02866591|EXPERIMENTAL|Arm A|Patients have a mammography performed by themselves according to auto-compression procedure. The radiologist leads the compression at a minimum threshold of 40 Newton, then leaves the control of the compression to the patient. The radiologist treats only the positioning of the breast on the sensor.
62707393|NCT05002725|EXPERIMENTAL|PENG|An ultrasound guided PENG catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
61976233|NCT02550366||CMR|Subjects with no contraindication to magnetic resonance imaging, who will undergo cardiac MRI scanning.
61976234|NCT01948453|ACTIVE_COMPARATOR|Garlic|daily consumption of two odor controlled garlic tablets
62351428|NCT03351439|EXPERIMENTAL|Group 2|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Zopiclone 7.5 mg nightly for 7 days
62351429|NCT03351439|EXPERIMENTAL|Group 3|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Gabapentin 600 mg pre-operatively for one dose and 600 mg post-operatively for one dose
62351430|NCT03351439|EXPERIMENTAL|Group 4|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Celebrex 400 mg pre-operatively for one dose
62351431|NCT04470128|EXPERIMENTAL|Stage I: HSK21542 0.5 μg/kg|intravenous injection
62351432|NCT04470128|EXPERIMENTAL|Stage I: HSK21542 1 μg/kg|intravenous injection
62351433|NCT04470128|EXPERIMENTAL|Stage II : HSK21542 0.5 μg/kg|intravenous injection
62351434|NCT04470128|EXPERIMENTAL|Stage II : HSK21542 1 μg/kg|intravenous injection
62351435|NCT04470128|EXPERIMENTAL|Stage II : HSK21542 2 μg/kg|intravenous injection
62351436|NCT04470128|PLACEBO_COMPARATOR|Stage II : placebo|intravenous injection
62351437|NCT04696237||orthodontists|orthodontists with more than 2 years of working experience
62351438|NCT04696237||general dentists|with more than 2 years of working experience
62351439|NCT04696237||oral and maxillofacial surgeons|with more than 2 years of working experience
62351440|NCT04696237||plastic surgeons|with more than 2 years of working experience
62351441|NCT04696237||cleft nurses|with more than 2 years of working experience
62351442|NCT04696237||speech therapists|with more than 2 years of working experience
62351443|NCT04696237||ENT specialists|with more than 2 years of working experience
62351444|NCT04696237||psychiatrists|with more than 2 years of working experience
62351445|NCT04696237||Social workers|with more than 2 years of working experience
62351446|NCT01005446||RSP Device|Post Market Study
62351447|NCT02436733|EXPERIMENTAL|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
62351448|NCT02436733|ACTIVE_COMPARATOR|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
62351449|NCT05995925||Patients with planned ICU admission|Patients with preoperative planned ICU admission
62351450|NCT05995925||Patients with unplanned ICU admission|Patients with preoperative unplanned ICU admission
62351451|NCT05482282|EXPERIMENTAL|Recombinant Hep B new Bulk + Penta with Recombinant HepB new Bulk|1 dose Recombinant Hepatitis B new Bulk vaccine at birth + 3 doses Pentavalent with Recombinant HepB new Bulk vaccine
62351452|NCT05482282|ACTIVE_COMPARATOR|Hep B (Registered) + Pentabio (Registered)|1 dose Recombinant Hepatitis B vaccine (Registered) + 3 doses Pentabio with Recombinant HepB new Bulk vaccine
62351453|NCT04930211|ACTIVE_COMPARATOR|Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
62351454|NCT04930211|ACTIVE_COMPARATOR|Degenerative disc disease without Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
62351455|NCT04721574|ACTIVE_COMPARATOR|Bright light therapy|Daily exposure to a high brightness LED light box for 30 minutes as soon as possible after awakening, preferably between 7 and 8 AM in the patient's hospital room The device emits 10,000 lux of cool-white fluorescent light at 50-75 cm from the screen to the cornea with an ultraviolet filter
62509872|NCT02866591|ACTIVE_COMPARATOR|Arm B|Patients have a mammography performed by the radiologist according to standard procedure.
62707394|NCT05002725|ACTIVE_COMPARATOR|Femoral Block|An ultrasound guided Femoral Nerve catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
62707395|NCT02000102||Diabetic Macular Edema Patients Switched to Aflibercept|
62509873|NCT00759720|EXPERIMENTAL|TAK-559 16 mg QD + Glyburide QD|
62509874|NCT00759720|EXPERIMENTAL|TAK-559 32 mg QD + Glyburide QD|
62707396|NCT00855361|EXPERIMENTAL|Rabeprazole sodium|
62736700|NCT01919073|EXPERIMENTAL|Immediate Treatment Group|The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
61976235|NCT01948453|PLACEBO_COMPARATOR|Placebo|daily consumption of placebo
61976236|NCT02865187|EXPERIMENTAL|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
61976237|NCT02865187|ACTIVE_COMPARATOR|Vit D + non-hormonal contraception|600IU/day Vitamin D
62351456|NCT04721574|SHAM_COMPARATOR|Sham Therapy|Light-therapy with filters that reduced lamp output to less than 50 lux. for 30 minutes as soon as possible after awakening.
62351457|NCT05306548|ACTIVE_COMPARATOR|Surgery treatment strategy|Primary open surgical carpal tunnel release. Treatment effect is monitored on scheduled follow-up visits. Re-operation may be performed if medically indicated (e.g. postoperative complication, or failure of the primary procedure)
62509875|NCT00759720|ACTIVE_COMPARATOR|Glyburide QD|
62509876|NCT04075851||Hashimoto or Grave's disease patients in treatment|Draw 10 ml venous blood
62509877|NCT04075851||Hashimoto or Grave's disease patients on initial treatment|10 ml of venous blood was extracted every month for three months
62509878|NCT04075851||Pregnant woman with Hashimoto or Grave's disease|10 ml venous blood was extracted every month to postpartum for 6 months
62509879|NCT04075851||Healthy crowd|Draw 10 ml venous blood
61969241|NCT06340815|EXPERIMENTAL|single-arm objective performance criteria (OPC)|According to the NMPA Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response (CR) + Partial Response (PR)+ Stable Disease (SD), and the definition of tumor disease control rate in this clinical trial is basically identical. Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate; the main safety evaluation by incident of acute radiation injury and adverse event.
61969242|NCT01753791|EXPERIMENTAL|Cohort 1|
61969243|NCT01753791|EXPERIMENTAL|Cohort 2|
61969244|NCT01753791|EXPERIMENTAL|Cohort 3|
61969245|NCT01753791|EXPERIMENTAL|Cohort 4|
61969246|NCT02344485|EXPERIMENTAL|OMM treatment|Subject will receive osteopathic manipulative treatment protocol for constipation in Parkinson's disease once a week for 4 weeks, in addition to continuing with their routine care
61969247|NCT02344485|NO_INTERVENTION|Control|Subjects will continue with their routine care. No OMM will be performed during this study period
61969248|NCT05608889|EXPERIMENTAL|Mindfulness Enhanced Web App-enabled Total Worker Health Program|The Total Worker Health Mindful Program will include 12, 45-minute sessions completed each week at participant's workplace. Sessions will be guided by written curriculum and focus on healthy eating, exercise, sleep and stress reducing behaviors enhanced by mindfulness activities. Participants will be provided with free enrollment codes to use the Headspace® application (app).
61969249|NCT03085420|EXPERIMENTAL|≥30% TBSA burn injury|For patients in Group 1 with ≥30% TBSA, a baseline Echocardiogram (ECHO) will be obtained approximately one week from admission and monthly (+/- 1 week) or at an interval determined by cardiology during the acute inpatient stay. ECHO tests will be discontinued after 3 negative exams or when discontinued by cardiology, whichever comes first.
61969250|NCT03085420|NO_INTERVENTION|<30% TBSA burn injury|For patients in Group 2 with \<30% TBSA and presence of a cardiac abnormality standard clinical care appropriate for the type of arrhythmia will be followed.
61969251|NCT04744142|NO_INTERVENTION|Placebo|Received 10% protein in nutrition + placebo supplement
61969252|NCT04744142|EXPERIMENTAL|Ketone|Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day
61969253|NCT04744142|EXPERIMENTAL|High protein|Received 30% protein in nutrition + placebo supplement
61969254|NCT04744142|EXPERIMENTAL|High protein + ketone|Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day
61969255|NCT02986399||Standard care|Hip fracture patients operated at Akershus University hospital in 2012 and 2013.
62509880|NCT06103279|EXPERIMENTAL|Empa Arm|"(Intervention group = 20 patients) \>\> will receive the standard chemotherapy protocol (DOX-based chemotherapy) plus Empagliflozin.~Empagliflozin dose and duration:~According to the Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction with or without diabetes, The recommended dose of empagliflozin is 10 mg once daily.~1 tablet once daily of continuously starting from 1 week before starting DOX till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol."
62509881|NCT06103279|NO_INTERVENTION|Control Arm|(Control group = 20 patients) \>\> will receive the standard chemotherapy protocol (DOX-based chemotherapy) only.
62509882|NCT01355848|EXPERIMENTAL|Brief Intervention|The brief intervention consists of stepped care protocol, including building rapport, functional analysis of suicidal behavior, and crisis planning
62509883|NCT01355848|NO_INTERVENTION|care as usual|Patients randomized to the care as usual arm will not receive the brief intervention.
62509884|NCT02857647|EXPERIMENTAL|The experimental group|"Participants who will assigned to the experimental group will be asked to watch an information video of 30 minutes 1-2 weeks prior to the surgery date.~n=100."
62509885|NCT02857647|NO_INTERVENTION|The control group|"Participants who will assigned to the control group will receive standard care and will not asked to watch a videotaped lecture prior to the surgery.~n=100."
62509886|NCT05755087|EXPERIMENTAL|Treatment (Tegavivint)|Patients receive tegavivint IV on study. Patients also undergo CT and/or PET and undergo blood sample collection throughout the trial.
61969256|NCT02986399||Fast track patient pathway|Hip fracture patients operated at Akershus University hospital in 2014 and 2015.
61969257|NCT04661540|EXPERIMENTAL|Auxora|"Auxora will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours; After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
61969258|NCT04661540|PLACEBO_COMPARATOR|Placebo|"Placebo will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours. After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
61969259|NCT03859349|ACTIVE_COMPARATOR|Systematic Sampling|Patients will undergo systematic sampling of lymph node stations in the mediastinum with a minimum sampling of 3 stations: 4R, 4L and 7, as is the standard of care. Other stations may be included at the endoscopist's discretion. CLNS is not used for this arm.
61969260|NCT03859349|EXPERIMENTAL|Selective Targeted Sampling|"Patients will first undergo endosonographic assessment of 3 mediastinal lymph node stations (i.e. 4R, 4L, and 7) using the four criteria of the CLNS. Lymph node stations that exhibit a CLNS \>1/4 will be biopsied as is standard of care. Lymph node stations with CLNS ≤ 1/4 will be marked as not requiring biopsy but will be biopsied nevertheless, so that there is no deviation from the standard of care. Other stations may be included at the endoscopist's discretion."
62509887|NCT04014582|EXPERIMENTAL|Communal Coping Intervention|This group will participate in diabetes education + a communal coping based intervention.
61969261|NCT05544357|EXPERIMENTAL|Resistance training with short set configuration performed by normotensive postmenopausal women|Normotensive postmenopausal women performing resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
61969262|NCT05544357|EXPERIMENTAL|Resistance training with short set configuration performed by hypertensive postmenopausal women|Hypertensive postmenopausal women performing resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
61969263|NCT05544357|EXPERIMENTAL|Resistance training with long set configuration performed by normotensive postmenopausal women|Normotensive postmenopausal women performing resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a long set configuration protocol
62509888|NCT04014582|ACTIVE_COMPARATOR|Control|This group will participate in diabetes education and an individual intervention.
62509889|NCT05685277|OTHER|Sequence TR|25 subjects assigned to the sequence TR will receive a single 10 mg/25 mg dose of the test product Ramipril/Hydrochlorothiazide (1 x 10 mg/25 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg/25 mg dose of the reference product Tritace® Plus (1 x 10 mg/25 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62509890|NCT05685277|OTHER|Sequence RT|25 subjects assigned to the sequence RT will receive a single 10 mg/25 mg dose of the test product Tritace® Plus (1 x 10 mg/25 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg/25 mg dose of the reference product Ramipril/Hydrochlorothiazide (1 x 10 mg/25 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62509891|NCT03810573|EXPERIMENTAL|NB1-1.5|NB1 low dose
62509892|NCT03810573|EXPERIMENTAL|NB1-2.0|NB1 high dose
61969264|NCT05544357|EXPERIMENTAL|Resistance training with long set configuration performed by hypertensive postmenopausal women|Hypertensive postmenopausal women performing resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a long set configuration protocol
61969265|NCT03806998|EXPERIMENTAL|Ketoacid supplementation|Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight
62509893|NCT03810573|NO_INTERVENTION|Autograft|Autograft
62509894|NCT02744755|EXPERIMENTAL|GP2017|Group 1 will receive treatment with 40mg GP2017 (Adalimumab - GP2017) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response continue treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
62509895|NCT02744755|ACTIVE_COMPARATOR|US Licensed Humira|Group 2 will receive treatment with 40mg Humira® (Adalimumab - US licensed Humira®) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response will be switched to treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
62509896|NCT06130787|EXPERIMENTAL|All patients|
62509897|NCT06617637|EXPERIMENTAL|Aerobic-Based Virtual Reality Exercise Training Group|Aerobic exercise training will be applied to the aerobic-based virtual reality exercise group with an Xbox Kinect 360 (Microsoft, Washington, USA) for 20 sessions, 2 days a week, for 10 weeks.
61969266|NCT03806998|PLACEBO_COMPARATOR|Placebo|Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight
61969267|NCT02365792|ACTIVE_COMPARATOR|CDSS1|The CDSS1 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
61969268|NCT02365792|ACTIVE_COMPARATOR|CDSS2|The CDSS2 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
61969269|NCT02365792|PLACEBO_COMPARATOR|Booklet|The control group will provide prehospital patient care with usual decision support: a pocket-size booklet, backed by a mobile phone through which the PIT can get in contact with an Emergency Physician.
62351458|NCT05306548|EXPERIMENTAL|Injection treatment strategy|Primary treatment with ultrasound-guided corticosteroid injection. Treatment effect is monitored on scheduled follow-up visits. One additional injection may be administered, and subsequently surgical carpal tunnel release is performed in case of unsatisfactory treatment effect of the injection therapy. Treatment effect is graded on a 5-leve scale by subject from 1 (complete improvement) to 5 (severe worsening) of symptoms. Incomplete improvement (score 2 or higher) results in a second injection or secondary surgery.
62351459|NCT01508494|ACTIVE_COMPARATOR|Galantamine|16mg galantamine progressively
62351460|NCT01508494|PLACEBO_COMPARATOR|placebo|placebo
62509898|NCT06617637|ACTIVE_COMPARATOR|Traditional Aerobic Exercise Training Group|The traditional aerobic exercise group will receive treadmill training under the supervision of a physiotherapist 2 days a week for 10 weeks.
62509899|NCT06617637|NO_INTERVENTION|Control Group|Participants in the control group will be advised to continue with their standard daily living activities.
62509900|NCT00699478|EXPERIMENTAL|1|post total gastrectomized patients due to gastric cancer who has vitamin B12 deficiency - given oral vitamin B 12 supplementation
61969270|NCT00756860|ACTIVE_COMPARATOR|2|30 subjects will be randomized on Day -1
61969271|NCT00756860|EXPERIMENTAL|1|30 subjects will be randomized on Day -1
61969272|NCT06381050|EXPERIMENTAL|SHR-7631|
62351461|NCT02448316|ACTIVE_COMPARATOR|endoscopic surgery|Endoscopic operation through 2 portals profound for the fascia plantaris
62509901|NCT02008708|EXPERIMENTAL|Livestock microfinance|Participants randomized to the microfinance intervention receive a female pig loan with ongoing support to manage health and care of the pig by trained agents.
61969273|NCT03758352|EXPERIMENTAL|intervention group (rIC)|The rIC procedure will be applied on seated patients, who have been resting for at least five minutes. The active rIC procedure consists of four five-minute inflations of a pneumatic tourniquet to 100 mmHg above the patient's systolic blood pressure separated by five-minute periods of complete deflation. Placement of the pneumatic tourniquet will be unilaterally on a lower limb (right thigh)
62351462|NCT02448316|ACTIVE_COMPARATOR|conservative treatment|The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
62351463|NCT02960698|ACTIVE_COMPARATOR|TREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
62351464|NCT02960698|ACTIVE_COMPARATOR|UNTREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
61969274|NCT03758352|OTHER|control group (non-rIC)|The control group will be a retrospective group, who have undergone a liver transplantation and meet the inclusion criteria.
61969275|NCT02113592|EXPERIMENTAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
61969276|NCT02113592|NO_INTERVENTION|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
61969277|NCT02049281|EXPERIMENTAL|Vintafolide|Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
61969278|NCT01127074|EXPERIMENTAL|KS24.22-vaccination|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated. KS24.22 cells were adjusted to 10E7/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
61969279|NCT03998033|EXPERIMENTAL|ET140202 T cells|ET140202 Receptor (+) T Cells
61969280|NCT01092104|EXPERIMENTAL|TBR-652 25 mg QD|TBR 25 mg QD for 10 days
61969281|NCT01092104|PLACEBO_COMPARATOR|Placebo|Matching Placebo QD for 10 days
61969282|NCT01092104|EXPERIMENTAL|TBR-652 50 mg QD|TBR-652 50 mg QD for 10 days
61969283|NCT01092104|EXPERIMENTAL|TBR-652 75 mg QD|TBR-652 75 mg QD for 10 days
61969284|NCT01092104|EXPERIMENTAL|TBR-652 100 mg QD|TBR-652 100 mg QD for 10 days
61969285|NCT01092104|EXPERIMENTAL|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
61969286|NCT01506206||Patients with Deep Brain Stimulators|Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
61969287|NCT01506206||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
61969288|NCT03507894||m-health stroke rehabilitation|8-week multimodal exercise rehabilitation program (MERP) based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
61969289|NCT05138497|EXPERIMENTAL|HILIT group|An experimental group (EG) that after an initial evaluation and with their consent, will be subjected to a directed physical training program for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 50 min per session. The exercises to be carried out will be divided into three different phases: warm-up during the first 10 minutes; the main part with a duration of 30 minutes (where each exercise should be performed for 20 to 30 seconds as intense or fast as possible without generating joint impact, and then take a break for 10 to 15 seconds, before repeating it); and the return to calm, based mainly on stretching exercises with a total duration of 10 minutes.
61969290|NCT05138497|NO_INTERVENTION|Control group|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study. The participants assigned to this group will receive general advice on the positive effects of the regular practice of physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
61969291|NCT03920033|EXPERIMENTAL|Hypofractionated|65 Gy/ 26 fractions (fraction size 2.5 Gy)
62351465|NCT02960698|PLACEBO_COMPARATOR|Healthy volunteers|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects
62351466|NCT04201938|ACTIVE_COMPARATOR|Symbiter-Omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
61969292|NCT03920033|ACTIVE_COMPARATOR|Standard|66 Gy/ 33 fractions (fraction size 2 Gy)
61969293|NCT02708121|EXPERIMENTAL|Intervention arm|Participant receives intervention to motivate weight loss treatment initiation and access to weight loss treatment.
61969294|NCT02708121|ACTIVE_COMPARATOR|Comparator Arm|Participant receives access to weight loss treatment alone.
61969295|NCT02448420|EXPERIMENTAL|Arm A: HER2-positive/Hormone receptor-negative (Recruitment Closed)|"Patients with hormone receptor-negative, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
61969296|NCT02448420|EXPERIMENTAL|Arm B1: HER2+/Hormone receptor-positive (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
62351467|NCT04201938|PLACEBO_COMPARATOR|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
61969297|NCT02448420|EXPERIMENTAL|Arm B2:HER+/HR+: trastuzumab + palbociclib +letrozole (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib + letrozole Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Letrozole: daily oral dose of 2.5 mg."
61969298|NCT02448420|EXPERIMENTAL|Arm C1: Palbociclib, trastuzumab and endocrine therapy|"HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy~Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Palbociclib: oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.~Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant, or Tamoxifen."
61969299|NCT02448420|ACTIVE_COMPARATOR|Arm C2: Treatment based of physician's choice|HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment based on physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab or endocrine therapy (Aromatase Inhibitor, Fulvestrant or Tamoxifen) in combination with trastuzumab.
61969300|NCT05577390|EXPERIMENTAL|Intraneural Facilitation Therapy Treatment Group|Subjects will receive nine 60-minute INF® Therapy Treatments during sessions 2 through 10. INF® Therapy is a non-invasive treatment that helps eliminate pain, tingling, numbness, and other symptoms that come with neuropathy.
61969301|NCT05577390|EXPERIMENTAL|Standard Physical Therapy Treatment Group|Subjects will receive nine 60-minute standard physical therapy treatments during sessions 2 through 10.
61969302|NCT00642876|ACTIVE_COMPARATOR|Control|The Control cohort are patients that receive the fusion treatment.
61969303|NCT00642876|EXPERIMENTAL|Investigational|The Investigational cohort are the study patients that received the PRESTIGE® Cervical Disc.
61969304|NCT01678677|EXPERIMENTAL|Group A|Subjects in this group will receive formulation 1 of NTHi vaccine.
61969305|NCT01678677|EXPERIMENTAL|Group B|Subjects in this group will receive formulation 2 of NTHi vaccine.
61969306|NCT01678677|EXPERIMENTAL|Group C|Subjects in this group will receive formulation 3 of NTHi vaccine.
61969307|NCT01678677|EXPERIMENTAL|Group D|Subjects in this group will receive formulation 4 of NTHi vaccine.
61969308|NCT01678677|EXPERIMENTAL|Group E|Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
61969309|NCT01678677|EXPERIMENTAL|Group F|Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
61969310|NCT01678677|EXPERIMENTAL|Group G|Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
61969311|NCT01678677|EXPERIMENTAL|Group H|Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
62351468|NCT01279304||Group 1. Low risk|"1. Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~   a. all nodes negative: ycN0~   or~2. Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~   a. only micrometastases in the SN, and no risk factors (grade 3, LVI, tumour size \> 3 cm)~   or~3. Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~   1. no metastases in the post chemo SN"
61969312|NCT01678677|PLACEBO_COMPARATOR|Group Placebo 1|Subjects in this group will receive placebo.
61969313|NCT01678677|PLACEBO_COMPARATOR|Group Placebo 2|Subjects in this group will receive placebo.
62351469|NCT01279304||Group 2: Intermediate risk|"1. Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~   a. 1-3 nodes positive: ypN1~   or~2. Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~   1. micrometastases in the SN and at least 1 risk factor; or~  2. ≤ 2 macrometastases and no risk factor~   or~3. Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~   1. micrometastases in the post chemo SN and no risk factors (grade 3, LVI, tumour size \> 3 cm)"
62351470|NCT01279304||Group 3. High risk|"1. Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~   a. 4 or more nodes positive: ypN2~   or~2. Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~   1. ≤ 2 macrometastases in the sentinel node prior to primary systemic treatment in the presence of risk factors like Grade 3, lymphangioinvasion, tumour size \> 3 cm; or~  2. 3 macrometastases, 2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases.~   or~3. Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~   1. Micrometastases in the post chemo SN, and at least one risk factor~  2. ≤ 3 macrometastases in the post chemo SN; or~  3. 2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases"
62351471|NCT05992168|EXPERIMENTAL|Stent-Retriever arm|Device: Stent-Retriever
61969314|NCT03268720|OTHER|healthy controls|FODMAP low diet gluten-free diet
61969315|NCT03268720|OTHER|NCGS patients|FODMAP low diet gluten-free diet
61969316|NCT05171595||no myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
61969317|NCT05171595||Myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
61976238|NCT02041611|OTHER|Standard Care Pts Eval of T-Cell Immune Status|Pts undergoing standard radiation/TMZ and adjuvant TMZ will have blood collections at 6 different time points throughtout their treatment to evaluate T Cell changes
61976239|NCT05356494|EXPERIMENTAL|postural drainage|(Group A will be treated with postural drainage)
61976240|NCT05356494|EXPERIMENTAL|positive expiratory pressure technique|(Group B will be treated with positive expiratory pressure technique).
61976241|NCT04734223||Group 1|The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis
61969318|NCT02407704|EXPERIMENTAL|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
61969319|NCT02407704|ACTIVE_COMPARATOR|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
61969320|NCT05660551|NO_INTERVENTION|Control Group|
61969321|NCT05660551|EXPERIMENTAL|Demonstration group|
61969322|NCT05660551|EXPERIMENTAL|Telesimulation Group|
61969323|NCT05660551|EXPERIMENTAL|Kahoot Game Group|
61969324|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
61969325|NCT01267734|EXPERIMENTAL|EECSS + DDAT|Promus Element stent + double-dose clopidogrel anti-platelet therapy
61969326|NCT01267734|ACTIVE_COMPARATOR|ZECSS + DDAT|Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy
61969327|NCT01267734|EXPERIMENTAL|EECSS + TAT|Promus Element stent + triple anti-platelet therapy
61969328|NCT01267734|ACTIVE_COMPARATOR|ZECSS + TAT|Endeavor Resolute stent + triple anti-platele therapy
61969329|NCT04868890|EXPERIMENTAL|Active|Ampion
61969330|NCT04868890|PLACEBO_COMPARATOR|Control|Placebo
61969331|NCT01401283|ACTIVE_COMPARATOR|Study group|intraoperative guidance of hemodynamics by measures of cardiac index and pulse pressure variation, measurement of cardiac output and pulse pressure variation, hemodynamic optimization according to cardiac index and pulse pressure variation
61969332|NCT01401283|NO_INTERVENTION|Control group|hemodynamic management according to institutional clinical standards
61969333|NCT03423095|PLACEBO_COMPARATOR|Active Jaw Exercise with Relaxation|Participants randomized to this arm will complete active jaw exercises and visualization relaxation exercise (control group).
61969334|NCT03423095|ACTIVE_COMPARATOR|Active Tongue Exercise|Participants randomized to this arm will complete active tongue exercises only.
61969335|NCT03423095|EXPERIMENTAL|Active Tongue Exercise + Mental Practice|Participants randomized to this arm will complete active tongue exercises and mental practice of tongue exercise via motor imagery.
61969336|NCT03423095|EXPERIMENTAL|Mental Practice Tongue Exercise|Participants randomized to this arm will complete mental practice of tongue exercise via motor imagery only.
61969337|NCT04500002|EXPERIMENTAL|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
61969338|NCT04500002|ACTIVE_COMPARATOR|Misoprostol|Misoprostol Alone 800 mcg every three hours up to maximum three doses
62145286|NCT06403410|EXPERIMENTAL|Experimental|In the intervention group, initially, the Patient Identification Form, RASS, and Nu-DESC will be administered. The RASS and Nu-DESC forms will continue to be applied once a day throughout the patient's follow-up period in the intensive care unit, every 12 hours. Each intervention group patient randomized will receive the Delirium Prevention Guideline. The guideline includes standard practices used by intensive care nurses in patient monitoring. In addition to routine follow-ups, eye masks and earplugs will be applied to patients in the intervention group between 24:00 and 06:00. It is expected that the guideline will be used once every 24 hours, in the morning, to ensure standardization
62736701|NCT01919073|ACTIVE_COMPARATOR|Delayed Treatment Group|The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (in about 11-12 months from the initial appointment).
61969339|NCT04740502|OTHER|Concordant preoperative studies|Patients with concordant neck ultrasound and MIBI scan
61969340|NCT04740502|OTHER|Unclear preoperative studies|Patients with discordant or negative neck ultrasound and MIBI scan
61969341|NCT05662228|EXPERIMENTAL|Lorazepam|Participants will receive lorazepam as an oral pill three times daily for 12 weeks as well as titration doses for an additional 4 weeks (approximately).
61969342|NCT05662228|EXPERIMENTAL|Intravenous immunoglobulin (IVIG)|Participants will receive 4 doses of IVIG treatment over 12 weeks.
61969343|NCT05662228|EXPERIMENTAL|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
61969344|NCT04432857|EXPERIMENTAL|Ph1a: Urothelial carcinoma of the bladder and NSCLC|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
61969345|NCT04432857|EXPERIMENTAL|Phase 1b: Urothelial carcinoma of the bladder|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
61969346|NCT04432857|EXPERIMENTAL|Phase 1b: Non-Small Cell Lung Cancer (NSCLC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
62736702|NCT05551169||Patients with stable COPD in Stage1|no intervention
61969347|NCT04432857|EXPERIMENTAL|Phase 1b: Triple-negative breast cancer (TNBC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
61969348|NCT04432857|EXPERIMENTAL|Phase 1b: Cervical|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
61969349|NCT04432857|EXPERIMENTAL|Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
61969350|NCT01514929|EXPERIMENTAL|Supratherapeutic Dose|20mg/kg ACHN-490 Injection
61969351|NCT01514929|EXPERIMENTAL|Possible Therapeutic Dose|15mg/kg ACHN-490 Injection
61969352|NCT01514929|ACTIVE_COMPARATOR|Moxifloxacin|400mg moxifloxacin
61969353|NCT01514929|PLACEBO_COMPARATOR|Placebo|Placebo
61969354|NCT02338414|OTHER|Romiplostim|Patients receiving romiplostim due to ITP
61969355|NCT05179473||Acute stroke patients|12 weekly evaluations starting within the first week post-stroke. Follow-up assessment at week 16. MRI at week 6.
61969356|NCT05531084|EXPERIMENTAL|Thoracoabdominal aortic aneurysm extent I-III|Thoracoabdominal aortic aneurysm extent I-III (proximal seal can be from the left carotid artery to directly after the left subclavian artery):
61969357|NCT05531084|EXPERIMENTAL|Failed EVAR|Failed EVAR (defined as type IA endoleak or increase in aneurysm sac size in the setting of proximal seal loss)/juxtarenal/Pararenal/paravisceral/thoracoabdominal aortic aneurysm extent IV-V:
61969358|NCT05130177|EXPERIMENTAL|Zimberelimab plus Domvanalimab|"Treatment Phase 1: Zimberelimab, 360mg, IV, every 3 weeks for 3 cycles. Domvanalimab, 15mg/kg, IV, every 3 weeks for 3 cycles. After 3 cycles, scans will be performed. If it is determined that the cancer is stable or responding patients will continue with Treatment Phase 2.~Treatment Phase 2: Zimberelimab, 360mg, IV, every 3 weeks for 3 cycles. Domvanalimab, 15mg/kg, IV, every 3 weeks, for up to 24 months."
61969359|NCT04616378|OTHER|Phase 2 Prescribed Prosthesis|Participants everyday use of prosthesis
61969360|NCT04616378|EXPERIMENTAL|Phase 2 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
61969361|NCT04616378|OTHER|Phase 3 Prescribed Prosthesis|Participants everyday use of prosthesis
61969362|NCT04616378|EXPERIMENTAL|Phase 3 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
61969363|NCT04616378|EXPERIMENTAL|Phase 3 No Prosthesis|Participant performs tasks with no prosthetic device attached
61969364|NCT03369392|EXPERIMENTAL|Feasibility Cycle 1|Participants use the initial PANDA application.
61969365|NCT03369392|EXPERIMENTAL|Feasibility Cycle 2|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1.
61969366|NCT03369392|EXPERIMENTAL|Feasibility Cycle 3|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1 and 2.
61969367|NCT04068090||Patients with CIPN|Patients with peripheral neuropathy after treatment with taxanes
61969368|NCT04068090||Patients without CIPN|Patients treated with taxanes and don't develop will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age, tumor stage, chemotherapy regimen or total taxane dosage
61969369|NCT04069494||patients|People diagnosed with advanced lung cancer and scheduled to receive palliative RT will be invited to participate between 1st July 2019 and 31st January 2020.
61969370|NCT04069494||care giver|Patients' family caregivers will also be invited to participate
62145287|NCT06403410|NO_INTERVENTION|Control|Routine delirium monitoring conducted in the intensive care clinic will be performed for patients in this group. There is no standard form used for delirium in the unit where the study is conducted. At the beginning of data collection, the Control group patients will undergo the Patient Identification Form, RASS, and Nu-DESC (once every 12 hours). The RASS and Nu-DESC forms will continue to be applied once a day throughout the patient's follow-up period in the intensive care unit. Data collection will be terminated in case of delirium development in patients.
61969371|NCT02302001|EXPERIMENTAL|Primary Breast Augmentation|
62145288|NCT06510244||One group of patients between 20-60 years old|Patients between 20-60 years old with a tooth health and no history of dental alveolar trauma or pulp chamber calcification.
62145289|NCT04413526||radiofrequency-assisted liver resection|radiofrequency-assisted liver resection for intractable liver cancer
62145290|NCT04413526||TACE(transcatheter arterial chemoembolization)|temporary TACE for intractable liver cancer
61969372|NCT03029065||lung adenocarcinoma with brain (meningeal) metastasis|
62145291|NCT04413526||radiofrequency ablation plus TACE|radiofrequency ablation plus TACE for intractable liver cancer
62145292|NCT02759575|EXPERIMENTAL|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
62351472|NCT04618926||intubating Laryngeal Tube Suction Disposable|intubating Laryngeal Tube Suction Disposable Airway control
61969373|NCT00214175||patients|patients who will receive XRT
61969374|NCT00214175||matched volunteers|Spouse or sibling
61969375|NCT01185132|EXPERIMENTAL|IMRT|Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
61969376|NCT01185132|ACTIVE_COMPARATOR|3D-CRT|Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
61969377|NCT02915276|ACTIVE_COMPARATOR|Blastocentisis|The blastocoelic fluid will be aspirated from the embryonic cavity on day 5 or 6 of development and will be subjected to genetic analysis
61969378|NCT02915276|ACTIVE_COMPARATOR|Trophectoderm biopsy|Throphectoderm cells will be removed from the embryo on day 5 or 6 of development and will be subjected to genetic analysis
61969379|NCT01599234|EXPERIMENTAL|Sativex|Active treatment
61969380|NCT01599234|PLACEBO_COMPARATOR|Placebo|Control
61969381|NCT04614831||Psoriasis and Psoriatic Arthritis|The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis
61969382|NCT00025766|EXPERIMENTAL|1|PCI with stenting of the occluded culprit infarct-related artery plus optimal medical therapy
61969383|NCT00025766|ACTIVE_COMPARATOR|2|Optimal medical therapy alone without PCI of the occluded culprit artery
61969384|NCT05225766|ACTIVE_COMPARATOR|Group ESPB|Erector spinae plane block
61969385|NCT05225766|ACTIVE_COMPARATOR|Group RSB|Rectus sheath block
61976242|NCT04734223||Group 2|The 2nd group (N=390) was obtained by subtracting the 1st group from all cases.
61976243|NCT04734223||Group 3|The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging
62145293|NCT01542255|EXPERIMENTAL|Combined Low Dose Treatment|"A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv"
62351473|NCT04618926||intubating laryngeal Tube suction Disposable|intubating laryngeal Tube Suction Disposable
62351474|NCT04024072|EXPERIMENTAL|Perrigo active|Test product
61969386|NCT04953468||ANXA2 high expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level ≥6 points were identified as the ANXA2 high expression group
61969387|NCT04953468||ANXA2 low expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level \<6 points were identified as the ANXA2 low expression group
61969388|NCT04953468||ANXA2 high expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level ≥2 were regarded as the ANXA2 high expression group
61969389|NCT04953468||ANXA2 low expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion \< 10%, grade 2 for those with staining proportion ≥10% and \< 50%, grade 3 for those with staining proportion ≥50% and \< 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level \<2 were regarded as the ANXA2 low expression group
61969390|NCT03295578|EXPERIMENTAL|Personalized feedback group|In between the two measurement periods, the personalized feedback group will receive an explanation and personalized feedback on their self-measured data (interstitial glucose, cognition, wellbeing and food intake).
61969391|NCT03295578|PLACEBO_COMPARATOR|General feedback group|The generic feedback group will receive a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
61969392|NCT02023398|EXPERIMENTAL|HFT group|Subjects in the High Frequency Therapy (HFT) group will be treated with the BTL-9000 HFT
61969393|NCT02023398|PLACEBO_COMPARATOR|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 HFT
61969394|NCT04944953|ACTIVE_COMPARATOR|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®) 100 Unit
61969395|NCT04944953|EXPERIMENTAL|Botulinum toxin type A(HG-102)|Botulinum toxin type A(HG-102) 100 Unit
61969396|NCT01880164||Nonoperative|Adult spinal deformity (degenerative or idiopathic) with an ODI of 30 or greater
61969397|NCT03476694|EXPERIMENTAL|20ml of 0.75% Ropivacine|
61969398|NCT03476694|EXPERIMENTAL|25ml of 0.75% Ropivacine|
61969399|NCT02769455|NO_INTERVENTION|Control|The control group will not be exposed to any FOP nutrition labels
61969400|NCT02769455|EXPERIMENTAL|Front-of-pack labelling (Reference Intakes)|The second group will be exposed to a FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are presented in the form of a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.
61969401|NCT02769455|EXPERIMENTAL|Front-of-pack labelling (5-CNL)|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format of the 5-CNL system therefore includes five categories of nutritional quality of food products, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the letter/colour corresponding to the product being enlarged."
61969402|NCT02663674|PLACEBO_COMPARATOR|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
61969403|NCT02663674|EXPERIMENTAL|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
61969404|NCT04938193|EXPERIMENTAL|68Ga-citrate PET/CT|
61969405|NCT05815940|EXPERIMENTAL|pilot study|This was followed by the second phase, during which the mobile application developed was pilot tested with 10 children. Based on the feedback received from the users, the mobile application was finalized.
61969406|NCT00924456|EXPERIMENTAL|Transcendental Meditation program|a natural effortless mental technique practiced sitting quietly 20 minutes twice a day
61969407|NCT00924456|PLACEBO_COMPARATOR|Wait list control|student subjects on wait list control
61969408|NCT01574040|EXPERIMENTAL|Staff (and visitors) of the University Medical Centre Utrecht|This is a dynamic study population
61976244|NCT04734223||Group 4|The 4th group (N=247) was obtained by subtracting the 3rd group from all cases.
62145294|NCT05077670||Study group|"* LAA + LA Map in AF~* Identify LAA connections and detect rotors with CartoFinder~* Electrical cardioversion. Sinus rhythm restoration~* Pacing from the coronary sinus at 300 and 600ms periods~* Analyze COHERENT activation maps in sinus rhythm~* Ablation as suggested by current clinical guidelines and the characteristics of the patient"
62351475|NCT04024072|ACTIVE_COMPARATOR|Reference active|Azopt ophthalmic suspension
62351476|NCT01014949|OTHER|Control, Diabetes and Metabolic Syndrome|
62509902|NCT02008708|ACTIVE_COMPARATOR|Delayed Control Group|Participants randomized to delayed control group receives pig loan 12 months after the intervention group
61969409|NCT02982876|NO_INTERVENTION|Medical Management Group|The patients assigned to the medical management group will be placed on a scheduled institution protocol using mucolytic and expectorant therapy (nebulizer treatments using mucolytic (N-acetylcysteine) for 15 minutes BID, Guafenesin (Mucinex®) 1200 mg BID, codeine as needed and Flutter valve BID.
61969410|NCT02982876|ACTIVE_COMPARATOR|Treatment group|The patients assigned to treatment group will undergo flexible bronchoscopy with dynamic maneuvers, rigid bronchoscope , tracheobronchial wash and airway stent placement
61969411|NCT02176811||Non-alcoholic Fatty Liver Disese|no treatment
61969412|NCT02176811||healthy controls|no treatment
61969413|NCT04984083|EXPERIMENTAL|Group I|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
61969414|NCT04984083|NO_INTERVENTION|Group II|patients will not take vitamin k before cesarean section
61969415|NCT01823523|ACTIVE_COMPARATOR|Cefazolin, Cephalexin, Clindamycin|"Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin~Clindamycin will be used in patients with allergy"
61969416|NCT01823523|PLACEBO_COMPARATOR|cefazolin, clindamycin, placebo|"Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo~clindamycin will be used if patient has allergy"
61969417|NCT02838303|OTHER|Group A|Initial spray session: organophosphate. Crossover spray session: placebo
61969418|NCT02838303|OTHER|Group B|Initial spray session: placebo. Crossover spray session: organophosphate
61969419|NCT03545165|EXPERIMENTAL|All Subjects|"177Lu-PSMA-617 \[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)\] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~177Lu-J591 \[1.35 GBq/m2 or 36.5 mCi/m2\] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~68Ga-PSMA-HBED-CC \[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
61969420|NCT02338440|EXPERIMENTAL|lipoprostaglandin E1 treatment arm|"* lipoprostaglandin E1 1mcg/kg/day, continuous infusion~* lipoprostaglandin E1 1.5mcg/kg/day, continuous infusion (for patients with elevating total bilirubin, hepatomegaly, right upper quadrant abdominal pain, unexplained weight gain)"
61969421|NCT00240162|EXPERIMENTAL|PTK787/ZK 222584|Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.
61969422|NCT05854082|OTHER|Condition|Typical Reader or Individual with Dyslexia
61969423|NCT06310720|EXPERIMENTAL|Written Discharge Education + Video Education|These patients will view a 12-minute educational video on SMM warning signs, in addition to the written discharge instructions provided by nursing staff. At the completion of the video, they will complete a post-video questionnaire to assess their knowledge on the covered topics.
61969424|NCT06310720|NO_INTERVENTION|Written Discharge Education|They will receive the written discharge instructions provided by nursing staff and complete the post-discharge instruction questionnaire.
61969425|NCT02037698|EXPERIMENTAL|Pre-PCI CT scan group|Pre-PCI CT scan
61969426|NCT02037698|NO_INTERVENTION|Control group|Control
61969427|NCT02438098|OTHER|Rivaroxaban arm|Pharmacokinetics / Pharmacodynamics
61969428|NCT01446900|EXPERIMENTAL|Rituximab cladribine|
62145295|NCT02848625|EXPERIMENTAL|Group A|Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF.
62145296|NCT02848625|NO_INTERVENTION|Group B|Patients who are not randomized to yoga sessions will continue with their usual care and usual activities
62145297|NCT01271244|ACTIVE_COMPARATOR|PTSD Depression Group|Escitalopram 10-20 mg/day
62145298|NCT01271244|ACTIVE_COMPARATOR|Major Depression Group|Escitalopram 10-20 mg/day
62145299|NCT04567459|NO_INTERVENTION|control group: chemotherapy|No intervention
62509903|NCT03419104|EXPERIMENTAL|Preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
61969429|NCT02538250|EXPERIMENTAL|1 Nutricomp Drink Plus|Nutricomp Drink Plus
61969430|NCT04630171|EXPERIMENTAL|Group 1: VerTouch for labor epidural or spinal anesthesia procedure|VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
61969431|NCT04630171|ACTIVE_COMPARATOR|Group 2: Ultrasound (US) for labor epidural or spinal anesthesia procedure|Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
61969432|NCT04630171|ACTIVE_COMPARATOR|Group 3: Control group, palpation for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
61969433|NCT04630171|EXPERIMENTAL|Group 4: VerTouch for lumbar puncture procedure|VerTouch utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
61969434|NCT04630171|ACTIVE_COMPARATOR|Group 5: Ultrasound (US) for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
61969435|NCT04630171|ACTIVE_COMPARATOR|Group 6: Control group, palpation for lumbar puncture procedure|Control group, palpation utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
61969436|NCT02733068|EXPERIMENTAL|HPV-16/18 vaccine|Including 6000 participants who received the HPV-16/18 vaccine 0.5ml.
61969437|NCT02733068|PLACEBO_COMPARATOR|HPV-16/18 placebo|Including 6000 participants who received the HPV-16/18 placebo 0.5ml.
62145300|NCT04567459|EXPERIMENTAL|experimental group: chemotherapy and nutrition support|Premium amino acids 1pc bid for 6 months
62145301|NCT03075878|EXPERIMENTAL|Cohort 1: ALXN1830|SYNT001 Dose 1
62145302|NCT03075878|EXPERIMENTAL|Cohort 2: ALXN1830|SYNT001 Dose 2
62145303|NCT01249638|EXPERIMENTAL|Cap+Bev until PD followed by CAPIRI +Bev|"Capecitabine + Bevacizumab~In case of Progression Escalation to:~Capecitabine + Irinotecan + Bevacizumab"
62145304|NCT01249638|ACTIVE_COMPARATOR|Capiri + Bev|Capecitabine + Irinotecan + Bevacizumab
62509904|NCT01230294||control|participants without structural heart disease
61969438|NCT06043089|PLACEBO_COMPARATOR|Placebo group|Athletes received 7 days of placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
61969439|NCT06043089|EXPERIMENTAL|Beetroot group|Athletes received 7 days of beetroot juice (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK).
61969440|NCT02974166|ACTIVE_COMPARATOR|Conventional Group|Individuals with temporomandibular disorder were used rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions during four weeks.
61969441|NCT02974166|EXPERIMENTAL|Osteopathic Group|Individuals with temporomandibular disorder received the same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week until the end of dental and speech therapy treatments (4 weeks).
61969442|NCT00788476||Childhood Cancer Survivors|
61969443|NCT00788476||Primary Caregivers|
61969444|NCT00349804|OTHER|Air cooled (COOL)|Subjects will complete the intermitent exercise protocol with cool dry air blown under the shoulder pads during the rest periods and recovery session
61969445|NCT00580606|EXPERIMENTAL|Low Dose Peanut SLIT (Double Blind to Open Label)|Subjects ingest peanut protein (glycerinated peanut allergenic extract) daily starting with 0.000165 mcg, followed by a build-up phase (escalating peanut doses every 2 weeks, achieving maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for \>= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and continue on an open label peanut protein maintenance dose of 1,386 mcg/day or may attempt escalation up to this dose. Subjects who at the Week 116 OFC are unable to consume \>= 5,000 mg peanut powder or 10-fold the amount of peanut powder compared to the baseline OFC will discontinue study therapy. SLIT=Sublingual Immunotherapy.
61969446|NCT00580606|PLACEBO_COMPARATOR|Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL)|Subjects ingest placebo (glycerin) daily beginning with a dose of 0.000165 mcg, followed by a build-up phase (escalating placebo doses every 2 weeks, achieving a maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for \>= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and subjects no longer receive placebo dosing but are crossed over and receive open label high dose peanut SLIT; the study procedures and schedule are the same as for the Low Dose Peanut SLIT group, the only difference is the maximum maintenance dose is almost 3-fold higher at 3,696 mcg/day. DB=Double Blind, SLIT=Sublingual Immunotherapy, OL=Open Label.
61969447|NCT02585960|EXPERIMENTAL|Pharmacokinetic (PK) evaluation of BAX 855|Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.
61969448|NCT02585960|EXPERIMENTAL|FVIII trough target 1-3%|Standard treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 1-3%
61969449|NCT02585960|EXPERIMENTAL|FVIII trough target 8-12%|Intensified treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 8-12%
61969450|NCT03305653|EXPERIMENTAL|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
61969451|NCT03352830|NO_INTERVENTION|Control|All individuals in each arm will receive a new LPG cookstove. The control arm will receive an orientation for safe operation of the new LPG stove. Participants in the control arm will, however, receive no other intervention.
61969452|NCT03352830|EXPERIMENTAL|No Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
61969453|NCT03352830|EXPERIMENTAL|Delivery, No Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand.
61969454|NCT03352830|EXPERIMENTAL|Agent Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand. Participants in this arm also receive a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
61969455|NCT01315678|EXPERIMENTAL|Arikayce™|Arikayce™ is liposomal amikacin for inhalation
61969456|NCT01315678|ACTIVE_COMPARATOR|TOBI®|TOBI® is tobramycin inhalation solution
61969457|NCT05177978|EXPERIMENTAL|Phosphatidylserine|100 mg elemental phosphatidylserine
61969458|NCT05177978|PLACEBO_COMPARATOR|Placebo|Placebo comparator
61969459|NCT00546637|EXPERIMENTAL|Fesoterodine 4mg or 8mg|
61969460|NCT00546637|PLACEBO_COMPARATOR|Placebo|
61969461|NCT01223001|ACTIVE_COMPARATOR|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
61969462|NCT01223001|PLACEBO_COMPARATOR|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
61969463|NCT03165656||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
61969464|NCT03165656||High altitude control|Healthy highlanders living above 2500 m.
61969465|NCT03165656||Low altitude control|Healthy lowlanders living below 1000 m.
61969466|NCT03252834||Patients with endometrial or ovarian cancer|
61969467|NCT03252834||Patients with colorectal cancer|
61969468|NCT01803919|EXPERIMENTAL|Silver Alloy-Coated Urinary Catheters|Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
62509905|NCT01230294||CHF|patients with chronic heart failure of the left ventricle affecting the right heart
62736703|NCT05551169||Patients with stable COPD in Stage2|no intervention
62736704|NCT05551169||Non-COPD subjects in Stage2|no intervention
61969469|NCT01803919|OTHER|Conventional Urinary Catheter|Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
61969470|NCT01110434|EXPERIMENTAL|Topiramate|Topiramate (200 mg daily)
61969471|NCT01110434|PLACEBO_COMPARATOR|Sugar pill|
61969472|NCT01689701|EXPERIMENTAL|Hizikia Fusiformis extract|
61969473|NCT01689701|PLACEBO_COMPARATOR|Placebo|
61969474|NCT05241496|EXPERIMENTAL|Marina Ramsis|In the other group, 70 women will be randomly assigned for ibuprofen; participants will take 1 tablet (400mg) immediately \& clinicians will wait at least 45 minutes before inserting the copper IUD
61969475|NCT04975685|EXPERIMENTAL|TAU + SMART|Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
61969476|NCT04975685|SHAM_COMPARATOR|TAU + Sham training|Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
61969477|NCT04975685|NO_INTERVENTION|TAU (treatment-as-usual)|Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
61969478|NCT02231541|EXPERIMENTAL|Very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
61969479|NCT02231541|PLACEBO_COMPARATOR|Turned off very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
61969480|NCT03187197||Cohort A|consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
61969481|NCT03187197||Cohort B|patients being newly diagnosed with NVAF and initiated on Pradaxa®
61969482|NCT03876197|EXPERIMENTAL|Autologous Adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia
61969483|NCT03876197|PLACEBO_COMPARATOR|Placebo|2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%
61969484|NCT03513562|EXPERIMENTAL|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO daily on days 1-28 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 or 24 courses in the absence of disease progression or unacceptable toxicity. Participants with MRD negativity after 12 or 24 courses discontinue treatment, while participants with MRD positivity continue treatment with venetoclax in the absence of disease progression or unacceptable toxicity.
61969485|NCT03356990|EXPERIMENTAL|Resistant Starch|"Intervention:~Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose in the evening~Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks)."
61969486|NCT05351762|EXPERIMENTAL|study arm|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
61969487|NCT02744235|OTHER|Patients undergoing Polysomnography|
61969488|NCT06499155|ACTIVE_COMPARATOR|tissue adhesive group|Only tissue adhesive will be used for primary closure of the donor area. After the flap is closed with sutures in the recipient area, it will be supported with tissue adhesive.
61969489|NCT06499155|ACTIVE_COMPARATOR|suture group|The donor and recipient areas will be closed with sutures.
61969490|NCT01135199|OTHER|Treatment|Open label
61969491|NCT03697629|EXPERIMENTAL|Daratumumab|Increased infusion rate daratumumab monotherapy
61969492|NCT03957720|EXPERIMENTAL|homo-R778L|When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
61969493|NCT03957720|EXPERIMENTAL|R778L+truncation mutation|"When patients carrying R778L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
61969494|NCT03957720|EXPERIMENTAL|Homo-P992L|"When patients carrying Homo-P992L mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
62145305|NCT05331872|EXPERIMENTAL|human umbilical cord-derived mesenchymal stem cell transplantation for patients with liver cirrhosis|"Umbilical cords from healthy donor are processed with 24 hours after vaginal delivery.~The cords are delivered in a sterilized jar the laboratory to process. After washing in PBS to remove any contaminating blood, the cord is cut into small pieces. The pieces are minced and digested by enzyme. The UC-MSCs is cultured and expanded using commercially available serum-free and xeno-free medium at 37°C in a humidified atmosphere with 5% CO2. The UC-MSCs is suspended in 15 ml of saline buffer"
62509906|NCT01230294||PAH|patients with pulmonary arterial hypertension without left ventricular dysfunction
62736705|NCT04311268|EXPERIMENTAL|Observational|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
62736706|NCT03780530|ACTIVE_COMPARATOR|subcuticular suturing|
61969495|NCT03957720|EXPERIMENTAL|P992L+truncation mutation|"When patients carrying P992L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form:DMSA:750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form:DMSA:35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
61969496|NCT03957720|EXPERIMENTAL|T935M+other point mutations|When patients carrying T935M and other point mutations are in hospital, they randomly receive DMPS or penicillamine treatment; Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; Dosage Form: penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years; When being off hospital, they receive DMSA treatment or penicillamine. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
61969497|NCT03957720|EXPERIMENTAL|Presymptomatic patients with Wilson's disease|"According to different age group, they receive various dosage of Zinc Gluconate treatment.~Patient aged≤6 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:BID, Zinc Gluconate Duration: 5 years; Patient aged from 6 to 14 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years; Patient aged≥14 years,Dosage Form: Zinc Gluconate: 210mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years;"
61969498|NCT02345681|EXPERIMENTAL|Test Furosemide|We will test our furosemide algorithm in one arm
61969499|NCT02345681|NO_INTERVENTION|Classical Strategy|It's a classical strategy without diuretics
61969500|NCT03383679|EXPERIMENTAL|Arm 1 Darolutamide|Darolutamib: 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally, continuously until disease progression
61969501|NCT03383679|OTHER|Arm 2 Capecitabine|"according to the 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC3) capecitabine monotherapy is one of the recommended options even in first line (Cardoso et al, 2017).~According to each center policy (minimum 1000 mg/m²) twice daily for 2 weeks followed by 1-week rest period, until progression or unacceptable toxicity"
61969502|NCT02655939|ACTIVE_COMPARATOR|Reflex Plus|Reflex Plus TM, Sachets to be taken once in a day Before breakfast for the study duration
61969503|NCT02655939|PLACEBO_COMPARATOR|Placebo|Placebo Sachets to be taken once in a day Before breakfast for the study duration
61969504|NCT04906213|ACTIVE_COMPARATOR|Arm I: With Type II Diabetes|Kidney Transplant recipient with Type II diabetes, randomized to either Empagliflozin or a placebo.
61969505|NCT04906213|ACTIVE_COMPARATOR|Arm 2: Without Diabetes|Kidney Transplant recipient without Type II diabetes, randomized to either Empagliflozin or a placebo
61969506|NCT03291808|EXPERIMENTAL|Weight loss intervention|Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
61969507|NCT02882009|EXPERIMENTAL|Gantenerumab + Placebo|Participants will be randomized to receive gantenerumab HCLF and placebo solution via SC injection according to different sequences for the site of administration and different injection speeds.
61969508|NCT01647620|ACTIVE_COMPARATOR|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily
61969509|NCT01647620|PLACEBO_COMPARATOR|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
61969510|NCT04219553|OTHER|Retrospective group|Comparator group (pre-intervention)
61969511|NCT04219553|EXPERIMENTAL|Prospective group|Study group (post-intervention)
61976245|NCT05576740||natural cycle|In this group, women have a natural menstrual cycle, not intervened by exogenous hormones. The interventions performed in this group are the same as in the other groups.
62145306|NCT01409837|PLACEBO_COMPARATOR|Sugar pill|Started with Placebo until the crossover.
62145307|NCT01409837|EXPERIMENTAL|Lisinopril|Started with Lisinopril until the crossover
62145308|NCT01487837|ACTIVE_COMPARATOR|Fibrinogen if FibTEM < 8 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF \< 8 mm
62145309|NCT01487837|EXPERIMENTAL|Fibrinogen if FibTEM < 13 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF \< 13 mm
62509907|NCT06230627|EXPERIMENTAL|Rehabilitation program|The Home-Based Rehabilitation Program (HBRP) As a first procedure, detailed interviews were conducted with each participant at the beginning of the study to gather information about their physical, psychological, and social well-being. This information helped the authors create personalized rehabilitation plans for each participant to ensure their participation in the study for the entire 6 months period. Through our study objectives, the authors used body composition such as height, weight, BMI and some anthropometric measurements for body parts circumferences by using tape measurements. Also, muscle strength tests were performed on participants\&#39; lower and upper extremities, head, and trunk to measure various movements. The 2nd control group completed their measurements and tests at college. Additionally, a clinical test using the American Spinal Injury Association scale (ASIA) was conducted on each participant to assess sensory feeling.
62736707|NCT03780530|ACTIVE_COMPARATOR|surgical glue|
62145310|NCT01595269|PLACEBO_COMPARATOR|Education mode 1 (control)|Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants.
62145311|NCT01595269|ACTIVE_COMPARATOR|Education mode 2 (static interface)|Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
62736708|NCT03780530|ACTIVE_COMPARATOR|adhesive steri-strip tape|
62736709|NCT01808638|OTHER|Lead in safety period|Cohort of three subjects with non-pancreatic cancer for whom conventional treatment options have failed, will be treated. If one of the subjects in the safety cohort experiences an unacceptable toxicity, the safety cohort is expanded to six subjects.
61969512|NCT00002862|EXPERIMENTAL|Arm I|Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined. Treatment at the assigned dose continues until disease progression or unacceptable toxicity intervenes. Patients with stable disease after 8 weeks of treatment are removed from study.
61969513|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
61969514|NCT02239978||Control|Age-matched healthy adults
61969515|NCT00667368|NO_INTERVENTION|Control|Bi-monthly testing for BV without treatment.
61969516|NCT00667368|EXPERIMENTAL|Intervention|Metronidazole 500mg twice daily for 7 days for Bacterial Vaginosis (BV) detection
61969517|NCT02254187|EXPERIMENTAL|Salmeterol capsule via Handihaler - low|
61969518|NCT02254187|EXPERIMENTAL|Salmeterol capsule via Handihaler - high|
61969519|NCT02254187|ACTIVE_COMPARATOR|Salmeterol via Serevent® Diskus®|
61969520|NCT04316715|EXPERIMENTAL|Life-Steps for PreP|Participants in this group will receive standard of care treatment plus daily text message reminders. A subset of participants who demonstrate continued adherence challenges will also receive 4-6 weekly sessions of the Lifesteps for PrEP intervention.
61969521|NCT04316715|NO_INTERVENTION|Standard of Care|Participants in this group will not receive an intervention outside the standard of care.
61969522|NCT00003479|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
61969523|NCT03853265|NO_INTERVENTION|Control|
61969524|NCT03853265|EXPERIMENTAL|Virtual Reality|Simulated dental office visit
61969525|NCT01490229|ACTIVE_COMPARATOR|Ezetimibe|Patients assigned to ezetimibe will receive for 1 year ezetimibe (10 mg/day)
62736710|NCT01808638|EXPERIMENTAL|Treatment arm 1|Subjects with advanced pancreatic cancer will be treated.
61969526|NCT01490229|ACTIVE_COMPARATOR|Nutraceuticals|Patients assigned to nutraceuticals will receive for 1 year 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg
61969527|NCT03551054|EXPERIMENTAL|Healthy for Two, Healthy for You|Remotely delivered behavioral health coaching in pregnancy and postpartum
62351477|NCT01601470|EXPERIMENTAL|Period 1:Sildenafil;Period 2:LCZ696;Period 3:LCZ696+Sildenafil|During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
62351478|NCT06447571|EXPERIMENTAL|Trunk Group|Trunk exercises in multiplanar movement coupled with dual tasks on unstable surfaces.
62351479|NCT06447571|ACTIVE_COMPARATOR|Core stability Group|Standard Core stability exercises carried in one plane on stable surfaces without dual tasks.
62351480|NCT02679196|EXPERIMENTAL|KA2237|Open label treatment with KA2237
62351481|NCT03465176|EXPERIMENTAL|Intervention|The women in this arm will receive an essential oil blend to inhale each afternoon for two weeks.
62351482|NCT03465176|PLACEBO_COMPARATOR|Control|The women in this arm will receive an odorless vegetable based oil to inhale each afternoon for two weeks as a control/placebo.
62509908|NCT06230627|NO_INTERVENTION|First Control Group Five People with SCI|This group only conducted the pre-post1 and post2-tests
61969528|NCT03551054|ACTIVE_COMPARATOR|Pregnancy Health Education|Single health education visit with study staff member
61969529|NCT06319508|EXPERIMENTAL|routine rehabilitation treatment+Stellate ganglion block|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The experimental group was given Stellate Ganglion Block.
61969530|NCT06319508|PLACEBO_COMPARATOR|routine rehabilitation treatment+Placebo|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
61969531|NCT00948987|EXPERIMENTAL|Aspirin|single dose of aspirin 325 mg p.o.
61969532|NCT01690208|EXPERIMENTAL|EMERALD|Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
61969533|NCT01690208|ACTIVE_COMPARATOR|Usual Care|"Irrespective of the assignment group, all patients will undergo a baseline comprehensive assessment using the JADE portal disease management system. All patients will also receive a 2-hour session on how to interpret their individualised JADE report and risk profiles, whilst the importance of achieving targets and optimizing self care will be reinforced.~Patients assigned to the UC group will be followed up in their usual clinic according to the 'standard' practice."
61969534|NCT05647434|NO_INTERVENTION|group C|conventional ventilation
61969535|NCT05647434|ACTIVE_COMPARATOR|group SI|Sustained inflations done after ultrasound during capnoperitoneum every 20 min.
61969536|NCT02193568|EXPERIMENTAL|Arm I (light sedation)|Patients receive light sedation (awake) and undergo craniotomy.
61969537|NCT02193568|ACTIVE_COMPARATOR|Arm II (intubated general anesthesia)|Patients receive intubated general anesthesia and undergo craniotomy.
61969538|NCT03683108|EXPERIMENTAL|Resveratrol and Carbossimetyl Beta Glucan|
61969539|NCT03683108|PLACEBO_COMPARATOR|Saline solution|
61969540|NCT01244724|EXPERIMENTAL|Lexapro|escitalopram 10 mg or 20 mg/d
62736711|NCT01808638|EXPERIMENTAL|Treatment arm 2|Subjects with advanced pancreatic cancer will be treated.
62736712|NCT04599491|EXPERIMENTAL|INTELLiVENT-ASV with sidestream capnography|Patients randomized into the 'Sidestream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring.
61969541|NCT03019822|OTHER|Placebo, LSD, d-Amphetamine, MDMA|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
61969542|NCT03019822|OTHER|LSD, d-Amphetamine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
61969543|NCT03019822|OTHER|d-Amphetamine, MDMA, LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
61969544|NCT03019822|OTHER|MDMA, LSD, Placebo, d-Amphetamine,,|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
61969545|NCT04153240|EXPERIMENTAL|Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'THERAPY' mode (ie. vibration feedback will be given in response to supine position)
61969546|NCT04153240|SHAM_COMPARATOR|Sham Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'MONITOR' mode (ie. no vibration feedback will be given)
61969547|NCT05451368||calcified group|"A calcified coronary culprit lesion was defined as readily apparent densities noted within the apparent vascular wall at the site of the stenosis. target lesions were classified as severe (radio opacities noted without cardiac motion prior to contrast injection generally involving both sides of the arterial wall),moderate (densities noted only during the cardiac cycle prior to contrast injection).Severe and moderate calcification is classified as a calcified group."
61969548|NCT05451368||non-calcified group|none/mild(lesions other than severe and moderate calcified lesions). none/mild calcification is classified as a non-calcified group.
61969549|NCT04274842|OTHER|D-OCT image observational|Patients clinically eligible for IPL treatment of facial telangiectasia were D-OCT scanned before, after, 1-3 days after and 1 month after treatment
61969550|NCT01656473|EXPERIMENTAL|MI and DBT|Individual Motivational Interview session followed by 12-week Dialectical Behaviour Therapy skills group
61969551|NCT04056689|EXPERIMENTAL|DNL151 Low Dose|
61969552|NCT04056689|EXPERIMENTAL|DNL151 Mid Dose|
61969553|NCT04056689|EXPERIMENTAL|DNL151 High Dose|
61969554|NCT04056689|PLACEBO_COMPARATOR|Placebo|
62509909|NCT06230627|NO_INTERVENTION|Healthy Group Five people|This group only conducted the pre-post1 and post2-tests
62509910|NCT02387567|EXPERIMENTAL|Lidocaine|Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
62509911|NCT02387567|SHAM_COMPARATOR|Sham lidocaine|Sham Injection, without lidocaine, combined with standard treatment.
62707397|NCT06032130||Parkinson Disease Group (PD)|"1. Anamnesis~2. Measurement of best visual acuity with an EDTRS (Early Treatment Diabetic Retinopathy Study) test~3. Measurement of refraction with trial frame refraction~4. Measurement of pupillary diameter under photopic and mesopic illumination conditions using a specific millimetric ruler~5. Measurement of ocular sensory dominance with the red filter test~6. Measurement of binocular vision status with the Cover Test, prism bar and Maddox wing~7. Photopic and mesopic achromatic contrast sensitivity using the Functional Test Analyzer device~8. Stereopsis using the Titmus Test~9. Colour vision using the Farnsworth-Munsell 100 Hue sorting test~10. Measurement of eye movements with aDEMd (adult Developmental Eye Movement) test and NSUCO (Northeastern State University College of Optometry)~11. Measurement of reading speed with Radner-Vissum test~12. National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25)"
62736713|NCT04599491|ACTIVE_COMPARATOR|INTELLiVENT-ASV with mainstream capnography|Patients randomized into the 'Mainstream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring.
61969555|NCT04183595|EXPERIMENTAL|Arm A: NBMI (Study Medication)|600mg / day N1, N3-BIS- (2-MERCAPTOETHYL) ISOPHTHALAMIDE (NBMI) treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours.
61969556|NCT04183595|PLACEBO_COMPARATOR|Arm B: Placebo|(Excipients microcrystalline cellulose, silica and magnesium stearate) capsules will be administered every 24 hours for 14 days.
61969557|NCT05657314|ACTIVE_COMPARATOR|Comparator|15 grams of pea protein dissolved in 12 ounces of water.
61969558|NCT05657314|EXPERIMENTAL|Active|15 grams of pea protein + probiotic blend (1 billion CFU/capsule - blend of Lactobacillus rhamnosus, Lactobacillus acidophilus, Saccharomyces boulardii, and Bifidobacterium breve) dissolved in 12 ounces of water.
61969559|NCT06049784|EXPERIMENTAL|Visual Biofeedback using self operated home ultrasound device|"Sonographic fetal weight and biophysical profiles will be done at the hospital clinic. A single ultrasound biofeedback session using trans-perineal Ultrasound (TPU) will guide maternal pushing. The process includes (a) Ultrasound assessing fetal head descent with the screen facing the provider, measuring the angle of progression (AOP); (b) Explaining anatomical landmarks to the patient; (c) Repeat AOP measurement with the screen facing the patient for biofeedback; (d) Reassess with the screen turned away.~Participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home, ideally twice a week, up to 4 times. Session records will be sent electronically to the sonographer for assessment and feedback.~All groups will complete questionnaires three times: (1) baseline, (2) about two weeks later (after home biofeedback training), and (3) six to eight weeks postpartum."
61976246|NCT05576740||artificial cycle|In this group, women with an artificial menstrual cycle, i.e. women using hormonal contraception, oral or vaginal, are selected. The interventions carried out in this group are the same as in the other groups.
62509912|NCT02387567|ACTIVE_COMPARATOR|Standard treatment only|The only intervention is the standard treatment. No lidocaine or shame injection was used.
62509913|NCT00986024|EXPERIMENTAL|aerobic exercise|
62509914|NCT00986024|EXPERIMENTAL|strength training|
62509915|NCT00986024|NO_INTERVENTION|control group|
62509916|NCT04172025||Patients with colonization or infections with a pathogen|All patients with either colonisations or infections with either a bacterial or a viral pathogen, where whole genome sequencing data and available minimal epidemiological, demographic and clinical data
61969560|NCT06049784|ACTIVE_COMPARATOR|Visual biofeedback at the Hospital|"A sonographic fetal weight estimate and biophysical profile will occur at the hospital clinic for all patients. A single ultrasound-based biofeedback session will employ TPU for maternal pushing guidance. This process involves (a) Assessing fetal head descent with ultrasound to measure the angle of progression (AOP) during rest and pushing; (b) Explaining anatomical landmarks to the patient; (c) Repeating the AOP measurement as biofeedback; (d) Reassessing with the screen turned away.~Participants will complete questionnaires three times: (1) baseline, (2) two weeks later, and (3) six to eight weeks postpartum."
61969561|NCT06049784|NO_INTERVENTION|Control / Standard care - Obstetrical ultrasound only|"A sonographic estimated fetal weight and biophysical profile will be performed in the hospital.~The participant will fill in questionnaires at three time points: (1) at baseline, before the ultrasound examination; (2) about two weeks later (i.e., after completing the self-operated visual biofeedback training at home, or at an equivalent time for the other two groups); (3) six to eight weeks postpartum."
61969562|NCT01325415|EXPERIMENTAL|A|NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
61969563|NCT01325415|EXPERIMENTAL|B|NKTR-118 150 mg (6x25 mg tablet)
61969564|NCT01325415|PLACEBO_COMPARATOR|C|NKTR-118 placebo (6x placebo tablets)
61969565|NCT01325415|ACTIVE_COMPARATOR|D|Moxifloxacin (1 x 400 mg tablet)
61969566|NCT02573857|EXPERIMENTAL|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
61969567|NCT02573857|EXPERIMENTAL|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
61969568|NCT02573857|EXPERIMENTAL|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
61969569|NCT02709785|EXPERIMENTAL|Group 1 SmartMouth|24 subjects with plaque and gingival inflammation
61969570|NCT02709785|EXPERIMENTAL|Group 2 Chlorhexidine|28 subjects with plaque and gingival inflammation
61969571|NCT02709785|PLACEBO_COMPARATOR|Group 3 Placebo|28 subjects with plaque and gingival inflammation
61969572|NCT04165434|EXPERIMENTAL|Experimental|Untrained unilateral transtibial amputees who underwent the assessment and recommended training.
61969573|NCT04165434|NO_INTERVENTION|Control|Untrained unilateral transtibial amputees who after the evaluation were not included for the recommended training.
61969574|NCT04362787||High pressure _ low pressure non-invasive ventilation|"In the high-pressure NIV,52 patients will undergo pressure-limited NPPV at a higher IPAP level. IPAP is initially set at 20 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (up to 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 15 mL/kg of IBW.~2- EPAP for patients with COPD will be started at EPAP 5 and will be increased till 7 and for the patients with hypoventilation syndrome will be increased up to EPAP 8.~3-Respiratory rate 10-12 b/min."
61969575|NCT05350553||Healthy Control|Patients 45-75 years of age without Type 2 Diabetes and without chronic low back pain.
61969576|NCT05350553||Type 2 Diabetic with Painful Neuropathy|Patients 45-75 years of age with Type 2 Diabetes and experiencing painful neuropathy (painful numbness or tingling in hands and/or feet)
61969577|NCT05350553||Chronic Low Back Pain as a Result of Lumber Disc Aberrancy|Patients 45-75 years of age with chronic low back pain as a direct result of non-operative lumber disc aberrancy (lumbar disc herniation, protrusion, or extrusion).
62736714|NCT03645941|NO_INTERVENTION|Quitline/Treatment Referral|Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)
61969578|NCT01214629|EXPERIMENTAL|LY2523355|
61969579|NCT01214629|EXPERIMENTAL|LY2523355 + pegfilgrastim|
61969580|NCT01987505|EXPERIMENTAL|Subcutaneous Rituximab|Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
61969581|NCT04173078|EXPERIMENTAL|Computerized Distress Intolerance Intervention|Two, 1-hour computerized sessions that include psychoeducation about emotional avoidance, idiographic emotional exposure, and construction of idiographic implementation intentions to practice distress tolerance skills outside of session.
61969582|NCT04173078|PLACEBO_COMPARATOR|Computerized Healthy Behaviors Intervention|Two, 1-hour computerized sessions that focus on psychoeducation about the importance of a healthy lifestyle.
61969583|NCT02811250|EXPERIMENTAL|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
61969584|NCT02811250|EXPERIMENTAL|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
61969585|NCT02811250|EXPERIMENTAL|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
61969586|NCT02811250|EXPERIMENTAL|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
61969587|NCT00845689|PLACEBO_COMPARATOR|1|liver resection with Pringle + placebo
61969588|NCT00845689|ACTIVE_COMPARATOR|2|liver resection with Pringle + adenosine preconditiong
61969589|NCT00845689|ACTIVE_COMPARATOR|3|liver resection with Pringle + adenosine pre- and postconditioning
61976247|NCT05576740||natural cycle with deficient luteal phase|In this group, women have a natural menstrual cycle, with a low progesterone level during the luteal phase, and are not intervened by exogenous hormones. The interventions performed in this group are the same as in the other groups.
61976248|NCT06040554|EXPERIMENTAL|Exercise Program|Participants will participate in a group resistance exercise program for 8 weeks, using elastic bands.
61969590|NCT03406455||Primary TKA|A cohort of 25 patients undergoing primary TKA for osteoarthritis at our hospital will be enrolled into the study, which will receive IRB approval and be registered on ClinicalTrials.gov and RedCap. Patients will download the mobile application onto their personal smartphones (iOS) to record baseline activity and PROMs in the 2-4 weeks leading up to surgery. During the hospital admission, the knee sleeve will be fitted to the patient. The patient cohort will be followed for three months and four data points (both passive and active) will be extracted from the dashboard: PROMs, mean daily steps, ROM (particular attention to 2 weeks postoperatively), and home exercise plan (HEP) compliance.
61969591|NCT03919214|OTHER|QardioArm and Messaging System|Participants will self-monitor their blood pressure using the Qardio Bluetooth device and obtain 3 separate blood pressure measurements per week (2 morning, 1 evening) for 12 weeks. An automated messaging system for blood pressure management will be triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg. This automated message will be sent to the participant's primary care provider, with copies to the participant and the primary medical oncologist.
61969592|NCT05311540|EXPERIMENTAL|Zinc intervention|9 mg/day Zinc suspension via og tube along with the routinely used standard multivitamin product containing 3 mg daily dose of Zn, started on day 7 until discharge from hospital
61969593|NCT05311540|NO_INTERVENTION|Control|These infants received only standard commercial multivitamin product containing 3 mg daily dose of Zn
61969594|NCT01356472|NO_INTERVENTION|Linezolid alone|the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
61969595|NCT04238598|ACTIVE_COMPARATOR|Active|intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone + sham Pulsed Radiofrequency
61969596|NCT04238598|PLACEBO_COMPARATOR|Control|intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency
61969597|NCT04238598|EXPERIMENTAL|Experimental|intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency
61969598|NCT03326765|OTHER|Children|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
61969599|NCT03326765|OTHER|Adults|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
61969600|NCT06454383|EXPERIMENTAL|Treatment (gemcitabine, leflunomide)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle and leflunomide PO QD on days -3 to -1 prior to cycle 1 and days 1-28 of each cycle thereafter. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive cholestyramine PO TID for 11 days at the end of treatment in the absence of unacceptable toxicity. Patients also undergo CT, MRI, or other imaging scans as clinically indicated throughout the study, as well as blood sample collection on study and during follow up.
61969601|NCT01293175|EXPERIMENTAL|Whole grains|Subjects will consume whole grains every day for two months
61969602|NCT01293175|NO_INTERVENTION|Control|Subjects will consume their habitual diet
62509917|NCT04744155|EXPERIMENTAL|Multi-Level Intervention|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral.Those randomized to MLI will be offered immediate, ED-based contraception (i.e., oral pill, transdermal patch, vaginal ring, injection, subdermal implant) in addition to receive a warm referral (provider helping to schedule follow-up appointment) to follow-up on selected method (or to initiate in clinic, if preferred)
62509918|NCT04744155|ACTIVE_COMPARATOR|Enhanced Standard of Care|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral. eSOC participants may obtain contraception only at the referral.
61969603|NCT02674529|ACTIVE_COMPARATOR|Antidepressant Treatment|20mg of escitalopram will be taken over an 8-week period, starting with 10mg for the first week.
61969604|NCT02674529|PLACEBO_COMPARATOR|Placebo|A placebo pill will be taken over an 8-week period.
61969605|NCT02032810|EXPERIMENTAL|Dose Escalation|Dose Escalation of Panobinostat + Ipilimumab. Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
61969606|NCT04931745|EXPERIMENTAL|Virtual Reality|The Oculus 2 headset will be used during port access. The device features a stereoscopic display mounted on a lightweight wireless head mounted display weighing 503 g with built-in 3D audio and an adjustable head strap and adjustable lens distance. The software used will be the Might Pebbles VR Game developed by ManageXR. It is a child-friendly VR game that does not require the use of hand controllers. It also provides an option to increase the cognitive load, making it appropriate for children of all ages. The experimental group will be given up to 10 minutes to familiarize themselves with the device, assisted by the research assistant and will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
61969607|NCT04931745|ACTIVE_COMPARATOR|Tablet|The child will watch a video on a tablet or iPad that is appropriate for their age during port access. They will begin using it 5-10 minutes prior to port access. The content of the video will be at the discretion of the child life specialist, nurse, or caregiver. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
62509919|NCT05365490||Standard-risk patients requiring carotid intervention|Symptomatic or asymptomatic patients with a discrete lesion located in the internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA), who require carotid artery revascularization.
61976249|NCT06040554|NO_INTERVENTION|Unchanged Activities of Daily Living|Participants will be asked not to change their activities of daily living for the duration of the research.
61976250|NCT03965533|PLACEBO_COMPARATOR|Part A: Placebo IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of 0.9% weight by volume (w/v) saline placebo.
62509920|NCT02156921|NO_INTERVENTION|Control group|Self-guided training without app-based training (written hand-outs)
62509921|NCT02156921|ACTIVE_COMPARATOR|Intervention group|Self-guided training with app-based training
61969608|NCT04931745|ACTIVE_COMPARATOR|No or non-technologic distraction|This is no distraction or non-technologic distraction measures such as bubbles, etc., facilitated by the child life specialist, nurse, or caregiver during port access. The measure will be documented for the purposes of analysis. They will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
61969609|NCT06374160|EXPERIMENTAL|Arm A (endurance training + strength training)|"Frequency: 2 supervised exercise sessions per week.~Session Breakdown:~Duration: 60 minutes per session. Aerobic Endurance Training: 20 minutes. Strength Training: 40 minutes.~Aerobic Interval Training:~Set at 50% of maximal workload based on spiroergometry. Five sets of 2 minutes of exertion; 5 sets of 1 minute of recovery; Total exertion time: 20 minutes~Strength Training:~Muscle Groups Targeted: Major muscle groups. Sets and Repetitions: 2 sets with 8-12 repetitions.~Training Intensity:~Range: 50-80% of 1-RM (1-repetition maximum)"
61969610|NCT06374160|EXPERIMENTAL|Arm B (endurance exercise)|"Frequency: 2 supervised exercise sessions per week.~Session Breakdown:~Duration: Approximately 30 minutes. Focus: Aerobic endurance training. Followed by 10 minutes of Respiratory therapy.~Endurance Training:~Method: Intervals for a balance between exertion and recovery. Intensity: Set at 50% of maximal workload based on spiroergometry."
61969611|NCT06374160|NO_INTERVENTION|Arm C (Usual Care)|The control group receives a one-time sports consultation with general information about daily activities and sports participation, as well as individual training recommendations. After the 12 weeks, the control group will be randomized into one of the exercise therapies.
61969612|NCT03275662|EXPERIMENTAL|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
61969613|NCT03275662|EXPERIMENTAL|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
61969614|NCT04519710|EXPERIMENTAL|multiple sclerosis or other inflammatory neurological disease|HBV negative
61969615|NCT04519710|EXPERIMENTAL|systemic vasculitis|HBV negative
61969616|NCT04519710|EXPERIMENTAL|an autoimmune disease|HBV negative
61969617|NCT02018588|EXPERIMENTAL|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
61969618|NCT02236832|EXPERIMENTAL|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
61969619|NCT02236832|EXPERIMENTAL|PSP patients|progressive supra nuclear palsy patients
61969620|NCT02236832|ACTIVE_COMPARATOR|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
61969621|NCT02236832|EXPERIMENTAL|healthy participants|healthy participants that will participate to the TMS study.
61969622|NCT02236832|EXPERIMENTAL|healthy young participants|Healthy participants will be included for an EEG study
61969623|NCT02256904|EXPERIMENTAL|Anatomical|67 subjects will be randomized to receive an Anatomical TKA with the My knee instruments and a GMK sphere device.
61969624|NCT02256904|ACTIVE_COMPARATOR|Mechanical|67 subjects will be randomized to receive a Mechanical TKA with the My knee instruments and the GMK sphere device.
61969625|NCT04982887|EXPERIMENTAL|Experimental Group|
61969626|NCT04982887|EXPERIMENTAL|Control Group|
62145312|NCT01595269|ACTIVE_COMPARATOR|Education mode 3 (dynamic interface)|Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
62145313|NCT02082990|ACTIVE_COMPARATOR|Face-to-Face Brief Intervention Group|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
62145314|NCT02082990|EXPERIMENTAL|Online Brief Intervention Group|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
62145315|NCT01496339|ACTIVE_COMPARATOR|Traditional therapy control|
61969627|NCT05935852|OTHER|Study group 1|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged\> 18 years, with diabetic neuropathy
61969628|NCT05935852|OTHER|Study group 2|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged\> 18 years, without diabetic neuropathy
61969629|NCT05935852|OTHER|Study group 3|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged \< 18 years, disease activity 5 - 10 years, HbA1c \> 8,5%
62145316|NCT01496339|EXPERIMENTAL|Stem cell infusion|
62351483|NCT01966263|ACTIVE_COMPARATOR|Local Infiltration Analgesia (LIA)|local infiltration analgesia is an anesthetic technique that consists of the infiltration of operated tissue with a long acting local anesthetic during surgery to achieve postoperative pain relieve. In this study LIA of the knee will exist of: 1. local infiltration analgesia (LIA) of the posterior capsule of the knee, 2. LIA of the anterior capsule of the knee and 3. LIA of the subcutaneous tissue of the knee
61969630|NCT05935852|OTHER|Study group 4|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged \< 18 years, disease activity 5 - 10 years, HbA1c \< 7,5%
61969631|NCT01596400|EXPERIMENTAL|Sancuso Arm|
61969632|NCT01596400|ACTIVE_COMPARATOR|IV Granisetron Arm|IV
61969633|NCT02728076|EXPERIMENTAL|Radiation Therapy followed by Lumpectomy|Phase II-Preoperative MRI-BasedRadiation followed by Lumpectomy
61969634|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
61969635|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
61969636|NCT06001099||Cancer arm|Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected
61969637|NCT06001099||Healthy arm|Participants without a known cancer or certain benign disease, from whom blood samples will be collected
61969638|NCT00543140|OTHER|REALIZE™ Swedish Adjustable Gastric Band|All subjects have the REALIZE™ Swedish Adjustable Gastric Band. Single arm - no comparator.
61969639|NCT06150560|EXPERIMENTAL|Losartan Group|Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Losartan.
61969640|NCT06150560|ACTIVE_COMPARATOR|Amlodipine Group|Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Amlodipine.
61969641|NCT06150560|PLACEBO_COMPARATOR|Placebo Group|Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Placebo.
61969642|NCT05385393|EXPERIMENTAL|Arthroscopic posterior capsulotomy of the knee|
61969643|NCT03481322|ACTIVE_COMPARATOR|Cooked diet with controlled amount of salt|Patients will receive intervention diet (cooked with controlled amount of salt)
61969644|NCT03481322|PLACEBO_COMPARATOR|Cooked without salt|Patients will receive the standard diet (cooked without salt and 2 grams of salt separated will be added by the patient)
61969645|NCT05101005|EXPERIMENTAL|Drug-coated balloon|Drug-coated balloon is used to treat coronary artery stenosis lesions and improve myocardial blood flow.
61969646|NCT05101005|ACTIVE_COMPARATOR|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
62145317|NCT02039999|EXPERIMENTAL|Chronic cough|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
62509922|NCT05340582|EXPERIMENTAL|Combination Therapy|Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And study drug (intravenous acetaminophen 15 mg/kg/dose IV q6h for 3 days).
62509923|NCT05340582|PLACEBO_COMPARATOR|Standard Clinical Practice - Monotherapy|Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And Placebo \[(0.9% saline IV q6h for 3 days).
62509924|NCT00663715||1|Pediatric Patients of ages 11-17
62509925|NCT05274633||Participants With PNH|Data will be collected on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as per clinical practice.
62509926|NCT05736484|NO_INTERVENTION|Control|Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will complete milestones within the study, such as the Function assessment during the 6, and 12-month timepoints in the study. They will also complete a series of surveys during the 3, 6, 9, and 12-month timepoints in the study. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
62539397|NCT04869215|PLACEBO_COMPARATOR|Control consumed at breakfast followed by an ad lib meal.|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include the control bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
61969647|NCT04952402|EXPERIMENTAL|Cohort: ACTIV-2/A5401|Participants of the ACTIV-2/A5401 randomized trial who received a select investigational (active) therapy (AZD7442 IM or IV, BRII-196 + BRII 198 IV, SAB 185 (3,840 or 10,240 units/kg) IV, BMS 096414+BMS 986413 subcutaneous, Camostat Oral) or its corresponding comparator (Placebo).
61969648|NCT04952402|EXPERIMENTAL|Cohort: COVID-19 Naïve|Participants without known history of prior SARS-CoV-2 infection defined as no known history of any SARS-CoV-2 positive test (non-ACTIV-2/A5401 participants).
61969649|NCT01907815|EXPERIMENTAL|Treatment (trametinib, Akt inhibitor GSK2141795)|Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61969650|NCT00719134|EXPERIMENTAL|1|Maxalt administration at onset of migraine
61969651|NCT00719134|PLACEBO_COMPARATOR|2|
61969652|NCT00719134|EXPERIMENTAL|3|
61969653|NCT00719134|PLACEBO_COMPARATOR|4|
61969654|NCT00719134|EXPERIMENTAL|5|
61969655|NCT00719134|EXPERIMENTAL|6|
61969656|NCT02354989|ACTIVE_COMPARATOR|RR on first|Rate Response on first
61969657|NCT02354989|ACTIVE_COMPARATOR|RR off first|Rate Response off first
61969658|NCT04498013|EXPERIMENTAL|Treatment group|Patients will be treated with Cyclodynon 1 tablet per day 6 month in addition to lifestyle modification
61969659|NCT04498013|OTHER|Control group|Lifestyle modification only
61969660|NCT02737189|EXPERIMENTAL|Endovascular Arm|"Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration~Best Medical Treatment and maximum supportive care"
61969661|NCT02737189|OTHER|Control Arm|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
61969662|NCT01385553|ACTIVE_COMPARATOR|Individual Drug Counseling|
61969663|NCT01385553|EXPERIMENTAL|Fathers for Change|
61969664|NCT05480085|EXPERIMENTAL|School-based extracurricular intervention focusing on screen media use and time spent with friends|
61969665|NCT04214054|EXPERIMENTAL|Moldable self-hardening biphasic calcium phosphate graft|Easy graft, a moldable osteocondutive allograft formed of 60% hydroxylapatite and 40% β-tricalcium phosphate (Easy-graft, Sunstar, Gruidor, Degradable solutions AG, Swizerlard).
61969666|NCT04214054|PLACEBO_COMPARATOR|No graft material|
61969667|NCT01929278|EXPERIMENTAL|CT Gel patch|CT Gel is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1% and tretinoin 0.025%) in a modified vehicle. The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
61969668|NCT01929278|PLACEBO_COMPARATOR|Vehicle gel patch|The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
61969669|NCT01929278|EXPERIMENTAL|Blank patch|Blank patches did not contain CT Gel or vehicle gel.
61969670|NCT04397653|EXPERIMENTAL|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
62145318|NCT02039999|ACTIVE_COMPARATOR|Normal volunteer|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
61969671|NCT04397653|PLACEBO_COMPARATOR|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
61969672|NCT04441606|EXPERIMENTAL|Different types of cancer|"The study population will include up to 50 patients with disease in whom a diagnostic challenge is met, including but not limited to:~1. Inconclusive findings on 18F-FDG PET/CT or other imaging modalities.~2. Better delineation of tumor extent prior to therapy~3. Malignancies known to show variable avidity to FDG and at times, no uptake at all (e.g. Exocrine Pancreatic cancer, Gastric carcinoma, Mucin-producing or Signet-ring carcinoma).~4. Patients unable to optimally comply with the required preparation for FDG imaging.~   * The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff."
61969673|NCT01633333|EXPERIMENTAL|Water exchange|Colonoscopy with water exchange as the sole modality to reach the cecum. Carbon dioxide can be used in case of intubation failure with the test method.
61969674|NCT01633333|ACTIVE_COMPARATOR|Carbon dioxide insufflation|Carbon dioxide insufflation will be used in standard fashion to reach the cecum.
61969675|NCT05228262|OTHER|Cohort follow-up|Exploratory study involving functional explorations in longitudinal follow-up, initiated in parallel with a treatment indicated in the patient's usual care and management.
61969676|NCT02027389||control|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
61969677|NCT02027389||intervention|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
61969678|NCT02185833|EXPERIMENTAL|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
61969679|NCT02185833|ACTIVE_COMPARATOR|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
61969680|NCT06471452|EXPERIMENTAL|Intervention group|"The intervention consists of standard care and the app (called Interaktor) for routine symptom reporting of common symptoms regarding fatigue, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual health, in combination with health dialogues with a study-specific nurse. The reports are made weekly during the first month and thereafter as mutually agreed, at minimum once a month for six months, with instant self-care advice in combination with supportive care with a study-specific nurse. At health dialogues with the study-specific nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and to plan eventual additional actions needed.~The intervention will last for 6 months."
61969681|NCT06471452|NO_INTERVENTION|Control group|The participants in the control group will only receive standard care in the secondary care setting. Usually after ended primary treatment the follow-up is determined based on the severity of the tumour, the received postoperative treatment and the patient's general health status. Patients should be offered a yearly follow-up for at least five years where the patients are made a part of the decision-making process of the structure of the follow-up. All patients are allocated a contact nurse with a telephone number to contact when needed.
61969682|NCT02803489|EXPERIMENTAL|medical device intervention|
61969683|NCT03535116|EXPERIMENTAL|Patients receiving ketorolac|Patient receives 30mg IV ketorolac(single dose) towards the end of the operation.
62509927|NCT05736484|EXPERIMENTAL|Social Support Gamification|"Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 26-week intervention period. Participants will also work with a virtual health coach throughout the intervention period to increase their physical activity.~At the end of the 26 week intervention period, participants will enter a 26 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the Function assessment during the 6, and 12-month timepoints in the study. They will also complete a series of surveys during the 3, 6, 9, and 12-month timepoints in the study. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study."
62509928|NCT02010255|EXPERIMENTAL|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
62707398|NCT06032130||Control Group (GP)|"1. Anamnesis: name, sex, date of birth, contact, family contact, medical report, Hoehn \& Yahr classification, medication, systemic, ocular and family history, consumption of tobacco, alcohol, drugs, coffee, physical activity, eye colour, other observations~2. Measurement of best visual acuity with an EDTRS test~3. Measurement of refraction with trial frame refraction~4. Measurement of pupillary diameter under photopic and mesopic illumination conditions using a specific millimetric ruler~5. Measurement of ocular sensory dominance with the red filter test~6. Measurement of binocular vision status with the Cover Test, prism bar and Maddox wing~7. Photopic and mesopic achromatic contrast sensitivity using the Functional Test Analyzer device~8. Stereopsis using the Titmus Test~9. Colour vision using the Farnsworth-Munsell 100 Hue sorting test~10. Measurement of eye movements with aDEMd test and NSUCO~11. Measurement of reading speed with Radner-Vissum test~12. NEI VFQ-25"
61969684|NCT03535116|PLACEBO_COMPARATOR|Control|Patients receive saline intravenously towards the end of the operation.
61969685|NCT04675840|ACTIVE_COMPARATOR|intrathecal morphine|Spinal injection of 15mg Bupivakain and 0,25mg morphine before surgery.
61969686|NCT04675840|ACTIVE_COMPARATOR|opiate po/iv|Patient given 10mg Oxycodone orally before surgery.
61969687|NCT02310061|PLACEBO_COMPARATOR|Control arm|Standard protocol of fluid management in hemodialysis
61969688|NCT02310061|EXPERIMENTAL|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
62509929|NCT02010255|EXPERIMENTAL|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
61969689|NCT05035550|EXPERIMENTAL|Non-Deceptive Placebo|The NDP group was informed that the purpose of the study was to test a mind-body intervention that might help participants deal with the stress and anxiety that they are feeling during the pandemic. The intervention included two videos that introduced the effects of non-deceptive placebos, followed by a presentation on up-to-date non-deceptive placebo research. The participants then received instruction on how they would take their non-deceptive placebos for the next two weeks. Participants were asked to complete daily pill-taking adherence surveys (\~5 min) and weekly at midpoint (1-week) and endpoint (2-week).
61969690|NCT05035550|NO_INTERVENTION|No-Treatment Control|The Control group did not receive an intervention. Instead, participants were informed that the purpose of the study was to track individual psychological and physical health over longer time periods in the context of the pandemic. Participants were asked to complete weekly questionnaires at midpoint (1-week) and endpoint (2-week).
61969691|NCT02799511|OTHER|protein expression|
61969692|NCT03362476|EXPERIMENTAL|Computer-based alcohol reduction intervention + Clinician-delivered brief MET counseling|"Brief, computer-based, alcohol reduction intervention based on motivational enhancement therapy (MET) tailored for HIV/HCV co-infected women who used alcohol.~Clinician-based MET counseling plus standard-of-care (SOC) for current substance users."
61969693|NCT03362476|ACTIVE_COMPARATOR|Clinican-delivered brief MET counseling|Clinician-based brief MET counseling plus standard-of-care (SOC) for current substance users. only
61969694|NCT06295224||Anterior Iliac Block|Patients who were performed anterior iliac block with ultrasound guidance with 10-20 mL 0.25% bupivacaine.
61969695|NCT05303636|EXPERIMENTAL|Cohort 1 (adolescents aged 14-17) Hormonal Treatment Arm|Subjects in the USA will choose to use the LF111 tablets or drospirenone (DRSP) 3.5 mg chewable tablets; 1/3 of subjects in the USA should receive DRSP 3.5 mg chewable tablets. Only LF111 will be available to subjects in Europe.
61969696|NCT05303636|NO_INTERVENTION|Cohort 1 (adolescents aged 14-17) Non-Hormonal Contraceptive Arm|Subjects in this group will not receive any investigational product. They will be free to use a non-hormonal contraceptive method of their choice. Non-hormonal contraceptive methods include barrier contraceptive methods (condoms, female condoms, cervical caps, diaphragms, and contraceptive sponges), double barrier methods, non-hormonal IUD (e.g., copper IUD), surgical female sterilization, vasectomized partner, spermicides, and sexual abstinence.
61969697|NCT05303636|EXPERIMENTAL|Cohort 2 (adults aged 18-45) Hormonal Treatment Arm|Subjects in the USA will choose to use the LF111 tablets or drospirenone (DRSP) 3.5 mg chewable tablets; 1/3 of subjects in the USA should receive DRSP 3.5 mg chewable tablets. Only LF111 will be available to subjects in Europe.
61969698|NCT05303636|NO_INTERVENTION|Cohort 2 (adults aged 18-45) Non-Hormonal Contraceptive Method Arm|Subjects in this group will not receive any investigational product. They will be free to use a non-hormonal contraceptive method of their choice. Non-hormonal contraceptive methods include barrier contraceptive methods (condoms, female condoms, cervical caps, diaphragms, and contraceptive sponges), double barrier methods, non-hormonal IUD (e.g., copper IUD), surgical female sterilization, vasectomized partner, spermicides, and sexual abstinence.
61969699|NCT02054091|NO_INTERVENTION|Control group|Infants are fed according to the standard feeding practices at each hospital. At FWCH \& SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).
61969700|NCT02054091|EXPERIMENTAL|Colostrum group|Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH \& SBMCH.
61969701|NCT01767155|EXPERIMENTAL|AEZS-108 / zoptarelin doxorubicin|267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles up to 9 cycles
61969702|NCT01767155|ACTIVE_COMPARATOR|doxorubicin/ standard chemotherapy|60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
61969703|NCT00406445||carrier LFS family members|96 carrier LFS family members
62707399|NCT06032130||Therapy Parkinson Disease Group (TPD)|Oculomotor exercises such as tracking eye movements, saccadic eye movements and fixations will be performed. These exercises will be performed in a non-invasive manner using simple and easy-to-use instruments. An application on an electronic device, namely the virtual reality software Visionary, could also be used. If financial resources allow, the intention is to use tablets or computers for this purpose. Perceptual learning exercises will also be carried out on an electronic device. The following variables will be collected from these exercises: time taken to carry out the tests, errors made, speed of completion, latency, etc. These will be compared before and after the exercises in the third phase. In addition, the patients will be given indications for working on these exercises at home.
61969704|NCT00406445||non-carrier LFS family members or normal|60 non-carrier LFS family members or normal
61969705|NCT00406445||non-carrier mitochondrial disorder family members or normal controls|20 non-carrier mitochondrial disorder family members or normal controls
61969706|NCT00406445||normal controls for MR spectroscopy study|30 normal controls for MR spectroscopy study
61969707|NCT00406445||subjects with mitochondrial disorders|20 subjects with mitochondrial disorders
61969708|NCT01901497|EXPERIMENTAL|Solo nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator
61969709|NCT01901497|EXPERIMENTAL|Pro nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator
61969710|NCT01901497|EXPERIMENTAL|NIVO nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator
61969711|NCT01811160|EXPERIMENTAL|Melatonin 5mg (extended release capsules)|Subjects received melatonin (extended release) 5mg nightly during the follow up period
61969712|NCT01811160|PLACEBO_COMPARATOR|Placebo|Subjects received a placebo capsule nightly during the eight week follow up period.
61969713|NCT05219214||Chinese medicine group|
61969714|NCT03829982|EXPERIMENTAL|bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
61969715|NCT03829982|EXPERIMENTAL|dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
61969716|NCT05133453|ACTIVE_COMPARATOR|Pirfinedone group|asbestosis patients given pirfenidone drug
62145319|NCT02997410|EXPERIMENTAL|Ozone|Ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
62145320|NCT02997410|PLACEBO_COMPARATOR|Placebo|Sham ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
62145321|NCT02997410|EXPERIMENTAL|Occlusal splint|Occlusal splint use every night over a period of 4 weeks.
62145322|NCT04817345|EXPERIMENTAL|Plerixafor|Participants will receive a subcutaneous dose of 0.24 mg/kg of plerixafor once daily (Q24hr) x 2 days.
62145323|NCT05059106|EXPERIMENTAL|Group 1|Half dose of ChAdOx1 nCoV-19 (AZD1222) ) in a 2-dose schedule with an interval of 8 weeks.
62509930|NCT02010255|EXPERIMENTAL|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
62509931|NCT02010255|EXPERIMENTAL|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
62509932|NCT02010255|EXPERIMENTAL|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
62509933|NCT02010255|EXPERIMENTAL|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
61969717|NCT05133453|NO_INTERVENTION|Conventional group|Asbestosis patients on conventional treatment
61969718|NCT00869895|EXPERIMENTAL|1|
61969719|NCT03729505|ACTIVE_COMPARATOR|Pyloric injection of magnesium sulfate and lidocaine mixture|After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine
61969720|NCT03729505|ACTIVE_COMPARATOR|Pyloric injection of saline|After sleeve gastrectomy, the pylorus is injected with normal saline
61969721|NCT02916108||Concussion|"Study group include up to 30 children with history of concussion in the last 24 hours before admitting to emergency department.~Reading EEG."
61969722|NCT02916108||Isolated limb injury|"Cohort group include up to 30 children with history of isolated limb injury in the last 24 hours before admitting to emergency department.~Reading EEG."
61969723|NCT05466162|EXPERIMENTAL|Soft tissue mobilization + joint and nerve Mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
61969724|NCT05466162|ACTIVE_COMPARATOR|joint and nerve mobilizations|"Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
61969725|NCT02214524|EXPERIMENTAL|Bair hugger forced air warming therapy|Use of Bair Hugger forced-air warming system perioperatively to keep patient normothermia
61969726|NCT02214524|NO_INTERVENTION|conventional warming care|conventional warming care
61969727|NCT06508424|EXPERIMENTAL|PulseOn enriched crackers|PulseOn enriched crackers
62509934|NCT02010255|EXPERIMENTAL|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
62509935|NCT02010255|EXPERIMENTAL|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
61969728|NCT06508424|PLACEBO_COMPARATOR|Wheat Flour Control|Wheat Flour Control
62707400|NCT06032130||Control Parkinson Disease Group (CPD)|These patients will not receive oculomotor or perceptual therapy. They will be evaluated in the same manner as patients who will receive therapy, both at the beginning and at the end of therapy in the other group.
62707401|NCT01837355|PLACEBO_COMPARATOR|Placebo|placebo once daily for 12 weeks
62707402|NCT01837355|EXPERIMENTAL|Lactobacillus rhamnosus|lactobacillus rhamnosus once daily for 12 weeks
61969729|NCT01170858|EXPERIMENTAL|Icodextrin group|7.5% icodextrin dialysis solution
61969730|NCT01170858|ACTIVE_COMPARATOR|glucose solution group|2.5% or 4.25% glucose dialysis solution
61969731|NCT03629132|EXPERIMENTAL|PRP|Platelet-rich plasma
61969732|NCT03629132|SHAM_COMPARATOR|Gel|Self-crosslinking sodium hyaluronate gel
61969733|NCT03529916||CVD subjects|CVD will be defined as \>50% stenosis of one or more coronary arteries as assessed by coronary angiography.
62145324|NCT05059106|ACTIVE_COMPARATOR|Group 2|Standad dose of ChAdOx1 nCoV-19 (AZD1222) in a 2-dose schedule with an interval of 8 weeks.
62145325|NCT04594525|EXPERIMENTAL|Perinatal women receiving Low intensity psychosocial interventions|One Arm (Intervention): Will receive baseline assessment (personal characteristics) and standard psychological distress screening tools Plus WHO-low intensity psychological interventions through Telemental health.
62145326|NCT04594525|NO_INTERVENTION|Participants-Perinatal women (pregnant women and post-partum) not receiving intervention|One Arm (Control): baseline assessment (personal characteristics) and standard psychological distress screening tools without the WHO-low psychological intervention through Telemental health.
62145327|NCT03698383|EXPERIMENTAL|Herzuma plus Gedatolisib|
62145328|NCT03604809|EXPERIMENTAL|OT Guided Cognitive Interventions|Occupational Therapy interventions will be adjusted according to the patient's Richmond Agitation and Sedation Scale (RASS).
62145329|NCT03604809|NO_INTERVENTION|Usual Care|This will be the standard of care currently provided for delirium prevention within the Department of Critical Care Medicine in Calgary using the ABCDEF bundled approach.
62145330|NCT01726998|EXPERIMENTAL|Lokomat Group|
62145331|NCT01726998|ACTIVE_COMPARATOR|conventional gait training group|
61969734|NCT03529916||healthy controls|healthy controls defined as not having stenosis of coronary arteries as assessed by coronary angiography.
61969735|NCT03099421|EXPERIMENTAL|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
61969736|NCT06221540|EXPERIMENTAL|Received written patient information leaflet|
61969737|NCT06221540|NO_INTERVENTION|Routine education at first clinic appointment|Active Comparator
62509936|NCT02010255|EXPERIMENTAL|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
62509937|NCT02010255|EXPERIMENTAL|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
61969738|NCT04928040|EXPERIMENTAL|Fluid challenge|Fluid challenge effects on optic nerve sheath diameter
61969739|NCT00677508||C FR|Children with constipation and fecal incontinence.
61969740|NCT00677508||C|Children with constipation but without fecal incontinence.
61969741|NCT00677508||P-C FR|Parents of children with constipation and/or fecal incontinence.
61969742|NCT02397759|EXPERIMENTAL|Patients with severe SAH and vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) and presenting vasospasm
61969743|NCT02397759|EXPERIMENTAL|Patients with severe SAH without vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) without vasospasm
61969744|NCT02397759|ACTIVE_COMPARATOR|Patients with severe SAH without external ventricular derivati|Patients with severe severe SAH from ruptured aneurysm without necessitating a EVD subarachnoid hemorrhage
61969745|NCT03266094|OTHER|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs Radio frequency (RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
61969746|NCT01916213|ACTIVE_COMPARATOR|PICSI|PICSI dish ( MidAtlantic Diagnostics Inc) has been developed to select the specific sperm to be used for the ICSI procedure using the same principles as the Sperm Hyaluronan Binding Assay. HA-mediated ICSI sperm selection( PICSI) uses Falcon Petri dishes that feature three microdots of hyaluronan hydrogel attached to the interior bottom: mature, biochemically competent spermatozoa bind to hyaluronan, where they can be isolated and used for ICSI
61969747|NCT01916213|ACTIVE_COMPARATOR|ICSI|
62509938|NCT02010255|EXPERIMENTAL|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
62509939|NCT02010255|EXPERIMENTAL|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability \[weight-based maximum: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg\]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
62509940|NCT02010255|EXPERIMENTAL|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
62707403|NCT04450732|EXPERIMENTAL|Dose Escalation|GQ1001 will be administered intravenously every 21 days. Dose Escalation will be guided by a modified 3+3 design.
61969748|NCT00671892|EXPERIMENTAL|Challenge|"Experimental Challenge Challenge 1 saline 5000EU 10,000EU 20,000EU~Challenge 2 Saline 40,000EU 80,000EU"
61969749|NCT02356068||liver transplantation recepient|every patient who had a liver transplantation. 3 blood samples (2.7ml) for the ROTEM analysis
61969750|NCT00303277|ACTIVE_COMPARATOR|1|simvastatin
61969751|NCT00303277|ACTIVE_COMPARATOR|2|pravastatin
62145332|NCT01266369|EXPERIMENTAL|masitinib 3 mg/kg/day|masitinib 3 mg/kg/day
62145333|NCT01266369|EXPERIMENTAL|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
62509941|NCT02010255|EXPERIMENTAL|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: \< 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
62509942|NCT01758237|EXPERIMENTAL|Superior Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the superior aspect of the iris in the eye being treated. This will be in the 11 to 1 o'clock position.
62707404|NCT04450732|EXPERIMENTAL|Dose Expansion|GQ1001 at the Dose Recommended for Dose Expansion will be administered intravenously every 21 days. Dose expansion will further evaluate the MTD or DRDE in different types of malignant solid tumor in four cohorts.
62707405|NCT05368883|EXPERIMENTAL|One-legged cycling ergometer training|One-legged cycling ergometer training; 10 minutes for each leg in the first 2 weeks, 15 minutes of cycling training in the following weeks.
61969752|NCT03071770|EXPERIMENTAL|ivosidenib (AG-120)|
61969753|NCT02552199||with hyperhidrosis|Patients with primary palmar hyperhidrosis
61969754|NCT02552199||healthy|Healthy adult patients
61969755|NCT01032642|EXPERIMENTAL|thin catheter group|group of women where thin catheter will be used for hysterosalpingography
61969756|NCT03107754|PLACEBO_COMPARATOR|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
61969757|NCT03107754|EXPERIMENTAL|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
61969758|NCT02228629|EXPERIMENTAL|Typical house shoe|Subject's typical shoes worn in and around home
61969759|NCT02931487|EXPERIMENTAL|Attentional Bias Modification|ABM dot-probe task with image stimuli (faces) of three valences: positive (happy), neutral, or negative (angry and fearful). In the ABM condition, probes were located behind positive stimuli in 87 % of the trials (valid trials), as opposed to 13% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when completing the task.
61976251|NCT03965533|EXPERIMENTAL|Part A: GSK2831781 450 mg IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of GSK2831781 at a dose of 450 milligram (mg), diluted in 0.9% w/v saline.
62145334|NCT03967015|EXPERIMENTAL|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will receive MUAC training and nutritional education at enrollment. A short message service (SMS) message will be sent at 7 days following enrollment asking them to measure and send their child's MUAC. Weekly SMS messages asking for the child's MUAC measurement will be sent every 7 days until the last study visit at 180 days following enrollment.
62145335|NCT03967015|NO_INTERVENTION|Standard of care (SOC)|Participants randomized to the standard of care (SOC) arm will receive the same MUAC training and nutritional education as mothers in the MAMMS arm. To accurately simulate community malnutrition outreach programs, no SMS message will be sent to participants in this arm.
62145336|NCT03547167|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
62145337|NCT03547167|ACTIVE_COMPARATOR|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
61969760|NCT02931487|SHAM_COMPARATOR|Sham comparator|Sham condition without modification of attentional bias. These trials are identical in structure to the ABM trials with the exception that target probes replaced negative and positive images with equal frequency.
62707406|NCT05368883|ACTIVE_COMPARATOR|Two-legged cycling ergometer training|Two-legged cycling ergometer training; 20 minutes for the first 2 weeks, 30 minutes of cycling training in the following weeks.
62145338|NCT04320914|EXPERIMENTAL|High Intensity LASER Therapy group (HILT)|Fourty patients with chronic KOA in HILT group will receive Class IV LASER therapy. A Class IV LASER emits power more than 500 mW .
62145339|NCT04320914|ACTIVE_COMPARATOR|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in IGP group will administered with continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis
62145340|NCT03973515|EXPERIMENTAL|PB-201 50/50mg by mouth,every morning and noon for 7 days|
62145341|NCT03973515|EXPERIMENTAL|PB-201 100/50mg by mouth,every morning and noon for 7 days|
62145342|NCT03973515|EXPERIMENTAL|PB-201 100/100mg by mouth,every morning and noon for 7 days|
62509943|NCT01758237|EXPERIMENTAL|Temporal Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the temporal aspect of the iris in the eye being treated. The position will be in the 2 to 4 o'clock in the left eye and 8 to 10 o'clock in the right eye.
62509944|NCT04347525|EXPERIMENTAL|Intervention|This group will receive CaCBT based guided self-help using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
61969761|NCT01097447||Ciprofloxicine or Vigamox or other|up to qid till epithelialized.
61969762|NCT01097447||Topical Nonsteroidal (Acular, Acuvail, Voltaren Xibrom|up to qid for up to 5-10 days postop
61969763|NCT01097447||Topical steroid (FML, Pred Forte, Flarex|qid for up to 8 weeks
61969764|NCT02600702|NO_INTERVENTION|usual care|quadricep exercise
61969765|NCT02600702|EXPERIMENTAL|Siriraj home base exercise|Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
61969766|NCT02600702|ACTIVE_COMPARATOR|Modalities and exercise|Physical modalities for 6 weeks and Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
62145343|NCT03973515|PLACEBO_COMPARATOR|placebo|
62145344|NCT00481572|EXPERIMENTAL|1|Terlipressin
62145345|NCT00481572|EXPERIMENTAL|2|Vasopressin
62145346|NCT00481572|ACTIVE_COMPARATOR|3|titrated norepinephrine
61969767|NCT06417476|EXPERIMENTAL|Short-course radiotherapy followed by consolidation chemotherapy with mFOLFOXIRI|Patients receive short-course radiotherapy (25Gy/5 times) followed by consolidation chemotherapy with mFOLFOXIRI (Irinotecan 150 mg/m2 iv gtt (2h) d1, Oxaliplatin 85 mg/m2 iv gtt (2h) d1, Calcium folinate 400 mg/m2 iv gtt (2h) d1, Total amount of fluorouracil 2400 mg/m2 iv gtt (48h)), treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. The first efficacy evaluation occurs after the fourth chemotherapy cycle. If there is no progression (a complete response (CR), partial response (PR), or stable disease (SD) with reduction or stability in tumor size) , patients will proceed with an additional four cycles. Upon the final efficacy assessment after the eighth chemotherapy cycle, patients will received several pathways (watch \& wait approach; local resection;total mesorectal excision) are considered based on the assessments.
61976252|NCT03965533|PLACEBO_COMPARATOR|Part A: Placebo IV- Japanese Participants|Japanese male participants were administered a single IV infusion of 0.9% w/v saline placebo.
62145347|NCT04017104||18F-FDG PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-FDG PET/CT procedure.~18FFDG is considered standard care and has been approved by Health Canada."
62145348|NCT04017104||68Ga-DOTATOC PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 68Ga-DOTATOC PET/CT procedure.~The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
62145349|NCT04017104||18F-DCFPyL PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-DCFPyL PET/CT procedure.~The 18F-DCFPyL radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
62145350|NCT05445349||Asthma patients|Patients with proven record of asthma disease.
62145351|NCT05445349||COPD patients|Patients with proven record of COPD disease.
62145352|NCT05847452||All participants|"All eligible participants will be consented and enrolled into the study and given the IMP as follows:~Benzraliziumab 30mcg once a month for 3 months"
62509945|NCT04347525|NO_INTERVENTION|Control|This group will receive treatment as usual
62509946|NCT04257214|NO_INTERVENTION|Treatment as usual|Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.
62509947|NCT04257214|ACTIVE_COMPARATOR|Office based CBT|Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.
62509948|NCT04257214|ACTIVE_COMPARATOR|CRS/CPS|Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.
62145353|NCT05332613|EXPERIMENTAL|TRE plus SOC|Participants will be required to fast each day for 12 weeks and will be given lifestyle recommendations with respect to diet and exercise. The registered dietitian (RD) will obtain a baseline dietary record and provide counseling on the time-restricted eating regimen. The RD will collect the participant's normal diet and exercise routine. Counseling will involve instructing the participant to choose an eight-hour eating window (e.g., 10:00am - 6:00pm) during which the participant will be able to eat. During the 16-house fasting window (e.g., 6:00pm - 10:00 am), the participant is able to drink regular water and black coffee or tea. The RD will be available to answer any questions the participants may have pertaining to the regimen and will instruct the participants regarding standard of care lifestyle recommendations. This includes education of a low-calorie diet (500-1000 kcal) and moderate-intensity exercise.
62145354|NCT05332613|ACTIVE_COMPARATOR|SOC|lifestyle modifications and weight management. Participants will be given lifestyle recommendations with respect to diet and exercise. The registered dietitian (RD) will obtain a baseline dietary record and provide counseling on the time-restricted eating regimen. A baseline dietary record will be assessed prior to fasting initiation with the RD in person. The RD will also collect the subject's normal diet and exercise routine. The RD will instruct the participants regarding standard of care lifestyle recommendations. This includes education of a low-calorie diet (500-1000 kcal) and moderate-intensity exercise.
62145355|NCT05332613|EXPERIMENTAL|Crossover to TRE|Participants who have not lost weight or have lost less than or equal to 5% of their body weight, they will be given the option to crossover to the TRE arm. Following the initial 12-week period and end of study MRI, participants would restart another identical 12-week cycle but adhering to the exact steps of the TRE arm including another 4 visits with the registered dieticians (RDs) and an end of study visit with repeat Fibroscan, InBody 770 body composition scan, and MRI-PDFF.
62145356|NCT04808024|EXPERIMENTAL|Players of amateur football leagues|The players of amateur football leagues who will receive SelfMyofascial Release intervention
62145357|NCT04808024|NO_INTERVENTION|Control group|The players of amateur football leagues who will receive no intervention
62145358|NCT05350670|EXPERIMENTAL|perineal massage and cold compress group|
62145359|NCT05350670|NO_INTERVENTION|no intervention group|
62145360|NCT02394054|EXPERIMENTAL|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
62145361|NCT02394054|PLACEBO_COMPARATOR|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
62145362|NCT01685268|EXPERIMENTAL|Part A, Regimen 1|AT13387 given as a 1-hr IV infusion at a starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
62509949|NCT04257214|ACTIVE_COMPARATOR|CBT+CRS/CPS|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
62509950|NCT05305664|EXPERIMENTAL|Pelacarsen (TQJ230)|
62707407|NCT06642077|EXPERIMENTAL|EXPERIMENTAL GROUP|A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and Postoperative Recovery Index (PoRI) was recorded.
61969768|NCT06417476|EXPERIMENTAL|Long-course chemoradiation followed by consolidation chemotherapy with mFOLFOXIRI|Patients receive long-course chemoradiation (50Gy/25 times;capecitabine 825 mg/m² twice daily) followed by consolidation chemotherapy with mFOLFOXIRI (Irinotecan 150 mg/m2 iv gtt (2h) d1, Oxaliplatin 85 mg/m2 iv gtt (2h) d1, Calcium folinate 400 mg/m2 iv gtt (2h) d1, Total amount of fluorouracil 2400 mg/m2 iv gtt (48h)), treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. The first efficacy evaluation occurs after the fourth chemotherapy cycle. If there is no progression (a complete response (CR), partial response (PR), or stable disease (SD) with reduction or stability in tumor size) , patients will proceed with an additional four cycles. Upon the final efficacy assessment after the eighth chemotherapy cycle, patients will received several pathways (watch \& wait approach; local resection;total mesorectal excision) are considered based on the assessments.
61969769|NCT01415310||Geriatric psychiatry|Elderly patients with psychiatric disorders in geriatric psychiatry units
61969770|NCT02438202|EXPERIMENTAL|Electroconvulsive Therapy (ECT)|A modified Electroconvulsive Therapy Series in Patients with Alzheimer's Disease. Device for the intervention ECT will be the Thymatron IV device (Somatics, LLC. Lake Bluff, Illinois, USA).
61969771|NCT02957422|EXPERIMENTAL|Dietary intervention|Participants will receive dietary intervention. Participants will be taking 3 servings of dairy/day.
61969772|NCT02957422|ACTIVE_COMPARATOR|Control|Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
62509951|NCT05305664|PLACEBO_COMPARATOR|Placebo|
62509952|NCT05435586|EXPERIMENTAL|Web Based Breastfeeding Education and Counseling with Digital Game Support|"During pregnancy;~* Application of the Individual and Obstetrical Characteristics Evaluation Form of Pregnant Women and Breastfeeding Self-Efficacy Scale Antenatal Form (Pre-Test).(32-34 weeks of gestation)~* Program will be applied to 30 women at 35-37 gestational weeks.~* Breastfeeding Self-Efficacy Scale (Antenatal form) will be applied to at the end of 37th gestational week.~In the postpartum period;~* The LATCH Breastfeeding Diagnostic Tool and Breastfeeding Assessment Scale (IBFAT) will be administered on the first postpartum day.~* Program will be applied to 30 women during the first 2 weeks postpartum.~* At the end of the postpartum 2nd week, Breastfeeding Behavior and Breast Problems Evaluation Form will be administered.~* Breastfeeding Self-Efficacy Scale (Postpartum form) and Breast Problems Evaluation form will be administered at postpartum 8th week."
62707408|NCT06642077|NO_INTERVENTION|CONTROL GROUP|No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
62707409|NCT03532360|NO_INTERVENTION|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
62145363|NCT01685268|EXPERIMENTAL|Part A, Regimen 2|At13387 administered as a 1-hr IV infusion at a starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
62145364|NCT04943445|EXPERIMENTAL|Treatment: Single Arm|"Induction chemo-immunotherapy:~Carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.~Concurrent radio-immunotherapy:~Radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.~Consolidation immunotherapy:~Pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses."
62145365|NCT04216641|EXPERIMENTAL|Intervention arm|"At each meal: different elements will be presented to the patient (starter / main course / side dish / dessert).~For each of these elements, the patient will be offered 4 versions (a standard version and 3 adapted versions of the same food):~* The standard food.~* The food refers to a more elaborate texture.~* The food refers to a food with a stronger smell.~* The food refers to a more important flavor.~The patient will indicate the version of the food that will be preferred."
62145366|NCT04880837|EXPERIMENTAL|Prevention (educational session, handout, survey)|Participants attend educational session about HPV-related cancers, screening, and HPV vaccination and guidelines and receive informational infographic handout on HPV vaccination. Participants also complete surveys pre and post education session over 5 minutes each to assess HPV vaccination status among children of participants, HPV knowledge, and intentions to get the HPV vaccination, and screening among participants. In addition, participants complete surveys over telephone or face-to-face at 3 and 6 months.
62145367|NCT00403494|EXPERIMENTAL|Sapropterin dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
62145368|NCT00403494|PLACEBO_COMPARATOR|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
62145369|NCT05341037||Postoperative complications +|Patients who have postoperative complications during hospital stay after cardiac surgery
62145370|NCT05341037||Postoperative complications -|Patients who have not postoperative complications during hospital stay after cardiac surgery
62145371|NCT02286869|EXPERIMENTAL|Pressure Controlled Ventilation|"INTERVENTION: respiratory trial in pressure controlled mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the imposed respiratory rate is the same respiratory rate than baseline.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
62145372|NCT02286869|EXPERIMENTAL|Pressure Support Ventilation|"INTERVENTION: respiratory trial in pressure support mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a flow-trigger with medium sensitivity.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
62145373|NCT02286869|EXPERIMENTAL|Neurally Adjusted Ventilatory Assist|"INTERVENTION: respiratory trial in Neurally Adjusted Ventilatory Assist (NAVA) mode: (i) NAVA-level (gain) is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a neural trigger set at 0.5 microVolt.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
62145374|NCT05906966||CHILDREN|BORN FROM IN VITRO FERTILIZATION OF CRYOPRESERVED OOCYTES
62145375|NCT02336802||Healthy Control Group|Volunteers that meet no diagnostic criteria for mental disorders.
62145376|NCT02336802||Panic Disorder Group|Volunteers that meet diagnostic criteria for Panic Disorder.
62145377|NCT02336802||Phobic Disorder Group|Volunteers that meet diagnostic criteria for a Phobic Disorder.
62145378|NCT02336802||PTSD group|Volunteers that meet diagnostic criteria for Post-Traumatic Stress Disorder
62509953|NCT05435586|NO_INTERVENTION|Standardized breastfeeding education|"During pregnancy;~* Application of the Individual and Obstetrical Characteristics Evaluation Form of Pregnant Women and Breastfeeding Self-Efficacy Scale Antenatal Form (Pre-Test).(32-34 weeks of gestation)~* 30 women will receive the routine care applied during pregnancy in the hospital.~* At the end of the 37th week, the Breastfeeding Self-Efficacy Scale (Antenatal form) will be administered to the women in the control group.~In the postpartum period;~* 30 women will receive the standard breastfeeding training in the hospital.~* The LATCH Breastfeeding Diagnostic Tool and Breastfeeding Assessment Scale (IBFAT) will be administered on the first postpartum day.~* At the end of the postpartum 2nd week, the Breastfeeding Behavior and Breast Problems Evaluation Form will be applied.~* Breastfeeding Self-Efficacy Scale (Postpartum form) and Breastfeeding Behavior and Breast Problems Evaluation Form will be administered at the postpartum 8th week."
62509954|NCT00763555|EXPERIMENTAL|Calcitriol 3 mcg/g Spray|
62145379|NCT02293551|EXPERIMENTAL|Part A: Lispro (A)|Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.
62145380|NCT02293551|EXPERIMENTAL|Part A: Lispro (B)|Formulation B: Single dose of lispro administered SC in one of five periods.
62145381|NCT02293551|EXPERIMENTAL|Part A: Lispro (C)|Formulation C: Single dose of lispro administered SC in one of five periods.
62145382|NCT02293551|EXPERIMENTAL|Part A: Lispro (D)|Formulation D: Single dose of lispro administered SC in one of five periods.
62145383|NCT02293551|EXPERIMENTAL|Part A: Lispro (Reference)|Reference formulation: Single dose of lispro administered SC in one of five periods.
62509955|NCT00763555|PLACEBO_COMPARATOR|Calcitriol Vehicle|
62509956|NCT02762617|EXPERIMENTAL|TDF IVR group|"The Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core which contains the experimental drug, TDF, and sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
62145384|NCT02293551|EXPERIMENTAL|Part B: Lispro|Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.
62707410|NCT03532360|ACTIVE_COMPARATOR|Low-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 30 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
61969773|NCT03477877|EXPERIMENTAL|Indashyikirwa|Sectors which receive the full Indashyikirwa programme, including (1) couples training and activist training and support by RWAMREC, and (2) opinion leader training and establishment of women's spaces by the Rwanda Women's Network.
61969774|NCT03477877|ACTIVE_COMPARATOR|VSLA Only|Sectors that continue to receive only the village savings and loan association (VSLA) programmes offered by CARE Rwanda
61969775|NCT02788357|EXPERIMENTAL|Atomoxetine with motor training|40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
61969776|NCT02788357|PLACEBO_COMPARATOR|Placebo with motor training|Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays
61969777|NCT00573469|ACTIVE_COMPARATOR|1|D9421-C 9 mg
61969778|NCT00573469|ACTIVE_COMPARATOR|2|D9421-C 15 mg
61969779|NCT00573469|PLACEBO_COMPARATOR|3|Placebo
61969780|NCT03274440|EXPERIMENTAL|High THC/Low CBD Marijuana|This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (\<1%) content.
61969781|NCT03274440|EXPERIMENTAL|Low THC/High CBD Marijuana|This condition involves the ingestion of marijuana with a low THC (\<1%) and high CBD (\>10%) content.
61969782|NCT03274440|PLACEBO_COMPARATOR|No THC/No CBD|This condition involves the ingestion of a placebo control with no THC and no CBD content.
61969783|NCT05898477||Hemophagocytic lymphohistiocytosis (HLH) Patients|
61969784|NCT00774644|EXPERIMENTAL|1|clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
61969785|NCT00774644|ACTIVE_COMPARATOR|2|BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
61969786|NCT01083394|ACTIVE_COMPARATOR|conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.
61969787|NCT01083394|EXPERIMENTAL|PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.
62145385|NCT02753998|EXPERIMENTAL|Conventional angioplasty + paclitaxel-coated balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with paclitaxel-coated balloon
62351484|NCT01966263|ACTIVE_COMPARATOR|Femoral Nerve Block (FNB)|"a femoral nerve block is an anaesthetic technique that consists of anesthetizing the femoral nerve proximal of the operating area to achieve numbness distal of the block puncture site. A catheter can be placed, so the nerve can be anesthetized continuously or repeatedly for post-operative pain relieve.~In this study the FNB with catheter will be combined with local infiltration analgesia (LIA) of the posterior capsule of the knee"
62509957|NCT02762617|PLACEBO_COMPARATOR|Placebo IVR group|"The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
61969788|NCT06026761||Healthy individuals|Metabolic study protocol
61969789|NCT04160091|EXPERIMENTAL|FX006 32mg in Glenohumeral OA Population|Single intra-articular (IA) injection
61969790|NCT04160091|PLACEBO_COMPARATOR|Normal Saline in Glenohumeral OA Population|Single intra-articular (IA) injection
62509958|NCT04079049|EXPERIMENTAL|Surgical intervention|Surgical and oncological treatment
62509959|NCT04079049|ACTIVE_COMPARATOR|Control|Oncological treatment
62509960|NCT03056768|ACTIVE_COMPARATOR|active control|Health promotion provided by local health bureau.
61969791|NCT04160091|EXPERIMENTAL|FX006 32mg in Adhesive Capsulitis Population|Single intra-articular (IA) injection
61969792|NCT04160091|PLACEBO_COMPARATOR|Normal Saline in Adhesive Capsulitis Population|Single intra-articular (IA) injection
61969793|NCT03733795||Control|'Healthy babies' to establish 'normal' blood flow in neonates.
61969794|NCT03733795||ECMO|Children undergoing extracorporeal membrane oxygenation for acute respiratory failure.
61969795|NCT03733795||Conventional|Neonates undergoing conventional treatment for acute respiratory failure.
62145386|NCT02753998|PLACEBO_COMPARATOR|Conventional angioplasty + placebo balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with placebo balloon.
62351485|NCT03979027|NO_INTERVENTION|No Breakfast|Fasting. Ad libitum water intake permitted.
61969796|NCT01954602|ACTIVE_COMPARATOR|Touch group|Sphincterotome assisted guide-wire cannulation
61969797|NCT01954602|EXPERIMENTAL|No touch group|Guide-wire cannulation
61969798|NCT03275376|EXPERIMENTAL|Statin treated group|
61969799|NCT03275376|PLACEBO_COMPARATOR|Control group|
61969800|NCT01220843|PLACEBO_COMPARATOR|Placebo|DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal
61969801|NCT01220843|EXPERIMENTAL|Sevelamer carbonate|DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals
61969802|NCT00797472|ACTIVE_COMPARATOR|Arm I: R-mabHD|Anti-hodgkin disease agent
61969803|NCT00797472|ACTIVE_COMPARATOR|Arm II: ABVD|
61969804|NCT03007576|EXPERIMENTAL|RegStem|Autologous MSC, 5×10\^7 cells, one injection
61969805|NCT05953220||Smoking|People who smoke tobacco cigarettes at least daily and have not vaped an e-cigarette (except one or two puffs on a less than monthly basis), used NRT, smoking cessation medication or other tobacco products for the past 6 months.
61969806|NCT05953220||Vaping|People who vape e-cigarettes at least daily and have not smoked tobacco cigarettes (except one or two puffs on a less than monthly basis), used NRT, smoking cessation medication, or any other tobacco product for the past 6 months.
61969807|NCT05953220||Dual|"Dual users (predominant vapers): people who vape e-cigarettes at least daily and also smoke cigarettes at least weekly, and have not used NRT, smoking cessation medication, or any other tobacco product for the past 6 months.~Dual users (predominant smokers): people who smoke tobacco cigarettes at least daily and also vape e-cigarettes at least weekly, and have not used NRT, smoking cessation medication, or any other tobacco product for the past 6 months."
62145387|NCT06269068||Patients|Patients with lumbar disc herniation
62145388|NCT04860999|EXPERIMENTAL|Somatic Dysfunction|This is the single study arm. All participants completed an osteopathic postural examination and an osteopathic manipulative treatment. Participants also completed a biomechanical assessment prior to and following the osteopathic manipulative treatment to evaluate effects of the treatment on the gait asymmetry.
62145389|NCT04885673|ACTIVE_COMPARATOR|Group A (High flow nasal cannula group)|(Vapotherm) will be used during the bronchoscopy time flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
62145390|NCT04885673|ACTIVE_COMPARATOR|Group B (Apeieoc oxygenation group)|The standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
62145391|NCT04620252|EXPERIMENTAL|Chewing calcium supplements|"Participants were given one of 4 different treatments to chew: a negative control group and 3 calcium supplements with different calcium compositions.~Participants were randomized to determine the sequence of exposure to the different treatments."
62145392|NCT04620252|EXPERIMENTAL|Fluoride rinse|Participants rinsed with an over the counter sodium fluoride rinse for 1 min, after having chewed a candy (negative control), a calcium calcium carbonate or a calcium citrate supplement.
62145393|NCT04494399|ACTIVE_COMPARATOR|Treatment group|5-day course of daily subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and oral ribavirin 400mg twice daily plus standard care
62145394|NCT04494399|NO_INTERVENTION|Control group|Standard care alone
62509961|NCT03056768|EXPERIMENTAL|multidomain intervention|1-year multidomain health promotion (physical activities, cognitive training, nutritional sessions)
61969808|NCT05953220||Non-use|People who have neither smoked, vaped, used NRT, smoking cessation medication, nor any other tobacco product for the past 12 months.
61969809|NCT00905073|EXPERIMENTAL|cyclosporin+Methotrexate|cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.
61969810|NCT01655706|ACTIVE_COMPARATOR|escitalopram (10-20mg)|Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
61969811|NCT01655706|ACTIVE_COMPARATOR|aripiprazole (2-10mg)|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
61969812|NCT00218465|EXPERIMENTAL|GW468816|Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial
61969813|NCT00218465|PLACEBO_COMPARATOR|Placebo|Placebo, 200 mg/day, for a 5-week trial
62145395|NCT01769716|EXPERIMENTAL|Umbilical cord blood transplantation|Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.
62145396|NCT01138969|ACTIVE_COMPARATOR|Esomeprazole plus clopidogrel group|esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
62145397|NCT01138969|NO_INTERVENTION|Clopidogrel group|clopidogrel 75 mg qd for 6 months
62145398|NCT01267552|EXPERIMENTAL|Non drainage arm|No drains will be placed during operation
62145399|NCT01267552|ACTIVE_COMPARATOR|Drainage arm|Closed suction drains will be placed during operation
62145400|NCT00681941|EXPERIMENTAL|1|Sevelamer Carbonate Tablets Dosed Three Times A Day
62145401|NCT00001686||Cohort A|Children and adults with cancer (or a pre-cancer syndrome or rare disease), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
62145402|NCT04039776|EXPERIMENTAL|Bone patellofemoral joint indices|Evaluation of the bone index values in patients affected by patellofemoral joint disorders, obtained from CT scans performed in both orthostatism and clinostatism
62145403|NCT04813666|ACTIVE_COMPARATOR|TB group|
62145404|NCT04813666|PLACEBO_COMPARATOR|Non TB group|
62351486|NCT03979027|EXPERIMENTAL|Breakfast|Ad libitum intake of ready-to-eat-cereal with milk. Participants were given a choice of four commercially available RTECs with 1.8% fat cow's milk. Ad libitum water intake was also permitted. The four ready-to-eat-cereals were corn flakes, toasted rice, shredded whole wheat pieces with a sugar topping, and wheat, corn and oat shapes.
62539398|NCT04666805||Drug Group|Endocrine therapy drugs include selective estrogen receptor modulators (Tamoxifen, Toremifene) and aromatase inhibitors (Anastrozole, Letrozole, Exemestane), which have been widely used in the adjuvant treatment of hormone receptor positive breast cancer.
62707411|NCT03532360|ACTIVE_COMPARATOR|High-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
62145405|NCT01057082|EXPERIMENTAL|Juven|Participants in the treatment arm will receive the dietary supplement Juven.
62145406|NCT01057082|PLACEBO_COMPARATOR|Placebo|
62145407|NCT04180943|ACTIVE_COMPARATOR|liposomal bupivicaine|interscalene nerve block using liposomal bupivacaine (Exaprel) 10 ml mixed with 0.5% bupivacaine in same syringe - volume of bupivacaine per MD based on pt weight, etc but CANNOT EXCEED 13mL
62145408|NCT04180943|ACTIVE_COMPARATOR|bupivicaine|interscalene block using standard bupivicaine (combination of ropivacaine 0.5% and lidocaine 2%) (volume per MD based on pt weight) + decadron
61969814|NCT00790855|EXPERIMENTAL|Bendamustine|Starting dose 50 mg/m\^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.
61976253|NCT03965533|EXPERIMENTAL|Part A: GSK2831781 450 mg IV- Japanese Participants|Japanese male participants were administered a single IV infusion of GSK2831781 at a dose of 450 mg, diluted in 0.9% w/v saline.
61976254|NCT03965533|PLACEBO_COMPARATOR|Part B: Placebo SC|Caucasian male participants were administered three SC injections of 0.9% w/v saline placebo.
62145409|NCT06195345||Pediatric Patients|Children scheduled for clinical MR imaging.
62145410|NCT06511310|EXPERIMENTAL|Exercise Training|Subjects will complete a supervised high-intensity interval training program for 12 weeks, including four weekly training sessions. The training session will include a 3 minute warm-up followed by six 40 second bouts of high intensity (85-95% of VO2peak) with 3 minutes moderate intensity (45-55% of VO2peak) between each bout of high intensity, concluding with a 3 minute cool-down. Each participant's target heart rate will be specific to them, calculated from the exercise test completed during Visit 1.
62145411|NCT01792401|PLACEBO_COMPARATOR|Placebo|Patients on enteral feeding in intensive care units are administered a placebo
62509962|NCT03662256|ACTIVE_COMPARATOR|Current Primary Care Referral Process|In communities randomized to the current primary care process, families will be notified if their children refer hearing screening in exactly the same method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. Per current practice, most preschools also give the list of referred children to the Norton Sound Audiology Department, whose staff then reaches out to families to schedule appointments during the next available audiology clinic.
62509963|NCT03662256|EXPERIMENTAL|Expedited Telemedicine Referral|In communities randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
61969815|NCT03959358|EXPERIMENTAL|Lenalidomide|"Participants will only receive lenalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of lenalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with lenalidomide at."
61969816|NCT03959358|EXPERIMENTAL|Pomalidomide|"Participants will only receive pomalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of pomalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with pomalidomide at."
61969817|NCT00366288||1|
61969818|NCT00366288||2|
61969819|NCT00366288||3|
61969820|NCT00366288||4|
61969821|NCT00366288||5|
61969822|NCT00366288||6|
61969823|NCT00366288||7|
61969824|NCT04518150|EXPERIMENTAL|study group|patients with placenta previa undergoing cesarean section underwent bilateral uterine artery ligation plus insertion of Bakri balloon
61969825|NCT04518150|ACTIVE_COMPARATOR|control group|patients with placenta previa undergoing cesarean section underwent insertion of Bakri balloon
61969826|NCT04287244|EXPERIMENTAL|Active tSDCS|Anodal tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (designed by Sooma). The anode will be positioned over the spinal cord area at the level of the spinous processes of 10th-11th thoracic vertebra.
61969827|NCT04287244|SHAM_COMPARATOR|Sham tSDCS|Sham stimulation will be delivered to the same spinal cord area using a sham tSDCS device that delivers a direct current for 10 seconds at the beginning and end of tSDCS to provide sensory experiences similar to active stimulation.
61969828|NCT00585819|EXPERIMENTAL|2. Free breathing|Freebreathing in Body fix mold
62509964|NCT05022563||Parenteral anticoagulant only|LMWH, UFH
61969829|NCT00585819|EXPERIMENTAL|1. breathing cycle|reproducing breathing cycles
61969830|NCT05710536|EXPERIMENTAL|Formulation X|Participants will use the formulation once every 72 hour for 5 weeks
62145412|NCT01792401|ACTIVE_COMPARATOR|Probiotics|Patients on enteral feeding in intensive care unit are given a probiotic
62351487|NCT04248400|NO_INTERVENTION|Control|No intervention
62509965|NCT05022563||Warfarin-based|Warfarin only + parenteral anticoagulant bridged warfarin
62509966|NCT05022563||NOAC-based|"NOAC only + parenteral anticoagulant bridged NOAC~NOAC: apixaban, rivaroxaban, dabigatran, edoxaban"
61969831|NCT02857543|ACTIVE_COMPARATOR|plant-based diet|Plant-based diet with as few added oils and fats as possible
61969832|NCT02857543|ACTIVE_COMPARATOR|American Heart Association|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, and lean meat and fish in moderation.
61969833|NCT02857543|ACTIVE_COMPARATOR|Mediterranean|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, with more emphasis on fish and extra virgin olive oil and/or nuts.
61969834|NCT00572585|EXPERIMENTAL|AEB071|
61969835|NCT00572585|PLACEBO_COMPARATOR|Placebo|
61969836|NCT01962207|EXPERIMENTAL|ACWY<2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
62145413|NCT02384382|EXPERIMENTAL|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
62145414|NCT01604824|EXPERIMENTAL|GOFm PCSK9 (Cohort 1): Alirocumab From Day 1|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
62351488|NCT04248400|ACTIVE_COMPARATOR|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
62351489|NCT04248400|EXPERIMENTAL|Tai Chi|A 24 weeks Tai Chi training with three 1-hour section per week
61969837|NCT01962207|EXPERIMENTAL|ACWY≥2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
62707412|NCT03498716|EXPERIMENTAL|Atezolizumab + Chemotherapy|"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose~Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)"
62707413|NCT03498716|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
62707414|NCT01350323|ACTIVE_COMPARATOR|Type 3 NV|Wet-AMD related type 3 neovascularization
61969838|NCT01962207|EXPERIMENTAL|MenCCRM Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.
62145415|NCT01604824|EXPERIMENTAL|GOFm PCSK9 (Cohort 1): Alirocumab From Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 (\[matching placebo at Week 0 (Day 1), 10 and 14\]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
62145416|NCT01604824|EXPERIMENTAL|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 1|Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
62145417|NCT01604824|EXPERIMENTAL|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 (\[matching placebo at Week 0 (Day 1), 10 and 14\]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
62145418|NCT01451359|EXPERIMENTAL|endobronchial valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
62351490|NCT01213693|EXPERIMENTAL|ICS/LABA group|Patients assigned to this arm will take bid 50/500 mcg fluticasone/salmeterol combination
62351491|NCT01213693|ACTIVE_COMPARATOR|LABA group|Patients assigned to this arm will take bid 50 mcg salmeterol
62351492|NCT00570440|EXPERIMENTAL|A|
62707415|NCT01350323|ACTIVE_COMPARATOR|Type 2 NV|Wet-AMD related type 2 neovascularization
62707416|NCT01350323|ACTIVE_COMPARATOR|Type 1 NV|Wet-AMD related type 1 neovascularization
61969839|NCT01962207|EXPERIMENTAL|MenPS Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.
62539399|NCT03032016||sVOD patient treated with defibrotide|Patient diagnosed with severe hepatic VOD and treated with defibrotide
62707417|NCT01350323|OTHER|Controls|Aqueous sample (0.1ml) in patients undergoing cataract extraction
62707418|NCT06564493|EXPERIMENTAL|TMLI conditioning group|Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI) plus Cyclophosphamide
61969840|NCT03785002|EXPERIMENTAL|vegetarian|Individuals who do not consume meat (vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
61969841|NCT03785002|ACTIVE_COMPARATOR|non vegetarian|Individuals who do consume meat (non vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
61969842|NCT04168385|EXPERIMENTAL|Maralixibat|Participants will all receive Maralixibat oral solution
61969843|NCT05071989|EXPERIMENTAL|Sleep education group do not supported with social media reminders|Sleep education do not supported with social media reminders
61969844|NCT05071989|EXPERIMENTAL|Sleep education group supported with social media reminders|Sleep education group supported with social media reminders
61969845|NCT05071989|NO_INTERVENTION|Control group|No intervention was made in the control group.
61969846|NCT03053804|EXPERIMENTAL|MR/PET|hypothesize that MR/PET can have better information than current CT image study
61969847|NCT04682015|EXPERIMENTAL|Intervention|The intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.
62351493|NCT00570440|ACTIVE_COMPARATOR|B|
62351494|NCT04801797|EXPERIMENTAL|Standard of Care (Conventional Induction)|"Randomized participants will receive cytarabine and idarubicin \[or daunorubicin) per standard of care as follows:~Induction: cytarabine on days 1-7 and idarubicin (or daunorubicin) on days 1-3 of induction.~Second Induction (if needed): Cytarabine on days 1-5 and idarubicin (or daunorubicin) on days 1-2 of re-induction.~Consolidation (if needed): If \< 60 years, cytarabine days 1,3,5 of consolidation cycles, and if ≥60 years, cytarabine days 1-5 of consolidation cycles~Those with secondary or therapy-related AML can receive liposomal daunorubicin and cytarabine (Vyxeos) per standard of care as follows:~Induction: Liposomal daunorubicin and cytarabine (Vyxeos) on Days 1,3, 5 of induction.~Second Induction (if needed): Liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of re-induction Consolidation (if needed): liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of consolidation cycles"
62351495|NCT04801797|EXPERIMENTAL|Investigational (Venetoclax and Azacitidine)|Participants will receive azacitidine on days 1-7 and venetoclax daily for up to (3) three 28-day study cycles and evaluated for response or benefit. If benefit/response is achieved, azacitidine on days 1-7 and venetoclax on days 1-28 (or less if deemed necessary per protocol) will be given in repeating 28-day cycles until benefit/response is no longer achieved or until patient proceeds to transplantation.
62509967|NCT05076513|EXPERIMENTAL|Arm A: Presumed Newly-Diagnosed glioblastoma|Participants undergoing resection for a presumed newly-diagnosed glioblastoma (WHO grade 4) will be treated with niraparib for 4 days prior to surgical resection. Participants who proceed to the therapeutic expansion phase of this study will receive niraparib in combination with radiation (60 Gy over 6-7 weeks, as per standard of care). Following radiotherapy, eligible study participants may receive niraparib maintenance treatment.
62509968|NCT05076513|EXPERIMENTAL|Arm B: Recurrent Glioma (Grades II-IV)|Participants undergoing resection of a recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss will be treated with niraparib for 4 days prior to a planned surgical resection. Participants who proceed to the Expansion cohort will receive niraparib in 28d cycles after surgery.
62509969|NCT00707564|EXPERIMENTAL|1|HemCon Dental Dressing
62509970|NCT00707564|ACTIVE_COMPARATOR|2|Gauze with pressure
62509971|NCT02038504||gastrointestinal fistula|
62509972|NCT02105311|EXPERIMENTAL|Selective laser trabeculoplasty|Treating with the selective laser trabeculoplasty
62707419|NCT06564493|ACTIVE_COMPARATOR|TBI conditioning group|Total Body Irradiation (TBI) plus Cyclophosphamide
61969848|NCT04682015|NO_INTERVENTION|Control|Control group will receive usual care and follow up in hospitals and community health centers.
61969849|NCT01417234||SNaP® Wound Care System|
62351496|NCT01990755|ACTIVE_COMPARATOR|CBT (Cognitive Behavioral Therapy)|"Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
62351497|NCT01990755|ACTIVE_COMPARATOR|IBPP (IP brief psychotherapy )|"Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation."
62351498|NCT01990755|ACTIVE_COMPARATOR|CBT + OLANZAPINE (5 MG)|"The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
62351499|NCT03300258|OTHER|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
62351500|NCT03300258|OTHER|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
62351501|NCT03300258|EXPERIMENTAL|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
62351502|NCT03300258|ACTIVE_COMPARATOR|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
62351503|NCT00957255|ACTIVE_COMPARATOR|RCR without augmentation|Rotator cuff repair without OrthoADAPT augmentation
62351504|NCT00957255|EXPERIMENTAL|RCR with augmentation|Rotator cuff repair with OrthoADAPT augmentation
62351505|NCT06528015|EXPERIMENTAL|Experimental|Experimental participants will receive probiotics combined with enteric-coated budesonide capsules
62509973|NCT02105311|ACTIVE_COMPARATOR|Travoprost|Using eye drop: travoprost
62509974|NCT06085937|EXPERIMENTAL|Ketamine|All patients will receive the experimental drug.
62509975|NCT04865484|EXPERIMENTAL|SRES group|Surgical resection plus endoscopic stricturotomy for multiple fibrous stenosis
62351506|NCT06528015|PLACEBO_COMPARATOR|Comparator|Comparator participants will receive probiotics placebo combined with enteric-coated budesonide capsules
62351507|NCT00546286|EXPERIMENTAL|1|dorzolamide HCl/timolol maleate
62351508|NCT00546286|EXPERIMENTAL|2|dorzolamide hydrochloride/timolol maleate + prostaglandin
62509976|NCT04865484|ACTIVE_COMPARATOR|SRS group|Surgical resection plus strictureplasty for multiple fibrous stenosis
62509977|NCT03367689|EXPERIMENTAL|Olaparib 300 mg|Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.
62509978|NCT05227586||LA + RA ablation|Patients with persistent atrial fibrillation and right atrial enlargement received adjunctive right atrial ablation when left atrial ablation did not terminate atrial fibrillation.
61969850|NCT05573789||Patients with prostate cancer|Patients with recurrent locally advanced, metastatic and/or high-grade operable prostate cancer and available formalin-fixed paraffin-embedded tumor tissue. Patients received treatment at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology. Tumor molecular profiling was performed.
61969851|NCT03446469|EXPERIMENTAL|Individuals with Chronic Ankle instability|Individuals with history of ankle sprains will be screened using the inclusion criteria before being included in the study
62351509|NCT03858608|EXPERIMENTAL|Counterweight Plus|"Total Diet Replacement phase (0-12 weeks) 825-853kcal/day low energy liquid diet (LELD) for 12 weeks Food Reintroduction phase (13-18 weeks) Wk 13: 400kcal/d LELD + 1 low-fat meal/day (c. 360-400 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1000kcal/day Wk 15: 200kcal/d LELD + 2 low-fat meals/day (c. 720-800 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1200kcal/day.~Wk 17: 3 low-fat meals per day (c.1080-1200 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1400kcal/day.~Weight maintenance phase (wks 19-52) Low-fat healthy eating weight loss maintenance intervention \[target below 30% energy from fat, with flexibility to optimise individual compliance, to a maximum of 35%\]"
62351510|NCT03858608|ACTIVE_COMPARATOR|Usual asthma care|Usual asthma management
62509979|NCT05227586||LA ablation only|Patients with persistent atrial fibrillation and right atrial enlargement received left atrial ablation only
62707420|NCT03612570|EXPERIMENTAL|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
62707421|NCT01226108|ACTIVE_COMPARATOR|antinitus patch|One patch per day, Duration: three weeks, Administration: behind the ear
62509980|NCT01992016|EXPERIMENTAL|Arm I (localized prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
62351511|NCT06064903|EXPERIMENTAL|CD7-CART01|"A single IV infusion of CD7-CART01 (CD7-directed chimeric antigen receptor T-cells) on Day 0 after lymphodepleting regimen.~Patients will receive the following lymphodepleting regimen:~* Fludarabine 30 mg/m2 per day over 1 hour on days -6, -5, -4 and -3~* Cyclophosphamide 1000 mg/m2 per day on days -4 and -3.~CD7-CART01 will be infused at the following dose levels:~* DL1: 0.5 x 10\^6 CAR+ cells/kg~* DL2: 1 x 10\^6 CAR+ cells/kg~If 2 DLTs are observed an additional DL0 of 0.25 x 106 CAR+ cells /kg will be explored."
62351512|NCT04586556|EXPERIMENTAL|Artificial intelligence for real-time detection and monitoring of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information on the detection of polyps, follow-up and prediction of pathology. The full-length colonoscopy videos will be annotated for the exact time of the identification of the anatomical landmarks, polyps, also for polyp- and procedural-related characteristics.
62351513|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
62351514|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
62509981|NCT01992016|EXPERIMENTAL|Arm II (metastatic prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment.
62509982|NCT01357434||Adolescents|Participants 12-21 years old.
62509983|NCT03186599|NO_INTERVENTION|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
62509984|NCT03186599|NO_INTERVENTION|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
62509985|NCT03186599|EXPERIMENTAL|low adherence intervention group|"* Patient with the WALKON mobile application.~* Patient with monthly feedback call~* Patients on continuous MEMS monitoring."
62509986|NCT06227117|EXPERIMENTAL|Disitamab Vedotin + Toripalimab|Disitamab Vedotin with Toripalimab Arm
62509987|NCT06227117|EXPERIMENTAL|Disitamab Vedotin + Toripalimab+Carboplatin|Disitamab Vedotin + Toripalimab with Carboplatin Arm
62509988|NCT06227117|EXPERIMENTAL|Disitamab Vedotin + Toripalimab sequential Epirubicin+ CTX+ Toripalimab|Disitamab Vedotin + Toripalimab sequential Epirubicin+ CTX with Toripalimab Arm
62145419|NCT01262456|EXPERIMENTAL|Desmopressin 50 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
62145420|NCT01262456|EXPERIMENTAL|Desmopressin 75 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
62509989|NCT05108116||Study group|"18-30 year-old, healthy volunteers~* Age: 18-30 years~* BMI: \<30~* No previous surgery on lower limb or spine~* No known developmental disorder~* Without any orthopaedic complaint"
62509990|NCT06503549||Healthy control|
62509991|NCT06503549||Patient with rotator cuff-related shoulder pain|
62509992|NCT04714281|OTHER|Hemodiafiltration HDF|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
62509993|NCT04741152||Revealed insulinoma|Cases when the tumor was revealed by the preoperative diagnostics and confirmed after the tumor elimination
62509994|NCT04741152||Hidden Insulioma|Group when the insulinoma haven't been revealed preoperative and intraoperatively and the blind resection was performed.
62509995|NCT02614963|EXPERIMENTAL|Clostridium Butyricum group|Irritable bowel syndrome patients treated with Clostridium Butyricum
62707422|NCT03278522|ACTIVE_COMPARATOR|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
62707423|NCT03278522|ACTIVE_COMPARATOR|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
62707424|NCT06189794|EXPERIMENTAL|Rosa damascena oil group|Rosa Damascene oil will be used
62145421|NCT01262456|PLACEBO_COMPARATOR|Placebo Double-Blind / Desmopressin 100 μg Open-Label|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
62145422|NCT03999788|EXPERIMENTAL|multiple sclerosis patients|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
62145423|NCT03999788|EXPERIMENTAL|control subjects|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
61969852|NCT03714867|EXPERIMENTAL|Treatment|Treatment arm intervention consists of patients who will be administered a single enteral dose of concealed over-encapsulated Pregabalin 150mg in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
61969853|NCT03714867|PLACEBO_COMPARATOR|Control|Treatment arm consists of patients who will be administered a single enteral dose of concealed over-encapsulated placebo capsules in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
62509996|NCT02614963|PLACEBO_COMPARATOR|Placebo group|Irritable bowel syndrome patients treated with placebo
61969854|NCT04894773|EXPERIMENTAL|Imaginary Resisted Exercises|Handgrip exercises with the imagination of resistance in hand by getting feedback in VR Box will be given as an intervention. Stretching will be given at the beginning and the end of each session. This will include imaginary resistance exercises for handgrip by using Virtual Reality Box. Five types of different resistances will be imagined by patients by watching their own videos in VR box, which will be recorded on day one to make them familiar with the resistive objects and the resistance experienced from them by asking patients to perform 15-15 repetitions of each object. Every imaginary resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
61969855|NCT04894773|EXPERIMENTAL|Physical Resisted Exercises|Handgrip exercises with physical resistance in hand will be given as an intervention. Stretching will be given at the beginning and the end of the session. 5 different types of resistances will be given to patients for making themselves familiarize themselves with the type of resistance applied by each object, that they will experience in further sessions, by asking them to perform 15-15 repetitions of each object. Every physical resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
61969856|NCT01161147|EXPERIMENTAL|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
61969857|NCT01161147|ACTIVE_COMPARATOR|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
62145424|NCT03999788|EXPERIMENTAL|multiple sclerosis patients with spasticity and selected SNPs|iTBS therapeutic protocol
62145425|NCT02427516||NVAF-VKA cohort|NVAF patients who initiate a VKA treatment
62509997|NCT03482219|EXPERIMENTAL|Intensive treatment|"Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:~1. Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~2. Application of the Physiotouch (a low-intensity negative pressure device)~3. Passive Range of Motion~4. Active Range of Motion~5. Functional Activities"
62509998|NCT03482219|ACTIVE_COMPARATOR|Home app intervention|Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises.
62509999|NCT02629588||Persons in coma or vegetative state|People who survived TBI have a period of complete unconsciousness or coma with no awareness of themselves or their surroundings received multimodal or unimodal sensory stimulation.People in a coma are unaware and unresponsive, but not asleep as there is no sleep-wake cycle. While in a coma, people are unable to speak, follow commands or open their eyes. The person in coma may have a simple reflex in response to touch or pain, but essentially there is no meaningful response to external stimuli. There is an absence of awareness of self and the environment, even under conditions of vigorous external stimulation. Coma can last from hours to days, depending on the severity of the brain damage, and sometimes a person can remain in a comatose state for months and even years.
62145426|NCT02427516||VTE-VKA cohort|VTE patients who initiate a VKA treatment
62145427|NCT04180683||Semi-structured interview group|Participants assigned to this group will be administered the GDS-30, GDS-15, GDS-10 nad GDS-5, and also the BDI-II and a semi-structured interview based on the DSM-5 criteria. The psychologists performing the assessment will answer a questionnaire about which GDS version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
62145428|NCT04180683||No semi-structured interview group|Participants assigned to this group will be administered the GDS-30 and the GDS-15, and also the BDI-II.
62510000|NCT00737737|EXPERIMENTAL|Opioid|Participants will receive MS Contin over a 4 week period starting at 15 mg bid. Doses will titrated upwards as tolerated by increments of 15-30 mg to a highest attained dose or a maximum dose of 90 mg
62510001|NCT00737737|EXPERIMENTAL|Placebo|Participants will receive a similar number of placebo tablets which match the study drug with regards to appearance over a period of 4 weeks
62510002|NCT02607020|EXPERIMENTAL|Physical exercise|
62351515|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
62510003|NCT02607020|ACTIVE_COMPARATOR|Relaxation|
62510004|NCT04403516|EXPERIMENTAL|DEXTENZA Group|Patients with Pterygium DEXTENZA Group
62510005|NCT04403516|EXPERIMENTAL|Topical Prednisolone Acetate 1% Group|Patients with Pterygium Topical Prednisolone Acetate 1% Group
62510006|NCT02862249|EXPERIMENTAL|Faecal microbiota transplantation|Faecal microbiota transplantation.
62510007|NCT02862249|PLACEBO_COMPARATOR|Placebo|Placebo solution.
62510008|NCT00585260|EXPERIMENTAL|Exploratory Mannitol|This is an exploratory / ancillary study open to all participants in the BASALT trial \[NCT00495157\] who consented to undergo mannitol bronchoprovocation procedures during the 36 week treatment period
62510009|NCT06468696|EXPERIMENTAL|Suturing the cervical linea alba during endoscopic thyroid surgery|Suturing the cervical linea alba during endoscopic thyroid surgery.
61969858|NCT03125343|EXPERIMENTAL|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
62510010|NCT06468696|NO_INTERVENTION|Not suturing the cervical linea alba during endoscopic thyroid surgery|Not suturing the cervical linea alba during endoscopic thyroid surgery.
61969859|NCT03125343|ACTIVE_COMPARATOR|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
61969860|NCT03018171|EXPERIMENTAL|SC|this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
61969861|NCT03018171|ACTIVE_COMPARATOR|S|this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
62145429|NCT04701645|EXPERIMENTAL|Cohort 1: Primary cytoreduction|"Patients with a new or suspected diagnosis of ovarian cancer who are deemed surgical candidates for primary cytoreductive surgery (as per their surgical gynecologic oncologist) and who have not yet undergone surgery.~* Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~* The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
62510011|NCT06468696|OTHER|Thyroid papillary carcinoma group|Thyroid papillary carcinoma tissue.
62510012|NCT06468696|OTHER|Thyroid papillary carcinoma adjacent group|Thyroid papillary carcinoma adjacent tissue.
62510013|NCT06468696|OTHER|Lymph node metastasis group|Lymph node tissue with metastasis.
62510014|NCT06468696|OTHER|Non-lymph node metastasis group|Lymph node tissue without metastasis.
62510015|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
62510016|NCT01716676|ACTIVE_COMPARATOR|Standard CPAP follow-up|
62510017|NCT01716676|EXPERIMENTAL|Telemedicine CPAP follow-up|
62510018|NCT04352270|ACTIVE_COMPARATOR|Group 1- Printed educational materials|Parent-child dyads randomized to this group will receive printed educational materials in English or Spanish about atopic dermatitis.
62510019|NCT04352270|EXPERIMENTAL|Group 2- Educational videos|Parent-child dyads randomized to this group will receive an investigator developed educational video in English or Spanish about atopic dermatitis.
62510020|NCT01915342|EXPERIMENTAL|Focal muscle vibration|"Focal muscular vibration will be applied at mGCM of each subject for 10 minutes in each session.~Frequency: 40, 80, 120 Hz Amplitude: 0.1, 0.3, 0.5 mm"
62510021|NCT01128582|ACTIVE_COMPARATOR|Rozerem|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
62510022|NCT01128582|PLACEBO_COMPARATOR|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology
62510023|NCT02959476|EXPERIMENTAL|Ropivacaine 0.2%|"Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - Ropivacaine Infusion treatment arm"
62707425|NCT06189794|ACTIVE_COMPARATOR|Frankincense oil group|Frankincense oil will be used
62707426|NCT06189794|PLACEBO_COMPARATOR|Solution group|%0.9 NaCl Isotonical Solution will be used
61969862|NCT02521636|PLACEBO_COMPARATOR|Anibiotic therapy guided with actual french recommandations|Guided by the antibiotic 2006 recommendations of the French consensus conference on anti-infective therapy of respiratory tract infections in low immuno-competent adult.
62510024|NCT02959476|PLACEBO_COMPARATOR|Placebo|"Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - Placebo treatment arm"
62510025|NCT02593396|PLACEBO_COMPARATOR|placebo|Placebo BD
62510026|NCT02593396|EXPERIMENTAL|Active|Bupropion hydrochloride sustained-release 150mg BD
62510027|NCT04845516||plasma exchange|All patients underwent plasma exchanges between 2014 and 2019 for a neuropediatric pathology
62510028|NCT04845516||immunoadsorption|All patients who underwent immunoadsorptions between 2014 and 2019 for a neuropediatric pathology
62510029|NCT05981495||TB Suspects|TB Suspects recruited to this study will have blood drawn in a single visit.
62510030|NCT03955939|EXPERIMENTAL|LY3295668 Erbumine Part A|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
62510031|NCT03955939|EXPERIMENTAL|LY3295668 Erbumine Part B|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
62510032|NCT03955939|EXPERIMENTAL|LY3295668 Erbumine + Endocrine Therapy Cohort 1|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II).
62510033|NCT03955939|EXPERIMENTAL|LY3295668 Erbumine + Endocrine Therapy Continuation Part C|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
62510034|NCT03955939|EXPERIMENTAL|LY3295668 Erbumine + Endocrine Therapy Switch Part D|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
62510035|NCT03384433|EXPERIMENTAL|exosome or vesicle|CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal
62510036|NCT01584895|EXPERIMENTAL|Rehab|Patients randomized into early cardiac rehabilitation
62707427|NCT03910075|EXPERIMENTAL|I-ACQUIRE High Dose|High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks)
62707428|NCT03910075|EXPERIMENTAL|I-ACQUIRE Moderate Dose|Moderate Dose I-ACQUIRE (3 hrs/day, 5 day/wk X 4 wks)
62707429|NCT03910075|ACTIVE_COMPARATOR|Usual & Customary Treatment|Usual \& Customary Treatment
62145430|NCT04701645|EXPERIMENTAL|Cohort 2: Surgical assessment for primary surgery|"Patients with newly diagnosed ovarian cancers who are being considered for either primary surgery or neoadjuvant chemotherapy by their surgical gynecologic oncologist, and who require a laparoscopic procedure to determine their candidacy for surgery.~* Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~* The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
62145431|NCT04701645|EXPERIMENTAL|Cohort 3: Secondary cytoreduction|"Patients with recurrent ovarian cancer who are candidates for secondary cytoreduction, e.g.to confirm diagnosis of recurrent ovarian cancer and/or remove oligometastatic lesions.~* Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~* The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
62145432|NCT04701645|EXPERIMENTAL|Cohort 4: Interval debulking surgery following neoadjuvant chemotherapy|"Patients with newly diagnosed ovarian cancers who have undergone neoadjuvant chemotherapy and are deemed surgical candidates for interval debulking surgery (as per their surgical gynecologic oncologist) and who have not yet undergone surgery.~* Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~* The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
62510037|NCT01584895|NO_INTERVENTION|Control|No cardiac rehabilitation until after 6 week post assessment.
62510038|NCT00493779|NO_INTERVENTION|1|Effect of Clopidogrel withdrawal on biomarkers will be assessed via blood draws
62707430|NCT03362671|EXPERIMENTAL|Treatment Group|Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
62707431|NCT05245903||Parent Study Participants|The single group in this study will consist of individuals enrolled in the parent study (ClinicalTrials.gov identifier NCT04430517). We aim to enroll approximately 40 individuals aged 18 -89 (inclusive) with either MCI or mild AD who will have the Emerald device deployed in their home for up to 12 weeks, spanning the time of approval of parent study screening and formal study enrollment.
61969863|NCT02521636|EXPERIMENTAL|Anibiotic therapy guided with serum PCT value|"Guided antibiotic therapy serum PCT at admission, revalued at day 1, day 3 and day 6 as long as PCT is not less than 0.1 ng / mL:~* PCT \<0.1 ng / mL: no antibiotics~* 0.1 \<PCT \<0.25 ng / mL: antibiotic advised~* PCT\> 0.25 ng / mL: highly recommended antibiotics"
61969864|NCT05773508||Group with video-regulation and using of the emergency kit|Use of video regulation and/or emergency kit → addressing modified by the use of one or the other
61969865|NCT05773508||Group without video-regulation and using of the emergency kit|no video-regulation and no use of the emergency kit → addressing patients according to the standard of care
61969866|NCT00821977|EXPERIMENTAL|Vildagliptin Dose 1|
61969867|NCT00821977|EXPERIMENTAL|Vildagliptin Dose 2|
61969868|NCT00821977|PLACEBO_COMPARATOR|Placebo|
61969869|NCT05822713|EXPERIMENTAL|Experimental|Amisulpride at 5mg was given by slow iv administration during1 to 2 min at induction of anesthesia
61969870|NCT05822713|PLACEBO_COMPARATOR|Placebo|Placebo was given by slow iv administration during1 to 2 min at induction of anesthesia
61969871|NCT00211809|EXPERIMENTAL|Body dysmorphic disorder|Participants with body dysmorphic disorder
61969872|NCT04762433|EXPERIMENTAL|Kegel Exercise Pregnancy Training - App|The intervention arm will be given a mHealth app for two months duration with the usual antenatal follow-up.
62145433|NCT00746759||Standard of Care|
62145434|NCT02060487|EXPERIMENTAL|Low dose|
62145435|NCT02060487|EXPERIMENTAL|Medium dose|
62145436|NCT02060487|EXPERIMENTAL|High dose|
62510039|NCT00332124|PLACEBO_COMPARATOR|1|Participants will take placebo
62510040|NCT00332124|ACTIVE_COMPARATOR|2|Participants will take choline
62510041|NCT04341272|ACTIVE_COMPARATOR|Upper Extremity Compression Device|Patients randomized to have pneumatic compression device placed on upper extremity following surgery
62510042|NCT04341272|OTHER|Control|Patients randomized to have pneumatic compression device placed on lower extremity following surgery
62510043|NCT03576287|EXPERIMENTAL|apremilast|apremilast standard doses
61969873|NCT04762433|NO_INTERVENTION|Waitlist control|The control (waitlist) group will continue their usual antenatal follow-up and the KEPT-app will be given after the study ends.
61969874|NCT04462549|EXPERIMENTAL|Resource Facilitation|This group is receiving Resource Facilitation
61969875|NCT04462549|NO_INTERVENTION|Control|Not receiving Resource Facilitation
61969876|NCT00784992|NO_INTERVENTION|1|Endonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
61969877|NCT00784992|ACTIVE_COMPARATOR|2|Endonasal DCR without silicone tubes (this is the 'intervention' arm)
61969878|NCT00399776||Group A|Adolescents taking haloperidol, risperidone, or olanzapine
61969879|NCT00399776||Group B|Healthy adolescents
61969880|NCT03240614|ACTIVE_COMPARATOR|BMI <30 no lung disease|Patients with a BMI \<30 with no lung disease
61969881|NCT03240614|ACTIVE_COMPARATOR|BMI <30 with lung disease|Patients with a BMI \<30 with lung disease
61969882|NCT03240614|ACTIVE_COMPARATOR|BMI 30-35 with no lung disease|Patients with a BMI between 30 and 35 with no lung disease
62510044|NCT05865392|EXPERIMENTAL|Move physical activity support program|Participants receive the Move physical activity support program over 12 weeks.
61969883|NCT03240614|ACTIVE_COMPARATOR|BMI 30-35 with lung disease|Patients with a BMI between 30 and 35 with lung disease
62510045|NCT02153892|OTHER|Multi-center, prospective, single-arm study|To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.
61969884|NCT03240614|ACTIVE_COMPARATOR|BMI >35 with no lung disease|Patients with a BMI\> 35 with no lung disease
62145437|NCT03739606|EXPERIMENTAL|Treatment (flotetuzumab)|Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62145438|NCT02640703|ACTIVE_COMPARATOR|morning vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 am
62145439|NCT02640703|ACTIVE_COMPARATOR|evening vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 pm
61969885|NCT03240614|ACTIVE_COMPARATOR|BMI >35 with lung disease|Patients with a BMI\> 35 with lung disease
61969886|NCT02329730|EXPERIMENTAL|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
61969887|NCT02329730|EXPERIMENTAL|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
61969888|NCT02329730|EXPERIMENTAL|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
61969889|NCT05255068|EXPERIMENTAL|Staff|Start participants who enrolled in the study, received the OPTIMAL intervention, and were observed during data collection.
61969890|NCT05255068|EXPERIMENTAL|Resident|Resident participants who were cared in the study site, and received care from the staff participants before and after the OPTIMAL intervention was delivered to staff.
61969891|NCT06208033|EXPERIMENTAL|Treatment-naïve subjects with EGFR positive advanced Lung Adenocarcinoma|toripalimab：3mg/kg， Q2W； SMET12：60μg，Q2W； Pemetrexed Disodium 500mg/m2 d+Carboplatin AUV＝5 d1 Q3W，administered for 2\~4 cycles
61969892|NCT06208033|EXPERIMENTAL|Treatment-naïve subjects with EGFR positive advanced Lung Squamous Cell Carcinoma|toripalimab：3mg/kg， Q2W； SMET12：60μg，Q2W； paclitaxel 100mg/m2 d1，d8，d15+cisplatin 75mg/m2 d1 Q3W， administered for 2\~4 cycles
61969893|NCT06208033|EXPERIMENTAL|Subjects resistant to first-line treatment contain immune checkpoint inhibitors|toripalimab：3mg/kg， Q2W； SMET12：60μg，Q2W； Docetaxel 60-75 mg/m2 d1Q3W，administered for 2\~4 cycles
61969894|NCT01306591|ACTIVE_COMPARATOR|Bevacizumab 1|
61969895|NCT01306591|ACTIVE_COMPARATOR|Bevacizumab 2|
61969896|NCT02206334|EXPERIMENTAL|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis.
61969897|NCT01438424|EXPERIMENTAL|Entecavir, 1.0 mg, with or without lamivudine|
61969898|NCT05324553||Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
61969899|NCT05324553||Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional testing
61969900|NCT05324553||Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
61969901|NCT03297970||Bogota School Children Cohort|"Children are classified according to exposure levels of:~Micronutrient biomarker indicators:~* Ferritin~* Hemoglobin~* Mean corpuscular volume~* Zinc~* Vitamin A~* Vitamin B12~* Folate~* Vitamin D~Serum fatty acids~Inflammatory biomarkers:~* C-reactive protein~Diet~Socioeconomic status indicators~Anthropometric indicators~Incidence of infectious morbidity symptoms~DNA biomarkers"
61969902|NCT04325581|EXPERIMENTAL|Post LSG with Liraglutude|Liraglutide in incremental dose upto maximum of 1.8 mg per day subcutaneously once a day.
62145440|NCT03328637|EXPERIMENTAL|Intervention|Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman \& Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
62145441|NCT03328637|NO_INTERVENTION|Control|Control group will not receive CBT however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
62145442|NCT02322372|ACTIVE_COMPARATOR|Group F|"Ultrasound-guided femoral blockade with 15 mL of bupivacaine 0.5% diluted in 15 mL saline was performed in supine position. Then the patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 1 mL (5 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.~."
62145443|NCT02322372|ACTIVE_COMPARATOR|Group S|The patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 2 mL (10 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
61969903|NCT04325581|PLACEBO_COMPARATOR|Post LSG without Liraglutide|Normal Saline in equivalent per day subcutaneously once a day
62707432|NCT02947971|EXPERIMENTAL|OFDI Imaging|Experimental OFDI Imaging
62510046|NCT01685359|EXPERIMENTAL|Test Drug|Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration
62510047|NCT01685359|ACTIVE_COMPARATOR|Eprex|Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration
62510048|NCT05260021|EXPERIMENTAL|Tirzepatide Dose 1|"Double-Blind:~Participants receive Tirzepatide by weekly subcutaneous (SC) injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached.~Open-Label:~Participants will continue to receive Tirzepatide at the last dose level"
62510049|NCT05260021|EXPERIMENTAL|Tirzepatide Dose 2|"Double-Blind:~Participants receive Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 2 is reached.~Open-Label:~Participants will continue to receive Tirzepatide at the last dose level"
62510050|NCT05260021|PLACEBO_COMPARATOR|Placebo|"Double-Blind:~Participants receive placebo during the 30-week double-blind period.~Open-Label:~Participants will switch to Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached."
62510051|NCT04883424|EXPERIMENTAL|Diabetes Education Program Based on Health Belief Model|Experimental group After the diabetic patients were determined according to the research criteria, they were randomly divided into intervention and control groups. First, pre-tests were applied to diabetics and family members in the experimental group. Diabetes Education Program Based on Health Belief Model It will be administered in two sessions to people with diabetes and their family members. This program; definition of diabetes, the importance of healthy nutrition in diabetes, the importance of exercise, the importance of regular medication, fingertip blood glucose measurement, acute and chronic problems that may develop in diabetic patients, diabetic foot care, personal self-care and family support. A reminder text message will be sent twice a week to diabetics and family members in the intervention group to manage their diabetes well. Once a month, both the diabetic patient and their family member will be called by phone for counseling.
62510052|NCT04883424|NO_INTERVENTION|Control Group|First of all, pre-tests will be applied to diabetic patients in the control group. Diabetics in this group will not be intervened and their final tests will be made 3 months after the pre-test.
61969904|NCT03715764|OTHER|Physical therapy assessment|Patients allocated to the intervention group will be assigned to an assessment and evaluation by a physical therapist. If they are diagnosed with knee osteoarthritis they will get an offer to participate in a patient education program and physical training with an individualized exercise program made by a physical therapist. Patients will be offered individual treatment if they decline to participate in the education program, or if they have another diagnosis than osteoarthritis. Anytime after the first assessment by the physical therapist, the patient will be able to contact a physician if they want to.
62510053|NCT06452329||Participants who received first-line nivolumab therapy for advanced GC/GEJC|
61969905|NCT03715764|OTHER|Physician assessment|Allocation to the control group will involve an assessment and evaluation made by a physician. Further measures will then be determined by attending physician and the procedures that might get included are drug prescriptions, referral to x-ray examination, referral to a physical therapist or another health care provider. Anytime after the first assessment by the physician, the patient will be able to contact a physical therapist if they want to, even though if they have not been referred by the physician.
61969906|NCT04853511||OCT-FLIM dual modal intravascular imaging with serial 18F-FDG-PET/CT assessment|Group of patients undergoing PCI with comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular imaging followed by serial 18F-FDG-PET/CT imaging
61969907|NCT03021408|EXPERIMENTAL|MIRT + Treadmill|In the context of MIRT, the gait training in this group will be performed by using a treadmill without cues.
61969908|NCT03021408|EXPERIMENTAL|MIRT + Treadmill Plus|In the context of MIRT, the gait training in this group will be performed by using a treadmill with visual and auditory cues.
61969909|NCT03021408|EXPERIMENTAL|MIRT + Virtual Reality|In the context of MIRT, the gait training in this group will be performed by using Virtual Reality with enhanced perceptions (visual, auditory, and haptic inputs).
61969910|NCT06352281|EXPERIMENTAL|CAR-T Cells Therapy|Subjects who meet the enrollment conditions will receive intravenous infusion of CAR-T cells after lymphodepletion.
61969911|NCT05511051|EXPERIMENTAL|Fruquintinib + HAIC|Fruquintinib: 5 mg orally once daily for 21 days on followed by 7 days off (q4w); HAIC: oxaliplatin 100 mg/m2, leucovorin calcium 200 mg/m2, fluorouracil 2000 mg/m2 24-hour drip, q4w, 2 cycles; HAIC treatment was administered during fruquintinib rest; HAIC was discontinued 1 day before surgery, on the day of completion of surgery, and 5 days after surgery;
62510054|NCT00660868||1|Patients with posttraumatic, idiopathic, and postinflammatory cause of smell loss; patients age between 18 and 50 years. Odor threshold better than 1.
62510055|NCT04815395|EXPERIMENTAL|Oral Oxytocin|Oxytocin (24IU) orally
62510056|NCT04815395|EXPERIMENTAL|Intranasal Oxytocin|Oxytocin (24IU) intranasally
62510057|NCT04815395|PLACEBO_COMPARATOR|Oral Placebo|Placebo orally
62510058|NCT05229822||Malignant ABO|60 patients with malignant acute bowel obstruction
62510059|NCT05229822||CRC without ABO (control)|60 colorectal cancer patients without acute bowel obstruction (planned operations)
62510060|NCT05229822||Benign ABO|30 patients with benign acute bowel obstruction
62510061|NCT05999279||Patient|Convenient sampling of patients who took at least one medication in the past month
62510062|NCT01315028|EXPERIMENTAL|Psychological Therapy|Cognitive Interpersonal Therapy (CIT) was a psychological therapy which emphasised assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive-behavioural and interpersonal strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley \& Schwannauer, 2006).
62510063|NCT01315028|ACTIVE_COMPARATOR|Treatment As Usual|All participants continued to receive their usual care from their local community mental health team and other psychological therapies were not withheld during the conduct of the trial.
62510064|NCT02418455|EXPERIMENTAL|UX003|UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.
62510065|NCT05436704||EUS-FNB|
62510066|NCT03115606|ACTIVE_COMPARATOR|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
62510067|NCT03115606|ACTIVE_COMPARATOR|Fastrach LMA|Patients intubated with Fastrach LMA
62510068|NCT06563245|EXPERIMENTAL|Low risk group|Stage IA , no bulky Stage IIA, no bulky
62510069|NCT06563245|EXPERIMENTAL|Intermediate risk group|Stage IA, with bulky Stage IIA, with bulky Stage IB, with/without bulky Stage IAE, with/without bulky Stage IIAE, with/without bulky Stage IIIA, with/without bulky
62510070|NCT06563245|EXPERIMENTAL|High risk group|Stage IIB Stage IIIB Stage IV
62351516|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' \> 14 or septal E/e' ratio \> 15, peak tricuspid regurgitant jet velocity \>2.8 m/sec and septal e' velocity \< 7 cm/s. A sample size of about 250 patients is required.
62351517|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
62510071|NCT03793920|EXPERIMENTAL|PEA patients without alcohol disorder|A group of 36 PEA patient without alcohol-dependence (AD), performing 6 behavioral tasks.
62510072|NCT03793920|SHAM_COMPARATOR|PEA patients with alcohol disorder|A group of 36 PEA participants, currently alcohol-dependent, performing 6 behavioral tasks.
62145444|NCT01833598|ACTIVE_COMPARATOR|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
62510073|NCT03793920|SHAM_COMPARATOR|Healthy controls with AD father|A group of 36 non-alcohol-dependent controls whose father was alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
62510074|NCT03793920|SHAM_COMPARATOR|Healthy controls without AD father|A group of 36 non-alcohol-dependent controls whose father was not alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
62510075|NCT02870036|EXPERIMENTAL|Pharmacokinetic data investigation of Simmitecan|To further determine the pharmacokinetic (PK) characteristics of Simmitecan monotherapy in patients with advanced solid tumors
62510076|NCT02870036|EXPERIMENTAL|Dose escalation study of Simmitecan combined therapy|To determine the maximum tolerated dose (MTD) of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced solid tumor
62510077|NCT02870036|EXPERIMENTAL|Dose extension study of Simmitecan monotherapy|To preliminarily evaluate the anti-tumor activity of Simmitecan monotherapy in patients with advanced solid tumors, and to determine the recommended phase II dose (RP2D)
62510078|NCT02870036|EXPERIMENTAL|Dose extension study of Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced/metastatic colorectal cancer (CRC), and to determine RP2D
62510079|NCT02870036|EXPERIMENTAL|Dose escalation&extension Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with gastrointestinal tumors, and to determine RP2D and MTD
62510080|NCT02870036|EXPERIMENTAL|Dose extension study of Simmitecan combined therapy|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with specific tumors
62510081|NCT02775539|ACTIVE_COMPARATOR|Mirabegron|Oral mirabegron, starting with 50 mg once a day and titrated till a maximum of 200 mg once a day.
62510082|NCT02775539|PLACEBO_COMPARATOR|Placebo|Oral placebo, similarly titrated to ensure blindness.
62510083|NCT05387148|EXPERIMENTAL|Cannabidiol (CBD)|For a total of three days, so that both study participants and staff are blind to treatment condition
62510084|NCT05387148|PLACEBO_COMPARATOR|Placebo|For a total of three days, so that both study participants and staff are blind to treatment condition
62510085|NCT03762746|ACTIVE_COMPARATOR|Active|Intervention with transcranial magnetic stimulation (TMS) low frequency 1 Hz , 1000-pulse train, 20 minutes, 90% motor threshold in left temporo-parietal cortex for 10 consecutive days for 20 schizophrenia patients with auditory hallucination
62510086|NCT03762746|SHAM_COMPARATOR|Control|Control group is received treatment as usual
62510087|NCT03216109|EXPERIMENTAL|Weekly telephone symptom assessment|"Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Symptom assessments will be documented into an encrypted, HIPAA compliant digital platform which provides longitudinal symptom data management and also provides symptom assessment tools for the clinical team in their intervention strategies.~In addition, patients will complete symptom and quality of life surveys at 0, 3, 6 and 9 months."
62510088|NCT03216109|NO_INTERVENTION|Control Arm|Patients randomized to usual clinical care will receive standard of care for thoracic malignancies as provided by the VA Palo Alto Health Care System. Patients will complete outcome surveys at 0, 3, 6, and 9 months.
62510089|NCT02927834|ACTIVE_COMPARATOR|Antibiotic only|1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.
62510090|NCT02927834|ACTIVE_COMPARATOR|Augmentin with 6 day steroid|Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)
62510091|NCT02927834|ACTIVE_COMPARATOR|Augmentin with 21 day steroid|Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )
61969912|NCT05511051|ACTIVE_COMPARATOR|Fruquintinib|Fruquintinib: 5 mg orally once daily for 21 days on followed by 7 days off (q4w);
61969913|NCT00928681|OTHER|0.03 mg/kg or placebo iv|
62510092|NCT05365282||Group A|Access pathway a. radialis (right or left) and neurophysiological measurements of the same hand (ipsilateral intervention group).
61969914|NCT00928681|OTHER|0.1 mg/kg or placebo iv|
61969915|NCT00928681|OTHER|0.3 mg/kg or placebo iv|
62145445|NCT01833598|ACTIVE_COMPARATOR|PNT alone|percutaneous needle tenotomy alone
62145446|NCT05491291|OTHER|Patients with chronic wound of the lower limbs|Passing of the scale when the patient will come at the hospital for his routine health care visit in M@diCICAT center
62707433|NCT05975424||Subjects treated with AST-OPC1 in the initial dosing study AST-OPC1-01|Subjects treated with AST-OPC1 in the initial dosing study AST-OPC1-01 will be followed for 15-year long-term safety monitoring
61969916|NCT00928681|EXPERIMENTAL|1.0 mg/kg or placebo iv|
61969917|NCT00928681|OTHER|3.0 mg/kg or placebo sc|
61969918|NCT00928681|OTHER|10 mg/kg or placebo iv|
61969919|NCT00928681|OTHER|0.3 mg/kg or placebo sc|
61969920|NCT00928681|OTHER|0.1 mg/kg or placebo iv (multiple dose)|
61969921|NCT00928681|OTHER|0.3 mg/kg or placebo iv (multiple dose)|
61969922|NCT00928681|OTHER|3.0 mg/kg or placebo iv|
61969923|NCT00928681|OTHER|0.1 mg/kg or placebo sc|
61969924|NCT00928681|OTHER|0.3 mg/kg or placebo sc (multiple dose)|
62145447|NCT03998059||30 immune thrombocytopenia(ITP) patients|A total of 30 cases. The investigators plan to take 20ml of peripheral blood (PB) of these 30 ITP patients at 6 time points, including 1 day before surgery, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery
62145448|NCT03998059||20 normal controls|A total of 20 cases.18 age- and gender- matched healthy donor will also be enrolled as controls and taken 20ml of peripheral blood.
62145449|NCT03998059||Spleens of the 30 cases patients(ITP)|These 30 ITP patients agree to have splenectomy.The investigators will take a small amount of spleen tissue during surgery.
62145450|NCT03998059||Spleens of the 10 cases patients(normal controls)|The investigators also plan to take splenic tissue from 10 patients who have splenectomy due to hereditary spherocytosis or trauma.
61969925|NCT03551860|EXPERIMENTAL|TQL Group|Administration of a single shot transmuscular quadratus lumborum (TQL) peripheral nerve block following spinal neuraxial blockade.
61969926|NCT03551860|ACTIVE_COMPARATOR|FIB Group|Administration of a single shot fascia iliac (FIB) peripheral nerve block following spinal neuraxial blockade.
61969927|NCT06023823|ACTIVE_COMPARATOR|Toe spread out treatment|
61969928|NCT06023823|ACTIVE_COMPARATOR|Dry needling|
61969929|NCT02950025|ACTIVE_COMPARATOR|Online non-adaptive MRI-guided SBRT|"* All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~* Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~* All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~* Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
61969930|NCT02950025|EXPERIMENTAL|Arm B: Online-Adaptive MRI-guided SBRT|"* All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~* Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~* All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~* When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day~* Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
61969931|NCT01261689|ACTIVE_COMPARATOR|Epidural analgesia|Women will be allocated to the EA group. In the EA group, women are given an EA as soon as they are in labour.
61969932|NCT01261689|OTHER|Care as-usual pain treatment|Women will be allocated to the care-as-usual group. In this care-as-usual(restrictive) group, women receive pain relief only on their explicit request. If necessary epidural analgesia.
61969933|NCT00719121|NO_INTERVENTION|A|No Treatment
61969934|NCT00719121|ACTIVE_COMPARATOR|B|R115866 (0.35% gel)
62510093|NCT05365282||Group B|Access pathway a.radialis (right or left) and neurophysiological measurements of opposite hand (contralateral intervention group).
62510094|NCT06610760|EXPERIMENTAL|The ursodeoxycholic acid group|Patients in the ursodeoxycholic acid group will receive oral ursodeoxycholic acid at a dosage of 250 mg three times daily for 6 months.
61969935|NCT00719121|ACTIVE_COMPARATOR|C|R115866 Vehicle gel
61969936|NCT00719121|ACTIVE_COMPARATOR|D|Differin™, 0.1% adapalene gel
61969937|NCT02743871|EXPERIMENTAL|Cohort 1|10 mg of PF-06817024 or placebo
61969938|NCT02743871|EXPERIMENTAL|Cohort 2|30 mg of PF-06817024 or placebo
61969939|NCT02743871|EXPERIMENTAL|Cohort 3|100 mg of PF-06817024 or placebo
61969940|NCT02743871|EXPERIMENTAL|Cohort 4|300 mg of PF-06817024 or placebo
62145451|NCT03100188|EXPERIMENTAL|modified PD|Patients with residual renal kt/v were placed in intervention group
62145452|NCT05376397|EXPERIMENTAL|iTHRIVE 365|
62510095|NCT06610760|PLACEBO_COMPARATOR|The placebo group|Patients in the placebo group will receive oral placebo at a dosage of 250 mg three times daily for 6 months.
62707434|NCT05903703|EXPERIMENTAL|Canagliflozin and Gemcitabine|
62707435|NCT05903703|ACTIVE_COMPARATOR|standard cisplatin|
61969941|NCT02743871|EXPERIMENTAL|Cohort 5|1000 mg of PF-06817024 or placebo
61969942|NCT02743871|EXPERIMENTAL|Cohort 6|2000 mg of PF-06817024 or placebo
61969943|NCT02743871|EXPERIMENTAL|Cohort 7|30 mg subcutaneous dose of PF-06817024 or placebo
61969944|NCT02743871|EXPERIMENTAL|Cohort 8|300 mg of PF-06817024 or placebo
61969945|NCT02743871|EXPERIMENTAL|Cohort 9|IV dose to be determined of PF-06817024 or placebo
61969946|NCT02743871|EXPERIMENTAL|Cohort 10|PF-06817024 or placebo
62510096|NCT04489303|EXPERIMENTAL|Virtual Patient Behavioral Response Training|Caring Response mobile app with a behavioral training.
62510097|NCT04489303|ACTIVE_COMPARATOR|Educational Training|Traditional educational program.
62510098|NCT04567758|EXPERIMENTAL|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
62707436|NCT02094391|EXPERIMENTAL|Ipilimumab|
62707437|NCT02094391|NO_INTERVENTION|No Ipilimumab|
62707438|NCT01418521|ACTIVE_COMPARATOR|Ringer-albumin|Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
62510099|NCT04567758|ACTIVE_COMPARATOR|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
62510100|NCT03462836|EXPERIMENTAL|IV ketamine/lidocaine/IV PCA (MA) group|In addition to basic anesthetic methods, multimodal analgesia with IV ketamine, lidocaine and IV PCA apply
62510101|NCT03462836|ACTIVE_COMPARATOR|IV PCA only (CA) group|In addition to basic anesthetic methods, only IC PCA apply for pain control
62510102|NCT05631535|EXPERIMENTAL|Intervention with a very low-energy diet|
62510103|NCT05631535|ACTIVE_COMPARATOR|Control group|
62510104|NCT02262195||Carboxyhemoglobin|Induced carboxyhemoglobin levels up tp 15 percent.
62510105|NCT02262195||Methemoglobin|Induced methemoglobin levels up to 15 percent.
61969947|NCT02743871|EXPERIMENTAL|Cohort 11|PF-06817024 or placebo
61969948|NCT02743871|EXPERIMENTAL|Cohort 12|PF-06817024 or placebo
61969949|NCT02743871|EXPERIMENTAL|Cohort 13|PF-06817024 or placebo
61969950|NCT05748756|EXPERIMENTAL|Test group|
61969951|NCT05748756|ACTIVE_COMPARATOR|Control group|
61969952|NCT05289180||Participants undergoing Heart Catherization|Participants undergoing Heart Catherization and will complete a research survey focusing on the comfort and anxiety during procedure. Participants will be followed for 18 months after enrollment. For each clinically indicated Brachial RV-EMB Biopsy during the 18-month follow up period, data from biopsy and pre and post-procedure echocardiograms will be reviewed and recorded for research purposes. A post-procedure questionnaire and post-discharge phone call will also take place after each procedure.
61969953|NCT02615366|ACTIVE_COMPARATOR|Tranexamic Acid|Tranexamic acid will be provided as an intravenous infusion (1g in 100mL 0.9% NaCl solution \[1% TXA\] at 5 ml/min) 20 minutes pre-operatively, followed by an additional intravenous dose of the same dosing parameters postoperatively. Oral tablet doses containing 1 g of TXA (2x 500mg tablets) per dose will be administered to the patient to be taken orally by the patient according to a standard regimen; the first tablet dose will be taken on the same day as the surgery, in the evening. The patient will then take one tablet dose three times a day for a total of five days following the surgery (one dose in the morning, one dose mid-day, and one dose in the afternoon) for a 6 day total regimen.
61969954|NCT02615366|PLACEBO_COMPARATOR|Placebo Control|Placebo control will be either 100 ml of 0.9% NaCl solution or tablets of similar appearance containing no medicinal ingredients; placebo will be administered according to the same regimen as the intervention group.
61969955|NCT05792891||Covid-19 patients|
62145453|NCT04252638|EXPERIMENTAL|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment therapy is a well-established treatment for other disorders including depression, anxiety and chronic pain, but has not been thoroughly investigated for insomnia. The therapy consists of mindfulness, acceptance, identification of personal life values and committed action. In addition, patients in this group will receive sleep restriction, a behavioral therapy component of cognitive behavioral therapy for insomnia. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
62145454|NCT04252638|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy including Sleep Restriction|The control intervention is Cognitive Behavioral Therapy for insomnia (CBT-I). This is the first line treatment for adults with chronic insomnia. The therapy consists of education, relaxation, and behavioral therapy, including sleep restriction. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
62351518|NCT03049995||SEO: SE in Outdoor in Extreme conditions|SE can also be performed outdoors, with pocket size or portable instruments, in a setting of ecological stress entirely different from standard indoor testing. The diagnostic target is the early subclinical identification of pulmonary edema. Subjects involved in extreme sporting events (competitive triathlon, marathon, apnea diving etc) or ordinary exercise in extreme environments (trekking at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70).
62510106|NCT05528861|EXPERIMENTAL|Lirentelimab (AK002)|Subjects in this arm will receive lirentelimab (AK002) administered subcutaneously.
62510107|NCT05528861|PLACEBO_COMPARATOR|Placebo|Placebo
62510108|NCT01981317|EXPERIMENTAL|Stepped Care CBT|"All participants in this arm receive Step One which includes 3-in-office sessions lasting 1 hour each over 6 weeks and 6 weekly phone calls lasting 15 minutes or less. The in-office sessions are devoted to psychoeducation, cognitive therapy, and hierarchy development. These sessions will include all procedures of the standard therapist-delivered CBT but will be parent-led, therapist guided; thus, the parent is delivering evidence-based strategies with clinician guidance.~Children are then stepped up to Step Two of SC-CBT if it is determined that more therapy is needed following the post assessment. Step Two is a continuation of therapy and will include 9 additional in-office weekly session lasting 1 hour each over 9 weeks. These sessions will be therapist-led and are devoted to exposure and response prevention."
62510109|NCT01981317|ACTIVE_COMPARATOR|Standard CBT|All patients in this arm will receive 12 sessions of therapy over 12 weeks using the evidence-based cognitive behavioral therapy protocol in POTS (2004). Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-12 involve exposure and response prevention exercises specific to each youth.
61969956|NCT05792891||No Covid-19 patients|
61969957|NCT02840370|EXPERIMENTAL|transcranial direct current stimulation|tDCS
61969958|NCT02840370|SHAM_COMPARATOR|Sham tDCS|S-tDCS
61969959|NCT05050604|EXPERIMENTAL|Choline Alfoscerate|
61969960|NCT05050604|PLACEBO_COMPARATOR|Placebo of Choline Alfoscerate|
61969961|NCT04085809|EXPERIMENTAL|Left Leg: AmLactin® Rapid Relief / Right Leg: No Treatment|AmLactin® Rapid Relief, BID application for 14 days on left leg and no treatment on right leg
61969962|NCT04085809|EXPERIMENTAL|Left Leg: No Treatment / Right Leg: AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days on right leg and no treatment on left leg
61969963|NCT00644995|ACTIVE_COMPARATOR|Usual Care Control|Participants will receive usual care which includes advice to stop smoking and referral to standard care treatment available through participants' health insurance and health plan.
61969964|NCT00644995|EXPERIMENTAL|Step Up Intervention|Participants will receive the Step Up Wellness Program. The intervention is detailed below.
61969965|NCT02652520|EXPERIMENTAL|Kidney transplantation|HEMO2Life® use in organ preservation solution. Grafts removed and transplanted locally within the 6 kidney transplant centers participating in the study will be preserved with Hemo2life.
62145455|NCT06074744|ACTIVE_COMPARATOR|Intervention group: SSNB + IPACK (group 1)|"Subsartorial Nerve Block:~* 15ml bupivacaine 0.5% + clonidine 1mcg/kg for prolongation of the block effect~* anatomic landmarks: proximal adductor channel, intersection of the medial borders of the sartorius muscle and the adductor longus, guided by ultrasound control~* no patch to puncture site to not jeopardise the surgeon's blinding~* IPACK: 15ml bupivacaine 0.5% after completion of the femoral preparation"
62145456|NCT06074744|ACTIVE_COMPARATOR|Control group: FNB + IPACK (group 2)|"Femoral Nerve Block:~* 15ml bupivacaine 0.5% + clonidine 1mcg/kg for prolongation of the block effect~* anatomic landmarks: lateral to the femoral artery,level of the femoral crease (proximal to the vascular outlet of the deep artery of the thigh), femoral nerve lies on the surface of the iliopsoas muscle and is covered by the fascia iliaca, guided by ultrasound control~* no patch to puncture site to not jeopardise the surgeon's blinding~* IPACK: 15ml bupivacaine 0.5% after completion of the femoral preparation"
62510110|NCT01572519|EXPERIMENTAL|JNJ-40346527|
62510111|NCT05593731|OTHER|dental implants alone|dental implants alone
62510112|NCT05593731|ACTIVE_COMPARATOR|platelet rich fibrin|dental implants with platelet rich fibrin membrane
62510113|NCT05593731|ACTIVE_COMPARATOR|melatonin gel|dental implants with melatonin gel around dental implants
62510114|NCT05852925|OTHER|Human Blood Specimen Collection|Blood will be collected from each participant using two different methods: the Tasso+ device and the traditional venipuncture approach. Both collection procedures are carried out sequentially at the study site. A phlebotomist performs the traditional venipuncture and the participant collects blood using two Tasso+ devices, following provided instructions. The lab results will be analyzed to assess the correlation of biomarkers between blood samples obtained by the participant using the Tasso+ device and those collected via venipuncture.
62510115|NCT03485482|EXPERIMENTAL|Group Ivabradine|six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose
61969966|NCT02075450|NO_INTERVENTION|Arm 1|Practice CPRcard lights not visible, Practice Just in Time Video - not provided to study participants, CPRcard lights not visible during study scenario
61969967|NCT02075450|EXPERIMENTAL|Arm 2|Practice CPRcard light- not visible, Practice CPR Just in Time Video- not provided, CPRcard light visible during study scenario.
61969968|NCT02075450|EXPERIMENTAL|Arm 3|Practice CPRcard light- visible, Practice Just in Time Video- watched by study participant, CPRcard light- not visible during study scenario.
61969969|NCT02075450|EXPERIMENTAL|Arm # 4|Practice CPRcard visible and the study participants watch the Just in Time Video,CPRcard light visible during study scenario
62145457|NCT01911156|OTHER|Discontinue NA treatment|Subjects will not receive NA during the 72 week study period
62145458|NCT01911156|OTHER|NA treatment|Subjects will continue to receive their prescribed NA during the 72 week study period
62145459|NCT05973175||Women with PCOS|"The following inclusion criteria need to be met for the PCOS Study participants:~* Women with a confirmed diagnosis polycystic ovary syndrome with androgen excess on clinical or biochemical grounds~* BMI 20-40kg/m2~* Age range 18-50 years~* Ability to provide informed consent"
62145460|NCT05973175||Women without PCOS (controls)|"The following inclusion criteria need to be met for the control Study participants:~* No clinical features of possible polycystic ovary syndrome (absence of clinical features of androgen excess and ovulatory dysfunction).~* BMI 20-40kg/m2~* Age range 18-50 years~* Ability to provide informed consent"
62510116|NCT03485482|EXPERIMENTAL|Group Bisoprolol|six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg
61969970|NCT02753023||acute coronary syndromes|No intervention related
61969971|NCT02753023||acute decompensated heart failure|No intervention related
61969972|NCT02753023||warfarin intoxication|No intervention related
61969973|NCT02753023||acute pulmonary edema|No intervention related
61969974|NCT02753023||acute aortic dissection|No intervention related
61969975|NCT02753023||chest pain|No intervention related
61969976|NCT02753023||pulmonary embolism|No intervention related
61969977|NCT02753023||syncope|No intervention related
61969978|NCT00004978|EXPERIMENTAL|rIL-2|Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.
62510117|NCT03485482|EXPERIMENTAL|Group combination|six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg
62510118|NCT02241109|OTHER|All patients|Compare patients with high calcification propensity do have faster valve-stenosis progression
62510119|NCT03891329|OTHER|Acticor/Rivacor ICDs/CRT-Ds|Implant of the new Cor Family internal cardioverter defibrillators (ICDs) / Cardiac Resynchronisation Therapy-Defibrillators (CRT-Ds) and Plexa ProMRI S DX lead (if applicable). Device measurements, pre-defined programming and Adverse Event Reporting
62510120|NCT04972331|ACTIVE_COMPARATOR|CONTROL|Arthroscopic Partial menisectomy
61969979|NCT00004978|NO_INTERVENTION|No rIL-2|Control arm uses anti-HIV medication of choice without rIL-2.
61969980|NCT04425174||QL|QL = 30 patients representing the case group receiving QL block.
61969981|NCT04425174||EP|EP = 30 patients representing the control group receiving epidural anesthesia.
61969982|NCT00499876|ACTIVE_COMPARATOR|A|
61969983|NCT00499876|PLACEBO_COMPARATOR|B|
61969984|NCT04959344|EXPERIMENTAL|Kleb4V target dose|Study participants receive 2 target doses of the non-adjuvanted investigational product 2 months apart.
61969985|NCT04959344|EXPERIMENTAL|Kleb4V target dose + AS03|Study participants receive 2 target doses of the adjuvanted investigational product 2 months apart.
61969986|NCT04959344|EXPERIMENTAL|Kleb4V low dose|Study participants receive 2 low doses of the non-adjuvanted investigational product 2 months apart.
62145461|NCT00944359|EXPERIMENTAL|Daily preventive Zn; placebo treatment|7 mg zinc per day for 12 months and placebo supplement during diarrhea episode
62145462|NCT00944359|EXPERIMENTAL|Therapeutic Zn; daily placebo|20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement
62510121|NCT04972331|EXPERIMENTAL|INTERVENTION|Platet- Rich-Plasma
62145463|NCT00944359|EXPERIMENTAL|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode
62145464|NCT00944359|ACTIVE_COMPARATOR|Surveillance control group|Surveillance control group will be randomly assigned to intervention groups every 3 months
62145465|NCT00944359|NO_INTERVENTION|Non-intervention|Standard care provided by health system
62707439|NCT01418521|EXPERIMENTAL|Tetraspan|patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
62707440|NCT06232616|OTHER|Single arm|In this single-arm designed study, participants with idiopathic epiretinal membranes with macular oedema were assigned a vitrectomy with an intravitreal dexamethasone implant.
62707441|NCT04786964|EXPERIMENTAL|Cosibelimab|Participants receive cosibelimab 1200 mg intravenously (IV) PLUS pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by cosibelimab 1200 mg IV PLUS pemetrexed 500 mg/m\^2 IV Q3W until progression.
62707442|NCT04786964|ACTIVE_COMPARATOR|Control|Participants receive pemetrexed 500 mg/m\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pemetrexed 500 mg/m\^2 IV Q3W until progression.
62707443|NCT06015932|EXPERIMENTAL|Group I (CBCSM)|Patients participate in five CBCSM group sessions on study. Patients complete questionnaires throughout the trial and during follow-up at 1, 3, 6, and 12 months.
62145466|NCT04743388||Cohort 1|Approximately 300 volunteers, healthy or with chronic diseases (diabetes mellitus, hypertension, heart disease, CRF, etc.) with no autoimmune disorders.
62145467|NCT04743388||Cohort 2|People with hematological malignancies or solid tumors in various phases of their treatment (under treatment or in remission/ follow-up). This cohort may include patients with smoldering multiple myeloma (n=50), multiple myeloma (n=140), chronic lymphocytic leukemia (with or without hypoglobulinemia) (n=50), lymphoma (n=80), AL amyloidosis (n=30), patients who receive PARP (n=30), CDK4/6 (n=30), or immune checkpoint inhibitors (n=40), and patients under therapy with Androgen Receptor Targeted Agents (n=50).
62707444|NCT06015932|ACTIVE_COMPARATOR|Group II (no CBCSM)|Patients complete questionnaires throughout the trial and during follow-up at 1, 3, 6, and 12 months.
61969987|NCT04959344|EXPERIMENTAL|Kleb4V low dose + AS03|Study participants receive 2 low doses of the adjuvanted investigational product 2 months apart.
62145468|NCT01706666|EXPERIMENTAL|Arm A (bortezomib)|Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
62145469|NCT01706666|EXPERIMENTAL|Arm B (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
62351519|NCT03049995||SETOF: SE in operated Tetralogy of Fallot|Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age \> 10 years, height \> 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
62351520|NCT03049995||DOSPAH: Doppler SE in Pulmonary Arterial Hypertension|Patients at risk, borderline, or early established pulmonary hypertension capable of exercising will be recruited by regional reference centers, a physical stress will be performed and the hemodynamic assessment will include the assessment of pulmonary hemodynamics. The primary positivity criteria are the increase in systolic pulmonary artery pressure (\> 40 mmHg) and the flow-adjusted variation in pulmonary vascular resistances. A sample size of about 250 patients is required to detect a significant stress-induced hemodynamic changes with a 3 -year follow-up.
62510122|NCT03136406|EXPERIMENTAL|NANT Pancreatic Cancer Vaccine|"A combination of agents will be administered to subjects in this study:~cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011."
62510123|NCT05516888|EXPERIMENTAL|Radiofrequency of peripheral branches of the trigeminal nerve|pulsed radiofrequency treatment of the peripheral branches of the trigeminal nerve
62510124|NCT05516888|ACTIVE_COMPARATOR|Radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
62510125|NCT05707455||Aerobic group|long distance runners
62510126|NCT05707455||Anaerobic group|broad jumpers
62510127|NCT01358149|PLACEBO_COMPARATOR|placebo|cocoa-based food 1
62510128|NCT01358149|ACTIVE_COMPARATOR|Treatment 1|cocoa-based food 2
62510129|NCT04923126|EXPERIMENTAL|Phase I: Recurrent and/or progressive low-grade glioma without prior exposure to MEK inhibitors|Participants will receive mirdametinib at one of the dose levels twice daily days 1-28. For the first cycle of treatment, participants will take mirdametinib tablets dissolved in water. After the first cycle of treatment, participants may receive the medicine the same way (dissolved in water) or may receive capsules. Treatment repeats every 28 days for up to 26 cycles of treatment (24 months) in the absence of disease progression or unacceptable toxicity.
62707445|NCT04870866|EXPERIMENTAL|NR treated|Nicotinamide ribonuceloside (NR), sold under the trade name Niagen™
62707446|NCT06014762|EXPERIMENTAL|P-CD19CD20-ALLO1 CAR-T Cells (Arm S)|"P-CD19CD20-ALLO1 following conditioning chemotherapy regimen S.~Rimiducid may be administered."
62707447|NCT06014762|EXPERIMENTAL|P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 750)|"P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 750.~Rimiducid may be administered."
62707448|NCT06014762|EXPERIMENTAL|P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 1000)|"P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 1000.~Rimiducid may be administered."
62707449|NCT01675947|EXPERIMENTAL|Sirolimus|Monthly 20 μL (440 μg) intravitreal injection of sirolimus
62707450|NCT01675947|SHAM_COMPARATOR|Lidocaine|Monthly subconjunctival injection of 2% lidocaine
62707451|NCT03950856|EXPERIMENTAL|V114 Lot 1|Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)
62707452|NCT03950856|EXPERIMENTAL|V114 Lot 2|Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)
62145470|NCT01706666|EXPERIMENTAL|Arm C (bortezomib, lenalidomide)|Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
62510130|NCT04923126|EXPERIMENTAL|Phase 2, Cohort 1: Newly diagnosed and/or previously untreated (except surgery)|Participants will receive the RP2D of mirdametinib. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
62351521|NCT03049995||DITSE: Diagnosis of CAD by imaging SE|"A clear step-up in diagnostic sensitivity (with a modest loss in specificity) and risk stratification capability is obtained with assessment of coronary flow velocity reserve in the left anterior descending coronary artery,left ventricular contractile reserve through changes in left ventricular elastance, and B-lines. Allcomers referred to the SE lab with suspected CAD will be evaluated with standard regional wall motion analysis and also - whenever feasible - with left ventricular coronary flow reserve and left ventricular elastance reserve and - when possible- B-lines (quadruple imaging).A sample size of about 5,000 patients will be required."
62351522|NCT03049995||GENES: Genetic Stress echocardiography|The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
62351523|NCT01154881|EXPERIMENTAL|IDeg 100U/mL 0.4U/kg|
62707453|NCT03950856|EXPERIMENTAL|V114 Lot 3|Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)
62351524|NCT01154881|EXPERIMENTAL|IDeg 100U/mL 0.6U/kg|
62351525|NCT01154881|EXPERIMENTAL|IDeg 100U/mL 0.8U/kg|
62510131|NCT04923126|EXPERIMENTAL|Phase 2, Cohort 2: Recurrent and/or Progressive without prior exposure to MEK inhibitors|Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
62510132|NCT04923126|EXPERIMENTAL|Phase 2, Cohort 3a:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants with previous exposure to mirdametinib may receive a starting dose lower than the RP2D, depending on the dose they tolerated during their previous exposure. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
62510133|NCT04923126|EXPERIMENTAL|Phase 2, Cohort 3b:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
62510134|NCT00975741|EXPERIMENTAL|Monodose device|Mometasone furoate 400 µg DPI capsules administered through a monodose device.
62510135|NCT00975741|ACTIVE_COMPARATOR|Multidose device|Mometasone furoate 400 µg DPI capsules administered through a multidose device
62510136|NCT01310907||sinus node dysfunction|
62510137|NCT01310907||Atrioventricular block|
62510138|NCT01310907||control|
62707454|NCT03950856|ACTIVE_COMPARATOR|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
61969988|NCT04959344|PLACEBO_COMPARATOR|Placebo (Diluent)|Study participants receive 2 doses of the Placebo 2 months apart.
61969989|NCT02526745|EXPERIMENTAL|high doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
62510139|NCT00823199|EXPERIMENTAL|Allopurinal treatment|Allopurinal 300mg once daily by mouth for four weeks
61969990|NCT02526745|EXPERIMENTAL|low doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
61969991|NCT02526745|EXPERIMENTAL|high doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
62145471|NCT02650505|EXPERIMENTAL|LEO 43204|LEO 43204 will be applied topically to the skin under open conditions 10 times
62510140|NCT05380921|EXPERIMENTAL|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
62707455|NCT01395745|EXPERIMENTAL|blisibimod weekly dose|
61969992|NCT02526745|EXPERIMENTAL|middle doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with middle doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
61969993|NCT02526745|EXPERIMENTAL|low doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
61969994|NCT02526745|PLACEBO_COMPARATOR|placebo|placebo in 100 adults aged 50-80 years old on day 0
61969995|NCT03059823|EXPERIMENTAL|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks.
62351526|NCT01154881|EXPERIMENTAL|IDeg 200U/mL 0.6U/kg|
62707456|NCT01395745|PLACEBO_COMPARATOR|Placebo|
62707457|NCT02224339||plaque neovascular and stress echo|After the SE and CEUS examination, patients will be grouped per the result of SE and CEUS as follows: group I: plaque neovascularization and normal wall motion; group II: plaque neovascularization and abnormal wall motion; group III: no plaque neovascularization and abnormal wall motion; group IV: no plaque neovascularization and normal wall motion.
62707458|NCT03158831|OTHER|Placebo-Controlled Graded Drug Challenge|This is a single arm study. All patients will receive a placebo prior to a graded drug challenge. Each patient serves as his/her own control.
62707459|NCT02822664|OTHER|Pedophiles patients|Adults diagnosed with pedophilia
62145472|NCT02650505|PLACEBO_COMPARATOR|LEO 43204 vehicle|LEO 43204 vehicle will be applied topically to the skin under open conditions 10 times
62145473|NCT01147471|ACTIVE_COMPARATOR|Operative rib fixation|"Randomized subjects will be operated upon within 72 hours of ventilation (early fixation) to stabilize the stove-in segment. Where all fractured ribs are accessible and the number of fractured ribs is few, stabilization of all fractured ribs would be the goal. However, where fractured ribs are in areas difficult to access, enough ribs, based on surgeon judgment, would be fixed to stabilize the stove-in segment. Post-operatively, the patients would receive the standard of care, similar to what is outlined for the non-operative arm.~Operative fixation will be accomplished utilizing the MatrixRIB Fixation System (Synthes CMF, West Chester, PA, USA) according to the device's instructions for use. Sites will obtain the product based on their medical center's normal purchasing practices."
62510141|NCT05380921|EXPERIMENTAL|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
62510142|NCT03701711|EXPERIMENTAL|Lenalidomide escalation and expansion|Among the participants who will be receiving lenalidomide, the first 12 participants will be in the dose escalation phase; with the subsequent 8 participants anticipated to receive dose expansion.
62707460|NCT02822664|OTHER|Healthy subjects|Healhy subjects (not diagnosed with pedophilia)
62510143|NCT01749358|EXPERIMENTAL|High Therapy Dose|Sixty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
62510144|NCT01749358|EXPERIMENTAL|Moderate Therapy Dose|Thirty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
62510145|NCT01749358|EXPERIMENTAL|Low Therapy Dose|Fifteen total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
62707461|NCT01359124||Water Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a water-based treadmill.
61969996|NCT03059823|EXPERIMENTAL|Dose Escalation- Q3W|INCMGA00012 treatment once every 3 weeks.
61969997|NCT03059823|EXPERIMENTAL|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks.
61969998|NCT03059823|EXPERIMENTAL|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors.
61969999|NCT02507505|ACTIVE_COMPARATOR|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
61970000|NCT02507505|ACTIVE_COMPARATOR|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
61970001|NCT01240447|OTHER|Best support treatment|
61970002|NCT01240447|EXPERIMENTAL|Racotumomab vaccine|
61970003|NCT01842698|EXPERIMENTAL|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
61970004|NCT05145452|EXPERIMENTAL|Intervention Group|Subjects randomized to n-3 PUFA will receive a total of 4.2 g/d of fish oil.
61970005|NCT05145452|PLACEBO_COMPARATOR|Placebo Group|Subjects randomized to placebo will receive 4.2 g/d sunflower oil.
61970006|NCT05145452|NO_INTERVENTION|Control group|Subjects assigned to the control group will be tested once
61970007|NCT02775721|OTHER|Cohort A|"Head and Neck Cancer patients receiving Radiation Therapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts B and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H\&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
61970008|NCT02775721|OTHER|Cohort B|"Head and Neck Cancer patients receiving Chemotherapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H\&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
62145474|NCT01147471|NO_INTERVENTION|Non-operative arm|"Randomized subjects to receive standard of care therapy for blunt thoracic trauma (as per each participating institution's own protocols):~a. Ventilatory support b.Timing of extubation (removal from ventilator): c.Analgesia: institution should provide adequate analgesia utilizing available resources including oral, parenteral, epidural, local nerve blocks etc., d.Chest physical therapy, e.Postural drainage, f.Incentive spirometry - after extubation."
62145475|NCT03367832||Paediatric surgical patients|All patients \< 16 years, admitted to participating centres during the study period who undergo elective and non-elective surgery
62145476|NCT03281928|EXPERIMENTAL|Low Sodium plus Potassium Citrate|
62145477|NCT03281928|PLACEBO_COMPARATOR|Low Sodium plus placebo|
62510146|NCT01749358|OTHER|Active Monitoring|This is an observation only group.
62510147|NCT04964674|EXPERIMENTAL|Attentional Tests- Miyake and others|All participants will complete a series of behavioral tasks, including cued visual search with positive, negative, and neutral cues, Miyake executive attention tasks, and a visual working memory task. Single Arm.
62510148|NCT02394639|ACTIVE_COMPARATOR|conventional video-EEG monitoring|conventional video-EEG monitoring with cup-electrodes and collodion
62707462|NCT01359124||Land Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a land-based treadmill.
62707463|NCT01359124||Exercise Cycle|These subjects will participate in three monitored exercise sessions per week for 8 weeks using an upright exercise cycle.
62707464|NCT05326737||The study population|The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program and for a predefined list of surgeries.
62145478|NCT03281928|EXPERIMENTAL|High Sodium plus Potassium Citrate|
62145479|NCT03281928|PLACEBO_COMPARATOR|High Sodium plus placebo|
62145480|NCT02548299|EXPERIMENTAL|Cooking Lecture|Participants in this arm will receive cooking education through lecture/PowerPoint presentation led by our executive chef. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
62145481|NCT02548299|EXPERIMENTAL|Cooking Demo|Participants in this arm will receive cooking education through observation of our executive chef who will explain cooking techniques and healthy food preparation practices as he cooks a healthy recipe(s) for participants to sample. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
62145482|NCT02548299|EXPERIMENTAL|Hands-on Cooking|Participants in this arm will receive cooking education through hands on practical experience with our executive chef in a teaching kitchen. Participants will be able to sample what they prepare. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
62145483|NCT05004909|ACTIVE_COMPARATOR|1 Fingertip Unit 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 1 fingertip unit of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
62145484|NCT05004909|EXPERIMENTAL|2 Fingertip Units 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 2 fingertip units of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
62145485|NCT06021275|ACTIVE_COMPARATOR|Microneedling with topical application of regular insulin|
62351527|NCT04213040||Open-Heart Surgery for a six months duration|In a single group of patients including 146 patients undergoing openheart surgery during a period of six months, the collected parameters include; serum levels of procalcitonin, C-reactive protein, and lactate as well as postoperative complications and after this, depending on the development of postoperative complications or not in the intensive care unit patients were divided into two groups. The Group Without Complications, n=112, includes patients without a postoperative complication after open-heart surgery with cardiopulmonary bypass. The Group With Complications, n=34, includes patients with a postoperative complication after open-heart surgery with cardiopulmonary bypass.
61970009|NCT02775721|OTHER|Cohort C|"Head and Neck Cancer patients receiving Chemotherapy and Radiation therapy. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and B.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H\&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
61970010|NCT02104713|EXPERIMENTAL|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose.~Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
61970011|NCT03336853|EXPERIMENTAL|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
61970012|NCT03336853|PLACEBO_COMPARATOR|Control|5 cc of sterile saline water for 20 sec
61970013|NCT06248632||Patients with genetically confirmed XLH diagnosis treated with bursosumab|Blood sampling at D0 and D7 for monocytic cell extraction in vitro
61970014|NCT00635960|EXPERIMENTAL|1|Patients randomly assigned to treatment
61970015|NCT00635960|PLACEBO_COMPARATOR|2|Patients randomly assigned to placebo
61970016|NCT01536847|PLACEBO_COMPARATOR|Control Test Drink|Control drink
61970017|NCT01536847|EXPERIMENTAL|Experimental Test Drink 1|Control drink containing ingredient 1
61970018|NCT01536847|EXPERIMENTAL|Experimental Test Drink 2|Control drink containing ingredient 2
62145486|NCT06021275|ACTIVE_COMPARATOR|Microneedling only|
62145487|NCT04718285|EXPERIMENTAL|Montelukast|3x10 mg oral montelukast first day (morning, noon time and evening) and rest of the 13 days 1 x 10 mg montelukast.
62145488|NCT04718285|EXPERIMENTAL|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast at the first day and rest of the 13 days1 x 10 mg, concurrently.
62145489|NCT04718285|ACTIVE_COMPARATOR|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
62145490|NCT00366470|EXPERIMENTAL|A|Vitamin D in doses of 100,000 IU
62351528|NCT03222440|EXPERIMENTAL|SHR-1210+ Radiotherapy|Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
62707465|NCT01606618||Spina bifida aperta|
61970019|NCT03064360||Biomarker Testing, PROs, PRIs|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (Tnl), symptom and quality of life questionnaires, and patient metrics (activity, sleep, heart rate, heart rate variability).
61970020|NCT01010386|PLACEBO_COMPARATOR|atmospheric (20%) oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
61970021|NCT01010386|ACTIVE_COMPARATOR|physiologic (5%) oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
62145491|NCT00366470|PLACEBO_COMPARATOR|B|
62145492|NCT04254549|EXPERIMENTAL|Intervention Treatment|Subjects diagnosed with gastroparesis will receive Rifaximin
62145493|NCT04254549|PLACEBO_COMPARATOR|Placebo Group|Subjects diagnosed with gastroparesis will receive a placebo
62145494|NCT01582321|EXPERIMENTAL|Part 1 Male|16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
62145495|NCT01582321|EXPERIMENTAL|Part 1 Female|16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
61970022|NCT01813578|EXPERIMENTAL|Intervention|An SSED study is an open-label design where the individual is his or her own control. All patients included received the same exercise intervention.
61970023|NCT05601817|EXPERIMENTAL|Vita (virtual reality-based cognitive restoration intervention)|Participants randomized to Vita will receive a virtual reality head-mount device (e.g., Oculus Quest) to view nature pictures for 10 minutes (1 set of 10 pictures)/day, 2-3 days/week for 8 weeks (a total of 20 sets for 200 minutes, approximately 3.3 hours) based on the provided activity schedule. Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
62145496|NCT01582321|EXPERIMENTAL|Part 2 Male|12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
62145497|NCT01582321|EXPERIMENTAL|Part 2 Female|12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
62145498|NCT03496545|ACTIVE_COMPARATOR|Acetaminophen|Standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
62145499|NCT03496545|EXPERIMENTAL|Bromocriptine and Acetaminophen|Bromocriptine 5mg every 4 hours PO/NG/FT for 48 hours and acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
62145500|NCT04644887|EXPERIMENTAL|Healthy diet CC genotype|The participants will follow the intervention diet during the 12-week intervention period.
62145501|NCT04644887|ACTIVE_COMPARATOR|Control diet CC genotype|The participants will follow the control diet during the 12-week intervention period.
62145502|NCT04644887|EXPERIMENTAL|Healthy diet GG genotype|The participants will follow the intervention diet during the 12-week intervention period.
62145503|NCT04644887|ACTIVE_COMPARATOR|Control diet GG genotype|The participants will follow the control diet during the 12-week intervention period.
62145504|NCT05625230|EXPERIMENTAL|Behavior activation-PLUS T-RAC|Behavioral: Behavior activation/BA plus T-RAC Each session is focused on reviewing the activity log, planning anti-depressant activities for the next week, and finding support for the implementation of the activity. After activity planning, the participants will follow an XboxKinect exergame for 10 minutes, an actfulness exercise and will imagine one planned activity using dynamic imagery. From session 2 restructuring action memories are added.
62145505|NCT05625230|ACTIVE_COMPARATOR|Arm 2 Behavioral activation|"Behavioral: Behavior activation/BA Participants in the behavioral activation arm will undergo a BA procedure. A therapist will administer an 8 sessions behavioral activation intervention based on the manual used in the COBRA trial.~Each session is focused on reviewing the activity log, planning anti-depressant activities for the next week, and finding support for the implementation of the activity."
62145506|NCT05892445|EXPERIMENTAL|Aversive Visual Health Warnings|Study subjects in this arm will be exposed to experimental aversive visual health warnings depicting risks and adverse effects of e-cigarette use. They will answer survey questions about e-cigarette perceptions before and after exposure to health warnings.
62145507|NCT05892445|NO_INTERVENTION|No Warnings|Study subjects in this arm will answer the same survey questions about e-cigarette perceptions as those in the experimental arm, but they will not be shown aversive visual health warnings.
62145508|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
62145509|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
62145510|NCT06343493|EXPERIMENTAL|Group A (Interventional Group)|Hot saline with a temperature of 50°C used for irrigation during endoscopic sinus surgery. Frequency of the drug is according to the operative field and surgeon's need.
62145511|NCT06343493|NO_INTERVENTION|Group B (Control Group)|Saline at room temperature used for irrigation during endoscopic sinus surgery. Frequency according to the operative field and surgeon's need.
62145512|NCT01553266||MDET intervention|
62145513|NCT01553266||Control group|Patients who have not received the MDET intervention.
62145514|NCT01232101|ACTIVE_COMPARATOR|covered self expandable metallic stents|Patients with bile malignant bile duct strictures are randomized to covered or uncovered stent
62145515|NCT01232101|ACTIVE_COMPARATOR|Uncovered self expandable metallic stent|
62351529|NCT01883869|EXPERIMENTAL|ticagrelor|180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
62351530|NCT01883869|PLACEBO_COMPARATOR|placebo|One loading dose and then daily for 7 days or until hospital discharge if sooner
62351531|NCT04176744|EXPERIMENTAL|Magnetic Phrenic Nerve Stimulation|Each participant will be tested with 4 different stimulation setups (coils and stimulator) on 3 different days.
62351532|NCT04199793|ACTIVE_COMPARATOR|Lavare Cycle On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
62351533|NCT04199793|ACTIVE_COMPARATOR|Lavare Cycle Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
62510149|NCT02394639|EXPERIMENTAL|video-EEG monitoring with prototype|video-EEG monitoring of 5 hours with EEG-cap with dry electrodes
62145516|NCT01562964|EXPERIMENTAL|Hypnotherapy|Hypnotherapy will be conducted at the Royal Brompton Hospital by a qualified practician (DF). Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
62145517|NCT01562964|ACTIVE_COMPARATOR|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min. Patients will be encouraged to talk about their physical symptoms and any emotional issues, and to discuss how these might be coped with in a better way.
62145518|NCT00532766|EXPERIMENTAL|2|Jusline Humulin
62145519|NCT00963924|EXPERIMENTAL|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
62145520|NCT00963924|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
62145521|NCT01548703|EXPERIMENTAL|BCI-838 Dosing Arm 1|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
61970024|NCT05601817|EXPERIMENTAL|Com (computerized cognitive training intervention )|Participants randomized to Com will receive a tablet computer (e.g., iPad) to complete BrainHQ training for 1 hour (6 exercises)/day, 2-3 days/week for 8 weeks (total of 20 hours) based on the provided activity schedule. Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
61970025|NCT05601817|EXPERIMENTAL|Vita+Com (Both Vita and Com intervention)|Participants randomized to Vita+Com will receive both Vita and Com simultaneously. They will spend 10 minutes on Vita and then 1 hour on Com per day, 2-3 days/week for 8 weeks (a total of 23.3 hours). Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
61970026|NCT05601817|NO_INTERVENTION|Usual care|Participants randomized to this control condition will continue to receive their usual care, but no interventions from the study team. We will monitor changes in their activities that may affect changes in cognitive function (e.g., starting book clubs) by weekly check-in calls during the 8 weeks of intervention phase.
62145522|NCT01548703|EXPERIMENTAL|BCI-838 Dosing Arm 2|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
62145523|NCT01548703|EXPERIMENTAL|BCI-838 Dosing Arm 3|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
62145524|NCT01154504|OTHER|clinical treatment|"Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.~Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3)."
62145525|NCT01154504|EXPERIMENTAL|ultrafiltration|"ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).~Diuretic will be withdrawn during ultrafiltration."
61970027|NCT05673278||Children and young people diagnosed with inflammatory bowel disease aged 2-19 years|Diagnosis according to the modified Porto criteria All participants will undergo single ultrasound scan which will be evaluated with medical notes and results from routine care. No new samples will be taken outside of normal care.
62145526|NCT01154504|EXPERIMENTAL|isovolumetric hemofiltration|Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).
62145527|NCT00622700|PLACEBO_COMPARATOR|Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg|"Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally."
62145528|NCT00622700|EXPERIMENTAL|Teriflunomide 7 mg/7 mg|"Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally."
62145529|NCT00622700|EXPERIMENTAL|Teriflunomide 14 mg/14 mg|"Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally."
62145530|NCT05548049|EXPERIMENTAL|Piezosurgery Group|In the experimental group, a piezosurgical device was used to harvest the bone block from the ramus area.
62145531|NCT05548049|ACTIVE_COMPARATOR|Conventional Group|In the experimental group, a conventional burr was used to harvest the bone block from the ramus area.
62539400|NCT06582056|OTHER|Healthy Participant or Participant with Gingivitis with no Type 2 Diabetes Mellitus|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
62145532|NCT04388137||infants aged 0-3|No intervention.
62145533|NCT04388137||children aged 4-18|No intervention.
62351534|NCT05530278|EXPERIMENTAL|ABBV-576 with Galicaftor + Navocaftor|Participants will receive ABBV-576 for 14 consecutive days, with navocaftor + galicaftor for the latter 7 consecutive days.
62351535|NCT05530278|EXPERIMENTAL|Navocaftor + Galicaftor with ABBV 576|Participants will receive Navocaftor + galicaftor for 14 consecutive days, with ABBV 576 for the latter 7 consecutive days.
62351536|NCT05530278|EXPERIMENTAL|Optional: Navocaftor with ABBV 576|Participants will receive Navocaftor for 14 consecutive days with ABBV 576 for the latter 7 consecutive days.
62707466|NCT01606618||Acquired traumatic spinal cord injury|
62707467|NCT04765098|ACTIVE_COMPARATOR|Etoposide|
62707468|NCT04765098|EXPERIMENTAL|Tamoxifen|
62145534|NCT03585400||Observational Study|Observational Study: Not Applicable for Observational Studies
62145535|NCT01827761||Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
62510150|NCT00814606|EXPERIMENTAL|Single Group|8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing \< 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).
62510151|NCT04027881|EXPERIMENTAL|STAR - immediate|Receive 15-week STAR intervention immediately after pretest.
62510152|NCT04027881|NO_INTERVENTION|STAR - waitlist control|No intervention for the 15 weeks after pretest.
62510153|NCT03085225|EXPERIMENTAL|Combination of trabectedin with durvalumab|"Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level.~Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks."
62510154|NCT01162278|OTHER|single fraction|Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 35Gy in one fraction. Subsequent cohorts of patients will receive an additional 5Gy per treatment to a maximum planned dose of 50Gy in one fraction.
62510155|NCT05550376||HHT1|Mutations in the ENG (endoglin) gene
62510156|NCT05550376||HHT2|Mutations in the ALK-1 (activin receptor-like kinase) gene
62510157|NCT03836482|EXPERIMENTAL|Selective Cytopheretic Device|
62510158|NCT05532488|EXPERIMENTAL|Inulin 20 mg|Inulin 20 mg administrated orally q24h
62510159|NCT05532488|PLACEBO_COMPARATOR|Placebo|Matching placebo q24h
62510160|NCT06616428|EXPERIMENTAL|Aerobic Exercise|
62510161|NCT06616428|EXPERIMENTAL|Resistance Exercise|
62510162|NCT06616428|EXPERIMENTAL|Combined Exercise|
62510163|NCT06616428|NO_INTERVENTION|Control|
62510164|NCT05524311|EXPERIMENTAL|Baricitinib|
62510165|NCT04334928|EXPERIMENTAL|Emtricitabine/Tenofovir|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~1. Strength: 200 mg/245 mg tablets~2. Dose: one tablet once a day (both at dinner)"
62707469|NCT02164409||Patient|Subjects for this study will be either H. pylori positive with an active infection, cleared of an H. pylori infection or be both H. pylori antibody positive and have a malignancy of the gastrointestinal tract, specifically gastric adenocarcinoma.
62145536|NCT04256044||Observational|Observational
62510166|NCT04334928|EXPERIMENTAL|Hydroxychloroquine|"Hydroxychloroquine 200 mg + Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg~1. Strength: 200 mg tablets~2. Dose: one tablet once a day (both at dinner)"
62510167|NCT04334928|EXPERIMENTAL|Emtricitabine/Tenofovir+Hydroxychloroquine|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Hydroxychloroquine 200 mg~1. Strength FTC/TDF:200 mg/245 mg tablets~2. Strength HC: 200 mg tablets~3. Dose: one tablet FTC/TDF plus one tablet HC once a day (at dinner)"
62510168|NCT04334928|PLACEBO_COMPARATOR|Placebo|"Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~1. Placebo tablets with similar appearance to study drugs.~2. Dose: one tablet once a day (both at dinner)"
62510169|NCT03670134|EXPERIMENTAL|Volumetric laser Endomicroscopy (VLE)|Volumetric laser Endomicroscopy (VLE) is a second-generation optical coherence tomography platform that can image the human esophagus in cross-section at microscopic resolution this will performed by using the Nvision VLE Imaging System.
62510170|NCT02270749|ACTIVE_COMPARATOR|hydroxocobalamin injection|25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
62510171|NCT02270749|ACTIVE_COMPARATOR|FitForMe vitamin B12 tablets|25 patients receive a daily dose vitamine B12 tablets
62145537|NCT01289600|ACTIVE_COMPARATOR|Pressure support ventilation, ARDSnet|"Mechanical ventilator is set to pressure support ventilation (6 ml/kg) for 30 min with positive end expiratory pressure (PEEP) set according to the higher arm of the ARDS network consensus."
62510172|NCT05925244|EXPERIMENTAL|Control|The control condition did 30 minutes of walking exercise with their own body mass.
62510173|NCT05925244|EXPERIMENTAL|+12% Body Mass|The +12% body mass condition did 30 minutes of walking exercise wearing a weighted vest with +12% of their body mass applied.
62707470|NCT02164409||Control|A small subset of patients without H. pylori infection will be enrolled as well (n=30) to serve as a control group.
62707471|NCT01405430|EXPERIMENTAL|Bevacizumab + blood samples|
62707472|NCT04924348|EXPERIMENTAL|WALANT procedure|Local anesthesia of the WALANT type
62510174|NCT05925244|EXPERIMENTAL|-12% Body Mass|The -12% body mass condition did 30 minutes of walking exercise using a lower body positive pressure treadmill with -12% of their body mass applied.
62510175|NCT01594359|ACTIVE_COMPARATOR|High iron bean|High-iron bean
62510176|NCT01594359|PLACEBO_COMPARATOR|Low iron bean|Low-iron bean
61970028|NCT01380873|EXPERIMENTAL|Group1|
62510177|NCT02754024||Total shoulder arthroplasty (TSA)|Replacement of humeral head and glenoid
62510178|NCT02754024||Hemi shoulder arthroplasty (HSA)|Replacement of humeral head only
62510179|NCT00675298||1|Men with chronic prostatitis/chronic pelvic pain syndrome
62510180|NCT00675298||2|Women with painful bladder syndrome/interstitial cystitis
62510181|NCT00675298||3|Children with overactive bladder
62510182|NCT00675298||4|Bulgarian cohort with chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis and children with overactive bladder
62510183|NCT00675298||5|Asymptomatic healthy controls
62707473|NCT04924348|ACTIVE_COMPARATOR|Axial ALR|Axillary loco-regional anesthesia
62707474|NCT04924348|ACTIVE_COMPARATOR|Truncal ALR|Truncal loco-regional anesthesia
62510184|NCT04546048|EXPERIMENTAL|Exercise group (EG)|The exercise group (EG) were received an 8-week resistance training program in addition to standard post-transplant physiotherapy follow-up.
61970029|NCT01380873|EXPERIMENTAL|Group2|
62510185|NCT04546048|NO_INTERVENTION|Control Group (CG)|"The control group (CG) were received only standard physiotherapy program.~The usual post-transplant care consisting of preoperative patient education, respiratory physiotherapy program, active/active assistive exercises of cervical, upper and lower extremities, and early mobilization.~Patients were instructed about the postoperative physiotherapy process including all details within the preoperative education. Respiratory physiotherapy consisted of positioning, lung expansion exercises and bronchial hygiene techniques.~They were allowed to pursue their normal daily activities and mobilized as early as possible when clinically stable."
62510186|NCT01712815|EXPERIMENTAL|Diagnostic (fluorine F 18-clevudine PET/CT)|Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.
62510187|NCT00240617|ACTIVE_COMPARATOR|arm 1|Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA
62510188|NCT00240617|PLACEBO_COMPARATOR|arm 2|placebo to match
62510189|NCT04652544|EXPERIMENTAL|"Low dose"|One vial with 600 µg cholecalciferol (corresponding to a total of 24'000 IU vitamin D) and one vial with placebo every month.
62510190|NCT04652544|EXPERIMENTAL|"High dose"|Two vials with 600 µg cholecalciferol each (corresponding to a total of 48'000 IU vitamin D) every month.
62510191|NCT04652544|PLACEBO_COMPARATOR|Placebo|Two vials with a placebo every month.
61970030|NCT01380873|EXPERIMENTAL|Group3|
61970031|NCT04380168|ACTIVE_COMPARATOR|Modified pec 11 trunk block using ketamine additive|Ultasound guided modified pec 11 trunk block using ketamie hydrochoride 1mg/kg in 2ml volume added to 30ml bupivacaine 0.25% for trunk analgesia
62145538|NCT01289600|ACTIVE_COMPARATOR|Pressure control ventilation, ARDSnet|"Mechanical ventilator is set to pressure control ventilation (6 ml/kg) for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
62351537|NCT05530278|EXPERIMENTAL|Optional: Galicaftor with ABBV 576|Participants will receive Galicaftor for 14 consecutive days, with ABBV 576 for the latter 7 consecutive days.
62351538|NCT05530278|EXPERIMENTAL|Optional: Midazolam with ABBV-576 + Navocaftor|Participants will receive Midazolam alone and in combination with multiple doses of ABBV-576 + navocaftor.
62351539|NCT00500838|EXPERIMENTAL|1|Transthoracic impedance device implanted.
62351540|NCT01128335|ACTIVE_COMPARATOR|Arm 1|MMF(1000mg bid) + tacrolimus + standard of care medications
62351541|NCT01128335|EXPERIMENTAL|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
62351542|NCT01128335|EXPERIMENTAL|Arm 3|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
62351543|NCT01128335|EXPERIMENTAL|Arm 4|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
62351544|NCT00764946|EXPERIMENTAL|1|raltegravir
62351545|NCT02789449||precapillary|patients with PH and PAWP\<12mmHg
62351546|NCT02789449||postcapillary|patients with PH and PAWP\>18mmHg
62351547|NCT05419271|EXPERIMENTAL|experimental convection|session of dialysis with 9L internal convection
62351548|NCT05419271|NO_INTERVENTION|free internal convection|session of dialysis with free internal convection
62351549|NCT04345302|EXPERIMENTAL|Brief motivational treatment|"Participants in the intervention group will receive the Brief Motivational Treatment, which is a primary care-adaptation of the Motivational Enhancement Therapy as manualized in the Project MATCH \[19\]. This treatment consists of four 45-minute sessions, provided by a psychologist at weeks one, two, six, and twelve. The first three sessions, occurring during the first six weeks, are more active regarding the behavioural change, while the last session functions as closure and review of the process. If a participant asks for more support, they will be able to attend up to two extra sessions before the last one.~The main adaptations are:~* The translation into Chilean Spanish.~* Update of Motivational Interview concepts.~* Companion training material that includes a demonstrative video and practical exercises.~* An adapted personalized feedback procedure.~* Information on additional resources available in the primary care centre and the community."
62351550|NCT04345302|ACTIVE_COMPARATOR|Enhanced usual care|"All participants will receive an educational brochure on alcohol use disorder, with self-help materials and guides on how to get additional support.~The physicians within the PC centre will also receive information on how to diagnose alcohol use disorders, prescription guides for the medications that are available for treating these disorders in the PC centre (mainly Disulfiram and any other if available), and directions on when and where to refer clients for treatment."
62351551|NCT02473835|EXPERIMENTAL|Calorie Restriction|Participants reduced calorie intake by 50 % for a period of 3 consecutive days - the target calorie intake for each participant will be determined by a period of energy balance (diet and activity) monitoring.
62351552|NCT04403854||ME/CFS patients|Patients diagnosed according to Canada Criteria 2003
62351553|NCT04403854||Healthy Controls|Age and sex matched healthy controls
62351554|NCT01294982|EXPERIMENTAL|1.6 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
62351555|NCT01294982|EXPERIMENTAL|3.2 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
62707475|NCT04882943||patients with unexplained or refractory chronic cough|Patients with cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
62351556|NCT01294982|PLACEBO_COMPARATOR|Placebo|Matching Placebo Capsules
61970032|NCT04380168|ACTIVE_COMPARATOR|Modified pec 11trunk block using dexmedetomidine additive|Ultasound guided modified pec 11 trunk block using dexmedetomidine 1ug/kg in 2ml volume added to 30ml bupivacaine 0.25%
61970033|NCT04380168|ACTIVE_COMPARATOR|Modified pec 11trunk block without additive|Ultasound guided modified pec 11 trunk block using bupivacaine 0.25% added to 2ml saline
61970034|NCT06331416|EXPERIMENTAL|Telemonitoring|
61970035|NCT06331416|NO_INTERVENTION|Standard of care|
61970036|NCT00892853|OTHER|Bone Density Scanning|To acquire high resolution images of the bones and aid in determining bone density.
61970037|NCT04671407|ACTIVE_COMPARATOR|CONTROL|40ml of hypersal saline (3% NaCl) will be administered to bladder the after the surgery
62707476|NCT00846157|NO_INTERVENTION|control|Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.
62707477|NCT00846157|ACTIVE_COMPARATOR|Active|R-CHOP plus Natural Killer Cell therapy
62145539|NCT01289600|ACTIVE_COMPARATOR|Neurally adjusted ventilatory assist, ARDSnet|"Mechanical ventilator is set to NAVA for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
62145540|NCT01289600|ACTIVE_COMPARATOR|Neurally adjusted ventilatory assist, titrated|Mechanical ventilator is set to NAVA for 30 min with PEEP titrated using the diaphragm EMG signal.
62351557|NCT01792245|ACTIVE_COMPARATOR|NB-UVB|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
62351558|NCT01792245|ACTIVE_COMPARATOR|Topical PUVA|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
62351559|NCT03385499|OTHER|negative control group|blood additional samples on negative control group
62351560|NCT03385499|OTHER|positive control group|blood additional samples on positive control group
62351561|NCT03385499|OTHER|seroconversion group|blood additional samples on seroconversion group
62351562|NCT04209530|EXPERIMENTAL|Buttock & Posterolateral Thigh|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
62351563|NCT02294006|EXPERIMENTAL|everolimus+octreotide LAR+metformin|everolimus+octreotide LAR+metformin
62351564|NCT01543139|EXPERIMENTAL|Valproate+Cytidine-+Creatine-|The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate
62351565|NCT01543139|ACTIVE_COMPARATOR|Valproate+Cytidine-|The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate
62351566|NCT01543139|ACTIVE_COMPARATOR|Valproate|The subjects with bipolar depression, treated with valproate
62351567|NCT05657509|EXPERIMENTAL|Male field hockey players of Functional training|Functional training exercises focus on improving physical fitness and movement skills performance. Functional training targets the neuromuscular system through engagements of muscle groups as well as nerve function to optimize movements. The present study applied functional training to elite male field hockey players to assess fitness level as well as skill performance. Post-test 1 will be after 6 weeks, and post-test 2 after 12 weeks to measure performance.
62707478|NCT04275804|ACTIVE_COMPARATOR|Control group: conventional dressing|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Dressing by a specialized wound-nurse is the current gold-stand of treatment for diabetic ulcers.
62707479|NCT04275804|EXPERIMENTAL|Vibration group: conventional dressing and LMHFV|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Alternate dat 20-week course of whole-body vibration therapy Alternate day 20min sessions on a self-designed vibration platform with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm). Since the participants will return for dressing change on alternate days, the vibration group will also undergo the LMHFV on the same attendance.
61970038|NCT04671407|PLACEBO_COMPARATOR|PLACEBO|40ml of normal saline (0.9% NaCl) will be administered to bladder the after the surgery
61970039|NCT03731988|EXPERIMENTAL|5.5% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 5.5%, 350 µm ablation depth, level 1 coagulation and a single pulse
61970040|NCT03731988|EXPERIMENTAL|11% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 11%, 350 µm ablation depth, level 1 coagulation and a single pulse
61970041|NCT03731988|EXPERIMENTAL|22% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 22%, 350 µm ablation depth, level 1 coagulation and a single pulse
61970042|NCT03296930|ACTIVE_COMPARATOR|first drug group|Sofosbuvir 400 MG Oral Tablet
61970043|NCT03296930|ACTIVE_COMPARATOR|second drug group|Ombitasvir/paritaprevir/ritonavir
61970044|NCT03092154|EXPERIMENTAL|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
61970045|NCT03092154|NO_INTERVENTION|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
61970046|NCT02707991|NO_INTERVENTION|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
61970047|NCT02707991|EXPERIMENTAL|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
61970048|NCT02206568|EXPERIMENTAL|URAL vs. Insulin lispro|Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.
61970049|NCT02241174|EXPERIMENTAL|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
61970050|NCT02241174|PLACEBO_COMPARATOR|Placebo|100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
61970051|NCT05592964||Group A|Standard fasting group.
61970052|NCT05592964||Group S|The patient group who were given oral 5 ml/kg (maximum 250 ml) of water 1 hour ago.
61970053|NCT05592964||Group K|The patient group who were given an oral 5 ml/kg (maximum 250 ml) carbohydrate rich clear liquid 1 hour ago.
61970054|NCT06337188|EXPERIMENTAL|Experimental and Generic Communication Interfaces for AAC|Each participant receives both Experimental and Generic AAC systems to communicate - in that order.
61970055|NCT05893173||Major Depressive Disorder|Ten individuals (aged 18-85) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging and waking EEG prior to and following approximately 30 hours of total sleep deprivation.
62510192|NCT01758419||Tomotherapy|Breast cancer female s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT. Comparing the clinical follow-up data between different groups (left-sided s/p tomography, left-sided s/p conventional RT, and right-sided RT), respectively.
61970056|NCT03066089|EXPERIMENTAL|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
61970057|NCT03066089|NO_INTERVENTION|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
62510193|NCT05150756|ACTIVE_COMPARATOR|Group Lidocaine|At induction of anesthesia, patients will receive a loading dose of intravenous (IV) 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% via infusion pump. The infusion will be continued till the end of surgery.
62510194|NCT05150756|ACTIVE_COMPARATOR|Group Morphine|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
62145541|NCT02045498|EXPERIMENTAL|capnography, feedback, quality of cpr|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
62351568|NCT05657509|ACTIVE_COMPARATOR|Male field hockey players of traditional regular type of training exercises|The traditional training method involves exercises to increase the strength and durability of a certain muscle. Male field hockey players will be continuing their regular traditional type training exercises for 12 weeks.
62510195|NCT00172068|EXPERIMENTAL|Treatment Group|
62510196|NCT00172068|ACTIVE_COMPARATOR|Control Group|
62707480|NCT06267417|EXPERIMENTAL|Laser|21 patients will receive Low Level Laser therapy using the wavelength (660 nm) to provide biostimulation at 44 different points in the oral cavity along with the standard preventive protocol in the hospital.
62707481|NCT06267417|SHAM_COMPARATOR|Placebo|21 patients will receive a mock treatment which is the exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital.
61970058|NCT04133220||Cases|Patients with acute myeloid leukemia, associated to hyper leukocytosis
62351569|NCT04492878|EXPERIMENTAL|IKERVIS® (1mg/mL ciclosporin) eye drops|
61970059|NCT04133220||Control|Patients with acute myeloid leukemia, without hyper leukocytosis
61970060|NCT03872167|ACTIVE_COMPARATOR|MANUAL|Manual titration of non-invasive mechanical ventilation using polysomnography and randomized
62351570|NCT03121066|ACTIVE_COMPARATOR|Experimental group|Transcranial Magnetic Stimulation + Conventional intervention
62351571|NCT03121066|SHAM_COMPARATOR|Sham control group|Sham Transcranial Magnetic Stimulation + Conventional intervention
62351572|NCT03121066|NO_INTERVENTION|Non TMS Control group|Conventional intervention alone
62351573|NCT04818541|EXPERIMENTAL|Protected Percutaneous Coronary Intervention|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for PPCI. Duration of Impella use ≤ 6 hours if used for PPCI.
62510197|NCT01657084|EXPERIMENTAL|Tonic-clonic seizures|Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
62510198|NCT01657084|EXPERIMENTAL|Generalized Paroxysms|Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
62510199|NCT01657084|EXPERIMENTAL|Group 3|Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
62510200|NCT05340192|OTHER|Healthy Volunteer|Octreotide, 100 mcg (1 ml) s.c.
62510201|NCT02792218|EXPERIMENTAL|OMB 20 mg|Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
61970061|NCT03872167|ACTIVE_COMPARATOR|AUTOMATIC|Automatic titration of the non-invasive mechanical ventilation using the same device in an automatic mode with assured volume and pressure support.
61970062|NCT00869349|EXPERIMENTAL|IFS Intervention Group|
61970063|NCT00869349|ACTIVE_COMPARATOR|Education Group|
61970064|NCT00550706||1Pediatric Dept A|Children's files from this department will be analysed once weekly and medication prescription data will be registered
61970065|NCT00550706||2 Pediatric Dept B|Children's files from this department will be analysed once weekly and medication prescription data will be registered
61970066|NCT03454893|EXPERIMENTAL|Single Assignment AVR-RD-01|AVR-RD-01 is an autologous CD34+-enriched cell fraction transduced with LV/AGA containing an RNA transcript that, after reverse transcription, results in codon-optimized cDNA that, upon its integration into the human genome, encodes for functional human AGA.
61970067|NCT00359008||1|Intermediate AMD
62145542|NCT02045498|NO_INTERVENTION|conventional cpr|conventional cpr
62145543|NCT03028285|EXPERIMENTAL|Unifusol 250 ml IV, 3 ml/mil|Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.
62145544|NCT03028285|EXPERIMENTAL|Unifusol 250 ml IV, 4.5 ml/min|Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min
62351574|NCT04818541|EXPERIMENTAL|Cardiogenic shock|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for cardiogenic shock. Duration of Impella use \> 8 hours and ≤ 4 days.
62351575|NCT04447534|EXPERIMENTAL|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine alone
62351576|NCT04447534|EXPERIMENTAL|Chloroquine or hydroxychloroquine with zinc|Chloroquine or hydroxychloroquine with zinc
62707482|NCT05006066||Healthy volunteers - Pain-Free|"Each participant will be stimulated with 4 temporal summation stimulation conditions:~* continuous thermal (1 stimulation of two minutes)~* repetitive thermal (30 stimulations of 1 second)~* continuous mechanical (1 stimulation of two minutes)~* repetitive mechanical (30 stimulation of 1 second)"
62707483|NCT01107132||Diabetic Retinopathy|T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)
62707484|NCT03014635|EXPERIMENTAL|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
61970068|NCT00359008||2|New untreated CNV subject
61970069|NCT05573607|PLACEBO_COMPARATOR|Placebo|Consists of a maltodextrin tablet
62707485|NCT03014635|PLACEBO_COMPARATOR|Placebo|Biological/Vaccine: Placebos Intramuscular injection
62707486|NCT05731609|EXPERIMENTAL|Resistance Intensive Personal Training (RIPT)|All participants will participate in this arm involving 12 weeks of training 2-3 days/week in a group setting with each session involving 1:1 support for each participant's power training.
62707487|NCT06412887|ACTIVE_COMPARATOR|with force control (wfc)|Users play the game using the conventional virtual reality input system with force control
62707488|NCT06412887|EXPERIMENTAL|without force control (wofc)|Users play the game using the conventional virtual reality input system
62707489|NCT04461886|EXPERIMENTAL|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
61970070|NCT05573607|ACTIVE_COMPARATOR|Active|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
62707490|NCT01239940|ACTIVE_COMPARATOR|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
62707491|NCT01239940|ACTIVE_COMPARATOR|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
62707492|NCT01966146|EXPERIMENTAL|TAVI|Echocardiography after TAVI
62707493|NCT01966146|EXPERIMENTAL|MitraClip|Echocardiography after MitraClip procedure
62707494|NCT04989361|EXPERIMENTAL|Microneedle side|Apply soluble hyaluronic acid microneedle eye mask to the periorbital area after normal facial cleansing and skin care every night for 20 days. Press and hold for 3 minutes, and then remove it after 1 h. Every 2 days for the next 20 days, and every 3 days for the last 21 days. Follow-up time: every 20 days during the treatment period, and follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
62145545|NCT03028285|EXPERIMENTAL|Unifusol 500 ml IV, 4.5 ml/min|Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min
62145546|NCT00252382|EXPERIMENTAL|Treatment with 48 mg/m2 of SNS-595|Patients are treated with 48 mg/m2 of the drug SNS-595 injection once every 21 days for up to 6 cycles as a second -line therapy to patients with advanced non-small cell lung cancer (NSCLC)
62145547|NCT05505227|ACTIVE_COMPARATOR|Intervention|
62351577|NCT03058822|EXPERIMENTAL|Prefilled Syringe Upper Arm|Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699
62707495|NCT04989361|ACTIVE_COMPARATOR|Non-fractional laser side|The patient received non-ablative fractional laser treatment once. Follow-up time: follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
62707496|NCT02102009|EXPERIMENTAL|Vitafos|Complete enteral formula
62707497|NCT02102009|ACTIVE_COMPARATOR|Dietary Advise|Dietary advise according to the hospital routine clinical practice.
62145548|NCT05505227|PLACEBO_COMPARATOR|Control|
62145549|NCT03652493|EXPERIMENTAL|CARBOPLATIN|CARBOPLATIN in Intraveinous Dose AUC 5 according to Calvert every 3 weeks, for a duration of 6 to 9 cycles
62351578|NCT03058822|EXPERIMENTAL|Prefilled Syringe Thigh|Single subcutaneous dose from prefilled syringe into thigh of BMS-931699
62707498|NCT02150707||Dipeptidyl-Peptidase IV Inhibitors|Newly started on DPP4 inhibitor for hyperglycaemia
62707499|NCT02150707||Glucagon-Like Peptide 1|Newly started on GLP-1 for hyperglycaemia or obesity
61970071|NCT00435292|EXPERIMENTAL|flavocoxid 250 mg|flavonoid mixture
61970072|NCT00435292|ACTIVE_COMPARATOR|flavocoxid 500 mg|flavonoid mixture
61970073|NCT00435292|ACTIVE_COMPARATOR|naproxen|nonsteroidal antiinflammatory drug
61970074|NCT06065995|EXPERIMENTAL|Intervention|Access to the mobile application
61970075|NCT06065995|NO_INTERVENTION|Control group|Standard care, without access to the application
61970076|NCT03916276|ACTIVE_COMPARATOR|Cognitive Therapy (CT) Condition|Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain.
62145550|NCT01332552|EXPERIMENTAL|Part 1: Single dose escalation|GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food
62145551|NCT01332552|EXPERIMENTAL|Part 2: Repeat dose escalation|GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID
62145552|NCT01332552|EXPERIMENTAL|Part 3: GSK2485852 + Ritonavir|GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;
62145553|NCT04598139||Study group|
62145554|NCT05985265|EXPERIMENTAL|Nano fat grafting and fractional carbon dioxide laser resurfacing|treating of atrophic acne scars with nano fat and fractional carbon dioxide laser
62351579|NCT03058822|EXPERIMENTAL|Prefilled Syringe Abdomen|Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699
62351580|NCT03058822|EXPERIMENTAL|Drug in Vial Upper Arm|Single subcutaneous dose from drug in vial into upper arm of BMS-931699
62351581|NCT03058822|EXPERIMENTAL|Drug in Vial Thigh|Single subcutaneous dose from drug in vial into thigh of BMS-931699
62707500|NCT00270387|EXPERIMENTAL|001|Natrecor (nesiritide)
62707501|NCT03404180|EXPERIMENTAL|Peripheral nerve block|"Prospectively evaluate peripheral nerve blocks as a primary anesthetic in the setting of above-the-knee amputations.~All enrollees will be administered Intravenous sedatives using propofol or dexmedetomidine and have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator nerve blocks and lateral femoral cutaneous nerve blocks will also be performed."
62510202|NCT02792218|ACTIVE_COMPARATOR|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
62707502|NCT01958749|NO_INTERVENTION|Fat graft without Platelet Rich Plasma|"Step 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.~Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft."
62510203|NCT06457620|EXPERIMENTAL|conventional physiotherapy|
62707503|NCT01958749|EXPERIMENTAL|Fat graft with Platelet Rich Plasma|"Procedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -~* 10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation~* Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)~* Supernatant removed and collected into syringe~* Injected onto surface of fat graft~* Rest added to piece of gelfoam~* Place gelfoam + PRP on the TM perforation"
62707504|NCT04588142|EXPERIMENTAL|Experimental group|Participants are randomized to receive probiotics for 6 weeks
61970077|NCT03916276|ACTIVE_COMPARATOR|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
61970078|NCT03916276|ACTIVE_COMPARATOR|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
61970079|NCT05799729||CeK 0.1|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.1 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
61970080|NCT05799729||CeK 0.2|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.2 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
61970081|NCT05799729||CeK 0.4|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.4 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
61970082|NCT05799729||CeK 0.6|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.1 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
61970083|NCT02029625|EXPERIMENTAL|NVP-1205|administration of NVP-1205(rosuvastatin+ezetimibe)
61970084|NCT02029625|ACTIVE_COMPARATOR|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe
62351582|NCT03058822|EXPERIMENTAL|Drug in Vial Abdomen|Single subcutaneous dose from drug in vial into abdomen of BMS-931699
62707505|NCT04588142|PLACEBO_COMPARATOR|Placebo group|Participants are randomized to receive placebo for 6 weeks
62707506|NCT01164826|EXPERIMENTAL|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
62351583|NCT00051129|EXPERIMENTAL|Anecortave Acetate|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
62351584|NCT00051129|PLACEBO_COMPARATOR|Anecortave Acetate Vehicle|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
62351585|NCT02602717|EXPERIMENTAL|thyroid cancer|
62351586|NCT04783285|EXPERIMENTAL|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving CS or to a control group receiving treatment as usual. Participants in the intervention group will participate in two CS sessions per week for 16 weeks besides their treatment as usual. The sessions will be based on the existing protocol.
62510204|NCT06457620|OTHER|traditional physical treatment|
62707507|NCT01164826|ACTIVE_COMPARATOR|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
61970085|NCT00587639|EXPERIMENTAL|rTMS Treatment|All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
62510205|NCT06365294|EXPERIMENTAL|Rescue extracranial vertebral stenting|Rescue extracranial vertebral stenting in tandem occlusions
61970086|NCT04182360|ACTIVE_COMPARATOR|Carbetocin 10mcg|Patient is given 10mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61970087|NCT04182360|ACTIVE_COMPARATOR|Carbetocin 20mcg|Patient is given 20mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61970088|NCT04182360|ACTIVE_COMPARATOR|Carbetocin 40mcg|Patient is given 40mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61970089|NCT04182360|ACTIVE_COMPARATOR|Carbetocin 60mcg|Patient is given 60mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62351587|NCT04783285|NO_INTERVENTION|Control Group|Participants assigned to the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed psychotic-specific medication.
62510206|NCT03727698|EXPERIMENTAL|Radiotherapy delivered on the MR Linac|MR Guided radiotherapy treatment
62510207|NCT02524184|EXPERIMENTAL|Sildenafil|Eleven patients receive sildenafil 100mg/day (25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at 10 PM)for 7 days.
62510208|NCT02524184|PLACEBO_COMPARATOR|Placebo group|An identical placebo for 7 days in placebo group.
62707508|NCT06176547||H.pylori in predibetic with lipid profile|Lipid profile HbA1c
62707509|NCT02903485|EXPERIMENTAL|nurses (intervention arm)|for patients without risk factors, the anesthetic team is not involved in patients' care
61970090|NCT04182360|ACTIVE_COMPARATOR|Carbetocin 80mcg|Patient is given 80mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61970091|NCT04182360|ACTIVE_COMPARATOR|Carbetocin 100mcg|Patient is given 100mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
61970092|NCT01266512|EXPERIMENTAL|IMRT & docetaxel-cisplatin|"Concurrent chemo-RT:~Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -~Resting period: 2 weeks -~Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1\&8 - Cisplatin 35 mg/m² on D1\&8 -~Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration"
61970093|NCT01943903||Cohort 1 - Standard of Care|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
61970094|NCT01943903||Cohort 2 - FFRCT-guided|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
62510209|NCT03492658|EXPERIMENTAL|Combination therapy (MTX/abatacept)|Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
62510210|NCT03492658|ACTIVE_COMPARATOR|Methotrexate (MTX) monotherapy|Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
62707510|NCT02903485|ACTIVE_COMPARATOR|anesthetic team (control arm)|the anesthetic team is involved in every patient's care (with or without risk factors)
62707511|NCT05305469||GN|Gram-negative bacteria infection group
62707512|NCT05305469||GP|Gram-positive bacteria infection group
62707513|NCT05305469||Fungal|Fungal infection group
62707514|NCT05305469||Viral|Viral infection group
62707515|NCT05305469||Control|Non-sepsis group
62707516|NCT02630641||Prostate cancer patients|
62707517|NCT04277247|EXPERIMENTAL|Botulinum Toxin Type A Treatment|Injections
62707518|NCT04277247|PLACEBO_COMPARATOR|Placebo|Injections
62707519|NCT06545435||Obese Adults Cohort|This cohort includes Caucasian adult subjects with obesity (BMI ≥ 30 kg/m²). Participants have undergone baseline assessments using both Dual X-ray Absorptiometry (DXA) and Bioelectrical Impedance Analysis (BIA).
62707520|NCT06545435||MRI Validation Subset|A subset of participants from the Obese Adults Cohort selected for additional validation using Magnetic Resonance Imaging (MRI) to assess muscle size and architecture.
62707521|NCT00930124|EXPERIMENTAL|1|Group 1 will receive Conventional orthognathic surgery
62707522|NCT00930124|ACTIVE_COMPARATOR|2|Group 2 will receive distraction osteogenesis
62707523|NCT04801576|PLACEBO_COMPARATOR|Placebo mouthrinse|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse without flouride for 28 days; toothpaste with 1050 ppm F and mouthrinse without flouride for 28 days; toothpaste with 1450 ppm F and mouthrinse without flouride for 28 days.
62707524|NCT04801576|EXPERIMENTAL|Fluoride in mouthrinses|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse with 450 ppm F for 28 days; toothpaste with 1050 ppm F and mouthrinse with 450 ppm F for 28 days; toothpaste with 1450 ppm F and mouthrinse with 450 ppm F for 28 days.
62707525|NCT02727608|EXPERIMENTAL|Eculizumab|Intravenous infusion
62510211|NCT05403619||Patients|Patients hospitalized for shortness of breath with realization of an enhanced FoCUS
62510212|NCT03572842|OTHER|quantiferon monitor|Test measuring interferon gamma production after T cells and Natural Killers (NK) in vitro stimulation : QuantiFERON Monitor® (QFM)
62707526|NCT04120207|EXPERIMENTAL|Home-based Pilates|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
62707527|NCT04120207|OTHER|Delayed-Start Control|Participants randomized to Delayed-start will be instructed to maintain their pre-intervention physical activity levels during the trial and will be contacted by the lead researcher by email or telephone to ensure timely completion of the on-line outcome assessments at biweekly intervals. Following the 8-week intervention, Delayed start participants will be provided with the Pilates DVD for their own use, but no data will be collected. For both groups, participants who experience a relapse will be immediately withdrawn from the study, which will be recorded by the lead researcher.
62707528|NCT02433938|EXPERIMENTAL|Underwent tibial nerve stimulation|Patients that underwent standard postoperative protocol + tibial nerve stimulation for 3 days
62707529|NCT02433938|SHAM_COMPARATOR|Did not undergo tibial nerve stimulation|Patients that underwent standard postoperative protocol + sham tibial nerve stimulation (standard postoperative protocol+sham tns)
62510213|NCT03678935|ACTIVE_COMPARATOR|Low FODMAP diet (LFD)|The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
61970095|NCT01078012|ACTIVE_COMPARATOR|Trained counselling|Comparison of outcomes before intervention vs. 2 months after
61970096|NCT02692716|EXPERIMENTAL|Oral semaglutide|
61970097|NCT02692716|PLACEBO_COMPARATOR|Placebo|
61970098|NCT04030754|EXPERIMENTAL|amniotic membrane group|amniotic dressing will be applied to these patients
61970099|NCT04030754|EXPERIMENTAL|duoderm group|duoderm dressing will be applied to these patients as intervention
61970100|NCT01650623|EXPERIMENTAL|Gait training executive functions tasks|The experimental group will perform a gait training associated with the tasks that require the main executive functions (dual-task condition).
61970101|NCT01650623|ACTIVE_COMPARATOR|Gait training alone|The control group will perform a gait training alone, without associated tasks (single-task condition).
61970102|NCT00836290|EXPERIMENTAL|Pre-release|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
62145555|NCT01814605|EXPERIMENTAL|Subgluteal space group|"The patients in Subgluteal space group will receive sciatic block according to the approach described by Karmakar et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint will be designated with a marker and will be the site of needle entry.~A 50 to 90 mm 22 G insulated needle will be inserted at the midpoint previously designated and advanced under real time guidance in an out-of-plane approach until the needle reaches the subgluteal space."
62351588|NCT03678376|OTHER|complaint, cognitive and functional assessments|All patients will be included in a single arm. They will complete an evaluation with their General Practitioner, followed by an evaluation at the Memory Clinic with a specialist (neurologist, geriatrician or psychiatrist).
62351589|NCT05480254|EXPERIMENTAL|clamped catheter group|Q3 clamped catheter protocol is applied before urinary catheter removal
62351590|NCT05480254|NO_INTERVENTION|free dranaige group|Free dranaige is applied before urinary catheter removal
62351591|NCT04072172|EXPERIMENTAL|Female with leg spider veins|Females at the age of 20 to 45 not known diabetics or hypertensive complaining of leg spider veins.
62351592|NCT05397483|EXPERIMENTAL|LETiT|"The LETiT intervention will cover (a) Legal education with numerous aspects relating to human rights, access to legal support and tackling traumatic experiences.~(b) The Trauma-informed Therapy component will involve addressing trauma, dispelling negative thoughts and building more positive thinking.~It is worth adding that the LETiT intervention has undergone standardisation of procedure by adopting a coherent manual (e.g., the Legal Education plus Trauma-informed Therapy manual) specifically designed for the proposed intervention. For example, the legal education contents are collated from extant laws, including the 1999 Constitution of the Federal Republic of Nigeria."
62351593|NCT05397483|ACTIVE_COMPARATOR|Intervention As Usual (IAU)|"The Intervention As Usual (IAU) component of the proposed project is designed through a systematic collation of numerous government and non-governmental organisations' support information (e.g., news information and basic re-orientation of community members affected by terrorism). Thus, the IAU group will receive the government intervention involving media messages from the National Orientation Agency devoid of legal education or trauma-informed therapy.~The training materials are organised to address key aspects of care such as (a) acknowledgement of the severity of lived experiences (b) reflection of current help received from the government and humanitarian services (c) essential aspects of self-care and caring for the vulnerable family and community members (d) inspiration for the future etc."
62351594|NCT04152148|EXPERIMENTAL|500mg BAT4306F|3 weeks of a cycle
62351595|NCT04152148|EXPERIMENTAL|750mg BAT4306F|3 weeks of a cycle
62351596|NCT04152148|EXPERIMENTAL|900mg BAT4306F|3 weeks of a cycle
62351597|NCT04152148|EXPERIMENTAL|1000mg BAT4306F|3 weeks of a cycle
62351598|NCT05544227|EXPERIMENTAL|SV-102 Treatment Arm|SV-102 Treatment Arm
62351599|NCT01277497|EXPERIMENTAL|Sevelamer carbonate|1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
62351600|NCT01277497|ACTIVE_COMPARATOR|Calcium acetate|1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks
62351601|NCT03441347|EXPERIMENTAL|Specific rehabilitation program|Specific, personalized, multidisciplinary rehabilitation program consisting of physical- and occupational therapy.
62351602|NCT03441347|OTHER|Usual Care|Usual care for people with neuralgic amyotrophy, may vary per individual
62351603|NCT05781763|EXPERIMENTAL|HIIT-intervention group|12 weeks of structured high intensity interval training followed by 9 month of self-selected training
62351604|NCT05781763|ACTIVE_COMPARATOR|Control group|Continuing with their usual exercise habits during 12 months
61970103|NCT00836290|EXPERIMENTAL|Post-release|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
61970104|NCT00836290|NO_INTERVENTION|Control|Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study.
61970105|NCT03605459|EXPERIMENTAL|Device use|"Only one treatment arm; the Comfort Plug™ is a device designed to control urinary incontinence in male subjects by being placed in the urethra to stop urine leakage."
62351605|NCT03424577|EXPERIMENTAL|H3B-6527|Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).
62351606|NCT05296408|EXPERIMENTAL|M+ML|MyoPro paired with motor learning based therapy
62351607|NCT05296408|ACTIVE_COMPARATOR|ML-alone|motor learning based therapy alone
62351608|NCT05399550|EXPERIMENTAL|Balovaptan|Balovaptan will be administered as IV infusion once a day over 3 days
62351609|NCT05399550|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as IV infusion once a day over 3 days
62351610|NCT06322706|EXPERIMENTAL|ABSK021|
62351611|NCT06322706|EXPERIMENTAL|ABSK021and Omeprazole|
62707530|NCT02950259|EXPERIMENTAL|IRX-2 Regimen -Early Stage Breast Cancer|Enrolled subjects with early stage breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
62707531|NCT02950259|EXPERIMENTAL|IRX-2 Regimen -Triple Negative Breast Cancer|Enrolled subjects with triple negative breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
62707532|NCT01968980|EXPERIMENTAL|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
62707533|NCT01968980|PLACEBO_COMPARATOR|Placebo|
61970106|NCT01514812|EXPERIMENTAL|YM150-placebo sequence group|YM150+digoxin; Washout; Placebo+digoxin
62510214|NCT03678935|NO_INTERVENTION|Control|Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
62510215|NCT04415502||Measuring of CTHRc1 , its correlation with RAdisease activity|Measuring of CTHRc1 levels and its correlation with RA disease activity
62510216|NCT00305916|ACTIVE_COMPARATOR|1|conventional coronary angiography
62510217|NCT00305916|EXPERIMENTAL|2|multislice spiral computed tomography coronary angiography
62510218|NCT05363995|EXPERIMENTAL|Experimental|Blended e-health intervention
62510219|NCT01537731||hysterectomy|Patient who previously underwent vaginal or laparoscopic hysterectomy
62510220|NCT04411823|EXPERIMENTAL|Intervention arm|Undergo an upper endoscopy with EndoFLIP at baseline before sleeve gastrectomy
62510221|NCT05706064||COVID-19 Infection|
62510222|NCT03776734|EXPERIMENTAL|cryotherapy application|effect of cold application
62510223|NCT00612677|EXPERIMENTAL|Premetrexed and Oxaliplatin|Patients will be treated with oxaliplatin 120 mg/m\^2 i.v. over 2 hours and pemetrexed 500 mg/m\^2 i.v. over 10 minutes on Day 1 of a 21day cycle. Cycles of treatment will be repeated every 3 weeks. Folic acid and B12 supplementation is obligatory.
62707534|NCT05557708|EXPERIMENTAL|212-Lead Pentixather|"Single intravenous infusion of Pentixather radiolabeled with Lead-212. Administered activity to participant is calculated from bone marrow and renal radiation constraints.~Treatment is administered in 2 cycles with 6 weeks between the cycles."
62707535|NCT01701882|EXPERIMENTAL|tenofovir/emtricitabine/rilpivirine|A one pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
62707536|NCT02298621|EXPERIMENTAL|pomegranate juice|pomegranate juice: 500 ml
62707537|NCT02298621|PLACEBO_COMPARATOR|placebo|sugar + aroma+ color: 500ml
62707538|NCT03100526|EXPERIMENTAL|Intervention--PACT Intensive Management|The intervention is the PACT Intensive Management Program (PIM) which provides intensive interdisciplinary care planning, care coordination, patient self-management support, and tailored goal setting based on patient needs and preferences, and additional care management services.
62707539|NCT03100526|NO_INTERVENTION|Usual care|High-Risk patients receiving care in PACT.
62707540|NCT02350452|EXPERIMENTAL|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
62707541|NCT02350452|ACTIVE_COMPARATOR|Bipolar coaugulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
61970107|NCT01514812|EXPERIMENTAL|placebo-YM150 sequence group|Placebo+digoxin; Washout; YM150+digoxin
61970108|NCT01549860|NO_INTERVENTION|Standard of Care|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
61970109|NCT01549860|EXPERIMENTAL|SOC + Mist Therapy|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
62510224|NCT02270216|ACTIVE_COMPARATOR|elderly with isolated systolic hypertension|over 60 years of age with essential isolated systolic hypertension (stage I-II base on recommendation of JNC-VII) for the hypertension group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
62510225|NCT02270216|ACTIVE_COMPARATOR|healthy elderly|over 60 years of age with normal blood pressure in the healthy group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
62510226|NCT03418792|EXPERIMENTAL|Parotid-Sparing Head & Neck Radiation|Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head \& neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
62510227|NCT03030326|EXPERIMENTAL|Heart rate variability biofeedback|This group will receive treatment in the first three months of the study and will be observed during the second three months
62510228|NCT03030326|NO_INTERVENTION|Observation first|This group will be observed during the first three months and given biofeedback during the second three months
62510229|NCT03668431|EXPERIMENTAL|PDR001, Dabrafenib, Trametinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive PDR001, Dabrafenib, Trametinib. Treatment will be administered on an outpatient basis.~After the screening procedures confirm participation in the research study:~* Dabrafenib will be taken twice a day for 28 consecutive days~* Trametinib will be taken once a day for 28 consecutive days~* PDR001 will be administered IV every 28 days."
62707542|NCT03243084|SHAM_COMPARATOR|Sham tACS|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
62707543|NCT03243084|ACTIVE_COMPARATOR|Active 10 Hz tACS|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
62707544|NCT03499678||Lung Cancer|Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
62707545|NCT03499678||Control|Age and sex matched control individuals
62707546|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
62707547|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
62707548|NCT01920243|EXPERIMENTAL|Health Mechanics- New Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals with new-onset traumatic spinal cord injuries are eligible for this group.
62707549|NCT01920243|NO_INTERVENTION|Usual Care- New Injuries|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with new-onset traumatic spinal cord injuries.
62707550|NCT01920243|EXPERIMENTAL|Health Mechanics- Chronic Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals who have had traumatic spinal cord injuries for at least one year are eligible for this group.
62707551|NCT01920243|NO_INTERVENTION|Usual Care- Chronics|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with who have had traumatic spinal cord injuries for at least one year.
62707552|NCT01990690|ACTIVE_COMPARATOR|anti oxidant omega 3|The patients were randomized to receive either a daily dose of omega-3 plus as antioxidant once daily for two weeks or a daily placebo then stored in envelopes numbered from 1 to 140
61970110|NCT02417701|EXPERIMENTAL|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61970111|NCT04224649|EXPERIMENTAL|Test Device Group(HARA filler)|
61970112|NCT04224649|ACTIVE_COMPARATOR|Comparator Group(Restylane® Lidocaine)|
61970113|NCT02425657||Junior Doctors|Surgical trainees (PGY1, 2 and 3 - Danish equivalents: introduktionsstilling, hoveduddannelse 1, 2).
61970114|NCT01887873|OTHER|Hyaluronan Thiomer i.o. implantable device|active treatment
61970115|NCT03043131|ACTIVE_COMPARATOR|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
61970116|NCT03043131|EXPERIMENTAL|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
61970117|NCT01581931|EXPERIMENTAL|Linagliptin/metformin|fixed dose combination tablet (FDC)
62145556|NCT01814605|ACTIVE_COMPARATOR|Infragluteal space group|The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. After skin and transducer preparation, a curved 5 MHz(megahertz) transducer will be placed over the subgluteal region in a transverse plane to scan the sciatic nerve. A 50 to 90 mm 22 G needle is used and advanced under real time guidance in an out-of-plane approach until the needle tip is adjacent o the nerve.
61970118|NCT01581931|EXPERIMENTAL|Linagliptin and metformin|single tablets
61970119|NCT01411228|EXPERIMENTAL|60 Units/kg|
62145557|NCT01170936|EXPERIMENTAL|Canakinumab|
62351612|NCT00854555|EXPERIMENTAL|robot|30 persons with incomplete SCI who live within driving distance to Oslo and who meet the inclusion/exclusion criteria will be selected for randomization to robotic assisted training or control (conventional treatment). Intervention consists of locomotor training with robot for 60 days during 6 months period in an out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
62707553|NCT01990690|PLACEBO_COMPARATOR|placebo|"Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.~Group 2 was given a placebo once daily for two weeks."
61970120|NCT01411228|EXPERIMENTAL|30 Units/kg|
61970121|NCT02852408||Study|liver cauterized during laparoscopic cholecystectomy.
61970122|NCT02852408||Control|liver not-cauterized during laparoscopic cholecystectomy.
61970123|NCT01090960|EXPERIMENTAL|A|
61970124|NCT05195970|EXPERIMENTAL|Walnut Consumption|Following enrollment, participants will start a 7-day wash-out period where they will be asked to avoid foods and beverages high in ellagitannins. These include pomegranates, hazelnuts, pistachios, walnuts (besides the samples given by the researchers), strawberries, raspberries, blackberries, oak-aged wines and spirits; a full list of foods and beverages to avoid will be provided. Then, participants will consume 2 ounces of walnuts daily with their usual diet while continuing to avoid ellagitannins for 21 days prior to their routine colonoscopy.
61970125|NCT00867009|EXPERIMENTAL|Induction/maintenance Therapy|pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
62145558|NCT02444962|EXPERIMENTAL|HAVD implant|
62145559|NCT03186248|EXPERIMENTAL|Short myotomy|Per oral endoscopic myotomy extending from 3 cm cephalad to 3 cm distal to EGJ
62145560|NCT03186248|ACTIVE_COMPARATOR|Long myotomy|Per oral endoscopic myotomy extending from 6-8cm cephalad to and 3 cm distal to EGJ.
62707554|NCT00637910|EXPERIMENTAL|Erlotinib Arm|
62707555|NCT00637910|ACTIVE_COMPARATOR|Docetaxel Arm|
62707556|NCT00708357|OTHER|1|homozygous mutant: CC allele of the eNOS T-786C gene
62707557|NCT00708357|OTHER|2|homozygous mutant: TT allele of the eNOS T-786C gene
62707558|NCT03304366||Patients with primary pterygium|"* All eyes have primary pterygium and seeking for surgery due to Cosmetic problems, ocular irritation, and, or visual impairment.~* All selected patients will undergo complete ophthalmological examination including refraction, best corrected visual acuity, keratometry, and pentacam (scheimpflug imaging) preoperatively then will be followed up 2 and 6 months post pterygium excision."
61970126|NCT01155232||Forteo (teriparatide)|postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)
62510230|NCT06358196||Alcohol-associated hepatitis patients|"Inclusion criterion~• Patients older than 18 years with acute liver injury / acute liver failure with later confirmation of the AH diagnosis according to the NIAAA diagnostic criteria \[14\] who provided written informed consents for admission and further differentiation, and for study participation~Exclusion criteria~* Patients not confirmed to have alcohol-associated hepatitis~* Patients with malignancies (specifically those with life-expectancy limitation)~* Patients who withdrew consent for study participation"
62707559|NCT05597384|EXPERIMENTAL|Autologous Blood Marker Group|The tattooing was performed at 24-48 hours before the surgery. When the lesion was identified by endoscopy, 2-3 ml of the patient's peripheral venous blood without heparin preparation were injected submucosally at the distal side and proximal side of the lesion using a conventional endoscopic needle without submucosal injection of normal saline.
62707560|NCT05597384|ACTIVE_COMPARATOR|Intraoperative colonoscopy group|Under general anesthesia with endotracheal intubation, the patient was placed in the modified lithotomy position. After routine laparoscopic exploration, CO2-insufflated intraoperative colonoscopy was performed using a flexible videocolonoscope. Upstream small bowel clamping was applied before intraoperative colonoscopy. During intraoperative colonoscopy, CO2 pneumoperitoneum was maintained by the insufflator so that the laparoscope could guide the colonoscope effectively.
61970127|NCT01155232||Forteo (teriparatide) in AFF|women who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)
61970128|NCT03453710|ACTIVE_COMPARATOR|Bankart Repair and Remplissage|Patients randomized to the all-arthroscopic group (Bankart repair and remplissage) will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
61970129|NCT03453710|ACTIVE_COMPARATOR|Latarjet Coracoid Transfer|Patients randomized to the open Latarjet coracoid transfer will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
62707561|NCT06387862|EXPERIMENTAL|Levosimendan inhalation|Levosimendan 12µg/kg inhalation over 10 minutes, once
61970130|NCT05195125|EXPERIMENTAL|Direct Peritoneal Resuscitation (DPR) Group|At the time of abdominal closure and determination that the patient will either go to extended stay or the intensive care unit, three drains will be placed per standard of care. An additional 19 French drain will be placed at the ligament of Treitz at the base of the mesentery. Following abdominal closure DPR will be initiated with commercially available 2.5% glucose-based peritoneal dialysis solution at a rate of 1.5 cc/kg/hr based on previously reported therapy in trauma. Drains will be connected to continuous wall suction. This infusion will continue for the duration the patients stay in extended stay (8 hours) if they are deemed eligible for hospital ward admission, or for 24 hours if requiring ICU care. These patients will then be observed for their hospital course and monitored for outcomes listed above.
61970131|NCT04053205|EXPERIMENTAL|1 Gentuximab+ Paclitaxel|8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
61970132|NCT04053205|EXPERIMENTAL|2 Gentuximab+ Paclitaxel|12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
61970133|NCT01352299|ACTIVE_COMPARATOR|Macintosh|Laryngoscopy performed with Macintosh Laryngoscope
61970134|NCT01352299|ACTIVE_COMPARATOR|McCoy|Laryngoscopy performed with MacCoy Laryngoscope
61970135|NCT01352299|ACTIVE_COMPARATOR|Miller|Laryngoscopy performed with Miller Laryngoscope
61970136|NCT01352299|ACTIVE_COMPARATOR|TrueView|Laryngoscopy performed with TrueView Laryngoscope
61970137|NCT04086147|EXPERIMENTAL|Low dose tenecteplase|
61970138|NCT04086147|EXPERIMENTAL|High dose tenecteplase|
61970139|NCT01680705|ACTIVE_COMPARATOR|Frequency: Once Daily|Patients will use high volume saline irrigation once daily post operatively.
61970140|NCT01680705|ACTIVE_COMPARATOR|Frequency: Twice Daily|Patients will use high volume saline irrigation twice daily post operatively.
61970141|NCT01680705|ACTIVE_COMPARATOR|Frequency: Three Times Daily|Patients will use high volume saline irrigation three times daily post operatively.
62351613|NCT00854555|EXPERIMENTAL|manual assistance|30 persons with incomplete SCI who live outside driving distance to Oslo and who meet inclusion/exclusion criteria will be selected for manually assisted training in Tromsø or control (conventional treatment). Intervention consists of 60 days locomotor training with manual assistance during 6 months period in an in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
61970142|NCT03552315|ACTIVE_COMPARATOR|Water with amino acids and chromium|The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.
61970143|NCT03552315|PLACEBO_COMPARATOR|Carbonated water|The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.
62145561|NCT04432155|EXPERIMENTAL|NBTX-001|Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
62351614|NCT05785130|EXPERIMENTAL|background noise group|Background noise at bedtime.
62707562|NCT06387862|ACTIVE_COMPARATOR|Levosimendan intravenous|Levosimendan 12µg/kg intravenous over 10 minutes, once
62707563|NCT02906111|ACTIVE_COMPARATOR|Study Group on estriol vaginal gel|Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
61970144|NCT00642460|EXPERIMENTAL|1|
61970145|NCT00642460|PLACEBO_COMPARATOR|2|
61970146|NCT02324894|OTHER|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
61970147|NCT01797601|ACTIVE_COMPARATOR|Human Insulin|Nasal spray
61970148|NCT01797601|PLACEBO_COMPARATOR|Placebo solution|Nasal spray
61970149|NCT00380757|ACTIVE_COMPARATOR|CPR 30:2|30 chest compressions to 2 ventilations
61970150|NCT00380757|ACTIVE_COMPARATOR|CPR 15:2|15 chest compressions to 2 ventilations
62510231|NCT03176784|EXPERIMENTAL|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Nicotine Patches:~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
62510232|NCT03176784|EXPERIMENTAL|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
62510233|NCT03176784|EXPERIMENTAL|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Nicotine Patches:~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
62510234|NCT03176784|EXPERIMENTAL|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
62510235|NCT05303935|EXPERIMENTAL|Quetiapine|Quetiapine 50mg in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
62510236|NCT05303935|PLACEBO_COMPARATOR|Placebo|Placebo sugar pill in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
62510237|NCT05659524|ACTIVE_COMPARATOR|Nasal saline irrigation|Patients randomized to standard postoperative nasal care with twice a day saline sinonasal irrigations
62510238|NCT05659524|NO_INTERVENTION|No Intervention|Patients randomized to not performing saline sinonasal irrigations.
62510239|NCT04424966|EXPERIMENTAL|Arm 1|"Phase 0: 125 mg of infigratinib administered orally for 7 days prior to surgical resection.~Expansion Cohort: 125 mg of infigratinib administered orally for 21 days of a 28-day treatment cycles."
62510240|NCT04468906|EXPERIMENTAL|"Biceps self-locking T tenotomy"|
62510241|NCT04468906|ACTIVE_COMPARATOR|Biceps tenodesis (control)|
61970151|NCT01134783|EXPERIMENTAL|Intervention Group|The CHOICES intervention included a 1-credit, academic college course focusing on healthy weight behaviors and participation in a social networking and social support website
61970152|NCT01134783|NO_INTERVENTION|Control Group|Control group (serving as a comparison group)
61970153|NCT03008681|EXPERIMENTAL|Andresen functional removable orthodontic appliance|"All the enrolled patients was applied the Andresen Activator (a removable orthodontic appliance) 12-14 hours in a day in total.~Functional appliances helped the movement of the teeth, with the achievement of good facial muscle function. All patients in the cohort were treated with the andresen actovator appliancev for deep bite and class II malocclusion correction.~The appliances were individually manufactured of acrylic resin, with a central screw and a vestibular arch, fabricated through a wax bite registration; the patient was guided to close the mouth in mandibular protrusion with coincidence of the upper and lower midlines. The registration bite was very thin in order to obtain a minimum vertical dimension. The activator was modified every three months increasing its posterior vertical dimension in order to stimulate the mandibular ramus growth thanks to the dislocation of the mandibular condyle."
61970154|NCT04207970||Clients under PDS Community Team|27 adult clients under PDS Community Team
61970155|NCT02308085|EXPERIMENTAL|Endocrine therapy interruption|Endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months.
62145562|NCT04432155|PLACEBO_COMPARATOR|Placebo|Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume.
62145563|NCT03954860|EXPERIMENTAL|No Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. No drainage tube was placed after operation.
62145564|NCT03954860|ACTIVE_COMPARATOR|Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Drainage tube should be placed after operation.
62351615|NCT05785130|NO_INTERVENTION|conventional treatment group|Treatment as usual.
62510242|NCT06522269|EXPERIMENTAL|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
62145565|NCT05819294|EXPERIMENTAL|Standard thoracentesis followed by pre-aspiration fluid agitation|Participants will undergo the standard thoracentesis followed by the experimental pre-aspiration fluid agitation technique
62510243|NCT06522269|PLACEBO_COMPARATOR|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
62510244|NCT02849236|PLACEBO_COMPARATOR|Control group|PECS block performed with Saline solution instead of local anesthetic
62510245|NCT02849236|EXPERIMENTAL|PECS group|PECS block performed with Ropivacaine 3.75mg/mL
62510246|NCT05694182|EXPERIMENTAL|Oral superfruits supplement|Participants will consume oral superfruits supplement once daily for 6 weeks.
62510247|NCT00730951|EXPERIMENTAL|1|0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)
62510248|NCT00730951|EXPERIMENTAL|2|1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)
62510249|NCT00730951|EXPERIMENTAL|3|3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)
62510250|NCT00730951|EXPERIMENTAL|4|6g Korean Red Ginseng (12 capsules)
62510251|NCT00730951|EXPERIMENTAL|5|6g Corn Starch Control (12 capsules)
62707564|NCT02906111|ACTIVE_COMPARATOR|Control group, no estriol treatment|Procedure: vaginal surgery
61970156|NCT02782780|EXPERIMENTAL|CBTi|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep as well as to work with the patient toward altering sleep habits to increase sleep propensity and regularity. Specifically, participants will receive 8 weekly individual sessions of CBTi according to the VA CBTi protocol. The investigators will follow the semi-structured approach to treatment described in the VA CBTi protocol, which allows the case conceptualization to drive the order in which treatment components are introduced.
62145566|NCT05137366||Known Thoracic aortic aneurysm (TAA)|"* A medical confirmed TAA defined as an aneurysm measuring \>3cm in the thoracic aorta e.g. aortic arch, ascending aorta or descending thoracic aorta.~* Patients may also have a AAA~* Patients may have had a TEVAR and will have a residual sac~* A CT scan of the aorta in the last 3 years"
62145567|NCT05137366||Control group|A medically diagnosed Abdominal aortic aneurysm with a CT scan showing no TAA in the last three years. Patients who have also had their AAA repaired will also be eligible for this group.
62145568|NCT01828021|EXPERIMENTAL|margetuximab|Monotherapy of Anti-HER2 monoclonal antibody
62707565|NCT04653792|EXPERIMENTAL|Pregabalin|Participants received Pregabalin 75mg capsule twice daily from preoperative day to 1 week postoperative
62145569|NCT00142246|EXPERIMENTAL|1|Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
62510252|NCT05287503|EXPERIMENTAL|Ambroxol|"Ambroxol hydrochloride 200 mg tablets Dose: 1.2 g daily~Escalation scheme:~Day 1 - 5 200 mg 200 mg once a day Day 6 - 10 400 mg 200 mg twice a day Day 11 - 15 600 mg 200 mg three times a day Day 16 - 20 800 mg 400 mg twice a day Day 21 - 25 1000 mg 400 mg + 200 mg + 400 mg a day Day 26 - 365 1200 mg 400 mg three times a day"
62510253|NCT05287503|PLACEBO_COMPARATOR|Placebo|Excipients
62510254|NCT02053896||ISU302|15\~60U/kg (once every 2 weeks for 6 months)
62510255|NCT01283646|EXPERIMENTAL|Apevitin BC|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
62510256|NCT01283646|ACTIVE_COMPARATOR|Vitamin B Complex + Vitamin C|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
62510257|NCT05382156||Osilodrostat|Osilodrostat - tablets of 1mg, 5mg, 10mg - based on patients needs - up to 3 years
62510258|NCT01039454|PLACEBO_COMPARATOR|Placebo|2 way cross over.
62510259|NCT01039454|ACTIVE_COMPARATOR|Active|2 Way cross over
62510260|NCT04083352|EXPERIMENTAL|6-week ketone supplementation|Participants took a ketomax ketone salt supplementation for 6-weeks. They took 2 servings per day.
62510261|NCT04083352|PLACEBO_COMPARATOR|6-week placebo supplement|Participants took a placebo supplement for 6-weeks. The placebo was calorie, sodium, and flavor-matched to the experimental supplement.
62510262|NCT02081716||high CMV ELISPOT results|high spot counts in ELISPOT
62707566|NCT04653792|PLACEBO_COMPARATOR|Pregabalin Placebo|Participants received Pregabalin placebo capsule matching Pregabalin twice daily from preoperative day to 1 week postoperative
62707567|NCT01190319|PLACEBO_COMPARATOR|Placebo Beverage|The placebo beverage is matched in energy, macronutrient composition and sensory properties to the active beverage, but is devoid of strawberry polyphenols.
62707568|NCT01190319|EXPERIMENTAL|Strawberry Beverage|The strawberry beverage is matched in energy, macronutrient composition and sensory properties to the placebo beverage, but contains strawberry polyphenols.
62707569|NCT05978934|ACTIVE_COMPARATOR|L1 then L2 followed by L3 lighting condition|Participants will first experience a static lighting condition (L1) then a dynamic lighting condition (L2). After, participants will experience another dynamic lighting condition (L3) with increased morning brightness compared to L2.
62707570|NCT05978934|ACTIVE_COMPARATOR|L2 then L1 followed by L3 lighting condition|Participants will first experience a dynamic lighting condition (L2) then a static lighting condition (L1). After, participants will experience another dynamic lighting condition (L3) with increased morning brightness compared to L2.
62707571|NCT01378195|EXPERIMENTAL|CBT-based|CBT-based program (Cognitive Behavioral Therapy) with video, workbook, and website
62707572|NCT01378195|ACTIVE_COMPARATOR|Educational/Resources Materials|Educational/Resources Materials: video, workbook, and website.
62707573|NCT06350279|EXPERIMENTAL|HSK39297|Single or multiple oral doses of HSK39297
62145570|NCT00142246|PLACEBO_COMPARATOR|2|Dual placebo comparator
62145571|NCT02971215|EXPERIMENTAL|High-intensity laser therapy|High-intensity laser therapy application through iLux Laser device
62510263|NCT02081716||low CMV ELISPOT results|low spot counts in ELISPOT
62510264|NCT00855075||Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
62510265|NCT05309720|EXPERIMENTAL|Glyaderm|
62707574|NCT06350279|EXPERIMENTAL|Placebo|Placebo
62707575|NCT01507740||1|Control group n=20
62145572|NCT02971215|SHAM_COMPARATOR|Sham device|Sham high-intensity laser therapy application through sham iLux Laser device
62145573|NCT03649191|OTHER|Intervention ACP Group|The BABEL Approach to Advance Care Planning in Nursing Homes
62145574|NCT03649191|OTHER|Control ACP Group|Control group Advance Care Planning
62145575|NCT02869802||Biopsy Cohort|"Participants will undergo a tumour biopsy at baseline and an optional tumour biopsy at disease progression.~Participants will undergo serial collection of plasma and serum samples."
62145576|NCT02869802||Archival Cohort|"Genomic analyses will be performed on participants' archival tumour samples.~Participants will undergo serial collection of plasma and serum samples."
62145577|NCT06271850|ACTIVE_COMPARATOR|Ergonomic breastfeeding training (control group)|They will receive ergonomics breastfeeding training only.
62145578|NCT06271850|EXPERIMENTAL|Pilates exercises and ergonomic breastfeeding training (study group)|They will receive Pilates exercises, in addition to ergonomics breastfeeding training.
62145579|NCT00666705|EXPERIMENTAL|Maraviroc alone|
62145580|NCT00666705|EXPERIMENTAL|Maraviroc + Raltegravir|
62510266|NCT05633082|EXPERIMENTAL|Lens 1|All participants wore Lens 1 for 15 minutes (Period 1)
62707576|NCT01507740||2|investigational group (cancer patients) n=40 patients treated with antiangiogenic agent
62145581|NCT00666705|EXPERIMENTAL|Raltegravir alone|
62145582|NCT00586755|EXPERIMENTAL|Intensive Induction-BMT|Patients will undergo induction regimen and stem cell mobilization with cyclophosphamide for bone marrow transplant (BMT). This will be immediately followed by high dose therapy with stem cell support.
62145583|NCT05488405|EXPERIMENTAL|Mesalamine treatment|Treatment of patient with mesalamine oral suspension
62145584|NCT05026970|ACTIVE_COMPARATOR|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
62351616|NCT00745953|ACTIVE_COMPARATOR|Valsartan|This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 \& 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, \& 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 \& 3 are needed for the adjustment of medication to the final dose level. During visits 4 \& 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
62510267|NCT05633082|EXPERIMENTAL|Lens 2|All participants wore Lens 2 for 15 minutes (Period 2)
62707577|NCT06563947|EXPERIMENTAL|Patients with progressed HCC after treatment were given enterobacterium capsules|Patients were given oral enterobacterium capsules (300 mg/per capsule) 6 capsules/day for 10 consecutive days, and then discontinued to the next course of treatment.
61970157|NCT02782780|NO_INTERVENTION|Monitor Only|Study participants who are randomized to the Monitor Only (MO) control group will be followed for 8 weeks of usual care (i.e., they will be advised to continue doing whatever they were doing to manage their GWI and insomnia symptoms without change dosage or frequency of treatment). Participants randomized to the Monitor Only condition will have the option of receiving CBTi delivered by telephone, at no cost to them, upon completion of post-study procedures.
62510268|NCT02800031|EXPERIMENTAL|Participants|"* Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary).~* Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method.~* Plan of management for each patient will be based solely on the findings of pattern recognition and the patient's wishes.~* Exploratory laparotomy for excision of the ovarian mass either by ovarian Cystectomy or oophorectomy.~* All specimens will be examined histopathologically."
62707578|NCT05378802|EXPERIMENTAL|NAVA mode|"1. st select a NAVA level that gives peak pressure about 9-10 cm H2O assist keep NAVA level for 15 minutes, do ZAM breaths every 3 minutes (make sure not to disturb the patient). Insp Hold after every ZAM~2. nd increase NAVA level by 50% and repeat the protocol when patient's breathing has stabilized (only one increase) Do ZAM breaths every 3 minutes (make sure not to disturb the patient). Insp Hold after every ZAM"
62707579|NCT05378802|EXPERIMENTAL|N- PSV mode|"1. st PS level of 8-10 cmH2O, keep PS level for 15 minutes, do ZAM every 3 minutes (make sure not to disturb patient). Insp Hold after every ZAM At the end of protocol (minute 15) do one end-inspiratory hold-maneuver and one end-expiratory occlusion.~2. nd increase PS by 50% and repeat protocol when patient's breathing has stabilized (only 1 increase). Do ZAM every 3 minutes (make sure not to disturb patient). Insp Hold after every ZAM"
62707580|NCT05378802|ACTIVE_COMPARATOR|VCV mode|"no spontaneous breathing Set Vt, Ti and RR to match the breathing pattern observed during NAVA. Make sure each change in level does not increase the pressure by more than 1 cmH2O.~Mode PCV no spontaneous breathing-do ZAM after each PS level Increase PSV level from 8 to 20 in steps of 1 cmH2O every 2 minutes. Be careful at the higher pressures."
61970158|NCT01989078|EXPERIMENTAL|Losartan|Participants taking losartan, in addition to taking hydroxyurea therapy, as prescribed per standard of care
61970159|NCT05841394|ACTIVE_COMPARATOR|Esomeprazole Sodium|40 mg twice daily (q12h)
61970160|NCT05841394|EXPERIMENTAL|Ilaprazole Sodium|10 mg once daily, 20 mg dosed in the first day.
61970161|NCT05087212|EXPERIMENTAL|plerixafor|Participants will receive the first dose of plerixafor by subcutaneous (SC) injection on the evening of Day 4 (10 to 11 hours (± 1 hour) prior to the start of next day's apheresis). For a maximum of 4 days, patients will continue to receive daily plerixafor in the evening, followed by a morning dose of G-CSF and apheresis for up to a maximum of 4 apheresis or until ≥ 6×106 Cluster of differentiation 34 (CD34) + cells/kg were collected.
61970162|NCT04967833|EXPERIMENTAL|Tumor Infiltrating Lymphocytes|1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
61970163|NCT04769440|ACTIVE_COMPARATOR|M group (Mg sulphate )|patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes
61970164|NCT04769440|NO_INTERVENTION|C group (control )|patients will receive 100 ml of normal saline intravenously over 30 minutes followed by saline infusion for 90 minutes
61970165|NCT00872534|EXPERIMENTAL|PL-2200|PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
61970166|NCT00872534|ACTIVE_COMPARATOR|Aspirin|Immediate release 325mg aspirin
62510269|NCT03337217|EXPERIMENTAL|Prone Position|Position during colonoscopy
61970167|NCT03823352|EXPERIMENTAL|Antroquinonol|Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
62145585|NCT05026970|ACTIVE_COMPARATOR|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
61970168|NCT01779102|EXPERIMENTAL|0.1 µg C-Tb|The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
62145586|NCT05026970|ACTIVE_COMPARATOR|Biofeedback+Kegel|Biofeedback (6 sessions) Kegel exercises (twice daily)
62510270|NCT03337217|ACTIVE_COMPARATOR|Left lateral decubitus position|Position during colonoscopy
62510271|NCT00465231|ACTIVE_COMPARATOR|1|Epidural
62510272|NCT00465231|PLACEBO_COMPARATOR|2|Epidural - saline solution
62510273|NCT03767517|EXPERIMENTAL|Active Intervention|Usual Care + Tele-consult Intervention
62510274|NCT03767517|ACTIVE_COMPARATOR|Usual Care|Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
62510275|NCT00941720|EXPERIMENTAL|Busulfan Treatment|
62510276|NCT05146726||Prospective BARMER insured patients|"Group I: BARMER insured patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10%.~Central measures in this group are the IV contract for the creation of an organizational and financing structure for the guideline-compliant detection, diagnosis and treatment of preoperative anemia and the evaluation of the machine autotransfusion as part of the preoperative premedication visit in anesthesiology (implementation is the responsibility of the patient blood management (PBM) service)."
62510277|NCT05146726||Retrospective patients insured with another statutory health insurer than BARMER|Group II: Patients not insured with BARMER and with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10% and receive early anemia detection.
62510278|NCT06437314|EXPERIMENTAL|Aquatic program based on the back school|Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
62510279|NCT06437314|NO_INTERVENTION|Control|They will continue with their usual lifestyle.
61970169|NCT01779102|ACTIVE_COMPARATOR|2 T.U Tuberculin PPD RT 23 SSI|The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
61970170|NCT01779102|EXPERIMENTAL|0.1 µg C-Tb / 2 T.U Tuberculin PPD|The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme
61970171|NCT03026452|EXPERIMENTAL|RFA(radiofrequency ablation)|The investigators used percutaneously US-guided RFA(radiofrequency ablation) for small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
61970172|NCT04900220|ACTIVE_COMPARATOR|Betamethasone|betamethasone
61970173|NCT04900220|ACTIVE_COMPARATOR|Methylprednisolone|methylprednisolone
61970174|NCT01036841|ACTIVE_COMPARATOR|desmopressin tablet|
61970175|NCT01036841|EXPERIMENTAL|desmopressin MELT-formulation|
62510280|NCT05162729|EXPERIMENTAL|Working memory intervention group|Receive game-like working memory online training for 5 weeks, 3 times per week, each lasting for15 minutes.
61970176|NCT01598012|EXPERIMENTAL|Ayurved Siriraj Prasaplai|
62510281|NCT05162729|ACTIVE_COMPARATOR|Social emotional intervention group|Receive game-like social-emotional online training for 5 weeks, 3 times per week, each lasting for 15 minutes.
62510282|NCT05162729|NO_INTERVENTION|Control group|Receive no training
62510283|NCT06123026|EXPERIMENTAL|Cabergoline|1mg oral cabergoline administered once after patient's procedure
62510284|NCT06123026|PLACEBO_COMPARATOR|Placebo|1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure
61970177|NCT01598012|PLACEBO_COMPARATOR|placebo|
61970178|NCT03592199|EXPERIMENTAL|1st Line Sunitinib and 2nd Line Axitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
61970179|NCT00318110|EXPERIMENTAL|MUD treatment|NST using MUD for metastatic renal cell carcinoma
61970180|NCT06293755|EXPERIMENTAL|Microneedle patch with Botulinum toxin|Participants recieve microneedle path with 20 units Botulinum toxin at nose and cheek one side.
62510285|NCT01610063|EXPERIMENTAL|Guided|A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
62510286|NCT01610063|NO_INTERVENTION|Unguided|Treatment as usual
62510287|NCT01841073|EXPERIMENTAL|Inulin|Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
62510288|NCT01841073|PLACEBO_COMPARATOR|Cellulose|Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.
62510289|NCT02751827||Prospective cohort|"Prospective cohort involving patients treated in four distinct centers. Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
61970181|NCT06293755|ACTIVE_COMPARATOR|Intradermal Botulinum toxin injection|Participants recieve intradermal 20 units Botulinum toxin injection at nose and cheek in other side.
61970182|NCT03123653|EXPERIMENTAL|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.
61970183|NCT01090336||Clopidogrel group|At the discretion of the attending cardiologist patients are treated with clopidogrel (600mg loading and 75mg daily dose)
61970184|NCT01090336||Prasugrel group|At the discretion of the attending cardiologist patients are treated with prasugrel (60mg loading and 10mg daily dose)
61970185|NCT04811989|EXPERIMENTAL|Video Watching Group|Participants will watch an instructive video on diabetic foot care and will receive face-to-face teaching on diabetic foot care.
61970186|NCT04811989|EXPERIMENTAL|Real-time Leaflet Reading Group|Participants will receive a leaflet with diabetic foot care information, whose reading will be guided in real-time by the Researcher, and will also receive face-to-face teaching on diabetic foot care.
62145587|NCT02573129|EXPERIMENTAL|Red Meat Restricted|Following a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is restricted in lean, minimally processed red meat for 5 weeks.
62145588|NCT02573129|EXPERIMENTAL|Red Meat Rich|Following a 4-wk wash out period and a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is rich in lean, minimally processed red meat for 5 weeks.
62145589|NCT02206815|ACTIVE_COMPARATOR|Ticagrelor+Warfarin|Ticagrelor:Plain, round, yellow, film-coated tablet, 90mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
62145590|NCT02206815|ACTIVE_COMPARATOR|Clopidogrel+Aspirin+Warfarin|Clopidogrel:Light red bisulfate tablets, containing one 75mg; Aspirin:Plain, round, white, film-coated tablet, 100mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
62145591|NCT06020300|EXPERIMENTAL|Colchicine Post ST Elevation Myocardial Infarction (STEMI)|32 patients with STEMI are assigned for oral colchicine 0.6 mg once daily upon admission for 30 days
62145592|NCT06020300|PLACEBO_COMPARATOR|Placebo (Pyridoxine) Post ST Elevation myocardial Infraction (STEMI)|Another 32 patients with STEMI are assigned for placebo (oral pyridoxine 10 mg) once daily upon admission for 30 days
62145593|NCT03842332|EXPERIMENTAL|Resilience Training|This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
62145594|NCT03842332|NO_INTERVENTION|Standard Care|This group will receive case management referral to community training programs when requested by family, or need (as identified by case worker). Standard case management includes intake includes housing counseling, case management with mental health and behavioral services, and referral to day programs as needed and identified by case management
62145595|NCT05688605|EXPERIMENTAL|MRG003+HX008|"MRG003 will be administrated via intravenous infusion at 1.5, 2.0 mg/kg (MTD=2.5 mg/kg) once on Day 1 of every 3 weeks (21-day cycle).~HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day cycle)."
62510290|NCT02751827||Retrospective cohort A|"Retrospective cohort of patients treated at the Institut Bergonié (Bordeaux, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
61970187|NCT04811989|ACTIVE_COMPARATOR|Standard Care Group|Participants will receive the standard care that includes face-to-face teaching about diabetic foot care and will take a leaflet on diabetic foot care to read at home.
61970188|NCT00007657|EXPERIMENTAL|1|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
61970189|NCT00007657|ACTIVE_COMPARATOR|2|Intensive medical therapy
61970190|NCT05563233|EXPERIMENTAL|Helfer Skin Tap|"Helfer Skin Tap (rhythmic tapping of the skin at the injection site to relax the muscles during injection) is an effective method in reducing pain in intramuscular applications in studies performed with the injection technique.~Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~During the intramuscular injection to be applied to the ventrogluteal region, the level of pain and fear will be examined using the Helfer skin tap technique.~5 minutes after the injection, the pain and fear level of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
61976255|NCT03965533|EXPERIMENTAL|Part B: GSK2831781 150 mg SC|Caucasian male participants were administered a single SC injection of a unit dose strength of 150 mg per milliliter (mL) of GSK2831781, diluted in 0.9% w/v saline. Participants also received 2 dummy injections of 0.9% w/v saline placebo SC to maintain the blinding.
62145596|NCT03305172|NO_INTERVENTION|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
62351617|NCT00745953|ACTIVE_COMPARATOR|Hydrochlorothiazide|This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 \& 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, \& 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 \& 3 are needed for the adjustment of medication to the final dose level. During visits 4 \& 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
62145597|NCT03305172|EXPERIMENTAL|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
62145598|NCT03305172|EXPERIMENTAL|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
62351618|NCT03225937|EXPERIMENTAL|Cohort A|Trastuzumab and lapatinib
62351619|NCT03225937|EXPERIMENTAL|Cohort B|Pertuzumab and Trastuzumab-emtansine
62510291|NCT02751827||Retrospective cohort B|"Retrospective cohort of patients treated at the Centre Antoine Lacassagne(Nice, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
61970191|NCT05563233|EXPERIMENTAL|Shotblocker|"Shotblocker is a flat, horseshoe-shaped device with short, non-sharp 2 mm thick blunt protrusions that connect with the skin, and a hole in the middle to expose the injection site used to reduce pain during subcutaneous or intramuscular injection applications.~Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~During the intramuscular injection to be applied to the ventrogluteal region, the level of pain and fear will be examined by using Shot Blocker.~5 minutes after the injection, the pain and fear levels of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
61970192|NCT05563233|NO_INTERVENTION|control group|"Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~The level of pain and fear will be examined during intramuscular injection into the ventrogluteal region without any intervention.~5 minutes after the injection, the pain and fear level of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
61970193|NCT01010516|ACTIVE_COMPARATOR|High-dose rosuvastatin|40 mg of rosuvastatin
61970194|NCT01010516|ACTIVE_COMPARATOR|Stain plus fenofibrate|existing statin plus micronized fenofibrate 200 mg
61970195|NCT01010516|ACTIVE_COMPARATOR|Statin plus niacin ER/laropiprant|existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
61970196|NCT02345694|EXPERIMENTAL|Effective CPAP|Continuous Positive Airway Pressure (RESMED S9™ Series), all the nights, during 8 weeks.
61970197|NCT02345694|SHAM_COMPARATOR|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (RESMED S9™ Sham-Continuous Positive Airway Pressure System), validated placebo of Continuous Positive Airway Pressure, all the nights, during 8 weeks.
61970198|NCT05692934|EXPERIMENTAL|HR20031 FDC 10/100/1000 mg in the fast state|
61970199|NCT05692934|EXPERIMENTAL|HR20031 FDC 10/100/1000 mg in the fed state|
61970200|NCT05692934|EXPERIMENTAL|HR20031 FDC 5/50/750 mg*2 in the fast state|
61970201|NCT05692934|EXPERIMENTAL|HR20031 FDC 5/50/750 mg*2 in the fed state|
61970202|NCT00969202|EXPERIMENTAL|Stereotactic Radiosurgery using NovalisTx|Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
61970203|NCT06215248||LEAD|LEAD diagnosis confirmed by by ankle-brachial index (≤0,9 or \>1,3) or angiography. Fontaine I-IV class symptoms.
61970204|NCT06215248||Controls|Matched with LEAD group's patients as much as possible for age, sex, smoking history, hypertension, diabetes, coronary artery disease.
62145599|NCT03305172|EXPERIMENTAL|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
62145600|NCT03305172|EXPERIMENTAL|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
62145601|NCT01858324|EXPERIMENTAL|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
62145602|NCT01858324|NO_INTERVENTION|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
62145603|NCT02596061|NO_INTERVENTION|Control|These participants are made aware of all smoking cessation services offered by the clinic, for example group counseling or individual counseling, but are not offered any rewards for participating in these activities.
62145604|NCT02596061|EXPERIMENTAL|Intervention-Rewards Only|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for completing these activities and for utilizing counseling services at the clinic. At the 2 mo. mark, these participants come to the clinic for a biochemical verification of their smoking status. Their rewards are contingent on successfully passing this verification test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
62351620|NCT02278081|EXPERIMENTAL|treatment group|The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
62351621|NCT02278081|PLACEBO_COMPARATOR|placebo group|The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
62351622|NCT00099788|EXPERIMENTAL|1|Ranolazine
62351623|NCT00099788|PLACEBO_COMPARATOR|2|Placebo
61970205|NCT04443725|EXPERIMENTAL|Hydroxychloroquine plus Sofosbuvir/Daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days, Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days
61970206|NCT04443725|ACTIVE_COMPARATOR|Standard of care|Hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days
61970207|NCT01860651|ACTIVE_COMPARATOR|Web-monitoring|"There is two arms for intervention:~1) Patients in treatment with medicine administrated at home and 2) patients in treatment with biologicals."
61970208|NCT01860651|NO_INTERVENTION|Control|"Patients in treatment with medicine administrated at home: routine outpatient controls, four times a year.~Patients in treatment with biologicals: retrospective routine treatment algorithm"
61970209|NCT03676595|EXPERIMENTAL|Group A|Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
61970210|NCT03676595|EXPERIMENTAL|Group B|Group B had no exercise in the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
62351624|NCT05708768||Acutely ill persons in the municipality|Patients recieving services from a rapid response vehicle manned with dedicated physicians from the municipality
62510292|NCT01293266|ACTIVE_COMPARATOR|Propofol|Anesthesia is changed from Sevoflurane to Propofol after obtaining baseline blood gas analysis from the heart catheterisation sheath.
62510293|NCT01293266|NO_INTERVENTION|Sevoflurane|Sevoflurane anesthesia is maintained after obtaining a baseline blood gas analysis.
62510294|NCT04871568|ACTIVE_COMPARATOR|Right subclavian vein catheterization|The temporary central dialysis catheter is placed in the right subclavian vein.
62510295|NCT04871568|ACTIVE_COMPARATOR|Right internal jugular vein catheterization|The temporary central dialysis catheter is placed in the right internal jugular vein.
62510296|NCT05434130|EXPERIMENTAL|High Dose Exercise|The investigators will provide exercise dose recommendations for initial visit until symptom resolution, and revise upon symptom resolution (to use for the subsequent 8 weeks). These include intensity (target HR) and volume (frequency/duration). Intensity is calculated as 90% of the HR at the end of the exercise test. The volume recommendation is 150 mins/week (\~30 min/day; 5 days/week). The mode of exercise is another consideration. This will be left to participant preference, so that the investigators do not exclude potential participants due to lack of access to specific exercise equipment.
62510297|NCT05434130|NO_INTERVENTION|Standard-of-care|Participants are instructed to perform activity in line with physician recommendations. This consists of a general recommendation (no specific HR/volume) or symptom limited physical activity.
62510298|NCT04592523||All Participants|Participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who initiate treatment for the first time with brigatinib in a routine clinical practical setting will be observed prospectively for up to 24 month-surveillance period.
62510299|NCT05769426||PCOS-PRE|20 pre-menopausal women who have been diagnosed with polycystic ovarian syndrome (PCOS) will be recruited for this cohort. Participants in this group will complete a semi-structured virtual interview about barriers to healthy behaviors, self-efficacy and health literacy. The will also complete a battery of surveys related to following domains: sleep, anxiety, depression, satisfaction, physical activity, and dietary habits.
62510300|NCT05769426||PCOS-POST|20 post-menopausal women who have been diagnosed with polycystic ovarian syndrome (PCOS) will be recruited to this cohort. Participants in this group will complete a semi-structured virtual interview and a battery of surveys related to following domains: sleep, anxiety, depression, satisfaction, physical activity, and dietary habits. They will also complete a single in-person visit to the University of Texas Medical Branch where they will undergo a DEXA scan, anthropometric measurements and blood draw.
62510301|NCT05769426||CON-POST|20 post-menopausal women who have not been diagnosed with polycystic ovarian syndrome (PCOS) will be recruited for this cohort. Participants in this group will complete a battery of surveys related to following domains: sleep, anxiety, depression, satisfaction, physical activity, and dietary habits. They will also complete a single in-person visit to the University of Texas Medical Branch where they will undergo a DEXA scan, anthropometric measurements and blood draw.
61970211|NCT01265290|EXPERIMENTAL|Telemetric ECG monitoring|Telemetric Full Disclosure ECG monitoring
62351625|NCT06066957|EXPERIMENTAL|Letermovir|"Will include those participants who receive letermovir for CMV prophylaxis as provided through the clinical trial. The exposed group will be ascertained prospectively over a one-year period (the post-intervention period)."
62351626|NCT05974046|EXPERIMENTAL|Treatment|\[14C\]IDV184001AN
62351627|NCT00660777|SHAM_COMPARATOR|1|Control Group
62351628|NCT00660777|ACTIVE_COMPARATOR|2|Therapy Group
62351629|NCT01337167|EXPERIMENTAL|V419|V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
62351630|NCT01337167|ACTIVE_COMPARATOR|Control|Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
62351631|NCT04097015|EXPERIMENTAL|Treatment|The treatment or intervention is the use of NI-ES using a signal generator, Alpha-Stim M, with an Ocular Interface connected to one channel and a Spinal Interface to the other channel. The treatment is done at home for 40 minutes at a time, twice a day. The upper lids of the closed eyes are treated for 10 minutes and the lower lids of the closed eyes are treated for 10 minutes, alternated throughout the treatment time. The Spinal Interface is placed above the SCI for 40 minutes. The entire procedure is repeated for another 40 minutes for a second time. The participant will treat himself at home.
62510302|NCT02538835|EXPERIMENTAL|Metacognitive Therapy|
62510303|NCT02538835|ACTIVE_COMPARATOR|Mindfulness based cognitive therapy|
62510304|NCT02538835|PLACEBO_COMPARATOR|Support groups|
62510305|NCT04407299||1|180 patients diagnosed with autoimmune rheumatic disease. Patients are RA SLE Rhupus AS Behcet Sjogren Vasculitis FM Polymyalgia APA Sarcoidosis IBD Scleroderma DM PSA Mixed
62510306|NCT04407299||2|control group composed of 180 healthy individuals (matched for age and sex)
62510307|NCT04825002|EXPERIMENTAL|Urinary multimarker sensor arm|A urine of this group will be collected and measured using a newly developed urinary multimarker sensor (ANXA3, PSMA, ERG, ENG)
62510308|NCT05882734|EXPERIMENTAL|Dosing Regimen 1 (Phase 1b): M1774 + Cemiplimab|
61970212|NCT01265290|EXPERIMENTAL|24 hours standard Holter monitoring|
61970213|NCT06000514|EXPERIMENTAL|Topical Sm29 and Sbv|Use of topical Sm29 twice a day during 20 days and systemic Sbv during 20 days
61970214|NCT06000514|PLACEBO_COMPARATOR|Topical Placebo and Sbv|Use of topical placebo twice a day during 20 days and systemic Sbv during 20 days
62510309|NCT05882734|EXPERIMENTAL|Dosing Regimen 2 (Phase 1b): M1774 + Cemiplimab|
62510310|NCT05882734|EXPERIMENTAL|Stratum A (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b|
62510311|NCT05882734|EXPERIMENTAL|Stratum B (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b|
61970215|NCT02558140|EXPERIMENTAL|Part 1: Dose Escalation|All participants will be given RO6874813 as a single low dose of 0.5 milligrams per kilogram (mg/kg) via intravenous (IV) infusion in a 7-day pharmacokinetic (PK) run-in period (Cycle 0). This is followed by dose escalation (Cycle 1) for which participants will receive escalating doses of RO6874813 (starting dose = 1 mg/kg) via IV infusion every week (qw) or every 2 weeks (Q2W) for 28 to 42 days to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
61970216|NCT02558140|EXPERIMENTAL|Part 2: Tumor Biopsy and Imaging|The first 15 participants with fibroblast activation protein-alpha positive (FAP+) tumors will be treated at the RP2D and dosing schedule as determined in Part 1, and will undergo paired tumor biopsies for biomarker assessments. Up to 5 participants with FAP+ tumors will undergo baseline and on-treatment tumor biopsies for biomarker assessments at a dose below the RP2D. The dose for these participants can be escalated to RP2D after 4 weeks of treatment and upon completion of biomarker assessment.
62351632|NCT04711499|EXPERIMENTAL|Fatigue Group|The trial will recruit trainee anaesthetists of ST3 grade or higher who take part in a resident night-shift rota at Nottingham University Hospitals NHS Trust. Participants will undergo baseline psychometric testing to measure baseline mood. There will be a series of questions to ascertain levels of fatigue. All participants will then be asked to perform a standardised ultrasound-guided peripheral nerve blockade task using a high fidelity bench-top phantom model. Performance in this task will be independently assessed using a previously-validated scoring tool by two raters blinded to participant group allocation.
61970217|NCT02558140|EXPERIMENTAL|Part 3: Preliminary Efficacy Assessment|Participants with locally advanced or metastatic non-resectable FAP+ sarcoma will be treated with RO6874813 at the RP2D and as per schedule determined upon completion of Part 1. Participants continuing treatment with RO6874813 beyond 36 weeks will enter the extension phase of Part 3 and will be monitored for disease status and clinical safety per routine standard of care.
61970218|NCT06190223||PPTB Group|Patients will undergo anterior cruciate ligament reconstruction with the novel PPTB graft and a tibial press-fit technique.
61970219|NCT02684760|EXPERIMENTAL|Cohort 1: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
61970220|NCT02684760|EXPERIMENTAL|Cohort 2: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
62351633|NCT04711499|ACTIVE_COMPARATOR|Non Fatigued group|The non fatigued group will be asked to perform the same series of questions and tasks after a night at home with no work duties or commitments
62351634|NCT05730257|EXPERIMENTAL|Robot-assisted Kidney Transplantation (RAKT)|"Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels.~Participants will be managed according to the standard protocol for renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality. The anaestethic protocol will be tailored to suit robot-assisted surgery"
62351635|NCT05730257|ACTIVE_COMPARATOR|Open Kidney Transplantation (OKT)|"Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels.~Participants will be managed according to the standard protocol for anaesthesia and renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality."
62351636|NCT03825263|NO_INTERVENTION|Control|Participants receive normal treatment
62351637|NCT03825263|EXPERIMENTAL|Intervention|Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment
62351638|NCT02878512|ACTIVE_COMPARATOR|PCNL under General Anesthesia|Patients were premedicated with Inj. Atropine 0.06 mg intramuscularly half an hour prior to surgery, IV ranitidine 1mg kg-1, IV ondansetron 0.08mg kg-1 IV midazolam 0.02mg kg-1 and Pentazocine 0.3 mg/kg. Anaesthesia was induced with IV Thiopentone sodium 3-5 mg kg-1 and Vecuronium 0.1mg kg-1.and then intubated. Anaesthesia was maintained on 50 %:50% nitrous oxide and oxygen, vecuronium and propofol infusion . At the end of the surgery postoperative analgesia was given with IV tarmadol and local nfiltration with 0.25% bupivacaine at the surgical site. Patients were reversed with IV glycopyrrolate 0.008mg kg-1 and IV neostigmine 0.06mg kg-1 and extubated.
62510312|NCT05882734|EXPERIMENTAL|Stratum C (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b|
62510313|NCT00328679|EXPERIMENTAL|A|
62510314|NCT01959490|EXPERIMENTAL|Cohort 1P (HER2 positive)|Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
62510315|NCT01959490|EXPERIMENTAL|Cohort 1T (HER2 positive)|Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
62510316|NCT01959490|EXPERIMENTAL|Cohort II (HER2 negative)|Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.
61970221|NCT02684760|EXPERIMENTAL|Cohort 3: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
61970222|NCT02684760|EXPERIMENTAL|Cohort 4: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
61970223|NCT02684760|EXPERIMENTAL|Cohort 5: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
62510317|NCT01459263||GSV insufficiency|Patients with insufficiency of the greater saphenous vein (GSV) will be included.
62510318|NCT02610270|EXPERIMENTAL|2 Gums|Athletes that continued their usual training and diet, who took 2 gums of omega 3 (DHA 760 mg) during the experimental period.
62145605|NCT02596061|EXPERIMENTAL|Intervention-Pre-Commitment|Patients have access to a website where they can self-report smoking status, add supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. At enrollment, patients are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4 mos. and starts 2 mos. after the rewards contract. If, at the end of 6 mos., the patients pass the second verification test, their rewards are returned to them. At the 2 mo. mark, patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
62351639|NCT02878512|EXPERIMENTAL|PCNL under Segmental epidural Anesthesia|epidural space was located at T12 -L1 or L1-L2 space .The epidural catheter was inserted cephalad 5 cm upwards in the epidural space (tip approximately at T8 to T9). and test dose of 3 ml of 2% Adrenalized Lignocaine was administered..loading dose of 0.5% Bupivacaine, approximately 8 to 10 ml was injected epidurally with regular negative aspiration to block T6- T12 segments, if desired level was not achieved then additional dose of 1 to 1.5 ml 0.5% bupivacaine per spared segment was given to achieve the desired level.Motor blockade of the lower limbs was checked and noted before lithotomy, before prone and at the end of the surgery using Bromage scale. After two segment regression of sensory level epidural top up with 1/4th of initial dose 2 to 3 ml of 0.5% Bupivacaine was given. At the end of the surgery 8ml of 0.125% Bupivacaine was administered for postoperative analgesia and the catheter was removed.
62351640|NCT00290589|EXPERIMENTAL|Intramuscular methylprednisolone acetate|Methylprednisolone acetate 160mg intramuscular injection
62351641|NCT00290589|PLACEBO_COMPARATOR|Placebo|Placebo intramuscular injection
62510319|NCT02610270|EXPERIMENTAL|3 Gums|Athletes that continued their usual training and diet, who took 3 gums of omega 3 (DHA 1140 mg) during the experimental period.
62510320|NCT02610270|NO_INTERVENTION|Control|Athletes and coaches that continued their usual training and diet, but did not take any supplements during the experimental period.
62510321|NCT02399384||HIV+/CAD+|HIV+/CAD+
62510322|NCT02399384||HIV+/CAD-|HIV+/CAD-
62510323|NCT02399384||HIV-/CAD+|HIV-/CAD+
62707581|NCT05378802|ACTIVE_COMPARATOR|PCV mode|"Increase PSV level from 8 to 20 in steps of 1 cmH2O every 2 minutes. Be careful at the higher pressures The idea is not to have pressures as high as 20 cmH2O, it is important to have high enough VCV \& PCV flow rates so we can match the flow rates during spontaneous breathing. You might find that 15 or 16 cmH2O is enough to generate flow rates that match the maximum flow rate you saw during spontaneous breathing."
62707582|NCT05923684|EXPERIMENTAL|NLP Intervention Experimental Arm|20 men with newly diagnosed clinically localized prostate cancers and utilize NLP to extract key content using the top five sentences by NLP probability for key content areas will be generated and will be provided to patients and providers within 2 weeks after each case.
62707583|NCT06563765|EXPERIMENTAL|FAP-targeting PET/CT imaging|FAP-targeting PET/CT imaging will be performed on the enrolled patients.
62351642|NCT01454479|EXPERIMENTAL|Lapatinib (Tykerb) Plus Ixabepilone|
62510324|NCT01782534||aortic dissection|aortic dissection
62510325|NCT03743259|EXPERIMENTAL|LuminoMark inj. 0.1mL|Injection LuminoMark inj. 0.1mL once in this study.
62510326|NCT03743259|EXPERIMENTAL|LuminoMark inj. 0.2mL|Injection LuminoMark inj. 0.2mL once in this study.
62510327|NCT03743259|ACTIVE_COMPARATOR|Charcotrace Inj.|Charcotrace Inj. about 0.3\~1mL
62510328|NCT06533371|EXPERIMENTAL|Patients with pulmonary paraseptal or panlobular emphysema|"Ultrasonographic findings will be obtained with clinical machines. Additionally, ultrasonographic scans as acquired with research platform will also be gathered.~LUS findings will be compared to chest computed tomographic findings. Post-processing image analysis of chest CT findings will be performed on images by using automated detection of potential emphysema systems.~Finally, all COPD patients and subjects who participate in the screening program for lung cancer with CT evidence of paraseptal or panlobular emphysema will undergo respiratory oscillometry."
62510329|NCT06533371|EXPERIMENTAL|Healthy volunteers and participants without pulmonary emphysema|"Ultrasonographic findings will be obtained with clinical machines. Additionally, ultrasonographic scans as acquired with research platform will also be gathered.~LUS findings will be compared to chest computed tomographic findings. Post-processing image analysis of chest CT findings will be performed on images by using automated detection of potential emphysema systems."
62510330|NCT01461941|EXPERIMENTAL|Drug: 0.2% E6005 ointment|
62510331|NCT01461941|PLACEBO_COMPARATOR|Drug: 0.0% E6005 ointment (vehicle)|
62510332|NCT03250455||CTA+CTP|
62510333|NCT03250455||CTA only|
62510334|NCT02033135|EXPERIMENTAL|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy.
62510335|NCT02033135|ACTIVE_COMPARATOR|Best medical treatment|Unsupervised exercise therapy, smoking cessation advice and best medical therapy.
62510336|NCT02111122|EXPERIMENTAL|Sodium Oxybate|"Treatment (500mg Natrii oxybas/ml) will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. The dosage starts at 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
62510337|NCT02111122|PLACEBO_COMPARATOR|Placebo|"Treatment will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. As with the active compound, placebo will be given with a starting dose of 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
62510338|NCT02377180|EXPERIMENTAL|Part 1|Intramuscular injection of capsaicin for the study of pain and hyperalgesia
62510339|NCT02377180|ACTIVE_COMPARATOR|Part 2|Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.
61970224|NCT02684760|EXPERIMENTAL|Cohort 6: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
61970225|NCT02342327|OTHER|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
61970226|NCT02342327|OTHER|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
61970227|NCT04358380||Patients without Liver Injury|Hospitalized patients with COVID-19 disease who did not develop liver injury
61970228|NCT04358380||Patients with Liver Injury|Hospitalized patients with COVID-19 disease who develop liver injury
62351643|NCT04043715|OTHER|Comparison of transcutaneous & epidural stimulation|Comparison of transcutaneous vs epidural electrical stimulation
61970229|NCT04845789||Family caregivers|Family caregivers who were main caregiver to the person with dementia and who spent at least 10 hours a week providing care to the person with dementia.
61970230|NCT02079181|EXPERIMENTAL|Diagnostic (fluorine F 18 d-FMAU PET/CT scan)|Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
61970231|NCT01250834|EXPERIMENTAL|LY2189265 + Atorvastatin|"Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2.~Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3."
61970232|NCT06179797|SHAM_COMPARATOR|sham|BP cuff bilateral arm compression to 50 mmHg.
61970233|NCT06179797|ACTIVE_COMPARATOR|dose 1|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 2.5 minutes on/off for 4 cycles every other day.
61970234|NCT06179797|ACTIVE_COMPARATOR|dose 2|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off for 4 cycles every other day.
61970235|NCT06179797|ACTIVE_COMPARATOR|dose 3|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off once daily.
62351644|NCT03457103|EXPERIMENTAL|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
62351645|NCT03457103|ACTIVE_COMPARATOR|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
62351646|NCT06257537|EXPERIMENTAL|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 24 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3 megahertz(MHz) frequency and 0.132 watts/cm\^2 intensity.
62351647|NCT06257537|ACTIVE_COMPARATOR|SAM Ultrasound Device and SAM Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 24 weeks combined with SAM patch (0% diclofenac).
62351648|NCT06257537|ACTIVE_COMPARATOR|Diclofenac Patch|Patients wear 2.5% diclofenac patch for 4 hours at least 5 days a week for 24 weeks combined.
62351649|NCT06257537|PLACEBO_COMPARATOR|SAM Patch|Patients wear 0% diclofenac patch for 4 hours at least 5 days a week for 24 weeks combined.
62351650|NCT05649644|ACTIVE_COMPARATOR|Selective Trunk Block (SeTB)|Patient who scheduled an upper extremity surgery involving anywhere from the proximal humerus to distal hand or surgery involving any combination of these regions and randomized in SeTB group will receive a SeTB.It will be performed through two skin punctures and as three separate injections to the three trunks of the brachial plexus.
62351651|NCT05649644|ACTIVE_COMPARATOR|Supraclavicular Brachial Plexus Block (SC BPB)|Patient who scheduled an upper extremity surgery involving anywhere from the proximal humerus to distal hand or surgery involving any combination of these regions and randomized in SeTB group will receive a SC BPB. It will be performed using a single ultrasound window demonstrating the trunks and divisions of the brachial plexus in a superolateral position relative to the subclavian artery at the supraclavicular fossa.
62351652|NCT05576610|EXPERIMENTAL|Enzyme containing mouth spray + Standard Preventive Advice|Usage of Oral7 mouth spray along side with the Standard Preventive Advice
62351653|NCT05576610|PLACEBO_COMPARATOR|Normal Saline mouth spray +Standard Preventive Advice|Usage of normal saline containing mouth spray along side with the Standard Preventive Advice
62351654|NCT00400712|NO_INTERVENTION|Control|natural progression post-stroke
61970236|NCT06179797|ACTIVE_COMPARATOR|dose 4|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off twice daily.
62351655|NCT00400712|EXPERIMENTAL|Intervention|two weeks of goal directed intensive physical rehabilitation therapy at 6 months (and one year)
62351656|NCT06178900|EXPERIMENTAL|Assisted by the AI-Gatekeeper software group|After a baseline examination (chest X-ray, electrocardiogram, echocardiogram, clinical risk factors and blood test), the AI-Gatekeeper software will be used to guide clinical care.
62351657|NCT06178900|NO_INTERVENTION|Usual care group|The usual care group will be managed based on established guidelines.
62351658|NCT02128984|EXPERIMENTAL|Vitafos Junior|Symbiotic Formula with DHA and antioxidants
62510340|NCT02377180|ACTIVE_COMPARATOR|Part 3|Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.
62510341|NCT01416116|EXPERIMENTAL|Tramadol|Tramadol prior to QUTENZA
62351659|NCT02128984|ACTIVE_COMPARATOR|Standard Formula|Standard isocaloric and isonitrogenous formula.
62510342|NCT01416116|EXPERIMENTAL|Lidocaine|Lidocaine prior to QUTENZA
62510343|NCT02488031|EXPERIMENTAL|Error-reduction|The participants in the error-reduction group will participate in a 4-week home-based training intervention during the month between their pre- and post-test visits. During pre- and post- training visits, Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA), Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait analysis tests will be administered. Also biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted to evaluate the impact of the training on SCA individuals.
62539401|NCT06582056|OTHER|Healthy Participant or Participant with Gingivitis with Hemoglobin A1c level 6.5-7.8|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
62351660|NCT05202223|EXPERIMENTAL|Harmony at HOME|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
62351661|NCT03700632|EXPERIMENTAL|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week.
61970237|NCT00194064|EXPERIMENTAL|Olanzapine|Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg
61970238|NCT03826407||DOC patients|Patients in coma (GCS score of 3-8) or with other disorder of consciousness, primarily Minimally Conscious State (MCS) or Unresponsive Wakefulness Syndrome (UWS; also known as vegetative state)
61970239|NCT03826407||Healthy Control|Matched healthy controls without current neurological diagnoses
61970240|NCT03755492||Group 1 (Provided absorbent pads)|Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
61970241|NCT03755492||Group 2 (not provided absorbent pads)|Patients enrolled in the control arm will not receive absorbent pads.
61970242|NCT00429273|ACTIVE_COMPARATOR|Group 1: Guan-Guan+Placebo|weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
61970243|NCT00429273|ACTIVE_COMPARATOR|Group 2: Placebo-Placebo+DMPH|weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
61970244|NCT00429273|EXPERIMENTAL|Group 3: Guan-Guan+DMPH (Comb)|weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH
62351662|NCT03700632|NO_INTERVENTION|Control|no intervention will be done
61970245|NCT02377245||Juvenile Inflammatory Rheumatism|Juvenile Inflammatory Rheumatism patients
61970246|NCT04167202|EXPERIMENTAL|Hydrogen-rich water|Six 30-min ankle baths with hydrogen-rich water (one hydrotherapy every 4 hours)
61970247|NCT04167202|ACTIVE_COMPARATOR|RICE protocol for acute injury|RICE protocol include: (1) rest, (2) ice packs every 20 min every 3 hours (total of 8 sessions), (3) compression with elastic bandage for 24 h, and (4) leg elevation at all possible times of the injured area above the level of the heart
62351663|NCT00045487|EXPERIMENTAL|OSI-774|
61970248|NCT02272920|EXPERIMENTAL|Renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation: Medtronic Symplicity Flex, Medtronic Symplicity Spyral or St Jude EnligHTN.~Renal denervation is performed within seven days after PCI in patients with acute myocardial infarction and hypertension."
61970249|NCT02272920|NO_INTERVENTION|Control: Standard of care|Standard-of-care follow-up after ACS. Including nurse and physician out-patient visits.
61970250|NCT00447161|EXPERIMENTAL|1|Bacillus Clausii Multi ATB Resist
61970251|NCT00447161|PLACEBO_COMPARATOR|2|Placebo
61970252|NCT03950167||Hyperemesis gravidarum|pregnant women before 14 weeks of pregnancy diagnosed with hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
61970253|NCT03950167||Healthy pregnant women|Healthy pregnant women before 14 weeks of pregnancy without hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
61970254|NCT01171339|NO_INTERVENTION|Control|"Usual care in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
61970255|NCT01171339|EXPERIMENTAL|Intervention arm|"Intervention: Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
61970256|NCT00754819|ACTIVE_COMPARATOR|1|Colchicine 1mg daily oral
61970257|NCT00754819|PLACEBO_COMPARATOR|2|Placebo 1 capsule daily oral
62351664|NCT02528968|OTHER|Educational Package|Patients will receive a standardised PK focused educational package in the form of a short video film.
61970258|NCT01595698|SHAM_COMPARATOR|Control|
61970259|NCT01595698|EXPERIMENTAL|Physical Exercise|
61970260|NCT01919125|EXPERIMENTAL|Cohort 1: Child-Pugh Class A|Participants with mild hepatic impairment (Child-Pugh Class A score = 5-6) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
62351665|NCT01597011||Fibrin sealant group|Patients who have undergone laparoscopic inguinal hernia repair with fibrin sealant for mesh fixation
62351666|NCT01597011||Tissue-penetrating fixation group|Patients who have undergone laparoscopic inguinal hernia repair with the use of tacks, staples or sutures for mesh fixation
62351667|NCT05161312|EXPERIMENTAL|iACT-BC: Oncovox experimental|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years.
62351668|NCT05161312|NO_INTERVENTION|Wait list control group|Wait list, treatment as usual
62351669|NCT01682967||Experimental group|Patients suffering from PDPH would form this group
62351670|NCT01682967||Control group - Epidural|Patients who received an epidural during labour but did not have symptoms of PDPH would form this reference group
62351671|NCT01682967||Control Group without Epidural analgesia|Patients in labour who did not receive an EDA would form this cohort of controls
62145606|NCT02596061|EXPERIMENTAL|Intervention-Commitment|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. After 2 mos., this group is offered the chance to set aside some of their rewards towards a deposit contract that lasts for 4 months. If, after the 4 mos., the patients pass the second cessation verification test, their rewards are returned to them. At the 2 mo. mark, these patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
62351672|NCT02120144|EXPERIMENTAL|Intervention|15 young patients (\<65 years old) and 15 older patients (\>64 years old) are submitted to an observation phase and an imagination phase of walking at a precise rythm for 10 minutes
62351673|NCT02120144|ACTIVE_COMPARATOR|Reading|15 young patients (\<65 years old) and 15 older patients (\>64 years old) are submitted to a reading phase on a computer for 10 minutes.
61970261|NCT01919125|EXPERIMENTAL|Cohort 2: Child-Pugh Class B|Participants with moderate hepatic impairment (Child-Pugh Class B score = 7-9) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
61970262|NCT01919125|EXPERIMENTAL|Cohort 3: Child-Pugh Class C|Participants with severe hepatic impairment (Child-Pugh Class C score = 10-15) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
61970263|NCT03074591|ACTIVE_COMPARATOR|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
61970264|NCT03074591|PLACEBO_COMPARATOR|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
61970265|NCT04712305||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
62351674|NCT01446679||atrovastatin group|Who receive atrovastatin
62351675|NCT03860350|ACTIVE_COMPARATOR|Aged Garlic Extract|The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
62351676|NCT03860350|PLACEBO_COMPARATOR|Placebo|The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
62351677|NCT04591210|NO_INTERVENTION|No Treatment (Standard of Care)|Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.
62351678|NCT04591210|EXPERIMENTAL|ACEi treatment|The physician will initiate any ACE inhibitor and dose at their discretion.
61970266|NCT04712305||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
61970267|NCT05532839|EXPERIMENTAL|High intensity interval training|High-intensity interval training is a training that cycles between high bursts of activity and predetermined times of less intensive exercise or rest period.
61970268|NCT05532839|EXPERIMENTAL|Moderate intensity continuous interval training|Moderate-intensity continuous training consists of periods followed by 50 minutes of exercise - bicycling, running, jogging, marching, paddling, etc. - at a recorded frequency of 70-75 percent maximal heart rate.
62145607|NCT01253798|ACTIVE_COMPARATOR|Group training on land|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
62145608|NCT01253798|ACTIVE_COMPARATOR|Group training in water|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip
62145609|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
62145610|NCT04864899|EXPERIMENTAL|Recovered COVID-19 patients|
62145611|NCT04864899|EXPERIMENTAL|Recovered non-COVID-19 viral respiratory infections patients|
62145612|NCT04864899|EXPERIMENTAL|Age and gender matched controls|
62351679|NCT04591210|EXPERIMENTAL|ARB treatment|The physician will initiate any ARB and dose at their discretion.
62351680|NCT06303349|EXPERIMENTAL|experimental arm|"Patients with subarachnoid hemorrhage, whether aneurysmal or non-aneurysmal, who were admitted to the neuro-resuscitation unit within four days of onset.~Diagnosis was based on clinical presentation and confirmed by brain imaging"
62351681|NCT05145712|EXPERIMENTAL|Bowel readiness|
62351682|NCT05027919|OTHER|Within-subject design|All participants will undergo the same study design, which includes morphine stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).
62351683|NCT04164329||Exposed group|The exposed group will be composed by the patients that undergo CRT/ICD implantation (general anesthesia).
61970269|NCT04878588||patients receiving esophagectomy|the patients receiving esophagectomy during perioperative period. They receive barium examination and high resolution impedance manometry at the same time
61970270|NCT02671396|EXPERIMENTAL|Virtual reality based intervention|Virtual reality based balance training
61970271|NCT02671396|ACTIVE_COMPARATOR|Conventional intervention|Conventional balance training
61970272|NCT05156853|EXPERIMENTAL|Insect-based menu|Replacement of meat proteins with insect-based alternatives at main meals 3 times weekly.
61970273|NCT05156853|ACTIVE_COMPARATOR|Plant-based menu|Replacement of meat proteins with plant-based alternatives at main meals 3 times weekly.
61970274|NCT06474052||Gelofusine 4%|Adult patients undergoing uncomplicated vascular surgery.
61970275|NCT03752580|EXPERIMENTAL|Arm|Experimental: User Instructions of a Novel Nasal Mask Participants to interpret user instructions in a one hour daytime visit.
61970276|NCT04012775|ACTIVE_COMPARATOR|Insulin Humulin® NPH|Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
61970277|NCT04012775|EXPERIMENTAL|Insulin Rinsulin® NPH|Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
61970278|NCT01691001|EXPERIMENTAL|dexmedetomidine|
62510344|NCT02488031|EXPERIMENTAL|Best Medical Management|The participants in the best medical management group will undergo identical testing sessions (two visits one month apart) as those in the error-reducing group but will not receive the 4-week error reducing intervention. They will be administered the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) assessments and the following tests: Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait. Biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted at both visits.
62510345|NCT04509999|EXPERIMENTAL|Standard of care and Experimental treatment of Bicalutamide|Each subject will be administered bicalutamide 150 mg daily at 1:1 randomization for up to 4 weeks.
61970279|NCT01691001|PLACEBO_COMPARATOR|placebo group|normal saline
61970280|NCT06043440|ACTIVE_COMPARATOR|Oxygen plus supportive care (OXT)|Nocturnal oxygen therapy plus providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.
61970281|NCT06043440|NO_INTERVENTION|Supportive care (SC)|Providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.
61970282|NCT04369521|EXPERIMENTAL|Intervention|low free sugar diet with nutrition and exercise recommendation
61970283|NCT04369521|NO_INTERVENTION|control|regular diet with nutrition and exercise recommendation
61970284|NCT03510884|EXPERIMENTAL|Placebo/Alirocumab Q2W|Participants received subcutaneous (SC) injection of placebo (matched to alirocumab) based on their body weight (BW) (less than \[\<\] 50 kilograms \[kg\] or greater than or equal to \[\>=\] 50 kg) Q2W for 24 weeks in DB treatment period added to stable LMT. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 40 milligrams (mg) (for BW \<50 kg) or 75 mg (for BW \>=50 kg) Q2W from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 40 mg to 75 mg when BW increased from \<50 kg to \>=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 40 mg to 75 mg (for BW \<50 kg) or 75 mg to 150 mg (for BW \>=50 kg) or down titrated as 75 mg to 40 mg (for BW \<50 kg) or 150 mg to 75 mg (for BW \>=50 kg).
61970285|NCT03510884|EXPERIMENTAL|Alirocumab Q2W|Participants received SC injection of alirocumab 40 mg (for BW \<50 kg) or 75 mg (for BW \>=50 kg) Q2W for 24 weeks in DB treatment period added to stable LMT. Alirocumab dose was up-titrated to 75 mg or 150 mg Q2W from Week 12, when LDL-C level was \>=110 milligrams per deciliter (mg/dL) (2.85 millimoles per liter \[mmol/L\]) at Week 8. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 40 mg (for BW \<50 kg) or 75 mg (for BW \>=50 kg) from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 40 mg to 75 mg when BW increased from \<50 kg to \>=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 40 mg to 75 mg (for BW \<50 kg) or 75 mg to 150 mg (for BW \>=50 kg) or down titrated as 75 mg to 40 mg (for BW \<50 kg) or 150 mg to 75 mg (for BW \>=50 kg).
61970286|NCT03510884|EXPERIMENTAL|Placebo/Alirocumab Q4W|Participants received SC injection of placebo (matched to alirocumab) based on their BW (\<50 kg or \>=50 kg) Q4W for 24 weeks in DB treatment period added to stable LMT. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 150 mg (for BW \<50 kg) or 300 mg (for BW \>=50 kg) Q4W from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 150 mg to 300 mg when BW increased from \<50 kg to \>=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 150 mg Q4W to 75 mg Q2W (for BW \<50 kg) or 300 mg Q4W to 150 mg Q2W (for BW \>=50 kg) or down titrated as 75 mg Q2W to 40 mg Q2W (for BW \<50 kg) or 150 mg Q2W to 75 mg Q2W (for BW \>=50 kg).
62145613|NCT04627168|EXPERIMENTAL|Spinal cord injured persons|Persons living with spinal cord injury presenting with constipation due to neurogenic bowel dysfunction.
62145614|NCT04627168|EXPERIMENTAL|Persons without neurogenic bowel dysfunction|Abled-bodied persons with chronic constipation.
62145615|NCT01965990||NEP|Patients undergoing the administration of a homemade very low-calorie protein-based formula (2000 mL per day) by enteral route for 14 days
62145616|NCT04412005||Manhiça|Pregnant women attending the Manhiça District Hospital
62145617|NCT04412005||Ilha Josina|Pregnant women attending the Ilha Josina Health Center
62145618|NCT04412005||Magude|Pregnant women attending the Magude Health Center
62145619|NCT01128959|EXPERIMENTAL|Intravenous Carbamazepine (IV CBZ)|
62145620|NCT05454943|EXPERIMENTAL|Standardized TRE protocol + External Support|Participants will be asked to follow a standardized 16:8 TRE protocol with an 11 am to 7 pm eating window for 16 weeks. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
62145621|NCT05454943|EXPERIMENTAL|Standardized TRE protocol + Peer Support|Participants will be asked to follow a standardized 16:8 TRE protocol with an 11 am to 7 pm eating window for 16 weeks. Each participant will be matched with another participant in the same group to provide peer-based support to adhere to TRE. Study staff will introduce pairs and provide an introduction to TRE and then pairs will meet by phone/video at weeks 1, 3, 6, and 12 at a minimum, with additional contact encouraged.
62707584|NCT05238792|EXPERIMENTAL|Arm A for patients age ≥18 years and <70 years|Arm A will enroll patients age ≥18 years and \<70 years. TAA-T product will first be administered to patients as monotherapy at dose level 1 to determine safety. Following demonstration of safety in dose level 1, lymphodepleting chemotherapy will be administered prior to the first dose of TAA-Ts on the dose escalation phase (dose levels 2 and 3). The TAA-T product will be assessed for safety and anti-tumor activity.
62351684|NCT04164329||Not exposed group|The non-exposed group, or control group, will be composed by the patients undergo PM implantation (without anesthesia)
62351685|NCT02402712|EXPERIMENTAL|Herceptin SC + Perjeta IV + docetaxel IV|Single arm
62351686|NCT05113719|EXPERIMENTAL|Bridge exercise at knee angle 45 degree|The group will perform the bridge exercise at a 45-degree knee flexion angle.
62145622|NCT05454943|EXPERIMENTAL|Personalized TRE protocol + External Support|Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
62145623|NCT05454943|EXPERIMENTAL|Personalized TRE protocol + Peer Support|Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Each participant will be matched with another participant in the same group to provide peer-based support to adhere to TRE. Study staff will introduce pairs and provide an introduction to TRE and then pairs will meet by phone/video at weeks 1, 3, 6, and 12 at a minimum, with additional contact encouraged.
62145624|NCT05454943|NO_INTERVENTION|Control Group|Participants will be asked to maintain their usual diet and physical activity patterns for 16 weeks. They will receive the same number and timing of calls from study staff as the other groups (at randomization, 1, 3, 6, 12 weeks).
62145625|NCT01593644|EXPERIMENTAL|adenosine + dypiridamole|
62145626|NCT04541199|ACTIVE_COMPARATOR|Conventional|
61970287|NCT03510884|EXPERIMENTAL|Alirocumab Q4W|Participants received SC injection of alirocumab 150 mg (for BW \<50 kg) or 300 mg (for BW \>=50 kg) Q4W for 24 weeks in DB treatment period added to stable LMT. Alirocumab dose was up-titrated to 75 mg or 150 mg Q2W from Week 12, when LDL-C level \>=110 mg/dL (2.85 mmol/L) at Week 8. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 150 mg (for BW \<50 kg) or 300 mg (for BW \>=50 kg) from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 150 mg to 300 mg when BW increased from \<50 kg to \>=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 150 mg Q4W to 75 mg Q2W (for BW \<50 kg) or 300 mg Q4W to 150 mg Q2W (for BW \>=50 kg) or down titrated as 75 mg Q2W to 40 mg Q2W (for BW \<50 kg) or 150 mg Q2W to 75 mg Q2W (for BW \>=50 kg).
61970288|NCT05213650|NO_INTERVENTION|Invisalign control patients (liquid soap)|Patients who clean their plaques only with liquid soap and toothbrush
61970289|NCT05213650|EXPERIMENTAL|Invisalign non-abrasive toothpaste patients|Patients who clean their plaque with non-abrasive toothpaste and toothbrush
61970290|NCT05213650|EXPERIMENTAL|Invisalign abrasive toothpaste patients|Patients who clean their plaque with abrasive toothpaste and toothbrush
61970291|NCT05213650|EXPERIMENTAL|Invisalign Efferdent patients|Patients who clean their plaques with liquid soap and use Efferdent antibacterial cleaning tablet once a week
61970292|NCT05213650|EXPERIMENTAL|Invisalign Cleaning Crystals patients|Patients who clean their plaques with liquid soap and use Invisalign Cleaning Crystals tablet once a week
61970293|NCT04376710||Surgeons|
62145627|NCT04541199|EXPERIMENTAL|Closed-loop|
62145628|NCT02773732|EXPERIMENTAL|Ciprofloxacin Dose Level 0|
62145629|NCT02773732|EXPERIMENTAL|Ciprofloxacin Dose Level +1|
62145630|NCT02773732|EXPERIMENTAL|Ciprofloxacin Dose Level -1|
62145631|NCT04012905|EXPERIMENTAL|Short tapering corticosteroids|Corticosteroid taper over 28 weeks
62145632|NCT04012905|ACTIVE_COMPARATOR|Long tapering corticosteroids|Corticosteroid taper over 52 weeks
62145633|NCT01119651|EXPERIMENTAL|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
62145634|NCT01119651|EXPERIMENTAL|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
62351687|NCT05113719|EXPERIMENTAL|Bridge exercise at knee angle 60 degree|The group will perform the bridge exercise at a 60-degree knee flexion angle.
62351688|NCT05113719|EXPERIMENTAL|Bridge exercise at knee angle 90 degree|The group will perform the bridge exercise at a 90-degree knee flexion angle.
62351689|NCT01237561|EXPERIMENTAL|spirometry, patient activation tool|"* Receive Portable Spirometer~* Spirometry training of staff~* Provide clinician with web-based COPD interactive guideline tool~* Provide clinician with patient activation tool~* Train clinicians (tools, integration into workflow)~* Academic Detailing"
62351690|NCT01237561|NO_INTERVENTION|Usual Care|Spirometer and spirometry training of staff
62351691|NCT05560178|EXPERIMENTAL|Experimental: Training group|women in the intervention group will be given sexual health education once a week for 4 weeks
62351692|NCT05560178|NO_INTERVENTION|No Intervention: control group|Women will be monitored without any intervention
61970294|NCT04376710||Patients|
61970295|NCT02093832||Total hip arthroplasty|
61970296|NCT01348945|EXPERIMENTAL|Stump Preserving ACL Surgery|Patients of partial tear ACL injury fulfilling inclusion criteria received stump preserving ACL surgery, entered conventional ACL reconstruction rehabilitation program
61970297|NCT01348945|ACTIVE_COMPARATOR|ACL Reconstruction|Patients with complete tear ACL injury received ACL reconstruction entered conventional ACL rehabilitation program
61970298|NCT05945914||Study group|Patients with unilateral breast cancer received robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction.
61970299|NCT02846779|ACTIVE_COMPARATOR|Low intensity|All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
61976256|NCT03965533|EXPERIMENTAL|Part B: GSK2831781 450 mg SC|Caucasian male participants were administered three SC injections of a unit dose strength of 150 mg per mL of GSK2831781 to achieve a dose of 450 mg.
62351693|NCT02604810|ACTIVE_COMPARATOR|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
62351694|NCT02604810|EXPERIMENTAL|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
62145635|NCT01119651|EXPERIMENTAL|Tazarotene Foam & UVA/UVB/visible light|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB and visible light irradiation
62707585|NCT05238792|EXPERIMENTAL|Arm B for patients age ≥6 years and <18 years|Arm B will enroll patients age ≥6 years and \<18 years. TAA-T product will first be administered to patients as monotherapy at dose level 1 to determine safety. Following demonstration of safety in dose level 1, lymphodepleting chemotherapy will be administered prior to the first dose of TAA-Ts on the dose escalation phase (dose levels 2 and 3). The TAA-T product will be assessed for safety and anti-tumor activity.
61970300|NCT02846779|EXPERIMENTAL|Moderate intensity|Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program. The pharmacist will also provide limited follow-up with the participant's provider. Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
61970301|NCT02846779|EXPERIMENTAL|High intensity|Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up. The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist. Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
61970302|NCT03091634|EXPERIMENTAL|test group|the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.
61970303|NCT03091634|PLACEBO_COMPARATOR|control group|the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..
61970304|NCT05495256|OTHER|MDI Training|All participants are led through the MDI training with the Respimetrix Device. Protocol is within groups design.
61970305|NCT00543504|EXPERIMENTAL|Bevacizumab + Sunitinib|Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
61970306|NCT00543504|EXPERIMENTAL|Bevacizumab + Sorafenib|Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
61970307|NCT00543504|EXPERIMENTAL|Bevacizumab + Erlotinib + Cetuximab|Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
61970308|NCT00543504|EXPERIMENTAL|Bevacizumab + Trastuzumab + Lapatinib|Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
61970309|NCT00081484|EXPERIMENTAL|1|
61970310|NCT00081484|ACTIVE_COMPARATOR|2|
61970311|NCT02674152|EXPERIMENTAL|BI 836880|
61970312|NCT02106091|EXPERIMENTAL|AFM11|IV (intravenous) infusion, dose escalation
62145636|NCT01119651|PLACEBO_COMPARATOR|Vehicle Foam without irradiation,|Subjects will be exposed to Vehicle Foam Patch without irradiation
62145637|NCT01119651|PLACEBO_COMPARATOR|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
61970313|NCT03053284|PLACEBO_COMPARATOR|Placebo|Normal saline s.c. injection once
61970314|NCT03053284|EXPERIMENTAL|Pasireotide|Pasireotide 0.6mg s.c. once
61970315|NCT00225173|EXPERIMENTAL|Treatment|"* Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11~* Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11~* Cyclophosphamide 750 mg/m2 IV w 1, 5, 9~* Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11~* Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)~* Bleomycin 5 u/m2 IV w 2,4,6,8,10,12~* Gemcitabine 1250 mg/m2 IV w 13,15,17,19~* Vinorelbine 25 mg/m2 IV w 13,15,17,19~* Prednisone 40 mg/m2 PO qod w 1-10, taper"
62707586|NCT02660229|EXPERIMENTAL|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
62145638|NCT01119651|PLACEBO_COMPARATOR|Vehicle Foam with UVA & UVB visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
62145639|NCT01119651|SHAM_COMPARATOR|Blank patch without irradiation|Subjects will be exposed to blank patch without irradiation,
62510346|NCT04509999|PLACEBO_COMPARATOR|Standard of Care and Placebo|Each subject will be administered placebo as formulated at 1:1 randomization for up to 4 weeks.
62707587|NCT02660229|ACTIVE_COMPARATOR|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
62707588|NCT00895804|OTHER|Pindolol, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
61970316|NCT05246501|EXPERIMENTAL|Simulation|
61970317|NCT05246501|ACTIVE_COMPARATOR|control group|
61970318|NCT02402127|OTHER|TruEye, MyDay, clariti 1day|Narafilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 1 day (16 hours).
61970319|NCT02402127|OTHER|TruEye, clariti 1day, MyDay|Narafilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
61970320|NCT02402127|OTHER|MyDay, TruEye, clariti 1day|Stenfilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
61970321|NCT02402127|OTHER|MyDay, clariti 1day, TruEye|Stenfilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
61970322|NCT02402127|OTHER|Clariti 1day, TruEye, MyDay|Somofilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
61970323|NCT02402127|OTHER|Clariti 1day, MyDay, TruEye|Somofilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
61970324|NCT03764865|EXPERIMENTAL|day 3 embryo transfer|embryo transfer 3 days after fertilization
62145640|NCT01119651|SHAM_COMPARATOR|Blank patch with UVA and UVB irradiation|Subjects will be exposed to blank patch with UVA and UVB irradiation
62145641|NCT01119651|SHAM_COMPARATOR|Blank Patch with UVA & UVB visible light irradiation|Subjects will be exposed to Blank Patch with UVA and UVB and visible light irradiation
62510347|NCT01731522|EXPERIMENTAL|EF condition|
62145642|NCT04019067|EXPERIMENTAL|MCE first group|"Patients randomized to the MCE first group will have a MCE deployed as the first detection method."
62145643|NCT04019067|NO_INTERVENTION|standard of care group|For patients randomized to the Standard Care Group, gastroenterologists choose which procedures to perform and when to perform them based on their interpretation of the patient's presentation.
62145644|NCT04817059|EXPERIMENTAL|Head mold on|
62145645|NCT04817059|NO_INTERVENTION|Head mold off|
62145646|NCT01603836|EXPERIMENTAL|bone marrow concentrate|In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
62145647|NCT02220959|EXPERIMENTAL|walk test|morbid obese patients (BMI\>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC)
62145648|NCT04773145||Femoral neck fracture|Patients over 80 years when suffering of femoral neck fracture with at least one year follow-up.
62145649|NCT05826496|EXPERIMENTAL|Exercise|HLA-A2 positive participants will perform one bout of high-intensity interval training.
62145650|NCT03014037|OTHER|Unilateral Procurement of Bone Marrow|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.
62145651|NCT03014037|EXPERIMENTAL|Bilateral Bone Marrow Procurement|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow.
62145652|NCT03926806|ACTIVE_COMPARATOR|Plain yoghurt|2x200g plain yoghurt/day for 12 weeks
62145653|NCT03926806|EXPERIMENTAL|Vitamin B yoghurt|2x200g yoghurt enriched with vitamins B for 12 weeks
62510348|NCT02704195|ACTIVE_COMPARATOR|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
62707589|NCT00895804|OTHER|MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
61970325|NCT03764865|EXPERIMENTAL|day 5 embryo transfer|embryo transfer 5 days after fertilization
61970326|NCT03591471|EXPERIMENTAL|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
61970327|NCT03591471|ACTIVE_COMPARATOR|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
61976257|NCT02289079|EXPERIMENTAL|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
61976258|NCT02289079|ACTIVE_COMPARATOR|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
61976259|NCT00613249|EXPERIMENTAL|A|
61976260|NCT00613249|EXPERIMENTAL|B|
61976261|NCT00613249|PLACEBO_COMPARATOR|C|
62145654|NCT00454194|EXPERIMENTAL|Arm I|Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62145655|NCT00454194|ACTIVE_COMPARATOR|Arm II|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62145656|NCT02427191|EXPERIMENTAL|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
62145657|NCT02427191|PLACEBO_COMPARATOR|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
62145658|NCT03138499|EXPERIMENTAL|Module A|Nivolumab combined with Brentuximab
62145659|NCT03138499|EXPERIMENTAL|Module B|Brentuximab alone
62145660|NCT01708278|PLACEBO_COMPARATOR|Sugar chew-Cohort 1|contains 350 mg of vitamin C and 10 mg niacin
62145661|NCT01708278|ACTIVE_COMPARATOR|Quercetin 1-Cohort 1|Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
62145662|NCT01708278|ACTIVE_COMPARATOR|Quercetin 2-Cohort 2|Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
62145663|NCT01708278|ACTIVE_COMPARATOR|Quercetin 3-Cohort 3|Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
62145664|NCT01708278|PLACEBO_COMPARATOR|Sugar chew-Cohort 2|contains 350 mg of vitamin C and 10 mg niacin
62145665|NCT01708278|PLACEBO_COMPARATOR|Sugar Chew-Cohort 3|contains 350 mg of vitamin C and 10 mg niacin
62145666|NCT02740426|NO_INTERVENTION|Blank control|do not use prophylactic intravesical chemotherapy.
62145667|NCT02740426|EXPERIMENTAL|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
62145668|NCT05032716|ACTIVE_COMPARATOR|Balance exersices group|received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance
62510349|NCT02704195|EXPERIMENTAL|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
62707590|NCT04543851|EXPERIMENTAL|CARA positioning|Planning and Treatment using the CARA Device
61970328|NCT02151253|EXPERIMENTAL|Armodafinil First, Then Placebo|"During double-blind treatment subjects took armodafinil for 4 weeks before crossing over to placebo for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
62145669|NCT05032716|ACTIVE_COMPARATOR|Balance exersices and treadmill group|received the same traditional physical therapy program as the same applied in group of balance exercise (30 min), in addition to treadmill training (30 min)
62351695|NCT05560893|EXPERIMENTAL|Intervention Group|In this randomized controlled waitlist design, following a baseline assessment, we will randomly assign CSPs into the experimental group (n = 40) or a waitlist group (n = 40). The experimental group will receive the intervention immediately, whereas the waitlist control will wait 4 weeks and have a second baseline assessment before receiving the intervention. All participants will complete an identical assessment battery at pre-intervention baseline, immediately post-intervention, and 3-months following the intervention.
62510350|NCT02688296||Pilon Fractures|Patients who are implanted with Fibulock and have a Pilon fracture
61970329|NCT02151253|PLACEBO_COMPARATOR|Placebo First, Then Armodafinil|"During double-blind treatment subjects took placebo for 4 weeks before crossing over to armodafinil for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
61970330|NCT05430737|EXPERIMENTAL|stereotactic body radiotherapy|Long-term ADT of 2-3years were administered. Neoadjuvant ADT within 6 months was allowed.Then patients with high-risk prostate cancer recieve stereotactic body radiotherapy with pelvic radiation and GTV boost based on multiparameter magnetic resonance image.
61970331|NCT00483223|EXPERIMENTAL|Single Arm|Cisplatin or carboplatin (1 arm, 2 cohorts)
61970332|NCT04666051|EXPERIMENTAL|Fibrin glue|A fibrin glue was applied to the lymphadenectomy bed before wound closure and insertion of a drain.
61970333|NCT04666051|NO_INTERVENTION|Control|Lymphadenctomy wound was closed after insertion of a drain,
61970334|NCT05433805|EXPERIMENTAL|FMD first|"Patients receive nutritional counselling on the principles of the FMD diet and individual recommendations for optimising the micronutrient balance (vitamins, trace elements) based on their corresponding baseline values. A food diary is given to the patients to assess treatment adherence on FMD days.~This is followed by a combined nutritive and physiotherapeutic interventions from week 13 for a further 3 months. Patients will be instructed about ambulatory exercises during a physiotherapeutic counselling, scheduled in week 13. Physiotherapy exercises should only be carried out on FMD-free days. Patients also receive a diary in which they document daily physical activity."
61970335|NCT05433805|EXPERIMENTAL|Physiotherapy first|"Patients receive physiotherapy counselling, with structured ambulatory exercises shown and explained. The patients receive a diary where they have to document their physical activity every day.~This is followed by a combined nutritive and physiotherapeutic interventions from week 13 for a further 3 months. For this purposphe, nutritional counselling on the principles of the FMD diet is planned for week 13. In addition, individual recommendations for optimising the micronutrient balance (vitamins, trace elements) are given based on the respective baseline values. The physiotherapeutic exercises are to be carried out only on FMD-free days. Patients will also be given a food diary to assess treatment adherence on FMD days."
61970336|NCT02192931|ACTIVE_COMPARATOR|Creatine monohydrate|5 grams of daily creatine monohydrate for 8 weeks
61970337|NCT02192931|PLACEBO_COMPARATOR|Placebo|5 g of placebo for 8 weeks
61970338|NCT02192931|NO_INTERVENTION|Healthy Control|
62510351|NCT02688296||High Risk Patients|Patients who are implanted with Fibulock and are at high risk of complications from ankle surgery due to conditions such as diabetes, advanced age or osteoporosis
61970339|NCT03107936|EXPERIMENTAL|smokeSCREEN game play|Participants are instructed to access the web-based videogame intervention, smokeSCREEN, through a secured website and play the game using their unique User ID and password.
61970340|NCT03900351|ACTIVE_COMPARATOR|Group A: Study group|They will receive the Wii fit protocol of virtual reality games for 40 minutes, 3 times per week, for 8 weeks, in addition to the regular exercise rehabilitation protocol according to the criterion of Adams et al. (2012).
61970341|NCT03900351|EXPERIMENTAL|Group B: Control group|They will receive the regular exercise rehabilitation protocol only for 40 minutes, for 3 days per week, for 8 weeks.
61970342|NCT01264588|ACTIVE_COMPARATOR|topical calcium glycerophosphate lotion|
61970343|NCT01264588|NO_INTERVENTION|standard-of-care|
62145670|NCT03631966|EXPERIMENTAL|BTX-A injection|
62145671|NCT00070486|EXPERIMENTAL|Gem + Carboplatin + Zileuton|
62145672|NCT00070486|EXPERIMENTAL|Gem + Carboplatin + celecoxib|
62145673|NCT00070486|EXPERIMENTAL|Gem + carboplatin + zilueton + celecoxib|
62145674|NCT00840775|OTHER|Presillion™ Stent System|
62145675|NCT04026256|ACTIVE_COMPARATOR|Teriparatide only|daily subcutaneous injection teriparatide for 3 months
62145676|NCT04026256|ACTIVE_COMPARATOR|Denosumab only|one dose of subcutaneous injection denosumab
62145677|NCT04026256|ACTIVE_COMPARATOR|Denosumab and teriparatide|daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab
62145678|NCT01044446|EXPERIMENTAL|Icodextrin|peritoneal dialysate
62510352|NCT02688296||Otherwise Healthy Patients|Patients implanted with Fibulock who are healthy other than their ankle fracture
62145679|NCT01044446|ACTIVE_COMPARATOR|Glucose-based dialysate|peritoneal dialysate
62145680|NCT00213278|EXPERIMENTAL|1|
62145681|NCT01522014|ACTIVE_COMPARATOR|Ceramic on Ceramic|Subjects received a ceramic on ceramic bearing total hip replacement.
62145682|NCT01522014|ACTIVE_COMPARATOR|Ceramic-on-Highly Crosslinked Polyethylene|
62145683|NCT03314636|EXPERIMENTAL|PET-CT-positive patients|Carfilzomib 20/36mg/m2 days 1,2,8,9,15,16 Lenalidomide 25mg days 1-21 Dexamethasone 40mg days 1,8,15,22 28 day cycles 4 cycles
62145684|NCT01942954|EXPERIMENTAL|Mobile health cognitive stimulation|Experimental group
62145685|NCT01942954|NO_INTERVENTION|Treatment-as-usual|This group consists of treatment-as-usual for alcohol abstinence according to the Minnesota Model.
62145686|NCT05830279||Anti-depressants|Patients who have been prescribed either 1) the selective serotonin reuptake inhibitors (SSRI) citalopram or escitalopram, or 2) the selective norepinephrine reuptake inhibitors (SNRI) venlafaxine or desvenlafaxine
62145687|NCT05830279||Opioid pain medications|Patients who have been prescribed opioid pain medications including codeine, oxycodone, hydrocodone, or tramadol.
62145688|NCT05830279||Anti-metics|Patients who have been prescribed the antiemetic agent ondansetron
62351696|NCT05560893|OTHER|Waitlist Control Group|In this randomized controlled waitlist design, following a baseline assessment, we will randomly assign CSPs into the experimental group (n = 40) or a waitlist group (n = 40). The experimental group will receive the intervention immediately, whereas the waitlist control will wait 4 weeks and have a second baseline assessment before receiving the intervention. All participants will complete an identical assessment battery at pre-intervention baseline, immediately post-intervention, and 3-months following the intervention.
62351697|NCT03172481|EXPERIMENTAL|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
62351698|NCT03172481|PLACEBO_COMPARATOR|Placebo Treatment|
62510353|NCT04625062|EXPERIMENTAL|Visual-acoustic biofeedback|Visual- acoustic biofeedback treatment (behavioral) administered via telepractice
62351699|NCT04223401|EXPERIMENTAL|Prehabilitation group|Patients in the experimental group will undergo prehabilitation before the elective surgery for gastric cancer.
62351700|NCT04223401|NO_INTERVENTION|Control group|Patients in the control group will not undergo prehabilitation.
62510354|NCT04625062|EXPERIMENTAL|Motor-based treatment|Motor-based articulation treatment administered via telepractice
61970344|NCT01488682|EXPERIMENTAL|Harmonic scalpel|Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
61970345|NCT01488682|ACTIVE_COMPARATOR|conventional hand tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels.
62145689|NCT04723979||Exposed to recombinant FVIIa (NovoSeven®)|all women exposed to NovoSeven® during sPPH
62145690|NCT04723979||Standard of Care|Women with postpartum hemorrhage not exposed to NovoSeven®.
62145691|NCT00679406|EXPERIMENTAL|1|Brief Behavioral Treatment for Insomnia
62145692|NCT01211509|EXPERIMENTAL|montelukast sodium|Daily treatment with 10 mg montelukast after diagnosis of fibroproliferative BOS (fBOS) which is the low neutrophilic phenotype within BOS
62145693|NCT01211509|PLACEBO_COMPARATOR|placebo|Lactose monohydricum Ph.Eur.
62145694|NCT05563571|ACTIVE_COMPARATOR|Intra-articular cortisone injection|Ultra-sound guided single injection of Methylprednisolon 40 mg (1 ml) + 1 ml 10 % Lidocaine to shoulder joint
62145695|NCT05563571|ACTIVE_COMPARATOR|pulsed radiofrequency of shoulder joint and suprascapular nerve|Ultra-sound guided single treatment of shoulder joint and suprascapular nerve with pulsed radiofrequency (PRF) STP (Sluijter Teixeira pulse) 45 V 4 minutes each with 1 ml 10% Lidocaine to both shoulder joint and suprascapular nerve.
62145696|NCT03313726|EXPERIMENTAL|GnRh-antagonist A|
62145697|NCT03313726|EXPERIMENTAL|GnRh-antagonist B|
62145698|NCT01719172|EXPERIMENTAL|Veriset™ Hemostatic Patch|Topical hemostat
62145699|NCT04597931|EXPERIMENTAL|SC Romosozumab 210 mg/monthly|SC Romosozumab 210 mg/monthly
62145700|NCT04597931|ACTIVE_COMPARATOR|IV Zoledronic acid 5 mg|IV Zoledronic acid 5 mg
62145701|NCT04129372|EXPERIMENTAL|New Foods Take Time|"Head Start classrooms will receive New Foods Take Time, a series of five interactive weekly lessons designed to promote children's willingness to try new foods, particularly fruits and vegetables. Lessons will be delivered by nutrition educations. Children will also receive three tastings per week of the new foods discussed during the lessons."
62145702|NCT05953909||Eribulin-Based Regimen|Not Applicable since observational study
62145703|NCT05953909||nab-paclitaxel based regimen|Not Applicable since observational study
62145704|NCT05953909||Other Chemotherapy Regimen|Not Applicable since observational study
62351701|NCT01754207|EXPERIMENTAL|755nm Alexandrite Laser|755nm Alexandrite Laser
62351702|NCT02079558|EXPERIMENTAL|Oxytocin|A single 100 microgram IV dose of carbetocin after operation
62351703|NCT02079558|EXPERIMENTAL|Carbetocin|A standard 30 international units (IU) IV infusion of oxytocin during two hours
62351704|NCT03159806||Outpatients|Attendees at the nephrology outpatient clinic at Hammersmith Hospital will be invited to take part in microdialysis sampling
62351705|NCT03768141||Liver surgery|Any type of liver surgery
62351706|NCT05880407|ACTIVE_COMPARATOR|standard treatment|SERI osteotomy
62351707|NCT05880407|EXPERIMENTAL|experimental treatment|percutaneous osteotomy according to Chevron
62510355|NCT00546910|EXPERIMENTAL|Atomoxetine|0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
62510356|NCT00546910|PLACEBO_COMPARATOR|Placebo|Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine
62510357|NCT02466802|EXPERIMENTAL|A: regorafenib and sildenafil citrate|Patients receive regorafenib and sildenafil citrate by mouth every day (PO QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62510358|NCT00480649|ACTIVE_COMPARATOR|Sal/FP 50/250mcg|SERETIDE 50/250
62510359|NCT00480649|ACTIVE_COMPARATOR|Sal/FP 50/500mcg|SERETIDE 50/500
62510360|NCT05655455|EXPERIMENTAL|experimental group 1|group 1: walking group
62510361|NCT05655455|EXPERIMENTAL|experimental group 2|group 2: dance and movement therapy group
62145705|NCT01992965|EXPERIMENTAL|Continuous Glucose Monitoring Group|"Continuous Glucose Monitoring Group:~Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits（high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
62145706|NCT01992965|ACTIVE_COMPARATOR|Conventional Group|"Conventional Group：~Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
62145707|NCT00912171|ACTIVE_COMPARATOR|Nasal steroid|
62145708|NCT00912171|ACTIVE_COMPARATOR|Anti-leukotrienes|
62145709|NCT00912171|ACTIVE_COMPARATOR|Nasal steroid + anti-leukotrienes|
62145710|NCT06463301|EXPERIMENTAL|Treadmill Training in cp child|"Treadmill training for children should be carefully tailored to their developmental level, physical ability, and specific therapeutic goals. Initial Sessions start with shorter sessions, around 5-10 minutes, especially for children with disabilities.~Progression will be made when the child becomes more accustomed to the treadmill. Aim for a total of 20-30 minutes per session, including breaks if necessary then then Start at a slow walking pace, approximately 0.5 to 1.0 miles per hour (mph) or 0.8 to 1.6 kilometers per hour (kph). Adjust the speed based on the child's comfort and ability to maintain a safe and effective walking pattern.~Older Children (8-12 years Begin with a walking pace of 1.0 to 1.5 mph (1.6 to 2.4 kph). Gradually increase the speed to a brisk walk or light jog, up to 2.0 to 3.0 mph (3.2 to 4.8 kph), depending on the child's progress and comfort level along with conventional physical therapy"
62145711|NCT06463301|ACTIVE_COMPARATOR|Conventional Physical therapy|conventional physical therapy session would typically include gentle stretching, joint mobilization, range of motion exercises for both the upper and lower body, gait training, and standing frame activities. Each component is designed to improve various aspects of physical function, ensuring a comprehensive approach to rehabilitation
62145712|NCT02515123|EXPERIMENTAL|E-Motion System|E-motion tube + E-motion EPG 1000
62145713|NCT02515123|SHAM_COMPARATOR|E-Motion Sham Decive|E-motion tube + SHAM E-motion EPG 1000
61970346|NCT00085631|EXPERIMENTAL|Arm I|Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
61970347|NCT00085631|ACTIVE_COMPARATOR|Arm II|Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.
61970348|NCT04953546||ACL group|According to the previous clinical diagnosis, volunteers who has suffered the ACL injury.
61970349|NCT00294268|OTHER|1|20 weekly sessions of CBT integrated with motivational enhancement strategies
61970350|NCT04108533|EXPERIMENTAL|Text-Based Support|"Text-Based Support - Women randomized to this arm will receive text-based support via the Way to Health platform as described below.~Supportive texts - Encouraging text messages with prompts to ask questions will be sent twice weekly during the first four weeks postpartum and once weekly thereafter for the remaining two weeks of the program~Inquiry texts - Questions regarding infant feeding with prompts to answer will be sent three times weekly during the first two weeks postpartum and twice weekly thereafter for the remaining 4 weeks of the program.~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.~Women in this group will also have the option to send a text with a question or concern at any time during the study. Weekdays from 8am to 5 pm these will be fielded by a trained obstetrician. If a text is received after-hours or on the weekend, women will be instructed to reach out to their primary OBGYN provider."
61970351|NCT04108533|NO_INTERVENTION|Usual Care|"Usual care - Women randomized to this arm will receive usual postpartum care with the following exceptions:~Inquiry texts- Questions regarding infant feeding with prompts to answer will be sent once weekly for all 6 weeks of the program.~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.~Women in this group will be directed to their physician with any questions or concerns during the study period."
61970352|NCT06323278||PD with GBA gene mutation|Patients with Parkinson's disease and GBA gene mutation treated with cognitive training
61970353|NCT06323278||PD without genetic mutation|Patients with Parkinson's disease without genetic mutation treated with cognitive training
62145714|NCT02662816|EXPERIMENTAL|glutathion|The study will validate the detection and the quantification of glutathione in muscle and liver using 1H MRS
62707591|NCT03801525|EXPERIMENTAL|Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)|Participants were administered ublituximab, 150 milligrams (mg), intravenous (IV) infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6; umbralisib, 800 mg, oral tablet, once daily (QD) through Cycles 1-24; venetoclax, oral tablet, QD, 20 mg on Days 1-7, 50 mg on Days 8-14, 100 mg on Days 15-21, 200 mg on Days 22-28 of Cycle 4, followed by 400 mg on Days 1-28 of Cycles 5-24. MRD positive participants were administered umbralisib, 800 mg, oral tablet, QD, on Days 1-28 from Cycle 25 onwards (1 Cycle = 28 days), until disease progression, unacceptable toxicity, or withdrawal from the study.
61970354|NCT04095845|ACTIVE_COMPARATOR|CO THA|Computerised tomography based planning of conventional total hip arthroplasty
61970355|NCT04095845|EXPERIMENTAL|Mako THA|Mako robotic-arm assisted total hip arthroplasty
62145715|NCT01205633||CNS draining vein abnormalities|
62145716|NCT02053298|EXPERIMENTAL|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
62145717|NCT00884026|ACTIVE_COMPARATOR|1|Subjects that experience hypotension after spinal anesthesia.
62707592|NCT03801525|EXPERIMENTAL|Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)|Participants were administered ublituximab, 150 mg, IV infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6, 9,12, and 15; umbralisib, 800 mg, oral tablet, QD through Cycles 1-15; venetoclax, oral tablet, QD, 20 mg on Days 1-7, 50 mg on Days 8-14, 100 mg on Days 15-21, 200 mg on Days 22-28 of Cycle 4, followed by 400 mg on Days 1-28 of Cycles 5-15 (1 Cycle = 28 days).
62510362|NCT05655455|NO_INTERVENTION|control group|No intervention
61970356|NCT02421276|OTHER|Persons without Down syndrome|White blood cell analysis from persons without Down syndrome assessed by absence of trisomy 21.
61970357|NCT02421276|OTHER|Persons with Down syndrome|White blood cell analysis from persons with Down syndrome assessed by presence of trisomy 21.
61970358|NCT02743520|EXPERIMENTAL|Cardiac event monitor|Participants will under go evaluation with a two week cardiac event monitor.
61970359|NCT02852785||Asymptomatic volleyball attackers|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
61970360|NCT02852785||Asymptomatic bilateral overhead athletes|Asymptomatic swimmers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
61970361|NCT02852785||Asymptomatic non-athletes|Asymptomatic persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers),
62145718|NCT00884026|ACTIVE_COMPARATOR|2|Subjects that do not experience hypotension after spinal anesthesia.
62145719|NCT01529944|EXPERIMENTAL|Low dose 33 mcg/kg/day|
62145720|NCT01529944|EXPERIMENTAL|High dose 66 mcg/kg/day|
62145721|NCT01314066|EXPERIMENTAL|Bevacizumab 5 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
62145722|NCT01314066|EXPERIMENTAL|Bevacizumab at 10 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
62145723|NCT01314066|PLACEBO_COMPARATOR|Placebo|In addition to receiving the best standard supportive care for both diagnosis and treatment for individuals diagnosed with severe sepsis, they will receive an IV saline solution.
62145724|NCT00130091|EXPERIMENTAL|Clonidine|administer with local anesthetic
62145725|NCT00130091|PLACEBO_COMPARATOR|Local anesthetic|Local anesthetic without clonidine
62145726|NCT01857076|ACTIVE_COMPARATOR|Clinical|Subject submitted to clinical obesity treatment
62145727|NCT01857076|ACTIVE_COMPARATOR|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
62145728|NCT01857076|ACTIVE_COMPARATOR|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
62145729|NCT05773235||Patients with intracerebral hemorrhage|Patients with symptomatic intracranial hemorrhage (defined as non-traumatic intracerebral hemorrhage or convexity, non-aneurysmal subarachnoid hemorrhage) enrolled in the PRO-SVD study
62145730|NCT05773235||Healthy controls|Clinically healthy persons of at least 55 years of age
62145731|NCT04347941|EXPERIMENTAL|Prone Positioning|Intervention patients will remain up to 16 hours per day in Prone Positioning with 45 minutes breaks for meals
62145732|NCT04347941|ACTIVE_COMPARATOR|Standard Care|Control patients will receive full standard care. Prone Positioning as a rescue intervention is permitted and is recorded.
62145733|NCT01755559|OTHER|Artesunate-amodiaquine|Efficacy estimates at 95%
62145734|NCT01755559|OTHER|Dihydroartemisinin-piperaquine|Efficacy estimates at 95%
62351708|NCT04278482|ACTIVE_COMPARATOR|DHA supplement|Supplement rich in DHA form algae source
62510363|NCT05178914|EXPERIMENTAL|The interventional group|"Patients are defined by the disclosure of the IMR value. The initial IMR is used to guide therapy.~For patients with initial IMR ≥ 25 will benefit from intensified coronary artery disease treatment to manage the microcirculatory damage according to the recommendations and consensus of European experts.~For patients with a initial IMR \< 25 will benefit from de-escalade therapeutic adaptation."
61970362|NCT02852785||Asympt. athletes / scapula dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
61970363|NCT02852785||Symptom. athletes / scapula dyskinesis|Volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis and complaints of shoulder pain and disability
61976262|NCT02442869|EXPERIMENTAL|Stage 1 TAU plus Stage 2 CAMS|"Treatment as usual \[TAU\] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
62145735|NCT01755559|OTHER|Artemether-lumefantrine|Efficacy estimates at 95%
62145736|NCT04275583|EXPERIMENTAL|TQB3602 capsule|TQB3602 capsule administered orally on day 1, 8, 15 in 28-day cycle.
62145737|NCT00857766|ACTIVE_COMPARATOR|ADVAIR DISKUS|Subjects receive blinded Fluticasone Propionate/Salmeterol. At 4 months subjects will receive open label SPIRIVA HANDIHALER
62145738|NCT00857766|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo ADVAIR DISKUS. At 4 months subjects will receive open label SPIRIVA HANDIHALER
62145739|NCT03735381|ACTIVE_COMPARATOR|Intervention 1: pedometer|"Minimum intervention:~1. Use of pedometer watch from 12 to 32 GW~2. Recommendations of physical activity"
62145740|NCT03735381|EXPERIMENTAL|Intervention 2: pedometer+goal+reminds|"Maximum intervention:~1. Use of pedometer from 12 to 32 GW~2. Recommendations of physical activity~3. Information about get a goal of 11000 steps/day~4. Reminds the goal every two weeks."
62351709|NCT04278482|PLACEBO_COMPARATOR|Placebo|Placebo supplement
62351710|NCT02902029|EXPERIMENTAL|Arm A|"After a 3 months run-in period with vemurafenib and cobimetinib \[960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7\], all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7).~After progression of disease patients in Arm A will subsequently receive atezolizumab treatment (1200 mg/ q3w)."
62145741|NCT03735381|NO_INTERVENTION|Control: without pedometer|Women receive some recommendations of physical activity during pregnancy. They do not use the pedometer during pregnancy
62145742|NCT03536845|ACTIVE_COMPARATOR|400 IU|
62145743|NCT03536845|ACTIVE_COMPARATOR|1000 IU|
62145744|NCT00598234|ACTIVE_COMPARATOR|1|Celecoxib (Celebrex)
62145745|NCT00598234|PLACEBO_COMPARATOR|2|Placebo
62145746|NCT01846715|EXPERIMENTAL|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
62145747|NCT02246699|EXPERIMENTAL|KiOnutrime®-Cs|The product is presented as a capsule containing chitosan as ingredient supporting the activity.
62145748|NCT02246699|PLACEBO_COMPARATOR|Placebo|Placebo is presented as a capsule containing inactive ingredients.
62145749|NCT03883828|EXPERIMENTAL|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
62145750|NCT03883828|NO_INTERVENTION|Control|Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.
62145751|NCT05748184||Radiologists|
62145752|NCT01558908|EXPERIMENTAL|Intramuscular injection of ERC|
62145753|NCT01313884|EXPERIMENTAL|Combination Therapy|"Regimen A alternating with Regimen B every 21 days~Regimen A:~* Cytoxan 1200mg/m2~* Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2~* Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg~* Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle~Regimen B:~* Irinotecan 50 mg/m2/day x 5 days~* Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free"
62145754|NCT06246903||suspicious nevus/nevi|
62145755|NCT03831698|EXPERIMENTAL|Omega-3, 2 grams|Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months
62145756|NCT05072002||pregnant women with low back pain|
62145757|NCT03806309|ACTIVE_COMPARATOR|Arm A : maintenance with FOLFIRI|FOLFIRI (IV; folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2/46h (dose adjustment will be accepted).
62145758|NCT03806309|EXPERIMENTAL|Arm B : maintenance with OSE2101 plus FOLFIRI|"OSE2101 - subcutaneous injection on day 1 and day 15, every 4 weeks for 6 doses then every 8 weeks until month 12 then every 12 weeks up to 24 months.~FOLFIRI - schedules as in Arm A until disease progression on unacceptable toxicity"
62707593|NCT03801525|EXPERIMENTAL|Phase 3: Ublituximab + Umbralisib (U2)|Participants were administered ublituximab, 150 mg, IV infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6, then every three cycles along with umbralisib, 800 mg, oral tablet, QD (1 Cycle = 28 days) from Cycle 1 until disease progression, unacceptable toxicity, or withdrawal from the study.
62707594|NCT01605994|EXPERIMENTAL|Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution|"BMS-933043 2 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62707595|NCT01605994|EXPERIMENTAL|Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution|"BMS-933043 5 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
61970364|NCT02518750|EXPERIMENTAL|Study Participants|"Participants with ALL will receive the following interventions in three treatment blocks:~* Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.~* Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.~* Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide."
61970365|NCT02533427|EXPERIMENTAL|SOF/VEL/VOX + VOX|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX."
62145759|NCT00055991|EXPERIMENTAL|Bexarotene|Bexarotene / Targretin
62145760|NCT00055991|PLACEBO_COMPARATOR|Sugar Pill|Sugar pill / placebo
62351711|NCT02902029|EXPERIMENTAL|Arm B|"After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle.~After progression of disease patients in Arm B will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7)."
61970366|NCT00569699|EXPERIMENTAL|1|S-1, Bevacizumab
62351712|NCT05349942|EXPERIMENTAL|Intraoral scanning and data acquisition|
62707596|NCT01605994|EXPERIMENTAL|Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution|"BMS-933043 10 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
61970367|NCT02465801|EXPERIMENTAL|Group 1|"Intervention: HSA-GCSF 1.2 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
62145761|NCT03386500|OTHER|Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|One arm includes all enrolled patients.
62351713|NCT04387526|ACTIVE_COMPARATOR|SOF/DCV|"Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.~This arm included non-cirrhotic treatment-naïve patients"
62351714|NCT04387526|ACTIVE_COMPARATOR|SOF/DCV/RBV + Cirrhosis|This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
62351715|NCT04387526|ACTIVE_COMPARATOR|SOF/DCV/RBV + Non-Cirrhosis|This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
62351716|NCT01916707|ACTIVE_COMPARATOR|Standard Dosing|Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.
62351717|NCT01916707|EXPERIMENTAL|Weight Based Dosing|Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
62351718|NCT01390480|PLACEBO_COMPARATOR|Placebo|peanut oil
62351719|NCT01390480|ACTIVE_COMPARATOR|Vitamin D (Oleovit®)|cholecalciferol
62351720|NCT01481090|ACTIVE_COMPARATOR|Electro-Acupuncture|Group will receive 4 acupuncture treatments over 14 days during hormone treatment
62351721|NCT01481090|NO_INTERVENTION|Control|Group will not receive acupuncture.
62351722|NCT01752439|EXPERIMENTAL|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation
62351723|NCT01752439|SHAM_COMPARATOR|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation
62351724|NCT01752439|NO_INTERVENTION|Control group|
62351725|NCT04320277|EXPERIMENTAL|Patients|All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks.
61976263|NCT02442869|EXPERIMENTAL|Stage 1 TAU plus Stage 2 DBT|"Treatment as usual \[TAU\] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
61976264|NCT02442869|EXPERIMENTAL|Stage 1 CAMS plus Stage 2 CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Additional Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
61976265|NCT02442869|EXPERIMENTAL|Stage 1 CAMS plus Stage 2 DBT|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
61976266|NCT01578356||Radical Retropubic prostatectomy (RRP)|Men who underwent open radical prostatectomy in the past at our centre.
61976267|NCT01578356||Robot-assisted laparoscopic prostatectomy (RALP)|Men who undergo robot-assisted laparoscopic prostatectomy at our centre.
61976268|NCT00643682|EXPERIMENTAL|A|Patients in this arm will be given an educational card in addition to the standard pre-endoscopy instructions.
61976269|NCT00643682|NO_INTERVENTION|B|Patients in this arm will be given the standard pre-endoscopy instructions.
61976270|NCT05825846|EXPERIMENTAL|Slow breathing 1 (SB1)|Four second inhale through the nasal + hold two seconds + four second exhale through the mouth + hold for two seconds, repeat (\~25 breath cycles within the 5 min intervention)
61976271|NCT05825846|EXPERIMENTAL|Slow breathing 2 (SB2)|Four second inhale through the nose into the diaphragm followed by a two second exhale, repeat (\~50 breath cycles within the 5 min intervention)
61976272|NCT02769325|EXPERIMENTAL|Atropine|Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia
61976273|NCT02769325|PLACEBO_COMPARATOR|placebo|Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia
61976274|NCT00914524|EXPERIMENTAL|Treatment|16 weeks of treatment starting with 5 mg of olmesartan medoxomil. If tolerated, the dose was increased to the next higher dose at weeks 4, 8, and 12.
61976275|NCT03787953||Anti-PD-1/PD-L1 antibodies|Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy
61976276|NCT01986660|EXPERIMENTAL|Ibuprofen Cream (SST-0225)|
61976277|NCT05076474|EXPERIMENTAL|TR1R2|T(Orlistat 60-mg) R1(Alli 60-mg) R2（Alli 60-mg×2）
61976278|NCT05076474|EXPERIMENTAL|R2TR1|R2（Alli 60-mg×2） T(Orlistat 60-mg) R1(Alli 60-mg)
61976279|NCT05076474|EXPERIMENTAL|R1R2T|R1(Alli 60-mg) R2（Alli 60-mg×2） T(Orlistat 60-mg)
61976280|NCT01831999|EXPERIMENTAL|RecoveryTrack - Extended Care (RT-E)|Counselors will conduct monitoring and feedback sessions using the RecoveryTrack-Extended Care (RT-E) web-based monitoring system for clients newly admitted to Intensive Outpatient (IOP) treatment. Counselors will be instructed to document their reminders, contact attempts, and scheduling of RT-E appointments within a Contact Log incorporated into RT-E. All RT-E sessions will be audio recorded.
61976281|NCT01831999|NO_INTERVENTION|Treatment as Usual (TAU)|Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
61976282|NCT05407467|NO_INTERVENTION|Control Group|There is no additional intervention other than subject's standard diabetes treatment
61976283|NCT05407467|EXPERIMENTAL|Interventional Group|This group will received additional supplementation of curcumin and virgin coconut oil aside from their standard treatment
61976284|NCT02622542|ACTIVE_COMPARATOR|BMT Alone|Patients in this group will be managed with the best medical therapy (BMT) alone
61976285|NCT02622542|EXPERIMENTAL|BMT+TEVAR|Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
61976286|NCT01166724|ACTIVE_COMPARATOR|Sirolimus|patients will be switched from Tacrolimus to Sirolimus
61976287|NCT01166724|NO_INTERVENTION|Tacrolimus|Patient will stay on Tacrolimus
61976288|NCT02689024|EXPERIMENTAL|Continuous FICB with local anesthetics|"With ultrasound guidance, a Fascia Iliaca Compartment Block will be administered and a catheter left in the compartment underneath the iliac fascia. This catheter will remain in place until two days after surgery.~Initial pain treatment in the Emergency Department will be with 40 mL bupivacaine 0.25% or equipotent dosages of levobupivacaine or ropivacaine. Thereafter, until removal of the catheter, pain is treated by titrating local anesthetics according to pain scores."
61976289|NCT02689024|ACTIVE_COMPARATOR|Traditional care with systemic analgesia|"Traditional care (usual care) will be on the discretion of the treating physician or hospital protocols and will comprise of systemic opioids such as fentanyl or morphine.~Usually, these opioids are combined with several other drugs, such as: paracetamol, NSAIDs (diclofenac or ibuprofen or naproxen) or dipyrone. (Inter)national guidelines advice morphine as first line agent in elderly patients with hip fractures, as longer acting analgesics are usually required."
62145762|NCT02120807|EXPERIMENTAL|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin \& pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, \& subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg \& 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
62145763|NCT01463475|OTHER|Bone Marrow Aspirate|A qualified enrolled donor will have an aspirate bone marrow draw.
62707597|NCT01605994|EXPERIMENTAL|Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution|"BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62707598|NCT01605994|EXPERIMENTAL|Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution|"BMS-933043 50 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days~CSF sampling required"
62707599|NCT01605994|EXPERIMENTAL|Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution|"BMS-933043 100 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62707600|NCT01605994|EXPERIMENTAL|Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution|"BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62707601|NCT01605994|EXPERIMENTAL|Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose|"MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required~BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62707602|NCT01605994|EXPERIMENTAL|Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose|"Japanese Subjects. CSF sampling not required.~BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62707603|NCT01605994|EXPERIMENTAL|Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose|"BMS-933043 350 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62707604|NCT01605994|EXPERIMENTAL|CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose|"If Panel 5 does not run. CSF Sampling at steady state~BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
62145764|NCT00868894|EXPERIMENTAL|1|
62707605|NCT02725684||Glioblastoma|Observational study, no intervention
61976290|NCT05571098|EXPERIMENTAL|Experimental|Individualized colorectal cancer education, psycho-oncological counseling, and a nurse-managed telephone support hotline were provided to the individuals in the experimental group within the NNP. Data were collected before NNP (once in the first week after chemotherapy), during NNP (once in the second week after chemotherapy, once in the first week after the next chemotherapy), after NNP (once in the second week after the next chemotherapy). The duration of the interventions performed via the WhatsApp application varied between 45-60 minutes between individuals.
62707606|NCT02229357|EXPERIMENTAL|OrniFlu® inactivated vaccine|
62707607|NCT02740985|EXPERIMENTAL|Arm A|AZD4635 monotherapy as nanoparticle suspension 125 mg BID
62145765|NCT00868894|EXPERIMENTAL|2|
62351726|NCT04320277|ACTIVE_COMPARATOR|Controls|All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.
62707608|NCT02740985|EXPERIMENTAL|Arm B|AZD4635 monotherapy as nanoparticle suspension 75 mg QD
62707609|NCT02740985|EXPERIMENTAL|Arm C|AZD4635 monotherapy as nanoparticle suspension 100 mg QD
62510364|NCT05178914|SHAM_COMPARATOR|The control group|The control group is defined as follows: the initial IMR has been performed but its result is not undisclosed (sham procedure) ; patients will receive standard medical treatment according to the physician's preference.
62707610|NCT02740985|EXPERIMENTAL|Arm D|AZD4635 as nanoparticle suspension 75 mg QD plus durvalumab
62707611|NCT02740985|EXPERIMENTAL|Arm E|AZD4635 as nanoparticle suspension 100 mg QD plus durvalumab
62707612|NCT02740985|EXPERIMENTAL|Arm EA|AZD4635 as nanoparticle suspension plus enzalutamide
62707613|NCT02740985|EXPERIMENTAL|Arm AA|AZD4635 as nanoparticle suspension plus abiraterone acetate
62707614|NCT02740985|EXPERIMENTAL|Arm F|AZD4635 as nanoparticle suspension plus durvaluamb in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
62145766|NCT00868894|PLACEBO_COMPARATOR|3|
62145767|NCT00868894|ACTIVE_COMPARATOR|4|
62145768|NCT02305498|EXPERIMENTAL|Vigorous yoga practice|Supervised vigorous yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
62145769|NCT02305498|ACTIVE_COMPARATOR|Restorative (gentle) yoga practice|Supervised restorative (gentle) yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
62707615|NCT02740985|EXPERIMENTAL|Arm G|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
62707616|NCT02740985|EXPERIMENTAL|Arm H|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with other solid tumours.
62707617|NCT02740985|EXPERIMENTAL|Arm I|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
62707618|NCT02740985|EXPERIMENTAL|Arm J|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
62707619|NCT02740985|EXPERIMENTAL|Arm K|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with colorectal carcinoma.
62707620|NCT02740985|EXPERIMENTAL|Arm KD|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy-naïve patients with colorectal carcinoma.
61970368|NCT02465801|EXPERIMENTAL|Group 2|"Intervention:HSA-GCSF 1.5 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.5mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.~Intervention: Drug: TE or TEC"
61970369|NCT02465801|ACTIVE_COMPARATOR|Group 3|"Intervention: GCSF~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at night o'clock a.m. from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. The maximum of usage was continuous 14 days.~Intervention: Drug: TE or TEC"
61970370|NCT05785871||Untreated Hypertension|in office SBP ≥140 at two separate occasions and currently treated with antihypertensive medications (uncontrolled), or in office SBP ≥ 140 at two different occasions and no current treatment (untreated).
61970371|NCT05785871||Normotensive|in office SBP\<140 mmHg, no treatment with antihypertensive medications
61970372|NCT05785871||Controlled Hypertension|in office SBP \<140 and current treatment with antihypertensive medications
61970373|NCT05390281||Pre-diabetic group|Patients with preoperative HbA1c 5.7-6.4% (group A) (prediabetics)
61970374|NCT05390281||Diabetic group|Patients with preoperative HbA1c \> or = 6.5% till 7% or \> 7% in case of emergency surgery or rapidly progressive cases with no time for long-term glycemic control (group B) (diabetics)
61970375|NCT02207166||user group|volunteers who are willing to receive 40 minutes video monitoring and questionnaires while operation a electronic blood pressure measuring machines.
61970376|NCT01574326|PLACEBO_COMPARATOR|FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
61970377|NCT01574326|EXPERIMENTAL|FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.
61970378|NCT04353076|EXPERIMENTAL|Young adults|Young adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
61970379|NCT04353076|EXPERIMENTAL|Older adults (no cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
61970380|NCT04353076|EXPERIMENTAL|Older adults (cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity) with ambient cooling intervention (i.e., exposure to an air-conditioned room) for hours 5-6.
61970381|NCT01906203|EXPERIMENTAL|ultramarathon|
61970382|NCT03898154|EXPERIMENTAL|Glucocorticoid (GC) group|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
61970383|NCT03898154|NO_INTERVENTION|Control (non-GC) group|No GC administration
61970384|NCT01402791||The study population|All patients included according to state inclusion and exclusion criteria.
61970385|NCT06285981||patients with femur fractures|adult patients with pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur
61970386|NCT06363851|EXPERIMENTAL|Kylo-11|Single ascending doses of Kylo-11 administered subcutaneously (SC).
61970387|NCT06363851|PLACEBO_COMPARATOR|Placebo|Administered SC.
61970388|NCT01294657||HE Group|Health Education \[HE\] - Counseling, referrals to resources + self-help materials; 2 HE interventions at Baseline + 6 month visits.
61970389|NCT01294657||MAPS Group|Motivation And Problem Solving (MAPS) - HE + 12 telephone counseling sessions over 1-year period (average 1 call/month).
61970390|NCT04010357|EXPERIMENTAL|Abemaciclib|"* Subjects will receive Abemaciclib (200 mg), orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.~* Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment."
62707621|NCT02740985|EXPERIMENTAL|Arm L|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with other solid tumours.
61970391|NCT02309879|ACTIVE_COMPARATOR|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
61970392|NCT02309879|ACTIVE_COMPARATOR|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
61970393|NCT02309879|ACTIVE_COMPARATOR|Magnesium group|Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
61970394|NCT02309879|ACTIVE_COMPARATOR|Magnesium and Lidocaine group|Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
61970395|NCT02204163|EXPERIMENTAL|Eutropin|Eutropin 0.24mg/kg/week
61970396|NCT02204163|ACTIVE_COMPARATOR|Genotropin|Genotropin 0.24mg/kg/week
61970397|NCT04461730||Parkinson disease|
61970398|NCT04461730||essential tremor|
62145770|NCT03836651|ACTIVE_COMPARATOR|Control Group|Following completion of baseline data collection, participants will be randomized to one of two groups. The research assistant will open a pre-assigned envelope in which group assignment was determined by a random number/block generator. The intervention is designed to complement guideline directed medical management. Therefore, both the intervention and control group will continue to be medically managed by their health care provider as usual. In order to avoid introducing the confound of extra attention paid to the intervention group, the control group will have the same visit and call schedule as the intervention group.
62351727|NCT02636920|OTHER|TEP-CASES|"25 Case Patients will follow the Therapeutic Education to the Patient (TEP).~In addition the following procedures will be performed:~* Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~* Children Asthma Control Test (C-ACT);~* Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~* Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
62351728|NCT02636920|NO_INTERVENTION|TEP-CONTROLS|"25 Control Patients will follow the usual care program:~* The Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~* The Children Asthma Control Test (C-ACT);~* the Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~* Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
62351729|NCT05152277|EXPERIMENTAL|Single dose escalation of HRS9531 injection in healthy subjects|
61970399|NCT04461730||dystonia|
61970400|NCT04461730||OCD|
61970401|NCT04461730||healthy volunteers|
61970402|NCT04666584|ACTIVE_COMPARATOR|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon before implantation with a Magmaris bioresorbable scaffold
61970403|NCT04666584|ACTIVE_COMPARATOR|Standard non-compliant balloon|Pre-dilatation with a non-compliant balloon before implantation with a Magmaris bioresorbable scaffold
61970404|NCT04305483|ACTIVE_COMPARATOR|Laser Bleaching|35% Hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative containing bleaching agent activated with diode laser
61970405|NCT04305483|ACTIVE_COMPARATOR|Chemical Bleaching|35% Hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water containing chemical bleaching agent used for control group without a laser activation
61970406|NCT02487693|NO_INTERVENTION|RFA alone|Patients undergo radiofrequency ablation alone.
61970407|NCT02487693|EXPERIMENTAL|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
62351730|NCT05152277|PLACEBO_COMPARATOR|Single dose of placebo in healthy adults|
62351731|NCT05152277|EXPERIMENTAL|Multiple dose escalation of HRS9531 injection in healthy subjects|
62351732|NCT05152277|PLACEBO_COMPARATOR|Multiple dose of placebo in healthy adults|
62351733|NCT02690207|EXPERIMENTAL|HZ/su Group|Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm
62351734|NCT03807115|OTHER|Intervention|Arm: Intervention: Implementation of stroke mobility guidelines
61970408|NCT04590365|EXPERIMENTAL|Coldamaris plus|verum Coldamaris plus i.e. 0.12% Iota-Carrageenan plus 0.04% Kappa-Carrageenan in 0.5% saline
62351735|NCT03807115|NO_INTERVENTION|Control|Arm: Control: Usual care
62351736|NCT03499080||Patients in medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
61970409|NCT04590365|PLACEBO_COMPARATOR|Coldamaris sine|Coldamaris sine i.e. 0.5% saline
61970410|NCT05178524|EXPERIMENTAL|Bifico Group|Continued administration during perioperative period
61970411|NCT05178524|NO_INTERVENTION|Control Group|No intervention
61970412|NCT04205071|EXPERIMENTAL|Treatment (lorcaserin)|Patients receive lorcaserin PO on day 1. The starting dose of lorcaserin will be 10 mg.
61970413|NCT03552263|EXPERIMENTAL|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 19 days."
61970414|NCT03552263|EXPERIMENTAL|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 12 days followed by using four T89 capsules each time by oral administration twice daily for 7 days"
61970415|NCT03552263|PLACEBO_COMPARATOR|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 19 days.
61970416|NCT05445986||group1|socket with intact buccal bone plate
61970417|NCT05445986||group 2|socket with damaged buccal bone plate
61970418|NCT00326456|EXPERIMENTAL|carboplatin and liposomal doxorubicin|
61970419|NCT00326456|ACTIVE_COMPARATOR|carboplatin and paclitaxel|
61970420|NCT02708160|PLACEBO_COMPARATOR|Fluoride Free toothpaste|Fluoride free (0%), silica based toothpaste
61970421|NCT02708160|EXPERIMENTAL|1.1% Fluoride toothpaste|Prevident 5000 Plus, silica based toothpaste
61970422|NCT02708160|ACTIVE_COMPARATOR|0.243% Fluoride Toothpaste|silica based fluoride toothpaste
61970423|NCT01119885||001|fentanyl matrix Knee osteoarthritis starting with 12mcg/h (flexible dose)
61970424|NCT01119885||002|fentanyl matrix Hip osteoarthritis starting with 12mcg/h (flexible dose)
61970425|NCT01386554|EXPERIMENTAL|80 U Acthar|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) two times per week
61970426|NCT01386554|PLACEBO_COMPARATOR|1.0 mL Placebo|Placebo (1.0 mL) two times per week
61970427|NCT01386554|EXPERIMENTAL|40 U Acthar|Acthar (Repository Corticotropin Injection) 40 U (1.0 mL) two times per week
62145771|NCT03836651|EXPERIMENTAL|Intervention Group|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants assigned to the intervention group will receive dietary antioxidants as V8® Low Sodium 100% vegetable juice.
62145772|NCT04213807|EXPERIMENTAL|MAA868|Subcutaneous injection on Day 1 with two subsequent monthly injections
61970428|NCT05160220|ACTIVE_COMPARATOR|Psilocybe cubensis|0.5 g dried and powdered P. cubensis in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.
61970429|NCT05160220|PLACEBO_COMPARATOR|Inactive placebo|Same weight of inactive placebo in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.
62145773|NCT04213807|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
62145774|NCT05119699|EXPERIMENTAL|Active rTMS treatment|Patients will receive accelerated TBS
61970430|NCT05076903|EXPERIMENTAL|OFA group|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
61970431|NCT05076903|ACTIVE_COMPARATOR|Control group|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
61970432|NCT01694589|EXPERIMENTAL|LDE-225|LDE-225: dose - 800 mg, taken by mouth once daily for 2 weeks.
61970433|NCT05993260|ACTIVE_COMPARATOR|Control|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Please book yours now at \[LINK\] or by calling 119."
61970434|NCT05993260|EXPERIMENTAL|Simple|"Received the text message You can now book your free NHS Covid-19 vaccine. Please book yours now at \[LINK\] or by calling 119."
61970435|NCT05993260|EXPERIMENTAL|Reserved|"Received the text message Your free NHS Covid-19 vaccine is waiting for you. Please book yours now at \[LINK\] or by calling 119."
61970436|NCT05993260|EXPERIMENTAL|Top of queue|"Received the text message You've reached the top of the queue and are a priority for getting a free NHS Covid-19 vaccine. Please book yours now at \[LINK\] or by calling 119."
61970437|NCT05993260|EXPERIMENTAL|Join the millions|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Join the millions who have already had theirs. Please book yours now at \[LINK\] or by calling 119."
62145775|NCT01349270|EXPERIMENTAL|immunoglobulin|patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months
62145776|NCT01349270|ACTIVE_COMPARATOR|prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
62145777|NCT01332266|ACTIVE_COMPARATOR|Active Comparator; Phase 1b: Cohort 1,2,and 3|"Phase 1b:~Cohort 1; 200 mg E7050 + 250 mg/m2 cetuximab Cohort 2; 300 mg E7050 + 250 mg/m2 cetuximab Cohort 3; 400mg E7050 + 250mg/m2 cetuximab~Phase 2: Arm 1; MTD E7050 + 250 mg cetuximab Arm 2; 250 mg cetuximab~Interventions: Drug cetuximab"
62145778|NCT01332266|ACTIVE_COMPARATOR|Phase 2|"Phase 2:~Arm 1; MTD E7050 + 250 mg/m2 cetuximab Arm 2; 250 mg/m2 cetuximab"
62145779|NCT06064591||Pilot study Belgium Patients|"Patients (P. falciparum-infected)~No intervention 6 ml of venous blood sampled at one time point"
62145780|NCT06064591||Pilot study Belgium Controls|Control non-infected individuals No intervention 6 ml of venous blood sampled at one time point
62145781|NCT06064591||Work package 1 Burkina Faso Asymptomatic|Asymptomatic (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point. 300µl of finger prick blood at four follow-up visits 24, and 48 and 72h and day 10 after the enrollment.
62145782|NCT06064591||Work package 1 Burkina Faso uncomplicated patients|uncomplicated patients (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point.
62145783|NCT06064591||Work package 1 Burkina Faso Controls|Control non-infected individuals No intervention Venous blood sample (maximum of 8 ml) at 1 time point.
62145784|NCT06064591||Work package 2 Mozambique Uncomplicated malaria patients|Uncomplicated malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.
62145785|NCT06064591||Work package 2 Mozambique Severe malaria patients|Severe malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.
62145786|NCT05864196|EXPERIMENTAL|Men with low to intermediate risk prostate cancer|Once a patient is deemed eligible, they will be scheduled for treatment with SBRT, which should be completed within 14 days of screening. Follow up will occur 30 days post radiation and every 4 months, post- radiation for the first 2 years. After the first 2 years of follow up, visits will occur every 6 months until year 5.
62145787|NCT01049516|OTHER|Minimal Contact Control|
62145788|NCT01049516|EXPERIMENTAL|PE-Massed|
62145789|NCT01049516|ACTIVE_COMPARATOR|PE-Spaced|
62145790|NCT01049516|ACTIVE_COMPARATOR|Present-Centered Therapy (PCT)|
61970438|NCT05993260|EXPERIMENTAL|Convenience|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Choose a time and place that suits you. Please book yours now at \[LINK\] or by calling 119."
61970439|NCT05993260|EXPERIMENTAL|Protection against virus|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Getting vaccinated is the best protection against coronavirus. Please book yours now at \[LINK\] or by calling 119."
61970440|NCT05993260|EXPERIMENTAL|Protect you and those close to you|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Getting the vaccine is the best way to protect yourself and those close to you against coronavirus. Please book yours now at \[LINK\] or by calling 119."
61970441|NCT01342796|EXPERIMENTAL|Arm 1|
61970442|NCT01342796|ACTIVE_COMPARATOR|Arm 2|
61970443|NCT01832987|EXPERIMENTAL|co-trimoxazole|On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.
61970444|NCT04158440|EXPERIMENTAL|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg)|Participants receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
62145791|NCT04242797|ACTIVE_COMPARATOR|Calmare|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
61970445|NCT04158440|ACTIVE_COMPARATOR|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Participants receive totally 4 cycles of Placebo combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Placebo
61970446|NCT06436482||Control group|non-smoking with normal lung function, no other pulmonary diseases besides pulmonary nodule as indicated by chest computed tomography (CT).
61970447|NCT06436482||Pre-stage of Chronic Obstructive Pulmonary Disease (Pre-COPD)|Patients exhibit early pulmonary abnormalities, such as, CT scans show the presence of emphysema, bullae, and air trapping; pulmonary function manifested as preserved ratio impaired spirometry (PRISm). PRISm was defined as a normal ratio \[the forced expiratory volume in one second (FEV1) / forced vital capacity (FVC) ≥ 0.7\] after inhalation of a bronchodilator, but impaired ventilatory function \[percentage of forced expiratory volume in the first second to the expected value (FEV1%) and/or percentage of FVC to the expected value (FVC%) \< 80%\], with concurrent structural changes in the lungs (such as emphysema) and/or physiological abnormalities (such as hyperinflation, decreased diffusion capacity, rapid decline in FEV1 )
61970448|NCT06436482||Chronic Obstructive Pulmonary Disease (COPD)|COPD was diagnosed based on GOLD guideline \[1\]; No acute exacerbations within 4 weeks; CT scans show no other pulmonary diseases besides COPD; pulmonary function test results were available from within the last 3 days. All COPD patients were treatment-naive except for those with at stage III-IV who received maintenance therapy
61970449|NCT02345850|ACTIVE_COMPARATOR|Tacrolimus/Methotrexate Control Arm|"Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m\^2 for a maximum of 4 doses post-transplant.~Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice."
61976291|NCT05571098|NO_INTERVENTION|No intervention|No intervention was applied to this group.
61976292|NCT02268864|EXPERIMENTAL|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
62145792|NCT04242797|ACTIVE_COMPARATOR|Traditional TENS|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
62145793|NCT06356285|NO_INTERVENTION|Control Arm - Antimicrobial Resistance|"Participants will be shown an image of a poster at a bus stop. This will contain information about antibiotics, and will have the words Antimicrobial Resistance at the top."
62145794|NCT06356285|EXPERIMENTAL|Intervention Arm 1 - Superbugs|"Participants will be shown an image of a poster at a bus stop. This will contain information about antibiotics, and will have the word Superbugs at the top."
62145795|NCT06356285|EXPERIMENTAL|Intervention Arm 2 - Antibiotic Resistance|"Participants will be shown an image of a poster at a bus stop. This will contain information about antibiotics, and will have the words Antibiotic Resistance at the top."
62145796|NCT06356285|EXPERIMENTAL|Intervention Arm 3 - Antibiotic Crisis|"Participants will be shown an image of a poster at a bus stop. This will contain information about antibiotics, and will have the words The Antibiotic Crisis at the top."
62145797|NCT01328496|OTHER|Research Arm|"Participant with high-risk hematologic malignancies undergoing Hematopoietic Cell Transplantation, who do not have a suitable Human Leukocyte Antigen -matched related/sibling donor, Matched Unrelated Donor or Killer immunoglobulin receptors ligand mismatched haploidentical donor identified, will receive a single UCB unit.~Intervention: Preparative Regimen"
62145798|NCT01328496|OTHER|Observation Arm|"Patients requiring two UCB units will be eligible for UCBT01 on the observational arm.~Intervention: Preparative Regimen"
62145799|NCT01801007|OTHER|Flow Re-Direction Endoluminal Device|
62145800|NCT03196869|EXPERIMENTAL|Chrono-chemotherapy group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group
62145801|NCT03196869|OTHER|Routine intravenous drip|control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
62707622|NCT02740985|EXPERIMENTAL|Arm CA|AZD4635 capsule formulation monotherapy 75 mg, 150 mg, and 200 mg QD. A lower dose of 125 mg or 100 mg may be given. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CA. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycle 1 and Cycle 2 will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
62707623|NCT02740985|EXPERIMENTAL|Arm CB|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus durvalumab and oleclumab. The pharmacokinetics of AZD4635 capsule formulation will be characterized on Cycle 1, 2, and 4 (Day 1) in Arm CB. Steady-state pharmacokinetics will be assessed on Cycle 2 Day 15. Cycle 1 will be administered in a 3-week cycle to assess the safety and dose-limiting toxicity (DLT). PKs will also be collected on Day 1 of Cycles 3 and 5.
62145802|NCT00690404|EXPERIMENTAL|1|
62145803|NCT02089529|ACTIVE_COMPARATOR|Ibuprofen/Ibumetin|Ibumetin is administrated. Intervention: No information about the effect.
62145804|NCT02089529|PLACEBO_COMPARATOR|Placebo|Placebo is administrated. Intervention: No information about the effect.
62145805|NCT02089529|ACTIVE_COMPARATOR|Ibuprofen/Ibumetin+positive information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
62145806|NCT02089529|PLACEBO_COMPARATOR|Placebo+positive information|Placebo is administrated. Intervention:The patient receive written information that the capsule is Ibumetin.
62145807|NCT02089529|ACTIVE_COMPARATOR|Ibuprofen/Ibumetin+neutral information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
62145808|NCT02089529|PLACEBO_COMPARATOR|Placebo+neutral information|Placebo is administrated. Intervention:The patients receive information that the capsule is placebo.
62145809|NCT02089529|NO_INTERVENTION|Control|Control condition
62145810|NCT00777049|EXPERIMENTAL|ER+ and/or PgR+ (Arm I)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
62351737|NCT03499080||Patients in treatment as Usual Åråsen|Inpatient unit colocated with the medication free unit. Same level of care. Similar treatment program, shorter treatment duration (on average 3 weeks).
62145811|NCT00777049|EXPERIMENTAL|ER- and PgR- (Arm II)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
62145812|NCT01517503|EXPERIMENTAL|Cognitive Therapy (CT)|Cognitive Therapy (CT)
62510365|NCT01222949|EXPERIMENTAL|Asian Healthy Volunteers|Asian males with a body weight ≤ 65 kg (12 subjects) Asian females with a body weight ≤ 65 kg (12 subjects)
62510366|NCT01222949|EXPERIMENTAL|Caucasian Healthy Volunteers|Caucasian males with a body weight ≤ 65 kg (12 subjects) Caucasian females with a body weight ≤ 65 kg (12 subjects) Caucasian males with a body weight \> 65 kg (24 subjects)
61970450|NCT02345850|EXPERIMENTAL|CD34 Selection Arm|"Mobilized CD34-selected Peripheral Blood Stem Cell graft~Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.~Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).~Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products."
61970451|NCT02345850|EXPERIMENTAL|Post Transplant Cyclophosphamide|Unmanipulated Bone Marrow Graft with Cyclophosphamide
61970452|NCT03658655|EXPERIMENTAL|Stem Cells From Human Exfoliated Teeth|According to the weight of 0.1IU /kg with Stem Cells From Human Exfoliated Teeth, three injections will be given respectively at the time of enrollment, one week and four weeks after enrollment.
61970453|NCT00642577|EXPERIMENTAL|1|
62510367|NCT02285205|EXPERIMENTAL|Lobeglitazone|
62707624|NCT02740985|EXPERIMENTAL|Arm CC|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus docetaxel. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CC. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycles will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
62707625|NCT02320188|EXPERIMENTAL|Eccentric exercise|Thirty sessions of Eccentric training in twelve weeks. Average of two sessions per week without spacing higher than eight days between two sessions.
61970454|NCT00642577|ACTIVE_COMPARATOR|2|
61970455|NCT02635555|EXPERIMENTAL|Adjusted Spinal Dose|"Patients in this group receive height and weight adjusted dose for spinal anesthesia.During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
61970456|NCT02635555|ACTIVE_COMPARATOR|Standard Spinal Dose|"Patients in this group receive a fixed standard dose for spinal anesthesia. During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
62145813|NCT01517503|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT)
62145814|NCT01827982|EXPERIMENTAL|Part 1 - Cohort 1: JNJ-54861911 1 mg|Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.
62145815|NCT01827982|EXPERIMENTAL|Part 1 - Cohort 2: JNJ-54861911 3 mg|
62145816|NCT01827982|EXPERIMENTAL|Part 1 - Cohort 3: JNJ-54861911 9 mg|
62510368|NCT05373381|EXPERIMENTAL|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles.
62510369|NCT02720133||Patients with cardiovascular risk factors who fast Ramadan|Stable clinical and biochemical parameters before Ramadan fasting
62510370|NCT05149924|EXPERIMENTAL|QL1012，Recombinant Human Follicle Stimulating Hormone for Injection|
62510371|NCT05149924|ACTIVE_COMPARATOR|Gonal-f ®|
62510372|NCT01828645|NO_INTERVENTION|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
62510373|NCT01828645|EXPERIMENTAL|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
62707626|NCT02320188|EXPERIMENTAL|Concentric exercise|Thirty sessions of Concentric training in twelve weeks. Average of three sessions per week without spacing higher than eight days between two sessions.
62510374|NCT02070757|EXPERIMENTAL|Ceftolozane/tazobactam|Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.
62510375|NCT02070757|ACTIVE_COMPARATOR|Meropenem|Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.
62510376|NCT00858013|ACTIVE_COMPARATOR|Nateglinide|Nateglinide 90\~120mg three times a day
62510377|NCT00858013|ACTIVE_COMPARATOR|Glimepiride|Glimepiride 1\~2mg once a day
62510378|NCT00697840|EXPERIMENTAL|Group A|
61970457|NCT03266107|EXPERIMENTAL|Treatment|BVN Ablation
61970458|NCT04161560|EXPERIMENTAL|use of the cetuximab-IRDye800|four groups : control group, 1% dose group (1% of therapeutic dose; 2.5 Mg/m2) and 10% dose groups (10%of therapeutic dose ;25mg/m2) and 25% dose group (25%of therapeutic dose; 62.5mg/m2)
61970459|NCT01429753|ACTIVE_COMPARATOR|Standard LV lead placement|
61970460|NCT01429753|EXPERIMENTAL|Advanced Imaging Guided LV Lead Placement|
61970461|NCT00309387|EXPERIMENTAL|Centrum|multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
62145817|NCT01827982|EXPERIMENTAL|Part 2 - Cohort 4: JNJ-54861911 9 mg|
62145818|NCT01827982|EXPERIMENTAL|Part 2 - Cohort 5: JNJ-54861911 27 mg|
62145819|NCT01827982|EXPERIMENTAL|Part 2 - Cohort 6: JNJ-54861911 81 mg|
62145820|NCT01827982|EXPERIMENTAL|Part 2 - Cohort 7: JNJ-54861911 160 mg|
62145821|NCT01827982|EXPERIMENTAL|Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])|
62145822|NCT01827982|PLACEBO_COMPARATOR|Parts 1 through 3 - Placebo|Participants in each cohort will receive matching placebo.
62145823|NCT01728324|EXPERIMENTAL|Randomised 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
62145824|NCT01728324|EXPERIMENTAL|Randomised 16-week arm|BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
62510379|NCT00697840|ACTIVE_COMPARATOR|Group B|
62510380|NCT00697840|EXPERIMENTAL|Group C|
62510381|NCT03244475|EXPERIMENTAL|Transcranial Electrical Stimulation (TES)|mTBI Veterans blindly assigned to a 6 week of TES, either IASIS neurofeedback treatment or Nexalin, with 2-3 sessions per week.
62510382|NCT03244475|PLACEBO_COMPARATOR|Sham Treatment|mTBI Veterans blindly assigned to a sham treatment for 6 weeks with 2-3 sessions per week.
62510383|NCT03244475|NO_INTERVENTION|Control|Veterans who are age-, gender-, education-, combat exposure-, and socioeconomically-matched. They will not undergo a treatment.
62510384|NCT01647958|EXPERIMENTAL|Treatment Arm|Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
62510385|NCT01647958|ACTIVE_COMPARATOR|Control|Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial. Patients will be offered TIF crossover procedure upon completion of month-6 follow-up visit.
62510386|NCT06615830|EXPERIMENTAL|Organoid-driven second-line chemotherapy|"The arm will include patients with diagnosis of metastatic pancreatic adenocarcinoma. After complete disease staging, patients will undergo laparoscopic surgical biopsy of metastatic tumoral tissue. The tissue will serve for the generation of patient-derived organoids on which potentially effective drugs will be benchmarked.~Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist). Upon disease progression, the drug predicted to be the most effective agent will be implemented as second-line therapy."
62510387|NCT04355299|EXPERIMENTAL|Intervention group|a mixed exercise program including aerobic, balance, and resistance exercises that were personally tailored.
62510388|NCT04355299|OTHER|control group|usual care
62510389|NCT06004869|EXPERIMENTAL|EMA/I CBT-I group|The participants allocated to the EMI/A CBT-I group will receive 6 weeks of smartphone-based CBT-I for approximately 1 hour per week. The EMA feature will capture the participant's momentary ratings of experiences to support therapeutic decision making. The trained therapist will prescribe EMI, provide personalised sleep advice, and adjust the treatment by dynamically adapting real-time rest-activity assessments collected using EMA and wearable devices. The participants will receive tailored moment-specific feedback from therapists when daytime symptoms are indicated. Therapists will also monitor the relationship between daytime symptoms (EMA app) and the sleep-wake pattern (wearables).
62510390|NCT06004869|ACTIVE_COMPARATOR|Pure self-help CBT-I group|The participants in the pure self-help CBT-I group will receive 6 weeks of self-help CBT-I without EMA/I and therapist support. The CBT-I content will be identical to the content used in the EMI/A CBT-I group.
62510391|NCT06004869|NO_INTERVENTION|Care as usual|
62510392|NCT04974619||Aim 1 Only: Online Survey group|Spanish speaking young Latino men who have sex with men (YLMSM), ages 18-26 (approximately 260 in Florida and Puerto Rico) will be asked to complete a Qualtrics survey.
61970462|NCT00309387|PLACEBO_COMPARATOR|placebo|placebo pills. One tablet a day for the whole study duration.
61970463|NCT01749462||Oxis|
61970464|NCT03465202|EXPERIMENTAL|Capecitabine|
61970465|NCT03869346||GG|wild-type homozygote (CYP3A4\*1/\*1, GG)
61970466|NCT03869346||GA|mutant heterozygote (CYP3A4\*1/\*1G, GA),
61970467|NCT03869346||AA|mutant homozygote (CYP3A4\*1G/\*1G, AA)
62510393|NCT04974619||Aim 2 Only: Interview group|Individual interviews will be conducted with key healthcare stakeholders (i.e.,healthcare clinical leadership, providers and staff, community-based organization staff)
62510394|NCT04974619||Aim 3 Only: Focus Groups or Interview Group|Focus groups and/or individual interviews will be conducted in-person and/or remotely to receive feedback on the HPV vaccine education materials. Focus groups and/or individual interviews will be conducted with 24 young adult Latino men who have sex with men (YLMSM) in either English or Spanish (approximately 12 in Puerto Rico and approximately 12 in Florida). The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference, and aesthetics of the theoretically informed HPV education materials culturally targeted for Spanish- and/or English-speaking YLMSM.
61970468|NCT01804296|EXPERIMENTAL|Part 2 Active|Open-label, active repetitive transcranial magnetic stimulation
61970469|NCT01101932|EXPERIMENTAL|(Part 1) PF-04308515|
61970470|NCT01101932|PLACEBO_COMPARATOR|(Part 1) Solution Placebo|
61970471|NCT01101932|EXPERIMENTAL|(Part 2) PF-04308515 Tablet|
61970472|NCT01579175|NO_INTERVENTION|Standard postoperative care|
61970473|NCT01579175|EXPERIMENTAL|Chewing gum arm|Sugar free (extra, spearment) chewing gum given to the patient to chew during waking hours every four hours for 15 minutes
61970474|NCT01195415|EXPERIMENTAL|Treatment (vismodegib, gemcitabine hydrochloride)|Patients receive vismodegib PO QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 (beginning in course 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61970475|NCT00971854|EXPERIMENTAL|60 Hz stimulation|Experimental reduced frequency pallidal stimulation
61970476|NCT00971854|NO_INTERVENTION|130 Hz stimulation|Current standard pallidal stimulation setting
61970477|NCT02322567||LV diastolic dysfunction|
61970478|NCT02322567||No LV diastolic dysfunction|
61970479|NCT01616524|EXPERIMENTAL|Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir|
61970480|NCT01616524|EXPERIMENTAL|Arm 2: pegIFNλ + Ribavirin + Daclatasvir|
61970481|NCT01616524|EXPERIMENTAL|Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir|
61970482|NCT00873756|EXPERIMENTAL|A|
61970483|NCT06163170||Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma|
61970484|NCT06163170||Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma|
62145825|NCT01728324|EXPERIMENTAL|Allocated 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)
61970485|NCT00865774|EXPERIMENTAL|1|Arm number 1 focuses on the traditional quantity frequency model.
61970486|NCT00865774|EXPERIMENTAL|2|Arm number 2 targets subjective drunkenness.
61976293|NCT05308745|ACTIVE_COMPARATOR|Probiotic group|Participants within this group consumed Yakult® as research product 1 bottle/day for 24 weeks (168 days).
61976294|NCT05308745|PLACEBO_COMPARATOR|Placebo group|Participants within this group consumed placebo as research product 1 bottle/day for 24 weeks (168 days).
62510395|NCT04031092|EXPERIMENTAL|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for patients with chronic pain.
62510396|NCT04031092|ACTIVE_COMPARATOR|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
62510397|NCT01713088|EXPERIMENTAL|Multisystemic therapy|MST is a family- and community-based intervention that establishes close contact with families to understand and deal with the factors that cause the young person's antisocial behaviour. The intervention targets the individual's adjustment, family relationships, school functioning and peer group affiliations. Therapists help caretakers develop skills to intervene and operate changes in important domains such as young person's individual adjustment, their family relationships, school functioning, and peer group affiliations.
62510398|NCT01713088|ACTIVE_COMPARATOR|YOT (usual services)|YOT intervention consisted of services currently available to young offenders in accordance with the Youth Justice Board National Standards.These services included supporting the young person to re-engage with education, with substance misuse problems and anger management; training them in social problem-solving skills; and programs to decrease vehicle-crime, violent-offending and knife crime. The treatments were delivered by professional social workers, specialist therapists or probation officers.
62510399|NCT04828434|EXPERIMENTAL|Virtual Individual Cognitive Stimulation Therapy|"Virtual Cognitive Stimulation Therapy (V-iCST), a psychosocial intervention, is a modified version of CST for people with mild to moderate dementia. Like the original CST, each of the 14 sessions will begin with a warm-up activity, which includes an orientation task and discussion of current affairs, followed by a main activity.~V-iCST will be prescribed to participants twice a week, for 7 weeks and each session is approx. 45 minutes. The intervention will be delivered by trained professionals, such as research staff, psychologists, and trainee clinical psychologists. All facilitators will have experience in dementia care and will have completed the CST training."
62510400|NCT04828434|NO_INTERVENTION|Treatment as usual|Standard care.
62510401|NCT01099306|ACTIVE_COMPARATOR|intervention|pharmacist-physician collaborative approach to manage Metabolic syndrome
62510402|NCT01099306|NO_INTERVENTION|control|physician only team to manage Metabolic syndrome
62510403|NCT02367625|EXPERIMENTAL|Arm 1|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
62510404|NCT02367625|ACTIVE_COMPARATOR|Arm 2|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
62510405|NCT05039476|ACTIVE_COMPARATOR|Retinol face cream|Retinol face cream on one half of the participant's face
61970487|NCT00846430|EXPERIMENTAL|Open-Label Intervention|This is a phase II single arm study with sequential treatments available by response where all participants begin therapy with a combination of celecoxib and interferon alpha-2b (CI, treatment-1). Response to CI therapy will be assessed at six months by clinical and radiographic evaluations. Those patients who have achieved a partial response (improvement in pain, improvement in functioning, or ≥50% reduction in tumor size) or complete response (resolution of pain, and normalization of functioning with a ≥ 90% reduction in tumor size) will continue with the same CI therapy for up-to two years on study.
61970488|NCT00967772|EXPERIMENTAL|Naftopidil|
61970489|NCT05551559|EXPERIMENTAL|Bariatric surgery|
62510406|NCT05039476|PLACEBO_COMPARATOR|Placebo face cream|Placebo face cream on one half of the participant's face
62510407|NCT04819373|EXPERIMENTAL|BDB001|BDB001 will be administered intravenously as monotherapy in subjects with histologically-confirmed unresectable or metastatic solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment either as monotherapy or in combination with other therapies.
62510408|NCT06216171|EXPERIMENTAL|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of the dosis to actual anatomy of the day by a specialist of radiation oncology and a medical physicist
62510409|NCT06216171|ACTIVE_COMPARATOR|Standard conventional Treatment Arm, IGRT|Standard treatment option, image guided radiotherapy without online adaptation
62510410|NCT01784198|EXPERIMENTAL|Protein Intake|Dietary supplement:Protein intake
61970490|NCT03854305|EXPERIMENTAL|PRV-6527|Oral administration, 2X daily for 12 weeks
61970491|NCT03854305|PLACEBO_COMPARATOR|Placebo|Oral administration, 2X daily for 12 weeks
62145826|NCT02173288|ACTIVE_COMPARATOR|Standard medical therapy|Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
62539402|NCT06582056|OTHER|Healthy Participant or Participant with Gingivitis with Hemoglobin A1c level 8.0-10.0|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
62539403|NCT06582056|OTHER|Participant with Stage I/Stage II Periodontal Disease with no Type 2 Diabetes Mellitus|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
62707627|NCT02320188|NO_INTERVENTION|No training (control)|Usual activities. No further training during the observation period
62145827|NCT02173288|ACTIVE_COMPARATOR|Midodrine group|Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
62145828|NCT02173288|ACTIVE_COMPARATOR|Tolvaptan group|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
62145829|NCT02173288|EXPERIMENTAL|Tolvaptan plus midodrine arm|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day
62145830|NCT00655109|ACTIVE_COMPARATOR|1|Olopatadine
62145831|NCT00655109|ACTIVE_COMPARATOR|2|Fluticasone
62145832|NCT00655109|PLACEBO_COMPARATOR|3|Placebo nasal spray
62145833|NCT00655109|PLACEBO_COMPARATOR|4|Placebo Eyedrops
62351738|NCT03499080||Patients in treatment as Usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
62351739|NCT00781963|EXPERIMENTAL|CBT-I|Manual-based cognitive behavioral therapy for insomnia (CBT-I) provided in 5 individual or group sessions by a non-clinician sleep coach.
61970492|NCT05426902|EXPERIMENTAL|SLE@Duke|Clinic providers in Duke Rheumatology outside of the Duke Lupus Clinic are eligible to participate in the SLE@Duke intervention. Participants complete a baseline survey and training in the Type 1 \& 2 SLE Model. They are asked to perform the intervention for all eligible patients over 4 weeks. Patients complete a survey at the end of their clinic visit, and providers complete a survey at the end of the 4 week intervention period. All participating providers were invited to an in-depth interview at the end of the intervention period.
61970493|NCT01877070||early stage prostate patients & their partners/close allies|
61970494|NCT00441883|EXPERIMENTAL|PF-03187207 and Latanoprost Vehicle|One drop of each, once daily in study eye for 28 days
61970495|NCT00441883|ACTIVE_COMPARATOR|Latanoprost 0.005% and PF-03187207 Vehicle|One drop of each, once daily in study eye for 28 days
61970496|NCT00696696|EXPERIMENTAL|Combination GES|Combination of Gemcitabine, Erlotinib, and Sorafenib
61970497|NCT05384015|EXPERIMENTAL|Experimental|Trial Treatment administration: at induction phase cycles will be administered every 3 weeks. For carboplatin (AUC5) and etoposide (100mg/m2) the maximum dose exposure will be 4 cycles or until reaching a discontinuation criterion. At this induction phase lenvatinib (8mg) will be orally administered daily and pembrolizumab (200mg) IV every 3 weeks. At maintenance phase lenvatinib will be administered at 20 mg dose and pembrolizumab at the same dose (200mg) until study intervention completion (total of 35 cycles of pembrolizumab/no treatment duration limit for lenvatinib) or reaching a discontinuation criterion.
61970498|NCT04481581|EXPERIMENTAL|Intervention arm- Oxygen titration with electronic alerts|Oxygen titration will be done based on electronic alerts and decisions support tool by Respiratory Therapists, if FiO2=\> 0.4 and SpO2 =\>94% for more than 45 minutes
61970499|NCT04481581|NO_INTERVENTION|Control Arm- Oxygen titration by one time physician orders|Oxygen titration will be done ventilator management guidelines for the medical intensive care unit. Titration is done by one-time orders.
61970500|NCT02606604|EXPERIMENTAL|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
61970501|NCT02606604|ACTIVE_COMPARATOR|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
61970502|NCT02559245|EXPERIMENTAL|Ficus carica|45 grams Ficus carica before breakfast and lunch with 1 glass of water every day respectively (total consumption: Ficus carica 90g/d)
62510411|NCT05596292|EXPERIMENTAL|early mobilization protocol and immersive virtual reality|Three days of an early mobilization protocol using immersive virtual reality glasses. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation. The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
62145834|NCT04007705|EXPERIMENTAL|Anti-inflammatory and low FODMAPs diet|The anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy and processed food, for three months. During the first month, a low FODMAPs diet will be implemented, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months. Additionally, some potentially anti-inflammatory foods will be promoted: Omega-3 through specific fish (tuna fish, salmon, sardine, horse mackerel) and nuts, antioxidant rich foods, such as fruit and vegetables, and the maintenance of glycemic index.
62145835|NCT04007705|ACTIVE_COMPARATOR|Control|Dietary counselling based on general recommendations for healthy eating according to the World Health Organization
62145836|NCT03319836||Pre-very high protein enteral nutrition|20 enterally fed critically ill adult patients prior to the introduction of a very high protein enteral nutrition formula \[2015\].
62510412|NCT05596292|ACTIVE_COMPARATOR|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
61970503|NCT02559245|EXPERIMENTAL|Descurainia Sophia|30 grams Descurainia Sophia before breakfast and lunch with 1 glass of water every day respectively (total consumption: Descurainia Sophia 60g/d)
61970504|NCT02559245|NO_INTERVENTION|controled|participants will follow their usual diet
61970505|NCT01035515|EXPERIMENTAL|Arm One|Arm 1 of 6 cross-over arms
61970506|NCT01035515|EXPERIMENTAL|Arm Two|Arm 2 of 6 cross-over arms
62145837|NCT03319836||Post-very high protein enteral nutrition|20 enterally fed critically ill adult patients post the introduction of a very high protein enteral nutrition formula \[2016\].
62351740|NCT00781963|ACTIVE_COMPARATOR|Control|Non-directive sleep education provided in 5 group sessions by a health educator.
61970507|NCT01035515|EXPERIMENTAL|Arm Three|Arm 3 of 6 cross-over arms
61970508|NCT01035515|EXPERIMENTAL|Arm Four|Arm 4 of 6 cross-over arms
61970509|NCT01035515|EXPERIMENTAL|Arm Five|Arm 5 of 6 cross-over arms
61970510|NCT01035515|EXPERIMENTAL|Arm Six|Arm 1 of 6 cross-over arms
61970511|NCT03445650|EXPERIMENTAL|ADX-102 1% Topical Dermal Cream (reproxalap)|
61970512|NCT03445650|PLACEBO_COMPARATOR|Vehicle of ADX-102 Topical Dermal Cream|
61970513|NCT01852578|EXPERIMENTAL|1|
61970514|NCT03383107||Cohort 1a - Prostate Cancer|Standard fractionation RT to 81 Gy in 45 fx over 9 weeks
61970515|NCT03383107||Cohort 1b - Prostate Cancer|Hypofractionated RT to 36.25 Gy in 5 fx over 1-2 weeks
61970516|NCT03383107||Cohort 2a - Breast cancer|Standard fractionation breast and nodal RT to 50 Gy in 25 fx over 5 weeks
61970517|NCT03383107||Cohort 2b - Breast Cancer (Partial Breast )|Partial breast RT to 30 Gy in 5 fx over 2 weeks
61970518|NCT03314402|EXPERIMENTAL|group 1|Jaktinib Dihydrochloride Monohydrate
61970519|NCT03314402|PLACEBO_COMPARATOR|group 2|Placebo
62510413|NCT06368141|EXPERIMENTAL|NeoCHIC group|
62510414|NCT01790230|NO_INTERVENTION|Standard of Care|Standard of Care Arm - subjects treated by routine manner
61970520|NCT01405599|EXPERIMENTAL|Control|Healthy subjects
61970521|NCT01405599|EXPERIMENTAL|Severe hepatic impairment|CTP class C
61970522|NCT01405599|EXPERIMENTAL|Moderate hepatic impairment|CTP class B
61970523|NCT01405599|EXPERIMENTAL|Mild hepatic impairment|CTP class A
61970524|NCT02876263||Study group|Elective and emergency surgery for aneurysm or dissections of the ascending aorta, operated under extracorporeal circulation, protective deep therapeutic hypothermia and circulatory arrest.
61970525|NCT02876263||On-pump CABG Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease under extracorporeal circulation
61970526|NCT02876263||OPCAB Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease with a beating heart
61970527|NCT00776958||Ovarian or Breast Cancer Study Registry|
62510415|NCT01790230|EXPERIMENTAL|LifeSeal™ Kit|LifeSeal™ Kit Arm - subjects treated with the LifeSeal™ Kit device + Standard of Care treatment
62510416|NCT03318887||Sofosbuvir/daclatasvir|Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014
61970528|NCT01396148|EXPERIMENTAL|Children with GIST|children ages 6yrs-\<18yrs
61970529|NCT01396148|EXPERIMENTAL|Young adults with GIST|young adults ages 18yrs-\<21 yrs
61970530|NCT03879122|ACTIVE_COMPARATOR|ADT + Docetaxel|ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
61970531|NCT03879122|EXPERIMENTAL|ADT + Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
61970532|NCT03879122|EXPERIMENTAL|ADT + Ipilimumab / Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
61970533|NCT01971411||Community dwelling elderly black females|
62510417|NCT05061914|ACTIVE_COMPARATOR|pericardiocentesis|vitally unstable patients with tamponading pericardial effusion undergone percutaneous gradual drainage by a central venous catheter
62510418|NCT05061914|ACTIVE_COMPARATOR|subxiphoiodal drainage|drainage of the pericardial effusion through a subxiphoidal midline incision
62707628|NCT06109935||Children with GHD|Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. Administration will be according to the approved product labelling. The decision to treat a participant with Sogroya® is made at the treating physician's discretion before and independently from the decision to include the patient in this study.
61970534|NCT04245332|EXPERIMENTAL|Fish Oil|This group will receive fish oil (4g/d).
61970535|NCT04245332|PLACEBO_COMPARATOR|Placebo|This group will receive coconut oil (4g/d) as an iso-energetic, iso-lipidic placebo comparator to the fish oil arm.
62510419|NCT05061914|ACTIVE_COMPARATOR|thoracotomy|encysted and undiagnosed pericardial effusion drainage through anterior thoracotomy performing a pericardiopleural window and take a pericardial biopsy
61970536|NCT01088945|EXPERIMENTAL|Enhanced Discharge Process|Caregivers of these infants will receive individual coaching in order to enhance their understanding of their infant's problems and enhance their knowledge and skills to care for their fragile infants.
61970537|NCT01088945|ACTIVE_COMPARATOR|Standard Discharge Process|These infants will receive the hospital's current standard of care for the discharge of fragile infants from the NICU.
61970538|NCT04489823|EXPERIMENTAL|Paravalvular Leak Closure|Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
61970539|NCT02608710|EXPERIMENTAL|Single Dose|Single dose of RDEA3170 4.5 mg, RDEA3170 6 mg or RDEA3170 12 mg on Days 1, 5 and 9.
61970540|NCT02608710|EXPERIMENTAL|Multiple Dose|RDEA3170 12 mg once daily (qd)
61970541|NCT02608710|EXPERIMENTAL|Single Dose Food Effect|Since dose of RDEA3170 6 mg administered in fed or fasted state on Day 1 and Day 8.
61970542|NCT05718128|EXPERIMENTAL|Biopsy|patients
61970543|NCT03723759|EXPERIMENTAL|Group A|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation D, faster aspart 100 U/mL, formulation B, formulation A, formulation C, formulation E.~The dosing visits will be separated by wash-out periods (2-21 days)."
62145838|NCT03540524|EXPERIMENTAL|Cohort A - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)
62510420|NCT05061914|ACTIVE_COMPARATOR|VATS drainage|encysted and undiagnosed pericardial effusion drainage through VATS that permits performing a pericardiopleural window and take a pericardial biopsy with minimal incisions
62510421|NCT01825837|EXPERIMENTAL|BIA 2-093 1800 mg (Group 1)|BIA 2-093 1800 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
62510422|NCT01825837|EXPERIMENTAL|BIA 2-093 900 mg (Group 2)|BIA 2-093 900 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
62707629|NCT04047485||Elderly Female (A)|Female subjects between 65 and 85 years old
62707630|NCT04047485||Great Elderly Female (B)|Female subjects with more than 85 years old
62707631|NCT04047485||Elderly Male (C)|Male subjects between 65 and 81 years old
61970544|NCT03723759|EXPERIMENTAL|Group B|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation C, formulation B, formulation D, formulation E, formulation A, faster aspart 100 U/mL.~The dosing visits will be separated by wash-out periods (2-21 days)."
61970545|NCT03723759|EXPERIMENTAL|Group C|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation E, formulation C, formulation A, formulation B, faster aspart 100 U/mL, formulation D.~The dosing visits will be separated by wash-out periods (2-21 days)."
62145839|NCT03540524|EXPERIMENTAL|Cohort B - F508del heterozygous/potentiator nonresponsive|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)
62351741|NCT04715412|OTHER|Study group|"The standard training sessions were conducted for individual patient by the transplant physician to explain rejections, infections and tumor risks, post-transplant medication. After discharge, all patients had scheduled follow-up visits at the outpatient clinic of the transplant center, where immune suppressant blood levels were measured and their dosing adjusted accordingly. Patients also had the opportunity to discuss any concern of their condition or drug therapy with the transplant physician in charge.~in addition to this standard transplant training, patients received intensified care by a dedicated clinical pharmacist combining educational and technical interventions aiming at achieving and maintaining adherence to his/her prescribed medication and improving health outcomes."
62510423|NCT01825837|EXPERIMENTAL|BIA 2-093 300 mg (Group 3)|BIA 2-093 300 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
62707632|NCT04047485||Great Elderly Male (D)|Men subjects with more than 81 years old
62351742|NCT04638868|EXPERIMENTAL|Isolation of circulating tumor cells|Both portal venous and peripheral blood will be obtained from the patient and subjected to analysis for pancreatic cancer circulating tumor cells
62707633|NCT00969020|ACTIVE_COMPARATOR|Telemedicine|RRS via telemedicine. By developing the concept of Remote Rehabilitation Support (RRS) the investigators will try to bring preoperative education of the patient, dissemination of information and postoperative support to a new level.
62707634|NCT00969020|NO_INTERVENTION|Standard|The standard procedure for THA used under The Lundbeck Center for fast track hip and knee surgery
62707635|NCT06262542|EXPERIMENTAL|Experimental group (moxibustion and Chinese herbal medicine group)|
61970546|NCT03723759|EXPERIMENTAL|Group D|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation A, formulation D, formulation C, faster aspart 100 U/mL, formulation E, formulation B.~The dosing visits will be separated by wash-out periods (2-21 days)."
61970547|NCT03723759|EXPERIMENTAL|Group E|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~faster aspart 100 U/mL, formulation A, formulation E, formulation D, formulation B, formulation C.~The dosing visits will be separated by wash-out periods (2-21 days)."
61970548|NCT03723759|EXPERIMENTAL|Group F|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation B, formulation E, faster aspart 100 U/mL, formulation C, formulation D, formulation A.~The dosing visits will be separated by wash-out periods (2-21 days)."
61970549|NCT02740777|EXPERIMENTAL|2-dose adolescent|300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.
61970550|NCT02740777|EXPERIMENTAL|3-dose adolescent|300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
61970551|NCT02740777|EXPERIMENTAL|3-dose adult|300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
61970552|NCT01737944|EXPERIMENTAL|10mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
62145840|NCT03540524|EXPERIMENTAL|Cohort C - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)
62351743|NCT03693118|EXPERIMENTAL|Grup1, Grup2|
62351744|NCT03693118|EXPERIMENTAL|Grup1,Grup2|
62707636|NCT06262542|PLACEBO_COMPARATOR|Control group (sham moxibustion and placebo herbal medicine group)|
61970553|NCT01737944|EXPERIMENTAL|15mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
62351745|NCT04804280||Preterm children (PT)|"* gestational age at birth: 26+0 to 31+6 weeks;~* absence of documented neurological pathology;~* absence of sensory deficits;~* absence of malformative syndromes and/or major malformations."
62351746|NCT04804280||Full-term children (FT)|"* gestational age at birth ≥ 37 weeks;~* birth weight ≥ 2,500g;~* APGAR 5' ≥ 7~* delivery without any complications for baby and/or mother;~* no prenatal and/or postnatal clinical conditions;~* no hospitalizations at the time of birth or postpartum;~* absence of malformative syndromes and/or major malformations."
62351747|NCT01379170|EXPERIMENTAL|Type 2 diabetes, de novo hypothyrodism treatment|Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
62351748|NCT03099980|EXPERIMENTAL|Secukinumab|All participants will be assigned to receive secukinumab 300 mg (2 x 150 mg PFS subcutaneous injections) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 more weeks.
62510424|NCT01825837|EXPERIMENTAL|ESL (Part I)|In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks.
61970554|NCT01737944|EXPERIMENTAL|20mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
61970555|NCT01737944|EXPERIMENTAL|25mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
61970556|NCT01166113|EXPERIMENTAL|PCP|
62145841|NCT04262115|EXPERIMENTAL|AM-EX|Participants in this group will be prescribed morning aerobic exercise.
62707637|NCT03240328|EXPERIMENTAL|CAR-T therapy|Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA \<50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
62510425|NCT04629599|EXPERIMENTAL|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
62510426|NCT04629599|ACTIVE_COMPARATOR|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
62510427|NCT02396082|EXPERIMENTAL|MIND-S Intervention|Participants (persons with dementia (PWD) and their family caregiver (CG)) in this group will receive up to 18 months of the MIND-S dementia care coordination intervention by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (PWD and CG needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.
62510428|NCT02396082|OTHER|Augmented Usual Care|Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
62510429|NCT01933919|PLACEBO_COMPARATOR|placebo|"In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximum of three tablets twice a day. From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to two tablets/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by one tablet/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
62510430|NCT01933919|EXPERIMENTAL|Fluvoxamine|"In the double-blind placebo-controlled phase participants received 25 mg fluvoxamine once a day in week 1, 25 mg twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg (three tablets BID). From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose of decreased by up to 50 mg/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
62510431|NCT03509662|PLACEBO_COMPARATOR|Placebo group|Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
62510432|NCT03509662|ACTIVE_COMPARATOR|Vitamin C - 3 gr/day|Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
62510433|NCT03509662|ACTIVE_COMPARATOR|Vitamin C - 10 gr/day|Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
62510434|NCT01736787|EXPERIMENTAL|Cauliflower Mushroom extract|
62510435|NCT01736787|PLACEBO_COMPARATOR|Placebo|
62707638|NCT04586933|ACTIVE_COMPARATOR|Omega-3|"0,9 gram omega-3/capsule x 4 = 3,6 gram omega-3 daily~It will be investigated whether diet optimization followed with supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used"
62707639|NCT04586933|PLACEBO_COMPARATOR|Placebo capsules|Soya oil
62707640|NCT01987414|EXPERIMENTAL|Group A|Forearm rotation orthosis (6 weeks); Forearm rotation orthosis plus occupational therapy task-oriented approach (6 weeks)
62707641|NCT01987414|ACTIVE_COMPARATOR|Group B|no treatment (6 weeks); occupational therapy task-oriented approach (6 weeks)
62707642|NCT02225535|PLACEBO_COMPARATOR|Usual Care (NP)|Rural NP with client in-person, usual care
62707643|NCT02225535|ACTIVE_COMPARATOR|PT in-person|Urban PT travels to rural area to manage patient's back pain in-person.
62707644|NCT02225535|ACTIVE_COMPARATOR|PT/NP Telehealth|Intervention: Rural NP is joined by PT via Telehealth for interprofessional videoconference with patient
62707645|NCT00922961|EXPERIMENTAL|cellular apoptosis|
62707646|NCT02065284|ACTIVE_COMPARATOR|Walking-Rhythmic Auditory Stimulation|Walking daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
62510436|NCT01915641|ACTIVE_COMPARATOR|group A|group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
62510437|NCT01915641|SHAM_COMPARATOR|group B|group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
62510438|NCT00442546|EXPERIMENTAL|1|
62510439|NCT00442546|EXPERIMENTAL|2|
62510440|NCT00442546|PLACEBO_COMPARATOR|3|
62510441|NCT01592721|EXPERIMENTAL|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
62510442|NCT04575714||Acute low back pain|Adult patients with acute low back pain
62510443|NCT04045808||CAD(+) group|Participants were included in CAD (+) if they had more than 50% reduction in diameter in one or more major epicardial arteries,
62510444|NCT04045808||CAD(-) group|patients with less than 50% reduction in epicardial artery diameter were enrolled to CAD (-) group
62510445|NCT01909934|EXPERIMENTAL|Brentuximab Vedotin 1.8 mg/kg|Participants received brentuximab vedotin 1.8 mg/kg as a 30 minute intravenous (IV) infusion on Day 1 of each 3 week cycle. Participants with stable disease or better and without unacceptable toxicity were to receive a minimum of 8 cycles with the opportunity to receive a maximum of 16 cycles.
62510446|NCT02729779|EXPERIMENTAL|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
61970557|NCT01877434||Reversed TESS|Patient undergone reversed shoulder arthroplasty
61970558|NCT02566434|EXPERIMENTAL|Methionine|All participants will consume free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day for the duration of a 4-week intervention period. Participants will cease intake when signs of toxicity are measured in blood work.
62510447|NCT02729779|ACTIVE_COMPARATOR|Aerobic Group|The Aerobic Group will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
62510448|NCT02326363|EXPERIMENTAL|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
62510449|NCT02326363|ACTIVE_COMPARATOR|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery. The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
62510450|NCT05746377|EXPERIMENTAL|Metoclopramide|Given 10 mg Metoclopramide prior to Endoscopy
62510451|NCT05746377|PLACEBO_COMPARATOR|Placebo|Given saline flush prior to Endoscopy
62510452|NCT01350934|EXPERIMENTAL|Fosamax Plus|Participants received alendronate 70 mg plus vitamin D3 5600 IU in a combination tablet (FOSAMAX PLUS D) once weekly for 6 months (base study), and then once weekly for another 6 months (extension study).
62510453|NCT01350934|ACTIVE_COMPARATOR|Calcitriol|Participants received calcitriol 0.25 μg once daily orally for 6 months (base study), and then once daily orally for another 6 months (extension study).
62510454|NCT02605213|EXPERIMENTAL|Vancomycin|Vancomyicn 250 mg every 6 hours for 12 weeks
62510455|NCT02605213|PLACEBO_COMPARATOR|Placebo|placebo every 6 hours for 12 weeks
62707647|NCT02065284|ACTIVE_COMPARATOR|Walking- only|Walking daily with no Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
62707648|NCT02065284|ACTIVE_COMPARATOR|Rhythmic Auditory Stimulation (RAS)only|Listening to based music only daily for 4 weeks
61970559|NCT01730391||Study cohort|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and Vietnam.
61970560|NCT00698360||A|MDRD 10-30
61970561|NCT00698360||B|MDRD 30-60
61970562|NCT00698360||C|MDRD 60-80
61970563|NCT00698360||D|MDRD \> 80
61970564|NCT03837106|EXPERIMENTAL|Rehabilitation program|Home and supervised exercise program specific to musicians. Injury prevention and management education program specific to musicians.
61970565|NCT03837106|NO_INTERVENTION|No intervention|Control group, no intervention
61970566|NCT01082406|EXPERIMENTAL|Trial part 1|
61970567|NCT01082406|EXPERIMENTAL|Trial part 2|
62145842|NCT04262115|EXPERIMENTAL|PM-EX|Participants in this group will be prescribed evening aerobic exercise.
62510456|NCT05631821|ACTIVE_COMPARATOR|Prospective Range Spinal System|Adolescent (between the ages of 10-18 years of age), with Idiopathic Scoliosis Range Spinal System: rod contour changes utilizing Differential Rod Bending and pre-operative templating in Adolescent Idiopathic Scoliosis: A pilot study. The prospective arm consented subjects will use the Rod Counour measurement system
62510457|NCT05631821|NO_INTERVENTION|Retrospective|Retrospective matched cohort of subjects from the investigating surgeon are subjects that have not used the Rod contour measurement system. There is no intervention because the second arm is retrospective chart review.
62510458|NCT00510315||Women treated with SCT/TBI|
62510459|NCT00510315||1:1 Matched group of women|"Current age + or - 2 years~Race and ethnicity~Cancer diagnosis~Interval from completion of cancer therapy to study + or - 2 years"
62145843|NCT02028091||Diabetes mellitus|All patients over 18 years with diagnosed diabetes mellitus type II.
62145844|NCT02028091||Non Diabetic|Patients over 18 years with no known diabetes mellitus or other known/diagnosed vascular diseases.
62145845|NCT05292066|OTHER|Duloxetine Group|Oral intake Duloxetine tablets, 30mg/day for 12 weeks.
62510460|NCT02071056||history of visceral cancer|
62510461|NCT03490916|EXPERIMENTAL|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
62510462|NCT03490916|PLACEBO_COMPARATOR|Placebo|One (1) dose of placebo
62510463|NCT03808584|NO_INTERVENTION|Control group|The patients in the control group will receive standard physiotherapy and will be instructed to limit core muscle activity and weight bearing according to their pain symptomatology. Standard physiotherapy for all hospitalised patients includes early mobilization and exercises to prevent thrombosis and pulmonary complications (atelectasis, pneumonia, diaphragmatic deconditioning), balance training and endurance and exercise training
62510464|NCT03808584|EXPERIMENTAL|Intervention group|The patients in the intervention group will be given exercises to perform postoperatively.They will be instructed by a physiotherapist in how to perform the four specific exercises targeting core muscles. The patient will perform these exercises daily during hospitalization under the supervision of the physiotherapist and then at home for two months after the operation. The intensity of the exercises will be adjusted daily to the physical capabilities of the patient. They will also benefit from standard physiotherapy as described above.
62510465|NCT01559935|EXPERIMENTAL|Car-BiRD Therapy|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) \[Car-BiRD\]
62510466|NCT01766388||Pregnant women|Pregnant women of 13-22 weeks gestation
62510467|NCT03662763|PLACEBO_COMPARATOR|Placebo|
62510468|NCT03662763|EXPERIMENTAL|Extended-release Guanfacine Hydrochloride (SPD503)|
62510469|NCT03146273|ACTIVE_COMPARATOR|Tablet|The tablet/capsule will be administered as a single dose of Multivitamins in tablet after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs. The results will be used for the AUC calculation of the absorption in order to compare with the Gel administration absorption.
62510470|NCT03146273|ACTIVE_COMPARATOR|Gel|The gel will be administrated to the same group of patients in the single dose of Multivitamins in gel after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs. The results will be used for the AUC calculation of the absorption in order to compare with the Tablet administration absorption.
62510471|NCT02825576|ACTIVE_COMPARATOR|Sugammadex group|Sugammadex 2mg/kg intravenously at completion of surgery.
62510472|NCT02825576|ACTIVE_COMPARATOR|Neostigmine/Glycopyrrolate group|Neostigmine 50mcg/kg plus Glycopyrrolate 10mcg/kg intravenously at completion of surgery.
62510473|NCT03548662|EXPERIMENTAL|Platelet-Rich Plasma Protein (PRP) Group|Subjects in this group will receive PRP injection into tear site, followed by rehabilitative exercise
62510474|NCT03548662|ACTIVE_COMPARATOR|Hyaluronic Acid Group|Subjects in this group will receive one injection with hyaluronic acid followed by rehabilitative exercise
62707649|NCT00163189|EXPERIMENTAL|Somatropin|
62145846|NCT05292066|OTHER|Pregabalin Group|Oral intake of Pregabalin tablets, 75 mg/day for 12 weeks.
62145847|NCT04660799|ACTIVE_COMPARATOR|Rituximab IV+CHOP|Participants will receive 8 cycles of IV rituximab in combination with 6 or 8 cycles of CHOP chemotherapy administered every 3 weeks.
62145848|NCT04660799|EXPERIMENTAL|Rituximab SC+CHOP|Participants will receive 1 cycle of IV plus 7 cycles of SC rituximab in combination with 6 or 8 cycles of CHOP chemotherapy administered every 3 weeks.
62145849|NCT00686257|EXPERIMENTAL|1|Patients receiving NPPV by the 'Total Face Mask'
62145850|NCT00686257|ACTIVE_COMPARATOR|2|Patients receiving NPPV by 'standard oronasal mask'
62510475|NCT00805402|EXPERIMENTAL|1 flow cytometry|flow cytometry
62510476|NCT03959995|EXPERIMENTAL|exercise|Exercise group
62510477|NCT03959995|SHAM_COMPARATOR|control|active control group
62510478|NCT05965791||Healthy Adults|30 healthy adult participants aged 18-45 years performing the Phalen's wrist flexion test
62510479|NCT00319046|EXPERIMENTAL|Open-label miglustat|Oral administration of miglustat 100 mg t.i.d. for a period of 2 years
62510480|NCT00521989|EXPERIMENTAL|CRx-102 (2.7/90)|"2.7 mg prednisolone plus 90 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
62145851|NCT01934452||Complete Remission|Complete remission arm in mRCC patients treated with sunitinib.
62145852|NCT01934452||Non Complete Remission|Non complete remission arm in mRCC patients treated with sunitinib.
62145853|NCT01374152|EXPERIMENTAL|Perfetti|Cognitive sensory motor training method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
62145854|NCT01374152|NO_INTERVENTION|conventional rehabilitation|conventional occupational therapy method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
62145855|NCT01935375|EXPERIMENTAL|CNM Interpersonal Psychotherapy|CNM Interpersonal psychotherapy
62510481|NCT00521989|EXPERIMENTAL|CRx-102 (2.7/180)|"2.7 mg prednisolone plus 180 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
62510482|NCT00521989|EXPERIMENTAL|CRx-102 (2.7/360)|"2.7 mg prednisolone plus 360 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
62510483|NCT00521989|ACTIVE_COMPARATOR|Prednisolone|"2.7 mg prednisolone~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM."
62510484|NCT00521989|PLACEBO_COMPARATOR|Placebo|"Placebo~Subjects were dose twice daily through day 98."
62510485|NCT03460158|EXPERIMENTAL|Restylane-L®, Restylane-L® Lyft, and Restylane Silk®|Hyaluronic acid
62510486|NCT06329791|EXPERIMENTAL|AZR-MD-001|AZR-MD-001 sterile ophthalmic ointment 0.5% to be administered twice weekly at bedtime.
62707650|NCT05610735|EXPERIMENTAL|Combination of DOXIL and Ashwagandha|"The study contains two parts. In part 1 (Phase I), 18 patients with recurrent ovarian cancer will be recruited and administered IV with liposomal doxorubicin (DOXIL) 40 mg/m2 on day 1 of 28 days cycle for 4 cycles. Ashwagandha will be administered on daily basis for 2 years. Three doses of Ashwagandha (2 g, 4 g or 8.0 g) will be administered orally with water every day for two years to evaluate a tolerable dose of Ashwagandha. Six patients will be recruited for each dose.~In part 2 Phase II), 54 additional patients with recurrent ovarian cancer will be recruited and administered with DOXIL IV (40 mg/m2) and maximum tolerable dose of Ashwagandha (determined from part 1) in the form tables orally with water on daily basis for two years. The survival rate (SR), complete response (CR) and partial response (PR) will be evaluated."
62707651|NCT00940602|EXPERIMENTAL|Deferasirox|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
61970568|NCT01619774|EXPERIMENTAL|GSK2118436 + GSK1120212|GSK1120212 2 mg by mouth once a day, and GSK2118436 150 mg by mouth 2 times every day (1 time in the morning and 1 time in the evening, about 12 hours apart).
61970569|NCT00260494|EXPERIMENTAL|acupuncture|acupuncture to lower extremity postoperatively
61970570|NCT00260494|SHAM_COMPARATOR|sham acupuncture|sham acupuncture at same sites.
61970571|NCT00260494|NO_INTERVENTION|control|no acupuncture, otherwise the same care and measurements
61970572|NCT00733408|EXPERIMENTAL|Tx (chemo, MoAb, and enzyme inhibitor)|"INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity."
61970573|NCT01659775|EXPERIMENTAL|Sancuso patch|
61970574|NCT01659775|ACTIVE_COMPARATOR|Zofran|
61970575|NCT00870571|EXPERIMENTAL|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
62145856|NCT01935375|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual is psychotherapy with a mental health provider
62145857|NCT01513707||Hemodialysis group|Hemodialysis group
62145858|NCT01513707||peritoneal dialysis group|peritoneal dialysis group
62145859|NCT04783766|EXPERIMENTAL|CK-3773274 for Single Ascending Dose (SAD) Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274
62510487|NCT06329791|PLACEBO_COMPARATOR|Vehicle|AZR-MD-001 Vehicle to be administered twice weekly at bedtime.
62510488|NCT05664217|EXPERIMENTAL|Stage 1 NKTR-255 at 1.5 µg/kg|"In this arm of Stage 1 (Phase 2 of the study), NKTR-255 will be dosed at 1.5 µg/kg. NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
62539404|NCT06582056|OTHER|Participant with Stage I/Stage II Periodontal Disease with Hemoglobin A1c level 6.5-7.8|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
61970576|NCT00870571|ACTIVE_COMPARATOR|B|NorvasC® 10 mg Tablets, single dose
62145860|NCT04783766|PLACEBO_COMPARATOR|Placebo comparator for SAD Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator
62145861|NCT04783766|EXPERIMENTAL|CK-3773274 for Multiple Dose (MD) Cohort|Subjects will receive multiple doses of CK-3773274
62145862|NCT04783766|PLACEBO_COMPARATOR|Placebo comparator for MD Cohort|Subjects will receive multiple doses of placebo comparator
62145863|NCT01962597|ACTIVE_COMPARATOR|aerobic exercise|patients will undergo supervised exercise on a bike ergometer for 30 minutes three times per week during hemodialysis
62145864|NCT01962597|ACTIVE_COMPARATOR|resistance training|patients will undergo supervised lower extremity strength training three times per week pre-hemodialysis
61970577|NCT01634971|NO_INTERVENTION|External Drainage of pancreatic duct|External Drainage of pancreatic duct was used in PD.
61970578|NCT01634971|EXPERIMENTAL|Internal Drainage of Pancreatic Duct|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
62510489|NCT05664217|EXPERIMENTAL|Stage 1 NKTR-255 at 3.0 μg/kg|"In this arm of Stage 1 (Phase 2 of the study), NKTR-255 will be dosed at 3.0 μg/kg. NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
62510490|NCT05664217|EXPERIMENTAL|Stage 1 NKTR-255 at 3.0/6.0 μg/kg|"In this arm of Stage 1 (Phase 2 of the study), patients will be dosed with 3.0 μg/kg NKTR-255 in Cycle 1 (C1) and continue in Cycle 2 and subsequent cycles (C+) with 6.0 μg/kg NKTR-255 (hereinafter referred to as 3.0/6.0 µg/kg NKTR-255).~NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
62145865|NCT01962597|EXPERIMENTAL|aerobic exercise and resistance training|patients will undergo a combination of aerobic exercise and resistance training on an alternating schedule three time per week
62145866|NCT01990625|EXPERIMENTAL|Ultrasound scan|The group is pregnant women who reside in an intervention cluster who receive at least one antenatal ultrasound scan during antenatal care during the study time period.
62510491|NCT05664217|PLACEBO_COMPARATOR|Placebo|Placebo is commercially available 0.9% Sodium Chloride Solution for Injection (USP). Placebo will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion. Placebo will be infused every 3 weeks for up to 7 cycles or 5 months, whichever is earlier.
62510492|NCT05085769||Study group|15 patients who had bariatric surgery
62510493|NCT05085769||Control group-1|8 morbidly obese participants who did not have bariatric surgery
61970579|NCT01953588|ACTIVE_COMPARATOR|Arm I (anastrozole)|Patients receive anastrozole daily for 6 cycles followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
62145867|NCT01990625|NO_INTERVENTION|Routine antenatal care|The group is pregnant women that reside in the control clusters during the study time period. The group received routine antenatal care.
62145868|NCT02736422|OTHER|hyperpolarised xenon|evaluating the sensitivity of pulse sequences for 129Xe magnetic resonance imaging in the lungs, heart and brain and monitoring the transient changes in vital signs during and following the gas inhalation
62510494|NCT05085769||Control group-2|11 participants who were non-obese
62510495|NCT05621954|EXPERIMENTAL|Telehealth monitoring|"Telehealth remote monitoring provided by a specialised service with a monitoring and patient education app featuring:~* Symptom, blood pressure, weight, heart rate and oxygen saturation monitoring with optional step counters~* Customised algorithms with patient feedback for prehabilitation (e.g. patient self-reporting of symptoms, activities and health-related activities with positive feedback loops and recommendations for self-directed management)~* Centralised weekly review and escalation to expedited surgery if deteriorations noted~* Post-operative monitoring with symptom, blood pressure, weight, heart rate, oxygen saturation and photographic wound review with optional step counters"
62510496|NCT05621954|NO_INTERVENTION|Standard of Care|Standard of care will be no remote monitoring for patients whilst on the waiting list or after discharge from hospital. Access to tertiary services for advice, information or to report deteriorations will be through conventional existing modes such as printed or online literature provided at the time of outpatient review, telephone access to administrative staff allowing clinical information to be conveyed to the usual care team, and local primary care and emergency services for acute deteriorations. Existing standard of care remote services (e.g. wound monitoring by digital photograph reviews) will continue.
62510497|NCT04769752||No beta-blocker|Patient do no treat with beta-blocker before the surgery
62510498|NCT04769752||Beta blocker|Patient treat with beta-blocker in accordance to international guidelines
62145869|NCT05794594||3D printed|3D printed personalized extendable prosthesis replacement for limb preservation in children with osteosarcoma
62145870|NCT05794594||amputation|patients had undergone amputation of the limbs
62145871|NCT04648670|EXPERIMENTAL|Group intervention|"The experimental group consists of 101 participants have been subdivided into two groups of 25/26 that perform the same intervention but on a different day of the week.~The two subgroups have received 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~."
62510499|NCT04769752||Beta blocker2|Patient treat with beta-blocker without respect of international guidelines
62510500|NCT03585426|EXPERIMENTAL|Vancomycin 1g q12h|
62510501|NCT03585426|EXPERIMENTAL|Vancomycin 1g q8h|
62510502|NCT04311151|EXPERIMENTAL|self seizures visualization group|Visualization of the own epileptic seizures occured during hospital admission.
62510503|NCT04311151|NO_INTERVENTION|usual management|Usual way management
62510504|NCT05650086||Cohort 1: Biopsy|Subjects who are scheduled for biopsy will be enrolled.
61970580|NCT01953588|ACTIVE_COMPARATOR|Arm II (fulvestrant)|Patients receive fulvestrant on days 1 and 15 of cycle 1 and day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
62145872|NCT04648670|NO_INTERVENTION|Group Control|The control group consists of 100 participants. The no intervention group did not receive any type of intervention
62145873|NCT02123940|EXPERIMENTAL|nasal humidified high flow therapy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
61970581|NCT01953588|ACTIVE_COMPARATOR|Arm III (anastrozole and fulvestrant)|Patients receive anastrozole daily in combination with fulvestrant on days 1 and 15 of cycle 1, and on day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
61970582|NCT05715593|EXPERIMENTAL|Education|
61970583|NCT05715593|NO_INTERVENTION|Control|
62510505|NCT05650086||Cohort 2: Screening mammogram|Patients who underwent screening mammogram will be enrolled.
62510506|NCT05650086||Cohort 3: Diganostic mammogram|Subjects scheduled for diagnostic mammogram will be enrolled.
62510507|NCT05650086||Cohort 4: Prior history of lympectomy, routine mammogram|Subjects with prior history of lumpectomy scheduled for their routine mammogram will be enrolled.
62510508|NCT06210945|EXPERIMENTAL|CM-101|CM-101 will be administered
62510509|NCT06210945|PLACEBO_COMPARATOR|Placebo|Placebo will be administered
62510510|NCT02248506|OTHER|Clotrimazole|Clotrimazole 500 mg
61970584|NCT02412423|EXPERIMENTAL|treatment group|post-transplantation cyclophosphamide
61970585|NCT01134978|EXPERIMENTAL|Practice Schedules|Subjects are randomly assigned to either a blocked or random practice schedule when learning three 3-D computer mazes. A blocked practice schedule is created when the tasks to be learned are presented in a predictable order, while a random practice schedule has tasks presented in a nonsequential, unpredictable order. Neural activity and behavioral measures will differ for the two practice schedules. For memory and transfer, it is predicted that random practice will be better than blocked practice.
61970586|NCT00450684|EXPERIMENTAL|Group A|Implantation and testing of CRT
61970587|NCT00450684|EXPERIMENTAL|Group B|IImplantation and testing of CRT
61970588|NCT00147199|EXPERIMENTAL|Inhaled treprostinil|0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
61970589|NCT00147199|PLACEBO_COMPARATOR|Placebo|Placebo inhalation solution for use in ultrasonic nebulizer
61970590|NCT01092611|OTHER|Group A|Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study
61970591|NCT01092611|OTHER|Group B|Subjects who were administered placebo in primary studies and who accepted to participate in this study
61970592|NCT02927080|EXPERIMENTAL|ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) 150mg|ACE-083 150 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
61970593|NCT02927080|EXPERIMENTAL|ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
61970594|NCT02927080|EXPERIMENTAL|ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA bilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
61970595|NCT02927080|EXPERIMENTAL|ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) 150 mg|ACE-083 150 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
61970596|NCT02927080|EXPERIMENTAL|ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) 200 mg|ACE-083 200 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
62145874|NCT02123940|OTHER|standard strategy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
62145875|NCT00661206|ACTIVE_COMPARATOR|Clopidogrel|
62145876|NCT00661206|PLACEBO_COMPARATOR|Placebo|
61970597|NCT02927080|EXPERIMENTAL|ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) 240 mg|ACE-083 240 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
61970598|NCT02927080|PLACEBO_COMPARATOR|Placebo (Part 2, DB-PC) Tibialis Anterior (TA)|"Part 2, double-blind (DB) placebo-controlled (PC). Placebo TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
61970599|NCT02927080|EXPERIMENTAL|ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
62145877|NCT00850915|OTHER|1|in this arm contacts of enrolled TB-HIV index cases were actively approached and screened for TB and offered HIV testing by CHW at their homes
62510511|NCT03355209|EXPERIMENTAL|ZX008 0.2 or 0.8 mg/kg/day|Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 0.2 mg/kg/day or 0.8 mg/kg/day.
62145878|NCT00850915|OTHER|2|no interventation was done in this group, they received the regulare care and follow up following NTP guidelines
62510512|NCT03355209|PLACEBO_COMPARATOR|Matching Placebo|Part 1: Matching ZX008 placebo is supplied as an oral solution.
62510513|NCT03355209|EXPERIMENTAL|Open-Label|Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.
62510514|NCT03553875|ACTIVE_COMPARATOR|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
62510515|NCT03553875|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
62510516|NCT03207958|EXPERIMENTAL|Belimumab|"* Subjects meeting eligibility criteria will start treatment between Day +3- and Day +60 after alloHCT~* Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 7 cycles (6 months)"
62510517|NCT03648879|EXPERIMENTAL|1/Arm 1 - Upper white-light endoscopy and confocal endoscopic microscopy|Upper white-light endoscopy and confocal endoscopic microscopy
62510518|NCT06358274||thru-hiking on the Colorado Trail|"Thru-hikers planning to embark on the Colorado Trail are recruited through the Colorado Trail Foundation community page and email newsletter, ensuring a sample population representative of those undertaking this challenging endeavor.~Participants will be tracked over time to assess changes in their metabolic health and dietary habits."
61970600|NCT02927080|PLACEBO_COMPARATOR|Placebo (Part 2, DB-PC) Biceps Brachii (BB)|"Part 2, double-blind placebo-controlled. Placebo BB bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
61970601|NCT02927080|EXPERIMENTAL|ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
62510519|NCT04417751|EXPERIMENTAL|Intervention Group|Intervention group will receive 47 sessions of individual CS and participate in 3 evaluation sessions. The CS program will last 1 year and each individual CS session will last approximately 45 minutes.
61970602|NCT05791344||ECG Monitoring -TAVR patients|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
61970603|NCT05448833|EXPERIMENTAL|V-LAP™ System|Heart failure subjects - Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home and will be trained on the use of the device for self-management.
61970604|NCT02260921|EXPERIMENTAL|iovera° Treatment|Treatment with the iovera° device administered by a trained investigator to treat knee pain.
62510520|NCT04417751|NO_INTERVENTION|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
62510521|NCT02354911|EXPERIMENTAL|Immunoregulatory Dendritic Cells (iDC)|Biological intervention consisting of autologous dendritic cells treated in vitro to convert to active immunoregulatory dendritic cells.
61970605|NCT02260921|SHAM_COMPARATOR|Sham Treatment|Sham Treatment (similar device with no active therapeutic treatment) administered by a trained investigator to treat knee pain.
61970606|NCT02696473|EXPERIMENTAL|High Carrot Dose|The volunteer will eat 250g carrot for breakfast with 2 slices of bread and 10g butter
61970607|NCT02696473|EXPERIMENTAL|Low Carrot Dose|The volunteer will eat 100g of carrot for breakfast with 2 slices of bread and 10g butter
61970608|NCT00903695|EXPERIMENTAL|Memory XL|"Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion."
61970609|NCT00903695|PLACEBO_COMPARATOR|placebo|"Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion."
61970610|NCT05659095|EXPERIMENTAL|Experiment groups|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point.
62145879|NCT03393390||Healthy Controls|Subjects in this group will be defined as healthy controls after meeting with a clinician and determining that they do not meet the diagnostic criteria for any externalizing disorders or other psychiatric disorders.
61970611|NCT05659095|NO_INTERVENTION|Control groups|The control group was injected with the same volume of normal saline.
61970612|NCT00684593|EXPERIMENTAL|Navarixin|Navarixin 30 mg administered orally once daily for 28 days.
61970613|NCT00684593|PLACEBO_COMPARATOR|Placebo|Matching placebo to Navarixin administered orally once daily for 28 days.
62510522|NCT02354911|PLACEBO_COMPARATOR|Placebo Control|Saline injections administered blinded to subject and all study staff except for research pharmacist who is not involved in study conduct
61970614|NCT03102255|ACTIVE_COMPARATOR|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
61970615|NCT03102255|EXPERIMENTAL|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
62145880|NCT03393390||Externalizing|Subjects in this group will be defined as externalizing if the clinician determines that they meet the diagnostic criteria for one or more externalizing disorders, such as ADHD, ODD, or CD.
62145881|NCT00897858||Pediatric CNS tumor patients|Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy
62510523|NCT01748955|ACTIVE_COMPARATOR|Bupropion|Participants will receive bupropion XL for 8 weeks.
62510524|NCT01748955|ACTIVE_COMPARATOR|paroxetine CR|Participants will receive Paroxetine CR for 8 weeks.
62510525|NCT04212377|EXPERIMENTAL|exploratory|single arm exploratory, single-centre study
62510526|NCT02166853|EXPERIMENTAL|conventional group|"a conventional group, in which intravenous sedation with midazolam will be administered"
62351749|NCT02685657|EXPERIMENTAL|AC followed by Docetaxel with Selumetinib|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle, 75 mg of SELUMETINIB twice a day PO on days 1-21 of every 3 week cycle
62510527|NCT02166853|EXPERIMENTAL|sevoflurane group|"a sevoflurane group, in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices"
62510528|NCT04778618|EXPERIMENTAL|Individual dose of Thymoglobulin|Individual dose of Thymoglobulin (r-ATG) : Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg)
62510529|NCT04528576|EXPERIMENTAL|DragonFly-M|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Meditech Co., Ltd
62145882|NCT05518214|EXPERIMENTAL|Beetroot|Participants will receive nitrate-rich (70 ml, containing 6.4 mmol of nitrate) beetroot juice, by Beet It, James White. Participants will take 1 beetroot juice drink everyday for 12 weeks.
62510530|NCT01303068|EXPERIMENTAL|CF patients, 13C urea breath test kit|CF patients with Pseudomonas infection tested with 13C urea breath test
61970616|NCT01661491||Cystic Fibrosis|Infants and toddlers with Cystic Fibrosis
61970617|NCT01661491||Non-cystic fibrosis controls|Infants and toddlers without Cystic Fibrosis
61970618|NCT01722890||Cohort 1|TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
61970619|NCT01722890||Cohort 2(Control Group)|TNM stage II-IV breast cancer patients with trastuzumab-refractory disease.
62510531|NCT01303068|ACTIVE_COMPARATOR|Healthy controls, 13C urea breath test kit|Healthy subjects using 13C urea breath test kit
62510532|NCT02488668|EXPERIMENTAL|Surface Electrical Stimulation|Please see information under 'Detailed description'
62510533|NCT02406794|EXPERIMENTAL|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
62510534|NCT02406794|NO_INTERVENTION|No Kinesio taping|No Kinesio taping
61970620|NCT06321315|EXPERIMENTAL|Intervention group (Case-based instruction group)|Case-based teaching will be provided to second-year students who take the risky pregnancy and care course for the first time, who are included in the case-based teaching group by randomization method.
61970621|NCT06321315|NO_INTERVENTION|Control|The control group is the group in which no intervention was made.
61970622|NCT05261360|EXPERIMENTAL|SF-MSC-EX Treatment Group (Experimental group's left knees)|The left knee will receive 1 million cells/kg SF-MSC-EX (Synovial fluid mesenchymal stem cell-derived exosome) by intra-articular injection method.
61970623|NCT05261360|EXPERIMENTAL|SF-MSC Treatment Group (Experimental group's right knees)|The right knee will receive 1 million cells/kg SF-MSC (Synovial fluid-derived mesenchymal stem cell) by intra-articular injection method.
61970624|NCT05261360|NO_INTERVENTION|Control Group|Participants who received no treatment were defined as the control group.
61970625|NCT06000098||Patients undergoing robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|Patients with ASA( American Society of Anesthesiologists) physical status 1-3 who underwent robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position with restrictive fluid therapy
61970626|NCT04246008|EXPERIMENTAL|Neuromuscular training group|This group will receive a 60-min neuromuscular training sessions twice a week, for 10 weeks until the completion of twenty sessions
61970627|NCT04246008|ACTIVE_COMPARATOR|Conventional training group|This group will receive a 60-min convencional cardiac rehabiliation session twice a week, for 10 weeks until the completion of twenty sessions
61970628|NCT02809456|EXPERIMENTAL|Nicorandil|Beginning 4-6 weeks during radiation therapy, patients receive nicorandil is given during radiotherapy interval, 5mg each time, 3 times daily oral. Treatment repeats after completion of radiation therapy in the absence of disease progression or unacceptable toxicity.
61970629|NCT02809456|ACTIVE_COMPARATOR|observation|regular radiotherapy as our protocol
61970630|NCT04430543|EXPERIMENTAL|CBM Group|This group will receive Cognitive Bias Modification training
62145883|NCT05518214|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo beetroot juice with the nitrate removed, by Beet It, James White. Participants will take 1 placebo juice drink everyday for 12 weeks.
62145884|NCT01259570|ACTIVE_COMPARATOR|Skimmilk enriched with VD encapsulated in CM|
62145885|NCT01259570|ACTIVE_COMPARATOR|VD will be dissolved in milkfat and homogenized into skimmilk|VD will be dissolved in milkfat and homogenized into skimmilk
62145886|NCT01259570|ACTIVE_COMPARATOR|3% fat milk wherein the VD will be in CM|3% fat milk wherein the VD will be in CM
62145887|NCT01259570|ACTIVE_COMPARATOR|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
62145888|NCT03241810|EXPERIMENTAL|Arm A|"Seribantumab~Fulvestrant"
62145889|NCT03241810|ACTIVE_COMPARATOR|Arm B|"Placebo~Fulvestrant"
62510535|NCT03164837|EXPERIMENTAL|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
62510536|NCT01694082|EXPERIMENTAL|THRIVE replication|Participants in this condition receive THRIVE with a full list of direct and indirect protective behavioral strategies to reduce alcohol consumption.
62510537|NCT01694082|EXPERIMENTAL|THRIVE direct strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are directly related to alcohol drinking.
62510538|NCT01694082|EXPERIMENTAL|THRIVE indirect strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are indirectly related to alcohol drinking.
62510539|NCT01694082|SHAM_COMPARATOR|Brief brochure and assessment control|Participants will answer the same survey questions as participants in the THRIVE conditions, but will receive a brief alcohol-related brochure with only didactic content rather than the intervention components received by participants randomized to THRIVE conditions.
61970631|NCT04430543|SHAM_COMPARATOR|Control Group|This group will receive Sham (control) training
62145890|NCT03115099|PLACEBO_COMPARATOR|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
61970632|NCT04042337|EXPERIMENTAL|PRT Telehealth|Participating parents will receive 12 weekly 60-minute parent training sessions via secure videoconference to learn Pivotal Response Treatment
61970633|NCT04042337|NO_INTERVENTION|Waitlist|Participants will continue stable community-based treatments
62145891|NCT03115099|EXPERIMENTAL|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
62145892|NCT03115099|PLACEBO_COMPARATOR|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
62145893|NCT03115099|EXPERIMENTAL|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
62145894|NCT03115099|ACTIVE_COMPARATOR|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
62351750|NCT02685657|ACTIVE_COMPARATOR|AC followed by Docetaxel|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle
62510540|NCT06616974|EXPERIMENTAL|TX000045 Dose A|Participants will receive a single dose of TX000045 Dose A subcutaneously every 2 weeks for 24 weeks from Day 1 to Day 155.
62707652|NCT00940602|PLACEBO_COMPARATOR|Placebo|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
62707653|NCT02468583|EXPERIMENTAL|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
61970634|NCT00859768|EXPERIMENTAL|Intervention group 1|Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
61970635|NCT00859768|EXPERIMENTAL|Intervention group 2|No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
61970636|NCT00859768|NO_INTERVENTION|Control group 1|Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
61970637|NCT00859768|NO_INTERVENTION|Control group 2|No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
61970638|NCT01120223|EXPERIMENTAL|LEO 80185 gel once daily application|
61970639|NCT02123498|EXPERIMENTAL|Single Arm|
61970640|NCT00379574|EXPERIMENTAL|Bortezomib + CHOP every 2 weeks|Bortezomib + CHOP(Cycloophosphamide, vincristine, doxorubicin,and predinisolone) every 2 weeks
61970641|NCT01077856||Pre-Vaccine|Registry, survey, and HPV status data from 2004-2006
61970642|NCT01077856||Post-Vaccine|Registry, survey, and HPV status data from 2011-2012
61970643|NCT06034470|EXPERIMENTAL|Treatment (PVEK, FLAG-Ida)|See Detailed Description.
61970644|NCT04068662|EXPERIMENTAL|Pregnant Moms' Empowerment Program|Five session group therapy program covering safety planning, resilience and coping, infant care and parenting.
61970645|NCT04068662|ACTIVE_COMPARATOR|Nondirective Support Group|Five session nondirective support group with two co-leaders who assist in facilitating open discussion on women's self-identified discussion topics.
61970646|NCT00429104|EXPERIMENTAL|HER2+ Metastatic Breast Cancer|Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m\^2 subcutaneously
61970647|NCT00967525|EXPERIMENTAL|1|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
61970648|NCT03880071|EXPERIMENTAL|DBT + ACT group|- The experimental group (DBT+ ACT) led in Montpellier during 6 months.
61970649|NCT03880071|OTHER|DBT group|The control group (DBT) led in Geneva during 12 months.
61970650|NCT04775459||Surfactant administration without using score LUS|"It is a retrospective cohort : preterm newborns from august 2019 to december 2019 needed a surfactant administration.~The surfactant was administrated only if the fraction of inspired oxygen (FiO2) \>30% among the Guidelines of 2019"
61970651|NCT04775459||Surfactant administration using score LUS|"It is a prospective cohort : preterm newborns from january 2021 to juin 2020 needed a surfactant administration.~The surfactant is administrated if FiO2 \>30% OR if score LUS \>8/18 among the literature"
61970652|NCT05484739|EXPERIMENTAL|Very hot and dry|Subjects will be exposed to 3 hours in a climate chamber set to approximately 47 deg C and 15% relative humidity, which reflects a very hot and dry heat wave condition similar to the 2018 Los Angeles heat wave. Four visits will be required to complete this arm, with each visit a different cooling modality applied.
61970653|NCT05484739|EXPERIMENTAL|Hot and humid|Subjects will be exposed to 3 hours in a climate chamber set to approximately 41 deg C and 40% relative humidity, which reflects hot and humid heat wave similar to the 1995 Chicago heat wave. Four visits will be required to complete this arm, with each visit a different cooling modality applied.
62351751|NCT00734812|ACTIVE_COMPARATOR|1|Laparoscopic supracervical hysterectomy (LSH)
62351752|NCT00734812|ACTIVE_COMPARATOR|2|Total Laparoscopic Hysterectomy (TLH)
62351753|NCT02155348|ACTIVE_COMPARATOR|Multifocal group|Bilateral cataract surgery with implantation of multifocal IOLs
62351754|NCT02155348|ACTIVE_COMPARATOR|Monovision|Bilateral cataract surgery with monovision
62351755|NCT05381558|EXPERIMENTAL|spasmotic flatfoot patient|
62351756|NCT06057636|EXPERIMENTAL|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily, at home for 6 weeks. Hypnosis sessions are expected to last \~20 minutes. Practices using the recordings will be documented on the Hypnosis Practice Log.
62510541|NCT06616974|EXPERIMENTAL|TX000045 Dose B|Participants will receive alternating single doses of TX000045 Dose B and placebo subcutaneously every 2 weeks for 24 weeks from Day 1 to Day 155.
62707654|NCT02468583|ACTIVE_COMPARATOR|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
62707655|NCT06073522||Typically developing children|Children aged 5 to 15 years old with no clinically documented disorders.
62707656|NCT06073522||Children with Unilateral Cerebral Palsy|Children aged 5 to 15 years old with a diagnosis of Unilateral Cerebral Palsy
62707657|NCT01417884||ischemic heart disease|stable coronary artery disease, acute coronary syndromes
62707658|NCT01417884||non-ischemic heart disease|inflammatory heart disease, heart failure (non-ischemic), valvular heart disease
62707659|NCT05928988|EXPERIMENTAL|SHR8554 and itraconazole|"SHR8554 will be provided in a solution. Participants will receive 1 mg SHR8554 by intravenous pump on Day 1 and Day 9.~Itraconazole capsules 200 mg orally after meals twice daily for 7 days from Day 4 to Day 10."
62145895|NCT03115099|EXPERIMENTAL|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
62145896|NCT06207981|ACTIVE_COMPARATOR|Control arm|"Pelvic chemoradiotherapy Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes~Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given"
62145897|NCT06207981|EXPERIMENTAL|Exeprimental arm|"Induction chemotherapy with mDCF (4 cycles) followed by pelvic chemoradiotherapy~Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days) Chemoradiotherapy is the same as described above in control arm"
62510542|NCT06616974|PLACEBO_COMPARATOR|Placebo|Participants will receive a single placebo dose SC for 24 weeks from Day 1 to Day 155
62707660|NCT00718315|EXPERIMENTAL|1|
62707661|NCT00718315|EXPERIMENTAL|2|
62707662|NCT00718315|EXPERIMENTAL|3|
61970654|NCT04867603||Digital PET/CT using [Ga-68]PSMA|Following prostate Standard of Care MRI, eligible participants will receive a single injection of \[Ga-68\]PSMA followed by digital PET/CT imaging approximately 60 minutes later. PET/CT takes approximately 30-35 minutes, where the participant would lay still on a scanner table.
61970655|NCT01119612|ACTIVE_COMPARATOR|Iron|
61970656|NCT01119612|PLACEBO_COMPARATOR|Placebo|
61970657|NCT02630498|EXPERIMENTAL|study (first group)|The first group will include those who receive a single shot brachial plexus block with or without general anesthesia.
62145898|NCT01334840|EXPERIMENTAL|BW|Bicarbonated mineral water without meal
62351757|NCT06057636|ACTIVE_COMPARATOR|Self Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the virtual consent/baseline visit and the virtual education visit.
62351758|NCT00085917|ACTIVE_COMPARATOR|Standard dose arm|Pegylated interferon alfa -2a STANDARD DOSE Pegasys 180ug/week
62707663|NCT00969423|EXPERIMENTAL|5 mm equipment|5 mm videoscopic equipment
61970658|NCT02630498|NO_INTERVENTION|Controlled (second group)|The second group will be the control group and include those patients who receive general anesthesia only, without any block whether due to the preference of patient or the surgeon.
61970659|NCT05255406|EXPERIMENTAL|Furmonertinib|Furmonertinib (160mg)
61970660|NCT01974349|EXPERIMENTAL|selumetinib 75mg (oral capsule fasted)|Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state.
61970661|NCT01974349|EXPERIMENTAL|selumetinib 75mg (oral capusle fed)|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state.
61970662|NCT06289491|EXPERIMENTAL|Hydrus Microstent|
62145899|NCT01334840|EXPERIMENTAL|BW with meal|Bicarbonated mineral water with meal
62145900|NCT01334840|ACTIVE_COMPARATOR|CW|Mineral water low in mineral content (control) without meal
62145901|NCT01334840|ACTIVE_COMPARATOR|CW with meal|Mineral water low in mineral content (control) with a meal
62145902|NCT06269029|EXPERIMENTAL|patients with COPD assigned for chest mobility|This study will be carried on 30 patients with Chronic obstructivepulmonarydisease. Patients will be selected from department (3) Kaser EL-Ainy, Cairo University.
62145903|NCT06269029|EXPERIMENTAL|patients with COPD assigned for PNF|This study will be carried on 30 patients with Chronicobstructivepulmonarydisease. Patients will be selected from department (3) Kaser EL-Ainy, Cairo University.
62351759|NCT00085917|EXPERIMENTAL|Double dose arm|Double dose pegylated interferon with weight based Ribavirin
62351760|NCT01338935|EXPERIMENTAL|Part I|Ascending dose tolerance, PK, and estimation of ED95 for CW 002
62351761|NCT01338935|EXPERIMENTAL|Part II|Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal
62351762|NCT01338935|EXPERIMENTAL|Part III|Intubation with CW 002 and Neostigmine reversal
62351763|NCT00122421|ACTIVE_COMPARATOR|pharmacist recommendation|recommendations based on chart review by pharmacist, given to pcp at time of visit
62351764|NCT00122421|NO_INTERVENTION|usual care|usual care
62351765|NCT00529698|OTHER|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
62510543|NCT05085795||All participants|
62510544|NCT02601768||ASD II|Transcatheter closure of ASD II
62510545|NCT01481857|EXPERIMENTAL|Thoracolumbar proprioception|
62510546|NCT01481857|EXPERIMENTAL|Segmental Stabilization|
61970663|NCT06289491|EXPERIMENTAL|Incisional goniotomy|
61970664|NCT06289491|EXPERIMENTAL|Excisional goniotomy|
61970665|NCT01311570|EXPERIMENTAL|Buprenorphine|
61970666|NCT03542981|ACTIVE_COMPARATOR|Interferential Current Treatment|Interferential Current group received interferential current treatment 30 minutes, 2 times a day for 5 days after the surgery.
61970667|NCT03542981|SHAM_COMPARATOR|Sham Interferential Current Treatment|In the sham interferential Current treatment, no electrical stimulation was applied to the probes with the same pads for the same time.
62510547|NCT05735886|PLACEBO_COMPARATOR|Placebo|
62707664|NCT00969423|EXPERIMENTAL|10 mm|Use of standard 10 mm VATS equipment
62707665|NCT00647647|EXPERIMENTAL|1|Terbinafine Hydrochloride Tablets 250 mg
62707666|NCT00647647|ACTIVE_COMPARATOR|2|Lamisil® Tablets 250 mg
62707667|NCT06149182|EXPERIMENTAL|Life stress interview/therapeutic interview|"Revised Life stress interview according to protocol from emotional awareness and expression therapy"
62707668|NCT06149182|ACTIVE_COMPARATOR|Psychiatric interview|"Psychiatric interview (M.I.N.I. etc) according to Region stockholm - basutredning"
62707669|NCT05924802|PLACEBO_COMPARATOR|Placebo|Placebo given that mimics taste, weight, and size of the interventional supplement mirroring the same time points as the ketone ester supplement group. Mirrored imaging with MRI as well.
62707670|NCT05924802|EXPERIMENTAL|Ketone ester supplement|Ketone ester given daily for 12 weeks and scanned before and after intervention with MRI.
62707671|NCT04106778|EXPERIMENTAL|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
61970668|NCT02483728|OTHER|Metal Allergy Hx +, Metal Patch Test +|These are patients with a history of metal allergy who are patch test positive to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
61970669|NCT02483728|OTHER|Metal Allergy Hx +, Metal Patch Test -|These are patients with a history of metal allergy who are patch test negative to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
61970670|NCT05146401||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
61970671|NCT05146401||Healthy pregnant women|Pregnant women with fasting glucose \< 5.1 mmol/L (92 mg/dL), 1 h glucose \< 10.0 mmol/L (180 mg/dL) and 2 h glucose \< 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
62510548|NCT05735886|ACTIVE_COMPARATOR|Urolithin A (Mitopure)|
62510549|NCT06327217||Hip arthroscopy 5-10jr|
62707672|NCT04106778|EXPERIMENTAL|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
62707673|NCT05222685|EXPERIMENTAL|Intervention Group|Will receive the 6 month online group coaching program from 9/1/2022-3/1/23
62707674|NCT05222685|NO_INTERVENTION|Control Group|"Control group - no coaching intervention from 9/1/2022-3/1/23.~(They will receive the coaching intervention after study completion from 3/1/23-9/1/23)"
62707675|NCT06331377||Observational|Patients complete questionnaires and undergo blood and tissue sample collection. Patients' medical records are also reviewed.
61970672|NCT01074450|EXPERIMENTAL|1|Pramipexole Dihydrochloride 0.25 mg Tablets
62145904|NCT01915888||Complete Rotarix vaccination cohort|Subjects had received 2 doses of Rotarix within the vaccination window and the observation time is from the end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario) to end of observation.
62351766|NCT00529698|OTHER|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.
62351767|NCT00798577|EXPERIMENTAL|Vigamox|Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)
62351768|NCT00798577|PLACEBO_COMPARATOR|BSS Placebo|Balanced Salt Solution
62510550|NCT05335382|EXPERIMENTAL|Implementing PCBH directly|PCCs randomized to this arm will immediately start the implementation of PCBH.
62351769|NCT01601808|PLACEBO_COMPARATOR|Gemcitabine and Placebo|Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
62707676|NCT01469247|EXPERIMENTAL|Radiation Therapy|Starting dose of 24 Gray (Gy) in 2 Gy fractions.
61970673|NCT01074450|ACTIVE_COMPARATOR|2|Mirapex® 0.25 mg Tablets
62351770|NCT01601808|EXPERIMENTAL|Gemcitabine and vandetanib|Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
62510551|NCT05335382|ACTIVE_COMPARATOR|Delayed implementation of PCBH|PCCs randomized to this arm will have a delayed start of their PCBH implementation, waiting between 5-9 months. During this time, the same patient-level and organizational-level data will be collected from these centers while they continue to use traditional primary care / Care As Usual (CAU) .
62510552|NCT01109758|EXPERIMENTAL|1|
62510553|NCT01906424|OTHER|Control Grp#1: Training w/ and w/o Stim|Control- Group #1: 4 weeks training without any transcutaneous electrical stimulation followed by 2 weeks of training plus transcutaneous electrical spinal cord stimulation applied to one or two locations of the cervical (neck) region of the spinal cord.
62707677|NCT04485702|ACTIVE_COMPARATOR|MELT-100|3mg midazolam and 25mg ketamine sublingual tablet
62707678|NCT04485702|ACTIVE_COMPARATOR|IV midazolam|2mg Intravenous midazolam
62707679|NCT04485702|ACTIVE_COMPARATOR|IV ketamine|6mg Intravenous ketamine
62707680|NCT04882865||"healthy volunteers as patients"|"use of the device (AMMP) and the process on 5 healthy volunteers undergoing proning, as well as general care (movement up or down the bed, rotated laterally). As well, repositioning sheets will be used for general care. Surveys of the impressions of team members of the value (ease of use, efficiency, safety, physical demands) of using the AMMP and the repositioning sheets with these patients will be completed.~The impressions of the volunteers as patients will be surveyed, with particular reference to comfort and security during movement"
61970674|NCT03552198|NO_INTERVENTION|General public/usual health advice|Healthy participants with a self-reported existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
61970675|NCT03552198|EXPERIMENTAL|General public/alternative health advice|Generally healthy participants were randomised to receive targeted health advice about the adoption of protective behaviours in an alternative format.
62707681|NCT04882865||ICU patients severe respiratory failure|patients with severe respiratory failure eligible for prone ventilation will be recruited with surveys provided to team members to gauge their impressions of the value of using the AMMP with the proning process for these patients. Surveys for 40 proning processes will be obtained. Movement from back to stomach or from stomach to back is considered a single process. A single patient may undergo multiple proning processes as prone ventilation is delivered for several days, with multiple healthcare team members participating in their care. We anticipate this will involve 10 patients, and 3 team members to be involved with each proning process.
62707682|NCT04882865||Patients admitted to the ICU|40 patients will have the AMMP used for general care. An additional 40 will have repositioning sheets used for general care. Healthcare team members involved with the care of these patients will be surveyed re their impressions of the value of using the AMMP or the repositioning sheets. We cannot predict the number of healthcare team members involved with the care of each patient s because of clinical conditions and length of stay
62707683|NCT03124186|EXPERIMENTAL|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
62145905|NCT01915888||Incomplete Rotarix vaccination cohort|Subjects had received one vaccination of Rotarix within the vaccination window and the observation time is from end of vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario)(if still observed) to end of observation.
62351771|NCT04781907|EXPERIMENTAL|Home Expansion Group|Participants in home expansion group will perform the saline injection for their right tissue expander under clinic staff supervision on their 2nd and 3rd expansion. Beginning their 4th expansion, participants will perform saline injection at home prior to their regularly scheduled clinic visit.
62707684|NCT03124186|ACTIVE_COMPARATOR|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
62707685|NCT02347605|EXPERIMENTAL|Nicotine lozenge 4 mg prior to cue exposure|Nicotine lozenge is used 15 minutes prior to smoking cue exposure
62707686|NCT02347605|PLACEBO_COMPARATOR|Placebo lozenge prior to cue exposure|Placebo lozenge is used 15 minutes prior to smoking cue exposure
62145906|NCT01915888||Historical unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends on/before 12/31/2006) to end of observation.
62351772|NCT04781907|NO_INTERVENTION|Control Group|Standard of Care
62351773|NCT01040754|ACTIVE_COMPARATOR|Acupuncture|
62351774|NCT01040754|NO_INTERVENTION|Waitlist Control|
62351775|NCT04436380||Relapsed SAA Patients|Patients with Severe Aplastic Anemia who Relapsed after Immunosuppressive Therapy
62351776|NCT00673686|ACTIVE_COMPARATOR|Arm 2|
62351777|NCT00673686|EXPERIMENTAL|Arm 1|
62351778|NCT02356640|ACTIVE_COMPARATOR|EUS-guided celiac ganglion neurolysis|Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
62351779|NCT02356640|ACTIVE_COMPARATOR|Percutaneous celiac plexus neurolysis|Percutaneous celiac plexus neurolysis would be performed
62351780|NCT06068296|OTHER|Short term memory assessment in patients with aphasia.|Evaluation of short term memory in a patient population with poststroke aphasia using a dutch version of the Temple Assessment of Language and Verbal Short-Term memory in aphasia (TALSA).
62351781|NCT06068296|OTHER|short term memory assessment in healthy volunteers|Evaluation of short term memory in healthy volunteers using a dutch version of the Temple Assessment of Language and Verbal Short-Term memory in aphasia (TALSA).
62351782|NCT06517862|NO_INTERVENTION|preterm: control|phototherapy only
62351783|NCT06517862|EXPERIMENTAL|preterm: low dose of oral zinc sulfate|Neonates will receive oral Zn sulfate solution in low doses (10 mg/day) given as 5 mg twice daily.
62351784|NCT06517862|EXPERIMENTAL|preterm: high dose of oral zinc sulfate|Neonates will receive oral Zn sulfate solution in a high dose (20 mg/day) given as 10 mg twice daily.
62351785|NCT06517862|EXPERIMENTAL|preterm: low dose of oral UDCA|Neonates will receive oral UDCA solution at 10 mg/kg twice daily.
62351786|NCT06517862|NO_INTERVENTION|full-term: control|phototherapy only
62351787|NCT06517862|EXPERIMENTAL|full-term: low dose of oral zinc sulfate|Neonates will receive oral Zn sulfate solution in low doses (10 mg/day) given as 5 mg twice daily.
62351788|NCT06517862|EXPERIMENTAL|full-term: high dose of oral zinc sulfate|Neonates will receive oral Zn sulfate solution in a high dose (20 mg/day) given as 10 mg twice daily.
62351789|NCT06517862|EXPERIMENTAL|full-term: low dose of oral UDCA|Neonates will receive oral UDCA solution at 10 mg/kg twice daily.
62351790|NCT04263779|NO_INTERVENTION|Default List (case manager level)|In this condition, all SNF options will be presented to case managers in Repisodic in rank order according to Repisodic's algorithm that weights dimensions such as Centers for Medicare \& Medicaid Services (CMS) quality metric ratings, distance, and the match between SNF features and specific patient need. The list only includes SNFs that accept the patient's insurance.
62351791|NCT04263779|EXPERIMENTAL|P-SNF Top-Sorted List (case manager level)|"This condition is the same as the Default List, except that relevant providers (i.e., those meeting patient needs and located within a threshold distance to be determined per hospital) who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.~Situations in which there are no relevant P-SNFs will be flagged yet still assigned to this condition, in an intent-to-treat analysis; the default algorithm-based rank-ordered approach will be applied to all non-preferred providers."
62351792|NCT04263779|NO_INTERVENTION|Full List/Full Map/Default Video (patient level)|All SNF options, both P-SNFs and NP-SNFs (up to a maximum of 10 by default) that case managers preselected for patients will be presented to patients in rank order (according to Repisodic's algorithm, as described above). Patients will also have the option of viewing the default Repisodic map, which will show the SNFs on the list, and patients will be provided the link to an introductory video presenting the SNF selection and discharge process. When only a paper printout is available, the same SNF sorting order will be presented on paper.
62145907|NCT01915888||Contemporary unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends after 1/1/2007) to end of observation.
62145908|NCT02266927|ACTIVE_COMPARATOR|Flovent® HFA 440µg|Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg
62145909|NCT02266927|EXPERIMENTAL|OPTINOSE™ FLUTICASONE 400µg intranasal|OPTINOSE™ FLUTICASONE, single dose of 400 µg intranasally
62145910|NCT01085513|ACTIVE_COMPARATOR|Patients|Patients previously indicated for manometry
62145911|NCT01085513|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers
62145912|NCT03340259||Newborn infants with enterostomy|Infants with enterostomy after surgery due to congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation
62145913|NCT00825344|EXPERIMENTAL|1|Etanercept 50 mg preoperatively
62510554|NCT01906424|ACTIVE_COMPARATOR|Grp#2: Training+Single Site Stimulation|Group #2: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to one location along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
62510555|NCT01906424|ACTIVE_COMPARATOR|Grp #3: Training + Two Site Stimualtion|Group #3: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to two locations along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
61970676|NCT03552198|NO_INTERVENTION|At risk group/usual health advice|Participants with a self-reported pre-existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
61970677|NCT03552198|EXPERIMENTAL|At risk group/alternative health advice|Participants with a self-reported existing health conditions were randomised to receive targeted health advice (based on their health condition) about the adoption of protective behaviours in an alternative format.
61970678|NCT00656110|EXPERIMENTAL|1-T|Treatment Group
61970679|NCT00656110|PLACEBO_COMPARATOR|2-P|Placebo comparator
61970680|NCT01661439||Low molecular weight heparin|SC LMWH IN patients with recurrent pregnancy loss
61970681|NCT04219631|EXPERIMENTAL|WINNER- FLOW-URO-MG GROUP|After admission to the delivery room, all women assigned to WF + group will have an interview with one of the midwifes responsible for the study. The latter will explain the use of the WINNER FLOW®-URO MG® device which is the expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate. Then, WF+ patients will use the expiratory mouthpiece device during all their childbirth process.
61970682|NCT04219631|NO_INTERVENTION|NO WINNER-FLOW-URO-MG GROUP|Women enrolled in WF- group will be managed classically during their child birth process regardless to the study participation.
62145914|NCT00825344|PLACEBO_COMPARATOR|2|Subcutaneous saline preoperatively
62145915|NCT05213182|EXPERIMENTAL|Intervention|The intervention arm (n=104 adolescent mothers) participated in the 12 in-person peer support group sessions and completed sociodemographic, base-, mid-, and end-line surveys.
62145916|NCT05213182|NO_INTERVENTION|Control|The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys.
62510556|NCT05402787|EXPERIMENTAL|Experimental|The virtual visit will be started within the first 24 hours after birth. Mothers in this group will be informed about how the virtual visit will be. The virtual visit will be made online through the Whatshup video call program. The virtual visit will be twice a day, starting 24 hours after birth until the baby's first meeting with the mother. The first virtual visit to be made during the day will be aimed at understanding the mother's feelings, increasing her motivation and informing about the clinical condition of the baby. In the second interview, it will be supported to provide approximately 10 minutes of visual and audio communication that will help the mother to establish a connection with her baby. During the virtual visiting hour, the videos of the baby will be sent to the mother so that the mother can watch it. In each visit, it will be ensured that the mother sees her baby in every situation by paying attention to the fact that the baby is in a different situation.
62145917|NCT06510088|EXPERIMENTAL|3-week multimodal prehabilitation program+perioperative care guided by ERAS protocols|This program included four components: aerobic and resistance exercises, respiratory training, nutritional counseling with whey protein supplementation, and psychological adjustment.
62145918|NCT06510088|NO_INTERVENTION|perioperative care guided by ERAS protocols|Perioperative care of the control group was based on standardized ERAS recommendations that have been widely implemented to minimize heterogeneity in perioperative care. Typically, participants did not receive any preoperative interventions related to exercise, nutrition, or mental health.
62145919|NCT02054429|EXPERIMENTAL|Insulin|IIT arm subjects will receive an insulin aspart infusion at a minimal rate of 2 units/hr while maintaining blood glucose between 90-120mg/dl for 48 hrs
62510557|NCT05402787|NO_INTERVENTION|Control Groups|The mothers in the control group will be followed in line with the hospital's routine health monitoring and information.
62707687|NCT02347605|OTHER|Control condition: Lozenge after cue exposure|Lozenge is used immediately after smoking cue exposure
61970683|NCT00246727|PLACEBO_COMPARATOR|Study 1: Chemotherapy plus SV or Placebo|For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
61970684|NCT00246727|PLACEBO_COMPARATOR|Study 2: SV vs Placebo without chemotherapy|For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
61970685|NCT03236974|ACTIVE_COMPARATOR|Standard arm|Fulvestrant, 500 mg
61970686|NCT03236974|EXPERIMENTAL|AZD9496|250 mg bd taken orally for 5-14 days
61970687|NCT03939884|EXPERIMENTAL|Professional Therapy Muscle Care™ roll-on with MSM|
61970688|NCT03939884|EXPERIMENTAL|Professional Therapy Muscle Care™ roll-on without MSM|
62145920|NCT02054429|NO_INTERVENTION|Standard glycemic control|standard of care if not randomized to Insulin
62145921|NCT04235205|EXPERIMENTAL|Elobixibat and cholestyramine|The investigational product per dosing (elobixibat 10mg and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
62145922|NCT04235205|EXPERIMENTAL|Elobixibat|The investigational product per dosing (elobixibat 10mg and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
62145923|NCT04235205|EXPERIMENTAL|cholestyramine|The investigational product per dosing (elobixibat placebo and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
62145924|NCT04235205|PLACEBO_COMPARATOR|Placebo|The investigational product per dosing (elobixibat placebo and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
62145925|NCT05707494|EXPERIMENTAL|Basic therapy + Efferon LPS NEO|Study group: Basic therapy + Efferon LPS NEO - 80 patients, prospective enrollment.
62145926|NCT05707494|NO_INTERVENTION|Baseline therapy|Control group: Basic therapy - 160 patients, retrospective enrollment. Basic therapy is the routine practice of the institution for the treatment of patients with sepsis (conservative anti-infective therapy). Antibacterial therapy regimens, antibiotic dosage adjustment regimens for AKI and prolonged RRT procedures are not specifically prescribed in the CT Plan.
62145927|NCT02611869|EXPERIMENTAL|Cryoballoon|
62145928|NCT02611869|ACTIVE_COMPARATOR|RF ablation|
62351793|NCT04263779|EXPERIMENTAL|P-SNF List/P-SNF Map/P-SNF Video (patient level)|This is the same as the Full List condition, except that both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. Moreover, the link to viewing the optional introductory video will be highlighted, and the video will include sections describing the advantage of P-SNFs for care coordination. When only a paper printout is available, the same SNF sorting order will be presented on paper, with only the P-SNFs presented on the first page.
62351794|NCT05082298|EXPERIMENTAL|Dental Fear Intervention|All participants will receive a brief 2-step treatment for dental fear (Dental FearLess app, In-Chair Treatment)
61970689|NCT03939884|EXPERIMENTAL|Professional Therapy Muscle Care™ Ointment with MSM|
61970690|NCT03939884|EXPERIMENTAL|Professional Therapy Muscle Care™ Ointment without MSM|
61970691|NCT03939884|ACTIVE_COMPARATOR|Voltaren Emulgel|
61970692|NCT03939884|PLACEBO_COMPARATOR|Non-medicinal Placebo|
61970693|NCT01638065||Standard|Standard IV Access without device
61970694|NCT01638065||VeinViewer|IV access with VeinViewer device
61970695|NCT05377385||Study group|Children and adolescents with type 1 diabetes mellitus who started in 2021 in the Jessa Hospital with the Omnipod DASH insulin administration device.
61970696|NCT01080521||Observational (cognitive function during chemotherapy)|Patients receive standard chemotherapy. Treatment repeats for 6 courses. Patients complete neurocognitive evaluations (Patient Assessment and Own Functioning scale and HeadMinder Custom Research Tool) and quality-of-life assessments (Hospital Anxiety and Depression Scale, FACT-O, and FACT/GOG-Ntx subscale) at baseline, before the fourth course of chemotherapy, at 3 weeks after the sixth course of chemotherapy, and at 6 months after the sixth course of chemotherapy.
61970697|NCT05420129||MAD. Mandibular advancement Device|Patients diagnosed with Obstructive Sleep Apnea and treated with MAD
61970698|NCT05420129||CPAP. Continuous Possitive Airway Pressure|Patients diagnosed with Obstructive Sleep Apnea and treated with CPAP
61970699|NCT00380185||1|Subjects with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries
61970700|NCT00380185||2|Subjects with coronary artery disease only
61970701|NCT00380185||3|Subjects with both coronary artery disease and peripheral arterial disease
62145929|NCT04534738|EXPERIMENTAL|Mediterranean Diet|Participants in the Mediterranean Diet arm are asked to follow a Mediterranean Diet for 8 weeks. The diet is ad libitum. A combination of fresh, frozen, and shelf-stable meals are provided for the first 4 weeks. Also during the first 4 weeks, participants receive an education session to discuss how to effectively implement a Mediterranean Diet into their daily routine.
62351795|NCT02427750|EXPERIMENTAL|Trivalent Influenza Vaccine|One injection of Agrippal®
62351796|NCT02883777|EXPERIMENTAL|High Protein and Low Glycemic Index Diet|A protocol of a high protein and low glycemic index diet.
62351797|NCT02883777|ACTIVE_COMPARATOR|Conventional Diet|A protocol of a conventional diet.
62351798|NCT02591238|PLACEBO_COMPARATOR|non-smoker + placebo|non-smoker oral placebo
62351799|NCT02591238|ACTIVE_COMPARATOR|non-smoker + melatonin|non-smoker oral melatonin
62351800|NCT02591238|PLACEBO_COMPARATOR|smoker + placebo|smoker oral placebo
62351801|NCT02591238|ACTIVE_COMPARATOR|smoker + melatonin|smoker oral melatonin
62351802|NCT04370730|OTHER|prospective cohort|prospective monitoring of children and adolescents with schizophrenia and related psychotic disorders
61970702|NCT04432194|NO_INTERVENTION|Control group|The subjects in this group will receive the usual care, which includes the non-pharmacology recommendations by the European Society of Cardiologists 2006 (1) and COPD guides for treatment (6), both founded in the sodium and liquids restriction.
61970703|NCT04432194|ACTIVE_COMPARATOR|Pulmonary Rehabilitation Group|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months.
61970704|NCT04432194|EXPERIMENTAL|Pulmonary Rehabilitation Group plus HMB (4g)|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
61970705|NCT04432194|EXPERIMENTAL|Pulmonary Rehabilitation Group plus citrulline (3g)|Patients in this group will receive pulmonary rehabilitation specified by the doctor specialized in rehabilitation according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
61970706|NCT06044285|EXPERIMENTAL|Self-Guided Low UP Food Diet|Participants asked to eat a low UP food diet according to study provided nutritional guidance.
61970707|NCT06044285|EXPERIMENTAL|Meals Provided Low UP Food Diet|.Participants asked to eat a low UP food diet provided by the study team.
61970708|NCT06044285|ACTIVE_COMPARATOR|Control|Participants asked to eat as they usually do.
61970709|NCT01602146||ultramarathon runner|People who do the Mont Blanc ultramarathon (31/08/12 to 02/09/12)
61970710|NCT01321424||Aqueous Dificiency Dry Eye|20 Participants
61970711|NCT01321424||Meibomian Gland Disease Dry Eye|20 Participants
61970712|NCT01321424||Normal Eye|20 Participants
62351803|NCT06204302||Darolutamide|Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Darolutamide as initial treatment.
62351804|NCT06204302||Enzalutamide|Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Enzalutamide as initial treatment.
61970713|NCT06501768|EXPERIMENTAL|Genistein Therapy|Participants will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood samples are collected. And then, patients will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before blood are collected. Afterward, patients will take 750 mg of genistein BID (1500 mg total) for 4 weeks before blood samples are collected. Afterward, patients will be off Genistein for 6 weeks before returning for blood sample collection. The Genistein capsules are manufactured and obtained from MCS Formulas. The genistein is certified to be 98% pure genistein by HPLC and is good laboratory practice (GLP) certified. At baseline, and again before Genistein discontinuation (at 12 weeks), we will also perform transthoracic echocardiography and a 6-minute walk test.
61970714|NCT03458273||Zero fluoro|Patients in whom Zero fluoroscopy ablation was performed under the guidance of Ensite for mapping and ablation and fluoroscopy will not be used during the procedure.
61970715|NCT03458273||Conventional ablation without 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic guidance only.~Additional use of Ensite/Carto/Localisa for mapping was not allowed."
61970716|NCT03458273||Conventional ablation with 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic and Ensite/Carto guidance and ablation during the procedure.~Use of fluoroscopy and additional Ensite/Carto for mapping and ablation was mandatory."
61970717|NCT00118963|ACTIVE_COMPARATOR|3|BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
61970718|NCT00118963|ACTIVE_COMPARATOR|2|BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.
61970719|NCT00118963|OTHER|1|Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.
61970720|NCT05712616|ACTIVE_COMPARATOR|Strontium group|Trial drug given in the form of sachet 2gm/sachet once every day
61970721|NCT05712616|PLACEBO_COMPARATOR|Placebo (Lactose)|Look, smell, taste alike lactose 2gm/sachet in form of sachet
61970722|NCT04541550|EXPERIMENTAL|Low Dose AMP-001|12.5 mg AMP-001 in 3 ml Saline
61970723|NCT04541550|EXPERIMENTAL|Medium Dose AMP-001|25 mg AMP-001in 3 ml Saline
61970724|NCT04541550|EXPERIMENTAL|High Dose AMP-001|50 mg AMP-001 in 3 ml Saline
61970725|NCT05485038|EXPERIMENTAL|Awake surgery|Critical steps of brain mapping and tumor removal will be performed in awake patient
61970726|NCT05485038|ACTIVE_COMPARATOR|General anesthesia|Brain mapping and tumor removal will be performed in asleep patient
61970727|NCT04624568|EXPERIMENTAL|Papilocare group|"Papilocare® for 6 months according to the following schedule:~1 self-applying single dose per day for 21 days over 28 during the first month, then 1 day over 2 during the following 5 months, with a 7-day break during the menstrual period. (This break must be respected even in menopausal women or women undergoing artificial amenorrhea (amenorrhea induced by certain contraceptives: implant, hormonal IUD, micro-progestogen)."
61970728|NCT04624568|NO_INTERVENTION|Control group|No treatment for 12 months. Smear and HPV test will be perform by all patients at 6 and 12 months
61970729|NCT06151834|EXPERIMENTAL|Patients|Patients older than 18 years-old, with a surgical indication of interphalangeal arthrodesis of finger
61970730|NCT05281939|ACTIVE_COMPARATOR|Artificial intelligence diagnostic group|Women who show abnormalities in cervical cancer screening and require referral for colposcopy. Colposcopy was performed with the aid of an Artificial intelligence (AI) system.
61970731|NCT05281939|NO_INTERVENTION|Gynecologist diagnostic Group|Women who show abnormalities in cervical cancer screening and require referral for colposcopy. Colposcopy is performed independently by a gynecologist without any external assistance.
61970732|NCT03217487|EXPERIMENTAL|Corneal epithelial autograft|Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
61970733|NCT03217487|ACTIVE_COMPARATOR|Limbal conjunctival autograft|Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD
61970734|NCT05398211|EXPERIMENTAL|Preferred Recorded Music (PRM)|The Preferred Live Music (PLM) aims to elicit participants' responses from live music and the ensuing musical and non-musical interactions with the music therapist (MT). In the PLM intervention, preferred songs performed live on guitar or electronic keyboard will be played by a credentialed MT. When appropriate participants may also play percussion instruments offered to them. Elements of improvisation will be incorporated to allow for active engagement by the participants, and to provide opportunities for musical and non-musical attunement to emerge.
61970735|NCT05398211|EXPERIMENTAL|Preferred Live Music (PLM)|The Preferred Recorded Music (PRM) intervention aims to detect responses directly attributable to the music. Participants listen to pre-recorded preferred originally-published versions of music accessed by Spotify music-streaming service and played through loud-speakers. The MT will only start the music, and otherwise not be present during the interventions to ensure the minimal direct interaction with the participants.
61970736|NCT01447901||previously treated LPLD Cohort|Subjects in Cohort 1 (previously treated LPLD Cohort) must have received AMT-011 during Studies CT-AMT-011-01 or -02
61970737|NCT01447901||untreated LPLD control Cohort|Subjects in Cohort 2 (untreated LPLD control Cohort)) may have completed study PREPARATION-02 or known patients with genetically confirmed LPLD
62351805|NCT06204302||Apalutamide|Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Apalutamide as initial treatment.
62351806|NCT00605722|EXPERIMENTAL|bevacizumab + erlotinib|Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.
62510558|NCT06613087|EXPERIMENTAL|Foot bath|In the foot bath application, the feet will be kept in water at a constant temperature of 38-40 °C for about 20 minutes. During this time, the water temperature will be checked with a thermometer at intervals. Foot bath applications will be performed for 3 days, on the 2nd, 3rd and 4th days of hospitalization.
62510559|NCT06613087|NO_INTERVENTION|Control|The control group will receive standard care. No intervention will be applied to these patients during the follow-up period, only data collection forms will be applied. Data collection forms will be collected in the same time period as the intervention group.
62510560|NCT02063087|ACTIVE_COMPARATOR|Decision Aid|Head CT Decision Aid
62707688|NCT02578082|EXPERIMENTAL|Renal Impairment|Eight subjects with Severe Renal Impairment (eGFR \<30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.
62510561|NCT02063087|NO_INTERVENTION|Usual Care|Clinicians and patients do not have access to the Head CT Decision Aid
61970738|NCT01447901||normal healthy control Cohort|Volunteers in Cohort 3 (normal healthy control Cohort) must not have LPLD
62510562|NCT00271739|EXPERIMENTAL|Telemedicine case management|Telemedicine visits conducted by a registered nurse (RN) with remote monitoring of blood pressure (BP) and blood glucose through the use of a telemedicine home unit (HTU).
62510563|NCT00271739|ACTIVE_COMPARATOR|Usual care|usual care by primary care provider
62510564|NCT03631368|EXPERIMENTAL|Botox|
62510565|NCT05630625|EXPERIMENTAL|Drinking Dashboard|Day-level feedback on alcohol use and consequences
62510566|NCT05630625|NO_INTERVENTION|Assessment Only|Daily assessment control group
62510567|NCT05086198|EXPERIMENTAL|Mindfulness-based intervention (MBI)|A 8-week mindfulness-based intervention. From 15 to 30 minutes of practice per session, three times/week through audio guided meditations.
62510568|NCT05086198|ACTIVE_COMPARATOR|Physical exercise (PE)|A 8-week physical exercise intervention. From 15 to 30 minutes of practice per session, three times/week through workout videos.
62510569|NCT05086198|NO_INTERVENTION|Wait list (WL)|The participants will continue their work activity as usual. This arm will receive one of the two previous interventions once the study finished.
62510570|NCT01104428|PLACEBO_COMPARATOR|placebo|
62510571|NCT01104428|EXPERIMENTAL|"Drug:ziying"|
62510572|NCT06177847|EXPERIMENTAL|BIS Guided|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
62510573|NCT06177847|NO_INTERVENTION|BIS Blinded|The anesthesia protocol used in closed BIS is carried out like general anesthesia without using BIS.
62510574|NCT01359748|OTHER|Wrist Size <= 14.25 Cm|"* Blood pressure measured using the reference sphygmomanometer.~* Blood pressure measured using the Sphygmomanometer under test."
62510575|NCT01359748|OTHER|Wrist Size >=14.26 <16.50 Cm|"* Blood pressure measured using the reference sphygmomanometer.~* Blood pressure measured using the Sphygmomanometer under test."
62707689|NCT02578082|EXPERIMENTAL|Normal Renal Function|"Eight healthy participants matched to participants with severe renal impairment.~Intervention is TD-4208, 175mcg, inhaled, single dose."
62707690|NCT03781986|EXPERIMENTAL|APG-115 monotherapy|APG-115 will be administered in an open label fashion until progression, intolerance, or patient preference.
62707691|NCT03781986|EXPERIMENTAL|APG-115 + Carboplatin [terminated]|APG-115 and Carboplatin will be administered in an open label fashion until progression, intolerance, or patient preference. \[Phase 1 was terminated early and this arm was discontinued. An MTD was not established during Phase 1.\]
62510576|NCT01359748|OTHER|Wrist size >=16.5 <17.75 Cm|"* Blood pressure measured using the reference sphygmomanometer.~* Blood pressure measured using the Sphygmomanometer under test."
62510577|NCT01359748|OTHER|Wrist Size >=17.75 Cm|"* Blood pressure measured using the reference sphygmomanometer.~* Blood pressure measured using the Sphygmomanometer under test."
62510578|NCT03135899|EXPERIMENTAL|BI 443651|
62510579|NCT03135899|PLACEBO_COMPARATOR|Placebo|
62510580|NCT04858659|EXPERIMENTAL|PK101 group|
62510581|NCT04858659|ACTIVE_COMPARATOR|PK101-002 group|
62510582|NCT05058560|EXPERIMENTAL|BACE+Tislelizumab|BACE was performed on the first day of the first cycle, and the first 200 mg of tislelizumab was given 3-5 days later.
62510583|NCT05876117||Claustrophobic adult patients|Claustrophobic adult patients who are undergoing MRI scan as part of chronic pain management.
62707692|NCT05512624|EXPERIMENTAL|Intervention Arm|The course of Common Elements Treatment Approach (CETA - the intervention under study) is built to be flexible depending on need. Mild symptoms could result in fewer sessions (e.g., 5), while greater severity may require 8-12 sessions.
61970739|NCT02279173|EXPERIMENTAL|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.
61970740|NCT02933125|EXPERIMENTAL|Intervention group|The youths in the intervention group will participate in a weekly 10-session out-patient motivational enhancement psychotherapy (MEP) program. In addition to this, these youths' caregivers will be referred to simultaneously take part in a weekly 10-session out-patient parenting skill training (PST) program at Kaohsiung Chang Gung Memorial Hospital.
61970741|NCT02933125|ACTIVE_COMPARATOR|Comparison group|The comparison group consists of substance-using adolescents that receive only standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court. The protection officers provide the adolescents with moral education, as well as counseling in their work or studies.
61970742|NCT05759923|EXPERIMENTAL|OATD-02|
62510584|NCT06617507||Children with diparetic cerebral palsy|20 ambulatory diparetic CP cases were included. The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.
62510585|NCT05081245|EXPERIMENTAL|ML-004 (IR)/(ER) tablet|ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets).
62510586|NCT05081245|PLACEBO_COMPARATOR|ML-004 Placebo|Matched placebo oral tablets will consist of same excipients as the investigational drug but without any ML-004. Placebo taken orally once daily to match tablet number of ML-004 dose levels for 12 mg (1 tablet), 24 mg (1 tablet), 48 mg (2 tablets), and 72 mg (3 tablets).
62510587|NCT00992212|EXPERIMENTAL|Group A (Seasonal TIV + 7.5mcg HA+ full dose MF59)|
62510588|NCT00992212|EXPERIMENTAL|Group B (Ajuvanted Seasonal TIV + 7.5mcg HA+ full dose MF59)|
62510589|NCT00992212|EXPERIMENTAL|Group C (7.5mcg HA+ full dose MF59)|
62510590|NCT00992212|EXPERIMENTAL|Group D (7.5mcg HA+ full dose MF59 + Seasonal TIV)|
62510591|NCT00992212|EXPERIMENTAL|Group E (3.75mcg HA+ ½ dose MF59+ Seasonal TIV)|
62510592|NCT04485416|EXPERIMENTAL|Treatment group|Subjects will receive eltrombopag
62707693|NCT05512624|NO_INTERVENTION|Waitlisted Arm|The waitlisted arm will be offered the CETA approach upon conclusion of the endline data collection.
62510593|NCT05551702|EXPERIMENTAL|Treatment|This arm will receive 8 weeks of the text-based intervention (CBT-txt). CBT-txt is a version of Cognitive Behavioral Therapy tailored to be delivered by automated text message. This arm will also complete surveys at baseline, 1 month, 2 months, and 3 months.
62145930|NCT04534738|NO_INTERVENTION|Usual care|Participants in the usual care are will complete all the same study assessments as those in the intervention group. They will not receive any specific dietary advice, but they will be permitted to seek dietary advice outside the study. Data from this group are indispensable in understanding the nutritional habits and preferences of patients undergoing chemotherapy, and these data will be used to optimize nutritional interventions in future studies. At the end of the 8-week intervention, the participants in the usual care group will be provided the intervention materials gratis, including one-week of Mediterranean Diet food and education materials.
62145931|NCT04329585|EXPERIMENTAL|GABA antagonist|In the end of the experiment, 0.2mg of flumazenil(GABA antagonist) is given to the participant.
62145932|NCT04329585|PLACEBO_COMPARATOR|Placebo|In the end of the experiment, the same volume of normal saline is given to the participant.
62145933|NCT03278977|OTHER|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
62510594|NCT05551702|NO_INTERVENTION|Waitlist Control|This arm will not receive the text-based intervention during study participation. These participants will only complete surveys at baseline, 1 month, 2 months, and 3 months and will be given the option to receive CBT-txt after they complete study participation.
62510595|NCT04143282|EXPERIMENTAL|Metformin group|Non Diabetic metastatic breast cancer Patients will take metformin 1 gm. twice daily (Nathan 2009) along with standard chemotherapy
62510596|NCT04143282|OTHER|control group|Non Diabetic metastatic breast cancer Patients will take standard chemotherapy only
62510597|NCT04138706|PLACEBO_COMPARATOR|Control: Placebo|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will receive a placebo for an additional 14 days (twice a day x 7 days, then once a day for 7 days).
62510598|NCT04138706|ACTIVE_COMPARATOR|Intervention: Extended vancomycin regimen|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will receive active vancomycin for an additional 14 days (125mg twice a day x 7 days, then 125mg once a day for 7 days).
62510599|NCT00638144||1|patients with resolved infection
62510600|NCT00638144||2|chronically infected patients
62510601|NCT02358733|EXPERIMENTAL|Treatment|Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
62145934|NCT03278977|OTHER|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
62145935|NCT05643521|EXPERIMENTAL|Control Arm|2 days of eucaloric control diet prior to MRS estimating liver fat (control arm)
62145936|NCT05643521|EXPERIMENTAL|Hypocaloric low carbohydrate|2 days of eucaloric control diet + 2 days of hypocaloric (500-600 kcal m/f) low carbohydrate diet prior to liver fat estimated by MRS and metabolic testday.
62145937|NCT05643521|EXPERIMENTAL|Eucaloric low carbohydrate|2 days of eucaloric control diet + 2 days of eucaloric low carbohydrate diet prior to liver fat estimated by MRS and metabolic testday.
62145938|NCT02177825|EXPERIMENTAL|Imatinib Mesylate|Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
62145939|NCT01409772||Intestinal Rehab|Pediatric Patients Undergoing Intestinal Rehabilitation for short bowel syndrome
62510602|NCT02358733|ACTIVE_COMPARATOR|Control|Intracytoplasmic sperm injection (ICSI)
62510603|NCT06071195||Prostate Cancer Patients|"Patients will undergo a combined whole-body MRI + multiparametric prostate MRI examination along with routine staging examinations (PET, CT / bone scintigraphy).~Reporting will be performed without and with reference to the whole-body MRI examination. Differences in the resulting staging and in management recommendations based on the two reportings will be recorded."
62510604|NCT00265044|OTHER|Arm 1|
62510605|NCT05279638||psoriasis vulgaris patients|psoriasis vulgaris patients , both sex , 18,55 years old
62510606|NCT05279638||healthy participants|
62145940|NCT01585623|EXPERIMENTAL|Segment 1|two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
62145941|NCT01585623|EXPERIMENTAL|Segment 2|SAR302503 500 mg once daily without food in 28-day per cycle
62145942|NCT00416975|OTHER|Breast Cancer Risk Assessment Screening|Counseling Intervention and Eduation Intervention
62145943|NCT00346320|EXPERIMENTAL|Radiotherapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
62510607|NCT00671073|ACTIVE_COMPARATOR|1|Oglemilast low dose, oral administration once daily for 12 weeks
62510608|NCT00671073|ACTIVE_COMPARATOR|2|Oglemilast middle dose, oral administration, once daily for 12 weeks
62510609|NCT00671073|ACTIVE_COMPARATOR|3|Oglemilast high dose, oral administration, once daily for 12 weeks.
62145944|NCT03584074|EXPERIMENTAL|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
62510610|NCT00671073|PLACEBO_COMPARATOR|4|Placebo
62510611|NCT02574715||Levonorgestrel (Jaydess, BAY86-5028)|women aged 18 to 29 years following 6 (±1) months of Jaydess® use as their contraceptive method.
62510612|NCT02549846|ACTIVE_COMPARATOR|Acute Group|Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
62510613|NCT02549846|OTHER|Stable Group|Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
62510614|NCT03239977|EXPERIMENTAL|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
62510615|NCT03239977|PLACEBO_COMPARATOR|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
62510616|NCT01317784|EXPERIMENTAL|All tests.|Choose from all 16 possible tests.
62510617|NCT01317784|ACTIVE_COMPARATOR|HIV/HCV|Choice of 10 different HIV and hepatitis C tests in the bundle.
62510618|NCT01317784|ACTIVE_COMPARATOR|HIV/Syphilis|Choice of 7 different tests for HIV and syphilis.
62510619|NCT01317784|ACTIVE_COMPARATOR|HIV only|Choice of 4 rapid tests for HIV only.
62510620|NCT04351230|ACTIVE_COMPARATOR|Arm A (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62510621|NCT04351230|EXPERIMENTAL|Arm B (trastuzumab emtansine, abemaciclib)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 and abemaciclib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62510622|NCT00846794||1 Asymptomatic|students with conditions being studied
62510623|NCT00846794||2 Symptomatic|students without conditions being studied
62510624|NCT03710317|ACTIVE_COMPARATOR|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
62510625|NCT03710317|EXPERIMENTAL|Tranexamic acid plus misoprostol|400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
62510626|NCT02697539|PLACEBO_COMPARATOR|AmF/SnF2 group|Patients in this arm were adviced to use a standart dentifrice over the course of the study (AmF/SnF2, Meridol®, GABA, Lörrach, Germany).
62510627|NCT02697539|ACTIVE_COMPARATOR|mHA group|Patients in this arm were adviced to use the new dentifrice over the course of the study (mHA, BioRepair®, Wolff, Bielefeld, Germany).
62510628|NCT04624659|EXPERIMENTAL|Double blind etavopivat Low Dose|Double blind etavopivat Low Dose
62510629|NCT04624659|EXPERIMENTAL|Double blind etavopivat High Dose|Double blind etavopivat High Dose
62510630|NCT04624659|EXPERIMENTAL|Double blind placebo|Double blind placebo
62510631|NCT04624659|EXPERIMENTAL|Open label etavopivat|Open label etavopivat
62510632|NCT02612181|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine group: Dexmedetomidine infusion for dexmedetomidine group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Dexmedetomidine doses 0-0.7 mcg/kg/h
62510633|NCT02612181|PLACEBO_COMPARATOR|Control group|Control group: Placebo infusion for control group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Control drug doses 0-0.7 mcg/kg/h
62707694|NCT03483948|EXPERIMENTAL|HMPL-523 & Azacitidine|HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
62145945|NCT03584074|ACTIVE_COMPARATOR|COX-2 inhibitor|Celecoxib 200mg qd
61970743|NCT05950009||Cases _major depression patients|subjects with moderate or severe major depression, without severe suicide ideation, as characterized by the Patient Health Questionnaire (PHQ)-9 index (values of 9 or greater) and by the Structured Clinical Interview for DSM-5 - (SCID) will be selected.
62145946|NCT02867982|OTHER|Subcrestal|implants that are placed below the alveolar ridge
62145947|NCT02867982|OTHER|Paracrestal|implants that are placed flush to the alveolar ridge
62145948|NCT04074252|ACTIVE_COMPARATOR|Lofstrand Crutches|This group is given a set of Lofstrand crutches.
62510634|NCT06250751|EXPERIMENTAL|Behavioral exercise training (BET) to introduce behavioral skills for adopting an exercise program|Single-arm, ORBIT-prospective, multicenter, nonblinded clinical trial, feasibility pilot. The BET intervention will be delivered and refined over 12 weeks. The protocol aim is to enroll men from the same representative groups of underserved men in groups of 5-10, to foster social support and group cohesion.
62510635|NCT01877460|EXPERIMENTAL|Sodium alginate-free chocolate milk|Sodium alginate-free chocolate milk (1% fat) (Beatrice Ltd., Toronto, Ontario)
62510636|NCT01877460|EXPERIMENTAL|1.25% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 1.25% sodium alginate
62510637|NCT01877460|EXPERIMENTAL|2.5% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 2.5% sodium alginate
62510638|NCT01877460|EXPERIMENTAL|2.5% sodium alginate milk-free water-based solution|Water solution with 2.5% sodium alginate
62510639|NCT00935831|EXPERIMENTAL|Subjects with renal impairment, non-dialysis|Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
62510640|NCT00935831|EXPERIMENTAL|Healthy volunteers|Healthy subjects will be matched to the moderate and severe renally impaired subjects for gender, age, and BMI. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
62510641|NCT00935831|EXPERIMENTAL|Hemodialysis dependent subjects|The arm will consist of subjects with severe renal impairment (end-stage renal failure) who have been on stable hemodialysis treatment scheduled three times per week. Subjects will receive single oral doses of 150 mg GSK1278863A in each of 2 dosing periods in an open-label, fixed sequence. GSK1278863A will be administered just prior to receiving scheduled hemodialysis in Dosing Period 1. In Dosing Period 2, subjects will receive a single oral dose of GSK1278863 the morning after completion of a scheduled hemodialysis session.
62145949|NCT04074252|ACTIVE_COMPARATOR|Axillary Crutches|This group is given a set of axillary crutches.
62510642|NCT02107079|ACTIVE_COMPARATOR|melatonin 1 mg immediate release tablet|
62510643|NCT02107079|ACTIVE_COMPARATOR|melatonin 2,5mg immediate release capsule|
62510644|NCT02107079|ACTIVE_COMPARATOR|melatonin 0.1 mg oromucosal tablet|
62510645|NCT03808740|EXPERIMENTAL|Roux-en-Y gastric bypass (RYGB)/Atomoxetine|Participants with standard of care RYGB will receive atomoxetine, 0.5 mg/kg/day for 3 days
62510646|NCT03808740|EXPERIMENTAL|Vertical sleeve gastrectomy (VSG) /Atomoxetine|Participants with standard of care VSG will receive atomoxetine 0.5 mg/kg/day for 3 days
62510647|NCT03808740|PLACEBO_COMPARATOR|Roux-en-Y gastric bypass (RYGB)/Placebo|Participants with standard of care RYGB will receive placebo 0.5 mg/kg/day for 3 days
62510648|NCT03808740|PLACEBO_COMPARATOR|Vertical sleeve gastrectomy (VSG)/ Placebo|Participants with standard of care VSG will receive placebo 0.5 mg/kg/day for 3 days
62510649|NCT03401073|PLACEBO_COMPARATOR|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
62510650|NCT03401073|EXPERIMENTAL|Intravenous Immunoglobulin|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments
62510651|NCT03932331|EXPERIMENTAL|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
62510652|NCT02295813|EXPERIMENTAL|FBF001|"FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.~FBF001 is administered once during 1 day or once per day during 5 days."
62510653|NCT02295813|PLACEBO_COMPARATOR|Placebo|The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.
62510654|NCT02023840|ACTIVE_COMPARATOR|ultrasonics and erythritol, metronidazole gel|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of metronidazole gel
62510655|NCT02023840|PLACEBO_COMPARATOR|ultrasonics and erythritol, placebo|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of placebo
62510656|NCT03900117|EXPERIMENTAL|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
62510657|NCT06607718|EXPERIMENTAL|Resistance Training (RT)|They are performing programmed physical exercise started on the day of admission, focusing on muscle strength gain, and they are being taught how to continue exercising three times a week after discharge from hospital. Lower limb strength exercises (squats and knee extensions) and upper limb strength exercises (elbow flexion, lateral and frontal raises, and tractions) were performed. A progression of the load are being made by increasing one set per month and 2 to 4 repetitions per month depending on the patient's capabilities.
62510658|NCT06607718|EXPERIMENTAL|Oral Nutritional Supplementation (ONS)|They are receiving a hypercaloric, hyperproteic, oral nutritional supplement with vitamin D and CaHMB (ß-hydroxy-ß-methylbutyrate) (Ensure Plus Advance®), at a dose of two packets per day in two or more doses for 3 months.
62510659|NCT06607718|SHAM_COMPARATOR|Control Group (CG)|They are being treated according to standard clinical practice, which includes information from the health professionals on the ward on recommended dietary and exercise guidelines. When the treating team considers the use of an oral nutritional supplement to be indicated, it is being prescribed.
62510660|NCT06607718|EXPERIMENTAL|Resistance Training (RT) and Oral Nutritional Supplementation (ONS)|They receive joint treatment
62510661|NCT05982249|EXPERIMENTAL|Hypnosis (H)|Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten bone marrow (BM) examinations at the hematology institute. The length of the recording is about 7 minutes.
62510662|NCT05982249|EXPERIMENTAL|Virtual reality (VR)|Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
62510663|NCT05982249|NO_INTERVENTION|Control (C)|
62510664|NCT06322615|EXPERIMENTAL|Supportive Care (acupressure)|Patients undergo acupressure over 15-120 seconds at a time for up to 15 minutes. After completion of the session, patients may optionally receive an education session on using acupressure at home.
62510665|NCT06616701|EXPERIMENTAL|Follow up call within 5 days|Follow up call within 5 days
62510666|NCT06616701|NO_INTERVENTION|Follow up call within 10 days|Follow up call within 10 days
62510667|NCT06267794|EXPERIMENTAL|Prolonged release pirfenidone (PR-PFD), 1200 mg group|Subjects will receive one tablet during breakfast and 2 tablets during dinner.
62510668|NCT06267794|ACTIVE_COMPARATOR|PR-PFD, 1800 mg group|Subjects will receive one tablet during breakfast and 2 tablets during dinner.
62510669|NCT06267794|PLACEBO_COMPARATOR|Placebo group|Subjects will receive one tablet during breakfast and 2 tablets during dinner.
62510670|NCT01682629|NO_INTERVENTION|Non-Scripted Debriefing, Low Realism Simulation|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. In this arm, novice instructors were provided the scenario learning objectives but NO SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing. The simulation scenario itself was conducted with an infant simulator. The low realism group had the simulator with the compressor turned off, thus eliminating the functionality of physical findings.
62510671|NCT01682629|EXPERIMENTAL|Scripted debriefing, Low Realism|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The lo realism group had the simulator with the compressor turned on, thus eliminating the functionality of physical findings.
62707695|NCT02300545|EXPERIMENTAL|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
62707696|NCT04190264|EXPERIMENTAL|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
61970744|NCT05950009||Controls|subjects without mental health pathologies identified by SCID, who present an PHQ-9 index of 5 or below will be included as controls.
61970745|NCT04419584|EXPERIMENTAL|Modified Qing-Ying Decoction|Herbal granules, twice per day for 12 weeks
62707697|NCT04190264|ACTIVE_COMPARATOR|Cold Water Immersion|Participants, following exercise-induced hyperthermia, will be cooled using cold water immersion. Participants will be immersed up to their chest in cold water (\~50-55 Degrees Fahrenheit).
62707698|NCT04190264|NO_INTERVENTION|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
62707699|NCT02538614|EXPERIMENTAL|Phase 1b: Idelalisib + BI 836826|Participants will receive escalating dose of idelalisib at dose levels, 50 mg, 100 mg, and 150 mg + BI 836826 10 mg on Day 8, 50 mg on Day 9 and Day 15, and 100 mg on Day 22, every 2 weeks through Week 18, and every 4 weeks through Week 46. 2 dose combinations (highRP2D and lowRP2D) will be determined for further evaluations in Phase 2.
62707700|NCT02538614|EXPERIMENTAL|Phase 2 Idelalisib + BI 836826|Participants will be randomly assigned to receive 1 of the 2 dose combinations selected from Phase 1b.
62707701|NCT02621892|EXPERIMENTAL|50mg BID|Tenapanor
61970746|NCT04419584|PLACEBO_COMPARATOR|Identical looking placebo|Placebo granules, twice per day for 12 weeks
61970747|NCT05945043||Symptomatic pleural effuion|Patients with symptomatic unilateral pleural effusion of any cause who will be undergoing pleural fluid removal via thoracocentesis, chest drain insertion or IPC drainage for relief of their breathlessness.
61970748|NCT01533389|EXPERIMENTAL|Silodosin|8mg QD
61970749|NCT01533389|PLACEBO_COMPARATOR|Placebo|8mg QD
61970750|NCT05562076|EXPERIMENTAL|ZENFLEX ® Pinto|subjects using the spot stent(ZENFLEX ® Pinto) system
61970751|NCT05562076|ACTIVE_COMPARATOR|Everflex|subjects using the bare stent(Everflex) system
61970752|NCT02563353|ACTIVE_COMPARATOR|controlgroup|Teriparatide, 20 microgram/day. 24 months of treatment
61970753|NCT02563353|EXPERIMENTAL|studygroup 1|"Teriparatide, 20 microgram/day. 24 months of treatment.~12 months of Whole-body vibration on vibration platforms."
62510672|NCT01682629|EXPERIMENTAL|non-Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITHOUT A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing WITHOUT USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
62707702|NCT02621892|PLACEBO_COMPARATOR|Placebo|Placebo
61970754|NCT02563353|EXPERIMENTAL|studygroup 2|"Teriparatide, 20 microgram/day. 24 months of treatment.~24 months of Whole-body vibration on vibration platforms"
61970755|NCT00189254||Imiquimod 5% cream|No investigational treatments were given during this study.
61970756|NCT03970798|EXPERIMENTAL|KW-6356/Healthy Japanese adult male subjects|Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
62707703|NCT01066845||Patients prescribed Adcirca|all patients prescribed Adcirca during study period
61970757|NCT02099357|PLACEBO_COMPARATOR|Placebo|Daily supplementation with 3g of dextrose during eight weeks and placebo ampoules each two weeks.
61970758|NCT02099357|EXPERIMENTAL|Creatine|Daily supplementation with 3g of monohydrate creatine during eight weeks. Placebo ampoules each two weeks.
62351807|NCT04908241|EXPERIMENTAL|TRAIL|TRAIL is a 4-week progressive exercise and self-management intervention for lower extremity recovery delivered by a trained registered physical therapist, in a 2:1 participant-to-therapist ratio. Each participant grouping will receive two telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours).
62510673|NCT01682629|EXPERIMENTAL|Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
61970759|NCT02099357|ACTIVE_COMPARATOR|Vitamin D|Daily supplementation with 3g of dextrose during eight weeks. Vitamin D supplementation, 25000 IU each two weeks.
61970760|NCT05898555||Healthy individuals|Gait study protocol
61970761|NCT00275054|EXPERIMENTAL|Cohort I (FCR)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort I receive Fludarabine, Cyclophosphamide and Rituximab (FCR) chemoimmunotherapy.
61970762|NCT00275054|NO_INTERVENTION|Cohort II (W&W)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort II receive no treatment at all (watch \& wait).
61970763|NCT00275054|NO_INTERVENTION|Cohort III (W&W)|Patients with less than 2 risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) are assigned directly to cohort III and receive no treatment at all (watch \& wait).
62510674|NCT05569330|OTHER|Arm 1|Two of the four participating day care units are allocated in arm 1
62510675|NCT05569330|OTHER|Arm 2|Two of the four participating day care units are allocated in arm 2
62707704|NCT06272604|NO_INTERVENTION|No Intervention Control Group|The control group will not receive any specific intervention, continuing with their usual asthma management routine.
62707705|NCT06272604|EXPERIMENTAL|Exercise Rehabilitation Group|The experimental group will participate in a 12-week exercise intervention program.
62707706|NCT01596114|EXPERIMENTAL|Stop treatment|TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
62707707|NCT05876156|EXPERIMENTAL|VRPT then Traditional PT|Participants will receive Virtual Reality assisted Physical Therapy sessions (VRPT) in the first Physical Therapy (PT) session and will receive traditional Physical Therapy sessions (standard care) in the second Physical Therapy session under the supervision of the accredited physical therapist.
62707708|NCT05876156|EXPERIMENTAL|Traditional PT then VRPT|Participants will receive traditional Physical Therapy (PT) sessions (standard care) in the first Physical Therapy session and Virtual Reality assisted Physical Therapy sessions (VRPT) in the second Physical Therapy session under the supervision of the accredited physical therapist.
61970764|NCT02297477|ACTIVE_COMPARATOR|atovaquone-proguanil (AP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) for treatment of uncomplicated P. falciparum malaria.
62145950|NCT03848975|EXPERIMENTAL|Simulation training for ECV|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the Control group for VE : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
62707709|NCT06183398|EXPERIMENTAL|Eligible patients|
61970765|NCT02297477|ACTIVE_COMPARATOR|artesunate-atovaquone-proguanil (ASAP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) plus 3 days of artesunate (200mg per day) for treatment of uncomplicated P. falciparum malaria.
61970766|NCT01613404||Patients with nurse case manager|Patients will receive a dedicated nurse case manager (intervention group) in this group.
61970767|NCT01613404||Patients with no nurse case manager|Patients will not receive nurse case manager (control group) in this group.
61970768|NCT01093807|PLACEBO_COMPARATOR|Placebo|
61970769|NCT01093807|EXPERIMENTAL|Lercanidipine 10 mg|
61970770|NCT01093807|EXPERIMENTAL|Lercanidipine 20 mg|
61970771|NCT01093807|EXPERIMENTAL|Enalapril 10 mg|
61970772|NCT01093807|EXPERIMENTAL|Enalapril 20 mg|
61970773|NCT01093807|EXPERIMENTAL|Lercanidipine 10 mg/Enalapril 10 mg|
61970774|NCT01093807|EXPERIMENTAL|Lercanidipine 10mg/Enalapril 20 mg|
61970775|NCT01093807|EXPERIMENTAL|Lercanidipine 20mg/Enalapril 10 mg|
61970776|NCT01093807|EXPERIMENTAL|Lercanidipine 20mg/Enalapril20mg|
61970777|NCT04497805|EXPERIMENTAL|ALLO-ASC-SHEET|ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
61970778|NCT04497805|PLACEBO_COMPARATOR|Hydrogel SHEET(Vehicle control)|Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
61970779|NCT05433714||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform the figure of 8 walk test.
61970780|NCT06166849|EXPERIMENTAL|Experimental Fluoride Application|Two-step system, consisting of Component A (ammonium fluoride solution) and Component B (calcium fluoride application)
61970781|NCT06166849|NO_INTERVENTION|No Treatment|
61970782|NCT01497132|EXPERIMENTAL|Vitamin D3|
61970783|NCT01497132|PLACEBO_COMPARATOR|Placebo|
61970784|NCT01037647||Type 2 diabetic men|Men with type 2 diabetes
61970785|NCT01037647||Healthy men|Healthy men
61970786|NCT03815331|EXPERIMENTAL|PD treatment with Xiaflex® plus Aveed|Peyronie's Disease treatment with Xiaflex® and Aveed®. All 20 subjects will be treated with Xiaflex® and Aveed®. The data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD with Xiaflex® alone.
61970787|NCT03981211|EXPERIMENTAL|Cohort A: 8 weeks G/P standard therapy|8 weeks treatment of a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (standard duration therapy).
61970788|NCT03981211|EXPERIMENTAL|Cohort B: 4 weeks SOF/G/P shortened therapy|4 weeks treatment of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (shortened duration therapy).
61970789|NCT01156090||Vectibix|patients who received at least one treatment of Vectibix
61970790|NCT01082120|EXPERIMENTAL|1|AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15
62510676|NCT05773534||healthy group|"Multispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of one leg in healthy volunteers~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
62707710|NCT02756052|SHAM_COMPARATOR|Medical Student - Sham tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
61970791|NCT01082120|EXPERIMENTAL|2|Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15
61970792|NCT05659797|EXPERIMENTAL|FES BPET-DBT|FES-BPET/DBT imaging session
61970793|NCT05422703|EXPERIMENTAL|Study group|patients who will receive manual therapy and Kinesio taping, in additional to basic post operative care (ice pack , analgesics, Antibiotic treatment and mouth wash daily ) 3 times per week for two weeks.
61970794|NCT05422703|PLACEBO_COMPARATOR|Control group|patients who will receive basic post operative care (ice pack , analgesics, Antibiotic treatment and mouth wash daily ).
61970795|NCT03482375||No Stones on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
61970796|NCT03482375||Stones seen on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
61970797|NCT04398498||Cohort A: Clinical Practice|Subjects more than 60 days post-transplant
61970798|NCT04398498||Cohort B: Long Term Follow-Up|Subjects who are at least 2 years post transplant up to 5 years post-transplant
61970799|NCT03111602|EXPERIMENTAL|interventional group|The interventional group was submitted to dietary orientation to restrict polyphenol-rich foods
61970800|NCT03111602|NO_INTERVENTION|control group|healthy group as comparator
61970801|NCT03132207||Pregnant women|Pregnant women attending hospital during pregnancy monitoring and / or being hospitalized in one of the maternity wards associated with the project.
61970802|NCT03132207||Professional|health professionals in charge of the follow-up of these pregnant women and their childbirth.
62351808|NCT04908241|ACTIVE_COMPARATOR|EDUCATION|"The EDUCATION control arm is a 4-week education program focusing on stroke knowledge and risk factors. It will be delivered by health professionals who have experience working with individuals with stroke, knowledge of chronic disease self-management (e.g. physical or occupational therapists, nurses, kinesiologists), and who have completed study-specific training on the EDUCATION program~Participants will receive video conferencing sessions with the same schedule and 2:1 participant-to-coach ratio as TRAIL. Each participant grouping will receive two educational telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours)."
62351809|NCT02467829|NO_INTERVENTION|10° of elbow flexion|This handle height is the nearest position the walker can be set to to achieve 10° of elbow flexion. Elbow flexion is measured with the child standing in their walker using an electronic goniometer.
62510677|NCT05773534||Patients with PAD in Fontaine stage II|"Multispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
62510678|NCT00003330|EXPERIMENTAL|Arm I|See detailed description.
62510679|NCT00329628|EXPERIMENTAL|Arm 1|
62510680|NCT00329628|ACTIVE_COMPARATOR|Arm 2|
62510681|NCT01905059|ACTIVE_COMPARATOR|monoPI - boosted lopinavir or boosted darunavir|"boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96."
62510682|NCT01905059|ACTIVE_COMPARATOR|bi therapy - (boosted lopinavir or darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
62351810|NCT02467829|EXPERIMENTAL|30° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 30° of elbow flexion.
62351811|NCT02467829|EXPERIMENTAL|50° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 50° of elbow flexion.
62351812|NCT04984512|EXPERIMENTAL|Mitizodone Phosphate tablet 10mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 8 weeks, then placebo,orally,once daily for 2 weeks.
62351813|NCT04984512|EXPERIMENTAL|Mitizodone Phosphate tablet 20mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 7 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then placebo,orally,once daily for 1 weeks.
62351814|NCT04984512|EXPERIMENTAL|Mitizodone Phosphate tablet 40mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 40mg ,orally,once daily for 6 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks.
62351815|NCT04984512|ACTIVE_COMPARATOR|Placebo|Placebo,tablet,orally,once daily for 10 weeks.
62351816|NCT03203954|ACTIVE_COMPARATOR|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
62351817|NCT03203954|EXPERIMENTAL|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
62351818|NCT03203954|EXPERIMENTAL|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
62351819|NCT03084718|EXPERIMENTAL|Treatment A|CHF 718 pMDI 100 μg Total Daily Dose (TDD), Dose 1; CHF 718 pMDI 50 μg/actuation: 1 inhalation twice daily (BID);
62351820|NCT03084718|EXPERIMENTAL|Treatment B|CHF 718 pMDI 400 μg Total Daily Dose (TDD) 400 μg, Dose 2; CHF 718 pMDI 100 μg/actuation: 2 inhalations BID;
62351821|NCT03084718|EXPERIMENTAL|Treatment C|CHF 718 pMDI Total Daily Dose (TDD) 800 μg, Dose 3; CHF 718 pMDI 100 μg/actuation: 4 inhalations BID;
62351822|NCT03084718|PLACEBO_COMPARATOR|Treatment D|Placebo Control, Placebo; CHF 718 pMDI matched Placebo: 4 inhalations BID;
62510683|NCT03123978|EXPERIMENTAL|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62510684|NCT02512614|NO_INTERVENTION|Comparison|Hand hygiene education.
62510685|NCT02512614|EXPERIMENTAL|Intervention|Hand hygiene education and 4 antimicrobial hand towels
61970803|NCT01765205||Newborns with Pulse oximetry|Up to 50 healthy newborn participants will receive 15 minutes of pulse oximetry to determine the effectiveness of measuring somatic oxygen saturation.
62351823|NCT03084718|ACTIVE_COMPARATOR|Treatment E|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA), Total Daily Dose (TDD) 320 µg; QVAR® 80 μg/actuation: 2 inhalations BID;
62351824|NCT06063239|EXPERIMENTAL|Test Group|Subjects who will receive orally administred probiotics based on L. rhamnosus and L. plantarum for 90 days in adjunction to the instruction of their care-giver regarding oral hygiene procedures.
62351825|NCT06063239|ACTIVE_COMPARATOR|Positive Control|Subjects who will receive orally administred probiotics based on placebo for 90 days in adjunction to the instruction of their care-giver regarding oral hygiene procedures.
62510686|NCT04801719|EXPERIMENTAL|Experimental arm - endoluminal RFA|standard treatment protocol for malignant biliary stenosis + endoluminal RFA prior metal stent insertion
62510687|NCT04801719|NO_INTERVENTION|Control arm|standard treatment protocol for malignant biliary stenosis which includes metal stent insertion
62510688|NCT02989298||PD patients|End stage renal disease patients receiving peritoneal dialysis treatment
62510689|NCT05151393||Cases|Cases with uterine leiomyoma
62510690|NCT05151393||Controls|Cases free of uterine leiomyoma
62510691|NCT01610609|EXPERIMENTAL|Population Health Management Intervention|Participants randomized to this arm will receive the population health management intervention.
62510692|NCT01610609|NO_INTERVENTION|Usual Care Control Group|Participants randomized to this arm will receive usual care.
62510693|NCT02309424|ACTIVE_COMPARATOR|Vinegar|0,50mmol vinegar (6% acetic acid)
62510694|NCT02309424|PLACEBO_COMPARATOR|Placebo|50 ml water
62510695|NCT02012231|EXPERIMENTAL|Dose Escalation|Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
61970804|NCT01765205||CHD infant with pulse oximetry|Up to 10 infants diagnosed with congenital heart disease will receive 15 minutes of pulse oximetry using the INVOS Cerebral/Somatic Oximeter to determine the effectiveness of measuring somatic oxygen saturation.
62145951|NCT03848975|EXPERIMENTAL|Simulation training for VE|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the the control group for for ECV : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
62145952|NCT05983861||Multi drug resistant group|All critically ill adult patients (with no exclusion criteria) admitted to the ICU with microbiological confirmed diagnosis of infection at admission and multi drug resistant bacteria isolation :
62145953|NCT05983861||Multi sensible bacteria group|All critically ill adult patients (with no exclusion criteria) admitted to the ICU with microbiological confirmed diagnosis of infection at admission and multi drug sensible bacteria isolation :
62145954|NCT03960359||Episodic viral wheezers (EVW)|EVW: Wheezing during discrete time periods (exacerbations), absence of symptoms between exacerbations Among which SIW: EVW with ≥ 2 exacerbations over the last 6 months Clinical, microbiological and inflammatory phenotype
62145955|NCT03960359||Multiple trigger wheezers (MTW)|MTW : wheezing during exacerbations but also symptoms between episodes. Clinical, microbiological and inflammatory phenotype
62145956|NCT00624637|OTHER|A|infants after craniofacial surgery receive one massage with aromatherapy three hours postoperatively
62145957|NCT00624637|OTHER|B|infants after craniofacial surgery receive one massage with carrier oil three hours postoperatively
62145958|NCT00624637|NO_INTERVENTION|C|no intervention, standard postoperative care
62145959|NCT05160779|ACTIVE_COMPARATOR|Mild/asymptomatic cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed mild or asymptomatic conditions.
62145960|NCT05160779|ACTIVE_COMPARATOR|Serious cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed severe pathology.
62145961|NCT01204996|EXPERIMENTAL|1|CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
62351826|NCT06063239|OTHER|Negative Control|Subjects who will receive esclusively the instruction of their care-giver regarding oral hygiene procedures.
62351827|NCT04724304|EXPERIMENTAL|Healthy adults|Healthy adults will have blood flow to the heart evaluated using s Real-Time Myocardial Echocardiography (RTMPE) and magnetic resonance image (MRI) to the heart.
62351828|NCT03696940|EXPERIMENTAL|Experimental Group|2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
62351829|NCT03696940|ACTIVE_COMPARATOR|Control Group|2 tablets of: Atorvastatin 10 mg
62510696|NCT03829215|EXPERIMENTAL|CAERVest cooling device|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, the CAERvest device will be filled and placed on the supine patient's chest. A recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an additional endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device. The CAERvest device will be removed, when a temperature below 34°C is reached.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
62539405|NCT06582056|OTHER|Participant with Stage I/Stage II Periodontal Disease with Hemoglobin A1c level 8.0-10.0|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
61970805|NCT02243332|EXPERIMENTAL|Device (rehabilitation assistance)|Device: KneeStim mobile rehabilitation assistance device
61970806|NCT01672697|EXPERIMENTAL|Physical & Behavioral Therapy Group|"Intervention Group: Randomized to Physical Therapy (PT)~1. 2-week visit which includes: Demographic Data, Physical Exam, ehavioral Therapy (BT) handouts Functional questionnaires administered Physiologic measurements obtained~2. Follow-up Evaluation-6-week visit PT session #1 Functional questionnaires administered~3. Follow-up Evaluation-8-week visit PT session #2~4. Follow-up Evaluation-10-week visit PT session #3~5. Study Completion Visit-12-week visit Functional questionnaires administered PT session #4 Physiologic measurements Physical Exam~6. Long-term Follow-up-24-weeks Functional questionnaires administered by mail"
62351830|NCT01784588|ACTIVE_COMPARATOR|Solyx Single Incision Sling System|Solyx Single Incision Sling System
62351831|NCT01784588|ACTIVE_COMPARATOR|Obtryx II Sling System|Obtryx II Sling System
62351832|NCT04798313|EXPERIMENTAL|MW031|MW031 injection (60mg) by subcutaneous injection once on the first day of treatment.
62351833|NCT04798313|ACTIVE_COMPARATOR|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day of treatment.
62351834|NCT05421429|EXPERIMENTAL|KN057 (Cohort 1：HA/HB)|Injection, once a week
62351835|NCT05421429|EXPERIMENTAL|KN057 (Cohort 2：HA/HB)|Injection, once a week
62351836|NCT05421429|EXPERIMENTAL|KN057 (Cohort 3：HA/HB)|Injection, once a week
62510697|NCT03829215|NO_INTERVENTION|Control|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, a recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
62145962|NCT01204996|EXPERIMENTAL|2|CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
62351837|NCT05421429|EXPERIMENTAL|KN057 (Cohort 4：HAW/HBW)|Injection, once a week
62351838|NCT00118911|EXPERIMENTAL|Cognitive-Behavioral Therapy|Participants will receive cognitive-behavioral therapy following our protocol.
62351839|NCT00118911|ACTIVE_COMPARATOR|Relaxation with Educational Support|Applied relaxation plus educational support (RES).
62351840|NCT05259930|NO_INTERVENTION|Chronic gastrointestinal disease (IBD and liver cirrhotic patients)|Liver cirrhotic patients to receive best practice nutritional assessment and supports
62351841|NCT05259930|EXPERIMENTAL|branched-chain amino acid (BCAA)|Liver cirrhotic patients to receive best practice nutritional assessment and supports in addition to a 12-week course of BCAA supplementation
62351842|NCT05259930|NO_INTERVENTION|Healthy Control|Controls attending gastroenterology outpatient or endoscopy services with no chronic inflammatory GI disease.
62351843|NCT03438578|EXPERIMENTAL|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
62351844|NCT03438578|NO_INTERVENTION|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
62351845|NCT03411668|EXPERIMENTAL|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
62351846|NCT03411668|NO_INTERVENTION|Usual Educational Programme|Without intervention. The participants in this group will be maintain usual educational programme.
62351847|NCT02928380|ACTIVE_COMPARATOR|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
62351848|NCT02928380|EXPERIMENTAL|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
62351849|NCT02928380|NO_INTERVENTION|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
62351850|NCT06092632|EXPERIMENTAL|Pigmented Rice|Cooked black pigmented rice will be consumed for six weeks (twice per day)
62351851|NCT06092632|PLACEBO_COMPARATOR|White Rice|Cooked white rice will be consumed by the control group for six weeks (twice per day)
62351852|NCT02600741||Study group 1|Caregivers randomized to this group will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
62351853|NCT02600741||Study group 2|Caregivers randomized to this group will receive whatever caregiver support that is customarily available at the study site, if any. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
62351854|NCT03071380|EXPERIMENTAL|T test|Test drug (Repatoxaban) 1 tablet contains 10 mg rivaroxaban
62351855|NCT03071380|ACTIVE_COMPARATOR|B reference|Reference drug (Xarelto) 1 tablet contains 0 mg rivaroxaban
62351856|NCT04868747|EXPERIMENTAL|study group|The study group receives the intravenous 1% lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h during surgery and 1.0 mg/kg/h until 24 hours after surgery (Max.\<120 mg/h).
62351857|NCT04868747|PLACEBO_COMPARATOR|control group|The control group receives intravenous normal saline 0.15 ml/kg bolus followed by 0.15 ml/kg/h during surgery and 0.1 mg/kg/h until 24 hours after surgery.
62351858|NCT03655392|EXPERIMENTAL|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 monthly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
62351859|NCT03655392|EXPERIMENTAL|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 montly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
62351860|NCT04045626|ACTIVE_COMPARATOR|Transepithelial accelerated cross-linking|"Paracel is instilled 1 drop every 1.5 minutes for 4.5 minutes then vibex-xtra is instilled 4 drops at 5.5 minutes followed by 1 drop at 6.5 minutes for a total soak time of 11 minutes followed by ultraviolet-A UVA irradiation with intended irradiance of 45mW/cm2 for 2.4 minutes"
62351861|NCT04045626|ACTIVE_COMPARATOR|Epithelium-off accelerated cross-linking|"Vibex-rapid is instilled every 2 minutes for 10 minutes followed by ultraviolet-A UVA irradiation of 30 mW/cm2 for 4 minutes"
62510698|NCT05500768|EXPERIMENTAL|hypothermic compression bandage|
62510699|NCT05500768|ACTIVE_COMPARATOR|Conventional compression bandage|
62510700|NCT05361486||Health Care Provider managing vivax patients in study facilities|All HCPs working in the selected facilities who are involved in the management of vivax patients will be approached to participate in the study.
62510701|NCT05361486||Patients with confirmation of vivax, attending one of the study facilities|All patients aged 6 months onward, who have a confirmed P. vivax infection and who are in a study HF will be approached to participate in the study. This includes pregnant and lactating women, who have a contra-indication to both PQ and TQ, but for whom correct case management will be evaluated as part of the primary endpoints.
62351862|NCT04199195||Males and females aged at least 60 years.|"A longitudinal study of one cohort of 360 participants aged at least 60 years. Participants will be required to provide a stool sample, provide a blood sample and complete a health questionnaire every 6 months for 4 years. At alternate visits, participants will be required to under go cognitive assessments and physical measurements.~Participants will be required to under go an Optical Coherence Tomography Scan 3 times over 4 years.~Sub group 1 - During a routine care colonoscopy, at least 90 participants will have 6-8 colon tissue biopsies taken for research purposes.~Sub group 2 - Participants from cohort 3 only will be offered an optional brain MRI until the required number of 30 participants is achieved."
62510702|NCT01309217|ACTIVE_COMPARATOR|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. See below for a complete description.
62510703|NCT01309217|EXPERIMENTAL|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
62510704|NCT02384291|EXPERIMENTAL|Alpha-Bios GRAFT Natural Bovine Bone treatment|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
62510705|NCT02384291|ACTIVE_COMPARATOR|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
62510706|NCT04287868|EXPERIMENTAL|Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies|"Triple Therapy: PDS0101 + NHS-IL12 + M7824 (MSB0011395C); The dose level of NHS-IL12 may decrease depending on dose limiting toxicity (DLT) events. The dose level of human papillomavirus vaccine (HPV) vaccine and M7824 will remain constant.~If more than 3 of 8 participants have an objective response then accrual will be expanded to 20 evaluable participants."
62510707|NCT04287868|EXPERIMENTAL|Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy|"Triple Therapy: PDS0101 + NHS-IL12 + M7824 (MSB0011395C); PDS0101 + NHS-IL12 + M7824; Reduced doses.~May enroll up to 12 participants for a safety evaluation and up to 12 additional participants for preliminary evaluation of efficacy and further evaluation of safety."
62510708|NCT03547635|EXPERIMENTAL|AMNIOEXCEL Plus Amniotic Membrane|
62510709|NCT03547635|ACTIVE_COMPARATOR|A Marketed Comparator|
62510710|NCT03547635|OTHER|Standard of Care|
62510711|NCT03255863|OTHER|Questionnaire|Auto and hetero questionnaire
62510712|NCT00171340|EXPERIMENTAL|Upfront Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
62510713|NCT00171340|EXPERIMENTAL|Delayed Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
62510714|NCT01246713|PLACEBO_COMPARATOR|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
62510715|NCT01246713|ACTIVE_COMPARATOR|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
62510716|NCT01205893|EXPERIMENTAL|Reducer|Implant Reducer
62510717|NCT01205893|SHAM_COMPARATOR|Control|No treatment
62510718|NCT03887988||Orbital Fracture|Patients with dislocated fracture of the inferior and/or medial orbital wall
62510719|NCT02506231|EXPERIMENTAL|Folinic acid|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
62510720|NCT02506231|PLACEBO_COMPARATOR|Placebo|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
62510721|NCT00914979|EXPERIMENTAL|1|Single Arm - Interventional
62510722|NCT06293443|OTHER|Lower extremity unilateral amputee|Unilateral transtibial and unilateral transfemoral amputees were evaluated in the study. Criteria for autees to participate in the study; Being a unilateral lower extremity amputee, using a prosthesis, being literate, being between the ages of 18-65, having a healthy stump, and using their current prosthesis in daily life activities. Individuals who had knee disarticulation amputation and individuals who had hip disarticulation amputation were not included in the study.
62510723|NCT02246088|EXPERIMENTAL|MT + NE|A manual therapy (MT) intervention combined with neuroscience education (NE)
62510724|NCT02246088|ACTIVE_COMPARATOR|MT + E|Manual therapy (MT) intervention plus an educational program based on a traditional patho-anatomical or biomedical model (E)
62510725|NCT02623907||AS group|Severe AS patients, without severe AR
62510726|NCT02623907||AR|Severe AR patients, without severe AS
62351863|NCT01823770|ACTIVE_COMPARATOR|Rotigotine|Patients randomized to rotigotine who will be treated with rotigotine patchs
62351864|NCT01823770|PLACEBO_COMPARATOR|Placebo|Patients randomized on the placebo group who will be treated with placebo patchs
62351865|NCT01823770|NO_INTERVENTION|Control group|Volunteers matched on sex, age and BMI with RLS patients who will not receive treatment(no treatment)
62351866|NCT02398084|EXPERIMENTAL|Chewing of nuts|8 samples (4-5 g) of nuts (cashews or walnuts) on two separate visit days.
62351867|NCT04217083||Colorectal cancer patients|Patients with histologically proven Colorectal cancer detected during the colonoscopy
61970807|NCT01672697|NO_INTERVENTION|Control Group|"Control Group:~1. Baseline Data obtained at 2-week visit Demographic Data General Physical Exam findings Functional questionnaires administered in person (FIQOL, FISI, SF-12, FSFI, UDI-6, IIQ-7) Physiologic measurements obtained (Vaginal EMG, Anal-rectal manometry)~2. Follow-up Evaluation at 6-week visit Functional questionnaires administered in person at patient's previously scheduled postpartum office visit with primary Ob/Gyn or by mail~3. Study Completion Visit at 12-week visit Functional questionnaires administered Physiologic measurements obtained Physical Exam findings~4. Long-term Follow-up at 24-weeks - Functional questionnaires administered by mail"
62145963|NCT01204996|EXPERIMENTAL|3|CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
62145964|NCT01204996|EXPERIMENTAL|4|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
62145965|NCT03131713|NO_INTERVENTION|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
62145966|NCT03131713|EXPERIMENTAL|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
62145967|NCT02434783||1st level of arterial insufficiency|asymptomatic PAD patients
62145968|NCT02434783||2nd level of arterial insufficiency|Intermittent claudication patients
62510727|NCT01164215|EXPERIMENTAL|mFOLFOX6|"Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)"
62145969|NCT02434783||3rd level of arterial insufficiency|Critical limb ischemia patients
62145970|NCT02434783||No arterial insufficiency|Healthy individuals (control)
62145971|NCT05075200|EXPERIMENTAL|Group I|Participants with glomerular filtration rate (GFR) \< 60 mL/min/1.73m2 (and dialysis)
62510728|NCT04309526|EXPERIMENTAL|NCO-48 Fumarate|NCO-48 Fumarate
62510729|NCT04309526|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62510730|NCT02808819|OTHER|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
62510731|NCT02808819|OTHER|Benralizumab Arm B|Benralizumab administered subcutaneously every 8 weeks
62510732|NCT04766229|EXPERIMENTAL|Single Arm|All participants in single arm study
62510733|NCT05661461|EXPERIMENTAL|Experimental|nab-Sirolimus
62145972|NCT05075200|EXPERIMENTAL|Group II|Participants with GFR ≥ 60 mL/min/1.73m2
61970808|NCT03632525|EXPERIMENTAL|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
62145973|NCT04759794|EXPERIMENTAL|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
62145974|NCT02704052|ACTIVE_COMPARATOR|Standard enoxaparin dose|We will identify a convenience sample of surgical patients placed on enoxaparin prophylaxis at their attending surgeon's discretion-the proposed research will not dictate the initial enoxaparin dose magnitude or frequency. However, we will identify patients already on enoxaparin, evaluate peak and trough steady state aFXa levels, and adjust patient's dose if necessary based on steady state aFXa levels. Eligible patients will have enoxaparin prophylaxis started within 36 after surgery at their surgeon's discretion. Steady state peak and trough aFXa levels will be drawn at 4 and 12 hours, respectively, after the third enoxaparin dose. Goal peak aFXa levels will be 0.2-0.4 IU/mL for twice daily dosing and 0.3-0.5 IU/mL for once daily dosing.
62145975|NCT02704052|EXPERIMENTAL|Real time enoxaparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time enoxaparin dose adjustment and will receive followup steady state peak and trough aFXa levels. aFXa monitoring will be discontinued when in range peak levels are obtained, when enoxaparin prophylaxis is discontinued at surgeon discretion, or when the patient is discharged. Patients may be continued on enoxaparin prophylaxis after discharge per attending surgeon discretion but aFXa levels will not be followed in the outpatient environment.
62145976|NCT00258115|ACTIVE_COMPARATOR|salsalate|4.0 g/d divided dosing
62145977|NCT00258115|PLACEBO_COMPARATOR|placebo|placebo for salsalate
62145978|NCT02878616|EXPERIMENTAL|LFG316 + IVIG|
62145979|NCT02878616|EXPERIMENTAL|LFG316 alone|
62145980|NCT05851898|EXPERIMENTAL|Duloxetine 30mg|Duloxetine 30mg daily 90 day supply and 3 refills
62351868|NCT04217083||healthy controls|Patients with no sign of any colorectal disease who are submitted to colonoscopy
62351869|NCT02409758|ACTIVE_COMPARATOR|VFE voice therapy|Voice therapy: Vocal Function Exercises applied during 6 weeks
62351870|NCT02409758|EXPERIMENTAL|CVRP voice therapy|Voice therapy: Comprehensive Voice Rehabilitation Program applied during 6 weeks
62351871|NCT01584258|ACTIVE_COMPARATOR|PACE-A: Prostatectomy vs prostate SBRT|Low and intermediate risk patients, for whom surgery is considered, will be randomised to prostatectomy vs prostate SBRT delivered with 36.25 Gy in 5 fractions.
62510734|NCT01718171||Group I, Group II, Group III, Group IV|Values and results of the Systemic Inflammatory Response and C-reactive protein to appendicitis
62510735|NCT02371421||Allopurinol|Participants with history of gout indicated by the use of allopurinol or participants who have high serum uric acid without contraindication to use allopurinol.
62510736|NCT03246906|EXPERIMENTAL|Arm I (mycophenolate mofetil, cyclosporine, sirolimus)|Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.
62145981|NCT04634851|EXPERIMENTAL|Intervention|These participants will get virtual home visits with the urologist and dietitian
62510737|NCT03246906|EXPERIMENTAL|Arm II (cyclosporine, sirolimus, cyclophosphamide)|Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.
62510738|NCT02291367|EXPERIMENTAL|Duloxetine Delayed-Release Capsules, 60 mg|
62510739|NCT02291367|ACTIVE_COMPARATOR|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
62510740|NCT02026544|EXPERIMENTAL|Low Frequency Therapeutic Ultrasound|Low Frequency Therapeutic Ultrasound (LOTUS) applied transcutaneously
62510741|NCT00384293|EXPERIMENTAL|1|MK0524A
62510742|NCT00384293|PLACEBO_COMPARATOR|2|placebo
62351872|NCT01584258|ACTIVE_COMPARATOR|PACE-B: Conventionally Fractionated RT vs Prostate SBRT|Low and intermediate risk patients, for whom surgery is not considered or who refuse surgery, will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 39 fractions or 62 Gy in 20 fractions vs SBRT delivered with 36.25 Gy in 5 fractions.
62510743|NCT06287437|EXPERIMENTAL|Intervention|The subjects receive sequential once weekly and low frequency subcutaneous injection of HRS 9531
62510744|NCT06287437|PLACEBO_COMPARATOR|Control|The subjects receive low frequency subcutaneous injection of the placebo
62510745|NCT03451006|EXPERIMENTAL|Metformin|Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
62510746|NCT03451006|ACTIVE_COMPARATOR|Placebo|Placebo by mouth every 6 to 8 hours for one year
61970809|NCT05154006|ACTIVE_COMPARATOR|Active Control (Information only)|Women in the active control group receive instruction on safe carrying behaviors (reduce carried weight \& use safe lifting techniques) and information about benefits when performing the behavior and reducing strain on the pelvic floor.
62351873|NCT01584258|ACTIVE_COMPARATOR|PACE-C: Conventionally Fractionated RT vs Prostate SBRT|Intermediate and high risk patients, indicated for 6 months ADT, will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 60 Gy in 20 fractions vs SBRT delivered with 36.25 Gy in 5 fractions.
62351874|NCT03479216|EXPERIMENTAL|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
62351875|NCT03479216|EXPERIMENTAL|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
62351876|NCT01103778|EXPERIMENTAL|Velcade® therapy|Patients with greater than 1gm of proteinuria per day will receive Velcade®.
62510747|NCT04975893|OTHER|Primary Extension Phase|CMV-seropositive and CMV-seronegative participants who completed Study mRNA-1647-P202 will be followed every 6 months for 3 years in this study after the final visit in Study mRNA-1647-P202.
62510748|NCT04975893|EXPERIMENTAL|Optional Booster Phase - BD Recipients|Participants who opted to enroll into the optional Booster Dose phase will receive a single mRNA-1647 vaccine dose.
62510749|NCT04975893|OTHER|Optional Booster Phase - Observational Group|Participants who opted to enroll into the Observational Group will be followed in the optional BP until BP Month 12.
62510750|NCT01998386|PLACEBO_COMPARATOR|Placebo gel without hydrogen peroxide|The volunteers of this group will receive a placebo gel without hydrogen peroxide for whitening treatment.
62510751|NCT01998386|EXPERIMENTAL|6.0% hydrogen peroxide - White Class|Volunteers of this group will receive a gel with 6.0% hydrogen peroxide - White Class with calcium for whitening treatment.
62510752|NCT01998386|EXPERIMENTAL|7.5% hydrogen peroxide - White Class|The volunteers of this group will receive a gel with 7.5% hydrogen peroxide -White Class with calcium for whitening treatment.
62510753|NCT01998386|EXPERIMENTAL|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive disposable whitening strips - Oral-B 3D White for whitening treatment.
62510754|NCT04417647|EXPERIMENTAL|Group 1|Proximal wound SoC treatment - Distal wound VZ application
62510755|NCT04417647|EXPERIMENTAL|Group 2|Distal wound SoC treatment - Proximal wound VZ application
62145982|NCT04634851|NO_INTERVENTION|Control|These participants will get standard urologist and dietitian counseling
62145983|NCT05309057||Studies with intermittent fasting|Studies with intermittent fasting strategies.
62145984|NCT01270282|EXPERIMENTAL|AM-101 0.81 mg/mL|Gel for injection; single or triple injection
62145985|NCT01270282|PLACEBO_COMPARATOR|Placebo|Gel for injection; single or triple injection
62145986|NCT05589337|EXPERIMENTAL|Baduanjin intervention group|Participants randomized to Baduanjin intervention group receive health education plus a Baduanjin training program. The Baduanjin training program was a 16-week, instructor-led group training program that offers breathing training as a core skill.
62145987|NCT05589337|ACTIVE_COMPARATOR|Health education control group|Participants randomized to the health education control group only receive health education and no additional training program.
62351877|NCT00225147|EXPERIMENTAL|100 IU/kg rhC1INH|100 IU/kg Recombinant human C1 inhibitor
62351878|NCT00225147|EXPERIMENTAL|50 IU/kg rhC1INH|50 IU/kg Recombinant human C1 inhibitor
62351879|NCT00225147|PLACEBO_COMPARATOR|Saline|
62351880|NCT03934710|PLACEBO_COMPARATOR|Placebo|Placebo
62351881|NCT03934710|EXPERIMENTAL|Serotonin agonist 13ug|13ug of serotonin agonist
62351882|NCT03934710|EXPERIMENTAL|Serotonin agonist 26ug|26ug of serotonin agonist
62351883|NCT03385174|OTHER|Carbon monoxide|Each participant receives CO inhalation
62351884|NCT04257227|EXPERIMENTAL|rTMS Intervention Group|
62510756|NCT03359915|EXPERIMENTAL|Intervention Group|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
62510757|NCT03359915|NO_INTERVENTION|Control Group|COPD 'standard' care in local setting - Bhaktapur, Nepal; Lima, Peru; Nakaseke, Uganda
62510758|NCT01660022|EXPERIMENTAL|OZ439 100mg|100mg OZ439 single oral dose
62510759|NCT01660022|EXPERIMENTAL|OZ439 100 mg + PQP 160mg|100mg OZ439 single oral dose + 160mg Piperaquine single oral dose
62510760|NCT01660022|EXPERIMENTAL|OZ439 100 mg + PQP 480mg|100mg OZ439 single oral dose + 480mg Piperaquine single oral dose
62707711|NCT02756052|SHAM_COMPARATOR|General Surgery Resident - Sham tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
62707712|NCT02756052|EXPERIMENTAL|Medical Student - Anodal tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
62145988|NCT03412903||Control group|First observational period: Standard care without an advising pharmacist, 140 patients
62145989|NCT03412903||Implementation group|Second observational period: Standard care with an advising pharmacist, 140 patients
62145990|NCT03412903||Learning success group|Second observational period: Standard care without an advising pharmacist, 30 patients
62145991|NCT05185167|EXPERIMENTAL|Desflurane Group|Desflurane 1,0 minimum alveolar concentration will be administered during anesthesia maintenance
62145992|NCT05185167|EXPERIMENTAL|Propofol Group|Propofol 6 mg//kg/hour will be administered during anesthesia maintenance
62145993|NCT04580433|EXPERIMENTAL|Time-Restricted Feeding|Participants will receive 16:8 TRF.
62145994|NCT02311062|EXPERIMENTAL|Eccentric hamstring exercises|Three workouts per week on non-consecutive days for 6 weeks. 1)Assisted Nordic Curl: Kneeling on the ground with ankles fixed by a partner, participant lowering the trunk to the ground by eccentrically contracting the hamstrings. 2) Eccentric single stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the support leg knee and raising the other leg until form an straight line with the trunk4 3) Eccentric double stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the knees until the body parallel with the floor.
62510761|NCT01660022|EXPERIMENTAL|OZ439 100 mg + PQP 1440mg|100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
61970810|NCT05154006|EXPERIMENTAL|Individual promotion of self-efficacy|"The group Individual promotion of self-efficacy receives the same instructions and information on safe carrying behavior as the control group.~Additionally, this group will receive behavior change techniques (Michie et al., 2013) to increase self-efficacy (psychological activities to increase self-confidence / belief in own capability to reduce risks of carrying loads with own behavior)."
61970811|NCT05154006|EXPERIMENTAL|Promotion of self-efficacy + social support|"The group Promotion of self-efficacy + social support receives the same instructions for safe carrying behavior as the control group. The intervention will also include the same behavior change techniques to promote self-efficacy.~Additionally, a social partner from the same or neighboring household will be involved in the intervention activities. The partner will participate in the intervention activities and will be instructed to provide emotional, practical and informational social support."
61970812|NCT01506167||Bevacizumab and Capecitabine/Oxaliplatin|Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
62145995|NCT02311062|EXPERIMENTAL|Unistable exercises|Trained 3 times per week on non-consecutive days for 6 weeks for a total of 18 training sessions. UNS training consisted in the following three exercises: 1) One leg squat: Standing on the floor on one leg only and squat down until knee flexed to 900 and press back up with just that single leg. 2) One leg Squat on Bosu® balance Trainer: Standing on the Bosu® balance Trainer on one leg only and squat down until supported leg knee flexes to 900 and press back up with just that single leg. 3) Forward lunges on a Bosu® balance Trainer: position the forward leg on the Bosu® balance Trainer and squatting with the forward leg.
62145996|NCT02311062|ACTIVE_COMPARATOR|Control|Participants did not undergo any resistance training and continued with their regular soccer training.
62145997|NCT05772338|EXPERIMENTAL|BNP105 (25 + 25 + 15)|Up to six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
62145998|NCT05772338|PLACEBO_COMPARATOR|Placebo|Up to six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
62145999|NCT03233152|EXPERIMENTAL|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
62351885|NCT05551091|EXPERIMENTAL|GMP 25 mg BID|Investigators will conduct a pilot cross-over study in which 13 obese participants undergo measures of study outcomes: satiety hormones, glucose, amino acid and cytokine levels and changes in the fecal microbiota at baseline and after 7 days of consuming the supplement. On day one participants will consume a liquid soy breakfast, undergo study measures and then initiate GMP supplements twice a day (BID) x 7 days, with repeat study measures on day 7 of consuming the GMP supplement.
62351886|NCT05551091|EXPERIMENTAL|GMP 25 mg TID|After a washout period, the same 13 participants will undergo repeated measures of study outcomes (satiety hormones, glucose, amino acid and cytokine levels and changes in the fecal microbiota). On day one subjects will consume a liquid soy breakfast, undergo study measures and then initiate GMP supplements thrice a day (TID) x 7 days, with repeat study measures on day 7 of consuming the GMP supplement.
62510762|NCT01660022|EXPERIMENTAL|OZ439 300mg|300mg OZ439 single oral dose
62510763|NCT01660022|EXPERIMENTAL|OZ439 300 mg + PQP 1440mg|300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
62510764|NCT01660022|EXPERIMENTAL|OZ439 800mg|800mg OZ439 single oral dose
61970813|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
61970814|NCT01506167||Bevacizumab and Capecitabine|Participants who receive bevacizumab in combination with capecitabine
62146000|NCT01866800|ACTIVE_COMPARATOR|Renal Guard|Renal Guard in addition to Saline and N-Acetylcysteine
62146001|NCT01866800|PLACEBO_COMPARATOR|Conventional Treatment|Saline and N-Acetylcysteine
62351887|NCT02483078|ACTIVE_COMPARATOR|PRO 140|PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
62510765|NCT01660022|EXPERIMENTAL|OZ439 800 mg + PQP 1440mg|800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
61970815|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
61970816|NCT01506167||Bevacizumab and Capecitabine/Irinotecan|Participants who receive bevacizumab in combination with capecitabine/irinotecan
61970817|NCT01506167||Bevacizumab and Fluorouracil +/- Folinic Acid|Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
61970818|NCT01506167||Other|Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
61970819|NCT01426373|EXPERIMENTAL|Deoxycholic Acid 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
61970820|NCT03015389||Barrett's associated esophageal dysplasia|
61970821|NCT05830851|ACTIVE_COMPARATOR|aerobic exercise|Walk on a treadmill during 20-30 minutes at 60-80% of Heart Rate max
61970822|NCT05830851|SHAM_COMPARATOR|Sham tDCS|Application of tDCS during 30 seconds of 2 mA-intensity.
61970823|NCT05830851|EXPERIMENTAL|real tDCS|Application of real tDCS during 20 minutes at 2 mili Amper (mA)-intensity.
61970824|NCT01708681|EXPERIMENTAL|Lean seafood|Cross-over design, half of the subject will receive lean seafood in study period I and the other half in study period II
61970825|NCT01708681|ACTIVE_COMPARATOR|Meat, egg, milk|Cross-over design, half of the subject will receive meat, egg, milk in study period I and the other half in study period II
61970826|NCT01713686|EXPERIMENTAL|Ulthera System Treatment|A single triple-depth Ulthera System treatment of the decolletage delivering treatment at 4.5mm, 3.0mm and 1.5mm depths.
62351888|NCT02483078|PLACEBO_COMPARATOR|Placebo|Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
62351889|NCT00852306|EXPERIMENTAL|slow freeze|these recipients will have their first embryo transfer with oocytes frozen via the slow freeze method.
61970827|NCT04077983|EXPERIMENTAL|combined therapy using nab-paclitaxel and gemcitabine chemo|"1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses."
62351890|NCT00852306|EXPERIMENTAL|vitrification|these recipients will have their first attempt at an embryo transfer with oocytes frozen via the vitrification method.
62351891|NCT03060967|EXPERIMENTAL|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
61970828|NCT04023786|EXPERIMENTAL|56 patients, one arm|All patients benefits of a passive leg raising test and a PEEP test to compare these two tests.
62146002|NCT05267093|EXPERIMENTAL|Acupuncture group|Participants in acupuncture group will receive treatment at bilateral Baxie (EX-UE9), bilateral Houxi (SI3), bilateral Waiguan (TE5) and Ashi points. The acupuncture treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 4 weeks.
62351892|NCT03060967|EXPERIMENTAL|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
62351893|NCT03155633|NO_INTERVENTION|Rest Group|Rest during the 9 days after the race
62351894|NCT03155633|EXPERIMENTAL|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
62351895|NCT03155633|EXPERIMENTAL|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
62351896|NCT03956888|EXPERIMENTAL|N-acetylcysteine treatment|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
62351897|NCT05594212|EXPERIMENTAL|The effectiveness of receiving abdominal breathing training|The effectiveness of receiving abdominal breathing training Training for 8 weeks (1 time a week, 15 minutes each time). Performed one-on-one by a trainer in a sleep center. At home, you can use the abdominal breathing training video to train yourself (10 minutes a day, can be divided into 10 minutes), and you need to fill in the abdominal breathing training log.
62351898|NCT05594212|NO_INTERVENTION|The effectiveness of not receiving abdominal breathing training|The effectiveness of not receiving abdominal breathing training The trainer does not provide abdominal breathing training, does not perform abdominal breathing exercises at home, and does not need to fill in abdominal breathing training logs.
62351899|NCT04914117|EXPERIMENTAL|RC118 for injection|"Part A (Dose Escalation): RC118 will be administered through IV infusion at the various dose levels, including 0.25, 0.5, 1.0, 1.5, 2, 2.5, and 3 mg/kg, 1-12 subjects for each dose level.~Part B (Dose Confirmation): RC118 will be administered at up to two dose levels, which is equal or lower than MTD/MAD, through IV infusion. Each dose level contains 3-6 subjects."
62351900|NCT04850612||Healthcare professionals and researchers (HCPR)|All researchers and healthcare professionals involved in the management of patients with CSDH
62510766|NCT01660022|PLACEBO_COMPARATOR|Placebo|Placebo
62510767|NCT06253338|EXPERIMENTAL|Interventional Arm|
62510768|NCT02345291|EXPERIMENTAL|NRD135S.E1 A|A = 10 mg NRD135S.E1 once daily PO for 21 days
62146003|NCT05267093|PLACEBO_COMPARATOR|Sham acupuncture group|Participants in sham acupuncture group will receive treatment at bilateral Baxie (EX-UE9), bilateral Houxi (SI3), bilateral Waiguan (TE5) and Ashi points. The sham acupuncture treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 4 weeks.
62146004|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
62146005|NCT02305914||follow-up visit|Patients who come for follow-up visit will fill in the questionnaire and undergo regular laboratory examination such as liver function test and CRP,faecal elastase-1 as well as CT scanning.Additionally,blood sample of every patient will be collected and sent to the Lab for storage and further experimented.
61970829|NCT05167214|EXPERIMENTAL|Star tape|Group 1 ( n=35) was applied with the star technique. Visual Analogue Scale (VAS) to evaluate pain before taping, immediately after taping and 4 days after taping, Oswestry low back pain disability scale (OLBPDS) to assess disability level, Lumbar Flexion Repeat Speed Test, Sit-and-Stand Test to evaluate functional performance in both groups. Biering Sorenson Test was applied to evaluate the forward bending test with weight and trunk endurance. Individuals in both groups were told to continue with their daily lives while on the tapes. It was stated that the bands should stay on the applied area for 4 days, that they can have a bath while the bands are on, and that if the bands are uncomfortable or excessive itching on the skin, the individuals can remove the bandage with an oily solution. No itching, redness, or allergic reactions was observed in either group.
61970830|NCT05167214|PLACEBO_COMPARATOR|I Tape|Group 2 (n=35) was applied in the form of I tape. Visual Analogue Scale (VAS) to evaluate pain before taping, immediately after taping and 4 days after taping, Oswestry low back pain disability scale (OLBPDS) to assess disability level, Lumbar Flexion Repeat Speed Test, Sit-and-Stand Test to evaluate functional performance in both groups. Biering Sorenson Test was applied to evaluate the forward bending test with weight and trunk endurance. Individuals in both groups were told to continue with their daily lives while on the tapes. It was stated that the bands should stay on the applied area for 4 days, that they can have a bath while the bands are on, and that if the bands are uncomfortable or excessive itching on the skin, the individuals can remove the bandage with an oily solution. No itching, redness, or allergic reactions was observed in either group.
62146006|NCT06455306|EXPERIMENTAL|Test Group Erythritol Monthly Applications|Patients will receive monthly applications (months 0, 1, and 2) of treatment with an air-polishing device with erythritol, along with oral hygiene instructions
62146007|NCT06455306|NO_INTERVENTION|Control group|Patients will receive only oral hygiene instructions
62146008|NCT06455306|EXPERIMENTAL|Test Group Erythritol Single Application|Patients will receive a single application of treatment with an air-polishing device with erythritol, in addition to oral hygiene instructions
61970831|NCT02406976|EXPERIMENTAL|G1- EXERCISE|The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
61970832|NCT02406976|EXPERIMENTAL|G2- EXERCISE AND LIFESTYLE|"This groups will receive the same intervention of G1 group, associated with the weekly group with a psychologist.~These groups worked techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors, as well as the reduction or elimination of undesirable conduct."
62707713|NCT02756052|EXPERIMENTAL|General Surgery Resident - Anodal tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
62707714|NCT00049543|EXPERIMENTAL|Arm I (gefitinib)|Patients receive gefitinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
62146009|NCT01584674|EXPERIMENTAL|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
62146010|NCT01584674|NO_INTERVENTION|Control (untreated hemiface)|No treatment will be administered on the control hemiface
62146011|NCT02499094|EXPERIMENTAL|Intervention A- Heuristic based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as simple heuristic-based behavioral measures
62146012|NCT02499094|EXPERIMENTAL|Intervention B- Machine Learning Based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as machine learning model-based behavioral measures
62146013|NCT02499094|NO_INTERVENTION|Control|No intervention
62146014|NCT00019604|EXPERIMENTAL|Radiofrequency ablation in liver cancer|This trial is designed to gain experience with the use of ablation devices with liver tumors. Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.
62146015|NCT01545583|PLACEBO_COMPARATOR|Placebo intravenous|Placebo administered once intravenously
62510769|NCT02345291|EXPERIMENTAL|NRD135S.E1 B|B = 40 mg NRD135S.E1 once daily PO for 21 days
62707715|NCT00049543|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
62707716|NCT03526211|EXPERIMENTAL|Experimental|Patients with FES Cycling
62146016|NCT01545583|EXPERIMENTAL|0.1 milligram (mg) LY3016859 intravenous|0.1 mg LY3016859 administered once intravenously
62146017|NCT01545583|EXPERIMENTAL|1 mg LY3016859 intravenous|1 mg LY3016859 administered once intravenously
62146018|NCT01545583|EXPERIMENTAL|10 mg LY3016859 intravenous|10 mg LY3016859 administered once intravenously
62146019|NCT01545583|EXPERIMENTAL|50 mg LY3016859 intravenous|50 mg LY3016859 administered once intravenously
62146020|NCT01545583|EXPERIMENTAL|250 mg LY3016859 intravenous|250 mg LY3016859 administered once intravenously
62146021|NCT01545583|EXPERIMENTAL|750 mg LY3016859 intravenous|750 mg LY3016859 administered once intravenously
62146022|NCT01545583|PLACEBO_COMPARATOR|Placebo subcutaneous|Placebo administered once subcutaneously
62510770|NCT02345291|EXPERIMENTAL|NRD135S.E1 C|C = 150 mg NRD135S.E1 once daily PO for 21 days
62146023|NCT01545583|EXPERIMENTAL|50 mg LY3016859 subcutaneous|50 mg LY3016859 administered once subcutaneously
62146024|NCT05396001|ACTIVE_COMPARATOR|LowSalt4Life|
62146025|NCT05396001|EXPERIMENTAL|LowSalt4Life + just-in-time adaptive intervention (JITAI)|
62146026|NCT02109913|OTHER|Everolimus plus exemestane|Biomarker study in patients receiving standard treatment
62146027|NCT00385866|ACTIVE_COMPARATOR|Comparison Group|The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.
62146028|NCT00385866|ACTIVE_COMPARATOR|Intervention group|The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.
62510771|NCT02345291|PLACEBO_COMPARATOR|Placebo to match NRD135S.E1 D|D = Placebo once daily PO for 21 days
62510772|NCT03396874|EXPERIMENTAL|Patient participants|PET/CT imaging
61970833|NCT02406976|ACTIVE_COMPARATOR|G3- CONTROL|This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
61970834|NCT04334551|EXPERIMENTAL|switch from etravirine to doravirine|switches to doravirine,
61970835|NCT05593120||CT-FFR|All patients will be assessed and managed according to the results of CT-FFR test, assuming they have no prespecified contraindications to CT coronary angiography. The result of the CT-FFR will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
61970836|NCT05593120||Routine care|All patients will be assessed and managed exactly as they are usually treated by the investigator and the institution's heart team according to routine practice in Wuhan Asia Heart Hospital.
61970837|NCT03568760|EXPERIMENTAL|SFA treatment|Semantic feature analysis
61970838|NCT03568760|PLACEBO_COMPARATOR|Comprehension training|Comprehension training
61970839|NCT02483520|EXPERIMENTAL|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
61970840|NCT02483520|PLACEBO_COMPARATOR|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
61970841|NCT06028568||Elderly patients undergoing surgery|Older than or equal to 65 years of age; patients who intend to undergo major abdominal surgery under general anesthesia (grade 3-4 surgery based on surgical grade)
61970842|NCT06028568||Elderly healthy volunteers|Age-and sex-matched community population
61970843|NCT06334471||prospective study|The prospective study group includes patients aged 19 years or older who have provided written consent for participation, have the capability to consent voluntarily, are eligible for tissue examination and surgical removal for sample collection, and have confirmed or suspected breast cancer for pathological confirmation.
61970844|NCT06334471||Retrospective study|The retrospective study group includes patients who have been histologically confirmed with breast cancer and whose breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Human Biobank and available for distribution.
62146029|NCT04718259|EXPERIMENTAL|Group A|Will include patients who will receive bupivacaine intrathecal injection without adjuvant.
61970845|NCT00489541|EXPERIMENTAL|TAXUS Element Stent System|
61970846|NCT04358133|EXPERIMENTAL|Chlorhydrate de morphine|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea \<40 then relay subcut
61970847|NCT04358133|PLACEBO_COMPARATOR|NaCl 0,9%|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea \<40 then relay subcut
61970848|NCT06254586|EXPERIMENTAL|Aerobic exercise|This group received a single session of low-intensity cycling for 20 minutes.
61970849|NCT06254586|ACTIVE_COMPARATOR|Resisted exercises|This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with a 30 sec to 1 minute rest period between sets.
62146030|NCT04718259|EXPERIMENTAL|Group B|Will include patients who will receive bupivacaine and midazolam.
62146031|NCT06196164|EXPERIMENTAL|EUS-BD|Endoscopic Ultrasound-guided Biliary Drainage
62146032|NCT06196164|OTHER|ERCP-BD|Endoscopic Retrograde Cholangiopancreatography
62146033|NCT06239519|EXPERIMENTAL|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, and will receive access to the JoyPop app for 4 weeks.
62146034|NCT06239519|NO_INTERVENTION|Usual Practice|Participants will be monitored through existing wait-list practices. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
62146035|NCT02850939|EXPERIMENTAL|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.
62146036|NCT02850939|NO_INTERVENTION|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.
62146037|NCT06340984|ACTIVE_COMPARATOR|group moderate acne|patients with moderate acne vulgaris who will receive Montelukast therapy dose: 10mg/day, duration of therapy: three months, serum level of intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) before and after treatment
62510773|NCT05871333|NO_INTERVENTION|Standard of care|Patients will receive FOLFOX-6 regimen consisted of 2-hour infusion of oxaliplatin (100 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2) on Day 1, followed by 5-fluorouracil (5-FU) bolus (400 mg/ m2) on Day 1 and 46-hour infusion (2.4 g/m2) with cycle repeated every 2 weeks over range of 20-24 weeks depending on patients disease state.
62146038|NCT06340984|ACTIVE_COMPARATOR|group severe acne|patients with severe acne vulgaris who will receive Montelukast therapy dose: 10mg/day, duration of therapy: three months, serum level of intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) before and after treatment
62146039|NCT06340984|NO_INTERVENTION|control group|Healthy patients with Age and sex matching ,No history of acne, serum level of intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA)
62146040|NCT02442622|ACTIVE_COMPARATOR|Occupational therapy|Traditional therapy for de Quervain's Tenosynovitis
62146041|NCT02442622|EXPERIMENTAL|Occupational therapy with ASTYM|Traditional therapy for de Quervain's Tenosynovitis plus ASTYM
62146042|NCT02404844|EXPERIMENTAL|BKM120 + Tamoxifen|"BKM120 (Buparlisib): 100 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle~Tamoxifen: 20 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle"
62146043|NCT01695291|PLACEBO_COMPARATOR|Placebo|Participants randomized to placebo will receive pills that are identical in appearance to the study drug but contain no active medication.
62146044|NCT01695291|EXPERIMENTAL|Minocycline Augmentation|Those randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline (minimum 50 mg/day and maximum 200 mg/day). After randomization, participants will receive child proofed bottles that contain enough study medication until the next visit with an additional 3 days coverage in case of scheduling issues. All participants will have a minocycline level drawn at week 12 to confirm treatment adherence. Minocycline is FDA-approved in those ages 8 and above for treatment of infections and acne and has a favorable risk-benefit profile.
62146045|NCT06050941|EXPERIMENTAL|treatment group|Reduced intensive of 3 + 5 Idarubicin and Cytarabine plus Venetoclax as induction therapy
62146046|NCT02589457|ACTIVE_COMPARATOR|Viread® tablet|Tenofovir Disoproxil Fumarate
62146047|NCT02589457|EXPERIMENTAL|CKD-390|Tenofovir Disoproxil Fumarate
62146048|NCT00667017|EXPERIMENTAL|IMTOX25 at 2mg/m²/dose|Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.
62146049|NCT02149511||SCI subjects|
62146050|NCT02149511||healthy control subjects|
61970850|NCT01656785|EXPERIMENTAL|Brain 68Ga-BNOTA-PRGD2|We will perform brain 68Ga-BNOTA-PRGD2 PET/CT on stroke patients to determine its value.
61970851|NCT02519192|EXPERIMENTAL|VAC Arm, Vac sponge irrigations|For patients who fall under the VAC arm, a physician will do the initial placement of the wound VAC (V.A.C.Ulta™ Negative Pressure Wound Therapy System) at the patient's bedside. An information sheet will be provided to the patient, and the patient will be taught how to irrigate the sponge system independently. While inpatient, nursing will perform VAC sponge irrigation.
61970852|NCT02519192|ACTIVE_COMPARATOR|NonVac, ostomy bag, wet to dry dressings|For patients who fall under the non-VAC arm, a physician or wound care nurse will perform the initial application of the ostomy bag or wet to dry dressing change. An information sheet will be provided to the patient. While inpatient, members from the nursing or physician team will perform ostomy bag application and ostomy dressing changes.
61970853|NCT04669782|EXPERIMENTAL|Patients with osteoporosis treated with teriparatide + Vitamin K|Patients will have to take teriparatide (standard of care) + Vitamin K (MK7) at the dosage of 375 microg / day
61970854|NCT04669782|ACTIVE_COMPARATOR|Patients with osteoporosis treated with teriparatide|Patients will have to take teriparatide (standard of care)
61970855|NCT04669782|NO_INTERVENTION|Controls|Subject without osteoporosis, no treatment will be administered.
61970856|NCT05564689||Patients with or in need of CRT, left bundle branch block, without ischemic heart disease|
62146051|NCT03854565||Mild ARDS|patients have mild ARDS according to Berlin definition
62146052|NCT03854565||Moderate ARDS|patients have moderate ARDS according to Berlin definition
62146053|NCT03854565||Severe ARDS|patients have severe ARDS according to Berlin definition
62146054|NCT06028659|EXPERIMENTAL|Coffee|In this arm, volunteers will receive, once, 3 decaffeinated coffees (150 mL total) with sugar as a known source of (poly)phenols.
62146055|NCT06028659|OTHER|Control|In this arm, volunteers will receive, once, 150 mL of sugared water as control.
62146056|NCT01308684|EXPERIMENTAL|1|
62351901|NCT04850612||Patients and carers|Patients who have previously had a diagnosis of CSDH, and their carers
61970857|NCT01980992|ACTIVE_COMPARATOR|Wheat OIT|Active treatment participants receive Vital Wheat Gluten, and have up to four oral food challenges as directed by the protocol.
62146057|NCT01308684|EXPERIMENTAL|2|
62146058|NCT01213940|OTHER|baratric surgery|surgery vs.weight loss program 6 months prior to bariatric surgery
62146059|NCT01213940|OTHER|pre-bariatric weight loss program|weight loss program prior to bariatric surgery
62146060|NCT04493359|EXPERIMENTAL|Switch therapy|Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
62146061|NCT04493359|NO_INTERVENTION|Maintenance therapy|Renin-angiotensin system inhibitors will be kept during in-hospital stay
61970858|NCT01980992|PLACEBO_COMPARATOR|Placebo|Placebo for Vital Wheat Gluten followed by crossover to open-label active therapy (Vital Wheat Gluten), and up to three oral food challenges as directed by the protocol.
61970859|NCT04231864|EXPERIMENTAL|Treatment (durvalumab, epacadostat)|Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice a day (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study.
61970860|NCT01749514|EXPERIMENTAL|Luspatercept 0.125mg/kg (Cohort 1)|Participants receive luspatercept 0.125mg/kg as a subcutaneous (SC) injection every 3 weeks (Q3W) on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
61970861|NCT01749514|EXPERIMENTAL|Luspatercept 0.25mg/kg (Cohort 2)|Participants receive luspatercept titrated up to 0.25mg/kg via Fibonacci scheme, SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
62146062|NCT03900988|ACTIVE_COMPARATOR|intravenous N-acetylcysteine (NAC) and oseltamivir|
62146063|NCT03900988|PLACEBO_COMPARATOR|intravenous 5% dextrose and oseltamivir|
62510774|NCT05871333|EXPERIMENTAL|standard of care + Losartan|Patients will receive FOLFOX-6 regimen consisted of 2-hour infusion of oxaliplatin (100 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2) on Day 1, followed by 5-fluorouracil (5-FU) bolus (400 mg/ m2) on Day 1 and 46-hour infusion (2.4 g/ m2) with cycle repeated every 2 weeks over range of 20-24 weeks depending on patients disease state. In addition to Losartan 50 mg/day orally for 4 months.
62510775|NCT04091802|EXPERIMENTAL|single layer of L-PRF|single layer of L-PRF will be put in the vertical incision
61970862|NCT01749514|EXPERIMENTAL|Luspatercept 0.50mg/kg (Cohort 3)|Participants receive luspatercept titrated up to 0.50mg/kg via Fibonacci scheme, SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
61970863|NCT01749514|EXPERIMENTAL|Luspatercept 0.75mg/kg (Cohort 4)|Participants receive luspatercept titrated up to 0.75mg/kg via Fibonacci scheme, SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
61970864|NCT01749514|EXPERIMENTAL|Luspatercept 1.00mg/kg (Cohort 5)|Participants receive luspatercept titrated up to 1.00mg/kg via Fibonacci scheme, SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
61970865|NCT01749514|EXPERIMENTAL|Luspatercept 1.33mg/kg (Cohort 6)|Participants receive luspatercept titrated up to 1.33mg/kg via Fibonacci scheme, SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
61970866|NCT01749514|EXPERIMENTAL|Luspatercept 1.75mg/kg (Cohort 7)|Participants receive luspatercept titrated up to 1.75mg/kg via Fibonacci scheme, SC injection Q3W on Day 1 of each cycle for up to 5 cycles (each cycle length = 21 days).
61970867|NCT01749514|EXPERIMENTAL|Expansion Cohort|Participants receive an initial dose of luspatercept 1.0mg/kg SC on Day 1 of the Cycle 1 (Cycle length = 21 days). For each subsequent cycle (up to 5 cycles), the dose was titrated via Fibonacci scheme up to a maximum dose of 1.75mg/kg based on the safety review team (SRT) recommendations
61970868|NCT05575986|EXPERIMENTAL|Observation group|Herombopag Olamine Tablets
61970869|NCT00680381|ACTIVE_COMPARATOR|1|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly therapist phone calls for eight weeks.
61970870|NCT00680381|ACTIVE_COMPARATOR|2|Following 12 weeks of FFT, weekly one-hour group therapy for eight weeks
61970871|NCT00680381|ACTIVE_COMPARATOR|3|Following 12 weeks of FFT, an eight-week, customized series of therapist visits with the adolescent, family, teachers, coaches and others who can support the adolescent's reduced level of drug use.
61970872|NCT03381846|EXPERIMENTAL|MOHS treatment arm|Patients who have their dermatofibrosarcoma protuberans excised with MOHS surgery.
61970873|NCT05033353|ACTIVE_COMPARATOR|Group I|Mechanical ventilation was adjusted to maintain an EtCO2 of 33-38 mm Hg in group I regional cerebral oxygen monitoring
61970874|NCT05033353|ACTIVE_COMPARATOR|Group II|Mechanical ventilation was adjusted to maintain an EtCO2 of 39-45 mm Hg in group II regional cerebral oxygen monitoring
61970875|NCT01409655|EXPERIMENTAL|cognitive-behavioral therapy intervention|Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
61970876|NCT02180152|EXPERIMENTAL|Postprandial walk|
61970877|NCT02180152|NO_INTERVENTION|sedentary pregnant women|
61970878|NCT02588807|EXPERIMENTAL|Spirit1|Patients will take a daily nutritional supplement for 8 months
61970879|NCT01806545|ACTIVE_COMPARATOR|SRM003|One time implant (2 SRM003 pieces) on surgery day. Post-surgery, up to 26 weeks follow-up for assessment of efficacy/safety.
61970880|NCT01806545|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
62146064|NCT05991882|EXPERIMENTAL|Condition 1: Craving daily+PBS daily|EMA + Introduction Module + Craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily
62146065|NCT05991882|EXPERIMENTAL|Condition 2: Craving daily+PBS trigger|EMA + Introduction Module + Craving reduction messages delivered once daily and PBS trigger messages
61970881|NCT00420927|EXPERIMENTAL|ADA+MTX/PBO+MTX (Arm 1)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
61970882|NCT00420927|EXPERIMENTAL|ADA+MTX/ADA+MTX (Arm2)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
61970883|NCT00420927|EXPERIMENTAL|ADA+MTX/OL ADA+MTX (Arm 3)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
61970884|NCT00420927|EXPERIMENTAL|PBO+MTX/PBO+MTX (Arm 4)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
62351902|NCT04077229|EXPERIMENTAL|Intervention|A total of 28 intervention text messages (1/day for 4 weeks) will be sent to participants following the baseline self-report assessment. After each message is sent, participants will receive a second text message asking them to rate the utility of the message. Following the 4-week intervention, participants will complete the same self-report assessments as in the baseline assessment (via phone) and will provide feedback about the program. Finally, 4 weeks later (at 8 weeks), participants will repeat the self-report questionnaires by phone.
62146066|NCT05991882|EXPERIMENTAL|Condition 3: Craving trigger+PBS daily|EMA + Introduction Module + Craving reduction trigger messages and PBS messages delivered once daily
62146067|NCT05991882|EXPERIMENTAL|Condition 4: Craving trigger+PBS trigger|EMA + Introduction Module + Craving reduction trigger and PBS trigger messages
62351903|NCT03393468|EXPERIMENTAL|Sequence A: Dapivirine gel|Participants will receive 2.5 g of dapivirine gel administered rectally via an applicator, followed by a 2- to 4-week washout period. Participants will then receive a second dose of up to 10 g of dapivirine gel administered rectally via a coital simulation device.
62351904|NCT03393468|EXPERIMENTAL|Sequence B: Dapivirine gel|Participants will receive up to 10 g of dapivirine gel administered rectally via a coital simulation device, followed by a 2- to 4-week washout period. Participants will then receive a second dose of 2.5 g of dapivirine gel administered rectally via an applicator.
62146068|NCT05991882|EXPERIMENTAL|Condition 5: PBS daily+ PBS trigger|EMA + Introduction Module + PBS delivered once daily and PBS trigger messages
62146069|NCT05991882|EXPERIMENTAL|Condition 6: Craving daily+Craving trigger|EMA + Introduction Module + Craving reduction delivered once daily and craving reduction trigger messages
62146070|NCT05991882|EXPERIMENTAL|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|EMA + Introduction Module + Craving reduction delivered once daily, craving reduction trigger messages, PBS delivered once daily, and PBS trigger messages
62510776|NCT04091802|EXPERIMENTAL|multiple layers of L-PRF|multiple layers of L-PRF will be put in the vertical incision
62510777|NCT04397289|EXPERIMENTAL|Heparin group|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT/INR was kept at 1.25-1.5.
62146071|NCT05991882|OTHER|Condition 8: No daily or trigger craving or PBS|EMA + Introduction Module + no other messages
62146072|NCT05554445||Adult CD patients who are prescribed the Crohn disease exclusion diet|Clinically stable CD patients with active disease by CD symptoms score 4 \<Harvey-Bradshaw index (HBI) at baseline and Calprotectin\>50g/l / endoscopy / imaging proven active disease from the previous 4 months
61970885|NCT00420927|EXPERIMENTAL|PBO+MTX/OL ADA+MTX (Arm 5)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
61970886|NCT01119391||Patients undergoing IVF|Women undergoing an in vitro fertilization cycle
61970887|NCT03208855|EXPERIMENTAL|CBT-I|Participants will receive 8 1-hour sessions of group Cognitive Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
61970888|NCT03208855|NO_INTERVENTION|Treatment as Usual|Participants will receive treatment as usual for substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
61970889|NCT05759650|EXPERIMENTAL|Analyses of Kinematic and Kinetic parameters of movement|
61970890|NCT06145776|EXPERIMENTAL|dual-task group|Dual-Task Training Protocol (DTTP) The dual-task training protocol (DT) will consist in cognitive exercise categories: verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks, which will be associated to treadmill gait training (Sousa et al., 2016). Verbal commands will focus on the following: (1) large strides; (2) heel strike; (3) raising the knees while walking (Kelly et al., 2012).
61970891|NCT06145776|ACTIVE_COMPARATOR|control group|The participants will perform 21 min treadmill gait training associated to tDCS active in F3 for 20 min, 3 times a week for 4 weeks.
61970892|NCT00885105|EXPERIMENTAL|Fluzone® Vaccine-Primed Group|Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)
62146073|NCT01539252|ACTIVE_COMPARATOR|Single dialyzer|Single dialyzer
62146074|NCT01539252|EXPERIMENTAL|Double dialyzer|Two dialyzers in parallel
62146075|NCT00005379||IV drug users and their sexual contacts|This group will be made up of an already-recruited cohort
62146076|NCT00005379||Children who receive primary care at Bellevue Hospital|
62351905|NCT03694054|EXPERIMENTAL|Care coordination patients, caregivers|Patients and caregivers enroll in using care coordination tool during oncology care and treatment.
62351906|NCT03694054|NO_INTERVENTION|Standard of care patients, caregivers|Patients and caregivers receive oncology care and treatment.
62510778|NCT04397289|EXPERIMENTAL|Rivaroxaban group|Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.
61970893|NCT00885105|ACTIVE_COMPARATOR|Influenza Vaccine-Naive Group|Participants who have never received influenza vaccine (and not in Study GRC27)
61970894|NCT02257944|EXPERIMENTAL|Motivational Interviewing|Receive brief hospital-based intervention
61970895|NCT02257944|OTHER|Treatment as Usual|Treatment as Usual
61970896|NCT02148692|EXPERIMENTAL|Higher PEEP|PEEP of 12 cmH2O or higher and lung recruitment maneuvers
61970897|NCT02148692|ACTIVE_COMPARATOR|Lower PEEP|PEEP of 4 cmH2O without lung recruitment maneuvers
61970898|NCT05641207|EXPERIMENTAL|Experimental device RheOx™ with the RheOx™ Catheter was only used in the trial|All of participants who signed the ICF and meet all of inclution and exclution criterias will be enrolled to experimental arm.
61970899|NCT00005094|EXPERIMENTAL|Arm I (celecoxib)|Patients receive celecoxib twice a day for 3 years.
61970900|NCT00005094|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo twice a day for 3 years.
62510779|NCT04397289|SHAM_COMPARATOR|Control group|No preventive intervention measures.
62510780|NCT04776746|EXPERIMENTAL|Drug - trofinetide|trofinetide oral solution
62510781|NCT00949728|OTHER|Fibrin glue|
62510782|NCT02833194||Leiden Group|Women with an isolated F5 rs6025 polymorphism or an isolated F2 rs1799963 polymorphism.
62510783|NCT02833194||aP1Ab-positive|"Inclusion in the aP1Ab Group:~* Initially positive for aP1Ab~* Second positive aP1Ab test six months later"
61970901|NCT01937728|ACTIVE_COMPARATOR|A: Peg-interferon alpha-2a & Ribavirin|Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
62146077|NCT00005379||Bellevue Hospital inpatients/outpatients|Inpatients being treated for TB and outpatients receiving prophylactic treatment
62146078|NCT05640505|EXPERIMENTAL|Experimental|This group received 03 gratitude interventions for 4 weeks
62146079|NCT05640505|NO_INTERVENTION|Control Group|This group did not receive any intervention during active phase. Only the scores on dependent variables were measured. After completion of study, the same interventions were repeated with this group.
62146080|NCT01868061|EXPERIMENTAL|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.
62146081|NCT01868061|EXPERIMENTAL|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
62146082|NCT01868061|PLACEBO_COMPARATOR|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
62351907|NCT03694054|EXPERIMENTAL|Oncology Care Providers|Oncology care providers with patients enrolled in care coordination tool.
62351908|NCT01057914|EXPERIMENTAL|Supplemention|
62351909|NCT01057914|EXPERIMENTAL|Dietary advice|
62351910|NCT01057914|EXPERIMENTAL|Combination treatment|
62146083|NCT03375424||1st subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced Vedolizumab (VDZ) therapy (n=1.800). A former therapy with other biologics is allowed. More than 30% of these Vedolizumab patients will be biologics-naiv.
62146084|NCT03375424||2nd subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced anti-TNF-alpha therapy other than VDZ (n=350) in biologics-naiv patients.
62146085|NCT03375424||3rd subpopulation|IBD patients (age at enrollment: 18-80 years) with an early disease (n=350), who were first diagnosed \<2 years before the start of documentation in the Investigator initiated non-interventional study (NIS) but have not yet received and are not planned to receive biologics in the near future.
62146086|NCT01670799|EXPERIMENTAL|Ketorolac|"All patients will receive a single dose of IV ketorolac for pain management for the indication of post-operative pain control. Patients less than 65 years of age and in otherwise good health will receive a 30mg IV single dose. Patients 65 years of age or greater, or who have mild renal insufficiency or are of low weight (as per section 3.2) will receive a single 15 mg dose IV ketorolac.~In patients who have a clinical pain response and have no contraindications to multi-dose (every 6 hours over 24 hours), additional doses will be given per physician discretion based on clinical indication. Patients receiving 24 hour dosing will be eligible for sample time points after 24 hour dosing."
62146087|NCT04171674|EXPERIMENTAL|Patients treated with high-dose ceftobiprole|
62146088|NCT04103164|EXPERIMENTAL|Cutera® excel V laser arm|After the PWS is be divided into five equal portions, four of those portions treated once with a different laser fluence using the multiple-pass approach (2 J/cm² vs 4 J/cm² vs 6 J/cm² vs 8 J/cm²), and one of the portions treated with single-pass approach at 8 J/cm²
62146089|NCT04198441|ACTIVE_COMPARATOR|Omeza Value-based Bundle Test|The Omeza value-based bundle consists of lidocaine lavage, flowable collagen matrix and skin protectant products.
61970902|NCT01937728|EXPERIMENTAL|B: Peg-interferon alpha-2a & Ribavirin|"Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
61970903|NCT01937728|EXPERIMENTAL|C: Peg-interferon alpha-2a & Ribavirin|"Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
61970904|NCT01937728|ACTIVE_COMPARATOR|D: Peg-interferon alpha-2a & Ribavirin|"Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
61970905|NCT01937728|EXPERIMENTAL|E: Peg-interferon alpha-2a & Ribavirin|"Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
61970906|NCT01937728|EXPERIMENTAL|F: Peg-interferon alpha-2a & Ribavirin|"Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
61970907|NCT06030102||Healthy young population|
62146090|NCT04198441|ACTIVE_COMPARATOR|Standard Wound Care Control|Standard wound care control is saline wound wash and wet to dry dressing.
61970908|NCT03157778|EXPERIMENTAL|Obese men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.
61970909|NCT03157778|ACTIVE_COMPARATOR|Normal-weight men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.
61970910|NCT02036021||PRE/non-PRE|children who develop or did not perioperative respiratory events between November 2012 and December 2013
61970911|NCT04267367|EXPERIMENTAL|Intervention|The intervention will include a dietitian-led nutrition education, counseling session and individual basis diet plan emphasis on glycemic control diet targeted to T2DM patients attending during the OPD visits in hospital.
61970912|NCT04267367|NO_INTERVENTION|Usual care|The usual care arm will be only provided general education.
61970913|NCT05322876|EXPERIMENTAL|Healthy Hearts Family Program|Participants will be enrolled in the standard Healthy Hearts Family Program 6-month family-based cardiovascular disease prevention program.
61970914|NCT04337125|OTHER|ADHD group|ADHD children with their parents
62146091|NCT05162469|EXPERIMENTAL|SHR-1909 monotherapy|
62146092|NCT02399605|NO_INTERVENTION|Control|No intervention, group control.
62146093|NCT02399605|EXPERIMENTAL|Stimulation|Subcutaneous Electrical Intervention
62146094|NCT05476900|EXPERIMENTAL|12 mg HR19042 Capsules QD|
62146095|NCT05476900|EXPERIMENTAL|4 mg HR19042 Capsules TID|
62146096|NCT05476900|EXPERIMENTAL|8 mg HR19042 Capsules QD|
62146097|NCT05785325|EXPERIMENTAL|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks. Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made.
62146098|NCT02744066|OTHER|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
62146099|NCT03862898|EXPERIMENTAL|lumbar stabilization group- thoracic|Lumbar stabilization and thoracic mobilization in a closed kinetic chain (LSTMC) group performed this exercises from the least to the largest painless motion amplitude and accordingly divided into three phases. The first phase lasted for two weeks, the second three and the last third phase, also for three weeks, and a total of 8 weeks.
62146100|NCT03862898|ACTIVE_COMPARATOR|lumbar stabilization group|Lumbar stabilization in a closed and opened kinetic chain (LSCO) group also performed exercises from the least to the largest painless motion amplitude in three phases.
62146101|NCT02892591|EXPERIMENTAL|Cannabis|Medium dose THC, single administration, vaporized
62510784|NCT02833194||Thrombophilia-negative|Women with completely negative thombophilia screening results.
62510785|NCT01606228|EXPERIMENTAL|Paliperidone ER|
61970915|NCT04337125|OTHER|Control group|Children with typical development and their parents
61970916|NCT00616954|EXPERIMENTAL|1|with ATG-F
61970917|NCT00616954|NO_INTERVENTION|2|control
61970918|NCT04579731||Fecal Impaction (LUTD-FI)|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those with 50% of symptom improvement were assumed to have a significant improvement attributable to the development of Lower Urinary Tract Dysfunction- Fecal Impaction (LUTD-FI).
61970919|NCT04579731||Lower Urinary Tract Dysfunction Not Related to Fecal Impaction|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those without symptom improvement place into lower urinary tract dysfunction not related to fecal impaction (LUTD-FI). They serve as a control group.
61970920|NCT01058109|EXPERIMENTAL|calcium group|dietary calcium intake of 1500 mg/d
61970921|NCT01058109|EXPERIMENTAL|calcium-rich diet (1500 mg/d)|calcium intake from food
61970922|NCT00805103|EXPERIMENTAL|(HFA-SRT) in Large-Volume Brain Metastases|
61970923|NCT04253145|EXPERIMENTAL|PM01183 w/ Atezolizumab|Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.) as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every three weeks (q3wk). Following analysis of cohorts, dose levels can be escalated from 2.5mg to 3.2, to a maximum dose of 3.5 mg of PM01183
61970924|NCT00715078|ACTIVE_COMPARATOR|Cohort A|Sipuleucel-T with the concentration of 10 μg/mL PA2024 in a cell suspension of 1 x 10\^7 peripheral blood mononuclear cells (PBMCs) per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
61970925|NCT00715078|ACTIVE_COMPARATOR|Cohort B|Sipuleucel-T with the concentration of 5 μg/mL PA2024 in a cell suspension of 1 x 10\^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
62146102|NCT02892591|ACTIVE_COMPARATOR|Oxycodone|5-10 mg oxycodone hydrochloride, single administration, oral
62351911|NCT01057914|NO_INTERVENTION|Usual care|
62351912|NCT05716594|EXPERIMENTAL|Enteral-extended Anti-reflux Stents Group|Patients are going to implant enteral-extended anti-reflux stents
61970926|NCT00715078|ACTIVE_COMPARATOR|Cohort C|Sipuleucel-T with the concentration of 2 μg/mL PA2024 in a cell suspension of 1 x 10\^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
61970927|NCT02972489|EXPERIMENTAL|3D OFDI guidance arm|Bifurcation percutaneous coronary intervention (PCI) optimized by online-3D OFDI during and after procedure
61970928|NCT02972489|ACTIVE_COMPARATOR|Angio guidance arm|Bifurcation percutaneous coronary intervention (PCI) guided by angiography
61970929|NCT00934973|ACTIVE_COMPARATOR|mebeverine + no website|Mebeverine 135mg tds for 6 weeks
62146103|NCT02892591|PLACEBO_COMPARATOR|Placebo|No active study drug
62146104|NCT01136512||metformin use|Patients with type 2 diabetes treated with metformin
62146105|NCT01136512||no metformin use|Patients with type 2 diabetes who are not being treated with metformin
62146106|NCT01128322|EXPERIMENTAL|S-Amlodipine 2.5mg + Telmisartan 40mg|
62146107|NCT01128322|EXPERIMENTAL|S-Amlodipine 2.5mg + Telmisartan 80mg|
62351913|NCT05716594|ACTIVE_COMPARATOR|Traditional Stents Group|Patients are going to implant traditional stents
62146108|NCT01128322|EXPERIMENTAL|S-Amlodipine 5mg + Telmisartan 40mg|
62146109|NCT01128322|EXPERIMENTAL|S-Amlodipine 5mg + Telmisartan 80mg|
62146110|NCT01128322|ACTIVE_COMPARATOR|S-Amlodipine 2.5mg|
62146111|NCT01128322|ACTIVE_COMPARATOR|S-Amlodipine 5mg|
62146112|NCT01128322|ACTIVE_COMPARATOR|Telmisartan 40mg|
62146113|NCT01128322|ACTIVE_COMPARATOR|Telmisartan 80mg|
62146114|NCT01128322|PLACEBO_COMPARATOR|Placebo|
62351914|NCT02394795|EXPERIMENTAL|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks.
62351915|NCT02394795|ACTIVE_COMPARATOR|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks.
62351916|NCT05400187|EXPERIMENTAL|Body composition assessment and smart-phone based counselling group|"In this study, we consider body composition measurement together with an immediate brief counselling after the measurement as part of the intervention. The body composition measurement will allow the participants to get familiar with their own anthropometric data and serve as cues to actions of healthy diet adoption and weight management and control. Based on the measured body fat and anthropometric data, a trained research assistant will give brief individualized dietary and weight management counselling to the participants.~The Whatsapp-based counselling and communication will heighten the awareness through reinforcing the need and benefits of body composition and weight control, the importance of energy balance, as well as providing professional and tailor-made advice on healthy eating and weight management. Qualitative dietary counselling will be offered every two weeks through the Whatsapp."
62351917|NCT05400187|NO_INTERVENTION|Control group|Participants in the control group will receive the simple body composition measurement only, without an immediate counselling after the measurement. Whey will be informed the values of anthropometric data and body composition parameters, no detailed interpretation of the values will be delivered to them. They will also not receive the professional consultant of the healthy diet and weight management from the diatetitian during the intervention period.
62351918|NCT01742078|EXPERIMENTAL|7.5 mg LY2541546 - IV|Single dose of 7.5 mg LY2541546 administered intravenously (IV)
62351919|NCT01742078|EXPERIMENTAL|25 mg LY2541546 - IV|Single dose of 25 mg LY2541546 administered IV
62351920|NCT01742078|EXPERIMENTAL|75 mg LY2541546 - IV|Single dose of 75 mg LY2541546 administered IV
62510786|NCT04201470|EXPERIMENTAL|MS patients|Patients with atypical MS identified in our cohort
62510787|NCT04201470|ACTIVE_COMPARATOR|Controls|
62146115|NCT00841711|OTHER|Behavioral counseling|
62146116|NCT03942575|NO_INTERVENTION|No negative pressure wound therapy|Historical cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage and where negative wound pressure therapy has been omitted
62146117|NCT03942575|EXPERIMENTAL|Negative pressure wound therapy|Prospective cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage with negative wound pressure therapy
62510788|NCT06616493|EXPERIMENTAL|KT|subjects with kinesio taping
62510789|NCT06616493|PLACEBO_COMPARATOR|placebo KT|subjects with placebo kinesio taping
62510790|NCT06616493|NO_INTERVENTION|control|subjects with no kinesio taping
62510791|NCT00497250|OTHER|1|Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are \>=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, \>=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
62510792|NCT04475250|EXPERIMENTAL|Tetragraph|
61970930|NCT00934973|ACTIVE_COMPARATOR|methylcellulose + no website|methylcellulose 3 tablets twice a day for 6 weeks
62146118|NCT05734690|EXPERIMENTAL|Medication & Education-First|Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
62146119|NCT05734690|ACTIVE_COMPARATOR|Education-First|Patient will first receive curated patient education, an alert to providers, and provider education, and then after 3 months begin participation in the remote heart failure clinic.
62146120|NCT01187706||gynecological cancer survivors|"Criteria for including: (1)Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. (2)Age from 20 - 70 years old. (3) Agreed to participate in this study.~Criteria for exclusion: Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients."
62146121|NCT01187706||healthy controls|Criteria for including: (1)Not those who suffer from cancer.(2)20-70 years old.(3)Agreed to participate in this study.Criteria for exclusion:Had undergone gynecologic surgical removal of ovaries or uterus were.
62146122|NCT06061978|EXPERIMENTAL|left bundle branch of His pacing (LBTP) then right ventricular pacing (RVP)|
62146123|NCT06061978|EXPERIMENTAL|right ventricular pacing (RVP) then left bundle branch of His pacing (LBTP)|
62351921|NCT01742078|EXPERIMENTAL|225 mg LY2541546 - IV|Single dose of 225 mg LY2541546 administered IV
62510793|NCT01876238|EXPERIMENTAL|T-PAT Intervention|Prognosis discussion intervention with study team.
62510794|NCT01876238|ACTIVE_COMPARATOR|Control: Standard Care|Usual care appointment
61970931|NCT00934973|PLACEBO_COMPARATOR|placebo + no website|placebo tablets
62146124|NCT06287957|EXPERIMENTAL|ML|Patients with mini platform implants to be treated with Labrida Bioclean
62146125|NCT06287957|EXPERIMENTAL|RL|Patients with regular platform implants to be treated with Labrida Bioclean
62146126|NCT06287957|ACTIVE_COMPARATOR|ME|Patients with mini platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)
62510795|NCT02117388|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
62510796|NCT02117388|EXPERIMENTAL|Sleep Restriction|Sleep Restriction therapy will limit the time participants spend in bed in order to make sure they are sleepy enough to fall asleep quickly.
61970932|NCT00934973|ACTIVE_COMPARATOR|mebeverine + CBT website minimal support|mebeverine 135mg tds and access to website
61970933|NCT00934973|ACTIVE_COMPARATOR|methylcellulose + CBT website|methylellulose 3 tablets twice a day and access to website
61970934|NCT00934973|PLACEBO_COMPARATOR|placebo + CBT website minimal support|placebo tablets and access to website
61970935|NCT00934973|ACTIVE_COMPARATOR|mebeverine + CBT website with support|mebeverine 135mg tds and access to website with nurse support session
62146127|NCT06287957|ACTIVE_COMPARATOR|RE|Patients with regular platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)
62146128|NCT00914771|ACTIVE_COMPARATOR|H5N1 pandemic Influenza vaccine 3.75µg|
62146129|NCT00914771|ACTIVE_COMPARATOR|H5N1 pandemic Influenza vaccine 7.5µg|
62146130|NCT02281266|EXPERIMENTAL|treatment (T)|"The patients of treatment arm will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week for 12 months after curative resection, followed by 12 months observation.~Nucleoside analog plan to give to HBV DNA positive patients."
62146131|NCT02281266|OTHER|control (C)|"The patients of control arm will be followed up for 2 years periodically after curative resection, without the investigational product (Thymalfasin) therapy.~Nucleoside analog plan to give to HBV DNA positive patients."
62146132|NCT01554267|EXPERIMENTAL|Mastectomy Skin Flap SPY Excision|Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
62351922|NCT01742078|EXPERIMENTAL|750 mg LY2541546 - IV|Single dose of 750 mg LY2541546 administered IV
62351923|NCT01742078|EXPERIMENTAL|150 mg LY2541546 - SC|Single dose of 150 mg LY2541546 administered subcutaneous (SC)
62351924|NCT01742078|PLACEBO_COMPARATOR|Placebo|Single dose of placebo administered IV or SC
62351925|NCT01742078|EXPERIMENTAL|225 mg LY2541546 - IV, OL|Single dose of 225 mg LY2541546 administered IV, open label (OL)
62351926|NCT01742078|EXPERIMENTAL|750 mg LY2541546 - IV, OL|Single dose of 750 mg LY2541546 administered IV, OL
62351927|NCT03330041|EXPERIMENTAL|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
62146133|NCT04128670|EXPERIMENTAL|Kinesiotape (KT)|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. The tape will be applied with a tension of 10-20%.
62146134|NCT04128670|PLACEBO_COMPARATOR|Placebo Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
62146135|NCT04128670|NO_INTERVENTION|No Tape|This group will not receive any intervention.
62146136|NCT04183023||Single arm|"There is a unique arm in which all the participants will be included. The intervention consists in the collection of a salivary sample Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and a subset of 4,000 DNA will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
62146137|NCT02046304|EXPERIMENTAL|Gemcitabine + Radiation Therapy|Patients receive concurrent chemoradiation (days 1 - 33) consisting of external beam radiotherapy (EBRT) plus gemcitabine, administered in a phase I dose escalation format until MTD is reached. EBRT delivered preoperatively (for patients with measurable disease) or postoperatively (for patients who have undergone pre-referral excisional biopsy) to a dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks. Surgical resection of the post-treatment tumor mass performed 4 to 8 weeks after the final dose of gemcitabine. Gemcitabine administered intravenously (IV) on days 1, 8, 22, 29, 43, and 50, concurrently with radiotherapy. Starting dose of gemcitabine 400 mg/m2 by vein once a week.
62146138|NCT03540329|ACTIVE_COMPARATOR|I-A Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in patients in growing age.
61970936|NCT00934973|ACTIVE_COMPARATOR|methylcellulose + CBT website support|methylcellulose 3 tablets twice a day and access to website with nurse support
61970937|NCT00934973|PLACEBO_COMPARATOR|placebo + CBT website with support|placebo tablets and access to website with nurse support
61970938|NCT00594984|ACTIVE_COMPARATOR|Arm 1 - Phase 1|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
61970939|NCT00594984|PLACEBO_COMPARATOR|Arm 2 - Phase 2|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
61970940|NCT00812656||Stroke Panel group|Patients undergoing cardiac surgery with the use of cardiopulmonary bypass
61970941|NCT02322918||Participants admitted to BCPP|Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
61970942|NCT03718585||nocturnal group|Chronic kidney disease patients with nocturnal hypertension
61970943|NCT03718585||non-nocturnal group|Chronic kidney disease patients without nocturnal hypertension
61970944|NCT03718585||non-CKD group|patients without chronic kidney disease
62146139|NCT03540329|ACTIVE_COMPARATOR|I-A External distraction|External osteogenesis distractor in congenital mandibular deformities in patients in growing age.
62146140|NCT03540329|ACTIVE_COMPARATOR|I-B Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in adult patients.
62146141|NCT03540329|ACTIVE_COMPARATOR|I-B External distraction|External osteogenesis distractor in congenital mandibular deformities in adult patients.
62146142|NCT03540329|ACTIVE_COMPARATOR|II-A Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in patients in growing age
61970945|NCT01652560||bevacizumab combined neoadjuvant chemotherapy|
62146143|NCT03540329|ACTIVE_COMPARATOR|II-A External distraction|External osteogenesis distractor in acquired mandibular deformities in patients in growing age
62146144|NCT03540329|ACTIVE_COMPARATOR|II-B Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in Adult patients.
62146145|NCT03540329|ACTIVE_COMPARATOR|II-B External distraction|External osteogenesis distractor in acquired mandibular deformities in Adult patients.
62146146|NCT01920126|EXPERIMENTAL|Sodium bicarbonate group|Sodium bicarbonate group
62146147|NCT01920126|PLACEBO_COMPARATOR|Saline group|Saline group
62146148|NCT03353610||Patient-reported PSVT.|Participants who recorded a PSVT diagnosis.
62146149|NCT03353610||Suspected PSVT.|Participants who do not record a PSVT diagnosis.
61970946|NCT04357678|EXPERIMENTAL|Qi Gong Programme|Qi Gong Programme
61970947|NCT04357678|EXPERIMENTAL|Short Form Sun Style Tai Chi|Short Form Sun Style Tai Chi
61970948|NCT02520843|EXPERIMENTAL|Crohn's disease treated by SVF|Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection
61970949|NCT05513066||Ephedrine/phenylephrine mixture|10 mL of 0.75 mg/ml ephedrine and 10 mL of 37.5 μg/ml phenylephrine are mixed in a 20 mL syringe. The speed is generally started at 20 ml/h and then adapted according to blood pressure.
61970950|NCT05513066||baby noradrenaline|20 mL of baby norepinephrine 10µg/mL is prepared in a 50 mL syringe. The speed is generally started at 30 ml/h and then adapted according to blood pressure.
61970951|NCT00847704|EXPERIMENTAL|Test treatment group|Device: Assisted movement and enhanced sensation
61970952|NCT03210376|EXPERIMENTAL|Deep Neuromuscular Blockade (NMB) + Sugammadex|"Deep Neuromuscular Blockade (NMB) given during surgery.~Sugammadex intravenously as a single bolus injection after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
61970953|NCT03210376|EXPERIMENTAL|Moderate Neuromuscular Blockade (NMB) + Neostigmine|"Moderate Neuromuscular Blockade (NMB) given during surgery.~Neostigmine intravenously slowly over a period of at least 1 minute after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
61970954|NCT06195163|EXPERIMENTAL|Study group|Daily 10 mg transdermal testosterone for 21 days prior to the start of ovarian stimulation.
62707717|NCT04290624|EXPERIMENTAL|Intervention Group|Participants will be instructed to use a dentifrice containing 0.454 percent (%) weight by weight (w/w) Stannous fluoride, COREGA denture foaming cleanser and mouth rinse containing 90 parts per million (ppm) sodium fluoride. Participants will brush with a strip of the dentifrice (full brush head) applied to the full length of the toothbrush head for 2 minutes followed by 2 pumps of denture cleanser foam brushed onto removable partial denture (RPD) for 90 seconds and 10 milliliter (ml) of mouth rinse for swished around the mouth for 1 minute. Participants will apply all these products twice daily (morning and evening) for 12 weeks.
62707718|NCT04290624|NO_INTERVENTION|Reference Group|Participants will not be supplied any products and will continue with their existing dental/denture hygiene practices and should not make changes to either their established habits nor to the products they use following screening.
61970955|NCT06195163|ACTIVE_COMPARATOR|Control group|No pre-treatment prior to ovarian stimulation.
61970956|NCT01674270|EXPERIMENTAL|Degarelix|Degarelix Alone
61970957|NCT01674270|EXPERIMENTAL|Degarelix + Casodex|Degarelix and Casodex
61970958|NCT01674270|ACTIVE_COMPARATOR|LHRH Agonist + Casodex|LHRH Agonist and Casodex
61970959|NCT03705676|ACTIVE_COMPARATOR|Healthy controls - control condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
61970960|NCT03705676|EXPERIMENTAL|Healthy controls - fear condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
61970961|NCT03705676|ACTIVE_COMPARATOR|RLBP - control condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
61970962|NCT03705676|EXPERIMENTAL|RLBP - fear condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
61970963|NCT03705676|ACTIVE_COMPARATOR|CLBP - control condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
61970964|NCT03705676|EXPERIMENTAL|CLBP - fear condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
61970965|NCT04268810|EXPERIMENTAL|Chondroitin sulphate 2%|chondoritin sulphate 2% ( Uracyst) for bladder instillation. One bladeer instillation per week during 6 weeks.
61970966|NCT04268810|ACTIVE_COMPARATOR|DMSO 50%|DMSO 50% in saline for bladder instillation. One bladder instillation per week during 6 weeks
61970967|NCT00381095|EXPERIMENTAL|1|flexible dosing
61970968|NCT00381095|PLACEBO_COMPARATOR|2|
61970969|NCT03470818|EXPERIMENTAL|Intervention group|"Preparatory instructional videos (flipped classroom model)~32 participants~Application of a flipped classroom model~Prior to the simulation session, the intervention group will have received the study intervention. This consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
61970970|NCT03470818|SHAM_COMPARATOR|Control group|"Sham videos~Participants in the control group will also be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility.~This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
61970971|NCT04334161||PHH patients|Patients with Roux-en-Y gastric bypass ≥1 year ago and confirmed postprandial hyperglycaemic hypoglycaemia (PHH). PHH is defined as postprandial plasma or sensor glucose\<3.0mmol/l according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
61970972|NCT04334161||non-PHH gastric bypass patients|Patients with Roux-en-Y gastric bypass ≥1 year ago without evidence of PHH.
61970973|NCT04334161||non-PHH sleeve gastrectomy patients|Patients with sleeve gastrectomy ≥1 year ago without evidence PHH.
61970974|NCT04334161||non-PHH non-surgical controls|Absence of any conditions or previous surgery known to affect gastro-intestinal integrity and food absorption.
62146150|NCT03353610||Other subgroups.|Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.
62146151|NCT01989416|PLACEBO_COMPARATOR|Soap bathing|ICU patients will be bathing with soap at least once daily
62146152|NCT01989416|EXPERIMENTAL|2% chlorhexidine wipes|Use 2% chlorhexidine wipes to clean the patient at least once daily
62146153|NCT04796792|EXPERIMENTAL|Treatment group|This study is currently in Phase 1 where all subjects undergo the investigational study.
62146154|NCT05300594|EXPERIMENTAL|Audistim|The participants ingest the experimental product every day for 3 months. The experimental product contains a combination of plant extracts, vitamins and trace elements presented in 2 formulas: a day tablet (to be swallowed in the morning) and a night tablet (to be swallowed in the evening before going to bed).
62146155|NCT05300594|PLACEBO_COMPARATOR|Placebo|Participants ingest the placebo product every day for 3 months .The placebo is strictly identical in appearance to the experimental product and contains only excipients.
62146156|NCT02483468|EXPERIMENTAL|tDCS|Active Transcranial Direct Current Stimulation - Stimulation of the left dorsolateral prefrontal cortex with 2mA of electrical current
62146157|NCT02483468|SHAM_COMPARATOR|tDCS (sham)|Inactive (sham) Transcranial Direct Current Stimulation
62146158|NCT05918107|OTHER|PM8002+pemetrexed+platinum|Subjects will be administered with PM8002 plus pemetrexed+platinum via intravenously (IV) Q3W for 4-6 cycles,followed by PM8002 until disease progression intolerable toxicity for a maximum of 2 years.
62146159|NCT04799366||MC|MC patients with either dominant (Thomsens) or recessive (Becker) myotonia.
62146160|NCT04799366||Healthy Controls|Healthy controls age- and gender matched.
62146161|NCT03044457|EXPERIMENTAL|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
62146162|NCT03044457|ACTIVE_COMPARATOR|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
62146163|NCT05575505|NO_INTERVENTION|Control Group|Mesalamine group, who will receive 1 g mesalamine three times daily for 6 months.
62146164|NCT05575505|ACTIVE_COMPARATOR|Pentoxifylline group|The pentoxifylline group will receive 1 g mesalamine three times daily plus pentoxifylline 400 mg two times daily for 6 months.
62146165|NCT06494566|ACTIVE_COMPARATOR|Omega-3|Omega-3 2000mg (940mg of EPA and 660mg of DHA) in gastro resistant capsule by mouth once a day for 90 days, starting on day sixteen after surgery.
62146166|NCT06494566|PLACEBO_COMPARATOR|Placebo|Mineral oil capsule by mouth once a day for 90 days, starting on day sixteen after surgery.
62146167|NCT04009772|ACTIVE_COMPARATOR|"Cefepime , Maxipime® 1 gm"|"Patient will receive Cefepime ,Maxipime® 1 gm IV during cesarean section just before skin incision"
62146168|NCT04009772|ACTIVE_COMPARATOR|"Cefuroxime, Zinnat® 1gm plus metronidazoleFlagyl® 500"|"Patient will receive Cefuroxime, Zinnat® 1gm ,and metronidazoleFlagyl® 500 IV; just before skin incision for emergency cesarean section"
62146169|NCT01883609|ACTIVE_COMPARATOR|Group 1|Group 1 receive combination vaccination strategy: RTS,S/AS01B at weeks 0, ChAd63 ME-TRAP at week 2, RTS,S/AS01B at weeks 4 and 8, then MVA ME-TRAP at week 10 followed by sporozoite challenge (mosquito bite) at week 12.
62510797|NCT02117388|EXPERIMENTAL|Combined Therapy Treatment for Insomnia|Combined Therapy involves combining Sleep Restriction and Cognitive Therapy so that the two therapies reinforce each other.
62510798|NCT05237128|EXPERIMENTAL|Very low-carbohydrate diet|
62510799|NCT05237128|EXPERIMENTAL|Moderate-carbohydrate plate-method diet|
61970975|NCT01735682|EXPERIMENTAL|Whole body vibration|This group will receive whole body vibration and conventional exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
61970976|NCT01735682|ACTIVE_COMPARATOR|Conventional exercise|This group will receive convention exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
61970977|NCT01735682|ACTIVE_COMPARATOR|Control|This group will have exercise training that involve only the upper limbs (about 30 minutes per session, 3 sessions per week, for 8 consecutive weeks).
61970978|NCT02245308|EXPERIMENTAL|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
61970979|NCT02245308|ACTIVE_COMPARATOR|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
61970980|NCT02637453|ACTIVE_COMPARATOR|PVI|Pulmonary vein isolation (PVI)
61970981|NCT02637453|EXPERIMENTAL|PVI+6L|PVI plus 6 additional lines at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
61970982|NCT04644627|EXPERIMENTAL|Single arm|Each patient serves as its own control: one half is treated with the study treatment in addition to standard wound therapy, the other half receives standard wound therapy only.
61970983|NCT03441776|OTHER|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
61970984|NCT03441776|OTHER|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
61970985|NCT05633420|EXPERIMENTAL|Pyramax|pyronaridine-artesunate (180/160 mg)
61970986|NCT00949897|ACTIVE_COMPARATOR|Biofoam|
61970987|NCT00949897|ACTIVE_COMPARATOR|Iliac Crest Allograft with locked plate|
61970988|NCT02003820|EXPERIMENTAL|Group 1|Group 1 will receive plaque index exam and immediately start their three week intervention of watching a dental hygiene video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
61970989|NCT02003820|EXPERIMENTAL|Group 2|Group 2 will receive plaque index exam and immediately start their three week intervention of watching a control video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
61970990|NCT04716569|EXPERIMENTAL|intranasal Ivermectin group|Ivermectin group Patients who will receive intranasal ivermectin
61970991|NCT04716569|OTHER|Control group|patients who will receive regular protocol drugs
61970992|NCT05619081|EXPERIMENTAL|NAP GROUP|30min of Powernap before second performance measure
61970993|NCT05619081|NO_INTERVENTION|NO NAP GROUP|30min of free quiet occupation before second performance measure
61970994|NCT01618994||Expert Surgeons|Gynecologic robotic surgeons, each averaging \>75 robotic cases per year
61970995|NCT01618994||Study Surgeons|Gynecologic surgeons who are completely naive to robotics
61970996|NCT01618994||Control Surgeons|Gynecologic surgeons with full robotic privileges but were not averaging more than 2 cases a month and had never used the simulator
61970997|NCT05708287|EXPERIMENTAL|all patients|
61970998|NCT01031069|EXPERIMENTAL|HIV+/Cervarix Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
62146170|NCT01883609|ACTIVE_COMPARATOR|Group 2|Group 2 receive three vaccinations (RTS,S/AS01B) at weeks 0, 4 and 8 followed by sporozoite challenge (mosquito bite) at week 12.
62146171|NCT01883609|NO_INTERVENTION|Group 3|Groups 3 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 3 will undergo sporozoite challenge at the same time as Group 1 and 2 volunteers (week 12).
62146172|NCT01883609|NO_INTERVENTION|Group 4|Group 4 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 4 volunteers will be used as infectivity controls if any volunteers from groups 1 and 2 are rechallenged 5 - 7 months after the initial CHMI. CHMI may be administered in two separate cohorts if necessary due to limitations on volunteer availability.
62146173|NCT00597376|EXPERIMENTAL|1|On Cerefolin NAC and open-label multivitamin supplement
62351928|NCT03330041|EXPERIMENTAL|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
62510800|NCT05364437|ACTIVE_COMPARATOR|Dietary Fibres Supplement|Dietary fibre mix comprising of inulin, pectin and oat beta-glucan. The mix comes in a powdered form which can be added to participants' food.
62510801|NCT05364437|PLACEBO_COMPARATOR|Placebo|Placebo comprising of cellulose which will come in a powdered form that can be added to participants' food.
62510802|NCT02814955||referred for paroxysmal atrial fibrillation with fluindione|
62510803|NCT02814955||referred for paroxysmal atrial fibrillation with previscan|
62707719|NCT02523950|ACTIVE_COMPARATOR|Staged group|Procedure/Surgery: Phacoemulsification + IOL implantation is performed in the first stage and DMEK is performed secondarily.
61970999|NCT01031069|ACTIVE_COMPARATOR|HIV+/Gardasil Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
61971000|NCT01031069|EXPERIMENTAL|HIV-/Cervarix Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
61971001|NCT01031069|ACTIVE_COMPARATOR|HIV-/Gardasil Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
61971002|NCT06503224|EXPERIMENTAL|Anti-BCMA and CD19 CART|Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of Anti-BCMA and CD19 CART will be infused on day 0.
61971003|NCT03334448|EXPERIMENTAL|LY900014-U200|Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
61971004|NCT03334448|EXPERIMENTAL|LY900014-U100|Single SC dose of 15 U LY900014 U-100 in two of four study periods
61971005|NCT00911820|ACTIVE_COMPARATOR|Arm A: PCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally, on days 1 and 8 of each cycle, patients received cisplatin 30 mg/m2 IV over 30 minutes and then irinotecan 65 mg/m2 IV over 30 minutes of each 3-week cycle. Treatment could continue until disease progression or unacceptable toxicity.
61971006|NCT00911820|ACTIVE_COMPARATOR|Arm B: TPCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally on days 1 and 8 of each cycle, patients received docetaxel 30 mg/m2 IV over 30 minutes followed by cisplatin 25 mg/m2 IV over 30 minutes and then irinotecan 50 mg/m2 IV over 30 minutes of each 3-week cycle.
61971007|NCT05115734||Short stayers|Determination of the acylcarnitine profile during the 5 days following discharge of a short stay in ICU (maximum 2 days)
61971008|NCT05115734||Long stayers|Determination of the acylcarnitine profile during the year following discharge of a prolonged stay in ICU (7 days or more)
62146174|NCT00597376|PLACEBO_COMPARATOR|2|On placebo and open label multivitamin supplement
62146175|NCT00059826|EXPERIMENTAL|Interferon-based chemoradiation therapy|"Cycle 1: Chemoradiotherapy (CRT)~* 5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs~* cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)~* IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks~* XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks~Cycles 2 and 3: Post-CRT Chemotherapy~Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).~-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest"
62146176|NCT04784650|OTHER|Pre-dialysis population|Pre-dialysis population, consisting both Diabetes Mellitus (DM) and non-DM patients
62351929|NCT03076918|ACTIVE_COMPARATOR|Conventional PDT|Aktilite® Galderma
62351930|NCT03076918|EXPERIMENTAL|FLEXITHERALIGHT PDT|Light Emitting Textile Device
62351931|NCT05099237|ACTIVE_COMPARATOR|1. Colorectal Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with colorectal cancer who are about to start treatment. Participants will be asked to:~* Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~* Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-C survey).~* Report specific symptoms on an ad-hoc basis as they wish."
62510804|NCT02814955||referred for paroxysmal atrial fibrillation with apixaban|
62510805|NCT02814955||referred for paroxysmal atrial fibrillation with rivaroxaban|
62510806|NCT02814955||referred for paroxysmal atrial fibrillation with dabigatran|
62510807|NCT05583682|EXPERIMENTAL|Nano-filled resin-modified glass ionomer restoration|One of the carious mandibular first molar teeth will be restored according to randomisation with nano-filled resin-modified glass ionomer restorative material (Ketac N 100/3M ESPE, USA)
62707720|NCT02523950|ACTIVE_COMPARATOR|Combined group|Procedure/Surgery: Phacoemulsification + IOL implantation and DMEK are performed simultaneously.
62707721|NCT00716157||Observation|Adult patients receiving both radiation therapy and chemotherapy
62510808|NCT05583682|EXPERIMENTAL|Sub-micron hybrid resin composite|One of the carious mandibular first molar teeth will be restored according to randomisation with sub-micron hybrid resin composite restorative material (Spectrum TPH3, Dentsply Caulk, USA)
62510809|NCT01953094|OTHER|Anal Screening Pap Smear - Negative|Anal Pap Smear with no High Resolution Anoscopy
62510810|NCT01953094|OTHER|Anal Pap Smear - Positive Result - High Resolution Anoscopy|Patient who have a positive anal pap smear will go on to have a high resolution anoscopy.
62510811|NCT05732272|ACTIVE_COMPARATOR|Standard Treatment|250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
62510812|NCT05732272|ACTIVE_COMPARATOR|Extended Treatment|250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
62510813|NCT06318832|EXPERIMENTAL|Internet Delivered Cognitive Behavioural Therapy (ICBT)|ICBT: Participants will receive the 10-week tailored ICBT Wellbeing program consisting of 1) education about how taking on the role of care-partner can impact emotional and cognitive wellbeing through introduction to the CBT model; 2) structured problem solving; 3) cognitive therapy and thought challenging to manage one's wellbeing and impact of caregiving; 4) building communication and intimacy; 5) physical symptoms of depression (i.e., hypo-arousal), anxiety/anger (i.e., hyper-arousal); practicing behavioural activation and controlled relaxation; 6) overdoing-underdoing cycle of activity levels and issues around the fear avoidance of social, physical, and cognitive activities; practicing activity pacing and gradually tackling avoidance; 7) occurrence of setbacks in thought, physical, behavioural, and cognitive symptoms; signs of setbacks and creating setback plans.
62510814|NCT06318832|ACTIVE_COMPARATOR|ICBT and Therapist Guidance (TG)|ICBT Therapist Guidance: Weekly Guidance will be provided by a Guide who is a registered social worker with a Master's in Social Work. The Guide will spend \~15 -20 mins. per week/per participant. Weekly interaction will consist of: 1) assist participants practice skills, reinforce progress, engage with the program; 2) guide participants to learn material, highlight lesson content, answer questions, and problem solve on how to apply skills; 3) provide support through warmth and concern; 4) monitor symptoms and risk management.
62510815|NCT06318832|ACTIVE_COMPARATOR|ICBT and Peer Support (PS)|ICBT Focused Peer Group Discussion: The focused discussion will take the form of a group based virtual session of approximately 6-8 participants in each group The Groups will be moderated by a Spinal Cord Injury Ontario Client Services team member once every two weeks for the duration of the 10-week program.
62707722|NCT01103414|EXPERIMENTAL|Mitoglitazone 50 mg capsules|Mitoglitazone 50 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
62146177|NCT00386399|EXPERIMENTAL|Arm 1|Patients with BRCA2 gene will be treated with Mitomycin-C (MMC) on Day 1 at a dose of 10mg/m2 intravenously. This will be repeated every 28 days, which is one cycle. Treatment will continue until disease progression, serious toxicity, patient withdrawal or maximum cumulative dose of 60 mg/m2
62351932|NCT05099237|ACTIVE_COMPARATOR|2. Lung Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with lung cancer who are about to start treatment. Participants will be asked to:~* Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~* Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-L survey).~* Report specific symptoms on an ad-hoc basis as they wish."
62351933|NCT05099237|ACTIVE_COMPARATOR|3. Haematological Cancer|"Participants (with haematological malignancy about to start treatment with CAR T-cell therapy or another cellular therapy product) will be asked to:~* Wear an OURA ring and Withings ScanWatch for approx five weeks including whilst they are in hospital (prior to CAR T-cell therapy and continue for 28 days post infusion)~* Wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.~* Supported to take daily weights using Withings Body Scale.~* Asked to complete weekly electronic quality of life surveys~* Provide a series of 12 blood samples to measure inflammatory molecules at various intervals"
62351934|NCT04752943|EXPERIMENTAL|Children and caregivers receiving TipsByText messages|
62351935|NCT04752943|NO_INTERVENTION|Children and caregivers not receiving TipsByText texts|
62351936|NCT00361894|EXPERIMENTAL|Arm 1|
62351937|NCT00361894|ACTIVE_COMPARATOR|Arm 2|
62351938|NCT01926470|EXPERIMENTAL|anteroposterior approach group|anteroposterior approach group
62351939|NCT01926470|ACTIVE_COMPARATOR|oblique approach group|oblique approach group
62351940|NCT05610358|EXPERIMENTAL|Intervention|Participants in the intervention group will be provided the smartphone application and they will practice application based rehabilitation for 12 weeks.
62351941|NCT05610358|NO_INTERVENTION|Control|Participants in the control group will not practice rehabilitation program.
62146178|NCT03494413|EXPERIMENTAL|20 patients (1-20) validation arm|Accuracy of cerebral flow measurement between TPS and CDS in 20 patients undergoing cardiovascular surgery with cardiopulmonary bypass
62146179|NCT03494413|EXPERIMENTAL|20 patients (21-40) HCA arm|Assessment and comparison of TPS and CDS in hypothermic circulatory arrest (HCA) during cardiovascular surgery
62146180|NCT01794299|EXPERIMENTAL|ATIR|
62351942|NCT01313832|EXPERIMENTAL|remote ischemic preconditioning|
62351943|NCT03505749|EXPERIMENTAL|TI-MBRP|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
62510816|NCT06318832|ACTIVE_COMPARATOR|ICBT and Booster (B)|"ICBT~Booster sessions: Participants allocated to receive booster sessions will have access to a booster module at 16 weeks post enrollment. The booster module will include online materials that review core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure. The module will also discuss how to maintain motivation and continue to practice skills regularly. The Booster module will also include a Do-It-Yourself Guide for participants to print and practice the skills they have learned throughout the course."
62510817|NCT06318832|ACTIVE_COMPARATOR|ICBT+TG+PS|ICBT and TG and PS
62510818|NCT06318832|ACTIVE_COMPARATOR|ICBT+TG+B|ICBT and TG and B
62510819|NCT06318832|ACTIVE_COMPARATOR|ICBT+PS+B|ICBT and PS and B
62510820|NCT06318832|ACTIVE_COMPARATOR|ICT+TG+PS+B|ICBT and TG and PS and B
62510821|NCT04654234||Total-body PET/CT (uExplorer)|Patients with locally advanced NSCLC will receive total-body PET/CT (uExplorer) scans before, during and after the treatment
62510822|NCT01046578|EXPERIMENTAL|Single Dose 12mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
62510823|NCT01046578|EXPERIMENTAL|Single Dose 18mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
62510824|NCT01046578|EXPERIMENTAL|Single Dose Post Ovulation|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation
62510825|NCT01046578|EXPERIMENTAL|Multi Dose 12mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
62510826|NCT01046578|EXPERIMENTAL|Multi Dose 18mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
62510827|NCT01046578|EXPERIMENTAL|Multi Dose Post Ovulation|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation
61971009|NCT05977582|EXPERIMENTAL|Spanish Version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
61971010|NCT05977582|ACTIVE_COMPARATOR|Psychoeducational Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
61971011|NCT03519932|EXPERIMENTAL|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
61971012|NCT03519932|ACTIVE_COMPARATOR|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
61971013|NCT01894191|ACTIVE_COMPARATOR|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
61971014|NCT01894191|ACTIVE_COMPARATOR|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy.
61971015|NCT01894191|ACTIVE_COMPARATOR|water exchange|Water will be infused and removed during insertion phase of colonoscopy
62707723|NCT01103414|EXPERIMENTAL|Mitoglitazone 100 mg capsules|Mitoglitazone 100 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
62707724|NCT01103414|EXPERIMENTAL|Mitoglitazone 150 mg capsules|Mitoglitazone 150 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
61971016|NCT01548521|EXPERIMENTAL|Oxytocin|
61971017|NCT00569569|EXPERIMENTAL|1|Patients treated with Retaane
61971018|NCT05576714||encephalopathy/encephalitis|Children will be classified as the following four diagnoses: 1. Encephalopathy (MERS, ANEC, ASED); 2. Acute encephalitis; 3. ADEM; 4. Fulminant cerebral edema. The classification will be adjudicated and discussed by neurology and critical care experts on the NTUH and CGMH study team (W.T.L, J.J.L, and K.L.L.)
62146181|NCT03332875|EXPERIMENTAL|OurRelationship - 1 Coach Call|OurRelationship online program plus a single call with a coach.
62146182|NCT03332875|EXPERIMENTAL|OurRelationship - 4 Coach Calls|OurRelationship online program plus four calls with a coach.
62707725|NCT01103414|ACTIVE_COMPARATOR|Pioglitazone 45 mg capsules|Pioglitazone 45 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
62707726|NCT01103414|PLACEBO_COMPARATOR|Matching placebo|Placebo capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
62707727|NCT01518413|EXPERIMENTAL|Combination Therapy|Three to 6 patient will be enrolled at each dose level and dose escalations will proceed in the absence of dose-limiting toxicity attributed to therapy, first with dose escalation of sorafenib and then, if tolerated, escalation of irinotecan.
62707728|NCT04378868|ACTIVE_COMPARATOR|Surgery within 8 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
62146183|NCT02955966|EXPERIMENTAL|Patient with invasive pulmonary aspergillosis|Blood collection and imaging 18F-FDG-PET/CT
62510828|NCT01046578|NO_INTERVENTION|Control|No intervention given, followed for course of study on a natural cycle
62510829|NCT01279655|EXPERIMENTAL|tDCS and training|Transcranial Direct current stimulation (tDCS) is applied together with a bimanual learning task. tDCS is delivered through two gel-sponge electrodes (eldith DC Stimulator, neuroConn GmbH, Ilmenau, Germany) embedded in a saline-soaked solution. tDCS will be applied for 20 min, with a current intensity of 1mA.
62510830|NCT01279655|NO_INTERVENTION|Control|No intervention is applied
62510831|NCT01279655|PLACEBO_COMPARATOR|Sham tDCS + Training|The training consists of a bimanual training task. tDCS is only applied for a few seconds and will than be ramped-down.
62510832|NCT05022368|EXPERIMENTAL|Oral Safety Device|"patients on which the device LabraGuard is used."
62510833|NCT05217589|EXPERIMENTAL|Funny/Amusing Video Clips|Participants will watch 5-7-min video clips that are meant to be funny/amusing
62510834|NCT05217589|EXPERIMENTAL|Horror/Scary Video Clips|Participants will watch 5-7-min video clips that are meant to be scary
62510835|NCT05217589|EXPERIMENTAL|Thrilling/Suspenseful Video Clips|Participants will watch 5-7-min video clips that are meant to be thrilling/suspenseful
62707729|NCT04378868|EXPERIMENTAL|Surgery within 24 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
62707730|NCT04378868|EXPERIMENTAL|Surgery within 8 hours, antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
62707731|NCT04378868|EXPERIMENTAL|Surgery within 24 hours, antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
62707732|NCT00135083|EXPERIMENTAL|1|"Once daily:~* Insulin glulisine Dosing: Supper, Lunch, Breakfast~* Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch"
62707733|NCT00135083|EXPERIMENTAL|2|"Twice daily:~* Insulin glulisine Dosing: Supper \& Lunch, Lunch \& Breakfast, Breakfast \& Supper~* Monitoring Needed at: Bedtime \& Pre-Supper, Pre-Supper \& Pre-Lunch, Pre-Lunch \& Bedtime"
62351944|NCT03505749|ACTIVE_COMPARATOR|Standard MBRP|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
62351945|NCT00532428|ACTIVE_COMPARATOR|1|
62351946|NCT00532428|ACTIVE_COMPARATOR|2|
62707734|NCT00135083|EXPERIMENTAL|3|"Twice daily:~* Insulin glulisine Dosing: Supper, Lunch, Breakfast~* Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch"
62351947|NCT00532428|PLACEBO_COMPARATOR|3|
61971019|NCT05576714||MIS-C|The following 6 criteria for MIS-C have to be met: age 0 to 19 years, fever for ≥3 days, clinical signs of multisystem involvement (at least 2 systems), elevated markers of inflammation (e.g., CRP, procalcitonin or ferritin), evidence of SARS-CoV-2 infection and no other obvious microbial cause of inflammation.
62351948|NCT05570799|NO_INTERVENTION|Control group|No augmented reality or Kahoot game-based learning group (traditional lectures group)
62351949|NCT05570799|EXPERIMENTAL|Experimental group|Augmented reality learning and Kahoot game group
62351950|NCT01392378|EXPERIMENTAL|Group 1|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
62351951|NCT01392378|EXPERIMENTAL|Group 2|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
62351952|NCT01392378|EXPERIMENTAL|Group 3|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
62351953|NCT01392378|EXPERIMENTAL|Group 4|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
62351954|NCT01392378|EXPERIMENTAL|Group 5|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
62351955|NCT06431178|ACTIVE_COMPARATOR|General anesthesia|"General anesthesia will be induced by 6% sevoflurane with a face mask. An intravenous line(22-g cannula )will be inserted then fentanyl 1mcg-kg will be given . Endotracheal tube will be used to intubate the patient .Anesthesia will be maintained by 2%sevoflurane inhalation in an oxygen air compination 1:1 throught the operation.~Crystalloid solution was used to replenish fluid according 4/2/1-rule. Monitoring during the procedure include , ejection fraction (EF),blood pressure, heart rate, respiratory rate, and O2 saturation are measured at baseline, after induction, 10 min after catheter insertion,30 min during procedure and post emergence."
62351956|NCT06431178|EXPERIMENTAL|Local anesthesia|A nasal cannula was placed and oxygen delivered at 2 to 3 L/minute. An intravenous line will be inserted (22-g cannula). The sedation regimen will include loading dose of dexmedetomidine (1 mcg/kg) and ketamine (1mg/kg) over 10 minutes . The patient will receive an infusion of dexmedetomidine at 0.7 mcg/kg per hour and ketamine 0.5 mg/kg/hr as maintenance sedation .Local infilteration of xylocaine 2% at dose 2mg/kg will be given for vascular access in cardiac catheterization . After completion of the procedure the infusion pump will be stopped to ensure that the patient is fully awake and vitally stable
62351957|NCT06524427|EXPERIMENTAL|RATS group|Patients will receive robot-assisted lobectomy
62351958|NCT06524427|ACTIVE_COMPARATOR|VATS group|Patients will receive video-assisted lobectomy
62351959|NCT03125759||Control|patients without any history of stroke
62510836|NCT04147962||Patients with dry eye disease with meibomian gland dysfunction|"Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations).~- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light"
62510837|NCT02464488||Main cohort (only cohort of the study)|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly
61971020|NCT05576714||control group|Age and gender matched healthy control children or mild COVID-19 cases without MIS-C will be also included for further comparison
62510838|NCT00692952|EXPERIMENTAL|1|120 subjects using BenZalkonium Chloride Contraceptive Gel
61971021|NCT03520803|EXPERIMENTAL|Experimental|ERAS protocol
61971022|NCT03520803|NO_INTERVENTION|Control|Standard of care
62510839|NCT00692952|ACTIVE_COMPARATOR|2|120 subjects using Nonoxynol-9 contraceptive gel
62510840|NCT04823819|ACTIVE_COMPARATOR|rTMS stimulation|20 sessions of stimulation with increasing intensity, reaching maximum in the 4th session.
62510841|NCT04823819|ACTIVE_COMPARATOR|tDCS stimulation|The stimulation time will be 20 minutes, the current intensity will be 2mA.
62510842|NCT04823819|SHAM_COMPARATOR|Sham rTMS stimulation|20 sessions of stimulation, but without current.
62510843|NCT04823819|SHAM_COMPARATOR|Sham tDCS stimulation|The stimulation time will be 20 minutes, but without current.
62707735|NCT05599724||CASE|Patients who did not carry a pregnancy to term
61971023|NCT06243991||Control group|Nineteen patiens (20 eyes) received topical polyvinyl alcohol (Refresh, Allergan, Dublin, Ireland) three times daily until epithelial defect closure after CXL in control group.
62146184|NCT04364230|EXPERIMENTAL|All Participants|6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given on days 1, 22, 43, and 64. The vaccine will be given subcutaneously/intradermally.
62146185|NCT02233998|ACTIVE_COMPARATOR|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
62146186|NCT02233998|ACTIVE_COMPARATOR|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
62146187|NCT02233998|PLACEBO_COMPARATOR|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
62351960|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
62351961|NCT04635761|EXPERIMENTAL|Prevention (AIR Program)|Participants complete the Roswell Awareness, Information and Resources for Lung Cancer Screening (AIR) Program over 45 minutes and then receive the High-Risk Lung Cancer Tip Sheet..
62351962|NCT03918772||Perioperative immediate hypersensitivity|Patients having experienced perioperative immediate hypersensitivity
62351963|NCT02553317|EXPERIMENTAL|Caplacizumab|Caplacizumab 10 mg once daily
62351964|NCT02553317|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62351965|NCT00904995|EXPERIMENTAL|Group 1 - Oral|Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
62351966|NCT00904995|EXPERIMENTAL|Group 2 - IV + Oral|Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.
62351967|NCT06016140|EXPERIMENTAL|Intervention group|Medication Plan Prototype
62351968|NCT05066633|PLACEBO_COMPARATOR|Control Group|Matching placebo will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
61971024|NCT06243991||LMW-HA group|Twenty-two patiens (23 eyes) received topical LMW-HA (Thealose Duo®, Thea, Clermont-Ferrand, France) three times daily for 12 months.
62146188|NCT05044416|EXPERIMENTAL|VieScope|intubation with the VieScope laryngoscope
62146189|NCT05044416|ACTIVE_COMPARATOR|Videolaryngoscopy|intubation with videolaryngoscope
61971025|NCT06243991||HMW-HA group|Seventeen patiens (20 eyes) received topical HMW-HA (Comfort Shield®, i.com medical GmbH, Munich, Germany) three times daily for 12 months.
62351969|NCT05066633|EXPERIMENTAL|Treatment Group|Metoprolol succinate will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
62351970|NCT05950971|EXPERIMENTAL|Rate control strategy group|Patients are given diltiazem or esmolol to control heart rate less than 110/min.
62510844|NCT02449473|EXPERIMENTAL|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
62510845|NCT02449473|PLACEBO_COMPARATOR|Placebo Dose Regimen|Placebo Subcutaneous Injection
61971026|NCT00162201|EXPERIMENTAL|1|
61971027|NCT03580694|EXPERIMENTAL|Cemiplimab Monotherapy|In a single dose escalation cohort, participants will receive cemiplimab alone.
62146190|NCT01792557|ACTIVE_COMPARATOR|Phenol|Crystallized Phenol Group
62146191|NCT01792557|ACTIVE_COMPARATOR|Limberg|Limberg Flap Group
62146192|NCT01792557|ACTIVE_COMPARATOR|Modified Limberg|Modified Limberg Flap Group
62146193|NCT01792557|ACTIVE_COMPARATOR|Karydakis|Karydakis Flap Group
62146194|NCT01042184|EXPERIMENTAL|Group A|Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
62351971|NCT05950971|EXPERIMENTAL|Rhythm control strategy group|Patients are given amiodarone for conversion of cardiac rhythm to sinus rhythm.
62351972|NCT05606978|EXPERIMENTAL|FASTb|Participants receive FAST blended (FASTb): a combination of face-to-face and online therapy
62510846|NCT04735731||EBV-patients|Patients who are scheduled for a bronchoscopic lung volume reduction treatment using endobronchial valves
62707736|NCT05599724||CONTROL|patients who carried a pregnancy to term
62707737|NCT02646410|OTHER|FPD+NDOT|Fixed-point delivery (FPD) combined with non directly observed treatment (NDOT)
62707738|NCT02646410|OTHER|FPD+DOT|Fixed-point delivery (FPD) combined with directly observed treatment (DOT)
62707739|NCT02646410|OTHER|DDD+NDOT|door-to-door delivery (DDD) combined with non directly observed treatment (NDOT)
62707740|NCT02646410|OTHER|DDD+DOT|door-to-door delivery (DDD) combined with directly observed treatment (NDOT)
62510847|NCT01868282|EXPERIMENTAL|Group 1|Hamstrings block
62510848|NCT01868282|ACTIVE_COMPARATOR|Group 2|Obturator block
62510849|NCT01868282|SHAM_COMPARATOR|Group 3|Control group
62510850|NCT04436926|EXPERIMENTAL|opioid approach bias training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of opioid approach bias modification taking place over two weeks.
62510851|NCT04436926|SHAM_COMPARATOR|sham training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of sham training taking place over two weeks.
62146195|NCT01042184|EXPERIMENTAL|Group B: Sequential therapy for 10 days|
62146196|NCT01042184|ACTIVE_COMPARATOR|Group C: Triple therapy for 14 days|
62146197|NCT02542696|EXPERIMENTAL|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
62146198|NCT01399606|EXPERIMENTAL|BF2.649|
62146199|NCT05383989|EXPERIMENTAL|UniVenture- face-to-face (in-person format)|Personality-matched wellness program condition in face-to-face format (i.e., high AS student receives face-to-face AS program; high HOP student receives face-to-face HOP workshop: high SS student receives face-to-face SS workshop; high IMP student receives face-to-face IMP workshop)
62146200|NCT05383989|ACTIVE_COMPARATOR|UniVenture- online (distance-delivery format)|Personality-matched wellness program condition in distance-delivery format (i.e., high AS student receives online (distance-delivered) AS workshop; high HOP student receives online (distance-delivered) HOP workshop: high SS student receives online (distance-delivered) SS workshop; high IMP student receives online (distance-delivered) IMP workshop
62146201|NCT05383989|PLACEBO_COMPARATOR|UniVenture- service as usual (control)|Services-as-usual offered by the respective university
62146202|NCT05211596|OTHER|Single Intervention Arm (Main Intervention)|Main Intervention
62146203|NCT04529928|EXPERIMENTAL|Implanted|Subjects successfully implanted with the Carillon Mitral Contour System
62146204|NCT02662205|ACTIVE_COMPARATOR|Traditional Group|Traditional process psychotherapy group
62146205|NCT02662205|EXPERIMENTAL|Yoga Therapy Group|Psychotherapy group integrating yoga and process dialogue
62146206|NCT02662205|ACTIVE_COMPARATOR|Yoga Class|Yin yoga class
62146207|NCT00316797|EXPERIMENTAL|123-I INER|To assess 123-I INER
62146208|NCT04817293||COVID-19 positive|
62351973|NCT05606978|ACTIVE_COMPARATOR|FASTr|Participants receive FAST regular (FASTr): face-to-face therapy
62510852|NCT04945018|EXPERIMENTAL|HS-001 Low dose|HS-001 Low dose Administration
62510853|NCT04945018|EXPERIMENTAL|HS-001 High dose|HS-001 High dose Administration
62146209|NCT04817293||COVID-19 negative|
62146210|NCT02196337||Women of reproductive age|Age: 18-44 years
62146211|NCT02196337||Pregnant women|Age: 18-44 years
62146212|NCT02196337||Lactating women|Age: 18-44 years
62146213|NCT02196337||Young infants|Age: younger than 6 months
62146214|NCT02196337||Toddlers|Age: between 6 and 24 months
62351974|NCT03436771||JCAR017-treated|Patients who received previous treatment with JCAR017
62510854|NCT02040311|EXPERIMENTAL|Topiramate 96 mg daily|
62510855|NCT02040311|EXPERIMENTAL|Topiramate 192 mg daily|
62510856|NCT02040311|PLACEBO_COMPARATOR|placebo|
62146215|NCT02196337||School-aged children|Age: 6-12 years
62146216|NCT01080404|EXPERIMENTAL|Bariatric surgery (overall study)|A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
62146217|NCT01080404|EXPERIMENTAL|Bariatric surgery (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
62146218|NCT01080404|ACTIVE_COMPARATOR|CPAP (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
62146219|NCT01912300|EXPERIMENTAL|Lean adolescents|
62351975|NCT03436771||JCARH125-treated|Patients who received previous treatment with JCARH125
62351976|NCT03119818|EXPERIMENTAL|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
62351977|NCT04409301|EXPERIMENTAL|MSAD Intervention|Children receiving cancer treatment in a hospital randomized to the My Special Aflac Duck (MSAD) intervention.
62510857|NCT05966987|EXPERIMENTAL|i-PRF side: canine retraction|application of i-PRF with translation of maxillary canine that will be performed on intervention sides according to a standardized protocol
62510858|NCT05966987|NO_INTERVENTION|i-prf side control side|i-PRF side:canine retraction control side
62510859|NCT05966987|EXPERIMENTAL|LLLT side canine retraction|translation of maxillary canine that will be performed with LLLT application according to a standardized protocol
62510860|NCT05966987|NO_INTERVENTION|LLLT side canine retraction control side|LLLT side canine retraction control side wihout intervention
62510861|NCT05966987|EXPERIMENTAL|I-PRF groupMolar distalization group inrervention side|Idistalization assisted with Injectable platelet-rich fibrin (i-PRF) according to a standardized protocol
62510862|NCT05966987|NO_INTERVENTION|I-PRF groupMolar distalization group control side|distalization without i-PRF intervention
62707741|NCT04803279||Ponto 3 SuperPower users|"Patients who are fitted either unilaterlaly or bilatterally on abutment since the device came to the market in 2016, and who have follwoed the clinics normal routine fitting and follow up visits.~They must also have undergone the normal procedures performed as part of the clinics routine for fitting and following up. Data will be collected from these routine visits."
62146220|NCT01912300|EXPERIMENTAL|Obese adolescents|
62146221|NCT02941094|ACTIVE_COMPARATOR|angle 30 group|During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
62146222|NCT02941094|ACTIVE_COMPARATOR|angle 50 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 50-60 degree
62351978|NCT04409301|ACTIVE_COMPARATOR|Control Group|Children receiving cancer treatment in a hospital randomized to be a control hospital. Children in the control hospitals will receive the My Special Aflac Duck (MSAD) at the end of the intervention period.
62351979|NCT02278991||Lutonix Drug Coated Balloon|Paclitaxel coated balloon catheter
62351980|NCT03516409|ACTIVE_COMPARATOR|Bio-Kult Infantis|1 sachet once a day mixed with milk, water or food.
62351981|NCT03516409|PLACEBO_COMPARATOR|Placebo|1 sachet once a day mixed with milk, water or food.
62351982|NCT04202549|EXPERIMENTAL|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy
62351983|NCT06410924|EXPERIMENTAL|DD01|Study Drug
62351984|NCT06410924|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62351985|NCT02581982|EXPERIMENTAL|Treatment (pembrolizumab, paclitaxel)|Patients receive pembrolizumab IV over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62351986|NCT04780945|EXPERIMENTAL|Olaparib monotherapy|Patients, irrespective of BRCA status, will be treated with olaparib tablet 300 mg bid
62351987|NCT03101046|OTHER|Group1: Arm A (standard arm) + Arm B (experimental arm)|"Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization.~Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization."
62351988|NCT03101046|OTHER|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having \<5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)
62351989|NCT02633839|EXPERIMENTAL|Adults who smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
62351990|NCT02633839|EXPERIMENTAL|Adults who don't smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
62351991|NCT06031298|EXPERIMENTAL|Alveolar ridge preservation using demineralized dentin graft at 12 weeks.|
62351992|NCT06031298|ACTIVE_COMPARATOR|Alveolar ridge preservation using demineralized dentin graft at 18 weeks|
62351993|NCT06031298|ACTIVE_COMPARATOR|Alveolar ridge preservation using demineralized dentin graft at 24 weeks|
62351994|NCT02487134|PLACEBO_COMPARATOR|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
62351995|NCT02487134|ACTIVE_COMPARATOR|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
62351996|NCT04613999|OTHER|Single Arm|Subjects will receive regimens 50 mcg, 100 mcg and 150 mcg in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
62351997|NCT01174758||Parkinson's disease|Individuals participating in the study have been diagnosed with idiopathic Parkinson's disease.
62351998|NCT01928992||3D|Subjects that undergo 3D mammography
62351999|NCT01928992||2D|Subjects that undergo 2D mammography
62352000|NCT00565214|ACTIVE_COMPARATOR|Group 1|On Day 1, Group 1 will initiate in a double-blinded fashion, a once daily vitamin combination of selenomethionine(400 μg), vitamin E(400 IU), and vitamin C (1000 mg) orally for 30 days at home. After 30 days of treatment with Vitamin supplements, the gene expression of the airway epithelium will be compared to that of the Placebo group.
62352001|NCT00565214|PLACEBO_COMPARATOR|Group 2|On Day 1, Group 2 will initiate the placebo in a double-blinded fashion.
62352002|NCT00889681|EXPERIMENTAL|Ablation|All study subjects will be receive cryo ablation with the experimental devices and, optionally, an Atrial Fibrillation Drug.
62352003|NCT04325906|ACTIVE_COMPARATOR|high flow nasal cannula only|Receive high flow nasal cannula only
62352004|NCT04325906|EXPERIMENTAL|HFNC plus prone positioning|Receive high flow nasal cannula plus prone positioning
62352005|NCT05567393|PLACEBO_COMPARATOR|Part 1 (SRD): Pooled Placebo|TAK-951 placebo-matching, single dose, subcutaneous (SC) injection, on Day 1 in fasted healthy participants in the single-rising dose (SRD) period.
62352006|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 2: TAK-951 Dose 1|TAK-951 Dose 1, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62510863|NCT05966987|EXPERIMENTAL|LLLT group: distalization intervntion side|distalization will be commenced with application of LLLT according to a standardized protocol
62707742|NCT03914690|EXPERIMENTAL|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
61971028|NCT03580694|EXPERIMENTAL|Combination Therapy|"Dose Escalation cohorts:~In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination.~In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination.~Dose Expansion cohorts:~In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab."
61971029|NCT02902419|ACTIVE_COMPARATOR|1|Wound dressing removal was performed between 12-30 hours postoperatively.
62146223|NCT02941094|ACTIVE_COMPARATOR|angle 70 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 60-80 degree
62146224|NCT02085941|EXPERIMENTAL|MRI guided cryoablation +/- biopsy|Intraoperative MRI guidance for cryoablation of tumor using 17G Galil cryoprobe with concurrent biopsy with 18G Temno core biopsy needle if biopsy not previously performed
62146225|NCT02085941|EXPERIMENTAL|PET-CT guided cryoablation +/- biopsy|Intraoperative PET-CT guidance for cryoablation of tumor using 17G Galil cryoprobe with concurrent biopsy with 18G Temno core biopsy needle if biopsy not previously performed
62146226|NCT02736188|EXPERIMENTAL|Drug: Aceneuramic Acid Extended-Release Tablets|Participants will take 4 tablets (500 mg Ace-ER each for 2 g per dose) orally 3 times per day (TID).
62146227|NCT04144088|ACTIVE_COMPARATOR|Wu Ling San|"Drug : Wu Ling San Extract Granules Sun-Ten"
62146228|NCT04144088|ACTIVE_COMPARATOR|Yin-Chen Wu Ling San|"Drug : Yin-Chen-Wu-Ling-San Extract Power SUN-TEN"
62146229|NCT04144088|PLACEBO_COMPARATOR|Placebo|Drug : 1/10 Wu Ling San
62146230|NCT04338919|EXPERIMENTAL|O-APT group|Ticagrelor 90 mg twice daily plus aspirin 100mg once daily in the first month, Ticagrelor 90mg bid between the second and the sixth months Ticagrelor 45mg bid between the seventh and the twelfth months
62146231|NCT04338919|ACTIVE_COMPARATOR|S-APT group|ticagrelor 90 mg twice daily plus aspirin 100mg once daily for 12 months
62146232|NCT04377724||ETH cohort|employees or students at ETH Zurich, Switzerland
62146233|NCT04378413|EXPERIMENTAL|The Effect of Aquatic Exercises on Pain, quality of life|Water-based exercise program was conducted in the second group of 15 patients in an indoor swimming pool. Temperature of mineral water was 36 °C. The program included warming up by walking forwards, sideways and backwards through the water in the pool; active range of motion of the joints of the lower extremities; stretching lower extremities; strengthening exercises for hips, knees, arms, elbows and wrists; and cooling down (slow walking, squatting and standing).
62146234|NCT04378413|EXPERIMENTAL|The Effect of Land Exercises on Pain, Quality of life|Land-based exercise program included abdominal and back strengthening exercises.
62707743|NCT03914690|PLACEBO_COMPARATOR|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
62146235|NCT01939288|EXPERIMENTAL|Group 1|Half of recruited subjects (n=5)
62146236|NCT01939288|EXPERIMENTAL|Group 2|Other half of recruited subjects (n=5)
62510864|NCT05966987|NO_INTERVENTION|LLLT group: distalization control side|distalization will be commenced without application of LLLT according to a standardized protocol
62707744|NCT06022926|ACTIVE_COMPARATOR|Group 1: Patients warmed with electric blankets|"* Patients will be provided with electric blankets from the beginning to the end of the operation (approximately 1 hour)~* all patients will receive standard general anesthesia~* each patient will undergo tympanic temperature measurement immediately before induction of general anesthesia, 20 minutes after induction of anesthesia, immediately after extubation and during exit from the postanesthesia recovery unit.~* the same electric blanket was used for this group of patients~* each time the electric blankets were set to 38 degrees and the blankets were preheated to 38 degrees approximately 30 minutes before the patients were placed on the operating table.~* heat measurements will be made with the same tympanic heat meter device"
61971030|NCT02902419|ACTIVE_COMPARATOR|2|Wound dressing removal was performed between 30-48 hours postoperatively.
61971031|NCT01138033|EXPERIMENTAL|Part 1|Part 1 - dose escalation; starting dose 80 mg BID
61971032|NCT01138033|EXPERIMENTAL|Part 2|Part 2 - Dose expansion phase of the study at the maximum tolerated dose and schedule identified in Part 1 in patients with tumors known to over express FAK
61971033|NCT01138033|EXPERIMENTAL|Part 3|Part 3 - Characterize the biologically active dose range by analysis of PD markers in skin, hair and in tumor tissue in subjects with solid tumors amendable to biopsy and know to over express FAK
61971034|NCT01138033|EXPERIMENTAL|Part 4|Part 4 - Explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM).
62146237|NCT02659540|EXPERIMENTAL|Cohort A (Conventional RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a conventional total palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
62146238|NCT02659540|EXPERIMENTAL|Cohort B (Hypofractionated RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a hypofractionated high-dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
62146239|NCT01229176|EXPERIMENTAL|Vi-CRM, Adults|Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
62146240|NCT01229176|ACTIVE_COMPARATOR|Vi-PS, Adults|Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
62146241|NCT01229176|EXPERIMENTAL|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
62510865|NCT05966987|EXPERIMENTAL|i-PRF group: leveling and alignment|leveling and alignment assisted with Injectable platelet-rich fibrin (i-PRF) according to a standardized protocol
62146242|NCT01229176|ACTIVE_COMPARATOR|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
62146243|NCT01229176|EXPERIMENTAL|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
62146244|NCT01229176|ACTIVE_COMPARATOR|PNC13, Older infants|Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
62510866|NCT05966987|EXPERIMENTAL|LLLT group: leveling and alignment|leveling and alignment be commenced with application of LLLT according to a standardized protocol
62510867|NCT05966987|NO_INTERVENTION|leveling and alignment without intervention|leveling and alignment without intervention
61971035|NCT01138033|EXPERIMENTAL|Part 5|Part 5 will investigate the time course, the extent of an apparent change in the PK of GSK2256098 following repeated dosing, and screen for potential CYP3A induction as a possible mechanism of reduced systemic exposure of GSK2256098 at Day 15 and later time points.
61971036|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
61971037|NCT02365090|ACTIVE_COMPARATOR|patching (occlusion therapy)|2 hours per day patching of the sound eye (for strabismic, anisometropic, and combined mechanism amblyopia) or current patching regimen (deprivation amblyopia)
62146245|NCT01229176|EXPERIMENTAL|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
62146246|NCT01229176|ACTIVE_COMPARATOR|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
62146247|NCT03411382|EXPERIMENTAL|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
62510868|NCT05966987|EXPERIMENTAL|I-PRF group: Intrusion|intrusion assisted with Injectable platelet-rich fibrin (i-PRF) according to a standardized protocol
62510869|NCT05966987|EXPERIMENTAL|LLLT group: Intrusion|intrusion assisted with application of LLLT according to a standardized protocol
62510870|NCT05966987|NO_INTERVENTION|intrusion control group|intrusion without intervention
61971038|NCT02365090|EXPERIMENTAL|binocular games|1 hour per day (5 days per week) binocular game play
62146248|NCT03411382|EXPERIMENTAL|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
62146249|NCT03411382|EXPERIMENTAL|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
62146250|NCT03411382|PLACEBO_COMPARATOR|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
62146251|NCT04573218|PLACEBO_COMPARATOR|Group A|Glucose.
62146252|NCT04573218|ACTIVE_COMPARATOR|Group B|250 mg Oil Palm Phenolics.
62510871|NCT01223235|EXPERIMENTAL|bevacizumab & polyvalent vaccine-KLH conjugate + OPT-821|This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
62510872|NCT03331159|EXPERIMENTAL|NanoBone|The participants were treated with anterior lumbar interbody fusion (ALIF) with a new nanocrystalline hydroxyapatite embedded in a silica gel matrix (NH-SiO2)
62510873|NCT03331159|ACTIVE_COMPARATOR|Homologous bone|The participants were treated with anterior lumbar interbody fusion (ALIF) with homologous bone
62510874|NCT01853241||Single balloon|Single Balloon Enteroscopy
62510875|NCT01853241||Spirus|Spirus Enteroscopy
62510876|NCT00693225|ACTIVE_COMPARATOR|Omeprazole/sodium bicarbonate AM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken in the morning
62510877|NCT00693225|EXPERIMENTAL|Omeprazole/sodium bicarbonate PM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken at bedtime
62510878|NCT00852917|EXPERIMENTAL|1: Tramadol Once A Day 100mg|
62510879|NCT00852917|EXPERIMENTAL|2: Tramadol Once A Day 200mg|
62510880|NCT00852917|EXPERIMENTAL|3: Tramadol Once A Day 300mg|
62146253|NCT03153306|EXPERIMENTAL|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
62146254|NCT03153306|EXPERIMENTAL|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
62146255|NCT02251301|ACTIVE_COMPARATOR|Macronutrient isoenergetic control|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of macro nutrient matched isoenergetic control (whey/casein protein and dextrose/lactose) consumed immediately and 1 h after each training session
62146256|NCT02251301|EXPERIMENTAL|Skim Milk|Participants will also engage in twelve weeks of High intensity interval training with consumption of one serving (250 mL) of fat-free fluid milk immediately and 1 h after each training session
62510881|NCT00852917|PLACEBO_COMPARATOR|4: Placebo|
62510882|NCT02266394|ACTIVE_COMPARATOR|Mesenchymal stem cell delivery|To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.
62510883|NCT02266394|ACTIVE_COMPARATOR|Mesenchymal stem cell delivery with stent placement|To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting.
62510884|NCT04621916|ACTIVE_COMPARATOR|Emicizumab + FVIII weekly|In addition to emicizumab prophylaxis,participants will receive non-prophylactic exposure to FVIII concentrates through weekly 50 IU/kg ±10% doses - the choice of FVIII concentrate is at the discretion of the PI.
62510885|NCT04621916|ACTIVE_COMPARATOR|Emicizumab only|Participants will only receive emicizumab prophylaxis.
62510886|NCT02923414|ACTIVE_COMPARATOR|Standard escalating shocks|Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
62352007|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 1: TAK-951 Dose 2|TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
61971039|NCT02066870|EXPERIMENTAL|Icotinib and arsenic trioxide|"Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.~Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
61971040|NCT05240118||HFmrEF Group|"HFmrEF (Heart failure with mildly reduced ejection fraction): ESC Guideline heart failure 2021: patients with LVEF 41-49%.~non-cardiac events group versus cardiac events (cardiac death or heart failure-related rehospitalization) group"
62510887|NCT02923414|ACTIVE_COMPARATOR|High energy shocks|Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
62146257|NCT02251301|PLACEBO_COMPARATOR|Placebo|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of placebo (water) consumed immediately and 1 h after each training session.
62510888|NCT00493454|EXPERIMENTAL|Ibritumomab tiuxetan + Rituximab|Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
62510889|NCT00804206|EXPERIMENTAL|Group A|Bevacizumab before panretinal photocoagulation.
61971041|NCT05194592|ACTIVE_COMPARATOR|Dapagliflozin group|Dapagliflozin 10mg for 6 months.
62352008|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 15: TAK-951 Dose 2|TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352009|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 3: TAK-951 Dose 3|TAK-951 Dose 3, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352010|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 4: TAK-951 Dose 4|TAK-951 Dose 4, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352011|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 5: TAK-951 Dose 5|TAK-951 Dose 5, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352012|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 6: TAK-951 Dose 6|TAK-951 Dose 6, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352013|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 13: TAK-951 Dose 7|TAK-951 Dose 7, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352014|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 14: TAK-951 Dose 8|TAK-951 Dose 8, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352015|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 16: TAK-951 Dose 9|TAK-951 Dose 9, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352016|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 17: TAK-951 Dose 10|TAK-951 Dose 10, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352017|NCT05567393|EXPERIMENTAL|Part 1 (SRD): Cohort 18: TAK-951 Dose 11|TAK-951 Dose 11, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
62352018|NCT05567393|PLACEBO_COMPARATOR|Part 3 (MRD): Pooled Placebo|TAK-951 placebo-matching, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the multiple-rising dose (MRD) period.
62510890|NCT00804206|EXPERIMENTAL|Group B|Bevacizumab after panretinal photocoagulation
62510891|NCT06064825||patients received the investigational medicinal product acetaminophen in their first 5 days of life|This group of patients received the investigational product in their first 5 days of life during the Treocapa trial
62510892|NCT06064825||patients received the placebo (NaCl) in their first 5 days of life|This group of patients received the placebo in their first 5 days of life during the Treocapa trial
62510893|NCT02972021|OTHER|control|Pure oxygen by nasal cannula group
62510894|NCT02972021|EXPERIMENTAL|HFNC|oxygen by High-flow nasal cannula
61971042|NCT05194592|PLACEBO_COMPARATOR|Gemigliptin group|Gemigliptin 50mg for 6 months.
61971043|NCT02855333||Merendino Group (MER)|Patients who underwent merendino procedure for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
61971044|NCT02855333||Control Group (CON)|Patients who underwent alternative surgery for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
62146258|NCT01291212|ACTIVE_COMPARATOR|Testosterone and FSHr|
62146259|NCT01291212|ACTIVE_COMPARATOR|testosterone and FSHr-LHr|
62352019|NCT05567393|EXPERIMENTAL|Part 3 (MRD): Cohort 10: TAK-951 Dose 1A|TAK-951 Dose 1A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
62352020|NCT05567393|EXPERIMENTAL|Part 3 (MRD): Cohort 11: TAK-951 Dose 2A|TAK-951 Dose 2A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
62352021|NCT05567393|EXPERIMENTAL|Part 3 (MRD): Cohort 12: TAK-951 Dose 3A|TAK-951 Dose 3A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
62352022|NCT05567393|EXPERIMENTAL|Part 3 (MRD): Cohort 20: TAK-951 Dose 4A|TAK-951 Dose 4A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
62352023|NCT03293628|EXPERIMENTAL|Conization With Vaginal Packing|Experimental Arm. Haemostasis at the end of the procedure using vaginal packing and Monsel's solution.
62352024|NCT03293628|ACTIVE_COMPARATOR|Conization Without Vaginal Packing|Haemostasis at the end of the procedure using only Monsel's solution.
62352025|NCT05473104|EXPERIMENTAL|experimental group|Teens and parents participate in the training once a week for 14 consecutive weeks in parallel groups.
62539406|NCT06582056|OTHER|Participant with Stage III/Stage IV Periodontal Disease with no Type 2 Diabetes Mellitus|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
62146260|NCT01873898|EXPERIMENTAL|Single Arm|This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
62146261|NCT01159236|EXPERIMENTAL|Group 1: ER-Positive|"Participants with Estrogen Receptor (ER)-Positive breast cancers receive Standard T/FAC or T/FEC chemotherapy before surgery.~T/FAC or T/FEC: Combination chemotherapy with sequential paclitaxel (80 mg/m2) weekly x 12 weeks followed by 5-fluorouracil (500 mg/m2), cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) or epirubicin (100 mg/m2) (FAC or FEC) once every 3 weeks for 4 treatments."
62146262|NCT01159236|EXPERIMENTAL|Group 2: ER-Negative|Participants with ER-negative cancers (randomized between Group 2 \& Group 3), Standard T/FAC or T/FEC chemotherapy before surgery.
62146263|NCT01159236|EXPERIMENTAL|Group 3: ER-Negative + Bevacizumab|Participants with ER-negative cancers (randomized between Group 2 \& Group 3), T/FEC chemotherapy combined with 10 mg Bevacizumab every 2 weeks during first 3 treatments before surgery.
62510895|NCT06595147|EXPERIMENTAL|Experimental Arm: Structured Exercise Training|Participants randomized to exercise training will be provided with a 12-week structured exercise training program. The program includes 3 weekly sessions of aerobic exercise (e.g treadmill, cycling, elliptical machine) and/or resistance training (i.e lifting weights). The aerobic sessions will include long-endurance (40-60 minutes at moderate intensity), tempo (30-40 minutes at a moderate-vigorous intensity) and high-intensity interval exercise (10-15 intervals of 30-60 seconds at 100% peak aerobic power output, interspersed with 60 seconds of active recovery). Resistance training will include 4-6 lower body exercises performed for 2-3 sets of 8-20 repetitions at a load equivalent to 60-85% of their one repetition maximum. The program will be supervised by an exercise trainer (Clinical Exercise Physiologist, Physiotherapist, Kinesiologist or Research Associate with exercise training experience) and will be individualized each individual's baseline fitness and medical history.
62510896|NCT06595147|ACTIVE_COMPARATOR|Active Comparator: Group-based Yoga and Stretching|Participants allocated to the yoga and stretching group will provided with a once weekly yoga and stretching group class. The classes will consist of a combination of light-intensity yoga, balance and stretching exercises. The yoga and stretching class will be overseen by a yoga instructor, physiotherapist, physiotherapy trainee or research assistant with exercise training background
62510897|NCT06580327|ACTIVE_COMPARATOR|study group|Epidural analgesia will be maintained by receiving programmed intermittent 10ml bolus of 0.1% Bupivacaine and 2microgram\\ml Fentanyl every one hour, until the delivery is completed, and lacerations are sutured.
62510898|NCT06580327|ACTIVE_COMPARATOR|control group|Epidural analgesia will be maintained by receiving 10ml\\h continuous infusion of 0.1% Bupivacaine and 2microgram\\ml Fentanyl until the delivery is completed, and lacerations are sutured.
61971045|NCT06404216|EXPERIMENTAL|Nordic walking group training|"The intervention will consist of 60-minute NW group sessions, twice weekly, for two months (total 16 sessions). Participants will be provided with NW sticks to use during the sessions. Each session will be led by a qualified healthcare professional that received 4 hours NW guidance qualification, and participated in 4 sessions prior to leading one. Current qualified healthcare professionals are 2 physiotherapists, and a certified nurse. Final year physiotherapy students will assist, hence each session will be guided by two members of the research team- a clinician and a student.~A social worker will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period."
62146264|NCT01335100||ambulatory CP|ambulatory children with cerebral palsy undergoing Botulinum toxin injections to lower limbs
62146265|NCT01335100||controls|age and gender matched sibilings
62146266|NCT02454959|EXPERIMENTAL|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
62146267|NCT02454959|EXPERIMENTAL|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
62146268|NCT03862469|OTHER|Study Procedure (all participants)|"Diagnostic Phase (2 months): at-home urine hormone testing and completion of daily online surveys.~Individualized Task (-6 to -2 days from the subsequent menstrual cycle)"
62146269|NCT05387863|EXPERIMENTAL|Decision Aid (DA) Web Tool|
62352026|NCT05473104|NO_INTERVENTION|waiting-list group|Teens and parents participate in the training in a second moment, immediately after the experimental group concluded the program, once a week for 14 consecutive weeks in parallel groups.
62352027|NCT03674333|EXPERIMENTAL|Group A|Folic acid 1mg daily will be given to the participants of Group A.
62146270|NCT05387863|ACTIVE_COMPARATOR|Institutional Pamphlet|
62146271|NCT02240472|NO_INTERVENTION|Axillary clearance|Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis
62146272|NCT02240472|EXPERIMENTAL|No axillary clearance|Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis
62146273|NCT01341769|PLACEBO_COMPARATOR|Control Test Food|Snack base
62352028|NCT03674333|PLACEBO_COMPARATOR|Group B|A Placebo (a sugar pill) will be given to the participants of the Group B.
62352029|NCT03335787|EXPERIMENTAL|Intervention|Taping will be applied three times and will be reapplied one and two weeks later prior to first application for two weeks.
62352030|NCT03335787|OTHER|Control|Control group would not receive any taping in order to prevent sham taping sensory stimulation effect.
62510899|NCT06471543|EXPERIMENTAL|RN0361|subcutaneous injections
62510900|NCT06471543|PLACEBO_COMPARATOR|Placebo|calculated volume to match active treatment
62510901|NCT05131477|EXPERIMENTAL|KY1005 Dose Level 1|Every 4 weeks
62510902|NCT05131477|EXPERIMENTAL|KY1005 Dose Level 2|Every 4 weeks
62510903|NCT05131477|EXPERIMENTAL|KY1005 Dose Level 3|Every 4 weeks
62146274|NCT01341769|EXPERIMENTAL|Experimental Test Food 1|Snack Base containing ingredient 1
62146275|NCT01341769|EXPERIMENTAL|Experimental Test Food 2|Snack base containing ingredient 2
62352031|NCT02871401|EXPERIMENTAL|Valganciclovir|Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
62352032|NCT02871401|PLACEBO_COMPARATOR|Placebo|Placebo, 2 pills by mouth one time per day x 12 weeks
62510904|NCT05131477|EXPERIMENTAL|KY1005 Dose Level 4|Every 4 weeks
61971046|NCT06426121||BD BACTEC™ Plus Aerobic/F Culture Vials(test)|Additional blood sample collected compared to clinical routine care
62352033|NCT05897112|ACTIVE_COMPARATOR|Group A received cryotherapy|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
62352034|NCT05897112|ACTIVE_COMPARATOR|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% Potassium Hydroxide solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
62352035|NCT04234763|EXPERIMENTAL|T2D patients|T2D patients (n=24) will be randomized to high GI and low GI MCT randomly.
62352036|NCT04234763|ACTIVE_COMPARATOR|Healthy individuals|Healthy individuals (n=24) will be randomized to high GI MCT only.
62352037|NCT03962556||Non-Trigger Point|
62352038|NCT03962556||Trigger Point|
62352039|NCT04603040|EXPERIMENTAL|Experimental group|Experimental group:ToripalimabTreatment
62352040|NCT00764088||Anaysis of Full Thickness wounds|To demonstrate the effectiveness or ineffectiveness of novel treating agents or agents used for compassionate rescue, subjects and their wounds will be analyzed retrospectively and their non-identifiable information will be compiled in the form of case studies. Subjects who demonstrated characteristics of interest (e.g. healing) as determined by the PI will be chosen for case studies.
62352041|NCT04088331||AMS 800 Artificial Urinary Sphincter Recipients|Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
62352042|NCT02428972|EXPERIMENTAL|intravenous anesthesia|propofol infusion @ 100-200 mcg/kg/min for maintenance of anesthesia
62352043|NCT02428972|ACTIVE_COMPARATOR|inhalational anesthesia|sevoflurane MAC between 0.8-1.2 for maintenance of anesthesia
62352044|NCT00217516|EXPERIMENTAL|Arm I|Patients receive oral selenium for 3-6 weeks.
62352045|NCT00217516|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo for 3-6 weeks.
62352046|NCT05632029|ACTIVE_COMPARATOR|laser (active laser)|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
62352047|NCT05632029|SHAM_COMPARATOR|laser (sham laser)|32 lupus prediabetic women will receive laser acupuncture (sham . i.e power of the device will be zero) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
62352048|NCT04090268|EXPERIMENTAL|Children with malignant hemopathies|Children with malignant hemopathies attending a precision exercise training
62352049|NCT04090268|NO_INTERVENTION|Healthy children|Healthy children
62352050|NCT02243917|EXPERIMENTAL|Dose Escalation Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles; subjects who have completed at least one cycle may optionally participate in a food effect week, wherein CB-5083 will be orally administered once daily, on days 1 and 4, and thereafter return to the original dosing schedule
62352051|NCT02243917|EXPERIMENTAL|Dose Expansion Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles
62352052|NCT02243917|EXPERIMENTAL|Food Effect Stage - CB-5083|CB-5083 will be orally administered once daily, on days 1 and 4 of week 1, cycle 1, and orally administered daily, 4 days on and 3 days off, for the remaining 3 weeks of cycle 1; for subsequent 28 day cycles, CB-5083 will be orally administered daily, 4 days on and 3 days off
62510905|NCT05131477|PLACEBO_COMPARATOR|Placebo|Every 4 weeks
62510906|NCT00731224|EXPERIMENTAL|1|
61971047|NCT06426121||BD BACTEC™ Plus Aerobic/F Culture Vials(control)|clinical routine care
62352053|NCT05351710|EXPERIMENTAL|Exposure-Based Treatment for Perfectionism|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 2 days at home (8 treatment sessions total).
62352054|NCT05351710|ACTIVE_COMPARATOR|Stress Management Condition|This arm consists of a 2-week, computerized, stress-management condition in which participants watch videos of health habits (e.g., nutrition, exercise, sleep) and relaxation videos. These sessions are completed every 2 days at home (8 sessions total).
62352055|NCT05161754|EXPERIMENTAL|Treatment 1|Participants left tonsil: cold dissection and hot hemostasis. Participants right tonsil: cold dissection and cold hemostasis.
62510907|NCT00406588|EXPERIMENTAL|1|
61971048|NCT05065762||Phase 1|Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria
62510908|NCT00406588|PLACEBO_COMPARATOR|2|
62510909|NCT06516913|EXPERIMENTAL|Sequence 1 (ABHCGDFE)|Syringe pump is used to subcutaneously (SC) administer buffer solution with hyaluronic acid as a viscosity agent
61971049|NCT05065762||Phase 2|Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan
61971050|NCT02612974|EXPERIMENTAL|Group A|Hirudinaria granulosa and Qurse mafasil are given
61971051|NCT02612974|ACTIVE_COMPARATOR|Group B|Qurse mafasil only given
61971052|NCT06214182||Group T1|T1 is before CPB.
61971053|NCT06214182||Group T2|T2 is 2 hours after CPB.
61971054|NCT06214182||Group T3|T3 is 3 days after CPB.
62146276|NCT01341769|EXPERIMENTAL|Experimental Test Food 3|Snack base containing ingredients 1 and 2
62510910|NCT06516913|EXPERIMENTAL|Sequence 2 (BCADHEGF)|Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
62510911|NCT06516913|EXPERIMENTAL|Sequence 3 (CDBEAFHG)|Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
62510912|NCT06516913|EXPERIMENTAL|Sequence 4 (DECFBGAH)|Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
62510913|NCT06516913|EXPERIMENTAL|Sequence 5 (EFDGCHBA)|Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
62510914|NCT06516913|EXPERIMENTAL|Sequence 6 (FGEHDACB)|Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
62510915|NCT06516913|EXPERIMENTAL|Sequence 7 (GHFAEBDC)|Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
61971055|NCT06346964|EXPERIMENTAL|Education|6 weeks of health education will be provided to older adults. Once the intervention is completed, the scales will be re-administered face-to-face or online.
61971056|NCT06346964|NO_INTERVENTION|Control|No intervention has been made.
62352056|NCT05161754|EXPERIMENTAL|Treatment 2|Participants right tonsil: cold dissection and hot hemostasis. Participants left tonsil: cold dissection and cold hemostasis.
62510916|NCT06516913|EXPERIMENTAL|Sequence 8 (HAGBFCED)|Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
62510917|NCT06035484|EXPERIMENTAL|LL & 0|Wheelchair seat height will be positioned at lower leg length and set inclination will be zero
62510918|NCT06035484|EXPERIMENTAL|LL + 1|Wheelchair seat height will be positioned at the participant's leg length plus one inch with an inclination of zero
62510919|NCT06035484|EXPERIMENTAL|LL - 1|Wheelchair seat height will be positioned at the participant's leg length minus one inch with an inclination of zero
62510920|NCT06035484|EXPERIMENTAL|LL - 2|Wheelchair seat height will be positioned at the participant's leg length minus two inches with an inclination of zero
62510921|NCT06035484|EXPERIMENTAL|LL - 3|Wheelchair seat height will be positioned at the participant's leg length minus three inches with an inclination of zero
62510922|NCT06035484|EXPERIMENTAL|3 degrees Inclination|Wheelchair seat height will be positioned at the participant's leg length with a forward seat inclination of 3 degrees
62510923|NCT06035484|EXPERIMENTAL|6 degrees Inclination|Wheelchair seat height will be positioned at the participant's leg length with a forward seat inclination of 6 degrees
62510924|NCT06035484|EXPERIMENTAL|9 degrees Inclination|Wheelchair seat height will be positioned at the participant's leg length with a forward seat inclination of 9 degrees
62510925|NCT02085850||Subjects identified in the Tema Eye Survey|Subjects identified in the Tema Eye Survey
62510926|NCT02978352|EXPERIMENTAL|face-to-face|Traditional learning group (face-to-face): 4 different sessions will be conducted to suit the participants' convenience Duration of each session is 60-90 minutes Each session comprises lecture, video demonstration of CAM-ICU assessment, discussion, volunteer participation during class demonstration
62510927|NCT02978352|EXPERIMENTAL|E-learning|60-90 minute online course will be accessible through intranet Wi-Fi The course encompasses types, incidence, risk factors, significance and effects of delirium, diagnostic criteria and CAM-ICU application Inclusion of video demonstration of simulated patients and CAM-ICU application, common pitfalls of healthcare providers, and practice questions
62510928|NCT06616233|EXPERIMENTAL|Remote Ischaemic Conditioning with Exercise|Participants will be randomised to receive remote ischaemic conditioning (RIC) with exercise involving a 4-week home-based programme of RIC with exercise . The exercise will involve handgrip exercise during the cuff deflation phase of RIC.
62510929|NCT06616233|OTHER|Remote Ischaemic Conditioning|Participants will receive remote ischaemic conditioning (RIC) without exercise involving a 4-week home-based programme of RIC.
62510930|NCT06026631|EXPERIMENTAL|Intervention arm (breast cancer)|Lipidomic analysis for breast cancer patients
62510931|NCT06026631|OTHER|Control arm (healthy subject)|Lipidomic analysis for healthy subjects
61971057|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
62352057|NCT04182789|EXPERIMENTAL|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
62352058|NCT06196918|EXPERIMENTAL|Rivaroxaban group|Patients with highly suspected, newly diagnosed, untreated glioma undergo surgical resection. CT scan within 24 hours after surgery is performed to rule out intracranial hemorrhage and/or infarction. Then those patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.
62352059|NCT06196918|ACTIVE_COMPARATOR|Placebo group|Patients with highly suspected, newly diagnosed, untreated glioma undergo surgical resection. CT scan within 24 hours after surgery is performed to rule out intracranial hemorrhage and/or infarction. Then those patients with postoperative lower extremity dyskinesia are treated with placebo and compression stockings until 1 month after surgery.
62352060|NCT06226558||Category 1: Confirmed cCMV infection identified by NYS newborn screen|Infants who have both a positive cCMV NYS newborn screen AND are positive for cCMV on confirmatory testing
61971058|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
61971059|NCT00459953|EXPERIMENTAL|Extended treatment|extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
61971060|NCT00459953|NO_INTERVENTION|Control group|Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact
61971061|NCT05966181|EXPERIMENTAL|experimental group|They will perform repetitive simulation (standard patient simulation according to scenarios) with the students in the experimental group.
61971062|NCT05966181|OTHER|control group|A single simulation will be applied to the control group (standard patient simulation according to scenarios).
62146277|NCT01420757|ACTIVE_COMPARATOR|open|open incisional hernia repair
62510932|NCT03389087|EXPERIMENTAL|Apatinib and Etoposide Capsule|Apatinib and Etoposide Capsule
62510933|NCT05017779|EXPERIMENTAL|Intervention (Unstuck & On Target: High School)|School staff will receive training on the Unstuck and On Target: High School (UOT:HS) curriculum, and deliver lessons to students during the school day. Interventionists will have the option to participate in ongoing check-ins with study staff. Parents are provided home extensions for each lesson and have the option to participate in trainings delivered by study staff to support generalization of skills to the home environment.
62510934|NCT05017779|OTHER|Usual Care|Participants in schools assigned to the TAU condition will continue to receive the standard school-based Individualized Education Plan (IEP) accommodations and school supports that would typically be provided.
62146278|NCT01420757|ACTIVE_COMPARATOR|laparoscopic|laparoscopic incisional hernia repair
62146279|NCT03172975|EXPERIMENTAL|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
61971063|NCT02899988|EXPERIMENTAL|30 mg Mirikizumab|30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
61971064|NCT02899988|EXPERIMENTAL|100 mg Mirikizumab|100 mg Mirikizumab administered SC Q8W.
61971065|NCT02899988|EXPERIMENTAL|300 mg Mirikizumab|300 mg Mirikizumab administered SC Q8W.
62146280|NCT03172975|EXPERIMENTAL|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
62146281|NCT03172975|EXPERIMENTAL|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
62146282|NCT03172975|PLACEBO_COMPARATOR|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
62146283|NCT01228734|EXPERIMENTAL|Cetuximab + FOLFOX-4|Subjects received cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab was always administered every 7 days with an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions, followed by oxaliplatin 85 mg/m\^2 infused over 120 minutes at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA was administered at a dose of 200 mg/m\^2 infused over 120 minutes, on Day 1, Day 2, and every 2 weeks and then 5- FU was administered as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infused over 22 hours, on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
61971066|NCT02899988|PLACEBO_COMPARATOR|Placebo|Placebo administered SC Q8W.
62146284|NCT01228734|ACTIVE_COMPARATOR|FOLFOX-4|Subjects received FOLFOX-4 chemotherapy regimen that consists of a combination of oxaliplatin with 5-FU/FA. Oxaliplatin 85 mg/m\^2 infused over 120 minutes was administered first or simultaneously with FA at a dose of 200 mg/m\^2 infused over 120 minutes on Day 1, Day 2, and every 2 weeks and then 5-FU was administered as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infused over 22 hours on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
62146285|NCT00775398||A|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who received topical THROMBIN-JMI® during the study surgery.
62146286|NCT00775398||B|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who did not received THROMBIN-JMI® during the study surgery.
62146287|NCT00775398||C|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did receive THROMBIN-JMI® during the study surgery.
62146288|NCT00775398||D|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN-JMI® during the study surgery.
62352061|NCT06226558||Category 2: Confirmed cCMV infection NOT identified by NYS newborn screen|Infants who have both a NEGATIVE cCMV NYS newborn screen AND are found to have cCMV on confirmatory testing
62352062|NCT06226558||Category 3: False-positive cCMV NYS newborn screen|Infants who have both a positive cCMV NYS newborn screen AND are NEGATIVE for cCMV on confirmatory testing
61971067|NCT04245787|EXPERIMENTAL|Self assembling peptide with fluoride|
61971068|NCT04245787|ACTIVE_COMPARATOR|Casein-phosphopeptide/amorphous-calcium phosphate|
61971069|NCT02050529|EXPERIMENTAL|Labetalol|This group (Group A; Labetalol) receiveD intravenous(IV) labetalol manufactured by Zafa pharmaceutical, 50mg/10 ml ampoule) bolus doses administered over 2 minutes, at 10 minutes interval. Initially dose of 20 mg wAS administered, and if required repeated in increments of 40 mg,80 mg,80 mg,80 mg every 10 minutes till SBP became \<160 and DBP \<110 mm Hg, upto a maximum cululative dose of 300mg(total 5 bolus doses).During this time pulse and blood pressure were checked every 10 minutes.
61971070|NCT02050529|ACTIVE_COMPARATOR|Hydralazine|This group (Hydralazine;Group B) received intravenous Hydralazine and served control. Bolus doses of 5 mg administered over 2 minutes, at 20 minutes interval. Pulse and blood pressure were checked every 10 minutes interval. If SBP threshold of 160 mm Hg or DBP 110 mm Hg was still reached after 20 minutes, then second bolus was repeated. Similarly if after 20 minutes SBP was still ≥160 or DBP ≥110 mm Hg, then third dose was given. If SBP or DBP thresholds were still exceeded after 20 minutes then similarly 4th and 5th dose of 5 mg were given. Failure to reduce SBP\<160 or DBP\<110 after consecutive maximum 5 boluses(total 25 mg) was labeled as severe persistent hypertension.
61971071|NCT01333644||HIV-Infection|Treated HIV-infected individuals with an undetectable HIV RNA level (\< 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals.
61971072|NCT02516215||1_Hypertension|Patients with diagnosed hypertension, without other systemic diseases
61971073|NCT02516215||2_Diabetes mellitus|Patients with diagnosed diabetes mellitus, without other systemic diseases
61971074|NCT02516215||3_Hypertension and diabetes mellitus|Patients with both diagnosed hypertension and diabetes mellitus
61971075|NCT02516215||4_end stage renal disease with hemodialysis|Patients with end stage renal disease with hemodialysis
61971076|NCT02516215||5_Peripheral arterial occlusive disease|Patients with disgnosed peripheral arterial occlusive disease
61971077|NCT02516215||6_Coronary artery disease|Patients with diagnosed coronary artery disease
61971078|NCT02516215||7_liver cirrhosis|Patients with diagnosed liver cirrhosis
61971079|NCT02516215||8_Anemia|Patients with diagnosed anemia
62146289|NCT03192709|EXPERIMENTAL|A|Sildenafil vaginal suppositories users
61971080|NCT02284594|EXPERIMENTAL|text message|Receipt of series of text messages regarding influenza vaccination
61971081|NCT02284594|NO_INTERVENTION|usual care|
61971082|NCT02292979|ACTIVE_COMPARATOR|ABVD|Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
61971083|NCT02292979|EXPERIMENTAL|AVD+BV|Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
62146290|NCT03192709|PLACEBO_COMPARATOR|B|Daily vaginal placebo users with HMG administration
62146291|NCT03192709|PLACEBO_COMPARATOR|C|Daily vaginal placebo users with HMG administration day until the day of oocyte retrieval.
62510935|NCT06239688|EXPERIMENTAL|essentiALZ|Communities randomized to this arm will receive the essentiALZ training: a web-based training taken by AL staff that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
62539407|NCT06582056|OTHER|Participant with Stage III/Stage IV Periodontal Disease with Hemoglobin A1c level 6.5-7.8|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
61971084|NCT03292094||Black men|294 young healthy men were included (clinic normotensive, non-HIV)
61971085|NCT03292094||White men|284 young healthy men were included (clinic normotensive, non-HIV)
61971086|NCT03292094||Black women|312 young healthy women were included (clinic normotensive, non-HIV)
61971087|NCT03292094||White women|312 young healthy women were included (clinic normotensive, non-HIV)
61971088|NCT05331274|EXPERIMENTAL|exercise group|Only DYMK exercise training will be applied to the exercise group.
61971089|NCT05331274|EXPERIMENTAL|pain training group|In the pain training group, pain training will be applied in addition to the DYMK exercise training.
61971090|NCT01176084|EXPERIMENTAL|low carbohydrate diet|
61971091|NCT01176084|EXPERIMENTAL|diet & exercise|
61971092|NCT02240238|EXPERIMENTAL|NC-6004 and Gemcitabine|
61971093|NCT04086862|ACTIVE_COMPARATOR|The 1 MHz group|The 1 MHz group will receive therapeutic ultrasound at the 1 MHz setting.
61971094|NCT04086862|EXPERIMENTAL|The 3 MHz group|The 3 MHz group will receive therapeutic ultrasound at the 3 MHz setting.
61971095|NCT00573534|EXPERIMENTAL|Open Label Vyvanse|Open Label Vyvanse (lisdexamphetamine) in doses of 30-70 mgs over 8 weeks in younger siblings of substance abusing older siblings with a history of treatment for ADHD
61971096|NCT01463878|EXPERIMENTAL|Glycerna|Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
61971097|NCT01463878|ACTIVE_COMPARATOR|Control - Jevity|The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.
61971098|NCT03682666|ACTIVE_COMPARATOR|KT group|the patients will perform Kinesiotaping for 5 days per week for 3 weeks
61971099|NCT03682666|SHAM_COMPARATOR|mCIMT group|"the unaffected limb will be constraint for 2 hours a day, 5 days a week for three weeks.~And they will receive sham taping on the affected limb."
62146292|NCT03177226|EXPERIMENTAL|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase \[from full erection to ejaculation\]
62146293|NCT03177226|SHAM_COMPARATOR|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase \[from full erection to ejaculation\]
62146294|NCT01182532|ACTIVE_COMPARATOR|Western therapy|
62146295|NCT01182532|EXPERIMENTAL|TCM treatment|
62146296|NCT01182532|EXPERIMENTAL|Western therapy plus TCM treatment|The combination of both western therapy and TCM treatment.
61971100|NCT03682666|EXPERIMENTAL|KT+mCIMT group|the patients will perform Kinesiology taping for 5 days per week for 3 weeks, and while being taped, the modified Constraint Induced Movement Training would be also executed.
61971101|NCT02421315|EXPERIMENTAL|Participants With Obsessive-compulsive Disorder (OCD)|Children and adolescents who meet DSM-IV diagnostic criteria for OCD and had clinically significant obsessive-compulsive symptoms (CY-BOCS score\>15). Comorbid anxiety disorders, but no other lifetime psychiatric diagnoses, were permitted in the OCD group as long as OCD was the primary diagnosis. Participants were unmedicated and had not received a full course of CBT with exposure and response prevention for OCD prior to their participation in the study. Following baseline assessment and scan, patients with OCD underwent a course of manualized treatment of CBT with E/RP adapted for pediatric OCD delivered by a licensed clinical psychologist or advanced supervised graduate student in clinical psychology at the NYSPI.
61971102|NCT02421315|NO_INTERVENTION|Healthy Control (HC) Participants|Healthy control (HC) participants matched on age and sex with the OCD group. HC participants had no lifetime psychiatric disorders. HC participants were assessed and scanned at baseline and again after 12-16 weeks.
61971103|NCT01782495|EXPERIMENTAL|Arm A|Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
62146297|NCT03794232|EXPERIMENTAL|Test group|NIUCHANG（Soluble dietary fiber + prebiotics）：Oral, 1 bag (15g) once a day, taking 24 weeks
62146298|NCT03794232|PLACEBO_COMPARATOR|Control group|Placebo（inactive drug ingredient）：Oral, 1 bag (15g) once a day, taking 24 weeks
62146299|NCT03477266|EXPERIMENTAL|Mouth dissolving mosapride|Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
62146300|NCT03477266|PLACEBO_COMPARATOR|Placebo mouth dissolving tablets|Dummy identical tablets taken in the same way
62146301|NCT04530370|EXPERIMENTAL|Recovered covid 19 plasma|
62146302|NCT04530370|PLACEBO_COMPARATOR|controlled|
62146303|NCT05494658|EXPERIMENTAL|research group|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
62510936|NCT06239688|EXPERIMENTAL|essentiALZ + ECHO|Communities randomized to this arm will receive the essentiALZ training: a web-based training taken by AL staff that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks. Additionally, they will receive access to Project ECHO. ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
62510937|NCT06239688|NO_INTERVENTION|No Intervention|Standard care will be provided.
62510938|NCT06326034|EXPERIMENTAL|Dapagliflozin group|The study's outcomes measured the changes pre- and post-treatment with Dapagliflozin (week 0 to weeks 16). The following parameters being measured: HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG; glucose level measured 2 hours after standardized breakfast), body weight (BW), height (Ht), waist circumference (WC), body mass index (BMI), index of central obesity (ICO), and patients' QoL.
62510939|NCT06467552|ACTIVE_COMPARATOR|control group|The entire process is carried out according to Severance Hospital surgical protocols.
62510940|NCT06467552|EXPERIMENTAL|intervention group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
62510941|NCT01142531||COPD|COPD patients aged 40 or more, with a smoking history of \> 10 PY and a post-bronchodilator FEV1/VC \< 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.
62510942|NCT02507440|ACTIVE_COMPARATOR|Viscous Lidocaine|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of 2% lidocaine viscous solution and swallow.
62510943|NCT02507440|PLACEBO_COMPARATOR|Placebo|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of placebo and then swallow. Placebo will be 3% methylcellulose which will be flavored and colored to match the characteristics of 2 % lidocaine.
62707745|NCT06022926|OTHER|Group 2: Control group (patients without warming)|"* no electric blanket will be used, and no heating will be applied to this group of patients.~* all patients will receive standard general anesthesia~* all patients will undergo electrocardiogram, peripheral oxygen saturation by pulse oximetry, non-invasive blood pressure monitoring by automatic pneumatic manometer~* mean arterial pressure, intraoperative opioid consumption, nausea-vomiting, agitation, tremor and pain assessment will be performed on each patient immediately before induction of general anesthesia, 20 minutes after induction of anesthesia, immediately after extubation and during discharge from the postanesthesia recovery unit.~* temperature measurements will be performed with the same tympanic thermometer device"
62707746|NCT03134040|EXPERIMENTAL|Incentives (Rebate)|On a weekly basis, participants receive a small monetary incentive to exercise each time they attend the YMCA.
62707747|NCT03134040|EXPERIMENTAL|Incentives (Donation)|On a weekly basis, a small monetary incentive to exercise is provided in the form of a donation to a charity of the participant's choice for attendance at the YMCA.
62707748|NCT03134040|ACTIVE_COMPARATOR|Control|Participants receive feedback on their exercise attendance on a weekly basis.
62707749|NCT04816032|EXPERIMENTAL|Pennebaker's expressive writing|Three consecutive days for 20 minutes daily of expressive writing. The topic of the traumatic traveling experience, focalizing the attention on the deeper emotions, thoughts, and feelings.
62146304|NCT05494658|PLACEBO_COMPARATOR|control group|600ml water was consumed by patients 2-4h before suegery.
62146305|NCT05224232|EXPERIMENTAL|Access Socket|Patients will be fitted with the access socket
62146306|NCT05224232|ACTIVE_COMPARATOR|Rigid socket|Patients will be fitted with their usual rigid socket
62146307|NCT06294145|EXPERIMENTAL|Savoring intervention|7 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
62146308|NCT05125224||Dihydropyridine calcium channel blocker|Exposure group
62707750|NCT04816032|ACTIVE_COMPARATOR|Writing about different aspects of their knowledge|Three consecutive days for 20 minutes daily of neutral writing. Different topics of own knowledge Description of the city, their room, their place where they live, or easy procedure like, how to make a coffee (or something else), their population, trying to remain free from deep emotions, thoughts, or feelings.
62707751|NCT04816032|NO_INTERVENTION|Control|No intervention
62707752|NCT06079983|EXPERIMENTAL|JSKN003|Administered intravenously according to protocol.
62146309|NCT05125224||Hydrochlorothiazide|Reference group
62146310|NCT02165202|ACTIVE_COMPARATOR|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
62146311|NCT02165202|PLACEBO_COMPARATOR|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
62146312|NCT04419207||Patients with Surbery|Patients who with pulmonary nodules in computed tomography and planned to receive thoracic surgery will be included. And those who have other types of cancer, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
62510944|NCT00881413|EXPERIMENTAL|Esomeprazole|High-dose esomeprazole
62146313|NCT04419207||Healthy Controls|Adult participants (\>18 yr) who plan to receive annual physical examination and low-dose computed tomography will be included. And those who have history cancers, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
62146314|NCT03765385|EXPERIMENTAL|High-intensity training|Each high-intensity training (HIT) session will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIT is 20 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
62146315|NCT03765385|ACTIVE_COMPARATOR|Moderate-intensity continuous training|Each moderate-intensity continuous training (MICT) session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is 40 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
62146316|NCT01772199|EXPERIMENTAL|GSK239512 Arm|GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
62146317|NCT01772199|PLACEBO_COMPARATOR|Placebo Arm|Placebo once daily orally
62510945|NCT00881413|ACTIVE_COMPARATOR|Pantoprazole|High-dose pantoprazole
62510946|NCT02078921|EXPERIMENTAL|Treatment|Inorganic Nitrate
62510947|NCT02078921|PLACEBO_COMPARATOR|placebo|Placebo
62510948|NCT01200979||pregnant flu vaccinated|pregnant women that choose to receive the seasonal flu vaccine
62510949|NCT01200979||pregnant non-flu vaccinated|pregnant women that do not receive the flu vaccine
61971104|NCT01782495|EXPERIMENTAL|Arm B|Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
61971105|NCT01782495|EXPERIMENTAL|Arm C|Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
61971106|NCT01782495|EXPERIMENTAL|Arm D|Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
61971107|NCT01782495|EXPERIMENTAL|Arm E|Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
61971108|NCT01782495|EXPERIMENTAL|Arm F|Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
61971109|NCT01782495|EXPERIMENTAL|Arm G|Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
61971110|NCT01782495|EXPERIMENTAL|Arm H|Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
62146318|NCT01411137|EXPERIMENTAL|IPX066|Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
62146319|NCT05155358||Control group|Healthy volunteers
62146320|NCT05155358||Patients within the acute phase of disease|Patients within 24 hours after onset
62510950|NCT06430918||Patients with knee osteoarthritis|Knee OA patients diagnosed according to the ACR Classification Criteria
62510951|NCT04272476|EXPERIMENTAL|Acupuncture and moxibustion|Acupuncture points: Baihui(GV 20), Mingmen(GV 4), Bilateral Neiguan(PC 6), Bilateral Shenmen(HT 7), Bilateral Hegu(LI 4), Bilateral Zusanli(ST 36), Bilateral Taichong(LR 3). Each treatment takes about thirty minutes,3 times a week(treatment on Monday, Wednesday and Friday) for 8 weeks.
62146321|NCT05155358||Recovery stage of disease|Organ dysfunction was corrected, The patient had no obvious discomfort.
62510952|NCT04272476|ACTIVE_COMPARATOR|Western medicine|Fluoxetine 20 mg capsule by mouth every day for 8 weeks.
62510953|NCT01065116|EXPERIMENTAL|AL Blister-pack|
62510954|NCT01065116|ACTIVE_COMPARATOR|AL unit dose age specific pre-packs|
62510955|NCT05375019|EXPERIMENTAL|Intervention group (positive discipline program)|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program.
62510956|NCT05375019|ACTIVE_COMPARATOR|Active control group (free interaction)|while the active control group was provided with 8 weekly 90 minute sessions of free interaction.
62510957|NCT05375019|NO_INTERVENTION|No-contact group|No intervention was performed with the no-contact control group.
62510958|NCT06061406|EXPERIMENTAL|group1|Bariatric-metabolic surgery (Gastric sleeve, Roux-Y gastric bypass, omega-loop bypass) at least 24 months ago, 25-45 patients in this group (total sum of patients in all three groups: 100).
62510959|NCT06061406|EXPERIMENTAL|group 2|Patients participating in a full or partial (if primary indication) multimodal approach prior to bariatric surgery, 25-45 patients in this group (total sum of patients in all three groups: 100).
62510960|NCT06061406|EXPERIMENTAL|group 3|Conservative therapy: patients with overweight/obesity grade 1 (BMI 28-34.9 kg/m2), 25-45 patients in this group (total sum of patients in all three groups: 100).
62510961|NCT03645499|EXPERIMENTAL|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
62510962|NCT03645499|EXPERIMENTAL|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
62707753|NCT06079983|ACTIVE_COMPARATOR|The chemotherapy chosen by the investigator|The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization.
62707754|NCT01593540|EXPERIMENTAL|metal-free interdental brushes.|
62707755|NCT01593540|ACTIVE_COMPARATOR|metal-core interdental brushes|
61971111|NCT01782495|EXPERIMENTAL|Arm I|Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
61971112|NCT01782495|EXPERIMENTAL|Arm J|Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
61971113|NCT01782495|EXPERIMENTAL|Arm K|Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
61971114|NCT00088985|EXPERIMENTAL|Dendritic Cell Vaccine|Dendritic Cells: Dosage: 20 x 106 dendritic cells (DCs) given per treatment Vinorelbine:25 mg/m2 will be administered i.v biweekly Trastuzumab: 6mg/Kg administered by i.v. biweekly
61971115|NCT00859404|EXPERIMENTAL|1. oglemilast|
62707756|NCT02684461|ACTIVE_COMPARATOR|Arm A: Sequential Consolidation|Completion of four cycles of Sequential Consolidation of Pembrolizumab 200mg every 21 days and then four cycles Nab-paclitaxel 100 mg/mg2 on day 1 and day 8 every 21 days
62707757|NCT02684461|ACTIVE_COMPARATOR|Arm B: Sequential Consolidation|Completion of 4 cycles of Sequential Consolidation of Nab-paclitexel 100 mg/m2 on day 1 and day 8 every 21 days and then Pembrolizumab 200 mg every 21
62707758|NCT02684461|ACTIVE_COMPARATOR|Arm C: Concurrent Consolidation|Concurrent Consolidation of Nab paclitaxel 100 mg/m2 on day 1 and day 8 plus Pembrolizumab 200 m5 on day 1 every 21 days for four cycles
61971116|NCT00859404|EXPERIMENTAL|2. oglemilast|
61971117|NCT00859404|EXPERIMENTAL|3. oglemilast|
61971118|NCT00859404|PLACEBO_COMPARATOR|4. placebo|
61971119|NCT02303301|ACTIVE_COMPARATOR|Probiotics|Patients gurgle twice a day with a suspension of two probiotic strains of bacteria- Contains also a filling material - maltodextrin
61971120|NCT02303301|PLACEBO_COMPARATOR|Control|Patients gurgle twice a day with a suspension of the filling material - maltodextrin
61971121|NCT02000973|PLACEBO_COMPARATOR|Normal saline|General anesthesia combined with thoracic epidural 0.9% normal saline 8ml
61971122|NCT02000973|EXPERIMENTAL|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine 8ml
62510963|NCT03645499|EXPERIMENTAL|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
62707759|NCT02151240|EXPERIMENTAL|Arm I|Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV
62707760|NCT02151240|ACTIVE_COMPARATOR|Arm II|First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV
61971123|NCT02000973|EXPERIMENTAL|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine 8ml
62510964|NCT03645499|EXPERIMENTAL|Topical TA-102 D|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
62510965|NCT03645499|EXPERIMENTAL|Topical TA-102 E|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
62707761|NCT01966627||Pediatric NAFLD Cohort|Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
61971124|NCT02000973|EXPERIMENTAL|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine 8ml
61971125|NCT04430114|EXPERIMENTAL|TAAA spinal loop graft|
61971126|NCT00001723|PLACEBO_COMPARATOR|Placebo|Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
61971127|NCT00001723|EXPERIMENTAL|Orlistat|Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
61971128|NCT00022139|EXPERIMENTAL|carboplatin + paclitaxel + fluorouracil + radiation + surgery|"Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.~Patients are followed every 3 months for 4 years."
61971129|NCT00398892|OTHER|1|Crossover - placebo then active
61971130|NCT00398892|OTHER|2|Crossover - active then placebo
61971131|NCT05854732|EXPERIMENTAL|Inclined Treadmill Training Group|"The Inclined Treadmill Training Group will be considered as an Experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. The FITT program for the participants will be:~* Warmup: 5 mints~* Frequency: 5days/week for 4 weeks.~* Intensity: fixed speed of 5.0 mph and increased inclination of 1% after every one minute.~* Time: 30 minutes~* Type: 1% Inclined treadmill~* Cool down: 5 mints"
62510966|NCT06469112|EXPERIMENTAL|Experimental: Vibration Application Group|"With individuals in this group, device was used to provide vibration. This device, designed as a combination of cold application and local vibration to reduce pain experienced during invasive procedures, is frequently chosen for all age groups. There is a motor in the body which provides vibration. The device also has ice wings behind the body, which are used to provide cold, but these were not used in this research.~The device, at room temperature, was placed by the researcher 5 cm proximal to the injection site before the injection was performed. For one minute before the injection, a slight non-discomforting vibration was made, and this was continued while the injection was given. In this study, only the body of the device was used to provide vibration."
62510967|NCT06469112|PLACEBO_COMPARATOR|Placebo: Intervention Control Group|The device was used with participants in this group. The device, at room temperature, was placed by the researcher 5 cm proximal to the injection site before the injection was performed. With participants in this group, the device was placed on the procedure site, but no vibration was made. The device was held on the participants for one minute before the injection and throughout the procedure, with the vibration switched off.
62510968|NCT06469112|NO_INTERVENTION|Control: Nonintervention Group|No intervention was performed before or during the procedure with the participants in the control group, and the standard subcutaneous heparin injection procedure was carried out.
62707762|NCT01192880|EXPERIMENTAL|Bitopertin 10 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 10 milligrams (mg) tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 10 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50 percent (%) of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
61971132|NCT05854732|ACTIVE_COMPARATOR|Uninclined Treadmill Training Group|"The uninclined Treadmill Training Group will be considered as active comparator with no inclination of the treadmill and speed of 5.0 mph. The FIIT program for the participants will be:~* Warmup: 5 mints~* Frequency: 5days/week for 4 weeks.~* Intensity fixed speed of 5.0 mph and no inclination.~* Time: 30 minutes~* Type: uninclined treadmill~* Cool down: 5 mints"
61971133|NCT03220516|EXPERIMENTAL|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
61971134|NCT03220516|EXPERIMENTAL|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
61971135|NCT03220516|EXPERIMENTAL|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
61971136|NCT03585504|EXPERIMENTAL|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
61971137|NCT03585504|ACTIVE_COMPARATOR|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
61971138|NCT05550402|ACTIVE_COMPARATOR|Salbutamol then ipratropium|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
62146322|NCT02881229||Women in the Vulvar Specialty Clinic|Information will be collected from all patients presenting with vulvar complaints who have been seen by Dr. Schlosser in the Vulvar Mucosal Specialty Clinic at Northwestern Medical Group.
61971139|NCT05550402|ACTIVE_COMPARATOR|Ipratropium then salbutamol|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
61971140|NCT05550402|ACTIVE_COMPARATOR|Salbutamol plus ipratropium|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium)
62352063|NCT06226558||Category 4: Premature infants with confirmed CMV infection on late positive NBS|Infants who are: (a) born prior to 37 weeks gestation AND (b) cCMV positive on any NYS newborn screen collected prior to 44 weeks gestational age AND (c) Have a positive cCMV confirmatory test obtained within 14 days of a positive NYS newborn screen
62352064|NCT04545398|EXPERIMENTAL|Pasture-raised|The meal contains grass/pasture fed beef
62352065|NCT04545398|EXPERIMENTAL|Grain-fed|The meal contains grain-fed beef
62352066|NCT04545398|PLACEBO_COMPARATOR|Meat Alternative|The meal contains a meat alternative
62146323|NCT00669474|OTHER|1|Suction curettage
62352067|NCT04545398|EXPERIMENTAL|Lamb|The meal contains lamb
62510969|NCT05158140|EXPERIMENTAL|V110 Concomitant with mRNA-1273 (V110 Concomitant)|Participants received a single 0.5 mL intramuscular (IM) injection of V110 concomitantly with a single 0.25 mL IM injection of mRNA-1273 on Day 1, followed by a single 0.5 mL IM injection of placebo for V110 on Day 30.
62146324|NCT00669474|ACTIVE_COMPARATOR|2|Treatment with Botox
62146325|NCT01040312||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 with platinum analogues
62352068|NCT04514926||Healthy Controls|Participants with no history of asthma or other lung diseases.
62352069|NCT04514926||Asthmatics newly prescribed therapeutic proteins|Participants with asthma, have been newly prescribed therapeutic proteins and have yet to start on those therapeutics at the time of enrollment.
62352070|NCT04514926||Asthmatics already being treated with therapeutic proteins|Participants with asthma who have already started on therapeutic proteins.
62352071|NCT03716453|PLACEBO_COMPARATOR|Control group|Intraoperative fentanyl administration will be guided by standard protocol
62707763|NCT01192880|EXPERIMENTAL|Bitopertin 20 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 20 mg tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 20 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50% of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 20 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
61971141|NCT05550402|PLACEBO_COMPARATOR|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
61971142|NCT02384408|PLACEBO_COMPARATOR|Control|Control Group: Women without hormone replacement therapy. Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
61971143|NCT02384408|EXPERIMENTAL|Hormone treatment|"Group Drospirenone: To whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily for 24 weeks.~Group Tibolone: To whom treatment with tibolone 1.25 mg (Tib) will be administered daily for 24 weeks.~Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study"
61971144|NCT01827397|EXPERIMENTAL|EN41-UGR7C HIV vaccine|Group 1: IM injection of 210 µg UGR7-C in 560 µg of Alum at month 0, 1 and 4
62352072|NCT03716453|EXPERIMENTAL|ANI group|Intraoperative fentanyl administration will be guided by ANI protocol
62352073|NCT01324934|ACTIVE_COMPARATOR|Study Group|immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
62352074|NCT01324934|NO_INTERVENTION|Control Group|immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.
62352075|NCT04849819||never receive systemic medications|
62352076|NCT04849819||ever user of systemic medications|
62352077|NCT04849819||current user of systemic medications|
62352078|NCT05843812||Magnesium sulphate|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
62352079|NCT05843812||No Magnesium sulphate|Patients who did not receive preoperative magnesium sulfate infusion as part of their anesthetic management
62352080|NCT04087408|NO_INTERVENTION|control group|"1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6 - Blood sampling will be performed for progesterone 7 days after OPU.~7-Quantative BHCG will be performed 14 days after OPU."
62352081|NCT04087408|ACTIVE_COMPARATOR|study group|"1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU."
62352082|NCT03558451|EXPERIMENTAL|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
62352083|NCT03558451|ACTIVE_COMPARATOR|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
62352084|NCT02109848||keratoconus|
62352085|NCT02109848||post-keratoplasty|
62352086|NCT02109848||post-DSAEK|Descemet's stripping automated endothelial keratoplasty (DSAEK)
62352087|NCT02258945||Continuous Subcutaneous Insulin Infusion|This group will consist of patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy.
62352088|NCT02258945||Multiple Daily Injections|This group will consist of patients with Type 1 diabetes using multiple daily injection therapy.
62510970|NCT05158140|EXPERIMENTAL|V110 Nonconcomitant with mRNA-1273 (V110 Nonconcomitant)|Participants received a single 0.5 mL IM injection of placebo for V110 on Day 1 concomitantly with a single 0.25 mL IM injection of mRNA-1273, followed by a single 0.5 mL IM injection of V110 on Day 30.
61971145|NCT01827397|PLACEBO_COMPARATOR|NaCl|Group 2: IM injection of 700 µL of 0.9% sodium chloride (NaCl) at month 0, 1 and 4
61971146|NCT03528993|EXPERIMENTAL|Exercise by hippotherapy device group|The experimental group receive conventional rehabilitation for 45 min/day following by use of a hippotherapy device for 15 min/day, 5 times/week for 4 weeks
62352089|NCT01566201|ACTIVE_COMPARATOR|anakinra|
62352090|NCT01566201|PLACEBO_COMPARATOR|placebo|
62352091|NCT03343470||Cushing Syndrome (active phase)|Patients displaying biochemical and clinical features of active Cushing's syndrome
62352092|NCT03343470||Cushing Syndrome (during remission)|Patients at 3-6 months from remission with cortisol levels in the normal range
62352093|NCT04007913|EXPERIMENTAL|teleCBIT|Patient receive eight sessions of individual teleCBIT, in accordance with Woods et al's (2008) protocol, from a licensed psychologist.
62352094|NCT04083001|EXPERIMENTAL|OTR4132MD|One medical device will be administrated as a one shot-dose to the patient. The respective total dose of OTR4132 received by a patient will be one of the following: 0,20 mg, 0,50 mg, 1 mg, 1,5 mg, 2 mg and 2,5 mg.
62352095|NCT04197518|EXPERIMENTAL|Children With Enlargement Adenoid and Tonsils|Children With Enlargement Adenoid and Tonsils
62352096|NCT04219969|EXPERIMENTAL|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minutes and then undergo PET-MRI over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
62352097|NCT02451540|ACTIVE_COMPARATOR|Roflumilast|Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
62510971|NCT05158140|EXPERIMENTAL|V114 Concomitant with mRNA-1273 (V114 Concomitant)|Participants received a single 0.5 mL IM injection of V114 concomitantly with a single 0.25 mL IM injection of mRNA-1273 on Day 1, followed by a single 0.5 mL IM injection of placebo for V114 on Day 30.
62510972|NCT05158140|EXPERIMENTAL|V114 Nonconcomitant with mRNA-1273 (V114 Nonconcomitant)|Participants received single 0.5 mL IM injection of placebo for V114 on Day 1 concomitantly with a single 0.25 mL IM injection of mRNA-1273, followed by a single 0.5 mL IM injection of V114 on Day 30.
62510973|NCT06232239|EXPERIMENTAL|Sequence 1- Empagliflozin test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Empagliflozin Tablets 10 mg test product, treatment 2= Empagliflozin Tablets 10 mg reference product.
62510974|NCT06232239|EXPERIMENTAL|Sequence 2-Empagliflozin reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Empagliflozin Tablets 10 mg test product, treatment 2= Empagliflozin Tablets 10 mg reference product.
61971147|NCT03528993|OTHER|Control group|The control group will receive conventional rehabilitation for 45 min/day, following by postural control exercises 15 min/day 5 times/week for 4 weeks.
61971148|NCT05358951|ACTIVE_COMPARATOR|NON-COACHING CONDITION STEP-YA|"Participants will receive a single online education session and complete online questionnaires then be randomized to not receive additional coaching support sessions.~Participates will also complete follow up questionaires at 4 and 8 weeks post baseline."
61971149|NCT05358951|EXPERIMENTAL|COACHING CONDITION STEP-YA|"Participants will receive a single online education session and complete online questionnaire then be randomized to receive 2 individualized remote coaching sessions.~Participates will also complete follow up questionaires at 4 and 8 weeks post baseline."
62146326|NCT03731767|OTHER|Subject group|Distraction thrust manipulation of the talocural joint in supine position
62510975|NCT04802408|ACTIVE_COMPARATOR|Baby Shampoo Nasal Wash|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
61971150|NCT03764189|NO_INTERVENTION|en masse retraction only|anterior segment retraction on miniscrews without microosteoperforation
61971151|NCT03764189|ACTIVE_COMPARATOR|en masse retraction with alveocentesis|anterior segment retraction on miniscrews with microosteoperforation
61971152|NCT02563275|OTHER|Human fine motor skills measurements during weightlessness|
61971153|NCT02822768|ACTIVE_COMPARATOR|Packing|The patient is to have a long piece of gauze within the abscess cavity in an attempt to keep it open and allow purulent material to continue to drain after the initial incision and release of purulent material has been performed.
62146327|NCT02050555|PLACEBO_COMPARATOR|Koji-extracted beverage|100ml/day for 12 weeks
62146328|NCT02050555|EXPERIMENTAL|Koji-extracted beverage fermented with LP28|100ml/day for 12 weeks. 1x10\^11 cells (LP28)/day
62146329|NCT02265120|EXPERIMENTAL|primary care providers by region|A questionnaire will be given to a randomized sample of primary care providers who care for patients in the 194 federally designated regions of Primary Care provider shortage within California will be studied.
62146330|NCT03217123|EXPERIMENTAL|Deep Brain stimulation|After the surgery, a random sequence of contact activations (0 \[Nacc\],1,2 and 3), including sham (-), was generated for each patient. Each contact was activated using 130 Hz, 60 ms, and 4.5 V for three months (the sham activation was 0 V) following the patient's individual sequence, separated by one month of washout with the generator turned off
62146331|NCT00234000|EXPERIMENTAL|Arm 1|see description in intervention
62352098|NCT02451540|PLACEBO_COMPARATOR|Placebo|Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.
62352099|NCT01372449|ACTIVE_COMPARATOR|Memantine|
62352100|NCT01372449|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62510976|NCT04802408|ACTIVE_COMPARATOR|Listerine Gargle|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
62510977|NCT04802408|EXPERIMENTAL|Combination of Baby Shampoo Nasal Wash and Listerine Gargle|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
62510978|NCT04802408|PLACEBO_COMPARATOR|Saline Wash and Gargles|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
62510979|NCT00444236|ACTIVE_COMPARATOR|1|
62510980|NCT00444236|PLACEBO_COMPARATOR|2|
61971154|NCT02822768|PLACEBO_COMPARATOR|No packing|The patient is not to have packing of the abscess as part of the incision and drainage procedure
61971155|NCT03766308|EXPERIMENTAL|Highland barley diet|highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)
61971156|NCT03766308|ACTIVE_COMPARATOR|ADA diet|ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)
61971157|NCT01635972|EXPERIMENTAL|Isavuconazole and bupropion|Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.
61971158|NCT03758274|EXPERIMENTAL|CBT Phone Intervention|Cognitive-Behavioral Therapy for Treatment Seeking, CBT-TS, a manualized behavioral intervention, administered by telephone in a single session.
62146332|NCT06196853|NO_INTERVENTION|Control|5%DNSS/2 with KCL and MgSO4 IV infusion with rate 125 ml/m2/hr.
62146333|NCT06196853|EXPERIMENTAL|Treatment|5%DNSS/2 with KCL and MgSO4 IV infusion with rate 125 ml/m2/hr. plus aminophylline.
62146334|NCT05671211|ACTIVE_COMPARATOR|Control Group|Participants in control group will receive an exercise program consisted of upper and lower extremity strengthening and balance exercises.The exercises will be started as 8-10 repetitions and one set and the number of sets will be increased according to the progression of the patient. Exercises will be applied for 6 weeks, 5 days a week, for a total of 30 sessions, each session for 1 hour.
62352101|NCT00783172|EXPERIMENTAL|OGF & Gemcitabine|Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.
62352102|NCT02543502|EXPERIMENTAL|periodontal treatment|Group will receive treatment: periodontal treatment
62352103|NCT02543502|NO_INTERVENTION|Control Group.|Group will not receive treatment: periodontal treatment
62352104|NCT02986919|EXPERIMENTAL|CPI-0610 Treatment|CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break.
62510981|NCT04553913|EXPERIMENTAL|cooling device placed|A basic medical grade cooling pad will be secured to the non operative leg. Intermittent coolness will be assessed and subject will inform recovery room staff when sensation returns.
62707764|NCT01192880|PLACEBO_COMPARATOR|Placebo|Treatment Period 1: Participants will receive bitopertin matching placebo tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin matching placebo tablet orally once daily for 32 weeks (up to Study Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and will be switched to (in blinded manner) bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
62707765|NCT05503082|PLACEBO_COMPARATOR|w/o CGRPmAb|w/o CGRPmAb
62146335|NCT05671211|EXPERIMENTAL|Task-Oriented Training Group|Participants in the task-oriented training group will receive the same treatment given to the control group, with an additional 30 minutes of task-oriented training.Task-Oriented Training Program will include several everyday tasks (Getting up from the chair, walking 10 steps taking a book from the table and walking backwards to sit on the chair,Walking forward and sideways over obstacles...etc.).The exercises will be started as 12-15 repetitions and 1 set at the beginning, and the number of sets will be increased according to the progression of the patient. A total of 30 sessions will be applied, 5 days a week for 6 weeks, with a total of 1.5 hours of exercises.
62146336|NCT03406325||urticaria|Patients with this condition
62146337|NCT03406325||asthma|Patients with this condition
62707766|NCT05503082|ACTIVE_COMPARATOR|Tx w/ CGRPmAb|Tx w/ CGRPmAb
62707767|NCT03904485||SPKT|patients with end-stage diabetic nephropathy got simultaneous pancreas-kidney transplantation
62707768|NCT03904485||RT|patients with end-stage diabetic nephropathy got single kidney transplantation
62707769|NCT03381599|EXPERIMENTAL|Bone marrow aspirate|This study will utilize one group of participants. This group of participants will have bone marrow aspirate and a blood sample collected from the iliac crest and subsequently analyzed with the Arthrex Angel system. Thirty days following bone marrow aspiration, participants will receive a subcutaneous Filgrastim injection on four serial days. On the fifth day, a peripheral blood sample sample will be obtained.
62707770|NCT01014871|OTHER|intra-individual comparison|
62707771|NCT04606927|ACTIVE_COMPARATOR|Natriuresis guided treatment|
62707772|NCT04606927|NO_INTERVENTION|Standard of care|
61971159|NCT03758274|ACTIVE_COMPARATOR|Being Read A Pamphlet on Alcohol Treatment|Guided review of a National Institute on Alcohol Abuse and Alcoholism (NIAAA) pamphlet on AUD treatment, administered by telephone in a single session.
62510982|NCT04553913|NO_INTERVENTION|standard of care no intervention|Subjects in intervention arm will serve as their own control; standard nursing pinprick testing on the same (non-operative) thigh
62510983|NCT00097786|EXPERIMENTAL|Valsartan 160 mg + nateglinide 60 mg|For the first 2 weeks of treatment, patients took the combination of nateglinide 30 mg (3 times daily, ante cibum \[ac\] before meals) and valsartan 80 mg (once daily \[od\] in the morning). After 2 weeks, patients were up-titrated to nateglinide 60 mg ac and valsartan 160 mg od.
62707773|NCT01409096|ACTIVE_COMPARATOR|Pregnenolone|This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.
62707774|NCT01409096|PLACEBO_COMPARATOR|Placebo|The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks.
62707775|NCT04573972|ACTIVE_COMPARATOR|Regular incentive|During the two-week intervention period, the standard incentive group will earn $2 per day when they meet their step goal, and this reward is earned regardless of whether they walk alone or with others.
62707776|NCT04573972|EXPERIMENTAL|Social Incentive|During the two-week intervention period, he social incentive group will earn $1 per day when they meet their step goal and an additional $1 if they walk 2,000 steps together with another study participant.
62707777|NCT02542618|EXPERIMENTAL|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
62707778|NCT02542618|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
62707779|NCT04507763||Patients with ankylosing spondylitis|Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease
61971160|NCT05505214|EXPERIMENTAL|Bacterial decolonization|Validated decolonization regimen
61971161|NCT05505214|EXPERIMENTAL|Topical corticosteroid|Mometasone furoate 0.1% cream
61971162|NCT05505214|EXPERIMENTAL|Combination|Validated decolonization regimen and mometasone furoate 0.1% cream
61971163|NCT04990154|EXPERIMENTAL|experimental group|The experimental group received a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
61971164|NCT04990154|NO_INTERVENTION|control group|the control group maintained their usual lifestyles
62146338|NCT03406325||eczema|Patients with this condition
62146339|NCT03406325||food allergy|Patients with this condition
62146340|NCT03406325||anaphylaxis|Patients with this condition
62146341|NCT03406325||mastocytosis|Patients with this condition
62146342|NCT03406325||mast cell activating syndrome|Patients with this condition
62146343|NCT00774709||1|
62146344|NCT02517385|EXPERIMENTAL|Phosphatidylcholine paste|One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84
62146345|NCT06510855|EXPERIMENTAL|Severe Aortic Stenosis (sAS) Cohort|Subjects with symptomatic severe native aortic stenosis with a Heart Team determination of eligibility for delivery of the DurAVR™ THV prosthesis.
62146346|NCT06510855|EXPERIMENTAL|Failed Surgical Aortic Bioprosthetic Valve (FAV) Cohort|Subjects with severe degeneration of surgically implanted aortic bioprosthetic valves with a Heart Team determination of eligibility for delivery of the DurAVR™ THV prosthesis.
62352105|NCT05568927||Post-pulmonary embolism patients|"Consecutive patients who, during the study period, underwent the SEARCH algorithm to a diagnostic endpoint at one of the UCAPE network of outpatient pulmonary embolism clinics (UC San Diego, UC Irvine, UC Los Angeles-Harbor, UC Los Angeles, UC Riverside, UC Davis, UC San Francisco or UC San Francisco-Fresno) three months or more after the occurrence of acute pulmonary embolism or any risk type.~The SEARCH algorithm is the standard of care throughout the UCAPE network, so the experimental portion of this study is limited to the reporting of the (de-identified) results to the evaluation group and the analyses described in Aims 1 and 2. However, there may be patients who are lost to follow up or have other reasons for which the SEARCH algorithm is not followed. Those patients will not be included in the study. The numbers of such patients will be recorded at each center."
62352106|NCT01928563|EXPERIMENTAL|Dapoxetine|Dapoxetine is administered
62510984|NCT00097786|EXPERIMENTAL|Valsartan 160 mg + nateglinide placebo|For the first 2 weeks of treatment, patients took valsartan 80 mg capsules (once daily \[od\] in the morning). After 2 weeks, patients were up-titrated to 160 mg valsartan od. Patients also received nateglinide placebo tablets (3 times daily, ante cibum \[ac\] before meals).
62510985|NCT00097786|EXPERIMENTAL|Nateglinide 60 mg + valsartan placebo|For the first 2 weeks of treatment, patients took nateglinide 30 mg tablets (3 times daily, ante cibum \[ac\] before meals). After 2 weeks, patients were uptitrated to 60 mg nateglinide ac. Patients also received valsartan placebo capsules (once daily \[od\] in the morning).
62510986|NCT00097786|PLACEBO_COMPARATOR|Placebo|Patients took 3 nateglinide placebo tablets (3 times daily, ante cibum \[ac\] before meals) and 1 valsartan placebo capsule (once daily \[od\] in the morning).
62510987|NCT03645382|PLACEBO_COMPARATOR|baked barley powder consumption|Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
62510988|NCT03645382|EXPERIMENTAL|jeju steam onion powder consumption|Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
62510989|NCT05393128|OTHER|Control group (Supine position)|"The patient will remain in the supine position for 2 hours and will be followed up with the physician and nurse.~After the patient is given one of the supine position, at any time during the 2-hour follow-up period, in case the patient's vital findings and SpO2 levels are beyond the normal findings, in case of a deterioration in the general condition related to the position or another reason, the position will be terminated with the physician's recommendation and the patient will be excluded from the sample. Or except these, in case the physician evaluates the patient and suggests that the position should be changed, the current position will be terminated, and the patient will be excluded from the sample by making a position change."
62510990|NCT05393128|EXPERIMENTAL|Experimental Group (Right lateral position)|"The patient will remain in the right lateral position for 2 hours and will be followed up with the physician and nurse.~After the patient is given one of the right lateral position, at any time during the 2-hour follow-up period, in case the patient's vital findings and SpO2 levels are beyond the normal findings, in case of a deterioration in the general condition related to the position or another reason, the position will be terminated with the physician's recommendation and the patient will be excluded from the sample. Or except these, in case the physician evaluates the patient and suggests that the position should be changed, the current position will be terminated, and the patient will be excluded from the sample by making a position change."
62510991|NCT05393128|EXPERIMENTAL|Experimental Group (Left lateral position)|"The patient will remain in the left lateral position for 2 hours and will be followed up with the physician and nurse.~After the patient is given one of the left lateral position, at any time during the 2-hour follow-up period, in case the patient's vital findings and SpO2 levels are beyond the normal findings, in case of a deterioration in the general condition related to the position or another reason, the position will be terminated with the physician's recommendation and the patient will be excluded from the sample. Or except these, in case the physician evaluates the patient and suggests that the position should be changed, the current position will be terminated, and the patient will be excluded from the sample by making a position change."
62510992|NCT06402344||Gestrinone implant|Young women using hormonal implant with gestrinone.
62146347|NCT01380145|EXPERIMENTAL|recMAGE-A3 Protein + AS15 Adjuvant|Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
62146348|NCT05738785||Home health care patients|Home health patients registered in the Anatolian side of Istanbul
62146349|NCT04672174|OTHER|Effect of hearing loss on dementia|Effect of hearing loss on dementia, collected with a standardized questionnaire
62352107|NCT01928563|EXPERIMENTAL|Udenafil|Udenafil is administered
62352108|NCT01928563|EXPERIMENTAL|Udenafil and Dapoxetine|Udenafil and Dapoxetine are co-administered
62352109|NCT01529814|EXPERIMENTAL|New abutment connection implant|Implant with new abutment connection
62352110|NCT01529814|ACTIVE_COMPARATOR|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
62146350|NCT03353961|EXPERIMENTAL|Adjunctive Internet-delivered ERITA|Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
62146351|NCT03353961|ACTIVE_COMPARATOR|Treatment as usual|Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
62146352|NCT03418922|EXPERIMENTAL|Part 1: Lenvatinib Plus Nivolumab|Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
62352111|NCT00373100|EXPERIMENTAL|Zinc|Zinc acetate
62352112|NCT00373100|PLACEBO_COMPARATOR|Placebo|Placebo
62352113|NCT01236859|PLACEBO_COMPARATOR|placebo|The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation
62352114|NCT01236859|ACTIVE_COMPARATOR|gabapentin|Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.
62510993|NCT06402344||Control group|Young women who never used hormonal implant with gestrinone.
62707780|NCT05943821|ACTIVE_COMPARATOR|Allopurinol|The patients will receive allopurinol at an initial daily dose of 200 mg. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100 mg (up to 300 mg during V2). Similarly, the dose may be increased by another 100 mg at visit 3 and by another 100 mg at the visit 4 (up to 500 mg during V4).
62707781|NCT05943821|PLACEBO_COMPARATOR|Placebo|The patients will receive placebo at an initial daily dose of 200 mg. The dose may be increased by another 100 mg at visit 3 and by another 100 mg at the visit 4 (up to 500 mg during V4).
62707782|NCT01209767|EXPERIMENTAL|cryolipolysis|
62707783|NCT01209767|ACTIVE_COMPARATOR|subcision|
61971165|NCT05602181|EXPERIMENTAL|ALL Phonics Instruction|Lessons for the treatment group will be 30-min. long using the ALL app with a known service provider. Lessons will include systematic instruction with four subskills per session (e.g., letter-sounds, sound blending, typing, and sight words). The words and subskills with rotate based on the data collected and the machine learning within the technology. The child will complete 100 lessons. The systematic instruction with subksills (e.g., sound blending, decoding) includes 10 trials per word and an instructional sequence that introduces the skill, two models, six trials of guided practice, and two trials of independent practice with corrective feedback.
61971166|NCT05602181|ACTIVE_COMPARATOR|ALL Sight Word|Lessons for the comparison group will be 30-min. long using the ALL app with a known service provider. Lessons will include systematic instruction with sight words. The child will also complete 100 lessons.No phonics instruction will be provided to this group through the ALL app.
62352115|NCT04715048|EXPERIMENTAL|Onabotulinumtoxin A|8-10 units of Botox will be injected in the glabellar lines in one side of the face in 3 different locations. This injection will happen once.
62352116|NCT04715048|EXPERIMENTAL|Prabotulinumtoxin A|8-10 units of Jeuveau will be injected in the glabellar lines in the other side of the face in 3 different locations. This injection will happen once.
62352117|NCT01691287|EXPERIMENTAL|Michael Method|14 group meeting, taking place once a week during 14 consecutive weeks
62352118|NCT00618995|EXPERIMENTAL|A|Arm A: ER niacin/laropiprant + Placebo to laropiprant
62352119|NCT00618995|EXPERIMENTAL|B|Arm B: ER niacin + Placebo to laropiprant
62352120|NCT00618995|EXPERIMENTAL|C|Arm C: laropiprant + Placebo to ER Niacin/laropiprant
62352121|NCT00618995|PLACEBO_COMPARATOR|D|Arm D: Placebo
62352122|NCT04655963|EXPERIMENTAL|Dose 1|All participants would receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within a seven-day span. A single session=600 pulses at 120% rMT, iTBS triplets at 50 Hz for 2 s and repeated every 10 s for a total of 190 s to left dlPFC. Total pulses=14,400.
62352123|NCT02789605|EXPERIMENTAL|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months
62352124|NCT02789605|PLACEBO_COMPARATOR|Placebo|Patient receiving placebo, orally taken, 4 times a day, during 3 months
62352125|NCT04588831|EXPERIMENTAL|Pre-fabricated|
62352126|NCT04588831|EXPERIMENTAL|Mouth-formed|
62352127|NCT04588831|EXPERIMENTAL|Custom-fitted|
62352128|NCT01778400|EXPERIMENTAL|Radiofrequency ablation|Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
62510994|NCT03449199|EXPERIMENTAL|TMX-049 40 mg QD (Once Daily)|TMX-049: 40 mg of TMX-049 to be taken orally, once daily
62707784|NCT01209767|ACTIVE_COMPARATOR|Control|Areas with cellulite that had no treatment performed were considered the control arm.
62707785|NCT00107575|ACTIVE_COMPARATOR|Standard treatment (ST)|Standard smoking cessation treatment (ST)
61971167|NCT05637398|ACTIVE_COMPARATOR|Colchicine 0.5 bid|Eligible HFpEF patients will be randomized in 1:1 ratio by an investigator with either colchicine 0.5 twice daily or usual care for 12 weeks
62352129|NCT01778400|ACTIVE_COMPARATOR|Ethanol|Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
62352130|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
62352131|NCT03114878|ACTIVE_COMPARATOR|TRT / EMDR|Tinnitus Retraining Therapy / Eye Movement Desensitization Reprocessing
62352132|NCT03114878|ACTIVE_COMPARATOR|TRT / CBT|Tinnitus Retraining Therapy / Cognitive Behavioral Therapy
62352133|NCT00284739|EXPERIMENTAL|Alteplase|Multiple Alteplase injection into the abscess collection to improve percutaneous drainage
62352134|NCT00284739|PLACEBO_COMPARATOR|Saline|Multiple normal saline injection into the abscess collection to improve percutaneous drainage
62352135|NCT04225884|ACTIVE_COMPARATOR|DTx for pain|Treatment A software
62352136|NCT04225884|SHAM_COMPARATOR|Control|Treatment B software
62352137|NCT04225884|OTHER|Standard care|Pain medication
62352138|NCT01634945|PLACEBO_COMPARATOR|Placebo|Placebo
62352139|NCT01634945|EXPERIMENTAL|FeFum porridge + IPT of malaria|
62352140|NCT01634945|EXPERIMENTAL|IPT of malaria|
62352141|NCT01634945|EXPERIMENTAL|FeFum porridge|
62352142|NCT01634945|EXPERIMENTAL|FePP porridge|
62352143|NCT05698043|EXPERIMENTAL|Sequence 1|"* Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~* Period 2: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~* Period 3: D013, D326, D337- A single oral dose of 3tablets under fasting condition~* Period 4: CKD-386(5)- A single oral dose of 1 tablet under fasting condition"
62707786|NCT00107575|EXPERIMENTAL|ST-BI|Standard treatment plus a brief alcohol intervention
62707787|NCT01599884|ACTIVE_COMPARATOR|N-acetylcysteine|N-acetylcysteine, 1800 mg twice daily
62707788|NCT01599884|PLACEBO_COMPARATOR|Sugar pill|Identical to active drug
62707789|NCT00907621|EXPERIMENTAL|Acupuncture|"Acupuncture with Seirin 020x15 mm sterile acupuncture needle:~Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36 on infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks."
62510995|NCT03449199|EXPERIMENTAL|TMX-049 200 mg QD (Once Daily)|TMX-049: 200 mg of TMX-049 to be taken orally, once daily
62510996|NCT03449199|PLACEBO_COMPARATOR|TMX-049 Placebo|
62707790|NCT00907621|NO_INTERVENTION|Control|"Infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks.~The Control group will have no intervention."
62707791|NCT02940548|ACTIVE_COMPARATOR|Nifedipine GITS|Nifedipine GITS 30\~60mg/day
61971168|NCT05637398|NO_INTERVENTION|Usual Care|Eligible HFpEF patients will be randomized in 1:1 ratio by an investigator with either colchicine 0.5 twice daily or usual care for 12 weeks
62146353|NCT03418922|EXPERIMENTAL|Part 2: Lenvatinib Plus Nivolumab|If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
62352144|NCT05698043|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~* Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~* Period 3: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~* Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
62352145|NCT03874351|EXPERIMENTAL|Active tDCS|Twenty minutes of direct current at intensity of 1.5 milliamperes (mA).
62352146|NCT03874351|SHAM_COMPARATOR|Sham tDCS|Thirty seconds of direct current at 1.5 mA, followed by 0 mA for the remaining time of the 20-minute stimulation period.
62352147|NCT01736631|EXPERIMENTAL|Cognitive behavioural therapy|Cognitive behavioural therapy for social phobia in people with bipolar disorder
62352148|NCT06236230|EXPERIMENTAL|levodopa/carbidopa/entacapone|levodopa/carbidopa/entacapone is a combination drug consisting of levodopa, carbidopa, and entacapone. Each tablet contains a 1:4 ratio of carbidopa to levodopa and 200 mg of entacapone. The optimum daily dosage of levodopa/carbidopa/entacapone must be determined by careful titration in each patient.
62352149|NCT06155240|EXPERIMENTAL|Yoga participant|Providing once weekly class for 8 weeks, participants will take part in performing yoga poses and yoga breathing and meditation for stress management
62352150|NCT05836129|EXPERIMENTAL|TM Group|The intervention used for this group is instruction in the Transcendental Meditation practice. It is a four day course of instruction with 1.5 hours of instruction over four consecutive days, followed by an additional 1.5 hours of instruction ten days later.
62352151|NCT05836129|ACTIVE_COMPARATOR|Active Control Group|This group will be offered an online stress reduction course consisting of two 20-60 minute classes for the first month of the trial.
62352152|NCT03982238|ACTIVE_COMPARATOR|Control group|continuous subcutaneous insulin infusion therapy
62352153|NCT03982238|EXPERIMENTAL|Metformin|metformin therapy
62352154|NCT03982238|EXPERIMENTAL|Dapagliflozin|Dapagliflozin
62352155|NCT03350867|EXPERIMENTAL|Personalized Insole Group|The participants will use insole with personalized support directed to your biomechanics necessities.
62352156|NCT03350867|PLACEBO_COMPARATOR|Placebo Group|The participants will use plane insoles.
62352157|NCT05602285||Usual care group|Usual IV securement
62352158|NCT05602285||Dislodgement device group|Usual IV securement plus dislodgement device
62352159|NCT02253641|ACTIVE_COMPARATOR|Standard Weight Loss Intervention|"Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al. (Samuel-Hodge, Carmen D., et al. Randomized Trial of a Behavioral Weight Loss Intervention for Low?income Women: The Weight Wise Program. Obesity 17.10 (2009): 1891-1899). The only modifications to the content (other than some general formatting) will be the combining of sessions 3 and 4 and sessions 6 and 7. These changes will allow us to fit the original 16-session curriculum into the 14-session format of our intervention."
62510997|NCT03122717|EXPERIMENTAL|Gefitinib + Osimertinib|"* Gerfitinib will administered orally at a pre determine dose daily~* Osimertinib will administered orally at a pre determine dose daily"
62510998|NCT05353036||Adolescents|Patients 12-21 years undergoing anesthetic care
62707792|NCT02940548|ACTIVE_COMPARATOR|Amlodipine besylate|Amlodipine besylate 5\~10mg/day
62707793|NCT06126692||Severe asthma anti-IL5/IL-5R starters (including Benralizumab cohort)|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ\>1.5 AND Fulfils national criteria for specific biologic treatment.
61971169|NCT02229747|EXPERIMENTAL|Meloxicam suspension|
62510999|NCT02216799|ACTIVE_COMPARATOR|Regular Insulin incorporated in parenteral nutrition|Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk, will be added to parenteral nutrition to run over 24 hours as 80% of the total insulin requirement of the preceding day administered via subcutaneous sliding scale
61971170|NCT02229747|ACTIVE_COMPARATOR|Diclofenac suspension|
61971171|NCT02229747|ACTIVE_COMPARATOR|Nimesulide suspension|
61971172|NCT00615095||1|Cases will be patients 18 years or older with a histologically confirmed, second or multiple primary melanoma.
62146354|NCT03579407|ACTIVE_COMPARATOR|Traditional Open Ended Trocar|Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
62511000|NCT02216799|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine adminstred at daily night, calculated as 80% of the total insulin requirement of the preceding day from the insulin administered via subcutaneous sliding scale
62511001|NCT02914769|PLACEBO_COMPARATOR|placebo|patients receiving a passive placebo
62511002|NCT02914769|EXPERIMENTAL|Ayahuasca|patients receiving Ayahuasca
62511003|NCT04768296|EXPERIMENTAL|Safety run-in Part (Dose Level1 [DL 1]): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2|Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-daycycle in combination with Topotecan at a dose of 1.25mg/m\^2 intravenously on Days1 through 5 of each 21-day cycle in DL1 of safety run-in part until disease progression or other criteria for study intervention discontinuation are met.
62511004|NCT04768296|EXPERIMENTAL|Safety run-in Part (DL2) +Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2|Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in combination with Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL 1 and DL 2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
62511005|NCT00933881||Gestational Diabetes Mellitus (GDM)|
62511006|NCT04030520|EXPERIMENTAL|intervention|participants will receive a behavioral intervention including counseling and offer of HIV oral fluid self test and PrEP
62511007|NCT04030520|ACTIVE_COMPARATOR|comparison|participants will be not be offered HIV oral fluid self test but receive counseling, condoms and offered PrEP
62511008|NCT05844631|EXPERIMENTAL|Golo for Life® Plan(G4LP) and Release Supplement|Participants will be instructed to use the resources provided and follow the G4LP for the duration of the study period. Participants will also take one capsule of Release three times a day, to be taken at the beginning of or during each meal, starting on Day 1. If a dose is missed before or during a meal, participants are instructed to take the dose as soon as they remember after the meal. Participants will be advised not to exceed three capsules daily.
62511009|NCT00362817|EXPERIMENTAL|Temozolomide & Intra-Arterial (IA) carboplatin|Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
62511010|NCT02622659|EXPERIMENTAL|Fuganlin Oral Liquid|"Fuganlin Oral Liquid:oral~less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day~Xiaoer Jiebiao Oral Liquid placebo:oral~1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day"
62511011|NCT02622659|ACTIVE_COMPARATOR|Xiaoer Jiebiao Oral Liquid|"Xiaoer Jiebiao Oral Liquid:oral~1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day~Fuganlin Oral Liquid placebo:oral~less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
62511012|NCT01999426|EXPERIMENTAL|Airway clearance intervention|Non-respiratory on-call physiotherapy treatment using airway clearance techniques
62511013|NCT01999426|ACTIVE_COMPARATOR|Airway clearance intervention 2|Specialist respiratory physiotherapy intervention using airway clearance techniques
62511014|NCT01567826|ACTIVE_COMPARATOR|standard of care lipid therapy|standard-care lipid-lowering therapy: Zocor or Lipitor
62511015|NCT01567826|EXPERIMENTAL|aggressive lipid therapy|aggressive lipid therapy: Crestor
62511016|NCT01343524||all subjects|all subjects who are enrolled in an industry-sponsored study that utilizes a sponsor-supplied spirometer.
61971173|NCT00615095||2|Controls will be patients 18 years or older with a histologically confirmed first primary melanoma diagnosed no earlier than 12 months prior to the study start date.
61971174|NCT00615095||3|Healthy controls will be subjects 18 years or older recruited from the general population through random digit dialing. These subjects will have no history of melanoma. They will also be frequency matched to cases on the basis of sex and 10-year age group.
62352160|NCT02253641|EXPERIMENTAL|Stress-Focused Weight Loss Intervention|Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al.. The participants in this arm will receive all of the content that the comparison group receives (just moderately condensed to allow time for additional components) plus a stress-reduction intervention woven into each of the sessions. The stress-reduction content aims to reduce stress by helping participants: (1) identifying and reducing exposure (to the degree possible) of current stressors, (2) change their perceptions of current stressors and (3) use healthier stress-coping techniques (e.g. yoga, meditation, etc.)
62352161|NCT03461432|EXPERIMENTAL|Personalised Cognitive Remediation Therapy (pCRT)|A case-control study design with pre- and post-therapy assessment, comparing a group of participants with schizophrenia who received standard CRT, with a similar group of participants receiving pCRT.
62352162|NCT02521389|EXPERIMENTAL|Part 1|3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects, respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects, to assess alternative dose levels or formulations (described below), if required.
62511017|NCT04157517|EXPERIMENTAL|Phase 1b SA Dose Escalation|Modakafusp alfa 0.1 to 6 milligram per kilogram (mg/kg), infusion, intravenously, once on Day 1 of each 21-days treatment cycle for up to 1 year.
62511018|NCT04157517|EXPERIMENTAL|Phase 2 Safety Lead-in Dose Expansion: Modakafusp Alfa + Pembrolizumab|"Melanoma with primary resistance to prior anti-PD1, acquired resistance to prior anti-PD1 or naïve to anti-PD1.~Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years. The starting dose of modakafusp alfa for dose expansion safety lead-in phase will be the RP2D determined in the previous Phase 1b dose escalation phase."
62352163|NCT02521389|EXPERIMENTAL|Part 2|Single dose, 2-way crossover design to assess a selected formulation of PWT-143 in the fed and fasted states in 8 subjects.
62352164|NCT00671723|PLACEBO_COMPARATOR|Normal saline|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
62539408|NCT06582056|OTHER|Participant with Stage III/Stage IV Periodontal Disease with Hemoglobin A1c level 8.0-10.0|Participants will be screened via periodontal exam for periodontal disease staging and point-of-care hemoglobin A1c (HbA1c) testing for type 2 diabetes (T2DM) status. Blood, saliva, subgingival plaque, and gingival crevicular fluid (GCF) will be collected
61971175|NCT04557397|OTHER|Part A|Subjects will receive fruquintinib, alone and with itraconazole.
61971176|NCT04557397|OTHER|Part B|Subjects will receive fruquintinib, alone and with rifampin.
61971177|NCT04208698|EXPERIMENTAL|CIN-102 Tablets Dose 1|CIN-102 tablets by mouth twice daily for 14 days
61971178|NCT04208698|PLACEBO_COMPARATOR|Placebo for CIN-102 Dose 1|Placebo tablets by mouth twice daily for 14 days
61971179|NCT04208698|EXPERIMENTAL|CIN-102 Dose 2|CIN-102 tablets by mouth twice daily for 14 days
62511019|NCT04157517|EXPERIMENTAL|Phase 2 Dose Expansion: Modakafusp Alfa + Pembrolizumab (Melanoma With Primary Resistance)|Melanoma With Primary Resistance to prior anti-PD1. Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years, in participants with unresectable/metastatic cutaneous melanoma with primary resistance to no more than 2 prior lines of anti-PD1 containing treatments in the metastatic setting. The dose of modakafusp alfa for dose expansion phase will be the modakafusp alfa RP2D in combination with pembrolizumab determined in the previous Phase 2 dose expansion safety-lead in phase.
62511020|NCT04157517|EXPERIMENTAL|Phase 2 Dose Expansion: Modakafusp Alfa + Pembrolizumab (Melanoma With Acquired Resistance)|Melanoma With Acquired Resistance to prior anti-PD1. Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years, in participants with unresectable/metastatic cutaneous melanoma with acquired resistance to no more than 2 prior lines of anti-PD1 containing treatments in the metastatic setting. The dose of modakafusp alfa for dose expansion phase will be the modakafusp alfa RP2D in combination with pembrolizumab determined in the previous Phase 2 dose expansion safety lead-in phase.
62511021|NCT04157517|EXPERIMENTAL|Phase 2 Dose Expansion: Modakafusp Alfa + Pembrolizumab (Melanoma naïve to anti-PD1)|Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years, in participants with unresectable/metastatic cutaneous melanoma naive to prior line of anti-PD1 containing treatments in the metastatic setting. The dose of modakafusp alfa for dose expansion phase will be the modakafusp alfa RP2D in combination with pembrolizumab determined in the previous Phase 2 dose expansion safety lead-in phase.
62511022|NCT02450877|EXPERIMENTAL|Azacitidine Treatment|: Subjects randomized to the experimental arm will receive up to 3 cycles of IV azacitidine on Days 1 through 7 at the dose selected from the safety run-in part.
62511023|NCT02450877|OTHER|Control Arm: 'Watch and Wait'|Subjects randomized to the control arm will undergo 'watch and wait' until clinical relapse (defined as at least 5% blasts in PB (peripheral blood) and/or BM (bone marrow) and/or proven histological extramedullary relapse).
62511024|NCT00920894|EXPERIMENTAL|yoghurt type minidrink containing plant stanol ester|
62511025|NCT00920894|PLACEBO_COMPARATOR|yoghurt type minidrink without plant stanol ester|
62511026|NCT02842463||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
62511027|NCT03887416|ACTIVE_COMPARATOR|Dapagliflozin|"The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet \[Farxiga\] given once daily (film coated tablets, oral use).~Dapagliflozin 10 MG Oral Tablet \[Farxiga\] will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
62511028|NCT03887416|PLACEBO_COMPARATOR|Placebo matching dapagliflozin|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
62511029|NCT04944082|NO_INTERVENTION|Remdesivir only|(Dose 200 mg day one, 100 mg daily days 2-5), duration may extend to 10 days of remdesivir (200 mg day one, 100 mg daily days 2-10)
62511030|NCT04944082|EXPERIMENTAL|Combination remdesivir plus ivermectin group|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
62352165|NCT00671723|ACTIVE_COMPARATOR|Hypertonic saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
62352166|NCT00671723|ACTIVE_COMPARATOR|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
62352167|NCT03199638|EXPERIMENTAL|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
62352168|NCT03199638|EXPERIMENTAL|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
62511031|NCT02801435|EXPERIMENTAL|Cohort 1-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 0.5% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
62511032|NCT02801435|PLACEBO_COMPARATOR|Cohort 1-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
62511033|NCT02801435|EXPERIMENTAL|Cohort 2-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 1.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
62511034|NCT02801435|PLACEBO_COMPARATOR|Cohort 2-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
62511035|NCT02801435|EXPERIMENTAL|Cohort 3-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 2.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
61971180|NCT04208698|PLACEBO_COMPARATOR|Placebo for CIN-102 Dose 2|Placebo tablets by mouth twice daily for 14 days
61971181|NCT03950648|EXPERIMENTAL|Spatial Cognitive Training|map reading and route-learning skills
61971182|NCT00203177|EXPERIMENTAL|Experimental 1|0.5 mg rasagiline mesylate oral once daily
61971183|NCT00203177|EXPERIMENTAL|Expermental 2|1.0 mg rasagiline mesylate oral once daily
61971184|NCT01995240|EXPERIMENTAL|Optimization|For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2\* MRI and DWI MRI scan.
61971185|NCT01995240|EXPERIMENTAL|Reproducibility|For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2\* MRI and DWI MRI scans within one week.
62511036|NCT02801435|PLACEBO_COMPARATOR|Cohort 3-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
62707794|NCT06126692||Severe asthma anti-IL4R starters|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ\>1.5 AND Fulfils national criteria for specific biologic treatment.
62707795|NCT06126692||Severe asthma anti-TLSP starters|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ\>1.5 AND Fulfils national criteria for specific biologic treatment.
62707796|NCT06126692||Severe asthma anti-IgE starters|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ\>1.5 AND Fulfils national criteria for specific biologic treatment.
61971186|NCT01818908|EXPERIMENTAL|DA-EPOCH|"Infused agents:~Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;~Bolus agents:~Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;~The details of dose adjustment are described in ref 1.~If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
61971187|NCT05790629|ACTIVE_COMPARATOR|Group (I) control|young permanent pulpy exposed carious tooth of the selected participants will be treated with specific technique called apexogenesis using bio-compatible material (endo-sequence putty ). This material is administrated to the tooth by placing about 2-4 mm bulk of material in the pulp champers at the cervical line then sealing the capping material with glass ionomer and stainless steel crown.
61971188|NCT05790629|EXPERIMENTAL|Group (II)|young permanent pulpy exposed carious tooth of the selected participants will be treated with specific technique called apexogenesis using bio-compatible material (neo-MTA putty). This material is administrated to the tooth by placing about 2-4 mm bulk of material in the pulp champers at the cervical line then sealing the capping material with glass ionomer and stainless steel crown.
61971189|NCT03847233|EXPERIMENTAL|Jetstream Atherectomy System|
61971190|NCT01955733|EXPERIMENTAL|BI 695500|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
61971191|NCT03590106|EXPERIMENTAL|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:~1. Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.~2. Demonstrate negative drug screens done randomly during their hospitalization.~3. Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).~4. Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.~5. Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
62352169|NCT01746940|PLACEBO_COMPARATOR|Group 1, Placebo Topical Solution|Group 1: Placebo group -Placebo solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . All placebo subjects, regardless of Von Frey filament test results, will undergo Phase 1 recovery (i.e. at least 90 minutes after cotton pledget removal) and associated required study procedures (including the final 12 lead ECG). After a minimum of 24 hours from the time of study drug pledget removal, the subject may continue the procedure, and the treatment reverts to standard anesthetic management (suitable products at the discretion of the investigator). Alternatively, at the investigator's discretion, the diagnostic procedure or surgery may be delayed until study termination.
62352170|NCT01746940|ACTIVE_COMPARATOR|Group 2, Cocaine HCl 4% Topical Solution|Group 2: Cocaine HCI 4% Group - Cocaine HCl 4% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total amount of Cocaine HCl 4% topical solution used will be recorded.
62352171|NCT01746940|ACTIVE_COMPARATOR|Group 3, Cocaine HCl 10% Topical Solution|Group 3: Cocaine HCI 10% Group - Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total amount of Cocaine HCl 10% topical solution used will be recorded.
62352172|NCT00387348|PLACEBO_COMPARATOR|Placebo-Placebo|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
62352173|NCT00387348|OTHER|Placebo-Escitalopram|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
62352174|NCT00387348|OTHER|Escitalopram-Placebo|Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks
62511037|NCT02801435|EXPERIMENTAL|Cohort 4-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 4.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
62707797|NCT06126692||Mild/moderate controlled asthma|Low/Medium dose of ICS/LABA +/- LTRA. ACQ \< 1.5. No exacerbations in the last year or need of Prednisolone treatment (OCS). Markers of T2 inflammation (B-eos ≥ 0.15 actual or ≥ 0.30 the last year or Sputum eos ≥ 3%, FeNO ≥ 25 ppb, allergens positivity). Not direct candidate for treatments with monoclonal antibodies.
61971192|NCT04931108|EXPERIMENTAL|Sequence 1|One pill of nitrendipine/atenolol combination (5/10mg) once daily for 6 weeks first, and followed by monotherapy for another 6 weeks, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily.
61971193|NCT04931108|EXPERIMENTAL|Sequence 2|Monotherapy for 6 weeks first, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily, followed by one pill of nitrendipine/atenolol combination (5/10mg) once daily for another 6 weeks.
62511038|NCT02801435|PLACEBO_COMPARATOR|Cohort 4-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
62511039|NCT01523587|EXPERIMENTAL|Afatinib|Patients receive afatinib tablets once daily
62511040|NCT01523587|ACTIVE_COMPARATOR|Erlotinib|Patients receive erlotinib tablets once daily
62511041|NCT05125562|PLACEBO_COMPARATOR|Placebo|100ml normal saline
62511042|NCT05125562|EXPERIMENTAL|10ml ExoFlo|10ml ExoFlo + 90ml normal saline
62511043|NCT05125562|EXPERIMENTAL|15ml ExoFlo|15ml ExoFlo + 85ml normal saline
62511044|NCT05818982|EXPERIMENTAL|Cohort A|Group A received afatinib (40 mg oral/day) every 6 weeks
62511045|NCT05818982|ACTIVE_COMPARATOR|Cohort B|Group B received irinotecan (140-180mg/m2 intravenous) every 2 weeks
62511046|NCT06615700|EXPERIMENTAL|Participant Group/Arm- NA-931|Experimental: NA-931 Capsule of NA-931 intervention
62511047|NCT06615700|PLACEBO_COMPARATOR|Participant Group/Arm- Placebo|Placebo Comparator: Placebo Capsule of placebo
62511048|NCT06183450||hearing subject|Adult normal hearing subjects, evaluated annually for 5 years,
62511049|NCT02617082||partial breast irradiation|
62511050|NCT01253317|EXPERIMENTAL|rhIGF-1|Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.
62146355|NCT03579407|EXPERIMENTAL|Fenestrated Blunt Trocar|Patients will undergo bone marrow aspiration using the Marrow Cellution bone marrow aspiration needle. This needle has several fenestrations along the trocar through which the bone marrow is aspirated. Approximately 8-10 mL of high concentrate bone marrow will be collected, which will not be concentrated.
62511051|NCT01637649||Stroke patients with dysphagia|Stroke patients with confirmed evidence of aspiration and severe dysphagia tha would require modified diet or nasogastric tube feeding
62511052|NCT01637649||Stroke patients without dysphagia|Stroke patients but with no gross evidence of dysphagia or with mild dysphagia with a Penetration aspiration scale of less than 4
62511053|NCT01637649||healthy volunteer group|healthy volunteers with no prior history of dysphagia or stroke and who are not included in the exclusion criteria
62707798|NCT06126692||Healthy controls|No history of respiratory diseases. No history of asthma or respiratory symptoms, normal lung function, no history of allergies. No lower or upper respiratory infections in the past 4 weeks.
61971194|NCT01447095|ACTIVE_COMPARATOR|Low dose prostacyclin|
61971195|NCT01447095|ACTIVE_COMPARATOR|High dose prostacyclin|
62146356|NCT04063124|EXPERIMENTAL|Intermittent D+Q|Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
62146357|NCT01131546|EXPERIMENTAL|Levamlodipine besylate (2.5mg)|
62146358|NCT01131546|EXPERIMENTAL|Levamlodipine besylate (5mg)|
62352175|NCT03078023|EXPERIMENTAL|swallowed sponge device|Swallowing a sponge prior to a clinical upper endoscopy. Patients diagnosed with Eosinophilic Esophagitis (EoE) \> than 15 Eosinophils per high power field (phf) and failed to respond to Proton Pump Inhibitors (PPI) therapy. Will be asked to swallow a sponge, this is a 10 minute procedure done in the office prior to their clinical upper endoscopy. This will be sent for histology, \>15 Eos phf would be considered active disease. We will compare the results of the sponge using the EPO staining technique compared to histologic response.
62146359|NCT01131546|ACTIVE_COMPARATOR|Amlodipine maleate (5mg)|
62511054|NCT06193369|EXPERIMENTAL|Intervention|Participants assigned to the intervention arm will the receive digital peer navigation intervention.
62146360|NCT04084522|PLACEBO_COMPARATOR|Standard Treatment Group|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40 kcal. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30% from fat, a fixed amount of 50g of oil would be given and the remaining amount of fat would be met by the invisible dietary fat. The source of visible dietary fat would be refined soyabean oil. This group would not receive any fat in the form of Desi ghee or butter or any nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
62511055|NCT06193369|NO_INTERVENTION|Waitlist Control|Participants assigned to the control arm will receive usual care. After completion of the study, they will have the option to receive the digital peer navigation intervention.
62511056|NCT01849016|EXPERIMENTAL|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
62511057|NCT01849016|PLACEBO_COMPARATOR|Placebo|Placebo 1 oral tablet twice daily during 6 months
62511058|NCT00743509|EXPERIMENTAL|Oral Cyclophosphamide and Sirolimus (OCR)|Sarcoma patients were given oral Cyclophosphamide and Sirolimus (OCR) in 28 day cycles.
62511059|NCT04530279||Referring hospital|Burn assessments performed in referring hospitals
62511060|NCT04530279||Burn centre|Burn assessments performed in the national burn centre
62511061|NCT04424849||COVID-19 patients|Patient tested positive for COVID-19 who had a CT scan
62539409|NCT05444257|EXPERIMENTAL|VX-121/TEZ/D-IVA|Part A: Participants will receive VX-121/TEZ/D-IVA once daily for 96 weeks. Part B: Participants will receive VX-121/TEZ/D-IVA once daily for an additional 48 weeks.
62707799|NCT01138514|ACTIVE_COMPARATOR|Clindamycin 1%/Benzoyl Peroxide 5%|
62707800|NCT01138514|ACTIVE_COMPARATOR|Reference Product|
61971196|NCT01447095|PLACEBO_COMPARATOR|Placebo|
61971197|NCT05660772|ACTIVE_COMPARATOR|Corticosteroid Injection|The cases assigned to this group will be injected intra-articularly in the knee with a corticosteroid. It will be administered once at the baseline visit of the study.
62707801|NCT01138514|PLACEBO_COMPARATOR|Vehicle|
61971198|NCT05660772|EXPERIMENTAL|Microfragmented Adipose Tissue (Mfat)|"Injection of Microfragmented Adipose Tissue derived using Lipogems® Kit~The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo lipoaspiration of their own adipose tissue for Mfat then this Mfat will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study."
61971199|NCT01896440|ACTIVE_COMPARATOR|Group A - standard ondansetron dose first|Group A will receive the standard dose of ondansetron (0.15 mg/kg) with the first cycle of chemotherapy and the high dose (0.3 mg/kg) with second cycle.
62707802|NCT04510207|EXPERIMENTAL|Investigational Vaccine 1|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP according to the immunization schedule of D0 \& D21.
62707803|NCT04510207|EXPERIMENTAL|Investigational Vaccine 2|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP according to the immunization schedule of D0 \& D21.
62707804|NCT04510207|PLACEBO_COMPARATOR|Placebo|Participants will receive 2 doses of Placebo according to the immunization schedule of D0 \& D21.
62707805|NCT04510207|EXPERIMENTAL|Investigational Vaccine 1b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP after 3 months following two doses of immunization.
62707806|NCT04510207|EXPERIMENTAL|Investigational Vaccine 2b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP after 3 months following two doses of immunization.
62707807|NCT04510207|PLACEBO_COMPARATOR|Placebo-b|Participants will receive a booster dose of Placebo after 3 months following two doses of immunization.
61971200|NCT01896440|ACTIVE_COMPARATOR|Group B - high dose ondansetron first|Group B patients will receive the higher dose of ondansetron (0.3 mg/kg) with the first cycle of chemotherapy and the standard dose (0.15 mg/kg) with the second.
61971201|NCT05651451|ACTIVE_COMPARATOR|Laser acupuncture group|All women in group (B) were received 24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point. Total duration of the training session was 30 minutes.Before starting the first treatment session, each woman was instructed briefly about the nature of the treatment to gain her confidence and cooperation. The surface of the treated skin was cleaned with alcohol wipe in order to remove any material that could absorb or disperse the radiationon the surface.The laser handheld device (laser beam spot size ≤ 36 mm2) was applied directly and perpendicularly to avoid scattering the beam, The Laser probe was applied to the surface of skin before switching on apparatus.
61971202|NCT05651451|ACTIVE_COMPARATOR|Diet regimen group|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
61971203|NCT04982198|EXPERIMENTAL|TKA assisted with ROSA® Knee System|TKA assisted with ROSA® Knee System
61971204|NCT04982198|ACTIVE_COMPARATOR|TKA with conventional surgical instrumentation|TKA with conventional surgical instrumentation
61971205|NCT06391723|ACTIVE_COMPARATOR|Active rTMS group|5 active rTMS before starting ECT, then from the sixth ECT session, an active rTMS session will occur the day before each ECT session
61971206|NCT06391723|PLACEBO_COMPARATOR|Sham rTMS group|5 sham rTMS before starting ECT, then from the sixth ECT session, a sham rTMS session will occur the day before each ECT session
61971207|NCT02389348|EXPERIMENTAL|combination OZ439 and DSM265|"Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265.~Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics."
61971208|NCT04648072|EXPERIMENTAL|Periarticular Injection + Adductor Canal Block (Local Anesthestic)|"The experimental arm with receive both the periarticular injection and the adductor canal block.~The periarticular injection will be performed by the surgeon and will consist of 100 mL of injectate being distributed in the following manner: 30 mL to the posterior capsule, 10 mL to the medial collateral ligament, 10mL to the lateral collateral ligament (ensuring not to infiltrate common peroneal nerve), 20mL to the quadriceps and anterior capsule, and 30 mL to the subcutaneous tissue. The periarticular injection will consist of 250 mg of ropivacaine, 30 mg of ketorolac, and 0.5 mg of epinephrine.~The adductor canal block will be completed by the anesthesiologist after spinal anesthesia has been initiated, but before the surgery commences. The block will be completed using an aseptic technique under dynamic, in-plane US guidance. 20 mL of injectate consisting of 100mg of ropivicaine and 50 mcg of epinephrine will be injected around the hyperechoic saphenous nerve."
61971209|NCT04648072|PLACEBO_COMPARATOR|Periarticular Injection + Adductor Canal Block (Normal Saline)|"The control arm with receive a periarticular injection and a sham adductor canal block.~The periarticular injection will be carried out in the same manner as described for the experimental group. The technical aspects of the sham adductor canal block will be the same as for the experimental arm; however, the injectate will consist of 20 mL of normal saline."
61971210|NCT03915496|EXPERIMENTAL|PF-04965842 200 mg|
61971211|NCT03915496|EXPERIMENTAL|PF-04965842 100 mg|
61971212|NCT03915496|PLACEBO_COMPARATOR|Placebo|
62352176|NCT01932931|ACTIVE_COMPARATOR|Cholecalciferol supplement (50ug)|Cholecalciferol supplement is given for 1 year through randomisation of both MDD patients and healthy controls.
62707808|NCT03983421||Students Enrolled In Coordinated Specialty Care|The number of students determined eligible for Coordinated Specialty Care that were originally screened through the PQ-B at the college counseling center.
62707809|NCT04713189|EXPERIMENTAL|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
62146361|NCT04084522|ACTIVE_COMPARATOR|Intervention Arm|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40kcal and 1.2-1.5gm protein per kg ideal body weight per day. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30-35% from fat, a fixed amount of 50g of ghee would be given in 3 divided doses of 30 ml to be taken raw, 20 ml to be used for cooking and the remaining amount of fat would be met by the invisible dietary fat. The source of visible fat would be exclusively Desi ghee. This group would not receive any fat in the form of butter or any other oil or any other nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
62707810|NCT04713189|EXPERIMENTAL|Placebo|Participants in the stage I were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
62707811|NCT02781363|OTHER|Candidates patients chest X-ray with pneumonia|thoracic sonography CXR Clinical control 48h
62707812|NCT02781363|OTHER|Candidates patients chest X-ray without pneumonia|thoracic sonography CXR Clinical control 48h
61971213|NCT01516931|EXPERIMENTAL|active rTMS and venlafaxine|"rTMS：Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.~venlafaxine：150-225mg/day"
61971214|NCT01516931|PLACEBO_COMPARATOR|sham rTMS and venlafaxine|Sham stimulation will be given at the same site and frequency, using a Magstim sham-coil system. During rTMS, participants will be instructed to keep their eyes open and relax.
61971215|NCT01516931|PLACEBO_COMPARATOR|venlafaxine alone|responders will be maintained on the same effective dose of venlafaxine for the entire duration of the RCT, unless they relapse and will have to exit the protocol and enter a naturalistic follow-up
62146362|NCT00337610|EXPERIMENTAL|sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day|
62146363|NCT00337610|PLACEBO_COMPARATOR|sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day|
62146364|NCT05997563|ACTIVE_COMPARATOR|Micronized progesterone|
62146365|NCT05997563|NO_INTERVENTION|Control|
62146366|NCT04353583||ICU patients|Inpatients with COVID-19 requiring ICU care
62146367|NCT04353583||Non-ICU patients|Inpatients with COVID-19 not requiring ICU care
62146368|NCT04864834|EXPERIMENTAL|SOK583A1 (40 mg/mL)|Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
62352177|NCT01932931|PLACEBO_COMPARATOR|Placebo|Placebo treatment (tablet) is given for 1 year through randomisation of both MDD patients and healthy controls.
62352178|NCT00357149|ACTIVE_COMPARATOR|A|Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.
62352179|NCT00357149|EXPERIMENTAL|B|Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).
62352180|NCT02319213|NO_INTERVENTION|Group C|The control group (Group C) was not subjected to laparoscopic intervention
62352181|NCT02319213|EXPERIMENTAL|Group L|Intraocular pressure measurement with 9 mmHg insufflation
62352182|NCT02319213|EXPERIMENTAL|Group M|Intraocular pressure measurement with 12 mmHg insufflation
62352183|NCT02319213|EXPERIMENTAL|Group H|Intraocular pressure measurement with 15 mmHg insufflation
62352184|NCT03082053|EXPERIMENTAL|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
62352185|NCT03082053|EXPERIMENTAL|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
62352186|NCT01922245|EXPERIMENTAL|anodal tDCS|Soterix 1x1 device: anodal tDCS administered to the left hemisphere
62352187|NCT02268448|EXPERIMENTAL|Clonidine|Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
62352188|NCT02268448|EXPERIMENTAL|Naltrexone|Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
62352189|NCT05840978|EXPERIMENTAL|Probiotics combined strains|Probiotics combined strains administered as oral capsules once daily
62352190|NCT05840978|EXPERIMENTAL|Probiotics single strain|Probiotics single strain administered as oral capsules once daily
62352191|NCT05840978|PLACEBO_COMPARATOR|Placebo|Placebo capsule administered orally once daily
62352192|NCT02576457|EXPERIMENTAL|BMS-936559|BMS-936559 Intravenous infusion on specified days
62352193|NCT02576457|OTHER|Placebo|Placebo on specified days
62352194|NCT05445518|EXPERIMENTAL|Jump Start Plus COVID Support (JS+CS) Group|Participants in this group will receive the Jump Start Plus COVID Support intervention for 24 months.
62352195|NCT05445518|ACTIVE_COMPARATOR|Healthy Caregivers-Healthy Children (HC2) Control Group|Participants in this group will receive the Healthy Caregivers-Healthy Children intervention for 24 months.
62352196|NCT06391944|EXPERIMENTAL|JMT101 combined with Osimertinib|JMT101 6mg/kg iv Q2W or Q3W, osimertinib 80mg or 160mg po QD until a treatment discontinuation criterion is met.
62352197|NCT06042530||Post-COVID condition|Patients experiencing persisting cognitive dysfunction and fatigue after a SARS-CoV-2 infection, three months or more after the infections
62352198|NCT06042530||Non-symptomatic controls|Persons experiencing no symptoms after the SARS-CoV-2 infection or have not been subject for at SARS-CoV-2 infection
62352199|NCT01226706|PLACEBO_COMPARATOR|Placebos|Placebo injected into the detrusor at Day 1,
62352200|NCT01226706|EXPERIMENTAL|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
62352201|NCT00842361|ACTIVE_COMPARATOR|Mix30|
62352202|NCT00842361|EXPERIMENTAL|SIAC|
62352203|NCT01553071|EXPERIMENTAL|Investigational|Fenretinide (4-HPR) plus Intravenous Safingol
62146369|NCT04864834|ACTIVE_COMPARATOR|Eylea EU (40 mg/mL)|"IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.~EU: European"
62707813|NCT05829837||Motor incomplete paraplegia patients|Participants with the age of 18 - 65, were selected for the study based on the following inclusion criteria: diagnosis of motor incomplete paraplegia at C or D level according to the spinal cord injury classification of the American Spinal Injury Association (ASIA) Impairment Scale with a neurological injury level between T2-S1.
61971216|NCT02317068|EXPERIMENTAL|High Atrial Base Rate Pacing|The base rate of pacemaker will be determined 75-100 beats/minute in condition that during first step of follow-up, his/her atrial pacing will be more than 80% of atrial high rate/automatic mode switch
61971217|NCT02317068|ACTIVE_COMPARATOR|Device Default|The base rate of pacemaker will be determined 60 beats/minute
61971218|NCT04384328|EXPERIMENTAL|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
61971219|NCT04384328|NO_INTERVENTION|Standard Care|Standard follow-up within the RPSOF-ASNR network, without systematic speech therapy sessions.
61971220|NCT04930016||Former DIQOL intervention group|In the present follow-up study no interventions are administered. This group encompasses patients who had been part of the intervention group of the completed RCT DIQOL with the following intervention: Patients answered QoL questionnaires after surgery and at 3, 6, 12, and 18 months postoperatively. Results were transferred to a QoL-profile consisting of 13 QoL scales. Three experts with various professional background used the individual patient's QoL-profile and clinical and sociodemographic information to generate a QoL-report including therapy recommendations which was sent to the patient's doctor. Specific therapeutic options for the treatment of QoL had been defined: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, and fitness.
61971221|NCT04930016||Former DIQOL control group|In the present follow-up study no interventions are administered. This group encompasses patients who had been part of the control group of the completed RCT DIQOL: Patients answered QoL questionnaires after surgery and at 3, 6, 12, and 18 months postoperatively but their doctor neither received a QoL-profile nor a QoL-report.
61971222|NCT03049280|EXPERIMENTAL|Transoral robotic surgery|
61971223|NCT02113501||HGT1a|HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months).
61971224|NCT02113501||HGT1b|HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).
61971225|NCT00721552|EXPERIMENTAL|I|prednisolone + sitagliptin
61971226|NCT00721552|EXPERIMENTAL|II|prednisolone + sitagliptin-placebo
61971227|NCT00721552|EXPERIMENTAL|III|prednisolone-placebo + sitagliptin
61971228|NCT00721552|PLACEBO_COMPARATOR|IV|prednisolone-placebo + sitagliptin-placebo
61971229|NCT00721552|NO_INTERVENTION|Healthy controls|12 healthy men will be included to assess postprandial microvascular function.
62146370|NCT05643222|ACTIVE_COMPARATOR|TES and performance assessment with Type A Red Tint Lens|6 subjects will be inserted with the Type A red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
61971230|NCT00721552|NO_INTERVENTION|Type 2 diabetic subjects|12 men with type 2 diabetes will be included in order to assess postprandial microvascular function.
61971231|NCT06506760|EXPERIMENTAL|Immersive Virtual Reality Therapy|Conventional orthopedic rehabilitation supplemented by VR therapy
61971232|NCT06506760|ACTIVE_COMPARATOR|Conventional rehabilitation|Conventional orthopedic rehabilitation
61971233|NCT06502574|EXPERIMENTAL|mobile application|Older adults will be asked to use the mobile application for atleast 6 months, and the scales will be re-administered face toface or online in the 3rd and 6th months of the intervention.
62146371|NCT05643222|ACTIVE_COMPARATOR|TES and performance assessment with Type B Red Tint Lens|6 subjects will be inserted with the Type B red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
62707814|NCT05829837||Non-ambulatory patients with complete spinal cord injury|Participants with the age of 18 - 65, were selected for the study based on the following inclusion criteria: non-ambulatory patients with diagnosis of motor complete paraplegia at A level according to the spinal cord injury classification of the American Spinal Injury Association (ASIA) Impairment Scale with a neurological injury level between T2-S1.
62707815|NCT06062693|EXPERIMENTAL|smart sensor egg training|An interactive hand trainer with integrated sensors was developed and can be used as input devices to a training which runs on the smartphone or tablet computer to train different finger, hand, and wrist functions.
61971234|NCT06502574|NO_INTERVENTION|Control|No intervention has been made.
61971235|NCT04856774|EXPERIMENTAL|SHR -1701 + BP102|
61971236|NCT03578159||Arsha Vidya Chhatralaya|Chhatralaya is residential setting for children 8 to 16 years old. It provides residence,food and education opportunities along with regular practice of Yoga, Spiritual sessions and vedic practices to learn and follow.
61971237|NCT04047498|EXPERIMENTAL|Within-subjects comparison of constant and alternating DBS|
61971238|NCT01255059||Female lung cancer group|Female, non-smoker, non-small cell lung cancer
61971239|NCT01255059||Health control|Female, non-smokers, no lung cancer or other types of cancers' healthy population
61971240|NCT04825418|EXPERIMENTAL|Therapeutic Hypothermia Group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Decompressive Hemicraniectomy care based on international guidelines except therapeutic hypothermia using surface cooling device.
61971241|NCT03354611|EXPERIMENTAL|Diagnostic Workup|The subjects will first have a pre-contrast CBBCT scan. Iodinated contrast will be injected intravenously, and then another CBBCT scans will be performed to capture the tumor vasculature enhancement.
61971242|NCT01524692|EXPERIMENTAL|Single ARM Dovitinib treatment|Single ARM Dovitinib treatment
62146372|NCT05643222|ACTIVE_COMPARATOR|TES and performance assessment with Type C Red Tint Lens|6 subjects will be inserted with the Type C red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
62707816|NCT02428790||ABI Patients|Patients with acquired brain injury.
62707817|NCT02969135|EXPERIMENTAL|Progressive early passive and active movement|Active exercise starts one week after surgery.
62707818|NCT02969135|ACTIVE_COMPARATOR|Limited early passive movement|Active exercise starts six weeks after surgery.
61971243|NCT02976428|ACTIVE_COMPARATOR|Standard Soft Tissue Balancing|In the control group where the sensor device is not used in optimization of knee balance and alignment, definitive implants will be cemented in place and the sensor trial inserted using a thickness based on prior standard bearing insert trialing. Peak load data will be captured intraoperatively through full ROM. Custom shims will be affixed to the sensor to replicate thickness of the standard trial. The knee will then be cycled and loads recorded in the medial and lateral compartments at 10, 45 and 90 degrees of flexion. The surgeon will be blinded to the sensor output and the system will be located outside of their visual field.
62511062|NCT02577224|EXPERIMENTAL|Intervention|Participants randomized to the intervention group (patient-initiated treatment) will be asked to initiate their own treatment during the nine months they are taking part in the trial. Intervention group participants will receive information about when and how to initiate an appointment. Contact details for the service will be provided along with information on how quickly an appointment will be made, with whom and the procedure in the case of an emergency. All patients requesting an appointment will be booked in to the next available slot within the twice weekly ring-fenced nurse-led clinics. Any subsequent scheduled appointments will be cancelled and all future treatment will be initiated by the patient.
62511063|NCT02577224|NO_INTERVENTION|Control|Participants in the control group will receive treatment as usual. This consists of scheduled appointments in the hospital-based nurse-led botulinum toxin clinic. The frequency with which these appointments takes place are based on clinical judgement, but tend to range between every 6 weeks to every 4 months.
62511064|NCT05021237|EXPERIMENTAL|Safety Lead In|An interim safety evaluation will be conducted in a minimum of 10 assessable patients who received at least 3 radiation treatments (pulses) with 90 days follow up after radiation OR who experience a dose-limiting toxicity, as defined below. Patients not meeting these requirements will still count towards the overall trial enrollment target, however, the safety lead-in will continue until 10 fully assessable patients are reached (estimate 17 total patients needed for 40% attrition). These patients initially will be enrolled to the base dose-level of 8.5Gy/fraction.
62511065|NCT06612229|OTHER|operation for liver echinococcosis complicated by a biliary fistula|
62511066|NCT03968731|EXPERIMENTAL|ZEST treatment|The study subjects will receive the ZEST treatment protocol (Zocular Eyelid System treatment) to treat Meibomian Gland Dysfunction causing Contact Lens discomfort symptoms.
62511067|NCT02334241|EXPERIMENTAL|Sorbact®|The basic Sorbact® presentation is an antimicrobial, non-adhesive absorbent wound dressing. It consists of a highly absorbent hydropolymer matrix with an antimicrobial Sorbact® mesh (Sorbact® acetate fabric coated with dialkyl carbamoyl chloride - DACC) and is covered by a semipermeable polyurethane film.
62511068|NCT02334241|ACTIVE_COMPARATOR|Best local cares|Dressing requirements in this study have to be consistent with international guidelines.
62511069|NCT01838382|EXPERIMENTAL|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
62707819|NCT01162759|NO_INTERVENTION|Usual Care|The control group receiving usual care
62146373|NCT05643222|ACTIVE_COMPARATOR|TES and performance assessment with Type D Red Tint Lens|6 subjects will be inserted with the Type D red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
62146374|NCT00860457|EXPERIMENTAL|Chemotherapy|Fludarabine/Rituximab followed by Lenalidomide
62146375|NCT02162082|EXPERIMENTAL|stent or scaffold|implantation of stents or scaffolds after recanalization of coronary chronic total occlusions
62146376|NCT05410106|EXPERIMENTAL|PneuX endotracheal tube|Patients will be intubated using the PneuX endotracheal tube system
62511070|NCT01445418|EXPERIMENTAL|Arm 1|Standard dose escalation
62511071|NCT01445418|EXPERIMENTAL|Arm 2|Expanded cohort
62511072|NCT04877587|EXPERIMENTAL|Ascorbate in combination with Gemcitabine|"The study will begin with a safety run-in.~A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. Gemcitabine is administered following standard fixed dose infusion practice adopted at The University of Iowa Hospitals \& Clinics. Ascorbate is infused prior to gemcitabine. Cycles are 28 days. Patients will be treated for a total of 6 cycles and assessed every 2 cycles for disease response."
62511073|NCT04412057|EXPERIMENTAL|CERC-002|
62511074|NCT04412057|PLACEBO_COMPARATOR|Placebo|
62511075|NCT04657276||Down Syndome|Infants with Down Syndrome
62146377|NCT05410106|ACTIVE_COMPARATOR|Standard care|Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).
62146378|NCT06178380|ACTIVE_COMPARATOR|standard rehabilitation|rehabilitation of knee osteoarthritis patients using standard techniques of massage, stretching, muscle strengthening and balance work
62146379|NCT06178380|EXPERIMENTAL|instrumental rehabilitation|rehabilitation of knee osteoarthritis patients using isokinetic, posturograph and antigravity treadmill
62146380|NCT01620788|EXPERIMENTAL|Indapamide 1.5mg / Losartan 50mg|
62146381|NCT01620788|EXPERIMENTAL|Indapamide 1.5mg / Losartan 100mg|
62146382|NCT01620788|ACTIVE_COMPARATOR|Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)|
62511076|NCT00518622|EXPERIMENTAL|1|25 mg b.i.d. MK7009
62511077|NCT00518622|EXPERIMENTAL|2|75 mg b.i.d. MK7009
62511078|NCT00518622|EXPERIMENTAL|3|250 mg b.i.d. MK7009
62511079|NCT00518622|EXPERIMENTAL|4|500 mg b.i.d. MK7009
62511080|NCT00518622|EXPERIMENTAL|5|700 mg b.i.d. MK7009
62511081|NCT00518622|EXPERIMENTAL|6|125 mg q.d. MK7009
62707820|NCT01162759|EXPERIMENTAL|Home Blood Pressure Monitoring Group|Intervention group
62707821|NCT03713801|EXPERIMENTAL|Metformin|Dosage is increased over the first 3 weeks up to three 500 mg tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
62707822|NCT03713801|PLACEBO_COMPARATOR|Placebo|Placebo tablet dosage is increased over the first 3 weeks up to three tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
62707823|NCT01363102|NO_INTERVENTION|Control group|Group will undergo usual mobilization per standard SICU care
62146383|NCT01620788|ACTIVE_COMPARATOR|Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)|
62146384|NCT05873205|EXPERIMENTAL|Participants with Refractory Immune Cytopenias|Participants will be adults who develop Immune Cytopenias/ICs after Allogeneic Hematopoietic Cell Transplantation/allo-HCT and who did not respond to initial immunosuppressive therapy.
61971244|NCT02976428|EXPERIMENTAL|Sensor Guided Soft Tissue Balancing|In the experimental group where the sensor device is used to optimize balance and alignment, the sensor trial will be inserted and tibial baseplate rotated until medial and lateral femoral contact points are parallel on the sensor output. Quantitative balance is defined as a mediolateral intercompartmental loading difference of ≤15 pounds. Flexion balance is achieved when femoral contact point position is within the midposterior third of the tibial insert and intercompartmental loads are balanced. Loads in the medial and lateral compartments are recorded at 10, 45 and 90 degrees. If compartment loads differ by \>15 lbs between compartments, unbalanced, further soft tissue release/bone resection will be done to achieve a side to side compartment pressure difference of \<15 lbs through ROM.
62146385|NCT03314259|EXPERIMENTAL|Tamsulosin|Patients will then consume oral tamsulosin 0.4mg every morning daily for 5 days prior to elective surgery
62146386|NCT03314259|PLACEBO_COMPARATOR|Placebo|Patients will then consume placebo every morning daily for 5 days prior to elective surgery
62146387|NCT05370378|EXPERIMENTAL|Group A|This group of participants will receive Hold Relax with Agonist Contraction (HR-AC) technique with routine physical therapy. The protocol will be given to the participants for two weeks (6 sessions on alternate days, 3 session per week). Each session will be of 60 minutes. The data will be collected before applying intervention, at first week and at 2nd week.
62146388|NCT05370378|ACTIVE_COMPARATOR|Group B|This group of participants will receive Active Release Therapy, a kind of soft tissue mobilization along with routine physical therapy. The protocol will be given to the participants for two weeks (6 sessions on alternate days, 3 session per week). Each session will be of 60 minutes. The data will be collected before applying intervention, at first week and at 2nd week.
62146389|NCT05318963|EXPERIMENTAL|LCAR-AIO cells product|Each subject will be given a single-dose LCAR-AIO cells infusion at each dose level.
62146390|NCT04518709|EXPERIMENTAL|Posterior Annulus Elevation Technique Group|In patients who were determined in the treatment group, after the conventional procedure for mitral valve repair was completed, a posterior mitral valve elevation technique will be performed.
62511082|NCT00518622|EXPERIMENTAL|7|600 mg q.d. MK7009
62511083|NCT00518622|EXPERIMENTAL|8|Placebo
62511084|NCT01885416|ACTIVE_COMPARATOR|high fat meal without dairy products|high fat meal without dairy products
62511085|NCT01885416|EXPERIMENTAL|high fat meal with additional milk|high fat meal with additional milk
62707824|NCT01363102|EXPERIMENTAL|Study Group|Patient mobilization discussed on rounds, SOMS score goal created, specific attempt to mobilize patient and achieve goal throughout day.
62707825|NCT00646230|EXPERIMENTAL|Single arm of CIV infusion of emulsion 4-HPR|Single arm study of continuous intravenous infusion (CIV) of emulsion 4-HPR
62146391|NCT04518709|PLACEBO_COMPARATOR|Without Posterior Annulus Elevation Technique Group|No additional procedure will be done after conventional mitral valve repair
62511086|NCT01885416|EXPERIMENTAL|dairy product meal|dairy product meal
62511087|NCT01253395|EXPERIMENTAL|Strength training|Supervised strength training.
62511088|NCT01253395|ACTIVE_COMPARATOR|Aerobic exercise|Supervised aerobic exercise.
62511089|NCT02096484|EXPERIMENTAL|Metacognitive Therapy|Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
62146392|NCT04751981|EXPERIMENTAL|Patient Specific Guide|Patients randomized into this group will have pedicle screws placed with the aid of patient specific surgical guides.
62511090|NCT02096484|EXPERIMENTAL|Mindfulness Meditation Therapy|Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
62511091|NCT04213209||Brentuximab Vedotin 1.8 mg/kg (body weight)|The usual dosage for intravenous administration is 1.8 milligrams per kilograms (mg/kg) (body weight) as Brentuximab Vedotin (genetic recombination) once every three weeks (up to 12 months). The dose may be reduced appropriately according to the participant's condition. Participants receive interventions as part of routine medical care.
62511092|NCT00468793|ACTIVE_COMPARATOR|2|Fluid therapy guided by blood pressure and urine production
62146393|NCT04751981|OTHER|Navigation|Patients randomized into this group will have pedicle screws placed with conventional navigation.
62707826|NCT01133847|EXPERIMENTAL|Intensive Reading Instruction|Specialized phonologically-based reading instruction provided by well-trained tutors either individually (one-on-one) or to groups of two students for 45 minutes, four days per week, for 16 weeks. The instructional approach includes an individualized combination of published programs targeting word reading and decoding; reading fluency; and reading comprehension.
62146394|NCT03183050|EXPERIMENTAL|Question Prompt List|This is a single-arm study. Therefore, all participants will receive the prompt list.
62511093|NCT00468793|EXPERIMENTAL|1|ScvO2 guided fluid therapy
62511094|NCT06467565|EXPERIMENTAL|NALIRIFOX|NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
62511095|NCT03172052|EXPERIMENTAL|streptokinase instillation|Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred and if drained fluid through the tube was \<100 cc in 24 h provided that tube is patent and properly positioned.
62511096|NCT03172052|EXPERIMENTAL|instillation of MESNA|Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
62511097|NCT03172052|EXPERIMENTAL|Medical thoracoscopy procedure|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope
62511098|NCT03172052|EXPERIMENTAL|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
62511099|NCT03663790|NO_INTERVENTION|Control|No intervention
61971245|NCT02208557|ACTIVE_COMPARATOR|Control|Laparotomy closure will be done by continuous PDS suture following a SL:WL ratio of 4:1 only is used for midline laparotomy closure.
61971246|NCT02208557|EXPERIMENTAL|Reinforcement with Absorbable Mesh|"Closure of the midline laparotomy incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore \& Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a sandwich method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1."
61971247|NCT05285605||Emergency Contraceptive Group|Group of participants receiving emergency contraception in the form of 3 packages of ulipristal acetate to use at home if needed.
61971248|NCT00307294|EXPERIMENTAL|thalidomide and doxil|Combination of Thalidomide and Doxil
61971249|NCT00576121||1|Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
61971250|NCT00576121||2|End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
61971251|NCT00576121||3|End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
61971252|NCT06131697|EXPERIMENTAL|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises including retraction with neck flexion, extension, lateral flexion and rotation exercises.
62511100|NCT03663790|EXPERIMENTAL|Foot Progression|Participants will visualize a desired foot progression angle bandwidth in real-time that they should target with their foot angle
61971253|NCT06131697|EXPERIMENTAL|McKenzie Exercises with Mulligan Mobilization|McKenzie Exercises including retraction with neck flexion, extension, lateral flexion and rotation exercises and Sustained Natural Apophyseal glide.
61971254|NCT01464489|EXPERIMENTAL|Control group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.And receive normal saline for control group
62146395|NCT03754660|EXPERIMENTAL|Untreated patients (Part A and Part B)|"Part A: Untreated PAH and CTEPH patients will be enrolled to test 5 ascending doses of BAY1237592 with 4 patients per dose group up to a maximum dose of 4000 µg.~Part B: The highest safe, well tolerated and effective dose of Part A will be tested in further untreated patients."
62511101|NCT03663790|EXPERIMENTAL|Trunk Lean|Participants will visualize a desired trunk lean angle bandwidth in real-time that they should target with their trunk lean angle
61971255|NCT01464489|ACTIVE_COMPARATOR|Atropine group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.
61971256|NCT01065623|EXPERIMENTAL|Arm 1|
61971257|NCT02054221|OTHER|extended myectomy + MVreplacement|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy with full isscheniem subvalvular apparatus and mitral valve replacement.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
62146396|NCT03754660|EXPERIMENTAL|Monotherapy (Part B)|The highest safe, well tolerated and effective dose chosen from Part A will be tested in pre-treated patients with any kind of monotherapy for PAH/CTEPH.
62511102|NCT02948725|EXPERIMENTAL|cross-education + standard rehabilitation|The cross-education group will engage in strength training of the non-paretic hand in addition to standard rehabilitation. Cross-education will be progressive in nature, beginning with 2 sets of 8 repetitions and increasing up to a maximum of 6 sets of 8 repetitions of maximal voluntary effort isometric handgrip contractions as tolerated. Grip training will be performed using standard grip trainers (Digi-Flex Grip trainers) to train both finger flexors and full hand and wrist isometric contractions. In addition, patients will perform controlled dynamic wrist flexion and extension training of the non-paretic hand using exercise tubing with the same prescription. Patients will be asked to complete exercises 3 times per week for 26 weeks, and to record adherence in a training log. An average of one session per week will be considered 'trained'.
62511103|NCT02948725|NO_INTERVENTION|standard rehabilitation|Standardized rehabilitation involves several strategies tailored to the patient and remains somewhat based on clinician preference. These therapies may involve functional electrical stimulation, neuro-facilitation, strengthening, range of motion (ROM), mirror therapy, and force-use therapy (e.g., CIMT). Patients engage in therapy 5 days per week as inpatients, and 2 days per week as outpatients with additional home exercises. Specific therapies for each patient will be tracked using a therapy log.
62146397|NCT03754660|EXPERIMENTAL|Combined therapy (Part B)|The highest safe, well tolerated and effective dose from Part A will be tested in pre-treated patients with any kind of double combination treatment for PAH/CTEPH.
62511104|NCT00141661|EXPERIMENTAL|Low Dose Arm|
62511105|NCT00141661|EXPERIMENTAL|High Dose Arm|
62511106|NCT00141661|PLACEBO_COMPARATOR|Placebo Control|
62511107|NCT01139684|EXPERIMENTAL|Exercise|
62511108|NCT03275584|EXPERIMENTAL|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
61971258|NCT02054221|OTHER|extended myectomy + MVrepair|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles and the mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
62146398|NCT04042298||5-FU Chemotherapy (Experimental)|Comprised of newly diagnosed cancer patients 21 years or older who have received 5-FU chemotherapy within the past 30 days or are scheduled to receive 5-FU chemotherapy.
62352204|NCT01925612|EXPERIMENTAL|Part 1: BV(1.2 mg/kg) + RCHOP|"Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
62352205|NCT01925612|EXPERIMENTAL|Part 1: BV(1.8 mg/kg) + RCHOP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
62352206|NCT01925612|EXPERIMENTAL|Part 2: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
61971259|NCT04140292|EXPERIMENTAL|Vitamin D3 + Photodynamic therapy (PDT)|Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
61971260|NCT05779293|EXPERIMENTAL|non-invasive auricular vagus nerve stimulation|non-invasive auricular vagus nerve stimulation + Neuromuscular Electrical Stimulation (NMES) exercise under the supervision of a physiotherapist
61971261|NCT05779293|ACTIVE_COMPARATOR|Conventional physical therapy|NMES exercise under the supervision of a physiotherapist
61971262|NCT03147014|OTHER|Maternal Hyperoxygenation|Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.
61971263|NCT05909098|EXPERIMENTAL|NK cell|autologous NK cell adjuvant therapy
61971264|NCT01450436||preterm infants (<35 weeks gestation)|
61971265|NCT01080352|EXPERIMENTAL|Vitamin C treatment|"Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.~5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20."
61971266|NCT04672928|EXPERIMENTAL|IBI318 in combination with paclitaxel|
61971267|NCT03898141|EXPERIMENTAL|Animal-assisted placebo condition (AAPL)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream.~Additionally, they will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high de-gree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Therefore, the distance between participant and dog will always be the same. However, partici-pants will still be able to see the dog."
61971268|NCT03898141|PLACEBO_COMPARATOR|Placebo only (PO)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
62511109|NCT06188507|EXPERIMENTAL|Part 1: Cohort 1-GSK4347859 or Placebo|Participants in Part 1 Cohort 1 will receive a single dose level of GSK4347859 dose level 1 or placebo in treatment period 1, followed by GSK4347859 dose levels 2 and 3 or placebo in 3- period dose escalation design. Additionally, there will be an optional 4th treatment period with dose level 4. Followed by a wash out period of at least 7 days between each dose.
62146399|NCT04042298||Non-5-FU Chemotherapy (Sub-Control)|Comprised of newly diagnosed cancer patients 21 years or older who have received chemotherapy other than 5-FU within the past 30 days or are scheduled to receive chemotherapy other than 5-FU.
62146400|NCT04042298||Age/Sex matched Control (Control)|Age, biological sex, and prior health history (excluding cancer diagnosis) matched control for cancer patients
62146401|NCT04042298||5-FU Chemotherapy Cancer Survivor (Survivor)|Cancer survivors who have not received cancer therapy during the past year but previously received 5-Fluorouracil chemotherapy.
62146402|NCT04365205||severe asthma|"* Diagnosis of severe asthma according to the American Thoracic Society / European Respiratory Society task force.~* Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in Forced expiratory volume forced expiratory volume at one second (FEV1) within 12 months before enrollment.~* Documented blood eosinophils ≥ 300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1."
62146403|NCT04365205||non-severe asthma|• Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA).
61971269|NCT03898141|EXPERIMENTAL|Dog only (DO)|"Participants will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. During the experiment the dog will be lying in the room with some distance to avoid further physical interaction.~After the introduction of the dog, participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements"
61971270|NCT03898141|NO_INTERVENTION|No dog, no placebo (ND)|Participants will participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements.
61971271|NCT03592108|EXPERIMENTAL|CSR remote monitoring|The remote monitoring of CPAP treatment will be modified in order to detect the presence of CSR as soon as any significant increase of the apnea-hypopnea index occurs.
61971272|NCT01606930|NO_INTERVENTION|Usual Care Group|"Group will see their physician without receiving the activation instrument."
61971273|NCT01606930|ACTIVE_COMPARATOR|"Activated Group"|"Group will be given an activation instrument to complete before their appointment and instructed to refer to and use the instrument during their clinical encounter."
61971274|NCT04340401|EXPERIMENTAL|TNT+SHR1210|"Patients with high-risk locally advanced rectal cancer will receive chemotherapy and SHR-1210 before chemoradiaton, after chemoradiaton, patient will receive consolidation chemotherapy. This arm is called Total Neoadjuvant Treatment (TNT) plus SHR-1210. The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX ( Capecitabine + Oxaliplatin ) plus SHR-1210 over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs."
61971275|NCT00987220||Placebo|
61971276|NCT00987220||donepezil (Aricept)|
61971277|NCT01228760|EXPERIMENTAL|Dose level 1|
61971278|NCT01228760|EXPERIMENTAL|Dose level 2|
61971279|NCT01228760|EXPERIMENTAL|Dose level 3|
61971280|NCT01228760|EXPERIMENTAL|Dose level 4|
61971281|NCT01228760|EXPERIMENTAL|Dose level 5|
61971282|NCT01228760|EXPERIMENTAL|Dose level 5A|
61971283|NCT01228760|EXPERIMENTAL|Dose level 6|
61971284|NCT01228760|EXPERIMENTAL|Dose level 7|
61971285|NCT01228760|EXPERIMENTAL|Dose level 8|
61971286|NCT01228760|EXPERIMENTAL|Dose level 9|
61971287|NCT01228760|EXPERIMENTAL|Chemotherapy-naïve subjects|
61971288|NCT01228760|EXPERIMENTAL|Chemotherapy exposed subjects|
61971289|NCT00126568|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61971290|NCT05558514|EXPERIMENTAL|Place-based map|CIs will be mapped according to each participant's unique place-based map using MED-EL MAESTRO fitting software. Participants' audiological performance will be assessed in both the experimental and default programs at activation and at 6 months. At 1-month and 3-month visits, performance will be assessed in the participant's assigned program only. Following the 6-month testing interval, participants will listen to the alternative map than the one they were assigned for 1 additional month. At the 7-month visit, participants will be assessed in both programs. After the 7-month visit, participants will be given the choice to move forward with whichever map they prefer. The final assessment interval will take place at 1-year in the participant's chosen map.
62146404|NCT04365205||non-asthmatic controls|"* No prior history of any chronic respiratory disease including asthma.~* No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.~* No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1.~* Normal lung function with FEV1 \> 90%."
62352207|NCT01925612|ACTIVE_COMPARATOR|Part 3: RCHOP|"Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone."
62511110|NCT06188507|EXPERIMENTAL|Part 1: Cohort 2-GSK4347859 or Placebo|Participants in Part 1 Cohort 2 will receive a single dose level of GSK4347859 dose level 5 or placebo in treatment period 1, followed by GSK4347859 dose levels 6 and 7 or placebo in 3- period dose escalation design. Additionally, there will be an optional 4th treatment period with dose level 8. Followed by a wash out period of at least 7 days between each dose.
62511111|NCT06188507|EXPERIMENTAL|Part 2: Cohort 3-GSK4347859 or Placebo|Participants in Part 2 Cohort 3 will receive 14 days of repeat doses of GSK4347859 dose level A or placebo.
61971291|NCT05558514|ACTIVE_COMPARATOR|Default map|CIs will be mapped according to the clinical default program using MED-EL MAESTRO fitting software. Participants' audiological performance will be assessed in both the experimental and default programs at activation and at 6 months. At 1-month and 3-month visits, performance will be assessed in the participant's assigned program only. Following the 6-month testing interval, participants will listen to the alternative map for 1 additional month from the one they were randomly assigned. At the 7-month visit, participants will be assessed in both programs. After the 7-month visit, participants will be given the choice to move forward with whichever map they prefer. The final assessment interval will take place at 1-year in the participant's chosen map.
61971292|NCT05532592||no hesitancy group (NHG)|Participants who got vaccine after transplantation or were willing to be vaccinated.
61971293|NCT05532592||hesitancy group (HG)|Participants who were uncertain or refused to be vaccinated.
61971294|NCT05086991||Group Study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, cardiac holter) and self analysis (hemoglobin, hematocrit, creatinine).
61971295|NCT01896544|ACTIVE_COMPARATOR|Cholecalciferol Dose II|Oral suspension cholecalciferol 400,000 IU
61971296|NCT01896544|PLACEBO_COMPARATOR|Placebo|Oral suspension of placebo cholecalciferol
61971297|NCT01896544|ACTIVE_COMPARATOR|Cholecalciferol Dose I|Oral suspension cholecalciferol 200,000 IU
62146405|NCT05110794|EXPERIMENTAL|LY3502970 (Fed)|LY3502970 administered orally to participants who are in a fed state.
62146406|NCT05110794|EXPERIMENTAL|LY3502970 (Fasted)|LY3502970 administered orally to participants who are in a fasted state.
62707827|NCT01133847|EXPERIMENTAL|ADHD Intervention|Carefully-managed medication and behavioral parent training. Medication treatment begins with a four-week titration period, beginning with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions provided by a psychologist addressing ADHD and its treatment, principals of behavior modification, and evidence-supported practices for managing behavior.
62707828|NCT01133847|EXPERIMENTAL|Combined ADHD and Reading Instruction|"All interventions described in Reading Instruction and ADHD treatment arms:~Phonologically-based reading instruction provided for 45 minutes, four days per week, for 16 weeks. Carefully-managed medication and behavioral parent training. Medication treatment begins with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions on parenting a child with ADHD."
61971298|NCT02056782|EXPERIMENTAL|Dociparstat|"The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
61971299|NCT05163600|EXPERIMENTAL|COPD|Diagnosed COPD according to GOLD-guidelines
61971300|NCT05163600|EXPERIMENTAL|Healthy|Age ≥ 18 years Clinically healthy
61971301|NCT05456464|EXPERIMENTAL|Reiki|The researcher, a second-degree Reiki therapist, performed the Reiki therapy. Patients were told to lie comfortably on their backs after they were informed about the therapy. Each of the 7 Reiki hand positions was applied sequentially. Each of the hand positions took 2-3 minutes, requiring 30-40 minutes in total.
61971302|NCT05456464|NO_INTERVENTION|Control group|Routine maintenance will be applied
62146407|NCT02568306|EXPERIMENTAL|NNC0165-1562|
62146408|NCT02568306|PLACEBO_COMPARATOR|Placebo|
62146409|NCT00725959|EXPERIMENTAL|Facebook Arm|Participants in this arm will have exposure to innovative, dynamic and regularly updated HIV Prevention messages on Facebook
62707829|NCT04277312|EXPERIMENTAL|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
61971303|NCT02122393|ACTIVE_COMPARATOR|Sertraline|
61971304|NCT02122393|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy|
61971305|NCT02122393|ACTIVE_COMPARATOR|Combined Therapy|
61971306|NCT00883116|EXPERIMENTAL|Ixabepilone, 40 mg/m^2, intravenously (IV)|Participants received ixabepilone, 40 mg/m\^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
61971307|NCT00883116|ACTIVE_COMPARATOR|Control chemotherapy (Paclitaxel or Doxorubicin)|Participants received either paclitaxel, 175 mg/m\^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m\^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m\^2.
61971308|NCT06215040||Asymptomatic common bile duct stone|
61971309|NCT00371137|PLACEBO_COMPARATOR|1|
61971310|NCT00371137|EXPERIMENTAL|2|
61971311|NCT04542785|EXPERIMENTAL|Lenient rate control|Treating physicians will target a resting heart rate between 80 and 110 beats per minute on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
62146410|NCT00725959|ACTIVE_COMPARATOR|Control arm|Participants in this arm will have exposure to static information on HIV prevention currently available online
62146411|NCT05071677||Observational (survey, interview)|Patients participate in a standard of care treatment planning meeting over 3 hours with members of the multidisciplinary treatment team including, the oncologist, radiologist, oncology surgeon, and social worker. Patients then complete surveys over 20 minutes and within 30 days later. Some patients may participate in interviews over 30 minutes.
62146412|NCT04250623|EXPERIMENTAL|subjects, 18-70 y, healthy|subjects, 18-70 y, healthy
62146413|NCT02024217|EXPERIMENTAL|chemoradiotherapy, S1, oxaliplatin|chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.
62146414|NCT02409043||Control|Non-stroke participants. Blood drawn for analysis of biomarkers.
62146415|NCT02409043||Ischemic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
62146416|NCT02409043||Hemorrhagic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
62146417|NCT02409043||Stroke Mimic|Participants presenting at the University of Florida Shands Emergency Department with signs and symptoms resembling a stroke, but which are determined to be from another cause. Blood drawn during initial emergency room evaluation.
62146418|NCT02198417|EXPERIMENTAL|Metformin|Metformin ER 1500 mg per day treatment for 12 weeks
62146419|NCT03940339|EXPERIMENTAL|Suboccipital myofascial release|Treatment will be given for 3 minutes, 3 days per week for 4 weeks.
62511112|NCT06188507|EXPERIMENTAL|Part 2: Cohort 4-GSK4347859 or Placebo|Participants in Part 2 Cohort 4 will receive 14 days of repeat doses of GSK4347859 dose level B or placebo.
62511113|NCT06188507|EXPERIMENTAL|Part 2: Cohort 5-GSK4347859 or Placebo|Participants in Part 2 Cohort 5 will receive 14 days of repeat doses of GSK4347859 dose level C or placebo.
62511114|NCT06369649|EXPERIMENTAL|Coolsense|For children in this group, the standard approach of the clinic will be applied first. The researcher will apply scales to the child before the procedure, the Child-Parent Information Form to the parents, and the child, parent and independent observer before and after the procedure. The patient's physiological parameters will be recorded by the nurse performing the procedure before, during and after the procedure. The device, which is removed from the freezer just before the injection, will be applied by the researcher to the skin surface where the procedure will be performed for approximately 5-10 seconds before the injection, and then the injection will be performed.
62707830|NCT04277312|EXPERIMENTAL|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
61971312|NCT04542785|ACTIVE_COMPARATOR|Strict rate control|Treating physicians will target a resting heart rate a mean resting heart rate \< 80 bpm on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
62146420|NCT03940339|ACTIVE_COMPARATOR|Coventional Physiotherapy|Treatment will be given for 3 days per week for 4 weeks
62511115|NCT06369649|EXPERIMENTAL|Buzzy|For children in this group, the standard approach of the clinic will be applied first. The researcher will apply scales to the child before the procedure, the Child-Parent Information Form to the parents, and the child, parent and independent observer before and after the procedure. The patient's physiological parameters will be recorded by the nurse performing the procedure before, during and after the procedure. The device, which will be removed from the freezer just before the injection, will be placed by the researcher in contact with the skin, 3 to 5 cm above the injection site. Buzzy will be started 30-60 seconds before the process and will continue until the end of the process.
62707831|NCT04277312|EXPERIMENTAL|Nourish and Engage|This arm of the intervention delivered both the Nourish and Engage interventions as detailed above.
61971313|NCT05036551||Stage 2 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
61971314|NCT05036551||Stage 3 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
62146421|NCT02832128|EXPERIMENTAL|AUT00063 - Placebo|AUT00063 (800 mg/day) for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with placebo
62146422|NCT02832128|EXPERIMENTAL|Placebo - AUT00063|Placebo for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with AUT00063 (800 mg/day)
62146423|NCT03775213|EXPERIMENTAL|Standard Treatment Options + Active Monitoring|Participants explore decision support tool that includes current standard treatment options for DCIS, as well as active monitoring.
62146424|NCT03775213|ACTIVE_COMPARATOR|Standard Treatment Options|Participants explore decision support tool that includes current standard treatment options for DCIS.
62146425|NCT06233552|ACTIVE_COMPARATOR|conventional denture conversion|a conventional denture conversion will be done following the conventional fabrication technique.
62146426|NCT06233552|EXPERIMENTAL|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
62146427|NCT02675322|EXPERIMENTAL|Danlou Tablets|Danlou tablets (4.5 g oral dose taken once daily) for 90 days
62146428|NCT02675322|PLACEBO_COMPARATOR|placebo|matching placebo for 90 days
62511116|NCT06369649|NO_INTERVENTION|Control|For children in this group, the standard approach of the clinic will be applied first. The researcher will apply scales to the child before the procedure, the Child-Parent Information Form to the parents, and the child, parent and independent observer before and after the procedure. The patient's physiological parameters will be recorded by the nurse performing the procedure before, during and after the procedure.
62511117|NCT03623620|EXPERIMENTAL|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
62511118|NCT03623620|NO_INTERVENTION|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
62511119|NCT05814432|EXPERIMENTAL|Single high dose arm|Single high dose of liposomal amphotericin B (10 mg/kg)
62707832|NCT04277312|NO_INTERVENTION|Delayed|The delayed arm of the intervention was the control arm. Schools randomised to this arm of the study were offered the Engage intervention resources after endpoint data collection.
62707833|NCT00725985|EXPERIMENTAL|Cladribine 5.25 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.
61971315|NCT05533281|EXPERIMENTAL|tropisetron|Troisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
62146429|NCT02747537|EXPERIMENTAL|Arm 1: Sorafenib and Irinotecan|"* Sorafenib is an oral drug which will be administered on an outpatient basis twice a day continuously (every day of a 21-day cycle) at approximately the same times each day. For patients unable to swallow whole pills, an oral suspension may be prepared with tablets.~* Irinotecan will be administered orally (mixed with cranberry type juice) on an outpatient basis once a day on Days 1-5 of a 21-day cycle. Irinotecan should be given at least 1 hour after sorafenib."
62707834|NCT00725985|EXPERIMENTAL|Cladribine 3.5 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
62146430|NCT03839550|EXPERIMENTAL|Apatinib Mesylate +SHR-1210|Experimental arm: Apatinib mesylate +PD-1 antibody SHR-1210 for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
62146431|NCT03839550|ACTIVE_COMPARATOR|Hepatic Arterial Infusion(HAI)|Active Comparator arm: HAI for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
62146432|NCT03270709|EXPERIMENTAL|HIV+ smokers|Vitamin D3 450,000 IU orally
62146433|NCT03270709|ACTIVE_COMPARATOR|HIV- non-smokers|Vitamin D3 450,000 IU orally
62146434|NCT03270709|ACTIVE_COMPARATOR|HIV+ non-smokers|Vitamin D3 450,000 IU orally
62146435|NCT03270709|ACTIVE_COMPARATOR|HIV- smokers|Vitamin D3 450,000 IU orally
62146436|NCT00635700|EXPERIMENTAL|Ziprasidone|Patients will be treated with Ziprasidone for 6 months
62352208|NCT01925612|EXPERIMENTAL|Part 3: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy.~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
62511120|NCT05814432|ACTIVE_COMPARATOR|Standard dose arm|Standard treatment with 3 mg/kg of liposomal amphotericin B daily for 2 weeks
62511121|NCT05944250|NO_INTERVENTION|control wound|"standard of care treatment, dressing and bandages~participants will have the option to enroll in the open label extension phase after the randomization phase is complete"
62511122|NCT05944250|EXPERIMENTAL|matrix treated wounds|"wounds treated with Spincare matrix device up to once per week or as required at the discretion of the principal investigator~participants will have the option to enroll in the open label extension phase after the randomization phase is complete"
62511123|NCT05944250|EXPERIMENTAL|open-label phase (extension)|wounds treated with Spincare matrix device up to once per week or as required at the discretion of the principal investigator
62511124|NCT01702077|EXPERIMENTAL|Neurofeedback first|Neurofeedback then sham feedback
62511125|NCT01702077|EXPERIMENTAL|Sham first|Sham feedback then neurofeedback
61971316|NCT05533281|EXPERIMENTAL|metoclopramide|Metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
61971317|NCT05533281|EXPERIMENTAL|dexamethasone|Dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
61971318|NCT05533281|PLACEBO_COMPARATOR|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was given intravenously to ensure constant speed.
61971319|NCT00653250|EXPERIMENTAL|Therapeutic Intervention|Correlative
62146437|NCT00635700|PLACEBO_COMPARATOR|Placebo|Patients will be treated with placebo for 6 months
62146438|NCT01667198|EXPERIMENTAL|Train the leaders course|
62146439|NCT01667198|ACTIVE_COMPARATOR|Audit and feedback|
62146440|NCT00569634|OTHER|1|
62146441|NCT00357994|EXPERIMENTAL|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
62146442|NCT00357994|ACTIVE_COMPARATOR|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
62146443|NCT02941692|EXPERIMENTAL|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
62511126|NCT03297567|EXPERIMENTAL|verbal guidance and booklet|verbal guidance and a booklet on the importance and benefits of movement during hospital stay, as well as what the patients should do to increase the level of physical activity.
61971320|NCT01357187|OTHER|Control|
61971321|NCT01357187|EXPERIMENTAL|Treatment|
62146444|NCT02941692|PLACEBO_COMPARATOR|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
62146445|NCT04866160|EXPERIMENTAL|BI 1291583 low dose|
62146446|NCT04866160|EXPERIMENTAL|BI 1291583 high dose|
62146447|NCT04866160|PLACEBO_COMPARATOR|Placebo|
62146448|NCT04246866|EXPERIMENTAL|Dose 1|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the lowest dose of GEM103
62146449|NCT04246866|EXPERIMENTAL|Dose 2|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the medium dose of GEM103
62146450|NCT04246866|EXPERIMENTAL|Dose 3|A single dose of GEM103 will be administered via intravitreal injection. This arm will be a higher dose of GEM103
62511127|NCT03297567|NO_INTERVENTION|No Intervention|The control group will not receive any type of intervention
62511128|NCT03717493|EXPERIMENTAL|Affect Regulation Training (ART)|Affect Regulation Training (ART; Berking \& Whitley, 2014) is a transdiagnostic, group-based intervention aiming to enhance general affect regulation skills in individuals who meet criteria for mental disorders or are at-risk of developing mental-health problems.
62511129|NCT03717493|NO_INTERVENTION|Waitlist Control Condition (WLC)|In order to control for the effects of time, we compared changes during ART with changes during WLC. Participants in the WLC condition received no treatment within the study but were offered to participate in ART after completing all assessments.
62511130|NCT01579760|EXPERIMENTAL|aflibercept every 2 months|
62511131|NCT01579760|EXPERIMENTAL|aflibercept monthly|
62511132|NCT02137694|OTHER|PapU-APV|No drug and no placebo will be used in this study. For the study participants, only their medical history data and vaginal auto-takings ( APV) and urinary will be collected.
62511133|NCT05709652|EXPERIMENTAL|Experimental|Patients subjected to aortic CTA with a gantry revolution time of 0.23 sec
62511134|NCT05709652|ACTIVE_COMPARATOR|Control|Patients subjected to aortic CTA with a gantry revolution time of 0.28 sec
62707835|NCT00725985|PLACEBO_COMPARATOR|Placebo (ITP)|Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
62707836|NCT00725985|EXPERIMENTAL|Cladribine 5.25 mg/kg, Rebif (OLMP)|Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
62707837|NCT00725985|EXPERIMENTAL|Cladribine 3.5 mg/kg, Rebif (OLMP)|Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
62707838|NCT00725985|EXPERIMENTAL|Placebo, Rebif (OLMP)|Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
61971322|NCT00674700|ACTIVE_COMPARATOR|300 IR|300 IR house dust mites allergen extract tablet
61971323|NCT00674700|ACTIVE_COMPARATOR|500 IR|500 IR house dust mites allergen extract tablet
62146451|NCT04246866|EXPERIMENTAL|Dose 4|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the highest (extension) dose of GEM103
62352209|NCT05779345|ACTIVE_COMPARATOR|short implants|short 6 mm straumann blx implants
62352210|NCT05779345|ACTIVE_COMPARATOR|regular length + internal sinus lift|regular length implant 10 mm, in addition to internal sinus lift procedure
62352211|NCT02174783|ACTIVE_COMPARATOR|Control group|Standard of care group
62352212|NCT02174783|EXPERIMENTAL|Mediterranean diet|Mediterranean diet for 6 months
62352213|NCT02174783|EXPERIMENTAL|Protein-Sparing Modified Fast (PSMF)|PSMF for 6 months
62352214|NCT02079051|EXPERIMENTAL|High Intensity Weight Loss|High intensity medical weight loss
62352215|NCT02079051|ACTIVE_COMPARATOR|Moderate Intensity Weight Loss|Moderate intensity weight loss
62352216|NCT00628758|EXPERIMENTAL|Symbicort|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
62352217|NCT00628758|EXPERIMENTAL|Conventional BP|Conventional Best Practice for Treatment of Asthma
62352218|NCT01804036|ACTIVE_COMPARATOR|Zolpidem (Ambien) Treatment|A three week treatment of Zolpidem
61971324|NCT00674700|PLACEBO_COMPARATOR|Placebo|Placebo tablet
61971325|NCT03077750|EXPERIMENTAL|VBP-245|VBP-245 Topical Gel Applied to Affected Area BID
61971326|NCT03077750|PLACEBO_COMPARATOR|Vehicle|Vehicle Gel Applied to Affected Area BID
62352219|NCT01804036|EXPERIMENTAL|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
62352220|NCT01176370|EXPERIMENTAL|Implantable Counterpulsation Therapy|The study is a single arm study with up to 20 patients enrolled and implanted with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. There is not a control arm in this feasibility study.
62352221|NCT01957709|EXPERIMENTAL|Basic science (interferon gamma and MHC expression)|Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.
62352222|NCT03905668||ICU Patients|Adults in admitted to an ICU at University of Florida Health Gainesville with an expected length of stay greater than 24 hours which are not on any form of contact precaution or isolation. Patients will have continuous video, accelerometer, and electromyographic monitoring for up to seven days while in the ICU.
61971327|NCT01812824|EXPERIMENTAL|Intervention (Virtual Patient Advocate)|Participants assigned to the Intervention (Virtual Patient Advocate) arm will have access to the Virtual Patient Advocate system on-line for 6 months; they will be encouraged, but not required, to log on once a week.
62146452|NCT01317966||rhIL-11Combinating Low-dose Rituximab|"rhIL-11 (interleukin-11, Juheli) 50 mcg/kg subcutaneously daily for 14 days~Rituximab 100mcg weekly for 4 weeks"
62352223|NCT03905668||ICU Patient Friends/Family Members|Adult visitors of participating ICU patients that are willing to provide feedback to the learning algorithms.
62352224|NCT04280406|ACTIVE_COMPARATOR|Test|- 500mg of azithromycin one hour before implant placement
62352225|NCT04280406|PLACEBO_COMPARATOR|control|- identical placebo one hour before implant placement
62352226|NCT04248062||IEM experts|Heterogeneous group of health professionals (physicians, psychologists, nutritionists) working in the field of Inborn Errors of Metabolism (IEM)
62352227|NCT04248062||Paediatric IEM patients|IEM patients between 10 and 18 years
62511135|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
62511136|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
62511137|NCT02427984||Controls|Patients free from hip devices
62511138|NCT01946984|ACTIVE_COMPARATOR|Diclofenac,75 mg, 3 ml,|patients were given Diclofenac IM before ERCP.
62511139|NCT01946984|PLACEBO_COMPARATOR|Normal Saline, 3ml, IM|patients were given normal saline 3 ml before ERCP
62511140|NCT05132725|EXPERIMENTAL|Dietary intervention CHO counting combined with GFD|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants' recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' weight. The carbohydrate counts will be distributed into three main meals and 3 snacks, with the general dietary advice and diet that will be prescribed by hospital for participants
62511141|NCT05132725|EXPERIMENTAL|Dietary intervention CHO Counting with GFD & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (\>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet, with the general dietary advice and diet that will be prescribed by hospital for participants
62511142|NCT05132725|NO_INTERVENTION|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
62352228|NCT04248062||Parents of paediatric IEM patients and patient representatives|"* Parents of IEM patients (between 0 and 18 years)~* Patient representatives"
62707839|NCT00725985|EXPERIMENTAL|Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
61971328|NCT01812824|NO_INTERVENTION|Control (Letter)|Participants in the Control (Letter) arm will take the online Preconception Risk Assessment at baseline, but not have access to the Virtual Patient Advocate system during the 6 month study period. They will be sent a list of the Preconception Risks identified through their answers to the Risk Assessment, which they can choose to share with their healthcare provider(s).
61971329|NCT06001476|EXPERIMENTAL|Cold snare polypectomy group|
61971330|NCT06058481|EXPERIMENTAL|Group A|The investigator inserted the BlockBuster (supraglottic airway device) in Group A patients after induction of anaesthesia.
61971331|NCT06058481|ACTIVE_COMPARATOR|Group B|The investigator inserted the Proseal-LMA (supraglottic airway device) in Group B patients after induction of anaesthesia.
61971332|NCT06506734||Dental Dyschromia in Hyperbilirubinemia Patients|30 minutes
61971333|NCT04261751||Nurses|Nurses will be taking the Clinician Questionnaire electronically.
62146453|NCT05514184|EXPERIMENTAL|Plant-focused low-protein nutrition in diabetic CKD (PLAFOND)|Participants randomized to this arm will receive PLAFOND dietary intervention consisting of a flexible low-protein meal plan including 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-based sources, and the meal plan will be supported by dietitian who will provide dietary education and counseling to patients assigned to this arm.
62146454|NCT05514184|ACTIVE_COMPARATOR|Standard-of-care renal diet (control group)|Participants randomized to the control group will receive standard-of-care renal diet with low-potassium content based on dietitian counseling and guidance.
62146455|NCT02434705||Antigen (wheat base soy sauce) spray|"1. Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.~2. During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.~3. After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
62146456|NCT05818852|EXPERIMENTAL|Group 1|Participants will receive VX-548-matching placebo, moxifloxacin-matching placebo and VX-548 at different time points.
62146457|NCT05818852|ACTIVE_COMPARATOR|Group 2A|Participants will receive VX-548-matching placebo, moxifloxacin and moxifloxacin-matching placebo at different time points.
62146458|NCT05818852|ACTIVE_COMPARATOR|Group 2B|Participants will receive VX-548-matching placebo, moxifloxacin-matching placebo and moxifloxacin at different time points.
62352229|NCT01216397|EXPERIMENTAL|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
62352230|NCT01216397|EXPERIMENTAL|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
61971334|NCT03957304|EXPERIMENTAL|Dexmedetomidine 1 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 1 mcg/kg (max 100 mcg or 1 mL).
61971335|NCT03957304|ACTIVE_COMPARATOR|Dexmedetomidine 2 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 2 mcg/kg (max 100 mcg or 1 mL).
61971336|NCT03957304|ACTIVE_COMPARATOR|Dexmedetomidine 3 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 3 mcg/kg (max 100 mcg or 1 mL).
61971337|NCT03957304|ACTIVE_COMPARATOR|Dexmedetomidine 4 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 4 mcg/kg (max 100 mcg or 1 mL).
61971338|NCT00310791|PLACEBO_COMPARATOR|Sugar Pill|Placebo (sugar pill); identical to treatment medication capsule
62146459|NCT02394613|EXPERIMENTAL|ANX776|Using and increasing dose storer design, GLAUCOMA and NORMAL patients will be randomly grouped to received the intervention (0.1 mg, 0.2 mg, 0.4 mg, 0.5 mg). 1 NAION patient will receive each dose once it has been proven safe in GLAUCOMA and NORMAL patients, as part of the secondary objective of this trial.
62146460|NCT06510829||Group A|Group will be treated with intralesional bleomycin injection
61971339|NCT00310791|EXPERIMENTAL|DHEA + Hormone replacement therapy (estrogen/progestin)|Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (\> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
62146461|NCT06510829||Group b|Group will be treated with application of diode laser
62146462|NCT04300270||Validation cohort|Participants in validation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
62146463|NCT04300270||Clinical implementation cohort|Participants in a clinical implementation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
62707840|NCT00725985|EXPERIMENTAL|Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
61971340|NCT00936910|EXPERIMENTAL|Antifungal lock-treated patients|Intestinal failure and other patients with poor IV access and central line fungal-related infections will receive intravenous systemic antifungal therapy plus the instillation of Ambisome locks into the infected catheter.
61971341|NCT01294293|EXPERIMENTAL|Treatment (TLR8 agonist VTX-2337, PLD, and Paclitaxel)|Patients receive TLR8 agonist VTX-2337 SC on days 3, 10, and 17 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 or TLR8 agonist VTX-2337 SC on days 1, 8, and 15 and paclitaxel IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61971342|NCT00884312|EXPERIMENTAL|Carfilzomib|Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.
61971343|NCT01741701|EXPERIMENTAL|Oxaloacetate (OAA)|active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
61971344|NCT01741701|PLACEBO_COMPARATOR|Placebo|placebo capsules that contain only 100 mg ascorbate, taken daily
61971345|NCT00750204|EXPERIMENTAL|APRV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
61971346|NCT00750204|ACTIVE_COMPARATOR|Conventional MV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
62146464|NCT05764057|EXPERIMENTAL|Dapagliflozin 10mg daily + standard of care|Dapagliflozin 10mg per day will be administered orally, as in clinical practice
62146465|NCT05764057|PLACEBO_COMPARATOR|Placebo + standard of care|Placebo will be administered orally
62146466|NCT03135782|EXPERIMENTAL|Health Services Research (Chart review, training, coaching)|"MEDICAL CHART REVIEW: Medical charts from patients with diagnoses of head and neck cancer, lung cancer, prostate cancer, or breast cancer are reviewed at months 1-12 to determine the frequency of tobacco assessments and documentation of discussions with patients regarding tobacco use and utilization of cessation resources as before and after the proposed training.~PROVIDER TRAINING: Providers undergo training to use patient coaching such as the 5A's (Ask, Advise, Assess, Assist, and Arrange), to conduct regular tobacco intake assessment using motivational interviewing techniques. Providers also undergo training to use public/community tobacco cessation resources for patients ready to quit within six weeks, and have access to pharmacy residents for ad-hoc prescribing questions.~PATIENT COACHING: Patients attend 4 phone or in-person motivational interviewing coaching sessions over 30-45 minutes for 6-8 weeks or longer as needed."
62146467|NCT02076594|EXPERIMENTAL|Docetaxel & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)
62146468|NCT02076594|EXPERIMENTAL|Epirubicin & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)
62146469|NCT00220805|EXPERIMENTAL|Group 1|
62146470|NCT00220805|PLACEBO_COMPARATOR|Group 2|
62146471|NCT02814409|ACTIVE_COMPARATOR|Alteplase - standard care|Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).
62352231|NCT06376370|EXPERIMENTAL|Study|Patients with epilepsy who will receive a computer-assisted cognitive rehabilitation program
62352232|NCT06376370|NO_INTERVENTION|Control|Patients under routine follow-up of the clinic
62352233|NCT02451033|ACTIVE_COMPARATOR|standard medical therapy|Standard medical therapy
62352234|NCT02451033|ACTIVE_COMPARATOR|G-CSF|Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
62511143|NCT02012452|EXPERIMENTAL|tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
62511144|NCT02012452|SHAM_COMPARATOR|health education treatment|Participants will be provided education on a variety of health topics and will set health goals around each topic
62511145|NCT03901391||Retinitis Pigmentosa|
62511146|NCT01551147|EXPERIMENTAL|Experimental 200 mg dose|
62511147|NCT01551147|ACTIVE_COMPARATOR|Active Comparator|
61971347|NCT01116154|EXPERIMENTAL|Arm I|Patients receive oral vorinostat twice daily on days 1-14 and oral lenalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61971348|NCT00321802|EXPERIMENTAL|1|Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
61971349|NCT00321802|PLACEBO_COMPARATOR|2|Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.
61971350|NCT04234581|EXPERIMENTAL|Lysulin|Participants will be randomly allocated in blocks for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) per os with breakfast, lunch and dinner.
61971351|NCT04234581|PLACEBO_COMPARATOR|Placebo|Subjects will be instructed to take two tablets of placebo per os with breakfast, lunch and dinner.
62146472|NCT02814409|EXPERIMENTAL|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).
62146473|NCT05774262|ACTIVE_COMPARATOR|Group A - PACEMAKER|"Group A, n=50 patients aged 18-75 years with indications for elective PM implantation according to the 2021 ESC guidelines for cardiac pacing due to paroxysmal or persistent AVB with a positive results of atropine test.~Group A is early elective pacemaker implantation (PM) strategy in functional AVB."
62146474|NCT05774262|ACTIVE_COMPARATOR|Group B - CARDIONEUROABLATION|"Group B, n=50 patients aged 18-75 years with indications for elective PM implantation according to the 2021 ESC guidelines for cardiac pacing due to paroxysmal or persistent AVB with a positive results of atropine test.~Group B will undergo strategy of postponed/deferred PM implantation in functional AVB. Patients wil be implanted and monitored with ILR (in case of severe symptomatic AVB always the emergency system will be called). After cardiovascular autonomic testing (CAT), electrophysiological study (EPS), extra cardiac vagal nerve stimulation (ECVS) and cardioneuroablation will be performed. If CNA is succesful, pacemaker implantation will be cancelled. If CNA is unsuccessful, second session of CNA will be planned. In case of inefficient second attempt, patients will be referred for PM implantation. They will cross-over to PACEMAKER arm."
62146475|NCT01064609|ACTIVE_COMPARATOR|2. Biopsy with cryoprobes|Transbronchial cryobiopsy with a cryoprobe.
62146476|NCT01064609|ACTIVE_COMPARATOR|2.Biopsy with forceps|Transbronchial lung biopsy with conventional forceps.
62352235|NCT02451033|ACTIVE_COMPARATOR|G-CSF plus growth hormone|Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.
62352236|NCT05953571||GroupA|Laparoscopic assisted dismembered pyeloplasty in poorly function kidney
62511148|NCT01551147|PLACEBO_COMPARATOR|Placebo Comparator|
62511149|NCT01216657|EXPERIMENTAL|sunitinib|50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
61971352|NCT05118906|EXPERIMENTAL|BP1.4979|15 mg BID active treatment
61971353|NCT05118906|PLACEBO_COMPARATOR|Placebo|matching placebo
61971354|NCT01463540|ACTIVE_COMPARATOR|Push/pull endoscopic gastrostomy|
61971355|NCT01463540|EXPERIMENTAL|Gastrostomy after gastropexy|
62511150|NCT06601621|EXPERIMENTAL|True electroacupuncture + True self-acupressure|"Participants will receive two electroacupuncture treatments during the first week of the chemotherapy cycle. The acupuncturist will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. Participants will do acupressure daily during the second week of the chemotherapy cycle (two weeks for one chemotherapy cycle) or the second and third weeks (three weeks for one chemotherapy cycle). participants performed true self-acupressure, pressing each acupoint with their thumb to achieve deqi for three minutes."
62511151|NCT06601621|PLACEBO_COMPARATOR|Sham electroacupuncture + Sham self-acupressure|"The sham acupuncture is the use of minimally invasive shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group. Care was taken to avoid de qi sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
62511152|NCT04635332|EXPERIMENTAL|Intervention|In the intervention arm, participants will be exposed to the developed intervention materials and face to face group sessions.
62511153|NCT04635332|ACTIVE_COMPARATOR|Control arm|In the control arm, participants will only be given the developed intervention materials. Face to face group sessions will not be held for the control arm.
62511154|NCT06364254|EXPERIMENTAL|Cannabidiol|Cannabidiol capsules 2 hours prior to 2 mile run.
62511155|NCT06364254|PLACEBO_COMPARATOR|Placebo|Placebo capsules 2 hours prior to 2 mile run.
62511156|NCT03489226|ACTIVE_COMPARATOR|Capsimax 2 mg|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
62511157|NCT03489226|PLACEBO_COMPARATOR|Placebo|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
62511158|NCT03489226|ACTIVE_COMPARATOR|Capsimax 4 mg plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
61971356|NCT02756689|ACTIVE_COMPARATOR|Inpatient cervical Ripening|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
61971357|NCT02756689|ACTIVE_COMPARATOR|Outpatient cervical Ripening|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
61971358|NCT02949102|EXPERIMENTAL|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
62146477|NCT01038934|EXPERIMENTAL|buccal cytobrhsh|healthy young
62352237|NCT05953571||Group B|Open dismembered pyeloplasty in poorly function kidney
62352238|NCT06207929||Study Population|Adult participants (ages 18+) who reside in the contiguous United States
62511159|NCT03489226|PLACEBO_COMPARATOR|Placebo plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
62511160|NCT02079675|EXPERIMENTAL|SKI3246 Low Dose|Intervention: Drug: SKI3246 Low Dose
62511161|NCT02079675|EXPERIMENTAL|SKI3246 High Dose|Intervention: Drug: SKI3246 High Dose
62511162|NCT02079675|PLACEBO_COMPARATOR|Placebo|Intervention: Drug: Placebo
62511163|NCT00003130|EXPERIMENTAL|paclitaxel|Patients receive single fixed dose intravenous paclitaxel over 3 hours on day 1. Blood samples must be drawn prior to the first paclitaxel infusion and then at 1, 6, and 24 hours after the start of the infusion during course 1 only. Treatment courses of intravenous paclitaxel are repeated every 3 weeks at the discretion of the treating physician. Patients are evaluated for response after the second course. Patients are followed at the discretion of the physician.
62511164|NCT00680069|EXPERIMENTAL|High Dose Group|Volunteers will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart
61971359|NCT02949102|PLACEBO_COMPARATOR|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
61971360|NCT05454592|EXPERIMENTAL|Peer-presented group|The online outreach program focused on four key areas of mental health resilience-building: dealing with stress, decreasing self-criticism, improving self-care and help-seeking behaviours, and enhancing social connections and social support. Using videos, interactive infographics, guided audio recordings, and podcasts, students were provided with clear descriptions of each area of mental health resilience as well as a variety of evidence-based strategies specifically targeting one or more of these areas. A first video was sent to students describing the online program, its overall focus, and how to access the skills-based strategies on the website's interactive resource library. Two subsequent videos then were sent to (a) help students with problem-solving for common challenges to strategy practice, and (b) maintain long-term strategy practice habits. To assess differences in terms of preference for deliverer, this video series was delivered by undergraduate students (i.e., peers).
62146478|NCT03005106|EXPERIMENTAL|StrataGraft Skin Tissue|
62146479|NCT03338166||Group A|Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
62146480|NCT03338166||Group B|Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
62146481|NCT03338166||Group C|Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
62146482|NCT03338166||Group D|Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
62146483|NCT04803045||Follow Up Email|Patients received a follow up email 3 months after an initial consult with a physician but did not return to care.
62146484|NCT04803045||No follow up|Patients who did not receive any follow up after their initial consult, following clinic standard of care.
62146485|NCT06041932|EXPERIMENTAL|Pentoxiphylline plus Carvedilol|Pentoxiphylline plus Carvedilol
62146486|NCT06041932|ACTIVE_COMPARATOR|Carvedilol|PCarvedilol
62146487|NCT06365905||Observational|Patients undergo a transvaginal ultrasound examination and endometrial sampling per standard of care and have their medical records reviewed on study.
62146488|NCT05932303|EXPERIMENTAL|BMS-986278, followed by itraconazole|
62352239|NCT04031404|EXPERIMENTAL|Glucose drink followed by placebo|Participants will consume the glucose drink at session 1, then they will consume the placebo (water) at session 2.
62352240|NCT04031404|EXPERIMENTAL|Placebo followed by glucose drink|Participants will consume the placebo (water) at session 1, then they will consume the glucose drink at session 2.
62511165|NCT00680069|EXPERIMENTAL|Low Dose Group|Volunteers will receive 15 mcg intramuscularly (IM). Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart.
62511166|NCT04806620||People with ME/CFS|No intervention will be administered.
62511167|NCT04806620||People with Long-COVID|No intervention will be administered.
62511168|NCT04806620||Healthy Controls|No intervention will be administered.
62511169|NCT06236256|EXPERIMENTAL|AHCL group|Participants will be connected to the MiniMed 780G AHCL system for the 12 months study period. This group will have two additional visits to allow for patients to be trained on the AHCL system.
62511170|NCT06236256|PLACEBO_COMPARATOR|MDI/CSII group|The patient will continue MDI/CSII treatment as per their routine procedures. At the beginning, middle and end of the stage they will be connected to a standalone sensor from which glucose data will be collected.
62511171|NCT04492852|EXPERIMENTAL|Interventional Arm 1|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
62511172|NCT04492852|ACTIVE_COMPARATOR|Interventional Arm 2|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
62511173|NCT00101413|EXPERIMENTAL|Sorafenib|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
62511174|NCT05443906|EXPERIMENTAL|Home exercise|Individually designed home exercise program
62511175|NCT03323060||Male and/or females ≥ 22 yrs old|≥ 22 years of age requiring transanal procedures in the areas of the anus, rectum, and distal colon Transanal endoscopic surgical procedure
62146489|NCT05932303|EXPERIMENTAL|BMS-986278, followed by gemfibrozil|
62146490|NCT05932303|EXPERIMENTAL|BMS-986278, followed by carbamazepine|
62352241|NCT04219488|EXPERIMENTAL|Neuromobilization group|The neuromobilization group received a supervised home program plus radial nerve mobilization. Radial nerve mobilization exercises were performed by the physiotherapist for 3 days a week for 3 weeks. The patients in the neuromobilization group also performed self-neuromobilization exercises at home for 6 weeks. Supervised home program including patient education and eccentric exercises was administered three times daily for 6 weeks.
62352242|NCT04219488|ACTIVE_COMPARATOR|Control group|The control group received a supervised home program. Supervised home program including patient education and eccentric exercises was administered 3 times a day for 6 weeks.
62352243|NCT04929418|OTHER|10 km continuous running|Participants will perform a test of 10 km coninuous running.
62352244|NCT04929418|OTHER|1.5 km swimming|Participants will perform a test of 1.5 km coninuous swimming.
62352245|NCT00653913|ACTIVE_COMPARATOR|Group A|SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)
62511176|NCT05258851|EXPERIMENTAL|Ceftazidime-avibactam|Ceftazidime-avibactam 2.5 grams intravenous (IV) every 8 hours infused over two hours for a duration of 7-14 days, with dose adjustment for renal impairment according to the FDA prescribing information. Patients who have a positive Xpert Carb-R screening test or culture for CRE with metallo-beta-lactamases will receive aztreonam added to ceftazidime-avibactam.
62511177|NCT05258851|ACTIVE_COMPARATOR|Colistin|Colistin (9-million-unit loading dose IV followed with 9 million units IV daily divided into 3 doses), for 7 to 14 days. Patients with renal impairment will receive antibiotics with adjusted doses based on their glomerular filtration rate or the use and type of renal replacement therapy according to the 2019 International Consensus Guidelines for the Optimal Use of the Polymyxins.
62511178|NCT03470584||Tzu Chi Vegetarian Study|12062 Tzu Chi volunteers of the Buddhist Tzu Chi Foundation recruited throughout communities in Taiwan in the year 2005. All participants filled out a self-administered questionnaire on basic information, medical history, lifestyle, and diet. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
61971361|NCT05454592|EXPERIMENTAL|Mental health service provider-presented group|The program focused on four areas of mental health resilience-building: dealing with stress, decreasing self-criticism, improving self-care and help-seeking behaviours, and enhancing social connections and social support. Using videos, infographics, guided audio recordings, and podcasts, students were provided with clear descriptions of each area of mental health resilience as well as a variety of evidence-based strategies specifically targeting one or more of these areas. A first video was sent to students describing the online program, its overall focus, and how to access the skills-based strategies on the website's interactive resource library. Two subsequent videos were then sent to (a) help students with problem-solving for common challenges to strategy practice, and (b) maintain long-term strategy practice habits. To assess differences in terms of preference for deliverer, this video series was delivered by mental health service providers.
61971362|NCT05454592|NO_INTERVENTION|Wait-list comparison group|Participants in the wait-list comparison group did not receive any intervention throughout the duration of the study. However, they were asked to fill out the same baseline, post, and follow-up surveys as all other participants.
61971363|NCT02061267|EXPERIMENTAL|Niacin Control|The subjects will receive a vitamin B3 supplement (2 g)
61971364|NCT02061267|EXPERIMENTAL|Niacin + SAT|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
61971365|NCT02061267|EXPERIMENTAL|Niacin + ROO|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
61971366|NCT02061267|EXPERIMENTAL|Niacin + O3|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
61971367|NCT01878058|OTHER|MRI Scan|Patients will receive an extra MRI scan in addition to their routine scan.
62146491|NCT04161716|EXPERIMENTAL|NIRS module|Each patient has a NIRS module during a diagnosis urodynamic assessment provided for by the usual practice.
62146492|NCT02502019|EXPERIMENTAL|HEMOBLAST|All subjects will have the investigational device implanted
62146493|NCT02906657|EXPERIMENTAL|Medication reconciliation|Medication reconciliation involving a pharmacist using electronic pharmaceutical records
62146494|NCT02906657|NO_INTERVENTION|Control|Usual Care
62146495|NCT05149963|EXPERIMENTAL|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of CBT aiming to reduce their loneliness. The intervention is modular and has been developed for this study. In total there are 10 treatment modules, 1) Assessment, 2) Formulation and Psychoeducation, 3) Challenging Negative Interpersonal Appraisals and Counterproductive Behaviours, 4) Challenging Negative Thoughts and Cognitive Biases, 5) Challenging Self-focussed Attention, Hypervigilance and Camouflaging, 6) Values-based Social-skills Training, 7) Problem Solving, 8) Findings Friends, 9) Managing Emotions and 10) Relapse Prevention. All participants will complete module 1) Assessment and module 2) Formulation and Psychoeducation. They will then work with the clinician to collaboratively develop a treatment plan based on their formulation. The treatment will be comprised of one or more of the intervention modules. All participants will then complete module 10) Relapse Prevention at the end of their treatment.
61971368|NCT03063554|ACTIVE_COMPARATOR|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement. EUS via either stomach or duodenum.
61971369|NCT03063554|PLACEBO_COMPARATOR|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement only.
61971370|NCT01649687|EXPERIMENTAL|Mesenchymal stem cells(MSC) treatment|All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells
62352246|NCT00653913|ACTIVE_COMPARATOR|Group B|SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)
62352247|NCT00653913|ACTIVE_COMPARATOR|Group C|Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)
62352248|NCT00653913|ACTIVE_COMPARATOR|Group D|Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)
62352249|NCT00653913|ACTIVE_COMPARATOR|Group E|Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)
62352250|NCT00653913|ACTIVE_COMPARATOR|Group F|Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)
62511179|NCT03470584||Tzu Chi Health Study|6002 participants who came for health examination at the Dalin Tzu Chi Hospital between the years 2007 to 2009. 77% were Tzu Chi volunteers. All participants were interviewed on a structured questionnaire including basic information, medical history, lifestyle, and diet, and received a comprehensive health examination. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
62352251|NCT02894528|EXPERIMENTAL|Ridge Preservation (Test Group)|
62511180|NCT02265406|EXPERIMENTAL|Ceftriaxone|
62707841|NCT00725985|EXPERIMENTAL|Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
62707842|NCT00725985|EXPERIMENTAL|Cladribine 5.25 mg/kg, Rebif (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
61971371|NCT05693779|EXPERIMENTAL|Home exercise training|Individualized exercise prescription will be provided based on the gathered cardiopulmonary exercise test data.
61971372|NCT02403154|EXPERIMENTAL|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be internal fixator.
61971373|NCT02403154|EXPERIMENTAL|Randomized to External Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be external fixator.
61971374|NCT02403154|OTHER|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the internal fixator intervention based on their preference for the specific case or the patient chose the internal fixator.
61971375|NCT02403154|OTHER|Observational - External Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the external fixator intervention based on their preference for the specific case or the patient chose the external fixator.
61971376|NCT01772238|EXPERIMENTAL|A(reference)/B(test)|initial administration of reference and cross-over to test
61971377|NCT01772238|EXPERIMENTAL|B(test)/A(reference)|initial administration of test and cross-over to reference
61971378|NCT01402492|EXPERIMENTAL|BUP4+XR-NTX|4mg buprenorphine plus naltrexone for 8 weeks of treatment
61971379|NCT01402492|EXPERIMENTAL|BUP16+XR-NTX|16mg buprenorphine plus naltrexone for 8 weeks of treatment
61971380|NCT01402492|ACTIVE_COMPARATOR|PLB+XR-NTX|naltrexone for 8 weeks of treatment
61971381|NCT02052284|NO_INTERVENTION|Control|The control group will receive standard skin care of the NICU, which does not include specific measures to modulate skin-barrier function.The current practice at GWUH NICU is that nurses clean the bodies of newborns less than 1000 grams using a piece of damp cloth with warm water. This is performed at birth and consequently every other days.
62146496|NCT05149963|NO_INTERVENTION|Baseline Phase 1 (12 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
62352252|NCT02894528|ACTIVE_COMPARATOR|Ridge Preservation (Control Group)|
62146497|NCT05149963|NO_INTERVENTION|Baseline Phase 2 (19 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
62352253|NCT02645279|ACTIVE_COMPARATOR|oral 30% glucose|oral 30% glucose total 200 mg/kg with 0.5-1 mL increments
62352254|NCT02645279|ACTIVE_COMPARATOR|IV midazolam|intravenous administration of midazolam 0.1 mg/kg
62352255|NCT02895412|EXPERIMENTAL|Transplant Recipient|"The T cell product administration is personalized cellular therapy product, individually prepared for each participant.~Donor-derived WT1-CTL and P-CTL.~It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole.~One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs."
62352256|NCT02030470|OTHER|fotosan|
62511181|NCT02265406|PLACEBO_COMPARATOR|Sodium Chloride|
62511182|NCT00845325|ACTIVE_COMPARATOR|Group One|"The first group (early motion) will have a bulky dressing placed at the time of surgery. They will be instructed to remove the dressing on the first postoperative day and to place a band-aid over the incision. A set of non-weight bearing stretching exercises will be explained on the day of surgery and instructions with diagrams sent home with the patient. They will begin these exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work."
62511183|NCT00845325|OTHER|Behavorial Control Group Two|The second group will have wrist immobilization splints placed at the time surgery. The thumb and fingers will not have limited motion in this splint. Due to the splint placement, the patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
62511184|NCT04199117|EXPERIMENTAL|Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62511185|NCT04199117|EXPERIMENTAL|Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62707843|NCT00725985|EXPERIMENTAL|Cladribine 3.5 mg/kg, Rebif (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
62707844|NCT00725985|EXPERIMENTAL|Placebo, Rebif (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
62707845|NCT04116255|EXPERIMENTAL|exercises group|exercises group apply regular therapeutic home exercises programme
62707846|NCT04116255|EXPERIMENTAL|splint group|splint group use mandibular oral occlusal splint
62707847|NCT05480007|NO_INTERVENTION|Control|did not take medicine
62707848|NCT05480007|EXPERIMENTAL|DPPVI|received sitagliptin treatment (100mg per day)
62707849|NCT05480007|EXPERIMENTAL|metformin|received metformin (500mg three times per day)
61971382|NCT02052284|EXPERIMENTAL|Water wash|The study group will undergo a protocol of sterile water application in addition to routine skin care of the NICU. The study group will receive more frequent and standardized applications. A commercially sterile water bottle (Enfamil® Water) will be kept inside the isolette, to be maintained at isolette temperature, and will be changed on a daily basis. Nurses use sterile gloves as a routine for care of ELBW infants. A 2 inches x 2 inches sterile gauze will be soaked in sterile water and gently applied to all skin of the baby excluding umbilical cord and IV lines sites. This procedure will be repeated every 4 hours with routine patient care for the first 1 week of life.
61971383|NCT03965962|EXPERIMENTAL|Group 1: VRVg-2 + HRIG|Participants received 0.5 milliliters (mL) intramuscular (IM) injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
61971384|NCT03965962|ACTIVE_COMPARATOR|Group 2: Verorab + HRIG|Participants received 0.5 mL IM injection of Verorab on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
61971385|NCT03965962|ACTIVE_COMPARATOR|Group 3: Imovax Rabies + HRIG|Participants received 1 mL IM injection of Imovax Rabies on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
61971386|NCT03965962|EXPERIMENTAL|Group 4: VRVg-2|Participants received 0.5 mL IM injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28.
62146498|NCT05149963|NO_INTERVENTION|Baseline Phase 3 (26 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
61971387|NCT05012839||Complicated appendicitis|The development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
61971388|NCT05012839||Non-complicated appendicitis|No development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
62146499|NCT05149963|NO_INTERVENTION|Baseline Phase 4 (33 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
62707850|NCT05480007|EXPERIMENTAL|metformin +DPPVI|received sitagliptin (100mg per day) and metformin (500 mg three times per day)
62707851|NCT05835648|EXPERIMENTAL|Dietary fiber intervention group|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
62707852|NCT00468091|PLACEBO_COMPARATOR|saline-saline|"saline IV~+ saline IV"
62707853|NCT00468091|ACTIVE_COMPARATOR|saline-exendin(9-39)amide|"saline IV~+ exendin(9-39)amide IV"
62707854|NCT00468091|ACTIVE_COMPARATOR|saline-atropine|"saline IV~+ atropine IV"
62707855|NCT00468091|ACTIVE_COMPARATOR|exendin(9-39)amide-atropine|"exendin(9-39)amide IV~+ atropine IV"
62707856|NCT02673021|EXPERIMENTAL|Microwave Ablation|Microwave Ablation
62707857|NCT05960214||13 pts with BC+TM|Patients diagnosed with breast cancer and thalassemia minor
62707858|NCT05960214||13 pts with BC|Patients diagnosed with breast cancer for comparison.
62707859|NCT06295419|EXPERIMENTAL|cerebral palsy|cerebral palsy will be evaluated single and dual task conditions
62707860|NCT06295419|EXPERIMENTAL|healthy controls|Healthy controls will be evaluated single and dual task conditions
62707861|NCT04069442||cDC-1 positive|cDC-1 positive patients according to RNAseq and in situ analysis
62707862|NCT04069442||cDC-1 negative|cDC-1 negative patients according to RNAseq and in situ analysis
62707863|NCT03113279||Obese older individuals|Obese older individuals
62707864|NCT03113279||Lean older individuals|Lean older individuals
62707865|NCT03113279||Young lean individuals|Young lean individuals
62511186|NCT04199117|EXPERIMENTAL|Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62707866|NCT04501432||Cardiac Rehabilitation|Participants will be recruited from a group of patients who regularly attended group-based cardiac rehabilitation exercise training at the study site until COVID-19 restrictions (national lockdown) came into force on 16th March 2020.
62707867|NCT04955041||mild CSM|preoperative modified Japanese Orthopedic Association (mJOA) score ≥15
62707868|NCT04955041||moderate CSM|preoperative mJOA score 13\~14
62707869|NCT04955041||severe CSM|preoperative mJOA score ≤12
62707870|NCT00415090|NO_INTERVENTION|1|Follow with same ARV treatment
62707871|NCT00415090|EXPERIMENTAL|2|Switch one of ARV drugs to Nevirapine
61971389|NCT01428544||Patients with VTE treated with fondaparinux|Patients with VTE treated with fondaparinux
61971390|NCT01753856|EXPERIMENTAL|Teriparatide|"20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.~Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.~Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.~Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally."
62146500|NCT01564498|PLACEBO_COMPARATOR|White potato|Participants will consume 300-500 g of cooked white potatoes per day
62146501|NCT01564498|EXPERIMENTAL|Purple Potato|Participants will consume 300-500 g of cooked purple potato per day
62146502|NCT01564498|PLACEBO_COMPARATOR|Orange carrots|Participants will consume 200-300 g typical varieties of orange carrots during the intervention
62146503|NCT01564498|EXPERIMENTAL|Purple Carrots|Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
62352257|NCT02515708|EXPERIMENTAL|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device.
62352258|NCT02515708|OTHER|Normothermic Machine Perfusion (single pump)|This group has the liver grafts preserved using a single-pump variant of the Normothermic Liver perfusion Device.
62352259|NCT02576015|EXPERIMENTAL|Group L|Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
62352260|NCT02576015|SHAM_COMPARATOR|Group D|Participants in group D will receive the placement of femoral nerve catheter preoperatively. The same dose of 0.9% saline was injected and infused as group L intra-operatively. Bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 30-40.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
62352261|NCT01812070|EXPERIMENTAL|ACT|Acceptance \& Commitment Therapy
62707872|NCT00543985|EXPERIMENTAL|Stress Echocardiography|Echocardiography was performed prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
62707873|NCT04264000|EXPERIMENTAL|platelet-rich plasma|The perineural injection with PRP is a potential treatment for peripheral entrapment neuropathy
62146504|NCT01619319|EXPERIMENTAL|Cognitive Remediation Therapy|A computerised cognitive remediation intervention called the Brain Fitness program is compared against a placebo intervention consisting of computer games
62146505|NCT01619319|ACTIVE_COMPARATOR|computer games|computer games
62146506|NCT01404000|ACTIVE_COMPARATOR|Iodinated Active Charcoal|Iodinated activated charcoal 3 gram daily in the morning for 56 days +- 2 days (=8 weeks)
62146507|NCT01404000|PLACEBO_COMPARATOR|non-iodinated activated charcoal|3g non-iodinated activated charcoal is given daily for 8 weeks
62352262|NCT01812070|ACTIVE_COMPARATOR|CBT|Cognitive Behavioral Therapy
62352263|NCT00960713||The RITAI cohort|Every patient treated by rituximab off-label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (South of France) is eligible for the study, whatever the dose and planned infusions number. The enrolment is definitive when the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Department of Pharmacology Pharmacovigilance unit and to Health Authorities (AFSSAPS). Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco-immunological studies.
62352264|NCT01019252|EXPERIMENTAL|CBT for ADHD first, then follow-up|Participants received Cognitive Behavioral Therapy following randomization.
62707874|NCT04264000|ACTIVE_COMPARATOR|5% dextrose|The perineural injection of 5% dextrose is a novel management for peripheral entrapment neuropathy
62707875|NCT03898011|OTHER|Sequence Test-Reference (TR)|14 participants (total number of enrolled volunteers - 28) assigned to sequence TR will receive a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 1 and a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62511187|NCT04199117|EXPERIMENTAL|Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62511188|NCT04199117|EXPERIMENTAL|Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62511189|NCT04199117|EXPERIMENTAL|Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62146508|NCT05831566|EXPERIMENTAL|Intervention arm (EXACT@home)|"These patients will first undergo the systematic assessment (=EXACT@home) of +/- 6 weeks including a systematic anamnesis, questionnaires and home monitoring with multiple digital devices (digital inhaler, activity tracker, hand-held spirometer and FeNO measuring device) and a Personal Digital Health Environment (PDHE). Based on this evaluation and the degree of asthma control a treatment will be chosen: optimization of treatable traits if present and/or biologics.~The personal digital healthcare environment and digital inhaler will be used for 12 months and the activity tracker, hand-held spirometer and FeNO measuring device will be used for 12 weeks."
62511190|NCT04199117|EXPERIMENTAL|Incentive,Untailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62511191|NCT04199117|EXPERIMENTAL|Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62511192|NCT04199117|EXPERIMENTAL|No Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have not access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62511193|NCT04199117|EXPERIMENTAL|No Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62511194|NCT04199117|EXPERIMENTAL|No Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62511195|NCT04199117|EXPERIMENTAL|No Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62707876|NCT03898011|OTHER|Sequence Reference-Test (RT)|14 participants (total number of enrolled volunteers - 28) assigned to sequence RT will receive a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 1 and a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62707877|NCT05617027|EXPERIMENTAL|actual tDCS|"The actual transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of actual tDCS , 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session.~The tDCS current will be 2 mA for the whole 20-minute session."
62146509|NCT05831566|ACTIVE_COMPARATOR|Control arm (biologics)|"These patients will immediately receive a biologic after the indication is determined at the regional asthma Multi-Disciplinary Team Meeting (MDTM). These patients also have access to the Personal Digital Health Environment (PDHE) and they will also use the digital inhaler but without being able to see their own results or receiving feedback/reminders (silent).~The personal digital healthcare environment and digital inhaler will be used for 12 months."
62511196|NCT04199117|EXPERIMENTAL|No Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62707878|NCT05617027|PLACEBO_COMPARATOR|placebo tDCS|"The placebo transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of placebo tDCS, 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session.~The tDCS current will be 2 mA for 30 secondes, and then will strop for the rest of the 20-minute session (programming of the equipment)."
62511197|NCT04199117|EXPERIMENTAL|No Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62511198|NCT04199117|EXPERIMENTAL|No Incentive,Untailored,No Care Manage,IntensiveTreatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
62707879|NCT01690533||Group 1|
62707880|NCT03076684|EXPERIMENTAL|low-fructose diet|Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.
62707881|NCT03076684|EXPERIMENTAL|allopurinol treatment|Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
62707882|NCT03076684|NO_INTERVENTION|control arm|After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
62707883|NCT03447873|ACTIVE_COMPARATOR|Triple therapy|To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.
61971391|NCT01753856|ACTIVE_COMPARATOR|Denosumab|"60 mg denosumab administered SC once in 6 months.~DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.~TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 mg/day administered orally.~Vitamin D: Approximately 800 to 1200 IU/day administered orally."
61971392|NCT02739204|EXPERIMENTAL|Celecoxib|Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
62146510|NCT02751957|EXPERIMENTAL|Intervention|Receives caregiver coaching version of the Early Start Denver Model (ESDM) intervention, delivered by non-specialist workers. ESDM is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
62707884|NCT03447873|EXPERIMENTAL|Switch to dual therapy A|Switch to dual therapy with Darunavir/cobicistat (800150 mg) + lamivudine (300 mg) once daily once daily.
62707885|NCT03447873|EXPERIMENTAL|Switch to dual therapy B|Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily
62707886|NCT05241366|EXPERIMENTAL|Transcranial Magnetic Stimulation + usual treatment with SSRIs|"Transcranial Magnetic Stimulation + SSRIs The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over right dorsolateral prefrontal cortex with a total of 1500 each session.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
62707887|NCT05241366|SHAM_COMPARATOR|Sham TMS coil + usual treatment with SSRIs|"The sham TMS coil group will be comprised of 10 patients, sham TMS stimulation will be performed with the B-65 coil, which has similar sound and scalp contact to those experienced during active stimulation. The duration of treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
62707888|NCT00654108|EXPERIMENTAL|Cohort 1: vaccine dosage level 1 or placebo|Vaccine dose level 1: 1 X 10\^7 colony forming unit (CFU) or placebo, treated with Cipro on days 7-11.
62707889|NCT00654108|EXPERIMENTAL|Cohort 2: vaccine dosage level 2 or placebo|Vaccine dose level 2: 1 X 10\^8 CFU or placebo, treated with Cipro on days 7-11.
61971393|NCT02727023|EXPERIMENTAL|Osteopathic Manipulative Medicine|The thoracic inlet release, The Miller Thoracic Pump, Pedal Pump will be performed. These techniques are gentle and would be rhythmic in motion.
61971394|NCT05823961|EXPERIMENTAL|Eyedrops treatment arm|
62146511|NCT00997750|EXPERIMENTAL|Lornoxicam|Lornoxicam 8mg/day and 12mg/day for 15 days
62707890|NCT00654108|EXPERIMENTAL|Cohort 3: vaccine dosage level 3 or placebo|Vaccine dose level 3: 1 X 10\^9 CFU or placebo, treated with Cipro on days 7-11.
61971395|NCT00677612|EXPERIMENTAL|A|
62146512|NCT00470483|ACTIVE_COMPARATOR|arm 1|Paroxetine treatment during 8 weeks
62146513|NCT00470483|PLACEBO_COMPARATOR|arm 2|Placebo treatment during 8 weeks
62707891|NCT00654108|EXPERIMENTAL|Cohort 4: vaccine dosage level 4 or placebo|Vaccine dose level 4: 1 X 10\^10 CFU or placebo, treated with Cipro on days 7-11.
62707892|NCT01994876|EXPERIMENTAL|First Coloplast Test 1|"The subjects first test their own product to collect a baseline measurement~The subjects are randomised to first test Coloplast Test 1 and thereafter Coloplast Test 2"
62707893|NCT01994876|EXPERIMENTAL|First Coloplast Test 2|"The subjects first test their own product to collect baseline measurements~The subjects are randomised to first test Coloplast Test 2 and thereafter Coloplast Test 1"
62511199|NCT04199117|ACTIVE_COMPARATOR|No Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
62511200|NCT04047563|ACTIVE_COMPARATOR|Normal Saline + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
62707894|NCT06193707|EXPERIMENTAL|the Experimental Group|"* Teleconsultations: This involves using video calls, or phone calls once a month to connect patients for consultations, follow-ups, and discussions about conditions and symptom management.~* Remote Monitoring and Wearable Devices: Wearable devices and remote monitoring tools like Infrared Breast Temperature Detector and Dynamic blood pressure detector will be used once a week to track patients' vital signs and symptoms remotely.~* Mobile Applications: Specialized mobile apps will be used to provide a platform for patients to access educational materials, track their progress, manage management schedules, record symptoms, and connect with support groups or online communities.~* Educational Platforms and Remote Health Education: Online platforms and resources provide educational materials about breast cancer, treatment options, potential side effects, lifestyle adjustments, and overall wellness. These resources empower patients by providing comprehensive information."
62511201|NCT04047563|EXPERIMENTAL|PMZ-1620 (sovateltide) + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
62511202|NCT03370107|ACTIVE_COMPARATOR|Active rTMS and H coil|
62511203|NCT03370107|PLACEBO_COMPARATOR|sham rTMS and Hcoil|
62511204|NCT05016934|EXPERIMENTAL|A vaccine composed of a recombinant S1 antigen 10mcg|Two applications of 10mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
62707895|NCT06193707|ACTIVE_COMPARATOR|the Control Group|Ultrasound follow-up review is recommended no less than 3 to 6 months later. If there is no change at 2-year follow-up, it can be downgraded to BI-RADS 2; if there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
62707896|NCT00811460|EXPERIMENTAL|1|
62707897|NCT06449560|ACTIVE_COMPARATOR|Practice Group|Participants in this group engage in the traditional core course, followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.
61971396|NCT00540514|EXPERIMENTAL|Albumin-bound paclitaxel + Carboplatin|Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m\^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg\*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
61971397|NCT00540514|ACTIVE_COMPARATOR|Paclitaxel + Carboplatin|Participants received 200 mg/m\^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg\*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
62352265|NCT01019252|NO_INTERVENTION|Wait list first, then CBT for ADHD|Cross-over: Participants were assigned to a wait list after the initial assessment. They received Cognitive Behavioral Therapy after the 4 month assessment.
62352266|NCT01359046|EXPERIMENTAL|silver SPC|Subjects randomized to receive silver-impregnated SPC.
61971398|NCT01081925||Congestive heart failure|Patients suffering from sudden worsening of congestive heart failure
62352267|NCT01359046|ACTIVE_COMPARATOR|standard SPC|subjects randomized to receive standard SPC.
62707898|NCT06449560|EXPERIMENTAL|Video Feedback Group|Participants receive the traditional core course along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
62707899|NCT02095106|OTHER|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
62352268|NCT00547898|EXPERIMENTAL|Placebo|
62352269|NCT00547898|EXPERIMENTAL|Crofelemer 125 mg|
62352270|NCT00547898|EXPERIMENTAL|Crofelemer 250 mg|
62352271|NCT00547898|EXPERIMENTAL|Crofelemer 500 mg|
62352272|NCT02640066|EXPERIMENTAL|acupuncture|acupuncture treatment with Supportive care
62352273|NCT02640066|NO_INTERVENTION|standard treatment|Supportive care measures only
62352274|NCT03585673|EXPERIMENTAL|Docetaxel-PM+Oxaliplatin|"* Docetaxel-PM 35mg/m2 D1, 8 I.V.~* Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
62511205|NCT05016934|EXPERIMENTAL|A vaccine composed of a recombinant S1 antigen 25mcg|Two applications of a vaccine composed of a recombinant S1 antigen 28 days apart
62352275|NCT01847261|EXPERIMENTAL|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
62511206|NCT05016934|EXPERIMENTAL|A vaccine composed of a recombinant S1 antigen 50mcg|Two applications of 50mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
62511207|NCT05016934|PLACEBO_COMPARATOR|Placebo|Two applications of placebo 28 days apart
62511208|NCT02994628|ACTIVE_COMPARATOR|Water|Intervention, water and no banana carbohydrate: consume 3 ml/kg water every 15 min during 75 km cycling
62511209|NCT02994628|EXPERIMENTAL|Mini banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Mini banana with 3 ml/kg water every 15 minutes during 75 km cycling
62511210|NCT02994628|EXPERIMENTAL|Cavendish banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Cavendish banana with 3 ml/kg water every 15 minutes during 75 km cycling
62511211|NCT02994628|EXPERIMENTAL|6% sugar beverage|Intervention: pure banana carbohydrate in sugar beverage; ingest 0.2 g carbohydrate/kg body weight from a 6% sugar beverage every 15 minutes during 75 km cycling (contains 60 grams sugar per liter using the same sugar profile found in Cavendish bananas)
62511212|NCT02439632|EXPERIMENTAL|prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet without active components."
62511213|NCT02439632|ACTIVE_COMPARATOR|Levofloxacin|"Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.~Placebo of prulifloxacin film-coated tablet, without active components."
62511214|NCT03442959||patient with primary resection of the Small Intestinal TNE|
62511215|NCT03442959||patient without primary resection of the Small Intestinal TNE|
62511216|NCT03187028|ACTIVE_COMPARATOR|Diet only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
62511217|NCT03187028|EXPERIMENTAL|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling also receiving a fitness bracelet to facilitate counseling by the certified Cancer Exercise Trainer.
62352276|NCT01847261|ACTIVE_COMPARATOR|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
62352277|NCT03746067|EXPERIMENTAL|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
62511218|NCT06529939|EXPERIMENTAL|Psilocybin First|Individuals in this arm will be given psilocybin for their first scanning session. For their second scanning session (at least two weeks later), they will receive the placebo.
62511219|NCT06529939|EXPERIMENTAL|Placebo First|Individuals in this arm will be given the placebo for their first scanning session. For their second scanning session (at least two weeks later), they will receive psilocybin.
62511220|NCT00642421|EXPERIMENTAL|Population A|Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.
62511221|NCT00642421|EXPERIMENTAL|Population B|Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.
62511222|NCT03395639|EXPERIMENTAL|Edoxaban|Two out of three participants will be randomized for treatment with edoxaban solution or tablets
62511223|NCT03395639|ACTIVE_COMPARATOR|Standard of Care (SOC)|One out of three participants will be randomized for treatment with the institution's SOC regimen
61971399|NCT01411111|ACTIVE_COMPARATOR|Rosuvastatin foll by GSK2190915 30mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 30 mg/day for 7 days in treatment period 2A.
62146514|NCT06325228||Young Athletes|300 young athletes (boys and girls, 9 - 16 years-old) from clubs, teams, associations, sports classes of various disciplines in the Pomeranian Voivodeship
62511224|NCT04022824||OSA|
62511225|NCT04022824||Non-OSA|
62511226|NCT02669160|EXPERIMENTAL|Experimental|Group of communicating CP children receiving a 30 minutes daily session of verticalization with a motorized orthosis reproducing walking movement (PS Innowalk)
62511227|NCT02669160|OTHER|Control|Group of communicating CP children receiving a 30 minutes daily session of verticalization with their conventional passive stander.
62511228|NCT02224066|EXPERIMENTAL|Ticagrelor|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
62146515|NCT02013804|EXPERIMENTAL|Dose arms|Dose Escalation
62146516|NCT04377542|ACTIVE_COMPARATOR|LIFT|Ligation of intersphincteric fistula tract
62146517|NCT04377542|ACTIVE_COMPARATOR|Parks|Modified Parks technique
62146518|NCT04377542|ACTIVE_COMPARATOR|Seton|Two-stage seton placement
62146519|NCT01540500|EXPERIMENTAL|Steady State PK Group|
62146520|NCT04648215|EXPERIMENTAL|lavender oil|lavender oil as aromatherapy two drops dispensed on a 2x2 gauze and pinned to subject's gown
62511229|NCT02224066|ACTIVE_COMPARATOR|Aspirin/Clopidogrel|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
62511230|NCT02224066|NO_INTERVENTION|Registry arm|Patients with normal-on-treatment platelet reactivity (PRU \< 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.
62511231|NCT03802617|EXPERIMENTAL|MR13A9 low dose|
62511232|NCT03802617|EXPERIMENTAL|MR13A9 medium dose|
62511233|NCT03802617|EXPERIMENTAL|MR13A9 high dose|
62511234|NCT03802617|PLACEBO_COMPARATOR|Placebo|
62511235|NCT05039437|EXPERIMENTAL|MGF-4|Take two MGF-4 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-4 and other excipients.
62511236|NCT05039437|EXPERIMENTAL|MGF-7|Take two MGF-7 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-7 and other excipients.
62511237|NCT02470117|ACTIVE_COMPARATOR|Alginate-based reflux suppressant|Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
62511238|NCT02470117|SHAM_COMPARATOR|magnesium-aluminium antacid gel|magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
62511239|NCT03146637|EXPERIMENTAL|Activated CIK armed with bispecific antibody treatment group|CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
62511240|NCT03146637|ACTIVE_COMPARATOR|Traditional CIK treatment group|CIK cells were not activated
62707900|NCT02095106|OTHER|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
62707901|NCT00492557|EXPERIMENTAL|13vPnC+TIV Followed by Placebo 1 month later|
61971400|NCT01411111|ACTIVE_COMPARATOR|Rosuvastatin foll by GSK2190915 100mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 100 mg/day for 7 days in treatment period 2B.
62707902|NCT00492557|ACTIVE_COMPARATOR|Placebo+TIV Followed by 13vPnC 1 month later|
62707903|NCT01582750||Local advanced rectal cancer EUS|
61971401|NCT06452654|ACTIVE_COMPARATOR|Verum|"Comirnaty® 3 µg Omicron XBB.1.5 or future new variant developments replacing current Comirnaty vaccines for children~Suspension for injection, for intramuscular use~1. st dose at age 6.0 to 7.0 months~2. nd dose at least 3 weeks through to 6 weeks after 1st dose~3. rd dose at least 8 weeks after 2nd dose (around age 8.5 to 11 months)~Dose adjustment in case of COVID-19 infection."
61971402|NCT06452654|PLACEBO_COMPARATOR|Placebo|"0.9 % Sodium Chloride Solution (saline) for intramuscular injection Dosing: three doses~1. st dose at age 6.0 to 7.0 months~2. nd dose at least 3 weeks through to 6 weeks after 1st dose~3. rd dose at least 8 weeks after 2nd dose (around age 8.5 to 11 months)"
61971403|NCT06089928|ACTIVE_COMPARATOR|fixation free|sandwich osteotomy with Interpositional graft without fixation.
61971404|NCT06089928|ACTIVE_COMPARATOR|conventional sandwich osteotomy|sandwich osteotomy with Interpositional graft with fixation.
61971405|NCT02835508|EXPERIMENTAL|Treatment A|Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.
62707904|NCT06511583||Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department|Patients with aspiration pneumonia. For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient's head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.
62707905|NCT06511583||Aspiration Using Fibrobronchoscopy in the Emergency Department|"Patients with aspiration pneumonia. The bronchoscope will be gently inserted through the patient's nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions."
62707906|NCT02748447|EXPERIMENTAL|A-FiO2|24 hours in automated FiO2 adjustment to maintain SpO2 within a target range
62707907|NCT02748447|NO_INTERVENTION|M-FiO2|24 hours in manual adjustment of FiO2 to maintain SpO2 within a target range
62146521|NCT04648215|PLACEBO_COMPARATOR|grapeseed oil|grapeseed oil as aromatherapy two drops dispensed on a 2x2 gauze and pinned to subject's gown
62146522|NCT04648215|NO_INTERVENTION|Standard of Care|Routine nursing care at bedtime (HS)
62511241|NCT03052972|EXPERIMENTAL|Amyloid Positive|Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
62511242|NCT03052972|EXPERIMENTAL|Amyloid Negative|Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan
62511243|NCT05810025|EXPERIMENTAL|FHIR-Enhanced RealRisks|Participants will self-administer FHIR-enhanced RealRisks with access to risk communication games, family history pedigree and modules on chemoprevention and genetics testing, if relevant to them based on their risk and family history. The investigators are interested in gaining short-term feedback on patient activation and other patient reported outcomes, which will be assessed before and within 2 weeks after using RealRisks.
61971406|NCT02835508|EXPERIMENTAL|Treatment B|Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets\*60 mg) on Day 1.
62511244|NCT03765996|ACTIVE_COMPARATOR|Decongestive Physiotherapy|This group received Complex Decongestive Physiotherapy.
61971407|NCT02835508|EXPERIMENTAL|Treatment C|Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets\*60 mg) on Day 1.
61971408|NCT03944954|EXPERIMENTAL|Excitatory TMS|Individuals assigned to this group will receive excitatory (real and sham) TMS in combination with 0, 10, and 30mg THC.
62511245|NCT03765996|EXPERIMENTAL|Decongestive Physiotherapy plus taping|This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.
62511246|NCT04523610|EXPERIMENTAL|Program Users - Quantitative|The Telehealth Intervention Program (TIP-OA) for older adults was created during the COVID-19 pandemic to support the health of older adults who are isolated or have mental health/cognitive issues. Within the TIP-OA program, trained volunteers provide friendly phone calls once a week to older adults (age 60+). 200 participants will be recruited for the quantitative component of the study.
62511247|NCT04523610|OTHER|Program Users - Qualitative|Interviews will be conducted with 25 participants regarding their perceptions and experiences in the TIP-OA program.
62707908|NCT00473174|ACTIVE_COMPARATOR|1|Ramipril on awakening
62707909|NCT00473174|ACTIVE_COMPARATOR|2|Ramipril at bedtime
61971409|NCT03944954|EXPERIMENTAL|Inhibitory TMS|Individuals assigned to this group will receive inhibitory (real and sham) TMS in combination with 0, 10, and 30mg THC.
62146523|NCT01528683|EXPERIMENTAL|Carbon Ion Radiotherapy|
62146524|NCT00681109|ACTIVE_COMPARATOR|Treatment Arm 1|2.5% IL-1Ra
62146525|NCT00681109|PLACEBO_COMPARATOR|Placebo|Artificial Tear
62511248|NCT04523610|OTHER|Volunteers - Qualitative|15 volunteers taking part in the semi-structured interviews and 16 volunteers participating in the focus groups. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
62511249|NCT04523610|OTHER|Stakeholders - Qualitative|18 stakeholders (clinicians, community partners, TIP-OA team members) will participate in focus groups and interviews. Specifically, 10 clinicians will participate in one focus group and 8 community partners/team members will participate in interviews. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
62511250|NCT04266873|EXPERIMENTAL|AffloVest HFCWO intervention|Use of the AffloVest for 30 mins, twice a day for 6 weeks
62511251|NCT02568007|NO_INTERVENTION|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
62511252|NCT02568007|EXPERIMENTAL|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
62511253|NCT02568007|EXPERIMENTAL|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
62511254|NCT05839145|OTHER|Home to onsite monitoring|Patients will be monitored and evaluate in a first time at home then onsite.
62511255|NCT05839145|OTHER|Onsite to Home monitoring|Patients will be monitored and evaluate in a first time onsite then at home .
62511256|NCT04437888|ACTIVE_COMPARATOR|Racemic Ketamine|ketamine 0.5mg/kg bolus on induction of anesthesia and 10mcg/kg/min infusion initiated prior to incision and terminated at the completion of wound closure. Maximum ketamine dose will not exceed 500mg
62511257|NCT04437888|PLACEBO_COMPARATOR|Saline|saline in the same volume as the study drug, administered in the exact same format.
62511258|NCT04553991|ACTIVE_COMPARATOR|QL block group|For the ultrasound-guided quadratus lumborum block group, the patient was placed in lateral position . QL was identified medial to the aponeurosis of transversus abdominis muscle. Then the needle was inserted from supero-anterior to postero-inferior and advanced using in plane technique till the needle tip reached the anterolateral border of the QL at its junction with transversalis fascia.An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
62511259|NCT04553991|ACTIVE_COMPARATOR|TAP block group|For the ultrasound-guided TAP block,The probe was placed in the mid-axillary line above the level of the anterior superior iliac spine, then slided cranially till the three abdominal wall muscles identified (External oblique muscle (EAO), internal oblique muscle (IOM) and transverse abdominis muscle (TAM)). The needle was advanced using in-plane technique till it reached the transvers abdominis plane. An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
61971410|NCT06231615|EXPERIMENTAL|Treatment group|Patients in this group are the group to which fascia exercises are applied.
62511260|NCT06334861||Fragile patients vaccinated with herpes zoster vaccine|"Patients with immunodeficiency and/or immunosuppression afferent to the U.O.C. Rheumatology, U.O.C. Hematology and Hematopoietic Stem Cell Transplantation, U.O.C. Infectious Diseases and Geriatric Internal Medicine, Travel Clinic and Occupational Health Outpatient Clinic of FPU Agostino Gemelli IRCCS who meet the inclusion criteria will be recruited.~Inclusion Criteria.~* Patients with congenital and/or acquired immunodepression;~* Age \> 18 years;~* Signature of informed consent Exclusion criteria.~* Persons younger than 18 years of age"
62511261|NCT06045520|EXPERIMENTAL|IBM Educational Training|Intervention group participants will receive IBM skills model on educational training intervention for 8 weeks.
61971411|NCT06231615|OTHER|Control group|Patients in this group are the group to which conventional physiotherapy and breathing exercises are applied.
61971412|NCT03007160|EXPERIMENTAL|Experimental group|Potassium Citrate Extended-release Tablets
61971413|NCT03007160|NO_INTERVENTION|Blank control group|Subjects do not take the investigational product
61971414|NCT02464462|EXPERIMENTAL|CaD Group|This arm received total of 1800 IU of vitamin D3 and 720 mg of calcium
61971415|NCT02464462|PLACEBO_COMPARATOR|Placebo Group|This arm received rice powder pills
62511262|NCT06045520|NO_INTERVENTION|Control Group|No intervention was applied to the control group.
62511263|NCT06175247|EXPERIMENTAL|Low Glycemic Index Diet Group|A low glycemic index diet will be started with ongoing dietician support \& food questionnaires until pregnancy completion.
62511264|NCT06175247|NO_INTERVENTION|Standard Diet Group|A standard diet, as chosen by participants, will be followed with ongoing food questionnaires until pregnancy completion.
62511265|NCT00666887|ACTIVE_COMPARATOR|Minocycline|Minocycline 100 mg oral for up to 24 months
62511266|NCT00666887|PLACEBO_COMPARATOR|Placebo|Lactose Monohydrate NF (Spray-dried) 235 mg/cap Magnesium Stearate NF 1 mg/cap Croscarmellose Sodium NF 4 mg/cap Stearic Acid 10 mg/cap Placebo CAP Lt orange OP-Purple OP (APO 100)
62511267|NCT06185595|PLACEBO_COMPARATOR|Control|No sodium, No glycerol
62511268|NCT06185595|EXPERIMENTAL|Sodium only group 1|55 mmol/L sodium
62511269|NCT06185595|EXPERIMENTAL|Glycerol only|4.6% glycerol
62511270|NCT06185595|EXPERIMENTAL|Sodium and Glycerol group 1|55 mmol/L sodium and 4.6% glycerol
62511271|NCT06185595|EXPERIMENTAL|Sodium only group 2|27.5 mmol/L sodium
62511272|NCT06185595|EXPERIMENTAL|Sodium and Glycerol group 2|27.5 mmol/L sodium and 2.3% glycerol
62511273|NCT01368302|EXPERIMENTAL|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to normalize threat-related attention biases.
62511274|NCT01368302|PLACEBO_COMPARATOR|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
61971416|NCT04897360|EXPERIMENTAL|Normocapnic SRT, Hypocapnic SRT, Recovery SRT|Sharpened Romberg Test
61971417|NCT04771442|EXPERIMENTAL|Stromal vascular fraction injection|"Intervention:~Single injection with autologous adipose tissue-derived stromal vascular fraction cells in and around the plaque."
61971418|NCT01092559|EXPERIMENTAL|nitric oxide via GeNO Nitrosyl system|Nitric Oxide via GeNO Nitrosyl system
62146526|NCT00681109|ACTIVE_COMPARATOR|Treatment Arm 2|5% IL-1Ra
62146527|NCT00761267|EXPERIMENTAL|Anidulafungin IV|All subjects meeting screening criteria will receive IV anidulafungin.
62511275|NCT02014441|EXPERIMENTAL|Talimogene Laherparepvec|"Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first."
62511276|NCT01281787|ACTIVE_COMPARATOR|Losartan|angiotensin II-receptor blocker
62511277|NCT01281787|NO_INTERVENTION|no treatment|no preventive treatment
62511278|NCT01281787|ACTIVE_COMPARATOR|Metoprolol|beta-adrenergic antagonist
62511279|NCT01552031||Observational group|
62511280|NCT01467479|EXPERIMENTAL|T/PR + HAART Regimen (ATV/r-Based)|Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
62511281|NCT01467479|EXPERIMENTAL|T/PR + HAART Regimen (EFV-Based)|Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
62511282|NCT01467479|EXPERIMENTAL|T/PR + HAART Regimen (RAL-Based)|Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
62511283|NCT05440019||HEALTHY WOMEN IVI VALENCIA|"Participants will be exposed to four sessions of image captures using FERTIGO® device.~Prior to the session, a vaginal ultrasound (US) will be performed, for measuring the endometrial thickness as in the usual practice."
62511284|NCT00707434|EXPERIMENTAL|Glucose Monitoring Device|Continuous glucose monitoring in critically ill patients.
62511285|NCT04013074|EXPERIMENTAL|TIPS+Standard Medical Treatment|TIPS along with standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
62511286|NCT04013074|ACTIVE_COMPARATOR|Standard Medical Treatment|standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
62511287|NCT05093465|ACTIVE_COMPARATOR|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
62146528|NCT06305143|EXPERIMENTAL|intravitreal Conbercept|Participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
62511288|NCT05093465|EXPERIMENTAL|Technology Intervention|Participants were given the same intervention materials as the active control condition plus procedures to change technology use.
62511289|NCT05893316||Hematuria patients|Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria.
61971419|NCT03344250|EXPERIMENTAL|Main Study|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. Participants will receive the first and second infusions of EGFR BATs on days 14 and 21 after finishing concurrent RT and TMZ and then receive an infusion on day 21 of the first six cycles of TMZ.
61971420|NCT03344250|EXPERIMENTAL|Subcohort for MGMT unmethylated patients|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. About 4 weeks after completion of RT/TMZ, participants will receive 8 weekly doses of EGFR BATs.
62146529|NCT00951132|EXPERIMENTAL|2|Rosuvastatin
62146530|NCT00951132|PLACEBO_COMPARATOR|1|Placebo
62146531|NCT03592407|EXPERIMENTAL|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
62146532|NCT04637100|EXPERIMENTAL|Experimental|The patient will utilize their personal mobile or tablet device to play a pre-selected set of problem-solving games for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
62511290|NCT05893316||Non-hematuria patients|Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer.
61971421|NCT02551276|EXPERIMENTAL|Experimental|Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks
61971422|NCT02551276|PLACEBO_COMPARATOR|Control|Placebo and resistance training for 10 weeks
62146533|NCT04637100|ACTIVE_COMPARATOR|Control|The patient will utilize their personal mobile or tablet device to watch a pre-selected set of stroke-related educational videos for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
62146534|NCT00003088|EXPERIMENTAL|Sequential chemotherapy 21 days|Patients received doxorubicin 60 mg/m\^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m\^2 every 3 weeks for four cycles followed by cyclophosphamide 600 mg/m\^2 every 3 weeks for four cycles.
62146535|NCT00003088|EXPERIMENTAL|Concurrent chemotherapy 14 days|Patients received doxorubicin 60 mg/m\^2 plus cyclophosphamide 600 mg/m\^2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m\^2 every 2 weeks for four cycles with filgrastim days 3 to 10 of each cycle at 5 µg/kg rounded to either 300 or 480 µg total dose.
62511291|NCT01487655||healthy age matched controls|
62511292|NCT01487655||normal tension glaucoma patients|
62511293|NCT01487655||primary open angle glaucoma patients|
61971423|NCT01338792|EXPERIMENTAL|Treatment (chemotherapy and enzyme inhibitor)|Patients receive oxaliplatin IV over 2 hours and pemetrexed disodium IV on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
61971424|NCT01050868|EXPERIMENTAL|Single Arm|
61971425|NCT05255172|EXPERIMENTAL|Supervised exercise|The exercise intervention will include 2 supervised sessions of ergometer cycling with a warm up period of 10 minutes and 20 minutes of cycling at the aerobic intensity below the anaerobic threshold as determined from baseline results. Patients in the exercise arm will have 1 unsupervised exercise session where the participants walk or bicycle for 30 minutes at an intensity experienced as somewhat hard (Borg 13) according to the Borg Rating of Perceived Exertion Scale.
62146536|NCT00003088|EXPERIMENTAL|Sequential chemotherapy 14 days|Patients received doxorubicin 60 mg/m2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m2 every 2 weeks for four cycles followed by cyclophosphamide 600 mg/m2 every 2 weeks for four cycles, with filgrastim days 3 to 10 of each cycle (a total of seven doses) at 5 µg/kg, which could be rounded to either 300 or 480 µg total dose.
62352278|NCT03746067|PLACEBO_COMPARATOR|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, the 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
62352279|NCT05049447|ACTIVE_COMPARATOR|Verum arm|Intervention: Drug: Verum (Pascoflair)
62352280|NCT05049447|PLACEBO_COMPARATOR|Placebo arm|Intervention: Drug: Placebo
62352281|NCT04961060||Eosinophilic exacerbation|COPD exacerbation associated with eosinophilia.
62352282|NCT04961060||Viral exacerbation|COPD exacerbation associated with viral infection.
62352283|NCT04961060||Bacterial exacerbation|COPD exacerbation associated bacterial infection.
62352284|NCT04961060||Pauci-inflammatory exacerbation|Pauci-inflammatory COPD exacerbation
62352285|NCT00168324|EXPERIMENTAL|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
62352286|NCT00168324|EXPERIMENTAL|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
62352287|NCT00168324|SHAM_COMPARATOR|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
62352288|NCT00984880|EXPERIMENTAL|1|Intravenous solution given as a single ascending bolus dose
62352289|NCT00984880|EXPERIMENTAL|2|Intravenous solution given as a single ascending bolus dose followed by a single infusion
62352290|NCT04129086|EXPERIMENTAL|Ketamine plus Usual care|
62352291|NCT04129086|ACTIVE_COMPARATOR|Usual care|
62352292|NCT04365894|NO_INTERVENTION|Control|The study was applied in 2nd grade nursing students' disability health course. The control group was taught with the traditional method.
62352293|NCT04365894|EXPERIMENTAL|Intervention|The intervention group with learning activities based on the transformative learning theory.
62352294|NCT05006339|EXPERIMENTAL|Dental Monitoring|Orthodontic retention review via dental monitoring only
62352295|NCT05006339|ACTIVE_COMPARATOR|Clinic Review|Orthodontic retention review via in-office visits as per routine care
62511294|NCT01139749|ACTIVE_COMPARATOR|Oral isotretinoin|Subjects from treatment arm will be treated with low-dose oral isotretinoin - 20 mg a day, every other day, for six months
62511295|NCT01139749|ACTIVE_COMPARATOR|salicylic acid and ciclopirox olamine|Subjects from comparison arm will be treated with topical salicylic acid and ciclopirox olamine shampoo
62511296|NCT04330911|EXPERIMENTAL|The HIIT Group (High Intensity Interval Training Group)|
62511297|NCT04330911|EXPERIMENTAL|The MICT Group (Moderate Intensity Continous Training Group)|
62511298|NCT00643734|EXPERIMENTAL|1|
62511299|NCT00643734|EXPERIMENTAL|2|
62511300|NCT06502652|EXPERIMENTAL|hippotherapy|Group A includes Hippo Therapy. A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally
62707910|NCT01173744|EXPERIMENTAL|Gamma-3 Nail|
61971426|NCT05255172|NO_INTERVENTION|Standard of Care|The control group will receive advise to continue to live as usual. After 4 and 8 weeks, participants in the control group will be contacted by telephone for inquiry of general wellbeing. No other interventions will be performed in the control group.
61971427|NCT01879332|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets for oral administration
61971428|NCT01879332|EXPERIMENTAL|BIA 2-093 3000 mg once daily|Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
61971429|NCT01879332|EXPERIMENTAL|BIA 2-093 3600 mg once daily|Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
62352296|NCT01884961|EXPERIMENTAL|arm A|"Boost of radiotherapy + high dose IL-2 treatment: Three daily doses boost radiotherapy at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of IL-2 (Interleukin 2). The first day of administration of IL-2 of each cycle is the day +1.~Treatment with IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV (intravenous) infusion for 72 hours) will start on day +1 and will be administered every 3 weeks up to 4 cycles, than every 3-4 weeks for a further 2 cycles.~Patients will be evaluated every 8 weeks with computed tomography to determine the response, and every 3 months after completion of treatment until death."
62352297|NCT05094895|ACTIVE_COMPARATOR|Stretta Treatment|Patients will receive the Stretta treatment
62352298|NCT05094895|SHAM_COMPARATOR|Sham treatment|Patients will receive the sham treatment
62707911|NCT01173744|ACTIVE_COMPARATOR|DHS|
62707912|NCT01593371|ACTIVE_COMPARATOR|Metformin|patients receiving fixed dose metformin 1000 mg daily
62511301|NCT06502652|ACTIVE_COMPARATOR|balance training|The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
62511302|NCT05727449||General Anesthesia for Cesarean Delivery|
62511303|NCT05727449||Spinal Anesthesia for Cesarean Delivery|
62511304|NCT04596124|EXPERIMENTAL|fitostimoline plus cream|
62511305|NCT04596124|EXPERIMENTAL|fitostimoline plus gauze|
62511306|NCT04596124|ACTIVE_COMPARATOR|connettivina bio plus cream|
62511307|NCT04596124|ACTIVE_COMPARATOR|connettivina bio plus gauze|
62511308|NCT01961882|EXPERIMENTAL|OCV-501 arm|
62511309|NCT01961882|PLACEBO_COMPARATOR|Placebo arm|
62511310|NCT05738655|PLACEBO_COMPARATOR|Placebo group|Placebo capsule, one capsule/day (300 mg/day) for 3 months
62511311|NCT05738655|EXPERIMENTAL|Low dose|Pumpkin seed extract capsule, one capsule/day (300 mg/day) for 3 months
62511312|NCT05738655|EXPERIMENTAL|High dose|Pumpkin seed extract capsule, two capsules/day (600 mg/day) for 3 months
62511313|NCT05653635|EXPERIMENTAL|Simultaneous-integrated boost with Intensity-modulated radiation therapy (IMRT)|"* Planning Target Volume (PTV) 37,5 Gray (Gy): 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days~* Prescription isodose line (PIL) at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction~* PTV SIB 45 Gy: 45,0 Gy in 6 fractions of 7,50 Gy at the rate of one fraction each 2 days~* PIL at 80% corresponding to 36 Gy as total dose, or 6 Gy per fraction"
61971430|NCT01813097||combination iodine 125 seed implants|30 cases should be treated with iodine 125 seed implants 0.5 mc transperineal prostate implant +Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
62511314|NCT05653635|NO_INTERVENTION|Standard IMRT|"* PTV 37,5 Gy: 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days~* PIL at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction~* No SIB"
62511315|NCT04329715|EXPERIMENTAL|Expedited instructions|
62352299|NCT03843736|NO_INTERVENTION|Health control group|Participants are healthy women and there are no interventions.
62352300|NCT03843736|EXPERIMENTAL|Lifestyle interventions group|Participants are PCOS patients and only will be given lifestyle interventions.
62352301|NCT03843736|EXPERIMENTAL|Probiotic Agent group|Participants are PCOS patients and will be given lifestyle interventions + Probiotic Agent interventions.
62511316|NCT04329715|ACTIVE_COMPARATOR|Restricted instructions|
62511317|NCT04177641||low grade squamous intraepithelial lesion(LGSIL)|low grade squamous intraepithelial lesion(LGSIL) n=100
62511318|NCT04177641||high grade squamous intraepithelial lesion(HGSIL)|high grade squamous intraepithelial lesion(HGSIL) n=100
62511319|NCT04177641||Healthy controls|Healthy volunteers n=100
62511320|NCT04225286|EXPERIMENTAL|Intranasal human breast milk|"Human breast milk delivered intranasally to preterm infants (\<33 weeks gestation at birth, stratified \< and ≥28 weeks) with any grade IVH/intraparenchymal hemorrhage/infarction identified on head ultrasound in the first 10 days of life.~Dosing: Escalating dose starting at 0.2mL into one nostril with repeat dose 10-15 minutes later 1-2x daily, depending on availability of fresh HM"
61971431|NCT01813097||LHRH agonists|30 cases should be treated with Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
62511321|NCT06617624||Group 1: patient with paroxysmal AF (Atrial Fibrillation) (no AF during exam)|20 patients able to complete the full standard experimental examination corresponding to paroxysmal AF group
61971432|NCT00227695|ACTIVE_COMPARATOR|Arm A: Rituximab every 2 months x4|Rituximab 375 mg/m2 every 2 months x4
61971433|NCT00227695|ACTIVE_COMPARATOR|Arm B: Rituximab (5 years)|Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity
62352302|NCT03843736|EXPERIMENTAL|Oral contraceptive group|Participants are PCOS patients and will be given lifestyle intervention + Oral contraceptive interventions.
62352303|NCT02839941|EXPERIMENTAL|experiment|
62352304|NCT02839941|SHAM_COMPARATOR|Control|
62352305|NCT06177119|EXPERIMENTAL|Test 1|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days, starting with the first SRP session
62352306|NCT06177119|EXPERIMENTAL|Test 2|Scaling and root planing (SRP) + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) immediately after the end of the SRP in the following 14 days.
62352307|NCT02014727|EXPERIMENTAL|AMA1-DiCo + Alhydrogel|AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
62511322|NCT06617624||Group 2: patient with persistent AF (Atrial Fibrillation)|20 patients able to complete the full standard experimental examination corresponding to persistent AF group
62511323|NCT06617624||Group 3: patient with permanent AF (Atrial Fibrillation)|20 patients able to complete the full standard experimental examination corresponding to permanent AF group
62511324|NCT06617624||Group 4: healthy volunteer|60 age/sex BMI class matched healthy volunteers, able to complete the full standard experimental examination.
62511325|NCT02063308|EXPERIMENTAL|Oxaloacetate (OAA)|100 mg OAA to be taken twice daily over the course of a month
62511326|NCT04052698|EXPERIMENTAL|All patients|Patients with type 3, type 2 (except 2N), or severe type 1 VWD aged ≥6 years at screening receiving Wilate for prophylactic treatment.
62511327|NCT02372591|PLACEBO_COMPARATOR|Placebo|
62511328|NCT02372591|ACTIVE_COMPARATOR|Hydromorphone|
62511329|NCT02372591|EXPERIMENTAL|Buprenorphine|
62511330|NCT03500367|EXPERIMENTAL|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
62511331|NCT02112279|EXPERIMENTAL|Microbiota Transplant|Close relative or purchased donor microbiota transplant will be administered via colonoscopy; Donor microbiota applied via colonoscopy
62511332|NCT05202041|EXPERIMENTAL|AccuFFRangio Group|NSTE-ACS patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.
62707913|NCT01593371|ACTIVE_COMPARATOR|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
62352308|NCT02014727|EXPERIMENTAL|AMA1-DiCo+ GLA-SE|"Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
62352309|NCT02014727|EXPERIMENTAL|AMA1-DiCo + GLA-SE|"Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
62352310|NCT02014727|PLACEBO_COMPARATOR|Placebo|"Group B2 (18) : African volunteer : Placebo~Placebo : isotonic saline solution~Route : Intramuscular Vaccination schedule : Do, W4, W26"
62352311|NCT02016729|EXPERIMENTAL|AMG 232|AMG 232 is an anti-cancer agent
62352312|NCT02016729|EXPERIMENTAL|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
62511333|NCT05202041|ACTIVE_COMPARATOR|Angiography Group|The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis \> 70% based on angiographic results.
62511334|NCT01674439|EXPERIMENTAL|With supplementation of ADRC|Fat graft with supplementation of ADRC
62511335|NCT01674439|ACTIVE_COMPARATOR|Without supplementation of ADRC|Fat grafts without supplementation of ADRC
62511336|NCT01215071|EXPERIMENTAL|limited lymphadenectomy|Fields 5, 7, 9, 11, 13, 14 are removed
61971434|NCT04873791||Group 1|"Assessment Geriatric Individuals Living at Home were joined in Group 1.~Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
61971435|NCT04873791||Group 2|"Assessment Geriatric Individuals Living in Nursing Home were joined in Group 2. Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
62511337|NCT01215071|EXPERIMENTAL|extended lymphadenectomy|Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed
62511338|NCT04935788|EXPERIMENTAL|milk protein|milk protein supplement
62511339|NCT04935788|EXPERIMENTAL|micellar casein|casein supplement
62511340|NCT04935788|EXPERIMENTAL|pea protein|pea protein supplement
61971436|NCT03128892|EXPERIMENTAL|Test Subject|All subjects are enrolled into the test group and all subjects received the Noninvasive Oxygen Reserve Index - RD Lite Sensors
62352313|NCT06315582|ACTIVE_COMPARATOR|Study Intervention A (control group)|Hysteroscopic septoplasty utilizing bipolar electrosurgery
62352314|NCT06315582|EXPERIMENTAL|Study Intervention B (study group)|Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
62352315|NCT02282176|EXPERIMENTAL|Azithromycin|10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
62352316|NCT02282176|PLACEBO_COMPARATOR|Placebo|Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
62352317|NCT02637440|NO_INTERVENTION|Conservative|After the index primary PCI. The control group will receive best medical therapy and regular follow up and only PCI for recurrent angina with evidence of inducible ischaemia.
62352318|NCT02637440|ACTIVE_COMPARATOR|FFR guided|FFR group will undergo FFR at 4 weeks of the index primary PCI as OPD. If FFR is less than 0.8, then PCI will be performed
62352319|NCT02637440|ACTIVE_COMPARATOR|angiogram guided|The group will undergo PCI for all significant lesions more than 50
62352320|NCT05246670|PLACEBO_COMPARATOR|BID placebo|Patients receive placebo PO BID for 8 weeks.
62352321|NCT05246670|EXPERIMENTAL|Higher-dose PEA|Patients receive PEA PO BID for 8 weeks as long as there is not any unacceptable toxicity.
62352322|NCT05246670|EXPERIMENTAL|Lower-dose PEA|Patients receive PEA PO QD for 8 weeks as long as there is not any unacceptable toxicity.
62352323|NCT05246670|PLACEBO_COMPARATOR|QD placebo|Patients receive placebo PO QD for 8 weeks.
62352324|NCT02677818||experimental group|The risk of bleeding adverse reactions when FVIII below the normal level.
62511341|NCT04935788|EXPERIMENTAL|milk/pea protein|a blend of milk and pea protein
62511342|NCT02641002|EXPERIMENTAL|Dose escalation of CC-90002|CC-90002 by intravenous (IV) infusion on a 28 day cycle
62511343|NCT00908219|EXPERIMENTAL|Bevacizumab IV|All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study.
62511344|NCT01972035|EXPERIMENTAL|ValAcyclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValA or ValG in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
62511345|NCT01972035|ACTIVE_COMPARATOR|ValGanciclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValG or ValA in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
62511346|NCT05488717|EXPERIMENTAL|Application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
62511347|NCT03498599|EXPERIMENTAL|Novelty facilitated extinction|Behavioral intervention. After Pavlovian fear conditioning, the shock is omitted and replaced by a novel, surprising, and neutral auditory tone.
62511348|NCT03498599|OTHER|Standard extinction|The shock is omitted during standard extinction
62511349|NCT03328728|EXPERIMENTAL|Cellular Matrix / A-CP HA Kit|One intra-articular injection of a combination of PRP and non-crosslinked HA
62511350|NCT03328728|ACTIVE_COMPARATOR|Synvisc-One|One intra-articular injection of a crosslinked HA
62511351|NCT04590768|EXPERIMENTAL|Fermotein™|daily lunch with 11 grams of Fermotein™ dry powder, mixed in bread, soup or a burger
62511352|NCT04590768|ACTIVE_COMPARATOR|Matched control products|daily lunch with a control bread matched in macronutrient content. Control meat alternative burgers and soup from the local supermarket.
62511353|NCT01672359|EXPERIMENTAL|Ginkgo Synergy® and Choline|Ginkgo Synergy® (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)
62511354|NCT01672359|EXPERIMENTAL|OPC Synergy® and Catalyn|OPC Synergy® (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn® (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)
62511355|NCT01672359|PLACEBO_COMPARATOR|Placebo|cellulose pills to simulate actual products
62511356|NCT01215799|EXPERIMENTAL|Bafetinib|
62511357|NCT04243096|EXPERIMENTAL|Exercise-based Physical Therapy|12 week in-person exercise-based physical therapy
62511358|NCT01286558|EXPERIMENTAL|80mg telmisartan and 5mg amlodipine FDC|once daily
62511359|NCT01286558|ACTIVE_COMPARATOR|40mg telmisartan and 5mg amlodipine FDC|once daily
62511360|NCT01552369|EXPERIMENTAL|Preemptive Therapy|900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
62707914|NCT03067636|ACTIVE_COMPARATOR|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
61971437|NCT02726646|PLACEBO_COMPARATOR|Debridement|mechanical debridement in one session and application of 1 mg placebo microspheres in two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
61971438|NCT02726646|EXPERIMENTAL|Debridement plus Doxycycline|mechanical debridement in one session associated with the application of 1 mg of microspheres loaded with doxycycline per periodontal pockts, two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
61971439|NCT00545168|EXPERIMENTAL|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
61971440|NCT00545168|EXPERIMENTAL|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
62511361|NCT01552369|ACTIVE_COMPARATOR|Prophylaxis|900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88
62511362|NCT01529658|NO_INTERVENTION|No hypothermia|After clamping of the renal vessels, no ice slush will be used.
62511363|NCT01529658|EXPERIMENTAL|Hypothermia|saline ice slush around kidney for 10 minutes.
62511364|NCT00783575||Inflammatory Bowel Disease|Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD) are chronic, life-long, destructive inflammatory conditions of the gastrointestinal tract.
62511365|NCT06084741|ACTIVE_COMPARATOR|Drain group|In Group A the investigators will put intraabdominal drains
62511366|NCT06084741|EXPERIMENTAL|No drain group|The investigators will not put any intraabdominal drains
61971441|NCT00545168|ACTIVE_COMPARATOR|C - NIX|Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
61971442|NCT02579044|OTHER|Everolimus and Lonafarnib|Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
61971443|NCT02940977||Prostate cancer patients|Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.
62511367|NCT04134754|OTHER|Respiratory physiology testing|Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.
61971444|NCT03989453|EXPERIMENTAL|Chi Kung group|This group receives physical training based on Chi Kung.
62511368|NCT04869709|ACTIVE_COMPARATOR|Late Preterm Steroids 2 Days|
62511369|NCT04869709|ACTIVE_COMPARATOR|Late Preterm Steroids 7 Days|
62511370|NCT03829007|EXPERIMENTAL|PD-L1 imaging|89Zr-durvalumab iv injection followed by a PET/CT scan at day 5 after injection.
62511371|NCT01644487|EXPERIMENTAL|Primary stenting|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
62511372|NCT01644487|ACTIVE_COMPARATOR|Balloon only|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
62511373|NCT01471587||Patients with COPD|
62511374|NCT06206603||Colorectal polyps|Biopsies will be obtained from the polyp and from adjacent healthy intestinal mucosa. A blood sample will be collected to investigate if certain microRNA/mRNA profiles are traceable in the blood.
62707915|NCT03067636|ACTIVE_COMPARATOR|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
62707916|NCT03067636|NO_INTERVENTION|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
62707917|NCT05548426|EXPERIMENTAL|Linezolid 10 Day|Oral linezolid 600mg, taken twice a day for 10 days
62146537|NCT00003088|EXPERIMENTAL|Concurrent chemotherapy 21 days|Patients received doxorubicin 60 mg/m\^2 plus cyclophosphamide 600 mg/m\^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m\^2 every 3 weeks for four cycles.
62511375|NCT06206603||Colorectal cancer|Biopsies will be obtained from the cancer and from adjacent healthy intestinal mucosa. A blood sample will be collected to investigate if certain microRNA/mRNA profiles are traceable in the blood.
62511376|NCT06206603||Healthy controls|Biopsies will be obtained from predefined locations in the colon and rectum. A blood sample will be collected to investigate if certain microRNA/mRNA profiles are traceable in the blood.
62511377|NCT05663372|EXPERIMENTAL|Efez (Test)|A single oral dose of the test product Efez 50 mg eplerenone film-coated tablets.
62146538|NCT00530036||Continent|"54% of 699 patients followed as outpatient by the Fondation des Services d'Aide et de Soins à Domicile in Geneva without urinary incontinence"
62352325|NCT02677818||control group|The risk of bleeding adverse reactions when FVIII in normal level.
62352326|NCT00356057|ACTIVE_COMPARATOR|1|Biventricular pacing group with Closed Loop Stimulation rate adaptation (Protos CLS device)
62352327|NCT00356057|ACTIVE_COMPARATOR|2|Biventricular pacing group with accelerometer based rate adaption (Stratos LV device)
62352328|NCT00356057|ACTIVE_COMPARATOR|3|Right Ventricular pacing group with accelerometer based rate adaption (Stratos LV device)
62352329|NCT03852160|EXPERIMENTAL|Esketamine + Oral Antidepressants|Participants will receive esketamine as nasal spray (28 milligram \[mg\] \[initial dose for elderly participants 65-74 years of age\] on Day 1 and then uptitrated to 56 mg on Day 4, 56 mg \[initial dose for adult participants aged 18-64 years and may be used for all age groups throughout the study\] or 84 mg \[maximum uptitrated esketamine dose\]) twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral anti depressants (AD) (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
62352330|NCT03852160|ACTIVE_COMPARATOR|Placebo + Oral Antidepressants|Participants will receive matching placebo as nasal spray twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral AD (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
62352331|NCT02565732|EXPERIMENTAL|Dose A|Botulinum toxin type A
62352332|NCT02565732|EXPERIMENTAL|Dose B|Botulinum toxin type A
62352333|NCT02565732|PLACEBO_COMPARATOR|Dose C|Placebo comparator
62352334|NCT01081821|EXPERIMENTAL|001|single dose NJ-39758979/ matching placebo Single oral dose of JNJ-39758979 (either 50 100 300 600mg) or Placebo
62352335|NCT01081821|EXPERIMENTAL|002|multi-dose JNJ-39758979 /matching placebo JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
62352336|NCT01165099|EXPERIMENTAL|manual acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were manually manipulated during this time. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
62352337|NCT01165099|EXPERIMENTAL|electro acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were either electronically simulated withm2 Hz pulses of 0.5 msec duration for 30 minutes sufficient to cause non-painful muscle contractions. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
62352338|NCT01165099|SHAM_COMPARATOR|Sham manual or electro acupuncture|Sterile needles were inserted adjacent to the specific acupuncture sites identified for the manual and electro groups to a depth of 1-1.5mm only and insufficient to provoke an unusual sensation and left in position for a 30-60 minutes. Those randomised to 'sham-manual' received no stimulation and those randomised to 'sham-electro' were connected to the electrical stimulator but the current not activated.
62352339|NCT01165099|NO_INTERVENTION|control group|Following randomisation to be control group, no specific treatment was organised at this time.
62352340|NCT03870685|ACTIVE_COMPARATOR|TAP block with Exparel|Patients will receive immediate postoperative bilateral 2-quadrant TAP block with Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by the anesthesia team.
62352341|NCT03870685|ACTIVE_COMPARATOR|Surgical Site Infiltration of Exparel|Patients will receive surgical site infiltration of Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by surgeon.
62511378|NCT05663372|ACTIVE_COMPARATOR|INSPRA®|A single oral dose of the reference product INSPRA® 50 mg eplerenone film-coated tablets.
62511379|NCT02299219|EXPERIMENTAL|Taking Charge Experimental Group|
62511380|NCT02299219|ACTIVE_COMPARATOR|Control Group|
62146539|NCT00530036||Incontinent|"46% of 699 patients followed by the Fondation des Services d'Aide et de Soins à Domicile in Geneva and with an urinary incontinence"
62146540|NCT05017909|EXPERIMENTAL|Experimental Group 1|3-week web-based education group
62146541|NCT05017909|EXPERIMENTAL|Experimental Group 2|3-week face to face education group
62146542|NCT05017909|ACTIVE_COMPARATOR|Control Group|Uneducated group
62146543|NCT04630119||Study group of female homemakers with chronic neck pain|All female patients aged between 18-55 years with chronic neck pain (pain lasting for more than 3months) who were homemakers were included in the study. All participants reported the presence of pain in the preceding one week
62352342|NCT04345406|EXPERIMENTAL|ACEIs|ACEIs with conventional treatment for COVID19
62352343|NCT04345406|EXPERIMENTAL|Conventional treatment of COVID19|Conventional treatment of COVID19
62352344|NCT02651792|ACTIVE_COMPARATOR|ketamine- propofol|IV Ketamine 1mg/kg + Propofol 1.2 mg/kg will be given for sedation.
62352345|NCT02651792|ACTIVE_COMPARATOR|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
62511381|NCT01294566|EXPERIMENTAL|Cohort 1|GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)
62511382|NCT01294566|EXPERIMENTAL|Cohort 2|GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)
62352346|NCT00854256|EXPERIMENTAL|Canaloplasty|
62511383|NCT00894842|ACTIVE_COMPARATOR|Pregnenolone|
62511384|NCT00894842|PLACEBO_COMPARATOR|Sugar pill|
62511385|NCT00451152|EXPERIMENTAL|Anecortave Acetate Depot|
62511386|NCT00451152|PLACEBO_COMPARATOR|Anecortave Acetate Vehicle|
62511387|NCT04845646|EXPERIMENTAL|ASC41 + Itraconazole group|"1. ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 11.~2. Itraconazole oral capsule 200 mg po qd (2 capsules given 1x/day or 200 mg/day) on days 6-16."
62511388|NCT04845646|EXPERIMENTAL|ASC41 + Phenytoin group|"1. ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 19.~2. Phenytoin oral capsule 300 mg (100 mg 3 x/day) on days 6-19."
62511389|NCT04845646|EXPERIMENTAL|ASC41 group|(1) ASC41 5 mg po. One 5 mg ASC41 tablet on day 1.
62511390|NCT02428582|ACTIVE_COMPARATOR|bare stent inserted|Standard bare stent will be placed
62511391|NCT02428582|EXPERIMENTAL|Covered stent inserted|Covered stent will be placed
62511392|NCT04377048|EXPERIMENTAL|Nivolumab/GS|"Part-1: GS Induction~* Patients will receive GS for 1 cycle.~* S-1: 60/80/100 mg per day (based on body surface area, BSA); D1-12; 3 weeks per cycle~* BSA \< 1.25 m2: 60 mg/day; 1.25 m2 ≤ BSA \< 1.5 m2: 80 mg/day; BSA ≥ 1.5 m2: 100 mg/day~* Gemcitabine: 850 mg/m2; D1, 8; 3 weeks per cycle~* After GS, patients fulfilling the pre-defined CA 19-9 criteria will enter the Add-On part.~Part-2: Nivolumab Add-On~* Nivolumab: 3 mg/kg every 2 weeks, 6 weeks per cycle~* S-1: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~* Gemcitabine: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~The treatment will be continued until disease progression, intolerance to study treatment or death."
62511393|NCT01885182|EXPERIMENTAL|Oxycodone/Naloxone|5/2.5mg, 10/5mg, 20/10mg or 40/20mg
62511394|NCT01885182|ACTIVE_COMPARATOR|Oxycodone|5mg, 10mg, 20mg or 40mg
62511395|NCT00500006|OTHER|A|Arm A: Drug and comparator
62511396|NCT00500006|OTHER|B|Arm B: Drug and comparator
62511397|NCT01684215|EXPERIMENTAL|Single-agent PD-0332991|Phase 1 Part 1
62511398|NCT01684215|EXPERIMENTAL|PD-0332991 in combination with letrozole|Phase 1 Part 2
62511399|NCT01684215|EXPERIMENTAL|PD-0332991 with letrozole|Phase 2
62511400|NCT01047618||Thromboembolism|
62511401|NCT03083977|EXPERIMENTAL|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
61971445|NCT03989453|NO_INTERVENTION|Control Group|This group does not receive any treatment.
62511402|NCT01529307|EXPERIMENTAL|TAS266|
62511403|NCT03081039|ACTIVE_COMPARATOR|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
62511404|NCT03081039|ACTIVE_COMPARATOR|Arm B|Gemcitabine alone for 6 cycles
61971446|NCT05148754|EXPERIMENTAL|Elsulfavirin 400 mg.|Cohort I (N = 3). Single oral dose of 400 mg.
62352347|NCT00854256|ACTIVE_COMPARATOR|Trabeculectomy with mitomycin C|
62352348|NCT01833741|EXPERIMENTAL|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
62352349|NCT02031432|EXPERIMENTAL|Cebranopadol|"Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day."
62352350|NCT05566821|EXPERIMENTAL|STRENGTH Outreach Intervention|Participants enrolled in STRENGTH intervention elements
62352351|NCT02090985|EXPERIMENTAL|Lipomodelling|Lipomodelling of peri-stomal skin contour abnormalities
62352352|NCT06371664|PLACEBO_COMPARATOR|Conventional Tray (1 mm)|Patients put in their individualized 1 mm bleaching trays the bleaching treatment every day during three weeks.
62352353|NCT06371664|EXPERIMENTAL|Extended Tray (3 mm)|Patients put in their individualized 3 mm bleaching trays the bleaching treatment every day during three weeks.
62352354|NCT04694625|EXPERIMENTAL|Structured rehabilitation program|Structured rehabilitation program \& conventional physical therapy
62352355|NCT04694625|ACTIVE_COMPARATOR|conventional physical therapy|conventional physical therapy
62352356|NCT03125577|EXPERIMENTAL|4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123|Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
62352357|NCT05581706|ACTIVE_COMPARATOR|Regenerative endodontic treatment with calcium hydroxide|"Regenerative endodontic treatment (RET) performed with procedures of American Association of Endodontics (AAE) in two sessions. At the end of the first session, periapical tissue fluid samples (baseline samples) were collected.~Calcium hydroxide medicament was prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.~In the second session (14 days after first treatment), the medicaments in the root canals were carefully removed with 5 ml sterile distilled water irrigation. Periapical tissue fluid samples were obtained from the distal canal using the same protocol as described previously (final samples). Then RET was finished according to the treatment protocol of AAE."
62352358|NCT05581706|ACTIVE_COMPARATOR|Regenerative endodontic treatment with double antibiotic paste|"Regenerative endodontic treatment (RET) performed with procedures of American Association of Endodontics (AAE) in two sessions. At the end of the first session, periapical tissue fluid samples (baseline samples) were collected.~Double antibiotic paste (DAP) was prepared by mixing same amount of metronidazole and ciprofloxacin powdered antibiotics (1:1) and combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.~In the second session (14 days after first treatment) after removal of DAP in the root canals, periapical tissue fluid samples were obtained the same protocol as described previously (final samples). Then RET was finished according to the treatment protocol of AAE."
62352359|NCT05581706|ACTIVE_COMPARATOR|Radiographic evaluation|"Pre-operative, post-operative and final recall (12th months follow up) standart digital radiographs were taken from patients with film holder. The radiographs saved and transferred to Image J software (version 1.47, National Institutes of Health, Bethesda, MD). The standardized radiographs were further aligned using the TurboReg plugin (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) within the Image J toolkit to minimize any distortions caused by variability in the angulation.~All images were calibrated according to size #2 SPP (vertical dimension 31 mm, horizontal dimension 41 mm) using the ''set scale'' option in Image J. Thereafter, the root lengths, root width and radiographic root area were measured on both preoperative and final recall images to evaluate treatment outcomes."
61971447|NCT05148754|EXPERIMENTAL|Elsulfavirin 800 mg.|Cohort II (N = 3). Single oral dose of 800 mg.
61971448|NCT05148754|EXPERIMENTAL|Elsulfavirin 1 200 mg.|Cohort III (N = 3). Single oral administration at a dose of 1200 mg.
61971449|NCT05148754|EXPERIMENTAL|Elsulfavirin 1 200 mg*9|Cohort IV (N = 6). A single 1200 mg oral dose followed by 200 mg daily for 9 days.
61971450|NCT02877615|EXPERIMENTAL|S 44819 150 mg twice a day|
61971451|NCT02877615|EXPERIMENTAL|S 44819 300 mg twice a day|
61971452|NCT02877615|PLACEBO_COMPARATOR|Placebo|
62146544|NCT05544305|EXPERIMENTAL|Digitised Home Based Care pathway|The investigators have co-designed an innovative digital care pathway, Home Based Care (HBC), that delivers self-management support and clinical expertise to the patient's home, supported by digitally-enabled remote monitoring with a wrist-worn sensor, the Parkinson's Kinetograph, and digitally-delivered questionnaires, to replace the current pen-and-paper processes.
61971453|NCT02998593|EXPERIMENTAL|extracted red Bahman and white bahman|500 mg of extracted red Bahman and white bahman that is used once a day.
62511405|NCT04826068|EXPERIMENTAL|Emotional Processing|The intervention looks at emotional processing of face interpretation.
62511406|NCT04826068|PLACEBO_COMPARATOR|Control intervention|The control group is seeing the same faces and are asked questions regarding them.
62511407|NCT01132664|EXPERIMENTAL|HER2+ metastatic breast cancer|Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
62511408|NCT01132664|EXPERIMENTAL|HER2+ metastatic breast cancer with BM|Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
62511409|NCT00458419|PLACEBO_COMPARATOR|A: naloxone; B: normal saline|Arm A: IV naloxone Arm B: IV normal saline
62511410|NCT03989531|EXPERIMENTAL|Adrecizumab on top of standard of care|8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion
62511411|NCT03989531|PLACEBO_COMPARATOR|Placebo on top of standard of care|100 mL saline as single dose infusion
61971454|NCT02998593|PLACEBO_COMPARATOR|Placebo|500 mg of placebo once time a day
62146545|NCT04153851|OTHER|neurectomy of nasopalatine nerve|"1. Prophylactic preoperative antibiotic will be administered prior to surgery.~2. Oral disinfection will be performed before surgery.~3. Labial infiltration anesthesia and nasopalatine nerve block anasthesia.~4. The nasopalatine foramen will be exposed after reflection of a palatal and buccal flap.~5. Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal.~6. Dental implant will be inserted in the central incisor location."
62511412|NCT02985619|ACTIVE_COMPARATOR|IVB randomised group I|"Randomised patients \[intravitreal bevacizumab (IVB) group I\] with central foveal thickness \>300µm on OCT will be submitted to 6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata, or as needed), with monthly visits for central subfoveal thickness map more than 300µm by Optic Coherence Tomography. Care will be take in all cases to insure that the needle do not touch the lids or lashes. Bevacizumab (1.25 mg/0.05 cc; F. Hoffmann- La Roche Ltd., Basel, Switzerland) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus."
62511413|NCT02985619|ACTIVE_COMPARATOR|IVT randomised group II|Randomised patients \[intravitreal triamcinolone (IVT) group II\] with central foveal thickness \>300µm on OCT will be submitted to 6 months treatment with 0.03ml (1.20mg) intravitreous injection of triamcinolone each 3 months (prn, as needed) for central sufoveal thickness map more than 300µm by Optic Coherence Tomography. Care will be take in all cases to insure that the needle do not touch the lids or lashes. Triamcinolone (1.20 mg/ 0.03 cc; Opthaac, Ophthalmos, São Paulo, Brazil) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus.
62707918|NCT05548426|ACTIVE_COMPARATOR|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
61971455|NCT02075229||Group A|45 participants with AzBio baseline sentence scores between 41 - 50%
61971456|NCT02075229||Group B|45 participants with AzBio baseline sentence scores between 51 - 60%.
61971457|NCT02005445|EXPERIMENTAL|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure
61971458|NCT02005445|SHAM_COMPARATOR|Healthy Lifestyle and Sleep Education (HLSE)|Healthy living and sleep education
61971459|NCT04069091|EXPERIMENTAL|CBT intervention|Participants in the CBT intervention arm will undergo standard antenatal care and the 'Enjoy your Bump' (iloodottaa.fi) online self-help intervention employing elements of cognitive behavioral therapy (CBT)
61971460|NCT04069091|NO_INTERVENTION|Standard care|Participants in the Standard Care arm will undergo standard antenatal care.
61971461|NCT02789709||Non metastatic colon cancer patients|Consecutive patients undergoing elective surgery for non-metastatic colon or rectal cancer with curative intent.
61971462|NCT04019665|OTHER|SAGE and MMSE score|
61971463|NCT04531293|OTHER|Total-breath method followed by standard method|Total Lung Capacity (TLC) measurement performed on device EasyOne Pro (TM) according to total-breath method followed by TLC measurement performed on device MasterScreen (TM) according to standard method.
61971464|NCT04531293|OTHER|Standard method followed by total breath method|Total Lung Capacity (TLC) measurement performed on device Masterscreen (TM) according to standard method followed by TLC measurement performed on device EasyOne Pro (TM) according to total-breath method.
62146546|NCT02351674||Heart rate ≤70bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate ≤70 BPM.
61971465|NCT04782024|PLACEBO_COMPARATOR|Placebo|
61971466|NCT04782024|EXPERIMENTAL|7-Keto 50mg|
61971467|NCT04782024|EXPERIMENTAL|7-Keto 25mg|
61971468|NCT02959944|EXPERIMENTAL|Ibrutinib + Prednisone|"Ibrutinib (420 mg) given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. The 420 mg dose was adjusted for cytochrome P450 \[CYP\] inhibitors or hepatic dysfunction as applicable.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
61971469|NCT02959944|PLACEBO_COMPARATOR|Placebo + Prednisone|"Placebo given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
62511414|NCT02985619|ACTIVE_COMPARATOR|IVB group III (not randomised)|Patients with central foveal thickness ≤300µm at week visit 24 will be allocated to group III (IVB, intravitreal bevacizumab). So, it won't get IVB injection at week visit 24 due OCT regular thickness (≤300µm) but will do regular monthly follow-up visits and prn-IVB therapy if central foveal thickness \>300µm on OCT until last visit of study (48 week-visit). Care will be take in all cases to insure that the needle do not touch the lids or lashes. Bevacizumab (1.25 mg/0.05 cc; F. Hoffmann- La Roche Ltd., Basel, Switzerland) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus.
61971470|NCT02011737|ACTIVE_COMPARATOR|Naftopidil|Naftopidil 75mg once daily
61971471|NCT02011737|PLACEBO_COMPARATOR|Placebo|Placebo once daily
61971472|NCT01737151|ACTIVE_COMPARATOR|Arm I (standard stereotactic body radiation therapy (SBRT)|Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
61971473|NCT01737151|EXPERIMENTAL|Arm II (four fraction split-course SBRT)|Patients undergo 2 fractions of SBRT in weeks 1 and 4
61971474|NCT05951504|ACTIVE_COMPARATOR|Solumedrol 1 Dose|Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Remainder of management was as per protocol.
61971475|NCT05951504|ACTIVE_COMPARATOR|Solumedrol 4 Dose|Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
62146547|NCT02351674||Heart rate between 71 to 80bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 2 will be defined as subjects' mean heart rate between 71 to 80bpm.
62511415|NCT03040752|ACTIVE_COMPARATOR|Nifedipine|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
62511416|NCT03040752|ACTIVE_COMPARATOR|Ritodrine|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor.
62511417|NCT02837406||Doctors|specialists and general practitioners by ich territory
62511418|NCT02837406||Health professionals|"* pharmacists~* nurses~* physiotherapists~* Medical and social professionals: social workers, psychologists, educators ..."
62511419|NCT02837406||Medical-social institutes|"* Hospital,~* Healthcare structure,~* Local Centre of Information and Gerontological Coordination ..."
62511420|NCT03070691|ACTIVE_COMPARATOR|LDE225 0.75% cream|
62511421|NCT03070691|PLACEBO_COMPARATOR|Vehicle|
62511422|NCT01755117|ACTIVE_COMPARATOR|TKR, sciatic, femoral, obturator|TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
61971476|NCT04850131|ACTIVE_COMPARATOR|Desarda|Forty-one patients who were randomly assigned to the Desarda group underwent the Desarda repair for their problem. Patients were followed for various data point values during operation, immediately after the operation, and for a period of one year post-operatively.
61971477|NCT04850131|ACTIVE_COMPARATOR|Lichtenstein|Forty-one patients randomly assigned to the Lichtenstein group underwent the standard mesh repair and were followed for the same data point values and variables for the same specified period of time.
62511423|NCT01755117|ACTIVE_COMPARATOR|TKR sciatic nerve block, posterior lumbar plexus block|TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
62511424|NCT05589350|EXPERIMENTAL|High-fat yogurt|Daily consumption of 1-2 servings (based on daily calorie requirement) of high-fat yogurt
62511425|NCT05589350|ACTIVE_COMPARATOR|Low-fat yogurt and butter|Daily consumption of 1-2 servings of low-fat yogurt along with daily consumption of about 10 grams of animal butter
62511426|NCT06617091|EXPERIMENTAL|People living with HIV (PLWH) and People living without HIV (PLWoH)|"Participants living without HIV (PLWoH) will be assigned to receive either a single dose, 2 doses of the GRAdHIVNE1 vaccine, or placebo. Participants living with HIV (PLWH) will be assigned to receive either 2 doses of the GRAdHIVNE1 vaccine, or placebo.~Each participant is to receive GRAdHIVNE1 at vaccine dose 5x10\^10 or 2x10\^11 or to receive placebo."
62511427|NCT06617091|PLACEBO_COMPARATOR|Placebo NaCl for injection|"Participants living without HIV (PLWoH) will be assigned to receive either a single dose, 2 doses of the GRAdHIVNE1 vaccine, or placebo. Participants living with HIV (PLWH) will be assigned to receive either 2 doses of the GRAdHIVNE1 vaccine, or placebo.~Each participant is to receive GRAdHIVNE1 at vaccine dose 5x10\^10 or 2x10\^11 or to receive placebo."
62511428|NCT02356211|EXPERIMENTAL|Treatment|Geriatric Multifactorial Falls Assessment Clinic
61971478|NCT05871294|EXPERIMENTAL|Acoustic stimulation therapy|Patients in this group will receive acoustic stimulation therapy.
61971479|NCT05871294|EXPERIMENTAL|Repetitive transcranial magnetic stimulation therapy|Patients in this group will receive repetitive transcranial magnetic stimulation therapy.
61971480|NCT01711970|EXPERIMENTAL|VB-111|
61971481|NCT03421119|EXPERIMENTAL|CinnaGen-liraglutide|CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
62146548|NCT02351674||Heart rate between 81 to 90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate between 81 to 90bpm.
62511429|NCT02356211|NO_INTERVENTION|Control|Geriatric Evaluation and Management Service (GEM)
62511430|NCT05965102|EXPERIMENTAL|Tirelizumab in combination with chemotherapy monotherapy|This study is a one-arm, exploratory study and does not involve randomization. There was only one trial group of tirellizumab plus chemotherapy monotherapy.
61971482|NCT03421119|ACTIVE_COMPARATOR|Victoza®|Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
61971483|NCT00636142|ACTIVE_COMPARATOR|1|Infliximab
61971484|NCT00636142|PLACEBO_COMPARATOR|2|Placebo
61971485|NCT03421392||Idiopathic thrombocytopenic purpura|
61971486|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
61971487|NCT03421392||without thrombocytopenia|
61971488|NCT04233151|EXPERIMENTAL|mFOLFOX6 + QL1203|Participants receive QL1203, 6mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity
61971489|NCT04233151|ACTIVE_COMPARATOR|mFOLFOX6 + Placebo|Participants received Placebo，6 mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
61971490|NCT02856503|EXPERIMENTAL|Phase 1 - Group A - VD 3 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.
61971491|NCT02856503|ACTIVE_COMPARATOR|Phase 1 - Group B - VD 4 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks
61971492|NCT02856503|ACTIVE_COMPARATOR|Phase 1 - Group C - VD 5 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.
61971493|NCT02856503|EXPERIMENTAL|Phase 2 - VD|Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.
61971494|NCT01033266||CPET CPAP|
61971495|NCT06286904||Sleep position detection|Accuracy of Skiin Garment system for detecting sleep position of pregnant womem.
61971496|NCT04563923|EXPERIMENTAL|Drug|"Patients in this group will additionally receive 3 s.c. injections of avdoralimab every week during 12 weeks~They receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
61971497|NCT04563923|OTHER|Conventional therapy|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
61971498|NCT06399978|EXPERIMENTAL|Gamified DOT|Participants perform digital cognitive training with a program based on the Differential Outcomes Training (DOT) principle, in which each stimulus-response association to be learnt is followed by a unique reinforcer/outcome, in order to boost associative learning.
61971499|NCT06399978|ACTIVE_COMPARATOR|Gamified non-DOT|Participants perform digital cognitive training with a non-Differential Outcomes Training (NDOT) programme, in which each stimulus-response association to be learnt is followed by a random reinforcer/outcome.
62511431|NCT02529202|EXPERIMENTAL|Dexmedetomidine group|Neonates with hypoxic-ischemic encephalopathy will receive a dexmedetomidine maintenance infusion of 0.4 mcg/kg/hr during treatment with therapeutic hypothermia and during re-warming (78 hours total).
62511432|NCT05690815||gbMSM|This study will enroll gay, bisexual men who have sex with men (gbMSM), transgender and gender non-binary participants.
61971500|NCT03664557|EXPERIMENTAL|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
61971501|NCT05963217|EXPERIMENTAL|Experimental: Dose Level 1 to 3|0.3 to 3 x 10\^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide and fludarabine.
62146549|NCT02351674||Heart rate>90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 4 will be defined as subjects' mean heart rate\>90bpm
62511433|NCT06311669|ACTIVE_COMPARATOR|Isolated iliac vein stenting|
62511434|NCT06311669|ACTIVE_COMPARATOR|Concomitant iliac vein stenting with pelvic vein embolization|
61971502|NCT03839745|OTHER|Power level 10, 15, or 20 watts|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned battery power levels
61971503|NCT03839745|OTHER|1 of the other 2 remaining power levels|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 remaining power levels
61971504|NCT03839745|OTHER|Remaining power level|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining power level
61971505|NCT02733991|EXPERIMENTAL|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
61971506|NCT02733991|ACTIVE_COMPARATOR|Control|MiniMed™640G alone
61971507|NCT00678054|EXPERIMENTAL|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
61971508|NCT00864214|EXPERIMENTAL|1|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
61971509|NCT00864214|EXPERIMENTAL|2|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
61971510|NCT00864214|EXPERIMENTAL|3|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
61971511|NCT00864214|EXPERIMENTAL|4|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
61971512|NCT05209438|ACTIVE_COMPARATOR|Cereset Research|This will be the active intervention arm using 6 Cereset (CR) sessions and participants will continue current care.
61971513|NCT05209438|SHAM_COMPARATOR|Control|Participants will have 6 CR sessions of sham control tones and also continue their current care.
61971514|NCT06220682||normal group|25 patients angiographically normal coronaries
61971515|NCT06220682||atherosclerotic non dilated group|25 patients angiographically had atherosclerotic plaques with no coronary dilatations
61971516|NCT06220682||dilated non atherosclerotic group|25 patients angiographically involved coronary dilatations with no atherosclerotic plaques
62707919|NCT00832013|ACTIVE_COMPARATOR|1|"Propofol 1 % at a dose of 4mg/kg will be administered intravenously via a standard Medex Protégé® 3010 (Medex-A Furon. Healthcare Company, Duluth, GA, USA) infusion pump at a constant rate determined by the randomization schedule. Fresh gas flow will be maintained at 6 l/min throughout the induction procedure with the FiO2 increased to 0.5. Full cardiovascular, respiratory and EEG monitoring will continue during induction of anesthesia.~Once the loading dose of propofol has been delivered the propofol infusion will be maintained at a rate of 200mcg/kg/min or as determined by the attending anesthesiologist whilst the end-point respiratory responses are observed."
62707920|NCT00832013|ACTIVE_COMPARATOR|2|Same procedure as above. These subjects will be stratified by age and randomized, using the Biased Coin Design (BCD) principle to determine the infusion rate of propofol for delivery of the induction dose.
62707921|NCT05636839|EXPERIMENTAL|UVB treatment|"UVB treatment 3 times per week for 10 weeks~Before treatment starts, researchers will collect 20 ml of blood from participants. After 10-week treatment, researchers will collect 20 ml of blood from participants again."
62707922|NCT06005402|EXPERIMENTAL|CSX-1004|Single doses of CSX-1004 Injection
61971517|NCT06220682||dilated atherosclerotic group|25 patients angiographically had both coronary dilatations and atherosclerotic plaques
62352360|NCT05581706|ACTIVE_COMPARATOR|Periapical tissue exudate sample collection and Immunofluorometric assay MMP-8|"At the end of the first session, periapical tissue fluid samples (baseline samples) were collected by introducing 3 sterile #45 paper points into the root canal until 2 mm passing through the root apex from the distal canal. After waiting for 1 min, the paper points were withdrawn, the tip was cut from 4 mm and were transferred to sterile Eppendorf tubes. At the beginnign of the second session periapical tissue fluid samples were obtained from the distal canal using the same protocol as described in the first session (final samples).~Baseline and final MMP-8 concentrations were determined by a time-resolved immunofluorometric assay (IFMA). The monoclonal MMP-8 specific antibodies 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as a catching antibody and a tracer antibody, respectively. The tracer antibody was labeled using europium-chelate"
61971518|NCT05245370|ACTIVE_COMPARATOR|Control group 1: Control video|
61971519|NCT05245370|ACTIVE_COMPARATOR|Control group 2: Rationale video + control video|
62707923|NCT06005402|PLACEBO_COMPARATOR|Placebo|Sterile saline for injection
62707924|NCT05420571|EXPERIMENTAL|digital impression module|In the experimental group, digital impressions and 3D printed models were used and fitted pads were made. Patients were instructed to wear the hinge pad for 24 hours, and x-rays were taken and intraoral examinations were performed at 2 weeks and 4 weeks.
61971520|NCT05245370|EXPERIMENTAL|Rationale video + clinician testimonial|
61971521|NCT05245370|EXPERIMENTAL|Rationale video + patient testimonial|
61971522|NCT05245370|EXPERIMENTAL|Rationale video + clinician testimonial + patient testimonial|
61971523|NCT04501666|EXPERIMENTAL|Nemolizumab|Participants weighing less than (\<) 90 kilogram (kg) received two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once every 4 weeks (Q4W). Participants weighing greater than or equal to (\>=) 90 kg received two SC injections of 30 mg nemolizumab (60 mg total) at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
61971524|NCT04501666|PLACEBO_COMPARATOR|Placebo|Participants weighing \< 90 kg received two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing \>= 90 kg received two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
62352361|NCT02487888|EXPERIMENTAL|Pain|Patients presenting to a clinic for pain, that will be either blinded to genetic testing results or unblinded to genetic testing results
62707925|NCT05420571|ACTIVE_COMPARATOR|ordinary impression group|The control group used alginate impression and plaster model infusion to make the model and make the fitting pad. Patients were instructed to wear the pad for 24 hours, and x-rays and intraoral examinations were taken at 2 and 4 weeks.
61971525|NCT00672412|EXPERIMENTAL|1|Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
61971526|NCT00672412|EXPERIMENTAL|2|Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
61971527|NCT02890446|EXPERIMENTAL|External Focus (EF)|"Participants received arm training using the InMotion2 robot under external focus practice conditions and instructions. Participants practiced arm reaching by playing a simple video game.~EF instructions: Focus on moving the yellow ball on the screen in a smooth, straight line at a constant speed; Move the yellow ball toward the blinking red/orange light; and Hit the center of the target and try not to overshoot the target"
61971528|NCT02890446|EXPERIMENTAL|Internal Focus (IF)|"Participants received arm training using the InMotion2 robot without the video game interface. Participants were instructed to think about how they were moving their arm while completing the arm training tasks.~IF instructions:~think about how you're moving your arm; push your arm away from you; pull your arm toward you; move your arm to the right/left"
61971529|NCT00005937|EXPERIMENTAL|Antithymocyte globulin & cyclosporine|Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.
62352362|NCT02487888|EXPERIMENTAL|Mental Health|Patients presenting to a clinic for mental health disorders, that will be either blinded to genetic testing results or unblinded to genetic testing results
62511435|NCT02915237|EXPERIMENTAL|Low Dose - Concord grape juice|Daily dietary supplementation with 4 oz. of a commercially available Concord grape juice.
62707926|NCT03956160|EXPERIMENTAL|Intervention group|"For 12 months from the return home, patients in the intervention group will benefit from telephone support by a trained case-manager (number and frequency of contacts defined according to the patient's needs) and access to an Internet platform.~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon return home, including identifying and requesting the necessary health or social resources."
62707927|NCT03956160|NO_INTERVENTION|Control group|"Patients randomized to the control group will receive the usual practices. As part of the study, they will be contacted for data collection upon their return home, at 6 months and 12 months by a clinical research associate.~Access to the internet platform and an interview with the case-manager will be offered at the end of the study to patients in the control group."
62146550|NCT05015699|EXPERIMENTAL|HT Supreme|Device: HT Supreme ( R\&D by Sinomed, Tianjin, China) Drug: 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system interventions
62707928|NCT05994352|NO_INTERVENTION|control group|no intervention will be applied to the students in the control group
61971530|NCT02916342|ACTIVE_COMPARATOR|Interscalene brachial plexus block|An ultrasound-guided interscalene brachial plexus block will be performed prior to surgery.
61971531|NCT02916342|EXPERIMENTAL|Supraclavicular-axillary nerve blocks|A dual supraclavicular-axillary nerve blocks will be performed prior to surgery.
61971532|NCT05735132|ACTIVE_COMPARATOR|Line arm|Conventional line blocking is used in radial artery cannulation for local infiltration.
62352363|NCT02487888|EXPERIMENTAL|Cardiovascular|Patients presenting to a clinic for cardiovascular complications, that will be either blinded to genetic testing results or unblinded to genetic testing results
62511436|NCT02915237|EXPERIMENTAL|Moderate Dose - Concord grape juice|Daily dietary supplementation with 8 oz. of a commercially available Concord grape juice.
62707929|NCT05994352|EXPERIMENTAL|experimental group|virtual reality simulation will be applied to the experimental group
62707930|NCT02862093|ACTIVE_COMPARATOR|Deep rTMS|The intervention consisted of deep rTMS of dorsolateral prefrontal cortex through the Brainsway Deep TMS System using an H-shaped coil . The motor threshold was measured by delivering a single pulse to the motor cortex. The site of stimulation was located 5.5 cm anterior to the point at which maximum stimulation of the abductor pollicis brevis muscle was reached. Each patient received a total of 12 rTMS sessions (three sessions per week): 20 trains per session at an intensity of 100% of the motor threshold, 50 pulses per train at a frequency of 10 Hertz, an inter-train interval of 15 seconds.
62707931|NCT02862093|PLACEBO_COMPARATOR|Placebo|The sham stimulation consisted of rTMS sessions without an effective instrument operation.
62707932|NCT03057184|EXPERIMENTAL|Intervention group|behavioral intervention program
61971533|NCT05735132|EXPERIMENTAL|Bar arm|Bar-blocking is used in radial artery cannulation for local infiltration.
61971534|NCT05735132|EXPERIMENTAL|V arm|V-blocking is used in radial artery cannulation for local infiltration.
62352364|NCT02487888|EXPERIMENTAL|Arthritis|Patients presenting to a clinic for osteoarthritis or rheumatoid arthritis, that will be either blinded to genetic testing results or unblinded to genetic testing results
62352365|NCT02487888|EXPERIMENTAL|Type 2 Diabetes Mellitus|Patients presenting to a clinic for T2DM, that will be either blinded to genetic testing results or unblinded to genetic testing results
62707933|NCT03057184|NO_INTERVENTION|Usual care|Usual care
61971535|NCT05612984|EXPERIMENTAL|Calcium aspirin multiple micronutrients|"500 mg elemental calcium (as 1250 mg calcium carbonate) 81 mg aspirin~1 tablet United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formula, which is a Multiple Micronutrient Supplement (MMS) for pregnant women"
61971536|NCT05612984|ACTIVE_COMPARATOR|Iron folic acid|60 mg iron + 400 μg folic acid given as a combined tablet
61971537|NCT03146494||STAAD|
61971538|NCT03146494||Normal|
61971539|NCT03140553|EXPERIMENTAL|TCH|docetaxel/carboplatin/trastuzumab
61971540|NCT03140553|ACTIVE_COMPARATOR|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
62352366|NCT02169804|EXPERIMENTAL|70 years or older|Non-smoking healthy adult males \>or equal to 70 years of age.
62352367|NCT02169804|EXPERIMENTAL|Under 60 years of age|Non-smoking healthy adult males\<60 years of age.
62707934|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
62707935|NCT03830879||No treatment|This cohort study have any no treatment.
61971541|NCT04136860||Conservative management|Patients refused to accept any interventional treatment or patients were not suitable for any interventional treatment.
61971542|NCT04136860||Microsurgical resection|All microsurgical procedures were performed with intraoperative neuronavigation, ultrasonography, indocyanine fluorescence angiography (ICG), continuous monitoring of electroencephalogram and somatosensory evoked potential.
62146551|NCT03683849|EXPERIMENTAL|Dancing group|Dance intervention group, inspired by the rhythm of Salsa. Training will be administered for an hour twice a week, for six months.
62146552|NCT03683849|ACTIVE_COMPARATOR|Strength training group|Strength training group. Training will be administered for an hour twice a week, for six months.
62352368|NCT01146041|EXPERIMENTAL|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
62352369|NCT01146041|ACTIVE_COMPARATOR|exelon|Exelon 1.5 mg capsules of Novartis
62352370|NCT04656288|EXPERIMENTAL|Formula A under fasted conditions - Part 1|
62352371|NCT04656288|EXPERIMENTAL|Formula B under fasted conditions - Part 1|
62511437|NCT02915237|EXPERIMENTAL|High Dose - Concord grape juice|Daily dietary supplementation with 16 oz. of a commercially available Concord grape juice.
62511438|NCT02915237|PLACEBO_COMPARATOR|Low dose - placebo beverage|Daily dietary supplementation with 4 oz. of a placebo beverage
62511439|NCT02915237|PLACEBO_COMPARATOR|Moderate Dose - placebo beverage|Daily dietary supplementation with 8 oz. of a placebo beverage
62511440|NCT02915237|PLACEBO_COMPARATOR|High Dose - placebo beverage|Daily dietary supplementation with 16 oz. of a placebo beverage
62511441|NCT04190563|EXPERIMENTAL|Pain De-Catastrophizing|Brief behavioral education on how to modify the interpretation of pain.
61971543|NCT04136860||Embolization|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Multi-stage embolization and target embolization were widely used within the embolization. Onyx was the main embolization material.
61971544|NCT04136860||Embolization+Radiosurgery|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Radiosurgery management was recommended for the residual lesions about 3 months after the embolization if necessary.
61971545|NCT04136860||Single-stage hybrid surgery|Hybrid surgery is a new surgical strategy defined as single-stage combined microsurgical resection and embolization in which embolization is performed firstly on the deep feeding artery, aneurysm, AVF, and meningeal arteries involved in blood supply of the nidus, and then, the microsurgical resection was performed immediately. Intraoperative angiography was performed repeatedly before the skull was closed, confirming complete occlusion of the malformation.
61971546|NCT05186064|EXPERIMENTAL|whole genome sequencing after standard of care resection at first relapse|
62707936|NCT03772535|NO_INTERVENTION|Control Group|Subjects in this arm will receive the standard postoperative pain prescription protocol.
62511442|NCT04190563|PLACEBO_COMPARATOR|Pain Education|Brief behavioral education on pain.
62707937|NCT03772535|ACTIVE_COMPARATOR|Pharmacogenomics Guided Group|Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.
62511443|NCT01640184|ACTIVE_COMPARATOR|Active vitamin D|Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in Kidney Developement Improvement Global Outcomes (KDIGO) guidelines.
61971547|NCT03412487|ACTIVE_COMPARATOR|premature ovarian failure|women under 40 years old with History of oligomenorrhea or amenorrhea for 1 year or more FSH level \>20 IU/L at least 2 occasions 4-6 weeks apart (FSH level 20-40 IU/L indicates ovarian insufficiency, while level above 40 IU/L indicates complete failure).
62352372|NCT04656288|EXPERIMENTAL|Formula B under fasted conditions - Part 2|
62707938|NCT05354219||MPS patients|Any patient aged 0-100 with MPS type I, type III, type IV and type VI. Type VII MPS patients may also be eligible.
62707939|NCT05354219||Control|"For the control group -~Participants of any age currently being followed at MREH that have an eye condition unrelated to the cornea as established by clinical examination."
62707940|NCT04927702|EXPERIMENTAL|Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
62707941|NCT04927702|ACTIVE_COMPARATOR|Diabetic Foot Ulcer Participants Assigned to Standard of Care|Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
62707942|NCT04927702|EXPERIMENTAL|Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
61971548|NCT03412487|ACTIVE_COMPARATOR|Control group|A group of female patients presented with infertility but with regular menses and normal ovarian function (according to history, general examination, gynecological examination and FSH level).
62352373|NCT04656288|EXPERIMENTAL|Formula C under fasted conditions - Part 2|
62352374|NCT04656288|EXPERIMENTAL|Formula D under fasted conditions - Part 2|
62352375|NCT04656288|EXPERIMENTAL|Formula B under fed conditions - Part 2|
62352376|NCT05289076|EXPERIMENTAL|Colorectal liver metastsis, single arm|Tumour tissue from patients operated for colorectal liver metastases. A cubic centimeter of tumour tissue will be processed and implanted in zebra fish embryos. Tissue in zebrafish embryos will treated with different combinations of chemotherapy. Chemocombination of best effect will be offered patients in the third phase of the trial
62352377|NCT03819218|EXPERIMENTAL|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
61971549|NCT03027778|EXPERIMENTAL|Exercise|Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
61971550|NCT03027778|NO_INTERVENTION|Usual care|Participants receive their usual dialysis for the duration of 4 months.
62146553|NCT03683849|NO_INTERVENTION|Control|Control group
62352378|NCT00830960|EXPERIMENTAL|Prasugrel 60/10 Primary|Loading dose 60 mg followed by maintenance dose 10 mg/day
62352379|NCT00830960|EXPERIMENTAL|Prasugrel 30/7.5 Primary|Loading dose 30 mg followed by maintenance dose 7.5 mg/day
62352380|NCT00830960|EXPERIMENTAL|Prasugrel 30/5 Primary|Loading dose 30 mg followed by maintenance dose 5 mg/day
62352381|NCT00830960|ACTIVE_COMPARATOR|Clopidogrel 300/75 Primary|Loading dose 300 mg followed by maintenance dose 75 mg/day
62352382|NCT00830960|EXPERIMENTAL|Prasugrel 30/5 Low Weight/Elderly|Loading dose 30 mg followed by maintenance dose 5 mg/day
62352383|NCT00830960|ACTIVE_COMPARATOR|Clopidogrel 300/75 Low Weight/Elderly|Loading dose 300 mg followed by maintenance dose 75 mg/day
62511444|NCT01640184|EXPERIMENTAL|Ultrasonic ablation|Patients in Ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequency ablation.
62511445|NCT01640184|ACTIVE_COMPARATOR|Parathyroidectomy|Patients in parathyroidectomy group will be treated by parathyroid surgery.
62511446|NCT06306092|EXPERIMENTAL|"Sleep on Schedule - sleep education at school"|The sleep training includes five lessons during school hours, and will be held by school staff (teachers, school nurses and school counsellors). The teaching consists of sleep education (sleep knowledge and good sleep routines), time management (e.g., planning homework without distraction, planning other activities, quiet time before bedtime), information to guardians, and discussions with peers in the classroom (e.g., rules regarding evening interaction via electronic media). Homework/exercises and behavioral experiments are also included. Data collection takes place in connection with the first and last lesson of Sleep on Schedule.
62539410|NCT03795038|OTHER|Lipoprotein Apheresis MONET and DALI|"Patients routinely treated with MONET:~* The first subgroup will be treated first with the MONET adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber System.~* The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the MONET adsorber system"
61971551|NCT04320446|EXPERIMENTAL|Caffeine|A dose of 3 mg/kg of caffeine (i.e. a vegetable extraction from green coffee beans, Harrison Sport Nutrition®, Spain) was ingested before the beginning of each test.
61971552|NCT04320446|PLACEBO_COMPARATOR|Placebo|A dose of 3 mg/kg of placebo (i.e. 100% purity microcrystalline cellulose, Acofarma, Spain) was ingested before the beginning of each test.
61971553|NCT03500627|EXPERIMENTAL|Cohort 1|20 mg/kg OP-101 administered intravenously for over 1 hour.
62511447|NCT06306092|EXPERIMENTAL|"TechRest - reduction of electronic media use before bedtime"|This intervention has been tested in Australia with a small sample of teenagers, and it was associated with promising effects. The data collection consists of a digital questionnaire regarding sleep habits, insomnia, motivation, physical and mental health, and electronic media use; a selection of students will use the actigraph for a week. After the first week, the participants will be instructed to stop using screens 1 hour before their usual bedtime. After one week has passed, participants in the Technology restriction intervention will be asked to complete the previously mentioned questionnaires as well as questions about the intervention itself: its applicability, compliance, and whether or not they will continue to limit their screen time before bedtime. One year after the intervention, they will be asked to complete the same questionnaire as at baseline. A selection of students will also wear a wrist actigraph.
62511448|NCT06306092|NO_INTERVENTION|Control|School as usual
62146554|NCT04069455|EXPERIMENTAL|EPRO group|Clinical usual care plus ePRO App self-management online during postoperative adjuvant chemotherapy
62511449|NCT05248204|EXPERIMENTAL|Scotchbond Universal Plus Treatment|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using Scotchbond Universal Plus (SBU+) Adhesive (Treatment).
62707943|NCT04927702|ACTIVE_COMPARATOR|Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
62707944|NCT02852915|EXPERIMENTAL|Laparoscopic surgery for T4 colon cancers|Laparoscopic surgery for T4 colon cancers
62707945|NCT02852915|NO_INTERVENTION|Conventional open surgery for T4 colon cancers|Conventional open surgery for T4 colon cancers
62707946|NCT05443828|ACTIVE_COMPARATOR|Extruded puff with vitacel|The participants consumed a portion of extruded puff with added vitacel (cellulose) contained 11 g of fiber, in the context of a breakfast meal
62707947|NCT05443828|EXPERIMENTAL|AX bread|Participants consumed a portion of bread enriched with arabynoxylans (AX) contained 11 g of fiber, in the context of a breakfast meal
62707948|NCT05443828|EXPERIMENTAL|Wheat bran puff|Participants consumed a portion of wheat bran puff contained 11 g of fiber, in the context of a breakfast meal
62707949|NCT02194413|EXPERIMENTAL|Arm 1 (healing touch)|"Patients receive daily HT sessions comprising pain drain, chakra connection, magnetic clearing, and mind clearing over 30 minutes from day 1 until 2 days before discharge from the hospital (therapeutic touch).~Interventions: therapeutic touch, quality-of-life assessment, and questionnaire administration"
61971554|NCT03500627|EXPERIMENTAL|Cohort 2|40 mg/kg OP-101 administered intravenously for over 1 hour.
61971555|NCT03500627|EXPERIMENTAL|Cohort 3 (optional)|80 mg/kg OP-101 administered intravenously for over 1 hour.
61971556|NCT02706470|EXPERIMENTAL|Cyclosporin A|Patients allocated to Cyclosporin A group will receive oral Cyclosporin A in a dose of 50 mg three times a day for 20-30 days in early pregnancy.
61971557|NCT02706470|ACTIVE_COMPARATOR|Dydrogesterone|Patients allocated to dydrogesterone group will receive oral dydrogesterone in a dose of 10 mg three times a day for 30 days in early pregnancy.
62707950|NCT02194413|ACTIVE_COMPARATOR|Arm II (usual care)|"Patients receive routine nursing care from doctors and nurses from day 1 until 2 days before discharge from the hospital.~Interventions: quality-of-life assessment, and questionnaire administration"
62707951|NCT05432310|EXPERIMENTAL|Autologous mobilized peripheral blood (mPB) transduced with EFS ADA lentiviral vector|Evaluate safety and efficacy of this autologous gene therapy
61971558|NCT01979016|EXPERIMENTAL|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
61971559|NCT01979016|EXPERIMENTAL|Dupilumab 200 mg qw|Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.
62146555|NCT04069455|NO_INTERVENTION|Control group|Clinical usual care during postoperative adjuvant chemotherapy
62146556|NCT02177292|EXPERIMENTAL|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
62146557|NCT06140888|EXPERIMENTAL|The ginkgo biloba extract group|Ginkgo biloba extract 8 pills three times per day is administrated.
62146558|NCT06140888|NO_INTERVENTION|The control group|Standard medical therapy
62707952|NCT02164864|EXPERIMENTAL|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
62707953|NCT02164864|EXPERIMENTAL|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
61971560|NCT00369616|EXPERIMENTAL|NicQb vaccine|
61971561|NCT00369616|PLACEBO_COMPARATOR|Placebo vaccine|
61971562|NCT00737282|ACTIVE_COMPARATOR|25 mg Proellex|Proellex 25 mg once daily
61971563|NCT00737282|ACTIVE_COMPARATOR|Proellex 50 mg|Proellex 50 mg once daily
61971564|NCT03028714|EXPERIMENTAL|Technology-based nutrition education|Participants will receive access to a website including educational information about nutrition and related topics. Through the website they will be asked to play online quiz-games relevant to the content of the website to improve their knowledge.
61971565|NCT03028714|NO_INTERVENTION|Control group|Participants in the control group will receive no intervention.
61971566|NCT02659306|EXPERIMENTAL|Metformin|Assessment will be done at the baseline, during and after 12 week of metformin use.
61971567|NCT03580655|EXPERIMENTAL|Avapritinib|Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles
62146559|NCT00869856|EXPERIMENTAL|1|HX575, EPO Hexal
62707954|NCT02164864|ACTIVE_COMPARATOR|Warfarin|Warfarin doses to maintain INR
62707955|NCT02399293|EXPERIMENTAL|Patient N-back|Patients training the N-back task
62707956|NCT02399293|ACTIVE_COMPARATOR|Patient Visual Search|Patients training the Visual-Search task
62511450|NCT05248204|ACTIVE_COMPARATOR|Scotchbond Universal Comparator|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using the predicate device, Scotchbond Universal (SBU) Adhesive (Control).
62511451|NCT02221596|EXPERIMENTAL|vitamin D + aerobic training|vitamin D capsules every weekday (10,000IU/day) and exercise
62511452|NCT02221596|ACTIVE_COMPARATOR|vitamin D + no aerobic training|vitamin D capsules every weekday (10,000IU/day) and no exercise
62511453|NCT02221596|ACTIVE_COMPARATOR|placebo + aerobic training|placebo capsule every weekday and exercise
62511454|NCT02221596|NO_INTERVENTION|placebo + no aerobic training|placebo capsule every weekday and no exercise
62511455|NCT06429982|ACTIVE_COMPARATOR|Dexamethasone group|Dexamethasone five days with 0.6 mg/ kg dose per day max 16 mg dose. Standard care will also be provided.
62511456|NCT06429982|PLACEBO_COMPARATOR|Placebo group|Placebo for five days with one dose per day placebo oral dosing. Standard care will also be provided.
62707957|NCT02399293|EXPERIMENTAL|Non-impaired N-back|Non-impaired training the N-back task
62707958|NCT02399293|ACTIVE_COMPARATOR|Non-impaired Visual Search|Non-impaired training the Visual-Search task
61971568|NCT01714635|EXPERIMENTAL|Tecnis Multifocal Intraocular lens #1|A low diopter add multifocal intraocular lens
61971569|NCT01714635|EXPERIMENTAL|Tecnis Multifocal Intraocular Lens #2|A low diopter add multifocal intraocular lens
61971570|NCT01714635|ACTIVE_COMPARATOR|Monofocal Intraocular Lens|Commercially available monofocal intraocular lens (IOL)
61971571|NCT02050776|EXPERIMENTAL|Stem Cells|autologous bone marrow mononuclear cell transplantation
61971572|NCT03886974||Adults with type 1 diabetes|People with T1D who are 18 years or older.
61971573|NCT03886974||Parents of adults with type 1 diabetes|Parents who have adult children with type 1 diabetes.
62146560|NCT06031714|OTHER|Patients|Patients who have had at least one pregnancy and have a venous ulcer, diabetic ulcer or sickle cell ulcer
62146561|NCT06031714|OTHER|"Patient Controls group "|Post-partum women of the same age but without wounds.
62146562|NCT06031714|OTHER|Children|
62511457|NCT05403957|EXPERIMENTAL|TID video|
62511458|NCT05403957|ACTIVE_COMPARATOR|TID worksheet|
62511459|NCT05403957|PLACEBO_COMPARATOR|SSB worksheet|
62511460|NCT05530473|EXPERIMENTAL|CTR Group|Eyes had a capsular tension ring (CTR) implanted into the capsular bag during the cataract surgery.
62511461|NCT05530473|NO_INTERVENTION|NCTR Group|Eyes underwent cataract surgery without implanting a CTR.
62511462|NCT03121014|EXPERIMENTAL|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
62511463|NCT04531787||Vaccine, Pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
62707959|NCT05209035|ACTIVE_COMPARATOR|Trazodone|
62707960|NCT05209035|PLACEBO_COMPARATOR|Placebo|
61971574|NCT03886974||Healthcare providers managing patients with type 1 diabetes|Licensed healthcare providers who are managing patients with T1D (whether in adult or pediatric practice).
61971575|NCT02450903|EXPERIMENTAL|LDK378 (Ceritinib)|Participants who received LDK378 750mg once daily on a 28 day cycle.
61971576|NCT06074315|EXPERIMENTAL|Nail Genesis DLSO Product|Nail Genesis DLSO Product, poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.
61971577|NCT06074315|PLACEBO_COMPARATOR|Vehicle|poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.
61971578|NCT01320761|EXPERIMENTAL|Group 1A|"Left side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
61971579|NCT01320761|EXPERIMENTAL|Group 1B|"Right side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
61971580|NCT01320761|EXPERIMENTAL|Group 2A|"Left side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
61971581|NCT01320761|EXPERIMENTAL|Group 2B|"Right side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
61971582|NCT01647815|EXPERIMENTAL|50 healthy volunteers|The study population consists of healthy volunteers aged 18 to 50 years and without previous surgery, trauma, or thrombosis of the axilla or the shoulder girdle.
61971583|NCT06395974||preeclampsia|
61971584|NCT06395974||control|
62146563|NCT02684656|ACTIVE_COMPARATOR|Hemodialysis|Intervention: Patients will be switch to hemodialysis and basal plasma oxalate levels as well as oxalate removal by hemodialysis will be determined after two weeks of treatment.
62511464|NCT04531787||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
62511465|NCT04531787||Vaccine, Healthy Controls|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
62511466|NCT06079918|ACTIVE_COMPARATOR|MMS with 30 mg iron|MMS with standard UNIMMAP formulation of 15 micronutrients, including 30 mg of iron
62511467|NCT06079918|EXPERIMENTAL|MMS with 45 mg iron|MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients
62511468|NCT06079918|EXPERIMENTAL|MMS with 60 mg iron|MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients
62146564|NCT02684656|ACTIVE_COMPARATOR|Hemodiafiltration|Intervention: Patients will be switch back to hemodiafiltration and basal plasma oxalate levels as well as oxalate removal by hemodiafiltration will be determined after two weeks of treatment.
62146565|NCT04431128||study group|Adenoid hypertrophy
62146566|NCT04431128||Control group|UTI, GE, vomiting, diarrhea
62146567|NCT06459544|EXPERIMENTAL|Bobath Technique with core stability|
62352384|NCT04685499|EXPERIMENTAL|Telomelysin (OBP-301)|All patients will receive intratumoral injection(s) with OBP-301. If tolerated and no progression is observed, up to twelve injections may be given in each patient.
61971585|NCT00818233||Observation|Variability will be assessed between each examiner.
61971586|NCT00241280|ACTIVE_COMPARATOR|Control|etafilcon A contact lens being worn 7 days/6 nights.
61971587|NCT00241280|EXPERIMENTAL|Test|galyfilcon A contact lens being worn 7 days/6 nights.
61971588|NCT02151760|EXPERIMENTAL|18F-DCFPyL|
61971589|NCT00933374|EXPERIMENTAL|Paclitaxel and RAD001|175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
61971590|NCT02289040||Children undergoing cardiac surgery|Paediatric patients (\<17 years with a body weight \>2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
61971591|NCT03626623|PLACEBO_COMPARATOR|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
61971592|NCT03626623|ACTIVE_COMPARATOR|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
61971593|NCT03171623|EXPERIMENTAL|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
61971594|NCT03171623|PLACEBO_COMPARATOR|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
61971595|NCT03171623|PLACEBO_COMPARATOR|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
61971596|NCT03171623|PLACEBO_COMPARATOR|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
61971597|NCT03171623|PLACEBO_COMPARATOR|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
61971598|NCT04785014|EXPERIMENTAL|aspiration group|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
62146568|NCT06459544|OTHER|Conventional treatment for balance|
62352385|NCT06355401|EXPERIMENTAL|group A|DLBCL patients who achieve CR
62352386|NCT06355401|NO_INTERVENTION|group B|DLBCL patients who achieve CR will be under follow up only
62352387|NCT01311232||Case|Patients with HBV reactivation
62352388|NCT01311232||Control|Patients without HBV reactivation
62352389|NCT02320630|EXPERIMENTAL|A|Maintenance treatment group
62352390|NCT02320630|EXPERIMENTAL|B|Combination treatment group
62352391|NCT02320630|EXPERIMENTAL|C|Single drug group
62352392|NCT03056807|ACTIVE_COMPARATOR|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
62352393|NCT03056807|ACTIVE_COMPARATOR|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
62352394|NCT02769078||Patients who received dabigatran|Patients who received dabigatran
62352395|NCT02769078||Patients who received rivaroxaban|Patients who received rivaroxaban
62352396|NCT02769078||Patients who received apixaban|Patients who received apixaban
62352397|NCT02769078||Patients who received warfarin|Patients who received warfarin
62352398|NCT05651217|EXPERIMENTAL|trial group|Patients in this group used the disposable urinary catheter
62352399|NCT05651217|ACTIVE_COMPARATOR|control group|Patients in this group used super smooth antibacterial urinary catheter
62352400|NCT06282419|EXPERIMENTAL|Experimental group 1|Fetal images and fetal heart sound recordings will be taken from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images of their babies, taken with a portable USG device, and fetal heart sounds will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks).
61971599|NCT04785014|ACTIVE_COMPARATOR|control group|no aspiration was performed in the control group. Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
62146569|NCT04794244|EXPERIMENTAL|Experimental|group in which the experimental group training program is applied
62146570|NCT04794244|NO_INTERVENTION|No Intervention|group without control group training program
62146571|NCT02499497|PLACEBO_COMPARATOR|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
62146572|NCT02499497|ACTIVE_COMPARATOR|LY2452473 Dose 1|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
62352401|NCT06282419|PLACEBO_COMPARATOR|Experimental group 2|Fetal USG images and fetal heart sounds taken from the internet, which are not of their babies, will be sent to the prospective fathers by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers in experimental group 2 twice a week for 4 weeks after birth via WhatsApp application.
62352402|NCT06282419|NO_INTERVENTION|control group|No visual or auditory stimuli were sent.
62511469|NCT03917511|EXPERIMENTAL|Robotic training with mirror therapy|20 minutes mirror therapy followed by 40 minutes robotic-assisted training
62146573|NCT02499497|ACTIVE_COMPARATOR|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
62146574|NCT02499497|ACTIVE_COMPARATOR|LY2452473 Dose 3|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
61971600|NCT04984798|EXPERIMENTAL|Vitamin E Dose-Escalation|Subjects will take an oral Vitamin E (dl-alpha-tocopherol) supplement twice daily with a fat-containing meal for 6-9 weeks. The dose will be increased every 2-3 weeks over the course of the study (initial dose 600 IU twice daily, next dose 1,200 IU twice daily, final dose 2,400 IU twice daily). Formulations include softgel capsules in 200, 400, and 1,000 IU doses.
62146575|NCT04121741|ACTIVE_COMPARATOR|Singing intervention 1|Instructional sing-a-long video. A video series will be created and recorded for the purposes of the study. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
62146576|NCT04121741|ACTIVE_COMPARATOR|Singing intervention 2|In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
62146577|NCT04121741|SHAM_COMPARATOR|Control/sham intervention|"Subjects will have a 30-minute period of rest sitting upright (as they would be positioned for the singing interventions). This arm is meant to isolate the specific effects of the treatment rather than the potential incidental effects related to the research setting and measurements. During this time, subjects will undergo hearing testing. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after the 30 minute rest."
62146578|NCT04663256|EXPERIMENTAL|Cognitive Stimulation Group|This group receives physical training based on exercises for cognitive stimulation.
62146579|NCT04663256|NO_INTERVENTION|Control Group|This group does not receive any treatment.
62146580|NCT03755115|EXPERIMENTAL|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, D1,30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
62352403|NCT01593228|EXPERIMENTAL|1|"Patients receiving iniparib alone or in combination with other anti-cancer agents as defined by the parental study. Interventions:~* Drug: Iniparib monotherapy~* Drug: Iniparib + gemcitabine + carboplatin~* Drug: Iniparib + topotecan~* Drug: Iniparib + irinotecan~* Drug: Iniparib + paclitaxel~* Drug: Iniparib + liposomal doxorubicin + carboplatin"
61971601|NCT05038423|ACTIVE_COMPARATOR|A structured 12-week group walking program|Participants engaged in an evidence-based 12-week walking program.
61971602|NCT05038423|EXPERIMENTAL|A structured 12-week group walking program + 5RS|In addition to the 12-week group walking program, participants engaged in the 5R Shared Leadership Program, which implements a structure of shared leadership and strengthens the identity leadership skills of the appointed peer leaders.
61971603|NCT00002602|EXPERIMENTAL|Group 1|Clinical stages T1b-c or T2a-b with PSA + (\[Gleason -6\] x 10) is ≤ 15. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
61971604|NCT00002602|EXPERIMENTAL|Group 2|Clinical stages T1b-c or T2a-b with PSA + (\[Gleason -6\]x10)\>15. Any clinical T2c with PSA \< 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
62146581|NCT04386538|EXPERIMENTAL|Low Starch Diet (LSD)|Participants will receive the low starch diet program: restricts the daily amount of ingested rich starch food, to a reduction of at least 40% compared to usual daily individual starch intake.
62146582|NCT04386538|ACTIVE_COMPARATOR|Control|Participants will receive dietary counselling based on general recommendations for healthy eating.
62146583|NCT05483166|EXPERIMENTAL|ImPACT program|The ImPACT program consists of 8 weekly 1-hour sessions with homework between sessions.
62146584|NCT04996407|ACTIVE_COMPARATOR|survival thermal blanket|Patient will be using survival thermal blanket as substitute for perforated blanket with forced air warmer during anesthesia
62146585|NCT04996407|ACTIVE_COMPARATOR|draping fabric|Patient will be using draping fabrics as substitute for perforated blanket with forced air warmer during anesthesia
62146586|NCT05483985|NO_INTERVENTION|Traditional Morphology|The embryo selection will be based on standard of care traditional morphology only.
62352404|NCT01637870|EXPERIMENTAL|Negative pressure pump|Will have the Prevena negative pressure wound system placed at the time of surgery.
62352405|NCT03919838|ACTIVE_COMPARATOR|Probiotics|Participants will receive two lozenges containing probiotic bacteria and cranberry.
62352406|NCT03919838|PLACEBO_COMPARATOR|Placebo - No probiotics|Participants will receive a control two lozenges containing no probiotic bacteria.
62352407|NCT05155657|EXPERIMENTAL|Low dose umbilical cord mesenchymal stem cells (UCMSCs)|
62352408|NCT05155657|EXPERIMENTAL|Medium dose UCMSCs|
62352409|NCT05155657|EXPERIMENTAL|High dose UCMSCs|
62352410|NCT03120728|EXPERIMENTAL|12-14mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 12-14mm on transvaginal ultrasound.
62352411|NCT03120728|EXPERIMENTAL|15-17mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 15-17mm on transvaginal ultrasound.
62352412|NCT03120728|EXPERIMENTAL|18mm or greater leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 18mm or greater on transvaginal ultrasound.
62511470|NCT03917511|SHAM_COMPARATOR|Robotic-assisted training|20 minutes sham mirror therapy followed by 40 minutes robotic-assisted training
62511471|NCT00407745|PLACEBO_COMPARATOR|matched placebo|
62146587|NCT05483985|EXPERIMENTAL|Device: Hera System|For the Hera, the embryologist will use the consider both the standard morphology grade and the Hera System score on embryos that were already deemed suitable for transfer or freeze based on the standard morphology assessment to determine the most suitable embryo for transfer.
62146588|NCT03137784|OTHER|1(NVA237 50 ug/NVA237 25 ug/placebo)|Treatment sequence: NVA 237 50 ug, 25 ug and placebo
62146589|NCT03137784|OTHER|2(NVA237 50 ug/placebo/NVA237 25 ug)|Treatment sequence: NVA 237 50 ug, placebo and 25 ug
62146590|NCT03137784|OTHER|3 (NVA237 25 ug/NVA237 50 ug/placebo)|Treatment sequence: NVA237 25 ug, 50 ug and placebo
62146591|NCT03137784|OTHER|4 (NVA237 25 ug/placebo/NVA237 50 ug)|Treatment sequence: NVA 237 25 ug, placebo and 50 ug
62707961|NCT05578066|EXPERIMENTAL|Intervention group|"The experimental group will be composed by aproximately 8 CESFAM with 36 Primary Health Care providers that are currently employed with a total of 288 providers per arm. And some PHC users that have received care there for Mental Health Abuse Issues in the three months prior to study participation.~The interventions include a comprehensive, 18-month, recovery-oriented anti-stigma intervention is composed by five components.~1. Developing a Team of Local Champions~2. Analysis of Internal Policies, Procedures and Protocols~3. Raising Awareness~4. Innovative Contact-Based Education~5. Recovery based Arts.~Teams of leaders developed as part of the first component will assist the research team with the implementation of the anti-stigma intervention at their respective CESFAM."
61971605|NCT00002602|EXPERIMENTAL|Group 3|Clinical stage T3 with PSA \< 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
62146592|NCT03137784|OTHER|5 (placebo/NVA237 50 ug/ NVA237 25 ug)|Treatment sequence: Placebo, NVA237 50 ug and 25 ug
62707962|NCT05578066|NO_INTERVENTION|Control group|"The control group will be composed by aproximately 8 CESFAM with 36 Primary Health Care providers that are currently employed with a total of 288 providers per arm. And some PHC users that have received care there for Mental Health Abuse Issues in the three months prior to study participation.~Data will be collected from this group in order to generate an integrated analysis with the information recolected from the intervention group."
61971606|NCT02656121|EXPERIMENTAL|Vitamin D|1st subgroup will be tested and treated with vitamin D together with Clomiphene Citrate for induction of ovulation
62707963|NCT01822925|EXPERIMENTAL|DA-9801 300mg|DA-9801 will be administered in tablet form, 100mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
61971607|NCT02656121|ACTIVE_COMPARATOR|control|2nd subgroup will be treated with Clomophene Citrate only
61971608|NCT06437860|EXPERIMENTAL|MIND Diet|Participants in the active MIND diet group will be asked to consume one ready-to-eat meal per day from Daily Harvest® meal delivery service. The treatment meals will follow MIND diet guidelines and include leafy green vegetables, nuts, legumes, whole grains, berries, and extra virgin olive oil.
61971609|NCT06437860|ACTIVE_COMPARATOR|Control Diet|Participants in the control diet group will be asked to consume one ready-to-eat meal per day from Daily Harvest® meal delivery service. The Control group will receive daily meals that are isocaloric with the active/experimental meals but will follow a general diet based on the average American diet and Dietary Guidelines for Americans (i.e., vegetables, fruits, nuts, whole grains, and unsaturated fats).
61971610|NCT01186679|EXPERIMENTAL|Intralesional|"1. Surgical transplantation into the lesion site in chronic patients~2. Direct intrathecal implantation in acute and subacute patients"
61971611|NCT01186679|EXPERIMENTAL|intrathecal|direct into the CSF through lumbar puncture
61971612|NCT05304403||Chronic Opioid User|Patients identified to have chronic opioid use (identified in chronic pain clinic)
61971613|NCT05304403||Healthy Control|These patients will not be actively recruited in this study. The investigators will use national microbiome dataset as a comparison.
61971614|NCT05089760||Infants with bacteria sepsis|Infants diagnosed with culture-proven sepsis
62146593|NCT03137784|OTHER|6 (placebo/ NVA237 25 ug/NVA237 50 ug)|Treatment sequence: placebo, NVA237 25 ug and 50 ug
62146594|NCT05181735|EXPERIMENTAL|Arm A (Luspatercept alone)|Patients will receive Luspatercept 1mg/kg (every 3 weeks) with titration up to max of 1.75mg/kg, subcutaneously on day 1 of each 21 day cycle (every three weeks).
62146595|NCT05181735|EXPERIMENTAL|Arm B (Luspatercept + EPREX)|"Patients will receive Luspatercept (at the selected dose according to part A) subcutaneously on day 1 of each 21 day cycle (every three weeks) AND Epoetin alfa: At the selected dose (in part A) per week, subcutaneously, every week~Doses schedules Part A :~* Level 1 : Luspatercept 0.8 mg/kg + EPREX 30000 UI~* Level 2 : Luspatercept 1.33 mg/kg + EPREX 30000 UI~* Level 3 : Luspatercept 1.75mg/kg + EPREX 30000 UI~* Level 4 : Luspatercept 1.75mg/kg + EPREX 60000 UI"
62146596|NCT00090415|EXPERIMENTAL|1|Child participants with autism will undergo intensive behavioral therapy.
62146597|NCT00090415|NO_INTERVENTION|2|Child participants without autism will receive no treatment and will undergo assessments to determine brain functioning only.
61971615|NCT00352144|EXPERIMENTAL|1|eszopiclone 3 mg tablet
61971616|NCT00352144|PLACEBO_COMPARATOR|2|Placebo tablet
61971617|NCT01885143||Artifact Correction|A minimum of 6 subjects will be recruited for the purpose of evaluating artifact correction
61971618|NCT01885143||Lossy Compression|A minimum of 6 subjects will be recruited for the purpose of evaluating lossy compression
62146598|NCT04081532|ACTIVE_COMPARATOR|Surgical treatment|
62146599|NCT04081532|NO_INTERVENTION|No surgical treatment|
62146600|NCT06088576|OTHER|test group|"Following the inclusion interview, adolescents has access to the Together application.~During the duration of the support, he will have access to the news, chat and forum.~Teenager have 8 working days to appropriate the application. For 1 month, the chat can be used without any other means of communication. A chat is limited to 20-30 minutes, after that, a teleconsultation can be offer. At the end of the 1 month, teleconsultations or a home visit are possible (30 to 45 minutes). They are done between 1 to 4 sessions in the month. Following the orientation, the psychologists take over the visio for the next 2 months, up to 2 to 4 interviews per month. Teleconsultation appointments are made on the calendar of the application by the professional after obtaining advice from teenagers.~At the beginning of the 5th month of care, the professionals set up a mixed distance/presential care with the youth. They propose home visits, individual or group interviews on site."
62146601|NCT00703352|ACTIVE_COMPARATOR|1|Eplerenone
62707964|NCT01822925|EXPERIMENTAL|DA-9801 600mg|DA-9801 will be administered in tablet form, 200 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
62146602|NCT00703352|PLACEBO_COMPARATOR|2|Placebo
62146603|NCT04201314|PLACEBO_COMPARATOR|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
62146604|NCT04201314|EXPERIMENTAL|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
62146605|NCT01779141||CSII|Patients using CSII with or without CGM.
62146606|NCT00240994|EXPERIMENTAL|Alemtuzumab (Campath)|In this open-label, single-arm trial , participants will be administered a 0.3 mg/kg dose of alemtuzumab (Campath) intravenously one day prior to kidney transplantation and one day post kidney transplantation. Participants will then receive a maintenance immunosuppressive regimen of tacrolimus and mycophenolate mofetil (MMF) for 8 to 12 weeks, followed by sirolimus and MMF until 24 months post transplantation.
62352413|NCT06197022|OTHER|Scoring Balloon Angioplasty|Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
62352414|NCT05279105||Humanitarian workers|Staff working in humanitarian organisations will be recruited for interviews
62352415|NCT05279105||Internally displaced persons|Internally displaced persons living in conflict settings will be recruited for interviews
62146607|NCT00336882|ACTIVE_COMPARATOR|1|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
62146608|NCT00336882|EXPERIMENTAL|2|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
62146609|NCT06472713|EXPERIMENTAL|Mitoxantrone group|Mitoxantrone hydrochloride liposome (30 mg/cycle) injection combined with PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) once every 3 weeks for up to 8 cycles, following the uniform PD-1 blockade alone once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
62146610|NCT01946594|ACTIVE_COMPARATOR|Acetaminophen Arm|"Acetaminophen Suspension 160 mg / 5 mL:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
62352416|NCT01027013|EXPERIMENTAL|rebamipide 2% ophthalmic suspension|
62352417|NCT01027013|PLACEBO_COMPARATOR|Placebo eye drops|
62146611|NCT01946594|PLACEBO_COMPARATOR|Placebo Arm|"Placebo Suspension:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
62352418|NCT00515580|EXPERIMENTAL|A|Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.
62146612|NCT06465537|EXPERIMENTAL|Group 1: POAG without vision for interventional eye|Interventional eye of participants with POAG has no vision, with mutated or unmutated MYOC gene. Single dose of BD113vVLP will be administrated intracamerally for target interventional eye.
62146613|NCT06465537|EXPERIMENTAL|Group 2: POAG with vision for interventional eye|Interventional eye of participants with POAG has vision acuity, and MYOC gene mutation test is positive. Single dose of BD113vVLP will be administrated intracamerally for target interventional eye.
62146614|NCT03072862||Commercial Nucleus Cochlear Implant Systems|
62146615|NCT04187482|EXPERIMENTAL|Exercise training group|All participants will be receiving same exercise training intervention
62146616|NCT06509685|EXPERIMENTAL|Group A|9 participants will be in experimental group A and will perform ladder training protocol including two foot run, Ladder traps, Lateral angle leg hops, Single leg forward hop, two-foot lateral run, Fight shuffle exercises.
62146617|NCT06509685|EXPERIMENTAL|Group B|9 participants will be in experimental group B and will perform balance training protocol including balance and landing activities incorporating wobble boards and change of direction activities
62352419|NCT06418334||Patients aged 10-18 years who were diagnosed with thoracal hyperkyphosis deformity|Thoracal Hyperkyphosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who were diagnosed with thoracal hyperkyphosis deformity and applied to the scoliosis outpatient clinicwill be filled in detail.
62352420|NCT04220385|ACTIVE_COMPARATOR|Wii fit Plus|"This study group will perform the following Wii fit plus exercises~* Single-Leg Extension~* Arm and Leg Lift~* Balance Bridge~* Single-Leg Twist~* Single-Leg Reach~* Sideways Leg Lift~* Single Arm Stand~* Torso Twists~* Plank"
62352421|NCT04220385|ACTIVE_COMPARATOR|Core Stability|"This study group will perform the following exercises.~* Curl-up~* Side Bridge~* Bird Dog"
62352422|NCT04078542||Chronic cough|Subject complaining cough from at least 8 weeks
62352423|NCT05483361||smart phone addiction group|Smart phone addiction will be assessed using the Smart Phone Addiction Scale short version (SAS-SV) evaluation of pulmonary functions and functional capacity evaluation craniovertebral angle
62146618|NCT03651934|EXPERIMENTAL|Normal iron|
62352424|NCT01403831|EXPERIMENTAL|Text messages|Patients randomized to this arm will receive daily text messages to their mobile phones consisting of educational materials, motivational materials, trivia questions, and challenges to engage in healthy lifestyle choices
62352425|NCT01403831|NO_INTERVENTION|Control|
62352426|NCT04928495|PLACEBO_COMPARATOR|Treatment group 1|Control placebo (Vitamin C - 500mg / day, for 10 days)
62352427|NCT04928495|ACTIVE_COMPARATOR|Treatment group 2|N-acetylcysteine (NAC; 1800 mg / day, for 10 days)
62352428|NCT04928495|ACTIVE_COMPARATOR|Treatment group 3|NAC (1800 mg / day) + bromhexine-BMX (32 mg / day for 10 days)
62352429|NCT04060810|OTHER|grey zone hydrocephalic patients|MR CSF flowmetry CT brain Ventriculoperitoneal shunt
62352430|NCT05904353|EXPERIMENTAL|Cluster randomized intervention regions|Patients from the intervention regions will be followed the protocol of ambulant nurse-assisted administration of zoledronic acid
62511472|NCT00407745|EXPERIMENTAL|pregabalin|flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period
62707965|NCT01822925|EXPERIMENTAL|DA-9801 900mg|DA-9801 will be administered in tablet form, 300 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
62707966|NCT01822925|PLACEBO_COMPARATOR|Placebo|Placebo (same formulation as DA-9801 but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 12 weeks.
62707967|NCT03271775|NO_INTERVENTION|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
62707968|NCT03271775|EXPERIMENTAL|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
62707969|NCT03271775|EXPERIMENTAL|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
61971619|NCT01958320|EXPERIMENTAL|Early treatment|"Infants randomized to the early treatment group will receive pharmacologic treatment of the PDA to produce PDA closure. Within 24-36 hr following the last treatment dose an echocardiogram will be obtained to document the degree of ductus closure or patency.~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
61971620|NCT01958320|ACTIVE_COMPARATOR|Conservative Treatment|"Infants randomized to the Conservative Treatment approach will receive no pharmacologic treatment of the PDA but will be followed to determine if they meet criteria for later PDA rescue treatment (Infants will be eligible for rescue treatment of their persistent PDA if they meet the rescue treatment criteria.)~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
61971621|NCT03541720|EXPERIMENTAL|Injection of 18F-DA|18F-DA will be injected into a vein in the arm or leg, or via central venous access line.
61971622|NCT05552950|EXPERIMENTAL|experimental group|Individuals using the BioBlock® antiviral nasal spray immediately after waking up in the morning and thereafter once every 4 hours and so for 28 days.
61971623|NCT05552950|PLACEBO_COMPARATOR|control group|Placebo is used by individuals immediately after waking up in the morning and thereafter once every 4 hours and so for 28 days.
61971624|NCT00850824|EXPERIMENTAL|Behavioral|Community Health Worker home visits
61971625|NCT00850824|ACTIVE_COMPARATOR|Usual Care|Usual Care, Wait List Control
61971626|NCT02178228||Subjects over age 18|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are over the age of 18
61971627|NCT02178228||Subjects age 15-17|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are age 15-17 with one permission of one parent.
61971628|NCT04358029||COVID-19 patients|Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital
61971629|NCT04358029||Influenza patients|Patients who have been diagnosed with Influenza infection at Mount Sinai Hospital
61971630|NCT04358029||COVID-19 patients who were hospitalized with abnormal echocardiogram|Patients hospitalized for COVID-19 and who had an abnormal echocardiogram during hospitalization
61971631|NCT04358029||COVID-19 patients who were hospitalize with normal echocardiogram or no echocardiogram done|A matched cohort (for age, gender, troponin level, and days since hospital discharge) who did not have abnormalities on their echocardiograms (or who did not undergo echocardiogram) to ascertain that in this unusual disease, subjects did not develop echo abnormalities following hospital
61971632|NCT05796297||Patient with significant patient ventilator asynchrony|Active Comparator
61971633|NCT05796297||Patient without significant patient ventilator asynchrony|Active Comparator
61971634|NCT02859207|EXPERIMENTAL|Cohort 1|Participants with mild hepatic impairment (Child-Pugh class A).
61971635|NCT02859207|EXPERIMENTAL|Cohort 1C|Healthy participants (control) matched to participants in Cohort 1.
61971636|NCT02859207|EXPERIMENTAL|Cohort 2|Participants with moderate hepatic impairment (Child-Pugh class B)
61971637|NCT02859207|EXPERIMENTAL|Cohort 2C|Healthy participants (control) matched to participants in Cohort 2
61971638|NCT01366209|ACTIVE_COMPARATOR|Active Arm|
61971639|NCT01366209|PLACEBO_COMPARATOR|Placebo Arm|
61971640|NCT01220622|ACTIVE_COMPARATOR|Nimodipine|
61971641|NCT01220622|PLACEBO_COMPARATOR|Placebo|
61971642|NCT04508478|EXPERIMENTAL|Aerobic training|
61971643|NCT04508478|ACTIVE_COMPARATOR|Resistance training|
61971644|NCT04508478|PLACEBO_COMPARATOR|Control|
62707970|NCT06392425||- Group (1): stage(1) CKD patient group|Stage 1 of CKD (eGFR of 90 or greater)
62707971|NCT06392425||-Group (2): stage (2) CKD patient group|Stage 2 of CKD (eGFR between 60 and 89)
61971645|NCT00861276|EXPERIMENTAL|1|Arm instructed to use spray at least once an hour when awake.
61971646|NCT00861276|ACTIVE_COMPARATOR|2|Ad libitum: patients were instructed to use NNS when craving appears.
61971647|NCT06226753|ACTIVE_COMPARATOR|Stoma reversal under GA|Loop ileostomy closure will be performed under General anaesthesia
61971648|NCT06226753|EXPERIMENTAL|Stoma reversal under SA|Loop ileostomy closure will be performed under Spinal anaesthesia
62707972|NCT06392425||-Group (3) :stage(3) CKD patient group|Stage 3 of CKD (eGFR between 30 and 59)
62707973|NCT06392425||-Group (4) :stage (4) CKD patient group|Stage 4 of CKD (eGFR between 15 and 29)
62707974|NCT06392425||-Group (5):stage(5) CKD patient group|Stage 5 of CKD (eGFR less than 15)
62707975|NCT06392425||-Group (6) :control Group|apparently healthy individuals with matched age and sex are included in this study as a control group for comparison
61971649|NCT01705184|EXPERIMENTAL|BUCiL|"Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --\> Sequence 2~Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
61971650|NCT02554669|NO_INTERVENTION|Control|No physical activity
61971651|NCT02554669|EXPERIMENTAL|Postabsorptive physical activity|Physical activity performed before breakfast
62146619|NCT03651934|EXPERIMENTAL|Weak iron|
62707976|NCT02104934|NO_INTERVENTION|Local Infiltration Analgesia|The Local Infiltration Analgesia group will receive local infiltration of ropivacaine 150mg, ketorolac 30mg, morphine 10mg, adrenaline 200mcg and vancomycin 500mg in a total volume of 75mls by the surgeon.
62511473|NCT02740179|EXPERIMENTAL|Eplerenone|Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
62511474|NCT02740179|PLACEBO_COMPARATOR|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
62146620|NCT03651934|EXPERIMENTAL|Normal selenium|
62707977|NCT02104934|ACTIVE_COMPARATOR|Adductor Canal Block|The Adductor Canal Block group of patients will receive intravenous ketorolac 30mg intra-operatively and an adductor canal block at the end of surgery. The block will be performed under real time ultrasound guidance and 30mls of 0.5% ropivacaine (150mg) is injected with a Stimuplex A100, 21G needle.
61971652|NCT02554669|EXPERIMENTAL|Postprandial physical activity|Physical activity performed in the postprandial period after breakfast
61971653|NCT00296478|EXPERIMENTAL|1|Endometrin 100mg BID
61971654|NCT00296478|EXPERIMENTAL|2|Endometrin 100mg TID
61971655|NCT00296478|ACTIVE_COMPARATOR|3|Crinone
61971656|NCT03842124|ACTIVE_COMPARATOR|Intervention|Use of bidirectional rail (superior and inferior approaches) and force sensing using a force gauge to optimize Force application to less than 8 lbs during the extraction procedure.
61971657|NCT03842124|NO_INTERVENTION|Control|Conventional lead extraction procedures using a superior approach is performed by experienced operators. Although force information is available the operators are blinded to the information. Inferior rail is left to the discretion of the operator.
61971658|NCT03992859|EXPERIMENTAL|serratus catheter|Continuous serratus plane block: Ropivacaine 0.2% infusion through a multiple hole catheter (C-Cat Cimpax Denmark)at a fixed dose of 12 ml/h and a multimodal analgesia with acetaminophen and a PCA of morphine
61971659|NCT03992859|NO_INTERVENTION|standard treatment|Post-operative multimodal analgesia with Acetaminophen and PCA of Morphine
61971660|NCT01728701|EXPERIMENTAL|Grp 1: 75,000 PfSPZ Challenge, 3 immunizations|Grp 1 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 1 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 \& 64 (immunizations 1, 2 \& 3). 33 days after last dose of CQ, Grp 1 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
62352431|NCT05904353|ACTIVE_COMPARATOR|Cluster randomized control regions|Patients from the control regions are followed as usual. General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
62352432|NCT01539811|ACTIVE_COMPARATOR|Short course antibiotics|Surgical intervention followed by short course of antibiotics (\<2 weeks)
62352433|NCT01539811|ACTIVE_COMPARATOR|Long course antibiotics|Surgical intervention followed by a long course of antibiotics (\>2 weeks)
62352434|NCT05957588|EXPERIMENTAL|Proning group|COVID-19 hypoxemic patients that receive standard of care AND participate in self-proning following the research protocol.
61971661|NCT01728701|PLACEBO_COMPARATOR|Grp 2: Normal Saline (NS)|Grp 2 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 2 gets ID injections of normal saline, on days 8, 36 \& 64 (immunizations 1, 2 \& 3). 33 days after last dose of CQ, Grp 2 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
62352435|NCT05957588|OTHER|Control group|COVID-19 hypoxemic patients that receive standard of care.
62511475|NCT03020719|EXPERIMENTAL|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
62511476|NCT03020719|PLACEBO_COMPARATOR|Placebo|Placebo oral powder at 65mg/kg/day
62707978|NCT02665260|ACTIVE_COMPARATOR|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
62707979|NCT02665260|EXPERIMENTAL|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
61971662|NCT01728701|EXPERIMENTAL|Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations|Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 \& 64 (immunizations 1, 2 \& 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If \<75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
62146621|NCT03651934|EXPERIMENTAL|Weak selenium|
62146622|NCT03719547|EXPERIMENTAL|Robot-assisted radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
62146623|NCT03719547|ACTIVE_COMPARATOR|Abdominal radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
62146624|NCT02431442|ACTIVE_COMPARATOR|Cohort 1: RM-493 SC Infusion 14 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 14 days (1 panel, all male subjects)
62146625|NCT02431442|ACTIVE_COMPARATOR|Cohort 2: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
62146626|NCT02431442|ACTIVE_COMPARATOR|Cohort 3: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
62511477|NCT06616116|EXPERIMENTAL|Mindfulness with biosignal feedback|Biosignal Monitoring (EEG and HRV) with Real-time neurofeedback during Mindfulness
62511478|NCT06616116|SHAM_COMPARATOR|Mindfulness without biosignal feedback|Biosignal Monitoring (EEG and HRV) without Real-time neurofeedback during Mindfulness
62511479|NCT03768284||Psoriasis patients|Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
62707980|NCT02665260|PLACEBO_COMPARATOR|Placebo with occlusion|Placebo topical with occlusion
62707981|NCT02665260|PLACEBO_COMPARATOR|Placebo without occlusion|Placebo topical without occlusion
62707982|NCT02386956|EXPERIMENTAL|Active stretching|10 minutes of Postural Global Reeducation for the posterior muscle chain
62146627|NCT02431442|ACTIVE_COMPARATOR|Cohort 4: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.015 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
62511480|NCT03768284||Parents of psoriasis patients|Parents of patients who developed psoriasis before 12 years of age
62511481|NCT03768284||Up to third-degree family members with or without psoriasis|Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
62511482|NCT01911806|EXPERIMENTAL|Back care pillow & standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks \& back care pillow use during the day for 2 weeks
62511483|NCT01911806|ACTIVE_COMPARATOR|standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks
62511484|NCT03532230||Experimental Group|90 new patients seeking treatment for chronic low back pain. This group will receive standard care plus osteopathic manipulative treatment (OMT) for low back pain.
62511485|NCT03532230||Control Group|90 new patients seeking treatment for chronic low back pain. This group will receive only standard care without osteopathic manipulative treatment (OMT) for low back pain.
62511486|NCT04451187|EXPERIMENTAL|Treatment Sequence CADB|Participants will receive placebo once daily (OD) at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment C) in Period 1 followed by Dose 1 of seltorexant tablets and placebo OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment A) in Period 2 followed by Dose 2 of seltorexant tablets OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment D) in Period 3 followed by zopiclone on Day 1 and Day 8 and placebo from Day 2 to Day 7 OD at bedtime (Treatment B) in Period 4. There will be a washout period of 5 to 21 days between each period.
62511487|NCT04451187|EXPERIMENTAL|Treatment Sequence ABCD|Participants will receive Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3 followed by Treatment D in Period 4. There will be a washout period of 5 to 21 days between each period.
62707983|NCT02386956|EXPERIMENTAL|Dynamic Stretching|10 minutes of sciatic nerve manual movilization in two legs
61971663|NCT01728701|PLACEBO_COMPARATOR|Grp 4: Normal Saline (NS)|Grp 4 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 wks(98 days). In this time, Grp 4 gets ID injections of NS, on days 8, 36 \& 64 (immunizations 1, 2 \& 3). Grp 4 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If \<75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will receive 1 additional immunization (immunization 4), consisting of ID injections of NS, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 4 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
61971664|NCT06076161|EXPERIMENTAL|Spirulina supplementation and calorie restriction in obese men|Respondents will be divided into 2 groups, namely the intervention group and the control group. The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction.
62511488|NCT04451187|EXPERIMENTAL|Treatment Sequence BDAC|Participants will receive Treatment B in Period 1 followed by Treatment D in Period 2 followed by Treatment A in Period 3 followed by Treatment C in Period 4. There will be a washout period of 5 to 21 days between each period.
62511489|NCT04451187|EXPERIMENTAL|Treatment Sequence DCBA|Participants will receive Treatment D in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3 followed by Treatment A in Period 4. There will be a washout period of 5 to 21 days between each period.
62511490|NCT05329285|EXPERIMENTAL|Percutaneous Coronary Intervention (PCI)|Patients will be revascularized by PCI
62511491|NCT05329285|NO_INTERVENTION|Coronary artery bypass grafting (CABG)|Patients will be revascularized by CABG
62511492|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
62511493|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
61971665|NCT06076161|PLACEBO_COMPARATOR|Placebo capsules and calorie restriction in obese men|The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
61971666|NCT02891850|EXPERIMENTAL|Riociguat|PDE5i treatment will be stopped and riociguat treatment initiated following a defined washout period with a starting dose of 1 mg riociguat TID followed by an 8 weeks dose adjustment phase according to the approved riociguat dose adjustment scheme.
61971667|NCT02891850|ACTIVE_COMPARATOR|PDE-5i|Patients will continue to receive PDE5i treatment as well as other standard of care treatments at the discretion of the investigator up to Week 24. Patients in the experimental and active comparator treatment arms follow the same visit schedule.
62707984|NCT02386956|PLACEBO_COMPARATOR|Control|10 minutes with the patient lying on a machine off of magnetotherapy
62707985|NCT01862003|EXPERIMENTAL|Arm 1|AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
62707986|NCT00656370|EXPERIMENTAL|NS Infusion Group|Normal Saline (NS) and Hylenex
62707987|NCT00656370|EXPERIMENTAL|LR Infusion Group|Lactated Ringer's (LR) and Hylenex
61971668|NCT03924973|EXPERIMENTAL|Experimental group|"Children below the age of 3 in this group received 2 years of ESDM intervention for 12 hours per week, and then treatment as usual for the 3 following years.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community."
61971669|NCT03924973|OTHER|Control group|"Children in this group received treatment as usual delivered in the community for the 2 years of IDEA.~Participants will still receive treatment as usual delivered in the community during IDEA-2, in the 3 years following IDEA."
62352436|NCT01152489|NO_INTERVENTION|Standard Care|Immunizations are given with standard care of no pain control
62511494|NCT01684878|EXPERIMENTAL|Part 1: Pertuzumab + Topotecan|Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
62511495|NCT01684878|EXPERIMENTAL|Part 1: Pertuzumab + Paclitaxel|Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
61971670|NCT04520737|ACTIVE_COMPARATOR|16W group|Multimodal prehabilitation program (MPP) will be implemented during 16 weeks, 12 weeks during chemotherapy (CT) and 4 weeks while waiting for surgery.
61971671|NCT04520737|ACTIVE_COMPARATOR|4W group|Multimodal prehabilitation program (MPP) will start at the end of preoperative chemotherapy (CT) until surgery (4 weeks in total).
61971672|NCT03041402|ACTIVE_COMPARATOR|PSP ventilation|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
61971673|NCT03041402|ACTIVE_COMPARATOR|NAVA ventilation|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
61971674|NCT03041402|EXPERIMENTAL|PSN ventilation|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
61971675|NCT01511315|EXPERIMENTAL|Ustekinumab|
61971676|NCT01770626|NO_INTERVENTION|Single arm|evaluate the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis
61971677|NCT06499077||Tumor|Women carrying a breast cancer
61971678|NCT06499077||Control|Women with negative breast imaging
62146628|NCT02431442|ACTIVE_COMPARATOR|Cohort 5: RM-493 SC Injection 14 days|Double-blind RM-493 will be administered at a dose of 0.0075 mg/kg every 12 hours via a subcutaneous injection for 14 days (1 panel)
61971679|NCT00326989|ACTIVE_COMPARATOR|Low-dose shock wave treatment & Placebo|
61971680|NCT00326989|ACTIVE_COMPARATOR|low-dose shock-wave treatment & Cell therapy|
61971681|NCT00326989|ACTIVE_COMPARATOR|High-dose shock-wave treatment & Placebo|
61971682|NCT00326989|ACTIVE_COMPARATOR|High-dose shock-wave treatment & cell therapy|
61971683|NCT00326989|ACTIVE_COMPARATOR|Placebo shock-wave treatment & cell therapy|
62352437|NCT01152489|ACTIVE_COMPARATOR|Experimental|Vibrating device with cold pack held to arm proximal to injections within the same dermatome; caretakers offered and instructed in use of distraction cards.
62352438|NCT01152489|SHAM_COMPARATOR|Sham Device|The device without batteries or cold pack held to arm proximal to injections. No formal distraction.
62352439|NCT03967756|EXPERIMENTAL|AI-assisted withdrawal group|A deep learning-based automatic polyp detection system was used to assist the endoscopist.
62352440|NCT03967756|NO_INTERVENTION|Routine withdrawal group|Routine withdrawal without any assist.
61971684|NCT06397014||D-type|
61971685|NCT06397014||Sugerbaker|
61971686|NCT01613729|ACTIVE_COMPARATOR|Rosuvastation 5 Initiator Arm|These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
61971687|NCT01613729|ACTIVE_COMPARATOR|Rosuvastatin 10 initiator arm|These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
61971688|NCT05040321|EXPERIMENTAL|MIB-626|Subjects will either take MIB-626 or placebo tablet twice a day for 90 days. For those who receive MIB-626, we plan on giving subjects 1000mg of the drug, twice a day for 90 days. MIB-626 will be in two 500mg tablets.
61971689|NCT05040321|PLACEBO_COMPARATOR|Placebo Tablet|Subjects will be randomized to receive either the placebo or MIB-626 tablets twice a day orally.
61971690|NCT04970888|EXPERIMENTAL|Combined|Combined physical exercise and cognitive training. The combined intervention will include a cognitive training with aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
61971691|NCT04970888|EXPERIMENTAL|Exercise|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform exercise training sessions either home-based or centre-based.
61971692|NCT04970888|ACTIVE_COMPARATOR|Usual care|Usual medical care with no interventions
62352441|NCT03165864|EXPERIMENTAL|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
62352442|NCT03165864|PLACEBO_COMPARATOR|Placebo|Saline .9%
62352443|NCT00538746|EXPERIMENTAL|1|BIPAP (Bilevel Positive Airway Pressure) targeted on: TV 6-8 ml/kg, total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92% (with spontaneous RR between 20-40%)
62352444|NCT00538746|EXPERIMENTAL|2|PSV (pressure support ventilation) targeted on: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated.
62352445|NCT00538746|EXPERIMENTAL|3|PSV+CPAP (continuous positive airway pressure) targeted on: PSV: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated, CPAP (5-10 cmH2O) at least 2 hours a day. If during the CPAP periods at least 1 of the criteria T tube test failure occurs, the patients will come back immediately to PSV.
62352446|NCT00871377|PLACEBO_COMPARATOR|Placebo|Corn Oil Placebo (n-6 fatty acids)
62352447|NCT00871377|EXPERIMENTAL|High Dose Fish Oil|2160 mg of EPA + DHA
62352448|NCT00871377|EXPERIMENTAL|Low Dose Fish Oil|1060 mg of EPA + DHA
62352449|NCT01686958|EXPERIMENTAL|MR-Guided Transurethral US Ablation|MR-Guided Transurethral US Ablation of Prostate Tissue
62352450|NCT01817114|EXPERIMENTAL|Chronic Remote Ischemic Conditioning|Remote ischemic conditioning will be induced using an AutoRIC device (occluding arm bloodflow exactly like manual bloodpressure cuff). With the participant in a supine or seated upright position, the AutoRIC device will be placed on the right arm and will inflate to a pressure of 200mmHg for 5 minutes (ischemia). The device will then auto-deflate (reperfusion), completing one cycle of ischemia-reperfusion. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
62511496|NCT01684878|EXPERIMENTAL|Part 2: Pertuzumab+Chemotherapy|Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
62707988|NCT05482061||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury. The basic tool for pain intensity research was the VAS. The study of the neuropathic component of pain was carried out using the DN4. Study of the presence of an acute stress reaction - anamnesis + HADS. The diagnosis of ASR was established by a psychiatrist upon admission to the military mobile hospital. The presence of post-traumatic stress disorders (PTSD) was investigated using the Mississippi scale of post-traumatic stress disorders (military version). The presence of PTSD according to the MS PTSD (c). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
62707989|NCT05482061||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients who took part in the study with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception is the study period during treatment at the military medical clinical center: here it was 14 days.~In all patients with gunshot wounds, the outcome and effectiveness of pain management were assessed using the Visual Analogue Scale (VAS) and the Diagnostic Questionnaire for the Detection of the Neuropathic Pain Component Didier Bouhassiraa, Nadine Attala et al. Pain, 2005, 114: 29-36 (DN4)."
61971693|NCT04348929|EXPERIMENTAL|Confinement group|Delivery during covid-19 confinement period
61971694|NCT04348929|OTHER|Control group|Delivery after the withdrawal of all sanitary measures (mask, social distancing, limited visits during post-partum immediate)
61971695|NCT04348929|OTHER|Epidemic group|Delivery after confinement period and before the withdrawal of sanitary measures implemented (mask, social distancing, limited visits during post-partum immediate)
61971696|NCT02187250|ACTIVE_COMPARATOR|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
61971697|NCT02187250|ACTIVE_COMPARATOR|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
61971698|NCT02187250|ACTIVE_COMPARATOR|roflumilast|In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.
61971699|NCT05236569|EXPERIMENTAL|Tranexamic acid|The intervention was 1 ml of 10 mg/ml of tranexamic acid solution which was given intradermally.
61971700|NCT05236569|PLACEBO_COMPARATOR|Placebo|The placebo was 1 ml of 0.9% normal saline which was given intradermally.
61971701|NCT03241342|ACTIVE_COMPARATOR|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
61971702|NCT03241342|ACTIVE_COMPARATOR|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
61971703|NCT03241342|PLACEBO_COMPARATOR|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
62511497|NCT01684878|PLACEBO_COMPARATOR|Part 2: Placebo+Chemotherapy|Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
61971704|NCT01782144|ACTIVE_COMPARATOR|NutriSystem|weekly behavior group weight loss education
61971705|NCT01782144|PLACEBO_COMPARATOR|Education|monthly behavior group weight loss education
61971706|NCT05060055|EXPERIMENTAL|Test Group|Customized healing abutment inserted in immediate implant placement in association with the use of a connective tissue graft.
61971707|NCT05060055|ACTIVE_COMPARATOR|Control Group|Customized healing abutment inserted in immediate implant placement.
61971708|NCT01443650|EXPERIMENTAL|alirocumab SAR236553 (REGN727) (Formulation A x 1)|A single subcutaneous injection of Formulation A
61971709|NCT01443650|EXPERIMENTAL|alirocumab SAR236553 (REGN727) (Formulation B x 1)|A single subcutaneous injection of Formulation B
61971710|NCT01443650|EXPERIMENTAL|alirocumab SAR236553 (REGN727) (Formulation A x 2)|2 single subcutaneous injections of Formulation A
61971711|NCT05168488|EXPERIMENTAL|All participants|There is only one study arm consisting of all participants.
62511498|NCT01219452|EXPERIMENTAL|umbilical cord mesenchymal stem cells|intramuscular injection of umbilical cord mesenchymal stem cell
61971712|NCT01503151|PLACEBO_COMPARATOR|Placebo|repeated trials of a dot-probe task and repeated trials of an interpretation task, both not intended to change threat-related biases patterns.
61971713|NCT01503151|EXPERIMENTAL|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
61971714|NCT01503151|EXPERIMENTAL|Interpretation Bias Modification (IBM)|Interpretation training intended to facilitating a more benign interpretation bias
61971715|NCT01503151|EXPERIMENTAL|Attention and interpretation biases modification|Attention and interpretation training intended to direct cognitive biases away from threat stimulus.
61971716|NCT05090137|OTHER|Diuretic cessation|Participants will be asked to withhold their diuretic therapy (loop diuretics and mineralocorticoid receptor antagonists) 48 hours prior to visit
61971717|NCT05090137|OTHER|Usual diuretic regimen|Participants will take their usual diuretic regimen prior to study visit. At least one week is required between cross-over visits
61971718|NCT01723592|PLACEBO_COMPARATOR|Placebo|30 participants in this group receive a oral lactose placebo
61971719|NCT01723592|ACTIVE_COMPARATOR|Probiotics|"30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:~L.rhamnosus/ LbV96 (DSM 22560)~L.jensenii /LbV 116 (DSM 22567)~L.crispatus/ Lbv88 (DSM 22566)~L.gasseri /LbV 150N (DSM 22583)"
61971720|NCT01214811|OTHER|Mepilex Border Ag|Non comparative study with one active arm - Mepilex Border Ag
61971721|NCT03402386|EXPERIMENTAL|MT-6548|
62146629|NCT02431442|ACTIVE_COMPARATOR|Cohort 6: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
62511499|NCT00233987|EXPERIMENTAL|High-dose therapy plus tandem transplant|Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.
62146630|NCT02431442|PLACEBO_COMPARATOR|Cohort 1: Placebo SC Infusion 14 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 14 days (1 panel, all male subject)
62707990|NCT04667156|EXPERIMENTAL|Sequence 1|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 traditional formulation (R) in the last period
62146631|NCT02431442|PLACEBO_COMPARATOR|Cohort 2: Placebo SC Infusion 28 Days|Double-blind Placebo will be via subcutaneous continuous infusion for 14 days (1 panel)
61971722|NCT03283592|EXPERIMENTAL|Rank-Heat Plot|The intervention group will receive an online survey to evaluate their interpretation of the results from the NMA with a rank-heat plot including results from 2 outcomes that were selected by our knowledge users (#injurious falls, #fractures).
62707991|NCT04667156|EXPERIMENTAL|Sequence 2|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 new formulation 2 (T2) in the last period
62146632|NCT02431442|PLACEBO_COMPARATOR|Cohort 3: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
62511500|NCT03001999|EXPERIMENTAL|Intervention Arm|Participants will all undergo a 16-week PP-MI health behavior intervention.
62707992|NCT04667156|EXPERIMENTAL|Sequence 3|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 1 (T1) in the last period
61971723|NCT03283592|ACTIVE_COMPARATOR|SUCRA (surface under the cumulative ranking) Plot|The control group will receive an online survey to evaluate their interpretation of the results from the NMA with the SUCRA plots including results from the same 2 outcomes that will be presented to the intervention group (i.e., #injurious falls, #fractures).
62146633|NCT02431442|PLACEBO_COMPARATOR|Cohort 4: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
62146634|NCT02431442|PLACEBO_COMPARATOR|Cohort 5: Placebo SC Injection 14 days|Double-blind Placebo will be administered via a subcutaneous injection every 12 hours for 14 days (1 panel)
62511501|NCT01197768|EXPERIMENTAL|Nutrition Intervention|The intervention group will receive a full nutrition assessment and a nutrition intervention.
62511502|NCT01197768|NO_INTERVENTION|Control|This group will receive the nutrition assessment but no intervention from a Registered Dietician. If participant appears to be in danger due to BMI or Caloric intake status, their primary care physician will be notified.
62707993|NCT04667156|EXPERIMENTAL|Sequence 4|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 2 (T2) in the last period
61971724|NCT03182088|EXPERIMENTAL|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
61971725|NCT03182088|EXPERIMENTAL|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
62146635|NCT02431442|PLACEBO_COMPARATOR|Cohort 6: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
62146636|NCT00849446||Activity monitoring in CVA patients|
62146637|NCT00849446||Activity monitoring in healthy persons|
62146638|NCT01366456|ACTIVE_COMPARATOR|Shingigu|Treat with Shingigu
62146639|NCT01366456|ACTIVE_COMPARATOR|Charcoal|Treat with Charcoal
61971726|NCT03182088|EXPERIMENTAL|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
62146640|NCT01706159|EXPERIMENTAL|rFXIII|
62146641|NCT01706159|ACTIVE_COMPARATOR|Placebo|
62146642|NCT05330000|ACTIVE_COMPARATOR|Voriconazole (R)|
62146643|NCT05330000|EXPERIMENTAL|Voriconazole (T)|
62146644|NCT01090258|EXPERIMENTAL|Automated settings|Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
62146645|NCT01090258|ACTIVE_COMPARATOR|protocolized settings|Ventilator settings performed by the local respiratory therapists according to the local protocols
62146646|NCT04186377|ACTIVE_COMPARATOR|Standard-of-care managed group|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
62146647|NCT04186377|EXPERIMENTAL|S26E|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers plus daily S26E application
62146648|NCT06272032|ACTIVE_COMPARATOR|High-intensity focused ultrasound (HIFU)|"The High-Intensity Focused Ultrasound (HIFU) knife, also known as the High-Intensity Focused Ultrasound Tumor Treatment System or HIFU ablation therapy, abbreviated as the HIFU knife, is a non-invasive and non-intrusive tumor treatment method utilizing high-intensity focused ultrasound technology. This technology was successfully developed by the Ultrasound Medical Engineering Research Institute of Chongqing Medical University in 1997."
62511503|NCT01456741|EXPERIMENTAL|1-EBNA with ROSE|
62511504|NCT01456741|EXPERIMENTAL|1-EBNA without ROSE|
62511505|NCT01131962|ACTIVE_COMPARATOR|band ligation group|this group will have immediate control of the hematemesis by endoscopic band ligation.
62707994|NCT04667156|EXPERIMENTAL|Sequence 5|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 traditional formulation (R) in the last period
62707995|NCT04667156|EXPERIMENTAL|Sequence 6|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 new formulation 1 (T1) in the last period
62707996|NCT01958086|EXPERIMENTAL|Neural Communication System|The Neural Communication System consists of two Neuroport Multi-Port Arrays, which are descried in detail in the intervention description. One Neuroport Multi-Port Array is inserted into the posterior parietal cortex, an area of the brain used in reach planning. The second Neuroport Multi-Port Array is inserted into the motor cortex, which is primarily responsible for controlling movement. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
62707997|NCT05327647|EXPERIMENTAL|Bicalutamide|Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral bicalutamide for 90 days (in cohort A and cohort B)
62707998|NCT05327647|ACTIVE_COMPARATOR|Control Arm|"cohort A: Induction intravesical Bacille Calmette-Guérin treatment~cohort B: Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral placebo for 90 days"
62707999|NCT04153487|EXPERIMENTAL|ASTRALI Group|ASTRALI (AScorbic acid in TRALI) group (n=40)
61971727|NCT01727453|ACTIVE_COMPARATOR|Bemiparin|Group 1 (low molecular weight heparin: bemiparin), which is the study group: after passing the bleeding episode, will receive low molecular weight heparin (bemiparin) in anticoagulant dose. Check should be made by measurement of anti-factor Xa.
61971728|NCT01727453|ACTIVE_COMPARATOR|Warfarin|which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
61971729|NCT06124144|EXPERIMENTAL|Oleylphosphocholine capsules (IMP) oral administration|Participants will receive once Oleylphosphocholine (capsule/s) orally as a single dose under fed conditions.
62708000|NCT04153487|PLACEBO_COMPARATOR|Control Group|Control group (n=40)
62708001|NCT03981276||Primary participant:|"Participants affected by hereditary spastic paraplegia (HSP) or a phenotypically related disorder Primary participants will be followed at annual intervals. The workup includes clinical, imaging, sensor-based, patient/observer reported and molecular outcome parameters and biosampling.~Participants with unknown genetic diagnosis may receive genetic testing including whole exome or whole genome sequencing and other OMICS techniques."
61971730|NCT05486858||LBP individuals|People who suffer from pain in the lower back area.
62708002|NCT03981276||Secondary participant/ First or second-degree|First or second degree unaffected family members of primary participants. Secondary participants may undergo the same study procedures as primary participants.
62708003|NCT03981276||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as primary participants.
61971731|NCT05486858||asymptomatic individuals|People who has no low back pain in the patient history.
61971732|NCT02064868|EXPERIMENTAL|Serelaxin + Standard of Care|Serelaxin (30 µg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.
61971733|NCT02064868|OTHER|Standard of Care (SOC)|All patients were required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
61971734|NCT01113801|PLACEBO_COMPARATOR|Placebo|
62708004|NCT03035630|EXPERIMENTAL|Avelumab then Sunitinib for Investigational Arm A|"First-Line Medication:~* Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~  * Subjects will have a mandatory an inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~* Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
61971735|NCT01113801|EXPERIMENTAL|2 mg LY2382770|
61971736|NCT01113801|EXPERIMENTAL|10 mg LY2382770|
61971737|NCT01113801|EXPERIMENTAL|50 mg LY2382770|
61971738|NCT03211416|EXPERIMENTAL|Treatment (sorafenib tosylate, pembrolizumab)|Patients receive sorafenib tosylate PO BID on days -28 to -1 and 1-21. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
61971739|NCT01648205|EXPERIMENTAL|Placebo followed by Ranolazine Administration|Placebo for 1 month and Ranolazine for 5 months.
61971740|NCT06471816|EXPERIMENTAL|Intervention kindergartens|Participants (parents of kindergarten children) will take part in the biannual DBED parent-teacher meetings.
61971741|NCT06471816|ACTIVE_COMPARATOR|Control kindergartens|Participants (parents of kindergarten children) will take part in traditional parent-teacher meetings.
61971742|NCT02525341|EXPERIMENTAL|Yoga Group|Participants in the yoga group received a total of eight weekly 45 minute yoga classes. A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session. Handouts were provided for participants to practice the yoga program for additional 30 minutes a day, 4 days a week at home.
61971743|NCT02525341|ACTIVE_COMPARATOR|Aerobic and Strengthening Exercise Group|Participants in the exercise group received a total of eight weekly 45 minute exercise classes. A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants. Handouts were provided for participants to practice the program at home for 30 minutes a day, 3 days a week (on non-consecutive days).
61971744|NCT02525341|ACTIVE_COMPARATOR|General education|Participants in this group received a one-time OA educational brochures from the Arthritis Foundation including topics focusing on the disease process, diet and exercise and OA management education. Participants were instructed not to begin any new exercise programs during the study period.
62708005|NCT03035630|EXPERIMENTAL|Sunitinib then Avelumab for Investigational Arm B|"First-Line Medication:~* Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~  * Subjects will have a mandatory inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~* Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
61971745|NCT04084301|NO_INTERVENTION|Normal CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.4 L/min/m2 throughout the CPB period.
61971746|NCT04084301|EXPERIMENTAL|High CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.9 L/min/m2 throughout the CPB period.
61971747|NCT00632242|EXPERIMENTAL|TTP Remission Cohort 1|Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL
61971748|NCT00632242|EXPERIMENTAL|TTP Remission Cohort 2|Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL
61971749|NCT00632242|EXPERIMENTAL|TTP Remission Cohort 3|Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL
62146649|NCT06272032|PLACEBO_COMPARATOR|Placebo|For patients in the Placebo treatment group, treatment is provided based on the severity of their symptoms, following the protocols outlined in the Allergic Rhinitis (AR) diagnosis and treatment guidelines. Patients are administered intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines, as appropriate, in accordance with the severity of their symptoms.
62352451|NCT01817114|SHAM_COMPARATOR|SHAM Remote Ischemic Conditioning|Sham conditioning will involve the AutoRIC device being placed on the right arm and will inflate to a pressure of 10mmHg for 5 minutes (ie. no limb ischemia will occur). The device will then auto-deflate, completing one cycle. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
62708006|NCT00906763|ACTIVE_COMPARATOR|Dark Chocolate (85% cocoa)|Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
62352452|NCT00525239|EXPERIMENTAL|1: Ritonaivr|Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir
62352453|NCT05396794||Control Group|If the patient is in group 1, she will get standard education for weight loss, which will be provided by her Gynecologic Oncologist. This will take about 15 minutes.
62708007|NCT00906763|ACTIVE_COMPARATOR|White chocolate (0% cocoa)|Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.
62708008|NCT04194450|EXPERIMENTAL|Ketone monoester|Acute dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.3 g/kg body weight)
62708009|NCT04194450|PLACEBO_COMPARATOR|Placebo|Acute dose of flavour-matched placebo.
62708010|NCT00588432||1|Hemiparesis as the result of an ischemic hemispheric stroke.
61971750|NCT00632242|EXPERIMENTAL|Acute TTP Cohort 4|Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL
61971751|NCT00632242|EXPERIMENTAL|vWD-Type2b Cohort 5|Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.
61971752|NCT05717374|ACTIVE_COMPARATOR|Group Dexamethasone|will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) for caudal block
61971753|NCT05717374|EXPERIMENTAL|Group Methylprednisolone|will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) for caudal block
62352454|NCT05396794||Video Group|If the patient is in group 2, she will get standard education for weight loss provided by her Gynecologic Oncologist. Then she will be asked to view a 15-minute video to get information regarding obesity, the relationship of obesity and endometrial cancer, and the safety and benefits of bariatric surgery. These will take about 30 minutes.
62352455|NCT05424185||type 1 scapular dyskinesis|type 1 scapular dyskinesis classified by dyskinesis classification test
62352456|NCT05424185||type 2 scapular dyskinesis|type 2 scapular dyskinesis classified by dyskinesis classification test
62352457|NCT05424185||type 3 scapular dyskinesis|type 3 scapular dyskinesis classified by dyskinesis classification test
61971754|NCT03627533|EXPERIMENTAL|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on MA-IC3 endocrine (ear points), GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
62352458|NCT05424185||type 4 scapular dyskinesis|type 4 scapular dyskinesis classified by dyskinesis classification test
62352459|NCT02307539|EXPERIMENTAL|Supportive care (PCPI intervention)|"Patients receive a handbook titled Supporting You During Cancer Treatment with educational material on QOL issues. Patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. At the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs."
61971755|NCT03627533|SHAM_COMPARATOR|Sham electroacupuncture|Sham electroacupuncture are done at same electroacupuncture point location but puncture are not done, also electro stimulator are turned off.
61971756|NCT04981743|NO_INTERVENTION|group 1|Twenty five patients will be administered only the standard treatment regimen according to Ministry Of Health, and Population management protocol for COVID-19 patients (November 2020).
62352460|NCT03379480|ACTIVE_COMPARATOR|Yoga arm|Patients with Schizophrenia will undergo 12 sessions of yoga. According to randomization one group of patients will start yoga immediately after recruitment ,whereas another group will go into wait list for 12 weeks after which they will also undergo Yoga treatment.
62352461|NCT03379480|NO_INTERVENTION|Control arm|Healthy volunteers who will not receive yoga.
62352462|NCT05650515||Experts|A panel of experts in the geriatric field consisting of older adults (65+ years) as well as experts (geriatric rehabilitation/medicine/research)
62708011|NCT00588432||2|Immobilization following severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain.
62708012|NCT00588432||3|Myofascial trigger points in trapezius muscle.
62511506|NCT01131962|ACTIVE_COMPARATOR|sclerotherapy group|This group will have immediate control of hematemesis by endoscopic sclerotherapy
62511507|NCT03074864|EXPERIMENTAL|EGFR-mutant IIIA/IIIB NSCLC|Erlotinib Hydrochloride 150mg daily intercalated with radiotherapy
62511508|NCT02181296|ACTIVE_COMPARATOR|High concentration group|0.2% ropivacaine
62708013|NCT00588432||4|Hyperthyroid Myopathy
62708014|NCT03235050|EXPERIMENTAL|MEDI0382 low dose + Metformin|Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
62708015|NCT03235050|EXPERIMENTAL|MEDI0382 mid dose + Metformin|Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
62708016|NCT03235050|EXPERIMENTAL|MEDI0382 high dose + Metformin|Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
62708017|NCT03235050|PLACEBO_COMPARATOR|Placebo + Metformin|Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
62708018|NCT03235050|ACTIVE_COMPARATOR|Liraglutide + Metformin|Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
61971757|NCT04981743|ACTIVE_COMPARATOR|group 2|Twenty five patients will be administered a single dose (900mg) of Nigella Sativa capsule twice daily plus standard therapy
61971758|NCT04981743|ACTIVE_COMPARATOR|group 3|Twenty five patients will be administered a single dose (2000 IU) of vitamin D3 tablet once daily plus standard therapy
61971759|NCT04981743|ACTIVE_COMPARATOR|group 4|Twenty five patients will be administered a single dose (900 mg) of Nigella Sativa capsule twice daily, and single dose of vitamin D3 tablet (2000 IU) once daily plus standard therapy.
61971760|NCT02289898|EXPERIMENTAL|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
61971761|NCT02289898|EXPERIMENTAL|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
61971762|NCT02289898|EXPERIMENTAL|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
61971763|NCT01959789||Control|Standard treatment
62352463|NCT01371526|EXPERIMENTAL|Synacthen|active treatment
61971764|NCT01959789||2 days|bleaching treatments made in 2 days
62511509|NCT02181296|ACTIVE_COMPARATOR|Lower concentration group|0.1% ropivacaine
62352464|NCT05353868||Early PD|"1. Recruited in the baseline study as a subject of the Early PD group~2. Completed baseline assessment and stool sample collection~3. Being capable of giving informed consent for participation of the study"
62511510|NCT04847596||participants with RMS treated with ofatumumab|Relapsing MS participants receiving a full course (two doses) of a COVID-19 mRNA vaccine after starting ofatumumab 20 mg subcutaneous treatment
62511511|NCT02624167|ACTIVE_COMPARATOR|NW-3509A|Patients will start on NW-3509A 15 mg BID and be up-titrated to 20mg, and 25mg BID dependent on tolerability.
62511512|NCT02624167|PLACEBO_COMPARATOR|Placebo|Patients will receive matching placebo BID
62511513|NCT03327090|EXPERIMENTAL|Experimental Kinesio Tape|"The Kinesio Tape original brand was used in this study (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque). The application of the experimental Kinesio Tape was as Dr. Kenzo Kase demonstration for muscle facilitation (Kase. et al., 2003):~1. Gluteal maximus muscle.~2. Quadriceps muscle.~3. Gastrocnemius muscle and soleus muscle (triceps surae).~The tape was in tension (15%- 35%) and the muscles were stretched during the application."
62511514|NCT03327090|SHAM_COMPARATOR|Sham Kinesio Tape|"Same tape brand was used, but different application techniques were utilized for the three muscles.~1. Gluteal maximus muscle.~2. Quadriceps muscle.~3. Gastrocnemius muscle and soleus muscle (triceps surae).~There were no tension on the tape and no muscle stretching during the application."
62511515|NCT05254158|EXPERIMENTAL|NNC0174 0833 1.8 mg|Each participant will receive one single dose of NNC0174 0833
62511516|NCT05254158|EXPERIMENTAL|NNC0174 0833 0.9 mg|Each participant will receive one single dose of NNC0174 0833
62511517|NCT05254158|EXPERIMENTAL|NNC0174 0833 0.3 mg|Each participant will receive one single dose of NNC0174 0833
62352465|NCT05353868||iRBD|"1. Recruited in the baseline study as a subject of the iRBD group~2. Completed baseline assessment and stool sample collection~3. Being capable of giving informed consent for participation of the study"
62352466|NCT05353868||First degree relatives of patient with iRBD|"1. Recruited in the baseline study as a subject of the 'First degree relatives of patients with iRBD' group~2. Completed baseline assessment and stool sample collection~3. Not cohabiting with iRBD proband"
62352467|NCT05353868||Health control|"1. Recruited in the baseline study as a subject of the 'healthy controls' group~2. Completed baseline assessment and stool sample collection~3. Being capable of giving informed consent for participation of the study"
62352468|NCT02615067|EXPERIMENTAL|99mTc-MIP-1404 Injection|20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
62708019|NCT06179537|EXPERIMENTAL|Cohort 1|10 Japanese and 8 Caucasian subjects. 8 out of 10 Japanese subjects will receive BLU-5937 Dose A and 2 will receive placebo. All Caucasian subjects will receive BLU-5937 Dose A.
62708020|NCT06179537|EXPERIMENTAL|Cohort 2|8 Japanese subjects. 6 out of 8 will receive BLU-5937 Dose B and 2 will receive placebo.
62708021|NCT06179537|EXPERIMENTAL|Cohort 3|8 Japanese subjects. 6 out of 8 will receive BLU-5937 Dose C and 2 will receive placebo.
62708022|NCT04787315|ACTIVE_COMPARATOR|Intensive rehabilitation without workstation|
62708023|NCT04787315|EXPERIMENTAL|Intensive rehabilitation with workstations|
62708024|NCT01394159|ACTIVE_COMPARATOR|22G ProCore biopsy needle|Using the 22G ProCore needle for sampling pancreatic mass lesions, the tissue obtained will be compared to the standard FNA needle.
62708025|NCT01394159|ACTIVE_COMPARATOR|22G standard FNA needle|Using the 22G standard fine needle aspiration needle (FNA) for sampling pancreatic mass lesions, the tissue obtained will be compared to the 22 G ProCore needle.
62708026|NCT04337047||Vik sein|Vik sein users
62708027|NCT04337047||Vik asthme|Vik asthme users
62511518|NCT04881162|EXPERIMENTAL|NOVIS Transcarotid Neuroprotection System (NPS)|Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS.
62708028|NCT04337047||Vik migraine|Vik migraine users
61971765|NCT03024450||HER2 positive AGC treated with H+CT|HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.
62708029|NCT04337047||Vik depression|Vik depression users
62708030|NCT06408376|EXPERIMENTAL|physiological umbilical cord clamping|Immediately after birth, the newborn will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and will be intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation \>85% and HR\>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped and the procedures continued usual reception steps according to the unit´s CDH reception protocol.
61971766|NCT03866005|PLACEBO_COMPARATOR|Placebo Arm - Standard Treatment|50 subjects with center-involved diabetic macular edema (CI-DME) and scheduled for treatment with intravitreal injection of anti-VEGF agents will receive softgel placebo containing canola oil, 2 capsules per day during the study duration
61971767|NCT03866005|EXPERIMENTAL|Experimental Arm - 2 DiVFuSS formula softgel capsules|50 subjects receiving two DiVFuSS softgels per day
61971768|NCT03866005|EXPERIMENTAL|Experimental Arm - 4 DiVFuSS formula softgel capsules|50 subjects receiving 4 DiVFuss softgels per day
61971769|NCT04912947|ACTIVE_COMPARATOR|Dietary supplement|One cp/day of the IMMUSYSTEM food supplement for 3 months
61971770|NCT04912947|PLACEBO_COMPARATOR|Placebo|One cp/day of Placebo for 3 months
62708031|NCT06408376|NO_INTERVENTION|usual reception|Immediately after birth, the newborn is placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact will be intubated. According to the unit´s CDH reception protocol, patients with CDH cord clamping is done post intubation
61971771|NCT03003936|EXPERIMENTAL|Early Dinner Timing|Test the lack of concurrence of meal timing with endogenous melatonin concentrations
61971772|NCT03003936|EXPERIMENTAL|Late Dinner Timing|Test the concurrence of meal timing with elevated endogenous melatonin concentrations
61971773|NCT06495047||COPD cohort|Males and females aged 40 or greater with any severity of airflow obstruction (GOLD 1-4) who are currently experiencing and receiving treatment for a physician-diagnosed acute exacerbation (AECOPD) with both long-acting and short-acting bronchodilators prescribed by the treating team.
61971774|NCT02216188|EXPERIMENTAL|A: AFFITOPE® PD01A + Adjuvant|one injection of 15µg AFFITOPE® PD01A/ adjuvanted
61971775|NCT02216188|EXPERIMENTAL|B: AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/ adjuvanted
61971776|NCT02216188|OTHER|Control|Untreated control group
62352469|NCT06327620|EXPERIMENTAL|Daivobet Ointment|Daivobet Ointment Arm: Patients in this arm will be asked to topically apply Daivobet ointment three times daily for four weeks
62511519|NCT04625192|EXPERIMENTAL|Sinus lifting with trephine osteotomy|
62352470|NCT06327620|ACTIVE_COMPARATOR|Topical steroids|Patients in this arm will be asked to topically apply a steroid ointment three times daily for four weeks.
62511520|NCT00519922|EXPERIMENTAL|1|KBA = Kinesthesia, Balance, Agility Exercise Training
62511521|NCT00519922|ACTIVE_COMPARATOR|2|Standard Lower Extremity Strength Training
62511522|NCT02440035|EXPERIMENTAL|Group 1|Two subsequent Intramuscular injections of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10\^10 vp) on Day 169.
62511523|NCT02440035|EXPERIMENTAL|Group 2|Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 vp) on Day 1, an intramuscular injection of placebo control on Day 85 and an injection of Ad35.RSV.FA2 (1x10\^11 vp) on Day 169.
62708032|NCT03601299|EXPERIMENTAL|Traditional food arm|Traditional food-focused menu
62708033|NCT03601299|NO_INTERVENTION|Non-intervention arm|Standard RurAL CAP menu
62708034|NCT02554955|EXPERIMENTAL|Daclizumab + Mycophenolate mofetil|Participants will receive intravenous (IV) daclizumab (2 milligrams per kilogram \[mg/kg\] within 6 hours after transplantation and 1 mg/kg every 2 weeks for a total of five doses), along with mycophenolate mofetil (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg twice daily \[BID\] within first week and 1 grams per day \[g/day\] BID from second week onwards) and sirolimus (3 mg/day) for 6 months.
61971777|NCT01585194|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
61971778|NCT00603993|EXPERIMENTAL|Adalimumab|Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 \[NCT 00235872\]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
61971779|NCT01169974||healthy volunteers|
61971780|NCT03918590|ACTIVE_COMPARATOR|A single drop of nepafenac 0.3% suspension|A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
61971781|NCT03918590|OTHER|Patching|A light pressure patch applied for two hours
61971782|NCT03918590|PLACEBO_COMPARATOR|A single drop of preservative-free Artificial Tears|A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).
61971783|NCT02638727|ACTIVE_COMPARATOR|Drug Arm|This group treat with L-Citrulline (3 grams per day)
61971784|NCT02638727|PLACEBO_COMPARATOR|Placebo Arm|this group treat with placebi every day
61971785|NCT03070782|EXPERIMENTAL|Cohort A: ISIS 681257: 20 mg Q4W|Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
61971786|NCT03070782|EXPERIMENTAL|Cohort B: ISIS 681257: 40 mg Q4W|Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
61971787|NCT03070782|EXPERIMENTAL|Cohort C: ISIS 681257: 60 mg Q4W|Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
62708035|NCT03350464|EXPERIMENTAL|Pain in PD Arm|This arm will receive a total 10 sessions of TMS stimulation over 10 weeks. Pre and post intervention scales will be performed on week one and week 10.
62708036|NCT01347060||Medicare-eligible subjects with asthma|Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.
62708037|NCT04101773|OTHER|Rubber Band Ligation (RBL)|RBL is generallya simple, inexpensive procedure. It entails a ligation of haemorrhoids using rubber bands. In RBL, a disposable suction device applies a rubber band at least 2 cm proximal to the dentate line at the base of each haemorrhoidal cushion by using an anoscope. The banding process causes necrosis of the banded tissue and slough. The resultant inflammatory reaction causes refixation of the mucosa to the underlying tissue, helping to eliminate haemorrhoidal prolapse.The end result is a return of the haemorrhoidal cushions to a more normal size and configuration, with resolution of haemorrhoidal symptoms.
62708038|NCT04101773|OTHER|Sutured mucopexy|A sutured mucopexy is an operation performed under general anaesthesia. At 4 cm proximal of the dentate line, a Z- shaped stitch through the rectal wall is placed and then at the upper level of the haemorrhoidal tissue, pulling up the prolapsing haemorrhoid high into the anal canal.
62708039|NCT04101773|OTHER|Haemorrhoidectomy|Haemorrhoidectomy involves excision of the haemorrhoidal tissue. An elliptical incision is made in the external haemorrhoidal tissue extending proximally through the dentate line to the upper limit of the haemorrhoids. The base of the haemorrhoidal complex is ligated and the haemorrhoid is excised.
62708040|NCT02002325|EXPERIMENTAL|Alteplase|Intravenous tissue-type plasminogen activator (alteplase)
61971788|NCT03070782|EXPERIMENTAL|Cohort D: ISIS 681257: 20 mg Q2W|Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
61971789|NCT03070782|EXPERIMENTAL|Cohort E: ISIS 681257: 20 mg QW|Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
61971790|NCT03070782|PLACEBO_COMPARATOR|Placebo|Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).
61971791|NCT00647790||1|Patients with a confirmed diagnosis of invasive breast cancer who are undergoing surgery.
61971792|NCT03152851|EXPERIMENTAL|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior \& posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
61971793|NCT03152851|NO_INTERVENTION|Non-pressure stimulus group|No pressure stimulus would be given
61971794|NCT04101825|EXPERIMENTAL|Auralya|Auralya® 25 (Cross-linked Hyaluronic Acid) Injection
61971795|NCT04565860|ACTIVE_COMPARATOR|X-tra fil (bulk-filling) (X-traB)|X-tra fil composite placed as bulk-filling
61971796|NCT04565860|ACTIVE_COMPARATOR|X-tra fil (incremental) (X-traI)|X-tra fil composite placed as incremental
61971797|NCT04565860|ACTIVE_COMPARATOR|Filtek Bulk (bulk-filling) (FBB)|Filtek Bulk composite placed as bulk-filling
61971798|NCT04565860|ACTIVE_COMPARATOR|Filtek Bulk (incremental) (FBI)|Filtek Bulk composite placed as incremental
61971799|NCT05077397|ACTIVE_COMPARATOR|Group 1|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 1 will be monitored by the InSpectra Tissue Spectrometer, StO2, added to standard ASA monitorisation."
61971800|NCT05077397|ACTIVE_COMPARATOR|Group 2|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by O3TM Regional Oximeter System, added to standard ASA monitorisation."
61971801|NCT05077397|NO_INTERVENTION|Group 3|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by standard ASA monitorisation."
61971802|NCT04232124|EXPERIMENTAL|Hypertension Management Model|Aim 1. Execute a smaller version of the LA Barbershop BP Study through the new Nashville network as the test case for: A) recruiting regular patrons with uncontrolled HTN, B) conducting a research protocol and evaluating a HTN intervention; and C) creating a local registry of potential subjects as platform for enrolling black men in future research studies.
61971803|NCT03755102|EXPERIMENTAL|Cohort 1: Participants treated with dacomitinib alone|Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.
61971804|NCT03755102|EXPERIMENTAL|Cohort 2: Participants treated with dacomitinib in combination with osimertinib|Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation
61971805|NCT03589443|EXPERIMENTAL|Multiplexed heptapeptides|QRH \& KSP sprayed onto area of interest and imaged before and after application
61971806|NCT02965547|EXPERIMENTAL|RIPC Group|RIPC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take RIPC intervention, blood collection and 7 dCA measurements.
61971807|NCT05044598|OTHER|RAFT-OS|"Single-arm trial is to investigate if RAFT-OS ((Real Architecture for 3D Tissues Ocular Surface) is a safe and effective alternative treatment for patients with aniridia related keratopathy (ARK) in 21 patients.~The RAFT-OS will be transplanted into the participants worst affected eye. Following surgery, each participant will be assessed at days 1, 7, 14, 21, and 1-month for major or intermediate safety events. Participants will continue to be followed up to 12 months after transplantation and will be required to stay on the immune suppression therapy for the duration of the trial."
62352471|NCT01617655|PLACEBO_COMPARATOR|Placebo Q2W|Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
62352472|NCT01617655|EXPERIMENTAL|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.
62708041|NCT02002325|OTHER|Standard Care|Standard treatment for acute stroke
62708042|NCT02862886|OTHER|N°1|
62708043|NCT03120845|EXPERIMENTAL|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
62708044|NCT03120845|EXPERIMENTAL|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
62708045|NCT06458569||healthy subjects|subjects with NRS\<5
62708046|NCT06458569||patients with cronical pain|patients with NRS\>5
61971808|NCT03023475|ACTIVE_COMPARATOR|LigaSure endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the LigaSure device.
62708047|NCT04864691|EXPERIMENTAL|endovascular recanalization plus standard medical treatment|patients with symptomatic non-acute intracranial artery occlusion treated by endovascular recanalization and standard medical treatment after procedure
61971809|NCT03023475|ACTIVE_COMPARATOR|TLS2 endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the TLS2 device.
62511524|NCT02440035|EXPERIMENTAL|Group 3|One intramuscular injection of Ad35.RSV.FA2 (1x10\^11 vp) on Day 1 and an intramuscular injection of placebo control on Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10\^10 vp) on Day 169.
62511525|NCT02440035|EXPERIMENTAL|Group 4|Two subsequent intramuscular injections of placebo control on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169.
62511526|NCT04969042|EXPERIMENTAL|Stimulation|Participants will receive pre-implantation rehabilitation, implantation of the closed-loop spinal cord stimulator, and stimulation (according to the functional mapping) assisted rehabilitation post-implantation during the trial.
62511527|NCT04682509|EXPERIMENTAL|Study group|All study subjects will receive glecaprevir/pibrentasvir (Mavyret®) 300/120 mg orally x 14 days, starting on POD 0 prior to transplantation of the HCV positive kidney. If HCV RNA is detectable after 2 weeks of therapy, Mavyret® will be continued to complete a full course of 8 weeks per standard of care. Safety monitoring and frequent surveillance for HCV viremia will occur for all subjects throughout the duration of the study. The kidney transplantation procedure and routine post-transplant management will be performed per standard of care.
62708048|NCT04864691|ACTIVE_COMPARATOR|standard medical treatment|Patients take aspirin 100 mg/day or clopidogrel 75mg/day for the entire follow-up period (EVR patients take aspirin 100 mg/day and clopidogrel 75mg/day for 30-90 days after procedure)
61971810|NCT03934931|EXPERIMENTAL|Facilitated Directly Observed Therapy (DOT)|Facilitated DOT arm participants will attend the Mulago Immune Suppression Syndrome (ISS) clinic on a weekly basis to ingest 3HP medication under direct observation. DOT will be defined as a designated clinic staff member observing ingestion of each dose of 3HP. Additionally, participants randomized to facilitated DOT will receive: 1) DOT cards with instructions to present directly to the pharmacy for a pharmacy-only visit, without the need to wait in the general queue; 2) Automated short message service (SMS) or phone call reminders at no cost to participants the day before each appointment, 3) A fixed level of reimbursement (\~$5/visit) for each weekly visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
62352473|NCT01602549|EXPERIMENTAL|Cohort|1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days
62352474|NCT06051825||Patients with acute appendicitis|Patients with acute appendicitis, after surgery and with pathohistological confirmation
62352475|NCT06051825||Patients without acute appendicitis|Patients without acute appendicitis, after laboratory, clinical and/or radiological exclusion of acute admittance
62352476|NCT00776555|EXPERIMENTAL|Vyvanse™|50mg capsule that has been emptied and made into solution
62352477|NCT00776555|EXPERIMENTAL|ADDERALL XR®|20mg capsule that has been emptied, crushed, and made into solution
62352478|NCT04134741|EXPERIMENTAL|Kinetic Control Group|"The players participated in the classic training and for 4 weeks (3 times a week) underwent the Kinetic Control neuromuscular training with assistance of a physical therapist.~The duration of one training was 20-30 minutes."
62352479|NCT04134741|NO_INTERVENTION|Traditional Training Group|Players participated in the classic training.
62352480|NCT03713216|EXPERIMENTAL|Naldebain|Subjects will receive one dose of Naldebain before surgery.
62352481|NCT03713216|ACTIVE_COMPARATOR|Morphine|Subjects will receive morphine after surgery.
62352482|NCT02993458|EXPERIMENTAL|DASH diet-Low Na diet|DASH style diet, low sodium (1500 mg/d).
62352483|NCT02993458|ACTIVE_COMPARATOR|DASH diet-High Na diet|DASH style diet, high sodium (3500 mg/d).
62352484|NCT02993458|ACTIVE_COMPARATOR|Usual diet-Low Na diet|Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
62352485|NCT02993458|ACTIVE_COMPARATOR|Usual diet-High Na diet|Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).
62352486|NCT03053726|EXPERIMENTAL|Variable Frequency Stimulation|Subjects in this group received variable frequency stimulation of deep brain stimulation
62352487|NCT03053726|SHAM_COMPARATOR|Constant Frequency Stimulation|Subjects in this group received constant frequency stimulation of deep brain
62352488|NCT01078987|ACTIVE_COMPARATOR|Group 1|One to three 5-day course of plasma exchange (plasmapheresis)
62352489|NCT01078987|ACTIVE_COMPARATOR|Group 2|One to three 5-day course of plasma exchange (plasmapheresis)
62352490|NCT01078987|NO_INTERVENTION|Group 3|No intervention taken
62352491|NCT01078987|ACTIVE_COMPARATOR|Group 4|One to three 5-day course of plasma exchange (plasmapheresis)
62352492|NCT04671615||Patients with metastatic, HR+/HER2- breast cancer.|Patients who initiated first or subsequent lines of treatment with palbociclib
62352493|NCT04373785|EXPERIMENTAL|NG101m and standard treatment|"Concomittant therapy:~Radiation therapy, oral temozolomide, and oral NG101m~Adjuvant therapy:~Oral temozolomide and oral NG101m"
62352494|NCT02713789|ACTIVE_COMPARATOR|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
62352495|NCT02713789|PLACEBO_COMPARATOR|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
62352496|NCT06253234|EXPERIMENTAL|Treatment Sequence A|
62352497|NCT06253234|EXPERIMENTAL|Treatment Sequence B|
62352498|NCT00067613|ACTIVE_COMPARATOR|Intervention|Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.
62352499|NCT00067613|PLACEBO_COMPARATOR|Control|Clinical sites randomized to Control will continue with their normal management practices for BPD.
62352500|NCT01768312|ACTIVE_COMPARATOR|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
62352501|NCT01768312|EXPERIMENTAL|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
61971811|NCT03934931|EXPERIMENTAL|Facilitated Self-Administered Therapy (SAT)|Facilitated SAT participants will take their 1st dose of medication under direct observation and be given a 4-week 3HP supply to take weekly via self-administration. Participants will return to the Mulago ISS clinic after completing their 5th dose to review adherence data with the clinic pharmacy technician and receive 5 additional 3HP doses (doses 7-11). At the scheduled refill visit (dose 6) and end-of-treatment visit (dose 12) participants will ingest 3HP via direct observation. Participants will also receive: 1) Free automated SMS reminders or phone call reminders before each scheduled dose; 2) Weekly check-ins inquiring about side effects via two-way SMS with a follow-up phone call depending on participant response, 3) Fixed level of reimbursement (\~$5/visit) for the refill/end-of-treatment visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
62511528|NCT03920683||Diabete type 1 and 2|Data collection from patients treated in the diabetes department, in Pitié-Salpêtrière hospital, and adressed for a one-day hospitalization to assess cardiovascular comorbidities.
62511529|NCT06616935|OTHER|Routine referrals to community activities|"Routine referrals to community activities following receiving reablement and being discharged without further action.~Intervention group 1 referrals to community activities."
62352502|NCT03496129|EXPERIMENTAL|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
62511530|NCT06616935|OTHER|Online exercises and activity|Online exercises and activity group.
62511531|NCT04664816|EXPERIMENTAL|n-3PUFAs group|These patients will receive omega-3 plus (1200 mg) orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
62146650|NCT03014791||Healthy Volunteers|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~* Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~* Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~* Acetylcholine: 7.5μg/min, 15μg/min and 30μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~* Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~* LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
62352503|NCT03496129|EXPERIMENTAL|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
62352504|NCT03496129|ACTIVE_COMPARATOR|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
62352505|NCT04843969|EXPERIMENTAL|Stress task and smoking cue|Exposure to a psychosocial stress task followed by smoking video cues
62352506|NCT04843969|EXPERIMENTAL|Stress task and neutral cue|Exposure to a psychosocial stress task followed by neutral video cues
62352507|NCT04843969|ACTIVE_COMPARATOR|Control task and smoking cue|Exposure to a control task followed by smoking video cues
62352508|NCT04843969|ACTIVE_COMPARATOR|Control task and neutral cue|Exposure to a control task followed by neutral video cues
62352509|NCT03373110|EXPERIMENTAL|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
62352510|NCT03373110|EXPERIMENTAL|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
62352511|NCT03373110|ACTIVE_COMPARATOR|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
62352512|NCT01887106|EXPERIMENTAL|GLPG1205 single dose|Single oral dose of GLPG1205 suspension - ascending doses
62352513|NCT01887106|PLACEBO_COMPARATOR|Placebo single dose|Single oral dose of placebo suspension
62352514|NCT01887106|EXPERIMENTAL|GLPG1205 multiple doses|Multiple oral doses of GLPG1205 suspension - ascending doses
62352515|NCT01887106|PLACEBO_COMPARATOR|Placebo multiple doses|Multiple oral doses of placebo suspension
62352516|NCT00108953|EXPERIMENTAL|Sorafenib + Doxorubicin|"Sorafenib + Doxorubicin -- combination therapy: Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
62352517|NCT00108953|ACTIVE_COMPARATOR|Placebo + Doxorubicin|"Placebo + Doxorubicin -- monotherapy: Sorafenib (Nexavar, BAY43-9006) matching placebo tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
62708049|NCT05471921|EXPERIMENTAL|SBIRT|Experimental condition: Participants residing in the study community (displaced and host population) will receive Screening, Brief Intervention, and Referral to Treatment (SBIRT). The treatment will consist of brief intervention (CETA-BI) and full Common Elements Treatment Approach (CETA) depending on the severity of the participant's substance use.
62352518|NCT04861311|EXPERIMENTAL|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
62352519|NCT04861311|NO_INTERVENTION|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
62352520|NCT04782037|EXPERIMENTAL|L-methylfolate supplementation|Children under 1 year of age in group A will receive 3 drops (90mcg) of L-methylfolate calcium) while those older than 1 year of age will be given 5 drops (150mcg) daily fior 5 days
62352521|NCT04782037|PLACEBO_COMPARATOR|distilled water|Subjects in Group B will receive equal amount of distilled water as placebo (i.e. 3 drops to \<1yr age and 5 drops to \>1 yr.
62352522|NCT04720495|ACTIVE_COMPARATOR|One stage ridge splitting|
62352523|NCT04720495|EXPERIMENTAL|Two-stage ridge splitting|
62352524|NCT03009240|EXPERIMENTAL|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
62352525|NCT03278652||Patient with renal colic|
62352526|NCT00222742|EXPERIMENTAL|A|Induced moderate hypothermia (32-33 C)
62352527|NCT01170702|PLACEBO_COMPARATOR|Group 1|TAP Block utilizing 15mL of 0.9% normal saline per side
62352528|NCT01170702|EXPERIMENTAL|Group 2|TAP Block utilizing 15ml of 0.2% ropivacaine per side
62352529|NCT01170702|EXPERIMENTAL|Group 3|TAP Block utilizing 15ml of 0.5% ropivacaine per side
62352530|NCT01170702|EXPERIMENTAL|Group 4|TAP Block utilizing 15ml of 0.75% ropivacaine per side
62352531|NCT01646398|EXPERIMENTAL|>= 65-year age group-13vPnC|
62352532|NCT01646398|ACTIVE_COMPARATOR|>= 65-year age group-23vPS|
62352533|NCT00992602|EXPERIMENTAL|Treatment (liposomal cytarabine, high-dose methotrexate)|See Detailed Description
62352534|NCT01645085|EXPERIMENTAL|Treatment A|100mg MCC-based 13% drug-loaded tablets
62352535|NCT01645085|EXPERIMENTAL|Treatment B|100mg mannitol-based 38% drug-loaded tablets
62352536|NCT01645085|EXPERIMENTAL|Treatment C|150mg MCC-based 13% drug-loaded tablets
62352537|NCT01645085|EXPERIMENTAL|Treatment D|150mg mannitol-based 38% drug-loaded tablets
62352538|NCT00003595|EXPERIMENTAL|Arm I|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 3 and oral prednisone on days 3-7. Patients receive rituximab on day 1. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response in the absence of disease progression or unacceptable toxicity. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy with rituximab followed by radiotherapy beginning 3 weeks after completion of the third course. Patients who achieve partial response for a minimum of 28 days or complete response receive maintenance rituximab IV beginning on day 28 of the final course of chemotherapy. Maintenance rituximab treatment repeats every 4 weeks for 3 courses.
62352539|NCT00003595|ACTIVE_COMPARATOR|Arm II|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy. Patients receive radiotherapy beginning 3 weeks after completion of the third course of chemotherapy.
62352540|NCT00545480|EXPERIMENTAL|1|
61971812|NCT03934931|EXPERIMENTAL|Patient Choice between facilitated DOT and facilitated SAT|Participants randomized to the Patient Choice between facilitated DOT and facilitated SAT arm will be offered a choice between arms 1 and 2. A research nurse will review each section of the decision aid with participants, discuss values and preferences, and, after addressing any questions, ask participants to select facilitated DOT or facilitated SAT. Participants will have the option to switch between DOT and SAT at any time. The reason for switching and time spent under each strategy will be recorded.
62352541|NCT00545480|ACTIVE_COMPARATOR|2|
62352542|NCT05138237|ACTIVE_COMPARATOR|benign stricture|"no of cases suspected to be benign by using the diagnostic tools imaging , laboratory investigations , ERCP ,brushing ,cytology or histopathology"
62352543|NCT05138237|ACTIVE_COMPARATOR|malignant stricture|"no of cases suspected to be malignant by using the diagnostic tools imaging , laboratory investigations , ERCP ,brushing ,cytology or histopathology"
62352544|NCT02017899|EXPERIMENTAL|S. sonnei 1790GAHB - 1 mcg|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
62352545|NCT02017899|EXPERIMENTAL|S. sonnei 1790GAHB - 5 mcg|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
62352546|NCT02017899|EXPERIMENTAL|S. sonnei 1790GAHB - 25 mcg|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
62352547|NCT02017899|EXPERIMENTAL|S. sonnei 1790GAHB - 50 mcg|Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
62352548|NCT02017899|EXPERIMENTAL|S. sonnei 1790GAHB - 100 mcg|Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
62352549|NCT02017899|PLACEBO_COMPARATOR|Placebo|2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo. These were pooled in one Placebo group in the analyses
62708050|NCT05471921|ACTIVE_COMPARATOR|Treatment as usual|Comparison condition: Participants residing in the study community (displaced and host population) will receive the current standard of treatment.
62708051|NCT03489694||Subjects|Each subject will undergo skin test endpoint titrations with three different testers.
62708052|NCT02429011||MDD|patients with current MDD
62708053|NCT02429011||Healthy Control (HC)|healthy control volunteers
62511532|NCT04664816|PLACEBO_COMPARATOR|Control group|These patients will receive placebo orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
61971813|NCT05526430|EXPERIMENTAL|Harmine Dose|There will be a total of seven possible doses that include 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg. Each study subject will receive a single oral dose of harmine in this single ascending dose design.
61971814|NCT01125865|ACTIVE_COMPARATOR|SEMS|Self-expandable metallic stent will be inserted for the malignant hilar obstruction.
61971815|NCT01125865|ACTIVE_COMPARATOR|DLS|DoubleLayer plastic stent (Olympus) will be inserted for malignant hilar obstruction.
62352550|NCT02271009|PLACEBO_COMPARATOR|Placebo without Al(OH)3|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~* First three SC injections at weekly intervals.~* Fourth SC injection two weeks after the third injection.~* Fifth SC injection four weeks after the fourth injection."
62352551|NCT02271009|ACTIVE_COMPARATOR|AllerT (10 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~* First three SC injections at weekly intervals.~* Fourth SC injection two weeks after the third injection.~* Fifth SC injection four weeks after the fourth injection."
62352552|NCT02271009|ACTIVE_COMPARATOR|AllerT (25 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~* First three SC injections at weekly intervals.~* Fourth SC injection two weeks after the third injection.~* Fifth SC injection four weeks after the fourth injection."
62352553|NCT02271009|ACTIVE_COMPARATOR|AllerT (50 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~* First three SC injections at weekly intervals.~* Fourth SC injection two weeks after the third injection.~* Fifth SC injection four weeks after the fourth injection."
62352554|NCT01497080||1|
62352555|NCT01497080||activity level|
62352556|NCT01497080||no treatment|
62352557|NCT04070118||patients with previous cesarean section|presenting to the emergency department with pain, previous cesarean section; Patients measured niche thickness before operation
62352558|NCT03388086||Onabotulinum 300 units|
62352559|NCT03388086||Onabotulinum 200 units|
62352560|NCT03026049|ACTIVE_COMPARATOR|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
62352561|NCT03026049|NO_INTERVENTION|conservative managment|Conservative management of complaints
62352562|NCT02978209|NO_INTERVENTION|Only moisturizer, no carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. One body half
61971816|NCT06087276|EXPERIMENTAL|Parallel Design: ulixacaltamide arm|Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 70 days of 60 mg
61971817|NCT06087276|PLACEBO_COMPARATOR|Parallel Design: placebo arm|Double-blind Part: Oral dosing, once daily in the morning: 84 days of placebo
61971818|NCT06087276|EXPERIMENTAL|Randomized Withdrawal|"Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 42 days of 60 mg~Randomized Withdrawal Part: Following double-blind part: 1:1 randomization to placebo or 60 mg ulixacaltamide for 28 days"
61971819|NCT06087276|EXPERIMENTAL|Long-term Safety Study: Essential1 rollovers|Open-label Part: Oral dosing, once daily in the morning up to one year (365 days) of 60 mg ulixacaltamide
61971820|NCT06087276|EXPERIMENTAL|Long-term Safety Study: Parallel Design and Randomized Withdrawal rollovers|"Open-label Part for patients previously on placebo: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, up to 351 days of 60 mg~Open-label Part for patients previously on 60 mg ulixacaltamide: Oral dosing, once daily in the morning up to 365 days 60 mg ulixacaltamide"
61971821|NCT02375568||103024-F|For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.
62352563|NCT02978209|ACTIVE_COMPARATOR|Moisturizer + 7,5 % carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. Other body half
62352564|NCT02138396|EXPERIMENTAL|FSS first, then FCI|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single dose of fentanyl sublingual spray (FSS) at the first visit. After a washout period of at least seven days, they receive a single intramuscular fentanyl citrate injection (FCI) at the second treatment visit.
62352565|NCT02138396|EXPERIMENTAL|FCI first, then FSS|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single intramuscular fentanyl citrate injection (FCI) at the first visit. After a washout period of at least seven days, they receive a single dose of fentanyl sublingual spray (FSS) at the second treatment visit.
62352566|NCT03865511|EXPERIMENTAL|TAGRISSO® 80mg (Osimertinib)|"Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.~Tumor biopsies performed at baseline and clinical progression. ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial."
62352567|NCT03371732|OTHER|Groupe 1|G1 : Motivational Intervention group
62352568|NCT03371732|OTHER|Groupe 2|G2 : Educational advises group
62352569|NCT02584868|EXPERIMENTAL|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
62352570|NCT02584868|ACTIVE_COMPARATOR|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
62352571|NCT03427138|EXPERIMENTAL|Jasper|JASPER (Joint Attention Symbolic Play Engagement Regulation) is a targeted intervention that focusses on early communication skills.
62352572|NCT03427138|EXPERIMENTAL|Parent Education|Parent education intervention focusses on parenting a child with autism.
62352573|NCT02790463|NO_INTERVENTION|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
62511533|NCT06126861|EXPERIMENTAL|[14C]LP-168|Using 14C-labeled LP-168 as a marker to investigate the absorption characteristic, as well as to evaluate the metabolism and elimination pathways in healthy subjects
62511534|NCT03028896|NO_INTERVENTION|standard|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
62511535|NCT03028896|EXPERIMENTAL|rotational|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
62511536|NCT00833508|EXPERIMENTAL|Test arm|Patients undergoing preoperative chemoradiotherapy will have their exercise capacity measured before and after chemoradiotherapy.
62511537|NCT00966381|OTHER|Control|The minimal care group will receive standard public health information on nutrition from the American Heart Association twice during the 16-week intervention. Upon completion of the endpoint measurement (20 weeks postpartum), they will be given all intervention materials.
62511538|NCT00966381|EXPERIMENTAL|Exercise Group|The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 weeks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-week exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
62511539|NCT03991442|EXPERIMENTAL|BR1010 and Fimasartan/Amlodipine placebo|BR1010 or Fimasartan/Amlodipine
62708054|NCT01533415|ACTIVE_COMPARATOR|Active CES treatment|Out of the total population of 150 participants,75 of them will be assigned to the active treatment group. Because this is a double-blind study it is unknown which members will belong to this group until completion of the study.
61971822|NCT06051929|EXPERIMENTAL|MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems
62708055|NCT01533415|SHAM_COMPARATOR|Sham CES treatment|Of the 150 participants in this study, half of them will be assigned to the sham treatment group. Because this is a double-blind study, it is unknown which members will be assigned to this group until the completion of the study.
62708056|NCT00650507|EXPERIMENTAL|1|
62708057|NCT00650507|ACTIVE_COMPARATOR|2|
62708058|NCT03175107|EXPERIMENTAL|PD_patients|Patients with Parkinson disease or Parkinsonism (characteristic symptoms such as rigidity, extrapyramidal symptoms), with functional disorders in upper extremities and minor problems at daily activities, with the level 2-3 in the Hoehn and Yahr Scale. They will perform exergaming at home for up to 4 weeks.
61971823|NCT06051929|NO_INTERVENTION|Waitlist control group|no intervention.
61971824|NCT00901264||1|Patients with pathological diagnoses of cancer or leukemia
61971825|NCT00901264||2|3.1.3 Patients for whom chemotherapy is planned.
62352574|NCT02790463|ACTIVE_COMPARATOR|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
62352575|NCT00265967|EXPERIMENTAL|1|Irbesartan
62352576|NCT02417896|EXPERIMENTAL|Spironolactone|The intervention group will receive spironolactone. The drug will be administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently, three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3.
62352577|NCT02417896|NO_INTERVENTION|No spironolactone|Cardiac surgical patients requiring cardiopulmonary bypass and aortic cross clamp, randomised not to receive spironolactone will be followed for 10 days after surgery.
62352578|NCT05079867||Perimodiolar (PM)|Patients to be implanted with: Mid Scala or CI532 / 632 (Slim modiolar) electrode
62352579|NCT05079867||Lateral wall (PL)|Patients to be implanted with: Slim J or CI522 / 622 (Slim Lateral) electrode
62352580|NCT05096494|EXPERIMENTAL|SP-103|One SP-103 transdermal system is worn 12 hours per day for 28 days on the lower back.
62352581|NCT05096494|PLACEBO_COMPARATOR|Placebo|One placebo transdermal system is worn for 12 hours per day for 28 days on the lower back
62352582|NCT05666661|EXPERIMENTAL|Sound and light therapy group (BBT and FL group)|30 minutes of intervention every day for 14 consecutive days.
62352583|NCT05666661|EXPERIMENTAL|Sound therapy group (BBT)|30 minutes of intervention every day for 14 consecutive days.
62352584|NCT05666661|SHAM_COMPARATOR|Relaxing music group|30 minutes of intervention every day for 14 consecutive days.
62352585|NCT00916513||1|Patients ³ 40 years old, with T2DM diagnosed and followed up in the participating site at least 1 year prior to entry in the study, treated with diet, OADs and/or insulin for at least the past three months
62352586|NCT01324687||Control|Group without access to telemedicine in the home for acute care issues.
62352587|NCT01324687||Telemedicine care|Cohort with access to telemedicine in the home for acute care issues.
62352588|NCT01340963||Class I|Structurally normal heart, no bundle branch block
62352589|NCT01340963||Class II|Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction
62352590|NCT01340963||Class III|Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)
62352591|NCT06336343|EXPERIMENTAL|Individuals with moderate-to-severe psoriasis|Individuals with moderate-to-severe psoriasis who have failed similar therapies.
62352592|NCT00187889|ACTIVE_COMPARATOR|Eplerenone|Eplerenone 25 mg (1 pill)daily for 1 week then uptitrated to 50 mg (2 pills)daily for 15 weeks.
62352593|NCT00187889|PLACEBO_COMPARATOR|Placebo or sugar pill|Placebo blinded as 25 mg tablet once daily for 1 week then uptitrated to 2 pills daily for 15 weeks.
62352594|NCT01005056||Marvelon®|Single arm study. All participants receive Marvelon® according to the approved dosage and administration method.
62352595|NCT05279716|EXPERIMENTAL|omidenepag isopropyl 0.02mg|Instill 1 drop of Eybelis ophthalmic solution 0.002% once a day into the affected eye.
62511540|NCT03991442|ACTIVE_COMPARATOR|BR1010 placebo and Fimasartan/Amlodipine|BR1010 or Fimasartan/Amlodipine
62708059|NCT00772759|EXPERIMENTAL|1|Dry powder for oral inhalation
62708060|NCT00772759|PLACEBO_COMPARATOR|2|Dry powder for oral inhalation
62708061|NCT05990686||paracetamol plus tramadol|randomized selection of 66 adult patients
62708062|NCT05990686||fentanyl|randomized selection of 66 adult patients
62708063|NCT06537869|EXPERIMENTAL|iCBT Senior|iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)
62708064|NCT06537869|ACTIVE_COMPARATOR|Depression treatment-as-usual Senior|Depression treatment-as-usual for patient \>65 years
62708065|NCT03314090|EXPERIMENTAL|Silicone Gel Group|Intervention: Silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day (BID). The amount being similar in size to a grain of rice.
62708066|NCT05270993|ACTIVE_COMPARATOR|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
62708067|NCT05270993|EXPERIMENTAL|I-CREST group|A 6-week home-based remote supervision cardiac rehabilitation programme with an I-CREST application and smartwatch. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
62708068|NCT01969734|EXPERIMENTAL|Endobronchial valves|All subjects will have endobronchial valves inserted into the target lobe of the lung with the aim of complete lobar exclusion.
62352596|NCT01918787|EXPERIMENTAL|repetitive TMS|repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
62352597|NCT01043848|EXPERIMENTAL|Early pudendal stimulation|Subjects in this arm will start with the intervention within 2 weeks after SCI
62352598|NCT01043848|EXPERIMENTAL|Late pudendal stimulation|Subjects in this arm will start with the intervention 12 weeks after SCI
62352599|NCT01043848|NO_INTERVENTION|Control|Subjects in this arm will be treated according to standard therapy but will receive no pudendal stimulation
62352600|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
62352601|NCT00267371|ACTIVE_COMPARATOR|Test Arm with Premere investigational|PFO Closure with Premere investigational device.
62352602|NCT00267371|ACTIVE_COMPARATOR|Medical management/current medications|Patients in the control group arm will not receive the medical device and will continue medical management.
62352603|NCT05757089|EXPERIMENTAL|ALCOFILTRUM|"ALCOFILTRUM, 4 tablets in a single dose, 30 minutes prior to consumption of alcohol.~Ingredients per tablet:~Lignin hydrolyzed 800 mg; Glycine 150 mg; Dihydromyricetin 30 mg; Vitamin B1 30 mg."
62352604|NCT05757089|NO_INTERVENTION|Control|
62352605|NCT04871581|ACTIVE_COMPARATOR|Device|Subjects receiving the FDA-cleared device
62352606|NCT04871581|PLACEBO_COMPARATOR|Placebo|Subjects receiving the sham device
62352607|NCT05479266|EXPERIMENTAL|Muscle Energy Techniques|Muscle Energy Techniques and Conventional Physical Therapy
62352608|NCT05479266|EXPERIMENTAL|Myofascial Release|Myofascial Release and Conventional Physical Therapy
62352609|NCT04496557|EXPERIMENTAL|Patients diagnosed with PTSD|7-15 men and women with PTSD will be recruited from the community and from local clinical programs through a multi-modal outreach program.
62352610|NCT05157711|EXPERIMENTAL|Anusol ointment|Anusol ointment (Zinc oxide \[10.75g\], Bismuth subgallate \[2.25 g\], Balsam peru \[1.875 g\], Bismuth oxide \[0.875 g\] in each 100g of ointment).
62352611|NCT05157711|ACTIVE_COMPARATOR|Benchmark|RELIEF® rectal ointment (phenylephrine hydrochloride 2.5mg/g), marketed
62352612|NCT05157711|PLACEBO_COMPARATOR|Placebo|Anusol ointment after the removal of the active ingredients
62352613|NCT02532426||COPD patients with chronic hypoxemia|COPD patients with chronic and severe arterial hypoxemia at rest (paO2\<55mmHg).
62352614|NCT02532426||COPD patients with normoxia|COPD patients with normoxia at rest (paO2\>67mmHg), matched for age, sex, bronchial obstruction and lean mass.
62352615|NCT01225757|EXPERIMENTAL|Echocardiography|These patients will have echocardiography guided fluid management
62352616|NCT01225757|ACTIVE_COMPARATOR|Traditional fluid management|Fluid management will be guided by monitoring of central venous pressure and urine output.
62352617|NCT01670175|EXPERIMENTAL|Sirolimus, Cyclophosphamide, Topotecan|Sirolimus, Cyclophosphamide, Topotecan Patients accrued to dose levels in cohorts of 3 (3+3 design). Patients will receive daily oral sirolimus and cyclophosphamide days 1-21 in 28-day cycle, combined with oral topotecan given on days 1-14. Sirolimus will be dosed based on steady-state plasma trough concentrations.
62352618|NCT04010370||Healthy individuals|Cross-Sectional. No intervention. Patients of both sexes who are not sedentary or who participate in heavy physical activities and residents of the metropolitan area of Guadalajara
62352619|NCT03555240||Patient with Rheumatoid Arthritis|Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis
62352620|NCT04747522||Kidney Transplanted patients|Kidney transplanted patients transplanted at least 6 months prior to SARS-CoV-2 vaccination. Vaccination according to national plan with messenger Ribonucleic acid (mRNA) vaccine
62352621|NCT04747522||Healthy controls|Healthy hospital staff receiving SARS-CoV-2 mRNA vaccine as being front line Healthcare workers.
62352622|NCT06281379|EXPERIMENTAL|Group 1|Total gastrectomy+mesogastrectomy
62352623|NCT06281379|OTHER|Group 2|Total gastrectomy with concentional D2 lymphadenectomy
62352624|NCT06314165|EXPERIMENTAL|group practicing music medicine|There will be 2 follow-ups for each group. In the first follow-up for the experimental group, when symptoms begin on the first day of their menstrual period, they will be asked to fill out the Menstruation Symptom Scale and Visual Analogue Scale, and the designated music will be played for 30 minutes. After 30 minutes, he/she will be asked to fill out the same surveys again. In the 2nd follow-up (during the menstrual period one month after the first follow-up), they will be asked to repeat what was done in the 1st follow-up on the first day of their menstrual period.
62511541|NCT02647528|EXPERIMENTAL|Treatment|Patients in this arm receive treatment
62511542|NCT02647528|PLACEBO_COMPARATOR|Placebo|Patients in this arm do not receive treatment
62708069|NCT02688439|ACTIVE_COMPARATOR|Leg in a neutral position|Sciatic nerve block, with leg kept in a neutral position after anesthesia (control group)
62708070|NCT02688439|EXPERIMENTAL|Leg raised 30°|Sciatic nerve block, with leg raised 30° by placing the back of the foot over a support placed on the OR table and maintained in that position for 15 min
62708071|NCT02688439|EXPERIMENTAL|Distal tourniquet placed on the lower part of the leg|Sciatic nerve block, and distal tourniquet placed on the lower part of the leg (upper part of the tourniquet being about 4-6 inches from the ankle) with the leg in a neutral position.
62511543|NCT03758573|EXPERIMENTAL|Inspiratory Muscle Training (IMT)|IMT by means of the Powerbreath equipment (Classic, London, UK), according to the following parameters: initial loading of 40% of MIP, 3 sets of 10 repetitions with interval of 1 minute between each sets, 7 days a week, 2 times a day , with the patients in the bed with the angulation of 45 °. The IMT load settings will be adjusted according to the values evaluated weekly. If there is need for addition of supplemental oxygen will be performed to perform the IMT.
62352625|NCT06314165|NO_INTERVENTION|Group where music medicine is not applied|Two follow-ups will be applied to the groups. At the first follow-up for the control group, they will be asked to fill out the Menstruation Symptom Scale and Visual Analog Scale when symptoms begin on the first day of their menstrual period. In the 2nd follow-up (during the menstrual period one month after the first follow-up), they will be asked to repeat what was done in the 1st follow-up on the first day of their menstrual period.
62511544|NCT03758573|ACTIVE_COMPARATOR|Intensive Physiotherapy (IPT)|IPT will be to individualized and supervised intervention program consisting of any of the following procedures: passive, assisted, active or resisted mobilization, sedation and orthostasis depending on the functional level of the patient, as well as bronchial hygiene therapy and pulmonary expansion therapy.
62511545|NCT02336620|EXPERIMENTAL|Ringer Acetate|Ringer acetate 10-20 ml/kg IV bolus when patient need fluid bolus
62511546|NCT02336620|ACTIVE_COMPARATOR|Normal saline|NSS 10-20 ml/kg IV bolus when patient need fluid bolus
62511547|NCT01464151||Patients with inflammatory bowel disease|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
62511548|NCT05008016||Procalcitonine analysed|The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement
62511549|NCT02918682|EXPERIMENTAL|Exercise Group|The multimodal intervention protocol is described separated by day (1 to 24) and by weeks (1 to 12). Each session was built to last between 50 and 60 minutes.
62511550|NCT02918682|NO_INTERVENTION|Control Group|Participants from the control group will not perform any kind of physical exercise.
61971826|NCT00118365|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
61971827|NCT00118365|EXPERIMENTAL|Arm I (eflornithine and sulindac)|Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
62511551|NCT05546242|EXPERIMENTAL|CAB LA + RPV LA Arm|"The first 4 weeks of the treatment differ depending on whether participant opts for direct to injection (DTI) or Oral lead-in (OLI).~DTI: participants will remain on daily oral ART for 4weeks after randomization and will receive the 1st injection of IM CAB LA 600mg+RPV LA 900mg at the Month 1 visit. 2nd injections administered at Month 2, followed by maintenance injections every 2 months (Q2M)~OLI: participants will receive the study intervention in 2 phases:~1. Participants will receive CAB 30mg+RPV 25mg OD for 4weeks to be taken daily with food. The purpose of the optional OLI Phase is to allow an opportunity for participants to assess tolerability of the combination prior to administration of the injectables. There is no proven benefit to this approach~2. After 4weeks participants return for the Month 1 visit to receive the 1st IM CAB LA 600mg+RPV LA 900mg injections. The 2nd injections administered at Month 2 and then continuation injections will be administered Q2M"
62511552|NCT05546242|ACTIVE_COMPARATOR|ART Group|Participants will take a daily oral combination of 2 NRTIs plus DTG 50mg. Ideally, the single tablet fixed-dose combination regimen of (tenofovir disoproxil fumarate \[TDF\] 300 mg + lamivudine \[3TC\] 300 mg (or emtricitabine \[FTC\] 200 mg) + DTG 50 mg) will be used as per local country guidelines up to Month 24. If there are preexisting reasons why TDF or 3TC cannot be used as the NRTI backbone then alternative NRTIs are acceptable. Participants will be permitted to switch daily oral ART drugs in case of toxicity, after discussion with the coordinating center.
62708072|NCT01197547|OTHER|Genesys HTA|Genesys HTA Endometrial Ablation
62708073|NCT00034814|PLACEBO_COMPARATOR|1|Enzyme-inducing placebo TID
62708074|NCT00034814|EXPERIMENTAL|2|Enzyme-inducing Talampanel 35 mg TID
62708075|NCT00034814|EXPERIMENTAL|3|Enzyme-inducing TLP 50mg TID
61971828|NCT05508191|EXPERIMENTAL|Secretome + Fractional CO₂ Laser|This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 µm to eliminate the debris, then concentrated with CorningⓇ Spin-XⓇ UF 500 µL centrifugator. Stabilization analysis is performed before utilization. As for fractional CO₂ laser, AMIⓇ device is used with this following settings: 15 mJ energy, 900 µs pulse duration, density level 15, and depth level 2.
62708076|NCT00034814|PLACEBO_COMPARATOR|4|Non-enzyme-inducing placebo TID
62511553|NCT01914523|PLACEBO_COMPARATOR|Macintosh|tracheal intubation will be performed using a Macintosh
62511554|NCT01914523|ACTIVE_COMPARATOR|King Vision|tracheal intubation will be performed using a King Vision
62511555|NCT01914523|ACTIVE_COMPARATOR|Glidescope|tracheal intubation will be performed using a Glidescope
62511556|NCT01914523|ACTIVE_COMPARATOR|AirTraq|tracheal intubation will be performed using a AirTraq
62511557|NCT04831320|EXPERIMENTAL|nab-Paclitaxel + Nivolumab|"* nab-Paclitaxel 125 mg/m\^2 intravenous (IV) on days 1, 8 \& 15 of each 28-day cycle.~* Nivolumab 480 mg IV Day 1 of each 28-day cycle."
62708077|NCT00034814|EXPERIMENTAL|5|Non-enzyme-inducing TLP 25mg TID
62708078|NCT00034814|EXPERIMENTAL|6|Non-enzyme-inducing TLP 35mg TID
62708079|NCT00400686|EXPERIMENTAL|Epoetin Alfa - 80,000 U sc|Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
62511558|NCT06052787|NO_INTERVENTION|standard of care|"patients receiving the standard protocol of management of head injury in the ICU including~* Ventilatory support, sedation and analgesia.~* Hemodynamic support.~* Hyperosmolar therapy.~* Early post traumatic seizure prophylaxis.~* Nutritional support: will try to start enteral feeds as soon as possible or total parenteral~* nutrition will be used in the case of enteral feeding intolerance.~* Temperature management: to maintain normothermia~* Glycemic control: to maintain a glucose level of \[140 -180 mg/dl\]~* Peptic ulcer prophylaxis:~* Deep venous thrombosis (DVT) prophylaxis"
62511559|NCT06052787|EXPERIMENTAL|standard of care + Cerebrolysin|patients receiving the standard protocol of management of head injury in the ICU plus 2 cycles of Cerebrolysin , each cycle 10 days, for total 20 days. From day 1 to day 10: cerebrolysin 50 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes. From day 21-30 : cerebrolysin 20 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes.
62511560|NCT06052787|EXPERIMENTAL|standard of care + Cerebrolysin + Amantadine sulfate|patients receiving the standard protocol of management of head injury in the ICU plus amantadine sulfate at a dose of 100 mg twice daily on the day after randomization, with this dose will be continued for 14 days. The dose will be increased to 150 mg twice daily at week 3 and to 200 mg twice daily at week 4 (total 4 weeks), combined with 2 cycles of Cerebrolysin , each cycle 10 days, for total 20 days. From day 1 to day 10: cerebrolysin 50 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes. From day 21-30 : cerebrolysin 20 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes.
62511561|NCT03068845|EXPERIMENTAL|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
62511562|NCT03068845|ACTIVE_COMPARATOR|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
62511563|NCT01119807|EXPERIMENTAL|Intra Venous Access|Patient initially receives IV access during resuscitation
62511564|NCT01119807|EXPERIMENTAL|Humeral IO|Patient receives humeral IO access during resuscitation
62511565|NCT01119807|ACTIVE_COMPARATOR|Tibial IO|Patient receives tibial IO access during resuscitation
62511566|NCT03407612|ACTIVE_COMPARATOR|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
62511567|NCT03407612|NO_INTERVENTION|No CPM|No CPM was administered to these subjects.
62708080|NCT01051245|ACTIVE_COMPARATOR|Case management|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
62708081|NCT01051245|PLACEBO_COMPARATOR|Usual care group|Usual care provided by primary care physician and/or specialist. Free access to diabetes educational workshops. Regular delivery of educational brochures (not personally targeted).
62511568|NCT02656082|EXPERIMENTAL|Etanercept|Intradermal injection of etanercept. The dosage is determined based on discoid lesion radius. Weekly injection up to 12 weeks.
62511569|NCT04615845|EXPERIMENTAL|Cellgram-DC-PC|Cellgram-DC-PC is injected subcutaneously near the inguinal lymph nodes
62511570|NCT05410821|EXPERIMENTAL|177Lu-DOTA-EB-FAPI 1|177Lu-DOTA-EB-FAPI A maximum of 2 cycles of 60 mCi (2.22 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks
62511571|NCT05410821|EXPERIMENTAL|177Lu-DOTA-EB-FAPI 2|177Lu-DOTA-EB-FAPI A maximum of 2 cycles of 90mCi (3.33 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks
62708082|NCT00127439|EXPERIMENTAL|Robotic Assisted Locomotor Training|A robotic stepping device in concert with a body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. The robotic device provides the appropriate kinematics associated with standing and stepping.
62511572|NCT05410821|EXPERIMENTAL|177Lu-DOTA-EB-FAPI 3|177Lu-DOTA-EB-FAPI A maximum of 2 cycles of 135 mCi (4.99 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks
62511573|NCT02235584|EXPERIMENTAL|Dexamethasone|This is a before-after study. All subjects are administered dexamethasone 2mg BID for 5 days.
62511574|NCT02201979||Breast lift in combination with implants.|Patients undergoing breast lifts in combination with implants are studied using laser fluorescent imaging to evaluate blood supply.
62511575|NCT04082936|EXPERIMENTAL|Phase 1a (Dose Escalation)|Subjects will receive imvotamab via intravenous (IV) infusion weekly. No longer enrolling.
62511576|NCT04082936|EXPERIMENTAL|Phase 1a (Q3W)|Subjects will receive imvotamab via intravenous (IV) infusion every 3 weeks. No longer enrolling.
62511577|NCT04082936|EXPERIMENTAL|Phase 1a (Prior bi-specific)|Subjects treated with prior bi-specifics will receive imvotamab via IV infusion weekly. No longer enrolling.
62511578|NCT04082936|EXPERIMENTAL|Phase 2 (DLBCL)|DLBCL subjects will receive imvotamab via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data. No longer enrolling.
62511579|NCT04082936|EXPERIMENTAL|Phase 2 (FL)|FL subjects will receive imvotamab via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data. No longer enrolling.
62511580|NCT04082936|EXPERIMENTAL|Phase 1b (Combination)|Subjects will receive imvotamab via IV infusion weekly and loncastuximab tesirine via IV infusion every 3 weeks.
62511581|NCT01548989||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
62352626|NCT05066035|ACTIVE_COMPARATOR|Neostigmine|"The Group N (Neostigmine) (n=48), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
62352627|NCT05066035|ACTIVE_COMPARATOR|Neostigmine and Sugammadex|"In Group N+S (Neostigmine+Sugammadex) (n=50), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. After a three-minute waiting period, the study investigators administered an intravenous bolus half-dose of 1 mg/kg of sugammadex after the standard reversal dose.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
62352628|NCT00109772|EXPERIMENTAL|lenalidomide|10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.
62352629|NCT00109772|PLACEBO_COMPARATOR|Placebo|Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.
62352630|NCT05386927||GDM group|Pregnant women with positive OGTT results at 24-28 gestational weeks
62352631|NCT05386927||Control group|Pregnant women with negative OGTT results at 24-28 gestational weeks, and had baseline data that matched those in the GDM group
62352632|NCT04776564||Intensive courses|Participants on courses delivered within four days
62352633|NCT04776564||Long courses|Participants on courses delivered over minimum four weeks
62352634|NCT04776564||Clinical|Participants attending G7P courses delivered within the specialist health care setting
62352635|NCT04776564||Internett|Participants attending G7P courses delivered as an online course
62352636|NCT04776564||Professional|Participants attending G7P courses wihere professional health care personell are delivering the teaching
62352637|NCT04776564||Non-professional|Participants attending G7P courses wihere no professional health care personell are delivering the teaching
62352638|NCT04776564||Control group|A sample of couples from the public that do not at the moment participate in couple therapy or any couple enhancement programs
62352639|NCT01753388|EXPERIMENTAL|Treatment by the Liberty Stent|
62352640|NCT05835713|EXPERIMENTAL|Remimazolam besylate|Remimazolam group receive total intravenous anesthesia using remimazolam besylate and remifentanil during rigid bronchoscopy. Remimazolam group receive flumazenil during the emergence from anesthesia.
62352641|NCT05835713|ACTIVE_COMPARATOR|Propofol|Propofol group receive total intravenous anesthesia using propofol and remifentanil during rigid bronchoscopy.
62352642|NCT05731232|PLACEBO_COMPARATOR|Pacebo|Capsules containing maize starch with identical appearance as verum. One capsule taken per day before bedtime. Treatment duration 12 weeks.
62352643|NCT05731232|EXPERIMENTAL|Vivatlac Synbiotikum|Vivatlac Synbiotikum for twelve weeks. One capsule containing a mixture of nine different probiotic bacteria with a total amount of 4.5 x 10˄9 colony forming units taken per day before bedtime. Treatment duration 12 weeks.
62352644|NCT06229067|EXPERIMENTAL|adebrelimab + VEX|Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks, in combination with metronomic oral vinorelbine 20 mg every other day + cyclophosphamide 50 mg daily + capecitabine 500 mg three times daily
62352645|NCT06229067|ACTIVE_COMPARATOR|VEX|Metronomic oral vinorelbine 20 mg every other day + cyclophosphamide 50 mg daily + capecitabine 500 mg three times daily
62352646|NCT01769703|EXPERIMENTAL|Dabigatran|
62352647|NCT04662411|PLACEBO_COMPARATOR|Placebo|
62352648|NCT04662411|EXPERIMENTAL|butyrate and hexanoate amount 1|1325 mg of butyrate and hexanoate
62352649|NCT04662411|EXPERIMENTAL|butyrate and hexanoate amount 2|
62352650|NCT04662411|EXPERIMENTAL|butyrate and hexanoate amount 3|
62352651|NCT02818140|ACTIVE_COMPARATOR|Ropivacaine TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%
62352652|NCT02818140|PLACEBO_COMPARATOR|Placebo TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%
62352653|NCT02565498|OTHER|Preoperative Radiation Therapy (Arm A)|Preoperative intensity modulated radiation therapy followed by surgery
62352654|NCT02565498|EXPERIMENTAL|Postoperative Radiation Therapy (Arm B)|Surgery followed by postoperative intensity modulated radiation therapy
62352655|NCT05679609|EXPERIMENTAL|group 1|participants would use incentive spirometry for 2 months together with ordinary medical treatment
62352656|NCT05679609|NO_INTERVENTION|group 2|participants would receive only ordinary medical treatment for 2 months
62352657|NCT01771211|EXPERIMENTAL|anodal tDCS|anodal tDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left inferior frontal gyrus
62352658|NCT01771211|SHAM_COMPARATOR|sham tDCS|sham tDCS will be administered to the left inferior frontal gyrus
62352659|NCT04137146|EXPERIMENTAL|Sacral Nerve Stimulation|Intervention: Sacral nerve Stimulation Stimulation sites：S3 Postoperative study visits lasted approximately 3 hours and were conducted in 3 months.
62352660|NCT04137146|NO_INTERVENTION|No SNS Intervention|
62352661|NCT00014911|EXPERIMENTAL|Islet Transplantation|All study participants
62511582|NCT05451940|EXPERIMENTAL|Erythropoietin|Subjects on a stable dose of hydroxyurea will be treated with increasing doses of subcutaneous erythropoietin (EPO) as tolerated for an initial 12 weeks, during which the main safety and efficacy endpoints (including the primary endpoint of hemoglobin response) will be assessed. Subjects may continue on treatment for an additional 12 weeks as clinically indicated, with assessment of additional endpoints at the end of the 24-week study period.
62511583|NCT05004064|EXPERIMENTAL|Acalabrutinib and rituximab|Patients with untreated mantle cell lymphoma will receive acalabrutinib and rituximab for up to six cycles. Each cycle will comprise of acalabrutinib 100mg twice daily orally for 28 days and rituximab 375mg/m2 IV on day 1 (+/1 3 days) of every cycle.
62708083|NCT00127439|EXPERIMENTAL|Manually Assisted Locomotor Training|A body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. Therapists and trainers promote the appropriate kinematics associated with standing and stepping.
62708084|NCT00746811|OTHER|P-OM3 then Placebo|P-OM3 (4 g/d) for the first six weeks of treatment. Placebo (soy oil) for the second six weeks of treatment.
61971829|NCT05508191|EXPERIMENTAL|Secretome + Microneedle|This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 µm to eliminate the debris, then concentrated with CorningⓇ Spin-XⓇ UF 500 µL centrifugator. Stabilization analysis is performed before utilization. As for microneedle, DrPenⓇ dermapen is used in this following direction and order: vertical, horizontal, and diagonal, with the depth of 150 µm.
61971830|NCT04566991|EXPERIMENTAL|Deferoxamine lower dose|Deferoxamine 32 Milligram Per Kilogram (mg/kg)
61971831|NCT04566991|EXPERIMENTAL|Deferoxamine higher dose|Deferoxamine 48 mg/kg
61971832|NCT04566991|PLACEBO_COMPARATOR|Placebo|normal saline
61971833|NCT05151146|EXPERIMENTAL|ANJ900 in the fasted state|Single dose (1800 mg) of ANJ900
61971834|NCT05151146|EXPERIMENTAL|ANJ900 in the fed state|Single dose (1800 mg) of ANJ900
61971835|NCT05151146|ACTIVE_COMPARATOR|Metformin IR in the fasted state|Single dose (1000 mg) of metformin IR
62352662|NCT05514509|ACTIVE_COMPARATOR|Standard Implementation (SI)|PSPs will receive APRETUDE injection and could receive optional Cabotegravir tablets as oral lead in (OLI). The SI arm receives the standard toolkits that are anticipated to be available for APRETUDE that includes information resource for PSPs and SSPs.
62352663|NCT05514509|EXPERIMENTAL|Enhanced Implementation (EI)|PSPs will receive APRETUDE injection and could receive optional Cabotegravir tablets as OLI. The EI arm will receive all components of SI arm and additional provider-focused implementation strategies. Provider-focused strategies will include a patient-provider communication tool, Provider Education, and enhanced tool kit materials.
62352664|NCT05514509|EXPERIMENTAL|Enhanced Collaborative Implementation (ECI)|PSPs will receive APRETUDE injection and could receive optional Cabotegravir tablets as OLI. The ECI arm will involve implementation strategies to support patient activation and provider awareness. Clinics randomized to ECI will receive all components of SI and additional implementation strategies to support patient activation and ensure provider awareness. ECI strategies will include a patient information and product resources and peer support.
62352665|NCT05448599|EXPERIMENTAL|6MW3211|Phase I, 6MW3811 monotherapy in 2 dose levels of 30mg/kg or 45mg/kg; phase II, 6MW3811 will be given in combination with AZA( cohort1) and AZA plus VEN(cohort 2)
62352666|NCT03167164|EXPERIMENTAL|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
62352667|NCT01493141||MOMHR|Patients who have had metal-on metal hip resurfacing (MOMHR)
62352668|NCT01493141||THA|Patients who have had metal-on-polyethylene or ceramic total hip arthroplasty (THA)
61971836|NCT04843345||Reduced Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen positive for reduced salivary flow
61971837|NCT04843345||Normal Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen negative for reduced salivary flow
61971838|NCT02964351||High PSA (prostate-specific antigen) levels|
62352669|NCT01699412|EXPERIMENTAL|Dexamethasone|Patients under topical treatment with solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL
62352670|NCT01699412|EXPERIMENTAL|Clobetasol|Patients under topical treatment with solution of clobetasol 0.05% associated with nystatin 100,000 UI/mL
62352671|NCT01124019||Random Sample|A random sample of 600 women undergoing screening mammography
62511584|NCT05878379|EXPERIMENTAL|Dietary Iron Program|The dietary iron program was administered from weeks 2 to 15 in between pre-test and post-test measurements
62511585|NCT00777933|ACTIVE_COMPARATOR|cyclosporine|
62708085|NCT00746811|OTHER|Placebo then P-OM3|Placebo (soy oil) for the first six weeks of treatment. P-OM3 (4 g/d) for the second six weeks of treatment.
61976295|NCT02277301|EXPERIMENTAL|Mellow Babies|Mellow Babies is a group day programme, run one day a week over 14 weeks with a joint focus on maternal wellbeing and the parentinfant interaction: transport and crèche facilities are provided.The focus is to: (a) explicitly enhance close mother-infant attunement, using a combination of baby-massage, interaction coaching and infant focussed speech; and (b) offer mothers support for their own distress. Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
62511586|NCT00777933|EXPERIMENTAL|Tacrolimus|
62511587|NCT04651322|EXPERIMENTAL|Training group|
62511588|NCT04651322|OTHER|Control group|
62511589|NCT03261362|PLACEBO_COMPARATOR|Amino acid powder with all amino acids|amino acid powder 80 g oral Administration 1 week
62511590|NCT03261362|ACTIVE_COMPARATOR|Amino acid powder without BCAAs-reduced intake|Branched-chain amino acids reduced intake - amino acid powder lacking BCAAs 80 g oral Administration 1 week -
62708086|NCT05748002||stable group|
62708087|NCT05748002||subclinical keratoconus|
62708088|NCT05748002||normal group|
62708089|NCT05748002||follow up group|
61971839|NCT06292065|EXPERIMENTAL|Gastric Ultrasound|Gastric ultrasound will be performed shortly before induction; i.e. in the preoperative room. The exam will be performed by the treating anaesthetist experienced with gastric ultrasound. The gastric antrum will be visualised in supine position followed by a second visualisation of the antrum in right lateral decubitus. In the latter position the cross-sectional area of the antrum (RIGHT-LAT CSA) will be measured and used to calculate the gastric volume using the \[VOLUME (ML) = 27.0 + 14.6 X RIGHT-LAT CSA - 1.28 X AGE\] formula. The patient will be considered to have a full stomach or positive gastric ultrasound if solid gastric content is visible in any visualisation of the antrum or if calculated liquid gastric content exceeds 1.5 ml/kg of total body weight.
61971840|NCT02515058|EXPERIMENTAL|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
62352672|NCT01124019||BIRADS score of 4|An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
62352673|NCT03687086|EXPERIMENTAL|Program A|cognitive behavioral therapy type A plus medications in packaging type A
61971841|NCT02515058|ACTIVE_COMPARATOR|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
61971842|NCT01331551||men with inflammatory bowel disease|Men between the ages of 18-55 with inflammatory bowel disease who are taking mesalamine medication.
61971843|NCT05439226|EXPERIMENTAL|CMNT diet|The CMNT group was instructed to consumed the provided CMNT diet consisting of 6 cycles of 5 consecutive days followed by 10 days of ad libitum food consumption. Participants received a 917 kcal/day preprepared human CMNT diet (44.75% carbohydrate, 9.1% protein and 46.15% fat) for 5 consecutive days per cycle
62352674|NCT03687086|ACTIVE_COMPARATOR|Program B|cognitive behavioral therapy type B plus medications in packaging type B
62352675|NCT03013829|NO_INTERVENTION|Usual Care|"Potential LKDs and recipients will receive standard-of-care LD (Live Donor) and KPD education. As noted previously, during standard care, incompatible potential LKDs are informed of the KPD option and the potential LKD is provided with living donation information and a link to the UNOS KPD website, which includes a written description of KPD. This information is available in English and Spanish. For those who do not have internet access, the written educational materials are mailed. The potential LKD is advised to call the donor nurse coordinator with any questions about KPD and/or to initiate the full donation evaluation. This process occurs for the intended recipient only if their potential donor decides to initiate the full evaluation.~For study purposes, potential LKDs and waitlisted recipients assigned to the UC group will be sent an email after randomization, which will include a link and a reminder to review their transplant center's standard of care educational materials."
62352676|NCT03013829|EXPERIMENTAL|Video-Based KPD education|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch the embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
62352677|NCT05069805|ACTIVE_COMPARATOR|PECS II block group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanyl
62352678|NCT05069805|ACTIVE_COMPARATOR|ESP block group|Patients in ESP group will receive general balanced inhaled anesthesia with sevoflurane and fentanyl
62352679|NCT03361072|EXPERIMENTAL|Milk allergy|Milk oral immunotherapy intervention for milk allergy
62352680|NCT03361072|EXPERIMENTAL|Peanut allergy|Peanut oral immunotherapy intervention for peanut allergy
62352681|NCT03361072|EXPERIMENTAL|Egg allergy|Egg oral immunotherapy intervention for egg allergy
62352682|NCT04239547|EXPERIMENTAL|Recruitment|Patients classified to receive recruitment maneuver + 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
62352683|NCT04239547|EXPERIMENTAL|Non-recruitment|Patients classified to receive only 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
62352684|NCT05737407|EXPERIMENTAL|LUS-guided Peep|"After induction of anesthesia and intubation, patients will be briefly turned onto their side and LUS will be performed in the posterior areas of the lung; PEEP will be adjusted in increments of 1 cmH20/minute starting from zero while maintaining visual inspection of LUS up to the point where signs of eventual subpleural consolidations and/or multiple B lines are not present anymore.~FiO2 will be chosen as the minimum necessary to maintain SpO2 of 97-98%."
62352685|NCT05737407|ACTIVE_COMPARATOR|Standard setting of Peep|"After induction, patients will be similarly scanned with LUS on their side but PEEP will be set at 4 cmH2O independently from results of LUS.~FiO2 will be chosen as the minimum necessary to maintain SpO2 of 97-98%."
62352686|NCT04286464||Term born group (H)|Healthy, white and term Born infants and Children Born 38-42 weeks postconceptional
62511591|NCT01729026|EXPERIMENTAL|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
62511592|NCT01729026|ACTIVE_COMPARATOR|Wait-list, Then Adoption after 3 Months|After 3 months on a wait-list, Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
61971844|NCT05439226|NO_INTERVENTION|Usual Care|Dietary recommendations based on the Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) as the control group
62352687|NCT04286464||Preterm group (P)|Healthy, white preterm Born infants and Children Born \<37 weeks postconceptional Which comply with the international criteria (Jobe and Bancalari) of a diagnosis of bronchopulmonary dysplasia (BPD), or of chronic lung disease of the new-born (CLD)
61971845|NCT04201860||Blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue handled explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
62708090|NCT05472792|ACTIVE_COMPARATOR|Endocrine Therapy|Endocrine therapy will be chosen by the treating medical oncologist with an aim of 5 years duration, as tolerated by the patient.
62708091|NCT05472792|EXPERIMENTAL|Accelerated Partial Breast Irradiation (APBI)|APBI will consist of 5 fractions of radiation therapy delivered every other day to the lumpectomy cavity.
61971846|NCT04201860||Not blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue did not handle explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
62352688|NCT04286464||Risk pregnancy group (RP)|White preterm Born infants and Children, including Twins Born \<37 weeks postconceptional With fetal growth restriction (FGR), intrauterine growth restriction (IUGR) or preeclampsia (PE) With gestational Diabetes (GDM) With IVF or Amnion dysfunction
62352689|NCT02644148|OTHER|Conventional Roux-en-Y anastomosis|Conventional Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
62352690|NCT02644148|EXPERIMENTAL|Uncut Roux-en-Y anastomosis|Uncut Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
62352691|NCT03283618|NO_INTERVENTION|Control Group|The control group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) as well as caloric and step goals, but no health coaching. They will complete the same pre- and post-intervention measurements and consultations with the medical doctor and registered dietitian.
62352692|NCT03283618|EXPERIMENTAL|Video Conference-based Health Coaching|The video conference-based health coaching group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) meet the medical doctor at baseline and at 12 weeks via the Amwell® app using their smartphone. The participants will receive health coaching by meeting weekly (12 times) with the registered dietitian (RD) to discuss behavior modification, exercise, and nutrition goals.
62352693|NCT05755997|OTHER|Study group 1|Cerebrolysin - Placebo
62352694|NCT05755997|OTHER|Study group 2|Placebo - Cerebrolysin
62352695|NCT01345370||Stupp protocole|All subjects enrolled must be treated according to the Stupp schedule : surgical resection followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles of adjuvant Temzolomide.
61971847|NCT05015127|EXPERIMENTAL|HBM9161 680 mg qw by q2w from week 13|Subcutaneous injection; HBM9161 680 mg qw from week 13
61971848|NCT05015127|EXPERIMENTAL|HBM9161 680 mg qw by q2w from week 7|Subcutaneous injection; HBM9161 680 mg qw by q2w from week 7
61971849|NCT05015127|EXPERIMENTAL|Placebo|Subcutaneous injection; Placebo
61971850|NCT05015127|EXPERIMENTAL|Placebo qw by HBM9161 680mg qw from week 12|Placebo qw by HBM9161 680mg qw from week 12
61971851|NCT03053076|PLACEBO_COMPARATOR|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
61971852|NCT03053076|EXPERIMENTAL|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
61971853|NCT01920789|EXPERIMENTAL|Stereotactic radiotherapy|Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV.
61971854|NCT01920789|ACTIVE_COMPARATOR|Conventionally fractionated radiotherapy|Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.
62352696|NCT05583357|EXPERIMENTAL|Cohort 1|
62352697|NCT05583357|EXPERIMENTAL|Cohort 2|
62511593|NCT01398059|EXPERIMENTAL|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
62511594|NCT01398059|EXPERIMENTAL|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
62708092|NCT04629742|EXPERIMENTAL|Seawater Pizza|Administration of a seawater pizza
62708093|NCT04629742|ACTIVE_COMPARATOR|Standard Pizza|Administration of a Standard pizza
61971855|NCT03807466|ACTIVE_COMPARATOR|Dynamic/Interactive Report|LTC physician receives dynamic/interactive report only
61971856|NCT03807466|NO_INTERVENTION|Static/Paginated Report|LTC physician receives static/paginated report only
61971857|NCT03807466|ACTIVE_COMPARATOR|LTC Physicians Enrolled in Reports|"All LTC physicians who receive a dynamic or paginated report~\[note: this is not part of randomization assignment, but a quasi-experimental study\]"
61971858|NCT03807466|NO_INTERVENTION|LTC Physicians Not Enrolled in Reports|"All LTC physicians who do not receive a dynamic or paginated report~\[note: this is not part of randomization assignment, but a quasi-experimental study\]"
62352698|NCT05583357|ACTIVE_COMPARATOR|Cohort 3|
62352699|NCT05583357|ACTIVE_COMPARATOR|Cohort 4|
62352700|NCT00556335|EXPERIMENTAL|manual aspiration|manual aspiration
62352701|NCT00556335|ACTIVE_COMPARATOR|conventional drainage|conventional drainage
62352702|NCT03874754|EXPERIMENTAL|The iHBE program group|Tailored Technology-Enhance Home-based exercise program (iHBE)
62352703|NCT03874754|NO_INTERVENTION|Usual Care (Control group)|Participants were required to wear physical activity tracker (Fitbit) and respond to the daily symptoms survey (mEMA) while receiving usual care
62352704|NCT01095068|EXPERIMENTAL|physical exercise|Physical exercise
62352705|NCT03119246|EXPERIMENTAL|HD patients|
62352706|NCT03119246|EXPERIMENTAL|Controls|
62708094|NCT00909701|EXPERIMENTAL|Test|PreOP Booster (Fresenius Kabi, Bad Homburg, Germany)
62708095|NCT00909701|ACTIVE_COMPARATOR|Comparator|PreOP (Nutricia Clinical Care, Trowbridge, UK)
62708096|NCT00601341|EXPERIMENTAL|1|lumbosacral joint manipulation
62708097|NCT00601341|EXPERIMENTAL|2|lumbar passive range of motion
62708098|NCT00601341|OTHER|3|lie on exam table for 3 minutes
62708099|NCT02236091||Inpatients|
62708100|NCT04983784|EXPERIMENTAL|The Effectiveness of Walking on Sleep ,Depression and Quality of Life on intervention|"experimental group:~1. intervention home-style walking exercises~2. performed 12 weeks of 30 minutes walking exercise 2-3 times per week~3. assess on at baseline and 12 weeks"
62708101|NCT04983784|EXPERIMENTAL|No intervention group reaction|"control group:~1. no intervention~2. Routine care and follow-up~3. assess on at baseline and 12 weeks"
61971859|NCT01761331|ACTIVE_COMPARATOR|Group A: Standardized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Intervention: Infants in the standardized acupuncture group get minimal acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
62146651|NCT03014791||Hypertensive Patients (Case-control)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~* Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~* Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~* Acetylcholine: 7.5μg/min, 15μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~* Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~* LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
62146652|NCT03014791||Hypertensive Patients (Cross-sectional)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Forearm blood flow Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Recruited from community-based cohort studies - CLEAREST and ACCT~Equal recruitment across the following parameters:~* Age: 3 groups \<30, 30-60, \>60 years~* Gender~* BMI: 3 groups \<25, 25-30, \>30 Kg/m2"
62146653|NCT02424968|EXPERIMENTAL|Infusion of Allogeneic CD8+ Memory T-cells|All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).
62146654|NCT05139615|EXPERIMENTAL|APD418 (Part A: Dose Cohort 1-5)|
62146655|NCT05139615|EXPERIMENTAL|APD418 (Part B: Dose Group 1 and 2)|
62146656|NCT05139615|PLACEBO_COMPARATOR|Placebo (Part A: Cohort 1-5 and Part B)|
62352707|NCT02715583|EXPERIMENTAL|Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease.|"Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease planning to undergo Ra-223 therapy may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania.~Positron emission tomography (PET/CT) imaging will use the investigational radiotracer \[11C\]acetate. Imaging will occur prior to Ra-223 therapy and after 2 cycles, in addition to standard of care 99mTcMDP bone scan at baseline and a research 99mTc-MDP bone scan post-therapy~Patients will also undergo serial lab tests (PSA, and alkaline phosphatase levels). If these tests are done as part of clinical standard of care they will not need to be repeated for this study. Patients will be asked to complete a quality of life metric (short form of the McGill pain questionnaire) on the day of each PET/CT scan."
62708102|NCT04800692|EXPERIMENTAL|Tetrahydrobiopterin Dose 1 (Day 0 to 44)|All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.
62146657|NCT03849066||Cross-Sectional PRSA|This will be a cross-sectional analysis of children with neurological impairment and polypharmacy.
62146658|NCT01697228|OTHER|Immediate treatment group|This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months.
62146659|NCT01697228|OTHER|Delayed treatment group|This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months.
62146660|NCT02311413|EXPERIMENTAL|Cat-PAD|Subjects will be treated with four monthly doses of Cat-PAD, a peptide immunotherapy product consisting of Fel d 1 synthetic peptide immunoregulatory epitopes (SPIRE).
62146661|NCT02311413|PLACEBO_COMPARATOR|Placebo|Subjects will be treated with 4 monthly doses of Placebo.
62146662|NCT02269852|EXPERIMENTAL|trivalent seasonal influenza vaccine|"Northern hemisphere 2013-2014 trivalent seasonal influenza vaccine~* 60 infants: two-dose regimen with a 28-day interval;~* 60 adults: single-dose regimen;~* 60 seniors: single-dose regimen;"
62146663|NCT01486459|EXPERIMENTAL|PCI with lithium|Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
62146664|NCT01486459|NO_INTERVENTION|Standard|Prophylactic cranial irradiation alone.
62146665|NCT03681132|OTHER|Low-threshold re-start|Re-start antiviral therapy if HBV DNA viral load \>2000 IU/ml and ALT \>80 U/L.
62352708|NCT01351064|EXPERIMENTAL|CHICA ADHD Module|This arm received The CHICA ADHD Module
62708103|NCT04800692|EXPERIMENTAL|Tetrahydrobiopterin Dose 2 (Day 45 to 90)|All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.
62708104|NCT05092750|EXPERIMENTAL|FerroTraceTM (magnetic tracer)|a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.
61971860|NCT01761331|ACTIVE_COMPARATOR|Group B: Individualized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Infants in the individualized acupuncture group get acupuncture in points chosen by the acupuncturists according to symptoms: maximum 5 needles are inserted about 3 mm in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
62146666|NCT03681132|OTHER|High-threshold re-start|"Re-start antiviral therapy if:~* ALT \>100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR~* ALT \>400 U/L persisting for more than 2 months in consecutive assays."
62146667|NCT01701141||Individuals with MDD|Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.
62146668|NCT01701141||Healthy Controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment
62511595|NCT01398059|EXPERIMENTAL|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
62511596|NCT01279252|EXPERIMENTAL|Antibiotic regimen|
62511597|NCT03851588|ACTIVE_COMPARATOR|Supplementary dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
62511598|NCT03851588|PLACEBO_COMPARATOR|Placebo dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
61971861|NCT01761331|NO_INTERVENTION|Group C: No acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. The nurse hold the infant´s hand and talks to it but no acupuncture is given.
62511599|NCT02866240|EXPERIMENTAL|Single arm|Cathodal Transcranial Direct Current Stimulation (tDCS)
62511600|NCT04666688|EXPERIMENTAL|Part 1 single agent dose escalation|LYT-200 in metastatic solid tumors
61971862|NCT03606733|EXPERIMENTAL|A custom made Suprachoroidal needle for macular diseases|A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana
62511601|NCT04666688|EXPERIMENTAL|Part 1 combination agents dose expansion|LYT-200 in combination with chemotherapy or Tislelizumab in select metastatic solid tumors
62511602|NCT04666688|EXPERIMENTAL|Part 2|LYT-200 combination dose expansion in select metastatic solid tumors based on outcomes of Part 1
62511603|NCT06615232|EXPERIMENTAL|Vaginal washing cessation (intervention)|The intervention will consist of 3 small-group educational sessions focused on vaginal washing cessation.
62511604|NCT06615232|NO_INTERVENTION|Control|Women in the control arm will return for weekly visits (to answer study questionnaires), but will not attend group educational sessions.
62511605|NCT05312086|OTHER|patients with X-linked hypophosphatemic|Patient group composed of 10 patients aged between 5 to 17 years old, female or male, with X-linked hypophosphatemic (XLH) rickets, severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities) and ongoing growth (lesser bone age than 15 years old), child under conventional treatment
62511606|NCT05312086|OTHER|healthy volunteers|control group composed of 20 helthy volunteers aged between 5 to 17 years old, female or male, without any endocrine pathology, not suffering from XLH, matching by age (+/- 6 months) and sex
62708105|NCT01010464|EXPERIMENTAL|Adhesion Reduction Plan|Lysis of adhesions and application of Seprafilm
62708106|NCT01010464|NO_INTERVENTION|Standard Management|Standard management and no application of Seprafilm
62708107|NCT05683366||Single Group|No interventions, single group.
62708108|NCT02023437|EXPERIMENTAL|Experimental: Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
62708109|NCT02023437|ACTIVE_COMPARATOR|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
61971863|NCT01382056|EXPERIMENTAL|Mixed beans (higher amount)|Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
61971864|NCT01382056|EXPERIMENTAL|Mixed beans (lower aomunt)|Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
61971865|NCT01382056|ACTIVE_COMPARATOR|Control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
61971866|NCT04981951|EXPERIMENTAL|Dexmedetomidine and Bupivacaine|Patients will be given Dexemtomidine ( the intervention) added to the Bupivacaine
62708110|NCT05310253|EXPERIMENTAL|Fludrocortisone & TSST - BPD patients|intake of 0.4mg fludrocortisone (orally) before stress
62708111|NCT05310253|EXPERIMENTAL|Fludrocortisone & TSST - Healthy controls|intake of 0.4mg fludrocortisone (orally) before stress
61971867|NCT04981951|NO_INTERVENTION|Bupivacaine alone|patients will be given Bupivacaine alone
61971868|NCT01596608|EXPERIMENTAL|Magnetic Seizure Therapy|
61971869|NCT04492202||First group|Physiotherapists will be included in this group.
61971870|NCT04492202||Second group|Doctors will be included in this group.
61971871|NCT04492202||Third group|Nurses will be included in this group.
62146669|NCT04252950|EXPERIMENTAL|CB-SET Treatment|Participants randomized to this group will receive a community-based structured exercise therapy (CB-SET) along with the standard of care (revascularization)
62511607|NCT02339610||ATTUNE Primary, Cemented Total Knee Replacement|"Subjects will receive one of four available ATTUNE total knee implants:~(CR FB, CR RP, PS FB, PS RP)."
62511608|NCT04651192||Soldiers|50 Israeli Defense Forces (IDF) infantry soldiers, all male, aged 18 years, with Hebrew as the dominant language and no condition excluding an MRI scan.
61971872|NCT04492202||Fourth group|Other health professionals will be included in this group.
61971873|NCT05821114|EXPERIMENTAL|high flow oxygen|Oxygen supply (2L/kg/min.) during awakening from propofol anesthesia
61971874|NCT05821114|ACTIVE_COMPARATOR|Low flow oxygen|Oxygen supply (0.3L/kg/min.) during awakening from propofol anesthesia
61971875|NCT01970449|EXPERIMENTAL|Group 1: study vaccines with Nat-B env insert|Participants in this arm will receive DNA Nat-B env vaccine injections on Day 0 and Day 28 followed by NYVAC Nat-B env vaccine injections on Day 84 and Day 164.
61971876|NCT01970449|PLACEBO_COMPARATOR|Group 1: placebo vaccines with Nat-B env insert|Participants in this arm will receive placebo injections of DNA Nat-B env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Nat-B env vaccine on Day 84 and Day 164.
62511609|NCT04651192||Students|50 Reserve Officer Training Corps (ROTC) undergraduate students at Tel-Aviv University, all male, aged 18-19, with Hebrew as the dominant language and no condition excluding an MRI scan.
62511610|NCT06239714|EXPERIMENTAL|SGB-3403(SAD)|
62511611|NCT06239714|PLACEBO_COMPARATOR|placebo(SAD)|
62511612|NCT06239714|EXPERIMENTAL|SGB-3403(Non-Statin MAD)|
62511613|NCT06239714|PLACEBO_COMPARATOR|placebo(Non-Statin MAD)|
62511614|NCT06239714|EXPERIMENTAL|SGB-3403 and atorvastatin(statin MAD)|
62511615|NCT06239714|PLACEBO_COMPARATOR|placebo and atorvastatin(statin MAD)|
62511616|NCT01246141||Repair group|patients in repair group underwent tricuspid repair for functional tricuspid regurgitation.
62511617|NCT01246141||replacement group|In this group, patients underwent tricuspid valve replacement for functional tricuspid regurgitation.
62511618|NCT04549922|PLACEBO_COMPARATOR|Placebo|1.2 mL Normal Saline, single dose subcutaneous, after randomization
62511619|NCT04549922|ACTIVE_COMPARATOR|ISIS 721744|1.2 mL ISIS 721744, single dose subcutaneous, after randomization
62511620|NCT03543852|EXPERIMENTAL|SurvivorLink|Participants receiving treatment at a pediatric cancer survivor clinic randomized to this study arm will receive education on how to use SurvivorLink, late effects of treatment, and survivorship care through the system.
62511621|NCT03543852|NO_INTERVENTION|Usual care|Participants receiving treatment at a pediatric cancer survivor clinic randomized to the usual care study arm will receive the SurvivorLink intervention beginning at Month 12.
62511622|NCT06287268||eltrombopag|ATG treatment naïve pediatric patients with AA in routine clinical practice
62511623|NCT04081441|EXPERIMENTAL|Inyenyeri clean cookstove/fuel|A tier 4 clean Mimi-moto cookstove/pellet system
62511624|NCT04081441|EXPERIMENTAL|I-ACT behavioral empowerment intervention|A culturally adapted 2-day personal empowerment workshop (based on the Individual, Agency-Centered Training (I-ACT) to women and modified, condensed 1-day training for their male partners, if applicable
62511625|NCT04081441|EXPERIMENTAL|Cookstove and I-ACT empowerment|Access to both the clean cookstove system and I-ACT empowerment training
62511626|NCT04081441|OTHER|I-ACT Waitlisted control|These households include those that were offered cookstoves after 6 months (from baseline) and are waitlisted to receive the I-ACT intervention
62511627|NCT03221452|OTHER|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
62511628|NCT00686439|EXPERIMENTAL|adalimumab|
62511629|NCT02676791|EXPERIMENTAL|A (Povidone-Iodine)|Esophageal washout will be performed via a nasogastric tube with approx. 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) during esophageal resection.
62511630|NCT02676791|NO_INTERVENTION|B (Control)|Esophageal resection will be performed without esophageal washout.
62511631|NCT01469260|NO_INTERVENTION|Routine care|ACOG Exercise in Pregnancy pamphlet
62511632|NCT01469260|EXPERIMENTAL|Pedometer|ACOG Exercise in Pregnancy pamphlet, pedometer use, ultimate goal of 10,000 steps per day
62511633|NCT06055673||cases group|patients with ISR confirmed by coronary angiography
62511634|NCT06055673||patients without restenosis non ISR group|
62511635|NCT01915940|EXPERIMENTAL|13 mg Bimatoprost Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye and placebo eye drops twice a day in each eye for 6 months.
62511636|NCT01915940|ACTIVE_COMPARATOR|Timolol 0.5% + Placebo Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus placebo ocular insert for 6 months.
62511637|NCT05643274||Participants|Patients with neurodevelopmental disease and their both parents
62511638|NCT05171894|EXPERIMENTAL|Hemoporfin+A J/cm2 Green Light|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
62511639|NCT05171894|EXPERIMENTAL|Hemoporfin+B J/cm2 Green Light|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
62511640|NCT05171894|EXPERIMENTAL|Hemoporfin+C J/cm2 Green Light|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
62511641|NCT05171894|PLACEBO_COMPARATOR|Placebo+A J/cm2 Green Light|Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
62511642|NCT05171894|PLACEBO_COMPARATOR|Placebo+B J/cm2 Green Light|Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
62511643|NCT05171894|PLACEBO_COMPARATOR|Placebo+C J/cm2 Green Light|Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
62511644|NCT04340999||Manifested Group|Manifested Group , enrolled patients who had any of the following manifestations(Fatigue,muscle cramps or numbness)
62511645|NCT04340999||Non-Manifested Group|Non-manifested group in which enrolled patients didn't report any of the following manifestations
62511646|NCT05765799||Patient who receives a consultation before an interventional procedure|Any patient who receives a consultation before an interventional procedure will be included. Questionary will be administrated.
62511647|NCT02868541||Haaj pilgrim|Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135
62511648|NCT03714555|ACTIVE_COMPARATOR|Nab-Paclitaxel/Gemcitabine + DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Nab-Paclitaxel-Gemcitabine with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
62511649|NCT03714555|ACTIVE_COMPARATOR|FOLFIRINOX +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with FOLFIRINOX and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
62511650|NCT03714555|ACTIVE_COMPARATOR|Single-Agent Gemcitabine +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Single-Agent Gemcitabine and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
62511651|NCT01684527||Children Suffering From Bronchiolitis|Respiratory secretions obtained from children suffering from Bronchiolitis
62511652|NCT01684527||Healthy Children|Respiratory secretions obtained from children with no respiratory infection
62511653|NCT04978636|ACTIVE_COMPARATOR|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The investigator will investigate the effect of continuous low tidal volume ventilation with hyperoxia avoidance (using FiO2 of 0.21) on PPCs and 30-day mortality compared to low-tidal volume ventilation (with FiO2 of 0.21) or apnea during CPB, and during the sub-study.
62511654|NCT04978636|ACTIVE_COMPARATOR|Continuous low tidal volume ventilation with using FiO2 of 1.0|The investigator will investigate the effect of low tidal volume lung ventilation with hyperoxia avoidance (FiO2 of 0.21) on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or apnea during CPB, and during the sub-study.
62511655|NCT04978636|ACTIVE_COMPARATOR|Apnea|The investigator will investigate the effect of apnea during on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or hyperoxia avoidance (FiO2 of 0.21) during CPB, and during the sub-study..
62708112|NCT05310253|EXPERIMENTAL|Placebo pills & TSST - BPD patients|intake of placebo pill before stress
62708113|NCT05310253|EXPERIMENTAL|Placebo pills & TSST - Healthy controls|intake of placebo pill before stress
62708114|NCT05310253|EXPERIMENTAL|Fludrocortisone & Placebo-TSST- BPD patients|"intake of 0.4mg fludrocortisone (orally) before no stress"
62708115|NCT05310253|EXPERIMENTAL|Fludrocortisone & Placebo-TSST - Healthy controls|"intake of 0.4mg fludrocortisone (orally) before no stress"
62708116|NCT05310253|EXPERIMENTAL|Placebo pills & Placebo-TSST - BPD patients|"intake of placebo pill before no stress"
62708117|NCT05310253|EXPERIMENTAL|Placebo pills & Placebo-TSST - Healthy controls|"intake of placebo pill before no stress"
62708118|NCT01508364||Group 1|
62708119|NCT03606577|EXPERIMENTAL|Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone|
62708120|NCT04106505|EXPERIMENTAL|Biofeedback|The treatment comprises an app containing biofeedback training, instructions for self-delivery and a headache diary. The treatment utilizes these functionalities by a push-reminder in the app to complete a daily headache diary entry and a biofeedback session of 10 minutes duration daily. Prior to commencing treatment participants will be given basic information on the rationale behind biofeedback treatment, given instructions on how to use the equipment and software and instructions on how to complete a biofeedback session. The biofeedback is based on wireless sensors measuring muscle tension, finger temperature and heart rate.
62708121|NCT04106505|SHAM_COMPARATOR|Sham-biofeedback|Sham-biofeedback will be made by disrupting the connection between input of physiological parameters and the feedback. Thus, the feedback will simply be displayed as positive feedback occurring at random intervals throughout the sessions. The looks and contents of the normal app and the sham-app will be completely similar. The participants being allocated to the sham-goup will also use exactly the same sensor setup as the biofeedback group. The only difference between the two arms/interventions is the internal software algorithm, which will be inaccessible to the user. All participants in both groups will be given the same information and instructions.
62708122|NCT06206590||exposed group|Contains differential proteins
62708123|NCT06206590||non-exposed group|No differential protein
62708124|NCT04145596|ACTIVE_COMPARATOR|Compensated Chronic Liver Disease (Child-Pugh A)|
62708125|NCT04145596|ACTIVE_COMPARATOR|Decompensated Chronic Liver Disease (Child-Pugh B)|
62708126|NCT04145596|ACTIVE_COMPARATOR|healthy volunteers（Normal liver functions）|
62708127|NCT05093608|EXPERIMENTAL|Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab|60 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
62352709|NCT01351064|NO_INTERVENTION|CHICA ADHD Control|This arm received CHICA without the ADHD module
62708128|NCT05093608|EXPERIMENTAL|Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab|80 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
62708129|NCT01871376|ACTIVE_COMPARATOR|Previously Treated|"Patients that have previously received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm."
62352710|NCT04545099|EXPERIMENTAL|Sugammadex|Administration of Sugammadex
62352711|NCT04545099|ACTIVE_COMPARATOR|Neostigmine|Administration of Neostigmine
62352712|NCT05608330|EXPERIMENTAL|PETRUSHKA tool|The intervention is the PETRUSHKA web-based App (also called PETRUSHKA tool), a clinical decision-support system that incorporates a personalised evidence-based prediction model with individual patient preferences, to prescribe the best antidepressant to adults with depression
62352713|NCT05608330|PLACEBO_COMPARATOR|Usual Care|Routine care delivered in the NHS (i.e. selection of the antidepressant based primarily on the clinicians' judgement) termed 'usual care' in this study.
62352714|NCT05070416|EXPERIMENTAL|Crowns self-adhesively cemented|Group 1 receives crowns with an occlusal thickness of 1.5 mm and luted with a self-adhesive, self-curing resin cement (SpeedCem Plus, Ivoclar Vivadent AG).
62352715|NCT05070416|EXPERIMENTAL|Crowns adhesively luted|Group 2 receives crowns with an occlusal thickness of 1.2 mm delivered with a dual-curing resin cement (Variolink Esthetic (DC),Ivoclar Vivadent AG).
62352716|NCT05723458|ACTIVE_COMPARATOR|Cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa|
62352717|NCT05723458|PLACEBO_COMPARATOR|Placebo cream containing vaseline|
62352718|NCT04003181|ACTIVE_COMPARATOR|Positive breath test|Patients with a positive breath test are treated with antibiotics.
62352719|NCT04003181|ACTIVE_COMPARATOR|Positive SeHCAT scan|Patients with a positive SeHCAT scan are treated with a bile acid binder.
62352720|NCT04003181|NO_INTERVENTION|No intervention|Patients with a normal breath test and a normal SeHCAT scan receive no intervention.
62511656|NCT02309853|EXPERIMENTAL|Visual and tactile scanning training|20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space combined with trunk rotation
62511657|NCT02309853|ACTIVE_COMPARATOR|Unimodal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training
62511658|NCT01658202|OTHER|Sequence 1|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
62511659|NCT01658202|OTHER|Sequence 2|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
62511660|NCT03347357|EXPERIMENTAL|tacrolimus|
62511661|NCT01731899||agomelatine|patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
62511662|NCT02598895|EXPERIMENTAL|Treatment (docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
62511663|NCT04801108|NO_INTERVENTION|Medical management group|COPD patients with severe emphysema and incomplete lobar fissures will be placed on maximal medical therapy for 3 months. At the end of this 3 month period, patients will fill in an additional set of quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. New pulmonary function testing will be performed and crossover to the intervention group will be offered.
62511664|NCT04801108|EXPERIMENTAL|Intervention group|COPD patients with severe emphysema and incomplete lobar fissures will undergo video-assisted thoracic surgery fissure completion and valves placement. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
62511665|NCT04801108|EXPERIMENTAL|Crossover group|Subjects allocated to the medical management group will be offered to crossover after the 3 months follow-up period. The same procedure as in the intervention group will be performed. Follow-up after surgery will be the same as in the intervention group.
62511666|NCT05600881||ADHD|This study will recruit people aged 14-17 with ADHD who are 'Assigned Female At Birth' (AFAB). This is to include cisgender women alongside those who may not identify with womanhood such as those who are non-binary but AFAB or transgender men who have not undergone hormonal/medical transition.
62511667|NCT05734209|EXPERIMENTAL|Virtual, then real meal|Participant first had two lunch sessions eating virtual food (meal), with a wash-out period of three days. Participants then had two lunch sessions eating real food (meal), with a wash-out period of three days.
62511668|NCT05734209|EXPERIMENTAL|Real, then virtual meal|Participant first had two lunch sessions eating real food (meal), with a wash-out period of three days. Participants then had two lunch sessions eating virtual food (meal), with a wash-out period of three days.
62511669|NCT01776567|ACTIVE_COMPARATOR|Cobalt Chromium Everolimus-eluting stent (Xience Prime)|Cobalt Chromium Everolimus-eluting stent (Xience Prime)
62511670|NCT01776567|ACTIVE_COMPARATOR|Platinum Chromium Everolimus-eluting stent (Promus Element)|Platinum Chromium Everolimus-eluting stent (Promus Element)
62511671|NCT06444321|EXPERIMENTAL|Intervention|A structured, person-centred and coordinated treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level, and the patients' symptoms and needs will be developed by an interdisciplinary team from the hospital and the primary care service. The closest relatives were encouraged to participate. The plan will be followed-up and evetually adjusted after one week and then at least monthly by nurses in the municipality through phone calls and /or home visits. A detailed description will be manualized in a handbook.
61971877|NCT01970449|EXPERIMENTAL|Group 2: study vaccines with CON-S env insert|Participants in this arm will receive DNA CON-S env vaccine injections on Day 0 and Day 28 followed by NYVAC CON-S env vaccine injections on Day 84 and Day 164.
61971878|NCT01970449|PLACEBO_COMPARATOR|Group 2: placebo vaccines with CON-S env insert|Participants in this arm will receive placebo injections of DNA CON-S env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC CON-S env vaccine on Day 84 and Day 164.
61971879|NCT01970449|EXPERIMENTAL|Group 3: study vaccines with Mosaic env insert|Participants in this arm will receive DNA Mosaic env vaccine injections on Day 0 and Day 28 followed by NYVAC Mosaic env vaccine injections on Day 84 and Day 164.
61971880|NCT01970449|PLACEBO_COMPARATOR|Group 3: placebo vaccines with Mosaic env insert|Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.
62511672|NCT06444321|ACTIVE_COMPARATOR|Matche control group|A matched control-group will be recruited from the ongoing IT-HEART RCT
62511673|NCT05305768|ACTIVE_COMPARATOR|OLD (4 U per 0.1 mL)|Participants will receive a total Xeomin dose of 20U using a 4U per 0.1mL concentration divided into 5 intramuscular injections performed once.
62511674|NCT05305768|ACTIVE_COMPARATOR|COLD (4 U per 0.05 mL group)|Participants will receive a total Xeomin dose of 20U using a 4U per 0.05mL concentration divided into 5 intramuscular injections performed once.
62511675|NCT02804282|EXPERIMENTAL|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
62511676|NCT01997294|ACTIVE_COMPARATOR|sequential therapy group|80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
62511677|NCT01997294|PLACEBO_COMPARATOR|Usual Therapy of atorvastatin|20mg/d before and after PPCI for 1 year
62511678|NCT03123757|OTHER|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
61971881|NCT01899690|EXPERIMENTAL|antibiotic|7 days of preventive antibiotics after surgery
62708130|NCT01871376|ACTIVE_COMPARATOR|Treatment-Naive|"Patients that have not received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm."
62511679|NCT03652831|ACTIVE_COMPARATOR|Soft Tissues mobilization with Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques and Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
62511680|NCT03652831|ACTIVE_COMPARATOR|Soft Tissues mobilization without Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques.~Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
62511681|NCT05951348|NO_INTERVENTION|Immediate cord clamping|this arm where the patient didn't receive any special maneuver and immediate cord clamping after delivery of the fetus is done
62511682|NCT05951348|EXPERIMENTAL|Delayed cord clamping|this arm where the patient receive a delay in cord clamping for 30 seconds after delivery of the fetus
62511683|NCT05951348|EXPERIMENTAL|Umbilical cord milking|this arm where the patient receive stripping of the umbilical cord in the direction of the fetus 10 times in a time frame 10-15 seconds after delivery of the fetus
62511684|NCT05567939||Case|Individuals with laboratory confirmed MPXVID
62511685|NCT05567939||Control|Individuals without proctitis and without MPXVID-related symptoms
62511686|NCT04480801|EXPERIMENTAL|thermal evaluation and foot care|Participants in the experimental group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone. Thermal evaluation will be done. The application of the thermal evaluation, the foot areas to be applied and how to record the results of the application will be taught to the patient and / or their relatives. In addition, the thermal evaluation video will be uploaded to the phone of the patient and / or their relative. While the participants in the experimental group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions, Thermal evaluation registration form, Daily step number registration form will be provided and participants will be invited to check every 2 months.
62511687|NCT04480801|OTHER|foot care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone.While the participants in the control group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions will be provided and participants will be invited to check every 2 months.
62511688|NCT02765672|ACTIVE_COMPARATOR|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
62511689|NCT02765672|EXPERIMENTAL|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving tests, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure(FTDS), and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors and receiving feedback from the evaluator after driving the simulator.
62511690|NCT02765672|ACTIVE_COMPARATOR|Caregiver Control Group|Caregiver control group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
62511691|NCT02765672|ACTIVE_COMPARATOR|Caregiver Experimental Group|Caregivers of the experimental group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
62511692|NCT02765672|ACTIVE_COMPARATOR|On-road driving Group|A subset of 30 Combat Veterans will be drawn from the control group (15 no.) and experimental group (15 no.). This group of Combat Veterans will will undergo an on-road driving test at baseline and month 5
62511693|NCT02765672|ACTIVE_COMPARATOR|Simulator-drives Evaluation Group|This group will comprise of 30 Combat Veterans who will be drawn outside of the randomized experimental and and control groups participants. This group will only perform simulator driving triggers evaluation
62511694|NCT06433635|EXPERIMENTAL|Cariprazine|
62511695|NCT06433635|EXPERIMENTAL|Aripiprazole /Escitalopram combination|
62352721|NCT00799929|ACTIVE_COMPARATOR|ARM A - Mini IVF|The Mini IVF method entails pre-treatment with oral contraceptive pills. Ovarian stimulation is achieved using an oral anti-estrogen in conjunction with injections of gonadotropin (225IU-600IU per cycle), with initial dose of 75IU-150IU per injection. Ovulation is induced by a GnRH (gonadotropin-releasing hormone) agonist nasal spray/hCG (human chorionic gonadotropin) injection. Retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. Blastocyst stage embryos are vitrified using the CryoTop method. No fresh embryo transfer is conducted. Subsequently, SET of a thawed blastocyst is performed in a natural cycle/HRT that does not involve ovarian stimulation. SETs are conducted until pregnancy is achieved or all vitrified blastocysts have been used.
62352722|NCT00799929|ACTIVE_COMPARATOR|Arm B - Conventional IVF|The standard IVF method entails pre-treatment with a GnRH analog injections in the midluteal phase. Controlled ovarian hyperstimulation is achieved with injections of gonadotropin (150IU-300IU/day). Ovulation is induced by hCG injection and retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. If this occurs on day 5, then fresh SET/DET (single embryo transfer/double embryo transfer) is performed. Remaining blastocysts are cryopreserved and transferred in subsequent natural cycles/HRT (hormone replacement therapy) that does not involve ovarian stimulation.
62511696|NCT06433635|EXPERIMENTAL|Quetiapine|
62511697|NCT06433635|EXPERIMENTAL|Lurasidone|
62511698|NCT06615869|EXPERIMENTAL|Molnupiravir Treatment A|Participants receive molnupiravir reference capsule.
62511699|NCT06615869|EXPERIMENTAL|Molnupiravir Treatment B|Participants receive molnupiravir Formulation 1.
62511700|NCT06615869|EXPERIMENTAL|Molnupiravir Treatment C|Participants receive molnupiravir Formulation 1 after a high-fat meal.
62146670|NCT04252950|ACTIVE_COMPARATOR|Control|Participants randomized to this group will receive standard of care (revascularization)
62511701|NCT06615869|EXPERIMENTAL|Molnupiravir Treatment D|Participants receive molnupiravir Formulation 2.
62511702|NCT03003260|EXPERIMENTAL|Treatment A - Treatment B|20 patients receive first 3 weeks treatment A and after a week wash-out 3 weeks treatment B
62511703|NCT03003260|EXPERIMENTAL|Treatment B - Treatment A|20 patients receive first 3 weeks treatment B and after a week wash-out 3 weeks treatment A
62511704|NCT03836924||Perampanel|Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.
62511705|NCT04865315||Low grade glioma patients|Patients who have a MRI lesion suspected for a low grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
62511706|NCT04865315||High grade glioma patients|Patients who have a MRI lesion suspected for a high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
62511707|NCT00194792|EXPERIMENTAL|Treatment (hormone therapy and chemotherapy)|See detailed description
62511708|NCT02230618||Ryzodeg™|
62511709|NCT05197777|ACTIVE_COMPARATOR|Group 1 : conservator physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
62511710|NCT05197777|EXPERIMENTAL|Group 2- tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated to physical task from functional activity of daily life. Functional task for the assessment of pain with high-tech tools for the implementation an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. The dummy will be set at the height of the hands in a constrained position for the arms, i.e. with elbows flexed at 60 degrees. Elbow angles will be adjusted in a static position with a manual goniometer. The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes. The elbow will be in a prolonged constraint position, undergoing repetitive movements, for 30 consecutive minutes. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat
62511711|NCT02408445|EXPERIMENTAL|Testosterone treatment|Testosterone cypionate (200 mg/ml) intramuscular injection
62511712|NCT02408445|NO_INTERVENTION|No treatment|Subjects will not receive any testosterone during the study period.
62511713|NCT00385788|EXPERIMENTAL|Gemcitabine + Fludarabine + Melphalan|Gemcitabine 800 mg/m\^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m\^2 IV for 4 days; Melphalan 70 mg/m\^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
62511714|NCT00385788|EXPERIMENTAL|Fludarabine + Melphalan|Fludarabine 33 mg/m\^2 IV for 4 days; Melphalan 70 mg/m\^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
62511715|NCT06085339|EXPERIMENTAL|Social Media Intervention|In addition to receiving usual care, participants enrolled in the social media arm will receive diabetes education and support over the course of 6 months by following the study team's Instagram page and engaging with the study team and other adolescent participants on Instagram.
62708131|NCT04799795||healthy subjects|Age-matched healthy participants will be recruited via flyers at public education facilities and online advertisement. Participants need to be healthy and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
62146671|NCT01857999|EXPERIMENTAL|Losartan|Losartan 50 mg bid orally
62146672|NCT01857999|PLACEBO_COMPARATOR|Placebo|Placebo 1 pill bid orally
62146673|NCT03851094|NO_INTERVENTION|Standard of Care (Group A)|Standard of care is dictated by the HME normal practices for new CPAP patients.
62146674|NCT03851094|EXPERIMENTAL|Wellth App (Group B)|Intervention is use of the Wellth app during the initial compliance period.
62352723|NCT06123390|NO_INTERVENTION|Usual Care|"The 17 health centres randomized to Usual Care will provide care as per OptiMA program."
62352724|NCT06123390|EXPERIMENTAL|Intervention Arm|The 17 health centres randomized to the intervention arm will provide care as per OptiMA program with the addition of the RISQ System decision support.
62352725|NCT05271903|EXPERIMENTAL|Intervention|The MAMA intervention, which is a simulation training intervention for labor and delivery prviders.
62352726|NCT01285791||patients undergoing laparoscopic adjustable gastric banding|morbid obese patients undergoing laparoscopic adjustable gastric banding will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased.
62352727|NCT01285791||patients undergoing laparoscopic sleeve gastrectomy|morbid obese patients undergoing laparoscopic sleeve gastrectomy will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
62352728|NCT01285791||patients undergoing laparoscopic gastric bypass|morbid obese patients undergoing laparoscopic gastric bypass will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
62352729|NCT02595840|EXPERIMENTAL|Arm A: Afatinib|Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
62352730|NCT02595840|EXPERIMENTAL|Arm B: Pemetrexed|Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle
62352731|NCT03831893|SHAM_COMPARATOR|Control|A food product similar to the test products but without nopal
62352732|NCT03831893|EXPERIMENTAL|Nopal food product 1|Food product with Nopal
62352733|NCT03831893|EXPERIMENTAL|Nopal food product 2|Food product with Nopal
62511716|NCT06085339|NO_INTERVENTION|Usual Care|Usual care reflects the standard treatment currently provided to adolescents living with type 1 diabetes. Every adolescent with diabetes is cared for by a team of diabetes specialists which includes a provider (MD, Physician Assistant and/or Nurse Practitioner), registered nurse, nutritionist and social worker. Adolescents with type 1 diabetes are seen by their multidisciplinary team approximately every 3 months. In addition, they have access to their multidisciplinary care team via telephone and/or MyChart communication as often as is necessary between clinic visits.
62511717|NCT05445531|ACTIVE_COMPARATOR|Control|Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to STIKO, German vaccination committee)
62511718|NCT05445531|ACTIVE_COMPARATOR|Recovered|Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline not fulfilled.
62511719|NCT05445531|EXPERIMENTAL|Long Covid|Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline fulfilled.
62511720|NCT05341804|EXPERIMENTAL|the cognitive and balance dual task training group|It is performed using the CogBals software, emphasizing the completion of cognitive tasks while performing balance/strength training during the training process.
62511721|NCT05341804|EXPERIMENTAL|the balance training group|Balance/strength training without cognitive challenges.
62511722|NCT05341804|NO_INTERVENTION|the treatment as usual group|Maintain usual rehabilitation activities.
62511723|NCT01975194|EXPERIMENTAL|Rosuvastatin|Patients that receive rosuvastatin
62511724|NCT01592916||Fibromyalgia|Women with fibromyalgia, aged 20-50 years
62511725|NCT01592916||Healthy controls|Women without severe disease, aged 20-50 years
62511726|NCT05724368||Group 1|Patients with gastrointestinal symptoms and positive only for Blastocystis.
62511727|NCT05724368||Group 2|Patients with gastrointestinal symptoms and Blastocystis free.
62511728|NCT05724368||Group 3|Healthy volunteers with neither gastrointestinal symptoms nor parasitological infections.
62511729|NCT03945799|EXPERIMENTAL|Anlotinib|Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
62511730|NCT02788799||Control|
62511731|NCT02788799||Intervention|
62511732|NCT03302377|EXPERIMENTAL|Physical activity intervention|Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
62511733|NCT01941108|NO_INTERVENTION|Standard HIV Care Arm|Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
62511734|NCT01941108|EXPERIMENTAL|Peer Navigation Arm|Patients in the peer navigation arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will be assigned to a peer navigator who can assist them in overcoming obstacles to their HIV care. They will be given a smartphone with specialized software to help with their navigation. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months and interact with their navigator when necessary.
62708132|NCT04799795||patients with absence epilepsy|Apart from the diagnosis of epilepsy, patients need to be of good health and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
61971882|NCT01899690|NO_INTERVENTION|No antibiotic|No preventive postoperative antibiotics
62511735|NCT05241418||Patients with congenital heart disease undergoing a cardiac MRI with Gadolinium|Patients with congenital heart disease who are undergoing a clinically-ordered cardiac MRI and as part of that MRI the contrast agent, Gadolinium, will be administered.
62511736|NCT06052020||Alirocumab added to statin therapy|Alirocumab (75 mg every 2 weeks for 6 months) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management.
62511737|NCT01680874|EXPERIMENTAL|Probiotic|"This arm will receive a probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219).~The probiotic will be taken orally, once a week, for 4 weeks."
62511738|NCT01680874|PLACEBO_COMPARATOR|Placebo|A placebo will be taken orally, once a day, for 4 weeks.
61971883|NCT03353493|EXPERIMENTAL|MBCT + TAU|Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.
61971884|NCT03353493|OTHER|TAU|Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.
61971885|NCT02120534||Sepsis group|Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
62511739|NCT06168318|EXPERIMENTAL|Part 1 - Regimen A|VH4004280 Formulation A tablet administered in fed conditions.
62511740|NCT06168318|EXPERIMENTAL|Part 1 - Regimen B|VH4004280 Formulation B tablet administered in fed conditions.
62511741|NCT06168318|EXPERIMENTAL|Part 1 - Regimen C|VH4004280 Formulation C tablet administered in fed conditions.
62511742|NCT06168318|EXPERIMENTAL|Part 1 - Optional Regimen D|VH4004280 Formulation D tablet administered in fed conditions.
62511743|NCT06168318|EXPERIMENTAL|Part 1 - Optional Regimen E|VH4004280 Formulation E tablet administered in fed conditions.
62511744|NCT06168318|EXPERIMENTAL|Part 2 - Regimen A|VH4004280 Formulation A tablet administered in fasted conditions.
62511745|NCT06168318|EXPERIMENTAL|Part 2- Optional Regimen 1|VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions.
62708133|NCT04063813|EXPERIMENTAL|40 minute up trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree incline and at 75% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
62708134|NCT04063813|EXPERIMENTAL|40 minute down trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree decline and at 45% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
62708135|NCT04063813|EXPERIMENTAL|Two 20 minute up trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 75% of maximal effort, the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h..Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
62708136|NCT04063813|EXPERIMENTAL|Two 20 min down trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 45% of maximal effort , the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
62708137|NCT04063813|ACTIVE_COMPARATOR|Sedentary trial|No exercise day with isocaloric meals provided at 7:00, 13:00. and 19:00 h.
62708138|NCT03498573|EXPERIMENTAL|tunneling surgical technique|
62708139|NCT01940419|ACTIVE_COMPARATOR|Tranexamic Acid|1g Tranexamic acid iv just before surgery
62708140|NCT01940419|PLACEBO_COMPARATOR|Placebo|sterile sodium chloride 9mg/ml iv
62708141|NCT00980044|EXPERIMENTAL|Tramadol 200 mg then placebo|Tramadol 200 mg daily for 1 week then placebo given for 1 week
62708142|NCT00980044|PLACEBO_COMPARATOR|Placebo for two weeks|Medication
62708143|NCT00980044|EXPERIMENTAL|Tramadol 600 mg then placebo|Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
61971886|NCT02120534||SIRS group|Forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
62511746|NCT06168318|EXPERIMENTAL|Part 2- Optional Regimen 2|VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions.
62708144|NCT02328495|ACTIVE_COMPARATOR|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
62708145|NCT02328495|ACTIVE_COMPARATOR|bladder Filling|Uterine straightening by bladder filling before office hysteroscopy
62708146|NCT02746809|EXPERIMENTAL|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
62708147|NCT02134184|EXPERIMENTAL|CMV negative group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
62708148|NCT02134184|EXPERIMENTAL|CMV positive group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
62511747|NCT06168318|EXPERIMENTAL|Part 2- Optional Regimen 3|VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions.
62708149|NCT02134184|EXPERIMENTAL|Recent CMV Converters|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
62708150|NCT03026179|OTHER|Intervention parents|Parents were asked to view 5-10 minutes of a program designed to educate about discipline.
62708151|NCT06060873||Observational|Patients undergo blood sample collection during screening and throughout the study. Patients whose screening blood samples show elevated miRNA-371 proceed to standard RPLND surgery. Patients whose screening blood samples show normal levels of miRNA-371 undergo standard surveillance followed by standard RPLND surgery at the time of elevated miRNA-371 levels. Patients may also have their medical records reviewed.
62708152|NCT01662206|EXPERIMENTAL|Probiotic|Capsules containing Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum
62708153|NCT01662206|PLACEBO_COMPARATOR|Placebo|Capsules containing placebo
62708154|NCT01818778|EXPERIMENTAL|Stimulation Group|Cognitive Stimulation Group: One-on-one (one volunteer visiting one resident at a time), stimulation-group residents and stimulation-group volunteers met 3 times each week, for 8 weeks, to work through a variety of memory, reasoning, and selective attention exercises. Each visit was 20 minutes in length.
62708155|NCT01818778|ACTIVE_COMPARATOR|Control Group|"Standard Friendly Visit: Control-group residents and control-group volunteers, one-on-one, met for 8 weeks, 3 times each week, for friendly visits. Each visit was 20 minutes in length."
61971887|NCT00806754|ACTIVE_COMPARATOR|1|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and placebo azelastine nasal spray ( two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
61971888|NCT00806754|ACTIVE_COMPARATOR|2|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and azelastine nasal spray (137 mcg/spray, two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
62708156|NCT05106556|ACTIVE_COMPARATOR|Control Group|"Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 weeks. After the training given by the physiotherapist one exercise session will be supervised in a clinic per week, other sessions will be performed at home.~Maximal inspiratory mouth pressure measurements will be measured once a week to eliminate the effect of learning, however the training intensity will remain at the lowest intensity of the device for 8 weeks and will not be increased."
62708157|NCT05106556|EXPERIMENTAL|Inspiratory Muscle Training (IMT) Group|"In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training at %30 of the maximal inspiratory mouth pressure (MIP) value of at least five days a week, for 15 minutes twice days, for 8 weeks at home. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.~Maximal inspiratory mouth pressure measurements will be measured once a week. The training intensity will be increased weekly. At this rate it is 30% of the maximal inspiratory pressure value."
62708158|NCT03837509|EXPERIMENTAL|INCB001158 + daratumumab SC|INCB001158 + daratumumab
62708159|NCT03837509|ACTIVE_COMPARATOR|Daratumumab monotherapy and crossover to INC001158+ daratumumab SC|Daratumumab will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
62708160|NCT03837509|EXPERIMENTAL|INCB001158 monotherapy and crossover to INC001158+ daratumumab SC|INCB001158 will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
61971889|NCT05768880|EXPERIMENTAL|Arm A - DIPG|
61971890|NCT05768880|EXPERIMENTAL|Arm B - DMG & recurrent/refractory tumors|
61971891|NCT00053053|EXPERIMENTAL|Juven supplement|Juven nutritional supplement given twice a day for 8 weeks
61971892|NCT00053053|ACTIVE_COMPARATOR|Non-Juven supplement|Non-Juven nutritional supplement given twice a day for 8 weeks
61971893|NCT01282268|ACTIVE_COMPARATOR|Arbaclofen|
62708161|NCT01585727|EXPERIMENTAL|TME with neuromonitoring|Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
62708162|NCT01585727|ACTIVE_COMPARATOR|TME without neuromontoring|Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
62708163|NCT02107612|EXPERIMENTAL|Integrated system to insert two splinted (bar) miniimplants|Participants were randomly assigned to experimental group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
62708164|NCT02107612|ACTIVE_COMPARATOR|Denture|Participants were randomly assigned to comparator group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
62708165|NCT03715790||EP Referred Group|Subjects with EF ≤ 40% or meeting one of the referral criteria
62708166|NCT03715790||Non-Referred Group|Subjects with 40%\< EF \<50%.
62708167|NCT01596426|EXPERIMENTAL|Sancuso Arm|patch
62708168|NCT01596426|ACTIVE_COMPARATOR|IV granisetron|IV
61971894|NCT01282268|PLACEBO_COMPARATOR|Placebo|
61971895|NCT01890850||Pertussis Group|Infants less than one year of age diagnosed with pertussis/whooping cough infection within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
61971896|NCT01890850||Control Group|Infants with no evidence of pertussis/whooping cough during within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
62146675|NCT00407888|EXPERIMENTAL|Arm I|Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
62352734|NCT05984810|EXPERIMENTAL|10mg, administered 3-5 days before surgery|"Drug: SGM-101 Intravenous single injection of the targeted NIR fluorophore SGM-101. This targeted 700nm fluorophore developed by SurgiMab S.A.S., Montpellier, France.~Device: Intraoperative near-infrared fluorescence imaging Intraoperative imaging will be performed with the following CE-marked near-infrared (NIR) fluorescence imaging system: Quest Spectrum imaging platform (v2/3.0). With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure."
62708169|NCT06344091|EXPERIMENTAL|Bupivacaine Liposome Injection|
61971897|NCT04371991||Group 1|Ectopic pregnancy
61971898|NCT04371991||Group 2|Early viable pregnancy
61971899|NCT04371991||Group 3|incomplete miscarriage
61971900|NCT04371991||Group 4|Healthy women
61971901|NCT04653129|EXPERIMENTAL|Group (A): Primary nerve repair with autologous fat graft|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope with autologous fat grafting around site of repair
61971902|NCT04653129|ACTIVE_COMPARATOR|Group (B): Standard primary nerve repair|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope without fat grafting.
61971903|NCT02597894|OTHER|Prostate biopsy|Patients undergo two biopsies, the first at baseline before start of ADT and the second two months later during brachytherapy.
61971904|NCT01485770|EXPERIMENTAL|Placebo, Then ADX-N05|Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
61971905|NCT01485770|PLACEBO_COMPARATOR|ADX-N05, Then Placebo|Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).
61971906|NCT02598154||Study population|The study population consists of patients whose age is between 20 and 75 years and who experienced a supra-tentorial ischemic or hemorrhagic stroke. The study covers inpatients or patients consultating in the neurological rehabilitation service (NHS) at the Grau du Roi Medical Center, Nîmes University Hospital.
61971907|NCT03628560|EXPERIMENTAL|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
62146676|NCT02981329|EXPERIMENTAL|Group A: Hydroxyurea + Metformin|Subjects who are currently taking Hydroxyurea as part of standard of care and have sickle cell anemia.
62146677|NCT02981329|EXPERIMENTAL|Group B: Metformin (Group B has closed to enrollment)|Subjects who are not taking Hydroxyurea as part of standard of care and have sickle cell anemia.
61971908|NCT03628560|EXPERIMENTAL|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
62146678|NCT02693288|NO_INTERVENTION|Ultrasound-guided nerve block|
61971909|NCT03628560|EXPERIMENTAL|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
61971910|NCT03628560|EXPERIMENTAL|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
62511748|NCT06168318|EXPERIMENTAL|Part 3 - Optional Regimen 1|VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions.
62511749|NCT06168318|EXPERIMENTAL|Part 3- Optional Regimen 2|VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions.
62511750|NCT06168318|EXPERIMENTAL|Part 3 - Optional Regimen 3|VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions.
62511751|NCT06168318|EXPERIMENTAL|Part 3 - Optional Regimen 4|VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions.
62511752|NCT03124290|OTHER|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
62511753|NCT03124290|OTHER|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
62511754|NCT05523570|EXPERIMENTAL|20 mg HNC364|"pre-study will recruit 2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension.~Then 8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 20 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 80 days post dose."
62511755|NCT05523570|EXPERIMENTAL|40 mg HNC364|8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 40 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 29 days post dose.
62511756|NCT05523570|EXPERIMENTAL|60 mg HNC364|8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 60 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 60 days post dose.
62511757|NCT05523570|EXPERIMENTAL|80 mg HNC364|8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 80 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 60days post dose.
62708170|NCT04812327||Prospective Observational Diagnostic Evaluation|Potential participants will be recruited at study sites where they are admitted/held for COVID-19 isolation. On the first day of isolation (ideally on the day they first test positive for SARS-CoV-2), potential participants will be asked to participate in the study. After consent (Study Day 0), two nasopharyngeal swabs (NP swabs) and one nasal swab will be collected. One NP swab will be tested via viral culture and the other nasal swab will be tested by RT-PCR for SARS-CoV-2. The nasal swab will be tested on the BD Veritor System. Specimen collection and testing will be repeated every 2 days for 6 days (Study Day 2, Day 4, and Day 6) or until the RT-PCR Ct value is \>30, whichever comes first. Participants will be monitored for symptoms of COVID-19 throughout the study.
62708171|NCT03404882|EXPERIMENTAL|text messaging plus peer support arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. In addition to peer support, participants in this arm of the study will receive daily supportive text messages from an automated online application and reminder text messages for their community clinic/program appointments.
61971911|NCT03628560|ACTIVE_COMPARATOR|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
61971912|NCT03735225|EXPERIMENTAL|IV Dasiglucagon|Dasiglucagon 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
61971913|NCT03735225|EXPERIMENTAL|SC 0.6 mg Dasiglucagon|Dasiglucagon 0.6 mg administered SC as a single dose
62708172|NCT03404882|ACTIVE_COMPARATOR|supportive/reminder text message only arm|Patients in the supportive/reminder text message only arm of the study will receive daily supportive text messages from the automated online application and reminder text messages for their community clinic/program appointments.
62708173|NCT03404882|NO_INTERVENTION|Control arm|Patients in the control arm of the study will receive the usual follow-up appointment offered to all patients who are discharged from acute care. However, they will not receive peer support or supportive/reminder text messages.
61971914|NCT03735225|PLACEBO_COMPARATOR|IV Placebo|Placebo 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
61971915|NCT04893967|NO_INTERVENTION|No Intervention: RMS mean hip abduction, dynamometer|Isometric peak force hip abduction pre measurement. No tape.
61971916|NCT04893967|NO_INTERVENTION|No Intervention: Average force hip abduction, dynamometer|Isometric average force hip abduction pre measurement. No tape.
61971917|NCT04893967|NO_INTERVENTION|No Intervention: Time to reach peak force hip abduction, dynamometer|Time to reach peak force hip abduction pre measurement. No tape.
61971918|NCT04893967|NO_INTERVENTION|No Intervention: RMS mean hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) mean. No tape.
62146679|NCT02693288|EXPERIMENTAL|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaine 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
62511758|NCT02264535|EXPERIMENTAL|0.1mg/ml Ginkgolides Meglumine Injection|Injection, 0.1mg/ml.
61971919|NCT04893967|NO_INTERVENTION|No Intervention: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) mean per second. No tape.
61971920|NCT04893967|NO_INTERVENTION|No Intervention: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) Max. contraction test. No tape.
61971921|NCT04893967|EXPERIMENTAL|Experimental: peak force hip abduction, dynamometer|Isometric peak force hip abduction post experimental application measurement with Magnetic Tape application
61971922|NCT04893967|EXPERIMENTAL|Experimental: Average force hip abduction, dynamometer|Isometric average force hip abduction post experimental application measurement with Magnetic Tape application
61971923|NCT04893967|EXPERIMENTAL|Experimental: time to maximum force hip abduction, dynamometer|Time to maximum force hip abduction post experimental application measurement with Magnetic Tape application
62511759|NCT02264535|EXPERIMENTAL|1mg/ml Ginkgolides Meglumine Injection|Injection, 1mg/ml.
62708174|NCT03404882|ACTIVE_COMPARATOR|peer support only arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. Patients will not receive daily supportive/reminder text messages
62708175|NCT05120492|EXPERIMENTAL|Surgical weight loss|sleeve gastrectomy + dietary and lifestyle counseling prior to total knee replacement
61971924|NCT04893967|EXPERIMENTAL|Experimental: RMS mean hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) with Magnetic Tape application.
62708176|NCT05120492|NO_INTERVENTION|Standard of Care|dietary and lifestyle counseling prior to total knee replacement
62708177|NCT02891226|EXPERIMENTAL|Mirikizumab|"Period 1 (Weeks 0 -12): 200 Milligram (mg), 600 mg, and 1000 mg mirikizumab administered intravenously (IV) every 4 Weeks (Q4W).~Period 2 (Weeks 12 - 52): 200 mg, 600 mg, and 1000 mg mirikizumab administered IV Q4W; 300 mg mirikizumab administered subcutaneously (SC) Q4W; 1000 mg mirikizumab administered IV Q4W for non-improvers in period 1; and 1000 mg mirikizumab administered IV Q4W for participants on placebo during period 1.~Period 3 (Weeks 52 - 208): 300 mg mirikizumab administered SC Q4W."
62708178|NCT02891226|PLACEBO_COMPARATOR|Placebo|Period 1 (Weeks 0 -12): Participants received placebo administered intravenously (IV) Q4W.
62708179|NCT05511948|EXPERIMENTAL|DBI-102|Topical DBI-102 Gel, 0.8% twice daily for 12 weeks for the randomized cohort
61971925|NCT04893967|EXPERIMENTAL|Experimental: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) mean per second. With Magnetic Tape application.
61971926|NCT04893967|EXPERIMENTAL|Experimental: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) max. contraction test. With Magnetic Tape application.
61971927|NCT04893967|PLACEBO_COMPARATOR|Placebo: peak force hip abduction, dynamometer|Isometric peak force hip abduction post placebo measurement with kinesiology tape application
61971928|NCT04893967|PLACEBO_COMPARATOR|Placebo: Average force hip abduction, dynamometer|Isometric average force hip abduction post placebo application measurement with kinesiology tape application
61971929|NCT04893967|PLACEBO_COMPARATOR|Placebo: Time to reach peak force hip abduction, dynamometer|Time to reach peak force hip abduction post placebo application measurement with kinesiology tape application
61971930|NCT04893967|PLACEBO_COMPARATOR|Placebo: RMS mean hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) mean. With kinesiology tape application.
62708180|NCT05511948|PLACEBO_COMPARATOR|Vehicle gel|Inactive comparator
61971931|NCT04893967|PLACEBO_COMPARATOR|Placebo: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) mean per second. With kinesiology tape application.
61971932|NCT04893967|PLACEBO_COMPARATOR|Placebo: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) max. contraction test. With kinesiology tape application.
61971933|NCT03728660|EXPERIMENTAL|LVES 2 first LEGACY second|Virtual bioptic magnification with large field of view (LVES 2) followed by 22-week washout period and then Full field magnification with small field of view (LEGACY)
61971934|NCT03728660|ACTIVE_COMPARATOR|LEGACY first LVES 2 second|Full field magnification with small field of view (LEGACY) followed by 22-week washout period and then Virtual bioptic magnification with large field of view (LVES 2)
62708181|NCT05511948|ACTIVE_COMPARATOR|Hydroquinone cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
62708182|NCT00189423|EXPERIMENTAL|1|Active compression decompression cardiopulmonary resuscitation (ACD-CPR) with an impedance threshold device (ITD)
62708183|NCT00189423|ACTIVE_COMPARATOR|2|Conventional standard cardiopulmonary resuscitation (S-CPR)
62708184|NCT01527994|EXPERIMENTAL|Aprepitant 125 mg|Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
61971935|NCT06034236|EXPERIMENTAL|Resistance Training|"In Group A, Task oriented resistance training will be performed, there will be 5 workstations which include 2 task each given in the table below, after warm up exercises of head, neck, trunk and ankle.~Workstation 1: Sitting and reaching in different directions Sit to stand from different chair heights (higher to lower) Workstation 2: Step training (forward, backward, sideways) on blocks Heel lifts-sitting, standing (with and without support) Workstation 3: Reaching with narrow stance (feet in parallel, then in tandem stance) Reciprocal leg flexion and extension Workstation 4: Sit ups Chair stand and walk Workstation 5: Walking race Walking over obstacles This intervention will be given 3 times per week for 4 weeks, every station takes 5-6 minutes and the total intervention will be completed in 50-60 minutes."
62708185|NCT01527994|PLACEBO_COMPARATOR|Placebo|Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
62708186|NCT00468247|ACTIVE_COMPARATOR|1|Device , Navigator used for guiding haemodynamic care
62708187|NCT00468247|PLACEBO_COMPARATOR|2|Conventional care
62511760|NCT02264535|EXPERIMENTAL|5mg/ml Ginkgolides Meglumine Injection|Injection, 5mg/ml.
62708188|NCT00293176|EXPERIMENTAL|1|
62708189|NCT00293176|PLACEBO_COMPARATOR|2|
62708190|NCT06074432||Emergency Colorectal Cancer Resection|Patients that underwent emergent resection because of histopathologically confirmed colorectal carcinoma
62708191|NCT06264635|EXPERIMENTAL|Platelet-Rich-Plasma (PRP)|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
62708192|NCT06264635|PLACEBO_COMPARATOR|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
62511761|NCT04924244|ACTIVE_COMPARATOR|No Music|No music will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
62511762|NCT04924244|EXPERIMENTAL|Music Therapy|Music of the subject's preferred genre will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
62511763|NCT05518916|EXPERIMENTAL|Yakson Method Group|"* The mother is informed about the benefits of the Yakson method.~* Yakson method is taught practically to the mother. Education continues until the researcher is sure that the mother has done the method correctly. The mother starts the application 10 minutes before the heel lancing is done and continues for another 5 minutes after the heel lancing is done. During the application, the baby is recorded with the camera. Just before starting the Yakson method (initial assessment), at 10 minutes of the Yakson method (just before the heel lancing), during the heel lancing while the Yakson method is in progress, and 5 minutes after the procedure (just before the end of the tender touch), the newborn's pain and physiological parameters are evaluated. Evaluation results are recorded in the application observation form."
62511764|NCT05518916|EXPERIMENTAL|Swaddling Group|"* Parents are informed about the research and verbal consent is obtained.~* Written consent is obtained with an informed consent form.~* The Mother-Baby Information Form is filled.~* Babies are fed 1 hour before blood collection.~* And researher swaddling the baby"
62511765|NCT05518916|NO_INTERVENTION|Control Group|"Parents are informed about the research and verbal consent is obtained.~* Written consent is obtained with an informed consent form.~* The Mother-Baby Information Form is filled.~* Babies are fed 1 hour before blood collection.~* Before starting the heel lancing, a pulse oximeter probe will be attached to the baby's left big toe.~* Blood is taken from the right heel of the foot.~* During the application, the baby is recorded with the camera.~* Evaluation results are recorded in the application observation form."
62511766|NCT00727519|EXPERIMENTAL|PG|
62511767|NCT00727519|EXPERIMENTAL|PL|
62511768|NCT05197829|EXPERIMENTAL|Continuous Glucose Monitoring|
62511769|NCT05197829|ACTIVE_COMPARATOR|Care Coordination|
62511770|NCT01573533|EXPERIMENTAL|Rituximab|
62511771|NCT02201459|ACTIVE_COMPARATOR|Nilotinib|Control arm, this compound been licensed in this indication.
62511772|NCT02201459|EXPERIMENTAL|Peg-IFN alfa 2a (Pegasys®) and Nilotinib|Arm testing the efficacy of a combination of nilotinib and Peg-IFN alfa 2a as frontline therapy for first line chronic phase CML patients.
62511773|NCT05715476|ACTIVE_COMPARATOR|sea levelaltitude|Pregnant women living in Giresun(sea levelaltitude),Turkey and undergoing cesarean section under elective conditions.
62511774|NCT05715476|ACTIVE_COMPARATOR|moderate altitude|Pregnant women living in Çorum(moderate altitude),Turkey and undergoing cesarean section under elective conditions.
62511775|NCT05715476|ACTIVE_COMPARATOR|high altitude|Pregnant women living in Van(high altitude),Turkey and undergoing cesarean section under elective conditions.
62511776|NCT05743049||Blood specimens|Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.
62511777|NCT01562626|EXPERIMENTAL|Dose escalation|
62511778|NCT04079491||dental hygienists|all dental hygienists members in the trade union for dental hygienists
61971936|NCT06034236|EXPERIMENTAL|Otago Exercises|"Group B will be given Otago exercises, it has 17 exercises in total. 5 for strength and 12 for balance training.~1. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2. Muscle strengthening:~   Font knee strengthening exercise Back knee strengthening exercise Side hip strengthening exercise Calf raises (with support and without support) Toe raise (with support and without support).~3. Balance Training:~Knee bends Backward walking Heel toe standing Heel toe walking One leg stand Heel walking Sideways walk Toe walking Heel toe walking backwards Walk and turn around (figure of 8) Sit to stand Stair walks This intervention will be given 3 times per week for 4 weeks, each session will take 50 minutes to complete. And every exercise is repeated 10 times"
61971937|NCT05360576|EXPERIMENTAL|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|Test Product
62511779|NCT03400280|EXPERIMENTAL|Best practice|Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.
62511780|NCT03400280|NO_INTERVENTION|Current practice|Postoperative care according to current usual practice.
62511781|NCT00909584|EXPERIMENTAL|1|4-Week dose equilibration period with Telintra followed by 4 month treatment period
62511782|NCT00909584|NO_INTERVENTION|2|4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period
62511783|NCT03534193|OTHER|Group 1|Participants randomized to Group 1 will receive Standard Diabetic Education with Registered Nurse and Molly Center Diabetes Care Guide (paper-based)
62511784|NCT03534193|EXPERIMENTAL|Group 2|Participants randomized to Group 2 will receive Molly Center Standard Diabetes Education plus access to Tablet based interactive diabetes education modules
62511785|NCT03925935|EXPERIMENTAL|Experimental|Up to 3 sequential dose escalation cohorts of AB-205
62511786|NCT00945334|EXPERIMENTAL|Group 1|Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
62511787|NCT00945334|EXPERIMENTAL|Group 2|Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
62511788|NCT03326986|EXPERIMENTAL|Panel A|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
62539411|NCT03795038|OTHER|Lipoprotein Apheresis DIAMED and DALI|"Patients routinely treated with DIAMED:~* The first subgroup will be treated first with the DIAMED adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber system.~* The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DIAMED adsorber System."
62539412|NCT02055664|EXPERIMENTAL|treatment|
62708193|NCT06071676|OTHER|conventional impression procedures|Implant analogues were screwed to the transfer copings inside the impression and the master cast were obtained. Attachments were screwed to the analogues and metal housing wasplaced on their position on master cast. Master cast will be scanned extra orally to obtain STL file of the master cast.
62708194|NCT06071676|OTHER|digital impression procedures|"A digital scanner (shining 3D scanner, Germany) was utilized to fabricate the definitive prostheses. The attachments were screwed to the implants intra orally and metal housing on their position which scanned by using intra oral scanner.~* Intra oral scanner transformed into a virtual volume the three-dimensional geometry of dental arches using the principle of structured light. A scanning stitching strategy carried out by the same experienced investigator and applied to DIG group for the attachments on their position on implants.~* The software automatically was applied a stitching algorithm in order to merge the two halves, based on the area between the two anterior implants, shared by both the separate scans.~* The virtual model was created of the dental implant and attachments in position which used to obtain 3d printed master cast by using 3D printer (WANHAO desktop 3D printer, Zhejiang, China)."
61971938|NCT05360576|ACTIVE_COMPARATOR|NuvaRing® (etonogestrel/ethinyl estradiol 11.7/2.7 mg)|Reference Product
61971939|NCT06008457||Self-collection first|Subjects will self-collect an anterior nasal swab first
62708195|NCT02196922|ACTIVE_COMPARATOR|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
61971940|NCT06008457||HCP-collection first|Subjects will have their healthcare provider collect an anterior nasal swab first
61971941|NCT04016753|EXPERIMENTAL|Monotherapy|
62511789|NCT03326986|EXPERIMENTAL|Panel B|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
62511790|NCT03326986|EXPERIMENTAL|Panel C|Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
62511791|NCT05730712|EXPERIMENTAL|Treatment (HP, enzalutamide)|Patients receive pertuzumab, trastuzumab, and hyaluronidase-zzxf SC and enzalutamide PO on study. Patients undergo ECHO, biopsy, CT, and MRI scans. Patients also undergo collection of blood and tissue samples.
62511792|NCT04355949|EXPERIMENTAL|Patients with premature ejaculation|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
61971942|NCT03543579||Multiple myeloma patients|Patients with multiple myeloma and an indication to receive carfilzomib
62352735|NCT02877849||Individuals with Alcohol Use Disorder|Individuals with Alcohol Use Disorder will be recruited from Lodging Plus treatment program (Fairview Riverside Hospital, Minneapolis, MN). All patients will have between 2-3 weeks of abstinence from alcohol use. We will collect brain imaging data, this is an observational study.
62352736|NCT02877849||Healthy Volunteers|Healthy volunteers with comparable age and gender to the patient group will be recruited through community advertisements. We will collect brain imaging data, this is an observational study.
62352737|NCT02448004|EXPERIMENTAL|JNJ-63623872|Participants will receive a single 600-milligram (mg) dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
61971943|NCT02034279|EXPERIMENTAL|Intravenous infusion of albumin|Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics
61971944|NCT02034279|NO_INTERVENTION|No albumin|Only antibiotics
61971945|NCT01029795|EXPERIMENTAL|LY2599506|Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
61971946|NCT01029795|ACTIVE_COMPARATOR|Glyburide|Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
61971947|NCT02117648|EXPERIMENTAL|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
61971948|NCT02117648|EXPERIMENTAL|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
61971949|NCT02117648|EXPERIMENTAL|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
62352738|NCT00987519||Acute bronchiolitis|Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation.
62352739|NCT00987519||Acute gastroenteritis|Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study.
62352740|NCT00987519||Febrile convulsion|Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection.
62352741|NCT00987519||Control group|Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection.
62511793|NCT04355949|EXPERIMENTAL|Normal subjects|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
62511794|NCT00702208|OTHER|Single arm study|Paired laboratory results for clinician-collected and Screener collected specimens for cytology (and high-risk human papillomavirus testing for sub-sample)
62539413|NCT02055664|PLACEBO_COMPARATOR|control|
62511795|NCT02674633|ACTIVE_COMPARATOR|AKL-T01 (EVO Multi)|AKL-T01, or EVO Multi, is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
62511796|NCT02674633|ACTIVE_COMPARATOR|AKL-T09 (EVO Words)|AKL-T09, or EVO Words, is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
62511797|NCT05585931|EXPERIMENTAL|Cohort 1|9 subjects receive 10 mg TPN171H for Period 1; Placebo for Period 2
62511798|NCT05585931|EXPERIMENTAL|Cohort 2|9 subjects receive Placebo for Period 1; 10 mg TPN171H for Period 2
62511799|NCT05327855|EXPERIMENTAL|OPL-0301 Dose 1|Participants are randomized to OPL-0301 Dose 1 administered once daily for 90 days
62511800|NCT05327855|EXPERIMENTAL|OPL-0301 Dose 2|Participants are randomized to OPL-0301 Dose 2 administered once daily for 90 days
62511801|NCT05327855|PLACEBO_COMPARATOR|Placebo|Participants are randomized to matching placebo administered once daily for 90 days
62511802|NCT03345264|EXPERIMENTAL|Cancer patients, survivors, and partners|
62511803|NCT01688726|EXPERIMENTAL|SYSTANE BALANCE|SYSTANE® BALANCE eyedrops, 1 drop 4 times a day for a continuous period of 1 month
62511804|NCT01688726|ACTIVE_COMPARATOR|Minims Saline|Minims® Saline 0.9% eyedrops, 1 drop 4 times a day for a continuous period of 1 month
62511805|NCT05282979|EXPERIMENTAL|Tixel 2|Tixel 2 Treatment, 4 treatment sessions, followed by 2 Follow up sessions, 1 and 3 months after last treatment visit. Subject would be questioned about pain level, subjective downtime assessment and subjective response assessment. Images would be taken at the baseline and in Follow up visits.
62511806|NCT03988452|ACTIVE_COMPARATOR|Darunavir/r Zidovudine Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
62511807|NCT03988452|EXPERIMENTAL|Darunavir/r Tenofovir Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
62511808|NCT03988452|EXPERIMENTAL|Dolutegravir Zidovudine Lamivudine|Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
62511809|NCT03988452|EXPERIMENTAL|Dolutegravir Tenofovir Lamivudine|Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
62511810|NCT01918579|EXPERIMENTAL|CRP intervention|Patients will be tested by rapid POC CRP test
62511811|NCT01918579|NO_INTERVENTION|Control|Patients will not be tested by rapid POC CRP test
62708196|NCT02196922|EXPERIMENTAL|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
62511812|NCT00987831|EXPERIMENTAL|Blood drawing only Group C|Healthy controls, age, sex and ethnicity matched to the active study participants were recruited for two time blood donation as controls for the biomarker studies
62511813|NCT00987831|EXPERIMENTAL|Group A SLE prospective study|In Group A SLE patients enter with active disease. Any immune suppressant (e.g. methotrexate, azathioprine or mmf) is withdrawn and after blood drawing, depomedrol up to 160 mg IM is given. This may be repeated for a maximum of 160mg up to four times total in the first two weeks. Depomedrol is expected to last 1-3 months, serial biomarkers will be drawn until time of flare, at which time biomarkers will be drawn, patient is defined as meeting endpoint and new treatment initiated. Patients may elect to continue to donate blood samples per protocol up to one year.
62511814|NCT00987831|EXPERIMENTAL|Group B SLE one blood donation|SLE patients who meet the same entry criteria as Group A could elect to donate blood one time and not to continue in the prospective protocol. No extra intervention was performed other than blood draw and medical records review. This allowed an extension of cross sectional comparisons between biomarker changes related to background treatments by combining Group A baseline data with Group B data.
62511815|NCT03439579|EXPERIMENTAL|Home weight loss program|Participants will be instructed to daily monitor their body weight, minutes of activity, number of steps, and calories consumed for the duration of the pilot study, and they will receive recorded individualized feedback on this self-monitored data from Weight Management Center clinicians (registered dietitians, exercise psychologists, and behavioral specialists).
62511816|NCT00099268|EXPERIMENTAL|Carbidopa/levodopa/entacapone|Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
62511817|NCT00099268|ACTIVE_COMPARATOR|Immediate release carbidopa/levodopa|Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
62511818|NCT00221962|OTHER|Open label treatment with aripiprazole|After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.
62511819|NCT00058214|EXPERIMENTAL|Treatment (perifosine)|Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.
62511820|NCT02682186|NO_INTERVENTION|Control group (1)|The PECS Blocks are not (1) performed.
62511821|NCT02682186|EXPERIMENTAL|PECS group (2)|The PECS Blocks are performed (2): A single injection of Ropivacaine after dilution with sodium chloride 0.9% per fascial plane and per side.
62708197|NCT00590317|ACTIVE_COMPARATOR|Prochlorperazine|Patients receiving Prochlorperazine 10mg IV
62708198|NCT00590317|ACTIVE_COMPARATOR|Ondansetron|Patient receiving Ondansetron 4mg IV
62708199|NCT01086527|EXPERIMENTAL|SLCO2B1{NM_007256.2}:c.[935G>A] + [=]|Individuals in this group will be homozygous for SLCO2B1{NM_007256.2}:c.\[935G\>A\].
62708200|NCT02348190|ACTIVE_COMPARATOR|Lipid/heparin|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) lipid/heparin co-infusion for 8 hours.
62511822|NCT03060850|EXPERIMENTAL|AC0010MA|This is dose escalation study. Patients will receive AC0010MA 200mg bid,300mg bid,400mg bid or 500mg bid by mouth (the dose escalation whether ended depends on DLT and occupancy) everyday until intolerable toxicity or disease progression
62511823|NCT02297750|ACTIVE_COMPARATOR|single wire technique|single wire technique in patients undergoing ERCP with biliary cannulation
62511824|NCT02297750|ACTIVE_COMPARATOR|Double wire technique|double-wire technique in patients undergoing ERCP with biliary cannulation
62511825|NCT01768819|EXPERIMENTAL|Intervention Group|Physical Activity
62511826|NCT01768819|NO_INTERVENTION|Control Group|
62511827|NCT04919759|ACTIVE_COMPARATOR|Rashakaty Basic (R-Basic)|Participants in the R-Basic intervention arm had access to a website that contained the study questionnaires and nutrition education materials
62511828|NCT04919759|EXPERIMENTAL|Rashakaty Enhanced (R-Enhanced)|Participants in the R-Enhanced intervention were given access to smart phones applications for monitoring diet and physical activity levels as well as an online access to a nutritionist
62511829|NCT06453460|EXPERIMENTAL|AHCT recipients|
62511830|NCT01083680||Participants with Crohn's Disease (CD)|Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.
62511831|NCT05031247|EXPERIMENTAL|Community Navigator Social Support|More intensive case management and weekly check-ins with older adults. The Community Navigator will be focused on increasing social contact and connection for older adult refugees and immigrants. Those who receive the intervention will be offered up to ten (30-minute-long) meetings with a Community Navigator and access to up to three group sessions over a 3-month period, alongside the standard services they receive for enrollment with the organization.
62511832|NCT05031247|NO_INTERVENTION|Program Support as Usual|Standard program support will be provided to participants enrolled. These services are offered to all enrolled in the program and may include, but is not limited to the following: financial assistance services, case management, healthcare access services, employment and tax services, education services, citizenship and immigration services, community services and civic engagement, and refugee services.
62511833|NCT06616571|EXPERIMENTAL|24h group|
62511834|NCT06616571|ACTIVE_COMPARATOR|48h group|
62511835|NCT05699291||Patient eligible for the sentinel lymph node technique by lndocyanine Green.|To evaluate the overall cost at 1 month of the sentinel lymph node detection technique using Indocyanine Green in patients with breast cancer, from the point of view of the health insurance and the hospital.
62511836|NCT05699291||Patient eligible for the sentinel lymph node technique by isotopes.|To evaluate the overall cost at 1 month of the sentinel lymph node detection technique using isotopes in patients with breast cancer, from the point of view of health insurance and the hospital.
62511837|NCT05215171||World Trade Center - Airway Hyperreactivity (WTC-AHR)|WTC-AHR cases are defined as having either a positive MCT (PC20\<16) and/or positive BDR (by ATS/ERS guidelines with improvement of FEV1 by 12% and at least 200mL) post-9/11.
62511838|NCT05215171||Control Group|Cohort Controls will be randomly selected 10% of the baseline cohort
62511839|NCT02182167|EXPERIMENTAL|IV NAC|"Participants will receive IV N-acetylcysteine or placebo. The dosing regimen is based on the regimens used in paracetamol poisoning .~Initial dose: 150 mg/kg body mass of N-acetylcysteine/WFI infused in 200 mL of 5% dextrose intravenously over 60 minutes, followed by continuous infusion: 50 mg/kg body mass in 500 mL of 5% dextrose over next 4 hours, followed by 100 mg/kg body mass in 1 litre of 5% dextrose over 16 hours."
62511840|NCT02182167|PLACEBO_COMPARATOR|Placebo|Water
62511841|NCT05966311|EXPERIMENTAL|Percutaneous Ultrasound Gastrostomy (PUG)|Enrolled subjects will receive the PUG procedure using the PUMA-G Pediatric System performed by an Interventional Radiologist
62511842|NCT05966311|NO_INTERVENTION|Percutaneous Radiologic Gastrostomy|A matched, retrospective control cohort of patients previously admitted to hospital for the placement of gastrostomy tubes by Interventional Radiology will be used to compare performance of the PUMA-G Pediatric System to standard of care.
62511843|NCT02013752|ACTIVE_COMPARATOR|Perineal device during delivery|"Delivery should be managed by using the perineal protection device when the head was crowning and 5-6 cm of it was visible. One part the tongue was inserted between the head and the posterior vaginal wall and the two wings were held against the perineum and kept in place by the delivery attendant's hand."
62511844|NCT02013752|OTHER|Standard care|Standard care at delivery: Manual support of the perineum
62511845|NCT05354089|EXPERIMENTAL|Vaccine group 1|20 μg dose of SYS6006 vaccine IM, on day 0 and day 21.
62708201|NCT02348190|PLACEBO_COMPARATOR|Control|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and without (n=16) lipid/heparin co-infusion for 8 hours.
62511846|NCT05354089|EXPERIMENTAL|Vaccine group 2|30 μg dose of SYS6006 vaccine IM, on day 0 and day 21.
62511847|NCT05354089|PLACEBO_COMPARATOR|Placebo|Placebo IM, on day 0 and day 21.
62511848|NCT02471937|EXPERIMENTAL|Pregnant women negative for GBS colonization|Only women negative for GBS during all the study will be included.
62511849|NCT05909917|ACTIVE_COMPARATOR|In-Person|Participants will undergo a previously validated, half-day first responder training course, taught live in-person by local instructors in each study location. Participant knowledge acquisition will be measured via a 23-question pre/post-training assessment, administered in person. Participant skill performance will be measured via direct observation grading of a standardized patient encounter, performed in person.
62511850|NCT05909917|EXPERIMENTAL|Virtual|In a controlled computer laboratory setting, participants will undergo an experimental first responder training course consisting of a half-day of pre-recorded video, lecture notes, and illustrations. Participant knowledge acquisition will be measured via a 23-question pre/post-training assessment, administered in person. Participant skill performance will be measured via direct observation grading of a standardized patient encounter, performed in person.
62511851|NCT06318039|EXPERIMENTAL|Novel program|Rehabilitation using a novel program
62511852|NCT06318039|ACTIVE_COMPARATOR|Traditional program|Rehabilitation using a traditional program
62511853|NCT05542316||Patients with a recent diagnosis of PMR|
62511854|NCT04188548|EXPERIMENTAL|Dose Escalation LY3484356|LY3484356 given orally.
62511855|NCT04188548|EXPERIMENTAL|Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI|LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
62511856|NCT04188548|EXPERIMENTAL|Part B: Dose Expansion: Cohort E3: LY3484356|LY3484356 given orally.
62511857|NCT04188548|EXPERIMENTAL|Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus|LY3484356 and everolimus given orally.
62511858|NCT04188548|EXPERIMENTAL|Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib|LY3484356 and alpelisib given orally.
62511859|NCT04188548|EXPERIMENTAL|Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib|LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
62511860|NCT04188548|EXPERIMENTAL|Part D: Dose Expansion: LY3484356 +/- Abemaciclib|LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
62511861|NCT04188548|EXPERIMENTAL|Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab|LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
62511862|NCT04196452||Arm A: participants 12 to under 18|
62511863|NCT04196452||Arm B: participants under 12|
62511864|NCT01402154||All study patients|All patients included according to stated inclusion and exclusion criteria.
62511865|NCT05577806||DYG|oocyte donors undergoing controlled ovarian stimulation in a progestin-primed ovarian stimulation protocol with DYG protocol (20mg/day)
62511866|NCT05577806||Cetrorelix|oocyte donors undergoing controlled ovarian stimulation in a GnRH antagonist protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm
62511867|NCT00380549|ACTIVE_COMPARATOR|CONSERVE® A-Class THA BFH|CONSERVE® A-Class Total Hip with BFH technology. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® acetabular component and the CONSERVE® A-Class BFH femoral head. Blood ion levels will be collected and analyzed.
62511868|NCT00380549|ACTIVE_COMPARATOR|CONSERVE® Plus Total Resurfacing Hip System|CONSERVE® Plus Total Resurfacing Hip System. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® Plus Total Resurfacing Hip System. Blood ion levels will be collected and analyzed.
62511869|NCT01079819|ACTIVE_COMPARATOR|A1 (BMS-708163)|
62511870|NCT01079819|PLACEBO_COMPARATOR|A2 (Placebo)|
62511871|NCT01079819|ACTIVE_COMPARATOR|B1 (BMS-708163)|
62511872|NCT01079819|PLACEBO_COMPARATOR|B2 (Placebo)|
62511873|NCT05543694|EXPERIMENTAL|Dural Puncture Epidural Technique|"Laboring women receiving the Dural Puncture Epidural (DPE) Technique, after a lidocaine test dose, with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS \< 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg."
62511874|NCT05543694|ACTIVE_COMPARATOR|Epidural Technique|"Laboring women receiving the Conventional Epidural Technique (EPL), after receiving a lidocaine test dose with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS \< 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg."
62511875|NCT05540873|EXPERIMENTAL|IL13Rα2 targeted CAR-T|
62511876|NCT04341259|EXPERIMENTAL|Ipatasertib as a Single Agent|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD). This study has three study periods: a screening period (up to 14 days in length), followed by a treatment period of up to approximately 2 years (Cycle 1 will be 35 days in length, all subsequent cycles will be 28 days in length) and a 28-day follow-up period after the treatment discontinuation or study completion.
62511877|NCT03176355|OTHER|Chronic dacryocystitis patients|
62511878|NCT05362006|ACTIVE_COMPARATOR|Active|Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
62511879|NCT05362006|SHAM_COMPARATOR|Sham|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
62511880|NCT01118819|EXPERIMENTAL|Clostridium novyi-NT spores|
62511881|NCT06586151|EXPERIMENTAL|Information, Motivation and Skills arm|Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one's gender.
62352742|NCT02650297|EXPERIMENTAL|CDT and pneumatic compression pump|combined decongestive therapy consists of the pressure of bandage, manual lymphatic drainage, and exercises that increase the flow of lymph and skin care are used. Intermittent pneumatic pump is not as a part of CDT, but it can be used as an adjunct method. This device according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk.
62352743|NCT02650297|NO_INTERVENTION|not CDT and pneumatic compression pump|Patients in the control group received no treatment for lymphedema but were placed on the waiting list for CDT as soon as possible after the 8 weeks follow-up period.
62511882|NCT06586151|PLACEBO_COMPARATOR|Information Only arm|Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
62511883|NCT03171441||Controls|eutrophic children
62511884|NCT03171441||Overweight|Overweight children
62511885|NCT03171441||Obese|Obese children
62352744|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
62511886|NCT02113371|EXPERIMENTAL|Intervention|The intervention consists of monthly scripted, peer-led social support sessions covering health and safety topics.
62511887|NCT02113371|NO_INTERVENTION|Control|Usual practices with regard to health and work conditions.
62511888|NCT06616285|ACTIVE_COMPARATOR|Folk Dance Multidomain Lifestyle Intervention|Participants will receive structured, intensive lifestyle intervention through group and individual sessions. Main lifestyle components included: diet, physical exercise, mental stimulation, cardiovascular/metabolic risk monitoring, social interaction. The intervention will last for 6 months.
62511889|NCT06616285|SHAM_COMPARATOR|Self-Guided Multidomain Lifestyle Intervention|Participants will receive multi-domain lifestyle intervention that provides guidance on healthy diet, physical activity, and mental stimulation, and cardiovascular/metabolic risk factors monitoring. The intervention will last for 6 months.
62511890|NCT04845620|EXPERIMENTAL|ARQ-151 Cream 0.05%|Active comparator
62511891|NCT04845620|PLACEBO_COMPARATOR|ARQ-151 Vehicle Cream|Placebo comparator
62511892|NCT02650141|EXPERIMENTAL|ziyinxiehuo Granules|Children of ziyinxiehuo granules group will be treated with chinese herbal granules,3 times a day, for 6 months.
62511893|NCT02650141|ACTIVE_COMPARATOR|zishenqinggan Granules|Children of zishenqinggan granules group will be treated with chinese herbal granules, 3 times a day, for 6 months.
62511894|NCT01761669||healthy voulnters|
62511895|NCT05304026||Population|The group includes all patients undergoing EVAR, each patient is considered as both case and control of himself as the two CO2 injection techniques, through the 5F pigtail and through the 5F introducer, are both used during the procedure.
62708202|NCT01418859||radiation therapy only|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
61976296|NCT02277301|NO_INTERVENTION|Care as Usual|Routine care received by mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
62352745|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
62352746|NCT01078558||Patients with rheumatic disease|Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
62511896|NCT06355479|EXPERIMENTAL|OsrHSA|OsrHSA 20g, IV qd, Day1 up to Day 14
62511897|NCT06355479|ACTIVE_COMPARATOR|pHSA|pHSA 20g, IV qd, Day1 up to Day 14
62511898|NCT01381263|EXPERIMENTAL|Behavioural medicine|
62511899|NCT01381263|ACTIVE_COMPARATOR|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
62511900|NCT02589886|ACTIVE_COMPARATOR|intervention|This arm will receive the education and self-help internet intervention added to usual care
62708203|NCT01418859||concurrent chemoradiotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy. radiation therapy regimen is the same with radiation therapy only group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy.
61976297|NCT02592785|EXPERIMENTAL|BAY1163877|Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
62352747|NCT01576406|EXPERIMENTAL|A1: normal hepatic function|
62352748|NCT01576406|EXPERIMENTAL|A2: normal hepatic function|
62352749|NCT01576406|EXPERIMENTAL|B: mild hepatic impairment|
62352750|NCT01576406|EXPERIMENTAL|C: moderate hepatic impairment|
62352751|NCT01576406|EXPERIMENTAL|D: severe hepatic impairment|
62352752|NCT04262622|ACTIVE_COMPARATOR|Group TEA|
62352753|NCT04262622|ACTIVE_COMPARATOR|Group RSB|
62352754|NCT03448900|EXPERIMENTAL|Multicomponent intervention|The intervention group consisted in face-to-face 50-minute meeting \[motivational interviewing (MI)\]; online self-help material focused on: (1) decisions; (2) moods; (3) social life; (4) smoking health effects; and (5) quitting; e-mail 15 days before the MI, group therapy 2 months after the MI (60 minutes), a second follow-up visit 4 months after the MI (20 minutes).
62352755|NCT03448900|ACTIVE_COMPARATOR|Brief advice|The control group received a brief advice (5-10minutes) and a self-help pamphlet called 'Stop smoking'. Before giving brief advice, the nurse assessed smokers' habits and their willingness to quit. As is usually in this type of studies there were no follow-up sessions for this group.
62511901|NCT02589886|NO_INTERVENTION|control|This arm will receive usual care only
62511902|NCT04978844|ACTIVE_COMPARATOR|I-WotCH|I-WotCH- Inner World of the Child- is a novel innovative therapy developed in our clinic. The therapy is based on modern concepts of early childhood developments emphasizing themes related to emotional regulation, processes of socialization, observational research on interpersonal and behavior as well as recent developments on affiliative neuroscience. More specifically, the therapist, through play, identifies themes and emotions the child is preoccupied with. The therapist then assists the child in naming these emotions, validating them, exploring their nature and consequences. The therapists discussed ways of managing and self-regulating these emotions. These methods would include behavioral techniques, the ability to enlist help from others and reframing. In addition, the therapy will address dealing with complexed emotions and enhancing symbolic play and joyfulness.
62511903|NCT04978844|ACTIVE_COMPARATOR|Dyadic therapy|"Child parent psychotherapy: CPP consists of joint parent-child sessions that focus on the child's free play and spontaneous parent-child interaction. The CPP therapist acts to translate the developmental and emotional meaning of a child's emotions and actions to the parent. The target of treatment includes the both the child's and the caregiver's adaptive conflicts, including a parent's difficulty in providing sensitive and developmentally appropriate care. CPP fosters parent-child activities that foster mutual pleasure, interpersonal trust and understanding. In the purpose of this study only mothers will be included."
62511904|NCT04978844|NO_INTERVENTION|Control|Healthy control.
62511905|NCT05861219|EXPERIMENTAL|chronic kidney disease patients stage 3 and 4|50 chronic kidney disease patients stage 3 and 4 will perform mild exercise and water immersion
62511906|NCT00951951|ACTIVE_COMPARATOR|Anterior Surgical Approach|(AMIS)
62511907|NCT00951951|ACTIVE_COMPARATOR|Posterior Approach Group|Posterior surgical approach for total hip replacement.
62511908|NCT05370261|EXPERIMENTAL|Berberine LipoMicel soft-gel|"Each participant receives their treatment of Berberine LipoMicel soft-gel capsules at a total dose of 500 mg berberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Samples that are not processed the same day are kept frozen at -20°C until further processing and analysis. Processed samples are analyzed by LC-MS within 24 hours after processing.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 7 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
62511909|NCT05370261|EXPERIMENTAL|Regular Berberine hard-gel|"Each participant receives their treatment of regular Berberine hard-gel capsules at a total dose of 500 mg berberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Samples that are not processed the same day are kept frozen at -20°C until further processing and analysis. Processed samples are analyzed by LC-MS within 24 hours after processing.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 7 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
62511910|NCT04333017|EXPERIMENTAL|treated patient|Percutaneous radiofrequency ablation of parietal endometriosis
61971950|NCT06088706|EXPERIMENTAL|Intervention group 1 (O3 20mg)|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 micrograms is injected under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
62352756|NCT04437030|ACTIVE_COMPARATOR|Patient|Patient with Head and neck cancer
62352757|NCT04437030|OTHER|Healthy subjects|Healty subjects with not history of Tumor disease in the Head and neck region
62352758|NCT05716815|ACTIVE_COMPARATOR|2D Reconstruction|Before minimally invasive lung segmentectomy, preoperative chest CT scans are processed and evaluated with multi-plane (2D) reconstructions, according to the usual center protocol.
62352759|NCT05716815|EXPERIMENTAL|2D plus 3D Reconstruction|Before minimally invasive lung segmentectomy, preoperative chest CT scans are processed and evaluated with volume rendering (3D) reconstructions.
62352760|NCT04438772|EXPERIMENTAL|LPEC|
62352761|NCT04438772|SHAM_COMPARATOR|Sham procedure|
62352762|NCT05668676|EXPERIMENTAL|Interventional group|
62352763|NCT05668676|ACTIVE_COMPARATOR|Control group|
62352764|NCT00835003|ACTIVE_COMPARATOR|1|Elective caesarean section at 38 weeks and 3 days of gestation
62352765|NCT00835003|ACTIVE_COMPARATOR|2|Elective caesarean section at 39 weeks and 3 days of gestation
62352766|NCT02881983||STA group|Short-term alcohol abstinent patients (after 1 month of withdrawal)
62352767|NCT02881983||LTA group|Long-term alcohol abstinent patients (at least 6 months of abstinence)
62352768|NCT02881983||Control group|Healthy subjects
62352769|NCT05186272|EXPERIMENTAL|Intervention|Use of mHealth stress reduction program 'A' app 5-20 min daily for 6 weeks
62352770|NCT05186272|ACTIVE_COMPARATOR|Active control|Use of mHealth stress reduction program 'B' app 5-20 min daily for 6 weeks
62352771|NCT01116687|EXPERIMENTAL|Treatment (RO4929097)|See detailed description.
62352772|NCT02360696||Peds/Adol Pts w/ FD - CMH GI APT clinic|"Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (\> or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.~Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.~Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis."
62352773|NCT00657722|EXPERIMENTAL|1|Angiography and Computed Tomography
62352774|NCT04700436|EXPERIMENTAL|Test group|Subject administered with Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
62352775|NCT04700436|ACTIVE_COMPARATOR|Control group|Subject administered with Suvast tablet 10 mg (Rosuvastatin 10 mg)
62352776|NCT02205398|EXPERIMENTAL|c-MET positive mCRC and HNSCC|c-MET positive and K/NRAS WT mCRC and c-MET positive HNSCC patients
62352777|NCT03148106|EXPERIMENTAL|Somatosensory Electrical Stimulation|
62708204|NCT01418859||concurrent and additional chemotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy, and additional chemotherapy after concurrent treatment. radiation therapy regimen is the same with radiation therapy group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy. Additional chemotherapy regimen is the same with concurrent chemotherapy, and will be carry out in the 4th and 8th week after radiation therapy.
62708205|NCT01202695|EXPERIMENTAL|AVP-21D9|
61971951|NCT06088706|ACTIVE_COMPARATOR|Intervention group 2 (O3 40mg)|Just like intervention group 1, in this group, a predetermined concentration of 40 micrograms ozone is injected under sterile conditions.According to the standard treatment guidelines of the American College of Rheumatology, 1gram of acetaminophen in two doses of 500 mg is allowed up to two weeks after daily injections, which is applicable to all three groups.
61971952|NCT06088706|PLACEBO_COMPARATOR|Control group|Just like intervention group 1, in this group, a syringe containing oxygen without ozone is injected under sterile conditions.
62352778|NCT04477109|ACTIVE_COMPARATOR|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and a relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. the device will be applied on specific acupuncture points (N acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time, once per day, 3 times per week for three months
62708206|NCT01202695|PLACEBO_COMPARATOR|Placebo|
62708207|NCT03690778|EXPERIMENTAL|Group I|"Period I: administration of Metformin and Rosuvastatin seperately Period II: JLP-1310"
62146680|NCT05149950|EXPERIMENTAL|Increased therapist contact.|The patient gets access to the internet treatment via a secure login to 1177 The care guide-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
62352779|NCT04477109|SHAM_COMPARATOR|sham laser application in addition to diet recommendations|while the control group will stick to the same line of treatment but with sham laser application
62352780|NCT05825196||HBV-associated HCC group|The patient was finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete.
62352781|NCT05825196||negative control group|HBV positive but not HCC
62352782|NCT05825196||Healthy control group|Healthy crowd
62352783|NCT03036423|ACTIVE_COMPARATOR|Online video education|Participants will have computer access to a library of videos, including various lectures and demonstrations of interest, from which to select and view.
62708208|NCT03690778|EXPERIMENTAL|Group II|"Period I: JLP-1301 Period II: administration of Metformin' and Rosuvastatin seperately"
62708209|NCT01621646|PLACEBO_COMPARATOR|egg white (control)|egg whites, 4 ounces per day for six months
62708210|NCT01621646|EXPERIMENTAL|eggs|eggs, 2 large per day for 6 months
61971953|NCT00822835|ACTIVE_COMPARATOR|ILV-095|6 SC single dose injections
61971954|NCT00822835|PLACEBO_COMPARATOR|Placebo|Placebo
61971955|NCT02049957|EXPERIMENTAL|Phase 1 (Part 1): Sapanisertib 5 mg + Exemestane|Sapanisertib 5 mg, unmilled active pharmaceutical ingredient (API) capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 12 cycles).
61971956|NCT02049957|EXPERIMENTAL|Phase 1 (Part 1): Sapanisertib 5 mg + Fulvestrant|Sapanisertib 5 mg, unmilled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection, intramuscularly (IM), once on Day 1 of each cycle (Up to 57 cycles).
62352784|NCT03036423|ACTIVE_COMPARATOR|Computerized mental exercises|Participants will use a computer to do a variety of activities which are customizable to their own abilities and progress.
62352785|NCT04393077|NO_INTERVENTION|Control|Participants will complete the pre-tests of the introductory features form, SUD, STAI-I, and burnout scales sent via Survey Monkey. The participants (n=40) will be given 15 minutes of free time and asked to be in a position where the individuals were comfortable, in the quietest and most tranquil environment possible. At the end of this period, post-test SUD, STAI-I, and burnout scales will be sent to the participants and they will be asked to fill in the scores.
62352786|NCT04393077|EXPERIMENTAL|Intervention|Firstly, people in the entire group fill out the introductory features form on the online questionnaire form. The time of the meeting will be determined by collaborating with the participants in the experimental group. During the interview, they will be asked to be in a position that was comfortable for the individuals, in the quietest and calm environment possible. At the beginning of the meeting, they will be asked to fill in the pre-test SUD, STAI-I, and burnout scales sent via SurveyMonkey. Then, the EFT session (20 minutes) will be conducted once mutually with the researcher, who is an expert in their field. At the end of the session, they will be filled the post-test SUD, STAI-I and burnout scales
62352787|NCT01060683||Group 1: 15 patients|for elective hepatic resection
62352788|NCT01060683||Group 2: 15|for elective hepatic resection
62352789|NCT04387929||IgG negative|No intervantion. Only antibody mesurment from blood sample
62352790|NCT04387929||IgG positive, viral load negative|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
62708211|NCT00624858|EXPERIMENTAL|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/ day
62708212|NCT05447403|EXPERIMENTAL|Chewing gum combined with WeChat enhanced instructions group|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
61971957|NCT02049957|EXPERIMENTAL|Phase 1 (Part 2): Sapanisertib 3 mg + Exemestane|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 8 cycles).
61971958|NCT02049957|EXPERIMENTAL|Phase 1 (Part 2): Sapanisertib 3 mg + Fulvestrant|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle up to 14 cycles plus fulvestrant 500 mg, injection, IM, once on Day 1 of each cycle (Up to 14 cycles).
61971959|NCT02049957|EXPERIMENTAL|Phase 1 (Part 2): Sapanisertib 4 mg + Exemestane|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 18 cycles).
61971960|NCT02049957|EXPERIMENTAL|Phase 2: Sapanisertib 4 mg + Exemestane (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 14 cycles) in everolimus sensitive participants.
62708213|NCT05447403|NO_INTERVENTION|Control group|Patients in the control group are guided by regular instructions.
62708214|NCT01736917|EXPERIMENTAL|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone|"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.~* Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).~Acute emesis prophylaxis:~* Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.~* Dexamethasone 20mg PO (orally) daily, D1 and 2~* Fosaprepitant 150mg IV on day 3~Delayed emesis prophylaxis:~* Fosaprepitant 150mg IV on D5~* Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8~PRN antiemetics allowed at the discretion of the treating investigator~* No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods"
61971961|NCT02049957|EXPERIMENTAL|Phase 2:Sapanisertib 4 mg+Fulvestrant (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 17 cycles) in everolimus sensitive participants.
61971962|NCT02049957|EXPERIMENTAL|Phase 2: Sapanisertib 4 mg+Exemestane (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus once daily in a 28-day cycle (Up to 12 cycles) in everolimus resistant participants.
62708215|NCT04621578|EXPERIMENTAL|Transcutaneous electrical acupoint stimulation arm|Patients will be given TEAS treatment at the maximum tolerable intensity at a frequency of 2 Hertz (Hz) after surgery in postanesthesia care unit (PACU), and after returning to the ward.
62708216|NCT04621578|SHAM_COMPARATOR|Sham stimulation arm|Patients will use the same device, same stimulation site, and be treated at the same time points, but the lead of the device was damaged. Therefore, although the patients can see the stimulator running, there is actually no current passing through.
62708217|NCT05967754|OTHER|Patients with Obstructive sleep Apnea|Patients with Obstructive sleep Apnea
61971963|NCT02049957|EXPERIMENTAL|Phase 2: Sapanisertib 4 mg+Fulvestrant (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 9 cycles) in everolimus resistant participants.
62708218|NCT05964686|ACTIVE_COMPARATOR|Conventional group A|
61971964|NCT04998461||Obese patients with normal renal function|"* estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~* Body Mass Index (BMI) \> 30 kg/m2~* Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h"
61971965|NCT04998461||Obese patients with impaired renal function|"* estimated Glomerular Filtration Rate (eDFG) \< 60 ml/min/1.73 m2~* Body Mass Index (BMI) \> 30 kg/m2~* Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h"
62708219|NCT05964686|EXPERIMENTAL|Dual laser group B|
62708220|NCT05964686|EXPERIMENTAL|Combined group C|
61971966|NCT04998461||Non-obese patients with impaired renal function|"* estimated Glomerular Filtration Rate (eDFG) \< 60 ml/min/1.73 m2~* Body Mass Index (BMI) between 18 and 30 kg/m2~* Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h"
61971967|NCT04998461||Non-obese patients with normal renal function (control group)|"* estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~* Body Mass Index (BMI) between 18 and 30 kg/m2~* Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria \< 0.15 g/24h"
61971968|NCT01847417|EXPERIMENTAL|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
61971969|NCT00617773|EXPERIMENTAL|hu3S193|
61971970|NCT01230944|ACTIVE_COMPARATOR|Laparoscopic Nissen|Laparoscopic Nissen fundoplication
61971971|NCT01230944|ACTIVE_COMPARATOR|Open Nissen|Open (conventional) Nissen fundoplication
61971972|NCT02071251|EXPERIMENTAL|Prospective intervention|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
61971973|NCT04445922|EXPERIMENTAL|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
61971974|NCT04445922|EXPERIMENTAL|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
61971975|NCT02856230|EXPERIMENTAL|Ranger SL DEB angioplasty|patients filling general and angiographic inclusion/exclusion criteria will have an BTK angioplasty using one or several Ranger SL drug-eluting balloons
61971976|NCT02266225|EXPERIMENTAL|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
62352791|NCT04387929||IgG positive, viral load positive|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
62708221|NCT01493414|EXPERIMENTAL|INC424|5 - 25 mg twice a day (BID)
62708222|NCT00922363|EXPERIMENTAL|50 µg Ag85B-ESAT-6 alone|
62708223|NCT00922363|EXPERIMENTAL|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|
61971977|NCT01892228|EXPERIMENTAL|Two counties: Zhongshan and Pubei|"Immediate post-screening treatment education for HIV-positive participants residing in the Zhongshan and Pubei pilot sites in the Treat-All HIV Pilot Program"
62146681|NCT05149950|OTHER|Less therapist contact.|The feedback from the therapist will largely be general and not individually tailored. The general feedback is based on responses to the participants in the previous pilot study. No physical or digital meetings between patient and therapist take place during treatment.
62708224|NCT00922363|EXPERIMENTAL|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|
61971978|NCT01554384|EXPERIMENTAL|Xpert MTB/RIF|Patients in this arm will receive 1 sputum Xpert MTB/RIF test (point-of-treatment) and 1 sputum sample for MGIT liquid TB culture (regional lab)
61971979|NCT01554384|ACTIVE_COMPARATOR|Sputum smear microscopy|Patients in this study arm will receive 2 sputum samples for same-day smear microscopy and 1 of the sputum samples will have a MGIT Liquid culture (regional lab).
61971980|NCT04449198|EXPERIMENTAL|Individuals with type 1 diabetes|Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)
61971981|NCT04449198|NO_INTERVENTION|Healthy Controls|Healthy individuals who participate will receive no intervention and serve as controls.
62146682|NCT02808832|EXPERIMENTAL|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
62146683|NCT02808832|NO_INTERVENTION|Usual care|Usual care
62146684|NCT02359916||A|Snacks sold under equal pricing, no delays
62146685|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
62146686|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
62146687|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
62146688|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
62146689|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
62146690|NCT02359916||G|Snacks sold under equal pricing, no delays
62146691|NCT06270732|EXPERIMENTAL|Experimental: iMentalize Program (iMentalize)|iMentalize is a structured new program specifically designed to foster mentalization in non-clinical general population. Inspired in Mentalization Based Treatments, which foster mentalization as a principal factor for salutogenesis in clinical settings, iMentalize aims to promote the parents' mentalization stance by using 30 structured sessions where parents are trained in MISC components (Mediational Intervention for Sensitizing Caregivers) to specifically help children to mentalize about cartoon's characters, about themselves, about the caregiver's mental states and about other close others. iMentalize is administered to parent-child dyads who work together in weekly 45-minutes sessions across 1 year.
62146692|NCT06270732|EXPERIMENTAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered (MISC-SA)|This MISC version (MISC-SA) aims to transfer the MISC original training to wider communities by diminishing the cost of the teaching and learning. By implementing the MISC lessons in an online platform, thus allowing self-learning, the new Self- Administered version of MISC allows to obtain MISC training in 30 weekly sessions distributed across 12 months, in 2 blocks: 18 sessions from February to June, and 12 additional sessions from October to December. In contrast to the original version of MISC, this version allows the simultaneous self-training of a high number of participants with very low intervention of a supervisor, which diminishes the cost. MISC-SA keeps the core component of MISC training (video-feedback) by fostering participants to record interactions and then visualize them using guided reﬂection.
62146693|NCT06270732|ACTIVE_COMPARATOR|Mediational Intervention for Sensitizing Caregivers - Readings (MISC-R): Treatment as Usual (TAU)|"MISC-R is a more theoretical version of MISC training lacking the core MISC component (video-feedback). MISC-Readings provides the theoretical knowledge of MISC but lacking practice and reﬂection about MISC components by watching one's own video recorded interactions with the child. MISC-Readings substitutes all the time for practice and video-feedback with theoretical pills and readings, that is, with theoretical knowledge. Thus, this more theoretical MISC version can be assimilated to common intellectual trainings based on cognitive knowledge and pencil-and-paper exercises instead of skill-based training based on true practice for social-emotional skills development."
62146694|NCT01320124||osteoarthritis, total knee arthroplasty|The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
62146695|NCT01320124||contracture post arthroplasty|A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
62146696|NCT01021748|EXPERIMENTAL|MK-2206 45 mg QOD + AZD6244 75 mg QD|Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
62146697|NCT01021748|EXPERIMENTAL|MK-2206 45 mg QOD + AZD6244 75 mg BID|Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
62146698|NCT01021748|EXPERIMENTAL|MK-2206 90 mg QW + AZD6244 50 mg BID|Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
61971982|NCT02568085|EXPERIMENTAL|1|thyroidectomy + Arista
62708225|NCT00922363|EXPERIMENTAL|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|
62708226|NCT01170351|ACTIVE_COMPARATOR|Group-A|Treatment-naive AIH patients consenting to participate
62708227|NCT01170351|EXPERIMENTAL|Group-B|Treatment-naive AIH patients consenting to participate. This group will receive Cyclosporine-A according to a set protocol.
62708228|NCT01428635|EXPERIMENTAL|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD in the absence of disease progression or unacceptable toxicity.
62708229|NCT01368614|EXPERIMENTAL|AVAPS-AE|AVAPS-AE Mode of ventilation
61971983|NCT02568085|NO_INTERVENTION|2|Thyroidectomy
61971984|NCT02568085|EXPERIMENTAL|3|Thyroidectomy with neck + Arista
61971985|NCT02568085|NO_INTERVENTION|4|Thyroidectomy with neck
61971986|NCT01634815|EXPERIMENTAL|lactate group|
61971987|NCT00053040|EXPERIMENTAL|Surgery for tumor resection + IL13-PE38QQR infusion|
62708230|NCT01368614|ACTIVE_COMPARATOR|Respironics OmniLab Advanced BiPAP S mode|OmniLab Advanced BiPAP S Mode of ventilation
62708231|NCT01368614|ACTIVE_COMPARATOR|Respironics OmniLab Advanced CPAP mode|OmniLab Advanced CPAP Mode of ventilation
61971988|NCT04829708|ACTIVE_COMPARATOR|PCI Arm|Patients received PCI (recommended hippocampal protection) within 6 weeks after first-line treatment, with a total dose of 25 Gy, 2.5 Gy each time, once a day, 5 times a week, a total of 10 times. Brain enhancement MRI examination is performed every 3 months in first two years, and then performed every 6 months until the brain metastasis occur.
62708232|NCT03825705|EXPERIMENTAL|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62708233|NCT02041793|ACTIVE_COMPARATOR|Laparoscopic cystogastrostomy|Laparoscopic cystogastrostomy will be performed by using a stapled cystogastrostomy
61971989|NCT04829708|EXPERIMENTAL|MRI Arm|Patients undergo enhancement MRI examination every 3 months in first two years, and then performed every 6 months until the brain metastasis occur. Once brain metastases occur, brain radiotherapy and systemic treatment should be conducted with the follow-up observation of brain enhancement MRI continuing.
62708234|NCT02041793|ACTIVE_COMPARATOR|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance.
62708235|NCT04987372|NO_INTERVENTION|Classical protocol|"Fentanyl Max. 15µg/kg IV Per-operative~Ultiva (Remifentanyl) 0.02-0.1µg/kg/h IV Post-operative~Paracetamol 4x1g /24h IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in cas of break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
62708236|NCT04987372|ACTIVE_COMPARATOR|Multimodal protocol|"Lyrica (Pregabalin) 75mg PO 2 hours before the operation~Dexdor (Dexmedetomidine) 0.8µg/kg/h IV Per-operative / Post-operative~Ketalar (Ketamine) Bolus (0.5mg/kg) + 0.3mg/kg/h IV Per-operative until stop propofol~Linisol (Lidocain) Bolus (1.5mg/kg) + 1.3mg/kg/h IV Per-operatiive until 12h post-op~Magnesium Sulphate Induction (25mg/kg) + 25mg/kg weaning ECC IV Per-operative~Fentanyl 2.5µg/kg IV Per-operative~Paracetamol 4x1g /24u IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in case of Break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
61971990|NCT02205814|EXPERIMENTAL|Fasitibant low dose|Drug: solution for intra-articular injection
61971991|NCT02205814|EXPERIMENTAL|Fasitibant intermediate dose|Drug: solution for intra-articular injection
62146699|NCT01021748|EXPERIMENTAL|MK-2206 90 mg QW + AZD6244 75 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
62146700|NCT01021748|EXPERIMENTAL|MK-2206 90 mg QW + AZD6244 75 mg BID|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
62146701|NCT01021748|EXPERIMENTAL|MK-2206 90 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
62146702|NCT01021748|EXPERIMENTAL|MK-2206 90 mg QW + AZD6244 150 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
62352792|NCT04771026|NO_INTERVENTION|Control|Receiving routine conduct of general anaesthesia for supraglottic airway device
62511911|NCT03294616|EXPERIMENTAL|scleroderma patients-0|for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).
62511912|NCT03294616|EXPERIMENTAL|scleroderma patient-1|for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
61971992|NCT02205814|EXPERIMENTAL|Fasitibant high dose|Drug: solution for intra-articular injection
61971993|NCT02205814|PLACEBO_COMPARATOR|PLACEBO|Drug: solution for intra-articular injection
61971994|NCT01023230|EXPERIMENTAL|DV-601|
61971995|NCT00789139|OTHER|AF monitoring by ICM|Only one arm
61971996|NCT02839707|EXPERIMENTAL|Arm I (PLD, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15. (Closed to accrual as of February 09, 2021)
61971997|NCT02839707|EXPERIMENTAL|Arm II (PLD, bevacizumab, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15. Patients also undergo CT on study.
61971998|NCT02839707|ACTIVE_COMPARATOR|Arm III (PLD, bevacizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also undergo CT on study.
61971999|NCT00260351|EXPERIMENTAL|Group 1|Participants on Thai Red Cross, TRC-ID regimen
62146703|NCT01021748|EXPERIMENTAL|MK-2206 100 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
62352793|NCT04771026|EXPERIMENTAL|Dexamethasone|Receiving pre-operatively single dose nebulised dexamethasone 8mg prior to induction of general anaesthesia
62352794|NCT03256838|EXPERIMENTAL|Ferric citrate|Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).
62352795|NCT05514145|ACTIVE_COMPARATOR|Nance space maintainer|Conventional space maintainer for the maxillary arch as control
61972000|NCT00260351|EXPERIMENTAL|Group 2|Participants on Zagreb-IM regimen
61972001|NCT00260351|EXPERIMENTAL|Group 3|Participants on Essen-IM regimen.
61972002|NCT02975661||Observational 1|Huaier Granule
61972003|NCT02975661||Observational 2|Radiotherapy or chemotherapy
61972004|NCT02975661||Observational 3|treatment abandoned
62511913|NCT03294616|EXPERIMENTAL|scleroderma patients-2|for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
62511914|NCT04884061||Experimental|Patients hospitalized with SARS-CoV2 infection proven by RT-PCR test
62511915|NCT04884061||Comparator|Patients hospitalized with lower respiratory tract infections unrelated to SARS-CoV2 (RT-PCR negative for SARS-CoV2)
62511916|NCT04884061||Comparator 2|Patients who have had bronchoscopy performed as part of the assessment of a distal pulmonary nodule (RT-PCR negative for SARS-CoV2).
62511917|NCT05139277|EXPERIMENTAL|CONVIVO system|During tumor resection, study investigators trained in the use of the system will determine when the CONVIVO imaging system will be used for in vivo¬ imaging. At this point 5 mg/kg of fluorescein will be administered intravenously by an anesthesia provider over one minute.Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique.
62511918|NCT05139277|OTHER|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
62511919|NCT06118502|EXPERIMENTAL|Adaptive Randomization 1|This arm includes people who did not respond to 4 weeks of pharmacotherapy (either varenicline or combination NRT). After a 4-week course of pharmacotherapy, participants that are not responding to medication will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again
61972005|NCT02975661||Observational 4|Huaier Granule \& Radiotherapy or chemotherapy
61972006|NCT05838105|ACTIVE_COMPARATOR|Study group|"Patients will receive luteal support with GNRH agonist and HCG according to departmental protocol:~Cleavage stage embryo:~* ET day (embryo day 2-3) - Ovitrelle 125mcg~* Day 3 after ET - Ovitrelle 125mcg + Decapeptyl 0.1mg~* Day 6 after ET- Ovitrelle 125mcg~* Day 9 after ET - Ovitrelle 125mcg~Embryo blastocyst stage:~* ET day (embryo day 5-6) - Ovitrelle 125mcg + Decapeptyl 0.1mg~* Day 3 after ET - Ovitrelle 125mcg~* Day 6 after ET - Ovitrelle 125mcg"
61972007|NCT05838105|ACTIVE_COMPARATOR|Control group|Patients will receive luteal support with vaginal progesterone - 100 mg Endometrin twice daily until week 8 of pregnancy.
61972008|NCT01110954|ACTIVE_COMPARATOR|PD L 506 2nd dose|Different dosage
61972009|NCT01110954|EXPERIMENTAL|PD L 506|
61972010|NCT00477282|EXPERIMENTAL|Karenitecin|
61972011|NCT00477282|ACTIVE_COMPARATOR|Topotecan|
61972012|NCT03032731|EXPERIMENTAL|Website and pedometer Intervention|Participants allocated to this group will be given a one-off set-up session in which a researcher will show them the intervention website, create a user profile for them and provide guidance on how to use the site to gain health information, set personal behavioural goals and record and monitor their behaviour in relation to their goals. The researcher will also provide the participant with a pedometer and instruct them how to use this and where they can record their daily steps on the website. For 6 weeks, participants will be asked to use the website and be sent weekly email reminders to do so and log their goal progress. After 6 weeks, no further emails will be sent but participants will still be able to access the website and use the pedometer if they wish.
61972013|NCT03032731|OTHER|Control|Participants allocated to this group will be given a one-off session in which a researcher shows them publicly available web-based resources for health behaviour change (provided by the National Health Service (NHS)). Like those participants in the intervention group, they will be assessed again after 6 and 12 weeks. Participants in the control arm will be offered the intervention (access to the study website and a pedometer) after 12 weeks.
62352796|NCT05514145|EXPERIMENTAL|Nance/Transpalatal arch space maintainer|New design of a space maintainer for the maxillary arch
62352797|NCT00407173|EXPERIMENTAL|1|HCV-796 1000mg single dose
62352798|NCT02195817|OTHER|Selincro® 18 mg with continuous psychosocial support: Cohort A|Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support
62352799|NCT02195817|OTHER|Initial psychosocial support: Cohort B|Initial psychosocial support followed by usual care practice, 12-week Observational Period
62352800|NCT04402346|EXPERIMENTAL|Radiofrequency-assisted|
62352801|NCT04402346|ACTIVE_COMPARATOR|Stapler|
62352802|NCT04087603|EXPERIMENTAL|Weekend Morning Bright Light & Early Bedtime|"* Assigned a set sleep schedule for 2 weeks~* Receives evening time management goals to help facilitate scheduled bedtime~* Receives morning bright light from 2 light boxes (Phillips EnergyLights) on two weekend mornings."
62352803|NCT04087603|NO_INTERVENTION|Healthy Control|- Sleep as usual at home for 2 weeks
62352804|NCT05559073||Early referral to ablation within one year after first documented AF diagnosis|
62352805|NCT05559073||Delayed referral to ablation after one year after first documented AF diagnosis|
62352806|NCT00526461|EXPERIMENTAL|PDT using HPPH|Patients receive HPPH IV over 1 hour on day 1. Patients then receive photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
62352807|NCT02625987|EXPERIMENTAL|Continuous intradermic stitch|Closure was did with a continuous intradermic stitch.
62352808|NCT02625987|SHAM_COMPARATOR|Separated stitches|Like comparator was used a closure with separated stitches.
62511920|NCT06118502|EXPERIMENTAL|Non-Adaptive Randomization 1|This arm includes people who did not respond to 4 weeks of pharmacotherapy (either varenicline or combination NRT). After a 4-week course of pharmacotherapy, participants that are not responding to the medication will receive four additional weeks of the same medication with instructions to try to quit again
62511921|NCT06118502|EXPERIMENTAL|Harm Reduction Randomization 2|This arm includes people who did not respond to two 4-week courses of pharmacotherapy (either varenicline or combination NRT or both). After two 4-week courses of pharmacotherapy, participants who are not responding to medication will be randomly assigned to a harm reduction group (e-cigarettes). Participants assigned to the harm reduction group will receive four weeks of e-cigarette product with instructions to switch completely
62708237|NCT01188187|EXPERIMENTAL|Custirsen, Docetaxel, Prednisone|"Three doses of 640 mg custirsen administered intravenously (IV) as a loading dose between Days -9 to -1. Custirsen, 640 mg, given IV weekly on Days 1, 8, and 15 of each 21-day cycle. Docetaxel (75 mg/M\^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
62708238|NCT01188187|ACTIVE_COMPARATOR|Docetaxel, Prednisone|"Docetaxel (75 mg/M\^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
61972014|NCT03687489|EXPERIMENTAL|Intervention arm|Participants will be treated with Abdominal Aortic Aneurysm Stent Graft System
61972015|NCT01300039||Antibiotics for H. pylori|Patients who underwent upper endoscopy and were found to have H. pylori, and were then to be treated with antibiotics for eradication of H. pylori
62708239|NCT03435380|EXPERIMENTAL|Control (C)|Targeted mailed educational materials (C).
62511922|NCT06118502|EXPERIMENTAL|Non-Adaptive Randomization 2|This arm includes people who did not respond to two 4-week courses of pharmacotherapy (either varenicline or combination NRT or both sequentially). After two four-week courses of pharmacotherapy, participants that are not responding to the medication will receive four additional weeks of the same medication with instructions to try to quit again.
62708240|NCT03435380|EXPERIMENTAL|Patient activation (PA)|C + patient activation (PA) consisting of (1) smartphone app with HIPAA compliant survivorship care plan that can be viewed, printed, or emailed to their primary care provider; and (2) two-way (interactive) tailored text messages with links to video vignettes discussing the primary barriers to breast MRI and mammography.
62708241|NCT03435380|ACTIVE_COMPARATOR|Patient activation + primary care provider activation (PA+PCP)|C + PA + PCP activation (PA+PCP) with physician materials about breast cancer risk in this population along with national and international guidelines for breast cancer surveillance.
62708242|NCT01650402|EXPERIMENTAL|Intensive|Intensive anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 130 mmHg
62708243|NCT01650402|ACTIVE_COMPARATOR|Standard|Standard anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 145 mmHg
62708244|NCT01090947||Patients referred to CAG.|Sequential design with ProtoCAD and CAG
62708245|NCT01936558||Amputees|Amputee with one arm or one leg amputated/ Far infrared ray to the phantom limb site
62708246|NCT01936558||Healthy subjects|Healthy subjects under 30 years old/ Far infrared ray to the sole
62708247|NCT05973955|PLACEBO_COMPARATOR|Education Control|A combination of alcohol education and sleep hygiene education comprised of four telephone-based sessions delivered over six weeks.
62708248|NCT05973955|EXPERIMENTAL|Insomnia Treatment|Cognitive-behavioral therapy for insomnia adapted to hazardous alcohol users comprised of four telephone-based sessions delivered over six weeks.
62708249|NCT01357681|EXPERIMENTAL|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
61972016|NCT01300039||Control group, no H. pylori|Patients who underwent upper endoscopy and found to not have H. pylori, and then would not receive antibiotics
61972017|NCT06327451|EXPERIMENTAL|Atorvastatin administrating group|According to the clinical standard dose of lipid-lowering drugs, the subjects were enrolled in this study. After 2 weeks of glioma surgery, one tablet of liptor was taken orally every night on the basis of STUPP protocol.
61972018|NCT04661657||COVID-19|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have tested positive or have been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
61972019|NCT04661657||Control|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have never tested positive and/or has never been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
61972020|NCT04170114|EXPERIMENTAL|Cystic Fibrosis|Children with cystic fibrosis
62352809|NCT02999100|EXPERIMENTAL|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
62708250|NCT01357681|PLACEBO_COMPARATOR|Placebo|Placebo
62708251|NCT02702050|ACTIVE_COMPARATOR|Conventional treatment group|Conventional treatment group will receive an educational session before commencement of the program. Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises will be provided within a 6-week period (i.e., two sessions per week) to all subjects. No mechanical stimulation will be given.
61972021|NCT04170114|EXPERIMENTAL|Bronchiectasis|Children with bronchiectasis
61972022|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
62511923|NCT06490120||Protocol 1|Mental health is assessed over the course of 2 years, by survey on three occasions: at baseline and follow-ups at 1 and 2 years later.
62511924|NCT06490120||Protocol 2|Mental health is assessed over the course of 2 years, by survey on five occasions: at baseline and 6, 12, 18 and 24 months later.
62352810|NCT02999100|EXPERIMENTAL|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
62708252|NCT02702050|EXPERIMENTAL|Mechanical stimulation group|A 10 minute mechanical stimulation program - 'Mechanical stimulation (LPG system; Cellu M6 Integral I), will be provided after each of the twelve sessions of conventional treatment.
61972023|NCT03630627|EXPERIMENTAL|SB26 for Part 1|SB26: various single doses, administered to various cohorts
62708253|NCT03070626|EXPERIMENTAL|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
62708254|NCT03070626|NO_INTERVENTION|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
62708255|NCT02052973|EXPERIMENTAL|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
61972024|NCT03630627|EXPERIMENTAL|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
61972025|NCT03630627|PLACEBO_COMPARATOR|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
61972026|NCT03630627|PLACEBO_COMPARATOR|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
61972027|NCT04822064|EXPERIMENTAL|intranasal dexmedetomdine and kemtaine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
62708256|NCT01988753||Subjects with Liver Fibrosis|"1. Shearwave elastography is a non-invasive procedure for assessing liver status. Measurements of liver tissue elasticity will be obtained in the right lobe of the liver by using a curvilinear transducer (C5-1, Philips Healthcare) through intercostal spaces.~2. Biomarker Analysis~A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the purposes of the serum biomarker study. If subjects return for an additional liver biopsy in the future or a standard of care visit they may be asked to provide an additional sample for biomarker analysis. Blood will be processed, aliquoted and stored by pathology.~B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during the liver biopsy to be stained for additional biomarker analysis."
62708257|NCT05149729|EXPERIMENTAL|Crowe type 3 and 4 patients undergoing shortened hip replacement|Clinical and radiological results of Crowe type 3 and 4 patients who underwent shortened hip prosthesis at 12 and 24 months
62708258|NCT01959685|EXPERIMENTAL|Dose escalting|Placebo, 125 mg Androxal, 250 mg Androxal each given as a single dose
62708259|NCT05132972|EXPERIMENTAL|Treatment|Group receiving standard COVID-19 treatment and UCMSC infusion
62708260|NCT05132972|SHAM_COMPARATOR|Control|Group receiving standard COVID-19 treatment and normal saline infusion
62708261|NCT05201807|EXPERIMENTAL|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
62708262|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
62708263|NCT00427700|ACTIVE_COMPARATOR|Clomiphene|Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
62708264|NCT00427700|EXPERIMENTAL|Raloxifene|Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
62708265|NCT00152438|EXPERIMENTAL|1|Oral micronized progesterone
61972028|NCT04822064|ACTIVE_COMPARATOR|oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
61972029|NCT03571269|EXPERIMENTAL|OCT-guided group|Detailed methods of OCT examination are the same as above. Whether stenting or not will be decided by the operators according to the underlying mechanisms of culprit lesions. If stenting, OCT will be used to guide and optimize the whole process of PCI. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
62352811|NCT02999100|EXPERIMENTAL|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
62352812|NCT01666145|EXPERIMENTAL|Intraoperative Imaging|Laparoscopic microwave ablation surgery utilizing the Advanced Image Guidance system for needle placement.
62352813|NCT06093945|EXPERIMENTAL|SHR2554 and omeprazole|Sequential treatments of SHR2554 alone followed by SHR2554+ omeprazole, with a washout period in between.
62352814|NCT06034015|ACTIVE_COMPARATOR|Part A|
62352815|NCT06034015|ACTIVE_COMPARATOR|Part B|
61972030|NCT03571269|NO_INTERVENTION|Angiography-guided group|Detailed methods of angiography examination are the same as above. Whether stenting or not and the whole process of PCI will be decided by the operators according to the current treatment standard of angiography. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
61972031|NCT02062918|NO_INTERVENTION|Control group|Patients in the control group did not use an abdominal belt.
61972032|NCT02062918|EXPERIMENTAL|Experimental group|Patients were instructed in how to use the abdominal belt for activities of physical effort that exacerbated lumbar pain as well as during moments of pain, and not to use it during rest. They should record the number of hours of belt use per day on spreadsheets distributed for this purpose.
61972033|NCT02381249|EXPERIMENTAL|Esophagectomy|Double-blind single dose octreotide-placebo crossover
61972034|NCT02381249|EXPERIMENTAL|Gastrectomy|Double-blind single dose octreotide-placebo crossover
62352816|NCT05536154|EXPERIMENTAL|EAP regimen|The combination regimen of etoposide, cytarabine and PEG-rhG-CSF.
62352817|NCT04188002|OTHER|Control - Fruit and Vegetable|Participants in this arm will receive usual care.
62708266|NCT00152438|PLACEBO_COMPARATOR|2|Placebo
62708267|NCT04736355|EXPERIMENTAL|DAOIB|oral, for 24 weeks
62708268|NCT04736355|PLACEBO_COMPARATOR|Placebo|oral, for 24 weeks
62708269|NCT04881760|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
62708270|NCT04881760|EXPERIMENTAL|1 milligram (mg) LY3437943|Participants received 1 mg LY3437943 administered as SC injection QW.
62708271|NCT04881760|EXPERIMENTAL|4 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
62708272|NCT04881760|EXPERIMENTAL|4 mg LY3437943|Participants received 4 mg LY3437943 administered as SC injection QW.
62708273|NCT04881760|EXPERIMENTAL|8 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
62708274|NCT04881760|EXPERIMENTAL|8 mg LY3437943 (4 mg)|Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
62708275|NCT04881760|EXPERIMENTAL|12 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
62708276|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
62708277|NCT03178409||HCC|Patients affected by classical HCC
62146704|NCT01021748|EXPERIMENTAL|MK-2206 135 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
62146705|NCT05320094|EXPERIMENTAL|Mavacamten|
62708278|NCT03178409||MFCCC|Patients affected by classical MFCCC
62708279|NCT04768244||COVID19|- Women with SARS-CoV-2 infections
62708280|NCT04626726|EXPERIMENTAL|Volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with acute B lymphocytic leukemia expressing specific target antigens
62708281|NCT02604511|EXPERIMENTAL|Ibrutinib|This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
62708282|NCT00594750||Asthma|People who have been diagnosed with Asthma
62708283|NCT03081104|ACTIVE_COMPARATOR|hystroscopy|The procedure will be performed by a gynecological surgeon, under general anaesthesia with the patient in lithotomy position. Antibiotic prophylaxis may be administered, the cervix is grasped with pozzi forceps and dilated up to hegar 9 to facilitate insertion of the hysteroscopy. The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
62708284|NCT03081104|ACTIVE_COMPARATOR|ultrasound guided aspiration|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control. It was possible to keep the dilators and the suction cannula under constant view by slightly tilting the transducer as required. Advancement of any instrument was allowed only under direct ultrasound control.The completeness of the evacuation was confirmed by the scan in these cases.
62708285|NCT03081104|ACTIVE_COMPARATOR|blind aspiration|The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
62708286|NCT02317627|EXPERIMENTAL|Cohort 1|KD025 400 mg QD PO for 12 weeks
62708287|NCT02317627|EXPERIMENTAL|Cohort 2|KD025 200 mg BID PO for 12 weeks
62708288|NCT02317627|EXPERIMENTAL|Cohort 3|KD025 400 mg BID PO for 12 weeks
62708289|NCT03488771||Control|Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection
62708290|NCT03488771||Infection|Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)
62708291|NCT03488771||Rejection|Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.
62708292|NCT00791648|EXPERIMENTAL|statin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
62708293|NCT00791648|PLACEBO_COMPARATOR|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
62352818|NCT04188002|OTHER|Physical Activity Intervention|Participants in this arm will be encouraged via tailored newsletters and email/or text reminders to improve diet and physical activities.
62352819|NCT02988401|EXPERIMENTAL|Intranasal insulin 20 international units|Subjects will administer 20 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
62352820|NCT02988401|EXPERIMENTAL|Intranasal insulin 10 international units|Subjects will administer 10 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
61972035|NCT02381249|ACTIVE_COMPARATOR|Unoperated healthy control|Double-blind single dose octreotide-placebo crossover
61972036|NCT02381249|EXPERIMENTAL|Pancreaticoduodenectomy|Double-blind single dose octreotide-placebo crossover
62146706|NCT05320094|EXPERIMENTAL|Mavacamten and activated charcoal with sorbitol - Dose A|
62146707|NCT05320094|EXPERIMENTAL|Mavacamten and activated charcoal with sorbitol - Dose B|
62146708|NCT02381132|ACTIVE_COMPARATOR|MNK155|Hydrocodone Bitartrate/Acetaminophen Extended-Release Tablets
62146709|NCT02381132|ACTIVE_COMPARATOR|Norco 7.5mg/325mg|Norco 7.5mg/325mg
62146710|NCT06143124|ACTIVE_COMPARATOR|Therapeutic arm|Classical triple therapy according to the antibiotic susceptibility testing (two antibiotics+PPI)+ Bismuth subcitrate for 7 days
62708294|NCT04549454|EXPERIMENTAL|Intervention App|Students in arm of the study will have a parent who has access to the following content in the parent app: (a) FITSTART+ PBI materials (personalized normative feedback quiz, information on college student drinking, and alcohol-specific advice for parents of first year students); (b) general advice for parents of college students (e.g., improving communication; reducing conflict); (c) information about university resources; and (d) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
61972037|NCT02155842|EXPERIMENTAL|High intensity endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume high intensity endurance exercise, followed by 6 months non-supervised endurance exercise
62708295|NCT04549454|PLACEBO_COMPARATOR|Control App|Students in this arm of the study will have a parent who has access to the following content in the parent app: (a) general advice for parents of college students (e.g., improving communication; reducing conflict); (b) information about university resources; and (c) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
62146711|NCT06143124|NO_INTERVENTION|Control arm|Classical triple therapy according to the antibiotic susceptibility testing (two antibiotics+PPI) for 14 days
62146712|NCT00630500|ACTIVE_COMPARATOR|Memantine|Active treatment with memantine
62511925|NCT06490120||Protocol 3|Mental health is assessed over the course of 2 years, by survey on three occasions: at baseline and follow-ups at 1 and 2 years later. Additionally, a real-time data capture method, ecological momentary assessments (EMA) will be applied directly after baseline and 6, 12 and 18 months later. Participants in group 3 will asked to complete daily registrations using a selection of self-report measures during a one month period. The self-report questions will be distributed via the application with about 5 to 15 questions at a time.
62511926|NCT02810158||Patients with suspected OSA|Persons with clinical suspicion of obstructive sleep apnoea syndrome (OSA)
62511927|NCT04627831|EXPERIMENTAL|CE-Iohexol|Subject is randomized to receive CE-Iohexol Injection
62511928|NCT04627831|ACTIVE_COMPARATOR|Omnipaque™ (Iohexol)|Subject is randomized to receive Omnipaque™ Iohexol Injection
62511929|NCT04452695||Intervention arm|Patients presenting to the emergency department are triaged using a novel robotic telehealth triage system. Once triage is complete, patients complete a quantitative assessment to measure their acceptance and willingness to interact with the robotic telehealth system.
62511930|NCT00880087|EXPERIMENTAL|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
62511931|NCT00880087|ACTIVE_COMPARATOR|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
62511932|NCT04372849|ACTIVE_COMPARATOR|Nasal insulin spray|
62511933|NCT04372849|PLACEBO_COMPARATOR|Placebo spray|
62511934|NCT04832048|EXPERIMENTAL|High intensity training (HIT) group|The HIT group performed the exercises with loads at 80-90% of HRF.
62511935|NCT04832048|EXPERIMENTAL|Low-moderate intensity training (LMIT) group|The HIT group performed the exercises with the loads at 50-70% of the HRF
62511936|NCT04832048|PLACEBO_COMPARATOR|No training group|They did not perform any type of programmed physical exercise during the study.
62708296|NCT01195597|EXPERIMENTAL|E-Cigarette 7.2 mg nicotine|Well characterized group of 40 regular smokers not intending to quit experimenting the E-Cigarette with 7.2 mg nicotine cartridges.
62708297|NCT03159182|EXPERIMENTAL|Pressure garment and silicone insert|Custom measured pressure garment with a textile bonded silicone insert in either the distal or proximal portion of the pressure garment, to be worn 23 hours per day.
62708298|NCT03159182|ACTIVE_COMPARATOR|Pressure Garment|Custom measured pressure garment, to be worn 23 hours per day.
62708299|NCT04955548|EXPERIMENTAL|arthroscopic microfracture with autologous adipose gel|The experimental group will be treated with arthroscopic microfracture with autologous adipose gel.
62708300|NCT04955548|ACTIVE_COMPARATOR|arthroscopic microfracture|The control group will be treated with arthroscopic microfracture.
62708301|NCT02334657||non-aneurysmal subarachnoid hemorrhage|patients with non-aneurysmal subarachnoid hemorrhage, short-term outcome measured by modified Rankin Scale and long-term outcome by SF-36
61972038|NCT02155842|ACTIVE_COMPARATOR|Moderate continuous endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume moderate intensity endurance exercise, followed by 6 months non-supervised endurance exercise
62146713|NCT00630500|PLACEBO_COMPARATOR|Placebo|Placebo matching active study drug
62146714|NCT05395299|EXPERIMENTAL|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )|Injection at the level of the right and left prostate arteries of Squid until a complete occlusion of these arteries, and a filling of their intraprostatic branches
62146715|NCT01707303|OTHER|Usual Care|Usual hospital rehabilitative services
62146716|NCT01707303|EXPERIMENTAL|Early ICU Rehabilitation Strategy|Early ICU physical therapy will be applied in this arm
62511937|NCT05789758||Nusinersen Treated Participants|Pregnant participants with SMA who are exposed to nusinersen during the relevant window defined as 14 months prior to the first day of the participant's last menstrual period before conception, 14.5 months before conception and anytime during pregnancy and are enrolled in the registries, International Spinal Muscular Atrophy Registry (ISMAR) and SMArtCARE will be followed prospectively up to 3 months post-delivery, the infants will be followed up to 2 years post-delivery and the available data is collected retrospectively.
62511938|NCT04836520|EXPERIMENTAL|SHR6390+anatrozole|Hormone receptor positive, HER2 negative participants will receive SHR6390 in combination with anatrozole before surgery.
62511939|NCT06415968||Patients presenting at a biological hematology consultation|
62511940|NCT02280720|ACTIVE_COMPARATOR|CoCr-BAS|Stenting using Optimax™ cobalt-chromium alloy platform with a titanium-nitride-oxide coating
62511941|NCT02280720|ACTIVE_COMPARATOR|PtCr-EES|Stenting using PROMUS Element™ Plus durable polymer everolimus-eluting stent built on a platinum-chromium platform.
62511942|NCT01030211|ACTIVE_COMPARATOR|Platelet transfusion|4 units of platelets for patients with platelet count \<20x10\^3/uL
62511943|NCT01030211|OTHER|Supportive care|No platelet transfusion for patients with platelet count \<20x10\^3/uL
62511944|NCT03331614|NO_INTERVENTION|Control Group|This group will continue with their current treatment regimen during the course of the study. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
62146717|NCT03434600|ACTIVE_COMPARATOR|Oxford|Patients receiving an Oxford UKA, which is the standard treatment for patients with medial osteoarthritis of the knee at our department.
62146718|NCT03434600|EXPERIMENTAL|Sigma|Patients receiving a Sigma UKA, which is the experimental treatment.
62352821|NCT02988401|PLACEBO_COMPARATOR|Intranasal saline|Subjects will administer a sterile diluent containing inactive ingredients in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
62352822|NCT04496648|ACTIVE_COMPARATOR|Percutaneous Coronary Intervention|Conventional PCI and optimal medical therapy
62352823|NCT04496648|PLACEBO_COMPARATOR|Sham-percutaneous coronary intervention|Sham-PCI and optimal medical therapy
62511945|NCT03331614|ACTIVE_COMPARATOR|Active Treatment Group|This group will continue with their current treatment regimen during the course of the study. In addition they will be given an active intervention with the Flowaid FA-100 SCCD device to utilize at home daily. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
62511946|NCT05336435|NO_INTERVENTION|Control Arm - Current sex-uniform manufacturer provided 99th percentile URL of troponin|Standard use of the current sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women
62511947|NCT05336435|ACTIVE_COMPARATOR|Intervention Arm - New population and sex-specific 99th percentile URLs of troponin|Implementation of the new population and sex-specific 99th percentile URLs of troponin for the specific assay utilized at the enrolled centers.
62352824|NCT05543642|ACTIVE_COMPARATOR|Arm 1 (control group, sequential administration)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive sequential administration of both tdap booster and hepA vaccinations."
62511948|NCT04060511|EXPERIMENTAL|HS-10342|Each subject will receive a single dose(C0) of HS-10342 and then repeat doses(C1, C2...) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62708302|NCT02334657||perimesencephalic SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
62708303|NCT02334657||non-perimesencephalic (NPM) SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
62708304|NCT02334657||subgroup of NPM-SAH with Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and a Fisher 3 bleeding pattern
62708305|NCT02334657||subgroup of NPM-SAH w/o Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and not a Fisher 3 bleeding pattern
62511949|NCT00798382|EXPERIMENTAL|1: Soy formula|experimental soy formula #1
62511950|NCT00798382|ACTIVE_COMPARATOR|2: Soy Formula|Commercially available soy formula
62511951|NCT00798382|EXPERIMENTAL|3: Soy formula|experimental soy formula #2
62511952|NCT01655355||Revison of the hip joint|
62511953|NCT00794417|EXPERIMENTAL|Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
62511954|NCT00794417|EXPERIMENTAL|Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m\^2) and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
62511955|NCT00794417|EXPERIMENTAL|Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
62511956|NCT00794417|EXPERIMENTAL|Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.
62511957|NCT04461210||Vulvodynia|Women with localized, provoked vulvodynia
62511958|NCT04461210||Health Controls|Women without vulvar pain or other vulvar disorders.
62708306|NCT01741961||glaucoma, surgery, Ahmed valve|Patients with uncontrolled glaucoma undergoing Ahmed glaucoma valve implantation for intraocular pressure reduction.
62708307|NCT04614324|EXPERIMENTAL|RhinAer ARC Stylus Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nostrils treated in the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve.
62146719|NCT01429454|PLACEBO_COMPARATOR|Soybean-Corn Blend Capsule|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
62146720|NCT01429454|EXPERIMENTAL|Omega 3 long chain fatty acid|The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
62146721|NCT02481167||group1|This study was consisted of patients with older than 40 years of age who complained with dry eye.
62146722|NCT03727672||Tension type headache patients|30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
62146723|NCT03727672||Migraine patients|30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
62511959|NCT05487768|EXPERIMENTAL|Anterior cruciate ligament reconstruction group|Patients that underwent an anterior cruciate ligament reconstruction
62708308|NCT02064478||Tissue preservation|Ponto implant installed using a tissue preservation surgical technique
61972039|NCT01322360|OTHER|Morphine Sulfate|oral solution (10 mg/5 mL or 20 mg/5 mL) or tablets (15 mg or 30 mg)given based on based on the current pediatric prescribing guidelines
61972040|NCT01879150|EXPERIMENTAL|CYCLAPLEX bone anchors|"Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA \>12degree, =\<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.~The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.~Subjects will be followed-up for 50 weeks post-procedure."
62708309|NCT02064478||Tissue reduction|Ponto implant installed using a classical technique with skin thinning
62511960|NCT05487768|ACTIVE_COMPARATOR|Control group|Healthy matched controls
62511961|NCT02947620|ACTIVE_COMPARATOR|Metformin/Atorvastatin|Metformin/Atorvastatin, QD
61972041|NCT05241106|EXPERIMENTAL|HYML-122 treatment|HYML-122 tablets, 200mg spec, 28 days for each cycle. The first eligible three enrolled subjects will be administrated with 600mg bid dose regimen for 28 consecutive days ( 1 treatment cycle). The Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of these three subjects and make decision whether the regimen need to be adjusted (increasing/decreasing administration dosing or adjusting dosing frequency).
61972042|NCT04426981|EXPERIMENTAL|Intervention arm|Consenting patients will be enrolled into a Behavioral Activation treatment arm. Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities.
61972043|NCT00038857|EXPERIMENTAL|CD34 PBPC|CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m\^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m\^2 Fludarabine over 4 days on days -6, -5, -4, -3 and 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
61972044|NCT03012256|EXPERIMENTAL|Cardio-respiratory management model|Additional home care management includes medication reconciliation, self-care education, advanced care planning, as well as physician communication and transfer protocols
61972045|NCT03012256|NO_INTERVENTION|Control|Home care (standard of care)
61972046|NCT00658593|ACTIVE_COMPARATOR|GEMCAP|Gemcitabine 1000mg/m2 IV days 1 and 8 ever 21 days; Capecitabine 650mg/m2 PO BID days 1-14 every 21 days.
61972047|NCT00658593|ACTIVE_COMPARATOR|Gemcitabine Alone|Gemcitabine 1000mg/m2 IV days 1, 8 and 15 every 28 days
61972048|NCT01239654|ACTIVE_COMPARATOR|everolimus|everolimus-eluting stent
61972049|NCT01239654|ACTIVE_COMPARATOR|zotarolimus|zotarolimus-eluting stent
61972050|NCT00512707|EXPERIMENTAL|Active Testosterone Gel|Active Testosterone Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
62146724|NCT03727672||age matched controls|30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives
62146725|NCT01989793|ACTIVE_COMPARATOR|Losartan|For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.
62146726|NCT01989793|PLACEBO_COMPARATOR|Placebo|For those subjects randomized to placebo, they will receive a placebo to take for 24 weeks total.
62146727|NCT02684032|EXPERIMENTAL|Letrozole Cohort|Letrozole combination cohort in dose escalation
62146728|NCT02684032|EXPERIMENTAL|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
62146729|NCT02684032|EXPERIMENTAL|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
62511962|NCT02947620|PLACEBO_COMPARATOR|Metformin|Metformin, QD
62511963|NCT02947620|PLACEBO_COMPARATOR|Atorvastatin|Atorvastatin, QD
62511964|NCT02761213|EXPERIMENTAL|Oral sulfate solution (OSS)|oral sulfate solution (OSS)
62708310|NCT01782157||Prompt intervention|The prompt intervention group will receive context-aware text, audio, and video prompts to initiate specified activities of daily living.
62708311|NCT01782157||No prompt intervention|The no prompt intervention will not receive any prompts to initiate activities of daily living.
62708312|NCT05249959|EXPERIMENTAL|Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy|R/R MCL after one, two, three or four lines of treatment including BTKi treatment (or BTKi intolerant), with complete response (CR) or partial response (PR) or with stable disease (SD) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C x 2 cycles) will undergo consolidation with loncastuximab tesirine. A patient with CR, PR or SD after one R-BAC course, which is unable to undergo a second course due to toxicity to chemotherapy, can be considered to proceed for consolidation.
61972051|NCT00512707|PLACEBO_COMPARATOR|Placebo Gel|Placebo Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
61972052|NCT05065177|EXPERIMENTAL|Experimental Group|"* Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~* Intervention: investigational live attenuated mumps vaccine;"
61972053|NCT05065177|ACTIVE_COMPARATOR|Control Group|"* Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~* Intervention: control live attenuated mumps vaccine;"
62146730|NCT02684032|EXPERIMENTAL|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
62146731|NCT02684032|EXPERIMENTAL|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
62511965|NCT02761213|ACTIVE_COMPARATOR|2-L PEG/Asc|low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)
62511966|NCT01884584|EXPERIMENTAL|Indocyanine green (ICG)|ICG will be administered by intravenous infusion over a 20 second period in a 2-8 hour time window before the time of completion of the surgical procedure.
62511967|NCT01868763|NO_INTERVENTION|control (C) group|The control group will remain in routine care for 12 weeks.
62511968|NCT01868763|EXPERIMENTAL|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
62511969|NCT01868763|EXPERIMENTAL|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements.
62511970|NCT05178576|EXPERIMENTAL|Arm 1|ctDNA positive Gevokizumab for 1 year (maximum of 13 cycles)
62511971|NCT01529931|EXPERIMENTAL|Maintenance|This arm receives Hair2Go treatments once a month for 6 months
62511972|NCT00115934|ACTIVE_COMPARATOR|MBTS|Blalock-Taussig pulmonary artery shunt
62511973|NCT00115934|ACTIVE_COMPARATOR|RVPAS|Right ventricular to pulmonary artery shunt
62511974|NCT06257316|ACTIVE_COMPARATOR|0.1mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
62511975|NCT06257316|ACTIVE_COMPARATOR|0.2mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
61972054|NCT00937612|EXPERIMENTAL|concurrent chemoradiation|patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.
61972055|NCT01598051||Group 1|Patients treated with Xarelto under practical manner for SPAF.
61972056|NCT03223246|NO_INTERVENTION|Usual care|
61972057|NCT03223246|EXPERIMENTAL|Additional teaching|
62146732|NCT02684032|EXPERIMENTAL|Arm D|Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion
62352825|NCT05543642|ACTIVE_COMPARATOR|Arm 2 (co-administration group)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive co-administration of hepA vaccination."
62352826|NCT05543642|ACTIVE_COMPARATOR|Arm 3 (co-administration group)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive co-administration of tdap booster vaccination."
62352827|NCT05543642|NO_INTERVENTION|Arm 4 (Inflammatory arthritis patients using DMARDS)|"Individuals with inflammatory arthritis patients using DMARDS, who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will only receive the standard of care COVID-19 booster vaccination."
62352828|NCT04687488|OTHER|Fluorescein|"Fluorescein dye and ultraviolet (UV) light are used to assess the aerosol contamination during endonasal investigations. We will dilute medical fluorescein vials (FLUORESCEINE 10% Faure; SERB, 40 Avenue George V, 75008 Paris, France) to a concentration of 1% fluorescein in 10ml of normal saline solution. Next, we swab the nasal cavity with a compress soaked (15 droplets with a pipette) in fluorescein and we apply 5 droplets into the nasal cavity and nasopharynx at the beginning of the investigation.~After coating the nose with fluorescein, the patient will wear a surgical nose-mouth mask and will be positioned in the bed used for HRiM or MII-pH probe insertion. As the MII-pH probe is removed 24h after placement of the probe, prior to this activity the same fluorescein application method (fluorescein drops and a cotton swab) will be used."
62352829|NCT02671955|EXPERIMENTAL|Part 1: Dose Escalation|Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression. Dose escalation will continue until the maximum tolerated dose is reached.
62352830|NCT02671955|EXPERIMENTAL|Part 2: Biomarker Evaluation|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
62352831|NCT02671955|EXPERIMENTAL|Part 3: Dose Expansion|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
62352832|NCT02671955|EXPERIMENTAL|Part 4: Dose Expansion|Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
62352833|NCT01575899|EXPERIMENTAL|Levofloxacin-Amoxicillin/clavulanate|7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
62352834|NCT01575899|ACTIVE_COMPARATOR|Clarithromycin-Amoxicillin|7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.
61972058|NCT05016921|EXPERIMENTAL|Transcutaneous magnetic stimulation|Transcutaneous magnetic stimulation targeting the stellate ganglion
61972059|NCT04120545|EXPERIMENTAL|Microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
61972060|NCT04120545|PLACEBO_COMPARATOR|Placebo microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
61972061|NCT02039622||Patient under study condition|Patient under study condition
62352835|NCT04457570||exposed patients|"The exposed patients are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an exposed patient if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection."
62352836|NCT04457570||control patients|"The control patients  are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection"
62511976|NCT06257316|ACTIVE_COMPARATOR|0.3mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
62511977|NCT06257316|ACTIVE_COMPARATOR|0.5mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
62511978|NCT06257316|ACTIVE_COMPARATOR|1.0mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
62511979|NCT06257316|ACTIVE_COMPARATOR|1.2mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
62511980|NCT03778723|EXPERIMENTAL|Total intravenous anesthesia (TIVA)|Patients will receive total intravenous anesthesia using Propofol and Midazolam
62511981|NCT03778723|ACTIVE_COMPARATOR|Inhalation Anesthesia|Patients will receive Inhalation anesthesia using Sevoflurane
62511982|NCT02244294|EXPERIMENTAL|FLOMAX®|
62511983|NCT02244294|PLACEBO_COMPARATOR|Placebo|
62511984|NCT04025684|OTHER|Test toothbrush 1|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 1 after applying a strip of standard fluoride (1450 parts per million \[ppm\] fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
62511985|NCT04025684|OTHER|Test toothbrush 2|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 2 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
62511986|NCT04025684|OTHER|Test toothbrush 3|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 3 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
62511987|NCT04025684|OTHER|Test toothbrush 4|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 4 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
62511988|NCT01295086|EXPERIMENTAL|Her-TEX|
62511989|NCT01917435|EXPERIMENTAL|fiberoptic bronchoscope|Experimental: fiberoptic bronchoscope fiberoptic bronchoscope is used to facilitate for nasotracheal intubation.
62511990|NCT01917435|EXPERIMENTAL|video-stylet|Experimental: video-stylet video-stylet is used to facilitate for nasotracheal intubation.
62708313|NCT02285881|EXPERIMENTAL|shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
62352837|NCT02535637||Mothers-Infant|Mothers who were planning to exclusively breastfeed for six months were enrolled into the study along with their infant.
62352838|NCT03775590|ACTIVE_COMPARATOR|Water|Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
62511991|NCT06115304|OTHER|Intervention arm|
61972062|NCT02533154|EXPERIMENTAL|BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month
61972063|NCT02533154|ACTIVE_COMPARATOR|non-BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month
62511992|NCT05914545|EXPERIMENTAL|Experimental: FZ-AD004|Participants enrolled in the dose escalation part or dose expansion part
61972064|NCT00237198|EXPERIMENTAL|Letrozole|
62511993|NCT04253353|EXPERIMENTAL|rosuvastatin and tafamidis fixed sequence|"* Period 1: rosuvastatin 10 mg (single oral administration)~* Washout~* Period 2: tafamidis 61 mg capsule(multiple doses, twice a day) + rosuvastatin 10 mg (single oral administration)"
62511994|NCT03463018|EXPERIMENTAL|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
62511995|NCT03463018|PLACEBO_COMPARATOR|Placebo|Identical excipients as in the experimental arm, without the active ingredient
62511996|NCT05802199||Training cohort|"Patients were fulfilled diagnosis of non-alcoholic fatty liver disease based on radiological and clinical manifestation.~Patients were fulfilled diagnosis of hepatic fibrosis based on radiological and clinical manifestation."
62511997|NCT05802199||Validation cohort|"Patients were fulfilled diagnosis of non-alcoholic fatty liver disease based on radiological and clinical manifestation.~Patients were fulfilled diagnosis of hepatic fibrosis based on radiological and clinical manifestation."
62511998|NCT06286059|NO_INTERVENTION|Control group|Patients will receive conventional management including high dose atorvastatin and isotonic (0.9%) saline intravenous (IV) infusion at a rate of 1 ml/kg/hr for 12 hours or reduced to 0.5 ml/kg/hr if the patient's LVEF \< 40% or overt heart failure.
62511999|NCT06286059|EXPERIMENTAL|Phentolamine group|In addition to the conventional management, patients will receive phentolamine infusion.
62512000|NCT03220113|EXPERIMENTAL|Dexamethasone,Lidocaine,Thiamine cohort|"Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.~De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles."
62512001|NCT03662308|OTHER|Heated Vest Safety & Comfort (able-bodied subjects)|Able-bodied controls will be fitted with an appropriately sized heated vest, while wearing only a standard cotton T-shirt and shorts, and will remain seated in a wheelchair. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for 2 hours with the heated vest on full power. Outcome Variables for Visit 1: Skin thermocouple temperatures, subjective ratings of thermal sensation.
62512002|NCT03662308|EXPERIMENTAL|Heated Vest Efficacy (persons with tetraplegia)|Subjects with tetraplegia, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized heated vest. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the self-regulating heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
62708314|NCT02285881|NO_INTERVENTION|control group|Patients in the control practices will receive treatment-as-before, which means that the patients will not be offered the structured SDM process. So the GP will treat the former ADDITION patients as they were used during the period that followed after the ADDITION study (2009), either according to the national guidelines or to the ADDITION intensive treatment algorithm.
62708315|NCT01047995|ACTIVE_COMPARATOR|Group 1|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
62708316|NCT01047995|ACTIVE_COMPARATOR|Group 2|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2,~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
62708317|NCT04847687||Group 1|Patients who are started on 1 mg/kg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
62708318|NCT04847687||Group 2|Patients who are started on 250 mg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
62708319|NCT01651468|EXPERIMENTAL|HEMOFIX|3 grams a day
62708320|NCT03255616|EXPERIMENTAL|Healthy subjects|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
61972065|NCT02356744||surgery done less than 1 year|Pregnant women who had bariatric surgery done within the last year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
62146733|NCT04497415|EXPERIMENTAL|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
62512003|NCT03662308|ACTIVE_COMPARATOR|Non-Heated Vest control condition (persons with tetraplegia)|The same subjects with tetraplegia from the experimental arm, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized, similarly insulated, but non-heated vest (control condition). Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the non-heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
62512004|NCT04017754||Study sample|"In total, 267 women with unexplained recurrent pregnancy loss was included.~Only patients with a history of 3 or more consecutive spontaneous pregnancy losses are included. Both biochemical and clinical losses documented in hospital records are accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social reasons are not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement."
62512005|NCT04017754||Reference Group|The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information. After informed approval, all controls had an extra blood sample taken, which was analysed for p-MBL.
62512006|NCT00729131||A|Control group: subjects are homozygotic for major allele for TNF-308 promoter polymorphism.
62146734|NCT04497415|NO_INTERVENTION|Assessment only|Control
62146735|NCT02581904|EXPERIMENTAL|High Risk - Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
62146736|NCT02581904|ACTIVE_COMPARATOR|High Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
62146737|NCT02581904|ACTIVE_COMPARATOR|Low Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
62352839|NCT03775590|ACTIVE_COMPARATOR|Bleach|Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
62512007|NCT00729131||B|Case Group: subjects are homozygotic or heterozygotic for minor allele of TNF-308 promoter polymorphism.
62708321|NCT03255616|EXPERIMENTAL|Low back pain patients|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
61972066|NCT02356744||surgery done more than 1 year|Pregnant women who had bariatric surgery done more than 1 year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
62352840|NCT03775590|ACTIVE_COMPARATOR|Acetic acid|Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen
62352841|NCT04166656|OTHER|Arm A : Trumenba®: Standard vaccination|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
62352842|NCT04166656|OTHER|Arm B:Bexsero®: standard vaccination regimen|Two doses of 0.5 ml each at one month intervals
62352843|NCT04166656|OTHER|Arm C : Bexsero® Innovative vaccine strategy|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
62352844|NCT04273542|OTHER|Control cohort|"In this cohort, women recruited participated to organised breast cancer screening. They must not have an invasive breast cancer.~They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening)."
62352845|NCT04273542|OTHER|Patient cohort|"In this cohort, women for who an invasive breast cancer has been diagnose will be included.~Only one liquid biopsy will be collected before any treatment."
62352846|NCT04273542|OTHER|Exploratory cohort|"In this cohort, women with high risk of BRCA1/2 mutation but without invasive breast cancer.~6 liquid biopsies will be collected : each year after inclusion during 5 years."
62352847|NCT02801422||Cannabis Dependence|ages 18-40
62352848|NCT02801422||Healthy control subjects|socio-demographically matched
62352849|NCT02111967||Diabetes mellitus type 2, Metformin|The case group consists of patients with diagnosed diabetes mellitus type 2 treated with Metformin.
62352850|NCT02111967||Diabetes mellitus type 2|The control group consists of patients with diagnosed diabetes mellitus type 2 which do not have metformin treatment
62352851|NCT03670498|EXPERIMENTAL|4 channel Electrical Stimulation(revised sequential)|apply 4 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it sequentially Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
62352852|NCT03670498|ACTIVE_COMPARATOR|2 channel Electrical Stimulation(classical)|apply 2 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it simultaneously suprahyoid m (ch 1), thyrohyoid m (ch 2) with 2 channel electrical stimulation device.
62352853|NCT05825599|EXPERIMENTAL|Eyedrops treatment arm|
62352854|NCT06291506|EXPERIMENTAL|Pulmonary veins isolation plus linear left atrial ablation.|
62352855|NCT06291506|ACTIVE_COMPARATOR|Pumonary veins isolation only.|
62512008|NCT02266849|ACTIVE_COMPARATOR|Loperamide|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
61972067|NCT04378218|EXPERIMENTAL|HIIT Intervention|
62352856|NCT05870319|EXPERIMENTAL|SKB264 by IV infusion on Days 1 and 15 of each 4-week cycle;|
62352857|NCT05870319|ACTIVE_COMPARATOR|pemetrexed+ carboplatin or on Day 1 of each 3-week cycle, with 4 cycles chemo|
62512009|NCT02266849|PLACEBO_COMPARATOR|Placebo|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
62512010|NCT00176631|EXPERIMENTAL|licorice root extract and docetaxel|
62512011|NCT01123096||Stress Urinary Incontinence|Patients with the primary complaint of stress incontinence with minimal or no urge incontinence symptoms. They must be able to read English as the study involves use of validated questionnaires which have only been validated in English.
62512012|NCT02459717|EXPERIMENTAL|Probiotics and prebiotic|fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
62512013|NCT02459717|PLACEBO_COMPARATOR|Placebo|pasteurized fermented milk (125 grams) without prebiotics
62708322|NCT04445103||History of malaria|Individuals with a history of malaria infection
62708323|NCT04445103||Controls|Individuals without a history of malaria infection
62708324|NCT04445103||Symptomatic malaria|Patients with symptomatic malaria infection (complicated and uncomplicated)
61972068|NCT05940207|EXPERIMENTAL|e-Bandages 3 hours|Three subjects will wear the e-Bandage on their skin for 3 hours.
61972069|NCT05940207|EXPERIMENTAL|e-Bandages 6 hours|Three subjects will wear the e-Bandage on their skin for 6 hours.
62146738|NCT00529204|EXPERIMENTAL|Exenatide|exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
62146739|NCT03441490|ACTIVE_COMPARATOR|ICBT standard|Internet-based cognitive behavioural therapy with therapeutic guidance through mail
62352858|NCT02748122|EXPERIMENTAL|Adolescents with T2DM|
62352859|NCT03490435||Study participants|Both healthy and ailing individuals, both sex, including adults and children.
62352860|NCT06391658|EXPERIMENTAL|FT group|Functional Training group
62352861|NCT02447120||Normal Eyes|Subjects with no known ocular diseases will be scanned with the Maestro device
62352862|NCT01463020|EXPERIMENTAL|Smartphone delivered BA|
62352863|NCT01463020|ACTIVE_COMPARATOR|Smartphone delivered mindfulness|
62352864|NCT02224638|ACTIVE_COMPARATOR|TheraHoney HD|Honey product
62352865|NCT02224638|ACTIVE_COMPARATOR|SkinTegrity|Skin moisturizer
62352866|NCT06531226||High neuroticism score group|The neuroticism score was higher than the average score identified by the norm
62352867|NCT06531226||Low neuroticism score group|The neuroticism score was lower than the average score identified by the norm
62708325|NCT04546789|EXPERIMENTAL|Group 1: Normal Hepatic Function|Healthy participants who have normal hepatic function with sex, age (± 10 years; \>= 18 years old and =\< 79 years old), and weight (± 10 percent; \>= 50 kilogram (kg) and =\< 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).
62708326|NCT04546789|EXPERIMENTAL|Group 2: Mild Hepatic Impairment|Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).
62708327|NCT04546789|EXPERIMENTAL|Group 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).
62708328|NCT06565299||Group 1|Children with family anamnesis confounding factorss, such as family composition, living conditions, conflict families (members of family suffering from any type of addiction, prisoned members of family, conflicts in front of a child's eyes).
62708329|NCT06565299||Group 2|without family anamnesis confounding factors
61972070|NCT05940207|EXPERIMENTAL|e-Bandages 12 hours|Three subjects will wear the e-Bandage on their skin for 12 hours.
62708330|NCT04931381|EXPERIMENTAL|Organoid-Guided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
62708331|NCT04931381|NO_INTERVENTION|Physician-decided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
62708332|NCT05719220||Group preoperative pelvic floor training|Patients will receive group preoperative PFT, 4 weeks prior to HoLEP.
62708333|NCT05719220||No preoperative pelvic floor training|The control group will receive standard care, which may include patient education about postoperative care and pelvic floor muscle exercises, but will not receive structured group PFT.
62708334|NCT02331758|EXPERIMENTAL|Lifestyle counseling|The investigators use several methods to educate patients of controllable factors like lifestyle counseling, and monitor the factors like BMI and other index until the statistics become normal.
62708335|NCT02331758|NO_INTERVENTION|No treatment|Patients without any intervention and still have abnormal factors like BMI, etc.
62708336|NCT02191163|EXPERIMENTAL|Antistax®|1 x 360 mg for 42 days
61972071|NCT05940207|EXPERIMENTAL|e-Bandages 24 hours|Three subjects will wear the e-Bandage on their skin for 24 hours.
62146740|NCT03441490|EXPERIMENTAL|ICBT chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat
62708337|NCT02191163|PLACEBO_COMPARATOR|Placebo|
62708338|NCT06443853||Clinical scoring|The Turesky Modified Quigley Hein Plaque Index of anterior teeth of the volunteers' was recorded using clinical visual examination after dental plaque staining.
62708339|NCT06443853||Digital Camera|"Intraoral photographs of the volunteers were taken by using a digital camera (Canon EOS 700D; 100 mm macrolens, Canon Inc., Tokyo, Japan).~All taken photographs were transferred to the Image J V1.53 (National Institute for Health, Bethesda, USA) program. The plaque-covered area and the total surface area of the teeth were marked in the manual mode of the program."
62352868|NCT06552923|EXPERIMENTAL|ECHO Intervention Immediate|9 FQHC were randomized to start the ECHO program June 2021. The providers at participating FQHCs joined tele-education one hour sessions and received CME for learning about diabetes care-related topics. They attended sessions twice monthly for 6-months
62708340|NCT06443853||Intraoral Scanner|"3D images of the volunteers were recorded by an intraoral scanner (iTero Element Flex, Align Technologies, San Jose, California, USA).~All taken images were transferred to the Image J V1.53 (National Institute for Health, Bethesda, USA) program. The plaque-covered area and the total surface area of the teeth were marked in the manual mode of the program."
62708341|NCT02347384|EXPERIMENTAL|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will be implanted with Delta PLUS Femoral Head \& SL-TWIN Stem
62708342|NCT02347384|ACTIVE_COMPARATOR|BIOLOX forte ball head + SL-PLUS Stem|Subject will be implanted with BIOLOX forte ball head \& SL-PLUS Stem
62708343|NCT05105724|EXPERIMENTAL|PRP|ovarian injections of PRP were administered to the patients
62708344|NCT05105724|NO_INTERVENTION|No ovarian puncture or injection|no ovarian puncture or injection was used in the patients
62708345|NCT04039243|EXPERIMENTAL|Active Treatment|Up to 12 sessions of Parent-Child CBT using an adaptation of the Being Brave protocol
62708346|NCT04039243|ACTIVE_COMPARATOR|Parent Education|Parents receive educational materials about how to help young children overcome shyness and anxiety
62708347|NCT04039243|NO_INTERVENTION|Monitoring|
62708348|NCT00575224|OTHER|A|Pegylated interferon and ribavirin for 24 weeks
62708349|NCT00575224|OTHER|B|Pegylated interferon and ribavirin for 48 weeks
62708350|NCT04017234|EXPERIMENTAL|PMP group|children received health education for eye and the intervention(which included frequency following response, eye exercise, and transcutaneous electrical nerve stimulation) a 30 minute three times per week for four weeks.
61972072|NCT05010031|EXPERIMENTAL|radiation|Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases).
61972073|NCT05693441|ACTIVE_COMPARATOR|Active berry product|Once daily consumption over the period of the study
61972074|NCT05693441|PLACEBO_COMPARATOR|Reference berry-like product|Once daily consumption over the period of the study
62146741|NCT03441490|EXPERIMENTAL|ICBT learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail
61972075|NCT02663323|EXPERIMENTAL|MeRes100 - BRS|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
61972076|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
61972077|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
62512014|NCT05604079|EXPERIMENTAL|Electrolarynx|In this single arm study, all participants will receive training in the Electrolarynx
62512015|NCT04691375|EXPERIMENTAL|Part A: PY314 Single agent dose level 1|PY314 single agent dose level will depend on any safety signal observed in this cohorts only. Following the determination of the safety and tolerability of at least two PY314 dose levels by the safety review committee.
62512016|NCT04691375|EXPERIMENTAL|Part A: PY314 Single agent dose level 2|PY314 single agent dose level 2 dose escalation of PY314 as a single agent will continue in the absence of unacceptable dose limiting toxicity to the maximum administered dose as defined in the predefined dose escalation schema.
62512017|NCT04691375|EXPERIMENTAL|Part A: PY314 Single agent dose level 3|PY314 single agent dose level 3 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314
62512018|NCT04691375|EXPERIMENTAL|Part A: PY314 Single agent dose level 4|PY314 single agent dose level 4 to characterize the pharmacokinetic profile of PY314 as a single agent.
62512019|NCT04691375|EXPERIMENTAL|Part A: Combination dose level 1|Combination dose level 1 to characterize the safety and tolerability of PY314 as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including refractory to check point inhibitor.
62512020|NCT04691375|EXPERIMENTAL|Part A: Combination dose level 2|PY314 combination dose level 2 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314 administered alone and in combination with pembrolizumab.
62512021|NCT04691375|EXPERIMENTAL|Part A: Combination dose level 3|PY314 combination dose level 3 to characterize the pharmacokinetic profile of PY314 as a single agent and in combination with pembrolizumab.
62512022|NCT04691375|EXPERIMENTAL|Part A: Combination dose level 4|PY314 combination dose level 4 to describe, in subjects selected by pre-specified tumor histology, anti-tumor activity of PY314 administered alone and in combination with pembrolizumab.
62512023|NCT04691375|EXPERIMENTAL|Part B: Single agent dose expansion dose level 1|PY314 single agent dose expansion dose level 1 to define further the safety and tolerability of PY314 alone.
62512024|NCT04691375|EXPERIMENTAL|Part B: Combination dose expansion cohort 1|PY314 in combination with pembrolizumab dose expansion cohort 1 to define the safety and tolerability of PY314 alone and in combination with pembrolizumab over multiple treatment cycles in subjects with pre-defined tumor histologies and confirmed TREM2 expression.
62512025|NCT04691375|EXPERIMENTAL|Part B: Combination dose expansion cohort 2|PY314 in combination with pembrolizumab dose expansion cohort 2 to further characterize the PK profile of PY314 as a single agent and in combination with pembrolizumab.
62512026|NCT04691375|EXPERIMENTAL|Part B: Combination dose expansion cohort 3|PY314 in combination with pembrolizumab dose expansion cohort 3 to characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
62512027|NCT04691375|EXPERIMENTAL|Part B: Combination dose expansion cohort 4|PY314 in combination with pembrolizumab dose expansion cohort 4 to evaluate the incidence of ADA formation and TREM2 expression.
62512028|NCT04691375|EXPERIMENTAL|Part B: Combination dose expansion cohort 5|PY314 in combination with pembrolizumab dose expansion cohort 5 to further explore and characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
61972078|NCT02188212|OTHER|NobelProcera Crown Shaded Zirconia|NobelProcera Crown Shaded Zirconia molar
61972079|NCT00662363|EXPERIMENTAL|Lubiprostone and placebo Senna|Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon
61972080|NCT00662363|ACTIVE_COMPARATOR|Senna active plus Lubiprostone Placebo|Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID
61972081|NCT03684811|EXPERIMENTAL|Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)|
61972082|NCT03684811|EXPERIMENTAL|Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)|
61972083|NCT03684811|EXPERIMENTAL|Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)|
62146742|NCT03441490|EXPERIMENTAL|ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat
62512029|NCT04673708|OTHER|Hashim Talib Hashim|It is a video with +18 different contents to know the effect of much video than the others.
62512030|NCT04673708|EXPERIMENTAL|Mustafa Ahmed Ramadhan|Is is an assessment of the vital signs among the participants and the change with the showing of videos.
62512031|NCT04897191||Healthy|Healthy people age 20-70 years
61972084|NCT03684811|EXPERIMENTAL|Phase 1b and 2 Cohort Combination (Cohort 2b)|
61972085|NCT03684811|EXPERIMENTAL|Phase 1b and 2 Cohort Combination (Cohort 4b)|
61972086|NCT05699395||Aortic Dissection|
62512032|NCT06617299|EXPERIMENTAL|Responsive Feeding Group|Group to receive information on responsive feeding
62512033|NCT06617299|NO_INTERVENTION|Breastfeeding Group|Group to receive information disseminated by hospital staff on breastfeeding
62512034|NCT01625481|EXPERIMENTAL|Seal-V|A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.
62512035|NCT01158326|ACTIVE_COMPARATOR|Resfenol Solution oral|Acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride active drug
62512036|NCT01158326|PLACEBO_COMPARATOR|Placebo|Placebo oral solution
62512037|NCT01270620|ACTIVE_COMPARATOR|Propofol|Patients will receive propofol as general anesthetics.
62512038|NCT01270620|ACTIVE_COMPARATOR|Desflurane|Patients will receive desflurane as general anesthetics.
62512039|NCT01343069|NO_INTERVENTION|before surgical checklist|
62512040|NCT01343069|ACTIVE_COMPARATOR|after implementation surgical checklist|
62708351|NCT04017234|NO_INTERVENTION|control group|children just received health education for eye
61972087|NCT05699395||Non Aortic Dissection|
62146743|NCT05955807||Patients hospitalized due to severe risk of suicide|This is an observational study that focus on patients wellbeing and life-experience in the discharge period after a stay in psychiatric care due to severe risk of suicide. Patients will be treated according to usual pratice in clinical care
62146744|NCT05086874||Exposed group|A group of patients with ischemic stroke, treated with butylphthalide
61972088|NCT04604821|EXPERIMENTAL|Enhanced Milieu Teaching|Child-caregiver dyads receive up to 24 speech-language therapy sessions (50minutes, 2x per week for 3 months) where parents are taught by the interventionist to use Enhanced Milieu Teaching Strategies. Children and their families may continue to participate community-based educational programs.
62146745|NCT05086874||Non-exposed group|A group of patients with ischemic stroke, treated with Edaravone
62146746|NCT02553148||Argentina|One of the 23 countries studied
62352869|NCT06552923|EXPERIMENTAL|ECHO Intervention Delayed|11 FQHC were randomized to start the ECHO program in December 2021. The providers at participating FQHCs joined tele-education one hour sessions and received CME for learning about diabetes care-related topics. They attended sessions twice monthly for 6-months
62352870|NCT03594253|EXPERIMENTAL|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman \& Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
62512041|NCT05500092|ACTIVE_COMPARATOR|Nivolumab + Platinum Doublet Chemotherapy|All participants will receive platinum-based doublet chemotherapy (PDC) along with nivolumab for 3 cycles every 3 weeks. Carboplatinum (AUC=5) can be used instead of Cisplatin (75 mg/m2) from cycle 2 for Cisplatin induced neuro/oto/nephrotoxicity as long as the subject remains eligible for doublet chemotherapy. Participants with nonsquamous tumors will receive pemetrexed (500 mg/m2). Participants with squamous tumors will receive either docetaxel (75 mg/m2 on day 1) or gemcitabine (1000 mg/m2 on days 1, 8). Cycles will be every 3 weeks and a maximum of a 2 week delay will be permitted for resolution of toxicities.
62352871|NCT03594253|NO_INTERVENTION|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
62352872|NCT02700139|EXPERIMENTAL|Aspheric lens|An aspheric lens which is supposed to slow myopic progression in children by unique asphericity (proprietary information)
62352873|NCT02700139|NO_INTERVENTION|Single vision spheric/toric lenses|Control: single vision spheric/toric lenses
62352874|NCT05248555||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing.
62352875|NCT02711904|ACTIVE_COMPARATOR|Extubation U|Remifentanil concentration between 2 - 3 ng/ml.
62352876|NCT02711904|EXPERIMENTAL|Extubation T|Remifentanil concentration between 3 - 4 ng/ml
62352877|NCT02287870|EXPERIMENTAL|Chloroprocaine Group|Epidural anesthesia with 3% chloroprocaine.
62352878|NCT02287870|ACTIVE_COMPARATOR|Lidocaine Group|Epidural anesthesia with 2% lidocaine.
62352879|NCT05268705|ACTIVE_COMPARATOR|High-carbohydrate-low-fat-low-protein diet|
62352880|NCT05268705|ACTIVE_COMPARATOR|Low-carbohydrate-high-fat-low-protein diet|
62352881|NCT05268705|ACTIVE_COMPARATOR|Low-carbohydrate-low-fat-high-protein diet|
62352882|NCT00546429||A|Monitoring of trochanteric fractures after treatment with the ATN system.
62352883|NCT01183312|EXPERIMENTAL|Placebo, then Flumazenil|Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil
62352884|NCT01183312|EXPERIMENTAL|Flumazenil, then Placebo|Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo.
62352885|NCT04404023|EXPERIMENTAL|UB-221 (0.2 mg/kg)|Intravenous infusion
62352886|NCT04404023|EXPERIMENTAL|UB-221 (0.6 mg/kg)|Intravenous infusion
62352887|NCT04404023|EXPERIMENTAL|UB-221 (2 mg/kg)|Intravenous infusion
61972089|NCT04604821|OTHER|Community Treatment as Usual|Child-caregiver dyads may continue to participate in community-based educational programs. Researchers provide up to 4 educational sessions to caregivers (50 minutes, every 3 weeks). During educational sessions parents are taught developmental milestones from the CDC Learn the Signs Act Early Public Health Campaign.
61972090|NCT06378463|ACTIVE_COMPARATOR|active tDCS + CR|For active tDCS, the current will be 2 mA and will be administered for 20 min with a fade-in/out of 30 s.
61972091|NCT06378463|SHAM_COMPARATOR|sham tDCS + CR|For the sham tDCS, the fade-in will be identical as for the active tDCS. After 30 s the current will fade-out over 30 s. In addition to those above, a standard control pulse, with no therapeutic effect, will be frequently sent to monitor electric conductivity (\~ 0.02mA in duration of 3 s, send every 0.55 s).
62146747|NCT02553148||Armenia|One of the 23 countries studied
62146748|NCT02553148||Australia|One of the 23 countries studied
62146749|NCT02553148||Brazil|One of the 23 countries studied
62146750|NCT02553148||China|One of the 23 countries studied
62146751|NCT02553148||Egypt|One of the 23 countries studied
62146752|NCT02553148||Ethiopia|One of the 23 countries studied
62146753|NCT02553148||Germany|One of the 23 countries studied
62146754|NCT02553148||India|One of the 23 countries studied
62146755|NCT02553148||Indonesia|One of the 23 countries studied
62146756|NCT02553148||Jordan|One of the 23 countries studied
62146757|NCT02553148||Kenya|One of the 23 countries studied
62352888|NCT04404023|EXPERIMENTAL|UB-221 (6 mg/kg)|Intravenous infusion
62352889|NCT04404023|EXPERIMENTAL|UB-221 (10 mg/kg)|Intravenous infusion
62352890|NCT04676542|EXPERIMENTAL|One group taking part in 2 separate conditions|The proposed research design will be utilizing a randomized cross over repeated measures design. Subjects will take part in two separate conditions: 1) One hour of a beginning martial art class (EP), and 2) One hour walk at 4.0 mph pace (IP).
61972092|NCT04973826|EXPERIMENTAL|ATM-AVI treatment arm|Chinese healthy volunteers
62512042|NCT05500092|EXPERIMENTAL|Nivolumab + Platinum Doublet Chemotherapy + SBRT (8gy x 3)|SBRT will be delivered near the conclusion of cycle 1 with platinum-based doublet chemotherapy (PDC) along with nivolumab for 3 cycles every 3 weeks. The intent is to deliver SBRT on three consecutive days when the concentration of radiosensitizing chemotherapy agents in the subject's system is at a minimum, to minimize toxicity risks. It is expected that some subjects may not receive SBRT on three consecutive days due to machine breakdown, inclement weather, or other logistic issues. Subjects must not receive SBRT within 72 hours after a cisplatin or carboplatin infusion
62512043|NCT03027011|ACTIVE_COMPARATOR|Remote Ischemic Preconditioning(RIPC)|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
61972093|NCT03835585|EXPERIMENTAL|Gun lock|Participants will be provided a gun lock and video instructions for its proper use, in addition to standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling).
61972094|NCT03835585|ACTIVE_COMPARATOR|Standard intervention|Participants will be provided standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling) without a gun lock. A gun lock and video instructions will be provided upon completion of the study.
62512044|NCT03027011|PLACEBO_COMPARATOR|Control|Control group without remote ischemic preconditioning
62512045|NCT00490334||Cancer patients|Children with cancer aged 8 to 16 years
62512046|NCT00490334||Control (non-cancer)|Normal children aged 8 to 16 years, age- and gender-matched to the cancer cohort
62512047|NCT01270490|EXPERIMENTAL|Interferon-gamma|
62512048|NCT01270490|NO_INTERVENTION|No intervention|No adjunctive treatment
62512049|NCT05560555||Retrospective cohort ATTRv and ATTRwt patients enrolled in B3461028 and B3461045 studies in Spain|
62512050|NCT06609161|EXPERIMENTAL|Tedizolid Phosphate Oral Formulation 1 (Reference)|Participants will receive oral Formulation 1 (Reference).
62512051|NCT06609161|EXPERIMENTAL|Tedizolid Phosphate Oral Formulation 2 (Test)|Participants will receive oral Formulation 2 (Test).
62708352|NCT03890510|ACTIVE_COMPARATOR|Low PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 6\~9% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
62708353|NCT03890510|ACTIVE_COMPARATOR|High PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 13\~16% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
62708354|NCT05790291|EXPERIMENTAL|checklist|checklist
62708355|NCT05790291|NO_INTERVENTION|no intervention|no intervention
62708356|NCT01441960|EXPERIMENTAL|Succinylcholine first, then Rocuronium|Cross-over randomized controlled, assessor blinded clinical trial.
61972095|NCT04841031|EXPERIMENTAL|NET Treatment|Narrative Exposure Therapy (NET) Treatment: Treatment group consists of eligible individuals who are randomly assigned to receive NET treatment and are part of the study sample. Within each health center, treated individuals are randomly selected over several cohorts. In every cohort, the treatment group contained 6 individuals who received NET.
61972096|NCT04841031|OTHER|Control|This group contains eligible individuals who are randomly assigned to the control group and are part of the study sample. In every cohort, the control group contained 6 individuals.
62512052|NCT05118516|EXPERIMENTAL|Experimental|ASC43F for all subjects under the fasted state.
62708357|NCT01441960|EXPERIMENTAL|Rocuronium first, then succinylcholine|Cross-over randomized controlled, assessor blinded clinical trial.
62708358|NCT02561962|EXPERIMENTAL|Dose Exploration: AMG 224 Dose A|Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
62708359|NCT02561962|EXPERIMENTAL|Dose Exploration: AMG 224 Dose B|Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
61972097|NCT01124422|EXPERIMENTAL|fluticasone propionate/salmeterol DISKUS 250/50 + tiotropium|This is the active DISKUS (that is, containing fluticasone propionate/salmeterol combination) + open-label tiotropium
61972098|NCT01124422|PLACEBO_COMPARATOR|placebo DISKUS + tiotropium|This is the DISKUS and excipient minus the active ingredient (which is fluticasone propionate/salmeterol combination) + open-label tiotropium
62146758|NCT02553148||Kyrgyzstan|One of the 23 countries studied
62512053|NCT05246787|EXPERIMENTAL|Breastfeeding intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. If necessary, the researcher may verbally warn the mother in a calm tone to continue breastfeeding throughout the procedure. During the resting period (last 2 minutes) after the blood draw is completed, the baby stays on the mother's lap.
62512054|NCT05246787|EXPERIMENTAL|Shotblocker intervention|2 minutes before the procedure, the baby will be placed on the mother's lap. ShotBlocker is a small plastic tool that is blunt, short, has many points in contact with the skin, does not contain drugs, is in the shape of a horseshoe, invasive interventions can be applied through the space in the middle. It is positioned on the skin before the invasive procedure. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
62146759|NCT02553148||Malaysia|One of the 23 countries studied
62146760|NCT02553148||Malawi|One of the 23 countries studied
62146761|NCT02553148||Mexico|One of the 23 countries studied
62146762|NCT02553148||Russia|One of the 23 countries studied
62146763|NCT02553148||Serbia|One of the 23 countries studied
62708360|NCT02561962|EXPERIMENTAL|Dose Exploration: AMG 224 Dose C|Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
62708361|NCT02561962|EXPERIMENTAL|Dose Exploration: AMG 224 Dose D|Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
62708362|NCT02561962|EXPERIMENTAL|Dose Exploration: AMG 224 Dose E|Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
62708363|NCT02561962|EXPERIMENTAL|Dose Exploration: AMG 224 Dose F|Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
62708364|NCT02561962|EXPERIMENTAL|Dose Exploration: AMG 224 Dose G|Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
61972099|NCT04007094|EXPERIMENTAL|Study Arm|Participants will be entered into the single armed study in which one side of the fusion will be coated with milled local autograft bone and the opposite fusion side will be supplemented with an equal volume of Depuy Synthes ViviGen.
61972100|NCT02989194|EXPERIMENTAL|VIS410 low dose|Single intravenous fixed low dose of VIS410
61972101|NCT02989194|EXPERIMENTAL|VIS410 high dose|Single intravenous fixed high dose of VIS410
61972102|NCT02989194|PLACEBO_COMPARATOR|Placebo|Single intravenous placebo infusion
62146764|NCT02553148||South Africa|One of the 23 countries studied
62352891|NCT01879319|EXPERIMENTAL|Evolocumab AMD|Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
62352892|NCT01879319|EXPERIMENTAL|Evolocumab AI/pen|Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
62352893|NCT06138886|EXPERIMENTAL|Calisthenics exercise group|This group includes 30 burned patients who will perform calisthenics exercises program for 3 months (3 times/week) in addition to their traditional physical therapy program and medical treatment.
62352894|NCT06138886|EXPERIMENTAL|Pulsed electromagnetic therapy group|This group includes 30 burned patients who will receive pulsed electromagnetic therapy for 3 months (3 times/week) in addition to their traditional physical therapy program and medical treatment.
62352895|NCT06138886|EXPERIMENTAL|Calisthenics exercises and pulsed electromagnetic therapy group|This group includes 30 burned patients who will perform calisthenics exercises program and receive pulsed electromagnetic therapy for 3 months (3 times/week) in addition to their traditional physical therapy program and medical treatment.
62352896|NCT02384395|EXPERIMENTAL|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
62352897|NCT02423460|EXPERIMENTAL|Threonine requirement|The threonine requirement in healthy male subjects and in patients with Crohn's disease and Ulcerative colitis
62352898|NCT04328922|ACTIVE_COMPARATOR|Fecal microbial transplantation|FMT capsules fecal capsules on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will be matched to donors according to their CMV status (past exposure - CMV positive donors will be used for CMV positive patients, and CMV negative donors will be used for CMV negative patients).
62352899|NCT04328922|PLACEBO_COMPARATOR|Placebo|Placebo capsules placebo capsules- on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will receive placebo capsules.
62352900|NCT05016791|ACTIVE_COMPARATOR|Active|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider. In addition, participants in this arm shall be loaned an Apple Watch device and undergo an education session to familiarise themselves with the study recording schedule and how to perform recordings.
62352901|NCT05016791|NO_INTERVENTION|Control|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider.
62352902|NCT03823040|ACTIVE_COMPARATOR|Tinox® group|Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
62352903|NCT03823040|EXPERIMENTAL|Oxiconazole nitrate SLNs loaded gel group|13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
62352904|NCT01499719||Surgical checklist|Compliance for surgical checklist
62352905|NCT03350841|EXPERIMENTAL|Revascularization|platelet rich plasma injected in the canals
62352906|NCT03350841|ACTIVE_COMPARATOR|root canal treatment|endodontic treatment obturated with gutta percha
62352907|NCT01385267||Diamniotic twin gestations|
62708365|NCT02561962|EXPERIMENTAL|Dose Expansion: AMG 224 Dose H + prior CD38 targeting antibody treatment|Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose \[MTD\] based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
61972103|NCT03653650|EXPERIMENTAL|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
61972104|NCT03653650|ACTIVE_COMPARATOR|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
61972105|NCT03653650|ACTIVE_COMPARATOR|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
62146765|NCT02553148||Tajikistan|One of the 23 countries studied
62146766|NCT02553148||United Kingdom|One of the 23 countries studied
62146767|NCT02553148||United States|One of the 23 countries studied
62146768|NCT02553148||Zimbabwe|One of the 23 countries studied
62146769|NCT03335488|EXPERIMENTAL|RAVICTI -> RAVICTI|Initial Treatment, Maintenance, Safety Extension Periods: RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose. Dosing will be based on participants disease and treatment status at entry to the study.
61972106|NCT04159844|ACTIVE_COMPARATOR|Short stretch bandage|Application with 50% overlap in combinaison with wading
62352908|NCT06490926||Parkinson's disease|"Age range from 45 to 80 years old; ② Patients with idiopathic Parkinson's disease who meet the diagnostic criteria of the International Committee on Motor Disorders (MDS) for Parkinson's disease (2015); ③ Classification criteria for subtypes of Parkinson's disease:~Tremor predominant type: According to the MDS-UPDRS score, the ratio of average tremor score to average PIGD score is ≥ 1.15 PIGD type: According to the MDS-UPDRS score, the ratio of average tremor score to average PIGD score is ≤ 0.9"
62352909|NCT06490926||progressive supranuclear palsy|"PSP inclusion criteria ① Age range from 45 to 80 years old;~② PSP patients who meet the diagnostic criteria for progressive supranuclear palsy in China (2016) or the diagnostic criteria for progressive supranuclear palsy in the International Society for Parkinson's Disease and Movement Disorders (MDS) (2017)"
62352910|NCT06490926||healthy control|Volunteers aged 45-80 who are matched for age, gender, and underlying diseases, have no neurological disorders, and have not Take any medication.
62512055|NCT05246787|EXPERIMENTAL|Breastfeeding and Shotblocker intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
62512056|NCT05246787|NO_INTERVENTION|Control group/ Standard Care|The baby is placed on the mother's lap 2 minutes before the procedure and the mother is provided to hold the baby effectively and graspingly. Standard heel lance procedure is applied. No additional interventions are applied to the baby. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
62512057|NCT04626544||Dizziness|Patients with dizziness referred to a secondary referral center
62512058|NCT04626544||Healthy controls|Healthy controls without dizziness or neck pain symptoms for the last 3 months
62708366|NCT02561962|EXPERIMENTAL|Dose Expansion: AMG 224 Dose H + no prior CD38 targeting antibody treatment|Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
62708367|NCT03448328|EXPERIMENTAL|Pea Protein|NUTRALYS pea protein supplement
62708368|NCT03448328|EXPERIMENTAL|Whey Protein|Whey protein supplement
61972107|NCT04159844|ACTIVE_COMPARATOR|Multi componant bandage|Application with 50% overlap
62352911|NCT06490926||multiple system atrophy|"MSA inclusion criteria~* Age range from 45 to 80 years old; ② Meets the Chinese expert consensus on the diagnostic criteria for multiple system atrophy (2017) or the International Society for Parkinson's Disease and Movement Disorders (MDS) diagnostic criteria for multiple system atrophy (2022) ③ MSA subtype grouping: MSA is divided into MSA-P and MSA-C subtypes based on the severity of initial and/or motor symptoms, with Patients with Parkinson's syndrome as the main type are MSA-P, while patients with cerebellar syndrome as the main type are MSA-C."
62352912|NCT03921047||Ancillary-correlative (next generation sequencing)|Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for RNA-based next generation sequencing of TCRA and TCRB genes.
62352913|NCT02235402|EXPERIMENTAL|Lacidipine|
62352914|NCT02235402|ACTIVE_COMPARATOR|Bendrofluazide|
62352915|NCT02235402|PLACEBO_COMPARATOR|Placebo|
62352916|NCT03713957|EXPERIMENTAL|GRF6021|Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
62352917|NCT03713957|PLACEBO_COMPARATOR|Placebo|Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
62352918|NCT03342456|EXPERIMENTAL|group 1|week1 to week2：Doxycycline Hyclate Enteric-Coated Capsules 0.1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily
62352919|NCT03342456|ACTIVE_COMPARATOR|group 2|"Amoxicillin Capsules 1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily.~week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily"
62352920|NCT06283992|EXPERIMENTAL|Digital Navigation|Patients in this arm will receive 1:1 digital navigation support which will teach them about the functions of the patient portal and telehealth.
62352921|NCT06283992|NO_INTERVENTION|Standard of Care|Patients in this arm will receive the standard of care which will be an educational sheet.
62352922|NCT01313481|EXPERIMENTAL|Group exercise|Otago exercise performed in groups
62352923|NCT01313481|ACTIVE_COMPARATOR|Home exercise|Otago exercise performed as home exercise
62352924|NCT03130712|EXPERIMENTAL|GPC3-CART cells|
62352925|NCT04101578||Ocular MG|Patients with autoimmune MG whose symptoms restricted to extraocular muscles
62352926|NCT04101578||Generalized MG|Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
62352927|NCT00326222|EXPERIMENTAL|1|Lifestyle counseling
62352928|NCT00326222|NO_INTERVENTION|2|Usual care
62352929|NCT04973891|EXPERIMENTAL|Experimental: Canagliflozin/metformin group|Intervention with canagliflozin combined with metformin for three months
62352930|NCT04973891|ACTIVE_COMPARATOR|Active Comparator: Metformin group|Intervention with metformin for three months
61972108|NCT04159844|ACTIVE_COMPARATOR|Short stretch bandage bis|Application with 50% overlap in combinaison with wading
62352931|NCT01017341|NO_INTERVENTION|No hip protector|no hip protector
62708369|NCT03448328|ACTIVE_COMPARATOR|Apple juice|Apple juice
62708370|NCT02152748||Glioblastoma|The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
62708371|NCT05992272||alcohol use disorder (AUD)|"Participants with alcohol use disorder (mild to moderate or severe if no withdrawal symptoms) including:~* daily smokers (at least 1 cigarette per day in last 3 months)~* non-daily (min 1x/last 3months)~* non-smokers"
62708372|NCT05992272||non-AUD|"Participants with a maximum of 1 AUD criteria according to DSM-5, including:~* daily smokers (at least 1 cigarette per day in last 3 months)~* non-daily (min 1x/last 3months)~* non-smokers"
62708373|NCT03186547|EXPERIMENTAL|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
61972109|NCT04224311|ACTIVE_COMPARATOR|Low number plateletpheresis donations|Participants that have had 1-2 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
61972110|NCT04224311|ACTIVE_COMPARATOR|Medium number plateletpheresis donations|Participants that have had 3-19 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
61972111|NCT04224311|ACTIVE_COMPARATOR|High number plateletpheresis donations|Participants that have had 20-24 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
61972112|NCT01693926|EXPERIMENTAL|Acute physical activity intervention|25 min of moderate physical activity
62708374|NCT03186547|EXPERIMENTAL|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
61972113|NCT01693926|PLACEBO_COMPARATOR|Placebo|25 min of reading (instead of physical activity)
61972114|NCT01454622|EXPERIMENTAL|Treatment Sequence AB|
61972115|NCT01454622|EXPERIMENTAL|Treatment Sequence BA|
62708375|NCT03838835|EXPERIMENTAL|Equine-facilitated group therapy|
61972116|NCT00268957|EXPERIMENTAL|1|sevelamer carbonate powder
61972117|NCT00268957|ACTIVE_COMPARATOR|2|Sevelamer hydrochloride
61972118|NCT01867268|EXPERIMENTAL|Acetazolamide|administration of Acetazolamide for 10 days following the surgery
61972119|NCT01867268|NO_INTERVENTION|Control|control group without any intervention
61972120|NCT01867268|EXPERIMENTAL|Prone positioning|Positioning the patient following surgery for 10 days
62352932|NCT00961870|EXPERIMENTAL|Healthy postmenopausal women|Forearm vibration will be applied in women without postmenopausal osteoporosis
62512059|NCT05447806|EXPERIMENTAL|Active Inpatient Diabetes Clinical Decision Support|"The Active arm consists of participants treated during the ON phase of the GlucAlert-CDS tool. The tool operates through an automated process of rules embedded in the EMR recognizing hypoglycemia (established or impending); recurrent hyperglycemia (in type 1 and 2 DM, or stress hyperglycemia-SH); and inappropriate insulin use (sliding scales monotherapy if recurrent hyperglycemia in type 2 DM or SH, or any time in type 1 DM). If the tool's criteria are met, an alert in the EMR will notify the provider with the clinically recommended treatment."
62512060|NCT05447806|NO_INTERVENTION|Inactive Inpatient Diabetes Clinical Decision Support|"The Inactive arm consists of participants treated during the OFF phase of the GlucAlert-CDS Tool. Alerts will not be sent to provider's"
62708376|NCT03838835|EXPERIMENTAL|Augmented equine-facilitated CBT group program|
62708377|NCT03838835|OTHER|Wait List Control (WLC)|
61972121|NCT01867268|EXPERIMENTAL|Acetazolamide and Prone positioning|applying both Acetazolamide and prone positioning
62708378|NCT01634152|PLACEBO_COMPARATOR|Placebo QD|
62708379|NCT01634152|EXPERIMENTAL|Tiotropium low dose QD|
62708380|NCT01634152|EXPERIMENTAL|Tiotropium medium dose QD|
61972122|NCT04076319|OTHER|CAPABLE|CAPABLE Intervention
61972123|NCT04208984||Control|Patients randomized to this group will receive standard of care induction of anesthesia
61972124|NCT04208984||Study|Patients randomized to this group will receive induction of anesthesia using the Lullabreath game
61972125|NCT04208984||Music Video|Patients randomized to this group will receive induction of anesthesia using the music video game
61972126|NCT00507962|EXPERIMENTAL|Cisplatin + Liposomal Doxorubicin|Cisplatin 100 mg/m\^2 Intraarterial and Liposomal Doxorubicin starting dose 20 mg/m\^2 by vein on Day 1 every 4 weeks
61972127|NCT02955485||Patients with chronic ankle instability|All patients that develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Experiencing persisting complaints of instability for more than 6 months.
62352933|NCT00961870|EXPERIMENTAL|Osteoporotic postmenopausal women|Forearm vibration will be applied in women with postmenopausal osteoporosis
62512061|NCT00759434|ACTIVE_COMPARATOR|Surgery|
62512062|NCT00759434|EXPERIMENTAL|EVLT|
62708381|NCT05253040|EXPERIMENTAL|Intervention group|"The experimental group will receive:~Online education modules Online group discussions facilitated by Specialist Physiotherapist"
62708382|NCT05253040|ACTIVE_COMPARATOR|Control Group|The comparator for this study is usual care pathway. Under the usual care pathway, participants will receive education booklets on exercise by Parkinson's UK.
61972128|NCT02955485||Patients without chronic ankle instability|All patients that do not develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Complaints resolve within 6 months.
61972129|NCT02514447|EXPERIMENTAL|Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b|"Patients in Parts 2a and 2b were randomized 1:2 to placebo. Patients received placebo administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of placebo on Days 1 to 5, patients received IV topotecan (1.5 mg/m²)."
61972130|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a|"Patients in Part 2a were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
61976298|NCT04367610||Study Group|Kidney transplant recipients with biopsy-proven acute or chronic antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.
62512063|NCT04510129||head and neck squamous cell carcinoma (HNSCC)|
62708383|NCT00949533|EXPERIMENTAL|Standard Dose|Oseltamivir capsule will be administered orally at a dose of 75 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 milligrams/ milliliter \[mg/mL\]) based on their body weight with a starting dose of 30 mg BID to a maximum dose of 75 mg BID; for 5 days.
62512064|NCT04510129||non-small-cell lung cancer (NSCLC)|
62512065|NCT04510129||small cell lung cancer (SCLC)|
62512066|NCT04510129||urothelial carcinoma (UCC)|
62512067|NCT04510129||gastric or gastroesophageal junction adenocarcinoma|
62512068|NCT04510129||cervical cancer|
62512069|NCT04510129||esophageal squamous cell carcinoma (ESCC)|
62512070|NCT04510129||triple-negative breast cancer (TNBC)|
62512071|NCT04510129||hepatocellular carcinoma (HCC)|
62512072|NCT04510129||renal cell carcinoma (RCC)|
62512073|NCT04510129||colorectal cancer (CRC)|
62512074|NCT00898534|EXPERIMENTAL|Immediate Feedback|Subjects receive point-of-care hemoglobin A1c testing prior to their diabetes clinic visit, with results made available to the provider during the visit.
62512075|NCT00898534|NO_INTERVENTION|Conventional Feedback|Subjects receive laboratory hemoglobin A1c testing at the clinic visit, with results made available to the provider several days later.
62512076|NCT03212794|EXPERIMENTAL|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine or methadone treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
62512077|NCT03212794|NO_INTERVENTION|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine or methadone.
62708384|NCT00949533|ACTIVE_COMPARATOR|Double Dose|Oseltamivir capsule will be administered orally at a dose of 150 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 mg/mL) based on their body weight with a starting dose of 60 mg BID to a maximum dose of 150 mg BID; for 5 days.
62708385|NCT00531778||NYU OCEDP Population|
61972131|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b|"Patients in Part 2b were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.5 mg/m²)."
62352934|NCT00961870|EXPERIMENTAL|Healthy young adult women|Forearm vibration will be applied in healthy young adult women
62352935|NCT00961870|EXPERIMENTAL|Healthy young adult men|Forearm vibration will be applied in healthy young adult men
62352936|NCT05454397||case group|Patients with acute stroke with nutritional risk
62352937|NCT01119157|EXPERIMENTAL|humoral and cellular immune response|
62352938|NCT01119157|EXPERIMENTAL|reactogenicity|
62352939|NCT01273493|EXPERIMENTAL|Trabectedin 1.3 mg/m^2 plus Dexamethasone|Control group Trabectedin 1.3 mg/m\^2 i.v.will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
62352940|NCT01273493|EXPERIMENTAL|Trabectedin 0.58 mg/m^2 plus Dexamethasone|Hepatic dysfunction group Trabectedin 0.58 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
62352941|NCT02924688|EXPERIMENTAL|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62352942|NCT02924688|EXPERIMENTAL|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62352943|NCT02924688|EXPERIMENTAL|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62352944|NCT02924688|EXPERIMENTAL|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62352945|NCT02924688|ACTIVE_COMPARATOR|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62352946|NCT02924688|ACTIVE_COMPARATOR|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
62352947|NCT03909555||Short-term intensive insulin therapy|Patients who used to participated in short-term intensive insulin therapy for 14 days when diabetes was newly diagnosed
62352948|NCT03909555||Routine diabetic therapy|Received routine diabetic therapy
62352949|NCT00877604|EXPERIMENTAL|TUDCA|tauroursodeoxycholic acid di-hydrate
62352950|NCT00877604|PLACEBO_COMPARATOR|placebo|excipient lactose
62352951|NCT02166229|EXPERIMENTAL|Divalproex sodium|Divalproex sodium will be initiated at 125 mg twice daily and increased monthly to a maximum dose of 500 mg twice daily.
62352952|NCT04383314|EXPERIMENTAL|Exercise Program Group|Participants will be prescribed an individualized 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (ACSM) Guidelines.
62352953|NCT05264558|EXPERIMENTAL|Test and treat|This group will receive POC HCV viral load testing via a fingerstick using the Xpert HCV Viral load finger stick point of care test (Cepheid) in addition to the standard of care whole blood conventional laboratory based HCV PCR viral load testing. Participants who return a positive POC HCV viral load result will be provided with Epclusa on the same day as result. Follow up management will be determined by results received from standard of care blood. Service level data will be investigated to estimate HCV targeted treatment numbers prior to intervention arms implementation. Service level data will be measured post intervention periods.
62352954|NCT05264558|OTHER|General Practitioner Refresher and Clinic in reach|Perform hepatitis C education for GP and clinic staff at primary health services; on hepatitis testing and treatment at a service level will offer the opportunity to tailor education to the requirements of the clinic and staffing needs.Service level data will be investigated to estimate HCV targeted treatment numbers prior to intervention arms implementation. Service level data will be measured post intervention period
62352955|NCT05264558|OTHER|Incentive and Peer intervention in HCV care cascade|Assess the effectiveness in primary health services of engaging people in hepatitis C testing, and retention throughout the care cascade whilst employing innovative techniques including incentives and peer recruitment.Service level data will be investigated to estimate HCV targeted treatment numbers prior to intervention arms implementation. Service level data will be measured post intervention period
62512078|NCT05289934|EXPERIMENTAL|Children with Epilepsy|Children (age: 4- 17 years old) will participate in this study, and they will listen to Mozart K.448 (1st movement) and instrumental age-appropriate song with 10 minutes wash out in between, each lasting up to 9 minutes in the daytime (between 1-5 pm). The music stimuli will be randomly played in 2 to 7 days during the EMU stay (average 4 days). Music will be delivered via single-use earbuds.
62512079|NCT04649450|EXPERIMENTAL|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days (post-operative day 1, 2 and 3) at the neurosurgical ward they will receive music twice a day for 30 minutes. All participants will further receive standard of clinical care.
62512080|NCT04649450|NO_INTERVENTION|Standard of clinical care|Standard of clinical care.
62512081|NCT04667247|EXPERIMENTAL|Mushrooms|Fomitopsis officinalis and Trametes versicolor
62512082|NCT04667247|PLACEBO_COMPARATOR|Placebo|Organic brown rice
62512083|NCT02515292||IUGR: newborn with intrauterine growth restriction|"Inclusion criteria:~* newborn infants with symmetrical (both weight and height lower than 10th percentile) or asymmetrical (birth weight is lower than 10th percentile but height and age-appropriated height) intrauterine growth restriction~* agreement of the parents that their child to be included in the study"
62512084|NCT02515292||control: newborn without intrauterine growth restriction|"Inclusion criteria:~- matches newborn without intrauterine growth restriction in terms of gender and gestational age as IUGR group"
62512085|NCT00990847|EXPERIMENTAL|Procaterol|Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
62512086|NCT00990847|ACTIVE_COMPARATOR|Salbultamol|Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
62512087|NCT03648619|OTHER|Oncologic patients|Oncologic patients with a previous PET/CT for whole-body staging
62512088|NCT00860678|ACTIVE_COMPARATOR|A|Training group
62512089|NCT00860678|OTHER|B|Controls
62512090|NCT03483311|EXPERIMENTAL|psoriasis patients|Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
62512091|NCT03483311|EXPERIMENTAL|controls|Tissue levels of resolvin D1 in controls
62512092|NCT00389220|ACTIVE_COMPARATOR|BioMatrix Flex stent|Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer
62512093|NCT00389220|ACTIVE_COMPARATOR|Cypher Select stent|Coronary stent placement with Sirolimus coated stent with durable polymer
62512094|NCT00719979|EXPERIMENTAL|iCBT and TeleCoaching|Participants received the technology-assisted behavioral intervention (iCBT + TeleCoaching).
62512095|NCT00719979|EXPERIMENTAL|iCBT(MoodManager)|Participants received Internet-based cognitive behavioral therapy only.
62352956|NCT00959530|EXPERIMENTAL|lingualized|complete denture fabricated by lingualized occlusion scheme
62352957|NCT00959530|PLACEBO_COMPARATOR|Full Bilaterally Balanced Articulation|complete denture fabricated by Full Bilaterally Balanced Articulation scheme
62352958|NCT01772836|PLACEBO_COMPARATOR|Normal saline|Single and multiple dose of normal saline
62512096|NCT00719979|ACTIVE_COMPARATOR|Treatment as usual / Wait-list control|Participants received treatment as usual . For wait-list control, participants were not provided any intervention for 6 weeks, after which they were allowed to choose coached or self-directed moodManager.
62512097|NCT01485484||Sinus|Optic imaging use near-infrared trans-illumination methods
62512098|NCT04235972|OTHER|Arthrodesis surgery patients|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
62539414|NCT02074618|EXPERIMENTAL|Physical Exercise|The program of physical exercise was a resistance and aerobic training, initiated at low intensity and with a slow progressing according to the patient's tolerance. In aerobic exercise, for greater effectiveness of the training, the literature recommends moderate intensity, which corresponds with 50 to 70% of the maximum heart rate. Patients were instructed to keep the most constant as possible the speed during exercise on treadmill or cycle ergometer. For muscle strengthening exercises, the number of repetitions varied from 1 to 4 sets of 10 to 15 repetitions.
62539415|NCT06634147|NO_INTERVENTION|Control|No exercise during hospitalization
62539416|NCT06634147|EXPERIMENTAL|Intervention group|Exercise during hospitalization
62708386|NCT05069519|EXPERIMENTAL|Facebook Condition|Participants assigned to this intervention will take part in personalized Facebook health education, receive a smartwatch, receive weekly health education, share sentiments on Facebook, and receive personalized feedback.
62708387|NCT05069519|EXPERIMENTAL|Smartwatch Condition|Participants assigned to this intervention will use a Fitbit to track daily physical activity (PA), share PA data remotely, and receive personalized feedback.
62352959|NCT01772836|EXPERIMENTAL|Single dose IV of biapenem or RPX7009|Single dose IV infusion of biapenem or RPX7009
62352960|NCT01772836|EXPERIMENTAL|Single dose of biapenem or RPX7009|Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
62352961|NCT01772836|EXPERIMENTAL|Biapenem and RPX7009 in combination|Single dose followed by a multiple dose of biapenem and RPX7009 in combination
62352962|NCT01752972|EXPERIMENTAL|Palmer arsenical keratosis|Spirulina 10 g/day orally for 12 weeks
62708388|NCT05069519|EXPERIMENTAL|Combined Condition|Participants assigned to this condition will receive both Fitbit and Facebook health education programs, (The Smartwatch and Facebook Conditions). The investigators will also provide weekly personalized feedback, based on PA data and sentiment analysis, that have been developed in prior pilot studies.
62708389|NCT05069519|NO_INTERVENTION|Attention Control|Participants assigned to the control condition will not receive any intervention. They will receive a Fitbit smartwatch, and continue with their standard care currently done in their life during the intervention period.
62708390|NCT03060837|ACTIVE_COMPARATOR|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
62708391|NCT03060837|ACTIVE_COMPARATOR|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
62708392|NCT00047034|EXPERIMENTAL|Treatment (eribulin mesylate)|Patients receive E7389 IV over 1-2 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity.
62708393|NCT06192563||Adolescents with AD|Adolescent (aged 12 to 17 years) participants who suffer from severe AD with EASI score \< 16, eligible for systemic dupilumab treatment according to Italian reimbursement criteria.
62708394|NCT04630483||Group I: INHA|Inhalational anesthesia (INHA)
62708395|NCT04630483||Group II: TIVA|Total intravenous anesthesia (TIVA)
62708396|NCT06564285|PLACEBO_COMPARATOR|Placebo|Maltodextrin + Flavoring
62708397|NCT06564285|EXPERIMENTAL|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
62708398|NCT06453577||Patients with acute decompensated heart failure|"Patients presenting with acute decompensated heart failure (ADHF) at Saarland University Medical Center. (phase A)~ADHF (acutely decompensated CHF or new onset/ de novo HF):~Evidence of congestion and decompensation defined by physical abnormalities as follows: Physical evidence of congestion, including pitting edema \> 2 mm in the lower extremities extending from the ankles to mid-calf and rales on pulmonary examination (chest X-ray)"
62708399|NCT06453577||Patients after recompensation|"Same patients after recompensation. (phase B)~After resolution of the signs of congestion (mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan), as evidenced by the following:~1. A decrease in body weight and~2. Resolution of the physical findings (absence of signs) of congestion, including resolution of the physical findings of congestion including peripheral edema and rales on pulmonary examination (chest X-ray) according to the clinical judgment of the attending physician."
62708400|NCT04414787|ACTIVE_COMPARATOR|Intervention|PCplanner intervention during hospitalization
62708401|NCT04414787|NO_INTERVENTION|Usual care control|Usual care
62708402|NCT01478425|EXPERIMENTAL|Active|Lipidic Microemulsion
62708403|NCT01478425|PLACEBO_COMPARATOR|Control|Saline nose-spray device
62708404|NCT04154722|EXPERIMENTAL|meropenum and azithromycin group|inj meropenum 20mg/kg/dose I/v in 3 divided doses and syp azithromycin 20mg/kg/day in 2 divided doses.
62708405|NCT04154722|ACTIVE_COMPARATOR|meropenum group|inj meropenum 20mg/kg/dose I/v in 3 divided doses
62352963|NCT01752972|ACTIVE_COMPARATOR|Arsenic exposed controls|Spirulina 10 g/day orally for 12 weeks
62539417|NCT04494984|ACTIVE_COMPARATOR|Active|Subjects will receive a 1st intravenous dose of 4 mg/kg INM005 (Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F\[ab'\]2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM005. Each dose will be separated by 48 h (± 2 h).
62708406|NCT02347410|OTHER|Investigation Group|This is a single-arm investigation. All subjects were treated with the SIFS device filled with bone graft. Posterior fixation required.
62708407|NCT04958486|EXPERIMENTAL|Treatment|
62708408|NCT01646827|EXPERIMENTAL|Deltoid|Deltoid injection site
62708409|NCT01646827|EXPERIMENTAL|Gluteal|Gluteal injection site
62539418|NCT04494984|PLACEBO_COMPARATOR|Placebo|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 48 h (± 2 h).
62708410|NCT02157909|EXPERIMENTAL|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
62708411|NCT02157909|ACTIVE_COMPARATOR|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
62708412|NCT02940925|EXPERIMENTAL|Drug: Taxol,cisplatin and capecitabine|"Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy \|(CCRT)."
62708413|NCT02940925|ACTIVE_COMPARATOR|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
62708414|NCT02154061|EXPERIMENTAL|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
62708415|NCT02154061|ACTIVE_COMPARATOR|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
62708416|NCT04269954|EXPERIMENTAL|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin.
62708417|NCT04269954|OTHER|Low-molecular-weight heparin therapy|Low-molecular-weight heparin combined with routine drug therapy.
62708418|NCT02297516|EXPERIMENTAL|Azzalure/Dysport as single treatment|Azzalure/Dysport as single treatment at initial treatment
62708419|NCT02297516|EXPERIMENTAL|Filler as single treatment|Filler as single treatment at initial treatment
62708420|NCT02546323|EXPERIMENTAL|Rosuvastatin|20 mg tablets, Daily oral dose
62708421|NCT02546323|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets
62708422|NCT02826187||Patients with acetabular implant|"Data to be collected are :~* Early complications data related to implant or procedure of implantation~* Late stage complications data~* Efficacity of treatment with HIP score~* Patient satisfaction~* Radiographic evaluation during standard follow-up"
62708423|NCT04782921|EXPERIMENTAL|Gel 40|Application of Gel 40
62708424|NCT04782921|ACTIVE_COMPARATOR|Gen-Os|Application of Gen-Os
62708425|NCT02474810|EXPERIMENTAL|Intensive|In the Intensive Protocol, alteplase intervention is administered to all catheters based on blood flow and/or line reversal
62708426|NCT02474810|EXPERIMENTAL|Standard|In the Standard Protocol, alteplase intervention is administered to all catheters based only on blood flow.
62708427|NCT00185341|EXPERIMENTAL|CCR-1 Receptor Antagonist|Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily
61972132|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.50 mg/m²)."
62708428|NCT00185341|PLACEBO_COMPARATOR|Placebo|Subjects received placebo corresponding to verum
62708429|NCT01435161|ACTIVE_COMPARATOR|Nifedipine|Patients in arm 1 receive Nifedipine;
62708430|NCT01435161|ACTIVE_COMPARATOR|Telmisartan|Arm 2 receive telmisartan
62708431|NCT06216977|EXPERIMENTAL|Clear Liquids Arm|
62708432|NCT06216977|ACTIVE_COMPARATOR|Standard Of Care|
62708433|NCT01515371|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
62708434|NCT01515371|PLACEBO_COMPARATOR|Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
62146770|NCT03335488|ACTIVE_COMPARATOR|NaPBA -> RAVICTI|"Initial Treatment Period: NaPBA dosing based on participants disease and treatment status at entry to the study.~Transition, Maintenance, Safety Extension Periods: RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose. Dosing will be based on participants disease and treatment status at entry to the study."
62708435|NCT00261833|EXPERIMENTAL|Zemaira®|
62708436|NCT00261833|PLACEBO_COMPARATOR|Placebo|
62708437|NCT02009566|EXPERIMENTAL|Abdominal radiographs with microfabricated tags|
62708438|NCT00557193|EXPERIMENTAL|Arm A (standard risk MLL-G)|Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
62708439|NCT00557193|ACTIVE_COMPARATOR|Arm B (IR/HR MLL-R chemotherapy)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \>= 90 days at diagnosis and High Risk (HR) if age \< 90 days at diagnosis.
62708440|NCT00557193|EXPERIMENTAL|Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \>= 90 days at diagnosis and High Risk (HR) if age \< 90 days at diagnosis.
62708441|NCT01785030|EXPERIMENTAL|50% Nitrous oxide|
62146771|NCT02941549|PLACEBO_COMPARATOR|Placebo|2 x placebo 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
62146772|NCT02941549|EXPERIMENTAL|1000 mg Epeleuton|1 x Epeleuton 500 mg capsule and 1 x placebo 500 mg capsule orally administered twice a day (4 capsules daily) for 16 weeks
62708442|NCT01668680|EXPERIMENTAL|LDM anti-angiogenic chemotherapy|LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
62708443|NCT01668680|NO_INTERVENTION|observation|observation only
62708444|NCT00309283|EXPERIMENTAL|somatostatin|
62708445|NCT00309283|PLACEBO_COMPARATOR|Saline solution|
62708446|NCT03906526|EXPERIMENTAL|Monotherapy Arm 1: Nivolumab|Nivolumab IV every 2 weeks
62708447|NCT03906526|EXPERIMENTAL|Monotherapy Arm 2: Motolimod|Motolimod IT injection weekly
62708448|NCT03906526|EXPERIMENTAL|Combination Arm 3: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod IT injection weekly
62708449|NCT03906526|EXPERIMENTAL|Combination Arm 4: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod SC injection weekly
62708450|NCT00267930|PLACEBO_COMPARATOR|1|Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d
62708451|NCT00267930|EXPERIMENTAL|2|Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d
62708452|NCT00267930|EXPERIMENTAL|3|Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d
62708453|NCT02862119|EXPERIMENTAL|FFR Treatment Arm|"Following PCI of the infarct related artery it is up to the PCI operator to perform FFR-guided PCI of non-infarct related lesion(s) during the index procedure or later during the index hospital admission. For stenosis grade 90-99% FFR is not mandatory (but recommended). An FFR value of ≤0.80 is to be considered significant for ischemia with a recommendation that non-culprit PCI is performed. It is up to the operator to decide whether to use intra-venous or intracoronary adenosine during FFR. An FFR of \>0.80 is to be considered non-significant for ischemia with a recommendation that medical management is pursued.~Pressure wires: Only Fractional Flow Reserve pressure wires from St Jude Medical or Boston Scientific can be used in this study."
62708454|NCT02862119|ACTIVE_COMPARATOR|Conservative Treatment Arm|Only the infarct-related artery will be treated with PCI in this treatment arm during the index hospital admission. Medical therapy for angina pectoris is at the investigators discretion. Clinical follow-up of symptoms is recommended, but it is also acceptable to make a plan at hospital discharge for a later outpatient non-invasive stress-test. It is not acceptable to plan for an elective PCI in this treatment arm without signs of ischemia or symptoms.
62708455|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
62708456|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
62708457|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
62708458|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
62708459|NCT00584857|EXPERIMENTAL|Chemotherapy|Single
62512099|NCT05470829|EXPERIMENTAL|Part 1 75mg ZM-H1505R or placebo|"75 mg was selected for PK bridging.Twelve healthy subjects were enrolled,of which 8 subjects received ZM-H1505R and 4 subjects received placebo.~Subjects were administrated in the morning under fasting conditions on Day 1 and afterwards Day 4 - Day 14 once daily,i.e. after 3-day washout period and followed by 11-day consecutive administration.Safety and tolerability evaluation was performed on Day 3,Day 6,Day 10 and Day 17 after the initial administration.~Two sentinel subjects (one male and one female) were enrolled to reveived ZM-H1505R.When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects,and study drug concentration of sentinel subjects after the initial administration had been analysed so that PK sampling timepoints for the remaining subjects was determined, the remaining 10 subjects were enrolled to receive ZM-H1505R or placebo at a 3:2 ratio in a randomized manner."
62539419|NCT05024864|ACTIVE_COMPARATOR|Helicobacter pylori screening|At centers randomized to screening, all patients with confirmed MI will be tested H. pylori infection with a bedside UBT incorporated into MI routine care during the hospitalization period. In patients tested H. pylori positive, standard triple eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.
62708460|NCT01752049|ACTIVE_COMPARATOR|Topical timolol maleate|"Drug: • Topical timolol maleate 0.5% drops~* Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient telangiectasia per patient)."
62708461|NCT01752049|PLACEBO_COMPARATOR|Placebo|"placebo saline drops~-Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient."
61972133|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.25 mg/m²)."
61972134|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
61972135|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 1|"Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
61972136|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 1|"Patients received trilaciclib (280 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
61972137|NCT02514447|EXPERIMENTAL|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 1|"Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.0 mg/m²)."
61972138|NCT01285310|EXPERIMENTAL|Apremilast 30 mg|
62352964|NCT01752972|ACTIVE_COMPARATOR|Heathy volunteers|Spirulina 10 g/day orally for 12 weeks
62352965|NCT04886518|ACTIVE_COMPARATOR|Higher dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
62352966|NCT04886518|ACTIVE_COMPARATOR|Lower dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning"
62352967|NCT04886518|PLACEBO_COMPARATOR|Placebo|"Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
62352968|NCT05493540|ACTIVE_COMPARATOR|Medical treatment Group|40 preterm neonates will receive Ibuprofen oral suspension
62352969|NCT05493540|PLACEBO_COMPARATOR|Placebo Group|40 preterm neonates will receive oral placebo
62352970|NCT04976296||Stage I-IIIA NSCLC patients after complete resection|For stage I-IIIA NSCLC patients who underwent complete resection.
62352971|NCT04813276|EXPERIMENTAL|Serious game intervention|Participants receive the Strong Together serious game program on a tablet computer.
62352972|NCT04813276|ACTIVE_COMPARATOR|Enhanced care as usual|Participants receive a paper-based self-advocacy guide.
62352973|NCT03293186|EXPERIMENTAL|Use MEDICLORE|use mediclore at the end of surgery
62352974|NCT03293186|NO_INTERVENTION|No antiadhesive product|use no antiadhesive product at the end of surgery
62352975|NCT01800279|ACTIVE_COMPARATOR|Deontology Therapy|The patients in the control group will port a deprogramming occlusal splint to sleep every night, an average of 8 hours per day, for 12 weeks of the treatment.
62352976|NCT01800279|EXPERIMENTAL|Physiotherapy Protocol|The physiotherapy protocol involves the application of kinesitherapy techniques and a myofascial therapy protocol. This protocol will be administered twice a week for 12 weeks.
62352977|NCT00813618|EXPERIMENTAL|1|MEDI-507
62352978|NCT00813618|EXPERIMENTAL|2|MEDI-507
62352979|NCT00813618|EXPERIMENTAL|3|MEDI-507
62352980|NCT01692002|PLACEBO_COMPARATOR|Sodium chloride pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
62352981|NCT01692002|EXPERIMENTAL|Sodium propionate pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
62352982|NCT00180271|EXPERIMENTAL|CRT-D|CRT-D: Cardiac resynchronization therapy with defibrillation.
62352983|NCT00180271|ACTIVE_COMPARATOR|ICD|ICD: Implantable cardioverter defibrillator
62352984|NCT05871593|OTHER|Molecular genetic diagnostic|Next-Generation-Sequencing (NGS)-methods
62352985|NCT02727400||advanced maternal age|Infertile women due to advanced maternal age
62352986|NCT02727400||Young patients|women under 35 undergoing infertility treatments
62352987|NCT04377269|EXPERIMENTAL|Taping Group|33 participants, received ankle taping
62146773|NCT02941549|EXPERIMENTAL|2000 mg Epeleuton|2 x Epeleuton 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
62512100|NCT05470829|EXPERIMENTAL|Cohort 1 of Part 2 50mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 50 mg dose group (cohort 1). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated.~Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
62512101|NCT05470829|EXPERIMENTAL|Cohort 2 of Part 2 100mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 100 mg dose group (cohort 2). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated.~Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
62512102|NCT05470829|EXPERIMENTAL|Cohort 3 of Part 2 200mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 200 mg dose group (cohort 3). Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
62512103|NCT01311401||Rehania village (Kfar Rehania)|Circassian community
62512104|NCT01311401||Kama village (Kfar Kama )|Circassian community
62512105|NCT01856439|OTHER|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
62512106|NCT04373382|EXPERIMENTAL|Peer Resilience Champion Support|The clusters that receive this intervention will receive support from a Peer Resilience Champion.
62512107|NCT04373382|NO_INTERVENTION|No Peer Resilience Champion Support|The clusters in this arm of the study will not receive the Peer Resilience Champion support until they cross-over into the Peer Resilience Champion support arm.
62512108|NCT04373382|EXPERIMENTAL|Enriched Feedback|This arm of the study encompasses individuals who will receive feedback from the survey that will hopefully help provoke self-reflection.
62512109|NCT04373382|NO_INTERVENTION|Express Feedback|This arm of the study encompasses individuals who will not receive feedback from the survey.
62512110|NCT02310789|EXPERIMENTAL|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
62512111|NCT06616181|EXPERIMENTAL|Anodal tDCS over M1 + telerehabilitation|"tDCS over M1: The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.~Telerehabilitation Exercise: Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance exercise will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact."
62512112|NCT06616181|EXPERIMENTAL|Anodal tDCS over DLPFC + telerehabilitation|"tDCS over DLPFC: The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (F3), and the cathode will be positioned over the contralateral supraorbital area (F8). Once the electrodes are positioned, active tDCS will be applied at 2mA for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.~Tele-rehabilitation Exercise: Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance exercise will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact."
62539420|NCT05024864|NO_INTERVENTION|Usual care without Helicobacter pylori screening|At centers randomized to no screening, all MI patients will receive usual care and will be followed in national registries. Concerning the use of eradication therapy and other relevant medication), follow-up is performed in the National Drug Prescription Registry.
62539421|NCT05250011||Single-cohort|Patients initiated on dapagliflozin according to the approved indication for heart failure with reduced ejection fraction (HFrEF) and current medical practice
62539422|NCT02535871|EXPERIMENTAL|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
62708462|NCT04161924||X-ray imaging with physical grid using conventional processing|
62708463|NCT04161924||X-ray without physical grid using conventional processing|
62146774|NCT03333824|EXPERIMENTAL|Wee-1 kinase inhibitor AZD1775|To evaluate the effect of multiple doses of AZD1775 on the PK of substrates for CYP3A (midazolam), CYP2C19 (omeprazole), CYP1A2 (caffeine) and to evaluate the effect of multiple doses of AZD1775 on QT interval
62146775|NCT03392805|EXPERIMENTAL|sedentary life style|
62146776|NCT03392805|NO_INTERVENTION|physically active life style|
62708464|NCT04161924||X-ray imaging without physical grid using experimental SimGrid|
62708465|NCT05657158||Brolucizumab|brolucizumab in routine clinical practice
61972139|NCT01285310|EXPERIMENTAL|Apremilast 20 mg|
62512113|NCT06616181|PLACEBO_COMPARATOR|sham-tDCS + telerehabilitation|"Sham tDCS: The same electrode placement protocol used for the active tDCS M1 group will be followed in this group. Stimulation will begin with a 30-second ramp-up to reach an intensity of 2 mA, immediately followed by a 30-second ramp-down to 0 mA. This stimulation will be repeated at the beginning and end of the session. Similar to the active tDCS groups, each session will last 20 minutes.~Telerehabilitation Exercise: Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance exercise will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact."
62512114|NCT06615765|EXPERIMENTAL|Acupuncture group|"Acupuncture sessions will use sterile, disposable stainless-steel needles (0.3 mm × 40 mm and 0.3 mm × 75 mm). Each session has two phases:~Supine Position:~Needles (0.35 mm × 75 mm) are inserted into ST25, ST15, and SP14, reaching the abdominal muscle layer.~Needles (0.30 mm × 40 mm) are inserted into CV12, CV4, ST36, ST37, and SP6. Electroacupuncture (EA) at ST25, SP15, and ST36 uses a continuous 5 Hz wave, 0.1 to 2.0 mA.~Prone Position:~Needles are inserted into BL32, BL33, and BL35 with precise angles and depths. EA at BL32, BL33, and BL35 uses a continuous 5 Hz wave, 2.0 to 6.5 mA. Sessions occur three times a week for the first 4 weeks, then twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions."
62512115|NCT06615765|SHAM_COMPARATOR|Sham acupuncture group|Sterile, disposable stainless-steel needles (0.30 mm × 25 mm) will be used. After skin sterilization, needles will be inserted into the same points as the acupuncture group but to a shallow depth of 2 to 3 mm and lightly manipulated for blinding. Paired alligator clips will be attached to the same points, but the sham EA apparatus will have no current output, though it mimics the active EA apparatus in appearance and sound. Sham sessions will follow the same schedule as the acupuncture group: three times a week for the first 4 weeks and twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions.
62512116|NCT00942331|ACTIVE_COMPARATOR|Arm I (gemcitabine hydrochloride, cisplatin, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
62512117|NCT00942331|EXPERIMENTAL|Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab)|Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
62512118|NCT06406322|ACTIVE_COMPARATOR|Pelvic Floor Muscle Training (PFMT) Group|Training will be planned for patients, including strengthening and endurance exercises,
62512119|NCT06406322|EXPERIMENTAL|PFMT + Aerobic Exercise Group|Both groups will be given PFMT, and the Grup B group will be given aerobic exercise training in addition to PFMT.
62512120|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
62512121|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
62512122|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
62512123|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
62512124|NCT02784678|EXPERIMENTAL|closed reduction group|Patients will be assigned to C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws (experimental group).
62512125|NCT02784678|EXPERIMENTAL|open reduction group|Patients will be assigned to open reduction (palmar and dorsal incisions) and internal fixation with titanium plate (control group).
62708466|NCT03447392|EXPERIMENTAL|patient education and Chinese medicine|1-hour, one-on-one teaching session with a educator to the standard discharge education of Integrated Traditional and Western Medicine
61972140|NCT01285310|PLACEBO_COMPARATOR|Placebo|
61972141|NCT05604690|EXPERIMENTAL|Treatment Arm: Cohort 1 and 2|"Subjects will receive 2 doses of Avacc 10 via intranasal application.~* Cohort 1 will receive a low dose of Avacc 10~* Cohort 2 will receive a high dose of Avacc 10.~Dosage Form: Liquid Unit Dose: Investigational product (IP) in Phosphate Buffered Saline Route of Administration: Intranasal Physical Description: Slightly opalescent in glass vial"
61972142|NCT05604690|ACTIVE_COMPARATOR|OMV Arm: Cohort 1 and 2|"Subjects will receive 2 doses of Outer Membrane Vesicles (OMV) comparator via intranasal application.~Dosage Form: Liquid Unit Dose: OMV comparator in TRIS/sucrose buffer Route of Administration: Intranasal Physical Description: Slightly opalescent in glass vial"
62352988|NCT04377269|EXPERIMENTAL|Bandaging|33 participants, received ankle bandaging
62512126|NCT00779415||Partial Rotator Cuff Tear|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of shoulder pain and were treated by the Orthopaedic Department
62512127|NCT06308133||Patients|Patients are defined as subjects affected by a hematological or non-hematological disease for which an autologous stem cells transplantation is recommended. These cases are referred as autologous use of stem cells.
62708467|NCT03447392|NO_INTERVENTION|patient education|no discharge education
62708468|NCT03182855|ACTIVE_COMPARATOR|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
62512128|NCT06308133||Stem cells donors|Stem cells donors are volunteer healthy subjects who have decided to undergo the procedures needed to collect blood stem cells. These subjects can donate their blood stem cells in favor of a blood relative or, through subscription of a specific registry (IBMDR - International Bone Marrow Donor Registry), to an unknown subject. These cases are referred as allogenic use of stem cells.
62146777|NCT04815135||2020 group (COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the lockdown period due to the COVID19 pandemic
62146778|NCT04815135||2019 group (pre COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the similar period in 2019
62146779|NCT01774240|NO_INTERVENTION|before|no systematic approach
62146780|NCT01774240|EXPERIMENTAL|after|systematic screening and treatment of delirium
62512129|NCT00949988|ACTIVE_COMPARATOR|Dasatinib - 100 mg (Phase I)|Dasatinib - 100 mg (Phase I)
62512130|NCT00949988|ACTIVE_COMPARATOR|Dasatinib - 70 mg (Phase I)|Dasatinib - 70 mg (Phase I)
62512131|NCT02369718|EXPERIMENTAL|Implanted subjects|Listening to 12 Fournier's lists of words
62512132|NCT02369718|ACTIVE_COMPARATOR|Normal hearing subjects|Listening to 48 Fournier's lists of words
62512133|NCT02858726|EXPERIMENTAL|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
62512134|NCT02858726|EXPERIMENTAL|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
62512135|NCT02858726|EXPERIMENTAL|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
62512136|NCT02858726|PLACEBO_COMPARATOR|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
62512137|NCT03226119|EXPERIMENTAL|HTLV Infected (n=50)|Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)
62512138|NCT03226119|EXPERIMENTAL|Neurological Disorders (n=100)|Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica
62512139|NCT03118219|EXPERIMENTAL|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
62512140|NCT03118219|OTHER|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
62512141|NCT04862884|EXPERIMENTAL|HRS4800 tablets|
62512142|NCT04862884|PLACEBO_COMPARATOR|placebo|
62512143|NCT05261789|EXPERIMENTAL|Turkish Get Up exercise group|Turkish Get Up exercise was given this group
62512144|NCT05261789|EXPERIMENTAL|Core stability exercise group|Core stability exercise was given this group
62512145|NCT05261789|ACTIVE_COMPARATOR|Control group|No intervention
62146781|NCT01051869|ACTIVE_COMPARATOR|simple decompression|
62146782|NCT01051869|ACTIVE_COMPARATOR|anterior subcutaneous transposition|
62512146|NCT03536182|ACTIVE_COMPARATOR|Arm A: Carbon ion radiotherapy|"The dose calculation algorithms used in Japan and Europe (local effect model, LEM) are different, so the total dose must be modified to ensure consistency~1. Japan : 55.2 GyE in 4.6 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of each CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose.~2. European: . Patients treated in Europe should receive 57.6 GyE in 4.8 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose. This evaluation will occur in the LEM system"
62512147|NCT03536182|ACTIVE_COMPARATOR|Arm B: Photon radiotherapy|50.4-56 Gy in 1.8-2.0 Gy per fraction in 28 fractions delivered 5 days a week. The plan should be normalized such that 100% of the PTV receives at least 48.9 Gy (i.e. 97% of 50.4 Gy). In addition, 100% of the GTV should receive at least 50.4 Gy. The maximum dose allowed to a point volume (0.03 mL) is 115% of the prescribed dose.
62352989|NCT04377269|PLACEBO_COMPARATOR|Placebo Taping (Control) Group|34 participants, received ankle placebo taping
62512148|NCT06142188||Relmacabtagene Autoleucel|Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
62512149|NCT01337765|EXPERIMENTAL|BEZ235 + MEK162|
62146783|NCT03438565||Participants with intracranial large vessel occlusive stroke|50 patients who have been treated with the Asahi Chikai Black 18 neurovascular guidewire.
62146784|NCT03438565||Historical Control Group|The historical control will include 50 retrospective consecutive patients (who fulfill inclusion and exclusion criteria) treated for acute anterior circulation large vessel occlusive stroke prior to the initiation of the Sure -18 registry.
62146785|NCT01335061|OTHER|BeneFIX|
62146786|NCT04034966|ACTIVE_COMPARATOR|Claria|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) with the telemedicine module. The telemedicine module is the platform for storing patient information directly from the PD machine. Handling will be done according to the basic operating instructions established by the manufacturer.
62512150|NCT03842852||LTEPR|Patients who underwent inguinal hernia repair laparoscopic extra-peritoneal repair under general anesthesia.
62512151|NCT03842852||OPHSR|Patients that underwent inguinal hernia repair open using prolene hernia system mesh under general or regional anesthesia.
62512152|NCT04676815||NBI PATIENT|Diagnostic Test: NBI in combination with electronic bronchoscope
62512153|NCT04676815||Non-NBI PATIENT|Diagnostic Test: Electronic bronchoscope without NBI
62512154|NCT01730040|ACTIVE_COMPARATOR|Atorvastatin 40 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
62539423|NCT02535871|PLACEBO_COMPARATOR|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
62708469|NCT03182855|ACTIVE_COMPARATOR|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
62708470|NCT05787015|EXPERIMENTAL|Vaccine Norms Feedback|The participants in the treatment condition will receive personalized normative feedback (PNF) that entails correcting normative misperceptions for US young adults' vaccine uptake rates and prevalence of vaccine hesitancies (e.g., fear of side effects). Participants will be shown discrepancies between their perceived estimate of young adults' vaccination rates and actual national estimates derived from the US Census Bureau's Household Pulse Survey to highlight, in most cases, that they underestimated the vaccination norms.
62708471|NCT05787015|ACTIVE_COMPARATOR|Alcohol Norms Feedback|Participants randomized to control will complete all measures at the same time as participants in the treatment condition, but will not receive any normative information regarding vaccines. Instead, to match for attention and provide potential benefit, those in the control condition will receive a standard dynamic norms feedback pertaining to alcohol use norms and behaviors.
61972143|NCT05604690|PLACEBO_COMPARATOR|Placebo Are: Cohort 1 and 2|Subjects will receive 2 doses of placebo via intranasal application. Dosage Form: Liquid Unit Dose: Placebo in TRIS/sucrose buffer Route of Administration: Intranasal Physical Description: Clear, colorless in glass vial
62708472|NCT05754125|EXPERIMENTAL|Di-Leucine supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
62708473|NCT05754125|EXPERIMENTAL|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
61972144|NCT00456521|EXPERIMENTAL|NB32|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
62708474|NCT05754125|EXPERIMENTAL|Collagen Supplement|Participants will consume a amino acid supplement containing collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
62708475|NCT05589454|EXPERIMENTAL|High-dose atorvastatin|atorvastatin calcium tablets 80 mg, quaque nocte, continue to the end of the study
61972145|NCT00456521|PLACEBO_COMPARATOR|Placebo|Placebo with intensive group lifestyle modification counseling
61972146|NCT02875483|PLACEBO_COMPARATOR|Standard Scheduling|Group allocated to follow standard surgical scheduling practices
61972147|NCT02875483|EXPERIMENTAL|Expedited Scheduling|Group allocated to expedited scheduling practices
61972148|NCT03238508||Immediate stenting group|Conventional stenting immediate after the re-opening of infarct-related artery during primary PCI
61972149|NCT03238508||Deferred stenting group|Elective stenting following cooling down of infarct- related artery for several days after restoration of epicardial coronary blood flow during primary PCI
61972150|NCT03569540|EXPERIMENTAL|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
61972151|NCT03569540|PLACEBO_COMPARATOR|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
61972152|NCT05419700||Participants with Advanced NSCLC With EGFR Exon 20 Insertions Mutations|All participants diagnosed with advanced NSCLC with Epidermal growth factor receptor EGFR exon 20 insertion mutations will be enrolled in this study. All study data will be collected retrospectively from participants medical records via medical chart review.
62708476|NCT05589454|ACTIVE_COMPARATOR|Low-dose atorvastatin|atorvastatin calcium tablets 20 mg, quaque nocte, continue to the end of the study
62708477|NCT02406417|EXPERIMENTAL|Investigation for pituitary dysfunction|Further investigation for pituitary dysfunction by blood tests, dynamic function tests and pituitary imaging e.g. CT Scan with contrast. Patients identified as being at high risk of having pituitary dysfunction based on preliminary blood tests will have further tests added. If these results point to a likely pituitary dysfunction, the patient will be referred to the Endocrine team for further investigations including dynamic function tests and/or imaging.
62708478|NCT00814255|EXPERIMENTAL|2|Conservative medical therapy plus adalimumab
61972153|NCT04817371|OTHER|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
62708479|NCT00814255|ACTIVE_COMPARATOR|1|Conservative medical therapy (lisinopril, losartan, atorvastatin)
62708480|NCT00814255|EXPERIMENTAL|conservative medical therapy plus galactose|drug: galactose 0.2 g /kg/dose (maximum dose 15g) po BID
62708481|NCT04242680|EXPERIMENTAL|Brainstim DLPFC|tRNS over bilateral DLPFC + cognitive training
62708482|NCT04242680|EXPERIMENTAL|Brainstim PPC|tRNS over bilateral PPC + cognitive training
62708483|NCT04242680|SHAM_COMPARATOR|Brainstim Sham|Sham tRNS (bilateral DLPFC/bilateral PPC) + cognitive training
62708484|NCT04519333|OTHER|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with neck pain related to cervical disc herniation
61972154|NCT04817371|OTHER|Symptomatic patients with positive PCR for other respiratory virus|Patients with symptomatic respiratory disease of infectious origin with negative RT-PCR for SARS-CoV-2 and positive RT-PCR for other respiratory viruses
61972155|NCT04817371|OTHER|Asymptomatic patients or healthy volunteers|Patients or healthy volunteers with negative RT-PCR and negative serology
61972156|NCT04817371|OTHER|Volunteers or patients vaccinated against COVID-19|Volunteers or patients vaccinated against COVID-19 (complete vaccination scheme)
61972157|NCT03144362|ACTIVE_COMPARATOR|Bilateral Sliding Technique|
61972158|NCT03144362|ACTIVE_COMPARATOR|Unilateral Sliding Techniques|
61972159|NCT03144362|NO_INTERVENTION|Standard care|
61972160|NCT01580189|ACTIVE_COMPARATOR|Milk|Chocolate milk compared to protein supplement
61972161|NCT01580189|ACTIVE_COMPARATOR|Whey protein|Whey protein compared to milk
61972162|NCT01580189|PLACEBO_COMPARATOR|Sugar|Maltodextrin compared to treatments
62708485|NCT02373592|PLACEBO_COMPARATOR|Thermometry-only group|"Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet.~Some alarm signs have been pre-specified: 1) thermal image shows yellow spots in any area of feet for two consecutive days, 2) thermal image shows different colors in contralateral areas of the feet for two consecutive days or, 3) a dermal lesion. In any of these three scenarios, subjects will be instructed to contact the study nurse by phone. (See Detailed Description for more detail on the actions after an alarm sign has been observed)"
62708486|NCT02373592|EXPERIMENTAL|Thermometry plus SMS and voice messaging|"Thermometry-related intervention activities will be the same as those established for the thermometry-only group. In addition, this group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages has been developed and validated through both SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
62708487|NCT02498366|EXPERIMENTAL|experimental protocol|50 healthy, male, trained and aged 18-30 will be recruited and asked to undergo a series of physical tests.
62708488|NCT01409954||Spinal decompression|Spinal decompression with an instrumented posterolateral fusion
62708489|NCT03150264|EXPERIMENTAL|PCV-VG+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
62708490|NCT03150264|ACTIVE_COMPARATOR|PCV+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
62708491|NCT06131190|EXPERIMENTAL|study group|ADHD child who exposed to mindfulness training
62708492|NCT06131190|NO_INTERVENTION|control group|ADHD child take only pharmocological intervention
62708493|NCT04785209||No complication|Thrombolysis in myocardial infarction flow grade III flow after PPCI, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
62708494|NCT04785209||No reflow|No reflow phenomenon after pci on STEMI patients, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
61972163|NCT01218204|OTHER|Part A Run-in|Subjects on stable 40mg atorvastatin \> 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
61972164|NCT01218204|EXPERIMENTAL|Part A Co-Dosing 800mg GSK1292263|Dosing for 14 days
62708495|NCT01198665|EXPERIMENTAL|RAD001-CHOP|Prospective multicenter open-label phase I/II study Phase I: RAD001 2.5 - 10 mg PO daily D1-14 + CHOP every 3 weeks Phase II: Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be continued until planned 6 cycles or disease progression
62708496|NCT02014987|EXPERIMENTAL|Running training programmes|"Runners with a high body mass index are going to follow a training programme of 3 kilometres per week compared to a training programme of 6 kilometres per week.~The amount of running will be increased with 10 % per week."
62708497|NCT00406796|ACTIVE_COMPARATOR|1|0.5mg Ranibizumab
62708498|NCT00406796|ACTIVE_COMPARATOR|2|0.3mg Ranibizumab
62708499|NCT01332656|EXPERIMENTAL|Arm A|Ombrabulin, Paclitaxel and Carboplatin
62708500|NCT01332656|PLACEBO_COMPARATOR|Arm B|Placebo, Paclitaxel and Carboplatin
62146787|NCT04034966|NO_INTERVENTION|Control|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) without the telemedicine device. the device is used for automated peritoneal dialysis. Handling will be done according to the basic operating instructions established by the manufacturer.
62146788|NCT02383693|ACTIVE_COMPARATOR|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
62708501|NCT03626233||Vascular group|Pregnant women with vascular pathology
61972165|NCT01218204|OTHER|Part B Washout|Washout for 4 weeks
61972166|NCT01218204|ACTIVE_COMPARATOR|Part B Run-in 10mg atorvastatin|Dosing for 4 weeks
61972167|NCT01218204|ACTIVE_COMPARATOR|Part B Run-in 80mg atorvastatin|Dosing for 4 weeks
61972168|NCT01218204|EXPERIMENTAL|Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263|Dosing for 14 days
61972169|NCT01218204|EXPERIMENTAL|Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263|Dosing for 14 days
61972170|NCT01218204|EXPERIMENTAL|Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
61972171|NCT01218204|EXPERIMENTAL|Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe|Dosing for 14 days
61972172|NCT01218204|EXPERIMENTAL|Part B Dosing 100mg GSK1292263|Dosing for 14 days
61972173|NCT01218204|EXPERIMENTAL|Part B Dosing 300mg GSK1292263|Dosing for 14 days
62146789|NCT02383693|SHAM_COMPARATOR|Sham comparator|Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
62352990|NCT03924310|EXPERIMENTAL|Arm amputees|This single arm conducts all experiments. In three out of four experiments both interventions (with feedback \& without feedback) are used, the fourth experiment does not allow the intervention without feedback.
61972174|NCT01218204|EXPERIMENTAL|Part B Dosing 800mg GSK1292263|Dosing for 14 days
61972175|NCT01218204|EXPERIMENTAL|Part B Dosing Placebo GSK1292263|Dosing for 14 days
62708502|NCT03626233||Control group|"* Pregnancy without any vascular complication~* Delivery before or after 37 weeks of gestation (GW)~* In case of delivery after 37GW: birth by cesarean delivery"
62708503|NCT04748887||nonsmokers copd cases ,|Fourty subjects of COPD who are non-smokers or stopped smoking for more than 6 months
62708504|NCT04748887||non smokers healthy control|Thirty subjects of non smokers healthy control
62708505|NCT05388578||Primary cohort|All participants will receive the Stroke Box containing a wearable bloodpressure monitor, activity tracker and weighting scale, and associated apps.
62708506|NCT05388578||Patients with indication for AF|All participants will receive the Stroke Box containing a wearable bloodpressure monitor, activity tracker and weighting scale, and associated apps. Patients with an indication for atrial fibrillation (AF) will additionally receive a wrist-worn single-lead ECG device.
62708507|NCT02009579|ACTIVE_COMPARATOR|Experimental arm|Nintedanib/vargatef
62708508|NCT02009579|PLACEBO_COMPARATOR|Comparator arm|Placebo
62708509|NCT00626041|OTHER|1|referral to primary care network for management of blood pressure, lipids and diabetes.
61972176|NCT01218204|EXPERIMENTAL|Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
61972177|NCT01218204|EXPERIMENTAL|Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
62512155|NCT01730040|ACTIVE_COMPARATOR|Ezetimibe 10 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
62512156|NCT01730040|EXPERIMENTAL|Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
62512157|NCT01730040|ACTIVE_COMPARATOR|Atorvastatin 80 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
61972178|NCT01218204|EXPERIMENTAL|Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
62512158|NCT01730040|ACTIVE_COMPARATOR|Rosuvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
62146790|NCT02064283|EXPERIMENTAL|Diffusion MRI Assessment|Men with newly diagnosed metastatic disease initiating therapy with androgen deprivation, or men with hormone refractory prostate cancer initiating treatment with chemotherapy, will be assessed by diffusion MRI (Magnetic Resonance Imaging) at baseline, 2 weeks and again at 9-12 weeks.
62708510|NCT05790655|EXPERIMENTAL|oPRP injections|Patients own prepared PRP will be injected into each ovary
62708511|NCT05790655|PLACEBO_COMPARATOR|Placebo|Patient's serum will be injected into the ovary (not rich with platelets)
62708512|NCT04820023|EXPERIMENTAL|BBT-176|
62708513|NCT04096066|EXPERIMENTAL|KRd (Experimental Arm)|"Carfilzomib (K):~* 20 mg/m2 IV on day 1 of cycle 1;~* 56 mg/m2 IV on days 8 and 15 in cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 on days 1 and 15 from cycle 13 and onwards.~Lenalidomide (R):~- 25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.~Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration."
62708514|NCT04096066|ACTIVE_COMPARATOR|Rd (Control Arm)|"Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.~Until PD or intolerance."
62708515|NCT02185183|EXPERIMENTAL|AlequelTM|AlequelTM
62708516|NCT01344733||MDD|Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance.
62352991|NCT04740060|EXPERIMENTAL|Augmented Feedback without Virtual Reality(VR)|
62512159|NCT01730040|ACTIVE_COMPARATOR|Ezetimibe 10 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
62708517|NCT02951507|ACTIVE_COMPARATOR|Conventional partial denture|Intervention will be O T unilateral attachment
62708518|NCT02951507|ACTIVE_COMPARATOR|Conventional removal partial denture|Intervention will be new design of extra coronal attachment( O T unilateral attachment)
62708519|NCT01647854|EXPERIMENTAL|Device: Teleconsultation|"If patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The safety and efficacy of the introduction and operation of this system should be evaluated."
62352992|NCT04740060|EXPERIMENTAL|Augmented Feedback with Non-Game based VR|
62352993|NCT04740060|EXPERIMENTAL|Augmented Feedback with Game based VR|
62352994|NCT05657951||Normal eyes|
62352995|NCT02197611||Validation group|Group of patients who we will consult the characteristics of the scale designed and will be made the statistical calculations of validity, reliability and reproducibility
61972179|NCT06193720|EXPERIMENTAL|Arnica Montana|Patients will take Arnica montana before and after surgery
61972180|NCT06193720|PLACEBO_COMPARATOR|Control|Patients will take placebo pills to compare the results
61972181|NCT03316404||Cohort 1|Cohort 1 of the study will collect blood samples from participants in various states of the disease. After qualification and informed consent, accepted participants will be sent a blood collection kit and will be asked to complete a study-related questionnaire.
61976299|NCT05122273||Children and adults with confirmed neuromuscular disease|Children and adults with confirmed genetic Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), limb-girdle dystrophy, spinal muscular atrophy (SMA), myopathy or neuropathy.
62352996|NCT00648141|EXPERIMENTAL|A|
62352997|NCT00648141|EXPERIMENTAL|B|
62352998|NCT00648141|ACTIVE_COMPARATOR|C|
62352999|NCT02611700|EXPERIMENTAL|experimental group|Nimotuzumab+TP(paclitaxel+cisplatin)
62353000|NCT02611700|PLACEBO_COMPARATOR|control group|Placebo + TP(paclitaxel+cisplatin)
62708520|NCT06352346|NO_INTERVENTION|No Intervention: Baseline phase (Phase A)|o At the start of the study, all participants are assigned to the baseline phase (phase A). During phase A, patients do not receive interventions related to executive function problems. The start of the intervention phase (phase B) is determined randomly for each participant, given the restriction that phase A should last for at least three weeks (21 days) and at most five weeks (30 days). This means that phase B can start on any day between the 21th and the 30th days, resulting in a total of 10 possible assignments. So, in the first three weeks, all participants are in phase A. The duration of phase A will thus be different for each subject. Phase A acts as a control and is therefore compared with phase B.
62708521|NCT06352346|EXPERIMENTAL|Experimental: Intervention phase (Phase B): Goal Management Training|During the intervention phase (phase B), all included participants will have 6 sessions of Goal Management Training (GMT; twice per week) in which two individual chosen IADL-tasks will be subdivided into multiple steps under guidance of a therapist using the GMT method. In addition participants play the compensatory brain game in which they are challenged to apply the learned GMT strategy in an imaginary and safe environment.
62708522|NCT06352346|NO_INTERVENTION|Follow-up period|A follow-up period of six weeks takes place after phase B. During this follow-up period, patients receive no intervention.
62708523|NCT04846179|EXPERIMENTAL|Ginkgo biloba extract group|Group receiving ginkgo biloba extract supplementation
62708524|NCT02857972|EXPERIMENTAL|Wondaleaf®|This is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.
61972182|NCT03316404||Cohort 2|Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
61972183|NCT03298594|EXPERIMENTAL|specific cervicograph|Specific cervicograph, including an alert line (normal progression of cervical dilation, i.e. 1 cm per hour) and an action line 2 hours after the alert line. This should be completed after the diagnose of active labor
62708525|NCT05059886||lower limb amputee|No intervention, pure observational study
62708526|NCT06009302|EXPERIMENTAL|US block of mandibular nerve|"Extraoral ultrasound-guided block of the mandibular nerve will be performed iusing an ultrasound device. After visualisation of the pterygomandibular space, of the maxillary artery and the mandibular nerve next to it, at a depth of 2-4 cm, the detection of the maxillary artery is confirmed by Color Doppler. A needle enters between the coronoid and condylar processes, using the out of plane technique, near the maxillary artery, and after negative aspiration, local anesthetic ropivacaine (0.75%, 2.5 mL) will be applied."
62708527|NCT06009302|ACTIVE_COMPARATOR|intraoral block of lower alveolar nerve|During the intraoral block of the inferior alveolar nerve, the patient will lie with his mouth wide open, and the inferior alveolar, lingual and buccal nerves will be anesthetized using two injections. The anesthetic used will be 40 mg/mL articaine chloride+0.01 mg/mL epinephrine: the planned amount of anesthetic is 2×1.7 mL, and if anesthesia is not achieved, an additional volume of anesthetic will be added as needed, until anesthesia
61972184|NCT03298594|NO_INTERVENTION|Usual cervicograph|The usual cervicograph in our unit is not having lines
62708528|NCT02873156|EXPERIMENTAL|E2027|"Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 up to the maximum tolerated dose (MTD). A total of 6 participants per cohort will be randomized to E2027.Proposed doses of E2027 are:~* Part A Cohort 1: 50 mg (1 × 50 mg capsule)~* Cohort 2: 100 mg (2 × 50 mg capsules)~* Cohort 3: 200 mg (4 × 50 mg capsules)~* Cohort 4: 400 mg (8 × 50 mg capsules)~* Cohort 6: 25 mg (5 × 5 mg capsules) Part B~* Cohort 5: 400 mg (8 × 50 mg capsule)~Part C:~• Cohort 7: 50 mg (1 × 50 mg capsules)~Part D:~* Cohort 8: 5 mg (1 × 5 mg capsules)~* Cohort 9: 10 mg (2 × 5 mg capsules)"
62708529|NCT02873156|PLACEBO_COMPARATOR|Placebo|Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 matched placebo up to the MTD. A total of 2 participants per cohort will be randomized to E2027 matched placebo.
62708530|NCT01447992|EXPERIMENTAL|Portable artificial pancreas system with Control-To-Range|
61972185|NCT01169142|ACTIVE_COMPARATOR|Immediate Vitamin D3|Will start Vitamin D3 immediately
61972186|NCT01169142|ACTIVE_COMPARATOR|Three month delay|Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
62353001|NCT03706092||Before|Elderly patients \> = 70 in ICU without any intervention of the pharmacists and of the geriatricians
62353002|NCT03706092||After|Elderly patients \> = 70 in ICU with individualized intervention of the pharmacists and of the geriatricians
62353003|NCT05892263|EXPERIMENTAL|Early intestinal force-feeding and drugs to promote gastrointestinal motility|
61972187|NCT02562430|EXPERIMENTAL|Active Treatment|12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
61972188|NCT02562430|ACTIVE_COMPARATOR|Placebo Group|87.5% will be randomized to receive placebo in phase 1 of the study.
61972189|NCT00060112|EXPERIMENTAL|Treatment (oblimersen sodium and gemcitabine hydrochloride)|Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
61972190|NCT03030872||Predicate software|Olea Sphere PACS with Perfusion and DWI Modules
61972191|NCT03030872||Investigational software|Vue PACS v12.2 Magnetic Resonance (MR) Perfusion and Diffusion Weighted Imaging
61972192|NCT06422130||Pregnant women and their offspring|
61972193|NCT04203784||Meropenem treated patients|
61972194|NCT04203784||Piperacillin treated patients|
61972195|NCT00280462|ACTIVE_COMPARATOR|1|Nifedipine
62353004|NCT05892263|EXPERIMENTAL|early enteral feeding|
62353005|NCT05892263|NO_INTERVENTION|giving force-feeding after gas or defecation|
62353006|NCT05589480||postoperative recurrence|
62708531|NCT01335607|ACTIVE_COMPARATOR|Part A: Samatasvir cap→tab→tab; Part B: cap|Part A: Samatasvir capsule as a single dose on Day 1 (fasting state) followed by samatasvir tablet as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
62708532|NCT01335607|ACTIVE_COMPARATOR|Part A: Samatasvir tab→cap→tab; Part B: cap|Part A: Samatasvir tablet as a single dose on Day 1 (fasting state) followed by samatasvir capsule as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
62708533|NCT01471184|EXPERIMENTAL|Ectoin® Eye Drops/Nasal Spray|Eye Drops/Nasal Spray
61972196|NCT00280462|ACTIVE_COMPARATOR|2|L-Arginin
61972197|NCT00280462|PLACEBO_COMPARATOR|3|Placebo
62708534|NCT01471184|PLACEBO_COMPARATOR|Placebo Eye Drops/Nasal Spray|
62708535|NCT04077840||NCGS/NCWS patients|Adult patients with a definitive diagnosis of NCWS, based on DBPC wheat challenge, most of them suffering from IBS-like-clinical presentation, according to Rome IV criteria. The patients were consecutively recruited between January 2016 and October 2017 at the outpatient clinics of the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (both in southern Italy)
62708536|NCT04077840||Heathy blood donors|Consecutive healthy blood donors sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients.
61972198|NCT02759471|EXPERIMENTAL|comfilcon A asphere (test)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
61972199|NCT02759471|ACTIVE_COMPARATOR|comfilcon A sphere (control)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
61972200|NCT03156543|EXPERIMENTAL|Group A|This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
62708537|NCT04077840||IBS patients|"Consecutive patients with a diagnosis of IBS unrelated to NCWS or other types of food intolerance/allergy, who were consecutively recruited during the study period and sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients."
62708538|NCT05574881|EXPERIMENTAL|Arm1|Dalpiciclib 150 mg qd; Fulvestrant 500mg d1, 15, 29, and then q4w; Pertuzumab 840mg q3w, and then 420 mg q3w; Trastuzumab 8 mg/kg q3w, and then 6 mg/kg q3w
62708539|NCT00787150|EXPERIMENTAL|Apixaban 5mg BID|
61972201|NCT03156543|EXPERIMENTAL|Group B|This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.
61972202|NCT02401815|EXPERIMENTAL|Part 1: PLX9486 250 mg QD|Participants will receive PLX9486 250 milligrams (mg) orally once daily (QD) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
62708540|NCT00787150|EXPERIMENTAL|Apixaban 2.5mg BID|
62708541|NCT00787150|ACTIVE_COMPARATOR|Warfarin|
62708542|NCT01343472|EXPERIMENTAL|WISP supervision|Parolee supervised under WISP parole model.
62708543|NCT01343472|ACTIVE_COMPARATOR|Parole-as-usual|Parolees supervised under Washington State's parole-as-usual
62708544|NCT05085132|EXPERIMENTAL|MindFi app: Standard content|Participants will receive full access to the MindFi app, containing learning tracks, practice tracks, and assessments. Participants will be instructed to use a practice track for a minimum of 10 minutes a day, and may use other exercises or tracks if desired. The intervention will last 4 weeks.
62708545|NCT05085132|SHAM_COMPARATOR|Mindfi app: Standard content without practice|Participants will receive full access to the MindFi app, containing learning tracks, music tracks, and assessments. Participants will be instructed to use a music track for a minimum of 10 minutes a day, and may use other exercises or tracks if desired. The intervention will last 4 weeks.
62708546|NCT01728103||No Treatment|
62708547|NCT05334797|EXPERIMENTAL|Hot application|After the patients come to the service after the surgery, a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes. Pain assessment will be done before and after the application. However, 0-2-4-8-12-24. Routine pain assessment will be done at In addition, the type, route, effect and amount of analgesic done in this process will also be recorded. Response evaluation will follow. Response evaluation will follow. Hot application will be applied to every shoulder pain reported by the patients.
62708548|NCT05334797|NO_INTERVENTION|control group|First, an individual information form will be filled in for the control group patients who meet the sampling criteria. 0-2-4-8-12-24 after the patients come to the service after the surgery. Routine pain assessment will be done at In addition, the type, route, effect and amount of analgesic done in this process will also be recorded. Response evaluation will follow.
62708549|NCT02244515|PLACEBO_COMPARATOR|Group C|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered 10 ml NaCI 0.9%.
61972203|NCT02401815|EXPERIMENTAL|Part 1: PLX9486 350 mg QD|Participants will receive PLX9486 350 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972204|NCT02401815|EXPERIMENTAL|Part 1: PLX9486 500 mg QD|Participants will receive PLX9486 500 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972205|NCT02401815|EXPERIMENTAL|Part 1: PLX9486 1000 mg QD|Participants will receive PLX9486 1000 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972206|NCT02401815|EXPERIMENTAL|Part 1: PLX9486 500 mg BID|Participants will receive PLX9486 500 mg orally twice daily (BID) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972207|NCT02401815|EXPERIMENTAL|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Fasting)|Participants in fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61976300|NCT04298554|EXPERIMENTAL|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration - 1 ml (20mg) qd PO, hold under tongue for 1 minute and swallow daily
61976301|NCT04298554|PLACEBO_COMPARATOR|Placebo (hemp oil)|CBD PURE Hemp Oil- 1 ml qd PO, hold under tongue for 1 minute and swallow daily
61972208|NCT02401815|EXPERIMENTAL|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Non-Fasting)|Participants in non-fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972209|NCT02401815|EXPERIMENTAL|Part 2e: PLX9486 500 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 500 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972210|NCT02401815|EXPERIMENTAL|Part 2e: PLX9486 1000 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972211|NCT02401815|EXPERIMENTAL|Part 2e: PLX9486 1000 mg QD + Sunitinib 37.5 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 37.5 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
61972212|NCT00995826|PLACEBO_COMPARATOR|placebo|
61972213|NCT00995826|EXPERIMENTAL|CS-8958 DPI|
61972214|NCT02987920|ACTIVE_COMPARATOR|Placebo - Concentrate|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain"
61972215|NCT02987920|EXPERIMENTAL|Dextromethorphan|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily"
61972216|NCT05756946|EXPERIMENTAL|Test group|Test group will receive GTR + periodontal dressing (Coe-pak)
61972217|NCT05756946|ACTIVE_COMPARATOR|Control group|Control group will receive GTR only
61972218|NCT05846191|OTHER|serum pentraxin 3 and high sensitive CRP|female with gestational diabetes mellitus in 2nd trimester
61972219|NCT04752150|ACTIVE_COMPARATOR|Group ESPB = Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
62708550|NCT02244515|EXPERIMENTAL|Group D|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
62708551|NCT04362735||Study group|All patients using vedolizumab for Crohn's disease as first biologic agent (all patients naive to previous biological therapy)
61972220|NCT04752150|ACTIVE_COMPARATOR|Group RIB = RIB group|In group RIB, RIB block will be performed with patients in the lateral decubitus position while the surgical site up. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 30 ml 0,25% bupivacaine will be injectted into the fascial plane.
61972221|NCT04386980|EXPERIMENTAL|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume administered once intra-articularly
61972222|NCT04386980|PLACEBO_COMPARATOR|Placebo|5 mL of diluent in normal saline administered once intra-articularly
62146791|NCT04686617|NO_INTERVENTION|No-force group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction on one side and the other side was used as the premolar tooth control group. Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks. At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
61972223|NCT04850807|NO_INTERVENTION|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting
61972224|NCT04850807|EXPERIMENTAL|Music & Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences at early signs of agitation
61972225|NCT00511667|EXPERIMENTAL|MK0941|
61972226|NCT00511667|PLACEBO_COMPARATOR|Placebo|
61972227|NCT05552560||Experimental: Heterosexual couples, women or single women who have requested sperm donation|Heterosexual couples, female couples or single women who have requested a sperm donation in the center of the Toulouse University Hospital will be offered the study.
61972228|NCT00707824|PLACEBO_COMPARATOR|1|1= placebo
61972229|NCT00707824|ACTIVE_COMPARATOR|2|2=nalbuphine 5 mg
62353007|NCT05589480||postoperative non-recurrence|
62353008|NCT04426994||Case|Patients admitted with hypomagnesemia are evaluated for proton pump inhibitor use and likelihood of hypomagnesemia due to proton pump inhibitor use
61972230|NCT00707824|ACTIVE_COMPARATOR|3|3=nalbuphine 10 mg
61972231|NCT01824394|EXPERIMENTAL|nMARQ Catheter|nMARQ Catheter System
61972232|NCT01824394|ACTIVE_COMPARATOR|NaviStar ThermoCool Catheters|THERMOCOOL® Navigational family of catheters
62353009|NCT04426994||Control|Patients on long-term proton pump inhibitor without documented hypomagnesemia
62353010|NCT01619163|EXPERIMENTAL|prednisolone|
62353011|NCT01619163|PLACEBO_COMPARATOR|Placebo|
62708552|NCT05077423|EXPERIMENTAL|Subcutaneous administration of CD33*CD3 BsAb up to 12 cycles|Subcutaneous administration of CD33\*CD3 BsAb up to 12 cycles
62708553|NCT02083978||Bipolar Diagnosis|Individuals identified as having a Bipolar Diagnosis with a manic episode
62708554|NCT02083978||Control|Individuals identified as not having a major psychiatric diagnosis
62708555|NCT01908010|EXPERIMENTAL|Group 1, low dose|ABT-354
62708556|NCT01908010|EXPERIMENTAL|Group 2, high dose|ABT-354
62708557|NCT01482715|EXPERIMENTAL|Part 1 (Phase 1)|Rucaparib 40, 80, 160, 300, 500 mg QD and 240, 360, 480, 600, 840 mg BID, for continuous 21-day cycles. Patients in Part 1 were initially treated in a Dose-escalation Evaluation Period (Cycle 1) and could then continue to receive treatment in an optional Treatment-extension Period (Cycle 2 and beyond).
62708558|NCT01482715|EXPERIMENTAL|Part 2A (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
61972233|NCT03857191||Patients already treated for OSA|The first group involves patients already diagnosed and treated for sleep apnea that will follow the nutritional psychocomportemental rehabilitation
61972234|NCT03857191||Patients with a high OSA risk|This group concerns patients with a high OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
62708559|NCT01482715|EXPERIMENTAL|Part 2B (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
62708560|NCT01482715|EXPERIMENTAL|Part 3 (Phase 2)|Rucaparib 600 mg BID for 21-day cycles. Patients also received a single administration of 600 mg rucaparib on both Day -7 and Day 1 for assessing the effect of food on PK.
62708561|NCT01168596|PLACEBO_COMPARATOR|sugar pill|Placebo tablet, 1 per day, duration is approximately 12 weeks.
62708562|NCT01168596|ACTIVE_COMPARATOR|rasagiline|Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
62708563|NCT00931281|ACTIVE_COMPARATOR|1|ABT-450/ritonavir
62708564|NCT00931281|PLACEBO_COMPARATOR|2|Placebo for ABT-450/placebo for ritonavir
62708565|NCT06228378|EXPERIMENTAL|Unstable ankle|Unstable ankle
62708566|NCT06228378|ACTIVE_COMPARATOR|Stable ankle|
61972235|NCT03857191||Patients with a low OSA risk|This group concerns patients with a low OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
61972236|NCT04798001|EXPERIMENTAL|Cohort A / Dosage Group 1 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
61972237|NCT04798001|EXPERIMENTAL|Cohort A / Dosage Group 2 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
61972238|NCT04798001|EXPERIMENTAL|Cohort A / Dosage Group 3a (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
61972239|NCT04798001|EXPERIMENTAL|Cohort A / Dosage Group 3a (intranasal drops) / Two Doses|Participants in this arm (18-55 years) will receive an intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1. These participants will receive a second, identical dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 36.
62353012|NCT06323694||Patients with vertebroplasty|measuring the quality of life in patients on the waiting list for spinal surgery
62708567|NCT00399529|EXPERIMENTAL|Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide|"Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10\^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.~Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously~Cyclophosphamide : 300 mg/m\^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study"
62708568|NCT04609982|EXPERIMENTAL|wearing ear plugs|
62708569|NCT04609982|NO_INTERVENTION|Not wearing ear drops|
62708570|NCT01935453|EXPERIMENTAL|Recombinant HSV-1 Injection|Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.
62708571|NCT05383261||control|"patients will take medical treatment only~patients will receive medical treatment in addition to aerobic exercises"
62708572|NCT01323608|PLACEBO_COMPARATOR|Placebo|
61972240|NCT04798001|EXPERIMENTAL|Cohort A / Dosage Group 3b (intranasal spray) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of a nasal spray on Day 1.
62708573|NCT01323608|EXPERIMENTAL|Low Vitamin D Group|Subjects in this group will receive the equivalent of 400 IU/day.
62708574|NCT01323608|EXPERIMENTAL|Intermediate Vitamin D group|
62708575|NCT01323608|EXPERIMENTAL|High Vitamin D Group|
62708576|NCT05467657|EXPERIMENTAL|repetitive transcranial magnetic stimulation|Participants in the experimental group will receive one hour of rehabilitation therapy daily with 30 minutes of Task Oriented Training (TOT) and 30 minutes of Robotic-Assisted Therapy (RAT), 5 days per week, and repetitive Transcranial Magnetic Stimulation (rTMS) will be applied. This process will comprise 5 weekly sessions of excitatory stimulation over the primary somatosensory area of the participant's affected side. For this purpose, the motor area will be localised and a coil will be placed 2 cm posterior to it. An isolated pulse will be applied to the motor area to ensure that the coil is not placed over the motor area using 110% of the motor resting threshold. After this, 24 trains of 5 Hz at an intensity of 90% of the motor resting threshold will be applied for 10 seconds, with a rest between series of 5 seconds (a total of 1200 pulses).
62708577|NCT05467657|SHAM_COMPARATOR|Sham repetitive transcranial magnetic stimulation|The control group treatment will consist of a daily one-hour session of 30 minutes of task-oriented training (TOT) and 30 minutes of robotic-assisted therapy (RAT), for 5 days per week, to which the repetitive Transcranial Magnetic Stimulation (rTMS) placebo treatment will be added. To achieve the placebo, the localisation of the area to be stimulated will be carried out but the coil will be placed in a vertical position so the current wil not go through the skull and the patient will just feel the vibration, communicating to the participant that it is likely that during the stimulation process he/she will not feel anything.
61972241|NCT04798001|EXPERIMENTAL|Cohort B / Dosage Group 4 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
61972242|NCT04798001|EXPERIMENTAL|Cohort B / Dosage Group 5 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
61972243|NCT04798001|EXPERIMENTAL|Cohort B / Dosage Group 6 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
61972244|NCT01176669|EXPERIMENTAL|Apatinib|
61972245|NCT03066271|EXPERIMENTAL|Exercise + usual care|"The supervised exercise training is carried out on a ergometer cycle as individual daily (mon-fri) training and each exercise training session consists of 20min.~The training comprised a warm-up phase followed by 3 exercise phases. Warm-up consisted of 5min light stationary cycling, adjusted to 50-60% of the patients peak power output determine at the incremental cycle test (iPPO). The first exercise phase comprised of 5min interval training consisting of 5x30 sec intervals at 80-95% of the patient's iPPO. Between each interval, there is a 30 sec pause. The 2nd exercise phase consisted of 5min continuous cycling at an intensity equaling 80% of the patient's iPPO. The 3rd exercise phase was similar to the first exercise phase. Intensities increased progressively from the first week to the last week (from 50%, 80% and 70% of iPPO according to the three different phases to 60%, 95% and 80 % of iPPO respectively."
62708578|NCT02458235|EXPERIMENTAL|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
62708579|NCT03190421|EXPERIMENTAL|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
62708580|NCT03190421|ACTIVE_COMPARATOR|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
62708581|NCT04079738|EXPERIMENTAL|Phase I:TAK-659 + Ixazomib|Phase I: TAK-659 (Days 1-15) + Ixazomib dose escalation (Days 1, 8, 15)
62708582|NCT04079738|EXPERIMENTAL|Phase II:TAK-659 + Ixazomib|Phase II: TAK-659 at MTD (Days 1-15) + Ixazomib at MTD (Days 1, 8, 15)
62708583|NCT03808935|EXPERIMENTAL|Medical cannabis|Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
61972246|NCT03066271|EXPERIMENTAL|Control - usual care|The patients randomized to the control group received no training but will be wearing the activity tracker during the intervention.
61972247|NCT06460857|EXPERIMENTAL|Manual Diaphragmatic Release Technique|Manual Diaphragmatic Release Technique and Generalized Body Stretching
61972248|NCT06460857|EXPERIMENTAL|Chest Wall Expansion Exercises|Chest Wall Expansion Exercises and generalized Body stretching
61972249|NCT01777256|EXPERIMENTAL|GSK2586184 50 mg Arm|Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal
61972250|NCT01777256|EXPERIMENTAL|GSK2586184 100 mg Arm|Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
61976302|NCT02331836|ACTIVE_COMPARATOR|Arc Endocuff (AEC 110, 120, 130, 140)|Endocuff-assisted colonoscopy Colonoscopy with the Endocuff attached at the distal tip of the scope
62146792|NCT04686617|ACTIVE_COMPARATOR|Force Group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction to one side and the other side was used as the premolar tooth control group. As in no-force group, same device procedure was used for the application of vibration. Self-ligating Speed (Strite Industries, Cambridge, Ontario, Canada) tubes and brackets with 0.022×0.026 inch slots were bonded to the buccal surfaces of the right and left first molar teeth and first premolar teeth.150g of buccally directed forces, producing by a 0.017×0.025-in beta-titanium-molybdenum alloy (3M Unitek, Monrovia, Calif) cantilever spring, were applied to premolar teeth on both side.The force magnitude was measured with a strain gauge (Dentaurum). At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
62146793|NCT00539084|EXPERIMENTAL|1|Intradermal injection of Lidocaine followed by a painful stimulus (venipuncture)
62708584|NCT03808935|PLACEBO_COMPARATOR|Placebo Control|"Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis."
62708585|NCT05363592|EXPERIMENTAL|CT-L01 12.5/500 mg FDC Tablet|Alogliptin Benzoate 12.5 mg/Metformin HCl XR 500 mg, FDC Tablet
62708586|NCT05363592|ACTIVE_COMPARATOR|Alogliptin Benzoate 12.5 mg, Metformin HCl XR 500 mg|"1. Alogliptin Benzoate 12.5 mg~2. Metformin HCl XR 500 mg"
62708587|NCT01175122|EXPERIMENTAL|H2N3 MO 2003/AA ca Vaccine|Participants will receive a nasal spray administration of the H2N3 MO 2003/AA ca vaccine on Day 0 and Day 28.
62708588|NCT02271880|ACTIVE_COMPARATOR|Medication as usual|Medication as typically prescribed by physician.
62708589|NCT02271880|ACTIVE_COMPARATOR|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
62146794|NCT00539084|PLACEBO_COMPARATOR|2|Intradermal injection of placebo followed by a painful stimulus (venipuncture)
62353013|NCT06323694||Patients with spinal fusion|measuring the quality of life in patients on the waiting list for spinal surgery
62708590|NCT01528592|EXPERIMENTAL|On / Off medication|Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
62708591|NCT04541615|ACTIVE_COMPARATOR|Group 1: Online didactic to proficiency PBP+|Group 1 Pre-trained group will receive information on how to optimally perform the ORSI chicken anastomosis task and the material will be delivered online via the ORSI e-learning platform. They will be given access to the material two weeks before their training. Unlike the other groups, Group 1 will be required to study the material to a pre-defined performance benchmark or proficiency level. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
62708592|NCT04541615|ACTIVE_COMPARATOR|Group 2: Online didactic PBP+|The Pre-trained group (Group 2) will receive the exact same information as Group 1 on how to optimally perform the ORSI chicken anastomosis task but they are not required to study the material to a pre-defined proficiency benchmark. The time they spend on the task and effort expended will be logged. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
62708593|NCT04541615|ACTIVE_COMPARATOR|Group 3: Standard training group|The standard trained group will receive face-to-face lectures on how to perform the ORSI chicken anastomosis task. It will not differ from what they would normally receive during a traditional surgery training course when they arrive at the ORSI academy for their training. The content of the face-to face lecture is the same as in the e-learning courses. After the face-to face lecture, the participants have to perform the orsi chicken anastomosis task.
62708594|NCT04541615|ACTIVE_COMPARATOR|Group 4: Apprenticeship Group|The apprenticeship trained group will not receive face-to-face lectures or e-learning on how to perform the ORSI chicken anastomosis task. They will however receive hands-on practical one-to-one training during a traditional surgical training course, with deliberate practice. During this course, clinicians will train the participants on how to perform the orsi anastomosis task. They will also receive published materials describing how best to perform the task and mentoring on suturing and knot tying by a task expert who will guide their performance.
62708595|NCT05572294|EXPERIMENTAL|Mindfulness and Yoga Therapy|Participants will have access to video-guided mindfulness interventions.
62708596|NCT06565143|ACTIVE_COMPARATOR|transcranial alternating current stimulation-Real|Participants will receive real tACS once daily for 14 days
61972251|NCT01777256|EXPERIMENTAL|GSK2586184 200 mg Arm|Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
61972252|NCT01777256|EXPERIMENTAL|GSK2586184 400 mg Arm|Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
61972253|NCT01777256|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.
61972254|NCT03209687|EXPERIMENTAL|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
61972255|NCT03209687|NO_INTERVENTION|Routine care|This group will receive the routine care for luteal phase support
62708597|NCT06565143|SHAM_COMPARATOR|transcranial alternating current stimulation-Sham|Participants will receive sham tACS once daily for 14 days
61972256|NCT01508858|EXPERIMENTAL|Treatment period 1|
62708598|NCT00105898|EXPERIMENTAL|Arm 1|Intervention group
62708599|NCT00105898|ACTIVE_COMPARATOR|Arm 2|Comparator
62708600|NCT00105898|SHAM_COMPARATOR|Arm 3|Comparator
62708601|NCT02965781|ACTIVE_COMPARATOR|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
61972257|NCT01508858|PLACEBO_COMPARATOR|Treatment period 2|
61972258|NCT04128267|EXPERIMENTAL|Response to Pain|Brain's response to pain using magnetic resonance imaging (MRI)
62708602|NCT02965781|ACTIVE_COMPARATOR|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
61972259|NCT00612924|EXPERIMENTAL|Anaconda|
61972260|NCT02732704|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System
61972261|NCT00968994|EXPERIMENTAL|exSALT SD7™ Wound Dressing|The exSALT™ SD7 Wound Dressing provides an antimicrobial barrier that inhibits microbial growth in the dressing. The exSALT™ SD7 Wound Dressing consists of 3 layers: two non-adherent polyethylene mesh wound contact layers and one absorbent core made of polyester. All three layers are silver coated. The concentration of silver on the exSALT™ SD7 Wound Dressing is approximately 0.4 mg/cm2 (2.5% w/w).
61972262|NCT00968994|ACTIVE_COMPARATOR|Xeroform® Petrolatum Dressing|Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
62708603|NCT02965781|PLACEBO_COMPARATOR|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
62708604|NCT05477888||Questionnaires assessed e-cigarette users|"1. ≥18 years old;~2. Those who used e-cigarettes at least once a week for the past month;~3. Be able to read and communicate in Chinese."
61972263|NCT02496273|EXPERIMENTAL|CEA Specific CTL|Patients receiving CEA-specific CTLs as therapy for Gastric Cancer
61972264|NCT03117907||Infants with low infectious status|
61972265|NCT03117907||Infants with high infectious status|
61972266|NCT05957484|ACTIVE_COMPARATOR|Active Treatment|Study participants will receive \~18-minute active stimulation twice daily over 4 weeks, using a non-invasive brainstem modulation device.
62146795|NCT02424474|EXPERIMENTAL|Genetic NIPT and regular serum screening|All woman will be tested using the two tests, genetic NIPT (Non Invasive Prenatal Testing) and regular serum screening.
62146796|NCT03672032|ACTIVE_COMPARATOR|Fork-tip Needle|
62146797|NCT03672032|ACTIVE_COMPARATOR|Franseen Needle|
62146798|NCT01579071|EXPERIMENTAL|CO2 sufflation group|
62146799|NCT01579071|EXPERIMENTAL|Room air sufflation group|
61972267|NCT05957484|PLACEBO_COMPARATOR|Sham Treatment|Study participants will receive \~18-minute of sham stimulation twice daily over 4 weeks using a non-invasive brainstem modulation device.
61972268|NCT05957484|EXPERIMENTAL|Open Label|After completion of sham or active stimulation over 4 weeks, participants can choose to receive \~18-minute active stimulation twice daily for up to 12 weeks.
62708605|NCT01862354|ACTIVE_COMPARATOR|Group TAP block|Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia.
62708606|NCT01862354|ACTIVE_COMPARATOR|Group : Continuous wound infusion|Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia.
62708607|NCT01775384|EXPERIMENTAL|Nutrasorb|Soy protein powder sorbed with polyphenols from blueberries and green tea extract
62708608|NCT01775384|PLACEBO_COMPARATOR|Placebo|Soy protein isolate powder without polyphenols (with food coloring)
62708609|NCT02485184|ACTIVE_COMPARATOR|TIPS group|Transjugular intrahepatic portosystemic shunt
62708610|NCT02485184|ACTIVE_COMPARATOR|ET & drugs groups|"1. Endoscopic therapy.~2. Non-selective beta blockers.~3. Anticoagulation therapy."
61972269|NCT00925912|ACTIVE_COMPARATOR|1|"spinal anesthesia: Active Comparator~The SA group were received a subarachnoid block with 1.5-2.0 ml of 0.5% bupivacaine."
61972270|NCT00925912|EXPERIMENTAL|2|Perianal block with 0.25% bupivacaine
61972271|NCT01432860|ACTIVE_COMPARATOR|In-person Counseling and Education|In the in-person training the Research Assistant demonstrates the use of a mm ruler, a lighted magnifying lens, a set of body maps and a scorecard, 4 pens, ABCDE rule on the skin exam card and discusses the ABCDE rule by pointing to the color examples on the skin exam card. 165 pairs (330 subjects) are randomized to this arm.
61972272|NCT01432860|ACTIVE_COMPARATOR|Workbook|The workbook, which includes all of the information delivered in the in-person intervention, is 39 pages in length, and has 76 color figures. Each element of the in-person training represents a chapter in the workbook. The introduction explores the partners' understanding of melanoma and their personal risk of developing another melanoma, and attitudes about the benefit of early detection assisted by a partner. The early detection segment uses a skin diagram to illustrate the difference between thin and thick melanoma and presents the treatment based on the depth of the melanoma. 165 pairs (330 subjects) are randomized to this arm.
62708611|NCT02958345|ACTIVE_COMPARATOR|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
62708612|NCT02958345|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
62708613|NCT01466088|EXPERIMENTAL|AZD3480|
62708614|NCT01466088|ACTIVE_COMPARATOR|Donepezil|Donepezil will be administered at 5 mg daily for 4 weeks and escalated to 10 mg daily for the remainder of the study.
61972273|NCT01432860|NO_INTERVENTION|Control|Education and counseling as usually delivered in clinical practice. 100 pairs (200 subjects) are randomized to this arm.
62708615|NCT06521268|EXPERIMENTAL|Group 1|Inspiratory muscle training
61972274|NCT01432860|ACTIVE_COMPARATOR|Tablet Computer-Based Education|Education will be given by an interactive tablet app. Each pair will view video recordings of certain parts of the in-person presentation as well as select slides from the in-person PowerPoint presentation. Parts of the workbook will be incorporated as well. 70 pairs (140 subjects) are randomized into this arm.
61972275|NCT02408640|EXPERIMENTAL|Intervention group|"Individuals randomized to the intervention group will directly after randomization answer questions about alcohol and drug use (other than alcohol and cannabis), depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends.~Further, they will fill out a survey about Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will be able to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to complete the follow-up."
62708616|NCT06521268|ACTIVE_COMPARATOR|Group 2|Controls
62708617|NCT04993261|EXPERIMENTAL|Diagnostic (dual energy CT scan)|Patients undergo one dual energy CT scan during scheduled CT scan.
61976303|NCT02331836|ACTIVE_COMPARATOR|Cap|Cap-assisted colonoscopy Colonoscopy with the transparent Cap attached at the distal tip of the scope
62708618|NCT04189484|EXPERIMENTAL|Arm A: Evolocumab low dose|Single dose of evolocumab 21 mg subcutaneous (SC)
62708619|NCT04189484|EXPERIMENTAL|Arm B: Evolocumab intermediate low dose|Single dose of evolocumab 35 mg SC
62708620|NCT04189484|EXPERIMENTAL|Arm C: Evolocumab intermediate high dose|Single dose of evolocumab 70 mg SC
62708621|NCT04189484|EXPERIMENTAL|Arm D: Evolocumab high dose|Single dose of evolocumab 140 mg SC
62708622|NCT04189484|EXPERIMENTAL|Arm E: Alirocumab low dose|Single dose of alirocumab 15 mg SC
62708623|NCT04189484|EXPERIMENTAL|Arm F: Alirocumab intermediate low dose|Single dose of alirocumab 25 mg SC
62708624|NCT04189484|EXPERIMENTAL|Arm G: Alirocumab intermediate high dose|Single dose of alirocumab 50 mg SC
62708625|NCT04189484|EXPERIMENTAL|Arm H: Alirocumab high dose|Single dose of alirocumab 100 mg SC
62708626|NCT04189484|PLACEBO_COMPARATOR|Arm I: Placebo|Single dose of placebo SC
62708627|NCT05703399||Observational (biospecimen collection, questionnaire)|Patients undergo collection of blood samples throughout the study. Patients may also complete questionnaires and undergo the collection of tissue samples throughout the study.
62708628|NCT03069716|EXPERIMENTAL|Smartphone Text Messaging|"Group receives personalized, health coaching via smart text messages."
62708629|NCT03069716|OTHER|No Smartphone Text Messaging|"Group does not receive personalized, health coaching via smart text messages."
62708630|NCT02890875|ACTIVE_COMPARATOR|Ethanol lock|70% ethanol
62708631|NCT02890875|ACTIVE_COMPARATOR|Heparin lock|Heparinized saline (100 U/mL)
62708632|NCT02369536|ACTIVE_COMPARATOR|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
62512160|NCT01730040|EXPERIMENTAL|Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
62512161|NCT02639728|EXPERIMENTAL|Regular coffee|Will receive a 4oz cup coffee, three times daily (at 8:00, 12:00, and 16:00 hours)and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
62512162|NCT02639728|EXPERIMENTAL|Decaffeinated coffee|Will receive a 4oz cup of decaffeinated coffee (at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
62512163|NCT02639728|EXPERIMENTAL|Warm water|Will receive a 4oz cup of warm water at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
62512164|NCT04497272|OTHER|The metabolomic signature of COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
62512165|NCT06142669||Revision Total Knee Arthroplasty|Single study group with either newly or previously implanted subjects with the EVOLUTION® Revision Tibia and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Insert.
62512166|NCT06400485|EXPERIMENTAL|AMT-676 Dose escalation|Drug- AMT-676 Dosage level: AMT-676 will be administered as an intravenous (IV) infusion. Dosage form: Vial Route of administration: Intravenous Infusion
62512167|NCT05571033|EXPERIMENTAL|Spinal reflex conditioning|"The OC intervention includes 6 baseline sessions and 24 conditioning/ no conditioning sessions held 3 times/week.~To elicit an H-reflex, participants will be asked to stand in a comfortable position. Small pulses of energy will be applied to a nerve in the leg called the tibial nerve. We will record when the participant maintains leg muscle activity. During the intervention, participants will be trained to decrease their reflex in their calf."
62512168|NCT01353807|ACTIVE_COMPARATOR|Fish oil supplementation|These women received 4 1-g capsules of fish oil per day providing 2,7 grams long chain n-3 fatty acids per day, from gestation week 30 until delivery
62708633|NCT02369536|PLACEBO_COMPARATOR|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
62708634|NCT02530255|PLACEBO_COMPARATOR|Placebo|Study subjects receiving placebo: Intervention - two capsules, one morning and one night for one year; placebo for cycloastragenol
62708635|NCT02530255|ACTIVE_COMPARATOR|cycloastragenol|Study subjects receiving cycloastragenol: Intervention - cycloastragenol; oral capsules 8mg. per day (two capsules) one in the morning and one at night for one year.
62708636|NCT06120205|OTHER|Self-Collection / Clinician Collection|Patient serves as own comparator/control in this method comparison study where the investigational intervention is use of the self-collect device and the comparator is the standard of care clinician collection.
62353014|NCT01925391|ACTIVE_COMPARATOR|Sevoflurane, oxygen, intraocular pressure|Intraocular measurements under induction with Sevoflurane in oxygen
62512169|NCT01353807|PLACEBO_COMPARATOR|Olive oil|These women received 4 1-g capsules with olive oil per day from gestational week 30 until delivery
62512170|NCT01353807|NO_INTERVENTION|No oil supplement|These women received no capsules with oil
62512171|NCT04156412|EXPERIMENTAL|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
62512172|NCT01008137|EXPERIMENTAL|Group 1: Day 0-PANFLU.1; Day 21-ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
62512173|NCT01008137|EXPERIMENTAL|Group 2: Day 0-ANFLU; Day 21-PANFLU.1|50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
62512174|NCT01008137|EXPERIMENTAL|Group 3: Day 0-PANFLU.1+ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
62715071|NCT06093464|EXPERIMENTAL|Group B- Natural Compound B to Natural Compound C to Natural Compound A|"* Cycle 1 (4 weeks): use diffused Natural Compound B (essential oil) in a diffuser every night when sleeping~* Cycle 2 (4 weeks): will not use compounds/diffuser (wash-out period)~* Cycle 3 (4 weeks): use diffused Natural Compound C (control) in a diffuser every night when sleeping~* Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~* Cycle 3 (4 weeks): use diffused Natural Compound A (essential oil) in a diffuser every night when sleeping~* Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~There will be 3 natural compounds; the intervention compounds essential oils and are commercially available and there is a control compound (water). They will be used as intended with diffusers."
61976304|NCT02331836|ACTIVE_COMPARATOR|Standard Colonoscope|Standard colonoscopy without any additional device
62353015|NCT01925391|ACTIVE_COMPARATOR|Nitrous oxide/O2/tetracaine|intraocular pressures in children undergoing inhalation induction with nitrous oxide in oxygen
62353016|NCT06165380|EXPERIMENTAL|Cardenilimab Combined With Chemotherapy|
62353017|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
62353018|NCT00012883|OTHER|Arm 1|Homewalking Exercise Program
62512175|NCT02279784|EXPERIMENTAL|Freeway|angioplasty with Freeway drug-eluting balloon
62512176|NCT02279784|EXPERIMENTAL|Lutonix|angioplasty with Lutonix drug-eluting balloon
62512177|NCT05196516||Cases|Individuals at age 18 to 65 with a SARS-CoV-2 infection proven by a polymerase chain reaction (PCR) test at least 12 weeks prior to inclusion and who have been referred to the clinic of post-COVID conditions.
62512178|NCT05196516||Controls|Healthy volunteers at age 18 to 65 with a SARS-CoV-2 infection proven by a PCR test at least 12 weeks prior to inclusion.
62512179|NCT04859387|EXPERIMENTAL|group A|set of pragmatic shoulder techniques
62512180|NCT04859387|ACTIVE_COMPARATOR|group B|traditional physical therapy
62512181|NCT05208879||Case group.|"Patients with genetically proven familial hypocholesterolemia, who will accept to participate in this study and have been treated for this pathology since 1990 in the Department of Gastroenterology and Paediatric Nutrition (Pr Peretti) and continue their follow-up into adulthood at the GHE (Groupement Hospitalier Est) in Lyon in the endocrinology-nutrition service (Pr Moulin).~They may be girl/woman or boy/man over 6 years of age and over 12 kg at the time of inclusion (age required for cooperation on macular pigment measurement), agreeing to participate in the study with clear and informed consent. These patients are covered by social security."
62512182|NCT05208879||Control group.|The control group consists of children over 6 years old or adult patients, followed routinely in the ophthalmology department of the Edouard Herriot Hospital, Lyon (Pr Kodjikian) not suffering from genetic hypocholesterolemia and requiring a fundus examination as part of the usual follow-up of their ocular pathology, if this pathology does not interfere with the macular pigment density. An additional measurement of the macular pigment density will be made during this examination. The control group is only needed for the macular pigment analysis. No control group is considered for the characterization of plasma lutein and zeaxanthin deficiency and for the analysis of oxidative stress, so there will be no additional blood sampling for control patients.
62512183|NCT03276676|EXPERIMENTAL|Group A|Participants enrolled in Group A will undergo a maximum of 6 scans throughout this study. \[18F\]FLT- and \[18F\]Fluciclovine-PET/CT scans at up to three imaging time points: (1) prior to any tumor-directed therapy, (2) within 1-4 weeks after the conclusion of the intitial (\~6-8 weeks) chemoradiotherapy, and (3) following suspected recurrence/progression versus treatment effect (pseudoprogression) shown with MRI, within 6 months of the completion of chemoradiation
62512184|NCT03276676|EXPERIMENTAL|Group B|Participants enrolled in Group B will undergo 2 scans as part of this study. \[18F\]FLT- and \[18F\]Fluciclovine-PET/CT scans will be acquired at a single timepoint, at the time of suspected pseudoprogression.
62512185|NCT02971722|EXPERIMENTAL|0.3mg JY09(cohort 1)|0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
62512186|NCT02971722|EXPERIMENTAL|1.5mg JY09(cohort 1)|1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
62512187|NCT02971722|EXPERIMENTAL|6.0mg JY09(cohort 1)|6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
62512188|NCT02971722|PLACEBO_COMPARATOR|Placebo(cohort 1)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
62512189|NCT02971722|EXPERIMENTAL|0.7mg JY09(cohort2)|0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
62512190|NCT02971722|EXPERIMENTAL|3.0mg JY09(cohort2)|3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
62512191|NCT02971722|EXPERIMENTAL|12.0mg JY09(cohort2)|12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
61972276|NCT02408640|NO_INTERVENTION|Control group|"Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed).~Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se."
62146800|NCT05649891|EXPERIMENTAL|Patients managed with Emergency Manual access|Consecutive priority 1 patients managed by resuscitation teams with access to an Emergency Manual
62146801|NCT06482528|EXPERIMENTAL|Motor imagery group|Individuals who meet the inclusion criteria will fill out the demographic data form after signing the informed consent form. Then, individuals' motor imagery abilities will be evaluated using HIA-3, mental rotation and mental stopwatch. After the evaluation, the individuals will be taken to a quiet and isolated room and the Polar H10 device will be placed on the chest area of the individuals to measure heart rate variations and (MP36 system and BİOPAC software) will be placed to measure the electrodermal activities of the individuals. Then, a motor imagery session will be held for individuals with a physiotherapist who is an expert in the field.
61972277|NCT00707707|EXPERIMENTAL|1|paclitaxel + AZD2281
62512192|NCT02971722|PLACEBO_COMPARATOR|Placebo(cohort 2)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
62512193|NCT01920984|EXPERIMENTAL|pretreatment of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
62512194|NCT01920984|NO_INTERVENTION|No pretreatment of bevacizumab|Patients will not receive bevacizumab pretreatment before vitreous surgery.
61972278|NCT03770442|EXPERIMENTAL|Cycling with FES|"Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.~Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.~These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all)."
61972279|NCT03770442|ACTIVE_COMPARATOR|Control - routine physiotherapy|Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
61972280|NCT03415841|EXPERIMENTAL|mHealth|"50 patients who are randomized to the intervention group (mHealth remote monitoring devices) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics."
62146802|NCT03929471|EXPERIMENTAL|Intervention group|Patients to be subjected to a fluid overload correction protocol.
62146803|NCT03929471|NO_INTERVENTION|Control group|Patient will be followed but no fluid overload correction protocol will be applied.
62146804|NCT05549466|EXPERIMENTAL|Apatinib plus Camrelizumab and Chemotherapy|
62146805|NCT05549466|EXPERIMENTAL|Apatinib plus Camrelizumab|
62146806|NCT05549466|EXPERIMENTAL|Camrelizumab and Chemotherapy|
62708637|NCT02803905|ACTIVE_COMPARATOR|standard procedure: intrahepatic|Liver infusion: the islet mixture is delivered slowly via injection through a syringe attached to the catheter in the portal vein or portal vein tributary. Access to the portal vein is achieved by percutaneous transhepatic access under fluoroscopic, ultrasonographic, or real-time CT guidance. Alternatively access to a mesenteric or omental venous tributary of the portal vein can be obtained by mini-laparotomy under general anesthesia (transplant site preference or in the extremely rare circumstance that percutaneous access cannot be achieved). At a minimum, portal pressure will be monitored before and after infusion of the islet product. Portal pressure measurements will be documented in the medical record. Gel foam plugs and/or collagen/thrombin paste will be used to embolize the entire peripheral catheter tract immediately before the catheter is withdrawn, to reduce the chances of bleeding.
61972281|NCT03415841|NO_INTERVENTION|Control|The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics
62146807|NCT05549466|ACTIVE_COMPARATOR|Chemotherapy|
62512195|NCT04955366|ACTIVE_COMPARATOR|Belatacept group (Control Group)|"Participants will receive the following:~* Belatacept: 5 mg/kg i.v. monthly~* Blood draws for PD studies at baseline/Month 0 and Month 6 fora total of two timepoints.~* HLA labs at 6, 12 and 24 months~* Basic chemistry panel (CP Basic) every 3 months per clinical protocol for efficacy analysis~* Hemoglobin A1c at Screening visit~* Urine pregnancy test via test kit for WOCP at Screening visit~* BK and CMV testing at 6, 12, and 24 months"
62512196|NCT04955366|EXPERIMENTAL|Abatacept Group (Conversion Group)|"Participants will receive the following:~* Abatacept 125 mg s.c. weekly~* Safety labs every 2 weeks (months 0-3) then monthly (months 4-12)~* Blood draws forPK atMonth 6, Month 12, and two random time points in between Month 6 and Month 12 for a total of four time points.~* Blood draws for PD studies at baseline/Month0 and Month 6 fora total of two timepoints.~* HLA labs at 6, 12 and 24 months~* Basic chemistry panel (CP Basic) at each study visit per clinical protocol for efficacy analysis~* Hemoglobin A1c at Screening visit~* Urine pregnancy test via test kit for WOCP at screening~* BK and CMV testing at 6, 12, and 24 months"
62512197|NCT03393416|EXPERIMENTAL|MASCT-I or MASCT-I +PD1 antibody|"This study is divided into three stages:~The first, second stage is the stage of the dose climbing, and the third stage is the dose expansion stage. The first stage is MASCT-I, using 3+3 design. The second stage is divided into two groups: MASCT-I+PD1 antibody in low dose group and MASCT-I+PD1 antibody in high dose group, using 3+3 design. The third stage is the dose expansion stage , 10 patients in the low or high dose group were treated with the corresponding dose group."
62512198|NCT02746627|ACTIVE_COMPARATOR|Education|Participants receive educational materials in the mail every 2 weeks for 8 weeks.
62512199|NCT02746627|EXPERIMENTAL|Positive Affect - Text|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations, and gift cards) by SMS. Participants also receive educational materials in the mail every 2 weeks for 8 weeks.
62512200|NCT02746627|EXPERIMENTAL|Positive Affect - Phone|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
62512201|NCT02269631|EXPERIMENTAL|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
62512202|NCT02269631|ACTIVE_COMPARATOR|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
62512203|NCT01463150|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 150mg per day for 15 days
61972282|NCT00681369||1|Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
61972283|NCT02670564|EXPERIMENTAL|Total body irradiation (TBI)|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
62146808|NCT03676504|EXPERIMENTAL|Stratum I|Adult patients with relapsed or refractory ALL
62512204|NCT01463150|EXPERIMENTAL|Prasugrel|Prasugrel 5mg for 15 days
62512205|NCT03680976|EXPERIMENTAL|10-nitro-octadeca-9-enoic acid (CXA-10)|CXA-10 150 mg tablet taken orally once a day for 12 weeks
62512206|NCT03680976|PLACEBO_COMPARATOR|Placebo|Placebo 150 mg tablet taken orally once a day for 12 weeks
61972284|NCT02670564|EXPERIMENTAL|Busulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
61972285|NCT02670564|EXPERIMENTAL|Treosulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
61972286|NCT02031666|ACTIVE_COMPARATOR|Treatment A|15 participants will receive 240-mg dose as Softgel Capsule Formulation of JNJ-56021927.
61972287|NCT02031666|EXPERIMENTAL|Treatment B|15 participants will receive 240-mg dose as Tablet Formulation number 1 of JNJ-56021927.
61972288|NCT02031666|EXPERIMENTAL|Treatment C|15 participants will receive 240-mg dose as Tablet Formulation number 2 of JNJ-56021927.
61972289|NCT02031666|EXPERIMENTAL|Treatment D|15 participants will receive 240-mg dose as Tablet Formulation number 3 of JNJ-56021927.
62146809|NCT03676504|EXPERIMENTAL|Stratum II|Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL
62146810|NCT03676504|EXPERIMENTAL|Stratum III|Pediatric patients with relapsed or refractory ALL
62146811|NCT06435481|EXPERIMENTAL|Chewable Tablet Group|Group of patients receiving a new hydrocortisone formulation in the form of chewable tablets. Patients in this group will take the 3D printed chewable tablets orally for a duration of three months.
62146812|NCT06435481|ACTIVE_COMPARATOR|Oral Suspension Group|Group of patients receiving the standard hydrocortisone formulation in the form of an oral solution. Patients in this group will orally ingest the solution over a period of three months.
62146813|NCT04907617|EXPERIMENTAL|G1|After the induction of anaesthesia, the first group will be heated with only forced-air warming device.
62512207|NCT04100824|EXPERIMENTAL|Bupivacaine 0.5%|patient will take stellate ganglion block 10 ml bupivacaine 0.5% and nimodipine
61972290|NCT02031666|EXPERIMENTAL|Treatment E|15 participants will receive 240-mg dose as Tablet Formulation number 4 of JNJ-56021927.
62146814|NCT04907617|EXPERIMENTAL|G2|After the induction of anaesthesia, the second group will receive only warmed IV and irrigation fluids.
62512208|NCT04100824|ACTIVE_COMPARATOR|Nimodipine|patient will take nimodipine 60 mg every 4 h.
62512209|NCT00928226|EXPERIMENTAL|Arm 1 - 24 Grey SRS|24 Grey administered as 8 Gy x 3 fractions
62512210|NCT00928226|EXPERIMENTAL|Arm 2 - 27 Grey SRS|27 Grey administered as 9 Gy x 3 fractions
62512211|NCT00928226|EXPERIMENTAL|Arm 3 - 30 Grey SRS|30 Grey administered as 10 Gy x 3 fractions
62512212|NCT00928226|EXPERIMENTAL|Arm 4 - 33 Grey SRS|33 Grey administered as 11 Gy x 3 fractions
62512213|NCT01651611|EXPERIMENTAL|Extensive TTA interaction|Persons interested in quitting smoking will receive multiple in-person visits from a peer Tobacco Treatment Advocate (TTA) who will provide motivational interviewing, basic smoking cessation counseling assistance, navigation to smoking cessation resources, and social support.
62512214|NCT01651611|ACTIVE_COMPARATOR|Minimal TTA interaction|Persons interested in quitting smoking will receive a single in-person visit from a peer Tobacco Treatment Advocate (TTA) who will provide basic smoking cessation counseling assistance.
62512215|NCT01544218||YCMC|Youth ages 9-18 with one of four chronic medical conditions - asthma, diabetes, rheumatic or gastroenterologic conditions
62512216|NCT00652756|EXPERIMENTAL|1|Patient is placed on a transport ventilator.
62512217|NCT00652756|OTHER|2|Patient is ventilated using the current standard at this institution.
62512218|NCT01711749|ACTIVE_COMPARATOR|Sequence 1|01 tablet, single dose, of Reference Product in period 1 and 01 tablet, single dose, of Test Product in period 2.
62512219|NCT01711749|ACTIVE_COMPARATOR|Sequence 2|01 tablet of Test Product in period 1, and 01 tablet, single dose, of Reference Product in period 2.
62512220|NCT01045616||Prematurity|
62512221|NCT00915837|EXPERIMENTAL|Slow release formulation|Slow release formulation, helical intravitreal triamcinolone implant
62512222|NCT00915837|EXPERIMENTAL|fast release formulation|fast release formulation, helical intravitreal triamcinolone implant
62512223|NCT05132569|PLACEBO_COMPARATOR|Placebo/Tolebrutinib|Participants with moderate-to-severe gMG received placebo (matched to tolebrutinib) tablet orally once daily as an add-on therapy to their SoC for 26 weeks in the DB treatment period. Participants who completed the DB period entered the OLE period and received tolebrutinib 60 milligrams (mg) orally daily along with SoC starting from Week 27 up to an additional 35 weeks in the OLE period until the study termination (i.e., up to Week 61).
62512224|NCT05132569|EXPERIMENTAL|Tolebrutinib/Tolebrutinib|Participants with moderate-to-severe gMG received tolebrutinib 60 mg tablet orally once daily as an add-on therapy to their SoC for 26 weeks in the DB treatment period. Participants who completed the DB period entered the OLE period and continued to receive tolebrutinib 60 mg orally daily along with SoC starting from Week 27 up to an additional 35 weeks in the OLE period until the study termination (i.e., up to Week 61).
62512225|NCT04491578|EXPERIMENTAL|ACP programme|It is a theory-driven ACP programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model and shared decision-making model.
62512226|NCT06115863|ACTIVE_COMPARATOR|placebo group|"Delirium and cognitive functions will be assessed for patients in the control group twice per day for five consecutive days' pre and post conventional nursing care.~The researcher will observe the conventional nursing care provided by CCNs in the study setting which may affect delirium incidence and patients' cognitive functions for 45 minutes twice daily for five consecutive days. These traditional nursing practices may include a close conversation between the nurse and the patient, patient re-orientation, such as providing information about time, date, and location, tactile stimulation during various procedures, and changing patients' positions."
62512227|NCT06115863|EXPERIMENTAL|early cognitive stimulation Interventions group|"Beginning on the first day of the patient's admission to the ICU, the early cognitive stimulation interventions will be implemented for nearly 45 minutes twice daily for five days. One session will be conducted during the morning shift and the other during the evening shift. Each session will include the following:~1. Cognitive stimulation activities will be administered to patients in the intervention group by a member of his family for 15 minutes twice a day for five consecutive days.~2. Cognitive training exercises: The researcher will carry out these exercises for a total of 300 minutes over the course of five days, splitting the time between 30 minutes in the morning shift and 30 minutes in the evening shift."
62512228|NCT00918918|EXPERIMENTAL|Treatment B|Vodka + orange juice
62512229|NCT00918918|PLACEBO_COMPARATOR|Treatment A|Orange juice
62512230|NCT02457884|ACTIVE_COMPARATOR|Temporal Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
62512231|NCT02457884|ACTIVE_COMPARATOR|Spatial Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
61972291|NCT02031666|EXPERIMENTAL|Treatment F|15 participants will receive 240-mg dose as Tablet Formulation number 5 of JNJ-56021927.
61972292|NCT02031666|EXPERIMENTAL|Treatment G|15 participants will receive 240-mg dose as Tablet Formulation number 6 of JNJ-56021927.
61972293|NCT02031666|EXPERIMENTAL|Treatment H|15 participants will receive 240-mg dose as Tablet Formulation number 7 of JNJ-56021927.
61972294|NCT03621488|EXPERIMENTAL|Efficacy of Behavioral Self-Activation with virtual reality|"10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week~+ virtual reality activities of the session 4 to 9 lasting half an hour."
61972295|NCT03621488|SHAM_COMPARATOR|Efficacy of Behavioral Self-Activation without virtual reality|10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week.
61972296|NCT01428089|EXPERIMENTAL|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml)
61972297|NCT01428089|PLACEBO_COMPARATOR|placebo|placebo at 1100, 1500, and 1900 h.
61972298|NCT01990989||Clopidogrel treated patients|A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.
62708638|NCT02803905|EXPERIMENTAL|experimental procedure: omentum|Omentum infusion: briefly, islets are spread in the surface of the omentum, in a single omental pouch site. Transplanting in a single site will reduce risks. A single dose of at least 5000 IEQ/KG will be transplanted. The investigators should be able to achieve a meaningful metabolic improvement and prevention of severe hypoglycemia, as previously seen in experience with intraportal islet transplants. Recombinant human thrombin is added to the islets placed on the omentum to promote formation of a gel clot and facilitate adherence to the surface of the omentum. A pouch is then created by folding the omentum. The pouch is secured inn place with stitches.
62708639|NCT03580954|EXPERIMENTAL|Repetitive TMS (estimulation)|
62708640|NCT03580954|ACTIVE_COMPARATOR|Repetitive TMS (inhibition)|
62708641|NCT01669512|ACTIVE_COMPARATOR|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56 6 Volunteers
61972299|NCT05615272|EXPERIMENTAL|Bio-PRF|This is a blood-derived platelet rich concentrate from the patient's whole blood sample. The patient typically donates two 9ml (1.5 tablespoons) vials of blood that is then spun in a centrifuge.
61972300|NCT05615272|ACTIVE_COMPARATOR|Alveogyl|Alveogyl is an intraalveolar sedative, obtundent dressing, which contains the active ingredient eugenol.
62708642|NCT01669512|EXPERIMENTAL|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56 8 Volunteers
62708643|NCT01669512|EXPERIMENTAL|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56 8 Volunteers
62708644|NCT03901586|EXPERIMENTAL|Patients who had Richter intervention|
62708645|NCT00094276|EXPERIMENTAL|1|Breathmobile intervention combined with a Facilitated Asthma Communication intervention (FACI)
62708646|NCT00094276|ACTIVE_COMPARATOR|2|FACI intervention
62708647|NCT00094276|ACTIVE_COMPARATOR|3|Breathmobile intervention
61972301|NCT06098066||control|
61972302|NCT06098066||ECIC bypass|
61972303|NCT06098066||CEA|
61972304|NCT06098066||CAS|
61972305|NCT05486104|EXPERIMENTAL|Hemay005 45 mg BID group|3 tablets of Hemay005 (15mg/tablet) and 1 tablet of Hemay005 placebo will be orally administered twice daily.
62146815|NCT04907617|EXPERIMENTAL|G3|After the induction of anaesthesia, forced-air warming as well as warmed IV and irrigation fluids will be applied to the third group
62146816|NCT04907617|EXPERIMENTAL|G4|After the induction of anaesthesia, the fourth group will be the control group without any intervention.
62512232|NCT02457884|ACTIVE_COMPARATOR|Combined Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
62708648|NCT00094276|NO_INTERVENTION|4|Control group
62708649|NCT05495022|EXPERIMENTAL|MBSR group|Mindfulness-based stress reduction (MBSR) program
62708650|NCT05495022|NO_INTERVENTION|Control group|standard care group
62708651|NCT00265798|EXPERIMENTAL|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62708652|NCT03202394|ACTIVE_COMPARATOR|Active intervention|Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
62708653|NCT03202394|PLACEBO_COMPARATOR|Placebo intervention|Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
62708654|NCT05994430|EXPERIMENTAL|Training Group|"The End-of-Life Care Awareness Training Program in Intensive Care prepared by the researchers in line with the End-of-Life Nursing Education-Intensive Care (ELNEC-Critical Care) program was applied to the intensive care nurses in the training group. The program was implemented online by determining a common day and time interval suitable for the working hours of the nurses. Half an hour before the training, nurses were reminded of the training topics of the relevant week, time, and Zoom link address via text message.~40-60 minutes one day a week for 4 weeks in the training program; Week 1: Introduction of the training program and palliative care nursing in intensive care Week 2: Pain management and management of other symptoms (respiratory, gastrointestinal, etc.) Week 3 Communication, cultural and spiritual issues Week 4: Loss, grief, mourning, and ethics were covered."
62708655|NCT05994430|NO_INTERVENTION|Control Group|"Intensive care nurses in the control group did not receive any intervention during the study. The nurses in this group continued to participate in routine in-service trainings. Similar to the training group, the post-test forms/scales End-of-Life Care Knowledge Test and the Scale of Attitudes and Behaviors of Intensive Care Nurses Towards End-of-Life Care were administered to the intensive care nurses in the control group in order to determine the changes in the levels of knowledge, attitudes and behaviors towards end-of-life care over time and to compare them with the training group."
62708656|NCT05313490|ACTIVE_COMPARATOR|Beetroot Juice|The subject will ingest 140mL of a nitrate-rich beetroot juice each day for 7 consecutive days.
62708657|NCT05313490|PLACEBO_COMPARATOR|Placebo Beetroot Juice|The subject will ingest 140mL of a placebo (nitrate-depleted) beetroot juice each day for 7 consecutive days.
62708658|NCT03220438|ACTIVE_COMPARATOR|TMS|rTMS
61972306|NCT05486104|EXPERIMENTAL|Hemay005 60 mg BID group|4 tablets of Hemay005 (15mg/tablet) will be orally administered twice daily.
61972307|NCT05486104|PLACEBO_COMPARATOR|Hemay005 placebo BID group|4 tablets of Hemay005 placebo will be orally administered twice daily.
61972308|NCT02366520|NO_INTERVENTION|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
61972309|NCT02366520|EXPERIMENTAL|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
61972310|NCT02301884|EXPERIMENTAL|Allergen extract|"Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those.~Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection"
61972311|NCT04156425|EXPERIMENTAL|escitalopram + golimumab|Patients will be treated with escitalopram from the minimum dosage and golimumab according to direction for use.
61972312|NCT04156425|EXPERIMENTAL|escitalopram + calcium tablet|Patients will be treated with escitalopram from the minimum dosage and calcium tablet according to direction for use.
61972313|NCT04156425|ACTIVE_COMPARATOR|escitalopram|Patients will be treated with escitalopram from the minimum dosage.
61972314|NCT04211051|EXPERIMENTAL|Arm A|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
62708659|NCT03220438|SHAM_COMPARATOR|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
62708660|NCT03064308|NO_INTERVENTION|Control|Participants will receive standard NHS care with no intervention.
61972315|NCT03455920|EXPERIMENTAL|Multidisciplinary arm|Patients randomized in this group will have their first sleep clinic evaluation with the clinical nurse. She will then discuss each case with the pulmonologist and validate the diagnostic and therapeutic avenue.
61972316|NCT03455920|ACTIVE_COMPARATOR|Pulmonologist arm|Patients randomized in this group will have their first sleep clinic evaluation with the pulmonologist.
61972317|NCT04044612|EXPERIMENTAL|Medial Unloader Brace|
61972318|NCT00881712|EXPERIMENTAL|PET positive nodal disease measuring 15 mm or greater|Proton radiation with concomitant chemotherapy
61972319|NCT00881712|EXPERIMENTAL|PET positive nodal disease measuring less than 15 mm|Proton radiation
61972320|NCT00881712|EXPERIMENTAL|Patients considered resectable|Proton radiation plus surgery
61972321|NCT04693325|EXPERIMENTAL|Prolonged normothermic machina perfusion|Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.
61972322|NCT01550380|EXPERIMENTAL|All participants|
61972323|NCT02197715|EXPERIMENTAL|computer-adaptive SAFE|Computer-adaptive SAFE will consist of 4 60-minute sessions. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method. Session 4 will focus on effective strategies to communicate with a sexual partner. Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
61972324|NCT02197715|EXPERIMENTAL|Face-to-face SAFE|Face-to-face SAFE will consist of 4 60-minute sessions using motivational interviewing techniques. Each session will be led by an experienced counselor. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method, and relevant skills regarding how to use and negotiate use of contraceptive methods. Session 4 will focus on effective strategies to communicate with a sexual partner.
62512233|NCT02457884|PLACEBO_COMPARATOR|Control Group|Receive 6 weekly 1-hour training sessions of leisure reading activities
61972325|NCT02197715|ACTIVE_COMPARATOR|Usual Care|Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods. Contraceptive methods are discussed within this context. There will be no demand on participants to attend these sessions. Participants will receive written take-home materials to review on their own and/or with their sex partners.
61972326|NCT02999854|EXPERIMENTAL|ATIR101|T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
62146817|NCT03002194|EXPERIMENTAL|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
62146818|NCT03195998||Group A|Gestational Age 23 0/7 - 28 6/7 weeks
62146819|NCT03195998||Group B|Gestational Age 29 0/7 weeks - 34 6/7 weeks
62512234|NCT04360395|NO_INTERVENTION|Neurotypical Youth/Young Adults|No intervention administered. The controls will only undergo initial baseline assessments.
62512235|NCT04360395|EXPERIMENTAL|Cerebral Palsy Youth/Young Adults|Baseline and 8 week assessments; 8 week gait therapy
62512236|NCT04126486|OTHER|Zio®XT Monitor Arm|
62512237|NCT04126486|NO_INTERVENTION|Usual Care Arm|
62512238|NCT06083636||Hashimoto's hypothyroidism|Group of 100 patients with Hashimoto's hypothyroidism using levothyroxine
62512239|NCT06083636||Hypothyroidism after thyroidectomy after thyroid carcinoma|Group of 100 patients with hypothyroidism after thyroidectomy after thyroid carcinoma using levothyroxine
62512240|NCT06083636||Central hypothyroidism|Group of 100 patients with central hypothyroidism using levothyroxine
62708661|NCT03064308|OTHER|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
62708662|NCT04574336|EXPERIMENTAL|Surgical Treatment|Primary surgery of humeral shaft fracture with surgeons choice of osteosynthesis method
62708663|NCT04574336|ACTIVE_COMPARATOR|Non-surgical treatment|Treatment of humeral shaft fracture with sling and/or functional brace
62708664|NCT06205121|EXPERIMENTAL|Active Arm|Subjects will receive OATD-01 as 25mg film-coated tablets for oral administration once daily for 12 weeks
62708665|NCT06205121|PLACEBO_COMPARATOR|Placebo Arm|Subjects will receive placebo as film-coated tablets for oral administration once daily for 12 weeks
62708666|NCT02027792|EXPERIMENTAL|Cabbage leaf wraps|Daily application of cabbage leaf wraps over night, 4 weeks application
62708667|NCT02027792|ACTIVE_COMPARATOR|Diclofenac gel|daily application of diclofenac gel 4 weeks application
62708668|NCT02027792|NO_INTERVENTION|Usual care|no specific intervention
62512241|NCT06083636||Hypothyroidism during treatment for Graves' Disease|Group of 100 patients with hypothyroidism during treatment for Graves' Disease using levothyroxine
62512242|NCT06083636||Healthy controls|100 healthy euthyroid controls
62512243|NCT04756596||Study group|70 patients with normal vision (NVG) 30 patients with low vision (LVG) These patients will be tested on the DDVIT
62512244|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
62512245|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
62512246|NCT05644886|EXPERIMENTAL|Intervention Arm|"Male Family Physicians allocated to intervention arm will receive following:~Training and technical support and integrates them with the nearest pharmacies or drug shops for vertical referrals.~Technical support will include:~* Supportive supervision~* Peer-to-peer support~* Strengthening referrals for long-acting reversible contraceptives (LARC) and permanent methods~* Provision of information, education, and communication (IEC) material and LCD for display of visual material.~* Branding of clinics with name boards~* Provision of family planning prescription booklets"
62512247|NCT05644886|NO_INTERVENTION|Control Arm|the providers in the control group will continue to provide their services as usual with no exposure to intervention activities. After the end of the intervention period, providers that fall into control areas will be provided the same training.
62512248|NCT04368234||COVID-19 Patients|Any Duke patient that is being treated for COVID-19.
62512249|NCT04831138|EXPERIMENTAL|RCC Patients|Patients with locally advanced or metastatic renal cell carcinoma
62512250|NCT03389256|EXPERIMENTAL|apatinib combine with EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
62512251|NCT03389256|ACTIVE_COMPARATOR|EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
62512252|NCT01032460|ACTIVE_COMPARATOR|macintosh|
62512253|NCT01032460|ACTIVE_COMPARATOR|C-MAC|
62512254|NCT01032460|ACTIVE_COMPARATOR|Airtraq|
62512255|NCT02963584|EXPERIMENTAL|intervention group|Patients in this group will receive CTO Choice (decision aid).
62512256|NCT02963584|NO_INTERVENTION|control group|Patients in this group will receive usual primary care.
62512257|NCT01362426||001|paliperidone palmitate Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
62512258|NCT05227131|EXPERIMENTAL|Margetuximab + Tucatinib + Capecitabine|All eligible patients will receive the combination of margetuximab 15 mg/kg by intravenous infusion on Day 1 of each cycle (no loading dose is required), capecitabine at 1000 mg per square meter of body-surface area orally twice daily on days 1 to 14 of each 21-day cycle, and tucatinib 300 mg orally twice daily (every 12 hours) continuously in 21-day cycles.
62512259|NCT06461117|NO_INTERVENTION|Pre-Intervention|"In order to determine their standard performance in the first stage before the intervention, the swimmers were subjected to the 8x100 m freestyle maximum effort swimming test at 07:00 on Saturday morning without drinking any beverages. The sets were performed in 2 minutes, and the performance times for each 100-meter run were recorded with a stopwatch. At the end of the 8x100 meter test, the blood lactate values of the swimmers were measured 1 minute later with the Lactate Pro 2 analyzer. Additionally, the Borg Fatigue scale was administered to each swimmer after lactate measurement to measure fatigue levels. After the end of the test, placebo drinks were distributed to the swimmers for the second phase.~No information was given about whether the drinks given to the swimmers were beet juice or placebo. The swimmers participating in the study were doing double training three days a week and single training on the other days except Sunday."
62512260|NCT06461117|PLACEBO_COMPARATOR|Placebo Intervention|In the second stage of the research, swimmers were subjected to the 8x100 m freestyle maximum effort swimming test on the same day and time of the week after consuming a placebo drink. The swimmers' blood lactate values and fatigue scale were reapplied using the same procedure. After the analysis of the results of the placebo intervention, beetroot juice drinks were distributed to the swimmers to be used in the third stage. Swimmers were asked to consume 2x250 ml of beet juice on weekdays and 1x250 ml on Saturdays before the performance test. Swimmers consumed beetroot juice 2.5 hours before training on double training days. On single training days during the week, the patient was asked to consume 2x250 ml of beetroot juice at similar times to other days.
62512261|NCT06461117|ACTIVE_COMPARATOR|Beetroot Juice Intervention|In the third and final stage of the study, the 8x100 meter freestyle maximum effort performance test, blood lactate test, and Borg scale were repeated to make final evaluations of beet juice consumption on the same day and time, and the study was concluded.
62708669|NCT04116684|EXPERIMENTAL|Intervention Group (digital BP monitoring)|This group will receive a Withings digital BP monitor to transmit recordings to the study team who will make medication adjustments.
62512262|NCT05450484|EXPERIMENTAL|Durvalumab-680LT|
62512263|NCT04412486|EXPERIMENTAL|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Transfusion of COVID-19 convalescent plasma to participants with serious or life threatening complications from COVID-19 or are at high risk to develop serious complications.
62512264|NCT03153787|EXPERIMENTAL|Not pregnancy|Vaginal probiotic administration
62512265|NCT03973099|EXPERIMENTAL|Placebo|Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
62708670|NCT04116684|NO_INTERVENTION|Standard of care BP monitoring|This group will use a standard BP cuff and record and transmit data to their medical team as instructed by their providers or if they are concerned.
62708671|NCT01983111|EXPERIMENTAL|buprenorphine|Patch
62708672|NCT01983111|ACTIVE_COMPARATOR|tramadol/acetaminophen|Oral tablet
62708673|NCT01280968|EXPERIMENTAL|NIC002 Vaccine in Aluminum hydroxide|4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
61972327|NCT02999854|ACTIVE_COMPARATOR|PTCy|T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
61972328|NCT01014650|PLACEBO_COMPARATOR|IV normal saline|Single IV dose of normal saline as a control for safety and tolerability observations
61972329|NCT01014650|EXPERIMENTAL|IV GLYX-13|Single IV dose of GLYX-13
61972330|NCT01014650|EXPERIMENTAL|SC GLYX-13|Single SC dose
62708674|NCT01280968|PLACEBO_COMPARATOR|Placebo Vaccine - Aluminum hydroxide|4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
62708675|NCT02128022|EXPERIMENTAL|GLP-1 (7-36) amide and Glibenclamide|Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
62708676|NCT02128022|EXPERIMENTAL|Glibenclamide alone|Glibenclamide 5 mg orally prior to PCI
62708677|NCT02128022|ACTIVE_COMPARATOR|GLP-1 (7-36) amide|GLP-1 (7-36) amide
61972331|NCT03171129|EXPERIMENTAL|High flow nasal cannula system w/ ADINA|The intervention is the insertion of the the ADINA device into the high flow nasal cannula system. ADINA will be placed according to weight class recommendations to increase the positive end expiratory pressure (PEEP). ADINA is actually a combination of the Neotech RAM Cannula and a clear Regulator/Pop off valve.
62512266|NCT03973099|EXPERIMENTAL|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner.
61972332|NCT03171129|ACTIVE_COMPARATOR|high flow nasal cannula system|High flow nasal cannula will deliver oxygen at 2-4 lpm of flow. High flow cannula are used to provide the control interface.
61972333|NCT02703584|EXPERIMENTAL|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
61972334|NCT02703584|PLACEBO_COMPARATOR|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
61972335|NCT01379547|ACTIVE_COMPARATOR|Conventional Treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice
62708678|NCT02128022|NO_INTERVENTION|Saline control|0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)
62708679|NCT02983409||Pstone|Adult Patients (\> 18years) who were diagnosed as the urinary stone in the ED. All patients who visited the ED with compalin of acute pain, and urinary stone was idenfied by urinary CT in the ED.
61972336|NCT01379547|EXPERIMENTAL|procalcitonin-guided antibiotics treatment|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.
62512267|NCT00021216|EXPERIMENTAL|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62512268|NCT02000531|EXPERIMENTAL|Erlotinib-Chemotherapy|Erlotinib in first-line treatment, followed by chemotherapy in the second-line treatment
62708680|NCT01533545|ACTIVE_COMPARATOR|Plain mepivacaine|
62512269|NCT02000531|ACTIVE_COMPARATOR|Chemotherapy-Erlotinib|Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment
62512270|NCT05981287|EXPERIMENTAL|Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy|The experimental group undergo conventional physical therapy and additional task-oriented activities based on NDT (TOT-NDT) principle 10 - 36 sessions in 5-8 weeks, 2 to 6 days per sessions.
62708681|NCT01533545|ACTIVE_COMPARATOR|Mepivacaine with epinephrine|
61972337|NCT03516591|EXPERIMENTAL|Dose Escalation (3+3 design)|A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level. AMV564 will be tested as a 14-Day CIV regimen (14-Day Continuous Intravenous Infusion Regimen).
61972338|NCT03516591|EXPERIMENTAL|Dose Expansion|Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.
61972339|NCT00736723||Patients non-septic shock|Postoperative/posttraumatic critically ill patients with non-septic shock
61972340|NCT00736723||Patients septic shock|Postoperative/posttraumatic critically ill patients with septic shock
61972341|NCT05814978|EXPERIMENTAL|Experimental Scapular Therapeutic Exercise Group|Patients in this group will perform therapeutic exercises, recommended for subjects with shoulder pain and focusing the neuromuscular control, stretching and/or strengthening of the scapular muscles
61972342|NCT04806854|EXPERIMENTAL|LUM-201 (1.6 mg/kg/day)|
61972343|NCT04806854|EXPERIMENTAL|LUM-201 (3.2 mg/kg/day)|
61972344|NCT03729856|EXPERIMENTAL|B5 week,intervention,follow-up|Participants will undertake their usual activities for the 5 week baseline period. Participants will begin the 16 week intervention period at week 6 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 22, participants will have no contact with intervention personnel during the 5 week follow-up period.
62512271|NCT05981287|ACTIVE_COMPARATOR|Gross motor task training and Conventional physical therapy (CPT)|This group will receive conventional physical therapy and additional gross motor task training 10-36 sessions in 5-8 weeks, 2 to 6 days per sessions.
62512272|NCT06330350||Keratinisation disorders|Keratinisation disorders comprise a heterogeneous group characterised by abnormal epidermal differentiation, such as variants of ichthyosis and palmoplantar keratoderma.
62708682|NCT00893802|EXPERIMENTAL|Periodontal treatment|Scaling and root planning
62708683|NCT00893802|NO_INTERVENTION|Control|
62708684|NCT06452992||Cases|Children aged 6-11 years old with habitual snoring (≥3 nights per week) and PSG confirmed OSA (OAHI of ≥1/hour)
62708685|NCT06452992||Controls|Age, sex and BMI matched non-OSA control with PSG confirmed absence of OSA (OAHI \< 1 event/h)
62708686|NCT06034626|EXPERIMENTAL|OPL-I|Patients treated with OPL-I with the dual filter system
62708687|NCT06034626|ACTIVE_COMPARATOR|M22|Patients treated with OPL-I with the single filter system
62708688|NCT02148848|ACTIVE_COMPARATOR|Early bisphosphonate use|"Give risedronate (actonel) at 2 weeks after hemiarthroplasty for an osteoporotic femoral neck fracture. In addition, calcium and vitamin D supplementation will be given to all patients.~Risedronate (35 mg) 1 tablet orally once a week"
62708689|NCT02148848|NO_INTERVENTION|Late bisphosphonate use|"Give only calcium and vitamin D supplementation during the first 3 months after the surgery.~Bisphosphonate, risedronate (Actonel), will be given at 3 months after surgery for an osteoporotic femoral neck fracture."
62708690|NCT02456129|EXPERIMENTAL|Vilaprisan + Itraconazole|Vilaprisan (BAY1002670)
62708691|NCT06395558|EXPERIMENTAL|Lifestyle intervention|
62708692|NCT06395558|NO_INTERVENTION|Control|
62512273|NCT06330350||Skin fragility disorders|Skin fragility disorders comprise a group of inherited blistering diseases, such as variants of epidermolysis bullosa.
62512274|NCT06330350||Ectodermal dysplasias|Ectodermal dysplasias consists of multiple inherited disorders that are characterised by abnormalities of the embryonic ectoderm, such as hair, nails, sweat glands or teeth.
62512275|NCT06330350||Dermato-oncogenetic syndromes|This group are genodermatoses associated with the development of malignancies ((non-)cutaneous), such as basal cell nevus syndrome (BCNS), Birt-Hoog-Dubé syndrome, tuberous sclerosis, etc.
62512276|NCT06330350||Other genodermatoses|In this group genodermatoses are listed that do not fit the other groups as mentioned above, for example albinism and cutis laxa.
62512277|NCT06330350||Health care professionals|This group includes clinical geneticists, dermatologists and other clinicians involved in the care of patients with genodermatoses.
62512278|NCT05619159||endometrial carcinoma smples|
62512279|NCT05619159||endometrial hyperplasia samples|
62512280|NCT02390648|EXPERIMENTAL|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
62512281|NCT02390648|PLACEBO_COMPARATOR|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
62512282|NCT04750382|EXPERIMENTAL|HX008+Cisplatin+Gemcitabine|
62512283|NCT02946606|EXPERIMENTAL|Group 1: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
62512284|NCT02946606|EXPERIMENTAL|Group 2: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
62512285|NCT02946606|EXPERIMENTAL|Group 3: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
62512286|NCT03258879|EXPERIMENTAL|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
62512287|NCT03258879|ACTIVE_COMPARATOR|Dural puncture epidural|Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.
62512288|NCT02749760|OTHER|Minor league pitchers|Minor league pitchers from a single professional baseball organization. Strength tests of the elbows will be administered at spring training and end of season for 5 years. If strength correlates to injury, strengthening and exercise programs may be established to target the stabilizers of the elbows.
62512289|NCT05187858|EXPERIMENTAL|LNP3794|Participants will receive LNP3794 orally once daily at different doses in 28 day cycles on a continuous basis
62512290|NCT01904422|EXPERIMENTAL|conventional periodontal treatment|Treatment group by quadrant in five weeks. Patients in this group will receive periodontal treatment including plaque control instructions, supragingival and subgingival debridement and root planing. This treatment is done in 5 sessions with a periodicity of 1 session per week. In the first session patients will receive hygiene instruction and supragingival debridement performed with and ultrasonic device. In the following session, there will be done the scaling and root planing to one quadrant per session, using site specific hand curettes. In case of being partially edentulous patients will be implemented at least 3 teeth per quadrant in each session.
62512291|NCT01904422|EXPERIMENTAL|Intensive periodontal treatment|Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
62512292|NCT03844997|EXPERIMENTAL|Palbociclib + CPX-351|"Palbociclib will be administered orally on day -1 and -2 at 125 mg PO during the phase IIaportion (dose level 0).Day 0 will be rest and then CPX-351 at 100 u/m2 will be started on days 1, 3, and 5 along with Palbociclib day 2, 4, and 6 followed by rest/monitoring period (day 7-28).~If Grade 3-4 non-hematologic toxicity is observed in 1 or less of 6 patients treated, the study will move to Phase IIb. If Grade 3-4 non-hematologic toxicity is observed in 2 or more of 6 patients treated, 6 additional patients will be treated on the Phase IIa portion at a lower dose level (100 mg po) until a Phase IIb safe dose schedule is defined at which 1 or less out of 6 patients on the Phase IIa experience Grade 3-4 non-hematologic toxicity. After the Phase IIa portion ensures safety, the study will proceed with phase IIb. The phase IIb component is a Simon 2-stage design trial whose objective is to assess the clinical efficacy of the combination of Palbociclib and CPX-351."
62512293|NCT03282149|EXPERIMENTAL|Dose 1|Lowest trial dose of XT-150
62708693|NCT00884780||Pediatric Pain|Children between the ages of 8 and 17 experiencing pain.
62708694|NCT02752542|EXPERIMENTAL|Psychotherapy|Cognitive Behavioral Therapy
62708695|NCT02752542|EXPERIMENTAL|Pharmacotherapy|Antidepressant medication
61972345|NCT03729856|EXPERIMENTAL|B8 week,intervention,follow-up|Participants will undertake their usual activities for the 8 week baseline period. Participants will begin the 16 week intervention period at week 9 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 25, participants will have no contact with intervention personnel during the 5 week follow-up period.
61972346|NCT03729856|EXPERIMENTAL|B11 week,intervention,follow-up|Participants will undertake their usual activities for the 11 week baseline period. Participants will begin the 16 week intervention period at week 12 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 28, participants will have no contact with intervention personnel during the 5 week follow-up period.
61972347|NCT04300114|EXPERIMENTAL|Maintenance Fluzoparib monotherapy|
61972348|NCT04300114|PLACEBO_COMPARATOR|Maintenance placebo monotherapy|
61972349|NCT05157854||SH residents|Participants in the AiMH intervention
61972350|NCT05157854||SH staff|Staff in the SH, acting as AiMH supporters
61972351|NCT00162656|ACTIVE_COMPARATOR|Standard LMB B|
61972352|NCT00162656|EXPERIMENTAL|LMB B without COPADM3|
61972353|NCT00162656|EXPERIMENTAL|LMB B with half cyclophosphamide|
61972354|NCT00162656|EXPERIMENTAL|LMB B without COPADM3 and with half cyclophosphamide|
61972355|NCT00162656|ACTIVE_COMPARATOR|LMB C standard|
62512294|NCT03282149|EXPERIMENTAL|Dose 2|Second, escalating dose of XT-150
62512295|NCT03282149|EXPERIMENTAL|Dose 3|Third, escalating dose of XT-150
62512296|NCT03282149|PLACEBO_COMPARATOR|Saline placebo|2 of 8 participants in each cohort will randomly be assigned to placebo
62512297|NCT05220553|EXPERIMENTAL|Prosthesis|Participants will be given the PROLIMB II prosthesis to trial in our lab and in their daily lives
62146820|NCT04907383||Diverticular disease|"All consecutive patients admitted to a Surgical Unit with a diagnosis of left-side colinic diverticulitis will be enrolled in the registry. Patients will be identified through their medical record numbers. One investigator in each center will obtain written informed consent from each patient and keep the patients updated on data collection.~Inclusion criteria: 1) imaging-proven colonic diverticular disease 2) patient aged \> 18 years old; 3) Written informed consent obtained. 4) A colonoscopy showing diverticular disease will be required during the follow-up or before surgical treatment if possible"
62512298|NCT05717270||Prospective group|Acute Achilles tendon Rupture undergoing surgical repair.
62512299|NCT05717270||comparison group|Patients group from a previous trial (NCT04263493).
62512300|NCT00577148|EXPERIMENTAL|Rimonabant|Rimonabant 20 mg once daily.
62512301|NCT00577148|PLACEBO_COMPARATOR|Placebo|Placebo (for Rimonabant) once daily.
62512302|NCT02278718|EXPERIMENTAL|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm\^2 of TBSA for four hours.
62512303|NCT02278718|ACTIVE_COMPARATOR|Standard of Care|Non surgical and Surgical Debridement
62512304|NCT05801302|EXPERIMENTAL|Foam rolling (longer volume)|Participants will perform a single session with a longer foam rolling volume. The protocol will be 3 sets of 60 seconds, with between-sets intervals of 30 seconds and a standardized command to the participant to perform the highest pressure possible. The speed will be controlled through metronome (30 bpm). The foam rolling will be performed with the foam roller placed under the plantar flexors and Achilles tendon in a sitting position, with hands supported to the ground, keeping the body out of contact with the ground, with the unassessed leg crossed above the leg of interest. A standard device (smooth foam roller) with dimensions of 30 cm x 15 cm will be used.
62512305|NCT05801302|ACTIVE_COMPARATOR|Foam rolling (shorter volume)|Participants will perform a single session with a shorter foam rolling volume. The protocol will be 3 sets of 30 seconds, with between-sets intervals of 30 seconds and a standardized command to the participant to perform the highest pressure possible. The speed will be controlled through metronome (30 bpm). The foam rolling will be performed with the foam roller placed under the plantar flexors and Achilles tendon in a sitting position, with hands supported to the ground, keeping the body out of contact with the ground, with the unassessed leg crossed above the leg of interest. A standard device (smooth foam roller) with dimensions of 30 cm x 15 cm will be used.
62512306|NCT05801302|NO_INTERVENTION|Control condition|Participants will remain in the intervention position (in a sitting position, with hands supported to the ground, with the unassessed leg crossed above the leg of interest) for 180 seconds (longer volume time), without the application of any intervention
62512307|NCT05155605|EXPERIMENTAL|Participants 50 years of age or older|The study will aim to enroll a diverse participant population generally representative of the US population with respect to race, ethnicity, and sex. The target age categories of 60-69 years and 70-79 years will be enriched to increase the number of cancer events that are observed during the study.
62512308|NCT00618033|ACTIVE_COMPARATOR|1|
62512309|NCT00618033|ACTIVE_COMPARATOR|2|
61972356|NCT00162656|EXPERIMENTAL|LMB C with mini CYVE and without 3 maintenance courses|
61972357|NCT02523898|EXPERIMENTAL|metformine and clomiphene citrate|. metformin will be given at a dose of 500 mg three times a day for 8weeks. .In case of failure of ovulation after the end of this period, metformin was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene. When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose.
62353019|NCT03963804||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
62353020|NCT03963804||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
62353021|NCT05720273|EXPERIMENTAL|Palicalcitol|Maintenance hemodialysis patients with secondary hyperparathyroidism (SHPT) treat with palicalcitol
62512310|NCT01652976|EXPERIMENTAL|Treatment Arm|Dasatinib and mFOLFOX6
62512311|NCT05896215|EXPERIMENTAL|Low dose group|Topical administration of low dose of KPN2002
62512312|NCT05896215|EXPERIMENTAL|Middle dose group|Topical administration of middle dose of KPN2002
62512313|NCT05896215|EXPERIMENTAL|High dose group|Topical administration of high dose of KPN2002
62512314|NCT05896215|PLACEBO_COMPARATOR|Placebo group|Topical administration of placebo
62512315|NCT04500548|EXPERIMENTAL|Dose level -1 (nivolumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.~PART II: Patients receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
62512316|NCT04500548|EXPERIMENTAL|Dose level 1 (nivolumab, ipilimumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.~PART II: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
62708696|NCT06116097|EXPERIMENTAL|Nutrition education intervention group|Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
62708697|NCT06116097|NO_INTERVENTION|Control group|Control group has not taken any nutrition education but has been filled all of the questionnaires, acitivity logs and food diaries.
62708698|NCT02378480|EXPERIMENTAL|Omadacycline|Omadacycline IV; Omadacycline tablets
62708699|NCT02378480|ACTIVE_COMPARATOR|Linezolid|Linezolid IV; Linezolid tablets
62708700|NCT06008444||Post-COVID-19 group|This group will consist of individuals with Parkinson disease who have had COVID-19.
62708701|NCT06008444||Control group|The control group will consist of individuals with Parkinson disease without post-COVID-19.
62708702|NCT03396159|EXPERIMENTAL|mini fluid challenge|mini fluid will be given and stroke volume will be assessed before and after
62708703|NCT02499887|ACTIVE_COMPARATOR|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
62708704|NCT02499887|EXPERIMENTAL|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
61972358|NCT02523898|ACTIVE_COMPARATOR|placebo and clomiphene citrate|"The patients in group two will be receiving placebo. In case of failure of ovulation after the end of this period, placebo was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration .In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene.When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose. .~10 days). ."
61972359|NCT04772755|NO_INTERVENTION|Usual Care|Participants received usual care that followed administration of a vaccine and a 20 minute post vaccination observation period.
61972360|NCT04772755|EXPERIMENTAL|Buzzy ® and Electronic Game|Buzzy® was applied to the arm receiving vaccination for 30-60 seconds prior to vaccination and removed following vaccination. For the electronic game, participants were instructed to select a game from a prepopulated list of games on a tablet provided by the study team and then played that game for a specified amount of time before, during and after the vaccination administration.
62708705|NCT02001519|EXPERIMENTAL|adriamycin,cytoxan, cisplatin|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks
62708706|NCT02874092|ACTIVE_COMPARATOR|Rheumatoid Arthritis|-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks
61972361|NCT04334629|NO_INTERVENTION|Standard of care|
62146821|NCT00614614|EXPERIMENTAL|Menhibrix 1 Group|Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) \[Nimenrix 1 Group\] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) \[Menhibrix 2 Group\], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) \[Nimenrix 2 Group\].
62708707|NCT02874092|ACTIVE_COMPARATOR|Osteoarthritis|-Diagnosis of osteoarthritis made by physician.
62708708|NCT04336189|ACTIVE_COMPARATOR|SP + DP placebo every 4 weeks|
62708709|NCT04336189|ACTIVE_COMPARATOR|DP + SP placebo every 4 weeks|
62708710|NCT04336189|ACTIVE_COMPARATOR|SP + DP given every 4 weeks|
62708711|NCT02257320|OTHER|Feasibility|Assessing EMG activity with Bruxoff(TM) device
62512317|NCT02592772|EXPERIMENTAL|Reduced Nicotine Non-Menthol (RNC)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine non menthol cigarettes (RNC: NRC 200; 0.07 mg nicotine yield cigarettes without menthol) during the 6 week experimental phase.
62708712|NCT00156195|EXPERIMENTAL|1|
62708713|NCT00156195|EXPERIMENTAL|2|
61972362|NCT04334629|EXPERIMENTAL|Standard of care plus lipid ibuprofen|
61972363|NCT00426855|EXPERIMENTAL|Bendamustine and Bortezomib|Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
61972364|NCT01493570|EXPERIMENTAL|BI 409306 25mg|
61972365|NCT01493570|EXPERIMENTAL|BI 409306 50 mg|
61972366|NCT01493570|EXPERIMENTAL|BI 409306 100 mg|
61972367|NCT01493570|EXPERIMENTAL|BI 409306 200 mg|
61972368|NCT01493570|PLACEBO_COMPARATOR|Placebo|
62708714|NCT04570384|ACTIVE_COMPARATOR|IV L-Citrulline (Turnobi) Arm|Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
62708715|NCT04570384|PLACEBO_COMPARATOR|Placebo Arm|Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
61972369|NCT01027221|NO_INTERVENTION|0|primarily resectable pancreatic cancer patients
61972370|NCT01027221|ACTIVE_COMPARATOR|0,5 Gy|neoadjuvant Radiation of 0,5 Gy two days before resection
61972371|NCT01027221|ACTIVE_COMPARATOR|2 Gy|neoadjuvant Radiation of 2 Gy 2 days before resection
61972372|NCT01027221|ACTIVE_COMPARATOR|5 Gy|neoadjuvant Radiation of 5 Gy 2 days before resection
62146822|NCT00614614|ACTIVE_COMPARATOR|ActHIB- Infanrix Group|Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.
62146823|NCT02697552|EXPERIMENTAL|HBI-8000|HBI-8000 at the assigned dose twice weekly.
62146824|NCT05441293||debridements group|During study peroid, the patient who received debridement surgery for pressure injury
62146825|NCT05441293||flap reconstructions group|During study peroid, the patient who received flap reconstruction surgery for pressure injury
62708716|NCT04856527|EXPERIMENTAL|Experimental Group|Participants will receive physical therapist support to reduce postural sway while completing a precision aiming task in virtual reality, whether or not they require the support.
61972373|NCT02419053||Pre-checklist|Surgical interventions performed for children before the introduction of the surgical safety checklist in Ontario, from October 2008 to September 2009.
61972374|NCT02419053||Post-checklist|Surgical interventions performed for children after the introduction of the surgical safety checklist in Ontario, from October 2010 to September 2011.
62708717|NCT04856527|NO_INTERVENTION|Control Group|Participants will receive no physical therapist support while completing the task.
62146826|NCT02399956||Survivors|"Participants will be recruited from the St. Jude Lifetime Cohort (SJLIFE protocol) and the After Completion of Therapy (ACT) Clinic at St. Jude Children's Research Hospital.~Intervention: Survey"
62146827|NCT02364648|EXPERIMENTAL|MitoQ|4 week 20mg oral daily dose of MitoQ
62708718|NCT06224023||Patients with chronic liver failure and ascites|
62708719|NCT06203223|ACTIVE_COMPARATOR|Ova-max|antioxidant, dietary supplement
62708720|NCT06203223|PLACEBO_COMPARATOR|Placebo|placebo
62708721|NCT02327377|EXPERIMENTAL|Online Cognitive Behavior Therapy|Online cognitive behavior therapy for coping with pain
62708722|NCT02327377|ACTIVE_COMPARATOR|Online Education|Educational information about pain
62708723|NCT04858373|EXPERIMENTAL|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62708724|NCT04858373|EXPERIMENTAL|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62708725|NCT04858373|EXPERIMENTAL|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62146828|NCT02364648|PLACEBO_COMPARATOR|Placebo|4 week 20mg oral daily placebo
62146829|NCT03485105||CTX-benefit group|CTX-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will be beneficial from adjuvant chemotherapy
62146830|NCT03485105||no-benefit group|no-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will not be beneficial from adjuvant chemotherapy
62146831|NCT03485105||high-risk group|high-risk group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, the prognosis of this group will be worse compared to others regardless of the response to adjuvant chemotherapy
62146832|NCT05641857||Low back pain and disc degeneration among elite cross-country skiers|No intervention Interview, clinical examination and MRI
62146833|NCT05641857||Low back pain and disc degeneration among healthy volunteers|No intervention Interview, clinical examination and MRI
62146834|NCT06389266|ACTIVE_COMPARATOR|L DLPFC-Targeted iTBS, Then DMN-Targeted cTBS|Participants will first receive intermittent theta burst stimulation (iTBS) at 100% active motor threshold (AMT) anatomically targeted to the left dorsolateral prefrontal cortex for five consecutive days. iTBS will be administered in a pattern consisting of 2s trains of 3 pulses at 50Hz, repeated at 5Hz, every 10s for a total of 600 pulses. There will then be a washout period of at least two weeks before starting the DMN-Targeted cTBS. Participants will then receive continuous theta burst stimulation (cTBS) at 100% AMT targeted to an individual-specific map of the left parietal node of the default mode network for five consecutive days. cTBS will be administered in a pattern consisting of 1 60s train of 3 pulses at 50Hz, repeated at 5Hz, for a total of 600 pulses.
62353022|NCT01605383|EXPERIMENTAL|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head"
62353023|NCT01605383|SHAM_COMPARATOR|Standard Treatment|Isolated core decompression
62353024|NCT00505752|EXPERIMENTAL|AS900672-Enriched 50 mcg|
61972375|NCT01031732|EXPERIMENTAL|Two-incision|MIS-2 THA
62353025|NCT00505752|EXPERIMENTAL|AS900672-Enriched 100 mcg|
62353026|NCT00505752|EXPERIMENTAL|AS900672-Enriched 150 mcg|
62353027|NCT00505752|ACTIVE_COMPARATOR|Follitropin alfa 150 IU|
61972376|NCT01031732|EXPERIMENTAL|Watson-Jones|MIS-WJ
61972377|NCT01031732|EXPERIMENTAL|MIS-AL|
61972378|NCT01031732|EXPERIMENTAL|MIS-PL|
61972379|NCT00459667|EXPERIMENTAL|IFNB-1b 500 mcg|Interferon beta 1b (\[IFNB 1b\] Betaseron) 500 mcg administered s.c. every other day (double blind)
61972380|NCT00459667|EXPERIMENTAL|IFNB-1b 250 mcg|Interferon beta 1b (\[IFNB 1b\] Betaseron) 250 mcg administered s.c. every other day (double blind)
62146835|NCT06389266|ACTIVE_COMPARATOR|DMN-Targeted cTBS, Then L DLPFC-Targeted iTBS|Participants will first receive continuous theta burst stimulation (cTBS) at 100% AMT targeted to an individual-specific map of the left parietal node of the default mode network for five consecutive days. cTBS will be administered in a pattern consisting of 1 60s train of 3 pulses at 50Hz, repeated at 5Hz, for a total of 600 pulses. There will then be a washout period of at least two weeks before starting the L DLPFC-Targeted iTBS. Participants will receive intermittent theta burst stimulation (iTBS) at 100% active motor threshold (AMT) anatomically targeted to the left dorsolateral prefrontal cortex for five consecutive days. iTBS will be administered in a pattern consisting of 2s trains of 3 pulses at 50Hz, repeated at 5Hz, every 10s for a total of 600 pulses.
62146836|NCT03673618|EXPERIMENTAL|PROMOTIR soluble corn fiber|Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
62512318|NCT02592772|EXPERIMENTAL|Reduced Nicotine Menthol (RNC-Men)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine menthol cigarettes (RNC-Men: NRC 201; 0.07 mg reduced nicotine content menthol cigarettes) during the 6 week experimental phase.
62512319|NCT02592772|EXPERIMENTAL|Conventional Nicotine Non-Menthol (CN)|Study participants will be randomized from their own brand of menthol cigarettes to the regular/conventional nicotine non menthol cigarettes (CN: NRC 600; 0.8 mg nicotine content) during the 6 week experimental phase.
62512320|NCT03994367|NO_INTERVENTION|Standard protein (control)|
62512321|NCT03994367|EXPERIMENTAL|High animal protein isolate|
62512322|NCT03994367|EXPERIMENTAL|High animal protein whole food|
62708726|NCT04858373|EXPERIMENTAL|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62708727|NCT02881827|ACTIVE_COMPARATOR|Infrared Laser|Using a laser in the infrared wave spectrum (780 nm)
62708728|NCT02881827|ACTIVE_COMPARATOR|Red Laser|Using laser red wave spectrum (662 nm)
62708729|NCT02881827|PLACEBO_COMPARATOR|Placebo|Simulation of treatment with the device switched off
62708730|NCT02881827|ACTIVE_COMPARATOR|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two ( statistically ) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug , which serves to prevent bias and isolating effects of such drugs."
62708731|NCT04597749|EXPERIMENTAL|Concurrent PSG, HSAT, and Screener App Test|Participants will undergo a single night baseline PSG test with concurrent HSAT tests as well as non-contact screening mobile apps through a smartphone.
62708732|NCT05958602|EXPERIMENTAL|Technology|The interventional group will receive a standard, evidence-based DSMES curriculum and supplemental diabetes education-related technology to assess an improvement in participation, retention, engagement, and clinical outcomes (HbA1C).
62512323|NCT03994367|EXPERIMENTAL|High plant protein isolate|
62512324|NCT03994367|EXPERIMENTAL|High plant protein whole food|
61972381|NCT00459667|EXPERIMENTAL|IFNB-1b 250 mcg*|"Interferon beta 1b (\[IFNB 1b\] Betaseron) 250 mcg administered s.c. every other day~\*(Subjects who were administered Copaxone and subjects who had prematurely discontinued medication during BEYOND study.)"
61972382|NCT00139399|ACTIVE_COMPARATOR|Saphenous vein|Saphenous vein aortocoronary bypass graft
61972383|NCT00139399|EXPERIMENTAL|Radial artery|Radial artery aortocoronary bypass graft
61972384|NCT01149824|OTHER|Dose Escalating|
62512325|NCT06193031|EXPERIMENTAL|Cohort 1: Tyvaso®+C16TR Dose A or Tyvaso®+Placebo|Participants received a single dose of Tyvaso® on Day 1, then randomized to receive either a single dose of C16TR for inhalation (Dose A) or matching placebo on Day 2 in Cohort 1.
62512326|NCT06193031|EXPERIMENTAL|Cohort 2: C16TR Dose B or Placebo|Participants were randomized to receive a single dose of C16TR for inhalation (Dose B) or matching placebo on Day 1 in Cohort 2.
62512327|NCT06193031|EXPERIMENTAL|Cohort 3: C16TR Dose C or Placebo|Participants were randomized to receive a single dose of C16TR for inhalation (Dose C) or matching placebo on Day 1 in Cohort 3.
62512328|NCT03803111|EXPERIMENTAL|Initial FCM|Intravenous iron supplementation with FCM, subsequent (after 2 months) exercise training program
62512329|NCT03803111|EXPERIMENTAL|Initial exercise|Exercise training program, subsequent (after 2 months) intravenous iron supplementation with FCM
62512330|NCT01419899|EXPERIMENTAL|Brief Intervention|This arm of the study will receive an assessments survey followed by a brief intervention concerning the relationship between the participants use of drugs and/or sexual risk and rik for HIV and hepatitis C infections. Following the intervention the participants will be offered free rapid testing for HIV and hepatitis C.
61972385|NCT01407640|EXPERIMENTAL|1|Allergy tests
61972386|NCT01122836|EXPERIMENTAL|Massage Dose 1|This arm receives weekly 60-minute massage for 4 weeks after a 4-week period of no treatment.
61972387|NCT01122836|EXPERIMENTAL|Massage - Dose 2|This arm receives weekly 60-minute massage for 4 weeks.
61972388|NCT01122836|EXPERIMENTAL|Massage - Dose 3|This arm receives 2 weekly 30-minute massage for 4 weeks.
61972389|NCT01122836|EXPERIMENTAL|Massage - Dose 4|This arm receives 2 weekly 60-minute massages for 4 weeks.
61972390|NCT01122836|EXPERIMENTAL|Massage - Dose 5|This arm receives 3 weekly 30-minute massages for 4 weeks.
61972391|NCT01122836|EXPERIMENTAL|Massage - Dose 6|This arm receives 3 weekly 60-minute massages for 4 weeks.
61972392|NCT01128257||1|
61972393|NCT01128257||2|
62708733|NCT05958602|ACTIVE_COMPARATOR|Standard DSMES Only|The control group will receive a standard, evidence-based DSMES curriculum only to assess an improvement in participation, retention, engagement and clinical outcomes (HbA1C)
62708734|NCT05958602|ACTIVE_COMPARATOR|Traditional DSMES Recruitment Methods|The traditional DSMES recruitment method participants will be recruited using traditional methods such as flyers, word of mouth, and media ads to assess the effectiveness of traditional methods on recruiting and enrollment into to pharmacist-led DSMES programs.
62708735|NCT05958602|EXPERIMENTAL|CHW-Led DSMES Recruitment Methods|The CHW-led DSMES recruitment model participants will be recruited utilizing a CHW-led, multidirectional recruitment process involving community health workers (CHWs), primary care physicians, and community pharmacists to assess the effectiveness of a multidirectional recruitment process into pharmacist-led DSMES programs.
62708736|NCT05571293|EXPERIMENTAL|Cohort A: Botensilimab and balstilimab (bot/bal)|Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. Two doses of balstilimab (240 mg IV), will be administered approximately 2 weeks apart. A single dose of botensilimab (75 mg IV) will be administered on the same day as the first dose of balstilimab. Surgical resection will occur 1-6 weeks following the second dose of balstilimab.
62708737|NCT05571293|EXPERIMENTAL|Cohort B:|Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. Four doses of balstilimab (240 mg IV), will be administered approximately 2 weeks apart. A single dose of botensilimab (75 mg IV) will be administered on the same day as the first dose of balstilimab. Surgical resection will occur 1-6 weeks following the fourth dose of balstilimab.
61972394|NCT05491954||Euglycemic|Women who pass a 50g GCT with 1-hour glucose \<135 mg/dL
62146837|NCT03673618|PLACEBO_COMPARATOR|Malodextrin|Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
62146838|NCT05889494|EXPERIMENTAL|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal prior to cardiopulmonary bypass (CPB) with re-transfusion following weaning from CPB.
62146839|NCT05889494|ACTIVE_COMPARATOR|Allogenic and Derivative Transfusion|Control arm participants will receive standard care involving transfusion of plasma, platelets, cryoprecipitate, and/or lyophilized concentrates following weaning from CPB.
62146840|NCT00647075|EXPERIMENTAL|1|Yunzhi extract 3.5 g/day
62146841|NCT00647075|PLACEBO_COMPARATOR|2|Placebo
62146842|NCT03617575|PLACEBO_COMPARATOR|apo-Lactoferrin|unsaturated (= no iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal A1
62146843|NCT03617575|PLACEBO_COMPARATOR|holo-Lactoferrin|saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal B1
62146844|NCT03617575|PLACEBO_COMPARATOR|FeSO4|Ferrous sulfate = FeSO4 acting as the reference Test Meal C1
62708738|NCT05571293|EXPERIMENTAL|Cohort C:|Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. Four doses of balstilimab (240 mg IV), will be administered approximately 2 weeks apart. A single dose of botensilimab (75 mg IV) will be administered on the same day as the first dose of balstilimab. Surgical resection will occur 1-6 weeks following the fourth dose of balstilimab. Cohort C only includes patients with dMMR/MSI-High colorectal cancer.
62708739|NCT03217617|EXPERIMENTAL|Single arm|In vivo LV gene transfer to treat SCID-X1
62512331|NCT01419899|NO_INTERVENTION|Standard Care|This arm of the study will receive an assessments survey. Following the assessment the participants will be offered free rapid testing for HIV and hepatitis C.
62708740|NCT00890500|ACTIVE_COMPARATOR|Group 1|2 umbilical cord units: Second cord blood unit modulated with ProHema
62708741|NCT00890500|ACTIVE_COMPARATOR|Group 2|2 umbilical cord units: First cord blood unit modulated with ProHema
62708742|NCT04829513|ACTIVE_COMPARATOR|Home Exercise|The group will be given a home exercise programme involving flexibility and strengthening of the lower back, hip girdle and sacroiliac region.
62146845|NCT03617575|PLACEBO_COMPARATOR|1. FeSO4|Ferrous sulfate = FeSO4 Test Meal A2
62512332|NCT05589038|EXPERIMENTAL|Baby Wash/Shampoo|Parent participant will bathe the baby participants using baby wash/shampoo at least 3 times per week, but no more than once daily, up to 4 weeks.
62708743|NCT04829513|ACTIVE_COMPARATOR|Home Exercise and Ligament Correction Kinesiotaping|In addition to the home exercise program, ligament correction kinesiotaping will be applied to the patients' sacroiliac region.
62708744|NCT04829513|ACTIVE_COMPARATOR|Home Exercise and Lymphatic Correction Kinesiotaping|In addition to the home exercise program, lymphatic correction kinesiotaping will be applied to the patients' sacroiliac region.
62708745|NCT01365455|EXPERIMENTAL|AIN457 150 mg|AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
62708746|NCT01365455|EXPERIMENTAL|AIN457 300 mg|AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
61972395|NCT05491954||Possible glucose intolerance|Women who fail a 50g GCT (1-hour glucose \>135 mg/dL) and have 0/4 abnormal values on a 100g oral glucose tolerance test (OGTT) by Carpenter-Coustan values
61972396|NCT05491954||Confirmed glucose intolerance|Women who fail a 50g GCT (1-hour glucose \>135 mg/dL) and have 1/4 abnormal values on 100g GTT test by Carpenter-Coustan values
61972397|NCT05491954||Gestational Diabetes Mellitus|Women who fail a 50g GCT (1-hour glucose \>135 mg/dL) and have ≥2/4 abnormal values on 100g GTT test by Carpenter-Coustan values (Table 1), meeting criteria for GDM
62146846|NCT03617575|PLACEBO_COMPARATOR|FeSO4 after 1 day break|Ferrous sulfate = FeSO4 Test Meal B2
62146847|NCT03617575|PLACEBO_COMPARATOR|FeSO4 after 2 day break|Ferrous sulfate = FeSO4 Test Meal C2
62146848|NCT04834804|EXPERIMENTAL|Suspension training group|
62146849|NCT04834804|EXPERIMENTAL|Free weight training group|
62146850|NCT04834804|NO_INTERVENTION|Control group|
62353028|NCT05812937||Women with suspicion of deep bowel endometriosis|Women with suspicion of deep bowel endometriosis undergoing intraoperative ultrasound to assess its diagnostic value for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
61972398|NCT02999945|ACTIVE_COMPARATOR|SGA-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)
61972399|NCT02999945|OTHER|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
62708747|NCT01365455|PLACEBO_COMPARATOR|placebo|placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
62708748|NCT01365455|EXPERIMENTAL|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
62708749|NCT01365455|EXPERIMENTAL|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
62708750|NCT05026164|ACTIVE_COMPARATOR|Active|CHI-202. Participants will drink one 7.0g CHI-202 powder sachet mixed into 16oz of water twice daily.
62146851|NCT05405244|OTHER|Bromocriptine, then Placebo|During the first intervention visit, participants receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Following a 2-week washout period, participants return for the second intervention visit, where they receive 2 capsules of placebo (sugar free calcium supplement) matched in shape (circle) and color (white) to bromocriptine. Both bromocriptine and placebo are administered orally.
62146852|NCT05405244|OTHER|Placebo, then Bromocriptine|During the first intervention visit, participants receive 2 capsules of placebo (sugar free calcium supplement). Following a 2-week washout period, participants return for the second intervention visit, where they receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Both bromocriptine and placebo are administered orally.
62708751|NCT05026164|PLACEBO_COMPARATOR|Placebo|CHI-101. Participants will drink one 7.0g CHI-101 powder sachet mixed into 16oz of water twice daily.
62708752|NCT02390076|ACTIVE_COMPARATOR|Left active LLLT|Active LLLT targeting the left forehead Attention Bias Modification Left low level light therapy
62708753|NCT02390076|ACTIVE_COMPARATOR|Right active LLLT|Active LLLT targeting the right forehead Attention Bias Modification Right low level light therapy
62708754|NCT02390076|SHAM_COMPARATOR|Sham LLLT|Sham LLLT targeting the right forehead Attention Bias Modification Sham low level light therapy
62708755|NCT00970398|NO_INTERVENTION|Reference group|Human milk breastfeeding
62708756|NCT00970398|ACTIVE_COMPARATOR|Control formula|Standard infant formula, with no Osteopontin supplemented.
62708757|NCT00970398|ACTIVE_COMPARATOR|Formula with 50% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.
62512333|NCT05589038|EXPERIMENTAL|Baby Wash/Shampoo + Baby Lotion|Parent participant will bathe the baby participants using baby wash/shampoo at least 3 times per week, but no more than once daily, and apply lotion at least once daily after bathing, for 4 weeks.
62708758|NCT00970398|ACTIVE_COMPARATOR|Formula with 100% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.
62708759|NCT05269186|EXPERIMENTAL|Virtual reality|Virtual reality session performed before the planning CT scan
62708760|NCT05269186|NO_INTERVENTION|Normal care|Normal care without intervention
62708761|NCT02212860|EXPERIMENTAL|Single Fraction|Stereotactic neoadjuvant ablative radiation give in one single dose of 21 Gy. Lumpectomy to follow within 14-20 from radiation treatment date.
62708762|NCT02212860|EXPERIMENTAL|Three Fractions|Stereotactic neoadjuvant ablative radiation give in three doses of 10 Gy (30 Gy given in 3 fractions, one treatment every second business day). Lumpectomy to follow within 14-20 days from last radiation treatment.
61972400|NCT02999945|ACTIVE_COMPARATOR|IUGR-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
62146853|NCT02730091|ACTIVE_COMPARATOR|Letrozole or anastrozole|Letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
61972401|NCT02999945|OTHER|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
61972402|NCT04208620|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously
62353029|NCT01545024||DPP-IV inhibitor|
62708763|NCT06032611|EXPERIMENTAL|Intervention|Participants will complete a number of cognitive and fine motor tests on a touch-sensitive tablet. They will also be asked to complete a questionnaire on their habits and medical history. They will also be asked to wear a smartwatch for 7 days.
62708764|NCT01836354|ACTIVE_COMPARATOR|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
62708765|NCT01836354|NO_INTERVENTION|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
62708766|NCT05638113|ACTIVE_COMPARATOR|Blood pleurodesis|
62708767|NCT05638113|NO_INTERVENTION|Simple chest drainage (chest tube)|
62708768|NCT01318681|EXPERIMENTAL|Pollen provocation with systemic treatment|Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution
62708769|NCT01318681|EXPERIMENTAL|Pollen provocation with topical treatment|treatment with 25ug fluticasone furoate after a nasal pollen challenge
62708770|NCT01318681|PLACEBO_COMPARATOR|placebo treatment after pollen challenge|Placebo treatment after a nasal challenge with pollen solution
61972403|NCT04208620|EXPERIMENTAL|Cotadutide|Cotadutide administered subcutaneously
62708771|NCT01318681|NO_INTERVENTION|control condition|A placebo drug is administered after a sham nasal challenge with a pollen solution
62708772|NCT04041193|EXPERIMENTAL|SIDERA^B|Behavioral: telerehabilitation activities Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) 5 sessions/week of an individualized telerehabilitation program at home. The sessions will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by the therapist weekly. Each patient's performed session will be reviewed by the therapist.
62708773|NCT04041193|ACTIVE_COMPARATOR|usual care|Behavioral: paper and pencil activities as usual rehabilitation at home Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) of a usual rehabilitation program.
61972404|NCT01318304||Pregnant, HIV- negative|This cohort has completed accrual as of 12/28/11.
61972405|NCT01318304||Pregnant, HIV-positive|
62708774|NCT05024084|ACTIVE_COMPARATOR|Group Sevoflurane|The patients in this arm will be given Sevoflurane (2-3%) as volatile anesthetic throughout the duration of anesthesia.
62708775|NCT05024084|ACTIVE_COMPARATOR|Group Desflurane|The patients in this arm will be given Desflurane (7-8%) as volatile anesthetic throughout the duration of anesthesia.
62708776|NCT01297855|ACTIVE_COMPARATOR|Colistin|Colistate
62708777|NCT01297855|EXPERIMENTAL|Colistin plus Rifampicin|Colistate Rifampin
61972406|NCT01318304||Non-pregnant, HIV-negative|This cohort has completed accrual as of 12/28/11.
62708778|NCT06478862|EXPERIMENTAL|Pancreatic cancer|Eligible subjects with pancreatic cancer will be intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Each cycle may be extended for up to 3 additional weeks (i.e., up to a total of 7 weeks from previous Day 1), if tolerability issues arise.
62708779|NCT06478862|EXPERIMENTAL|Ovarian cancer|Eligible subjects with ovarian cancer will be intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Each cycle may be extended for up to 3 additional weeks (i.e., up to a total of 7 weeks from previous Day 1), if tolerability issues arise.
62708780|NCT04435626|EXPERIMENTAL|Arm 1_BAY94-8862|Adult patients receive BAY94-8862
61972407|NCT01318304||Non-pregnant, HIV-positive|This cohort has completed accrual as of 12/28/11.
61972408|NCT03272490|ACTIVE_COMPARATOR|Medartis|Surgery using the Medartis Implant
61972409|NCT03272490|ACTIVE_COMPARATOR|Synthes|Surgery using the Synthes implant
61972410|NCT02872467|EXPERIMENTAL|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
62146854|NCT02730091|EXPERIMENTAL|Vinorelbine + Anastrozole or letrozole|Oral vinorelbine 50 mg (1 soft capsule of 30 mg and 1 soft capsule of 20 mg) three times a week every ( Monday, Wednesday and Friday) before lunch and letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
61972411|NCT02872467|PLACEBO_COMPARATOR|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
62146855|NCT04269694|NO_INTERVENTION|Control|No dressing applied in the donor site after harvesting the graft
62146856|NCT04269694|EXPERIMENTAL|Test|An antibacterial honey dressing material (Medihoney, http://www.medihoney.com) will be applied to donor site.
62146857|NCT03656198|EXPERIMENTAL|Vaccine group|Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.
62146858|NCT03656198|PLACEBO_COMPARATOR|Control group|The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).
62146859|NCT05230433|EXPERIMENTAL|High-fat Metabolic Challenge|Participants will consume a high-fat agent one time, at the second study visit.
62146860|NCT01929161|EXPERIMENTAL|Oxytocin|Oxytocin intranasal spray, 6 intranasal sufflations which deliver a total of 24 international units of oxytocin
62708781|NCT04435626|PLACEBO_COMPARATOR|Arm 2_Placebo|Adult patients receive placebo
62708782|NCT02635295|EXPERIMENTAL|Mobile cooperation|Nursing student - nurse teacher mobile cooperation during the clinical practicum.
62708783|NCT02635295|NO_INTERVENTION|Standard cooperation|Nursing student - nurse teacher standard cooperation during the clinical practicum.
62708784|NCT02073474||Sativex® users|UK: All patients and who are prescribed Sativex®. Germany and Sweden: Patients who are prescribed Sativex® from selected specialist neurology centres.
62708785|NCT05700409|EXPERIMENTAL|Telemedicine|The telemedicine arm will include 30, mostly video, consultations for each participant: 3 physician appointments, 7 exercise consultations by our exercise physiologist, 10 dietary consultations by our pediatric dietitian, and 10 psychologist consultations to assist with goal setting and overall well-being. Three visits will be conducted in-office, for physician assessment, smartphone technical assistance and physical measurements (baseline, at 3 months and at the end of the 6-month period). Participants randomized to the telemedicine arm will have a step-counting rewarding app installed on their smartphone by our staff.
61972412|NCT04450966|NO_INTERVENTION|Usual Care|Clinicians randomized to this arm will not receive training in delivery of cSBI until study completion, and their participating patients will receive usual care.
61972413|NCT04450966|EXPERIMENTAL|Computer-facilitated screening and brief intervention|Clinicians randomized to this arm will receive training in delivery of cSBI and their participating patients will then receive the experimental intervention.
61976305|NCT04828447|EXPERIMENTAL|High Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet high in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
62146861|NCT01929161|PLACEBO_COMPARATOR|Placebo (for oxytocin)|Intranasal spray with all equivalent ingredients except oxytocin
62146862|NCT01929161|EXPERIMENTAL|Lovingkindness Meditation|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
62146863|NCT01929161|PLACEBO_COMPARATOR|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
62708786|NCT05700409|ACTIVE_COMPARATOR|On-site|The on-site arm will have 6 monthly visits during the study period, with two consultations performed in each visit - one by the physician or exercise physiologist, and one by our pediatric dietitian.
62708787|NCT06561139|EXPERIMENTAL|Intervention: treatment as usual + group mindfulness|Eight-week, weekly group sessions of mindfulness, as an add-on to treatment as usual for problem gambling.
62708788|NCT06561139|ACTIVE_COMPARATOR|Control: treatment as usual + waiting list for two months|Treatment as usual for problem gambling and waiting list for the mindfulness condition for two months, after which subjects are offered to undergo the same intervention as in the intervention group.
62708789|NCT05745714|EXPERIMENTAL|Ruxolitinib + venetoclax + dexamethasone + cyclophosphamide + cytarabine|"Each cycle has 28 days~Cycle 1: All patients will receive 14 days of of ruxolitinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 3) and two blocks of four consecutive days of cytarabine (days 5 to 8 and days 12 to 15). A 1-day venetoclax ramp-up is proposed in this study.~Cycle 2 and subsequent cycles:~All patients will receive 14 days of of ruxolitinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 1) and two blocks of four consecutive days of cytarabine (days 3 to 6 and days 10 to 13).~Patients in dose level -1, will receive a lower dose of venetoclax compared to dose level 1.~Patients in dose level 2, will receive a higher dose of venetoclax compared to dose level 1.~All patients receive age adapted intrathecal chemotherapy."
62708790|NCT03014466|ACTIVE_COMPARATOR|Tablet|Preoperative patients will utilize a video tablet for addressing pre anesthesia anxiety
62353030|NCT02182297|EXPERIMENTAL|BI 201335 NA in single rising doses|
62708791|NCT03014466|EXPERIMENTAL|Video Projector|Preoperative patients will utilize a video projection unit for addressing pre anesthesia anxiety
62353031|NCT02182297|PLACEBO_COMPARATOR|Placebo|
62353032|NCT02378246|EXPERIMENTAL|Tablet with vitamins and minerals, containing 150 ug iodine, 1 tablet daily|"Table of contents:~Vitamin B2 1.4 mg, Vitamin B12 15 µg, Iron 12 mg, Zinc 12 mg, Iodine 150 µg, Selenium 50 µg, Calcium 250 mg"
62708792|NCT06220110|EXPERIMENTAL|Experimental group|Probiotic intake containing 10 billions of Colony Forming Units of Lactobacillus plantarum (1 capsule per day)
62353033|NCT02378246|PLACEBO_COMPARATOR|Placebo: non-iodine containing multivitamin, 1 tablet daily|"Table of contents:~Vitamin A 400 µg, Vitamin B1 1.4 mg, Vitamin B2 1.7 mg, Vitamin B6 1.8 mg, Vitamin B12 3 µg, Vitamin C 60 mg, Vitamin D 5 µg, Vitamin E 10 mg, Niacin 19 mg, Folic acid 200 µg"
62708793|NCT06220110|PLACEBO_COMPARATOR|Placebo group|Placebo intake. Placebo capsules will contain dextrose (1 capsule per day)
62708794|NCT03393104|EXPERIMENTAL|Motor Control Exercise and Patient Education|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise and 4 sessions (1 session per week) of patient education program as described in respective protocol.~In addition, they will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
62708795|NCT03393104|EXPERIMENTAL|Motor Control Exercise|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
62708796|NCT03393104|EXPERIMENTAL|Patient Education|"Participants will receive patient education session once a week at interval of 1-week over 8-weeks (4 sessions). The program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
62708797|NCT03402841|EXPERIMENTAL|Olaparib|"Olaparib will be supplied as film-coated tablets containing 150 mg or 100 mg of olaparib.~Patients will be administered olaparib orally twice daily (bid) at 300 mg."
62146864|NCT03009344|EXPERIMENTAL|Tazemetostat 800 mg|Participants will receive oral tazemetostat at a starting dose of 800 milligrams (mg) as a single dose (Cycle 0) and 800 mg twice a day as continuous dosing (Cycle 1 and later) (Cycle 0 duration=4 days) (Cycle 1 and later duration= 28 days).
62146865|NCT01683669|OTHER|Noisy-PSV 1|different levels of variable pressure support
62146866|NCT01683669|OTHER|Noisy-PSV 2|different levels of variable pressure support
62146867|NCT00774878|EXPERIMENTAL|Arm A|
62353034|NCT05622357|EXPERIMENTAL|Short course RT followed by full course of chemotherapy then surgery|Short course radiation therapy ( 25 Gy/ 5 fractions/ 1 week) , followed by 6 cycles of chemotherapy CAPOX, followed 4-6 weeks by surgery.
62353035|NCT04350905|EXPERIMENTAL|Mosquito Feeding|Each participant will receive one mosquito feeding with 5 starved female Aedes aegypti mosquitoes.
62353036|NCT06044519|EXPERIMENTAL|alginate|
62146868|NCT00774878|ACTIVE_COMPARATOR|Arm B|
62146869|NCT04337593|EXPERIMENTAL|treatment arm|2500 IU/m2 pegaspargase given on day 1, 20 mg basiliximab given on day 1 and 8, repeated every 3 weeks
62353037|NCT06044519|EXPERIMENTAL|film|
62353038|NCT06044519|EXPERIMENTAL|guaze|
62353039|NCT06044519|EXPERIMENTAL|hydrocolloid|
62353040|NCT06044519|EXPERIMENTAL|hydrofiber|
62353041|NCT06044519|EXPERIMENTAL|silicon|
62353042|NCT01606397|PLACEBO_COMPARATOR|Placebo|Placebo administered orally once daily for 4 weeks
62353043|NCT01606397|EXPERIMENTAL|5 mg LY2409021|5 mg LY2409021 administered orally once daily for 4 weeks
62353044|NCT01606397|EXPERIMENTAL|30 mg LY2409021|30 mg LY2409021 administered orally once daily for 4 weeks
62353045|NCT01606397|EXPERIMENTAL|60 mg LY2409021|60 mg LY2409021 administered orally once daily for 4 weeks
62353046|NCT01606397|EXPERIMENTAL|90 mg LY2409021|90 mg LY2409021 administered orally once daily for 4 weeks
62353047|NCT03162458|EXPERIMENTAL|Anaferon for children|
62708798|NCT04622592|EXPERIMENTAL|QVLP15+Full AS03|Participants received one intramuscular (IM) injection (total volume 0.7 mL) of 15 μg/strain of the Quadrivalent virus-like particle (VLP) Influenza Vaccine adjuvanted with full dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
62708799|NCT04622592|EXPERIMENTAL|QVLP15+Half AS03|Participants received one IM injection (total volume 0.7 mL) of 15 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with half dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
62708800|NCT04622592|EXPERIMENTAL|QVLP30+Full AS03|Participants received one IM injection (total volume 0.7 mL) of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with full dose of AS03 on Day 0into the deltoid region of the non-dominant arm (if possible).
62708801|NCT04622592|EXPERIMENTAL|QVLP30+Half AS03|Participants received one IM injection (total volume 0.7 mL) of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with half dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
62708802|NCT04622592|EXPERIMENTAL|QVLP45+Full AS03|Participants received one IM injection (total volume 0.7 mL) of 45 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with full dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
62708803|NCT04622592|EXPERIMENTAL|QVLP45+Half AS03|Participants received one IM injection (total volume 0.7 mL) of 45 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with half dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
62708804|NCT04622592|ACTIVE_COMPARATOR|QVLP30 unadjuvanted|Participants received one IM injection of 0.7 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine unadjuvanted on Day 0 into the deltoid region of the non-dominant arm (if possible).
62708805|NCT04622592|ACTIVE_COMPARATOR|Fluzone HD Quad|Participants received one IM injection of 0.7 mL of 60 μg/strain of the Fluzone high dose (HD) Quadrivalent Influenza Vaccine on Day 0 into the deltoid region of the non-dominant arm (if possible).
62708806|NCT00485173|EXPERIMENTAL|INFUSE® Bone Graft|In this arm, patients will receive implant with INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate.
62708807|NCT01468155|ACTIVE_COMPARATOR|Dabigatran|Dabigatran will be compared to historical data using other OAC methods for Pulmonary Vein Ablation
62708808|NCT01502384||healthy relatives|healthy 1st degree relatives of PD patients
62708809|NCT01778413|EXPERIMENTAL|ATRIPLA three times a week.|Atripla (600 mg/200 mg/245 mg) three times a week.
62708810|NCT01778413|ACTIVE_COMPARATOR|ATRIPLA one time a day.|Atripla (600 mg/200 mg/245 mg) one time a day.
62146870|NCT02105571|EXPERIMENTAL|Intervention|Intervention activities take place over a 6-month period for each participant, and include a weight loss competition with self-monitoring and feedback; computer-based training units on healthy weight loss, healthy eating, exercise, and sleep; and up to four motivational interviews with a health coach by cell phone.
62708811|NCT05933811|EXPERIMENTAL|Pediatric patients with unilateral impalpable maldescended testis|Patients in the pediatric age group who presented by unilateral impalpable undescended testis
62146871|NCT02105571|NO_INTERVENTION|Control|"Continued work conditions and Usual Practices in that workplace"
62353048|NCT03162458|PLACEBO_COMPARATOR|Placebo|
62353049|NCT04420910||Parkinson's disease group|being diagnosed with PD by a neurologist, being in Hoehn \& Yahr Stage 1-3
62353050|NCT04420910||Healthy group|20 healthy volunteers with matching ages and genders.
62353051|NCT04938362||Brain abscess patients with cognitive dysfunction and/or fatigue|This group of patients experience cognitive dysfunction and/or fatigue after brain abscess.
62708812|NCT04204824|EXPERIMENTAL|Ultrasound and exercise|This group will receive ultrasound treatment, strengthening exercises and stretching exercises.
62708813|NCT04204824|ACTIVE_COMPARATOR|Sham Ultrasound and exercise|This group will receive sham ultrasound treatment, strengthening exercises and stretching exercises.
62708814|NCT01098422|EXPERIMENTAL|Yttrium-90 Radioactive Resin Microspheres|Yttrium-90 Radioactive Resin Microspheres
62708815|NCT03836404|EXPERIMENTAL|Iliac Crest reconstruction surgery|The patients in the study group will be surgically treated and the GreenBone bone substitute will be implanted
62708816|NCT05429606||Group 1: Fluoride gel|The fluoride gel used as conductive media for electric pulp tester in this group
62708817|NCT05429606||Group 2:Electrode gel|In Group 2 electrode gel applied as conductive media for electric pulp test.
61972414|NCT05279898|EXPERIMENTAL|Multimodal General Anesthesia (MMGA Bundle) - EEG Guided|"1. Routine anesthetic induction~2. Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.2% ropivacaine on both sides of the sternum after anesthetic induction but before surgical incision (total of 40mL)~3. Ketamine (0.1 to 0.2 mg.kg/hr)~4. Remifentanil (0.05-0.4 mcg/kg/min)~5. Dexmedetomidine (0.2-0.5 mcg/kg/hr)~6. Rocuronium intermittent bolus (TOF)~7. Propofol infusion (15 to 200 mcg/kg/min)~Postop~1. Standard pain management protocol~   * IV Acetaminophen~  * IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~  * Other oral pain medications as per standard of care (Oxycodone, etc)~2. Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~3. Propofol infusion may be added/used for sedation based on the treating physician's discretion~4. PIFB on postoperative day 1 (provided they are extubated/getting ready to be extubated)(for intervention group)~5. Lidocaine patches"
61972415|NCT05279898|NO_INTERVENTION|Standard of Care/Control|"EEG monitoring will be blinded, and not guide anesthesiologists. Patients will receive standard/routine anesthesia practice intraoperatively.~Postoperative Propofol infusion (15 to 200 mcg/kg/min) ± Sevoflurane~1. Standard pain management protocol~   * IV Acetaminophen (1 gram) x 4 doses at 6 hour intervals starting from 1 hr after ICU arrival~  * IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~  * Other oral pain medications as per standard of care (Oxycodone, etc)~2. Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~3. Propofol infusion may be added/used for sedation based on the treating physician's discretion~4. Lidocaine patches~5. Parasternal block (PIFB or Transversus Thoracic Plane Block) on Postoperative day 0 - currently incorporated into standard pain management after surgery based on physician discretion"
62353052|NCT04938362||Brain abscess patients without cognitive dysfunction and/or fatigue|This group of patients does not experience cognitive dysfunction and/or fatigue after brain abscess.
62353053|NCT03934424|EXPERIMENTAL|Weight Stigma|Weight stigma, read a weight stigma article for 5-10 minutes on one day
61972416|NCT06463210|NO_INTERVENTION|Nurse support during hysteroscopy: control group|"In our standard hysteroscopy protocol, all patients are advised to take an Ibuprofen 400-600mg or Paracetamol 650-1000 mg two hours before the procedure. They are also suggested to take Bromazepam 1.5 mg two hours before the procedure if they feel anxious.~As part of our standard procedure during the OH, a trained nurse with \>10 years of experience provides distraction and emotional support to the woman. She explains the patient how to breathe and what to expect during the different moments of the procedure, thus involving the women directly in what is happening during the procedure."
61972417|NCT06463210|EXPERIMENTAL|Virtual reality during hysteroscopy: study group|"In our standard hysteroscopy protocol, all patients are advised to take an Ibuprofen 400-600mg or Paracetamol 650-1000 mg two hours before the procedure. They are also suggested to take Bromazepam 1.5 mg two hours before the procedure if they feel anxious.~A 360º video was administered to the study group through an Oculus Quest 2™ headset (Meta Platforms, CA. USA). The video was administered through the headset just before the start of the procedure. The video chosen showed a gondola ride through the canals of Venice with relaxing music played on the headset"
61972418|NCT00528333|EXPERIMENTAL|1|Lintuzumab plus low dose cytarabine
61972419|NCT00528333|ACTIVE_COMPARATOR|2|Placebo plus low dose cytarabine
61972420|NCT04809207|EXPERIMENTAL|CF Wellness Program|Participants will receive CF Wellness Program sessions.
61972421|NCT02231333|EXPERIMENTAL|S-adenosylmethionine (SAMe)|
62512334|NCT02676284|EXPERIMENTAL|Durolane SJ|single dose injection. One infiltration of the study product in the trapeziometacarpal (TMC) joint. The study treatment contains sodium hyaluronate 20 mg/mL, in a 1 mL prefilled syringe.
62708818|NCT05429606||Group 3: chlorohexidine gluconate gel|chlorohexidine gluconate gel used as conductive media for electric pulp tester in group 3.
62708819|NCT05429606||Group 4:Colgate gel toothpaste|Colgate gel toothpaste gel used as conductive media for electric pulp tester in group 4.
62708820|NCT05429606||Group 5:Dentonic Ultrawhitening gel|Dentonic Ultrawhitening gel used as a conductive media in Group 5.
62708821|NCT02048202||premature neonate|premature neonate
62708822|NCT06571942|EXPERIMENTAL|COPD due to biomass exposure|Vilanterol / Umeclidinium 25/62.5 mcg once daily for three months = ANORO® Fluthicasone / Vilanterol / Umeclidinium 100/25/62.5 mcg once daily for three months = TRELEGY® Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg; two inhalations twice daily for three months = TRIMBOW® Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg; two inhalations twice daily for three months= TRIXEO®
62708823|NCT06571942|EXPERIMENTAL|Chronic bronchitis without obstruction due to biomass exposure|Vilanterol / Umeclidinium 25/62.5 mcg once daily for three months = ANORO® Fluthicasone / Vilanterol / Umeclidinium 100/25/62.5 mcg once daily for three months = TRELEGY® Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg; two inhalations twice daily for three months = TRIMBOW® Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg; two inhalations twice daily for three months= TRIXEO®
62708824|NCT06537791|EXPERIMENTAL|Home-Based Rehabilitation Program|Participants in this arm will receive a multidisciplinary home-based rehabilitation program. The intervention includes 32 sessions of physical therapy, 8 sessions of occupational therapy, 4 sessions of nutrition counseling, 8 sessions of psychological support, and 4 sessions of nursing and podiatry care. Each session lasts 60 minutes, and the total duration of the intervention is approximately 4 months. The program aims to improve motor function, balance, and mood among individuals with moderate neuromusculoskeletal disabilities.
62708825|NCT05358327|EXPERIMENTAL|Upper Arm|
62708826|NCT02260037|EXPERIMENTAL|Epinastine nasal|single rising doses
62708827|NCT02260037|PLACEBO_COMPARATOR|Placebo|
62708828|NCT03279952|OTHER|medication arm|CNS Stimulant
62708829|NCT06460272|EXPERIMENTAL|Medically Tailored Meals+ Shared Medical Appointments (MTMs + SMAs)|Participants will receive 2 meals per day for 7 days a week for a duration of 10 weeks and SMA weekly for 10 weeks. Participants will also have access to bi-monthly fresh produce pantry, where fresh produce will be guaranteed and available to them for pick-up.
62708830|NCT06460272|ACTIVE_COMPARATOR|Medically Tailored Meals (MTMs)|Participants will receive 2 meals per day for 7 days a week for a duration of 10 weeks. Individuals randomized to MTMs will receive electronic educational materials from the MTM + SMA group after the completion of the post-intervention study assessment.
62708831|NCT06460272|OTHER|Medically Tailored Meals - Later (MTM-Later)|Participants will receive 2 meals per day for 7 days a week for a duration of 10 weeks and educational materials (e.g., relevant handouts from the SMA) after the completion of the post intervention study assessment. This group will act as our Waitlist Control group.
62708832|NCT00906061|EXPERIMENTAL|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
62708833|NCT03688971|EXPERIMENTAL|Omiganan Topical Gel|Omiganan 1.75%
62708834|NCT03688971|ACTIVE_COMPARATOR|Ketoconazole Topical Cream|Ketoconazole 2.0%
62708835|NCT03688971|PLACEBO_COMPARATOR|Vehicle|
62708836|NCT04612426|EXPERIMENTAL|Brain-computer Interface-Pedaling Training System|
61972422|NCT02231333|ACTIVE_COMPARATOR|pentoxiphylline (PTX)|
61972423|NCT00179634|NO_INTERVENTION|1|Usual Care
61972424|NCT00179634|EXPERIMENTAL|2|Usual care and exposure to a visually enriched milieu (landscape photograph)
62708837|NCT04612426|SHAM_COMPARATOR|Traditional Pedaling Training System|Patients wear the same EEG equipment that only collect data, but not guide training.
62512335|NCT03647124||Lenalidomide treated Relapsed or refractory mantle cell lymphoma (R/R-MCL) participants in Europe|
62512336|NCT05307406|EXPERIMENTAL|XAB05|Single ascending dose from 0.25 mg/kg up to 20mg/kg IV infusion
62512337|NCT05307406|PLACEBO_COMPARATOR|Placebo|Single IV infusion
62708838|NCT04729790|ACTIVE_COMPARATOR|Patients with RCDI will receive FMT capsules from single donor|"Capsules made with intestinal bacteria from single healthy donor~1. st treatment day, lyophilized product generated from single donor (90g of stool)~2. nd treatment day, lyophilized product generated from single donor (90g of stool)"
62708839|NCT04729790|EXPERIMENTAL|Patient will receive FMT capsules from three donors|"Capsules made of intestinal bacteria from three healthy donors~1. st treatment day, lyophilized product generated from three donors (90g of stool)~2. nd treatment day, lyophilized product generated from three donors (90g of stool)"
62708840|NCT02407119|ACTIVE_COMPARATOR|7 day H.pylori eradication|Treatment: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
62512338|NCT04449224||RA patients who start bDMARD|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a biologic disease modifying antirheumatic drug (bDMARD) including Adalimuab, Etanercept, Tocilizumab or Abatacept after shared-decision making.
62708841|NCT02407119|PLACEBO_COMPARATOR|Placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + Placebo for two antibiotics (clarithromycin and amoxicillin) bid for 7 days
62708842|NCT00749346|EXPERIMENTAL|A|Treatment with concomitant Alimta and NovoTTF-100L
61972425|NCT00179634|EXPERIMENTAL|3|Usual care, exposure to a visually enriched milieu and audio taped guided visualization with healing suggestions.
62353054|NCT03934424|OTHER|Ethnic stigma|Ethnic stigma, read an ethnic stigma article for 5-10 minutes on one day
62353055|NCT05249712|EXPERIMENTAL|ADT with Darolutamide|"Pathological response rate after radical prostatectomy with dalotamide combined with androgen deprivation therapy (ADT) in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer.~Duration of treatment: 28-day cycle of darotamide treatment and 6 cycles of neoadjuvant therapy. ADT treatment continued during neoadjuvant therapy and was discontinued after surgery.~Adjusted dosing: When the serum testosterone concentration cannot be maintained at \<50 ng/dL, the dose and type of ADT can be adjusted. Investigators can adjust the dose of darostatide according to the situation."
62353056|NCT02273037|PLACEBO_COMPARATOR|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
62353057|NCT02273037|EXPERIMENTAL|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
62353058|NCT03595384|EXPERIMENTAL|Soccer-based adaptation to the DPP|Hispanic overweight male participants taking part in a 24 week soccer program as part of diabetes prevention.
62353059|NCT06187948|EXPERIMENTAL|1. group that watches an informative video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
62353060|NCT06187948|NO_INTERVENTION|2. group that does not watch an informative video|this group do not watch an informative video before recruitment
62353061|NCT01684891|EXPERIMENTAL|RG1662|
62353062|NCT05806736|EXPERIMENTAL|active transcutaneous auricular vagus nerve stimulatio|For Experimental Arm, active transcutaneous auricular vagus nerve stimulation, Patients underwent fourteen consecutive daily sessions of taVNS.
62353063|NCT05806736|SHAM_COMPARATOR|sham transcutaneous auricular vagus nerve stimulation|For sham transcutaneous auricular vagus nerve stimulation arm, Sham Comparator, patients underwent fourteen consecutive daily sessions of sham-taVNS (the electrodes were fixed at the left earlobe with the same stimulation parameters).
62353064|NCT03103880|EXPERIMENTAL|BreatheSmart|"104 subjects will be provided with the BreatheSmart platform, which consists of:~1. HeroTracker sensor that monitors real-time asthma medication adherence~2. BreatheSmart mobile application that provides patients with real-time alerts, environmental information (weather, pollution, etc.), and the ability to complete questionnaires / surveys."
62353065|NCT03234400|EXPERIMENTAL|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
62353066|NCT03234400|EXPERIMENTAL|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
62353067|NCT03234400|EXPERIMENTAL|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
62353068|NCT01699295|EXPERIMENTAL|A+PAAC|Lessons delivered using A+PAAC
62353069|NCT01699295|ACTIVE_COMPARATOR|CON|Regular sedentary lessons
62353070|NCT04035629|EXPERIMENTAL|Hyperpolarized 129Xe MRI for lung diagnosis|All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung.
62353071|NCT02087293|EXPERIMENTAL|Intervention group, IVR call, RPh counseling|Group receives interactive voice response automated call asking about side effects of newly prescribed medications; has opportunity to speak with study pharmacist via phone about medication
62353072|NCT02087293|NO_INTERVENTION|Control|Intervention patients are matched with control patients; control patients have only chart review completed.
62353073|NCT03005041|EXPERIMENTAL|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
62353074|NCT03005041|OTHER|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
62353075|NCT02759861|EXPERIMENTAL|Harvoni x 8 or 12 weeks|patient will receive 8 or 12 weeks depending on clinical data
62353076|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
62353077|NCT02521740||controls|someone who lives with an healthy elderly
62353078|NCT00765713|EXPERIMENTAL|CPAP|Continuous positive airway pressure
62353079|NCT00765713|NO_INTERVENTION|Conventional|Hygienic-dietetic recommendations
62353080|NCT04843826|EXPERIMENTAL|delayed implant|"1. Patients 18 years or older.~2. Periodontally and systemically healthy.~3. Sufficient bone width and height for implant placement~4. Adequate mesiodistal width and inter-arch space for placement of a delayed implant.~5. Full mouth plaque index less than 15% (Bentley and Disney, 1995)~6. cooperative patients who will comply to follow up visits"
62512339|NCT04449224||RA patients who start small molecule inhibitor|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a small molecular inhibitor including Tofacitinib or Baricitinib after shared-decision making.
62512340|NCT01796964|EXPERIMENTAL|ESBA1008|ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol
62512341|NCT01796964|ACTIVE_COMPARATOR|EYLEA|Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol
62708843|NCT04052165|EXPERIMENTAL|Glaucoma drainage device in glaucoma patient|GDD is inserted in glaucoma patients
62708844|NCT04840511|EXPERIMENTAL|lidocaine group|The study group receives perioperative lidocaine infusion with general anesthesia for robot-assisted prostatectomy
62708845|NCT04840511|PLACEBO_COMPARATOR|control group|The control group receives normal saline infusion with with general anesthesia for robot-assisted prostatectomy
62512342|NCT05923970||Women with low rubella antibodies|Women with rubella antibodies \<10 IU/mL
62512343|NCT05923970||Women with high rubella antibodies|Women with rubella antibodies ≥10 IU/mL
62512344|NCT02220725|EXPERIMENTAL|Andexanet 800mg bolus (Part I)|Andexanet (antidote) - 800 mg bolus
62512345|NCT02220725|EXPERIMENTAL|Andexanet 800mg + 960mg (Part II)|800 mg bolus + 960 mg infusion (8 mg/min)
62512346|NCT01914172||Online web-based questionnaire|Up to 200 patients with KS/CHH will be recruited to complete an online web-based questionnaire (less than 30 minutes to complete)
62512347|NCT01914172||Patient focus group|Focus groups (90-120 minutes in duration) with 6-12 patients. Up to 36 patients total
62512348|NCT01914172||Online web-based evaluation of patient education materials|Up to 100 patients with KS/CHH will be recruited to complete an online web-based questionnaire to evaluate patient education materials (less than 15 minutes to complete)
62512349|NCT03442010||People with adverse drug event|People with adverse drug event
62512350|NCT03442010||People without adverse drug event|People without adverse drug event
62512351|NCT02646917|ACTIVE_COMPARATOR|SkinPen II|Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.
62353081|NCT00603733|EXPERIMENTAL|Pentasa® modified extended release|5-ASA (5-Aminosalicylate)
62353082|NCT00603733|ACTIVE_COMPARATOR|Pentasa®|5-ASA (5-Aminosalicylate)
62353083|NCT05291572|ACTIVE_COMPARATOR|Group A|will be treated by speech therapy only (fluency shaping).
62353084|NCT05291572|ACTIVE_COMPARATOR|Group B|will be treated by speech therapy (fluency shaping) plus Hyperbaric oxygen therapy.
62353085|NCT05291572|ACTIVE_COMPARATOR|Group C|will be treated by speech therapy (fluency shaping) plus medical treatment (brain stimulant).
62353086|NCT02853981|ACTIVE_COMPARATOR|Harmonic scalpel group|group of donors whom will undergo liver transection using harmonic scalpel.
62353087|NCT02853981|ACTIVE_COMPARATOR|clamp-crush group|group of donors whom will undergo liver transection using Kelly clamp.
62512352|NCT02646917|ACTIVE_COMPARATOR|SkinPen Precision|Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.
62512353|NCT02644161|ACTIVE_COMPARATOR|Combination acupuncture treatment (CAI)|Post stroke depression patients will receive Dense Cranial Electroacupuncture Stimulation (DCEAS) and body acupuncture. Patients will continue their existing antidepressant and rehabilitation therapy as usual.
62512354|NCT02644161|SHAM_COMPARATOR|Least acupuncture stimulation (LAS)|Post stroke depression patients will receive Least acupuncture stimulation (LAS). Patients will continue their existing antidepressant and rehabilitation therapy as usual.
62512355|NCT01489618|ACTIVE_COMPARATOR|PPS|Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
62708846|NCT05936658|OTHER|The positive predictive values (PPV) of [18F]Florastamin PET/CT imaging|The positive predictive values (PPV) of \[18F\]Florastamin PET/CT imaging for the detection of recurrent or metastatic prostate cancer in subjects are evaluated.
62353088|NCT00815204||posttraumatic stress disorder|
62512356|NCT01489618|EXPERIMENTAL|PnCJ PPS|Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
62512357|NCT05073250|EXPERIMENTAL|Experimental arm|Enrolled patients will be administered IBI376 plus rituximab, induction therapy for 6 cycles (28-day cycle). Patients assessed as partial response (PR) after 6 cycles of induction therapy will receive another 6 cycles of IBI376 combined with rituximab induction therapy.
62512358|NCT00006473|EXPERIMENTAL|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
62512359|NCT06109701|ACTIVE_COMPARATOR|Control Group - Ultrassonic Devices|Supra and sub-gingival debridement with an ultrasonic device (DTE-D5, Woodpecker®, Guilin, China) with a plastic tip (Hu-Friedy®, Rockwell St, Chicago, IL, USA) and scaling with plastic curettes (Hu-Friedy®, Rockwell St, Chicago, IL, USA) around dental implants and a conventional metal tip for teeth will be used.
62512360|NCT06109701|EXPERIMENTAL|Test Group - Erythritol based air-polishing powder|Supra and sub-gingival debridement with an erythritol based air-polishing powder (Air-Flow, EMS, Nyon, CH) will be used during 5 seconds on each site (Schwarz et al., 2015).
62512361|NCT01456416||Glatiramer Acetate|GA administered SQ daily in MS patients who met all Inclusion-Exclusion Criteria and were approved by their Health Care Plans for GA treatment.
62512362|NCT06610474|EXPERIMENTAL|Talk to Nathan|"Participants in this arm will use the online Talk to Nathan about Prostate Cancer Screening decision aid before their clinic visit."
62512363|NCT06610474|ACTIVE_COMPARATOR|Standard decision aid|Participants in this arm will use a standard decision aid before their clinic visit.
62512364|NCT06610474|ACTIVE_COMPARATOR|Standard education materials|Participants in this arm will use standard education materials before their clinic visit.
62512365|NCT06213350||Needs Assessment Participants|
62512366|NCT06213350||Focus Group Participants|
62353089|NCT00815204||history of trauma exposure but no PTSD|
62512367|NCT03711214|ACTIVE_COMPARATOR|pSS patients|We will evaluate 40 patients with pSS (EULAR/ACR Classification Criteria, 2016) of both sexes before and after periodontal disease treatment.
62512368|NCT03711214|ACTIVE_COMPARATOR|Healthy individuals|We will evaluate 40 healthy controls before and after periodontal disease treatment.
62353090|NCT00815204||healthy controls|
62353091|NCT05069285|EXPERIMENTAL|Self-help book|A self-help book for insomnia (written in Norwegian)
62353092|NCT05069285|ACTIVE_COMPARATOR|Sleep hygiene advice|A sheet of paper with standard sleep hygiene advice
62353093|NCT05108688|ACTIVE_COMPARATOR|Mirtazapine Therapy group (M group)|
62353094|NCT05108688|ACTIVE_COMPARATOR|Sumatriptan Therapy group (S group)|
62353095|NCT05108688|PLACEBO_COMPARATOR|Control group ( C group)|
62353096|NCT01241955|NO_INTERVENTION|verbal description of CPR|verbal description of CPR
62353097|NCT01241955|EXPERIMENTAL|Video decision aid|Video decision aid of CPR
62353098|NCT01362699|EXPERIMENTAL|JNJ-31001074|
62353099|NCT01362699|PLACEBO_COMPARATOR|Placebo|
62512369|NCT06011382|ACTIVE_COMPARATOR|patients treated with amda®|two different treatment groups will be evaluated, from initiation of treatment until completion of maxillary molar distalization.
62512370|NCT06011382|ACTIVE_COMPARATOR|patients treated with buccal mini-implants|from initiation of treatment until completion of maxillary molar distalization.
62512371|NCT00977431|EXPERIMENTAL|Regimen U|BIBW2992 + Radiotherapy
62512372|NCT00977431|EXPERIMENTAL|Regimen M|BIBW2992 + Temozolomide + Radiotherapy
61972426|NCT00726661||Chemotherapy Cohort|Eligible participants with HER2-negative disease who received their first cytotoxic chemotherapy and/or targeted therapy were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
62512373|NCT01901848|EXPERIMENTAL|CPT+ICSC|This arm includes 12 sessions of combined Cognitive Processing Therapy (CPT) and Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
62512374|NCT01901848|ACTIVE_COMPARATOR|ICSC only|This arm includes 12 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
62512375|NCT01546142|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62512376|NCT01546142|EXPERIMENTAL|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
62512377|NCT01647711|EXPERIMENTAL|Afatinib|Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
62512378|NCT05338372|EXPERIMENTAL|Two days forest therapy|
62512379|NCT05338372|EXPERIMENTAL|Three days forest therapy|
62512380|NCT03669068||Elective endoscopy|Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.
62512381|NCT03669068||Gastrointestinal bleeding|Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately
62512382|NCT03226171|EXPERIMENTAL|Dose-adjusted SK-1403|
62512383|NCT02346851|EXPERIMENTAL|triggered FES|
62512384|NCT02346851|ACTIVE_COMPARATOR|conventional FES|
62708847|NCT02323711|NO_INTERVENTION|Control|This group would be receiving the standard of care. The subject would receive the standard dressing applied by a member of the surgical team in the standard fashion as follows: The closed incision will be covered first with a primary dressing consisting of a nonadherent, composite dressing (Telfa), which is covered with a secondary dressing consisting of an Army Battle Dressing (ABD), before removal of the sterile surgical drapes. This dressing is then held in place with an adhesive fabric tape, currently Mefix tape, which is typically applied by the surgical scrub tech.
61972427|NCT00726661||Hormonal Therapy Cohort|Eligible participants with hormone receptor positive disease who received their first hormonal therapy for advanced disease were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
61972428|NCT02633644|EXPERIMENTAL|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
61972429|NCT01705821||Skull Base Surgery Candidate|Patient with a skull base lesion will undergo use of standard surgical curette with force sensor built into shaft. 6-axis force and torque data will be collected during the surgical procedure.
61972430|NCT04914104|EXPERIMENTAL|Intervention|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
62353100|NCT01641965|ACTIVE_COMPARATOR|early non invasive ventilation|Patients assigned to this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB)immediately after randomization (when their FVC reaches the threshold of the 75% of the predicted value)
62353101|NCT01641965|ACTIVE_COMPARATOR|standard|patients in this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB) when they fulfil at least one of the following criteria: (i) FVC \< 50% predicted, (ii) orthopnea, and/or (iii) PaCO2 \> 45 mmHg.
62353102|NCT03046017|ACTIVE_COMPARATOR|real tDCS|In this group, the tDCS stimulates areas of the brain being examined in this study to increase their activity.
62353103|NCT03046017|SHAM_COMPARATOR|sham tDCS|In this group, sham tDCS does not provide real stimulation though participants will not know this until the debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
62353104|NCT03046017|OTHER|control group|In this group, participants will receive tDCS but will only receive a cream on their lower back.
62353105|NCT02281981|EXPERIMENTAL|Curcumin supplement|200 mg, curcuminoids, 7d of supplementation in capsular form
62353106|NCT02281981|PLACEBO_COMPARATOR|Placebo|sucrose, capsular
62353107|NCT06210958|EXPERIMENTAL|S-group|The patients will be received the single injection of ITPB at T5-6 level
62353108|NCT06210958|EXPERIMENTAL|T-group|The patients will be received the triple injection of ITPB at T4-5, 5-6, 6-7 levels
62353109|NCT02668744|EXPERIMENTAL|Intervention|TX Sprouts
62512385|NCT02346851|NO_INTERVENTION|control group|
62512386|NCT04464109|ACTIVE_COMPARATOR|Retro-scleral placement of the implant|"Surgical steps;~1. Two anterior scleral relaxing incisions~2. A 360° scleral incision around the optic nerve to disinsert it~3. Two posterior scleral relaxing incisions~4. The implant is inserted posterior to posterior scleral edges~5. The posterior sclera is closed then the anterior sclera is overlapped and closed.~6. The implant is completely seated in the intraconal space"
62512387|NCT04464109|ACTIVE_COMPARATOR|Intrascleral placement of the implant|"Anterior and posterior sclerotomies with the implant partly in the scleral shell and partly in the intraconal space.~1. Anterior relaxing sclerotomies not reaching the optic nerve~2. A 360° scleral incision around the optic nerve.~3. The anterior sclera flaps are overlapped and closed~4. Part of the implant remains in the scleral shell, while the remaining part is sitting in the intraconal space."
62353110|NCT02668744|PLACEBO_COMPARATOR|Control|Delayed Intervention
62512388|NCT02288208|EXPERIMENTAL|Antiviral Therapy & Birinapant|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.
62708848|NCT02323711|EXPERIMENTAL|2-octyl cyanoacrylate|This group would receive the experimental treatment. If allocated to coverage with glue, no dressing is placed. After closure of the incision with suture or staples, the incision is patted dry under sterile conditions. The incision is then covered longitudinally by a member of the surgical team with a thick layer of skin glue dispensed from 1 tube of surgical skin glue (2-octyl cyanoacrylate, currently using brand: Derma+Flex QS). The glue is then allowed to dry before the sterile surgical drapes are removed.
62708849|NCT02183584|EXPERIMENTAL|Rifampicin and Linagliptin|
62708850|NCT01427491|ACTIVE_COMPARATOR|Aquacel® Ag|
62708851|NCT01427491|ACTIVE_COMPARATOR|Mepilex® Border Ag|
62708852|NCT01264185||Asia--Thailand; S. America--Brazil|
62708853|NCT01264185||Africa--Zambia|
62708854|NCT01600287|EXPERIMENTAL|IAADS group|dosage of propofol adjusted automatically by IAADS
62708855|NCT01600287|ACTIVE_COMPARATOR|Manual group|dosage of propofol adjusted manually
62353111|NCT02679807|ACTIVE_COMPARATOR|Bifidobacterium lactis Bl-04|2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
61972431|NCT04914104|NO_INTERVENTION|Control|The control group will receive standard of care, which does not involve routine in-person or free access to mobile mindfulness therapy.
62353112|NCT02679807|PLACEBO_COMPARATOR|Placebo|sucrose
62353113|NCT04923698|ACTIVE_COMPARATOR|yoga|The yoga program consisted of 12 exercises, , 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
62353114|NCT04923698|ACTIVE_COMPARATOR|antidepressant|All women in group A were treated by antidepressant only for 12 weeks
62353115|NCT05075707|NO_INTERVENTION|control group|Participants will receive the descriptive medication by neurologist
62353116|NCT05075707|EXPERIMENTAL|electromagnetic group|Participants will receive the descriptive medication by neurologist in addition to electromagnetic therapy. Electromagnetic therapy will be applied for 20 min/session for three days each week for two months.
62353117|NCT05075707|EXPERIMENTAL|low laser therapy group|Participants will receive the descriptive medication by neurologist in addition to low laser therapy. Low laser therapy will be applied for 20 min/session for three days each week for two months.
62353118|NCT06197737|EXPERIMENTAL|Moderate Intensity Interval Training|These participants will perform moderate intensity interval training. The intervention will be applied thrice a week. Moderate intensity interval training in which they do stair climbing 3 times a week And for every 1 interval I will ask them to take rest for 3 minutes.
62353119|NCT06197737|EXPERIMENTAL|Sprint Interval Training|"These participants will perform sprint interval training and frequency will be 3 days a week.~The participants will perform sprint interval training in which they will do stair climbing 3 times a week with a fast pace."
62353120|NCT06197737|OTHER|pharmacological treatment|They will be on pharmacological treatment as prescribed by their pulmonologist.
62353121|NCT03994536|EXPERIMENTAL|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses (transition coordinators) who meet the participants at three occasions during the study period and participants will be offered to meet peers with type 1 diabetes during an adolescent day.
62353122|NCT03994536|EXPERIMENTAL|Comparison group: Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
62353123|NCT02528253|PLACEBO_COMPARATOR|Placebo to Week 16; tanezumab 5 mg SC|
62353124|NCT02528253|PLACEBO_COMPARATOR|Placebo to Week 16, tanezumab 10 mg SC|
62353125|NCT02528253|EXPERIMENTAL|Tanezumab 5 mg SC|
62353126|NCT02528253|EXPERIMENTAL|Tanezumab 10 mg SC|
62353127|NCT02528253|ACTIVE_COMPARATOR|Tramadol PR oral|
62353128|NCT00460837|ACTIVE_COMPARATOR|1 A|gastrofin \& Picolax
62353129|NCT00460837|ACTIVE_COMPARATOR|2|senna
62353130|NCT00003735|EXPERIMENTAL|Stratum 1 - Stage 1|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
62353131|NCT00003735|EXPERIMENTAL|Stratum 2 - Stage 2|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
62353132|NCT05622344|ACTIVE_COMPARATOR|Traditional VPT JHU|Subjects that have had their eighth cranial nerve resected will receive traditional vestibular rehabilitation exercises at Johns Hopkins University (JHU) site.
62353133|NCT05622344|EXPERIMENTAL|SWAN VPT JHU|Subjects that have had their eighth cranial nerve resected will receive the automated vestibular rehabilitation method
62353134|NCT05622344|EXPERIMENTAL|SWAN Motion Sick Dayton|Healthy control subjects that meet similar similar physical characteristics of astronauts will receive the automated vestibular rehabilitation method post motion sickness.
61972432|NCT04287491|EXPERIMENTAL|Virtual Reality Group|This group will receive the virtual reality intervention during out-patient bedside procedures.
62512389|NCT02288208|PLACEBO_COMPARATOR|Antiviral Therapy & Placebo|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.
62512390|NCT03416556|EXPERIMENTAL|Mobilization to the glenohumeral joint|This condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder
61972433|NCT01354951|EXPERIMENTAL|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.
61972434|NCT03305822|EXPERIMENTAL|LY900014|Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
61972435|NCT03305822|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods
61972436|NCT06040112|EXPERIMENTAL|Atelocollagen injection group|Atelocollagen injection
62512391|NCT03416556|SHAM_COMPARATOR|The manual contact condition|In this condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition.
62512392|NCT03416556|NO_INTERVENTION|No-contact condition|There was no manual contact between the therapist and the participant
62512393|NCT03093935|EXPERIMENTAL|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
62512394|NCT02198924|EXPERIMENTAL|Parecoxib and Celecoxib|"Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3."
62512395|NCT02198924|PLACEBO_COMPARATOR|placebo|"Patients in the control group are supplied with the corresponding placebo with the same instructions.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3."
62512396|NCT01082887|EXPERIMENTAL|TIL-Ad-INFg|
62512397|NCT04191824|ACTIVE_COMPARATOR|Immediate Return of Results|Immediate return of results to inform participant of APOL1 status (either positive or negative).
62512398|NCT04191824|ACTIVE_COMPARATOR|Delayed Return of Results|Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.
62512399|NCT04815252|EXPERIMENTAL|CHIME Intervention|Participants will complete an 8-week compassion and mindfulness-based intervention with a group facilitator. The curriculum focuses on providing mindfulness-based stress reduction techniques for use in the early childhood education environment.
62708856|NCT05309655|EXPERIMENTAL|Near-Complete Estrogen Deprivation Therapy Participants|Participants will receive cardiac imaging stress tests as well as study laboratory tests to monitor for changes in heart as well 30-day at the end of the study along with annual long-term follow up to 5 years from baseline imaging.
62146872|NCT00048932|ACTIVE_COMPARATOR|Double-blind abatacept|Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants \> 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs \[DMARDs\], or combination) throughout the double-blind treatment period
62353135|NCT05622344|NO_INTERVENTION|Traditional Motion Sick Dayton|Typically, the suggestion for treating motion sickness once it has started is to avoid motion. Therefore, healthy control subjects that meet similar similar physical characteristics of astronauts will not receive any post motion sickness treatment.
62708857|NCT03429140|EXPERIMENTAL|Group 1 - Gel-One|Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3
62708858|NCT03429140|PLACEBO_COMPARATOR|Group 1 - Saline Placebo|3 ml saline placebo one time injection at visit 3
61972437|NCT06040112|PLACEBO_COMPARATOR|Lidocain injection group|Lidocain injection
61972438|NCT02625259|EXPERIMENTAL|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
61972439|NCT02625259|EXPERIMENTAL|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
61972440|NCT02625259|EXPERIMENTAL|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
61972441|NCT02625259|EXPERIMENTAL|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
62512400|NCT04815252|NO_INTERVENTION|Waitlist control|Participants are placed on a wait-list to receive the intervention.
62512401|NCT00466804||Heart Transplant Recipients|People who will have a heart transplant
62512402|NCT00890552|EXPERIMENTAL|Lenalidomide+Melphalan+Dexamethasone|Patients received lenalidomide 10 mg/day orally on days 1-21, melphalan 0.18 mg/kg orally on days 1-4, and dexamethasone 40 mg orally once weekly of a 28-day cycle (MDR treatment).
62512403|NCT00766831|EXPERIMENTAL|Hydromorphone OROS|Participants will receive hydromorphone OROS (8 milligram \[mg\] up to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
62512404|NCT04593342|ACTIVE_COMPARATOR|Standard + B-Cure Pro|Subjects from the Standard + B-Cure Pro group will receive standard care and in addition will self-treat at home with the B-Cure device
62512405|NCT04593342|SHAM_COMPARATOR|Standard + Sham|Subjects from the Standard + Sham group will receive standard care and in addition will self-treat at home with the sham B-Cure device
62512406|NCT02154724|OTHER|aDBS|The aDBS (adaptive Deep Brain Stimulation) device is applied both in aDBS and in DBS modality, for two hours in random order for two days. The aDBS can be programmed to deliver aDBS controlled by local fields potential or conventional DBS.
62512407|NCT01130779|EXPERIMENTAL|tarceva|continuation of tarceva
62512408|NCT05993598|EXPERIMENTAL|Group 1 (Saddled)|Each group did a 30-minute hippotherapy session in the manege area. Before the application, the sitting balance of the children was evaluated by playing the Nintendo Wii Balance Platform and the Basic Balance Game. In addition, 10 m walking test was applied for walking speed. These assessments were repeated after the 30-minute session.
62512409|NCT05993598|EXPERIMENTAL|Group 2 (Saddleless, direct contact with horse)|Each group did a 30-minute hippotherapy session in the manege area. Before the application, the sitting balance of the children was evaluated by playing the Nintendo Wii Balance Platform and the Basic Balance Game. In addition, 10 m walking test was applied for walking speed. These assessments were repeated after the 30-minute session.
62708859|NCT03739619|EXPERIMENTAL|Gemcitabine, bendamustine, nivolumab|Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62708860|NCT06123299|ACTIVE_COMPARATOR|pHyph treatment|Initial treatment with pHyph vaginal tablet once daily during 6 consecutive days
61972442|NCT02625259|EXPERIMENTAL|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
61972443|NCT00936585|OTHER|Immunologic Monitoring|Blood draws and colonoscopy performed on patients enrolled in both intervention arms of the main study
61972444|NCT05908695|EXPERIMENTAL|GV-971|
61972445|NCT05908695|PLACEBO_COMPARATOR|Placebo|
61972446|NCT05778123||TBI|Patients with traumatic brain injury.
61972447|NCT05778123||Control|Patients with hydrocephalus.
61972448|NCT04687878|EXPERIMENTAL|Insulin|Regular Insulin, 20 IU twice a day, intranasally, every day for 12 weeks
61972449|NCT04687878|PLACEBO_COMPARATOR|Placebo|Normal saline, twice a day, intranasally, every day for 12 weeks
62353136|NCT05106218|EXPERIMENTAL|SurroundScope|For laparoscopic camera system, the SurroundScope, 270-degree angle videoscope (270Surgical, Israel) is used
61972450|NCT04859023|EXPERIMENTAL|mass screening SARS-COV-19|"20 0000 participant will be included during mass screening SARS-COV-19 of the population of the city of Saint-Etienne.~They will have two strategies both based on self-samples: (i) a saliva sample combined to an anterior nare self-swabbing tested by antigenic test versus (ii) a saliva sample tested by RT-PCR."
61972451|NCT06103357||subjects with clinical indication for coronary angioplasty|Twenty subjects with acute or chronic coronary syndrome that will be underwent to angioplasty procedure according to standard clinical practice.
62353137|NCT05106218|ACTIVE_COMPARATOR|Standard laparoscope|For laparoscopic camera system, the Standard laparoscope that is in a standard use at the medical center is used
62353138|NCT00047307|EXPERIMENTAL|Treatment (alvocidib, gemcitabine hydrochloride, 3DRT)|"Patients receive flavopiridol IV over 1 hour twice weekly (on days 1 and 4 or days 2 and 5) for 6 weeks. Concurrently, patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Four weeks after the completion of radiotherapy, patients are re-evaluated\*. Beginning within 4-7 weeks after the completion of chemotherapy and radiotherapy, patients receive gemcitabine hydrochloride alone or in combination with another cytotoxic agent or gemcitabine hydrochloride combined with a targeted drug (e.g., erlotinib or bevacizumab) at the discretion of the oncologist. NOTE: \*Patients whose imaging studies suggest potential curative resection are referred for a surgical evaluation before initiating gemcitabine hydrochloride therapy. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. Continued (see detailed description)"
62353139|NCT01674894||Group 1|Women treated with Menopur
62353140|NCT01674894||Group 2|Women treated with Menopur and Bravelle
62353141|NCT02204033|EXPERIMENTAL|99mTc - labelled hMAb BIWA 4 - low dose|
62353142|NCT02204033|EXPERIMENTAL|99mTc - labelled hMAb BIWA 4 - medium dose|
62353143|NCT02204033|EXPERIMENTAL|99mTc - labelled hMAb BIWA 4 - high dose|
62353144|NCT02204033|EXPERIMENTAL|186 Re - labelled hMAb BIWA 4 - escalating dose|
62353145|NCT03179410|EXPERIMENTAL|Neuroendocrine prostate cancer (NEPC)|Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
62353146|NCT03258463||Time Period 1|Women who obtained an abortion from January 1 2012-December 31 2012
62353147|NCT03258463||Time Period 2|Women who obtained an abortion from May 1 2014-April 30 2015.
62353148|NCT02375204|OTHER|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.~Cycles 1-4 (1 cycle = 21 days)~* paclitaxel 250 mg/m\^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~* ifosfamide 1500 mg/m\^2 IV daily on Days 2-5 with mesna protection as defined in the protocol~* cisplatin 25 mg/m\^2 IV daily on Days 2-5~* pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
61972452|NCT00290888|ACTIVE_COMPARATOR|ACR|Arthroscopic rotator cuff repair without acromioplasty
61972453|NCT00290888|EXPERIMENTAL|ACR-A|Arthorscopic rotator cuff repair with acromioplasty
61972454|NCT04051762||Preterm neonates on HFNC|neonates extubated to HFNC (High flow nasal cannula)
61972455|NCT04051762||Preterm neonates on NCPAP|neonates extubated to NCPAP ( nasal continuous positive airway pressure)
61972456|NCT02299609|ACTIVE_COMPARATOR|Beam Receiver|Philips HD11 XE® 30 min qid x 4 days
61972457|NCT02299609|SHAM_COMPARATOR|Beam Non-Receiver|Philips HD11 XE® (ultrasound turned-off) 30 min qid x 4 days
61972458|NCT02989675|EXPERIMENTAL|Dextrose|Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
61972459|NCT02989675|NO_INTERVENTION|Control|Usual care - the care that is currently provided in the hospital - will be provided. All children in the control group will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
61972460|NCT02226055||Arterial stiffness: CKDu patients|Cohort of 50 patients with CKD of unknown aetiology Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
61972461|NCT02226055||Arterial stiffness: CKD known cause|Cohort of 50 patients with CKD of known cause Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
61972462|NCT02226055||Arterial Stiffness: Healthy Sri Lankan volunteers|Cohort of 50 participants who are healthy Sri Lankan volunteers Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
61972463|NCT02226055||2nd aim: 250 CKDu patients for investigation of aetiology|"To recruit a cohort of up to 250 CKDu patients from specific CKDu clinics in Anuradhapura and Padavi-Sri Pura for detailed history, basic anthropometric tests, and further analysis of serum, and urine. Analysis for biomarkers of kidney damage, proteomics, exosomes, and DNA adducts will be used to seek information that may complement already collected data and help refine aetiological hypotheses.~Inclusion and Exclusion criteria as per CKDu cases in cohort 1"
61972464|NCT00329381|PLACEBO_COMPARATOR|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
61972465|NCT00329381|EXPERIMENTAL|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
61972466|NCT06347614||Two-step Radical Prostatectomy|
61972467|NCT05714813|EXPERIMENTAL|High-Speed Circuit Resistance Training Group|Participants in this group will receive high-speed circuit resistance training 3 times a week for 24 consecutive weeks for a total of 72 training sessions.
61972468|NCT05714813|OTHER|Control Group|Participants in this arm will receive two lectures on fitness, diet, or cognition each month for 24 weeks for a total of 12 lectures.
61972469|NCT01949051|EXPERIMENTAL|Levocabastine Arm|Subjects will be assigned to one of six treatment sequences (ABC, BCA, CAB, ACB, BAC, CBA) in accordance with the randomisation schedule. A = Two, 50 microgram (mcg) sprays per nostril of levocabastine QD in the morning. Total dose of 200 mcg. Two, 0 mcg sprays from placebo to match vehicle in the evening; B = Two, 50 mcg sprays per nostril of levocabastine BID in the morning and evening. Total dose of 400 mcg; C = Two, 0 mcg sprays per nostril from placebo vehicle in morning and evenings.
61972470|NCT01713972|EXPERIMENTAL|Treatment (dabrafenib, pazopanib hydrochloride)|Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61972471|NCT01713972|OTHER|Correlative Studies|"Pharmacokinetic studies: Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
62708861|NCT06123299|NO_INTERVENTION|No treatment|No initial treament during the first 7 days of the study
61972472|NCT02664441|ACTIVE_COMPARATOR|Exenatide once weekly extended-release|Injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (Bydureon®) for 36 weeks in randomized intervention followed by 18 weeks open label exenatide once weekly extended-release.
61972473|NCT02664441|PLACEBO_COMPARATOR|Matching placebo|Weekly injections of placebo for 36 weeks followed by 18 weeks open label exenatide once weekly extended-release.
61972474|NCT00844688|OTHER|sorafenib/gemcitabine|
61972475|NCT05502328|PLACEBO_COMPARATOR|Control 1|Energy Product Form 1 - control
61972476|NCT05502328|PLACEBO_COMPARATOR|Control 2|Energy Product Form 2 - control
62708862|NCT00498212|EXPERIMENTAL|1018 ISS-HBsAg-Single|Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
62708863|NCT00498212|EXPERIMENTAL|1018 ISS-HBsAg-Double|Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)
62708864|NCT01846312||All participants|
62708865|NCT00767026|EXPERIMENTAL|1|
62708866|NCT00767026|ACTIVE_COMPARATOR|2|
62708867|NCT00649584|EXPERIMENTAL|1|SGN-35 alone or in combination with gemcitabine
62708868|NCT01728246|EXPERIMENTAL|Tramadol/Paracetamol (APAP)|
62708869|NCT01728246|ACTIVE_COMPARATOR|Non-Tramadol/APAP|
62708870|NCT03481439||Primary cohort|Primary cohort : Cohort of patient between January and February 2017
62512410|NCT05993598|EXPERIMENTAL|Group 3 (Different tissue to be put on the saddle)|Bubbled nylon (pat-to-pat) was used as a different texture. Each group did a 30-minute hippotherapy session in the manege area. Before the application, the sitting balance of the children was evaluated by playing the Nintendo Wii Balance Platform and the Basic Balance Game. In addition, 10 m walking test was applied for walking speed. These assessments were repeated after the 30-minute session.
62512411|NCT02897817||Oral to Injectable|Patients treated with oral MTX and requiring a switch to injectable MTX
62512412|NCT02897817||Injectable to Injectable|Patients treated with injectable MTX and eligible for a change in MTX injection device.
62512413|NCT00467987|EXPERIMENTAL|androgel|androgel
62512414|NCT00467987|PLACEBO_COMPARATOR|placebo|placebo gel
62512415|NCT00467987|NO_INTERVENTION|no treatment|eugonadal comparison arm
62512416|NCT05767736||Vumerity Cohort|Participants who have been prescribed Vumerity as a newly initiating treatment and not previously treated with Tecfidera are selected and the available data is collected retrospectively.
62512417|NCT05767736||Tecfidera Cohort|Participants who have been prescribed Tecfidera as a newly initiating treatment and not previously treated with Vumerity are selected and the available data is collected retrospectively.
62512418|NCT05767736||Vumerity/Tecfidera Switch Cohort|Participants who have been treated with Tecfidera and then switched to Vumerity as per routine medical care are selected and the available data is collected retrospectively.
62512419|NCT05767736||Selected Disease Modifying Therapies (DMTs) Treated Cohort|Participants who have been prescribed with other selected DMTs (teriflunomide, beta-interferons, or glatiramer acetate) and are not previously treated with Vumerity or Tecfidera are selected and the available data is collected retrospectively.
62512420|NCT05686759|EXPERIMENTAL|Undiluted intravenous infusion of I.V.-Hepabig inj|Undiluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit within approximately 30 minutes
61972477|NCT05502328|EXPERIMENTAL|Energy Product 1.1|Energy Product Form 1 - active product 1
62512421|NCT05686759|ACTIVE_COMPARATOR|Diluted intravenous infusion of I.V.-Hepabig inj|Diluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit into Dextrose 5% in water within approximately 1 hour
62708871|NCT03481439||Secondary cohort|Secondary cohort : Cohort of patient between February and March 2018
62708872|NCT02563015|EXPERIMENTAL|Cholecalciferol 400|400 IU orally per day
62708873|NCT02563015|EXPERIMENTAL|Cholecalciferol 1000|1000 IU orally per day
62708874|NCT02563015|ACTIVE_COMPARATOR|Reference 400|400 IU orally per day
62708875|NCT00784615||1|Women with polycystic ovaries, oligo or anovulation and hyperandrogenism.
62708876|NCT00784615||2|Women with polycystic ovaries and oligo or anovulation without hyperandrogenism
62708877|NCT00784615||3|Women with normal ovaries, oligo or anovulation and hyperandrogenism
61972478|NCT05502328|EXPERIMENTAL|Energy Product 1.2|Energy Product Form 1 - active product 2
61972479|NCT05502328|EXPERIMENTAL|Energy Product 2.1|Energy Product Form 2 - active 1
61972480|NCT05502328|EXPERIMENTAL|Energy Product 2.2|Energy Product Form 2 - active 2
61972481|NCT04954274|EXPERIMENTAL|Fertiline group|Treated by supplementation of the culture medium with the molecule.
61972482|NCT04954274|NO_INTERVENTION|Control group|No supplementation
61972483|NCT05108831|EXPERIMENTAL|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
61972484|NCT05108831|NO_INTERVENTION|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
62146873|NCT00048932|PLACEBO_COMPARATOR|Double-blind Placebo|Participants received Placebo (dextrose 5% water \[D5W\] for injection U.S.P or normal saline \[NS\]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs \[DMARDs\], or combination) throughout the double-blind treatment period.
62146874|NCT00048932|ACTIVE_COMPARATOR|Open-label Abatacept|Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.
62512422|NCT03015064||Myocardial Infarction|Patients with first myocardial Infarction
62512423|NCT00848042|ACTIVE_COMPARATOR|AuroShell-3.5|Group treated with the lowest treatment level with 4.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 3.5 watts. Device: AuroLase Therapy
62512424|NCT00848042|ACTIVE_COMPARATOR|AuroShell-4.5|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 4.5 watts. Device: AuroLase Therapy
62512425|NCT00848042|ACTIVE_COMPARATOR|AuroShell-5.0|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 5.0 watts. Device: AuroLase Therapy
62512426|NCT04670406|EXPERIMENTAL|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
62708878|NCT00784615||4|Women with normal ovaries, oligo or anovulation and hyperandrogenism
62708879|NCT00784615||5|Women with out polycystic ovary syndrome
62708880|NCT02697357||Caregivers|This study is a pilot, single-arm intervention of Emotion Regulation Therapy for Cancer Caregivers (ERT-C). We plan to recruit a pilot sample 32 consented (24 evaluable) caregivers of patients diagnosed with cancer and measure their distress, anxiety, and other psychological outcomes at baseline. Caregivers will be consented into an 8-session ERT-C therapy (approximately 12 - 16 weeks).
62708881|NCT03840967|OTHER|Niraparib|
62146875|NCT02574286|EXPERIMENTAL|Velaglucerase alfa 60 U/kg|Participants will receive 60-minute intravenous infusion of 60 units per kilogram (U/kg) velaglucerase alfa every other week (EOW) and an oral daily dose of 800 IU vitamin D for 24 months (101 weeks).
62512427|NCT02231424||chronic obstructive respiratory tract disease patients|
62512428|NCT04910828|EXPERIMENTAL|Common foods of varying glycemic indices|Common foods of varying glycemic indices
61972485|NCT04190394||Patients following the CONT program|"In the  CONT continuous training group, the control group, the patient benefits from a retraining program according to the continuous mode (see details in section 3.4) for 8 weeks, with three 40-minute sessions per week."
61972486|NCT04190394||Patients following the IT program|"In the IT intermittent training group, group, (the experimental group), the patient benefits from a retraining program according to the intermittent mode (see details in section 3.4) for 8 weeks, with three 45-minute sessions per week."
61972487|NCT00560976|EXPERIMENTAL|Iron Saccharate (Venofer)|IV Iron Saccharate (Venofer)100 mg
62146876|NCT05357677|EXPERIMENTAL|SR419-Placebo sequence|30 mg of SR419 administered TID for 4 weeks followed by placebo administered TID for 4 weeks
62146877|NCT05357677|EXPERIMENTAL|Placebo-SR419 sequence|placebo administered TID for 4 weeks followed by 30 mg of SR419 administered TID for 4 weeks
62146878|NCT02442557|ACTIVE_COMPARATOR|single dose 4 mg|a single intravenous injection of 4 mg DC-TAB
62146879|NCT02442557|ACTIVE_COMPARATOR|single dose 12.5 mg|a single intravenous injection of 12.5 mg DC-TAB
62353149|NCT02375204|OTHER|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.~Cycles 1-2 (1 cycle = 14 days)~* paclitaxel 200 mg/m\^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~* ifosfamide 2000 mg/m\^2 IV daily on Days 1-3 with mesna protection as defined in the protocol~* G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)~* leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1~Cycles 3-5 (1 cycle = 21 days)~* carboplatin daily on Days 1-3~* etoposide 400 mg/m\^2 daily on Days 1-3~* stem cell reinfusion on day 5~* pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
62353150|NCT03271307|NO_INTERVENTION|AIm 1: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
62353151|NCT03271307|EXPERIMENTAL|Aim 1: Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
62353152|NCT03271307|EXPERIMENTAL|Aim 1: Facility HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
62353153|NCT03271307|NO_INTERVENTION|Aim 2: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients. Partner referral slips will be given to HIV-positive clients to encourage partner testing.
62353154|NCT03271307|EXPERIMENTAL|Aim 2: Index HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
62353155|NCT03201367|ACTIVE_COMPARATOR|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban"
62353156|NCT03201367|PLACEBO_COMPARATOR|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
62353157|NCT05566288|EXPERIMENTAL|Sequence 1|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~* Placebo (negative control) (8 placebo tablets)~* Moxifloxacin 400 mg PO (positive control) (1 tablet) There will be a minimum 5 day washout between dosing periods."
62512429|NCT06043791|EXPERIMENTAL|Treatment|Patients will be imaged with standard of care MRI shoulder arthrogram on a 1.5 T magnet and additionally with non-contrast MRI of the shoulder on a 3 T magnet. All patients will be dually imaged. Initial imaging will utilize the standard of care, and, subsequently, patients will be brought back within 2 weeks, for non-contrast MRI as part of the study protocol
62512430|NCT03589131|ACTIVE_COMPARATOR|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
62512431|NCT03589131|ACTIVE_COMPARATOR|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
62512432|NCT00841152||Hand lesions|Stratum I: comparison of three interventions (autograft, bioactive glass and beta-tricalcium phosphate)
62512433|NCT00841152||Long-bone lesions|Stratum II: comparison of three interventions (bioactive glass, beta-tricalcium phosphate, allograft)
61972488|NCT05679908|EXPERIMENTAL|TNX-1900 High Dose|30 IU oxytocin taken intranasally twice daily.
62146880|NCT02442557|ACTIVE_COMPARATOR|single dose 25 mg|a single intravenous injection of 25 mg DC-TAB
62146881|NCT02442557|ACTIVE_COMPARATOR|single dose 37.5 mg|a single intravenous injection of 4 mg DC-TAB
62146882|NCT02442557|PLACEBO_COMPARATOR|single dose placebo|a single intravenous injection of placebo
62146883|NCT02442557|ACTIVE_COMPARATOR|multiple dose 10 mg|three consecutive daily intravenous injections of 10 mg DC-TAB
61972489|NCT05679908|EXPERIMENTAL|TNX-1900 Low Dose|30 IU oxytocin taken intranasally once daily. Placebo taken intranasally once daily.
62146884|NCT02442557|ACTIVE_COMPARATOR|multiple dose 25 mg|three consecutive daily intravenous injections of 25 mg DC-TAB
61972490|NCT05679908|PLACEBO_COMPARATOR|Placebo|Placebo taken intranasally twice daily.
62146885|NCT02442557|ACTIVE_COMPARATOR|multiple dose 37.5 mg|three consecutive daily intravenous injections of 37.5 mg DC-TAB
62353158|NCT05566288|EXPERIMENTAL|Sequence 2|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~* Moxifloxacin 400 mg PO (positive control) (1 tablet)~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~* Placebo (negative control) (8 placebo tablets) There will be a minimum 5 day washout between dosing periods."
62353159|NCT05566288|EXPERIMENTAL|Sequence 3|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Placebo (negative control) (8 placebo tablets)~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~* Moxifloxacin 400 mg PO (positive control) (1 tablet)~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets) There will be a minimum 5 day washout between dosing periods."
62353160|NCT05566288|EXPERIMENTAL|Sequence 4|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Moxifloxacin 400 mg PO (positive control) (1 tablet)~* Placebo (negative control) (8 placebo tablets)~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets) There will be a minimum 5 day washout between dosing periods."
61972491|NCT00477971|ACTIVE_COMPARATOR|Arm A|"Patients receive low-dose melphalan IV over 15-30 minutes on day~1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses.~Study treatment beyond one year is not allowed."
62146886|NCT02442557|PLACEBO_COMPARATOR|multiple dose placebo|three consecutive daily intravenous injections of placebo
62146887|NCT00221065|NO_INTERVENTION|1|Control
62146888|NCT00221065|EXPERIMENTAL|2|CPAP
62146889|NCT03398980||survivors treated with CRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with convention radiotherapy (CRT).
62146890|NCT03398980||survivors treated with IMRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with intensity-modulated radiotherapy (IMRT).
62353161|NCT05566288|EXPERIMENTAL|Sequence 5|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~* Placebo (negative control) (8 placebo tablets)~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~* Moxifloxacin 400 mg PO (positive control) (1 tablet) There will be a minimum 5 day washout between dosing periods."
62353162|NCT05566288|EXPERIMENTAL|Sequence 6|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Placebo (negative control) (8 placebo tablets)~* Moxifloxacin 400 mg PO (positive control) (1 tablet)~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets) There will be a minimum 5 day washout between dosing periods."
62353163|NCT05566288|EXPERIMENTAL|Sequence 7|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~* Moxifloxacin 400 mg PO (positive control) (1 tablet)~* Placebo (negative control) (8 placebo tablets) There will be a minimum 5 day washout between dosing periods."
62353164|NCT05566288|EXPERIMENTAL|Sequence 8|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~* Moxifloxacin 400 mg PO (positive control) (1 tablet)~* Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~* Placebo (negative control) (8 placebo tablets)~* Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets) There will be a minimum 5 day washout between dosing periods."
62353165|NCT02001363|EXPERIMENTAL|liraglutide|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
62353166|NCT02001363|PLACEBO_COMPARATOR|liraglutide placebo|drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
62353167|NCT03248180||Guided dose reduction (GDR)|Patients in the GDR group will be advised to reduce \< 25% of their current dose of antipsychotic agents estimated on a weekly base and follow-up every 4 weeks for at least 12 weeks.
62353168|NCT03248180||Maintenance treatment group (MTG)|Patients in the MTG will be advised to stay on their current dose of antipsychotics throughout the observational period, follow-up every 12 weeks.
62353169|NCT01646463|EXPERIMENTAL|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills is the standard CenteringPregnancy prenatal healthcare intervention combined with mindfulness meditation and mindful movement/yoga applied to pregnancy, childbirth, and parenting.
62353170|NCT01646463|ACTIVE_COMPARATOR|CenteringPregnancy|CenteringPregnancy is group-based prenatal healthcare delivered according to the guidelines of the American College of Obstetrics and Gynecology. It includes assessment, support, and health education delivered in a healthcare empowerment framework.
62353171|NCT03783338|ACTIVE_COMPARATOR|Physical therapy group|Group A will consist of 15 children and will receive the conventional physical therapy program only. This group will be used to compare the results of the other two groups.
62353172|NCT03783338|EXPERIMENTAL|Physical therapy and aerobic exercises group|Group B will consist of 15 children and will receive the conventional physical therapy program and aerobic exercises.
62708882|NCT06186232|OTHER|patient with horizontally deficient ridge in ethetic maxilary zone need (GBR) and implant placement|a group of patients with with horizontally deficient ridge in esthetic maxillary zone will undergo ridge augmentation with guided bone regeneration (GBR) technique using polymethylmethacrylate (PMMA) polymer as membrane.
61972492|NCT00477971|EXPERIMENTAL|Arm B|Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
61972493|NCT01168167||raltegravir-based cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus raltegravir (n=10 patients) will be offered to participate in this observation arm, but only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of \>5,000 copies/mL and CD4-cell count of \>200/µL within 12 weeks before cART initiation.
62146891|NCT05793866|EXPERIMENTAL|BUTEYKO RESPIRATORY TECHNIQUE APPLIED GROUP|This group consists of children between the ages of 7 and 12 who are being treated for asthma. Children with written and verbal consent from their families will be filled with a personal information form, asthma control test and quality of life scale for children. The standard care and treatment of the asthmatic child included in the experimental group will be continued without any intervention. The child included in this group will be taught the Buteyko Breathing Technique (BST) via a smart phone, and the training video will be watched and taught. The training video will be watched on the official site that explains BST in a practical way. The video will be downloaded to the phone of the child or parent using a smartphone at home, for researchers to apply later at home. The participant will continue to apply this technique at home for 10 minutes in addition to his treatment when he needs a bronchodilator in the morning and evening for 4 weeks.
62353173|NCT03783338|EXPERIMENTAL|Physical therapy, aerobic exercises and vitamin D group|Group C will consist of 15 children and will receive the conventional physical therapy program, aerobic exercises and an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) .
62146892|NCT05793866|NO_INTERVENTION|GROUP WITH STANDARD CARE AND TREATMENT|This group consists of children aged 7-12 years with asthma who continue to receive standard care and treatment. Children with written and verbal consent from their families will be filled with a personal information form, asthma control test and quality of life scale for children. Asthma control test and quality of life scale for the child with asthma will be administered to the participant who continues the standard treatment and care for 4 weeks. After the research data are collected, the children in the control group will be shown a video explaining the BST in a practical way.
62146893|NCT00701259|EXPERIMENTAL|1|15 mg lansoprazole
62353174|NCT05059938|EXPERIMENTAL|MyFitnessPal user|Patients will be shown how to download and use MyFitnessPal onto the patient's smartphone. The patient will be asked to use the application to aid in the patient's weight loss plan over up to six months.
62353175|NCT05059938|NO_INTERVENTION|Traditional Weight Loss Counseling|Patients will be given traditional weight loss counseling from the physician and monitored over up to six months.
62353176|NCT03823807|EXPERIMENTAL|SH-1028|QD,Oral
62512434|NCT00418522|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
62512435|NCT00418522|EXPERIMENTAL|Exubera|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
62512436|NCT00919984|EXPERIMENTAL|IP Chemotherapy|Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
62512437|NCT04788537|EXPERIMENTAL|Intervention Group|
62512438|NCT04788537|NO_INTERVENTION|Nonintervention Group|
62512439|NCT06412926|EXPERIMENTAL|Period 1 Formulation A, fasted|All subjects will receive either Formulation A or Formulation B per randomisation scheme as a single dose in fasted state.
62353177|NCT03400215|ACTIVE_COMPARATOR|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
62512440|NCT06412926|EXPERIMENTAL|Period 1 Formulation B, fasted|All subjects will receive either Formulation A or Formulation B per randomisation scheme as a single dose in fasted state.
62512441|NCT06412926|EXPERIMENTAL|Period 2 - Crossover Formulation A, fasted|All subjects will receive either Formulation A or Formulation B Cross-over: dependent on what they received in period 1 per randomisation scheme as a single dose in fasted state
62512442|NCT06412926|EXPERIMENTAL|Period 2 - Crossover Formulation B fasted|All subjects will receive either Formulation A or Formulation B Cross-over: dependent on what they received in period 1 per randomisation scheme as a single dose in fasted state
62512443|NCT06412926|EXPERIMENTAL|Period 3 - no dose adjustment after Period 2|If no dose adjustment was needed after Period 2, all subjects will receive Formulation B in fed state
62512444|NCT06412926|EXPERIMENTAL|Period 3 - dose adjustment after Period 2, fasted|If dose adjustment was needed after period 2, all subjects will receive Formulation B as single dose either in fasted or in fed state
62512445|NCT06412926|EXPERIMENTAL|Period 3- dose adjustment after Period 2, fed|If dose adjustment was needed after period 2, all subjects will receive Formulation B as single dose either in fasted or in fed state
62708883|NCT02114645|ACTIVE_COMPARATOR|LongGnRH agonist protocol(controlgroup)|Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
62708884|NCT02114645|EXPERIMENTAL|Long protocol-leuprolide acetate|Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
62708885|NCT02114645|ACTIVE_COMPARATOR|GnRHantagonist protocol(control group)|GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
61972494|NCT01168167||standard of care-cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus either a boosted protease inhibitor or efavirenz (n=10 patients) at standard doses will be offered to participate in this observation arm. They will be offered to participate in this trial only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of \>5,000 copies/mL and CD4-cell count of \>200/µL within 12 weeks before cART initiation.
62512446|NCT06412926|EXPERIMENTAL|Period 4 - crossover following Period 3 (in case of dose adjustment after Period 2), fasted|All subjects will receive Formulation B as single dose either in fasted or in fed state depending on if they were in the fasted or fed group in Period 3
62512447|NCT06412926|EXPERIMENTAL|Period 4 - crossover following Period 3 (in case of dose adjustment after Period 2), fed|All subjects will receive Formulation B as single dose either in fasted or in fed state depending on if they were in the fasted or fed group in Period 3
62512448|NCT06412302|EXPERIMENTAL|Whey Protein+Resistance Training|Participants will undergo 8 weeks of resistance training and receive a whey protein shake after each exercise session.
62512449|NCT06412302|EXPERIMENTAL|Protein Yogurt+Resistance Training|Participants will undergo 8 weeks of resistance training and receive a yogurt shake after each exercise session.
62512450|NCT02861027|ACTIVE_COMPARATOR|PPTHA|Control Group performs the PPTHA.
62512451|NCT02861027|EXPERIMENTAL|FES and PPTHA|The Intervention Group performs the PPTHA associated with FES.
62512452|NCT03680079|OTHER|Youth with type 1 diabetes|A group of 16 teens (ages 13-18) with poorly -controlled type 1 diabetes will be recruited to participate in this study.
62512453|NCT06200428|EXPERIMENTAL|Experimental group|"First of all, the pregnant women included in the experimental group;~* Survey forms and scales will be applied in the pre-test (in weeks 29-30).~* Then, a pregnancy pillow will be given and necessary explanations will be given about its use.~* Second follow-up 33-34. It will be done during the first week of pregnancy and the scales will be repeated.~* The last test is 37-38. It will be done during the gestational week (before birth) and the research will be completed.~* Pregnancy pillow provides support and relief to 5 different parts of the body simultaneously.~* It protects the health of expectant mothers during pregnancy and helps reduce neck, abdominal, waist, back and leg pain.~* It does not lose its shape, become felt or flat with use.~* Thanks to its zipper, the cover can be easily removed and washed, and can be put on just as easily."
62512454|NCT06200428|NO_INTERVENTION|Control group|"To the pregnant women included in the control group, the researcher;~* The survey forms and scales will be applied in the pre-test and no other intervention will be applied (in weeks 29-30).~* Pregnant women in the control group were given 33-34 and 37-38 days. The last test will be done in a week."
62512455|NCT00891423|ACTIVE_COMPARATOR|Meropenem short infusion|"Meropenem 1g infused over 30 minutes~* every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~* every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
62512456|NCT00891423|EXPERIMENTAL|Meropenem extended infusion|"Meropenem 500mg infused over 3 hours~* every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~* every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
62512457|NCT03840499||Willing to participate in clinical study|
62512458|NCT03840499||Not-willing to participate in clinical study|
62512459|NCT05329818|EXPERIMENTAL|Prefrontal stimulation.|Participants receive anodal tDCS on the ipsilesional dlPFC for 5days/week for 2 weeks.
62512460|NCT05329818|EXPERIMENTAL|Cerebellar stimulation.|Participants receive anodal tDCS on the contralesional cerebellum for 5days/week for 2 weeks. min of HD-tDCS with 2.0mA.
62512461|NCT05329818|EXPERIMENTAL|Fronto-cerebellar stimulation.|Participants receive simultaneous anodal tDCS on the ipsilesional dlPFC and in contralesional cerebellum for 5days/week for 2 weeks.
62512462|NCT05329818|SHAM_COMPARATOR|Sham stimulation.|Participants receive sham tDCS for 5days/week for 2 weeks.
62512463|NCT03136874||Donors who procreated|
62512464|NCT03136874||Donors who don't procreated|
62512465|NCT05203445|EXPERIMENTAL|Olaparib in Combination with Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks in conjunction with olaparib (for the first 12 weeks) and cytotoxic chemotherapy (after olaparib has been completed) if administered prior to surgery and if the patient is not deemed to have tumor growth.
62512466|NCT04187209|OTHER|Non-traumatic hemiplegia in post stroke acute subacute phase|
62512467|NCT01178164|EXPERIMENTAL|Diagnosis of Fabry disease|
62146894|NCT00701259|EXPERIMENTAL|2|30 mg lansoprazole
62512468|NCT06060548||Patients with PVCs|Patients referred for management of symptomatic or asymptomatic PVCs. Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs.
62512469|NCT01044394|EXPERIMENTAL|same day, reduced volume PEG-ELS prep|Patients with colonoscopies scheduled in the afternoon will complete 2 liters of PEG-ELS solution the morning of their colonoscopy.
62512470|NCT02292511|EXPERIMENTAL|Square-Stepping Exercise Intervention|Participants in this group will attend a square-stepping exercise intervention 60 minutes on two days a week at a community location.
61972495|NCT02228785|EXPERIMENTAL|100µg dose of G17DT|Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
62146895|NCT00701259|PLACEBO_COMPARATOR|3|placebo
62353178|NCT03400215|ACTIVE_COMPARATOR|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
62353179|NCT06061640||case group|MAFLD patients
62353180|NCT06061640||control group|health people
62512471|NCT02292511|NO_INTERVENTION|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
62512472|NCT06094998||children born after ART|120 children born after assisted reproductive technologies
62512473|NCT06094998||children conceived spontaneously|132 children conceived spontaneously
62512474|NCT04880382|OTHER|Standard Arm A: treatment by ICI will be continued|After achieving objective response between 6 and 12 months after treatment onset, for these patients ICI treament will continue as per market authorization
62512475|NCT04880382|EXPERIMENTAL|Experimental Arm B: treatment by ICI will be discontinued|After achieving objective response between 6 and 12 months after treatment onset, for these patients first-line or second line regimen should be discontinued. Patients will be followed as per standard management.
62512476|NCT01478828|EXPERIMENTAL|Lovastatin|After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.
62512477|NCT03475628|EXPERIMENTAL|Daratumumab|Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
62708886|NCT02114645|EXPERIMENTAL|antagonist protocol-leuprolide acetate|GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
61972496|NCT02228785|EXPERIMENTAL|200µg dose of G17DT|Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
62146896|NCT05156606|EXPERIMENTAL|treatment|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
62146897|NCT02133625|EXPERIMENTAL|Pioglitazone and Carboplatin|"MTD Determination~* Pioglitazone: 45 mg Once Daily by mouth,Cycle 1Days 1-28; Subsequent cycles: Days 1-21~* Carboplatin:6 AUC IV 60 minute infusion (or per institutional policy) Cycle 1: Day 8; Subsequent cycles: Day 1"
62146898|NCT02133625|EXPERIMENTAL|MTD Expansion Carboplatin and Pioglitazone|"MTD Expansion:~* Carboplatin alone on cycle 1, day 1.~* Pioglitazone Over days 15-21 of the cycle pioglitazone will be administered alone.~* On cycle 2, day 1, both carboplatin and pioglitazone will be administered. Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks"
62146899|NCT04654390|EXPERIMENTAL|DWP16001 Amg, Dapagiflozin Bmg placebo|Tablets, Orally, Once daily
62146900|NCT04654390|ACTIVE_COMPARATOR|DWP16001 Amg placebo, Dapagliflozin Bmg|Tablets, Orally, Once daily
62146901|NCT05626907|EXPERIMENTAL|Assigned Diet #1|
62146902|NCT05626907|EXPERIMENTAL|Assigned Diet #2|
62146903|NCT05626907|OTHER|Assigned Diet #3|
62146904|NCT02531126|EXPERIMENTAL|RPC0163 (Ozanimod)|
62146905|NCT02258178||1, Flucelvax|Flucelvax exposure in pregnancy
62146906|NCT05407051|ACTIVE_COMPARATOR|Treatment as Usual|In the Treatment as Usual condition, parents will simply be given a list of mental health referrals and crisis numbers.
62146907|NCT05407051|EXPERIMENTAL|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
62146908|NCT03895567|EXPERIMENTAL|ABC|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg)
62146909|NCT03895567|EXPERIMENTAL|ACB|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg)
62146910|NCT03895567|EXPERIMENTAL|BAC|B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg)
62353181|NCT01025947||Study group|Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted
62353182|NCT04965168|ACTIVE_COMPARATOR|controls|phacoemulsification and IOL implantation
62708887|NCT05790356|EXPERIMENTAL|Fecal Microbial Transplant|Participants will be administered 35-40 FMT capsules orally with water, for a total dose of 80-100g. This will only occur once and takes approximately 30 minutes.
62708888|NCT05790356|PLACEBO_COMPARATOR|Placebo|Participants will be administered 35-40 placebo capsules orally with water. This will only occur once and takes approximately 30 minutes.
62708889|NCT04946604|OTHER|Ashtangayoga|Participants attanded eight yoga sessions, one hour long.
61972497|NCT02228785|EXPERIMENTAL|500µg dose of G17DT|Patients in this arm received a 500µg dose of G17DT via intramuscular injection.
61972498|NCT05277740||CIS|Diagnosis of Clinically Isolated Syndrome (CIS) with abnormal MRI.
62146911|NCT03895567|EXPERIMENTAL|BCA|B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
62146912|NCT03895567|EXPERIMENTAL|CAB|C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg)
62146913|NCT03895567|EXPERIMENTAL|CBA|C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
62146914|NCT05300672|EXPERIMENTAL|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
62353183|NCT04965168|ACTIVE_COMPARATOR|diabetic without pseudoexfoliation|phacoemulsification and IOL implantation
62353184|NCT04965168|ACTIVE_COMPARATOR|non-diabetic with pseudoexfoliation|phacoemulsification and IOL implantation
62353185|NCT04965168|ACTIVE_COMPARATOR|diabetic with pseudoexfoliation|phacoemulsification and IOL implantation
62512478|NCT04881734||the control group and the overtime group|Patients who started surgery between 8:00 and 16:59 were included in the control group.
62512479|NCT04881734||the overtime group|Patients who started surgery from 17:00 to 22:00 were included in the overtime group.
62708890|NCT03526263|EXPERIMENTAL|Gastric mucosal devitalization arm|"Patients will be enrolled into the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care at Johns Hopkins Bayview. The cost of the surgery will be covered by the patient's insurance and there will no extra procedural element that would add time to surgery.~The intervention will occur on the excised specimen ex vivo (outside the body) and will involve devitalization of the gastric mucosa using Argon Plasma Coagulation."
62146915|NCT05300672|NO_INTERVENTION|No fibrinogen infusion|No fibrinogen infusion
62512480|NCT04683588|EXPERIMENTAL|intervention arm|"1. Polyclinic: Pre-tests (pain, anxiety, self-care and daily living activities), General coaching, 60 minutes~2. Before Surgery: Nursing coaching, 30-45 minutes~3. Surgery Day: Nursing coaching, 30-45 minutes~4. Postoperative 1st Day: Nursing coaching, 30-45 minutes~5. Postoperative 2nd Day: Nursing coaching practice, 30-45 minutes~6. Day of discharge: Nursing coaching, 30-45 minutes.~7. 15 days after discharge: Nursing coaching, 60 minutes~8. 45 days after the operation: Nursing coaching, 60 minutes.~9. 90 days after surgery: Nursing coaching, 60 minutes."
62512481|NCT04683588|NO_INTERVENTION|Control arm|Patients in the control group will receive routine postoperative nursing care.
62512482|NCT02958852|ACTIVE_COMPARATOR|Letrozole|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
62512483|NCT02958852|EXPERIMENTAL|Letrozole+Atorvastatin|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily, with the addition of atorvastatin, 40 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
61972499|NCT05277740||RRMS|Diagnosis of Relapsing-Remitting MS (RRMS).
61972500|NCT05277740||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
61972501|NCT05188950|EXPERIMENTAL|treatment group|The intervention involved the participants' use of the mobile application.
61972502|NCT05188950|NO_INTERVENTION|control group|As usual.
62146916|NCT01450397|OTHER|XIAFLEX|XIAFlEX
62146917|NCT02443909|ACTIVE_COMPARATOR|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w Holmium laser device who have 2-3 cm kidney stones
62146918|NCT02443909|ACTIVE_COMPARATOR|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power) who have 2-3 cm kidney stones
62146919|NCT02443909|ACTIVE_COMPARATOR|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power) who have 2-3 cm kidney ston
62353186|NCT06016257|EXPERIMENTAL|VirtuaCare Group|"For the subjects in Group 1, the physical therapist will set up the patients within the VirtuaCare™ system and build their treatment plan.~Each time a patient in the VirtuaCare returns for a clinic visit, the physical therapist will review their VirtuaCare™ patient report displaying information such as exercises completed along with their measured form, pace, range of motion, and exertion. From the review, they will help the patient understand any corrections they need to make in the following week when at home. The therapist can add or adjust any exercises they deem necessary for the next phase of the patient's rehabilitation."
62353187|NCT06016257|NO_INTERVENTION|Usual and Customary Group|This study involves a medical record review for the control group. Data will be abstracted from closed medical records after completion of shoulder physical therapy.
62353188|NCT02532387||MGH ED/EDOU patients|"Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
62353189|NCT02532387||BWH ED/EDOU patients|"Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
62353190|NCT02532387||Control subjects|"1. Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment~2. Historical controls:~   1. Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.~  2. Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol."
62353191|NCT00863980|EXPERIMENTAL|Telmisartan|Treatment with Telmisartan
62353192|NCT00863980|ACTIVE_COMPARATOR|Candesartan|Treatment with Candesartan
62353193|NCT05518669||Peripheral Pulmonary Nodules|Patients with peripheral pulmonary nodules on chest computed tomography suspicion of malignancy who are scheduled to reach the target lesion for diagnosis by mobile cone-beam CT combined with electromagnetic navigation bronchoscopy.
62353194|NCT02993913|EXPERIMENTAL|Simmiparib tablet monotherapy|Drug: Simmiparib tablet oral Qd or Bid
62353195|NCT02366741|OTHER|Pilot group|Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
62512484|NCT02958852|OTHER|Fulvestrant|Fulvestrant will be used as second line endocrine treatment upon progression on first line with letrozole +/- atorvastatin.
62512485|NCT05866718|ACTIVE_COMPARATOR|Self-Compassionate Touch Intervention Alone|All participants will receive the self-compassion intervention after completing their baseline assessment, which will contain the same instructions used in the initial study (see NCT05199779).
62512486|NCT05866718|EXPERIMENTAL|Self-Compassionate Touch Intervention Plus Habit Formation Tools|SCT+HABITS participants will receive the abovementioned procedures, and will also receive evidence-based tools for forming habits.
62708891|NCT01988077|OTHER|Adoptive cell transfer combined with Ipilimumab|Adoptive cell transfer combined with Ipilimumab
62708892|NCT02361892|EXPERIMENTAL|Ulipristal acetate|Women will be treated with 5mg/die of Ulipristal acetate for 2 courses of 3 months each
62146920|NCT06353620||Epilepsy|EEG resting state recording, neuropsychological evaluation
62146921|NCT06353620||Angelman Syndrome|EEG resting state recording, neuropsychological evaluation
62146922|NCT06353620||Dup15q Syndrome|EEG resting state recording, neuropsychological evaluation
62146923|NCT06353620||Control Group|EEG resting staterecording
62708893|NCT05595109|PLACEBO_COMPARATOR|Group one: (Placebo group)|"which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day)~followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily."
62512487|NCT05281926|EXPERIMENTAL|Poly-ICLC|Hiltonol is a poly-ICLC developed by the Oncovir, Inc. A phase I study of hiltonol monotherapy in solid tumors was completed (NCT01984892). Clinical trials of hiltonol plus ICIs are undergone in various type cancers (NCT03721679, NCT02834052).
62512488|NCT00708708||A|Patients with moderate to severe plaque psoriasis
62512489|NCT03704857|ACTIVE_COMPARATOR|Foraminal enlargement with sodium hypochlorite as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512490|NCT03704857|EXPERIMENTAL|Foraminal enlargement with sodium hypochlorite and photobiomodulation|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, photobiomodulation (antimicrobial photodynamic therapy and low-level laser therapy), lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512491|NCT03704857|EXPERIMENTAL|Foraminal enlargement with chlorhexidine as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, chlorhexidine as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512492|NCT03704857|ACTIVE_COMPARATOR|Foraminal enlargement with sodium hypochlorite and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with AH Plus.The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512493|NCT03704857|ACTIVE_COMPARATOR|Foraminal enlargement with conventional irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, conventional irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62539424|NCT04762849|EXPERIMENTAL|laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR)|Laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. A ring with shape memory put on the gastric pouch
62708894|NCT05595109|ACTIVE_COMPARATOR|Group two: (Silymarin group)|which will receive the same regimen plus silymarin 140mg once daily.
62708895|NCT04442269|EXPERIMENTAL|dupilumab|Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
62708896|NCT04442269|EXPERIMENTAL|Placebo|Matching dupilumab without active substance
62708897|NCT02878434||Study group|
62708898|NCT02878434||control group|
62708899|NCT01448616|NO_INTERVENTION|Run-in Phase|Women will first participate in a run-in phase with twice daily swabbing.
62708900|NCT01448616|EXPERIMENTAL|Study Drug Phase: TDF|Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
61972503|NCT01414114|EXPERIMENTAL|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) administered by intravenous bolus injection at the end of each hemodialysis session for 12 weeks. The starting dose was 5 mg and may have been titrated every 4 weeks based on the preceding serum parathyroid hormone (PTH) and corrected calcium (cCa) levels to a maximum dose of 20 mg per hemodialysis session in order to achieve the targeted PTH range while maintaining serum calcium within an acceptable range.
61972504|NCT05073991||Lung surgery|Patients underwent lung surgery.
62708901|NCT01448616|EXPERIMENTAL|Study Drug Phase: Vaginal TFV Gel|Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
61972505|NCT05073991||Open aortic suregry|Patients underwent open aortic surgery.
61972506|NCT05073991||Thoracic endovascular aortic repair (TEVAR)|Patients underwent TEVAR.
62708902|NCT01448616|PLACEBO_COMPARATOR|Study Drug Phase: Double Placebo|Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
62708903|NCT05155111|EXPERIMENTAL|Telemedicine arm|Neonates will have telemedicine consultation to evaluate symptoms of neonatal encephalopathy
62708904|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
62708905|NCT05287451|OTHER|Risk-Reducing Salpingectomy-RRS|Can help to lower the risk of ovarian cancer with a delayed removal of 1.
62708906|NCT05287451|OTHER|Risk-Reducing Oophorectomy-RRO|Can help to lower the risk of ovarian cancer removing both fallopian tubes.
62708907|NCT05287451|OTHER|Risk-Reducing Salpingo-Oophorectomy-RRSO|Can help to lower the risk of ovarian cancer as well as the standard-of-care risk-reducing procedure involving the removal of the fallopian tubes and ovaries (risk-reducing salpingo-oophorectomy-RRSO)
62708908|NCT04260477|EXPERIMENTAL|6EH³R3Z|(Rifampicin (R)/ Isoniazid (H) / Pyrazinamide (Z)/Ethambutol (E)) 6-month high-dose treatment; New high-dose isoniazid / high-dose rifampicin retreatment regimen (6EH³R3Z) - that includes triple-dose rifampicin (R3; 30 mg/kg), and triple-dose isoniazid (H3; 15 mg/kg), complemented with pyrazinamide (Z) and ethambutol (E).
62708909|NCT04260477|ACTIVE_COMPARATOR|6EHRZ|Standard of care: 6-month 6RHZE regimen with dose combination tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E)
61972507|NCT05073991||Endovascular aneurysm repair (EVAR)|Patients underwent EVAR.
62708910|NCT02614820|EXPERIMENTAL|treatment group|inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals
62708911|NCT02614820|OTHER|control group|inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals
62708912|NCT02908711|ACTIVE_COMPARATOR|Patients receiving ACB before primary TKA|"Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block prior to incision after induction of general anesthesia"
62708913|NCT02908711|ACTIVE_COMPARATOR|Patients receiving ACB after primary TKA|"Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block at the end of the surgery."
62146924|NCT05414825||11 to 14 years old teenagers|Semi-structured discussion group with only young teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the young teenagers suffering from severe dysmenorrhea.
62353196|NCT05400356||Complication group|"Postoperative complications are defined as postoperative death, vital organ dysfunction, and mechanical ventilation duration greater than 24 hours.The vital organ dysfunction includes new developed acute kidney injury, long-term low cardiac output, severe liver function injury and neurological function injury.~The time of occurrence is defined as from the beginning of surgery to 30 days after surgery or to discharge from hospital."
62353197|NCT05400356||Non-complication group|"Patients with none of postoperative complications which showed in Complication group.~The time of occurrence is defined as from the beginning of surgery to 30 days after surgery or to discharge from hospital."
62353198|NCT05996380|EXPERIMENTAL|SHR-3167|
62539425|NCT04762849|ACTIVE_COMPARATOR|laparoscopic one anastomosis gastric bypass (MGB/OAGB) without band: standard surgery|Laparoscopic one anastomosis gastric bypass (MGB/OAGB) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
62146925|NCT05414825||15 to 17 years old teenagers|Semi-structured discussion group with older teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of these patients suffering from severe dysmenorrhea.
62353199|NCT05996380|PLACEBO_COMPARATOR|SHR-3167 Placebo|
62353200|NCT03380624|EXPERIMENTAL|Refresh Optive, then Refresh Optive MEGA-3|"Participants first utilized one drop of Refresh Optive in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements.~."
62353201|NCT03380624|EXPERIMENTAL|Refresh Optive MEGA-3, then Refresh Optive|Participants first utilized one drop of Refresh Optive MEGA-3 in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive before taking lipid layer thickness measurements.
62353202|NCT02739256|EXPERIMENTAL|voiding trial 4 hours post-op|
62353203|NCT02739256|ACTIVE_COMPARATOR|voiding trial post-op day 1|
62539426|NCT01143766|ACTIVE_COMPARATOR|Standard sedation|Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.
62708914|NCT00948350|ACTIVE_COMPARATOR|translaryngeal injection|translaryngeal injection of local anesthetics before the awake intubation
62708915|NCT00948350|ACTIVE_COMPARATOR|spray as you go|local anesthetics are given through the fiberoptic during awake intubation
62708916|NCT01115504|EXPERIMENTAL|Thiamine|Thiamine tablets of 300mg are prescribed for 1 months
62708917|NCT01115504|PLACEBO_COMPARATOR|Plascebo|Tablets of 300mg placebo are prescribed for 1 months
61972508|NCT00848705|ACTIVE_COMPARATOR|Measurement Only|
61972509|NCT00848705|EXPERIMENTAL|Internet Intervention|
61972510|NCT03174236|EXPERIMENTAL|Ceftriaxone|Arm 1 IV Ceftriaxone: Participants in this group receive 80mg/kg IV ceftriaxone once a day for a minimum of 48 hours and a usual maximum of seven days.
61972511|NCT03174236|ACTIVE_COMPARATOR|Benzyl penicillin plus gentamicin|Arm 2 IV Benzyl penicillin plus gentamicin (usual care): Participants in this group receive 50 000 U/kg IV benzyl penicillin every six hours for a minimum of two days and a maximum of seven days.
61972512|NCT03174236|EXPERIMENTAL|Metronidazole|Arm 1 Metronidazole: Participants receive 10 to 16 mg/kg oral metronidazole twice a day for seven days.
61972513|NCT03174236|PLACEBO_COMPARATOR|Placebo|Arm 2 Placebo: Participants receive an oral placebo dose to match that for Metronidazole twice a day for seven days.
61972514|NCT00822250|OTHER|1|cutting hair, skin phenotype description
61972515|NCT05253053|EXPERIMENTAL|Arm A: TT-00420 Tablet Monotherapy|TT-00420 tablets will be administered once daily in 21-day cycles. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
61972516|NCT05253053|EXPERIMENTAL|Arm B: TT-00420 tablet in combination with Atezolizumab Injection (Tecentriq ®)|TT-00420 tablets will be administered once daily in 21-day cycles. Atezolizumab(1200 mg/20 mL) will be administered intravenously on Day 1 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
61972517|NCT05253053|EXPERIMENTAL|Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®)|TT-00420 tablets will be administered once daily in 21-day cycles. Nab-paclitaxel 125 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
62708918|NCT02715284|EXPERIMENTAL|Part 1: Participants receiving dostarlimab|Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.
62708919|NCT02715284|EXPERIMENTAL|Part 2A: Participants receiving dostarlimab|In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.
62708920|NCT02715284|EXPERIMENTAL|Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer|Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage \>= IIIB) disease.
62708921|NCT02715284|EXPERIMENTAL|Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer|Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage \>=IIIB) disease.
62708922|NCT02715284|EXPERIMENTAL|Part 2B: Cohort E NSCLC|Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
62708923|NCT02715284|EXPERIMENTAL|Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers|Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers, and gastrointestinal cancers, who have received prior systemic therapy and, who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
61972518|NCT01059799|EXPERIMENTAL|IDeg OD|
61972519|NCT01059799|ACTIVE_COMPARATOR|IGlar OD|
61972520|NCT05048940|EXPERIMENTAL|HETEROLOGOUS VACCINE|COVID-19 Vaccine Janssen, injectable suspension
62353204|NCT01913860|NO_INTERVENTION|Control|Control group will receive usual care
62353205|NCT01913860|ACTIVE_COMPARATOR|Improve GP prescribing behaviour|Improve GP prescribing behaviour will be promoted through personalised audit and feedback reports, delivered through face to face workshops within practice.
62708924|NCT02715284|EXPERIMENTAL|Part 2B: Cohort G PROC without known BRCA|Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
62708925|NCT05664373|ACTIVE_COMPARATOR|extraoraly de-epithelialized free gingival graft in combination with CAF|Epithelium will be removed after harvesting the graft by using the blade. By using the blade the epithelium will be separated from the connective tissue.
62708926|NCT05664373|EXPERIMENTAL|intraoraly de-epithelialized free gingival graft in combination with CAF|The epithelium will be removed prior to harvesting the graft from the palate. By using a diamond bur the epithelium will be removed until the connective tissue is exposed on the whole area of the intended graft size. Thereafter, the graft will be harvested.
61972521|NCT05048940|ACTIVE_COMPARATOR|HOMOLOGOUS VACCINE|Spikevax (Moderna), injectable dispersion
61972522|NCT06415292|EXPERIMENTAL|Winlevi (clascoterone) 1% treated|
61972523|NCT00035620|ACTIVE_COMPARATOR|Filgrastim|Filgrastim
61972524|NCT00035620|EXPERIMENTAL|Pegfilgrastim|Pegfilgrastim
61972525|NCT04646889|EXPERIMENTAL|Renal Impairment|Subjects with various degrees of renal impairment
61972526|NCT04646889|EXPERIMENTAL|Normal Renal Function|Subjects with normal renal function
62353206|NCT01913860|ACTIVE_COMPARATOR|Improved delayed GP prescribing|Improved delayed GP prescribing will be promoted through the antibiotic prescribing guidelines and personalised audit and feedback reports. Additional scientific evidence will be provided related to delayed prescribing.
62539427|NCT01143766|ACTIVE_COMPARATOR|Gapabentin|Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.
62539428|NCT05997732|EXPERIMENTAL|Control Condition|Normal saline will be infused through the brachial artery catheter at the same calculated rate as propranolol + phentolamine in the α+β-blockade condition to control for volumetric effects.
61972527|NCT01759667|EXPERIMENTAL|A standard mixed Meal|The standard mixed meal was composed of a chicken salad sandwich and 200ml of coconut water, totalling 260 kcal, distributed among carbohydrates (62%), proteins (12%) and lipids (26%).
61972528|NCT01443754||Hybrid group|Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)
62708927|NCT03518021|EXPERIMENTAL|Naloxone, intranasal|
62146926|NCT05414825||11 to 14 years old teenagers' parents|Semi-structured discussion group with parents of young teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the parents on the care and feelings of their child suffering from severe dysmenorrhea.
62353207|NCT01957787|EXPERIMENTAL|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. Tumors in both lungs are to be treated at an appropriate interval, determined on an individual basis. Treatment of bilateral index tumors in a single treatment session will not be performed. All participants will receive cryoablation of up to 6 metastatic lung tumors. Treatment of all study index tumors are to be completed within an 8-week window.
62353208|NCT01022385|NO_INTERVENTION|12-hour fast|
62353209|NCT01022385|ACTIVE_COMPARATOR|24-hour low-residual diet and 12-hour fast|
62353210|NCT00599235|EXPERIMENTAL|1|
62353211|NCT00599235|ACTIVE_COMPARATOR|2|
62353212|NCT03678584|EXPERIMENTAL|Handling Medium Supplemented with Chaetoglobosin A|
62353213|NCT03678584|NO_INTERVENTION|handling Medium as it is.|
62353214|NCT01473303|EXPERIMENTAL|Arm I|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 48 hours beginning on day 2 (mFOLFIRINOX) and ganitumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
62353215|NCT01473303|EXPERIMENTAL|Arm II|Patients receive mFOLFIRINOX as in arm I and placebo IV over 30-60 minutes on day 1.
62353216|NCT01057134|EXPERIMENTAL|Site treated with UHAIR|The arm, calf, and thigh will be treated
62353217|NCT06261112|EXPERIMENTAL|Experimental group|Experimental group kaleideskope, pain and fear
62353218|NCT06261112|NO_INTERVENTION|No intervention group|No intervention group Control not pain and fear
62353219|NCT01757977|EXPERIMENTAL|Vivasight DL|placement and intraoperative use of Vivasight DL double lumen endobronchial tube
62539429|NCT05997732|EXPERIMENTAL|β-Adrenergic Blockade|β-adrenoreceptors will be blocked locally in the forearm using propranolol. Normal saline will be co-infused at the calculated rate of phentolamine in the α+β-blockade condition to control for volumetric effects.
62539430|NCT05997732|EXPERIMENTAL|α+β-Adrenergic Blockade|α-adrenoreceptors will be blocked locally in the forearm using phentolamine. Propranolol will be co-infused to maintain β-blockade.
62708928|NCT03518021|ACTIVE_COMPARATOR|Naloxone, intramuscular|
62708929|NCT03518021|PLACEBO_COMPARATOR|placebo, intranasal|
62708930|NCT03518021|PLACEBO_COMPARATOR|placebo, intramuscular|
62708931|NCT01067807|EXPERIMENTAL|Proellex Formulation 1|25 mg Proellex Gelucire and PEG (original formulation)
62708932|NCT01067807|EXPERIMENTAL|25 mg Proellex Formulation 2|25 mg Proellex coated with MCC
62353220|NCT01757977|ACTIVE_COMPARATOR|standard DLT|placement and intraoperative use of a standard double lumen endotracheal tube.
62353221|NCT04873869|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo for up to 18 weeks.
62353222|NCT04873869|EXPERIMENTAL|NBI-921352|In the first 6 weeks participants will receive increasing doses of NBI-921352 (Titration Period) based on weight, followed by 10 weeks of treatment at their final tolerated dose (Maintenance Period) and 2 weeks of treatment with decreasing doses (Taper Period).
62353223|NCT06268587||control group|The control group is made up of patients, without age limit, who underwent an outpatient surgery from 01/09/19 to 28/02/20 inclusive and accepted post-operative monitoring by SMS. These patients leaves the hospital with instructions and prescriptions.
62353224|NCT06268587||experimental group|The experimental group is made up of patients, without age limit, who underwent an outpatient surgery procedure from 1/9/21 to 28/2/22 inclusive and accepted post-operative monitoring by SMS. The patients leaves the hospital with instructions, analgesics for a maximum of two days with detailed dosages and an explanatory booklet on postoperative pain.
62353225|NCT06342570||There is no group to describe.|There is no group to describe.
62353226|NCT06053619|EXPERIMENTAL|GaitTrainer|This group of participants will benefit from 3 consecutive sessions of classic GaitTrainer without VR and then these same participants will benefit from 3 consecutive sessions of GaitTrainer with VR
62353227|NCT05955079||Endometrial Cancer|Patients over 18 years old with a biopsy-proven endometrial cancer, at FIGO stage I to IV, and amenable and undergoing surgical treatment
62353228|NCT01726283||low risk subjects for developing post-operative ectasia|Patients undergoing vision correction surgery who are not at a higher risk for developing post-op ectasia
62353229|NCT01726283||Subjects at Risk for Ectasia|Patients undergoing vision correction surgery who are at a higher risk for developing post-operative ectasia
62353230|NCT02020460|ACTIVE_COMPARATOR|Subdural trial lead|SCS trial lead in the subdural space.
62353231|NCT02020460|ACTIVE_COMPARATOR|Epidural trial lead|SCS trial lead in the epidural space.
62353232|NCT01985373|EXPERIMENTAL|Intravenous immunoglobulin infusion|One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)
62353233|NCT05278286|EXPERIMENTAL|Crawli Group|Participants from the Crawli Group will benefit from the crawling stimulation intervention with the crawliskate
62708933|NCT01067807|EXPERIMENTAL|25 mg Proellex Formulation 3|25 mg Proellex blended with MCC
62708934|NCT01067807|EXPERIMENTAL|50 mg Proellex Formulation 3|50 mg Proellex blended with MCC
62708935|NCT03271333||patients with systemic sclerosis|
62708936|NCT01604317|ACTIVE_COMPARATOR|Resuscitation-torso plastic bag|Resuscitation with plastic bag covering torso and lower extremities for first hour to assist with temperature regulation.
62708937|NCT01604317|ACTIVE_COMPARATOR|Resuscitation-partial-head plastic bag|Resuscitation with plastic bag covering torso, upper and lower extremities, and a portion of the head for first hour after birth to assist with temperature regulation.
62353234|NCT05278286|ACTIVE_COMPARATOR|Mattress Group|Participants from the Mattress Group will benefit from the tummy time intervention
62353235|NCT05278286|NO_INTERVENTION|Control Group|Control group infants benefit from usual care.
62353236|NCT02029638|EXPERIMENTAL|RICG, BMT and high dose PT/Cy+SOC|"Reduced-intensity conditioning regimen (RICG), bone marrow transplantation (BMT), high dose post-transplant cyclophosphamide (PT/Cy) and Standard of Care (SOC).~Participants will receive: ATG (pre-transplant), pre-medicated with acetaminophen, diphenhydramine; steroid taper of methylprednisolone; fludarabine (2-6 days before transplant), and low-dose cyclophosphamide (pre- transplant); total body irradiation the day before transplant. Participants will receive a living renal transplant followed by BMT. High-dose cyclophosphamide will be given on days 3 and 4 post-transplant with MESNA. Filgrastim will be given on day 5 post-transplant and continue until absolute neutrophil recovery. Standard immunosuppression of tacrolimus, MMF, and prednisone will begin on day 5 post-transplant and be given ≥26 weeks post-transplant. Eligible participants will be gradually withdrawn from medication over a period of 24-40 weeks."
62353237|NCT06182540|EXPERIMENTAL|Ileostomy cohort|
62353238|NCT06182540|EXPERIMENTAL|Non-Ileostomy cohort|
62708938|NCT05159674|EXPERIMENTAL|Dexmedetomidine+electroacupuncture compound anesthesia|EA was given every day three days before surgery, 30 minutes before induction of anesthesia + the whole course of surgery, and every 12 hours from the first day after surgery, each treatment was performed for 30 minutes until 48 hours after surgery. During the operation, only dexmedetomidine was used to make BIS\<80.
62708939|NCT05159674|NO_INTERVENTION|Dexmedetomidine anesthesia|There was no EA treatment before, during or after operation. During the operation, only dexmedetomidine was used to make BIS\<80.
62708940|NCT01664624|EXPERIMENTAL|Roflumilast + alogliptin|Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.
62708941|NCT01664624|EXPERIMENTAL|Alogliptin alone|Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.
62708942|NCT01664624|EXPERIMENTAL|Roflumilast alone|Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.
62708943|NCT01664624|ACTIVE_COMPARATOR|Exenatide|Exenatide 5 μg subcutaneous injection twice a day for 11 days.
61972529|NCT05557461||Group-1|"group with fluid responsiveness in passive leg raise test After the patients are in a semi-sitting position (at least 2 minutes), two healthcare professionals will take the supine position and then lift their legs 45 degrees, wait for 2 minutes and return to the initial position.~10% change in stroke volume will be considered positive and patients will be divided into 2 groups as fluid-responsive and non-responsive."
62708944|NCT02695654||Chronic pain in knee osteoarthritis|Ultrasound guided single shot Adductor canal block with 0,25% Levobupivacaine 14 ml and 100 mcg Clonidine
62708945|NCT05021939|NO_INTERVENTION|Control Group|No treatment will be given to the control group. Evaluation will be done at the at the baseline and 8th week.
61972530|NCT05557461||Group-2|"group with no fluid response in passive leg raise test After the patients are in a semi-sitting position (at least 2 minutes), two healthcare professionals will take the supine position and then lift their legs 45 degrees, wait for 2 minutes and return to the initial position.~10% change in stroke volume will be considered positive and patients will be divided into 2 groups as fluid-responsive and non-responsive."
61972531|NCT05675943|EXPERIMENTAL|Anti-COVID-19 Antibody SA55 for Injection|Anti-COVID-19 Antibody SA55 for Injection
61972532|NCT05675943|PLACEBO_COMPARATOR|Placebo|Anti-COVID-19 Antibody SA55 for Injection administered intramuscular
61972533|NCT04508244|ACTIVE_COMPARATOR|TBI with positive troponin|Patients will receive IV propranolol for 6 days
61972534|NCT04508244|PLACEBO_COMPARATOR|TBI with negative troponin (a)|Patients will receive IV placebol for 6 days
61972535|NCT04508244|EXPERIMENTAL|TBI with negative troponin (b)|Patients will receive IV propranolol for 6 days
61972536|NCT03985449|OTHER|Active Implementation phase|See the 'detailed description' section to read about the intervention(s) clinicians will use during the active implementation phase of the randomized stepped-wedge design.
61972537|NCT00894049|EXPERIMENTAL|Flu-Bu-ATG|Fludarabine (30mg/m²/5 days) Oral Busulfan (8 mg/kg over 2 days) Thymoglobuline (2.5 mg/m²/1day).
61972538|NCT00894049|EXPERIMENTAL|Fluda-TBI|Fludarabine (25mg/m²/ 3 days) 2 Gy TBI
61972539|NCT04921254|EXPERIMENTAL|BSG005|Active antifungal drug
61972540|NCT04921254|PLACEBO_COMPARATOR|Placebo|Will be a 5% glucose infusion
62353239|NCT04889963|PLACEBO_COMPARATOR|control group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)
62353240|NCT04889963|ACTIVE_COMPARATOR|conditioned medium group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium
62353241|NCT04889963|ACTIVE_COMPARATOR|stem cells group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition
62353242|NCT04889963|EXPERIMENTAL|composite group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium
62539431|NCT04261907|EXPERIMENTAL|ASC09/ritonavir group|ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
62539432|NCT04261907|ACTIVE_COMPARATOR|lopinavir/ritonavir group|Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment
62539433|NCT03876262|EXPERIMENTAL|Annual Moxidectin|Moxidectin 8mg per oral, administered annually for 24 months
62539434|NCT03876262|EXPERIMENTAL|Biannual Moxidectin|Moxidectin 8mg per oral, administered biannually for 24 months
61972541|NCT03848650|EXPERIMENTAL|Opsens Medical OptoWire|Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
61972542|NCT00345345|EXPERIMENTAL|Alemtuzumab in patients with T cell large granular lymphocytic leukemia (T-LGL)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
61972543|NCT03138889|EXPERIMENTAL|Dose Optimization, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)|Cohort 1: NKTR-214 will be combined with pembrolizumab
61972544|NCT03138889|EXPERIMENTAL|Dose Expansion, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)|Cohort 2: NKTR-214 will be combined with pembrolizumab
61972545|NCT03138889|EXPERIMENTAL|Dose Expansion, Combo of NKTR-214 + Pembrolizumab (KEYTRUDA®)|Cohort 3: NKTR-214 will be combined with pembrolizumab
62512494|NCT03704857|EXPERIMENTAL|Foraminal enlargement with passive ultrasonic irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, passive ultrasonic irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512495|NCT03704857|EXPERIMENTAL|Foraminal enlargement with cryotherapy|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, cryotherapy with saline solution, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512496|NCT03704857|EXPERIMENTAL|Foraminal enlargement with cryotherapy and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, cryotherapy with saline solution, lateral condensation filling with AH Plus. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512497|NCT03704857|EXPERIMENTAL|Foraminal enlargement with ozone therapy|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, ozone therapy, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512498|NCT03704857|EXPERIMENTAL|Foraminal enlargement with ozone therapy and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, ozone therapy, lateral condensation filling with AH Plus. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
62512499|NCT01353248|ACTIVE_COMPARATOR|Arm 1|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.
62353243|NCT03046043|EXPERIMENTAL|Low-Voltage & CFAE guided ablation|"* Pulmonary isolation will be performed~* Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation~* CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™~* Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.~* CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage \& CFAE guided ablation)"
62353244|NCT03046043|ACTIVE_COMPARATOR|PV Isolation Only|"* Pulmonary vein isolation will be performed.~* Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
62353245|NCT01852929|OTHER|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
62353246|NCT01852929|OTHER|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
62353247|NCT02709772|ACTIVE_COMPARATOR|Provider Alert|This arm is the intervention arm. This arm will receive the Electronic Record Alert.
62353248|NCT02709772|NO_INTERVENTION|No Provider Alert|This arm is the control arm.
62353249|NCT03404518|EXPERIMENTAL|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
62353250|NCT03404518|ACTIVE_COMPARATOR|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
62353251|NCT05289856|EXPERIMENTAL|combination of Avelumab and Cabozantinib|800 mg Avelumab every 2 weeks and 40 mg Cabozantinib daily
61972546|NCT03138889|EXPERIMENTAL|Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed|Cohort 4: NKTR-214 will be dosed in combination with pembrolizumab and either cisplatin, or carboplatin and pemetrexed, per investigator discretion
61972547|NCT03138889|EXPERIMENTAL|Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel|Cohort 5: NKTR-214 will be dosed in combination with pembrolizumab and carboplatin and either nab-paclitaxel or paclitaxel, per investigator discretion
62512500|NCT01353248|ACTIVE_COMPARATOR|Arm 2|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 12 or 24 weeks.
62512501|NCT00360737|EXPERIMENTAL|NP-018 - 1 vial|Subjects received one vials of NP-018 administered intravenously.
62512502|NCT00360737|EXPERIMENTAL|NP-018 - 2 vials|Subjects receive two vials of NP-018 administered intravenously.
62512503|NCT04663438||Arm A|200/Atezolizumab combined with EC regimen Atezolizumab:1200 mg Q3w
62512504|NCT04663438||Arm B|100/Atezolizumab combined with chemotherapy Atezolizumab:1200mg Q3w
62512505|NCT04601233|EXPERIMENTAL|Treatment open label arm|Open-label feasibility study to determine the effects of testosterone (Xyosted 75mg subcutaneous once per week for 3 months) on erectile function in male Multiple Sclerosis patients with low testosterone.
62512506|NCT02377921|EXPERIMENTAL|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
62512507|NCT02377921|PLACEBO_COMPARATOR|Placebo|Matching placebo TID for 48 weeks.
62512508|NCT02507245||GHD Children|Treatment with Growth Hormone-Releasing Hormone in children affected by idiopathic growth hormone deficiency (GHD)
62512509|NCT02316158|EXPERIMENTAL|Webb-based support and education|It contains of two parts 1) evidence based information (about mental diseases, early signs, coping strategies, what you can do for your relative or close friend, what you can do for yourself, addresses to networks and web sites, relevant juridical issues, etc), 2) FAQ, where you directly can find answers to common questions.
62708946|NCT05021939|EXPERIMENTAL|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
62708947|NCT05021939|EXPERIMENTAL|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
62708948|NCT02623244||ovarian endometrioma|Women with ovarian endometrioma noted by ultrasonography.
62708949|NCT02623244||The control group|Women with age and body mass index matched and without ovarian endometrioma in ultrasonography
62708950|NCT02408744|EXPERIMENTAL|Pirfenidone|Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.
62708951|NCT05481684|EXPERIMENTAL|Normal Progesterone group|Progesterone level ≥ 10 ng/mL on ET day.
62708952|NCT05481684|ACTIVE_COMPARATOR|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. Grup a Rescue vaginal progesterone, Grup b Rescue subcutan progesterone
62512510|NCT02316158|ACTIVE_COMPARATOR|Available support in society|Available support in society for young persons presented in a brochure
62512511|NCT00772616|EXPERIMENTAL|1|Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).
62512512|NCT00772616|ACTIVE_COMPARATOR|2|Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria
62512513|NCT01543711||Breast cancer survivors|Women treated for breast cancer, without signs of recurrence or metastasis
62512514|NCT05592093|EXPERIMENTAL|KRGO group|Korean red ginseng capsule (KRGO)marketed product in Korea donated by The Korean Society of Ginseng.
62512515|NCT05592093|PLACEBO_COMPARATOR|placebo group|Same smell, color and shape as Korean red ginseng capsule (KRGO)without herbs in capsules.
62512516|NCT03056079|OTHER|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
62512517|NCT06133218|ACTIVE_COMPARATOR|Intervention side - Mepitel Film|This was an intra-patient randomized study. The patient was randomized for Mepitel film (barrier film) applied on the medial or lateral side of their breast or chest wall during the entire course of radiotherapy; making the patients their own control.
62512518|NCT06133218|NO_INTERVENTION|Control side - standard care|The other side of the breast or chest wall is the intra-patient control as the skin on this side was treated according to standard guidelines for skin care during radiotherapy when symptoms or skin reactions occured.
62512519|NCT04703842|EXPERIMENTAL|SRD-001|3E13 or 4.5E13 vg; one-time intracoronary infusion
62512520|NCT04703842|PLACEBO_COMPARATOR|Placebo|One-time intracoronary infusion
62512521|NCT02166320|ACTIVE_COMPARATOR|Partially covered SEMS|Boston Scientific Ultraflex SEMS
62512522|NCT02166320|EXPERIMENTAL|Fully covered SEMS|Boston Scientific Wallflex Esophageal SEMS.
62512523|NCT06463717||ASCT regimen|Primary multiple myeloma patients who receive autologous hematopoietic stem-cell transplantation (ASCT) after they achieved MRD negativity after induction
61972548|NCT03138889|EXPERIMENTAL|Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®) or Atezolizumab (TECENTRIQ®)|Cohort 0 (Before Protocol Amendment 5.0): NKTR-214 will be combined with pembrolizumab or atezolizumab
61972549|NCT06472765||Premenopausal Healthy|Premenopausal Healthy
62512524|NCT06463717||non ASCT regimen|Primary multiple myeloma patients who receive non autologous hematopoietic stem-cell transplantation (ASCT) regimen such as 4-6 cycles of bortezomib-lenalidomide-dexamethasone after they achieved MRD negativity after induction
62539435|NCT03876262|ACTIVE_COMPARATOR|Annual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
62539436|NCT03876262|EXPERIMENTAL|Biannual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
62512525|NCT00653159|ACTIVE_COMPARATOR|Mirena IUD [LNG-IUS]|Participants in this arm had a Levonorgestrel-releasing intrauterine device (LNG-IUS), also known as the Mirena IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
62512526|NCT00653159|ACTIVE_COMPARATOR|Paragard IUD [Copper T380A]|Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
62512527|NCT04919382|EXPERIMENTAL|Cohort I (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62512528|NCT04919382|EXPERIMENTAL|Cohort II (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive temozolomide PO QD on days 1-14 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62512529|NCT01358539|EXPERIMENTAL|Pain education|Patients receiving pain education
62512530|NCT01358539|NO_INTERVENTION|No Pain education|Control group, patients receiving no pain education
62512531|NCT00697216|EXPERIMENTAL|Group A|
61972550|NCT06472765||Perimenopausal Healthy|Perimenopausal Healthy
61972551|NCT06472765||Postmenopausal Healthy|Postmenopausal Healthy
61972552|NCT06472765||Bacterial Vaginosis|Bacterial Vaginosis
61972553|NCT06472765||Candidiasis|Yeast Infections
62353252|NCT02437552|PLACEBO_COMPARATOR|Control group: routine physiotherapy|Are patients who carry out the routine already established the Unit, consisting of the first post surgery, the patient lying down doing the breathing exercises, active exercises ends and active-assisted upper (UL) and lower limbs (LL),
62353253|NCT02437552|ACTIVE_COMPARATOR|Intervention group: ergometer cycle exercise|Are the patients who will carry out the exercises routine over the cycle ergometer twice daily from 3 PO for 5 minutes with its progressiveness at discharge for ward for 10 minutes
62353254|NCT01160471||Healthy Volunteers|Adult men and women without a clinical diagnosis of heart failure
62353255|NCT01160471||Patients|Adult men and women with a clinical diagnosis of heart failure
62353256|NCT04600921|ACTIVE_COMPARATOR|Ertugliflozin|The subject will receive Ertugliflozin 5mg.
62353257|NCT04600921|PLACEBO_COMPARATOR|Placebo|The subject will receive Placebo 5mg.
62353258|NCT05321095||Screening|Only one group will be evaluated during the SALINE study. Everyone that meets the inclusion criteria of having a high risk for albuminuria is invited to participate. During participation, subjects are asked to collect one or more urine samples for albuminuria determination. If albuminuria is high (\>= 3,0 mg/mmol) subjects are invited for a visit. During the visit non-invasive measurements (BMI, PoC HbA1c, eGFR, blood pressure and heart rate) are taken to determine the cardiovascular risk. Furthermore, medication use is reviewed.
62353259|NCT00663598|EXPERIMENTAL|Arm 1|
62353260|NCT00871572|PLACEBO_COMPARATOR|Placebo|
62353261|NCT00871572|EXPERIMENTAL|LY2409021 10 milligrams (mg)|
62353262|NCT00871572|EXPERIMENTAL|LY2409021 30 mg|
62353263|NCT00871572|EXPERIMENTAL|LY2409021 60 mg|
62353264|NCT02665078||Thoracoscopic Ultrasound|Patients who undergo lobectomy or an anatomical segmental resection for malignant lung tumors will be enrolled in the study. After lung resection, the lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross section with maximum diameter. The ultrasound image with size measurement of the tumor will be recorded using an ultrasound scanner (EU-Y0008, OLYMPUS MEDICALSYSTEMS CORP., Tokyo, Japan). After ultrasound evaluation, the specimen will be delivered directory to the pathology laboratory and the actual tumor size and histological diagnosis will be determined. In addition, we will evaluate the differences between US image and pathological morphology using HE slides of lung tumor.
62353265|NCT03628950|ACTIVE_COMPARATOR|ICSSB group|infraclavicular suprascapular nerve block administered group
62353266|NCT03628950|ACTIVE_COMPARATOR|ISB group|interscalene nerve block administered group
62353267|NCT03384524|ACTIVE_COMPARATOR|Combination regiment|A combination regiment of Bromocriptine (2.5 mg/day), Metoprolol (25 mg/day) and Tamsulosin (0.4 mg/day)
62353268|NCT03384524|PLACEBO_COMPARATOR|Placebo|Three placebo pills, matching the external appearance of active drugs
62353269|NCT03944083||ADHD with and without DMDD|ADHD with DMDD versus ADHD without DMDD. Observational study at referral and after 6 and 12 months.
62353270|NCT02881879|EXPERIMENTAL|Allergovac depot with HDM extract|Extract of mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae (50:50) adsorbed onto aluminum hydroxide 0.33%.
62353271|NCT01153841|EXPERIMENTAL|Synflorix Group|Subjects receiving Synflorix™(GSK 1024850A) co-administered along with Infanrix hexa™.
62512532|NCT00697216|ACTIVE_COMPARATOR|Group B|
62512533|NCT05918809||CAR-T IP|Chimeric antigen receptor modified T cells inpatient cohort
62512534|NCT05918809||CAR-T OP|Chimeric antigen receptor modified T cells outpatient cohort
62512535|NCT05918809||CAR-T Overall|Chimeric antigen receptor modified T cells overall cohort
62512536|NCT05918809||allo-HSCT|Allogeneic hematopoietic stem cell transplant cohort
62512537|NCT02839993|EXPERIMENTAL|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
62512538|NCT02839993|SHAM_COMPARATOR|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
62512539|NCT00172419|EXPERIMENTAL|Atorvastatin|
62512540|NCT06061705|EXPERIMENTAL|procedure/surgery: Tumor biopsy|Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180.
61972554|NCT06472765||Urinary Tract Infection|Premenopausal and Postmenopausal Women
61972555|NCT06472765||Genitourinary Syndrome of Menopause|Vaginal Atrophy
61972556|NCT06472765||Lichen Sclerosus/Planus|Lichen Sclerosus/Planus
61972557|NCT06472765||Vulvodynia|Vulvodynia
62146927|NCT05414825||15 to 17 years old teenagers' parents|Semi-structured discussion group with parents of older teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the parents on the care and feelings of their child suffering from severe dysmenorrhea.
62146928|NCT05414825||caregivers|Semi-structured discussion group with medical staff in services potentially treating dysmenorrhea patients, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the caregivers on the care and feelings of the patients suffering from severe dysmenorrhea.
62146929|NCT01058018|EXPERIMENTAL|A - 100 mg per day RVX000222|Arm A: Treatment with RVX000222 at 50 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
62146930|NCT01058018|EXPERIMENTAL|B - 200 mg per day RVX000222|Arm B: Treatment with RVX000222 100 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
62146931|NCT01058018|EXPERIMENTAL|C - 300 mg per day RVX000222|Arm C: Treatment with RVX000222 150 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
62146932|NCT01058018|PLACEBO_COMPARATOR|D - Placebo|Arm D: Treatment with placebo for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
62146933|NCT03719352|EXPERIMENTAL|Deep dry needling|Deep dry needling will be applied in the upper trapezius myofascial trigger point
62146934|NCT03719352|EXPERIMENTAL|Superficial dry needling|Superficial dry needling will be applied in the upper trapezius myofascial trigger point
62146935|NCT03719352|PLACEBO_COMPARATOR|Placebo Gastrocnemius dry needling|A technique simulating dry needling will be applied in the gastrocnemius myofascial trigger point with a needle guard guide tube, without any therapeutic manoeuvre will be applied.
62146936|NCT06032689|ACTIVE_COMPARATOR|Xtra-fill|Bulk-fill high-viscosity methacrylate-based resin composites.
62146937|NCT06032689|ACTIVE_COMPARATOR|X-base|Bulk-fill low-viscosity methacrylate-based resin composites.
62353272|NCT01153841|ACTIVE_COMPARATOR|Control Group|Subjects receiving Infanrix hexa™ vaccine alone.
62146938|NCT06032689|ACTIVE_COMPARATOR|Admira fusion x-tra|Bulk-fill high-viscosity ormocer-based resin composites.
62146939|NCT06032689|ACTIVE_COMPARATOR|Admira fusion x-base|Bulk-fill low-viscosity ormocer-based resin composites.
62146940|NCT00012688|OTHER|Arm 1|
62146941|NCT04751097|EXPERIMENTAL|Digital Platform|
62146942|NCT04751097|NO_INTERVENTION|Routine Care|
62146943|NCT03260998||diabetic patients type 1|electrocardiogram will be done for 60 children and adolescents with type 1 diabetes
62146944|NCT03260998||healthy persons|electrocardiogram will be done for 60 age and sex matched non diabetic children and adolescents
61972558|NCT06472765||Endometriosis|Endometriosis
61972559|NCT06472765||Ureaplasma|Ureaplasma
62146945|NCT05445050|OTHER|clinical application of mULM to support breast cancer diagnosis and therapy|"The study arm includes three parts A, B and C. In part A, the scan protocol, including the injection of the clinically approved contrast agent SonoVue® and the data acquisition time range, is optimized based on the mULM measurements of participants with primary breast cancer.~The following part B consists of 2D-mULM measurements applied to triple-negative breast cancer patients throughout their neoadjuvant chemotherapy cycles with the aim to evaluate to which degree 2D-mULM allows for an assessment of the tumor response during therapy.~In the last part C, participants with neoplasms of uncertain dignity will be investigated by 2D- and 3D-mULM measurements and the accuracy of differentiation between the lesions assessed."
62146946|NCT02381028|EXPERIMENTAL|Study area|Human milk and emollient: Apobase creme® (Actavis Norway AS)
62146947|NCT02381028|ACTIVE_COMPARATOR|Control area|Emollient: Apobase creme® (Actavis Norway AS)
62146948|NCT03167008||idiopathic male infertility|"* total of 30 male patients with idiopathic male infertility.~* Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~* blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
62353273|NCT05082402|EXPERIMENTAL|All Participants|50 participants identified in the Northwestern Medicine Division of Vascular Surgery.
62353274|NCT04327518|EXPERIMENTAL|TECNIS® Toric II|Subjects will be implanted in one or both eyes with the study lens
62353275|NCT05289206|EXPERIMENTAL|Intervention - single arm|Oxford/AstraZeneca (ChAdOx1-S/nCoV-19 \[recombinant\]) - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
62353276|NCT06012292||Group A Not addicted to mobile phone|Addicted to mobile phone less than four hours per day.
62353277|NCT06012292||Group B addicted to mobile phone|Addicted to mobile phone more than four hours per day.
61972560|NCT06472765||Desquamative Inflammatory Vaginitis (DIV)|Desquamative Inflammatory Vaginitis (DIV)
61972561|NCT06472765||Cancer|"Group 1: Breast cancer patients diagnosed at stages 1-3, post-menopausal (due to surgical, chemical reasons, or age-related natural processes), and currently receiving anti-estrogen treatment for a minimum of 90 days.~Group 2: Breast cancer patients diagnosed at stages 1-3, pre-menopausal, and undergoing anti-estrogen endocrine therapy for at least 90 days.~Group 3: Participants diagnosed with any type of cancer at stages 1-3, not receiving anti-estrogen therapy, but have been using vaginal estrogen, prasterone, or DHEA for 90 days or more. Should not be on systemic hormone replacement therapy (estrogen with or without progesterone).~Group 4: Diagnosed with any type of cancer at stages 1-3, and should not be receiving any anti-estrogen therapy or using vaginal estrogen, prasterone, or DHEA. These individuals must not be on systemic hormone replacement therapy.~Group 5: Participants diagnosed at stage 4"
61976306|NCT04828447|EXPERIMENTAL|Low Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet low in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
62539437|NCT05871723||Stroke Patients|Patients diagnosed with stroke.
61976307|NCT06125587|EXPERIMENTAL|Chiglitazar group|Chiglitazar, tablet, 32mg, taken orally once daily for 3 months
62512541|NCT01344616|NO_INTERVENTION|usual clinical care|usual clinical care with no intervention
62512542|NCT01344616|EXPERIMENTAL|lifestyle counseling|computer-based clinical support to patient
62512543|NCT04558333||LTx (lung transplant) patients|identification of possible biomarkers
62512544|NCT02269956|ACTIVE_COMPARATOR|Intervention|The 2 NH's not used in the focus groups will receive the intervention, a 12-week feasibility study. At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for 3 meals over 2 days at baseline and again at week 6 and 12, and a medical record review will be conducted. After baseline data is collected, the training program will be delivered in 5 weekly modules with group coaching sessions completed the same week.
62512545|NCT02269956|NO_INTERVENTION|Focus Groups|Year 1 focus groups will aim to identify how nursing staff feel about usual interventions for feeding behaviors of PWD and staff responses when a PWD displays difficult eating behaviors. Year 2 focus groups will evaluate the revised dementia feeding skills training program, the coaching interventions, and case scenarios, and indicate how realistic and compatible the intervention is with their work environment.
62512546|NCT04821752|EXPERIMENTAL|Toxicant avoidance and glucose dysregulation|To investigate whether or not the excretion of urinary toxicant metabolites is reduced by dietary modification and lifestyle intervention in people with glucose dysregulation; whether the participant's ranked glucose dysregulation correlates with the amount and/or type of toxic metabolites excreted at baseline; and whether the body's immediate response to glucose is improved by the reduction of toxicant burden.
62512547|NCT02044432|EXPERIMENTAL|Ginger compress|
62512548|NCT02044432|NO_INTERVENTION|Wait list|
62512549|NCT02640365|EXPERIMENTAL|GROUP A / GROUP B (two differents cohorts)|"GROUP A (Patients with unresectable advanced non-colorectal cancer ) - irinotecan + MM-398 dose escalation (3-18 patients)~Level 1 : initial DOUBLIRI dose 60/90 (0-3 patients)~* MM-398 : 60mg/m²~* Irinotecan (CPT-11) : 90mg/m²~Level 2: DOUBLIRI dose 80/90 (9 - 18 patients)~* MM-398 : 80mg/m²~* CPT-11: 90mg/m²~Level 3A: DOUBLIRI dose 60/120 (12-18 patients)~* MM-398 : 60mg/m²~* CPT-11: 120mg/m²~Level 3B: DOUBLIRI dose : 80/120 (12-18 patients)~* MM-398 : 80mg/m²~* CPT-11 : 120 mg/m²~GROUP B (Patients with unresectable metastatic colorectal cancer)- LV/5FU-bevacizumab+irinotecan+MM-398 dose Escalation (3-18 patients)~same level as group A + LV/5FU - bevacizumab regimen :~* Bevacizumab : 5mg/kg(day (d) 1)~* Leucovorin (LV) : 400mg/m² (d1)~* 5-fluorouracile infusion (5 FU) :2400mg/m² (d1,2)"
62512550|NCT05414864|OTHER|Control Group|Sleep hygiene alone (control group)
62512551|NCT05414864|OTHER|Intervention Group|Sleep Hygiene and Ramelteone (RozeremTM) 8 mg at night
62512552|NCT04446988|EXPERIMENTAL|Ultrasound(US)|Sacroiliac joint injection using ultrasound
62512553|NCT04446988|EXPERIMENTAL|Fluoroscopy(FL)|Sacroiliac joint injection using fluoroscopy
62512554|NCT00631306||Bottle number 615|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
62512555|NCT00631306||Bottle number 429|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
62512556|NCT00811434|ACTIVE_COMPARATOR|Lactulose|3 months of Lactulose therapy based on pt. weight
62512557|NCT00811434|PLACEBO_COMPARATOR|placebo|1.5 ml/kg day po of sugar water placebo for three months
62512558|NCT02551393|EXPERIMENTAL|Intervention Group|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home Blood pressure monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
62512559|NCT02551393|NO_INTERVENTION|Control Group|Usual Care of hypertension in primary care clinic
62512560|NCT04206722|EXPERIMENTAL|Treatment group|Shock Wave therapy on the affected hip, for 10 days, 1 application every 2 days
62708953|NCT04394494|EXPERIMENTAL|Motor Imagery|Patients are instructed in a motor imagery protocol of imaging extension exercises (similar to the CG), without doing the actual extension exercises. Patients will be instructed in visualizing them moving into extension and back as well as common sensations they may experience (as if doing the actual exercise). They will repeat the visualization process 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 visualization exercises.
62146949|NCT03167008||fertile male group|"* total of 30 fertile male (as control)~* Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~* blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
62146950|NCT01068977|EXPERIMENTAL|Stage I|
62512561|NCT04206722|ACTIVE_COMPARATOR|Control group|Ultrasound therapy on the affected hip, for 10 days, 1 application daily
61976308|NCT06125587|ACTIVE_COMPARATOR|Metformin group|Metformin, tablet, 0.5g, taken orally twice daily for 3 months
61976309|NCT01189812|PLACEBO_COMPARATOR|sugar pill|
61976310|NCT01189812|ACTIVE_COMPARATOR|Lithium|
61976311|NCT00799604|EXPERIMENTAL|clevidipine|"Patients were sequentially assigned to one of following three planned dose cohorts for Bolus 1 within the clevidipine arm:~* Cohort 1: clevidipine 250 µg (0.5 mL)~* Cohort 2: clevidipine 500 µg (1 mL)~* Cohort 3: clevidipine 125 µg (0.25 mL or 0.5 mL of a 1:1 solution)"
62512562|NCT04344626|EXPERIMENTAL|Brain tonometry|Participants undergoing intra-operative brain tissue stiffness measurements using a digital tonometer. Evaluated brain tissue is both presumed normal and abnormal based on results of pre-operative evaluations.
62146951|NCT01068977|EXPERIMENTAL|Stage II|
62146952|NCT01068977|EXPERIMENTAL|Stage III|
62512563|NCT05487560||12-hour interval group (No interventional)|DAPT(Clopidogrel + Aspirin) and Esomezol Cap taken every 12 hours
62512564|NCT05487560||co-administration group (No interventional)|Taking DAPT(Clopidogrel + Aspirin) and Esomezol Cap at the same time
62512565|NCT06084169|ACTIVE_COMPARATOR|Intensity SL IOL|29 patients will be implanted bilaterally with Intensity SL IOL
62512566|NCT06084169|ACTIVE_COMPARATOR|Panoptix IOL|29 patients will be implanted bilaterally with PanOptix IOL
62353278|NCT01165697||Fabry disease biomarker|Neuro-retinal fluorescein angiography (NRFA) exam will be administered once every 6 months for up to 3 years.
62512567|NCT04276935||Health Services Research (cognitive interviews)|Participants take part in cognitive interviews in Spanish over 45-60 minutes.
62512568|NCT02809820|ACTIVE_COMPARATOR|Carvedilol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
62512569|NCT02809820|ACTIVE_COMPARATOR|Metoprolol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
62512570|NCT05326620||localized RCC|all patients with localized RCC
62512571|NCT05326620||metastatic RCC|all patients with metastatic RCC, synchronous or metachronous
62512572|NCT05343221|EXPERIMENTAL|Haptic|"Practice in Haptic Group: Students will be taught cardiopulmonary resuscitation skills with the 3D Systems Touch Haptic Simulator. During the application, there will be 2 researchers and the student who made the application in the room. While one of the researchers will be with the student only for support during the practice, the other researcher will fill the Cardiopulmonary Resuscitation Skills Checklist by evaluating the cardiopulmonary resuscitation skill of the student."
62512573|NCT05343221|EXPERIMENTAL|High Fidelity Simulator|Application in the Simulator Group with High Fidelity: Students will be taught cardiopulmonary resuscitation skills with the CPR Simulator. The student and 2 researchers who will practice will remain in the environment, and the student will also be asked to practice.
62512574|NCT00373425|EXPERIMENTAL|Erlotinib|Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
62512575|NCT00373425|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
62708954|NCT04394494|ACTIVE_COMPARATOR|Control|Patients are instructed in extension exercises and actually, physically doing the actual extension exercises. Patients will physically repeat the extension exercises 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 exercises.
62146953|NCT04214457||Myometrial tumor with suspected leiomyosarcoma|Women between 18 and 75 years of age diagnosed with a myometrial tumor (probably leiomyoma) with suspected leiomyosarcoma
62353279|NCT02794090|ACTIVE_COMPARATOR|Usual care, individual visits|Usual care according to regular treatment routines at the clinic during 18 months. The Child and parent(s) at regular visits to the nurse at the clinic.
62353280|NCT02794090|ACTIVE_COMPARATOR|Telephone coaching|Intervention: Telephone consultation each months except for summer holidays during 18 months. The treating nurse communicated with one of the parents.
62353281|NCT05278676|EXPERIMENTAL|Cohort A Single Dose: Dotinurad|Participants will receive dotinurad 1 milligram (mg) (1\*1 mg tablet) as a single oral dose after 10-hour fasting on Day 1 in the morning.
62512576|NCT00946491|EXPERIMENTAL|1|Haloperidol 10 mg Tablets (Cord Laboratories)
62512577|NCT00946491|ACTIVE_COMPARATOR|2|Haldol 10 mg Tablets (McNeil Pharmaceuticals)
62512578|NCT02731963|EXPERIMENTAL|Mechanical bowel preparation|80 Patients who received mechanical bowel preparation with 4 packets of polyethylene glycol in 4 liters of water, 4 hours before intervention.
62512579|NCT02731963|NO_INTERVENTION|No mechanical bowel preparation|81 Patients who received clear liquid diet 1 day before intervention.
62708955|NCT01365754|ACTIVE_COMPARATOR|A|A - Fusion
62708956|NCT01365754|ACTIVE_COMPARATOR|B|B - Dynamic (new)
62512580|NCT02597582|ACTIVE_COMPARATOR|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
62146954|NCT03026166|EXPERIMENTAL|Rovalpituzumab Tesirine and Nivolumab|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression."
62146955|NCT03026166|EXPERIMENTAL|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
62146956|NCT03026166|EXPERIMENTAL|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
62539438|NCT01990482|EXPERIMENTAL|coffee|coffee
62539439|NCT01990482|PLACEBO_COMPARATOR|water group|water
62539440|NCT04244578|EXPERIMENTAL|Active-Sham tDCS|Each tDCS sessions will be delivered for 5 days for a total of non consecutive two weeks. The first session will be active tDCS and two months after, a sham tDCS will follow.
62708957|NCT03673176|EXPERIMENTAL|Stereotactic Ablative Radiotherapy|Experimental stereotactic ablative radiation treatment
62708958|NCT05391776|EXPERIMENTAL|A single ascending dose of TST002 Intervenous Injection|Four single dose cohorts are designed in this study, 8 subjects will be enrolled in each cohort, Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.
62708959|NCT05391776|PLACEBO_COMPARATOR|A single ascending dose of placebo Intervenous Injection|Four single dose cohorts are designed in this study, 8 subjects will be enrolled in each cohort, Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.
62708960|NCT04501926||Controls|Asthma patients who did not report asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
62708961|NCT04501926||Cases|Asthma patients that reported asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
62708962|NCT01923376|OTHER|Lactulose|per standard of care
62353282|NCT05278676|EXPERIMENTAL|Cohort B Multiple Dose: Dotinurad|Participants will receive dotinurad 4 mg (2\*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning. A washout period of 3 days will be maintained after single dose on Day 1 and then participants will receive dotinurad 4 mg (2\*2 mg tablets) after 10-hour fasting from Day 4 to Day 10 once daily in the morning.
62708963|NCT01923376|ACTIVE_COMPARATOR|polyethylene glycol 3350 (Golytely)|
62708964|NCT00754884|EXPERIMENTAL|A|200 U.I. of intranasal salmon calcitonin
62708965|NCT00754884|PLACEBO_COMPARATOR|B|intranasal saline solution and glycerol
62353283|NCT05278676|EXPERIMENTAL|Cohort C Single Dose: Dotinurad|Participants will receive dotinurad 10 mg (5\*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning.
62708966|NCT04585178|EXPERIMENTAL|Biobeat patch|Patients will be asked to keep Biobeat patch during 72 hours after their surgery.
62353284|NCT01641757|EXPERIMENTAL|periodontal treatment group|non surgical periodontal therapy will be given to study subjects which will be selected by randomization from total study sample. at the end of study, serum albumin levels of both study and control groups will be compared.
62708967|NCT02716441||Radio-opaque Tissue Markers|Patients undergoing rotator cuff repair with implantation of radio-opaque tissue markers
61972562|NCT05316753|EXPERIMENTAL|Schiller Defigard HD- 7 - DGHD7|Device: Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard HD- 7 - DGHD7, Schiller Medical, France) with adult pads (0-21-0003 Schiller) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 200J, 200J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 min post-shock), otherwise after the 3rd shock Other Name: DGHD7
61972563|NCT05316753|ACTIVE_COMPARATOR|LIFEPAK 15, Physio-Control - LP15|"Device: Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 360J, 360J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock.~Other Name: LP15"
62353285|NCT02017821|EXPERIMENTAL|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
62353286|NCT02017821|NO_INTERVENTION|care as usual|
62708968|NCT02622061||PCD Subjects|Participants 5 and older with PCD.
62708969|NCT02622061||Healthy Subjects|Participants 5 and older without any pulmonary disease.
62708970|NCT03373435|EXPERIMENTAL|Treatment Group 1|patients will receive two dose regimens of exendin 9-39 and one placebo
62708971|NCT03373435|EXPERIMENTAL|Treatment Group 2|patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
62708972|NCT05547035|EXPERIMENTAL|Wearable monitor collected phydiological measurements|This is a single arm study with a wearable monitor that collects physiological measures (falling in the categories physical activity, heart rate, heart rate variability, breathing rate and sleep) 24/7 in ambulatory.
62146957|NCT00390845|EXPERIMENTAL|SB681323|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
62146958|NCT00390845|EXPERIMENTAL|Placebo|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
62146959|NCT03210324|EXPERIMENTAL|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
62146960|NCT03210324|EXPERIMENTAL|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
62708973|NCT01685684|EXPERIMENTAL|Oxycodone DETERx|
62708974|NCT01685684|PLACEBO_COMPARATOR|Placebo|
62708975|NCT02434861|EXPERIMENTAL|Part A|Rolapitant IV and Digoxin
62708976|NCT02434861|EXPERIMENTAL|Part B|Rolapitant IV and Sulfasalazine
62708977|NCT02434861|EXPERIMENTAL|Part C|Rolapitant IV and Cooperstown Cocktail
62708978|NCT05641766|EXPERIMENTAL|THC|Participants will receive THC into a rapidly flowing IV infusion.
62146961|NCT03210324|EXPERIMENTAL|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
62146962|NCT00446368|EXPERIMENTAL|RAD001|Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
62146963|NCT04057261|ACTIVE_COMPARATOR|Liraglutide|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen.
62146964|NCT04057261|PLACEBO_COMPARATOR|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
62146965|NCT05352737||Pri-Meta|patients with breast cancer metastasis at first diagnosis
62146966|NCT05352737||Sec-Meta|patients with early breast cancer developed distant metastasis within 5 years
62146967|NCT05352737||Non-Meta|patients with early breast cancer did not develop distant metastasis within 5 years
62539441|NCT04244578|ACTIVE_COMPARATOR|Sham-Active tDCS|"Each tDCS sessions (sham tDCS and active tDCS) will be delivered for 5 days for a total of non consecutive two weeks.~The first session will be sham tDCS and two months after, an active tDCS will follow."
61972564|NCT02664454|EXPERIMENTAL|Systematic nurse-led GA|Interactive educational seminar for GPs and nurses, and focused on geriatric assessment in primary care combined with Systematic nurse-led GA and dedicated hotline for GPs seeking geriatric advice
62708979|NCT05641766|OTHER|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
62708980|NCT03939390|NO_INTERVENTION|follicular phase stimulation|
61972565|NCT02664454|EXPERIMENTAL|GP-led GA on a case-by-case basis, as decided by the GP|Interactive educational seminar for GPs, and focused on Geriatric assessment in primary care combined with a GP-led GA on a case-by-case basis, as decided by the GP, and a dedicated hotline for GPs seeking geriatric advice
61972566|NCT02664454|NO_INTERVENTION|No intervention|No educational seminar Usual care
61972567|NCT05931354||CIN_Group|Those with a previous history of cervical cancer or CIN before incident VaIN and those with VaIN detected concomitantly with cervical cancer or CIN for whom both vaginal biopsy and cervical specimens were available in our hospital were eligible.
61972568|NCT01588808|ACTIVE_COMPARATOR|Immobilization with protein (elderly)|Immobilization with twice-daily protein supplementation - in the elderly
61972569|NCT01588808|PLACEBO_COMPARATOR|Immobilization without protein (elderly)|Immobilization without twice-daily protein supplementation - in the elderly
61972570|NCT01588808|ACTIVE_COMPARATOR|Immobilization without protein (young)|Immobilization without twice-daily protein supplementation - in the young
61972571|NCT03404557||Crohn's Disease patients group|44 patients
62146968|NCT05352737||older|patients with breast cancer older than 70 years old with G8 screening
62512581|NCT02597582|OTHER|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
62512582|NCT02096588|EXPERIMENTAL|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.
62146969|NCT05352737||pCR|patients with breast cancer reached pCR after neoadjuvant chemotherapy
62512583|NCT02096588|ACTIVE_COMPARATOR|No drug|Participant not randomized to simvastatin will participate in all aspects of the study, including planned doxorubicin/cyclophosphamide chemotherapy, with the exception of simvastatin administration.
62512584|NCT04722328||CNS infection|
62512585|NCT04722328||Non-CNS infection|
62708981|NCT03939390|EXPERIMENTAL|luteal phase stimulation|
62512586|NCT05944458|ACTIVE_COMPARATOR|Acetylcysteine group|"Generic name: N-acetylcysteine.~* Trade name: Fluimucil.~* Company: Zambon.~* Dosage form: ampoules for intravenous administration.~* Dose: 600mg taken every 12 hours daily with a fixed dose as there is no need for renal or hepatic adjustment, starting with the inception of linezolid therapy.~* Duration: at least one day or more"
62512587|NCT05944458|PLACEBO_COMPARATOR|Placebo|They will receive placebo drug.
61972572|NCT03404557||Ulcerative Colitis patients group|22 patients
61972573|NCT03404557||Healthy volunteers group|22 patients
61972574|NCT05668455|EXPERIMENTAL|HYDROCORTISONE|Topical corticosteroid : hydrocortisone
61972575|NCT05668455|EXPERIMENTAL|DEXAMETHASONE|Topical corticosteroid : dexamethasone
61972576|NCT05668455|PLACEBO_COMPARATOR|POVIDONE|Topical : tear substitute
61972577|NCT01500629|EXPERIMENTAL|C-1266-7|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-7. After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-6 (placebo).
61972578|NCT01500629|EXPERIMENTAL|Placebo|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-6 (placebo). After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-7.
61972579|NCT02387853|EXPERIMENTAL|LEO 90100|
62146970|NCT05352737||non-pCR|patients with breast cancer did not reach pCR after neoadjuvant chemotherapy
62146971|NCT01841515|EXPERIMENTAL|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
62146972|NCT02082002||MS-Group|MS-Group
62146973|NCT02082002||Healthy control|Healthy control
62146974|NCT01951703|ACTIVE_COMPARATOR|Control, senofilcon A|Subjects received Control lens, senofilcon A during the first two weeks of the study then Test lens, senofilcon A in the last two weeks of the study.
62512588|NCT01556152|ACTIVE_COMPARATOR|Treatment Arm 1|
62512589|NCT01556152|ACTIVE_COMPARATOR|Traetment Arm 2|
62512590|NCT01556152|PLACEBO_COMPARATOR|Treatment Arm 3|
62512591|NCT05650424|ACTIVE_COMPARATOR|Wait-listed Control|wait-listed control group will be put on wait list and receive abdominal massage class training on week 4 (posttest)
62512592|NCT05650424|EXPERIMENTAL|Intervention (Receive abdominal massage training)|Intervention group will receive abdominal massage training class and they will perform abdominal massage on their baby for 4 week. Parental stress level will be assessed on week 0 and week 4
62512593|NCT01198834|PLACEBO_COMPARATOR|Placebo Patch|Treatment with Placebo Patch
62512594|NCT01198834|EXPERIMENTAL|MRX-7EAT Patch|Treatment with MRX-7EAT Patch
62512595|NCT01198834|EXPERIMENTAL|Lidocaine Patch|Treatment with Lidocaine Patch
62512596|NCT01198834|EXPERIMENTAL|Etodolac Patch|Treatment with Etodolac Patch
61972580|NCT00706407|EXPERIMENTAL|Fully integrated Uro-NIRS:UDS|
61972581|NCT04464512|NO_INTERVENTION|Standard (control) treatment|"The control group receives 1mcg/kg fentanyl followed by fentanyl 0.5-1mcg/kg q10 minute PRN, ketorolac 0.5mg/kg up to 30mg max IV, and acetaminophen 1000mg IV for pain control intraoperatively. The patient is then treated with hydromorphone 0.005mg/kg q10minutes the post-anesthesia recovery. The patient would then receive hydromorphone 0.005 mg/kg q1hr PRN, 1 gram acetaminophen IV scheduled q6hr, and methocarbamol 750mg QID following discharge from the PACU and transfer to the hospital floor. The patient is converted to oxycodone 10mg (Roxicodone) q4hr PRN and 975 mg PO APAP scheduled for pain control on postoperative day number 1 or when appropriate for PO intake. The patients receives their home dose of suboxone onpostoperative day number 1 or when appropriate for PO intake.~On postoperative day number 2 number 3, patients are transitioned to an increased dose of their Suboxone for pain control in preparation for discharge."
61972582|NCT04464512|ACTIVE_COMPARATOR|Treatment Group|Buprenorphine-sufentanil group receives sufentanil 0.03mcg/kg followed by sufentanil 0.01-0.03 mcg/kg q10 min PRN, IV ketorolac 0.5mg/kg up to 30mg max and IV acetaminophen 15mg/kg up to 1000mg for pain control intraoperatively. In the PACU, IV buprenorphine 0.3mg IV q30 minutes would be given as the first line choice for pain control for 3 doses. IV PCA sufentanil is used as a second line therapy if patient comfort is not achieved by IV buprenorphine alone. The patient receives 0.3 mg buprenorphine IV Q6hr PRN, scheduled IV acetaminophen 1 gram for 24 hrs and methocarbamol 750mg QID after discharge from the PACU and transfer to the floor. The patient is converted to buprenorphine2mg q6hr PRN and 975 gram PO APAP scheduled for pain control on postoperative day 1. The patient receives their home dose of Suboxone starting on postoperative day 1 if tolerating PO intake. On postoperative day 2, patients would be transitioned to an increased dose of their Suboxone.
61972583|NCT03140020||Clipping|Clipping of an aneurysm of the anterior communicating artery - A titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after microsurgical aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from microsurgical treatment.
62708982|NCT05890209|NO_INTERVENTION|Personalized Weight Management group (PWM)|The group will receive a personalized diet and physical activity plan and five one-to-one online support meetings with a trained dietitian over the first 12 weeks of the program (in weeks 1, 2, 4, 8, and 12). The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, and physical activity). Participants will be asked to self-manage during weeks 12 - 24 and asked to maintain the diet, PA recommendations, and monitoring based on the advice and training provided in the first 12 weeks of the program.
62708983|NCT05890209|EXPERIMENTAL|PWM + Continuous Glucose Monitoring (CGM)|This group will receive the same support as the PWM group. The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, physical activity, and glucose level). In addition, participants will be provided with a CGM device and guidance on how to use this to support weight loss maintenance. They will be provided with CGM devices for the whole study duration.
61976312|NCT04528849|ACTIVE_COMPARATOR|Early dose increment|Patients who have received 25 IU gonadotropin dose increment on 7th day of ovulation induction
62146975|NCT01951703|EXPERIMENTAL|Test, senofilcon A|Subjects received Test lens, senofilcon A during the first two weeks of the study then Control lens, senofilcon A in the last two weeks of the study.
62708984|NCT04942847|NO_INTERVENTION|The control group|The control group received routine nursing, including diet nursing, life nursing, direct and indirect training, health education and so on. Patients were followed up regularly by telephone after discharge
62708985|NCT04942847|EXPERIMENTAL|Dual task training group|On the basis of routine swallowing function training, the use of sucking training rehabilitation device is mainly used for tongue muscle training and lip muscle training to improve the control and delivery ability of tongue muscle to food.At the same time,adopt Troup's playing and comprehensive analysis ability training.Disrupt the three sets of cards, instruct the patient to read words or say colors, and measure the patient's reaction time with an electronic timer.Comprehensive analysis ability training: including digital training or item classification training.
62708986|NCT03297658|ACTIVE_COMPARATOR|electro-acupuncture (EA) intervention|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects will receive electro-acupuncture (EA) (treatment) mixed frequency( continuous plus dense disperse) will be at 2Hz and 100 Hz the amplitude will be 1000 microA.
62708987|NCT03297658|SHAM_COMPARATOR|sham electro acupuncture|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects Receive sham (control) will not have stimulation.
62708988|NCT02234362|EXPERIMENTAL|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
62708989|NCT06171061|EXPERIMENTAL|Experimental group|basic medication + Yangxinshi tablet
62708990|NCT06171061|OTHER|Control group|basic medication.
62146976|NCT05594732|EXPERIMENTAL|Weak outdoor light|4000Lux natural light exposure
62146977|NCT05594732|EXPERIMENTAL|Strong outdoor light|10000Lux natural light exposure
62146978|NCT06272526|EXPERIMENTAL|Guided Web-Based Intervention|Participants in this group will use the web-based intervention (https://kendikendineyardim.org) with guidance support.
62353287|NCT04416945|EXPERIMENTAL|RACD|Reactive case detection led by VMWs in response to cases in study area HCCA, with follow up testing with HS-RDTs/RDTs in both villages and forest workers; referrals for qualitative G6PD testing for P. vivax cases and 14-day PQ for G6PD non-deficient
62512597|NCT01678651|ACTIVE_COMPARATOR|Human FSH|Human FSH
62512598|NCT01678651|ACTIVE_COMPARATOR|Recombinant FSH|Recombinant FSH
62512599|NCT00922324|EXPERIMENTAL|STP206|STP206 administered either as a single dose or as a daily dose for seven consecutive days
62708991|NCT04363346|EXPERIMENTAL|Dose Strategy 1|"Dose Strategy 1:~Day 1 - FT516 is given at 9x107 cells/dose (low)"
62708992|NCT04363346|EXPERIMENTAL|Dose Strategy 2|"Dose Strategy 2:~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid)"
62708993|NCT04363346|EXPERIMENTAL|Dose Strategy 3|"Dose Strategy 3:~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid) + Day 7 - FT516 is given at 9x108 cells/dose (high)"
62708994|NCT04259216|EXPERIMENTAL|IMPACT Intervention|"1. Remote brief video session, introducing basic principles of cognitive behavioral theory and the structure of the mobile application message portion of the intervention.~2. Eight-weeks longitudinal tailored Cognitive Behavioral Therapy (CBT)-based messaging program"
62708995|NCT04259216|ACTIVE_COMPARATOR|Control Enhanced Online Resources (EOR)|1. We will provide a link to an online resource packet with information on bullying and mental health resources.
62708996|NCT02418091|EXPERIMENTAL|Intervention Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
61972584|NCT03140020||Coiling|Coiling of an aneurysm of the anterior communicating artery - Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after endovascular aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from endovascular treatment.
61972585|NCT03140020||Healthy Controls|Healthy controls will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after baseline examinations. Furthermore all subjects will undergo additional neuropsychological examinations 12 months after baseline examination.
61972586|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
61972587|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
61972588|NCT05070533|ACTIVE_COMPARATOR|Individual treatment|The strength and balance activities of the LiFE program will be carried out. Participants will receive 7 home visits and will be given the support material for the manual (diptychs, pictures, etc.).
62708997|NCT02418091|NO_INTERVENTION|Control/No Intervention|Group of subjects that will serve as a comparison group. These subjects will not be approached/enrolled for this study.
62708998|NCT04670796|EXPERIMENTAL|HLX02|patient receive one dose of HLX02
61972589|NCT05070533|EXPERIMENTAL|Groupal treatment|The strength and balance activities of the LiFE program will be carried out. Participants will be invited to participate in groups of about 8 - 12 people in community venues.
62512600|NCT00922324|PLACEBO_COMPARATOR|Vehicle Control|STP206 vehicle administered as either a single dose or as a daily dose for 7 consecutive days
62708999|NCT04670796|ACTIVE_COMPARATOR|EU-sourced Trastuzumab (Herceptin®)|patient receive one dose of EU-sourced Trastuzumab (Herceptin®)
62709000|NCT04670796|ACTIVE_COMPARATOR|US-licensed Trastuzumab (Herceptin®)|patient receive one dose of US-licensed Trastuzumab (Herceptin®)
62709001|NCT05004415|EXPERIMENTAL|AT-527 550 mg (R07496998)|
62709002|NCT01772940|ACTIVE_COMPARATOR|nevirapine and tenofovir/emtricitabine|nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
62709003|NCT01772940|EXPERIMENTAL|lopinavir/r and tenofovir/emtricitabine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
62709004|NCT01772940|ACTIVE_COMPARATOR|Nevirapine and zidovudine/lamivudine|nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
62709005|NCT01772940|EXPERIMENTAL|Lopinavir/r and zidovudine/lamivudine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
62709006|NCT02281045|EXPERIMENTAL|EVODIAL dialyzer and Selectbag citrate|Intervention for anticoagulation during dialysis: Combination of Heparin-coated AN69ST membrane (EVODIAL, Gambro-Hospal, Meyzieu, France) and citrate-containing dialysate (Selectbag citrate, Gambro, Lund, Sweden).
62709007|NCT02281045|ACTIVE_COMPARATOR|Regional citrate anticoagulation|Regional citrate anticoagulation, using a hypertonic sterile solution of trisodium citrate dihydrate (1.035 Mol/L, Baxter, Lessines, Belgium), infused into the afferent blood line. Citrate will be infused at a rate of 62.1 mM/h (60 mL/h). The anticoagulant effect of citrate will be neutralized using calcium containing dialysate (Ca 1.50 mmol/L). Dialysate sodium content will be set at 135 mEQ/L, and bicarbonate will be reduced to 25 mEq/L.
62709008|NCT05229614|EXPERIMENTAL|Solid cancers with stable disease|"Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.~Patients diagnosed with NSCLC, HNSCC, melanoma and urothelial carcinoma will be eligible for the study."
62512601|NCT02445287|EXPERIMENTAL|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
62709009|NCT01400711|ACTIVE_COMPARATOR|ERAS patients|Patients planned to undergoing major intrabdominal surgery, following the ERAS perioperative care.
61972590|NCT01622153|PLACEBO_COMPARATOR|Formocresol (control)|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
61976313|NCT04528849|ACTIVE_COMPARATOR|Late dose increment|Patients who have received 25 IU gonadotropin dose increment on 14th day of ovulation induction
62709010|NCT01400711|ACTIVE_COMPARATOR|Control patients|Patients planned to undergo major intrabdominal surgery, following the conventional perioperative care.
62512602|NCT02445287|EXPERIMENTAL|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
62709011|NCT05781789||Patient participants|"Patient booked for elective surgery and:~Age 21 to 70 years English literacy Willing to provide signed consent Of any nationality Able to give own legal consent"
62709012|NCT05781789||Healthcare provider participants|"Criteria:~* Age 21 to 70 years~* Healthcare professionals comprising clinic staff (surgical outpatient clinics, PAS), clinicians (anaesthetists, surgeons), and health service managers)~* working in the perioperative clinical areas"
62709013|NCT02793960|EXPERIMENTAL|Topical BPM31510 3.0% Cream|Patients/ caregiver will apply topical BPM31510 3.0% cream from every other day to twice per week to wounded skin, and every day to a section of intact skin for up to 12 weeks.The area to be covered may not exceed 10% BSA inclusive of intact skin area, and other lesions.
62709014|NCT04146155|EXPERIMENTAL|Liraglutide+standard-of-care treatment|Intervention: Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies.
62709015|NCT04146155|ACTIVE_COMPARATOR|standard-of-care treatment|standard-of-care treatment with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
62709016|NCT01697644|EXPERIMENTAL|Low dose|
62709017|NCT01697644|EXPERIMENTAL|High dose|
62709018|NCT06564025|EXPERIMENTAL|Pilot group for program|To assess program feasibility, acceptability, and preliminary efficacy, we will pilot the intervention with a purposive sample of 50 father-teen pairs (100 participants total). All participants will receive the program.
62709019|NCT01413815|ACTIVE_COMPARATOR|L-arginine|L-Arginine
61972591|NCT01622153|ACTIVE_COMPARATOR|Laser|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
61972592|NCT02212392|NO_INTERVENTION|control|This arm was not given any prophylactic antibiotics. Patients were managed in the surgical ward by post graduate residents under the supervision of consultants
61972593|NCT02212392|EXPERIMENTAL|Antibiotics|this arm was given IV antibiotics, prophylactically, right from the day of admission. They were given intravenous broad spectrum (MEROPENEM) twice daily at 12 hours interval for 7-10 days
61972594|NCT06320028|EXPERIMENTAL|Non-invasive Transcranial Focused Ultrasound|"Device: Transcranial Ultrasound Power~The ultrasound will be delivered using a custom Neuromodulation device consisting of 128 element ultrasound array (Openwater) with the ultrasound beam having the following parameters: acoustic frequency = 400 kHz, pulse duration = 5 ms, pulse repetition rate (PRR) = 10 Hz, spatial peak/temporal average acoustic intensity = 435 mW /cm2, peak negative pressure 650 kPa. The ultrasound probe will be secured by a custom-designed headset created by Openwater. The Localite Neuronavigation Software (TMS Navigator 3.3 adapted for ultrasound device), including a 3D camera, fiducial markers on the headset and pointer, and software will register the position of the probe with respect to the patient's structural MRI."
61972595|NCT05211791|ACTIVE_COMPARATOR|Group TEA|insertion of Thoracic epidural anesthesia plus GA with lung isolation using suitable size double lumen tube at level T6
61972596|NCT05211791|ACTIVE_COMPARATOR|Group ESB|U/S guided erector spinae block anesthesia using 15 ml local anesthesia plus GA with lung isolation using a suitable size double-lumen tube
61972597|NCT05211791|ACTIVE_COMPARATOR|Group PVB|U/S guided paravertebral block anesthesia using 15 ml local anesthesia as total volume plus GA with lung isolation using suitable size double lumen tube
61972598|NCT05600491|EXPERIMENTAL|Early TMZ chemotherapy|Patients were treated with standard concomitant radiochemotherapy regimen (Stupp) plus early postsurgical temozolomide.
62709020|NCT01413815|PLACEBO_COMPARATOR|corn starch|Placebo: Corn Starch
62709021|NCT02103465|EXPERIMENTAL|Rotigotine|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
62709022|NCT02103465|PLACEBO_COMPARATOR|Placebo|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
61972599|NCT05752201|EXPERIMENTAL|Gamma variant vaccine (Phase 2 and Phase 3)|Participants will be included in this group during phase 2 and phase 3. All participants will receive one dose of gamma variant vaccine and one dose of placebo 28 days apart, in a crossover design.
61976314|NCT04054388|EXPERIMENTAL|300 Randomized to re-education group|LINE re-education of colon preparation
62709023|NCT05769114|ACTIVE_COMPARATOR|Surgical treatment|The surgeon will perform a minimally invasive (percutaneous) posterior stabilization of the injured spinal segments. Transpedicular screws will be inserted into the vertebral body superior and inferior to the fractured vertebra under fluoroscopic control. In a second stage procedure a lumbo- or thoracotomy (depending on the fracture level below or above the diaphragm) is performed to remove the fractured part of the vertebral body (hemicorporectomy) including the intervertebral disc segments. The resulting void is replaced by an (expandable) spacer/cage.
62709024|NCT05769114|NO_INTERVENTION|Non-surgical treatment|The patients will receive an external bracing (3-point hyperextension brace) for six weeks, which must be always worn except when lying flat in bed. The brace is adjusted by an experienced orthopedist. A physiotherapist will instruct the patient to accomplish daily activities with the restriction he or she will have by wearing the brace.
62709025|NCT05769114|OTHER|Observational arm|Patients who do not agree to randomization will be given the option to participate in the observational arm of the study. Their treatment will be surgical fixation with an anterior-posterior stabilization (as per our current internal hospital standard).
62709026|NCT04039932|EXPERIMENTAL|Intervention|
62709027|NCT04039932|NO_INTERVENTION|Standard of Care|
62709028|NCT05959525||Ovoid dental arch|
62709029|NCT05959525||Square dental arch|
62709030|NCT05959525||Tapered dental arch|
61972600|NCT05752201|EXPERIMENTAL|Omicron variant vaccine (Phase 3)|Participants will be included in this group during phase 3. All participants will receive one dose of omicron variant vaccine and one dose of placebo 28 days apart, in a crossover design.
62353288|NCT04416945|ACTIVE_COMPARATOR|Control|Standard of care including case management through health facilities and malaria posts/VMWs; village-based RACD conducted by district staff in some areas
62353289|NCT04705337|EXPERIMENTAL|Levosimendan|administration of levosimendan
61972601|NCT05752201|EXPERIMENTAL|Bivalent vaccine (gamma and omicron variants) (Phase 3)|Participants will be included in this group only during phase 3. All participants will receive one dose of bivalent gamma omicron vaccine and one dose of placebo 28 days apart, in a crossover design.
61972602|NCT03281681|EXPERIMENTAL|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
62512603|NCT01803269|ACTIVE_COMPARATOR|Arm A (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62709031|NCT03336229|ACTIVE_COMPARATOR|Intervention|
61972603|NCT00754624|EXPERIMENTAL|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
61972604|NCT04951284||Arm 1: MCI amyloid positive|"* Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
61976315|NCT04054388|NO_INTERVENTION|300 Randomized to control group|education of colon preparation 1 time in hospital
62146979|NCT06272526|NO_INTERVENTION|Waitlist|The waiting list control group participants will be controlled for time and assessed during the first 7-week period. Participants will have no contact with the study team during the waiting period. Immediately after the waiting period, they will receive the internet-based intervention with the experimental group.
62353290|NCT04705337|PLACEBO_COMPARATOR|Placebo|administration of placebo
62353291|NCT03517449|EXPERIMENTAL|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
62353292|NCT03517449|ACTIVE_COMPARATOR|Treatment of Physician's Choice|Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m\^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m\^2 OR paclitaxel 80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
62353293|NCT00101153|EXPERIMENTAL|Tipifarnib with conventional induction and consolidation|
62353294|NCT01113996|NO_INTERVENTION|Standard treatment - usual care|
62353295|NCT01113996|EXPERIMENTAL|Protein supplementation|
62353296|NCT01113996|EXPERIMENTAL|Protein supplementation and strength training|
62353297|NCT02378883|OTHER|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
62353298|NCT05008458||children with febrile seizures|
62353299|NCT05008458||febrile children without seizures|
62353300|NCT05008458||healthy control children|
62353301|NCT04006912|EXPERIMENTAL|Minimal residual theoretical astigmatism group|
62353302|NCT04006912|ACTIVE_COMPARATOR|Steep meridian incision design group|
62353303|NCT01818986|EXPERIMENTAL|arm one|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR)
62353304|NCT06580730|EXPERIMENTAL|Test group|Endovascular treatment combined with standard medical treatment
62353305|NCT06580730|OTHER|Control group|Standard medical treatment
62353306|NCT03032510|EXPERIMENTAL|Eravacycline (Intravenous)/Levofloxacin (Oral)|
62353307|NCT03032510|ACTIVE_COMPARATOR|Ertapenem (Intravenous)/Levofloxacin (Oral)|
62353308|NCT02493322|EXPERIMENTAL|Test 1: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 12,5 mg) a day, in the morning.
62353309|NCT02493322|EXPERIMENTAL|Test 2: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 25 mg) a day, in the morning.
62353310|NCT02493322|EXPERIMENTAL|Comparator: Benicar HCT®|The patients will take 1 tablet (Olmesartan 20 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
62353311|NCT04911699||breast adenocarcinoma|"1. The surgical pathological tissue report confirms the diagnosis of breast adenocarcinoma women with stage I\~III~2. Those who are admitted to the hospital and receive adjuvant chemotherapy for the first time.~3. Age (inclusive) over 20 years old."
62353312|NCT04911699||Control|"1. The surgical pathological tissue report establishes women diagnosed as stage 0 to stage III breast cancer~2. Those who are admitted to the hospital to receive anti-hormonal drug treatment.~3. Age (inclusive) over 20 years old."
62353313|NCT00125372|EXPERIMENTAL|Erlotinib and Bexarotene|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.
62512604|NCT01803269|EXPERIMENTAL|Arm B (CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX10 cyclodextr1 IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62512605|NCT01741467|EXPERIMENTAL|RT-CGM|Patients using the RT-CGM for the intervention portion of the study.
62512606|NCT03717519||s-CRLM|Patients with synchronous colorectal liver metastases who underwent surgical resection
62512607|NCT04632706|EXPERIMENTAL|50mcg/kg (oral)|Ivermectin loading dose of 200 mcg/kg followed by daily doses of 50mcg/kg from D2 to D28
62512608|NCT04632706|EXPERIMENTAL|75mcg/kg (oral)|Ivermectin loading dose of 200 mcg/kg followed by daily doses of 75mcg/kg from D2 to D28
62512609|NCT04632706|EXPERIMENTAL|100mcg/kg (oral)|Ivermectin loading dose of 200 mcg/kg followed by daily doses of 100mcg/kg from D2 to D28
62709032|NCT03336229|NO_INTERVENTION|Control|
62709033|NCT02119273|EXPERIMENTAL|Steroid|The steroid arm will take prednisone 10mg tabs starting 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
61972605|NCT04951284||Arm 2: MCI amyloid negative|"* Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62353314|NCT02151682|ACTIVE_COMPARATOR|Morphine prolonged-release (Part 1)|"10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 200 mg per day."
61972606|NCT04951284||Arm 3: CN amyloid positive|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
61972607|NCT04951284||Arm 4: CN amyloid negative|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
61972608|NCT02062723||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
61972609|NCT00751829|EXPERIMENTAL|1|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP
61972610|NCT00751829|ACTIVE_COMPARATOR|2|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
62709034|NCT02119273|PLACEBO_COMPARATOR|Placebo|The placebo arm will receive placebo pills identical in appearance to prednisone 10mg pills. They will start taking them 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
62709035|NCT03610048|EXPERIMENTAL|ALKS 5461|Sublingual tablets
61972611|NCT06023342||New users|"Approximately 1000 adults (≥18 years old), new to WayBetter app, who have entered into a 7-day free trial, will be studied. Each new user receives a free 1-week trial (that they need to opt into) and $10 USD deposit from WayBetter Inc. They can use the deposit for any game during trial, regardless of continuing membership. To continue to use the app, users pay $69 USD for 6 months. Each game lasts between 1-4 weeks and requires players to achieve a specific behavioural goal. Games require $10-30 deposit, chosen at signup. Validation methods vary; some sync with wearables, others submit activity photos (steps, meals). A user can join up to 10 games simultaneously. Winners of each game share deposits, gaining original deposit plus profit, based on 'losses'."
61972612|NCT04793685|EXPERIMENTAL|Active Drug|Prazosin (16mg/day) versus Placebo comparator, administered in t.i.d schedule, in capsules, over a 12 week period, with 2 weeks titration in weeks 1-2 and a 5-day taper in week 12.
61972613|NCT04793685|PLACEBO_COMPARATOR|Placebo Drug|Placebo for 12 weeks.
61972614|NCT03182101|EXPERIMENTAL|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
61972615|NCT01572545|EXPERIMENTAL|Denosumab|
61972616|NCT01572545|EXPERIMENTAL|Zoledronic Acid|
61972617|NCT01003730|ACTIVE_COMPARATOR|1|High tidal volume (15mL/kg PBW0 with low PEEP (3cm H2O
61972618|NCT01003730|ACTIVE_COMPARATOR|2|Low tidal volume (6mL/kg PBW) and high PEEP (3cm H2O)
61972619|NCT01003730|ACTIVE_COMPARATOR|3|low tidal volume (6mL/kg PBW) and high PEEP (10cm H2O)
62146980|NCT03717207||type 2 diabetes mellitus (T2DM) patients under SGLT2-I therapy (SGLT2-I users)|"T2DM patients affected by vaso vagal syncope, and under SGLT2-I therapy. All these patients were in stable sinus rate before performing the HUT They performed a 24 hours ECG Holter to assess sinus rhythm, HR, HRV, and the MIBG myocardial scintigraphy before receiving a HUT.~."
62146981|NCT03717207||type 2 diabetes mellitus (T2DM) patients without SGLT2-I therapy (Non-SGLT2-I users)|T2DM patients affected by vaso vagal syncope, and without SGLT2-I therapy. All these patients were in stable sinus rate before performing the HUT They performed a 24 hours ECG Holter to assess sinus rhythm, HR, HRV, and the MIBG myocardial scintigraphy before receiving a HUT.
62146982|NCT01844401|EXPERIMENTAL|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
62353315|NCT02151682|EXPERIMENTAL|Tapentadol prolonged-release (Part 1)|"25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 500 mg per day."
62512610|NCT04632706|PLACEBO_COMPARATOR|Matching Placebo (oral)|Placebo using tablets identical to the Active IMP
62512611|NCT00007761|EXPERIMENTAL|1|Bipolar Disorder Program
62709036|NCT01583907||different dietotherapy strategies|
62709037|NCT03650023|EXPERIMENTAL|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.
61972620|NCT05693246|EXPERIMENTAL|Glycopyrrolate|
61972621|NCT05693246|PLACEBO_COMPARATOR|Control|
61972622|NCT02961751|OTHER|Ciprofloxacin|One dose of directly-observed ciprofloxacin 500 mg administered orally. N=381
61972623|NCT00931762|EXPERIMENTAL|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, with or without food, three times a week on Monday, Wednesday, and Friday for up to 6 treatment cycles (each cycle of 28-days) with dose adjustments possible.
61972624|NCT01075945|EXPERIMENTAL|Dihydroartemisinin- piperaquine|orally tablets
61972625|NCT01075945|ACTIVE_COMPARATOR|artemether- lumefantrine|oral tablets
61972626|NCT01373372|EXPERIMENTAL|Functional Dyspepsia cohort|Cohort of subjects with functional dyspepsia
61972627|NCT01373372|OTHER|Control cohort|Control group of subjects with no functional dyspepsia
61972628|NCT02455622|EXPERIMENTAL|Enrolled Patients|Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are \<6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were \< 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
61972629|NCT04101357|EXPERIMENTAL|Part 1A - monotherapy dose escalation|BNT411 monotherapy
62146983|NCT01844401|EXPERIMENTAL|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
62353316|NCT02151682|EXPERIMENTAL|Tapentadol in Part 2 after Tapentadol or Morphine in Part 1|Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily.
62512612|NCT00007761|ACTIVE_COMPARATOR|2|Usual (psychiatric) Care
62709038|NCT03650023|PLACEBO_COMPARATOR|White egg|White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.
62353317|NCT02151682|NO_INTERVENTION|Observation Period after Tapentadol in Part 1|Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed).
62353318|NCT02151682|NO_INTERVENTION|Observation Period after Morphine in Part 1|Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed).
62709039|NCT01233544|EXPERIMENTAL|Stereotactic body radiation therapy|Colorectal liver metastases treated by SBRT
62709040|NCT01233544|ACTIVE_COMPARATOR|Radiofrequency ablation|Colorectal liver metastases treated by RFA
62709041|NCT06413914|EXPERIMENTAL|Cognitive behavioral Therapy|"Cognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns.~A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment."
62709042|NCT06137248|EXPERIMENTAL|Energy drink intervention|
62709043|NCT06137248|NO_INTERVENTION|Control arm|Participants on this arm will only consume their normal diet for 4 weeks.
62709044|NCT03703557|EXPERIMENTAL|Sorbstar®|Odour sampling: Rub hands with Sorbstar® before and post-surgery
62709045|NCT03703557|EXPERIMENTAL|Dog detection|Odour sampling: Sleep over a night with a compress on the affected breast before and after surgery
62709046|NCT05694247|EXPERIMENTAL|CorNeat KPro|Intraocular implantation of the CorNeat KPro
62709047|NCT01240057|PLACEBO_COMPARATOR|expectant management during pregnancy|watchful waiting during pregnancy
62709048|NCT01240057|EXPERIMENTAL|fetal endoluminal tracheal occlusion|fetoscopic balloon occlusion at 27 to 29+6 weeks of gestation
62512613|NCT04193384||Group 1≤ (G1≤)|Group 1≤ (G1≤) - patients that performed bariatric surgery for ≤ 1 year
62709049|NCT02969577|EXPERIMENTAL|Staying Strong & Healthy Intervention (SS&H)|Participants will take part in a 6-month exercise program and diet and nutrition coaching program. Also part of this arm is a nutritional and lifestyle counseling program to be lead by a member of the study team. Participants will also receive the usual care they would normally receive if not taking part in this study.
62709050|NCT02969577|ACTIVE_COMPARATOR|Usual Care with Attention (UCA)|Participants will receive the usual care they would normally receive if not taking part in this study.
62709051|NCT00548886|EXPERIMENTAL|Epinephrine|Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.
62709052|NCT03209258|OTHER|Goal-directed care bundle|Management policy to receive a goal-directed care bundle that involves the rapid correction (\<1 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 7 days or hospital discharge (or death, if sooner)
62709053|NCT03209258|OTHER|Usual care group|Patients receive the usual management based on local guidelines and hospital's individual policy.
62512614|NCT04193384||Group 1> (G1>)|Group 1\> (G1\>) - patients that performed bariatric surgery for \> 1 year
62709054|NCT02424162|EXPERIMENTAL|2.75 group|Patients with 2.75 diopters multifocal intraocular lens
62709055|NCT02424162|ACTIVE_COMPARATOR|3.25 group|Patients with +3.25 diopters multifocal intraocular lens
61972630|NCT04101357|EXPERIMENTAL|Part 1B - combination dose escalation|BNT411 in combination with atezolizumab, carboplatin, and etoposide
62512615|NCT03184532||D|diabetic patients
62512616|NCT03184532||ND|non-diabetic patients
61972631|NCT04101357|EXPERIMENTAL|Part 2 - expansion cohorts|BNT411 either as monotherapy or in combination with with atezolizumab, carboplatin, and etoposide
61972632|NCT02596191|EXPERIMENTAL|patients with mild CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 1 and 10
61972633|NCT02596191|EXPERIMENTAL|patients with moderate CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 11 and 20
61972634|NCT02596191|EXPERIMENTAL|patients with severe CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score ≥21
62512617|NCT00738361|EXPERIMENTAL|nab-paclitaxel|Administered via intravenous bolus at a dose of 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
62512618|NCT01205841|EXPERIMENTAL|Adults|Patients from 16 years of age onwards
62512619|NCT01205841|EXPERIMENTAL|Children|Patients aged 5 to 15 years
62512620|NCT03795584||Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized.
62512621|NCT06616909|EXPERIMENTAL|game ACP module|,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents
62512622|NCT06616909|PLACEBO_COMPARATOR|ACP Manual|
62512623|NCT05178108|OTHER|healthy individuals|
62512624|NCT01090999|NO_INTERVENTION|1|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The No Intervention group will undergo a standard, minimal monitoring program."
62512625|NCT01090999|ACTIVE_COMPARATOR|2|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The active comparator group will undergo an intensive maintenance program after the initial in-hospital rehabilitation program."
62512626|NCT01167517|EXPERIMENTAL|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge.
62512627|NCT01167517|PLACEBO_COMPARATOR|Instructions in print format|Breast milk expression instructions provided in print format at the time of hospital discharge.
62512628|NCT06218992||Study group|Type 2 diabetic patients
62512629|NCT06218992||Control group|Age- and sex-matched subjects without DM
62512630|NCT03798379|ACTIVE_COMPARATOR|Exercise group|Eligible patients who were planned to receive neurotoxic chemotherapy
62512631|NCT03798379|NO_INTERVENTION|Control group|Patients eligible for the study and received the 3rd cycle of chemotherapy
62512632|NCT02286973|ACTIVE_COMPARATOR|Only Intravenous Group|Only Intravenous Injection During Operation, 10mg/kr
62512633|NCT02286973|ACTIVE_COMPARATOR|Intravenous + Topical 1g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 1g"
62512634|NCT02286973|ACTIVE_COMPARATOR|Intravenous + Topical 2g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 2g"
62512635|NCT02286973|ACTIVE_COMPARATOR|No Intravenous, Only Topical 2g Group|Only Topical Injection 2g
62512636|NCT02270424|EXPERIMENTAL|Conventional medicine+ placebo TCM|Patients in this group will be given conventional medicine, Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three placebo TCM treatment, which are which are placebo Bufeijianpi granule, placebo Bufeiyishen granule and placebo Yiqizishen granule corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
62512637|NCT02270424|EXPERIMENTAL|conventional medicine+ TCM|Patients in this group will receive Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three types of TCM treatment, which are Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule. A herbal extract twice daily for 52 weeks for lower dosage. The three granules are corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
62512638|NCT01631682|ACTIVE_COMPARATOR|Propranolol|a single dose of 40mg propranolol may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
62146984|NCT00879632||1|TREATMENT AS USUAL
62512639|NCT01631682|ACTIVE_COMPARATOR|Reactivation with time delay|For those not receiving propranolol on visit 2, one experimental CS will be reactivated, followed by a 10 minute break and subsequently extinction
62512640|NCT01631682|EXPERIMENTAL|Mifepristone|a single dose of 1800mg (200mg tablets) mifepristone may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
62512641|NCT01631682|EXPERIMENTAL|Intranasal oxytocin|A single 32IU dose of Syntocinon (intranasal oxytocin) is given to begin visit 2, followed by a 10 minute wait and subsequent CS reactivation.
62146985|NCT00879632||2|CONTROLS
62146986|NCT01480375|EXPERIMENTAL|Navigo™ and Smartbx™ system.|all biopsy cores were handled using the Smartbx™ system. part of the procedures were performed with both Navigo™ and Smartbx™ system.
62146987|NCT01480375|NO_INTERVENTION|standard method|all biopsy cores were handled using standard method - shaking the biopsy needle into formalin vial. no navigation system.
62146988|NCT03385291|EXPERIMENTAL|patients with disorders of consciousness|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
62512642|NCT04233879|EXPERIMENTAL|Group 1: DOR/ISL|Treatment-naïve participants with HIV-1 receive blinded DOR/ISL and placebo to BIC/FTC/TAF once daily (QD) from Day 1 to Week 96, and open-label DOR/ISL up to Week 144. Participants who are benefitting from treatment are then eligible to continue on open-label DOR/ISL up to Week 168.
62512643|NCT04233879|ACTIVE_COMPARATOR|Group 2: BIC/FTC/TAF|Treatment-naïve participants with HIV-1 receive blinded BIC/FTC/TAF and placebo to DOR/ISL QD from Day 1 to Week 96, and open-label BIC/FTC/TAF up to Week 144. Participants who are benefitting from treatment are then eligible to continue on open-label BIC/FTC/TAF up to Week 168.
62512644|NCT02375217|ACTIVE_COMPARATOR|Group 1 : (NS)|"Group 1 Drug combination:~patients receive half of the recommended dose of sugammadex plus dose of neostigmine~1. Sugammadex IV= -1 mg/kg( moderate NMB) or~   * 2 mg/kg (deep NMB)~2. neostigmine IV = 50mcg/kg~3. glycopyrrolate 10 mcg/kg"
62512645|NCT02375217|ACTIVE_COMPARATOR|Group 2 : (S)|"patients receive Full recommended dose of sugammadex~Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)"
62512646|NCT00467831|EXPERIMENTAL|Multi-Drug Regimen|Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
62512647|NCT05236842|ACTIVE_COMPARATOR|Sulthiame 100 mg|Sulthiame film-coated tablets 100 mg once daily 15 weeks
62146989|NCT03385291|EXPERIMENTAL|healthy control group|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
62146990|NCT05019859|ACTIVE_COMPARATOR|Intervention|low carb diet
62146991|NCT05019859|NO_INTERVENTION|Control|traditional low fat diet
62709056|NCT03663543|ACTIVE_COMPARATOR|Active Arm|Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
62709057|NCT03663543|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
61972635|NCT02596191|OTHER|control group|Healthy volunteers
61972636|NCT03874247|EXPERIMENTAL|Pelubiprofen|
62146992|NCT03138720|EXPERIMENTAL|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
62709058|NCT04931576|NO_INTERVENTION|Routine application of drainage tube|After TOETVA, patients will receive one drainage tube through anterior cervical area.
62709059|NCT04931576|EXPERIMENTAL|Omission of drainage tube|After TOETVA, patients will receive complete omission of drianage tube and directly close the incision.
62709060|NCT02048007|ACTIVE_COMPARATOR|Biannual mass oral azithromycin|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years~Morbidity monitoring:~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community.~Anthropometry for all children aged 1 to 60 months per community.~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint."
62709061|NCT02048007|PLACEBO_COMPARATOR|Biannual mass oral placebo|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community~Anthropometry for all children aged 1 to 60 months per community~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint"
62709062|NCT05287321|EXPERIMENTAL|Aspirin 100mg + Hydroxychloroquine 200mg|Aspirin 100mg 1T daily PO + Hydroxychloroquine 200mg 1T daily PO
62709063|NCT05894603||Oral antiviral A|Patients with an indication for treatment with nirmatrelvir + ritonavir (Paxlovid®).
61972637|NCT03874247|PLACEBO_COMPARATOR|Pelubiprofen placebo|
62146993|NCT03138005|ACTIVE_COMPARATOR|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
62709064|NCT05894603||Oral antiviral B|Patients with an indication for treatment with molnupiravir (Lagevrio®).
62709065|NCT04627129|EXPERIMENTAL|SHR2554+Itraconazole|SHR2554 50 mg QD on Day 1 and Day 8, Itraconazole 200 mg once daily (QD) from Study Day 4 - 12
62709066|NCT00441025|ACTIVE_COMPARATOR|1|1 Alemtuzumab
62709067|NCT01280942|NO_INTERVENTION|Control|Patients admitted to 4 GHWs designated as controls. Nurses will not be notified when patients on these GHWs satisfy the EWS algorithm. They will also not wear the wireless sensor devices.
61972638|NCT03151460|EXPERIMENTAL|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
61972639|NCT03151460|NO_INTERVENTION|Normal Controls|Age and education comparable healthy subjects
61972640|NCT02257788|ACTIVE_COMPARATOR|Treatment Arm 1|PRO 140: one SC dose, 350 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
62709068|NCT01280942|EXPERIMENTAL|Nurse notification of EWS alert|Patients admitted to 4 GHWs designated as intervention wards at BJH. Nurses will be notified when patients on these wards satisfy the EWS algorithm. Some patients will be asked to wear the wireless remote sensors.
62709069|NCT06399055|EXPERIMENTAL|Reference-Test|
62709070|NCT06399055|EXPERIMENTAL|Test- Reference|
61972641|NCT02257788|ACTIVE_COMPARATOR|Treatment Arm 2|PRO 140: one SC loading dose, 700 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
61972642|NCT02257788|ACTIVE_COMPARATOR|Treatment Arm 3|PRO 140: one SC loading dose, 700 mg (day 1), followed by one single SC dose 350 mg (day 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
61972643|NCT02257788|ACTIVE_COMPARATOR|Treatment Arm 4|PRO 140: one SC dose, 700 mg (day 1) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
61972644|NCT06466122|EXPERIMENTAL|Treatment (pirtobrutinib, venetoclax)|Patients receive pirtobrutinib PO QD on days 1-28 of each cycle and receive venetoclax PO QD on days 1-28 of cycles 2-20. Cycles repeat every 28 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression within 12 months of stopping combination treatment may receive pirtobrutinib PO QD in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy and CT throughout the study.
62146994|NCT03138005|EXPERIMENTAL|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
62146995|NCT05766943|ACTIVE_COMPARATOR|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
62146996|NCT05766943|PLACEBO_COMPARATOR|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
62353319|NCT02151682|NO_INTERVENTION|Observation Period after Tapentadol in Part 2|Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2.
62353320|NCT05736562|EXPERIMENTAL|Ritual Epre|This group will receive 2 Ritual Epre multivitamin-mineral supplement pills daily.
62353321|NCT05736562|PLACEBO_COMPARATOR|Control|This group will receive a blank placebo.
62709071|NCT02829372|EXPERIMENTAL|GBR 1302|Dose escalation
62709072|NCT03676387|NO_INTERVENTION|Aged based group (group AB) (n = 27)|ETT size was determined according to age
62709073|NCT03676387|ACTIVE_COMPARATOR|Ultrasound based group (group UB) (n = 27): ETT was determined|ETT was determined according to the subglottic transverse diameter that was estimated with ultrasonography.
62709074|NCT01987557|EXPERIMENTAL|Treadmill Intervention 1: Rate Group|Participants in this condition will walk with a cadence (steps per minute) that is approximately 35% faster than comfortable walking pace. In this condition, participants will maintain a step length that is similar to that of their comfortable walking pace.
61972645|NCT00390858|EXPERIMENTAL|Deferasirox|Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
61972646|NCT03926273||group 1|Epileptic participants group consisted of 40 adults (15 females and 25 males) clinically and electrophysiological were diagnosed according to the international league against epilepsy classification 2010.
61972647|NCT03926273||group 2|Control group consisted of 40 adults (16 females and 24 males) non - epileptic healthy subjects.
61972648|NCT00877383|EXPERIMENTAL|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
61972649|NCT00877383|ACTIVE_COMPARATOR|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
61972650|NCT03557463|ACTIVE_COMPARATOR|Soy protein|Low isoflavone soy protein powder: Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
61972651|NCT03557463|EXPERIMENTAL|Dairy protein|UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
61972652|NCT04517474|EXPERIMENTAL|CANreduce with psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
62709075|NCT01987557|EXPERIMENTAL|Magnitude treadmill group|In this condition participants will walk on a treadmill with weights on their ankles to elicit a greater magnitude of instrinsic feedback from force sensitive golgi tendon organs
61972653|NCT04517474|EXPERIMENTAL|CANreduce without psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use without psychological support
62146997|NCT03001635|EXPERIMENTAL|conventional treatment and oxytocin|26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers \& ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
62146998|NCT03001635|PLACEBO_COMPARATOR|conventional treatment only|26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers \& ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.
62709076|NCT01987557|PLACEBO_COMPARATOR|regular treadmill walking|participants will walk at a comfortable self-selected pace on a treadmill
62709077|NCT02348021|OTHER|Drug Coated Stent|All patients in the one arm will be treated by PCI with the Drug Coated Stent.
62709078|NCT02264314|EXPERIMENTAL|Intervention|This group received an audiological rehabilitation program with a tele-educative intervention boost
62709079|NCT02264314|PLACEBO_COMPARATOR|Control|This group received no intervention
62709080|NCT02004626|ACTIVE_COMPARATOR|Collagenase|"Each gram of ointment contains :~Collagenase ...0.6 U~Vehicle qs ... 1 g~Presentation:~Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .~Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day."
62709081|NCT02004626|ACTIVE_COMPARATOR|Kollagenase|"Each gram of ointment contains :~Collagenase ... 0.6 U~Vehicle qs ... 1 g~Presentation~Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.~Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day."
62709082|NCT02636010|EXPERIMENTAL|MK-3475 Pembrolizumab|MK-3475 at a dose of 200 mg every three weeks for 1 year with a potential expansion of 1 additional year of treatment in case of clinical benefit and patient agreement
62709083|NCT04556253|EXPERIMENTAL|treatment arm|Subjects will receive AK104 by intravenous administration.
61972654|NCT04517474|NO_INTERVENTION|Treatment as usual|Users will be prompt to a web with a list of the treatment centers nearby their postal code
62146999|NCT00987324|EXPERIMENTAL|Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus)
62147000|NCT00987324|ACTIVE_COMPARATOR|Plain Balloon|plain balloon angioplasty
62709084|NCT03961126|EXPERIMENTAL|Group autologous platelet-rich plasma injection|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
62709085|NCT03961126|ACTIVE_COMPARATOR|Group Control|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
62709086|NCT04494789|ACTIVE_COMPARATOR|Fludrocortisone dosing regime: 24hrs|Receive 50mcg doses of fludrocortisone every 24hrs
62709087|NCT04494789|ACTIVE_COMPARATOR|Fludrocortisone dosing regime: 12hrs|Receive 50mcg doses of fludrocortisone every 12hrs
62512648|NCT05236842|ACTIVE_COMPARATOR|Sulthiame 200 mg|Sulthiame film-coated tablets 200 mg once daily 15 weeks
62512649|NCT05236842|ACTIVE_COMPARATOR|Sulthiame 300 mg|Sulthiame film-coated tablets 300 mg once daily 15 weeks
62512650|NCT05236842|PLACEBO_COMPARATOR|Placebo|Placebo film-coated tablets once daily 15 weeks
62512651|NCT01872702|EXPERIMENTAL|malaria elimination using DP and low-dose primaquine|Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
62512652|NCT01872702|NO_INTERVENTION|Control villages|"Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13."
61972655|NCT01840501|EXPERIMENTAL|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
62512653|NCT03479931|EXPERIMENTAL|Without placement of a catheter|Without preoperatively placement of an indwelling catheter during Caesarean section
61972656|NCT01840501|EXPERIMENTAL|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
62709088|NCT04494789|ACTIVE_COMPARATOR|Fludrocortisone dosing regime: 6hrs|Receive 50mcg doses of fludrocortisone every 6hrs
62709089|NCT04494789|PLACEBO_COMPARATOR|Control Arm|Receives standard treatment without fludrocortisone dosing regime
62709090|NCT06563622|EXPERIMENTAL|Group P|In ultrasound-guided pericapsular nerve group block Group , the patient will be positioned in a supine position. The anatomical landmarks, including ilio-pubic eminence, the iliopsoas muscle and tendon, the femoral artery and vein, and the pectineus muscle, will be identified using a 9-12 MHz superficial linear transducer. A lateral to medial in-plane technique will be used to insert a 22-gauge, 50-mm needle. the needle's tip will be positioned at the musculofascial plane, located between the ilio-pubic ramus posteriorly and the psoas tendon anteriorly. Following negative aspiration to avoid intravascular injection, 0.5-1 ml of normal saline will be injected to confirm the correct needle site. A 0.5 ml/kg plain bupivacaine 0.25% will be injected.
62709091|NCT06563622|ACTIVE_COMPARATOR|Group C|"the caudal epidural block will be established in the lateral decubitus position, the high-frequency linear transducer will be first placed transversely at the midline to obtain a frog eye sign view of the sacral cornu, the sacro-coccygeal ligament, the sacrum, and the sacral hiatus. At this position, the USG transducer will be rotated by 90° to obtain a longitudinal view. The needle will be inserted in-plane into the sacral canal and the Local anaesthetics will be injected under real-time visualization by a dose of 0.5 ml/kg plain bupivacaine 0.25%."
62709092|NCT03588754|EXPERIMENTAL|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
62147001|NCT00987324|EXPERIMENTAL|Paclitaxel-eluting balloon|SeQuent Please
62512654|NCT03479931|ACTIVE_COMPARATOR|With placement of a catheter|Normal pre-operative routines with placement of an indwelling catheter during Caesarean section
62512655|NCT01026259|EXPERIMENTAL|Local incision warming|Local warming applied to surgical incision for 6 treatments beginning in post anesthesia recovery through the second postoperative day.
62512656|NCT01026259|ACTIVE_COMPARATOR|No warming to surgical incision|Incisions covered with same postoperative dressing as in Arm 1 but without warming treatments.
62512657|NCT01850719|EXPERIMENTAL|Arthroscopic Partial Meniscectomy|
62512658|NCT01850719|ACTIVE_COMPARATOR|Physical Therapy|
62709093|NCT03588754|PLACEBO_COMPARATOR|Placebo|Administered orally once daily at 10:00PM
62709094|NCT01011608|EXPERIMENTAL|Medical Food Supplement|Medical food supplement to be given in divided portions in morning, afternoon and evening
62709095|NCT01011608|ACTIVE_COMPARATOR|standard hospital food|standard hospital diet
62709096|NCT06546124|ACTIVE_COMPARATOR|Deep fascia dry needling technique|Deep fascia dry needling technique
62709097|NCT06546124|ACTIVE_COMPARATOR|İntramuscular trigger point dry needling technique|İntramuscular trigger point dry needling technique
62709098|NCT02661750||Step 1|Patients who had inadequate preparations for colonoscopy with a standard dose of bowel cleansing agent.
62709099|NCT02661750||Step 2|Patients who had inadequate preparations for colonoscopy with a step 1 dose of bowel cleansing agent.
62709100|NCT02661750||Step 3|Patients who had inadequate preparations for colonoscopy with a step 2 dose of bowel cleansing agent.
62709101|NCT02661750||Step 4|Patients who had inadequate preparations for colonoscopy with a step 3 dose of bowel cleansing agent.
62709102|NCT02661750||Step 5|Patients who had inadequate preparations for colonoscopy with a step 4 dose of bowel cleansing agent.
62709103|NCT01916473|ACTIVE_COMPARATOR|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
61972657|NCT01840501|EXPERIMENTAL|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
61972658|NCT01840501|EXPERIMENTAL|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
61972659|NCT01840501|EXPERIMENTAL|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
61972660|NCT01840501|EXPERIMENTAL|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
61972661|NCT01840501|EXPERIMENTAL|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
61972662|NCT01840501|EXPERIMENTAL|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
62512659|NCT04104984|EXPERIMENTAL|control group not follow NICE guide lines|All pregnant women who fulfil the same inclusion criteria, exclusion criteria, diagnoses established as short cervix , and do not managed according to NICE guide lines will be treated and managed according to their units as a control group.
62512660|NCT04104984|EXPERIMENTAL|study group follow NICE guide lines|- All pregnant women will attend hospital between 14-24 weeks and fulfil inclusion and exclusion criteria will be approached for possibility to be included in the study . and will be managed according NICE guide lines
62512661|NCT05291052|EXPERIMENTAL|TIS combined therapy|All patients will be treated with the combination of tisleizumab , lenvatinib and XELOX regimen (oxaliplatin combined with capecitabine) until disease progression , unacceptable toxicity, death or the patient meets any other discontinuation criteria described in the protocol, whichever occurs first. Subjects can receive up to 8 cycles of the XELOX regimen. For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
62512662|NCT02092883|EXPERIMENTAL|Infantile Spasms|
62512663|NCT05424718|EXPERIMENTAL|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile application for the first three months of the trial and then the intervention is removed at the 3 month follow-up visit.
62512664|NCT05424718|EXPERIMENTAL|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile for the first 3 months of the study and will receive access to the MyPEEPS Mobile App at the 3 month follow-up visit.
62512665|NCT04274582|EXPERIMENTAL|Chokeberry extract consumption|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
62512666|NCT02864004|EXPERIMENTAL|APO group|An apomorphine pump will be installed and adjusted. The target dose corresponds to the patient's individual optimized dose :maximum dose of 10 mg/hour for 16 hours
62512667|NCT02864004|ACTIVE_COMPARATOR|Control group|Patients will be optimally treated with oral dopaminergic therapy to obtain the best medical treatment (BMT) defined as the most efficient single treatment options or their combination.
62512668|NCT00548379|ACTIVE_COMPARATOR|1|Vitamin D
62512669|NCT00548379|PLACEBO_COMPARATOR|2|
62512670|NCT00005090|ACTIVE_COMPARATOR|ABVD x 5 + ABVD x 3|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m\^2, bleomycin 10 U/m\^2, vinblastine 6 mg/m\^2, dacarbazine 375 mg/m\^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
62512671|NCT00005090|EXPERIMENTAL|ABVD x 5 + ABVD x 1 + HDT + PBSCT|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m\^2, bleomycin 10 U/m\^2, vinblastine 6 mg/m\^2, dacarbazine 375 mg/m\^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m\^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
61972663|NCT01840501|EXPERIMENTAL|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
61972664|NCT01840501|EXPERIMENTAL|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
61972665|NCT01840501|PLACEBO_COMPARATOR|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
61972666|NCT01840501|EXPERIMENTAL|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
62147002|NCT06459167|EXPERIMENTAL|Group S|Patients needing sedation for procedure or surgery are assisted into supine position before they were sedated and kept during the procedure.
62512672|NCT03199313|ACTIVE_COMPARATOR|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
61972667|NCT01840501|EXPERIMENTAL|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
62512673|NCT03199313|PLACEBO_COMPARATOR|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
62512674|NCT03199313|ACTIVE_COMPARATOR|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
62512675|NCT03199313|PLACEBO_COMPARATOR|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
62512676|NCT03199313|ACTIVE_COMPARATOR|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
62512677|NCT03199313|PLACEBO_COMPARATOR|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
62512678|NCT03199313|ACTIVE_COMPARATOR|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
62512679|NCT03199313|PLACEBO_COMPARATOR|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
62512680|NCT03199313|ACTIVE_COMPARATOR|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
61972668|NCT01840501|EXPERIMENTAL|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
61972669|NCT01840501|EXPERIMENTAL|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
61972670|NCT01840501|EXPERIMENTAL|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
62147003|NCT06459167|EXPERIMENTAL|Group L|Patients needing sedation for procedure or surgery are assisted into lateral position before they were sedated and kept the procedure.
62147004|NCT01279707|EXPERIMENTAL|A: Veltuzumab and chemotherapy|Veltuzumab and modified UKALL XII chemotherapy
62147005|NCT01279707|EXPERIMENTAL|B: epratuzumab and chemotherapy|epratuzumab and modified UKALL XII chemotherapy
62147006|NCT01279707|EXPERIMENTAL|C: veltuzumab and epratuzumab and chemotherapy|Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
62512681|NCT03199313|PLACEBO_COMPARATOR|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
62512682|NCT04532398|OTHER|Swallowing test|
62512683|NCT03544814|EXPERIMENTAL|Concurrent therapy group|Icotinib combined with pemetrexed plus cisplatin.
62512684|NCT03544814|EXPERIMENTAL|Sequential therapy group|First icotinib and then pemetrexed plus cisplatin.
62512685|NCT03316326|EXPERIMENTAL|SIROX|Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination
62512686|NCT02759341|OTHER|Cardiac X Syndrome (CSX)|patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)
62512687|NCT02759341|OTHER|Takotsubo Cardiomyopathy (TTC)|Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)
62512688|NCT02759341|OTHER|Acute myocardial infarction (AMI)|Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction \[STEMI\] and Non ST-segment elevation acute myocardial infarction \[NSTEMI\] acute coronary syndrome \[ACS\] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)
62512689|NCT02412462|EXPERIMENTAL|AB-16B5|Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
62512690|NCT01602172|EXPERIMENTAL|Brief Alcohol Intervention (BI)|The 3-part Brief Intervention (BI) consists of . Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
62512691|NCT01602172|ACTIVE_COMPARATOR|Attention Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity. Two weeks later, the Research Assistant calls subjects in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. This intervention is designed to provide all the information and assessments that that Brief Intervention participants as well as all the alcohol consumption and motivation to change measures-- it is designed to control for the attention that the BI participants receive w/o the motivational interventions
62512692|NCT01602172|ACTIVE_COMPARATOR|Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. Subjects complete only drinking quantity measures at baseline and 6 months post baseline. The inclusion of this group tests whether completing more extensive questionnaires (in comparison the Attention Control group) decreases alcohol consumption.
62512693|NCT00111956|EXPERIMENTAL|Etanercept|
62512694|NCT00111956|PLACEBO_COMPARATOR|Placebo|
62512695|NCT03447340|EXPERIMENTAL|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
62512696|NCT03447340|ACTIVE_COMPARATOR|Cafeteria only|Receives only cafeteria intervention
62512697|NCT04395248|ACTIVE_COMPARATOR|Risk factors of difficult intubation|Appearance anpalpationpalpationpalpationd ultrasound features for predicting difficult laryngoscopy intubation
62512698|NCT04395248|ACTIVE_COMPARATOR|Radial artery cannulation using ultrasound or blind palpation|In the ultrasound group, a linear vascular probe in the frequencies 5 to 13 MHz (GE 12L-RS, GE Healthcare, Chicago, IL, USA) of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image.
62709104|NCT01916473|EXPERIMENTAL|Continuous wound infusion|The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.
62512699|NCT04395248|ACTIVE_COMPARATOR|Preoxygenation using high-flow nasal cannula or facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher \& Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs.
62512700|NCT04395248|ACTIVE_COMPARATOR|Type of volatile anesthetics and M-Entropy guidance|Patients will be randomized by a computer-generated list into one of the four groups, desflurane with usual care (N=20), desflurane with M-Entropy guidance (N=20), sevoflurane with usual care (N=20), and sevoflurane with M-Entropy guidance (N=20).
62512701|NCT05640687||aPAP|
62512702|NCT05640687||healthy control|
62512703|NCT05394766|NO_INTERVENTION|Does not receive access to Omada Health program|Participants manage hypertension with usual care alone.
61972671|NCT01840501|EXPERIMENTAL|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
62539442|NCT06165952||Adolescent youth age 13-15|age- and sex- adjusted body mass index (zBMI) scores between the 25th and 75th percentile
62539443|NCT06634316|ACTIVE_COMPARATOR|Mediterranean diet|Mediterranean diet and physical exercise
62539444|NCT06634316|EXPERIMENTAL|Standard hypercaloric hyperproteic Oral supplement|Standard hypercaloric hyperproteic oral supplement plus Mediterranean diet and physical exercise
62539445|NCT06634316|EXPERIMENTAL|Protein module|Protein module (10g/day) plus Mediterranean diet and physical exercise
62709105|NCT05349734|EXPERIMENTAL|overbody blanket|
62709106|NCT05349734|ACTIVE_COMPARATOR|underbody blanket|
62709107|NCT01907282|EXPERIMENTAL|Family Focused Treatment|Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months
61972672|NCT01840501|PLACEBO_COMPARATOR|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
61972673|NCT01113281|EXPERIMENTAL|VPM1002 in three dosages|
61972674|NCT01113281|ACTIVE_COMPARATOR|BCG|
62512704|NCT05394766|EXPERIMENTAL|Receives access to Omada Health program|In addition to usual care, participants will gain access to the Omada Program, an online program that offers lifestyle self-management support for hypertension. Participants will be assigned a health coach and a hypertension specialist via Omada's secure app. Participants will receive hypertension education and resources and communicate with their care team through asynchronous, in-app messaging features. Participants will receive digital tools that connect with the Omada app to help track their food intake, physical activity, and blood pressure (BP). Participants who also have diabetes will receive a digital blood glucose meter and/or a continuous glucose monitor as well. The care team will support patients with lifestyle self-management support, adherence to their current medication regimen, improved BP control, and use of monitors for self-management of their BP and/or blood glucose values.
62512705|NCT03221231|EXPERIMENTAL|N-acetylcysteine|
62512706|NCT03221231|PLACEBO_COMPARATOR|Placebo|
62512707|NCT03221231|ACTIVE_COMPARATOR|Healthy controls|
62512708|NCT05021913|EXPERIMENTAL|Investigational device|DKL crosslinked sodium hyaluronate 23
62512709|NCT05021913|ACTIVE_COMPARATOR|Comparator product|Juvéderm Volift™ with lidocaine (Allergan, Inc)
62512710|NCT01991288|EXPERIMENTAL|SNB Saphenous Nerve block|Patients received SNB preoperatively at mid thigh level with ultrasound guidance. 10 mls 0.5% bupivacaine was administered for nerve block by the anesthetist. All patients also received peri operative Local Infiltration Analgesia by the surgeon. All patients will receive preoperative oxycontin, peri operative paracetamol and diclofenac. Post operatively all patients received regular paracetamol 1g 6 hourly, Diclofenac sodium 12 hourly and oxycontin 10-20 mg 12 hourly. All patients received standardized spinal block by the same anesthetist, post nerve block for surgery.
62512711|NCT01991288|ACTIVE_COMPARATOR|NSNB Non Saphenous Nerve Block|Patients only received Local Infiltration Analgesia. As per protocol all patients received the same pre, peri and post operative analgesia as described in the experimental group. All patients had a standardized spinal block for surgery.
62512712|NCT02285634|EXPERIMENTAL|Oxymetazoline 0.05%|Oxymetazoline 0.05%
62512713|NCT02285634|EXPERIMENTAL|Phenylephrine 0.25%|Phenylephrine 0.25%
62512714|NCT02285634|EXPERIMENTAL|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
62512715|NCT02285634|PLACEBO_COMPARATOR|Bacteriostatic 0.9% sodium chloride (NaCL)|Bacteriostatic 0.9% NaCL
62512716|NCT05128370||Stroke group|Stroke patients who can walk independently for at least 10 meters without rest. Unilateral walking aids are allowed.
62512717|NCT02854696|EXPERIMENTAL|Islet graft|Patients who receive islet graft Intervention : Procedure/Surgery
62512718|NCT02854696|ACTIVE_COMPARATOR|Best medical care|Patients who continue their optimal medical treatment (insulin pump therapy coupled with real time continuous glucose monitoring) Intervention : insulin treatment
62512719|NCT03340987|EXPERIMENTAL|Vista technique with SCTG|vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
62512720|NCT03340987|ACTIVE_COMPARATOR|coronally advanced flap with SCTG|coronally advanced flap combined with subepithelial connective tissue graft
62512721|NCT04667936||moderate to severe COVID-19 ARDS|patients with an oxygenation index \<200 under intubation anesthesia and mechanical ventilation.
62512722|NCT06142149|EXPERIMENTAL|Ultrasound group|Use ultrasound to check the position of the endotracheal tube cuff, check its movement according to the surgical position, and position the cuff according to the size of the endotracheal tube.
62512723|NCT06142149|NO_INTERVENTION|Conventional group|Adjust the position of the endotracheal tube to account for movement in the surgical position and confirm that the endotracheal tube air sac is palpable at the suprasternal notch in the final position for surgery.
62512724|NCT06094907|EXPERIMENTAL|N,N-Dimethyltryptamine|Administration of up to 2 inhaled doses of DMT within a single day (15 mg, followed by 60 mg) with a 1-hour dose interval.
62709108|NCT01907282|ACTIVE_COMPARATOR|Enhanced Care|Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms
61972675|NCT04049968|EXPERIMENTAL|Experimental group|Patients in the experimental group were individually assessed by a mobile health application (APP).
62512725|NCT04554706|EXPERIMENTAL|a JITAI interactive narrative condition (Narrative JITAI)|This arm is an exploratory condition, which tested whether story-based JITAI would be an effective way to deal with rumination.
62512726|NCT04554706|EXPERIMENTAL|a JITIAI non-interactive condition|This arm uses the regular JITAI ( mobile phone delivered) intervention to provide treatment for ruminative thoughts.
62512727|NCT04554706|NO_INTERVENTION|a wait-list control condition|Participants in this arm will be put on a waitlist without receiving active treatment upon the end of the study.
62512728|NCT06295744|EXPERIMENTAL|WBI with SIB|
62512729|NCT02304549||patients with BPH undergoing TUV-P|patients with Benign Prostatic Hyperplasia undergoing TUV-P
62512730|NCT03660215|NO_INTERVENTION|control group|usual charge
62709109|NCT04462289|NO_INTERVENTION|Usual Care|Randomly assigned sample who will receive usual care for tobacco cessation treatment
62709110|NCT04462289|EXPERIMENTAL|Proactive Outreach|Randomly assigned sample who will receive a proactive offer of tobacco treatment with connection to motivational texting program.
62512731|NCT03660215|EXPERIMENTAL|experimental group|"Mediation:~The mediator will intervene on several levels: planning of care according to the medical prescriptions on a support adapted and comprehensible by the patient according to his level of health literacy and his linguistic capacities, coaching on the management of the chronic diseases, possible orientation towards a workshop of therapeutic education, appointments calendar, clear indication of treatment changes, provision of contact information for allied health professionals , assistance in making appointments, possible accompaniments at a professional health."
62539446|NCT05373004|EXPERIMENTAL|Empagliflozin 25 mg arm (SGLT2 inhibitor)|empagliflozin 10 mg once daily plus a placebo enalapril 10 mg tab, along with conventional antihypertensive (for hypertension patients) \& glycemic control therapies (if present). After four weeks, the dose of empagliflozin will be increased to 25 mg once (with Enalapril 20 mg placebo) daily throughout the study for one year.
62709111|NCT00358878|EXPERIMENTAL|Satavaptan|
62709112|NCT00358878|PLACEBO_COMPARATOR|Placebo|
62709113|NCT02051426|EXPERIMENTAL|D-serine|single P.O. administration of D-serine (2.1g)
62709114|NCT02051426|PLACEBO_COMPARATOR|Placebo|single P.O. administration of corn starch
62512732|NCT04183179|EXPERIMENTAL|Program|"The 14-week healthy eating program activities including four components:~1. A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~2. Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~3. 14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~4. Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
62709115|NCT03747055|EXPERIMENTAL|Group problem management plus|Five sessions of group low intensity psychological intervention
61972676|NCT04049968|ACTIVE_COMPARATOR|Control group|Patients in the control group were individually assessed by a traditional routine health care and instruction.
62147007|NCT02950961|OTHER|Arm 1: Mixed Methods Implementation Evaluation|The investigators used mixed methods to evaluate the implementation in two VA Women's Practice Based Research Network (PBRN) sites, describing services and patterns of care utilized by patients prior to seeing a care manager, and then 30, 60, 180, and 365 days post initiation of care with the care manager. Investigators also evaluated facilitators and barriers to implementation of this collaborative care model.
62512733|NCT03703024|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62512734|NCT03703024|ACTIVE_COMPARATOR|Low dose|200mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
62512735|NCT03703024|ACTIVE_COMPARATOR|High dose|400mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
62512736|NCT01246362|PLACEBO_COMPARATOR|Control|Given placebo tablets preoperatively
62512737|NCT01246362|ACTIVE_COMPARATOR|Etoricoxib|Given etoricoxib preoperatively
62512738|NCT05183412|ACTIVE_COMPARATOR|Ultrasound-guided regional nerve block and hand surgery without VR glasses|Patients will not receive the VR glasses during the ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery.
62512739|NCT05183412|EXPERIMENTAL|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Patients will receive the VR glasses during the ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery.
62512740|NCT06083090|EXPERIMENTAL|Yogatherapy|Randomization of 36 patients in the yogatherapy group.
62512741|NCT06083090|ACTIVE_COMPARATOR|Physiotherapy|Randomization of 36 patients in the physiotherapy group.
62512742|NCT01087021|EXPERIMENTAL|cabazitaxel|"At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.~An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion."
62512743|NCT03020381||Cognitively Normal (Control Group)|Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD.
62512744|NCT03020381||Subjective Cognitive Impairment (SCI)|"Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
62512745|NCT03020381||Mild Cognitive Impairment (MCI)|Participants aged 60 and older that have self-experienced persistent decline in cognitive capacity and unrelated to an acute event. MCI is operationalized following Peterson's criteria as: i) presence of subjective memory complaints from the patient and family; ii) objective memory impairment in cognitive tests (below 1.5 SD on standardized cognitive tests adjusted by age, sex, and education-); iii) preserved activities of daily living (assessed using the Lawton-Brody scale); iv) absence of clinical dementia established using DSM-IV-TR (from 2007 to 2013) and DSM V (from 2014 and onwards)
62512746|NCT01593072|ACTIVE_COMPARATOR|AVI-7537|AVI-7537
62512747|NCT01593072|OTHER|Placebo|Normal Saline Solution (NSS)
62512748|NCT04782128|EXPERIMENTAL|intravitreal 1.0mg RC28-E injection Q8|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
62512749|NCT04782128|EXPERIMENTAL|Experimental: intravitreal 1.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
62512750|NCT04782128|EXPERIMENTAL|Experimental: intravitreal 2.0mg RC28-E injection Q8|Subjects received 2.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
62512751|NCT04782128|EXPERIMENTAL|Experimental: intravitreal 2.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
62512752|NCT06332313|NO_INTERVENTION|Group control|The control group is followed with PCA without a block.
62709116|NCT03747055|ACTIVE_COMPARATOR|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
62709117|NCT03589742|EXPERIMENTAL|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
62709118|NCT03332147|EXPERIMENTAL|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
62709119|NCT03332147|ACTIVE_COMPARATOR|reference group-Earlysense system|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
61972677|NCT03719976|EXPERIMENTAL|Healthcare navigation workshops|All enrolled caregivers and parents will partake in the group-based educational intervention.
62147008|NCT00856362|EXPERIMENTAL|1|
62353322|NCT00903370|ACTIVE_COMPARATOR|MVS|All participants will undergo mitral valve surgery with ligation/excision of left atrial appendage.
61972678|NCT05109650|EXPERIMENTAL|0.1mg/kg of BAT6026 + 300mg of BAT1308|0.1mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 0.1mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
61972679|NCT05109650|EXPERIMENTAL|0.3mg/kg of BAT6026 + 300mg of BAT1308|0.3mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 0.3mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
62709120|NCT04133415|EXPERIMENTAL|Lattice stereotactic body radiation therapy|-Lattice SBRT prescribed to a dose of 20 Gy in 5 fractions with a simultaneous integrated boosts of 66.7 Gy in 5 fractions
62709121|NCT03972527|ACTIVE_COMPARATOR|Active Device Treatment Cohort - Chemoradiation therapy|The MuReva Phototherapy System consists of Light Control Unit and two Mouthpiece Cable Assemblies. Subjects will begin device treatment photobiomodulation sessions on the first day of radiotherapy (RT) treatment. They will receive once-daily investigative device photobiomodulation treatments prior to radiation therapy (RT) with their assigned Mouthpiece for 5 days per week for the duration of their CRT treatment. Each device treatment session will last up to 5 minutes, not including up to 5 additional minutes for treatment breaks. All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period. Each patient will be assigned their own Mouthpiece Cable Assembly set.
62709122|NCT03972527|SHAM_COMPARATOR|Sham Device Treatment Cohort- Chemoradiation therapy|The MuReva Phototherapy System (or sham control) is a Light Control Unit and a set of Mouthpiece Cable Assemblies. The sham control Mouthpiece Cable Assemblies will appear identical to the active Mouthpiece Cable Assembly, and will be used in the same manner as the active cohort. However, the sham control device will be configured where the mouthpiece will not emit any light at any time during the study. The same Light Control Unit will be used with sham and active Mouthpiece Cable Assemblies. Each patient will be assigned their own Mouthpiece Cable Assembly set.
61972680|NCT05109650|EXPERIMENTAL|1mg/kg of BAT6026 + 300mg of BAT1308|1mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 1mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
61972681|NCT05109650|EXPERIMENTAL|3mg/kg of BAT6026 + 300mg of BAT1308|3mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 3mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
62512753|NCT06332313|ACTIVE_COMPARATOR|Group E20|Group E20 receive PCA with 20cc volume of ESP block
62709123|NCT03972527|ACTIVE_COMPARATOR|Active Device Treatment Cohort - Radiation therapy only|The MuReva Phototherapy System consists of Light Control Unit and two Mouthpiece Cable Assemblies. Subjects will begin device treatment photobiomodulation sessions on the first day of radiotherapy (RT) treatment. They will receive once-daily investigative device photobiomodulation treatments prior to radiation therapy (RT) with their assigned Mouthpiece for 5 days per week for the duration of their CRT treatment. Each device treatment session will last up to 5 minutes, not including up to 5 additional minutes for treatment breaks. All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period. Each patient will be assigned their own Mouthpiece Cable Assembly set.
62709124|NCT03972527|SHAM_COMPARATOR|Sham Device Treatment Cohort- Radiation therapy only|The MuReva Phototherapy System (or sham control) is a Light Control Unit and a set of Mouthpiece Cable Assemblies. The sham control Mouthpiece Cable Assemblies will appear identical to the active Mouthpiece Cable Assembly, and will be used in the same manner as the active cohort. However, the sham control device will be configured where the mouthpiece will not emit any light at any time during the study. The same Light Control Unit will be used with sham and active Mouthpiece Cable Assemblies. Each patient will be assigned their own Mouthpiece Cable Assembly set.
62709125|NCT00133705|EXPERIMENTAL|Mifepristone|Mifepristone 5 MG capsule taken once daily by mouth
62709126|NCT00133705|PLACEBO_COMPARATOR|Inert capsule|Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth
62709127|NCT02995590|EXPERIMENTAL|MRI of lung motion during breathing|"* A medical history will be obtained defining any present and past history of respiratory illnesses, medications, and hospitalizations and the ability to have MR imaging.~* A urine pregnancy test will be done for women of childbearing potential, who report the possibility that they might be pregnant.~* Before and after MR imaging, a physical exam, spirometry, and a baseline %PO2 will be performed.~* During the MR imaging procedure, the subject's heart rate and blood oxygen saturation will be monitored using an MR compatible pulse oximeter.~* Once positioned in the MR scanner, conventional proton images of the thorax will be obtained to define the lung boundaries for subsequent image alignment. -Free breathing conventional MR imaging will be performed.~* Hyperpolarized helium 3 imaging will be performed at breath hold."
62709128|NCT03185221|EXPERIMENTAL|Cordimax|Rapamycin Eluting Coronary Stent
62709129|NCT03185221|ACTIVE_COMPARATOR|XIENCE V|Everolimus Eluting Coronary Stent
62512754|NCT06332313|ACTIVE_COMPARATOR|Group E30|Group E30 receive PCA with 30 volume of ESP block çevir
62512755|NCT02034695||RAMP and Non-RAMP|
62147009|NCT03150758|EXPERIMENTAL|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
62147010|NCT02188602||High Chloride Dose|Patients receiving high dosing of chloride
62147011|NCT02188602||Low Chloride Dose|Patients receiving low dosing of chloride
61972682|NCT05109650|EXPERIMENTAL|6mg/kg of BAT6026 + 300mg of BAT1308|6mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 6mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
61972683|NCT05109650|EXPERIMENTAL|10mg/kg of BAT6026 + 300mg of BAT1308|10mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 10mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
62147012|NCT00986869||echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
62147013|NCT00380250|EXPERIMENTAL|Lubiprostone|8 mcg capsule twice daily (BID)
62147014|NCT00380250|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule twice daily (BID)
62512756|NCT05064774|ACTIVE_COMPARATOR|control group|Patients who underwent arthroscopic rotator cuff repair surgery (n=10). They were implemented physiotherapy after the surgery once a week for 12 weeks. They were encouraged to do exercises 3 to 5 times every day.
62709130|NCT01342094|EXPERIMENTAL|DE-111 ophthalmic solution|DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.
62709131|NCT01342094|ACTIVE_COMPARATOR|Timolol ophthalmic solution 0.5%|Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes.
62709132|NCT04345393|EXPERIMENTAL|Digital Transformation Network (DTN) Program|IBD patients at the 3 sites will be sent a message to their Smartphone
62709133|NCT04345393|ACTIVE_COMPARATOR|Control Arm|Patients will enter the control group once they initially complete the ePRO and online assessment tools. They will remain in the control group, and then at set intervals each site will transition these patients into the DTN intervention arm.
62709134|NCT01005290|EXPERIMENTAL|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
62709135|NCT01005290|ACTIVE_COMPARATOR|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
62709136|NCT02284191|ACTIVE_COMPARATOR|CT Coronary Angiogram|CT Coronary Angiogram plus standard care
62709137|NCT02284191|NO_INTERVENTION|Standard Care|Standard care only
62709138|NCT01817387|EXPERIMENTAL|PRIME + CT|4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
61972684|NCT03883620|EXPERIMENTAL|Cohort 1 (Initial Safety Cohort) 1 mg/kg|4 participants will be administered Dengushield at 1 mg/kg body weight as Intravenous injection.
61972685|NCT03883620|EXPERIMENTAL|Cohort 2 Experimental 3mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
61972686|NCT03883620|PLACEBO_COMPARATOR|Cohort 2 Placebo 3 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo and enrolled.
61972687|NCT03883620|EXPERIMENTAL|Cohort 3 Experimental 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
61972688|NCT03883620|PLACEBO_COMPARATOR|Cohort 3 Placebo 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
61972689|NCT03883620|EXPERIMENTAL|Cohort 4 Experimental 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
62353323|NCT00903370|EXPERIMENTAL|Ablation|Participants will undergo mitral valve surgery with ligation/excision of left atrial appendage plus surgical ablation with pulmonary vein isolation or biatrial lesion set.
62353324|NCT01084109|ACTIVE_COMPARATOR|1|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
62353325|NCT01084109|ACTIVE_COMPARATOR|2|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
62353326|NCT05589844|EXPERIMENTAL|Treatment (CMV-alphaDC1)|Patients undergo standard of care allogeneic hematopoietic stem cell transplant on day 0 and receive CMV-alphaDC1 vaccine intradermally on days 28, 42, 56, and 70.
62353327|NCT05646654|ACTIVE_COMPARATOR|Erector spinae plane block group|3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected.
62353328|NCT05646654|ACTIVE_COMPARATOR|Interscalene group|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
62353329|NCT04742049|EXPERIMENTAL|Telerehabilitation|Telerehabilitation based exercise training will be given to the study group.
62353330|NCT04742049|EXPERIMENTAL|Exercise brochure|Exercise training will be provided by sending a document to the control group
62353331|NCT01758211|EXPERIMENTAL|fMRI guided resection of AVM|fMRI Navigation AVM resection in AVM patients
62353332|NCT01758211|ACTIVE_COMPARATOR|conventional AVM resection|conventional resection of AVM
62353333|NCT02562872|EXPERIMENTAL|Cohort 1 Active DSM265|
62709139|NCT01817387|EXPERIMENTAL|Daily Goals + CT|4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training
62709140|NCT01214837|EXPERIMENTAL|MenACWY3|Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
62353334|NCT02562872|PLACEBO_COMPARATOR|Cohort 1 Placebo|
62353335|NCT02562872|EXPERIMENTAL|Cohort 2a Active DSM265|
62353336|NCT02562872|PLACEBO_COMPARATOR|Cohort 2a Placebo|
62353337|NCT02562872|EXPERIMENTAL|Cohort 2b Active DSM265|
62353338|NCT02562872|PLACEBO_COMPARATOR|Cohort 2b Placebo|
62709141|NCT01214837|EXPERIMENTAL|MenACWY4|All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
62709142|NCT01214837|PLACEBO_COMPARATOR|Routine Vaccines|Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.
62709143|NCT01681147|NO_INTERVENTION|Standard Care|Standard postpartum care after a pregnancy with gestational diabetes
62709144|NCT01681147|EXPERIMENTAL|Standard Care+Education Classes|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes"
62512757|NCT05064774|EXPERIMENTAL|myofascial release group|Patients who underwent arthroscopic rotator cuff repair surgery (n=10). They were implemented physiotherapy the same as the control group once a week for 12 weeks. In addition to physiotherapy they took myofascial release sessions twice a week for 4 weeks between 4 and 7 weeks.
62512758|NCT05172102|EXPERIMENTAL|study group|"Will receive diaphragmatic breathing with pursed lips as (breathing exercise), They will instruct to perform 3 different conditions will be registered: (1) 6 min of quiet breathing (3 sets of 2 min each), defined as spontaneous breathing pattern; (2) 6 min of diaphragmatic breathing (3 sets of 2 min each); and (3) 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).~For aerobic exercises: Will include the following exercises: walking, cycling, running and intermittent running. The exercises will perform for 18-60 minutes for 1-2 sets per week.~For resistance exercises: Will include the following 8 exercises: shoulder press, biceps curl, triceps curl, bench press, leg squats, leg press, leg curl and toe raise. The exercises will perform for 60 minutes for 2-3 sets per week."
62512759|NCT05172102|NO_INTERVENTION|control group|not receiving any exercises
62512760|NCT04633642|EXPERIMENTAL|Ultrasound Group (UAW group)|UAW debridement was performed using an UAW SONOCA 185 device (Söring GmbH, Germany). The UAW device generates an ultrasound low frequency of 25kHz and is equipped with three UAW instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth, which ranges from superficial to deep. The UAW instrument piezoelectrically transforms the electrical energy delivered from the UAW device into mechanical oscillations in the sonotrode tip. For most wounds in the UAW group, a two-minute treatment with 40% intensity was performed by holding the sonotrode in contact mode, holding it perpendicular to the wound bed and moving it across in an up-and-down pattern.
62512761|NCT04633642|ACTIVE_COMPARATOR|Surgical group|"All debridement procedures were performed by the same surgeon (J.L.M.), who is specialist in diabetic foot surgery with more than 20 years of experience.~Surgical debridement involved removal of all necrotic and devitalized tissue that was incompatible with healing, as well as surrounding callus."
62512762|NCT06148545|EXPERIMENTAL|Iron supplementation|Children with a diagnosis of iron deficiency anemia. Patients who received standard therapy (Fe preparations) 3 mg/kg BW/day for 4 weeks, were then checked again for complete blood count, serum fe, and serum ferritin.
62512763|NCT06148545|EXPERIMENTAL|Iron and Vitamin D supplementation|Children with a diagnosis of iron deficiency anemia. Patients who received standard therapy (Fe preparations) 3 mg/kgBW/day and received standard therapy combination vitamin D, 400 IU for 4 weeks, were then checked again for complete blood count, serum fe, and serum ferritin.
62512764|NCT02774486|EXPERIMENTAL|IQP-AK-102|2 capsules to be taken 3 times daily orally, 30 min before each main meal (breakfast, lunch, dinner) with 250 mL of water
62512765|NCT02587312|ACTIVE_COMPARATOR|Normal Nicotine Content Cigarettes|SPECTRUM cigarette: 0.8 mg nicotine with 10.5 mg tar (standard nicotine and tar yields of commercially available cigarettes; control condition)
62512766|NCT02587312|EXPERIMENTAL|Very Low Nicotine Content Cigarettes|SPECTRUM cigarette: 0.03 mg nicotine with 9 mg tar
62512767|NCT02658916|EXPERIMENTAL|Panel 1: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
62512768|NCT02658916|EXPERIMENTAL|Panel 2: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
62512769|NCT02658916|EXPERIMENTAL|Panel 3: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
62512770|NCT02658916|EXPERIMENTAL|Panel 4: BIIB092 (Expansion Panel)|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
62512771|NCT03452124|ACTIVE_COMPARATOR|IQOS|I quit ordinary smoking (IQOS) assistes cessation program
62512772|NCT03452124|ACTIVE_COMPARATOR|Smoker control|Conventional cigarette smoking continuation
62512773|NCT00284804|EXPERIMENTAL|MDX-060 plus standard of care|MDX-060 in combination with gemcitabine
62512774|NCT00284804|ACTIVE_COMPARATOR|Standard of care|Gemcitabine
62512775|NCT03323723|OTHER|RS-2 SUI Device|Comparing use of device to non-treatment phase
62512776|NCT00596206|EXPERIMENTAL|1|100 mg of leflunomide
62512777|NCT00596206|ACTIVE_COMPARATOR|2|20 mg of leflunomide
62147015|NCT00927966|EXPERIMENTAL|RAD001 in combination with figitumumab|
62353339|NCT01977339|EXPERIMENTAL|Liposome Bupivacaine|Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline
62353340|NCT01977339|ACTIVE_COMPARATOR|Bupivacaine|Single shot femoral nerve block with 20cc of 0.25% bupivacaine
62353341|NCT00651612|EXPERIMENTAL|1|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
62709145|NCT01681147|EXPERIMENTAL|Standard Care+Education Classes+Glucose Monitoring|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes~Self monitoring of blood glucose levels"
62709146|NCT04961905|EXPERIMENTAL|Single tablet fist, fasted|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
62353342|NCT00651612|ACTIVE_COMPARATOR|2|Concurrent Brimonidine 0.2% and 0.5% Timolol
62353343|NCT00411086|EXPERIMENTAL|Rituximab + GM-CSF|Rituximab 375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22. Sargramostim (GM-CSF) 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
62512778|NCT05200910||Patient|Patients whose ventricular septal defect closed percutaneously.
62512779|NCT05200910||Control|Healthy children
62709147|NCT04961905|EXPERIMENTAL|FDC fist, fasted|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
62709148|NCT04961905|EXPERIMENTAL|Single tablet fist, fed|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
62147016|NCT01112800||Participants|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH) between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT, rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375 mg/m2.
62147017|NCT05582824||Main group|All patients included
62147018|NCT02597166|OTHER|Ledipasvir/Sofosbuvir|Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir, given orally, once daily for 24 weeks.
62147019|NCT00998517|ACTIVE_COMPARATOR|Soy/peanut fortified spread|
62147020|NCT00998517|EXPERIMENTAL|Milk fortified corn/soy blend|
62709149|NCT04961905|EXPERIMENTAL|FDC fist, fed|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
62709150|NCT05453461|EXPERIMENTAL|new COMs for non ambulant FSHD patients|
62709151|NCT04692922||Patients with disorders of consciousness|patients with a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
62709152|NCT00309218|ACTIVE_COMPARATOR|A|Steroid withdrawal
62709153|NCT00309218|PLACEBO_COMPARATOR|B|continuos Steroid treatment
61972690|NCT03883620|PLACEBO_COMPARATOR|Cohort 4 Placebo 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
61972691|NCT06401395|NO_INTERVENTION|Control arm|conventional follow-up only, i.e. a consultation with the neurologist every 6 months
61972692|NCT06401395|EXPERIMENTAL|Telemonitoring arm|remote monitoring using the DIGIPARK MONITOR application in addition to conventional monitoring.
62709154|NCT01468064|EXPERIMENTAL|BMSCs group|
62709155|NCT01468064|EXPERIMENTAL|EPCs group|
61972693|NCT01045512|ACTIVE_COMPARATOR|statins, standardised physical training|
61972694|NCT01045512|NO_INTERVENTION|to continue with current lifestyle|
61972695|NCT00714454|ACTIVE_COMPARATOR|APS|
62147021|NCT00998517|ACTIVE_COMPARATOR|Supplementary Plumpy®|
62147022|NCT04572867|EXPERIMENTAL|Aquapheresis|Per protocol, if randomized to Aquapheresis arm (AQ), all diuretics are discontinued and AQ will be administered as per established protocol. BMP and CBC will be checked prior to initiation and as needed, 7-10 days, 30, 60 and 90 days post discharge. Note, aquapheresis rate is to be decreased by 100 cc/hr if Hgb increases by 1gm/dL, and stopped if rate is decreased to 50 cc/hr or reaches euvolemia, whichever comes first.
62709156|NCT01468064|PLACEBO_COMPARATOR|Control group|
61972696|NCT00714454|PLACEBO_COMPARATOR|Vehicle|
62147023|NCT04572867|ACTIVE_COMPARATOR|IV Diuretics|Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If a patient in IV arm is refractory to maximum 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
61972697|NCT02747589|EXPERIMENTAL|Treatment Group|Subjects will be implanted to assess the feasibility of stimulating visual cortex to restore vision in blind volunteers.
61972698|NCT00649701|NO_INTERVENTION|1|
61972699|NCT00649701|EXPERIMENTAL|2|Text-based webpage
61972700|NCT00649701|EXPERIMENTAL|3|Talking about HIV video
61972701|NCT00649701|EXPERIMENTAL|4|The Morning After video
61972702|NCT00649701|EXPERIMENTAL|5|Both videos
61972703|NCT04472624|EXPERIMENTAL|Fasting arm|Participants will be fasting during 72 hours
61972704|NCT04472624|EXPERIMENTAL|Diet arm|Participants will be using ketogenic diet for 14 days
61972705|NCT02415660|EXPERIMENTAL|SMT and TDN|Thoracic spinal manipulation and trigger point dry needling using Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
61972706|NCT02415660|SHAM_COMPARATOR|SMT and Sham TDN|Thoracic spinal manipulation and trigger point dry needling sham. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
62147024|NCT01523392|EXPERIMENTAL|Ticagrelor|
62147025|NCT01523392|ACTIVE_COMPARATOR|Clopidogrel|
62709157|NCT01588327||Experimental|Patient taking FDA approved dose of dabigatran
62709158|NCT01588327||Control group|Person not taking any form of anticoagulation.
62709159|NCT01710566|EXPERIMENTAL|Group 1|600 mcg oral misoprostol
62709160|NCT01710566|EXPERIMENTAL|Group 2|10 IU oxytocin in Uniject
62709161|NCT05822310|EXPERIMENTAL|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves applied
62709162|NCT05822310|ACTIVE_COMPARATOR|intraairticular steroid injection|intraairticular steroid injection applied
62709163|NCT05822310|ACTIVE_COMPARATOR|pericapsular nerve group (PENG) block|pericapsular nerve group (PENG) block applied
62709164|NCT00448448|ACTIVE_COMPARATOR|Brace|This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
62709165|NCT00448448|ACTIVE_COMPARATOR|Observation|Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.
62709166|NCT05821946|EXPERIMENTAL|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|In addition to routine training, web-based multi-source training will be provided on the prevention of urinary tract infections in adult kidney transplant recipients.
62709167|NCT05821946|NO_INTERVENTION|Control group|Routine training and before discharge will be directed to the organ transplant handbook on the transplant center's website.
62709168|NCT02876731|OTHER|single group|PET-CT MRI
62709169|NCT02639689|EXPERIMENTAL|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
62709170|NCT05130593||Nutrasorb bar evaluation|Participants in Phase 1 will taste test the bar for acceptability. Participants in Phase 2 will consume the bar and have blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2).
62709171|NCT03695445||Peripheral Norepinephrine|Patients who will undergo surgery with need for vasopressor support.
62709172|NCT02791243|EXPERIMENTAL|Finasteride 0.25%|approximately 0.2 ml of P-3074 (0.25% finasteride)
62709173|NCT02791243|PLACEBO_COMPARATOR|Placebo for Finasteride 0.25%|approximately 0.2 ml of the vehicle cutaneous solution
62709174|NCT02791243|OTHER|Negative Control|approximately 0.2 ml of 0.9% aqueous NaCl
62709175|NCT03232788|EXPERIMENTAL|Test group|Bone regeneration with autogenous bone + scaffold.
62709176|NCT03232788|ACTIVE_COMPARATOR|Control group|Bone regeneration with autogenous bone + collagen membrane.
62709177|NCT04749914|EXPERIMENTAL|150 Milligram (mg) Dabigatran Etexilate + 200mg Lasmiditan - Part 1|Participants received 150 mg dabigatran etexilate on Day 1 followed by 200 mg lasmiditan once daily (QD) on Days 8 and 9, and 150 mg of dabigatran etexilate along with 200 mg lasmiditan on Day 10. All treatments were administered orally
62709178|NCT04749914|EXPERIMENTAL|10 mg Rosuvastatin + 200 mg Lasmiditan - Part 2|Participants received 10 mg rosuvastatin on Day 1 followed by 200 mg lasmiditan QD on Days 8 and 9, and 10 mg of rosuvastatin along with 200 mg lasmiditan on Day 10. All treatments were administered orally.
62709179|NCT04329884|ACTIVE_COMPARATOR|Intra-articular corticosteroid injections|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. Radiology guidance will be used to guide needle placement within the affected hip to administer lidocaine and a corticosteroid intra-articularly.
62709180|NCT04329884|ACTIVE_COMPARATOR|Cooled radiofrequency ablation|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. The HALYARD\* COOLIEF\* SINERGY\* Cooled Radiofrequency Probe (sterile, single use) is inserted through a COOLIEF\* SINERGY\* Introducer used with fluoroscopy guidance in the AP view to visualize the hip joint and sensory nerve areas over the acetabulum (femoral) and ischium (obturator) where the cooled radiofrequency ablation will be applied to create a focal thermal lesion to encompass and denervate the targeted nerves.
61972707|NCT02159495|EXPERIMENTAL|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at \> 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
62709181|NCT02135484|EXPERIMENTAL|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
61972708|NCT00113217|EXPERIMENTAL|Bevacizumab|10 mg/kg intravenous (IV) Day 1 of 14-day cycle.
62709182|NCT04879407||Warfarin|Reference group
62709183|NCT04879407||Rivaroxaban|Exposure group
62147026|NCT02604251|EXPERIMENTAL|Treatment with KLOX BioPhotonic WoundGel System|One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.
62147027|NCT02604251|ACTIVE_COMPARATOR|Treatment with silicone sheets|The second breast will be randomized to be treated with silicone sheets.
62709184|NCT02356237|EXPERIMENTAL|No episiotomy|Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
62709185|NCT02356237|NO_INTERVENTION|Selective episiotomy|The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.
62709186|NCT03157947|EXPERIMENTAL|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
62147028|NCT02067663||Mirena Group|Women who have a postplacental Mirena IUD placed. (LNG-IUS)
62147029|NCT02067663||Paragard Group|Women who have a postplacental Paragard IUD placed. (Copper IUD - T380A)
62147030|NCT01653652|PLACEBO_COMPARATOR|Placebo|maltodextrin powder to be taken daily
62147031|NCT01653652|ACTIVE_COMPARATOR|Probiotic|Probiotic blended in maltodextrin powder to be taken daily
62147032|NCT04490694|EXPERIMENTAL|TACE Combined with Lenvatinib|
62147033|NCT04566185||Patients with recurrent glioblastoma|
62147034|NCT03004989||Programme 1|RTW group in day clinics
61972709|NCT04474704|EXPERIMENTAL|Cheetah® non-invasive cardiac monitoring system|Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 24 hours postpartum.
61972710|NCT04474704|OTHER|Standard of care|24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
62147035|NCT03004989||Programme 2|RTW group in day clinics for people with fibromyalgia
62147036|NCT03004989||Programme 3|My work and I
62147037|NCT06478979|EXPERIMENTAL|Treatment group|The patient with Idiopathic Normal Pressure Hydrocephalus (iNPH) who will be treated with the medical device-Neuclare
62147038|NCT00726505|ACTIVE_COMPARATOR|Group 1|Subjects with T2DM - Dapagliflozin 5 mg
62147039|NCT00726505|ACTIVE_COMPARATOR|Group 2|Subjects with T2DM - Dapagliflozin 20 mg
62147040|NCT00726505|ACTIVE_COMPARATOR|Group 3|Healthy Subjects - Dapagliflozin 20 mg
62147041|NCT01427517|EXPERIMENTAL|NAC in PD|single intravenous administration of N-acetylcysteine in PD patients
62147042|NCT01427517|EXPERIMENTAL|NAC in GD|single intravenous administration of N-acetylcysteine in GD patients
62147043|NCT01427517|EXPERIMENTAL|NAC in controls|single intravenous administration of N-acetylcysteine in control subjects
62709187|NCT00416741||1 Usual Care-Lifestyle counseling|Metabolic syndrome
62709188|NCT00416741||2 Intensive care-Lifestyle counseling|Metabolic Syndrome Implementation of guidelines
62709189|NCT00775957||1|FLT-PET Scan
61972711|NCT04193657||Chemotherapy|30 participants starting chemotherapy
62147044|NCT04816305|EXPERIMENTAL|rTMSc + physiotherapy|A conventional high-frequency rTMS (rTMSc) will be applied over the lesioned hemisphere over the motor cortex. After rTMSc, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
62512780|NCT04647617|EXPERIMENTAL|Quantitative Weight-bearing|Experimental wearing 0.5 kg quantitative sandbag 12\~15 Repetitions/set X 5 set X 3day. Weight adjustment: After the first month of intervention, if the experimental can perform for more than 20 repetitions/set , we will asked to increase the weight of the sandbag to 1 kg until the end of the experiment
62709190|NCT00775957||2|FDG-PET Scan
62709191|NCT01057979|EXPERIMENTAL|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
62709192|NCT01057979|ACTIVE_COMPARATOR|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
62709193|NCT04661527|EXPERIMENTAL|Sarilumab arm|
62709194|NCT01498861|OTHER|Run-In Period|Ortho-Cyclen for 21 days. Only for subjects who are not already taking Ortho-Cyclen prior to the study
62709195|NCT01498861|EXPERIMENTAL|Sequence AB|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
62512781|NCT04647617|PLACEBO_COMPARATOR|Control group|They are keep their normal live style
62709196|NCT01498861|EXPERIMENTAL|Sequence BA|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
62709197|NCT02900014|EXPERIMENTAL|Children with cleft|
62709198|NCT02724202|EXPERIMENTAL|Open Label|All subjects will receive induction oral curcumin 500 mg twice per day for 2 weeks. Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5FU.
62709199|NCT03412929|EXPERIMENTAL|Honey Impregnated Dressing|Honey Impregnated Dressing
62709200|NCT04056247||Newly diagnosed NSCLC stage IV|Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
62709201|NCT04056247||NSCLC stage IV 2nd line and further of immunotherapy|Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.
62709202|NCT04056247||Malignant melanoma stage IV|Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.
62709203|NCT04056247||Malignant melanoma stage IIIb-d|Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.
62709204|NCT04056247||SCLC stage IV|Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
62709205|NCT00314977|EXPERIMENTAL|A|Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
62709206|NCT00314977|EXPERIMENTAL|B|Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel
62709207|NCT01832727|EXPERIMENTAL|Cohort 180 mg 5/14 Schedule (Phase 1b)|Oprozomib 180 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
62709208|NCT01832727|EXPERIMENTAL|Cohort 210 mg 5/14 Schedule (Phase 1b)|"Oprozomib 210 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 5/14 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
62709209|NCT01832727|EXPERIMENTAL|Cohort 150/180 mg 5/14 Schedule (Phase 1b)|Oprozomib 150 mg once daily treatment for 5 consecutive days (days 1, 2, 3, 4, and 5 of a 14-day cycle) followed by a step-up in oprozomib once daily dose to 180 mg starting in cycle 2 and moving forward. Dexamethasone 20 mg once daily was administered on days 1, 2, 8, and 9 of each 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
62709210|NCT01832727|EXPERIMENTAL|Cohort 210 mg 2/7 Schedule (Phase 1b)|"Oprozomib 210 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 2/7 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
61972712|NCT04193657||Abiraterone|20 participants starting Abiraterone
61972713|NCT04193657||Enzalutamide|20 participants starting Enzalutamide
61972714|NCT04193657||Radium-223|20 participants starting Radium-223
61972715|NCT00814398|EXPERIMENTAL|SET on day 3|Single embryo transfer on day 3 of embryo development
61972716|NCT00814398|EXPERIMENTAL|DET on day 3|Double embryo transfer on day 3 of embryo development
61972717|NCT00814398|EXPERIMENTAL|SET on day 5|Single embryo transfer on day 5 of embryo development
62512782|NCT04432519|EXPERIMENTAL|Group CA|Customized healing abutment inserted in immediate implant placement.
62512783|NCT04432519|ACTIVE_COMPARATOR|Group CM|Resorbable Collagen Membrane for socket closure in immediate implant placement.
62512784|NCT04871516|EXPERIMENTAL|Treatment (radiation therapy boost, WBI)|Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
62147045|NCT04816305|EXPERIMENTAL|rTMSp + physiotherapy|A personalized high or low-frequency rTMS (rTMSp) will be applied to the lesioned or non-lesioned hemisphere depending on cortical biomarkers assessment guide a personalized stimulation for each patient in this group. After rTMSp, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
62512785|NCT04776057|OTHER|lying|after cataract lying for 1 hour
62512786|NCT04776057|OTHER|sitting, walkin|after cataract sitting or walking for 1 hour
62512787|NCT06483737|EXPERIMENTAL|Modified dosage group|Intravenous infusion of human albumin 30-60g.
62512788|NCT06483737|ACTIVE_COMPARATOR|Routine dosage group|Intravenous infusion of human albumin 10-20g.
62512789|NCT04692025|EXPERIMENTAL|Group 1|ASC41 one tablet, on Day 1 before meal；ASC41 one tablet, on Day 15 after meal.
62512790|NCT04692025|EXPERIMENTAL|Group 2|ASC41 one tablet, on Day 1 after meal；ASC41 one tablet, on Day 15 before meal.
62512791|NCT02439476||Relapsed multiple myeloma patients who are considered eligible|Patients mobilized using G-CSF+Plerixafor according to Plerixafor label in France will be included. Apheresis will be performed according to standard practice and local guidelines. Once the autologous stem cell product becomes available, patients will undergo ASCT conditioned by high dose Melphalan according to standard practice in each centre
62512792|NCT04247984|EXPERIMENTAL|mXELIRI+ Bevacizumab|
62512793|NCT04247984|ACTIVE_COMPARATOR|FOLFIRI + Bevacizumab|
62512794|NCT01929395|ACTIVE_COMPARATOR|Arm 1 addition of supine MRI to conventional imaging|Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.
62512795|NCT01929395|ACTIVE_COMPARATOR|Arm 2 randomize to SOC vs supine MRI + SOC|Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.
62512796|NCT05742919|EXPERIMENTAL|NNC0194-0499 12 mg|Participants will receive a single subcutaneous (s.c.) dose of 12 milligrams (mg) NNC0194-0499 on Day 1.
62512797|NCT05742919|EXPERIMENTAL|NNC0194-0499 30 mg|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
62512798|NCT05742919|EXPERIMENTAL|NNC0194-0499 96 mg|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
62512799|NCT00337428|EXPERIMENTAL|Group 1|Concomitant/CMF
62512800|NCT00337428|EXPERIMENTAL|Group 2|Non-Concomitant/CMF
62512801|NCT00337428|EXPERIMENTAL|Group 3|Concomitant/FMF
62512802|NCT00337428|EXPERIMENTAL|Group 4|Non-Concomitant/FMF
62512803|NCT04071054||Hemodialysis patients|
62512804|NCT06616129|EXPERIMENTAL|PRIME-Group|
62512805|NCT06616129|NO_INTERVENTION|Control Group|
62512806|NCT03082235|EXPERIMENTAL|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
62512807|NCT03082235|PLACEBO_COMPARATOR|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
62512808|NCT03082235|EXPERIMENTAL|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
62512809|NCT03082235|PLACEBO_COMPARATOR|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
62512810|NCT03082235|EXPERIMENTAL|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
62512811|NCT03082235|PLACEBO_COMPARATOR|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
62512812|NCT03082235|EXPERIMENTAL|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
62512813|NCT03082235|PLACEBO_COMPARATOR|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
62512814|NCT03082235|EXPERIMENTAL|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
62512815|NCT03082235|PLACEBO_COMPARATOR|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
62512816|NCT03082235|EXPERIMENTAL|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
62512817|NCT03082235|PLACEBO_COMPARATOR|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
62512818|NCT03082235|EXPERIMENTAL|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
62512819|NCT03082235|PLACEBO_COMPARATOR|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
62512820|NCT02771041|EXPERIMENTAL|Group with D-8 medical consultation|"A medical consultation 8 days before surgery would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
62512821|NCT02771041|NO_INTERVENTION|Group without D-8 medical consultation|
62512822|NCT06139055|EXPERIMENTAL|Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet|Participants will receive a single dose of GSBR-1290 oral capsule formulation on Day 1 in Treatment Period 1 followed by GSBR-1290 oral tablet formulation on Day 8 (Day 1 of Treatment Period 2).
62512823|NCT06139055|EXPERIMENTAL|Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule|Participants will receive a single dose of GSBR-1290 oral tablet formulation on Day 1 in Treatment Period 1 followed by GSBR-1290 oral capsule formulation on Day 8 (Day 1 of Treatment Period 2).
62512824|NCT06139055|EXPERIMENTAL|Part 2 (Cohort 1): GSBR-1290/Placebo Tablet|Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks.
62512825|NCT06139055|EXPERIMENTAL|Part 2 (Cohort 2): GSBR-1290/Placebo Tablet|Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks.
62512826|NCT06139055|EXPERIMENTAL|Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule|Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks. In the last 4 weeks, participants will be further randomized to GSBR-1290 capsules or tablets or matching-placebo at Week 9 to 10 followed by alternate (capsule or tablet) formulation of either GSBR-1290 or placebo at Week 11 to 12.
62512827|NCT04965857||Slides from the German Co-Screening program|From 25,000 LBC slides (ThisPrep, Hologic Inc., USA) from the German Co-screening program evaluated using the Genius Digital cytology system all abnormal findings according to Munich III groups (II-p - V) and each 10th normal slide (Munich III group I and II) will be selected for the prospective evaluation by manual microscopy.
62512828|NCT01355159|EXPERIMENTAL|Folic Acid 4 mg|Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
62512829|NCT01355159|PLACEBO_COMPARATOR|Placebo|Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo
62353344|NCT04789863|OTHER|Intervention group|Intervention group (IG) patients will receive usual care plus the SMILe-ICM (see below) when they come to their planned follow-up appointments at the University Hospital Basel. Thus, while IG participants will receive the same number of follow-up appointments as CG participants (depending on their state of health), they will also receive the SMILe-ICM, i.e., tailored self-management and behavioural support delivered by the combination of totally 12 face-to-face meetings with a Care Coordinator (CC) and the SMILeApp. The personal meetings with the CC will last around 40-90 minutes. The first three of them will occur during the initial alloSCT hospitalization, and the other nine will occur in the outpatient setting, beginning with biweekly and expanding to bi-monthly intervals until one year post-alloSCT.
62353345|NCT04789863|OTHER|Control group|"see Intervention section"
62353346|NCT02294695||Appropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
62512830|NCT05311761|EXPERIMENTAL|CogMe Personal Assistant (PA)|The CogMe PA is a dedicated application built by CogMe with the purpose of assessing the cognitive functions of patients and providing them with a short and stimulating interaction. The application runs on a standard tablet. The CogMe PA is designed to be easily understandable and usable also for older adults with little or no experience in mobile applications. The questions in the Q\&A session are based on validated cognitive tests shown to be associated with delirium and are built to assess the subjective wellbeing and cognitive function of the patients. The repeated use of the application will allow to detect any changes or anomalies during the hospitalization period.
62512831|NCT04916483|EXPERIMENTAL|Exploring the effectiveness of GCST in people with schizophrenia.|The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.
62512832|NCT04916483|NO_INTERVENTION|Control group|The control group maintains the usual care.
62512833|NCT01553747|EXPERIMENTAL|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
62709211|NCT01832727|EXPERIMENTAL|Cohort 240 mg 2/7 Schedule (Phase 1b)|Oprozomib 240 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
62709212|NCT01832727|EXPERIMENTAL|Cohort 270 mg 2/7 Schedule (Phase 1b)|Oprozomib 270 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
62709213|NCT01832727|EXPERIMENTAL|Cohort 300 mg 2/7 Schedule (Phase 1b)|Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
62709214|NCT01832727|EXPERIMENTAL|Cohort 330 mg 2/7 Schedule (Phase 1b)|Oprozomib 330 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
62709215|NCT01832727|EXPERIMENTAL|Phase 2 300 mg 2/7 Schedule|The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
61972718|NCT00814398|EXPERIMENTAL|DET on day 5|Double embryo transfer on day 5 of embryo development
61972719|NCT06504602|EXPERIMENTAL|Active Virtual Reality|Within the active virtual reality group virtual environment, participants will play the game Bearblast using Oculus Go Headset for patients 8-21 years old. In BearBlast, participants travel on a pre-set path through an interactive environment.
61972720|NCT06504602|EXPERIMENTAL|Passive Virtual Reality|Within the passive virtual reality group virtual environment and age appropriate movie.
61972721|NCT06504602|NO_INTERVENTION|Standard of Care|Participants will receive standard of care distraction methods.
61972722|NCT02468323|PLACEBO_COMPARATOR|Placebo group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.
61972723|NCT02468323|EXPERIMENTAL|Ondansetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.
61972724|NCT02468323|EXPERIMENTAL|Palonosetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.
62709216|NCT02657148||Immediate postpartum Nexplanon|Participants who choose to enroll in the immediate postpartum Nexplanon arm will have a etonogestrel contraceptive implant (68 mg) (Nexplanon) placed in the immediate postpartum period (2-4 days following delivery), prior to hospital discharge.
61972725|NCT01545284|EXPERIMENTAL|Acitretin|Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
62353347|NCT02294695||Inappropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
62512834|NCT01553747|EXPERIMENTAL|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
62512835|NCT01553747|PLACEBO_COMPARATOR|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
62512836|NCT03585907|EXPERIMENTAL|Modified Atkins Diet (MAD)|A diet that can produce ketones
61972726|NCT00827424|EXPERIMENTAL|1|This arm will receive Lifestyle counseling by applying a modified PACE protocol
62353348|NCT04562558|EXPERIMENTAL|Arm1-Methotrexate|Patients receive methotrexate intramuscularly（50mg） on Days 1, 3, 5, 7 (4 doses per cycle) with Leucovorin (15mg) on Days 2, 4, 6, 8. Repeat every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment. If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
61972727|NCT00827424|NO_INTERVENTION|2|Subject in this arm will be recruited but will receive no intervention
62512837|NCT03585907|ACTIVE_COMPARATOR|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
62512838|NCT06304714||Patient from french Guiana|15 patients suffering from envenomation by Bothrops bites endemic to French Guiana
62512839|NCT06304714||Patient from Martinique|15 patients suffering from envenomation by Bothrops Lanceolatus bites endemic to Martinique.
61972728|NCT01561365|EXPERIMENTAL|Emergency|
62353349|NCT04562558|EXPERIMENTAL|Arm 2-Dactinomycin|Patients will receive IV pulse actinomycin-D (1.25mg/m2，2mg max dos) every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment.If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
62353350|NCT03702426|EXPERIMENTAL|Norfloxacin with GM-CSF|Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B
62353351|NCT03702426|ACTIVE_COMPARATOR|Norfloxacin|Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.
62353352|NCT01726712|NO_INTERVENTION|Routine Care|
62512840|NCT05790148|OTHER|Evaluation precision of different scan-bodies|Three different brand scanbodies (Straumann, Medentika, 3Shape) that applied in same participant group with randomization are used in this clinical study. These three different scan bodies are digitized using an intraoral scanner. Three different temporary restorations are designed in the CAD program and three different bridges are produced with the milling technique using the temporary restoration block. Clinical and analytic evaluations were perform and primarly, seconderly outcomes were achieved.
62512841|NCT04227938|EXPERIMENTAL|ALPN-101|All subjects will receive a single dose of ALPN-101. In Part A, ascending dose levels of ALPN-101 will be evaluated. In Part B, a single dose level of ALPN-101-as identified in Part A-will be evaluated.
62512842|NCT00201916|EXPERIMENTAL|1|5250 cGy in 20 fractions over 28 days
62512843|NCT00201916|ACTIVE_COMPARATOR|2|6600 cGy in 33 fractions over 45 days
61972729|NCT01561365|EXPERIMENTAL|Orthopedic residents|
61972730|NCT05738161|EXPERIMENTAL|Magrolimab in combination with Cisplatin and Gemcitabine|Magrolimab therapy in combination with standard first line platinum-based chemotherapy (with Cisplatin / Gemcitabine) in advanced urothelial carcinoma.
61972731|NCT00953446|EXPERIMENTAL|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|"* ASL MRI~* Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment"
61972732|NCT01923701|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy group receives group, individual, and family Cognitive Behavioral Therapy in addition to standard care.
61972733|NCT01923701|NO_INTERVENTION|Monitoring|This group receives standard care only.
61976316|NCT02508402|ACTIVE_COMPARATOR|dexamethasone group|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
62353353|NCT01726712|ACTIVE_COMPARATOR|Supportive Contact|
62353354|NCT00747994||1|
62353355|NCT01061320|ACTIVE_COMPARATOR|alpha tocopherol|
62353356|NCT01061320|PLACEBO_COMPARATOR|placebo|
62512844|NCT05117047||robot-assisted liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 71 HCC patients were included in robotic liver resection cohort.
62709217|NCT02657148||Control|Participants who choose to enroll in the control arm will receive standard postpartum contraceptive care: condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.
62147046|NCT04816305|SHAM_COMPARATOR|tDCS sham + physiotherapy|The sham protocol will be delivered to each patient of this arm imitating the exat sound of the equipment and structure of the experimental arms. After rTMS sham, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
62512845|NCT05117047||laparoscopic liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 141 HCC patients were included in laparoscopic liver resection cohort.
62709218|NCT05756322|EXPERIMENTAL|Dose Finding and Expansion Phase|Phase 1: Dose finding phase to evaluate LBS-007 as a monotherapy and combination with Venetoclax and Azacitidine Phase 2: Dose expansion phase to evaluate LBS-007 as a monotherapy and combination therapy at the optimal dose identified by phase 1 (dose finding)
62709219|NCT01480687|EXPERIMENTAL|Omega-3 fatty acid|
62709220|NCT01480687|ACTIVE_COMPARATOR|Ciprofibrate|
62709221|NCT05556902|EXPERIMENTAL|Treatment|Patients that proceed with permanent implantation of a spinal cord stimulator.
61972734|NCT02898246||Patients with chronic heart failure|"Fear of physical activity (exposure) will be assessed in adult outpatients with diagnosed, chronic heart failure (with reduced ejection fraction or with preserved ejection fraction).~Hospitals provide medical data to assess patients' disease severity. Additional measures assessed via questionnaire include demographic characteristics, State and Trait depression and anxiety, heart failure related symptom distress, and coping dispositions relevant for coping with physical threat.~Fear of physical activity (FActS-HF 15) is reassessed after 4 weeks to evaluate the instrument's retest reliability.~After questionnaire completion, a subsample of participants will wear the MOVE III accelerometer for one week to objectively assess everyday physical activity and fill in an activity diary."
61972735|NCT03992742|EXPERIMENTAL|Intervention Group (subgroup A+B+C)|Personalized instant messaging (PIM) + optional cocktail interventions (OCI) + AWARD advice + referral card + warning leaflet+ COSH booklet
61972736|NCT03992742|EXPERIMENTAL|Control Group (subgroup D+E+F)|Regular instant messaging (RIM) + personalized instant messaging (PIM) + AWARD advice + referral card + warning leaflet+ COSH booklet
62353357|NCT05169346|ACTIVE_COMPARATOR|Active Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of active neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
62353358|NCT05169346|SHAM_COMPARATOR|Sham Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of sham (placebo) neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
62353359|NCT01078714|EXPERIMENTAL|Bumetanide|
62512846|NCT05117047||open liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 157 HCC patients were included in open liver resection cohort.
62512847|NCT05160636||COVID-19 Positive|Test-confirmed COVID-19 illness and at least one patient-reported symptom
62512848|NCT05160636||Influenza Positive|Test-confirmed influenza illness and at least one patient-reported symptom
62512849|NCT03452618|EXPERIMENTAL|patients with a NIV equipment|Determination of diagnosis variables in a group of patient who benefit of the Non Invasive ventilation equipment one year after the diagnostic
62512850|NCT03452618|ACTIVE_COMPARATOR|patients without a NIV equipment|Determination of diagnosis variables in a group of patient who not benefit of the Non Invasive ventilation equipment one year after the diagnostic
62512851|NCT01729988|EXPERIMENTAL|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
62512852|NCT04375995|OTHER|Asthma group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed to all asthmatic patients.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. Asthma control test (ACT) and asthma quality of life scale (AQLQ) will be applied. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for asthma.
62512853|NCT04375995|OTHER|Healthy control group|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
62512854|NCT01514084||PEM group|Patients whose lacerations have been repaired by PEM trained physicians.
62512855|NCT01514084||GP group|Patients whose lacerations have been repaired by general pediatricians.
62512856|NCT01514084||PNP group|Patients whose lacerations have been repaired by PNPs.
62709222|NCT05556902|NO_INTERVENTION|Control|Patients who do not proceed with permanent implantation of a spinal cord stimulator.
62709223|NCT05549544|EXPERIMENTAL|LBBAP group|Device: Left bundle branch area pacing(LBBAP) LBBAP is a novel physiological pacing form for ventricular pacing. In patients who received LBBAP, the pacing lead will be placed at the left bundle branch area to achieve a narrow-paced QRS duration.
62709224|NCT05549544|ACTIVE_COMPARATOR|BiVP group|Device: Biventricular pacing (BiVP) Biventricular pacing is the traditional pacing modality for patients with heart failure. For BiVP, one pacing lead was placed in the coronary sinus, named LV lead, and another lead was placed in the right ventricule.
62709225|NCT01999530|EXPERIMENTAL|Prazosin Hydrochloride|Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
61972737|NCT05833295|EXPERIMENTAL|Walking on flat ground|Patients will walk for 20 minutes at a 0% slope.
61972738|NCT05833295|EXPERIMENTAL|-%7.5 Downhill walking|They will walk downhill for 20 minutes at a -(negative)7.5% gradient.
62147047|NCT00105846|OTHER|Arm 1|
62147048|NCT01246804|EXPERIMENTAL|ginkgo biloba + raltegravir|15 days ginkgo biloba 120mg BID + raltegravir 400mg SD
62147049|NCT01246804|ACTIVE_COMPARATOR|raltegravir|single dose raltegravir 400mg
62353360|NCT01078714|PLACEBO_COMPARATOR|Control|
62353361|NCT01319279|EXPERIMENTAL|Normal Hepatic Function|Intervention Drug: Hydrocodone bitartrate extended-release tablet
62709226|NCT02288130|ACTIVE_COMPARATOR|GnRHa and placebo tablets|11.25 mg Leuproreline injections at the onset of pretreatment with placebo tablets (once daily)
62709227|NCT02288130|ACTIVE_COMPARATOR|Ulipristal|Three months of Ulipristal 5 mg once daily combined with a single saline injection at the onset of pretreatment (produced as placebo of Leuproreline)
61972739|NCT05833295|EXPERIMENTAL|-%15 Downhill walking|They will walk downhill for 20 minutes at a -(negative)15% gradient.
62512857|NCT01514084||RN group|Patients whose lacerations have been repaired by suture RNs.
62512858|NCT00616174|OTHER|1|Active warming with Bair Hugger blanket
62512859|NCT06420414|EXPERIMENTAL|Virtual Reality (VR) HIIT|"Participants in this arm underwent a single session of High-Intensity Interval Training (HIIT) via the Facebook Oculus Quest 2 virtual reality headset and FitXR fitness game. This immersive VR environment engaged participants in a 15-minute HIIT session, involving squats, lunges, and punches to virtual targets. The intensity was comparable to traditional HIIT, with a 10-second rest between intervals."
62512860|NCT06420414|ACTIVE_COMPARATOR|Traditional HIIT|"Participants in this arm underwent a single session of traditional High-Intensity Interval Training (HIIT), mirroring the movements and duration of the FitXR VR game. Exercises like squats, lunges, and punching targets were replicated, ensuring the same 15-minute workout duration and 10-second rest intervals, as in the VR arm."
62353362|NCT01319279|EXPERIMENTAL|Moderate Hepatic Impairment|Intervention Drug: Hydrocodone bitartrate extended-release tablet
62512861|NCT03235609|ACTIVE_COMPARATOR|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
62512862|NCT03235609|ACTIVE_COMPARATOR|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
62512863|NCT05143203||Staff trained in October 2021|22 nursing staff will follow two days of Self-Hypnosis training in October 2021
62512864|NCT05143203||Staff trained in May 2021|22 nursing staff will follow two days of Self-Hypnosis training in May 2021
62512865|NCT05143203||Control staff without training|22 nursing staff will not follow any training
62512866|NCT00049842|EXPERIMENTAL|PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)|PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up
62512867|NCT00049842|NO_INTERVENTION|Untreated Control|
62512868|NCT01739634|EXPERIMENTAL|Active Drug|After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.
62709228|NCT02288130|NO_INTERVENTION|Control|No pre-treatment prior to laparoscopic myomectomy
62709229|NCT06458556|EXPERIMENTAL|Treatment with Morpheus|
62709230|NCT05081830|EXPERIMENTAL|transdiagnostic intervention via the Internet|Treatment provided in eight individual sessions of 60 min., Once a week by videoconference. The integrity of the treatment will be controlled through the therapist's manual (Barlow et al., 2011) adapted for the Mexican population and to the online modality.
62709231|NCT05081830|ACTIVE_COMPARATOR|TCC intervention via the Internet|The TCC intervention program is short, with active, focused and directive participation, in 8 individual weekly sessions of one hour by videoconference.
61972740|NCT03382392||ALS|
61972741|NCT03382392||control 1|
61972742|NCT03382392||control 2|
61972743|NCT05729659|EXPERIMENTAL|Sideritis Scardica (SidTea+) extract|Sideritis Scardica (SidTea+) extract will be administered to participants in this arm.
61972744|NCT05729659|PLACEBO_COMPARATOR|Placebo|Placebo will be administered to participants in this arm.
61972745|NCT06085079|EXPERIMENTAL|2-week dosing|Subjects will self-administer subcutaneous injection of ixekizumab during the baseline week (Week 0) using a loading dose of 160 mg of subcutaneous ixekizumab (Taltz), followed by 80 mg of subcutaneous ixekizumab Q2 weeks for 24-weeks.
62353363|NCT00643344|EXPERIMENTAL|CALMM+|Participants receiving CALMM intervention, ie program that combines stress reduction, mindful eating practices with diet and exercise
62353364|NCT00643344|ACTIVE_COMPARATOR|TLC|Participants receiving diet and exercise classes only
62353365|NCT02480894|EXPERIMENTAL|Sequential Dosing|Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18
62353366|NCT03494426|EXPERIMENTAL|interventional group|patients will receive Radiofrequency thoracic sympathectomy then will receive pregabalin ,tramadol,and tricyclic antidepressants
62353367|NCT03494426|ACTIVE_COMPARATOR|control group|patients will receive pregabalin ,tramadol,and tricyclic antidepressants
62353368|NCT02073903||LEP inpatients and their providers|This is a feasibility project with the goal of improving communication between limited English proficiency (LEP )inpatients and their providers. Quantitative data will be obtained via two surveys: a patient survey to assess patients' feedback on the effectiveness of the communication during their hospital stay and their understanding of their medical care, and a provider survey to assess the handset's impact on the effectiveness of the communication. From this data we will be able to assess patient and provider communication effectiveness with both the current various practices at MSKCC and the new intervention.
62512869|NCT05540652|EXPERIMENTAL|Mindfulness-Based Queer Resilience (MBQR)|This is a single arm trial testing an internet delivered mindfulness-based intervention. All enrolled participants will receive the study intervention.
62709232|NCT05081830|NO_INTERVENTION|waiting list control.|Participants in the control group on the waiting list will be assigned to the intervention after 2 months after randomization and will join the Transdiagnostic intervention.
62709233|NCT02200601|EXPERIMENTAL|Seipher Wellness|
62709234|NCT00916448|PLACEBO_COMPARATOR|Placebo|placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
62709235|NCT00916448|ACTIVE_COMPARATOR|Atazanavir|Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
62709236|NCT01659060|EXPERIMENTAL|Dark chocolate|
62709237|NCT01659060|PLACEBO_COMPARATOR|Placebo chocolate|
62709238|NCT00769054|ACTIVE_COMPARATOR|1|Local Infiltration with Ropivacaine
62709239|NCT00769054|PLACEBO_COMPARATOR|2|Local Infiltration with Placebo
62709240|NCT01876498||Patient with M. Dupuytren|Xiaflex Surgery
62353369|NCT01237028|EXPERIMENTAL|oral calcitriol|Calcio®
62353370|NCT01237028|NO_INTERVENTION|placebo|
62512870|NCT01174524|EXPERIMENTAL|gestoden and ethinylestradiol|"Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.~The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients."
62353371|NCT02307656|OTHER|Atazanavir and Cobicistat|"Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)~Stage 2:Taste Optimization using API (flavours and sweeteners)~Stage 3:Prototypes of the API - containing clinical trial materials"
62512871|NCT02331238|NO_INTERVENTION|Control School|"Control schools (where the coaches do not receive the Coaching Boys into Men training until following academic year ;wait list control)"
62512872|NCT02331238|EXPERIMENTAL|Intervention School|"Intervention schools (where coaches receive the Coaching Boys into Men training at start of each sports season).~Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
62709241|NCT02993263|OTHER|Noncardiac surgery|VectraplexECG System with CEB® will be recorded after surgery and on day 1, 2 and 3 post operatively
62512873|NCT00479388|OTHER|1|One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
62512874|NCT00479388|ACTIVE_COMPARATOR|2|Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
62512875|NCT04892316||Junior doctor group|Patients receive assisting devices fitting services from junior doctors
62512876|NCT04892316||Senior doctor group|Patients receive assisting devices fitting services from senior doctors
62512877|NCT04892316||Algorithm assisted group|Patients receive assisting devices fitting services from junior doctors assisted by the machine learning model
62512878|NCT06279806|EXPERIMENTAL|İntervention Group|Mobile health application use
62512879|NCT06279806|EXPERIMENTAL|Control Group|Information of the breast cancer survivor period booklet
62512880|NCT02327793|NO_INTERVENTION|Mean Arterial Pressure <100 mmHg|Patients with mean arterial pressure \<100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.
62512881|NCT02327793|EXPERIMENTAL|Mean Arterial Pressure 100-120 mmHg|Patients with mean arterial pressure between 100-120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with sublingual 0.3 mg nitroglycerin. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of nitroglycerin administration. After a sustained drop of blood pressure (\>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
62512882|NCT02327793|EXPERIMENTAL|Mean Arterial Pressure >120 mmHg|Patients with mean arterial pressure \>120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with intravenous 10-20mg labetalol injection. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of labetalol injection. After a sustained drop in blood pressure (\>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
62709242|NCT01093014|EXPERIMENTAL|Arm 1: High-force muscle stimulation|High-force muscle stimulation
62709243|NCT01093014|EXPERIMENTAL|Arm 2: Low-force muscle stimulation|Low-force muscle stimulation
62709244|NCT01093014|EXPERIMENTAL|Arm 3: Sequential low-force and high-force muscle stimulation|Sequential low-force and high-force muscle stimulation
62709245|NCT00633841|ACTIVE_COMPARATOR|1|AFFITOPE AD02 without adjuvant
62353372|NCT05037669|EXPERIMENTAL|Cohort A: Acute Lymphoblastic Leukemia (ALL)|Adult patients aged \>18 with relapsed or refractory B cell malignancies - Acute Lymphoblastic Leukemia (ALL)
62709246|NCT00633841|ACTIVE_COMPARATOR|2|AFFITOPE AD02 with adjuvant
62709247|NCT02824679|ACTIVE_COMPARATOR|20mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
62709248|NCT02824679|ACTIVE_COMPARATOR|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
62709249|NCT02824679|PLACEBO_COMPARATOR|Saline|They received two ml of normal saline intravenously as a placebo
62709250|NCT00914576|ACTIVE_COMPARATOR|1|
62353373|NCT05037669|EXPERIMENTAL|Cohort B: Chronic Lymphocytic Leukemia (CLL) + Non-Hodgkin's Lymphoma (NHL)|Adult patients aged \>18 with relapsed or refractory B cell malignancies - Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL).
62709251|NCT00914576|PLACEBO_COMPARATOR|2|
61972746|NCT06085079|EXPERIMENTAL|4-week dosing|Subjects will self-administer subcutaneous injection of ixekizumab during the baseline week (Week 0) using a loading dose of 160 mg of subcutaneous ixekizumab (Taltz), followed by 80 mg of subcutaneous ixekizumab Q4 weeks for 24-weeks.
62709252|NCT03381989|EXPERIMENTAL|Single arm: open-label treatment|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
62709253|NCT01350726||Normal control|Subjects without liver cirrhosis and normal volunteers.
62709254|NCT01350726||Cirrhosis group|Subjects with liver cirrhosis.
62709255|NCT01903746||Patients in septic shock|
62709256|NCT00854360|EXPERIMENTAL|BDP HFA 80 µg/day|During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.
62709257|NCT00854360|EXPERIMENTAL|BDP HFA 160 µg/day|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.
62353374|NCT06335420|ACTIVE_COMPARATOR|Carrot juice|"The cultivation of Yellowstone carrots will be conducted by DanRoots A/S.DanRoots, Organic Vegetables, Bjerringbro, Denmark.Juice is produced and taste corrected by Orskov Food, Denmark in collaboration with Naturfrisk, Ørbæk.~Analysis of carrot juice for falcarinol and falcarindiol content will be done at random from 10 samples leaving the factory and 10 samples collected after 30 days storage at participant's homes for each batch."
62512883|NCT00321594|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62512884|NCT05253222|EXPERIMENTAL|retrograde imaging by colonic TET|Contrast fluid will be injected through colonic TET in participants with bowel obstruction. Image parameters detected by CT and X-ray fluoroscopy will be evaluated.
62512885|NCT01267006|PLACEBO_COMPARATOR|Placebo|Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule.
62512886|NCT01267006|EXPERIMENTAL|GSK1325756 200 mg|Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
62512887|NCT01267006|EXPERIMENTAL|GSK1325756 50 mg|Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
62512888|NCT01267006|EXPERIMENTAL|GSK1325756 100 mg|Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule.
62512889|NCT05421793|EXPERIMENTAL|Gut barrier function treatments|Stressor, fibre, combination of treatments.
62512890|NCT02731014|EXPERIMENTAL|Dry Needling Group|Dry Needling, Manual Therapy, and Exercise.
62512891|NCT02731014|SHAM_COMPARATOR|Sham Dry Needling Group|Sham Dry Needling, Manual Therapy, and Exercise.
62512892|NCT03752398|EXPERIMENTAL|XmAb®23104 Monotherapy|XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles
62512893|NCT03752398|EXPERIMENTAL|XmAb®23104 Combination Therapy with Ipilimumab|XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab)
62512894|NCT04707586|NO_INTERVENTION|Control|No application will be made to patients in this group. Routine patient care will be provided. After the patients who develop pain are recorded, the application will be made with a cold application bandage.
62512895|NCT04707586|EXPERIMENTAL|experimental group|Patients in this group will be applied cold application with cold application bandage for 20 minutes as soon as the infusion begins.
62512896|NCT01726114|EXPERIMENTAL|Non-invasive Optical Glucose Monitor™|Test device
62512897|NCT03699241|PLACEBO_COMPARATOR|Group 1|HIV-Uninfected participants
62512898|NCT03699241|PLACEBO_COMPARATOR|Group 2|HIV-Uninfected participants
62512899|NCT03699241|PLACEBO_COMPARATOR|Group 3|HIV-Uninfected participants
62512900|NCT03699241|PLACEBO_COMPARATOR|Group 4|HIV-Uninfected participants
62512901|NCT03699241|PLACEBO_COMPARATOR|Group 5|HIV-Uninfected participants
62512902|NCT05605912|EXPERIMENTAL|Myosuit intervention|Participants perform Myosuit training sessions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home for six weeks and a recommendation for physical activity at home.
62512903|NCT05605912|ACTIVE_COMPARATOR|Control|Participants perform conventional training sessions. After the clinical training program, participants receive a recommendation for physical activity at home. After the conventional training program the control group will receive the Myosuit intervention.
62512904|NCT00824369|NO_INTERVENTION|Anti-retroviral therapy|Anti-retroviral therapy
62512905|NCT03122587|SHAM_COMPARATOR|Active Sham (Session 1 and Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
62512906|NCT03122587|EXPERIMENTAL|Active Sham (Session 1) and tACS at 10 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
62709258|NCT00854360|EXPERIMENTAL|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
62709259|NCT00854360|PLACEBO_COMPARATOR|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
62512907|NCT03122587|EXPERIMENTAL|Active Sham (Session 1) and tACS at 40 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
62512908|NCT02498275||Healthy volunteers|Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.
62512909|NCT02498275||Nucleoside/nucleotide analogue-treated CHB patients|Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
62512910|NCT02498275||Treatment-naive CHB patients|Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
62512911|NCT01363141|ACTIVE_COMPARATOR|Regular AGE Diet|Regular AGE Diet
62512912|NCT01363141|ACTIVE_COMPARATOR|Low AGE Diet|One year reduction in dietary AGE intake
62512913|NCT04894084|EXPERIMENTAL|Test product|Subjects are requested to use the test device (supporting product) beneath their ostomy baseplate. Subjects may change their appliance as they wish, either they may change due to a notification from the app and/or follow their change routine.
62709260|NCT03306550|ACTIVE_COMPARATOR|aspirin arm|only take aspirin (100mg,qd) orally for 10 days treatment course
62512914|NCT03786419|EXPERIMENTAL|Atezolizumab|Participants with unresectable or advanced malignant pleural mesothelioma who have progressed after platinum-based chemotherapy will receive atezolizumab 1200 mg every 21 days, until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
62512915|NCT04540055||Paravertebral (Group P)|Patients underwent MRM under the combination of general anesthesia and paravertebral block.
62512916|NCT04540055||General Anesthesia (Group G)|Patients underwent MRM under general anesthesia.
62709261|NCT03306550|ACTIVE_COMPARATOR|salvianolate injection arm|only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
62709262|NCT03306550|EXPERIMENTAL|aspirin and salvianolate injection arm|take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
62512917|NCT04059549|ACTIVE_COMPARATOR|A-CHESS Drinker|Patients randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
62512918|NCT04059549|EXPERIMENTAL|PartnerCHESS Drinker|Patients randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
62709263|NCT06461780|EXPERIMENTAL|Intervention|The Line-based questionnaire follow-up app will be used to collect and follow patients' condition and syndrome.
62709264|NCT04968483||Study group|Patients with spine deformity undergoing surgical treatment
62709265|NCT03969173|ACTIVE_COMPARATOR|PEEP3|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
62709266|NCT03969173|ACTIVE_COMPARATOR|PEEP6|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
62709267|NCT03969173|ACTIVE_COMPARATOR|PEEP9|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
62709268|NCT04722666|EXPERIMENTAL|MIJ821 (mg/kg) - very low dose|MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
61972747|NCT02825992|OTHER|AcQMap System|All patients who underwent catheter ablation using the AcQMap System
61972748|NCT04702334|EXPERIMENTAL|Hyaluronic acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel . This adjunctive treatment was performed at baseline and at the 3 months control.
62709269|NCT04722666|EXPERIMENTAL|MIJ821 (mg/kg) - low dose|MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
62709270|NCT04722666|EXPERIMENTAL|MIJ821(mg/kg) - high dose|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
62709271|NCT04722666|EXPERIMENTAL|MIJ821 (mg/kg) - very high dose|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
62709272|NCT04722666|PLACEBO_COMPARATOR|Placebo|40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
62709273|NCT04722666|EXPERIMENTAL|MIJ821 (mg/kg) - high dose/Placebo|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
62709274|NCT04722666|EXPERIMENTAL|MIJ821 (mg/kg) - very high dose/Placebo|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
62709275|NCT01656161|EXPERIMENTAL|Triptorelin embonate 22.5 mg|Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
62709276|NCT02514655|EXPERIMENTAL|1: Nosten® monitoring|One experimental group with the control of the cuff pressure by Nosten® device
62709277|NCT02514655|ACTIVE_COMPARATOR|2: Manual monitoring|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
62709278|NCT04138056|EXPERIMENTAL|RSV120_dTpa_RSV120(Pooled)|Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and either one dose of 300 μg or 500 μg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
62709279|NCT04138056|PLACEBO_COMPARATOR|RSV120_Placebo_RSV120(Pooled)|Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
62709280|NCT04138056|EXPERIMENTAL|RSV60_dTpa_RSV120(Pooled)|Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
61972749|NCT04702334|PLACEBO_COMPARATOR|Lidocaine|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic. This adjunctive treatment was performed at baseline and at the 3 months control.
61972750|NCT01457521|ACTIVE_COMPARATOR|Therapeutic|Ibuprofen
62353375|NCT06335420|PLACEBO_COMPARATOR|Placebo juice|Placebo juice is produced from natural flavours and taste corrected by Orskov Food, Denmark in collaboration with Naturfrisk, Ørbæk. The taste is corrected to prevent enabling differentiation between carrot juice and placebo.
62512919|NCT04059549|ACTIVE_COMPARATOR|A-CHESS Partner|Patient's partner randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
62512920|NCT04059549|EXPERIMENTAL|PartnerCHESS Partner|Patient's partner randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
62512921|NCT00518882|EXPERIMENTAL|Liraglutide|Liraglutide 1.8 mg once daily + subject's own OAD treatment
62512922|NCT00518882|ACTIVE_COMPARATOR|Exenatide|Exenatide 10 mcg twice daily + subject's own OAD treatment
62512923|NCT06097559||Clinical Outcomes in a Receptive Endometrium|"Enrolled patients that according to the ERA® report are receptive.~The only additional intervention that patients will undergo, apart from those already scheduled for their ART, is the collection of an endometrial biopsy and endometrial fluid.~No drugs will be administered as per the study."
62709281|NCT04138056|PLACEBO_COMPARATOR|RSV60_Placebo_RSV120(Pooled)|Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
62709282|NCT04138056|PLACEBO_COMPARATOR|dTpa_Placebo_RSV120(Pooled)|Subjects received one dose of Placebo and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
62709283|NCT04863742|EXPERIMENTAL|Dextenza Arm|
62709284|NCT04863742|ACTIVE_COMPARATOR|Prednisolone Acetate 1%|
62709285|NCT01627886|EXPERIMENTAL|Ibandronate sodium tablets 150 mg|Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
61972751|NCT01457521|ACTIVE_COMPARATOR|Prophylactic|Ibuprofen
61972752|NCT03025503|EXPERIMENTAL|nipple stimulation|
61972753|NCT03025503|NO_INTERVENTION|no intervention|
61972754|NCT05039645|OTHER|Open Arm Study - All participants|"Study is open arm with no blinding or randomisation. Patients will receive standard care including frequent clinical visits, education, and preventative foot care/podiatry as required. Patients will also be given a DFS thermovisual scanner device. Patients will be instructed to use the DFS on a daily basis, at home, to record thermovisual data about the soles of their feet.~Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of \>2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment)."
61972755|NCT02050074|EXPERIMENTAL|Colesevelam|
62147050|NCT02843100|EXPERIMENTAL|Group 1|Modified Exclusive Enteral Nutrition including two weeks of Exclusive Enteral Nutrition (EEN) using Modulen followed by Partial Enteral Nutrition (PEN) along with the Crohn's Disease Exclusion Diet (CDED) phases 2 \& 3 for 24 weeks
62147051|NCT02843100|ACTIVE_COMPARATOR|Group 2|Standard Exclusive Enteral Nutrition for 8 weeks using Modulen, followed by free diet with gradual reduction of Modulen to 25% of energy needs by week 24.
62147052|NCT05858359|EXPERIMENTAL|ImPACT program|The ImPACT program consists of 8 weekly 1-hour sessions with homework between sessions.
62147053|NCT05858359|NO_INTERVENTION|Waitlist|Waitlist control
62147054|NCT03608111|ACTIVE_COMPARATOR|single task balance training|
62147055|NCT03608111|ACTIVE_COMPARATOR|dual task balance training|
62147056|NCT04290741|EXPERIMENTAL|Auricular (Battlefield) Acupuncture|Auricular acupuncture involves placement of needles based on battlefield acupuncture protocol which involves the placement of needles in up to 5 sites on each ear to treat pain.
62147057|NCT04290741|EXPERIMENTAL|Peripheral Acupuncture|Peripheral acupuncture involves placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
62147058|NCT04290741|NO_INTERVENTION|Control|Standard of care without acupuncture
62147059|NCT00667732|ACTIVE_COMPARATOR|1|Participants will receive exenatide as part of their diabetes treatment
62147060|NCT00667732|PLACEBO_COMPARATOR|2|Participants will receive placebo rather than exenatide as part of their diabetes treatment
62147061|NCT04422392|EXPERIMENTAL|Neoadjuvant PD-1 antibody puls chemotherapy|"Neoadjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3) Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of combinded adjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will be administered. Thirteen cycles of PD-1 antibody will start within day 21-24 days from day 1 of adjuvant cycle 2."
62147062|NCT04422392|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|"Neoadjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3).~Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of adjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will be administered."
62147063|NCT04741009|EXPERIMENTAL|CI632 Slim Modiolar Electrode|
62147064|NCT00253266|EXPERIMENTAL|Verum|Quetiapine augmentation
62147065|NCT00253266|PLACEBO_COMPARATOR|Placebo|"Placebo augmentation"
62147066|NCT01829711|EXPERIMENTAL|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
62147067|NCT00064883||Patients|Pediatric cancer patients referred to the ROB who have received or require radiation therapy
62147068|NCT04171011|EXPERIMENTAL|Nerve Stimulation|Participants will undergo brief NVB stimulation during the esophagectomy procedure.
62709286|NCT01627886|ACTIVE_COMPARATOR|Boniva|Boniva Tablets 150 mg of Roche Laboratories Inc, USA
62709287|NCT04834921|EXPERIMENTAL|MCO-CVVHD|CVVHD with MCO filter for 24 hours
62709288|NCT04834921|ACTIVE_COMPARATOR|HFF-CVVHDF|CVVHDF with high flux filter for 24 hours
62709289|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
62709290|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
62147069|NCT01229332|PLACEBO_COMPARATOR|Carbidopa|
62147070|NCT01229332|PLACEBO_COMPARATOR|Placebo|
62709291|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
62709292|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
62709293|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
62709294|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
62709295|NCT04636632|EXPERIMENTAL|Weekly Arm|fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during concurrent chemoradiotherapy
62709296|NCT04636632|ACTIVE_COMPARATOR|Triweekly Arm|fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during concurrent chemoradiotherapy
61972756|NCT02050074|EXPERIMENTAL|Metformin|
62709297|NCT04715035|ACTIVE_COMPARATOR|Conventional treatment|Physical therapy: education, mobilizations, stretch, active exercises, home excercises.
61972757|NCT02050074|EXPERIMENTAL|Placebo|
61972758|NCT02050074|EXPERIMENTAL|Colesevelam + exendin (9-39)|
61972759|NCT02050074|EXPERIMENTAL|Metformin + exendin (9-39)|
61972760|NCT02050074|EXPERIMENTAL|Placebo + + exendin (9-39)|
61972761|NCT02801292|OTHER|administering of ketamine|adjuvant to standard of care
61972762|NCT02944474|EXPERIMENTAL|Cohort 1 (200 mg)|Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
61972763|NCT02944474|EXPERIMENTAL|Cohort 2 (500 mg)|Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
61972764|NCT02944474|EXPERIMENTAL|Cohort 3 (500 mg)|Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
61972765|NCT02944474|EXPERIMENTAL|Cohort 4 (1000 mg)|Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
61972766|NCT02944474|PLACEBO_COMPARATOR|Placebo cohorts 1 to 4|Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
61972767|NCT05546567|EXPERIMENTAL|Nicotinamide Riboside|Open Label. Nicotinamide Riboside 1200mg x1 daily
61972768|NCT04470674|ACTIVE_COMPARATOR|Arm A (Durvalumab)|Durvalumab 1500 mg IV every 4 weeks for 13 cycles.
62709298|NCT04715035|EXPERIMENTAL|Conventional treatment + eccentric exercises|Physical therapy: education, mobilizations, stretch, active exercises, home exercises, eccentric exercises.
62709299|NCT03986957||Hypertensive patients|Patients with SBP: 140-159; DBP: 90-99
62709300|NCT04050384|NO_INTERVENTION|No vibratory stimulus before or during heel lance|Baseline measurements and readings after vibration alone will be done, but no vibratory stimulus will be provided immediately preceding or during heel lance.
62709301|NCT04050384|EXPERIMENTAL|Vibratory stimulus before and during heel lance|Baseline measurements and readings after vibration alone will be done, as well as a vibratory stimulus that will be provided immediately preceding and during heel lance.
62709302|NCT00929266|EXPERIMENTAL|1|"The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects."
61972769|NCT04470674|EXPERIMENTAL|Arm B (Durvalumab plus chemotherapy)|Durvalumab 1500 mg IV plus carboplatin AUC 5 IV and pemetrexed 500 mg/m2 IV every 3 weeks for 4 cycles followed by durvalumab and pemetrexed every 3 weeks for 13 more cycles.
61972770|NCT02504008|EXPERIMENTAL|AXS-02 (oral zoledronate)|Administered orally in the morning on Days 1, 8, 15, 22, 29, and 36
61972771|NCT02504008|PLACEBO_COMPARATOR|Placebo|Administered orally in the morning on Day 1, 8, 15, 22, 29, and 36
61972772|NCT04147221|EXPERIMENTAL|Imipenem-Relebactam|Participants will receive a single dose of intravenous imipenem-relebactam (500mg-250mg) as a 30 minute infusion.
61972773|NCT02093845|ACTIVE_COMPARATOR|SYNERGY|Coronary implantatation of the SYNERGY everolimus-eluting stent
61972774|NCT02093845|ACTIVE_COMPARATOR|Biomatrix Neoflex|Coronary implantation of the biolimus-eluting Biomatrix NeoFlex stent
61972775|NCT05295043|EXPERIMENTAL|HR+/HER2- advanced breast cancer patients receiving CDK4/6 inhibitor combined with endocrine therapy|According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
61972776|NCT04588948|EXPERIMENTAL|Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
61972777|NCT04588948|EXPERIMENTAL|Non-Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
61972778|NCT05887726|EXPERIMENTAL|Zanubrutinib + R-CHOP|
61972779|NCT01654731|EXPERIMENTAL|Bezafibrate|400 mg/Day
61972780|NCT01654731|PLACEBO_COMPARATOR|Placebo|1 tablet/ day
62353376|NCT03316872|EXPERIMENTAL|Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)|"Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks~SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days."
61972781|NCT00664976|EXPERIMENTAL|1|Electroconvulsive therapy
61972782|NCT00664976|ACTIVE_COMPARATOR|2|Treatment as usual
61972783|NCT00531999|ACTIVE_COMPARATOR|1|Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
61972784|NCT00531999|ACTIVE_COMPARATOR|2|"* Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.~* Raltegravir 400 mg twice daily for the last 14 days of the study."
61972785|NCT05378490||Intravenous thrombolysis (IVT)|All patients treated with IVT in the acute stroke care pathway 2012-2025
61972786|NCT05378490||Intracerebral hemorrhage (ICH)|All patients with intracerebral hemorrhage 2012-2019
61972787|NCT05378490||Acute ischemic stroke (AIS) and Intracerebral hemorrhage (ICH)|All patients with acute ischemic stroke or intracerebral hemorrhage 2015-2017
62709303|NCT00560417|ACTIVE_COMPARATOR|ILPS|Insulin Lispro Protamine Suspension (ILPS)
62709304|NCT00560417|ACTIVE_COMPARATOR|Glargine|Insulin Glargine
61972788|NCT05378490||Stoke care pathway|All patients admitted to the stroke care pathway (ischemic stroke, intracerebral hemorrhage, transient ischemic attack and stroke mimics) 2015-2017
62709305|NCT05521932||IUA organoid|Organoids were generated from endometrial specimens remaining from pathological testing following adhesiolysis surgery.
61972789|NCT05378490||Endovascular treatment|All stroke patients treated with endovascular treatment 2012-2025
61972790|NCT05378490||Cerebellar hematoma (cICH)|All patients with cerebellar hematoma 2008-2019
61972791|NCT05397756|EXPERIMENTAL|group (OT+)|In this group (OT +), during the whole training day, the observers will use an observer tool (based on non-technical skills) when they will be not role role-playing
61972792|NCT05397756|NO_INTERVENTION|group (OT-)|In this group (OT-), the resident will not be given the observer tool and will observe other residents without any physical support.
62147071|NCT04346784|EXPERIMENTAL|maintaining positive working memory training|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
61972793|NCT05436392|NO_INTERVENTION|Control|
61972794|NCT05436392|EXPERIMENTAL|Peer Comparison Feedback|
62512924|NCT06097559||Clinical Outcomes in a Non-receptive Endometrium|"Enrolled patients that according to the ERA® report have a displaced WOI and are non-receptive.~The only additional intervention that patients will undergo, apart from those already scheduled for their ART, is the collection of an endometrial biopsy and endometrial fluid.~No drugs will be administered as per the study."
62512925|NCT02971982|EXPERIMENTAL|rituximab /Dex/CTX|rituximab /Dexamethasone/cyclophosphamide 6 cycles followed by rituximab (at least 2 cycles) rituximab:375mg/m2 d1 Dexamethasone:40mg d1-4 cyclophosphamide:750mg/m2,d1-28
61972795|NCT05436392|EXPERIMENTAL|Patient Informational Letter|
62147072|NCT04346784|EXPERIMENTAL|repressing negative working memory training|Repressing negative working memory training is a dual n-back task containing visual and auditory stimulus.Both two types of stimulus are negative.In this training, subjects are required to identify whether the location of picture presented on the screen or the word appeared in the headphone is the same as the picture or the word presented n before, then react with typing correspondingly.Each training session contains 16 blocks which are consisted with 20+n trails.
62353377|NCT01882244|EXPERIMENTAL|Neural Pathfinder Training|Neural Pathfinder training (PATH) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the PATH intervention.
62709306|NCT00004466|EXPERIMENTAL|Atorvastatin|
62709307|NCT00004466|PLACEBO_COMPARATOR|Placebo|
61972796|NCT05436392|EXPERIMENTAL|Peer Comparison Feedback plus Patient Informational Letter|
61972797|NCT05953246|ACTIVE_COMPARATOR|Neutral labels|Labels shown will be QR codes with and without neutral text (i.e., not mentioning environmental impacts)
61972798|NCT05953246|EXPERIMENTAL|Numeric text-only sustainability labels|Labels shown will contain numeric text depicting the greenhouse gas emissions associated with production of the menu item
61972799|NCT05953246|EXPERIMENTAL|Endorsement text-only sustainability labels|Labels shown will contain text endorsing menu items as having low environmental impact
61972800|NCT05953246|EXPERIMENTAL|Endorsement icon-only sustainability labels|Labels shown will contain icons endorsing menu items as having low environmental impact
61972801|NCT05953246|EXPERIMENTAL|Endorsement text-plus-icon sustainability labels|Labels shown will contain both text and icons endorsing menu items as having low environmental impact
61972802|NCT02196558|EXPERIMENTAL|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
61972803|NCT02196558|EXPERIMENTAL|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
62512926|NCT02971982|EXPERIMENTAL|Velcade/Dex/CTX|Velcade/Dexamethasone/cyclophosphamide 6 cycles followed by velcade (at least 2 cycles) Velcade:1.3mg/m2 d1,d4,d8,d11 Dexamethasone:20mg d1-2,d4-5,d8-9,d11-12 cyclophosphamide:750mg/m2,d1-28
62512927|NCT02523937||Group without PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for exclusion of PE or DVT are:~* low or intermediate clinical probability and D-dimer \<0,50 µg/mL~* low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)~* high clinical probability and negative CT and US.~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
62709308|NCT06306001|EXPERIMENTAL|Methylene blue|Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
62709309|NCT06306001|PLACEBO_COMPARATOR|Placebo infusion|Subjects in the control arm will receive a placebo infusion (normal saline) at the same volumetric rate.
62709310|NCT02016521|EXPERIMENTAL|Cooling Fabric|Garment made of 100% nylon fabric consisting of long sleeved shirt and full trouser.
62709311|NCT02016521|PLACEBO_COMPARATOR|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser.
62709312|NCT05173779|EXPERIMENTAL|Left atrial isolation arm|All the enrolled subjects will receive left atrial isolation through catheter ablation.
62709313|NCT01183351|EXPERIMENTAL|Psychosocial intervention|This is a single-group pilot-study
62709314|NCT02243358|EXPERIMENTAL|Neoadjuvant Chemo-Radiotherapy and Resection|2 cycles - FOLFOX6 (1 month) Gemcitabine/RT (5-6 weeks) Rest period 2 weeks Re-staging evaluation (CT scan to be done during the 2 weeks of rest) Surgery (To be performed no later than 6 weeks after completion of chemo-radiation)
61972804|NCT02196558|EXPERIMENTAL|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
61972805|NCT04276597|EXPERIMENTAL|Lu177 DOTATOC treatment|4 doses of 200mCi 177Lu- DOTATOC PRRT
62147073|NCT04346784|EXPERIMENTAL|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
62512928|NCT02523937||Group with PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for confirmation of PE or DVT are:~* PE on spiral computed tomography (CT)~* proximal deep vein thrombosis on ultrasonography (US).~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
62709315|NCT05612230||Hospitalized patients|The diseases were included based on the results of the preliminary data exploration and standardization according to ICD-10.
62512929|NCT02187107|EXPERIMENTAL|TMC114 + rtv|Every participant recieves 2 tablets of TMC114, 300 mg, combined with one tablet of rtv (ritonavir), 100mg, orally twice daily, every 12 hours
62512930|NCT06610461|NO_INTERVENTION|Control group|Supplemental oxygen throughout anesthesia in accordance with hospital guidelines.
62512931|NCT06610461|ACTIVE_COMPARATOR|Intervention group|HFNO- treatment
62512932|NCT01957345|OTHER|bleeding disorder|"Blood punction at patients with bleeding disorder definitely other than of platelet origin (e.g. low von Willebrand)"
62512933|NCT01957345|OTHER|constitutional platelet disorder|Blood punction at patients with constitutional platelet disorder (e.g. Glanzmann thrombasthenia)
62512934|NCT01957345|OTHER|defect of platelet function|Blood punction at patients with defect of platelet function of unknown origin, potentially defective in signalling pathway.
62512935|NCT02433119|EXPERIMENTAL|Amlodipine orotate & Valsartan|Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks
62512936|NCT02433119|ACTIVE_COMPARATOR|Valsartan & Hydrochlorothiazide|Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks
62512937|NCT06617559|EXPERIMENTAL|All-inside Quadriceps Tendon Graft Group|
62512938|NCT06617559|EXPERIMENTAL|All-inside Hamstring Tendon Graft Group|
61972806|NCT04294472|EXPERIMENTAL|Cohort 1|Cohort 1: MAU868 1350 mg IV approximately every 28 days for a total of 4 doses
61972807|NCT04294472|EXPERIMENTAL|Cohort 2|Cohort 2: MAU868 6750 mg IV on Study Day 1 and then 1350 mg IV approximately every 28 days for a total of 4 doses
61972808|NCT04294472|EXPERIMENTAL|Cohort 3|Cohort 3: MAU868 6750 mg IV approximately every 28 days for a total of 4 doses
61972809|NCT04294472|PLACEBO_COMPARATOR|Placebo Cohort 1, 2, 3|5% dextrose in water \[D5W\] IV delivered every 28 days for a total of 4 doses
61972810|NCT01504945|ACTIVE_COMPARATOR|RBC transfusion|
61972811|NCT01504945|PLACEBO_COMPARATOR|Normal saline infusion|
61972812|NCT01680523|EXPERIMENTAL|RH group|Radical hysterectomy followed by tailored adjuvant therapy
62512939|NCT02380079|EXPERIMENTAL|SCD-101|SCD-101 dosed TID for 28-days
62512940|NCT02380079|PLACEBO_COMPARATOR|Placebo|Placebo dosed TID for 28-days
62512941|NCT04714151|EXPERIMENTAL|Treatment A|K-877 ER 0.2 mg/day (once daily)
62512942|NCT04714151|EXPERIMENTAL|Treatment B|K-877 ER 0.4 mg/day (once daily)
62512943|NCT04714151|ACTIVE_COMPARATOR|Control A|K-877 IR 0.2 mg/day (twice daily)
62512944|NCT01513031|EXPERIMENTAL|Phone follow-up|All study participants will be receiving education and monthly telephone follow-up.
62512945|NCT04359563|EXPERIMENTAL|Mindfulness-Based Intervention|The MBI programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on the investigator's ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
62512946|NCT04776954|ACTIVE_COMPARATOR|Forced Air Warming System|Participants in this arm will receive warming using a forced air warming system.
62512947|NCT04776954|ACTIVE_COMPARATOR|Resistive Blanket Warming System|Participants in this arm will receive warming using a resistive blanket warming system.
61972813|NCT01680523|ACTIVE_COMPARATOR|CCRT group|Primary concurrent chemoradiation therapy
62512948|NCT02974491|EXPERIMENTAL|Apple Juice|
62512949|NCT02560974|EXPERIMENTAL|Capecitabine + Oxaliplatin|Patients will receive oral capecitabine (1000 mg/m\^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m\^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).
62512950|NCT02560974|NO_INTERVENTION|Observation|Participants will not receive any treatment but will be seen regularly by a physician.
62512951|NCT03018093|EXPERIMENTAL|C-CAR011|In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
62512952|NCT06023862|EXPERIMENTAL|Group A|Dostarlimab monotherapy
62512953|NCT06023862|EXPERIMENTAL|Group B|Dostarlimab + Bevacizumab combination therapy
62512954|NCT06023862|ACTIVE_COMPARATOR|Group C|General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)
62512955|NCT04417049|EXPERIMENTAL|Pentoxifylline|
62512956|NCT04073017|EXPERIMENTAL|Enterade|Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
62709316|NCT02966483|EXPERIMENTAL|Transanal Total Mesorectal Excision|The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.
62709317|NCT02966483|ACTIVE_COMPARATOR|Laparoscopic Total Mesorectal Excision|The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.
62709318|NCT03243461|EXPERIMENTAL|Temozolomide + Valproic acid|E.g. Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), \[10 mg/kg/d\] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): \[75 mg/m2/d\] during simultaneous radiochemotherapy (7 days a week, max. 49 days); \[150-200 mg/m2/d\] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
62353378|NCT01882244|ACTIVE_COMPARATOR|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
62353379|NCT00129792|EXPERIMENTAL|1|Has 100% expectation of receiving supplement
62353380|NCT00129792|SHAM_COMPARATOR|2|Has 50% expectation of receiving supplement
62353381|NCT00129792|OTHER|3|Has 0% expectation of receiving supplement.
62353382|NCT00676208|EXPERIMENTAL|Shared Medical Appointments|Medical students participated in shared medical appointments for patients with diabetes for one month.
62353383|NCT00676208|NO_INTERVENTION|No shared medical appointments|Medical students in this arm did not participate in shared medical appointments.
62353384|NCT04125173|ACTIVE_COMPARATOR|1. Pneumoperitoneum pressure = 15mmHg|1. Pneumoperitoneum will be set at 15mmHg
62353385|NCT04125173|ACTIVE_COMPARATOR|2. Pneumoperitoneum pressure = 12mmHg|2.Pneumoperitoneum will be set at 12mmHg
62353386|NCT04125173|ACTIVE_COMPARATOR|3. Pneumoperitoneum set at 10mmHg|3. Pneumoperitoneum will be set at 10mmHg
62353387|NCT05351333|EXPERIMENTAL|Conditioning Open-Label Placebo|Days 1 to 3 will include the acquisition phase where the opioid medication will be prescribed on a schedule of 3-4 times per day and paired with an open-label placebo. Day 4 and 6 will be the evoked phase, and patients will receive only the open-label placebo pill. On day 5 the opioid medication will be re-introduced as pharmacological reinforcement.
62353388|NCT05351333|NO_INTERVENTION|Treatment as usual|Patients in the standard of care group will receive their analgesic treatment through Spaulding Pharmacy as prescribed by their treating physicians. The treatment regime will include an opioid medication at the standard recommended dosage. Participants in this group will receive the treatment orally for 6 consecutive days.
62353389|NCT06086756|EXPERIMENTAL|Positive Mood Induction via positive film clips|"The standardized procedures outlined in our laboratory's previously conducted study (Stathopoulou, Pollack, \& Otto, 2018) will be followed. Participants will be presented with two brief film clips on a computer monitor or TV screen. These film clips were selected to elicit positive affect. As utilized in past lab study procedures, participants will be asked to: Let yourself experience whatever emotions you have, as fully as you can. Don't try to hold back, or hold in, your feelings (Stathopoulou, Pollack, \& Otto, 2018). Together, the two film clips will last for approximately 5 minutes."
62353390|NCT06086756|EXPERIMENTAL|Negative Mood Induction via negative film clips|"The standardized procedures outlined in our laboratory's previously conducted study (Stathopoulou, Pollack, \& Otto, 2018) will be followed. Participants will be presented with two brief film clips on a computer monitor or TV screen. These film clips were selected to elicit negative affect. As utilized in past lab study procedures, participants will be asked to: Let yourself experience whatever emotions you have, as fully as you can. Don't try to hold back, or hold in, your feelings (Stathopoulou, Pollack, \& Otto, 2018). Together, the two film clips will last for approximately 5 minutes."
62353391|NCT04390568|EXPERIMENTAL|Spesolimap (BI 655130) - 450 milligram (mg) - intravenous (IV)|A single dose of 450 mg Spesolimap was administered as solution for infusion intravenously over 90 minutes (mins) after an overnight fast.
62353392|NCT04390568|EXPERIMENTAL|Spesolimap - 900 mg - IV|A single dose of 900 mg Spesolimap was administered as solution for infusion intravenously over 90 mins after an overnight fast.
62353393|NCT04390568|EXPERIMENTAL|Spesolimap - 1200 mg - IV|A single dose of 1200 mg Spesolimap was administered as solution for infusion intravenously over 90 mins after an overnight fast.
62353394|NCT04390568|EXPERIMENTAL|Spesolimap - 300 mg - subcutaneous (SC)|A single dose of 300 mg Spesolimap was administered as solution for injection subcutaneously in the abdominal region within 60 seconds (s) after an overnight fast.
62353395|NCT04390568|EXPERIMENTAL|Spesolimap - 600 mg - SC|A single dose of 600 mg Spesolimap was administered as solution for injection subcutaneously in the abdominal region within 60 s after an overnight fast.
62353396|NCT06418776|ACTIVE_COMPARATOR|Intensive arm|Fit patients who could potentially undergo courses of intensive chemotherapy and are randomized to intensive chemotherapy courses
62353397|NCT06418776|ACTIVE_COMPARATOR|Low-intensive arm|Fit patients who could potentially undergo courses of intensive chemotherapy and are randomized to low intensity courses
61972814|NCT04245696|EXPERIMENTAL|Single Group|Single Arm: All subjects will undergo treatment for skin laxity in the submentum with a Dermal and SubQ handpiece
61972815|NCT05533021|EXPERIMENTAL|intervention group|Training and consultancy
62353398|NCT00805610|EXPERIMENTAL|Hepatocyte Transplantation|Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
62353399|NCT04318912||COPD patients|Adults age 40 or older with a diagnosis of chronic obstructive pulmonary disease (COPD) having been prescribed any COPD treatment (initial or subsequent) outside of a clinical trial.
62353400|NCT02992704|EXPERIMENTAL|PEG 24 weeks|peginterferon alpha 2a 180mcg for 24 weeks
61972816|NCT05533021|NO_INTERVENTION|control group|Standard postpartum care
62353401|NCT02992704|EXPERIMENTAL|PEG 48 weeks|peginterferon alpha 2a 180mcg 48 weeks
62709319|NCT04484857|EXPERIMENTAL|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant require roxadustat \<60 milligrams (mg)/week to maintain hemoglobin (Hb) levels, the dose frequency will be reduced in a stepwise manner, for example, to twice weekly (BIW), and then once weekly (QW). For participants converted from an ESA, the initial roxadustat dose will be based on the average prescribed ESA dose in the last 4 weeks (for epoetin alfa and darbepoetin alfa) or 8 weeks (for methoxy polyethylene glycol-epoetin beta \[Mircera®\]). For participants with \<6 weeks of prior ESA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.
62709320|NCT00470015|EXPERIMENTAL|MART1 Analog, gp100 and Survivin|
62709321|NCT04278404||Children and young adults who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.
62709322|NCT03953807|EXPERIMENTAL|Ozurdex|OZURDEX implant 700 μg
62709323|NCT05703230|NO_INTERVENTION|Preoperative care as usual|Patients undergoing preoperative care as usual, which does not include a structured preoperative multidisciplinary team meeting (no sMDT meeting)
62709324|NCT05703230|ACTIVE_COMPARATOR|Structured preoperative multidisciplinary team meeting|Patients are discussed preoperatively in a structured preoperative multidisciplinary team meeting
61972817|NCT06187727|EXPERIMENTAL|henagliflozein group|Patients in henagliflozein group was given henagliflozein once a day for 6 months after myocardial infarction.
61972818|NCT06187727|NO_INTERVENTION|Placebo group|Patients in placebo group was given palcebo once a day for 6 months after myocardial infarction.
62709325|NCT02055846|EXPERIMENTAL|prostate cancer|Realisation of blood sample, urinary sample and tumor biopsy
62709326|NCT02908178||Aim 1 Cohort|"The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
62709327|NCT02908178||Aim 2 Cohort|"The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
61972819|NCT01829334|ACTIVE_COMPARATOR|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
61972820|NCT01829334|EXPERIMENTAL|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
62709328|NCT05017558||intervention|Measurement of viral load in HIV-1 infected mothers at delivery by POC to optimise post-natal prophylaxis and neonatal diagnosis of children according to the estimated risk of MTCT (high risk:VL at delivery ≥ 1000 copies/mL, low risk: VL at delivery \< 1000 copies/mL) in Conakry, Guinea.
62709329|NCT03605693|ACTIVE_COMPARATOR|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
61972821|NCT01829334|EXPERIMENTAL|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
61972822|NCT01829334|EXPERIMENTAL|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
61972823|NCT04934384||Positive prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
61972824|NCT04934384||Negative or not performed prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
61972825|NCT04304807|EXPERIMENTAL|Group I|Forty five preterm infants with signs of feeding intolerance who received 20 mg of melatonin treatment in addition to traditional antibiotic treatment.
62353402|NCT02992704|NO_INTERVENTION|Control|No treatment for 72 weeks
62353403|NCT04655703|EXPERIMENTAL|DJO X4 Brace with Motion Intelligence Platform: Home discharge|Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
62709330|NCT03605693|NO_INTERVENTION|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
62709331|NCT05762432|EXPERIMENTAL|Study Device|This Arm of the study will receive the study device. Although the Study Device is not experimental as it is already CE marked and being used for it's intended purpose.
62709332|NCT05762432|ACTIVE_COMPARATOR|Standard of Care|This arm of the study will use the NHS' existing standard of care device as is normally used in podiatry clinics.
62353404|NCT04655703|NO_INTERVENTION|Control group: Home discharge|Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
61972826|NCT04304807|SHAM_COMPARATOR|Group II|Forty five preterm infants with signs of feeding intolerance who received traditional antibiotic treatment only.
61972827|NCT00137046|ACTIVE_COMPARATOR|Subcutaneous Insulin|
61972828|NCT00137046|EXPERIMENTAL|Inhaled Insulin|
61972829|NCT01732250|EXPERIMENTAL|Colistin and Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
61972830|NCT01732250|ACTIVE_COMPARATOR|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
61972831|NCT04070950||Single group|Interview of patients with cancer of the cervix or uterine body, or ovary between the time of diagnosis and 3 months after the end of their last cancer treatment (not the object of the study).
61972832|NCT04541940|ACTIVE_COMPARATOR|Telerehabilitation|
61972833|NCT04541940|ACTIVE_COMPARATOR|In-Person Rehabilitation|
61972834|NCT00547092|ACTIVE_COMPARATOR|1|tadalafil given the first 12 weeks and after a 4 week washout sildenafil is given for 12 weeks.
62709333|NCT03516721|OTHER|Obese adolescents|
62709334|NCT03516721|OTHER|Lean adolescents|
62709335|NCT04747288||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG). Exclusion Criteria: NA.
62709336|NCT04747288||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 and 1997 revised Systemic lupus erythematosus criteria. Exclusion Criteria: NA.
61972835|NCT00547092|ACTIVE_COMPARATOR|2|sildenafil given the first 12 weeks and after a 4 week washout tadalafil is given for 12 weeks.
61972836|NCT03211689|EXPERIMENTAL|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
62709337|NCT04747288||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min. Exclusion Criteria: NA.
62709338|NCT04747288||non AIDDES Healthy Controls|Non AIDDES Healthy Controls were enrolled with inclusion criteria: (1) aged between 20 and 75 years; (2) without any Chronic disease. Exclusion Criteria: any Sjögren's syndrome, Systemic lupus erythematosus, or Dry eye syndrome.
62709339|NCT00773084|ACTIVE_COMPARATOR|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
61972837|NCT03211689|NO_INTERVENTION|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
62147074|NCT04346784|PLACEBO_COMPARATOR|Positive placebo ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
62353405|NCT04655703|EXPERIMENTAL|DJO X4 Brace with Motion Intelligence Platform: Discharge to rehabilitation center|Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
62709340|NCT05782348|EXPERIMENTAL|Test Group I|A commercially available fluoride toothpaste (1450 ppm F) A commercially available Smart Electric toothbrush Cognitive behavioral intervention (CBI)
62709341|NCT05782348|ACTIVE_COMPARATOR|Control group I|A commercially available fluoride toothpaste (1450 ppm F) A commercially available Smart Electric toothbrush
62709342|NCT05782348|NO_INTERVENTION|Control group II|A commercially available fluoride toothpaste (1450 ppm F) A commercially available soft bristle toothbrush
62709343|NCT01069549||subjects with diabetic nephropathy.|"Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.~Subject must be of north Indian origin.~Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study."
62709344|NCT01069549||Subjects without Diabetic nephropathy.|This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
62709345|NCT02089204||FMISO-PET/CT|18F-MISO PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
62353406|NCT04655703|NO_INTERVENTION|Control group: Discharge to rehabilitation center|Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
62512957|NCT04073017|EXPERIMENTAL|Experimental|Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
62512958|NCT00474604|ACTIVE_COMPARATOR|Participants without breast cancer|
62709346|NCT02089204||FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
62709347|NCT02089204||contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy . GTVs were delineated based on fusing diagnostic CT images with simulation CT images.All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
62709348|NCT05058326||TEST GROUP|Women with fecal incontinence referred to outpatients clinic.
62512959|NCT00474604|EXPERIMENTAL|Participants with breast cancer|
62512960|NCT01726127|EXPERIMENTAL|Broccoli and Brussels Sprouts|Subjects will consume broccoli or Brussels sprouts (40g daily) for 8 weeks.
62512961|NCT01726127|EXPERIMENTAL|Cruciferous Complete|Subjects will take Cruciferous CompleteTM supplements (2 capsules, 3 times daily) for 8 weeks.
61972838|NCT00891254|ACTIVE_COMPARATOR|1. Intraperitoneal repair|Patients with incisional hernia, 5 cm in diameter or with an area of 25 cm2, submitted to elective surgery
61972839|NCT00891254|ACTIVE_COMPARATOR|2. On-Lay repair|Patients with incisional hernia, with a diameter of 5 cm or an area of 25 cm2, submitted to elective surgery
62512962|NCT01726127|PLACEBO_COMPARATOR|Placebo|Subjects will take placebo capsules (2 capsules, 3 times daily) for 8 weeks.
62512963|NCT05633914|EXPERIMENTAL|Tucidinostat and nab-paclitaxel|
62709349|NCT04172675|EXPERIMENTAL|Cohort 1: Erdafitinib|Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.
61972840|NCT01896531|EXPERIMENTAL|Ipatasertib + mFOLFOX6|Participants will receive oral ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
62709350|NCT04172675|ACTIVE_COMPARATOR|Cohort 1: Investigators Choice|Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC) or hyperthermic MMC. Participants who are randomized to gemcitabine or MMC or hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.
61972841|NCT01896531|PLACEBO_COMPARATOR|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
61972842|NCT02269345|EXPERIMENTAL|Battlefield Acupuncture|BFA at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
61972843|NCT02269345|PLACEBO_COMPARATOR|Standard Treatment|Standard Treatment alone
61972844|NCT04169321|EXPERIMENTAL|Single Arm|All participants will receive a mass dose of 40 μg or less of \[68Ga\]-NOTA-hGZP (radioactivity dose of 3 mCi to 8 mCi) and have a PET and CT scan.
61972845|NCT01521208|ACTIVE_COMPARATOR|LUCAS, Continuous chest compressions|Mechanical continuous chest compressions performed by LUCAS device (also during defibrillation)
61972846|NCT01521208|ACTIVE_COMPARATOR|Manual chest compressions|Manual chest compression is performed, chest compressions halted during defibrillation
61972847|NCT03080311|EXPERIMENTAL|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
61972848|NCT03867981|EXPERIMENTAL|Internet weight loss + possibility of brief phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive a brief period (i.e., once/week for 3 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
61972849|NCT03867981|EXPERIMENTAL|Internet weight loss + possibility of extended phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive an extended period (i.e., once/week for 12 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
62147075|NCT06275594|EXPERIMENTAL|Remimazolam|American Society of Anesthesiologists (ASA) I-II: initial dosing 5mg, maintenance dosing: 2.5mg, interval ≥2minutes ASA III: initial dosing 2.5mg, maintenance dosing: 1.25mg, interval ≥2minutes Remimazolam dose limitation: none Fentanyl: 25-50mcg, interval ≥5mintues, max: 200mcg
62353407|NCT04758598|EXPERIMENTAL|Direct Selective Laser Trabeculoplasty (DSLT)|Direct Selective Laser Trabeculoplasty (DSLT): employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
62353408|NCT04758598|ACTIVE_COMPARATOR|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
62353409|NCT02366390|EXPERIMENTAL|Psychoeducative intervention|A psychoeducative dialogue and one telephone booster session
62353410|NCT02366390|NO_INTERVENTION|Usual care|Usual care according to current guidelines.
62353411|NCT03782636|EXPERIMENTAL|Aldesleukin|Ultra-low dose aldesleukin injected subcutaneously, at a dose of 0.2 x 106 IU/m2 twice-weekly , three days apart, for 6 months.
62353412|NCT03782636|PLACEBO_COMPARATOR|Placebo|Placebo sc, at a similar dose (expressed in ml) to the active drug
62512964|NCT03042468|EXPERIMENTAL|All subjects|"1. 177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)~2. 68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging"
62512965|NCT06012721|EXPERIMENTAL|Part 1 Treatment A|30 mg ORIC-114 (3 x 10 mg tablets) administered at Hour 0 on Day 1 under fasting conditions.
62512966|NCT06012721|EXPERIMENTAL|Part 1 Treatment B|30 mg ORIC 114 (3 x 10 mg tablets) administered at Hour 0 on Day 1, 30 minutes after the start of a meal.
62512967|NCT06012721|EXPERIMENTAL|Part 2 Treatment A|xx mg ORIC-114 (n x 10 mg tablets) administered at Hour 0 on Day 1 under fasting conditions.
62709351|NCT04172675|EXPERIMENTAL|Cohort 2|Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.
62147076|NCT06275594|ACTIVE_COMPARATOR|Real world Midazolam|Initial dosing 2-3mg, maintenance dosing: 0.5-1mg, interval ≥2minutes Remimazolam dose limitation: 7.5mg Fentanyl: 25-50mcg, interval ≥5mintues, max: 200mcg
62147077|NCT06275594|ACTIVE_COMPARATOR|On label Midazolam|"\<60years old and healthy: initial dosing 1.75mg, maintenance dosing: 1.0mg, interval ≥2minutes~≥60years old or debilitated/chronically ill: initial dosing 1.0mg, maintenance dosing: 0.5mg, interval v2minutes Remimazolam dose limitation: 7.5mg Fentanyl: 25-50mcg, interval ≥5mintues, max: 200mcg"
62147078|NCT04878679|EXPERIMENTAL|"Strength training + WB-EMS"|Strength training combined with WB-EMS : 2 times/week for 20 minutes
62147079|NCT04878679|EXPERIMENTAL|Cardiovascular training + WB-EMS|Cardiovascular training, using rowing machine, combined with WB-EMS : 2 times/week for 20 minutes
62512968|NCT06012721|EXPERIMENTAL|Part 2 Treatment B|xx mg ORIC 114 (n x 10 mg tablets) administered at Hour 0 on Day 1, 30 minutes after the start of a meal.
62512969|NCT01929772||severe sepsis or septic shock|patients with severe sepsis or septic shock
62512970|NCT05886231|EXPERIMENTAL|music group (Group M)|"Group M patients were fitted with headphones that covered the entire ear and suppressed hearing of the sounds in the operating room. The level of the music sound was adjusted to the level where patients felt comfortable by asking them before induction.~Mean arterial pressure (MAP) greater than 20% of the initial value for one minute or longer was first evaluated in favor of superficial anesthesia, while its continuation was considered hypertension.~If the TOF value was higher than 70 for a long time, 0.1 mg/kg rocuronium iv was administered, and 50 µg fentanyl iv was administered in the need for opioids. In the last 20 minutes of the surgical period, 1 mg/kg tramadol and 20 mg/kg paracetamol IV were administered to all patients in accordance with conventional treatment for postoperative analgesia."
62512971|NCT01473550|EXPERIMENTAL|Early Intervention|At Phase 1 (first 3 months of project), the 200 participants in Group 1 will be provided with a Personal Health Record (PHR) through TELUS Health Space, as well as they will be introduced to smart phone technology to ready them for deployment of the prompts and reminders. Two months later, they will be provided with a smart phone.
62512972|NCT01473550|EXPERIMENTAL|Later Intervention|A delayed implementation plan will be used (but will have no effect on the standard of care for the remaining 200 participants), so the remaining 200 participants in Group 2 will initially act as a control group, but at Phase 2 (six months later - approximately June 2012) the remaining 200 participants will be introduced to the technology in the same order (PHR -\> Smart Phone). Group 2 will have the benefit of any enhancements made during Phase 1 of the project.
62512973|NCT02152202|EXPERIMENTAL|Semi-upright position|Semi-upright position defined as 45 degrees incline from horizontal of the patients bed during nocturnal sleep, for two postoperative nights. Daytime naps will be excluded. A regular pillow may be used by the patients based upon the level of comfort and also to support the head in a neutral position.
62512974|NCT02152202|OTHER|Control group (Supine position)|In this group patients' bed will be set into Supine/0 degree angle during sleep in the night time. Patient will be managed according to routine care
62512975|NCT01577693|EXPERIMENTAL|0.5 mg novel dose form (test)|0.5 mg novel dose form (test)
62512976|NCT01577693|OTHER|0.5 mg Soft Gel Capsule|0.5 mg Soft Gel Capsule (reference)
62512977|NCT01616121|ACTIVE_COMPARATOR|Conventional Treatment Heart Failure|Conventional Treatment
62709352|NCT04172675|EXPERIMENTAL|Cohort 3|Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.
61972850|NCT03867981|ACTIVE_COMPARATOR|Internet weight loss only|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
61972851|NCT02630433|EXPERIMENTAL|Index cholecystectomy|Cholecystectomy within 48 hours after inclusion.
62147080|NCT04878679|ACTIVE_COMPARATOR|Control group|No physical activity
62512978|NCT01616121|EXPERIMENTAL|Lung Impedance-Guided Therapy|Lung Impedance-Guided Therapy
62512979|NCT02130531|EXPERIMENTAL|Cohort 1|"Two dose periods in any sequence (subjects will be assigned to 1 of 2 possible sequences):~* Emixustat HCl Tablet Strength B (mid dose); 1 tablet once daily \& 1 placebo tablet once daily for 7 days~* Emixustat HCl Tablet Strength A (low dose); 1 tablet twice daily for 7 days"
62512980|NCT02130531|EXPERIMENTAL|Cohort 2|"Three dose periods in any sequence (subjects will be assigned to 1 of 6 possible sequences):~* Emixustat HCl Tablet Strength A (low dose); 1 tablet daily for 7 days~* Emixustat HCl Tablet Strength B (mid dose); 1 tablet daily for 7 days~* Emixustat HCl Tablet Strength C (high dose); 1 tablet daily for 7 days"
62512981|NCT01722682|ACTIVE_COMPARATOR|A: intraportal islet infusion|Patients will received islet into the liver through the portal venous circulation (standard procedure)
62709353|NCT03502681|EXPERIMENTAL|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
62709354|NCT00000395|EXPERIMENTAL|Group 1 - Folinic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folinic acid daily for 1 week.
61972852|NCT02630433|ACTIVE_COMPARATOR|Scheduled cholecystectomy|Cholecystectomy 6 weeks after inclusion.
61972853|NCT03327883||1/Patients medical records|Medical records of patients with metastatic bladder cancer
62147081|NCT05200624|ACTIVE_COMPARATOR|Active laser|Application of the active 2RT sub threshold laser
62147082|NCT05200624|SHAM_COMPARATOR|Sham laser|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant)
62147083|NCT03046706|ACTIVE_COMPARATOR|standard voice rest|This group maintains postoperative voice rest. Namely, absolute voice rest for a week, followed by a week of relative voice rest sound (talking is allowed for 20 minutes a day). post operative voice rest
62147084|NCT03046706|EXPERIMENTAL|no voice rest|This group has no limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions.
62147085|NCT00925561||No treatment|
62147086|NCT02314975|EXPERIMENTAL|AcceleDent vibrational device|Fixed appliances with supplementary vibrational force
62147087|NCT02314975|SHAM_COMPARATOR|Sham AcceleDent device|Fixed appliances with supplementary sham device
61972854|NCT02480842|EXPERIMENTAL|Alloplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
61972855|NCT02480842|EXPERIMENTAL|Alloplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
61972856|NCT02480842|EXPERIMENTAL|Oncoplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
61972857|NCT02480842|EXPERIMENTAL|Oncoplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
61972858|NCT02263794|EXPERIMENTAL|Image guided bronchial thermoplasty|At pre-treatment Visit 3, imaging data will be acquired to generate a patient-specific bronchial thermoplasty treatment plan which will include 15-20 target airways, prioritized in order of importance and grouped by lobe, to be targeted during a single session BT treatment procedure. Airways demonstrating dynamic or static bronchoconstriction will be targeted for BT treatment based on their spacial proximity to ventilation defects.
61972859|NCT02263794|ACTIVE_COMPARATOR|Conventional bronchial thermoplasty|Patients in this group will undergo conventional 3 stage bronchial thermoplasty (during 3 separate bronchoscopies).
62709355|NCT00000395|EXPERIMENTAL|Group 2: Folic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folic acid daily for 1 week.
62709356|NCT05958186||Children group|Ages≤18
61972860|NCT03613012||Pain index|Pain index will be extracted from the EEG of chronic pain patients before and after pain treatments
61972861|NCT02701439||HIV-infected|"Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention"
61972862|NCT02701439||HIV negative|"Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention"
61972863|NCT03530904|ACTIVE_COMPARATOR|early mobilization after cardiac device implantation|mobilization after 4 hours
61972864|NCT03530904|ACTIVE_COMPARATOR|Late mobilization after cardiac device implantation|Mobilization after 24 hours
61972865|NCT04356664|NO_INTERVENTION|Frozen embryo transfer with Hormonal Replacement Therapy (HRT)|Patient will received usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
61972866|NCT04356664|EXPERIMENTAL|Frozen embryo transfer with HRT and GnRH agonist|Patient will received 1 or 2 injection of GnRH agonist priori to usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
62147088|NCT02314975|ACTIVE_COMPARATOR|Fixed appliance only|Fixed appliances only
62709357|NCT05958186||Adults group|Ages\>18
62709358|NCT01083602|EXPERIMENTAL|panobinostat + bortezomib & dexamethasone|panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
62709359|NCT02696135||Hypertrophic cardiomyopathy|Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
62709360|NCT00741078|EXPERIMENTAL|atorvastatin, amlodipine|
62709361|NCT04164381|EXPERIMENTAL|Robotic assisted intervention|Upper limb robotic therapy using a set of robotic and sensor based devices and exercises specifically selected to train cognitive functions.
62709362|NCT05709847|ACTIVE_COMPARATOR|Conventional coffee|Participants will be provided with a conventional, low CGA coffee to brew and consume which contains less CGA than the experimental arm.
62709363|NCT05709847|EXPERIMENTAL|CGA-rich coffee (Speciality coffee)|Participants will be provided with a single origin, CGA-rich specialty coffee as graded by the Specialty Coffee Association of America's Q-grading system to brew and consume
62709364|NCT01471613|EXPERIMENTAL|Group C - Cord blood cell|Conventional treatment, cord blood cell transplant and placebo
62709365|NCT01471613|PLACEBO_COMPARATOR|Group A - Control|Conventional treatment and placebo
62709366|NCT01471613|EXPERIMENTAL|Group B - Lithium Carbonate|Conventional treatment and lithium carbonate
61976317|NCT02508402|PLACEBO_COMPARATOR|Placebo group|and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.
61976318|NCT00460408||Observational study, no comparator|Observational study of patients with AMD treated with Macugen, no comparator
62147089|NCT06154161|EXPERIMENTAL|Whey protein consumption|Participants will receive 20g total protein of whey protein isolate in 115 mls of water to consume daily for up to 6 months
62147090|NCT04914702||Everion® only|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
62147091|NCT04914702||CORE® only|A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
62709367|NCT01471613|EXPERIMENTAL|Group D - Combination Therapy|Conventional treatment, cell transplant and 6-weeks course of lithium carbonate
62709368|NCT06544915|EXPERIMENTAL|Synbiotic|synbiotic (Triplex (2x/day Probiotic capsules (2 billion CFU/capsule, ProBio5), 2x/day Capsules of gut supporting micronutrients; magnesium, vitamin c and citrus bioflavonoids (BioCleanse) and 2x/day Pre-biotic drink mixes (Slim Microbiome Activating), Plexus®, Scottsdale, AZ, USA)
62512982|NCT01722682|EXPERIMENTAL|B: intra BM islet infusion|Patients will received an intra BM islet infusion at the level of the iliac crest. The direct intra BM administration will be performed following the same procedures that our institution utilizes for administration of cord-blood cells in patients with acute leukemia (Lancet Oncol. 2008;9:831). The procedure is easy and reproducible: a standard needle for BM aspiration is inserted in the iliac crest and cells are gently infused.
62512983|NCT06260020|EXPERIMENTAL|Children [4-10 years] with ASD with sleep disorder|"Development of module by Delphi method:components of Module include Behavioural intervention Modifying stimulus by change in location,using bedtime stories. Giving schedules to activities which interfere with sleep before bedtime. Using a bedtime pass to allow child to make a prefixed number of requests for parental attention while in bed.~Giving sleep items like cuddle toys to replace parental presence. Gradually delaying the bedtime so the child feels urge to sleep. Sleep hygiene by providing suitable environment to sleep, proper bedtime routine, sleep wake schedules Providing rewards for following good bedtime routine as positive reinforcement. Pharmacological intervention Sleep disorders due to underlying ENT, pulmonary conditions, to be treated as per standard protocol Usage of melatonin if required for sleep onset difficulty An 80%agreement over an intervention will be included in the module"
62512984|NCT01704937|EXPERIMENTAL|Colonoscopy|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy"
62512985|NCT01704937|EXPERIMENTAL|Nasogastric Tube (NGT)|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT"
62512986|NCT05927181|EXPERIMENTAL|Trimodal Approach with Osseous and Mucosal compartment modification: TAOM|Flapless immediate implant placement and provisional restoration with alveolar filling and connective tissue graft.
62512987|NCT05927181|ACTIVE_COMPARATOR|Trimodal Approach: TA|Flapless immediate implant placement and provisional restoration.
62512988|NCT04681196||patients affected by OSA treated with CPAP / paradox effect group|patients with obstructive sleep apnea, exhibiting persistent obstructive events and paradoxical obstruction when wearing oronasal masks during CPAP, that were fully recovered with the shift to nasal one with the same or also lower pressure
62512989|NCT04681196||patients affected by OSA treated with CPAP / control group (no paradox effect)|patients with obstructive sleep apnea, with no obstructive events when wearing oronasal masks during CPAP
62512990|NCT04413734|EXPERIMENTAL|Triprilumab in combination with chemotherapy of GP|Triprilumab, 240 mg, every 3 weeks (Q3W), Day 1 of each 3 week cycle PLUS Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity .
62512991|NCT04413734|ACTIVE_COMPARATOR|Mono-chemotherapy of GP|Gemcitabine, 1000 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m\^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity.
62512992|NCT00827086||1|Patients with non-infectious Uveitis
62512993|NCT00827086||2|Patients with scleritis
62512994|NCT02255188||Graft type - PCL|PCL - polycaprolactone
62512995|NCT02255188||Graft type - PCL/ gelatin|polycaprolactone/ gelatin/poorly permeable layer;
62512996|NCT02255188||Graft type - PLGA/PCL/gelatin|PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer
62512997|NCT02255188||Graft type - nylon 6|
62512998|NCT04784884|EXPERIMENTAL|HSI-Pilot|Diagnostic hyperspectral imaging of the bronchus stump or bronchus anastomosis after lung resection and calculating the stump or anastomotic Perfusion measures, respectively
62512999|NCT00402220|ACTIVE_COMPARATOR|1|active TMS
62513000|NCT00402220|PLACEBO_COMPARATOR|2|Sham TMS
62513001|NCT00754442|ACTIVE_COMPARATOR|teriparatide control|control subject
61976319|NCT04288648||SUI group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
62513002|NCT00754442|EXPERIMENTAL|Teriparatide Patient|Patient with secondary hyperparathyroidism
62513003|NCT05082324|EXPERIMENTAL|adapted physical activity|
62513004|NCT01387425|ACTIVE_COMPARATOR|varenicline|varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
62513005|NCT01387425|PLACEBO_COMPARATOR|control group|
62513006|NCT05754424|EXPERIMENTAL|AT278|Single subcutaneous injection of 0.5 U/kg
62513007|NCT05754424|ACTIVE_COMPARATOR|NovoRapid|Single subcutaneous injection of 0.5 U/kg
62513008|NCT02062801|ACTIVE_COMPARATOR|Prophylactic ephedrine|Ephedrine 10mg iv once at time of combined spinal epidural insertion
62513009|NCT02062801|PLACEBO_COMPARATOR|Normal saline (placebo) control group|1ml normal saline intravenously once at time of combined spinal epidural insertion
62513010|NCT01232491|ACTIVE_COMPARATOR|Control|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
62513011|NCT01232491|EXPERIMENTAL|Dietician|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects received dietary consultation according to local standard during 3 face-to-face meetings and 3 phone contacts. Insulin doses were individually adjusted.
62513012|NCT03363477|EXPERIMENTAL|AB treatment sequence|Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)
62513013|NCT03363477|ACTIVE_COMPARATOR|BA treatment sequence|Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)
62513014|NCT05088031||1- Group ( A): 20 patients underwent shock wave therapy|1-Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head for 15 minutes on alternate days for four weeks for a total of 12 sessions14.
62513015|NCT05088031||2-Group (B): 20 patients would undergo intermittent mechanical traction|"2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest) 3 times weekly day after day for four weeks for a total of 12 sessions."
62513016|NCT05088031||Group (C): (Control group) 20 patients would underwent conventional physical therapy|"3-Group (C): (Control group) 20 patients would underwent conventional physical therapy consisted of hyperthermia using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the back, iliopsoas, and hamstring muscles and strengthening exercises for the abdominal muscles for 30 minutes."
62513017|NCT00539708|EXPERIMENTAL|NIV|Non-invasive ventilation
62513018|NCT00539708|ACTIVE_COMPARATOR|Control|Oxygen therapy
62513019|NCT01344382|EXPERIMENTAL|CRAFT|All parents will be scheduled for 12 individual Community Reinforcement and Family Training for parents (CRAFT-P) training sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
62513020|NCT01344382|ACTIVE_COMPARATOR|Al-Anon Facilitation|All parents will be scheduled for 12 individual Alanon/Naranon Facilitation Training (ANF) sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
62513021|NCT06151782|ACTIVE_COMPARATOR|Wheat gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
62513022|NCT06151782|EXPERIMENTAL|Barley gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
62513023|NCT06151782|EXPERIMENTAL|Low dose barley gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
62513024|NCT06151782|EXPERIMENTAL|Low dose hydrolyzed barley gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
62513025|NCT03010618|OTHER|Study Group|
62513026|NCT01627925|EXPERIMENTAL|Face mask and nasal mask without PEEP|Face mask ventilation and nasal mask ventilation without PEEP
62513027|NCT01627925|EXPERIMENTAL|Nasal mask and face mask with PEEP|Nasal mask ventilation and face mask ventilation with PEEP
62513028|NCT06164275|EXPERIMENTAL|Treatment (Pembrolizumab and AVD)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo disease assessment. Patients with a response complete 3 additional cycles of pembrolizumab, undergo disease assessment and proceed to consolidation. Patients without response or with progressive disease proceed to consolidation.~CONSOLIDATION: Patients receive doxorubicin IV, vinblastine IV and dacarbazine IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for 2 to 6 cycles dependent upon response and disease type. Patients undergo echocardiography/MUGA scan, CT scan, PET scan and blood sample collection throughout the study and may undergo tumor biopsy during screening."
62513029|NCT05333848|EXPERIMENTAL|COMBO condition|An interactive stigma content website.
62513030|NCT05333848|EXPERIMENTAL|STIGMA condition|A non-interactive stigma content website.
62709369|NCT06544915|ACTIVE_COMPARATOR|Probiotic|probiotic (2x/day probiotic capsules (2 billion CFU/capsules, NOW supplement), 2x/day capsules of collagen (Plexus), and 2x/day placebo drink mixes of corn-based maltodextrin (Plexus))
62353413|NCT03292393|ACTIVE_COMPARATOR|Group Contingency Management|During the intervention phase, the Group Contingency Management (GCM) arm will continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a home blood pressure monitoring reading using the HBPM. Participants in the GCM arm will receive a payment after each phone call, dependent on their medication adherence assessment. The GCM arm will also receive an additional payment based on their group's medication adherence.The intervention administered is the Financial Reward and Social Norms.
62353414|NCT03292393|ACTIVE_COMPARATOR|Individual Contingency Management|During the intervention phase, those in the Individual Contingency Management (ICM) arm will also continue to take their hypertensive medication for the four-month period but will receive a payment after each phone call, dependent on their medication adherence assessment.The intervention administered is the Financial Reward.
62353415|NCT03292393|PLACEBO_COMPARATOR|Control Arm|During the intervention phase, those in the control arm will be asked to continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a blood pressure reading using the HBPM. Those in the control arm will only be paid for their participation in the study regardless of medication adherence assessment.
62353416|NCT02211183|SHAM_COMPARATOR|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
62353417|NCT02211183|ACTIVE_COMPARATOR|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
62353418|NCT06373276|EXPERIMENTAL|Balance training|multiplanar balance training exercise with education
62353419|NCT06373276|PLACEBO_COMPARATOR|control|Education only
62513031|NCT05333848|EXPERIMENTAL|INTERACT condition|An interactive non-stigma content website.
62709370|NCT06544915|PLACEBO_COMPARATOR|Placebo|placebo control (4x/day collagen capsules and 2x/day placebo drink mixes (maltodextrin), Plexus)
62709371|NCT02210676|EXPERIMENTAL|Patients with Mallet Finger|All enrolled patients
61976320|NCT04288648||control group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
61976321|NCT03702946|EXPERIMENTAL|study group|
62353420|NCT06528743|EXPERIMENTAL|Primer shot treatment break of 1 week|Patients receive an increasing primer shot treatment break. In arm 1, the break between the first and the second radiotherapy fraction is 1 week
62353421|NCT06528743|EXPERIMENTAL|Primer shot treatment break of 2 weeks|Patients receive an increasing primer shot treatment break. In arm 1, the break between the first and the second radiotherapy fraction is 2 weeks
61972867|NCT03666715||Participants with Schizophrenia|Participants diagnosed with schizophrenia who switched from oral antipsychotics (OAPs) to Paliperidone Palmitate 1-month formulation (PP1M), with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment, and who switched to PP1M at least 6-months after it was available for reimbursement in Portugal will be observed. The primary data source for this study will be the medical records of each participant.
62709372|NCT05364398|ACTIVE_COMPARATOR|ACL reconstruction with stump preservation|
62709373|NCT05364398|ACTIVE_COMPARATOR|ACL reconstruction with stump resection|
61972868|NCT01302587||Albuterol MDI|All participants in this study will receive an albuterol MDI inhaler.
61972869|NCT00616200|EXPERIMENTAL|A|
61972870|NCT04840615|EXPERIMENTAL|1/Intra-tumoral LMB-100 Administration|Those with pleural or peritoneal mesothelioma receiving intra-tumoral administration of LMB-100 + ipilimumab for up to 4 cycles.
61972871|NCT02046356||Early-Stage HCC|Early-Stage hepatocellular carcinoma From January 2014 to January 2015, a total of 139 patients with early HCC from the First Affiliated Hospital, the Second Affiliated Hospital and the Third Affiliated Hospital of the Third Military Medical University were prospectively recruited according after MESS-RFA
61972872|NCT02018328|NO_INTERVENTION|Triple therapy, helicobacter pylori|
62147092|NCT04914702||Everion® first, CORE® second|"Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.~Then a CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene."
62147093|NCT04914702||CORE® first, Everion® second|"A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.~Then two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene."
62147094|NCT04914702||Everion® and CORE® simultaneously|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, and one CORE® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
62147095|NCT06303128|EXPERIMENTAL|One-dose group|Patients assigned to this group will receive a liquid placebo followed by full-dose liquid amoxicillin 250mg PO thirty minutes later.
62147096|NCT06303128|ACTIVE_COMPARATOR|Graded, two-dose group|Patients assigned to this group will receive liquid amoxicillin (25% of 250mg dose), followed by liquid amoxicillin 187.5mg PO (75% of 250mg dose) thirty minutes later.
62513032|NCT05333848|PLACEBO_COMPARATOR|CONTROL condition|A non-interactive non-stigma content website.
62513033|NCT04815694|EXPERIMENTAL|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction >13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI \> 13.1 will underwent RT dose intensification on GTV + 3 mm to 60.1 Gy with a Simultaneous Integrated Boost (SIB).
62709374|NCT04470765|ACTIVE_COMPARATOR|Active Treatment|Active Zida device to be delivered for use by patient
62709375|NCT04470765|SHAM_COMPARATOR|Sham Treatment|Identical Sham device to be delivered for use by patient
62709376|NCT04120987|ACTIVE_COMPARATOR|Lifitegrast|One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.
62709377|NCT04120987|NO_INTERVENTION|Control|No treatment
61972873|NCT02018328|EXPERIMENTAL|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
61972874|NCT01412346|ACTIVE_COMPARATOR|Plant-based food and fish with salt restr.|The subjects consume plant based foods (fruits, berries, vegetables, whole grain) and fish in addition to a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
61972875|NCT01412346|PLACEBO_COMPARATOR|Diet with salt restriction|The subjects follow a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
61972876|NCT06289608||Self-reported Bruxism|Those dental patients responding positively to at least 2 of the 6 items of the Pintado et al Self-reported Bruxism Inventory
61972877|NCT04240925|EXPERIMENTAL|Standard NIMV protocol with sigh breaths|
61972878|NCT04240925|ACTIVE_COMPARATOR|Standard NIMV protocol without sigh breaths|
61972879|NCT05113472||Ecuadorian Healthcare Workers|All individuals involved were part of the first phase of the national COVID-19 vaccination plan in our country and were contacted through a local registry established by a local private university.
61972880|NCT04539847|EXPERIMENTAL|High-end hearing aid|Patients will be fitted with premium level hearing aid technology
62147097|NCT00724009|EXPERIMENTAL|Clofarabine|Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days
62147098|NCT01436214|EXPERIMENTAL|APC-100|
62147099|NCT03726593|EXPERIMENTAL|ASPY|Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
62513034|NCT04815694|NO_INTERVENTION|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction < 13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI \< 13.1 will underwent standard RT dose of 55Gy on tumor and corresponding mesorectum
62709378|NCT05181228|EXPERIMENTAL|Intervention Group (Web-based family-centered empowerment program intervention)|Intervention group participants will receive the web-based family-centered empowerment intervention for 10 weeks.
61972881|NCT04539847|EXPERIMENTAL|Basic hearing aid|Patients will be fitted with basic level hearing aid technology
61972882|NCT02891083|EXPERIMENTAL|Adjuvant chemotherapy group|Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.
62709379|NCT05181228|NO_INTERVENTION|Control Group|No intervention was applied to the control group.
62709380|NCT00458549|EXPERIMENTAL|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
62513035|NCT04654897|EXPERIMENTAL|Elinzanetant (NT-814, BAY3427080)|Subjects received a single dose of 120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) orally.
62513036|NCT03358160||TKA|Orthopaedic patients who underwent surgical operation for total knee arthroprothesis.
62513037|NCT03358160||Rizoarthrosis|Orthopaedic patients who underwent surgical operation to treat chronic arthrosis of the thumb.
62513038|NCT03358160||Healthy Controls|Healthy age-matched controls.
62513039|NCT03420612||training|The training cohort was used to determine the influencing factors of the pain during the colonoscopy and establish the intubation discomfort score (IDS)
62513040|NCT03420612||validation|The validation cohort was used to verify the IDS
62513041|NCT01872845|ACTIVE_COMPARATOR|Rosuvastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a\> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b\> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
62513042|NCT01872845|EXPERIMENTAL|Pravastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a\> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b\> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
62513043|NCT01863056|EXPERIMENTAL|Sit-Stand Desk|Cross-over trial: so one group got the intervention in period 1 and didn't get the intervention in period 2 (serving as control for self in period 2) and the other group got the intervention in period 2 and didn't get the intervention in period 1 (serving as control for self in period 1).
62513044|NCT01863056|NO_INTERVENTION|Control|Used normal work desk which only allows working sitting down
62513045|NCT03352375|ACTIVE_COMPARATOR|Orotracheally Intubation|Intervention:orotracheally intubation
62513046|NCT03352375|ACTIVE_COMPARATOR|Laryngeal Mask Airway|Intervention: Laryngeal Mask Airway
62513047|NCT00601757|OTHER|1|Participants assigned to the Postpartum Prevention Program
62513048|NCT00601757|OTHER|2|Participants assigned to enhanced care as usual
62709381|NCT00458549|PLACEBO_COMPARATOR|Corn Oil|Oral 8g once a day for 21 days prior to (biopsy) surgery
62709382|NCT03748914|EXPERIMENTAL|Intervention Group|Milking the cut umbilical cord once towards the Infant at a speed of 10cm/second.
62709383|NCT03748914|ACTIVE_COMPARATOR|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
62709384|NCT01348893|NO_INTERVENTION|Physical education as usual|High school physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
62709385|NCT01348893|EXPERIMENTAL|Yoga during physical education|
62709386|NCT06486883|EXPERIMENTAL|Arm A|
62709387|NCT06486883|ACTIVE_COMPARATOR|Arm B|
62709388|NCT01879007|EXPERIMENTAL|group 1|received one intravenous administration and one oral medication with interval of 1 week,
62709389|NCT01879007|EXPERIMENTAL|group 2|received one oral administration and one intravenous medication with interval of 1 week
62709390|NCT01883921||Immunoglobulin Therapy|
62709391|NCT02893891|ACTIVE_COMPARATOR|Laparoscopic sleeve gastrectomy|Patients undergoing bariatric surgery procedure of laparoscopic sleeve gastrectomy.
62709392|NCT02893891|ACTIVE_COMPARATOR|Laparoscopic gastric plication|Patients undergoing bariatric surgery procedure of laparoscopic gastric plication.
61976322|NCT03702946|NO_INTERVENTION|control group|
62513049|NCT04686227||Group-1, women with normal uterus|
62513050|NCT04686227||Group-2, women with any uterine malformations|Group-2 is going to be sub-grouped according to ASRM and ESHRE classifications
62513051|NCT00523328|EXPERIMENTAL|BG9924|dosage administered as per Biogen-idec protocol
62513052|NCT05766020|EXPERIMENTAL|Immediate training group|Participants in this group will train immediately for 4 weeks. Afterwards, they will not train for the 8 remaining weeks.
62513053|NCT05766020|EXPERIMENTAL|Delayed Training Group|Participants in this group will receive delayed training after 4 weeks of no training.
62513054|NCT05766020|EXPERIMENTAL|Active control group|Participants in this group will perform an active control for 4 weeks, followed by 4 weeks of training.
62513055|NCT02056964||Post-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain after implementation of the HEART Pathway decision aid.
62513056|NCT02056964||Pre-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain prior to Implementation of the HEART Pathway decision aid.
62513057|NCT04912115|EXPERIMENTAL|Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.1 mg/kg/hr to 0.30 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).
62513058|NCT04912115|ACTIVE_COMPARATOR|Midazolam|Midazolam will be administered as intravenous infusions with infusion rates ranging from 0.009 mg/kg/hr to 0.027 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).
62513059|NCT00864617|EXPERIMENTAL|A|Nifedipine Extended Release tablets 60 mg, single dose
62513060|NCT00864617|ACTIVE_COMPARATOR|B|ADALAT® CC Extended Release Tablets 60 mg
62513061|NCT06048094|EXPERIMENTAL|18F-Fluciclovine PET Imaging|Participants will undergo a 18F-fluciclovine PET scan at the time of their SRS planning magnetic resonance imaging (MRI). Then participants will undergo single-fraction SRS as standard of care (SOC). A second 18F-fluciclovine PET scan will be completed 8 weeks (± 2 weeks) after SRS.
62513062|NCT02244749||skin specimen|skin specimen
62709393|NCT02893891|ACTIVE_COMPARATOR|Intragastric balloon|Patients undergoing bariatric surgery procedure with intragastric balloon implantation.
62709394|NCT00963872|EXPERIMENTAL|Complement Fragment 3A - Small Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
62709395|NCT00963872|EXPERIMENTAL|Complement Fragment A - Larger Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
62709396|NCT06163131||Patients|COPD patients treated with endobronchial valves.
62353422|NCT06528743|EXPERIMENTAL|Primer shot treatment break of 3 weeks|Patients receive an increasing primer shot treatment break. In arm 1, the break between the first and the second radiotherapy fraction is 3 weeks
62513063|NCT01788891||second-line pediatric cohort|Asian HIV-positive children \<18 years old who are receiving HIV care at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD) sites that have been identified for TASER-P participation will be monitored for treatment failure of second-line ART
62709397|NCT02059447|EXPERIMENTAL|Mindfulness Based Cognitive Therapy|An 8 week course of Mindfulness Based Cognitive therapy
62709398|NCT02059447|ACTIVE_COMPARATOR|Relaxation Therapy|An 8 week course of Relaxation Therapy.
62709399|NCT01307449|EXPERIMENTAL|Older Group on PREVNAR|Participants between the ages of 60-89 received PREVNAR
62709400|NCT01307449|EXPERIMENTAL|Younger Group on PREVNAR|Participants between the ages of 25-40 years received PREVNAR
62709401|NCT01307449|EXPERIMENTAL|Older Group on PNEUMOVAX|Participants between the ages of 60-89 received PNEUMOVAX
62709402|NCT01307449|EXPERIMENTAL|Younger Group on PNEUMOVAX|Participants between the ages of 25-40 years received PNEUMOVAX
61972883|NCT02891083|EXPERIMENTAL|Adjuvant radiotherapy group|Surgery followed by 50Gy adjuvant radiotherapy
61972884|NCT02891083|OTHER|Control group|Surgery alone
62709403|NCT04497714||Cervical lymph nodes tuberculosis|The patients with Cervical lymph nodes tuberculosis
62709404|NCT04497714||Cervical lymphoma|The patients with
62709405|NCT04497714||Cervical lymph node metastasis|The patients with
62709406|NCT04497714||Cervical Reactive hyperplasia|The patients with
62709407|NCT04817150|EXPERIMENTAL|3D-laparoscopy|patients who underwent 3D laparoscopic ventral rectopexy
62709408|NCT04817150|ACTIVE_COMPARATOR|2D-laparoscopy|patients who underwent conventional 2D laparoscopic ventral rectopexy
62709409|NCT05334238|EXPERIMENTAL|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
62709410|NCT05334238|NO_INTERVENTION|No Orelabrutinib|no treatment after autologous transplantation
61972885|NCT02645110|EXPERIMENTAL|MC Hand soap|For bacterial removal trial: Hand washing with the tested soap following bacterial application
61972886|NCT02645110|SHAM_COMPARATOR|Water|For bacterial removal trial: Hand washing with tap water alone following bacterial application
61972887|NCT05427253|EXPERIMENTAL|C106 solution|Part A: Oral administration start dose, Single dose 5 mg Part B: Oral administration start dose 20 mg twice daily for 8 days
61972888|NCT05427253|PLACEBO_COMPARATOR|Placebo|Part A and B: Placebo to C106 without the active pharmaceutical ingredient
61972889|NCT05964244|EXPERIMENTAL|Noninvasive ventilation (CPAP or bilevel) with the Vela investigational mask for 1 hour|Pressure settings for noninvasive ventilation to be set as required to provide optimal respiratory support for each patient. Not to be changed during the 2 hours of the study.
61972890|NCT05964244|ACTIVE_COMPARATOR|Noninvasive ventilation (CPAP or bilevel) with the standard mask (Nivairo) for 1 hour|Pressure settings for noninvasive ventilation to be set as required to provide optimal respiratory support for each patient. Not to be changed during the 2 hours of the study.
61972891|NCT03619486|PLACEBO_COMPARATOR|Placebo|Placebo treatment (shock wave probe w/o energy)
61972892|NCT03619486|EXPERIMENTAL|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
61972893|NCT03762824|ACTIVE_COMPARATOR|PCV13+PPV23 vaccinated patients|Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
62147100|NCT03726593|EXPERIMENTAL|AP+ASPY|Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking
62709411|NCT01582217||SA + 5mg prasugrel|Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
62513064|NCT05545111|EXPERIMENTAL|Dose Level A|Participant administered Dose Level A (6 weeks)
62709412|NCT01582217||ASA + 10 mg prasugrel|Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
62709413|NCT01582217||ASA + 75 mg clopidogrel daily|Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age \>75; Wt\< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
62709414|NCT03507595||Patients with initial diagnosis of PCa|"1. T2 stage: PSA\>20ng/ml, Gleason Score \>= 8;~2. T3 or T4 stage;~3. The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity."
62709415|NCT03507595||Patients with biochemical recurrent PCa|"1. After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera;~2. After the radiotherapy: the lowest PSA is up to 2 ng/ml."
62709416|NCT03507595||Patients with CRPC|"1. The serum testosterone is in the castration level (\< 50 ng/dL or \< 1.7 nmol/L);~2. The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA \> 2ng/mL(the interval is one week);~3. The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks;~4. Despite the continued standard androgen deprivation therapy, the PSA is still progressing."
62709417|NCT01916031|EXPERIMENTAL|Education|Upper Respiratory Infection education in Fall
62709418|NCT01916031|NO_INTERVENTION|Standard Curriculum|
62709419|NCT01450345|EXPERIMENTAL|Pregabalin Group|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
62709420|NCT02746315|EXPERIMENTAL|Experimental 1|Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.
62709421|NCT02746315|EXPERIMENTAL|Experimental 2|Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.
62709422|NCT02746315|EXPERIMENTAL|Experimental 3|Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.
62513065|NCT05545111|EXPERIMENTAL|Dose Level B|Participant administered Dose Level B (6 weeks)
62513066|NCT05545111|EXPERIMENTAL|Dose Level C|Participant administered Dose Level C (6 weeks)
61972894|NCT03762824|ACTIVE_COMPARATOR|PCV13+PPV23 vaccinated controls|Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
62709423|NCT02746315|EXPERIMENTAL|Experimental 4|Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.
62709424|NCT03400423|EXPERIMENTAL|Non-caffeine exercise|Exercise cognition score
62709425|NCT03400423|ACTIVE_COMPARATOR|Non-caffeine cognition|Caffeine cognition score
62709426|NCT03400423|EXPERIMENTAL|Caffeine consumption exercise|Exercise cognition score
62709427|NCT03400423|ACTIVE_COMPARATOR|Caffeine consumption cognition|Caffeine cognition score
62709428|NCT03400423|EXPERIMENTAL|Deprived Caffeine consumers exercise|Exercise cognition score
62709429|NCT03400423|ACTIVE_COMPARATOR|Deprived caffeine consumers cognition|Caffeine administration cognition score
62709430|NCT06513208|ACTIVE_COMPARATOR|Ketorolac arm|
62709431|NCT06513208|PLACEBO_COMPARATOR|Placebo Arm|
62709432|NCT01821183||hip rotators muscle strength|
62709433|NCT01821183||control group|no intervention
62709434|NCT05042921||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 60 months and the available data is collected retrospectively.
62709435|NCT05042921||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 60 months.
62513067|NCT05545111|EXPERIMENTAL|Dose Level D|Participant administered Dose Level D (6 weeks)
62513068|NCT05545111|PLACEBO_COMPARATOR|Placebo Schedule|Participant administered placebo (6 weeks)
62709436|NCT00882089|EXPERIMENTAL|1|A Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial irradiation begins.
62709437|NCT04766567|EXPERIMENTAL|Serosal myomectomy|Patients with singleton pregnancy, who had serosal myomectomy during cesarean section
62709438|NCT04766567|EXPERIMENTAL|Endometrial myomectomy|Patients with singleton pregnancy, who had endometrial myomectomy during cesarean section
62709439|NCT04766567|PLACEBO_COMPARATOR|Control group|Patients with singleton pregnancy, who did not have myomectomy during cesarean section
62709440|NCT00508521|EXPERIMENTAL|FES and Motor Learning Training|participants \<6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
62709441|NCT00508521|OTHER|Control group|Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance
62709442|NCT03944395|OTHER|Assisted Partner notification services|Voluntary assisted partner notification (VAPN) services will be offered at facilities according to a stepped wedge design. Once VAPN services are activated at a facility, HIV positive individuals will be offered four options (3 voluntary assisted partner notification options and 1 standard of care option) for inviting their contacts, which they can choose to accept or decline.
62513069|NCT00462891|EXPERIMENTAL|IT System|IT system to send reminder letters to patients overdue for breast cancer screening.
62513070|NCT00462891|NO_INTERVENTION|Usual Care|
62709443|NCT02461186|EXPERIMENTAL|Arterolane maleate-piperaquine phosphate (Synriam)|
62709444|NCT02461186|EXPERIMENTAL|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
62709445|NCT03968874|EXPERIMENTAL|Light box|Commercially available lightbox emitting 10,000 lux of light. Subjects asked to use lightbox everyday for an hour for 4 weeks upon waking.
62709446|NCT03968874|SHAM_COMPARATOR|Negative Ion Generator|Commercially available negative ion generator. Subjects asked to use everyday for an hour for 4 weeks upon waking.
62709447|NCT04247438|OTHER|Biofilm formation|Biofilm formation after 12 and 36 h on PMMA (polymethyl methacrylate) dentures and the number of brushing cycles needed to remove it.
62709448|NCT04626102|NO_INTERVENTION|Enrollment|"Participants were recruited by using a convenience sampling method. Potential participants were reached through lecturers and professors who are teaching classes at different universities in Istanbul, Turkey.~Participants were asked to fill out a questionnaire package covering Demographic Information Form, Eating Disorders Examination Questionnaire (EDEQ), Eating Attitudes Test - 40 (EAT-40), Body Image Satisfaction Questionnaire (BISQ), and Sociocultural Attitudes towards Appearance Questionnaire-4-Revised (SATAQ-4R). Filling out the questionnaire package took approximately 25-minutes."
62709449|NCT04626102|EXPERIMENTAL|Intervention Period|"Participants were randomly assigned to one of these conditions:~Experimental condition: Healthy Eating Attitudes and Behaviours Group Program - 6 weekly sessions, each session was about 45-minutes to 60-minutes~Active control condition: Eating Disorders and Body Dissatisfaction: A Group Work - single session about 1.5 hours to 2 hours~Wait-list control condition: Participants in this condition were informed that they will be asked to fill out questionnaires that sent to them, and at the end of 6 months, they will be invited to participate in Healthy Eating Attitudes and Behaviours Group Program."
62709450|NCT05448456|ACTIVE_COMPARATOR|Hexakakapron group|women with an episiotomy after vaginal delivery
62709451|NCT05448456|PLACEBO_COMPARATOR|control group|women with an episiotomy after vaginal delivery
62709452|NCT02599116|OTHER|Microbiome cohort|"1. Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.~2. Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires~3. Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires"
62709453|NCT00646386|ACTIVE_COMPARATOR|A|
62709454|NCT00646386|PLACEBO_COMPARATOR|B|
61972895|NCT03762824|ACTIVE_COMPARATOR|PPV23-booster to previous PCV-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
61972896|NCT03762824|ACTIVE_COMPARATOR|PCV13 to previous PPV23-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.
61972897|NCT03762824|ACTIVE_COMPARATOR|PPV23-booster to previous PCV-vaccinated controls|Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
62513071|NCT02262858|EXPERIMENTAL|Telmisartan and HCTZ (fix dose combination)|
62709455|NCT04768153||Patients|
62709456|NCT02112084|NO_INTERVENTION|Usual Care|Usual care participants do not receive an intervention.
62709457|NCT02112084|EXPERIMENTAL|Individualized DPM|Individualized DPM
61972898|NCT03903445|EXPERIMENTAL|MaPa Kids|"Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids) Parenting training for parents of children aged 2-9~* Program length: 8 consecutive weekly sessions~* Incentive: PHP 500 or approximately £7 per participant~* Participants: N=15 per group"
61972899|NCT03903445|EXPERIMENTAL|MaPa Teens|"Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens) Parenting training for parents of children aged 10-17~* Program length: 9 consecutive weekly sessions~* Adult Incentive: PHP 500 or approximately £7 per participant~* Child incentive: PHP 300 or approximately £4 per participant~* Participants: N=15 per group"
62353423|NCT06445894|ACTIVE_COMPARATOR|Active rTMS to M1|iTBS will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided with neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target M1. Participants will receive 14 days of stimulation. During each treatment day, three iTBS sessions separated by 15-minute intervals will be delivered. Each iTBS session consists of 600 stimuli delivered in 50 Hz bursts of 3 pulses at 70% of the resting motor threshold. In total, individuals will receive 1800 stimuli delivered each day as performed elsewhere . Following iTBS individuals will participate in 10 minutes of balance training performed on balance board (BTracks https://balancetrackingsystems.com).
62353424|NCT06445894|ACTIVE_COMPARATOR|Active rTMS to DLPFC|iTBS will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided with neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target DLPFC. Participants will receive 14 days of stimulation. During each treatment day, three iTBS sessions separated by 15-minute intervals will be delivered \[13,22\]. Each iTBS session consists of 600 stimuli delivered in 50 Hz bursts of 3 pulses at 70% of the resting motor threshold. In total, individuals will receive 1800 stimuli delivered each day as performed elsewhere \[13,23,27\]. Following iTBS individuals will participate in 10 minutes of balance training performed on balance board (BTracks https://balancetrackingsystems.com).
62353425|NCT06445894|PLACEBO_COMPARATOR|Placebo rTMS to M1|sham iTBS will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided with neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target M1. Participants will receive 14 days of placebo stimulation. Following sham iTBS individuals will participate in 10 minutes of balance training performed on balance board (BTracks https://balancetrackingsystems.com).
62353426|NCT02293096|EXPERIMENTAL|Metoprolol succinate, CYP2D6 Genotyping, CYP2D6 Phenotyping|"The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol. The following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.~metoprolol succinate~Genotyping: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete.~CYP2D6 Phenotyping: Phenotype can be discordant from what is predicted by genotype. CYP2D6 henotyping using dextromethorphan will be used. Investigators will be blind to the patient blood pressure outcome for this intervention."
62353427|NCT05797688|EXPERIMENTAL|Treatment|Patients will undergo a fat harvest procedure and the tissue will then be processed by The Celution System to isolate a 5 mL aliquot including stem cells. This will then be injected into the base and within in perimeter of the target wound.
62353428|NCT01768234|EXPERIMENTAL|Supplemental water|This arm receives up to 2 L of supplemental water during the course of the testing day.
62353429|NCT01768234|NO_INTERVENTION|Control|No supplemental water provided
62353430|NCT00898404||Arm I|Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
62353431|NCT01661166|EXPERIMENTAL|Fesoterodine 4mg|Fesoterodine 4mg, Oral once daily for three months
62353432|NCT01661166|PLACEBO_COMPARATOR|Placebo|Placebo Oral once daily for three months
62353433|NCT05838547||Patients treated with Optimal Medical Therapy (OMT) alone.|Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler ≥ 60% diameter stenosis who are clinically referred for OMT alone.
62513072|NCT02262858|ACTIVE_COMPARATOR|Telmisartan and HCTZ (monocomponent)|
62709458|NCT04899765|EXPERIMENTAL|Measles vaccine|Measles vaccine in standard dose of 0.5 ml.
62709459|NCT04899765|EXPERIMENTAL|BCG vaccine|BCG vaccine in standard dose of 0.1 ml.
62709460|NCT04899765|PLACEBO_COMPARATOR|Placebo|Saline injection
62709461|NCT05155982|EXPERIMENTAL|Group A (18-54 yrs)|COVAC-1 25 ug
62709462|NCT05155982|PLACEBO_COMPARATOR|Group B (18-54 yrs)|Placebo Control
62709463|NCT05155982|EXPERIMENTAL|Group C (18-54 yrs)|COVAC-1 50 ug
62709464|NCT05155982|PLACEBO_COMPARATOR|Group D (18-54 yrs)|Placebo Control
62709465|NCT05155982|EXPERIMENTAL|Group E (55+ yrs)|COVAC-1 25 ug
62709466|NCT05155982|PLACEBO_COMPARATOR|Group F (55+ yrs)|Placebo Control
62709467|NCT05155982|EXPERIMENTAL|Group G (55+ yrs)|COVAC-1 50 ug
62709468|NCT05155982|PLACEBO_COMPARATOR|Group H (55+ yrs)|Placebo Control
62709469|NCT02665910|EXPERIMENTAL|SHR0302|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets
61972900|NCT05911776|ACTIVE_COMPARATOR|Group NP (nasal packing Dexmedetomidine)|Patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
61972901|NCT05911776|ACTIVE_COMPARATOR|Group IV (Intravenous Dexmedetomidine)|Patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg IV infusion Dexmedetomidine and nasal packing with saline.
61976323|NCT01614067|EXPERIMENTAL|Delayed Start|Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.
62513073|NCT00002787|EXPERIMENTAL|Treatment (vaccine therapy)|Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
62513074|NCT01237314||Glargine Group|After baseline titration of metformin, this group will take glargine along with metformin.
62513075|NCT01237314||Exenatide Group|After baseline titration of metformin, this group will take exenatide along with metformin.
62513076|NCT01237314||Glargine and Exenatide Group|After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
62513077|NCT01886482|ACTIVE_COMPARATOR|nutrition intervention|high protein diet
62513078|NCT01886482|NO_INTERVENTION|no intervention|control diet
62513079|NCT06615895|EXPERIMENTAL|Telehealth group|An online video course for 6 weeks. The therapist will provide online video courses 3-5 times a week and record the implementation on the online platform every week. The course includes action plans, two Lateral integration/cross-midline, vestibular system, visual perception, opto-motor integration, eye movements, core strength activities and balance ability, etc.
62709470|NCT02665910|PLACEBO_COMPARATOR|SHR0302 placebo comparator|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)
62709471|NCT01276626|EXPERIMENTAL|Bifidobacterium longum|
62709472|NCT01276626|PLACEBO_COMPARATOR|Maltodextrin|
61972902|NCT04880512|EXPERIMENTAL|SYHX 1901 tablets for SAD|Two subjects will be enrolled in a single dose group which is recommended as the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of SYHX 1901 tablets in fasted state.
62353434|NCT05838547||Patients treated with OMT and carotid endarterectomy (CEA).|Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler ≥ 60% diameter stenosis who are clinically referred for OMT and CEA.
62353435|NCT02854553|EXPERIMENTAL|TAP|Transversus abdominis plane block
62353436|NCT02854553|EXPERIMENTAL|TAP and rectus sheath block|Transversus abdominis plane block with rectus sheath block
62353437|NCT02854553|NO_INTERVENTION|control|no truncal blocks, conventional analgesia
62353438|NCT03922893||Proband|First individual in a family to consent to this protocol
62353439|NCT03922893||Family Member Participants|Family members of the proband will be approached to consent to this protocol
62353440|NCT02090946||parental experiences|interviews
62513080|NCT06615895|NO_INTERVENTION|Waiting group|"The waiting group was provided with an explanation of the objectives of the course. After the objectives of the study were explained in the first course, they waited for 6 weeks before receiving remote intervention."
62513081|NCT03128736|EXPERIMENTAL|dexlansoprazole group|dexlansoprazole 60mg
62513082|NCT03128736|EXPERIMENTAL|esomeprazole group|esomeprazole 40mg
62513083|NCT02940730|ACTIVE_COMPARATOR|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
62513084|NCT02940730|ACTIVE_COMPARATOR|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
62513085|NCT05077956||Recently Diagnosed Multiple Sclerosis|Recently diagnosed MS, who have had a clinical attack within the last 6 months, have not received steroids in the last 30 days, and have not started on a disease modifying therapy (DMT).
62513086|NCT05077956||Clinically Stable Relapsing Multiple Sclerosis|Clinically stable relapsing MS, who are receiving a FDA-approved MS DMT and have had no evidence of a clinical relapse for at least the past 12 weeks or gadolinium enhancing lesions on MRI in the prior 4 weeks.
62513087|NCT05077956||Relapsing Multiple Sclerosis on Disease Modifying Therapy|Relapsing MS on a FDA-approved DMT with evidence of recent breakthrough disease, with a documented clinical relapse and/or gadolinium-enhancing lesion(s) on brain or spinal cord MRI taken within the 4 weeks.
62513088|NCT05077956||Healthy Volunteers|Patients without evidence of inflammatory systemic or CNS disease, who require CSF removal for some other cause, such as for idiopathic intracranial hypertension or communicating hydrocephalus.
62513089|NCT02214719|EXPERIMENTAL|Baseline observation for EASI-IDM use|Baseline observation period to gather information on current practice about diabetes care
62513090|NCT05421104||Ruxolitinib (RUX)|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
62709473|NCT04454515|EXPERIMENTAL|dexmedetomidine|patient recieving dexmedetomidine
61972903|NCT04880512|PLACEBO_COMPARATOR|Placebo for SAD|2 out of 10 healthy subjects will be randomized to receive a single dose of placebo in fasted state
61972904|NCT04880512|EXPERIMENTAL|SYHX 1901 tablets for MAD|8 out of 10 healthy subjects will be randomized to receive multiple doses of SYHX 1901 tablets in fasted state
62353441|NCT03182127|OTHER|one Group|Magnetic resonance imaging and ultrasound will be done for all patient
62353442|NCT01747811|EXPERIMENTAL|wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
62353443|NCT01747811|PLACEBO_COMPARATOR|wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
62353444|NCT05557123|EXPERIMENTAL|MEDI-app|conventional treatment with MEDI-app feedback
62353445|NCT05557123|ACTIVE_COMPARATOR|conventional treatment|conventional treatment
62353446|NCT03206112||Focal Dystonia|Subjects diagnosed with Focal Dystonia
62353447|NCT03206112||Healthy Volunteers|Healthy Volunteers
62513091|NCT05421104||Best available therapy (BAT)|PV patients who were resistant to or intolerant of Hydroxyurea (HU) (as defined on the index date) and continued HU treatment or switched to other available therapies other than RUX in the post-index period.
62513092|NCT01002313||normal control|
62513093|NCT01002313||Patient treatment group|Treatment with prednisone
62709474|NCT04454515|PLACEBO_COMPARATOR|placebo|patients receiving placebo
62709475|NCT01604460|SHAM_COMPARATOR|Resuscitation-no plastic bag|Resuscitation per standard of care without a plastic bag
61972905|NCT04880512|PLACEBO_COMPARATOR|Placebo for MAD|2 out of 10 healthy subjects will be randomized to receive multiple doses of placebo in fasted state
61972906|NCT01817998|EXPERIMENTAL|High Intensity Endurance Physical Exercise|High Intensity endurance physical exercise, intensity measured on Borg Scale with progression from Borg 10-13 (50% of maximum) to 17-18 (80 % of maximum). One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
61972907|NCT01817998|ACTIVE_COMPARATOR|Low Intensity Endurance Physical Exercise|Low Intensity endurance physical exercise, intensity measured on Borg Scale, Borg 10-13 (50% of maximum) with no progression in intensity. One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
61972908|NCT03247855|OTHER|Minimal invasive coronary artery bypass graft|
61972909|NCT00976092|EXPERIMENTAL|Prasugrel + Bivalirudin|60 mg prasugrel plus bivalirudin
61972910|NCT00976092|ACTIVE_COMPARATOR|Clopidogrel + Heparin|clopidogrel as loading and heparin
61972911|NCT03634449|EXPERIMENTAL|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
62353448|NCT01175629||Group 1|The Vietnam Era Twin (VET) Registry is a closed cohort composed of 7,369 middle-aged male-male twin pairs both of whom served in the military during the time of the Vietnam conflict (1965-1975). The Registry is a United States Department of Veterans Affairs resource that was originally constructed from military records; the Registry has been in existence for more than 15 years. It is one of the largest national twin registries in the US and currently has subjects living in all 50 states. Initially formed to address questions about the long-term health effects of service in Vietnam the Registry has evolved into a resource for genetic epidemiological studies of mental and physical health conditions. Several waves of mail and telephone surveys have collected a wealth of health-related information on Registry twins. Other data collection efforts have focused on specific sets of twin pairs and conducted detailed clinical or laboratory testing.
61972912|NCT03634449|ACTIVE_COMPARATOR|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
62147101|NCT03726593|EXPERIMENTAL|AP+ASMQ|Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.
62353449|NCT06422429|PLACEBO_COMPARATOR|Control group|traditional Youtiao
62353450|NCT06422429|EXPERIMENTAL|Intervention group|Personalised and innovative Youtiao
62353451|NCT04535206||With AT-Ⅲ, PC, PS activity decreased|Any decreased in AT-Ⅲ, PC, PS activity before catheter intubation is regarded as the exposure group
62353452|NCT04535206||AT-Ⅲ, PC, PS activity are at normal value|The activities of AT-Ⅲ, PC and PS are all at normal values before catheter intubation
61972913|NCT00875212|EXPERIMENTAL|dentifrice intervention|4 types of dentifrices were used in 4 different periods in a crossover study design.
61972914|NCT00609492|EXPERIMENTAL|Preterm I Group|Children born after a gestation period of 27-30 weeks
61972915|NCT00609492|EXPERIMENTAL|Preterm II Group|Children born after a gestation period of 31-36 weeks
61972916|NCT00609492|ACTIVE_COMPARATOR|Full term Group|Children born after a gestation period of more than 36 weeks
61972917|NCT04857242|EXPERIMENTAL|apnea test, recruitment manoeuvre|"1. Continuous electric impedance tomography (EIT) recording. Recording of initial vital parameters and arterial blood gas results. Adjusment of PaCO2 between 38-42 mmHg, 10 minutes of preoxygenation with FiO2 of 1.0 then disconnection of the patient from the ventilator.~2. Continuous administration of 6 L/min O2 flow via a catheter into the tracheal tube.~3. Arterial blood gas sampling and recording of vital parameters in every second minutes. Detection of any spontaneous respiratory movement by the apnoe test investigator or by EIT signals.~4. Reconnection with respirator if there is any sign of spontaneous breathing effort or if there is no spontaneous breathing effort and the PaCO2 is over 60 mmHg. Recording of vital parameters.~5. Recruitment manoeuvre (PEEP 20 cmH2O, pressure control 20 cmH20 for 40 minutes) then set up of the initial ventilator parameters.~6. Terminal arterial blood gas results and vital parameters 5 minutes following the end of the recruitment manoeuvre."
62353453|NCT05705895|EXPERIMENTAL|Intervention Group|Catheter care is provided in line with the CVC care protocol developed by the researcher.
62353454|NCT05705895|NO_INTERVENTION|Control Group|No intervention will be made to the patients in the control group, and catheter care will be provided in line with the clinical routine.
62353455|NCT01621854|EXPERIMENTAL|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
61972918|NCT06291025|EXPERIMENTAL|PEX-FREE|Replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
61972919|NCT02234960||Cohort of RA Participants|Participants with RA treated with tocilizumab at a dose and duration at the discretion of physician in accordance with the summary of product characteristics as per routine clinical practice were observed for a period of 6 months with the length of entire study for 24 months.
61972920|NCT01503944|OTHER|Dementia with Lewy Bodies|
61972921|NCT01503944|OTHER|Parkinson's disease|
61972922|NCT01503944|OTHER|Healthy Elderly Volunteers|
61972923|NCT01503944|OTHER|Alzheimer's Disease|
61972924|NCT03566394|EXPERIMENTAL|Prophylactic Gabapentin|Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
61972925|NCT03566394|NO_INTERVENTION|Observation|
61976324|NCT01614067|ACTIVE_COMPARATOR|Conventional Start|Ovarian stimulation with standard antagonist protocols (no delay).
62147102|NCT04413994|ACTIVE_COMPARATOR|Randomized study product group|"receiving study product (human milk fortifier Humavant) until a gestational age of 36 weeks"
61976325|NCT02786251|OTHER|BAT+|Individuals with significant amounts of BAT (\>20 ml)
62513094|NCT02696031|EXPERIMENTAL|Secukinumab, 150 mg Load (Core phase)|Secukinumab 150 mg s.c., pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4, Load, Core phase
62513095|NCT02696031|EXPERIMENTAL|Secukinumab, 150 mg No Load (Core phase)|Secukinumab 150 mg s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4, No Load, Core phase
61972926|NCT02524795|EXPERIMENTAL|Hiomega-3 supplement|"Patients in the study group received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company). Participants were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
61976326|NCT02786251|OTHER|BAT-|Individuals with no/minimal amounts of BAT (\<20 ml)
62353456|NCT03965793|ACTIVE_COMPARATOR|Manual management of hypotension|Fluid and vasopressor will be managed as standard practice ( manually infusion of both fluid and vasopressors) following the investigators manual individualized hemodynamic protocol.(objective being to keep both stroke volume and MAP within 90 % of the target values)
62353457|NCT03965793|EXPERIMENTAL|Automated management of hypotension|Fluid and vasopressor will be managed with a novel active clinical decision support system to guide fluid administration and automated closed-loop system to maintain MAP within 90% of patient' baseline.
62353458|NCT05666440|ACTIVE_COMPARATOR|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.
62353459|NCT05666440|ACTIVE_COMPARATOR|Rigid probe Viscotrabeculotomy|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.
62353460|NCT01567891|EXPERIMENTAL|Cohort 1|This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells.
62353461|NCT03819478|ACTIVE_COMPARATOR|RecProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
62353462|NCT03819478|ACTIVE_COMPARATOR|6-mo HiProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
62353463|NCT03819478|ACTIVE_COMPARATOR|18-mo HiProt|"Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643):~Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
62353464|NCT01164592|ACTIVE_COMPARATOR|Therapy with adaptive servo ventilation|optimal medical therapy + adaptive servoventilation
62353465|NCT01164592|NO_INTERVENTION|Optimal medical therapy according to guidelines|optimal medical therapy
62353466|NCT03997929||CASE (intra abdominal candidiasis)|Critically ill patients with a confirmed diagnosis of intra abdominal candidiasis (IAC) Definition of IAC : sterilely collected peritoneal fluid cultures that are positive for Candida spp. as determined by the signs and symptoms consistent with an active infection
62353467|NCT03997929||CONTROL (bacterial intra abdominal infection)|Critically ill patients with a non candida intra abdominal infection (bacterial peritonitis)
62353468|NCT02317341|EXPERIMENTAL|1|Single intravenous dose given over 40 minutes
62353469|NCT02317341|ACTIVE_COMPARATOR|2|Single intravenous dose goven over 40 minutes
62353470|NCT05505097|OTHER|ABCD-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence A-B-C-D during the corresponding study periods 1, 2, 3, and 4
62353471|NCT05505097|OTHER|BCDA-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence B-C-D-A during the corresponding study periods 1, 2, 3, and 4
62353472|NCT05505097|OTHER|CDAB-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence C-D-A-B during the corresponding study periods 1, 2, 3, and 4
62513096|NCT02696031|PLACEBO_COMPARATOR|Placebo (Core phase)|Placebo s.c., PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4, Core phase
62513097|NCT02696031|EXPERIMENTAL|Core Phase Responder 150 mg (Extension phase)|Core Phase Responder 150 mg blinded: secukinumab 150 mg s.c. PFS and placebo (1 mL) s.c. PFS every four weeks, in the Extension phase
62353473|NCT05505097|OTHER|DABC-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence D-A-B-C during the corresponding study periods 1, 2, 3, and 4
62353474|NCT00740324|ACTIVE_COMPARATOR|N|
62353475|NCT00740324|ACTIVE_COMPARATOR|B|
62353476|NCT00740324|ACTIVE_COMPARATOR|G|
62353477|NCT01201707|EXPERIMENTAL|Treatment of CCSVI with Angioplasty|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will be treated with angioplasty.
62353478|NCT01201707|SHAM_COMPARATOR|Observation of CCSVI|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will not be treated with angioplasty. These patients will be observed after treatment and compared to those patients who received treatment.
62353479|NCT03714503|OTHER|One day post-operative head positioning|patients will be assigned to remain a one-day post operative head positioning following retina re-attachment surgery
62353480|NCT01445964|EXPERIMENTAL|1|SLCO2B1 wild type allele
62353481|NCT01445964|EXPERIMENTAL|2|SLCO2B1 variant allele
62353482|NCT03823599|EXPERIMENTAL|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
62353483|NCT03823599|ACTIVE_COMPARATOR|control group|Alcohol brief intervention
61976327|NCT01287689||Patient treated with any IgG|Any marketed SC or IV IgG can be documented
61976328|NCT04053192||High-Gradient Aortic Stenosis (HG-AS)|(Pmean \>40mmHg, AVA \<1cm\^2, Vmax \>4m/s)
62147103|NCT04413994|ACTIVE_COMPARATOR|Randomized control group|receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation
62147104|NCT04413994|NO_INTERVENTION|Term control group|Term-born controls as a reference group for outcome parameters
62513098|NCT02696031|EXPERIMENTAL|Core Phase Responder 300 mg (Extension phase)|Core Phase Responder 300 mg blinded: 2 injections with secukinumab 150 mg s.c. PFS every four weeks, in the Extension phase
62513099|NCT02696031|EXPERIMENTAL|Core Phase Non-Responder 300 mg (Extension phase)|Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg s.c. PFS every four weeks open-label, in the Extension phase
62513100|NCT04507594||Patients undergoing Thoracic Surgery|
62513101|NCT01272921|ACTIVE_COMPARATOR|Bupivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
62513102|NCT01272921|ACTIVE_COMPARATOR|Ropivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
62513103|NCT02172677|EXPERIMENTAL|Healthy participants|Structural and functional MRI and memory assessment
62513104|NCT00285584|ACTIVE_COMPARATOR|Bupropion|Participants in this arm received bupropion.
62513105|NCT00285584|PLACEBO_COMPARATOR|Placebo|Participants in this arm received placebo that looked identical to the active comparator medication.
62513106|NCT04028154|EXPERIMENTAL|ESP Block|
62513107|NCT04028154|ACTIVE_COMPARATOR|TLIP Block|
62513108|NCT01563237|EXPERIMENTAL|MIDI Arrow|Implantation of MIDI Arrow
62513109|NCT04203121|EXPERIMENTAL|arm1|"An initial 5 patients will be enrolled in the first treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.~subjects 1-5 : 9 Gy in 5 fractions of 1.8 Gy on 5 consecutive days"
62513110|NCT04203121|EXPERIMENTAL|arm2|"Subjects in this arm will be enrolled in the second treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.~subjects 6-10 : 5.4 Gy in 3 fractions of 1.8 Gy on 3 consecutive days"
62513111|NCT00635518|OTHER|I, Intervention|
62353484|NCT05816694|ACTIVE_COMPARATOR|CEP|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
62353485|NCT05816694|EXPERIMENTAL|NAB-Paclitaxel|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
62353486|NCT00369967|EXPERIMENTAL|Quick start|Start contraceptive method (NuvaRing) day of enrollment
62353487|NCT00369967|ACTIVE_COMPARATOR|Traditional start|Start contraceptive method (NuvaRing) after next menses (per package insert)
62353488|NCT04697602|EXPERIMENTAL|Dose titration group|Stepwise dose titration of febuxostat and low-dose colchicine
62353489|NCT04697602|ACTIVE_COMPARATOR|Standard treatment group|Fixed dose febuxostat and low-dose colchicine
62353490|NCT01052753||ADHD group|
62353491|NCT01052753||Control group|
62353492|NCT02906956|EXPERIMENTAL|Preferred Music Playlist|All participants will have this phase twice in the protocol. See description in intervention section.
62353493|NCT01539278|ACTIVE_COMPARATOR|Observation, no surgery (control)|Patients have been diagnosed with mild OSA, no intervention is done; enrolled patients may be randomly or nonrandomly placed in this group
62353494|NCT01539278|EXPERIMENTAL|Surgery (adenotonsillectomy)|Patients who have been diagnosed with mild OSA. Patient may be randomly assigned or non-randomly choose to be in this group; all undergo adenotonsillectomy
62353495|NCT03792802|ACTIVE_COMPARATOR|classic port sites|. Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent
62353496|NCT03792802|ACTIVE_COMPARATOR|same dermatome port sites|One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port.
62353497|NCT03903120|EXPERIMENTAL|ASSIST|Study 1 and 2
62147105|NCT05536869|ACTIVE_COMPARATOR|Patient with intraperitoneal caesarean section|
62147106|NCT05536869|EXPERIMENTAL|patient with extraperitoneal caesarean section|Faucs technique
62147107|NCT04970732|EXPERIMENTAL|Experimental group|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
62147108|NCT04970732|NO_INTERVENTION|Control group|The control group received routine nursing after surgery.
62353498|NCT03903120|NO_INTERVENTION|Delayed Control|Study 1 and 2
62353499|NCT03903120|EXPERIMENTAL|Massed ASSIST|Study 3
62353500|NCT03903120|EXPERIMENTAL|Distributed ASSIST|Study 3
62513112|NCT05270928|EXPERIMENTAL|IBI346|Single arm
62513113|NCT03392675|EXPERIMENTAL|Self-monitoring of BF and intervention|Self-monitoring and regulation skills will be provided to mothers at discharge. Aside from daily diaries outlining, infant feeding behaviors and pain, mothers will be instructed to watch several 5-minute video modules to assist with self-management of breast and nipple pain. These videos include: pain neurophysiology; non-pharmacological strategies; common BF issues and intervention; catastrophizing; stress reactivity; deep breathing; guided imagery and support (informational and instrumental). These mothers will also be asked to complete study questionnaires and measures at specified time points.
62513114|NCT03392675|NO_INTERVENTION|Control|Usual care and asked to complete measures at follow-up time points.
62513115|NCT06363630|EXPERIMENTAL|Part 1|
62513116|NCT06363630|EXPERIMENTAL|Part 2|
62513117|NCT01077817||Esophageal Cancer Cases|Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
62709476|NCT01604460|ACTIVE_COMPARATOR|Resuscitation-torso bag|Use of plastic bag covering the torso and lower extremities for temperature regulation during and after resuscitation for the first hour after birth
62513118|NCT01077817||Comparison Sample (Case-Cohort)|Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.
62513119|NCT01077817||Non-treated Comparators|Participants who did not initiate treatment of osteoporosis with a study drug
62513120|NCT01077817||Alendronate|Participants initiating treatment for osteoporosis with alendronate
62513121|NCT01077817||Etidronate|Participants initiating treatment for osteoporosis with etidronate
62513122|NCT01077817||Ibandronate|Participants initiating treatment for osteoporosis with ibandronate
62513123|NCT01077817||Risedronate|Participants initiating treatment for osteoporosis with risedronate
62513124|NCT01077817||Raloxifene|Participants initiating treatment for osteoporosis with raloxifene
62513125|NCT05592353|ACTIVE_COMPARATOR|Brace|
62513126|NCT05592353|NO_INTERVENTION|No Brace|
62513127|NCT06440187|EXPERIMENTAL|gemcitabine+ nivolumab|Nivolumab administration on D1 and D15 every cycle, with 3mg/kg with gmecitabine co-administration on D1 and D15 every cycle, with 1250mg/m2
62513128|NCT01385826|EXPERIMENTAL|adalimumab|Anti-tumor necrosis factor alpha monoclonal antibody
62513129|NCT01385826|PLACEBO_COMPARATOR|placebo|placebo
62513130|NCT03702049|EXPERIMENTAL|RN/CHW TBI|Nurse-led Community Health Worker TBI (RN/CHW TBI) program
62513131|NCT00904748|EXPERIMENTAL|Test 1|
62709477|NCT05677880||Non-Carrier Cohort|About 100 participants who are at-risk, healthy family members with No NOTCH3 Mutation and no symptoms or signs of cognitive decline.
62147109|NCT01976507|EXPERIMENTAL|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
62147110|NCT02405000|EXPERIMENTAL|Intraoperative CT imaging|
62147111|NCT06167421|EXPERIMENTAL|Kimura group|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique.
62513132|NCT00904748|EXPERIMENTAL|Test 2|
62513133|NCT00904748|ACTIVE_COMPARATOR|Reference|
62513134|NCT03446352|EXPERIMENTAL|Psychomotor exercise program|The experimental group 1 (EG1) intervention comprises a psychomotor program. The program integrates 3 sessions / week of 75 minutes on alternated days. The psychomotor intervention includes exercises promoting simultaneous motor and cognitive stimulation (interval training).
62513135|NCT03446352|EXPERIMENTAL|Combined exercise program|The experimental group 2 (EG2) intervention combines the psychomotor program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.
62513136|NCT03446352|NO_INTERVENTION|Control Group|Usual care. After the study, control group (CG) participants will be offered the opportunity to integrate a similar fall prevention program.
62513137|NCT05827484|ACTIVE_COMPARATOR|10 patients with acute skeletal muscle injury underwent PRP injection|Patients with acute skeletal muscle injury received a single ultrasound guided local PRP injection in the site of injury in day 1 or 2 of the injury.
62513138|NCT05827484|EXPERIMENTAL|10 patients with acute skeletal muscle injury underwent PRP injection and oral LOSARTAN|Patients with acute skeletal muscle injury received a single ultrasound guided local PRP injection in day 1 or 2 of injury in addition to administration of oral (50mg LOSARTAN /day) from day 5 to day 30.
62513139|NCT02841748|EXPERIMENTAL|Pembrolizumab|200mg, every three weeks, iv, x 1 year
62513140|NCT02841748|EXPERIMENTAL|Placebo|iv, every 3 weeks, x 1 year
62513141|NCT01002794|EXPERIMENTAL|Arthroscopic partial meniscectomy|Standard arthroscopic partial meniscectomy - NGD 1
62513142|NCT01002794|EXPERIMENTAL|Exercise Therapy|Supervised neuromuscular- and strength training
62709478|NCT05677880||Pre-Symptomatic NOTCH3 Cohort|About 133 participants who are pre-symptomatic, at-risk, and healthy (with verified NOTCH3 mutation) family members with no symptoms.
62709479|NCT05677880||Symptomatic NOTCH3 Cohort - No Functional Decline|About 134 participants who are symptomatic (with verified NOTCH3 mutation) family members and no functional decline (e.g., mild cognitive impairment (MCI) with premorbid functional levels maintained).
62709480|NCT05677880||Symptomatic NOTCH3 Cohort - Functional Decline|About 133 participants who are symptomatic family members with a verified NOTCH3 CADASIL mutation and evidence of functional decline consistent with early dementia.
62147112|NCT06167421|ACTIVE_COMPARATOR|Warshaw group|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique.
62353501|NCT01754675|EXPERIMENTAL|Soccer|Watching the soccer match at the time that the favorite team is playing
62353502|NCT01754675|PLACEBO_COMPARATOR|Movie|Watching a movie at the time that the favorite team is playing
62513143|NCT04452279|EXPERIMENTAL|Ocular Surface Disease post-stenting|Eyes will undergo phacoemulsification cataract surgery combined with iStent or iStent inject implantation according to standard clinical practice. From baseline through 3 months postoperatively, participants will complete subjective and objective assessments of ocular surface disease.
62513144|NCT01913379|EXPERIMENTAL|1: MDV3100|
62513145|NCT01913379|EXPERIMENTAL|2: MDV3100 and gemfibrozil|
62709481|NCT03295344||Patients|
62709482|NCT03295344||Healthy volunteers|
62147113|NCT01217736|EXPERIMENTAL|VTP-27999|
62147114|NCT01217736|ACTIVE_COMPARATOR|aliskiren|
62147115|NCT01217736|PLACEBO_COMPARATOR|placebo|
62147116|NCT03559959|EXPERIMENTAL|$0 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to redeem an HIV self-testing kit free of charge.
62513146|NCT01913379|EXPERIMENTAL|3: MDV3100 and itraconazole|
62513147|NCT05342649|EXPERIMENTAL|Main treatment group|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
62513148|NCT05342649|ACTIVE_COMPARATOR|Control group|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
62513149|NCT04625075||Healthy Volunteer|Age and sex matched healthy volunteer
62709483|NCT05639959||Commercial product group|group who are taking commercial nasal spray products
62709484|NCT05639959||New formulation product group|who are taking new formulation nasal spray product with same strength
61972927|NCT02524795|NO_INTERVENTION|Control group|"Patients in the control group did not receive the nutrient nor any kind of placebo. They were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
61972928|NCT00894569|ACTIVE_COMPARATOR|A|6 cycles of carboplatin/paclitaxel
62147117|NCT03559959|EXPERIMENTAL|$0.5 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $0.5.
62147118|NCT03559959|EXPERIMENTAL|$1 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $1.
62147119|NCT03559959|EXPERIMENTAL|$2 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $2.
62147120|NCT03559959|EXPERIMENTAL|$3 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $3.
62513150|NCT04625075||COVID-19 with myocardial injury|Patients hospitalised with severe COVID-19 infection and evidence of myocardial. Involvement: elevation of plasma cardiac troponin concentration (\>99th centile of the upper reference limit), abnormalities on electrocardiography or abnormal echocardiography. Some patients will have suspected myocarditis or takotsubo cardiomyopathy. We will identify subgroups of interest who have left/right ventricular systolic dysfunction ± regional wall motion abnormalities, on echocardiography.
62147121|NCT02516085|EXPERIMENTAL|L-arginine and metformin|7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks
62147122|NCT06501950||Core centre|Persons that will be included by the core centre will be examined every 6 months by clinical testing, blood tests, and optical coherence tomography. A MRI will be conducted every 12 month. Additional digital monitoring using a smartwatch and smartphone ist optional.
62147123|NCT06501950||Other study centre|Persons that will be included by the other study centre will be examined every 6 months by clinical testing and blood tests. Additional digital monitoring using a smartwatch and smartphone ist optional.
62147124|NCT01355445|ACTIVE_COMPARATOR|Vincristine / Irinotecan|Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV
62147125|NCT01355445|EXPERIMENTAL|Vincristine / Irinotecan / Temozolomide|Vincristine, Irinotecan, Temozolomide
62147126|NCT05840185|EXPERIMENTAL|Experimental: Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
62513151|NCT04625075||COVID-19 without myocardial injury|Patients hospitalised with severe COVID-19 infection but without known elevation of plasma cardiac troponin concentration, clinically significant ECG abnormalities or an abnormal echocardiogram.
62513152|NCT06616454|EXPERIMENTAL|Control group - Calorie-restricted feeding|Participants will be applied a nutrition plan prepared in line with the principles of the Mediterranean Diet without any time restrictions.
62513153|NCT06616454|EXPERIMENTAL|Intervention group - Time restricted feeding|Participants will be applied with an ad libitum nutrition plan between 10:00 and 18:00.
62513154|NCT01158352|EXPERIMENTAL|Nutritional supplemntation formula|Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
61972929|NCT00894569|EXPERIMENTAL|B|carboplatin/paclitaxel plus cetuximab until disease progression
61972930|NCT01030939|EXPERIMENTAL|Cohort 1: SB-649868|Healthy adult male subjects
62147127|NCT01738997|EXPERIMENTAL|Group A|Dilation 10 sec
61972931|NCT01030939|EXPERIMENTAL|Cohort 2|Healthy adult female subjects
62147128|NCT01738997|ACTIVE_COMPARATOR|Group B|Dilation 2 min
62147129|NCT02467985|NO_INTERVENTION|Control|
62147130|NCT02467985|EXPERIMENTAL|intervention|Flow of insufflation will be set to 2-3L / min. After the intervention, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. Suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who applies 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 sec. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures.
62513155|NCT01158352|PLACEBO_COMPARATOR|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
62539447|NCT05373004|ACTIVE_COMPARATOR|Enalapril 20 mg arm (ACE inhibitor)|enalapril 10 mg tab once daily plus a placebo empagliflozin 10 mg tab, along with conventional antihypertensive (for hypertension patients) \& glycemic control therapies (if present). After four weeks, the dose of enalapril will be increased to 20 mg once (with Empagliflozin 25 mg placebo) daily throughout the study for one year.
61972932|NCT01030939|EXPERIMENTAL|Cohort 3|Healthy male elderly subjects
61972933|NCT01030939|EXPERIMENTAL|Cohort 4|Healthy female elderly subjects
61972934|NCT01829191|EXPERIMENTAL|Test Lens A|Test lenses will be worn in a daily wear modality
61972935|NCT01829191|EXPERIMENTAL|Test Lens C|Test lenses will be worn in a daily wear modality
61972936|NCT03587012|EXPERIMENTAL|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
61972937|NCT03587012|EXPERIMENTAL|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD combined with simultaneous transcranial alternating current stimulation (tACS)
61972938|NCT03757897|EXPERIMENTAL|Dexmedetomidine induced sleep patients|All subjects will be measured for CSF volume, diffusion parameters and mechanical 'stiffness' of the brain during wakefulness and during sleep-induced with dexmedetomidine (DEXM).
61972939|NCT04920604||Teleconsultation|
61972940|NCT04920604||Control group|
62709485|NCT00744861|ACTIVE_COMPARATOR|Exogen 4000+|Low intensity pulsed ultrasound (LIPUS) delivered via Exogen 4000+ (single transducer) device for a treatment duration of 20 minutes per fusion site per day.
62709486|NCT00744861|SHAM_COMPARATOR|Exogen 4000+ sham|Non-active sham device identical to Exogen 4000+ (single transducer); treatment duration of 20 minutes per fusion site per day
62353503|NCT06041685|NO_INTERVENTION|Non-warming group (C)|After induction, the baseline artery ultrasonography images are collected for the internal diameter and cross-sectional area of the artery. In the non-warming group (C), local warming is not applied on the catheterization site. Before catheterization, the artery ultrasonography images are collected. Then, arterial catheterization is applied.
62353504|NCT06041685|EXPERIMENTAL|Warming group (W)|In the warming group (W), local warming is applied on the catheterization site. Before catheterization, the artery ultrasonography images are collected. Then, arterial catheterization is done.
62353505|NCT01752621||acromegaly|patients with acromegaly
62353506|NCT01752621||comparison population|matched background population
62353507|NCT03920865|EXPERIMENTAL|Part 1|Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
62353508|NCT03920865|EXPERIMENTAL|Part 2|Participants with moderate hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
62353509|NCT06402279||Basic therapy + Efferon CT|Patients in group 1 (n = 65) received basic COVID-19 medication: 2 to 5 days before hemosorption, they all received anti-inflammatory drugs, glucocorticoid therapy (16 to 24 mg/day of dexamethasone), oxygen therapy, and heparin. The transfer to an intensive care unit (ICU) was accompanied by transfer to a non-invasive ventilator.
62353510|NCT06402279||Baseline therapy|Group 2 patients (n=65) were matched to patients of group 1 and received basic COVID-19 drug therapy and no hemoperfusion procedure using Efferon CT device.
62353511|NCT05884476|EXPERIMENTAL|REST + TAU|Veterans in this condition will complete the REST intervention and be expected to remain engaged in their standard course of health care as described in the TAU condition.
62353512|NCT05884476|OTHER|TAU|Veterans in this condition will be expected to engage in their standard course of heath care.
62353513|NCT03134924|EXPERIMENTAL|Experimental condition|The WASH (Women's and Sexual Health) intervention included the elements of the enhanced standard of care condition and in addition, a group-based, culturally-tailored intervention to enhance the uptake of the recommendations. Facilitators covered an intervention manual on risks associated with IVP, symptoms of vaginal infections, vaginal health, women's experience with alternative methods for vaginal care, and communication with partners about vaginal health and the risks associated with IVP.
62353514|NCT03134924|OTHER|Enhanced Standard of Care|"This study provided an enhanced standard of care (SOC+) comparison condition, consisting of a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV using the Nugent criteria and provision of medication (oral metronidazole) within 48 hours of the examination in women with Nugent score of 7-10, regardless of the presence of symptoms. In addition, at baseline, participants received an individual education session on the risk of engaging in IVP, advice to discontinue IVP, and tips for healthy vaginal hygiene, emphasizing avoiding IVP and suggesting replacing IVP by external vaginal cleansing."
62353515|NCT03109756|EXPERIMENTAL|Single-dose 5 mg OV101|
62353516|NCT05969912|ACTIVE_COMPARATOR|Graston Technique (Instrumented assisted soft tissue mobilization)|Graston technique + Conventional PT
62353517|NCT05969912|ACTIVE_COMPARATOR|Bowen's Technique (Soft tissue technique)|Bowen's technique + Conventional PT
62353518|NCT01330641|ACTIVE_COMPARATOR|Anterior injection Route|Group of patients injected with medication using the anterior route
62353519|NCT01330641|ACTIVE_COMPARATOR|Posterior Injection|Group of patients receiving injection through a posterior route
62353520|NCT01330641|ACTIVE_COMPARATOR|Lateral Injection|Group of patients receiving subacromial injection through a lateral route
62353521|NCT01998438|EXPERIMENTAL|small dose|10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
62709487|NCT00744861|ACTIVE_COMPARATOR|Exospine|Low intensity pulsed ultrasound delivered via Exospine device (dual transducers); treatment duration of 20 minutes per day
62709488|NCT00744861|SHAM_COMPARATOR|Exospine sham|Non-active sham device identical to Exospine (dual transducers); treatment duration of 20 minutes per day
62353522|NCT01998438|EXPERIMENTAL|medium dose|20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
62353523|NCT01998438|EXPERIMENTAL|large dose|30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
62353524|NCT04950842|EXPERIMENTAL|JB-101|induced T cell with suppressive function
62353525|NCT01899586|EXPERIMENTAL|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
62353526|NCT01899586|EXPERIMENTAL|Aerobic Exercise (AE)|Whole-body aerobic exercise at \>50% of heart rate reserve (HRR) for 45 minutes, three days per week.
62353527|NCT02233907||Chronic obstructive pulmonary disease patients|
62353528|NCT05841108|EXPERIMENTAL|experimental group|
62353529|NCT05841108|ACTIVE_COMPARATOR|control group|
62513156|NCT00717496|EXPERIMENTAL|A|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. This group will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
62539448|NCT04471025|ACTIVE_COMPARATOR|Group I|USG guided infraclavicular block with single operator jedi grip technique
62709489|NCT02254291|EXPERIMENTAL|Semaglutide 0.5 mg|
62709490|NCT02254291|EXPERIMENTAL|Semaglutide 1.0 mg|
61972941|NCT01936688|EXPERIMENTAL|MK-3222 200 mg + Placebo to Etanercept|MK-3222 200 mg subcutaneously (SC) on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
61972942|NCT01936688|EXPERIMENTAL|MK-3222 100 mg + Placebo to Etanercept|MK-3222 100 mg SC on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
61972943|NCT01936688|PLACEBO_COMPARATOR|Placebo to MK-3222 + Placebo to Etanercept|Placebo to MK-3222 administered SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12, then once weekly up to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive MK-3222 high dose or MK-3222 low dose on Weeks 12, 16, and 28 and, optionally, every 12 weeks thereafter through Week 220.
62709491|NCT02254291|ACTIVE_COMPARATOR|Sitagliptin 100 mg|
62709492|NCT02172794|EXPERIMENTAL|tiotropium|
62709493|NCT02172794|ACTIVE_COMPARATOR|salmeterol|
62709494|NCT04756830|OTHER|Vaccination|All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
61972944|NCT01936688|ACTIVE_COMPARATOR|Placebo to MK-3222 + Etanercept 50 mg|Matching placebo to MK-3222 SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and then once weekly through Week 28.
62709495|NCT03949517|EXPERIMENTAL|68-Ga RM2+68-Ga PSMA11|68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
62709496|NCT03949517|EXPERIMENTAL|68-Ga PSMA11+68-Ga RM2|68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
62147131|NCT05206994|EXPERIMENTAL|Close to Home Intervention|Sites receiving the intervention arm were determined prior to the initiation of the research. The rape crisis center in each community applied for funding from the California Department of Public Health to implement the Close to Home model in their community and they were accepted via a competitive application process. Close to Home (C2H) is a community mobilization model developed in Boston and adapted for California and is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms.
62147132|NCT05206994|NO_INTERVENTION|Control Program|"The control program is the 4-H Youth Development Program, which is implemented across every county in California via the University of California Cooperative Extension. In 4-H programs, kids and teens complete hands-on projects in areas like health, science, agriculture and civic engagement in a positive environment where they receive guidance from adult mentors and are encouraged to take on proactive leadership roles. The model does not use community mobilization and does not address sexual violence.~Control communities were selected based on propensity score matching using sociodemographic and community-level variables related to risk for sexual violence. The closest match was recruited first, and a next-best match was used if the first match declined participation."
62147133|NCT04705051|EXPERIMENTAL|Venglustat|Participants were to be treated with venglustat 15 milligrams once daily orally for 24 months or until venglustat was commercially available, whichever came first.
62709497|NCT01876381|EXPERIMENTAL|OPC-41061|
62709498|NCT01918137|EXPERIMENTAL|chocolate bar|
61972945|NCT06083116|EXPERIMENTAL|healthy subjects|
62513157|NCT00717496|NO_INTERVENTION|B|Mothers assigned to the control group will receive usual care. This group will also receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream.
62513158|NCT02227459|EXPERIMENTAL|Experimental: Arm A|Once a week dosing
61972946|NCT00847236||Subjects with Polymyalgia Rheumatica|50 subjects with Polymyalgia Rheumatica, both acute and chronic
61972947|NCT00847236||Subjects w/o Polymyalgia Rheumatica|50 subjects with Rheumatic Disease other than polymyalgia Rheumatica
61972948|NCT00847236||Subjects w/o Rheumatic Disease|50-Non Rheumatic disease subjects
61972949|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
61972950|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
61972951|NCT06045767|EXPERIMENTAL|Pembrolizumab + Carboplatin+ Pemetrexed|
61972952|NCT02814513|EXPERIMENTAL|ANDAGO|ANDAGO
62147134|NCT04039646|ACTIVE_COMPARATOR|Standard postoperative care group|Patients received standard postoperative care as ususal.
62147135|NCT04039646|EXPERIMENTAL|ERAS group|Patients received postoperative ERAS treatment.
61972953|NCT02728050|EXPERIMENTAL|Treatment (sorafenib, G-CLAM)|See Detailed Description.
62147136|NCT01351259|EXPERIMENTAL|Pneumatic device, tapered cuff|Intervention: continuous control of cuff pressure using a pneumatic device, tapered polyurethane cuff
62147137|NCT01351259|EXPERIMENTAL|Pneumatic device, cylindrical cuff|Continuous control of cuff pressure using a pneumatic device in patients intubated with cylindrical polyurethane cuffed tracheal tubes
62709499|NCT01918137|EXPERIMENTAL|porridge|
61972954|NCT03134287|ACTIVE_COMPARATOR|two-finger method|Those who received nasogastric tube placement by two-finger method
62709500|NCT06222021|OTHER|Genetic analysis of polymorphisms of membrane receptors involved in lactate transport|Before the start of surgery, after arterial line cannulation, a blood sample will be collected in an ethylenediaminetetraacetic acid (EDTA) test tube for genetic analysis of polymorphisms of membrane receptors involved in lactate transport including transporter family monocarboxylates 1 (MTC1), transporter family monocarboxylates 4 (MTC4) and Gi-coupled protein receptor 81 (GPR81).
61972955|NCT03134287|ACTIVE_COMPARATOR|reverse sellick's method|Those who received nasogastric tube placement by reverse sellick's method
62709501|NCT01503320|EXPERIMENTAL|Enteral glutamine|
62709502|NCT01503320|PLACEBO_COMPARATOR|Placebo|
62709503|NCT02682056|OTHER|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
62709504|NCT05871957||Serum vitamin D deficiency in Hashimoto's thyroiditis during hypothyroidism|Serum vitamin D levels are lower than normal
62709505|NCT05871957||Patients with normal serum vitamin D during hypothyroidism in Hashimoto's thyroiditis|Serum vitamin D levels are within normal limits
62709506|NCT02441218|EXPERIMENTAL|Ivabradine|
62709507|NCT02441218|PLACEBO_COMPARATOR|Placebo|
62709508|NCT03768037|EXPERIMENTAL|Anlotinib plus Pemetrexed|Anlotinib plus Pemetrexed
62709509|NCT03768037|OTHER|Pemetrexed|Pemetrexed
62513159|NCT02227459|EXPERIMENTAL|Experimental: Arm B|Twice a week dosing
62513160|NCT02792348||children with congenital urine flow impairment|this group contain children with an unilateral urinary tract dilatation diagnosed by prenatal ultrasonography
62513161|NCT02792348||control group|this group contains children, between 1 and 3 months of age, without nephrological or urological anomaly
62513162|NCT01373060|EXPERIMENTAL|ASP1941 group|
62513163|NCT01373060|PLACEBO_COMPARATOR|placebo group|
62513164|NCT06357923|OTHER|evaluation of LAMP-2 protein expression|dosing of level expression of LAMP-2
62709510|NCT02398019|EXPERIMENTAL|CPB-OXIRIS®|Non emergent cardiac surgery patients with CPB requirement.
61972956|NCT04020679|NO_INTERVENTION|Control arm|Participants will not receive GOCI materials
61972957|NCT04020679|EXPERIMENTAL|Intervention|Participants will receive GOCI materials and clinicians will receive training.
61972958|NCT01655550|OTHER|Standard of Care|Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice
61972959|NCT01655550|EXPERIMENTAL|Withold Oral Contrast|Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine
61972960|NCT06121687|EXPERIMENTAL|Shaeer-I|Shaeer-I High Vein Ligation surgery will be performed. A hockey-stick or vertical incision encompassing the target point is cut, lateral to anal cleft. Subcutaneous fat is dissected down to the gluteus maximus, which is split along the direction of its fibers. The internal pudendal vein can be identified and ligated deep to the muscle, coursing between the pudendal nerve medially and the pudendal artery laterally.
62147138|NCT01351259|ACTIVE_COMPARATOR|Routine care, tapered cuff|Routine care of cuff pressure using a manometer, tapered polyurethane cuff
62353530|NCT05533333|EXPERIMENTAL|Self administered dual-task training|"The exercise intervention will continue for 9 months, beginning with 12 weeks of training accompanied by workshops to teach the exercises.~Experimental group: sDTT group participants will be instructed to perform 10 minutes of warm-up, 40 minutes of dual-task training and 10 minutes of cool-down exercises. The size of the workshop will be limited to 10 participants. The sDTT programme includes performing a selection of six cognitive tasks during walking, the sit-to-stand movement, heel and toe raising, stepping, tandem standing and walking and multidirectional reaching tasks. The cognitive tasks will include mental tracking, working memory, auditory cues and verbal fluency tasks. Participants will be given the freedom to mix and match the physical and cognitive tasks to make them more challenging."
62353531|NCT05533333|ACTIVE_COMPARATOR|Self-administered singletask training|Control group: The self-administered single-task training group will receive 10 minutes of warm-up, 20 minutes of physical tasks (as outlined above) and 20 minutes of cognitive tasks (as outlined above) followed by 10 minutes of cool-down exercises. Participants will be instructed to perform the exercises for the same dosage as the experimental group. After a 6-month follow-up period, the control group will receive two complimentary sessions of self-administered dual-task training.
62353532|NCT04249167|EXPERIMENTAL|Treatment (cryoablation, atezolizumab, nab-paclitaxel)|Patients undergo cryoablation of the primary tumor over about 1 hour. After 2-3 weeks, patients receive atezolizumab IV on days 1 and 15 and nab-paclitaxel IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62353533|NCT05130372|ACTIVE_COMPARATOR|Static Stretching Group|The static stretching method was actively applied while standing.The person was positioned facing the wall, supporting the wall with both hands, with the dominant foot behind. The point where a feeling of tension in the plantar flexor muscles was created and held in this position for 30 seconds. Afterward, a 15-second rest break was given. After completing 3 repetitions (3x30sec) in total, measurements were started.
62513165|NCT01647503||Tumor group|Parathyroid adenoma, hyperplasia and carcinoma
62513166|NCT01647503||Normal|Normal parathyroid samples
62513167|NCT06188052|ACTIVE_COMPARATOR|Group (A), tranexamic acid IV|tranexamic acid will be given 1 hr preoperatively as 1mg/kg intravenously
62513168|NCT06188052|ACTIVE_COMPARATOR|Group (B), topical tranexamic acid|topical tranexamic acid will be given as an irrigation by 40 ml of tranexamic acid 2mg/kg dissolved in 200ml to the surgical site every 1 hour for the first 5 hours .
62513169|NCT06188052|PLACEBO_COMPARATOR|Group (C), control group.|Saline will be given intravenously instead of tranexamic acid And irrigation with Saline instead of tranexamic acid
62513170|NCT05553782|EXPERIMENTAL|IMD PLACEMENT + SURGICAL RESECTION + ADJUVANT TREATMENT ARM|"Newly diagnosed, localized ACC salivary cancers undergoing surgical resection~* Interventional radiology guided IMD placement~* Planned oncologic resection with IMD retrieval 3-5 days after placement~* Standard of care adjuvant treatment~* Tumor specimen analysis for local drug response and molecular analysis"
62513171|NCT04669548||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay
62513172|NCT06415214|PLACEBO_COMPARATOR|Group A，Subjects will receive Placebo administered orally|
62513173|NCT06415214|EXPERIMENTAL|Group B，Subjects will receive HRS-7535 administered orally|
62513174|NCT06415214|EXPERIMENTAL|Group C，Subjects will receive escalated HRS-7535 administered orally|
62513175|NCT03804164|EXPERIMENTAL|Supportive Care (psycho-educational sessions)|Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
62513176|NCT04855448|EXPERIMENTAL|Surgeon A|This group is consisted of 56 cases performed using the Micro Hand S robot and da Vinci robot by one single surgeon in low anterior resection for rectal cancer
62513177|NCT04855448|ACTIVE_COMPARATOR|Surgeon B|This group is consisted of 56 cases performed using the da Vinci robot by one single surgeon in low anterior resection for rectal cancer
61972961|NCT06121687|ACTIVE_COMPARATOR|PPI|Penile prosthesis implantation (PPI) will be performed.
62147139|NCT01351259|ACTIVE_COMPARATOR|Routine care, cylindrical cuff|Routine care of cuff pressure using a manometer, cylindrical polyurethane tracheal cuff
62513178|NCT00980889|ACTIVE_COMPARATOR|steel|Insertion of Metalic Steel Stent, Wallstent® in malignant distal bile duct obstruction
62709511|NCT02398019|NO_INTERVENTION|CPB-Standard|Non emergent cardiac surgery patients with CPB requirement.
62709512|NCT05790694|EXPERIMENTAL|HBM9378 (SKB378) Injection|Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously
62513179|NCT00980889|ACTIVE_COMPARATOR|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
62513180|NCT06617442|EXPERIMENTAL|90W|Pulmonary vein isolation performed using very-high power short duration applications (90-watt applications lasting 4 seconds).
62513181|NCT06617442|ACTIVE_COMPARATOR|50W|Pulmonary vein isolation performed using high power short duration applications (50-watt applications guided by ablation index).
62513182|NCT04924374|EXPERIMENTAL|anti PD1 therapy plus Microbiota Transplant|"Active arm: Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (\>30g/day).~anti PD1 therapy every 2-3 weeks"
62513183|NCT04924374|ACTIVE_COMPARATOR|anti PD1 therapy|Control arm: no intervention before anti PD1 therapy
62513184|NCT03804788|EXPERIMENTAL|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for six (6) weeks.
62513185|NCT03804788|ACTIVE_COMPARATOR|Sleep Hygiene|Sleep hygiene handout delivered once to all participants.
62513186|NCT02166034|EXPERIMENTAL|garden intervention|Schools assigned to the garden intervention receive raised bed garden kits and access to a toolkit of garden-based curriculum
62513187|NCT02166034|NO_INTERVENTION|Control|Wait-list control (no garden intervention + lessons) until end of the study.
62513188|NCT04211519|EXPERIMENTAL|Permanent teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
61972962|NCT04769544|ACTIVE_COMPARATOR|Medial pivot group|Device used: medial pivot total knee arthroplasty design
61972963|NCT04769544|ACTIVE_COMPARATOR|Conventional group|Device used: conventional total knee arthroplasty design
62147140|NCT00701415|EXPERIMENTAL|Fabrazyme 0.5 mg/kg|Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
62147141|NCT00701415|EXPERIMENTAL|Fabrazyme 1.0 mg/kg|Fabrazyme 1.0 mg/kg was administered every 4 weeks (up to 66 infusion) up to 260 weeks, the total infusion time was not less than 90 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
62513189|NCT04211519|EXPERIMENTAL|Primary teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
62513190|NCT02883517||Aggressive primary cutaneous lymphomas|"* Mycosis fungoides ≥ T2b~* Primary cutaneous T helper follicular lymphoma ≥ T2~* Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome."
62513191|NCT03399994|EXPERIMENTAL|ABLUMINUS DES+|device implantation during coronary angioplasty
62513192|NCT03399994|ACTIVE_COMPARATOR|Everolimus-eluting DES|device implantation during coronary angioplasty
62513193|NCT00882206|EXPERIMENTAL|Decitabine / Vorinostat|This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
62539449|NCT04471025|ACTIVE_COMPARATOR|Group 2|USG guided infraclavicular block with conventional double operator technique
62539450|NCT02315430|EXPERIMENTAL|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62539451|NCT02111603|OTHER|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
62709513|NCT05790694|PLACEBO_COMPARATOR|Placebo|Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously
62709514|NCT04015258|EXPERIMENTAL|Blueberries|Fresh blueberries purchased from local supermarket will be distributed to each participant for 1 week's consumption, 160 grams per day
62147142|NCT02436070|ACTIVE_COMPARATOR|Control|Subjects receive general, health-related text messages applicable for children with asthma.
62539452|NCT05971940|EXPERIMENTAL|Orforglipron Dose 1|Participants will receive orforglipron orally.
62709515|NCT04015258|EXPERIMENTAL|Blueberry powder|Freeze-dried blueberry powder will be distributed to each participant for 1 week's consumption, 20 grams per day, equivalent to 160 grams of fresh blueberries
62539453|NCT05971940|EXPERIMENTAL|Orforglipron Dose 2|Participants will receive orforglipron orally.
62709516|NCT04015258|PLACEBO_COMPARATOR|Blueberry components capsules|Encapsulated microcrystalline cellulose powder will be blinded as blueberry components capsules to be distributed to each participant for 1 week's consumption
61972964|NCT04052893|EXPERIMENTAL|Study group|100 patients will be assigned into a study group.
61972965|NCT04052893|ACTIVE_COMPARATOR|Control group|100 patients will be assigned into a control group.
61972966|NCT01252017|EXPERIMENTAL|Nilotinib|Single arm, open label study
61972967|NCT02512237|EXPERIMENTAL|Phase 1a: Dose-Escalation|Six cohorts with escalated dose levels of ARX788 at 0.33 mg/kg, 0.66 mg/kg, 1.3 mg/kg, 2.2 mg/kg, 2.9 mg/kg and 3.8 mg/kg will be administered every 3 weeks via intravenous infusion to determine the MTD.
61972968|NCT02512237|EXPERIMENTAL|Phase 1b: Dose-evaluation 1|Breast cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
62513194|NCT05185258|EXPERIMENTAL|Enstilar|Participants will need to have two separate clinically healed psoriasis plaques. At baseline (visit 2), one target lesion (plaque # 1) will be actively treated with once-daily cutaneous application of Enstilar® foam and one target lesion (plaque # 2) will be treated with placebo-vehicle. Participants will then simultaneously be treated three-weekly with full-body NB-UVB for 8 weeks (or a minimum of 20 sessions in total). After 4 weeks of Enstilar® and emollient, treatment application will be changed to twice-weekly until EOT (visit 5). First dose of IMP will be administered by trained personal. Subsequent doses will be administered by the participant. Study visits will occur at Screening, Baseline (Week 0), Weeks 8, 13, and 18. At baseline, week 8, week 13, and week 18 two skin punch biopsies will be acquired from each target lesion.
62513195|NCT05185258|PLACEBO_COMPARATOR|Placebo-vehicle|Placebo-vehicle will be given as explained for the arm description under Enstilar.
62513196|NCT05975177|EXPERIMENTAL|Sterify Gel + SRP|Scaling and root planing in the assigned site, followed by intra-pocket administration of Sterify Gel, applied to the bottom of the pocket until the gel emerges or becomes visible at the gingival margin
62513197|NCT05975177|ACTIVE_COMPARATOR|SRP only|Scaling and root planing in the assigned site.
62513198|NCT05983666||Patients undergoing scheduled and/or emergency surgery requiring orotracheal intubation.|
62513199|NCT01258101|EXPERIMENTAL|Peginterferon/Ribavirin 800 mg (24 Weeks)|Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).
62513200|NCT01258101|EXPERIMENTAL|Peginterferon/Ribavirin 400 mg (24 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.
62513201|NCT01258101|EXPERIMENTAL|Peginterferon/Ribavirin 800 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.
62513202|NCT01258101|EXPERIMENTAL|Peginterferon/Ribavirin 400 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.
62513203|NCT02238561||Elective major abdominal surgery|Patients undergoing elective major open or laparoscopic abdominal surgery at Plymouth Hospitals National Health Service (NHS) Trust (PHNT)
62513204|NCT00920088|EXPERIMENTAL|Cohort 1|GSK2248761 with LPV/RTV arm and probes
62513205|NCT00920088|EXPERIMENTAL|Cohort 2|GSK2248761 with DRV/RTV
62513206|NCT04734834|PLACEBO_COMPARATOR|Placebo|"Placebo will be provided orally to the Placebo Group. Placebo will be blinded and labeled either as A or B."
62513207|NCT04734834|ACTIVE_COMPARATOR|"Prodovite® VMP35"|"Prodovite® VMP35 will be provided orally to the Treatment Group. Prodovite® VMP35 will be blinded and labeled either as A or B."
62513208|NCT03297372|EXPERIMENTAL|IOL Implantation experimental|Implantation of Micropure 1.2.3. in one of the eyes of the study subject
62513209|NCT04661826|EXPERIMENTAL|Oncofid-P-B|Oncofid-P-B will be administered once a week for 6 weeks in the first treatment phase and once a month for 6 months followed by other 6 months in the second maintenance phase
62513210|NCT02332213||1. Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
62513211|NCT02332213||2. Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.
62513212|NCT02332213||3. Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria
62709517|NCT05333926|EXPERIMENTAL|MHNA-001|
62147143|NCT02436070|EXPERIMENTAL|Test group|Subjects receive specific, targeted text messages for post-emergency department discharge asthma care.
62709518|NCT02525679|EXPERIMENTAL|BI 655130 (spesolimab)|
61972969|NCT02512237|EXPERIMENTAL|Phase 1b: Dose-evaluation 2|Breast cancer subjects with mid/low HER2 expression, categorized as ISH negative AND IHC2+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
62513213|NCT02332213||4. Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.
62513214|NCT02332213||5. Gastric cancer|Patients with histologically confirmed gastric cancer (adenocarcinoma)
62513215|NCT02332213||6. Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach
62513216|NCT02332213||7. High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)
62513217|NCT02332213||8. Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded
62513218|NCT02332213||9. Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.
62513219|NCT02323165||Burns and Wound Care|Blood samples will be taken to detect and identify a molecular detection of bacteria in the bloodstream. In addition, data will be collected from the standard of care blood samples and compared.
62513220|NCT03291041|EXPERIMENTAL|tasimelteon|tasimelteon, administered as oral capsule(s)
62513221|NCT03291041|PLACEBO_COMPARATOR|Placebo|Placebo, administered as oral capsule(s)
62709519|NCT02525679|PLACEBO_COMPARATOR|Placebo|
62709520|NCT01295489||Group A (IP catheter removed)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and blood (for cell, plasma, and serum isolations) is collected before courses two and three for translational research.
61972970|NCT02512237|EXPERIMENTAL|Phase 1b: Dose-evaluation 3|Gastric cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
62147144|NCT05260944|EXPERIMENTAL|Group A|Group A. Thirty patients will receive a two supervised session using Acapella three sets for 10 repetitions two times daily from first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, Percussion and vibration).
62513222|NCT05724446|EXPERIMENTAL|Clobetasol propionate|One drop of Clobetasol propionate ophthalmic nanoemulsion, 0.05% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.
62513223|NCT05724446|ACTIVE_COMPARATOR|Prednisolone acetate|One drop of Prednisolone ophthalmic suspension, 1% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.
62513224|NCT05281978|EXPERIMENTAL|Decrease Sedentary Time + Increase MVPA|Participants in this group will receive a 12-week, social cognitive theory-based intervention targetting reduction of daily sedentary time. This information will be delivered to them in the form of Zoom workshops, a program workbook, personalized step count goals, and a private social media page. The aim of this component will be to have participants displace their daily sedentary time with light-intensity physical activity, such as casual walking. The second component of this intervention will be increasing participants' weekly MVPA engagement. Participants will participate in 1 live, virtual aerobics-based exercise class per week and complete 2 additional sessions on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
62513225|NCT05281978|ACTIVE_COMPARATOR|Increase MVPA only|Participants in this group will only receive the MVPA-promoting component (which will be the same delivery as the intervention group). Participants in this arm will participate in 1 live, virtual aerobics-based exercise class per week (held separately from the intervention group) and will complete 2 additional exercise classes on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
61972971|NCT05783778|EXPERIMENTAL|Toxoplasmosis seropositive female patients with active acne vulgaris|
61972972|NCT05783778|EXPERIMENTAL|Toxoplasmosis seronegative in female patients with active acne vulgaris|
62709521|NCT01295489||Group B (IP catheter in place)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolations) before courses two and three for translational research.
62513226|NCT01371084|EXPERIMENTAL|Physical activity treatment group|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
61972973|NCT03704207|OTHER|Nasal Nitric Oxide testing and collection of clinical data|Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data
61972974|NCT03584711|EXPERIMENTAL|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
62147145|NCT05260944|EXPERIMENTAL|Group B|Thirty patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days(André L.et al., 2016), in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration).
62513227|NCT01371084|PLACEBO_COMPARATOR|Wait List Control|
61972975|NCT02059460|EXPERIMENTAL|Terlipressin group|Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
61972976|NCT02059460|PLACEBO_COMPARATOR|Control group|
62513228|NCT00183586|EXPERIMENTAL|1|Participants will receive family-based treatment
61972977|NCT03982823|EXPERIMENTAL|Hand-Sewn Sleeve Gastrectomy|
61972978|NCT03982823|ACTIVE_COMPARATOR|Stapled Sleeve Gastrectomy|
61972979|NCT00865124|EXPERIMENTAL|Spironolactone (mineralocorticoid receptor [MR] blockade)|
61972980|NCT00865124|ACTIVE_COMPARATOR|Hydrochlorothiazide + potassium|
61972981|NCT00865124|PLACEBO_COMPARATOR|Placebo capsule|
61972982|NCT01285674|EXPERIMENTAL|Intra-tympanic steroid injection|
61972983|NCT01486251|EXPERIMENTAL|experimental|"axitinib will be given BID orally. One cycle is defined as a 14-day period (7 days ON / 7 days OFF). The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade \> 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
61972984|NCT00799240|ACTIVE_COMPARATOR|Arm A Pemetrexed Cisplatin|Arm A: Pemetrexed, cisplatin: pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days. Patients will be treated for a maximum of 6 cycles.
61972985|NCT00799240|EXPERIMENTAL|Arm B Permetrexed, Cisplatin, MK-0646|Pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days in combination with MK-0646 given IV, 10 mg/Kg, Days 1, 8 and 15 weekly
62513229|NCT00183586|ACTIVE_COMPARATOR|2|Participants will receive individual adolescent focused therapy
62539454|NCT05971940|EXPERIMENTAL|Orforglipron Dose 3|Participants will receive orforglipron orally.
62539455|NCT05971940|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally.
61972986|NCT06144489|ACTIVE_COMPARATOR|Low Dose|Low dose (3g) of Vistula tart cherry, freeze dried. 60-78 mg of anthocyanins, 8.07 kcal and had a macronutrient content of 1.215 g, 0.003 g, 0.042 g, for carbohydrates, fat and protein, respectively.
62709522|NCT04147273|OTHER|Evaluation of CGM compared with standard measurements|Two products were studied: white bread (Butter Toast®, Golden Toast, Wittenberg, Germany) and whole grain bread (1688 Mehrkorn®, Harry-Brot, Schenefeld, Germany). One portion (containing 50 g digestible carbohydrates) was eaten immediately before the beginning of the test in the morning after an overnight fast of at least 10 h. Before testing, participants ate as usual on the previous day without a standard meal and refrained from consuming alcohol and exercising for 72 h. A 200-ml glucose drink (Accu-Chek Dextrose O.G.-T. Saft®, Roche Diabetes Care, Mannheim, Germany), containing also 50 g of carbohydrates, was used as the reference product.
62709523|NCT00822276||ADEH+ participants colonized with MSSA|
61972987|NCT06144489|ACTIVE_COMPARATOR|High Dose|High dose (6g) of Vistula tart cherry, freeze dried. 120-156 mg of anthocyanins, 16.14 kcal with 2.43 g, 0.006 g, 0.08 g for carbohydrates, fat and protein, respectively.
61972988|NCT06144489|PLACEBO_COMPARATOR|Placebo|Matched with the active low dose, this placebo was matched for calorific content.
61972989|NCT05872646|EXPERIMENTAL|patient group|parkınson patient group
62709524|NCT00822276||ADEH+ participants colonized with MRSA|
62709525|NCT00822276||Uncolonized ADEH+ participants|
62709526|NCT00822276||ADEH- participants colonized with MSSA|
62709527|NCT00822276||ADEH- participants colonized with MRSA|
61972990|NCT05872646|OTHER|healthy group|age-gender matched healthy group
61972991|NCT01934530|ACTIVE_COMPARATOR|Connective Tissue Graft - Control|The donor tissue was harvested from tissue palatal to maxillary premolars and anterior to the mesial of the first molars. A horizontal incision corresponding to the width of the recipient bed plus 4mm was made 3 mm apical to the gingival margin. A small secondary vertical incision was tolerated on the mesial aspect of the surgical site to allow for a split thickness technique. The flap was then positioned over the graft and sutured with attempts to cover the grafted tissue to 2mm coronal to the implant/abutment interface pending flap tension. Follow up was monitored over 6 months at various time-points.
62709528|NCT00822276||Uncolonized ADEH- subjects|
61972992|NCT01934530|EXPERIMENTAL|Alloderm - Test|ADM graft was prepared according to the manufacturer's instructions. The preparation requires rehydration in 50ml sterile saline or Ringers Solution for five minutes and repeated twice. The graft was then transferred to the recipient bed with the basement membrane side facing up and connective tissue on the periosteum. The allograft was trimmed to cover the defect dimensions up to the implant-abutment interface. There was a 4mm margin added to the width on each side to account for lateral contraction as with the connective tissue. With sterile moist gauze, pressure was applied to the graft for proper adaptation to the wound bed. The graft was sutured with a single sling and the flap with a double sling. Simple interrupted sutures were used to close vertical releases.
61972993|NCT00760578|PLACEBO_COMPARATOR|Placebo|Microcrystaline cellulose once daily
61972994|NCT00760578|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 45 mg once daily
61972995|NCT00760578|EXPERIMENTAL|MSDC-0160 90 mg|MSDC-0160 90 mg once daily
62709529|NCT00822276||Non-atopic uncolonized S. aureus participants|
61972996|NCT00760578|EXPERIMENTAL|MSDC-0160 220 mg|MSDC-0160 220 mg once daily
61972997|NCT04537767|EXPERIMENTAL|ES group|Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.
61972998|NCT04537767|PLACEBO_COMPARATOR|control group|Patients randomly assigned to the control group were treated with placebo.
61972999|NCT02564289||Healthy Chronic snus users|Healthy subjects that used snus for more than 15 years.
61973000|NCT02564289||Healthy Controls|Healthy subjects that are never-users of snus.
61976329|NCT04053192||Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)|(Pmean \<40mmHg, AVA \<1cm\^2, Vmax \<4m/s, EF \<50%)
62709530|NCT01006161|EXPERIMENTAL|Low dose SCH 527123|
62709531|NCT01006161|EXPERIMENTAL|Medium dose SCH 527123|
62709532|NCT01006161|EXPERIMENTAL|High dose SCH 527123|
62709533|NCT01006161|PLACEBO_COMPARATOR|Placebo|
62709534|NCT05425160|EXPERIMENTAL|Progressive lower limb activities (Chair rise and Step ups)|Chair rise and Step ups Exercises
62709535|NCT05425160|ACTIVE_COMPARATOR|Standard aerobic exercise i.e. low intensity walking|aerobic exercise i.e. low intensity walking
62709536|NCT01444781|EXPERIMENTAL|Study Group 1|Participants previously primed with DTaP-IPV-Hep B-PRP\~T, will receive one dose of DTaP-IPV-Hep B-PRP\~T vaccine + one dose of Prevenar™
62709537|NCT01444781|ACTIVE_COMPARATOR|Study Group 2|Participants previously primed with DTaP-IPV-Hep B-PRP\~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
62709538|NCT01444781|EXPERIMENTAL|Study Group 3|Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP\~T + one dose of Prevenar™.
62709539|NCT03315585|EXPERIMENTAL|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
62709540|NCT00536289|ACTIVE_COMPARATOR|1|Sharp needles
62709541|NCT00536289|EXPERIMENTAL|2|Blunt tipped needles
62709542|NCT05182918||Patients in OMT and other SUD treatment|Patients in opioid maintenance treatment and other substance use disorder treatment
62709543|NCT05732064|EXPERIMENTAL|Dexmedetomidine and esketamine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) and esketamine 0.2 mg/kg (25 mg/ml) are administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
62709544|NCT05732064|PLACEBO_COMPARATOR|Normal saline|Same volumes of normal saline are administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
62709545|NCT04603183|EXPERIMENTAL|Interventional Arm (Arm A)|Abemaciclib 150 mg orally twice daily (BID) during each 28 day cycle combined with ET (2.5 mg letrozole, orally administered and taken daily during each 28-day cycle, or 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter.
62709546|NCT04603183|ACTIVE_COMPARATOR|Control Arm (Arm B)|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
61973001|NCT06245330|EXPERIMENTAL|Dose escalation phase|AST-001 (5.0 mg/m\^2 to 40.0 mg/m\^2) will be administered by IV infusion on Days 1, 8 and 15 of each 28-day cycle to determine the MTD and RP2D with a BOIN design.
61973002|NCT06245330|EXPERIMENTAL|phase II pancreatic cancer|AST-001 (RP2D) will be administered by IV infusion on Days 1, 8 and 15 of each 28-day cycle
61973003|NCT05586529|EXPERIMENTAL|Cholecalciferol group|patients will recieve one dose of Vitamin D 200000 IU PO at the time of admission
61973004|NCT05586529|NO_INTERVENTION|Control|Patients will not recieve any vitamin D before admission
62709547|NCT03312647||Latent tuberculosis infection|Identified subjects with latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays. All enrolled subjects were treated with one of the recommended regimens for LTBI treatment: 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid plus rifampin. Blood, urine sampling, and monitoring frequencies of adverse reactions of anti-TB drugs were performed.
62709548|NCT03694028|EXPERIMENTAL|Limb Loading|This group will be exposed to a sudden unilateral lowering of the supporting surface to induce lateral weight transfer of the paretic limb.
62709549|NCT03694028|ACTIVE_COMPARATOR|Conventional Training|This group will practice weight shifting and step training that focuses on the paretic limb.
62709550|NCT00991640|NO_INTERVENTION|Control|No intervention
62709551|NCT00991640|EXPERIMENTAL|Preceptorships|Preceptorships with e-learning
62709552|NCT05314660|EXPERIMENTAL|Silver diamine fluoride group|Application of 38% SDF.
62709553|NCT05314660|EXPERIMENTAL|Atrumatic restorative technique|
62709554|NCT05314660|EXPERIMENTAL|Ultra conservative treatment (UCT)|
62709555|NCT00790673|EXPERIMENTAL|1|CF102 1 mg qd
62709556|NCT00790673|EXPERIMENTAL|2|CF102 1 mg bid
62709557|NCT00790673|EXPERIMENTAL|3|CF102 1 mg bid; 16 weeks
61973005|NCT02041468||Pharmacoeconomic main study|Patients from Quebec and Ontario (first or second line treatment)
62709558|NCT00790673|PLACEBO_COMPARATOR|5|
62709559|NCT05185076|EXPERIMENTAL|CureSight eye-tracking-based|Device: CureSight Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
62709560|NCT05185076|ACTIVE_COMPARATOR|Patching occlusive deprivation|"Device: Patching Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
61973006|NCT02041468||Biomarker sub-study|Patients from Quebec only (first or second line treatment)
61973007|NCT02543645|EXPERIMENTAL|Varlilumab and Atezolizumab|
61973008|NCT00064844|PLACEBO_COMPARATOR|Nicotine patch plus placebo gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
61973009|NCT00064844|ACTIVE_COMPARATOR|Nicotine patch plus active gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
61973010|NCT04080297|EXPERIMENTAL|100 mg Q-122|10 patients treated with Q-122, 100 mg. Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.
61973011|NCT04080297|EXPERIMENTAL|200 mg Q-122|11 patients treated with Q-122, 200 mg. Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.
61973012|NCT04057391||QT Scanner in comparison to mammography|Women who have experience with both technologies (QT Scanner/Breast mammography
62709561|NCT05458960|EXPERIMENTAL|Arm 1: Social needs navigator program|Participants will be paired with a community health worker who will provide tailored support to address unmet social needs. The number and frequency of calls will be limited only by participants' needs, interest, and willingness to interact. The type of contact could include phone calls, or home/community visits. The community health worker will: (1) identify and assess patients' unmet social needs; (2) jointly generate solutions; (3) help prioritize among multiple needs; (4) identify community resources that could help resolve the problem(s); (5) determine eligibility for services; (6) help patients access available resources by scheduling appointments and providing appointment reminders; (7) prepare patients to interact with service agencies and/or act as an advocate; (8) provide support such as arranging transportation; (9) oversee follow-up problem-solving actions; and (10) review progress made towards resolving unmet social needs and adapt solutions.
62709562|NCT05458960|ACTIVE_COMPARATOR|Arm 2: Enhanced usual care|Participants will receive verbal referral to a federally funded, free, 24-hr assistance hotline, United Way 2-1-1, which connects callers with community services to help address unmet social needs.
62709563|NCT05458960|NO_INTERVENTION|Arm 3: Clinic provider|4 WUSM colposcopy providers, 4 staff members, and 1 community health worker will be surveyed to assess potential for dissemination.
62709564|NCT05951907|ACTIVE_COMPARATOR|control group|A control group in which the extraction of the maxillary premolar's teeth was carried out under buccal and palatal infiltration anesthesia with 1.8 mL 2% lidocaine hydrochloride with 1:80,000 epinephrine.
62709565|NCT05951907|EXPERIMENTAL|study group|A study group in which the extraction of the maxillary premolar's teeth proceeded under buccal without palatal infiltration anesthesia with 1.8 mL, 4% articaine hydrochloride with 1:100,000 epinephrine.
62709566|NCT03790748|EXPERIMENTAL|Conventional Epidural Technique|Procedure: Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L4-5 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
62709567|NCT03790748|ACTIVE_COMPARATOR|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|Procedure: 25G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
62709568|NCT03790748|ACTIVE_COMPARATOR|Dural Puncture Epidural Technique using pencil-point 27G Whitacre needle|Procedure: 27G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
62709569|NCT01287299|EXPERIMENTAL|Low Glycemic Load Diet|Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.
61973013|NCT02598076|ACTIVE_COMPARATOR|control|Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
62353534|NCT05130372|ACTIVE_COMPARATOR|PNF Stretching Method Group|The person was positioned supine, and the ankle joint was dorsiflexed by the physiotherapist to the point where the tension was felt. Then, while the person was trying to push the foot towards the plantarflexion direction for 10 seconds, the movement was prevented by the physiotherapist and isometric contraction was achieved at 20% of the maximum voluntary contraction. After 10 seconds, the person was asked to relax slowly and passive stretching was applied to the plantar flexors for 20 seconds. The contract-relax technique was applied for 30 seconds and completed with 3 repetitions (3x30sec) with 15-second rest intervals.
62709570|NCT01287299|EXPERIMENTAL|Low Fat Diet|Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.
62709571|NCT06032039|ACTIVE_COMPARATOR|Corticosteroid Injection|This arm will receive a corticosteroid (Triamcinalone) injection.
62709572|NCT06032039|ACTIVE_COMPARATOR|Platelet Rich Plasma Injection (PRP)|This arm will receive a PRP injection.
62709573|NCT01078948|EXPERIMENTAL|Active 2mA tDCS|The stimulator will be used to deliver anodal stimulation to the left prefrontal cortex and cathodal stimulation to the right prefrontal cortex. The placement of the anode is proposed to enhance activity in the left frontal cortex; the cathode aims to reduce activity in the right prefrontal cortex.
62709574|NCT01078948|SHAM_COMPARATOR|Sham tDCS|The system setup is identical to that of active tDCS; however, the stimulator will be turned off after 30 seconds.
62709575|NCT01217034|EXPERIMENTAL|TACE with sorafenib|TACE(on demand) with sorafenib till untreatable progression
62709576|NCT01217034|ACTIVE_COMPARATOR|TACE alone|TACE(on demand) till unreatable progression
62709577|NCT04235309||Total Knee Replacement Cohort|Any patients who are scheduled to undergo a total knee replacement.
62709578|NCT06058091|PLACEBO_COMPARATOR|Phase II-Placebo group|Receive the best basic treatment
62709579|NCT06058091|EXPERIMENTAL|Phase II-low-does group|Receive the best basic treatment and a million cells per kilogram of body weight
62709580|NCT06058091|EXPERIMENTAL|Phase II-high does group|Receive the best basic treatment and two million cells per kilogram of body weight
61976330|NCT04053192||Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)|Pmean \<40mmHg, AVA \<1cm\^2, Vmax \< 4m/s, EF \>50%)
61976331|NCT00763308|EXPERIMENTAL|1|Participants will use the Web-based Heart Healthy program.
61976332|NCT00763308|NO_INTERVENTION|2|Participants will receive treatment as usual.
61976333|NCT04399577|EXPERIMENTAL|Wart Patients|Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
62353535|NCT05130372|ACTIVE_COMPARATOR|Myofascial Relaxation Method Group|A comfortable position was achieved by placing a rolled towel on the front of the ankle. The roller was massaged along with the plantar flexors for 30 seconds. The movement of the cylinder from bottom to top and from top to bottom was done for a second. Three repetitions were completed (3x30sec) with a 15-second rest break. For the pressure of the roller to be stable during the application, the numbered pain scale was shown to the participants, and attention was paid to ensure that the perceived severity was 7/10 according to the numbered pain scale. Participants with dry skin in the application area were asked to moisturize with cream beforehand to avoid complications.
62353536|NCT02703987|EXPERIMENTAL|Group I|Fermented infant milk formula
62353537|NCT02703987|ACTIVE_COMPARATOR|Group II|Non-fermented infant milk formula
62353538|NCT03611998|EXPERIMENTAL|Survivors of Sex Trafficking|Survivors of sex trafficking (SST) who were living in a residential facility participated in this project by receiving occupation-based programming to address limitations in executive function skills over the course of the 8-month project. Sessions were held twice-monthly for an hour duration at each session.
62353539|NCT00828503|ACTIVE_COMPARATOR|1 Certican + Valganciclovir|Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
62353540|NCT00828503|ACTIVE_COMPARATOR|2 Valganciclovir alone|Valganciclovir will be added alone.
62353541|NCT03235375|EXPERIMENTAL|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl \<20ml/min will receive MEDI0382 administered subcutaneously
62353542|NCT03235375|EXPERIMENTAL|Group 2: Severe and ESRD Subjects|Subjects with CrCl \>20 and \< 30 ml/min will receive MEDI0382 administered subcutaneously
62353543|NCT03235375|ACTIVE_COMPARATOR|Group 3: Healthy Subjects|Subjects with CrCl \>90 ml/min will receive MEDI0382 administered subcutaneously
62353544|NCT03235375|EXPERIMENTAL|Group 4: Moderate Renal Disease|Subjects with CrCl \> or equal to 30 and \< 60 mL/min will receive MEDI0382 administered subcutaneously
62353545|NCT05295745|EXPERIMENTAL|Cognitive remediation therapy and multidisciplinary intervention|The participants (obese adults) in the experimental group will receive treatment with cognitive remediation therapy, nutritional and physical activity instruction through 18 weekly sessions of intervention.
62353546|NCT05295745|NO_INTERVENTION|Control|The control group participants will not receive the treatment until the experimental group participants complete the intervention and carry out the measurements
62353547|NCT01259635|EXPERIMENTAL|Bio feedback for freezing|When ever freezing occures, a metronom sound will be heard
62709581|NCT03950232|EXPERIMENTAL|Etrasimod 2 mg|
62709582|NCT01216488|ACTIVE_COMPARATOR|40 ml of Xylocaine|
62709583|NCT01216488|EXPERIMENTAL|25 ml of Xylocaine|
62709584|NCT01907893|EXPERIMENTAL|Trauma Collaborative Care Plus Treatment as Usual|Three components: (1) Services provided through the Trauma Survivors Network (TSN) Program; (2) Provider training to reinforce referral to and use of TSN programs; and (3) Enhancement of collaborative care through the use of a TSN Coordinator (TSN-C).
62709585|NCT01907893|NO_INTERVENTION|Treatment as Usual|Study patients treated at Control Sites will have access to all services typically available to patients treated at these centers.
62709586|NCT02012517|ACTIVE_COMPARATOR|short antibiotic course|Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery
62709587|NCT02012517|EXPERIMENTAL|Prolonged antobiotic treatment|Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
62709588|NCT00992550|EXPERIMENTAL|Hookah visit, then cigarette visit|4-day inpatient stays for profile of biomarker excretion
62709589|NCT00992550|EXPERIMENTAL|Cigarette visit, then Hookah visit|4-day inpatient stay for profile of biomarker excretion
62709590|NCT00133445|EXPERIMENTAL|Group A|Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
62709591|NCT00133445|ACTIVE_COMPARATOR|Group B|Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
62709592|NCT02629861|PLACEBO_COMPARATOR|Placebo|Matching Placebo
61973014|NCT02598076|EXPERIMENTAL|MI|"Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms)."
62147146|NCT05260944|ACTIVE_COMPARATOR|Group C|Thirty patients will receive only routine physical Therapy program.
61973015|NCT01011634|ACTIVE_COMPARATOR|Moderate sedation|
61973016|NCT01011634|ACTIVE_COMPARATOR|Oral medication|
62147147|NCT04787198|EXPERIMENTAL|hypertonic saline|
62147148|NCT04787198|PLACEBO_COMPARATOR|isotonic saline|
62353548|NCT04675606|ACTIVE_COMPARATOR|Low fiber diet|Patients in this arm will receive low fiber diet starting postoperative day 1. This is currently the standard protocol at our institution.
62353549|NCT04675606|EXPERIMENTAL|Regular diet|Patients in this arm will receive regular diet starting postoperative day 1. This will be the experimental arm.
61973017|NCT00727181|OTHER|Trifecta Valve|The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.
61973018|NCT05522101|EXPERIMENTAL|Mini-sized MCE|AKES-31SW Capsule Endoscopy
61973019|NCT05522101|PLACEBO_COMPARATOR|Normal sized CE|PillCam Capsule Endoscopy
61973020|NCT02818686|EXPERIMENTAL|TD-1473 low dose|10 subjects will be randomized to receive low-dose TD-1473 orally daily for 28 days
61973021|NCT02818686|EXPERIMENTAL|TD-1473 mid dose|10 subjects will be randomized to receive mid-dose TD-1473 orally daily for 28 days
61973022|NCT02818686|EXPERIMENTAL|TD-1473 high dose|10 subjects will be randomized to receive high-dose TD-1473 orally daily for 28 days
62353550|NCT04600687|EXPERIMENTAL|Intervention Arm|Participants will be enrolled in a single arm with a cross over design. Each participant will receive both placebo tablets about 30 minutes apart. Questionnaires will be completed prior to and after each placebo tablet is swallowed.
62353551|NCT04871230||Pregnant women suspected TB|This group enrolled as cases
62353552|NCT04871230||Pregnant women without signs suspected TB|This group enrolled as controls
62709593|NCT02629861|EXPERIMENTAL|Fremanezumab 675 mg/placebo/placebo|Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
61973023|NCT02818686|PLACEBO_COMPARATOR|Placebo|10 subjects will be randomized to receive placebo orally daily for 28 days
61973024|NCT02298803|OTHER|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
61973025|NCT03991715|EXPERIMENTAL|Activity Tracker|Participants provided an activity tracker to wear and weekly reports
62147149|NCT03516071|EXPERIMENTAL|Brivanib 800 mg, QD + BSC|
62147150|NCT03516071|EXPERIMENTAL|Brivanib 400 mg, BID + BSC|
62147151|NCT01536704|EXPERIMENTAL|Test nicotine lozenge (2 mg)|2 mg test nicotine lozenge to be chewed.
62147152|NCT01536704|EXPERIMENTAL|Test nicotine lozenge (4 mg)|4 mg test nicotine lozenge to be chewed.
62147153|NCT01536704|ACTIVE_COMPARATOR|Reference nicotine lozenge (2 mg)|2 mg reference nicotine lozenge to be chewed.
62147154|NCT01536704|ACTIVE_COMPARATOR|Reference nicotine lozenge (4 mg)|4 mg reference nicotine lozenge to be chewed.
62147155|NCT02522104|EXPERIMENTAL|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
62709594|NCT02629861|EXPERIMENTAL|Fremanezumab 225/225/225 mg|Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.
62709595|NCT01352429||Phase 1 Feasibility|
62709596|NCT01352429||Phase 2 Registration|
62709597|NCT04322461|EXPERIMENTAL|Parkinson disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
62709598|NCT04322461|EXPERIMENTAL|Alzheimer's disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
62709599|NCT04068805|ACTIVE_COMPARATOR|Positive affect condition|Participants use Happify and have the option to use a diabetes-specific track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
62709600|NCT04068805|SHAM_COMPARATOR|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
61973026|NCT05939986|EXPERIMENTAL|Multimodal Virtual Reality Exposure Treatment (VRET-M)|VRET with multimodal feedback including visual, auditory and vibrotactile cues.
61973027|NCT05939986|ACTIVE_COMPARATOR|Bimodal Virtual Reality Exposure Treatment (VRET-B)|VRET with bimodal feedback including visual and auditory cues.
61973028|NCT05939986|ACTIVE_COMPARATOR|Imagery Exposure Treatment (IET)|Imagery exposure treatment without sensory cues.
62147156|NCT02522104|EXPERIMENTAL|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR \> 130 mL/min/1.73m2 in women and GFR \> 140 mL/min/1.73m2 in men.
62709601|NCT02030626|EXPERIMENTAL|active rTMS or active tDCS or placebo|Active rTMS (10 Hz) of the motor cortex followed by active tDCS (2 mA) of the motor cortex or conversely
62709602|NCT02030626|PLACEBO_COMPARATOR|Sham rTMS followed by tDCS (or conversely)|Placebo rTMD followed by placebo tDCS or conversely
62709603|NCT02628535|EXPERIMENTAL|MGD009|Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein
61973029|NCT05860803|NO_INTERVENTION|Control group of standard physician directed care|Subjects will receive pulmonary rehabilitation via standard physician directed care (i.e., 'normal care').
62709604|NCT02100826|ACTIVE_COMPARATOR|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
61973030|NCT05860803|EXPERIMENTAL|Home-based specific breathing and respiratory muscle training group|In addition standard of care pulmonary rehabilitation, subjects will participate in an 8-week home-based specific breathing and respiratory muscle training via the LungTrainers Pulmonary Rehabilitation regime (LT-PR).
61973031|NCT05819515|ACTIVE_COMPARATOR|Connective Tissue Graft|A connective tissue graft from the patient's palate will be used
61973032|NCT05819515|EXPERIMENTAL|Allogenic Dermal Matrix with Platelet-Rich Fibrin|An allogenic dermal matrix with the patient's platelet-rich fibrin will be used
61973033|NCT00004196|EXPERIMENTAL|AI|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Patients receive adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks, then subcutaneously 3 times a week for 48 weeks
61976334|NCT03206853|EXPERIMENTAL|Hybrid operation group|Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion.
62147157|NCT02522104|EXPERIMENTAL|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
62147158|NCT04689932|EXPERIMENTAL|Pre- Dialyzer Infusion and Post- Dialyzer Infusion|On study day 1, day 3 and day 5, patients will receive 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the pre-dialyzer blood line. On study day 2, day 4 and day 6, patients will receive the 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the post dialysis blood line.
62147159|NCT02309892|EXPERIMENTAL|Pemetrexed and Carboplatin plus L-DOS47|Patients will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort for the first and last two dosing cohorts, and a minimum of 1 and a maximum of 2 patients for the middle three dosing cohorts. The starting dose of L-DOS47 will be 0.59 µg/kg; further planned dose levels to be assessed are 0.78, 1.5, 3.0, 6.0, 9.0 and 12.0 µg/kg. The standard of care doses of pemetrexed \[500 mg/m2\] and carboplatin \[AUC6\], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
62147160|NCT01443156||Caregivers|Employees at a local medical facility, including (but not limited to): nurses, laboratory technicians, non-clinical hospital staff
62147161|NCT02068053|EXPERIMENTAL|Arm A - BMS-986020|600 mg (approximately 80 micro Curie) of \[14C\] BMS-986020 Single Dose for 1 Day (Day 1) orally
62147162|NCT05333666||Age over 20 years and under non-vitamin K antagonist oral anticoagulant therapy|
62353553|NCT04751968|EXPERIMENTAL|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
62353554|NCT04751968|OTHER|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
62353555|NCT05143944||Nice clinical guidelines for intrapartum care for healthy women and babies|define gold standards in intrapartum care for healthy women and babies
62353556|NCT05143944||performance in the care provided to patients in periods of audit|measure performance in the care provided to the patients in the period of audit
62353557|NCT00250406|ACTIVE_COMPARATOR|1|Percuflex Plus Ureteral Stent
62353558|NCT00250406|EXPERIMENTAL|2|TRIUMPH stent (triclosan-eluting stent)
62709605|NCT02100826|EXPERIMENTAL|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
62709606|NCT01373281|EXPERIMENTAL|Dengue Vaccine Group|Participants were to receive CYD dengue vaccine at 0, 6, and 12 months.
62709607|NCT01373281|PLACEBO_COMPARATOR|Control Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
62709608|NCT01677988|EXPERIMENTAL|Chemotherapy, Chemoradiation, Surgery|Neoadjuvant Chemotherapy- Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles for 3 cycles with growth factor support Chemoradiation Surgical Resection
62709609|NCT02896205|EXPERIMENTAL|Mycophenolate mofetil|Subjects will be started on Mycophenolate Mofetil 500mg twice a day and increased by 500mg every 2 weeks, if tolerated, to a target dose of 2gram per day.
62147163|NCT02476929|ACTIVE_COMPARATOR|Nasal nitrous oxide|Mesurement of Nasal nitrous oxide in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group
62147164|NCT02476929|ACTIVE_COMPARATOR|Electronic nose|Measurement with the Electronic nose in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group.
62513230|NCT04514055|EXPERIMENTAL|De-epithelialized connective tissue graft wall|"Simplified papilla preservation flap will be applied in the narrow interproximal spaces (≤2 mm), where an oblique incision starting from the gingival margin at the buccal-line angle of the involved tooth reaching the mid-interproximal portion of the papilla under the contact point of the adjacent tooth will be performed using a 15c blade.~A free gingival graft will be obtained from the hard palate and de-epithelized extra-orally.~A Coronally advanced flap will be performed. The de-epithelialized FGG will be sutured coronally using a 6-0 vicryl suture to the anatomical papillae of the two teeth adjacent to the defect and apically to the periosteum left in place apical to the exposed bone.~The flap will be sutured using internal Horizontal mattress suture at the base of the simplified papilla and a vertical mattress suture will be placed in a more coronal position so complete soft tissue closure can be obtained."
62513231|NCT02215148||Brain injured patients with hyponatremia|Patients with acute brain injury who develop hyponatremia and are administered tolvaptan via the nasogastric tube, deemed necessary by the primary medical team.
62513232|NCT04206228|ACTIVE_COMPARATOR|Active treatment|Active drug: Intravenous iron isomaltoside dissolved in 100 ml NaCl 0.9 %
62513233|NCT04206228|PLACEBO_COMPARATOR|Placebo|Placebo: Intravenous NaCl 0.9 % dissolved in 100 ml
62513234|NCT01884688|EXPERIMENTAL|ENK Cell Infusion|Expanded Natural Killer Cell Infusion
62513235|NCT05333224|EXPERIMENTAL|Telerehabilitation|A telerehabilitation-based exercise group where the therapist coaches the family, performs one-on-one exercises with families with a doll in his hand, and can perform the necessary interventions such as promoting good practices and preventing bad practices, and the other 2 days where the families show their exercises by sending videos to the therapist, and again provide the therapist's intervention and follow-up via videos
62513236|NCT05333224|OTHER|Control|The control group that will be given exercise training in 1., 4., 8., and 12. week.
62513237|NCT05298787|EXPERIMENTAL|SAD - 2mg/kg or placebo IV infusion|Single IV infusion
62513238|NCT05298787|EXPERIMENTAL|SAD - 10mg/kg or placebo IV infusion|Single IV infusion
62513239|NCT05298787|EXPERIMENTAL|SAD - 40mg/kg or placebo IV infusion|Single IV infusion
62513240|NCT05298787|EXPERIMENTAL|MAD - 2mg/kg or placebo IV infusion|IV infusion given every 8 hours over 3 days for a total of 9 doses
62513241|NCT05298787|EXPERIMENTAL|MAD - 10mg/kg or placebo IV infusion|IV infusion given every 8 hours over 3 days for a total of 9 doses
62513242|NCT05298787|EXPERIMENTAL|SAD - 120mg/kg or placebo IV infusion|Single IV infusion
62513243|NCT05298787|EXPERIMENTAL|MAD - 40mg/kg or placebo IV infusion|IV infusion given every 8 hours over 3 days for a total of 9 doses
62513244|NCT03581188|EXPERIMENTAL|Patient-led surveillance|Participants receive a mobile dermatoscope that attaches to their smartphone to take photos of skin lesions for teledermatology, instructions on skin self-examination from the ASICA skin checker App, text and email reminders to perform self-examination every 2 months, an educational booklet 'Your guide to early melanoma', and scheduled visits to their clinician as required.
62513245|NCT03581188|ACTIVE_COMPARATOR|Clinician-led surveillance|Participants receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
62513246|NCT02970552|ACTIVE_COMPARATOR|Vaginal Progesterone|Daily self-administered vaginal progesterone
62513247|NCT02970552|PLACEBO_COMPARATOR|Placebo|Daily self-administered indistinguishable placebo
62513248|NCT04421092|EXPERIMENTAL|Steroid-Lidocaine Mixture|Will receive numbing injection, which is a mixture of steroid and lidocaine
62513249|NCT04421092|PLACEBO_COMPARATOR|Placebo|Will receive saline injection as a placebo
62513250|NCT00588328|EXPERIMENTAL|1|
62709610|NCT02896205|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will be given matching placebo, made of lactulose, starting at two tablets per day and increased by one tablet every 2 weeks to a target of 4 tablets per day.
61976335|NCT03206853|OTHER|Traditional therapy group|The aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.
62513251|NCT03405376|EXPERIMENTAL|Branch retinal vein occlusion|Aflibercept 2mg is injected into the vitreous cavity. Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
62513252|NCT04217655|EXPERIMENTAL|Low-dose computed tomography group|Patients undergo low-dose computed tomography-guided lung biopsy for lung nodule on day 1.
62513253|NCT04217655|ACTIVE_COMPARATOR|Standard-dose computed tomography group|Patients undergo standard-dose computed tomography-guided lung biopsy for lung nodule on day 1.
62513254|NCT03009487|EXPERIMENTAL|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
62513255|NCT03009487|PLACEBO_COMPARATOR|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
62513256|NCT03009487|PLACEBO_COMPARATOR|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
62513257|NCT00206102|EXPERIMENTAL|1|Quetiapine fumarate
62513258|NCT00206102|ACTIVE_COMPARATOR|2|Risperidone
62513259|NCT03658473|ACTIVE_COMPARATOR|Treatment A|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
62513260|NCT03658473|ACTIVE_COMPARATOR|Treatment B|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole 1x daily over 7 days.
62513261|NCT03658473|ACTIVE_COMPARATOR|Treatment C|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
62513262|NCT03658473|PLACEBO_COMPARATOR|Treatment D|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
62513263|NCT01096979|EXPERIMENTAL|LIPO-102, High|LIPO-102, High
62513264|NCT01096979|EXPERIMENTAL|LIPO-102, Low|LIPO-102, Low
62513265|NCT01096979|EXPERIMENTAL|Placebo|Pbo
61976336|NCT03829150|EXPERIMENTAL|Dexlansoprazole MR group|Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
62147165|NCT01883063|EXPERIMENTAL|WRx™ Intramedullary Nail|Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
62147166|NCT01883063|ACTIVE_COMPARATOR|Non surgical treatment (Cast)|Patients in this arm of the study will be treated with a cast for their wrist fracture.
62147167|NCT03031509|EXPERIMENTAL|hAECs treatment|Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
62513266|NCT00616044|EXPERIMENTAL|CSA|For CSA, an 22-G catheter (Spinocath, B.Braun Melsungen, Germany) over a 27-G Quincke needle was used. After identification of the epidural space with a Crawford needle, the catheter with the spinal needle inside was advanced through the epidural space until the dural puncture was felt and CSF was seen in the catheter. The catheter was then fed over the needle into the intrathecal space. The spinal needle and the modified Tuohy needle were removed and a luer connector and a filter previously filled with the anesthetic solution were attached to the catheter.
62539456|NCT05336383|EXPERIMENTAL|Radiation Therapy|Radiation treatment will be to bony or soft tissue plasmacytomas in up to five radiation treatment fields to 10-20Gy (or equivalent dose in 2Gy fractions of 10-21Gy
62353559|NCT02212145||Screened group|Screened group is defined as those individuals who were willing to participate in the cardiovascular prevention program and all the individuals who lived in Sollentuna during the intervention.
62353560|NCT02212145||Relatives to the screened group|Relatives to individuals included in the screened group, who lived in Stockholm County at least during one year at the time of the intervention.
62353561|NCT02212145||Control group|"Matched controls is going to be selected randomly from the population of Stockholm County minus Sollentuna Municipality with relevant background factors. The whole population will be used as a comparison group when evaluating the result from all the municipality of Sollentuna during 1988-1993."
62353562|NCT02302144|EXPERIMENTAL|Early Multi-Ex-PD|Immediately following enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
62353563|NCT02302144|EXPERIMENTAL|Late Multi-Ex-PD|Three months after enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
62353564|NCT00966693|EXPERIMENTAL|Treatment (lenalidomide, thalidomide, dexamethasone)|"Participants receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Participants also receive dexamethasone PO QD on days 1-4, 9-12, and 17-20 of courses 1-2, and days 1, 8, 15, and 22 of subsequent courses. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Participants who have stable or responding disease to treatment receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants may receive dexamethasone at the discretion of the investigator."
62353565|NCT02234557|EXPERIMENTAL|Tai Chi|Tai Chi instruction, 1 hour, twice per week Home Tai Chi practice with video, requesting 15-30 minutes, 3 times per week, monitored by practice log
62353566|NCT02481063|ACTIVE_COMPARATOR|Eccentric|6 Weeks Training with eccentric Overload (Squat with Yoyo Technology) 3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
62353567|NCT02481063|ACTIVE_COMPARATOR|Control|3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
62353568|NCT03163108|NO_INTERVENTION|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
62353569|NCT03163108|ACTIVE_COMPARATOR|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
62353570|NCT03163108|EXPERIMENTAL|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
62353571|NCT03645889|EXPERIMENTAL|Paediatric Lung Tonic (PLTG)|Traditional Chinese Medicine (TCM) in granules dosage form to be dissolved for consumption.
62353572|NCT03645889|PLACEBO_COMPARATOR|PLTG Placebo|Starch granules with 10% TCM to mimic the colour, taste and smell of active TCM.
62353573|NCT05862948|EXPERIMENTAL|CADe Colonoscopy|Colonoscopy with the help of CADe system (ENDO-Aid)
62353574|NCT05862948|NO_INTERVENTION|Conventional Colonoscopy|Standard Colonoscopy with white light
62353575|NCT02939599|EXPERIMENTAL|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg~-active patients will continue at the dose they finished on the QCC374X2201 study"
62353576|NCT05138341|EXPERIMENTAL|Mechanical Minimal Invasive Surgical (MIS) management|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
62539457|NCT02263950|EXPERIMENTAL|LON002|(Artemether sublingual spray)
61976337|NCT03829150|EXPERIMENTAL|lansoprazole group|Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
61976338|NCT04791566|ACTIVE_COMPARATOR|Intestinal obstruction, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
61976339|NCT04791566|PLACEBO_COMPARATOR|Intestinal obstruction, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
61976340|NCT04791566|ACTIVE_COMPARATOR|Perforated viscus, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
61976341|NCT04791566|PLACEBO_COMPARATOR|Perforated viscus, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
62709611|NCT00025415|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
62709612|NCT01300026|EXPERIMENTAL|Part II Dose Expansion|Dose selected from Part I dose exploration
62709613|NCT01300026|EXPERIMENTAL|Part I Dose Exploration|The AMG 319 doses proposed for this study are 25, 50, 100, 200, 300 and 400 mg administered by mouth once daily.
62709614|NCT02692196|EXPERIMENTAL|Neurofeedback Training|Neurofeedback training - neurofeedback of fronto-limbic functional connectivity.
61973034|NCT00004196|EXPERIMENTAL|Arm AII|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Observational arm: Patients with metastases in more than one sentinel node with evidence of extracapsular extension or metastasis in any nonsentinel node receive adjuvant high-dose interferon alfa-2b as in arm AI.
62709615|NCT02692196|SHAM_COMPARATOR|Sham Control|Sham training - feedback that is not related with fronts-limbic connectivity (motor connectivity)
62709616|NCT01475721|EXPERIMENTAL|ADVAIR 100/50mcg|experimental drug
62709617|NCT01475721|EXPERIMENTAL|ADVAIR 250/50mcg|experimental drug
62709618|NCT01475721|EXPERIMENTAL|ADVAIR 500/50mcg|experimental drug
62709619|NCT01475721|ACTIVE_COMPARATOR|FLOVENT 100mcg|active comparator
62709620|NCT01475721|ACTIVE_COMPARATOR|FLOVENT 250mcg|active comparator
62709621|NCT01475721|ACTIVE_COMPARATOR|FLOVENT 500mcg|active comparator
61973035|NCT00004196|EXPERIMENTAL|Arm BI|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
61973036|NCT00004196|EXPERIMENTAL|Arm B II|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
61973037|NCT00004196|EXPERIMENTAL|Arm BIII|"Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection followed by adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks.~Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
61973038|NCT00766480|EXPERIMENTAL|Regimen 1|Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on days 1-4 and 29-32. Patients undergo salvage surgery if needed.
61973039|NCT00766480|EXPERIMENTAL|Regimen 2|Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and salvage surgery as in regimen 1.
61973040|NCT03548909||ED Setting|An acute HF population enrolled at EDs. Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
61973041|NCT03548909||Outpatient Setting|A non-acute population enrolled at outpatient centers.Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
62709622|NCT06164158|EXPERIMENTAL|Study Group|Half were made to watch the procedural videos and learn the steps of the procedure and then made to perform procedure
62709623|NCT06164158|EXPERIMENTAL|Control Group|Other half group did not watch the procedural videos and were made to perform procedure.
62709624|NCT01575574|OTHER|GADOXETIC ACID|Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
62709625|NCT02434081|EXPERIMENTAL|Chemo-radiotherapy with concurrent nivolumab|4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.
62709626|NCT03416816|EXPERIMENTAL|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
62709627|NCT04955288|EXPERIMENTAL|Aortic balloon Assisted resuscitation group|The aortic balloon-assisted resuscitation group uses aortic balloon occlusion technology on the basis of the traditional resuscitation mode, that is, when the cardiopulmonary resuscitation begins, the aortic balloon catheter is quickly punctured and inserted to the distal end of the aortic area I via ultrasound. (Septum level), then continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
62709628|NCT04955288|ACTIVE_COMPARATOR|Traditional cardiopulmonary resuscitation group|The traditional cardiopulmonary resuscitation group uses the traditional manual chest compression mode, that is, referring to the latest version of the cardiopulmonary resuscitation guidelines, manual chest compressions are performed under the monitoring of the compression quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, Conditions such as a fixed compression position and sufficient chest wall rebound.
62709629|NCT04955288|EXPERIMENTAL|Esophageal cooling group|The esophageal cooling group adopts a new transesophageal cooling method, that is, an esophageal cooling catheter is placed after resuscitation in patients with cardiac arrest, and then a small temperature-controlled water circulation system is continuously perfused with 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature is adjusted Control the water circulation system to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
62513267|NCT00616044|EXPERIMENTAL|CSE|"CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany). The block consists of performing a spinal block via a 27-G spinal needle (Spinocan 125mm) introduced through an 18-G Tuohy needle (Perican 88mm) which was placed cranially directed in the epidural space. We did rotate the Tuohy needle between the spinal block and the insertion of the epidural catheter."
62513268|NCT05857462|EXPERIMENTAL|Post-admission FICB|Post-admission FICB, drug 0.33% bupivacaine 30 ml + Pre-operative FICB 0.33% bupivacaine 30 ml. Peri-operative pain management protocol : paracetamol + opioid.
62513269|NCT05857462|NO_INTERVENTION|Only preoperative FICB|No post-admission FICB + Pre-operative FICB 0.33% bupivacaine 30 ml. Peri-operative pain management protocol : paracetamol + opioid.
62513270|NCT03469817|NO_INTERVENTION|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
62513271|NCT03469817|OTHER|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
62513272|NCT06290219|EXPERIMENTAL|platelet-rich plasma combined with hyaluronic acid nasal injection|a nasal injection of platelet-rich plasma combined with hyaluronic acid at the first day of the treatment. At the same time, one tablet of zinc gluconate (10mg) three times a day for 12 weeks and traditional olfactory training with 4 separate bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil. Patients were told to sniff each odorant for 10 seconds, twice a day for 12 weeks.
62513273|NCT06290219|ACTIVE_COMPARATOR|Control|one tablet of zinc gluconate (10mg) three times a day for 12 weeks and traditional olfactory training with 4 separate bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove. Patients were told to sniff each odorant for 10 seconds, twice a day for 12 weeks.
62513274|NCT02170350|EXPERIMENTAL|Brief mindful meditation practice|Patients use brief mindful meditation practice (sitting meditation in which the mind is guided to focus in the present, thinking of your existence, and allowing sensations to arise with an openness and curiosity) over 12 minutes daily for 14 days during radiation therapy.
62513275|NCT04049916|ACTIVE_COMPARATOR|Pyronaridine-artesunate (PA)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days.
62513276|NCT04049916|EXPERIMENTAL|PA with single low dose primaquine (PQ)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days, and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
62513277|NCT04049916|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine (DP)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days.
62513278|NCT04049916|ACTIVE_COMPARATOR|DP with single low dose primaquine (PQ)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days., and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
62513279|NCT03504761|EXPERIMENTAL|ClariCore System|ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
61973042|NCT00505531||Tramadol ER- 200mg|Tramadol Extended Release capsules Weeks 1 \& 6- 100 mg/day Weeks 2-5- 200 mg/day
62147168|NCT03031509|SHAM_COMPARATOR|debridement surgery|debridement surgery
62353577|NCT05138341|NO_INTERVENTION|Best Medical Management (MM)|Best medical management per standard of care
62353578|NCT05408117|EXPERIMENTAL|A= left/superior half of wound|Patients with skin of color undergoing dermatologic surgery with planned standard elliptical excision with wound length of 3 cm or greater
62353579|NCT05408117|EXPERIMENTAL|B= right/inferior half of wound|Patients with skin of color undergoing dermatologic surgery with planned standard elliptical excision with wound length of 3 cm or greater
62353580|NCT01525940|OTHER|Colon capsule and CT-colonography|PillCam Colon Capsule Endoscopy (Given® Diagnostic System) ingestion first and CT-colonography about 10-12 hours post-ingestion
62353581|NCT02198651|EXPERIMENTAL|Adalimumab 40 mg eow|40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
62353582|NCT02198651|ACTIVE_COMPARATOR|Adalimumab Tapering|40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
62353583|NCT02198651|PLACEBO_COMPARATOR|Adalimumab Withdrawal Arm|Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
62353584|NCT02198651|EXPERIMENTAL|Adalimumab 40 mg eow Rescue Arm|40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
62353585|NCT02420301|EXPERIMENTAL|Exercises on real points|Self administered exercises were done in real treatment points
62353586|NCT02420301|PLACEBO_COMPARATOR|Exercises on false points|Self administered exercises were done in false treatment points
62353587|NCT04403529|EXPERIMENTAL|Traditional Chinese Medicine|"60 days of oral Traditional Chinese Medicine (prescription for breast cancer Traditional Chinese Medicine formulation)"
62353588|NCT04403529|PLACEBO_COMPARATOR|Placebo|"60 days of oral placebo (placebo contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler)"
62353589|NCT02138149||spinal cord injury|individuals with neurogenic lower urinary tract dysfunction
62353590|NCT02138149||control group|individuals with physiologic bladder function
62353591|NCT02452268|EXPERIMENTAL|NIZ985|"* Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.~* Cycle length 28 days.~* Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.~* MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.~* Following identification of the MTD / RDE, dose expansion will follow."
62513280|NCT05813379|EXPERIMENTAL|exosome injection|The Exosome will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing
62513281|NCT03447886||Quality Of Life|"This study uses qualitative research methods, specifically semi-structured interviews.~* This will include moderator guide development,~* Phone interviews with breast cancer survivors will be conducted~* Qualitative data analysis of the phone interviews will be conducted"
62147169|NCT06309355|EXPERIMENTAL|Active dose|The intervention is YR001 ointment on a range of body surface area for multiple topical administration
62513282|NCT00335335|EXPERIMENTAL|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
62513283|NCT04113824|EXPERIMENTAL|trapezius motion style acupuncture treatment|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
62513284|NCT04113824|ACTIVE_COMPARATOR|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
62513285|NCT04099212||Cases|Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
62513286|NCT03612739|EXPERIMENTAL|Cohort 1|5-azacytidine + 1x10\^8 NKR-2 CAR-T Cells
62513287|NCT03612739|EXPERIMENTAL|Cohort 2|5-azacytidine + 3x10\^8 NKR-2 CAR-T Cells
62513288|NCT03612739|EXPERIMENTAL|Cohort 3|5-azacytidine + 1x10\^9 NKR-2 CAR-T Cells
62513289|NCT01345994|EXPERIMENTAL|Acupuncture - local|acupuncture on forearm only
62513290|NCT01345994|EXPERIMENTAL|acupuncture - distal|acupuncture on both arm and leg
62709630|NCT04955288|ACTIVE_COMPARATOR|Traditional cooling group|The traditional cooling group uses the traditional body surface ice blanket cooling method, that is, the patients with cardiac arrest lie on the temperature control blanket after resuscitation, and then use the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃ After that, adjust the ice blanket host to control the circulating water temperature to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
62709631|NCT01352884|EXPERIMENTAL|Stage 1|Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
61973043|NCT00505531||Tramadol ER- 300mg|Tramadol Extended Release capsules Weeks 1 \& 7- 100 mg/day Weeks 2 \& 6- 200 mg/day Weeks 3-5- 300 mg/day
61973044|NCT00505531||Placebo|Diphenhydramine capsules Weeks 1-6- 25 mg/day
61973045|NCT05901168|ACTIVE_COMPARATOR|Active Video Games Intervention|"Active video games intervention will be carried out with a virtual reality system (XBOX360, Microsoft, USA) consisting of a console and sensor.~Active video games consist of Rally Ball, Rive Rush and Reflex Ridge games."
61973046|NCT05901168|ACTIVE_COMPARATOR|Traditional Exercise Intervention|Traditional Exercise Intervention consist of active exercises for the upper extremities, active exercises for the lower extremities, active exercises for the body.
62353592|NCT02452268|EXPERIMENTAL|NIZ985 + PDR001|"* The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.~* On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.~* Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual."
61973047|NCT00617123|EXPERIMENTAL|Vorapaxar|Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year
61973048|NCT00617123|PLACEBO_COMPARATOR|Placebo|Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year
61973049|NCT02110290||Children with Physical Disabilities|This group includes children 8-18 years old participating in an adapted ski/snowboarding program with any type of physical disability, including cerebral palsy, traumatic brain injury, spinal cord injury, and amputation.
61973050|NCT01523860|EXPERIMENTAL|1|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.
62353593|NCT06446180|EXPERIMENTAL|Experimental group|SsK12@Lip@GSH
62147170|NCT06309355|EXPERIMENTAL|Placebo dose|The intervention is Placebo on a range of body surface area for multiple topical administration
62353594|NCT01612377|EXPERIMENTAL|prednisolone-dipyridamole|
62353595|NCT01612377|ACTIVE_COMPARATOR|prednisone 5mg|
62353596|NCT01612377|ACTIVE_COMPARATOR|prednisone 7.5mg|
62353597|NCT04564716|EXPERIMENTAL|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
62353598|NCT04564716|PLACEBO_COMPARATOR|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
62353599|NCT01315002|ACTIVE_COMPARATOR|Nicotine Patch|Transdermal nicotine patch
62353600|NCT01315002|PLACEBO_COMPARATOR|Placebo patch|Placebo patch
61973051|NCT02043249|NO_INTERVENTION|CORD MILKING|WITHOUT MILKING
61973052|NCT03668314|EXPERIMENTAL|Cohort 1:1 - 1:6 RDN-929|RDN-929 single dose capsule
62353601|NCT04806633|ACTIVE_COMPARATOR|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following cardiac catheterization and PCI
62513291|NCT03845413|ACTIVE_COMPARATOR|Intervention|The intervention arm consisted of 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
62513292|NCT03845413|ACTIVE_COMPARATOR|Control|The control arm consisted of a home visit by the Community Health Worker scheduling an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
62513293|NCT03964636||no contraceptive intake|
62513294|NCT03964636||combined 1st/2nd generation oral contraceptives intake|
62513295|NCT03964636||3rd/4th generation combined oral contraceptives intake|
62513296|NCT01453621|EXPERIMENTAL|Clinical decision support (post-intervention phase)|Clinicians will receive computerized clinical decision support regarding the risk of clinically important traumatic brain injury (TBI) based on the prediction rules
62513297|NCT01453621|NO_INTERVENTION|Standard care (pre-intervention phase)|Prior to implementation of the computerized clinical decision support, we will collect data to determine the baseline rate of CT use for children with minor blunt head trauma at very low risk of clinically-important traumatic brain injuries.
62513298|NCT04886557||DDS fixation|Adult patients with degenerative spondylolisthesis over L4-L5 received DDS with a minimum of 2-year follow-up were reviewed. Surgical indications were patients who failed to respond to conservative treatment for at least 6 months. The exclusion criteria were: (1) presence of degenerative scoliosis or spinal deformity, (2) prior spine surgery, (3) lost to follow-up, or (4) failure to complete the questionnaires or radiographic examinations.
62513299|NCT01629394|ACTIVE_COMPARATOR|Group A: Sugammadex CBW-open|Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\] when T2 arises in adductor pollicis.
62513300|NCT01629394|ACTIVE_COMPARATOR|Group B: Sugammadex IBW-open|Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
62513301|NCT01629394|ACTIVE_COMPARATOR|Group C: Neostigmine CBW-open|Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]when T2 arises in adductor pollicis.
62513302|NCT01629394|ACTIVE_COMPARATOR|Group D: Neostigmine-IBW|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
62513303|NCT01629394|ACTIVE_COMPARATOR|Group E: Sugammadex CBW-Lap|Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\] when T2 arises in adductor pollicis.
62513304|NCT01629394|ACTIVE_COMPARATOR|Group F: Sugammadex IBW-Lap|Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
62513305|NCT01629394|ACTIVE_COMPARATOR|Group G: Neostigmine CBW-Lap|Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]when T2 arises in adductor pollicis.
62513306|NCT01629394|ACTIVE_COMPARATOR|Group H: Neostigmine IBW-Lap|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
62513307|NCT06614660||the colorectal cancer group|Metabolism genomics and imaging genomics were collected via blood and CT images for colorectal cancer patients.
62513308|NCT00554320|ACTIVE_COMPARATOR|A|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
62513309|NCT00554320|PLACEBO_COMPARATOR|C|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
62513310|NCT05357859|EXPERIMENTAL|Intervention: solubilized vitamin D3 in MCT|The intervention dose and duration aims to correct their vitamin D deficiency to sufficient status (total serum 25(OH)D \>/=30 ng/mL or 75 nmol/L). According to an oral cholecalciferol (D3) loading dose guideline for vitamin D-deficient adults (van Groningen et al. 2010), cumulative dose of more than 200,000 IU solubilized vitamin D3 would be applied in current RCT, with make sure the sufficient supplement. Intervention group will receive 144,000 IU in week0 (W0) and then every 2 weeks of 72,000 IU for total 8 weeks (totally 5 times: 144,000 IU wk0/ 72,000 IU wk2/ 72,000 IU wk4/ 72,000 IU wk6/ 72,000 IU wk8), theoretically to achieve sufficient levels of vitamin D.
62513311|NCT05357859|PLACEBO_COMPARATOR|Placebo: MCT with same amount|control group will receive same volume amount of medium chain triglyceride (MCT).
62513312|NCT04882982|EXPERIMENTAL|Caria app|"The Caria app is publically available on the Apple app store. It is an interactive native app that provides education on menopause as well as symptom tracking/feedback features, social support as well as cognitive behavioral and relaxation techniques. Participants will be given an unlocked version with all content available at no charge. The app sends out occasional automated emails to users to remind of features of the app and to encourage them to return to the app. Users can opt out of reminder features."
62513313|NCT04882982|ACTIVE_COMPARATOR|Menopause education|Participants will receive educational material about menopause from the North American Menopause Society, a well respected menopause organization.
62513314|NCT00970255|ACTIVE_COMPARATOR|Frenotomy|
62513315|NCT00970255|SHAM_COMPARATOR|Sham Frenotomy|
62513316|NCT04223778|EXPERIMENTAL|Doravirine/Islatravir (DOR/ISL)|Participants who were previously treated with continuous background antiretroviral therapy (ART) will receive DOR/ISL, a fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) orally once daily for 96 weeks.
62513317|NCT04223778|ACTIVE_COMPARATOR|Baseline Background Antiretroviral Therapy (ART)|Participants will receive continuous background ART for 48 weeks and DOR/ISL, a FDC of 100 mg DOR/0.75 mg ISL orally once daily for 48 weeks.
62513318|NCT03301818|EXPERIMENTAL|Patients undergoing USI repair|
62513319|NCT03736187|EXPERIMENTAL|Cephalexin|Group a will receive cephalexin 1gm before skin incision intravenous
62513320|NCT03736187|EXPERIMENTAL|Cephalexin &metronidazole|Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision
61973053|NCT03668314|PLACEBO_COMPARATOR|Cohort 1:1 - 1:6 placebo|Placebo single dose capsule
62539458|NCT01616030|EXPERIMENTAL|Strength training, fractured limb|"Knee-extension strength training of the fractured limb:~Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery."
61973054|NCT03668314|EXPERIMENTAL|Cohort 2:1|Fed/Fast RDN-929
61973055|NCT03668314|EXPERIMENTAL|Cohort 3:1- 3:4 RDN-929|RDN-929 multiple dose capsules once daily for 12 days
61973056|NCT03668314|PLACEBO_COMPARATOR|Cohort 3:1- 3:4 placebo|placebo multiple dose capsules once daily for 10 days
62147171|NCT03658603|EXPERIMENTAL|Study group|Thoracodorsal artery perforator flap
62147172|NCT03658603|ACTIVE_COMPARATOR|control group|Conventional free flaps
62513321|NCT06468748|EXPERIMENTAL|Semaglutide Treatment|"Semaglutide will be self-administered by participants with a prefilled pen injector on the same day each week, at any time of day, with or without meals. It will be initiated at a dose of 0.25 mg once weekly for the first 4 weeks, with the dose increased every 4 weeks to reach a maintenance dose of 2.4 mg weekly by week 16. They will remain on the maintenance dosage of 2.4mg until week 24. If participants cannot reach 2.4 mg/week they will stop at the maximal tolerable dose (e.g., 1.7 mg/week).~After 24-weeks, treatment will be stopped, and participants will remain in the trial for 1 year with follow-up assessments at week 48 and week 76."
62513322|NCT03746002|ACTIVE_COMPARATOR|Metolazone Pre-dosing|Metolazone 5 mg by mouth administered 60 minutes prior to furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
62513323|NCT03746002|ACTIVE_COMPARATOR|Metolazone Concurrent Dosing|Metolazone 5 mg by mouth administered at the same time as furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
62513324|NCT02588547|ACTIVE_COMPARATOR|Granisetron 1|Intravenous granisetron 1 mg
62513325|NCT02588547|ACTIVE_COMPARATOR|Granisetron 0.7|Intravenous granisetron 0.7 mg
62513326|NCT02588547|PLACEBO_COMPARATOR|Placebo|intravenous 0.9% Sodium chloride (2 ml)
62513327|NCT01865929|ACTIVE_COMPARATOR|Robotic hysterectomy|Minimally invasive hysterectomy by robotic surgery
62513328|NCT01865929|ACTIVE_COMPARATOR|Vaginal or laparoscopic hysterectomy|Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
62513329|NCT04660955||Patients|Patients who had ACL reconstruction
62513330|NCT04660955||Controls|Controls who have no previous knee injury or surgery, no diagnosis of osteoarthritis
62513331|NCT03382249|PLACEBO_COMPARATOR|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
62513332|NCT03382249|EXPERIMENTAL|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
62513333|NCT00690482|EXPERIMENTAL|AZD1981|AZD1981 Oral tablet, twice daily
62513334|NCT00690482|PLACEBO_COMPARATOR|Placebo|Placebo Oral tablet, twice daily
62513335|NCT03964519|EXPERIMENTAL|20% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 20% less compared to the first repetition.
62513336|NCT03964519|EXPERIMENTAL|40% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 40% less compared to the first repetition.
62513337|NCT03964519|PLACEBO_COMPARATOR|Control group|This group will be just tested as a control group.
62513338|NCT02453633|EXPERIMENTAL|Emotional SMS text|Patients in this arm will receive an emotion-based SMS reminder of their scheduled outpatient clinic appointment.
62513339|NCT02453633|ACTIVE_COMPARATOR|Standard SMS text|Patients in this arm will receive the standard SMS reminder of their scheduled outpatient clinic appointment.
62513340|NCT00427674|EXPERIMENTAL|injection of 5 mCi of 123-I mZINT|
62513341|NCT05519657||postoperative pulmonary complications group|Postoperative pulmonary complications group no intervention
62513342|NCT05519657||non-postoperative pulmonary complications group|Non-postoperative pulmonary complications group no intervention
62513343|NCT06617702|EXPERIMENTAL|A text message alcohol intervention focused on cognitive, behavioral, and peer influences|
62513344|NCT06617702|ACTIVE_COMPARATOR|A text message alcohol intervention focused on cognitive and behavioral influences|
62513345|NCT01058551|EXPERIMENTAL|Reveal XT ILR|Implantable Loop Recorder Insertion
62513346|NCT04685694|NO_INTERVENTION|Expectant|No medication is assigned.
62513347|NCT04685694|EXPERIMENTAL|Medical|SL 800 mcg Misoprostol
62513348|NCT02562417|PLACEBO_COMPARATOR|No IV dexamethasone|Patients will receive an equivalent volume of normal saline.
62513349|NCT02562417|EXPERIMENTAL|IV dexamethasone|Patients will receive 0.1 mg/kg of dexamethasone.
62513350|NCT04130178|ACTIVE_COMPARATOR|Bupivacine injected|Half ml of Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was injected through a 27G needle at the level of the volar proximal digital crease of the 2nd and 3rd PIP on each side of the selected joint.
61973057|NCT05951062|EXPERIMENTAL|five sessions of educational interview|The intervention included five educational sessions focused on anti-hypertensive medication-related information, the importance of medication refills, motivation, self-management and self-check skills.
61973058|NCT05951062|OTHER|treatment as usual|usual care provided by facility,such as regular blood pressure checking and meals
61973059|NCT05292040|EXPERIMENTAL|LY3857210|Single doses of LY3857210 administered orally.
61973060|NCT02683889|EXPERIMENTAL|One arm|One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.
61973061|NCT06163313||Calculosis patients|Patients suffering from kidney stones
61973062|NCT02118051|EXPERIMENTAL|CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.|"Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle\> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles\> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
61973063|NCT02118051|ACTIVE_COMPARATOR|hMG ,Ganirelix,choriogonadotropin alfa,progesterone|"Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation.~Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle\> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles\> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
61973064|NCT02597075|ACTIVE_COMPARATOR|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
61973065|NCT02597075|ACTIVE_COMPARATOR|Arm B:|Standard therapy
61973066|NCT00667004|EXPERIMENTAL|1|ecabet ophthalmic solution
62513351|NCT04130178|PLACEBO_COMPARATOR|Control group|Saline was injected subcutaneously in the 2nd and 3rd PIP on each side of the selected joint.
62513352|NCT04963387|EXPERIMENTAL|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps vibration exposure was given in 1-minute bouts, with rest period of one to two minutes between bouts, with the exposure whole body vibration for about four minutes on every session. The duration of vibration exposure was preset with the automatic set time intervals in the vibration machine Prior to each vibration bout. When the predefined time was reached the machine automatically turned off . Based on previous researches the total exposure of four minutes per session interval was selected. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
62513353|NCT04963387|ACTIVE_COMPARATOR|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
62513354|NCT06322459|EXPERIMENTAL|Sport Eucation Curriculum|The Teaching experiment period of the Sport Education Model was 12 weeks, 40 minutes per lesson which included warm-up (10 minutes), basic content (20 minutes), rest of basic content (5 minutes), and cool-down (5 minutes).
62513355|NCT06322459|ACTIVE_COMPARATOR|Normal Teaching|The Teaching experiment period of Normal Teaching was 12 weeks, 40 minutes per lesson which included warm-up (10-min), basic content (20min), rest of basic content (5min), and cool-down (5min). Normal Teaching includes Teacher-directed learning (10 minutes) and Individual practice (10 minutes).
61973067|NCT00667004|PLACEBO_COMPARATOR|2|Placebo comparator
61973068|NCT02981498|EXPERIMENTAL|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
62513356|NCT06364332|EXPERIMENTAL|Intervention|#Chatsafe suicide prevention content.
62147173|NCT03864159|EXPERIMENTAL|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time.The intervention through the suction cups will consist of its application and produce increased flexibility of the hamstring musculature. The technique will be performed with the subject in prone position, on the stretcher, while the physiotherapist will be placed next to the member to be treated. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
62513357|NCT06364332|ACTIVE_COMPARATOR|Control|Sexual health and wellbeing content
61973069|NCT01529255|EXPERIMENTAL|ROADMAP|
61973070|NCT01529255|ACTIVE_COMPARATOR|SOC (Standard of Care)|
62513358|NCT02070926||Perform coronary CT angiography|
62513359|NCT02070926||Do not perform coronary CT angiography|
62513360|NCT01397617|EXPERIMENTAL|NobelActive Internal|NobelActive Internal implant
62353602|NCT04806633|PLACEBO_COMPARATOR|Placebo|Patients who will be randomized to receive placebo following cardiac catheterization and PCI
62353603|NCT06507085||Patients undergoing radio-guided interventional radiology|All patients undergoing interventional radiology to correct heart rhythm disorders
62513361|NCT01397617|EXPERIMENTAL|NobelActive External|NobelActive External implant
61973071|NCT04026867|ACTIVE_COMPARATOR|Clinician Referral Only|"The Clinician Referral arm will serve as an active control and baseline standard of care. All individuals who test positive for HCV antibodies or are identified with untreated, active HCV will be informed of their result and receive the following information from their clinical care teams in the ED: (a) explanation of process and rationale for follow-up RNA testing; (b) delivery of simple posttest counseling (e.g., risk for liver disease, risks of transmission); and (c) provision of a list of insurance enrollment resources, as needed, along with (d) a list of HCV treatment providers and their contact information as provided in aftercare instructions. For new HCV diagnoses, patients will be instructed to access their electronic patient portal (MyChart) for their RNA test results or to call a designated results line. Post-testing counseling messages and follow-up instructions will be included on the patient discharge papers."
61973072|NCT04026867|EXPERIMENTAL|Clinician Referral + Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS). Individuals randomized to this intervention will be contacted by a linkage navigator either during the ED visit (if during business hours) or the following business day (if during non-business hours). If the navigator does not contact the patient at the time of ED visit, they will offer to meet with the patient in person or over the phone. For all individuals in this arm, a structured linkage navigation process will include motivational interviewing and (a) reiteration of posttest counseling messages, (b) assessment of the patient's needs for medical insurance and substance abuse treatment, c) assistance scheduling and/or rescheduling appointments for HCV treatment, and d) follow-up phone call after the first HCV treatment appointment and thereafter as needed up to 6 months after ED visit.
62513362|NCT01397617|ACTIVE_COMPARATOR|NobelReplace Tapered Groovy|NobelReplace Tapered Groovy implant
62513363|NCT00604201|EXPERIMENTAL|Co-infusion of UCB and Haploidentical CD34+ cells|Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)
62513364|NCT03176368|EXPERIMENTAL|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
62709632|NCT01352884|EXPERIMENTAL|Stage 2|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood specimens will be evaluated for pharmacodynamic markers/activity at specified timepoints throughout the study.
62513365|NCT05032326|OTHER|OXYTOCIN (OT) Treated cohort|babies treated with Oxytocin during the OTBB3 study
62513366|NCT05032326|OTHER|Untreated cohort|babies not included in the OTBB3 study and therefore never treated with Oxytocin
62709633|NCT06195852|ACTIVE_COMPARATOR|Usual Safe Touches|Delivered by 2 facilitators in a classroom by utilizing live puppet skits
62513367|NCT05752916|EXPERIMENTAL|Intravenous rhTNK-tPA|rhTNK-tPA(0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 5-10 seconds as per the standard manufacturers' instructions for use.
62513368|NCT05752916|ACTIVE_COMPARATOR|Antiplatelet agents|Patients will be treated with standard guideline-directed antiplatelet treatment-choice at the discretion of the clinician. Aspirin will be the choice of most physicians; some will choose to use the clopidogrel. Standard of care medication(s) should be given immediately upon randomization.
62513369|NCT02326974|EXPERIMENTAL|T-DM1 and Pertuzumab|T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy.
62513370|NCT01368627|EXPERIMENTAL|Supralimus® Sirolimus-Eluting Coronary Stent|
62513371|NCT03399617|ACTIVE_COMPARATOR|Standard Care+MNPs|Participants will receive standard health care services provided by the Ministry of Health, including micronutrient powders (MNPs). Children 6 months old will receive 1 gram of powdered micronutrients for 60 days every 6 months until 24 months of age.
62513372|NCT03399617|EXPERIMENTAL|SPOON behavioral change strategy+SQ-LNS|Participants will receive Small Quantity Lipid-based Supplements (SQ-LNS) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
62513373|NCT03399617|EXPERIMENTAL|SPOON behavioral change strategy+MNPs|Participants will receive micronutrient powders (MNPs) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of MNPs will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities.
62513374|NCT02485821|EXPERIMENTAL|Estradiol + Misoprostol|100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated every 6hours up to five doses.
62513375|NCT02485821|PLACEBO_COMPARATOR|Placebo + Misoprostol|100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated every 6 hours up to five doses.
62513376|NCT00465049|EXPERIMENTAL|primary closure|suture after I\&D
62709634|NCT06195852|EXPERIMENTAL|Modified Safe Touches|Delivered by 1 facilitator in the classroom by utilizing prerecorded workshop skit videos
62709635|NCT03981874|EXPERIMENTAL|Telephonic interview|Parents or patients will be contacted by phone in order to precise whether there are persistent sequelae or not
62709636|NCT04256655|EXPERIMENTAL|Cohort 1 0.225 g|Randomized to treatment with either CDX-6114 0.225g or matching Placebo
62353604|NCT05102513|EXPERIMENTAL|Unilateral Cleft Lip Repair with the New Hybrid Technique|
62513377|NCT00465049|PLACEBO_COMPARATOR|SECONDARY CLOSURE|LEAVE TO HEAL BY SECONDARY INTENTIN AFTER I\&D
62709637|NCT04256655|EXPERIMENTAL|Cohort 2 0.75g|Randomized to treatment with either CDX-6114 0.75g or matching Placebo
62709638|NCT04256655|EXPERIMENTAL|Cohort 3 2.25g|Randomized to treatment with either CDX-6114 2.25 g or matching Placebo
62709639|NCT06456840||Group 1|40 Parkinson's patients who described pain in at least one shoulder (VAS\>3)
62709640|NCT06456840||Group 2|0 Parkinson's patients with undefined pain in both shoulders (VAS: 0)
62709641|NCT06456840||Group 3|40 patients of similar age and gender, without a Parkinson's diagnosis, with any shoulder pain (VAS\>3)
62709642|NCT06456840||Group 4|40 patients of similar age and gender, diagnosed without Parkinson's disease and without pain in both shoulders (VAS: 0)
62709643|NCT02972645|EXPERIMENTAL|LY3305677|Single escalating doses of LY3305677 administered subcutaneously (SC)
62709644|NCT02972645|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62709645|NCT03429088|EXPERIMENTAL|Telephone counseling|Participants were provided with approximately 7 telephone-based motivational interviewing over a 24-week period to increase their physical activity.
62709646|NCT03429088|NO_INTERVENTION|Usual care|Participants in the usual care arm received a packet of places near their home in which they could engage in physical activity if they chose.
62709647|NCT01072526|ACTIVE_COMPARATOR|Intervention|Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) .
62709648|NCT01072526|PLACEBO_COMPARATOR|Control|Subjects will receive placebo in combination with cyclosporin solution (Restasis) .
62709649|NCT01038323|EXPERIMENTAL|CBT and milnacipran|Subjects randomized to this group will receive a combination of eight telephone sessions of Cognitive Behavior Therapy (CBT) and a 21-week regimen of milnacipran.
62513378|NCT01000363||Spanish speaking group|Diabetes medical group visits will be held at the Grady North DeKalb satellite clinic the third Thursday of the month starting in October 2009. There will be two cohorts of patients- English speaking patients and Spanish speaking patients. Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.
62539459|NCT05574608|EXPERIMENTAL|Experimental: Experimental: CD123-CAR-NK.|The relapsed/refractory AML patients will receive allogenic CD123-Targeted CAR-NK cells infusion (1x10\^9, 1-2x10\^7/kg) after precondition chemotherapy.
62539460|NCT05549609|EXPERIMENTAL|XSTEM-VLU|Single topical dose of XSTEM-VLU
62709650|NCT01038323|PLACEBO_COMPARATOR|CBT and placebo|Subjects randomized to this arm will receive a series of eight telephone sessions of Cognitive Behavioral Therapy (CBT) along with a 21-week regimen of a placebo(sugar pill)medication.
62709651|NCT01038323|ACTIVE_COMPARATOR|Educational with milnacipran|Subjects randomized to this group will receive a series of eight educational phone calls regarding fibromyalgia along with a 21-week regimen of milnacipran.
61973073|NCT00905151||HIV Positive|Across-sectional analysis of 200 HIV+ patients with varying levels of kidney function
62353605|NCT05102513|ACTIVE_COMPARATOR|Unilateral Cleft Lip Repair with the Millard II Technique|
62513379|NCT01000363||English speaking group|"Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.~This visit will only focus on the patient's diabetes care. Each patient will continue to see their regular physician for their health care.~All of the services that will be provided at the medical group visit are standard of care and are the same that the patient will receive in a one-on-one visit. However, this format will allow the patient to been seen by the physician and receive diabetes education in one visit."
62513380|NCT01328912|EXPERIMENTAL|Remote ischemic preconditioning stimulus|
62513381|NCT01328912|PLACEBO_COMPARATOR|Control|
62513382|NCT03440424|EXPERIMENTAL|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant \[E2006\] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
62513383|NCT03440424|EXPERIMENTAL|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant \[E2006\] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
62513384|NCT03440424|EXPERIMENTAL|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index \[BMI\]) will receive a single 10 mg dose (1 × 10 mg lemborexant \[E2006\] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
62513385|NCT06296524|EXPERIMENTAL|Footcore exercises and conventional therapy|Participants received Footcore exercises along with conventional therapy for 4 weeks, twice a day Footcore exercises includes toe yoga, toe spreads, foot doming, calf stretch, ball rolling. + conventional therapy
62513386|NCT06296524|ACTIVE_COMPARATOR|Conventional Therapy|Participants received conventional physiotherapy treatment, which includes toe curl, picking of small object, heel raise (For 4 weeks, twice a day).
61973074|NCT02966587|EXPERIMENTAL|Treatment (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
62147174|NCT03864159|ACTIVE_COMPARATOR|Foam roller|The intervention will be carried out before starting the training session. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
62513387|NCT02025231|EXPERIMENTAL|External beam radiotherapy|Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.
62513388|NCT01923194|EXPERIMENTAL|Test Group|
62513389|NCT01923194|ACTIVE_COMPARATOR|Comparator Group|
62513390|NCT00845052||First group of house staff|First group of house staff to be surveyed
62513391|NCT00845052||Second group of house staff|Second group of house staff to be surveyed
62513392|NCT00845052||Thirst group of house staff|Third group of house staff to be surveyed
62513393|NCT05511220|EXPERIMENTAL|PRIMeR|Virtual parent coaching in use of a novel intervention consisting of Social Routines and Reciprocal Imitation Training strategies
62513394|NCT05511220|ACTIVE_COMPARATOR|PRT|Virtual parent coaching in use of Pivotal Response Treatment strategies
62513395|NCT04435002|EXPERIMENTAL|Intervention Group|For 9 different points acupressure technique applied to this group for 4 weeks
62513396|NCT04435002|NO_INTERVENTION|Control Group|
62513397|NCT03392740|EXPERIMENTAL|Lisinopril treatment|These patients will be initiated at 5mg lisinopril daily by the research nurse at the time of enrollment. The drug will then be titrated up by the research nurse in a stepwise fashion from 5mg, to 10mg, and then to 20mg once a day every 1 to 3 weeks according to their regular/scheduled next office visits. Blood pressure will be monitored at every visit by the research nurse if it is less than or equal to 90 mmHg
62513398|NCT03392740|PLACEBO_COMPARATOR|Placebo Oral Tablet|These patients will be started on the placebo medication at the time of enrollment. According to their regular scheduled visits every 1 to 3 weeks, they will meet with the research nurse and be given a new placebo medication to take once a day.
62147175|NCT02893800|OTHER|Himatic locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
62147176|NCT02893800|OTHER|ReSOS locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
62147177|NCT03836885|EXPERIMENTAL|Apremilast|Oral tablet
62147178|NCT03836885|PLACEBO_COMPARATOR|Placebo|Oral tablet
62513399|NCT05800145|EXPERIMENTAL|resource referral|will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address Food Insecurities (FI) Supplemental Nutrition Assistance Program (SNAP).
62513400|NCT05800145|ACTIVE_COMPARATOR|community health worker (CHW) intervention|assist participants in addressing FI and supporting them in their blood pressure management
62513401|NCT05800145|ACTIVE_COMPARATOR|medically tailored meals (MTM)|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
62513402|NCT05188183|EXPERIMENTAL|M1 anodal home-based tDCS and somatosensory training|Investigators will use the Soterix Medical 1X1 tDCS mini-CT stimulator device (© Soterix Medical Inc.) an home-based tDCS device used in several clinical trials with no adverse events. It sends a low-level current from the positive electrode, anode, to the negative electrode, cathode. During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. HB-TDCS will be combined with somatosensory training that will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks.
62513403|NCT05188183|EXPERIMENTAL|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
62147179|NCT05222100||Women without breast implants|Women without breast implants participating in the mammography screening program.
62147180|NCT05222100||Women with breast implants|Women with breast implants participating in the mammography screening program.
62513404|NCT01491308|ACTIVE_COMPARATOR|Restrictive|Hemoglobin concentrations will be maintained in the range of 7.5 to 9.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 7.5 g per deciliter.
62513405|NCT01491308|ACTIVE_COMPARATOR|Liberal|Hemoglobin concentrations will be maintained in the range of 10.0 to 12.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 10.0 g per deciliter.
62513406|NCT01470196|EXPERIMENTAL|Treatment Arm|Carfilzomib, dexamethasone, rituximab
62513407|NCT02750735||Retrospective NCWS patients|The clinical charts of NCWS patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca were retrospectively reviewed. Patients had all been diagnosed with NCWS between January 2001 and June 2011, by a DBPCC method, and included in a previously published study. These charts included specific sections for the presence of associated atopic diseases, including nickel allergy. In this way, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy. Incomplete clinical charts were excluded.
62513408|NCT02750735||Prospective NCWS patients|The investigators also prospectively surveyed adult patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS. The patients were recruited between December 2014 and March 2016 at 3 centers: the two already mentioned and the Gastroenterology Unit of the ARNAS Civico Hospital of Palermo, Italy. Most of the patients had been referred due to gastrointestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. Again, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy.
62513409|NCT02750735||Retrospective NCWS control patients|To compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 irritable bowel syndrome (IBS) patients, was selected. These controls were randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- (+/-2 years) and sex-matched (+/-5%) with the NCWS patients. The IBS controls had been receiving the same elimination diet as the NCWS patients and had not shown any clinical improvement; they belonged to the cohort of subjects the investigators had studied previously.
62513410|NCT02750735||Prospective NCWS control patients|As for the retrospective study, to compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 patients with functional gastroenterological symptoms, was selected, with the same criteria adopted for the retrospective study.
62513411|NCT05414084|EXPERIMENTAL|(Poly)phenol tablets|Single ingestion of 3 tablets containing different amounts of the most representative dietary (poly)phenols (i.e. flavonoid subclasses, phenolic acids, lignans, ellagitannins, stilbenes, flavonols, procyanidins and phenylethanoids)
62513412|NCT03341000|EXPERIMENTAL|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.
62513413|NCT03740620|ACTIVE_COMPARATOR|intervention group|In the intervention group, a nasotracheal tube is inserted into the nostril with the bevel of the tube facing the cephalad direction of the patient.
62513414|NCT03740620|ACTIVE_COMPARATOR|conventional group|In the conventional group, a nasotracheal tube is inserted in a usual way, i.e., with the bevel of the tube facing the left side of the patient.
62513415|NCT02712437|EXPERIMENTAL|PROSPECT|Participants who have received treatment for early stage breast cancer and who experience chronic insomnia as assessed by difficulty sleeping for \>30 days with an insomnia severity index score of \>14. Participants will complete baseline symptom questionnaires and actigraphy, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 6 weeks. Participants will then repeat questionnaires and actigraphy at 6 weeks and questionnaires at 12 weeks.
62513416|NCT00792519|EXPERIMENTAL|CBT|group cognitive behavioral treatment
62513417|NCT00792519|ACTIVE_COMPARATOR|HIV support group|group support
62513418|NCT03244124|ACTIVE_COMPARATOR|SET (Self-Etching)|50 teeth will receive restorations using Self-Etching Application Strategy
62513419|NCT03244124|EXPERIMENTAL|SEE (Selective Enamel Etching)|50 teeth will receive restorations using Enamel Etching Application Strategy
62513420|NCT03244124|EXPERIMENTAL|ERDry (Etch&Rinse Dry)|50 teeth will receive restorations using Etch\&Rinse Dry Application Strategy, leaving dentin dry (but not overdry)
62513421|NCT03244124|EXPERIMENTAL|ERWet (Etch&Rinse Wet)|50 teeth will receive restorations using Etch\&Rinse Wet Application Strategy, leaving dentin wet
62513422|NCT04671537|EXPERIMENTAL|Study group (preloading with crystalloid fluid - isotonic solution)|Preloading with crystalloid fluid (isotonic solution) at 10 ml/kg of ideal body weight
62513423|NCT04671537|NO_INTERVENTION|Control group (not preloading)|no preloading
62513424|NCT03077529|EXPERIMENTAL|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
62513425|NCT03077529|PLACEBO_COMPARATOR|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
62513426|NCT04892121|EXPERIMENTAL|Intervention group|The teams in the intervention group will have to follow a warm-up prevention program twice a week
62147181|NCT05652907|EXPERIMENTAL|FSD201|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally from Day 0 to Day 56.
62147182|NCT05652907|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets twice daily (BID) orally from Day 0 to Day 56.
62513427|NCT04892121|NO_INTERVENTION|Control group|The teams in the control group will have to reply each month to a questionnaire about the potential injuries they experienced during the previous month.
62513428|NCT05693818||PersonaIQ|Patients indicated for a PersonaIQ total knee arthroplasty
62147183|NCT03340961|EXPERIMENTAL|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
62147184|NCT03340961|EXPERIMENTAL|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
62147185|NCT03340961|EXPERIMENTAL|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
62147186|NCT03340961|PLACEBO_COMPARATOR|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
62513429|NCT02619682|EXPERIMENTAL|Treatment (ixazomib citrate and lenalidomide)|Within 30-120 days after finishing autologous transplant, patients receive ixazomib citrate PO on days 1, 8 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-28. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients will continue to alternate between ixazomib citrate and lenalidomide every 2 courses for up to 24 months in the absence of disease progression or unacceptable toxicity.
62513430|NCT00152191|EXPERIMENTAL|1|UFT (uracil, tegafur)
62513431|NCT00152191|ACTIVE_COMPARATOR|2|CMF(cyclophosphamide, methotrexate, and fluorouracil)
62513432|NCT06207123|EXPERIMENTAL|All Participants (Single Arm)|"All study participants will receive LP-118 and ponatinib. The initial dose of LP-118 to be tested is 100 mg, and initial dose of ponatinib to be tested is 30 mg. Higher doses of LP-118 will only be tested if the study doctor feels it is safe to do so. A member of the study team will let study participants know which doses they are assigned.~Study drugs will be given in 21-day cycles. There will be 7 study visits in cycle 1 (on Days 1, 5, 6, 7, 15, 22, and 28). LP-118 and ponatinib will be taken at home every day. Dexamethasone will be taken between days 1-7 and days 15-22. For Cycles 2-12, study participants will have 5 study visits per cycle (on Days 1, 8, 15, 22, and 28). On all days, study participants will take LP-118 and ponatinib at home.~Participants in this group will also receive standard of care vincristine, dexamethasone, and methotrexate during study cycles."
62513433|NCT06159309||Long Covid patients|All post-COVID patients that are referred for hyperbaric oxygen (and that are eligible for treatment)
62513434|NCT01048502|EXPERIMENTAL|Fenofibrate (Tricor) (145 mg/day)|Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
62513435|NCT01048502|PLACEBO_COMPARATOR|Placebo|Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
62513436|NCT01048502|EXPERIMENTAL|Lovaza (900 mg/day)|Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
62513437|NCT01048502|EXPERIMENTAL|Lovaza (3,600 mg/day)|Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
62513438|NCT03554252|EXPERIMENTAL|Frequencies|
62513439|NCT03554252|EXPERIMENTAL|Percentages|
62513440|NCT03748394|EXPERIMENTAL|Work-directed rehabilitation|Work-directed, person-centered plan using modules of occupational therapy and physical therapy
62513441|NCT03748394|ACTIVE_COMPARATOR|Physical activity|Physical activity according to national health recommendations
62513442|NCT03708159|EXPERIMENTAL|active tDCS + mindfulness meditation|Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
62513443|NCT03708159|SHAM_COMPARATOR|sham tDCS + mindfulness meditation|Participants randomized to this group will receive sham tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
62513444|NCT02713815|SHAM_COMPARATOR|control group|sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
62513445|NCT02713815|ACTIVE_COMPARATOR|rTMS group|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
62513446|NCT02443584|OTHER|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
61973075|NCT04155112|EXPERIMENTAL|Physical activity (PA)|For 6 months, the participants will be recommended to increase physical activity to ≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week. The participants will take part in supervised group classes, twice per week. Each participant will receive a heart rate monitor to bring home and to use while reporting activity via a physical activity diary.
61976342|NCT04602182|EXPERIMENTAL|music therapy gruop (experimental group)|Experimental group: Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
62147187|NCT02779426|EXPERIMENTAL|Text Message Intervention + Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution as well as daily text messages with information about atopic dermatitis and treatment reminders. 1-2 times/week they will receive a message asking if they were able to complete their treatments in the last day. They will respond with 1=yes, 2=no, 3= I have questions about the treatment. Those who respond with 3 will be sent the contact information for the office. No other communications will be sent through text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
62513447|NCT02443584|OTHER|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
62513448|NCT03192852|EXPERIMENTAL|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
62513449|NCT03192852|ACTIVE_COMPARATOR|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula \& Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
62539461|NCT05549609|PLACEBO_COMPARATOR|Vehicle|Single topical dose of CryoStor CS10
62513450|NCT03192852|ACTIVE_COMPARATOR|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
62513451|NCT03192852|EXPERIMENTAL|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
62513452|NCT03192852|ACTIVE_COMPARATOR|CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula \& Ação, São Paulo, Brazil)
62513453|NCT04596306||UNDER 70 Y-O|
62513454|NCT04596306||OVER 70 Y-O|
62513455|NCT00379223|NO_INTERVENTION|1|Standard treatment of central retinal vein occlusion : the rheologic correction
62513456|NCT00379223|EXPERIMENTAL|2|Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy
62513457|NCT01771315|EXPERIMENTAL|telephone follow-up|Nurse led follow-up in form of consultation by telephone 4 days and 2weeks after discharge, respectively as a supplement to conventional admission course.
62513458|NCT01771315|NO_INTERVENTION|Usual treatment|All patients follow conventional admission course which implies preoperative seminar and a discharge planning consultation on the day of discharge. The patients are discharged to home, referred to physiotherapy in the community and a scheduled follow-up by the surgeon after 3 month in the orthopedic outpatient clinic.
62513459|NCT03508869|ACTIVE_COMPARATOR|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
62513460|NCT03508869|ACTIVE_COMPARATOR|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
62513461|NCT03508869|ACTIVE_COMPARATOR|Dysport® in conjunction with Mirvaso|Dysport® in conjunction with Mirvaso
62513462|NCT05752292|EXPERIMENTAL|Condition 1|Standard health message + VA + TRI + MI+ AP
62513463|NCT05752292|EXPERIMENTAL|Condition 2|Standard health message + VA + TRI + MI
62513464|NCT05752292|EXPERIMENTAL|Condition 3|Standard health message + VA + TRI + AP
62513465|NCT05752292|EXPERIMENTAL|Condition 4|Standard health message + VA + TRI
62513466|NCT05752292|EXPERIMENTAL|Condition 5|Standard health message + VA + MI+ AP
62513467|NCT05752292|EXPERIMENTAL|Condition 6|Standard health message + VA + MI
62513468|NCT05752292|EXPERIMENTAL|Condition 7|Standard health message + VA + AP
62513469|NCT05752292|EXPERIMENTAL|Condition 8|Standard health message + VA
62513470|NCT05752292|EXPERIMENTAL|Condition 9|Standard health message + TRI + MI+ AP
62513471|NCT05752292|EXPERIMENTAL|Condition 10|Standard health message + TRI + MI
62513472|NCT05752292|EXPERIMENTAL|Condition 11|Standard health message + TRI + AP
62709652|NCT06091904|EXPERIMENTAL|sufentanil group|sufentanil is administered for analgesic during general anesthesia
61976343|NCT04602182|ACTIVE_COMPARATOR|control group|Control group: Patient will follow the usual clinical practice for the weaning from mecanichal ventilation to the end of the weaning.
61976344|NCT02202408|EXPERIMENTAL|SKI2670|"Single-dose escalation/ Subjects received an oral single dose of SKI2670 capsule by dosing group~-Dosing Group 1, Dosing Group 2, Dosing Group 3, Dosing Group 4"
62513473|NCT05752292|EXPERIMENTAL|Condition 12|Standard health message + TRI
62513474|NCT05752292|EXPERIMENTAL|Condition 13|Standard health message + MI+ AP
62513475|NCT05752292|EXPERIMENTAL|Condition 14|Standard health message + MI
62513476|NCT05752292|EXPERIMENTAL|Condition 15|Standard health message + AP
62513477|NCT05752292|EXPERIMENTAL|Condition 16|Standard health message
62513478|NCT05681754|EXPERIMENTAL|RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic-periodontal disease patients undergoing root canal treatment using hydraulic calcium silicate sealer and L-PRF + GTR (bone substitute + collagen membrane)
62513479|NCT05681754|EXPERIMENTAL|RCT using conventional sealer and L-PRF + GTR|Endodontic-periodontal disease patients undergoing root canal treatment using conventional sealer and L-PRF + GTR (bone substitute + collagen membrane)
62513480|NCT05681754|EXPERIMENTAL|RCT using hydraulic calcium silicate sealer and GTR|Endodontic-periodontal disease patients undergoing root canal treatment using hydraulic calcium silicate sealer and GTR (bone substitute + collagen membrane)
62513481|NCT05681754|ACTIVE_COMPARATOR|RCT using conventional sealer and GTR (bone substitute + collagen membrane)|"Endodontic-periodontal disease patients undergoing root canal treatment using conventional sealer and GTR (bone substitute + collagen membrane)~This is our control group Both the endodontic and periodontal lesions are managed using gold standard of care biomaterials and techniques"
62513482|NCT04977037|EXPERIMENTAL|Active tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered at 2mA for 20 minutes
62513483|NCT04977037|SHAM_COMPARATOR|Sham tDCS|Sham transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered at 2mA for 20 minutes
62513484|NCT03063424|OTHER|Healthy subjects|
62513485|NCT03063424|OTHER|Asthmatics with EIB|
62513486|NCT00682617|EXPERIMENTAL|Waitlist Control|Delayed intervention. 3 months on waitlist, crossover to intervention (3 additional months)
62513487|NCT00682617|EXPERIMENTAL|3 Month Exercise Program|3 month exercise program
62513488|NCT01174355|EXPERIMENTAL|ND0801|
62513489|NCT00093002|EXPERIMENTAL|1|250 mg fulvestrant
62513490|NCT00093002|EXPERIMENTAL|2|500 mg fulvestrant
62513491|NCT02531594|EXPERIMENTAL|SBIRT|"An assessment form, motivational interviewing, personalized educational materials, immediate access to cessation resources, a 12-week supply of nicotine replacement therapy and weekly booster materials for 12 weeks.~nicotine"
62539462|NCT00650208|EXPERIMENTAL|1|Lamotrigine Tablets 25 mg
62709653|NCT06091904|ACTIVE_COMPARATOR|remifentanil group|remifentanil is administered for analgesic during general anesthesia
62709654|NCT02551315||Type 2 diabetics, no fractures|Postmenopausal women and men with T2DM, without prevalent fragility fractures (longitudinal follow-up)
62709655|NCT02551315||Type 2 diabetics, prevalent fractures|Postmenopausal women and men with T2DM, with prevalent fragility fractures
62513492|NCT02531594|PLACEBO_COMPARATOR|HHC|The Healthy Habits Control program has been previously developed and used in the out-patient setting, and will be used as an attention control in which caregivers will receive instruction on healthy lifestyle choices to improve their child's health. Cessation assistance will be offered at the study's conclusion.
62513493|NCT00444821|NO_INTERVENTION|Surveillance|
62513494|NCT00444821|EXPERIMENTAL|Early Endovascular Repair|
62513495|NCT03736928|PLACEBO_COMPARATOR|Placebo|Intramuscular single treatment
62513496|NCT03736928|EXPERIMENTAL|AbobotulinumtoxinA dose level 1 or 2|Intramuscular single treatment
62513497|NCT03736928|EXPERIMENTAL|AbobotulinumtoxinA dose level 3|Intramuscular single treatment
62513498|NCT03736928|EXPERIMENTAL|AbobotulinumtoxinA dose level 4|Intramuscular single treatment
62513499|NCT01514825|EXPERIMENTAL|YM150 low dose group|
62513500|NCT01514825|EXPERIMENTAL|YM150 middle dose group|
62513501|NCT01514825|EXPERIMENTAL|YM150 high dose group|
62147188|NCT02779426|NO_INTERVENTION|Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution. They will not receive text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
62147189|NCT04082598|EXPERIMENTAL|Tooth extraction and antibiotic treatment|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days
62147190|NCT04082598|EXPERIMENTAL|tooth extraction and antibiotic treatment + dietary supplement|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days
62147191|NCT04082598|NO_INTERVENTION|Tooth extraction|tooth extraction without antibiotics and/or Bifidobacterium longum and Lactoferrin
62147192|NCT01698918|EXPERIMENTAL|Everolimus+letrozole/exemestane (first line and second line treatment)|Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)
62147193|NCT04343417||Biorepository|Participants who contributed biospecimen samples (kidney tissue, blood, urine, DNA).
62147194|NCT06300294|EXPERIMENTAL|acupressure|acupressure application and Routine care and treatment (filling out the initial hospitalization documents, measuring vital signs, taking an ECG, preparing for the CAG procedure, administering the ordered medications).
62513502|NCT01514825|PLACEBO_COMPARATOR|placebo group|
62513503|NCT05704972||Operation Room Nurses|
62513504|NCT05686148|EXPERIMENTAL|Intervention|Vibration will be applied to the injection site for 5 minutes before the procedure.
62513505|NCT05686148|NO_INTERVENTION|Control|No application will be made
62513506|NCT06147531|EXPERIMENTAL|Intervention Group|Patients randomized to the Delayed Cold-Stored Platelet Group will receive ABO-identical buffy-coat platelets (pathogen reduced products) maintained at 22°C for up to 4 days then placed at 4°C for a minimum of 1 day (24 hours), with expiration at 14 days after collection.
62513507|NCT06147531|ACTIVE_COMPARATOR|Control Group|Those randomized to the Room Temperature Platelet Group will receive ABO-identical buffy-coat platelets (pathogen reduced products) maintained at 22°C for up to 7 days (as per current standard of care).
62513508|NCT03857672|EXPERIMENTAL|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT arm will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). The participants will undergo 6 weekly sessions each lasting 30-40 minutes.
62513509|NCT03857672|NO_INTERVENTION|Usual Care|The study therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their pain. The study therapist will emphasize the importance of completing the outcome assessments. The treatments usual care participants actually received will be assessed at 6 and 12 weeks.
62513510|NCT05171764||Coronary CTA|After the subject undergoes the standard of care, clinically indicated cardiac CT scan for diagnostic purposes, the investigational scan using the GSI Cardiac Scan Mode will be conducted utilizing the same contrast administration.
62513511|NCT03116061||Multimorbidity cohort|The study population included a random sample of multimorbid patients (according to the EGPRN definition of multimorbidity). Patients were selected by 19 FPs in their offices in the county of Finistere (in north-west France) from July 2014 to December 2014. Randomization was achieved by including the first four multimorbid patients (according to the inclusion criteria) encountered during their second working day of each week. As patients were booking their appointments with the practice without the FPs' clearance, the FPs were not able to select them
62513512|NCT05251506|EXPERIMENTAL|laser lancing device (LMT-1000) first user|Subjects measure blood glucose using laser lancing device (LMT-1000) for first 2 months, then take a month for wash out period, after that do using lancet for following 2 months.
62147195|NCT06300294|NO_INTERVENTION|control|Routine care and treatment (filling out the initial hospitalization documents, measuring vital signs, taking an ECG, preparing for the CAG procedure, administering the ordered medications).
62147196|NCT00706888|ACTIVE_COMPARATOR|1|Female with active product
62147197|NCT00706888|ACTIVE_COMPARATOR|2|Male with active product
62147198|NCT00706888|PLACEBO_COMPARATOR|3|Female with placebo
62147199|NCT00706888|PLACEBO_COMPARATOR|4|Male with placebo
62147200|NCT01584648|EXPERIMENTAL|Dabrafenib + Trametinib|Dabrafenib and Trametinib combination
62147201|NCT01584648|ACTIVE_COMPARATOR|Dabrafenib + Placebo|Dabrafenib and Trametinib placebo
62513513|NCT05251506|ACTIVE_COMPARATOR|lancet first user|Subjects measure blood glucose using lancet for first 2 months, , then take a month for wash out period, after that do using laser lancing device (LMT-1000) for following 2 months.
62513514|NCT03382431|EXPERIMENTAL|PC786|Repeat dose
62513515|NCT03382431|PLACEBO_COMPARATOR|Placebo/vehicle|Repeat dose
62513516|NCT01949714||Pheochromocytoma patients|Pheochromocytoma patients
62513517|NCT06366945|EXPERIMENTAL|treatment group|Neoadjuvant therapy will be performed for a total of 3 cycles, with 21 days as a cycle, which includes: ① Carboplatin: AUC5, weeks 1, 3, and 6, Q3W; ② Polymeric Micellar Paclitaxel: 300mg/m2, weeks 1, 3, and 6, Q3W for three cycles; ③Tirelizumab: 200 mg weeks 1, 3, and 6, Q3W for three cycles; if adjuvant immunotherapy is omitted, Tirelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery .Participants with clinical N-positive resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
62513518|NCT06412042|EXPERIMENTAL|Probiotic BLa80|Participants receive one sachet per day containing probiotic BLa80 and maltodextrin (Day 0 to Day 84).
62513519|NCT06412042|PLACEBO_COMPARATOR|Maltodextrin|Participants receive one sachet per day containing maltodextrin only, serving as the placebo (Day 0 to Day 84).
62147202|NCT06509009|EXPERIMENTAL|Nimotuzumab combine with TGP|Base on TGP(Toripalimab, Gemcitabine, and Cisplatin) regimen, the patients will receive Nimotuzamab treatment.
62709656|NCT02551315||Controls, no fractures|Age and sex-matched non-diabetic controls, without fragility fractures (longitudinal follow-up)
62513520|NCT06412042|NO_INTERVENTION|Blank|Participants in this arm will not receive any intervention or placebo.
62513521|NCT02752841|EXPERIMENTAL|Intervention|Nutritional vitamin D repletion and maintenance
62513522|NCT02112721|EXPERIMENTAL|Vitamin D Group|Each participant will be given an initial stat dose of 2500 μg (100,000 IU) of Ostelin (Reckitt Benckiser). Thereafter, participants will take 100 μg/day (4,000 IU, 4 tablets) Ostelin daily for a period of 16 weeks.
62513523|NCT02112721|PLACEBO_COMPARATOR|Placebo group|Each participant will be given an equivalent number of placebo tablets
62513524|NCT04372290|EXPERIMENTAL|Product usage order ABECD|Subjects will use each of the 5 products sequentially (ABECD) during an evaluation period, followed by a 6 hour Test Session.
62513525|NCT04372290|EXPERIMENTAL|Product usage order BCADE|Subjects will use each of the 5 products sequentially (BCADE) during an evaluation period, followed by a 6 hour Test Session.
62513526|NCT04372290|EXPERIMENTAL|Product usage order CDBEA|Subjects will use each of the 5 products sequentially (CDBEA) during an evaluation period, followed by a 6 hour Test Session.
62513527|NCT04372290|EXPERIMENTAL|Product usage order DECAB|Subjects will use each of the 5 products sequentially (DECAB) during an evaluation period, followed by a 6 hour Test Session.
62513528|NCT04372290|EXPERIMENTAL|Product usage order EADBC|Subjects will use each of the 5 products sequentially (EADBC) during an evaluation period, followed by a 6 hour Test Session.
62513529|NCT04372290|EXPERIMENTAL|Product usage order DCEBA|Subjects will use each of the 5 products sequentially (DCEBA) during an evaluation period, followed by a 6 hour Test Session.
62147203|NCT01446718||Gardasil Vaccine|"This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya study."
62513530|NCT04372290|EXPERIMENTAL|Product usage order EDACB|Subjects will use each of the 5 products sequentially (EDACB) during an evaluation period, followed by a 6 hour Test Session.
62513531|NCT04372290|EXPERIMENTAL|Product usage order AEBDC|Subjects will use each of the 5 products sequentially (AEBDC) during an evaluation period, followed by a 6 hour Test Session.
62513532|NCT04372290|EXPERIMENTAL|Product usage order BACED|Subjects will use each of the 5 products sequentially (BACED) during an evaluation period, followed by a 6 hour Test Session.
62513533|NCT04372290|EXPERIMENTAL|Product usage order CBDAE|Subjects will use each of the 5 products sequentially (CBDAE) during an evaluation period, followed by a 6 hour Test Session.
62513534|NCT04306640|EXPERIMENTAL|intervention group|the intervention group will receive the denneroll cervical traction orthotic in an attempt to improve the altered sagittal cervical spine alignment (AHT and ARA C2-C7).
62513535|NCT04306640|ACTIVE_COMPARATOR|Control group|Both the intervention group and the control group will complete a multimodal program of 10 weeks consisting of myofascial release, thoracic spine mobilization and manipulations, and physical pain relief methods.
62513536|NCT01239472|NO_INTERVENTION|tacrolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone.
62513537|NCT01239472|ACTIVE_COMPARATOR|everolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone, and converted for everolimus, mycophenolate sodium, and prednisone 90 days after renal transplantation.
62513538|NCT01001260||No Aspirin Treatment|
62513539|NCT01001260||81 mg Aspirin Treatment|
62513540|NCT01001260||325 mg Aspirin|
62513541|NCT05550220|EXPERIMENTAL|Modified Cuff Leak Test|"The subject was placed in a semi-recumbent position.~The subjects were placed in volume assist-control mode with the following parameters:~* respiratory rate 15 breaths/min~* original oxygen concentration~* PEEP 0 cm H2O~* the VT was set according to the subject's stable VT in the previous ventilator mode~* inspiratory flow was set at 30 L/min with square waveform Positive cutoff value of the air leak volume was 116 mL and the air leak ratio was 0.32."
62513542|NCT05550220|ACTIVE_COMPARATOR|Usual Cuff Leak Test|"The subjects were placed in volume assist-control mode with the following parameters:~* respiratory rate was adapted to patient comfort~* original oxygen concentration and PEEP~* the VT about 8ml/Kg IBW~* inspiratory flow was set at 60 L/min with square waveform Positive cutoff value of the air leak volume was 110 mL and the air leak ratio was 0.15."
62513543|NCT02556307||Peginterferon alfa-2a + Ribavirin|
62513544|NCT00378950|ACTIVE_COMPARATOR|1|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups.
62709657|NCT02551315||Controls, prevalent fractures|Age and sex-matched non-diabetic controls
62147204|NCT06343181||Metastatic breast cancer (BC)|Patients with diagnosis of BC
62147205|NCT02202317|EXPERIMENTAL|Y90 Based PET/CT Scan|
62513545|NCT00378950|EXPERIMENTAL|2|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups, as well as additional information on diuretic self adjustment. This group will then get several follow-up phone calls over the course of the year to reinforce these topics and help them master the knowledge and encourage behavior and lifestyle changes to align with these topics.
62513546|NCT05688397|EXPERIMENTAL|Experimental 1|L. gasseri oral capsule
61973076|NCT04155112|EXPERIMENTAL|Hypocaloric Mediterranean diet (MeDi)|For 6 months, the participants will be recommended to consume a diet for 5-10% body weight loss. This diet will be based on the Mediterranean diet pattern. For the 6 months of the intervention, the participants will weigh themselves weekly and report their progress to the investigator. Adaptations to the diet will be made to ensure the goal of 5-10% weight loss is achieved. Each participant will receive a scale to bring home and to use while reporting weight loss.
62147206|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.~A BMI under 35 and no pregnancy."
62709658|NCT04405531|EXPERIMENTAL|task-oriented training(TOT)|The first phase of the TOT, functional activity analysis, was performed for the activities, for which performance problem was determined by Canadian Occupational Performance Measure (COPM) and Functional Independence Measure for Children (WeeFIM). In the second phase, the occupational performance, fatigue and functional independence levels that prevent the realization of the activity were determined by functional activity analysis. These designated occupational performance, fatigue and functional independence levels constitute the task of this study, as we aim to improve children's functionality. In the third phase, various functional activities including these tasks were executed. The TOT was practiced by following the above mentioned steps for each performance area. All the activities were designed for the inpatient settings of children.
61973077|NCT04155112|NO_INTERVENTION|Control|At baseline, participants will receive usual care, which consists of general information regarding the importance of lifestyle for BP. This information will not be reinforced throughout the study duration.
61973078|NCT04142853|EXPERIMENTAL|Persons with MS, dance group|
61973079|NCT04142853|ACTIVE_COMPARATOR|Persons with MS, art group|
61973080|NCT04883190||1. after SARS-CoV-2 infection|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
61973081|NCT04883190||2. control group with negative antibody test|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
62147207|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
62147208|NCT00927849|ACTIVE_COMPARATOR|surgical group lateral sphincterotomy|underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
62147209|NCT00927849|ACTIVE_COMPARATOR|Glycerin trinitrate group|all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
62353606|NCT01893684|EXPERIMENTAL|Protein + Exercise|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period.
62353607|NCT01893684|EXPERIMENTAL|Protein|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams.
62353608|NCT01893684|EXPERIMENTAL|Carbohydrate + Exercise|Diet will provide dietary protein at 0.8 g.kg-1.d-1 (\~ 18% of energy intake) with a ratio of carbohydrates/protein \> 3.5 and dietary lipids at \~30% energy intake. Again, energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period.
62353609|NCT04391972|OTHER|SAV multifocal IOL|Subjects who have cataract surgery with SAV multifocal IOL
62513547|NCT05688397|EXPERIMENTAL|Experimental 2|L. gasseri + L. crispatus oral capsule
62513548|NCT05688397|PLACEBO_COMPARATOR|Placebo|Maltodextrin (E1400, qs) oral capsule once a day
62513549|NCT02477241|OTHER|Healthy female subjects|Healthy female subjects with or without overactive bladder undergoing functional MRI brain and urodynamic study.
62513550|NCT01754818|PLACEBO_COMPARATOR|Placebo|Placebo, oral capsule, no active study drug, single dose
62513551|NCT01754818|EXPERIMENTAL|Bendavia 10mg|Bendavia, oral capsule, 10mg, single dose
62513552|NCT01754818|EXPERIMENTAL|Bendavia 50mg|Bendavia, oral capsule, 50mg, single dose
62513553|NCT01754818|EXPERIMENTAL|Bendavia 100mg|Bendavia, oral capsule, 100mg, single dose
62513554|NCT02839486||vancomycin and cefoxitin pharmacokinetics|This is surgical prophylaxis and cefoxitin/vancomycin have to be administered to each patient of the study, before surgery
62513555|NCT00857259|EXPERIMENTAL|Everolimus 5 mg|5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28
62513556|NCT00857259|ACTIVE_COMPARATOR|Ranibizumab 0.5 mg|Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline)
62513557|NCT00857259|ACTIVE_COMPARATOR|Oral Everolimus (5mg) and Ranibizumab (0.5mg)|Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)
62513558|NCT05887219|ACTIVE_COMPARATOR|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily)
62513559|NCT05887219|ACTIVE_COMPARATOR|Group B Azelaic Acid 20 % cream for 6 months|group B was managed with topical 20% azelaic acid (daily at night) for six months.
62513560|NCT05134194|EXPERIMENTAL|Arm A|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
62513561|NCT05134194|EXPERIMENTAL|Arm B|Capecitabine or eribulin or gemcitabine or vinorelbine
62513562|NCT03054831|ACTIVE_COMPARATOR|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
62513563|NCT03054831|ACTIVE_COMPARATOR|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
62513564|NCT03054831|ACTIVE_COMPARATOR|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
62709659|NCT04405531|EXPERIMENTAL|conventional occupational therapy (COT)|The treatment efficacy determined by the therapist was provided by considering the functional level in order to achieve the desired goal by the participant. The COT included functional activities based on the client-centered principles of the neuro-developmental approach. All the sessions started with relaxation training combined with breathing exercises. At the end of approximately 10 minutes of application time, individualized functional activities were implemented.
62513565|NCT03054831|ACTIVE_COMPARATOR|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
62513566|NCT04611984|EXPERIMENTAL|Piezocision|Piezocision was performed on the mesial and distal side of the maxillary right canine tooth which was served as the piezocision group. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
62513567|NCT04611984|ACTIVE_COMPARATOR|Control|Maxillary left canine served as the control group and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
62513568|NCT03808870|EXPERIMENTAL|NBM-BMX|
62513569|NCT00021060|EXPERIMENTAL|Arm I (paclitaxel and carboplatin)|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
62709660|NCT05759403||Patients with parkinson's disease|Genetic analysis, clinical data , cortical excitbility
62513570|NCT00021060|EXPERIMENTAL|Arm II (paclitaxel, carboplatin, and bevacizumab)|"Patients receive paclitaxel and carboplatin as in arm I followed by bevacizumab IV over 30-90 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~After completion of 6 courses, patients in arm II with stable or responding disease continue to receive bevacizumab only. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
62513571|NCT02283450||the experimental group|The patients in experimental group received the relevant tests and inspections before the beginning of experiment，signed the informed consent. Then we get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day，four tablets at a time. Afrer a month，we evaluated the symptoms，the function of heart，blood pressure，heart rate and keep blood specimens. Three and six month later，electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done.
62513572|NCT02283450||the placebo group|The placebo group was followed up in the same way.
62709661|NCT05759403||patients with Parkinson dementia complex|Genetic analysis, clinical data , cortical excitbility
62513573|NCT03902002|EXPERIMENTAL|Group 1: matched healthy subjects|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
62513574|NCT03902002|EXPERIMENTAL|Group 2: subjects with mild hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
62513575|NCT03902002|EXPERIMENTAL|Group 3: subjects with moderate hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
62513576|NCT03902002|EXPERIMENTAL|Group 4: subjects with severe hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
62539463|NCT00650208|ACTIVE_COMPARATOR|2|Lamictal® Tablets 25 mg
62709662|NCT02031614|EXPERIMENTAL|Phlebotomy|Subjects in this arm will undergo phlebotomy of 500 mL of blood.
62709663|NCT01142180|ACTIVE_COMPARATOR|TAE group|Patients will be undergone TAE after endoscopic hemostasis.
62513577|NCT01714050|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT)|"The CBT is a SAD-tailored version of Beck et al.'s (1979) cognitive therapy for depression called Coping with the Seasons (Rohan, 2008). The rationale addresses environmental changes, thoughts, and behaviors in SAD onset and maintenance. It seeks to change behaviors and thoughts to improve coping with winter. Behaviors that promote enjoyment in the winter are increased. Negative thoughts that interfere with self-esteem and negative thoughts about winter are identified and addressed. A relapse-prevention component addresses early identification of negative anticipatory thoughts about winter and SAD-related behavior changes, using the CBT skills learned to cope with subsequent winter seasons, and development of a personalized relapse-prevention plan. The CBT sessions are administered twice a week over 6 weeks (total of 12 sessions) with 4-8 participants per group. The CBT is led by one of three licensed Ph.D.-level psychologists working on the project."
62513578|NCT01714050|EXPERIMENTAL|Light Therapy (LT)|LT will be initiated at 30-minutes in the morning at home, first thing upon awakening, using a light box with an ultraviolet shield that emits 10,000-lux of white fluorescent light. After the first week, an M.D. light therapy consultant will recommend individually-tailored, clinical adjustments to the duration and timing of light use to maximize response and reduce any reported side effects. For each of the 6-weeks of LT, LT participants will complete a Light Therapy Side Effects Questionnaire to assess side effects attributed to LT. Participants will keep daily LT compliance diaries to record the timing and duration of LT. After the 6-weeks of monitoring, participants may choose to continue using the light box through April. We will offer LT participants who wish to use light therapy in the next fall/winter season access to our light boxes if they agree to followup with a physician or other qualified professional for monitoring and side effects management.
62513579|NCT05342207|EXPERIMENTAL|cases|
62513580|NCT03362996|EXPERIMENTAL|Experimental Group|"50 patients Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days.~Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
62513581|NCT03362996|PLACEBO_COMPARATOR|Control group 1|50 patients Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days. Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)
62513582|NCT03362996|OTHER|Control Group 2|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
62513583|NCT02336516|EXPERIMENTAL|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ®
62513584|NCT02336516|PLACEBO_COMPARATOR|Glucose solution 10%|Glucose solution 10%
62513585|NCT06064734|EXPERIMENTAL|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
62513586|NCT06064734|NO_INTERVENTION|Control|Routine treatment.
62513587|NCT05026931|EXPERIMENTAL|Group A|Foam Rolling
62513588|NCT05026931|ACTIVE_COMPARATOR|Group B|Stretching exercises
62513589|NCT01639950||Adults Group 1|Adults patients with cancer or neurofibromatosis 1 (NF1)
62513590|NCT01639950||Adults Group 2|Adults with sickle cell disease (SCD)
62513591|NCT01639950||Children|Children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
62513592|NCT01639950||Parents|Parents of children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
62513593|NCT03432988|EXPERIMENTAL|nurses in the hemodialysis service|Nursing Solution-Focused: Two two-hour training modules were designed by two recognized solution-focused therapy experts. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays.
62513594|NCT04880720||COVID-19 Patients|
62513595|NCT04880720||Rheumatoid Arthritis Patients|
62513596|NCT04880720||Healthy Comparator|
62513597|NCT06090682||Cognitive Impairment (CI) group and No Cognitive Impairment (NCI) group|"We intend to recruit 200 patients with primary PD to undergo DBS surgery or only TMS treatment according to whether the surgical indication is available. We will observe the changes in cognitive function of patients before and after different brain stimulation treatments.~Parkinson's disease patients with cognitive impairment after brain stimulation were divided into cognitive impairment group, and those without cognitive impairment after treatment were divided into no cognitive impairment group"
62513598|NCT00789113|EXPERIMENTAL|Extended Release Lamotrigine|Extended Release Lamotrigine
62513599|NCT03629028|ACTIVE_COMPARATOR|Single Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
62513600|NCT03629028|ACTIVE_COMPARATOR|Double Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
62513601|NCT03163433|EXPERIMENTAL|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
62513602|NCT03163433|NO_INTERVENTION|Control|Usual consultations
62709664|NCT01142180|ACTIVE_COMPARATOR|No TAE group|No TAE procedure will be performed after endoscopic treatment.
62513603|NCT04786977||VIPN Patients|
62513604|NCT04786977||Healthy Volunteers|
62539464|NCT05229003|EXPERIMENTAL|cohort A|"Anlotinib + Irinotecan:~Anlotinib, 10mg, oral, once daily, D1-10, q2W; Irinotecan, 180mg/m2, iv drip, d6, q2w."
62539465|NCT05229003|EXPERIMENTAL|cohort B|"Anlotinib + Penpulimab + Irinotecan:~Anlotinib, 8mg, oral, once daily, d1-10, q2w; Penpulimab 200mg, i.v. d6, q2w; Irinotecan, 180mg/m2, iv infusion, d6, q2w."
62539466|NCT06599580|NO_INTERVENTION|Standard of care treatment and follow-up schedule without alteration (control arm)|This arm with serve as the control arm and receive the current standard of care, which is no caregiver training to conduct mid-upper arm circumference screenings and monthly clinic-based follow-up appointments for 3 months with a final visit at 6 months post enrollment.
62513605|NCT03443518|EXPERIMENTAL|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical land mark for psoas plexus, also normal saline 0.9% IV infusion will be in the same rate of the Remifentanil infusion for the other group.
62513606|NCT03443518|EXPERIMENTAL|L.A infiltration /Remifentanil infusion|L.A infiltration (lidocaine) 5 ml of 2% will be injected subcutaneous as L.A infiltration then Remifentanil infusion with rate 0.03-0.1 μg / kg / min to achieve Visual Analog Scale 3 or less.
62709665|NCT00582907|EXPERIMENTAL|1|Treatment Arm A: Rilonacept (IL-1 Trap) at a dose of 2.2 mg/kg/wk (max 160 mg)given by subcutaneous injection for 3 months plus colchicine at a stable dose for those subjects already taking colchicine, or without colchicine for those intolerant or non-compliant with colchicine. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention
62709666|NCT00582907|PLACEBO_COMPARATOR|2|Treatment Arm B: Placebo given by subcutaneous injection weekly with or without colchicine for 3 months. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention.
62709667|NCT04999267|EXPERIMENTAL|INVEST Intervention School Districts|
62709668|NCT00788112|EXPERIMENTAL|Vorinostat|
62709669|NCT04104347|EXPERIMENTAL|Metacognitive training (MCT)|
61973082|NCT04359433|NO_INTERVENTION|Standard group|The participates in this group would provide normal health education of scientific and rational diet.
62147210|NCT00927849|ACTIVE_COMPARATOR|botulinum toxin injection|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
62709670|NCT04104347|ACTIVE_COMPARATOR|Support group|
62709671|NCT02683902|ACTIVE_COMPARATOR|Active tDCS + Diet|The participants will receive active tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
62709672|NCT02683902|SHAM_COMPARATOR|Sham tDCS + Diet|The participants will receive sham tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
62147211|NCT05543109|ACTIVE_COMPARATOR|Psoas compartment block|After induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
62147212|NCT05543109|ACTIVE_COMPARATOR|Suprainguinal fascia iliaca compartment block|After induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
62147213|NCT05466786||Experimental ARM|All patients received standard care for postoperative management.
62709673|NCT01219257||SpA patients|The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
62709674|NCT05875961|EXPERIMENTAL|Group A|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of low dose A/H2N3c + standard dose MF59 adjuvant
62709675|NCT05875961|EXPERIMENTAL|Group B|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of intermediate dose A/H2N3c + standard dose MF59 adjuvant
62709676|NCT05875961|EXPERIMENTAL|Group C|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of high dose A/H2N3c + standard dose MF59 adjuvant
62709677|NCT05875961|EXPERIMENTAL|Group D|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of high dose A/H2N3c non-adjuvanted
62709678|NCT05875961|EXPERIMENTAL|Group E|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of lowest dose A/H2N3c + high dose MF59 adjuvant
62709679|NCT05875961|EXPERIMENTAL|Group F|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of low dose A/H2N3c + high dose MF59 adjuvant
62709680|NCT04293198||control arm|Cryoballoon PVI procedure where the freeze was initiated based on the occlusion assessed using fluoroscopy
62709681|NCT04293198||Kodex arm|Cryoballoon PVI where the freeze was initiated based on the outcome of the KODEX occlusion Viewer
62709682|NCT04666792|OTHER|PrEP for HIV-1 uninfected for women accessing family planning|Women accessing family planning will be assessed for HIV risk and PrEP eligibility. If eligible and willing to initiate PrEP, they will be provided PrEP in accordance with national guidelines as part of their standard of care at the family planning clinic.
61973083|NCT04359433|EXPERIMENTAL|Exercise intervention group|Besides normal health education of scientific and rational diet，the participates in this group would be suggested to carry out an anaerobic exercise named Tabata.
61973084|NCT02648178|ACTIVE_COMPARATOR|HALO G6|HALO cigalike model
62147214|NCT04427124||Prospective|Patients admitted into the hospital will receive care based on a multidisciplinary team approach and Institutional critical limb ischemia protocol.
62147215|NCT04427124||Retrospective|A retrospective analysis of all patients with CLI admitted to the hospital from 2017-2019 will serve as a baseline comparator for overall CLI care and long-term mortality out to 2 years will be analyzed in the retrospective cohort using the national death index. Patients will be identified by the following ICD codes: 440.22 (ASVD of extremities with rest pain), 440.23 (ulceration), and 440.24 (gangrene).
62147216|NCT05028465|EXPERIMENTAL|EP combined with RFA|Endoscopic Papillectomy Combined with Endobiliary Radiofrequency Ablation
62147217|NCT04924296|EXPERIMENTAL|Treatment group A|
62513607|NCT01015092||unselected HIV outpatient attendees|All HIV patients attending for general HIV care at 2 London Hospitals
62513608|NCT01322971|ACTIVE_COMPARATOR|Metronidazole|Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
62513609|NCT01322971|PLACEBO_COMPARATOR|Placebo|Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
62709683|NCT03830437||Case group|The group will be subjected to double weighing, before and after the next 6 breastfeeding. Breastfeeding will be carried out each 4 hr.
62709684|NCT03830437||Control group|The group will be subjected to monitoring of body weight only at 24, 36 hr and 48 hr of life.
62709685|NCT01447537|ACTIVE_COMPARATOR|Exercise, relaxation|Active comparator: Exercise + relaxation Patients will perform exercise + relaxation for 3 months
62353610|NCT02610205||Caring touch interventions|The study was conducted as a mixed-methods design. A recruitment of potential study participants was made up from a list of incoming patients arriving at the emergency department following an MVA, and who upon medical examinations were given an injury severity score between 0-3 and subsequently discharged straight home. ISS is a 0-8 point scale rating injury severity, where a rating of 0 indicates no physical injury; 1-3 represents minor physical injuries. The patients were informed about the study by mail during the week after the MVA, and those interested in participating in the caring touch intervention were asked to contact the investigator and subsequently completed a written informed consent form during the first encounter with the therapist.
62709686|NCT01447537|OTHER|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
62709687|NCT05465304||Control group|control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy.
62709688|NCT05465304||Azithromycin group|the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month
61973085|NCT02648178|ACTIVE_COMPARATOR|HALO Triton|HALO tank model
62147218|NCT04924296|PLACEBO_COMPARATOR|Treatment group B|
62709689|NCT05465304||Azithromycin plus Clindamycin group|the second test group in which the pregnant women administerated Azithromycin and clindamycin (Dalacin®) vaginal gel 5 times per month.
62147219|NCT04957277|EXPERIMENTAL|load modulation|Participants will experience different body weight loading conditions - with body weight added by a weighted vest or removed using the ZeroG overhead harness.
62709690|NCT02491879|EXPERIMENTAL|Ketoprofen|Ketoprofen gel
62709691|NCT02491879|PLACEBO_COMPARATOR|Placebo|Placebo form of ketoprofen gel
62709692|NCT05489328|EXPERIMENTAL|Candidate-1|Participants to receive a single injection of Candidate-1.
62709693|NCT05489328|EXPERIMENTAL|Candidate-2|Participants to receive a single injection of Candidate-2.
62709694|NCT05489328|EXPERIMENTAL|Candidate-3|Participants to receive a single injection of Candidate-3.
62709695|NCT05489328|EXPERIMENTAL|Candidate-4|Participants to receive a single injection of Candidate-4.
62147220|NCT01849536|EXPERIMENTAL|SENSIMED Triggerfish®|SENSIMED Triggerfish®
62147221|NCT01677832||ADHD/Taiwan|
62147222|NCT01677832||Control/Taiwan|
62147223|NCT01677832||ADHD/Germany|
62147224|NCT01677832||Control/Germany|
62147225|NCT04592926|EXPERIMENTAL|Accuro ultrasound|
62709696|NCT05489328|EXPERIMENTAL|Candidate-5|Participants to receive a single injection of Candidate-5.
62147226|NCT04592926|SHAM_COMPARATOR|Control|
62709697|NCT05489328|EXPERIMENTAL|Candidate-6|Participants to receive a single injection of Candidate-6.
61973086|NCT02555189|EXPERIMENTAL|Treatment (enzalutamide, ribociclib)|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, tumor biopsy, ECHO or MUGA, bone scan, and CT or MRI on study.
61973087|NCT02601508|ACTIVE_COMPARATOR|Modarate Blockade Group|Neuromuscular blocking agent, cis-atracurium will be administered after skin incision and reversal agents, pyridostigmine \& glycopyrrolate will be given for the recovery.
62147227|NCT02757911|EXPERIMENTAL|open label|X vivo gene therapy
62147228|NCT03288506|EXPERIMENTAL|Google Hangout (VC) group|This group receive peer led support for depression via Google Hangouts for 8-weeks
62147229|NCT03288506|NO_INTERVENTION|Waiting list control group|Waiting list
62147230|NCT02418689|EXPERIMENTAL|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
62147231|NCT02038049|EXPERIMENTAL|VAY736|Intravenous infusion of VAY736
62147232|NCT02038049|PLACEBO_COMPARATOR|Placebo to VAY736|Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
62353611|NCT04183894|EXPERIMENTAL|Personalized Intervention Based on Network|Participants will receive personalized interventions based on their personalized network.
62353612|NCT01684683|EXPERIMENTAL|Theophylline|Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks
62353613|NCT01684683|PLACEBO_COMPARATOR|placebo|Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks
62353614|NCT00939939|EXPERIMENTAL|sitagliptin|
62709698|NCT05489328|ACTIVE_COMPARATOR|Candidate Control|Participants to receive a single injection of Candidate Control.
62709699|NCT05489328|OTHER|13-valent pneumococcal conjugate vaccine (13vPnC)|Participants to receive a single injection of 13vPnC.
62709700|NCT05489328|OTHER|15-valent pneumococcal conjugate vaccine (PCV15)|Participants to receive a single injection of PCV15.
62709701|NCT03817684|EXPERIMENTAL|BPN14770 10mg bid|10 mg bid dose of the Drug BPN14770
62709702|NCT03817684|EXPERIMENTAL|BPN 14770 25mg bid|25mg bid dose of the Drug BPN14770
62709703|NCT03817684|PLACEBO_COMPARATOR|Placebo|
62709704|NCT04089020|EXPERIMENTAL|Psychosocial intervention|Text messaging and health coaching over the telephone to address goal setting, monitoring, motivation, problem solving, and related skills, delivered over 6 weeks.
62709705|NCT00093509|EXPERIMENTAL|Magnetic Resonance Based Thermometry|"Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90. Interstitial temperature measurements will be taken by placing a single (less than or equal to) 15 gauge thermometry catheter into the tumor.~In addition to hyperthermia treatment and radiation therapy all patients will receive conventional surgery for the removal of their tumors. Some patients will also receive chemotherapy if their treating physician thinks it is the their best interested (including the possibility of doxorubicin hydrochloride or ifosfamide and mesna)."
62513610|NCT00641784|EXPERIMENTAL|1|Oral Nifedine
62513611|NCT00641784|ACTIVE_COMPARATOR|2|Intravenous Magnesium
62709706|NCT05406583|EXPERIMENTAL|Cohort 1|"Cohort 1 will be opened first to accrual, with Strata 1A and 1B being opened concurrently, to evaluate the PK and safety of two single DTG liquid suspension doses for the relevant stratum. Stratum 1C will only be opened to accrual if PK and safety data from Strata 1A and 1B infants support administration of DTG 5 mg DT across all neonates, or only in neonates with a minimum birth weight.~* Stratum 1A (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)~* Stratum 1B (DTG-exposed): Infants with in utero exposure to maternal DTG (mothers who receive at least one dose of DTG within 72 hours prior to delivery)~* Stratum 1C (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)."
62709707|NCT05406583|EXPERIMENTAL|Cohort 2|"Cohort 2, Strata 2A and 2B, will be opened to accrual when the DTG dose and formulation to be administered for each stratum are established based on the PK and safety data from all Cohort 1 strata (Strata 1A and 1B, and 1C if applicable) and available data from other studies.~* Stratum 2A (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)~* Stratum 2B (DTG-exposed): Infants with in utero exposure to maternal DTG (mothers who receive at least one dose of DTG within 72 hours prior to delivery)"
62709708|NCT04326738|PLACEBO_COMPARATOR|normal saline (N) group|N group received corresponding intravenous normal saline of 1ml·kg-1.
62709709|NCT04326738|ACTIVE_COMPARATOR|midazolam (M) group|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam.
62353615|NCT00939939|ACTIVE_COMPARATOR|glimepirid|
62353616|NCT00532714|NO_INTERVENTION|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 (intravenously once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period) Capecitabine (orally at a dose of 1,000 mg/m2 twice daily 3-week cycles (2 weeks of treatment followed by a 1-week rest period))
62353617|NCT01079650||children suffering from abdominal or testicle pain|
62513612|NCT05487365|EXPERIMENTAL|Patients with application|"Eligible patients are consecutive patients that are hospitalised for HF decompensation. The patients will be included in the programme during their hospitalisation or up to one month after hospitalisation. All eligible patients will be offered to participate. At the time of inclusion, patients must be in NYHA class II, III, or IV with a left ventricular ejection fraction (LVEF) of ≤50%. A total of 165 patients with app will be included over 6 month. Patients are not randomised and will all be participating in the smartphone digital support intervention.~Patients are not randomised and will all be participating in the smartphone digital support intervention.~So the app will be made available to 165 patients for home monitoring and another group of 165 patients without an application will be asked to answer quality of life questionnaires.~Patients who agree to use the application can continue to use it after the study, if they wish."
62513613|NCT05487365|ACTIVE_COMPARATOR|Patients without application|"Patients refusing participation will also be asked to complete a quality of life (QOL)-questionnaire at 6 months and 12 months which will be answered online. A total of 165 patients (who do not want to participate) will be asked to answer this questionnaire.~So the app will be made available to 165 patients for home monitoring and another group of 165 patients without an application will be asked to answer quality of life questionnaires.~Patients who agree to use the application can continue to use it after the study, if they wish."
62513614|NCT03609281||Scheduled cesaren group|Patient delivered by elective cesarean section without labour pains
62513615|NCT03609281||Emergency cesarean group|Patients delivered by cesarean section due to an emergency
62709710|NCT03563547|ACTIVE_COMPARATOR|Fat modified diet|Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
62709711|NCT03563547|EXPERIMENTAL|Fat modifed diet enriched with soy protein|"Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects in this arm were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
62709712|NCT01145950|EXPERIMENTAL|Group 1|
62709713|NCT01145950|EXPERIMENTAL|Group 2|
62709714|NCT03616821|EXPERIMENTAL|Brazikumab Dose 1|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through week 50
62709715|NCT03616821|EXPERIMENTAL|Brazikumab Dose 2|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
62353618|NCT03303287|EXPERIMENTAL|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
62513616|NCT05854459|EXPERIMENTAL|HIIT and Nordic Curl exercise group|The participants will perform a weekly 50 minutes session for four weeks.
62513617|NCT05854459|ACTIVE_COMPARATOR|HIIT-only group|The participants will perform a weekly 40 minutes session for four weeks.
62353619|NCT03303287|NO_INTERVENTION|control|usual
62353620|NCT04021459|OTHER|women with endometrial cancer|
62353621|NCT04839224|EXPERIMENTAL|Carbogen group|
62353622|NCT04839224|ACTIVE_COMPARATOR|Phenylephrine group|
62353623|NCT02584777|EXPERIMENTAL|Pacritinib|Oral administration
62353624|NCT02781012||Healthy|Healthy volunteers without any known pancreatic disease
62353625|NCT02781012||Healthy At-Risk|Healthy volunteers with no known benign or malignant pancreatic disease, AND with one first-degree relative with pancreatic cancer, OR two second-degree relatives with pancreatic cancer. These subjects also include those who have undergone surgery for suspected pancreatic cancer, and who are found to have a non-pancreatic cancer pathology upon final local site or central pathology review.
62353626|NCT02781012||Pancreatitis|Subjects diagnosed with acute or chronic pancreatitis
62513618|NCT04286919|ACTIVE_COMPARATOR|ExRx#1: Physical Activity Guidelines|ExRx#1 uses the Frequency, Intensity, Time, and Type or FITT principle of exercise prescription to prescribe the Physical Activity Guidelines for Americans which is a weekly goal of 150-minutes of moderate intensity aerobic physical activity plus 2 days of muscle strengthening physical activity. ExRx#1 communicates the ultimate goal of the physical activity guidelines for Americans using an image adopted from the physical activity guidelines website that depicts the weekly goal. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the physical activity guidelines ultimate weekly goal by providing a weekly prescription of Frequency, Intensity, Time, and Type of physical activity that accomplishes meeting the physical activity guidelines weekly goal.
62513619|NCT04286919|EXPERIMENTAL|ExRx#2: Heat Map|ExRx#2 uses the heat map image published in the 2018 Physical Activity Guidelines Advisory Committee Scientific Report that communicates the dose-response relationship between increased physical activity and improved health to prescribe the message that all physical activity across all Frequencies, Intensities, Time bouts and Types (FITT) counts towards health. ExRx#2 is founded in the Integrated Behavior Change Theory and emphasizes that all physical activity matters regardless of FITT as depicted by the heat map image. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the ExRx#2 heat map ultimate weekly goal of moving more throughout the day across all intensities in order to achieve optimal health as represented by the deep green color on the bottom right of the heat map image.
62513620|NCT01685658|ACTIVE_COMPARATOR|Ketaprofen|"Patients randomized to this arm will receive intravenous ketaprofen when treating renal colic.~Intervention: intravenous ketaprofen"
62513621|NCT01685658|EXPERIMENTAL|Paracetamol|"Patients randomized to this arm will receive intravenous paracetamol when treating renal colic.~Intervention: intravenous paracetamol"
62513622|NCT05813938|EXPERIMENTAL|Intervention arm|
62513623|NCT00854373|EXPERIMENTAL|1|Bravelle
62513624|NCT00854373|PLACEBO_COMPARATOR|2|Saline
62513625|NCT02976259|EXPERIMENTAL|Patient HIV primary infection|HIV primary infection Patient male receiving Dolutegravir
62709716|NCT03616821|PLACEBO_COMPARATOR|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous every 4 weeks beginning on day 71 through Week 50.
62709717|NCT05170971|OTHER|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times.
62709718|NCT04252209|EXPERIMENTAL|patients with sjogren's received natural mixture|"The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
62709719|NCT04252209|ACTIVE_COMPARATOR|patients with sjogren's recievrd CMC|"the control is a moisturizing gel containing 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
61973088|NCT02601508|EXPERIMENTAL|Deep Blockade Group|Neuromuscular blocking agent, rocuronium will be administered after skin incision and reversal agent, Sugammadex will be given for the recovery.
61973089|NCT05030038||Aromatase inhibitor for breast cancer treatment|Participants will receive their standard of care for breast cancer treatment which includes an aromatase inhibitor. Pre-study assessments will be done at baseline as well as stool and blood samples at baseline, then again at 4 weeks and at 12 weeks during the course of the trial.
62147233|NCT03377049|EXPERIMENTAL|Acetazolamide Challenge|Participants entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
62353627|NCT02781012||Early Stage/Borderline/Locally Advanced|Subjects diagnosed with early stage pancreatic cancer who undergo surgery as standard of care therapy with or without preoperative (neoadjuvant) chemotherapy and/or radiation therapy; subjects diagnosed with borderline pancreatic cancer, or subjects diagnosed with locally advanced pancreatic cancer.
62353628|NCT02781012||Metastatic|Subjects diagnosed with metastatic pancreatic cancer and treated with any standard of care therapy/therapies.
62513626|NCT06616922|EXPERIMENTAL|Test arm|Patients will be randomly assigned (1:1) to one of the two treatment groups
61973090|NCT01092754|OTHER|A: Other|
62513627|NCT06616922|ACTIVE_COMPARATOR|Standard drug arm|Patients will be randomly assigned (1:1) to one of the two treatment groups
62513628|NCT05175924|EXPERIMENTAL|Virtual reality|In the Aquarium VR group, virtual reality headset compatible with iPhone 7 (Apple) was used to distract attention. Before use, the headsets were tested on five children for face fit and visibility of the application used. Written and verbal consent of the children and their parents was obtained to test the headsets. The children who tested the headsets were not included into the study. The headset offered a soft and comfortable experience in contact with the skin due to its leather and pad covering. It also had a wide viewing angle and an optical zoom button. Due to its noise isolation function, it did not disturb anyone or make noise.
62709720|NCT02803684|EXPERIMENTAL|Single arm|Whole cohort
62709721|NCT03997721||Perforation|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal perforation or ( small intestine, large intestine), perforated ventricular or duodenal ulcer
62709722|NCT03997721||Obstruction|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal obstruction
61973091|NCT01092754|OTHER|B: Other|
61973092|NCT06046339||Patients|Patients hospitalized at Necker Hospital for an extra-hospital cardiac arrest between January 1, 2015 and October 31, 2019.
61973093|NCT06359067||Treated by bispecific antibodies|Patients with multiple myeloma, penta-drug or triple class refractory and treated by bispecific antibodies, teclistamab or elranatamab
61973094|NCT06359067||Control group|Patients with multiple myeloma, penta-drug or triple class refractory and not treated by bispecific antibodies
62513629|NCT03729154|EXPERIMENTAL|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
62513630|NCT03729154|NO_INTERVENTION|Treatment as Usual|Participants in the Treatment as Usual condition will receive behavioral and counseling services typically provided by their preschool.
62513631|NCT01613664|EXPERIMENTAL|tisseel|tisseel will be applied during the surgery
62513632|NCT01613664|PLACEBO_COMPARATOR|no tisseel|no tisseel will be applied during the surgery
62513633|NCT03902899|EXPERIMENTAL|Intervention-arm|"All endoscopists employed by 9 semi-randomly chosen hospitals in the Netherlands will be exposed to an educational intervention (oral presentation): an oral awareness training which will be delivered twice, first in 2014 and then in 2016/2017.~In total 38 endoscopists are included from these 9 hospitals."
62513634|NCT03902899|NO_INTERVENTION|Control arm|A random set of 100 endoscopists will be selected ass a reference group. These 100 endoscopists were unaware of the present study, and were thus blinded for their allocation.
62513635|NCT02502734|EXPERIMENTAL|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
62513636|NCT02502734|EXPERIMENTAL|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
62513637|NCT05833152||<5°|
62513638|NCT05833152||5-10°|
62513639|NCT05833152||10-15°|
62513640|NCT05833152||≥15°|
62513641|NCT03179449|EXPERIMENTAL|Diagnostic (ferumoxytol-enhanced MRI)|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
62513642|NCT06127017|PLACEBO_COMPARATOR|Titanium bar|6 implants in each participant will be immediately loaded and splinted with intraorally welded titanium bar.
62513643|NCT06127017|ACTIVE_COMPARATOR|PEEK bar|6 implants in each participant will be immediately loaded and splinted with PEEK bar.
62513644|NCT05045313|EXPERIMENTAL|The DDI of DBPR108 and Warfarin Sodium Tablets|Subjects will receive a single dose of Warfarin sodium 5 mg on Day 1, then take DBPR108 100 mg once-daily on Day 15 through Day 26 and a single dose of Warfarin sodium 5 mg on Day 19.
62513645|NCT05045313|EXPERIMENTAL|The DDI of DBPR108 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take DBPR108 100 mg once-daily on Day 6 through Day 15 and a single dose of Digoxin 0.25 mg on Day 10.
62513646|NCT05045313|EXPERIMENTAL|The DDI of DBPR108 and Probenecid Tablets|Subjects will receive a single dose of DBPR108 100 mg on Day 1, then take Probenecid 500 mg twice-daily on Day 5 through Day 9 and a single dose of DBPR108 100 mg on Day 7.
62513647|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
62513648|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
62513649|NCT04684524|EXPERIMENTAL|Dupilumab|Dupilumab administered every 2 or 4 weeks based on weights
62513650|NCT04684524|PLACEBO_COMPARATOR|Matching placebo|Placebo administered every 2 or 4 weeks based on weights
62513651|NCT03861663|OTHER|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
62513652|NCT05089929||Endoflip 2.0|The investigators will perform FLIP topography (Endoflip 2.0) analysis on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
62513653|NCT01221090|EXPERIMENTAL|Personal Digital Assistant|Individuals in this arm were taught to use a diabetes self-care software, Diabetes Pilot™ (Digital Altitudes, Arlington Heights, IL), developed for PalmOS® (Palm, Sunnyvale, CA) which was loaded on to compatible PDAs, the Tungsten™ E2 handheld device. The Diabetes Pilot allowed participants to monitor their blood glucose, blood pressure, medication usage, physical activity, and dietary intake by tracking these measures in an electronic diary.
62513654|NCT01221090|ACTIVE_COMPARATOR|CDSMP|6-week, classroom-based program for diabetes self-management. The CDSMP, developed by Stanford University, equipped participants with the education and skill sets needed to take a more proactive approach in managing their chronic condition(s) and related symptoms.
62709723|NCT03997721||Anasomotic leak|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of anastomotic leak following elective surgery.
62709724|NCT06133023|EXPERIMENTAL|Plastic stent group|In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed.
62513655|NCT01221090|ACTIVE_COMPARATOR|PDA/CDSMP|Combined intervention
62513656|NCT01221090|NO_INTERVENTION|Control|Usual Care
62513657|NCT01468376|EXPERIMENTAL|GLU-01|
62513658|NCT01468376|EXPERIMENTAL|GLU-02|
62513659|NCT01468376|EXPERIMENTAL|GLU-03|
62513660|NCT01468376|EXPERIMENTAL|GLU-04|
62513661|NCT01468376|EXPERIMENTAL|GLU-05|
62513662|NCT01468376|EXPERIMENTAL|GLU-06|
62709725|NCT06133023|ACTIVE_COMPARATOR|LAMS group|In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed.
62513663|NCT06504498|ACTIVE_COMPARATOR|0.5 mm-thick Duran® clear aligners|0.5 mm-thick clear aligners (Duran®; Scheu-Dental GmBH, Iserlohn, Germany).
62709726|NCT04620161|EXPERIMENTAL|Pradigastat Tablets 20mg|The patients in this arm will receive one tablet a day of Pradigastat 20mg and one tablet a day of Pradigastat 40mg matching placebo
62709727|NCT04620161|EXPERIMENTAL|Pradigastat Tablets 40mg|The patients in this arm will receive one tablet a day of Pradigastat 40mg and one tablet a day of Pradigastat 20mg matching placebo
62709728|NCT04620161|PLACEBO_COMPARATOR|Placebo|The patients in this arm will receive one tablet a day of Pradigastat 20mg matching placebo and one tablet a day of Pradigastat 40mg matching placebo
62709729|NCT01664884||Bipolar Disorder Patients|Bipolar Disorder Patients, with age between 18 to 40 years old, at euthymic phase.
62709730|NCT01664884||Schizophrenia Patients|Schizophrenia Patients, with age between 18 to 40 years old, with minimum or none positive symptoms.
62353629|NCT04913441|EXPERIMENTAL|Routine physical therapy|"Patients in this group will get every session of 30 min 3 times per week on alternative days for 12 weeks~1. TENS and hot pack for 15 minutes~2. Ultra sound for 5 minutes~3. ROM exercises repeats 5 times for 10 minutes"
62353630|NCT04913441|EXPERIMENTAL|Manual physical therapy with routine physical therapy|"Patients in group B will get every session 30 minutes 3 times per week on alternative days~1. TENS and hot pack for 15 minutes~2. Ultra sound for 5 minutes~3. Mulligan technique (NAGS and SNAGS) will repeats 5 times for 10 minutes"
62353631|NCT04913441|EXPERIMENTAL|Stretching physical therapy with routine physical therapy|"Patients in this group will get every session 30 minutes 3 times per week on alternative days~1. TENS and hot pack for 15 minutes~2. Ultra sound for 5 minutes~3. Stretching exercises repeats 5 times for 10 minutes"
62353632|NCT02915887|EXPERIMENTAL|cervical taping|Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
62353633|NCT01238913||benign esophageal lesions|All patients who have a benign esophageal lesion where it is medically indicated that they receive a stent.
62353634|NCT00593658|EXPERIMENTAL|single|
62353635|NCT01906957|EXPERIMENTAL|Elderly healthy subjects|"Randomization into :~1. high intensity interval training (HIIT)(n=20)~   or~2. moderate intensity intensity continuous exercise (n=20)"
62353636|NCT01906957|EXPERIMENTAL|Patients with metabolic syndrome|"Randomization into :~1. high intensity interval training (HIIT)(n=20)~   or~2. moderate intensity intensity continuous exercise (n=20)"
62353637|NCT01906957|EXPERIMENTAL|coronary patients|"Randomization into :~1. high intensity interval training (HIIT)(n=20)~   or~2. moderate intensity intensity continuous exercise (n=20)"
62353638|NCT01906957|EXPERIMENTAL|heart failure patients|"Randomization into :~1. high intensity interval training (HIIT)(n=20)~   or~2. moderate intensity intensity continuous exercise (n=20)"
62353639|NCT03476382|EXPERIMENTAL|Experimental Group|Participants use active Ultrasound Bone Growth Stimulator device according to Investigational Protocol.
62353640|NCT01345851|EXPERIMENTAL|Treatment (dose-escalation of RT)|Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.
62353641|NCT02204813|EXPERIMENTAL|Post RYGB Surgery|Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
62353642|NCT05628155|EXPERIMENTAL|Oral diet including n-3 PUFA intake|Oral diet covering the nutritional requirements in macronutrients as recommended for people over 65 years of age (ANSES, 2019) and including intakes of n-3 PUFAs corresponding to the recommendations for people over 65 years of age
62353643|NCT05628155|NO_INTERVENTION|Control|
62513664|NCT06504498|EXPERIMENTAL|0.75 mm-thick Duran® clear aligners|0.75 mm-thick clear aligners (Duran®; Scheu-Dental GmBH, Iserlohn, Germany).
62513665|NCT04394338|ACTIVE_COMPARATOR|plastic sheath covering|plastic sheath was prepared with the standard 9 cmx15cm self-gripping mesh. Then the meshe were folded and unfolded over or under the plastic sheaths in different directions.
62513666|NCT04394338|NO_INTERVENTION|mesh placement without plastic sheath|self-gripping mesh were placed without plastic sheath.
62513667|NCT05384886||Group1: COVID-19 patients in 2020|All patients over the age of 18 diagnosed with COVID-19 in 2020
62513668|NCT05384886||Group: COVID-19 patients in 2022|All patients over the age of 18 diagnosed with COVID-19 in 2022
62513669|NCT06242743|EXPERIMENTAL|Test group|
62709731|NCT03448211|EXPERIMENTAL|Para-toluenesulfonamide Injection (PTS)|Investigational product
62709732|NCT02256995||Pregnant Women (>22 weeks gestation)|Biomarkers tracked over 3 antenatal care visits via standard of care (dipstick, manually/visually assessed) and via uChek (automated assessment via computer application)
62709733|NCT03904160|SHAM_COMPARATOR|Nurse-lead group|Nurse-lead sessions for weight management. Ten sessions lasting 90 minutes each in three groups of 10-14 participants. Each session comprise education about healthy diet, psychoeducation and discussions.
62709734|NCT03904160|EXPERIMENTAL|Web-based group|Web-based weight management system with peer-based conversation possibility. Three groups of 10-14 participants who gather together for three nurse-lead sessions in the weeks 0, 5, and 12. The web-based program can be used for a year.
62709735|NCT03904160|EXPERIMENTAL|Web-based personal|Web-based weight management system with conversation possibility with the nurse for 12 weeks. Altogether 37 participants who can use the web-based weight management system for one year.
62353644|NCT03949140|EXPERIMENTAL|Laser hair removal treatment|Patients who choose to enroll will plan to undergo a total of up to 8 laser hair removal sessions every 4-6 weeks. If patients develop abscess or infection during this time, they will undergo I\&D and/or antibiotics, consistent with standard therapy for infection or abscess. If patients have 2 or more infections in 1 year, pain or drainage for more than 1 month, or miss more than 1 week of school or work due to ineffective treatment of pilonidal disease, these patients will undergo surgical excision and subsequent follow-up at surgeon's discretion. Patients will follow up at 2-4-week intervals for 3 months, then at 6, 9, and 18 months after conclusion of the laser therapy sessions. At all follow-up sessions, patients will be given the DQLI, CDQLI, and Promis 3A Pain survey. Unscheduled visits such as unplanned clinic visits, emergency department encounters, and hospitalizations, will be included in data collected for analysis of primary and secondary outcomes.
62513670|NCT06242743|ACTIVE_COMPARATOR|Control group|
62513671|NCT04788446|EXPERIMENTAL|Mini-flipped Game-based Learning|"1. group diet education, an interactive food card game, and guidance on the Mediterranean diet~2. once a week for 40 minutes.~3. lasts for 8 weeks"
62513672|NCT04788446|PLACEBO_COMPARATOR|Balanced diet|"1. given a leaflet on balanced diet and nutrition among the elderly~2. lasts for 8 weeks"
62513673|NCT05022134|EXPERIMENTAL|Intervention (CHOICE-AYA)|The impact of CHOICE-AYA contraceptive counseling on contraceptive use, satisfaction, and continuation will be assessed.
62513674|NCT02346682|ACTIVE_COMPARATOR|LDQS group|"Liver Depression and Qi Stagnation (LDQS)group,Liver Depression and Qi Stagnation Syndrome should include at least the following 5 symptoms and signs: emotional depression or sadness, pessimism, short breath, sigh, dysphoria，thin coating，stringy pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week venlafaxine administration."
62513675|NCT02346682|ACTIVE_COMPARATOR|DBHS group|"Deficiency of Both Heart and Spleen (DBHS) group,Deficiency of Both Heart and Spleen Syndrome should include at least following 6 symptoms and signs: emotional depression, thinking torpidity, tiredness, forgetfulness, insomnia, loose stool, sweating, pale tongue body, thin tongue coating, and thin and deep pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week ."
62513676|NCT02346682|NO_INTERVENTION|the normal controls group|The normal controls group including the healthy volunteer None drug The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline .
62513677|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
62513678|NCT04681651|EXPERIMENTAL|NBO group|Normobaric Hyperoxia combined with endovascular mechanical thrombectomy
62513679|NCT04681651|PLACEBO_COMPARATOR|Control group|Inhale air placebo plus endovascular mechanical thrombectomy
62513680|NCT02180698|EXPERIMENTAL|Treatment (TLR4 agonist GLA-SE, radiation therapy)|Patients receive TLR4 agonist GLA-SE intratumorally once weekly for 8 weeks. Within 2 weeks of starting treatment, patients also undergo radiation therapy over 2 weeks for a total of 5-6 fractions.
62513681|NCT05002686|EXPERIMENTAL|Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection|
62513682|NCT02839668|EXPERIMENTAL|Sevoflurane|The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
62513683|NCT02839668|ACTIVE_COMPARATOR|Sevoflurane+Lidocaine|The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
62513684|NCT02839668|EXPERIMENTAL|TIVA-TCI|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.
62709736|NCT01744015|EXPERIMENTAL|Patient Decision Making Tool|Patients will be given an opportunity to use a decision making tool to assist in decision making of their care
62147234|NCT04275544||Patients with PCs|"HOCM Patients developing postoperative complications (PCs) following septal myectomy.~PCs include all-cause mortality, heart failure, low cardiac output syndrome, stroke, spinal cord injury, acute respiratory distress syndrome, reintubation, reoperation, permanent implantable cardioverter defibrillator, kidney injury, renal failure, liver injury, and liver failure."
62147235|NCT04275544||Patients without PCs|HOCM Patients do not develope postoperative complications following septal myectomy.
62513685|NCT02839668|ACTIVE_COMPARATOR|TIVA-TCI+lidocaine|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.
62709737|NCT01744015|ACTIVE_COMPARATOR|Standard of care|Control group consisting of normal care
62147236|NCT01327014|PLACEBO_COMPARATOR|Placebo group|
62147237|NCT01327014|EXPERIMENTAL|1,200 mg/day of XZK group|
62147238|NCT01327014|EXPERIMENTAL|2,400 mg/day of XZK group|
62353645|NCT05983835|EXPERIMENTAL|combined segmentectomy|
62513686|NCT05434858|EXPERIMENTAL|Patient at high risk for gout due to elevated serum urate concentrations (≥ 8 mg/dL)|"Patients at high risk for gout due to elevated serum urate concentrations (≥ 8 mg/dL) will be included.~The participants included will be followed for a period of 60 months, with an initial visit, a final visit as well as an additional visit in case of suspicion of gout.~The presence of symptoms suggestive of gout will be evaluated during regular contact with the participants: a telephone call every 6 months as well as a postal or electronic mail every 3 months. Participants will be asked to contact the investigator if new symptoms or relevant medical events occur.~Blood (32.5 ml maximum) and urine (4 ml) samples will be taken from participants who have given their specific consent for a biological collection with a particular genetic aim."
62513687|NCT05672927|ACTIVE_COMPARATOR|Females, 3-dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (27-45 years of age) at 0, 2, and 6 months.
62513688|NCT05672927|EXPERIMENTAL|Females, 2-dose alternative|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (27-45 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
62513689|NCT00298740|EXPERIMENTAL|Aventis U-400 Insulin|
62513690|NCT02823730||Synergy Stent Cohort|Retrospective registry of 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
62513691|NCT02823730||Xience V Cohort|500 patients that are propensity matched to the 500 patients that underwent PCI with a Synergy stent, eligible for similar time points of follow-up following the PCI.
62513692|NCT02450526|EXPERIMENTAL|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
62513693|NCT02450526|ACTIVE_COMPARATOR|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
62513694|NCT02450526|PLACEBO_COMPARATOR|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
62513695|NCT02450526|PLACEBO_COMPARATOR|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
61973095|NCT01901237|OTHER|Hatha Yoga Program|Single-arm pilot study of a 7-week home/hospice-based Hatha yoga program for adolescent and young adults with non-curative cancer.
61973096|NCT01066533|EXPERIMENTAL|Mineral Trioxide Aggregate(MTA)|MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
61973097|NCT01066533|EXPERIMENTAL|NEC cement|NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.
62353646|NCT05983835|PLACEBO_COMPARATOR|lobectomy|
62353647|NCT03457311|OTHER|OGSP measurement|For the OGSP measurement, subjects will be orally administered with 1.25 ml/kg G.S.P. oral solution (400 mg/ml of galactose). At least 20 ml water will be given to subjects after drinking G.S.P. oral solution within 3 to 5 minutes. Sixty minutes after oral G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of OGSP value.
62353648|NCT01270230|EXPERIMENTAL|Comparison Group, Standard HIV-CT|The comparison group will receive standardized HIV counseling and testing (HIV-CT), with referrals to case management.
62353649|NCT01270230|EXPERIMENTAL|Intervention Group, Bruthas Counseling|Participants assigned to this arm receive four individual HIV prevention counseling sessions.
62353650|NCT02846805|NO_INTERVENTION|complete dentures|complete dentures will be provided for all subjects according to the standardized treatment protocol
62353651|NCT02846805|EXPERIMENTAL|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible ,and continue wearing their complete denture in the maxilla
62353652|NCT02205918||Sham TMS|"Participants in this group will receive one, 30 minute session of inactive (sham) TMS."
62353653|NCT02205918||Active TMS|Participants in this group will receive one, 30 minute session of 1hz TMS.
62353654|NCT03618602|EXPERIMENTAL|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
62353655|NCT03618602|EXPERIMENTAL|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
62353656|NCT03618602|EXPERIMENTAL|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
62353657|NCT03618602|EXPERIMENTAL|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
62353658|NCT02422082|ACTIVE_COMPARATOR|L. reuteri|Lactobacillus reuteri (L. reuteri) ATCC PTA 6475 at a dose of 5 000 000 000 CFU as a powder in a stick-pack, orally twice daily (morning and evening) yielding a total daily dose of 10 000 000 000 CFU per day, for 12 months.
62353659|NCT02422082|PLACEBO_COMPARATOR|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 12 months.
62353660|NCT04019769|EXPERIMENTAL|1|All patients will receive L-glutamine 10-30mg daily based on weight for 3 months
62353661|NCT04461028|OTHER|GROUP 1 Liposomal Bupivacaine|Will receive a 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
62513696|NCT02815202|EXPERIMENTAL|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62513697|NCT03969199|EXPERIMENTAL|MANNA Food Delivery Service|MANNA will deliver meals to patients randomized to the intervention arm of the study every week on the same day for 90 days. Each delivery will include: 7 breakfast meals, 7 lunch meals, 7 dinner entrees, health desserts, and fresh fruit. Meals will be delivered frozen and can be stored in a freezer until ready to eat. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
62513698|NCT03969199|NO_INTERVENTION|Standard of Care Counseling|Patients randomized to the control arm will receive standard or care dietary counseling from either their physician or a dietician. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
62513699|NCT05987735|EXPERIMENTAL|BLAME-LESS Program|If allocated to the intervention group, participants will have direct access to the online intervention for two weeks after allocation.
62513700|NCT05987735|NO_INTERVENTION|Waiting-list control group|When a participant is assigned to the waiting-list control group, he or she has a two-week waiting period, after which the participant will have access to the intervention.
62513701|NCT06241859|ACTIVE_COMPARATOR|Light sedation according to BIS|Sedation depth will be monitored according to BIS.
62513702|NCT06241859|SHAM_COMPARATOR|Sedation according to clinical signs|Sedation depth will be monitored according to clinical signs using RASS scale, which aim is -3.
62513703|NCT05556343|EXPERIMENTAL|Cohort 1|Participants will receive MYK-224 either as a monotherapy or in combination with standard-of-care consisting of a beta-blocker. Participants who complete Cohort 1 will be eligible for an optional open label extension period
62513704|NCT05556343|EXPERIMENTAL|Cohort 2|Participants will receive MYK-224 in combination with standard-of-care consisting of either a calcium channel blocker or disopyramide (which is given in combination with either a beta-blocker or calcium channel blocker). Participants who complete Cohort 2 will be eligible for an optional open label extension period
62513705|NCT01891812|EXPERIMENTAL|Nitrous oxide 50%|Nitrous oxide 50% administered for 20 minutes.
62513706|NCT04056052|SHAM_COMPARATOR|Home Activity Only|Over the 8-week project, families were asked to try eight different vegetable recipes from a choice of 12. All family members could participate in the home activities as the families wished. Families were also asked to complete a weekly recipe cooking tracking sheet.
62513707|NCT04056052|ACTIVE_COMPARATOR|Home Activity + cooking Workshop|The 8-week cooking workshop condition incorporated all of the home activities previously described, however, this cohort also participated in two, two-hour cooking workshops held at a local cooking school.
62513708|NCT01800435|ACTIVE_COMPARATOR|aPCC, aPCC + TXA|aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
62513709|NCT01800435|ACTIVE_COMPARATOR|rFVIIa, rFVIIa + TXA|rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
62513710|NCT00918463|EXPERIMENTAL|all patients|
62513711|NCT04948294|EXPERIMENTAL|Channeled group|Group of patients using a channeled blade for videolaryngoscopy
62513712|NCT04948294|ACTIVE_COMPARATOR|Non-channeled group|Group of patients using a non-channeled blade (standard type) for videolaryngoscopy
62513713|NCT02144974||Patients undergoing total pelvic exenteration|Patients undergoing total pelvic exenteration for gynecological malignancies and reconstruction of the pelvic floor with a TMG flap.
62513714|NCT03050034|EXPERIMENTAL|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
61973098|NCT06076057||8:00 Measurement team|At 08:00 , monitoring respiratory rate, pulse rate, oxygen saturation, body position, thoracic and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration, partial pressure of transcutaneous oxygen, and partial pressure of transcutaneous carbon dioxide.
61973099|NCT06076057||10:30 Measurement team|At 10:30 , monitoring respiratory rate, pulse rate, oxygen saturation, body position, thoracic and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration, partial pressure of transcutaneous oxygen, and partial pressure of transcutaneous carbon dioxide.
61973100|NCT06076057||16:30 Measurement team|At 16:30 , monitoring respiratory rate, pulse rate, oxygen saturation, body position, thoracic and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration, partial pressure of transcutaneous oxygen, and partial pressure of transcutaneous carbon dioxide.
61973101|NCT06076057||high altitude environment|In high altitude environments, monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
61976345|NCT02202408|PLACEBO_COMPARATOR|Placebo|Subjects received an oral single dose of placebo capsule matched to the SKI2670 dose (Placebo for SKI2670)
62709738|NCT05539326||PIQ Patients|"Patient is scheduled for or has undergone primary total knee arthroplasty (TKA) using a Persona Personalized Knee System with Canary Tibial Extension (PIQ) TKA implant according to the appropriate surgical technique and IFU. If you decide to take part in this research study, the general procedures include one follow-up visit where you will be asked to complete two performance-based tests that are used to assess your physical function following Total Knee Arthroplasty (TKA). As part of your standard of care, you will receive a Zimmer Persona® Personalized Knee System with Canary canturioTM (CTE) tibial extension. As part of this study, subjects will be asked to perform two performance based tests called the 4 meter walk test and the timed up and go test. Subjects will also be asked to complete a series of patient questionnaires that will assess their post-operative function."
62709739|NCT00918619|EXPERIMENTAL|Sangustop|
62709740|NCT00918619|ACTIVE_COMPARATOR|Tachosil|
62353662|NCT04461028|OTHER|GROUP 2 Bupivacaine with dexamethasone|Will receive 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
62513715|NCT03050034|ACTIVE_COMPARATOR|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
62513716|NCT05068960|EXPERIMENTAL|Study group|The study group will receive an interscalene block consisting of 10 mL 0.5% bupivacaine and 10 mL of liposomal bupivacaine \[133mg\].
62513717|NCT05068960|ACTIVE_COMPARATOR|Control group|The control group will receive an interscalene block consisting of 20 mL of 0.5%bupivacaine alone.
62513718|NCT04162353|EXPERIMENTAL|BCMA-CD19 cCAR|Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg
62513719|NCT00006333||Subjects with known or suspected arthritis|Subjects with known or suspected arthritis will be evaluated longitudinally
62513720|NCT06614959|EXPERIMENTAL|Oscillatory Positive Expiratory Pressure (OPEP) therapy arm|Participants will receive and use the smart OPEP device at least twice a day in the home environment for 4 consecutive weeks.
62513721|NCT00643214|EXPERIMENTAL|1|Twice daily topical application
62513722|NCT00643214|PLACEBO_COMPARATOR|2|Twice daily topical application
62513723|NCT01365702||Tiotropium in TB destroyed lung|
62513724|NCT00103402|EXPERIMENTAL|Alfuzosin|10 mg of alfuzosin once daily for 12 weeks
62513725|NCT00103402|PLACEBO_COMPARATOR|Placebo|10 mg of an identical-looking placebo once daily for 12 weeks
62513726|NCT02480426|EXPERIMENTAL|CT-image guidance|Previously acquired portal venous phase of CT datasets and intra-operative CT datasets were registered on a dedicated workstation. The selected volume of interest of the CT-image showing portal vein vasculature was overlaid onto the fluoroscopic display as real-time 3D CT-image guidance during the procedure.
62513727|NCT02480426|ACTIVE_COMPARATOR|CO2 portography|two two-dimensional (2D) CO2 portograms
62513728|NCT00897949|EXPERIMENTAL|Rizatriptan 10 mg|
62513729|NCT00897949|EXPERIMENTAL|Rizatriptan 5 mg|
61973102|NCT06076057||limited space|In limited space environments, monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
61973103|NCT06076057||electrified operation|In electrified operation , monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
61973104|NCT06076057||work site|In work site , monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
62513730|NCT00897949|PLACEBO_COMPARATOR|Placebo|
62513731|NCT05154552|EXPERIMENTAL|group A/ routine physical therapy and PNF|"In group A, PNF based gait training (15 minutes) and conventional physical therapy (45 minutes) will be performed.~PNF exercises involved PNF pelvic patterns (pelvic interior elevation and posterior depression), PNF lower extremity D1 Flexion and PNF lower extremity D1 extension (Unilateral during 1st to 3rd week and bilateral from 4th week onwards). Exercises will progress from rhythmic initiation and then progress to slow reversal and agonistic reversal up to 6th week of therapy and continues until 12th week. Each exercise will be repeated for 10 to 20 times.~Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson's disease.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises"
62513732|NCT05154552|ACTIVE_COMPARATOR|group B/ routine physical therapy|"Conventional physical therapy (45 minute session) will be performed in group B.Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson disease.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises"
62513733|NCT02924376|EXPERIMENTAL|Cohort A Pemigatinib|Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
62513734|NCT02924376|EXPERIMENTAL|Cohort B Pemigatinib|Pemigatinibin subjects with other FGF/FGFR alterations
62513735|NCT02924376|EXPERIMENTAL|Cohort C Pemigatinib|Pemigatinib in subjects negative for FGF/FGFR alteration
62513736|NCT03629613|SHAM_COMPARATOR|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place \~2 hours after antioxidant intake.~During baseline testing, no supplement or placebo intake will be used."
62709741|NCT03906643|EXPERIMENTAL|HS-201|HS-201 will be administered intravenously as a single dose
61976346|NCT03827304|EXPERIMENTAL|Burns dressings patients|Virtual Reality pain distraction games scenarios
62353663|NCT00340834|EXPERIMENTAL|Fingolimod 1.25 mg|
62353664|NCT00340834|EXPERIMENTAL|Fingolimod 0.5 mg|
62353665|NCT00340834|ACTIVE_COMPARATOR|Interferon β-1a 30 µg|
62353666|NCT04578015|ACTIVE_COMPARATOR|Metronidazole 500 mg|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
62353667|NCT04578015|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo
62353668|NCT01229241|OTHER|levobupivacaine|
62353669|NCT01229241|OTHER|ropivacaine|
62353670|NCT05718206|EXPERIMENTAL|Coronary stenosis|
62353671|NCT05718206|OTHER|Control|
62353672|NCT01688635|EXPERIMENTAL|LY2963016|Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
62353673|NCT01688635|EXPERIMENTAL|US-approved Lantus|Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
62353674|NCT05374837|NO_INTERVENTION|Control group|The control group will not receive any intervention. After the endline data collection is completed, the intervention will be delivered to the control group.
62353675|NCT05374837|EXPERIMENTAL|Infant and young child feeding (IYCF) voice messaging intervention|The voice messaging intervention group will receive voice/text messages for a period of 16 weeks.
62513737|NCT03629613|EXPERIMENTAL|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place \~2 hours after antioxidant intake.~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
62513738|NCT02396173|EXPERIMENTAL|Risk Score for non-return to work|The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
62513739|NCT02396173|NO_INTERVENTION|Control group|In this group the medical staff will not be informed about the risk score (WORRK).
62513740|NCT05009368|EXPERIMENTAL|Arm A - Sequence AC|Treatment A in Period 1 and Treatment C in Period 2
62513741|NCT05009368|EXPERIMENTAL|Arm B - Sequence BC|Treatment B in Period 1 and Treatment C in Period 2
62513742|NCT01976455||20% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
62513743|NCT01976455||40% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
62513744|NCT04817215|EXPERIMENTAL|Patients who are Drug naïve or diet controlled|
62513745|NCT04817215|EXPERIMENTAL|Patients on Metformin only|
62513746|NCT04817215|EXPERIMENTAL|Patients on two or three oral glucose-lowering agents|
62513747|NCT03466541|EXPERIMENTAL|Riskbruk|The employees randomised to the Riskbruk group will be offered two consultations a ∼15 min with the OHS. The subjects will receive individual feedback on the screening results. During these sessions, Motivational Interviewing will be used.
62513748|NCT03466541|EXPERIMENTAL|Balance|The group allocated to the Balance intervention will follow a comprehensive multi-session eHealth intervention with personalised feedback on the screening results.
62513749|NCT03466541|NO_INTERVENTION|Control group/usual care|The control group will receive the usual follow-up provided by the OHS for persons with risky alcohol behaviour. In order to provide something that appears as a plausible follow-up to the control participants, they will be given a booklet that covers general information about alcohol and potential risks and harms of drinking. The booklet contains no advise on how to achieve a change in drinking behaviour.
62513750|NCT05150418|EXPERIMENTAL|Oxygen|Oxygen 15 l/min administered with face mask with reservoir.
62513751|NCT05150418|PLACEBO_COMPARATOR|Room air|Room air 15 l/min administered with face mask with reservoir.
62147239|NCT02085512|EXPERIMENTAL|Neurocognitive retraining|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
62147240|NCT02085512|PLACEBO_COMPARATOR|Control, Web Based Tasks|Engaging daily, for 30 days in web-based video games or reading tasks that do not specifically engage or train neurocognitive functions.
62147241|NCT02865785|ACTIVE_COMPARATOR|Study Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20% (100 mL of intralipid 20% diluted in 250 mL sterile i.v. saline administered i.v. over two hours), once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
62147242|NCT02865785|PLACEBO_COMPARATOR|Placebo Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
62147243|NCT00291941|EXPERIMENTAL|1|Henogen HB vaccine
62513752|NCT02057445|EXPERIMENTAL|Recipient|EBV+ patients will receive 3rd party LMP-CTLs for treatment of EBV infection and/or disease
62513753|NCT02057445|OTHER|Donor|Healthy donors who are EBV+ will be asked to donate 60-120 ml of peripheral blood for development of cell lines to be stored for cell line bank.
62513754|NCT04600024||Piriformis syndrome group|Patients who were diagnosed as PS by diagnostic injection with ultrasound guidance
62513755|NCT04600024||Age and sex match control group|Patients who were excluded from the diagnosis of PS and had anteroposterior (AP) direct radiographic imaging
62513756|NCT04920903|EXPERIMENTAL|COR588|
62513757|NCT04920903|PLACEBO_COMPARATOR|Placebo|
62513758|NCT01021267|EXPERIMENTAL|Saw palmetto berry extract|Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
62513759|NCT04593212||Septic Shock Survivors|
62513760|NCT04593212||Septic Shock Non-Survivors|
62513761|NCT04610060|EXPERIMENTAL|Power walking group|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary \& Meir, 2018)."
62513762|NCT04610060|ACTIVE_COMPARATOR|Standardised outpatient cardiac rehabilitation group|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary \& Meir, 2018).
62513763|NCT02521077|EXPERIMENTAL|Odd Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
62147244|NCT00291941|ACTIVE_COMPARATOR|2|Fendrix vaccine
62147245|NCT04440540|EXPERIMENTAL|lifestyle modification program group|
62147246|NCT04440540|EXPERIMENTAL|usual care group (control)|
62147247|NCT02761317|ACTIVE_COMPARATOR|GroupA：standard preparation|Subjects who are randomized into group A receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
62513764|NCT02521077|EXPERIMENTAL|Even Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
62513765|NCT00972907|EXPERIMENTAL|Treatment|Nifedipine coated suppositories BID.
62513766|NCT00638794||Surgical|Patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
62513767|NCT00638794||Observational|Consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications
62513768|NCT00725621||Remicade|Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.
62513769|NCT02212340|EXPERIMENTAL|TIVA group|Anesthesia is maintained with fresofol and remifentanil
62513770|NCT02212340|ACTIVE_COMPARATOR|Des group|Anesthesia is maintained with desflurane and remifentanil
62513771|NCT03574311|EXPERIMENTAL|Ferric carboxymaltose|Preoperative 1000 mg intravenous single dose as 30 minute infusion
62513772|NCT03574311|PLACEBO_COMPARATOR|Placebo|Preoperative 100 ml saline as 30 minute infusion
62513773|NCT02315547|OTHER|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
62513774|NCT05260723|EXPERIMENTAL|Sit Less|The primary goal of the Sit Less arm is to reduce the total amount of time spent sitting each day and break up prolonged bouts of sitting.
62513775|NCT02029781|OTHER|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
62709742|NCT04517435|EXPERIMENTAL|ME-401 + R-CHOP|Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP. ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
62513776|NCT04703621|EXPERIMENTAL|Intervention ( safety run-in, cohort 1, cohort 2)|"Safety run-in( 3 patients): daratumumab once a week x 4 doses. If no worsening of thrombocytopenia can be attributed to study treatment or any other life-threatening events, the study will proceed to the main part.~Cohort 1 ( 9 patients): daratumumab once a week x 8 doses~If response is \<100%:~Cohort 2 ( 9 patients): daratumumab once a week x 8 doses followed by daratumumab every 2 weeks x 2 doses"
62513777|NCT04641247|EXPERIMENTAL|Participants receiving niraparib|Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
62513778|NCT06308172|EXPERIMENTAL|Single-layer|Patients who are randomized in this arm undergo a single layer-hysterotomy closure
62513779|NCT06308172|EXPERIMENTAL|Double-layer|Patients who are randomized in this arm undergo a double layer-hysterotomy closure
62513780|NCT02155374|ACTIVE_COMPARATOR|Sliding scale insulin|Sliding scale insulin Glucose 7.8-12 mmol/l --\> 2 IU insulin, glucose 12.1-17 mmol/l --\> 4 IU insulin, glucose ≥17.1 mmol/l --\> 6 IU insulin. In case of insufficient control, insulin doses will be increased
62513781|NCT02155374|EXPERIMENTAL|Intermediate acting insulin|Intermediate acting insulin, 0.01 IU / mg prednison / kg body weight with a maximum of 0.5 unit insulin per kg body weight. In case of age \> 70 years or diminished renal function (GFR \<30ml/min)
62513782|NCT05129254|EXPERIMENTAL|Thulium laser (1927nm) and post-treatment topically administered platelet rich plasma (PRP)|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied autologous platelet rich plasma at monthly intervals for a total of 4 treatment. The total duration of laser application, venipuncture, PRP preparation, and topical administration will take approximately 30 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
62709743|NCT05671250|EXPERIMENTAL|PRP gel and SOC-treatment|platelet-lysate loaded lyophilized gel in addition to standard of care
62147248|NCT02761317|EXPERIMENTAL|Group B:low-volume preparation|Subjects who are randomized into group B receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure. ( 2L PEG-ELS and 10mg bisacodyl )
62147249|NCT02761317|EXPERIMENTAL|Group C：high-volume preparation|Subjects who are randomized into group C will receive 2L PEG-ELS at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure. (4 L PEG-ELS)
62709744|NCT05671250|EXPERIMENTAL|Trigel and SOC-treatment|Erythropoietin/isosorbide dinitrate loaded cryogel scaffold in addition to standard of care
62709745|NCT05671250|ACTIVE_COMPARATOR|standard of care alone|sharp debridement, saline washing and saline dressing
62709746|NCT04206761|EXPERIMENTAL|Treatment - QVM149|Participants will complete a two week treatment with QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate) 150/50/160 μg delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication via inhalation.
62709747|NCT04206761|ACTIVE_COMPARATOR|Control|Participants will continue their clinically prescribed treatment with a high dose dual therapy of Inhaled Corticosteroid (ICS)/Long-Acting Beta2-Agonist (LABA) in any approved drug formulation and delivery device for the treatment period of two weeks. (Participants will continue receiving high dose ICS/LABA therapy at the same dose and in the same formulation as at baseline).
62709748|NCT03140618|EXPERIMENTAL|LEPPIC|The light and environment project in psychiatric inpatient care
62353676|NCT03723499||endoscopic treatment|Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.
62353677|NCT06120309||NACT Group|
62513783|NCT05129254|EXPERIMENTAL|Platelet rich plasma injection|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with autologous platelet rich plasma injection at monthly intervals for a total of 4 treatment. The total duration of venipuncture, PRP preparation, and injection will take approximately 15 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
62147250|NCT04730726|EXPERIMENTAL|Patients with thyroid nodules|Patients with thyroid nodules that underwent or will undergo an ultrasound with FNA if indicated and if indicated will be scheduled for a (hemi)thyroidectomy
62353678|NCT06375252|EXPERIMENTAL|intervention-control group|Participants assigned to the intervention-control group of the study performed activities using the central jugular vein catheter lumen retainer apparatus.
62353679|NCT06375252|NO_INTERVENTION|control-intervention group|Participants in the control-intervention group first performed the activities without the central jugular vein catheter lumen retainer apparatus, and then performed the activities with the apparatus.
62513784|NCT06239961|EXPERIMENTAL|Physical Activity Coaching|The intervention involves physical activity sessions tailored for people with HIV. Participants engage in physical activities targeting health improvement and fall prevention, promoting physical activity self-efficacy and outcome expectations. Coaches identify individual exercise goals, assess access to physical activity options, and focus on safe, unsupervised strength and balance physical activities at home. Tailored exercise materials, including handouts and videos, are accessible through a website. Additionally, participants are encouraged to follow a structured walking program.
62709749|NCT05168761||laparoscopic partial nephrectomy|The investigators included all hospitalisations for LPN using CCAM(Classification Commune des actes médicaux) code (JAFC005) after removing the 83 hospitals using RAPN in 2017. LPN complications were from hospitals using exclusively LPN.
62147251|NCT05308589|EXPERIMENTAL|Continuous Postoperative Pericardial Flushing|Continuous Postoperative Pericardial Flushing (inflow of 500 ml NaCl 0,9% flushing fluid into the pericardial cavity during the first 8 postoperative hours) executed with the Haermonics investigational device
62147252|NCT05308589|NO_INTERVENTION|Control|Standard care
62353680|NCT01743885|ACTIVE_COMPARATOR|propanolol|Propanolol (Syprol:oral solution)
62353681|NCT01743885|ACTIVE_COMPARATOR|Acebutolol|Acebutolol (Sectral:oral solution)
62513785|NCT06239961|EXPERIMENTAL|Nutritional Assessment|Participants will complete a mini nutritional assessment and keep a food diary. Each participant will meet with a registered dietician for an evaluation. The coaching will be personalized based on the dietician's advice and will include information about community resources for food, making sure health options are available, and suggesting diets and recipes for better eating options.
62513786|NCT06239961|EXPERIMENTAL|Behavioral Activation|Participants receive brief BA (Behavioral Activation) coaching through remote interactions (phone or videoconference) with lay coaches. The structured behavioral approach focuses on identifying and scheduling values-based, rewarding social engagements and activities. Coaches assist in overcoming barriers to social connectedness, involving a review of daily activity patterns, setting activity goals, creating implementation plans, and assessing successes and areas for improvement. The program is adapted for individuals aging with HIV, with community collaboration to tailor content and delivery methods.
62513787|NCT03235869|EXPERIMENTAL|Radiation Therapy + Durvalumab|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions) Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
62513788|NCT02575339|EXPERIMENTAL|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
62513789|NCT02575339|EXPERIMENTAL|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
62513790|NCT02575339|ACTIVE_COMPARATOR|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
62513791|NCT05520606||minimally invasive surgery|laparoscopic pancreatoduodenectomy.
62513792|NCT05520606||open surgery|open pancreatoduodenectomy
62513793|NCT01606059|ACTIVE_COMPARATOR|DW-0919|
62513794|NCT01606059|EXPERIMENTAL|DW-0920|
62513795|NCT01959906||R0|Complete resection
62513796|NCT01959906||R1|Incomplete resection, microscopical tumor residu left behind
62513797|NCT01959906||CRM<1mm|complete resection (R0), however tumor spreads till less than 1 mm from the section pane.
62513798|NCT04711720|EXPERIMENTAL|Navigation|
62513799|NCT04711720|NO_INTERVENTION|Control|
62709750|NCT05168761||open partial nephrectomy|OPN has its own CCAM codes; they group laparotomy (JAFA019 / JAFA030) and lumbotomy (JAFA008 / JAFA024)
62147253|NCT00664599|EXPERIMENTAL|1|Rituximab
62147254|NCT00664599|ACTIVE_COMPARATOR|2|Cytotoxics combination
62353682|NCT01639456|EXPERIMENTAL|Patients Using CD3-/CD19- NK cell product|Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
62513800|NCT01202617||Schizophrenic outpatients between 18 & 70 years of age|
62513801|NCT02322788|ACTIVE_COMPARATOR|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
62709751|NCT05168761||robot assisted partial nephrectomy|At the time of this study, RAPN did not have a specific coding. The investigators had contacted the hospitals with Vinci robotic surgical procedures in 2013 and the investigators included here PN from hospitalisations from the 25 centres using exclusively RAPN for more than five years. Thus, in this study, RAPN was performed by experts in robotic surgery.
62709752|NCT00549159|EXPERIMENTAL|Cavaterm|
62709753|NCT00549159|ACTIVE_COMPARATOR|TCRE|Transcervical resection of the endometrium
62709754|NCT04487405||Group A|Symptomatic with adnexal mass
62709755|NCT04487405||Group B|Asymptomatic with adnexal mass
62709756|NCT04487405||Group C|Women with a predisposition in developing ovarian cancer due to a positive, pathogenic variant
62709757|NCT06047938||carotid intima thickness measurment|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
62709758|NCT05164471|EXPERIMENTAL|FLT180a|A single dose of FLT180a will be administered. Dose will be determined by enrollment cohort. The first 3 patients will receive 7.7 x 10e11 vg/kg. The dose in subsequent cohorts will be determined by the DMC based on review of data from the prior cohort(s).
62709759|NCT03639610|EXPERIMENTAL|Cohort 1a|Patients with moderate renal impairment (eGFR ≥30 to \<45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg
62709760|NCT03639610|EXPERIMENTAL|Cohort 1b|Patients with moderate renal impairment (eGFR ≥30 to \<45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg
62709761|NCT03639610|EXPERIMENTAL|Cohort 2a|Patients with severe renal impairment (eGFR ≥15 to \<30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg
62709762|NCT03929679||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
62709763|NCT04883138|EXPERIMENTAL|5 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 5 mg GIGA-2050 per kg BW
61973105|NCT05744154|EXPERIMENTAL|Audit & feedback with educational outreach and facilitation|The intervention includes: 1) refinement with end users, 2) an A\&F report sent to local governing authorities presenting for each practice: performance compared to peers (simple A\&F), a summary message indicating if action is required and a list of potential actions, 3) educational materials (a clinical vignette; consequences of the practice; links to practice guidelines, clinical decision rules and shared decision-making tools; a case review tool), 4) virtual educational meetings with the local trauma Medical Director, trauma program manager and data analyst, and 5) two virtual facilitation visits 2 and 4 months after the transmission of the report to support committees in preparing their action plan.
61973106|NCT05744154|OTHER|Simple audit & feedback|The control arm will receive the quality improvement intervention currently in place in the Québec Trauma Care Continuum (i.e. simple A\&F report presenting their performance compared to peers on quality indicators measuring adherence to high-value care and risk-adjusted outcomes) with the addition of quality indicators on low-value care (already planned by provincial authorities for the 2023 evaluation cycle). Simple A\&F was chosen for the control because it is standard practice in Québec and in most integrated trauma systems and the effectiveness of A\&F for de-implementation has been documented.
61973107|NCT00005970|EXPERIMENTAL|Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor)|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
61976347|NCT01883830|EXPERIMENTAL|gaming therapy (Xbox)|Subjects belonging to the first group will receive a gaming therapy protocol using the Xbox console. They will receive 24 sessions of treatment within 8 weeks (3 sessions per week). Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling and impulsiveness reactions.
61976348|NCT01883830|ACTIVE_COMPARATOR|Dynamic balance platform training|Control group will receive the same amount of therapy (24 sessions) using a dynamic balance platform (Biodex).
62513802|NCT02322788|ACTIVE_COMPARATOR|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
62513803|NCT02322788|PLACEBO_COMPARATOR|Turbuhaler M2, Placebo|Placebo powder for inhalation
62709764|NCT04883138|EXPERIMENTAL|15 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 15 mg GIGA-2050 per kg BW, or as determined by SRC review
62709765|NCT04883138|EXPERIMENTAL|50 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 50 mg GIGA-2050 per kg BW, or as determined by SRC review
62709766|NCT02681393|EXPERIMENTAL|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
62709767|NCT02681393|ACTIVE_COMPARATOR|Brochure Only|Participants will receive the Aerobic Exercise After Stroke educational brochure only.
62709768|NCT03289754|EXPERIMENTAL|ConforMIS iTotal Knee with iPoly Insert|The tibial insert being utilized in this study will be a highly-crosslinked, Vitamin-E enriched UHMWPE (iPoly XE) instead of traditional tibial inserts.
62709769|NCT01561976|ACTIVE_COMPARATOR|Metformin hydrochloride prolonged release|1000mg in fasting state
62709770|NCT01561976|ACTIVE_COMPARATOR|metformin hydrochloride prolonged release|1000mg In fed state
62709771|NCT01561976|ACTIVE_COMPARATOR|Metformin hydrochloride sustained release/Glimepiride|1000/2mg In fed state
62709772|NCT03733548|EXPERIMENTAL|Regulating Emotions Like An eXpert (RELAX)|Families at the Virginia Commonwealth University Center for Psychological Services and Development or Clark-Hill Institute for Positive Youth Development
62709773|NCT01708044|EXPERIMENTAL|Pramlintide 6 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
62353683|NCT01639456|EXPERIMENTAL|Patients Using CD3-/CD56+ purified NK cell product|Patients receive the apheresis product (collected day -1): purified for NK cells using the CliniMACS® CD3 Reagent System (Miltenyi Biotec) in combination with the large-scale tubing set to deplete CD3+ cells and then use the CliniMACS® CD56 Reagent System to enrich CD56+ NK cells (CD3-CD56+ natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
62353684|NCT04526067|ACTIVE_COMPARATOR|Cognitive Adaptation Training (CAT)|A home delivered adherence intervention used by managed care used to improve outcomes across multiple conditions.
62709774|NCT01708044|EXPERIMENTAL|Pramlintide 9 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
62709775|NCT01708044|EXPERIMENTAL|Pramlintide 12 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
62709776|NCT01708044|PLACEBO_COMPARATOR|Placebo|
61973108|NCT00005970|EXPERIMENTAL|Arm II (AC, paclitaxel, trastuzumab, tamoxifen)|Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
61976349|NCT00271050|EXPERIMENTAL|1|
62709777|NCT03085901|ACTIVE_COMPARATOR|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
62709778|NCT03085901|ACTIVE_COMPARATOR|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
62709779|NCT00317837|ACTIVE_COMPARATOR|1|Patients treated with a cemented modular hemiarthroplasty, with a unipolar head
62709780|NCT00317837|ACTIVE_COMPARATOR|2|Patients treated with a modular cemented hemiarthroplasty with a bipolar head.
62709781|NCT01738243|EXPERIMENTAL|Unilateral Upper Eyelid Retraction|"This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection"
62147255|NCT03776604|EXPERIMENTAL|PEG-rhG-CSF|"Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
62147256|NCT01472159|NO_INTERVENTION|CGM-Usual Care|* Routine CGM education
62147257|NCT01472159|EXPERIMENTAL|CGM-Teamwork|"* Routine CGM education~* CGM Family Teamwork Intervention"
62709782|NCT01738243|EXPERIMENTAL|Bilateral Upper Eyelid Retraction|"This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection"
62709783|NCT02060981|ACTIVE_COMPARATOR|Interview only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
62147258|NCT03542747|EXPERIMENTAL|Time to ventilation with the iLTS|Measuring the time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
61976350|NCT00416078|EXPERIMENTAL|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
62147259|NCT03542747|EXPERIMENTAL|Time to ventilation with the Fastrach|Measuring time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
62147260|NCT02387606|EXPERIMENTAL|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
62147261|NCT02387606|EXPERIMENTAL|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
62147262|NCT02387606|EXPERIMENTAL|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
62353685|NCT04526067|ACTIVE_COMPARATOR|Remote Cognitive Adaptation Training (R-CAT)|A primarily remotely delivered workable adherence intervention used by managed care used to improve outcomes across multiple conditions.
62353686|NCT01583985|ACTIVE_COMPARATOR|Opioid-intensive|Opioid-intensive prescribing strategy
62147263|NCT00569166|ACTIVE_COMPARATOR|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
62147264|NCT00569166|ACTIVE_COMPARATOR|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
62353687|NCT01583985|ACTIVE_COMPARATOR|Opioid-avoidant|Opioid-avoidant prescribing strategy
62709784|NCT02060981|PLACEBO_COMPARATOR|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey. These patients will be asked to review the brochure, complete the survey, and mail it back to the research team using a self-addressed stamped envelope.
62709785|NCT02060981|EXPERIMENTAL|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension, and to provide feedback regarding a new tool for helping patients learn more about their medications. Interview plus patients' index date for follow-up is the date of the scheduled interview.
62709786|NCT00545779|EXPERIMENTAL|Ibandronate|Participants completed Candidate Identification Questionnaire (CIQ) in Part A and received Ibandronate 150 milligram (mg) tablet orally once-monthly up to 6 months in Part B of the study.
62709787|NCT02431156||monovision|Presbyopic patients that underwent mini-monovision correction with bilateral implantation of monofocal intraocular lenses. Their visual capacity in ADLs will be assessed.
62709788|NCT06146816|EXPERIMENTAL|high intensity fIR therapy|Patients will undergo 10 sessions of 30 minutes high intensity fIR therapy at the IBD clinic of the TLVMC by a trained and qualified staff member. Each abdominal quadrant will receive a similar amount of time of exposure to the IR, except for the quadrant of the inflamed intestine (usually the right lower quadrant) which will be exposed longer to the IR. During the treatment, energy levels and skin temperature will be recorded at 10 minutes intervals. Patients responding to therapy (clinical response: ∆HBI≥3 and/or 50% reduction in calprotectin), who did not achieve remission can continue for 10 more treatments.
62709789|NCT06146816|PLACEBO_COMPARATOR|lowest intensity fIR therapy|Patients will undergo 10 sessions of 30 minutes lowest intensity fIR therapy, at the IBD clinic of the TLVMC by a trained and qualified staff member. Each abdominal quadrant will receive a similar amount of time of exposure, except for the quadrant of the inflamed intestine (usually the right lower quadrant) which will be exposed longer. During the treatment, energy levels and skin temperature will be recorded at 10 minutes intervals.
62709790|NCT03290352||Head and neck cancer patients|Patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis who received free flap reconstruction would be enrolled in this study. However, we excluded the patients with distant metastasis identified in their medical records, and those undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps.
62709791|NCT00805389|EXPERIMENTAL|GSK223192A 1 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
62709792|NCT00805389|EXPERIMENTAL|GSK223192A 2 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
62709793|NCT00805389|EXPERIMENTAL|GSK223192A 3 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
62709794|NCT00805389|EXPERIMENTAL|Fendrix Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
62709795|NCT00805389|ACTIVE_COMPARATOR|Engerix-B Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
62709796|NCT01374360||Receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are receiving Soliris or Ultomiris
62709797|NCT01374360||Not receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are not receiving Soliris or Ultomiris
62709798|NCT00673920|PLACEBO_COMPARATOR|Placebo|"Participants received matching placebo:~* on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)~* on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)"
62709799|NCT00673920|EXPERIMENTAL|Ocrelizumab 400mg|Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.
62709800|NCT00673920|EXPERIMENTAL|Ocrelizumab 200mg|Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.
62709801|NCT00673920|EXPERIMENTAL|Ocrelizumab 200mg/ Ocrelizumab 200mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
62709802|NCT00673920|EXPERIMENTAL|Ocrelizumab 200mg/ Ocrelizumab 400mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
62709803|NCT00673920|EXPERIMENTAL|Ocrelizumab 400mg/ Ocrelizumab 400mg|Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
62709804|NCT00673920|EXPERIMENTAL|Placebo/ Ocrelizumab 200mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
62709805|NCT00673920|EXPERIMENTAL|Placebo/ Ocrelizumab 400mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
62353688|NCT02663479|EXPERIMENTAL|Cardiopressin|A 5 capsule proprietary blend of herbal extracts and nutrients
62709806|NCT02943694|EXPERIMENTAL|TaTME with CS-Compact (GelPoint Path)|Based on newly-designed devices tailored for transanal TME, CS-Compact, GelPoint and Octoport are employed for the clinical applications.
62709807|NCT02348203|EXPERIMENTAL|Arm I (aspirin, zileuton)|Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
62709808|NCT02348203|PLACEBO_COMPARATOR|Arm II (double placebo)|Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
62709809|NCT05896241||Patients taking Dospray = 63|Patients who were prescribed Dospray as part of routine medical practice
62709810|NCT05896241||Рatients on other alternative treatment = 63|Patients who have been prescribed other alternative treatment as part of routine medical practice
62709811|NCT05875857|NO_INTERVENTION|Control|Control group will receive current standard of care education and surveys at 6-8 weeks post discharge.
62709812|NCT05875857|EXPERIMENTAL|Intervention|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge. Surveys will be sent to group at 6-8 weeks post discharge.
62709813|NCT00237042|ACTIVE_COMPARATOR|Self Management|Dental hygienist-delivered pain self-management treatment
62709814|NCT00237042|EXPERIMENTAL|Targeted Self Management|Dental hygienist-delivered pain self-management treatment with a focus on menstrual cycle-related changes in pain and other symptoms
62709815|NCT00237042|EXPERIMENTAL|Continuous Oral Contraceptives|"Oral contraceptive (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months with no spacer pills."
62709816|NCT02466919|EXPERIMENTAL|Levofloxacin-based concomitant|Pantoprazole 40 mg BID day1\~day10 Amoxicillin 1000 mg BID day1\~day10 Metronidazole 500 mg BID day1\~day10 Levofloxacin 500 mg QD day1\~day10
62709817|NCT02466919|ACTIVE_COMPARATOR|Sequential|Pantoprazole 40 mg BID day1\~day10 Amoxicillin 1000 mg BID day1\~day5 Metronidazole 500 mg BID day6\~day10 Clarithromycin 500 mg BID day6\~day10
62709818|NCT04592809|ACTIVE_COMPARATOR|Ketamine|0.5 mg/kg intravenous ketamine will be administered 4 times in a 2 week period. Ketamine will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
62513804|NCT02322788|PLACEBO_COMPARATOR|Turbuhaler M3, Placebo|Placebo powder for inhalation
62709819|NCT04592809|ACTIVE_COMPARATOR|Midazolam|0.02 mg/kg midazolam will be administered 4 times in a 2 week period. Midazolam will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
62709820|NCT00413114|EXPERIMENTAL|Obatoclax Mesylate|Obatoclax Mesylate 30mg
62709821|NCT05104060|EXPERIMENTAL|pectoralis minor intervention group|The participants in pectoralis minor group will received manual therapy for pectoralis minor by investigators, the technique including stretch and soft tissue mobilization. The participants asked to perform the scapular control exercise and shoulder strength exercise. Participants will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
62709822|NCT05104060|ACTIVE_COMPARATOR|shoulder strengthening group|The participants in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
62709823|NCT05104060|NO_INTERVENTION|Healthy subject group|Healthy participants will be recruited. No Intervention will be provided. The correlation between measures of pectoralis minor length and scapular kinematics will be assessed. Measurement will be the same as pectoralis minor intervention group and shoulder strengthening group
61973109|NCT00005970|EXPERIMENTAL|Arm III (AC, paclitaxel, trastuzumab, tamoxifen)|"Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy."
62709824|NCT02031406|NO_INTERVENTION|Usual care|No extra post-discharge pharmacist counseling is explicitly provided to patients, although some patients may receive it depending on their care setting
62709825|NCT02031406|EXPERIMENTAL|Post-discharge pharmacist counseling|Patients will receive post-discharge telephonic pharmacist counseling at around 72 hours after hospital discharge.
62709826|NCT03126487|EXPERIMENTAL|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
62709827|NCT05475808|ACTIVE_COMPARATOR|Splint|Patients in Group 1 will be applied to only static wrist splint treatment for 8 week.
62709828|NCT05475808|ACTIVE_COMPARATOR|Tendon and nerve gliding exercise|Patients in Group 2 will be applied to tendon and nerve gliding exercises for the wrist in addition to static wrist splint treatment for 8 week.
62709829|NCT05475808|ACTIVE_COMPARATOR|local steroid injection|Patients in Group 3 will be applied to local steroid injection to wrist in addition to static wrist splint treatment for 8 week.
62709830|NCT04544306|NO_INTERVENTION|Control arm|Standard of Care (intravenous antimicrobial therapy according to the American Heart Association Guideline 2015)
61976351|NCT00416078|ACTIVE_COMPARATOR|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
61976352|NCT03037411||ELUVIA stent implantation|Peripheral stenting
61976353|NCT00293254|EXPERIMENTAL|1|raltegravir potassium
61976354|NCT00293254|PLACEBO_COMPARATOR|2|Placebo
61976355|NCT06120231|EXPERIMENTAL|Pedicle Screw Stimulation Arm|
61976356|NCT00541489|PLACEBO_COMPARATOR|1|
61976357|NCT00541489|ACTIVE_COMPARATOR|2|Naproxen 500 mg
62709831|NCT04544306|EXPERIMENTAL|Partial oral treatment arm|The mode of antimicrobial delivery is switched to oral therapy after at least 10 days of IV therapy, guided by antimicrobial susceptibility
62709832|NCT03554655|EXPERIMENTAL|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
62513805|NCT05365152|EXPERIMENTAL|Meal replacement intervention group|"On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to ideal weight \* 25/kcal (BMI \> 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2. The meal replacement intervention group replaced the daily meal with meal replacement on the basis of the conventional diabetic diet. About 400kcal calories in carbohydrates."
62513806|NCT05365152|NO_INTERVENTION|diabetes diet group|"On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to ideal weight \* 25/kcal (BMI \> 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2."
62513807|NCT06227702|ACTIVE_COMPARATOR|VeXus|Patients in the intervention arm wil be assessed by VeXus. Patients without signs of venous congestion (VeXus = 0) will be observed every 6 hours. In patients with VeXus ≥1, continuous infusion of intravenous furosemide will be initiated. During the first 48 hours, furosemide infusion will be adjusted according to VeXus . All other aspects of care will be managed according to routine unit protocols
62513808|NCT06227702|NO_INTERVENTION|Usual care|The usual care arm will follow the management protocols of the unit which are based in the Surviving Sepsis Campaign guidelines.
62709833|NCT03554655|NO_INTERVENTION|Control|Control Group will receive treatment as usual without the Momentum app.
62353689|NCT02663479|PLACEBO_COMPARATOR|Placebo|A 5 capsule placebo matched in color and size to the Experimental supplement
62353690|NCT05534841||Pathological complete response|Patients with a complete response to the neoadjuvant therapy on the definitive anatomopathology study.
62353691|NCT05534841||Non pathological complete response|Patients without complete response to the neoadjuvant therapy on the definitive anatomopathology study.
62353692|NCT01565590|ACTIVE_COMPARATOR|Propofol|
62353693|NCT01565590|EXPERIMENTAL|Dexmedetomidine|
62353694|NCT05099536|EXPERIMENTAL|3D011-08|
62353695|NCT02675725||Post cardiac surgery|Patients after cardiac surgery with signs of decreased organ perfusion and the need of fluid therapy.
62353696|NCT00870974|EXPERIMENTAL|Assess [18F]FPEB and PET imaging|To assess \[18F\] FPEB and PET imaging in subjects with neuropsychiatric conditions.
62353697|NCT05725330|EXPERIMENTAL|Intervention Group|Application of data collection forms for the initial evaluation. Teaching the use of mobile games, monitoring the use of mobile games in the experimental group by the researcher for six weeks, and applying data collection forms to the patients in the sixth week.
62353698|NCT05725330|NO_INTERVENTION|Control Group|Application of data collection forms for the initial evaluation. Application of data collection forms to the patients in the sixth week. No intervention will be made to the patients in the control group other than the routine education given in the diabetes outpatient clinic.
62353699|NCT01712217|EXPERIMENTAL|AT13387 and Crizotinib|Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
62353700|NCT01712217|ACTIVE_COMPARATOR|Crizotinib versus crizotinib + AT13387|Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the MTD established in Part A. Part B will enroll 128 patients with NSCLC who have been treated with crizotinib for at least 8 weeks and are still tolerating treatment without evidence of disease progression.
62353701|NCT01712217|ACTIVE_COMPARATOR|AT13387 or AT13387 + crizotinib|Part C is an open-label, randomized, Phase 2, Simon's 2-stage design of AT13387 administered alone once weekly for 3 weeks (QW×3) or in combination with crizotinib at the MTD established in Part A.
62353702|NCT03946293|ACTIVE_COMPARATOR|White bread|White bread 3 x 30 g, single serving
62353703|NCT03946293|ACTIVE_COMPARATOR|Wholegrain|Standard wholegrain, 3 x 30 g, single serving
62353704|NCT03946293|EXPERIMENTAL|Wholegrain Enzyme|Enzyme-treated wholegrain, 3 x 30 g, single serving
62353705|NCT00004732|ACTIVE_COMPARATOR|Carotid Artery Endarterectomy (CEA)|Carotid endarterectomy is surgery to remove plaque buildup that causes narrowing (stenosis) in the carotid artery.
62353706|NCT00004732|ACTIVE_COMPARATOR|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) is a procedure used to open narrowed carotid arteries. During the procedure, a small, expandable wire tube called a stent is permanently inserted into the carotid artery.
62353707|NCT04114513|PLACEBO_COMPARATOR|Maltodextrin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
62353708|NCT04114513|EXPERIMENTAL|Inulin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
62353709|NCT04114513|EXPERIMENTAL|Pectin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
62353710|NCT04114513|EXPERIMENTAL|Beta-glucan|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
62513809|NCT01941888|EXPERIMENTAL|propofol|Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 µg/ml. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
62709834|NCT05320978||patients undergoing minimally invasive pylor-preserving pancreaticoduodenectomy|Adult patients aged 20 years or older and who underg minimally invasive pylor-preserving pancreaticoduodenectomy
61976358|NCT00541489|EXPERIMENTAL|3|Naproxcinod 750 mg
61976359|NCT03051035|EXPERIMENTAL|KO-947|
62513810|NCT01941888|ACTIVE_COMPARATOR|midazolam|Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg if aged\< 70 - 0.03 mg/kg if aged\> 70. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
62513811|NCT04357613|EXPERIMENTAL|Expérimental ARM|800mg/d IMATINIB during 14days
62513812|NCT04357613|NO_INTERVENTION|Comparator ARM|Standard of care
62513813|NCT04417582||life syte modification only|obese patients followed with life style modification
62709835|NCT03034889||Exposed|Children age 4-10 who required general anesthesia before the age of 36 months in the context of surgical and diagnostic procedures or sedation during intensive care, excluding neurosurgical interventions or cardiac surgery as well as preexisting hereditary or acquired neurocognitive deficits
62709836|NCT03034889||Control|Children age 4-10 who did not require any anesthesia before the age of 36 months. Excluding preexisting hereditary or acquired neurocognitive deficits.
62709837|NCT05375630|PLACEBO_COMPARATOR|Placebo|micro-crystalline cellulose placebo (one 380 mg tablet per day)
62709838|NCT05375630|ACTIVE_COMPARATOR|Vitamin K2|micro-crystalline cellulose (one 380 mg tablet per day) where vitamin K2 (K2VITAL® 0.2% DELTA powder) is mixed into the formulation to a final vitamin K2 concentration of 240 μg/tablet
62709839|NCT05558969|ACTIVE_COMPARATOR|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia
62709840|NCT05558969|PLACEBO_COMPARATOR|control group|Pregnant will be operated under general anesthesia
62709841|NCT01468480|EXPERIMENTAL|Pro Root MTA- standard method|application of MTA in second group and 24 hour interval before restoration
61976360|NCT02379806|ACTIVE_COMPARATOR|Active enoxaparin 40 mg|One 0.4 ml prefilled syringe containing 40 mg enoxaparin active substance administered once daily for 10 ± 4 days
61976361|NCT02379806|PLACEBO_COMPARATOR|Placebo of enoxaparin 40 mg|One 0.4 ml placebo syringe of enoxaparin 40 mg administered once daily for 10 ± 4 days
62353711|NCT04114513|EXPERIMENTAL|Galactooligosaccharides|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
62353712|NCT06403748|ACTIVE_COMPARATOR|Dietary supplement|
62353713|NCT06403748|PLACEBO_COMPARATOR|Placebo|
62353714|NCT01962688|EXPERIMENTAL|Handheld ultrasound - inpatient|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
62353715|NCT01962688|SHAM_COMPARATOR|Sham ultrasound - inpatient|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
62353716|NCT01962688|EXPERIMENTAL|Handheld ultrasound - ambulatory|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
62353717|NCT01962688|SHAM_COMPARATOR|Sham ultrasound - ambulatory|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
62353718|NCT01245205|EXPERIMENTAL|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive Akt inhibitor MK2206 PO QOD for 28 days (35 days for course 1) and lapatinib ditosylate PO QD or BID on days 1-28 (days 9-35 for course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62353719|NCT03331224|EXPERIMENTAL|OTSC|Initial treatment with the OTSC for non-variceal upper GI-bleedings with high risk of recurrency.
62353720|NCT03331224|ACTIVE_COMPARATOR|Standard therapy|Endoscopic standard therapy (two techniques e.g. clip and injection)
62353721|NCT06040307|EXPERIMENTAL|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electric) Healthcare, Boston, Massachusetts, US. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger photoplethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide opioid analgesics. 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
62353722|NCT06040307|NO_INTERVENTION|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation, sweating and spontaneous movements of the patient. As an orientation anesthesiologists are advised to administer 5 µg sufentanil if systolic blood pressure is \> 140 mmHg or mean blood pressure is \> 100 mmHg or heart rate is \> 90 /min. If assessed necessary, the anaesthesiologists are allowed to administer higher or lower sufentanil doses up to their discretion.
62353723|NCT04117399|EXPERIMENTAL|IMT group|Inspiratory muscle training + aerobic exercice
62353724|NCT04117399|ACTIVE_COMPARATOR|Control group|aerobic exercice
62353725|NCT02810951|EXPERIMENTAL|FCX-007|"In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.~In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.~All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results.~One wound in each target wound pair will be used as control for efficacy and safety evaluations."
62513814|NCT04417582||medical teatment with antiobesity drugs|patients prescribed antiobesity drugs
62513815|NCT04417582||bariatric surgery|patients undergone bariatric surgery
62513816|NCT03020784|PLACEBO_COMPARATOR|Placebo|IV placebo
62513817|NCT03020784|EXPERIMENTAL|PF-06818883|Experimental drug
62709842|NCT01468480|EXPERIMENTAL|Pro Root MTA- single visit|Intervention/Control application of MTA in third group and 15 minute interval before restoration
62709843|NCT01468480|EXPERIMENTAL|MultiCal / LimeLite|application of Multical in forth group
62709844|NCT01468480|ACTIVE_COMPARATOR|Dycal|application of Dycal in first group as a pulp dressing agent
62513818|NCT00768118|EXPERIMENTAL|Curcumin, Green Tea extract, Polygonum Cuspidatum & Soybean|Total number of visits: 2, pre-intervention blood draw and urine sample collection, post-intervention blood draw and urine sample collection and interview Length of each visit: 15-30 minutes Total expected duration of participants' involvement: 15 days During the two-week intervention, volunteers will take two 1/2g capsules of the combination capsule, twice daily immediately after morning and evening meals.
62513819|NCT01046630|EXPERIMENTAL|1|single infusion
62513820|NCT01046630|ACTIVE_COMPARATOR|2|single infusion
62513821|NCT01046630|PLACEBO_COMPARATOR|3|single infusion
62513822|NCT04186559|EXPERIMENTAL|Topical pentoxifylline (PTX) gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical PTX gel in their initial course of treatment will receive topical placebo gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
62513823|NCT04186559|PLACEBO_COMPARATOR|Topical placebo gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical placebo gel in their initial course of treatment will receive topical PTX gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
62709845|NCT01734525|EXPERIMENTAL|Anidulafungin|Patients at risk will receive therapy with anidulafungin
62709846|NCT03015285|EXPERIMENTAL|Anxiety Sensitivity Cognitive Therapy|Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
62709847|NCT03015285|ACTIVE_COMPARATOR|Disorder specific Cognitive Therapy|Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
62709848|NCT03383666|EXPERIMENTAL|Treatment Group|PulseRider® Aneurysm Neck Reconstruction in conjunction with coil embolization for unruptured wide-neck intracranial aneurysms.
62709849|NCT00484263|ACTIVE_COMPARATOR|1|
62709850|NCT02176915|EXPERIMENTAL|Group program|8-session group weight loss program and 4 follow-up phone counseling sessions
62709851|NCT02176915|ACTIVE_COMPARATOR|Print Materials|8 weekly mailings of print materials covering weight loss topics through US mail.
62709852|NCT00674921|PLACEBO_COMPARATOR|1|It will comprise patients randomized to receive the placebo (stop cotrimoxazole prophylaxis) at CD4 counts of 200 or more but less than 350 cells/ul as they continue with HAART. Patients will be followed until they achieve a CD4 count of 350 cells/ul.
62709853|NCT00674921|ACTIVE_COMPARATOR|2|It will comprise patients randomized to continue with cotrimoxazole prophylaxis and HAART at CD4 counts of 200 or more but less than 350 cells/ul. These patients will be followed until they achieve a CD4 count of 350 cells/ul and above, at which point they will be considered for the second randomization.
62709854|NCT00674921|PLACEBO_COMPARATOR|A|This arm will comprise patients who have achieved a CD4 count of 350 or more cells/ul either at the beginning of the study or once they have reached this threshold at the end of follow up in arms 1 and 2. They (including those previously in Arm 1) will receive the placebo (stop cotrimoxazole prophylaxis) after the second randomization but continue with HAART.
62709855|NCT00674921|ACTIVE_COMPARATOR|B|It will comprise patients randomized to continue or start with cotrimoxazole prophylaxis and HAART at CD4 of 350 or more cells/ul after second randomization. Some of them will have used cotrimoxazole prophylaxis whilst they were in arm 2 and others in arm 1 will restart cotrimoxazole prophylaxis at this stage.
62353726|NCT05008172|EXPERIMENTAL|Splenic Artery Embolization (SAE)|If a patient is randomized to the SAE arm, the Interventional Radiology (IR) team will be notified of the patient's enrollment. The timing of embolization is left to the IR team but will occur within 6-12 hours of enrollment.
62353727|NCT05008172|NO_INTERVENTION|Observation|Patients assigned to the observation arm will be transferred from the trauma bay to floor or the ICU for monitoring and continuous care under the Trauma team.
62353728|NCT02061579|EXPERIMENTAL|Once-Weekly Structured Contact|Participants in the Once Weekly Structured Contact group will take part in an 6-month exercise intervention and attend one structured group exercise session per week. They will engage in aerobic and resistance training for approximately 80 minutes per exercise session. Additionally, they will attend three exercise evaluations and six study visits.
62353729|NCT02061579|EXPERIMENTAL|Thrice-Weekly Structured Contact|Participants in the Thrice-Weekly Structured Contact group will take part in an 6-month exercise intervention and attend three structured group exercise sessions per week. In total, they will engage in aerobic and resistance training sessions for approximately 200 minutes per week. Additionally, they will attend three exercise evaluations and six study visits.
62353730|NCT02061579|NO_INTERVENTION|Usual Care|Participants in the Usual Care group will not take part in an 6-month exercise intervention. They will continue to seek regular care from their primary care providers and attend six study visits.
62353731|NCT00769236|OTHER|1|Patients with crohn disease
62353732|NCT00769236|OTHER|2|Patients reached by hemorrhagic first side-colitis
62353733|NCT00769236|OTHER|3|Patients controls
62353734|NCT02806947|EXPERIMENTAL|Sirolimus|Sirolimus, a steroid-free therapy, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
62513824|NCT00810888|ACTIVE_COMPARATOR|Group 1-Recombinant activated factor VII|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL)."
62353735|NCT02806947|ACTIVE_COMPARATOR|Prednisone|Prednisone, standard of care therapy for GVHD, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
62353736|NCT03947567|EXPERIMENTAL|Recombinant Human Coagulation FVIII|
62513825|NCT00810888|PLACEBO_COMPARATOR|Group 2 - Placebo|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive placebo."
62513826|NCT00810888|NO_INTERVENTION|Group 3 - Observation Only Arm|"Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA spot sign negative) enrolled into a prospective observational group."
62513827|NCT00478452|EXPERIMENTAL|DC Ova|DC Ova vaccine administered day 2 and week 3,6,9
62709856|NCT01937702|EXPERIMENTAL|Anti-diabetes medication|Insulin
62709857|NCT04542681|PLACEBO_COMPARATOR|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo (0.9% normal saline) (n=10)
61973110|NCT04533438|ACTIVE_COMPARATOR|RhinAer Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session. Each nostril will be treated at 1, 2, 3, 4 or 5 nonoverlapping positions depending on the size of the target treatment area. Treatment settings to be used are temperature 60 °C, power 4 watts, treatment time 12 seconds, and cooling time 0 seconds
62353737|NCT04950205|EXPERIMENTAL|Sevoflurane post conditioning group（S1）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery ,1% sevoflurane plus after open Carotid artery until the end of surgery
62709858|NCT04542681|ACTIVE_COMPARATOR|MANP - 1st Cycle|Subjects will receive a single SQ injection of 2.5 μg/kg MANP (n=10)
62709859|NCT04542681|ACTIVE_COMPARATOR|MANP - 2nd Cycle|Subjects will receive a single SQ injection of 5 μg/Kg MANP (n=10)
62709860|NCT02184533|EXPERIMENTAL|Treatment (sodium selenite and radiation therapy)|Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
62709861|NCT02257684|EXPERIMENTAL|Pegcrisantaspase|
62353738|NCT04950205|NO_INTERVENTION|The control group（P）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery without sevoflurane
62513828|NCT00478452|ACTIVE_COMPARATOR|DC Ova with Cyclophosphamide|Cyclophosphomide administered at day 0 prior to administration of DC Ova vaccine administered day 2 and week 3,6,9
62513829|NCT04026373|EXPERIMENTAL|modified Prolonged Exposure|
62709862|NCT01527565|EXPERIMENTAL|Formulation A|
62353739|NCT03256071|EXPERIMENTAL|Decitabine plus Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.
62709863|NCT01527565|EXPERIMENTAL|Formulation B|
62709864|NCT02872038|EXPERIMENTAL|Treatment|Cefepime intraperitoneal continuous dosing
62709865|NCT02872038|ACTIVE_COMPARATOR|Control|Cefazolin plus Ceftazidime intraperitoneal continuous dosing
62353740|NCT03256071|ACTIVE_COMPARATOR|Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.
62513830|NCT04026373|ACTIVE_COMPARATOR|Treatment as usual|
62513831|NCT05466279|EXPERIMENTAL|Remazolam general anesthesia group (R group)|
62709866|NCT03827317|OTHER|HER2 positive metastatic breast cancer|8 HER2 positive patients (determined using the most recent biopsy) will be recruited. Dynamic \[18F\]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of \[18F\]GE-226 and hence determine the optimal imaging time point for \[18F\]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
62709867|NCT03827317|OTHER|HER2 negative metastatic breast cancer|8 HER2 negative patients (determined using the most recent biopsy) will be recruited. Dynamic \[18F\]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of \[18F\]GE-226 and hence determine the optimal imaging time point for \[18F\]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
62709868|NCT05688085|EXPERIMENTAL|Irbesartan High/Amlodipine Fixed dose combination|participants will receive one tablet of Irbesartan High/Amlodipine FDC in a crossover design
62513832|NCT05466279|ACTIVE_COMPARATOR|Propofol + midazolam general anesthesia control group (group P)|
62513833|NCT06388837|EXPERIMENTAL|Group I (Symphysis Onlay bone graft with injectable platelet rich fibrin placement)|Patients underwent mandibular symphysis Onlay bone graft mixed with injectable platelet rich fibrin (I-PRF) placement.
62513834|NCT06388837|EXPERIMENTAL|Group II (Symphysis Onlay bone graft mixed with Xenograft)|Patients underwent mandibular symphysis Onlay bone graft mixed with Xenograft (InterOss® Anorganic Cancellous Granules).
62513835|NCT06389513|EXPERIMENTAL|ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)|Intramuscular injection, 0.5ml
62709869|NCT05688085|EXPERIMENTAL|Co-administration of Irbesartan High and Amlodipine|participants will receive one table each of Irbesartan High and Amlodipine in a crossover design
62513836|NCT03968497|OTHER|Postoperative pain assessment|Postoperative pain evaluation by a female and a male investigator, respectively at approximately 15-minute intervals.
62709870|NCT02009826||Healthy controls|Healthy age- and sex-matched controls
62709871|NCT02009826||Schizophrenia patients|Young schizophrenia patients 18-40y
62709872|NCT01480167|ACTIVE_COMPARATOR|RF-TVA with STABILIT Vertebral Augmentation System|All RadioFrequency-Targeted Vertebral Augmentation (RF-TVA) arm participants will be treated with the StabiliT Vertebral Augmentation System. This system is a commercially available device in the United States designed to perform percutaneous vertebral augmentation (also known as kyphoplasty).
62709873|NCT01480167|ACTIVE_COMPARATOR|Non Operative Management|All non-operative management (NOM) arm participants will receive non-operative standard of care management, which can include: analgesics, bed rest, back braces, physiotherapy, rehabilitation programs, and walking aids according to standard practices of participating institutions.
62709874|NCT04278248|EXPERIMENTAL|experimental group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine(experimental vaccine), 0.5 ml/dose
62709875|NCT04278248|ACTIVE_COMPARATOR|Positive control group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine (positive control vaccine), 0.5 ml/dose
62709876|NCT00698841|EXPERIMENTAL|Cetuximab|
62709877|NCT00700206|EXPERIMENTAL|1|Dose Schedule 1: Two weeks treatment with Telintra 3000 mg per day in two divided doses followed by one week with no treatment per three week cycle.
62709878|NCT00700206|EXPERIMENTAL|2|Dose Schedule 2: Three weeks treatment with Telintra 2000 mg per day in two divided doses followed by one week with no treatment per four week cycle.
62513837|NCT01695096|EXPERIMENTAL|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
62513838|NCT01695096|PLACEBO_COMPARATOR|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to \> 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
62513839|NCT04719741||O-4PI|4 mg Ondansetron given Pre-Induction
62513840|NCT04719741||O-8PI|8 mg Ondansetron given Pre-Induction
62513841|NCT04719741||O-4PE|4 mg Ondansetron given Pre-Emergence
62513842|NCT04719741||O-8PE|8 mg Ondansetron given Pre-Emergence
62513843|NCT04719741||D-4PI|4 mg Dexamethasone given Pre-Induction
62513844|NCT04719741||D-8PI|8 mg Dexamethasone given Pre-Induction
62513845|NCT04719741||D-4PE|4 mg Dexamethasone given Pre-Emergence
62513846|NCT04719741||D-8PE|8 mg Dexamethasone given Pre-Emergence
62513847|NCT04719741||O-4PI+D-8PI|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-induction
62513848|NCT04719741||O-4PI+D-8PE|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-emergence
62513849|NCT04719741||O-4PE+D-8PI|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-induction
62513850|NCT04719741||O-4PE+D-8PE|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-emergence
62513851|NCT04719741||Placebo Group|2 ml Saline 0.9%
62513852|NCT03509714|ACTIVE_COMPARATOR|Experimental: Part 1 Oxaloacetate Random|Participants take 2 capsules Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend per day during their entire menstrual cycle (approximately 28 days) or 2 capsules of 250 mg rice flour (Placebo). After one menstrual cycle, they cross-over to the other option.
62513853|NCT03509714|ACTIVE_COMPARATOR|Experimental: Part 2 Oxaloacetate Second|Participants take 2 capsules of 250 mg rice flour (Placebo) per day during their entire menstrual cycle (approximately 28 days). After one menstrual cycle, they cross-over to 2 capsules of Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend.
62513854|NCT04186598|EXPERIMENTAL|Experimental: CPAP|Participants will be treated with CPAP. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
62513855|NCT04186598|PLACEBO_COMPARATOR|Control: High flow oxygen|Participants will be treated with an altered CPAP mask that will deliver high flow oxygen. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
61973111|NCT04533438|SHAM_COMPARATOR|Control Treatment|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
61973112|NCT02566655|EXPERIMENTAL|Fucosylated MSC for Osteoporosis|Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
61973113|NCT02627781||suspected appendicitis|This group includes all patients with suspected appendicitis, who are admitted to our University Hospital.
61973114|NCT05803057|EXPERIMENTAL|TMS treatment|Using nrTMS coli to stimulate the thumb related motor cortex with high-frequency.
61973115|NCT05803057|SHAM_COMPARATOR|TMS Sham-treatment|Using nrTMS sham-coli to stimulate the thumb related motor cortex with high-frequency.
61973116|NCT02226406|EXPERIMENTAL|Legs Cycloergometer Group (A)|Patients randomized in this group will do 10 minutes of legs cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
62513856|NCT02237742|EXPERIMENTAL|PF-06427878|
62513857|NCT05248984||Ketorolac 30 mg|Participants will receive single dose of intravenous (IV) Ketorolac 30mg
62513858|NCT05248984||Ketorolac 60 mg|Participants will receive single dose of intravenous (IV) Ketorolac 60mg
62513859|NCT01123317|EXPERIMENTAL|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
62513860|NCT05881642|EXPERIMENTAL|Prostate and seminal-sparing Cystectomy|Patients undergoing transurethral resection and enucleation of the prostate before robot-assisted cystectomy
62513861|NCT05881642|PLACEBO_COMPARATOR|Conventional Radical Cystoprostatectomy|Patients undergoing conventional robot-assisted radical cystoprostatectomy
62513862|NCT02898103|EXPERIMENTAL|Active Current then Sham then Active Current|Electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes; then sham/placebo for 5 minutes; and then active electrical current for the following 2-4 weeks
62513863|NCT02898103|ACTIVE_COMPARATOR|Sham then Active Current|Sham/placebo will be introduced to the insulated percutaneous lead(s) for 5 minutes; then active electrical current for the following 2-4 weeks
62513864|NCT01226251||Healthy adults|Subjects consulting a bad breath clinic at the Department of Periodontology, KULeuven
62513865|NCT03971578||Autism Spectrum Disorders Group|Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old
62513866|NCT03971578||Normal Control Group|Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old
62513867|NCT03476317|EXPERIMENTAL|Group 1-Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
62513868|NCT03476317|PLACEBO_COMPARATOR|Group 1-Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
62513869|NCT03476317|NO_INTERVENTION|Group 2|Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.
62513870|NCT03879096|EXPERIMENTAL|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
62513871|NCT05365659|EXPERIMENTAL|Dose Escalation Cohort (Part 1)|Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62513872|NCT05365659|EXPERIMENTAL|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62709879|NCT03461718|EXPERIMENTAL|Ketamine|Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
61973117|NCT02226406|EXPERIMENTAL|Hands Cycloergometer Group (B)|Patients randomized in this group will do 10 minutes of hand cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
61973118|NCT02226406|EXPERIMENTAL|Walk in place (C)|Patients randomized in this group will do 10 minutes of active walk in place. Continuously evaluated with electric impedance tomography.
61973119|NCT01901198|EXPERIMENTAL|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
61973120|NCT01901198|ACTIVE_COMPARATOR|Pegasys|Peginterferon 180 mcg single dose S.C.
61973121|NCT02622581||NSCLC, Non-squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~At least 3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)"
61973122|NCT02622581||NSCLC, Squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~At least 1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)"
62147265|NCT00569166|PLACEBO_COMPARATOR|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
62513873|NCT05365659|EXPERIMENTAL|Dose Expansion: Follicular Cell Lymphoma Participants|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62513874|NCT05365659|EXPERIMENTAL|Dose Expansion: Mantle Cell Lymphoma Participants|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62513875|NCT05365659|EXPERIMENTAL|Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
62513876|NCT04737850|EXPERIMENTAL|PartA, open-label|Hetrombopag plus standard of care
62147266|NCT03311880|EXPERIMENTAL|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
62513877|NCT04737850|EXPERIMENTAL|PartB, double-blind treatment group|Hetrombopag plus standard of care
62709880|NCT03461718|ACTIVE_COMPARATOR|Control|This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
62147267|NCT02444195|EXPERIMENTAL|Guided Imagery|Guided Imagery With Audio Media
62147268|NCT02444195|NO_INTERVENTION|Routine Postoperative Care|Subjects will receive routine pre-operative, intra-operative, post-operative, chemotherapy, and radiation care as dictated by pathologic diagnosis.
62513878|NCT04737850|PLACEBO_COMPARATOR|Placebo Comparator|Placebo plus standard of care Part B, double-blind treatment group
62709881|NCT02478151|EXPERIMENTAL|OrganOx Metra|OrganOx Metra Device
62709882|NCT03732989|ACTIVE_COMPARATOR|Control group: Non-interactive toy prototype|30 children will be given the same toy as participants in the experimental group, but without the interactive features (haptic feedback).
62709883|NCT03732989|EXPERIMENTAL|Experimental: Interactive toy prototype|30 children will be given the same toy as participants in the control group, but with the interactive features (haptic feedback).
62709884|NCT04373304|EXPERIMENTAL|low FODMAP diet|
62513879|NCT03721302||Main Study Clinical Sepsis|Clinical and Antimicrobial Assessments
62513880|NCT03721302||Microbiology Sub study|Clinical and Antimicrobial Assessments
62513881|NCT04410575|EXPERIMENTAL|Intervention Group (Standard Pharmacist Care + Pharmacist Interventions)|Participants enrolled in the intervention group will receive pharmacist interventions, in addition to standard care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians), at enrollment (month 0) and at 1, 3, and 6 month in-person follow-up appointments
62709885|NCT04862494||diaphragmatic eventation with medical surveillance|Patients with a diagnosis of diaphragmatic eventration without respiratory or digestive consequences, thus not requiring surgical repair.
62709886|NCT04862494||diaphragmatic eventration treated with plication|Patients with a diagnosis of diaphragmatic eventration with respiratory or digestive repercussion, requiring surgical repair.
62709887|NCT03942081|EXPERIMENTAL|Ulcer Measurement and Photo Group|Diabetic patients with foot ulcers being seen in clinic.
62709888|NCT03942081|NO_INTERVENTION|Healthy Control Group|Patients without foot ulcers being seen in the clinic.
62709889|NCT05034926||Cohort 1|Participants with locally advanced or metastatic (stage IIIB-IV) non-small cell lung cancer (NSCLC)
62709890|NCT05270525|EXPERIMENTAL|Treatment Sequence 1|Treatment Period 1 (blinded Ensifentrine) followed by Treatment Period 2 (blinded Placebo)
62709891|NCT05270525|EXPERIMENTAL|Treatment Sequence 2|Treatment Period 1 (blinded Placebo) followed by Treatment Period 2 (blinded Ensifentrine)
62709892|NCT05640089|EXPERIMENTAL|Emotion network up-regulation + standard care|NF protocol targeting emotion networks (NFE) (plus standard care)
62709893|NCT05640089|NO_INTERVENTION|Standard care|Continuation of treatment as usual.
62709894|NCT03234634|NO_INTERVENTION|Group 1: patients with good collateral|
62513882|NCT04410575|ACTIVE_COMPARATOR|Control Group (Standard Pharmacist Care)|Patients randomized to the usual care group will receive standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians) and physician care, at enrollment (month 0) with no specific interventions for the duration of 6 months, until the 6 month in-person follow-up appointment
62513883|NCT01345318|EXPERIMENTAL|Open-label Treatment|
62513884|NCT06106451|ACTIVE_COMPARATOR|Standard of Care plus Enhanced Patient Education|Each participant in this arm will receive enhanced patient education. The research staff will discuss the benefits of cardiac rehabilitation and provide a pamphlet describing the benefits discussed. The research staff will also call the patient four times throughout their participation in the study to encourage physical activity. The enhanced patient education program will begin approximately 2 weeks after the TAVR procedure.
62513885|NCT06106451|ACTIVE_COMPARATOR|Motivational Interviewing Intervention|Each participant in this arm will have a motivational interviewing program created by a psychologist. The motivational interviewing program will be tailored to the individual participant. The goal of the motivational interviewing program is improved adherence to standard of care cardiac rehabilitation. The motivational interviewing program will begin approximately 2 weeks after the TAVR procedure.
62513886|NCT06106451|ACTIVE_COMPARATOR|Home-Based Activity Program plus Motivational Interviewing Intervention|Each participant in this arm will be evaluated by a physical therapist and psychologist. The physical therapist will use the evaluation to create an individually tailored home-based activity program plan. This home-based activity program will be implemented at the 1-month post-operative cardiology clinic appointment. The psychologist will use the evaluation to create an individually tailored motivational interviewing program. The motivational interviewing program will begin approximately 2 weeks after the TAVR procedure.
62513887|NCT01876849|EXPERIMENTAL|Group A|Exenatide injection 5mcg or 10 mcg, twice daily
62513888|NCT05420779|EXPERIMENTAL|TSL-1502 low dose group|TSL-1502 capsules 350 mg,qd,po
62709895|NCT03234634|EXPERIMENTAL|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
62709896|NCT03234634|NO_INTERVENTION|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
62709897|NCT03659578|EXPERIMENTAL|Thymosin α1|Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
62709898|NCT02865174|ACTIVE_COMPARATOR|Topical tranexamic acid|Intraarticular application of tranexamic acid Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
62353741|NCT03683056|ACTIVE_COMPARATOR|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
62353742|NCT03683056|NO_INTERVENTION|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
62353743|NCT01286701|EXPERIMENTAL|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
62353744|NCT01286701|ACTIVE_COMPARATOR|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
62353745|NCT01760187|EXPERIMENTAL|Cohort 1|12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive 10 mg lomitapide and 2 will receive placebo.
62353746|NCT01760187|EXPERIMENTAL|Cohort 2|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 20 mg lomitapide and 2 will receive placebo.
62353747|NCT01760187|EXPERIMENTAL|Cohort 3|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 40 mg lomitapide and 2 will receive placebo.
62353748|NCT01760187|EXPERIMENTAL|Cohort 4|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 60 mg lomitapide and 2 will receive placebo.
62353749|NCT01343017|OTHER|Increased tidal volume (IVT)|In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
62353750|NCT01343017|OTHER|Normal tidal volume (NVT), with PEEP|In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
62353751|NCT02732353|ACTIVE_COMPARATOR|Minced beef|Minced beef
62353752|NCT02732353|EXPERIMENTAL|Hydrolyzed beef|Hydrolyzed beef
62353753|NCT00516984|PLACEBO_COMPARATOR|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
62353754|NCT00516984|SHAM_COMPARATOR|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
62353755|NCT00516984|ACTIVE_COMPARATOR|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
62353756|NCT02752724|EXPERIMENTAL|Ketamine Interventional Arm|1.0 mg/kg IV ketamine (experimental arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
62709899|NCT02865174|ACTIVE_COMPARATOR|Floseal®|"Floseal® was applied on potential bleeding sites before prosthesis implantation.~Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay"
62709900|NCT02865174|PLACEBO_COMPARATOR|Control group|No intervention before closure of joint capsule. Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
62513889|NCT05420779|EXPERIMENTAL|TSL-1502 high dose group|TSL-1502 capsules 500 mg,qd,po
62513890|NCT05420779|ACTIVE_COMPARATOR|Positive control group|Investigator selects chemotherapy regimens according to the subjects' conditions.
62513891|NCT02128555|ACTIVE_COMPARATOR|Arthrodesis|Ankle arthrodesis (fusion)
62513892|NCT02128555|EXPERIMENTAL|Total Ankle Replacement|Total Ankle Replacement
62513893|NCT06111079|EXPERIMENTAL|Aspirin discontinuation group|initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, discontinuing aspirin at 28 weeks of gestation.
62513894|NCT06111079|ACTIVE_COMPARATOR|Control group|initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, continuing aspirin until 36 weeks of gestation.
62513895|NCT04715776|PLACEBO_COMPARATOR|Pre-DM patients with placebo|Pre-Diabetes patients uptake placebo as dietary supplement
62513896|NCT04715776|EXPERIMENTAL|Pre-DM patients with supplement|Pre-Diabetes patients uptake Brown seaweed as dietary supplement
62513897|NCT04715776|PLACEBO_COMPARATOR|DM patients with placebo|Diabetes patients uptake placebo as dietary supplement.
62513898|NCT04715776|EXPERIMENTAL|DM patients with supplement|Diabetes patients uptake Brown seaweed as dietary supplement
62513899|NCT01862419|EXPERIMENTAL|Alert|Text page sent to patient's covering provider and unit pharmacist informing them of the presence of AKI as detected by changes in serum creatinine.
62513900|NCT01862419|NO_INTERVENTION|Usual Care|Usual care arm. No alert will be provided to the patient's covering provider or unit pharmacist.
62513901|NCT00792623|EXPERIMENTAL|Varilrix Group|Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation.
62513902|NCT02645344|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation (rTMS)|Low frequency rTMS at 1 Hz was applied over P5 of the contralesional hemisphere in addition to conventional rehabilitation
62513903|NCT02645344|EXPERIMENTAL|rTMS combined with sensory cueing (SC)|Vibration cueing was emitted using a wristwatch device on the hemiplegic arm combined with low frequency rTMS in addition to conventional rehabilitation
62513904|NCT02645344|ACTIVE_COMPARATOR|Conventional rehabilitation|Physical therapy and occupational therapy
62513905|NCT01360827|EXPERIMENTAL|Arm 1 (Part 1)|
62513906|NCT01360827|EXPERIMENTAL|Arm 2 (Expansion cohorts -Part 2 and Part 2a)|
62513907|NCT01247779|ACTIVE_COMPARATOR|Standard Coelioscopy|gynecologic surgery - standard coelioscopy
62513908|NCT01247779|EXPERIMENTAL|Robot-assisted coelioscopy|gynecologic surgery - robot assisted coelioscopy
62513909|NCT06367036|EXPERIMENTAL|Hypericum Perforatum Oil group|This research is a self-controlled study. One injected arm of the patient will be assigned to the intervention group and the other arm to the control group. İn the experimental arm, the research nurse working in the Coronary Intensive Care unit (CICU) applied 5-6 drops of HP oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied. The assessment of ecchymosis and pain at the injection site was performed by two other investigators at the 48th hour of the injection (Single blind).
62513910|NCT06367036|NO_INTERVENTION|Control group|This research is a self-controlled study. One injected arm of the patient will be assigned to the intervention group and the other arm to the control group.In the control arm, no treatment was performed before injection.The assessment of ecchymosis and pain at the injection site was performed by two other investigators at the 48th hour of the injection (Single blind).
62513911|NCT04080609|EXPERIMENTAL|Sequential arm|Dorzagliatin was administered single dose; after wash-out, rifampicin was dosed continuously for 9 days, with Dorzagliatin dosed simultaneously on day 8.
62513912|NCT06424717|EXPERIMENTAL|Avelumab with tuvusertib|
62709901|NCT04857554|EXPERIMENTAL|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62513913|NCT06260826|EXPERIMENTAL|Auto-CPAP via nasal mask|Patients connected to the JPAP system (Metran, Saitama, Japan) via a nasal mask with the initial CPAP 2 cmH2O, then reach CPAP 7.5 cmH2O after a ramping time of 5 minutes.
62513914|NCT06260826|ACTIVE_COMPARATOR|Constant-CPAP via facial mask|Patients connected to the O2-Max Trio CPAP system (Pulmodyne, Indianapolis, USA) with a facial mask and maintained a CPAP at 7.5 cm H2O
62513915|NCT02681484|EXPERIMENTAL|Hypertensive|Patients diagnosed with hypertension (I10, either on drug therapy or verified by 24h blood pressure measurements) administered to anthroposophic speech therapy (intervention).
62513916|NCT02681484|ACTIVE_COMPARATOR|Normotensive|Patients diagnosed with tension headache (G 44.2) or anxiety disorders (F41) administered to anthroposophic speech therapy (intervention).
62513917|NCT06284447||Observational|Participants complete a survey on study.
62513918|NCT04149028|EXPERIMENTAL|PRP injection|injection of PRP inside ovary by the assistance of laparoscopy
62513919|NCT02533284|EXPERIMENTAL|Magnesium sulfate group|US guided TAP with magnesium sulfate
62513920|NCT02533284|EXPERIMENTAL|B group|TAP bupevecaine
62513921|NCT02533284|PLACEBO_COMPARATOR|C group|control TAP saline
62513922|NCT02787317|ACTIVE_COMPARATOR|heparin|For the heparin group, a bolus dose of 100 U/kg was administered according to current guidelines.
62513923|NCT02787317|EXPERIMENTAL|not prolong infusion Bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure .
62513924|NCT02787317|EXPERIMENTAL|prolong infusion bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and prolong for 4 hours after procedure.
62513925|NCT03113526|ACTIVE_COMPARATOR|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
62513926|NCT03113526|ACTIVE_COMPARATOR|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
62513927|NCT05037773|EXPERIMENTAL|Group 1|In this condition, the intervention is administered immediately after the baseline.
62513928|NCT05037773|EXPERIMENTAL|Group 2 (waiting-list group)|This group is both a control and an experimental group. Indeed, the intervention (i.e., the same as for group 1) is administered but after a second baseline which is held after the completion of the Group 1. This condition will allow to check the specific efficiency of the intervention.
62513929|NCT00094458|EXPERIMENTAL|003|infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
62513930|NCT00094458|EXPERIMENTAL|001|infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
62513931|NCT00094458|EXPERIMENTAL|002|infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
62513932|NCT04940702|EXPERIMENTAL|Focal Vibration Group|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~the training is the same as the contol group with the difference of FV addiction."
62513933|NCT04940702|ACTIVE_COMPARATOR|Blood Flow Restriction Group|"Training with Blood Flow Restriction a pressure cuff occludes in the proximal part of the lower limb. Time of training 20-25 min.~the training is the same as the contol group with the difference of BFR addiction."
62513934|NCT04940702|ACTIVE_COMPARATOR|Training Group|"Traditional training. 3 times a week~1. Warm-up:~2. Main work:~   1. Aerobic training~  2. Strength training~  3. Balance and coordination training~3. Return to calm"
61973123|NCT02622581||NSCLC, Non-squamous cell carcinoma (not tested)|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~Up to 5,000 patients not tested for molecular alterations (CRISP satellite untested patients stage IIIB/IIIC/IV).)."
61973124|NCT02622581||NSCLC, Stage I/II/III|Up to 1600 patients with NSCLC stage I, or stage II, or stage IIIA, or with NSCLC stage IIIB/C if they are eligible for curative surgery and/or radiochemotherapy, or are receiving best supportive care
61973125|NCT02622581||Small cell lung cancer (SCLC)|Up to 1200 patients with SCLC (limited stage (LD) or extensive stage (ED)) if they are eligible for surgery and/or radio(chemo)therapy and/or systemic therapy, or are receiving best supportive care
61973126|NCT06142045||Children (7-10 years)|All groups of the experiment will be exposed to the same intervention. The intervention the participants are exposed to is the use of the computer controlled gas blender system for manipulation of end-tidal and arterial blood gases. This will be used for the following protocols, to either clamp end-tidal concentrations at resting levels or administer a hypercapnia challenge. The protocol includes assessment of cerebral blood flow responses (measured using ultrasound) to carbon dioxide; including a hypercapnia ramp protocol followed by a transient protocol. Following at least 30 minute wash out, participants will then perform isometric exercise at 30% of their maximal voluntary contraction for 2 minutes. Participants will perform the isometric handgrip exercise under 2 different conditions (hypercapnia (+9 mmHg) and clamped breathing; to maintain baseline end-tidal carbon dioxide and oxygen concentrations) with a 20-minute recovery period between each bout.
61976362|NCT05357950|ACTIVE_COMPARATOR|PrimeC|2 tablets of PrimeC administered twice daily (4 tablets a day), at a daily dose of 1496 mg
62147269|NCT05944094||Group 1: exposed patients|Group 1: pregnant women who received intravaginal chlorhexidine before 16 weeks of gestation Group 2: pregnant women who did not received intravaginal chlorhexidine e before 16 weeks of gestation
62513935|NCT00956787|EXPERIMENTAL|Treatment with AR-67|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days.
62513936|NCT02591212|ACTIVE_COMPARATOR|#ConnectDots|"Green Dot Intensive Bystander Training (INT Condition) (Randomized):~Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.~Administered by: UK VIP Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training."
62513937|NCT02591212|PLACEBO_COMPARATOR|#ConnectWell|"Wellness Initiatives for Student Empowerment delivered by UK's Student Wellness Office Programming: Addresses elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.~Administered by: UK VIP/Student Wellness Ambassadors Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training"
62513938|NCT00038831|EXPERIMENTAL|Chemotherapy + ATG + Stem Cell Infusion|
62513939|NCT03779152||non asthmatic subjects|
62513940|NCT03779152||intermittent asthmatics|
62513941|NCT03779152||severe asthmatics sensitive to corticosteroids|
62513942|NCT03779152||severe asthmatics resistant to corticosteroids|
62513943|NCT03779152||moderate asthmatics|
61976363|NCT05357950|PLACEBO_COMPARATOR|Placebo|2 tablets of Placebo administered twice daily (4 tablets a day). Placebo tablets are matched in size, color and taste.
61976364|NCT03993340||1|Rescue stenting group
61976365|NCT04199572|EXPERIMENTAL|Diclofenac and Oral Paracetamol|Diclofenac (75mg intramuscular), Placebo (100ml intravenous Normal Saline), Paracetamol (per oral 1gm)
62353757|NCT02752724|ACTIVE_COMPARATOR|Methohexital Control Arm|1mg/kg of methohexital (standard arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
62513944|NCT00567476|ACTIVE_COMPARATOR|Omalizumab + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
62709902|NCT04857554|EXPERIMENTAL|White bread as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61976366|NCT04199572|EXPERIMENTAL|Diclofenac and IV Paracetamol|Diclofenac (75mg intramuscular), Paracetamol (intravenous1gm in 100ml solution), Placebo (sugar tablets)
61976367|NCT04199572|EXPERIMENTAL|Diclofenac and Placebo|Diclofenac (75mg intramuscular),Placebo (100ml intravenous Normal Saline),Placebo (sugar tablets)
62353758|NCT03825107|ACTIVE_COMPARATOR|Patching|2 hours per day 7 days per week patching of the fellow eye
61976368|NCT00740844|NO_INTERVENTION|1|No intermittent pneumatic compression of the lower limbs during patient hospitalisation in réanimation unit
61976369|NCT00740844|EXPERIMENTAL|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
61976370|NCT05729464||cancer patients with venous thrombosis|
61976371|NCT05729464||cancer patients without venous thrombosis|
61976372|NCT00299455|EXPERIMENTAL|1|Reconstituted amoxicillin-clavulanate at 40/5.7 mg/kg/day in 2 divided doses for 7 days.
62353759|NCT03825107|EXPERIMENTAL|Dichoptic Videos|watching 6 dichoptic videos during each 2 week period
62353760|NCT01828099|EXPERIMENTAL|Ceritinib|Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
62353761|NCT01828099|ACTIVE_COMPARATOR|Chemotherapy|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors, etc (other usual rule to stop treatment).
62353762|NCT00880763|EXPERIMENTAL|Vaniprevir 200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
62353763|NCT00880763|EXPERIMENTAL|Vaniprevir 600 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
62353764|NCT00880763|EXPERIMENTAL|Vaniprevir 1200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
62353765|NCT00880763|PLACEBO_COMPARATOR|Placebo + peg-IFN + ribavirin|Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
62353766|NCT05594368|EXPERIMENTAL|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|
62353767|NCT05285436|EXPERIMENTAL|CloudCath detection|Active monitoring of dialysate effluent by the CloudCath System.
62353768|NCT01002053||Diabetics with peripheral neuropathy|Patients with diabetes and peripheral neuropathy.
62353769|NCT04250376|EXPERIMENTAL|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
62353770|NCT04915326||Retrospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The first step will be a retrospective and exploratory analysis of FFPE slides retrieved from the pathology archives testing a panel of molecular marker exploring the immune reaction to the cancer (i.e. antigen presenting cells and T lymphocytes activation).
62353771|NCT04915326||Prospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The second step will be a prospective and validating analysis. Tissue samples will be obtained from normal rectal mucosa adjacent to the cancer at the time of the trans anal or trans abdominal resection. In patients with early rectal cancer, the combination of immunological markers on healthy rectal mucosa adjacent to the cancer obtained in the part 1a of the study will be validated to identify the patients that will have not any nodal metastasis.
62353772|NCT03544632|EXPERIMENTAL|Acellular Adipose Tissue (AAT)|This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
62353773|NCT05321966|EXPERIMENTAL|Visual Education Group|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
62353774|NCT05321966|NO_INTERVENTION|no intervention|No intervention was made to the individuals in the control group.
62353775|NCT01541501||Pachymetry|All recruited volunteers in present study, that underwent pachymetry measurement with four different instruments
62353776|NCT02356146||All KT recipient|
62513945|NCT00567476|ACTIVE_COMPARATOR|Conventional Therapy|Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
62513946|NCT06234774||Robot-assisted surgery|Patients receiving abdominal surgical procedures with robot-assisted videolaparoscopic approach
62513947|NCT06234774||Non-robotic laparoscopic surgery|Patients receiving abdominal surgical procedures with conventional (non-robotic) videolaparoscopic approach
62513948|NCT01857648|EXPERIMENTAL|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
62513949|NCT01857648|NO_INTERVENTION|Control|Control group.
62513950|NCT04273282|ACTIVE_COMPARATOR|Dexycu Group|A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.
62513951|NCT04273282|ACTIVE_COMPARATOR|Control Group|A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
62513952|NCT03069677|ACTIVE_COMPARATOR|Music group|research-selected music
62513953|NCT03069677|ACTIVE_COMPARATOR|Midazolam group|IV midazolam (1mg to 2mg max)
62513954|NCT05125731|EXPERIMENTAL|Parental absence|The parent will not be present in the dental clinic during the treatment. Parents will be instructed to wait in a waiting room outside the clinic, out of sight of the child.
61976373|NCT00299455|PLACEBO_COMPARATOR|2|Reconstituted placebo in 2 divided doses for 7 days.
61976374|NCT06498947||Group A|Group A is defined as those whose physiological hyperopia (sphere+1/2 cylinder) of at least - 0.5 diopters(D) in either eye.
62353777|NCT02027922|EXPERIMENTAL|Fluoride varnish Fluor Protector S|Fluoride varnish Fluor Protector S (Ivoclar Vivadent) with 1.5% ammonium fluoride was not scored. The emergence of a new varnish implies the necessity to compare the effectiveness of both agents in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
62353778|NCT02027922|ACTIVE_COMPARATOR|Duraphat|5% Sodium fluoride varnish Duraphat Colgate implies the necessity to compare the effectiveness with Fluor Protector S in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
62353779|NCT02027922|NO_INTERVENTION|an oral hygiene tutorial|an oral hygiene tutorial
62353780|NCT01867567|EXPERIMENTAL|6 Hours|Removal of bandage after 6 hours
62353781|NCT01867567|ACTIVE_COMPARATOR|24 hours|removal of bandage after 24 hours
62513955|NCT05125731|ACTIVE_COMPARATOR|Parental visual support|The parent will watch and wait behind a transparent barrier without disrupting the interaction between the dentist and the child. This type of separation differs from the total absence of the parent because the parent is within the child's sight.
62513956|NCT05125731|ACTIVE_COMPARATOR|Parental presence|One of the parents will accompany the child during the dental treatment. The parent is allowed to sit next to the child without disturbing the interaction between the dentist and the child.
62513957|NCT01679197|EXPERIMENTAL|Treatment|Metreleptin
62513958|NCT04065568|EXPERIMENTAL|Intervention group|The patient will receive conventional out patient rehabilitation after discharge to the home after stroke. In addition an individualized training program with gamified excercises for motor function will be set and followed up by clincians using video communication, as part of the DISKO-tool. Patients are instructed to train self sufficiently 5 days a week and will be supervised by the treating physiotherapist. The intervention will last for 6 weeks.
62513959|NCT04065568|NO_INTERVENTION|Control group|Conventional rehabilitation in primary care after discharge to the home after stroke.
62513960|NCT04250831|EXPERIMENTAL|Glucomannan, oligofructose and chromium mixture|Agglomerated glucomannan, oligofructose and chromium mixture as the functional ingredient in a calorie
62513961|NCT02779751|EXPERIMENTAL|NSCLC KRAS mt, PD-L1+|Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62513962|NCT02779751|EXPERIMENTAL|NSCLC Squamous|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62513963|NCT02779751|EXPERIMENTAL|HR+, HER2- Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62513964|NCT02779751|EXPERIMENTAL|HR+, HER2- Locally Advanced or Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle and anastrozole given orally Q24H on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
62513965|NCT01702779|OTHER|optiflow|
62513966|NCT01702779|OTHER|O2|
61976375|NCT06498947||Group B|Group B is defined as whose physiological hyperopia exceeds 95% confidence interval for children of same age (Near Myopia).
61976376|NCT06498947||Group C|Group C is defined as whose physiological hyperopia exceeds 90% confidence interval for children of same age.
62513967|NCT04813016|ACTIVE_COMPARATOR|Early tramal/bupivacaine|patients received 50 ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% immediately before creation of a pneumoperitoneum and placement of the first two trocars before starting the surgery.
62513968|NCT04813016|ACTIVE_COMPARATOR|Late tramal/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
62513969|NCT04813016|ACTIVE_COMPARATOR|Early dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% before creation of a pneumoperitoneum and placement of the first two trocars before the start of surgery.
62513970|NCT04813016|ACTIVE_COMPARATOR|Late dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
62513971|NCT05015374|PLACEBO_COMPARATOR|placebo|Compared the difference of changes in psychometrics between Astaxanthin users and placebo group.
62513972|NCT05015374|ACTIVE_COMPARATOR|Astaxanthin|Compared the difference in adverse effects between Astaxanthin users and placebo group.
62513973|NCT04423159|EXPERIMENTAL|OCV vaccine|Shanchol 1.5mL to be administered orally. Each dose contains V.cholerae O1 Inaba El Tor Strain, Inaba classical strain, ogawa classical strain and O139 strain. As well as Thiomersal and a buffer
62513974|NCT04628936|EXPERIMENTAL|KZR-616 45 mg + standard therapy (open-label)|All patients received a SC injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 up to a maximum of 96 weeks. Study drug administration ended for all patients in Study KZR-616-003E when the last patient enrolled completed 48 weeks of dosing.
62513975|NCT03104348|OTHER|COPD screening|
61976377|NCT03463343|EXPERIMENTAL|Manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
62513976|NCT06198530|ACTIVE_COMPARATOR|cognitive training in NLCs|computerized cognitive training (CCT) was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time. All the patients were capable of performing the training under the guidance of advanced practicing nurses (APNs). At the same time, according to the caregivers' feedback, APNs will give them the desired care guidance.
62513977|NCT06198530|ACTIVE_COMPARATOR|cognitive training in home|CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system. The data results of each training will be automatically stored in the personal information database in the cloud. And, a training report will be generated, including training difficulty, training results and training time. Nurses can examine patients' training through the cloud.
62709903|NCT04857554|EXPERIMENTAL|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61976378|NCT03463343|ACTIVE_COMPARATOR|Mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
61976379|NCT03463343|PLACEBO_COMPARATOR|Placebo|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
61976380|NCT03463343|NO_INTERVENTION|Control|The subjects stayed in supine position and no intervention occurred.
62353782|NCT02576886|EXPERIMENTAL|Supine/Prone Imaging|The patient will be imaged in the standard supine position and then an additional image will be acquired of the patient in the prone position.
62353783|NCT03550742|EXPERIMENTAL|Intervention|Daily administration of 5g of Fuco-N-Tetraose as a bolus for a period of 12 weeks.
62353784|NCT03625154|ACTIVE_COMPARATOR|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
62353785|NCT03625154|ACTIVE_COMPARATOR|non operative experimental group|Patients with positive gravity stress (medial clear space \> 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to \<4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
62353786|NCT03625154|ACTIVE_COMPARATOR|operative observational group|Patients with positive gravity stress (medial clear space \> 4 mm) who undergo a reduction with closing of the medial clear space to \<4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
62353787|NCT01300364|PLACEBO_COMPARATOR|sugar pill|
62353788|NCT01300364|ACTIVE_COMPARATOR|reboxetine (NRI)|
62353789|NCT01300364|ACTIVE_COMPARATOR|citalopram (SSRI)|
62353790|NCT02963896|EXPERIMENTAL|gentamicin|intratympanic application of gentamicin 0.5 ml
62353791|NCT06048367|EXPERIMENTAL|CNSI-Fe(II) 30 mg|30 mg
62353792|NCT06048367|EXPERIMENTAL|CNSI-Fe(II) 60 mg|60 mg
62353793|NCT06048367|EXPERIMENTAL|CNSI-Fe(II) 90 mg|90 mg
62353794|NCT05488704||CONTROL GROUP|Control Group \[NST device volume turned off\]
62353795|NCT05488704||Intervention Group I|Intervention Group I \[NST device volume 1-35 dB(A)\]
62353796|NCT05488704||Intervention Group II|Intervention Group II \[NST device volume 36-60 dB(A)\]
62353797|NCT05488704||Intervention Group III|Intervention Group III \[61 dB( A) and above\]
62353798|NCT00292747|EXPERIMENTAL|drotaverine + Ibuprofen placebo|Drotaverine 80 mg plus ibuprofen placebo orally
62353799|NCT00292747|ACTIVE_COMPARATOR|Drotaverine placebo + ibuprofen|Drotaverine placebo plus ibuprofen 400 mg orally
62513978|NCT06198530|PLACEBO_COMPARATOR|cognitive training in tradition|the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed. And, the patients and their families were given detailed health education on the definition, clinical manifestations, drug and non-drug treatment, home nursing, the significance of cognitive training and the methods of cognitive training. Meanwhile, we established connection with patients for later follow-up
62513979|NCT05122221|EXPERIMENTAL|CRTE7A2-01 TCR-T cell therapy|Patients will undergo lymphocytapheresis, then treatment with TCR-T cell (at escalating doses) + IL-2
62513980|NCT00452608|PLACEBO_COMPARATOR|amido pill|
62513981|NCT00452608|EXPERIMENTAL|atorvastatina|atrovastatina 80 mg/d by mouth for 10 days
62513982|NCT04303702|OTHER|Discontinue Oxytocin|
62513983|NCT04303702|ACTIVE_COMPARATOR|Continue Oxytocin|
61973127|NCT06142045||Adolescents (12-16 years)|All groups of the experiment will be exposed to the same intervention. The intervention the participants are exposed to is the use of the computer controlled gas blender system for manipulation of end-tidal and arterial blood gases. This will be used for the following protocols, to either clamp end-tidal at resting levels or administer a hypercapnia challenge. The protocol includes assessment of cerebral blood flow responses (measured using ultrasound) to carbon dioxide; including a hypercapnia ramp protocol followed by a transient protocol. Following at least 30 minute wash out, participants will then perform isometric exercise at 30% of their maximal voluntary contraction for 2 minutes. Participants will perform the isometric handgrip exercise under 2 different conditions (hypercapnia (+9 mmHg) and clamped breathing; to maintain baseline end-tidal carbon dioxide and oxygen concentrations) with a 20-minute recovery period between each bout.
61976381|NCT02536352|EXPERIMENTAL|Fluoride prenatal vitamin|Prenatal vitamin-mineral containing 3 mg fluoride
61976382|NCT02536352|ACTIVE_COMPARATOR|Standard prenatal vitamin|Prenatal vitamin-mineral containing 0 mg fluoride
62147270|NCT01630304|EXPERIMENTAL|WelTel SMS service|"In addition to standard care, weekly text messages will be delivered to participants randomized to this arm for a one year period. Participants will be requested to respond to the outgoing message Mambo? within 48 hours; they may respond that they are doing well (sawa) or that they have a problem (shida). A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
62513984|NCT02544542|EXPERIMENTAL|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
62513985|NCT02544542|ACTIVE_COMPARATOR|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
62513986|NCT05235659|EXPERIMENTAL|Condition 1|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
62513987|NCT05235659|EXPERIMENTAL|Condition 2|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
62513988|NCT05235659|EXPERIMENTAL|Condition 3|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
62513989|NCT05235659|EXPERIMENTAL|Condition 4|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
62513990|NCT05235659|EXPERIMENTAL|Condition 5|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
62513991|NCT05235659|EXPERIMENTAL|Condition 6|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
62513992|NCT05235659|EXPERIMENTAL|Condition 7|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
62513993|NCT05235659|EXPERIMENTAL|Condition 8|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
61976383|NCT03178981|ACTIVE_COMPARATOR|Conventional cigarette|Commercially-available combustible cigarette
61976384|NCT03178981|EXPERIMENTAL|Second-generation e-cigarette A|Prototype second-generation (closed-tank) e-cigarette
62147271|NCT01630304|NO_INTERVENTION|Standard care|This arm will receive standard clinical care.
62147272|NCT05532553||Group 1|Patient with T2DM and fatty liver.
62513994|NCT05235659|EXPERIMENTAL|Condition 9|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
62513995|NCT05235659|EXPERIMENTAL|Condition 10|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
62513996|NCT05235659|EXPERIMENTAL|Condition 11|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
62513997|NCT05235659|EXPERIMENTAL|Condition 12|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
61976385|NCT03178981|EXPERIMENTAL|Second-generation e-cigarette B|Prototype second-generation (closed-tank) e-cigarette
61976386|NCT03178981|EXPERIMENTAL|Second-generation e-cigarette C|Prototype second-generation (closed-tank) e-cigarette
62147273|NCT05532553||Group 2|patients with fatty liver only ( control group).
62147274|NCT03015220|EXPERIMENTAL|Oral semaglutide 3 mg|
62147275|NCT03015220|EXPERIMENTAL|Oral semaglutide 7 mg|
62513998|NCT05235659|EXPERIMENTAL|Condition 13|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
62513999|NCT05235659|EXPERIMENTAL|Condition 14|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
62514000|NCT05235659|EXPERIMENTAL|Condition 15|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
62514001|NCT05235659|EXPERIMENTAL|Condition 16|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
62514002|NCT03321994|EXPERIMENTAL|Stereotaxic unit, navigation|
62514003|NCT03321994|ACTIVE_COMPARATOR|Conventional biopsy technique|
62514004|NCT06468306||individuals with NIV treatment|Patients that use oronasal face masks in their ordinary care to measure early-stage medical devise-related tissue damage during routine management regimes of NIV. Approximately 150 adult patients of both sexes will be recruited, from facilities that employ oronasal face masks in the routine care.
62514005|NCT06449872|OTHER|Comparison scanning protocol for OB and GYN clinical applications|Image quality comparative assessment
62514006|NCT06301087||users|users of the web-application
62514007|NCT03885219|EXPERIMENTAL|nab-paclitaxel and S-1|chemotherapy of Nab-Paclitaxel and S-1, repeat 21 days for up to 8 cycles. The following treatment including pancreatectomy, continuing same chemotherapy, S-1 maintenance therapy, or radiotherapy will be decided after discussion between physicians and patients.
62514008|NCT03944681|OTHER|Droperidol group|Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus
62514009|NCT03380520|EXPERIMENTAL|Ferric carboxymaltose|Ferric carboxymaltose according to SmPC
62514010|NCT03380520|PLACEBO_COMPARATOR|Placebo|Normal saline (0.9%)
62514011|NCT03870477|OTHER|THP Hip Fracture Plating System|THP Hip Fracture Plating System in Intracapsular and Intertrochanteric Femur Fractures
62514012|NCT00873119|EXPERIMENTAL|Arm A - BelCaP|Group A: belinostat 1000 mg/m² administered as a 30 minute IV infusion once daily on days 1, 2 and 3, with at least 18 hours between infusions, followed by belinostat 2000 mg administered orally once daily on days 4 and 5, every 3-weeks, in combination with paclitaxel 175 mg/m² administered as an IV infusion following the infusion of belinostat on cycle day 3, and carboplatin (AUC 6) administered as a 30-60 minute IV infusion directly after the paclitaxel administration on cycle day 3.
62514013|NCT00873119|ACTIVE_COMPARATOR|Arm B - CaP|Group B: paclitaxel 175 mg/m² administered as an IV infusion directly followed by carboplatin (AUC 6) administered as a 30-60 minute IV infusion on cycle day 1 of a 3-weekly cycle.
62514014|NCT01045707|EXPERIMENTAL|IDegAsp OD|
62514015|NCT01045707|EXPERIMENTAL|IGlar OD|
62514016|NCT02950142|EXPERIMENTAL|CPOE with order sets|Physicians who use CPOE including order sets for large range of indications.
62514017|NCT02950142|ACTIVE_COMPARATOR|CPOE without order sets|Physicians who use CPOE without order sets.
62514018|NCT04894071|EXPERIMENTAL|QA102 group|
62514019|NCT04894071|PLACEBO_COMPARATOR|Placebo group|
62709904|NCT04857554|EXPERIMENTAL|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62514020|NCT05060731|ACTIVE_COMPARATOR|Oral iron supplementation|Patients randomized to receive oral ferrous sulfate, ca. 200-300 mg every day for 3 months.
62514021|NCT05060731|ACTIVE_COMPARATOR|Intravenous iron supplementation|Patients randomized to receive one dose of 1000 mg intravenous ferric carboxymaltose.
62514022|NCT01330667|EXPERIMENTAL|Formula Supplementation|Participants will supplement feedings with early limited formula following nursing.
62514023|NCT01330667|NO_INTERVENTION|Control|Participants will be instructed to continue exclusively breastfeeding with no formula supplementation.
62514024|NCT03015714|ACTIVE_COMPARATOR|MIRT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment (MIRT).
62353800|NCT00292747|ACTIVE_COMPARATOR|Drotaverine + ibuprofen|Drotaverine 80 mg plus ibuprofen 400 mg orally
62514025|NCT03015714|ACTIVE_COMPARATOR|MIRT-AT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment associated with Aquatic Therapy (MIRT-AT).
62514026|NCT01418677|ACTIVE_COMPARATOR|Cohort 1|
62514027|NCT01418677|ACTIVE_COMPARATOR|Cohort 2|
62514028|NCT01418677|ACTIVE_COMPARATOR|Cohort 3|
62514029|NCT06214611|OTHER|Adaptive Radiotherapy|Adaptive Radiation Therapy
62514030|NCT06214611|ACTIVE_COMPARATOR|Standard Treatment Arm, IGRT|Standard Treatment Arm, IGRT
62514031|NCT00826033||Therapy monitoring|
62514032|NCT04047537|OTHER|Experimental: WBF-0011|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
62514033|NCT04047537|OTHER|Experimental: WBF-0011 (0.2X concentration)|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
62514034|NCT04047537|OTHER|Placebo|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
62514035|NCT05669807|EXPERIMENTAL|A: Camrelizumab+Albumin-bound paclitaxel|Camrelizumab 200mg d1, one cycle every 14 days on the first day; albumin binding paclitaxel: 100 mg/m2, one cycle every 28 days on the first, eighth and fifteenth days
62514036|NCT05669807|EXPERIMENTAL|B: Camrelizumab+Irinotecan|Camrelizumab 200mg d1, the first day, every 14 days as a cycle Irinotecan: 180 mg/m2, the first day, every 14 days as a cycle
62514037|NCT01872052|EXPERIMENTAL|Acutus Medical System|
62514038|NCT00906373|ACTIVE_COMPARATOR|Cohort 1, IMC A12 - 10 mg/kg|Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or withdrawal. If any participant experiences a dose-limiting toxicity (DLT), an additional 3 participants will be enrolled at this dose level (for a total of 6). If no further DLTs, enrollment into Cohort 2 will occur.
62514039|NCT00906373|ACTIVE_COMPARATOR|Cohort 2, IMC A12 20 - mg/kg|Treatment cycles will repeat until there is evidence of PD, toxicity, or withdrawal.
62514040|NCT06212050||Patients with severe symptomatic BAV stenosis|Patients with severe symptomatic BAV stenosis who underwent TAVI using the ACURATE neo2 THV.
62514041|NCT05558449|ACTIVE_COMPARATOR|VR|"Patients in the VR group (19 patients) will receive VR alone without hypnosedation. The VR headset will be used on these patients without an external voice or device allowing hypnosis. The VR module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
62514042|NCT05558449|EXPERIMENTAL|VRH|"The patients in the VRH group (19 patients) will benefit from a hypnosedation session with a VRH headset during the local anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
62514043|NCT05558449|ACTIVE_COMPARATOR|C|Patients in group C (control group, 19 patients) will receive only midazolam-based pharmacological sedation. This will be administered with intermittent boluses of 1 mg until patient comfort and sedation on the Richmond analgo-sedation scale (RASS) of -3 (response to verbal stimulus) is achieved.
62514044|NCT04998422|EXPERIMENTAL|Part A: HG381 Monotherapy Dose Escalation Cohort|Subjects will receive HG381 IV at every one week intervals (Q1W). Escalating doses of HG381 will be evaluated by the traditional 3+3 design.
61973128|NCT06142045||Adults (18-35 years)|All groups of the experiment will be exposed to the same intervention. The intervention the participants are exposed to is the use of the computer controlled gas blender system for manipulation of end-tidal and arterial blood gases. This will be used for the following protocols, to either clamp end-tidal at resting levels or administer a hypercapnia challenge. The protocol includes assessment of cerebral blood flow responses (measured using ultrasound) to carbon dioxide; including a hypercapnia ramp protocol followed by a transient protocol. Following at least 30 minute wash out, participants will then perform isometric exercise at 30% of their maximal voluntary contraction for 2 minutes. Participants will perform the isometric handgrip exercise under 2 different conditions (hypercapnia (+9 mmHg) and clamped breathing; to maintain baseline end-tidal carbon dioxide and oxygen concentrations) with a 20-minute recovery period between each bout.
62514045|NCT04998422|EXPERIMENTAL|Part B: HG381 Monotherapy Dose Expansion Cohort|Subjects will be administered the recommended Phase 2 dose of HG381 IV Q1W established in Part A of the study.
62514046|NCT02177006||Caregivers|Caregivers of children 2-6 years of age
62514047|NCT02177006||Pediatric clinicians|Pediatricians and nurse practitioners at Lake Forest Pediatric Associates
62514048|NCT04491357|EXPERIMENTAL|Intervention arm|Intervention arm will receive 1 ampoule of intravenous calcium gluconate within 4 hours of skin closure post total thyroidectomy
62514049|NCT04491357|PLACEBO_COMPARATOR|Placebo arm|Placebo arm will receive 100ml of normal saline within 4 hours of skin closure post total thyroidectomy
62514050|NCT03739138|EXPERIMENTAL|MK-4621 Monotherapy (Arm 1)|Participants receive MK-4621 once a week (Q1W) during each 21-day cycle for a maximum duration of 6 cycles.
62514051|NCT03739138|EXPERIMENTAL|MK-4621 + Pembrolizumab (Arm 2)|Participants receive escalating doses of MK-4621 Q1W during each 21-day cycle for a maximum duration of 6 cycles in combination with pembrolizumab at a fixed dose 200 mg every 3 weeks (Q3W) for a maximum duration of 6 cycles. Participants may continue on treatment with pembrolizumab after Cycle 6 for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621 will be based on safety and tolerability.
61973129|NCT05699798|EXPERIMENTAL|Conservative Treatment (CT)|Includes Hotpack, TENS, Ultrasound and home exercise programs. HP, US and TENS applications were applied for 3 weeks, with a total of 15 sessions, 5 sessions per week. HP application for 20 minutes, ultrasound for 5 minutes and TENS for 20 minutes were applied to the patients. The CT protocol was applied to all three groups in the same way.
62514052|NCT03739138|EXPERIMENTAL|Intrahepatic MK-4621 + Pembrolizumab (Arm 3)|Participants receive MK-4621 as monotherapy on Day 1 only of the first 21-day cycle (run-in phase). After the run-in phase, participants receive escalating doses of MK-4621 Q3W in combination with pembrolizumab at a fixed dose 200 mg Q3W for a maximum duration of 5 cycles (Cycles 2-6). Participants may continue on treatment with pembrolizumab for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621 will be based on safety and tolerability.
62514053|NCT05536037|EXPERIMENTAL|Prevention (metformin)|Patients receive metformin PO QD on days 1-3 and then PO BID for up to 12 months in the absence of unacceptable toxicity.
62514054|NCT01507090||Normal Children|Otherwise healthy children 2 months to 16 years of age.
62514055|NCT05019482|EXPERIMENTAL|University-based 8-weeks intervention to promote Physical Activity (PA)|Experimental group: 8-weeks program of Physical Activity constructed by users during a design-based innovative workshops before the beginning of the interventions .
61973130|NCT05699798|EXPERIMENTAL|Instrument Assisted Soft Tissue Mobilization (IASTM)|Includes Hotpack, TENS, Ultrasound, home exercise programs and Instrument-assisted Soft Tissue Mobilization Technique. The IASTM therapy was applied for three weeks, two sessions per week, for a total of 6 sessions.
61973131|NCT05699798|EXPERIMENTAL|Extracorporeal Shock Wave Therapy (ESWT)|Includes Hotpack, TENS, Ultrasound, home exercise programs and Extracorporeal Shock Wave Therapy treatment. The ESWT therapy was applied for three weeks, two sessions per week, for a total of 6 sessions.
61973132|NCT03546192|EXPERIMENTAL|Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years|Participants aged 18 to 60 years received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
62514056|NCT05019482|NO_INTERVENTION|Control Group|Control group: No intervention, only two measurement times
62514057|NCT03512184|OTHER|YMCA Class|This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.
62514058|NCT03588052|EXPERIMENTAL|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
62514059|NCT03588052|ACTIVE_COMPARATOR|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
62514060|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
62514061|NCT02611011||Women|Women seeking health services will perform the Congo Red Dot test (GV-005) individually by following the the test instructions
62514062|NCT05616403||Textbook outcome group|Achieving textbook outcome after laparoscopic pancreaticoduodenectomy
62514063|NCT05616403||Non-Textbook outcome group|Not achieving textbook outcome after laparoscopic pancreaticoduodenectomy
62514064|NCT02276768|EXPERIMENTAL|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
62514065|NCT02276768|EXPERIMENTAL|GIC-1001 high-dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
62514066|NCT02276768|ACTIVE_COMPARATOR|GIC-1002 mid-dose|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg) 345 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
62514067|NCT02276768|ACTIVE_COMPARATOR|GIC-1002 high-dose|GIC-1002 460 mg (equimolar to GIC-1001 500 mg) 460 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
62514068|NCT02276768|PLACEBO_COMPARATOR|Placebo matching GIC-1001 and GIC-1002|"Placebo matching GIC-1001 doses Placebo matching GIC-1002 doses~Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)"
62514069|NCT04159519|EXPERIMENTAL|Treatment reduction arm|All participants will receive Fasenra® 30 mg Q8W + SMART or Symbicort® reliever only (starting with medium-dose Symbicort® 200/6 μg ×2 inhalations BID maintenance + Symbicort® 200/6 μg reliever PRN; tapering to Symbicort® 200/6 μg reliever only, as per tapering scheme and depending on degree of asthma control). The reduction period in this arm will last 32 weeks.
62514070|NCT04159519|EXPERIMENTAL|Reference arm|All participants will receive Fasenra® 30 mg Q8W + high-dose Symbicort® maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm will continue on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment for 32 weeks.
62514071|NCT00256776|EXPERIMENTAL|Thal + Dex + Velcade|
62514072|NCT00256776|ACTIVE_COMPARATOR|Thal + Dex|Standard treatment
62514073|NCT04727684|ACTIVE_COMPARATOR|Agonist Group (long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
61973133|NCT03546192|EXPERIMENTAL|Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older|Participants aged 61 years or older received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
62147276|NCT03015220|EXPERIMENTAL|Oral semaglutide 14 mg|
62147277|NCT03015220|ACTIVE_COMPARATOR|Dulaglutide 0.75 mg|
62147278|NCT02337114|EXPERIMENTAL|Intervention group|Treatment as Usual and Acceptance \& Commitment Therapy
62514074|NCT04727684|EXPERIMENTAL|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
62514075|NCT03859128|ACTIVE_COMPARATOR|Group A|TORIPALIMAB 240mg ,Q3W, up to 16 cycles
62514076|NCT03859128|PLACEBO_COMPARATOR|Group B|Placebo 240mg Q3W, up to 16 cycles
62514077|NCT01329224||TAM patients|All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
62514078|NCT01084382|ACTIVE_COMPARATOR|Arthrospira platensis supplement|
62514079|NCT01084382|PLACEBO_COMPARATOR|Protein/Dextran supplemented|
62514080|NCT01014624|EXPERIMENTAL|Prasugrel|Prasugrel 10mg administered for 7 days followed by a Washout Period up to 12 days.
62514081|NCT01014624|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75mg administered for 7 days followed by a 12 day Washout Period up to 12 days.
62514082|NCT02581072|EXPERIMENTAL|SB204 4%|SB204 4% once
61973134|NCT02181023|EXPERIMENTAL|Aclidinium - Glycopyrronium|Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
62147279|NCT02337114|OTHER|Comparison group|Treatment as Usual
62147280|NCT01228565|PLACEBO_COMPARATOR|Placebo|Radiotherapy+Erbitux+Placebo
62147281|NCT01228565|EXPERIMENTAL|OTD70DERM|Radiotherapy+Erbitux+OTD70DERM®
62514083|NCT02581072|EXPERIMENTAL|SB204 8% or 12 %|SB204 8 or 12 % (supratherapeutic) once
62514084|NCT02581072|NO_INTERVENTION|Moxifloxacillin|Moxifloxacillin 400 mg orally
62514085|NCT02581072|PLACEBO_COMPARATOR|Vehicle Gel|Placebo
62514086|NCT01298778|PLACEBO_COMPARATOR|Standard of care|Spinal consists of duramorph 150 mcg combined with fentanyl and bupivacaine in conjunction with placebo capsules 2 PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
62514087|NCT01298778|ACTIVE_COMPARATOR|Acetaminophen and increased dose of Duramorph|Spinal consists of duramorph 300 mcg combined with fentanyl and bupivacaine in conjunction with Acetaminophen 1 Gm PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
62514088|NCT03844789|EXPERIMENTAL|Closed Loop Control (CLC)|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem Control-IQ Technology \& Dexcom G6 CGM vs Control Group for 16 weeks. Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 16 weeks. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
62514089|NCT03844789|ACTIVE_COMPARATOR|Control Group|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Control Group for 16 weeks. All participants will be provided the option of using t:slim X2 with Control-IQ system in a 12 week Extension Phase.
62514090|NCT05054894|EXPERIMENTAL|Experimental Group (Plasmapheresis for Age-Related Frailty)|Participants will receive plasmapheresis once a month for six months. All participants will be in this arm.
62514091|NCT04290286|EXPERIMENTAL|intervention group|TGD people (n = 82) receive 4 months of e-health intervention according to the i2TransHealth model of care (intervention group)
62514092|NCT04290286|NO_INTERVENTION|waiting group|TGD people (n = 82) wait 4 months until they are offered regular care (waiting group), which can include video consultation
62514093|NCT04977609|EXPERIMENTAL|VR+MUSIC|Upper limb repetitive training activities through the imitation of movements (i.e., unscrew the cap of a bottle, pour water into a glass, drink water from a glass, sugaring coffee, placing an object in a box) synchronized with a musical accompaniment (i.e., a selection of classical music pieces). Participants will wear a VR headset (Gear VR, Samsung) through which they will observe egocentric 180° 3D videoclips shot from a first-person perspective, as if the patient himself was performing the movement, while listening to music.
61973135|NCT02181023|EXPERIMENTAL|Glycopyrronium - Aclidinium|Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).
61973136|NCT04037605|EXPERIMENTAL|Control Condition|"8 am - Saline Solution for Injection~10 am - Placebo oral capsule~1 pm - Saline Solution for Injection~4 pm - Placebo oral capsule \& start hourly blood sampling~7 pm- Gonadorelin (GnRH) and Corticorelin (CRH) injections~9 pm - Saline Solution for Injection \& last blood sample"
62514094|NCT04977609|EXPERIMENTAL|VR|Upper limb repetitive training activities through imitation of movements, without any musical accompaniment. Participants will wear a VR headset through which they will observe egocentric 180° 3D silent videoclips.
62514095|NCT04977609|ACTIVE_COMPARATOR|TAU|Treatment as usual (TAU). Patients will be engaged in upper limb repetitive training activities through traditional physiotherapy rehabilitation.
61973137|NCT04037605|EXPERIMENTAL|Hypothalamic Condition|"8 am -Ganirelix~10 am - Placebo oral capsule~1 pm - Dexamethasone injection~4 pm- Placebo oral capsule and start of hourly blood sampling~7 pm - GnRH and CRH injections~9 pm - Saline Solution for Injection and last sample blood sample"
61973138|NCT04037605|EXPERIMENTAL|Pituitary Condition|"8 am - Saline Solution for Injection~10 am - Ketoconazole Pill~1 pm - Saline Solution for Injection~4 pm - Ketoconazole Pill \& start of hourly blood sampling~7 pm - GnRH and CRH~9 pm - Hydrocortisone Injection and last blood sample"
61976387|NCT03178981|EXPERIMENTAL|Second-generation e-cigarette D|Prototype second-generation (closed-tank) e-cigarette
62147282|NCT02729246|NO_INTERVENTION|Control Group|
62353801|NCT05464472||Transcatheter Aortic Valve Implantation|Patients are assessed for cognitive function pre and post transcatheter aortic valve implantation.
62353802|NCT05464472||Control matched population|Control matched population are assessed for cognitive function at day 0 and at 6 month
62514096|NCT01705860||Assessment|All subjects will receive same assessments.
62514097|NCT01415050|ACTIVE_COMPARATOR|Alendronate|
62514098|NCT01415050|ACTIVE_COMPARATOR|Raloxifane|
62514099|NCT01594047|NO_INTERVENTION|zero/morphine|Patient received a standard balance anaesthesia and morphine for post operative pain.
62514100|NCT01594047|EXPERIMENTAL|ketamine/morphine|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery.
62514101|NCT01594047|EXPERIMENTAL|zero/metadone|Methadone PCA
62514102|NCT01594047|EXPERIMENTAL|ketamine/methadone|"Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery.~Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)."
62514103|NCT05274672|EXPERIMENTAL|Patients not receiving postoperative antibiotics|Patients who will not receive prophylactic postoperative antibiotics after HoLEP.
62514104|NCT05274672|ACTIVE_COMPARATOR|Patients receiving postoperative antibiotics|Patients who will receive3 days prophylactic postoperative antibiotics after HoLEP.
62514105|NCT06164028||Caregiver|"Participants will take part in a semi-structured qualitative interview (\~1 hour).~The first set of questions will provide an opportunity for the caregiver to describe the type of conditions or injuries their child has experienced and how their child reacted to the potentially painful experiences.~Subsequently, the cognitive interview scripts will be structured to evaluate different components of the questionnaire (ObsRO measure), including the instructions, the question stems, the response options, and other key aspects of the COA.Once the participant has completed the questionnaire, the interviewer will probe on additional issues related to informing the assessment of content validity."
62514106|NCT06164028||Clinician|"Participants will take part in a semi-structured qualitative interview (\~1 hour).~The first set of questions will provide an opportunity for the clinicians to describe observable indicators that a young child is in pain.~4 YouTube video links based on age groups (birth to 1 month,1 month to 6 months, 6 months to 12 months, and12 months to 24 months), will be reviewed by participants. Clinicians will be asked to rate the child's pain using the ClinRO measures while being probed for question content and understanding.~Subsequently, the cognitive interview scripts will be structured to evaluate different components of the ClinRO measures, including the instructions, the question stems, the response options, and other key aspects of the COA. Once the participant has completed the questionnaire, the interviewer will probe on additional issues related to informing the assessment of content validity."
62514107|NCT05194449|EXPERIMENTAL|Comfort Talk® App (Cft) Group|Mobile app with elements of relaxation, self-hypnosis, and reframing of distress
62514108|NCT05194449|PLACEBO_COMPARATOR|Placebo Group|Mobile app with white noise choices having the same looks and functionality as the active Comfort Talk® 1st app
62514109|NCT01720420|EXPERIMENTAL|Mandible|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
62514110|NCT01720420|EXPERIMENTAL|Maxilla|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
62514111|NCT02516384|EXPERIMENTAL|Fecal Microbiota Transplantation|Individuals with Ulcerative Colitis will undergo a fecal microbiota transplantation.
62514112|NCT03601624|EXPERIMENTAL|Experimental|"1. Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~2. Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~3. Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
62514113|NCT01161394|EXPERIMENTAL|Pioglitazone 15mg|8 patient will receive this drug
62514114|NCT01161394|EXPERIMENTAL|pioglitazone 30mg|8 patients will get this drug
62514115|NCT01161394|PLACEBO_COMPARATOR|Placebo|8 patient will get this drug
62514116|NCT04143295|ACTIVE_COMPARATOR|Prenatal Treatment Protocol|This protocol involves administering DITPA to pregnant women diagnosed with fetuses exhibiting MCT8 deficiency. Early initiation of treatment is critical as it targets the crucial period of neurological development, aiming to mitigate severe deficits typically associated with MCT8 deficiency. Following birth, the child will continue to receive treatment until the age of 3 years. All elements of this clinical protocol are essential and directly applicable to this arm of the study.
62514117|NCT04143295|ACTIVE_COMPARATOR|Postnatal Treatment Options|"* 2(a) Immediate Post-Birth Treatment: This approach is designated for neonates who were diagnosed with MCT8 deficiency in utero but were not included in ARM 1. Treatment with DITPA will commence within the first 24 hours post-birth. This prompt initiation is intended to capitalize on the immediate postnatal period to optimize therapeutic outcomes.~* 2(b) Delayed Post-Birth Treatment: This option is for neonates diagnosed with MCT8 deficiency after birth. Treatment will begin several days post-birth, ensuring that those not identified during the prenatal period still receive early intervention following diagnosis. This strategy is essential for improving long-term endocrine and neurodevelopmental health.~* Only relevant sections of the clinical protocol for AHDS (MCT8 deficiency) will apply to both ARM 2(a) Immediate Post-Birth Treatment and ARM 2(b) Delayed Post-Birth Treatment."
62514118|NCT03488030||All Participants|Participants diagnosed with moderate to severe UC or CD from the 7 participating sites will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years from the date of UC or CD diagnosis until Day 1 to assess the IBD treatments, medical history and comorbidities, treatment patterns and use of health resources.
61973139|NCT04037605|EXPERIMENTAL|Adrenal/Testis Condition|"10 pm - Ganirelix Injection \& Dexamethasone Pills (night before)~8 am - Start of hourly blood sampling~10 am - Dexamethasone Pills~11 am - Last hourly blood sample taken~11:30 am - Start of blood sampling every 10 minutes~1 pm - Recombinant Human Luteinizing Hormone (rhLH) Injection~3 pm - rhLH Injection~5 pm - rhLH Injection~5 pm - Cosyntropin Injectable product~7 pm - GnRH and CRH Injections~9 pm - Last blood sample"
62514119|NCT03658187|PLACEBO_COMPARATOR|Placebo|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
62514120|NCT03658187|EXPERIMENTAL|IP|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
62514121|NCT01519102|ACTIVE_COMPARATOR|CHO-independent partial insulin bolus with closed-loop|
62514122|NCT01519102|ACTIVE_COMPARATOR|CHO-dependent full insulin bolus combined with closed-loop|
62514123|NCT01618682||Hand Transplant Patients|These will be subjects who have undergone a hand transplant.
62514124|NCT01618682||Hand Replant Patients|These will be patients who have undergone a hand replant procedure.
62514125|NCT02239198|EXPERIMENTAL|C|Nutrition bar without omega-3 fatty acids
62514126|NCT02239198|EXPERIMENTAL|B|Nutrition bar without added minerals and vitamins
62514127|NCT02239198|ACTIVE_COMPARATOR|A|Complete nutrition bar
62147283|NCT02729246|OTHER|Surgery Group|The patients in this group will undergo Laparoscopic Gastric Bypass surgery
62147284|NCT00579839|EXPERIMENTAL|A|Delayed Cord Clamping
62147285|NCT00579839|ACTIVE_COMPARATOR|B|Immediate cord clamping
62514128|NCT02340494|NO_INTERVENTION|Control group|Women without access to the website.
62514129|NCT02340494|EXPERIMENTAL|Intervention group|Women with access to the website.
62514130|NCT06096714|ACTIVE_COMPARATOR|Nicotine|Adaptation Session followed by 4 Test Days. The Adaptation Session will familiarize the participants with study procedures. In each Test Day, a different nicotine dose (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) will be compared to saline for nicotine discrimination, subjective effects, and reinforcement. Participants will first sample the assigned nicotine dose and saline, followed by 4 trials to test their ability to discriminate it from saline. This will be followed by 4 Choice trials where participants will be able to choose between nicotine (at the session-assigned dose) or saline (A or B).
62514131|NCT06096714|PLACEBO_COMPARATOR|saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
62514132|NCT01668121|EXPERIMENTAL|Symbicort Turbohaler|Symbicort Turbohaler
62514133|NCT01668121|ACTIVE_COMPARATOR|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
62514134|NCT02858648|EXPERIMENTAL|Behavior intervention with smart phone based self-monitoring|Patients in this group were asked to attend 11 group and 1 individual session over 6 months, and received a smartphone with two downloaded applications to monitor diet, physical activity, weight, and blood glucose (connected with a blue tooth glucometer) throughout 6 months.
62709905|NCT04857554|EXPERIMENTAL|Cocoa drink|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62514135|NCT02858648|EXPERIMENTAL|Behavior intervention with paper diary based self-monitoring|Patients in this group were asked to attend 11 group sessions and 1 individual session over 6 months, and received paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer to monitor diet, physical activity, weight, and blood glucose throughout 6 months.
62514136|NCT02858648|NO_INTERVENTION|Usual care|Patients in this group received no intervention, they continue to receive usual diabetes care and education from the recruitment clinic.
61973140|NCT03140644|EXPERIMENTAL|Patients with thoracic sarcoidosis|Patients routinely followed-up for thoracic sarcoidosis with a CT scan indicated in the follow-up
61973141|NCT00438113|ACTIVE_COMPARATOR|Aggressive Blood Pressure control|"The experimental arm will receive open label therapy to achieve a target systolic blood pressure less than or equal to 120 mmHg.~If the average BP is found to be \> 120 mmHg at the baseline, telephone or clinic followup visits, treatment will be recommended based on the following regimen (For details, please see Appendix 4):~Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od. Step 3 - Addition of Atenolol 50 mg po od. Step 4 - Addition of Norvasc 2.5-10 mg po od. Step 5 - Addition of Terazosin 1 mg po od."
61976388|NCT03178981|ACTIVE_COMPARATOR|Second-generation e-cigarette E|Commercially-available second-generation (closed-tank) e-cigarette
62353803|NCT05572346||Home-based telerehabilitation group|"For each subject, the treatment will lasts 8 weeks. The intervention will include both endurance and resistance exercises as prescribed by the pneumologist at the time of the hospital discharge.~The intervention will be delivered and monitored through a digital app with appropriate sensors."
62514137|NCT00752284|EXPERIMENTAL|A|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
62514138|NCT00752284|ACTIVE_COMPARATOR|B|"Control Group:~total excision of lower wisdom tooth"
62514139|NCT01526460|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin 80 mg
62353804|NCT01690104|ACTIVE_COMPARATOR|Rifampicin|Rifampicin 600 mg daily
62353805|NCT01690104|PLACEBO_COMPARATOR|Placebo|Placebo daily
62514140|NCT01526460|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin 40 mg
62514141|NCT01526460|PLACEBO_COMPARATOR|No statin loading dose|No statin loading dose
62514142|NCT06384729|EXPERIMENTAL|Exopulse on group|An individual assessment will be conducted to determine the parameters of the suit, and they will wear the suit for 60 minutes three times a week for three weeks. An initial assessment will be conducted, followed by another assessment after the 3-week treatment period.
62514143|NCT06384729|PLACEBO_COMPARATOR|Exopulse of group|"The suit will be worn with the parameters set to 0 for 60 minutes, three times a week, for three weeks. An initial assessment will be conducted, followed by another assessment after the 3-week treatment period.~The suit will be worn with the parameters set to 0 for 60 minutes, three times a week, for three weeks. An initial assessment will be conducted, followed by another assessment after the 3-week treatment period."
62514144|NCT02148913|ACTIVE_COMPARATOR|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
62709906|NCT00977210|EXPERIMENTAL|OXi4503|
62514145|NCT02148913|ACTIVE_COMPARATOR|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
62709907|NCT06345885|EXPERIMENTAL|Group A|Bivalent HPV Vaccine (Cecolin)
62709908|NCT06345885|ACTIVE_COMPARATOR|Group B|Quadrivalent HPV vaccine (Gardasil)
62709909|NCT00738296|ACTIVE_COMPARATOR|A|Group A: Comparator
62709910|NCT00738296|ACTIVE_COMPARATOR|B|Group B: Comparator
62353806|NCT05431569|EXPERIMENTAL|6MW3211|6MW3211injection,30mg/kg,Q2W
62709911|NCT00738296|EXPERIMENTAL|C|Group C: Drug
62353807|NCT02090270||Ischemic stroke|Sudden onset of focal neurologic deficit lasting more than 24 hours, with cerebral hemorrhage ruled out by brain CT, in the absence of obvious causes of embolic stroke.
62709912|NCT03825627|ACTIVE_COMPARATOR|Antisaccade Task (active tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
62514146|NCT02148913|ACTIVE_COMPARATOR|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
62709913|NCT03825627|SHAM_COMPARATOR|Antisaccade Task (sham tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm sham Transcranial Direct Current Stimulation will be used during the task.
62514147|NCT02148913|ACTIVE_COMPARATOR|Cohort 3: Carfilzomib 27mgm2|Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
62514148|NCT04659551|EXPERIMENTAL|Arm 1|Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses plus exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) started concomitantly to anthracycline based chemotherapy, to be continued until surgery.
62514149|NCT03918941|EXPERIMENTAL|Carey|
62514150|NCT03918941|ACTIVE_COMPARATOR|conventional information|
62514151|NCT02252523|EXPERIMENTAL|DEXMEDETOMIDINE|
62514152|NCT03100890|NO_INTERVENTION|Control|Non-active comparator
62514153|NCT03100890|ACTIVE_COMPARATOR|Balance-Proprioception (Hospital)|Preoperative training (hospital)
62514154|NCT03100890|EXPERIMENTAL|Balance-Proprioception (Home)|Preoperative training (home)
62514155|NCT05127694|EXPERIMENTAL|Vestibular Rehabilitation Group|Investigators applied vestibular rehabilitation in this group. This group was consist of 15 participants. After the evaluation investigators gave the patients repetitive vestibular exercises for 4 weeks and in the first week investigators performed canalith repositioning procedure depending on the affected canal. If affected posterior semicircular canal investigators applied Epley maneuver. If affected horizontal semicircular canal also applied barbeque roll maneuver.
62514156|NCT05127694|NO_INTERVENTION|Pharmacological Control Group|Investigators did not apply any treatment in this group. Participant in this group just used medications doctor-prescribed.
62514157|NCT03928535|OTHER|High-Flow Nasal Cannula|High-flow oxygen was applied immediately after extubation through specific nasal cannula.
62514158|NCT03928535|OTHER|Noninvasive Ventilation|Noninvasive Ventilation was applied immediately after extubation.
62514159|NCT02287324|ACTIVE_COMPARATOR|Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine
62514160|NCT02287324|PLACEBO_COMPARATOR|Manual Contact|Manual contact to suboccipital region of the cervical spine for 5 minutes
62514161|NCT00865631|EXPERIMENTAL|A|Gabapentin 800 mg tablets, single dose (1 tablet)
62514162|NCT00865631|ACTIVE_COMPARATOR|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
62514163|NCT01264640|EXPERIMENTAL|A|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
62514164|NCT01917968|ACTIVE_COMPARATOR|Uphold Lightweight Vaginal Support System|Transvaginal repair with mesh (Uphold LITE)
62514165|NCT01917968|ACTIVE_COMPARATOR|Traditional native tissue repair|Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
62514166|NCT06269809|EXPERIMENTAL|Temporary artery clipping|Patients undergoing a robotically-assisted myomectomies, with temporary clipping of the uterine arteries and the utero-ovarian ligmants.
62514167|NCT06269809|ACTIVE_COMPARATOR|Control|Patients undergoing a robotically-assisted myomectomies, without temporary clipping of the uterine arteries and the utero-ovarian ligmants.
62514168|NCT00688428|EXPERIMENTAL|1|combination capsule of Esomeprazole 40mg + ASA 325mg
62514169|NCT00688428|EXPERIMENTAL|2|Esomeprazole 40 mg capsule and ASA 325 mg tablet
62514170|NCT01602016|NO_INTERVENTION|Phase I|Baseline Visit Phase 1: The screening portion of the CELF will be administered to the child to screen for language impairment. If a child is determined to be pre-verbal they will automatically qualify,If there is no language impairment, the subject will not be eligible. If language impairment is confirmed, the participant will immediately go on to the baseline visit of Phase 2.
62514171|NCT01602016|OTHER|Phase II: 12 week Folinic Acid or Placebo intervention|The child will be consented for Phase 2 (the RCT) and undergo a blood draw (up to 20mL) for metabolic and autoantibody testing. the child will undergo language and behavioral assessment while the parent will be interviewed for the Vineland and other questionnaires (ASQ, RBS-R, SRS, and ABC). Demographic information including; age, race, gender, and ethnicity will be collected. The research pharmacist will randomize the participant to either Intervention A or B (only the research pharmacist will know which intervention has the folinic acid). The research pharmacist will distribute the drug or placebo to the parent and instruct the parent of the proper administration of the intervention. This will be considered the 12 week randomly controlled clinical trial that is investigating the safety and efficacy of folinic acis interventions in ASD and will last for approximately 12 weeks. At the end of 12 weeks, the same assessments that were conducted at baseline will be readministered
62514172|NCT01602016|EXPERIMENTAL|Phase III: Open Label Extension of Folinic Acid|If consent for Phase 3 is signed by parents with children who qualify for Phase 3, the research pharmacist will provide a 12 week supply of folinic acid to the parent. This arm will be offered to all clients that completed phase 2 of the trial. After consenting and 12 weeks of folinic acid dosing, the client will come back and complete the same protocol and be tested on the same measures used in phase II of the study. This will be a rolling stopping point so that new therapies can be started, if the parent/caregiver is so inclined
62514173|NCT06061783|ACTIVE_COMPARATOR|Intravenous hypotonic solution|"In this group, the administration will be according to the presence of basal hyperglycemia on the day before the assignment (\>180mg/dL).~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily.~If there is no hyperglycemia, it will be 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day."
62514174|NCT06061783|PLACEBO_COMPARATOR|Enteral water|This group will receive bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
62514175|NCT01008384|NO_INTERVENTION|placebo|
62514176|NCT01008384|EXPERIMENTAL|Vitamin D3|Vitamin D3 given for 8 weeks
62514177|NCT03552419||Level Red|A level red refers to a case with an immediate threat to the life of the fetus or mother and may not be delayed under any circumstance.
62514178|NCT03552419||Level Orange|A level orange case requires the patient to arrive in the OR within 30 minutes from the time of decision with the approximate estimated time of arrival determined by the obstetrician.
62514179|NCT03552419||Level Yellow|A level yellow case requires operative intervention, but there is no maternal and/or fetal compromise at the time of evaluation. Timing to the OR is agreed upon by both the anesthesiology and obstetrical providers. The case may be delayed if a level red or orange case is identified. Possible
62514180|NCT03552419||Level Green|A level green case is most dependent on the acuity of the OR suite and unit. The patient and/or fetus are stable with no threat to the health of either.
62514181|NCT02667678|EXPERIMENTAL|Cohort HIVOL, patients infected by HIV|Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2. The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
62514182|NCT00603863|EXPERIMENTAL|multiple dose levels|1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine.
62514183|NCT02168140|EXPERIMENTAL|Treatment (CPI-613 and bendamustine hydrochloride)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 of week 1 and on days 1 and 4 of weeks 2 and 3. Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62514184|NCT04086641|EXPERIMENTAL|Foot 1: Crossover Foot, Foot 2: Energy Storing Foot|Participant randomized to crossover foot as first condition, energy storing foot as second condition
62514185|NCT04086641|EXPERIMENTAL|Foot 1: Energy Storing Foot, Foot 2: Crossover Foot|Participant randomized to energy storing foot as first condition, crossover foot as second condition
62514186|NCT02438982|ACTIVE_COMPARATOR|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
62514187|NCT02438982|EXPERIMENTAL|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3 , it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
62514188|NCT02331693|EXPERIMENTAL|anti-EGFR CAR T|
62514189|NCT05828121|EXPERIMENTAL|Point1|Receiving treatment
62353808|NCT02090270||Control|Patients admitted to an internal medicine department for indications other than stroke or acute myocardial ischemia.
62514190|NCT06445218||Data collection|Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
62514191|NCT00396461|ACTIVE_COMPARATOR|TPN A (Group I)|Emulsion based on 20% MCT/LCT (50:50 ratio)
62514192|NCT00396461|EXPERIMENTAL|TPN B (Group II)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides
62514193|NCT04557176|EXPERIMENTAL|POC CRP-based TB screening|Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (\<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.
62514194|NCT04557176|NO_INTERVENTION|Symptom-based TB screening|Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
62514195|NCT00303667|EXPERIMENTAL|SCT w/Donor Natural Killer Cells - short schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 40mg/m\^2), cyclophosphamide (administered on Day -15 only), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
62514196|NCT00303667|EXPERIMENTAL|SCT w/Donor Natural Killer Cells - extended schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 35mg/m\^2), cyclophosphamide (administered on Days -15 and -16), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
62514197|NCT03352752|EXPERIMENTAL|Possess HTC Vive before the operation|The experimental group was wearing VR helmet before operation, and the immersion experience was selected from the video content library pre-selected. After 3 minutes of the VR experience, the surgeon started the fractional laser operation (Notify the patient). The operating area is continuous 10 maximum square spot areas.The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
62514198|NCT03352752|EXPERIMENTAL|Without HTC Vive before the operation|The control group was wearing a blindfold before operation. The operating area is continuous 10 maximum square spot areas. The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
62514199|NCT01216098|EXPERIMENTAL|Experimental arm - D|Experimental arm - Women randomized to this arm will receive doula support alongside standard care.
62514200|NCT01216098|NO_INTERVENTION|No intervention - ND|No intervention - Women randomized to this arm will receive standard care alone.
62514201|NCT01841216|EXPERIMENTAL|Low Back Pain|Lower Body Exercises with and without resistance
62514202|NCT01841216|EXPERIMENTAL|Healthy|Lower Body Exercises with and without resistance
62514203|NCT01534078|EXPERIMENTAL|Treatment Arm|Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine
62514204|NCT04072549|EXPERIMENTAL|Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
62514205|NCT04072549|NO_INTERVENTION|Comparison/Control|The children in the control group will be children enrolled in the same schools as those randomized to receive summer programming. The comparison/control group will not receive a voucher to attend a summer camp.
62514206|NCT03512002|ACTIVE_COMPARATOR|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
62514207|NCT03512002|OTHER|Continued Current Care|Participants will continue their current care.
62514208|NCT01758822|EXPERIMENTAL|No Endotracheal suction|In the experimental group, endotracheal suction will not be performed during the initial steps of resuscitation of non-vigorous meconium stained neonate
62514209|NCT01758822|NO_INTERVENTION|Endotracheal suction|In the No intervention group endotracheal suction will be performed during the initial steps of resuscitation of non - vigorous meconium stained neonate
62514210|NCT01245036|ACTIVE_COMPARATOR|Glucocorticoid arm|Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
62514211|NCT05442203|OTHER|AF Cohort|Will be comprised of 500 participants predicted to be increased risk for Atrial Fibrillation (AF) will receive a 2-week ECG patch monitor to wear (up to 3 times over 12 months),
62514212|NCT05442203|OTHER|SHD Cohort|Will be comprised 500 participants at increased risk for Structural Heart Disease (SHD) will be referred for a single echocardiogram.
62514213|NCT05073120||Piqray Prescriber's/HCP receiving the guide for hyperglycemia|HCPs prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material).
62514214|NCT01051713|EXPERIMENTAL|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
62709914|NCT03825627|ACTIVE_COMPARATOR|Approach Avoidance Task (active tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
62353809|NCT02670928|ACTIVE_COMPARATOR|Active group of patients|Active group of patients underwent program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
62514215|NCT01051713|EXPERIMENTAL|Technology Supported condition|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
62353810|NCT02670928|EXPERIMENTAL|Control group of patients|Control group pf patients were being monitored for the same criteria as active group but did not take part in the lifestyle change management program.
62353811|NCT05126940||nurses|ED nurses trained to perform LUS and blinded to the final diagnosis
62353812|NCT05126940||emergency physician|"certified emergency physician who had accomplished a full mentoring program for Ultra-Sound Life Support."
62353813|NCT02433860|EXPERIMENTAL|pregnant nicotine users|watch video and tobacco cessation counselling using SCRIPT protocol
62514216|NCT01051713|NO_INTERVENTION|Self-Guided|Participants in the Self-Guided condition will receive DPP DVDs (3 DVDs and 1 CD) at the beginning of the study. This condition will not receive any direct dietary or physical activity interventions outside of the DVDs. Although Self-Guided participants will be receiving the same 7% weight loss goal as the other two groups, they will not be receiving physical activity or diet goals. The DVDs cover the initial 12-weekly sessions of the DPP, with the sessions portrayed by professional actors. They will also be provided with a supplemental DVD which includes a manual for each of the 12 sessions. They will also be giving the Keeping Track booklets and asked to record their diet and activity daily.
62514217|NCT03349827|EXPERIMENTAL|Experimental|HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
62514218|NCT00710749|EXPERIMENTAL|Disposable device first, then Digital device|
62514219|NCT00710749|EXPERIMENTAL|Digital device first, then Disposable device|
62514220|NCT03471208|EXPERIMENTAL|Dynamic Navigation|Dental implant surgery via dynamic navigation assistance
62514221|NCT03471208|ACTIVE_COMPARATOR|Freehand|Dental implant surgery via conventional freehand
62514222|NCT03353298|ACTIVE_COMPARATOR|Arm A|Allopurinol 300 mg
62514223|NCT03353298|PLACEBO_COMPARATOR|Arm B|Placebo Oral tablets
62514224|NCT05772884|EXPERIMENTAL|Supervised Exercise Intervention|Participants will be asked to complete 3 walking sessions per week for 12 weeks. We will ask them to complete at least 1 of these sessions in-person on-site and they will be given the option to complete up to 2 walking sessions per week off-site. Exercise training on-site will be performed on an indoor walking path, 50 min/session (plus 5 min. for each warm-up and cool down).
62514225|NCT04119219|ACTIVE_COMPARATOR|Ranibizumab|Arm 1
62514226|NCT04119219|ACTIVE_COMPARATOR|Aflibercept|Arm 2
62514227|NCT06503107|EXPERIMENTAL|Effective of nanobody-based biepitope BCMA-targeting CAR-T cells|The recommended reinfusion dose of biepitope BCMA-targeting CAR-T cells in this trial is: 1 × 10\^6/kg, 2 × 10\^6/kg CAR-T cells.
62514228|NCT02907099|EXPERIMENTAL|Treatment (CXCR4 antagonist BL-8040, pembrolizumab)|Patients receive CXCR4 antagonist BL-8040 SC on days 1-5 and 8-12 of cycle 1 and days 1, 4, 8, and 11 of subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over about 30 minutes on day 1. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62514229|NCT00356824||1|HIV-infected children in Uganda
62514230|NCT02329119|EXPERIMENTAL|G1-SCZ|patients with schizophrenia as defined in DSM IV-TR
62514231|NCT02329119|ACTIVE_COMPARATOR|G2-TAB|patients with bipolar affective disorder (BD) type I as defined by the DSM IV-TR
62514232|NCT02994251|EXPERIMENTAL|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
62514233|NCT03492970|OTHER|10 adult patients with SMS|Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
62514234|NCT05081336||High-intensity statin|
62514235|NCT05081336||High-intensity statin plus ezetimib|
62514236|NCT05081336||High-intensity statin plus ezetimib plus PCSK9 inhibitor|
62514237|NCT05062915|NO_INTERVENTION|Baseline population|Historic cohorte for comparisson in study 1. Baseline population 1 all patients with AVS. Baseline 2 population part of baseline 1 but with peripheral cause of AVS. Are offered late onset vestibular rehabilitaion if they have balance deficit.
62514238|NCT05062915|ACTIVE_COMPARATOR|Study population|"The study population is divided into 2 groups, based on the findings in the clinical investigation.~study population 1: all patients with acute Vestibular syndrome (AVS) Study population 2: all patients from study group 1, with vestibular/peripheral cause of AVS. They are offered early onset rehabilitation.~Arm 1 and 2 are compared for cost-effectiveness and compared to the costs of the diagnosis."
62514239|NCT06077734||Muscle impaired elderly|Elderly scheduled for hip/knee/back surgery with III-IV ASA score, low grip strength and high scoring for sarcopenia
62514240|NCT06077734||Lung cancer cachexia|Non-small cell lung cancer patients stage III with reported cachexia
62514241|NCT06077734||Controls|Elderly scheduled for hip/knee/back surgery without any recorded muscle defects, I-II ASA score, average or high grip strength, low scoring for sarcopenia.
62514242|NCT06292494|EXPERIMENTAL|FUS-treated epilepsy|
62514243|NCT01976728|EXPERIMENTAL|LutrePulse 10 µg/pulse|Gonadorelin acetate 10 µg/pulse
62514244|NCT01976728|EXPERIMENTAL|LutrePulse 15 µg/pulse|Gonadorelin acetate 15 µg/pulse
62514245|NCT01976728|EXPERIMENTAL|LutrePulse 20 µg/pulse|Gonadorelin acetate 20 µg/pulse
62514246|NCT01976728|PLACEBO_COMPARATOR|Placebo|Placebo
62514247|NCT03827018|ACTIVE_COMPARATOR|mavrilimumab|Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
62514248|NCT03827018|PLACEBO_COMPARATOR|placebo|Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
62514249|NCT02843659|EXPERIMENTAL|BMS-931699|Subcutaneous weekly injection + daily oral placebo tablets
62514250|NCT02843659|EXPERIMENTAL|BMS-986142|Daily oral tablets + subcutaneous placebo (weekly) injection
62514251|NCT02843659|PLACEBO_COMPARATOR|Placebo|Weekly subcutaneous placebo injection +daily oral placebo tablets
62514252|NCT00747292|ACTIVE_COMPARATOR|Epidural|Epidural
62514253|NCT00747292|ACTIVE_COMPARATOR|2|Spinal
62514254|NCT00747292|ACTIVE_COMPARATOR|3|Patients in this limb receive a PCA
62514255|NCT04142242|EXPERIMENTAL|Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment \[Day 0\]) followed by a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0, during Stage I in the present study (MEQ00066).
62514256|NCT04142242|EXPERIMENTAL|Group 2: MenACYW Conjugate Vaccine (MET49 - MenACYW Conjugate Vaccine-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment \[Day 0\]) followed by a single IM dose of MenACYW Conjugate vaccine at Day 0, during Stage I in the present study (MEQ00066).
62514257|NCT04142242|EXPERIMENTAL|Group 3: MenACYW Conjugate Vaccine (MET49: Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066), followed by receiving a single IM dose of MenACYW Conjugate vaccine at Stage II in the present study (MEQ00066).
62353814|NCT01058733|OTHER|Internet|New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
62353815|NCT01425749|EXPERIMENTAL|Arm A|Intramuscular injections of recMAGE-A3 + AS15 ASCI.
62353816|NCT01425749|EXPERIMENTAL|Arm B|Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
62353817|NCT01754077|EXPERIMENTAL|Thirty Million Words Project|The participants in the intervention group receive the LENA linguistic feedback reports intervention and the home visiting educational session intervention. Participants in this arm complete the same assessments as participants in the control group.
62353818|NCT01754077|OTHER|Control Group|The control group receives the Childhood Nutrition Education intervention. Participants in this group completed the same assessments as the treatment group. Following participation in the control group, eligible families were offered the opportunity to continue into the experimental group.
62353819|NCT00050960|EXPERIMENTAL|bexarotene with carboplatin and paclitaxel|
62353820|NCT00050960|EXPERIMENTAL|carboplatin and paclitaxel|
62353821|NCT06213610|OTHER|Sequence TR|25 subjects assigned to the sequence TR will receive a single oral dose of the test product Perindopril 8 mg tablet, marked as T in the sequence, in Period 1 and a single oral dose of the reference product Prestarium® A 10 mg tablet, marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62353822|NCT06213610|OTHER|Sequence RT|25 subjects assigned to the sequence RT will receive a single oral dose of the reference product Prestarium® A 10 mg tablet, marked as R in the sequence, in Period 1 and a single oral dose of the test product Perindopril 8 mg tablet, marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62353823|NCT05411328|EXPERIMENTAL|traditional physical therapy group|received traditional physical therapy protocol
62353824|NCT05411328|EXPERIMENTAL|virtual reality group|received the same traditional physical therapy in addition to virtual reality games
62353825|NCT02084069|ACTIVE_COMPARATOR|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
62353826|NCT02084069|PLACEBO_COMPARATOR|Control|Placebo
62353827|NCT02016898|EXPERIMENTAL|Sponge placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age \< 65), baseline IOP (IOP ≥ 28 mmHg or IOP \< 28 mmHg), and concurrent cataract surgery.
62353828|NCT02016898|EXPERIMENTAL|Irrigation placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age \< 65), baseline IOP (IOP ≥ 28 mmHg or IOP \< 28 mmHg), and concurrent cataract surgery.
62353829|NCT04254796|EXPERIMENTAL|TARA Training|12-week group TARA Training
62353830|NCT04254796|NO_INTERVENTION|Control|Waitlist Control
62353831|NCT03752333|EXPERIMENTAL|Pembrolizumab|All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
62353832|NCT04689841|EXPERIMENTAL|Vojta Therapy|In Vojta therapy, the therapist selectively presses certain areas of the body, with the patient lying prone, - supine or - lateral. These types of stimuli, in humans of any age, provoke automatically and without their own initiative, that is, without the active voluntary collaboration of the person
62353833|NCT04689841|PLACEBO_COMPARATOR|Control Group|In the control group, a placebo intervention is administered, similar to an experimental intervention
62514258|NCT04142242|EXPERIMENTAL|Group 4: MenACYW Conjugate Vaccine (MET49: MenACYW-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066), followed by receiving a single IM dose of MenACYW Conjugate vaccine at Stage II in the present study (MEQ00066).
62353834|NCT00769808|EXPERIMENTAL|Technolas 217z Excimer Laser|Bausch \& Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
62353835|NCT03428451|ACTIVE_COMPARATOR|Group A (Hypertonic saline )|patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr.
62353836|NCT03428451|ACTIVE_COMPARATOR|Group B (Hypertonic saline)|patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr.
62353837|NCT03428451|ACTIVE_COMPARATOR|Group C (Normal saline)|patients will receive NaCl 0.9% NS at a dose of 6 ml/kg/hr.
62514259|NCT04142242|OTHER|Group 5: Menomune-primed Participants (MET44)|Participants who received a single dose of Menomune vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
61973142|NCT00438113|NO_INTERVENTION|Standard Blood Pressure control|Treatment will be carried out as per the CHEP guidelines. These patients may require ACEi or ARBs for their treatment. No changes to their drug regimen will be made as long as BP measurements are congruent with current guidelines. These modifications will be made as per standard practice by the physician who is primarily involved with their care (this may be a family physician or a specialist, depending on the patient). Patients with diabetes in the standard arm will be treated to a target BP of \<130/80 as per the CHEP guidelines.
61973143|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
62147286|NCT06377137|EXPERIMENTAL|Small-sided soccer games groups (SSSG)|"SSSG will perform 16 weeks of training, 3 sessions/week, and \~55 minutes/session. Each session will begin with a 15-minute warm-up, 32 minutes of principal activity, and 5 minutes of cool down. The SSSG will consist of a program based on high-intensity SSSG.~The training protocol is based on a pilot study conducted to characterize the exertion profile. The SSSG will be performed in a fractional regimen of 8 sets of 4 minutes and 2 minutes rest. The format of the SSGs will be 3v3, although they can be adapted to 2v2 or 4v4 when necessary. In addition, it will take place in a playing area of 9 x 18 meters equivalent to 27 square meters per player. To encourage high intensity, the following will be used (i) man-to-man marking; (ii) to score a goal, the entire team must be in the opponent's half of the field; (iii) balls will be available to reduce stoppages in play; (iv) the coach will motivate the team to maintain high intensity."
62514260|NCT04142242|OTHER|Group 6: MenACYW Conjugate Vaccine-primed Participants (MET44)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
62514261|NCT01157715|EXPERIMENTAL|0.5 mg cohort|patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
62147287|NCT06377137|EXPERIMENTAL|Traditional soccer training groups (TSG)|"SSSG will perform 16 weeks of training, 3 sessions/week, and \~55 minutes/session. Each session will begin with a 15-minute warm-up, 32 minutes of principal activity, and 5 minutes of cool down.~The TSG group will base its training on 30 minutes of technical exercises with the ball individually or in pairs (dribbling, shooting and passing), ending with 10 minutes of a match organized according to the original characteristics of an indoor soccer game."
62147288|NCT06377137|NO_INTERVENTION|Control Group (CG)|CG will perform only regular school physical education classes without any additional intervention
62353838|NCT03289871|EXPERIMENTAL|Excilor|2 applications per day for 6 months
62353839|NCT03289871|ACTIVE_COMPARATOR|Loceryl 5%|1 application per week for 6 months
62353840|NCT05322057||patients with Crohn's disease and complex perianal fistula|14 patients with Crohn's disease refractory to standard treatment for complex perianal fistula got enrolled in this study.
62353841|NCT01540968|EXPERIMENTAL|Nutrition & physical exercise|
62353842|NCT01540968|NO_INTERVENTION|Control|
62353843|NCT02003729|ACTIVE_COMPARATOR|Portable Sleep Monitor|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from portable monitor sleep studies.
61973144|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
61973145|NCT01431560|ACTIVE_COMPARATOR|metallic implant|fixation of the ankle fracture with metallic implants
61973146|NCT01431560|ACTIVE_COMPARATOR|biodegradable implant|fixation of the ankle fracture with Freedom plate and screws
61973147|NCT02655562|EXPERIMENTAL|biomarker treatment arm|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
62147289|NCT02417350|EXPERIMENTAL|Ketogenic diet first|Starting with ketogenic diet first and then switching to a NFA recommended diet
62147290|NCT02417350|EXPERIMENTAL|NFA recommended diet first|Starting with NFA recommended diet first and then switching to a ketogenic diet
62147291|NCT01536964|EXPERIMENTAL|Morphine|the effect of morphine on prasugrel absorption will be tested
62147292|NCT01536964|PLACEBO_COMPARATOR|Saline|
62147293|NCT03564106|EXPERIMENTAL|group A|receive intraarticular radiofrequency + methylprednisolone (30 mg)
62353844|NCT02003729|NO_INTERVENTION|Polysomnography|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from polysomnography from the sleep clinic.
62353845|NCT03296852|EXPERIMENTAL|Healthy Volunteers|
62353846|NCT04110860|EXPERIMENTAL|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
62514262|NCT01157715|EXPERIMENTAL|2.0 mg cohort|patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
62514263|NCT00502801|EXPERIMENTAL|Doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
62514264|NCT01677013|NO_INTERVENTION|Oral medication treatment|type 2 diabetics with only oral medications
62514265|NCT01677013|EXPERIMENTAL|Oral medication plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
62514266|NCT01677013|NO_INTERVENTION|Oral medication plus insulin treatment|Type 2 diabetics who need insulin therapy with oral medications
62353847|NCT04110860|EXPERIMENTAL|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
62353848|NCT04110860|PLACEBO_COMPARATOR|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
62353849|NCT05867199|EXPERIMENTAL|MI+AOT|Subjects assigned to this group will be asked to perform Motor Imagery and Action Observation Training during immobilisation period after surgery. The training will be performed once a day, for three weeks. The duration of the training will last about 15 minutes.
62353850|NCT05867199|NO_INTERVENTION|Control|Subjects assigned will be asked to follow standard care pathway during immobilisation period.
62353851|NCT01017887||Airseal port for laparoscopic surgery|Airseal access port for laparoscopic surgery with standard ports.
62353852|NCT01017887||Standard Laparoscopy ports|Uses standard laparoscopy ports.
62353853|NCT05637801|EXPERIMENTAL|Active|Treatment Group: Subjects are treated with the Active Sensory Stimulation System at home for 60 minutes daily for up to12 months.
62353854|NCT05637801|SHAM_COMPARATOR|Control|Control Group: Subjects are treated with a Sham Sensory Stimulation System at home for 60 minutes daily for up to 12 months.
62353855|NCT04969341||Screening (survey, medical record review)|Patients complete survey over 20 minutes consisting of validated and piloted items related to cost and convenience barriers in lung cancer screening, personal financial and lung cancer risk perception questions, and the Telehealth Satisfaction and Usefulness questionnaire. Patients also have their medical records reviewed retrospectively.
62353856|NCT03104998|OTHER|coenzyme Q10|Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
62353857|NCT03707158|ACTIVE_COMPARATOR|Web-based CBT|The online, multimedia suite of Cool Kids CBT web-based programs for youth anxiety is a supported, largely self-administered online digital cognitive-behavioral therapy anxiety management intervention, with adjunctive therapist phone support. Treatment content runs directly parallel to that included in the therapist-led Cool Kids face-to-face suite of interventions. The online suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
62353858|NCT03707158|ACTIVE_COMPARATOR|Face-to-Face CBT|The Cool Kids suite of face-to-face (office-based or telehealth) CBT-based programs for youth anxiety is a well-supported therapist-led, clinic-based anxiety management intervention. The face-to-face cognitive-behavioral therapy treatment content runs directly parallel to that included in the Cool Kids online suite of interventions. The face-to-face suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
62353859|NCT03745300|ACTIVE_COMPARATOR|GROUP 1|Scaling and root planing (SRP) followed by 1.2% atorvastatin gel local drug delivery
62353860|NCT03745300|ACTIVE_COMPARATOR|GROUP 2|Scaling and root planing (SRP) followed by 1.2% simvastatin gel local drug delivery
62514267|NCT01677013|EXPERIMENTAL|Oral medication plus insulin plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
62709915|NCT03825627|SHAM_COMPARATOR|Approach Avoidance Task (sham tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm sham Transcranial Direct Current Stimulation will be used during the task.
62709916|NCT03625076|EXPERIMENTAL|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
62147294|NCT03564106|EXPERIMENTAL|group C|receive intraarticular methylprednisolone (30 mg)
62353861|NCT03745300|PLACEBO_COMPARATOR|GROUP 3|Scaling and root planing (SRP) followed by placebo gel local drug delivery
62353862|NCT04920539|EXPERIMENTAL|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
62353863|NCT02375269|EXPERIMENTAL|RIPC (Remote Ischemic Preconditioning)|Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
62353864|NCT02375269|NO_INTERVENTION|Control|Preoperatively in the operation theater a tourniquet will be applied to the left arm. The tourniquet will not be insufflated. The tourniquet will be removed after 30 minutes.
62353865|NCT03954977|EXPERIMENTAL|Ultrasound vs Radiograph|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
62353866|NCT01865045||no treatment|no treatment
62709917|NCT03625076|ACTIVE_COMPARATOR|Procedural Sedation|Intravenous etomidate or propofol
62709918|NCT05951426||experimental group|40 patients in whom Endometrial carcinoma was diagnosed as part of the experimental group.
62514268|NCT02503475|OTHER|Project 1- Real-Time fMRI|"This arm investigates Real-Time fMRI within 4 groups:~Attention Regulation (AR) Group- Experimental Cognitive Regulation (CR) Group- Experimental Sham Group- Sham Comparator Free Strategy Group- Active Comparator"
62514269|NCT02503475|EXPERIMENTAL|Project 2 - CBT/MBSR|"This arm investigates 2 experimental groups:~Cognitive Behavioral Therapy (CBT) Mindfulness Based Stress Reduction (MBSR)"
62514270|NCT02503475|OTHER|Project 3- Acupuncture|"This arm investigates Acupuncture within 2 groups:~Verum- Experimental Sham- Sham comparator"
62514271|NCT02954159|ACTIVE_COMPARATOR|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
62514272|NCT02954159|PLACEBO_COMPARATOR|Placebo Arm|vedolizumab at standard regimen with placebo.
62514273|NCT03027921|EXPERIMENTAL|hepatic ultrasound|all patients will have hepatic ultrasound
61973148|NCT02655562|PLACEBO_COMPARATOR|standard treatment arm|Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
62514274|NCT06504147|EXPERIMENTAL|Radspherin|
62514275|NCT06504147|NO_INTERVENTION|Control|
62514276|NCT01189526|EXPERIMENTAL|IVRI|IVRI : intravitreal ranibizumab (0.5mg) injection
62514277|NCT01189526|ACTIVE_COMPARATOR|Laser|Laser : macular laser photocoagulation
62514278|NCT05440331||Experimental group|Experimental group with training after randomization immediately
62514279|NCT05440331||Control group with delayed training|Control group with training: the training will delayed from time of randomization
62514280|NCT05440331||Control group without training|Control group without training
62514281|NCT04951414||ICF|
62514282|NCT04951414||Control|
62514283|NCT01368926|EXPERIMENTAL|Part 1|
62514284|NCT01368926|EXPERIMENTAL|Part 2|
62514285|NCT00622115|EXPERIMENTAL|A|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 4 hours following the last injection of enoxaparin
62514286|NCT00622115|EXPERIMENTAL|B|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 6 hours following the last injection of enoxaparin
62514287|NCT00622115|EXPERIMENTAL|C|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 10 hours following the last injection of enoxaparin
62514288|NCT02607423|EXPERIMENTAL|Diagnostic (18F-FDG PET/CT)|"Patients undergo fludeoxyglucose F-18 PET/CT at baseline and after course 1 of chemotherapy. Patients undergo 1 of 3 chemotherapy regimens at the discretion of the investigator.~CHEMOTHERAPY REGIMEN 1: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, and 8. Patients also receive cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 2: Patients receive docetaxel IV over 60 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 3: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
62514289|NCT06076369||The tubular adenoma group|The anatomical site was determined, and the size and morphology of the polyps were observed. The classification of the microvascular ECV of the polyps and its adjacent normal mucosal microvascular ECV (white light+NBI) was observed, and methylene blue staining was used to approach and magnify the glandular duct opening to observe the IIIL type (pit pattern). Magnified to the maximum magnification of EC endoscopy to the clearest cell level (approximately 520 times), and observed the morphology of the opening of the IIIL type glandular duct and the opening of the colonic innominate groove, including the morphology of cell cytoplasm and nucleus, proportion of opening length to field of view (more than 1 field of view is calculated as 1.0), and ratio of maximum to minimum opening diameter; Distribution characteristics of glandular duct openings.
62514290|NCT06076369||the colonic innominate groove group|The methylene blue staining area of the normal mucosa adjacent to the polyp was observed to identify the colonic innominate groove.Magnified to the maximum magnification of EC endoscopy to the clearest cell level (approximately 520 times), and observed the morphology of the opening of the IIIL type glandular duct and the opening of the colonic innominate groove, including the morphology of cell cytoplasm and nucleus, proportion of opening length to field of view (more than 1 field of view is calculated as 1.0), and ratio of maximum to minimum opening diameter; Distribution characteristics of glandular duct openings.
62514291|NCT06013917||Patients on ECG monitoring post-transcatheter aortic valve replacement (TAVR) or other cardiac event|Patients at our clinical collaborators practices who have undergone TAVR or other cardiac event and who are placed on ECG monitoring will be placed on an FDA cleared cardiac monitor. We adopt an FDA cleared, reusable, single-lead OEM patch Holter made of flexible material to make long-term wearing more comfortable and more patient compliance.
62514292|NCT04702724|EXPERIMENTAL|Experimental group|
62514293|NCT04254640|EXPERIMENTAL|C-CAG|cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.
62514294|NCT03443817|NO_INTERVENTION|Control group|There is no conventional rehabilitation follow up program, but all patients are encouraged to continue training
62514295|NCT03443817|EXPERIMENTAL|Intervention group|The intervention group will obtain telerehabilitation
62709919|NCT05951426||control group|20 patients in whom cancer or atypical hyperplasia of the endometrium was excluded histopathologically.
61973149|NCT04911530||elderly patients (aged ≥ 65 years)|elderly patients undergo surgeries
62147295|NCT04111159|EXPERIMENTAL|HSK3486|Subjects \< 65 years old:0.4mg/kg/0.15mg/kg;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
62514296|NCT01407224|EXPERIMENTAL|Only training|Training on Early Breastfeeding Practices to front line health workers
62514297|NCT01407224|ACTIVE_COMPARATOR|Training and supervision|Training as well as supervision by field supervisor for six months intervention
62514298|NCT01407224|NO_INTERVENTION|Control|No intervention such as training or supervision
62514299|NCT01355718||Repaglinide|
62514300|NCT01419587|EXPERIMENTAL|Ketogenic diet|Diet formulated to maintain elevated ketones during therapy
62147296|NCT04111159|ACTIVE_COMPARATOR|Propofol|Subjects \< 65 years old:2mg/kg/0.75mg/kg;Subjects≥ 65 years old:75% of the dose for subjects \< 65 years old.
62514301|NCT02303314|OTHER|Drug: Trigonella Foenum-graecum|in this group patients use Trigonella Foenum-graecum seed extract twice daily.
62514302|NCT02303314|OTHER|Drug: Placebo|in this group patients use placebo twice daily.
62514303|NCT02737592|EXPERIMENTAL|Healthy subject|"Healthy subject exposed to Trojan Simply Pleasures Personal Lubricant at least four times weekly for two weeks"
62514304|NCT02521181|EXPERIMENTAL|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
62514305|NCT02521181|EXPERIMENTAL|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
62514306|NCT02521181|PLACEBO_COMPARATOR|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
62514307|NCT06615791|EXPERIMENTAL|FIT FIRST Teen|"School teachers will attend a one-day training course and will be given the FIT FIRST Teen manual, which will contain all the activities to be provided during physical education.~Three 45-minute lessons per week for an entire school year will be administered to students by their teachers."
62514308|NCT06615791|NO_INTERVENTION|Control|School teachers will continue to offer the usual physical education curricula to students.
62514309|NCT05786001||Unhealthy group|Individuals with CLTI
62514310|NCT05786001||Age control group|Healthy individuals over the age of 50
62514311|NCT05786001||Healthy group|Healthy and young individuals
62514312|NCT06063096|ACTIVE_COMPARATOR|Allulose Dose 1|Fruit-flavoured drink with allulose at Dose 1 (2.5 g per 120 ml)
62514313|NCT06063096|ACTIVE_COMPARATOR|Allulose Dose 2|Fruit-flavoured drink with allulose at Dose 2 (4.3 g per 120 ml)
62514314|NCT06063096|PLACEBO_COMPARATOR|Placebo Comparator: Control (CON)|Control drink containing high fructose corn syrup.
62514315|NCT03694808|ACTIVE_COMPARATOR|Fluad Vaccine|A single adjuvanted dose (AD) intramuscular injection
62514316|NCT03694808|ACTIVE_COMPARATOR|Fluzone Vaccine|A single high dose (HD) intramuscular injection
62514317|NCT00622999||All|All patients
62514318|NCT05262192|EXPERIMENTAL|study group|Nutrition education will be given to the experimental group.
62514319|NCT05262192|NO_INTERVENTION|control group|No intervention will be applied to the control group.
62514320|NCT06405542|EXPERIMENTAL|EX-CIPN Exercise- Based intervention|This arm is provided with an intervention that includes an individualized exercise program, remote monitoring, and remote person-to-person clinical support.
62514321|NCT04959383|EXPERIMENTAL|Low complexity Exergame balance training group|Wobble board based exergame balance training, the game complexity will be low for this group.
62514322|NCT04959383|EXPERIMENTAL|Moderate complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be moderate for this group.
62514323|NCT04959383|EXPERIMENTAL|High complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be high for this group.
61973150|NCT00742001|EXPERIMENTAL|Mirasol Illumination Dose #1|Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)
61973151|NCT00742001|EXPERIMENTAL|Mirasol Illumination Dose #2|Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs
61973152|NCT00742001|EXPERIMENTAL|Mirasol Illumination Dose #3|Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs
61973153|NCT05989126|EXPERIMENTAL|8 mg Dose|Only 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.
61973154|NCT02354079|OTHER|genetic analysis|
62514324|NCT04959383|ACTIVE_COMPARATOR|Control group|Wii fit based Exergame training on a stable surface
62514325|NCT01028911|EXPERIMENTAL|PF-03654746|
62514326|NCT01028911|PLACEBO_COMPARATOR|Placebo|
62514327|NCT02378441|EXPERIMENTAL|CJ-30056 20/750mg|fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg
62514328|NCT02378441|EXPERIMENTAL|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
62514329|NCT01039194|ACTIVE_COMPARATOR|galantamine 8 mg (ER)|
62514330|NCT01039194|ACTIVE_COMPARATOR|galantamine 16 mg (ER)|
62514331|NCT01039194|ACTIVE_COMPARATOR|BMS-708163|
62514332|NCT04851275|EXPERIMENTAL|Shared decision making for men with lower urinary tract symptoms|Participants used the Visual Analogue Uroflowmetry Score so report their symptoms and were attended by Primary Care Physicians trained in shared decision making
62514333|NCT04851275|ACTIVE_COMPARATOR|No shared decision making for men with lower urinary tract symptoms|Participants did not use the Visual Analogue Uroflowmetry Score to report their symptoms and received usual care by Primary Care Physicians not trained in shared decision making
62514334|NCT01787279|EXPERIMENTAL|Peginterferon alpha-2a, 180 mcg/48 weeks|Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.
62514335|NCT02560779|EXPERIMENTAL|Carotuximab (TRC105) and Sorafenib|Carotuximab (TRC105) in combination with standard dose Sorafenib.
62514336|NCT04917081|EXPERIMENTAL|Mindful Self-Compassion|
62514337|NCT04917081|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|
62514338|NCT02194010||Participants evaluated at INC sites|Participants being evaluated at the INC sites will participate in both the DSI and HMSN-R-ODS by completing these PROs during their visit.
62514339|NCT02194010||INC Contact Registry|INC Contact Registry completes the HMSN-R-ODS on web http://rarediseasesnetwork.epi.usf.edu/INC/
62514340|NCT06155773|EXPERIMENTAL|Highly viscous Glass Ionomer|Highly viscous glass ionomer restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
62514341|NCT06155773|EXPERIMENTAL|Low shrinkage Flowable Composite|Low shrinkage Flowable Composite restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
62514342|NCT06155773|EXPERIMENTAL|Resin Modified Glass Ionomer|Resin Modified Glass Ionomer restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
62514343|NCT06155773|EXPERIMENTAL|Bioactive Ionic Resin|Bioactive Ionic Resin restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
62514344|NCT03727737|NO_INTERVENTION|Sham|Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment
62514345|NCT03727737|ACTIVE_COMPARATOR|ACTIVE|Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment
62514346|NCT00149149|EXPERIMENTAL|Indomethacin treated volunteers|5d of indomethacin treatment (50 mg t.i.d) with ZnC (37.5 mg b.i.d) coadministration.
62514347|NCT00149149|PLACEBO_COMPARATOR|Placebo treated volunteers|5 days of indomethacin treatment (50 mg t.i.d) with placebo coadministration.
62514348|NCT01430819|EXPERIMENTAL|Fluzone® Vaccine Group|Participants will receive the Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
62514349|NCT01430819|ACTIVE_COMPARATOR|Fluzone® High-Dose Vaccine Group|Participants will receive the Influenza Virus Vaccine, Fluzone® High-Dose 2011-2012 Formulation.
62514350|NCT01183117|EXPERIMENTAL|SM-01|
62514351|NCT01183117|ACTIVE_COMPARATOR|PTA|
62514352|NCT01980160|ACTIVE_COMPARATOR|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
62514353|NCT01980160|SHAM_COMPARATOR|Unactivated Nometex Device|The Nometex device will not be activated and therefore have no effect on the nausea/vomiting associated with chemotherapy.
62514354|NCT06334419|EXPERIMENTAL|All Study Participants|Participants received, in random order, a single dose of placebo or Gaboxadol with a two-week washout period between doses. The gaboxadol dosage selected for this study is 10 mg or Placebo as a single dose on each study visit (two at home and two in clinic).
62514355|NCT01694017|ACTIVE_COMPARATOR|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
62514356|NCT01694017|ACTIVE_COMPARATOR|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
62514357|NCT05356182|ACTIVE_COMPARATOR|Control Diet Arm|control diet arm (\~20% protein content)
62514358|NCT05356182|ACTIVE_COMPARATOR|Low-Protein Diet Arm|intervention low-protein diet arm (10% protein content)
62514359|NCT04639297|EXPERIMENTAL|NeuroVision® IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
62514360|NCT04639297|ACTIVE_COMPARATOR|Conventional hospital based IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
62514361|NCT05349578|OTHER|Tissue|conventional RUT using biopsied tissue
62514362|NCT05349578|EXPERIMENTAL|Swab|RUT using swab
62514363|NCT03995017|EXPERIMENTAL|Safety Lead In|"* Rucaparib 600 milligrams twice daily~* Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~* Nivolumab 480 milligrams intravenous every 4 weeks~* Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~* One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients~* 1 cycle= 28 days"
62514364|NCT03995017|EXPERIMENTAL|Cohort A|"* Rucaparib 600 milligrams twice daily~* Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~* Nivolumab 480 milligrams intravenous every 4 weeks~* Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~* 1 cycle= 28 days"
62514365|NCT03995017|ACTIVE_COMPARATOR|Cohort B|"* Rucaparib 600 milligrams twice daily~* Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~* Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~* 1 cycle= 28 days"
62514366|NCT06245759||the U.S. National Cancer Center SEER database|The Chinese NMIBC cohort includes patients from January 1996 to December 2019 at 15 institutions.
62514367|NCT06245759||the Chinese Bladder Cancer Alliance CBCC database|SEER\*Stat software (version 8.4.1.1) collected 17 registries cohort data on NMIBC patients diagnosed between 2000 and 2020.
62514368|NCT01502124|ACTIVE_COMPARATOR|Lyophilized|
62514369|NCT01502124|EXPERIMENTAL|Liquid|
62514370|NCT05048641|EXPERIMENTAL|WhatsApp Reminder group|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
62514371|NCT05048641|NO_INTERVENTION|No Reminder (NR) group|Subjects who are allocated to the NR group received standard-of-care service which is no reminder text messages via WhatsApp Messenger prior to their scheduled repeat mammography and no follow up phone reminder until the completion of the outcome measurement period.
62514372|NCT03848247|EXPERIMENTAL|Control group|Participants will be injected with 0.5ml Isotonic saline into a neck muscle
62514373|NCT03848247|EXPERIMENTAL|Neck pain|Participants will be injected with 0.5ml NGF into the a neck muscle
62514374|NCT05510115|EXPERIMENTAL|Experimental|Empagliflozin
61973155|NCT01221883|PLACEBO_COMPARATOR|Placebo|Placebo capsule in ER, identical follow up like those in the active arm.
62514375|NCT05510115|PLACEBO_COMPARATOR|Placebo comparator|Placebo
62514376|NCT05571072|ACTIVE_COMPARATOR|Standard Opioid Prescription|Patients will be given a prescription for opioid pain medication to use for acute postoperative pain as would be typical for the attending surgeon performing the surgery.
62514377|NCT05571072|EXPERIMENTAL|Opioid Calculator Prescription|Patients will be a given a prescription for opioid pain medication based on the opioid calculator.
62514378|NCT00085306|EXPERIMENTAL|Recombinant interferon beta|
61973156|NCT01221883|EXPERIMENTAL|Diazepam|10 mg of Diazepam mg orally at ER only (a single administration)
62514379|NCT05665959||Reiki Group|Patient Information Form (PIF), Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Holistic Well-Being Scale (HWS) were administered to the Reiki group. After the pretests of the patients were completed, the primary investigator with Reiki second degree applied Reiki therapy to the patients for 40 minutes. On the second and third days, she applied distant reiki. After 3 days and 10 days after the patients were included in the study, the post-tests were performed by calling the patients.
62514380|NCT05665959||Control Group|Patient Information Form (PIF), Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Holistic Well-Being Scale (HWS) were administered to the control group. After 3 days and 10 days after the patients were included in the study, the post-tests were performed by calling the patients.
62147297|NCT02010866|OTHER|Counseling|in-person counseling through RFWP to distressed respondents on the ISP and patients who seek counseling without completing the ISP
62147298|NCT05704192||Clinically significant portal hypertension (CSPH) group|A CT-based HVPG Score, whose computed formula was: 17.37-4.91\*ln(Liver/Spleen volume ratio) +3.8\[If presence of peri-hepatic ascites\],was used to diagnose CSPH (HVPG\>10mmHg) with a cut-off value 11.606.
62147299|NCT05704192||non-CSPH group|A CT-based HVPG Score, whose computed formula was: 17.37-4.91\*ln(Liver/Spleen volume ratio) +3.8\[If presence of peri-hepatic ascites\],was used to diagnose CSPH (HVPG\>10mmHg) with a cut-off value 11.606.
61973157|NCT01784640|EXPERIMENTAL|Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)|Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
62147300|NCT00893009|PLACEBO_COMPARATOR|Placebo|
62147301|NCT00893009|ACTIVE_COMPARATOR|Theophylline|100 twice a day
62147302|NCT00089609|EXPERIMENTAL|Main cohort - Prostate Cancer|Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days. Thalidomide 200 mg by mouth daily throughout the cycle. Prednisone 10 mg by mouth daily throughout the cycle. Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
62514381|NCT01844531|EXPERIMENTAL|FDC empagliflozin dose 1 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
62514382|NCT01844531|ACTIVE_COMPARATOR|empagliflozin dose 1 + metformin tablets|single tablets after intake of a high fat, high caloric meal
62514383|NCT01844531|EXPERIMENTAL|FDC empagliflozin dose 2 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
62514384|NCT01844531|ACTIVE_COMPARATOR|empagliflozin dose 2 + metformin tablets|single tablets after intake of a high fat, high caloric meal
62514385|NCT05449782|OTHER|Healthy participants: Cocoa flavanol - Placebo|Healthy participants receiving cocoa flavanols on first study day and placebo on second study day
61973158|NCT03273374|EXPERIMENTAL|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
61973159|NCT01996982|EXPERIMENTAL|Device|CCS Device application
61973160|NCT00856284|EXPERIMENTAL|Metformin + Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
62147303|NCT00089609|EXPERIMENTAL|Expansion cohort - Prostate Cancer|Docetaxel 75 mg/m\^2 intravenously over 60 minutes and Bevacizumab 15 mg/kg intravenously was given for 2 cycles. After two cycles Prednisone 10 mg by mouth daily and Thalidomide 200 mg by mouth daily was added.
61973161|NCT00856284|EXPERIMENTAL|Metformin + Alogliptin 25 mg|Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
62147304|NCT05579184|EXPERIMENTAL|[177Lu]Ludotadipep 100 mCi|100 mCi of \[177Lu\] ludotadipep shall be administered to the subject repeatedly up to 6 times at intervals of 8 weeks (±2 weeks).
62147305|NCT01026207||Chronic Obstructive Pulmonary Disease|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months, and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.Patients has been underwent one night by polysomnography and one night with portable monitoring.
62147306|NCT04863339|EXPERIMENTAL|Tranexamic Acid|Participants in the Tranexamic Acid arm will receive a dose of Tranexamic Acid.
62147307|NCT04863339|PLACEBO_COMPARATOR|Placebo|Patients in the placebo arm will receive a saline placebo.
62147308|NCT03679299||Healthy Control|Healthy controls will be recruited from the general population and will be matched based on age, sex, and BMI. They will be assess at two time points, 48 hours apart. At each testing day, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity.
62147309|NCT03679299||Asthma|Individuals experiencing an asthma exacerbation will be recruited from the University of Alberta Hospital Emergency Department. Once discharged, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity. Participants will complete the same assessments at a follow up date 48 hours and 14 days post-discharge, with the addition of a full pulmonary function test, physical activity assessment via a Fitbit, and the completion of two questionnaires: Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire.
62514386|NCT05449782|OTHER|Healthy participant: Placebo - Cocoa flavanol|Healthy participants receiving placebo on first study day and cocoa flavanols on second study day
62514387|NCT05449782|OTHER|Type 2 diabetes participants: Cocoa flavanol - Placebo|Participants with type 2 diabetes receiving cocoa flavanols on first study day and placebo on second study day
62514388|NCT05449782|OTHER|Type 2 diabetes participants: Placebo - Cocoa flavanol|Participants with type 2 diabetes receiving placebo on first study day and cocoa flavanols on second study day
62514389|NCT01713179|EXPERIMENTAL|ambroxol|"Ambroxol hydrochloride (Mucopect®, trans-4\[2-amino-3.5-dibrombenzylamino\]-cyclohexanhydro-chloride, 60 mg, Boehringer Ingelheim) was administered orally to subjects in the ambroxol group immediately after initial examination (10 AM).~one dose for one day"
62514390|NCT01713179|NO_INTERVENTION|control|
62514391|NCT01436565|EXPERIMENTAL|dose escalation and expansion|SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose
62514392|NCT00964288|OTHER|Period 1|
62514393|NCT00964288|OTHER|Period 2|
62514394|NCT00964288|OTHER|Period 3|
62514395|NCT00964288|OTHER|Period 4|
62514396|NCT04351841|PLACEBO_COMPARATOR|control|15 g maltodextrin per day consumed in the morning
62514397|NCT04351841|EXPERIMENTAL|Active|15 g arabinogalactan per day consumed in the morning
62514398|NCT04172519|EXPERIMENTAL|Group A|Patients who before prostate cancer surgery will receive: psychological consultation, nursing consultation, physiotherapy consultation and intervention (4 visits which will be implemented pelvic floor muscle training). Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Then, 6 months after the surgery, there will also be a physiotherapy consultation.
62514399|NCT04172519|EXPERIMENTAL|Group B|Patients who will receive: psychological consultation, nursing consultation, physiotherapy consultation before prostate cancer surgery. Subsequently, patients will have the procedure performed laparoscopic radical prostatectomy, immediately after which they receive psychological consultation, nursing consultation. The physiotherapist consultation will be two weeks after the surgery, during which the physiotherapist will provide an instruction pelvic floor muscle training. Patients do the exercises themselves at home according to the instructions, 3 times a day for 3 months). Physiotherapeutic consultation 6 months after surgery.
62514400|NCT04172519|EXPERIMENTAL|Group C|Patients who will not receive any intervention before prostate cancer surgery. Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Physiotherapeutic consultation 6 months after surgery.
62514401|NCT04172519|NO_INTERVENTION|Group D|Control group, patients after radical laparoscopic prostatectomy, without additional interventions
62514402|NCT05815082|EXPERIMENTAL|Watching and waiting group|Watch and Wait strategy is one of the treatment strategies of advanced rectal cancer, which recommends no immediate surgery with close surveillance.
62514403|NCT05815082|ACTIVE_COMPARATOR|Adjuvant chemotherapy group|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
62353867|NCT06442657|EXPERIMENTAL|Hydrocellular|Application of hydrocellular dressings prior to prone positioning and standard pressure sore prevention strategy. Dressings can remain in place for up to 7 days.
62353868|NCT06442657|ACTIVE_COMPARATOR|Hydrocolloid|Application of hydrocolloids dressings prior to prone positioning and standard pressure sore prevention strategy. Dressings are removed after each prone position.
62514404|NCT03360175||Thoracic Surgery Patients|"Inclusion criteria include: Patients scheduled to undergo thoracic surgery at Brigham and Women's Hospital, between the ages 18-85 years old. Exclusion criteria are: pre-existing chronic pain or opioid use; current treatment with corticosteroids; evidence of active infection; chronic liver disease; end-stage renal disease (CKD-5); chronic inflammatory disorders; recent major surgery or illness within 30 days; use of immunosuppressive medication; history of organ transplantation.~Pro-inflammatory eicosanoid and pro resolving lipid mediator temporal profiles will be determined pre-operatively, on post-operative day 1 and on post-operative day 14. In addition, daily pain scores will be recorded for 60 days after surgery and at 3, 6 and 12 months."
62514405|NCT02358850|ACTIVE_COMPARATOR|Tonsillectomy and Norco|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
62514406|NCT02358850|ACTIVE_COMPARATOR|Tonsillectomy and Percocet|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
62709920|NCT03173937|EXPERIMENTAL|1|CordIn is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
62147310|NCT01474382|EXPERIMENTAL|OraVerse|OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)
62147311|NCT01474382|SHAM_COMPARATOR|Sham injection|Dentist simulates injection with dental syringe
62353869|NCT00002718|EXPERIMENTAL|Candidates for transplant|Pts stratified by number of HLA-incompatible alleles(1 vs 2 or 3). Harvest:Begin 6-10 d before transplant,allogeneic BM is harvest \& tx in vitro. Begin 5-6 d before transplant,G-CSF-stimulated,PBSC harvest,selected for CD34+ cells,\& treatment in vitro. If doable,ABM harvest in event of allogeneic graft failure. Myeloablation:Pts u/g TBI 3x d days -9 to -6, thiotepa IV over 4hrs days -5 \& -4, \& cyclophosphamide IV days -3 \& -2. Transplant:CD34+, E-rosette \& T-cell-depleted PBSC infuse over 15mins \& T-cell-depleted bone marrow infused over 1-5mins day 0. Pts get G-CSF IV over 30 min begin day 1 \& continue til blood counts recover \& tapering. Pts get anti-thymocyte globulin IV over 4-6hrs days 8,10,12,\&14 \& oral methylprednisolone days 8-14 followed by tapered doses days 15-17. See detailed description for more details.
62353870|NCT04505150|EXPERIMENTAL|Monitoring of lifestyle change activities|The intervention arm will involve (i) the delivery of a blended learning education program and (ii) weekly phone calls to participants. The lectures will be delivered to 10 teams, comprised of about 15 participants in each team and lead by a volunteer team leader using the ORCD's laptop, overhead projector and the sound system in local clubs, school premises or participants' houses. The ORCD investigator including the physician and an information technology person will facilitate the education programs. The interpretations or additional explanations will be made by the physician following WHO guidelines and recommendations\[36\]. The investigator will maintain a folder for each team and will communicate at least with the team leaders by phone calls once every week to remind them to adhere to lifestyle modification intervention program. The weekly monitoring program will continue until the study ends.
62353871|NCT04505150|NO_INTERVENTION|lifestyle change activities: non-monitoring|The control group will only receive the printed materials, no active monitoring
62147312|NCT05654285|PLACEBO_COMPARATOR|Carbonated water|355ml of an orally ingested carbonated water
62514407|NCT02358850|ACTIVE_COMPARATOR|Tonsillectomy and Dilaudid + Tylenol|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)
61973162|NCT00856284|ACTIVE_COMPARATOR|Metformin + Glipizide|Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.
61973163|NCT05000177|OTHER|Experimental group: Non-specific chronic neck pain group|Subjects with non-specific chronic neck pain will be included to perform 30-minute computer typing task and assess neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation.
61973164|NCT05000177|OTHER|Control group: Healthy subjects group|Healthy subjects will be included to compare the differences in neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with non-specific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
62353872|NCT05067452|NO_INTERVENTION|Standard of care including diabetes self-management education|"Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. Control participants will participate in the Diabetes Self-Management Program, an evidence-based program that takes place over 6 weeks that meets the standard of care for diabetes education.~At the end of follow up, the control arm will receive three months diabetes-tailored food support consisting of diabetes-tailored grocery boxes and nutrition case-management."
62353873|NCT05067452|EXPERIMENTAL|Diabetes-tailored food support plus diabetes self-management education|"The intervention has two components: 1) diabetes-tailored food support that consists of weekly, home-delivered medically tailored meals, and monthly home-delivered healthy groceries, from baseline to 24 weeks, and 2) three case-management sessions with client services staff from the partnering nutrition agency over the 12 weeks of intervention.~The intervention will be delivered in addition to a base condition consisting of remote participation in the Diabetes Self-Management Program, an evidence-based diabetes education program that takes place over 6 weeks also received by the control group as part of the standard of care."
62353874|NCT04828356|EXPERIMENTAL|Foot reflexology group|The first researcher received hands-on training about reflexology application before the study started. The researcher applied foot reflexology on the patients with liver transplantation in the experimental group in one session (30 minutes) after the operation. Patient confidentiality was maintained in all procedures. The patient identity form was implemented before reflexology application. Pain and comfort levels were assessed as the pre-test. Then, venous blood was taken to determine the plasma β-End level. Foot reflexology was first applied on the right foot, which is effective on the sympathetic nervous system, for 15 min and then, on the left foot, which is effective on the parasympathetic nervous system, for 15 min. Same process was performed on the left foot and the reflexology application was completed within 15 min. Venous blood was taken again to assess the β-End level as the post-test after the application, and the NPS and PCQ were implemented again.
62353875|NCT04828356|NO_INTERVENTION|No treatment group|The patient identity form, NPS and PCQ were applied on the patients in the control group as the pre-test. After the questions were answered, venous blood was taken to determine the plasma β-End level. No intervention other than clinical protocol was applied on the control group, and after taking venous blood after 30 minutes to determine β-End level, the NPS and PCQ were re-applied as the post-test.
62353876|NCT03234972|EXPERIMENTAL|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9 as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) or will have the option to switch to daratumumab subcutaneously (SC) on Day 1 of any cycle, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m\^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
62353877|NCT03234972|EXPERIMENTAL|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles). Participants who have sponsor-confirmed disease progression while being treated with Vd or on observation, will be offered the option for treatment with daratumumab monotherapy (16 mg/kg weekly for Cycles 1 and 2, every other week for Cycles 3 to 6, and every 4 weeks for Cycles 7 and onwards until disease progression, unacceptable toxicity, pregnancy, loss of follow-up, withdrawal of consent, or death \[each cycle is 28 days\]), if recommended by the site investigator.
62353878|NCT06248697|EXPERIMENTAL|CAR T cells|αPD1/CTLA4-MSLN-CAR T Cells
62353879|NCT03148951||Group 1|Group 1: patients receiving general anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
62353880|NCT03148951||Group 2|Group 2: patients receiving general anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
62353881|NCT03148951||Group 3|Group 3: patients receiving regional (spinal) anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
62353882|NCT03148951||Group 4|Group 4: patients receiving spinal anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
62353883|NCT04540835|EXPERIMENTAL|Teethmate|Half of the cavities will be applied Teethmate Desensitizer following manufacturer instructions before restoration
62353884|NCT04540835|NO_INTERVENTION|Negative Control|Half of the cavities will be restored without application of Teethmate Desensitizer
62514408|NCT02492841|EXPERIMENTAL|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
62514409|NCT02492841|ACTIVE_COMPARATOR|Calcium hydroxide|-material for pulp capping
62514410|NCT02492841|EXPERIMENTAL|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
62514411|NCT03245034|EXPERIMENTAL|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
62514412|NCT02305342||Urinary Tract Infections (UTIs)|Uncomplicated UTIs
62514413|NCT00809237|EXPERIMENTAL|Gefitinib, Hydroxychloroquine|"For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.~After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg of Gefitinib and the MTD dose of HCQ."
62514414|NCT01682148|EXPERIMENTAL|NMJ Targeted|NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
61973165|NCT05000177|OTHER|Pilot study: Healthy subjects group|Healthy subjects will be included to test reliability of single-pulse and paired-pulse TMS, including its associated neurophysiological measurements, and also to test reliability of Liberty electromagnetic tracing system and surface electromyography. Subjects in this group will received the same assessment as the NCNP group.
62147313|NCT05654285|EXPERIMENTAL|Cola beverage with aspartame and acesulfame K|355ml of an orally ingested carbonated cola drink, sweetened with 142mg of aspartame and acesulfame k, combined (soft drink in its commercial presentation)
62147314|NCT05654285|EXPERIMENTAL|Cola beverage with sucrose and stevia|355ml of an orally ingested carbonated cola drink, sweetened with 16g of sucrose and 15.62mg of stevia (soft drink in its commercial presentation)
62514415|NCT01682148|ACTIVE_COMPARATOR|Current Clinical Practice|"Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).~A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment."
62514416|NCT04161183|PLACEBO_COMPARATOR|Placebo|Placebo treatment (shock wave probe w/o energy)
62514417|NCT04161183|EXPERIMENTAL|Extracoporeal shock wave therapy|Extracoporeal shock wave therapy (shock wave probe w/ energy)
62514418|NCT05883033|EXPERIMENTAL|Vacuum Assisted Closure device|Vacuum Assisted Closure device for healing enhancement
62514419|NCT05883033|EXPERIMENTAL|Conventional dressing|Unprocessed Honey, malysia glycerine and betadine ointment
62514420|NCT06331520|ACTIVE_COMPARATOR|NEO-DXMS GROUP|NEPA(1 capsule, day1, PO)+ Olanzapine(5mg, day1-4, PO)+ dexamethasone(12mg, day1; 8mg day2-4, PO/IV).
62514421|NCT06331520|ACTIVE_COMPARATOR|HALF-DXMS GROUP|NEPA(1 capsule, day1, PO)+ Olanzapine(5mg, day1-4, PO)+ dexamethasone(6mg, day1, PO/IV)
62514422|NCT06331520|EXPERIMENTAL|NEO GROUP|NEPA(1 capsule, day1, PO)+ Olanzapine(5mg, day1-4, PO).
62514423|NCT06473506|OTHER|Saliva collection|Self-collected saliva sample
62514424|NCT05098457|EXPERIMENTAL|GP0112|Single injection and optional touch up injection with GP0112
62514425|NCT05098457|ACTIVE_COMPARATOR|Restylane Lyft Lidocaine|Single injection and optional touch up injection with Restylane Lyft Lidocaine
62514426|NCT03637335|EXPERIMENTAL|irradiation + carboplatin|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
62514427|NCT03637335|PLACEBO_COMPARATOR|irradiation + placebo|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
62514428|NCT02253602|EXPERIMENTAL|Ferumoxytol Dose optimization|"We will assess three different dose levels of Ferumoxytol (4 mg/kg, 6 mg/kg, 8 mg/kg).~Images will be acquired at baseline (before Ferumoxytol administration), during injection of Ferumoxytol and 24, 48 and 72 hours after Ferumoxytol administration to identify the optimal moment of scanning.To assess whether USPIOs are sufficiently cleared within 12 weeks from lymph nodes, the MRI scans will be repeated in all six volunteers at 12 weeks after Ferumoxytol administration. Thus, volunteers will undergo an MRI scan for five times. Ferumoxytol is administered only once"
61973166|NCT04104412|EXPERIMENTAL|treatment group A （with mesenchymal stem cell intervention）|observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2\*10\^7/ml normal saline) and Low temperature plasma vaporization ablation
61973167|NCT04104412|NO_INTERVENTION|control group B|observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation
61973168|NCT05816512|EXPERIMENTAL|Gold Nano particle from Pelargonium Graveolens Mouthwash group|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied as a mouthwash for three weeks and then follow up .
62147315|NCT05654285|ACTIVE_COMPARATOR|Cola beverage with sucrose|355ml of an orally ingested carbonated cola drink, sweetened with 37g of sucrose
62514429|NCT02253602|EXPERIMENTAL|Before Surgery|Twenty patients will be measured directly before surgery. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, depending on the results of the dose optimization study. MR parameters will be correlated with pathology data.
62514430|NCT02253602|EXPERIMENTAL|Before Neoadjucant therapy|Ten patients will be measured before start of neoadjuvant chemoradiation. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, based on the dose optimization study. MR parameters will be correlated with pathology data.
62514431|NCT04353024|PLACEBO_COMPARATOR|Placebo|Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min, resulting in a total dose of 0 mg DMT.
62514432|NCT04353024|EXPERIMENTAL|Low dose|Intravenous bolus of 0 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 54 mg DMT.
62514433|NCT04353024|EXPERIMENTAL|Low dose with bolus|Intravenous bolus of 15 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 69 mg DMT.
62514434|NCT04353024|EXPERIMENTAL|High dose|Intravenous bolus of 0 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 90 mg DMT.
62514435|NCT04353024|EXPERIMENTAL|High dose with bolus|Intravenous bolus of 25 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 115 mg DMT.
62514436|NCT06161142||Persistant hypophosphatasemia|"Patients with persistant hypophosphatasemia are highly suspicious for hypophosphatasia, and as such are the main focus of this study.~In case of persistently low alkaline phosphatase (2nd measurement, 2-4 weeks after the 1st measurement) with normal serum calcium and phosphate values (exclusion of secondary hypophosphatemia due to e.g. rickets or malnutrition) and exclusion of other causes of secondary hypophosphatemia, genetic testing for a pathological ALP gene is performed as part of routine diagnostics.~This study involves the structured recording of specific symptoms, the entire course of the disease since childhood, laboratory parameters and genetic testing."
62514437|NCT06161142||Transient hypophosphatasemia (Control group without hypophosphatasia)|"In patients, in which the initial hypophosphatasemia does not confirm with the second ALP testing, the former suspicion of hypophosphatasia must be discarded. With the exclusion of a hypophosphatasia (characterized by a persistant hypophosphatasemia among other criteria) this group of patients qualifies as a control group of patients without hypophosphatasia.~Data from this control group will be analyzed in order to investigate patient historical, clinical and laboratory features that may help in the discrimination of hypophosphatasia patients against healthy individuals."
62514438|NCT04689347|EXPERIMENTAL|FLIRT-bevacizumab|"Bevacizumab intravenous infusion (IV), irinotecan IV, leucovorin (LV) IV, 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU), given every 14 days, in combination with oral (PO) temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days.~The treatment will consist of an induction period of four 28-day cycles of FLIRT- bevacizumab followed by maintenance regimen of 5-FU/LV-bevacizumab administered every 14 days in combination with PO temozolomide according to dose level over days 1-5 every 28 days in patients without progressive disease at the end of the induction period."
62514439|NCT02847208||cystic fibrosis women|It was a cohort of 155 CF women attending the Lyon adult centre. Women attending the CF adult centre in 2014 completed a written questionnaire about their contraceptive choices, frequency of gynaecological follow-up and cervical screening. Other clinical data were collected from the CF adult centre registry.
62514440|NCT02188082|EXPERIMENTAL|IvabRadine hemisulfate Sustained-release Tablets|5-15mg qd
62514441|NCT02188082|PLACEBO_COMPARATOR|placebo|5-15mg qd
62709921|NCT03089814|ACTIVE_COMPARATOR|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
62709922|NCT03089814|ACTIVE_COMPARATOR|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
62709923|NCT05288556|EXPERIMENTAL|Stoma Site Accessory|Stoma site accessory with enteral tube replacement procedure.
62709924|NCT02466828|EXPERIMENTAL|Single patient group receiving Feraheme®|Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
62147316|NCT01894737|PLACEBO_COMPARATOR|immobilisation and placebo|Seven days of one-legged knee immobilisation with placebo supplementation
62147317|NCT01894737|EXPERIMENTAL|immobilisation and creatine|Seven days of one-legged knee immobilisation with creatine supplementation
62147318|NCT00708266|PLACEBO_COMPARATOR|V2|28 hours continuous saline venous infusion.
62147319|NCT00708266|EXPERIMENTAL|V3|28 hours continuous lipid-heparin venous infusion.
62709925|NCT06357104|EXPERIMENTAL|GABA Cocktail|
62709926|NCT02874729||Healthy donors|No interventions
62709927|NCT02874729||Cancer patients|No interventions
62709928|NCT03542617|PLACEBO_COMPARATOR|Normal Saline Solution|The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .
62709929|NCT03542617|ACTIVE_COMPARATOR|10 mg Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia
61973169|NCT05816512|ACTIVE_COMPARATOR|Chlorhexidine gluconate mouth wash group|Chlorhexidine gluconate mouth wash will be applied as a mouthwash for three weeks and then follow up .
61973170|NCT03338855|ACTIVE_COMPARATOR|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
61973171|NCT03338855|PLACEBO_COMPARATOR|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
61973172|NCT05891314|ACTIVE_COMPARATOR|Botox injection post hemorridectomy|after piles excision this group will be subjected to botox injection in the internal sphincter
61973173|NCT05891314|NO_INTERVENTION|Hemorridectomy alone|Just hemorridectomy without botox injection(control group)
61973174|NCT05891314|ACTIVE_COMPARATOR|Hemorridectomy plus internal sphincterotomy|after piles excision patients will undergo internal sphincterotomy
61973175|NCT05558163|OTHER|PPI through traditional penoscrotal approach|cases of erectyl dysfunction who underwent PPI throug penoscrotal approach
61973176|NCT05558163|OTHER|PPI through novel transverse scrotal approach|cases of erectyl dysfunction who underwent PPI throug novel transverse scrotal approach
61973177|NCT06255314|EXPERIMENTAL|trans abdominal retromusclar laparoscopic ventral hernia repar|
61973178|NCT06255314|EXPERIMENTAL|enhanced view totally extraperitoneal laparoscopic ventral hernia repair|
61973179|NCT06255314|EXPERIMENTAL|open sublay ventral hernia repair|
61973180|NCT03577353|EXPERIMENTAL|experimental-DTW|The intervention of the experimental group was based on dual-task treadmill walking while using the Virtual Reality (VR) tool.
61973181|NCT03577353|ACTIVE_COMPARATOR|Control- TMW|The intervention of the control group was based on single-task treadmill walking.
61973182|NCT01643655|EXPERIMENTAL|Autologous Adipose Tissue Derived MSCs|
61973183|NCT06197854||Sublay hernioplasty in incisional hernia|Group that will undergo Sublay hernioplasty in management of incisional hernia
61973184|NCT06197854||Onlay Hernioplasty in incisional hernia|Group that will undergo Onlay hernioplasty in management of incisional hernia
62709930|NCT03542617|ACTIVE_COMPARATOR|40 mg Dexamethasone|The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia
61973185|NCT03721601||Atrial fibrillation|Patients in atrial fibrillation as recorded by 3-lead Holter.
61973186|NCT03721601||Sinus rhythm|Patients in sinus rhythm as recorded by 3-lead Holter.
61973187|NCT03980106|EXPERIMENTAL|Experimental RI-PI|They receive the Reciprocal Inhibition (RI) technique in the first stage and then the Post-isometric Inhibition (PI) technique in the second stage.
62147320|NCT03676088|EXPERIMENTAL|Test group - rhPDGF-BB+MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The test group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB
62147321|NCT03676088|ACTIVE_COMPARATOR|Control group - MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The control group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft alone
62147322|NCT00736502||Patients HIV-1 positive|
62147323|NCT02327442||Volunteers|Healthy Volunteers undergo whole-body 68Ga-NOTA-NFB PET/CT scans 0, 0.5, 1.0, 2.0, and 3.0 hours after tracer injection. During the imaging period, 1 mL blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, and 180 minutes after the injection, for time-activity curve calculations.
62353885|NCT06527196|ACTIVE_COMPARATOR|Early Identification Universal Depression Screening Condition|"In the comparison implementation strategy (early identification universal depression screening), multiple discrete strategies will used including depression screening training in which providers and staff are provided:~1. Training in the depression screening tool (Patient Health Questionnaire)~2. Orientation to the clinical pathway (i.e., screening conducted at every urgent care or emergency department visit and every 30 days for all other medical visits)~3. Expectations for handoff to the next step in the care cascade"
62353886|NCT06527196|EXPERIMENTAL|Team Communication Training Condition|"The team communication training intervention will include:~1. Two initial 2-hour didactic sessions on effective communication between team members (information-based methods) and simulation exercises based on mock clinical cases (practice-based methods)~2. Biweekly performance feedback about intra-team communication in the electronic medical record (demonstration-based methods) provided during regularly scheduled supervision meetings~3. 1-hour booster coaching sessions approximately every 2 months. It is expected that team communication training will take place in the context of weekly or bi-weekly clinical supervision meetings to fit within routine clinical workflows."
62353887|NCT05474807|EXPERIMENTAL|Intervention group|The experimental arm will receive the online strengths use intervention program over a period of 6 weeks, through an LMS software solution.
62353888|NCT01192711|EXPERIMENTAL|insulin + DID|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections per day of insulin glulisine associated with basal insulin glargine; the DID will be used to estimate the CHO content of the food intended to eat. Insulin doses in this group will be adjusted based on DID calculations and pre-meal BG values.
62353889|NCT01192711|NO_INTERVENTION|insulin + usual care|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections of insulin glulisine associated with basal insulin glargine. Insulin doses in group B will be adjusted based on SMBG values reviewed during the doctor office visit.
62709931|NCT04843280|ACTIVE_COMPARATOR|Traditional Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of formal outpatient physical therapy
62709932|NCT04843280|ACTIVE_COMPARATOR|Internet Based Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of internet based rehabilitation regime in the home through the online recovery program, FORCE Therapeutics
62709933|NCT05455892||Elder patients hospitalized for COVID-19 in geriatric short stay units.|All patients over 70 years of age, with a positive Polymerase Chain Reaction or a high presumption of COVID-19, hospitalized in short geriatric units in University Hospital of Lyon, who agree with retrospective collection of their clinical datas.
62709934|NCT06477627|OTHER|Studygroup that will move from inland to the coast for one month|This group normally lives inland and live at the coast in august. We investigate the change to the coast environment
62709935|NCT06477627|OTHER|reference group coast|This group lives inland the whole year round
61973188|NCT03980106|EXPERIMENTAL|Experimental PI-RI|They receive the Post-isometric Inhibition (PI) technique in the first stage and then the Reciprocal Inhibition (RI) technique in the second stage.
61973189|NCT03398395|ACTIVE_COMPARATOR|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
61973190|NCT03398395|ACTIVE_COMPARATOR|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
61973191|NCT00371423|EXPERIMENTAL|Arm 1|
61973192|NCT00371423|OTHER|Arm 2|Control data derived from ATLAS Workhorse Trial
61973193|NCT04242303|EXPERIMENTAL|EM Technique|use of extramedullary technique by means of inertial sensors for the execution of femoral cuts
61973194|NCT04242303|ACTIVE_COMPARATOR|IM Technique|Use of conventional intramedullary technique for the execution of femoral cuts
62147324|NCT02327442||Glioma Patients|Glioma Patients enrolled for the clinical study of diagnosing glioma are performed with both 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scans before surgery.
61973195|NCT02957877|EXPERIMENTAL|LMWH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using low-molecular weight heparin (nadroparin) as anticoagulation
62147325|NCT02327442||Breast Cancer Patients|68Ga-NOTA-NFB PET/CT and 18F-FDG PET/CT scans will undergo in patients with breast cancer before and after neoadjuvant chemotherapy.
62147326|NCT04927078||Participants with COVID 19 diagnosis|We will measure the breathing rate (BR) before and after the clinical diagnosis of COVID 19.
62147327|NCT04927078||Participants without COVID 19 diagnosis|Breathing rates will be measured for the same time duration as the cases.
62147328|NCT02280759|ACTIVE_COMPARATOR|Gelatin Tannate|"Gelatin Tannate:~4 times 250 mg/daily for 5 days for children under 3. years old or 4 times 500mg/daily for 5 days for children older then 3. years and under 5 years."
62147329|NCT02280759|PLACEBO_COMPARATOR|Placebo|Placebo consists of an identical formulation, except active substance.
62514442|NCT00227266|PLACEBO_COMPARATOR|Cohort 1a|Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
62514443|NCT00227266|ACTIVE_COMPARATOR|Cohort 1b|Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.
62514444|NCT00227266|EXPERIMENTAL|Cohort 2|Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
62514445|NCT01569347||1: Cocaine users|Adults, cocaine users
62514446|NCT02456649|EXPERIMENTAL|MarginProbe|Single arm study - MarginProbe in addition to standard procedure
62514447|NCT02744599|EXPERIMENTAL|Device prompting|
62514448|NCT02744599|NO_INTERVENTION|Control|Patients receive standard of care
62514449|NCT03496883|ACTIVE_COMPARATOR|Recombinant Activated Factor VII (rFVIIa)|rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset
62514450|NCT03496883|PLACEBO_COMPARATOR|Placebo|Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset
62514451|NCT06177002||Male COVID-19 patients|Male patients with an age \> 18 affected by COVID-19 with biological samples positive for SARS-CoV-2 but with negative test
62514452|NCT06177002||male healthy individuals|Healthy donors with an age\> 18 accessing the IRCCS OSR Blood Donor Center
62514453|NCT01972347|EXPERIMENTAL|Dabrafenib and Trametinib|Dabrafenib 150mg bid orally and Trametinib 2mg od orally for 52 weeks
62514454|NCT01521078|EXPERIMENTAL|Intervention|Provided access to the Check Your Drinking University version (CYDU).
62514455|NCT01521078|NO_INTERVENTION|Control|No invention control group
62514456|NCT06240689|EXPERIMENTAL|Interventional arm|The experimental group started treatment within 1 month after the end of chemoradiotherapy, and Sintilimab was given intravenously on the first day of each cycle, and a cycle of 21 days, and a total of 18 cycles were expected to be administered, or until disease progression.
62514457|NCT06240689|PLACEBO_COMPARATOR|Control arm|The control group started treatment within 1 month after the end of chemoradiotherapy, and placebo was given intravenously on the first day of each cycle, and a cycle of 21 days, and a total of 18 cycles were expected to be administered, or until disease progression.
62709936|NCT06477627|OTHER|reference group inland|This group lives inland all year round.
62709937|NCT06560944|EXPERIMENTAL|Oral contraceptive|Participants existing oral contraceptive to be ingested at 8am on a day between 3 to 21 of pill consumption. Placebo consumed \~2 hours later
62709938|NCT06560944|PLACEBO_COMPARATOR|Placebo|Placebo ingested at 8am on a day between 3 to 21 of pill consumption. Participants existing oral contraceptive consumed \~2 hours later
62709939|NCT05644873|ACTIVE_COMPARATOR|Magnesium sulfate|Before induction, a bolus of 20 mg/kg magnesium sulfate in 100 mL saline was administered for 15 minutes, followed by a continuous infusion of 20 mg/kg/hour until the skin was closed.
62514458|NCT00706355|EXPERIMENTAL|1|
62514459|NCT03039348||Breast reconstruction|The patients choosing for breast reconstruction after mastectomy for breast cancer.
62514460|NCT03039348||No breast reconstruction|The patients not choosing breast reconstruction after mastectomy for breast cancer.
61973196|NCT02957877|ACTIVE_COMPARATOR|UFH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using unfractionated heparin as anticoagulation
61973197|NCT05485597|EXPERIMENTAL|Study Group: Neurological inpatients with Gait disorders|The group participates in the study intervention (they will undergo the Myosuit-based gait training)
61973198|NCT01314443|EXPERIMENTAL|Placebo + Smoking Cessation|Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
62147330|NCT00038038|EXPERIMENTAL|PET + 18F-fluoromisonidazole|
62514461|NCT04025138|EXPERIMENTAL|female subjects involved in races over 100 km (F>100)|Female subjects involved in races over 100 km (F\>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
62514462|NCT04025138|EXPERIMENTAL|female subjects involved in races less than 60 km (F<60)|Female subjects involved in races less than 60 km (F\<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
62514463|NCT04025138|EXPERIMENTAL|male subjects involved in races over 100 km (H>100)|Male subjects involved in races over 100 km (H\>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
62709940|NCT05644873|ACTIVE_COMPARATOR|Placebo|The control group received only 100 ml of saline 15 minutes before induction.
62709941|NCT02526914|EXPERIMENTAL|Intranasal Oxytocin|Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
62709942|NCT02526914|EXPERIMENTAL|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
62709943|NCT02526914|PLACEBO_COMPARATOR|Intranasal placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.
62709944|NCT02647671|EXPERIMENTAL|Aquamin®|Experimental: Aquamin® (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
62514464|NCT04025138|EXPERIMENTAL|male subjects involved in races less than 60 km (H<60)|Male subjects involved in races less than 60 km (H\<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
62514465|NCT04995757|EXPERIMENTAL|MicroPort NeuroTech Stentretriever|
62514466|NCT04995757|ACTIVE_COMPARATOR|Solitaire FR|
62514467|NCT02975037|EXPERIMENTAL|sildenafil+clarithromycin|Sildenafil 25 mg PO (single dose); Clarithromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Clarithromycin 250 mg PO (single dose)
62514468|NCT02975037|EXPERIMENTAL|sildenafil+itraconazole|Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)
62514469|NCT02409186|ACTIVE_COMPARATOR|Nimotuzumab plus chemoradiotherapy|Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
62514470|NCT02409186|PLACEBO_COMPARATOR|placebo plus chemoradiotherapy|placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
62514471|NCT03033719|ACTIVE_COMPARATOR|Laparotomy|Open surgery
62514472|NCT03033719|EXPERIMENTAL|Laparoscopy|Minimally invasive surgery
62514473|NCT02365948|EXPERIMENTAL|Certolizumab Pegol 100 mg|"Subjects will receive100 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment on Day 1.~To achieve an injectable CZP 100 mg dose, a manual process will be applied by the unblinded site pharmacist."
62514474|NCT02365948|EXPERIMENTAL|Certolizumab Pegol 200 mg|Subjects will receive 200 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 100 mg. Dose escalation will be suspended according to the predefined criteria and process.
62514475|NCT02365948|EXPERIMENTAL|Certolizumab Pegol 400 mg|Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
62514476|NCT02365948|PLACEBO_COMPARATOR|Placebo|For assessment of the Adverse Event (AE) profile, there are 2 placebo controls in each dose group. The placebo subjects receive the injection of saline (NaCl 0.9 %) at the same time (and of the same volume) as the CZP subjects.
62514477|NCT01194102|EXPERIMENTAL|Stroke Community Wellness Program|"Participants with stroke will attend a 12 week Community Wellness Program. The program consists of a Community Based Exercise Program at the YMCA (2x 1 hour exercise sessions per week with specially trained fitness instructors). They will also attend a 1 hour long Living with Stroke education session one time per week and an independent exercise session in the fitness centre one time per week."
62709945|NCT02647671|ACTIVE_COMPARATOR|Calcium Carbonate|Active Comparator: Calcium Carbonate (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
62147331|NCT02225171||Physicians|15 physicians each will be interviewed from the specialties of reproductive endocrinology and obstetrics/gynecology.
62147332|NCT05905549||extended pancreatic transection cohort|cases in which the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy, as judged by postoperative abdominal CT scan.
62514478|NCT01194102|ACTIVE_COMPARATOR|Regular YMCA membership|"The control group will have access to YMCA facilities to use at their discretion but will not attend the Community Based Exercise Program for stroke survivors or the Living with Stroke education program. YMCA staff working with the control group will not receive specialized training in exercise and education for stroke survivors but will be trained on important safety precautions and contraindications to exercise after stroke."
62514479|NCT06443359|EXPERIMENTAL|Group 1: sentinel lymph node procedure with or without select removal of clipped lymph nodes|Group 1: sentinel lymph node procedure with or without select removal of clipped (clinically involved) lymph nodes. Patients who have more than 5 sentinel lymph nodes removed will be stratified into group 2.
62514480|NCT06443359|EXPERIMENTAL|Group 2: axillary lymph node dissection|Group 2: axillary lymph node dissection (with or without sentinel lymph node procedure). Patients who have more than 5 sentinel lymph nodes removed will be stratified into group 2.
62514481|NCT01269450|ACTIVE_COMPARATOR|Utrogestan|
61973199|NCT01314443|EXPERIMENTAL|Supplement + Smoking Cessation|Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
62514482|NCT01269450|PLACEBO_COMPARATOR|placebo|
62514483|NCT01843686|EXPERIMENTAL|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
62514484|NCT01843686|PLACEBO_COMPARATOR|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
62514485|NCT03445299|EXPERIMENTAL|Music|Daily music listening for 30 minutes at bedtime
62514486|NCT02032355||hypotension|
62514487|NCT01393730|EXPERIMENTAL|Abiraterone+prednisone+dutasteride|Abiraterone acetate 1000mg orally once per day + prednisone 5mg orally once per day for two months, followed by abiraterone 1000mg orally once per day + prednisone 5mg orally once per day + dutasteride 3.5mg orally once per day in 28-day cycles until symptomatic or radiographic progression
62514488|NCT00251641|EXPERIMENTAL|Infliximab|
62514489|NCT00251641|ACTIVE_COMPARATOR|Methotrexate|
62514490|NCT04633655||Patients who are receiving a neurotoxic chemotherapy|"List of neurotoxic drugs eligible for enrolment~* Platinum drugs~* Taxanes~* Vinca alkaloids~* Epothilones~* Proteasome inhibitors~* Thalidomide~* Vedotin-based drugs~* checkpoint inhibitors~* Any combination of the aforementioned drugs"
62709946|NCT02647671|PLACEBO_COMPARATOR|Placebo|Placebo (Maltodextrin) - 4 capsules; 2 to be taken in the morning and 2 in the evening
62709947|NCT06571344||25(OH)D < 30 ng/mL|Dialysed patients with vitamin D level (25(OH)D) \< 30 ng/mL administered cholecalciferol
62709948|NCT06571344||25(OH)D 30 - 49.9 ng/mL|Dialysed patients with vitamin D level (25(OH)D) 30-49.9 ng/mL administered cholecalciferol
62353890|NCT04212052|EXPERIMENTAL|split-course radiotherapy|"The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).~Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment."
62709949|NCT06571344||25(OH)D 50-80 ng/mL|Dialysed patients with vitamin D level (25(OH)D) 50-80 ng/mL administered cholecalciferol
62709950|NCT01731925|EXPERIMENTAL|Sunitinib|Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
62514491|NCT06293326|EXPERIMENTAL|Night-time sequence|The night-time treatment sequence consists of two Treatment periods (Period 1 and Period 2) with each period consisting of a single dose of Investigational Medicinal Product (IMP). The two Treatment periods are separated by a least 6-8-day wash-out phase between IMP administration in Period 1 and 2.
62709951|NCT01731925|PLACEBO_COMPARATOR|Placebo|Placebo (for sunitinib). Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
61973200|NCT01314443|EXPERIMENTAL|Placebo + Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
61973201|NCT01314443|EXPERIMENTAL|Supplement+Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
61973202|NCT02042885|EXPERIMENTAL|1: Regimen A Escalation|1: OPB-111001, orally, once weekly
61973203|NCT02042885|EXPERIMENTAL|2: Regimen A Extension|2: OPB-111001, orally, once weekly
61973204|NCT02042885|EXPERIMENTAL|3: Regimen B Escalation|3: OPB-111001, orally, 2 - 3 times per week
62353891|NCT03957356|EXPERIMENTAL|HLBLS-200|HLBLS-200, absorbent hemostactic powder, will be applied intraoperatively to stop blood oozing during hepatic resection.
62353892|NCT03496727||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation, patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
62353893|NCT03496727||Patient controlled analgesia|Anesthesia induction was performed on all patients.At the end of the operation, all patients were performed with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
62353894|NCT03879876|EXPERIMENTAL|Human T Lymphoid Progenitor (HTLP) injection|Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines
62353895|NCT05831527|EXPERIMENTAL|Gut Health Group|Subjects with self-reported digestive issues (abdominal pain, gas production, bloating after meals, or heartburn after meals) Dose: two sachets daily (1g each) mixed with a cold drink, for 12 weeks.
62353896|NCT05831527|EXPERIMENTAL|Exercise Performance Group|Subjects that are physically active three or more days a week. Dose: two sachets daily (1g each) mixed with a cold drink, for 12 weeks.
62353897|NCT02598505|EXPERIMENTAL|Indacaterol|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
62353898|NCT02598505|PLACEBO_COMPARATOR|Placebo|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
62353899|NCT01790789|EXPERIMENTAL|Stress reduction program|
62353900|NCT01790789|OTHER|Attention control|
62353901|NCT00722709|EXPERIMENTAL|LA|Use of Ropivacaine
62353902|NCT00722709|PLACEBO_COMPARATOR|Placebo|Use of 0.9% saline
62353903|NCT05677295|EXPERIMENTAL|Duloxetine|
62353904|NCT05677295|ACTIVE_COMPARATOR|Imipramine|
62353905|NCT04197141|ACTIVE_COMPARATOR|Conventionally-fractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
62353906|NCT04197141|EXPERIMENTAL|Hypofractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
62353907|NCT01080456|ACTIVE_COMPARATOR|Prograf® Capsule 1 mg|
62353908|NCT01080456|EXPERIMENTAL|Tacrolimus Capsule 1 mg|
62353909|NCT02348424|EXPERIMENTAL|Female solithromycin|14 females will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
62353910|NCT02348424|EXPERIMENTAL|Male solithromycin|14 males will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
62353911|NCT05496218|EXPERIMENTAL|Endometriosis group|Endometriosis group are women aged 18-45 with a histologically confirmed diagnosis of endometriosis. At study entry, we will collect morning blood samples.
62353912|NCT05496218|EXPERIMENTAL|Control Group|Control group are women aged 18-45 surgically verified not to have endometriosis. At study entry, we will collect morning blood samples.
62709952|NCT06325215|EXPERIMENTAL|Hydrocolloid tape group|In this group, after the columella and nasal area of preterm infants were cleaned and dried with sterile water, hydrocolloid dressings were applied to the areas in contact with the nasal cannula. NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. If the hydrocolloid dressings melted or peeled off, they were removed, the area was cleaned, and then reapplied. In the data collection process, assessments of the included preterm infants were conducted by two nurses. The upper lip, nasal passages, nasal septum, and columella region of the preterm infants were evaluated.
62514492|NCT06293326|EXPERIMENTAL|Day-time sequence|The day-time treatment sequence consists of two Treatment periods (Period 1 and Period 2) with each period consisting of a single dose of IMP. The two Treatment periods are separated by a least 6-8-day wash-out phase between IMP administration in Period 1 and 2.
62147333|NCT05905549||conventional pancreatic transection cohort|cases in which the pancreatic transection was performed at the pancreatic neck above the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy, as judged by postoperative abdominal CT scan.
62147334|NCT02962024|ACTIVE_COMPARATOR|morphine sulphate|10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
62147335|NCT02962024|PLACEBO_COMPARATOR|bupivacaine hydrochloride|0.25%locally bupivacaine hydrochloride once
62147336|NCT06510413|OTHER|Loxoprofen Sodium Patches (Sequence TR)|"Dosage form: patch~Dosage: 100 mg/ patch~Frequency and duration: single dose~Subjects receive the test product (T) in the first period, then the reference product (R) in the second period."
62147337|NCT06510413|OTHER|Loxoprofen Sodium Patches (Sequence RT)|"Dosage form: patch~Dosage: 100 mg/ patch~Frequency and duration: single dose~Subjects receive the reference product (R) in the first period, then the test product (T) in the second period"
61973205|NCT02042885|EXPERIMENTAL|4: Regimen B Extension|4: OPB-111001, orally, 2 - 3 times per week
62709953|NCT06325215|NO_INTERVENTION|Control group|In this group, premature infants underwent the routine procedure of the NICU. As per the clinic's routine procedure, after cleaning and drying the columella and nasal area with sterile water, NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. In the data collection process, assessments of the included preterm infants were conducted by two nurses. The upper lip, nasal passages, nasal septum, and columella region of the preterm infants were evaluated.
62147338|NCT02993926||Treatment Phase: Enantone|Participants with CPP who were treated with Enantone (≥ 30 μg/kg up to 180 μg/kg) for at least 9 continuous months and who initiated and received the last dose of treatment during the index period from 01 September 1998 to 30 September 2018 (the mean duration of Enantone exposure was 22.3 months, ranging from 10.1 to 52.4 months).
62147339|NCT02993926||Follow Up: Participants No longer Treated for CPP|Participants who had completed their CPP during the treatment phase with Enantone and were no longer on treatment in the follow-up phase (the mean duration of follow up was 8.75 months with a range of 1.9 to 29.5 months).
62147340|NCT02993926||Follow Up: Treated with Non-Enantone GnRHa after Enantone|Participants who were continuing their CPP treatment with a non-Enantone gonadotropin releasing hormone agonist (GnRHa) after treatment with Enantone in the follow-up phase (the mean duration of follow up while on another GnRHa was 10.80 months with a range of 2.8 to 20.5 months, and the mean duration of follow up after stopping treatment was 4.26 months with a range of 0.0 \[i.e. 1 day\] to 12 months).
62147341|NCT02761356||Tc99-MAA and SPECT-CT|26 of the patients were examined with Tc99-MAA and SPECT-C
61973206|NCT00793403||1|As per routine clinical care
62147342|NCT02761356||Tc99-MAA , SPECT-CT and PET-CT|24 patients were examined with Tc99-MAA , SPECT-CT and PET-CT.
61973207|NCT02467010|EXPERIMENTAL|Bortezomib, cyclophosphamide, dexamethason|"* To assess the efficacy of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy.~* To assess the safety of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy in patients with refractory or relapsed multiple myeloma."
61973208|NCT06378567|PLACEBO_COMPARATOR|Placebo comparator|Investigational liquid shot beverage product: prototype 60ml product that does not contain study ingredients
61973209|NCT06378567|EXPERIMENTAL|Experimental Product 1|Developmental liquid shot beverage product: prototype 60ml product that contains study ingredients
61973210|NCT06378567|EXPERIMENTAL|Experimental Product 2|Developmental liquid shot beverage product: prototype 60ml product that contains study ingredients
61973211|NCT05127005|EXPERIMENTAL|Trapeziectomy|Trapeziectomy
61973212|NCT05127005|SHAM_COMPARATOR|Sham surgery|Sham surgery
62147343|NCT02102724|EXPERIMENTAL|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
62147344|NCT02102724|PLACEBO_COMPARATOR|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
62147345|NCT02343094|EXPERIMENTAL|PBA 7,5g/d|Treatment for 14 days
62514493|NCT00850681|EXPERIMENTAL|1|PEP005 (ingenol mebutate) Gel
62514494|NCT04897113|EXPERIMENTAL|plasmapheresis with albumin compensation|a course of hardware plasmapheresis procedures with replacement by colloidal (5% albumin solution) and crystalloid solutions (saline) in a ratio of 1: 3
62514495|NCT04897113|EXPERIMENTAL|plasmapheresis without albumin compensation|a course of hardware plasmapheresis procedures without replacement by albumin solution, only crystalloid solutions (saline).
62514496|NCT05947526||Women referring to infertility clinic for IVF treatment|Women who were referred to infertility clinic with complaint of not having baby go through IVF treatment, and having oocyte pick-up procedure with different sizes of ovarian follicles
61973213|NCT05127005|OTHER|Non-randomized observational arm|Non-randomized observational arm (trapeziectomy, not blinded)
62147346|NCT02343094|EXPERIMENTAL|PBA 15g/d|Treatment for 14 days
62147347|NCT00943969|OTHER|obemo|
62147348|NCT00905294||coronary artery disease|Subjects with coronary artery disease undergoing percutaneous coronary intervention
62147349|NCT06511219|ACTIVE_COMPARATOR|maxillary segmental distalization using infrazygomatic digitally printed appliances|maxillary segmental distalization using infrazygomatic digitally printed appliances
62147350|NCT06511219|ACTIVE_COMPARATOR|maxillary segmental distalization using palatal digitally printed appliances|maxillary segmental distalization using palatal digitally printed appliances
62514497|NCT05680870|NO_INTERVENTION|Control group|Control grp will not receive omeprazole . They will receive chemotherapy protocols only
62514498|NCT05680870|EXPERIMENTAL|Intervention group|Intervention group will receive omeprazole plus chemotherapy protocols
62709954|NCT03621280|EXPERIMENTAL|Levoketoconazole|Levoketoconazole taken twice daily up to 1200 mg daily
62709955|NCT03819309|EXPERIMENTAL|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
62709956|NCT03819309|ACTIVE_COMPARATOR|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
62514499|NCT03005067|EXPERIMENTAL|Carbomer 980 (1146A)|Participants will be administered test product (nasal spray) containing carbomer 980 gel. Three actuations per nostril per dose will be applied, each actuation will be 140µL (microliters) i.e. equivalent to 140mg.
61973214|NCT05381116|ACTIVE_COMPARATOR|Experimental Arm|Avation System
62147351|NCT01214200|EXPERIMENTAL|High Intensity Non Invasive Pos.Pressure|The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV) for 90 days. Participants will receive HINPPV via bilevel positive airway pressure (BiPAP Synchrony) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O (centimeters of water); or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
62353913|NCT05395741|EXPERIMENTAL|R1 - Regorafenib Arm|R1 - the experimental group. Standard oncological treatment will be started. Additionally, patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy.
62353914|NCT05395741|NO_INTERVENTION|R2 - Control Group|R2 - the control group - will receive only standard treatment. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
62353915|NCT03794713|EXPERIMENTAL|Patient support tool group|Subjects were managed the HR by using the Patient Support Tool through a smart phone application and a wristband and be guided by physicians
62353916|NCT03794713|NO_INTERVENTION|Control group|Subjects were received a usual patient care at baseline, which left to the discretion of physicians, without any specific intervention at follow-up period
62353917|NCT02767180||Critical care survivors|Former ICU-patients recruited six months to three years after discharge from the ICU
62353918|NCT02767180||Matched controls|Control patients who have not been critically ill, matched for age and sex.
62353919|NCT02376595||Rocuronium Bromide|Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
62353920|NCT06027944|EXPERIMENTAL|Scene|High fidelity scene of nature emitted from a monitor
62353921|NCT06027944|ACTIVE_COMPARATOR|Scrambled scene|The same pixels that are used to create the scene in the alternate arm will be randomly scrambled on the monitor
62353922|NCT01206790|EXPERIMENTAL|Narrative Exposure Therapy (NET)|
62514500|NCT03005067|PLACEBO_COMPARATOR|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980. Three actuations of placebo nasal spray per nostril per dose; each actuation will be 140µL.
61973215|NCT05381116|SHAM_COMPARATOR|Control Arm|Sham Avation System
62353923|NCT01206790|NO_INTERVENTION|Waitinglist Control Group|
62353924|NCT01788072|ACTIVE_COMPARATOR|Intranasal Oxytocin|
62353925|NCT01788072|PLACEBO_COMPARATOR|Placebo|
62353926|NCT03185416|NO_INTERVENTION|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
62353927|NCT03185416|EXPERIMENTAL|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
62353928|NCT00873288|ACTIVE_COMPARATOR|Usual Care mailing intervention|routine colposcopy reminder letter mailed
62353929|NCT00873288|EXPERIMENTAL|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
62353930|NCT02016222|EXPERIMENTAL|Tears sampling|
62353931|NCT01412060|EXPERIMENTAL|Cariprazine - Open-label Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
62353932|NCT01412060|EXPERIMENTAL|Placebo - Double-blind Treatment Phase|Participants received placebo orally once a day for 26 to 72 weeks.
62353933|NCT01412060|EXPERIMENTAL|Cariprazine - Double-blind Treatment Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks
62353934|NCT05831345|ACTIVE_COMPARATOR|S Group|Patients receiving sufentanil during induction of general anesthesia
62353935|NCT05831345|EXPERIMENTAL|M Group|Patients receiving methadone during induction of general anesthesia
62353936|NCT02452112|ACTIVE_COMPARATOR|Lidocaine|Active arm with administration of active 5% Lidocaine patch
61973216|NCT02643082|EXPERIMENTAL|GFF MDI, 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
61973217|NCT02643082|PLACEBO_COMPARATOR|Placebo MDI|Placebo Metered Dose Inhaler (MDI)
61973218|NCT03108833|EXPERIMENTAL|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
62353937|NCT02452112|PLACEBO_COMPARATOR|Placebo|Placebo arm with administration of placebo patch
62353938|NCT04011800|ACTIVE_COMPARATOR|Catheter ablation|Patients will undergo catheter ablation of atrial fibrillation.
62353939|NCT04011800|EXPERIMENTAL|Risk factor modification|Patiemt will undergo risk factor intervention and antiarrhythmic drugs
62353940|NCT00787540||I|Coronary Slow Flow Patients
62353941|NCT00787540||II|Coronary Artery Occlusion Patients
62353942|NCT00209170|EXPERIMENTAL|Beating the Blues CBT + Escitalopram|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with the selective serotonin reuptake inhibitor (SSRI) antidepressant, escitalopram (10 mg taken orally once or twice daily) for 6 months
62709957|NCT04894682||Vaccinated Case|Pulmonary nodules/lung cancer patients who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
62514501|NCT06177314||Active contact dermatitis|patient suffering from contact dermatitis and presenting active cllinical lesions. Allergic or non allergic form of contact dermatitis was diagnose based on patch-test results and exposure assessment
62514502|NCT03883282||study group|Patients who have been participated in RCT in the period from 2011 to 2018 (study group)
62514503|NCT03883282||control group|- Patients who have never participated in RCT
62514504|NCT02540499|EXPERIMENTAL|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
62514505|NCT01176019|EXPERIMENTAL|Interactive Video|In addition to standard care, the experimental arm will receive an interactive video designed to inform and educate patients about the choices that exist concerning prenatal screening and diagnosis.
62514506|NCT01176019|NO_INTERVENTION|Control|A control arm will receive standard care, which is the opportunity to meet with a genetic counselor.
62514507|NCT04197128|ACTIVE_COMPARATOR|Resorbable collagen membrane and bone graft|Subjects will receive bovine derived bone graft and resorbable collagen membrane for augmentation.
62514508|NCT04197128|EXPERIMENTAL|Ribose cross-linked collagen matrix|Subjects will receive ribose cross linked collagen matrix for augmentation
61973219|NCT03108833|EXPERIMENTAL|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
61973220|NCT03108833|ACTIVE_COMPARATOR|Active Comparator Controlled Group|Alteplase:100mg if weight\>=65kg, 1.5mg/kg if weight\<65kg
62514509|NCT00071084|EXPERIMENTAL|HuMax-CD4 280 milligrams (mg)|
62514510|NCT00071084|EXPERIMENTAL|HuMax-CD4 980 mg|
62514511|NCT02197026|EXPERIMENTAL|Synvisc group|injection of Synvisc® at day 1, day 8 and day 15; in the mean time it will be recommended to decrease or stop all other OA treatments
62514512|NCT02197026|ACTIVE_COMPARATOR|Osteoarthritis standard treatment group|Treatment will be left to the discretion of the investigator who could prescribe any therapies, except viscosupplementation product
62514513|NCT04800341||Patients ESADA follow-up|Patients included in the ESADA European database and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire.
61973221|NCT00680667|EXPERIMENTAL|Trametes Versicolor|Females with Stage I-III infiltrating ductal adenocarcinoma of the breast being treated with Trametes versicolor capsules for 6 weeks after receiving radiation therapy.
61973222|NCT02050360|EXPERIMENTAL|Sildenafil 80 mg|Sildenafil 80 mg
61973223|NCT02050360|EXPERIMENTAL|Sildenafil 40 mg|Sildenafil 40 mg
62147352|NCT03051568|EXPERIMENTAL|PTCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
62147353|NCT06488742|EXPERIMENTAL|3% Kanuka Oil Cream|3% kanuka oil cream will be applied topically to the affected area twice a day for 28 days
62147354|NCT06488742|ACTIVE_COMPARATOR|1% Hydrocortisone Cream|1% Hydrocortisone Cream will be applied topically to the affected area twice a day for 28 days
62514514|NCT01417819|OTHER|SMS reminder|SMS reminders four days and one day before their appointments
62514515|NCT04953078|EXPERIMENTAL|10 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (10 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
62514516|NCT04953078|EXPERIMENTAL|50 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (50 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
62514517|NCT04953078|EXPERIMENTAL|100 μg Baiya SARS-CoV-2 VAX1, Adult Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
62147355|NCT01604122||Patients|Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
62147356|NCT01604122||Caregivers|Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
62147357|NCT05283018||Surgery under general anesthesia|Patients undergoing urgent or scheduled surgery at Lariboisière Hospital
62514518|NCT04953078|EXPERIMENTAL|10 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (10 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
62514519|NCT04953078|EXPERIMENTAL|50 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (50 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
62514520|NCT04953078|EXPERIMENTAL|100 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
61973224|NCT02050360|PLACEBO_COMPARATOR|Placebo|placebo
61973225|NCT05798949|ACTIVE_COMPARATOR|Exposure in vivo-therapy|"In the first phase, patients with idiopathic small fiber neuropathy will receive exposure in vivo therapy for at least 4 weeks, 2 sessions/week.~In the second phase, the therapy will be expanded with either 4 weeks or 6 weeks, 2sessions/week, depending on the outcome of the first session."
61973226|NCT05798949|ACTIVE_COMPARATOR|Graded activity-therapy|"In the first phase, patients with idiopathic small fiber neuropathy will receive graded activity-therapy for at least 4 weeks, 2 sessions/week.~In the second phase, the therapy will be expanded with either 4 weeks or 6 weeks, 2sessions/week, depending on the outcome of the first session."
61973227|NCT05798949|ACTIVE_COMPARATOR|Acceptance and commitment therapy|"In the first phase, patients with idiopathic small fiber neuropathy will receive acceptance and commitment therapy for at least 4 weeks, 2 sessions/week.~In the second phase, the therapy will be expanded with either 4 weeks or 6 weeks, 2sessions/week, depending on the outcome of the first session."
62514521|NCT00838942||1|Patients suffering from both Alzheimer's disease and low vision due to a bilateral impeding cataract.
62514522|NCT03865537|EXPERIMENTAL|Cold snare & Eleview injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Eleview
62514523|NCT03865537|EXPERIMENTAL|Cold Snare & Placebo injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Placebo
62514524|NCT03865537|ACTIVE_COMPARATOR|Hot snare & Eleview injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Eleview
62147358|NCT06002867|ACTIVE_COMPARATOR|Group SAPB (Serratus anterior plane block)|"Active Comparator: Group SAPB (Serratus anterior plane block) After the operation is completed, the block operation will be performed while intubated. The patient will be in the supine position.~The area where the procedure will be performed will be cleaned with povidone iodine.~The latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs using a 22-gauge, 80 mm insulated Quincke type needle with the 'in plane' technique, accompanied by a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath. .~After the fascia between the two muscles is fixed, the block needle will be advanced from caudal to cranial and 40 ml (20 ml local anesthetic + 20 ml saline) 0.25% local anesthetic will be injected on the serratus muscle between the two muscles."
62147359|NCT06002867|NO_INTERVENTION|Group Control|The action will not be applied
62514525|NCT03865537|ACTIVE_COMPARATOR|Hot snare & Placebo injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Placebo
62709958|NCT04894682||Vaccinated Healthy Control|Healthy people who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
61973228|NCT02468544|EXPERIMENTAL|Single Arm Intervention Study|All participants will receive individualized text messages based on a schedule determined during the development and refinement of the mHealth text messaging intervention (i.e., once or twice a week). All participants will receive text messages for: 1) medication reminders, 2) appointment reminders, and 3) text messages addressing barriers (educational information to improve HIV knowledge) or promoting facilitators (e.g., routinizing taking of HIV antiretroviral medication) of care engagement. Each participant will complete baseline assessments, and will select their preferences for personalized messages on the day of baseline assessments. Text messages will be deployed for the duration of the 30-day trial. Participants will be followed-up at the completion of the 30-day intervention. Each participant will be asked to complete a follow-up survey, including questions on the acceptability of the mHealth intervention.
62353943|NCT00209170|ACTIVE_COMPARATOR|Beating the Blues CBT + Placebo|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with placebo (taken orally one to two tablets daily) for 6 months
62353944|NCT06380582|EXPERIMENTAL|Air flow|low airflow and high airflow
62353945|NCT06380582|EXPERIMENTAL|Temperature|23C 40%RH or 35C 40%RH
62353946|NCT04446871|PLACEBO_COMPARATOR|Standard care|Placebo
62353947|NCT04446871|EXPERIMENTAL|Methylene blue|Methylene blue
62353948|NCT02219997|EXPERIMENTAL|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
62353949|NCT02219997|ACTIVE_COMPARATOR|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
62353950|NCT01462916||honey, no honey|
62353951|NCT01919151||Gastrointestinal cancer patients|Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
62353952|NCT03229681|EXPERIMENTAL|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
62353953|NCT03229681|ACTIVE_COMPARATOR|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
62353954|NCT02066519|EXPERIMENTAL|Physical exercise arm|Arm with physical exercise on rowing machine between M3 and M6
62353955|NCT02066519|NO_INTERVENTION|Control arm|Arm with standard medical care without additional physical exercise
62353956|NCT01867645|ACTIVE_COMPARATOR|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
62353957|NCT01867645|PLACEBO_COMPARATOR|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
62353958|NCT02030665|ACTIVE_COMPARATOR|Standardized MET plus CB (SMET-CB)|Motivational Enhancement plus Cognitive-Behavioral treatment
62353959|NCT02030665|EXPERIMENTAL|SMET+ CM (SMET-CB-CM)|Motivational Enhancement plus CB treatment plus contingency management
62353960|NCT02030665|EXPERIMENTAL|Individualized Assessment & Treatment (IATP)|Individualized Assessment and Treatment Program; Cognitive-Behavioral Treatment based on in-depth field monitoring of patient behavior
62353961|NCT02030665|EXPERIMENTAL|IATP + CM (IATP-CM).|Individualized Assessment and Treatment plus Contingency Management
62353962|NCT03803202|EXPERIMENTAL|Stage 1, Group 1 Adults, ASP3772 Low dose|Healthy adults aged 18 to 64 years received a low dose \[1 microgram (μg)\] of ASP3772 intramuscularly on Day 1.
62353963|NCT03803202|EXPERIMENTAL|Stage 1, Group 1 Adults, ASP3772 Medium dose|Healthy adults aged 18 to 64 years received a medium dose (2 μg) of ASP3772 intramuscularly on Day 1.
62353964|NCT03803202|EXPERIMENTAL|Stage 1, Group 1 Adults, ASP3772 High dose|Healthy adults aged 18 to 64 years received a high dose (5 μg) of ASP3772 intramuscularly on Day 1.
62353965|NCT03803202|ACTIVE_COMPARATOR|Stage 1, Group 1, PCV13 Pooled Comparator|Healthy adults aged 18 to 64 years received a single dose of PCV13 0.5 milliliter (mL) intramuscularly on Day 1. Data from participants in each group given PCV13 were pooled for comparison with each ASP3772 dose group (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose).
62353966|NCT03803202|EXPERIMENTAL|Stage 2, Group 2 Older Adults, ASP3772 Low dose|Healthy older adults aged 65 to 85 years received a low dose (1 μg) of ASP3772 intramuscularly on Day 1.
62514526|NCT00549016|EXPERIMENTAL|1|
62514527|NCT00706992|EXPERIMENTAL|Arm I - Adj-4 A2 F5 cells|Patients receive anti-MART-1 F5 TCR-transduced peripheral blood lymphocytes (PBLs) intravenously (IV) over 20-30 minutes on day 0. 1 x 10e9 to 5 x 10e10 IV.
62709959|NCT04894682||Unvaccinated Case|Pulmonary nodules/lung cancer patients who are not vaccinated against the SARS-CoV-2
62709960|NCT06376955|EXPERIMENTAL|Group A High intrerval trainig exercise group|Group A will receive high intensity interval exercise 2 times per week for 4 months in addition to intermitted fasting diet.
62709961|NCT06376955|EXPERIMENTAL|Group B Focused ultrasound group|Group B will receive focused ultrasound 2 times per week for 4 months in addition to intermitted fasting diet.
62709962|NCT05176587||Integrated group (SPOC)|
62709963|NCT05176587||Control group|
62709964|NCT05656157||Antifungal treatment prescribed by the clinician for an invasive fungal disease|
62709965|NCT05656157||Antifungal treatment recommended by the clinical decision support system|
62514528|NCT00706992|EXPERIMENTAL|Arm II-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously.
61973229|NCT01698801|EXPERIMENTAL|Lenalidomide plus dexamethasone|Lenalidomide plus low-dose dexamethasone
62514529|NCT00706992|EXPERIMENTAL|Arm III-Adj-4 A2 F5 cells + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
62514530|NCT00706992|EXPERIMENTAL|Arm IV-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide+SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
62514531|NCT00706992|EXPERIMENTAL|Arm V-Adj-4 A2 F5 cells + ALVAC MART-1:26-35(27L) Vaccine|Patients receive anti-MART-1 F5 TCR-transduced PBLs IV over 20-30 minutes on day 0, and ALVAC-MART-1 vaccine SC on days 0 and 14. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10\^6.4 to 10\^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
62514532|NCT00706992|EXPERIMENTAL|Arm VI-Adj-4 A2 F5 cells + ALVAC MART-1 VAccine + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs and ALVAC-MART-1 vaccine as in arm V, and low-dose aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10\^6.4 to 10\^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL)+ 125,000 IU/kg/day subcutaneously.
62514533|NCT00706992|EXPERIMENTAL|Arm VII-Adj-4 A2 ALVAC MART-1:26-35(27L) Vaccine|Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10\^6.4 to 10\^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
62514534|NCT05430945|EXPERIMENTAL|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62514535|NCT03224247|ACTIVE_COMPARATOR|Transverse splitting|transverse cutting and/or pulling of lower uterine segment during lower segment cesarean section.
61973230|NCT03441854||HFNC group|The investigators will prospectively include 30 patients admitted to 13- bed PICU after liver transplantation and treated with HFNC oxygen delivery after extubation.
62147360|NCT02504801|ACTIVE_COMPARATOR|nebulized Budesonide 2mg/4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
62147361|NCT02504801|PLACEBO_COMPARATOR|nebulized saline 4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
61973231|NCT03441854||Control Group|For each study group patient, a match control subject (matching criteria: age ± 10%, PaO2/FiO2 ± 30, diagnosis, Model for End-Stage Liver Disease (MELD) ± 10%) will be chosen from a group of 70 patients treated with conventional oxygen delivery (Venturi Mask) during the previous 2 years.
62514536|NCT03224247|ACTIVE_COMPARATOR|Vertical splitting|vertical splitting,of lower uterine segment during lower segment cesarean section.
62514537|NCT03173170|EXPERIMENTAL|TAK-954 0.2 mg + Itraconazole 200 mg and TAK-954 0.2mg|TAK-954 0.2 milligram (mg), infusion, intravenously, once on Day 1 of First Intervention Period, followed by a minimum of 7-day washout period, further followed by Itraconazole 200 mg, capsule, orally, once daily on Days 1 to 8 along with TAK-954 0.2 mg, infusion, intravenously on Day 4 of Second Intervention Period.
62514538|NCT06423157|EXPERIMENTAL|Experimental group|"The intervention period will last 6 weeks, with a periodicity of 2 weekly sessions of 20 minutes each. All interventions will take place at the Palacio de los Deportes de Murcia. All interventions will be carried out by the same physiotherapist, following the same protocol.~The intervention of the experimental group will consist of a protocol using plyometric and stability exercises."
62514539|NCT06423157|NO_INTERVENTION|Control group|The athletes included in the control group will not undergo any intervention and will continue with their usual routine.
62514540|NCT01655524|EXPERIMENTAL|ASSUAGE Protocol|There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared.
62514541|NCT04637633|EXPERIMENTAL|Cyclosporine A|All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
62514542|NCT04904016|EXPERIMENTAL|Intervention FlowOx treatment|Each participating subject will be provided with one FlowOx™ system, which will be used about 1 hour per day every day of the week for a 4-week period with the option to extend the treatment time to up to 6 months if the patients would like to continue.
62514543|NCT01597479|NO_INTERVENTION|No dPNBs group|Patients in this group didn't receive any intervention in the postoperative period.
62514544|NCT01597479|EXPERIMENTAL|dPNBs group|"Patients in this group received ultrasound guided dPNBs on radial and median nerves (target nerves of TRA) in the postoperative period, before discharge.~The procedural objective of dPNBs was to place local anesthetic around the target nerves to achieve a long lasting, sensitive and selective block in the surgical area. dPNBs were performed with 5 ml/nerve of levobupivacaine 0,125%.~Ultrasound guidance allowed us to verify the correct distribution of LA around the target nerves target and optimize needle position if it was necessary, always avoiding the intraneural injection."
62514545|NCT06069869|EXPERIMENTAL|MM 30mg; then MMS 45mg; then MMS 60mg|Participants first receive MMS with 30 mg for one month, then MMS with 45 mg of iron for one month, then MMS with 60 mg of iron for one month
61973232|NCT01627522|ACTIVE_COMPARATOR|Finastide low dose|2 weeks of daily 5mg finastride before operation
62514546|NCT06069869|EXPERIMENTAL|MM 30mg; then MMS 60mg; then MMS 45mg|Participants first receive MMS with 30mg for one month, then MMS with 60mg of iron for one month, then MMS with 45 mg of iron for one month
62147362|NCT03153176|EXPERIMENTAL|intervention|Training program for Physical Education teacher. Individual level: moderate to vigorous physical activity. Organizational level: school health policy for healthy lifestyle
62147363|NCT03153176|NO_INTERVENTION|no intervention|Physical Education and school curriculum as usual
62147364|NCT02203656|PLACEBO_COMPARATOR|Placebo Supplement|Daily placebo supplement for 30 days after discharge.
62514547|NCT06069869|EXPERIMENTAL|MM 45mg; then MMS 30mg; then MMS 60mg|Participants first receive MMS with 45 mg for one month, then MMS with 30 mg of iron for one month, then MMS with 60 mg of iron for one month
62514548|NCT06069869|EXPERIMENTAL|MM 45 mg; then MMS 60mg; then MMS 30mg|Participants first receive MMS with 45 mg for one month, then MMS with 60 mg of iron for one month, then MMS with 30 mg of iron for one month
62514549|NCT06069869|EXPERIMENTAL|MM 60mg; then MMS 30mg; then MMS 45mg|Participants first receive MMS with 60 mg for one month, then MMS with 30 mg of iron for one month, then MMS with 45 mg of iron for one month
62514550|NCT06069869|EXPERIMENTAL|MM 60mg; then MMS 45mg; then MMS 30mg|Participants first receive MMS with 60 mg for one month, then MMS with 45 mg of iron for one month, then MMS with 30 mg of iron for one month
62147365|NCT02203656|EXPERIMENTAL|Nutritional Supplement|Daily nutritional supplement for 30 days after discharge.
62147366|NCT02203656|EXPERIMENTAL|In-home exercise + placebo|in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
62147367|NCT02203656|EXPERIMENTAL|In-home exercise + nutrition|in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
62353967|NCT03803202|EXPERIMENTAL|Stage 2, Group 2 Older Adults, ASP3772 Medium dose|Healthy older adults aged 65 to 85 years received a medium dose (2 μg) of ASP3772 intramuscularly on Day 1.
62353968|NCT03803202|EXPERIMENTAL|Stage 2, Group 2 Older Adults, ASP3772 High dose|Healthy older adults aged 65 to 85 years received a high dose (5 μg) of ASP3772 intramuscularly on Day 1.
62353969|NCT03803202|ACTIVE_COMPARATOR|Stage 2, Group 2, PCV13 Pooled Comparator|Older adults aged 65 to 85 years received a single dose of PCV13 0.5 mL intramuscularly on Day 1. Data from participants in each group given PCV13 were pooled for comparison with each ASP3772 dose group (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose).
62353970|NCT03803202|ACTIVE_COMPARATOR|Stage 2, Group 3, PPSV23 Comparator|Older adults aged 65 to 85 years who had been previously vaccinated with PCV13, were enrolled and received a single of dose PPSV23 on Day 1.
62353971|NCT06311110||DCD case group|The case group consists of children with developmental coordination disorder.
61973233|NCT01627522|ACTIVE_COMPARATOR|Finastide high dose|4 weeks of daily 5mg finastride before operation
61973234|NCT01627522|NO_INTERVENTION|Control|Control
62353972|NCT06311110||TDC control group|The control group consists of typically developing children, grade and gender matched with the DCD case group.
62353973|NCT03411577|EXPERIMENTAL|Behavioral Intervention|The adolescent HIV/STI risk-reduction intervention aims to: (a) increase knowledge of HIV risk and prevention; (b) strengthen behavioral beliefs regarding abstinence and safer sex; (c) increase self-efficacy and intentions to avoid unsafe sex; and (d) increase sexual communication and refusal skills. The mother component includes much of the same prevention knowledge and addresses parent-teen sexual risk communication, monitoring, and sexual role modeling. Interventions are held on two consecutive Saturdays for 6 hours each day. Mothers' groups meet separately from daughters' groups, although the groups will come together for the last module of each day.
62353974|NCT03411577|NO_INTERVENTION|Control Group|"The control / comparison group is essentially a no intervention / wait-list control group. However, during pilot testing, participants expressed a strong desire to engage in some type of health activity. As a result, the control group members, both mothers and daughters, participated in a brief educational activity on reducing risk for cardiovascular disease. The educational activity was limited to a few hours on one Saturday. Participants returned the following week to complete post-test questionnaires along with the participants in the experimental group."
62353975|NCT02146833|EXPERIMENTAL|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
62353976|NCT02146833|EXPERIMENTAL|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
62353977|NCT02146833|EXPERIMENTAL|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
61973235|NCT05984732|EXPERIMENTAL|Reminiscence with digital storytelling|Older adults in the intervention group will receive 10 sessions of life-review or reminiscence discussion with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). At the end of the study, they create a digital storybook based on their previous discussion.
61973236|NCT05984732|SHAM_COMPARATOR|Social wellness with scrapbook or journal|Older adults in the control group will have general social wellness discussion with the young adult volunteers. At the end of the study, they will create a journal/scrapbook.
62147368|NCT02203656|EXPERIMENTAL|Testosterone|Single testosterone injection within 24 hours of hospital discharge.
62147369|NCT04148378||Patients|Patients who have been diagnosed with colorectal cancer.
62147370|NCT00800176|PLACEBO_COMPARATOR|Placebo|"During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast.~During the 12-week double-blind treatment period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test."
62147371|NCT00800176|EXPERIMENTAL|RO4998452 10mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 10 mg of RO4998452.
62353978|NCT04693923|EXPERIMENTAL|Group A (rapid fluid challenge)|Patients will receive a rapid fluid challenge (4ml/kg of crystalloids in 5 minutes using a syringe of 60 mL and a timer in the multiparameter monitor).
62353979|NCT04693923|ACTIVE_COMPARATOR|Group B (standard fluid challenge)|Patients will receive a standard fluid challenge (500 ml of crystalloids in 30 minutes).
62353980|NCT03573440|NO_INTERVENTION|no mindful eating education|"* Subject will be asked to eat their meal with an investigator present.~* They will inform the investigator verbally when they are feeling full.~* After they have decided to end their meal, they will be asked to fill out a questionnaire"
62514551|NCT02651142|EXPERIMENTAL|SLNB with para-SLN dissection|patients receive sentinel lymph node biopsy patients receive para-sentinel lymph node dissection
62514552|NCT02651142|EXPERIMENTAL|SLNB without para-SLN dissection|patients received sentinel lymph node biopsy
62514553|NCT02066337|PLACEBO_COMPARATOR|placebo gel|scaling and root planing with placebo gel
62514554|NCT02066337|ACTIVE_COMPARATOR|Ozonated olive oil gel|scaling and root planing with Ozonated olive oil gel
62709966|NCT03683979|EXPERIMENTAL|Interpretation bias modification program|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
62147372|NCT00800176|EXPERIMENTAL|RO4998452 2.5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 2.5 mg of RO4998452.
62147373|NCT00800176|EXPERIMENTAL|RO4998452 20mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 20 mg of RO4998452.
62353981|NCT03573440|EXPERIMENTAL|mindful eating education|"* After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.~* They will inform the investigator verbally when they are feeling full.~* After they have decided to end their meal, they will be asked to fill out a questionnaire"
62353982|NCT05682313|EXPERIMENTAL|Elastography arm|single arm that includes all patient who have consented for ultrasound elastography
62353983|NCT03431909|EXPERIMENTAL|Kallikrein group|Subjects receive kailikang treatment according to real clinical practice (suggest above 14 days treatment),0.15 peptide nucleic acids(PNA), once a day.
62514555|NCT03416491|EXPERIMENTAL|NC_30|Non-cirrhotic subjects were medicated with KW-136 capsules 30 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
62514556|NCT03416491|EXPERIMENTAL|NC_60|Non-cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
62514557|NCT03416491|EXPERIMENTAL|LC_60|Cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
62514558|NCT01852734|OTHER|embolizations, uterine fibroid|embolization interventions with microspheres
62514559|NCT04598334||COVID-19 positive by RT-PCR|specified number of COVID-19 positive patients will be followed up from admission to outcome (discharge/death/referral). Blood samples will be tested at different time points; cytokines and stool microbiota will be tested at the end of the study and we will analyze the study findings.
62514560|NCT04625452|EXPERIMENTAL|BBCC+5A's+GS|Brief behavior change counseling using 5A's + Guiding style (from motivational interviewing) + Printed education materials ( at baseline, 12 weeks, 24 weeks)
62514561|NCT04625452|NO_INTERVENTION|Normal care|They will receive the normal care: simple advice on changing lifestyle risk factors + medications for diabetes or hypertension ( at baseline, 12 weeks, 24 weeks)
62514562|NCT02333487|EXPERIMENTAL|Lu AF35700 (Group D1)|Up to 3 PET scans, besides baseline scan, using \[11C\]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
62514563|NCT02333487|EXPERIMENTAL|Lu AF35700 (Group D2)|Up to 3 PET scans, besides baseline scan, using \[11C\]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
62514564|NCT02333487|EXPERIMENTAL|Lu AF35700 (Group 5-HT6)|Up to 3 PET scans, besides baseline scan, using \[11C\]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700
62514565|NCT04916496|EXPERIMENTAL|ACT-LCP Group|An Acceptance and Commitment Therapy-based healthy lifestyle counselling programme (ACT-LCP) and routine psychiatric outpatient/rehabilitation services of the study hospital.
62514566|NCT04916496|PLACEBO_COMPARATOR|Control Group|A healthy lifestyle talk and routine psychiatric outpatient/rehabilitation services of the study hospital.
62514567|NCT04432675|EXPERIMENTAL|hydroxyethl starch group|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
62514568|NCT04432675|ACTIVE_COMPARATOR|The control group|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
62514569|NCT04825717|EXPERIMENTAL|Intervention group|Patients in this group will be administered nutrition and fluid plans prepared by the department dietitian using calorimetry-based measurements
62514570|NCT04825717|NO_INTERVENTION|Control group|Nutrition plans of patients in this group will be calculated by the department dietitian using the standard, currently accepted RDI (recommended dietary intake) formula.
62514571|NCT01049412|EXPERIMENTAL|LY2605541 First, Then Insulin Glargine|Participants received LY2605541 for 8 weeks, followed by insulin glargine for 8 weeks.
62514572|NCT01049412|ACTIVE_COMPARATOR|Insulin Glargine First, Then LY2605541|Participants received insulin glargine for 8 weeks, followed by LY2605541 for 8 weeks.
62514573|NCT02131623||Validation Group|Subjects with ALGS or PFIC and/or their caregivers
62514574|NCT01974882|EXPERIMENTAL|Cryotherapy|Patients in the cryotherapy study group will have ice packs placed on their abdominal wound for the first hour following surgery.
62514575|NCT01974882|NO_INTERVENTION|Control|No adjunctive therapy following abdominal surgery.
62514576|NCT01793818|PLACEBO_COMPARATOR|Group 1 Phase I/II|Three injections with no active principle
62514577|NCT01793818|ACTIVE_COMPARATOR|Group 2 Phase I/II|Three injections of Tat Oyi vaccine containing 11 µg of active principle
62514578|NCT01793818|ACTIVE_COMPARATOR|Group 3 Phase I/II|Three injections Tat Oyi vaccine containing 33 µg of active principle
62514579|NCT01793818|ACTIVE_COMPARATOR|Group 4 Phase I/II|Three injections Tat Oyi vaccine containing 99 µg of active principle
62514580|NCT05842304|ACTIVE_COMPARATOR|active cTBS group|active cTBS combined with conventional rehabilitation therapy
62514581|NCT05842304|SHAM_COMPARATOR|sham cTBS group|Sham cTBS combined with conventional rehabilitation therapy
62709967|NCT03683979|SHAM_COMPARATOR|Control training program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
62709968|NCT02249078|EXPERIMENTAL|Cohort 1|100 mg subcutaneous once every 2 weeks with initial double dose (200 mg total)
61973237|NCT05687591||Patients indicated for LAAO with the Amplatzer Amulet|All subjects who are indicated for LAAO with the Amplatzer Amulet are eligible for the study.
62709969|NCT02249078|EXPERIMENTAL|Cohort 2|200 mg subcutaneous once every 2 weeks with initial double dose (400 mg total)
62709970|NCT02249078|EXPERIMENTAL|Cohort 3|400 mg subcutaneous once every 2 weeks with initial double dose (800 mg total)
61973238|NCT03599024|EXPERIMENTAL|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
61973239|NCT03599024|ACTIVE_COMPARATOR|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
61973240|NCT01943292|EXPERIMENTAL|Defactinib|Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
61973241|NCT04140851|EXPERIMENTAL|overweight/obesity diet intervention group|Dietary fiber intervention
62147374|NCT00800176|EXPERIMENTAL|RO4998452 40mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 40 mg of RO4998452.
62709971|NCT02249078|EXPERIMENTAL|Cohort 4|10 mg/kg IV at Day 1, Day 8, Day 15, and every 2 weeks thereafter
61973242|NCT04140851|PLACEBO_COMPARATOR|overweight/obese normal diet group|Normal diet
62147375|NCT00800176|EXPERIMENTAL|RO4998452 5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 5 mg of RO4998452.
62709972|NCT02249078|PLACEBO_COMPARATOR|Placebo|Placebo 2-mL vial solution for injection
62709973|NCT03618537|EXPERIMENTAL|ixazomib|"Enrolled patients will receive ixazomib at a fixed dose of 4mg on days~1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities."
62709974|NCT00902330|EXPERIMENTAL|Arm I (cranial microcurrent electrical stimulation [CES])|Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
62353984|NCT03431909|SHAM_COMPARATOR|Control group|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
62353985|NCT02297113|ACTIVE_COMPARATOR|conventional endotracheal intubation|Patients assigned to this group will be intubated using conventional Macintosh blade in adequate size.
62709975|NCT00902330|SHAM_COMPARATOR|Arm II (sham CES)|Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
62709976|NCT04445948|ACTIVE_COMPARATOR|Triple Therapy|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days.
62147376|NCT03155022|EXPERIMENTAL|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
62353986|NCT02297113|ACTIVE_COMPARATOR|C-MAC|Patients assigned to this group will be intubated using C-MAC videolaryngoscope in adequate size.
62353987|NCT00719862|PLACEBO_COMPARATOR|Placebo Nasal Spray|0mg Placebo Nasal Spray
62353988|NCT00719862|ACTIVE_COMPARATOR|0.15% azelastine hydrochloride nasal spray|0.15% azelastine hydrochloride
62353989|NCT03522194||Sevoflurane|Anesthesia maintenance
62353990|NCT03522194||Propofol|Anesthesia maintenance
62709977|NCT04445948|ACTIVE_COMPARATOR|Sequential Therapy|Received the sequential therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 g tablets twice daily for 5 days, then esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus metronidazole 500 milligrams tablets twice daily plus clarithromycin 500 milligrams tablets twice daily after meal for another 10 days.
62353991|NCT03967509|EXPERIMENTAL|Behavioral teacher training|Behavioral preschool teacher training (BPTT) delivered in an educational group format during nine 2,5-hour biweekly sessions with training at sessions and in between followed by supervisor's feedback on the practice and two optional coaching occasions on the spot.
62353992|NCT03967509|NO_INTERVENTION|Waiting list control group|Preschool teachers worked with children as usual.
61973243|NCT04140851|NO_INTERVENTION|healthy control group|Healthy people
61973244|NCT00491998|EXPERIMENTAL|2-hourly dosing|6 Doses of IMP at 2-hourly intervals
61973245|NCT00491998|EXPERIMENTAL|3-hourly dosing|4 doses of IMP at 3-hourly intervals
61973246|NCT00491998|ACTIVE_COMPARATOR|3-hourly dosing plus Entacapone|4 doses of IMP plus Entacapone at 3-hourly intervals
61973247|NCT04488900|EXPERIMENTAL|Part 1. CKD-508 Capsule in Single Dose|Single dose of CKD-508 capsules
61973248|NCT04488900|PLACEBO_COMPARATOR|Part 1. Placebo Capsule in Single Dose|Single dose of Placebo capsules
61973249|NCT04488900|EXPERIMENTAL|Part 2. CKD-508 Tablet in Single Dose|Single dose of CKD-508 tablets for biocompartibility
61973250|NCT04488900|PLACEBO_COMPARATOR|Part 2. Placebo Tablet in Single Dose|Single dose of Placebo tablets for biocompartibility
61973251|NCT04488900|EXPERIMENTAL|Part 3. CKD-508 Tablet in Single Dose|Single dose of CKD-508 tablets for food effect
61973252|NCT04488900|PLACEBO_COMPARATOR|Part 3. Placebo Tablet in Single Dose|Single dose of Placebo tablets for food effect
61973253|NCT04488900|EXPERIMENTAL|Part 4. CKD-508 Tablet in Multiple Dose|Multiple dose of CKD-508 tablets
62147377|NCT03155022|OTHER|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
62514582|NCT01188265|EXPERIMENTAL|Valproate & dextromethorphan 30 mg|Valproate and dextromethorphan 30 mg per day
62514583|NCT01188265|EXPERIMENTAL|VPA & dextromethorphan 60 mg|VPA \& dextromethorphan 60 mg per day
62514584|NCT01188265|ACTIVE_COMPARATOR|VPA & Placebo|VPA \& placebo
62514585|NCT04339426|EXPERIMENTAL|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)
62514586|NCT04945772|EXPERIMENTAL|MCO-010- High Dose|Participants receive 1.2E11gc/eye of MCO-010
62514587|NCT04945772|EXPERIMENTAL|MCO-010- Low Dose|Participants receive 0.9E11gc/eye of MCO-010
62514588|NCT04945772|SHAM_COMPARATOR|Sham Injection|Participants receive sham injection
62514589|NCT00958867|EXPERIMENTAL|1|Six-month, twice-weekly aerobic training (AT) program
62514590|NCT00958867|EXPERIMENTAL|2|Six-month, twice-weekly resistance training (RT) program
62514591|NCT00958867|ACTIVE_COMPARATOR|3|Six-month, twice-weekly stretch \& relax (S \& R; control) program
62514592|NCT01037582|EXPERIMENTAL|Trial part 1|
62514593|NCT01037582|EXPERIMENTAL|Trial part 2|
62514594|NCT03617627|EXPERIMENTAL|Experimental group|Patients will be included in a self-management intervention.
62514595|NCT03617627|NO_INTERVENTION|Control group|Patients will receive a booklet with information.
62514596|NCT01300624|EXPERIMENTAL|Verb Network Strengthening Treatment|Verb Network Strengthening Treatment (VNeST) tasks involve the retrieval of nouns related to a target verb. For example, for the verb measure, participants would come up with people who measure and what they measure (e.g., carpenter/lumber, chef/sugar). They would then answer questions related to why, where, and when these things might occur (e.g., for carpenter/measure, they might say to get the right length of board, (why) at a construction site, (where) and when building a house (where). Cues and assistance are provided to the participants when they are unable to complete any given task. As the participants improve, cues are reduced.
62514597|NCT04624152|EXPERIMENTAL|Normobaric Hypoxia|"Large weather balloons will be filled with a normobaric hypoxic inspirate (FiO2 = 0.15) produced by a nitrogen generator (CAT 12; Colorado Altitude Training, Boulder, CO) to simulate an altitude of 2600 m (8500 ft). Participants breathed this inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
62514598|NCT04624152|PLACEBO_COMPARATOR|Normobaric Normoxia|"Large weather balloons will be filled with room air (FiO2 = 0.21). Participants breathed this normobaric normoxic inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
62514599|NCT00938145|EXPERIMENTAL|MRI+surgery|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
62514600|NCT00938145|EXPERIMENTAL|MRI+surgery+chemotherapy|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
62514601|NCT02477852|EXPERIMENTAL|anti-tuberculosis treatment two weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.
62514602|NCT02477852|EXPERIMENTAL|anti-tuberculosis treatment four weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.
62514603|NCT04507035|EXPERIMENTAL|Anlotinib group|After 2 cycles of anlotinib treatment, we evaluate the therapeutic effect of tumor treatment: If it achieve downgrading and is operable, surgical treatment will be performed; if it is still inoperable and could accept radiotherapy, radiotherapy and chemotherapy will be combined with oral chemotherapy of anlotinib until the end of radiotherapy. Efficiency and side effects will be evaluated within 3 months after therapy. Finally, the survival is in follow-up.
62514604|NCT05606588|EXPERIMENTAL|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for the duration of their medical therapy, in addition to usual care.
62514605|NCT05606588|NO_INTERVENTION|Control group|The control group receives treatment as usual. The control group will be given the opportunity to participate in the intervention after therapy.
62514606|NCT01663727|EXPERIMENTAL|A|Paclitaxel + Bevacizumab \[Avastin\]
62514607|NCT01663727|EXPERIMENTAL|B|Paclitaxel + Placebo
61973254|NCT04488900|PLACEBO_COMPARATOR|Part 4. Placebo Tablet in Multiple Dose|Multiple dose of placebo tablets
62514608|NCT04768894|ACTIVE_COMPARATOR|14-28 days|In group 1,the time interval between initial and re-TUR was 14-28 days,
62514609|NCT04768894|ACTIVE_COMPARATOR|29-42 days|In group 2, the time interval between initial and re-TUR was 29-42 days
62514610|NCT04768894|ACTIVE_COMPARATOR|43-56 days|In group 3, the time interval between initial and re-TUR was 43-56 days
62514611|NCT00839059|EXPERIMENTAL|Lenalidomide|
62514612|NCT03135652|EXPERIMENTAL|chemoradiotherapy|radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
62514613|NCT03135652|ACTIVE_COMPARATOR|chemotherapy|chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
62514614|NCT02075606|EXPERIMENTAL|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
62514615|NCT00110188|EXPERIMENTAL|Ridaforolimus|50 mg of ridaforolimis intravenously over 30 minutes, weekly
62514616|NCT06297655|EXPERIMENTAL|Recombinant human activated coagulation factor Ⅷ for injection|Each subject in this study receive on-demand treatment with recombinant human coagulation factor VIII for injection for 180 days, with an increase in medication frequency based on the relief after medication.
62514617|NCT03413384|EXPERIMENTAL|Ceftriaxone|"1. Name: Ceftriaxone~2. Dosage form: crystalline powder for intramuscular injection~3. Dose(s): 1 g~4. Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
62514618|NCT03413384|PLACEBO_COMPARATOR|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
62514619|NCT00955552|ACTIVE_COMPARATOR|Cosamin DS®|"glucosamine hydrochloride 500 mg and chondroitin sulfate 400 mg (Cosamin DS®, Nutramax Laboratories).~The medication was supplied as capsules, with the daily dose of 3 capsules."
62514620|NCT00955552|EXPERIMENTAL|Glucosamine/ chondroitin sulphate|Glucosamine hydrochloride 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal The medication was supplied as capsules, with the daily dose of 3 capsules.
62514621|NCT03104933||Patients with septic shock|patients in septic shock admitted to the ICU
62514622|NCT01613378||Rheumatoid Arthritis Cohort|The cohort included participants with moderate to severe rheumatoid arthritis (RA) in whom the treating physician made the decision to initiate tocilizumab treatment.
62514623|NCT02855619|ACTIVE_COMPARATOR|Martin|A threshold-based IMT is performed like used by Martin in a randomized trial in 2011, in a view of inspiratory strength increase.
62514624|NCT02855619|ACTIVE_COMPARATOR|Cader|A threshold-based IMT is performed like used by Cader in a randomized trial in 2012, in a view of inspiratory endurance increase.
62514625|NCT02855619|EXPERIMENTAL|EDRIC|A new threshold-based IMT is performed, in a view of both inspiratory strength and endurance increase.
62514626|NCT04571892|EXPERIMENTAL|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
62514627|NCT06451718|EXPERIMENTAL|Study group|Participants with study disease
62514628|NCT01839370|EXPERIMENTAL|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
62514629|NCT01839370|PLACEBO_COMPARATOR|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
62514630|NCT01582919|EXPERIMENTAL|Participant from AMI cohort|
62514631|NCT01582919|ACTIVE_COMPARATOR|Participant from 3Ccohort|
62514632|NCT00107042|ACTIVE_COMPARATOR|1|Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
62514633|NCT00107042|EXPERIMENTAL|2|Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
62514634|NCT03037034|EXPERIMENTAL|Forcep Strip Method Treatment|patients who have Gastrointestinal Subepithelial Tumors Originating from the Muscularis Propria are enrolled
62514635|NCT00648024|EXPERIMENTAL|1|Anagrelide Hydrochloride Capsules 1 mg
62514636|NCT00648024|ACTIVE_COMPARATOR|2|Agrylin® Capsules 1 mg
62514637|NCT02808208|EXPERIMENTAL|Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Subjects who receive a radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)
62514638|NCT02808208|NO_INTERVENTION|No Treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Patients receive standard of care.
62514639|NCT02808208|EXPERIMENTAL|Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at time of first stage of BBF
62147378|NCT04901416|EXPERIMENTAL|Experimental Arm|"1. Lymphodepleting (LD) chemotherapy will be administered daily for 3 days to all subjects prior to DVX201. Lymphodepleting chemotherapy will consist of the following:~   1. Cyclophosphamide 300 mg/m2 IV over 30 to 60 minutes daily x 3 (day -5 to day - 3)~  2. Fludarabine 30 mg/m2 IV over 30 minutes daily x 3 (day -5 to day -3)~2. Patients will receive DVX201 at one of 3 prespecified doses infused on day 0 and 7 (± 1 day) for 1 cycle."
62514640|NCT02808208|EXPERIMENTAL|AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at first and second stage of BBF
62514641|NCT02808208|PLACEBO_COMPARATOR|Placebo treatment in brachiobasilic arteriovenous fistula|Subjects will receive placebo at first and second stage of BBF
62514642|NCT06273787|EXPERIMENTAL|diaphragmatic release|diaphragmatic myofascial release
62514643|NCT06273787|ACTIVE_COMPARATOR|positioning|positioning instruction for sleep apnea
62514644|NCT04008693|ACTIVE_COMPARATOR|Kyolic® Hi-Po Formula - Kyolic|Aged garlic extract
62514645|NCT04008693|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62514646|NCT01506908|ACTIVE_COMPARATOR|Nicotine Polacrilex mint mini lozenge|
62514647|NCT01506908|PLACEBO_COMPARATOR|placebo|mint mini lozenge with no active
62514648|NCT04704349|EXPERIMENTAL|Scintigraphy acquisitions|All patients will undergo scintigraphy on 2 distinct devices and the images obtained will be compared.
62514649|NCT00578071|EXPERIMENTAL|Treatment|panitumumab, oxaliplatin, capecitabine and EBRT
62514650|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
62514651|NCT04882319|EXPERIMENTAL|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously.
62514652|NCT04447937||Multiple Sclerosis and Related Diseases|Individuals with one or more immunoglobulin level results and medical histories available for data collection will be included. Subjects will be 18 years of age or older at the time of data collection.
62514653|NCT05156424|EXPERIMENTAL|Aerobic Emphasised Exercise Intervention|The intervention will comprise of 24 weeks of twice weekly supervised exercise sessions, emphasising aerobic exercise. To reflect a real-world setting, each group will experience both aerobic and resistance exercise, but there will be a 75%:25% predominant: subsidiary mode emphasis based on exercise duration within each session.
61973255|NCT03942627|EXPERIMENTAL|Mindfulness Program|The intervention consists of an introductory video in which a mindfulness expert explains the program's approach and models practices to increase women's comfort with the material, four audio-recorded mindfulness practices for mothers' use when the baby is in the NICU, each available in 5- and 10-minute versions, and a brief video and four additional audio mindfulness practices (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
61973256|NCT03942627|PLACEBO_COMPARATOR|Infant Health Education Program|The intervention consists of an introductory video explaining the program's approach, four audio recordings providing education about infant health and development, each available in 5- and 10-minute versions, and a brief video and four additional educational recordings (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
61973257|NCT05526495|EXPERIMENTAL|De-implementation|"A multi-behaviour technique will be used along with theoretical domains framework.~Clinicians will be provided with continuing multi-behaviour component intervention to increase accountability for preoperative test ordering in patients having low risk surgeries."
61973258|NCT05526495|NO_INTERVENTION|Comparator|Standard of care
61973259|NCT03117101|EXPERIMENTAL|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
61973260|NCT06101979||Fortiva Tissue Matrix|
61973261|NCT06057168|EXPERIMENTAL|Elucirem®|Patient will undergo a DSC-MRI perfusion using Elucirem®
61973262|NCT06057168|ACTIVE_COMPARATOR|Dotarem®|Patient will undergo a DSC-MRI perfusion using Dotarem®
61973263|NCT01246414||Allergic asthma|Patients with allergic asthma
61973264|NCT01246414||Non-allergic asthma|Patients with non-allergic asthma
61973265|NCT01246414||Non-asthmatic controls|Non-asthmatic controls
61973266|NCT00258245|EXPERIMENTAL|Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide \[AT\] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day
61973267|NCT04111484|ACTIVE_COMPARATOR|Adrenomedullin|Will received 19.9 picomol/kg/min of adrenomedullin over 20 min
61973268|NCT04111484|PLACEBO_COMPARATOR|Saline|Saline
61973269|NCT02064894|EXPERIMENTAL|oral morphine and oral ibuprofen|Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
61973270|NCT02064894|EXPERIMENTAL|morphine and placebo of ibuprofen|Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
61973271|NCT02064894|ACTIVE_COMPARATOR|ibuprofen and placebo of morphine|Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
61973272|NCT06036667|EXPERIMENTAL|Study group|All patients undergone Uniportal-VATS upper lobectomy with 28Fr Smart Coaxial drain placed at the end of surgery
61973273|NCT06036667|NO_INTERVENTION|Study group 1|All patients undergone Uniportal-VATS upper lobectomy with standard 28Fr chest drain placed at the end of surgery
62353993|NCT05855395|EXPERIMENTAL|Group A|Experimental group with standard of care combined with glucocorticoid（dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
62147379|NCT04920968|EXPERIMENTAL|Obinutuzumab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
61973274|NCT06036667|EXPERIMENTAL|Study group 2|All patients undergone Biportal-VATS upper lobectomy with 28Fr Smart Coaxial drain placed at the end of surgery
62353994|NCT05855395|NO_INTERVENTION|Group B|Control group with standard of care（The clinical standard of care of COVID-19 includes general treatment, oral antiviral drugs, immunotherapy, oxygen therapy and respiratory support, etc.）
62353995|NCT01787799|EXPERIMENTAL|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)
62353996|NCT00357422|ACTIVE_COMPARATOR|surgery|
62353997|NCT00357422|ACTIVE_COMPARATOR|local therapy|
62353998|NCT03956329|NO_INTERVENTION|Usual care, control arm|Usual care in which participants will not see a video intervention. This group will attend their influenza vaccination appointment as usual, without intervention. Participants will receive Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
62353999|NCT03956329|EXPERIMENTAL|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
62354000|NCT03956329|EXPERIMENTAL|Individualised Digital Intervention|Similar to the standardised digital intervention, however participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
62354001|NCT01309867|EXPERIMENTAL|Investigational Toric Lens|Bausch + Lomb investigational toric contact lenses
62354002|NCT01309867|ACTIVE_COMPARATOR|PureVision Toric Lens|Currently marketed Bausch + Lomb PureVision toric contact lenses
62354003|NCT06366334|EXPERIMENTAL|Ketamine|Participants in the intervention group will receive 0.5mg/kg of 1mg/mL intravenous ketamine (50 mg maximum) over 40 minutes.
62354004|NCT06366334|PLACEBO_COMPARATOR|Normal Saline|Participants in the control group will receive 0.5mL/kg intravenous normal saline (50 ml maximum) over 40 minutes
62354005|NCT01946412|NO_INTERVENTION|Observational Arm|
62514654|NCT05156424|EXPERIMENTAL|Resistance Emphasised Exercise Intervention|The intervention will comprise of 24 weeks of twice weekly supervised exercise sessions, emphasising resistance exercise. To reflect a real-world setting, each group will experience both aerobic and resistance exercise, but there will be a 75%:25% predominant: subsidiary mode emphasis based on exercise duration of exercise within each session.
62514655|NCT01652729|EXPERIMENTAL|Exenatide once weekly suspension|Exenatide once weekly suspension 2mg subcutaneous injection
62514656|NCT01652729|ACTIVE_COMPARATOR|Sitagliptin 100mg|Overencapsulated Sitagliptin 100mg oral tablet once daily
62514657|NCT01652729|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule once daily
62514658|NCT04882917|EXPERIMENTAL|Experimental: Dose Escalation Cohort (Part 1A): M4076 Monotherapy|Participants will receive M4076 film coated tablet at escalated doses orally, once daily under fasting condition until disease progression, death, Adverse events (AEs) leading to discontinuation of study intervention(s), or withdrawal of consent, whichever occurs first.
62514659|NCT04882917|EXPERIMENTAL|Experimental: Preliminary Food Effect Assessment Cohort (Part 1B): M4076|Participants in food effect assessment will receive M4076 at the dose and schedule determined as recommended dose for expansion (RDE) in Part 1A. A single dose of M4076 will be administered on Day -7 under a fed or fasted condition, followed by a 1-week washout period.
62514660|NCT02914249|EXPERIMENTAL|Orange juice|Orange juice: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) plus 100% orange juice (500 mL/d) during 12 weeks.
62709978|NCT04445948|ACTIVE_COMPARATOR|Triple Therapy plus Lactoferrin|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days. in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner for 14 days.
62354006|NCT01946412|EXPERIMENTAL|Ivacaftor|"Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:~* 50 mg q12h for subjects 2 to \<6 years of age and \<14 kg,~* 75 mg q12h for subjects 2 to \<6 years of age and ≥ 14 kg, or~* 150 mg q12h for subjects ≥ 6 years of age."
62354007|NCT06295406||Cases|Participants with age range between 11 and 16 years, with overweight (BMI\>85° ) or obesity (BMI\>95°)
62354008|NCT02670915|EXPERIMENTAL|Meal-time faster-acting insulin aspart and insulin degludec|
62354009|NCT02670915|ACTIVE_COMPARATOR|Meal-time NovoRapid® (insulin aspart) and insulin degludec|
62354010|NCT02670915|EXPERIMENTAL|Post-meal faster-acting insulin aspart and insulin degludec|
62354011|NCT03449121|EXPERIMENTAL|Slow breathing|Slow breathing techniques with exhale greater than inhale
62514661|NCT02914249|NO_INTERVENTION|Control|Control: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) during 12 weeks.
62514662|NCT02613078|EXPERIMENTAL|Gut-Directed Hypnotherapy (GDH)|Gut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week)
62514663|NCT02613078|EXPERIMENTAL|Probiotic (NS)|Nutritional supplement SymbioLact B once a day diluted in water or tea
62514664|NCT02613078|ACTIVE_COMPARATOR|Active Controls (AC)|AC group keeps a symptom dairy (self-monitoring)
62147380|NCT04920968|ACTIVE_COMPARATOR|Rituximab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
62147381|NCT04131257|EXPERIMENTAL|Continuum of care|Trained diabetes nurses will provide continuum of care to the participants that includes: conducting community awareness campaigns, screening programs, linkage to clinical care, community follow-up counseling and support for individuals with diabetes, and prevention programs for individuals with pre-diabetes.
62147382|NCT04131257|ACTIVE_COMPARATOR|Usual care|The control group will receive usual diabetic care without the nurse coordination and supervision as in the intervention group.
62147383|NCT04317885|EXPERIMENTAL|Prizloncabtagene Autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion
62147384|NCT02567591|EXPERIMENTAL|A: physical activity program|at home physical activity program (during 12 weeks)
62147385|NCT02567591|NO_INTERVENTION|B: conventional management|conventional management
62147386|NCT00886834|EXPERIMENTAL|Misoprostol|Misoprostol 400 micrograms inserted vaginally or buccally, per the participants desire.
62147387|NCT00886834|PLACEBO_COMPARATOR|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
62147388|NCT04895085|EXPERIMENTAL|Caregiver of Children with medical complexity (CMC)|
62147389|NCT01802424|EXPERIMENTAL|The Friends program|Youth with increased levels of anxiety are thought to regulate their fear by recognizing bodily cues, learning relaxation, regulating thoughts and feelings and expose themselves to situations and objects that activate their anxiety.
62147390|NCT00552591|EXPERIMENTAL|1|Family Heart Health Program
62147391|NCT00552591|NO_INTERVENTION|2|Usual Care
62147392|NCT03985397|EXPERIMENTAL|Experimental group (EG)|At the first interview, after the application of the scales to the intervention group patients, planned discharge training and the manual prepared by the researcher were given. The second interview was performed 4 weeks later and the same scales were reapplied.
62147393|NCT03985397|NO_INTERVENTION|Control group|In the first interview, scales were applied to the control group patients but planned discharge training was not given. The second interview was carried out 4 weeks later, and after the same scales were reapplied to the control group patients, planned discharge training was given. Therefore, the right of individuals to get education was not prevented.
62354012|NCT00605696|EXPERIMENTAL|1|Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
62354013|NCT00605696|ACTIVE_COMPARATOR|2|Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
62354014|NCT05301413|ACTIVE_COMPARATOR|Standard|Standard Diabetes Prevention Program (DPP)
62354015|NCT05301413|EXPERIMENTAL|Culturally Tailored DPP|DPP culturally tailored for African Americans
62514665|NCT02553278|EXPERIMENTAL|Treatment with VelaShape device|"One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment"
62514666|NCT02553278|EXPERIMENTAL|Treatment with Contour I V3 device|"One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment"
62514667|NCT04909541||Patient with ureteral stent|Patients with ureteral stent that meet the inclusion, exclusion criteria complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
62514668|NCT05481359||EGF-Guided Ablation Therapy|Subjects will be treated with cardiac ablation guided by the Ablamap Electrographic Flow (EGF) Mapping System.
62514669|NCT06098287|ACTIVE_COMPARATOR|Intervention (Exhaust-only ventilation)|A study group with a continuous exhaust-only ventilation system
62514670|NCT06098287|ACTIVE_COMPARATOR|Intervention (Central-fan-integrated-supply ventilation)|A study group with an intermittent central-fan-integrated-supply ventilation system and air filtration upgrades
62514671|NCT06098287|ACTIVE_COMPARATOR|Intervention (Balanced energy recovery ventilation)|A study group with a continuous balanced energy recovery ventilation system and air filtration upgrades
62514672|NCT02777684||knee osteoarthritis|
62514673|NCT03744221|EXPERIMENTAL|Corn protein|Corn protein powder
62514674|NCT03744221|EXPERIMENTAL|Bovine plasma protein|Bovine plasma protein powder
62514675|NCT03744221|ACTIVE_COMPARATOR|control benchmark protein Whey|Whey protein powder
62514676|NCT05711342|ACTIVE_COMPARATOR|Treatment as usual (TAU)|In this control condition, participants receive in-person aggression treatment as usual (TAU). No changes to the way treatment is provided as usual are made. In general, this refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient in a one-on-one setting. The main focus of treatment as usual should lie on aggression regulation. Additionally, patients should receive individual, one-on-one treatment and should not participate in group treatment of aggression during data collection.
62514677|NCT05711342|EXPERIMENTAL|Treatment as usual (TAU) +Internet-based intervention Aggression|In the experimental condition, participants receive TAU, and additionally work on the 10-week internet-based intervention 'Aggression', on which they can work in their own time, i.e. outside of treatment sessions. Consequenlty, the intervention is used in a blended way. The intervention is focused on three main objectives: (1) increasing the motivation to change, (2) acquiring skills for dealing with conflict, and (3) breaking the cycle of aggression by providing knowledge on situational, emotional, cognitive and physical triggers. The module consists of 10 lessons:
62514678|NCT02698865|EXPERIMENTAL|MONOVISC|MONOVISC High Molecular Weight Hyaluronan
62514679|NCT02698865|PLACEBO_COMPARATOR|Saline|Physiologic saline
62514680|NCT02257619|EXPERIMENTAL|Itacitinib plus docetaxel|
62147394|NCT00903864||stethoscopy|
62147395|NCT00903864||BPM|blood pressure monitor
62514681|NCT01370486|ACTIVE_COMPARATOR|melatonin|
62514682|NCT01370486|PLACEBO_COMPARATOR|placebo|
62514683|NCT06451393||Neoadjuvant chemotherapy with radical tumor resection surgery|(i) Patients with indistinguishable tumor lesions on the CT images due to insufficient filling of the stomach during the CT inspection; (ii) patients without indistinguishable tumor cell on the pathological slides due to inadequate sampling; (iii) patients with insufficient data.
62147396|NCT03080805|EXPERIMENTAL|Pyrotinib Plus Capecitabine|
62147397|NCT03080805|ACTIVE_COMPARATOR|Lapatinib Plus Capecitabine|
62147398|NCT04976829||adult (≥ 18 years) inpatients (hospitalised ≥ 48h)|
62147399|NCT05379166|EXPERIMENTAL|Treatment (venetoclax, azacitidine)|Patients receive venetoclax PO QD on days 1-14 and azacitidine IV over 10-40 minutes on days 1-7 or days 1-5 of week 1 and days 1 and 2 of week 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62354016|NCT05301413|EXPERIMENTAL|Culturally Tailored DPP Enhanced with Socioeconomic Supports|Culturally tailored DPP plus promotions for class attendance, hybrid attendance (in-person and virtual), and linkage to care services provided by a community health worker
62354017|NCT01861145|ACTIVE_COMPARATOR|Bed Alarm|Patients in the control arm will use only the bed alarm for treatment of their enuresis
62354018|NCT01861145|EXPERIMENTAL|Bed alarm + intranasal steroids|"Intervention: Nasonex (Mometasone furoate aqueous nasal spray) Children 5-11: 50 mcg/metered spray, 1 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm.~Children ≥ 12: 50 mcg/metered spray, 2 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm."
62354019|NCT00855387||Costs|Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections).
62514684|NCT06347432|EXPERIMENTAL|Group A: Experimental Group|Group A: The Experimental Group will receive the 8-week evidence-based PWC skills training using the IndieTrainer System following T0 baseline testing
62514685|NCT06347432|NO_INTERVENTION|Group B: Wait List Control Group|Group B: The Wait List Control Group will receive the 8-week evidence-based PWC skills training using the IndieTrainer System following T2 testing
62514686|NCT01932814||Aminoglycosides|have received aminoglycosides
62514687|NCT01932814||No Aminoglycosides|did not receive aminoglycosides
62514688|NCT00764231|EXPERIMENTAL|Exercise|This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.
62514689|NCT00764231|OTHER|Wait list control|This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.
62514690|NCT00932282|ACTIVE_COMPARATOR|12 month maintenance of PnOIT|"Randomized subjects who will stay on the maintenance dose of oral peanut immunotherapy (PnOIT) for 12 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (\~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
62514691|NCT00932282|ACTIVE_COMPARATOR|24 month maintenance of PnOIT|"All subjects will be on the same intervention until Randomization. Randomized subjects who will stay on the maintenance dose of peanut oral immunotherapy (PnOIT) for 24 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (\~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
62514692|NCT05712642|EXPERIMENTAL|Group A recieved 0.3125mg intravitreal bevacizumab in both eyes|9 infants in group A with type 1 ROP , received 0.3125mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .
62514693|NCT05712642|ACTIVE_COMPARATOR|Group B received 0.625mg intravitreal bevacizumab in both eyes|10 infants in group B with type 1 ROP , received 0.625mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .
62514694|NCT00822393|ACTIVE_COMPARATOR|1|Busulfan
62514695|NCT00822393|EXPERIMENTAL|2|Treosulfan
62514696|NCT01471899|ACTIVE_COMPARATOR|Naproxen|2 tablets every 8 hours for 4 days.
62709979|NCT04445948|ACTIVE_COMPARATOR|Sequential Therapy plus Lactoferrin|Received the sequential therapy in the form of esomeprazole 40 milligrams once daily 30 minutes before breakfast plus amoxicillin 1 gram twice daily for 5 days, then esomeprazole 40 mg once daily 30 minutes before breakfast plus metronidazole 500 milligrams twice daily plus clarithromycin 500 milligrams twice daily after meal for another 10 days in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner throughout the 15 days.
61973275|NCT04285879|EXPERIMENTAL|BFR Exercise Group|"In addition to the standard ACL protocol, patients in this study will utilize the Owen Recovery Science exercise protocol for BFR \[18\]. The following guidelines will be followed concerning exercise progression, occlusion pressure and difficulties with volume achievement.~A total of 20 youth and adolescent patients undergoing a surgical procedure for ACL reconstruction at Connecticut Children's Elite Sports Medicine and completing physical therapy at Connecticut Children's Sports Physical Therapy will be recruited for this study."
61973276|NCT04285879|NO_INTERVENTION|Non-BFR exercise group|As part of this pilot study, the investigators will additionally collect prospective controls. This population will be patients not participating in physical therapy at Connecticut Children's but underwent ACL reconstruction by Elite Sports Medicine
61973277|NCT00592839|EXPERIMENTAL|1|0.3 mg SCE-B Daily
61973278|NCT00592839|EXPERIMENTAL|2|0.625 mg SCE-B Daily
61973279|NCT00592839|PLACEBO_COMPARATOR|3|Placebo
62354020|NCT02403713|EXPERIMENTAL|Test Treatment|Fluticasone/formoterol 125/5 µg BAI
62354021|NCT02403713|ACTIVE_COMPARATOR|Active Comparator 1|Fluticasone/formoterol 125/5 µg pMDI with spacer
62354022|NCT02403713|ACTIVE_COMPARATOR|Active Comparator 2|Fluticasone/formoterol 125/5 µg pMDI without spacer
62354023|NCT02403713|ACTIVE_COMPARATOR|Active Comparator 3|Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose
62354024|NCT02403713|ACTIVE_COMPARATOR|Active Comparator 4|Formoterol (12 µg) without spacer
62354025|NCT03962712||Low-Wage Workers from Minneapolis, MN|Low-wage workers from Minneapolis, MN, where the minimum wage will be increased to $15-an-hour over the study period.
62354026|NCT03962712||Low-Wage Workers from Raleigh, NC|Low-wage workers from Raleigh, NC, where the minimum wage will not be significantly changed over the study period.
62354027|NCT06220552|EXPERIMENTAL|Low-dose Radiotherapy Combined With Sintilimab and Temozolomide|
62514697|NCT01471899|EXPERIMENTAL|Ketorolac Tromethamine|10 drops every 8 hours for 4 days
62514698|NCT01014416|EXPERIMENTAL|Arm 1|Single dose, Tolvaptan 15mg or Placebo/day
62514699|NCT01014416|EXPERIMENTAL|Arm 2|Single dose, Tolvaptan 30mg or Placebo/day
62354028|NCT01080144|EXPERIMENTAL|Critical Flicker Frequency|Critical Flicker Frequency Procedure
62354029|NCT01730287|EXPERIMENTAL|Control|No lining applied in group1.
62514700|NCT01014416|EXPERIMENTAL|Arm 3|Single dose, Tolvaptan 60mg or Placebo/day
62514701|NCT01774825|ACTIVE_COMPARATOR|IQP-CL-101|2 softgels twice a day
62514702|NCT01774825|PLACEBO_COMPARATOR|Placebo|2 softgels twice a day
62514703|NCT02430805|OTHER|NOE|multicentric family-based cohort. prospective and transversal study
62354030|NCT01730287|EXPERIMENTAL|CEM cement|CEM cement applied over remained caries in group4.
62354031|NCT01730287|EXPERIMENTAL|Mineral Trioxide Aggregate (MTA)|MTA applied over remained caries in group3.
62354032|NCT01730287|EXPERIMENTAL|Calcium Hydroxide|Calcium Hydroxide applied over remained caries in group2.
62354033|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
62354034|NCT02540772|EXPERIMENTAL|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
62354035|NCT02540772|NO_INTERVENTION|No treatment|Patients in the control group only performed the baselines.
62354036|NCT01187836|EXPERIMENTAL|TRV120027|
62354037|NCT01187836|PLACEBO_COMPARATOR|Placebo|
62514704|NCT01464554|ACTIVE_COMPARATOR|Usual Care|Teens will receive six sessions of an alcohol and drug education group
62514705|NCT01464554|EXPERIMENTAL|Project Free Talk|Teens will receive six sessions of and evidenced based motivational interviewing alcohol and drug program
62514706|NCT06612203|EXPERIMENTAL|Debio 0123 + Sacituzumab govitecan|"Phase Ib of the study will adopt the Bayesian Logistic Regression Model (BLRM) with Overdosing Control. Patients with TNBC and HR+/HER2- advanced/metastatic breast cancer will receive multiple doses of Debio 0123 administered orally during 6 days of each 21-day cycle and 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle in order to find the RP2D for Debio 0123 when administered in combination with Sacituzumab govitecan.~In phase II study, patients with TNBC or HR+/HER2- advanced/metastatic breast cancer will receive the RP2D of Debio 0123 administered orally during 6 days of each 21-day cycle in combination with 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first."
62514707|NCT06616350|EXPERIMENTAL|Experimental group|Participants used the app esTOCma
62514708|NCT06616350|NO_INTERVENTION|Control group|Participants did nothing
62514709|NCT00726102|ACTIVE_COMPARATOR|Meat|Provide locally available meat daily to infants from 6 to 18 mos of age
62514710|NCT00726102|ACTIVE_COMPARATOR|Control|Daily provision of cereal to infants from 6-18 mos
62514711|NCT00726102|ACTIVE_COMPARATOR|Fortified rice cereal|Provide equi-caloric serving of fortified rice cereal on daily basis from 6-18 months of age
61973280|NCT03757689|EXPERIMENTAL|Neoadjuvant Pembrolizumab|Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
61973281|NCT01733771||CAM with standard care|Symptomatic hospitalized people referred by the medical team to CAM treatments on top of standard of care
61973282|NCT01733771||Standard care only|Symptomatic patients who are referred to CAM treatments but are not interested in such treatments
61973283|NCT01506427|EXPERIMENTAL|[F-18] HX4|
61973284|NCT01012960|PLACEBO_COMPARATOR|Placebo|Placebo= normal saline
61973285|NCT01012960|ACTIVE_COMPARATOR|methylnaltexone|peripheral opioid antagonist
61973286|NCT04920370|EXPERIMENTAL|ALXN1720 Single Dose SC|Participants will receive a single dose of ALXN1720 SC.
62514712|NCT03827928|EXPERIMENTAL|Yoga/meditation|A 6-week yoga/meditation intervention.
62514713|NCT03827928|NO_INTERVENTION|Wait list|A wait list control period.
62514714|NCT03104621|EXPERIMENTAL|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
62514715|NCT03104621|EXPERIMENTAL|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
62514716|NCT05264961|OTHER|control group|dysphonic children without behavioral abnormalities
62514717|NCT05264961|OTHER|study group|dysphonic children with behavioral abnormalities
62514718|NCT02172352|EXPERIMENTAL|Ba 679 BR low dose|
62514719|NCT02172352|PLACEBO_COMPARATOR|Placebo inhalation powder|
62514720|NCT02172352|EXPERIMENTAL|Ba 679 BR middle dose|
62514721|NCT02172352|EXPERIMENTAL|Ba 679 BR high dose|
62514722|NCT02556892|EXPERIMENTAL|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
62514723|NCT01404117|EXPERIMENTAL|Laquinimod 0.6|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
62514724|NCT01404117|EXPERIMENTAL|Laquinimod 1.2|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
62514725|NCT01404117|EXPERIMENTAL|GA or IFN + Placebo|GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
62514726|NCT00767520|ACTIVE_COMPARATOR|A|
62514727|NCT00767520|PLACEBO_COMPARATOR|B|
62514728|NCT00110344|EXPERIMENTAL|Arm 1|
62514729|NCT00110344|PLACEBO_COMPARATOR|Arm 2|
62514730|NCT04614987||Participants undergoing CAR T transfusion|Participants will undergo baseline examination followed by evaluations between Days 3 and 5 post-transfusion, on Day 30 post-transfusion date (PTD), PTD 90, and PTD 180. At baseline this will include plasma testing, lumbar puncture (voluntary), neuroimaging (voluntary) and neuropsychiatric performance testing (voluntary). Between post-transfusion Day 3 and day 5, participants will undergo repeat exam, plasma testing, lumbar puncture (voluntary), and neuroimaging (voluntary). Day 30 testing will again test all modalities, including serum, CSF/lumbar puncture (voluntary), brain imaging (voluntary), and formal neuropsychiatric performance testing (voluntary). Finally, Day 90 and 180 will repeat serum testing, brain imaging, and formal neuropsychological performance testing.
62514731|NCT04797442|EXPERIMENTAL|Experimental|
62514732|NCT04797442|PLACEBO_COMPARATOR|Placebo comparator|
61973287|NCT04920370|EXPERIMENTAL|ALXN1720 Multiple Dose SC|Participants will receive multiple doses of ALXN1720 SC.
61973288|NCT04920370|EXPERIMENTAL|ALXN1720 Single Dose SC + rHuPH20|Participants will receive a single dose of ALXN1720 SC in combination with rHuPH20.
61973289|NCT04920370|EXPERIMENTAL|ALXN1720 Single Dose IV|Participants will receive a single dose of ALXN1720 IV.
61973290|NCT04920370|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
61973291|NCT05205733|NO_INTERVENTION|In-Clinic Semen Analysis Testing|Men needing semen analysis for infertility work-up.
61973292|NCT05205733|EXPERIMENTAL|No in-clinic semen analysis testing|Men needing semen analysis for infertility work-up.
61973293|NCT00518986|ACTIVE_COMPARATOR|1|armodafinil 200 mg/day
61973294|NCT00518986|PLACEBO_COMPARATOR|2|Placebo
61973295|NCT03374878|EXPERIMENTAL|oral contraceptive and training|Users of oral contraceptive training for 10 weeks
61973296|NCT03374878|PLACEBO_COMPARATOR|no oral contraceptive and training|Non-users of oral contraceptive training for 10 weeks
62147400|NCT06501027|EXPERIMENTAL|Mindfulness-Based Self-Compassion and vagal nerve stimulation|"Mindfulness-Based Self-Compassion and vagal nerve stimulation were administered to the Intervention I group. Mindfulness-Based Self-Compassion intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified Mindfulness-Based Self-Compassion instructor will teach the courses in a group-based format for 90 minute sessions, once per week for three weeks.~Vagal nerve stimulation was administered to all participants in both groups using the on-invasive Auricular Vagus Nerve Stimulation device. The stimulation was biphasic, with a frequency of 10 Hz and a pulse width of 300 μs in Modulation mode. Current intensity was adjusted by attaching the device to the participant's right or left ears, ensuring that they felt the current comfortably, and maintaining a constant level. Stimulation sessions occurred every 3 weeks, with non-invasive auricular vagus nerve stimulation applied for 20 minutes per session over a period of 3 days."
62514733|NCT06175936|EXPERIMENTAL|Laughter yoga group|"Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session). Laughter yoga consists of four parts. Firstly, it starts with warm-up exercises including hand clapping (applause), singing ho ho ha ha to relax the facial muscles of the participants and body movements. Secondly, the lungs are prepared with breathing exercises and the mind is prepared for laughter with childish games. This is followed by laughter exercises. Deep breathing exercises are performed between laughter exercises. Laughter yoga is concluded with clapping, singing and relaxation exercises."
62514734|NCT06175936|NO_INTERVENTION|Control group|No laughter yoga intervention will be applied to the control group.
62514735|NCT06093087|EXPERIMENTAL|SAIF|patients will be treated with kyphoplasty surgery combined with pedicular screw-assisted internal fixation for vertebral augmentation
62514736|NCT06093087|ACTIVE_COMPARATOR|BKP|patients will be treated with balloon kyphoplasty surgery for vertebral augmentation
62514737|NCT02673879|ACTIVE_COMPARATOR|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase.
62514738|NCT02673879|OTHER|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated.
62514739|NCT05754229|OTHER|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
61973297|NCT05066594||Transoral incisionless fundoplication with EsophyX device (EndoGastric Solutions)|Patients treated by transoral incisionless fundoplication (TIF) using the EsophyX device (EndoGastric Solutions) for gastro-esophageal reflux disease will be enrolled in the registry and clinically followed-up for 5 years from the date of TIF procedure.
61973298|NCT01961388||Group 1|Acarbose_BAY G5421
61973299|NCT01961388||Group 2|Metformin
62514740|NCT04316130|EXPERIMENTAL|Exercise using Uincare Homeplus|Uincare Homeplus
62514741|NCT04316130|ACTIVE_COMPARATOR|Exercise using brochure|brochure
61973300|NCT06395454|EXPERIMENTAL|Procalcitonin guided antibiotics treatment duration|Procalcitonin test in addition to standard care blood investigations
62514742|NCT04410484||1|Admitted patients with IBD (with IBD OR due to COVID) whether tested or not tested for COVID between 1st March and 30th June 2020
62147401|NCT06501027|EXPERIMENTAL|Vagal nerve stimulation|Only vagal nerve stimulation was administered to the Intervention II group. Vagal nerve stimulation was administered to all participants in both groups using the Non-invasive Auricular Vagus Nerve Stimulation device. The stimulation was biphasic, with a frequency of 10 Hz and a pulse width of 300 μs in Modulation mode. Current intensity was adjusted by attaching the device to the participant's right or left ears, ensuring that they felt the current comfortably, and maintaining a constant level. Stimulation sessions occurred every 3 weeks, with non-invasive auricular vagus nerve stimulation applied for 20 minutes per session over a period of 3 days.
62147402|NCT02111551|EXPERIMENTAL|DMXB-A 75 mg|DMXB-A 75 mg dose followed by a second dose of 37.5 mg at 2 hours to maintain the blood level
62147403|NCT02111551|EXPERIMENTAL|DMXB-A 150 mg|DMXB-A 150 mg followed by a second dose of 75 mg at 2 hours to maintain the blood level
62514743|NCT04410484||2|Patients with IBD self-isolating with suggestive COVID19 symptoms (Fever or persistent Cough) or tested positive for COVID19 during same period
62514744|NCT04410484||3|Patients with active IBD identified during the same study period. (definition: increased symptoms suggestive of flare, raised calprotectin, raised CRP, endoscopy or imaging during the previous 6 weeks showing active disease and contacted/reviewed during the study period , admission with IBD ( These will be identified through your helpline/ virtual clinics/Hot clinics/flare lines
62514745|NCT04410484||Control Group|Consecutive patients with active IBD between 1st March 2019-30th June 2019
62514746|NCT02689999|EXPERIMENTAL|Dexrabeprazole 10 mg Enteric-Coated Tablets|Dexrabeprazole 10 mg Enteric-Coated Tablets / once daily
62514747|NCT03919448|ACTIVE_COMPARATOR|Zutrab® (Bevacizumab Richmond)|a single 1 mg/kg IV dose of Bevacizumab
62514748|NCT03919448|ACTIVE_COMPARATOR|Avastin®|a single 1 mg/kg IV dose of Bevacizumab
62514749|NCT03919448|ACTIVE_COMPARATOR|Cizumab®|a single 1 mg/kg IV dose of Bevacizumab
62514750|NCT02171767|EXPERIMENTAL|BIBW 2992 MA2 - single rising dose|
61973301|NCT06395454|NO_INTERVENTION|Standard care guided antibiotics treatment duration|
61973302|NCT02388204|EXPERIMENTAL|Parkinson's disease patients|Group description: PD patients with locomotion problems as the primary complain with no interventions other than medication and rehabilitation therapies Intervention: Implantable spinal cord stimulation.
61973303|NCT02388204|EXPERIMENTAL|DBS Parkinson's disease patients|"Group description: PD patients with locomotion problems as the primary complain after cardinal symptoms are controlled by DBS.~Intervention: Implantable spinal cord stimulation."
61973304|NCT00005610|EXPERIMENTAL|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) over 10-15 minutes twice daily for 7 days. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and prior to course 5.~Patients are followed every 2 months for at least 1.5 years."
61973305|NCT05104892|EXPERIMENTAL|Rilzabrutinib|Rilzabrutinib BID or TID and ICS/LABA
61973306|NCT05104892|PLACEBO_COMPARATOR|Placebo|Placebo and ICS/LABA
61973307|NCT00516204||Patients at very high risk|
61973308|NCT00516204||Patients at high risk|
61973309|NCT00516204||Patients at medium risk|
61973310|NCT00516204||Patients at low risk|
62514751|NCT02667821|EXPERIMENTAL|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
62709980|NCT06469983|EXPERIMENTAL|Robotic Verticalization|Erigo® gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance. The Erigo verticalization is coupled with the rhythmic passive movement of the lower limbs ensuring the more normal range of motion (ROM) and the alternation of loading and unloading of the lower limbs, based on patient's osteo-articular condition (e.g., ROM=45°; cadence=min. 24 steps per minute).
62709981|NCT06469983|ACTIVE_COMPARATOR|Traditional Verticalization|gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
62709982|NCT00603681|EXPERIMENTAL|T|Test product
62709983|NCT00603681|ACTIVE_COMPARATOR|C|Reference product
62709984|NCT05160389|EXPERIMENTAL|Fasted|Study drug will be administered with water, after an overnight fast.
62709985|NCT05160389|EXPERIMENTAL|Low-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard low-fat breakfast will be given.
61973311|NCT04907721|EXPERIMENTAL|Measuring glucagon sensitivity in humans|Participants will be subjected to two experimental days.
61973312|NCT06494839|EXPERIMENTAL|Bipolar electrocautery tonsillectomy group|
62709986|NCT05160389|EXPERIMENTAL|High-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard high-fat breakfast will be given.
62709987|NCT06544720|EXPERIMENTAL|SCG142 TCR-T cells|Monotherapy of SCG142
62147404|NCT02111551|PLACEBO_COMPARATOR|Sugar Pill|placebo comparator dose followed by a second placebo dose at 2 hours to maintain blind
62147405|NCT00822432||1|
62147406|NCT00022165|PLACEBO_COMPARATOR|Placebo|Selenium yeast
62514752|NCT06013059|ACTIVE_COMPARATOR|level (I) arthroscopy (Lysis and lavage)|
62709988|NCT03585387||Main|Each subject in this group will be its own control for the two navigation methods.
62709989|NCT05115266|EXPERIMENTAL|Experimental group (EG)|Receive animal-assisted therapy and usual treatment (ATT)
62147407|NCT00022165|EXPERIMENTAL|Selenium yeast 100 micrograms per day|100 micrograms per day
62514753|NCT06013059|ACTIVE_COMPARATOR|level (II) arthroscopy (operative arthroscopy)|
62709990|NCT05115266|ACTIVE_COMPARATOR|Control group|Receive usual treatment
62709991|NCT00734552|ACTIVE_COMPARATOR|1|α-Keto Acid plus low protein diet
62709992|NCT00734552|OTHER|2|Normal protein diet
62514754|NCT06013059|ACTIVE_COMPARATOR|level (III) arthroscopy (operative arthroscopy + disc repositioning and fixation)|
62514755|NCT00878696||Tinnitus|Tinnitus patients
62709993|NCT04908644|EXPERIMENTAL|MS-20 oral solution|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
62709994|NCT04908644|PLACEBO_COMPARATOR|Placebo|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
62709995|NCT01564017|EXPERIMENTAL|Allergovac depot. Group 1|Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
62147408|NCT00022165|EXPERIMENTAL|Selenium yeast 200 micrograms per day|200 micrograms per day
62147409|NCT00022165|EXPERIMENTAL|Selenium yeast 300 micrograms per day|300 micrograms per day
62709996|NCT01564017|EXPERIMENTAL|Allergovac depot. Group 2|Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
62709997|NCT01564017|EXPERIMENTAL|Allergovac depot. Group 3|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
62709998|NCT01564017|EXPERIMENTAL|Allergovac depot. Group 4|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
61973313|NCT06494839|EXPERIMENTAL|Cold steel dissection group|
61973314|NCT00446290|EXPERIMENTAL|Docetaxel, Capecitabine and Oxaliplatin|
61973315|NCT00296374|EXPERIMENTAL|1|Rosuvastatin 10 mg
61973316|NCT00296374|EXPERIMENTAL|2|Rosuvastatin 40 mg
61973317|NCT00296374|ACTIVE_COMPARATOR|3|Atorvastatin 80 mg
61973318|NCT03111901|EXPERIMENTAL|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
61973319|NCT03111901|EXPERIMENTAL|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
61973320|NCT04542655|OTHER|Cycling first|Ergometer cycling then treadmill running then rest
61973321|NCT04542655|OTHER|Running first|Treadmill running then ergometer cycling then rest
61973322|NCT03853395|ACTIVE_COMPARATOR|Control Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will not receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant.
62147410|NCT04665583||Prehabilitation|All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.
62147411|NCT03042767|EXPERIMENTAL|IMM-124E Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive 600mg of IMM-124E powder three times daily for twelve weeks.
62709999|NCT01564017|EXPERIMENTAL|Allergovac depot. Group 5|Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
62710000|NCT01564017|PLACEBO_COMPARATOR|Allergovac depot placebo. Group 6|The same scheme of treatment as the active groups
62514756|NCT01284855|ACTIVE_COMPARATOR|Low initial dose|This arms corresponds to Nepal national protocol and involves the initial administration of 2 vials of antivenom over one hour followed by the slow infusion of 4 vials over 4 hours
62514757|NCT01284855|EXPERIMENTAL|High initial dose|This arms corresponds to Indian national protocol and involves the initial administration of 10 vials of antivenom over one hour followed by the slow infusion of saline over 4 hours
62514758|NCT01754506|EXPERIMENTAL|EPA+DHA|EPA+DHA (fish oil)
62514759|NCT01754506|PLACEBO_COMPARATOR|Placebo|mineral oil
62514760|NCT03232099|EXPERIMENTAL|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
62514761|NCT03232099|ACTIVE_COMPARATOR|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
62514762|NCT05273931|EXPERIMENTAL|Lifestyle intervention|Lifestyle intervention among participants of the French colorectal cancer screening program
62514763|NCT06456879|ACTIVE_COMPARATOR|Stainless Steel Crown|crown
62514764|NCT06456879|ACTIVE_COMPARATOR|• NuSmile zirconia crown|crown
62514765|NCT06456879|ACTIVE_COMPARATOR|• CAD CAM zirconia crown|crown
62514766|NCT06456879|ACTIVE_COMPARATOR|• CAD CAM hybrid crown|crown
62514767|NCT03875014||group 1|Bipolar hemiarthroplasty grop
62514768|NCT03875014||group 2|Total hip replacement dual mobility group
62514769|NCT05310799|NO_INTERVENTION|Current Best Practice|"Physicians randomized to this arm will provide current care and treatment decisions with patients will be made in accordance with current best practices. Will not engage in structured shared decision making (SDM) discussion and will not have access to PERSON-JIA Reports.~Patients will be consented to enroll in the CAPRI Registry at the clinic visit when they are diagnosed. Registry enrollment will allow collection and input of clinical data into the Registry.~Clinic visit and discussion will remain unchanged for physicians, patients and their families. Questionnaires will be collected at enrollment, at the second visit and a 6-month and 12-month follow-up visits."
62710001|NCT00775255|EXPERIMENTAL|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
62147412|NCT03042767|PLACEBO_COMPARATOR|Placebo Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive placebo powder three times daily for twelve weeks.
62710002|NCT00775255|ACTIVE_COMPARATOR|2|Biaxin® granules 250 mg/5 mL oral suspension
62710003|NCT05873088|OTHER|Isometric|
62147413|NCT01961076|EXPERIMENTAL|uncooked corn starch|Patients receive uncooked corn starch before bed-time
62147414|NCT01961076|EXPERIMENTAL|modified corn starch|Patients receive modified corn starch before bed-time
62710004|NCT05873088|EXPERIMENTAL|Isotonic Exercise|
62710005|NCT03041220||cesarean section|Obese pregnant patients who have had a cesarean section.
62710006|NCT01126073|PLACEBO_COMPARATOR|placebo|
62710007|NCT01126073|ACTIVE_COMPARATOR|Niacin/Laropiprant 2000mg/40 mg|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will be randomized in the ratio 1:1 to either receive ER niacin/laropiprant or placebo in addition to the statin therapy. Patients in the ER niacin/laropiprant group will receive 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
62710008|NCT03152578|ACTIVE_COMPARATOR|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
62710009|NCT03152578|ACTIVE_COMPARATOR|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
62147415|NCT01961076|EXPERIMENTAL|other carbohydrate (starch) containing meal|Patients receive a carbohydrate (starch) containing meal before bed-time
62147416|NCT03847727||Experimental: 6 cycles BR -> 4 x BR|Induction plus BR as maintenance (N=56)
62710010|NCT03152578|PLACEBO_COMPARATOR|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
62710011|NCT00474903|ACTIVE_COMPARATOR|Arm I (placebo, esomeprazole magnesium)|Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
62710012|NCT00474903|EXPERIMENTAL|Arm II (low-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
62147417|NCT03847727||Proper historical control: 6 cycles BR|Induction only (N=56)
62147418|NCT04070105|EXPERIMENTAL|CAESAR Foot, Prescribed Feet, AllPro|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is CAESAR Foot, Prescribed Feet, AllPro.
62147419|NCT04070105|EXPERIMENTAL|CAESAR Foot, AllPro, Prescribed Feet|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is CAESAR Foot, AllPro, Prescribed Feet
62147420|NCT04070105|EXPERIMENTAL|Prescribed Feet, AllPro, CAESAR Foot|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is Prescribed Feet, AllPro, CAESAR Foot
62539467|NCT06599580|EXPERIMENTAL|Caregiver mid-upper arm circumference (MUAC) screening and a standard of care follow-up schedule|This arm will include caregiver screening with a mid-upper arm circumference tape at home weekly. Caregivers will be trained to screen their child for malnutrition relapse using mid-upper arm circumference tapes and requested to bring their child back to the clinic when relapse is detected. Additionally, this arm will receive the standard of care, which includes a monthly follow-up schedule for the first 3 months post enrollment and a final follow-up at 6 months.
62710013|NCT00474903|EXPERIMENTAL|Arm III (higher-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
62710014|NCT04046939|PLACEBO_COMPARATOR|placebo BID|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.
62710015|NCT04046939|ACTIVE_COMPARATOR|37.5 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.
62710016|NCT04046939|ACTIVE_COMPARATOR|75 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.
62710017|NCT04046939|ACTIVE_COMPARATOR|150 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.
61973323|NCT03853395|EXPERIMENTAL|Experimental Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant. They will be able to act accordingly.
62514770|NCT05310799|EXPERIMENTAL|Shared Decision Making (SDM)|"Physicians will use the PERSON-JIA Report to guide discussions with the newly diagnosed patient and family. The intervention will not dictate the use of specific medications or treatment strategies, only facilitate better informed treatment choices according to patient circumstances.~The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis. Discussion is guided by the PERSON-JIA Report, which is generated in real time, on the physician's smart phone.~Patients newly-diagnosed with JIA will be consented to both enrollment in the CAPRI Registry and enrollment in the PERSON-JIA trial.~Clinic visit and discussion between the physician, patient and family will be facilitated by the PERSON-JIA report to support a shared decision making process. Questionnaires will be collected at enrollment, at the second visit and at 6-month and 12-month follow-up visits."
62710018|NCT01067430|ACTIVE_COMPARATOR|Etoricoxib 90 mg|Subject will take Etoricoxib 90 mg for 14 days
62354038|NCT04286828||Females with Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
62710019|NCT01067430|ACTIVE_COMPARATOR|Diclofenac|Film coated tablet 50 mgs given three times a day for 14 days
62710020|NCT06157073|ACTIVE_COMPARATOR|Open-loop ventilator|Prior to the rapid sequence intubation, patients' gender and height are set on the ventilator. The physician in-charge will setup the ventilator based on the lung condition, following the research protocol. Patients will be connected to this ventilator upon securing the airway. Ventilator setting parameters will be manually adjusted by the in-charge physician following local guidelines.
62710021|NCT06157073|EXPERIMENTAL|Closed-loop ventilator|Prior to the rapid sequence intubation, patients' gender and height are set on the ventilator. Patients' condition settings are selected depending on the lung condition. The sensors for end-tidal carbon dioxide (EtCO2) and oxygen saturation (SpO2) will be connected. Patients will be connected to this ventilator upon securing the airway. Ventilator setting parameters will be set following the study protocol.
62710022|NCT04951349|EXPERIMENTAL|Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using GX-03 administered intranasally TID for 5 days.
62354039|NCT04286828||Healthy Females|20 healthy volunteers with matching ages and genders.
62354040|NCT00229229|OTHER|1|Low glycemic load diet
62514771|NCT01150552||Poultry exposed individuals|Any individual who had an occupational contact with poultry in the previous five years will be considered exposed. Individuals working on poultry farms, poultry wet markets, or keeping limited numbers of poultry in their backyard, are considered exposed.
62710023|NCT04951349|PLACEBO_COMPARATOR|Placebo Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 5 days.
62710024|NCT04951349|EXPERIMENTAL|Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using GX-03 administered intranasally TID for 10 days.
62710025|NCT04951349|PLACEBO_COMPARATOR|Placebo Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 10 days.
62710026|NCT02179073||neurogenic bladder dysfunction|
62710027|NCT01074931||Lopinavir/ritonavir group|This study is a non-interventional, observational study in which lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of China market authorization with regards to dose, population and indication. It is planned to enroll approximately 100 patients in total.
62710028|NCT03434834|EXPERIMENTAL|OCT of esophagus|optical coherence tomography of esophagus
62710029|NCT05086484||Endometriosis group|Women diagnosed with endometriosis.
62710030|NCT05086484||Control group|Women diagnosed without endometriosis.
62710031|NCT01076114||Control|Patients with no evidence of glaucoma or as a suspect with normal intraocular pressure, normal cup to disc ratio with no other ocular pathology and a normal ophthalmic exam.
62710032|NCT01076114||Glaucoma Suspect|Patients with abnormal cup to disc ratio or increased intraocular pressure (\>21mm/Hg) with an otherwise normal ophthalmic exam.
62710033|NCT02136784|EXPERIMENTAL|morphine sulfate|30mg, single dose,
62710034|NCT02136784|EXPERIMENTAL|hydrocodone|10mg single dose
61973324|NCT00711854|EXPERIMENTAL|1|trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
61973325|NCT00711854|ACTIVE_COMPARATOR|2|Linezolid
61973326|NCT04035681|EXPERIMENTAL|Problem-Solving Therapy|Participants who are assigned to receive problem-solving therapy will work with a research team member for six, one-hour sessions. During each session, participants will identify a problem (big or small) and create a plan to work on that problem.
62147421|NCT04070105|EXPERIMENTAL|Prescribed Feet, CAESAR Foot, AllPro|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is Prescribed Feet, CAESAR Foot, AllPro
62147422|NCT04070105|EXPERIMENTAL|AllPro, Prescribed Feet, CAESAR Foot|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is AllPro, Prescribed Feet, CAESAR Foot
62710035|NCT02136784|EXPERIMENTAL|hydromorphone HCI|4mg single dose
62710036|NCT02136784|EXPERIMENTAL|oxycodone|10 mg single dose
62710037|NCT02136784|EXPERIMENTAL|buprenorphine|4 mg single dose
62354041|NCT00229229|OTHER|2|Canada Food Guide Diet
62354042|NCT00229229|OTHER|3|Low glycemic index diet
62354043|NCT00229229|OTHER|4|Low carbohydrate diet
62354044|NCT05843071|EXPERIMENTAL|Nasal spray treatment arm|
62710038|NCT02136784|PLACEBO_COMPARATOR|oral tablet placebo|single dose
61973327|NCT04035681|ACTIVE_COMPARATOR|Stroke-Related Health Education|Participants who are assigned to receive stroke-related health education will work with a research team member who will teach them about various topics related to stroke over six, one-hour sessions. Each session will cover information about a different topic related to stroke.
61973328|NCT04316754|NO_INTERVENTION|Control group|No music will be played to the control group.
61973329|NCT04316754|ACTIVE_COMPARATOR|Intervention 1|During angiography, the Intervention-1 group will listen to the music that the child wants to listen.
61973330|NCT04316754|ACTIVE_COMPARATOR|Intervention-2|"The Intervention-2 group will listen to the music which determined by the researchers. The music which determined by the researchers is The art of fugue by Johann Sebastian Bach. The music to be played has been decided by examining the literature. (DOI: 10.4274/jpr.24892)"
61973331|NCT05855850|EXPERIMENTAL|Active H4-coil dTMS treatment|
61973332|NCT05855850|EXPERIMENTAL|Active H7-coil dTMS treatment|
61973333|NCT00010374|EXPERIMENTAL|NeuRx DPS|Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.
61973334|NCT01094223|EXPERIMENTAL|Mindfulness|Mindfulness Based Relapse Prevention (MBRP). Meditation based therapy group incorporating relapse prevention skills training.
62147423|NCT04070105|EXPERIMENTAL|AllPro, CAESAR Foot, Prescribed Feet,|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is AllPro, CAESAR Foot, Prescribed Feet
62147424|NCT04820491|ACTIVE_COMPARATOR|X-Ray|
62147425|NCT04820491|ACTIVE_COMPARATOR|Ultrasound|
62710039|NCT02136784|PLACEBO_COMPARATOR|sublingual tablet placebo|single dose
62710040|NCT05517408|EXPERIMENTAL|Ciprofol group|
62710041|NCT06113861||Presumptive pediatric TB cases-- Test population|"Inclusion criteria: Children ages 2 months to 14 years with symptomatic disease and suspicion of TB (based on Bolivian Ministry of Health guidelines).~Exclusion criteria (prior treatment for TB in 12 mo, current treatment for TB, weight \< 2.5 kg., instability, positive COVID-19 test) Study subgroups are determined in part based on the results of diagnostic tests and on clinical response.~A. Confirmed TB~* Symptomatic by case definition from the 2015 NIH Expert Panel~* Positive culture or positive Xpert MTB/RIF from at least one sample.~B. Unconfirmed TB-~* Symptomatic and clinical/radiographic evaluation consistent with TB, by case definition from the 2015 NIH Expert Panel~* Negative M. tuberculosis culture and negative Xpert MTB/RIF from all samples.~C. Unlikely TB---~* Symptomatic BUT clinical/radiographic eval does NOT meet criteria for Unconfirmed TB, per clinical definition-2015 Expert Panel~* Negative culture and negative Xpert MTB/RIF from all specimens."
62710042|NCT06113861||Control group--Test population|"Well Children Control Group-One for each child in groups A-C above, age matched for paired case.~* Well children presenting for reasons other than respiratory diseases, and not symptomatic for TB.~* Clinical and radiographic evaluation (if performed) NOT suggestive of TB, and NOT diagnosed or treated for TB during the follow-up period (minimum 8 weeks).~* Divided into 2 subgroups based on presence or absence of LTBI (by Quantiferon Gold assay)."
62147426|NCT04852237||Pregnancies from ICSI-TESE cycles for obstructive azoospermia.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI-TESE cycles for obstructive azoospermia.
61973335|NCT01094223|ACTIVE_COMPARATOR|Health Education|Health education, psychoeducation group focused on various topics pertaining to physical health
61973336|NCT06154785||International cohort|This is an international cohort (France and other international centers) which consists of including patients undergoing colorectal surgery performed at low pressure for benign or malignant pathology.This stage 2b cohort study is a pilot study assessing the best operative association with stable low-pressure pneumoperitoneum in order to optimize postoperative outcomes after mini invasive colorectal surgery.
61973337|NCT06224101|NO_INTERVENTION|Conventional training group|The conventional training group will visualize a video-recorded simulation procedure with duration of 20 minutes, in which the steps of the ICA are explained.
61973338|NCT06224101|EXPERIMENTAL|Simulation training group|The simulation training group will perform coronary angiography simulated training with 3D printed simulator SimulHeart in groups of two, with debriefing and feedback. Participants will be taught on how to perform each step of the procedure and guide on safety measures concerning catheter handling, radiation exposure, and contrast administration. The duration of simulated training will be 20 minutes per group.
61973339|NCT00556712|EXPERIMENTAL|Erlotinib|Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
61973340|NCT00556712|PLACEBO_COMPARATOR|Placebo|Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.
61973341|NCT06184815|EXPERIMENTAL|Educational programme 12|The educational programme consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months. The multidisciplinary treatment consists of 4, each one every month, consultations of specialties of nutrition, endocinrology and psychology.
62147427|NCT04852237||Pregnancies from ICSI cycles with ejaculated sperm.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI cycles with ejaculated sperm.
62147428|NCT06261905|ACTIVE_COMPARATOR|Calcitriol|Subjects with OUD will receive a baseline MRI. On the night before and day of testing, subjects with OUD will receive two doses of calcitriol (3.0mcg total), followed by PHNO injection and PET Scan for the calcitriol condition. All subjects will complete the study with both active calcitriol and a placebo control and the order these interventions are received will be randomized.
62354045|NCT06105203|OTHER|RATME|In RaTME groups, the low anterior resection and TME was finished with the assistance of robot (da Vinci Xi surgical system)
62354046|NCT06105203|OTHER|LATME|In LaTME groups, the low anterior resection and mesorectal excision procedures was completed under laparoscopy.
62354047|NCT05904691|EXPERIMENTAL|Cohort A - Dose 1|
62514772|NCT01150552||Non-poultry exposed adult controls|Unexposed individuals must have no occupational exposure to poultry in their lifetime and must also not be exposed to poultry purchased from live bird markets.
62514773|NCT06469177|EXPERIMENTAL|Pain Coach App Users|Participants enrolled in Pain Coach App software and directed to download on their mobile device
61973342|NCT06184815|ACTIVE_COMPARATOR|Standard|The standard educational program consists of outpatient management with diabetic education slides and material for the patient, with a duration of 4 months. Standard treatment consists of endocrinology consultation with nutrition and psychology referral if required
61973343|NCT04960150|EXPERIMENTAL|Acupuncture group|Intervention of press tack needle acupuncture
62354048|NCT05904691|EXPERIMENTAL|Cohort A - Dose 2|
62354049|NCT05904691|EXPERIMENTAL|Cohort A - Dose 3|
62354050|NCT05904691|EXPERIMENTAL|Cohort B - Dose TBD|
62354051|NCT05019495|NO_INTERVENTION|Treatment as Usual|Treatment as Usual (TAU) participants will follow traditional clinic pathways for receiving tobacco treatment in the Medical University of South Carolina Health Infectious Disease outpatient clinic. All patients randomized to TAU will have the opportunity to access smoking cessation pharmacotherapy from the Infectious Disease clinical pharmacist.
62354052|NCT05019495|EXPERIMENTAL|ProMOTE|In the PrOMOTE group, the participants will be contacted by the clinical pharmacist on the tobacco treatment staff three times for medication prescriptions and refills. They will also receive brief counseling and motivational interviewing by the clinical pharmacist.
62354053|NCT02157246|OTHER|Group A, pimonidazole, no CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI, Pimonidazole
62354054|NCT02157246|OTHER|Group B, CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI
62354055|NCT03890393||patients with episodic headache|
62354056|NCT03890393||patients with chronic headache|
62354057|NCT03890393||healthy controls|
62354058|NCT03711877|EXPERIMENTAL|scalp cooling system|'Scalp cooling device' will be used to prevent alopecia during chemotherapy regimen infusion.
62354059|NCT03711877|ACTIVE_COMPARATOR|cold cap|'Cold cap' will be used to prevent alopecia during chemotherapy regimen infusion.
62354060|NCT01312324|EXPERIMENTAL|neoadjuvant chemotherapy|3 cycles of docetaxel/cisplatin before operation
62354061|NCT02765503|ACTIVE_COMPARATOR|Control|'Standard' external beam radiotherapy to deliver 66Gy in 33 fractions treating with 6 fractions a week.
62354062|NCT02765503|EXPERIMENTAL|HYPNO|The experimental regimen in which patients receive external beam radiotherapy to deliver 55Gy in 20 fractions treating 5 times a week.
62354063|NCT05944653||Women with hormonal contraception|
62354064|NCT05944653||Women without hormonal contraception|
62354065|NCT00376246|OTHER|Group 1|1st group will receive Ezetimibe for 2 weeks followed by washout (no medication) period for 4 weeks and followed by placebo for 2 weeks.
62354066|NCT00376246|OTHER|Group 2|2nd group will receive Ezetimibe and placebo in reverse order with interspaced 4-week washout period.
62354067|NCT03649334|OTHER|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
62354068|NCT03649334|OTHER|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
62354069|NCT04616495||Liver transplanted patients|
62354070|NCT04469803|EXPERIMENTAL|No nap, brief nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
62354071|NCT04469803|EXPERIMENTAL|No nap, longer nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
62354072|NCT04469803|EXPERIMENTAL|Brief nap, no nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
62354073|NCT04469803|EXPERIMENTAL|Brief nap, longer nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
62354074|NCT04469803|EXPERIMENTAL|Longer nap, brief nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
61973344|NCT04960150|PLACEBO_COMPARATOR|Control group|Intervention of placebo acupuncture
62514774|NCT06469177|NO_INTERVENTION|Standard of Care|Participants received traditional standard of care supports for joint arthroplasty surgery
62514775|NCT01891305|EXPERIMENTAL|VT-1161 200/50mg|
62514776|NCT01891305|EXPERIMENTAL|VT-1161 600/150mg|
62514777|NCT01891305|EXPERIMENTAL|VT-1161 1200/300mg|
62514778|NCT01891305|PLACEBO_COMPARATOR|Matching placebo|
61973345|NCT04542772|EXPERIMENTAL|Mirror Therapy + Standard of Care|Participants in this group will receive standard of care based on their needs along with mirror therapy education.
61973346|NCT04542772|ACTIVE_COMPARATOR|Standard of Care|Participants in this group will receive only standard of care based on their needs.
62715072|NCT06093464|EXPERIMENTAL|Group C- Natural Compound C to Natural Compound A to Natural Compound B|"* Cycle 1 (4 weeks): use diffused Natural Compound C (control) in a diffuser every night when sleeping~* Cycle 2 (4 weeks): will not use compounds/diffuser (wash-out period)~* Cycle 3 (4 weeks): use diffused Natural Compound A (essential oil) in a diffuser every night when sleeping~* Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~* Cycle 3 (4 weeks): use diffused Natural Compound B (essential oil) in a diffuser every night when sleeping~* Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~There will be 3 natural compounds; the intervention compounds essential oils and are commercially available and there is a control compound (water). They will be used as intended with diffusers."
62514779|NCT04729465|ACTIVE_COMPARATOR|Active Comparator|"Active Comparator: Control Patients with cardiac disaese receive general anesthesia with Propofol~Interventions:~Drug: Propofol"
62514780|NCT04729465|EXPERIMENTAL|Experimental|"Experimental: Bispectral Index Monitor Patients with cardiac disease receive a general anesthesia with Propofol where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Interventions:~Drug: Propofol Device: Bispectral Index Monitor"
62514781|NCT00877552||Control|Typically developing
62514782|NCT00877552||Mild ventriculomegaly (MVM)|Fetal isolated mild ventriculomegaly
62514783|NCT00877552||Schizophrenia High Risk|Offspring of mothers with schizophrenia
62514784|NCT00877552||Bipolar High Risk|Offspring of mothers with schizophrenia
62514785|NCT00963079|EXPERIMENTAL|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
61973347|NCT01144923|ACTIVE_COMPARATOR|Conservative treatment|Pharmacotherapy with nortriptyline and/ or gabapentin, physical therapy (e.g. range of motion, therapeutic massage, strengthening exercises), and possibly others (e.g. acupuncture)
62354075|NCT04469803|EXPERIMENTAL|Longer nap, no nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
62354076|NCT03398733|OTHER|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively.
62354077|NCT00734487||1. AREDS2 subjects|Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.
62354078|NCT00734487||2. Controls|Age-matched subjects without retinal pathology
62354079|NCT03027843|ACTIVE_COMPARATOR|GH group|patients in group mini-dose GnRH-a long protocol combine with growth hormone
62354080|NCT03027843|NO_INTERVENTION|control group|patients in group mini-dose GnRH-a long protocol without growth hormone
62354081|NCT00707460|ACTIVE_COMPARATOR|1|Please, see design section for details.
62354082|NCT00707460|EXPERIMENTAL|2|"Traditional Diet~Please, see design section for details."
62354083|NCT00707460|EXPERIMENTAL|3|"Healthy Store-bought Diet~Please, see design section for details."
62354084|NCT06397742|EXPERIMENTAL|Physical activity under supervision|The subjects receive physical therapy three times a week for 45 minutes, during a six-week period under professional supervision.
62354085|NCT06397742|ACTIVE_COMPARATOR|Home exercise|"The subjects receive a set of exercises and a recommendation to perform them at least three times a week for 45 minutes.~To ensure compliance the subjects receive journals to record the performed exercises. Additionally subjects are contacted by phone to motivate them to exercise with adequate intensity. Furthermore the proper exercise technique is verified at periodic control visits."
62354086|NCT00649051|EXPERIMENTAL|1|Metolazone Tablets 2.5 mg
62354087|NCT00649051|ACTIVE_COMPARATOR|2|Zaroloxyn® Tablets 2.5 mg
62354088|NCT05389384|EXPERIMENTAL|Peripheral fatigue - No support|peripheral fatigue induced and overhead work performed without exoskeleton support
62354089|NCT05389384|EXPERIMENTAL|Peripheral fatigue - Exoskeleton support|peripheral fatigue induced and overhead work performed with exoskeleton support
62715073|NCT05918445|EXPERIMENTAL|PM8002|PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)
61973348|NCT01144923|EXPERIMENTAL|Epidural Steroids|A series of up to 3 epidural steroid injections (ESI)with depo-methylprednisolone
62354090|NCT05389384|EXPERIMENTAL|No fatigue - No support|peripheral fatigue induced and overhead work performed without exoskeleton support
62354091|NCT05389384|EXPERIMENTAL|No fatigue - Exoskeleton support|peripheral fatigue induced and overhead work performed with exoskeleton support
62354092|NCT05652413|EXPERIMENTAL|Adapted-Engage-PA|Participants will receive two sessions, lasting 60 minutes each, of behavioral intervention strategies to increase daily walking routines and prevent pain flares.
62354093|NCT04205695|ACTIVE_COMPARATOR|CEMP (closed-ended multiport catheter) group|Infraclavicular closed-ended multiport nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
62354094|NCT04205695|ACTIVE_COMPARATOR|OESP (open-ended single port catheter) group|Infraclavicular open-ended single port nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
62514786|NCT00963079|ACTIVE_COMPARATOR|Fresh blastocyst transfer|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
62514787|NCT01207440|EXPERIMENTAL|Cohort A: CP-CML R-I|CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
62514788|NCT01207440|EXPERIMENTAL|Cohort B: CP-CML with T315I Mutation|CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
62514789|NCT01207440|EXPERIMENTAL|Cohort C: Accelerated Phase (AP)-CML R-I|AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
62514790|NCT01207440|EXPERIMENTAL|Cohort D: AP-CML with T315I Mutation|AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
62710043|NCT06113861||Presumptive pediatric TB cases-- Validation population|"Inclusion criteria: Children ages 2 months to 14 years with symptomatic disease and suspicion of TB (based on Bolivian Ministry of Health guidelines).~Exclusion criteria (prior treatment for TB in 12 mo, current treatment for TB, weight \< 2.5 kg., instability, positive COVID-19 test) Study subgroups are determined in part based on the results of diagnostic tests and on clinical response.~A. Confirmed TB~* Symptomatic by case definition from the 2015 NIH Expert Panel~* Positive culture or positive Xpert MTB/RIF from at least one sample.~B. Unconfirmed TB-~* Symptomatic and clinical/radiographic evaluation consistent with TB, by case definition from the 2015 NIH Expert Panel~* Negative M. tuberculosis culture and negative Xpert MTB/RIF from all samples.~C. Unlikely TB---~* Symptomatic BUT clinical/radiographic eval does NOT meet criteria for Unconfirmed TB, per clinical definition-2015 Expert Panel~* Negative culture and negative Xpert MTB/RIF from all specimens."
62710044|NCT06113861||Control group--Validation population|"Well Children Control Group-One for each child in groups A-C above, age matched for paired case.~* Well children presenting for reasons other than respiratory diseases, and not symptomatic for TB.~* Clinical and radiographic evaluation (if performed) NOT suggestive of TB, and NOT diagnosed or treated for TB during the follow-up period (minimum 8 weeks).~* Divided into 2 subgroups based on presence or absence of LTBI (by Quantiferon Gold assay)."
61973349|NCT01144923|EXPERIMENTAL|Combination Treatment|These patients will receive both treatments. They can have up to 3 epidural steroid injections (ESI) with depo-methylprednisolone, and conservative treatment (i.e. pharmacotherapy with nortriptyline and/ or gabapentin, and physical therapy)
61973350|NCT06205004||Young adults in HK|questionnaire based study
61973351|NCT02336711|EXPERIMENTAL|Dose escalation|Dose escalation
62514791|NCT01207440|EXPERIMENTAL|Cohort E: Blast Phase (BP)-CML/Ph+ ALL R-I|BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
62710045|NCT02040389|ACTIVE_COMPARATOR|pictures book + standard education|arm with children undergoing urological procedures and their parents will receive standard preoperative education + pictures book with pictures of surgical wound in different stages of healing
62710046|NCT02040389|ACTIVE_COMPARATOR|Standard preoperative education|Arm with children undergoing urological procedures and their parents will receive only standard preoperative education
61973352|NCT03661632|EXPERIMENTAL|Dose Escalation|"Part 1: BMS-986310 + Nivolumab Combination Dose Escalation~Sub-Study A: A cohort of Cisplatin Ineligible Muscle Invasive Bladder Cancer patients will receive either monotherapy BMS-986310, or BMS-986310 + Nivolumab, or Nivolumab monotherapy.~Sub-Study B: A cohort of PD\[L\]1 relapsed / refractory tumor cancer patients will be treated with monotherapy BMS-986310 followed by BMS-986310 + nivolumab"
61973353|NCT03661632|EXPERIMENTAL|Cohort Expansion|"Part 2: Cohort Expansion will initiate upon consideration of the totality of data from Part 1.~BMS-986310 + Nivolumab combination will be administered in specific patient populations."
61973354|NCT05736744|ACTIVE_COMPARATOR|Rocuronium/MgSO4|"1. The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.~2. Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval"
61973355|NCT05736744|ACTIVE_COMPARATOR|Cis-Atracurium/MgSO4|"1. The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.~2. Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals."
61973356|NCT03032094|ACTIVE_COMPARATOR|1mm thick graft|connective tissue graft of 1mm thickness
61973357|NCT03032094|ACTIVE_COMPARATOR|2mm thick graft|connective tissue graft of 2mm thickness
61973358|NCT02150798|EXPERIMENTAL|High fat and low carbohydrate diet|High fat low carbohydrate diet composition was 40 % of carbohydrates, 40 % of lipids (12 % saturated, 18 % monounsaturated and 10% polyunsaturated, ) and 20 % of protein for two months
61973359|NCT02150798|ACTIVE_COMPARATOR|Control diet|the standard diet composition was 50 % of carbohydrates, 30 % of lipids (10 % saturated, 10 % polyunsaturated, and 10 % monounsaturated) and 20 % of protein for two months
61973360|NCT03935529|EXPERIMENTAL|Behavioural Acitivation|Behavioural Activation. Originally a component of cognitive behavioural therapy, Behavioural Activation is a structured psychotherapeutic approach which aims to (a) increase engagement in activities associated with pleasure or mastery, (b) decrease engagement in activities that maintain depression, and (c) problem solve barriers limiting access to reward or maintain aversive control. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
61973361|NCT00439842|EXPERIMENTAL|HF group clinic appointments|HF group clinic appointments Heart failure multidisciplinary group clinic appointments (Arm 1 - HFcareGroup) includes 6 teaching sessions with patients led by nurse practitioner.
61973362|NCT00439842|NO_INTERVENTION|Standard HF care|Standard HF care Standard heart failure education includes cardiologists instructions and hospital discharge information.
61973363|NCT04955522||metastases|patients with spinal metastases
61973364|NCT04955522||multiple myeloma|patients with spinal multiple myeloma
61973365|NCT03339960|ACTIVE_COMPARATOR|Robotic camera controlled|
61973366|NCT03339960|ACTIVE_COMPARATOR|Human camera controlled|
61973367|NCT01385202|EXPERIMENTAL|THERMOCOOL® SMARTTOUCH™ Catheter|
61973368|NCT05628454|EXPERIMENTAL|EBUS-TBNSP|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
61973369|NCT05628454|EXPERIMENTAL|EBUS-TBNA|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
61973370|NCT05628454|EXPERIMENTAL|EBUS-TBNCS|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
61973371|NCT03227029|EXPERIMENTAL|RSV ΔNS2/Δ1313/I1314L vaccine|Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
61973372|NCT03227029|EXPERIMENTAL|RSV 276 vaccine|Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
61973373|NCT03227029|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo at study entry (Day 0).
61973374|NCT01442233|EXPERIMENTAL|plasma exchange|6 plasma exchanges during 2 weeks after randomization
61973375|NCT01442233|SHAM_COMPARATOR|sham exchange|6 sham plasma exchanges during 2 weeks after randomization
61973376|NCT05919433||Patients with positive AMA and/or ANA anti-gp210/sp100 identified in the hospital database|
62710047|NCT03890211|EXPERIMENTAL|Non-Electric Infant Warmer|In line with current recommended practice, the mother will be encouraged to provide KMC whenever possible. For hypothermic infants, if the temperature is not rising by ½°C per hour with KMC alone, the Infant Warmer will be offered as an addition. In these cases, the heat will be provided by placing the Infant Warmer over the infant's back while the mother provides KMC. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the Infant Warmer by being placed directly on the warmer as it lies flat. Use of hat and socks will be encouraged by additional clothes will only be added in addition to the warmer per caregiver request, as it reduces heat transfer.
62710048|NCT03890211|NO_INTERVENTION|Control|Data such as infant temperature, date of birth, etc. will be collected from those who enroll in the control group. No experimental intervention will be administered.
62710049|NCT01099488|OTHER|All subjects|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received a GSK2231392A vaccine, were enrolled for blood withdrawal to support the development of CD8+ T cell immunological detection assays.
62514792|NCT01207440|EXPERIMENTAL|Cohort F: BP-CML or Ph+ ALL with T315I Mutation|BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
62514793|NCT01207440|EXPERIMENTAL|Unassigned to Cohorts A-F|Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not R-I to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
62514794|NCT04567576||Exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed infection by 2019-nCoV (COVID-19) who at the time of diagnosis (of infection) receive pharmacological treatment with disease modifying antirheumatic drugs (DMARDs).
62514795|NCT04567576||Un-exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed 2019-nCoV (COVID-19) infection who at the time of diagnosis (of infection) are not receiving pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs).
62514796|NCT03030716|EXPERIMENTAL|0.03 mg 95% condensed proanthocyanidin|0.03 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.03 g 95% condensed proanthocyanidins from grape seed extract at week 4
62354095|NCT06108245|EXPERIMENTAL|Values Clarification Condition|Participants will be asked to respond to values clarification prompts twice a day over 28 days \[4 weeks\]. In each session, participants will receive a randomly assigned writing prompt from a pool of four categories: hierarchical, conditional, distinction, and perspective-taking prompts. In the initial session, participants will be asked to respond to a brief set of questions pertaining to their hoarding behavior in the past 12 hours and their motivation to declutter right now. From that point on, participants will respond to a brief set of questions before each writing prompt pertaining to their hoarding behaviors in the time since the previous writing prompt. After the writing prompt, they will be asked about how motivated they are to declutter right now. Each writing prompt is anticipated to take up to 10 minutes to complete and participants will receive notifications to use the app twice daily in addition email reminders twice a week to engage with the app.
62710050|NCT00499044|EXPERIMENTAL|1|MATRICS Consensus Cognitive Battery
62710051|NCT00499044|EXPERIMENTAL|2|Cognitive Drug Research Computerized Cognitive Assessment System
62710052|NCT02982226|EXPERIMENTAL|ReNu Injection|Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
61973377|NCT01329731|ACTIVE_COMPARATOR|Test|1.25% fluoride (elmex® gelée)
61973378|NCT01329731|PLACEBO_COMPARATOR|Control|0% fluoride (negative control)
62710053|NCT02982226|ACTIVE_COMPARATOR|Corticosteroid Injection|Plantar Fascia injection with Corticosteroids.
62710054|NCT03044145|EXPERIMENTAL|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
61973379|NCT04342364|ACTIVE_COMPARATOR|Slush nitrogen|oocytes are randomized to undergo vitrification utilizing slush nitrogen
61973380|NCT04342364|ACTIVE_COMPARATOR|Liquid Nitrogen|oocytes are randomized to undergo vitrification utilizing liquid nitrogen which is the current standard of care
61973381|NCT04766580|EXPERIMENTAL|Children with ADHD group|The same protocol is used for both groups
61973382|NCT04766580|ACTIVE_COMPARATOR|Children with no ADHD group|The same protocol is used for both groups
61973383|NCT04655274||RayOne Trifocal intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of RayOne Trifocal (Rayner IOL, Ltd.) intraocular lenses
62147429|NCT06261905|PLACEBO_COMPARATOR|Placebo|Subjects with OUD will receive a baseline MRI. On the night before and day of testing, subjects with OUD will receive two doses of an inactive placebo, followed by PHNO injection and PET Scan for the placebo condition. All subjects will complete the study with both active calcitriol and a placebo control and the order these interventions are received will be randomized.
62147430|NCT00950456||H1N1 Pandemic Influenza Vaccine|Subjects will be enrolled and vaccinated according to national policy and standard practice.
62147431|NCT01698541|EXPERIMENTAL|Tacni|Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center
61973384|NCT04655274||AcrySof IQ PanOptix intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of AcrySof IQ PanOptix (Alcon Laboratories, Inc.) intraocular lenses
61973385|NCT05567692||T2D group|subjects with type 2 diabetes
62147432|NCT01698541|ACTIVE_COMPARATOR|Prograf|Tacrolimus administered as Prograf in according to standard protocol at the transplant center
62147433|NCT03176407|EXPERIMENTAL|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
62514797|NCT03030716|EXPERIMENTAL|0.25 g 95% condensed proanthocyanidin|0.25 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.25 g 95% condensed proanthocyanidins from grape seed extract at week 4
62514798|NCT03030716|EXPERIMENTAL|1.5 g 95% condensed proanthocyanidin|1.5 g 95% condensed proanthocyanidins from grape seed extract at week 0 1.5 g 95% condensed proanthocyanidins from grape seed extract at week 4
62147434|NCT01806207|ACTIVE_COMPARATOR|Durolane injection|Intraarticular injection of 3 ml Durolane.
62514799|NCT02582918|NO_INTERVENTION|Group 1: Usual Care|Usual care with opportunistic visit-based HCC surveillance.
62147435|NCT01806207|PLACEBO_COMPARATOR|Saline injection|Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.
62147436|NCT06058130|ACTIVE_COMPARATOR|Anticoagulation alone|Rivaroxaban 20mg once daily or 15mg once daily / Dabigatran 110mg twice daily or 150mg twice daily
62147437|NCT06058130|EXPERIMENTAL|Anticoagulation combined with antiplatelet therapy|Rivaroxaban 20mg once daily or 15mg once daily or 10mg once daily / dabigatran 110mg twice daily or 150mg twice daily+ aspirin 100mg once daily / clopidogrel 75mg once daily / ticagrelor 90mg twice daily / cilostazol 100mg twice daily
62514800|NCT02582918|EXPERIMENTAL|Group 2: Patient Education and Patient Navigation Services|Mailed HCC surveillance outreach with patient education and patient navigation services.
62514801|NCT01427166|EXPERIMENTAL|Ultrasound imaging|Cords that are present in the participant's axilla and/or arm will be imaged with an ultrasound
62514802|NCT00869986|EXPERIMENTAL|Dirucotide|
62514803|NCT00869986|PLACEBO_COMPARATOR|Placebo|
62514804|NCT00817947|ACTIVE_COMPARATOR|Usual airway clearance technique|Airway clearance using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure or oscillating positive expiratory pressure
62147438|NCT02255474|ACTIVE_COMPARATOR|Biofinity|Soft spherical contact lens
62147439|NCT02255474|EXPERIMENTAL|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
62147440|NCT02255474|EXPERIMENTAL|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
62147441|NCT01124552|EXPERIMENTAL|RT001 Botulinum toxin Type A (Dose A)|RT001 (Botulinum toxin Type A)
62147442|NCT01124552|EXPERIMENTAL|RT001 Botulinum toxin type A (Dose B)|RT001 (Botulinum Toxin Type A)
62147443|NCT01124552|OTHER|Dose C|Vehicle Control
62514805|NCT00817947|OTHER|HFCWO|High frequency chest wall oscillation
62514806|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
62514807|NCT01609621||Retrograde access|
61973386|NCT05567692||Non-T2D group|healthy subjects
61973387|NCT03398681|ACTIVE_COMPARATOR|Intravenous ferric carboxymaltose|Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
61973388|NCT03398681|PLACEBO_COMPARATOR|Normal saline|Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.
61973389|NCT00823394||Windsor Village United Methodist Church|Questionnaire + Body Measurements + Self-help Materials
61973390|NCT04327557|EXPERIMENTAL|MBCP Childbirth Education Course|This arm will undergo the 9-week MBCP course.
61973391|NCT04327557|ACTIVE_COMPARATOR|Non-MBCP Childbirth Education Course|This arm will undergo the TAU (treatment as usual) childbirth education course (one that does not have a huge mindfulness component).
61973392|NCT02656979|OTHER|Blood flow pre&post IOP lowering|After measurement of blood flow with MRI and measurements of ocular parameters the patient receives the IOP lowering eye drop latanoprost once daily in one eye for approximately one week and then the measurements are are repeated in the same manner.
62147444|NCT01124552|PLACEBO_COMPARATOR|Dose D|Placebo
62147445|NCT04106739|ACTIVE_COMPARATOR|Active Arm|Active arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate the outer auditory canal. It will deliver with a pulse width of 500 ms. The stimulation frequency pattern is 1.12Hz(hertz), 2.24Hz,4.56Hz, 9.12Hz, 100Hz then 9.12Hz, 4.56Hz,2.28Hz,1.12Hz. This cycle will keep on continuing. An input voltage will be 4.2V(volt).
62147446|NCT04106739|SHAM_COMPARATOR|Sham Arm|Sham arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate centre of the left ear lobe to a pulse width of 500 ms at same pattern of stimulation frequency mentioned in active PENFS with an input voltage of 4.2V
62147447|NCT06397586|EXPERIMENTAL|GROUP I: STATICK|static motor imagery and movement observation-based plyometric training
62514808|NCT04948957||esmolol (Group E)|
62514809|NCT04948957||nitroglycerin (Group N)|
62514810|NCT05518448|EXPERIMENTAL|Ketone|Ketone monester (beta-hydroxybutyrate (β-OHB)
62514811|NCT05518448|PLACEBO_COMPARATOR|Placebo|Non-caloric placebo
61973393|NCT02656979|NO_INTERVENTION|Blood flow|The subjects will do blood flow measurements with MRI and measurements of ocular parameters only once. No intervention with IOP lowering drops.
62514812|NCT06082297|EXPERIMENTAL|Single arm where repeated measures where performed in 15 participants.|Each of the 15 participants in the arm was, in addition to the resting state (no intervention), exposed to 10 different interventions repeated after each other to enable repeated measures of the outcomes.
62710055|NCT03044145|EXPERIMENTAL|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
62514813|NCT04349631|EXPERIMENTAL|HB-adMSCs|Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2, 6, 10, 14, 18, 22, 26.
62514814|NCT01932099|EXPERIMENTAL|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
62147448|NCT06397586|EXPERIMENTAL|GROUP II: DYNAMIC|dynamic motor imagery and movement observation-based plyometric training
62354096|NCT06108245|PLACEBO_COMPARATOR|Self-Reflection Condition|Participants in this condition will be asked to respond to a set of randomly selected self-reflection prompts twice a day over 28 days \[4 weeks\]. As with the experimental condition, participants in the initial session will be asked to respond to a brief set of questions pertaining to their hoarding behavior in the past 12 hours and their motivation to declutter right now. From that point on, participants will be asked to respond to a brief set of questions before each writing prompt pertaining to their hoarding behaviors in the time since the previous writing prompt. After the writing prompt, they will be asked about how motivated they are to declutter right now. Each writing prompt is anticipated to take up to 10 minutes to complete, and participants will receive notifications to use the app twice daily in addition to email reminders twice a week to engage with the app.
62514815|NCT04577573|ACTIVE_COMPARATOR|No cognitive feedback|Perform task without cognitive feedback.
62514816|NCT04577573|ACTIVE_COMPARATOR|Intermediate feedback.|Perform task with intermediate feedback.
62514817|NCT04577573|EXPERIMENTAL|Enhanced feedback|Perform task with virtual reality and/or haptic feedback.
62514818|NCT04203160|EXPERIMENTAL|Phase 1 and Phase 2, Arm A (investigational)|On Day 1 and Day 8 of each 3-week cycle, patients will receive CPI-613 + gemcitabine and cisplatin. Patients may continue gemcitabine, cisplatin and CPI-613 for up to 2 years in absence of disease progression or unacceptable toxicity.
62514819|NCT04203160|ACTIVE_COMPARATOR|Phase 2, Arm B (standard of care)|On Day 1 and Day 8 of each 3-week cycle, patients will receive gemcitabine and cisplatin. Patients may continue gemcitabine and cisplatin for up to 2 years in absence of disease progression or unacceptable toxicity.
61973394|NCT03394807|EXPERIMENTAL|LaGRA|regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
61973395|NCT03394807|PLACEBO_COMPARATOR|Placebo|Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
61973396|NCT03763591|EXPERIMENTAL|Psychological Skills Group (e.g., Active Intervention)|10-week Psychological Skills Group.
62514820|NCT01807117|EXPERIMENTAL|Diagnostic (PET-CT and PET-MRI)|Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
62514821|NCT06401967|EXPERIMENTAL|Pivot Clear|A program for alcohol reduction
62514822|NCT03647631||Patients affected to porocarcinoma|
62514823|NCT03647631||patients affected to porocarcinoma in our centre|
61973397|NCT05277714|EXPERIMENTAL|NF|
61973398|NCT05277714|SHAM_COMPARATOR|Sham|
62147449|NCT06397586|ACTIVE_COMPARATOR|GROUP III: ACTIVE CONTROL|plyometric training
62147450|NCT01596686|ACTIVE_COMPARATOR|sodium picosulphate and magnesium citrate (Picoprep)|
62147451|NCT01596686|ACTIVE_COMPARATOR|polyethylene glycol (Fortrans)|
62354097|NCT06108245|NO_INTERVENTION|Waitlist Condition|Participants assigned to the waitlist will not receive access to any intervention for 8 weeks. After 8 weeks, they will receive access to either the values clarification or self-reflection mobile application.
62354098|NCT01896856|EXPERIMENTAL|Phase 1: Dose Escalation|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Various doses of SGI-110 are tested to determine the maximum tolerated dose in combination with irinotecan."
62514824|NCT06067451|EXPERIMENTAL|SMART GOAL Arm|"The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem.~The study group participants will also be asked to summarize the information discussed during the visit, and then will receive the SMART (Specific, Measurable, Attainable, Realistic, Time sensitive) Goal Setting Protocol (SGSP)."
62514825|NCT06067451|NO_INTERVENTION|Standard of Care Arm|"Participants randomized to this group will receive standard of care.~At the end of each visit, the participants in the standard of care (SOC) group will be asked to provide a summary of topics discussed and what they plan to improve on from now and their next visit:"
61973399|NCT05713721||SMC DYT/PARK-TAF1|Symptomatic mutation carriers (SMC) of the TAF1 gene, which is associated with X-linked Dystonia-Parkinsonism, will be examined.
61973400|NCT05713721||AMC DYT/PARK-TAF1|Asymptomatic mutation carriers (AMC) of the TAF1 gene will be examined.
61973401|NCT05713721||SMC DYT/PARK-GCH1|Symptomatic mutation carriers (SMC) of the GCH1 gene, which is associated with dopa-responsive Dystonia, will be examined.
61973402|NCT05713721||AMC DYT/PARK-GCH1|Asymptomatic mutation carriers (AMC) of the GCH1 gene will be examined.
61973403|NCT05713721||SMC PARK-Parkin/PARK-PINK1|Symptomatic mutation carriers (SMC) of the Parkin or PINK1 genes, which is associated with Parkinsonism, will be examined.
61973404|NCT05713721||AMC PARK-Parkin/PARK-PINK1|Asymptomatic mutation carriers (SMC) of the Parkin or PINK1 genes will be examined.
61973405|NCT05713721||Control group|A healthy control group will be examined.
62147452|NCT04987528||Patients with pulmonary fibrosis|"All ICU patients for which one of the non-invasive criteria of pulmonary fibrosis is reached :~* Typical CT scan patterns (reticulation and/or bronchiectasia)~* Serum PIIINP above 16 µg/L~* BAL PIIINP above 9 µg/L"
62147453|NCT04987528||Patients without pulmonary fibrosis|All ICU patients for which none of the non-invasive criteria of pulmonary fibrosis are reached.
62147454|NCT04693169|EXPERIMENTAL|[Al18F]PSMA137 PET/CT imaging|All study participants will be allocated to this arm (single-arm study).Study participants will undergo \[Al18F\]PSMA137 PET/CT scans.
62514826|NCT05057052|EXPERIMENTAL|Cryoablation in combination with Sintilimab plus regorafenib|
62514827|NCT00971984||Alpha thalassemia patients|Patients diagnosed with alpha thalassemia mutations and anemia
62710056|NCT03044145|ACTIVE_COMPARATOR|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
62147455|NCT06254976|ACTIVE_COMPARATOR|2 week home exercise program|Joint range of motion exercises, four-way straight leg raises, isotonic quadriceps strengthening, hamstring and quadriceps stretching exercises were given. The exercise program was demonstrated by the same physiotherapist. The patients' exercise compliance was questioned and noted.
62147456|NCT06254976|ACTIVE_COMPARATOR|2 doses of intraarticular PRP application, 1 week apart|2 doses of intra-articular 3 cc LP-PRP were applied to the patients, 1 week apart, from the inferolateral aspect of the patella, in accordance with antisepsis conditions, by a physical medicine and rehabilitation specialist.
62147457|NCT06499142|EXPERIMENTAL|Parathyroidectomy|Patients undergoing parathyroidectomy for Hyperparathyroidism
62354099|NCT01896856|EXPERIMENTAL|Phase 2: Arm A SGI-110 + irinotecan|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Growth factor support (filgrastim and peg-filgrastim) is given during cycle 1 with option to give additional growth factor support at subsequent cycles per clinician judgement."
62354100|NCT01896856|ACTIVE_COMPARATOR|Phase 2: Arm B regorafenib or TAS-102|"Subjects received either regorafenib or TAS-102 based on physician and patient preference. Subjects that had received one of these standard of care drugs (regorafenib or TAS-102) prior to enrollment received the other on study.~Regorafenib taken daily from days 1-21 of each 28-day cycle or TAS-102 taken twice daily on days 1-5 and 8-12 of each 28-day cycle.~Subjects who had disease progression on Arm B were given the option to receive Arm A study drugs after a 14 day wash-out period."
62354101|NCT01184729||Spinal Cord Injury|
62354102|NCT01081717||001|golimumab as prescribed
62354103|NCT01081717||002|anti-TNF biologics as prescribed
62354104|NCT01081717||003|non-anti-TNF biologics as prescribed
62354105|NCT01081717||004|systemic non-biological treatments as prescribed
62354106|NCT01081717||005|general population non-treated cohort
62354107|NCT06145464|ACTIVE_COMPARATOR|Control|Adolescents will be recommended to use the sun protection interventions implemented on Foz do Lizandro beach (collective shadow, sun protector, and information about healthy behaviors of sun protection disposed in an infographic installed near the collective shadow), without a previous health literacy session about skin cancer prevention provided 15 days before the beginning of the use of the interventions on the beach.
62354108|NCT06145464|EXPERIMENTAL|Interventional EST SUP|Adolescents will be recommended to use the sun protection interventions implemented on Foz do Lizandro beach (collective shadow, sun protector, and information about healthy behaviors of sun protection disposed in an infographic installed near the collective shadow), with a previous health literacy session about skin cancer prevention provided 15 days before the beginning of the use of the interventions on the beach by students on ongoing graduation at the University of Lisbon.
62354109|NCT06145464|EXPERIMENTAL|Interventional FARMA|Adolescents will be recommended to use the sun protection interventions implemented on Foz do Lizandro beach (collective shadow, sun protector, and information about healthy behaviors of sun protection disposed in an infographic installed near the collective shadow), with a previous health literacy session about skin cancer prevention provided 15 days before the beginning of the use of the interventions on the beach by community pharmacists who will be working on pharmacies located in Mafra.
62354110|NCT03855033|EXPERIMENTAL|Media Aware Sexual Health - High School|Students received the web-based Media Aware Sexual Health - High School program.
62354111|NCT03855033|NO_INTERVENTION|Typical Health Education Programming|Students received their regular health education programming not related to sexual health education.
62354112|NCT04768530|ACTIVE_COMPARATOR|Scaling and Root Planing (SRP)|
62354113|NCT04768530|EXPERIMENTAL|Scaling and Root Planing with Nitazoxanide hydrogel|
62354114|NCT04186715||TOETVA|The demographic data of the patients undergoing TOETVA surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
62354115|NCT04186715||Open thyroidectomy|The demographic data of the patients undergoing open thyroidectomy surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
62354116|NCT03374644|EXPERIMENTAL|ETCO2 monitoring with nasal cannula|SentriTM ETCO2 adult nasal cannula (Intersurgical ® code 1144002) will be placed into patient's nostril following radial artery catheter insertion. A baseline (without oxygen flow) ETCO2, PaO2, SPO2, RR and PaCO2 will be recorded. Oxygen will then be administered at 2,4, and 6 liters per minute for a period of five minutes.ETCO2, PaCO2 and PaO2 will be recorded for each level of oxygen administration.Sedation will be given during intra-operative period with the target of Observer Assessment of alertness/sedation scale (OAA/S) score of 3. During intraoperative period, oxygen will be administered at 2 and 4 liters per minute for a period of five minutes. ETCO2, PaCO2 and PaO2 level will be recorded during each level of oxygen administration.
62514828|NCT01885702|EXPERIMENTAL|MSI-positive CRC patients|I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)
62514829|NCT01885702|EXPERIMENTAL|Carriers of germline MMR-gene mutation|II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC
62710057|NCT01206127|OTHER|Postoperative positioning: Bed rest|Patients in this group must be lying down facing up 2 hours postoperatively
62710058|NCT01206127|OTHER|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperatively
62710059|NCT04618471|EXPERIMENTAL|WaveWriter Settings|
62710060|NCT00272181|EXPERIMENTAL|Dose Determination|The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
62514830|NCT05206422|EXPERIMENTAL|ADHF patients|ADHF patients with insufficient response to diuretics treated with the Doraya catheter
62147458|NCT03629366|EXPERIMENTAL|Supported Employment (SE)|Follow-up with Supported Employment (SE), provided by a job specialist trained in the eight evidence-based principles of Individual Placement and Support (IPS). The SE intervention is provided in addition to the mandatory introduction program for refugees in Norway (treatment as usual).
62354117|NCT04223063|EXPERIMENTAL|Exercise Intervention|Participants allocated to the exercise intervention will engage in a multimodal, home-based program including strength and endurance exercises. Participants will initially be seen in person and instructed to begin a moderate-intensity (i.e., 3-4 on 10-point Borg Scale) walking (or preferred aerobic exercise) program for a minimum of 30 minutes/day, 3-5 days/week and perform strength exercises at least 2 days/week.
62514831|NCT06175429||Cardiac surgery|Patients undergoing elective cardiac surgery
62514832|NCT03352895|PLACEBO_COMPARATOR|control|Control group will receive placebo medication therapy
62514833|NCT03352895|EXPERIMENTAL|test group|resveratrol group will receive oral resveratrol (100 mg per day)
62514834|NCT03716934|EXPERIMENTAL|Cryoablation|Cryoablation for bidirectional block of all pulmonary veins
62514835|NCT03716934|ACTIVE_COMPARATOR|Antiarrythmics|The drug will be chosen based on the preference of the researcher based on clinical practice guidelines.
62514836|NCT01443559|EXPERIMENTAL|Xenogenic cornea|
62514837|NCT01443559|ACTIVE_COMPARATOR|human cornea|
62514838|NCT02601274|EXPERIMENTAL|Single Group Assignment|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .
62514839|NCT04392557|ACTIVE_COMPARATOR|metformin/alogliptin|metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months
62514840|NCT04392557|ACTIVE_COMPARATOR|metformin/pioglitazone|metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months
62514841|NCT04392557|ACTIVE_COMPARATOR|triple therapy|metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months
62514842|NCT01563926|EXPERIMENTAL|Somatropin|
62514843|NCT03353402|EXPERIMENTAL|Fecal Microbiota Transplant (FMT)|FMT includes a colonoscopy conducted by a gastroenterologist followed by stool capsules which will be swallowed by the patient.
62514844|NCT02373995|ACTIVE_COMPARATOR|LAB4|In addition to conventional Anti Thyroid Drug (ATD), LAB4 probiotic preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store LAB4 at 8°C.
62514845|NCT02373995|PLACEBO_COMPARATOR|Placebo|In addition to conventional Anti Thyroid Drug (ATD) a LAB4 placebo preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store placebo at 8°C.
62514846|NCT05336110||Patient with a positive preoperative SARS-CoV-2 test|Patient with a positive preoperative SARS-CoV-2 test
62514847|NCT03686020||Group I|participants suffering from oral potentially malignant lesions
62514848|NCT03686020||Group II|participants suffering from diagnosed oral malignant lesions
62514849|NCT03686020||Group III|healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
62354118|NCT04223063|NO_INTERVENTION|Control|Participants allocated to the control group will not receive any formal exercise prescription or guidance, however they will be offered the opportunity to participate in a home-based intervention pending the completion of data collection.
62354119|NCT06027879|EXPERIMENTAL|Viral Specific T-Lymphocytes|Viral Specific T-Lymphocytes Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
62354120|NCT05172037|ACTIVE_COMPARATOR|Novaferon|Inhaled Novaferon, given 20 ug BID, daily for 7 days
62514850|NCT04574128|EXPERIMENTAL|Retransfusion of cardiotomy blood or not|Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.
62514851|NCT04574128|NO_INTERVENTION|No retransfusion of cardiotomy blood|
62354121|NCT05172037|PLACEBO_COMPARATOR|Placebo|Inhaled saline (placebo), given BID, daily for 7 days
62514852|NCT03996720||severe sepsis|patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay
62514853|NCT03996720||sepsis|patients recover from sepsis without developing into organ dysfunction
62514854|NCT00894114|OTHER|Stratum 1|Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
62514855|NCT00894114|EXPERIMENTAL|Stratum 2|Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
62514856|NCT00894114|EXPERIMENTAL|Stratum 3|Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
62514857|NCT00894114|EXPERIMENTAL|Stratum 4|High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
62514858|NCT02167542|EXPERIMENTAL|NPPV group|Patients assigned to noninvasive positive pressure ventilation (NPPV) are connected to the ventilator through a face mask (VBM Endoscopy Mask) that is secured to the patient's face by the investigator.
62514859|NCT02167542|ACTIVE_COMPARATOR|CPAP valve group|Patients assigned to CPAP valve (Boussignac valve, Vygon, Inc) are connected to this device through a standard face mask that is secured to the patient's face with elastic straps.
62514860|NCT04523402|EXPERIMENTAL|Neoadjuvant chemotherapy following liver section|"1. GEMOX chemotherapy:~1. It is performed within one week after the identification of ICC;~2. Day1 Oxaliplatin 85mg/m2 + gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2;~3. Three weeks is a course of treatment;~4. A total of 3 courses.~2. Liver resection: It is performed 1 month after chemotherapy"
62514861|NCT04523402|NO_INTERVENTION|Liver resection|"Liver resection:~It is performed within one week after the identification of ICC."
62514862|NCT00456495|EXPERIMENTAL|Subconjunctival ranibizumab|Patients will receive subconjunctival ranibizumab every 2-4 weeks.
62514863|NCT00746902|ACTIVE_COMPARATOR|1|Arm 1: Active CPAP, a nasal continuous positive airway pressure
62514864|NCT00746902|SHAM_COMPARATOR|2|Arm 2 : Sham CPAP :Placebo/CPAP
62514865|NCT03103074|EXPERIMENTAL|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
62514866|NCT03103074|PLACEBO_COMPARATOR|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
62514867|NCT02039752||Multivessel|from 1995
62514868|NCT04526392||Questionnaire|Patients will choose how they wish to complete the Pubertal Course Questionnaire: electronically (web link), on paper, by telephone, or face-to-face at a follow-up consultation.
62514869|NCT04467359|EXPERIMENTAL|The experimental group|ERAS intervention group
62514870|NCT04467359|PLACEBO_COMPARATOR|The control group|Sports medicine rehabilitation nursing group
62514871|NCT05695495|EXPERIMENTAL|Randomized|Subjects will be administered intravenous DMT in 4 different bolus doses or placebo in randomized, counter-balanced order. The bolus applications will be separated by one hour.
62514872|NCT05695495|EXPERIMENTAL|Dose ecalation|Subjects will be administered a placebo and a maximum of 5 DMT bolus doses in an escalating dose order. The bolus applications will be separated by one hour.
62514873|NCT01394848|ACTIVE_COMPARATOR|Genous stent group|Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
62147459|NCT03629366|ACTIVE_COMPARATOR|Treatment as usual (TAU)|Follow-up with treatment as usual, which involves participation in the mandatory introduction program provided for all refugees in Norway. The program includes training in Norwegian language and culture, as well as the various traditional employment schemes offered by the Norwegian labor and welfare Administration.
62514874|NCT01394848|ACTIVE_COMPARATOR|Xience stent group|Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
62514875|NCT01394848|ACTIVE_COMPARATOR|Atorvastatin 20mg group|
62514876|NCT01394848|ACTIVE_COMPARATOR|Atorvastatin 80mg group|
62514877|NCT01546324||Pregnant women|Women pregnant following the use of Natera's PGS/PGD testing
62514878|NCT05356936|EXPERIMENTAL|Vitamin K2(MK-7) and Vitamin D3|Participants randomized to this group will receive Vitamin K2 (MK-7) and Vitamin D3 by mouth.
62710061|NCT03122184|EXPERIMENTAL|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
62710062|NCT03122184|ACTIVE_COMPARATOR|Motivational Interviewing Health Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week. Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
62710063|NCT05309525|ACTIVE_COMPARATOR|Cohort A|"Per treatment area, subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple). A treatment area is defined as a left or right buttock, so patients may receive up to 1.84 mg, or 24 injections total (2 areas per treatment visit). The minimum dosage of QWO will be 0.92 mg, or 6 injections per treatment area (2 areas per treatment visit.~Cohort A subjects will be given 1300 mg tranexamic acid PO TID prior to the day of the first CCH injections, the day of the first CCH injections, and the 3 days following the first CCH injections."
62514879|NCT05356936|NO_INTERVENTION|Control|Participants to this group will receive no intervention.
62514880|NCT01418716|EXPERIMENTAL|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
62514881|NCT01418716|ACTIVE_COMPARATOR|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
62147460|NCT00519207|ACTIVE_COMPARATOR|1|This group will receive lidocaine and sucrose placebo (water).
62514882|NCT01757899|ACTIVE_COMPARATOR|Methylprednisolone Arm|"The patients in this arm will receive methylprednisolone, which is available in vials containing 125 mg/2mL after dilution, as it follows:~Day 0 Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day"
62514883|NCT01757899|PLACEBO_COMPARATOR|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
62147461|NCT00519207|ACTIVE_COMPARATOR|2|This group will receive lidocaine placebo and sucrose.
62147462|NCT00519207|ACTIVE_COMPARATOR|3|This group will receive lidocaine and sucrose.
62147463|NCT02827201|EXPERIMENTAL|nab-paclitaxel + gemcitabine/FOLFIRI.3|"Alternance of :~* 2 months with nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m², 30 min in IV, 3 injections follow by 1 week free)~* follow by 2 months with FOLFIRI.3 (irinotecan: 90 mg/m² at D1, acid folinic 400 mg/m², 5Fu continus: 2000 mg/m² IV 46 hours, and irinotecan at D3, 90 mg/m²) This alternance continus until progression"
62514884|NCT01795079|EXPERIMENTAL|Active tDCS|Subjects will undergo 20 minutes active tDCS.
62514885|NCT01795079|SHAM_COMPARATOR|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
62514886|NCT04658316||20-39Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
62514887|NCT04658316||40-59Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
62514888|NCT04658316||60-79Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
62514889|NCT04658316||20-39Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
62514890|NCT04658316||40-59Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
62514891|NCT04658316||60-79Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
62514892|NCT06128694|EXPERIMENTAL|ONS (oral nutrition supplement) group|ONS will be consumed 3 times a day, for 8 weeks. Per serving/sachet ONS (±81g) contains 350 kcal of energy, 9 g of fat, 20 g of protein, 48 g of carbohydrates, 400 mg of DHA (Docosahexaenoic acid), 300 mg of EPA (Eicosapentaenoic Acid) 0.92 g of Omega-3, 1 g of L-Valine, 2.1 g of L-. Isoleucine 1.1 g, L-Leucine 2.1 g, Sodium 75 mg, 12 vitamins and 9 minerals. Consumed as a morning snack (between breakfast and lunch); afternoon snack (between lunch and dinner) and evening snack (before bedtime). Subject will also received dietary counseling for 8 weeks
62514893|NCT06128694|NO_INTERVENTION|Control group|only received dietary counseling for 8 weeks without ONS supplementation.
62514894|NCT03675334|ACTIVE_COMPARATOR|Test Group|"Active comparator: gingival recession~the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions"
62514895|NCT03675334|PLACEBO_COMPARATOR|Control Group|the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions. The control group was treated with the same technique as the collagen matrix graft.
62514896|NCT00183885|EXPERIMENTAL|Cisplatin + Mitomycin-C|CDDP 60mg/m2 + Mitomycin-C 12mg/m2
62514897|NCT01659164|EXPERIMENTAL|Group treatment (uncontrolled)|Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
62514898|NCT04301245||ETEP group|Exercise Training and Educational Program (ETEP) group. Patients who accepted the educational program in addition to the exercise training.
62514899|NCT04301245||ET group|Exercise Training (ET) group. Patients who refused the educational program and did only the exercise training.
62514900|NCT03614494|ACTIVE_COMPARATOR|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
62514901|NCT03614494|PLACEBO_COMPARATOR|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
62710064|NCT05309525|ACTIVE_COMPARATOR|Cohort B|"Per treatment area, subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple). A treatment area is defined as a left or right buttock, so patients may receive up to 1.84 mg, or 24 injections total (2 areas per treatment visit). The minimum dosage of QWO will be 0.92 mg, or 6 injections per treatment area (2 areas per treatment visit.~Cohort B subjects will be given 1300 mg tranexamic acid PO TID prior to the day of the first and second CCH injections, the day of the first and second CCH injection, and the 3 days following the first and second CCH injections."
62514902|NCT03348748|EXPERIMENTAL|Study 1 (highest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the peripheral lung undergo highest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
62514903|NCT03348748|EXPERIMENTAL|Study 2 (lowest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
62514904|NCT03348748|EXPERIMENTAL|Study 3 (lowest- or higher-dose of SBRT, surgery)|Patients with stage IIIA NSCLC in the any lung location undergo lowest- or higher-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
62147464|NCT02827201|ACTIVE_COMPARATOR|nab-paclitaxel + gemcitabine|nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m² - 30 min in IV) 3 injections follow by 1 week free, until progression
62147465|NCT05109598|EXPERIMENTAL|Population I|Population I has 400 subjects aged 3 to 17 who were recruited by this trial.
62514905|NCT02879110|EXPERIMENTAL|Sulforaphane group|The patients will take sulforaphane for 12 weeks.
62514906|NCT02879110|PLACEBO_COMPARATOR|Placebo group|The patients will take placebo for 12 weeks.
62147466|NCT05109598|EXPERIMENTAL|Population II|Population II will use 400 subjects aged of 18-59 in the phase III clinical trial in China whose blood has been collected.
62354122|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
62514907|NCT04458493|EXPERIMENTAL|control|no supplement will be provided on the day of the experiment
62514908|NCT04458493|EXPERIMENTAL|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 400ml, 20% solution)
62514909|NCT02555293|EXPERIMENTAL|film-coated Rifaximin (550 mg)|(550 mg) tablet twice daily for at least 14 days but up to 28 days dependent on the need for a PVE and the period between PVE (portal vein embolization) or randomization and surgery. Preoperative Rifaximin treatment in case of a PVE will start the day after PVE and will last for 14-21 days. In case patients are not pre-treated with a PVE they will receive Rifaximin for 7-10 days prior to surgery. Regardless of PVE, patients will receive additional Rifaximin treatment the first 7 days postoperatively.
62514910|NCT02555293|NO_INTERVENTION|standard therapy|Patients directed to the control group will not receive Rifaximin.
62514911|NCT01937247|PLACEBO_COMPARATOR|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
62710065|NCT05309525|ACTIVE_COMPARATOR|Cohort C|"Per treatment area, subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple). A treatment area is defined as a left or right buttock, so patients may receive up to 1.84 mg, or 24 injections total (2 areas per treatment visit). The minimum dosage of QWO will be 0.92 mg, or 6 injections per treatment area (2 areas per treatment visit.~Cohort C subjects will be given 1300 mg tranexamic acid PO TID prior to the day of the first, second, and third CCH injections, the day of the first, second, and third CCH injection, and the 3 days following the first, second, and third CCH injections."
61973406|NCT04549506||ASD group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. All ASD participants were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders 5th Edition's (DSM-5) diagnostic criteria (APA, 2013) and conﬁrmed by clinical consensus. ASD individuals were recruited from a community autism program and referred to children's health doctors and child psychiatrists. Exclusion criteria for all participants were neurological abnormalities, a history of epilepsy or seizures, head trauma and IQ \<75. The subjects did not participate in any intervention or drug programs during the experimental period.
61973407|NCT04549506||Control group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. The participants in the age- and sex-matched control group were recruited from the local community, and screened for major psychiatric illnesses by conducting structured interviews.
62354123|NCT04777318|EXPERIMENTAL|Conventional physiotherapy|The individuals in the control group was taken in a total of 12 sessions of conventional physiotherapy program for 4 weeks, 3 days a week.
62354124|NCT04777318|EXPERIMENTAL|Muscle Energy Technique (MET)|In addition to the conventional physiotherapy program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique was applied to the individuals in the second group.
62354125|NCT04777318|EXPERIMENTAL|Cervical Mobilization Techniques (CMT)|In the third group, cervical mobilization techniques was applied in addition to the conventional physiotherapy program for a total of 12 sessions for 4 weeks, 3 days a month.
62354126|NCT02424812|EXPERIMENTAL|Intervention|school based handwashing education programme
62354127|NCT02424812|NO_INTERVENTION|Control|no intervention
62354128|NCT05142449|EXPERIMENTAL|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day.
62354129|NCT05142449|PLACEBO_COMPARATOR|Placebo|Patients receive 8 capsules Placebo perioperatively and for the next 3 days 6 capsules per day.
62354130|NCT04829266|EXPERIMENTAL|process simulation group|an experimental group with process simulation with elements of relaxation
62354131|NCT04829266|EXPERIMENTAL|outcome simulation group|an experimental group with outcome simulation with elements of relaxation
62354132|NCT04829266|OTHER|control group|a control group with no process and outcome simulations, but with elements of relaxation
62354133|NCT03289741|EXPERIMENTAL|Octreotide then Lanreotide|Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
62354134|NCT03289741|EXPERIMENTAL|Lanreotide then Octreotide|Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
62354135|NCT05979714|EXPERIMENTAL|Cheeky Study Intervention|This study represents a hybrid design type 3 focusing primarily on implementation outcomes and secondarily on clinical effectiveness among trans women living with HIV receiving care within primary care clinics in San Francisco. A type 3 design was chosen, as the clinical efficacy of CAB- RPV LA has been established in clinical trials, and the focus of this study is on initial implementation of CAB-RPV LA within these clinics.
62354136|NCT06251869||hip electrocoagulation|group subjected to the use of electrocoagulation
62354137|NCT06251869||hip scalpel|group subjected to the use of traditional hemostatic technique
62354138|NCT06251869||knee electrocoagulation|group subjected to the use of electrocoagulation
62354139|NCT06251869||knee scalpel|group subjected to the use of traditional hemostatic technique
62354140|NCT01388868|ACTIVE_COMPARATOR|TOF count guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by No. of response to TOF stimulation
62354141|NCT01388868|EXPERIMENTAL|T1/T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T1 twitch height as compared with control (T0)
62354142|NCT01388868|EXPERIMENTAL|T2/ T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T2 twitch height as compared with baseline (T0)
62354143|NCT03258632|NO_INTERVENTION|Usual Care|Under usual care, when a patient screens positive on the AUDIT-C administered at intake, a provider (social worker, nurse) provides Brief Intervention (BI), i.e., tells the patient that problems are associated with alcohol use, and about recommended drinking limits; notes the patient as ready to change drinking or not, and as agreeing to treatment or not. If the patient agrees to treatment, specialty addiction services are notified.
62354144|NCT03258632|EXPERIMENTAL|Intervention|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
62354145|NCT01234896|EXPERIMENTAL|Nicotine Gum 6|6 mg Nicotine medicated gum
62354146|NCT01234896|ACTIVE_COMPARATOR|Nicotine Gum 4|4 mg Nicotine Gum
62354147|NCT01234896|ACTIVE_COMPARATOR|Nicotine Gum 2|2 mg Nicotine Gum
62354148|NCT01234896|ACTIVE_COMPARATOR|Nicotine Lozenge|4 mg Nicotine Lozenge
62354149|NCT04433156|EXPERIMENTAL|VR-CAP|Rituximab, 375 mg/m2, Intravenous administration on day 0, Bortezomib, 1.3 mg/m2 hypodermic injection on day 1 and 4, combined with regimen: Cyclophosphamide, Epirubicin, and Prednisone: repeated every 3 weeks, up to 6 cycles.
62354150|NCT01924156|EXPERIMENTAL|adenovirus-transfected DC + CIK|adenovirus-transfected autologous DC vaccine plus CIK cells
62354151|NCT01572818|EXPERIMENTAL|Phlebotomy|phlebotomy associated with dietary and lifestyle counseling
62514912|NCT01937247|ACTIVE_COMPARATOR|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
62514913|NCT01774279||anaplastic thyroid cancer|
62514914|NCT04908202|EXPERIMENTAL|Deucravacitinib|
62514915|NCT04908202|PLACEBO_COMPARATOR|Placebo|
62514916|NCT02946684|PLACEBO_COMPARATOR|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
62514917|NCT02946684|ACTIVE_COMPARATOR|Letrozole 5mg|2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
62514918|NCT01875471|ACTIVE_COMPARATOR|delefilcon A|Spherical daily disposable soft contact lens
62514919|NCT01875471|EXPERIMENTAL|narafilcon A|Spherical daily disposable soft contact lens Class 1 UV blocking
62514920|NCT00911755|OTHER|Laryngoscopy|
62514921|NCT00911755|OTHER|Videolaryngoscopy|
62514922|NCT01449045|PLACEBO_COMPARATOR|Community Case Management|Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
62354152|NCT01572818|ACTIVE_COMPARATOR|Lifestyle counseling|dietary and lifestyle counseling
62710066|NCT06030518|EXPERIMENTAL|Patient undergoing upper Gi endoscopy|"Children attending Sheffield Childrens' Hospital Gastroenterology out-patients departments between the ages of 11-16 years of age who require OGD to investigate abdominal pain or discomfort will be invited to take part in the study.~Interventions~The study will begin when capsule endoscopy is performed by a Clinical Research Fellow at the Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust."
62710067|NCT00151177|EXPERIMENTAL|A|treatment with three nights of CPAP ventilation starting the first night of admission
62710068|NCT00151177|NO_INTERVENTION|B|usual Stroke Unit care
61973408|NCT03900078|ACTIVE_COMPARATOR|Control group|After subcuticular skin suture, patients receive standard dressing with adhesive wound tapes.
62354153|NCT05459792|EXPERIMENTAL|ultrasound guided median nerve block|A linear transducer will be placed on the ventral aspect of the mid-forearm, where the median nerve is visible in the fascial plane between the flexor digitorum superficialis and flexor digitorum profundus after raising a skin wheal using local anesthetic, the needle will be introduced in-plane view from lateral to medial and aimed at the fascial plane adjacent to the median nerve.
62354154|NCT05459792|EXPERIMENTAL|ultrasound guided radial nerve block|A linear transducer will be placed on the forearm: at the elbow (the radial nerve between the brachioradialis and the biceps muscle). the preferred approach is to start proximally above the elbow and identify the radial nerve as a triangular hyperechoic structure coming off the distal humerus. then following this distally to the antecubital fossa, where the nerve will branch into its superficial and deep branches. the needle will be introduced in-plane view from lateral to medial aimed at the fascial plane adjacent to the radial nerve.
62354155|NCT05459792|PLACEBO_COMPARATOR|local infiltration|Intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle.
62354156|NCT06122987|EXPERIMENTAL|Single Arm|Drug: Angiotensin II Other Names: Giapreza
62354157|NCT00806078|EXPERIMENTAL|1|Single dose intact capsules 2 x 324 mg
62354158|NCT00806078|EXPERIMENTAL|2|Single dose contents of two capsules (2 x 324 mg) opened and mixed in 120 mL of chocolate pudding
62354159|NCT04099849|EXPERIMENTAL|Group A|"Diet-ZnBfR zinc biofortified rice-based diet~Diet- CR conventional rice-based diet"
62354160|NCT04099849|EXPERIMENTAL|Group B|"Diet-ZnBfR zinc biofortified rice-based diet~CR + Zn conventional rice-based diet plus zinc fortificant (Diet-CR+Z)."
62354161|NCT01181778||All Qualified Participants|All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment
62715074|NCT03827239|NO_INTERVENTION|Control|No intervention. Study participants will be seated during the entire sedentary 3-hour time period and wheeled to phlebotomy (and exercise) stations when required. During the sedentary period, participants will eat the food according to the study protocol and be seated at desks and allowed to read and use computers.
62715075|NCT03827239|EXPERIMENTAL|Intervention|Will disrupt their sedentary time with 3 minute exercise sessions every 30 minutes
62715076|NCT01977222|EXPERIMENTAL|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|
61973409|NCT03900078|EXPERIMENTAL|Incisional negative pressure group|After subcuticular skin suture, patients receive an incisional negative pressure dressing for 5 days.
62514923|NCT01449045|EXPERIMENTAL|Community Case Management plus IPTc|Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management
62514924|NCT05604937|OTHER|Manual therapy group|Patients receive Shi's traumatology osteopathic manipulative treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments.
62514925|NCT05604937|OTHER|Merislon group|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to the control group, for 2 weeks, 6mg a day, three times a day.
62514926|NCT05009836|EXPERIMENTAL|Savolitinib|Savolitinib 600 mg or 400 mg QD orally +Osimertinib 80 mg QD orally ( every 3 weeks)
62514927|NCT05009836|PLACEBO_COMPARATOR|placebo|placebo 600 mg or 400 mg QD orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
62514928|NCT03720769|EXPERIMENTAL|Step-by-Step|
62514929|NCT03720769|ACTIVE_COMPARATOR|Enhanced care as usual|
62514930|NCT05616078|EXPERIMENTAL|laser treatment|LP-Nd:YAG laser treatment
62514931|NCT05616078|ACTIVE_COMPARATOR|cryotherapy|cryotherapy with liquid nitrogen
62514932|NCT05568979||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
62514933|NCT05568979||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
62514934|NCT03333499|PLACEBO_COMPARATOR|the control group|YanXinShi placebo pills
62514935|NCT03333499|EXPERIMENTAL|YanXinShi group|YanXinShi pills
62514936|NCT03333499|ACTIVE_COMPARATOR|Trimetazidine group|Trimetazidine pills
62514937|NCT03333499|OTHER|YangXinShi and Trimetazidine group|YanXinShi and Trimetazidine pills
62514938|NCT02484313|EXPERIMENTAL|Greek yogurt|25 g available carbohydrates
62710069|NCT00320606|EXPERIMENTAL|Immunosuppression Withdrawal|"Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results."
62514939|NCT02484313|EXPERIMENTAL|Cookies|25 g available carbohydrates
62514940|NCT04798482|EXPERIMENTAL|Dexmedetomidine|This is a single arm, open label, interventional study examining the effects of dexmedetomidine on anal manometry. All subjects will be administered dexmedetomidine following their baseline manometry measurements. Following dexmedetomidine administration, anal manometry measurements will be observed for 15 minutes.
62514941|NCT02135406|EXPERIMENTAL|Multiple Myeloma Patients|Adult subjects (18 years or older) with multiple myeloma and with poor prognosis by virtue of having relapsed/progressive disease within one year of first autologous stem cell transplantation.
62514942|NCT01111214||group 1|Hospitalized children ≤14 years of age with invasive pneumococcal disease
62514943|NCT04837027|EXPERIMENTAL|Aerobic training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
62514944|NCT04837027|ACTIVE_COMPARATOR|Balance training|Balance Training A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance
62514945|NCT06364878||Patents with suspected infectious keratitis|
61973410|NCT03846011||Experiment group|All eligible patients administered for active stone removal.
62354162|NCT05506917|EXPERIMENTAL|Periodontal treatment group|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
62354163|NCT01051115|EXPERIMENTAL|Dasatinib|Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.
62354164|NCT02570646|EXPERIMENTAL|QA-DDS|Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
62354165|NCT05275296|EXPERIMENTAL|experimental group|Microport NeuroTech Intracranial Visualized Stent
62354166|NCT05275296|ACTIVE_COMPARATOR|control group|LVIS™ and LVIS™ Jr
62354167|NCT02255643|EXPERIMENTAL|-10% of effective PMT|Patients are set to a voltage 10% less than their original PMT at start of study, Changes in PMT settings
62354168|NCT02255643|ACTIVE_COMPARATOR|former setting (+/- 0% of PMT)|Patients are set to their original PMT at start of study, Changes in PMT settings
62514946|NCT06364878||Healthy controls|
62710070|NCT04005300|EXPERIMENTAL|low calorie feeding group|Enteral nutrition was fed at 10-20kcal/kg/d for the first three days before identifying the refeeding syndrome
62710071|NCT04005300|ACTIVE_COMPARATOR|standard calorie feeding group|Enteral nutrition was fed at 500-750kcal/d for the first three days before identifying the refeeding syndrome
62715077|NCT00403130|EXPERIMENTAL|Phase II 3-drug regimen|Gemcitabine + Paclitaxel + Bevacizumab
62715078|NCT02273089||OSA w/o EDS|Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
62715079|NCT02273089||OSA w EDS|Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
62354169|NCT02255643|EXPERIMENTAL|+10% of effective PMT|Patients are set to a voltage 10% more than their original PMT at start of study, Changes in PMT settings
62354170|NCT03468049|EXPERIMENTAL|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
62354171|NCT03468049|EXPERIMENTAL|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
61973411|NCT00940420|EXPERIMENTAL|A|
61973412|NCT00940420|EXPERIMENTAL|B|
61973413|NCT01279278|NO_INTERVENTION|Control|
61973414|NCT01279278|EXPERIMENTAL|Co-signed Letter|
62514947|NCT02249221|EXPERIMENTAL|Quadrivalent cell-culture based influenza vaccin|Day 1: GC3106, 0.5ml, intramuscular, a single dosing
62514948|NCT02249221|ACTIVE_COMPARATOR|Trivalent influenza vaccine|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
62514949|NCT05271136|ACTIVE_COMPARATOR|Cell 1: Anti-aging Serum|"Dosage form: Anti-aging Serum~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum.~Study Duration: 7 days"
62514950|NCT05271136|ACTIVE_COMPARATOR|Cell 2: Anti-aging Serum and Facial Moisturizer|"Dosage form: Anti-aging Serum and Facial Moisturizer~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum, and then 2 pumps of the Facial Moisturizer to the global face.~Study Duration: 7 days"
62514951|NCT04269733||Subjects with a DDD-pacemaker due to high-degree AV block|
62514952|NCT03537157|EXPERIMENTAL|Rifaximin delayed release tablets|Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
62514953|NCT03537157|PLACEBO_COMPARATOR|Placebo|Two placebo tablets twice a day for 26 weeks
62514954|NCT01797926|EXPERIMENTAL|Group 1 (5 mg amlodipine and 50 mg losartan)|Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design
62514955|NCT01797926|EXPERIMENTAL|Group 2 (5 mg amlodipine and 100 mg losartan)|Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design
62514956|NCT04914624|PLACEBO_COMPARATOR|Regular ACBT training|Including quitting smoking, ACBT training, cough practicing.
62514957|NCT04914624|EXPERIMENTAL|Positive expiratory pressure therapy|Use acpella®PEP therapeutic system and regular nursing care.
62514958|NCT04914624|EXPERIMENTAL|External diaphragm pacemaker|Patients are trained to use external diaphragm pacemaker and receive regular nursing care.
62514959|NCT05845294|ACTIVE_COMPARATOR|Control group|
62514960|NCT05845294|EXPERIMENTAL|Experimental group|
62514961|NCT05859399|EXPERIMENTAL|Experimental (laughter yoga) group|The intervention group will receive 12 online laughter yoga sessions, only one session per week for 12 weeks. In this study, the number of laughter yoga sessions was determined in line with the studies in the literature. Each laughter yoga session is planned to last approximately 40-45 minutes. Each session of laughter yoga consists of clapping and warm-up exercises, deep breathing exercises, childlike play and laughter.
62514962|NCT05859399|NO_INTERVENTION|Control group|The control group will receive no intervention for 12 weeks.
62514963|NCT04652284|ACTIVE_COMPARATOR|Rifabutin full dose|oral amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd 14 days
62514964|NCT04652284|ACTIVE_COMPARATOR|Rifabutin low dose|oral amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd 14 days
62514965|NCT04652284|ACTIVE_COMPARATOR|Standard of Care|Standard of care in previously untreated patients will consist of concomitant treatment (oral amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole 40 mg all given twice daily for 14 days). In previously treated patients standard of care will consist of bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment where available
62514966|NCT01042535|EXPERIMENTAL|Treatment (vaccine therapy, 1-methyl-d-tryptophan)|Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62514967|NCT06233357||N, no casirivimab / imdevimab or tocilizumab|No intervention
62514968|NCT06233357||C, treated with casirivimab / imdevimab|Active comparator
61973415|NCT05398562|EXPERIMENTAL|RTA / 0.1 μg / 0.1 mL|at stage I - 5 healthy volunteers; at stage II - 20 healthy volunteers. frequency and route of administration: once, intradermally
62514969|NCT06233357||T, Treated with Tocilizumab|Active comparator
61973416|NCT05398562|EXPERIMENTAL|RTA / 0.2 μg / 0.1 mL|at stage I - 5 healthy volunteers; at stage II - 20 healthy volunteers. frequency and route of administration: once, intradermally
61973417|NCT05398562|PLACEBO_COMPARATOR|Placebo / 0.1 mL|at stage I - 5 healthy volunteers; at stage II - 20 healthy volunteers. frequency and route of administration: once, intradermally
62514970|NCT06233357||C + T, treated with casirivimab / imdevimab and tocilizumab|Active comparator
62514971|NCT05905016||Esophageal POEM|Data will be collected for patients under going standard of care Esophageal POEM (E-POEM)
62514972|NCT05905016||Gastric POEM|Data will be collected for patients under going standard of care Gastric POEM (G-POEM)
62514973|NCT05905016||Zenker's POEM|Data will be collected for patients under going standard of care Zenker's diverticulum POEM (Z-POEM)
62514974|NCT01922219|OTHER|Cognitive Behavioral Therapy|Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).
62514975|NCT04845906||Healthy volunteers|There will be 4 separate StatLock™ devices being tested, which will be randomly applied to the participants on their inner (ventral) forearms. Each participant will have 2 separate devices applied, one to each arm. Those participants who have the StatLock ™ Arterial Plus, StatLock™ Dialysis II, or the StatLock IV Select, will also have the foam strip applied.
62514976|NCT05563818||Arabic-speaking individuals with schizophrenia|Approximately 56-60 Arabic-speaking individuals with a DSM-5 diagnosis of schizophrenia
62514977|NCT05506878|ACTIVE_COMPARATOR|NSS-2 BRIDGE device|"This experimental arm involves the use of the NSS-2 BRIDGE device, which is a disposable device that stimulates the branches of cranial nerves and of the superficial cervical plexus innervating the ear. It will be placed on the subject immediately after surgery and worn for 5 days.~It is a percutaneous nerve field stimulator (PNFS) system, that can be used as an aid to reduce the symptoms of opioid withdrawal, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination."
62514978|NCT05506878|SHAM_COMPARATOR|Placebo Bridge|"The sham group involves the use of 3 non-active points, or nonfunctional points. The sham device will be placed on the subject immediately post-operatively and worn for 5 days just like the active group."
62514979|NCT02332408|EXPERIMENTAL|Cybernetic microradiosurgery|Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,
62514980|NCT02332408|ACTIVE_COMPARATOR|Conventional radiotherapy|Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,
62514981|NCT06304909|EXPERIMENTAL|Dexmedetomidine group will receive 0.5 mcg/kg|
62514982|NCT06304909|EXPERIMENTAL|Dexamethasone group will receive 8mg/kg|
62514983|NCT06304909|EXPERIMENTAL|Control group will receive equivalent volume of saline 0.9%.|
62514984|NCT01095419|NO_INTERVENTION|Control|Patients were seated in a chair for the same period then those from MT group, but did not receive intervention
62514985|NCT01095419|EXPERIMENTAL|Massage Therapy|Patients in the postoperative period of coronary artery bypass graft surgery, which receive intervention for 3 consecutive days
62514986|NCT01923584|ACTIVE_COMPARATOR|EPI-743 400mg|EPI-743 at a dose of 400 mg three times daily
62514987|NCT01923584|ACTIVE_COMPARATOR|EPI-743 200mg|EPI-743 at a dose of 200 mg three times daily
62514988|NCT00933959|EXPERIMENTAL|Mind-Body Bridging Program|"Subjects will undergo two approximately 1.5 hr training sessions using MBBP spaced one week apart at the VASLCHCS. Each training session will comprise a number of objectives:~Session 1:~1. The patient will discover the underlying cause of the insomnia.~2. The patient will learn how to use easy to apply tools to quieten the mind to sleep soundly.~Session 2:~1. The patient will learn how to reduce daytime stress.~2. The patient will experience a greater sense of self.~To be maximally effective, the participant should master these objectives and practice MBBP on a daily basis. Bridging and all the other MBBP techniques can be implemented at any time throughout the day and right up to the onset of sleep."
62514989|NCT00933959|ACTIVE_COMPARATOR|Sleep Hygiene|Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
61973418|NCT00398060|EXPERIMENTAL|A|
61973419|NCT04271891|EXPERIMENTAL|With WBPC|Intensive rehabilitation programs :The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks additional WBPC: The duration will be 30 minutes a time
61973420|NCT04271891|PLACEBO_COMPARATOR|Control|Intensive rehabilitation programs: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks without WBPC.
61973421|NCT02159014|EXPERIMENTAL|Phase 1|Facilitated group-based physical activity (aerobic dance), online physical activity (video based aerobic dance) and nutritional intervention (nutritional education, cooking skill training, access and use of NHS Change4Life Eat Well web resource).
61973422|NCT02159014|ACTIVE_COMPARATOR|Phase 2|Self-paced online physical activity (video based aerobic dance) intervention and use of NHS Change4Life Eat Well web resource.
62514990|NCT02667002|EXPERIMENTAL|Bilateral Abdominal Sacral Hysteropexy|Bilateral abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
62514991|NCT02667002|EXPERIMENTAL|Classic Abdominal Sacral Hysteropexy|Conventional abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
62514992|NCT02667002|ACTIVE_COMPARATOR|Women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
62514993|NCT02921503|EXPERIMENTAL|Topical Corticosteroids App Users|Practitioners will asked to use a novel application during their patient encounters over the next three months. This application should not modify treatment, it will only act as a vehicle to present evidence based research. Patients will not be subjects of this research, as the app is only presenting best practice which the physicians should be aware of.
62514994|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
62710072|NCT04005300|NO_INTERVENTION|RFS group|The definition of RFS is that serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded. And it is divided into three sub-group that is Group 1 that a drop of \>0.16 mmol/L from any previous measurement, to below 0.65 mmol/L within 72 h after starting nutritional support, Group 2 that their serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded, and Group 3 that their serum phosphate concentration decreased to below 0•32 mmol/L within 72 h after starting nutritional support.
62710073|NCT04005300|NO_INTERVENTION|nRFS group|It is not up to the RFS definition
61973423|NCT01960244||hypercholesterolemia|familial hypercholesterolemia
62710074|NCT04422496|EXPERIMENTAL|HEC96719 tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B: There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
61973424|NCT02510859|EXPERIMENTAL|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
62710075|NCT04422496|PLACEBO_COMPARATOR|placebo tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B:There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
62710076|NCT04740151|EXPERIMENTAL|BEST PEEP|During OLV an individualized PEEP will be applied i.e. the one corresponding to the lower driving pressure, + 2 cmH2O
62710077|NCT04740151|ACTIVE_COMPARATOR|STANDARD PEEP|During OLV a PEEP of 5 cmH2O will be applied
62710078|NCT00922129|EXPERIMENTAL|Conversion to sirolimus|
62514995|NCT01731249|PLACEBO_COMPARATOR|Placebo|Placebo sublingual solution
62514996|NCT01731249|EXPERIMENTAL|Birch pollen allergen extract|Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years
62514997|NCT05680779|EXPERIMENTAL|PNM group|Subjects were treated once time. The technique consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, with 250 μs pulse width and the maximal torelable intensity to cause an exacerbated muscle contraction during ten seconds with a rest period of another ten seconds y total number of ten times. The subjects were lying in lateral decubitus. The common peroneal nerve was located with ultrasound (cross section) near to the peroneal head. After, an acupuncture needle (0,30mm x 30mm) was inserted in a long axis approach until the perineurium of the common peroneal nerve (in close proximity)
62514998|NCT05680779|OTHER|Control group|Subjects were treated once time. The subjects were lying in lateral decubitus. The common peroneal nerve was located with ultrasound (cross section) near to the peroneal head. After, an acupuncture needle (0,30mm x 30mm) was inserted in a long axis approach until the perineurium of the common peroneal nerve (in close proximity). The needle remains in this location during 200 seconds without any electrical current.
62514999|NCT01820858|EXPERIMENTAL|Adjuvant Chemotherapy|Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.
62515000|NCT01820858|ACTIVE_COMPARATOR|Adjuvant Radiotherapy|"1. Histopathological grade G3 and \<50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;~2. Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;~3. ≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times."
62515001|NCT03064321|EXPERIMENTAL|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
62515002|NCT03064321|OTHER|Information Control|General health information website
62515003|NCT05372276||Inactive|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is \<600 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
62515004|NCT05372276||Low Level Physical Activity (PA)|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is 600 - 3000 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
62515005|NCT05372276||Adequate Level Physical Activity (PA)|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is \>3000 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
62515006|NCT01784354|PLACEBO_COMPARATOR|Education|target education toward Raynaud's
62515007|NCT01784354|ACTIVE_COMPARATOR|Acupressure|acupressure- dilatation
62515008|NCT01784354|ACTIVE_COMPARATOR|Acupressure relaxation|acupressure relaxation protocol
62515009|NCT04523324|ACTIVE_COMPARATOR|RIV4 (Flublok Quadrivalent)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
62515010|NCT04523324|ACTIVE_COMPARATOR|IIV4 (Vaxigrip Quadrivalent)|VaxigripTetra™ by Sanofi, Inc., 15µg of HA per strain, egg-based
62515011|NCT06471920|ACTIVE_COMPARATOR|Educational Control|Patients randomized to the educational control group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest. To promote increased physical activity levels, the website will also include pictures and videos of common exercises targeting the lumbopelvic region that patients can perform independently without the need for exercise equipment.
62515012|NCT06471920|EXPERIMENTAL|Telerehabilitation|"Based on prior STarT Back Tool (SBTS) screening risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to psychological informed physical therapy (PIPT) telehealth visits (high-risk).~The SBTS is a short questionnaire that assesses an individual's physical, psychosocial, and psychological risk factors for chronic back pain that can be improved with treatment."
62515013|NCT01978899|ACTIVE_COMPARATOR|Immediate Weight Loss Program Group|"Immediate Weight Loss Program Group~* The weight loss Program Group will include weekly in-person sessions comprised of dietary counseling and increased physical activity. Patients will also be provided with exercise and dietary goals each week to implement at home.~* Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks."
62515014|NCT01978899|ACTIVE_COMPARATOR|Delayed Weight Loss Program Group|The Delayed Weight Loss Program Group will take part in the weight loss intervention after the 16-week control period. Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks
61973425|NCT02510859|NO_INTERVENTION|Traditional nutritional follow up|Traditional nutritional follow up that is to say with a nutritional consultation before starting treatment and then when necessary on medical advice
61973426|NCT01252108|EXPERIMENTAL|Treatment|All subjects receive SQ109
61973427|NCT02590848|NO_INTERVENTION|Group with no intervention|This group will receive healthy recommendations of eating fresh fruits
61973428|NCT02590848|EXPERIMENTAL|Group with walnut intake|This group will receive healthy recommendation of eating fresh fruits + 30 g of walnut kernels per day during 6 months.
62515015|NCT06022367|EXPERIMENTAL|Raise-Turn Sequence|Participant performs cVEMP twice using the head raise activation technique followed by the head turn activation technique.
62515016|NCT06022367|EXPERIMENTAL|Turn-Raise Sequence|Participant performs cVEMP twice using the head turn activation technique followed by the head raise activation technique.
62515017|NCT00484419|EXPERIMENTAL|colesevelam|colesevelam tablets 625 mg
62515018|NCT00484419|ACTIVE_COMPARATOR|rosiglitazone|rosiglitazone maleate 4mg
62515019|NCT00484419|ACTIVE_COMPARATOR|sitagliptin|sitagliptin phosphate tablets
62515020|NCT01909128|EXPERIMENTAL|fermented milk|
62515021|NCT01909128|EXPERIMENTAL|fermented rice|
62515022|NCT01909128|PLACEBO_COMPARATOR|placebo|
62515023|NCT00389779|EXPERIMENTAL|Darusentan|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks
62515024|NCT00389779|ACTIVE_COMPARATOR|Guanfacine|Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks
62515025|NCT00389779|PLACEBO_COMPARATOR|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
62515026|NCT01202071|EXPERIMENTAL|Rabeprazole sodium Tablets, 5 mg|
62515027|NCT01202071|EXPERIMENTAL|Rabeprazole sodium Tablets, 10 mg|
62515028|NCT01202071|EXPERIMENTAL|Rabeprazole sodium Tablets, 20 mg|
62515029|NCT01202071|EXPERIMENTAL|Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets)|
62515030|NCT03544398|ACTIVE_COMPARATOR|exoskeleton|We will use exoskeleton type robot assisted gait training for spinal cord injury rehabilitation
62515031|NCT03544398|ACTIVE_COMPARATOR|end-effector|We will use end-effector type robot assisted gait training for spinal cord injury rehabilitation
62515032|NCT03544398|PLACEBO_COMPARATOR|conventional physiotherapy|
62515033|NCT02938520|EXPERIMENTAL|CAB LA + RPV LA every 4 weeks|After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
62710079|NCT00922129|ACTIVE_COMPARATOR|Calcineurim inhibitor reduction|
62515034|NCT02938520|ACTIVE_COMPARATOR|ABC / DTG / 3TC (600 mg/50mg/300mg) once daily|After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
62515035|NCT01671982|EXPERIMENTAL|Tenofovir-containing HAART|
62515036|NCT04399265|EXPERIMENTAL|Trehalose|Trehalose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
62515037|NCT04399265|PLACEBO_COMPARATOR|Maltose placebo|Isocaloric maltose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
62710080|NCT03791879|ACTIVE_COMPARATOR|• Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k|
62710081|NCT03791879|ACTIVE_COMPARATOR|• Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.|
62710082|NCT03791879|ACTIVE_COMPARATOR|• Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/|
62710083|NCT03791879|ACTIVE_COMPARATOR|• Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.|
62710084|NCT02109276|ACTIVE_COMPARATOR|Spheric Sensar(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive a Spheric Sensar(R) 3-piece IOL
62710085|NCT02109276|EXPERIMENTAL|Aspheric Tecnis(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive an Aspheric Tecnis(R) 3-piece IOL
62710086|NCT01144819||STEMI|Patients with STEMI according to ESC STEMI guidelines: Age above 18 years and able to give written, informed consent to participation in the project.
62710087|NCT01502735|EXPERIMENTAL|DENV-1 PIV (high dose)|
62710088|NCT01502735|EXPERIMENTAL|DENV-1 PIV (low dose)|
62515038|NCT03339505|ACTIVE_COMPARATOR|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
62515039|NCT03339505|PLACEBO_COMPARATOR|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
62515040|NCT01739725|EXPERIMENTAL|Helical stent insertion|Study participants will receive the helical stent
62515041|NCT01201759|EXPERIMENTAL|Placebo to Salsalate 2gr BID|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
62515042|NCT01201759|EXPERIMENTAL|Salsalate 2gr BID to placebo|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days.
62515043|NCT05470933|EXPERIMENTAL|WJ01075 tablets|Once a week (QW).
62515044|NCT04952831||Patients with mild CSM|mJOA score ≥15
62515045|NCT04952831||Patients with moderate CSM|mJOA score 13\~14
62515046|NCT04952831||Patients with severe CSM|mJOA score ≤ 12
62515047|NCT04952831||Controls|health volunteers
62515048|NCT03256422|EXPERIMENTAL|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
62515049|NCT03256422|ACTIVE_COMPARATOR|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
62515050|NCT05275959|OTHER|Intervention|Intervention measures will be taken against children and adolescents' myopia and obesity at four levels: individual (individual centered activities), environment (supportive family and school settings), and supervision (family, school, program team, and clinical) and feedback (timely feedback from the WeChat applet).
62710089|NCT04954664|EXPERIMENTAL|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
62710090|NCT04954664|ACTIVE_COMPARATOR|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
62710091|NCT05437991|OTHER|Morphological quantification of low-grade carotid stenosis|Morphological quantification using ECST method and implying two independent observers
62515051|NCT05275959|NO_INTERVENTION|Control|health education
62515052|NCT02504723|EXPERIMENTAL|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
62515053|NCT02504723|ACTIVE_COMPARATOR|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
62515054|NCT05410054||good prognosis|Patients with higher Fugl-Meyer motor function scale (upper limb part) and higher Action Research Arm Test (ARAT) score.
62515055|NCT05410054||poor prognosis|Patients with lower Fugl-Meyer motor function scale (upper limb part) and lower Action Research Arm Test (ARAT) score.
62515056|NCT04711967|EXPERIMENTAL|Fecal Microbiota Transplantation group|treat with FMT
62515057|NCT04711967|ACTIVE_COMPARATOR|Control group|treat with traditional medicine
62515058|NCT03360357|EXPERIMENTAL|guided drills|These people will be going through all the guided drills before being evaluated.
62515059|NCT03360357|NO_INTERVENTION|Self-trained|These people will watch a video and be able to practice by themselves without having any direction regarding how and what to practice.
62515060|NCT02776813|EXPERIMENTAL|ACTR087, in combination with rituximab|
62515061|NCT03336242|EXPERIMENTAL|Cohort 1: Cannabidiol Oral Solution 20 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 20 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) for 4 weeks.
62515062|NCT03336242|EXPERIMENTAL|Cohort 2: Cannabidiol Oral Solution 30 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days.~Treatment Period: Cannabidiol Oral Solution 30 mg/kg/day divided BID for 4 weeks."
62515063|NCT03336242|EXPERIMENTAL|Cohort 3: Cannabidiol Oral Solution 10 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 10 mg/kg/day divided BID for 4 weeks.
62515064|NCT03301103|PLACEBO_COMPARATOR|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
62515065|NCT03301103|EXPERIMENTAL|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
62515066|NCT03409991|EXPERIMENTAL|Experimental|Receives the 12-week Opening Doors group sessions, and up to 8 individual career counseling sessions.
62515067|NCT03409991|NO_INTERVENTION|Waitlist Control|Offered non-vocational classes at the Boston University Center for Psychiatric Rehabilitation, and offered the chance to attend the Opening Doors program at the end of their enrolled 12-month study period.
62515068|NCT03629600|EXPERIMENTAL|Aggressive Hydration|Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) \[COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA\] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
62515069|NCT03629600|ACTIVE_COMPARATOR|Rectal Indomethacin|Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin \[Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA\] just after the completion of ERCP procedure.
62710092|NCT03156114|EXPERIMENTAL|Part I - Dose--Escalation|
62515070|NCT06417164|NO_INTERVENTION|Control, Traditional Physical Training Group|The control group will use traditional physical training methods.
62515071|NCT06417164|EXPERIMENTAL|Intervention, Functional Training Group,|Intervention, Functional Training Group will use functional movement training methods based on FMS.
62515072|NCT01949116|EXPERIMENTAL|Low-dose methotrexate (LDMTX)|From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
62710093|NCT03156114|EXPERIMENTAL|Part II - Dose-Expansion|
62515073|NCT01949116|PLACEBO_COMPARATOR|Placebo|From study entry through Week 1, participants received 5 mg of placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of placebo, all participants continued taking folic acid for an additional 4 weeks.
62515074|NCT02150759|EXPERIMENTAL|Dexmedetomidine-ketamine|Dexmedetomidine-ketamine group
62515075|NCT02150759|ACTIVE_COMPARATOR|Dexmedetomidine-fentanyl|Dexmedetomidine-fentanyl group
62710094|NCT00226005|ACTIVE_COMPARATOR|Vatalanib|Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
62710095|NCT06561802|EXPERIMENTAL|periodontally healthy|Full-mouth clinical periodontal measurements recorded and GCF and saliva obtained.
62710096|NCT06561802|EXPERIMENTAL|gingivitis|Full-mouth clinical periodontal measurements recorded and GCF and saliva obtained.
62710097|NCT06561802|EXPERIMENTAL|periodontitis|Full-mouth clinical periodontal measurements recorded and GCF and saliva obtained.
62710098|NCT01382108||Normal participants|
62710099|NCT01382108||Meibomian Gland Dysfunction|
62715080|NCT04073056|ACTIVE_COMPARATOR|Quadratus Lumborum II Group|The QL 2 group will receive 15 mL bupivacaine 0.25% on both sides for a total of 30 mL once the surgery is done but prior to extubation under ultrasound guidance.
62715081|NCT04073056|ACTIVE_COMPARATOR|Conventional Therapy|Conventional therapy consists of the injection of 30 mL of bupivacaine 0.25% directly into the incision sites by the surgeon at the end of the procedure.
62515076|NCT04705116||Vaccinated pregnant women|Pregnant women who received at least one dose of a COVID-19 vaccine from 30 days prior to the first day of the LMP to end of pregnancy.
62515077|NCT04705116||Non-vaccinated pregnant women|Pregnant women who have not received a COVID-19 vaccine during pregnancy.
62515078|NCT05209828||pfmmedical port implantation|Port implantation for continous vascular access.
62515079|NCT03026907|ACTIVE_COMPARATOR|Alitretinoin|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with alitretinoin.
62515080|NCT03026907|ACTIVE_COMPARATOR|Azathioprine|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with azathioprine.
62515081|NCT03282006|EXPERIMENTAL|Pivmecillinam|Patients treated with pivmecillinam
62515082|NCT04787952||Group 1= healthy subjects|"Inclusion criteria to the group 1 (healthy males) N=20:~1. BMI \<25 kg/m2;~2. RR\<140/90mmHg;~3. age 21-43 years~4. fasting glycemia \<100mg/dl; 2h-OGTT \<140mg/dl;~5. no chronic disease"
62515083|NCT04787952||Group 2 = overweight/obese subjects|"Inclusion criteria to the group 2 ( overweight/obese males ) N=20:~1. Blood pressure \< 140/90 mmHg (well controlled by inh ACE; no beta-blockers)~2. No chronic disease~3. BMI \> 25 \<35kg/m²~4. fasting glycemia \<100mg/dl; 2h-OGTT \<140mg/dl;~5. age 21-43 years"
62515084|NCT06027138|ACTIVE_COMPARATOR|blood flow resistance training|"vertical jump test~1RM tests times pull ups and push ups test"
62515085|NCT06027138|EXPERIMENTAL|slow motion strength training|"vertical jump test~1RM tests times pull ups and push ups test"
62515086|NCT02340221|EXPERIMENTAL|Taselisib + Fulvestrant|Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
62515087|NCT02340221|PLACEBO_COMPARATOR|Placebo + Fulvestrant|Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
62515088|NCT00733031|EXPERIMENTAL|gemcitabine|gemcitabine administered in combination with AZD6918
62515089|NCT00733031|EXPERIMENTAL|pemetrexed|pemetrexed administered in combination with AZD6918
62515090|NCT00733031|EXPERIMENTAL|AZD6918|AZD6918 administered alone
62515091|NCT05189236|OTHER|Control Group (Only Algorithm of Febrile Neutropenia Management)|The algorithm of febril neutropenia management is used to treat children who are followed up at the paediatric oncology service, where the study will be conducted, due to febrile neutropenia. The control group will consist of children who have been treated using this algorithm (only the Algorithm of Febrile Neutropenia Management).
62710100|NCT02441894|EXPERIMENTAL|Cabazitaxel|"25 mg/m\^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks.~Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles."
62710101|NCT05098392|NO_INTERVENTION|Treatment as usual/Sibling interaction|Children with autism will spend time with their typically developing siblings for 20-30 mins at least three times a week
62715082|NCT03319641|EXPERIMENTAL|PSMA-PET/CT scan|PSMA-PET/CT imaging in advanced ACC/SDC
62354172|NCT03468049|EXPERIMENTAL|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
62354173|NCT03468049|ACTIVE_COMPARATOR|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
62354174|NCT03543670|EXPERIMENTAL|Oncoxin-Viusid|
62354175|NCT05287607||Newborn Infants|Newborn infants delivered at study hospital and admitted to neonatal unit. Babies anticipated to stay for at least 5 days.
62354176|NCT05658263|ACTIVE_COMPARATOR|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
62354177|NCT05658263|EXPERIMENTAL|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
62354178|NCT03472599|EXPERIMENTAL|Genital Nerve Stimulation|Study participants in this arm will use take-home genital nerve stimulation for 24+ months in order to assess its effectiveness at decreasing urinary incontinence. In order to set effective genital nerve stimulation parameters, study participants will undergo clinical urodynamics every 6 months in which sensitivity to and tolerance of electrical stimulation are assessed.
62354179|NCT03304327|EXPERIMENTAL|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
62354180|NCT06014580||Patients diagnosed with endometrial cancer|Patients diagnosed with endometrial cancer between January 2016 and December 2019 at participating sites will be included.
62354181|NCT02447458|EXPERIMENTAL|Cohort 1: MLN3126 300 mg|MLN3126 300 mg tablets, orally, fasting, once on Day 1.
62354182|NCT02447458|EXPERIMENTAL|Cohort 2: MLN3126 600 mg|MLN3126 600 mg tablets, orally, fasting, once on Day 1.
62710102|NCT05098392|EXPERIMENTAL|Sibling-mediated intervention|Children with autism will receive explicit instruction from their typically developing siblings
61973429|NCT02814851|EXPERIMENTAL|Non valvular cardiac surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and cardiology wards. Subjects referred for non valvular cardiac surgery will be prospectively included during the first 6 months following the onset of the protocol.
61973430|NCT04058145|EXPERIMENTAL|Pembrolizumab+AMD3100 q3w|"* Pembrolizumab is administered intravenously on day 1 of each cycle~* AMD3 100 is administered via injection subcutaneously on day 1 of each cycle"
61973431|NCT04058145|EXPERIMENTAL|Pembrolizumab+AMD3100 weekly|"* Pembrolizumab is administered intravenously on day 1 of each cycle~* AMD3 100 is administered via injection subcutaneously on a weekly basis"
62354183|NCT02447458|EXPERIMENTAL|Cohort 3: MLN3126 1000 mg|MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.
62354184|NCT02447458|EXPERIMENTAL|Cohort 4: MLN3126 1500 mg|MLN3126 1500 mg administered orally as tablets, once on Day 1.
62354185|NCT02447458|EXPERIMENTAL|Cohort 5: MLN3126 2000 mg|MLN3126 2000 mg tablets, orally, fasting, once on Day 1.
62354186|NCT02447458|EXPERIMENTAL|Cohort 6|Did not take place due to termination of the study.
62354187|NCT02447458|PLACEBO_COMPARATOR|Placebo: Cohort 1-6|Placebo-matching MLN3126 tablets, orally, once on Day 1.
62354188|NCT01196299||Severe Traumatic Brain Injury Group|The severe traumatic brain injury group are patients admitted to the study with an admission GCS between 3 and 8.
62354189|NCT01196299||Moderate Head Injury Group|The moderate head injury group are patients admitted to the study with an admission GCS from 9 to 12.
62354190|NCT01196299||Mild Head Injury Group|The mild head injury group are patients admitted to the study with an admission GCS from 13 to 15.
62354191|NCT01196299||Healthy Volunteer Group|Healthy volunteers will be selected to match the age distribution of the TBI groups. They must be absent of any abnormal radiological findings.
62354192|NCT01441791|EXPERIMENTAL|Lung protective strategy ventilation|Lung protective strategy ventilation: PEEP at 12 cmH2O, Recruitment maneuvers (after intubation, after any disconnection from the mechanical ventilator, directly before detubation)
62354193|NCT01441791|NO_INTERVENTION|Conventional Strategy|"* PEEP at maximum 2 cmH2O, if possible 0 cmH2O~* No recruitment maneuvers Patients are randomized and intra-operatively ventilated with conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers)."
62354194|NCT01948869|EXPERIMENTAL|Phoenix II|Application over 29 days twice daily
62354195|NCT01948869|ACTIVE_COMPARATOR|Phoenix I|Application over 29 days twice daily
62354196|NCT01948869|NO_INTERVENTION|Untreated skin|Untreated skin areas of subjects will be observed over 29 days
62354197|NCT04066946|EXPERIMENTAL|Group 1 = Intervention group|Standard of care (hydration + silicone gel sheet) + Microcurrent
62354198|NCT04066946|ACTIVE_COMPARATOR|Group 2 = Control Group|Standard of care (hydration + silicone gel sheet)
62354199|NCT00106288|EXPERIMENTAL|1|
62354200|NCT00106288|ACTIVE_COMPARATOR|2|
62354201|NCT03460925|EXPERIMENTAL|SBRT plus chemotherapy|"Patients with unresectable or borderline resectable locally advanced pancreatic carcinoma at time of diagnosis"
62354202|NCT02562183|EXPERIMENTAL|kallikrein group|Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
62354203|NCT03059472|EXPERIMENTAL|Group 1 (Intervention)|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
62354204|NCT03059472|EXPERIMENTAL|Group 2 (Delayed intervention)|Delayed intervention participants will participate in the same activities as Group 1 but 6 months after Group 1.
62354205|NCT03920878|EXPERIMENTAL|Aflibercept injected Pre- and Post-operatively|Pre- and Post-operative time of Aflibercept injections
62354206|NCT03920878|ACTIVE_COMPARATOR|Aflibercept injected intraoperatively|Intraoperative time of Aflibercept injection
62354207|NCT04105855||Older Infants|Infants age 6-12 months presenting for routine healthy visits
62354208|NCT04105855||Pregnant Women|Women 18 years and older (and emancipated minors) presenting for routine antenatal visits
62354209|NCT05603754|EXPERIMENTAL|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1.
62354210|NCT05603754|PLACEBO_COMPARATOR|Vehicle|Healthcare professional-administered intra-articular injection; performed on Day 1.
62354211|NCT00730626|EXPERIMENTAL|1|L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract
62354212|NCT00730626|EXPERIMENTAL|2|L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract
62354213|NCT00730626|PLACEBO_COMPARATOR|3|Placebo
62354214|NCT02750579|ACTIVE_COMPARATOR|Control group|control group: Percutaneous coronary intervention for revascularization delayed intervention (12 to 72 hours)
62354215|NCT02750579|EXPERIMENTAL|experimental group|experimental group: early Percutaneous coronary intervention for revascularization intervention (\<2 hours)
62354216|NCT01335698|EXPERIMENTAL|Stage 1: Atazanavir + Ritonavir|Participants received atazanavir powder orally (dosed by weight: 5 to \<10 kg=150 mg, 5 to \<10 kg=200 mg, 10 to \<15 kg=200 mg, 15 to \<25 kg=250 mg, 25 to \<35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to \<25 kg=80 mg, 25 to \<35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to \<35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to \<35 kg=100 mg)
62354217|NCT01744457|OTHER|20 patients with dry eye syndrome|Patients with dry eye syndrome defined as outlined in the inclusion and exclusion criteria
62354218|NCT01744457|OTHER|20 healthy control subjects|age- and sex-matched controls
62354219|NCT05688072|ACTIVE_COMPARATOR|study group (A)|
62354220|NCT05688072|ACTIVE_COMPARATOR|Study group (B)|
62354221|NCT05626244|EXPERIMENTAL|Intervention Group|The intervention group will be receiving the parenting intervention (name of the intervention: Being a Parent).
62710103|NCT03769350|EXPERIMENTAL|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
62515092|NCT05189236|EXPERIMENTAL|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|The experimental group will consist of the children who will be applied to cold steam in addition to this algorithm (Algorithm of Febrile Neutropenia Management + cold steam application).
62515093|NCT04272203|EXPERIMENTAL|Dose Escalation: Participants With AML|Participants with relapsed or refractory (R/R) AML will receive escalating doses of ABBV-184
62710104|NCT03769350|OTHER|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
62710105|NCT01570387|EXPERIMENTAL|Phase I - cohort 1 (Pomalidomide 2mg) plus Dexamethasone|Pomalidomide 2 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
62710106|NCT01570387|EXPERIMENTAL|Phase I - cohort 2 (Pomalidomide 3mg) plus Dexamethasone|Pomalidomide 3 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
62710107|NCT01570387|EXPERIMENTAL|Phase I - cohort 3 (Pomalidomide 4mg) plus Dexamethasone|Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
62710108|NCT01570387|EXPERIMENTAL|Phase II Expansion- (Pomalidomide 4mg) plus Dexamethasone|"Expansion Phase:~Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle"
62147467|NCT05243459|EXPERIMENTAL|Gaze-Contingent Feedback Training|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the veteran will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracking technology, the veteran will be instructed to view the matrices of faces as he chooses, as described above in the assessment task. The music chosen by the veteran will play only when s/he is looking at neutral faces and it will stop when s/he looks at threatening faces.
62354222|NCT05626244|NO_INTERVENTION|Waitlist Control Group|The control group will be in a waitilist condition, in which they will not receive any intervention during the trial, but posteriorly will have the opportunity to receive the parenting intervention.
62515094|NCT04272203|EXPERIMENTAL|Dose Escalation: Participants With NSCLC|Participants with relapsed or refractory (R/R) NSCLC will receive escalating doses of ABBV-184
62710109|NCT00399087|EXPERIMENTAL|Perifosine D1 + Docetaxel|
62710110|NCT00399087|EXPERIMENTAL|Perifosine D1+ Docexatel+Prednisone|
62710111|NCT00399087|EXPERIMENTAL|Perifosine+ D1,8 and 15+Docetaxel+Prednisone|
62710112|NCT06570122|EXPERIMENTAL|AI chatbot support group|AI-powered chatbot support+ 5A's/5R's advice + health warning leaflet
62710113|NCT06570122|ACTIVE_COMPARATOR|Control group|5A's/5R's advice + health warning leaflet
62710114|NCT04862754|EXPERIMENTAL|interval training|Aerobic interval training. It consisted of a modified interval cycle ergometer training program (3 days a week for 8 weeks). AIT consisted of 8 min warm up, followed by four times of 4-min intervals with HR at 80% of submaximal predetermined HR, with active phases of 3 min of cycling at 60% of submaximal predetermined HR. The exercise session was terminated by 5 min cool down
62710115|NCT04862754|NO_INTERVENTION|medical treatment|hypertensive medication
62710116|NCT03464825|OTHER|Intervention|Participants in the intervention group receive balance training during 3 months 3 times per week
61973432|NCT04058145|EXPERIMENTAL|Pembrolizumab+AMD3100|"* Pembrolizumab is administered intravenously~* AMD3 100 is administered via injection subcutaneously"
61973433|NCT00923598|ACTIVE_COMPARATOR|1) 0.1% Ropivicaine on Right Leg|Patients will be randomized ot 0.1% Ropivicaine infusion on the right leg and therefore 0.4% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
62354223|NCT05592418|EXPERIMENTAL|Ampligen / rintatolimod|Subjects will receive rintatolimod (intravenous \[IV\]), up to 400 mg twice weekly for 12 weeks.
62354224|NCT05592418|PLACEBO_COMPARATOR|Placebo / Saline|Subjects will receive placebo / normal saline (intravenous \[IV\]), up to 160 mL twice weekly for 12 weeks.
62515095|NCT04272203|EXPERIMENTAL|Dose Expansion: Participants With AML|Participants with R/R AML will receive ABBV-184 at recommended Phase 2 dose (RP2D) determined in dose escalation phase for AML
62515096|NCT04272203|EXPERIMENTAL|Dose Expansion: Participants With NSCLC|Participants with R/R NSCLC will receive ABBV-184 at RP2D determined in dose escalation phase for NSCLC
62515097|NCT04546932|EXPERIMENTAL|Lung-protective mechanical ventilation|Vt=7 ml/kg IBW; an intraoperative 10 cmH2O in PEEP, recruitment maneuvers applying a stepwise increase in PEEP.
62515098|NCT04546932|NO_INTERVENTION|Conventional mechanical ventilation|the tidal volume was set at 10 ml/kg IBW without PEEP and (recruitment maneuvers) RM
62354225|NCT01039636|EXPERIMENTAL|FBS0701 - 5 escalating doses|5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
62710117|NCT03464825|NO_INTERVENTION|Control|Care as usual
62710118|NCT04866719|EXPERIMENTAL|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
62710119|NCT01854528|EXPERIMENTAL|3-DAA/RBV|3-DAA (ABT-450/r/ABT-267 \[150 mg/ 100 mg/ 25 mg once daily\] and ABT-333 \[250 mg twice daily\]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
62710120|NCT01854528|ACTIVE_COMPARATOR|TPV/RBV|TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously \[SC\] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.
62710121|NCT03048370|EXPERIMENTAL|Left body temperature VS|Left body temperature (37°C) vestibular stimulation
62710122|NCT03048370|EXPERIMENTAL|Right body temperature VS|Right body temperature (37°C) vestibular stimulation
62710123|NCT03048370|EXPERIMENTAL|Left warm CVS|Left warm (44°C) caloric vestibular stimulation
62710124|NCT03048370|EXPERIMENTAL|Right warm CVS|Right warm (44°C) caloric vestibular stimulation
62710125|NCT03048370|EXPERIMENTAL|Left cold CVS|Left cold (30°C) caloric vestibular stimulation
62710126|NCT03048370|EXPERIMENTAL|Right cold CVS|Right cold (30°C) caloric vestibular stimulation
61973434|NCT00923598|ACTIVE_COMPARATOR|2) 0.4% Ropivicaine on Right Leg|Patients will be randomized ot 0.4% Ropivicaine infusion on the right leg and therefore 0.1% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
62147468|NCT05243459|ACTIVE_COMPARATOR|RT-Based Attention Bias Modification|"The task consists of 160 trials. Each trial begins with a centrally-presented fixation cross (+), on which the participant is asked to focus for 500ms. When it disappears, two stimuli will be presented 1.5cm above and below the previous fixation cross for 500ms. After the stimuli disappear, a target probe (right- or left-pointing arrowhead) will appear in place of one of the stimuli, and the participant will be asked to indicate which target probe is presented by pressing the respective key. The target probe will remain on the screen until the participant's response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the neutral face location. Thus, over multiple trials, learning occurs that the threatening face predicts the location of the target probe, thereby achieving the desiring change in attention patterns."
62147469|NCT05243459|PLACEBO_COMPARATOR|Non-Contingent Feedback Training|This condition is based on the aforementioned eye-tracking task with a fundamental change - The music chosen by the veteran will play continuously without any reinforcement for looking at threat or neutral faces.
62147470|NCT01061307|EXPERIMENTAL|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
62147471|NCT06474039|EXPERIMENTAL|Treatment 1|Phase 1
62147472|NCT06474039|EXPERIMENTAL|Treatment 2|Phase 2
62147473|NCT01429285|EXPERIMENTAL|Hydromorphone|Hydromorphone protocol
62147474|NCT01429285|ACTIVE_COMPARATOR|Usual care|Usual care
62147475|NCT05845398|EXPERIMENTAL|DCR-AUD|Multiple doses of DCR-AUD. Subcutaneous administration of of DCR-AUD.
62147476|NCT05845398|PLACEBO_COMPARATOR|DCR-AUD Placebo|Multiple doses of placebo comparator. Subcutaneous administration of Placebo for DCR-AUD, volume to match active single dose
62147477|NCT04183491|EXPERIMENTAL|Arm A: Interferon beta-1a low dose|Single dose of interferon beta-1a 7.5 µg intramuscular (IM)
62147478|NCT04183491|EXPERIMENTAL|Arm B: Interferon beta-1a intermediate dose|Single dose of interferon beta-1a 15 µg IM
62147479|NCT04183491|EXPERIMENTAL|Arm C: Interferon beta-1a high dose|Single dose of interferon beta-1a 30 µg IM
62147480|NCT04183491|EXPERIMENTAL|Arm D: Peginterferon beta-1a low dose|Single dose of peginterferon beta-1a 31.25 µg subcutaneous (SC)
62147481|NCT04183491|EXPERIMENTAL|Arm E: Peginterferon beta-1a intermediate dose|Single dose of peginterferon beta-1a 62.5 µg SC
62147482|NCT04183491|EXPERIMENTAL|Arm F: Peginterferon beta-1a high dose|Single dose of peginterferon beta-1a 125 µg SC
62147483|NCT04183491|PLACEBO_COMPARATOR|Arm G: Placebo|Single dose of placebo
62147484|NCT02084615|EXPERIMENTAL|81mg aspirin|This arm will include perioperative 81 mg of aspirin.
62147485|NCT02084615|EXPERIMENTAL|325mg aspirin|Subjects will be taking 325mg of aspirin.
61973435|NCT05877833||Vibrancy|Healthy adults
62147486|NCT02069028||Low intensity intervention|human oriented interventions with less consideration to the system based act including, but not limited to, education, training, sepsis profile and posters with protocol algorithms.
62147487|NCT02069028||Intermediate intensity intervention|interventions that lie in between human oriented and system oriented Including, but not limited to, sepsis protocols, daily audits, feedback and clinical pathway
62147488|NCT02069028||High intensity intervention|system based interventions with less involvement of human effect including, but not limited to, electronic alert systems and sepsis response team.
62147489|NCT05485493|EXPERIMENTAL|experimental group|The counseling program is 6 sessions, and it is the sessions will last 60-90 minutes on average once a week and be conducted via online video-conference applications. The first session is informing group members about emotional eating and solution-oriented approach, determining members' goals and expectations. Second session; It aims to ensure that emotions are noticed, to clarify the goals with the miracle question technique, and to focus on the solution by getting away from the problems. In the third session; Exception questions focus on recognizing exceptional situations, strengths, and skills. In the fourth session; It is aimed to discuss the existing coping methods of the group members, to recognize the useful coping methods and strengths and to increase their use. In the fifth session; focuses on designing a positive future and steps towards achieving a positive future. In the sixth session, the sessions are summarized by the group leader and members.
62710127|NCT02825108|EXPERIMENTAL|experimental group|The patients who receive 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
62147490|NCT05485493|SHAM_COMPARATOR|control group|A one-session nutrition education will be given to the control group. Students will be informed about the emotional eating behavior and they will be informed about the physical exercise and nutrition regulation process. Measurements will be repeated at the end of the session and 2 weeks later.
62354226|NCT00418210|EXPERIMENTAL|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
61973436|NCT02281461|EXPERIMENTAL|Early ifants|Intervention Male circumcision using a non-surgical device
61973437|NCT02281461|EXPERIMENTAL|Cildren|Intervention Male circumcision using a non-surgical device
61973438|NCT01708733|PLACEBO_COMPARATOR|KSY diluted|KSY diluted, 100mg decoction by mouth per day for 6 weeks
62147491|NCT06246890||Screening + Autism ALERT|Families with children under 54 months, without a medical ASD diagnosis, who are referred by an autism clinic or primary care provider to Autism ALERT
62147492|NCT02166632|EXPERIMENTAL|Intracapsular Injection|Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed.
62354227|NCT00074802|EXPERIMENTAL|Paroxetine Continuation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine for 16 additional weeks.
61973439|NCT01708733|EXPERIMENTAL|KSY|KSY, 100mg decoction by mouth per day for 6 weeks
61973440|NCT02024633|EXPERIMENTAL|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
61973441|NCT01948050|EXPERIMENTAL|real tDCS stimulation|non-invasive transcranial direct current stimulation (tDCS) at 2 milliamiampers (2mA)for 20 minutes at each session, on five consecutive days.
61973442|NCT01948050|SHAM_COMPARATOR|Sham tDCS|sham non-invasive transcranial direct current stimulation (tDCS) consisting of 30 seconds of tDCS stimulation at 2mp and 19 minutes and 30 seconds of tdcs at 0mp stimulation,on five consecutive days.
61973443|NCT02921854|EXPERIMENTAL|All included patients|3 times Blood withdrawal for each patient (25ml each)
61973444|NCT05496387|EXPERIMENTAL|Study Group One|Sciatic nerve neuromobilization techniques (tension) was applied to the dominant side lower extremities of all participants in the study.
61973445|NCT05496387|EXPERIMENTAL|Study Group Two|Sciatic nerve neuromobilization techniques (sliding) was applied to the dominant side lower extremities of all participants in the study.
61973446|NCT05496387|SHAM_COMPARATOR|Control Group|No application was applied to the sham group
61973447|NCT05948254|OTHER|Triple Function Scan Body|Full arch implants were placed, a triple function scan Body and thus simplifying the workflow for full arch cases and reducing the number of visits to only 3 visits. Scan bodies were utilized for implant position scanning, facial scan alignment and as stoppers for jaw relation capturing as scan bodies were used as stoppers for jaw relation registration.
61973448|NCT01220323|ACTIVE_COMPARATOR|direct current stimulation|The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm.
61973449|NCT01220323|SHAM_COMPARATOR|sham stimulation|
62147493|NCT02166632|ACTIVE_COMPARATOR|Periarticular Injection|Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed.
62147494|NCT03822806|EXPERIMENTAL|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise (using the videogame JustDance) for the first 30 minutes of those 2 hours using the video game (continuing to wear the patch for 90 minutes after exercise).
62147495|NCT03360617|EXPERIMENTAL|Syringe Arm|IV antibiotics will be delivered by syringe IV push over 2-3 minutes
62147496|NCT03360617|SHAM_COMPARATOR|Piggyback Arm|IV antibiotics will be delivered by IV piggyback over 30 minutes
62147497|NCT05636397|EXPERIMENTAL|BPD±PH|"Arm 1: BPD±PH~Total of 12-24 infants; 6-12 at each dose level of oral dosage form of L-Citrulline. (300 or 500 mg/kg/day divided q6 hours).~Dose Level 1 = 300 mg/kg/day Dose Level 2 = 500 mg/kg/day"
62147498|NCT05636397|EXPERIMENTAL|Surgical NEC|"Arm 2: sNEC~A total of 18-36 infants with Stage III NEC; 6-12 at each dose level of oral dosage form of L-Citrulline. (75, 150 or 225 mg/kg/day divided q6 hours)~Dose Level 1 = 75 mg/kg/day Dose Level 2 = 150 mg/kg/day Dose Level 3 = 225 mg/kg/day"
62147499|NCT02123953|EXPERIMENTAL|TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once, daily, Days 1 to 7.
62147500|NCT02123953|EXPERIMENTAL|TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once, daily, Days 1 to 7.
62147501|NCT02123953|EXPERIMENTAL|TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once, daily, Days 1 to 7.
62147502|NCT02123953|EXPERIMENTAL|TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once, daily, Days 1 to 7.
62515099|NCT03438539|SHAM_COMPARATOR|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
62515100|NCT03438539|EXPERIMENTAL|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
62710128|NCT02825108|PLACEBO_COMPARATOR|placebo group|The patients who receive only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
62710129|NCT02825108|OTHER|control group|The patients for whom the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups
62147503|NCT02123953|EXPERIMENTAL|TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once, daily, Days 1 to 7.
62147504|NCT02123953|PLACEBO_COMPARATOR|Placebo|TAK-438 placebo-matching tablets, orally, once, daily, Days 1 to 7.
62710130|NCT05023161||Patient having a fetus with intra-uterine growth restriction diagnosis below the 3rd percentile|
62147505|NCT06226441|ACTIVE_COMPARATOR|CRRT group|Patients receiving aminoglycosides and submitted to CRRT
62147506|NCT06226441|NO_INTERVENTION|no-CRRT group|Patients receiving aminoglycosides and no CRRT
62147507|NCT02647333|EXPERIMENTAL|Omega-3 fatty acid|Omega-3 fatty acids for 8 weeks, dosage are 3 and 4 g/day for women and men, respectively.
62147508|NCT02647333|EXPERIMENTAL|Omega-6 fatty acid|Omega-6 fatty acids for 8 weeks, dosage are 20 and 27 g/day for women and men, respectively.
62147509|NCT03021616|EXPERIMENTAL|Energy drink|Two 16 oz bottles of energy drink will be consumed at baseline.
62147510|NCT03021616|ACTIVE_COMPARATOR|Moxifloxacin control|32oz of active control drink will contain 400mg moxifloxacin with inactive flavoring ingredients.
62147511|NCT03021616|PLACEBO_COMPARATOR|placebo control|32oz placebo control drink
62147512|NCT00911404|EXPERIMENTAL|Low CHO|Diet with 40% total calories from carbohydrates.
62147513|NCT00911404|ACTIVE_COMPARATOR|High CHO|Diet with 55% total calories from carbohydrates.
62147514|NCT02412904|OTHER|drug to ovulation induction: rFSH|Patients submitted to IVF that will use rFSH (Puregon®, Organon Ltd., Ireland) for ovarian stimulation
62147515|NCT02412904|OTHER|drug to ovulation induction :HMG|Patients submitted to IVF that will use hMG (Menopur®, Ferring Pharmaceuticals, Denmark) for ovarian stimulation
62515101|NCT03438539|EXPERIMENTAL|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
62515102|NCT03438539|NO_INTERVENTION|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
62515103|NCT03438539|EXPERIMENTAL|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
62515104|NCT03438539|EXPERIMENTAL|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
62515105|NCT02540447|EXPERIMENTAL|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
62515106|NCT02540447|NO_INTERVENTION|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
62515107|NCT04551820||Regular Hours|These subjects have undergone a cholecystectomy during regular hours at the Institution.
62515108|NCT04551820||After Hours|These subjects have undergone a cholecystectomy during after hours at the Institution.
62515109|NCT04216420|EXPERIMENTAL|MERM-observed self-administered therapy (SAT)|A participant in the intervention arm (n = 57) will receive a 15-day TB medication supply in the evriMED500 MERM device to self-administer. The participant returns every 15 days, where the healthcare provider counts any remaining tablets in the pillbox device, connects the MERM module with a computer and downloads the pill-taking data, reviews the event reports together with the participant and captures the data, underwent IsoScreen urine isoniazid test and refills the participant with a 15-day medication supply in the MERM device.
62354228|NCT00074802|EXPERIMENTAL|Paroxetine with CBT Augmentation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine plus cognitive behavioral therapy (CBT) for 16 additional weeks.
62354229|NCT06230835|EXPERIMENTAL|Intervention Group|The intervention of the study will be the Community Health Workers implementation strategy
62710131|NCT01657981|EXPERIMENTAL|Treatment arm 1|
62710132|NCT03268564|EXPERIMENTAL|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders"
62710133|NCT03493139|EXPERIMENTAL|PAAC-R|Physical Activity Across the Curriculum-Remote (PAAC-R) will include protocol specific activity breaks delivered remotely via a television in the classroom.
62710134|NCT03493139|EXPERIMENTAL|PAAC-T|Physical Activity Across the Curriculum-Teacher (PAAC-T) will include protocol specific activity breaks delivered by the classroom teacher.
62710135|NCT04435158|EXPERIMENTAL|Cohort 1：SHR-1222|Subcutaneous injection of SHR-1222 dosage 1 monthly × 6 months
62710136|NCT04435158|EXPERIMENTAL|Cohort 2：SHR-1222|Subcutaneous injection of SHR-1222 dosage 2 monthly × 6 months
62354230|NCT06230835|NO_INTERVENTION|Control Arm|Routine hypertension care
62354231|NCT04318379|EXPERIMENTAL|Low dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
62710137|NCT04435158|EXPERIMENTAL|Cohort 3：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 monthly × 6 months
62354232|NCT04318379|EXPERIMENTAL|High dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of high dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
62354233|NCT06089070|NO_INTERVENTION|Control|Participants will not have access to view the data from the CGM sensor during the screening period, nor during the main part of the study.
62354234|NCT06089070|EXPERIMENTAL|Intervention|Participants will wear the CGM sensor and have access to the data during the main part of the study.
62354235|NCT00877006|EXPERIMENTAL|Bendamustine and Rituximab (BR)|Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m\^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m\^2 IV on Day 1
62147516|NCT01939509|EXPERIMENTAL|Atenolol-Bisoprolol|
62147517|NCT05519306|EXPERIMENTAL|Mental Practice Patients|Patients with upper extremity hemiparesis following a stroke.
62515110|NCT04216420|NO_INTERVENTION|Standard directly observed therapy (DOT)|"The provider handles a participant in the control arm (n = 57) according to the standard DOT, where the participant visits the healthcare facility each day throughout the intensive phase to swallow the daily dose with direct observation by the healthcare provider. The participant will undergo the urine isoniazid test every 15 days.~Both arms will be treated based on the WHO-recommended two-month fixed-dose-combination of first-line anti-TB drug (2RHZE) delivered as a single daily dose and followed throughout the intensive phase that lasts two months. In the end, participants will undergo a microbiological test to assess sputum smear conversion and trained study staff will complete several data tools, including a treatment outcome monitoring tool, adherence self-report, HRQoL, cost, treatment satisfaction, and MERM usability tools."
62515111|NCT00506506|EXPERIMENTAL|1|N-acetylcysteine 1200 mg twice daily x 48 hours
62515112|NCT00506506|PLACEBO_COMPARATOR|2|
62515113|NCT02979093|OTHER|Addicted|The addiction group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
62515114|NCT02979093|OTHER|Control|The control group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
62515115|NCT03907514|EXPERIMENTAL|Intervention Group (IG)|"The adolescents in this group will use the FALE application through a smartphone in the waiting room before the dental appointment. When starting to answer the application, the adolescent will report his/her level of dental anxiety through the question, How do you feel about coming to see your dentist today?, and record his/her answer on a seven-point face scale. Then the participant will continue to answer the 12 other questions, and finally registers his/her anxiety level once more through the same question."
62515116|NCT03907514|NO_INTERVENTION|Control Group (CG)|"Similarly to IG, the adolescents in this group will use the FALE application through a smartphone, but only to record their level of anxiety by answering the question How do you feel about coming to see your dentist today? using a seven-point face scale. Instead of continuing to answer the other questions, the application will guide him to wait for the one-minute interval (expected time to answer the questionnaire) and, once more, ask the same question regarding his/her feeling about the experience with the dentist."
62515117|NCT02529306||two parallel group|group with inflammatory markers high levels and control group with inflammatory normal levels markers.
62515118|NCT02190448|EXPERIMENTAL|study herbal tea|Supplementation of 3-5, 8 oz cups of study tea daily for 4 weeks.
62515119|NCT02190448|PLACEBO_COMPARATOR|herbal placebo tea|Supplementation of 3-5, 8oz cups of tea daily for 4 weeks.
62515120|NCT03490474|EXPERIMENTAL|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
62515121|NCT03490474|ACTIVE_COMPARATOR|Pain Free Massage|Participants will receive light touch applied to one myofascial trigger point.
62515122|NCT03490474|PLACEBO_COMPARATOR|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
62515123|NCT04429529|EXPERIMENTAL|TY027 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
62515124|NCT04429529|PLACEBO_COMPARATOR|Placebo 0.5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62515125|NCT04429529|EXPERIMENTAL|TY027 5mg/kg|Subject will be administered with 5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
62515126|NCT04429529|PLACEBO_COMPARATOR|Placebo 5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62515127|NCT04429529|EXPERIMENTAL|TY027 10 mg/kg|Subject will be administered with 10 mg/kg of TY027 via IV infusion over a period of 30 minutes.
62515128|NCT04429529|PLACEBO_COMPARATOR|Placebo 10 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62515129|NCT04429529|EXPERIMENTAL|TY027 20 mg/kg|Subject will be administered with 20 mg/kg of TY027 via IV infusion over a period of 30 minutes.
62515130|NCT04429529|PLACEBO_COMPARATOR|Placebo 20 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62515131|NCT04429529|EXPERIMENTAL|TY027 30 mg/kg|Subject will be administered with 30 mg/kg of TY027 via IV infusion over a period of 30 minutes.
62515132|NCT04429529|PLACEBO_COMPARATOR|Placebo 30 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
62515133|NCT05540821||conventional transvaginal ultrasound group|
62515134|NCT05540821||double contrast-enhanced ultrasound group|perfromed hysterosalpingo-contrast sonography and sonoPODography examination
62710138|NCT04435158|EXPERIMENTAL|Cohort 4：SHR-1222|Subcutaneous injection of SHR-1222 dosage 4 every 2 months × 6 months
62147518|NCT05519306|NO_INTERVENTION|Occupational Therapists|Licensed, full-time, or part-time occupational therapists currently working in the inpatient rehabilitation unit of Adventist Healthcare Rehabilitation
62515135|NCT01587794||retinal detachment group|Patients who were diagnosed with unilateral rhegmatogenous retinal detachment involving only the superior or inferior half of the retina and who underwent successful scleral buckling procedure or vitrectomy by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study sample.
62515136|NCT04528199|EXPERIMENTAL|[18F]FLOR (FC303)|\[18F\]FLOR (FC303) PET/CT imaging.
62515137|NCT02497794|ACTIVE_COMPARATOR|postoperative chew gum|The patients in the study group will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours.
62515138|NCT02497794|PLACEBO_COMPARATOR|without postoperative chew gum|The control group will be followed without chew gum.
62515139|NCT03329534|EXPERIMENTAL|Subjects with GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health care professional will be administered for one month's time.
62515140|NCT03329534|ACTIVE_COMPARATOR|Subjects without GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health-care professional will be administered for one month's time.
62710139|NCT04435158|EXPERIMENTAL|Cohort 5：SHR-1222|Subcutaneous injection of SHR-1222 dosage 5 every 2 months × 6 months
62147519|NCT01386372|EXPERIMENTAL|Tolvaptan|
62147520|NCT01386372|ACTIVE_COMPARATOR|standard therapy|
62147521|NCT02060084|EXPERIMENTAL|a control group|a control group : the same dose of luke warm water
62515141|NCT01401387|ACTIVE_COMPARATOR|Standard treatment|Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
62515142|NCT01401387|ACTIVE_COMPARATOR|Preventive treatment|Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
62515143|NCT03418857|EXPERIMENTAL|Experimental|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains 3.16 × 109 colony forming units (CFU) bifidobacterium animalis subsp. lactis BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
62515144|NCT03418857|PLACEBO_COMPARATOR|Control|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains no BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
62515145|NCT02116699|EXPERIMENTAL|oropharyngeal mother's milk|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
62515146|NCT02116699|PLACEBO_COMPARATOR|oropharyngeal sterile water|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
62515147|NCT00722631|EXPERIMENTAL|1|up to 30 mg pioglitazone, tablet, orally, once daily
62515148|NCT00722631|ACTIVE_COMPARATOR|2|up to 4 mg/day glimepiride, tablet, orally, once daily
62515149|NCT02458092|EXPERIMENTAL|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant given intramuscularly in the deltoid muscle of the non-dominant arm.
62515150|NCT02458092|EXPERIMENTAL|Rabies Vaccine Rabipur|Rabies Vaccine Rabipur given intramuscularly in the deltoid muscle of the non-dominant arm.
61973450|NCT06504225||Active Comparator: Control|"Drug: Anti R-IL2 + Cyclosporine~* Anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* Cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~* Corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
61973451|NCT06504225||Experimental: CNI-free|"Drug: Thymoglobulin + Everolimus~* Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* Everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~* Corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
61973452|NCT06504225||Experimental: Switch|"Drug: Anti R-IL2 + Cyclosporine then Everolimus~* Anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~* Cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~* Corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
61973453|NCT02482623|EXPERIMENTAL|Intervention|Dyads in this arm will receive care provided by an interprofessional team trained through the DSM-H to provide patient/caregiver-centered dementia care through home healthcare.
62147522|NCT02060084|EXPERIMENTAL|treatment group|treatment group: viable Bifidobacterium 0.5 bid po
62147523|NCT01115036|EXPERIMENTAL|panobinostat|
62147524|NCT04614129|EXPERIMENTAL|Low-Dose CT|Low Dose CT Scan of the Chest
62515151|NCT02501551|EXPERIMENTAL|Regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
62515152|NCT06132633|EXPERIMENTAL|Neospot Vitals Measurement|Neospot is a 5-in-1 wearable vitals measurement device designed to measure temperature, blood pressure, pulse rate, respiratory rate and blood oxygen saturation. For the standard of care vitals measurement, conventional vital signs will be measured using mercury blood pressure cuffs and infrared or mercury thermometers for blood pressure and temperature respectively, pulse oximeter for oxygen saturation and a 1-minute count of heart rate and breathing rate.
62515153|NCT02985879|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride Injection/Solution for Infusion; intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks
62147525|NCT06151106|EXPERIMENTAL|Chidamide combined with Duvillisib|
62515154|NCT02985879|EXPERIMENTAL|ABBV-8E12 2000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
62515155|NCT02985879|EXPERIMENTAL|ABBV-8E12 4000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
62515156|NCT05424614||intracerebral hemorrhage group|Patients with the intracerebral hemorrhage who presented to the hospital within 24 hours of symptom onset
62515157|NCT03974165|EXPERIMENTAL|Cereal-legume product 1|Treatment with cereal-legume product-1
62515158|NCT03974165|EXPERIMENTAL|Cereal-legume product 2|Treatment with cereal-legume product-2
62147526|NCT04931303||Study Group|Enrolled patients receive a medical device which monitors gait quality and collects information about the patients health status. Possible changes of intervention (drug or physical therapy) within the observational phase (8 weeks) are initiated and prescribed by physicians as a result of routine care process or patient contact based on their (deteriorated) health status. With the chosen endpoints, changes of patients empowerment, gait quality and system usability by using a monitoring device are monitored.
62147527|NCT02333318|EXPERIMENTAL|Single Dose_VVZ-149 injection|"1. Cohort A (50-64 years old), Cohort B (65-84 years old)~2. For 2.5, 5mg/kg~3. 4-hr intravenous infusion of VVZ-149 injection~4. 6 subjects will be administered within each age group. Total 24 subjects will participate."
62147528|NCT02333318|EXPERIMENTAL|Loading/Maintenance_VVZ-149 injection|"1. Cohort A (50-64 years old) This trial is conducted only in the Cohort A one week after the single IV infusion.~2. For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~3. intravenous infusion~4. 4 subjects will be randomly assigned within each dose group, respectively. Total 8 subjects will participate."
62515159|NCT03974165|EXPERIMENTAL|Cereal product|Treatment with cereal product
62147529|NCT02333318|PLACEBO_COMPARATOR|Loading/Maintenance_Placebo|"1. Cohort A (50-64 years old)~2. For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~3. intravenous infusion~4. 2 subjects will be randomly assigned within each dose group, respectively. Total 4 subjects will participate."
62147530|NCT04305340|EXPERIMENTAL|SKIIN Textile Device in children with healthy hearts|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down.
62147531|NCT04305340|EXPERIMENTAL|SKIIN Textile Device in children with heart failure|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down
62147532|NCT04780152|EXPERIMENTAL|tDCS arm|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
62147533|NCT04780152|PLACEBO_COMPARATOR|Control arm|Participant receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
62147534|NCT03784105|EXPERIMENTAL|Codeine|
62147535|NCT03784105|PLACEBO_COMPARATOR|Siripus simplex|
62147536|NCT00778856|EXPERIMENTAL|Hand Transplant|
62147537|NCT03691441|EXPERIMENTAL|Resection/adjuvant radio(-chemo)therapy|"* Transoral surgical resection within 4 weeks after randomization~* Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization~* 6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery"
62147538|NCT03691441|ACTIVE_COMPARATOR|Adjuvant radio(-chemo)therapy/salvage neck dissection|"* 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization~* 70-72 Gy, SIB possible~* Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33~* +/- Salvage neck dissection 12±2 weeks after treatment"
62147539|NCT02005172|OTHER|Alivecor device and event monitor|Both the Alivecor device (experimental) and the standard of care (event monitor) will be provided to all patients for the duration of the study
62147540|NCT01354509||Current protocol group|Patients treated with current standards based on physician discretion.
62147541|NCT01354509||Normothermia group|Normothermia protocol, using Hydrogel cooling Pads(Arctic Sun) applied for 96 hrs starting upon admission to the ICU
62147542|NCT05778409|EXPERIMENTAL|Cordyceps Cicadae extract group|500 mg/ day for 1 month
62147543|NCT06407648|EXPERIMENTAL|Personalized Assessments|12 sessions of exposure with response prevention (ERP) that is guided by personalized assessments.
62147544|NCT06407648|ACTIVE_COMPARATOR|Standard of Care|12 sessions of exposure with response prevention (ERP) that is guided using standard practice.
62147545|NCT01271894|EXPERIMENTAL|Reduced dose Efavirenz arm|Participants randomized in main study to receive EFV (400 mg once daily; 2 x 200 mg + 1 x placebo once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
62515160|NCT03974165|ACTIVE_COMPARATOR|Reference food|Treatment with reference food
62710140|NCT04435158|EXPERIMENTAL|Cohort 6：placebo|Subcutaneous injection of placebo × 6 months
62710141|NCT05699200|OTHER|Spontaneous coronary artery dissection (SCAD) group|Subject with a history of SCAD will undergo a series of diagnostic studies to assess neurovascular function.
62710142|NCT05699200|OTHER|Healthy Control Group|Healthy subjects will undergo a series of diagnostic studies to assess neurovascular function.
62710143|NCT06006104|EXPERIMENTAL|HRS-4357 injection|
62147546|NCT01271894|ACTIVE_COMPARATOR|Normal Efavirenz dose arm|Patients randomized in the main study to receive EFV (600 mg once daily; 3 x 200 mg once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
62147547|NCT01319058|ACTIVE_COMPARATOR|Electrocautery tonsillectomy|Children undergoing tonsillectomy and adenoidectomy for obstructive sleep apnea
62147548|NCT01319058|ACTIVE_COMPARATOR|Debrider tonsillotomy|Children undergoing debrider tonsillotomy + adenoidectomy for obstructive sleep apnea.
62147549|NCT01319058|ACTIVE_COMPARATOR|Laser tonsillotomy|Children undergoing laser tonsillotomy + adenoidectomy for obstructive sleep apnea.
62147550|NCT01966705|EXPERIMENTAL|Therapist-guided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, supported self-help
62147551|NCT01966705|EXPERIMENTAL|Unguided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, self-help only
62147552|NCT01966705|EXPERIMENTAL|Cognitive Behavior Therapy-based bibliotherapy|Cognitive Behavior Therapy delivered in book form: 12 weeks, self-help only
62147553|NCT01966705|NO_INTERVENTION|Waiting-list condition|No intervention: 12 weeks
62147554|NCT03553225|PLACEBO_COMPARATOR|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsules regimen (1g)
62147555|NCT03553225|ACTIVE_COMPARATOR|Concord Grape Extract 1|1 g Concord Grape Extract in 2 capsules
62147556|NCT03553225|ACTIVE_COMPARATOR|Concord Grape Extract 2|500 mg Concord Grape Extract in 2 capsules
62147557|NCT00250770||1|"Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.~Women undergoing hysterectomy for benign conditions."
62147558|NCT01496794||Endophthalmitis cultures|
62147559|NCT04154085|EXPERIMENTAL|Study Group|This study only has one arm; all patients receive the treatment intervention.
62147560|NCT05870163||RefluxStop patients|
62147561|NCT05870163||Nissen fundoplication patients|
62147562|NCT04568213|EXPERIMENTAL|Hypochlorous Gel Application|
62515161|NCT06483256|OTHER|radiographic control|Standard AP and LL X-Rays of the affected elbow
62710144|NCT06546527|EXPERIMENTAL|[177Lu]Lu-PSMA-137；[177Lu]Lu-PSMA-617|\[177Lu\]Lu-PSMA-137 500 MBq；\[177Lu\]Lu-PSMA-617 500 MBq；\[177Lu\]Lu-PSMA-137 50% optimal dose；\[177Lu\]Lu-PSMA-137 100% optimal dose；
62710145|NCT03615885|PLACEBO_COMPARATOR|Placebo Drink|Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.
62710146|NCT03615885|EXPERIMENTAL|Montmorency Tart Cherry Capsules|10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.
62710147|NCT03615885|EXPERIMENTAL|Montmorency Tart Cherry Juice|Single-bolus of Montmorency tart cherry juice (130 mL)
62354236|NCT00877006|ACTIVE_COMPARATOR|R-CHOP/R-CVP|"Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.~R-CHOP: rituximab 375 mg/m\^2 IV on Day 1; vincristine 1.4 mg/m\^2 (up to 2 mg/m\^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m\^2 IV Day 1; cyclophosphamide 750 mg/m\^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5~R-CVP: rituximab 375 mg/m\^2 IV on Day 1; cyclophosphamide 750 mg/m\^2 IV on Day 1 or cyclophosphamide 1000 mg/m\^2 IV on Day 1; vincristine 1.4 mg/m\^2 (up to 2 mg/m\^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5"
62710148|NCT02519842|EXPERIMENTAL|Fosaprepitant Regimen Cycle 1|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
61973454|NCT02482623|NO_INTERVENTION|Control|Dyads in this arm will receive usual care provided in the home healthcare setting.
61973455|NCT05151484|ACTIVE_COMPARATOR|Group 1 Low Turnover|Teriparatide (anabolic) For 1 Year
61973456|NCT05151484|ACTIVE_COMPARATOR|Group 2 Low Turnover|"Standard of Care - Control:~Treated with Alendronate (antiresorber) For 1 Year"
61973457|NCT05151484|ACTIVE_COMPARATOR|Group 3 Normal-High Turnover|Standard of Care Treatment with Alendronate (antiresorber) For 1 Year
61973458|NCT02485574|EXPERIMENTAL|Left cage- auto bone|At the operated segment, left cage was filled with auto bone only. We evaluated bone bridging between inside and outside the cage in transforaminal lumbar interbody arthrodesis.
61973459|NCT02485574|EXPERIMENTAL|Right cage- auto local bone mixed with β-calcium phosphate + hydroxyapatite|At the operated segment, right cage was filled with auto local bone mixed with β-calcium phosphate + hydroxyapatite. We evaluated bone bridging between inside and outside the cage in transforaminal lumbar interbody arthrodesis.
61973460|NCT06190639|EXPERIMENTAL|Experimental group|
61973461|NCT04776499|EXPERIMENTAL|Healthy volunteers receiving propylthiouracil, riociguat, and perphenazine|Eight healthy volunteers will be included. Up to 15 healthy volunteers will be screened to reach the goal of 8 exposed volunteers. Sex is not expected to have an impact on the short-term evaluation of the potential drug-drug interactions. Therefore female and male participants will be included in an undefined proportion.
61973462|NCT05652946|EXPERIMENTAL|Inpatient Rehabilitation with ART|Inpatient rehabilitation with advanced rehabilitation technology
61973463|NCT05652946|ACTIVE_COMPARATOR|Inpatient Rehabilitation without ART|Inpatient rehabilitation without advanced rehabilitation technology
61973464|NCT04171778|EXPERIMENTAL|Intervention|Subjects in this arm will immediately begin a whole-food, plant-based nutrition program consisting of weekly educational group meetings and prepared meals delivered to the subjects' homes for the first 12 weeks followed by monthly educational group meetings for an additional 6 months.
61973465|NCT04171778|OTHER|Wait List Control|Subjects in this arm will continue their usual care as directed by their nephrologist for 12 weeks before starting the same whole-food, plant-based nutrition program as the intervention arm subjects.
61973466|NCT04012385|NO_INTERVENTION|Control|Subjects assigned to control group receives only a booklet including the recommendations for a correct diet by the Italian National Institute for Research on Food and Nutrition (INRAN), presently called (CRA-NUT) .
61973467|NCT04012385|EXPERIMENTAL|Intervention|"Subjects assigned to the intervention group will follow a nutritional pathway based on a Mediterranean diet pattern for 4 months and receive suggestions on the regular practice of physical activity, under the guide of some nutritionists, who will propose individualized diets for each subject.~All subjects of both groups will undergo urologic examination, measurement of weight, height and abdominal circumference, an interview on demographic data and lifestyle variables, and will provide blood and semen samples in fasting conditions, at the enrollment (baseline), at the end of the intervention phase (after 4 months) and at the end of follow-up (after 8 months)."
61973468|NCT04067895||human bone graft screw|human bone graft screws will be used during the epiphysiodesis
61973469|NCT04570150|ACTIVE_COMPARATOR|Sugammadex|
61973470|NCT04570150|PLACEBO_COMPARATOR|Neostigmine|
61973471|NCT04411875|ACTIVE_COMPARATOR|Amlodipine|amlodipine reference formulation at a single dose of 10 mg
61973472|NCT04411875|EXPERIMENTAL|Levamlodipine|levamlodipine test formulation at a single dose of 5 mg
61973473|NCT04184869|OTHER|Wild Type UGT1A1|"Cohort A: Wild Type, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
61973474|NCT04184869|OTHER|Heterozygous UGT1A1*28|"Cohort B: Heterozygous, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
61973475|NCT04184869|OTHER|Homozygous UGT1A1*28|"Cohort C: Homozygous, UGT1A1, Belinostat IV Dose: 750 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
62354237|NCT01353755|EXPERIMENTAL|recombinant Phleum (rPhleum) allergen cocktail|The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate. The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities. The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
62354238|NCT01353755|PLACEBO_COMPARATOR|Placebo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
62354239|NCT02514772|EXPERIMENTAL|GP2013 - proposed biosimilar rituximab|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration, two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
62715083|NCT03787329||Bone marrow concentration group|The patients receive core decompression surgery with bone marrow concentration.
62715084|NCT03787329||Historical control group|The previous age-, gender-, and stage-matched patients who received core decompression surgery only.
62515162|NCT03264820|EXPERIMENTAL|Patients with scleroderma and potential arterial disease|"The patients (33) will undergo a medical examination in order to analyse their medical history, parameters and check inclusion and non-inclusion criterions.~Then will be performed :~Visit 1 :~* Biology report \* (\* Biological evaluation carried out in all healthy subjects and in subjects whose biological check-up dates more than 2 years,+ urinary pregnancy test (if applicable))~* Laser measurements at the forearm (with laser speckle)~* Laser measurements at the level of each finger~* Pain evaluation (EVA)~* Measurement of blood pressure and heart rate~* Environmental measures and skin temperature~Visit 2 :~* Laser measurements at the level of each finger~* Pain evaluation (EVA)~* Measurement of blood pressure and heart rate~* Environmental measures and skin temperature"
61973476|NCT04184869|OTHER|Belinostat & Atazanavir|"Arm: Homozygous UGT1A1\*28 genotype subjects with Belinostat IV \& Atazanavir~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir)~Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
62515163|NCT03264820|EXPERIMENTAL|Healthy volunteers|"The healthy volunteers (11) will undergo :~Visit 1 :~* Biology report (+ urinary pregnancy test (if applicable))~* Laser measurements at the forearm (with laser speckle)~* Laser measurements at the level of each finger~* Pain evaluation (EVA)~* Measurement of blood pressure and heart rate~* Environmental measures and skin temperature~Visit 2 :~* Laser measurements at the level of each finger~* Pain evaluation (EVA)~* Measurement of blood pressure and heart rate~* Environmental measures and skin temperature"
62515164|NCT03936179|EXPERIMENTAL|high dose radiochemotherapy|A total dose of 86 Gy to residual metabolic disease with concurrent chemotherapy
62515165|NCT05385848|EXPERIMENTAL|PRP Injection Arm|"All patients recruited will come down to KKIVF Centre on Day 2-3 of the menstrual cycle to do blood tests (Anti-Mullerian Hormone (AMH)) and an ultrasound scan (Antral Follicular Count (AFC)). In the same menstrual cycle/month, autologous PRP injection will be done on Day 5-15 of the cycle.~Patients will return to KKIVF Centre 1-3 months after the PRP injection on Day 2-3 of the menstrual cycle to repeat blood tests (AMH) and Ultrasound scan (AFC).~IVF stimulation cycle as per KKIVF protocol will be started within 6 months from PRP injection. Patients will be followed up as per routine, with no more additional visits pertaining specifically to the study."
62515166|NCT03594357||Multiple sclerosis|MS patients (EDSS: 0-5,5)
62515167|NCT03594357||Control|Healthy individuals without chronic disease
62515168|NCT03232255|EXPERIMENTAL|Treatment Group|
62515169|NCT05628558||GIDEMHA-1|"First descriptive cohort of the study with patients with mild/moderate hemophilia A retrospectively enrolled for data soon recorded in medical files during the period 2010-2020 in 4 French hemophilia treatment centers (Angers, Caen, Nantes and Rennes).~All these patients received desmopressin with FVIII levels measurements pre/post desmopressin infusion.~Actual number of patients: 429"
62515170|NCT05628558||GIDEMHA-2|"Replication cohort including patients with mild/moderate hemophilia A retrospectively enrolled for data soon recorded in medical files:~* during the period 2020-2023 by the initial 4 hemophilia treatment centers (Angers, Caen, Nantes and Rennes)~* during the period 2010-2023 by 2 other hemophilia treatment centers (Brest and Tours).~All these patients received desmopressin with FVIII levels measurements pre/post desmopressin infusion.~Anticipated number of patients : 371"
62515171|NCT02165306|EXPERIMENTAL|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
62515172|NCT02165306|ACTIVE_COMPARATOR|Active Comparator|Usual Care The usual care group received routine counseling performed by the neurologist/neurosurgeon and nurses.
62515173|NCT01233843|OTHER|Drug and radiation|Radiotherapy : 70 grays , fractionization : 2Gy/day, 5 days / week, for 7 weeks . Concurrent administration of Carboplatin: 70 mg/m2/day (day 1 until day 4)and 5FU 600 mg/m2/day (day 1 until day 4). Weeks 1; 4; 7.
62515174|NCT01233843|EXPERIMENTAL|drug and radiation|"Induction chemotherapy by Docetaxel 100mg/m2, day 1; cisplatin 100mg/m2, day 1; 5-Fluorouracil 1000mg/m2 (from day 1 to day 5), for a total of three cycles .Those cycles are administrated at day 1; day 22, day43.~This induction chemotherapy is followed ( for responders or stable disease patients)by radiotherapy (70 grays for 7 weeks) and concurrent Erbitux( weekly administration)."
62515175|NCT01880788||CNV secondary to CSC|
62515176|NCT01880788||CSC without CNV|
62515177|NCT01880788||CNV secondary to advanced AMD|
62515178|NCT00304707|EXPERIMENTAL|2|participants in this arm receive bupropion
62515179|NCT00304707|PLACEBO_COMPARATOR|1|placebo
62515180|NCT02623452|EXPERIMENTAL|Part A:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin once in each of 3 periods
62515181|NCT02623452|ACTIVE_COMPARATOR|Part A:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin once in each of 3 periods
62710149|NCT02519842|PLACEBO_COMPARATOR|Control Regimen Cycle 1|Participants received a single dose of matched placebo for fosaprepitant IV on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
62710150|NCT02519842|EXPERIMENTAL|Fosaprepitant Regimen Cycles 2-6|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) IV on Day 1 prior to chemotherapy plus a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 prior to chemotherapy and per product label or standard of care. Participants may also have received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
61973477|NCT01964703|PLACEBO_COMPARATOR|control|
62710151|NCT01459120|EXPERIMENTAL|Door-to-Door|Health care workers propose the integrated service package including VCT at the peoples' homes.
61973478|NCT01964703|ACTIVE_COMPARATOR|Rubus occidentalis extract 900mg|taking Rubus occidentalis extract 900mg/day for 12weeks
61973479|NCT01964703|ACTIVE_COMPARATOR|Rubus occidentalis extract 1800mg|taking Rubus occidentalis extract 1800mg/day for 12weeks
61973480|NCT04062175|ACTIVE_COMPARATOR|cephalosporin arm|72 women will receive single antibiotic chemotheraby first generation cephalosporin (cefazolin) 2 gm iv within 30 minutes before skin incision
62710152|NCT01459120|ACTIVE_COMPARATOR|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (pitso)."
61973481|NCT04062175|ACTIVE_COMPARATOR|cephalosporin +azithromycin arm|72 women will receive combined antibiotic chemotherapy azithromycin (Azrolid) 1 gm single oral dose 2 hours before cesarean delivery + cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
62515182|NCT02623452|EXPERIMENTAL|Part B:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin with each meal for 14 days
62515183|NCT02623452|ACTIVE_COMPARATOR|Part B:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin with each meal for 14 days
62515184|NCT05592249|EXPERIMENTAL|Motor - Cognitive|Motor - Cognitive group will receive motor and cognitive dual task intervention.
62515185|NCT05592249|EXPERIMENTAL|Motor - Motor|Motor - Motor group will receive motor and motor dual task intervention.
62710153|NCT01459120|NO_INTERVENTION|control|Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level. These villages get no particular intervention (VCT-campaign). However, routine services continue to be provided. These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
62710154|NCT04167943|EXPERIMENTAL|indirect pulp capping|TheraCAL PT will be applied to affected dentin covering the pup.
61973482|NCT00003204|EXPERIMENTAL|Arm I (cyclophosphamide, fludarabine)|Patients receive cyclophosphamide IV over 30-45 minutes on day 1 and fludarabine IV over 10-20 minutes on days 1-5. Treatment repeats every 28 days in the absence of disease progression for a minimum of 4 courses and a maximum of 6 courses.
61973483|NCT00003204|EXPERIMENTAL|Arm II (cyclophosphamide, vincristine, prednisone)|Patients receive cyclophosphamide IV over 30-45 minutes and vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of disease progression for a minimum of 6 courses and a maximum of 8 courses.
61973484|NCT00003204|EXPERIMENTAL|Arm III (rituximab)|Patients receive maintenance therapy with rituximab (IDEC-C2B8 monoclonal antibody) IV weekly for 4 weeks. Courses repeat every 6 months for 2 years. Maintenance therapy begins 4 weeks after the last chemotherapy.
61973485|NCT00003204|NO_INTERVENTION|Arm IV (no intervention)|Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.
61973486|NCT05894629|EXPERIMENTAL|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|"Intervention Group (IG):~12-week program consisting of:~* 6 PNE sessions (1 session of 90 minutes per week for 5 weeks).~* 19 sessions of TE (2-3 weekly sessions of 60 minutes, for 7 weeks)."
61973487|NCT05894629|ACTIVE_COMPARATOR|Usual treatment|Delivery of a printed document with exercises to be performed at home for patients with persistent pain endorsed by a Scientific Society, as has been done in the Spanish Health Care Public System's usual practice with patients with chronic pain.
61973488|NCT06508125|EXPERIMENTAL|cross-linked hyaluronic acid group|cross-linked hyaluronic acid injection, one-time, plus physical therapy
61973489|NCT06508125|ACTIVE_COMPARATOR|non-cross-linked hyaluronic acid group|non-cross-linked hyaluronic acid injection, one-time, plus physical therapy
61973490|NCT05781607||PE|Patient education combined with drug therapy group
61973491|NCT05781607||PT|Individualized comprehensive physical therapy group
61973492|NCT00840346|EXPERIMENTAL|1|The first patients enrolled in the trial will be successively distributed into three cohorts of patients for each dose level of panobinostat (20 mg, 30 mg, 40 mg) in combination with idarubicin and cytarabine, according to the classical 3+3 schedule
61973493|NCT00523003|EXPERIMENTAL|1,|2.2 g protein/kg LBM/day high protein diet
61973494|NCT00523003|PLACEBO_COMPARATOR|2, standard protein|1.1 g protein/kg LBM/day standard protein diet
61973495|NCT00783250|EXPERIMENTAL|Salbutamol+Tiotropium|Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms
62710155|NCT04167943|EXPERIMENTAL|Direct pulp Capping|TheraCAL PT will be applied to pinpoint pulp exposures surrounded by sound dentin.
61973496|NCT00783250|PLACEBO_COMPARATOR|placebo + Tiotropium|Placebo using MDI + administration of Tiotropium after 20 minutes
61973497|NCT04256070|EXPERIMENTAL|Education, tele-consultation and training booklet|"* Informed Consent Form will be taken in written from those who agree to participate in the research.~* In the first intervention, Information Form Based on Watson's Human Care Theory, Chronic Obstructive Pulmonary Disease Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected. Subsequently, education, counseling nursing care and education booklet based on Watson's Human Care Theory will be given.~Teleconsultation based on Watson's Human Care Theory will be given during the intervention at weeks 2, 4, 6, 8 and 10.~* 24-hour tele-consultancy will be given on subjects determined for the management of COPD in case of necessity at the request of the individual.~* In the last intervention in the 12th week, face to face with the individual, Consultancy based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form, Telephone Interview Evaluation Form will be applied."
62354240|NCT02514772|ACTIVE_COMPARATOR|Originator rituximab - Rituxan ® or MabThera ®|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
62515186|NCT01072786|EXPERIMENTAL|TetraVax-DV Vaccine-Admixture 1|Participants will receive the TetraVax-DV admixture 1 vaccine.
62515187|NCT01072786|EXPERIMENTAL|TetraVax-DV Vaccine-Admixture 2|Participants will receive the TetraVax-DV admixture 2 vaccine.
62515188|NCT01072786|EXPERIMENTAL|TetraVax-DV Vaccine-Admixture 3|Participants will receive the TetraVax-DV admixture 3 vaccine.
62515189|NCT01072786|EXPERIMENTAL|TetraVax-DV Vaccine-Admixture 4|Participants will receive the TetraVax-DV admixture 4 vaccine.
62515190|NCT01072786|PLACEBO_COMPARATOR|Placebo|Participants will receive the placebo.
62515191|NCT01072786|EXPERIMENTAL|TetraVax-DV Vaccine-Admixture 5|Participants will receive the TetraVax-DV admixture 5 vaccine.
62710156|NCT04167943|EXPERIMENTAL|Partial Pulpotomy|Pulp exposure will be enlarged to a depth of 1-3 mm by a sterile round diamond bur, and then TheraCAL PT will applied after hemostasis.
62515192|NCT04701034|ACTIVE_COMPARATOR|Active treatment group|"Intravenous immunoglobulin(IVIg) and prednisolone. IVIG is administered at the time of embryo/blastocyst transfer (ET) (5 days before to 2 days after ET) and if the participant becomes pregnant, the infusion (same dose) is repeated in gestational week 5, 6, and 7.~Participants with pre-pregnancy weight ≤70 kg will receive 25 g immunoglobulin (250 ml), participants with weight 70-85 kg will receive 30 g immunoglobulin (300 ml), and participants with weight ≥85 kg will receive 35 g immunoglobulin (350 ml) at each infusion, which will approximate 0.4 g IVIg per kg body weight.~Prednisolone, tablets, 5mg. 1 tablet daily started within first 3 days of menstrual cycle and until ET. On the day of ET, the participant will double her dose to 2 tablets daily until a negative pregnancy test, the time of biochemical loss/miscarriage, or pregnancy week 8+0, whichever comes first. Gradual discontinuation four days with one tablet before completing cessation."
62515193|NCT04701034|PLACEBO_COMPARATOR|Passive treatment group|"Human albumin infusion and placebo tablets.~Human albumin, 5%, (CLS Behring). Participants with pre-pregnancy weight ≤70 kg will receive 250 ml, participants with weight 70-85 kg will receive 300 ml, and participants with weight ≥85 kg will receive 350 ml at each infusion. Administration is planned at the time of ET (5 days before to 2 days after ET) and if the participant becomes pregnant, the infusion is repeated in the same volume in gestational week 5, 6, and 7.~Placebo tablets: contain 85 mg of lactose monohydrate, 86 mg potato starch, 8.1 mg talc, 3 mg gelatine, and 0.9 mg magnesium stearate. 1 tablet daily started within first 3 days of menstrual cycle and until ET. On the day of ET, the participant will double her dose to 2 tablets daily until a negative pregnancy test, the time of biochemical loss/miscarriage, or pregnancy week 8+0, whichever comes first. Gradual discontinuation four days with one tablet before completing cessation."
62515194|NCT03515902|EXPERIMENTAL|mouthguard|Mouthguard arm is application of mouthguard while swimming
62515195|NCT03515902|EXPERIMENTAL|mouthguard with desensitizing toothpaste|Mouthguard with desensitizing toothpaste arm is application of mouthguard with desensitizing toothpaste containing 8% arginine and calcium carbonate while swimming
62515196|NCT03013881|EXPERIMENTAL|UB-921 2 mg/kg (Main-study)|Intravenous infusion
62515197|NCT03013881|EXPERIMENTAL|UB-921 6 mg/kg (Main-study)|Intravenous infusion
62515198|NCT03013881|EXPERIMENTAL|UB-921 8 mg/kg (Main-study)|Intravenous infusion
62710157|NCT04167943|EXPERIMENTAL|pulpotomy|complete removal of coronal pulp tissue will be attempted if bleeding persisted after attempting Partial pulpotomy for exposures that are not eligible for DPC. TheraCAL PT will be applied thereafter, after achieving hemostasis.
61973498|NCT04256070|NO_INTERVENTION|Standart care, no intervention|"* Informed Consent Form will be taken in writing from those who agree to participate in the research.~* At the first meeting, Information Form Based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected.~Interventions will not be applied to individuals in this group and routine treatment and follow-up will continue.~- COPD Self-efficacy Scale, face-to-face meeting at the end of the 12th week. George Quality of Life Scale, Respiratory Function Test Form will be repeated.~A training booklet for COPD management will be provided."
61973499|NCT00110149|EXPERIMENTAL|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
61973500|NCT02520076|EXPERIMENTAL|AAT treated group|Study subjects will receive Alpha-1 Antitrypsin (AAT) study drug intravenously in 4 doses over 15 days around the time of their transplant. The islets will also be prepared in a solution of AAT.
61973501|NCT01437046|EXPERIMENTAL|Doxazosin|Doxazosin 16mg/day
61973502|NCT01437046|PLACEBO_COMPARATOR|Placebo|Placeno
61973503|NCT04602455|EXPERIMENTAL|Heartfulness Group|Participants were asked to practice relaxation tools for 15 minutes a day using the calendar and HeartBot app, and participate in once a week webinar for 30 minutes during the four weeks. UCLA Loneliness scale was recorded prior to the start of the study and at its end after the duration of 4 weeks. The score was reviewed to see the changes in the loneliness scale.
62354241|NCT04990375|SHAM_COMPARATOR|Early relapse (2-week follow-up)|We compare 5 sessions of active tDCS (2 mA) vs. 5 sessions of sham tDCS (0 mA) to observe if tDCS can reduce early relapse (2-week follow-up). The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
62354242|NCT04990375|EXPERIMENTAL|Craving|We compare scored craving before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
62515199|NCT03013881|EXPERIMENTAL|UB-921 6 mg/kg (Sub-study)|Intravenous infusion
62710158|NCT01627184||Athletes with diabetes mellitus|Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time
62710159|NCT04353687||Cohort 1 Open Surgeons|Primarily open inguinal hernia surgeon with no or limited previous robotic-assisted experience.
62710160|NCT04353687||Cohort 2 Laparoscopic Surgeons|Primarily laparoscopic inguinal hernia surgeon with no or limited previous robotic-assisted experience.
62710161|NCT04228458|EXPERIMENTAL|Thermal Imaging|Thermal Imaging acquisition
62710162|NCT00724763|EXPERIMENTAL|1|Treatment group.
62710163|NCT00724763|SHAM_COMPARATOR|2|control group
62710164|NCT04314622|EXPERIMENTAL|Supaglutide (Part A)|Four investigational doses of Supaglutide administered weekly (or bi-weekly) and subcutaneously (SC) in T2DM patients.
61973504|NCT04602455|NO_INTERVENTION|Control Group|The control group had no change in their daily routines.
61973505|NCT01274754||erythromycin group|Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.
61973506|NCT01274754||control group|no administration of erythromycin
61973507|NCT01852110|EXPERIMENTAL|MK-7622 High Dose - 45 mg (Stage 1)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
61973508|NCT01852110|PLACEBO_COMPARATOR|Placebo (Stage 1)|Matching placebo to MK-7622 capsule once daily, taken orally.
62354243|NCT04990375|EXPERIMENTAL|Working memory|We compare reverse memory span before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
62515200|NCT03013881|ACTIVE_COMPARATOR|Herceptin 6 mg/kg (Sub-study)|Intravenous infusion
62515201|NCT05992428|EXPERIMENTAL|Part 1 or 2|\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
62515202|NCT04127955|EXPERIMENTAL|Intervention|"Quasi-experimental design with one-group, pre-post test~A nurse-led Theory of Planned Behavior based Physical Activity intervention consists of five component. These are a health education, a group walking, an individually tailored counseling session grounded on motivational interview technique, having the individuals keep track their physical activity levels with a pedometer, and use of physical activity pamphlet and posters as a reminder was planned. This intervention will be completed in eight weeks."
62515203|NCT03330236|EXPERIMENTAL|Study arm|"All patients in the study arm will receive the anesthetic care guided by the SedLine EEG Brain Function Monitor in addition to the conventional monitors. In addition to the conventional/standard interventions of anesthetic care, an additional intervention related to this trial is the anesthetic depth management via the titration of the propofol and remifentanil infusion rates to maintain SEF and PSI in the targeted ranges based on the SedLine EEG monitoring."
62515204|NCT03330236|NO_INTERVENTION|Control arm|All patients in the control arm will receive the anesthetic care guided by the conventional monitors only. Patients in the control arm will be monitored using the SedLine EEG Brain Function Monitor; however, the screen of this monitor will be covered by an opaque cloth and blinded to the anesthesia team.
62515205|NCT03016338|EXPERIMENTAL|Niraparib +TSR-042|200/300 mg Niraparib by mouth once a day for 21 days cycle. 500 mg of TSR-042 intravenously on the first day of each cycle.
62515206|NCT01818518||Preterm Labor|Group who goes into labor prior to 32 weeks of gestation
62515207|NCT01818518||Prelabor rupture of membranes|Group who have prelabor rupture of membranes are those who break their bag of water prior to 32 weeks gestation in the absence of labor.
62515208|NCT01818518||Premature birth before 32 weeks gestation|Premature birth before 32 weeks gestation not including PTL or PROM
62515209|NCT03557359|EXPERIMENTAL|Nivolumab|Nivolumab 240 mg will be given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg will be given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab will be administered as a 30-minute infusion. A finite treatment duration with immune therapies in this participant population remains an area of ongoing research; therefore the treatment duration chosen was 2 years.
62515210|NCT04686513||Obese young adult|
62515211|NCT04686513||Non Obese young adult|
62515212|NCT02382549|EXPERIMENTAL|6MHP and MEKi and BRAFi|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously.~A selective BRAF inhibitor and a selective MEK inhibitor will be administered in accordance with the prescribing information."
62515213|NCT04520776|EXPERIMENTAL|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis
62515214|NCT04520776|ACTIVE_COMPARATOR|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc
62515215|NCT05473000|EXPERIMENTAL|Ozone (O3)|Participants of the experimental group will perform sub-maximal exercise (power output associated with 10% below anaerobic threshold for 30 minutes) and maximal exercise (time-to-exhaustion test at 5% above previously determined maximal power output) on a cycle ergometer while inhaling 170ppb ozone delivered continuously during each exercise session.
62515216|NCT05473000|SHAM_COMPARATOR|Room air|Participants of the sham group will perform sub-maximal exercise (power output associated with 10% below anaerobic threshold for 30 minutes) and maximal exercise (time-to-exhaustion test at 5% above previously determined maximal power output) on a cycle ergometer while inhaling room air during each exercise session.
62354244|NCT04990375|EXPERIMENTAL|Depressive symptoms|We compare scored BDI-II before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
62354245|NCT04655053|ACTIVE_COMPARATOR|Goal intention condition|"Participants in this condition are asked to form the goal condition: I will walk as fast as I can for as long as I can"
62515217|NCT01640873|EXPERIMENTAL|MK-8655 80 mg/MK-8655 320 mg|Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
62515218|NCT01640873|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
62515219|NCT03922074|EXPERIMENTAL|Non-anesthesiologist administered propofol|Sedation directed by an endoscopist in which the intravenous drugs are propofol and fentanyl . Target level sedation: moderate - deep.
62515220|NCT03922074|ACTIVE_COMPARATOR|Monitored anesthesia care|Sedation directed by an anesthesiologist in which the used intravenous drugs and target level sedation are chosen by the anesthesiologist.
62515221|NCT01466322|EXPERIMENTAL|Oral formulations of GSK2018682|Three oral formulations of GSK2018682. A: CD2 Capsule; B: CD3 non-micronised Tablet; C: CD3 micronised Tablet; D: CD3 non-micronised Tablet in fed state
62515222|NCT02269644|EXPERIMENTAL|Dalbavancin|Dalbavancin randomized subjects will receive one dose of dalbavancin 1500 mg IV over 30 minutes on Day 1 plus azithromycin 500 mg IV on Day 1. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis. All patients in the dalbavancin group will receive placebo linezolid infusions or tablets to maintain the blinding. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis
62515223|NCT02269644|ACTIVE_COMPARATOR|Linezolid|Linezolid randomized subjects will receive linezolid 600 mg every 12 hours for a minimum of 10 days, and a maximum of 14 days. All patients will receive at least one IV dose of linezolid initially plus azithromycin 500 mg IV only on Day 1. Subjects then may then be switched to oral linezolid at the discretion of the investigator, if clinical improvement in the signs and symptoms of pneumonia is observed, to complete the 10-14 day course of therapy,. No dose adjustment is required for renal insufficiency.
62710165|NCT04314622|PLACEBO_COMPARATOR|Placebo(Part A)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
62710166|NCT04314622|EXPERIMENTAL|Supaglutide (Part B)|Two investigational doses of Supaglutide administered weekly (or bi-weekly) and SC in T2DM patients.
62515224|NCT02269644|OTHER|Linezold Placebo IV and Oral Capsules|Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
62515225|NCT02269644|OTHER|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose will also receive 500 mg of IV azithromycin
62515226|NCT03099629|EXPERIMENTAL|IMT|inspiratory muscle training
62515227|NCT04579315|ACTIVE_COMPARATOR|Intervention group, NNRD group|"Main principles of the interventional whole food approach are:~* Maximum of 850 mg phosphorous/day~* Protein: 0.8 g/kg/day~* 80% vegetable products; 20% animal products~* Maximum of 5-7 g NaCl/day (table salt)~* Fresh raw products~* Seasonal oriented~* Fish: At least once a week~* Vegetarian: At least once a week~* Wide range of fruit and vegetables~* Easy to follow in daily practice~* Rich in flavors~* Sufficient content of micro- and macronutrients"
62515228|NCT04579315|NO_INTERVENTION|Control group|There is no intervention, patients are following their habitual diet
62515229|NCT06227624|OTHER|combined oral zinc salts with phototherapy|neonates received combination therapy which is phototherapy and oral zinc sulfate in a dose of 5 mg every 12 hours using a calibrated dropper provided with the bottle, during the period of NICU admission of neonates on phototherapy
62515230|NCT06227624|NO_INTERVENTION|phototherapy group|neonates receiving phototherapy alone
62515231|NCT02404519|ACTIVE_COMPARATOR|Menaquinone-7|Menaquinone-7 180 microgram tablet, by mouth, daily for 1 year
62515232|NCT02404519|PLACEBO_COMPARATOR|Placebo|Placebo tablet, by mouth, daily for 1 year
62515233|NCT05660031|NO_INTERVENTION|Leaving LHB Intact|The long head of the biceps (LHB) will be left intact.
62710167|NCT04314622|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
61973509|NCT01852110|EXPERIMENTAL|MK-7622 Low Dose - 5 mg (Stage 2)|Single 5 mg MK-7622 capsule once daily, taken orally.
61973510|NCT01852110|EXPERIMENTAL|MK-7622 Mid Dose - 15 mg (Stage 2)|Single 15 mg MK-7622 capsule once daily, taken orally.
61973511|NCT01852110|EXPERIMENTAL|MK-7622 High Dose - 45 mg (Stage 2)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
62354246|NCT04655053|EXPERIMENTAL|Implementation intention (behavior initiation) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if I do the task, then I will walk as much as I can!)"
62354247|NCT04655053|EXPERIMENTAL|Implementation intention (goal preference management) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if at this moment I prefer not to walk because of my pain (or fatigue; depending on person), then I will accept that I have this difficulty and I will walk as much as I can!)"
62354248|NCT03652272|EXPERIMENTAL|EMC2|"Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications:~1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~2. Patients will receive a Medication Guide + Summary with their After Visit Summary~3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
62354249|NCT03652272|NO_INTERVENTION|Usual Care|Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
62354250|NCT03288740|EXPERIMENTAL|Semaglutide 0.5 mg|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
62354251|NCT03288740|PLACEBO_COMPARATOR|Semaglutide 0.5 mg placebo|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
62354252|NCT03288740|EXPERIMENTAL|Semaglutide 1.0 mg|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
62354253|NCT03288740|PLACEBO_COMPARATOR|Semaglutide 1.0 mg placebo|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.
62354254|NCT02266732|OTHER|Interscalene block|
62354255|NCT02266732|OTHER|Femoral block|
62354256|NCT01263314|EXPERIMENTAL|Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
62354257|NCT01263314|EXPERIMENTAL|Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
62354258|NCT01263314|EXPERIMENTAL|Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
62515234|NCT05660031|EXPERIMENTAL|LHB tenotomy|The long head of the biceps (LHB) will be cut at its origin.
62515235|NCT05660031|EXPERIMENTAL|LHB Tenodesis|The long head of the biceps (LHB) will be cut at its origin and reattached.
62710168|NCT01914588|EXPERIMENTAL|Telemonitoring + Standard care|
62710169|NCT01914588|ACTIVE_COMPARATOR|Standard care|
61973512|NCT01852110|PLACEBO_COMPARATOR|Placebo (Stage 2)|Matching placebo to MK-7622 capsule once daily, taken orally.
61973513|NCT01957553|EXPERIMENTAL|Treatment sequence 1, First Coloplast Test product|Subjects first allocated to Coloplast Test product will after cross-over test SenSura
62515236|NCT04787770||diabetes without complications|diabetes without complications
62515237|NCT04787770||diabetes with Peripheral Arterial Disease|diabetes with Peripheral Arterial Disease
62515238|NCT04787770||diabetic foot group|diabetic foot group
62515239|NCT02499224|EXPERIMENTAL|YYB101|Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks
62710170|NCT01368094|ACTIVE_COMPARATOR|Standard drainage|
62710171|NCT01368094|EXPERIMENTAL|Short drainage|
62710172|NCT00688714|EXPERIMENTAL|1|
62515240|NCT03311152|EXPERIMENTAL|HCC-free cirrhotic patients (Controls)|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
62515241|NCT03311152|EXPERIMENTAL|HCC-positive cirrhotic patients (Cases)|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
62515242|NCT00305552|EXPERIMENTAL|1|THALIDOMIDE
62515243|NCT05369013||A|Biosimilar Teriparatide
62515244|NCT05369013||B|Original Teriparatide
62515245|NCT00650988|EXPERIMENTAL|Barrett's Esophagus with intramucosal carcinoma (IMCA)|
62515246|NCT00650988|EXPERIMENTAL|Barrett's Esophagus with High Grade Dysplasia (HGD)|
62710173|NCT00688714|PLACEBO_COMPARATOR|2|
62354259|NCT01263314|PLACEBO_COMPARATOR|Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)|Placebo to MK-8266 single dose
62354260|NCT01263314|EXPERIMENTAL|Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
62354261|NCT01263314|EXPERIMENTAL|Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
62354262|NCT01263314|EXPERIMENTAL|Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
62354263|NCT01263314|PLACEBO_COMPARATOR|Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)|Placebo to MK-8266 single dose
62354264|NCT01398527|NO_INTERVENTION|LTC Osteoporosis Toolkit Only|Homes will receive the LTC osteoporosis toolkit only and will be required to attend an online webinar to outline the toolkit contents.
62354265|NCT01398527|ACTIVE_COMPARATOR|Educ sessions & LTC Osteoporosis toolkit|LTC homes will receive the LTC osteoporosis toolkit, on line webinar. Three educational sessions lead by an osteoporosis expert will also take place, 1 on-site visit and 2 webinars.
62354266|NCT01560611||High-risk cardiac surgery patient|
62354267|NCT01179347|EXPERIMENTAL|tiotropium|2 inhalations once daily delivered with Respimat® inhaler
62354268|NCT01179347|PLACEBO_COMPARATOR|placebo|2 inhalations once daily delivered with Respimat® inhaler
62354269|NCT06424392||6-9 years children with fetal diagnoses of CLM|6-9 years children with fetal diagnoses of CLM and included in MALFPULM who have had at least one follow-up visit between 0 and 2 years of age.
62354270|NCT02468206|ACTIVE_COMPARATOR|BRTO|Balloon-occluded retrograde transvenous obliteration
62354271|NCT02468206|ACTIVE_COMPARATOR|NBCA|Endoscopic Cyanoacrylate injection in the gastric varix
62354272|NCT05631262|EXPERIMENTAL|SKB264 (Cohort 1)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
62354273|NCT05631262|EXPERIMENTAL|SKB264 (Cohort 2)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
62515247|NCT05449093||Stage 3 Grade C Periodontitis|Generalized stage 3 periodontitis patients had interproximal clinical attachment loss ≥ 5 mm at 30 % of the teeth or more. Care was taken to ensure that clinical attachment loss was caused by periodontal causes. These patients had also radiographic bone loss extending to the mid-third of the root or beyond and probing depth ≥ 6 mm at 30 % of the teeth or more as well as Class II-III furcation involvement. The grade of periodontitis was estimated with indirect evidence of progression through % of bone loss/age. Radiographic bone loss of each natural tooth was assessed by using the panoramic radiograph. The tooth showing the most extensive bone loss was determined and % of bone loss/age were calculated. If this value was higher than 1.0, the patients were assigned to grade C.
62515248|NCT05449093||Stage 3 Grade B Periodontitis|Generalized stage 3 periodontitis patients had interproximal clinical attachment loss ≥ 5 mm at 30 % of the teeth or more. Care was taken to ensure that CAL was caused by periodontal causes.These patients had also radiographic bone loss extending to the mid-third of the root or beyond and probing depth ≥ 6 mm at 30 % of the teeth or more as well as Class II-III furcation involvement. The grade of periodontitis was estimated with indirect evidence of progression through % of bone loss/age. Radiographic bone loss of each natural tooth was assessed by using the panoramic radiograph. The tooth showing the most extensive bone loss was determined and % of bone loss/age were calculated. When this value was between 0.25 and 1.0, patients were included in grade B.
62515249|NCT05449093||Gingivitis|Gingivitis patients showed probing depth ≤ 3 mm with bleeding on probing ≥ 30 % in the entire mouth as well as no interproximal clinical attachment loss or radiographic bone loss.
62515250|NCT05449093||Periodontal Health|Periodontally healthy individuals in the control group had an intact periodontium or a reduced periodontium (without detectable interproximal clinical attachment loss or radiographic bone loss) in a non-periodontitis patient. In this group, probing depth was ≤ 3 mm and bleeding on probing was \< 10 % in the whole mouth.
62710174|NCT04850326|EXPERIMENTAL|AP green tea extract|
62710175|NCT04850326|NO_INTERVENTION|No intervention control|
62354274|NCT05631262|EXPERIMENTAL|SKB264 (Cohort 3)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
62354275|NCT05631262|EXPERIMENTAL|SKB264 (Cohort 4)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
62354276|NCT05631262|EXPERIMENTAL|SKB264 (Cohort 5)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
62354277|NCT05631262|EXPERIMENTAL|Part II Test group|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
62354278|NCT05631262|ACTIVE_COMPARATOR|Part II Control group|Docetaxel will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle
62354279|NCT04154943|EXPERIMENTAL|Cemiplimab|Will receive IV infusion Q3W
62354280|NCT04141215|EXPERIMENTAL|BIOBank bone paste (PPT322)|Allogeneic bone paste derived from human living donor femoral heads
62710176|NCT01872884|EXPERIMENTAL|General anaesthesia|General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
62710177|NCT01872884|PLACEBO_COMPARATOR|Sedation|Sedation with spontaneous breathing. Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg
62710178|NCT01257685||Control Group|Normal group
62710179|NCT01257685||NAFLD Group|NAFLD in the present study was defined a value of LAI \<5 HU using an unenhaned CT.
62710180|NCT05124730|EXPERIMENTAL|Treatment A|Metformin 500 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
62710181|NCT05124730|ACTIVE_COMPARATOR|Treatment B|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
61973514|NCT01957553|EXPERIMENTAL|Treatment seqence 2; First SenSura|Subjects first allocated to SenSura will after cross-over test Coloplast Test product
62147563|NCT04072133|EXPERIMENTAL|Meditative Movement Intervention|Participants will complete the following components of baseline (T1) data collection: demographics, biometric measurements, a heart rate variability assessment, and questionnaires. Participants will be asked to provide six saliva samples via passive drool to measure cortisol levels. Participants will be assigned into hour-long meditative movement (MM) classes for eight weeks total. Participants will be asked to practice their MM skills at home for at least 30 minutes most days per week. The study will distribute hard-copy movement manuals and DVD instruction videos for guidance. Participants will be asked to provide a log of all dates and lengths of their at-home practice. After the eighth class, participants will return for post-intervention (T2) data collection, consisting of biometric measurements, a heart rate variability assessment, and questionnaires. Participants will provide six more saliva samples via passive drool method.
61973515|NCT00492661|EXPERIMENTAL|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
61973516|NCT03163615|EXPERIMENTAL|Tibet Rhodiola Capsule|
61973517|NCT03163615|PLACEBO_COMPARATOR|Placebo oral capsule|
61973518|NCT04282993|EXPERIMENTAL|Wearable Devices Monitoring|Patients will be provided with wearable devices for at-home monitoring heart rhythm and rate, blood pressure, pulse oximetry, quality and quantity of sleep, and pace counting.
61973519|NCT04282993|ACTIVE_COMPARATOR|Standard of Care Monitoring|Patients will be evaluated by periodical clinical visits.
61973520|NCT05403125|EXPERIMENTAL|Package|Topical application of 38% silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
62147564|NCT04530032|EXPERIMENTAL|TBI KD/MAD|TBI subjects on a ketogenic/modified Atkins diet
62147565|NCT04530032|SHAM_COMPARATOR|TBI SD|TBI subjects on a standard (normal) diet
62147566|NCT06037707||Ancestral variant|Ancestral variant is the first subtype of SARS CoV-2 virus which is the agent of first COVID-19 infection in Wuhan. Thromboembolic complications of this group were detected among patients which were infected with ancestral variant of COVID-19
62147567|NCT06037707||Delta Variant|Delta variant is the subtype of SARS CoV-2 virus which is first COVID-19 subtype identified in India. Thromboembolic complications of this group were detected among patients which were infected with delta variant of COVID-19
62147568|NCT06037707||Alpha variant|Alpha variant is the subtype of SARS CoV-2 virus which is first identified COVID-19 subtype in United Kingdom. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19
62147569|NCT06037707||Other variants|Other variants is the subtype of SARS CoV-2 virus which were identified in Brazil, South Africa..etc. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19
62354281|NCT04141215|ACTIVE_COMPARATOR|BIOBank cortico-cancellous bone powder (PPT6)|Allogeneic bone powder derived from human living donor femoral heads (used in current practice)
62354282|NCT03129633|EXPERIMENTAL|Promotores Network|Promotores will engage participants using the materials A Page of My Life and the Success Plan. Promotores will ask participants to rank their satisfaction with each of the domains included in the A Page of My Life and ask them what domain they want to change. Using non-directive questions, promotores will guide the participant to draft a plan for success. The promotor/a will follow up with participants within a week of enrollment and at least monthly via phone/text during six months. During the intervention period, promotores will meet with participants (child and parent together, if applicable) at least three times in-person during which they will deliver the short (15-minutes) educational components of the intervention.
62710182|NCT04719156|OTHER|ICG use followed by SPY-PHI imaging.|Participants will be injected with 2.0mg/kg of ICG dye to access tumor margin using Stryker SPY imaging technology.
62710183|NCT00587119|EXPERIMENTAL|1|Single arm, active treatment
62710184|NCT00221767|EXPERIMENTAL|1|Brindley technique (bladder system)
62710185|NCT00221767|NO_INTERVENTION|2|Reference group
62710186|NCT01374425|EXPERIMENTAL|Bevacizumab + mFOLFOX6|Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
62710187|NCT01374425|EXPERIMENTAL|Bevacizumab + FOLFIRI|Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
61973521|NCT05403125|ACTIVE_COMPARATOR|Gel Alone|Placebo application of silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
61973522|NCT03569553||AIGIV|Inhalational anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
61973523|NCT02036463|ACTIVE_COMPARATOR|Immediate Release Prednisone|During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
61973524|NCT02036463|EXPERIMENTAL|Delayed Release Prednisone|During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
61973525|NCT02036463|PLACEBO_COMPARATOR|Placebo-Delayed Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
62515251|NCT03651726|EXPERIMENTAL|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
62515252|NCT03651726|PLACEBO_COMPARATOR|Placebo|"Double-blind phase:~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
62710188|NCT05825040|EXPERIMENTAL|Online guided transdiagnostic cognitive behavioral therapy|In the online guided transdiagnostic cognitive behavioral therapy group, participants will go through 8 modules with coach support in 8 weeks. They will complete 6 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks, and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
62147570|NCT02050815|EXPERIMENTAL|MEK162|A minimum of 24 subjects (6 subjects per group) will be enrolled. Enrollment into Group 1 (control group with normal hepatic function) should be similar to the enrollment into Group 2, 3 and 4 with respect to age, gender, and body weight. Enrollment into Group 1 will remain open until the enrollment into the mild, moderate, and severe impairment groups are complete with matching controls for comparison. Serum level of total bilirubin and AST will be used to determine which group the hepatic impaired patient will be allocated l. Dosing of the different treatment groups will be staggered. Initially, 6 subjects in Group 1 (normal hepatic function) and 6 subjects in Group 2 will receive a single oral dose of MEK162 on Day 1.
62147571|NCT03357237|EXPERIMENTAL|XYLOGLUCAN|treatment regimen with oral rehydration solution and xyloglucan
62710189|NCT05825040|EXPERIMENTAL|Online self-guided transdiagnostic cognitive behavioral therapy|In the online self-guided transdiagnostic cognitive behavioral therapy group, participants will go through 8 modules without coach support in 8 weeks. They will complete 6 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks, and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
61973526|NCT02036463|PLACEBO_COMPARATOR|Placebo-Immediate Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.
62147572|NCT03357237|PLACEBO_COMPARATOR|PLACEBO|rehydration solution and placebo.
62147573|NCT04185818|EXPERIMENTAL|Reading group|"Participants will:~1. Read a book for 15 to 30 mins~2. Read immediately before trying to go to sleep."
62147574|NCT04185818|NO_INTERVENTION|Control Group|"Participants will:~1. Not read a book"
62710190|NCT05825040|NO_INTERVENTION|Waitlist control group|In the waitlist control group, participants are to refrain from using online psychological interventions until they finished the final questionnaire. They will complete 4 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
61973527|NCT01824901|EXPERIMENTAL|Phase I|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61973528|NCT01824901|EXPERIMENTAL|Arm I (docetaxel; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.
61973529|NCT01824901|EXPERIMENTAL|Arm II (docetaxel and AZD4547; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
61973530|NCT01824901|EXPERIMENTAL|Phase II step II|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61973531|NCT02801240|EXPERIMENTAL|Nutrition Support Product|Participants will be asked to take a nutrition support product twice per day for a period of 12 weeks.
61973532|NCT03590379|EXPERIMENTAL|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
61973533|NCT03590379|ACTIVE_COMPARATOR|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
61973534|NCT03590379|ACTIVE_COMPARATOR|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
61973535|NCT03537898|ACTIVE_COMPARATOR|Lactated Ringer's|Patients in a MICU block randomized to lactated Ringer's will receive lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
62515253|NCT04710537|ACTIVE_COMPARATOR|AlloDerm|AlloDerm will be surgically implanted into each participant (either in their left or right breast) at the time of their breast reconstruction surgery. AlloDERM will be placed in the breast opposite to the breast in which DermACELL is placed, so that the patient has AlloDERM in the right breast and DermACELL in the left breast, or vice versa.
62515254|NCT04710537|ACTIVE_COMPARATOR|DermACELL|DermACELL will be surgically implanted into each participant (either in their left or right breast) at the time of their breast reconstruction surgery. DermACELL will be placed in the breast opposite to the breast in which AlloDERM is placed, so that the patient has AlloDERM in the right breast and DermACELL in the left breast, or vice versa.
62515255|NCT02997657|EXPERIMENTAL|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
62515256|NCT02997657|ACTIVE_COMPARATOR|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
61973536|NCT03537898|ACTIVE_COMPARATOR|Normosol|Patients in a MICU block randomized to Normosol will receive Normosol-R pH 7.4 whenever isotonic intravenous fluid administration is ordered by the treating provider.
61973537|NCT01288469|PLACEBO_COMPARATOR|Placebo + Atorvastatin 80 mg|Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.
62147575|NCT01544907|ACTIVE_COMPARATOR|Conventional PTA only|"Treatment Arm 1- Conventional PTA only~The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.~An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.~At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of \>30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation."
62515257|NCT01712919|EXPERIMENTAL|cetuximab|Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
62147576|NCT01544907|EXPERIMENTAL|Drug Eluting Balloon (DEB)|"Treatment arm 2 - Conventional Balloon with DEB~A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel."
62515258|NCT04572139||Young participants|18-45 years old
62515259|NCT04572139||Old participants|55-80 years old
62515260|NCT04572139||Oldest old participants|over 80 years old
62515261|NCT04176588|EXPERIMENTAL|Experimental: Etrasimod 2mg|2mg/tablet, administratered orally, once daily
62515262|NCT04176588|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|matching tablet, administratered orally, once daily
62515263|NCT04176588|EXPERIMENTAL|Etrasimod 2mg (optional open-label extension period)|2mg/tablet, administratered orally, once daily
62515264|NCT02836301|ACTIVE_COMPARATOR|Testimonials-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
62515265|NCT02836301|ACTIVE_COMPARATOR|Testimonials-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
62515266|NCT02836301|ACTIVE_COMPARATOR|Testimonials-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
62515267|NCT02836301|EXPERIMENTAL|Documentary-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
62515268|NCT02836301|EXPERIMENTAL|Documentary-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
62515269|NCT02836301|EXPERIMENTAL|Documentary-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
61973538|NCT01288469|EXPERIMENTAL|Alirocumab + Atorvastatin 10 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.
61973539|NCT01288469|EXPERIMENTAL|Alirocumab + Atorvastatin 80 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.
61973540|NCT00001596|ACTIVE_COMPARATOR|Pirfenidone|Subjects received pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
61973541|NCT00001596|PLACEBO_COMPARATOR|Placebo|Subjects received placebo (3 pills), three times daily.
61973542|NCT02940145|EXPERIMENTAL|intervention 1|"The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums.The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise.~Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise"
61973543|NCT02940145|NO_INTERVENTION|control group|The control group did not perform any type of physical exercise during the intervention period.
61973544|NCT02520050|ACTIVE_COMPARATOR|Traditional MNT|Will be instructed to follow a MNT plan as recommended by the ADA through consultation with a RD.
62515270|NCT02401477|EXPERIMENTAL|Ilaprazole + Amoxicillin|Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days
62515271|NCT04425889||exposed Healthcare workers|Healthcare workers working for 8 weeks in a COVID-19 area
62515272|NCT02740920|EXPERIMENTAL|Pembrolizumab|200mg IV Day 1 every 3 weeks.
62515273|NCT06051604|SHAM_COMPARATOR|Group I (sham)|2 LPM of ambient air administered intermittently via Mi-Helper for 15 minutes
62515274|NCT06051604|EXPERIMENTAL|Group II (active treatment 1)|4 LPM of dehumidified air administered via Mi-Helper for 15 minutes
62515275|NCT06051604|EXPERIMENTAL|Group III (active treatment 2)|6 LPM of dehumidified air administered via Mi-Helper for 15 minutes
61973545|NCT02520050|ACTIVE_COMPARATOR|Structured MNT|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day.
61973546|NCT02520050|ACTIVE_COMPARATOR|Structured MNT plus Weekly Support|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal-replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day plus weekly coaching.
61973547|NCT03968484|EXPERIMENTAL|<50.000/µl|Transfusion of platelets starting with a platelet count \<50.000/µl
61973548|NCT03968484|EXPERIMENTAL|<20.000/µl|Transfusion of platelets starting with a platelet count \<20.000/µl
62515276|NCT06051604|EXPERIMENTAL|Group IV (active treatment 3)|10 LPM of dehumidified air administered via Mi-Helper for 15 minutes
62515277|NCT04932941|EXPERIMENTAL|MP1032|Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.
62515278|NCT04932941|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.
62515279|NCT04574115|EXPERIMENTAL|Study Eye|study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.
62515280|NCT04574115|ACTIVE_COMPARATOR|Control Eye|Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).
62515281|NCT03329976||patient|any person about to undergo combined surgery for cataract and ERM
62515282|NCT03235479|EXPERIMENTAL|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
62515283|NCT03235479|PLACEBO_COMPARATOR|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
62515284|NCT04681625|ACTIVE_COMPARATOR|Standard silodosin treatment|Peroral treatment with silodosin at a dose of 8 mg daily
62515285|NCT04681625|EXPERIMENTAL|Standard silodosin treatment with PFMT|Peroral treatment with silodosin at a dose of 8 mg daily Intervention: Behavioural: Pelvic floor muscle training (PFMT) with suppressive urgency technique
62515286|NCT06552104|EXPERIMENTAL|ACUPRESSURE|In the study, acupressure was applied to the LI4 and HT7 points of the women for approximately 8-11 minutes during the episiotomy repair by BI, one of the researchers who has an acupressure application certificate. The researcher received training and certification in acupressure techniques before starting the intervention.During the episiotomy repair, acupressure was applied by the researcher twice in total. The first acupressure application was started with the first episiotomy suture being placed during the episiotomy repair (with the start of the internal perineal suturing). The second acupressure application was started with the end of the internal perineal suture and the first episiotomy suture of the skin suture. Each application was applied for approximately 4-6 minutes.
62515287|NCT06552104|NO_INTERVENTION|Control group|control groups Control group standard care group
62515288|NCT01931527|NO_INTERVENTION|Obese subjects with normal uric acid|Subjects with a body mass index = or \> 30 kg/m² with normal uric acid (= or \< 5 mg/dL)
62515289|NCT01931527|EXPERIMENTAL|Obese subjects with high uric acid|"Subjects with a body mass index = or \> 30 kg/m² with high uric acid (\>6 mg/dL)~Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
62515290|NCT00850226|EXPERIMENTAL|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
62515291|NCT00850226|EXPERIMENTAL|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
62515292|NCT01413282|ACTIVE_COMPARATOR|Cardiac CT|Triage based on cardiac CT results.
62515293|NCT01413282|NO_INTERVENTION|Standard Care|Standard diagnostic management according to the European guidelines.
62515294|NCT01163084|EXPERIMENTAL|Arm I (leuprolide acetate, goserelin acetate, vismodegib)|Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
62515295|NCT01163084|ACTIVE_COMPARATOR|Arm II (leuprolide acetate, goserelin acetate)|Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
62515296|NCT06180408|EXPERIMENTAL|manual therapy for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
62515297|NCT06180408|EXPERIMENTAL|lumbar stabilization exercise|core training and myofascial release therapy
62710191|NCT05825040|EXPERIMENTAL|Online self-guided mindfulness-based intervention|In the online self-guided mindfulness-based intervention group, participants will go through 6 modules in 8 weeks without coach support. They will complete 6 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks, and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
61973549|NCT06374706|EXPERIMENTAL|Morning Walk Training for Stroke|
61973550|NCT06374706|ACTIVE_COMPARATOR|Morning Walk Training for Healthy|
62515298|NCT03313882||donor|donor: normal heart samples from donor
62515299|NCT03313882||ICM|ICM: heart samples with ischemic cardiomyopathy
62515300|NCT03313882||NICM|NICM: heart samples with non-ischemic cardiomyopathy
62515301|NCT03738527|EXPERIMENTAL|TXA arm|
62515302|NCT03738527|PLACEBO_COMPARATOR|Placebo arm|
62515303|NCT02382926|EXPERIMENTAL|contactless heart-, breathing rate, ECG|
62515304|NCT04385524|OTHER|Vaccination|"Heplisav B vaccine will be administered to subjects demonstrating completion of two prior series of standard 3-dose Hepatitis B vaccine but still without evidence of seroconversion.~One dose (20 mcg) of vaccine will be administered intramuscularly followed by Hepatitis B quantitative antibody titer 30-60 days later.~If still Hepatitis B antibody negative, a second dose (20 mcg) of vaccine will be administered intramuscularly followed by a Hepatitis B quantitative titer 30-60 days later.~If still no evidence of Hepatitis B immunity (10iU antibody or greater), will be deemed a non-responder to this vaccine"
62710192|NCT00137592|EXPERIMENTAL|Lifestyle counseling|Behavioral: small media, group education (multicomponent)
62710193|NCT01720368||1st Group of 50 patients|
62710194|NCT01720368||2nd Group of 50 patients|
62710195|NCT02497105|EXPERIMENTAL|Epilepsy/Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
62147577|NCT01124045|EXPERIMENTAL|DUREZOL|Difluprednate ophthalmic emulsion, 0.05%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
62515305|NCT00766155|ACTIVE_COMPARATOR|Arm I|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62515306|NCT00766155|EXPERIMENTAL|Arm II|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62515307|NCT00697606|EXPERIMENTAL|A|Seprafilm®
61973551|NCT01798004|EXPERIMENTAL|Treatment (induction therapy, consolidation therapy, ASCT)|"INDUCTION THERAPY:~COURSES 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for 2 courses.~COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 3 weeks for 2 courses.~COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, and doxorubicin hydrochloride IV over 24 hours on days 1-3. Treatment repeats every 3 weeks for 1 course.~Treatment continues in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. Patients undergo ASCT on day 0.~Some patients also undergo EBRT after induction and consolidation."
62147578|NCT01124045|ACTIVE_COMPARATOR|PRED FORTE|Prednisolone acetate ophthalmic suspension, 1.0%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
62515308|NCT00697606|SHAM_COMPARATOR|B|Control
62515309|NCT03813693|EXPERIMENTAL|towels with chlorhexidine gluconate 2%|Composed of 25 patients, who received 2 towels with chlorhexidine gluconate 2% packages each containing six towels and detailed instructions on the form and sequence of application of the towels; the time of application, that is, the night before surgery, between 20 and 22h, and, on the morning of surgery, between 5 and 6h; besides other general orientations.
62515310|NCT03813693|ACTIVE_COMPARATOR|chlorhexidine gluconate 2% liquid|Composed of 23 patients, two 100 ml flasks of chlorhexidine gluconate 2% liquid were supplied, and detailed instruction manual for the product, containing form and application sequence; time of application (the night before surgery, between 20 and 22h, and on the morning of surgery, between 5 and 6h); and general guidelines.
61973552|NCT00740701|SHAM_COMPARATOR|Sham TMS|A Sham TMS coil, designed to elicit sham cerebellar transcranial magnetic stimulation, is used to administer sham TMS pulses after letters are presented.
62147579|NCT04108104|EXPERIMENTAL|Low-dose group|Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
62147580|NCT04108104|EXPERIMENTAL|High-dose group|Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg \[2 tablets of 5 mg\] once a day slow-release: evening administration)
62147581|NCT04108104|PLACEBO_COMPARATOR|Placebo group|Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)
62147582|NCT03287232|PLACEBO_COMPARATOR|Placebo|
62147583|NCT03287232|EXPERIMENTAL|Prasterone|
62147584|NCT01192555|EXPERIMENTAL|Treatment Plan|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)
62147585|NCT04217252|EXPERIMENTAL|the experimental group|high throughput sequencing of infectious pathogens
62354283|NCT03129633|NO_INTERVENTION|Wait-list Control|The community liaison will deliver a short (15-minute) educational session on the benefits of a healthy lifestyle and preventive use of health care, and give participants a pamphlet with relevant local health care and social service resources.
62354284|NCT02776501|EXPERIMENTAL|BAY987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62147586|NCT04217252|NO_INTERVENTION|the control group|no intervention
62147587|NCT00653185|EXPERIMENTAL|SYR-472 25 mg QD|(with lifestyle modification and/or metformin therapy)
62147588|NCT00653185|EXPERIMENTAL|SYR-472 50 mg QD|(with lifestyle modification and/or metformin therapy)
62147589|NCT00653185|EXPERIMENTAL|SYR-472 100 mg QD|(with lifestyle modification and/or metformin therapy)
62147590|NCT00653185|EXPERIMENTAL|SYR-472 200 mg QD|(with lifestyle modification and/or metformin therapy)
62147591|NCT00653185|PLACEBO_COMPARATOR|Placebo QD|(with lifestyle modification and/or metformin therapy)
62147592|NCT01929291||Boostrix Group|Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.
62354285|NCT04211844||sofosbuvir plus daclatasvir|50 patients receiving 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
62354286|NCT04211844||sofosbuvir plus ledipasvir|50 patients receiving 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
62515311|NCT02234752|EXPERIMENTAL|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS \& Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS \& Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS \& Memantine XR 21 mg HS
62515312|NCT05002114|PLACEBO_COMPARATOR|Placebo Group|Does not get active topical CBD. Instead, gets an identical placebo-containing topical agent.
62515313|NCT05002114|EXPERIMENTAL|Active Group|Does get active topic CBD.
62515314|NCT02948790|EXPERIMENTAL|Neuristim|Electrical stimulation with the Neuristim and auditory nerve electrical response measurements (wave V).
62515315|NCT02948790|ACTIVE_COMPARATOR|Digisonic SP EVO cochlear implant|Electrical stimulation with the patient's cochlear implant and auditory nerve electrical response measurements (wave V).
62515316|NCT06218121||Frail Older Adult Patients|For the cohort study, 500 frail older adult patients will be evaluated by means of instrumental and functional tests that assess their functional capacity, in addition to ultrasound imaging to study sarcopenia and nutrition, as well as psychological variables. The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters. All available information will be collected during the follow-up in order to generate Machine Learning on the objective evolution and symptomatology of these patients, generating profiles that facilitate the most accurate and appropriate treatment for each patient.
62515317|NCT04953416|EXPERIMENTAL|Scalp treatment with ResurFX|
62515318|NCT06023849|ACTIVE_COMPARATOR|PPIUD|trans cesarean IUD insertion immediately post placental
62515319|NCT06023849|ACTIVE_COMPARATOR|interval|IUD insertion 6 weeks interval post-partum
62515320|NCT06342024|EXPERIMENTAL|Arm 1: Pistachio group|Participants will receive 1.5 ounces of pistachios to consume every day for 6 months. We will provide them a 3-month supply of pistachios, and they will receive another 3-month supply when they come in for their 3-month study visit (blood draw).
62515321|NCT06342024|NO_INTERVENTION|Arm 2: No pistachio group|This group will not get any pistachios.
62515322|NCT00609284|EXPERIMENTAL|1|Radiotherapy 70Gy, Erbitux, Carboplatin-5FU
62515323|NCT00609284|ACTIVE_COMPARATOR|2|Radiotherapy 70Gy, Erbitux
62515324|NCT00078507|ACTIVE_COMPARATOR|Opening Exercises Only|Standard of care opening exercises following BSSO surgery to regain mouth opening
62515325|NCT00078507|EXPERIMENTAL|Sensory Retraining Exercises|3 sets of facial exercises performed with soft cosmetic brush 1 wk - 4 wks after surgery; 4wks to 3 mos after surgery; 3 mos to 6 mos after surgery.
62515326|NCT01709994|ACTIVE_COMPARATOR|aspirin|Aspirin dosage 100 mg/day
62515327|NCT01709994|NO_INTERVENTION|standard medication|the patients will continue with standard medication
62515328|NCT04928534||Athletes with rmTBI history|50 active or retired athletes from the Weightlifting, Wrestling, Judo, Boxing and Taekwondo Sports Management Center of Tianjin Sports Bureau
62515329|NCT04928534||Patients with rmTBI history|50 patients with multiple (≥2 times) exposure to brain trauma attending Tianjin Medical Insurance designated hospitals such as Tianjin Medical University General Hospital
62515330|NCT04928534||Healthy volunteer|20 healthy volunteers
62515331|NCT03812991|NO_INTERVENTION|Non-Treatment Group|This is the Non-Treatment Arm of the study. No intervention is to be administered.
62515332|NCT03812991|EXPERIMENTAL|Miacalcin Calcitonin Salmon Nasal Spray|1 spray (200 IU) qDay, alternate nostrils daily
62515333|NCT00888784|ACTIVE_COMPARATOR|1. Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in the gastric varix
62710196|NCT02497105|NO_INTERVENTION|Epilepsy/Non-Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.
62147593|NCT05606185|ACTIVE_COMPARATOR|Two step retraction|teeth will be retracted in two stages
62147594|NCT05606185|EXPERIMENTAL|En masse retraction|teeth will be retracted in one stage
62147595|NCT01338506|EXPERIMENTAL|COPE Therapy|Combined prolonged exposure therapy for PTSD with cognitive behavioral therapy for substance use disorder.
62147596|NCT01338506|ACTIVE_COMPARATOR|Treatment as usual|CBT for substance use disorder.
62515334|NCT00888784|PLACEBO_COMPARATOR|2. Beta-blocker|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
62515335|NCT03119493|EXPERIMENTAL|Periodized aerobic interval training|The experimental groups will participate in a 16 week, three times a week based-program of periodized aerobic interval training that consist in warming \[5 minutes of general stretching and 5 minutes of walking on treadmill with heart rate less than 20 percent of heart rate reserve (HHR)\], followed by periodized aerobic interval training on treadmill, and cooling down \[5 minutes of walk in treadmill with a heart rate less than 20 percent of HRR and 5 minutes of rest\]
62515336|NCT03119493|NO_INTERVENTION|Control group|Participants in the control group will be instructed not to take part in any regular exercise programs during the study period.
62539468|NCT06599580|EXPERIMENTAL|Caregiver mid-upper arm circumference (MUAC) screening and a reduced follow-up schedule|This arm will include caregiver screening with a mid-upper arm circumference tape at home weekly. Caregivers will be trained to screen their child for malnutrition relapse using mid-upper arm circumference tapes and requested to bring their child back to the clinic when relapse is detected. Additionally, this arm will receive a reduced follow-up schedule at the clinic, which will include one planned visit at 3 months post enrollment and a final follow-up visit at 6 months.
62539469|NCT04918485|EXPERIMENTAL|the experimental group received psychological intervention|
62710197|NCT02612246|EXPERIMENTAL|GLPG1972 single dose|Single oral dose of GLPG1972 solution - ascending doses
62710198|NCT02612246|PLACEBO_COMPARATOR|Placebo single dose|Single oral dose of placebo solution
62710199|NCT02612246|EXPERIMENTAL|GLPG1972 multiple doses|Multiple oral doses of GLPG1972 solution - ascending doses
62515337|NCT06406439|EXPERIMENTAL|Treatment Group|For the treatment group, education sessions will be conducted during the baseline visit on carb counting and bolus calculator methods, installation, and usage instructions for DIA:CONN P8 and DIA:CONN app, as well as CGM and CGM app. During the 12-week, for basal insulin, the treatment group will input and inject the dosage using the DIA:CONN P8, using only the insulin injection and injection recording functions, same as the blind CGM period. For bolus insulin, when the carbohydrate counting is entered or the type of meal is selected into the DIA:CONN P8 application, the insulin dosage is automatically calculated and set using the entered information and other indicators. Subjects inject the insulin at that calculated dosage using the DIA:CONN P8. Insulin injection dosage, time stamps, and other related details will be recorded into DIA:CONN P8 device and app.
62515338|NCT06406439|NO_INTERVENTION|Control Group|The control group will receive education on insulin pen and CGM usage, maintaining their conventional multiple dose insulin therapy while implementing CGM. During the 12-week, the control group will use DIA:CONN P8 to manually input and inject the dosage of both basal and bolus insulin, only using the insulin injection and injection recording functions, same as the blind CGM period. Insulin injection dosage, time stamps, and other related details will be recorded into DIA:CONN P8 device and app.
62515339|NCT01283815|ACTIVE_COMPARATOR|Conservative management|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
62515340|NCT01283815|EXPERIMENTAL|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group
62515341|NCT04199884|EXPERIMENTAL|Active IU-focused Psychoeducation Intervention|
62515342|NCT04199884|ACTIVE_COMPARATOR|Health-focused Psychoeducation Intervention|
62515343|NCT05177159||Postoperative delirium|
62515344|NCT05177159||Non postoperative delirium|
62515345|NCT03123783|EXPERIMENTAL|Phase 1b escalation 0.03 mg/kg|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M 0.03 mg/kg and nivolumab 360 mg every 3 weeks"
62710200|NCT02612246|PLACEBO_COMPARATOR|Placebo multiple doses|Multiple oral doses of placebo solution
61973553|NCT00740701|EXPERIMENTAL|TMS|A genuine TMS coil is used to administer cerebellar transcranial magnetic stimulation pulses after letter presentation.
61973554|NCT02356224|EXPERIMENTAL|Cohort 1|SHR3824 2.5 mg/day or placebo.
61973555|NCT02356224|EXPERIMENTAL|Cohort 2|SHR3824 5 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
61973556|NCT02356224|EXPERIMENTAL|Cohort 3|SHR3824 10 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62147597|NCT03205488|ACTIVE_COMPARATOR|Cohort 1|Moderate to Advanced PD Population Randomized 1:1:1
62147598|NCT03205488|ACTIVE_COMPARATOR|Cohort 2|Early/de novo Randomized 2:1
62147599|NCT03102892|ACTIVE_COMPARATOR|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
62147600|NCT03102892|EXPERIMENTAL|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
62354287|NCT03674658|EXPERIMENTAL|A drug|Rhynorm(A drug)
62354288|NCT03674658|ACTIVE_COMPARATOR|B drug|Rytmonorm (B drug)
62515346|NCT03123783|EXPERIMENTAL|Phase 1b escalation 0.1 mg/kg|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M 0.1 mg/kg and nivolumab 360 mg every 3 weeks"
62147601|NCT01487954|EXPERIMENTAL|Arm I: alkaline water|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
62354289|NCT03106012|EXPERIMENTAL|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
62354290|NCT01235728|EXPERIMENTAL|Treatment Sequence 1|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
62515347|NCT03123783|EXPERIMENTAL|Phase 1b escalation 0.3 mg/kg|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
62515348|NCT03123783|EXPERIMENTAL|Phase 2 expansion Cohort 1|"Immunotherapy naïve, metastatic or locally advanced NSCLC~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
62515349|NCT03123783|EXPERIMENTAL|Phase 2 expansion Cohort 2|"Metastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
62515350|NCT03123783|EXPERIMENTAL|Phase 2 expansion Cohort 3|"Metastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1:~* Group A: best response of progressive disease or with stable disease \< 16 weeks~* Group B: tumor response or with stable disease ≥ 16 weeks"
62515351|NCT01522950|ACTIVE_COMPARATOR|Nebivolol|5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
62515352|NCT01522950|ACTIVE_COMPARATOR|Atenolol|25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
62710201|NCT00431964|ACTIVE_COMPARATOR|Active|azithromycin 250 mg tablets
62710202|NCT00431964|PLACEBO_COMPARATOR|Placebo|placebo tablets (matched to active drug in appearance)
62710203|NCT03829592|PLACEBO_COMPARATOR|misoprostol in neutral media|Intervention : misoprostol in a neutral media will be given to women to induce labour
61973557|NCT02356224|EXPERIMENTAL|Cohort 4|SHR3824 25 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
61973558|NCT02356224|EXPERIMENTAL|Cohort 5|SHR3824 50 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62354291|NCT01235728|EXPERIMENTAL|Treatment Sequence 2|Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
62515353|NCT01522950|PLACEBO_COMPARATOR|Placebo|"Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur."
62515354|NCT05684146|EXPERIMENTAL|Emboliner Embolic Protection Device|Emboliner embolic protection device to be used during TAVR procedures for stroke prevention
62515355|NCT05684146|ACTIVE_COMPARATOR|Sentinel Cerebral Protection System|Sentinel Cerebral Protection System to be used during TAVR procedures for stroke prevention
62710204|NCT03829592|ACTIVE_COMPARATOR|Misoprostol in acidic media|Intervention : misoprostol in acidic media will be given to induce labour
62710205|NCT03829592|SHAM_COMPARATOR|Misoprostol in alkaline media|Intervention : misoprostol in alkaline media will be given to induce labour
62710206|NCT00753532|PLACEBO_COMPARATOR|MRI(+ve),|121 volunteers in MRI(+ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 62 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 59 received placebo. They were followed up every 3 months for a period of 2 years for their blood biochemistry profile and MRI of the brain was conducted at baseline, 12 months and 24 months..
62710207|NCT00753532|PLACEBO_COMPARATOR|MRI(-ve)|120 volunteers in MRI(-ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 63 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 57 received placebo. They were followed up every 3 months for a period of 1 year for their blood biochemistry profile and MRI of the brain was conducted at baseline and 12 months.
62354292|NCT01235728|EXPERIMENTAL|Treatment Sequence 3|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
62354293|NCT01235728|EXPERIMENTAL|Treatment Sequence 4|Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
62354294|NCT01235728|EXPERIMENTAL|Treatment Sequence 5|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
62354295|NCT01235728|EXPERIMENTAL|Treatment Sequence 6|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
62354296|NCT01235728|EXPERIMENTAL|Treatment Sequence 7|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
62354297|NCT01235728|EXPERIMENTAL|Treatment Sequence 8|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
62354298|NCT02170038|EXPERIMENTAL|Arm 1|Healthy premenopausal subjects will receive multiple oral doses of Microgynon for 21days
62354299|NCT02170038|EXPERIMENTAL|Arm 2|Healthy premenopausal subjects will receive a single intramuscular dose of Noristerat
62354300|NCT02030444|NO_INTERVENTION|Standard diagnostic work-up|All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
62354301|NCT02030444|EXPERIMENTAL|Extensive diagnostic work-up|All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).
62354302|NCT03644108|EXPERIMENTAL|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
62354303|NCT01646801|EXPERIMENTAL|Experimental|NMB's Paclitaxel Drug ejecting balloon catheter
62354304|NCT04295356|ACTIVE_COMPARATOR|Auto injector|a single dose (40 mg) of CT-P17 via AI
62354305|NCT04295356|ACTIVE_COMPARATOR|Pre-filled syringe|a single dose (40 mg) of CT-P17 via PFS
62354306|NCT05444985|EXPERIMENTAL|External Oblique Intercostal Block Group|While patients are still under general anesthesia, external oblique intercostal block (EOIB) will be performed bilaterally according to appropriate asepsis/antisepsis rules before awakening.
62354307|NCT05444985|ACTIVE_COMPARATOR|Control|Patients in the control group will not have any intervention concerning regional anesthesia.
62354308|NCT02527486||No predefined subgroups|
62515356|NCT06196593|EXPERIMENTAL|All eyes|All eyes implanted with AcrySof™ IQ Vivity™ Toric intraocular lens
62515357|NCT06074302|EXPERIMENTAL|Treatment of radial cheek lines with RHA Redensity|"A total of 20 patients with facial fine lines of the cheeks/radial cheek lines will be treated with RHA Redensity. They will receive 2 treatments.~During the first treatment visit, up to 2cc of RHA Redensity will be injected in a microdroplet technique per cheek. The boundaries of the injection area will be defined by the nasolabial fold, nasojugal groove, palpebromalar groove, mandible, and preauricular crease. Patients will return in 4 weeks for another treatment visit using the same technique. At 8 weeks, they will return for a follow-up visit."
62515358|NCT01448356|EXPERIMENTAL|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~1. 25°C and 45% humidity;~2. 25°C and 65% humidity;~3. 30°C and 45% humidity;~4. 30°C and 65% humidity"
62354309|NCT05480839|EXPERIMENTAL|Manual Immediately Sequential Bilateral Cataract Surgery (MCS)|
62354310|NCT05480839|EXPERIMENTAL|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Early|
62354311|NCT05480839|EXPERIMENTAL|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Standard|
62354312|NCT01998880|EXPERIMENTAL|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
62354313|NCT01998880|ACTIVE_COMPARATOR|rituximab + chlorambucil (RClb)|Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
62515359|NCT04038086|EXPERIMENTAL|oral glucose tolerance test|
62515360|NCT04038086|OTHER|circadian rhythm|
62515361|NCT04038086|EXPERIMENTAL|effect of insulin on peptide transport|
62515362|NCT01727349|OTHER|Type 2 diabetic subject|Subject with type 2 diabetes
62710208|NCT02645864|EXPERIMENTAL|Apatinib and Irinotecan|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and irinotecan 150mg q2w. Cohort 2: apatinib 500 mg per day and irinotecan 150mg q2w. Cohort 3: apatinib 750 mg per day and irinotecan 150mg q2w.~A dose limiting toxicity (DLT) event is defined as any of the following events:~* CTCAE Grade 4 event~* Grade 3 non-hematologic toxicity including fever, nausea, vomiting, and diarrhea that continues despite optimal medical management) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If two (2) DLTs are experienced in any cohort, the study will stop and the dose of combination treatment in this cohort will be documented."
62515363|NCT01727349|OTHER|healthy subject|Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
62515364|NCT05618145||PSC population residing in Italy|All PSC patients living in Italy and aged at least 17 years can be included in the database.
62515365|NCT04517929|NO_INTERVENTION|control group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia.
62515366|NCT04517929|EXPERIMENTAL|intervention group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia and group psychotherapy.
62515367|NCT04441645|EXPERIMENTAL|the acupoint-on-head group|pressing acupoints only on head
62515368|NCT04441645|EXPERIMENTAL|the acupoint-on-body group|pressing acupoints only on body
62515369|NCT04441645|EXPERIMENTAL|the acupoint-on-head-and-body group|pressing acupoints on head and body
62515370|NCT04441645|NO_INTERVENTION|the control group|routine care
62515371|NCT01590927||20 healthy women|
62710209|NCT01928433|EXPERIMENTAL|Finafloxacin 5 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 5 days."
62710210|NCT01928433|EXPERIMENTAL|Finafloxacin 10 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 10 days."
62710211|NCT01928433|ACTIVE_COMPARATOR|Ciprofloxacin 10 days|"Intervention:~Ciprofloxacin 400 mg i.v. twice daily and Finafloxacin placebo i.v. once daily Ciprofloxacin 500 mg oral twice daily and Finafloxacin placebo tablets once daily Ciprofloxacin (i.v. and oral) for a total of 10 days."
62710212|NCT00285051|EXPERIMENTAL|Group 1|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 300 mcg of delta-8-THC per dose
62354314|NCT01998880|ACTIVE_COMPARATOR|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
62515372|NCT01473576|EXPERIMENTAL|Nitrate|Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
62515373|NCT01473576|PLACEBO_COMPARATOR|Sodium chloride|Sodium chloride placebo group
62515374|NCT03417791||kidney function recovery|the registry and follow up of consecutive patients with increased serum creatinine during hospital in 2007
62515375|NCT04747314|EXPERIMENTAL|Antidepressant (AD)|Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks. Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months.
62515376|NCT04747314|EXPERIMENTAL|Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment. Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months.
62515377|NCT04747314|EXPERIMENTAL|Antidepressant (AD) + Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will receive a combination of antidepressant medication and physical therapy for 8 months, in addition to their current opioid prescription and weaning guidelines, if applicable. No re-randomization will be done in this treatment group.
62515378|NCT04747314|EXPERIMENTAL|AD -> EFAR|"Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months. Those re-randomized to receive EFAR for another 4 months will receive a combination of antidepressant medication and physical therapy, in addition to their current opioid prescription and weaning guidelines, if applicable."
62710213|NCT00285051|EXPERIMENTAL|Group 2|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 600 mcg of delta-8-THC per dose
62710214|NCT00285051|EXPERIMENTAL|Group 3|Chemo cycle 1 - 300 mcg of delta-8-THC per dose, Chemo cycle 2 - IV Ondansetron
62710215|NCT00285051|EXPERIMENTAL|Group 4|Chemo cycle 1 - 600 mcg of delta-8-THC per dose Chemo cycle 2 - IV Ondansetron
62710216|NCT06312215|EXPERIMENTAL|Closed System Peripheral Catheters|After the area where the catheter would be inserted was cleaned with an antiseptic solution and allowed to dry, a closed-system catheter was applied. Closed-system catheters are devices that allow access through needleless mechanisms, protecting the patient from accidental needle puncture injuries. They have mechanisms preventing blood leakage or pathogen entry.
62710217|NCT06312215|NO_INTERVENTION|Control|After the area where the catheter would be inserted was cleaned with an antiseptic solution and allowed to dry, a catheter was applied.
62710218|NCT00575666|EXPERIMENTAL|A|Intranasal Insulin Treatment
62710219|NCT00575666|PLACEBO_COMPARATOR|B|Drug: Placebo
62354315|NCT01332604|EXPERIMENTAL|A|
62354316|NCT01332604|EXPERIMENTAL|B|
62354317|NCT01287546|EXPERIMENTAL|LY2875358|
62354318|NCT01287546|EXPERIMENTAL|LY2875358 + erlotinib|
62354319|NCT01287546|EXPERIMENTAL|LY2875358 at Part A highest dose|
62354320|NCT01287546|EXPERIMENTAL|LY2875358 at Part A highest dose + trametinib|
62515379|NCT04747314|EXPERIMENTAL|EFAR -> AD|"Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months. Those re-randomized to receive AD for another 4 months will be under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks."
62515380|NCT03501537|EXPERIMENTAL|Surgical treatment with free gingival graft|Free gingival graft harvested from the palate will be placed around the diseased implant
62710220|NCT03410654|EXPERIMENTAL|adult kidney transplant recipients|Adult kidney transplant recipients on tacrolimus immediate release for at least six months who are being converted to tacrolimus extended release Envarsus XR® (TAC XR) for any reason by a transplant nephrologist and are willing to participate in cognitive assessment will be offered the opportunity to participate in the study. An assessment is also made at the 3 month point as baseline.
62147602|NCT01487954|ACTIVE_COMPARATOR|Arm II: distilled water|Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy
62147603|NCT03417700|EXPERIMENTAL|Training NW|exercise and supplementation
62354321|NCT00454272|ACTIVE_COMPARATOR|1, Vancomycin|Vancomycin
62354322|NCT00454272|ACTIVE_COMPARATOR|2, Teicoplanin|Teicoplanin
62354323|NCT01877785|EXPERIMENTAL|MHAA4549A Arm|
62354324|NCT01877785|PLACEBO_COMPARATOR|Placebo Arm|
62354325|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
62515381|NCT02282202|OTHER|Off/on for 3 weeks followed by on/off for 3 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device (Aerobika ®) or no device for three weeks, then crossover for the following three weeks.
62515382|NCT04075552|EXPERIMENTAL|Participants|Participants are students from a specialized school for children with autism.
62515383|NCT01084434|EXPERIMENTAL|Probiotic group|Group of 25 volunteers consuming probiotic product once a day for 7 weeks
62515384|NCT01084434|EXPERIMENTAL|Prebiotic group|Group of 25 volunteers consuming prebiotic product once a day for 7 weeks
62515385|NCT01084434|EXPERIMENTAL|Synbiotic group|Group of 25 volunteers consuming synbiotic product once a day for 7 weeks.
62710221|NCT03505333|EXPERIMENTAL|conventional suture ligature|use of conventional sutures for hysterectomy
62710222|NCT03505333|ACTIVE_COMPARATOR|Liga Sure|use of conventional sutures plus use of Liga-sure for hysterectomy
62354326|NCT03332303|EXPERIMENTAL|Experimental: Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC)|"Estradiol Vaginal Cream, USP, 0.01%, administered once daily for 7 days.~Intervention: Drug: Estradiol Vaginal Cream, USP, 0.01%"
62354327|NCT03332303|ACTIVE_COMPARATOR|Active Comparator: Estrace® Cream|"Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%), administered once daily for 7 days.~Intervention: Drug: Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%)"
62710223|NCT06029205|EXPERIMENTAL|The Effect of Conscious Awareness-Based Educatıon on Perceived Work Stress in Nurses|mindfulness-based education
62354328|NCT03332303|PLACEBO_COMPARATOR|Placebo Comparator: Placebo (Test vehicle cream) Vaginal Cream|"Placebo (Test vehicle cream) Vaginal Cream, administered once daily for 7 days.~Intervention: Drug: Placebo (Test vehicle cream) Vaginal Cream"
62354329|NCT02938221|EXPERIMENTAL|Telemedical video-oculography|Execution of three oculomotor tests using a telemedical video-oculography system
62710224|NCT06029205|PLACEBO_COMPARATOR|The effect of stress coping training on nurses|stress coping training
62710225|NCT00822380|EXPERIMENTAL|Anemic children|
62710226|NCT05229016|EXPERIMENTAL|Positive health-related experiences and EQ-5D-5L|Reflecting on positive health-related experiences EQ-5D-5L questionnaire
62710227|NCT05229016|EXPERIMENTAL|Negative health-related experiences and EQ-5D-5L|Reflecting on negative health-related experiences EQ-5D-5L questionnaire
61973559|NCT02356224|EXPERIMENTAL|Cohort 6|SHR3824 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62354330|NCT01453998|EXPERIMENTAL|GSK217744 Group 1|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
62515386|NCT01084434|PLACEBO_COMPARATOR|Placebo group|Group of 25 volunteers consuming placebo product once a day for 7 weeks
62515387|NCT00836719|EXPERIMENTAL|Polyphenon E|Standarized green tea extract containing 50% EGCG
62147604|NCT03417700|EXPERIMENTAL|Training HICT and vitamin D|Training HICT plus vitamin D
62515388|NCT02355756|EXPERIMENTAL|Active|Intradermal injection of maxadilan solution
62515389|NCT02355756|PLACEBO_COMPARATOR|Placebo|Intradermal injection of placebo (=vehicle) solution
62515390|NCT06502587|EXPERIMENTAL|blood flow restriction training|we will apply blood flow restriction training with low intensity exercises on patients with knee osteoarthritis to check pain,quality of life and range of motion.
62515391|NCT06502587|ACTIVE_COMPARATOR|ultrasound application only|in this group we will apply ultrasound therapy on knee joint for 7 minutes.
62147605|NCT03417700|EXPERIMENTAL|Placebo|placebo Vitamin D
62147606|NCT00797550|ACTIVE_COMPARATOR|Control|The Control arm of the study will receive bone autograft.
62147607|NCT00797550|EXPERIMENTAL|Treatment|The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
62147608|NCT04383392|EXPERIMENTAL|Rate adaptive pacing|Turn on Rate adaptive pacing
62710228|NCT05229016|NO_INTERVENTION|Control and EQ-5D-5L|No intervention/ control group EQ-5D-5L questionnaire
62515392|NCT02610920|EXPERIMENTAL|Iron-tracer Injection and Biopsy|Single injection of 30mg of iron sucrose followed by axillary ultrasound-guided biopsy of lymph node within 2 hours.
62515393|NCT01342978||oropharyngeal cancer case|208 oropharyngeal cancer cases were enrolled
62515394|NCT01342978||partner or spouse of case|110 partners of patients with oropharyngeal cancer were enrolled
62515395|NCT01342978||control|A convenience group of 106 non-cancer controls were enrolled at some study sites at cancer screening events
62515396|NCT00536484|EXPERIMENTAL|Fesoterodine (Double-Blind)|
62147609|NCT04383392|ACTIVE_COMPARATOR|No Rate adaptive pacing|Turn off Rate adaptive pacing
62147610|NCT02302157|EXPERIMENTAL|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
62147611|NCT05056194|EXPERIMENTAL|Valiloxybate|XW10172 Modified Release (MR) Granules for Oral Suspension
62515397|NCT00536484|PLACEBO_COMPARATOR|Placebo (Double-Blind)|
62515398|NCT01699529|EXPERIMENTAL|Renal Denervation|
62147612|NCT05056194|PLACEBO_COMPARATOR|Placebo|Placebo Granules for Oral Suspension
62147613|NCT01138657|EXPERIMENTAL|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses every other week (eow) starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
62147614|NCT01138657|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection at Baseline followed by eow dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
62147615|NCT01703598|EXPERIMENTAL|DBS surgery|Single arm
62354331|NCT01453998|EXPERIMENTAL|GSK217744 Group 2|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
62354332|NCT01453998|ACTIVE_COMPARATOR|Infanrix hexa Group|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
62354333|NCT04864678||Young people who are experiencing or at risk of homelessness|Young people aged 15-24 years who have accessed a homeless youth service, refuge, or flexible learning center in Melbourne, Australia.
62354334|NCT02641314|EXPERIMENTAL|metronomic therapy|Treatment consists of eight alternating 28-day-cycles of propranolol, celecoxib, cyclophosphamide, vinblastine, etoposide (PCCVE) and of propranolol, celecoxib, cyclophosphamide, vinblastine (PCCV) followed by five cycles PCCV resulting in a total of 13 cycles (364 days of treatment)
62354335|NCT04155658|EXPERIMENTAL|Experimental SMFP Toothpaste|Toothpaste containing 1450ppm SMFP with additional calcium and phosphate
62354336|NCT04155658|ACTIVE_COMPARATOR|SMFP Toothpaste|Toothpaste containing 1450ppm SMFP
62354337|NCT04155658|PLACEBO_COMPARATOR|Negative control toothpaste|Toothpaste with no fluoride
62354338|NCT02884518|EXPERIMENTAL|patient group|The patient group recruits subjects diagnosed with first episode psychosis which occurred within 2 years and having been treated with antipsychotics for 1 year. Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity. And patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
62515399|NCT02207335|EXPERIMENTAL|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
62515400|NCT02207335|ACTIVE_COMPARATOR|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
62515401|NCT02691832|EXPERIMENTAL|research arm|"the trial contains one group which will undergo the described protocol three times:~1. connected to rectal thermistor and to the double sensor~2. connected to rectal thermistor, double sensor and cooling system of Icetron Technologies Ltd.~3. connected to rectal thermistor and to the double sensor integrated into a helmet."
62515402|NCT01908894|EXPERIMENTAL|BIOD-123|SC administration of 0.20 U/kg
62147616|NCT04588207|EXPERIMENTAL|On Urea, Then Off Urea|Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
62515403|NCT01908894|EXPERIMENTAL|BIOD-125|SC administration of 0.20 U/kg
62515404|NCT01908894|ACTIVE_COMPARATOR|Humalog|SC administration of 0.20 U/kg
62515405|NCT03811132||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D \< 22, PAID \< 40)
62515406|NCT03811132||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D \< 22, PAID ≥ 40)
62515407|NCT03811132||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID \< 40)
62515408|NCT03811132||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
62147617|NCT04588207|EXPERIMENTAL|Off Urea, Then On Urea|Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)
62515409|NCT00411398|EXPERIMENTAL|Memantine 5-20mg/d flexible dose|Memantine tablets 5-20mg/d flexible dose
62515410|NCT03351231|EXPERIMENTAL|Dose Escalation|BMS-986242 administered in combination with Nivolumab
62515411|NCT03351231|EXPERIMENTAL|Dose Expansion|BMS-986242 administered in combination with Nivolumab
62515412|NCT02056470|EXPERIMENTAL|Freedom Total Knee Replacement|Freedom Total Knee
62515413|NCT05850052|OTHER|Efficacy of conventional direct laryngoscopy|The researchers seeks to compare the efficacy of conventional direct laryngoscopy using a Macintosh blade,
62515414|NCT05850052|EXPERIMENTAL|McGrath Videolaryngoscope for rapid endotracheal intubation|The researchers will use the McGrath videolaryngoscope for rapid sequence endotracheal intubation.
62515415|NCT00978913|EXPERIMENTAL|DC vaccination and Cyclophosphamide|
62515416|NCT03606720|EXPERIMENTAL|group(A) low level laser therapy|composed of 30 patients who received pelvic stabilization exercises and low level laser therapy For 12 sessions over six week's period by 2 sessions per week.
62515417|NCT03606720|ACTIVE_COMPARATOR|group(B) pelvic stabilization exercises only|composed of 30 patients who pelvic stabilization exercises only For 12 sessions over six week's period by 2 sessions per week.
62515418|NCT03606720|ACTIVE_COMPARATOR|group (C) low level laser therapy only|composed of 30 patients who low level laser therapy only For 12 sessions over six week's period by 2 sessions per week.
62515419|NCT05918822|EXPERIMENTAL|Part 1, Sequence 1: Treatment A + Treatment B + Treatment C|Participants will receive maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 1 under fasting condition (Treatment A), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 under fasting condition (Treatment B), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of a minimum of 72 hours between each treatment.
62515420|NCT05918822|EXPERIMENTAL|Part 1, Sequence 2: Treatment A + Treatment C + Treatment B|Participants will receive maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 1 under fasting condition (Treatment A), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal (Treatment C), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 under fasting condition (Treatment B). There will be a washout period of a minimum of 72 hours between each treatment.
62515421|NCT05918822|EXPERIMENTAL|Part 1, Sequence 3: Treatment B + Treatment A + Treatment C|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 under fasting condition (Treatment B), followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 2 under fasting condition (Treatment A), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of a minimum of 72 hours between each treatment.
62515422|NCT05918822|EXPERIMENTAL|Part 1, Sequence 4: Treatment B + Treatment C + Treatment A|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 under fasting condition (Treatment B), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal (Treatment C), and further followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 3 under fasting condition (Treatment A). There will be a washout period of a minimum of 72 hours between each treatment.
62515423|NCT05918822|EXPERIMENTAL|Part 1, Sequence 5: Treatment C + Treatment A + Treatment B|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 2 under fasting condition (Treatment A), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 under fasting condition (Treatment B). There will be a washout period of a minimum of 72 hours between each treatment.
62515424|NCT05918822|EXPERIMENTAL|Part 1, Sequence 6: Treatment C + Treatment B+ Treatment A|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 under fasting condition (Treatment B), and further followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 3 under fasting condition as (Treatment A). There will be a washout period of a minimum of 72 hours between each treatment.
62515425|NCT05918822|EXPERIMENTAL|Part 2: Treatment D: maribavir 200 mg|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 under fasting condition (Treatment D).
62515426|NCT05918822|EXPERIMENTAL|Part 2, Treatment E: rabeprazole 20 mg + maribavir 200 mg|Participants will receive rabeprazole single 20 mg tablet, once daily on Days 1 to 5 of Treatment Period 2 under fasting condition followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose, 2 hours after rabeprazole dosing on morning of Day 5 of Treatment Period 2 under fasting condition (Treatment E). There will be a washout period of a minimum of 72 hours between maribavir dosing in Treatment Period 1 and first dose of rabeprazole in Treatment Period 2.
62515427|NCT03585959|EXPERIMENTAL|Fluoroscopic Navigation Arm|An Electromagnetic navigation bronchoscopy (ENB) system which provides enhanced three-dimensional fluoroscopy to improve lesion visibility and to compensate for CT-to-body divergence, with an integrated real-time local registration feature allowing the operator to update the catheter position relative to the target during the procedure.
62515428|NCT05407506|EXPERIMENTAL|THYROID AI|
62354339|NCT02884518|OTHER|healthy control group|Screening tests for healthy volunteers included physical examination, vital signs, laboratory will test (hematology, blood chemistry, and urinalysis), and a 12-lead electrocardiograms. A psychiatric interview with the Structured Clinical Interview for text revision of the Diagnostic and Statistical Manual of Mental Disorders -IV(DSM-IV-TR) Axis I disorders, Research Version, Nonpatient Edition (SCID-I/NP) (First et al. 2002) will be conducted. Subjects with any medically significant abnormality on investigations and/or psychiatric disease will be excluded. Also, healthy control group will take a PET scan at 0, 2, 4, 6, and 8 week and clinical scales at baseline.
62147618|NCT01159600|EXPERIMENTAL|BI 10773 Arm 2|BI 10773 once daily high dose
62354340|NCT06157372||Non-Infection group|Participants received traditional etiological culture of suspected site of infection.
62147619|NCT01159600|PLACEBO_COMPARATOR|Placebo|Placebo matching BI 10773
62147620|NCT01159600|EXPERIMENTAL|BI 10773 open-label|BI 10773 once daily high dose open label
62147621|NCT01159600|EXPERIMENTAL|BI 10773 Arm 1|BI 10773 once daily low dose
62147622|NCT02469025|EXPERIMENTAL|Resting position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in a resting position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
62515429|NCT05871086|EXPERIMENTAL|Coenzyme Q10 Group|Patients will receive their JIA standard treatment plus 100 mg Coenzyme Q10 capsules daily for 3 months.
62515430|NCT05871086|PLACEBO_COMPARATOR|Control Group|Patients will receive their standard JIA treatment plus placebo
62515431|NCT02486913|NO_INTERVENTION|Conventional Health Check|Patients undergoing conventional National Health Service Health Check
62515432|NCT02486913|EXPERIMENTAL|Enhanced Health Check|Patients undergoing National Health Service Health Check enhanced by risk report
62515433|NCT05904249|EXPERIMENTAL|Internet Based Synchronized Telerehabilitation Group (Group 1)|The treatments of the participants who meet the inclusion criteria in the study will be conducted remotely via instant video communication. The Specialist Physiotherapist will apply the necessary exercises, verbal guidance or repetition of the movements shown, according to the patient's condition, synchronized via instant video and audio calls (Whatsapp or Zoom).
62515434|NCT05904249|EXPERIMENTAL|Face-to-Face Rehabilitation Group (Group 2)|The treatments of the participants that meet the inclusion criteria of the study will be administered by Specialist Physiotherapist. The progress of the patients will be regularly followed up on a weekly basis, and treatments will be applied in accordance with the program in rehabilitation.
62515435|NCT03560921||Stored blood transfusion|measurement of urinary NGAL
62515436|NCT03560921||Fresh blood transfusion|measurement of urinary NGAL
62515437|NCT04954378||Positive lymph node metastasis|pathological diagnosis :Positive lymph node metastasis
62515438|NCT04954378||Negative lymph node metastasis|pathological diagnosis :Negative lymph node metastasis
62515439|NCT01508819||1|Guidelines for ICU admission of elderly patients arriving in Emergency Departments with a life threatening conditions
62515440|NCT01508819||2|no intervention
62515441|NCT04008537|EXPERIMENTAL|Halcyon kV CBCT imaging|-Each patient will undergo five Halcyon kV CBCT imaging sessions that will then be utilized to simulate the CBCT-guided online ART workflow. Halcyon imaging will be scheduled as per the patient's schedule and availability, with intent but not mandate for imaging on the same days as clinical treatments, preceding clinical treatment. Multiple images may be acquired in one session but no more than 6 Halcyon kV CBCT images will be acquired per day. No more than 6 additional Halcyon kV CBCT images will be acquired in one imaging session and no more than 10 total additional Halcyon kV CBCT images for the duration of the study
62710229|NCT05229016|EXPERIMENTAL|Positive health-related experiences and PROMIS|Reflecting on positive health-related experiences PROMIS Global health v1.2 questionnaire
62147623|NCT02469025|EXPERIMENTAL|End range position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in an end range position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
62147624|NCT03838757||Patients|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
62147625|NCT03838757||Healthy controls|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
62515442|NCT00724373||Participants with genotype 1 Hepatitis C Virus infection.|Participants with genotype 1 Hepatitis C Virus (HCV) infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months
62515443|NCT04882137|NO_INTERVENTION|Standard Education|Pediatric Providers in this arm will receive a continuing medical education on etonogestrel contractive implant but will not receive specialist coaching on how to manage side effects.
62515444|NCT04882137|EXPERIMENTAL|Standard Education plus Coaching|Pediatric Providers in this arm will receive a continuing medical education program on etonogestrel contraceptive implant. Providers in this arm will also receive a tip-sheet on how to manage side effects as well as a number to directly access a specialist who places them if needed.
62515445|NCT02589158|EXPERIMENTAL|Evotaz®, washout, then Rezolsta®|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days, undergo a ten-day wash out period and then take Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
62515446|NCT04660305|EXPERIMENTAL|AT278|Single subcutaneous injection 0.3U/kg
62515447|NCT04660305|ACTIVE_COMPARATOR|NovoRapid|Single subcutaneous injection 0.3U/kg
62710230|NCT05229016|EXPERIMENTAL|Negative health-related experiences and PROMIS|Reflecting on negative health-related experiences PROMIS Global health v1.2 questionnaire
62710231|NCT05229016|NO_INTERVENTION|Control and PROMIS|No intervention/ control group PROMIS Global health v1.2 questionnaire
62710232|NCT05229016|EXPERIMENTAL|Positive health-related experiences and SF-36|Reflecting on positive health-related experiences SF-36 questionnaire
62710233|NCT05229016|EXPERIMENTAL|Negative health-related experiences and SF-36|Reflecting on negative health-related experiences SF-36 questionnaire
62710234|NCT05229016|NO_INTERVENTION|Control and SF-36|No intervention/ control group SF-36 questionnaire
62710235|NCT05229016|EXPERIMENTAL|Positive health-related experiences and SNOT-22|Reflecting on positive health-related experiences SNOT-22 questionnaire
62710236|NCT05229016|EXPERIMENTAL|Negative health-related experiences and SNOT-22|Reflecting on negative health-related experiences SNOT-22 questionnaire
62710237|NCT05229016|NO_INTERVENTION|Control and SNOT-22|No intervention/ control group SNOT-22 questionnaire
62515448|NCT04399642|ACTIVE_COMPARATOR|Standard|Patients receiving single dose of IV cefazolin (2 grams if \< 120kg; 3 grams if \>120kg) 10-60 minutes before incision
62515449|NCT04399642|EXPERIMENTAL|Vanco|Patients receiving a single dose of IV cefazolin (2 grams if \< 120kg; 3 grams if \>120kg) 10-60 minutes before incision + a single dose of intra-articular vancomycin powder (1 gram) before articulation (hip or knee) closure
62515450|NCT01005329|EXPERIMENTAL|Treatment (IMRT, cisplatin,bevacizumab,carboplatin,paclitaxel)|Patients undergo pelvic IMRT once daily, 5 days a week, for 5 weeks. Patients may also undergo optional nodal boost radiotherapy and/or vaginal brachytherapy boost. Patients also receive concurrent cisplatin IV over 1 hour on days 1 and 29 and bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Beginning 4-6 weeks after completing IMRT, cisplatin, and bevacizumab, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment with carboplatin and paclitaxel repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62515451|NCT01421199|OTHER|Myringotomy|On arm
62515452|NCT05985382|EXPERIMENTAL|Lower Body Resistance Exercise|Participants will perform a leg extension exercise with weight that is 75% of their estimated 1-repetition maximum (1-RM) for 3 sets of 10 repetitions.
62515453|NCT05985382|EXPERIMENTAL|Upper Body Resistance Exercise|Participants will perform a shoulder press with weight that is 75% of their estimated 1-repetition maximum (1-RM) for 3 sets of 10 repetitions.
62515454|NCT02168725|EXPERIMENTAL|briciclib|The starting dose of briciclib in the Escalation Stage will be 17 mg/week, with subsequent dose escalation levels of 35 mg, 70 mg, 140 mg, 280 mg, 560 mg, and 1120 mg. The dose of briciclib in the RPTD Confirmation Stage will be the dose as determined during the escalation stage. At each dose level, briciclib will be administered as a 2-hour intravenous infusion, once-a-week per 3-week cycles.
62515455|NCT06014528|EXPERIMENTAL|Experimental Arm|IN10018+PLD
62515456|NCT06014528|PLACEBO_COMPARATOR|Control Arm|Placebo of IN10018+PLD
62515457|NCT05735964|EXPERIMENTAL|ICG|Patients in this single arm will receive ICG during their surgery
62710238|NCT05229016|EXPERIMENTAL|Positive health-related experiences and RSDI|Reflecting on positive health-related experiences RSDI questionnaire
62710239|NCT05229016|EXPERIMENTAL|Negative health-related experiences and RSDI|Reflecting on negative health-related experiences RSDI questionnaire
62710240|NCT05229016|NO_INTERVENTION|Control and RSDI|No intervention/ control group RSDI questionnaire
62710241|NCT05229016|EXPERIMENTAL|Positive health-related experiences and mini-RQLQ|Reflecting on positive health-related experiences Mini-RQLQ questionnaire
62710242|NCT05229016|EXPERIMENTAL|Negative health-related experiences and mini-RQLQ|Reflecting on negative health-related experiences Mini-RQLQ questionnaire
62710243|NCT05229016|NO_INTERVENTION|Control and mini-RQLQ|No intervention/ control group Mini-RQLQ questionnaire
62710244|NCT05136716|ACTIVE_COMPARATOR|Control|Children in this group received traditional physical therapy
62515458|NCT02208115|EXPERIMENTAL|Meal composition - High GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
62515459|NCT02208115|EXPERIMENTAL|Meal composition - Low GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
62710245|NCT05136716|EXPERIMENTAL|Study|Children in this group received the same traditional physical therapy plus hyperbaric oxygen therapy
62710246|NCT02507986|ACTIVE_COMPARATOR|7-Day Holter monitor|This arm will receive a 7-Day Holter monitor directly after randomization.
62515460|NCT04528888|ACTIVE_COMPARATOR|LMWH group|The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). Patients in this group will be administered enoxaparin at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment with enoxaparin will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The treatment will be administered subcutaneously, daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
62515461|NCT04528888|EXPERIMENTAL|LMWH + steroids group|"The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization).~Patients in this group will receive enoxaparin and methylprednisolone. Enoxaparin will be administered at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered subcutaneously daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14."
62539470|NCT04918485|NO_INTERVENTION|the control group receive normal process before surgery|
62539471|NCT06393946||Dupilumab|The information will be collected during consultation as part of the patient's usual follow-up.
62539472|NCT01324505|EXPERIMENTAL|One-sequence cross-over arm|
62539473|NCT00052299|EXPERIMENTAL|ARM A|GO + MICE for remission induction followed by GO + mini-ICE for consolidation
62539474|NCT00052299|ACTIVE_COMPARATOR|ARM B|MICE for remission induction followed by mini-ICE for consolidation
62539475|NCT01398215||transvaginal NOTES|
62710247|NCT02507986|EXPERIMENTAL|Single lead ECG device|This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.
62710248|NCT05960578|EXPERIMENTAL|Treatment (golimumab, apalutamide)|Patients receive golimumab SC every 4 weeks for 6 doses and apalutamide PO daily. Treatment with apalutaminde continues in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy at baseline and during cycle 4. Patients also undergo CT scans or MRI, PSMA PET, and collection of blood samples at baseline, during cycle 4, and at end of treatment.
62147626|NCT05787236||Secukinumab|Clinical psoriasis patients who received secukinumab treatment in Indonesia from 1 August 2017 to 31 October 2020.
61973560|NCT02356224|EXPERIMENTAL|Cohort 7|SHR3824 200 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
62710249|NCT02250989||Hyperinsulinemia/Euglycaemia|In this group study, a condition of Hyperinsulinemia/Euglycaemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
62710250|NCT02250989||Hyperinsulinemia/Hyperglycemia|In this group study, a condition of Hyperinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
62710251|NCT02250989||Hypoinsulinemia/Hyperglycemia group|In this group study, a condition of Hypoinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
62710252|NCT04955821||VAP group|Children with respiratory tract infection by mechanical ventilation
62710253|NCT02738463||Group 1 case|This group will include 32 pregnant females whose fetuses show intrauterine growth restriction at full term ( the 32 neonates with birth weight less than 10th percentile for corresponding gestational age will be included as small for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
62710254|NCT02738463||Group 2 control|This group will include at least 32 pregnant females whose fetuses are appropriate for gestational age at full term ( the 32 neonates with birth more than or equal to the 10th percentile for corresponding gestational age will be included as average for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
61973561|NCT03153254|EXPERIMENTAL|Healthy persons|Test upper limb robot assisted therapy device. During 1 session of 1/2 hour.
61973562|NCT03153254|EXPERIMENTAL|Stroke patients|Training with new upper limb robot assisted therapy device. During 2 to 5 sessions of 1/2 hour.
61973563|NCT00319644|EXPERIMENTAL|Minibal Arm|Using Mini bronchoalveolar lavage
62147627|NCT02819999|EXPERIMENTAL|Rovalpituzumab Tesirine|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
62147628|NCT02819999|EXPERIMENTAL|Rovalpituzumab Tesirine followed by Cisplatin, Etoposide|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion
62147629|NCT02819999|EXPERIMENTAL|Rovalpituzumab Tesirine with Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusion
62147630|NCT02819999|EXPERIMENTAL|Rovalpituzumab Tesirine following Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
62147631|NCT01404338|ACTIVE_COMPARATOR|Active Arm|1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
61973564|NCT00319644|NO_INTERVENTION|Tracheal Aspirates|standard of care for ICU.
62147632|NCT01404338|PLACEBO_COMPARATOR|Vehicle Arm|Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
62147633|NCT00794807|EXPERIMENTAL|Alefacept|
62147634|NCT01686152|EXPERIMENTAL|Investigational Test Product|Imiquimod Cream, 3.75% (Teva)
62147635|NCT01686152|ACTIVE_COMPARATOR|Reference Listed Drug|Zyclara® (imiquimod Cream), 3.75% (Medicis)
62147636|NCT01686152|PLACEBO_COMPARATOR|Vehicle|Vehicle of Test Product (Teva)
62147637|NCT01295099|ACTIVE_COMPARATOR|5-Fluorouracil|Patients with small keloidal scars to have intralesional 5FU injected
62147638|NCT01295099|ACTIVE_COMPARATOR|Radiotherapy|Large keloid scars undergo extralesional excision and radiotherapy
62147639|NCT01295099|ACTIVE_COMPARATOR|TAC|
61973565|NCT00292695|EXPERIMENTAL|chemoradiation|Chemoradiation: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
61973566|NCT02667574|OTHER|open-label|Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance
62354341|NCT06157372||Infection group|Participants received traditional etiological culture, metagenomic next-generation sequencing of infectious sites.
61973567|NCT04406727|EXPERIMENTAL|UB-421|"2-arm Comparison Phase: UB-421(25 mg/kg, every 2 weeks) in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
61973568|NCT04406727|ACTIVE_COMPARATOR|Placebo|"2-arm Comparison Phase: Placebo in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
62147640|NCT02792907|EXPERIMENTAL|Compressive Stockings group|Patients with compressive stockings at the operated foot for 4 weeks
62147641|NCT02792907|NO_INTERVENTION|No compressive stockings group|Patients with no compressive stockings at the operated foot
62147642|NCT05829668|EXPERIMENTAL|ABA-based functional analysis and treatment|Assessment and Treatment for problem behavior exhibited by children with CdLS
62147643|NCT05829668|NO_INTERVENTION|No Problem behavior Control Group|Quarterly Monitoring of children with CdLS that do not exhibit problem behavior
62147644|NCT01829594|EXPERIMENTAL|Case Management|
62147645|NCT00506896|ACTIVE_COMPARATOR|1|
62147646|NCT04704440|EXPERIMENTAL|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62147647|NCT04704440|SHAM_COMPARATOR|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62147648|NCT04704440|EXPERIMENTAL|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62147649|NCT04704440|ACTIVE_COMPARATOR|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
62147650|NCT00249405|EXPERIMENTAL|1|citalopram
62147651|NCT00249405|PLACEBO_COMPARATOR|2|Placebo
62147652|NCT03541525||Affected patients|Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
62147653|NCT03541525||Non affected relatives|Biological samples of blood for all relatives.
62147654|NCT05171426||incidental cancer|familial adenomatous polyposis with incidental cancer
62710255|NCT01346124|EXPERIMENTAL|IMPT|High dose IMPT
62539476|NCT04480021|EXPERIMENTAL|Multiuser Interactive Health Response Application (MITHRA)|Randomization is at the level of the Community Based Organization (CBO). CBOs randomized to MITHRA will have access to the MITHRA app on tablets. MITHRA app will include depression screening and behavioral activation modules.
62710256|NCT04708522|EXPERIMENTAL|Breath Control|Participants in the breath control study arm will be given a breathing exercise that is to be completed in a comfortable upright seated posture. This intervention exercise will be completed daily for a period of 8 weeks.
62539477|NCT04480021|PLACEBO_COMPARATOR|Enhanced Usual Care (EUC)|CBOs randomized to EUC will receive standardized monthly group education (45 min) regarding the symptoms of depression
62710257|NCT04708522|EXPERIMENTAL|Guided Mindfulness|Participants in the guided mindfulness study arm will be lead through a seated mindfulness exercise. This intervention exercise will be completed daily for a period of 8 weeks.
62710258|NCT04708522|SHAM_COMPARATOR|Control|Participants in the control group will receive a sham intervention. The sham intervention will involve minimal instructed meditation exercise. This intervention exercise will be completed daily for a period of 8 weeks.
61973569|NCT03157258|EXPERIMENTAL|Social Network Endorsement|All participants will receive a brief single care-related counseling session and referral to HIV medical care upon enrollment. After randomization to this arm, all members of HIV+ social networks will attend a multi-session group intervention during which they will be trained to deliver messages endorsing compliance with medical guidelines and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained how to deliver effective messages.
61973570|NCT03157258|ACTIVE_COMPARATOR|HIV Counseling and Referral to Care|All study participants will receive a brief single care-related counseling session and referral to HIV medical care at baseline.
62354342|NCT04681729|EXPERIMENTAL|Dupilumab|Dose regimens, on top of regular or as needed non-sedating H1-antihistamine
62354343|NCT04681729|PLACEBO_COMPARATOR|Matched Placebo|Placebo, on top of regular/as needed non-sedating H1-antihistamine
62354344|NCT06106243|ACTIVE_COMPARATOR|The conventional heat pressing temporary flexible maxillary removable partial denture|
62354345|NCT06106243|EXPERIMENTAL|3D-printed and digitally designed temporary flexible maxillary removable partial denture .|
62354346|NCT00753688|PLACEBO_COMPARATOR|PLACEBO|matching placebo 800 mg once daily orally
62354347|NCT00753688|EXPERIMENTAL|PAZOPANIB|800 mg once daily orally
62354348|NCT01519401|ACTIVE_COMPARATOR|3 mg drospirenone and 20 µg ethinyl-estradiol|
62354349|NCT01519401|ACTIVE_COMPARATOR|3 mg drospirenone and 30 µg ethinyl-estradiol|
62354350|NCT00444470|ACTIVE_COMPARATOR|A|Active drug being tested in this study is Tranexamic Acid
62354351|NCT00444470|PLACEBO_COMPARATOR|B|Normal saline was used as the Placebo
62354352|NCT06140277|EXPERIMENTAL|Chitosan|group will be treated using chitosan as a replacement of bone particles with collagen membrane after tooth extraction
62354353|NCT06140277|ACTIVE_COMPARATOR|Allograft|after extraction, the group will be treated using the gold standard protocol which is the (allograft) bone particles with collagen membrane.
62354354|NCT06140277|PLACEBO_COMPARATOR|placebo|the extraction will be done without placing any bone material inside
62354355|NCT00879437|EXPERIMENTAL|valproic acid and radiation, followed by valproic acid and bevacizumab|radiation phase (week 1-6): daily valproic acid and radiation, for approximately 6 weeks post-radiation phase (week 7-10): valproic acid daily maintenance phase (starting week 11): daily valproic acid, and bevacizumab once every 2 weeks; to continue for a maximum duration of 2 years
62354356|NCT05129761||• Patient with a clinical history of cough|Syrup Hydryllin ( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine) in the symptomatic management of cough in routine practice by physicians. Subjects will be observed for overall safety and effectiveness of study drug from visit 1 (baseline visit, screening, and start of treatment), to visit 2 (Week 1-2, end of treatment) in the routine practice.
62354357|NCT01225172|EXPERIMENTAL|BMS-754807|
62354358|NCT01225172|EXPERIMENTAL|BMS-754807 + letrozole|
62710259|NCT05619237|NO_INTERVENTION|Control Period|"Patients receive the current standard of care for their chronic wound in the first four weeks of enrollment~Standard of care (SOC) involves:~* Offloading of pressure as needed~* High compression bandaging, as needed~* Debridement, as needed~* Nutrition management, as needed~* SOC dressings, such as silver/iodine dressings, antibiotic ointment~* Management of infection~* Management of pain during debridement, as needed"
62710260|NCT05619237|EXPERIMENTAL|Intervention Period|Patients receive the intervention, NanoSALV wound dressing, in the consecutive four weeks following the control period
62354359|NCT01577199|ACTIVE_COMPARATOR|High dose gonadotropins|High dose gonadotropins protocol compared to Low-dose Clomiphene
62539478|NCT01782430|EXPERIMENTAL|Standard oxygenation|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
62710261|NCT02428426||gastric intestinal metaplasia|patients were diagnosed gastric intestinal metaplasia
62710262|NCT02428426||gastritis|patients were diagnosed non atrophic gastritis
62710263|NCT01858727|ACTIVE_COMPARATOR|forced air warming group|30 minutes before the preoperative will use forced air warming.
62710264|NCT01858727|NO_INTERVENTION|control group|do not active heating group
62710265|NCT01354093||MacTel Type 2 20 mg/day dose group|Participants will have macular telangiectasis type 2 as confirmed by the reading center. Participants will take 20 mg of zeaxanthin per day.
62147655|NCT06466551|EXPERIMENTAL|Pain scores intravenous catheterization between the groups|
62147656|NCT06466551|EXPERIMENTAL|Fear scores intravenous catheterization between the groups|
62354360|NCT01577199|EXPERIMENTAL|Low-dose Clomiphene|clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins
62354361|NCT06354699||Group Elective|Patient is undergoing a surgical procedure for circumcision, hypospadias, orchidopexy or laparoscopic appendicectomy.
62354362|NCT06354699||Group Emergency|Patient is undergoing a surgical procedure for laparoscopic appendicectomy or scrotal exploration.
62354363|NCT01677507|EXPERIMENTAL|timolol|To compare the variation in response to timolol between individuals
62354364|NCT01677507|ACTIVE_COMPARATOR|latanoprost|To compare the variation in response to latanoprost between individuals
62515462|NCT04528888|EXPERIMENTAL|UFH + steroid group|The treatments will be initiated as soon as possible after randomization (maximum 12h). Patients will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
62147657|NCT04053699||Patients undergoing treatment with a VWF-containing product|Patients with type 3, type 2 (except 2N), or severe type 1 VWD undergoing routine on-demand treatment with a VWF-containing product over a period of 6 months
62147658|NCT01750788||Group 1|
62147659|NCT02677766|EXPERIMENTAL|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
62515463|NCT01020799|EXPERIMENTAL|AZD7268|The AZD7268 15 mg BID arm consisted of 3 AZD7268 5 mg capsules dosed orally in the morning and evening. In addition, 2 placebo tablets to match encapsulated escitalopram tablets were dosed orally in the morning only.
62515464|NCT01020799|PLACEBO_COMPARATOR|Placebo|The placebo arm consisted of 3 placebo capsules to match AZD7268 capsules dosed orally in the morning and evening. In addition, 2 placebos to match encapsulated escitalopram tablets were dosed orally in the morning only.
62515465|NCT01020799|ACTIVE_COMPARATOR|Escitalopram|The escitalopram 20 mg QD arm consisted of 3 placebo to match AZD7268 capsules dosed orally in the morning and evening. In addition, during Week 1, one encapsulated 10-mg escitalopram tablet and 1 placebo to match encapsulated escitalopram tablet were dosed orally in the morning only. During Weeks 2 through 4, two encapsulated 10-mg escitalopram tablets were dosed orally in the morning only.
62515466|NCT05676255|EXPERIMENTAL|Cognitively-Based Compassion Training for Survivors (CBCT-S)|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
62515467|NCT05676255|EXPERIMENTAL|Cognitively-Based Compassion Training for Dyads (CBCT-D)|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
62515468|NCT05676255|ACTIVE_COMPARATOR|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
62515469|NCT04594915||Study Group|Patients diagnosed with AF who are currently using Edoxaban for stroke prevention in Turkey.
62710266|NCT01354093||MacTel Type 2 10 mg/day dose group|Participants will have macular telangiectasia type 2 as confirmed by the reading center. Participants will take 10 mg of zeaxanthin per day.
62710267|NCT02398331|EXPERIMENTAL|arm|Standardised information and education on sexuality in women with spinal cord injury
62710268|NCT02398331|NO_INTERVENTION|Control arm|Usual care (no structured information or education on sexuality)
62710269|NCT01765400|ACTIVE_COMPARATOR|Prasugrel|Prasugrel oral 10 mg once daily for 2 weeks
62710270|NCT01765400|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel oral 75 mg once daily for 2 weeks
62710271|NCT03037970|EXPERIMENTAL|ABSOLVE|Type I collagen sheet soaked in a solution containing rhPDGF-BB.
62147660|NCT02677766|ACTIVE_COMPARATOR|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
62147661|NCT06031818||Patients with HCC|Patients who underwent curative liver resection for HCC in the First Affiliated Hospital of Sun Yat-Sen University in China.
62147662|NCT00491101||1|Children with asthma, both genders, from 7-18 years old.
62147663|NCT02530892||Measurement Group|"This group contains oocytes and embryos which have their mechanical properties (elasticity and viscosity) measured prior to fertilization (oocytes) or within 24 hours after fertilization (embryos). The investigators are calling this mechanical measurement the EmbryoHug. All participants in the study will have half their embryos measured in this group. Outcomes will be evaluated after 6 days of embryo culture, at the time of pregnancy test, at 5-6 weeks, and at 8-10 weeks, and correlated with EmbryoHug parameters."
62710272|NCT03037970|PLACEBO_COMPARATOR|Placebo|Collagen sheet soaked with saline solution.
62710273|NCT00030264|EXPERIMENTAL|Methotrexate & Vinblastine|Methotrexate and Vinblastine will be given once a week for the first 26 weeks and then every two weeks for the next 26 weeks or until disease progression (whichever occurs first).
62354365|NCT02824848|ACTIVE_COMPARATOR|Passive Stretching|Passive Stretching intervention components include static passive stretching, active assistive range of motion, assisted stretching of the involved cervical musculature, and associated strengthening activities aimed to elicit head righting in developmentally appropriate positions and during developmentally appropriate movement transitions. Intervention is progressed by increasing head tilt angles, duration of head righting, and frequency and number of repetitions.
62710274|NCT06317935|OTHER|ArmeoSenso|ArmeoSenso virtual reality application will be applied to group A in the 0-3 weeks of the study and to group B in the 3-6 weeks.
62710275|NCT06317935|OTHER|Traditional rehabilitation|Traditional rehabilitation (physiotherapy and occupational therapy) approaches will continue to be applied to groups A and B at all stages of the research.
62710276|NCT04552054|ACTIVE_COMPARATOR|CT guided localization|Computerized Tomography(CT)-guided percutaneous lung puncture staining marker localization
62710277|NCT04552054|EXPERIMENTAL|MR+3D guided localization|Mixed reality(MR)+3D printing-guided percutaneous lung puncture staining marker localization
62710278|NCT01849276|EXPERIMENTAL|Treatment (enzyme inhibitor and chemotherapy)|Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.
61973571|NCT00972569|ACTIVE_COMPARATOR|BNP with PDE-V|BNP (Nesiritide) will be infused starting at 0.0025 g/Kg/min IV for 3 hours, if tolerated increased to 0.005 g/kg/min for 45 hours without bolus with PDEV inhibition, they will also receive Sildenafil 12.5 mg at timepoints 0,12, 24 and 36 hours
61973572|NCT00972569|ACTIVE_COMPARATOR|BNP (Nesiritide) will be infused at 0.005 u/Kg/min IV for 48 h|BNP (Nesiritide) will be infused at 0.025 ug/Kg/min IV for 3 hours then 0.005ug/kg/min 45 hours without bolus. No PDE-V is given.
62710279|NCT01203007|EXPERIMENTAL|Tailored diet|Tailored diet according to demonstrated food sensitivity
61973573|NCT00972569|NO_INTERVENTION|standard care|Patients randomized to this group will continue to receive therapy at the discretion of the heart failure specialist who is managing the patient (with the exception of BNP and low dose dopamine). Blood and Urine will be collected after the patient has been randomized for 48 hours
61973574|NCT04557371|EXPERIMENTAL|Developmental Serum|The participants will apply a developmental serum topically to the face twice daily (morning and evening) to freshly cleansed with normal moisturizing routine for 21 days.
61973575|NCT04557371|EXPERIMENTAL|Developmental Lotion|The participants will apply a developmental lotion topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
62710280|NCT01203007|EXPERIMENTAL|Low-antigen content (LAC) diet|Low-antigen content diet
62515470|NCT05114759|EXPERIMENTAL|SHR-A2009 for Injection will be administrated per dose level in which the patients are assigned.|
62515471|NCT04147819|EXPERIMENTAL|Dose escalation of BAY2701439|The target population consists of participants with advanced HER2-expressing/amplified breast, gastric or gastroesophageal cancer.
62515472|NCT04147819|EXPERIMENTAL|HER2 overexpressing breast cancer|Dose expansion of BAY2701439
62515473|NCT04147819|EXPERIMENTAL|HER2 low expressing breast cancer|Dose expansion of BAY2701439
62515474|NCT04147819|EXPERIMENTAL|Other HER2 overexpressing advanced carcinomas|Dose expansion of BAY2701439
62515475|NCT04923711|EXPERIMENTAL|Moderate Intensity Group|Group received a moderate exercise prescription of moderate intensity
62515476|NCT04923711|EXPERIMENTAL|High Intensity Group|Group received a moderate exercise prescription of high intensity
62515477|NCT02440516|ACTIVE_COMPARATOR|Neurorehabilitation program|Standardized comprehensive ambulatory neurorehabilitation program
62515478|NCT02440516|PLACEBO_COMPARATOR|Waiting list|Waiting list
62515479|NCT01706016|EXPERIMENTAL|Patients with breast cancer smaller than 20mm|
62515480|NCT02708888|EXPERIMENTAL|Trunk training|Exercises: Core stability training
62515481|NCT02708888|SHAM_COMPARATOR|Cognitive exercises|Exercises: The RevArte Visual Search Test (RVST) of Lafosse et al (2013) and the Visuospatial Neglect Test Battery (VNTB) of Vaes et al. (2015)
62515482|NCT03441295|EXPERIMENTAL|Study 1 Ligamys|Repair Surgery.
62515483|NCT03441295|EXPERIMENTAL|Study 1 Internal Bracing|Repair Surgery.
62515484|NCT03441295|EXPERIMENTAL|Study 2 Internal Bracing|Repair Surgery.
62515485|NCT03441295|ACTIVE_COMPARATOR|Study 2 Reconstruction|Reconstructive Surgery.
62515486|NCT05636995||Primary Hyperaldosteronism Diagnosed Women|Post-partum women who had a hypertensive disorder of pregnancy and a screened primary hyperaldosteronism (positive aldosterone/renin ratio).
62710281|NCT04825743|EXPERIMENTAL|zalunfiban Dose 1 (0.110 mg/kg)|Subjects will receive a single subcutaneous injection containing zalunfiban Dose 1 (0.110 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
62710282|NCT04825743|EXPERIMENTAL|zalunfiban Dose 2 (0.130 mg/kg)|Subjects will receive a single subcutaneous injection containing zalunfiban Dose 2 (0.130 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
62710283|NCT04825743|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single subcutaneous injection containing Placebo in the ambulance after diagnosis of STEMI and before hospital arrival
62710284|NCT03763630|ACTIVE_COMPARATOR|Intervention arm|House dust-mite SLIT
62710285|NCT03763630|PLACEBO_COMPARATOR|Control arm|Normal saline
62710286|NCT03763630|NO_INTERVENTION|Observation cohort|ITEC observational cohort, no intervention administered
62710287|NCT05410730|EXPERIMENTAL|SHR-1501|"* Phase I：Phase Ia and Ib： Phase Ia include SHR-1501 dose escalation and expansion; Phase Ib ： SHR-1501 in combination with BCG dose escalation~* Phase II：SHR-1501 in combination with BCG dose expansion in NMIBC Cohort 1: No previous BCG treatment (n=30); Cohort 2: CIS (with or without Ta or T1) with or without prior BCG response (n=30); Cohort 3: BCG-unresponsive Ta or T1 (without CIS) (n=30)"
62710288|NCT01442987|EXPERIMENTAL|Irbesartan/Atorvastatin A|
62710289|NCT01442987|ACTIVE_COMPARATOR|Irbesartan|
62515487|NCT05636995||Control Women|Post-partum women who had a hypertensive disorder of pregnancy without underlying primary hyperaldosteronism (negative aldosterone/renin ratio)
62515488|NCT03083626||Prescription opioid abusers|Patients 21-65 years old taking suboxone or methadone, currently experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
62710290|NCT01442987|ACTIVE_COMPARATOR|Atorvastatin A|
62710291|NCT01442987|PLACEBO_COMPARATOR|Placebo|
62710292|NCT01442987|EXPERIMENTAL|Irbesartan/Atorvastatin B|
62710293|NCT01442987|ACTIVE_COMPARATOR|Atorvastatin B|
62710294|NCT03057704|ACTIVE_COMPARATOR|Intravenous lidocaine: flushed|Lidocaine injection flushed
62710295|NCT03057704|EXPERIMENTAL|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
62710296|NCT04824833|ACTIVE_COMPARATOR|Serratus anterior plane block|
62515489|NCT03083626||Healthy control participants|Patients 21-65 years old not taking suboxone or methadone, not experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
62515490|NCT02694549|EXPERIMENTAL|CaveoVasc|
62515491|NCT00921037|EXPERIMENTAL|Erbium YAG Laser|Patients with Neurofibromatosis Type 1 (Recklinghausen)
62515492|NCT03547726|ACTIVE_COMPARATOR|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
62515493|NCT03547726|EXPERIMENTAL|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
62515494|NCT03044236|EXPERIMENTAL|Novel Stretching Technique|Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
62515495|NCT03044236|ACTIVE_COMPARATOR|Traditional Stretching Technique|Participants will perform the modified sleeper stretch in a side-lying position on the side of the throwing shoulder with the throwing shoulder and elbow flexed to 90° . The participants will be instructed to allow the throwing shoulder to naturally fall into internal rotation to the end ROM where resistance will be felt . The participants will be then instructed to use the non-throwing hand to push the throwing shoulder into further internal rotation to the point of mild discomfort by applying pressure at the area of the wrist joint.
62515496|NCT04792879|EXPERIMENTAL|Peripheral veins Doppler ultrasound|
62515497|NCT05841147|EXPERIMENTAL|The intervention group|An intravenous bolus (6µg/kg) over a 3 min period and a maintenance dose of 0.1µg/kg/min for 18 hour were used in this group.
62515498|NCT05841147|ACTIVE_COMPARATOR|The control group|The same dose of normal saline was used instead of tirofiban.
62515499|NCT02747004|EXPERIMENTAL|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
62515500|NCT02747004|EXPERIMENTAL|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
62515501|NCT02747004|EXPERIMENTAL|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
62515502|NCT03335579||non-MACE|patients without major postoperative cardiac or cerebral complications
62515503|NCT03335579||MACE|patients with major postoperative cardiac or cerebral complications
62515504|NCT05123729|EXPERIMENTAL|Crowdsourced campaign package|The intervention will be developed through a crowdsourcing process, including an open call for submissions.
62515505|NCT05123729|ACTIVE_COMPARATOR|Standard information|The control will be the provision of standard information (e.g., view standard informational videos promoting the adoption of health-protective behaviors and COVID-19 testing).
62515506|NCT05602402|ACTIVE_COMPARATOR|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule beforebreakfast (preferably with milk/butter/ghee)
62515507|NCT05602402|PLACEBO_COMPARATOR|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
62515508|NCT05918757|EXPERIMENTAL|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day in critically ill patients receiving invasive mechanical ventilation
62515509|NCT05918757|ACTIVE_COMPARATOR|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day in critically ill patients receiving invasive mechanical ventilation
62515510|NCT02303886|ACTIVE_COMPARATOR|A Methylene blue 10 mg/ml 2mg/kg|ten patients that recieved MB1 methylene blue 2 mg/kg infusion under 60 min
62515511|NCT02303886|PLACEBO_COMPARATOR|B Methylene blue 10 mg/ml 0.02 mg/kg|Same patients received MB2 Methylene blue 0.02 mg/kg infusion under 60 min
62515512|NCT04208269|ACTIVE_COMPARATOR|Postcard campaign|
62515513|NCT04208269|ACTIVE_COMPARATOR|Provider-only intervention|
61973576|NCT04557371|EXPERIMENTAL|Developmental Cream|The participants will apply a developmental cream topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
62515514|NCT04208269|ACTIVE_COMPARATOR|Patient and provider intervention|
62515515|NCT04208269|NO_INTERVENTION|Standard care|
62515516|NCT04577885|EXPERIMENTAL|experimental group|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
62515517|NCT01980342|EXPERIMENTAL|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
62515518|NCT03710590|ACTIVE_COMPARATOR|Cigarette smokers|
62515519|NCT03710590|ACTIVE_COMPARATOR|Electronic cigarette users|
62515520|NCT01969474|EXPERIMENTAL|Cannabis|Treatment with a Cannabis capsule
62515521|NCT01969474|PLACEBO_COMPARATOR|Placebo|Placebo
62515522|NCT03684031|EXPERIMENTAL|Cognitive Control Training|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
62515523|NCT03684031|SHAM_COMPARATOR|Sham Cognitive Control Training Program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
62539479|NCT01782430|EXPERIMENTAL|High flow nasal oxygen therapy|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
62710297|NCT04824833|NO_INTERVENTION|control group|
62710298|NCT02510456|EXPERIMENTAL|Diffuse Optical Spectroscopy Imaging - Neoadjuvant Chemo (NAC) Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 6 time points.
62515524|NCT00017394|EXPERIMENTAL|Treatment (bevacizumab, vinorelbine tartrate)|Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.
62515525|NCT06598293||Test group: REPROM group|"Subjects in the test group will self-report symptoms that occur using smartphones before radiotherapy, once a week during treatment, at the end of treatment, once a week until one month after treatment, and at 1 month and 3\~6 months after treatment (PRO-CTCAE, Pain NRS). The radiation oncologist will identify the symptoms reported in the REPROM and take appropriate medical measures to improve the symptoms based on this.~A survey alert will be sent to the patient at the time of REPROM implementation, and the subject will self-report the patient's symptoms through the mobile messenger KakaoTalk using a smartphone. The survey data is automatically sent to the EMR and can be checked by the attending physician at the time of consultation. A score of 4 or higher will be automatically alerted to the attending physician and the research nurse, and the research nurse may contact the subject if necessary and recommend additional care to the attending physician."
62515526|NCT06598293||Control group: Standard care group|"Control subjects receive standard care without self-report of REPROM. Both groups may receive appropriate medical attention for the symptoms observed at the time of examination.~Both groups will administer HR-QOL questionnaires (EORTC-QLQ-C30, EQ-5D-5L, EQ-VAS) before radiotherapy, at the end of treatment, 1 month after treatment, and 3\~6 months after treatment."
62515527|NCT00604903|EXPERIMENTAL|Patients implanted with Pressure Sensor|Implant of Pressure sensor. These are patients, who were implanted with the Remon CHF Implantable Pressure Sensor utilizing the corresponding delivering system.
62515528|NCT02021253|PLACEBO_COMPARATOR|Placebo of Probiotics|"Placebo: Composition: Each capsule contains 560 mg:~* 459 mg of corn starch~* 6 mg of magnesium stearate~Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime.~Methods of administration: Oral.~Duration of treatment: 14 days"
62515529|NCT02021253|ACTIVE_COMPARATOR|Probiotics- Lactibiane Tolerance|"Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10\^9 probiotic / capsule~Composition: One capsule of 560 mg contains Lactibiane tolerance:~* 345 mg of corn starch~* 114 mg premix lactic~* 6 mg of magnesium stearate Excipients: magnesium stearate~Method of administration: Oral~Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;"
62515530|NCT04415684|EXPERIMENTAL|Test Arm|
62515531|NCT04289454|OTHER|Effect of flavor modifiers|Intervention in the study: Subjects will taste model KE drinks with (control condition) and without (experimental condition) added flavors. Design is within-subjects (subjects will taste both the experimental and control drinks), with order counter-balanced across subjects.
62515532|NCT00606502|EXPERIMENTAL|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
62515533|NCT00606502|ACTIVE_COMPARATOR|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
62515534|NCT02116517|EXPERIMENTAL|green tea extract first|green tea extract (EGCG) 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally cellulose 500mg tid for 6 weeks total 14 weeks
62515535|NCT02116517|PLACEBO_COMPARATOR|Placebo first|cellulose 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally EGCG 500mg tid for 6 weeks total 14 weeks
62515536|NCT02979457|NO_INTERVENTION|no awareness of Degree of Worry|Call handler is not made aware of caller's DOW on computer screen
62515537|NCT02979457|EXPERIMENTAL|awareness of Degree of Worry|Call handler is made aware of caller's DOW on computer screen alongside patient information as address etc.
62515538|NCT04321798|EXPERIMENTAL|Physical Activity|Promoting Engagement in Physical Activity
62515539|NCT00986453|EXPERIMENTAL|PlasmaBlade arm|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
62515540|NCT00986453|ACTIVE_COMPARATOR|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
62515541|NCT05279508|EXPERIMENTAL|Prevention treatment group|"10 week stroke prevention program with six group sessions on pre-set themes targeting modifiable stroke risk factors . The group sessions are chaired by health professionals but also consists of peer learning to support change in lifestyle habits and activity patterns and reduce stroke risk. The change process is supported with a mHealth application for daily registrering of six domains; stroke risk factors, EEA, stress and goal achievement.~A lifestyle and stroke risk analysis will be performed at baseline measures, at follow up and at 12 month follow up."
62515542|NCT05279508|NO_INTERVENTION|Standard treatment group|Usual care within primary healthcare. At baseline, follow up and at 12 month follow up a lifestyle and stroke risk analysis will be conducted.
62515543|NCT01189500|EXPERIMENTAL|Tamoxifen and Desvenlafaxine SR|
62710299|NCT02510456|EXPERIMENTAL|Diffuse Optical Spectroscopy Imaging - Non-NAC Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 1 time point.
62710300|NCT01646411||assorted acute infection|300 patients diagnosed with assorted acute infection.
62710301|NCT05210816|EXPERIMENTAL|ACT|''Acceptance and Commitment Therapy (ACT) Based Intervention Program was applied to the intervention group.
61973577|NCT02252094|ACTIVE_COMPARATOR|Conventional lung protective ventilation|Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
62147664|NCT04970602|EXPERIMENTAL|MB group|This group will be given 2mg/kg methylene blue infusion within 20 minutes, 2 hours later followed by 0.5mg/kg/h for 4 hours.
62710302|NCT05210816|NO_INTERVENTION|Control|Only data collection was carried out. No attempt was made by the researcher during the study.
62710303|NCT05323656|EXPERIMENTAL|Setanaxib 800 mg and Pembrolizumab 200 mg|Participants will be administered Setanaxib 800 mg twice daily. Participants will also be administered Pembrolizumab 200 mg intravenously every 3 weeks.
62710304|NCT05323656|ACTIVE_COMPARATOR|Placebo and Pembrolizumab 200 mg|Participants will be administered placebo throughout the 24 month treatment period. Participants will also be administered Pembrolizumab 200 mg intravenously every 3 weeks.
62147665|NCT04970602|NO_INTERVENTION|control group|This group will be given conventional vasopressors, except methylene blue, based on the attending doctor's decision.
62515544|NCT01996059|EXPERIMENTAL|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
62515545|NCT01996059|ACTIVE_COMPARATOR|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
62515546|NCT00645424|EXPERIMENTAL|Arm A|
62515547|NCT00645424|EXPERIMENTAL|Arm B|
62515548|NCT00645424|EXPERIMENTAL|Arm C|
62515549|NCT02904668|EXPERIMENTAL|Experimental group|Patients allocated to the experimental group were included in a self-management program and manual therapy program
62515550|NCT02904668|ACTIVE_COMPARATOR|Control group|"The intervention consisted of 45-minute manual therapy sessions. Manual therapy included hands-on muscular mobilization techniques (aimed at improving soft tissue function), specific articular mobilization techniques (to improve overall joint function and decrease any restrictions in movement at single or multiple segmental levels in the cervical spine), and coordination or stabilization techniques (to improve postural control, coordination, and movement patterns by using the stabilizing cervical musculature)"
62515551|NCT01476228|EXPERIMENTAL|study group|EEG recording
62515552|NCT02521818|EXPERIMENTAL|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
62515553|NCT02521818|ACTIVE_COMPARATOR|NIA Diet for Seniors|Diet recommended by NIA for seniors
62515554|NCT01345526|EXPERIMENTAL|Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream|
62515555|NCT01345526|PLACEBO_COMPARATOR|Metastatic colorectal cancer, Doxycycline, Cream|
62515556|NCT05082363||systemic lupus wth renal affection|pt diagnosed with lupus nephritis
62515557|NCT05082363||systemic lupus without renal affection|pt diagnosed as systemic lupus without renal affection
62515558|NCT06085573||Dexmedetomidine Hydrochloride|"Pediatric patients (1 month to \< 18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation of non-intubated pediatric patients for non-invasive procedures and tests"
62515559|NCT03939988|ACTIVE_COMPARATOR|Experimental group|In this study, immediately after the installation of the separators, the subjects of the experimental group will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
62515560|NCT03939988|PLACEBO_COMPARATOR|Placebo group|In the placebo group, the same procedures will be made, but the laser will be switched off.
62515561|NCT02335515|EXPERIMENTAL|Soctec / Capsule|HS intakes one(1) Soctec Capsule after standardized breakfast
62515562|NCT02490306|EXPERIMENTAL|Hemorrhagic stroke|"Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.~Interventions: Strokefinder MD100 measurement"
62147666|NCT01303471|EXPERIMENTAL|opioïd|Different levels of remifentanyl of each group during nociceptive stimulation
62147667|NCT02715388|EXPERIMENTAL|Silicon oil removal 3D visualization|
62147668|NCT04325425|EXPERIMENTAL|mFOLFIRINOX|mFOLFIRINOX will be administered once every 14 days for up to 12 cycles. One cycle consists of 14 days (2 weeks) with injection on D1 of each cycle (D1=D15). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
62515563|NCT02490306|EXPERIMENTAL|Ischemic stroke|"Patient group B is defined as patients that are diagnosed with ischemic stroke.~Interventions: Strokefinder MD100 measurement"
62515564|NCT02490306|EXPERIMENTAL|Stroke mimics|"Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.~Interventions: Strokefinder MD100 measurement"
62515565|NCT00591331|EXPERIMENTAL|1|NatrOVA Creme Rinse - 1%
62515566|NCT00591331|EXPERIMENTAL|2|NatrOVA Creme Rinse Vehicle Only
62515567|NCT00591331|PLACEBO_COMPARATOR|3|Blank patch
62515568|NCT01017419||Audiology counseling|
62515569|NCT03180801|PLACEBO_COMPARATOR|Group 1 adjuvanted placebo|0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0
62515570|NCT03180801|EXPERIMENTAL|Group 2 adjuvanted FLU-v one dose|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0
62515571|NCT03180801|EXPERIMENTAL|Group 3 adjuvanted FLU-v two doses|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0
62515572|NCT00619359|EXPERIMENTAL|1|Arm 1: study medication
62515573|NCT00619359|ACTIVE_COMPARATOR|2|Arm 2: Active comparator
62515574|NCT03517254|EXPERIMENTAL|Glutamine and strength training program|Three times per week, standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks of follow up. At the beginning and at the end of the training session, the experimental group will receive by mouth 10 grams of glutamine dissolved in 120 milliliters of water, all participants and team of researchers will not be aware of the supplement.
62539480|NCT01782430|OTHER|invasive ventilation (VNI)|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
62147669|NCT04325425|ACTIVE_COMPARATOR|platinum - etoposide|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
62539481|NCT00358410|EXPERIMENTAL|GW679769|120mg once a day
62147670|NCT03100370|EXPERIMENTAL|tsDCS-Anodal & robotic arm training (RAT), then tsDCS-Cathodal & RAT, then tsDCS-Sham & RAT|anodal tsDCS over cervical spine, 2.5mA for 20 minutes
62710305|NCT04641091||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
62710306|NCT04641091||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
62515575|NCT03517254|PLACEBO_COMPARATOR|Placebo and strength training program|Three times per week a standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks after discharge. At the beginning and at the end of the training session, the placebo group will receive by mouth10 grams of maltodextrin dissolved in 120 milliliters of water. All participants and team of researchers will not be aware of the supplement content.
62515576|NCT01168570||SAA monitored group|FMF-Amyloidosis patients receiving colchicine with a purpose to normalize SAA levels
62515577|NCT01168570||Historical control group|FMF-Amyloidosis patients receiving colchicine at a dose determined to stop FMF attacks. obtained from the Fibrillex study
62515578|NCT06616207|PLACEBO_COMPARATOR|Placebo|Placebo (double distilled water matched in color and taste) will be applied
62515579|NCT06616207|EXPERIMENTAL|Povidone-iodine solution|10% Povidone and Iodine will be applied
62515580|NCT05557903|EXPERIMENTAL|Treatment Group of anti-CD52 monoclonal antibody|safety and tolerability, pharmacokinetic characteristics and preliminary efficacy in the treatment of relapsed and refractory nhl (including cll/sll, pll, ptcl, diffuse large b-cell lymphoma, follicular cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma) and initially treated t-pll of recombinant humanized anti-cd52 monoclonal antibody injection
62515581|NCT04825041||Infertilite women|Subjected to three successive hysteroscopic tests
62710307|NCT04500145|ACTIVE_COMPARATOR|SIB-IMRT|patients received radiotherapy using IMRT or VMAT，60Gy is given to the field of tumor and metastatic lymph nodes and 50Gy given to CR lesion and high-risk area.concurrent or sequential with 4-6 circles of chemotherapy of EP.
62147671|NCT03100370|EXPERIMENTAL|tsDCS-Anodal & robotic arm training (RAT), then tsDCS-Sham & RAT, then tsDCS-Cathodal & RAT|cathodal tsDCS over cervical spine, 2.5mA for 20 minutes
61973578|NCT02252094|EXPERIMENTAL|Ultra-protective ventilation|Ultra-protective ventilation (\</= 3ml/kg predicted body weight) targeting plateau pressure of \</= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
61973579|NCT05237154|EXPERIMENTAL|Intermittent fasting (IF)|Alternate-day intermittent fasting. Consumption of 25% of daily energy requirements on scheduled fasting days involving energy restriction for 2 non-consecutive days of the week and ad libitum feeding on the other 5 days of the week. Period: 8 weeks.
61973580|NCT05237154|EXPERIMENTAL|Exercise: High-Intensity Interval Training (HIIT)|High intensity circuit training. Progressive training protocol 3x/week, for 8 weeks, with at least 1 day of rest between sessions and duration of 25 minutes each session - 4 minutes of initial warm-up, 18 minutes of the main part and 3 minutes of relaxation. First and second week: 30 second run and recovery time. Third and fourth week: 35-second runtime and 25-second recovery time. Fifth and Sixth Week: 40-second runtime and 20-second recovery time. Seventh and eighth weeks: 45-second runtime and 15-second recovery time.
61973581|NCT02175589|OTHER|Study group|Colchicine Cessation in FMF patients with one MEFV mutation
61973582|NCT02175589|NO_INTERVENTION|Control group|The control group includes FMF patients that will be kept on a daily colchicine treatment
61973583|NCT04300127|EXPERIMENTAL|Pioglitazone|Candidates who after the screening period are eligible to receive Pioglitazone
62147672|NCT03100370|EXPERIMENTAL|tsDCS-Cathodal & robotic arm training (RAT), then tsDCS-Anodal & RAT, then tsDCS-Sham & RAT|sham tsDCS over cervical spine, 2.5mA for 20 minutes
61973584|NCT01502449|EXPERIMENTAL|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program over 8 weeks that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
62515582|NCT01477814|ACTIVE_COMPARATOR|physician chart reminder|either a paper or an electronic reminder placed on the subject's medical record to remind the physician to screen for colorectal cancer
62515583|NCT01477814|ACTIVE_COMPARATOR|chart reminder, educational mat'ls, FIT|physician chart reminder plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test
62515584|NCT01477814|ACTIVE_COMPARATOR|CR, ed mat'ls, FIT, phone call|physician chart reminder (CR) plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test, and a motivational telephone call designed to elicit barriers and preferences and motivate individuals to complete a CRC screening test.
62515585|NCT04683237|OTHER|MA alone|enrolled patients will receive megestrol acetate 160mg po qd
62515586|NCT04683237|EXPERIMENTAL|MA+liraglutide|enrolled patients will receive megestrol acetate 160mg po qd plus liraglutide (1.8mg/d or the max tolerable dosage)
62539482|NCT00358410|PLACEBO_COMPARATOR|Placebo|Placebo once a day
62710308|NCT04500145|OTHER|routine|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
62710309|NCT01158859|EXPERIMENTAL|Pregabalin|
62710310|NCT01158859|PLACEBO_COMPARATOR|Placebo|
61973585|NCT01502449|ACTIVE_COMPARATOR|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
62710311|NCT00872300|EXPERIMENTAL|1|
62710312|NCT00691626|EXPERIMENTAL|Arm 1: CBT for Insomnia plus Imagery Rehearsal|CBT for Insomnia plus Imagery Rehearsal
62710313|NCT00691626|ACTIVE_COMPARATOR|Arm 2: CBT for Insomnia|CBT for Insomnia
62710314|NCT01005173||Group A|Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
62710315|NCT01005173||Group B|Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
62710316|NCT01005173||Group C|Acetaminophen Overdose Subjects - Hospitalized 90 Subjects
62147673|NCT03100370|EXPERIMENTAL|tsDCS-Cathodal & robotic arm training (RAT), then tsDCS-Sham & RAT, then tsDCS-Anodal & RAT|
62147674|NCT03100370|EXPERIMENTAL|tsDCS-Sham & robotic arm training (RAT), then tsDCS-Anodal & RAT, then tsDCS- Cathodal & RAT|
62147675|NCT03100370|EXPERIMENTAL|tsDCS-Sham & robotic arm training (RAT), then tsDCS-Cathodal & RAT, then tsDCS-Anodal & RAT|
62710317|NCT05520684||positive for bacteriuria/ urinalysis abnormality|The patients who have any growth in urine culture or urinalysis abnormality at the initiation of SGLT2 inhibitor (dapagliflozin or empagliflozin)
62710318|NCT05520684||negative for bacteriuria/ urinalysis abnormality|The patients who do not have growth in urine culture or do not have abnormality in urinalysis at the initiation of SGLT2 inhibitor (dapagliflozin or empagliflozin)
62147676|NCT01662193|EXPERIMENTAL|vitamin D3|vitamin D3 supplement 50000 IU vitamin D3 per week
62710319|NCT05233839|EXPERIMENTAL|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
62710320|NCT05233839|ACTIVE_COMPARATOR|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
62710321|NCT02150161|EXPERIMENTAL|lidocaine/ ketamine infusion|lidocaine 1mg/Kg bolus, followed by continuous infusion 1 mg/kg/h AND ketamine 1mg/Kg bolus followed by continuous infusion 1 mg/kg/h
62710322|NCT02150161|ACTIVE_COMPARATOR|fentanyl|iv fentanyl, 3ug/kg bolus
62147677|NCT01662193|EXPERIMENTAL|calcium supplement|calcium supplement 1000 mg calcium carbonate daily
62147678|NCT01662193|EXPERIMENTAL|vitamin D and calcium supplement|vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
62354366|NCT02824848|ACTIVE_COMPARATOR|Perception-Action Approach|P-A Approach intervention components include environmental set-up for activity and participation in play, and manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions. Both components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing environmental supports provided to the infant's body parts, and by removing the therapist's hands from the infant's body to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
62354367|NCT01786863||Neuromuscular blockade|
62354368|NCT05877703|EXPERIMENTAL|Group A: close kinetic chain exercises|Group A will be treated with close kinetic chain exercises including static cycling with lifestyle modification and patient's education including quadriceps drill with lifestyle modification and patient's education about 30 minutes per session including 10 min of walking as a warm up for total duration of 12 weeks with 3 sessions per week. Assessment will be done by therapist at 0 week, 4 weeks, 8 weeks and 12 weeks
62710323|NCT01530958|EXPERIMENTAL|ATSM + Health Coach and CKD Registry|
62710324|NCT01530958|ACTIVE_COMPARATOR|CKD Registry|
62710325|NCT01530958|ACTIVE_COMPARATOR|ATSM + Health Coach|
62710326|NCT01530958|PLACEBO_COMPARATOR|Usual Care (no interventions)|
62354369|NCT05877703|ACTIVE_COMPARATOR|Group B: open kinetic chain exercises|Group B will be treated with open kinetic chain exercises including quadriceps drill with lifestyle modification and patient's education about 30 minutes per session including 10 min of walking as a warm up for total duration of 12 weeks with 3 sessions per week. Group B performed scar mobilization exercises only for 3 weeks. Assessment will be done by therapist at 0 week, 4 weeks, 8 weeks and 12 weeks
62710327|NCT01938729|EXPERIMENTAL|HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE|"This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.~Level 1: Systemic gemcitabine 650mg/m\^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m\^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m\^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14"
62710328|NCT03313934|PLACEBO_COMPARATOR|Hyaluronic Acid Filler with Saline|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with saline. This arm will act as a control to evaluate the efficacy of PRF with hyaluronic acid.
62710329|NCT03313934|EXPERIMENTAL|Hyaluronic Acid Filler with Platelet Rich Fibrin (PRF)|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with Platelet Rich Fibrin (PRF). This study seeks to determine the efficacy of PRF in volumization of the tear trough and improvement of skin quality. This is the experimental condition.
62147679|NCT01662193|PLACEBO_COMPARATOR|placebo|placebo
62147680|NCT01595867|PLACEBO_COMPARATOR|Treatment A|Placebo
62147681|NCT01595867|EXPERIMENTAL|Treatment B|EMBEDA 30 mg crushed
62147682|NCT01595867|ACTIVE_COMPARATOR|Treatment C|Morphine Sulfate Controlled Release 30 mg crushed
62147683|NCT01014559|ACTIVE_COMPARATOR|Prolonged release tablet|OxyCodone Naloxone controlled release tablet
62147684|NCT01014559|ACTIVE_COMPARATOR|Tablet|Oxycodone PR Tablets
62147685|NCT05960669|EXPERIMENTAL|3D model guided SR|A prostate model was 3D printed from preoperative pelvic MRI data and used during surgery to mark a positive surgical margin and guide secondary resection.
62147686|NCT05552105|OTHER|Cohort|
62354370|NCT03000634|EXPERIMENTAL|Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD|Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
62710330|NCT02362685||metabolic exercise testing|All the subjects referred to performed a metabolic exercise testing.
62710331|NCT03377751|EXPERIMENTAL|Additional posterior wall isolation|Operator will perform pulmonary vein isolation (PVI) and additional posterior wall isolation if low voltage area exists more than 10% of the left atrium
62710332|NCT03377751|EXPERIMENTAL|Voltage-guided substrate homogenization|Operator will perform pulmonary vein antrum isolation (PVI) and additional substrate modification based on the degree of low voltage area.
61973586|NCT03506815|EXPERIMENTAL|Rivaroxaban Thromboprophylaxis|Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
62354371|NCT03000634|OTHER|VRD-bortezomib, lenalidomide, dexamethasone|Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
62710333|NCT03377751|ACTIVE_COMPARATOR|PVI only group|Operator will perform PVI only
62710334|NCT01293331||Study Cohort (Case )|Participants will be examined for fever in dengue endemic regions
62710335|NCT00713011|EXPERIMENTAL|Arm 1|
62515587|NCT04740931|EXPERIMENTAL|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
62515588|NCT04740931|ACTIVE_COMPARATOR|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
62515589|NCT05563181|PLACEBO_COMPARATOR|Control bar code|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
62515590|NCT05563181|EXPERIMENTAL|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
62515591|NCT05563181|EXPERIMENTAL|Control bar code + informational campaign about warning labels|Viewing an informational campaign about warning labels followed by viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
62710336|NCT00713011|ACTIVE_COMPARATOR|Arm 2|
62710337|NCT01775540|EXPERIMENTAL|Systane Ultra|Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
62710338|NCT01775540|PLACEBO_COMPARATOR|Saline solution|Saline solution Eyedrop, 1 drop used QID for 4 weeks
62710339|NCT01775540|ACTIVE_COMPARATOR|Maxidex|Steroid eyedrop, 1 drop QID for 4 weeks
62710340|NCT01689948|EXPERIMENTAL|Home rehabilitation therapy|12 weekly sessions of Home rehabilitation therapy
62710341|NCT02092181|ACTIVE_COMPARATOR|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 mg daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or, for those in the placebo arm, two placebo tablets.
62710342|NCT02092181|PLACEBO_COMPARATOR|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
62710343|NCT03744390|EXPERIMENTAL|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.
62710344|NCT02803385|ACTIVE_COMPARATOR|Continous Epidural Analgesia|Continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The Patient Controlled Analgesia pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes
61973587|NCT03506815|NO_INTERVENTION|Standard of care|No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.
61973588|NCT00604539|EXPERIMENTAL|1|Chondroitin sulphate
61973589|NCT00604539|PLACEBO_COMPARATOR|2|
61973590|NCT03852355|ACTIVE_COMPARATOR|Radiofrequency|bilateral 3rd occipital nerve RF under fluoroscopic guidance
61973591|NCT03852355|ACTIVE_COMPARATOR|Systemic steroid|received systemic steroids oral prednisolone tablet, 10 mg/day.
61973592|NCT00248989|EXPERIMENTAL|Placebo|
61973593|NCT00248989|EXPERIMENTAL|DHEA|
61973594|NCT05654753|EXPERIMENTAL|Experimental|active FMT
61973595|NCT05654753|PLACEBO_COMPARATOR|Placebo|placebo
61973596|NCT03732001|EXPERIMENTAL|Anlotinib combined Docetaxel|patients treated with Anlotinib and Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
62354372|NCT05772442||No pathological signs of rejection|Routine endomyocardial biopsy did no show pathological signs of rejection (0R) based on the International Society for Heart and Lung Transplantation (ISHLT) 2004 acute cellular rejection grading scheme.
62354373|NCT05772442||With pathological signs of rejection|Routine endomyocardial biopsy showed pathological signs of rejection (1R, 2R, and 3R) based on the International Society for Heart and Lung Transplantation (ISHLT) 2004 acute cellular rejection grading scheme.
62354374|NCT01305304||1|"15 healthy male veteran runners (marathon, triathlon, orienteering) aged between 40 and 65 years with a history of competitive running at a national level during a period of at least 5 years, implicating normally a runner career with at least 50km per week over more than 10 years"
62354375|NCT01305304||2|15 healthy male volunteers, matched for age and bmi, without a history of competitive physical exercise (i.e. sedentary controls)
62354376|NCT01978509|ACTIVE_COMPARATOR|Low volume prep (Prepopik)|Low volume prep for colonoscopy (Prepopik)
62354377|NCT01978509|ACTIVE_COMPARATOR|Moderate volume prep (Moviprep)|Moderate volume prep for colonoscopy (Moviprep)
62354378|NCT01978509|ACTIVE_COMPARATOR|High volume prep (Golytely)|High volume prep for colonoscopy (Golytely)
62354379|NCT03095404|EXPERIMENTAL|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
62515592|NCT05563181|EXPERIMENTAL|Warning label + informational campaign about warning labels|"Viewing an informational campaign about warning labels followed by viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
62515593|NCT04958122|EXPERIMENTAL|Cefixime|Oral cefixime 400mg, taken twice a day for 10 days
62515594|NCT04958122|ACTIVE_COMPARATOR|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
62515595|NCT03718741|EXPERIMENTAL|Adiuvant Radiotherapy +/- CT|"The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:~* R0: PTVb + PTVn 50 Gy in 25 fractions~* R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy~Patients with ECOG PS\<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery."
62515596|NCT05423470|EXPERIMENTAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
62515597|NCT05423470|SHAM_COMPARATOR|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
62515598|NCT03716531|EXPERIMENTAL|IORT|"* IORT will be administered as determined to be best practice by the treating radiation oncologist,~* Electron beam intraoperative radiation therapy will occur in a hybrid operating room with a portable linear accelerator"
62515599|NCT04984421|ACTIVE_COMPARATOR|Basic|All schools will receive the HSS program. Schools randomly assigned to group 1 will receive implementation strategy bundle 1 (Basic).
62515600|NCT04984421|EXPERIMENTAL|Enhanced|All schools will receive the HSS program. Schools randomly assigned to group 2 will receive implementation strategy bundle 1+2 (Enhanced).
62515601|NCT03937349||sPTx group|Patients underwent subtotal parathyroidectomy due to severe secondary hyperparathyroidism
62515602|NCT03937349||TPTx+AT group|Patients underwent total parathyroidectomy with immediate autotransplantation of parathyroid tissue due to severe secondary hyperparathyroidism
62515603|NCT03937349||Control group|Patients with severe SHPT on conservative treatment (calcimimetics, active vitamin D analogues, phosphate-binders) who are likely to undergo surgery in a period of 12 months
62515604|NCT02575508|EXPERIMENTAL|Treatment (oxaliplatin, irinotecan, fluorouracil, BGJ398)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on days 1 and 15. Patients also receive pan FGFR kinase inhibitor BGJ398 PO QD on days 8-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62515605|NCT00742599|ACTIVE_COMPARATOR|N|
62515606|NCT00742599|PLACEBO_COMPARATOR|P|
62515607|NCT01376310|EXPERIMENTAL|Cohort A|Subjects on GSK1120212 Monotherapy who have been treated less than 24 weeks in their parent study.
62515608|NCT01376310|EXPERIMENTAL|Cohort B|Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.
62515609|NCT05514236|EXPERIMENTAL|Virtual reality group|"Participants assigned to the Visual reality group will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
62515610|NCT05514236|EXPERIMENTAL|Music group|"Participants in the music group will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the sound according to her comfort."
62515611|NCT05514236|NO_INTERVENTION|Control group|While participants in the control group will not be given any Virtual reality or music device.
62515612|NCT03707041|EXPERIMENTAL|P218 1000 mg (Oral Capsules) - Cohort 1|Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart
62147687|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
62147688|NCT06193499|ACTIVE_COMPARATOR|Platelet rich plasma (PRP)|High-concentration PRP injection PRP injection (0,6-1ml). Arthrex ACPmax system.
62147689|NCT06193499|PLACEBO_COMPARATOR|Placebo|intraarticular saline injection (0,6-1ml)
62147690|NCT04990856|EXPERIMENTAL|Experimental arm|Blood flow of the tumor experimented
62147691|NCT03528304|EXPERIMENTAL|Smoking arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking.
62147692|NCT03528304|EXPERIMENTAL|Weight loss arm|As part of the CM intervention women attend visits for smoking and weight loss assessment and are rewarded with prizes for losing some weight.
62515613|NCT03707041|PLACEBO_COMPARATOR|P218 Placebo Oral Capsules - Cohort 1|Two administrations of P218 placebo (capsules p.o.), 48 hours apart
62515614|NCT03707041|EXPERIMENTAL|P218 1000 mg (Oral Capsules) - Cohort 2|One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.
62515615|NCT03707041|PLACEBO_COMPARATOR|P218 Placebo Oral Capsules - Cohort 2|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.
62515616|NCT03707041|EXPERIMENTAL|P218 100 mg (Oral Capsules) - Cohort 3|One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.
62710345|NCT02803385|ACTIVE_COMPARATOR|Patient Controlled Epidural Analgesia|Patient controlled epidural analgesia in form of PCA pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .
62710346|NCT05353439|EXPERIMENTAL|Treatment (tazemetostat, pembrolizumab, topotecan)|Patients receive tazemetostat PO BID on days 1-21, pembrolizumab IV over 30 minutes on day 1, and topotecan IV over 30 minutes on days 1-5. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study and may also undergo biopsy and collection of blood on study.
62515617|NCT03707041|ACTIVE_COMPARATOR|P218 Placebo Oral Capsule - Cohort 3|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.
62515618|NCT05424575||Group Nonfrail (Group NF)|Modified fraility index was calculated in all patients. Modified fraility index \< 0.27 were included to Group NF.
62515619|NCT05424575||Group Frail (Group F)|Modified fraility index was calculated in all patients. Modified fraility index ≥ 0.27 were included to Group F.
62515620|NCT03794518|EXPERIMENTAL|Pioglitazone Plus dapaglifliozin|Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
62515621|NCT03794518|PLACEBO_COMPARATOR|Placebo|Beta blockers, ACEI, ARB, and aldosterone
62515622|NCT03155737|EXPERIMENTAL|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
62515623|NCT03155737|ACTIVE_COMPARATOR|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
62515624|NCT04365179|EXPERIMENTAL|NEROFE|"Dose Level - Nerofe Dose~-1 - 6mg/m2~1. - 12 mg/m2~2. - 24 mg/m2~3. - 48 mg/m2~4. - 96 mg/m2~5. - 150mg/m2"
62515625|NCT02857829|PLACEBO_COMPARATOR|Placebo|
62515626|NCT02857829|ACTIVE_COMPARATOR|Caffeine-alone|The effects of the combination will be compared to both placebo and caffeine-alone, to test the hypothesis that the blend of ingredients will enhance cognitive measures greater than the most commonly used cognitive enhancer, caffeine.
62515627|NCT02857829|EXPERIMENTAL|CAF+|
62710347|NCT00772057|ACTIVE_COMPARATOR|Propranolol group|
62710348|NCT00772057|PLACEBO_COMPARATOR|Placebo group|
62354380|NCT03095404|EXPERIMENTAL|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
62539483|NCT05209594|EXPERIMENTAL|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|Students in grades 9 to 12 participating in GSAs where the HRP for 2SLGBTQIA+ Youth is being implemented.
62710349|NCT06488755|PLACEBO_COMPARATOR|Placebo|Placebo
62710350|NCT06488755|EXPERIMENTAL|SIM0718 injection|SIM0718 injection
62710351|NCT00626236|EXPERIMENTAL|Treatment 1|
62710352|NCT00626236|EXPERIMENTAL|Treatment 2|
62710353|NCT00626236|EXPERIMENTAL|Treatment 3|
62710354|NCT00626236|EXPERIMENTAL|Treatment 4|
62710355|NCT02854163|EXPERIMENTAL|Secukinumab|"Secukinumab will be given to all 20 patients registered (Secukinumab group). All doses will be given subcutaneously using the following schedule: 4 weekly injections of 150 or 300 mg subcutaneous injections depending the severity of skin involvement, followed by 11 monthly subcutaneous injections of 150mg.~Patients will continue to use their normal DMARDs treatment."
61973597|NCT03732001|ACTIVE_COMPARATOR|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
61973598|NCT01602874|EXPERIMENTAL|A. Tigecycline|
61973599|NCT01602874|ACTIVE_COMPARATOR|B. Ceftriaxone regimen|
62354381|NCT00378976|EXPERIMENTAL|1|
62354382|NCT00378976|PLACEBO_COMPARATOR|2|
62354383|NCT04373993||Nordlandssykehuset HF|
62710356|NCT00778427|EXPERIMENTAL|1|metformin hydrochloride 1000 mg tablets of Ranbaxy
62710357|NCT00778427|ACTIVE_COMPARATOR|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
62710358|NCT01152437|EXPERIMENTAL|BIBW 2992|Patients receive BIBW 2992 tablets once daily
62710359|NCT01152437|ACTIVE_COMPARATOR|Cetuximab|Patients receive cetuximab intravenously once a week, every week
62710360|NCT00108381|EXPERIMENTAL|Arm 1|Standard and Tailored Conditions
62710361|NCT01542970|PLACEBO_COMPARATOR|Placebo|Placebo for both L. reuteri and omega-3 fatty acids.
61973600|NCT02532933|ACTIVE_COMPARATOR|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
62354384|NCT04373993||Akershus universitetsssykehus|
62354385|NCT04373993||Helgelandssykehuset|
62354386|NCT04373993||Basel University Hospital|
62354387|NCT01622491||Case control|A case-control study with cases (individuals hospitalized with influenza or pneumonia during the second wave of the pandemic) and controls (non-hospitalized individuals) identified using the MH Hospital Separation Abstract Database and the MH Population Registry, respectively. Information on receipt of vaccines will be obtained by record linkage to the MIMS.
62354388|NCT01035008|EXPERIMENTAL|Diagnostic|The investigators are testing a new method called confocal laser endomicroscopy to see if it can detect pre-cancerous abnormalities in the lining of the cysts found in your pancreas. This will involve using a very thin fiber-shaped microscope which will be passed through a needle during the EUS procedure.
62354389|NCT03384628|ACTIVE_COMPARATOR|First Pair Senofilcon A contact lens|The first pair of Senofilcon A contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the first pair Senofilcon A contact lens and subsequent removal.
62354390|NCT03384628|ACTIVE_COMPARATOR|Second pair Senofilcon A contact lens|The second pair of contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the second pair Senofilcon A contact lens and subsequent removal.
62710362|NCT01542970|EXPERIMENTAL|L. reuteri and placebo|Active Lactobacillus reuteri and placebo for omega-3 fatty acids
62710363|NCT01542970|EXPERIMENTAL|Omega-3 fatty acids and placebo|Placebo for L. reuteri and active for omega-3 fatty acids
62710364|NCT01542970|EXPERIMENTAL|L. reuteri and omega-3 fatty acids|Active L. reuteri and active omega-3 fatty acids
61973601|NCT02532933|ACTIVE_COMPARATOR|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
62147693|NCT03528304|EXPERIMENTAL|Smoking and weight loss arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking and for losing some weight.
62147694|NCT03528304|NO_INTERVENTION|Control|Women attended clinic visits for smoking status and weight loss assessment.
62147695|NCT00748982|EXPERIMENTAL|1|
61973602|NCT02069301|EXPERIMENTAL|Integrated Depression/Microfinance Group|LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.
61973603|NCT02069301|OTHER|Treatment as Usual|Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs
62147696|NCT00748982|PLACEBO_COMPARATOR|2|
62710365|NCT00437749|ACTIVE_COMPARATOR|CBT-1|
62710366|NCT00437749|PLACEBO_COMPARATOR|Placebo|
61973604|NCT05486676|EXPERIMENTAL|VR-Moodboost|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
62710367|NCT01159834||Gardasil, HPV infection|
62710368|NCT05654584||agression before surgery|The group that the aggression assessment when morbidly obese before surgery
61973605|NCT06037291|EXPERIMENTAL|Coriander Seed Oil|Dietary supplement - Coriander Seed Oil
61973606|NCT06037291|PLACEBO_COMPARATOR|Placebo|Dietary supplement - Placebo
61973607|NCT03096054|EXPERIMENTAL|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
61973608|NCT03096054|EXPERIMENTAL|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
61973609|NCT06362811|NO_INTERVENTION|General anesthesia|Patients will go under general anesthesia and receive only 1mcg/kg fentanyl and 10mg/kg paracetamol as analgesia intraoperatively
61973610|NCT06362811|ACTIVE_COMPARATOR|General anesthesia + Sacral ESP block|Patients will go under general anesthesia, receive only 1mcg/kg fentanyl and 10mg/kg paracetamol intraoperatively, and bilateral sacral ESP block
61973611|NCT00402766|EXPERIMENTAL|Cisplatin + Imatinib + Pemetrexed|Cisplatin 60 mg/m\^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m\^2 by vein, Over 40 Minutes. Dexamethasone 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
61973612|NCT00779467|EXPERIMENTAL|Bupivacaine with Neostimgine 8 mcg/ml|STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
61973613|NCT00779467|EXPERIMENTAL|Bupivacaine and Neostigmine 4 mcg/ml|STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
61973614|NCT00779467|EXPERIMENTAL|Bupivacaine with Neostigmine 2 mcg/ml|STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
61973615|NCT00779467|ACTIVE_COMPARATOR|BUPIVACAINE WITH FENTANYL 2 MCG/ML|Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
62147697|NCT04101045|ACTIVE_COMPARATOR|Poorly-controlled T1D|Patients in this group will have poorly-controlled T1D (HbA1c \>8.5%).
62147698|NCT04101045|ACTIVE_COMPARATOR|Controlled T1D|Patients in this group will have T1D and achieve targeted glycemic control (HbA1c \<7.5%).
62147699|NCT04101045|ACTIVE_COMPARATOR|Lean controls|Patients in this group will not have T1D.
62147700|NCT06172036|EXPERIMENTAL|Arm A|Preoperative adliberlizumab + irinotecan liposome + oxaliplatin + 5-FU / LV (28 days as one cycle, 2 treatment cycles). Surgery was performed within 2 to 4 weeks after completion of neoadjuvant therapy and addebelizumab + irinotecan liposomes + oxaliplatin + 5-FU / LV (28 days as one cycle, 4 treatment cycles) within 4 to 6 weeks after surgery, followed by maintenance therapy with addebelizumab until disease progression or intolerable toxicity. The cumulative postoperative duration of adbelizumab should not exceed 1 year. Tumor recurrence, safety and survival follow-up was evaluated after completion of the drug.
62147701|NCT06172036|EXPERIMENTAL|Arm B|Irinotecan liposome + oxaliplatin + 5-FU / LV (28 days one cycle, 2 treatment cycles), 2-4 weeks after completion of neoadjuvant therapy and 4-6 weeks after surgery, adjuvant irinotecan liposome + oxaliplatin + 5-FU / LV (28 days one cycle, 4 treatment cycles). Tumor recurrence, safety and survival follow-up were performed after the end of the adjuvant treatment phase.
62147702|NCT06172036|ACTIVE_COMPARATOR|Arm C|Upfront surgery, and postoperative adjuvant regimen as with ArmB. Tumor recurrence, safety and survival follow-up were performed after the end of the adjuvant treatment phase.
62710369|NCT05654584||agression after surgery|group reassessed for aggression following postoperative weight loss
62710370|NCT05406973|OTHER|Moria SBK microkeratome|Comparative non randomized Interventional clinical study between SBK microkeratome versus femtosecond laser in flap creation during LASIK surgery for myopia
62710371|NCT05406973|OTHER|200-kHz Femtosecond laser system|Comparative non randomized Interventional clinical study between SBK microkeratome versus femtosecond laser in flap creation during LASIK surgery for myopia
62715085|NCT06589050|EXPERIMENTAL|"Toe flexor device experimental group"|"Participants will complete:~* 3 sets of 15 repetitions with a 90-second break between each set.~* Tempo 2-0-2-0~* 4 times per week~* Progression will be achieved by increasing the stiffness of the elastic band whenever the participant can perform 15 repetitions without great effort."
62715086|NCT06589050|EXPERIMENTAL|"Inclined Heel Rise experimental group"|"Participants will complete:~* 3 sets of 10 to 15 repetitions with a 90-second break between each set.~* Tempo 2-0-2-0~* 4 times per week~* Progression will be achieved by increasing the number of repetitions to 15 and then adding weights to be held in the ipsilateral hand."
61973616|NCT01148823|EXPERIMENTAL|Postoperative day 1|Dressing was removed on the first postoperative day
61973617|NCT01148823|EXPERIMENTAL|Postoperative day 6|Dressing was removed on the 6th postoperative day
61973618|NCT04937829|EXPERIMENTAL|BI 1569912 treatment group|
61973619|NCT04937829|PLACEBO_COMPARATOR|Placebo group|
61973620|NCT02348541|OTHER|CollaGUARD|
62147703|NCT02074228|EXPERIMENTAL|Methylphenidate|Methylphenidate (Concerta) 18mg or 36mg 1# qd, 12 weeks
61973621|NCT01572454|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
62515628|NCT05510024|EXPERIMENTAL|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous Immunotherapy|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous Immunotherapy will be conducted in participants with severe house dust mite-sensitized allergic rhinitis.
62515629|NCT05510024|ACTIVE_COMPARATOR|Subcutaneous Immunotherapy (SCIT)|Allergen-specific subcutaneous Immunotherapy will be conducted in participants with severe house dust mite-sensitized allergic rhinitis.
62515630|NCT06326177||Competitive Swimmer Group|Spine posture, spine movement, scapular dyskinesia, ısometric and eccentric shoulder strength and core muscle endurance will be assessed.
62515631|NCT06326177||Recreational Swimmer Group|Spine posture, spine movement, scapular dyskinesia, ısometric and eccentric shoulder strength and core muscle endurance will be assessed.
62515632|NCT02083926|EXPERIMENTAL|Ketamine infusion|A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
62515633|NCT02083926|EXPERIMENTAL|Saline infusion|A saline infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
62515634|NCT02408328|ACTIVE_COMPARATOR|Inpatient Observation|Continued inpatient monitoring of apnea, bradycardia, and/or desaturation until an event free period of time (5 days per the current standard of care at each participating institution) has been established and deemed appropriate for discharge home per the discretion of the responsible provider.
62515635|NCT02408328|ACTIVE_COMPARATOR|Caffeine and Outpatient Monitoring|Patients will receive a loading dose of caffeine on day 1 with a daily maintenance dose thereafter. Infants will then receive continued inpatient monitoring of apnea/bradycardia/desaturation until an event free period of time has been established and deemed appropriate for discharge home per the discretion of the responsible provider. Infants discharged home on caffeine therapy will receive instructions regarding use of a home monitor. Follow up in the pulmonary clinic will be arranged at 42-43 weeks gestational age. At 43 weeks corrected gestational age, caregivers will be instructed to discontinue caffeine therapy. An outpatient recorded oximetry study will be arranged at least 1 week after discontinuation of caffeine therapy. Home pulse oximetry monitoring will be discontinued if no significant events, as previously defined, are recorded.
62515636|NCT02823314|EXPERIMENTAL|Intervention group|One piece of a special hypoallergenic adhesive tape, called Cure Tape®, they will have a size of 12-20 cm and will be attached in the front and back torso area on the T7- T8 dermatomes.
62515637|NCT02823314|PLACEBO_COMPARATOR|Placebo group|Two piece of a special hypoallergenic adhesive tape, called Cure Tape®, have a size of 2.5 cm x 2 cm and they will have to be placed near the greater trochanter area.
62515638|NCT02211014|EXPERIMENTAL|Cohort 1|Acalabrutinib 100 mg twice daily (bid) continuously
62515639|NCT02211014|EXPERIMENTAL|Cohort 2|Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
62515640|NCT00573170|OTHER|TPB|TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
62515641|NCT00573170|OTHER|TBP|TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
62515642|NCT00573170|OTHER|BTP|BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
62515643|NCT00573170|OTHER|BPT|BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
62515644|NCT00573170|OTHER|PTB|placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
62515645|NCT00573170|OTHER|PBT|placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)
62515646|NCT01401374||Vitiligo Patients|patients with vitiligo vulgaris
62515647|NCT01401374||Controls|Individuals without vitiligo vulgaris
62515648|NCT01546649|EXPERIMENTAL|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
62515649|NCT01546649|ACTIVE_COMPARATOR|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
62515650|NCT04764630|EXPERIMENTAL|A. Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min)
62515651|NCT04764630|EXPERIMENTAL|B. Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
62515652|NCT04764630|ACTIVE_COMPARATOR|C. Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
62515653|NCT05208658|EXPERIMENTAL|Classical Vision Therapy Treatment: vision therapy exercises for fusional vergence abilities|"The Experimental Group (EG) it consist in a Classical Vision Therapy Treatment. This group will do weekly office-based therapy of 45 minutes of visual exercises during 12 weeks. The office-based done by the EG consists of a vergence therapy and its protocol will follow Scheiman's Protocol and Indications.~The exercises do not tough the eye or use drugs. They are just visual training exercises that improve fusional convergence and divergence response."
62515654|NCT05208658|PLACEBO_COMPARATOR|Eye Movement Therapy Treatment: vision therapy placebo exercises not improve fusional vergence|"The Control Group or Placebo Group consist in a Control: Eye Movement Therapy Treatment. This group will do weekly office-based placebo therapy of 15 minutes during 12 weeks of visual exercises. This placebo therapy will consist of smooth-pursuit and discrimination exercises that do not influence vergence response.~The exercises do not tough the eye nor use drugs. They are just visual training exercises that do not improve fusional vergence response as they improve smooth-pursuit eye movements."
62515655|NCT02035020|EXPERIMENTAL|Gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
62515656|NCT06199713||Advanced Melanoma Patients with Immune Checkpoint Inhibitors|
61973622|NCT01572454|ACTIVE_COMPARATOR|Remifentanil group|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
62515657|NCT01758146|EXPERIMENTAL|Arm A- Letrozole|Aromatase inhibitor- letrozole 2.5mg once daily for 5 years
62515658|NCT01758146|ACTIVE_COMPARATOR|Arm B- Tamoxifen|Tamoxifen 20 mg once daily for 5 years
62515659|NCT04508920||Basal|"All adults (age \>18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2019 ( without covid-19 )"
62515660|NCT04508920||Ourbreak|"All adults (age \>18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2020 ( ongoing covid-19 )"
62515661|NCT05683210|EXPERIMENTAL|Cup feeding|The infants in the control group were fed with a cup. During feeding, all infants in this group were placed in semi-elevated supine position. The position of the infant was adjusted so that when the milk reached the tongue, the infant would start foraging, dip his/her tongue into the milk by dimpling and slurp the milk with his/her tongue through a negative pressure, swallow as much as he/she wants and leave the rest back to the cup. The stopwatch was activated when the infant began to drink the milk from the cup, and the stopwatch was stopped when the infant no longer slurped the milk, and the feeding process was completed. When the infant was physiologically (HR of 120-160/min, SpO2 ≥90) and behaviourally ready, feeding was resumed and the infant was prevented from getting tired during feeding and actively participated in feeding. Feeding time was limited to 30 minutes in either group, including the infants' resting time.
62515662|NCT05683210|EXPERIMENTAL|Bottle feeding|The infants in the experimental group were fed with a bottle. The teat of the feeding bottle was selected to be smaller in size, softer and with a smaller hole than the teat of the term infant and suitable for preterm infants. The same brand and model of bottle and teat were used for each infant. All infants in this group were fed in a semi-elevated side-lying position, as it was more similar to the position in which the infant suckled the mother's breast. The infant's lips were tapped with the bottle teat for stimulating to feed, and when the infant opened his/her mouth and drooped his/her tongue, the teat of the bottle was put into his/her mouth. The time elapsed from when the infant started to suck the bottle until he/she released the bottle from his/her mouth was considered as the feeding phase.
62515663|NCT00982891|EXPERIMENTAL|Morphine, low dose, in addition to conventional treatment|Morphine dose titration
62515664|NCT00070616|EXPERIMENTAL|Palifermin 6 x 60 μg/kg/day|The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).
62515665|NCT00070616|EXPERIMENTAL|Palifermin 2 x 180 μg/kg/day|The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion
62515666|NCT06617338|EXPERIMENTAL|Participant receives bilateral knee CT preoperatively|The P.I. (Dr. Malkani) will use normal contralateral side joint numbers as the target alignment for RA-TKA
62515667|NCT06617338|ACTIVE_COMPARATOR|Participant receives unilateral CT of the operative knee preoperatively|The P.I. will use the traditional method to obtain target alignment for RA-TKA.
62515668|NCT02128529||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
62515669|NCT04109859|EXPERIMENTAL|Methylene blue group|Before the anesthesia was intubated, the patients in the methylene blue group were given a 2 mg/Kg methylene blue 50 ml intravenously for 10 min; continuous constant speed pumping methylene blue(0.5mg/Kg/h).
62515670|NCT04109859|PLACEBO_COMPARATOR|Placebo group|Before the anesthesia was intubated, the placebo group was given 50 ml of normal saline for 10 min.continuous constant speed pumpingnormal saline (10ml/h).
62515671|NCT05213260|EXPERIMENTAL|intervention group (Flipped Teaching Method Group)|"Flipped classroom for intervention group:~The students allotted to the flipped classroom teaching approach will receive the pre-session learning materials (video access links) three days prior to the clinical case session through their institutional email addresses. Students will be encouraged to complete the assigned tasks before coming to class.~The session will start by reviewing the objectives, discussing the difficult points they have in the preparation materials, and answering any question. They also will be shortly briefed about how the scenario would run. They will have a fixed time to take the cardiovascular history, perform examination, order appropriate investigations, reach a differential diagnosis, and formulate a treatment plan. During the session, the instructor will evaluate these students at each level of clinical case-solving. Finally, post-session survey will be disseminated via email to know the students' perception of the flipped teaching."
62515672|NCT05213260|NO_INTERVENTION|Control group (Traditional Method Group)|This group of students, included 20 participants, will be briefed by the instructors for 30 minutes immediately before the clinical skill session about the clinical case which will include: history taking, examination, investigations, diagnosis, and treatment plan. Following that, there will be time for practice and discussion amongst the students on a high-fidelity manikin. Of note, these students will not receive any pre-session teaching material as the intervention group.
62539484|NCT05209594|ACTIVE_COMPARATOR|Regular GSA Programming|Students in grades 9 to 12 participating in regular GSA programming.
61973623|NCT00099853|EXPERIMENTAL|Vildagliptin 50 mg qd + pioglitazone 45 mg qd|Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks
62354391|NCT03384628|ACTIVE_COMPARATOR|Third pair Senofilcon A contact lens|The third pair of Senofilcon A contact lens is applied (according to the fitting schedule), allowed to settle before assessment of the third pair Senofilcon A contact lens and subsequent removal.
61973624|NCT00099853|EXPERIMENTAL|Vildagliptin 50 mg bid + pioglitazone 45 mg qd|Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks
62354392|NCT02406053||OSAS|Obstructive sleep apnea syndrome
62354393|NCT02406053||COPD|Chronic obstructive pulmonary disease
62354394|NCT02406053||LC|Lung cancer
62354395|NCT02406053||HC|Healthy controls
62354396|NCT04733872|PLACEBO_COMPARATOR|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
62354397|NCT04733872|EXPERIMENTAL|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
62354398|NCT02920606|ACTIVE_COMPARATOR|Endodontic treatment|"The patient will benefit from a conventional treatment : a root canal treatment.~The root canal treatment consists of removing the pulp tissue from all the canals, disinfecting the root canal system with sodium hypochlorite and filling the root with a root canal sealer and gutta percha."
61973625|NCT00099853|PLACEBO_COMPARATOR|Vildagliptin placebo + pioglitazone 45 mg qd|Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks
61973626|NCT04400240|EXPERIMENTAL|Intervention|complete questionnaires and phone sessions
61973627|NCT04400240|NO_INTERVENTION|Control|complete questionnaires only
61973628|NCT01781403|EXPERIMENTAL|Capecitabine, Temozolomide, Radiotherapy|"The total dose of radiotherapy will be 50.4 Gy, with a daily dose of 1.8 Gy administered on 5 days of each week, comprising a total of 45 Gy to the whole pelvis, followed by a 5.4 Gy boost to the primary tumor.~The doses and schedules for capecitabine will be fixed, with only temozolomide being prescribed using a dose-escalation schedule. Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break)."
61973629|NCT05502393|EXPERIMENTAL|JS107|
61973630|NCT05502393|EXPERIMENTAL|JS107 combination with Toripalimab|
61973631|NCT02766725|EXPERIMENTAL|preparation F12 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
61973632|NCT02766725|ACTIVE_COMPARATOR|preparation F2 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
61973633|NCT02766725|PLACEBO_COMPARATOR|placebo gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator
62147704|NCT03652610|EXPERIMENTAL|GSK3536820A ACWY_Liq Group|Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
62147705|NCT03652610|ACTIVE_COMPARATOR|ACWY Group|Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).
62515673|NCT03595163|EXPERIMENTAL|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
62539485|NCT04320342|EXPERIMENTAL|BDP/FF/GB - CHF 5993|Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler
61973634|NCT05001386|EXPERIMENTAL|Lymphoproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .
61973635|NCT05001386|SHAM_COMPARATOR|Control group|Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)
61973636|NCT05001386|EXPERIMENTAL|Myeloproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).
61973637|NCT06043076|EXPERIMENTAL|Active then sham stimulation|Active iTBS over the left M1 hand region, followed after 1 week washout period by sham iTBS over the left M1 hand region
61973638|NCT06043076|EXPERIMENTAL|Sham then active stimulation|Sham iTBS over the left M1 hand region, followed after 1 week washout period by active iTBS over the left M1 hand region
61973639|NCT05153239|EXPERIMENTAL|Lurbinectedin|Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)
61973640|NCT05153239|EXPERIMENTAL|Lurbinectedin plus Irinotecan|"Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):~* Irinotecan (Day 1 and Day 8)~* Lurbinectedin (Day 1)"
61973641|NCT05153239|ACTIVE_COMPARATOR|Control arm|"Best Investigator's choice prior to randomization between:~* Irinotecan on Day 1 q3wk~* Topotecan on Days 1-5 q3wk"
61973642|NCT00741637|EXPERIMENTAL|Vaccine|Live attenuated oral CholeraGarde® (5x107 to 1x109 CFU) vaccine
61973643|NCT00741637|PLACEBO_COMPARATOR|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
61973644|NCT01586676|EXPERIMENTAL|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP)
61973645|NCT01586676|ACTIVE_COMPARATOR|Supervision-as-usual|Supervision-as-usual consists of the typical clinical supervision services provided to clinicians by their supervisors in their community programs.
61973646|NCT01694641|EXPERIMENTAL|time-lapse morphokinetic evaluation|"Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention."
61973647|NCT01694641|NO_INTERVENTION|standard embryo monitoring|Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.
61973648|NCT06462807|EXPERIMENTAL|Accessibility, Responsiveness, Continuity (ARC)|
61973649|NCT06462807|NO_INTERVENTION|Standard of Care (SOC)|
62147706|NCT02095678|EXPERIMENTAL|HCC or metastatic Liver Lesions|Patients with HCC or metastatic liver lesions who are refered to the abdominal imaging and biopsy clinic will have a liver biopsy performed. 3-5 days after a clinical MRI indicating a cancerous lesion, patients will return for the free-breathing MRI and a liver biopsy. These images will be compared to the clinical MRI and to images of the benign lesions.
62539486|NCT04320342|ACTIVE_COMPARATOR|BDP/FF - CHF 1535|Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler
62515674|NCT03595163|ACTIVE_COMPARATOR|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
62515675|NCT00266240|EXPERIMENTAL|1|
62515676|NCT00266240|EXPERIMENTAL|2|
62515677|NCT00266240|EXPERIMENTAL|3|
62515678|NCT00266240|EXPERIMENTAL|4|
62515679|NCT00266240|PLACEBO_COMPARATOR|5|
62515680|NCT02384850|EXPERIMENTAL|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
62515681|NCT06617273|OTHER|A) IOP 28mmHg on the better eye and IOP 50mmHg on the worse eye|Near normal intraocular pressure cataract surgery using active anterior chamber pressure sensing and regulation
62515682|NCT06617273|OTHER|B) IOP 28mmHg on worse eye and IOP 50mmHg on the better eye|Near normal intraocular pressure cataract surgery using active anterior chamber pressure sensing and regulation
62515683|NCT06132620|EXPERIMENTAL|the experimental group|
62515684|NCT06132620|ACTIVE_COMPARATOR|the control group|
62515685|NCT01373879|EXPERIMENTAL|Group 1A|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
62515686|NCT01373879|EXPERIMENTAL|Group 1B|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME TRAP
62515687|NCT01373879|EXPERIMENTAL|Group 2A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
62515688|NCT01373879|EXPERIMENTAL|Group 2B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
61973650|NCT01550640|EXPERIMENTAL|remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
61973651|NCT01550640|NO_INTERVENTION|standard|control standard group
62515689|NCT01373879|ACTIVE_COMPARATOR|Group 2C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
62515690|NCT01373879|EXPERIMENTAL|Group 3A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
61973652|NCT06214104|EXPERIMENTAL|acupressure|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.
61973653|NCT06214104|EXPERIMENTAL|fetal position|The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
62515691|NCT01373879|EXPERIMENTAL|Group 3B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
62515692|NCT01373879|ACTIVE_COMPARATOR|Group 3C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
62515693|NCT06193824|EXPERIMENTAL|downhill treadmill walking -10% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% incline)
62515694|NCT06193824|EXPERIMENTAL|downhill treadmill walking -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-20% incline)
61973654|NCT06214104|NO_INTERVENTION|Control group|no intervention
61973655|NCT02894918|EXPERIMENTAL|Combination group|Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
62515695|NCT01280617|EXPERIMENTAL|Thymoglobulin 1.25mg/kg dose|The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.
62515696|NCT01280617|EXPERIMENTAL|Thymoglobulin 0.75mg/kg dose|The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.
62515697|NCT04579276|EXPERIMENTAL|"surgical method"|
62515698|NCT04579276|ACTIVE_COMPARATOR|"anesthetic method"|
62515699|NCT06363253||Obese|Patients with BMI \> 27.5 kg/m2
62515700|NCT06363253||Sarcopenic|"Patients who are sarcopenic, defined by the Asian Working Group on Sarcopenia 2014 criteria, which is defined as~1. having low handgrip strength (\<26kg for males; \<18kg for females) AND/OR~2. Low gait speed (\<0.8m/s) AND~3. Low muscle mass (\<7.0kg/m2 for males; \<5.7kg/m2 for females)"
62515701|NCT06363253||Controls|Healthy volunteers who are not obese (BMI \<27.5kg/m2), OR who are screened and found to not be sarcopenic
62515702|NCT06188130|EXPERIMENTAL|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. The patient received robotic therapy for lower extremity just after each active TMS sessions
62515703|NCT06188130|SHAM_COMPARATOR|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil. The patient received robotic therapy for lower extremity just after each sham TMS sessions
62515704|NCT06188130|EXPERIMENTAL|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions. The patient received robotic therapy for lower extremity just after each active tDCS sessions
61973656|NCT02894918|NO_INTERVENTION|Mono NA group|Maintain NAs mono-therapy oral-daily for 48 weeks.
62515705|NCT06188130|SHAM_COMPARATOR|sham tDCS|Participants recevied sham stimulation. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
62515706|NCT01293552|PLACEBO_COMPARATOR|Control|blank vehicle formulation
61973657|NCT01817621|EXPERIMENTAL|Experimental Intervention|
61973658|NCT01817621|ACTIVE_COMPARATOR|TAU Condition|
61973659|NCT00459108|EXPERIMENTAL|Oral Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61973660|NCT03655197|NO_INTERVENTION|Healthy Subjects|Healthy subjects will receive no intervention and will have samples collected only at one visit after Dove soap washout.
62515707|NCT01293552|EXPERIMENTAL|Dose 1|Dose 1
62515708|NCT01293552|EXPERIMENTAL|Dose 2|Dose 2
62515709|NCT01293552|EXPERIMENTAL|Dose 3|Dose 3
62515710|NCT01293552|EXPERIMENTAL|Dose 4|Dose 4
62515711|NCT06226948|EXPERIMENTAL|Intervention group 1|Participants will use a continuous blood glucose monitoring and visualization of CVDs risk.
62515712|NCT06226948|EXPERIMENTAL|Intervention group 2|Participants will use a continuous blood glucose monitoring.
62515713|NCT06226948|EXPERIMENTAL|Intervention group 3|Participants will use a visualization of CVDs risk.
62515714|NCT06226948|NO_INTERVENTION|Control group|No intervention.
62147707|NCT02095678|ACTIVE_COMPARATOR|Benign Liver Lesion|Patients with benign liver lesions will be referred to the study team. 3-5 days after a clinical MRI an experimental, free-breathing MRI will be performed on these patients. The results will be compared to their clinical MRI images and to images of HCC or metastatic lesions
62515715|NCT01514994|EXPERIMENTAL|AngioScore's Valvuloplasty Scoring Balloon|
62515716|NCT03243929|EXPERIMENTAL|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
62515717|NCT03243929|OTHER|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
62515718|NCT00903552|EXPERIMENTAL|Low Dose|
62515719|NCT00903552|PLACEBO_COMPARATOR|PBS|
62515720|NCT00903552|EXPERIMENTAL|High Dose|
62515721|NCT04352465|EXPERIMENTAL|A|Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
62515722|NCT04352465|EXPERIMENTAL|B|Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
62515723|NCT04352465|EXPERIMENTAL|C|Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
62515724|NCT05530070|ACTIVE_COMPARATOR|Dietary intervention|Patients randomized to the dietary intervention group.
62515725|NCT05530070|ACTIVE_COMPARATOR|Standard of care|Patients randomized to the standard of care group.
62515726|NCT04702763||Multiple Sclerosis (Eye-Tracker®T2 + e-VOG)|Multiple Sclerosis subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
62515727|NCT04702763||Multiple Sclerosis (e-VOG + Eye-Tracker®T2)|Multiple Sclerosis subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
62515728|NCT03528473|EXPERIMENTAL|Exercise|Patients involved in the 6 months-physical training group.
62515729|NCT03528473|NO_INTERVENTION|Control|Patients in control group carry on their usual follow-up programme.
62515730|NCT05319613|OTHER|Telemedicine Clinical Care|Rural participants who enter PrEP clinical care with University of Colorado HIV Prevention Program will receive care via telemedicine with mailed lab kits and mailed HIV PrEP.
62515731|NCT03803033|EXPERIMENTAL|Intervention|The objective of the group was to introduce an experimental clinical pharmacy-based home medication review service in the outpatient clinic setting of the Jordan University Hospital in Amman, Jordan. The intervention under evaluation in the study is the pharmacy-based home medication review service.
62515732|NCT03803033|NO_INTERVENTION|Control|The objective of the control group was to identify changes in treatment and associated costs that take place in patients as part of the usual practice, as compared to the intervention arm, regardless of the clinical pharmacist service intervention.
62515733|NCT03463993|EXPERIMENTAL|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
62515734|NCT03463993|ACTIVE_COMPARATOR|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
62515735|NCT02385201|EXPERIMENTAL|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
62515736|NCT00295139|EXPERIMENTAL|1|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
62515737|NCT00295139|EXPERIMENTAL|2|Behavioral Treatment for Substance Abuse in SPMI (BTSAS) + Critical Time Intervention (CTI)
62515738|NCT00295139|ACTIVE_COMPARATOR|3|Supportive Treatment in Addiction Recovery (STAR)
62715087|NCT06589050|NO_INTERVENTION|Control group|The control group will continue with the ballet school's normal training schedule.
62715088|NCT05962229|EXPERIMENTAL|S-nicotine (tobacco) as the starting condition|Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.
62147708|NCT02809755|EXPERIMENTAL|4% lidocaine|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
62515739|NCT03570450|EXPERIMENTAL|Adipose derived Stem Cells - 1.10^6cells/kg|ADSC, single, IV, 1.10\^6cells/kg
62515740|NCT03570450|EXPERIMENTAL|Adipose derived Stem Cells - 2.10^6cells/kg|ADSC, single, IV, 2.10\^6cells/kg
62515741|NCT03570450|EXPERIMENTAL|Adipose derived Stem Cells - 2,5.10^6cells/kg|ADSC, single, IV, 2,5.10\^6cells/kg
62515742|NCT03570450|EXPERIMENTAL|Adipose derived Stem Cells - 3.10^6cells/kg|ADSC, single, IV, 3.10\^6cells/kg
62515743|NCT03570450|PLACEBO_COMPARATOR|placebo|Placebo
62515744|NCT02883478|ACTIVE_COMPARATOR|Treatment group A|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 3 milliwatt/cm² (mW/cm²) for 30 minutes.~Device: UV-X 1000 irradiator (3 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
62515745|NCT02883478|ACTIVE_COMPARATOR|Treatment group B|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 9 mW/cm² for 10 minutes.~Device: UV-X 2000 irradiator (9 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
62715089|NCT05962229|EXPERIMENTAL|R-nicotine (synthetic) as the starting condition|Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.
61973661|NCT03655197|EXPERIMENTAL|Ocular Rosacea Subjects|Ocular rosacea subjects will receive mandatory Doxycycline intervention and will have samples collected at two visits, before starting intervention and at the completion of the intervention.
61973662|NCT03655197|OTHER|Cutaneous Rosacea Subjects|Doxycycline intervention is optional for cutaneous rosacea subjects. If they do not participate, samples will only be collected at one visit after Dove soap washout. If they do decide to participate, samples will also be collected after completion of the Doxycycline intervention.
61973663|NCT05484518|EXPERIMENTAL|Method of Levels Therapy|Method of levels therapy, see intervention details. All participants will receive therapy and must attend a minimum of one session for their data to be included in the study.
61973664|NCT01635101|EXPERIMENTAL|Low Dose Acetaminophen|Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours
61973665|NCT01635101|EXPERIMENTAL|High Dose Acetaminophen|Participants receive a low dose of acetaminophen (IV) for 24 hours
61973666|NCT01635101|PLACEBO_COMPARATOR|Placebo|Participants receive matching placebo (IV) for 24 hours
61973667|NCT04931862|EXPERIMENTAL|WVE-004 (Dose A) or placebo|
62515746|NCT02592759|EXPERIMENTAL|Smart Glove Group|The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
62515747|NCT02592759|NO_INTERVENTION|Homework group|The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
61973668|NCT04931862|EXPERIMENTAL|WVE-004 (Dose B) or placebo|
61973669|NCT04931862|EXPERIMENTAL|WVE-004 (Dose C) or placebo|
61973670|NCT04931862|EXPERIMENTAL|WVE-004 (Dose D) or placebo|
61973671|NCT03017651|EXPERIMENTAL|OM3-supplement 1|1 g capsule for OM3-supplement 1 given once
61973672|NCT03017651|ACTIVE_COMPARATOR|OM3-supplement 2|1 g capsule for OM3-supplement 2 given once
61973673|NCT02287272|ACTIVE_COMPARATOR|Treatment period R|single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
61973674|NCT02287272|ACTIVE_COMPARATOR|Treatment period T|Cimetidine plus CHF5993 pMDI: repeated doses of oral cimetidine for 6 days plus a single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
61973675|NCT01723852|ACTIVE_COMPARATOR|Vitamin D supplement|Vitamin D supplement according to national guidelines (10 ug/day) from 2 weeks to 2 years of age
61973676|NCT01723852|ACTIVE_COMPARATOR|Vitamin D supplement at 30 ug/day|Vitamin D supplement at 30 ug/day from 2 weeks to 2 years of age
61973677|NCT02194205|EXPERIMENTAL|COMBIVENT HFA|
61973678|NCT02194205|PLACEBO_COMPARATOR|Placebo HFA|
61973679|NCT02194205|ACTIVE_COMPARATOR|COMBIVENT (CFC)|
61973680|NCT02194205|PLACEBO_COMPARATOR|Placebo CFC|
61973681|NCT05856201|ACTIVE_COMPARATOR|laparoscopic cervicosacropexy (CSP)|
61973682|NCT05856201|ACTIVE_COMPARATOR|Shull technique via V-NOTES (VNS)|
61973683|NCT01280916|EXPERIMENTAL|Mind-body intervention|Mindful Awareness in Body-oriented Therapy
61973684|NCT01280916|NO_INTERVENTION|Treatment as Usual|
61973685|NCT01601626|EXPERIMENTAL|A: Standard-dose LPV/r w/RBT|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
61973686|NCT01601626|ACTIVE_COMPARATOR|B: Double-dose LPV/r w/RIF|"ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
62147709|NCT02809755|PLACEBO_COMPARATOR|Placebo Saline|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
62515748|NCT00685802|EXPERIMENTAL|Cilostazol 50 mg Tablets|A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
62515749|NCT00685802|EXPERIMENTAL|Cilostazol (Pletal® ) 50 mg Tablets|A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
62515750|NCT02172482||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
62515751|NCT01435447|EXPERIMENTAL|FLu-Bu-Cy|Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
61973687|NCT01601626|EXPERIMENTAL|C: Standard-Dose LPV/r w/RBT + RAL|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
61973688|NCT04945551|EXPERIMENTAL|Diabetes|Aerobic exercise training
61973689|NCT04945551|EXPERIMENTAL|Healthy|Aerobic exercise training
61973690|NCT04506554|EXPERIMENTAL|AMVAC + nivolumab|This will be a single-arm, open-label, multicenter phase 2 study of neoadjuvant nivolumab with AMVAC. Approximately 70 evaluable patients will be enrolled into this study. Eligible patients will be those with diagnosis of muscle invasive urothelial carcinoma of the bladder who are cT2 or cT3 but not clinical N1 at diagnosis. Clinical stage is confirmed by transurethral resection of bladder tumor (TURBT#1).
61973691|NCT01740986|EXPERIMENTAL|SA09012 Low dose|
61973692|NCT01740986|EXPERIMENTAL|SA09012 High dose|
61973693|NCT01740986|PLACEBO_COMPARATOR|Placebo|
61973694|NCT02423577|EXPERIMENTAL|FF-3 dry powder|FF-3
61973695|NCT02423577|PLACEBO_COMPARATOR|Placebo|
61973696|NCT04333823|EXPERIMENTAL|Intervention (Dapagliflozin)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
62515752|NCT01583517|ACTIVE_COMPARATOR|Biliary sphincterotomy|Cutting of the biliary sphincter muscle alone
62515753|NCT01583517|ACTIVE_COMPARATOR|Dual sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
62515754|NCT01583517|SHAM_COMPARATOR|Sham|Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
62515755|NCT01583517|ACTIVE_COMPARATOR|Biliary sphincterotomy - Normal SOM|Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
62515756|NCT03170388|EXPERIMENTAL|IDP-126 Gel|Gel
62515757|NCT03170388|ACTIVE_COMPARATOR|IDP-126 Component A|Component A
62515758|NCT03170388|ACTIVE_COMPARATOR|IDP-126 Component B|Component B
62515759|NCT03170388|ACTIVE_COMPARATOR|IDP-126 Component C|Component C
62515760|NCT03170388|PLACEBO_COMPARATOR|IDP-126 Vehicle Gel|Vehicle Gel
62515761|NCT01766791|EXPERIMENTAL|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1 Repetition Maximum (1RM)
62515762|NCT01766791|EXPERIMENTAL|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - \<75% 1RM
62515763|NCT01766791|EXPERIMENTAL|HIT-exercise with protein|High Intensity Resistance Exercise Training with protein supplementation
62515764|NCT01766791|PLACEBO_COMPARATOR|Control|No physical exercise intervention
61973697|NCT04333823|PLACEBO_COMPARATOR|Control (Placebo)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
62515765|NCT03004859||Adults ≥ 65 with a positive test result|Adults ≥ 65 that are got a positive test result were asked to visit their general practitioner and are called for an interview two times, 8 weeks and 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacies as well as of the two telephone interviews are compared to the results of the adults ≥ 65 with a negative test result.
62515766|NCT03004859||Adults ≥ 65 with a negative test result|Adults ≥ 65 that are got a negative test result are called for an interview 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacy as well as of the telephone interview are compared to the results of the adults ≥ 65 with a positive test result.
61973698|NCT04980690|EXPERIMENTAL|Phase Ia - Dose escalation(Acceleration Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~Acceleration Stage: The initial increasing dose is 0.025 mg/kg, and the dose is increased in 100% increments. Each dose group will enroll 1 subject."
61973699|NCT04980690|EXPERIMENTAL|Phase Ia - Dose escalation(3+3 Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~3+3 Stage: The dose is increased in 30%-50% increments between adjacent dose groups, and the increment is determined by the investigator and the sponsor based on the safety data obtained in the previous period.Each dose group will enroll 3 to 6 evaluable subjects (evaluable: at least complete the DLT observation period), and this period continues until the maximum tolerated dose (MTD) is reached."
61973700|NCT04980690|EXPERIMENTAL|Phase Ib - Dose extension|"Phase Ib is an open, non-random, single-arm, multi-center research design.~When phase Ia is transformed into 3+3 stage, a certain dose group meets the conditions for increasing the next dose group (after the DLT observation period of the last subject in the dose group has passed, the safety assessment of the current dose group will be completed) , The dose extension study of this dose group can be carried out, and 6 evaluable (evaluable: at least 2 cycles of dosing and observation) subjects with advanced malignant tumors who have failed standard treatments will be included in this dose group."
61973701|NCT04980690|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage(Group A)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group A: Recurrent or metastatic triple-negative breast cancer that failed standard treatment."
61973702|NCT04980690|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage(Group B)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group B: Locally advanced/metastatic non-small cell lung cancer without driver gene mutations that failed standard treatment."
61973703|NCT04980690|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage(Group C)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group C: Recurrent or metastatic head and neck squamous cell carcinoma that failed standard treatment."
62147710|NCT00724737|ACTIVE_COMPARATOR|fMRI of the brain, no surgery|Healthy volunteers will undergo an fMRI (functional MRI of the brain).
62147711|NCT00724737|EXPERIMENTAL|fMRI of the brain, presurgical|Patients scheduled to have brain surgery will undergo an fMRI (functional MRI of the brain).
62147712|NCT01558349||Hospitalized controls|Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
62147713|NCT01558349||Metastatic melanoma|This cohort includes patients with metastatic melanoma.
62515767|NCT04987255|ACTIVE_COMPARATOR|Free visit|Free visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
62515768|NCT04987255|EXPERIMENTAL|Guided visit|Guided visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
62515769|NCT04987255|OTHER|Guided visit for individuals after stroke|This arm is specific for individuals with motor disability after stroke (non randomized condition)
62515770|NCT03046719|ACTIVE_COMPARATOR|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
62515771|NCT03046719|PLACEBO_COMPARATOR|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
62515772|NCT03327714|EXPERIMENTAL|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
62515773|NCT03327714|NO_INTERVENTION|Control group|The control group consists of children who do not perform mindfulness in school.
62515774|NCT00977548|EXPERIMENTAL|Erlotinib Treatment|Erlotinib was given as an oral 150 mg daily dose for 16 weeks. The dose was adjusted for diarrhea, rash and pulmonary toxicity.
62515775|NCT04158817|EXPERIMENTAL|Experimental Arm|All Prostate cancer patients recruited to the study will be administered 2.11 MBq/kg of 68Ga-THP-PSMA in a single dose injection.
62515776|NCT04617392|ACTIVE_COMPARATOR|controlled group|25 patients after bariatric-metabolic surgery without controlled postprocedural training
62515777|NCT04617392|EXPERIMENTAL|active group|25 patients after bariatric-metabolic surgery with controlled postprocedural training
62515778|NCT04222114|EXPERIMENTAL|Catumaxomab group|
62147714|NCT01106885|NO_INTERVENTION|Enhanced Usual Care|"Adult patients with diabetes and depression.~* Report screening results~* Notify PCP of screening results (optional per patient)~* PCP referrals~* Educational materials regarding diabetes, physical activity, and depression"
62515779|NCT04222114|ACTIVE_COMPARATOR|IC group|IC group is defined as the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
62515780|NCT03410043|EXPERIMENTAL|Group I (LCT)|Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62515781|NCT03410043|EXPERIMENTAL|Group II (no LCT)|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62515782|NCT04693338|EXPERIMENTAL|Supportive care (ICP)|Patients complete surveys for 4 common symptoms: fatigue, hot flashes, insomnia, and sexual dysfunction and receive educational material via mobile app to help with bothersome symptoms. Patients also complete questionnaires.
62515783|NCT01131299|ACTIVE_COMPARATOR|Alpha cyclodextrin first then placebo|Randomized subjects will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks. After the one week washout, the subjects will receive 2 tablets orally of placebo (three times a day for 12-14 weeks).
62515784|NCT01131299|PLACEBO_COMPARATOR|Placebo first then Alpha cyclodextrin|Participants will receive 2 tablets orally of placebo (three times a day for 12-14 weeks). The subjects will have a one-week washout. After the washout, the participants will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks.
62515785|NCT02610816|ACTIVE_COMPARATOR|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
62515786|NCT02610816|ACTIVE_COMPARATOR|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
62515787|NCT02610816|OTHER|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
62515788|NCT02610816|OTHER|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
62515789|NCT00597116|ACTIVE_COMPARATOR|1|Vinorelbine
62515790|NCT00597116|EXPERIMENTAL|2|Vandetanib
62515791|NCT00627471|ACTIVE_COMPARATOR|A|This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
61973704|NCT04980690|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage(Group D)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group D: Recurrent or metastatic peripheral T-cell lymphoma that failed standard treatment."
61973705|NCT02130973|ACTIVE_COMPARATOR|Standard Clinical Practice Regimen|Standard Clinical Practice (Daily) Regimen: 18 months of daily subcutaneous Forteo followed by denosumab therapy for 18 months (18 months of Forteo then 3 injections of Prolia at 18, 24 and 30 months).
61973706|NCT02130973|EXPERIMENTAL|Experimental (cyclic) regimen|Experimental (Cyclic) Regimen: three separate 6-month cycles of daily subcutaneous Forteo, each followed by one subcutaneous injection of Prolia (Forteo from 0 to 6 months, and then from 12 to 18 months and then from 24 to 30 months, for a total dose of 18 months; 3 injections of Prolia at 6, 18 and 30 months).
61973707|NCT02323477|EXPERIMENTAL|Allogeneic umbilical cord MSC group|Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF\<%45)
61973708|NCT02323477|ACTIVE_COMPARATOR|Autologous bone marrow-derived MNC group|Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF\<%45)
61973709|NCT02323477|NO_INTERVENTION|Control group|20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF\<%45) whom will not received any further transplantation
61973710|NCT01050972|EXPERIMENTAL|Cognitive and physical program|Experimental: Cognitive and physical program. Non randomized residents in the territory of Piedmont (Piemonte) Italy.
61973711|NCT03407105|EXPERIMENTAL|Arm 2|Specified dose on specified days
61973712|NCT02845544|EXPERIMENTAL|Experimental group - Pilates|A Pilates-based exercises program of 6 weeks' duration
61973713|NCT02845544|NO_INTERVENTION|Control group - no exercises|
61973714|NCT04973124|ACTIVE_COMPARATOR|SEVODEX Group|The SEVODEX group will receive intraoperative dexmedetomidine at a fixed infusion rate of 0.25 mcg/kg/h
61973715|NCT04973124|PLACEBO_COMPARATOR|SEVO Group|The SEVO group will not receive dexmedetomidine during surgery.
62147715|NCT01106885|EXPERIMENTAL|Staged Care Management|Adult patients with diabetes and depression
62147716|NCT01000467|ACTIVE_COMPARATOR|2|Group 2(probucol 500mg BID)
62147717|NCT01000467|ACTIVE_COMPARATOR|1|Group 1(Probucol 250mg)
62147718|NCT01000467|ACTIVE_COMPARATOR|3|Group 3(Probucol 500mg once daily)
62515792|NCT00627471|ACTIVE_COMPARATOR|B|This is the control group, following the physician's standard practice.
62515793|NCT00685490||Surgical|Retrospective chart review of 70 eyes of 70 consecutive patients who underwent PPV, with and without ILM peeling, for persistent macular edema associated with BRVO
62715090|NCT05962229|EXPERIMENTAL|Racemic (50:50 S- and R- nicotine) as the starting condition|Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.
62715091|NCT06263595||GLP-1 Agonist Group|Intervention: elective surgical patients taking GLP-1 receptor agonists
62715092|NCT06263595||Non GLP-1 Agonist Group|Intervention: elective surgical patients not taking GLP-1 receptor agonists
61973716|NCT03985631|EXPERIMENTAL|Telerehabilitation|Tai Chi intervention by telerehabilitation (3-month intervention, three sessions per week: two supervised session and one unsupervised session).
61973717|NCT00418314|EXPERIMENTAL|QuickOpt (Treatment)|Frequent optimization using QuickOpt to optimize the AV/PV and VV Delays.
62147719|NCT00310037|EXPERIMENTAL|Arm A maintenance therapy|Patients receive bortezomib 1.6 mg/m\^2 IV on days 1, 8, 15, and 22 once daily for 4 weeks. There will be a 4 week rest period. One cycle is a total of 8 weeks. A total of 10 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
62515794|NCT00248170|EXPERIMENTAL|Letrozole|2.5 mg by mouth (p.o.) once daily
62515795|NCT00248170|ACTIVE_COMPARATOR|Anastrozole|1 mg p.o. once daily
61973718|NCT00418314|ACTIVE_COMPARATOR|Control|Empiric programming or one-time optimization using a non-IEGM method.
61973719|NCT04937621||SARS-CoV-2 infection|This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
61973720|NCT01571427|PLACEBO_COMPARATOR|Control group|No daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
61973721|NCT01571427|ACTIVE_COMPARATOR|Active social engagement group|Engage in 30 minutes video chat daily (5 times per week, except weekend) with interviewers for 6 weeks. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
61973722|NCT04044716|EXPERIMENTAL|Auricular acupressure Group|The Auricular acupressure (AA) nurses will place the acupressure pellet pads on the participants in this group post-operatively.
62354399|NCT02920606|EXPERIMENTAL|Pulpotomy|The patient will benefit from an experimental treatment : a pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
62354400|NCT02571608|ACTIVE_COMPARATOR|Metformin|Metformin, dosage same as the patient's regular dosage
62354401|NCT02571608|PLACEBO_COMPARATOR|Placebo|Placebo
62354402|NCT01040338||OPRM1 A118G AA genotype|Individuals with the AA genotype at the OPRM1 A118G polymorphism.
62354403|NCT01040338||OPRM1 A118G AG or GG genotype|Individuals with the \*/G allele at the OPRM1 A118G polymorphism
62354404|NCT01677624|EXPERIMENTAL|E7040|
62354405|NCT05304819||AchilloCordPLUS|End to end repair for acute Achilles tendon rupture with AchilloCordPLUS
62354406|NCT00400439|EXPERIMENTAL|dalcetrapib (RO4607381)|
62354407|NCT00400439|PLACEBO_COMPARATOR|placebo|
62354408|NCT03395756|ACTIVE_COMPARATOR|12-14 mm follicle size group|Once the participant's leading follicle reaches 12-14mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
62354409|NCT03395756|ACTIVE_COMPARATOR|15-17 mm follicle size group|Once the participant's leading follicle reaches 15-17mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
62354410|NCT03395756|ACTIVE_COMPARATOR|18 mm or greater follicle size group|Once the participant's leading follicle reaches 18mm or greater, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
62354411|NCT05145400|EXPERIMENTAL|Single Arm|All subjects will receive the same treatment on the study, consisting of isatuximab, lenalidomide, and dexamethasone with 28 days cycles.
62354412|NCT03515018|EXPERIMENTAL|Hydroxyurea|Drug: hydroxyurea, pulse therapy
62354413|NCT03515018|ACTIVE_COMPARATOR|imatinib|Drug: imatinib, 400mg PO per day
62354414|NCT06014294|EXPERIMENTAL|High-intensity interval training (HIIT)|HIIT program for 16 weeks with a frequency of 2 times per week.
62354415|NCT06014294|ACTIVE_COMPARATOR|Moderate intensity continuous training (MICT)|Baduanjin exercise as MICT will be applied with the same program duration and frequency as the HIIT group. The entire set of Baduanjin Qigong exercises in the current study includes 8 postures.
62354416|NCT06014294|PLACEBO_COMPARATOR|Non-exercise control|Participants will not receive any exercise training, but attending 32 recreation workshops.
62354417|NCT02455778|EXPERIMENTAL|Cinnamon|3 grams of oral cinnamon per day in form of capsules (6) along with standard diet and exercise protocol
61973723|NCT04044716|ACTIVE_COMPARATOR|Standard of care Group|Participants in this group will receive standard of care pain management by the treating physician.
62354418|NCT02455778|PLACEBO_COMPARATOR|Placebo|2.5 grams of wheat flour per day in form of capsules ( 6) along with standard diet and exercise protocol
62354419|NCT01459068|NO_INTERVENTION|Waitlist-Control|Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
62515796|NCT04762940|ACTIVE_COMPARATOR|Control group|They will receive 24 robotics sessions with Amadeo robot three times a week for movement, but without specifically receiving vibration therapy.
62515797|NCT04762940|EXPERIMENTAL|Experimental group|They will recieve three times a week with 24 sessions plus vibration duration of approximately 20 minutes with a high vibration frequency. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible will be conducted prior to robotic treatments with Amadeo.
62515798|NCT02358967|PLACEBO_COMPARATOR|Placebo|Standard renal care + 300 mg placebo daily for 1 year
62515799|NCT02358967|ACTIVE_COMPARATOR|Treatment|Standard renal care + 300 mg TRF daily for 1 year
62515800|NCT01372124|EXPERIMENTAL|NOX-E36|All subjects included in this study will receive the same dose of NOX E36.
62515801|NCT00802282|EXPERIMENTAL|1|First of 5 groups, as described in the protocol and to which volunteers are blinded
62515802|NCT00802282|EXPERIMENTAL|2|Second of 5 groups, as described in the protocol and to which volunteers are blinded
62515803|NCT00802282|EXPERIMENTAL|3|Third of 5 groups, as described in the protocol and to which volunteers are blinded
62515804|NCT00802282|EXPERIMENTAL|4|Fourth of 5 groups, as described in the protocol and to which volunteers are blinded
62515805|NCT00802282|EXPERIMENTAL|5|Fifth of 5 groups as described in the protocol and to which volunteers are blinded
62515806|NCT02791386||Chinese Patients With CHB and Drug Resistance to NA Therapy|
62515807|NCT01025674|EXPERIMENTAL|7 Treatment Schools|The Positive Action program was implemented over 6 years, starting with Grade 3, then continuing through Grade 8.
62515808|NCT01025674|NO_INTERVENTION|7 Control Schools|Standard educational practice
62515809|NCT04239118|EXPERIMENTAL|Applications of autoplasma, enriched with platelets and|Endoscopic applications of autoplasma, enriched with platelets and granular sorbent aseptisorb-A in bleeding gastroduodenal ulcers
62515810|NCT04239118|OTHER|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents.
62354420|NCT01459068|EXPERIMENTAL|Common Elements Treatment Approach|Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.
62515811|NCT04618978|OTHER|PSG and actigraphy device evaluations|All patients will be evaluated and diagnosed according to the records by Gold standard for PLMs diagnosis and also by the actigraphy devices recording.
62354421|NCT03852121|EXPERIMENTAL|Intervention group|Participants will receive bibliotherapy without withdrawing from the usual care. They will be asked to read the designated manual (consists of eight chapters) within a recommended period of time (over 8 weeks). Weekly telephone coaching will also be provided to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves. An orientation will be organized before the first session. Two booster sessions will be organized during the study.
62354422|NCT03852121|NO_INTERVENTION|Control group|The participants in the control group will only receive usual care provided by the community health professionals.
62354423|NCT03444571|NO_INTERVENTION|Control|
62354424|NCT03444571|EXPERIMENTAL|DNA based diagnosis|
62354425|NCT01683968||Sickle cell|Patient who are admitted with sickle cell crises
62354426|NCT05385627||Ankle block|Any participant receiving an ankle block (local infiltration analgesia).
62354427|NCT03307863|EXPERIMENTAL|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
62354428|NCT03307863|EXPERIMENTAL|Topiramate-Implant|Women with epilepsy using topiramate for at least 3 months will have an etonogestrel-releasing implant inserted
62354429|NCT03307863|ACTIVE_COMPARATOR|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
62354430|NCT00270413|EXPERIMENTAL|1|sutent
62354431|NCT00270413|NO_INTERVENTION|2|
62354432|NCT04035538|EXPERIMENTAL|A group|
62354433|NCT04035538|EXPERIMENTAL|B group|
62515812|NCT05472441|ACTIVE_COMPARATOR|Mid Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
62515813|NCT05472441|EXPERIMENTAL|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
62515814|NCT05472441|EXPERIMENTAL|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
62515815|NCT05472441|EXPERIMENTAL|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
62515816|NCT00375492|EXPERIMENTAL|Group A|
62515817|NCT00375492|PLACEBO_COMPARATOR|Group B|
62515818|NCT06616168|EXPERIMENTAL|Women with bacterial vaginosis|Women with bacterial vaginosis (symptomatic or asymptomatic)
62715093|NCT05804721|EXPERIMENTAL|T test|1 orally disintegrating tablet contains 10 mg Aripiprazole administrated according to a randomization scheme with 240 ml of water
62715094|NCT05804721|ACTIVE_COMPARATOR|R Reference|1 orodispersible tablet contains 10 mg Aripiprazole administrated according to a randomization scheme with 240 ml of water
62354434|NCT03638557|EXPERIMENTAL|Intervention|"The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
62515819|NCT06616168|EXPERIMENTAL|Pregnant women|Pregnant women with different ifections
62515820|NCT06616168|EXPERIMENTAL|Women with asymptomic infections|Women with asymptomic infections of urogenital tract
61973724|NCT04044716|NO_INTERVENTION|Nurse Interventionists|Nurses who were trained to apply the auricular acupressure pads/pellets in the the holding room prior to surgery.
62515821|NCT00290251|ACTIVE_COMPARATOR|ulipristal acetate -20 mg|20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
62515822|NCT00290251|ACTIVE_COMPARATOR|ulipristal acetate - 10 mg|10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
62515823|NCT00290251|PLACEBO_COMPARATOR|Placebo|Placebo taken daily for three menstrual cycles or up to 102 days
62515824|NCT00290251|NO_INTERVENTION|Pre-ulipristal acetate 10 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 10 mg arm
62515825|NCT00290251|NO_INTERVENTION|Pre-ulipristal acetate 20 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 20 mg arm
62515826|NCT00290251|NO_INTERVENTION|Pre-placebo|Subjects were studied during one baseline cycle without any intervention before entering placebo arm
62515827|NCT00911599|ACTIVE_COMPARATOR|Conserve Total Hip with BFH|CONSERVE® A-Class Total Hip with BFH technology. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
62515828|NCT00911599|ACTIVE_COMPARATOR|Metal with Polyethylene Liner|Metal on polyethylene total hip replacement. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
62515829|NCT03919487||Back-to-back colonoscopy group|As I described the study method in the protocol, the experimental group will be a screening colonoscopy cohort with back to back method. In fact, this study is to evaluate the correlation between quality indicators of colonoscopy and adenoma miss rate (AMR), and intervention is a single arm for back-to-back colonoscopy.
62515830|NCT06615843|NO_INTERVENTION|Traditional In-Person Follow-Up|Participants in this arm will receive traditional in-person follow-up at the hospital. They will have scheduled consultations at the emergency department where they will undergo necessary evaluations and receive instructions for follow-up visits. Contact information for urgent needs will also be provided, allowing patients to reach medical services 24/7 if required
62515831|NCT06615843|EXPERIMENTAL|Dematerialized Follow-Up|Participants in this arm will receive post-emergency gynecological follow-up at home using a connected health app.
62710372|NCT00101348|EXPERIMENTAL|Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)|"Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.~Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression."
62710373|NCT05486767||Community cohort|SIRIUS study team will travel to pre-determined sociomes and perform transient elastography and other examinations
61973725|NCT03187262|EXPERIMENTAL|Daratumumab|"* Daratumumab will be administered in three phases: Induction, consolidation and maintenance~* During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day~* During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle~* During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
62710374|NCT05486767||Outpatient cohort|Patients recruited during the elective / preventive examinations at the primary-care clinics or at other outpatient-clinics will have performed Hep-calculator for FIB-4 w/wo transient elastography
62710375|NCT06277440|EXPERIMENTAL|Intervention group|Traditional rehabilitation program with additional cognitive training
62710376|NCT06277440|OTHER|Active Control|Traditional rehabilitation programs without additional cognitive training
61973726|NCT01773382|NO_INTERVENTION|control|standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP \<130/80 mmHg)
61973727|NCT01773382|EXPERIMENTAL|weight reduction|target weight reduction is 3-5% from baseline
61973728|NCT01744054|OTHER|PET/MR or PET/CT|"* Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT~* Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver"
62147720|NCT00310037|EXPERIMENTAL|Arm B consolidation therapy|Patients receive bortezomib 1.3 mg/m\^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
62147721|NCT03230084|EXPERIMENTAL|Urine PDG test|Urine pregnanediol 3-glucuronide (PDG) test strip
62515832|NCT05403710||single group assignment|men or women between the ages of 18-75 who have an established diagnosis of Hidradenitis Suppurativa
62515833|NCT02635581|EXPERIMENTAL|DELTA TT|
62515834|NCT04920526||QHPV Vaccine|all participants have received QHPV
62515835|NCT00896194|ACTIVE_COMPARATOR|1: Standard Behavioral Treatment (SBT)|This group receives standard behavioral treatment for weight loss as described below.
62515836|NCT00896194|EXPERIMENTAL|2: Modified SBT + Self-Efficacy|This group receives modified SBT with an additional self-efficacy component as described below.
62515837|NCT01583257|EXPERIMENTAL|Active Video Gaming|An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
62515838|NCT02459418|EXPERIMENTAL|Afolia - US Gonal-f® (Sequence A) Arm|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
62515839|NCT02459418|ACTIVE_COMPARATOR|US Gonal-f® - Afolia (Sequence B) Arm:|During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
62515840|NCT05472402|EXPERIMENTAL|LADIES online intervention (R33 phase)|Participants will include 30 women who will be randomized to receive six (6) months of online group-based intervention sessions that teach participants how to increase physical activity levels.
62515841|NCT05472402|PLACEBO_COMPARATOR|LADIES online control (R33 phase)|Participants will include 30 women who will be randomized to receive self-guided materials that teach participants how to increase physical activity levels. Placebo comparator participants will receive their materials via the online platform.
62515842|NCT04684173||Term infants|The inclusion criteria for term infants are: gestational age 37-42 weeks, birth weight \>2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
62515843|NCT04684173||Preterm infants|The inclusion criteria for preterm infants are: gestational age \<37 weeks, birth weight \<2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
62515844|NCT02049021|EXPERIMENTAL|Electroconvulsive Therapy|Patients in use of clozapine randomized to receive ECT treatment
62515845|NCT02049021|SHAM_COMPARATOR|SHAM ECT|Patients receiving clozapine randomized to sham ECT (placebo)
62515846|NCT01135628|ACTIVE_COMPARATOR|MHE and diet plus lactobacillus reuteri|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.
62515847|NCT01135628|ACTIVE_COMPARATOR|MHE and diet|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.
62515848|NCT01135628|ACTIVE_COMPARATOR|MHE and diet plus nitazoxanide|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.
62710377|NCT02806414|EXPERIMENTAL|Ivermectin|All subjects will be treated with topical ivermectin daily for up to 12 weeks.
62710378|NCT06156150||glioma patients receiving conventional treatment|surgery+radiotherapy+chemotherapy
62710379|NCT06156150||glioma patients with tumor vaccine|surgery+radiotherapy+chemotherapy+tumor vaccine
62710380|NCT05858931||CSD patients|All women suffered from abnormal uterine bleeding and were evaluated in a standardized way with hysteroscopy before vaginal surgery.
62710381|NCT06655740|EXPERIMENTAL|Study arm- RF Vapor Ablation arm|This is a single arm study. All enrolled patients will be included in this arm
62710382|NCT05779930|EXPERIMENTAL|Treatment|"Leukopharesis: cells collected with a target of ≥1 x10\^9 TNC with ≥3% CD3+ cells.~Lymphodepleting chemotherapy: 4 days of IV chemotherapy with fludarabine and cyclophosphamide.~* Fludarabine 30 mg/m2/day IV x 4 days (days -6 through -3)~* Cyclophosphamide 500 mg/m2/day IV x 2 days (days -6 and-5)~anti-CD19 CAR T cells:~* 0.3 - 1 x 10\^6 per kilogram for patients \<50 kg~* Flat dose of 0.3 - 1 x 10\^8 for patients ≥50 kg~The cell infusion will take place on day 0 (at least 2 days after completion of lymphodepleting chemotherapy). The patient will receive pre-medication with acetaminophen and diphenhydramine 30-60 minutes prior to the cell infusion."
62710383|NCT04471311|NO_INTERVENTION|Primary closure of midline laparotomy|Primary closure of midline laparotomy
62710384|NCT04471311|EXPERIMENTAL|Sub-lay mesh supported closure|Sub-lay permanent mesh supported the closure
62710385|NCT02192957|OTHER|Ottawa AF Cardioversion|elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
62147722|NCT02052167|EXPERIMENTAL|Methotrexate|
62147723|NCT01812330|EXPERIMENTAL|group 1|Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial
62147724|NCT01812330|EXPERIMENTAL|group 2|Group 2 will be administered with Clopidogrel 150mg daily until the end of trial
62515849|NCT04438590|EXPERIMENTAL|Kelulut Honey|"Medical Grade Kelulut Honey which will be in 2 doses.~The first would be diluted to 800 ml of water, and the second dose in 400ml of water."
62515850|NCT04438590|ACTIVE_COMPARATOR|Carborie|Carborie Load which will be 100g of carbohydrate in 800 ML of water and 50g of carbohydrate in 400ml of water.
62515851|NCT00860691|ACTIVE_COMPARATOR|ARM I - Open colorectal surgery|Open colorectal surgery
62515852|NCT00860691|EXPERIMENTAL|ARM II - Laparoscopic colorectal surgery|Laparoscopic colorectal surgery
62515853|NCT00860691|OTHER|Control - reference value|Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum. Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay. Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay. Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. . Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube. burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
62515854|NCT05646628||Participants|Older adults (aged 65 years and over) enrolled in the BASIL+ trial randomized to receive the intervention (collaborative care focusing on behavioral activation) and confirmed as having chronic pain
62710386|NCT02001246|ACTIVE_COMPARATOR|Real Deal program for Anger Management|"The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict."
62715095|NCT00812955|EXPERIMENTAL|A - ABT-143 capsules 5/135 mg|ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
62715096|NCT00812955|EXPERIMENTAL|B - ABT-143 capsules 10/135 mg|ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
62147725|NCT01812330|EXPERIMENTAL|group 3|Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial
62147726|NCT00878189|EXPERIMENTAL|1|
62147727|NCT00341991||1|Cases from hospitals
62147728|NCT00341991||2|Controls from the general populations
62147729|NCT00341991||3|Biological Samples
62147730|NCT05366478|EXPERIMENTAL|Autologous tumor infiltrating lymphocytes (TILs)|In vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors
62515855|NCT04736108|EXPERIMENTAL|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before radical prostatectomy
62515856|NCT01120769|ACTIVE_COMPARATOR|Acetaminophen|
62515857|NCT01120769|PLACEBO_COMPARATOR|Placebo|
62515858|NCT04070287|ACTIVE_COMPARATOR|SMART Pack|"This involves using SMART Pack a HIV self-testing kit to promote uptake of HIV self-testing among young people at community centers."
62515859|NCT04070287|ACTIVE_COMPARATOR|Luv Box|"The intervention involves using Luv Box a box that include personal hygiene products and HIV self-testing kit as strategy to promote uptake of HIV testing among young people."
62515860|NCT04070287|ACTIVE_COMPARATOR|Bili Vibes|"The intervention involves using a program program called Bili that leverages community youth events such as football matches as a strategy to promote the uptake of HIV self-testing among young people."
62515861|NCT04070287|ACTIVE_COMPARATOR|BeterDoc|"This intervention involve using BeterDoc Safety kits that includes HIV self-testing kit, location and phone number to the health centers in the community as a strategy to promote update of HIV self-testing among young people."
62515862|NCT04070287|ACTIVE_COMPARATOR|IUNGO|This intervention involves using a program utilizes community vocational skills training centers to promote uptake of HIV self-testing among young people.
62515863|NCT04531670|EXPERIMENTAL|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
62515864|NCT04531670|ACTIVE_COMPARATOR|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
62515865|NCT05216588||EVUSHELD (tixagévimab/cilgavimab) 300 mg|"Patients who may be included in this group are patients eligible for prophylaxis treatments for COVID-19, under a cohort Temporary Authorization for Use (ATUc) of EVUSHELD 300mg. Patient are treated and monitored according to the Therapeutic Use Protocols specific for EVUSHELD defined by the ANSM.~In addition to their follow-up planned for usual care (including protocol for ATU), they are invited to participate in the research."
62515866|NCT05216588||EVUSHELD (tixagévimab/cilgavimab) 600 mg|"Patients who may be included in this group are patients eligible for prophylaxis treatments for COVID-19, under a cohort Temporary Authorization for Use (ATUc) of EVUSHELD 600mg. Patient are treated and monitored according to the Therapeutic Use Protocols specific for EVUSHELD defined by the ANSM.~In addition to their follow-up planned for usual care (including protocol for ATU), they are invited to participate in the research."
62515867|NCT04815382|EXPERIMENTAL|Dynamic Upper Limb Orthosis group|"The dynamic upper limb orthosis group will receive a treatment based on the use of a dynamic upper limb orthosis.~Participants of this group will continue to receive their regular therapy"
62515868|NCT04815382|NO_INTERVENTION|Control group|The control group will not receive any type of intervention Participants of this group will continue to receive their regular therapy
62515869|NCT04637126||mechanically ventilated and sedated patients with sinus rhythm|all mechanically ventilated and sedated patients with sinus rhythm hospitalized in our ICU and fitted with an hemodynamic monitoring by thermodilution technique due to hemodynamic failure
62515870|NCT04995120|EXPERIMENTAL|Induction chemotherapy and Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If ORR of primary tumor is CR/PR, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
62515871|NCT02992626|EXPERIMENTAL|starting with dog|Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog.
62515872|NCT02992626|EXPERIMENTAL|starting with control|Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog.
62515873|NCT06058221|EXPERIMENTAL|Hybrid technique|
62515874|NCT06058221|ACTIVE_COMPARATOR|Supraglottic airway|
62515875|NCT00809965|EXPERIMENTAL|Rivaroxaban 2.5 mg bid|One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
62515876|NCT00809965|EXPERIMENTAL|Rivaroxaban 5 mg bid|One 5 mg rivaroxaban tablet twice daily for up to 6 months
62710387|NCT02001246|EXPERIMENTAL|Mind-body Bridging program|The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.
61973729|NCT06403995|EXPERIMENTAL|Self-referred, undirected iCBT|These individuals will do the program, but will not receive follow-up contact during the program. In case of severe psychological distress (i.e. score ≥30 on Kessler's 10-item psychological distress scale (K10), participants will receive an automated email with a list of resources and emergency contact numbers.
62515877|NCT00809965|PLACEBO_COMPARATOR|Placebo|One placebo tablet twice daily for up to 6 months
62515878|NCT02790034|EXPERIMENTAL|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 5 mg bid (≥13 years of age and weighing ≥25 kg)
62710388|NCT02303262|EXPERIMENTAL|Mocetinostat and gemcitabine|For each 21-day cycle, gemcitabine is administered on days 5 and 12 and mocetinostat is administered 3 days a week.
62710389|NCT03490994|EXPERIMENTAL|Rivaroxaban|Rivaroxaban
62147731|NCT03942094|EXPERIMENTAL|Nilotinib|
62515879|NCT02790034|EXPERIMENTAL|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 10 mg bid (≥13 years of age and weighing ≥25 kg)
62515880|NCT02790034|PLACEBO_COMPARATOR|Placebo|Placebo bid for 24 wks DB age 4 and above
62515881|NCT01576302|EXPERIMENTAL|Diaphragmatic breathing|Training in diaphragmatic breathing as response incompatible with rumination.
62515882|NCT01576302|ACTIVE_COMPARATOR|Muscle relaxation|Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate
62515883|NCT06205706|EXPERIMENTAL|Phase I, Part A - Dose escalation and safety of BI-1910 as single agent|Dose escalation of BI-1910 administered as a single agent.
62515884|NCT06205706|EXPERIMENTAL|Phase I, Part B - Dose escalation and safety of BI-1910 in combination with pembrolizumab|Dose escalation of BI-1910 in combination with pembrolizumab.
62515885|NCT06205706|EXPERIMENTAL|Phase 2a, Part A - Dose expansion of BI-1910 as single agent|BI-1910 administered as a single agent at the hypothesized recommended phase 2 dose determined in Phase 1.
62515886|NCT06205706|EXPERIMENTAL|Phase 2a, Part B - Dose expansion of BI-1910|BI-1910 administered in combination with pembrolizumab at the respective hypothesized recommended phase 2 doses determined in Phase 1
62515887|NCT05904275|EXPERIMENTAL|Group RD|Group RD - caudal epidural injection with 0.25% ropivacaine 20 ml containing dexamethasone 8 mg (0.5% Ropivacaine 10 ml + 8 mg/2 ml Dexamethasone + 8 ml NS)
62515888|NCT05904275|EXPERIMENTAL|Group R|Group R- caudal epidural injection with 0.25% ropivacaine 20 ml
62515889|NCT03696355|EXPERIMENTAL|Stratum A1|"Dose Escalation Phase:~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive single-agent oral GDC-0084 at one of the 4 dose levels once daily in cycles of 28 days. During cycle 1 only, a single dose of GDC-0084 will be withheld on day 2, for a total of 27 doses. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.~Dose Expansion Phase~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive the MTD dose established in the Stratum A dose escalation phase. Subjects who completed the first course of therapy may take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity."
62515890|NCT03696355|EXPERIMENTAL|Stratum A2|Four to 12 weeks after the completion of standard RT, subjects will received the MTD dose established in the Stratum A1 dose escalation phase. Subjects who are unable to swallow capsules will initially be enrolled until the Stratum A1 expansion cohort is filled. Once the Stratum A1 expansion cohort has been filled, both subjects who are able to swallow capsules and those unable to swallow capsules may be enrolled. Subjects who are unable to swallow capsules will take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Subjects who have completed the first course of therapy and are able to swallow capsules may take GDC-0084 as capsules. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
62515891|NCT04442724|EXPERIMENTAL|Single Arm - Bladder Chemo-Radiotherapy|Fiducial marker placement \& cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.
62515892|NCT01538836|NO_INTERVENTION|Weight maintenance|Weight maintenance with normal protein intake
62515893|NCT01538836|ACTIVE_COMPARATOR|Weight loss with normal protein intake|
62515894|NCT01538836|EXPERIMENTAL|Weight loss with protein supplementation|
62515895|NCT04363749|EXPERIMENTAL|15 COVID positive patients|dyspnea rating to various dyspneic stimulus
62515896|NCT04363749|ACTIVE_COMPARATOR|15 healthy controls|dyspnea rating to various dyspneic stimulus
62515897|NCT01352728|EXPERIMENTAL|TACE+Axitinib|
62710390|NCT03490994|ACTIVE_COMPARATOR|Warfarin|warfarin + enoxaparin
62710391|NCT03880357|EXPERIMENTAL|Test Product|Betamethasone Scalp Suspension 0.064%;0.0005% (Taro Pharmaceuticals Inc.)
62710392|NCT03880357|ACTIVE_COMPARATOR|Reference Product|Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)
62147732|NCT01039610|EXPERIMENTAL|Part A|GSK945237 2400mg single dose
62515898|NCT05418075|EXPERIMENTAL|Home Treatment as add on to Familiy-based Treatment|
62515899|NCT05418075|ACTIVE_COMPARATOR|Familiy-based Treatment|
62515900|NCT05418075|ACTIVE_COMPARATOR|Mindfulness based stress reduction training|
62515901|NCT00556491|ACTIVE_COMPARATOR|minocycline|
62515902|NCT00556491|PLACEBO_COMPARATOR|placebo|
62515903|NCT03239236|EXPERIMENTAL|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
62515904|NCT03239236|EXPERIMENTAL|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
62710393|NCT03880357|PLACEBO_COMPARATOR|Placebo|Vehicle of the test product (Taro Pharmaceuticals Inc.)
62710394|NCT03249363|EXPERIMENTAL|Group A - Pulsed PVP-I Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with Povidone-Iodine (PVP-I) diluted to a 3% concentration (30g/l) in 2 l of saline performed before applying the bone graft
62710395|NCT03249363|ACTIVE_COMPARATOR|Group B - Pulsed Saline Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with only 2 litres of saline solution (without povidone Iodine) performed before applying the bone graft
62715097|NCT00812955|EXPERIMENTAL|C - ABT-143 capsules 20/135 mg|ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
62147733|NCT01039610|EXPERIMENTAL|Part B Cohort 1|GSK945237 400 mg QD, 7 Days 4 subjects GSK945237:2 subjects Placebo
62515905|NCT03239236|EXPERIMENTAL|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
62515906|NCT03239236|EXPERIMENTAL|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
62515907|NCT02545647|NO_INTERVENTION|Standard RYGB|65 patients undergo a standard Roux-en-Y gastric bypass
62515908|NCT02545647|ACTIVE_COMPARATOR|Banded RYGB|65 patients undergo a banded RYGB (BRYGB)
62710396|NCT04846595|OTHER|Self questionnaire|The study will be offered to all patients who have been treated for HIV infection for at least 6 months, during a follow-up consultation. A self questionnaire will be administered only once per patient during the usual consultation, there is no follow-up planned.
62715098|NCT00812955|ACTIVE_COMPARATOR|D - Simvastatin capsules 40 mg|Simvastatin capsules 40 mg daily for 8 weeks
62147734|NCT01039610|EXPERIMENTAL|Part B Cohort 2|GSK945237 400 mg QD, 14 Days 4 subjects GSK945237:2 subjects Placebo
62147735|NCT01039610|EXPERIMENTAL|Part B Cohort 3|GSK945237 400 mg BID, 14 Days 4 subjects GSK945237:2 subjects Placebo
62147736|NCT01039610|EXPERIMENTAL|Part B Cohort 4|GSK945237 800 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
62147737|NCT01039610|EXPERIMENTAL|Part B Cohort 5|GSK945237 1200 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
62147738|NCT01039610|EXPERIMENTAL|Part B Cohort 6|GS945237 1600 mg QD, 14 Days 9 subjects GSK945237:3 subjects Placebo
62354435|NCT06066840|EXPERIMENTAL|vedolizumab+basiliximab|Patients with steroid-refractory aGVHD with gastrointestinal involvement receive combined therapy of vedolizumab and basiliximab.
62354436|NCT03858270|EXPERIMENTAL|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
62354437|NCT03858270|PLACEBO_COMPARATOR|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
62354438|NCT02485548|EXPERIMENTAL|Raltitrexed plus cisplatin|Raltitrexed plus cisplatin and IMRT
62354439|NCT02485548|ACTIVE_COMPARATOR|5-fluorouracil plus cisplatin|5-fluorouracil plus cisplatin and IMRT
62354440|NCT02821130||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis
62354441|NCT00613717|EXPERIMENTAL|a|pre- and early postnatal iron
62354442|NCT00613717|EXPERIMENTAL|b|iron prenatal only
62354443|NCT00613717|EXPERIMENTAL|c|iron early postnatal only
62354444|NCT00613717|ACTIVE_COMPARATOR|d|no iron pre- or postnatal
62354445|NCT03482128||preAlgorithm|Standard coagulation management of patients undergoing cardiac surgery
62354446|NCT03482128||postAlgorithm|Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery
62354447|NCT03663140||Group 1-Health periodontal|This group created by individuals with healthy periodontal tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
62354448|NCT03663140||Group 2- Healthy peri-implant|This group created by individuals with healthy peri-implant tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
62354449|NCT03663140||group 3- Gingivitis|This group created by individuals with gingivitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
62354450|NCT03663140||Group 4-Peri-implant Mucositis|This group created by individuals with peri-implant mucositis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
62354451|NCT03663140||Group 5-Periodontitis|This group created by individuals with periodontitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
62147739|NCT01039610|ACTIVE_COMPARATOR|Part C|Linezolid 600 mg BID, 14 Days 9 subjects Linezolid:3 subjects Placebo
62147740|NCT01039610|ACTIVE_COMPARATOR|Part D|"2 period crossover Period 1: Placebo 1 day; GSK945237 dose to be determined, 5 Days Period 2: Placebo 5 days; moxifloxacin 400 mg single dose~16 subjects"
62147741|NCT04514562|OTHER|Intervention|NeVa Stent Retrievers
62147742|NCT05048485||LEOPARD Cohort 1|"Control group: The study will enroll 50 newly diagnosed smear-positive (\>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are not receiving nutritional supplementation.~TB LION group: The study will enroll 50 newly diagnosed smear-positive (\>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are receiving nutritional supplementation."
62147743|NCT05048485||LEOPARD Cohort 2|The study will enroll 300 newly diagnosed smear-positive (\>/=1+ AFB) pulmonary TB patients whose household contacts are not enrolled in the TB-LION study.
62354452|NCT03663140||Group 6-Periimplantitis|This group created by individuals with peri-implantitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
62354453|NCT01896388|ACTIVE_COMPARATOR|Ifenprodil Tartrate|Oral Administration of Ifenprodil Tartrate 40mg/day (20mg After breakfast, 20mg After supper)
62354454|NCT01896388|PLACEBO_COMPARATOR|Placebo|Oral Administration of Placebo (After breakfast, After supper)
62515909|NCT05113459|EXPERIMENTAL|disitamab vedotin + PD-1+Capecitabine|disitamab vedotin：2.5mg/kg,iv,d1,q2w ,6cycle PD-1: 200mg,iv,d1,q2w，6cycle Capecitabine：1000mg/m2 ,po, bid,d1-14,q3w, 4cycle
62354455|NCT00682240|ACTIVE_COMPARATOR|group 3|"Group 3: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation.~Intervention: All patients will receive a multi-session panretinal laser treatment according to the conventional protocol, using a conventional laser system."
62710397|NCT02266160|EXPERIMENTAL|1|"71 tinnitus patients treated with 2 gram EMLA 5% cream a day for 4 days, 4 hours a day.~we will compare the questionnaires results before and after 4 days of treatment to see whether EMLA cream changes the degree of suffer from tinnitus"
62710398|NCT02266160|SHAM_COMPARATOR|2|71 tinnitus patients using cetomacrogol cream (lotion cream, does not contain any drug) for 4 days. these patients will fulfill the questionnaires as the investigational group.
62515910|NCT06427902||depression with gingivitis (DG) group|"The diagnosis of depressive disorder was established using the Structured Clinical Interviews for Axis I Disorders (SCID) criteria of the Diagnostic and Statistical Manual of Mental Disorders.~the gingivitis group was determined by the criteria of pocket depth of 3 mm or less."
62515911|NCT06427902||depression with periodontally healthy (DPH) patients|The diagnosis of depressive disorder was established using the Structured Clinical Interviews for Axis I Disorders (SCID) criteria of the Diagnostic and Statistical Manual of Mental Disorders.
62515912|NCT06427902||systemically and periodontally healthy (SPH) individuals|This group contists of individuals who are systemically and periodontally healthy
62515913|NCT01098994|OTHER|Haptoglobin 1/1|Individuals with type 1 diabetes and the Haptoglobin 1/1 phenotype
62515914|NCT01098994|OTHER|Haptoglobin 2/1|Individuals with type 1 diabetes and the Haptoglobin 2/1 phenotype
62515915|NCT01098994|OTHER|Haptoglobin 2/2|Individuals with type 1 diabetes and the Haptoglobin 2/2 phenotype
62515916|NCT01276717|EXPERIMENTAL|Vorinostat + Carfilzomib|
62515917|NCT04414475|EXPERIMENTAL|Selinexor + Low-dose Dexamethasone (Sd-40 BIW)|Participants will receive fixed dose of 40 milligram (mg) of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet twice weekly (BIW) on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle.
62515918|NCT04414475|EXPERIMENTAL|Selinexor + Low-dose Dexamethasone (Sd-100 QW)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet followed by 40 mg of low-dose Dexamethasone oral tablet once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone may be given as 20 mg on days 1 and 2 of each week).
62515919|NCT04414475|EXPERIMENTAL|Selinexor + Low-dose Dexamethasone (Sd-80 BIW)|Participants will receive fixed dose of 80 mg of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet BIW on Days 1, 3, 8, 10,15, 17, 22, and 24 of each 28-day cycle.
62515920|NCT04414475|EXPERIMENTAL|Selinexor + Bortezomib + Dexamethasone (SVd)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet on Days 1, 8, 15, 22, and 29 followed by 1.3 milligram per square-meter (mg/m\^2) of Bortezomib subcutaneous (SC) injection on Days 1, 8, 15, and 22 and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, 22, and 29 of each 35-day cycle (Dexamethasone dose may be split to 20 mg on days 1 and 2).
62515921|NCT04414475|EXPERIMENTAL|Selinexor + Pomalidomide + Dexamethasone (SPd)|Participants will receive fixed dose of 40 mg of Selinexor oral tablet on Days 1, 8, 15, and 22 of each 28-day cycle followed by Pomalidomide 4 mg PO on Days 1 through 21 of each 28-day cycle and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone dose 20 mg QW for those of \>75 years old at the Investigator's discretion, before QW dosing of Selinexor; it may be divided over 1 to 4 days at the Investigator's discretion).
62515922|NCT02019082|ACTIVE_COMPARATOR|electrical stimulation|electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
62515923|NCT02019082|PLACEBO_COMPARATOR|placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero.
62515924|NCT00720226|EXPERIMENTAL|Losartan|Losartan 100 mg daily
62710399|NCT06146647|EXPERIMENTAL|Intervention condition: 15 minute (approx.) show with positive body image messaging|Those assigned to this arm will watch the 15 minute tv show with positive body image content.
62710400|NCT06146647|ACTIVE_COMPARATOR|Control condition: 15 minute (approx.) show without positive body image messaging|"Those assigned to this condition will watch a 15 minute tv show that does not contain positive body image content.~The show that will be used for this condition is about a tv character visiting the dentist."
62710401|NCT06146647|EXPERIMENTAL|Intervention condition: Music video with positive body image messaging|Those assigned to this condition will watch the music video containing positive body image messaging.
62710402|NCT06146647|ACTIVE_COMPARATOR|Control condition: Music video without positive body image content|"Those assigned to this condition will watch a music video without positive body image messaging.~The music video that will be used for this condition is about brushing teeth."
62710403|NCT02750969|EXPERIMENTAL|1. lidoderm patches first|"29 tinnitus patients treated first with 3 patches of lidoderm for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 neutral patches (containing no drug) attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
62710404|NCT02750969|EXPERIMENTAL|2. tegaderm patches first|"29 tinnitus patients treated first with 3 patches of tegaderm (neutral patch containing no drug) for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 lidoderm patches attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
62710405|NCT06058416|OTHER|immunogenicity group with vaccination interval of 6 month|
62710406|NCT06058416|OTHER|immunogenicity group with vaccination interval of 18 month|
62515925|NCT00720226|PLACEBO_COMPARATOR|Placebo|Placebo 1 pill daily
62515926|NCT02489591|NO_INTERVENTION|Control|No oral appliance (control) first, oral appliance (BluePro oral appliance or other device) second
62515927|NCT02489591|EXPERIMENTAL|Oral appliance|oral appliance (BluePro oral appliance or other device) first, no oral appliance (control) second
62710407|NCT06058416|OTHER|immunogenicity group with vaccination interval of 36 month|
62354456|NCT00682240|ACTIVE_COMPARATOR|group 2|"Group 2: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group 2.~Intervention: This group will receive multi-session panretinal laser treatment. The treatment will be performed using Pascal laser system."
62354457|NCT00682240|ACTIVE_COMPARATOR|group 1|"Group 1: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group1.~Intervention: One group will receive a single-session panretinal laser treatment, performed using Pascal laser system."
62354458|NCT00682240|ACTIVE_COMPARATOR|group 4|"Group 4: 20 patients with persistent central or para-central diabetic macular edema receiving focal or grid laser treatment. As the treatment will be performed according to the conventional protocol (single spot), only the Pascal laser system will be used.~Intervention: focal or grid laser treatment"
62354459|NCT04730310||Regional Anesthesia (RA)|"RA~* Includes spinal, epidural, peripheral nerve block, excludes local infiltration (unlikely that any major open revascularization can be done under local)~* Defined as: NSQIP Principal (ANESTHES) or additional (ANESTHES_OTHER) anesthesia technique = regional, spinal, epidural, or MAC (in NSQIP RA/Spinal/Local + MAC are coded as MAC; while this includes local + MAC, it would be unlikely that local anesthesia would be sufficient for open revascularization)"
62354460|NCT04730310||General Anesthesia (GA)|"GA~* Defined as: NSQIP Principal or additional anesthesia technique = general~* Since GA is selected as the principal anesthetic technique by default when multiple techniques are present, GA + RA could potentially have been coded as GA if the optional variable of additional anesthesia technique is not filled in, leading to differential misclassification of patients with GA + RA (most likely epidural and peripheral nerve block) in the GA group."
62354461|NCT05218577|EXPERIMENTAL|HSFF group|the group was given high selenium funtion selenium for 3 months
62354462|NCT05218577|EXPERIMENTAL|Selenium suplemen group|the group was given selenium suplemen
62354463|NCT05218577|PLACEBO_COMPARATOR|Control group|the group was given placebo
62354464|NCT04359342|EXPERIMENTAL|HIIT + protein|High-intensity interval training (HIIT) combined with protein supplementation
62354465|NCT04359342|PLACEBO_COMPARATOR|HIIT + placebo|High-intensity interval training (HIIT) combined with placebo
62354466|NCT04359342|EXPERIMENTAL|HIIT and resistance training + protein|High-intensity interval training (HIIT) and resistance training combined with protein supplementation
62354467|NCT04359342|PLACEBO_COMPARATOR|HIIT and resistance training + placebo|High-intensity interval training (HIIT) and resistance training combined with placebo
62354468|NCT03392987|EXPERIMENTAL|OTL-200 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.
62354469|NCT02177175|EXPERIMENTAL|Carvedilol|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
62354470|NCT02177175|PLACEBO_COMPARATOR|placebo|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
62354471|NCT02299648|OTHER|Single arm|molecular profiling, patient derived cells
62354472|NCT00753597|EXPERIMENTAL|1|Receiving active treatment
62354473|NCT02863705|EXPERIMENTAL|COMBIGAN®|One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months
62354474|NCT02863705|EXPERIMENTAL|COMBIGAN® + LUMIGAN® 0.01%|LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.
62354475|NCT02137837|PLACEBO_COMPARATOR|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 \&15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
62354476|NCT02137837|EXPERIMENTAL|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 \&15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
62354477|NCT02137837|EXPERIMENTAL|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 \&15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
62354478|NCT03779633|EXPERIMENTAL|Linoladiol Estradiol|Linoladiol Estradiol cream 6 weeks before surgery of pelvic organ prolapse
62354479|NCT03779633|PLACEBO_COMPARATOR|Placebo|Placebo cream 6 weeks before surgery of pelvic organ prolapse
62354480|NCT05394103|EXPERIMENTAL|Dose escalation (Q901)|
62354481|NCT05394103|EXPERIMENTAL|Q901 Single-Agent Expansion Cohorts|
62354482|NCT05394103|EXPERIMENTAL|Q901 + KEYTRUDA® (pembrolizumab) Cohorts|
62354483|NCT03420443|EXPERIMENTAL|Oat bran|45 g oat bran
62354484|NCT03420443|EXPERIMENTAL|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
62354485|NCT03420443|OTHER|No oral supplementation|No oral supplementation.
62354486|NCT01015729|ACTIVE_COMPARATOR|1|Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule
62354487|NCT01015729|ACTIVE_COMPARATOR|2|Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
62354488|NCT01015729|ACTIVE_COMPARATOR|3|Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
62354489|NCT00880880|EXPERIMENTAL|pre-visit e-PAQ-PF|Participants assigned to fill out the e-PAQ-PF prior to their clinic visit. Participants will arrive early to clinic appointment and fill out e-PAQ-PF. Results will be given to clinician and participant. After their visit they will complete the post visit questionnaire.
62710408|NCT06058416|OTHER|immunogenicity group with vaccination interval of 60 month|
62710409|NCT06058416|OTHER|safety observation group|
62710410|NCT05904717|EXPERIMENTAL|A (PXS-4728)|IP Name: PXS-4728 Dosage: 15 mg Mode: oral administration (PO)
62710411|NCT05904717|PLACEBO_COMPARATOR|B (Matching Placebo)|Matching placebo to PXS-4728
62147744|NCT04078607|EXPERIMENTAL|Distraction|Distraction during eating using the Rapid Visual Information Processing task as the distraction
62147745|NCT04078607|PLACEBO_COMPARATOR|Control|No distraction during eating
62354490|NCT00880880|NO_INTERVENTION|post-visit e-PAQ-PF|Participants assigned to complete the e-PAQ-PF after their clinic visit. Pre-visit participants will sign consent form - but otherwise will receive no study interventions. Post-visit they will fill out e-PAQ-PF and post visit questionnaire.
62354491|NCT05475600|EXPERIMENTAL|Classical APA group|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on Rated Perceived Exertion (RPE) Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20 min / stretching / Objective: to bring the body back to a resting state
62354492|NCT05475600|EXPERIMENTAL|APA with Exergaming device|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20 min / stretching / Objective: to bring the body back to a resting state
62354493|NCT05475600|EXPERIMENTAL|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with an Exergaming device 3 - Cool down: 20 min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
62354494|NCT03788863||Pregnant women exposed to glucocorticoids|Pregnant women exposed to any glucocorticoid or corticosteroid or steroids in early pregnancy or first trimester of pregnancy
62354495|NCT03788863||Non-exposed pregnant women|Women not using any glucocorticoid or corticosteroid or steroids during pregnancy
62354496|NCT03750240|EXPERIMENTAL|Triple Negative Breast Cancer Patients|scanned 4 times to assess breast cancer response to NACT with the proposed method.
62354497|NCT04449276|EXPERIMENTAL|Dose Escalation CVnCoV|"Participants will be vaccinated with CVnCoV at escalating dose levels on Day 1 and Day 29. Safety data will inform the decision to continue enrolling at the current dose level, or to proceed to dose escalation. Initially, dose levels of 2, 4 and 8 μg will be evaluated.~Dose levels of 2, 4, 6, 8 and 12µg will be evaluated with potential increase to dose levels up to 20 μg."
62354498|NCT04449276|PLACEBO_COMPARATOR|Dose Escalation Placebo|Participants will be given placebo on Day 1 and Day 29.
62354499|NCT02770118|EXPERIMENTAL|PSR-TSD|Partial sleep restriction (PSR) followed by total sleep deprivation (TSD). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
62354500|NCT02770118|EXPERIMENTAL|TSD-PSR|Total sleep deprivation (TSD) followed by partial sleep restriction (PSR). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
62354501|NCT05482035|EXPERIMENTAL|Blood pressure measured by wrist blood pressure monitor and mercury sphygmomanometer|
62354502|NCT01946789|EXPERIMENTAL|ALT-803|
62354503|NCT01268033|EXPERIMENTAL|Rituximab|two infusions of Rituximab - at the dose of 375 mg/m²
62354504|NCT01268033|PLACEBO_COMPARATOR|placebo|two infusions of placebo
62354505|NCT01104363|EXPERIMENTAL|Snow white Plaster 2|Test
62354506|NCT01104363|ACTIVE_COMPARATOR|Primopattern LC gel + PVS|Control
62710412|NCT02691156||Premature Infants|Premature infants GA 24 to ≤34 wks at risk for hyperbilirubinemia will have BBC, ETCOc, and COHbc measured during 0-7 days of life.
62354507|NCT04552717|EXPERIMENTAL|Intervention|"Participants will complete a web based pre-assessment and then given access to the app My Grief for three months followed by a web based post-assessment and an interview via telephone regarding their experiences of using the app, and follow-up questionnaires."
62354508|NCT04552717|NO_INTERVENTION|Waitlist controll|Participants will get access to the app after three months.
62354509|NCT00005812|EXPERIMENTAL|Temozolomide|"Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:~* disease progression~* intolerable toxicity~* complete response - 2 full additional cycles~* if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response."
62354510|NCT03998761|ACTIVE_COMPARATOR|Micronized progesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening).
62354511|NCT03998761|ACTIVE_COMPARATOR|Micronized progesterone plus dydrogesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening).
62354512|NCT00588887||1|
62354513|NCT00588887||2|
62354514|NCT05840341|EXPERIMENTAL|Experimental group|QingyiHuaji optimized formula combined with standard treatment
62710413|NCT04883268|EXPERIMENTAL|Intervention Group|Participants in the intervention group completed the Expand Your Horizon programme (Alleva et al., 2015).
62354515|NCT05840341|PLACEBO_COMPARATOR|Placebo group|placebo combined with standard treatment
62515928|NCT02790541|EXPERIMENTAL|Treatment|Hyperbaric Oxygen Therapy: 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
62147746|NCT04370561|ACTIVE_COMPARATOR|1/3 tubular plate|"Standard care according to AO guidelines using the Implant 1/3 tubular plate"
62147747|NCT04370561|ACTIVE_COMPARATOR|Active ankle plate|"Actual care using the new implant using the Implant Active ankle plate"
62147748|NCT06238310|EXPERIMENTAL|Patients in the intensive care unit and outpatients with acute or chronic kidney insufficiency|Measuring glomerular filtration rate (GFR) with two different marker and the same measuring protocol.
62354516|NCT03673696|EXPERIMENTAL|50 mg single dose|It includes two group, one group is pilot study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=2) . Another group is formal study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
62515929|NCT02790541|OTHER|Control/Crossover|Hyperbaric Oxygen Therapy: 3 months control period (no treatment) followed by 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
62515930|NCT02113176|EXPERIMENTAL|Minocycline|"* 200 mg IV/placebo~* Followed by 100 mg IV BID x 7days~* Followed by 200 mg tablet QD x 14days"
62710414|NCT04883268|NO_INTERVENTION|Comparison Group|Participants in the comparison group did not complete any intervention (i.e., this was a waitlist comparison group).
61973730|NCT06403995|EXPERIMENTAL|Recommended, undirected iCBT|Participants will have received the recommendation from a healthcare professional (e.g., family physician, nurse or social worker, psychologist) to complete the adapted program without guidance. Clinicians will provide the name and email of the patients they are referring the program to without providing participants with in-program support but will consult the dashboard as they have clinical responsibility for the patient. In case of severe distress (i.e., K10 score ≥30), the referring healthcare professional will receive an automated email informing them to go to their dashboard to identify that patient. Participants will also receive an automated email with a list of resources and emergency contact numbers. To support the generalization of findings to the real-world (ecological validity), clinicians may follow-up with patients at their discretion.
62147749|NCT03820024|EXPERIMENTAL|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
62147750|NCT03820024|NO_INTERVENTION|No Messages|No feedback messages
62147751|NCT01199315|EXPERIMENTAL|1|Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel.
62147752|NCT01199315|PLACEBO_COMPARATOR|2|Oral capsule. Dose single and followed by 5-day repeated dosing.
62354517|NCT03673696|EXPERIMENTAL|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
62354518|NCT03673696|EXPERIMENTAL|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg HEC74647PA capsule (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
62354519|NCT03673696|EXPERIMENTAL|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
62354520|NCT03673696|EXPERIMENTAL|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
62354521|NCT03673696|EXPERIMENTAL|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
62354522|NCT03673696|EXPERIMENTAL|100 mg multiple doses|Healthy subjects, receiving 100 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
62354523|NCT03673696|EXPERIMENTAL|200 mg multiple doses|Healthy subjects, receiving 200 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
62354524|NCT03673696|EXPERIMENTAL|400 mg multiple doses|Healthy subjects, receiving 400 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
62354525|NCT01962285|EXPERIMENTAL|propofol slow infusion|"(healthy volunteers, non invasive monitoring and O2 supply via nasal cannula) Target controlled infusion of propofol using Schnider´s pharmacokinetic parameters in a slow, stepped fashion. beginning at Cp 0.5 mcg/ml and increasing in 0.5 mcg/ml every 7 minutes until LOC occurred, then a prolonged step of 14 minutes (2 samples), increase 2 steps further and then decrease in 0.5 mcg/ml steps until ROC and a 7 minute registry after ROC.~Blood sampling for propofol plasma level every 7 minutes (at the end of each step, allowing for pseudo-equilibrium condition.~32 channel-EEg and BIS continuous monitoring"
62354526|NCT02376491|ACTIVE_COMPARATOR|High Frequency Left repetitive|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
62710415|NCT00003525|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62147753|NCT03683615|OTHER|patients with traumatic recent orbital blow out fractures|
62147754|NCT01824849|EXPERIMENTAL|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients.
62147755|NCT01824849|EXPERIMENTAL|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients.
62147756|NCT00678002||QOL###|All child subjects in this cohort will be listed for or already have received a solid organ transplant (kidney, heart, or liver).
62354527|NCT02376491|EXPERIMENTAL|intermittent Theta Burst Stimulation (iTBS)|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
62354528|NCT04178577|EXPERIMENTAL|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
62515931|NCT02113176|PLACEBO_COMPARATOR|Placebo|200 mg IV/placebo
62515932|NCT06237387||Group A|Patients with Allen-Smith acne score 0 and 2 (Mild lesions)
62354529|NCT00345501|EXPERIMENTAL|1|Iloprost
62354530|NCT00345501|PLACEBO_COMPARATOR|2|Placebo
62354531|NCT02897869|EXPERIMENTAL|Treatment sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
62354532|NCT02897869|EXPERIMENTAL|Treatment sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, Amikacin; Period 2, POL7080; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
62515933|NCT06237387||Group B|Patients with Allen-Smith acne score 4 (Moderate lesions)
62515934|NCT06237387||Group C|Patients with Allen-Smith acne score 6 and 8 (Severe lesions)
62515935|NCT02758249|ACTIVE_COMPARATOR|sevoflurane|patients under sevoflurane anesthesia
62515936|NCT02758249|ACTIVE_COMPARATOR|propofol|patients under propofol anesthesia
62515937|NCT06583850||chronic neck pain|chronic neck pain (CNP) (persists longer than 3 months.
62710416|NCT03276442|EXPERIMENTAL|Healthy diet|'Low-fat dietary intervention' to be administered to participants
62710417|NCT03276442|EXPERIMENTAL|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
62515938|NCT06583850||control|healthy controls
62515939|NCT05828355|NO_INTERVENTION|Clinic-based Rehabilitation|Individualised clinic-based face-to-face sessions with a physiotherapist in public or private rehabilitation facility
62515940|NCT05828355|EXPERIMENTAL|Knee Care@Home|Individualised synchronous internet-based remote sessions at home via conferencing software under the supervision of a certified exercise and health coach as a complement to conventional clinic-based rehabilitation sessions.
62515941|NCT02857556|OTHER|group with stage 3 kidney failure (diabetic or not)|
62515942|NCT02857556|OTHER|group with stage 5 kidney failure (diabetic or not)|
62515943|NCT03424850|EXPERIMENTAL|HDR brachytherapy - 21 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.
62515944|NCT03424850|EXPERIMENTAL|HDR brachytherapy - 23 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.
62515945|NCT03424850|EXPERIMENTAL|HDR brachytherapy - 25 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.
62515946|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
62515947|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
62515948|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 1: Double-blind Risankizumab Dose 3|Participants randomized to receive risankizumab dose 3 administered by intravenous (IV) infusion.
62515949|NCT03398148|PLACEBO_COMPARATOR|Substudy 1, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
62515950|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 1: Open-label Risankizumab Dose 1|Participants receive risankizumab dose 1 administered by intravenous (IV) infusion.
62515951|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
62515952|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
62515953|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
62515954|NCT03398148|EXPERIMENTAL|Substudy 1, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
62354533|NCT02228564|EXPERIMENTAL|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
62354534|NCT02533193|ACTIVE_COMPARATOR|enhanced recovery after surgery protocal|ERAS perioperative cares patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
62354535|NCT02533193|ACTIVE_COMPARATOR|Conventional perioperative cares|Conventional perioperative cares patents will be managed by our hospital's critical pathways.
62354536|NCT04886193|EXPERIMENTAL|FLOT combined with PD-1|"The enrolled patients will receive 4 cycles of FLOT regimen + teriprizumab treatment before surgery Q2W.~If the transformation is successful, the patient undergoes R0 surgical resection of D2 lymph node dissection, and will continue to receive 4 cycles of FLOT regimen + Teripril after surgery. Anti-treatment, the treatment plan is the same as before.~After completing the 4 cycles of treatment, oral Tiggio Capsule (S-1) and Teriprizumab were maintained for 1 year."
62354537|NCT04255017|NO_INTERVENTION|Symptomatic supportive treatment|Symptomatic supportive treatment
62354538|NCT04255017|EXPERIMENTAL|Abidol hydrochloride was added on the basis of group I.|Abidol hydrochloride 0.2g once,3 times a day,2 weeks
62354539|NCT04255017|EXPERIMENTAL|Oseltamivir was added on the basis of group I.|Oseltamivir 75mg once,twice a day,2 weeks
62354540|NCT04255017|EXPERIMENTAL|Lopinavir/ritonavir was added on the basis of group I.|Lopinavir/ritonavir 500mg once,twice a day,2 weeks
62515955|NCT03398148|EXPERIMENTAL|Substudy 2, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
62354541|NCT02640118|ACTIVE_COMPARATOR|Pancreatectomised + Lixisenatide|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
62354542|NCT02640118|PLACEBO_COMPARATOR|Pancreatectomized + lixisenatide-placebo|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously."
62515956|NCT03398148|PLACEBO_COMPARATOR|Substudy 2, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
62515957|NCT03398148|EXPERIMENTAL|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
62515958|NCT03398148|EXPERIMENTAL|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
62515959|NCT03398148|EXPERIMENTAL|Substudy 2, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
62710418|NCT04201535||Group 1A:|at least 10 patients, maximum 70,with RA in remission, but presenting p• Group 1B: at least10 patients maximum 70, with RA in remission, without bone erosion A group of 80 controls,
62147757|NCT04928937||bariatric surgery|consisting of gastric bypass surgery: Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG)
62710419|NCT04201535||Group 2:|10 patients with osteoarthritis (OA) who must undergo a surgical procedure.
62710420|NCT04201535||Group 3|"70 without RA and OA but hospitalized for any other orthopedics pathology who must undergo a surgical procedure.~rogressive bone erosion who must undergo a surgical procedure."
62147758|NCT04928937||conservative therapy|consisting of medical visits, nutritional counseling, physiotherapy, anti-obesogenic medication and psychological coaching
62354543|NCT02640118|ACTIVE_COMPARATOR|Healthy + Lixisenatide|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
62710421|NCT04203472|EXPERIMENTAL|Budesonide or budeosonide/formoterol administered by DPI|In every patient cough severity and tolerance of therapy will be analyzed during therapy with budesonide and/ or formoterol administered by DPI for 14 days
62354544|NCT02640118|PLACEBO_COMPARATOR|Healthy + lixisenatide-placebo|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously"
62354545|NCT03297333|EXPERIMENTAL|Resistance training group|Resistance training will consist of a supervised circuit training 3 sessions/week for approximately 45-50 min/session. The circuit will include 7 strength exercises engaging the major muscle groups (leg press, rows, back squats, weighted crunches, deadlifts, bench press, and squat jumps with weights). The participants will perform 3 sets of 10 repetitions with resting periods of 30 seconds between exercises, and 2 minutes between sets. The overall OMNI-Resistance Exercise Scale per set will range between 8-10. Heart rate and exercise energy expenditure during the workout will be monitored. The load will be changed depending on the participants' perception when needed. In addition, the intensity will be monitored assessing Lactate concentrations at baseline and at the end of each session. Circuit will be repeated until meeting the targeted exercise energy expenditure of 450-500 kcal/session.
62354546|NCT03297333|EXPERIMENTAL|Aerobic interval training group|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure. Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity, and the second period the intensity will be reduced for 2 minutes. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion as needed. Heart rate and exercise energy expenditure during the workout will be monitored. Intensity will be monitored assessing Lactate concentrations at the end of each session. Intervals will be repeated until meeting the targeted exercise energy expenditure (450-500 kcal/session).
62354547|NCT03297333|NO_INTERVENTION|Control group|Participants in the control group will not participate in the training programs.
62354548|NCT02294422|EXPERIMENTAL|2. LOR and aneroid manometer group|after inflating the endotracheal tube (ETT) cuff using a loss of resistance syringe (BD Epillor LOR), the LOR syringe is left attached to the pilot balloon and and any excess pressure will be passively released until the plunger stops drawing back.
62354549|NCT02294422|PLACEBO_COMPARATOR|1. PBP and aneroid manometer group|The anaesthesia care provider shall inflate the ETT cuff via the pilot balloon with small volumes of air as he/she 'feels ' for the pressures in the pilot balloon to a pressure he/she thinks is just enough. An aneroid manometer (VBM, Germany. Accurate in the range 0-120 cmH2O +-2 cmH2O) shall then be attached by the investigator and measurement of the pressure taken.
62354550|NCT00615797|EXPERIMENTAL|1|Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
62354551|NCT00615797|PLACEBO_COMPARATOR|2|Group randomized to receive standard intervention for sydenham's chorea alone
62354552|NCT03682380|EXPERIMENTAL|Part 1: Seltorexant High Dose|In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
62354553|NCT03682380|EXPERIMENTAL|Part 2: Seltorexant High Dose|Participants will receive the following treatments: Treatment G: Two low doses of seltorexant tablets (Reference formulation), Treatment H: High dose or two low doses of seltorexant tablet (Test formulation 1), Treatment I: High dose of seltorexant tablet (Test formulation 2), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-3). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
62710422|NCT04203472|ACTIVE_COMPARATOR|Budesonide or budeosonide/formoterol administered by MDI|In every patient inhaler will be changed and cough severity and tolerance of therapy will be analyzed during therapy with the same drugs administered by MDI . Order of using different types of inhalers will be accidental
62710423|NCT04214249|EXPERIMENTAL|Arm I (cytarabine, idarubicin, daunorubicin, HSCT)|See Detailed Description.
62710424|NCT04214249|ACTIVE_COMPARATOR|Arm II (cytarabine, idarubicin, daunorubicin, HSCT)|See Detailed Description.
62710425|NCT01329861|EXPERIMENTAL|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
62147759|NCT05991804|ACTIVE_COMPARATOR|Inpatient rehabilitation alone|Standard inpatient rehabilitation received at the Royal National Orthopaedic Hospital NHS Trust
62147760|NCT05991804|EXPERIMENTAL|Transcutaneous spinal cord stimulation added to inpatient rehabilitation|Transcutaneous spinal cord stimulation added to standard inpatient rehabilitation, targetting the upper limbs, received at the Royal National Orthopaedic Hospital NHS Trust
62147761|NCT05832593||Group 1|
62147762|NCT05832593||Group 2|
62515960|NCT03398148|EXPERIMENTAL|Substudy 2, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
62515961|NCT01021228||group1|continuous volatile anesthesia (sevoflurane) during the liver resection
62515962|NCT01021228||group2|continuous intravenous anesthesia (propofol) during the liver resection
62515963|NCT01021228||group3|preconditioning volatile anesthesia (sevoflurane) 30 minutes before ischemia (inflow occlusion)
62710426|NCT01329861|NO_INTERVENTION|Control condition|Wait-list condition, received treatment after post-treatment assessment.
61973731|NCT06403995|EXPERIMENTAL|Recommended, directed iCBT|Participants will be recommended the intervention by a healthcare professional and be provided low-intensity guidance (e.g., email or brief phone contact \[5 to 10 minutes\] after Lesson 1 and 2, and then on an as-needed basis or patient request). Clinicians at the primary care sites participating in the study will be able to recommend the adapted program to their patients, will remain responsible for their patients and, will check their dashboard to see how their patients are progressing through the program. In the event of severe distress (i.e., K10 score ≥30) in a patient, the referring healthcare professional will receive an automated email informing them to go to their dashboard to identify that patient and assess the appropriate action to take. Participants will also receive an automated email with a list of resources and emergency contact numbers.
62354554|NCT03682380|EXPERIMENTAL|Part 3: Seltorexant Low Dose or High Dose|Part 3 will have 3 subparts (Part 3A, Part 3B, and Part 3C). In Part 3A and 3B, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7) respectively in a different food conditions on Day 1 in each treatment Periods (Periods 1-5). In Part 3C, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7 ) on Day 1 in each period (Period 1 and 2). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
62710427|NCT02953769||Arm 1|Ventral hernia repair using standard wound care.
62147763|NCT04257916|EXPERIMENTAL|Experimental group|"The intervention by kinesiotape will be done with the player in supine position with the foot in dorsal flexion, anchoring the strip below the sole of the foot without tension, adding 50-70% tension until internal and external malleolus, and ending without tension. Another strip will be placed under the external malleolus, anchoring the bandage and following the talus (50-70% tension), leaving the scaphoid bulge free, surrounding the plant without tension and leaving the 5th metatarsal free. The bandage continues on the peroneal-astragalin ligament and the external malleolus (50-70% tension), until the tendon without tension. In the end we will surround the internal malleolus to the Achilles tendon without tension, ending with the same tension in the external malleolus and the neck of the talus.~The myofascial technique and strength training will be the same in both groups."
62354555|NCT05096546||Group I|"1. 20 years old or older (regardless of sex)~2. Outpatients~3. Newly-diagnosed with dry eye disease (DED) within 6 months prior to signing the informed consent under hospital-based practice in Taiwan"
62354556|NCT05096546||Group II|"1. 20 years old or older (regardless of sex)~2. Outpatients~3. Patients who had undergone cataract surgery and~   1. was suspected to have dry eye disease (dry eye evaluations conducted based on the routine practice) within 6 months prior to signing the informed consent or~  2. was diagnosed with dry eye disease within 6 months prior to signing the informed consent"
62354557|NCT01769144|ACTIVE_COMPARATOR|Acticoat Absorbent|Acticoat Absorbent wound dressing
62354558|NCT01769144|EXPERIMENTAL|BCT wound dressing|wound dressing
62354559|NCT01383109|EXPERIMENTAL|Pyronaridine|All subjects will receive a single dose of Pyronaridine
62354560|NCT04507776||Patients with spondyloarthropathies|Patients with spondyloarthrosis that received Etanercept as treatment for disease
62354561|NCT02816437|EXPERIMENTAL|OpenBiome FMT retention enema|OpenBiome Fecal Microbiota Transplantation retention enema, one rectal application.
62354562|NCT04294654|EXPERIMENTAL|Vortioxetine|5 - 20 mg/day tablets
62354563|NCT05504577|EXPERIMENTAL|QCG group|After the prosthesis are all implanted, apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes, then remove the QCG from the knee joint and throughout check bleeders before closure of the joint capsule. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation
62354564|NCT05504577|ACTIVE_COMPARATOR|Surgical gauze group|After the prosthesis are all implanted, apply the surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes, then remove the gauze from the joint and throughout check bleeders before closure of the joint capsule. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation
62354565|NCT05504577|PLACEBO_COMPARATOR|Control group|fter the prosthesis are all implanted, we close the joint capsule directly. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
62354566|NCT04391855|EXPERIMENTAL|Tramadol with ropivacaine|Tramadol 2mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
62354567|NCT04391855|EXPERIMENTAL|Dexmedetomidine with ropivacaine|Dexmedetomidine 1μg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
62354568|NCT04391855|EXPERIMENTAL|Magnesium with ropivacaine|Magnesium sulfate 10 mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
62354569|NCT04391855|PLACEBO_COMPARATOR|Placebo with ropivacaine|Ropivacaine (10mg/ml) 100mg with 5ml isotonic saline for wound infiltration
62354570|NCT02573233|PLACEBO_COMPARATOR|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
62354571|NCT02573233|EXPERIMENTAL|Dupilumab|Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
62710428|NCT02953769||Arm 2|Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™
62710429|NCT04755647|EXPERIMENTAL|Nitric Oxide-Releasing Solution (NORS)|Five litre foot bath delivery NORS
62354572|NCT04265898||Test Group|Reported mild cognitive deficits
62515964|NCT01709734|EXPERIMENTAL|Dose Confirmation|"Dose A - galeterone tablets once daily PO for three months + extension~Dose B - galeterone tablets once daily PO for three months + extension~Dose C - galeterone tablets once daily PO for three months + extension"
62515965|NCT01709734|EXPERIMENTAL|Dose Expansion|Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
62515966|NCT02917408||Primary biliary cholangitis during January 2001 to July 2016|
62515967|NCT00749502|EXPERIMENTAL|Part A-Dose escalation and confirmation|
62515968|NCT00749502|EXPERIMENTAL|Part B - Prostate/Ovarian Cancer Cohort|
62515969|NCT00749502|EXPERIMENTAL|Part C - T-PLL/CLL cohort|
62515970|NCT00749502|EXPERIMENTAL|Part D - CRC, endometrial, breast, and ovarian cancer cohort|
62515971|NCT06264791|EXPERIMENTAL|Stress alcohol|These participants will undergo a stress induction and receive alcoholic beverages to raise their BAC to .06%
62354573|NCT04265898||Control Group|No cognitive deficits
62354574|NCT05996783|NO_INTERVENTION|Control - no intervention|"This control group will receive no intervention. Cervical cancer screening (having a Pap smear taken by a clinician for cytology-based screening) is completely opportunistic, i.e. based on the initiative of the participant or their clinician.~No reminder letter will be sent."
62354575|NCT05996783|NO_INTERVENTION|Control - (recall) invitation letter|"This control group will receive the standard (recall) invitation letter send out by the Centre for Cancer Detection (CvKO). In this invitation letter, participants are encouraged to make an appointment with their clinician to have a Pap smear taken (for cytology-based screening).~A reminder letter will be sent after 5-6 months."
62354576|NCT05996783|EXPERIMENTAL|Opt-out first-void urine|"Women will receive a first-void urine self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
62354577|NCT05996783|EXPERIMENTAL|Opt-in first-void urine|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a first-void urine self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
62354578|NCT05996783|EXPERIMENTAL|Opt-out vaginal self-sample|"Women will receive a vaginal self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
62515972|NCT06264791|EXPERIMENTAL|Stress no alcohol|These participants will undergo a stress induction and receive non-alcoholic beverages
62515973|NCT06264791|EXPERIMENTAL|No stress alcohol|These participants will undergo a neutral induction and receive alcoholic beverages to raise their BAC to .06%
62515974|NCT06264791|NO_INTERVENTION|No stress no alcohol|These participants will undergo a neutral induction and receive non-alcoholic beverages
62515975|NCT02083419||LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
62515976|NCT03913182|EXPERIMENTAL|apatinib group|apatinib：500mg po Qd
62515977|NCT01297816|PLACEBO_COMPARATOR|placebo|100mg-
62710430|NCT04755647|PLACEBO_COMPARATOR|Saline|Five litre foot bath delivery NORS
62354579|NCT05996783|EXPERIMENTAL|Opt-in vaginal self-sample|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a vaginal self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
62354580|NCT02746848|EXPERIMENTAL|Patients with cornea injury|Patients with cornea injury who received healing Amniotic Membrane Extract Eye Drop.
62354581|NCT03748485|EXPERIMENTAL|wait and watch group|clinical local advanced colorectal cancer (cTxN1/2M0) following pre-operational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) without adjuvant chemotherapy
62354582|NCT03748485|ACTIVE_COMPARATOR|adjuvant chemotherapy group|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) with adjuvant chemotherapy
62354583|NCT00936299|ACTIVE_COMPARATOR|Bupropion + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.
62354584|NCT00936299|PLACEBO_COMPARATOR|Placebo + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.
62354585|NCT03291158|EXPERIMENTAL|Minocycline IV|Open label Minocin IV
62515978|NCT01297816|PLACEBO_COMPARATOR|minocyclin|
62515979|NCT04331964|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate (MTA)|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The exposed pulp tissues will be directly capped with a 3mm of MTA (Pro Root MTA) layer.
62515980|NCT04331964|EXPERIMENTAL|MTA with platelet rich fibrin (PRF).|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The PRF membrane obtained after centrifugation of the patient's own blood is going to be placed over the exposed pulp. Then, a 3mm of MTA (Pro Root MTA) will be placed over the PRF membrane.
62515981|NCT04310306||Rescue stenting group|
62515982|NCT00668720|EXPERIMENTAL|1|
62515983|NCT00668720|SHAM_COMPARATOR|2|
62710431|NCT06451588|EXPERIMENTAL|Donor A FMT|Active treatment contain 60g of feces from a single healthy, screened donor. The feces is combined with glycerol and saline to a total volume of 440 ml in an enema bag. Each participant will only receive a single treatment at baseline.
62710432|NCT06451588|EXPERIMENTAL|Donor B FMT|Active treatment contain 60g of feces from a single healthy, screened donor. The feces is combined with glycerol and saline to a total volume of 440 ml in an enema bag. Each participant will only receive a single treatment at baseline.
62515984|NCT03940482|EXPERIMENTAL|Single Arm|Subjects will act as their own controls
62354586|NCT02685995|ACTIVE_COMPARATOR|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
62354587|NCT02685995|ACTIVE_COMPARATOR|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
62354588|NCT01510834|EXPERIMENTAL|All STR2IVE Participants|All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.
62354589|NCT00554138|PLACEBO_COMPARATOR|1|
62354590|NCT00554138|EXPERIMENTAL|2|
62354591|NCT01688063||Part A: 3 Arms|Subjects will be recruited and enrolled to fill one of three Arms. The first Arm will include 25 subjects who are scheduled to receive resurfacing or tightening procedures AS STANDARD OF CARE (CO2 resurfacing or tightening procedure (1 treatment), radiofrequency (2 tx), Fraxel ( 2 tx), or PDL. These subjects will have baseline elasticity measurements recorded on their face and right forearm before their procedures, and follow up measurements will be repeated 3 months following their last treatment. The second Arm will include 25 subjects who are not scheduled to receive any cosmetic procedures but who agree to return for repeated measurements 3 months following the first. Baseline elasticity measurements will be recorded from subjects' face and right forearm and subjects will return in 3 months for follow-up measurements. The third Arm will include the remaining 50 subjects; these subjects will have the elasticity measurements performed only once on their face and forearm.
62354592|NCT01688063||Part B|The study population in the second cohort will consist of 250 subjects who have a surgical scar \>2 cm in length. Subjects enrolled will have three elasticity measurements performed in one study visit. Elasticity will be measured directly in the center of the scar, 3cm perpendicular to the center of the scar, and 3cm in line from one end of the scar (Appendix 2).
62354593|NCT04228887|ACTIVE_COMPARATOR|Control Group|The control group will be receive 45 minutes training sessions 3 times a week for 8 weeks; 2 days a week for home based balance training and 1 day for supervisory training with Bio-Dex Balance-System ®.
62354594|NCT04228887|ACTIVE_COMPARATOR|Training Group|The training group will receive inspiratory muscle training; 15 minutes sessions 5 times a week for 8 weeks in addion to balance training same as control.
62354595|NCT03705312|PLACEBO_COMPARATOR|Guideline-directed medical therapy|Standard guideline-directed medical treatment for heart failure
62354596|NCT03705312|EXPERIMENTAL|Transcatheter Mitral valve repair|MitraClip treatment
62354597|NCT01760759|NO_INTERVENTION|Usual care|Patients receive usual care from their medical providers.
62354598|NCT01760759|EXPERIMENTAL|Usual care plus cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
62354599|NCT01760759|EXPERIMENTAL|Usual care, reminders & contingency management for adherence|Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
62354600|NCT03069898|EXPERIMENTAL|TRUE Dads program track|In the TRUE Dads program, fathers and co-parents begin with a Core workshop meeting weekly for 6 weeks. After a check-in, a male-female group leader team focuses on a single topic that represents one of the three main goals of the project as a whole: Co-parenting relationships, Parenting, or Employment and financial stability. From 10 to 18 couples, seated at small tables in a large room, hear mini-lectures, watch videos, and engage in interactive exercises. Fathers then choose to attend one of three intensive workshops focused on couple relationships OR parenting OR economic self-sufficiency meeting 3 hours per week for the next 6 weeks. On an as-needed basis, fathers may be referred for employment programs and fathers and co-parents may be referred for mental health or other services.
62354601|NCT03069898|NO_INTERVENTION|Control condition study track|Participants (fathers and co-parents) complete intake interview and fill out Baseline survey. They fill out follow-up survey one year later
62354602|NCT03178799||FLS|Fracture Liaison Service (Care managers based coordination service for fragility fracture patients with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years (to 2028).)
62354603|NCT03178799||UC|usual care (Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years (to 2028). )
62354604|NCT01450475|EXPERIMENTAL|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
62354605|NCT01450475|NO_INTERVENTION|control|A blood cuff was around leg without inflation or deflation.
62354606|NCT02083146||Patients with CAD|Acute coronary syndromoe (ACS) patients who were admitted to the coronary care unit.
62354607|NCT01573403|EXPERIMENTAL|Treatment 1|one dose of DLBS2411 @250 mg
62354608|NCT01573403|EXPERIMENTAL|Treatment II|two doses of DLBS2411 @250 mg
62515985|NCT00733369|OTHER|PFC Sigma RP-F|125 patients to be allocated to this arm according to blinding envelopes
62515986|NCT00733369|ACTIVE_COMPARATOR|PFC Sigma RP|125 patients to be allocated to this arm according to blinding envelopes
62715099|NCT05324579|EXPERIMENTAL|Neurosurgical subjects|Subjects undergoing intracranial neurosurgical procedures
61973732|NCT03355521|EXPERIMENTAL|Nordic walking Experimental|Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (NW); (c) return to the calm and ultimate stretching.
62354609|NCT01573403|PLACEBO_COMPARATOR|Treatment III|
62354610|NCT02762019|EXPERIMENTAL|Laser therapy|Children are allocated to receive Laser therapy
62354611|NCT02762019|SHAM_COMPARATOR|Sham therapy|Children are allocated to receive Sham therapy
62354612|NCT05671315|EXPERIMENTAL|Combined treatment group|Peginterferon alfa-2b Injection combined Nucleos (t) ide Analogue therapy
62354613|NCT05671315|ACTIVE_COMPARATOR|Monotherapy group|Nucleos (t) ide Analogue monotherapy
62354614|NCT04323150|EXPERIMENTAL|Closed suction systems|
62354615|NCT04323150|OTHER|Open (conventional) suction|control group
62354616|NCT03628599|EXPERIMENTAL|TOTAL1|Delefilcon A contact lenses worn bilaterally (in both eyes) for 4 weeks in a daily disposable modality
62354617|NCT03628599|ACTIVE_COMPARATOR|1-DAY|Senofilcon A contact lenses worn bilaterally for 4 weeks in a daily disposable modality
62354618|NCT04587596||Clinical staff|All clinical staff employed at one surgery in Middlesbrough, UK who wish to participate
62354619|NCT01297309|EXPERIMENTAL|NPSP558|titration of 25, 50, 75 or 100 μg
62354620|NCT01316029||laying-on-of-hands|44,587 Japanese volunteers with/without illness, who were interested in receiving laying-on-of-hands
62354621|NCT02209038|EXPERIMENTAL|Expanded AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~4 answer choices:~* Yes, I would like to complete a comprehensive version of an advance directive.~* Yes, I would like to complete an expanded version of an advance directive.~* Yes, I would like to complete a brief version of an advance directive.~* No, I do not wish to complete an advance directive."
62354622|NCT02209038|NO_INTERVENTION|Standard AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~2 answer choices:~* Yes, I would like to complete an AD.~* No, I do not wish to complete an advance directive."
62354623|NCT02209038|EXPERIMENTAL|Expanded Life-sustaining therapy Choice|"For each hypothetical illness state described in the living will:~4 answer choices:~* No, I would not want life support.~* Yes, I would want life support.~* I would want life support if my doctor believes it could help, but I want to stop receiving life support if at any time my doctor believes it is only delaying the moment of my death.~* I do not wish to specify a preference at this time."
62354624|NCT02209038|NO_INTERVENTION|Standard Life-sustaining Therapy Choice|"For each hypothetical illness state described in the living will:~3 answer choices:~* No, I would not want life support.~* Yes, I would want life support.~* I do not wish to specify a preference at this time."
62354625|NCT01797445|EXPERIMENTAL|E/C/F/TAF (Double-Blind)|"E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
62354626|NCT01797445|ACTIVE_COMPARATOR|E/C/F/TDF (Double-Blind)|"E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
62354627|NCT01797445|EXPERIMENTAL|Open-Label E/C/F/TAF|After the unblinding visit, in countries where E/C/F/TAF is not commercially available, participants (except in UK) who complete 144 weeks of study will be given the option to receive open-label E/C/F/TAF and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
62354628|NCT04117412|OTHER|Patients with COPD|Patients with COPD will undergo two different one bout of exercise training after maximal exercise test.
62354629|NCT01892644|ACTIVE_COMPARATOR|Deferasirox HC|10 patients with hemochromatosis treated with Deferasirox
62354630|NCT01892644|ACTIVE_COMPARATOR|Venesection HC|10 patients with hemochromatosis treated with venesection
62354631|NCT01892644|ACTIVE_COMPARATOR|Deferasirox MDS|20 patients with myelodysplastic syndrome treated with Deferasirox
62354632|NCT01892644|NO_INTERVENTION|Controls|10 healthy control persons to assess the normal level of investigational blood tests.
62515987|NCT05122767|EXPERIMENTAL|Single Arm in 4 groups|There will be four groups. Group 1a and Group 1b will provide semi-intensive PK data and safety monitoring to allow for comparison of twice-daily dolutegravir exposures together with HP vs. when DTG is given alone. Group 2a and Group 2b will provide semi-intensive PK data and safety monitoring for either twice-daily or once-daily dolutegravir together with HIV vs when DTG is given alone. All groups will provide safety and tolerability data, HIV virologic outcome data, and information about dolutegravir and rifapentine PK.
62354633|NCT00806689||Cardiac surgery patients|Patients in atrial fibrillation being scheduled for cardiac surgery and concomitant ablation procedure
62354634|NCT03277508|EXPERIMENTAL|BCI robot assisted hand therapy|Brain-computer integration robot assisted hand therapy
62354635|NCT03277508|ACTIVE_COMPARATOR|CPM robot assisted hand therapy|Continue Passive Movement robot assisted hand therapy
62354636|NCT04207268|EXPERIMENTAL|Gardening and Nutrition Advice|Participate in gardening activities, food demonstrations and nutrition advice
62354637|NCT04207268|PLACEBO_COMPARATOR|Nutrition Advice alone|Participate in only nutrition advice
62354638|NCT01655238||95-99% BMI ASC|Patients having a BMI between 95-99% who are seen in the ambulatory surgery centers.
62354639|NCT01655238||95-99% BMI NCH main OR|Patients having a BMI between 95-99% who are seen in the main operating rooms.
62354640|NCT01655238||>99% BMI NCH main OR|Patients having a BMI \>99% who are seen in the main operating rooms.
62354641|NCT04261049|EXPERIMENTAL|ZILRETTA Injection|All patients upon enrolling in the study will receive a single 5 mL injection of 32 mg ZILRETTA into the affected knee joint.
62354642|NCT01624506||Magnetic Sphincter Augmentation|Patients will be treated with magnetic sphincter augmentation via the LINX Reflux Management System
62354643|NCT01624506||Fundoplication|Patients treated with laparoscopic fundoplication
62354644|NCT01442701||No triclosan / Triclosan|Participants are randomized to receive household and personal cleaning products from one of 2 arms: products that either do not contain triclosan or that may contain triclosan. Participants select products from an arm-specific list of commercially available items.
61973733|NCT03355521|ACTIVE_COMPARATOR|Free walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
62147764|NCT04257916|ACTIVE_COMPARATOR|Control group|"The myofascial technique will be carried out by positioning the caudal hand of the physiotherapist in the astragalin and heel region, and the cranial hand in the middle foot. With a tibiotarsal traction, the foot will be everted, performing a shear in the astragalin zone, using a combined and slow technique.~All players will warm up for 10 minutes on tape, at a speed of 7 km / h without inclination. The strength work was carried out with an isoinertial machine (Space Whell) with intervalic methodology: 20 -10, with 4 series and doing three exercises: Squat, Lunges and Deadlift. One minute breaks will be made between sets."
62147765|NCT00068107|EXPERIMENTAL|Relagal|All participants received Relagal administered weekly
62354645|NCT02811796||angio-based FFR estimation|The investigators will include all patients receiving successful coronary stent implantation. In these patients the investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
62354646|NCT03957746|EXPERIMENTAL|3 sets of resistance exercise|
62354647|NCT03957746|EXPERIMENTAL|6 sets of resistance exercise|
62354648|NCT03957746|EXPERIMENTAL|9 sets of resistance exercise|
62354649|NCT03957746|NO_INTERVENTION|Rest|
62354650|NCT03457740|EXPERIMENTAL|Formula 1|Formula 1 with nutrients and herbs, 4 capsules daily, 6 weeks
62354651|NCT03457740|EXPERIMENTAL|Formula 2|Formula 2 with nutrients and herbs, 4 capsules daily, 6 weeks
62354652|NCT03457740|PLACEBO_COMPARATOR|Placebo|Placebo, 4 capsules daily, 6 weeks
62354653|NCT04412070||Patient with Non-Muscle invasive Bladder Cancer|Patients in this group will be enrolled before the start of their treatment with BCG. This will start within 4 weeks after the transurethral bladder resection, in accordance with the guidelines
62354654|NCT04412070||Patient with Muscle Invasive Bladder Cancer|Patients in this group will be enrolled in the study before surgical treatment by radical cystectomy
62354655|NCT05911412|EXPERIMENTAL|NMBCT intervention|Participants in this arm enter the 8-week NMBCT course immediately after the baseline visit.
62147766|NCT01617785||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
62147767|NCT01617785||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization
62147768|NCT01617785||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
62147769|NCT01981746|EXPERIMENTAL|30 ml|30 ml ropivacaine 0.1%, single bolus
62354656|NCT05911412|EXPERIMENTAL|Waitlist|Participants in the waitlist control arm will wait for 8 weeks after the baseline visit, and then will be offered an identical 8-week NMBCT course.
62354657|NCT00609453|EXPERIMENTAL|1|Individuals with major depressive disorder receiving therapy
62354658|NCT02360553|EXPERIMENTAL|Intervention|ObeseGO!-web-based intervention
62354659|NCT02360553|OTHER|Control|Given pamphlets education mainly on diet and physical activity
62515988|NCT06437106|ACTIVE_COMPARATOR|A blanket impregnated with the mother's odor|Intervention group 1 consists of premature babies who receive a blanket impregnated with the mother's odor.
62515989|NCT06437106|ACTIVE_COMPARATOR|blanket without mother's smell|Intervention group 2 includes premature babies who receive a blanket without the smell of the mother.
62515990|NCT06437106|ACTIVE_COMPARATOR|control group|The control group includes premature babies who receive no intervention and receive routine care.
62515991|NCT04539626|EXPERIMENTAL|Estrogen Therapy|"Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg~Dosage form: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)"
62147770|NCT01981746|EXPERIMENTAL|10 ml|10 ml 0.1% ropivacaine, single bolus
62147771|NCT00826826|ACTIVE_COMPARATOR|Amiodarone|
62147772|NCT00826826|PLACEBO_COMPARATOR|Placebo|
62354660|NCT03341611||Adults 55 and younger|
62354661|NCT03341611||Adults 55 and older|
62354662|NCT04874532|EXPERIMENTAL|Community Paramedic (CP) program and Education Materials|Subjects will receive CP home visits and telephone calls for 1 month, along with printed diabetes education materials and a resource guide for contacting their diabetes care team in addition to usual care.
62354663|NCT04874532|ACTIVE_COMPARATOR|Usual Care and Education Materials|Subjects will receive printed diabetes education materials and a resource guide for contacting their diabetes care team in addition to usual care.
62354664|NCT06365242||DOACs treated patients|Patients treated with DOACs undergoing oral extractions
62354665|NCT05660213|EXPERIMENTAL|Arm 1|"Huaier granules combined with targeted drug and anti- PD-(L)1 antibody.~There are there specific regimens:~Huaier granules combined with Atezolizumab and Bevacizumab, Huaier granules combined with Camrelizumab and Apatinib, Huaier granules combined with Sintilimab and Bevacizumab."
62354666|NCT05660213|ACTIVE_COMPARATOR|Arm 2|"Targeted drug combined with anti-PD-(L)1 antibody.~There are there specific regimens:~Atezolizumab combined with Bevacizumab, Camrelizumab combined with Apatinib, Sintilimab combined with Bevacizumab."
62354667|NCT00851253|EXPERIMENTAL|Group 1 (CK SRS boost therapy)|Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.
62354668|NCT00851253|EXPERIMENTAL|Group 2 (CK SRS salvage therapy)|Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.
62354669|NCT02251678|EXPERIMENTAL|Elimune capsules|Elimune capsules 2 capsules BID (four total capsules per day)
62354670|NCT02882737|EXPERIMENTAL|Exercise and glucagon before exercise|"120 minutes after breakfast; a single subcutaneous bolus of 200µg glucagon is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~When exercise is ended a single subcutaneous bolus of 0.2 ml saline is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
62515992|NCT04539626|NO_INTERVENTION|Control Group|Patients who will receive conventional COVID-19 treatment
62515993|NCT02947724|NO_INTERVENTION|drainage only|50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
62515994|NCT02947724|NO_INTERVENTION|cystectomy only|50 patients underwent laparoscopic excision of the endometrioma cyst wall
61973734|NCT02837094|EXPERIMENTAL|Safety of C19A3 GNP (general safety and induction of hypersensitivity).|To assess general safety different parameters were taken into account: A physical examination at screening and 0, 4, 8 and 14 weeks, a review of AEs at all visits and blood tests at screening, weeks 4, 9, 14 \& 20 for full blood count; urea, electrolytes and creatinine; liver function tests; (prothrombin time, total bilirubin, total protein, albumin, AST (SGOT), SGPT (ALT), alkaline phosphatase; thyroid stimulating hormone; immunoglobulins (G, A, M); calcium; magnesium, phosphate, lipid profile (total cholesterol, LDL, HDL, triglyceride), urinalysis for pH blood, protein, urine beta-2-microglobulin and albumin/creatinine ratio at screening and visits 1, 2, 4, 5 and 6 and urine for cystatin-c was tested at visits 1, 4, 5 \& 6, a urine pregnancy test in females only, at all trial visits. Subjects were observed for systemic hypersensitivity to C19-A3 GNP during the immediate period after peptide injection.
61973735|NCT01450839|EXPERIMENTAL|E2020 5 mg tablet and tape|
61973736|NCT01450839|PLACEBO_COMPARATOR|2|
62515995|NCT02947724|ACTIVE_COMPARATOR|drainage & Surgicel|50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
61973737|NCT00919724||HIV-Infected|HIV-infected participants who are not currently receiving antiretroviral medications
61973738|NCT00919724||HIV-Uninfected|HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
61973739|NCT05084274|ACTIVE_COMPARATOR|Lifestyle intervention group|12-week lifestyle modification programme through face-to-face lifestyle counseling and physiotherapy combined with a follow-up programme using video consultations and online training sessions
62354671|NCT02882737|ACTIVE_COMPARATOR|Exercise and glucagon after exercise|"120 minutes after breakfast; a single subcutaneous bolus of 0.2 ml saline is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~Low-dose glucagon phase: When exercise is ended or when hypoglycemia occurs (≤3.9 mmol/l); a single subcutaneous bolus of 200μg glucagon is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
62354672|NCT02882737|ACTIVE_COMPARATOR|Resting and glucagon after resting|"120 minutes after breakfast; a single subcutaneous bolus of 200μg placebo is administered.~Resting: After placebo injection the patient will be resting on a hospital bed for 45 minutes. The patient do not know if placebo or glucagon is administered.~Low-dose glucagon phase: After 45 minutes of resting or when hypoglycemia occurs, a single subcutaneous bolus of 200μg glucagon is administered.~Safety issues: If plasma glucose drops \< 2.5 mmol/l at two consecutive measurements with 5 min interval or the patient experiences unbearable symptoms of hypoglycemia even after glucagon administration, 20 g carbohydrate is given orally. If plasma glucose drops\< 2.3 mmol/l or doesn't raise sufficient after oral glucose, we will give intravenøs glucose to the patient. The study will then end and a new study day will be planned."
62354673|NCT03701204|EXPERIMENTAL|DynamiCare Rewards|The study will test the feasibility/acceptability and efficacy of DynamiCare Rewards™. DynamiCare Rewards is an iOS/Android app which automates Contingency Management (CM) to help the patient self-monitor and focus attention on his/her behavioral goals (i.e., abstinence) for alcohol or other substance use disorders.
62354674|NCT03701204|NO_INTERVENTION|Control|Treatment as usual
62354675|NCT01582802||Pregnant women carrying multiples|Healthy pregnant women carrying twins, triplets and quadruplets will be recruited.
62354676|NCT06121362|PLACEBO_COMPARATOR|Placebo|The placebo pill is made of inactive cellulose. Participants will be asked to take 2 capsules daily by mouth in the morning 30 minutes before eating for a total of 14 days (Day 1 - Day 14).
62515996|NCT02947724|ACTIVE_COMPARATOR|cystectomy & Surgicel|50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
62515997|NCT06317584|EXPERIMENTAL|Empowerment Application for CAM Health Education.|Using empowerment software applications for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of the assistive tool of the empowerment software application
62515998|NCT06317584|PLACEBO_COMPARATOR|Written Paper for CAM Health Education.|Using written paper for complementary and alternative therapy education, explaining the risk factors that need to be considered
62515999|NCT02904499||VKA|First Initiators of VKA for non-valvular atrial fibrilation
62516000|NCT02904499||Dabigatran|First Initiators of Dabigatran for non-valvular atrial fibrilation
62516001|NCT01643226|EXPERIMENTAL|riboflavin solution and KXL System|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
62516002|NCT01643226|PLACEBO_COMPARATOR|placebo solution and KXL System|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
62516003|NCT01103479|NO_INTERVENTION|Control|Participants will complete interviewer-administered pre- and post-test
62516004|NCT01103479|EXPERIMENTAL|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer screening guidelines, communication skills, and health literacy training
62516005|NCT01103479|EXPERIMENTAL|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational digital video disc (DVD) on CRC and CRC screening
61973740|NCT05084274|NO_INTERVENTION|Standard-of-care group|No intervention
61973741|NCT00629681|EXPERIMENTAL|1|
61973742|NCT03747328|EXPERIMENTAL|ABI-009|nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))
62516006|NCT03998436|ACTIVE_COMPARATOR|Galnobax® 14% gel plus SoC|Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)
62516007|NCT03998436|SHAM_COMPARATOR|SoC Only|Only Standard of Care will be administered twice daily (150 subjects)
62147773|NCT01852045|EXPERIMENTAL|OnabotulinumtoxinA 50 U|OnabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 (NCT01852058) if qualified.
62147774|NCT01852045|EXPERIMENTAL|OnabotulinumtoxinA 100 U|OnabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
62516008|NCT03998436|PLACEBO_COMPARATOR|Vehicle plus SoC|Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)
62516009|NCT01316419||Patients with essential hypertension|
62516010|NCT01597219|EXPERIMENTAL|Reduced intensity haploidentical transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4
62710433|NCT06451588|EXPERIMENTAL|Donor C FMT|Active treatment contain 60g of feces from a single healthy, screened donor. The feces is combined with glycerol and saline to a total volume of 440 ml in an enema bag. Each participant will only receive a single treatment at baseline.
62710434|NCT06451588|PLACEBO_COMPARATOR|Placebo/autologous FMT|Placebo treatment will be processed identically to active treatment, but with paritcipants own stool. The patients in the placebo group will consequently receive an enema with 60g of their own feces combined with glycerol and saline as a single treatment at baseline.
62710435|NCT06104345|ACTIVE_COMPARATOR|Vivotif|Three oral doses of typhoid fever vaccine (Vivotif®).
62516011|NCT01597219|EXPERIMENTAL|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0
62516012|NCT02291692|ACTIVE_COMPARATOR|Paravertebral blockade|Paravertebral blockade
62516013|NCT02291692|NO_INTERVENTION|Paracetamol|The patients was given 15 mg/kg of paracetamol.
62516014|NCT05820386|EXPERIMENTAL|Skin-to-skin contact during the transfer between the delivery room and the neonatal care unit|Preterm infants will be transferred using a direct skin-to-skin contact with their father from the delivery room to the intensive neonatal care.
62710436|NCT06104345|ACTIVE_COMPARATOR|Dukoral|Two oral doses of cholera vaccine (Dukoral®).
62710437|NCT06104345|EXPERIMENTAL|Dukoral+Vivotif|Oral typhoid fever and cholera vaccines (Vivotif® and Dukoral®) administered simultaneously.
62710438|NCT03136055|EXPERIMENTAL|Part A: Pembrolizumab only|Participants will receive 200 mg of pembrolizumab via IV over 30 minutes every 3 weeks for 24 months or 35 administrations (whichever comes first).
62710439|NCT03136055|EXPERIMENTAL|Part B: Pembrolizumab + Chemotherapy|Participants will receive 200 mg of pembrolizumab via IV over 30 minutes every 3 weeks for 24 months or 35 administrations (whichever comes first) and chemotherapy treatment of 125 mg/m\^2 of irinotecan via IV on days 1 and 8 of each 21-day cycle or paclitaxel via IV on days 1, 8, and 15 of each 21-day cycle per physician discretion
62710440|NCT05013814||Children with unilateral cerebral palsy|
62710441|NCT05013814||Typically developed children|
62147775|NCT01852045|EXPERIMENTAL|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
62354677|NCT06121362|EXPERIMENTAL|Protocatechuic Acid or PCA|Participants will be asked to take 2 capsules (500 mg each of protocatechuic acid or PCA) daily by mouth in the morning 30 minutes before eating for a total of 14 days (Day 1 - Day 14).
62516015|NCT05820386|ACTIVE_COMPARATOR|Transfer in incubator between the delivery room and the neonatal care unit|Preterm infants will be transferred in an incubator set to 36°C from the delivery room to the intensive neonatal care.
62354678|NCT02741089||Indication for a flexible bronchoscopy|Patients representing to the hospital with the indication for a flexible bronchoscopy
62516016|NCT04822376|EXPERIMENTAL|High risk arm|Mabs at day 0 and vaccine at week 6
62516017|NCT04822376|EXPERIMENTAL|High risk arm (Immunological ancillary study)|Mabs at day 0 and vaccine at week 6
62516018|NCT04822376|ACTIVE_COMPARATOR|Control arm (Immunological ancillary study)|Vaccine at day 0 for contacts eligible for vaccination
62516019|NCT04265950|EXPERIMENTAL|Arm 1 (3 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment, and at 2 and 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
62516020|NCT04265950|EXPERIMENTAL|Arm 2 (2 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment and at 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
62516021|NCT04265950|EXPERIMENTAL|Arm 3 (1 dose of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
62710442|NCT05093972|EXPERIMENTAL|Panel A: Mild HI|Participants with mild HI receive a single oral dose of ulonivirine 400 mg on Day 1.
62710443|NCT05093972|EXPERIMENTAL|Panel B: Moderate HI|Participants with moderate HI receive a single oral dose of ulonivirine 400 mg on Day 1.
62710444|NCT05093972|ACTIVE_COMPARATOR|Panel C: Healthy Controls|Healthy matched control participants receive a single oral dose of ulonivirine 400 mg on Day 1.
62710445|NCT01196715|ACTIVE_COMPARATOR|Darbepoetin Alfa|
62710446|NCT01196715|ACTIVE_COMPARATOR|G-CSF|
62710447|NCT01196715|ACTIVE_COMPARATOR|Best Supportive Care|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl
62715100|NCT00216281|ACTIVE_COMPARATOR|clozapine with AZT added|Clozapine augmented with Atomoxitine up to 40mg
62715101|NCT00216281|PLACEBO_COMPARATOR|placebo|Subjects will have a placebo pill added to their clozapine regimen.
62715102|NCT06157034|NO_INTERVENTION|Exploratory|"* After sampling the study population of 200 will be divided into four (04) treatment groups i.e. T1 (Placebo), T2 (Zingiber officinale), T3 (Carum carvi, L), and T4 (Mentha spicata L).~* Each group will be allotted 50 subjects"
62516022|NCT04265950|ACTIVE_COMPARATOR|Arm 4 (1 dose of 9vHPV vaccine)|Participants without HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment . Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
62516023|NCT06324058|EXPERIMENTAL|Cryoablation group|Transurethral resection of bladder tumor, instant cryoablation of the bladder tumor resection site.
62516024|NCT06324058|ACTIVE_COMPARATOR|Control group|Transurethral resection of bladder tumor, conventional BCG instillation after surgery
62516025|NCT05295654|EXPERIMENTAL|Kinect validation|Kinect measurements will be compared with the vicon measurements to validate the kinect system.
62516026|NCT05391711|EXPERIMENTAL|Culturally Smart Relationships|The mentors assigned to this group will receive additional trainings and support related to Justice, Equity, Diversity and Inclusion (JEDI).
62516027|NCT05391711|NO_INTERVENTION|Control Group|The mentors assigned to this group will NOT receive an intervention. They will receive the regular training activities that the agency provides.
62516028|NCT03421041|EXPERIMENTAL|Dexamethasone group|
62516029|NCT03421041|NO_INTERVENTION|control group|
62516030|NCT02743728||All Infants|Each infant will receive an Magnetic Resonance Imaging, then Transcranial Magnetic Stimulation Cortical Excitability testing, and General Movement Assessment. These 3 different components of the one arm in which all infants are involved will be collectively assessed.
62516031|NCT01145924|ACTIVE_COMPARATOR|EBUS TBNF|single arm trial, patients with enlarged mediastinal nodes will be examine
62516032|NCT02276898|ACTIVE_COMPARATOR|Hypertonic Saline|The treatment intervention is 1 inhalation of 7% hypertonic saline (4ml)
62516033|NCT02276898|PLACEBO_COMPARATOR|Isotonic Saline|The placebo intervention is 1 inhalation of 0.9% isotonic saline
62516034|NCT03988517|ACTIVE_COMPARATOR|levothyroxine at Iftar|Patients took levothyroxine 30 minutes before breaking the fast at sunset (iftar)
62516035|NCT03988517|ACTIVE_COMPARATOR|Levothyroxine at Suhour|Patients took levothyroxine 30 minutes before an early morning meal before sunrise (suhour)
62516036|NCT03686150|EXPERIMENTAL|Part 1, Cohort 1 Vitamin D3 oral regimen|Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
61973743|NCT03457129|ACTIVE_COMPARATOR|Fycompa 2 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
61973744|NCT03457129|EXPERIMENTAL|Fycompa 3 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for three weeks, then up-titrated by 2 mg every three weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
61973745|NCT05025761|EXPERIMENTAL|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN),insect repellent (DEET), Insecticide-treated clothes (ITC), and mobile and migrant population-tailored behavioural change communication (BCC) package
61973746|NCT05025761|NO_INTERVENTION|Control|No personal protection package
61973747|NCT02113605|EXPERIMENTAL|Cognitive behavior therapy|All included children are treated with a face-to-face exposure-based cognitive behaviour therapy for 10 weeks. There will be no comparison arm.
61973748|NCT00003623|EXPERIMENTAL|Multivitamin|Patients receive multivitamins orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
61973749|NCT00003623|PLACEBO_COMPARATOR|Placebo|Patients receive placebo orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
62354679|NCT02181985|ACTIVE_COMPARATOR|TNK-tPA + heparin|
62354680|NCT02181985|EXPERIMENTAL|TNK-tPA + enoxaparin|
62516037|NCT03686150|EXPERIMENTAL|Part 1, Cohort 2 Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
62516038|NCT03686150|EXPERIMENTAL|Part 1, Cohort 3 Vitamin D3 oral regimen|Vitamin D: 6000 IU daily dose
62516039|NCT03686150|ACTIVE_COMPARATOR|Part 1, Cohort 4 Vitamin D3 oral regimen|Vitamin D: 600 IU daily dose
62516040|NCT03686150|EXPERIMENTAL|Part 2, Cohort A Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
62516041|NCT03686150|ACTIVE_COMPARATOR|Part 2, Cohort B Vitamin D oral regimen|Vitamin D: 600 IU daily dose
62516042|NCT03116321|EXPERIMENTAL|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
62516043|NCT03116321|EXPERIMENTAL|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
62354681|NCT02181985|EXPERIMENTAL|TNK-tPA + abciximab + heparin|
62516044|NCT03116321|ACTIVE_COMPARATOR|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
62516045|NCT06274866|EXPERIMENTAL|Study Group|After total hip arthroplasty, participants who take supervised home based exercised program which consists especially early weight bearing hip specific mobilization and strengthening exercises.
62516046|NCT06274866|OTHER|Control group|After total hip arthroplasty, participants who take an educational booklet (about exercise program) at hospital stay
62516047|NCT05990504|EXPERIMENTAL|Dural Puncture Epidural Group|Dural Puncture Epidural is a new type of labor analgesia technology.
62516048|NCT05990504|ACTIVE_COMPARATOR|Epidural Group|Epidural is a traditional labor analgesia technique.
62147776|NCT02231970|EXPERIMENTAL|Endoscopic sleeve gastroplasty|The intervention is an endoscopic procedure: to perform endoscopic sleeve gastroplasty we used a cap-based flexible endoscopic suturing system (OverStitch™, Apollo, Inc. Austin, Texas) mounted on a double-channel endoscope (GIF-2T160; Olympus Medical Systems Corporation, Tokyo, Japan) to achieve full-thickness, running sutures through the gastric wall from antrum to fundus.
62354682|NCT00759746|ACTIVE_COMPARATOR|Weight Maintenance Education|Participants assigned to this group will receive the Weight Maintenance Education intervention. They will meet every other week during the maintenance phase of the study for a total of 16 sessions over 8 months. During the visit, participants will participate in a series of interactive workshops within child and parent groups to learn general information about healthy eating and physical activity.
62354683|NCT00759746|EXPERIMENTAL|SFM+ Low Dose|Participants assigned to this group will receive the SFM+ Low Dose.
62354684|NCT00759746|EXPERIMENTAL|SFM+ High Dose|Participants assigned to this group will receive the SFM+ High Dose.
62354685|NCT00884689||1|Asthma patient with specific treatment
62354686|NCT00884689||2|Asthma patient on different specific treatment compared to the other group
62354687|NCT02828007|EXPERIMENTAL|Treatment/Intervention|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
62354688|NCT05220137|ACTIVE_COMPARATOR|1|Core Session 1, Core Session 2, Module Choice, Final Session
62354689|NCT05220137|ACTIVE_COMPARATOR|2|Core Session 1, Core Session 2, Modified A-B-C, Final Session
62354690|NCT05220137|ACTIVE_COMPARATOR|3|Core Session 1, Core Session 2, Challenging Questions, Final Session
62354691|NCT05220137|ACTIVE_COMPARATOR|4|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Module Choice, Final Session
62354692|NCT05220137|ACTIVE_COMPARATOR|5|Core Session 1, Core Session 2, Problematic Patterns, Final Session
62354693|NCT05220137|ACTIVE_COMPARATOR|6|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Module Choice, Final Session
62354694|NCT05220137|ACTIVE_COMPARATOR|7|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Module Choice, Final Session
62354695|NCT05220137|ACTIVE_COMPARATOR|8|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Final Session
62354696|NCT05220137|ACTIVE_COMPARATOR|9|Core Session 1, Core Session 2, Challenging Beliefs, Final Session
62354697|NCT05220137|ACTIVE_COMPARATOR|10|Core Session 1, Core Session 2, Modified A-B-C , Challenging Beliefs, Module Choice, Final Session
62354698|NCT05220137|ACTIVE_COMPARATOR|11|Core Session 1, Core Session 2, Challenging Questions, Challenging Beliefs, Module Choice, Final Session
62354699|NCT05220137|ACTIVE_COMPARATOR|12|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Challenging Beliefs, Final Session
62354700|NCT05220137|ACTIVE_COMPARATOR|13|Core Session 1, Core Session 2, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
62354701|NCT05220137|ACTIVE_COMPARATOR|14|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Challenging Beliefs, Final Session
62354702|NCT05220137|ACTIVE_COMPARATOR|15|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Challenging Beliefs, Final Session
62354703|NCT05220137|ACTIVE_COMPARATOR|16|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
62354704|NCT04193670|EXPERIMENTAL|Atopic dermatitis classical form|15 patients
62354705|NCT04193670|EXPERIMENTAL|Atopic dermatitis with atopic prurigo type|10 patients
62354706|NCT04656392|OTHER|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
62354707|NCT02226978|EXPERIMENTAL|TPV/r with valaciclovir|VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)
62354708|NCT04372043||Lebanese population|"The Sleep Hygiene Index with other demographic questions will be applied to the Lebanese population."
62354709|NCT02492087|ACTIVE_COMPARATOR|Tranexamic acid (TXA) Group|Subjects in the TXA group will receive the topical tranexamic acid solution which will be administered intra-operatively, during the caesarean section on the surgical wound and into the intrauterine cavity after the delivery of the baby and the placenta. 60mls of the solution will be applied topically to the placental bed as identified by the surgeon carrying out the surgery by spraying the study solution using a syringe into the uterine cavity. Another 30mls of the solution will be applied to the open incision wound. The surgeon will then proceed to close the first layer of the uterus in the usual manner. The remaining 30mls of the study drug solution is then applied topically on the closed incision wound
62354710|NCT02492087|SHAM_COMPARATOR|Control Group|Subjects in the Control group will receive topical normal saline solution which will be administered intra-operatively in the same manner as described for the TXA group.
62354711|NCT01436695||Epicall group|patients will be connected to Epicall sensor
62354712|NCT04298190|EXPERIMENTAL|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
62354713|NCT04298190|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
62354714|NCT03518632|ACTIVE_COMPARATOR|Control group|
62354715|NCT03518632|EXPERIMENTAL|Interval training 1|
62354716|NCT03518632|EXPERIMENTAL|Interval training 2|
62354717|NCT02174016|EXPERIMENTAL|Ketogenic diet|All subjects will be started on ketogenic diet formula feeding after enrollment for 2 weeks.
62354718|NCT02017886|ACTIVE_COMPARATOR|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
62354719|NCT02017886|PLACEBO_COMPARATOR|Placebo|Placebo tablet twice daily for three weeks
62354720|NCT03724617|EXPERIMENTAL|stem cell therapy|
62516049|NCT01560507|ACTIVE_COMPARATOR|varenicline (Chantix)|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
62516050|NCT01560507|ACTIVE_COMPARATOR|nicotine patches|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
62516051|NCT01560507|ACTIVE_COMPARATOR|bupropion (Zyban) and nicotine patches|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.
62516052|NCT00396331|EXPERIMENTAL|G-CSF plus Plerixafor|
62516053|NCT04224727|NO_INTERVENTION|Control|Subjects are not offered a group commitment contract, individual commitment contract, or individual monetary rewards. Subjects do not receive additional information treatments.
62516054|NCT04224727|EXPERIMENTAL|Group Commitment Contract + Information|Subjects are offered a group commitment contract for smoking cessation or weight loss and receive additional information treatments.
62516055|NCT04224727|EXPERIMENTAL|Individual Monetary Rewards + Information|Subjects are offered individual monetary rewards for smoking cessation or weight loss and receive additional information treatments.
62516056|NCT04224727|EXPERIMENTAL|Individual Commitment Contract + Information|Subjects are offered an individual commitment contract for smoking cessation or weight loss and receive additional information treatments.
62516057|NCT04224727|EXPERIMENTAL|Group Commitment Contract|Subjects are offered a group commitment contract for smoking cessation or weight loss and receive no additional information treatments.
62516058|NCT04224727|EXPERIMENTAL|Individual Monetary Rewards|Subjects are offered individual monetary rewards for smoking cessation or weight loss and receive no additional information treatments.
62516059|NCT04224727|EXPERIMENTAL|Individual Commitment Contract|Subjects are offered an individual commitment contract for smoking cessation or weight loss and receive no additional information treatments.
62516060|NCT03914118|ACTIVE_COMPARATOR|Preoperative modafinil + postoperative placebo|
62516061|NCT03914118|ACTIVE_COMPARATOR|Preoperative modafinil + postoperative modafinil|
62147777|NCT02496559|ACTIVE_COMPARATOR|Pre-consultation CRP|Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
62147778|NCT02496559|NO_INTERVENTION|CRP requested|No intervention, the consultation with children as normal, the CRP is used at doctors request.
62354721|NCT05736978|EXPERIMENTAL|Treatment regimen based on C1D14 MRD|Untreated acute myeloid leukemia who are ineligible for intensive chemotherapy will be given azacitidine 75mg/m2, d1-7 and venetoclax 100mg on day 1 and 200mg on day 2, 400mg on day 3-28. Based on MRD results on C1D14, MRD negative patients will go on azacitidine and venetoclax regimen and for patients with MRD positive, selinexor 60mg on D15 and D22 will be added. Patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive treatment until disease progression or unacceptable toxic effects.
62354722|NCT03552627|ACTIVE_COMPARATOR|80% Oxygen|Patients will receive 80% oxygen throughout anaesthesia in accordance with current World Health Organisation Recommendations
62354723|NCT03552627|ACTIVE_COMPARATOR|55% Oxygen|Patients will receive 55% oxygen throughout anaesthesia in accordance with current UK clinical practice
62354724|NCT03552627|EXPERIMENTAL|30% Oxygen|Patients will receive 30% oxygen throughout anaesthesia in accordance with this research's hypothesis that lowering intraoperative oxygen concentrations may benefit patients
62354725|NCT05414149|ACTIVE_COMPARATOR|IVR group|Patients that received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery were assigned to IVR group 3-5 days before three-port transconjunctival 25-G pars plana vitrectomy (PPV). All patients underwent 25-gauge transconjunctival sutureless vitrectomy using the 25-gauge Constellation system (Alcon, Fort Worth, TX, USA) system under local or anesthesia. A speed of 5000 cuts per minute was used for vitrectomy.
62354726|NCT05414149|EXPERIMENTAL|IVC group|Patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery were assigned to IVC group 3-5 days before three-port transconjunctival 25-G pars plana vitrectomy (PPV). All patients underwent 25-gauge transconjunctival sutureless vitrectomy using the 25-gauge Constellation system (Alcon, Fort Worth, TX, USA) system under local or anesthesia. A speed of 5000 cuts per minute was used for vitrectomy.
62354727|NCT03525626|EXPERIMENTAL|Online Mindfulness-based Tic Reduction|
62354728|NCT01612117||consecutive, PCP patients|All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
62354729|NCT05561894|PLACEBO_COMPARATOR|A (control)|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation index guided fluid therapy): PPVI will be measured using invasive blood pressure monitor. Ringer acetate solution will be administrated whenever PPV is higher than 12%.
62354730|NCT05561894|ACTIVE_COMPARATOR|B|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation index guided fluid therapy): PPVI will be measured using invasive blood pressure monitor. Ringer acetate solution will be administrated whenever PPV is higher than 16%.
62354731|NCT01012349|EXPERIMENTAL|Test|Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)
62354732|NCT01012349|ACTIVE_COMPARATOR|Comparator|Acetylsalicylic acid - (Aspirin - Bayer)
62354733|NCT03713606||Overall eligible participants|Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.
62354734|NCT01754597|EXPERIMENTAL|Peptide Natriurétique de type B|Peptide Natriurétique de type B
62516062|NCT03914118|PLACEBO_COMPARATOR|Preoperative placebo + postoperative placebo|
62516063|NCT03914118|NO_INTERVENTION|Control group|
62147779|NCT00853593|EXPERIMENTAL|Model 4396 LV Lead|Non-randomized study.
62147780|NCT00539812|OTHER|1|Standard Care only (standard batterer intervention program)
62147781|NCT00539812|OTHER|2|Brief alcohol intervention combined with standard care
62147782|NCT02161354|EXPERIMENTAL|2mg dose of NTC-510 or placebo|Subjects will be dosed with 2 mg of NTC-510 or placebo.
62147783|NCT02161354|EXPERIMENTAL|4 mg dose of NTC-510 or placebo|Subjects will be dosed as a split dose of 2 mg followed by 2 mg an hour later of NTC-510 or placebo.
62516064|NCT05759117||Pleural effusion|All patients with pleural effusion who will undergo thoracentesis
62516065|NCT05814991||Patients undergoing bimaxillary osteotomy under general anesthesia|
62516066|NCT00669981|EXPERIMENTAL|1|Participants will receive immediate cognitive behavioral couples therapy for PTSD.
62516067|NCT00669981|ACTIVE_COMPARATOR|2|Participants will receive delayed cognitive behavioral couples therapy for PTSD after a 3-month waitlist period.
62516068|NCT04913207|SHAM_COMPARATOR|Traditional echo-fluoroscopy guided group|LAA angiography is performed with a 6F pigtail catheter in LAA at the view of RAO 30°, CAU 20° and RAO 30°, CRA 20°. Next, the outline of the LAA will be drawn on the screen according to the LAA angiography. LAmbre device size selection is based on diameters of LAA ostium and landing zone measured on LAA angiography. The process of device implantation, assessment, releasing will be carried out at RAO 30°, CAU 20°. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
62516069|NCT04913207|EXPERIMENTAL|3D-CTA guided group|Patients in 3D-CTA based perimeter group will undergo CCTA examination before LAAO and a 3D model of the left atrium is reconstructed by a workstation. LAmbre device size selection is based on perimeters of LAA ostium and landing zone which are obtained by the measurement method shown previously in this protocol. After transseptal puncture, LAA angiography is performed with a 6F pigtail catheter in LAA at the tangent angle view which is obtained preoperatively by 3D-CCTA. Then, the outline of the LAA will be drawn on the screen according to the LAA angiography. The process of device implantation, assessment, releasing will be carried out at this tangent angle view. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
62516070|NCT01481870|ACTIVE_COMPARATOR|Sorafenib-sunitinib|Sorafenib is first line treatment followed by sunitinib.
62354735|NCT01429610|EXPERIMENTAL|Rituximab+mVPDL|Patients who were CD20(+), newly-diagnosed adult ALL and treated with rituximab + mVPDL treatment plan
62516071|NCT01481870|ACTIVE_COMPARATOR|Sunitinib-sorafenib|Sunitinib is first line treatment followed by sorafenib.
61973750|NCT00939081|ACTIVE_COMPARATOR|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
62147784|NCT02161354|EXPERIMENTAL|6 mg dose of NTC-510 or placebo|Subjects will be dosed with 6 mg of NTC-510 or placebo.
62354736|NCT06415162|EXPERIMENTAL|Cooling Pillowcases|The intervention group will be given 'Patient Information Form, Menopause Specific Hot Flash Scale, Pittsburgh Sleep Quality Index and FACT-B Quality of Life Scale' to be filled in the 1st week, training on treatment side effects, training booklet and 'Hot Flash Diary' to record the hot flashes they experience. A cooling pillowcase will be given and its use will be explained. In the 5th week, 'Practices for Coping with the Side Effects of Hormone Therapy Form' will be filled out to evaluate the training given and the training will be repeated. A total of 3 follow-ups will be carried out by using the 'Patient Follow-up Form' by telephone in the 3rd and 7th weeks and face-to-face interview in the 5th week. In the 9th week, 'Menopause Specific Hot Flush Scale, Pittsburgh Sleep Quality Index and FACT-B Quality of Life Scale' and 'Practices for Coping with Side Effects of Hormone Therapy Form' will be completed to evaluate the effectiveness of the retraining given in the 5th week.
62354737|NCT06415162|NO_INTERVENTION|Control Group|No intervention will be given to the patients in the control group.
62354738|NCT03492645|ACTIVE_COMPARATOR|Office Group|
62516072|NCT04146831|EXPERIMENTAL|Sintilimab|Sintilimab is administered in this arm.
62516073|NCT03754751|EXPERIMENTAL|Modified ERAS program group|Laparoscopic cholecystectomy with the implementation of modified ERAS program
62516074|NCT03754751|ACTIVE_COMPARATOR|Conventional care group|Laparoscopic cholecystectomy with standard perioperative treatment
62516075|NCT03678779|EXPERIMENTAL|Incentive|Each week parents received one $5 grocery store gift card per child in the household, intended for the purchase of healthy snacks, donated to the study by a partnering grocery store
62516076|NCT03678779|EXPERIMENTAL|Education|Parents received brief weekly nutrition education videos (approximately one minute in length, uploaded on YouTube and viewable on most operating systems and on mobile devices
62516077|NCT03678779|EXPERIMENTAL|Combined|Parents received both the Incentive and Education arm interventions
61973751|NCT00939081|EXPERIMENTAL|Adaptive recommendation|The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
62147785|NCT02161354|EXPERIMENTAL|2 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 2mg of NTC-510A or placebo
62147786|NCT02161354|EXPERIMENTAL|4 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 4 mg of NTC-510A or placebo
62354739|NCT03492645|EXPERIMENTAL|Telephone Group|
62354740|NCT00829127|EXPERIMENTAL|1|
62354741|NCT00829127|PLACEBO_COMPARATOR|2|
62354742|NCT00633308|EXPERIMENTAL|A|Long hemodialysis
62354743|NCT04874688|ACTIVE_COMPARATOR|IYCF-Only|Infants in the IYCF-only arm will receive white maize and SQ-LNS daily from 6 months of age, and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
62354744|NCT04874688|EXPERIMENTAL|IYCF-Plus|Infants in the IYCF-plus arm will receive orange provitamin A-fortified maize and SQ-LNS daily from 6 months of age, plus powdered NUA-45 sugar beans, moringa leaf powder, and powdered whole egg; and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
62354745|NCT02037451|EXPERIMENTAL|intervention group|intervention group which receive auditory cueing while performing movement
62354746|NCT02037451|NO_INTERVENTION|Control group|control group which performing movement after listen to required movement rhythm.
62354747|NCT01548794|ACTIVE_COMPARATOR|Bupivacaine(Group B)|spinal anesthesia
62516078|NCT04364737|ACTIVE_COMPARATOR|Convalescent donor plasma|
62516079|NCT04364737|PLACEBO_COMPARATOR|Lactated ringer's solution or sterile saline solution|
62147787|NCT02161354|EXPERIMENTAL|6 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 6 mg of NTC-510A or placebo
62147788|NCT06253299||Group L|Just before the vascular access is opened, a 4x5 cm sized marble stone will be applied to the carotid in the left lateral neck region (2-3 cm above the clavicle, on the sternocleidomastoid muscle (SKM)) for 30 seconds, and then the vascular access will be opened
62516080|NCT01964443||all included patients|Men and women, 18 years of age and older, who have had the onset of the first symptoms of plaque psoriasis less than 10 years before study entry, are naïve or experienced to topical treatment, and are eligible for phototherapy or systemic treatment
62147789|NCT06253299||Group R|Just before the vascular access is opened, a 4x5 cm cold marble stone will be held on the carotid in the right lateral neck area (2-3 cm above the clavicle, on the sternocleidomastoid muscle (SKM)) for 30 seconds (sec), and then the vascular access will be opened.
62516081|NCT03720574|EXPERIMENTAL|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
62516082|NCT03720574|PLACEBO_COMPARATOR|Matching Placebo BID|Matching Placebo tablet each morning and evening
62516083|NCT05479422||Treatment of stricture of the anterior urethra with optilume DCB|Standard of care treatment of stricture of the anterior urethra using the Optilume Drug Coated Balloon.
62516084|NCT05382520|EXPERIMENTAL|Explicit sensory retraining for lower extremity in individuals with CIPN|Explicit sensory retraining for lower extremity function (pain, sensory, balance, gait). five one-hour sessions, a week apart: Pre-Post assessment sessions with 3 treatment sessions in between. Home exercise assigned.
62516085|NCT01014962|EXPERIMENTAL|Albaconazole 400 mg cohort 1|Albaconazole 400 mg
62516086|NCT01014962|PLACEBO_COMPARATOR|Placebo cohort 1|Placebo once daily
62147790|NCT00645411|EXPERIMENTAL|Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV|All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 \[H1N1\]-like, A/Wisconsin/67/2005 \[H3N2\]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
62516087|NCT01014962|EXPERIMENTAL|Albaconozole 400 mg cohort 2|Albaconozole 400 mg every 12 hours
62516088|NCT01014962|PLACEBO_COMPARATOR|Placebo cohort 2|Placebo every 12 hours
61973752|NCT02282020|EXPERIMENTAL|1/OLAPARIB|olaparib 300mg oral tablets; twice daily
61973753|NCT02282020|ACTIVE_COMPARATOR|2/CHEMOTHERAPY|Physician's choice single agent chemotherapy
62147791|NCT00645411|ACTIVE_COMPARATOR|Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV|All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 \[H1N1\]-like, A/Wisconsin/67/2005 \[H3N2\]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.
62516089|NCT01014962|EXPERIMENTAL|Albaconozole 400 mg cohort 3|Albaconozole 400 mg every 8 hours
62516090|NCT01014962|PLACEBO_COMPARATOR|Placebo cohort 3|Placebo every 8 hours
62516091|NCT03977259|NO_INTERVENTION|Standard fortification|Standard of care fortification with multicomponent human milk fortifier (24 kcal/oz) and liquid protein (0.27 g/dL); additional protein and/or calories added only for growth faltering.
61973754|NCT03578601||Thyroid surgery|Patient undergoing thyroid surgery
61973755|NCT02734238|PLACEBO_COMPARATOR|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
61973756|NCT02734238|EXPERIMENTAL|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
62147792|NCT00645411|EXPERIMENTAL|Cohort 3 (3-8 Yrs) cTIV|All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 \[H1N1\]-like, A/Wisconsin/67/2005 \[H3N2\]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
62516092|NCT03977259|EXPERIMENTAL|Individually targeted fortification|"Standard of care fortification plus extra protein and/or calories to ensure that base milk has protein 1 g/dL and calories 67/dL."
62516093|NCT00805155||Cohort Group 1|Subjects number 1 to 20
62516094|NCT00805155||Cohort Group 2|Subjects number 21 to 50
62516095|NCT00805155||Cohort Group 3|Subject Numbers 51 to 80
62516096|NCT00307931|EXPERIMENTAL|Certolizumab pegol|certolizumab pegol 400 mg
62516097|NCT04745208|NO_INTERVENTION|standard discharge education|The control group will receive only the standard discharge education.
62516098|NCT04745208|EXPERIMENTAL|standard discharge education+Simulation based education|The intervention group will receive standard discharge education and then simulation based education will be performed
62516099|NCT00177463|EXPERIMENTAL|L- Carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
62516100|NCT00177463|PLACEBO_COMPARATOR|Placebo|Placebo
62516101|NCT00865098|EXPERIMENTAL|Cetuximab With Radiotherapy|
62516102|NCT04785157||severe COVID-19 patients with delirium|i) SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF) ii) systemic and central immune response characterization, associated to the assessment of CNS damage biomarkers (peripheral blood and CSF) iii) in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia) iv) structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity) v) multi-domains neurocognitive assessment.
62516103|NCT01264549|EXPERIMENTAL|PCT guided arm|
61973757|NCT05891262|EXPERIMENTAL|BMS-986196 and Loestrin|
61973758|NCT05908370|EXPERIMENTAL|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|
62516104|NCT01264549|NO_INTERVENTION|Control|Standard treatment
62516105|NCT05862272|EXPERIMENTAL|Relugolix Combination Tablet|Participants will receive relugolix combination therapy orally once daily for 48 months.
61973759|NCT05908370|NO_INTERVENTION|Maxillary orthognathic surgery using 2 patient specific osteosynthesis (2-Plates)|
61973760|NCT06385223|ACTIVE_COMPARATOR|Beam F3 targeting of accelerated iTBS|"Patients will receive anatomically-guided (Beam F3) accelerated iTBS.~Participants will receive an accelerated iTBS treatment delivered with a MagVenture MagPro X100 system (MagVenture A/S, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A/P coil. The treatment course is comprised of 10 treatment sessions daily for 5 consecutive workdays for a total of 50 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines."
61973761|NCT06385223|EXPERIMENTAL|Individualized connectome-guided accelerated iTBS|"Patients will receive individualized connectome-guided accelerated iTBS.~Participants will receive an accelerated iTBS treatment delivered with a MagVenture MagPro X100 system (MagVenture A/S, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A/P coil. The treatment course is comprised of 10 treatment sessions daily for 5 consecutive workdays for a total of 50 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines."
61973762|NCT06434844|EXPERIMENTAL|1st visit Auricular acupuncture; 2nd visit Placebo sham acupuncture|The subjects will receive auricular acupuncture in the 1st visit and placebo sham acupuncture in the 2nd visit.
61973763|NCT06434844|SHAM_COMPARATOR|1st visit Placebo sham acupuncture; 2nd visit Auricular acupuncture|The subjects will receive placebo sham acupuncture in the 1st visit and auricular acupuncture in the 2nd visit.
61973764|NCT01190878|EXPERIMENTAL|ISV-303 BID|
61973765|NCT01190878|EXPERIMENTAL|ISV-303 QD|
61973766|NCT01190878|ACTIVE_COMPARATOR|Xibrom BID|
61973767|NCT01190878|PLACEBO_COMPARATOR|DuraSite Vehicle BID|
61973768|NCT03618992|ACTIVE_COMPARATOR|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
61973769|NCT03618992|NO_INTERVENTION|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
62516106|NCT04704141||Infertile men with leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
61973770|NCT03618992|NO_INTERVENTION|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
61973771|NCT03413566||Children with clinical diagnosis of CP|All children residing in Norway with a validated diagnosis of cerebral palsy.
62147793|NCT00645411|ACTIVE_COMPARATOR|Cohort 3 (3-8 Yrs) eTIV|All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 \[H1N1\]-like, A/Wisconsin/67/2005 \[H3N2\]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
62354748|NCT01548794|EXPERIMENTAL|Bupivacaine+Lidocaine (Group BL)|spinal anesthesia
62516107|NCT04704141||Infertile men without leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
62516108|NCT04704141||Infertile men with hypogonadism|Standard fertility evaluation and treatments, including hormone replacement therapy such as with clomiphene citrate
62516109|NCT00296491|ACTIVE_COMPARATOR|Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)|Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD
62516110|NCT00296491|ACTIVE_COMPARATOR|Fluticasone Propionate/Salmeterol (FSC)|FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD
62516111|NCT00296491|ACTIVE_COMPARATOR|Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)|Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD
62516112|NCT00296491|ACTIVE_COMPARATOR|Montelukast (MON)|Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD
62516113|NCT06326502|EXPERIMENTAL|ETN101|ETN101
62516114|NCT03365544|EXPERIMENTAL|6am-2pm eating window|4 weeks of time restricted eating between 6am-2pm.
62516115|NCT03365544|EXPERIMENTAL|2pm-10pm eating window|4 weeks of time restricted eating between 2pm-10pm.
62516116|NCT02678442|ACTIVE_COMPARATOR|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
62516117|NCT02678442|ACTIVE_COMPARATOR|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
62516118|NCT00053235||Ancillary-Correlative|Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
62516119|NCT04265690|EXPERIMENTAL|Teen and Tot Centering subjects|The cooking classes and text messages will supplement the subject's standard of care by incorporating text messages and a cooking class.
62516120|NCT02695940|ACTIVE_COMPARATOR|LEO 124249 ointment 30 mg/g|Drug LEO 124249 ointment 30 mg/g twice daily application for 6 weeks, maximum of 1.44 g ointment per day
62516121|NCT02695940|PLACEBO_COMPARATOR|LEO 124249 ointment vehicle|LEO 124249 ointment vehicle twice daily application for 6 weeks, maximum of 1.44 g ointment per day
62516122|NCT02716350|EXPERIMENTAL|B-GOS|powder, 3.5g/day
62516123|NCT02716350|PLACEBO_COMPARATOR|Maltodextrin|powder, 3.5g/day
62516124|NCT02655055|EXPERIMENTAL|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
62516125|NCT02655055|NO_INTERVENTION|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
62516126|NCT05380323|EXPERIMENTAL|LY3541105 (Part A)|Single ascending doses of LY3541105 administered subcutaneously (SC).
62516127|NCT05380323|EXPERIMENTAL|LY3541105 (Part B)|Multiple ascending doses of LY3541105 administered SC.
62516128|NCT05380323|EXPERIMENTAL|LY3541105 (Part C)|Escalating doses of LY3541105 administered SC.
61973772|NCT03413566||Children without CP|All children residing in Norway without a diagnosis of cerebral palsy.
61973773|NCT04069611|EXPERIMENTAL|Test Group|Subjects in the test group will receive scaling and root planing, plus the take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
62516129|NCT05380323|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC.
62516130|NCT05380323|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC.
62516131|NCT05380323|PLACEBO_COMPARATOR|Placebo (Part C)|Placebo administered SC.
62516132|NCT01443910||behavior, supportive|receiving information about behavior with supportive provider communication
62516133|NCT01443910||behaviors, directive|receiving information about behavior with directive provider communication
61973774|NCT04069611|PLACEBO_COMPARATOR|Control Group|Subjects assigned to the placebo group will receive scaling and root planing, and will take lozenges exactly like the test ones but without bacteria.
62516134|NCT01443910||genetics, directive|receiving information about genetics with directive provider communication
61973775|NCT01308346|EXPERIMENTAL|Bioresorbable Vascular Scaffold (BVS)|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
61973776|NCT01308346|ACTIVE_COMPARATOR|XIENCE V® or XIENCE PRIME®|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) or XIENCE PRIME®
61973777|NCT03244345|EXPERIMENTAL|Epileptic patient|
62516135|NCT01443910||genetics, supportive|receiving information about genetics with supportive provider communication
61973778|NCT03687853|EXPERIMENTAL|Intrahepatic Arterial Infusion chemotherapy|chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.
61973779|NCT03687853|NO_INTERVENTION|control|chemotherapy through Peripheral venous is one of the regularly used method.
61973780|NCT02742324|EXPERIMENTAL|Ruxolotinib and peg-IFN alpha -2a|"Phase I~LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly~Phase II~Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I"
61973781|NCT05554705|EXPERIMENTAL|experimental|standard of care + lifestyle intervention
61973782|NCT05554705|NO_INTERVENTION|control|no intervention (control group)
62516136|NCT02695719|EXPERIMENTAL|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
62516137|NCT02695719|PLACEBO_COMPARATOR|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
62516138|NCT04834739|ACTIVE_COMPARATOR|Study group (30 volunteer healthcare workers who had Covid-19|30 volunteer healthcare workers who had Covid-19 and stayed in hospital or at home were included.
62516139|NCT04834739|ACTIVE_COMPARATOR|Control group (30 volunteer healthcare workers who had not have Covid-19)|In control group, 30 volunteer healthcare workers who were matched for age ande gender with study group were included and these persons had not have Covid-19.
62516140|NCT01983514|ACTIVE_COMPARATOR|1 international unit (IU) intravenous oxytocin|Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
62516141|NCT01983514|PLACEBO_COMPARATOR|Placebo|Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)
62516142|NCT01983514|EXPERIMENTAL|8IU intranasal oxytocin|Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
62516143|NCT01983514|EXPERIMENTAL|24IU intranasal oxytocin|Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
62516144|NCT02159937||Patients with metastatic cancer|Blood sampling by vena punction.
61973783|NCT04686981||mesenteric artery thromboembolism patients|If all the radiography, physical signs, and laboratory markers hint at intestinal necrosis, exploratory laparotomy followed by enterectomy and thrombectomy is the first choice. If none of them hint at intestinal necrosis, endovascular therapy is superior. Laparoscopic exploration followed by endovascular therapy was performed for other patients, after that the intestinal blood supply was evaluated again by laparoscopy.
62516145|NCT01819324|EXPERIMENTAL|Targeting the Teachable Moment|Receiving Targeting the Teachable Moment Intervention materials (focusing on health behaviors and issues specific to breast cancer survivors) every other week for 4 months
62516146|NCT01819324|ACTIVE_COMPARATOR|Standardized Lifestyle Management|Receiving Standardized Lifestyle Management materials (focusing mostly on health behaviors) every other week for 4 months
61973784|NCT06207994|NO_INTERVENTION|Standard Target Range|The SpO2 TR width is set to 5% SpO2, as is routine in the department. The actual TR will vary depending on the GA, as is standard practice in the department.
61973785|NCT06207994|EXPERIMENTAL|Narrow Target Range|The SpO2 TR width is set narrower than the Standard TR. The actual TR will vary depending on the GA, as is standard practice in the department.
61973786|NCT06207994|EXPERIMENTAL|Shifted Target Range|The SpO2 TR width is set as the Standard TR. The median of the TR is shifted up compared to the Standard TR. The actual TR will vary depending on the GA, as is standard practice in the department.
62354749|NCT01548794|ACTIVE_COMPARATOR|Local Infitration Anesthesia(Group LI)|local infiltration anesthesia
62354750|NCT03831815||Grupo C: cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
62354751|NCT03831815||Grupo R: rocuronium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
62354752|NCT02758613|EXPERIMENTAL|2 milligram (mg) Baricitinib|2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
62354753|NCT02758613|EXPERIMENTAL|4mg Baricitinib|4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
62354754|NCT02758613|EXPERIMENTAL|10mg Baricitinib|10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
62354755|NCT02758613|PLACEBO_COMPARATOR|Placebo|Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
62354756|NCT01877590|PLACEBO_COMPARATOR|placebo group|An identical placebo daily
62354757|NCT01877590|EXPERIMENTAL|alpha-lipoic acid group|alpha-lipoic acid 600 mg daily for one year.
62354758|NCT06173661|ACTIVE_COMPARATOR|Patients receiving active medication|These patients will receive 675 mg of fremanezumab for two total doses administered 3 months apart.
62354759|NCT06173661|PLACEBO_COMPARATOR|Patients receiving placebo|These patients will receive placebo injections for two total doses administered 3 months apart.
62354760|NCT04489004|EXPERIMENTAL|Driver ablation+CPVI|Driver ablation plus CPVI (circumferential pulmonary vein isolation)
62354761|NCT04489004|ACTIVE_COMPARATOR|Stepwise ablation|Stepwise ablation
62354762|NCT04101448||Group A|COPD patients with bronchiectasis
62354763|NCT04101448||Group B|COPD patients without bronchiectasis
62354764|NCT04467632|EXPERIMENTAL|Patients affected with idiopathic Parkinson Disease|
62354765|NCT00934011|EXPERIMENTAL|Group 1 - C-reactive protein (CRP) guided ab therapy|Intervention on antibiotic therapy will be based on circulating CRP levels
62354766|NCT00934011|ACTIVE_COMPARATOR|Group 2 - procalcitonin (PCT) guided ab therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
62354767|NCT02707679|OTHER|Effects of Mulligan's Mobilization|The patients in this arm (n=18) received two techniques pertaining to Mulligan's Mobilization with movement approach (Mulligan's Straight Leg-Raise with Traction and Tibial Gliding) along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed before the treatment, 45 minutes after the initial treatment, at the end of the 4-session-treatment during 2-week period and 6 weeks later.
62354768|NCT02707679|OTHER|Effects of Kinesiotaping|Patients in this arm were applied kinesiotaping on quadriceps and hamstring muscle along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. The same assessment parameters was conducted on this arm too.
62354769|NCT03046160|EXPERIMENTAL|experimental group|"where treatment will involve conventional and Manual therapy (Mobilization with movement)+ tape (postural correction of scapular anterior tilt)~1. The Manual therapy (Mobilization with movement)intervention was of grade III mobilizations with movement performed in sitting for 6-10 repetitions for 3 sets~2. tape (postural correction of scapular anterior tilt)~3. A program of 12 neck and scapular exercises."
62354770|NCT03046160|ACTIVE_COMPARATOR|control group|"treatment will consist of the conventional approach+ tape (postural correction of scapular anterior tilt)~1. tape (postural correction of scapular anterior tilt)~2. A program of 12 neck and scapular exercises."
62354771|NCT04953065||interventional|Single arm, interventional. All participants will be contacted over the phone to answer questions from a COVID-19 vaccine hesitancy and acceptance survey.
62354772|NCT03943108||Obese teenagers within the PAIDOS clinic|Obese children within the PAIDOS clinic, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
62354773|NCT03943108||Healthy children|Healthy children living in Mexico City, Mexico.
62354774|NCT03943108||Children with Type 2 Diabetes|Chjildren with Type 2 Diabetes attending the Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
62354775|NCT01875705|EXPERIMENTAL|Stage I-Dose Escalation|
62354776|NCT01875705|EXPERIMENTAL|Stage II-Cohort-Expansion|
62516147|NCT01819324|NO_INTERVENTION|Usual Care|Receiving SLM materials at the end of the 7 months
62516148|NCT00485030|EXPERIMENTAL|Cypher|sirolimus-eluting stent
62516149|NCT00485030|ACTIVE_COMPARATOR|Xience-V|everolimus-eluting stent
62516150|NCT02235220|EXPERIMENTAL|Composite resin restoration|A canine guidance is reestablished by additive composite resin restorations of the canine cusp.
62516151|NCT01421121|EXPERIMENTAL|100U EV71 vaccine with adjuvant|120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
62516152|NCT01421121|EXPERIMENTAL|200 U EV71 vaccine with adjuvant|120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
62516153|NCT01421121|EXPERIMENTAL|400U EV71 vaccine with adjuvant|120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
62710448|NCT00579644|ACTIVE_COMPARATOR|1 Methotrexate* & minocycline|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
61973787|NCT02697786|ACTIVE_COMPARATOR|AVR preformed with full sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
61973788|NCT02697786|EXPERIMENTAL|AVR preformed with minimal invasive sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
61973789|NCT03916328|ACTIVE_COMPARATOR|DMPA+ and TDF+|HIV-infected women on DMPA, and TDF containing ART.
61973790|NCT03916328|EXPERIMENTAL|DMPA+ and B/F/TAF+|HIV-infected women on DMPA, and B/F/TAF.
62354777|NCT02678312|EXPERIMENTAL|Part 1: LCZ696 open label|LCZ696 open label: For Age Groups 1 and 2, either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. For Age Group 3, either 1) 0.4 mg/kg or 2) 1.6 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril provided locally by the study site, or standard of care also provided locally by the study site, for heart failure treatment, if patient intended to participate in Part 2.
62354778|NCT02678312|ACTIVE_COMPARATOR|Part 2: Enalapril|The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose). Administered in a double-blind fashion.
62354779|NCT02678312|EXPERIMENTAL|Part 2: LCZ696|LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight. Administered in a double-blind fashion.
62354780|NCT04077411||Children with severe TBI|Children with severe Traumatic Brain Injury
62354781|NCT03481387|OTHER|Aortic Valve Replacement with Perceval S sutureless heart valve|Patient undergoing Aortic Valve Replacement with Perceval S sutureless heart valve
62354782|NCT05854069|EXPERIMENTAL|FAMS-T1D|"Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes.~All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes."
62354783|NCT05854069|PLACEBO_COMPARATOR|Digital resources for diabetes|All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
62354784|NCT05165550|EXPERIMENTAL|Cohort 1|Elsulfavirine 20 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
62354785|NCT05165550|EXPERIMENTAL|Cohort 2|Elsulfavirine 40 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
62354786|NCT05165550|EXPERIMENTAL|Cohort 3|Elsulfavirine 80 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
62354787|NCT01349972|EXPERIMENTAL|Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride)|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
62354788|NCT01349972|ACTIVE_COMPARATOR|Arm II (cytarabine, daunorubicin hydrochloride)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
62354789|NCT00556621|OTHER|gemcitabine, cisplatine, radiotherapy|
62354790|NCT05653804|EXPERIMENTAL|tele-visit by HCP|Patients receive a annual CPAP remote visit by HCP technician, then home visit the following year
62354791|NCT05653804|NO_INTERVENTION|home visit by HCP|Standard care : patients receive an annual CPAP home visit by HCP technician
62354792|NCT02227056|EXPERIMENTAL|Methylphenidate treatment|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
62354793|NCT02227056|NO_INTERVENTION|Control|On three different days each participant will be re-evaluated without recieveing Methylphenidate.
62516154|NCT01421121|EXPERIMENTAL|200U EV71 vaccine without adjuvant|60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
62516155|NCT01421121|PLACEBO_COMPARATOR|Placebo|120 infants received 2 doses of placebo 28 days apart.
62516156|NCT05767203|EXPERIMENTAL|Patients with Down syndrome or other Intellectual deficiency of genetic origin|Patients with Down syndrome or with other intellectual deficiency of genetic origin followed at the outpatients clinic of the Institut Jérôme Lejeune.
62354794|NCT02076048||Previous LCPUFA Supplementation|Children between the ages of 7 and 10 that were previously enrolled in a study of supplemented LCPUFA formula.
62516157|NCT02036450|EXPERIMENTAL|ILR group|Receive implantable loop recorder (ILR, Medtronic Reveal LINQ(TM)) with continuous monitoring, and will be followed by daily automated remote transmissions. Study visits are scheduled annually until the 4th visit, and furthermore, endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
62516158|NCT02036450|NO_INTERVENTION|Control group|Followed according to standard care, i.e. by their general practitioner. Study visits are scheduled at inclusion and after 3 years. Furthermore, the participants are contacted by telephone after 1 and 2 years of follow-up, and endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
62516159|NCT06489834|ACTIVE_COMPARATOR|Drumming Arm|Participants in this arm will undergo weekly group drumming for 8 weeks.
61973791|NCT03916328|EXPERIMENTAL|DMPA- and B/F/TAF+|HIV-infected women on non hormonal contraception, and B/F/TAF.
62516160|NCT06489834|NO_INTERVENTION|Waitlist Control Arm|Participants in this arm will not undergo any intervention while the intervention arm is ongoing and assessed for comparison.
62516161|NCT05962502|EXPERIMENTAL|cetuximab plus irinotecan|Cetuximab 500 mg/m2 iv drip 90 min d1, Irinotecan 180 mg/m2 iv drip d1 (For patients with UGT\*28 7/7 or UGT\*6 A/A or UGT\*28 6/7 plus UGT\*6 A/G, irinotecan 150 mg/m2 is used) The above regimen is repeated every 2 weeks
62516162|NCT01477502|ACTIVE_COMPARATOR|individual homeopathic treatment|participants receive homeopathic treatment in addition to standard prevention measures for UTI
62516163|NCT01477502|OTHER|standard prophylaxis|
62516164|NCT02281331|ACTIVE_COMPARATOR|Supplement|Each day, participants in this group will receive a supplement that provides a total of protein, creatine monohydrate, calcium, vitamin D and carbohydrate. This supplement will be provided to participants in beverage format, twice daily.
62516165|NCT02281331|PLACEBO_COMPARATOR|Placebo|The placebo will provide participants with maltodextrin (carbohydrate) and sucrose.
62516166|NCT04732988|EXPERIMENTAL|HSG4112 30 mg Single Dose|Single oral dosing of HSG4112 30 mg
62516167|NCT04732988|PLACEBO_COMPARATOR|Placebo 30 mg Single Dose|Single oral dosing of Placebo 30 mg
62516168|NCT04732988|EXPERIMENTAL|HSG4112 60 mg Single Dose|Single oral dosing of HSG4112 60 mg
62516169|NCT04732988|PLACEBO_COMPARATOR|Placebo 60 mg Single Dose|Single oral dosing of Placebo 60 mg
62516170|NCT04732988|EXPERIMENTAL|HSG4112 120 mg Single Dose|Single oral dosing of HSG4112 120 mg
61973792|NCT05463575|EXPERIMENTAL|PF-06835919|KHKi
61973793|NCT05463575|PLACEBO_COMPARATOR|Placebo|Placebo
61973794|NCT06234007|EXPERIMENTAL|SCRT followed by fruquintinib plus adebrelimab and CAPOX|
61973795|NCT03259204|NO_INTERVENTION|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
61973796|NCT03259204|EXPERIMENTAL|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
61973797|NCT02097810|EXPERIMENTAL|Entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)
61973798|NCT00066950|NO_INTERVENTION|Counseling Only|Oral Health Counseling Only
62354795|NCT03703362|EXPERIMENTAL|Progressive resistance training|Progressive resistance training tested in patients with external snapping hip
62354796|NCT05765292|ACTIVE_COMPARATOR|probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day.
62354797|NCT05765292|PLACEBO_COMPARATOR|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
61973799|NCT00066950|EXPERIMENTAL|CHX+Counseling (caregiver) + FV (child)|Oral Health Counseling plus Chlorhexidine for caregiver plus fluoride varnish every 6 months from 12mo to 30mo of age for child
61973800|NCT04719754||Pregnant women with abnormal vaginal discharge|
61973801|NCT04719754||Pregnant women without abnormal vaginal discharge|
61973802|NCT03579160|EXPERIMENTAL|0.25% Timolol gel applied to full-thickness skin graft|"1. During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~2. During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~3. After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
62354798|NCT01619592|ACTIVE_COMPARATOR|Intervention group|webbased education (telemonitoring)
62354799|NCT01619592|NO_INTERVENTION|control group|standard care
62354800|NCT03850418|EXPERIMENTAL|AZA|azacitidine
62354801|NCT05520918|OTHER|COVID-19 pneumonia patients|sequential LIT was performed to this patient group
62516171|NCT04732988|PLACEBO_COMPARATOR|Placebo 120 mg Single Dose|Single oral dosing of Placebo 120 mg
62516172|NCT04732988|EXPERIMENTAL|HSG4112 240 mg Single Dose (Fasted)|Single oral dosing of HSG4112 240 mg under fasted conditions
62516173|NCT04732988|EXPERIMENTAL|HSG4112 240 mg Single Dose (Fed)|Single oral dosing of HSG4112 240 mg under fed conditions
62516174|NCT04732988|PLACEBO_COMPARATOR|Placebo 240 mg Single Dose|Single oral dosing of Placebo 240 mg
62516175|NCT04732988|EXPERIMENTAL|HSG4112 480 mg Single Dose|Single oral dosing of HSG4112 480 mg
62516176|NCT04732988|PLACEBO_COMPARATOR|Placebo 480 mg Single Dose|Single oral dosing of Placebo 480 mg
62516177|NCT04732988|EXPERIMENTAL|HSG4112 720 mg Single Dose|Single oral dosing of HSG4112 720 mg
62516178|NCT04732988|PLACEBO_COMPARATOR|Placebo 720 mg Single Dose|Single oral dosing of Placebo 720 mg
62516179|NCT04732988|EXPERIMENTAL|HSG4112 240 mg Multiple Dose|Once-daily multiple oral dosing of HSG4112 240 mg for 14 days
62516180|NCT04732988|PLACEBO_COMPARATOR|Placebo 240 mg Multiple Dose|Once-daily multiple oral dosing of Placebo 240 mg for 14 days
62516181|NCT04732988|EXPERIMENTAL|HSG4112 480 mg Multiple Dose|Once-daily multiple oral dosing of HSG4112 480 mg for 14 days
62516182|NCT04732988|PLACEBO_COMPARATOR|Placebo 480 mg Multiple Dose|Once-daily multiple oral dosing of Placebo 480 mg for 14 days
62516183|NCT03050697|EXPERIMENTAL|HMTIOL|HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
61973803|NCT03579160|ACTIVE_COMPARATOR|Standard of Care dressings|"1. FTSG surgery as per SOC~2. After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
62516184|NCT03661606|EXPERIMENTAL|Monitoring arm|Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.
62516185|NCT01425255||Parents of children with Type 1 diabetes|before and several weeks after initiating using RT-CGM of their children.
62516186|NCT02291471|EXPERIMENTAL|T0001|
62516187|NCT05896969|EXPERIMENTAL|SAD Cohort|SAD Cohort 1 - 8 : Subjects in each cohort will be randomised will receive a single SC dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
62516188|NCT05896969|EXPERIMENTAL|MAD cohort|MAD Cohort 1 - 8 : Subjects in each cohort will be randomized will receive the active SNK-396 with dose range of SNK-396 anticipated to be from 25 to 800 mg or matching placebo
61973804|NCT01275391|NO_INTERVENTION|Treatment as Usual Group 1|Participants will receive treatment as usual and will complete a baseline and 1-month post-visit assessment
61973805|NCT01275391|NO_INTERVENTION|Treatment as Usual Group 2|Participants will receive treatment as usual and complete only the 1-month post-visit assessment
61973806|NCT01275391|EXPERIMENTAL|Intervention Group 1|Computer Screening, Brief Intervention, Referral toTreatment. Participants will receive the intervention and complete a baseline and 1-month post-visit assessment
61973807|NCT01275391|EXPERIMENTAL|Intervention Group 2|Computer Screening, Brief Intervention, Referral toTreatment Participants will receive the intervention and complete only the 1-month post-visit assessment
61973808|NCT05526820|EXPERIMENTAL|The combined immunization group|225 participants received one dose of live attenuated varicella vaccine and the first dose inactivated hepatitis A vaccine on day 0 and the second dose of inactivated hepatitis A vaccine on day 180.
61973809|NCT05526820|ACTIVE_COMPARATOR|The Non-combined immunization group|225 participants received one dose of live attenuated varicella vaccine on day 0,the first dose of inactivated hepatitis A vaccine on day 42 and the second dose of inactivated hepatitis A vaccine on day 222.
61973810|NCT03327649|SHAM_COMPARATOR|Sham control|Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
61973811|NCT03327649|EXPERIMENTAL|Active treatment|Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
61973812|NCT05691452|EXPERIMENTAL|Intervention Group|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth.
62354802|NCT04560140|EXPERIMENTAL|Intervention group|Eligible participants will be randomly assigned to receive usual care with the novel 24-week Narrative and Skills-building Intervention.
62354803|NCT04560140|NO_INTERVENTION|Usual care group|Participants will receive usual stroke care.
62354804|NCT05594433|EXPERIMENTAL|Experimental|Sub cutaneous injection of Lenograstim with blood donation (450ML) after 4 days of mobilization
62354805|NCT00119236|EXPERIMENTAL|Arm I|Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)\* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.
62354806|NCT01250756|EXPERIMENTAL|1|Experimental
62354807|NCT01250756|EXPERIMENTAL|2|Active comparator
62354808|NCT03979846|EXPERIMENTAL|Arm I (usual care, computer-based symptom reporting)|Participants receive usual care for 3 weeks, then use a computer based symptom reporting system for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
62354809|NCT03979846|EXPERIMENTAL|Arm II (computer-based symptom reporting, usual care)|Participants use a computer based symptom reporting system for 3 weeks, then receive usual care for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
62354810|NCT03299036|EXPERIMENTAL|Taiwan ACE Beads with doxorubicin|The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.
62354811|NCT04397029|EXPERIMENTAL|Subjects without messes|Subjects who are believed to be free of masses.
62516189|NCT06465732|EXPERIMENTAL|dupilumab plus tofacitinib|this arm receives dupilumab injection and oral tofacitinib.
62516190|NCT06465732|ACTIVE_COMPARATOR|dupilumab mono|this arm receives dupilumab treatment only.
62516191|NCT00614822|OTHER|one arm for study|Carboplatin, Pemetrexed and Bevacizumab are given day 1 every 3 weeks for 6 cycles and will be continued if patient tolerates treatments and has stable disease. The Bevacizumab will be continued every 3 weeks for 1 year if the patient tolerates treatment and has stable disease.
61973813|NCT04519684|EXPERIMENTAL|Mesenchymal stem cells|Direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
62147794|NCT02322489|SHAM_COMPARATOR|Sham microcurrent therapy|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but it lasts only for 5 seconds.
62354812|NCT04397029|EXPERIMENTAL|Subjects with known masses|Subjects with known masses.
62354813|NCT00309257|EXPERIMENTAL|ACE inhibitor, ATA II antagonists and Statins|
62354814|NCT06206902|EXPERIMENTAL|Assigned Interventions|
62354815|NCT04142749|ACTIVE_COMPARATOR|Oltipraz|Oltipraz 30mg
62354816|NCT04142749|PLACEBO_COMPARATOR|Placebo|Placebo 30mg
62354817|NCT04880265||Patients undergoing cardiac surgery|
62516192|NCT00591435||1|200 laparoscopic cholecystectomies will be included, consultant cases will be compared to resident cases
62516193|NCT00591435||2|200 laparoscopic pelviscopies will be included, consultant cases will be compared to resident cases
62516194|NCT00591435||3|200 transurethral resection of urinary bladder or prostate gland will be included, consultant cases will be compared to resident cases
62516195|NCT01633294|ACTIVE_COMPARATOR|Antibiotic group|women submitted to antibiotic prophylaxis
62516196|NCT01633294|NO_INTERVENTION|Control group|
62516197|NCT04039919|EXPERIMENTAL|Part A: Padsevonil and Ethanol|Subjects will be randomized to receive Padsevonil and Ethanol.
62516198|NCT04039919|PLACEBO_COMPARATOR|Part A: Padsevonil and Ethanol-Placebo|Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
62516199|NCT04039919|NO_INTERVENTION|Part A: Ethanol and Ethanol-Placebo|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
62516200|NCT04039919|NO_INTERVENTION|Part A: Ethanol-Placebo and Ethanol|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
62516201|NCT04039919|EXPERIMENTAL|Part B: Padsevonil and Cannabidiol|Subjects will be randomized to receive Padsevonil and Cannabidiol.
62516202|NCT04039919|PLACEBO_COMPARATOR|Part B: Padsevonil-Placebo and Cannabidiol|Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.
62516203|NCT01382745|EXPERIMENTAL|Nimotuzumab|Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
62516204|NCT03163849|PLACEBO_COMPARATOR|control group|oral tablets
62516205|NCT03163849|EXPERIMENTAL|Study group|sofosbuvir , daclatasvir oral tablets
62516206|NCT01587131|EXPERIMENTAL|Group 1- DNA prime DNA boost|0.9 mg of FVH1 vaccine delivered ID followed by electroporation on Day 0, Week 15 and Week 27
61973814|NCT04519684|PLACEBO_COMPARATOR|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into ileal pouch fistula(s).
61973815|NCT04525664|EXPERIMENTAL|Participants who test positive for Helicobacter pylori|Participants who test positive for Helicobacter pylori by fecal antigen testing will be offered treatment with triple therapy (clarithromycin 500 mg per os twice daily, amoxicillin 1 g per os twice daily, omeprazole 40 mg per os twice daily) for 14 consecutive days. Two to four weeks following the completion of treatment, participants will repeat fecal antigen testing to confirm whether they eradicated the Helicobacter pylori.
62147795|NCT02322489|EXPERIMENTAL|Microcurrent Group|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started.
62147796|NCT01439854|PLACEBO_COMPARATOR|Placebo|this arm is control
62516207|NCT01587131|EXPERIMENTAL|Group 2 - DNA prime Seasonal Vaccine boost|0.9 mg FVH1 vaccine delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
62516208|NCT01587131|PLACEBO_COMPARATOR|Group 3 - sWFI prime Seasonal Vaccine boost|100 microliters of sterile water for injection delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
62516209|NCT03758482|OTHER|Men|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
62516210|NCT03758482|OTHER|Women|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
62516211|NCT00617370|EXPERIMENTAL|1|The regimen consists of EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 with pegfilgrastim subcutaneously (SQ) on day # 2, followed by paclitaxel (175 mg/m2) q 14 days x 6 with pegfilgrastim SQ on day # 2.
62516212|NCT01051180||Doppler|Those patients where the doppler was randomised to be on
62516213|NCT01051180||Non doppler patients|those with no doppler guidance
62516214|NCT00214331||1|ciprofloxacin
62516215|NCT00214331||2|azithromycin
62516216|NCT00214331||3|gentamicin
62516217|NCT04062682|NO_INTERVENTION|Controls|No changes in dietary habits
62516218|NCT04062682|EXPERIMENTAL|Healthy Diet|Changes in dietary habits only
62516219|NCT05526859|EXPERIMENTAL|Group 1|Hyperactive muscle correction for wrist extensors: Kinesiotape was applied to facilitate wrist extensor muscles from proximal to distal with 15-35% tension in therapeutic zone and no tension at anchor and end.
62516220|NCT05526859|EXPERIMENTAL|Group 2|Hypoactive muscle correction for wrist flexors: Wrist flexors muscles were inhibited by applying tape from distal to proximal with 15-25% tension in therapeutic zone and no tension at anchor and end.
62516221|NCT05007184|NO_INTERVENTION|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart, which replicates the traditional shopping experience of online grocery stores.
62147797|NCT01439854|EXPERIMENTAL|Dapagliflozin|Interventional arm
62516222|NCT05007184|EXPERIMENTAL|Warning Label Arm (Arm 2)|Similar to Arm 1 except that products are labeled with Chilean warning FOP labels.
62516223|NCT05007184|EXPERIMENTAL|Nutri-Score Arm (Arm 3)|Similar to Arm 1 except that products are labeled with NutriScore FOP labels.
62516224|NCT01494441|EXPERIMENTAL|rhBMP-2/BCP|
62516225|NCT01494441|EXPERIMENTAL|rhBMP-2/BCP/TSRH® Spinal System|
62516226|NCT01494441|ACTIVE_COMPARATOR|Autograft/TSRH® Spinal System|
62516227|NCT05877391|OTHER|SGM Communication Intervention|The goal of the arm is to train hospice staff in person-centered communication that includes SOGI data collection to promote authentic end-of-life care for SGM patients and their caregivers.
62516228|NCT06422338|EXPERIMENTAL|IMCI-enhanced by sTREM-1 levels (SoC + sTREM-1 POC)|IMCI-guidelines (standard of care) + Point-Of-Care Rapid Triage Test (POC-RTT) based on sTREM-1 quantification
62516229|NCT06422338|NO_INTERVENTION|IMCI alone|IMCI-guidelines (standard of care)
62516230|NCT05840094|EXPERIMENTAL|PET/CT+MR+EBUS|Subjects will receive 18F-FDG PET/CT and MR STIR sequence combined with EBUS-TBNA, to diagnose the N-stage of NSCLC
62516231|NCT05840094|EXPERIMENTAL|PET/CT+EBUS|Subjects will receive 18F-FDG PET/CT and EBUS-TBNA, to diagnose the N-stage of NSCLC
62516232|NCT05840094|EXPERIMENTAL|MR+EBUS|Subjects will receive 18F-FDG PET/CT and EBUS-TBNA, to diagnose the N-stage of NSCLC
62516233|NCT03475134|EXPERIMENTAL|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
62516234|NCT01575717|EXPERIMENTAL|Vitamin D 4000|Subjects taking 4000 IU of vitamin D
62147798|NCT03936166|EXPERIMENTAL|Single Ascending Dose (Part 1)|
62147799|NCT03936166|EXPERIMENTAL|Multiple Ascending Dose (Part 2)|
62516235|NCT01575717|EXPERIMENTAL|Vitamin D 2000|Subjects taking 2000IU of vitamin D
62516236|NCT01575717|NO_INTERVENTION|No Intervention|
62516237|NCT02054013|EXPERIMENTAL|Prostatic artery embolization|Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure with rapid recovery and low morbidity
62516238|NCT02054013|OTHER|Conventional monopolar transurethral prostatectomy|Standard treatment
62516239|NCT02135120|ACTIVE_COMPARATOR|Morphine group|Patients will receive a combined spinal epidural anesthesia technique with intrathecal morphine
62516240|NCT02135120|ACTIVE_COMPARATOR|Morphine-femoral group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block
62516241|NCT02135120|ACTIVE_COMPARATOR|Morphine-femoral-sciatic group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
62516242|NCT04598178||Taiwan Cohort|For normative Taiwan people, cognitive function will be assessed by the Taiwan version of questionnaire Qmci (Qmci-TW) on Day 0, Day 2, Day 180.
62516243|NCT03965637|EXPERIMENTAL|vitamin C|Intervention patients will be received double dose of Ascorbic acid via intravenous injection
62516244|NCT03965637|NO_INTERVENTION|Control|Control patients will not be received any intervention
62516245|NCT00752674|EXPERIMENTAL|1|Neuromuscular balance
62516246|NCT03032822||All Patients|All cystectomy patients who consent for the study
62516247|NCT01320020|EXPERIMENTAL|catumaxomab|
62516248|NCT04588441|EXPERIMENTAL|Adenosine|Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer
62516249|NCT05674214||birth weight-discordant group|the birth weight difference within twins is greater than 20%
62516250|NCT05674214||the birth weight-concordant group|the birth weight difference within twins is less than or equal to 20%
62516251|NCT01155778|EXPERIMENTAL|10 mg rhHNS|10 mg monthly via an IDDD (every 28 \[±7 days\]) for a total of 6 months
62516252|NCT01155778|EXPERIMENTAL|45 mg rhHNS|45 mg monthly via an IDDD (every 28 \[±7 days\]) for a total of 6 months
62516253|NCT01155778|EXPERIMENTAL|90 mg rhHNS|Given IDDD as a 45 mg dose every 14 \[±2 days\] for a monthly total of 90 mg for 6 months
62516254|NCT05393063|EXPERIMENTAL|AK127|Subjects will receive AK127 by intravenous administration
62516255|NCT05161819|EXPERIMENTAL|High-frequency rTMS at left DLPFC|Receive an rTMS course with high-frequency stimulation at left DLPFC
62516256|NCT05161819|SHAM_COMPARATOR|High-frequency sham stimulation at left DLPFC|Receive an sham rTMS course with high-frequency stimulation at left DLPFC with the sham coil
62516257|NCT01690975|PLACEBO_COMPARATOR|Placebo|Placebo Control
62516258|NCT01690975|EXPERIMENTAL|Benzonatate|Benzonatate Active
62516259|NCT05612282||G1a - women|The G1a group consisted of women with obesity, in whom no additional components of the metabolic syndrome were found (n =16)
62147800|NCT03936166|PLACEBO_COMPARATOR|Elderly Cohort (Part 3)|
62516260|NCT05612282||G1b - men|The G1b group consisted of men with obesity, in whom no additional components of the metabolic syndrome were founds (n =6)
62516261|NCT05612282||G2a - women|The G2a group consisted of women with obesity, in whom only one additional component of the metabolic syndrome was found (e.g. triglycerides ≥ 150 mg/dl, HDL cholesterol in women \< 50 mg/dl, and in men \< 40 mg/dl, or glycaemia ≥ 100 mg/dl), but it was not a disease previously diagnosed and treated (n=19)
62516262|NCT05612282||G2b - men|The G2a group consisted of men with obesity, in whom only one additional component of the metabolic syndrome was found (e.g. triglycerides ≥ 150 mg/dl, HDL cholesterol in women \< 50 mg/dl, and in men \< 40 mg/dl, or glycaemia ≥ 100 mg/dl), but it was not a disease previously diagnosed and treated (n=11)
62516263|NCT05612282||G3a - women|Group G3a consisted of women who met the full criteria for diagnosing the metabolic syndrome (n=24)
62147801|NCT00487045|EXPERIMENTAL|1|Hem-Avert Perianal Stabilizer, single use, disposable, sterile, individually packaged instrument
62147802|NCT00487045|NO_INTERVENTION|2|
62516264|NCT05612282||G3b - men|Group G3a consisted of men who met the full criteria for diagnosing the metabolic syndrome (n=15)
62516265|NCT04589702||females with isolated patellofemoral arthritis|those with anterior knee pain
62516266|NCT04589702||healthy females|those without anterior knee pain
62516267|NCT00856505|EXPERIMENTAL|Everolimus and mycophenolate sodium|Combination of experimental immunosuppressants for GvHD prophylaxis
62516268|NCT06160414|EXPERIMENTAL|Cohort 1|On Day 1, all participants will receive a single oral dose (fasted) of Metformin followed by a single oral dose (fasted) of Rosuvastatin on Day 3.
62147803|NCT03845881|ACTIVE_COMPARATOR|Opioid|Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty
62147804|NCT03845881|PLACEBO_COMPARATOR|Non Opioid|Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty
62147805|NCT05794074|EXPERIMENTAL|lutéine|10 mg/d lutéine
62147806|NCT05794074|EXPERIMENTAL|zeaxanthine|10 mg/d zéaxanthine
62147807|NCT05794074|EXPERIMENTAL|lutéine and zeaxanthine|10 mg/d lutéine + 2 mg/d zéaxanthine
62147808|NCT05794074|PLACEBO_COMPARATOR|placebo|same excipient used in the other arms with a carmine red dye
62516269|NCT06160414|EXPERIMENTAL|Cohort 2|All participants will receive ALXN2080 twice daily (BID) on Day 1 to Day 11. On the morning of Day 6, participants will be given a single dose of Metformin co-administered with the morning dose of ALXN2080. On the morning of Day 8, participants will be given a single dose of Rosuvastatin co-administered with the morning dose of ALXN2080.
62516270|NCT02631876|EXPERIMENTAL|Mirvetuximab Soravtansine|Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee \[BIRC\]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
61973816|NCT04525664|EXPERIMENTAL|Patients with dyspepsia and negative for Helicobacter pylori|Participants who report chronic dyspepsia but are negative for Helicobacter pylori by fecal antigen testing will receive daily omeprazole (20 mg per os) for one month. Their symptoms will be reassessed after completion of the month treatment.
61973817|NCT05337007|EXPERIMENTAL|dietary intervention, high protein diet|commercially available high protein ultraprocessed food items (30% protein content), cross-over design, all subjects receive all interventions
61973818|NCT05337007|ACTIVE_COMPARATOR|dietary intervention, moderate protein diet|commercially available moderate protein ultraprocessed food items (13% protein content), cross-over design, all subjects receive all interventions
61973819|NCT06001424|EXPERIMENTAL|study group|will receive physical therapy program of in addition to life kinetik training.
62147809|NCT01823406|EXPERIMENTAL|Type 1 Diabetes no complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
62147810|NCT01823406|EXPERIMENTAL|Type 1 Diabetes with microalbuminuria|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
62354818|NCT04906486||Observational: Patients with restless legs syndrome|A total of 70 patients who diagnosed with primary restless legs syndrome according to the five essential criteria as established by the International Restless Legs Syndrome Study Group.
62354819|NCT04906486||Observational: Healthy controls|The control group consisted of 85 age- and gender-matched healthy volunteers.
62354820|NCT03182413|PLACEBO_COMPARATOR|PBO|Placebo
62354821|NCT03182413|ACTIVE_COMPARATOR|MOD|Modafinil 100mg
62354822|NCT03182413|EXPERIMENTAL|THN102 100/1|modafinil 100 mg + 1 mg flecainide
62354823|NCT03182413|EXPERIMENTAL|THN102 100/3|modafinil 100 mg + 3 mg flecainide
62354824|NCT03182413|EXPERIMENTAL|THN102 100/9|modafinil 100 mg + 9 mg flecainide
62354825|NCT05794789|NO_INTERVENTION|PA education and planning condition|This group will receive sessions and information-based booklet and series of worksheets that provide a tangible knowledge translation product for the family. The material will consist of Canada's PA guidelines recommending 60 minutes of MVPA a day and a breakdown of ways for the parent to help their child achieve this PA, outlining three main domains of parental support (encouragement, logistical support, and PA together). The material also contains information about the benefits of PA for the child and how to plan for family PA. The material specifically includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past. The investigators will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids. An additional two sessions will include education and planning material related to family healthy eating.
62354826|NCT05794789|EXPERIMENTAL|Identity formation condition|This group will receive the same content as the education+planning comparison condition but with two additional coaching sessions. The session will include short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques that align with these approaches and are included in the coaching session include identity salience, identity similarity, as well as identity fit and contrast. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity.
62354827|NCT03097614|EXPERIMENTAL|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
61973820|NCT06001424|ACTIVE_COMPARATOR|control|will receive physical therapy program
61973821|NCT01494194|PLACEBO_COMPARATOR|placebo for food challenge|
61973822|NCT01494194|EXPERIMENTAL|ASP Skin prick solution|
61973823|NCT01494194|EXPERIMENTAL|ASP sorbet|
61973824|NCT02326961|EXPERIMENTAL|Celution ADRCs; Low Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
61973825|NCT02326961|EXPERIMENTAL|Celution ADRCs; High Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
61973826|NCT02326961|PLACEBO_COMPARATOR|Placebo|Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
62354828|NCT05382702|OTHER|High Fat Yogurt - Low Fat Yogurt|Participants will eat yogurt described as 'high fat' at Study Visit 2 and yogurt described as 'low fat' at Study Visit 3.
62354829|NCT05382702|OTHER|Low Fat Yogurt - High Fat Yogurt|Participants will eat yogurt described as 'low fat' at Study Visit 2 and yogurt described as 'high fat' at Study Visit 3.
62354830|NCT03342937|EXPERIMENTAL|Oxaliplatin+Capecitabine+Pembrolizumab|
62354831|NCT00345540|EXPERIMENTAL|NOV-002 plus Carboplatin|NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles.
62354832|NCT01601951||Hip Osteoarthritis|
62354833|NCT01601951||Knee Osteoarthritis|
62354834|NCT02022033|EXPERIMENTAL|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
62354835|NCT01949298|EXPERIMENTAL|Immediate implant loading|The test group had implant immediately loaded by means of a implant supported mandibular denture connected with locator abutment.
62516271|NCT02631876|EXPERIMENTAL|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m\^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
62516272|NCT00379990|EXPERIMENTAL|GW274150 60 mg once daily for 28 days|60 mg GW274150 taken once daily for 28 days
62516273|NCT00379990|ACTIVE_COMPARATOR|Prednisolone 7.5 mg once daily for 28 days|7.5 mg prednisolone taken once daily for 28 days
62516274|NCT00379990|PLACEBO_COMPARATOR|Placebo once daily for 28 days|Placebo taken once daily for 28 days
61973827|NCT02470234|EXPERIMENTAL|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended Release Capsules, 10 mg. Active drug, administered once
61973828|NCT02470234|EXPERIMENTAL|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended Release Capsules, 15 mg. Active drug, administered once
61973829|NCT02470234|EXPERIMENTAL|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended Release Capsules, 20 mg. Active drug, administered once
61973830|NCT01286181|EXPERIMENTAL|Device-guided slow breathing|
61973831|NCT05954026|OTHER|Single arm|Prospective, open label, single-arm multicenter study
62516275|NCT04911465||Pediatric Trauma Patients|All pediatric patients \>31 days who meet criteria for highest level trauma activation (Level Red or Level 1) at the Children's Hospital Colorado.
62516276|NCT01749748|OTHER|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy for asymptomatic women breasts.
62516277|NCT04818996|EXPERIMENTAL|Mediterranean Diet|In the study, the participants were applied a diet compatible with the Mediterranean diet for 8 weeks.
62516278|NCT00965445||cardiac surgery with CPB|
62516279|NCT03250975|EXPERIMENTAL|Medical Therapy|medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days
61973832|NCT02530554|EXPERIMENTAL|CHG Cloth|3 min application time
61973833|NCT02530554|ACTIVE_COMPARATOR|Comparator CHG|Marketed 2% CHG
61973834|NCT02599272|OTHER|Rice with vegetables but no added spice|Control session - rice with control vegetables (tomatoes and aubergines) - no mixed spices
62354836|NCT01949298|ACTIVE_COMPARATOR|Delayed implant loading group|The control group had implant loaded after 3 months of submerged healing by means of a implant supported mandibular denture connected with locator abutment.
62354837|NCT01106482|ACTIVE_COMPARATOR|Arm 1|
62354838|NCT01106482|ACTIVE_COMPARATOR|Arm 2|
62354839|NCT01106482|ACTIVE_COMPARATOR|Arm 3|
62354840|NCT01106482|ACTIVE_COMPARATOR|Arm 4|
62516280|NCT03250975|PLACEBO_COMPARATOR|Placebo Control|Placebo control medication for 14 days
62516281|NCT02045004||Surgery Group Sevoflurane|Patients aged ≥ 65 years undergoing major surgical procedures.
62516282|NCT02045004||Control Group|Healthy study participants aged ≥ 65 years (no surgical intervention).
62516283|NCT05256472|EXPERIMENTAL|AK104 monotherapy cohort (Part 1)|Subjects in this cohort will randomly receive three different dosage of AK104 monotherapy administered intravenously.
62516284|NCT05256472|EXPERIMENTAL|combination treatment cohort (Part 2)|Subjects in this cohort will receive AK104 (RP2D, administered intravenously) plus Axitinib 5 mg bid, administered orally.
62516285|NCT05768659||Cases|Participants affected by obesity (the level of body mass index (BMI) higher or equal to 30).
62516286|NCT05768659||Controls|Not-hospitalized participants with a healthy weight
62516287|NCT02610764|EXPERIMENTAL|Experimental diagnostic test|"Evaluation and enumeration of circulating Tumor cells from the blood with two different CTC-detection platforms: one established test (CellSearch) and one experimental test (ScreenCell).~Control diagnostic test: CT-Scan of the Chest and the Abdomen, Endoscopy and Endosonography, Clinical response and histo pathologic response. (% Of vital tumor Cells in the histologic specimen)."
62516288|NCT03897478||Ischemic Stroke|"Ischemic stroke subjects presenting within 30 hours from symptom onset will have al PAX Gene Blood RNA tubes drawn upon arrival to the Emergency Department (if available) or hospital.~Biomarker blood draw"
61973835|NCT02599272|ACTIVE_COMPARATOR|Rice with vegetables and low spice|Dose 1 mixed spice session - rice with 6 g powdered mixed spices and 40 g polyphenol rich vegetables (onions, ginger and garlic)
61973836|NCT02599272|ACTIVE_COMPARATOR|Rice with vegetables and high spice|Dose 2 mixed spice session - rice with 12 g powdered mixed spices and 80 g polyphenol rich vegetables (onions, ginger and garlic)
61973837|NCT03916198|EXPERIMENTAL|PDRN(polydeoxyribonucleotide)|polydeoxyribonucleotide 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
61973838|NCT03916198|PLACEBO_COMPARATOR|CONTROL(normal saline)|normal saline 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
61973839|NCT05120297|EXPERIMENTAL|AK101|
61973840|NCT05120297|PLACEBO_COMPARATOR|Placebo|
61973841|NCT05738005|OTHER|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|MyFitnessPal smartphone application is used to track daily dietary intake and herbal/alternative supplements.
61973842|NCT03210597|EXPERIMENTAL|hydro-aerobic|Water aerobics exercise
61973843|NCT03210597|EXPERIMENTAL|hydro-power|Resistance water exercise
61973844|NCT03210597|EXPERIMENTAL|hydro-combined|Water aerobics and resistance water exercise
62354841|NCT03228498|EXPERIMENTAL|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day~concomitant administration"
62354842|NCT03228498|PLACEBO_COMPARATOR|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only~concomitant administration"
62354843|NCT04624217|EXPERIMENTAL|SHR-1701|SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel
62516289|NCT03897478||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn. Control group matched with ischemic stroke subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
62516290|NCT04997655||Upper Transabdominal Plain Block|All patients in this group are routinely administered general anesthesia. After extubation, the subcostal transverse abdominis area block was directed laterally along the rectus abdominis muscle by finding the linea alba under the xiphoid region under ultrasound guidance with a 22G echogenic block needle, and 20 ml (8 ml 0.5% bupivacaine, 7 ml prilocaine) into the fascia between the rectus abdominis and transverse abdominis muscles. , 5 ml of saline) drug mixture will be performed by the anesthesiologist in charge of that day, who is not aware of the observational measurement to be made, if there is an indication, as a blind practitioner.
61973845|NCT00233103|EXPERIMENTAL|Sertraline|Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg).
61973846|NCT00233103|PLACEBO_COMPARATOR|Placebo|Placebo for 10 weeks.
61973847|NCT04309188|EXPERIMENTAL|Stroboscopic Training Group|Treatment group, which will receive stroboscopic training during hitting and fielding drills. The glasses look like sunglasses but have liquid crystal technology that causes a flicker from clear to opaque. The glasses flickering will be controlled on the side of the glasses by the researcher. When the athlete can complete a skill proficiently by catching or hitting during training the level of flickering will be increased to challenge the visual system more.
61973848|NCT04309188|ACTIVE_COMPARATOR|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
61973849|NCT05604222|EXPERIMENTAL|Mirabegron|Mirabegron for 8 weeks
62147811|NCT01823406|EXPERIMENTAL|Type 1 Diabetes with advanced complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
62147812|NCT01823406|EXPERIMENTAL|Aged and sex matched healthy control volunteers|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
62147813|NCT05064072|EXPERIMENTAL|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
62147814|NCT05064072|EXPERIMENTAL|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube
62147815|NCT05064072|ACTIVE_COMPARATOR|Silk plaster|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube
62147816|NCT03879265||Study group|No intervention. Couples who come to the study center to carry out a PGT-A cycle will be selected. Only couples that will use their own gametes will be selected and the indication of PGT-A will be advanced maternal age, failure of implantation, repeat abortion, male factor or structural chromosomal alterations. The results of chromosomal status of the embryo will be compared using the NICS and the conventional invasive method (PGT-A).
62354844|NCT04763590|EXPERIMENTAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) had 3 principal components: (1) psychoeducation, (2) cognitive restructuring, and (3) exposure. In this treatment, derived from an empirically-supported treatment for panic disorder, psychoeducation consisted of teaching about the interrelationship between thoughts, feelings, and physical sensations during weaning. The cognitive component taught patients how to challenge their thoughts, with a particular focus on identifying thoughts that over-estimated the probability of negative medical events. The behavioral component consisted of reducing the need for mechanical ventilation in a step-wise, graduated, manner.
62354845|NCT02659475|EXPERIMENTAL|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
62354846|NCT05923892|EXPERIMENTAL|3 dose groups of OPS-2071|OPS-2071 tablets, 50 mg OPS-2071 tablets, 100 mg OPS-2071 tablets, 200 mg Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
62354847|NCT05923892|PLACEBO_COMPARATOR|placebo group|Placebo tablets Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
62354848|NCT06056128|EXPERIMENTAL|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures performed using the Galaxy System.
62354849|NCT01566591|SHAM_COMPARATOR|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
62354850|NCT01566591|ACTIVE_COMPARATOR|Deep TMS Treatment|Deep TMS treatment is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions.
62354851|NCT02621619|EXPERIMENTAL|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
62354852|NCT02621619|PLACEBO_COMPARATOR|Normal saline + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
62516291|NCT04997655||Opioid analgesia|All patients in this group are routinely administered general anesthesia. Apart from this, in the other group, which does not have peripheral nerve block and only routine opioid analgesia is considered sufficient, only routine peroperative USG diaphragm measurements will be recorded observationally.
62516292|NCT02668822|EXPERIMENTAL|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
62516293|NCT02668822|PLACEBO_COMPARATOR|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
62516294|NCT02171390|ACTIVE_COMPARATOR|Daily testosterone transdermal gel|
61973850|NCT05604222|EXPERIMENTAL|Mirabegron plus Brief Behavioral Treatment for Insomnia (BBTI)|Mirabegron for 8 weeks and a 4 week behavioral intervention for insomnia
62516295|NCT02171390|ACTIVE_COMPARATOR|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
62516296|NCT05440630|EXPERIMENTAL|Probiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
62516297|NCT05440630|EXPERIMENTAL|Postbiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (Heat treated bacteria) for 16 weeks.
61973851|NCT00106392|EXPERIMENTAL|Tacrolimus|Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
61973852|NCT00106392|PLACEBO_COMPARATOR|Placebo|Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.
62516298|NCT05440630|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
62516299|NCT04154826|EXPERIMENTAL|low dose|CYT107 10µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 10µg/kg/week for 4 weeks (wk9-12)
62516300|NCT04154826|EXPERIMENTAL|high dose|CYT107 20µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 20µg/kg/week for 4 weeks (wk9-12)
62516301|NCT01497626|EXPERIMENTAL|Bortezomib plus lapatinib|Combination treatment with lapatinib and bortezomib
62516302|NCT02536235|EXPERIMENTAL|Intervention: intraoperative topical heat|
62516303|NCT02536235|NO_INTERVENTION|Control: no intraoperative heat|
61973853|NCT03253250|ACTIVE_COMPARATOR|Group A|The subjects will be treated by NAs (ETV, 0.5mg，qd；TDF，300mg，qd；ADV，10mg，qd）for 96 weeks
61973854|NCT03253250|EXPERIMENTAL|Group B|The subjects will be treated by peginterferon alfa-2a （135μg/week）combination with NAs(ETV\\TDF\\ADV) for 96 weeks.
61973855|NCT04488289|OTHER|Parallel measurement of blood pressure|Office blood pressure, self-directed and ambulatory blood pressure measurement.
62354853|NCT03556748|NO_INTERVENTION|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
62354854|NCT03556748|EXPERIMENTAL|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
62354855|NCT00595257|EXPERIMENTAL|1|injection of BMAC into ischemic limb
62354856|NCT00595257|ACTIVE_COMPARATOR|2|Injection and Infusion of BMAC into ischemic lower limb
62516304|NCT03213431||IQ of <90 and ≥40|Patient-Reported Outcomes (PRO) will be evaluated in a group of 30 childhood cancer survivors with global neurocognitive impairment classified by IQ of \<90 and ≥40 and 30 of their parents.
62516305|NCT03213431||IQ of ≥90|Patient-Reported Outcomes (PRO) will be evaluated in a group of 10 childhood cancer survivors with global neurocognitive unimpairment classified by IQ of ≥90 and 10 of their parents.
62516306|NCT01236157||Chest Pain|All patients that call to the SAMU-ACS because of chest pain are included
62516307|NCT01817192|ACTIVE_COMPARATOR|Observation|Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
61973856|NCT02496897|EXPERIMENTAL|FP-02.2 Low Dose|A low dose of the FP-02.2 vaccine.
61973857|NCT02496897|EXPERIMENTAL|FP-02.2 High Dose|A high dose of the FP-02.2 vaccine.
61973858|NCT02496897|EXPERIMENTAL|FP-02.2 Low Dose with IC31® Adjuvant|A low dose of the FP-02.2 vaccine with IC31® Adjuvant.
62516308|NCT01817192|ACTIVE_COMPARATOR|Adjuvant Chemotherapy|Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.
62516309|NCT01921491|OTHER|Standard of Care|Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice Offloading. Reassessment weekly at office visit.
62516310|NCT01921491|ACTIVE_COMPARATOR|Other Commercially Available Product|Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
62516311|NCT01921491|EXPERIMENTAL|dHACM|Application of dHACM with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
62516312|NCT01602471|EXPERIMENTAL|[F-18]RDG-K5|\[F-18\]RDG-K5 was administred and PET scan performed
62516313|NCT00809315|ACTIVE_COMPARATOR|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
62516314|NCT00809315|EXPERIMENTAL|Fostering Healthy Futures (FHF) Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
61973859|NCT02496897|EXPERIMENTAL|FP-02.2 High Dose with IC31® Adjuvant|A high dose of the FP-02.2 vaccine with IC31® Adjuvant.
61973860|NCT02496897|PLACEBO_COMPARATOR|Placebo|Placebo component.
62354857|NCT00425113|EXPERIMENTAL|Metronidazole|Metronidazole added to background TB treatment regimen during initial 2 months
62354858|NCT00425113|PLACEBO_COMPARATOR|Placebo|Placebo added to background TB treatment regimen during initial 2 months
61973861|NCT02496897|EXPERIMENTAL|IC31® Adjuvant|IC31® Adjuvant alone.
61973862|NCT02793141||ICU Nosocomial Pneumonia|Nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ward patients (= or \> 48 hours after hospital admission) that due to deterioration are subsequently admitted to ICU or nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ICU patients (= or \>48 hours after hospital admission) or ventilator-associated pneumonia with onset = or \> 48 hours after intubation. No intervention will be administered.
62516315|NCT01612884|OTHER|TEG|Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA\<69
61973863|NCT03489447||Sepsis group|All adult (\>= 18 years) patients with a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
61973864|NCT03489447||Non-sepsis group|All adult (\>=18 years) patients without a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
61973865|NCT03504150|EXPERIMENTAL|SPHERE|It is an online self-guided comprehensive cognitive-behavioural therapy program that offers a headache diary, learning modules that teach a variety of cognitive and behavioural skills to cope better with their headaches, and a discussion forum where users may interact.
62147817|NCT04942288|EXPERIMENTAL|Acupressure + Massage Group|"Acupressure + Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention. On the second day, VAS will be applied before and after the intervention. On the third day, VAS before and after the intervention VAS, GMSSS will be applied.~Second menstrual cycle~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
62147818|NCT04942288|EXPERIMENTAL|Massage Group|"Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention (1st hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied.~Second menstrual cycle~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
62147819|NCT04942288|NO_INTERVENTION|Control Group|"Control Group First menstrual cycle~- On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF-36 will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.~Second menstrual cycle - On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.~Third menstrual cycle~- On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS and Quality of Life Scale Short Form SF-12 will be applied."
62354859|NCT02908633|ACTIVE_COMPARATOR|canaloplasty ab externo and phacoemulsification|As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation
62354860|NCT02908633|ACTIVE_COMPARATOR|canaloplasty ab interno and phacoemulsification|This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.
62354861|NCT02908633|ACTIVE_COMPARATOR|minicanaloplasty and phacoemulsification|The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation
62354862|NCT01570933|EXPERIMENTAL|NAVAfirst|Starting crossover by NIVnava mode
62354863|NCT01570933|ACTIVE_COMPARATOR|Cpap first|Start crossover by Cpap on nasal canula
62354864|NCT04735393|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for two weeks.|
62354865|NCT04735393|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution QID for four weeks followed by BID for two weeks.|
62354866|NCT04735393|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for 11 months.|
62354867|NCT04735393|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution QID for four weeks followed by BID for 11 months.|
62354868|NCT00795171|EXPERIMENTAL|Docetaxel + Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
62354869|NCT00795171|ACTIVE_COMPARATOR|Taxotere|docetaxel 75mg/m2 day1 q 21d x 4 cycles
62354870|NCT04397796|EXPERIMENTAL|BM-Allo.MSC|Subjects in the experimental arm will be administered BM-Allo.MSC
62354871|NCT04397796|PLACEBO_COMPARATOR|Placebo|Subjects in the control arm will be treated with placebo
62516316|NCT01612884|OTHER|Light transmittance aggregometry|Clopidogrel non-response defined as MPA ADP \>42.9% Clopidogrel response defined as MPA ADP \<42.9%
62516317|NCT01788124||Metal Speculum|exam with metal speculum
62516318|NCT01788124||Plastic Speculum|exam with plastic speculum
61973866|NCT03504150|EXPERIMENTAL|PRISM|It is an online self-guided brief cognitive-behavioural therapy program that offers a headache diary and helps users discover their headache triggers and non-triggers. Then the program provides the users with a few personalized recommendations to help them to cope with their triggers.
61973867|NCT03504150|NO_INTERVENTION|Usual care|
61973868|NCT05985889|EXPERIMENTAL|Robotic|They performed training with a robot 15 times over 3 weeks.
62516319|NCT03494114|EXPERIMENTAL|COPD Patients|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ. In addition, PET imaging data will be compared with disease severity, based on pulmonary function testing.
62516320|NCT03494114|EXPERIMENTAL|Individuals without COPD|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ.
62516321|NCT05098002|EXPERIMENTAL|Mindful based stress classes|6 week mindfulness program
62516322|NCT05732181|EXPERIMENTAL|Lidocaine patch|
61973869|NCT05985889|EXPERIMENTAL|Fizio|They receive physiotherapy treatment.
62516323|NCT05732181|NO_INTERVENTION|Placebo|
62516324|NCT02715219|EXPERIMENTAL|intervention group|Subjects in intervention group will be given an appointment date to attend the an Asthma Education Programme.
62516325|NCT02715219|NO_INTERVENTION|control group|Subjects in control group will routinely go for the normal follow up in Respiratory Clinic without receive any intervention.
62516326|NCT01166555|EXPERIMENTAL|1|
62516327|NCT05189314||Thyroidectomy|Patients with benign thyroid nodules who undergo surgical resection
62516328|NCT05189314||RFA|Patients with benign thyroid nodules who undergo radiofrequency ablation
62516329|NCT04109313|EXPERIMENTAL|All participants|"Participants with UAS7\<16 at Week 16 of CLOU064A2201 were followed up to 12 weeks without receiving treatment (observational period). If participants relapsed (UAS7≥16 at least once), they were transitioned to the treatment period. Otherwise, they were discontinued from the study.~Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered 100 mg of LOU064 b.i.d. open-label for up to 52 weeks."
61973870|NCT05985889|EXPERIMENTAL|EXE1|Virtual reality treatment is performed once a day.
61973871|NCT05985889|EXPERIMENTAL|EXE2|Virtual reality treatment is performed twice a day.
62147820|NCT05919732|EXPERIMENTAL|Caudal Infusion|Awake continuous caudal infusion.
62354872|NCT01837017|EXPERIMENTAL|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb \& core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
62354873|NCT01837017|NO_INTERVENTION|Control|Wait-list control.
62354874|NCT01817647||PCT|Patients undergoing colorectal surgery with an anastomosis performed
62354875|NCT06379438|EXPERIMENTAL|Photodynamic Therapy (PDT) Group|Patients in the PDT group were treated in a single session on the day of admission to the clinic. Indocyanine green (Perio green, Elexxion AG, Radolfzell, Germany) prepared and applied according to manufacturer's instructions steps (mixing, application, soaking phase, rinsing, activation) in a concentration with 0.1mg/mL was administered via fine-needle syringe as the photosensitizer. Following the completion of topical application of the photosensitizer to the lesion surface, a (GaAlAs) diode laser device (Cheese Diode Laser, Wuhan Gigaa Optronics Technology Co. Ltd, China) in continuous mode (810 nm, 300 mW, 10,000 kHz, 1.26 cm2 spot area), with a 400 μm polymethylmethacrylate optical fiber tip, scanning from the periphery to the center of the lesion with an energy density of approximately 10 J/cm2 for 40 s and applied non-contact at a distance of 1 mm.
62354876|NCT06379438|NO_INTERVENTION|Control Group|The lesions of the patients in the control group were not treated but only followed up. Recommendations were made to reduce their pain (avoidance of hot, spicy and acidic foods, attention to oral hygiene, etc.)
62354877|NCT00554463|EXPERIMENTAL|Combined Modality Therapy with Growth Factor Support|Concurrent radiation therapy, cisplatin, etoposide, and filgrastim followed by adjuvant cisplatin, etoposide, and pegfilgrastim.
62516330|NCT00604227|EXPERIMENTAL|1|high altitude exposure
62516331|NCT04009889|ACTIVE_COMPARATOR|verum|probiotic bland with 5 different lactobacilli
62516332|NCT04009889|PLACEBO_COMPARATOR|placebo|Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
62516333|NCT03168321|EXPERIMENTAL|IDP-123 Lotion|Tazarotene 0.045% Lotion
62516334|NCT03168321|PLACEBO_COMPARATOR|IDP-123 Vehicle Lotion|Vehicle Lotion
62516335|NCT05516459||Three doses of vaccination|Subjects received three pfizer BNT162b2 vaccination at least four month before recruitment
61973872|NCT05985889|EXPERIMENTAL|EXE+ROB|Virtual and robotic treatments are performed once a day.
61973873|NCT03958955|EXPERIMENTAL|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 6 weeks
61973874|NCT03958955|PLACEBO_COMPARATOR|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 6 weeks
61973875|NCT05392998||Vivity patients|"The study will include patients \>40 years old that undergo routine cataract surgery and implantation of Vivity ®. Exclusion criteria include corneal astigmatism ≥1.0 diopters (D ), amblyopia, previous ocular surgery and presence of ocular pathologies and abnormal iris. Patients with intra- or postoperative complications, with a postoperative best distance corrected visual acuity (BDCVA) \< 20/20 and with postoperative refractive astigmatism \> 0.50D will be also excluded .~Inclusion and exclusion criteria will be assessed by an ophthalmologic examination including refraction, screening for ocular conditions and/or systemic diseases, slit-lamp biomicroscopy and fundus examination."
61973876|NCT01519414|EXPERIMENTAL|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62147821|NCT05919732|ACTIVE_COMPARATOR|General anesthesia|General anesthesia and single-dose caudal injection
62516336|NCT05516459||Four doses of vaccination|Subjects received three pfizer BNT162b2 vaccination at least four month before recruitment and decided to receive another dose at time of recruitment or followup
62516337|NCT02994355|EXPERIMENTAL|Intervention Clinics|Clinics randomized to the intervention will be introduced to the Systems Analysis and Improvement Approach (SAIA) to understand barriers to HIV testing in family planning clinics. Sequential process flow mapping will be used to highlight areas for improvement and then specific interventions will be implemented for the clinics with the goal of increasing HIV testing rates.
62516338|NCT02994355|NO_INTERVENTION|Control Clinics|Clinics randomized to the control arm of the study will continue HIV testing as per usual procedures.
62516339|NCT01352182|EXPERIMENTAL|Pioglitazone hydrochloride|Pioglitazone hydrochloride treatment group
62516340|NCT01352182|NO_INTERVENTION|Normal standard care|Normal standard care control group
62516341|NCT04623021|NO_INTERVENTION|Standard of Care|Standard of Care Treatment for COVID-19 Infection
61973877|NCT01519414|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
61973878|NCT04455802|ACTIVE_COMPARATOR|Morphine|Infants randomized to the morphine arm will start at a dose of 0.06 mg/kg/dose every 4 hours. A buprenorphine placebo will also be given at the same frequency as a faux drug.
61973879|NCT04455802|EXPERIMENTAL|Buprenorphine|"Infants randomized to the buprenorphine arm will be started on a dose of 10 mg/kg/dose every 8 hours. A morphine placebo will also be given at the same frequency as a faux drug.~Patients can only be randomized to only one arm."
61973880|NCT00774618|EXPERIMENTAL|Resection|Those subjects undergoing resection with or without plate fixation
62354878|NCT01882777|NO_INTERVENTION|Existing water management and cooking practices|Households in the control arm continue following their existing drinking water management and cooking practices
62354879|NCT01882777|ACTIVE_COMPARATOR|Provision of water filters and improved cookstoves|Households in intervention arm are provided with drinking water filters and improved cook stoves
62354880|NCT01225120|EXPERIMENTAL|Gait Training|
62354881|NCT03057951|EXPERIMENTAL|10 mg Empagliflozin|
62354882|NCT03057951|PLACEBO_COMPARATOR|Placebo|
62354883|NCT02899377|EXPERIMENTAL|Group A: Health subjects|During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)
62354884|NCT02899377|EXPERIMENTAL|Group B: pSS subjects|During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of \<=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)
62354885|NCT00810459|EXPERIMENTAL|Trilogy ventilator|Trilogy ventilator
62516342|NCT04623021|EXPERIMENTAL|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
61973881|NCT00774618|NO_INTERVENTION|Nonoperative|These patients were not considered candidates for surgical intervention by the investigators, declined surgical intervention, or did not receive insurance approval for surgery
62516343|NCT00736918|EXPERIMENTAL|Case management|Case management
61973882|NCT03824327|EXPERIMENTAL|Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)|Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.
62516344|NCT00736918|ACTIVE_COMPARATOR|Enhanced usual care|Enhanced usual care
62516345|NCT02442271|EXPERIMENTAL|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
62516346|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
61973883|NCT00061698|ACTIVE_COMPARATOR|Cognitive Behavior Therapy Child Only|Participants completed 20 sessions of CBT
61973884|NCT00061698|ACTIVE_COMPARATOR|CBT plus Parent training|Child participants completed 20 sessions of CBT and parents completed 8 sessions of parent training
61973885|NCT00061698|NO_INTERVENTION|Minimal Contact Control|Participants waited 12 weeks for treatment but their safety and well-being were monitored during this time
61973886|NCT03232957|EXPERIMENTAL|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
61973887|NCT03232957|EXPERIMENTAL|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
62354886|NCT00810459|ACTIVE_COMPARATOR|Standard of Care|Participants currently prescribed ventilator
62354887|NCT05200884|ACTIVE_COMPARATOR|: A (Lidocaine 2%)|"20 children will be injected with 1 ml of lidocaine 2% with epinephrine. each one received lidocaine2% at his\\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e. 20 injections will be distributed randomly to the two drugs using the randomization table"
62354888|NCT05200884|EXPERIMENTAL|B (Articaine 4%)|"20 children will be injected with 1 ml of Articaine 4% with epinephrine. each one received articaine 4% at his\\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e.20 injections will be distributed randomly to the two drugs using the randomization table"
62354889|NCT02790710|EXPERIMENTAL|Propanolol|Propranolol 40 mg capsule, given once after fear reactivation procedure
62516347|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
62516348|NCT03531008||Treatment-resistant focal epilepsy|Individuals with treatment-resistant focal epilepsy
62516349|NCT05727475|ACTIVE_COMPARATOR|Study group|In this group, a composite facing will be placed on the anterior incisors to mask the opacity. Minimal invasive treatment will be done without drilling or removal of enamel. They will be asked to fill in the Child Oral Health Impact Profile-Short Form (C-OHIP-SF19) questionnaire pre and 1 month post treatment.
62516350|NCT05727475|ACTIVE_COMPARATOR|Control group|"In this group, fluoride gel application will be done for all teeth using 1.23% APF gel delivered through a foam tray. They will be asked to fill in the Child Oral Health Impact Profile-Short Form (C-OHIP-SF19) questionnaire pre and 1 month post treatment.~After filling the C-OHIP-SF19 questionnaire 1 month post treatment, if the child is not happy with the appearance after fluoride gel application, a composite facing will be offered."
62516351|NCT04441099|EXPERIMENTAL|Dose-escalation Cohort (DEC)|Escalating doses of NBE-002 depending on cohort at enrollment.
62516352|NCT04441099|EXPERIMENTAL|Safety-expansion Cohort (SEC)|Dose to be determined based on DEC.
62516353|NCT04441099|EXPERIMENTAL|Expansion Cohort 1 (EC1)|Dose to be determined based on DEC and SEC.
62516354|NCT04441099|EXPERIMENTAL|Expansion Cohort 2 (EC2)|Dose to be determined based on DEC and SEC.
62516355|NCT05307159|EXPERIMENTAL|bean protein supplement|The supplement will be consumed daily for 21 days in the athletes' snack, the supplement contains 7 g of bean protein mixed in 60 mL of milk and 60 mL of strawberry drinkable yogurt
62516356|NCT00430950|EXPERIMENTAL|1|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ) 40/25 mg + OM/HCTZ 20/25 mg matching placebo
62516357|NCT00430950|EXPERIMENTAL|2|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ)20/25 mg + OM/HCTZ 40/25 matching placebo
62516358|NCT00350402|ACTIVE_COMPARATOR|High Intensity Muscle Strength Training|This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
62516359|NCT00350402|SHAM_COMPARATOR|Sham MST|This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.
62516360|NCT04128202|ACTIVE_COMPARATOR|Sunnyside|An online intervention to better manage mood during and after pregnancy.
62516361|NCT04128202|EXPERIMENTAL|Sunnyside Plus|An online intervention to better manage mood and promote and support breastfeeding during and after pregnancy.
62516362|NCT01780779||Osteosarcoma|"All patients with Osteosarcoma), proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURAMOS protocol)~An MRI will be performed before, during and post-treatment"
62516363|NCT01780779||Ewing Sarcoma|"All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURO-EWING protocol)~An MRI will be performed in all included patients before, during and after the chemotherapy"
62516364|NCT01680783|OTHER|Usual Care|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
62516365|NCT01680783|EXPERIMENTAL|Non invasive ventilation via helmet|Patients requiring more than 8 hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet instead of face mask for treatment of respiratory failure
62516366|NCT02098421|NO_INTERVENTION|Control|No oxytocin while the Foley bulb is in place
62710449|NCT00579644|ACTIVE_COMPARATOR|2 Methotrexate|"Methotrexate Dosing:~1. Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2. 2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~3. 4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~4. 6, 8 and 10 month evaluations:~   * If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~  * If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month~5. 12 month evaluation: End of the blinded portion of the study."
61973888|NCT03232957|EXPERIMENTAL|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
62516367|NCT02098421|EXPERIMENTAL|Oxytocin|Use of oxytocin while the Foley bulb is in place
62516368|NCT02098421|EXPERIMENTAL|PROMS Foley and oxytocin|Subjects who are induced due to premature rupture of membranes randomized to use of Foley bulb and oxytocin once the bulb is removed.
62516369|NCT02098421|NO_INTERVENTION|PROMS no Foley bulb|Subjects who are induced due to premature rupture of membranes randomized to no Foley bulb.
62516370|NCT00905788|NO_INTERVENTION|Control Group|Embryo transfer without any intervention
62516371|NCT00905788|EXPERIMENTAL|Embryo Expulsion|
62516372|NCT00419549|ACTIVE_COMPARATOR|1|Valdecoxib
62516373|NCT00419549|ACTIVE_COMPARATOR|2|
62516374|NCT00419549|NO_INTERVENTION|3|
62516375|NCT04588688|EXPERIMENTAL|Mifepristone|Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.
61973889|NCT05340608||Observation Group One|Twenty subjects with high functioning autism spectrum disorder, aged between 20 and 40 years, residing at home.
62516376|NCT00788593|PLACEBO_COMPARATOR|Placebo|
62516377|NCT00788593|EXPERIMENTAL|EUR-1008 (APT-1008) High Dose|
62516378|NCT00788593|EXPERIMENTAL|EUR-1008 (APT-1008) Low Dose|
62516379|NCT01564459|EXPERIMENTAL|MK-6096 10 mg→MK-6096 10 mg|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period.
62516380|NCT01564459|PLACEBO_COMPARATOR|MK-6096→Placebo|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.
62710450|NCT04234893||Drug-coated balloon|The Patients who treated with Bingo drug-coated balloon
62516381|NCT06273020|EXPERIMENTAL|Intravenous thrombolysis and cerebrolysin|"Group 1: 20 patients with previous intravenous thrombolysis (IVT) in the qualifying stroke and who agreed to receive and got selected (through randomization) cerebrolysin.~Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days"
62516382|NCT06273020|ACTIVE_COMPARATOR|Intravenous thrombolysis without cerebrolysin|Group 2 : 20 patients with previous IVT in the qualifying stroke and who agreed to receive cerebrolysin but they were not choose through randomization.
62516383|NCT06273020|OTHER|Patients with cerebrolysin without IVT|"Group 3: 20 patients that they were not candidates to receive IVT (out of therapeutic window) but agreed to receive cerebrolysin (randomization not used)~Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days"
62516384|NCT00253981|EXPERIMENTAL|Infrared Light Therapy|Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
62516385|NCT00253981|PLACEBO_COMPARATOR|Standard of Care|Standard of care was characterized by the use of standard medical treatment to include medication.
62710451|NCT04252014|NO_INTERVENTION|Non-Tobacco Messages|Participants in the control group will receive messages about health topics unrelated to tobacco use (e.g., sun safety). Messages will be delivered online through 4 brief study communications.
62710452|NCT04252014|EXPERIMENTAL|Hookah Tobacco Messages|Participants in the hookah tobacco messaging group will receive hookah tobacco public education messages delivered online through 4 brief study communications. Messages will communicate about the risks of hookah tobacco use in the following theme areas: 1) Health Harms; 2) Addictiveness; 3) Social Use; 4) Flavorings. The order of message themes delivered in each study communication will be randomized.
62710453|NCT06635863|EXPERIMENTAL|Immunosuppression|Prednisone 40mg x 8weeks + GDMT
61973890|NCT05340608||Control Group|Twenty typically-developed subjects matched for sex and age distribution with participants in the Observation Group One.
61973891|NCT05340608||Observation Group Two|This group will include ten people with autism spectrum disorders, aged between 20 and 40 years, residing at home and presenting aggressive or disruptive challenging behaviors, and their caregivers.
61973892|NCT05340608||Proof of Concept|One participant with autism spectrum disorder, aged between 20 and 40 years attending a special school and living at home and exhibiting aggressive or disruptive challenging behavior, and healthcare professionals and teachers who care for him in the school setting, will participate in the proof-of-concept phase of the present study.
61973893|NCT05075304|EXPERIMENTAL|A low dose of BDB-001|6 patients administered low dose of BDB-001 injection
61973894|NCT05075304|EXPERIMENTAL|A intermediate dose of BDB-001|6 patients administered intermediate dose of BDB-001 injection
61973895|NCT05075304|EXPERIMENTAL|A high dose of BDB-001|3-6 patients administered high dose of BDB-001 injection
61973896|NCT06208228|EXPERIMENTAL|kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
61973897|NCT06208228|NO_INTERVENTION|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
61973898|NCT06208891||Robotic myomectomy|Women who received robotic myomectomy
61973899|NCT03680573|ACTIVE_COMPARATOR|Control- Lactated Ringers|This site will serve as the control site and will receive lactated Ringer's (saline solution) at an infusion rate of 2 µl/min.
62354890|NCT02790710|PLACEBO_COMPARATOR|Placebo capsule|Placebo capsule, given once after fear reactivation procedure
62516386|NCT02612454|EXPERIMENTAL|Body weight ≥60 kg|Administered every two weeks (Q2W)
61973900|NCT03680573|EXPERIMENTAL|Apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone)|This site will receive 100 µM apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone) at an infusion rate of 2 µl/min.
61973901|NCT03680573|EXPERIMENTAL|Allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)|This site will receive 10 µM allopurinol (1H-pyrazolo\[3,4-d\]pyrimidin-4(2H)-one)at an infusion rate of 2 µl/min.
61973902|NCT03680573|EXPERIMENTAL|BH4 ((6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride)|This site will receive 10 mM (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) at an infusion rate of 2 µl/min.
61973903|NCT04367220||Patients with known or suspected cardiovascular disease|All patients with known or suspected cardiovascular disease are studied with a-priori stratification of specific disease-based cohorts.
62516387|NCT02612454|EXPERIMENTAL|Body weight 30 kg to <60 kg|Administered Q2W
62516388|NCT02612454|EXPERIMENTAL|Body weight 15 kg to <30 kg|Administered every 4 weeks (Q4W)
62516389|NCT02612454|EXPERIMENTAL|Body weight 5 kg to <15 kg|Administered Q4W
62516390|NCT01733147|PLACEBO_COMPARATOR|Placebo|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive a placebo which looks exactly like the study drug, but contains no active ingredient, to be taken orally for six months.
62516391|NCT01733147|ACTIVE_COMPARATOR|Omega-3 polyunsaturated fatty acids|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive Omega-3 free fatty acids supplements to be taken orally for six months.
61973904|NCT00940251|PLACEBO_COMPARATOR|CORN STARCH|
62354891|NCT05082064||MELD score group A|MELD score :group A\<25
62516392|NCT00654654|EXPERIMENTAL|Active|
62710454|NCT06635863|NO_INTERVENTION|Standard of Care|GDMT alone
62710455|NCT01563055|EXPERIMENTAL|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
62710456|NCT01599286|EXPERIMENTAL|Active Comparator|Parallel Trial Comparing NCG + Standard of Care Treatment
62354892|NCT05082064||MELD group B|Group B\>25
62354893|NCT05082064||MELD-PACO2 Group C|Group C\<25
62354894|NCT05082064||MELD -PACO2 Group D|Group D\>25
62354895|NCT05082064||MELD-BICARBONATE score Group E|Group E\<23
62354896|NCT05082064||MELD-BICARBONATE Group F|Group F\>23
62354897|NCT05610657|EXPERIMENTAL|Mitapivat|Mitapivat tablet as a single oral dose, under fasted conditions on Day 1 to compare participants with normal hepatic function to participants with moderate hepatic function (Child-Pugh \[C-P\] Score B, score of 7 to 9).
62710457|NCT01599286|ACTIVE_COMPARATOR|Placebo Comparator|Placebo and Standard of Care Therapy
62147822|NCT01750424|EXPERIMENTAL|Fat Grafted|The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.
62147823|NCT01750424|PLACEBO_COMPARATOR|Non-fat grafted|The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.
61973905|NCT00940251|ACTIVE_COMPARATOR|Mersina, Diet and exercise|
61973906|NCT00426491|ACTIVE_COMPARATOR|A|Four 200 ug tablets of Misoprostol
62354898|NCT04948814|EXPERIMENTAL|ASD children|20 ASD children who meet the eligibility requirements will receive a fecal microbiota transplantation following a 2-week treatment with Vancomycin (40mg/kg/day) after 3 month waiting period. Fresh stool sample will be obtained from the donor. Fecal bacteria transplantation will be achieved via endoscopy, nasogastric/nasointestinal tubes, the proximal colon by colonoscopy, or the distal colon by enema, rectal tube, or sigmoidoscopy or a combined approach. The amount of fecal bacterial liquid transplantation for children is 5ml/kg each time. Fecal microbiota transplantation will be conducted at week 3-4, week 6-7, week 9, week 11 and week 13 for total 5 round.
62354899|NCT03966729||HFrEF|"HFrEF (Heart failure with reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF \< 40%.~LVEF = Left ventricular ejection fraction"
61973907|NCT00426491|PLACEBO_COMPARATOR|B|
62147824|NCT03163472|ACTIVE_COMPARATOR|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
62354900|NCT03966729||HFmrEF|"HFmrEF (Heart failure with mid-range reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF 40-49%.~LVEF = Left ventricular ejection fraction"
62354901|NCT03966729||HFpEF|"HFmrEF (Heart failure with preserved ejection fraction): ESC Guideline heart failure 2016: patients with LVEF \> 50%.~LVEF = Left ventricular ejection fraction"
62354902|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter \<3 mm.
62354903|NCT04961086|EXPERIMENTAL|energy drink arm|an open label branded energy drink which contains any one or more of the following ingredients: caffeine, ginseng, taurine
62710458|NCT05982093|EXPERIMENTAL|Elacestrant|without ovarian function suppression
61973908|NCT01026467||Supportive Care (frailty index, geriatric assessment, chemo)|Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy. Patients receive standard-of-care chemotherapy comprising carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses
61973909|NCT01883843|EXPERIMENTAL|real tDCS + TOCT|"Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode.~The current reaches 0.5mA and decreases with a ramp of 10 seconds."
61973910|NCT01883843|ACTIVE_COMPARATOR|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
61973911|NCT00686660|EXPERIMENTAL|1|C-W G: in training period, patients do cycling on cycle ergometry at hospital. in non-training period, patients walk at community.
61973912|NCT00686660|OTHER|2|C-nonW G: in training period, patients do cycling at cycle ergometry at hospital, in non-training period, patients don't walk at community.
61973913|NCT00686660|EXPERIMENTAL|3|W-W G: in training period, patients do walking along 60 meters place at hospital, in non-training period, patients do walking in community
62354904|NCT04961086|ACTIVE_COMPARATOR|tea 5gm sugar arm|the usual easily available black tea with sugar 5 grams, and milk
62354905|NCT00222417||Myringoplasty|Patients subject to myringoplasty for tympanic membrane perforations.
62354906|NCT00222417||Otosclerosis|Patients subject to stapes surgery
62354907|NCT05019651|EXPERIMENTAL|Single Arm- Apollo Wearable System|Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
62710459|NCT05982093|ACTIVE_COMPARATOR|Elacestrant + Triptorelin|with ovarian function suppression
62710460|NCT02017184|EXPERIMENTAL|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
62710461|NCT00699595||Term pregnant women|Healthy women scheduled for elective Cesarean section.
62710462|NCT01730430||Collection of CSF|"1. Those with Alzheimer's disease~2. Those with non-Alzheimer's disease dementia~3. Healthy elderly volunteers"
62147825|NCT03163472|EXPERIMENTAL|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
62147826|NCT02322645|EXPERIMENTAL|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
62147827|NCT02322645|ACTIVE_COMPARATOR|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
62516393|NCT03354455|EXPERIMENTAL|REAL TMS|30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.
61973914|NCT00686660|OTHER|4|W-nonW G: in training period, patients do walking along 60 meter place, in non-training period,patients don't walk at community.
61973915|NCT02267811|EXPERIMENTAL|Fixed Orthodontic Treatment with OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
62354908|NCT01826526|ACTIVE_COMPARATOR|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
62354909|NCT01826526|PLACEBO_COMPARATOR|Saline solution 0.9%|"5 ml of saline will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of saline administration in this trial will be 12 months."
62710463|NCT03891888|NO_INTERVENTION|Control|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
62710464|NCT03891888|EXPERIMENTAL|Intervention|Patients in this group will receive a bone graft in addition to the undergoing standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
61973916|NCT02267811|EXPERIMENTAL|Fixed Orthodontic Treatment|Subjects assigned to this group receive orthodontic treatment with no OrthoPulse™ treatment.
61973917|NCT03746873|EXPERIMENTAL|COPD Web|Participants randomised to experimental group will be introduced to the COPD Web by a letter containing written information. All participants will receive a pedometer and written information about the importance of physical activity.
61973918|NCT03746873|NO_INTERVENTION|Control|Other than receiving a pedometer and written information about the importance of physical activity the patients in the control group will not receive any intervention.
61973919|NCT04502953|ACTIVE_COMPARATOR|Vertical plication|Vertical plication of the rectovaginal septum was done
61973920|NCT04502953|ACTIVE_COMPARATOR|Horizontal plication|Horizontal plication of the rectovaginal septum was done
62354910|NCT03267771|ACTIVE_COMPARATOR|progesterone suppositories vaginal group|vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.
62354911|NCT03267771|EXPERIMENTAL|Dydrogesterone oral tablets group|20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.
62354912|NCT05491447|ACTIVE_COMPARATOR|Study Drug Treated, BMX-010 0.5%|n=72
62354913|NCT05491447|ACTIVE_COMPARATOR|Study Drug Treated, BMX-010 0.1%|n=72
62354914|NCT05491447|PLACEBO_COMPARATOR|Placebo Treated|n=72
62354915|NCT04254432|EXPERIMENTAL|remote ischemic conditioning arm|Device: remote ischemic conditioningRIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 30+/-2days. Other Names:• RICDevice: ambulatory blood pressure monitoring diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment
62516394|NCT03354455|SHAM_COMPARATOR|SHAM TMS|30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.
62516395|NCT01333072|ACTIVE_COMPARATOR|Risperidone|Atypical antipsychotic
62516396|NCT01333072|ACTIVE_COMPARATOR|Aripiprazole|Atypical antipsychotic
62710465|NCT00786422|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|
62710466|NCT05470400|EXPERIMENTAL|Dose Escalation - Group 1|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
62147828|NCT00798863|EXPERIMENTAL|operative group|The patients of the group will have the operation of two step video assisted submandibular sialadenectomy.
62147829|NCT02142309|EXPERIMENTAL|Glimepiride|up to 4 mg/day
62147830|NCT02142309|EXPERIMENTAL|Vildagliptin|50 mg bid
62147831|NCT02142309|EXPERIMENTAL|Pioglitazone|up to 30 mg/day
62147832|NCT02142309|EXPERIMENTAL|Canagliflozin|300 mg/day
62147833|NCT02874391||AV fistula group|
62147834|NCT02874391||Control group|
62147835|NCT01404637|EXPERIMENTAL|Tamsulosin 0.4mg|
62147836|NCT01404637|ACTIVE_COMPARATOR|tamsulosin 0.2mg|
62147837|NCT01065532|ACTIVE_COMPARATOR|1|SeQuent Please Drug-eluting balloon
62147838|NCT01065532|ACTIVE_COMPARATOR|2|Xience V Drug-eluting stent
62147839|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
62147840|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
62147841|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
62147842|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
62147843|NCT01005615|SHAM_COMPARATOR|No FES Cycling|
62147844|NCT01005615|ACTIVE_COMPARATOR|FES Cycling|
62147845|NCT01347294|EXPERIMENTAL|Bleomycin + Fibrovein|"1) Fibrovein 3% foamed with air 50/ 50. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.~2) wait 5 minutes~3) Bleomycin 1000 iu / ml. Injected volume same as volume of Fibrovein foam."
62516397|NCT00204022|EXPERIMENTAL|1|Mycophenolate mofetil (target dose 2g/day)
62516398|NCT00204022|ACTIVE_COMPARATOR|2|Azathioprine (target dose 2mg/kg/day)
62516399|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
62516400|NCT06030349||Standard|In addition to data from clinical assessment, sleep studies and non-invasive ventilator downloads recorded as part of standard care participants will undergo questionnaire assessment of behaviour, quality of life and barriers to tolerating treatment. Participants aged 3 years and above will receive the Child Sleep Habits Questionnaire, Obstructive Sleep Apnoea-18 questionnaire and Adherence Barriers to CPAP (Continuous Positive Airway Pressure) Questionnaire. Participants aged 6 months to 3 years will receive the Brief Infant Sleep Questionnaire, Infant Toddler Quality of Life - Short Form 47, Obstructive Sleep Apnoea -18 Caregiver Concern Domain and a modified version of the Adherence Barriers to CPAP Questionnaire.
62516401|NCT06030349||Advanced|In addition to all elements of the standard testing group, a sub-group of up to 20 participants will be invited to take part in 45-60 minute semi-structured interviews exploring expectations, experiences and barriers encountered.
62516402|NCT05205018|EXPERIMENTAL|Motivational Interviewing Arm|This Arm will receive a remote intervention (via videacalls) based on motivational interviewing to improve self-care. The intervention will be delivered seven time over 12 months.
62516403|NCT05205018|NO_INTERVENTION|Standard care Arm|This Arm will receive the standard of care.
62516404|NCT00751738|EXPERIMENTAL|1|125 mg azimilide
62516405|NCT01783002|EXPERIMENTAL|Primary hyperparathyroidism|Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
62516406|NCT04445064|EXPERIMENTAL|Arm A: IO102 vaccine|Randomization between arm A and B. Patients in arm A will receive IO102 3 to 4 times prior to curative treatment
62516407|NCT04445064|NO_INTERVENTION|Arm B: Control group|Randomization between arm A and B
62516408|NCT04445064|EXPERIMENTAL|Arm C: IO103|No randomization. Patients in arm C will receive IO103 3 to 4 times prior to curative treatment
62516409|NCT05302921|EXPERIMENTAL|All patients|"Patients less than 40 years old with relapsed/refractory solid tumors and at least 2 sites of measurable disease will receive the current pediatric RP2D of nivolumab and ipilimumab for one cycle and undergo cryoablation therapy of one tumor site. Patients will continue to receive cycles of checkpoint inhibition as long as there is no disease progression of unacceptable toxicity (maximum of 13 cycles \[12 months\]).~There are 4 patient cohorts:~1. Osteosarcoma~2. Ewing sarcoma~3. Rhabdomyosarcoma~4. All other solid tumors (non-statistical)"
62516410|NCT04088266|OTHER|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA® sublingual film 16 mg buprenorphine with 4 mg naloxone
62516411|NCT01584531|EXPERIMENTAL|21-Day Regimen|560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle
62516412|NCT03676166|EXPERIMENTAL|0mg THC smoked cannabis|placebo smoked cannabis
62516413|NCT03676166|EXPERIMENTAL|10mg THC smoked cannabis|smoked cannabis containing 10mg THC
62516414|NCT03676166|EXPERIMENTAL|25mg THC smoked cannabis|smoked cannabis containing 25mg THC
62516415|NCT03676166|EXPERIMENTAL|0mg THC vaporized cannabis|placebo vaporized cannabis
61973921|NCT06186011|ACTIVE_COMPARATOR|Wire-guided|Wire guided localization (WGL) is considered the standard method for intraoperative localization of non-palpable breast lesions, chosen by many centers worldwide. It involves the placement of a wire or barbed needle that is percutaneously introduced into the lesion using a guide. It is cost-effective, easy to place guided by ultrasound or stereotaxis, allows for repositioning in case of error, and its safety and efficacy have been widely demonstrated in the literature.
62354916|NCT04344145||Target Group|This group includes frontline healthcare workers who are actively involved in the management of the Covid-19 outbreak: from emergency units, non-intensive Covid-19 and intensive Covid-19 units. They will fill self-reported questionnaires and scales upon their inclusion.
62354917|NCT04344145||Control group|"This group includes healthcare workers who are actively involved in usual medical care units, referred in this study as non-Covid-19 units. They will fill same self-reported questionnaires and scales than those filled in the Target group, also upon their inclusion.This group will be the comparator of the Target Group to assess the frontline Covid-19 condition."
62516416|NCT03676166|EXPERIMENTAL|10mg THC vaporized cannabis|vaporized cannabis containing 10mg THC
61973922|NCT06186011|ACTIVE_COMPARATOR|Intraoperative Ultrasound|The use of intraoperative ultrasound (IOUS) is an effective method that is controlled by the surgeon and does not require the involvement of other departments or preoperative invasive procedures. IOUS has been introduced into clinical practice as a tool for visualizing non-palpable tumors, demonstrating the detection of nearly 100% of lesions, and a rate of negative margins and re-excision similar to WGL. One of the challenges of the technique in ultrasound-guided surgery arises when the tumor is \<5mm, making it difficult to visualize by ultrasound, or when there are microcalcifications not visible by ultrasound.
62516417|NCT03676166|EXPERIMENTAL|25mg THC vaporized cannabis|vaporized cannabis containing 25mg THC
62516418|NCT04762459|ACTIVE_COMPARATOR|Almonertinib|Drug: Almonertinib 110 mg A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.
62516419|NCT04762459|EXPERIMENTAL|Almonertinib/Pemetrexed/Cisplatin|"Drug: Almonertinib 110 mg Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years."
62539487|NCT06362694|EXPERIMENTAL|Intervention group|Patients with BRAF-positive anaplastic thyroid cancer who were previously treated with dabrafenib and trametinib (with a clinical or objective response at the start of treatment) and later with tumor progression during anti-BRAF therapy with the transition to at least one line of chemotherapy (treatment with taxane-containing regimens is mandatory) followed by progression on it.
62147846|NCT01347294|ACTIVE_COMPARATOR|Bleomycin|Bleomycin 1000 iu/ ml. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.
62516420|NCT04762459|ACTIVE_COMPARATOR|Pemetrexed/Cisplatin|"Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. If disease progresses during the treatment period and conditions required for the cross-treatment are met according to the assessment process, the patient can start to receive the open cross-treatment of Almonertinib. The overall treatment last for 3 years."
62516421|NCT06229821|OTHER|Intervention group|
62516422|NCT01005706|ACTIVE_COMPARATOR|Tacrolimus Withdrawal Arm|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
62516423|NCT01005706|ACTIVE_COMPARATOR|Tacrolimus Minimization Arm|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
62710467|NCT05470400|EXPERIMENTAL|Dose Escalation - Group 2|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
62354918|NCT01245764|EXPERIMENTAL|GARDASIL™ 9 to 12 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
62147847|NCT01347294|EXPERIMENTAL|Natrium Tetradecyl Sulphate (Fibrovein )|Fibrovein 3% foamed with air 50/ 50. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.
62147848|NCT06510868||Previous PRRT|Patients who have received PRRT within the last 4 years. There are no baseline levels available for cohort A patients. Sample size: 20.
62147849|NCT06510868||Planned for PRRT|Patients who are scheduled to start PRRT in the next 3 months. Pre-PRRT clonal expansion status will only be available form this cohort. These patients will provide a comprehensive record of development of CH from exposure to PRRT. Sample size: 20.
62354919|NCT01245764|EXPERIMENTAL|GARDASIL™ 13 to 15 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
62354920|NCT01245764|EXPERIMENTAL|GARDASIL™ 16 to 26 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
62354921|NCT01245764|PLACEBO_COMPARATOR|Placebo 9 to 12 Years Old|Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
62354922|NCT00592917|ACTIVE_COMPARATOR|Ia|1718 subjects randomised for active calcium and vitamin-D -intervention, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except Ib (every four months)
62354923|NCT00592917|ACTIVE_COMPARATOR|Ib|random sample of 292 of 1718 (Ia), data collection by questionnaires mentioned in Ia, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
62354924|NCT00592917|NO_INTERVENTION|IIa|1714 subjects randomised to no intervention group, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except IIb (every four months)
62354925|NCT00592917|NO_INTERVENTION|IIb|random sample of 314 of 1714 (IIa), data collection by questionnaires mentioned in IIa, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
62354926|NCT01838590|EXPERIMENTAL|SOF+RBV 12 Weeks|Participants will receive SOF+RBV for 12 weeks.
62354927|NCT01838590|EXPERIMENTAL|SOF+RBV 24 Weeks|Participants will receive SOF+RBV for 24 weeks.
62354928|NCT00397878|EXPERIMENTAL|Treatment (saracatinib)|Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62354929|NCT06185894|PLACEBO_COMPARATOR|conservation without the use of a tourniquet|surgical conservation of placenta accreta spectrum cases with Kasr alainy conservative management technique, without the use of a tourniquet
62354930|NCT06185894|ACTIVE_COMPARATOR|conservation with the use of a tourniquet|surgical conservation of placenta accreta spectrum cases with Kasr alainy conservative management technique, with the use of a uterovesical tourniquet before fetal extraction
62354931|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
62354932|NCT00051090|EXPERIMENTAL|A|All eligible study participants
62354933|NCT01634464||Control group|women with 18.5 \> BMI \< 25
62354934|NCT01634464||Pregnant women with overweight|BMI≥25 before the pregnancy
62354935|NCT01634464||Pregnant women with obesity|BMI≥30 before the pregnancy
62354936|NCT01634464||Pregnant women with gestational diabetes|Gestational diabetes
62354937|NCT01618318||General asthma population|People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
61973923|NCT06186011|ACTIVE_COMPARATOR|Radioactive seed|Radioactive seeds are composed of a titanium capsule with an I-125 filament inside. They have low radioactivity, which can range from 7 to 200 μCi. During surgery, the seeds are detected using a portable gamma ray detection probe typically used for sentinel lymph node biopsy, configured to detect an I-125 source (27 keV). This probe has a wide detection range through tissue (\>10 cm), currently offering the greatest detection range compared to other available localization devices. Radioactive seed localization (RSL) require coordination between the radiology and nuclear medicine departments for marking. The results in terms of lesion localization and margin involvement rates are comparable to WGL.
62516424|NCT04062994||Intervention Group|All patients scheduled for surgery at a UCLA site in the one year period after go-live
61973924|NCT00869531|EXPERIMENTAL|WW|wholegrain wheat
62516425|NCT01434576|EXPERIMENTAL|HGS1025 2 mg/kg|
62516426|NCT01434576|EXPERIMENTAL|HGS1025 10 mg/kg|
62516427|NCT01434576|PLACEBO_COMPARATOR|Placebo|
62516428|NCT04760392|EXPERIMENTAL|GDM|Goal-directed mobilization
61973925|NCT00869531|ACTIVE_COMPARATOR|RW|refined wheat
62354938|NCT02693236|EXPERIMENTAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
62516429|NCT04760392|NO_INTERVENTION|Control|Standard of care
62516430|NCT01465282|EXPERIMENTAL|0.05% (w/w) CT327 ointment|0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
62516431|NCT01465282|EXPERIMENTAL|0.1% (w/w) CT327 ointment|0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
62516432|NCT01465282|EXPERIMENTAL|0.5% (w/w) CT327 ointment|0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
62516433|NCT01465282|PLACEBO_COMPARATOR|Placebo ointment|Placebo ointment
62516434|NCT02854059|EXPERIMENTAL|Treatment IdeS (0.25 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of safety and efficacy in 3 patients receiving 0.25 mg/kg there will be a potential to increase the IdeS dose to 0.5 mg/kg for the remaining 3 patients.
62516435|NCT02854059|EXPERIMENTAL|Treatment IdeS (0.50 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.50 mg/kg).
61973926|NCT01096524|OTHER|Control group standard physiotherapy|Standard pathway of care pre-and post-TKA without using NMES.
61973927|NCT01096524|EXPERIMENTAL|Kneehab|Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
61973928|NCT02763189|ACTIVE_COMPARATOR|Control|Control group will study the learning material independently. 'Self-study'.
61973929|NCT02763189|EXPERIMENTAL|Mentored|Mentored group will study the learning materials and then receive expert mentoring
61973930|NCT02136524|EXPERIMENTAL|Capsule formulation|
62354939|NCT03805971||patient aged more than 18 years admitted for thoracoscopy|Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies
62354940|NCT00617591|EXPERIMENTAL|Induction and Maintenance Therapy|"Induction Phase Followed by Maintenance Therapy.~Patients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.~At the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.~Dd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description."
62354941|NCT00943085|EXPERIMENTAL|Family-focused therapy|Participants will receive family-focused therapy.
62354942|NCT00943085|ACTIVE_COMPARATOR|Brief educational treatment|Participants will receive one session of diagnostic feedback, recommendations for continued treatment, and crisis intervention as needed.
62354943|NCT01847898|EXPERIMENTAL|Vertebral Body Stenting (VBS)|
62354944|NCT01847898|EXPERIMENTAL|Balloon Kyphoplasty|
62354945|NCT01847612|EXPERIMENTAL|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
62354946|NCT01847612|ACTIVE_COMPARATOR|methylene blue|injection of methylene blue during the surgery
62354947|NCT02700919|EXPERIMENTAL|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
62354948|NCT02700919|EXPERIMENTAL|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
62354949|NCT02700919|PLACEBO_COMPARATOR|Regimen 3|Placebo Day 1 to Day 5
62354950|NCT01520584|ACTIVE_COMPARATOR|vitamale|
62354951|NCT01520584|PLACEBO_COMPARATOR|sham pill|
62354952|NCT02549248||Idiopathic interstitial diseases|" Test group : patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
62354953|NCT02549248||Non idiopathic intertitial diseases|" Control group : patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
62354954|NCT01977248|EXPERIMENTAL|SMART therapy|The Sensorimotor Affect Relationship-based Therapy (SMART) program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
62354955|NCT06314997|EXPERIMENTAL|RAS unmutated CTCs HER positive|
62539488|NCT06633341|EXPERIMENTAL|Administration of CD5+ T-lymphoma Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62539489|NCT02045589|EXPERIMENTAL|Dose Escalation, Combination|Three intratumoral administrations of VCN-01 oncolytic adenovirus every 28 days in combination with Abraxane® and Gemcitabine.
62539490|NCT00299286|EXPERIMENTAL|Lapatinib|lapatinib oral 1500mg daily taken as 6 tablets as one dose 10-14 days presurgery
62516436|NCT04746599|EXPERIMENTAL|Patients with critic limb ischemia|"Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions.~After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs."
62516437|NCT05329493|EXPERIMENTAL|Cooling digit device application|Device: Cooling digit device. The cooling finger device will be applied in the subjects on their right hand. Subjects will serve as their own control.
62516438|NCT05513716||All patients|Colorectal cancer patients
62516439|NCT05859321|EXPERIMENTAL|virtual reality|virtual reality exercises will be administered along with routine physiotherapy
62516440|NCT05859321|ACTIVE_COMPARATOR|Routine Physiotherapy (treatment as usual)|transcutaneous electrical nerve stimulation,Heat Therapy, Stretching and strengthening exercises with Cycling will be administered
62516441|NCT03523247|EXPERIMENTAL|Whole Food Plant Based Diet|Single-arm whole-food, plant-based diet will explore the effects on primary prevention in a free-range environment
62516442|NCT05690074|EXPERIMENTAL|Patients with chronic spinal cord injury|80 sessions each of epidural spinal cord stimulation for 1) autonomic functions 2) voluntary movement; and 3) standing
62516443|NCT05580952|EXPERIMENTAL|Experimental: Treatment|Device: J-Valve® valve delivery system
61973931|NCT02136524|EXPERIMENTAL|Tablet formulation|
62516444|NCT02389101|EXPERIMENTAL|Lymphoma|Newly diagnosed lymphoma, all subtypes allowed
62516445|NCT06314516||Body Composition|Radiologic assessment of fat and muscle components of body composition at presentation and following initial treatment for esophageal cancer.
62516446|NCT05215093|EXPERIMENTAL|Direct physiotherapy pathway|People with acute low back pain will directly go to a physiotherapist, who will treat the patient without prescription of the general practitioner.
61973932|NCT05609461||Chronic stroke patients with knee hyperextension|
61973933|NCT00711711|EXPERIMENTAL|Manual lymphatic drainage|this arm will receive 5 manual lymphatic drainage treatments from day 2 to day 7 post surgery
62516447|NCT05215093|ACTIVE_COMPARATOR|Usual care pathway|People with low back pain will receive usual care by the general practitioner (with or without referral to physiotherapy).
62516448|NCT00836147|PLACEBO_COMPARATOR|1|250 ng dose
62516449|NCT00836147|ACTIVE_COMPARATOR|2|250 ng dose
61973934|NCT00711711|PLACEBO_COMPARATOR|Relaxation|This arm will receive 5 relaxation treatments from day 2 to day 7 post surgery
61973935|NCT05782465||Participants with IM of OLGIM Stage 2 to 4|Participants with Intestinal Metaplasia of Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) that is evaluated to be Stage 2 to 4.
61973936|NCT02466360||chronic lower back pain|
61973937|NCT05875090|EXPERIMENTAL|AI-enhanced Retinography-based screening|"Screening in Lisbon arm will be done by an Artificial Intelligence (AI) software reading an optic disc entered retinography. Outcome of this analysis is referral vs non-referral based on a pre-established threshold.~IOP 24mmHg or higher will be also be referred, regardless of optics disc analysis"
61973938|NCT05875090|ACTIVE_COMPARATOR|OCT-based screening|"Screening in the Minho arm will be done based on optic coherence Tomography (OCT) retinal nerve fibre layer thickness (RNFL). Existence of a single sector outside normal limits (\>95%) will be considered referrable.~IOP 24mmHg or higher will be also be referred, regardless of optics disc analysis"
61973939|NCT06069245|PLACEBO_COMPARATOR|Placebo|Gelatin capsules
62516450|NCT00775606|ACTIVE_COMPARATOR|ARM A/Lopinavir/ritonavir|Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
62516451|NCT00775606|ACTIVE_COMPARATOR|ARM B/Efavirenz|Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD
62516452|NCT06309316|EXPERIMENTAL|Person-centred care (PCC)|"Intervention PCC:~In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. The primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.~Usual care:~Patients with GD have regular meetings with the endocrinologist during the treatment with anti-thyroid drugs and leave blod sampels. Many patients are on sick leave in the beginning of treatment. If questions occur between meetings, patients contact a service centre and get feed-back from the nurse or physician on duty at Sahlgrenska University Hospital in Gothenburg."
62516453|NCT06309316|NO_INTERVENTION|Usual care|"Usual care:~Patients with GD have regular meetings with the endocrinologist during the treatment with anti-thyroid drugs and leave blod sampels. Many patients are on sick leave in the beginning of treatment. If questions occur between meetings, patients contact a service centre and get feed-back from the nurse or physician on duty at Sahlgrenska University Hospital in Gothenburg."
62516454|NCT01589861|EXPERIMENTAL|BKM120+Lapatinib|"BKM120 40, 60 or 80 mg/day per os for 28 days cycle~+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle"
62539491|NCT00299286|PLACEBO_COMPARATOR|Lapatinib-Placebo|placebo comparator 6 tablets taken as one dose daily
61973940|NCT06069245|EXPERIMENTAL|MitoQ|Commercially available MitoQ (80mg)
61973941|NCT03912285|EXPERIMENTAL|Amlodipine, losartan, and amlodipine plus losartan|"Period 1:~amlodipine 10mg will be administered orally once a day for 9 days.~Period 2:~losartan 100mg will be administered orally once a day for 9 days after 13 days of the washout period.~Period 3:~amlodipine 10mg once a day plus losartan 100mg once a day will be administered orally for 9 days after 6 days of the washout period."
61973942|NCT00523354|EXPERIMENTAL|1 (open-label)|prospective, open label, uncontrolled trial
61973943|NCT01426880|EXPERIMENTAL|Carboplatin + background treatment|Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
61973944|NCT01426880|ACTIVE_COMPARATOR|background treatment only|background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
61973945|NCT01017614|EXPERIMENTAL|Monofer|"* administered as intravenous infusions (A1)~* administered as intravenous bolus injections (A2)"
62710468|NCT05470400|EXPERIMENTAL|Dose Escalation - Group 3|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
61973946|NCT01017614|ACTIVE_COMPARATOR|Iron Sulphate|tablets administered orally
61973947|NCT00901446||Imaging|Subjects who receive intracoronary imaging with the investigative device.
62516455|NCT05069155|NO_INTERVENTION|Control|Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
62516456|NCT05069155|EXPERIMENTAL|Gamification|"Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 12-week intervention period.~At the end of the 12 week intervention period, participants will enter a 6 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and intervention design."
62516457|NCT00854802|EXPERIMENTAL|Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
62516458|NCT00854802|EXPERIMENTAL|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
62710469|NCT05470400|EXPERIMENTAL|Dose Escalation - Group 4|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
61973948|NCT06071091|EXPERIMENTAL|Intracranial stenting|Rescue Intracranial Stenting + best medical treatment
61973949|NCT06071091|ACTIVE_COMPARATOR|Best medical management alone|Best medical treatment with no additional thrombectomy passes
62354956|NCT06314997|EXPERIMENTAL|CTCs|
62354957|NCT06314997|EXPERIMENTAL|RAS unmutated CTCs HER negative|
62354958|NCT03279341|ACTIVE_COMPARATOR|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
62354959|NCT03279341|ACTIVE_COMPARATOR|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
62354960|NCT03279341|ACTIVE_COMPARATOR|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
62354961|NCT02889757|EXPERIMENTAL|NAC 1200 mg|patients with add NAC (600) 1# bid use per day during the study period
62354962|NCT02889757|EXPERIMENTAL|NAC 2400 mg|patients with add NAC (600) 2# bid use per day during the study period
62354963|NCT02889757|PLACEBO_COMPARATOR|NAC 0 mg|patients with add NAC (600) 0# (placebo) use per day during the study period
62354964|NCT02715999|ACTIVE_COMPARATOR|Quadratus Lumborum Block|Quadratus Lumborum block group (QL) patients will receive unilaterally Quadratus Lumborum block using Bupivacaine 0.2 %
62354965|NCT02715999|ACTIVE_COMPARATOR|Transversus abdominis plane block|Transversus abdominis plane block (TAP) patients will receive unilaterally TAP block using Bupivacaine 0.2 %
62516459|NCT00854802|EXPERIMENTAL|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
61973950|NCT02368431|EXPERIMENTAL|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
61973951|NCT02368431|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
61973952|NCT03055260|EXPERIMENTAL|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
61973953|NCT03055260|PLACEBO_COMPARATOR|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
61973954|NCT03709771||VEGF inhibitor alone|
61973955|NCT03709771||Immune Checkpoint Inhibitor (ICI) alone|
61973956|NCT03709771||Combination (VEGF inhibitor + ICI, or combination of ICI)|
62354966|NCT04568018||1 cohort|"Patients with mild ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
62710470|NCT05470400|EXPERIMENTAL|Dose Escalation - Group 5|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
62710471|NCT05470400|EXPERIMENTAL|Prime Boost Regimen - Group 6|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
62516460|NCT00854802|PLACEBO_COMPARATOR|Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
62516461|NCT03046498|EXPERIMENTAL|Program participants|Patients enrolled in the DSMP and DPP who provide consent.
61973957|NCT03709771||No treatment|
61973958|NCT05235074|EXPERIMENTAL|Dose escalation and dose expansion|The dose-escalating phase of the phase I trial of OH2 injection is divided into two dose groups (10\^6 CCID50/mL and 10\^7 CCID50/mL).It will be administered by Ommaya reservoir injection, and the total amount of each dose in each dose group should not exceed 2ml according to the size of the tumor cavity.
62710472|NCT05470400|EXPERIMENTAL|Prime Boost Regimen - Group 7|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
62710473|NCT05470400|EXPERIMENTAL|Prime Boost Regimen - Group 8|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
62710474|NCT00043602|EXPERIMENTAL|1|Participants will receive clinician-managed interpersonal psychotherapy
62710475|NCT00043602|ACTIVE_COMPARATOR|2|Participants will receive standard interpersonal psychotherapy
62710476|NCT04534673|EXPERIMENTAL|Intervention group|Pegylated interferon lambda + Standard of care treatment
62710477|NCT04534673|NO_INTERVENTION|Control group|Standard of care treatment
62516462|NCT01347658|EXPERIMENTAL|Etravirine + echinacea|etravirine + root of Echinacea purpurea
62710478|NCT02112656|EXPERIMENTAL|ThermoDox 50 mg/m2|ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
62710479|NCT02112656|PLACEBO_COMPARATOR|Dummy infusion|standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
62710480|NCT03304964|EXPERIMENTAL|100 mg FP-025 (b.i.d)|
61973959|NCT03630003|EXPERIMENTAL|Use of MOCS with post-use interview|"The patients in this arm will be asked to utilize the Manually Operated Communication System (MOCS) device and will then be asked to provide feedback on their experiences.~Subjects will be asked to complete up to 3 sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, the session may last up to one hour.~The study team will perform post-study interviews with each subject to ask about their experience with MOCS. The data collection forms will be filled out during the session by a member of the research team."
61973960|NCT01614054|EXPERIMENTAL|Survey Group|Patients will receive a survey along with their meal tray, provided by Food and Nutrition Services. The survey will consist of questions related to smoking habits, desire for NRT and desire for assistance with smoking cessation. The results of these surveys will be collected by allied health professionals and forwarded to the CTU team. The CTU team will then be encouraged to use that information to engage in a discussion with the patient regarding prescription of NRT. It will then be left to the discretion of the HCP whether or not to prescribe NRT taking into account patient preference, absence of contraindications and clinical benefit. All those participating in the survey will be offered referral to a smoking cessation clinic upon discharge.
62354967|NCT04568018||2 cohort|"Patients with moderate ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
62516463|NCT02477774|EXPERIMENTAL|Arista|Arista to ALT donor site
62516464|NCT02477774|NO_INTERVENTION|Control|No Arista to ALT donor site
62710481|NCT03304964|EXPERIMENTAL|200 mg FP-025 (b.i.d.)|
62710482|NCT03304964|EXPERIMENTAL|400 mg FP-025 (b.i.d)|
62516465|NCT06166784||Mectascrew B|
62710483|NCT03304964|EXPERIMENTAL|200 mg FP-025 (single dose; fasted)|
62516466|NCT00594113|EXPERIMENTAL|1|Multimedia Colorectal Cancer Screening
62516467|NCT00962988|EXPERIMENTAL|Cost-Free Group|
62516468|NCT00962988|OTHER|Prescription Only Group|
62516469|NCT00868296|ACTIVE_COMPARATOR|Low dose|
62516470|NCT00868296|ACTIVE_COMPARATOR|High dose|
62516471|NCT04111588||Glioma|"20 low-grade (LGG) and 40 high-grade glioma (HGG) patients will be included from the Department of Neurosurgery at St. Olavs Hospital and the Department of Neurosurgery at the University hospital of North Norway and examined with 18F-FACBC PET/MRI at baseline and 4-6 months after surgery. Furthermore, 10 of the LGG patients and 10 of the HGG patients will be examined with an additional 18F-FET PET/MRI at baseline for comparison with 18F-FACBC.~30 recurrent HGG patients will be recruited from the Department of Neurosurgery and the Department of Oncology at the Haukeland University Hospital. These patients will be examined with 11C-MET PET/MRI at treatment/baseline and 1 month after radiosurgery."
62710484|NCT03304964|EXPERIMENTAL|200 mg FP-025 (single dose; fed condition)|
62710485|NCT04301830||Spinal anesthesia|Patients undergoing cesarean section under spinal anesthesia
62710486|NCT04076033|EXPERIMENTAL|ECF ESPIRAL|The volunteer is submitted to four-layer spiral functional compressive bandage, then performs Taylor's Jebsen manual function test with comprehensive functional bandage (ECF).
62710487|NCT04076033|EXPERIMENTAL|ECF OITO|The volunteer is submitted to functional compressive bandage in eight with four layers, then performs the Taylor Jebsen manual function test with the comprehensive functional bandage (ECF).
62147850|NCT06510868||Post PRRT Diagnosed with t-MN (MDS or AML)|Patients who have t-MN (MDS or AML). Sample size: 5.
62710488|NCT06081894|EXPERIMENTAL|Aficamten|Participants in this arm will receive a single daily oral dose of 5 mg, 10 mg, 15 mg, or 20 mg of aficamten with dose levels guided by echocardiography assessments, for up to 72 weeks.
62710489|NCT06081894|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive placebo, for up to 72 weeks.
62710490|NCT02004158|EXPERIMENTAL|Positive psychology|Positive psychology intervention
62147851|NCT05918549||Popolation|
62516472|NCT04111588||Brain Metastases|Patients with brain metastases (18F-FACBC: n=20, 18F-FET: n=20 and 11C-MET: n=30) will be included from the Department of Neurosurgery at St. Olavs Hospital, the Department of Neurosurgery at Haukeland University Hospital and the Department of Neurosurgery at the University hospital of North Norway, and examined with amino acid PET/MRI at baseline, 1 month after surgery/stereotactic radiosurgery (St. Olavs Hospital/UNN: Linac, Haukeland University Hospital: Gamma Knife® radiosurgery) and at suspicion of recurrence.
62710491|NCT05770284|EXPERIMENTAL|Subject will receive 12 weeks of exercise with standard medical management (SMT)|"* Subjects will be given exercise protocol Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc~* Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol)~* Aerobic exercises consist of Brisk walking~* Resistance Exercises consist of movements targeting the major muscle groups with weight lifting~* Intensity:~Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10.~* Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength~* End point: 12 weeks~* Stopping rule:~* Interruption of Exercise for \> 7 consecutive days due to non-compliance or clinical events.~* Progression to exclusion criteria i.e. decompensation etc~Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day"
62710492|NCT05770284|ACTIVE_COMPARATOR|standard medical management (SMT)|standard medical management (SMT)
62516473|NCT05678855|NO_INTERVENTION|control group|Control Group: The topics of the course were prepared by the researcher using PowerPoint. Before starting the courses, it is ensured that all students attended the course using the Microsoft Teams program. The contents prepared were presented to the students in the control group with the traditional education method on a weekly basis.
62710493|NCT05631847|SHAM_COMPARATOR|Direct endovascular treatment group|Direct endovascular treatment (EVT) without intravenous thrombolysis (IVT)
62710494|NCT05631847|ACTIVE_COMPARATOR|Bridging treatment group|Intravenous thrombolysis (IVT) followed by endovascular treatment (EVT)
62710495|NCT04017130|EXPERIMENTAL|Part 1: Dose Escalation|"Weekly Dosing Intravenous (IV) infusion of MT-0169 every 7 days: Days 1, 8, 15, and 22 in a 28-day treatment cycle.~Every 2 Weeks IV infusion of MT-0169 every 14 days: Days 1 and 15 in a 28-day treatment cycle with escalating doses starting at the MTD/RP2D determined by the weekly dose escalation cohort.~Patients will continue to receive treatment until progressive disease, unacceptable toxicity or withdraw from the study for other reasons. Decision to escalate/deescalate/stay on the same dose/discontinue MT-0169 will be based on number of DLTs per number of patients enrolled at each dose level as predetermined by the mTPI-2 statistical model. Subsequent doses will be determined by the frequency and severity of adverse events in previous cohorts. The investigator and sponsor review of available safety, PK, pharmacodynamics, and efficacy data in the previous cohorts will also be factored in the decision."
62710496|NCT05472493|EXPERIMENTAL|CETO|The consented participants will receive the \[18-F\] CETO through the IV and a PET/CT scan afterwards.
62710497|NCT04035031|EXPERIMENTAL|Forxiga first, placebo second|Forxiga followed by placebo
62710498|NCT04035031|EXPERIMENTAL|Placebo first, Forxiga second|Placebo followed by forxiga
62710499|NCT01084889||symptomatic genital descensus|"Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention.~Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally."
62710500|NCT02250248|ACTIVE_COMPARATOR|AttraX Putty|Patient will be treated with AttraX Putty intraoperatively.
62147852|NCT05035563|NO_INTERVENTION|Traditional communication management (Pre-intervention)|"Traditional communication practices are maintained, which consists of reporting the patient's medical conditions or specific requirements of the case, between the health team and the family.~According to the social and administrative conditions of each centers, medical telephone information is provided on the conditions of the patients."
62147853|NCT05035563|EXPERIMENTAL|Early and integral communication strategy (EICS) (Post-intervention)|"EICS that includes a bundle of various strategies that allow to favor communication and contact between family members, patients and health team.~That considers the delivery of: (1) Receive timely and understandable information; (2) Receive visits, companionship, and spiritual assistance"
62710501|NCT02250248|ACTIVE_COMPARATOR|Iliac Crest Bone Graft (ICBG)|Patients will be treated with ICBG harvested during surgery.
62710502|NCT00359268||1|Any patient with a condition or disease whose etiology is unknown.
62710503|NCT03537443|PLACEBO_COMPARATOR|Group A (Placebo)|Children whose mothers were randomized to receive a weekly dose of placebo from 17-24 weeks of gestation to 26 weeks postpartum.
62147854|NCT06464302||Operative|Patients receiving surgical stabilisation of rib fractures (SSRF) by any operative technique
62147855|NCT06464302||Non-operative|Patients not receiving surgical stabilisation of rib fractures (SSRF)
62147856|NCT04602949|EXPERIMENTAL|COVID-19 patients|subjects who were found as COVID-19 positive patients by swab RT-PCR
62147857|NCT04602949|OTHER|Healthy controls|subjects who were found as COVID-19 Negative, by swab RT-PCR
62147858|NCT01947114|ACTIVE_COMPARATOR|Group Propofol|
62147859|NCT01947114|ACTIVE_COMPARATOR|Group Ketamine|
62147860|NCT05556369||Single Arm Study|The study involves the execution of a genetic analysis using a panel of 54 genes conducted on blood obtained from peripheral venous sampling, the collection of clinical / instrumental / biological data in a dedicated prospective register in the form of a pseudo-anonymized database and the follow-up clinical up over time of patients. The study also provides for the execution of: a cardiological examination with electrocardiogram, Echocardiogram-color doppler and Basic blood tests: CBC, renal function, electrolytes, hepatic profile, NT-proBNP, lipid profile.
62516474|NCT05678855|EXPERIMENTAL|experimental group|a) Experimental Group: First, the topics of the course were prepared by the researcher using multimedia tools. Before starting the courses, it is ensured that all students attended the course using the Microsoft Teams program. The contents prepared were presented to the students in the experimental group in an interactive way on a weekly basis.
62516475|NCT02972177|EXPERIMENTAL|Radiofrequency ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
62516476|NCT02972177|EXPERIMENTAL|Microwave ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
62516477|NCT06389006|EXPERIMENTAL|Disitamab Vedotin combined with Toripalimab sequential chemotherapy（Epirubicin +CTX）|Disitamab Vedotin combined with Toripalimab sequential chemotherapy arm
62516478|NCT00965770||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
61973961|NCT01614054|NO_INTERVENTION|Standard of Care|In the control arm, surveys will also be given out to all patients along with their meal trays. However, these surveys will include only questions related to smoking habits in order to get a baseline number of smokers. The surveys will then be collected by the allied health and nursing staff and forwarded only to the research team. The HCP taking care of the patients will still provide standard of care treatment with NRT and smoking cessation referral as clinically indicated.
62354968|NCT04568018||3 cohort|"Patients with mild ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
62516479|NCT03499119|OTHER|Cohort 1|Subjects with a body weight at Day 1 of less than weight threshold.
62516480|NCT03499119|OTHER|Cohort 2|Subjects with a body weight at Day 1 of weight threshold or more.
62516481|NCT04933786|EXPERIMENTAL|Digital Health Nudging|During 12-week intervention period participants receive daily text messages via WhatsApp on their smartphone to encourage them to be physically active in their daily lives.
62516482|NCT04933786|NO_INTERVENTION|Control|During 12-week control period participants receive no text messages.
62516483|NCT04754802|EXPERIMENTAL|PH94B|3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time
62516484|NCT04754802|EXPERIMENTAL|Placebo|Placebo intranasal spray (100 microliters to each nostril) one time
62516485|NCT00140413|EXPERIMENTAL|Treatment Group 1: Receiving GH Treatment|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with growth deceleration were assigned to the GH treatment group in accordance with standard of care. Subjects with normal growth were randomized to treatment or to control (no intervention). The intervention was Nutropin AQ. The starting dose was calculated as 0.3 mg/kg/wk and subsequently modified based on observed length/height velocity and serum IGF-I levels.
62516486|NCT00140413|NO_INTERVENTION|Treatment Group 2: Control|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with normal growth were randomized to treatment or to control. The control group received no intervention; however, control subjects were switched (crossed over) to the GH replacement group if, during the course of the study, they met criteria for growth deceleration.
62516487|NCT05613751|EXPERIMENTAL|Pregnant women-COVID-19 vaccine RCT - intervention group|Women randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get the COVID-19 booster vaccine
61973962|NCT01847222|EXPERIMENTAL|SANGUINATE™|PEG-bHb-CO
61973963|NCT01847222|PLACEBO_COMPARATOR|Normal Saline Solution|Saline Solution
61973964|NCT02886520|ACTIVE_COMPARATOR|PVDF transobturator tape|Transobturator tension-free suburethral tape made of polyvinylidene fluoride.
61973965|NCT02886520|ACTIVE_COMPARATOR|PP transobturator tape|Transobturator tension-free suburethral tape made of polypropylene.
61973966|NCT04059094|PLACEBO_COMPARATOR|Placebo|2 puffs ofmatching placebowere inhaledorally via theRespimat®inhaler twice dailyfor a treatmentperiod of 4 weeksin patients withcystic fibrosis.
61973967|NCT04059094|EXPERIMENTAL|BI 1265162 50 μg b.i.d.|2 puffs of 25micrograms (μg)BI 1265162(Total: 50μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:100μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
62147861|NCT04169802||Normal subjects|Age ≥ 50 years, Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye.
62147862|NCT04169802||Subjects with neovascular AMD|Age ≥ 50 years, History of neovascular age-related macular degeneration, in the study eye, Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye.
62147863|NCT06210152||Radial Extracorporeal Shockwave Therapy|
62354969|NCT04568018||4 cohort|"Patients with moderate ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
62147864|NCT06210152||Sham Extracorporeal Shockwave Therapy|
62354970|NCT03999112|EXPERIMENTAL|Metacognitive Reflection and Insight Therapy (MERIT) 4 week|Standard MERIT + 4 week baseline period
62354971|NCT03999112|EXPERIMENTAL|Metacognitive Reflection and Insight Therapy (MERIT) 6 week|Standard MERIT + 6 week baseline period
62354972|NCT03999112|EXPERIMENTAL|Metacognitive Reflection and Insight Therapy (MERIT) 8 week|Standard MERIT + 8 week baseline period
62354973|NCT04919746|EXPERIMENTAL|Group Acupuncture 1 - GA1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
61973968|NCT04059094|EXPERIMENTAL|BI 1265162 100 μg b.i.d.|2 puffs of 50micrograms (μg)BI 1265162(Total: 100μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:200μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
62516488|NCT05613751|NO_INTERVENTION|Pregnant women-COVID-19 vaccine RCT - standard care group|Women randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get the COVID-19 booster vaccine. They will receive normal care at the hospital.
61973969|NCT04059094|EXPERIMENTAL|BI 1265162 200 μg b.i.d.|2 puffs of 100micrograms (μg)BI 1265162(Total: 200μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:400μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
61973970|NCT04059094|EXPERIMENTAL|BI 1265162 20 μg b.i.d.|2 puffs of 10micrograms (μg)BI 1265162(Total: 20μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:40μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
62516489|NCT05613751|EXPERIMENTAL|Pregnant women-influenza vaccine RCT - intervention group|Women randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get the annual influenza vaccine
61973971|NCT01438957|PLACEBO_COMPARATOR|Placebo|Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
61973972|NCT01438957|EXPERIMENTAL|Dexmedetomidine 0.067 mcg/kg|Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
61973973|NCT01438957|EXPERIMENTAL|Dexmedetomidine 0.25 mcg/kg|Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
62516490|NCT05613751|NO_INTERVENTION|Pregnant women-influenza vaccine RCT - standard care group|Women randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get the annual influenza vaccine. They will receive normal care at the hospital.
62516491|NCT05613751|EXPERIMENTAL|Medically at risk children-COVID-19 vaccine RCT - intervention group|Parents of medically at risk children randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get their child the COVID-19 vaccine
62516492|NCT05613751|NO_INTERVENTION|Medically at risk children-COVID-19 vaccine RCT - standard care group|Parents of medically at risk children randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get their child the COVID-19 vaccine. They will receive normal care at the hospital.
61973974|NCT01438957|EXPERIMENTAL|Dexmedetomidine 0.5 mcg/kg|Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
61973975|NCT01438957|EXPERIMENTAL|Dexmedetomidine 1.0 mcg/kg|Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
61973976|NCT05971810|EXPERIMENTAL|Group A (immunonutrition and oral chlorhexidine decontamination, IN&CD)|Patients in this group will receive immunonutrition supplementation from the day of allocation at the preoperative anesthesia clinic until the day before surgery (usually 1-3 weeks), which is oral intake of ORAL IMPACT™ 2 servings per day. Patients will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
61973977|NCT05971810|EXPERIMENTAL|Group B (immunonutrition and routine oral care, IN&RC)|Patients in this group will receive immunonutrition supplementation from the day of allocation at the preoperative anesthesia clinic until the day before surgery (usually 1-3 weeks), which is oral intake of ORAL IMPACT™ 2 servings per day. For oral health care, they will receive routine oral care which is routine toothbrushing twice daily.
61973978|NCT05971810|EXPERIMENTAL|Group C (routine nutrition advice and oral chlorhexidine decontamination, RN&CD)|Patients in this group will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. They will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
62354974|NCT04919746|EXPERIMENTAL|Group Acupuncture 2 - GA2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
62354975|NCT04919746|EXPERIMENTAL|Group Acupuncture 3 - GA3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
62354976|NCT04919746|NO_INTERVENTION|Group Control 1 - GC1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
62354977|NCT04919746|NO_INTERVENTION|Group Control 2 - GC2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
62354978|NCT04919746|NO_INTERVENTION|Group Control 3 - GC3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
62354979|NCT04369768|ACTIVE_COMPARATOR|direct composite restorations|
62516493|NCT05613751|EXPERIMENTAL|Medically at risk children-influenza vaccine RCT - intervention group|Parents of medically at risk children randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get their child the annual influenza vaccine
62710504|NCT03537443|EXPERIMENTAL|Group B (4200:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 4200 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
62354980|NCT04369768|ACTIVE_COMPARATOR|preformed metal crowns|
62354981|NCT01595438|EXPERIMENTAL|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
62354982|NCT01595438|ACTIVE_COMPARATOR|Doripenem|IV treatment
62354983|NCT02545491|EXPERIMENTAL|Care for Child Development group|Training of caregivers on the Care for Child Development (CCD) program, in addition to the training on Infant and Young Child feeding program by World Vision.
62354984|NCT02545491|ACTIVE_COMPARATOR|World Vision Lebanon training group|caregivers will receive training in Infant and Young Child Feeding (WV-IYCF) offered by World Vision.
62354985|NCT01690715||Hepatocellular carcinoma underwent surgery|
62354986|NCT05632848|EXPERIMENTAL|Treatment arm|Chidamide and Zimberelimab
61973979|NCT05971810|NO_INTERVENTION|Group D (routine nutrition advice and routine oral care, RN&RC)|Patients in this group will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. They will also receive routine oral care which is routine toothbrushing twice daily.
61973980|NCT01832376|EXPERIMENTAL|Ultrasound guided needle lavage|Ultrasound guided needle lavage
62147865|NCT05062070|ACTIVE_COMPARATOR|5 Percent TolaSure Topical Gel|5% (w/w) TolaSure Gel
62710505|NCT03537443|EXPERIMENTAL|Group C (16800:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 16800 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
62710506|NCT03537443|EXPERIMENTAL|Group D (28000:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
62147866|NCT05062070|PLACEBO_COMPARATOR|Topical Vehicle Gel|TolaSure Vehicle Gel
62516494|NCT05613751|NO_INTERVENTION|Medically at risk children-influenza vaccine RCT - standard care group|Parents of medically at risk children randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get their child the annual influenza vaccine. They will receive normal care at the hospital.
62516495|NCT05466175|EXPERIMENTAL|Treatment Group|combination of Olverembatinib with chemotherapy
62516496|NCT01100879|ACTIVE_COMPARATOR|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).
62516497|NCT01100879|NO_INTERVENTION|Local standard of care.|Subjects will be treated according to the local institutional practice.
62516498|NCT02973321|PLACEBO_COMPARATOR|Placebo|Placebo (for SAR425899) subcutaneous (SC) injection once daily (QD) from Week 1 to Week 26, matching 3 SAR425899 dose levels of 0.12 mg, 0.16 mg and 0.20 mg.
62516499|NCT02973321|EXPERIMENTAL|SAR425899 0.12 mg|SAR425899 SC injection QD at maintenance dose of 0.12 mg for 25 weeks (Week 2 to Week 26) following 1 week dose increase step (0.06 mg at Week 1).
62147867|NCT03863405|EXPERIMENTAL|Metformin Group|850 mg metformin twice daily for six months in addition to standard therapy
62516500|NCT02973321|EXPERIMENTAL|SAR425899 0.16 mg|SAR425899 SC injection QD at maintenance dose of 0.16 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase step (0.06 mg at Week 1 and 0.12 mg at Week 2).
62516501|NCT02973321|EXPERIMENTAL|SAR425899 0.20 mg|SAR425899 SC injection QD at maintenance dose of 0.20 mg for 23 weeks (Week 4 to Week 26) following 3 weeks dose increase step (0.06 mg at Week 1, 0.12 mg at Week 2 and 0.16 mg at Week 3).
62516502|NCT02973321|ACTIVE_COMPARATOR|Liraglutide|Liraglutide SC injection QD at maintenance dose of 1.8 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase steps (0.6 mg daily at Week 1 and by 1.2 mg daily at Week 2).
62516503|NCT03204474|EXPERIMENTAL|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets \[100 mg each\]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
62516504|NCT03204474|EXPERIMENTAL|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets \[100 mg each\])
62710507|NCT03537443|EXPERIMENTAL|Group E (28000:28000 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by the same dose (28000 IU/week vitamin D3) from delivery to 26 weeks postpartum.
62710508|NCT03985202|EXPERIMENTAL|Structured Exercise Programme|"An initial 45 min exercise counselling incorporating behaviour modification techniques.~Participants will be offered three sessions per week of aerobic interval exercise on a cycle ergometer over nine weeks. Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.~Following this:~Participants will be encouraged to comply with current physical activity recommendations: 150 min of moderate intensity aerobic exercise per week (brisk walking / cycling). They will also be sign posted to local exercise facilities."
62710509|NCT01468545||Group 1|
62710510|NCT01468545||Group 2|
62147868|NCT03863405|ACTIVE_COMPARATOR|Control Group|placebo in addition to standard therapy for rheumatoid arthritis
62147869|NCT04001777|EXPERIMENTAL|APG-1252 plus Osimertinib (AZD9291)|APG-1252 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase; Dose of osimertinib will be fixed at 80mg QD based on approved label.
62147870|NCT02802488|EXPERIMENTAL|D-dimers|This arm encompasses patients between 18 and 80 years old and diagnosed with atrial fibrillation.
62147871|NCT02387385|ACTIVE_COMPARATOR|Intervention|Whole body cooling to 33 degrees C to 34 degrees C
62516505|NCT01928303||Chronic Pain Patients taking opioid medications|Oral fluid, blood and urine samples will be obtained from chronic pain patients who are taking pain medications from the opioid class of drugs.
62516506|NCT01928303||Negative controls|At least 10% of the total subject population. Chronic pain patients who are not taking pain medication from the opioid class of drugs.
62516507|NCT06204419|EXPERIMENTAL|A (XH-S002)|Participants will receive XH-S002 once or twice daily on scheduled days.
62516508|NCT06204419|EXPERIMENTAL|B (Placebo)|Participants will receive matching placebo once or twice daily on scheduled days.
62516509|NCT05336305|PLACEBO_COMPARATOR|Placebo Group|Administration of corn starch daily for 2 months
62516510|NCT05336305|EXPERIMENTAL|polydextrose|Administration of 12g polydextrose daily for 2 months
62516511|NCT05386524|EXPERIMENTAL|SBP group|sintilimab 200mg, ivgtt，d1， bevacizumab biosimilar 15mg/kg，ivgtt d1， pegylated liposomal doxorubicin 30mg/m2 d1，q3w
62516512|NCT05667636|EXPERIMENTAL|single arm, non randomized|SBRT 30 Gy/ 5 fractions
62516513|NCT05667636|EXPERIMENTAL|radiation, SBRT|SBRT 30 Gy/5 fractions to the prostatic bed +/- 25 Gy/5 fractions to the pelvic lymphnodes
61973981|NCT06239376|ACTIVE_COMPARATOR|GnRH agonist + Letrzole - Artificial Cycle|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients will take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before initiating progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
62147872|NCT02387385|NO_INTERVENTION|Standard of Care|Standard of care
62147873|NCT04514081|EXPERIMENTAL|Chidamide+Decitabine+Camrelizumab|
62147874|NCT04514081|ACTIVE_COMPARATOR|Decitabine+Camrelizumab|
62147875|NCT03675321|EXPERIMENTAL|Auricular Neurostimulation|Intervention: Active Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks
62147876|NCT03675321|SHAM_COMPARATOR|Sham Auricular Neurostimulation|Intervention: Sham (Inactive) Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks.
62354987|NCT02855138|ACTIVE_COMPARATOR|study group|The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
62354988|NCT02855138|NO_INTERVENTION|control group|The control group of this study was pretreatment period of the same volunteer patients.
62354989|NCT02372097|EXPERIMENTAL|Group A|Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
62354990|NCT02372097|EXPERIMENTAL|Group B|Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
62354991|NCT02524756|ACTIVE_COMPARATOR|Group (A)|laparoscopic nerve sparing radical hysterectomy type III/C1
62354992|NCT02524756|ACTIVE_COMPARATOR|Group (B)|laparoscopic radical hysterectomy type III/C2
62354993|NCT01610908|EXPERIMENTAL|Schroth exercises|The experimental group receives the Schroth exercises treatment.Patients in this arm receive 5 individual sessions with a Schroth therapist for introduction to the approach. They they receive a home program consisting of 3-4 exercises to do at home everyday for 30-45 minutes. They come to weekly group therapy sessions to where exercise prescription is adjusted.
62354994|NCT01610908|NO_INTERVENTION|Standard of care|"The Standard of care is a control group that will continue receiving the standard North American treatment prescribed by a surgeon (observation or brace \[if meeting SRS criteria\]) for of 6 months. After 6 months, the participants will receive the Schroth exercises intervention for 6 months."
62354995|NCT01610908|ACTIVE_COMPARATOR|Global Postural Re-education (Montréal)|"The active group (in Montréal only) receives the Global Postural Re-Education exercises treatment.Patients in this arm come to weekly individual 1 hour long therapy sessions where exercise prescription is adjusted. Selection of posture exercises is based on scoliosis type, on muscular chain stiffness associated with posture alterations and on position increasing scoliosis or pain (lying, sitting, standing).~They they receive a 15-min home program consisting of 1 to 2 exercises to do at home everyday."
62354996|NCT06530121|EXPERIMENTAL|Toolbox trainings|Training given with a single page material, lasting between 10-15 minutes, aimed at on-the-job application.
62354997|NCT06530121|NO_INTERVENTION|control group|uninterrupted and monitored group
62354998|NCT02539303|EXPERIMENTAL|Intervention|Infusion of Yamani-15/5 chemical solution.
62354999|NCT06000436|EXPERIMENTAL|Intervention/treatment|Health education, mobile applications, monitoring, Cardiovascular disease risk assessment
62355000|NCT06000436|ACTIVE_COMPARATOR|Active group|Cardiovascular disease risk assessment
62355001|NCT05460572|OTHER|Patients undergoing PVI procedure and who are treated with peripheral parental nutrition|Patients undergoing elective PVI procedure who will receive peripheral parental nutrition before start of the procedure.
62355002|NCT01165918||Donated embryos|
62355003|NCT05759546|EXPERIMENTAL|Cohort 1|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with Fluzoparib(Parp inhibitor) and endocrine therapy.
62355004|NCT05759546|ACTIVE_COMPARATOR|Cohort 2|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with endocrine therapy.
62516514|NCT04841330||Healthy volunteers|A minimum of 100 healthy volunteer participants (14yo and older)
62516515|NCT04812639|EXPERIMENTAL|buccal infiltartion technique|local anesthetic technique
62516516|NCT04812639|ACTIVE_COMPARATOR|Inferior alveolar nerve block technique|local anesthetic technique
62516517|NCT06226701|EXPERIMENTAL|Impact of cryolipolsis on hormonal profile in obese women with pcos|The patients will receive cryolipolysis session in abdomen for 45minute ,session every two week and 1200kcal diet and exercise for 3 months
62516518|NCT06226701|EXPERIMENTAL|Impact of cryolipolysis in hormonal profile in obese women with pcos|All patient will receive same diet 1200kcal diet ,and exercise for 3 months
62355005|NCT03024840|EXPERIMENTAL|sevoflurane|Sevoflurane is inhalated with 1%-2% after anesthesia induction until end of the surgery.
62355006|NCT03024840|EXPERIMENTAL|propofol|Propofol is injected with 9-15 mg/kg/h after anesthesia induction until end of the surgery.
62516519|NCT05424484|EXPERIMENTAL|Hernia prevention cohort|single arm study, no control arm
62516520|NCT04062149|ACTIVE_COMPARATOR|Control Group|The control group will be the group where the participants receive only their normal physiotherapy treatment.
62516521|NCT04062149|EXPERIMENTAL|Experimental Group|The experimental group will be the group where participants receive physiotherapy aimed at improving their ability to stand on their weaker leg alongside their normal physiotherapy treatment.
62516522|NCT03128684|EXPERIMENTAL|Small Green Lentil Muffin|
62516523|NCT03128684|EXPERIMENTAL|Split Red Lentil Muffin|
62516524|NCT03128684|PLACEBO_COMPARATOR|Wheat Muffin|
62516525|NCT03128684|EXPERIMENTAL|Small Green Lentil Chili|
62516526|NCT03128684|EXPERIMENTAL|Split Red Lentil Chili|
62516527|NCT03128684|PLACEBO_COMPARATOR|Rice Chili|
62355007|NCT03358654|EXPERIMENTAL|mesenchymal stem cells|Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection
61973982|NCT06239376|ACTIVE_COMPARATOR|Artificial Cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
61973983|NCT03951792||Colorectal Cancer Subjects|Subjects under going colorectal resection with colorectal cancer will have tissue and stool collected
61973984|NCT03951792||Benign Colon Resection Subjects|Subjects under going colorectal resection without colorectal cancer will have tissue and stool collected
62355008|NCT06114004|EXPERIMENTAL|gemcitabine + selinexor:|"Selinexor will be given at 60 mg once per week orally days 1, 8 and 15 every 21 days~Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days"
62355009|NCT03498547|ACTIVE_COMPARATOR|Caudal Block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ultrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
62355010|NCT03498547|ACTIVE_COMPARATOR|Saddle Block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonography guidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
62355011|NCT05129787|ACTIVE_COMPARATOR|Surgical resection|Liver resection
62355012|NCT05129787|EXPERIMENTAL|Thermal ablation|Thermal ablation (Microwave or radiofrequency)
62355013|NCT01189799|EXPERIMENTAL|Motivational Therapy Aftercare|Twelve, 60 minute weekly structured manualized therapy sessions.
62355014|NCT01189799|ACTIVE_COMPARATOR|Dual Recovery Anonymous/Tx as usual|Aftercare Treatment as Usual,which is twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
62355015|NCT06317922|EXPERIMENTAL|treatment arm|"Installation of artificial tears of Thealoz DUO (Investigational medical device containing trehalose 3 g and hyaluronic acid 0.15 g ), 10 ml.~Dosage:1 drop x 4 times/day by 1 week before the Intravitreal injection until 3 months afterward."
62355016|NCT06317922|PLACEBO_COMPARATOR|control arm|"Installation of saline solution (Hydrabak containing Sodium Chloride 0,9 g, Sodium Dihydrogen Phosphate Dihydrate, Disodium Hydrogen Phosphate Dodecahydrate),10 ml.~Dosage: 1 drop x 4 times/day by 1 week before the Intravitreal injection up to 3 months after it."
62355017|NCT02751021|OTHER|Sleep apnea diagnosis|The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.
62355018|NCT01721148|OTHER|Cohort Dose Escalation|open label dose escalation study of ASLAN002 administered orally on a once daily schedule to subjects with advanced or metastatic solid tumours, who have either progressed on standard therapy or for whom standard therapy is not known
62355019|NCT01532570|EXPERIMENTAL|TA-650|
62355020|NCT03007719|EXPERIMENTAL|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with \[18F\]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
62355021|NCT03007719|EXPERIMENTAL|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with \[18F\]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
62355022|NCT04307173|EXPERIMENTAL|Cohort 1|9 subjects for MAD 1 cohort. 6 subjects on KBL693, 3 subjects on placebo.
62355023|NCT04307173|EXPERIMENTAL|Cohort 2|9 subjects for MAD 2 cohort. 6 subjects on KBL693, 3 subjects on placebo.
62355024|NCT00799760|EXPERIMENTAL|1|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
62355025|NCT00799760|ACTIVE_COMPARATOR|2|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
62355026|NCT00799760|ACTIVE_COMPARATOR|3|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
62355027|NCT04712799|EXPERIMENTAL|COPD patients|Wlaking tests before and afrer 1 spray with oxymetazoline
62355028|NCT01641718|EXPERIMENTAL|Single sided glue|Mesh is fixed with Tisseel for single sided inguinal hernias.
62355029|NCT01641718|ACTIVE_COMPARATOR|Single sided stapled|Mesh is fixed with staples for single sided inguinal hernias.
61973985|NCT00748033|EXPERIMENTAL|LoFric POBE Hydro-Kit II, 5 seconds and then LoFric POBE Hydro-Kit II, 24 hours|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 5 seconds.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 24 hours."
62516528|NCT03913260|EXPERIMENTAL|Part A: LY3375880 Formulation A|LY3375880 Formulation A administered subcutaneously (SC).
62516529|NCT03913260|EXPERIMENTAL|Part A: LY3375880 Formulation B|LY3375880 Formulation B administered subcutaneously SC.
62516530|NCT03913260|EXPERIMENTAL|Part A: LY3375880 Formulation C|LY3375880 Formulation C administered SC.
62516531|NCT03913260|PLACEBO_COMPARATOR|Part A: Positive Control|Positive Control (buffer matrix, only) administered SC.
62516532|NCT03913260|EXPERIMENTAL|Part B: LY3375880 Test 1|LY3375880 Test 1 Formulation administered SC.
62516533|NCT03913260|EXPERIMENTAL|Part B: LY3375880 Test 2|LY3375880 Test 2 Formulation administered SC.
62516534|NCT03913260|EXPERIMENTAL|Part B: LY3375880 Test 3|LY3375880 Test 3 Formulation administered SC.
61973986|NCT00748033|EXPERIMENTAL|LoFric POBE Hydro-Kit II, 24 hours and then LoFric POBE Hydro-Kit II, 5 seconds|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 24 hours.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 5 seconds."
62516535|NCT01795248|EXPERIMENTAL|Liraglutide|1.8 mg liraglutide, subcutaneous, once-daily for five years
62516536|NCT01795248|PLACEBO_COMPARATOR|Placebo|Placebo, subcutaneous, once-daily for one year
62516537|NCT01795248|NO_INTERVENTION|Control|Control without previous GDM.
62516538|NCT05369078|EXPERIMENTAL|THR-1442 20mg Single dose group|THR-1442 20mg Single dose group: subject will be administrated 1 dose of 20mg THR-1442 on day1, the follow up till day 7.
62516539|NCT05369078|EXPERIMENTAL|THR-1442 20mg Multiple dose group|THR-1442 20mg Multiple dose group: subject will be administrated THR-1442 20mg QD on Day1-Day7, the follow up till day 14.
62516540|NCT04117737|EXPERIMENTAL|Intervention|Single-arm
62516541|NCT03465748|EXPERIMENTAL|Experimental-OrthoK|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles or soft contact lenses (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
62516542|NCT03465748|NO_INTERVENTION|Control|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
62516543|NCT04760600||IBD GROUPS|PATIENT WITH IBD DISEASE
62516544|NCT04760600||IBS GROUP|PATIENT WIT IBS DISEASE
62516545|NCT04760600||CONTROL 1|CONTROL WITH POSITIVE PARASITIC INFECTION AN POSITIVE GIT SYMTOMS
62516546|NCT04760600||CONTROL2|HEALTHY VOLUNTEARS
62516547|NCT04965389|EXPERIMENTAL|Treatment Sequence 1|
62516548|NCT04965389|EXPERIMENTAL|Treatment Sequence 2|
62516549|NCT04965389|EXPERIMENTAL|Treatment Sequence 3|
61973987|NCT03365739|ACTIVE_COMPARATOR|Active Comparator 1|Treatment - Mango (pulp/flesh-500 g)
62355030|NCT01641718|OTHER|Bilateral glue right|"For bilateral inguinal hernias mesh on the right side is fixed with Tisseel, on the left with staples.~Experimental treatment and active comparator in the same patient."
62516550|NCT04965389|EXPERIMENTAL|Treatment Sequence 4|
62355031|NCT01641718|OTHER|Bilateral glue left|"For bilateral inguinal hernias mesh on the left side is fixed with Tisseel, on the right with staples.~Experimental treatment and active comparator in the same patient."
62355032|NCT04469816|EXPERIMENTAL|Behavioral: Family Check-Up 4 Health|Families will receive the FCU4Health program 3 times annually in a health maintenance model. The FCU4Health coordinator reviews the assessment results with the parents, using motivational interviewing strategies to create a tailored plan to address family needs. This plan may include referrals to community resources or parenting modules that focus on family management.
62516551|NCT03159286|EXPERIMENTAL|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
62516552|NCT03159286|EXPERIMENTAL|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
62710511|NCT05111067||Nova scotia TNBC cohort|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc). Transcriptome data will be used to categorize specimens into one of four distinct mRNA subgroups and will be compared between cohorts.
61973988|NCT03365739|ACTIVE_COMPARATOR|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
61973989|NCT03365739|PLACEBO_COMPARATOR|Control Comparator|Vitamin C (100 mg)
61973990|NCT02590653|EXPERIMENTAL|Group A|Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI
61973991|NCT02590653|ACTIVE_COMPARATOR|Group K|Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI
62355033|NCT04469816|EXPERIMENTAL|Control-Services as Usual|"Families will continue with their medical standard of care and referrals for services as appropriate from the healthcare staff in their respective FQHCs or primary healthcare clinics.~Families will receive brochures about the community programs to which families in the FCU4Health arm are referred."
62355034|NCT01265342|PLACEBO_COMPARATOR|Placebo|
62516553|NCT03159286|EXPERIMENTAL|Control|Participants view social networking site profiles with no alcohol content.
62516554|NCT01244373||Patients with senile cataract|Patients with senile cataract
62516555|NCT01615263|ACTIVE_COMPARATOR|Double lumen tube|Lung isolation with a left double lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland.
62516556|NCT01615263|ACTIVE_COMPARATOR|Bronchial blocker|Lung isolation with a bronchial blocker with the inner channel closed (Fuji Uniblocker 9F, Fuji System Corporation, Tokyo, 113-0033, Japan) inserted via a 8.0 mm simple lumen endotracheal tube.
62516557|NCT01000610|EXPERIMENTAL|single arm|
62516558|NCT05671172|EXPERIMENTAL|Group H1|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline containing 750 IU hyaluronidase as an adjuvant in each side after closing skin.
62516559|NCT05671172|EXPERIMENTAL|Group H2|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline containing 1500 IU hyaluronidase as an adjuvant in each side after closing skin.
62516560|NCT05671172|PLACEBO_COMPARATOR|Group C|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline without any adjuvant in each side after closing skin.
62516561|NCT05001464||Reflectance Pulse Oximeter|The participants wear reflectance pulse oximeter for continuous monitoring when carrying out PSG . Oxygen desaturation index (ODI), average blood oxygen saturation, minimum blood oxygen saturation, percentage of blood oxygen saturation less than 90% in the whole recording time (TS90%), fastest heart rate, slowest heart rate and average heart rate are recorded by reflectance pulse oximeter.
62516562|NCT04085536|OTHER|Chronic maxillary sinusitis(for more than 12 weeks)|Patients for whom chronic maxillary sinusitis will be diagnosed in the first ENT consultation, will then be seen in a stomatology consultation to determine whether or not a dental cause is objective.
62355035|NCT01265342|EXPERIMENTAL|Beclomethasone|Beclometasone suspension 400 mcg will be administered through a nebuliser twice a day, in the morning and in the evening, for 10 days
62516563|NCT06104631|EXPERIMENTAL|BK003|Dietary Supplement: BK003 The product is a combination of chitin-glucan and micronutrients. The dose of chitin-glucan is 3 g/day. The product is provided as sachets containing powder to be dissolved in a glass of water (about 250 ml) and taken orally.
62516564|NCT06104631|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: BK003 placebo The placebo product has the same composition in excipient, same form and same posology as BK003.
62516565|NCT00876018|NO_INTERVENTION|No intervention|No intervention
62516566|NCT00876018|EXPERIMENTAL|Nutritional supplement|Fortified nutritional powder
62516567|NCT00876018|PLACEBO_COMPARATOR|Placebo|Un-fortified nutritional powder
62516568|NCT05322902|EXPERIMENTAL|Remimazolam group|Total intravenous anesthesia with remimazolam and remifentanil
62516569|NCT05322902|ACTIVE_COMPARATOR|Propofol group|Total intravenous anesthesia with propofol and remifentanil
62516570|NCT00775788|EXPERIMENTAL|Implant Failure|
62516571|NCT00775788|EXPERIMENTAL|Post mastectomy breast reconstruction|
62516572|NCT00775788|EXPERIMENTAL|Congenital malformations|
62516573|NCT00775788|EXPERIMENTAL|Breast Ptosis|
62516574|NCT00775788|EXPERIMENTAL|Micromastia|
62516575|NCT00775788|EXPERIMENTAL|Asymmetric Breasts|
62516576|NCT01173913|EXPERIMENTAL|ModraDoc001 10 mg capsules|The optimal dose weekly bi-daily oral docetaxel - ModraDoc001 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
62516577|NCT01173913|EXPERIMENTAL|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|Both new oral dosage forms, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets will be investigated to see whether these new formulations have comparable pharmacokinetic characteristics, in terms of systemic exposure to docetaxel, as ModraDoc001 10 mg capsule.
62516578|NCT01173913|EXPERIMENTAL|ModraDoc006 10 mg tablet|The optimal dose weekly bi-daily oral docetaxel - ModraDoc006 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
62516579|NCT03554603|EXPERIMENTAL|Modified Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
62516580|NCT03554603|NO_INTERVENTION|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
62516581|NCT05870371|EXPERIMENTAL|Feldenkrais Awareness Through Movement|Application of the Feldenkrais Awareness Through Movement technique in group sessions.
62710512|NCT05111067||Nigerian TNBC cohort|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc). Transcriptome data will be used to categorize specimens into one of four distinct mRNA subgroups and will be compared between cohorts.
62710513|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
62516582|NCT05870371|ACTIVE_COMPARATOR|Acupuncture and Stretching|Acupuncture protocol in combination with stretching exercises.
62516583|NCT01321281|EXPERIMENTAL|AquaCal|Osteoarthritis and healthy volunteers
62516584|NCT01321281|ACTIVE_COMPARATOR|AquaPT|Osteoarthritis
62516585|NCT04121117||Tobacco detoxication cohort|Patients appointed in a tobacco detoxication consultation
62516586|NCT03356886|EXPERIMENTAL|Spinal Manipulative Technique (SMT)|This protocol of combined manipulation and mobilization techniques was adopted in view of the previous findings of a systematic review in which the combination of thrust mobilization and non-thrust techniques showed greater (moderate) evidence for chronic low back pain when compared to each technique alone (limited evidence). In addition, the thrust manipulation will be administered at the thoracic spine considering that a previous study found no differences in pain intensity after lumbar spine high-velocity manipulation versus non-region-specific manipulation in patients with chronic low back pain.
62516587|NCT03356886|ACTIVE_COMPARATOR|SMT + Pain Neuroscience Education|Content: 1) Contextualization on the importance of the program; 2) Initial concepts on neuroscience and pain, 3) How context can influence pain perception; 5) human beings as a multisensory complex; 6) Pain and memory; 7) Nociception and nociceptors; 8) The incorrect concepts on pain; 9) Concepts on pain neurophysiology; 10) Types of sensitization; 11) Descending inhibitory system; 12) The danger message and the brain processing; 13) The sensitized brain and its relationship to chronic pain; 14) The contribution of other systems to pain experience; 15) How bone, muscles and nerves send sensory information all the time; 16) Fear avoidance model revisited; 17) Encouragement to change; 18) How to develop positive attitudes and 19) Concepts of gradual exposition and gradual activity
62516588|NCT02880748|EXPERIMENTAL|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum.
62710514|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
62710515|NCT02020161|EXPERIMENTAL|ATRA-Idarubicin|
62710516|NCT05189665|EXPERIMENTAL|Extraperitoneal high sacral ligament suspension Group|We will recruit 62 POP patients ,and perform Surgery Extraperitoneal high sacral ligament suspension surgery on them.
62516589|NCT02880748|ACTIVE_COMPARATOR|Air insufflation (AI) method|Air insufflation (AI) method was used for insertion to the cecum.
62516590|NCT01612039|EXPERIMENTAL|ASP3291|
62516591|NCT01612039|PLACEBO_COMPARATOR|Placebo|
62516592|NCT04332016||COVID-19 infected patients|
61973992|NCT02662946|EXPERIMENTAL|ICG- angiography|"Colonic resection margins and colo-rectal anastomosis are intraoperatively assessed using fluorescence angiography to evaluate colonic perfusion. If perfusion at the resection margin is judged insufficient the colon is re-resected to obtain a satisfactory perfusion"
62516593|NCT01947478|EXPERIMENTAL|MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon
62516594|NCT01947478|ACTIVE_COMPARATOR|Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution
62516595|NCT02537873|EXPERIMENTAL|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
62516596|NCT02537873|PLACEBO_COMPARATOR|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
62516597|NCT00946049|EXPERIMENTAL|Vicryl Plus|
62516598|NCT00946049|ACTIVE_COMPARATOR|Vicryl|
62516599|NCT01057927|EXPERIMENTAL|OC000459|
62516600|NCT01057927|PLACEBO_COMPARATOR|Placebo|
62516601|NCT03142035|EXPERIMENTAL|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
62516602|NCT03142035|ACTIVE_COMPARATOR|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
62710517|NCT05189665|ACTIVE_COMPARATOR|Sacrospinous Ligament Suspension Group|We will recruit 62 POP patients ,and perform sacrospinous ligament suspension surgery on them.
61973993|NCT02662946|ACTIVE_COMPARATOR|No angiography|Subjective measures are employed to determine anastomotic perfusion
61973994|NCT01662258|EXPERIMENTAL|Point-of-Care diagnostic laboratory test|Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests.
61973995|NCT01662258|NO_INTERVENTION|Empiric therapy|Option of no application of POC laboratory tests
62516603|NCT03142035|OTHER|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
62516604|NCT03384706|ACTIVE_COMPARATOR|Cognitive Processing Therapy (CPT)|PTSD Psychotherapy CPT will be implemented using the Cognitive-Only version, excluding the trauma account.
62516605|NCT03384706|EXPERIMENTAL|Accelerated Resolution Therapy (ART)|PTSD Psychotherapy
62516606|NCT03384706|NO_INTERVENTION|Wait List Control|Wait List control will include a 7 week minimal attention control period with weekly check-in calls to ensure that the participant has not experienced any significant worsening in their symptoms that might require interventions, (e.g. suicidal intent).
62516607|NCT01764243|EXPERIMENTAL|MT-4666 Low Dose|low dose
62516608|NCT01764243|EXPERIMENTAL|MT-4666 High Dose|high dose
62516609|NCT01764243|PLACEBO_COMPARATOR|Placebo|placebo
62516610|NCT02860182||experimental|patients with acute type A dissection
62516611|NCT02860182||control|patients without any pathology of the ascending aorta, but having the same characteristics as the sick patients, in terms of age and vascular risk factors including high blood pressure
62516612|NCT00692224|ACTIVE_COMPARATOR|1|study group received zinc gluconate in a dose of 10 mg/day
62516613|NCT00692224|PLACEBO_COMPARATOR|2|placebo group received placebo which was identical in color, taste and appearance and packaged in similar looking bottles.
62516614|NCT06083402|ACTIVE_COMPARATOR|Active|Participants receive 1 HyaCera™ capsule orally once daily for 12 weeks
62516615|NCT06083402|PLACEBO_COMPARATOR|Placebo|Participants receive 1 placebo capsule orally once daily for 12 weeks
62516616|NCT00983918|ACTIVE_COMPARATOR|Desflurane|General Anesthesia with Desflurane
62516617|NCT00983918|ACTIVE_COMPARATOR|Sevoflurane|General Anesthesia with Sevoflurane
62516618|NCT00983918|ACTIVE_COMPARATOR|Isoflurane|General Anesthesia with Isoflurane
62516619|NCT00983918|ACTIVE_COMPARATOR|Propofol|General Anesthesia with Propofol
62516620|NCT04986852|EXPERIMENTAL|Olinvacimab (TTAC-0001) 16 mg/kg and Pembrolizumab (Keytruda®) 200 mg|"* Olinvacimab (TTAC-0001) 16 mg/kg on D1, D8 and D15~* Pembrolizumab (Keytruda®) 200 mg on D1 Cycle: 3 weeks (21 days per cycle)"
62516621|NCT00543452|ACTIVE_COMPARATOR|oxygen|4 liters of oxygen a minute
62516622|NCT00543452|PLACEBO_COMPARATOR|air|4 liters of room air
62516623|NCT06233019|OTHER|efficacy of glycolic acid 15%plus salicylic acid 2% gel in treatment of Plane wart .|
62516624|NCT02876367||Acute scrub typhus (Group 1)|Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using \<1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
62516625|NCT02876367||Scrub typhus serosurvey (Group 2)|Villagers who are living in an identified scrub typhus environment will be informed about the study and asked to give written informed consent. If they agree to join the study they will be asked to give a finger prick dried blood spot (DBS) test on which scrub typhus ELISA and IFA will be performed.
62516626|NCT02206620|EXPERIMENTAL|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
62516627|NCT02206620|PLACEBO_COMPARATOR|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
62516628|NCT03451240|EXPERIMENTAL|Intervention|
62516629|NCT02619136|EXPERIMENTAL|Restrictive Transfusion Strategy|We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization
62516630|NCT02619136|ACTIVE_COMPARATOR|Liberal Transfusion Strategy|We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.
62710518|NCT04635852|EXPERIMENTAL|Fentanyl|Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet)
62147877|NCT01560429|EXPERIMENTAL|Patient controlled epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion until stable pain scores of ≤ 3 were reached while in PACU. Once stable, they were allocated to their preoperatively determined randomization which meant they still received 2/3rd of the anesthetic as a background infusion but also had the option to self-administer the remaining 1/3rd dose as patient controlled epidural analgesia (PCEA). Rescue analgesia was available upon request.
62516631|NCT02903238|EXPERIMENTAL|Placebo|placebo capsule
62355036|NCT02213822||Pts with Solid Tumors/ Hematological Cancer|Patients on this study must have either a suspected or confirmed solid tumor or hematological cancer. The intervention performed in this study is the molecular analysis of cancer. The samples will be taken at the time of the patient's planned diagnostic or staging procedure. If the patient is scheduled for surgery a sample of tissue not required for their diagnosis will be obtained and used for this research study. If the patient has undergone a previous diagnostic procedure, some of the stored tissue from that procedure will be submitted for molecular analysis as well.
62516632|NCT06044194|PLACEBO_COMPARATOR|Treatment group|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group)
62516633|NCT06044194|NO_INTERVENTION|Control group|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of Placebo for 3 months (control group)
62516634|NCT01011075|EXPERIMENTAL|Imatinib mesylate + Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
62516635|NCT01749670||Autism|Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
62516636|NCT01749670||Control|Age- and gender-matched controls with typical neuropsychological developmental patterns
62516637|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
62710519|NCT04635852|ACTIVE_COMPARATOR|Immediate release morphine|Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration)
62710520|NCT02190500|ACTIVE_COMPARATOR|Mobile Stroke Unit Management|Acute ischemic stroke patients treated in the Mobile Stroke Unit
62710521|NCT02190500|NO_INTERVENTION|Standard Management|Acute ischemic stroke patients receiving standard management
62355037|NCT01697852|EXPERIMENTAL|LLIN plus IRS|LLIN by universal coverage campaign 2 rounds of indoor residual spraying with bendiocarb insecticide
62355038|NCT01697852|ACTIVE_COMPARATOR|LLIN only|LLIN by universal coverage campaign
62355039|NCT05121831|EXPERIMENTAL|Single Ascending Dose Cohort S1|Subjects will receive a single dose of either dose level 1 of DGX-001 or placebo
62355040|NCT05121831|EXPERIMENTAL|Single Ascending Dose Cohort S2|Subjects will receive a single dose of either dose level 2 of DGX-001 or placebo
62355041|NCT05121831|EXPERIMENTAL|Single Ascending Dose Cohort S3|Subjects will receive a single dose of either dose level 3 of DGX-001 or placebo
62355042|NCT05121831|EXPERIMENTAL|Single Ascending Dose Cohort S4|Subjects will receive a single dose of either dose level 4 of DGX-001 or placebo
62355043|NCT05121831|EXPERIMENTAL|Multiple Ascending Doses Cohort M1|Subjects will receive multiple doses of either dose level 1 of DGX-001 or placebo
62355044|NCT05121831|EXPERIMENTAL|Multiple Ascending Doses Cohort M2|Subjects will receive multiple doses of either dose level 2 of DGX-001 or placebo
62355045|NCT05121831|EXPERIMENTAL|Multiple Ascending Doses Cohort M3|Subjects will receive multiple doses of either dose level 3 of DGX-001 or placebo
62355046|NCT05121831|EXPERIMENTAL|Stress Exposure Resilience Panel Cohort 1|Subjects will receive any of the MAD dose panel or placebo
62355047|NCT01725256|EXPERIMENTAL|80mg AIR001 four times daily|80mg AIR001 nebulized four times daily for 16 weeks
62516638|NCT03421756|EXPERIMENTAL|Non Myeloablative regimen (Alemtuzumab)|Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
62710522|NCT05401981|NO_INTERVENTION|Standard care|Clinician not given any cards about the patient's story.
62710523|NCT05401981|EXPERIMENTAL|Story checklist|Clinician given a card with talking points in the form of a checklist about the patient's story.
62355048|NCT01725256|EXPERIMENTAL|46mg AIR001 four times daily|46mg AIR001 nebulized four times daily for 16 weeks
62355049|NCT01725256|EXPERIMENTAL|80mg AIR001 once daily|80mg AIR001 nebulized once daily for 16 weeks
62355050|NCT03428256|ACTIVE_COMPARATOR|Pre-oxygenation with a standard anaesthetic face mask|Pre-oxygenation delivered in the standard way; 3 minutes, Fraction of inspired oxygen (FiO2) 1.0, 8 vital capacity breaths in the last minute
62355051|NCT03428256|EXPERIMENTAL|Pre-oxygenation using Optiflow and THRIVE technique|Pre-oxygenation delivered via nasal high flow humidified oxygen (Optiflow) and THRIVE technique. Gradually increased to 70 litres/minute, mouth closed, 8 vital capacity breaths in the last minute
62355052|NCT05438459|EXPERIMENTAL|GAIA-102 as a single agent|GAIA-102: 1 vial (2 x 10\^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.
62516639|NCT06231394|ACTIVE_COMPARATOR|daytime incontinence|This group will consist of participants who will be diagnosed with daytime incontinence by a pediatric urologist according to the International Children's Continence Society criteria.
62516640|NCT06231394|ACTIVE_COMPARATOR|nocturnal enuresis|This group will consist of participants who will be diagnosed with nocturnal enuresis by a pediatric urologist according to the International Children's Continence Society criteria.
62516641|NCT06231394|ACTIVE_COMPARATOR|combined daytime incontinence and nocturnal enuresis|This group will consist of participants who will be diagnosed with combined daytime incontinence and nocturnal enuresis by a pediatric urologist according to the International Children's Continence Society criteria.
62710524|NCT04931238|EXPERIMENTAL|JS016 treatment group|Standard therapy + JS016 injection Standard therapy including vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.
62516642|NCT01905709|EXPERIMENTAL|All patients|150-500 ml of human fecal matter
62516643|NCT04461132|ACTIVE_COMPARATOR|Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included manual lymphatic drainage on the leg, skin care, bandaging and exercise.
62516644|NCT04461132|SHAM_COMPARATOR|Shame Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included shame manual lymphatic drainage on the leg, skin care, bandaging and exercise. Shame manual lymphatic drainage include light touches instead of real manual lymphatic drainage techniques
62516645|NCT06260579|SHAM_COMPARATOR|Low intensity training (LIT)|6 months of low-intensity flexibility and balance exercises, not followed by a formal physical activity intervention
62516646|NCT06260579|EXPERIMENTAL|Moderate-intensity training (MIT)|6 months of exercise intervention (moderate intensity), followed by a co-developed physical activity intervention
62516647|NCT06260579|EXPERIMENTAL|Moderate- and high-intensity training group (MHIT)|6 months of exercise intervention (moderate-intensity followed by high-intensity), followed by a co-developed physical activity intervention
62516648|NCT05946174|EXPERIMENTAL|Outpatient clinic/community participants receiving exercise sessions and meals (A1)|Outpatient clinic/community participants receiving intervention Set A (exercise sessions and meals over approximately 12 weeks)
62516649|NCT05946174|NO_INTERVENTION|Outpatient clinic/community participants receiving control/usual care (A2)|Outpatient clinic/community participants receiving control/usual care
62516650|NCT05946174|EXPERIMENTAL|Step-down community hospital participants receiving exercise sessions and meals (B1)|Step-down community hospital participants receiving Intervention Set B (exercise sessions and meals over approximately 3 weeks)
62516651|NCT05946174|NO_INTERVENTION|Step-down community hospital participants receiving control/usual care (B2)|Step-down community hospital participants receiving control/usual care
62710525|NCT04931238|NO_INTERVENTION|Control group|Standard therapy Standard therapy includes vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.
62710526|NCT01871649|ACTIVE_COMPARATOR|methotrexate|methotrexate is the active comparator, it will be compared to golimumab + methotrexate
62710527|NCT01871649|EXPERIMENTAL|golimumab and methotrexate|The combination of golimumab en methotrexate will be compared to methotrexate alone.
61973996|NCT04189211|EXPERIMENTAL|1.2mg/kg of BAT8001|BAT8001 100mg/box, 1.2mg/kg IV infusions
61973997|NCT04189211|EXPERIMENTAL|2.4mg/kg of BAT8001|BAT8001 100mg/box, 2.4mg/kg IV infusions
61973998|NCT04189211|EXPERIMENTAL|3.6mg/kg of BAT8001|BAT8001 100mg/box, 3.6mg/kg IV infusions
61973999|NCT04189211|EXPERIMENTAL|4.8mg/kg of BAT8001|BAT8001 100mg/box, 4.8mg/kg IV infusions
62355053|NCT05438459|EXPERIMENTAL|GAIA-102 and pembrolizumab in combination|"GAIA-102: 1 vial (2 x 10\^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.~Pembrolizumab：200 mg on Day 1."
62355054|NCT03907787|OTHER|One-group pretest-posttest quasi-experimental design|50 subjects with moderate knee osteoarthritis were supplied for four weeks with two tablets/day, each containing 350 mg of standardized extracts of Zingiber officinale and Acmella oleracea.
62355055|NCT01267604|ACTIVE_COMPARATOR|Recombinant FSH|225IU rFSH
62355056|NCT01267604|EXPERIMENTAL|Recombinant FSH Inositol Melatonin|225IU rFSH, 4g Inositol and 3mg Melatonin
62355057|NCT00599170|EXPERIMENTAL|Arm 1|Rituximab 375 mg/m2 iv on day 1 q 15 days just prior to CHOP, beginning with cycle 1.
62355058|NCT03999541|EXPERIMENTAL|Freeze-all|Good quality embryos (either day 3 or 5) will be frozen and subsequent frozen embryo transfer will be arranged within three months of the egg retrival.
62355059|NCT03999541|NO_INTERVENTION|Fresh embryo transfer|Women will undergo fresh embryo transfer at the cleavage (day 3) or blastocyst stage (day 5).
62355060|NCT00383578|EXPERIMENTAL|Vildagliptin|
62355061|NCT00383578|ACTIVE_COMPARATOR|Metformin|
62355062|NCT01280266|EXPERIMENTAL|Amlodipine-Udenafil (AU) arm|Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
62355063|NCT01280266|EXPERIMENTAL|Udenafil-Amlodipine (UA) arm|Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks
62355064|NCT01293006|EXPERIMENTAL|Suvorexant first, then placebo|"During Period 1, participants \<65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening and participants ≥65 years of age were administered a 30-mg oral dose of~suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening."
62516652|NCT05946174|EXPERIMENTAL|Acute hospital participants receiving meals (C1)|Acute hospital participants receiving Intervention Set C (meals over approximately 3 weeks)
62516653|NCT05946174|NO_INTERVENTION|Acute hospital participants receiving control/usual care (C2)|Acute hospital participants receiving control/usual care
62516654|NCT02350582|EXPERIMENTAL|Telerehabilitation|Resistence and endurance exercise adapted to individual requeriment using internet to monitor progression during chemotherapy treatment. Telerehabilitation eCUIDATE system
62710528|NCT02036346|EXPERIMENTAL|Oral rehydration solution|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
61974000|NCT04189211|EXPERIMENTAL|6.0mg/kg of BAT8001|BAT8001 100mg/box, 6.0mg/kg IV infusions
61974001|NCT06408532|ACTIVE_COMPARATOR|Premixed insulin dose optimization group|The participants in this group will get optimized insulin dosage adjustment on premixed insulin.
61974002|NCT06408532|EXPERIMENTAL|IDegLira once daily injection group|The participants in this group will switch from premixed insulin to IDegLira once daily injection therapy.
61974003|NCT01710254|EXPERIMENTAL|Regadenoson MRI|Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine
61974004|NCT00329654|EXPERIMENTAL|Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation.
61974005|NCT01265732|ACTIVE_COMPARATOR|oral single dose dispersion 100mg|Subjects receive a single dose of PF-04191834 as a dispersion
61974006|NCT01265732|ACTIVE_COMPARATOR|oral wet milled suspension 100mg|Subjects receive a single dose of PF-04191834 as a suspension
62710529|NCT02036346|EXPERIMENTAL|No intervention|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
62516655|NCT02350582|NO_INTERVENTION|Control group|usual care offered to patients during chemotherapy treatment
62516656|NCT03765086|ACTIVE_COMPARATOR|Karydakis procedure|Karydakis Procedure: In this procedure the pilonidal sinus will be excised by semilunar incision so that the incision line closure will be away from midline.
62516657|NCT03765086|ACTIVE_COMPARATOR|Limberg Flap|Limberg Flap: In this procedure the pilonidal sinus will be excised by diamond shaped incision and the defect will be closed by random pattern flap.
62516658|NCT04636593|EXPERIMENTAL|Induction group|If the lung V20 of initial radiation plan is equal to or more than 28%, then the patient will receive 2 months almonertinib before concurrent thoracic radiotherapy
62147878|NCT01560429|ACTIVE_COMPARATOR|continuous epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion rate until stable pain scores of ≤ 3 were reached while in PACU (as described in the PCEA group). Once stable, they were allocated to their preoperatively determined randomization assignment which for the CEA group meant they remained on the continuous background epidural infusion rate previously determined to maintain pain scores ≤ 3 while in PACU. Rescue analgesia was available as needed.
62516659|NCT04636593|EXPERIMENTAL|Concurrent group|If the lung V20 of initial radiation plan is less than 28%, then the patient will receive concurrent thoracic radiotherapy with almonertinib.
62516660|NCT05365841||Severe asthma without CRSwNP|control group; n\~20 of anti-IL5 naïve severe asthmatics
62516661|NCT05365841||Severe asthma with CRSwNP|n\~40 of anti-IL5 naïve severe asthmatics
62516662|NCT05365841||subjects CRSwNP with mild or no asthma|\~25;2nd control group
62516663|NCT00537108|EXPERIMENTAL|HV|Intervention arm.
62516664|NCT00537108|NO_INTERVENTION|Cntr|Usual care control
62516665|NCT03433755|PLACEBO_COMPARATOR|Placebo Q2W|Placebo subcutaneous (SC) Q2W for 12 weeks
62516666|NCT03433755|PLACEBO_COMPARATOR|Placebo QM|Placebo SC QM for 12 weeks
62516667|NCT03433755|EXPERIMENTAL|Evolocumab 140 mg Q2W|Evolocumab 140 mg SC Q2W for 12 weeks
62516668|NCT03433755|EXPERIMENTAL|Evolocumab 420 mg QM|Evolocumab 420 mg SC QM for 12 weeks
62516669|NCT01046552|ACTIVE_COMPARATOR|PES/LC|preoperative ES followed by LC within the same hospital admission
62516670|NCT01046552|ACTIVE_COMPARATOR|LC/IOES|laparoscopic cholecystectomy with intraoperative ercp under the same anesthesia
62516671|NCT04252482|EXPERIMENTAL|cpap|usage cpap 3month
62516672|NCT04252482|NO_INTERVENTION|Usual care|Usual care 3month
61974007|NCT01265732|ACTIVE_COMPARATOR|oral wet milled suspension 300mg|Subjects receive a single dose of PF-04191834 as a suspension
62516673|NCT04291807|EXPERIMENTAL|Video education|A video of ERCP procedure has been viewed to the patients who will undergo ERCP and questions about the procedure had been answered by the primary investigator (experienced endoscopy nurse)
62516674|NCT04291807|NO_INTERVENTION|Direct ERCP|Patients arranged ERCP for any reason underwent directly to the ERCP without any video education.
62516675|NCT03097588|EXPERIMENTAL|Supportive care (NEPA)|"Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.~Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies"
62516676|NCT03201354|ACTIVE_COMPARATOR|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
62516677|NCT03201354|ACTIVE_COMPARATOR|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
62516678|NCT03442881||benign adnexal mass|pathological examination of the specimen after excision reveals benign criteria
62516679|NCT03442881||Malignant adnexal mass|pathological examination of the specimen after excision reveals malignant criteria
62516680|NCT05052242||one group compared two measurement methods|one group compared two measurement methods
62516681|NCT04744324|EXPERIMENTAL|Self-supporting Care Group|Self-supporting Care in home
62516682|NCT04744324|ACTIVE_COMPARATOR|Control group|Home Health Education
61974008|NCT05981417|EXPERIMENTAL|Supervised exercise|Exercise sessions will beguided by a physiotherapist.
61974009|NCT05981417|ACTIVE_COMPARATOR|Home exercise|Exercise sessions will be perfomed at home.
61974010|NCT06038084|EXPERIMENTAL|Bronpass Tab.|
61974011|NCT06038084|ACTIVE_COMPARATOR|Erdos capsule|
62147879|NCT01959776|OTHER|Vitrectomy|
62516683|NCT04638439|EXPERIMENTAL|P1101 + Nivolumab + Entecavir|
62516684|NCT00686582|EXPERIMENTAL|Initially Vaccinia Naive, 2 dose primed, 1 booster dose|"Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
62516685|NCT00686582|EXPERIMENTAL|Initially Vaccinia Naive, 1 dose primed, 1 booster dose|"Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
62516686|NCT00686582|OTHER|Vaccinia Experienced, boosted, blood draw only|"Group 4 Vaccinia Experienced~1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)"
62516687|NCT05402982|OTHER|GROUP A|Fluid administration in the form of lactated ringer will be managed by Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2(10). Rohrich formula represents fluid maintinance,deficit and replacement fluid ( 0.25 ml crystalloid given for each 1 ml above 4 litre of lipoaspirate).
62516688|NCT05402982|OTHER|GROUP B|Patients will receive fluid maintenance of lactated ringer 2 ml/kg/h, cardiometry guided SVV will be measured before and after induction then every 30 min ,it ranges between 5-15%, fluid bolus of lactated ringer 4 ml /kg over 15 min will be administered if SVV ˃ 15% .
62516689|NCT04686656|ACTIVE_COMPARATOR|nasal oxygen supplementation group|supplemental oxygen will be administered with nasal cannula
62516690|NCT04686656|ACTIVE_COMPARATOR|buccal oxygen supplementation group|supplemental oxygen will be administered with Ring-Adair-Elwyn (RAE) tube
62516691|NCT05444322|EXPERIMENTAL|RD14-01 cell infusion|Infused i.v. in a single dose
62516692|NCT00210899|ACTIVE_COMPARATOR|Vancomycin plus Ceftazidime|Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
62516693|NCT00210899|EXPERIMENTAL|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
62516694|NCT03432065|EXPERIMENTAL|Buspirone|Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.
62516695|NCT04998578|ACTIVE_COMPARATOR|Microneedling- Group A|Participants will only perform microneedling
62516696|NCT04998578|ACTIVE_COMPARATOR|Microneedling and outpatient Cosmetics- Group B|Microneedling associated with the use of outpatient cosmetics
62516697|NCT04998578|ACTIVE_COMPARATOR|microneedling and home use cosmetics - Group C|Microneedling associated with home use cosmetics
62516698|NCT04998578|ACTIVE_COMPARATOR|Non-ablative radiofrequency - Group D|Participants will perform only non-ablative radiofrequency
62516699|NCT03507413|ACTIVE_COMPARATOR|INVESTIGATIONAL DRUG|oral metformin treatment with 2000Mg daily: Glucophage 500mg Tablet (2-0-2) daily for 1 year
62516700|NCT03507413|PLACEBO_COMPARATOR|COMPARATIVE DRUG|Placebo matching M90 Oral Tablet treatment twice daily (2-0-2) for 1 year
62516701|NCT01120652|EXPERIMENTAL|Mind-Body Skills Training|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices.
62516702|NCT01120652|ACTIVE_COMPARATOR|Supportive Counseling|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice.
62516703|NCT05151575|EXPERIMENTAL|group-based walking intervention with professional trainer's supervision|Participants will conduct the intervention in groups under the supervision of a professional fitness trainer.
62516704|NCT05151575|ACTIVE_COMPARATOR|individual-based walking intervention without professional trainer supervision|Participants will conduct the intervention individually, without the supervision of a professional fitness trainer
62516705|NCT05151575|NO_INTERVENTION|control group|No intervention will be given to the control group.
62516706|NCT03432234||COPD and frequent exacerbation|Patient with COPD diagnosis and at least two exacerbations by year (FE)
62516707|NCT03432234||COPD no frequent exacerbation|Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).
62516708|NCT03432234||Healthy (control)|Healthy volunteers patients (H)
62516709|NCT03418168|EXPERIMENTAL|Molidustat (BAY85-3934)|Molidustat group
62516710|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
62516711|NCT03589248||US score|assess the AGI by ultrasonography(US) score
62516712|NCT00195013|EXPERIMENTAL|Glutamine|10 grams three times a day (orally) for four days and then stop
62355065|NCT01293006|EXPERIMENTAL|Placebo first, then suvorexant|"During Period 1, participants \<65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening and participants ≥65 years of age received one placebo tablet matching~suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening."
62355066|NCT00583661|EXPERIMENTAL|EXCOR Pediatric|Implantation of the EXCOR Pediatric Ventricular Assist Device
62355067|NCT04563819||Newborns with DDH|Newborns (born 1988-90) with sonographic hip dysplasia (DDH)
62516713|NCT00195013|PLACEBO_COMPARATOR|Placebo|10 grams three times a day (orally) for four days and then stop
62516714|NCT02194569|EXPERIMENTAL|High citrate group|Blood flow according to weight.Target citrate concentration is 4,5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 0.8-1.1 mg/dL.
62516715|NCT02194569|EXPERIMENTAL|Low citrate group|Blood flow according to weight. Target citrate concentration is 2.5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 1.3-1.6 mg/dL.
62355068|NCT04563819||Newborns without DDH|Newborns (born 1988-90) without sonographic hip dysplasia (DDH)
62355069|NCT04563819||Hip dysplasia at skeletal maturity|Subjects that show signs of acetabular dysplasia at skeletal maturity (age 17-19 years), in 2007-09, when hip radiographs and salivary samples were collected.
62516716|NCT00793741||1|Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate
61974012|NCT05599607|EXPERIMENTAL|Probiotic group|Probiotic in capsule format administered orally. This probiotic product contains a mixture of strains of lactobacillus and bifidobacteria, called BTHS21, at concentrations equal to or greater than 1x109 cfu/dose.
61974013|NCT05599607|PLACEBO_COMPARATOR|Placebo group|Maltodextrin, masked in an identical and indistinguishable format to that of the probiotic
62355070|NCT04137562|EXPERIMENTAL|ADSTEM Inj.|ADSTEM Inj. hAD-MSC 1.0x10\^8 cells
62516717|NCT00793741||2|Healthy control subjects
62516718|NCT04960319|EXPERIMENTAL|Intravascular Lithotripsy|Study Device Treatment: IVL balloon catheter size is chosen in a 1:1 ratio to the distal reference vessel diameter. If the IVL balloon cannot be delivered into the target lesion a Guide catheter extension is recommended. The balloon catheter is then inflated to 4 ATM and 10 impulses are delivered. The balloon is then inflated to 6 ATM and deflated to reestablish blood flow. Up to 80 impulses can subsequently be delivered and the balloon can be repositioned within the lesion. In multiple lesions with different reference vessel diameters different sizes of IVL balloon can be used.
62516719|NCT04960319|ACTIVE_COMPARATOR|Rotational Atherectomy|Control group treatment: Rotablation should be performed as described in the ESC-Consensus document. Burr/vessel-ratio is 0.5 - 0.75. The use of different burr sizes as well as the use of a temporary pacemaker is left to the operator's discretion.
62516720|NCT01349101|EXPERIMENTAL|Myeloablative HSCT|Myeloablative Hematopoietic Stem Cell Transplantation (HSCT): Patients will receive myeloablative transplants or nonmyeloablative transplants depending on their disease type.
62710530|NCT02036346|ACTIVE_COMPARATOR|Colorectal resection without an ileostomy|Patients who have undergone colorectal resection surgery without an ileostomy creation
62710531|NCT01761578|EXPERIMENTAL|ART18Z Bioresorbable stent|
62710532|NCT04539171|EXPERIMENTAL|Intervention|Pain neuroscience education (Health education) and Physical exercise program: 6 weekly sessions (2 hours each), and a reminder session one month later
62710533|NCT04539171|NO_INTERVENTION|Control|Standard of care.
62516721|NCT01349101|EXPERIMENTAL|Reduced Intensity HSCT|Reduced Intensity Hematopoietic Stem Cell Transplantation (HSCT): Patients who have received a previous transplant, patients who have received dose limiting radiation, and patients with a DLCO \<45% will receive the reduced intensity conditioning regimen.
62516722|NCT03060759|ACTIVE_COMPARATOR|Light Therapy-Spectrum 1|Light from 'active' spectrum
62516723|NCT03060759|PLACEBO_COMPARATOR|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
62516724|NCT00109837|EXPERIMENTAL|Induc x2, Consol, Maint|Induc 1: Allopurinol; Daunorubicin; Vincristine; Prednisone; asparaginase; Bactrim Induc 2: Allopurinol; cytarabine; Dexamethasone; filgrastim; mitoxantrone; Methotrexate; leucovorin Consol: Cyclophosphamide; cytarabine; 6-mercaptopurine; Methotrexate; filgrastim Maint:Course 1: 6-mercaptopurine; Methotrexate Course 2: Vincristine; doxorubicin; Dexamethasone Course 3: Cyclophosphamidee; thioguanine; cytarabine Course 4: 6-mercaptopurine; methotrexate
62516725|NCT00302549|ACTIVE_COMPARATOR|FK506|
62355071|NCT04137562|PLACEBO_COMPARATOR|Placebo|0.9% Normal Saline Inj.
62355072|NCT03273504|EXPERIMENTAL|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.~The placebo product will be applied in the same way, on the controlateral leg."
62516726|NCT04115709|EXPERIMENTAL|Intervention: Device attached with advice activated|Beacon Caresystem device will be attached to the patients and its ventilator advice will be activated.
62516727|NCT04115709|ACTIVE_COMPARATOR|Control: standard care with device attached without advice|Beacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated.
62516728|NCT01493349||Controls|No diverticular disease or other gastrointestinal and liver diseases
62516729|NCT01493349||Uncomplicated diverticular disease|
62516730|NCT01493349||History of complicated diverticular disease|
62516731|NCT01493349||Current complicated diverticular disease|
62516732|NCT02135965|EXPERIMENTAL|Albuterol 2mg|2 mg of Albuterol is in a pill form or placebo
62516733|NCT02135965|EXPERIMENTAL|Albuterol 4mg|4mg of Albuterol or placebo is given in pill form
62516734|NCT02135965|EXPERIMENTAL|Caffeine 100mg|100mg of Caffeine or placebo is given in a pill form.
61974014|NCT00386776|EXPERIMENTAL|'Computer-based medical history|A computer-based medical history to take in their homes via the Internet. The history is divided into 24 modules- family history, social history, cardiac history, pulmonary history, and the like.
62147880|NCT01815359|EXPERIMENTAL|Appendiceal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~1. Exposure to chemotherapy in the prior 6 months vs. no such exposure~2. Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
62355073|NCT01001364|EXPERIMENTAL|Formoterol/Budesonide|
62355074|NCT01001364|ACTIVE_COMPARATOR|Foraseq|
62516735|NCT02135965|EXPERIMENTAL|Caffeine 200mg|200mg of Caffeine or placebo is given in a pill form
62516736|NCT02135965|EXPERIMENTAL|Albuterol 2mg & Caffeine 100mg|100mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
62516737|NCT02135965|EXPERIMENTAL|Albuterol 2mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
62516738|NCT02135965|EXPERIMENTAL|Albuterol 4mg and Caffeine 100mg|100mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
62516739|NCT02135965|EXPERIMENTAL|Albuterol 4mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
62516740|NCT03036774|EXPERIMENTAL|Diabetic patient|Diabetic patients (type 1 or type 2 diabetes) with scheduled surgery . Ultrasonic measurement of antral area
62516741|NCT03036774|OTHER|Non diabetic patient|"Patients with scheduled surgery without history of diabetes or a current, treated or untreated, diabetic disease.~Ultrasonic measurement of antral area"
62516742|NCT05666947|EXPERIMENTAL|Home-based resistance exercise|The experimental group participated in a home-based exercise program for eight weeks, namely elastic-band resistance exercise. Participants were forwarded to the next exercise session every two weeks and completed the exercise program within eight weeks. The program included upper and lower limb exercises. The home-based exercise program contained four sessions, namely: warm-up, start-up, vigorous, and reinforcement sessions. Participants received guidelines from a booklet and video about elastic-band resistance.
62355075|NCT05149612|EXPERIMENTAL|Heat Therapy Group|The patients in the intervention group will be treated with hot water bags twice, for 20 minutes in the morning and 20 minutes in the evening, to the shoulder area, starting four hours after the operation, until the patient is discharged.
62516743|NCT05666947|PLACEBO_COMPARATOR|Non-resistance exercise|The control group participated in an exercise program for eight weeks, namely conventional non-resistance exercise, which contained four sessions: warm-up, start-up, vigorous, and reinforcement. Participants were forwarded to the next exercise session every two weeks and completed the exercise program within eight weeks. Participants in the control group received guidelines from a booklet and video about the conventional non-resistance exercise.
62516744|NCT05732259|ACTIVE_COMPARATOR|Percussion therapy group|"Group A was given Conventional treatment along with percussion therapy with Theragun PRO (1750-2400 rpm).~•Participants lying in prone position on the couch received percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest"
62516745|NCT05732259|ACTIVE_COMPARATOR|Manual Myofascial Release technique group|Group B was given Conventional treatment along with manual myofascial release technique for 90 sec continuous.
62516746|NCT02839421|EXPERIMENTAL|Scaling and Root Planing plus moxifloxacin|The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.The experimental treatment group consist of SRP combined with systemically administered MOX at the dosage of 400 mg once daily for 7 days.One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the MOX group will be extensively informed about the intake of the prescribed medication.
62516747|NCT02839421|ACTIVE_COMPARATOR|Scaling and Root Planing plus amox-metro|"The active comparator is Scaling and Root Planing (SRP) combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days. The active comparator group consist of SRP combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days.~One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the amox-metro group will be extensively informed about the intake of the prescribed medication."
62516748|NCT02839421|PLACEBO_COMPARATOR|Scaling and Root Planing plus placebo|Scaling and Root Planing (SRP) + placebo once daily for 7 days. The placebo comparator group consist of SRP combined with systemically administered placebo once daily for 7 days. One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The placebo agent will start at the SRP visit. Subjects in the placebo group will be extensively informed about the intake of the prescribed medication.
62516749|NCT05364008|EXPERIMENTAL|Green tea extract containing 45% epigallocatechin gallate (EGCG)|Low caffeine green tea extract (1650mg in 6 capsules) taken orally on a daily basis (QD) along with Clomiphene citrate-intrauterine insemination (CC_IUI) cycle, up to 4 cycles if no pregnancy is achieved, participant will stop green tea if she becomes pregnant
62516750|NCT05364008|PLACEBO_COMPARATOR|Placebo|Placebo (1650mg in 6 capsules) matched (smell, taste, color, texture) capsules taken orally on a daily basis (QD) along with Clomiphene citrate-intrauterine insemination (CC_IUI) cycle, up to 4 cycles if no pregnancy is achieved, participant will stop placebo if she becomes pregnant
61974015|NCT06131307|EXPERIMENTAL|Experimental group|Managers of this group will be given paternalistic leadership training. Before the training, paternalistic leadership perception, motivation, organizational commitment, and performance levels will be measured. Two months after the paternalistic leadership training given to managers, the paternalistic leadership perception, motivation, organizational commitment and performance levels of the same participants will be measured again.
62516751|NCT04835649|EXPERIMENTAL|Exercise group|The group that will receive task-oriented training via telerehabilitation
62516752|NCT04835649|PLACEBO_COMPARATOR|Control group|The control group only will be given a home program that includes walking and balance exercises
62516753|NCT06460441||Suspected OSAHS|
62516754|NCT00892281|OTHER|Oracea® as monotherapy|Oracea as monotherapy
61974016|NCT06131307|NO_INTERVENTION|Control group|Managers of this group will not be given paternalistic leadership training. At the same time as the first group, paternalistic leadership perception, motivation, organizational commitment, and performance levels will be measured.
61974017|NCT04328584|EXPERIMENTAL|SNS|Intraoperative imaging/surgical navigation system (SNS)
61974018|NCT04607850|EXPERIMENTAL|Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^7 pfu)
61974019|NCT04607850|EXPERIMENTAL|Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu)
61974020|NCT04607850|EXPERIMENTAL|Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10) vp and MVA-HPV (1 x 10\^8 pfu)
61974021|NCT04607850|EXPERIMENTAL|Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu)
61974022|NCT04607850|EXPERIMENTAL|Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^7 pfu)
61974023|NCT04607850|EXPERIMENTAL|Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^8 pfu)
61974024|NCT04607850|EXPERIMENTAL|Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^8 pfu)
62355076|NCT05149612|NO_INTERVENTION|Control group|When the individuals in the control group have pain, analgesic drug treatment will be applied at the request of the physician, and no other intervention will be applied.
62355077|NCT06244537|EXPERIMENTAL|MR-linac|Patients enrolled will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX chemotherapy.
62355078|NCT04932044|EXPERIMENTAL|Early Sleep Facilitation Program|Perform sleep circadian rhythm training during hospitalization, and provide caregivers with nursing guidance to promote sleep of premature infants before discharge
62355079|NCT04932044|ACTIVE_COMPARATOR|routine care and provide general discharge care and nursing guidance|Routine care and provide general discharge care and nursing guidance.
62355080|NCT02593968|EXPERIMENTAL|Treatment|subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
62355081|NCT02593968|PLACEBO_COMPARATOR|Plcaebo|subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
62355082|NCT02249026|EXPERIMENTAL|BZDs + opiate exposure treated with BPN|In-utero opiate and BZD exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
61974025|NCT04607850|EXPERIMENTAL|Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^8 pfu)
61974026|NCT04607850|PLACEBO_COMPARATOR|Group 6 Placebo Saline|Sodium Chloride (0.9%)
61974027|NCT01945957|EXPERIMENTAL|OT (24 IU)|Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
61974028|NCT01945957|EXPERIMENTAL|OT (8 IU and 40IU)|Each phase will require a separate subject consent. Phase II Aim 2a. (fMRI) Will determine the effect of oxytocin dose (8 or 40 IU) on neural activation and connectivity. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin (8 or 40 IU) in an eye-tracking task (social vs. non-social image).
62516755|NCT00892281|OTHER|Oracea® as add-on therapy|Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides
62516756|NCT01524302|ACTIVE_COMPARATOR|Levofloxacin|Pharmacodynamics
62516757|NCT01524302|ACTIVE_COMPARATOR|Ceftaroline|Pharmacodynamics
62516758|NCT02406638||TVT Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT 3 years before clinical and 3D pelvic floor ultrasound evaluation.
62516759|NCT02406638||TVT-O Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT Obturator System, inside-out approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation.
62516760|NCT02406638||TVT-S Group|"Women who underwent to stress urinary incontinence surgery using GynecareTVT-Secur System, in U approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation."
61974029|NCT03999372|EXPERIMENTAL|PICSI procedure|PICSI procedure: PICSI dishes are conventional plastic culture dishes pre-prepared with 3 microdots of powdered. The powdered HA is re-hydrated by adding 5 μL droplets of fresh culture medium to each of the three microdots. A 2 μL droplet with suspension of treated spermatozoa is then connected with a pipette tip to these culture medium droplets. The PICSI dish is incubated under oil; within 5 minutes the bound spermatozoa are attached by their head to the surface of the HA-microdots and are spinning around their head. An ICSI injecting pipette is used to pick the best motile HA-bound sperm up and inject them one by one into an oocyte. The ICSI injecting pipette can be previously loaded with viscous medium (PVP or Sperm Slow) to facilitate sperm micromanipulation.
62516761|NCT03936049||DPP-4 inhibitor|Reference group
62516762|NCT03936049||Liraglutide|Exposure group
62516763|NCT02710682|ACTIVE_COMPARATOR|Mini-open surgery|Surgery
62516764|NCT02710682|EXPERIMENTAL|Ultrasound-guided Tendon fenestration|Tendon fenestration
62516765|NCT05466344|ACTIVE_COMPARATOR|Herbst Group|Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the type IV Herbst appliance (mini plate anchored appliance). The age of patients will be (18-20y).
62516766|NCT05466344|ACTIVE_COMPARATOR|TFBC Group|Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the Twin Force Bite Corrector appliance (dentally anchored appliance). The age of patients will be (18-20y).
61974030|NCT03999372|ACTIVE_COMPARATOR|ICSI procedure|ICSI procedure: following sperm preparation as described before, samples were incubated until time of injection. Each oocyte was injected with a single morphologically abnormal and immobilized in polyvinyl Pyrolidone (PVP) spermatozoon. Individual sperm subjected to ICSI was examined and evaluated. The injection procedure was carried out in a sterilized dish using holding pipette and injection needle. Intra cytoplasmic sperm injection was performed according to the protocol of Van Steirteghem.
62147881|NCT01815359|EXPERIMENTAL|Appendiceal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~1. Exposure to chemotherapy in the prior 6 months vs. no such exposure~2. Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
62355083|NCT02249026|ACTIVE_COMPARATOR|Opiates exposure treated with BPN|In-utero opiate exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
62355084|NCT04994080|EXPERIMENTAL|Treatment group A/B|
62355085|NCT04994080|PLACEBO_COMPARATOR|Treatment group C|
62355086|NCT04435561|EXPERIMENTAL|Standard physiotherapy rehabilitation and dry needling|"In addition to the usual therapy, the experimental group will receive the application of dry needling technique in the hemiparetic limbs.~Dry needling intervention will take place over a period of one and a half months (6 weeks), with a total of 6 sessions. Each session will be performed once a week, where a single puncture will be made in each muscle to be treated, using Hong´s technique and lasting 60 seconds per muscle (or until the muscle is release).~The muscles that will receive dry needling are the following ones:~* Upper limb: infraspinatus, teres minor, pectoralis major, deltoid.~* Lower limb: gastrocnemius, soleus and anterior tibial muscles."
62355087|NCT04435561|OTHER|Standard physiotherapy rehabilitation|The control group will receive the usual therapy and treatment.
62355088|NCT02156804|EXPERIMENTAL|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
62355089|NCT00249795|EXPERIMENTAL|Irbesartan|150 mg for 2 weeks, then up-titrated to 300 mg up to final follow-up visit
62516767|NCT05915286|EXPERIMENTAL|Diuretic Therapy|
62516768|NCT03513042||Cohort|"Intervention:~- Standard of care Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy.~Baseline measurements:~- All patients undergo baseline FDG PET-CT and FAZA PET-CT of the head-neck area.~Interim measurements conventional):~* FDG PET-CT will be repeated at the end of the second week of IMPT.~* FAZA PET will only be repeated at the end of the second week of IMPT if a hypoxic tumour volume was found at baseline scanning.~* A subcohort will also undergo activation PET imaging three times during IMPT."
62516769|NCT02463799|EXPERIMENTAL|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
62516770|NCT02463799|ACTIVE_COMPARATOR|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
62516771|NCT00489281|EXPERIMENTAL|Transplant - 200 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 200. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
62516772|NCT00489281|EXPERIMENTAL|Transplant - 400 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 400. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
62516773|NCT05787002|EXPERIMENTAL|Treatment sequence A-B|Participants will receive treatments in the following sequence, a single dose of rosuvastatin tablet alone (Treatment A) in period 1, and then a single dose of rosuvastatin tablet + Dose X AZD0780 tablet (Treatment B) in period 2.
62710534|NCT00876447|EXPERIMENTAL|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
62355090|NCT00249795|PLACEBO_COMPARATOR|Placebo|Matching placebo up to final follow-up visit
62355091|NCT03437044|EXPERIMENTAL|Ticagrelor|180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD
62355092|NCT03437044|ACTIVE_COMPARATOR|Clopidogrel|600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD
62355093|NCT06282536|EXPERIMENTAL|Neoadjuvant Therapy With Iruplinalkib|In this arm, 20 patients with III-IVA stage, potentially resectable ALK Positive non-small cell lung cancer will receive 4 circles of neoadjuvant Iruplinalkib. And the patients who are resectable after neoadjuvant therapy will be treated with surgery. Postoperative patients receive adjuvant Iruplinalkib therapy up to 2 years/until the disease progressed.
62355094|NCT02584413|EXPERIMENTAL|Arm 1: MRI of brain with gadolinium contrast|-Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes
62355095|NCT01539213|EXPERIMENTAL|AIN457|secukinumab (AIN457)
62355096|NCT01272817|OTHER|Cladribine + melphalan|Cladribine + melphalan conditioning
62355097|NCT01272817|OTHER|TLI|Total lymphoid irradiation conditioning
62355098|NCT00818311|OTHER|5|
62355099|NCT01538147||Cases|Patients with Severe preeclampsia
62355100|NCT01538147||Control|Patients with normal pregnancies at term
62355101|NCT06138990|EXPERIMENTAL|Intervention arm: Pharmacoscopy-guided clinical standard-of-care|Patients in the PCY-guided treatment arm will receive one of the clinical standard-of-care treatments suggested by their own PCY results, and confirmed by the treating physician.
62355102|NCT06138990|ACTIVE_COMPARATOR|Control arm|Patients in the control arm will be treated with clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
62355103|NCT04844242||Group 1|Prior SARS-CoV2 infection as defined by being positive for IgG
62355104|NCT04844242||Group 2|COVID-19 disease as defined as children positive by RT-PCR
62355105|NCT04844242||Group 3|Children with MIS-C according to the WHO or CDC criteria
62355106|NCT04844242||Group 4|Control children who are negative for both RT-PCR and antibody
62355107|NCT03118011|ACTIVE_COMPARATOR|No smoking|The ward where the patients can not go out to smoke
62355108|NCT03118011|PLACEBO_COMPARATOR|Smoking|The ward where the patients can go out to smoke.
62355109|NCT03772340|EXPERIMENTAL|Tradipitant|
62355110|NCT03772340|PLACEBO_COMPARATOR|Placebo|
62355111|NCT03316677|OTHER|colorectal resection and anastamosis|"Intraoperative testing of colorectal anastomoses~1. Insert a Foley catheter through the anus into the rectum.~2. Insufflate the Foley balloon with 5 cc of air.~3. fill the pelvic space with 500 CC of warm saline~4. Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~5. Remove the saline from the pelvic space.~6. Inject methylene blue in to the rectum up to a pressure of 35 mmH2o measured by external manometer~7. Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
62355112|NCT01988597||Dry Eyes|
62355113|NCT03124901|EXPERIMENTAL|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
62355114|NCT04904380|EXPERIMENTAL|Intervention|HMS, HBS and peer learning in combination with AIR and PRISMS
62355115|NCT04904380|ACTIVE_COMPARATOR|Comparison arm|HMS, HBS and peer learning in combination with PRISMS but no AIR
62355116|NCT02181036|EXPERIMENTAL|family work shop|2 to 3 hours per session, one session per week, for a total of 6 weeks of family work shop
62355117|NCT06271928|EXPERIMENTAL|Treatment group|Once enrolled, participants will be administrated Yijing Keli and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
62355118|NCT03830255||Renal Transplant patients treated with cyclosporine|Detecting the genetic polymorphism affecting cyclosporine level
62355119|NCT03830255||Renal Transplant patients treated with tacrolimus|Detecting the genetic polymorphism affecting tacrolimus level
62355120|NCT04255277|OTHER|Period 1: First administration of combined oral contraceptives|Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 1.
62355121|NCT04255277|OTHER|Period 2: Second administration of Combined Oral Contraceptive|Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 42.
62355122|NCT04255277|EXPERIMENTAL|Period 2: Cenerimod 0.5 mg|Participants randomized to cenerimod 0.5 mg will receive a single oral dose in the morning from Day 7 to Day 56.
62355123|NCT04255277|EXPERIMENTAL|Period 2: Cenerimod 4 mg|Participants randomized to cenerimod 4 mg will receive a single oral dose in the morning from Day 7 to Day 56.
62355124|NCT04255277|OTHER|Period 2: Moxifloxacin|Participants randomized to moxifloxacin will receive a single oral 400 mg dose in the morning of Day 42.
62355125|NCT04255277|PLACEBO_COMPARATOR|Period 2: Placebo|Participants randomized to placebo will receive a single oral dose of placebo in the morning from Day 7 to Day 56.
62355126|NCT04255277|EXPERIMENTAL|Period 3: Cenerimod 0.5 mg and charcoal|Participants randomized to cenerimod 0.5 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
62355127|NCT04255277|EXPERIMENTAL|Period 3: Cenerimod 4 mg and charcoal|Participants randomized to cenerimod 4 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
62355128|NCT04255277|NO_INTERVENTION|Period 3: Cenerimod elimination period|Participants randomized to cenerimod 0.5 mg or 4 mg in Period 2 will receive no treatment (i.e., activated charcoal from Day 57 to Day 67) but will have blood samples taken.
62355129|NCT04172701||LAMA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed long-acting muscarinic antagonists (LAMA) monotherapy between 01 January 2005 and 30 April 2015.
62516774|NCT05787002|EXPERIMENTAL|Treatment sequence B-A|Participants will receive 1 treatment during each study period in the following sequence: a single dose of rosuvastatin tablet + AZD0780 tablet (Treatment B) in period 1 and then a single dose of rosuvastatin tablet alone (Treatment A) in period 2.
62516775|NCT02677259|EXPERIMENTAL|Estradiol + Standard Luteal Phase Support|"1. 17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation~2. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation"
62516776|NCT02677259|ACTIVE_COMPARATOR|Standard Luteal Phase Support|1. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
62516777|NCT06470360|ACTIVE_COMPARATOR|Single absorbable|Cystic duct to be closed with absorbable single clip
62516778|NCT06470360|ACTIVE_COMPARATOR|Single Hem-o-lok|Cystic duct to be closed with Hem-o-lok single clip
62516779|NCT02941510|EXPERIMENTAL|Budesonide|Will participate in all study activities but will receive budesonide.
62516780|NCT02941510|PLACEBO_COMPARATOR|Placebo|Will participate in all study activities but will receive placebo.
62516781|NCT05017259|EXPERIMENTAL|low carbohydrate trial|The energy distribution was carbohydrate 10%, protein 40-50%, fat 40-50% in the LC trial.
62516782|NCT05017259|ACTIVE_COMPARATOR|high carbohydrate trial|The energy distribution was carbohydrate 60-65%, protein 30-40%, fat 5-10% in the HC trial.
62516783|NCT05623631|OTHER|Delphi study|Participants were asked to complete three rounds of surveys. These surveys collected information on which steps and errors can occur during CTI, and which of these should be included in an assessment tool.
62516784|NCT01997021|EXPERIMENTAL|US/IW/CW|This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
62516785|NCT01997021|EXPERIMENTAL|IW/US/CW|This is a 3 arm crossover design. Arm IW/US/CW corresponds to the group of participants randomized to Intermittent Walking (IW) first, then uninterrupted sitting (US), and then continuous walk (CW).
62516786|NCT01997021|EXPERIMENTAL|IW/CW/US|This is a 3 arm crossover design. Arm IW/CW/US corresponds to the group of participants randomized to Intermittent Walking (IW) first, then Continuous Walk (CW) and then Uninterrupted Sitting (US).
62516787|NCT01997021|EXPERIMENTAL|CW/IW/US|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Intermittent Walking (IW) and then Uninterrupted Sitting (US).
62516788|NCT01997021|EXPERIMENTAL|CW/US/IW|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Uninterrupted Sitting (US), and then Intermittent Walking (IW).
62516789|NCT01997021|EXPERIMENTAL|US/CW/IW|This is a 3 arm crossover design. Arm US/CW/IW corresponds to the group of participants randomized to Uninterrupted Sitting (US) first, then Continuous Walk (CW), and then Intermittent Walking (IW).
62516790|NCT01197157|PLACEBO_COMPARATOR|placebo|"• Group A: comprises 100 chronic hepatitis patients who will receive placebo twice daily orally with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
62516791|NCT01197157|EXPERIMENTAL|Nitazoxanide|"• Group B: comprises 100 CHC patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
62516792|NCT05973682|EXPERIMENTAL|Group A: post isometric relaxation and ConVentional treatment.|Post Isometric Relaxation: The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.
61974031|NCT05951790|ACTIVE_COMPARATOR|Inspiratory Muscle Training (IMT)|Use of Powerbreathe Device associated with aerobic excercise tailored for walking and non-walking subjects
61974032|NCT05951790|EXPERIMENTAL|Inspiratory Muscle Training (IMT) + Air Stacking|Use of Powerbreathe Device and application of Air-Stacking maneuvres associated with aerobic excercise tailored for walking and non-walking subjects
61974033|NCT04356131|EXPERIMENTAL|experimental group|Students in the experimental group were taught about massage and progressive relaxation exercises (PRE). The phases of the massage and PRE trainings were first explained by being demonstrated by the author on herself. In the meantime, the trainings were video-taped and uploaded to the mobile phones of the students. After the author, each student was made to perform massage and PRE. Both the exercises and massage techniques were daily performed 3 times a day after pain had started and relaxation exercises lasted 30 minutes whereas massage was performed for 15 minutes consecutively
61974034|NCT04356131|NO_INTERVENTION|control group|The students in the control group continued their routines during the study.
62516793|NCT05973682|ACTIVE_COMPARATOR|Group B: Conventional treatment|hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
62516794|NCT06403683||Females with primary dysmenorrhoea|75 females complain from primary dysmenorrhoea according to WaLIDD score.
62516795|NCT06403683||Females without primary dysmenorrhoea|75 females don't complain from primary dysmenorrhoea according to WaLIDD score.
62516796|NCT00453817|EXPERIMENTAL|Study subjects|One-arm observational study
62516797|NCT00958126|EXPERIMENTAL|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
62516798|NCT00958126|EXPERIMENTAL|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
62516799|NCT00958126|EXPERIMENTAL|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
62516800|NCT00958126|PLACEBO_COMPARATOR|Placebo|Vaccine diluent. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
62516801|NCT04136418|ACTIVE_COMPARATOR|Usual care|Patients currently self-manage their condition using antibiotics and steroids when their disease symptoms match the criteria in information provided by a clinician
62516802|NCT04136418|EXPERIMENTAL|Mobile App device|Patients enter their health status onto an App which is relayed to the healthcare team, who can then provide further information or clinical intervention should they so choose
61974035|NCT02374554|OTHER|Respiratory Rate Measurement Comparision|To demonstrate equivalence of the Thora-3Di Structured Light Plethysmography device and a Clinician Over-scored End Tidal C02 (COSC)derived from a BCI Capnograph 9004 (Smiths Medical) for measurement of Respiratory Rate
62355130|NCT04172701||ICS/LABA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed a fixed-dose combination (FDC) of inhaled corticosteroid (ICS)/long-acting beta agonists (LABA) between 01 January 2005 and 30 April 2015.
62516803|NCT02418117|EXPERIMENTAL|Stereolitographic template's accuracy|Evaluating the accuracy of stereolitographic template comparing the final implant insertion to the planned implant position at coronal and apical level
62516804|NCT03902652|EXPERIMENTAL|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
62516805|NCT03902652|ACTIVE_COMPARATOR|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
62516806|NCT00112294|ACTIVE_COMPARATOR|Cetuximab+Taxane+Carboplatin (C/T/C)|Cetuximab was administered at an initial dose (Week 1) of 400 mg/m\^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m\^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m\^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m\^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
62516807|NCT00112294|ACTIVE_COMPARATOR|Taxane+Carboplatin (T/C)|A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m\^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m\^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
62516808|NCT00913198|EXPERIMENTAL|IV CP-4126|
62516809|NCT00345059|ACTIVE_COMPARATOR|docetaxel|single agent docetaxel
62516810|NCT00345059|EXPERIMENTAL|docetaxel + vinorelbine OR gemcitabine|docetaxel in combination with either vinorelbine or with gemcitabine
61974036|NCT03015012|ACTIVE_COMPARATOR|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
62516811|NCT00345059|EXPERIMENTAL|docetaxel + capecitabine|docetaxel in combination with capecitabine
62516812|NCT02773199||Cohort 1- Morning Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in morning hours (until 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for 8 hours
62516813|NCT02773199||Cohort 2- Afternoon Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in afternoon hours (after 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for more than 12 hours
62516814|NCT03329079|EXPERIMENTAL|Mobile Technology Plus (MT+)|Experimental arm will receive a 3-month MT+ intervention using the premium mobile phone app version with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
62516815|NCT03329079|ACTIVE_COMPARATOR|Mobile Technology (MT)|Comparison group will receive the basic version of the mobile phone app only.
62516816|NCT02122718|EXPERIMENTAL|Allopurinol|
62516817|NCT02122718|PLACEBO_COMPARATOR|Placebo|
62539492|NCT03127683|EXPERIMENTAL|AuraGain group|"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."
62710535|NCT00876447|EXPERIMENTAL|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.
62355131|NCT04796428|ACTIVE_COMPARATOR|canagliflozin|100 mg (or 50/850 mg and 50/1000 mg of the fixed association with metformin) or 300 mg (or the 150/850 mg and the 150/1000 mg fixed association with metformin).
62355132|NCT04796428|ACTIVE_COMPARATOR|dapagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 10/5 mg of the fixed dapagliflozin / saxagliptin combination)
62355133|NCT04796428|ACTIVE_COMPARATOR|empagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 5/5 mg of the empagliflozin / linagliptin combination) or 25 mg (or the 12.5/850 mg and the 12.5/1000 mg fixed association with metformin; or the 12.5/5 mg empagliflozin / linagliptin combination).
62355134|NCT03260907|EXPERIMENTAL|Electroacupuncture|The patients in this group received electroacupuncture using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
61974037|NCT03015012|EXPERIMENTAL|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
61974038|NCT02389010|EXPERIMENTAL|Allogeneic Cord Blood Platelet Gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
62355135|NCT03260907|EXPERIMENTAL|Acupuncture|The patients in this group received acupuncture without electric stimulation using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
62355136|NCT02253017||Children operated on for cataract|
62516818|NCT00111358|ACTIVE_COMPARATOR|Lifestyle Modification|Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: \<35% calories from fat, \< 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, \>10,000 steps in daily activity, measured by pedometer. The curriculum is modeled after the Diabetes Prevention Program. Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
62516819|NCT00111358|PLACEBO_COMPARATOR|Control|
61974039|NCT02389010|ACTIVE_COMPARATOR|Standard Local Medications-SLM|1 administration every 3-4 days for 4 weeks. Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
62516820|NCT04778293|EXPERIMENTAL|Experimental Group|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized (random.org), in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
62516821|NCT04778293|NO_INTERVENTION|Control Group|No intervention
62516822|NCT01321021|EXPERIMENTAL|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan, Diphenhydramine
62516823|NCT03856593|EXPERIMENTAL|Standard letter|Prescribers randomized to this arm will be sent the standard letter.
61974040|NCT03936543|EXPERIMENTAL|Extended axillary midline|Operator stands at the bedside on extended midline of the patient's lt. axilla during lt. internal jugular vein catheterization
61974041|NCT03936543|ACTIVE_COMPARATOR|Extended head midline|Operator stands at the bedside on extended midline of the patient's head during lt. internal jugular vein catheterization.
61974042|NCT03068130|EXPERIMENTAL|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
62355137|NCT01213498|ACTIVE_COMPARATOR|Atorvastatin|
62355138|NCT01213498|PLACEBO_COMPARATOR|Unikalk|
62355139|NCT00745381||1|This registry will be open to all patients with GEPNET or NET of unknown primary.
62355140|NCT02292498|EXPERIMENTAL|FLIR ONE thermal camera|Thermal camera (FLIR ONE)
62355141|NCT01664858|ACTIVE_COMPARATOR|3T CMR-guided management|Patient to be managed according to the results of 3T CMR imaging
62355142|NCT01664858|ACTIVE_COMPARATOR|SPECT-guided management|Patients to be managed according to the results of SPECT
62355143|NCT01664858|ACTIVE_COMPARATOR|NICE-guidelines based management|"Patients will be receive NICE-guidelines based management and will receive the imaging strategy specified by NICE according to their pre-test likelihood of having CHD.~10-29% - CT calcium score +/- CT coronary angiography; 30-60% - SPECT; 61-90% - X-Ray coronary angiography"
62355144|NCT02705768|NO_INTERVENTION|Healthy control|Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
62516824|NCT03856593|EXPERIMENTAL|Comparator letter|Prescribers randomized to this arm will be sent the comparator letter.
62516825|NCT04445220|EXPERIMENTAL|Low dose cohort|SBI-101 device containing 250 million MSCs
62516826|NCT04445220|EXPERIMENTAL|High dose cohort|SBI-101 device containing 750 million MSCs
62516827|NCT04445220|NO_INTERVENTION|Case controls|Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants.
62516828|NCT03695705|OTHER|Primary prophylaxis arm|28 Patients with decompensated cirrhosis without past history of SBP were randomised to receive Rifaximin at dose 550 mg twice daily.29 Patients with decompensated cirrhosis without past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
62516829|NCT03695705|OTHER|Secondary prophylaxis arm|26 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Rifaximin at dose 550 mg twice daily.33 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
62516830|NCT01810094||Minimally invasive Approach|Patients with a thoracolumbar Fracture A3.1 to A 3.3 treated by fracture fixation by a minimally invasive approach
62516831|NCT05196360|EXPERIMENTAL|MAX-10181|tables
62516832|NCT05265819|ACTIVE_COMPARATOR|Group A|Group A: Control group No intervention was provided for 12 weeks except thyroid hormone replacement therapy
62516833|NCT05265819|EXPERIMENTAL|Group B|Group B: Exergaming exercise The volunteers carried out 36 exergaming sessions
61974043|NCT04919850|ACTIVE_COMPARATOR|Intervention group|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
61974044|NCT04919850|PLACEBO_COMPARATOR|Placebo group|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
62516834|NCT05265819|EXPERIMENTAL|Group C|Group C: Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
62516835|NCT05265819|EXPERIMENTAL|Group D|Group D: Exergaming exercises and Mediterranean diet Exergaming exercises are used in addition to Mediterranean diet
62516836|NCT02032251|EXPERIMENTAL|ginger|The patients with infertility that underwent oral administration of ginger.
62516837|NCT02032251|PLACEBO_COMPARATOR|Placebo|The patients with infertility that receive placebo.
62516838|NCT06338735|EXPERIMENTAL|Sjogren's syndrome|patients with Sjogren's syndrome diagnosed according to the ACR/EULAR criteria
62516839|NCT01481740|EXPERIMENTAL|Phenylephrine bolus|
62516840|NCT01481740|EXPERIMENTAL|Phenylephrine infusion|
62516841|NCT06374966||Patients with focal epilepsy|who using zonisamide as an add-on anti-seizure drug
62516842|NCT01369017|ACTIVE_COMPARATOR|Anakinra|All subjects will undergo 2 CCRE challenges. Each subject will be given either anakinra or placebo prior to CCRE challenge
61974045|NCT03836612||People with inflammatory bowel disease|Adults (18+) with inflammatory bowel disease registered with a contributing GP practice during the study period
61974046|NCT03836612||Controls|Adults (18+) without inflammatory bowel disease registered with a contributing GP practice during the study period
62147882|NCT01815359|EXPERIMENTAL|Colorectal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~1. Exposure to chemotherapy in the prior 6 months vs. no such exposure~2. Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
62355145|NCT02705768|EXPERIMENTAL|Carbamazepine group|Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
62355146|NCT02705768|EXPERIMENTAL|Oxcarbazepine group|Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
62355147|NCT06139536|EXPERIMENTAL|A/ Standard 3+3 1.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 1.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
62516843|NCT01369017|PLACEBO_COMPARATOR|Placebo|Normal saline injection
62516844|NCT05351814|ACTIVE_COMPARATOR|Control group|Control group; traditional patellofemoral pain syndrome exercises; isometric exercises 3 sets of 10 repetitions in one session, balance exercise 30/45 sec, one leg balance exercise 45/60 sec , stretching exercises 4 sets 5 repetitions 20 sec duration, off kinetic chain (CHC) AND open kinetic chain (ACZ) exercises were planned as 3 sets for 4 weeks and 3 days a week.
62516845|NCT05351814|EXPERIMENTAL|Core Stability group|Core stability group; In addition to traditional patellofemoral pain syndrome exercises; hip muscle strengthening exercises are 3 sets of 10 repetitions in each session, and (core) stabilization exercises are 1st and 2nd weeks 2 sets 15 repetitions 3rd and 4th weeks 2 sets 5 repetition was planned for 4 weeks and 3 days a week.
62516846|NCT01922752|EXPERIMENTAL|CEP-37440|
62516847|NCT02324673|EXPERIMENTAL|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose \[10 milligrams/kilogram/day (mg/kg/day)\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
62516848|NCT02324673|EXPERIMENTAL|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose \[20 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
62516849|NCT02324673|EXPERIMENTAL|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose \[40 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
62516850|NCT04821388|EXPERIMENTAL|intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries.|
62516851|NCT00411957|ACTIVE_COMPARATOR|1|ATV/r 300/100 mg
62516852|NCT00411957|ACTIVE_COMPARATOR|2|ATV/r 200/100 mg OD
62516853|NCT03996551|EXPERIMENTAL|Intervention Group|This group will receive access to the 12-week kidney transplant specific weight gain prevention online resource (ExeRTiOn online resource). After the 12 weeks, they will be offered the option to continue using the website up until the completion of the study (12 months)
62710536|NCT01179230||PET SPECT|Subjects will have both types of imaging performed, PET and SPECT
62516854|NCT03996551|NO_INTERVENTION|Control group|This group will not receive the online resource. They will receive the standard encouragement to follow a healthy diet and perform physical activity during routine transplant follow up appointments.
62516855|NCT02447926|OTHER|Leaukapheresis of End Stage Liver Disease Patients|Leukapheresis. All subjects will receive the same treatment arm.
62516856|NCT01815112|EXPERIMENTAL|Alzheimer|Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
62539493|NCT00760851|EXPERIMENTAL|1|Bb-12 supplemented strawberry yogurt drink
62710537|NCT05387746|OTHER|Caring Science, Mindful Practice and Reiki Training|
62710538|NCT01752803|EXPERIMENTAL|probiotic|subjects in this arm will receive probiotic supplementation for 12 weeks.
61974047|NCT03393546|EXPERIMENTAL|Auricular Point Acupressure - Interventionist|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day). The treatment will be administered by the research team's trained acupressure interventionist.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
61974048|NCT03393546|EXPERIMENTAL|Auricular Point Acupressure - Caregiver Training|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day).~If participants live more than 15 miles away from the research team's office, the caregiver will receive in-person training by the interventionist on how to administer the treatment to their patient for the 4 weeks of treatment.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
62516857|NCT01815112|EXPERIMENTAL|Vascular dementia|Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
62516858|NCT01815112|EXPERIMENTAL|Mild cognitive impairment (MCI)|Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
61974049|NCT01797692|OTHER|geriatric assessment|geriatric assessment
61974050|NCT02186912|EXPERIMENTAL|mandible|Nobel Active Nobel Procera IBO
61974051|NCT02186912|EXPERIMENTAL|maxilla|Nobel Active Nobel Procera IBO
61974052|NCT01750242||Parkinson's disease Subjects|Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).
61974053|NCT03491241|EXPERIMENTAL|pre-diabetics obese patients|These pre-diabetic obese patients will be treated by hypocaloric diet therapy. these patients were under metformine therapy at enrollment.
61974054|NCT03491241|PLACEBO_COMPARATOR|pre-diabetics patients|These pre-diabetic patients will be treated by hypocaloric diet therapy alone.
62516859|NCT01815112|EXPERIMENTAL|Healthy subjects (MRI)|Healthy subjects agreeing to undergo magnetic resonance imaging examination.
62516860|NCT01815112|EXPERIMENTAL|Healthy subjects (PET)|Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
62516861|NCT03967340||Lung transplant|
62516862|NCT05442242|ACTIVE_COMPARATOR|Unicompartmental knee osteoarthritis|
62516863|NCT05442242|ACTIVE_COMPARATOR|High tibial osteotomy|
62516864|NCT06172413|EXPERIMENTAL|active transcranial alternating current stimulation (tACS)|true stimulation.
62516865|NCT06172413|SHAM_COMPARATOR|Sham tACS|no active stimulation
61974055|NCT03491241|ACTIVE_COMPARATOR|obese patients|These obese patients will be treated by hypocaloric diet therapy.
61974056|NCT05091099|ACTIVE_COMPARATOR|On time Zoledronate|Zoledronate would be given (one dose for one year) after the completiong of denosumab on time
61974057|NCT05091099|EXPERIMENTAL|Alendronate and Zoledronate|Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
62147883|NCT01815359|EXPERIMENTAL|Colorectal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~1. Exposure to chemotherapy in the prior 6 months vs. no such exposure~2. Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
62516866|NCT01888341|EXPERIMENTAL|Isotretinoin capsules, 20 mg|Isotretinoin Capsules, 20 mg of Dr.Reddy's Laboratories Ltd
62147884|NCT04921540|EXPERIMENTAL|Dermatologic intervention|Surgery with chemical cauterisation TCA
62147885|NCT04921540|ACTIVE_COMPARATOR|Orthopedic intervention|Only surgery
62147886|NCT03032757|EXPERIMENTAL|Resting leg of young males|
62147887|NCT03032757|EXPERIMENTAL|Exercising leg of young males|
62516867|NCT01888341|ACTIVE_COMPARATOR|ACCUTANE|ACCUTANE 20 mg of Roche Laboratories Inc
62516868|NCT00393120|EXPERIMENTAL|Treatment A - INCB009471 100mg IR|INCB009471, 100 mg IR orally once daily
62516869|NCT00393120|EXPERIMENTAL|Treatment B - INCB009471 300mg SR|INCB009471, 300 mg SR orally once daily
62516870|NCT00393120|PLACEBO_COMPARATOR|Treatment C - Placebo|Placebo matching INCB009471
62516871|NCT01289951|EXPERIMENTAL|Patients with Child-Pugh C hepatic-cirrhosis.|VIH/VHC coinfected patients with advanced (Child-Pugh C) hepatic cirrhosis.
62147888|NCT03032757|EXPERIMENTAL|Resting leg of elderly males|
62516872|NCT01289951|ACTIVE_COMPARATOR|VIH/VHC coinfected patients without liver damage.|
62516873|NCT03196674|ACTIVE_COMPARATOR|manipulated feedback|
62516874|NCT03196674|ACTIVE_COMPARATOR|non-manipulated feedback|
62516875|NCT01638858|EXPERIMENTAL|Lucentis (Ranibizumab)|
62516876|NCT01566019|EXPERIMENTAL|Patients with non curable metastatic cancer|
62516877|NCT05206487|EXPERIMENTAL|Polydextrose|Patients will receive PDX 15 days prior and for a 6 month periods after TIPS.
62516878|NCT01931228|EXPERIMENTAL|MI-E plus manually assisted coughing|
62516879|NCT01931228|EXPERIMENTAL|Manually assisted coughing only|
62516880|NCT01047579|OTHER|Rivastigmine transdermal|
62516881|NCT05104099|EXPERIMENTAL|Metvixia application for Photodynamic diagnosis|Patients who benefit Metvixia application to the vulva to realize fluorescence guided biopsies (Photodynamic diagnosis).
62516882|NCT02072551||Adult with neonatal diabetes|Adult with neonatal diabetes (before 1 year ) and need for insulin
62516883|NCT02072551||non diabetic adults with a relative with neonatal diabetes|
62516884|NCT02065713|EXPERIMENTAL|Golimumab in combination with methotrexate|"Golimumab 50mg, subcutaneous, once monthly, for 24 weeks, in combination with MTX.~MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity"
62539494|NCT00760851|PLACEBO_COMPARATOR|2|Regular strawberry yogurt drink with no Bb-12 added
62516885|NCT02065713|ACTIVE_COMPARATOR|Placebo in combination with methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity.
62516886|NCT01334684|OTHER|Metformin|"At study entry, all oral hypoglycemic agents will be discontinued for 5 days and then metformin (2,550 mg/daily) will be given for 3 months. Fasting plasma glucose will be measured at baseline and 3 months after metformin treatment. Patients will be stratified according to the median value of metformin efficacy as indicated by fasting glucose change after metformin treatment (i.e. baseline fasting glucose minus 3-month fasting glucose).~So, two subgroups of patients will be obtained, defined as relatively high responders (individual fasting glucose change \> median value) or relatively low responders (individual fasting glucose change \< median value) to metformin monotherapy."
62516887|NCT00603291|EXPERIMENTAL|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
62516888|NCT00603291|EXPERIMENTAL|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
62516889|NCT00603291|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo tablet each morning and evening
62516890|NCT02894866|EXPERIMENTAL|hyperbaric oxygen|Newborns with hypoxic ischemic encephalopathy treated with intensive care and hyperbaric oxygen
62516891|NCT02894866|NO_INTERVENTION|control|Newborns with hypoxic ischemic encephalopathy treated with intensive care only
62516892|NCT03664050|EXPERIMENTAL|Group A Letrozole group|2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.
62516893|NCT03664050|ACTIVE_COMPARATOR|Group B laparoscopic ovarian drilling group|bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
62516894|NCT03527251|EXPERIMENTAL|Sequential group|intravenous ipilimumab following by intravenous SHR-1210
62516895|NCT01252849|EXPERIMENTAL|First Arm: One iStent, medication|Device: One iStent, medication
62516896|NCT01252849|EXPERIMENTAL|Second Arm: Two iStents, medication|Device: Two iStent devices, medication
62516897|NCT01252849|EXPERIMENTAL|Third Arm: Three iStents, medication|Device: Three iStent devices, medication
62516898|NCT05893511|ACTIVE_COMPARATOR|Antibiotics first group|Antibiotics first equals to intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
62516899|NCT05893511|ACTIVE_COMPARATOR|Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD)|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). Antibiotics would be continued for up to one week after the procedure.EUS-GBD would be performed by either the conventional or direct method.
62710539|NCT01752803|PLACEBO_COMPARATOR|placebo|subjects in this arm will receive placebo in identical sachets similar to probiotics which only differs in the codes mentioned on the label of sachets.
61974058|NCT03149185|ACTIVE_COMPARATOR|T-CBSM|Technology based cognitive behavioral stress management.
61974059|NCT03149185|ACTIVE_COMPARATOR|T-HP|Technology based health promotion (control condition)
61974060|NCT03856840||Bullous Pemphigoid Patients|Bullae and blood serum, which are obtained before and under treatment, will be compared in each other regardless of any condition.
61974061|NCT04946838|EXPERIMENTAL|TENS|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
61974062|NCT04946838|SHAM_COMPARATOR|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
61974063|NCT03779204|EXPERIMENTAL|Rent subsidies + Mentorship|Participants in this arm (n = 12) will receive rent subsidies (ranging from $400 - $500/month) for 24 months as part of the intervention and be matched with an adult mentor recruited by one of the community partners.
61974064|NCT03779204|ACTIVE_COMPARATOR|Rent subsidies only|Participants in this arm (n = 12) will receive rent subsidies only (ranging from $400 - $500/month) for 24 months as part of the comparator group intervention. This group will not receive mentorship.
61974065|NCT01288248|EXPERIMENTAL|Airway laryngeal mask classic|Ventilation with Airway laryngeal mask classic during surgery
62147889|NCT03032757|EXPERIMENTAL|Exercising leg of elderly males|
62147890|NCT01567852|EXPERIMENTAL|Ketamine First|This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
62147891|NCT01567852|EXPERIMENTAL|Methohexital First|This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
61974066|NCT01288248|ACTIVE_COMPARATOR|endotracheal tube|Ventilation with endotracheal tube during surgery
62516900|NCT06481098|EXPERIMENTAL|HM15275|"Active comparator:~Part A: single-ascending dose~Single doses of HM15275 in healthy adults administered via subcutaneous injection.~Part B: multiple-ascending dose~Multiple doses of HM15275 in obese adults administered via subcutaneous injection."
62516901|NCT06481098|PLACEBO_COMPARATOR|Placebo of HM15275|"Placebo comparator:~Part A: single-ascending dose~Single doses of HM15275 placebo in healthy adults administered via subcutaneous injection.~Part B: multiple-ascending dose~Multiple doses of HM15275 placebo in obese adults administered via subcutaneous injection."
62516902|NCT03734887|ACTIVE_COMPARATOR|Private Feedback|Participants will receive a smart pill bottle that will collect data on their medication usage and provide real-time data about adherence to study staff. Study staff will provide participants with private feedback about adherence in the form of meeting with a pharmacist. Feedback will be provided at the start of the study. A semi-structured interviews will be performed among a random sub-sample of participants afterwards.
62516903|NCT03734887|EXPERIMENTAL|Social Network Intervention|Participants will receive the same treatment as the Private Feedback arm but they will additionally have Social Network Feedback. A biweekly feedback text messages will be sent to both the participant and a designated loved-one or friend of the participants for 12 weeks.
62516904|NCT04251091|EXPERIMENTAL|ReWalk Soft Exosuit|During this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out an 18 session training protocol.
62516905|NCT06094049||Preference test|A preference test using a 5-unit hedonic scale will be conducted to assess the women liking of the meal prepared with fortified flour only.
62147892|NCT02535221|EXPERIMENTAL|Endocrine therapy;|Interventions：Goserelin+TAM+AI：Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
62516906|NCT06094049||Triangle test|A triangle tests will be carried out to detect any difference between the food prepared with fortified and unfortified flour.
62516907|NCT01059721|EXPERIMENTAL|Soft tissue realignment|group cohort label
62516908|NCT05010733|EXPERIMENTAL|Thick-Layer Technique|Total hip arthroplasty using the Exeter V40 cemented femoral stem \[Stryker Orthopaedics, Mahwah, New Jersey\].
62516909|NCT05010733|ACTIVE_COMPARATOR|Thin-Layer Technique (French Paradox)|Total hip arthroplasty using the Müller Straight Stem \[Zimmer, Winterthur, Switzerland\].
62516910|NCT00933283|EXPERIMENTAL|Telaprevir + Methadone|Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.
61974067|NCT01706081|EXPERIMENTAL|Acupuncture|Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.
61974068|NCT01706081|EXPERIMENTAL|Wait-list|Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
62516911|NCT02079168|EXPERIMENTAL|Cohort 1|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.
62516912|NCT02079168|EXPERIMENTAL|Cohort 2|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.
62516913|NCT03544359|ACTIVE_COMPARATOR|Active tES|
62516914|NCT03544359|SHAM_COMPARATOR|Sham/Inactive tES|
62710540|NCT01814982|EXPERIMENTAL|Part 1: JNJ-17299425|JNJ-1729425 will be administered once as 1 milligram (10 milliliter of a 0.1 milligram/milliliter (mg/ml) solution) intravenous bolus injection over 2 minutes in central vein. In case of no toxicity or Intra cranial pressure response, dose will be increased to a maximum of 200 milligram (mg).
62710541|NCT01814982|EXPERIMENTAL|Part 2: JNJ-17299425|JNJ-1729425 will be repeated once at a dose (which is, determined by Investigator in Part 1) as intravenous bolus injection over 2 minutes in central vein.
62710542|NCT00365807|ACTIVE_COMPARATOR|Brief Family Intervention (Primarily education)|Behaviorally based family group intervention using standard education and nutrition counseling. Three hours of client contact
61974069|NCT06277921||Patients with morbidity and mortality|Patients who suffered from any type of morbidity after surgery
62147893|NCT02535221|ACTIVE_COMPARATOR|Chemotherapy|Interventions：Epirubicin+CTX+5-Fu：Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
62710543|NCT00365807|EXPERIMENTAL|Positively Fit|12 week (90 minute per session) behavioral group intervention for children and their parents. Children and parent attend parallel group with identical (but developmentally appropriate) information presented.
62710544|NCT03047135|EXPERIMENTAL|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
62147894|NCT00851513|EXPERIMENTAL|Group B|local anesthetics (lidocaine) associated with local steroids (depo-medrol)
62710545|NCT01061528|EXPERIMENTAL|New Smoking Cessation Counseling|"* One 60-minute individual session~* Seven 2-hour group sessions~* Two individual brief telephone contacts over an eight-week period.~* Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
61974070|NCT06277921||Patients without morbidity and mortality|Patients who did not suffer from any type of morbidity after surgery
61974071|NCT02924779||Women during labour|Women receiving lumbar epidural anaesthesia for pain during birth
62147895|NCT00851513|EXPERIMENTAL|Group C|local anesthetics (lidocaine) associated with local steroids (depomedrol) and important volumes of physiological serum
62147896|NCT00851513|ACTIVE_COMPARATOR|Group A|only local anesthetic (lidocaine)
62147897|NCT02232737|EXPERIMENTAL|0.8 mg nicotine|0.8 mg nicotine cigarettes
62147898|NCT02232737|EXPERIMENTAL|0.12 mg nicotine|0.12 mg nicotine cigarettes
62147899|NCT02232737|EXPERIMENTAL|0.03 mg nicotine|0.03 mg nicotine cigarettes
62147900|NCT03118206|ACTIVE_COMPARATOR|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
62516915|NCT04867421||TANOs|Adult patients with osteosarcoma or chondrosarcoma
62516916|NCT00052026|PLACEBO_COMPARATOR|1|Placebo
62516917|NCT00052026|EXPERIMENTAL|2|Low-dose carvedilol
62516918|NCT00052026|EXPERIMENTAL|3|high-dose carvedilol
62516919|NCT01359176||Healthy volunteers|
62516920|NCT02359201|EXPERIMENTAL|Sequence 1|Treatment group sequence: Test Product (V0018) on Day 1 and Placebo on Day 2
62516921|NCT02359201|EXPERIMENTAL|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product (V0018) on Day 2
62516922|NCT03482167|PLACEBO_COMPARATOR|Placebo|placebo
62516923|NCT03482167|EXPERIMENTAL|Nicotinamide Riboside|Niagen® (ChromaDex, Inc.) 500 mg, twice daily
62516924|NCT04462484|NO_INTERVENTION|Control group|No intervention
62516925|NCT04462484|EXPERIMENTAL|Intervention group|Videoconference
62516926|NCT01060475|EXPERIMENTAL|A|Low dose LIM-0705 and tacrolimus.
62516927|NCT01060475|EXPERIMENTAL|B|High dose LIM-0705 and tacrolimus.
62516928|NCT01060475|EXPERIMENTAL|C|Placebo LIM-0705 and tacrolimus.
62516929|NCT01060475|EXPERIMENTAL|D|High dose LIM-0705 and placebo tacrolimus.
62516930|NCT03465319||Sevoflurane|10 patients receiving an anesthesia with sevoflurane
62516931|NCT03465319||Desflurane|10 patients receiving an anesthesia with desflurane
62516932|NCT00842530|EXPERIMENTAL|CYD Dengue Vaccine Group|Participants (both Cohort 1 and 2) received 3 injections of the CYD Dengue vaccine, 1 injection each at 0, 6, and 12 months.
62516933|NCT00842530|PLACEBO_COMPARATOR|Control Group|Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (Cohort 2) received placebo at 0, 6, and 12 months.
62516934|NCT02006537|EXPERIMENTAL|Cohort 1|Cohort 1 will enrol 8 healthy male volunteers, who will receive a single 10 mg dose of GSK225694 in the fasted state.
62516935|NCT02006537|EXPERIMENTAL|Cohort 2|Cohort 2 will enrol 20 healthy elderly male and female volunteers (10 males and 10 females), who will receive a single 10 mg dose of GSK225694 in the fasted or fed state according to the randomization schedule.
62516936|NCT02242721||Intensive care unit patients needing renal replacement therapy|Male and female patients in the intensive care unit (ICU), needing renal replacement therapy due to renal dysfunction and are treated with antiinfective drugs.
62516937|NCT03896282|ACTIVE_COMPARATOR|daycare facility|After surgery patient stay at daycare facility for mobilisation and stay until discharge or transfer to standard patient ward if nor discharged by 20.000
62516938|NCT03896282|ACTIVE_COMPARATOR|standard patient ward|After surgery patients are transferred to standard patient ward for mobilisation and stay until discharge.
62516939|NCT01242761||Symptomatic rotator cuff tear|Patients with symptomatic rotator cuff tears presenting to hospital clinic after having ultrasound exam in community with indications for surgery
62516940|NCT02201290|EXPERIMENTAL|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of \< 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
62516941|NCT02059720|ACTIVE_COMPARATOR|auto|patients receive autologous SCT
62516942|NCT02059720|ACTIVE_COMPARATOR|haplo|patients receive haplo-SCT
62516943|NCT06617767|EXPERIMENTAL|Reiki|The Reiki group received 20 minutes of remote Reiki once a day for 4 consecutive days
62516944|NCT06617767|NO_INTERVENTION|Control|No intervention was applied to the control group
62516945|NCT01751542|EXPERIMENTAL|Mindfulness + residential treatment|Mindfulness and Acceptance Group Therapy + residential treatment
62516946|NCT01751542|ACTIVE_COMPARATOR|Residential Treatment|Residential treatment alone
62516947|NCT05698706|EXPERIMENTAL|De-novo BCC with thickness not more than 2.0 mm|Areas with de-novo BCC of thickness not more than 2.0 mm (as confirmed by ultrasound imaging or histopathological examination) will be treated by high intensity focused ultrasound
62516948|NCT05451732|EXPERIMENTAL|Nanofat grafting|Nanofat grafting with tissue transfer by injection in the urethral stricture
62516949|NCT02668848|EXPERIMENTAL|urine monitoring group|Patients of urine monitoring group will be checked for urine specific gravity (USG) once between 6a.m. to 12 m.d. in the first 5 days after admission. Patients will be advised to have water according to the level of USG.
62516950|NCT02402075||Brain tumor|patients with glioma
62516951|NCT02027870||EXCEL-II DES|Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD
62516952|NCT06001723|EXPERIMENTAL|Forest Therapy|This is a pretest-posttest designed experiment. A two-hour guided forest healing activity was used as an intervention method. For the purpose of comparison, an urban area adjacent to the Taipei Botanical Garden, specifically the Wanhua district, was selected. This choice ensures the exclusion of extensive green spaces commonly used for walking.
62516953|NCT05322629|EXPERIMENTAL|Intervention (enhanced PrEP HIV biofeedback)|"Women in the intervention arm (n=375) will receive enhanced PrEP bio-feedback adherence counseling:~* Real-time novel immunoassay using urine that measures tenofovir and enhanced bio-feedback counseling. The novel urine assay shows tenofovir concentrations if PrEP is taken in the past 48 hours thereby enabling counselors to provide feedback on adherence levels, immediately.~* Enhanced counseling on recent adherence levels~* Rapid PrEP collection~In second randomization at 6m, women on PrEP with poor adherence or continuation, will be offered differentiated PrEP delivery in the community or in the clinic. The study will follow these participants for 15m to assess longer term PrEP continuation and adherence."
62516954|NCT05322629|ACTIVE_COMPARATOR|Standard of care|Women in the standard of care arm (n=375) will receive facility-based PrEP and monthly HIV testing in pregnancy and quarterly in postpartum. PrEP prescriptions and HIV testing will be provided according to the national PrEP guidelines. The women will be followed through 6m postpartum for the first randomization and through 15m with the standard of care for the second randomization.
62516955|NCT01920542|EXPERIMENTAL|no dexmedetomidine|no administration of dexmedetomidine
61974072|NCT02634684|ACTIVE_COMPARATOR|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
62516956|NCT01920542|ACTIVE_COMPARATOR|dexmedetomidine|administration of 0.5ug/kg dexmedetomidine for 10 min and infusion of 0.5ug/kg/h of dexmedetomidine until weaning of cardiopulmonary bypass
62516957|NCT05603052|EXPERIMENTAL|Test group(EuCorVac-19) - Cohort A|Cohort A - Immunogenicity cohort
62516958|NCT05603052|ACTIVE_COMPARATOR|Comparator group(ChAdOx1) - Cohort A|Cohort A - Immunogenicity cohort
62516959|NCT05603052|EXPERIMENTAL|Test group(EuCorVac-19) - Cohort B|Cohort B - Safety cohort
62516960|NCT05603052|ACTIVE_COMPARATOR|Comparator group(ChAdOx1) - Cohort B|Cohort B - Safety cohort
62516961|NCT02129647|EXPERIMENTAL|Axitinib|5 mg axitinib orally twice daily, with increase to 7 mg orally twice daily and 10 mg orally twice daily after 2 and 4 weeks, respectively, provided no adverse reactions (i.e., not exceeding grade 2 toxicities) and normotensive and not receiving antihypertension medications. Axitinib will be given continuously in 28-day cycles until disease progression or unacceptable toxicity.
62516962|NCT03560687|EXPERIMENTAL|CardioSIDERAL|Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
62516963|NCT03560687|NO_INTERVENTION|Control|
62516964|NCT04462016|ACTIVE_COMPARATOR|Reference drink|Healthy volunteers' blood glucose response to reference drink (glucose)
62516965|NCT04462016|EXPERIMENTAL|Test drink|Healthy volunteers' blood glucose response to test drink (calamansi)
62516966|NCT02322619|EXPERIMENTAL|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
62516967|NCT02322619|ACTIVE_COMPARATOR|Avelox Tablets 400 mg|Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.
62516968|NCT01906359|EXPERIMENTAL|Dietary fat - PO|Native palm olein (IV56)
62516969|NCT01906359|EXPERIMENTAL|Dietary fat - IPO|Chemically interesterified palm olein (IV56)
62516970|NCT01906359|EXPERIMENTAL|Dietary fat - HOS|High oleic sunflower oil
62516971|NCT02214420|ACTIVE_COMPARATOR|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
62516972|NCT02214420|ACTIVE_COMPARATOR|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
62516973|NCT02986035|EXPERIMENTAL|Intervention|
62516974|NCT06021678|EXPERIMENTAL|EX103 injection|From Cycle 0 to Cycle 2, the subject will receive the preset dose of EX103 once a week (QW), and from Cycle 3, the subject will receive the preset dose of EX103 once every two weeks (Q2W). The recommended dose is MTD or OBD, and a cycle of treatment is 28 days.
62516975|NCT04283916||Botox injection|30 consecutive patients will have 300 IU of botulinum toxin injected to six spots in abdominal wall to gain abdominal wall musculature relaxation.
62147901|NCT03118206|ACTIVE_COMPARATOR|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
62147902|NCT03118206|ACTIVE_COMPARATOR|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
62355148|NCT06139536|EXPERIMENTAL|B/ Standard 3+3 2.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 2.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
62355149|NCT06139536|EXPERIMENTAL|C/ Standard 3+3 3.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 3.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
62355150|NCT06139536|EXPERIMENTAL|D/ Standard 3+3 6.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 6.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
62355151|NCT06139536|EXPERIMENTAL|E/ Standard 3+3 10.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 10mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
62355152|NCT01691053|ACTIVE_COMPARATOR|Spironolactone|
62355153|NCT01691053|PLACEBO_COMPARATOR|Placebo|
62355154|NCT00655057|ACTIVE_COMPARATOR|1|Healthy participants will undergo TRODAT-1 SPECT imaging.
62355155|NCT00655057|EXPERIMENTAL|2|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with s-citalopram.
62355156|NCT00655057|ACTIVE_COMPARATOR|3|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with cognitive behavioral therapy.
62355157|NCT01924299|EXPERIMENTAL|Baricitinib + Ketoconazole|"Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2.~Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2."
62355158|NCT01924299|EXPERIMENTAL|Baricitinib + Fluconazole|"Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.~Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2."
62355159|NCT03655587|EXPERIMENTAL|Solid ankle foot orthotic|This is a leg brace that is made to fit the contour of the patient's foot, ankle, and lower leg. The two pull solid ankle AFO is fabricated from a rigid polypropylene outer boot and a more flexible silicone inner boot. It is commonly used in rehabilitation to improve gait in pediatric and adult populations. A certified orthotist fabricates the device. This device is lawfully marketed in the United States. It is not regulated by the FDA.
62355160|NCT03655587|ACTIVE_COMPARATOR|Resting night splint|An ankle resting night spring (RNS) is an off-the-shelf device that provides static sagittal plane dorsiflexion. The RNS is worn nocturnally to provide maximal stretch/length to the gastrocsoleus to maintain or increase dorsiflexion ROM and/or to prevent further regressions in ankle range. It is not regulated by the FDA.
62355161|NCT06271239|EXPERIMENTAL|Intervention group (ViviFrail)|Intervention Group: 25 participants will be guided to perform one of the home-based exercise programs from the VIVIFRAIL® protocol, tailored to their clinical conditions and functional capacity.
62355162|NCT06271239|ACTIVE_COMPARATOR|Group Suggestions for a Healthy Life (CG)|The control group, also consisting of 25 participants, will receive exercise suggestions and guidance on maintaining a healthy routine for three months. Subsequently, the participants will undergo the intervention with the VIVIFRAIL® program for three months.
62355163|NCT02568163|OTHER|questionary|
62355164|NCT02148211||Exposed cohort|Pregnant women, vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccine(s) (GSK sIIVs): Fluarix/ FluLaval/Fluarix Quadrivalent /FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
62355165|NCT02549963|EXPERIMENTAL|WATCHMAN LAA Occlusion Device|Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
62355166|NCT02549963|ACTIVE_COMPARATOR|Rivaroxaban|Subjects assigned to receive the Rivaroxaban therapy.
62516976|NCT04647383|EXPERIMENTAL|OSA Cohort, Sequence A: Placebo + Lemborexant 10 mg|Participants with OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
62516977|NCT04647383|EXPERIMENTAL|OSA Cohort, Sequence B: Lemborexant 10 mg + Placebo|Participants with OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
62516978|NCT04647383|EXPERIMENTAL|COPD Cohort, Sequence C: Placebo + Lemborexant 10 mg|Participants with COPD will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
62516979|NCT04647383|EXPERIMENTAL|COPD Cohort, Sequence D: Lemborexant 10 mg + Placebo|Participants with COPD will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
62516980|NCT04684693|EXPERIMENTAL|Laser Group|
62516981|NCT04684693|ACTIVE_COMPARATOR|Control Group|
62516982|NCT05915793|EXPERIMENTAL|Diaphragm strengthening and accessory muscles stretchings|
62516983|NCT05915793|ACTIVE_COMPARATOR|Diaphragm strengthening|
62516984|NCT05608681|EXPERIMENTAL|EP-104IAR 4 mg|4 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516985|NCT05608681|EXPERIMENTAL|EP-104IAR 8 mg|8 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516986|NCT05608681|EXPERIMENTAL|EP-104IAR 20 mg|8 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516987|NCT05608681|EXPERIMENTAL|EP-104IAR 30 mg|12 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516988|NCT05608681|EXPERIMENTAL|EP-104IAR 48 mg|12 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516989|NCT05608681|EXPERIMENTAL|EP-104IAR 64 mg|16 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516990|NCT05608681|EXPERIMENTAL|EP-104IAR 72 mg|12 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516991|NCT05608681|EXPERIMENTAL|EP-104IAR 96 mg|16 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516992|NCT05608681|EXPERIMENTAL|EP-104IAR 120 mg|20 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
62516993|NCT02428179||Control group without Study intervention|Control group without Study intervention
62516994|NCT02428179||Group with Study intervention|Group with Study intervention
62516995|NCT04209010||One-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in one stage using silicone implant and acellular dermal matrix.
62710546|NCT01061528|ACTIVE_COMPARATOR|Standard Smoking Cessation Counseling|"* One 60-minute individual session~* Seven 2-hour group sessions~* Two individual brief telephone contacts over an eight-week period.~* Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
62710547|NCT03666390|EXPERIMENTAL|0.5mg/kg Ketamine|Anesthesia
62710548|NCT03666390|ACTIVE_COMPARATOR|0.045mg/kg Midazolam|Benzodiazepine
62147903|NCT01597856|EXPERIMENTAL|SBIRT|"The SBIRT-VA manual codifies basic substance abuse screening, treatment, Motivational Interviewing and referral procedures. It is designed for providers with minimal substance abuse expertise and is easy for experienced substance abuse providers to deliver.~Study sessions include identifying the Veterans' values through a card sort, the change ruler, on which the Veteran rates his/her willingness to change current behavior, listing the pros and cons of changing."
62516996|NCT04209010||Two-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in two stages using expander to silicone implant technique.
62516997|NCT04092920|EXPERIMENTAL|laser and SLA implants|extraction of badly broken maxillary and mandibular teeth with immediate implant placement using laser surface treated and SLA surface treated dental implants
62516998|NCT04816747|EXPERIMENTAL|Autologous PRP|Participants with diagnosed lumbar DDD are planned to be managed via intradiscal injection of 0.5-1 ml autologous PRP, whereas participants with FJS will be injected with 0.5 ml of respective solution. All procedures will be performed in surgical theatre under constant fluoroscopic guidance.
62516999|NCT01716650||Saphenous nerve block|Data collection after saphenous nerve block placement
62517000|NCT02447159|EXPERIMENTAL|Intervention|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
62517001|NCT02447159|NO_INTERVENTION|Control|Antenatal care utilization data will be extracted from the administrative records. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
62517002|NCT00678626|EXPERIMENTAL|Arm A|combination of CP-751,871 + docetaxel administered
62517003|NCT00678626|ACTIVE_COMPARATOR|Arm B|chemotherapy
62517004|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
62517005|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
62710549|NCT02220634|EXPERIMENTAL|Regadenoson|Intravenous infusion of the A2A agonist regadenoson has a preferential vasodilator effect on pulmonary vasculature that is comparable to iNO, the current gold standard for pulmonary vasoreactivity studies.
62710550|NCT05135728|EXPERIMENTAL|Unstuck and On Target-Preschool|"UOT-P is based on the foundational principles of UOT for improving EF as well as evidence-based teaching methods (e.g., positive behavior supports, visual aids). Through this program, children, teachers and parents develop a shared self-regulatory vocabulary that enables children to improve EF at home and school through adult modeling and gradual scaffolding. The self-regulatory vocabulary (e.g., Flexible, Make a New Plan, Unstuck) becomes a contagious common language. We hypothesize this is the mechanism of change by which children will show improved EF skills, leading to increased academic readiness, improved social competence and reduced externalizing behaviors."
62710551|NCT05135728|ACTIVE_COMPARATOR|Waitlist Control|Children at clinic sites beginning in Year 4 will be placed in Arm 2, in which a waitlist control model will be used. Assessment of participants on outcome measures will occur at pre-intervention, followed by a 16-week waitlist period, again at baseline, followed by a 16-week intervention, and then finally at endpoint. All participants in Arm 2 will receive UOT-P as their intervention (see Experimental Arm).
62710552|NCT06405633|EXPERIMENTAL|WVE-006 (Dose 1)|
62517006|NCT03529643|EXPERIMENTAL|Anesthesia with dexmedetomidine|"Anesthesia with sevoflurane-remifentanil-dexmedetomidine~Dexmedetomidine :Continuous infusion of dexmedetomidine with loading dose of 1.0 μg/kg (0.25 ml/kg) for 10 minutes, then followed by maintenance dose of 0.4 µg/kg/hr (0.1 ml/kg/hr)."
62517007|NCT03529643|PLACEBO_COMPARATOR|Anesthesia without dexmedetomidine|"Anesthesia with sevoflurane-remifentanil~Normal saline :Continuous infusion of normal saline with loading dose (0.25 ml/kg) for 10 minutes, then followed by maintenance dose (0.1 ml/kg/hr)."
62517008|NCT02662088||Laparoscopic-lavage|Patients with colonic diverticulitis submitted to laparoscopic lavage
62517009|NCT01343095|NO_INTERVENTION|Usual Care|Usual Care between 10pm-6am
62517010|NCT01343095|ACTIVE_COMPARATOR|Earplugs|Application of foam earplugs from 10pm-6am nightly for seven nights or until ICU discharge.
62517011|NCT01343095|ACTIVE_COMPARATOR|Earplugs and Headphones|Foam Earplugs and Noise canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge.
62517012|NCT02896777|EXPERIMENTAL|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
62517013|NCT02896777|EXPERIMENTAL|Transfer embryos from 7.3±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
62517014|NCT02896777|EXPERIMENTAL|Transfer embryo from 7.4±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
62517015|NCT00362830|EXPERIMENTAL|1|
62517016|NCT03546803||Cohort A|Head and Neck Patients; Photon or Proton Treatment with product
62517017|NCT03546803||Cohort B|Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
62517018|NCT03546803||Cohort C|Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
62517019|NCT06427525|EXPERIMENTAL|Intervention group|mobile application at preventing overweight and obesity in childhood
62517020|NCT06427525|NO_INTERVENTION|Control group|health education
62517021|NCT05978739|EXPERIMENTAL|Orelabrutinib high dose|
62517022|NCT05978739|EXPERIMENTAL|Orelabrutinib low dose|
62517023|NCT04449536|EXPERIMENTAL|Mesna|Administration of a single oral dose of 400 mg, 800 mg, 1200 mg or 1600 mg
62710553|NCT06405633|EXPERIMENTAL|WVE-006 (Dose 2)|
62710554|NCT06405633|EXPERIMENTAL|WVE-006 (Dose 3)|
62710555|NCT03162432|EXPERIMENTAL|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
62710556|NCT02108288|EXPERIMENTAL|OPC-1085EL ophthalmic solution|Once daily
62355167|NCT05060172|EXPERIMENTAL|Bloomlife MFM-Pro|
62355168|NCT03780491|NO_INTERVENTION|Control|The first 50 patients will have usual care with providers conducting the visit in their typical manner.
62355169|NCT03780491|EXPERIMENTAL|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
62355170|NCT04791787|ACTIVE_COMPARATOR|Standard Weight Maintenance|Standard weight maintenance diet will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
62355171|NCT04791787|ACTIVE_COMPARATOR|Isocaloric Diet|Isocaloric diet will be provided for 10 days for subjects who are currently treated with a T2DM medication included in the inclusion criteria
62355172|NCT04791787|ACTIVE_COMPARATOR|Isocaloric Diet with Beta-hydroxy butyrate|Isocaloric diet with Beta-hydroxy butyrate will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
62355173|NCT05389956||Ulsan University Hospital-Health Screening Cohort (UUH-HEALS)|Ulsan University Hospital-Health Screening Cohort is a prospective cohort of participants who participated in general health screening programs at the Health Promotion Center of Ulsan University Hospital (Ulsan, South Korea). This cohort includes health screening participants aged 19 years and older from community and workplace. The purpose of this cohort is to offer relevant and useful data on health risk factors in the field of non-communicable diseases such as cardiovascular disease and malignancy.
62355174|NCT01410799|EXPERIMENTAL|Growth Hormone Releasing Hormone (GHRH)|Drug: GHRH
62355175|NCT05798806||Patients with diagnosis of cN+ breast cancer who underwent neoadjuvant treatment|Patients with diagnosis of cN+ breast cancer who underwent neoadjuvant treatment and then treated with lymph node biopsy or axillary lymphadenectomy
62355176|NCT01052519|NO_INTERVENTION|obese control|
61974073|NCT02634684|PLACEBO_COMPARATOR|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
61974074|NCT02733588|EXPERIMENTAL|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
62517024|NCT02631837|EXPERIMENTAL|vNOTES hysterectomy|vaginal Natural Orifice Transluminal Endoscopic Surgery
61974075|NCT03906903|ACTIVE_COMPARATOR|5 Hz Stimulation|This group will receive 5Hz (Hertz) Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, three per weekday, with a final result of 30 sessions in this modality with a 30 minutes Cognitive Stimulation after session.
62517025|NCT02631837|ACTIVE_COMPARATOR|LSC hysterectomy|Laparoscopic hysterectomy
62517026|NCT04012372|EXPERIMENTAL|ROSA water|Ad libitum hydration with ROSA oligomineral water
62517027|NCT04012372|ACTIVE_COMPARATOR|Control water|Ad libitum hydration with other waters
62517028|NCT00780260|EXPERIMENTAL|1|5 session strengths-based case management intervention delivered by a professional case manager and a peer support specialist team
62517029|NCT00780260|ACTIVE_COMPARATOR|2|5 session strengths-based case management intervention delivered by a professional case manager.
62517030|NCT03581513|EXPERIMENTAL|IMR<40 and defer PCI|Patients whose IMR\<40 undergo stent implantation after an interval of 7±2 days.
62517031|NCT03581513|ACTIVE_COMPARATOR|IMR<40 and immediately PCI|Patients whose IMR\<40 undergo immediately stent implantation.
62517032|NCT03581513|EXPERIMENTAL|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo stent implantation after an interval of 7±2 days.
62517033|NCT03581513|ACTIVE_COMPARATOR|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation.
62517034|NCT02229565||Caucasian|Caucasian subjects having a biopsy or prostatectomy.
62517035|NCT02229565||African American|African American subjects having a biopsy or prostatectomy.
62517036|NCT00028535|EXPERIMENTAL|Arm I|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
62517037|NCT04267263|NO_INTERVENTION|Delayed Treatment Control group|Participants will receive the treatment after completion of the 3-month follow-up assessment
62355177|NCT01052519|ACTIVE_COMPARATOR|obese goal-directed|
62355178|NCT01052519|ACTIVE_COMPARATOR|non-obese goal directed|
62517038|NCT04267263|EXPERIMENTAL|Lifestyle group|Participants will receive the treatment immediately
62517039|NCT05246033|EXPERIMENTAL|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection
62517040|NCT05246033|EXPERIMENTAL|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
62710557|NCT02108288|ACTIVE_COMPARATOR|Carteolol long-acting ophthalmic solution|Once daily
62355179|NCT03779061|EXPERIMENTAL|Remimazolam Tosilate|
62517041|NCT05246033|PLACEBO_COMPARATOR|Placebo|Placebo delivered once weekly by subcutaneous injection
62517042|NCT05146349|EXPERIMENTAL|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
62517043|NCT05146349|NO_INTERVENTION|Control|The control group does not receive the full set of RETAIN intervention activities.
62517044|NCT01312181|ACTIVE_COMPARATOR|HealthCall +Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
62517045|NCT01312181|ACTIVE_COMPARATOR|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
62517046|NCT01312181|PLACEBO_COMPARATOR|HIV/AIDS health education - DVD control|HIV/AIDS health education - DVD control. The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
62517047|NCT04731584||AVC|Patients hospitalized for TM after a proximal ischemic stroke of the middle cerebral artery and whose reperfusion is satisfactory (TICI 2b, 2c and 3). Additional blood sample will be taken during usual treatment the day of the stroke.
62517048|NCT04731584||Control|Population of control patients, consisting of patients admitted on an outpatient basis for a diagnostic cerebral arteriography.
62517049|NCT02459665|NO_INTERVENTION|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
62517050|NCT02459665|OTHER|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
62710558|NCT02108288|ACTIVE_COMPARATOR|Latanoprost ophthalmic solution|Once daily
62710559|NCT05768594||Patients with aortic stenosis, surgical valve replacement|15 patients undergoing surgical valve replacement (SAVR)
62710560|NCT05768594||Patients with aortic stenosis, undergoing transcatheter aortic valve implantation|15 patients undergoing transcatheter aortic valve replacement (TAVR)
62710561|NCT00665834|PLACEBO_COMPARATOR|1|Rosuvastatin 20 mg versus placebo 20 mg
62710562|NCT00665834|ACTIVE_COMPARATOR|2|rosuvastatin 20 mg versus atorvastatin 80 mg
62517051|NCT02459665|ACTIVE_COMPARATOR|Group 3|After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
62517052|NCT02459665|ACTIVE_COMPARATOR|Group 4|After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
62517053|NCT04595266|ACTIVE_COMPARATOR|Control|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab).
62517054|NCT04595266|EXPERIMENTAL|Experimental|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
62710563|NCT04897022|EXPERIMENTAL|Participants with malignant pleural mesothelioma (MPM)|Participants will be diagnosed with malignant pleural mesothelioma and be deemed unresectable per thoracic surgeon assessment
62710564|NCT06278493|EXPERIMENTAL|AL2846 capsules + Gemzar injection|AL2846 capsules combined with Gemzar injection,28 days as a treatment cycle
61974076|NCT03906903|PLACEBO_COMPARATOR|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 30 sessions, three per weekday with a 30 minutes Cognitive Stimulation afterwards.
61974077|NCT03363204|EXPERIMENTAL|BRUXENSE|Patients corresponding to selection criteria will use the BRUXENSE occlusal splint for 10 consecutive nights.
61974078|NCT01671189|EXPERIMENTAL|SMS Appointment Reminders|150 patients will be randomly assigned to the intervention arm of the study and receive text reminders about their upcoming appointments.
61974079|NCT01671189|NO_INTERVENTION|Existing Reminder Protocol|150 patients will be randomly assigned to the control arm of the study and will not receive SMS reminders about their upcoming appointments. They will, however, be subject to the clinics' existing reminder protocol (phone call reminders by either clinic personnel or computer machine).
62355180|NCT03779061|ACTIVE_COMPARATOR|Propofol|
62355181|NCT01270958|EXPERIMENTAL|TREATMENT|50 adult patients with Perennial Allergic Rhinities treated with Avamys.
62355182|NCT01078519|NO_INTERVENTION|Massages baths|doulas, massages and baths
62355183|NCT01078519|ACTIVE_COMPARATOR|Combined spinal-epidural anesthesia|local anesthetics in low doses with opioids
62355184|NCT02578472|EXPERIMENTAL|Group 1 (Sequence ABC)|Participants will receive Treatment A (2 capsules of 20 milligram \[mg\] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
62355185|NCT02578472|EXPERIMENTAL|Group 2 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
62355186|NCT02578472|EXPERIMENTAL|Group 3 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
62355187|NCT02578472|EXPERIMENTAL|Group 4 (Sequence ABC)|Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
62355188|NCT02578472|EXPERIMENTAL|Group 5 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
62355189|NCT02578472|EXPERIMENTAL|Group 6 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
62355190|NCT05868980||supine|supine position: Evaluation position for the first 10 minutes after birth
62517055|NCT01930175|PLACEBO_COMPARATOR|Placebo|single dose iv of Placebo
62517056|NCT01930175|EXPERIMENTAL|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
62517057|NCT01930175|EXPERIMENTAL|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg initiated following a safety review of patients receiving VAY736 3 mg/kg or placebo.
62517058|NCT05368441|EXPERIMENTAL|Midazolam-Group M|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room.
62517059|NCT05368441|PLACEBO_COMPARATOR|Control- Group S|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room.
62517060|NCT02327507||Toothpaste & Telephone Support|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions in both English and Spanish will be mailed to the homes of all OHP children and adolescents every three months. Half the populations will be assigned to also receive telephone support.
62517061|NCT02327507||Toothpaste only|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions will be mailed every three months
62355191|NCT05868980||right-side|right-side position: Evaluation position for the first 10 minutes after birth
62355192|NCT05868980||left-side|left-side position: Evaluation position for the first 10 minutes after birth
62517062|NCT00963651||Suspicion of pulmonary nodules|Eligible participants will include those referred for x-ray computed tomography (CT) of the chest for suspicion of a pulmonary nodule or other unrelated reasons.
62517063|NCT05576623|EXPERIMENTAL|1 dose of AdCLD-CoV19-1 OMI (Part A)|Group in Part A will receive 1 dose of AdCLD-CoV19-1 OMI
62710565|NCT02725463|EXPERIMENTAL|vestibular implant|Up to 30 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
62710566|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
62355193|NCT05868980||prone|prone position: Evaluation position for the first 10 minutes after birth
62355194|NCT03657810|EXPERIMENTAL|CL-108 5 mg|Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet
62355195|NCT03657810|ACTIVE_COMPARATOR|Norco|hydrocodone 5 mg/APAP 325 mg
62355196|NCT03657810|PLACEBO_COMPARATOR|Placebo|Placebo 0 mg matching CL-108
62517064|NCT05576623|EXPERIMENTAL|1 dose of AdCLD-CoV19-1 OMI (Part B)|Group 1 in Part B will receive 1 dose of AdCLD-CoV19-1 OMI
62517065|NCT05576623|PLACEBO_COMPARATOR|Placebo (Part B)|Group 2 in Part B will receive 1 dose of placebo
62517066|NCT06490575|NO_INTERVENTION|Control|Participants in the control group received no educational or counseling sessions until the final post-survey questionnaires were administered.
62517067|NCT06490575|EXPERIMENTAL|Nutrition Education|Participants in the intervention group attended four face-to-face educational workshops (one session per week).
62517068|NCT05917028|EXPERIMENTAL|Transcatheter Arterial Micro-Embolization|If abnormal blood vessels related to pain are identified by angiography, selective embolization is performed using Nexsphere-F.
62517069|NCT02121561|EXPERIMENTAL|Self-Acceptance Group Therapy|Participants receive Self-Acceptance Group Therapy
62517070|NCT00780923|EXPERIMENTAL|CPAP|
62517071|NCT00608595|EXPERIMENTAL|Therapeutic Intervention/Celecoxib|Celecoxib
62517072|NCT00589849||1|
62517073|NCT03407118|EXPERIMENTAL|LY900014|Single, 15 units (U)LY900014 administered subcutaneously (SC) in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus (T1DM).
62517074|NCT03407118|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Single, 15 U insulin lispro administered SC in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus.
62147904|NCT01597856|NO_INTERVENTION|No additional treatment|Veterans assigned to the control condition will not receive any study-related therapy. A Veteran who completes a Compensation examination ordinarily has no further treatment, referral, or debriefing as part of the Compensation examination.
62147905|NCT03560804|ACTIVE_COMPARATOR|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
62517075|NCT04715997|EXPERIMENTAL|GX-19: Dose A|Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29.
62517076|NCT04715997|PLACEBO_COMPARATOR|Placebo: Normal saline|Placebo will be intramusculary administered via EP on day 1 and day 29.
62517077|NCT05294419|OTHER|cardiovascular integrated risk score (CVD-IRT)|The CVD IRT device will generate a result based on the polygenic risk score derived from participant genomic information
62517078|NCT03866018|EXPERIMENTAL|Adapted physical activity|Patients will participate in an adapted physical activity workshop.
62517079|NCT02826291||RD-100i, OSNA|SLNM and OSNA assessment of sentinel lymph nodes compared to ultrastaging
62517080|NCT05614206|EXPERIMENTAL|Toddlers at elevated likelihood of developing autism with autistic signs, with early intervention|Toddlers at elevated likelihood of developing autism with clinical autistic signs who receive an early intervention from 18 to 24 months
62517081|NCT05614206|NO_INTERVENTION|Toddlers at elevated likelihood of developing autism with autistic signs, without early intervention|Toddlers at elevated likelihood of developing autism with clinical autistic signs who do not receive an early intervention
62517082|NCT05614206|NO_INTERVENTION|Toddlers at elevated likelihood of developing autism without autistic signs who received monitoring|Toddlers at elevated likelihood of developing autism without clinical autistic signs who only received assessment and monitoring
62517083|NCT05614206|NO_INTERVENTION|Typically developing toddlers who received monitoring|Typically developing toddlers who only received assessment and monitoring
62517084|NCT05438355||The infertility women with PCOS|Infertile women undergoing assisted reproduction were consecutively recruited at Ji Ai G-IVF institute from March 2021 to December 2021. Women aged \< 38 years without endometriosis and more than 6 oocytes were retrieved . Patients were divided in PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
62517085|NCT05438355||The infertility women without PCOS|Infertility women with fallopian tubal factor infertility and with normal menstrual cycles were undergoing IVF/ICSI cycles at Shanghai Ji Ai G-IVF institute from March 2021 to December 2021.Women aged \< 38 years without endometriosis and more than 6 oocytes were retrieved.
62517086|NCT00109759|EXPERIMENTAL|RagweedMATAMPL|
62710567|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
62517087|NCT00109759|PLACEBO_COMPARATOR|Placebo|
62710568|NCT03319576|EXPERIMENTAL|Early feeding|Patients randomized to early feeding will be fed 4 hours following gastrostomy tube placement
62517088|NCT03916042|EXPERIMENTAL|Reproxalap (0.25% Novel Formulation) QID to BID|
62517089|NCT03916042|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution QID to BID|
62147906|NCT03560804|ACTIVE_COMPARATOR|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
62147907|NCT03035526||3161 men (45-84 years old)|3161 men without known coronary artery disease
62147908|NCT01681823|EXPERIMENTAL|PectaSol-C Modified Citrus Pectin (MCP)|Treatment with 4.8 grams PectaSol-C Modified Citrus Pectin three times a day, away from meals for six months.
62355197|NCT00958516|EXPERIMENTAL|LEO 29102 cream|
62355198|NCT01511510|EXPERIMENTAL|PF-04958242|
62355199|NCT01511510|PLACEBO_COMPARATOR|Placebo|
62355200|NCT04583761||cases|Healthcare workers with mild symptoms of COVID-19 and a positive RT-PCR test for SARS-CoV-2
62517090|NCT05681312|ACTIVE_COMPARATOR|systemic proteolytic enzyme|Tibrolin combination of (Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg) one by one for five day
62517091|NCT05681312|PLACEBO_COMPARATOR|amoxicillin, metronidazol, doliprane|amoxicillin 500 mg one by three metronidazol 500 mg one by three doulprane 1000 mg one by one
62710569|NCT03319576|NO_INTERVENTION|Standard feeding|Patients randomized to standard feeding will be fed 24 hours following gastrostomy tube placement
62710570|NCT01942109|ACTIVE_COMPARATOR|Furosemide|This group will receive furosemide as a diuretic treatment
62710571|NCT01942109|EXPERIMENTAL|Torasemide|This group will receive torasemide as a diuretic treatment
62710572|NCT00114348|ACTIVE_COMPARATOR|R-Blöcke|Blocktherapie
62710573|NCT00114348|EXPERIMENTAL|Prot-II-Ida|a
62517092|NCT00646620|EXPERIMENTAL|1|budesonide/formoterol
62517093|NCT00646620|ACTIVE_COMPARATOR|2|fluticasone/salmeterol
62517094|NCT00646620|ACTIVE_COMPARATOR|3|albuterol
62517095|NCT04104555|ACTIVE_COMPARATOR|Usual supportive care - exercises and footwear advice|"OSTRICH main trial:~Participants will be offered an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
62517096|NCT04104555|EXPERIMENTAL|Prefabricated, off-the-shelf orthoses|"OSTRICH main trial:~A pair of prefabricated, off-the-shelf orthoses (i.e. mass produced to a generic shape but can be adapted by a clinician) plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
62517097|NCT04104555|EXPERIMENTAL|Signposting to multimedia|OSTRICH 'signposting to multimedia' Study within a trial (SWAT) Participants will be given signposting information to the multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
61974080|NCT06364540|ACTIVE_COMPARATOR|Nebulized KetaBAN|Nebulized ketamine administered at 0.75 mg/kg via BAN to adult patients presenting to the ED of Maimonides Medical Center with acute painful conditions of moderate to severe intensity.
61974081|NCT06364540|ACTIVE_COMPARATOR|Nebulized FentaBAN|Nebulized fentanyl administered at 3 mcg/kg via BAN to adult patients presenting to the ED of Maimonides Medical Center with acute painful conditions of moderate to severe intensity.
62517098|NCT04104555|NO_INTERVENTION|Standard written information only|OSTRICH signposting to multimedia' Study within a trial (SWAT) Participants will receive the standard written information sheet only. This will not include signposting to the multimedia trial information resources, in the OSTRICH recruitment pack.
62517099|NCT04104555|EXPERIMENTAL|Birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a birthday card on or shortly before their birthday from the OSTRICH study team to encourage completion of questionnaires.
62517100|NCT04104555|NO_INTERVENTION|No birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will not be sent a birthday card during the trial.
62710574|NCT01395134|NO_INTERVENTION|Visualization of the EBSLN and RLN|Visual inspection of the nerves.
61974082|NCT02744391|EXPERIMENTAL|L-DOPA|Patients will receive titration of L-DOPA from 150 mg to 450 mg.
61974083|NCT03181568|OTHER|Control|This arm group (control) will receive standard wound care of chronic wounds
61974084|NCT03181568|OTHER|Treatment|The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
61974085|NCT00814190|EXPERIMENTAL|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
61974086|NCT00814190|NO_INTERVENTION|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
61974087|NCT03408756|ACTIVE_COMPARATOR|Oral Methotrexate|Participants will receive methotrexate through oral route of administration
61974088|NCT03408756|ACTIVE_COMPARATOR|Subcutaneous Methotrexate|Participants will receive methotrexate through subcutaneous route of administration
61974089|NCT03869866|EXPERIMENTAL|MenACYW conjugate vaccine|MenACYW conjugate single injection at Day 0
61974090|NCT00718497||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
61974091|NCT01170091||Pramipexole|
61974092|NCT03555201|EXPERIMENTAL|Manual therapy|Protocol of soft tissue techniques
62147909|NCT05076825|EXPERIMENTAL|Neurodynamic Sliding|participents receive routine physical therapy along with TENS, Hot pack and Neurodynamic Stretching. (For 30 seconds, 3 times per session for 3 alternative days a week \& duration of 4 weeks).
62517101|NCT03975413||N=1 MS patient|"Single-Arm, Non-Randomized, Time Series, Single-Subject Study. Observational study of the FMT intervention.~Single subject studies are based on repeated observations within an individual over time and are acknowledged as an important research method for generating scientific evidence about the health or behavior of an individual. This design is desirable when the available patient pool is limited and thus it is not optimal to randomize participants to a control arm. The subject serves as his/her own control, rather than using another individual/group.These designs are used primarily to evaluate the effect of a variety of interventions in early stage clinical research development."
62517102|NCT02801552|EXPERIMENTAL|Regenerative Endodontic Procedure + PRF|Visit 1: root canal dressing with triple antibiotic paste. Visit 2: a 5 ml sample of whole blood was drawn intravenously from the patient's forearm. The blood sample is centrifuged at 400 g for 10 min. The prepared PRF membrane is cut into segments, the fragments are placed into the canal space. The coronal is sealed mineral trioxide aggregate and composite resin.
62710575|NCT01395134|EXPERIMENTAL|Neuromonitoring of the EBSLN and RLN|Electrical stimulation and monitoring of the nerves' function.
62710576|NCT05955339|ACTIVE_COMPARATOR|NOTES|Patients in this arm will receive only the NOTES intervention.
62710577|NCT05955339|ACTIVE_COMPARATOR|NOTES + AUDIO|Patients in this arm will receive both the NOTES and AUDIO intervention.
62710578|NCT02712788|ACTIVE_COMPARATOR|Milrinone|Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
61974093|NCT03555201|ACTIVE_COMPARATOR|Regular treatment control.|Regular treatment control.
61974094|NCT01719523|EXPERIMENTAL|EPI-743|EPI-743- Participants will receive 200mg three times a day of EPI-743 for 2 weeks and then receive 300mg of EPI-743 for an additional 2 weeks.
61974095|NCT05615389|EXPERIMENTAL|Medicinal Cannabis C12T12|C12T12 Ruby Balanced Oil (Cannatrek Ltd, Australia). 12.5mg/ml CBD and 12.5mg/ml THC in sunflower oil.
62355201|NCT04583761||controls|Healthcare workers with mild symptoms of COVID-19 and a negative RT-PCR test for SARS-CoV-2
62355202|NCT00728936|EXPERIMENTAL|IMO-2125 0.04 mg/kg q week|IMO-2125 given weekly at 0.04 mg/kg
62355203|NCT00728936|EXPERIMENTAL|IMO-2125 0.08 mg/kg q week|IMO-2125 given weekly at 0.08 mg/kg
61974096|NCT05615389|EXPERIMENTAL|Medicinal Cannabis C20T5|C20T5 Ruby CBD Oil (Cannatrek Ltd, Australia). 20mg/ml CBD and 5mg/ml THC in sunflower oil.
62147910|NCT05076825|ACTIVE_COMPARATOR|Static Streching|Participent receive the routine physical therapy treatment that will include TENS, Hot pack and static stretching for 30 seconds and 3 times per session for 3 alternative days a week (duration of 4 weeks).
62355204|NCT00728936|EXPERIMENTAL|IMO-2125 0.16 mg/kg q week|IMO-2125 given weekly at 0.16 mg/kg
62355205|NCT00728936|EXPERIMENTAL|IMO-2125 0.32 mg/kg q week|IMO-2125 given weekly at 0.32 mg/kg
62355206|NCT00728936|EXPERIMENTAL|IMO-2125 0.48 mg/kg q week|IMO-2125 given weekly at 0.48 mg/kg
62355207|NCT00728936|PLACEBO_COMPARATOR|Placebo|Weekly saline placebo
62355208|NCT00728936|EXPERIMENTAL|IMO-2125 0.16 mg/kg twice a week|IMO-2125 given twice a week at 0.16 mg/kg
62355209|NCT02267226|EXPERIMENTAL|Octafibrin|
62355210|NCT02482012||Staff|Staff nurses and physicians in the NICU
62355211|NCT02482012||Parents|Parents of infants in the NICU and a smaller group of parents of infants in the well baby nursery.
62355212|NCT03419936||Helicobacter pylori(HP) positive|Participants who are diagnosed with gastric cancer and Helicobacter Pylori infection will be treated with subtotal gastrectomy.
62355213|NCT02972957|EXPERIMENTAL|LAIV-vaccinated group 1|Nasovac-S vaccination group A , blood samples days 0, 2, 21
62355214|NCT02972957|EXPERIMENTAL|LAIV-vaccinated group 2|Nasovac-S vaccination group B, blood samples at days 0, 7, 21
62355215|NCT02972957|NO_INTERVENTION|Unvaccinated|control group C
62355216|NCT02972957|EXPERIMENTAL|Oral Azithromycin & vaccination|group D - a single dose of oral Azithromycin will be given 28 days prior to Nasovac-S vaccination
62355217|NCT00738829|EXPERIMENTAL|Treatment Arm|Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy
62355218|NCT05186987|SHAM_COMPARATOR|Start with: Concentric (normal) cycling|
62355219|NCT05186987|EXPERIMENTAL|Start with: Eccentric cycling|
62355220|NCT02309814|EXPERIMENTAL|eyelid motion sensor device|all volunteers will wear the monitor eyelid sensor device (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance.
62355221|NCT04254055|EXPERIMENTAL|Experimental group|"Exercise 1 with medicine ball. Standing player with 90º shoulder abduction and elbow flexion. He will receive the ball with an external rotation returning it with internal rotation. Exercise 2 with elastic band. From standing, he will fix the elastic band with his foot and perform a shoulder flexion with his contralateral limb. Exercise 3 of iron with support of the hands on the floor and shoulder, elbow and wrist aligned. You should perform a scapula approach and separation without altering its initial position. Exercise 4 BodyBlade ©. From standing with 90º of 90 ° shoulder abduction and elbow flexion. It will perform an anteroposterior thrust, causing a wave effect to stabilize the shoulder joint for 30 seconds.~Athletes will do 15 repetitions of each exercise."
62355222|NCT04254055|NO_INTERVENTION|Control group|Players included in the control group will not receive any intervention.
62355223|NCT01993056|EXPERIMENTAL|warm-up with 11+|"The FIFA 11+ is a complete warm up program aiming on reduce common soccer injuries"
62355224|NCT01993056|PLACEBO_COMPARATOR|control|the control group follows its regular training routine
62355225|NCT04666025||Observational (biospecimen collection, medical chart review)|"DONORS: Prior to HCT, sibling donors (MRD and haplo) undergo a nasopharyngeal swab per standard of care for SARS-Cov-2 testing. For MUD donors, initial testing may consist of a questionnaire. All donors undergo collection of blood and saliva at the time of granulocyte-colony stimulating factor (G-CSF). Donors' medical charts are also reviewed.~RECIPIENTS: Patients undergo a nasopharyngeal swab for SARS-Cov-2 testing at 30, 60, 90, 120 days post-HCT, and afterwards as deemed necessary by the treating physician. Patients also undergo the collection of blood and saliva specimens at days 30, 60, 90, 120, 150, and 180 post-HCT. Recipients' medical charts are also reviewed."
62355226|NCT02131246|EXPERIMENTAL|Faster-acting insulin aspart|Each subject will be allocated to two treatments (in random sequence).
62355227|NCT02131246|ACTIVE_COMPARATOR|NovoRapid®|Each subject will be allocated to two treatments (in random sequence).
61974097|NCT06128395||Aspirin 81 mg for Frozen Embryo Transfer (FET)|Subjects were prescribed Aspirin 81 mg to be started on the third day of their menstrual cycle in preparation for their FET.
62355228|NCT01684735||women with BRCA and chemotherapy|women recently diagnosed with breast cancer and start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy
62355229|NCT01367314|EXPERIMENTAL|NVC-422 Dermal Gel, 1.5%|
62355230|NCT01367314|EXPERIMENTAL|NVC-422 Dermal Gel, 0.5%|
62355231|NCT01367314|EXPERIMENTAL|NVC-422 Dermal Gel, 0.1%|
62355232|NCT03917082|EXPERIMENTAL|standard of care endocrine therapy for two years|Standard of care adjuvant endocrine therapy for two years. for postmenopausal women, initial therapy will be aromatase inhibitor unless contraindicated, in which case tamoxifen may be used. For premenopausal and perimenopausal women, initial therapy will be tamoxifen unless contraindicated, in which case an lutenizing hormone releasing hormone (LHRH) agonist with / without aromatase inhibitor may be used.
62355233|NCT04392869|EXPERIMENTAL|CRAFT group|This arm will instruct the students on an adapted and extended version of the CRAFT program. This is a mindfulness based program which is a systematic combination of practices derived from ancient philosophies, such as yoga and Buddhism, in conjunction with more recent disciplines such as mindfulness, emotional intelligence and positive psychology. The contents are structured along in five consecutive modules aimed at cultivating and enhancing consciousness, relaxation and regulation, attention, bliss and transcendence.
62355234|NCT04392869|EXPERIMENTAL|MBSR group|This arm will instruct the students on an adapted and extended version of the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
62355235|NCT04392869|NO_INTERVENTION|No intervention group|This group does not receive any instruction. The aim of this arm is to determine if there are any differences in outcomes between the two groups that receive intervention and this one.
62355236|NCT02168881|ACTIVE_COMPARATOR|misoprostol|oral misoprostol in solution 25 microgram every 2 hours
62355237|NCT02168881|ACTIVE_COMPARATOR|dinoprostone|3 mgs dinoprostone vaginally every six hours
62517103|NCT02801552|NO_INTERVENTION|Regenerative Endodontic Procedure|Regenerative Endodontic Procedure Visit 1: root canal dressing with triple antibiotic paste. Visit 2: Blood clot formation is induced in the root canal after disinfection. No PRF was used in this group. Then the canal access is sealed with mineral trioxide aggregate and composite resin.
62517104|NCT02549794|ACTIVE_COMPARATOR|High concentration (370)|CT angiography with hign concentration iodine contrast agent of 370 mg iodine/ml
62517105|NCT02549794|EXPERIMENTAL|Low concentration (320)|CT angiography with low concentration iodine contrast agent of 320 mg iodine/ml
62517106|NCT02549794|EXPERIMENTAL|Low concentration (270)|CT angiography with low concentration iodine contrast agent of 270 mg iodine/ml
62517107|NCT02963402||Tocilizumab treated|
62517108|NCT02963402||Anti-TNF treated|
62517109|NCT02926781|EXPERIMENTAL|osteotome technique|transcrestal sinus floor elevation using osteotomes
62517110|NCT02926781|ACTIVE_COMPARATOR|drills|transcrestal sinus floor elevation using drills
62517111|NCT01366443||women pregnant|Healthy pregnant women between 15 or greater weeks gestation reporting with signs or symptoms of rupture of membranes.
62517112|NCT05664282|ACTIVE_COMPARATOR|Damon self-ligating brackets|A multi-centre two-arm parallel-group randomized controlled trial with a 1:1 allocation ratio, comparing/evaluating tooth alignment, function and adverse side effects, Patients' perception of pain, function and quality of life Cost-effectiveness for adolescents with crowding and displaced teeth treated with self-ligating (Damon).
62517113|NCT05664282|ACTIVE_COMPARATOR|Victory conventional brackets|A multi-centre two-arm parallel-group randomized controlled trial with a 1:1 allocation ratio, comparing/evaluating tooth alignment, function and adverse side effects, Patients' perception of pain, function and quality of life Cost-effectiveness for adolescents with crowding and displaced teeth treated with conventional brackets (Victory).
62517114|NCT00865514|EXPERIMENTAL|Haplotypes and DCA metabolism|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
62517115|NCT05416463|SHAM_COMPARATOR|Control|The control group will receive primary elective THA as per standard of care surgical protocols for this type of surgery
62517116|NCT05416463|EXPERIMENTAL|Treatment|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
62517117|NCT04918160||Conference Attendees|"Volunteering healthcare practitioners (medical doctor, nurse, nurse assistant, physiotherapist and psychotherapist) attending the FICS annual congress will be proposed to participate to the study.~After giving their consent, participants will be asked to perform a COVID-19 antigenic screening self-test at day 7 (+/- 1) of the last day of the meeting (June 11th 2021) and to fill a questionnaire at day 21 of the last day of the meeting (June 11th 2021)."
62517118|NCT04918160||Controls|"Volunteering healthcare practitioners (medical doctor, nurse, nurse assistant, physiotherapist and psychotherapist) not attending the FICS annual congress will be proposed to participate to the study. They will be recruited in the same medical departments as the Conference Attendees.~After giving their consent, controls will be asked to perform a COVID-19 antigenic screening self-test at day 7 (+/- 1) of the last day of the meeting (June 11th 2021) and to fill a questionnaire at day 21 of the last day of the meeting (June 11th 2021)."
62517119|NCT02356991|EXPERIMENTAL|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
62517120|NCT02356991|PLACEBO_COMPARATOR|Placebo|Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
62517121|NCT00613834|EXPERIMENTAL|Lidocaine group|Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization
61974098|NCT06128395||Aspirin 162 mg for Frozen Embryo Transfer (FET)|Subjects were prescribed Aspirin 162 mg to be started on the third day of their menstrual cycle in preparation for their FET
61974099|NCT00384995|EXPERIMENTAL|Bicarbonate|Bicarbonate solution infusion
61974100|NCT00384995|ACTIVE_COMPARATOR|Saline|Standard volume expansion
61974101|NCT03067649|EXPERIMENTAL|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
62710579|NCT02712788|PLACEBO_COMPARATOR|Placebo|Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
61974102|NCT03067649|OTHER|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
62355238|NCT06334172|PLACEBO_COMPARATOR|Placebo|Infusion of placebo
62355239|NCT06334172|EXPERIMENTAL|Oxytocin 0.1 IU/min|Infusion of oxytocin 0.1 IU/min
62355240|NCT06334172|EXPERIMENTAL|Oxytocin 0.2 IU/min|Infusion of oxytocin 0.2 IU/min
62355241|NCT02409056|EXPERIMENTAL|workplace-tailored CDSMP|Group will receive the CDSMP program which has been modified to fit the unique characteristics of the workplace.
62517122|NCT00613834|PLACEBO_COMPARATOR|Control group|Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization
62517123|NCT01615887|EXPERIMENTAL|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
62517124|NCT01615887|PLACEBO_COMPARATOR|Sugar pill|Placebo will be administered in the same fashion as the treatment arm
62517125|NCT01520636|PLACEBO_COMPARATOR|group 1: standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
62710580|NCT04976777|EXPERIMENTAL|Updated Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) 0.7 mg|DEX PS DDS 0.7 mg implant was administered intravitreally into the study eye using updated applicator at Day 1 and followed until Day 7.
62355242|NCT02409056|ACTIVE_COMPARATOR|CDSMP usual care|Group will receive the standard CDSMP program which is currently being offered in a variety of community settings.
62517126|NCT01520636|EXPERIMENTAL|group 2: experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
62517127|NCT01825135|EXPERIMENTAL|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes
62517128|NCT01825135|SHAM_COMPARATOR|Sham stimulation|Sham stimulation will be applied to the quadriceps for 30 minutes
62517129|NCT00522444|EXPERIMENTAL|nebulized magnesium sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
61974103|NCT02042378|EXPERIMENTAL|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
62517130|NCT00522444|PLACEBO_COMPARATOR|normal saline nebulization|standard of care
62517131|NCT01791153|EXPERIMENTAL|Part 1: Tocilizumab qw + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
62517132|NCT01791153|EXPERIMENTAL|Part 1: Tocilizumab q2w + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
62517133|NCT01791153|PLACEBO_COMPARATOR|Part 1: Placebo + 26 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
62517134|NCT01791153|PLACEBO_COMPARATOR|Part 1: Placebo + 52 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.
62517135|NCT01791153|EXPERIMENTAL|Part 2: Open-Label Tocilizumab qw|Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.
62517136|NCT04825015||OLTx|Liver insufficiency patients undergoing transplantation surgery
62517137|NCT03051139|EXPERIMENTAL|ICU A and ICU B|This is the intervention group.
62517138|NCT03051139|NO_INTERVENTION|ICU C and ICU D|This is the usual care group.
62517139|NCT00867841||Pneumonia|Children diagnosed with community-acquired pneumonia by the emergency department physician
62517140|NCT03078582|EXPERIMENTAL|Zilucoplan (RA101495) treatment naive|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
62517141|NCT03078582|EXPERIMENTAL|Zilucoplan (RA101495) previously on eculizumab|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
62517142|NCT01319786|OTHER|Low- polyphenol diet|
62517143|NCT01319786|ACTIVE_COMPARATOR|High-polyphenol diet|
62517144|NCT05187611|EXPERIMENTAL|Conduction system pacing|"Pacing the His-Purkinje system.~Crossover to biventricular pacing was allowed in case of failed conduction system pacing: failed His bundle pacing and failed Left bundle branch pacing (high thresholds (\>3.5V / 1ms); no left bundle branch pacing criteria; no left bundle branch correction).~Electrocardiographic optimization allowed in order to obtain the narrowest QRS."
62517145|NCT05187611|ACTIVE_COMPARATOR|Biventricular pacing|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.~Crossover from biventricular pacing to conduction system pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
62517146|NCT03512496|PLACEBO_COMPARATOR|Acute energy drink - Control|Coloured Water was given 40 min prior to the OGTT test.
62517147|NCT03512496|ACTIVE_COMPARATOR|Acute energy drink - Caffeine|Sugar Free energy drink at 5mg/kg caffeine was given 40 min prior to OGTT test.
62710581|NCT04976777|ACTIVE_COMPARATOR|Approved DEX PS DDS 0.7 mg|DEX PS DDS 0.7 mg implant was administered into the study eye using currently approved applicator at Day 1 and followed until Day 7.
61974104|NCT06199531|EXPERIMENTAL|Cohort 1a|13-18 years old, then 6-12 years old (Low dose GS-100)
61974105|NCT06199531|EXPERIMENTAL|Cohort 2a|13-18 years old, then 6-12 years old (Mid dose GS-100)
61974106|NCT06199531|EXPERIMENTAL|Cohort 3a|13-18 years old, then 6-12 years old (High dose GS-100)
61974107|NCT06199531|EXPERIMENTAL|Cohort 1b|2-5 years old (Low dose GS-100)
62517148|NCT03512496|SHAM_COMPARATOR|Acute energy drink- Decaf|Sugar free decaf energy drink (vitamins only) was given 40 min prior to OGTT test. Amount of drink was same as that of Caffeine
62517149|NCT01700478|EXPERIMENTAL|Misoprostol + vasopressin, Vasopressin|Misoprostol 400ug given rectally one hour before surgery.
62517150|NCT03827941|ACTIVE_COMPARATOR|1 Hz group|1 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
62517151|NCT03827941|ACTIVE_COMPARATOR|20 Hz group|20 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 20 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
62517152|NCT02365259|EXPERIMENTAL|Phototherapy|This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
62710582|NCT04627714|EXPERIMENTAL|Early Fencing|"patients of the Early Fencing arm will start adapted fencing practice (1h30/week) within 4 weeks after the breast surgery and for a duration of 3 months"
62710583|NCT04627714|EXPERIMENTAL|Delayed Fencing|"patients of the Delayed Fencing arm will start adapted fencing practice (1h30/week) 3 months after the breast surgery and for a duration of 3 months"
62710584|NCT04549467|EXPERIMENTAL|Dolutegravir + lamivudine|Dolutegravir 50 mg, 1 tablet QD plus lamivudine 300 mg, 1 tablet QD
62517153|NCT02365259|PLACEBO_COMPARATOR|Shame phototherapy|This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
62517154|NCT02240563|EXPERIMENTAL|Low-level laser therapy|This group of patients was treated with a continuous wave diode laser device (830 nanometer, infrared) with a beam area of 0.002827 cm2 using the punctual method on the continuous emission mode at an output power of 50 milliwatts and a fluence of 707 Joules/cm2 six years before.
62517155|NCT02240563|PLACEBO_COMPARATOR|Non laser ordinary red light|This group of patients was treated using the same method and equipment, except that a non laser ordinary red light, an output power of 0.1 Watt and a fluence of 1.41 Joules/cm2 and an irradiance value of 0.0002827 Watts/cm2 (the placebo), indistinguishable from the laser beam, was used. Therefore, the patients were blinded to which treatment they received.
62517156|NCT03603938|EXPERIMENTAL|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
62517157|NCT03603938|EXPERIMENTAL|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
62517158|NCT03935022|EXPERIMENTAL|Black rice Venere|Healthy volunteers will receive the black rice Venere in a cross-over randomized clinical trial (after 7 days wash-out).
61974108|NCT06199531|EXPERIMENTAL|Cohort 2b|2-5 years old (Mid dose GS-100)
62517159|NCT03935022|EXPERIMENTAL|Black rice Artemide|Healthy volunteers will receive the black rice Artemide in a cross-over randomized clinical trial (after 7 days wash-out).
62517160|NCT03935022|SHAM_COMPARATOR|Complete white rice|Healthy volunteers will receive the complete white rice in a cross-over randomized clinical trial (after 7 days wash-out).
62517161|NCT03282734|EXPERIMENTAL|The smart rehab group|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for 4 weeks
62517162|NCT03282734|ACTIVE_COMPARATOR|The control group|Conventional home rehabilitation exercise education for 4 weeks
61974109|NCT06199531|EXPERIMENTAL|Cohort 3b|2-5 years old (High dose GS-100)
61974110|NCT04768231|EXPERIMENTAL|R35HZE|Participants treated with rifampicin at a dose of 35 mg per kilogram of body weight per day, added to the standard doses of isoniazid, pyrazinamide and ethambutol.
61974111|NCT05752903|ACTIVE_COMPARATOR|Dexmedetomidine-propofol|Dexmedetomidine-propofol bolus will be administered then Dexmedetomidine-propofol infusion continued during the procedure
61974112|NCT05752903|ACTIVE_COMPARATOR|ketamine-propofol|ketamine-propofol bolus will be administered then Dexmedetomidine-propofol infusion continued during the procedure
61974113|NCT00975481|EXPERIMENTAL|dimebon 20 mg|
62147911|NCT06122025|ACTIVE_COMPARATOR|Intervention [access to electronic healthcare records; EHR]|"For those in the intervention group, the participant will receive personalised access to their secondary electronic healthcare record (EHR) for 6 months. Individual access will be activated by the clinical team at the start of the study and will include views for;~1. Current problems~2. Current medication~3. Test requests~4. Letters~5. Consultations~6. Allergies~7. Immunisations"
62147912|NCT06122025|NO_INTERVENTION|Control [no access]|For those in the control group, participants will not receive access to their electronic healthcare record for the 6 month period. After the study, participants in the control group will have the opportunity to have access to their healthcare records
62147913|NCT04393402||Patients with Covid-19 and admitted in critical care unit|
62517163|NCT03914768|EXPERIMENTAL|Immunomodulatory DC vaccine to target DIPG and GBM|Patients will receive immune modulatory treatment consisting of cyclophosphamide (200 mg/m2) and bevacizumab (15 mg/kg), before and after DC vaccine injection, respectively.
62517164|NCT05824117|EXPERIMENTAL|Intervention Group (TAU+SEE)|The experimental intervention is treatment as usual (TAU) for adolescents and young adults with early psychosis in the respective recruitment centers for 12 months plus Supported Employment and Education following the Individual Placement and Support model.
62517165|NCT05824117|NO_INTERVENTION|Control Group (TAU)|The control condition is treatment as usual (TAU) for adolescents and young adults with early psychosis in the respective recruitment centers for 12 months (including medical review, pharmacological treatment, and psychosocial support: group programs and social counseling to external government-funded vocational programs).
62517166|NCT05877079|EXPERIMENTAL|Menthol group|Hand and foot wraps with 8% w/w menthol lotion (20 grams each) will be delivered to each subject to wear for 5 min 5 days per week. The total duration is 4 weeks.
62517167|NCT05877079|PLACEBO_COMPARATOR|Non-Menthol group|Hand and foot wraps containing the lotion (20 grams each) without menthol will be delivered to each subject to wear for 5 min 5 days per week. The total duration is 4 weeks.
62710585|NCT04549467|ACTIVE_COMPARATOR|Dolutegravir + emtricitabine/tenofovir (FTC/TDF)|Dolutegravir 50 mg, 1 tablet QD plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
62710586|NCT04490681|EXPERIMENTAL|Ertugliflozin|Ertugliflozin 5mg
62517168|NCT05443100|EXPERIMENTAL|Rehabilitation|Multidisciplinary rehabilitation program consisting of diet and physical exercise for 4 weeks.
62517169|NCT05443100|EXPERIMENTAL|Whole-Body Cryotherapy|Rehabilitation program consisting of 10 WBC sessions over two weeks.
62517170|NCT05528640|EXPERIMENTAL|Mental Health Literacy Educational Program|An educational program consisting of six 30-minutes online educational sessions and one 60-minutes face-to-face session.
62517171|NCT05528640|NO_INTERVENTION|Control Group|No active intervention
62517172|NCT03138902|EXPERIMENTAL|Glucose Tolerance Beverage|75 g. of a fruit punch flavored oral glucose solution
62517173|NCT02555020|EXPERIMENTAL|Allocated to MN NPO group,|"1. Patients was administered in hospital~2. Randomization~3. Patient was allocated to MN group~4. Patients were NPO from mid night (MN) to Surgery"
62710587|NCT04490681|PLACEBO_COMPARATOR|placebo|Placebo
62710588|NCT00251433|EXPERIMENTAL|Phase I|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
61974114|NCT00975481|EXPERIMENTAL|dimebon 40 mg|
61974115|NCT00975481|EXPERIMENTAL|dimebon 60 mg|
61974116|NCT00975481|PLACEBO_COMPARATOR|placebo|
61974117|NCT00975481|ACTIVE_COMPARATOR|alprazolam 1 mg|
61974118|NCT00975481|ACTIVE_COMPARATOR|alprazolam 3 mg|
62517174|NCT02555020|PLACEBO_COMPARATOR|Allocated to Placebo group|"1. Patients was administered in hospital~2. Randomization~3. Patient was allocated to Placebo group~4. Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
61974119|NCT05370222|EXPERIMENTAL|Experimental group|
61974120|NCT05752279|ACTIVE_COMPARATOR|Plasma-Lyte® 148|Plasma-Lyte® 148 fluid 1L given intravenously for fluid replacement
62517175|NCT02555020|ACTIVE_COMPARATOR|Allocated to Carbohydrated group|"1. Patients was administered in hospital~2. Randomization~3. Patient was allocated to Carbohydrated group~4. Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
62517176|NCT01782482|EXPERIMENTAL|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
62517177|NCT01782482|ACTIVE_COMPARATOR|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
62517178|NCT05842967|EXPERIMENTAL|Substudy A - RSVpreF|Participants will receive a single 120-µg dose of RSVpreF at Visit 1
62517179|NCT05842967|PLACEBO_COMPARATOR|Substudy A - Placebo|Participants will receive placebo at Visit 1
62517180|NCT05842967|EXPERIMENTAL|Substudy B - RSVpreF|Participants will receive 120-µg doses of RSVpreF at Visit 1 and Visit 2 (open label, single arm only)
62517181|NCT01557842|ACTIVE_COMPARATOR|Treatment Group|This group receives radiofrequency catheter ablation and drug treatment.
62517182|NCT01557842|EXPERIMENTAL|Control Group|This group receives only drug treatment.
62517183|NCT00164749|PLACEBO_COMPARATOR|Placebo|Color-matched placebo
62517184|NCT00164749|EXPERIMENTAL|1 gram|1 g/day curcumin
62517185|NCT00164749|EXPERIMENTAL|4 gram|4 g/day curcumin
62517186|NCT05557448|ACTIVE_COMPARATOR|Test drug|200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
62517187|NCT05557448|PLACEBO_COMPARATOR|Placebo|200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
62517188|NCT05811026|EXPERIMENTAL|Arm A: 2-week interval between treatments|The interval between the first, second, and third treatments in this arm is two weeks, and the follow-up session will take place four weeks after the third treatment.
62517189|NCT05811026|EXPERIMENTAL|Arm B: 4-week interval between treatments|The interval between the first, second, and third treatments in this arm is four weeks, and the follow-up session will take place four weeks after the third treatment.
62517190|NCT06468423|EXPERIMENTAL|Deferasirox (DFX) group|DFX group (n=71) included children who used oral (tablet) DFX at a dose of 30 mg/kg once daily for a duration of 6 months.
62517191|NCT06468423|EXPERIMENTAL|Desferioxamine (DFO) group|DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week
62517192|NCT06304649|EXPERIMENTAL|Cast21 Short Arm Product|
62517193|NCT00431158|ACTIVE_COMPARATOR|1|ARDSnet Protocol
62517194|NCT00431158|ACTIVE_COMPARATOR|2|OLA Protocol
62517195|NCT04854252|EXPERIMENTAL|Inflammatory response to opioid vs opioid free anesthesia|Patients were randomly assigned to two anesthesia groups: opioid-containing (n=20) or opioid-free (n=20). The opioid used in the opioid-containing anesthesia group was fentanyl.
62517196|NCT06484322|EXPERIMENTAL|Experimental group|The experimental group will receive the internet-based intervention 'SEE' focusing on supporting self-management of activities in everyday life to promote health. Beside SEE, they will also receive care as usual.
62710589|NCT02394561|EXPERIMENTAL|Cw6-positive AIN457 300 mg|Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
61974121|NCT05752279|ACTIVE_COMPARATOR|0.9% sodium chloride|Normal saline fluid 1L given intravenously for fluid replacement
61974122|NCT03937427||CRS with Asthma|
61974123|NCT03937427||CRS without Asthma|
61974124|NCT04784949|EXPERIMENTAL|Portland cement|pulpotomy with PRF and white Portland cement
61974125|NCT04784949|EXPERIMENTAL|Mineral trioxide aggregate|pulpotomy with PRF and Mineral trioxide aggregate
61974126|NCT04784949|EXPERIMENTAL|Biodentine|pulpotomy with PRF and Biodentine
61974127|NCT03181204||Patients likely to develop COPD|"Patients in this group are relatively light smokers who have developed chronic obstructive lung disease (COPD).~Intervention: Bronchial biopsy~Intervention: Skin biopsy~Intervention: Blood sample"
61974128|NCT03181204||Patients not likely to develop COPD|"Patients in this group are heavy smokers who have no signs of chronic obstructive lung disease (COPD).~Intervention: Bronchial biopsy~Intervention: Skin biopsy~Intervention: Blood sample"
62517197|NCT06484322|NO_INTERVENTION|Control|The control group will be put on a wait list for SEE. During their time on the wait list the patient will receive care as usual decided by care givers at their primary care facility.
62517198|NCT05941273|EXPERIMENTAL|Implanted Eye with SING IMT|The SING IMT is implanted in on eye and safety endpoints are aimed at following that eye over time post-implant
62517199|NCT04380675|ACTIVE_COMPARATOR|Music during ESWL|Patients listen to music during ESWL
62517200|NCT04380675|NO_INTERVENTION|ESWL without music|Patients don't listen to music during ESWL
62517201|NCT03927924|EXPERIMENTAL|High-intensity focused ultrasound|
62517202|NCT05198882|EXPERIMENTAL|LITT technology|Laser-induced thermocoagulation of intracerebral lesions responsible for drug-resistant epilepsy.
61974129|NCT01152086|ACTIVE_COMPARATOR|Hiking first|This group first starts with mountain hiking over 9 weeks followed by a 9 weeks control period.
62517203|NCT02480231|ACTIVE_COMPARATOR|Babcock tensioning technique|Group for whom the retropubic mid-urethral sling was tensioned using a Babcock clamp.
62517204|NCT02480231|ACTIVE_COMPARATOR|Scissor spacer technique|Group for whom the retropubic mid-urethral sling was tensioned using a surgical scissor as a spacer.
62517205|NCT03923699|NO_INTERVENTION|Standard of care arm|Operating rooms in the standard of care group will be monitored but, the ACT clinicians will not contact the operating room unless it is clinically necessary for patient safety purposes.
62517206|NCT03923699|EXPERIMENTAL|Anesthesia Control Tower monitoring|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room using AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes.
62517207|NCT00767338|ACTIVE_COMPARATOR|No surgery + IUI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
62517208|NCT00767338|ACTIVE_COMPARATOR|No Surgery + TI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
62517209|NCT00767338|ACTIVE_COMPARATOR|Surgery + IUI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
62517210|NCT00767338|ACTIVE_COMPARATOR|Surgery + TI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
62517211|NCT00349726|EXPERIMENTAL|Inositol low volume|Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes
62517212|NCT00349726|EXPERIMENTAL|Inositol high volume|Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes
62517213|NCT00349726|PLACEBO_COMPARATOR|Placebo low volume|Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.
62517214|NCT00349726|PLACEBO_COMPARATOR|Placebo high volume|Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes
62517215|NCT02342249|PLACEBO_COMPARATOR|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
62517216|NCT02342249|ACTIVE_COMPARATOR|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
61974130|NCT01152086|ACTIVE_COMPARATOR|Control first|This group first starts with the control period (9 weeks) followed by the 9 weeks mountain hiking intervention.
61974131|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
61974132|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
61974133|NCT02371551||1|All patients
62147914|NCT00415649|EXPERIMENTAL|A|DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6.
62147915|NCT00415649|PLACEBO_COMPARATOR|B|Placebo vaccine
62147916|NCT02732990|EXPERIMENTAL|Exercise training - Whole body exercise|Control subjects will train 2-legged cycling (whole body exercise) for 6 weeks
62355243|NCT02409056|NO_INTERVENTION|control|Group will receive no intervention for the first 6 months (pre / post), then be randomly assigned to one of the above interventions.
62355244|NCT00395213||1|Children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
62355245|NCT03181841|EXPERIMENTAL|Active dose 1|Single dose of PF-06412562 in low dosage strength
62355246|NCT03181841|EXPERIMENTAL|Active dose 2|Single dose of PF-06412562 in medium dosage strength
62355247|NCT03181841|EXPERIMENTAL|Active dose 3|Single dose of PF-06412562 in higher dosage strength
62355248|NCT03181841|PLACEBO_COMPARATOR|Placebo|Single dose of placebo
62355249|NCT02722772|EXPERIMENTAL|Etanercept treatment group|Intra-articular injection of etanercept of 25 mg/w/joint and Health education, exercise and diet guidance; treatment: 5 weeks (If both knees are involved, the more significant symptomatic side is chosen for injection by etanercept)
62355250|NCT02722772|PLACEBO_COMPARATOR|Routine care group|Health education, exercise and diet guidance; treatment: 5 weeks
62355251|NCT05648838|EXPERIMENTAL|Pivot Balloon|mornitoring with transcatheter Tricuspid Regurgitation reduction system
62355252|NCT03024255|EXPERIMENTAL|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
62355253|NCT03024255|EXPERIMENTAL|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
62355254|NCT03024255|EXPERIMENTAL|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
62355255|NCT03024255|PLACEBO_COMPARATOR|Vehicle|Placebo, applied once to each axilla daily
62355256|NCT05456412|EXPERIMENTAL|Treatment JAK inhibitor|Clinical practice is followed for all patients treated with JAK inhibitor. Additional biopsies and blood is taken.
62355257|NCT02270801|EXPERIMENTAL|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
62355258|NCT03814005|EXPERIMENTAL|Control Arm|Pevonedistat 20 milligram per square meter (mg/m\^2), infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m\^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 20 mg/m\^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
61974134|NCT06346496|EXPERIMENTAL|AI conversation intervention|Participants in the intervention group received a 28-day AI conversation intervention after completing the baseline questionnaire. We asked users in the intervention group to use the web link every day, upload the start and end times of their conversations with the AI bot and screenshots of their chats; users who chatted for more than 5 minutes were considered to have successfully punched in for that day. Participants who clocked more than 8 days in the first 14 days were allowed to complete the second questionnaire at the two-week mark. Similarly, participants who quit more than eight times between days 15 and 28 could complete the third questionnaire at the four-week mark. Therefore, all users in the intervention group who completed the third questionnaire received at least 16 AI conversation interventions.
61974135|NCT06346496|OTHER|Waiting group|The waiting group received the same intervention as the intervention group after a 28-day waiting period.
61974136|NCT05515757|OTHER|Mobile app-based contingency management|All participants will be enrolled into an 8-week mobile app-based contingency management intervention starting during a prolonged hospitalization.
61974137|NCT03713970|EXPERIMENTAL|Celtra duo press|Celtra duo press ingot 20g for three laminate veneers
61974138|NCT03713970|ACTIVE_COMPARATOR|IPS e.max press|IPS e.max press ingot 20g for three laminate veneers
62517217|NCT02342249|ACTIVE_COMPARATOR|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2\*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
62517218|NCT02342249|ACTIVE_COMPARATOR|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2\*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
62517219|NCT01019707|PLACEBO_COMPARATOR|Sugar pill|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
62517220|NCT01019707|ACTIVE_COMPARATOR|Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
62517221|NCT05497141|EXPERIMENTAL|tricuspid valve edge-to edge Repair group|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm
62517222|NCT05320848|EXPERIMENTAL|Treatment group|the patients treated with cardiac rehabilitation intervention.
62517223|NCT05320848|NO_INTERVENTION|Control group|the patients treated without cardiac rehabilitation intervention.
62517224|NCT00701974|EXPERIMENTAL|1|patients treated with collagenase (IRUXOL)
62517225|NCT00701974|EXPERIMENTAL|2|patients treated with collagenase (Kollagenase)
62710590|NCT02394561|EXPERIMENTAL|Cw6-negative AIN457 300 mg|Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
62147917|NCT02732990|EXPERIMENTAL|Exercise training - One-legged exercise|Control subjects will train high intense one-legged exercise for 6 weeks
62147918|NCT02732990|EXPERIMENTAL|Exercise training - 2-legged cycling CHF|CHF patients will train 2-legged cycling (whole body exercise) for 6 weeks
62147919|NCT02732990|EXPERIMENTAL|Exercise training - CHF|CHF Patients will train high intense one-legged exercise for 6 weeks
62147920|NCT03316690|EXPERIMENTAL|Metformin treatment|
62147921|NCT03316690|PLACEBO_COMPARATOR|Placebo treatment|
62517226|NCT01319201||Impaired glucose regulation|This group of subjects was diagnosed as impaired glucose regulation using oral glucose tolerance test.
62517227|NCT01319201||Type 2 diabetes|This group of subjects was diagnosed as type 2 diabetes using oral glucose tolerance test.
62517228|NCT01319201||Normal glucose regulation|This group of subjects was considered normal regarding glucose metabolism using oral glucose tolerance test.
62517229|NCT02430415|EXPERIMENTAL|Group A|laryngoscope-assisted lightwand intubation - traditional lightwand intubation
62517230|NCT02430415|EXPERIMENTAL|Group B|traditional lightwand intubation - laryngoscope-assisted lightwand intubation
62517231|NCT00466973|ACTIVE_COMPARATOR|Dry bipolar radiofrequency (RF) clamp|used for ablation during surgical procedure
62517232|NCT00466973|ACTIVE_COMPARATOR|Unipolar microwave antenna|used for ablation during surgical procedure
62517233|NCT00466973|ACTIVE_COMPARATOR|Unipolar cryothermic probe|used for ablation during surgical procedure
62517234|NCT00466973|ACTIVE_COMPARATOR|Irrigated unipolar RF antenna|used for ablation during surgical procedure
62517235|NCT00466973|ACTIVE_COMPARATOR|Irrigated bipolar RF clamp|used for ablation during surgical procedure
62517236|NCT00466973|ACTIVE_COMPARATOR|Hi-intensity focused ultrasound wand|used for ablation during surgical procedure
62517237|NCT04429334|EXPERIMENTAL|nangibotide|Continuous infusion of experimental agent for up to 120 hours
62517238|NCT04429334|PLACEBO_COMPARATOR|placebo|Continuous infusion of matched placebo for up to 120 hours
62517239|NCT00118378|EXPERIMENTAL|Modafinil|Participants will take modafinil for 4 weeks.
62517240|NCT00118378|PLACEBO_COMPARATOR|Placebo|Participants will take placebo for 4 weeks.
62517241|NCT06231459|EXPERIMENTAL|Evolocumab|Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response.
62517242|NCT01792960||familial hypertrophic cardiomyopathy|familial hypertrophic cardiomyopathy patients and their relatives
62517243|NCT02152735|ACTIVE_COMPARATOR|Cleaning the uterine cavity|Cleaning the uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus.
62517244|NCT02152735|NO_INTERVENTION|Not cleaning the uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
62517245|NCT02494050|EXPERIMENTAL|Behavioral Activation-Full|Twelve weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
62517246|NCT02494050|EXPERIMENTAL|Behavioral Activation-Short|Eight weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
62517247|NCT02494050|ACTIVE_COMPARATOR|Bipolar Disorder Collaborative Care|Twelve weekly sessions of phone therapy using BDCC manual adapted for anhedonia.
62517248|NCT04531657||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
62517249|NCT04531657||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
62517250|NCT06209801|EXPERIMENTAL|Experimental group|Individuals with peripheral nerve injuries
62517251|NCT06209801|ACTIVE_COMPARATOR|Control group|Healthy individuals
62517252|NCT06142370|OTHER|Positive LCV|A patient who tests positive by clinical exam of a LCV.
62517253|NCT04053413|NO_INTERVENTION|Usual care|Women in this group will undergo usual care and the complete the survey questions on knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean.
62517254|NCT04053413|ACTIVE_COMPARATOR|Decision Aid|Women in this group will receive a decision aid prior to undergoing counseling by their physician. Following completion of the decision aid and physician counseling, they will complete a series of survey questions to assess their perceptions of their knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean delivery.
62517255|NCT01435031|OTHER|CTO Treatment|"Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation"
62517256|NCT01770431|EXPERIMENTAL|Huaier Granule group|"Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..~Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule."
62517257|NCT01770431|NO_INTERVENTION|Bank-control group|"Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.~During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles."
62710591|NCT04876911|NO_INTERVENTION|Control/Usual Care|No intervention delivered and care is provided as usual.
62710592|NCT04876911|EXPERIMENTAL|Simulated Presence Therapy (SPT)|Participants begin to receive the SPT.
61974139|NCT04925128|EXPERIMENTAL|Experimental (Moderate Physical Activity + Conventional Physical Therapy)|"Conventional Physical Therapy group recieved Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set). Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain~Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
61974140|NCT04925128|ACTIVE_COMPARATOR|Control (Conventional Physical Therapy)|Conventional Physical Therapy group recieved Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set). Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain
61974141|NCT05816551||Younger participants|Individuals aged 18-39 years
61974142|NCT05816551||Older participants|Individuals aged over 65 years
61974143|NCT05734625|EXPERIMENTAL|Greater Occipital Nerve block group|Subjects will receive bilateral greater occipital nerve blocks for a total of 2 blocks
62517258|NCT03433365||1|Potential study subjects will sign an informed consent prior undergoing any study related procedure. Patients enrolled in this study will receive Lenalidomide-based regimen as maintenance therapy according to their previous decided therapeutic schedule. All consecutive patients treated with Lenalidomide-based regimen as maintenance therapy and with inclusion criteria will be asked to participate to this study.
62517259|NCT03624179||Rheumatoid arthritis patients|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
62517260|NCT03624179||healthy control|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
62517261|NCT00576641|EXPERIMENTAL|Vaccine|
62517262|NCT03478228|EXPERIMENTAL|Multi-Sensory Training (MST)|Multi-Sensory Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
62710593|NCT04423432|ACTIVE_COMPARATOR|Control|
62710594|NCT04423432|EXPERIMENTAL|Creatine Supplementation|
62710595|NCT04423432|EXPERIMENTAL|Glucoseamine/ Chondritin Sulfate Supplementation|
62710596|NCT04518137|EXPERIMENTAL|ATG-008|Enrolled patients will be treated with ATG-008 at an oral fixed milligram (mg) dose of 30 mg QD
62736790|NCT02250079|EXPERIMENTAL|Polyethilene body bag group|The intervention group infants were provided the same care as control infants, but were dressed with the polyethylene body bag immediately after birth. The bag had an upper opening for the head and a seal at the bottom. The intervention group infants remained in the plastic bag for the first 10 minutes after birth. The same process was done in surgery room in case of cesarean. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process were done in surgery room in case of cesarean
62517263|NCT03478228|ACTIVE_COMPARATOR|Wrist Stabilisation Training (WT)|Wrist Stabilisation Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
62517264|NCT03519984|EXPERIMENTAL|Arm A (sEPHB4-HSA, cytarabine)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and cytarabine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62517265|NCT03519984|EXPERIMENTAL|Arm B (sEPHB4-HSA, vincristine liposomal)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and vincristine liposomal IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62517266|NCT05785689|EXPERIMENTAL|DEX: Bolus dexmedetomidine 0,5 mcg/kg|Intravenous infusion during first 10 minutes of anesthesia
62517267|NCT05785689|PLACEBO_COMPARATOR|Placebo (PCB): Bolus isotonic saline|Intravenous infusion during first 10 minutes of anesthesia
62517268|NCT04792814||MAT-RAP group|MAT and RAP
62517269|NCT04792814||historical group|standard procedure
62517270|NCT03674502|EXPERIMENTAL|ADU-1604|ADU-1604 administered as an IV infusion
62517271|NCT02794155|EXPERIMENTAL|Test Group|HDV Insulin Lispro subcutaneous, pre-prandial dosing, 26 week treatment period
62517272|NCT02794155|ACTIVE_COMPARATOR|Control Group|Insulin Lispro subcutaneous, Pre-prandial dosing, 26 week treatment period
62517273|NCT02740829|PLACEBO_COMPARATOR|Intranasal placebo|placebo comparator
62517274|NCT02740829|EXPERIMENTAL|Intranasal glucagon|active intervention
61974144|NCT05734625|EXPERIMENTAL|Multiple Peripheral Nerve block group|Subjects will receive 10 nerve blocks to include bilateral greater occipital, lesser occipital, auriculotemporal, supraorbital and supratrochlear nerves.
62710597|NCT02007629|EXPERIMENTAL|Riociguat|Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
62517275|NCT01012557|ACTIVE_COMPARATOR|Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant|
62710598|NCT03281057|EXPERIMENTAL|Individual CRAFT|Individual CRAFT is offered to 135 participants and each participants are going to get 6 sessions.
62710599|NCT03281057|EXPERIMENTAL|Group CRAFT|Open group CRAFT is offered to 135 participants in 6 sessions.
61974145|NCT04698902||Circumferential calcification|Patients with circumferential pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium \>180 degrees)
61974146|NCT04698902||Eccentric calcification|Patients with an eccentric pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium \<180 degrees)
61974147|NCT04698902||Nodular calcification|Patients with calcium nodules identified by OCT (Optical coherence tomography) assessment
62517276|NCT01012557|ACTIVE_COMPARATOR|Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant|
62517277|NCT01012557|ACTIVE_COMPARATOR|Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted|
62517278|NCT01012557|ACTIVE_COMPARATOR|Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant|
62517279|NCT06414239|EXPERIMENTAL|Interventional group|Coloscopy with a virtual reality mask
62517280|NCT06414239|OTHER|Control group|Coloscopy without any premedication or anesthesia
62517281|NCT03858426||Children with eosinophilic esophagitis|"Inclusion criteria:~* Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus \> 15 eos / CGA)~* And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids~Exclusion criteria:~* Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)~* Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids)."
62517282|NCT04781114|EXPERIMENTAL|JS002|Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);
62517283|NCT04781114|PLACEBO_COMPARATOR|Placebo|Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);
62517284|NCT06400108|EXPERIMENTAL|Dementia Moves|"Dementia Moves is a multi-component exercise intervention that was developed to provide evidence informed exercise-based physical rehabilitation for LTC residents with dementia. The intervention is based on a recent systematic review that examined the effectiveness of physical rehabilitation interventions for LTC residents with dementia and a qualitative study that describes the goals of rehabilitation as described by residents, family members, and staff. The systematic review identified common interventions and their effectiveness, outcome measures, and gaps in the literature, while the qualitative study provided perspective on common goals to determine a future primary outcome of interest.~Dementia Moves will be delivered to a group of residents (e.g., 4 residents) for 30 minutes, 3 times per week, for a duration of 6 months by a physiotherapist, physiotherapy assistant, and volunteers."
62710600|NCT03281057|EXPERIMENTAL|Self-help materials|Self-help materials (control group) are going to be offered a self-help book, because it is unethically not to offer any intervention, as the CRAFT intervention in early studies have shown to be very effectful
62710601|NCT05392816|OTHER|Study group 1. Texturized fava protein meal and beef protein meal|Participants recruited to study group 1 will be served a meal with fava bean protein (B) and beef protein (A), each meal twice which in total brings four meals on four consecutive days as fasting breakfast. Meals are served in the order BBAA
62710602|NCT05392816|OTHER|Study group 2. Texturized fava protein meal and cod protein meal|Participants recruited to study group 1 will be served a meal with fava bean protein (B) and cod protein (A), each meal twice which in total brings four meals on four consecutive days as fasting breakfast. Meals are served in the order BBAA
62517285|NCT02239107|EXPERIMENTAL|N-Acetyl cysteine|Laparoscopic ovarian drilling followed by NAC 1200mg daily in two divided doses for five days starting cycle day 2 for 6 month
62517286|NCT02239107|ACTIVE_COMPARATOR|laparoscopic drilling group|laparoscopic drilling only will be done
62517287|NCT00359632|EXPERIMENTAL|Linezolid|Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
62517288|NCT00359632|ACTIVE_COMPARATOR|Matched control|Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
62517289|NCT02046668|ACTIVE_COMPARATOR|spironolactone|25mg spironolactone daily
62517290|NCT02046668|PLACEBO_COMPARATOR|Placebo|Matched Placebo
62517291|NCT04119999|ACTIVE_COMPARATOR|CPAP|Continuous Positive Airway Pressure
62517292|NCT04119999|EXPERIMENTAL|MAD|Mandibular Advancement Device
62517293|NCT06265207|EXPERIMENTAL|Experimental group|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
62517294|NCT06265207|ACTIVE_COMPARATOR|Control group|No additional application to routine procedures will be applied to the control group.
62517295|NCT02907541|EXPERIMENTAL|QI4U Group|Group 1 - Learners who will learn QI methods using eLearning through QI4U
62517296|NCT02907541|ACTIVE_COMPARATOR|Facilitated Learning Group|Group 2 - Learners who will learn QI methods by facilitated teaching
62517297|NCT02907541|ACTIVE_COMPARATOR|QI4U and Facilitated Learning Group|Group 3 - Learners who will learn QI methods using a combination of QI4U and facilitated teaching
62517298|NCT00969124|EXPERIMENTAL|Third Eye Retroscope|All subjects underwent the same intervention, consisting of examination of the colon using a colonoscope along with the Third Eye Retroscope device, with removal of any polyps that were detected during the procedure.
62517299|NCT02591576||ST-elevation myocardial infarction (STEMI)|
62517300|NCT02591576||non-ST-elevation myocardial infarction (NSTEMI)|
62517301|NCT00974064||A-Healthy Non smokers|Healthy nonsmokers. Defined as non-smokers by self report and urine cotinine levels consistent with a nonsmoker (urine cotinine \<5 ng/mL).
62517302|NCT00974064||B-Healthy smoker|"Healthy current smokers. Subjects categorized as healthy according to criteria under Collection (#1204012331) protocol."
62517303|NCT00974064||C-Healthy smoker to quit|Healthy smokers willing to quit. Defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine \>50 ng/mL).
62517304|NCT00974064||D-Current smoker w. COPD|Current smokers with COPD. COPD as defined by the GOLD criteria and currently smoking as defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine \>50 ng/mL)
62517305|NCT00974064||E-Current COPD smoker to quit|Current smokers with COPD willing to stop smoking. Subjects have COPD as defined by the GOLD criteria
62517306|NCT03978091|EXPERIMENTAL|Arm 1|2.5g dose of ceftazidime-avibactam (AVYCAZ) administered intravenously as a 2-hour infusion, every 8 hours for 7 days. N=8
62517307|NCT03978091|EXPERIMENTAL|Arm 2|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion once, then 0.32g dose per hour daily as a continuous infusion (7.5 g/day) for 7 days. N=8
62517308|NCT03978091|EXPERIMENTAL|Arm 3|2g dose of aztreonam (ATM) administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
62517309|NCT03978091|EXPERIMENTAL|Arm 4|2g of ATM administered intravenously as a 2-hour infusion once, then 0.33g dose administered intravenously per hour, daily as a continuous infusion (8 g/day) for 7 days. N=8
62517310|NCT03978091|EXPERIMENTAL|Arm 5|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion, every 8 hours for 7 days, and a 1.5g dose of ATM administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
61974148|NCT06192186|EXPERIMENTAL|Adebrelimab combined with SOX regimen|Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
62147922|NCT05098405|EXPERIMENTAL|Dose-escalation Cohorts (q3w)|"The starting dose is 0.03 mg/kg every 3 weeks (q3w) and up to 6 dose levels are planned.~Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first."
62517311|NCT03978091|EXPERIMENTAL|Arm 6|2.5 g dose of AVYCAZ administered intravenously as a 2-hour infusion every 8 hours for 7 days, and a 2g dose of ATM as a 2-hour infusion every 6 hours for 7 days. N=8
62517312|NCT02547402|EXPERIMENTAL|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
62517313|NCT01409590|OTHER|Exercise and Diet program|All patients recruited in the study, participated in an homogeneous exercise program and diet.
62517314|NCT01094028|EXPERIMENTAL|Saline group|Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
62517315|NCT05547334|OTHER|A non-concurrent multiple baseline design|A non-concurrent multiple baseline design
62517316|NCT06446310|EXPERIMENTAL|12-weeks double-blind period-QLG2198|"Interventions:~Drug: QLG2198 Injection"
62517317|NCT06446310|PLACEBO_COMPARATOR|12-weeks double-blind period- placebo|"Interventions:~Drug: Placebo Injection"
62517318|NCT06446310|EXPERIMENTAL|14-weeks open-label period following the double-blind period- QLG2198|"Interventions:~Drug: QLG2198 Injection"
62517319|NCT04108559|EXPERIMENTAL|Kinesiologic Tape Group|After the routine impacted third molar surgery, the kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. Kinesiologic tape will be removed on the second postoperative day, and all sutures on will be removed on 7. postoperative day.
62710603|NCT03067181|EXPERIMENTAL|Arm I (bleomycin, carboplatin, etoposide)|Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
62517320|NCT04108559|EXPERIMENTAL|Surgical Drain Group|After routine impacted third molar surgery, plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa.
62517321|NCT04108559|PLACEBO_COMPARATOR|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
62710604|NCT03067181|EXPERIMENTAL|Arm II (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
61974149|NCT06192186|ACTIVE_COMPARATOR|Placebo combined with SOX (S-1/oxaliplatin) regimen|Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles(stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
62710605|NCT03067181|EXPERIMENTAL|Arm III (bleomycin, etoposide, carboplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
62710606|NCT03067181|EXPERIMENTAL|Arm IV (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
62710607|NCT03067181|EXPERIMENTAL|Low-Risk (observation)|Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma or seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial.
61974150|NCT02461563|EXPERIMENTAL|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
62710608|NCT04476992|ACTIVE_COMPARATOR|NO High Concentration|Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.
62710609|NCT04476992|EXPERIMENTAL|NO High Concentration + Continuous Low Concentration|"Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.~This arm will receive in addition a continuous low flow of Nitric Oxide at 20 ppm among the high concentration treatments."
62710610|NCT05223673|EXPERIMENTAL|Futuximab/modotuximab combined with trifluridine/tipiracil (Safety Lead-In and Phase III parts)|
62710611|NCT05223673|ACTIVE_COMPARATOR|Trifluridine/tipiracil (Phase III part)|
62710612|NCT02146157|ACTIVE_COMPARATOR|herb and mineral combination product|Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period.
62710613|NCT02146157|PLACEBO_COMPARATOR|placebo|Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period
62710614|NCT03730519|ACTIVE_COMPARATOR|Patients with refractory hypertension|Patients with refractory hypertension which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
62517322|NCT02999594|EXPERIMENTAL|tramadol|50mg tramadol hydrochloride will be used intramuscularly as an experimental drug for evaluating its safety and efficacy as labor analgesic
62517323|NCT02999594|PLACEBO_COMPARATOR|distilled water|2ml distilled water intramuscularly will be used as a placebo.
62517324|NCT01826461|EXPERIMENTAL|PDI-192 Foam, 0.1%|topical foam, 0.1% concentration, twice daily
62517325|NCT01826461|EXPERIMENTAL|PDI-192 Foam, 0.15%|topical foam, 0.15% concentration, twice daily
62517326|NCT01826461|PLACEBO_COMPARATOR|Vehicle Foam|topical foam, 0% concentration, twice daily
62517327|NCT05636566|ACTIVE_COMPARATOR|Group (S)|sevoflurane inhalational anaesthesia for induction, then sevoflurane and fentanyl infusion for maintenance ,
62517328|NCT05636566|ACTIVE_COMPARATOR|Group P|propofol infusion for induction afterward propofol and fentanyl infusions for maintenance of anaesthesia
62517329|NCT05636566|ACTIVE_COMPARATOR|Group D|dexmedetomedine infusion for induction after that dexmedetomedine and fentanyl infusions for maintenance
62517330|NCT04233086||Patients referred through the BNP pathway|Patients throughout 2016 referred through the BNP pathway at Queen Alexandra Hospital will retrospectively be assessed for Reddy et al (2018) H2FPEF score.
61974151|NCT02461563|EXPERIMENTAL|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
61974152|NCT02461563|EXPERIMENTAL|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
62147923|NCT05098405|EXPERIMENTAL|Dose-escalation Cohorts (q1w)|"The starting dose is 0,5 mg/kg every week (q1w) and up to 3 dose levels are planned.~Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first."
62517331|NCT06397820||Positive for PET-derived indexes|Patients who had decreased stress myocardial blood flow (MBF) or relative flow ratio (RFR) on PET
62517332|NCT06397820||Negative for PET-derived indexes|Patients who had preserved stress myocardial blood flow (MBF) or relative flow ratio (RFR) on PET
62517333|NCT00791141|EXPERIMENTAL|Cetuximab|Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
62517334|NCT02980250|EXPERIMENTAL|low dose|The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
62517335|NCT02980250|EXPERIMENTAL|normal dose|The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
62517336|NCT02980250|EXPERIMENTAL|over dose|The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
62517337|NCT02980250|PLACEBO_COMPARATOR|placebo|The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.
62517338|NCT05946902|ACTIVE_COMPARATOR|mirabegron|mirabegron 25 mg
62517339|NCT05946902|ACTIVE_COMPARATOR|tolterodine|tolterodine 4 mg
62517340|NCT05946902|EXPERIMENTAL|combined therapy|tolterodine 4 mg \& mirabegron 25 mg
62517341|NCT06454942|EXPERIMENTAL|Regular egg with habitual diet|Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 regular egg/day for 12 weeks.
62517342|NCT06454942|EXPERIMENTAL|Nutrient-fortified egg with habitual diet|Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 nutrient-fortified egg/day for 12 weeks.
62517343|NCT01129453|EXPERIMENTAL|Vaccine-recipients|
62517344|NCT01129453|PLACEBO_COMPARATOR|Placebo|
62517345|NCT05692284|OTHER|routine care group|Routine clinic nursing care in hospital, no follow-up after discharge.
62517346|NCT05692284|EXPERIMENTAL|Care in accordance with Orem's theory group|care in accordance with Orem's theory in the hospital process and follow-up with a mobile application designed according to Orem's theory after discharge
62517347|NCT01447134||Surgical|Group (a) \[Those to undergo surgical excision or biopsy\] patients will receive RGD-K5 scan within two weeks of conventional image evaluations. The image result will be confirmed with histopathological results.
62517348|NCT01447134||Chemotherapy concurrent Radiation|Group (b) patients \[Those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy\] will receive RGD-K5 scan prior to beginning of the therapy, after induction chemotherapy, within two weeks after concurrent chemoradiotherapy and two months after completion of concurrent chemoradiotherpy; all within two weeks of conventional image evaluations.
62517349|NCT01447134||RGD-K5 scan|Group (c) patients \[Those with M1 disease to receive biotherapy or chemotherapy\] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
62517350|NCT00777127|EXPERIMENTAL|1|Aldara 5% Cream
62517351|NCT00777127|ACTIVE_COMPARATOR|2|Solaraze 3% Gel
62517352|NCT05470764|EXPERIMENTAL|PERINDOPRES® TRIO (Test)|A single oral dose of the test product PERINDOPRES® TRIO 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets.
62517353|NCT05470764|ACTIVE_COMPARATOR|TRIPLIXAM® 10 mg /2.5 mg/10 mg|A single oral dose of the reference product TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets.
62517354|NCT03023657|EXPERIMENTAL|Severe brain-damaged patient in coma awakening|For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.
62710615|NCT03730519|ACTIVE_COMPARATOR|Patients with highly variable BP|Patients with symptomatic highly variable blood pressure due to afferent baroreceptor failure which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
62517355|NCT01154959|EXPERIMENTAL|Regimen 1|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 3 months (3RHZEM)
62517356|NCT01154959|EXPERIMENTAL|Regimen 2|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin daily for 2 months (2 RHZEM daily / 2 RHM daily)
62517357|NCT01154959|EXPERIMENTAL|Regimen 3|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2RHM thrice weekly)
62517358|NCT01154959|EXPERIMENTAL|Regimen 4|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, ethambutol and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2 RHEM thrice weekly)
62517359|NCT01154959|ACTIVE_COMPARATOR|Control Regimen|Rifampicin, isoniazid, pyrazinamide and ethambutol thrice weekly for 2 months followed by rifampicin and isoniazid thrice weekly for 4 months (2 RHZE thrice weekly / 4 RH thrice weekly)
62517360|NCT06496074||Positive head-up tilt test|Patients who underwent to head-up tilt test (HUTT) and met criteria for positive exam according to the defined in guidelines.
62517361|NCT06496074||Negative head-up tilt test|Patients who underwent to head-up tilt test (HUTT) and did not met criteria for positive exam according to the defined in guidelines.
62517362|NCT04694612|PLACEBO_COMPARATOR|Mild condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive the same quantity of Placebo.~Duration of treatment : 5 days in each group"
61974153|NCT02461563|EXPERIMENTAL|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
61974154|NCT02461563|EXPERIMENTAL|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
62517363|NCT04694612|ACTIVE_COMPARATOR|Moderate condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive Inj Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily.~Duration of treatment : 10 days in Favipiravir group \& 5 days in Remdesivir group"
62517364|NCT01792414|ACTIVE_COMPARATOR|Active TES|Active TES
62710616|NCT02998190|EXPERIMENTAL|Single oral dose of EB8018|Single ascending doses, sequential group design
62710617|NCT02998190|PLACEBO_COMPARATOR|Single oral dose of placebo|Single doses, matching placebo
61974155|NCT02461563|EXPERIMENTAL|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
61974156|NCT02707250|PLACEBO_COMPARATOR|Placebo|Oblique subcostal tap block with normal sterile saline ,20 ml, bilateral, single shot,24h
61974157|NCT02707250|ACTIVE_COMPARATOR|Bupivacaine|Oblique subcostal tap block with bupivacaine 0,25% ,20 ml, bilateral, single shot,24h
61974158|NCT02707250|ACTIVE_COMPARATOR|Pethidine|Oblique subcostal tap block with pethidine 1% ,10 ml,bilateral,single shot,24h
61974159|NCT02707250|ACTIVE_COMPARATOR|Pethidine Local Infiltration (L.I.)|Local infiltration of pethidine 1% at trocar insertion sites, 5ml /site, 24h compared with Tap Block with pethidine 1%
61974160|NCT04063709|EXPERIMENTAL|Symptomatic with 50-69% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
61974161|NCT04063709|EXPERIMENTAL|Symptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
61974162|NCT04063709|EXPERIMENTAL|Asymptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
61974163|NCT04063709|EXPERIMENTAL|Asymptomatic with 50-69% stenosis|Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
61974164|NCT03199586|EXPERIMENTAL|NP-G2-044|capsule
61974165|NCT01141907|EXPERIMENTAL|Heart Failure Self Care Support|The goal of the Heart Failure Self Care Support Intervention (Navigator Program), delivered by a nurse and community health navigator team over 3 months post discharge from the index hospitalization, was to improve care transitions by providing patients with tools and support that promote knowledge and skills for HF self care as they transition from hospital to home. The multifaceted Navigator Intervention included the following intervention components: HF home automated telemonitoring support, medication and symptom self management, patient-centered record, HF care follow up, and activation of key supporter.
61974166|NCT01141907|ACTIVE_COMPARATOR|Usual Heart Failure Care|Usual care for HF patients included the following: 1) Referral to HF clinic if the patient has no usual source of HF outpatient care, 2) HF patient education by HF care coordinator (advanced practice nurse), and 3) HF self care guide. All participants were treated by their usual source of HF care in the usual manner.
61974167|NCT06182189||Patients with a benign prostatic hyperplasia condition|Patients with a benign prostatic hyperplasia condition
61974168|NCT04386421|EXPERIMENTAL|video group|Group A: A 3 minute video will be shown providing information regarding the care of the dentition during Fixed Appliance Treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions. Participants in this group will also receive the same video graphic educational material through their Whats app once weekly for a total duration of 3 months.
61974169|NCT04386421|EXPERIMENTAL|Plaque disclosing tablet|Group B: Plaque-disclosing tablets will be taken by patients on chair-side showing the location of the biofilm. The patients will be given plaque disclosing tablets to be used once weekly for 3 months to evaluate their oral hygiene at home. They will be given written information in the form of leaflets on importance of cooperation and compliance. Participants in this group will receive a reminder log fill, and tablets that are not used will be asked to return to the investigator by the participants to check the compliance.
62147924|NCT05794295|ACTIVE_COMPARATOR|Acoustic Stimulation (AS)|Participants in this arm will be exposed to acoustic stimulation while they sleep during a night of monitoring.
62147925|NCT05794295|SHAM_COMPARATOR|SHAM Stimulation|Participants in this arm will not be exposed to any stimulation while they have their sleep monitored for one night.
62147926|NCT00958048|EXPERIMENTAL|2|ALS with non-invasive ventilation
62147927|NCT00958048|NO_INTERVENTION|1|ALS without non-invasive ventilation
62147928|NCT00715182|EXPERIMENTAL|TKI258|
62147929|NCT02579109|OTHER|autistic patient|patient with autistic trouble
62147930|NCT02579109|OTHER|healthy volunteers|healthy volunteers
62147931|NCT04908930|NO_INTERVENTION|Unexposed practice group- Aim 1|Data from an unexposed sample (football players practicing as they would otherwise).
62147932|NCT04908930|EXPERIMENTAL|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
62710618|NCT02998190|EXPERIMENTAL|Multiple oral doses of EB8018|Multiple ascending doses, daily for 14 days
62710619|NCT02998190|PLACEBO_COMPARATOR|Multiple oral doses of placebo|Multiple ascending doses, daily for 14 days
62355259|NCT03814005|EXPERIMENTAL|Renal Arm|Pevonedistat 20 mg/m\^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m\^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8-9 in combination with a starting dose of pevonedistat 10 mg/m\^2 to a maximum dose of pevonedistat 15 mg/m\^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
62355260|NCT03814005|EXPERIMENTAL|Mild Hepatic Arm|Pevonedistat 20 mg/m\^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m\^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with a starting dose of pevonedistat 10 mg/m\^2 to a maximum dose of pevonedistat 20 mg/m\^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
62355261|NCT04757922||Intervention: bilateral salpingectomy|Premenopausal women between 30 and 45 years of age, who will undergo sterilization through Opportunistic Salpingectomy will be asked to participate in the STOPOVCAyoung study.
62355262|NCT04757922||Control: tubal ligation or no sterilization|The control group will consists of women who chose for sterilization by clips/tubal ligation supplemented by friend/acquaintances, around the same age, who are not planning to undergo sterilization.
62355263|NCT01142193|EXPERIMENTAL|USL255|
62355264|NCT01142193|PLACEBO_COMPARATOR|Placebo|
61974170|NCT04386421|NO_INTERVENTION|Control. verbal instructions|Control Group C: Controls will be given only routine verbal OHI and will be briefed on the importance of cooperation and compliance at every orthodontic visit for a period of 3 months study. They will receive a reminder log that they will return at the end of the study to check compliance.
61974171|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
62355265|NCT05733260|EXPERIMENTAL|Culturally Tailored|10 weeks of resistance training utilizing culturally tailored prompts, feedback and high autonomy approaches.
62355266|NCT05733260|EXPERIMENTAL|Control|10 weeks of resistance training
62355267|NCT01349985|EXPERIMENTAL|AGATE|To evaluate whether AGATE, a smartphone medication reminder and assessment system, effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking.
62355268|NCT01349985|ACTIVE_COMPARATOR|SASED|The control condition for the proposed study is a smartphone alcohol and side-effects diary (SASED, a smartphone alcohol and side effects diary).
62355269|NCT03214926|EXPERIMENTAL|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
62355270|NCT00696436|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD|
62355271|NCT00696436|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD|
62355272|NCT00696436|ACTIVE_COMPARATOR|Valsartan 320 mg QD|
62355273|NCT00696436|ACTIVE_COMPARATOR|Olmesartan 40 mg QD|
62355274|NCT00696436|PLACEBO_COMPARATOR|Placebo QD|
62355275|NCT06186804|EXPERIMENTAL|ABSK021|Patients will be instructed to take a specified dose of ABSK021 at the same time each day.
43195284|NCT06051994||AI-guided VA ablation|"This is a prospective observational multicenter registry. Patients presenting for a VT ablation at Rush will be screened for inclusion/exclusion criteria and will be included in the study appropriately. The EP specialist conducting the ablation and/or the electrophysiology fellows involved in the procedure will be responsible for patients screening and inclusion. Further data completion (pre-ablation diagnostic procedures, baseline characteristics, ablation data, periprocedural period before discharge home) will be extracted from EPIC and from the study center's Cardiac Mapping System's hard drive.~Follow-up data will be collected from any in-person and virtual clinic visits as per standard of care within 12 months after the index ablation procedure. Follow-up data will also be collected by chart review from routine in-person and remote device interrogations of their ICD devices also conducted as standard of care."
62355276|NCT04154371|EXPERIMENTAL|Single-arm or non-randomized trial|Six post-stroke patients, in the chronic recovery stage, will receive a treatment in which motor execution is promoted by virtual and augmented reality using serious gaming controlled by myoelectric pattern recognition. The aim of this treatment is to improve upper limb functionality.
62355277|NCT05826990|EXPERIMENTAL|cefepime and enmetazobactam unique study arm|Each study participant will receive a two-hour intravenous administration of cefepime and enmetazobactam every 8 hours, as single drug in fixed dose combination (FDC) formulation at a ratio of 4 to 1.
62355278|NCT03487393|EXPERIMENTAL|Vitalflow treatment|The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).
62355279|NCT04593875|EXPERIMENTAL|Active, then Sham|Active Low intensity focused ultrasound pulsation (LIFUP) will be administered to the internal globus pallidus while participants are in the MRI scanner. Then, 2 weeks later, sham LIFUP will be administered.
62355280|NCT04593875|EXPERIMENTAL|Sham, then Active|Sham low intensity focused ultrasound pulsation (LIFUP) will be administered while participants are in the MRI scanner. Then, 2 weeks later, active LIFUP will be administered to the internal globus pallidus.
62517365|NCT01792414|SHAM_COMPARATOR|Sham TES|Sham TES
62517366|NCT05991596|EXPERIMENTAL|Psychodramatic Psychotherapy|"This experimental arm will include 12 patients with vitiligo (randomly assigned to this arm), attending the dermatology services of APSS Trento.~This experimental group will receive the drug treatment usually recommended for vitiligo, in addition to 6 months of psychodramatic psychotherapy."
62539495|NCT06625632|EXPERIMENTAL|Antiemetic drug + Vitamin B6 + Home care advice + Kinesiotaping|It will be consisted of 25 pregnant women who will receive kinesiotaping (I band) for 5 days in addition to antiemetic drugs (ondansetron 4 mg, every 12 hours), vitamin B6 (50 mg, once daily), and home care advice.
61974172|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
61974173|NCT00372125|ACTIVE_COMPARATOR|Norditropin SimpleXx|0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
61974174|NCT00372125|PLACEBO_COMPARATOR|Placebo|Placebo for 12 months
62147933|NCT04277156|EXPERIMENTAL|Flostrum Baby|"The test product will be Flostrum Baby, which is a food supplement consisting of two bacterial strains: Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri DSM 29063, 5x10\^9 CFU and 1x10\^8 CFU, respectively, per seven drops.~Flostrum Baby - in children below 12 years of age, 7 drops, twice daily; in children older than 12 years, 14 drops, twice daily."
62517367|NCT05991596|ACTIVE_COMPARATOR|Self-help activities|This is a control arm which will include 12 patients with vitiligo (randomly assigned to this arm), attending the dermatology services of APSS Trento. This control group will receive the drug treatment usually recommended for vitiligo, in addition to 6 months of self-help activities.
62517368|NCT05590156|EXPERIMENTAL|Action Observation Therapy (AOT)|"AOT is a method based on the principle that the patient watches the movements of a healthy individual and then tries to imitate them. AOT consists of a monitoring-imitation cycle. A cycle consists of 3 minutes of observation, and 3 minutes of imitation. The intervention will consist of 10 cycles for simple functions. Complex movements will be applied by separating them into their components. The cycle time for each component is the same. Take for example, the cup-reaching function: The first component is the cup-reaching activity. The second component is the glass grip. One cycle will be completed on the first component (6 minutes), then one cycle will be completed for the second component (6 minutes) and one cycle (6 minutes) will be completed for the entire movement. Cycles will follow each other for 60 minutes.~For the AOT, 31 different videos were prepared for the shoulder, elbow, and wrist. Applications will be made in the hospital under the supervision of a physiotherapist."
62517369|NCT05590156|EXPERIMENTAL|Robotic Rehabilitation|"The robotic rehabilitation application will be performed with the ExoRehab X (HoustonBionics, Inc.) device. There is no engine to create any repulsive-pulling force in this device. It is a system that works entirely with the patient's active movement.~Active movements of the shoulder, elbow, and wrist in all directions can be performed with the device. Motion is detected with the help of the device's censor, and the avatar moves on the screen. There are 10 different purposeful games embedded in the device. The device also allows resistance exercise thanks to resistance modules.~Which joint will be trained will be determined according to the potential of the patient. For example, if programming will be done for the shoulder, elbow and wrist, the treatment time will be 20 minutes for each joint.~Applications will be made in the hospital under the supervision of a physiotherapist."
62517370|NCT01164306|EXPERIMENTAL|LifeSkills training|
62517371|NCT01164306|ACTIVE_COMPARATOR|Healthy Lifestyle Behaviors|
62517372|NCT06250036|EXPERIMENTAL|Single agent zimberelimab|Single agent zimberelimab (PD-1 inhibitor) Q3W
62517373|NCT06250036|EXPERIMENTAL|Combination zimberelimab + domvanalimab|Combination zimberelimab + domvanalimab
62517374|NCT00937651|PLACEBO_COMPARATOR|Placebo|Placebo, 3 tablets
62517375|NCT00937651|ACTIVE_COMPARATOR|BR-A-657•K 20 mg group|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
62517376|NCT00937651|ACTIVE_COMPARATOR|BR-A-657•K 60 mg group|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
62517377|NCT00937651|ACTIVE_COMPARATOR|BR-A-657•K 180 mg group|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
62517378|NCT03452072|EXPERIMENTAL|0.25% Timolol gel under the paraffin gauzes|"1. Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied~2. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing~3. This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
62517379|NCT03452072|ACTIVE_COMPARATOR|Standard of Care dressings|"1. Vaseline will be applied to wound bed immediately after surgery before dressing is applied~2. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing~3. This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
62517380|NCT03204071|PLACEBO_COMPARATOR|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
62517381|NCT03204071|ACTIVE_COMPARATOR|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
62517382|NCT03204071|ACTIVE_COMPARATOR|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
62517383|NCT03738176|EXPERIMENTAL|sesame oil in orabase|20 gm sesame oil-80 gm CMC 3 times per day for one month
61974175|NCT05296759|ACTIVE_COMPARATOR|botulinum toxin A injection|botulinum toxin A injection
61974176|NCT05296759|ACTIVE_COMPARATOR|gabapentin|gabapentin
61974177|NCT05296759|ACTIVE_COMPARATOR|duloxetine|duloxetine
61974178|NCT00433849|EXPERIMENTAL|1|
61974179|NCT00433849|EXPERIMENTAL|2|
61974180|NCT05183373||Aneurysmal coronary artery disease|Patients with coronary artery ectasia or/and aneurysm diagnosed during coronary angiography
61974181|NCT05183373||Abdominal aortic aneurysm|Patients with diagnosed with abdominal aortic aneurysm
61974182|NCT05183373||Coronary artery disease|Patients with diagnosed with coronary artery disease
62147934|NCT04277156|ACTIVE_COMPARATOR|Dicoflor|"The control product will be Dicoflor, which is a food supplement containing L rhamnosus ATCC 53103, 5x10\^9 CFU, per five drops.~Dicoflor - the manufacturer recommends 5-10 drops daily, with no age specification. For the purposes of this study, 5 drops, twice daily, in children below 12 years of age; 10 drops, twice daily, in children older than 12 years."
62147935|NCT05786378|EXPERIMENTAL|platlet rich plasma|
61974183|NCT03096210|OTHER|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
61974184|NCT03096210|OTHER|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
61974185|NCT03447132|ACTIVE_COMPARATOR|Fulvestrant 500mg + Palbociclib 125mg|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
61974186|NCT03447132|PLACEBO_COMPARATOR|Fulvestrant 500mg + Placebos|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
62355281|NCT03614819|EXPERIMENTAL|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
62517384|NCT03738176|ACTIVE_COMPARATOR|triamcinolone in orabase|140 gm triamcinolone-50 gm Na CMC 3 times per day for one month
62517385|NCT01578668|EXPERIMENTAL|Erlotinib, pemetrexed, cisplatin|
62517386|NCT01578668|EXPERIMENTAL|erlotinib|
62517387|NCT03903159|OTHER|Treatment Group|Positive Peer Journaling (PPJ)
62517388|NCT00252174|EXPERIMENTAL|Stage 1 Active methylenedioxymethamphetamine & psychotherapy|8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
62517389|NCT00252174|ACTIVE_COMPARATOR|Stage 1 low dose methylenedioxymethamphetamine & Psychotherapy|4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
62517390|NCT00252174|EXPERIMENTAL|Stage 2 Active methylenedioxymethamphetamine & Psychotherapy|The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
62517391|NCT06415617|EXPERIMENTAL|Experimental group|Participants will receive 60-minute weekly online group-based psychoeducation sessions for 12 weeks.
62517392|NCT06415617|ACTIVE_COMPARATOR|Control group|Participants will receive 60-minute weekly online group-based physical health sessions for 12 weeks.
62517393|NCT04821765|EXPERIMENTAL|Chemoradiotherapy Combined With PD-1 Antibody|The arm received chemoradiotherapy, 50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week) to recurrent sites combined with chemotherapy（Cisplatin 75 mg/m2/day 1, and albumin paclitaxel 150 mg/m2/day 1 , every 3 weeks, 2 cycles ).PD-1 antibody (Tislelizumab) was performed simultaneously with concurrent chemoradiotherapy (Triprizumab 200mg，d1，every 3 weeks，2 cycles). After completion of chemoradiotherapy, PD-1 antibody was given continuously with 2-4 cycles of chemotherapy (the same regimen with concurrent chemotherapy) until 1 year or desease progression.
62517394|NCT00303875|NO_INTERVENTION|Wait-list control|Wait-list control received diet \& exercise counseling during year 2 as a courtesy
62517395|NCT00303875|EXPERIMENTAL|Lifestyle counseling|subjects randomized to receive diet \& exercise counseling for one year
62517396|NCT04153448||Bronchiectasis|Children with bronchiectasis
62517397|NCT04153448||Healthy Controls|Age-matched healthy volunteers
62517398|NCT02960438|EXPERIMENTAL|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
62517399|NCT02960438|EXPERIMENTAL|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
62517400|NCT02960438|EXPERIMENTAL|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
62517401|NCT02960438|PLACEBO_COMPARATOR|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
62517402|NCT04840784|EXPERIMENTAL|ETH-155008|Dose level: 10mg/day, 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 3-6 subjects, taking ETH-155008 tablets once daily.
62517403|NCT03654664|EXPERIMENTAL|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
62517404|NCT03654664|ACTIVE_COMPARATOR|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
62517405|NCT06533462|ACTIVE_COMPARATOR|Group A: Allergic children - Multiallergen OIT|"Children with food allergy receiving multiallergen powder OIT. Multiallergen food challenge is done before randomization and one and two years after inclusion. OIT multiallergen powder with slow up-dosing until 3 teaspoons of the multiallergen powder is reached and taken daily. 2 years treatment.~Number = 40 patients~Intervention: multiallergen powder"
62517406|NCT06533462|NO_INTERVENTION|Group B: Allergic children - Placebo powder|"Children with food allergy receiving OIT with placebo powder (gluten-free oatmeal). Multiallergen food challenge is done before randomization and one and two years after inclusion.~Number = 40 patients"
62517407|NCT06533462|ACTIVE_COMPARATOR|Group C: Non-allergic children - low dose multiallergen powder|"Children not reacting to the baseline challenge who will be randomized to eat a low dose of the multiallergen powder, 1 teaspoon daily. Multiallergen food challenge is done before randomization and one year after inclusion. 1 year treatment.~Number = X~Intervention: Multiallergen powder"
62517408|NCT06533462|NO_INTERVENTION|Group D: Non-allergic children - placebo powder|"Children not reacting to the baseline challenge who will be randomized to eat placebo powder (gluten-free oatmeal) and no specific advice.~Number= X"
62517409|NCT02692482|EXPERIMENTAL|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
62517410|NCT02692482|ACTIVE_COMPARATOR|standard care|
62517411|NCT01312311|EXPERIMENTAL|weekly docetaxel and cisplatin|Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
62517412|NCT03623464|ACTIVE_COMPARATOR|Mobile app and Fitbit + Standard of care|Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
62517413|NCT03623464|OTHER|Standard of care|Participants will receive standard of care
62517414|NCT00957619|ACTIVE_COMPARATOR|pentoxyfilline group|pentoxyfilline group
62710620|NCT05973643|OTHER|Electroconvulsive therapy|simple-blind, any adult patient presenting a characterized depressive episode in the context of unipolar major depressive disorder or bipolar disorder who consents and requires an ECT treatment. study including 50 patients.
62355282|NCT03614819|ACTIVE_COMPARATOR|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
62517415|NCT00957619|PLACEBO_COMPARATOR|placebo group|placebo group
62517416|NCT06330519|EXPERIMENTAL|intraligamentary dexamethazone|
62517417|NCT06330519|ACTIVE_COMPARATOR|Endo-ice cryotherapy|
62517418|NCT06330519|ACTIVE_COMPARATOR|Intraoral soft tissue cryotherapy|
62517419|NCT06330519|NO_INTERVENTION|Inferior Alveolar nerve block only|
62517420|NCT06004778|EXPERIMENTAL|Motivational Support Program|Training booklet will be provided.A total of 5 sessions of sleep training will be given by dividing them into groups of 30 minutes, 3 days a week for 2 weeks.Individual motivational interviews will be held with students and reminder messages will be sent twice a week.
62355283|NCT00789646|EXPERIMENTAL|NSS/Lidocaine|First injection: Normal saline Second injection: 2% Lidocaine without adrenaline
62355284|NCT00789646|EXPERIMENTAL|Lidocaine/NSS|First injection: 2% Lidocaine without adrenaline Second injection: Normal saline
62355285|NCT06006910||Pre-Nudge Deployment into EHR|Rates of SLNB will be recorded for the 12 month period prior to nudge deployment.
62355286|NCT06006910||Post-Nudge Deployment into EHR|Rates of SLNB will be recorded for the 12 month period following nudge deployment into the EHR.
62355287|NCT00169910|ACTIVE_COMPARATOR|1|AUC monitored withdrawal of MMF
62355288|NCT00169910|ACTIVE_COMPARATOR|2|AUC monitored withdrawal of CNI
62355289|NCT03250156|EXPERIMENTAL|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
62355290|NCT03250156|ACTIVE_COMPARATOR|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
62355291|NCT03250156|NO_INTERVENTION|No Training Control|This group will receive no intervention.
62355292|NCT05684588|OTHER|Instrumental diagnostic evaluation|After enrollment all patients will undergo an instrumental evaluation including a radiography (according to clinical practice) and a magnetic resonance (experimental procedure outside clinical practice), at 1 year from previous hospitalization
62355293|NCT02424006|EXPERIMENTAL|RHCIII-MPC cornea|Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique
62355294|NCT02424006|ACTIVE_COMPARATOR|Donor cornea|Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique
62355295|NCT05015738|OTHER|Traditional diabetes education|"The subjects and activities were applied to the control group, who received traditional diabetes education, between 8:00 and 10:00 with the classical method, which lasted 2 hours, for 10 weeks. The training was completed by the researcher with the verbal narration method. Diabetes Achievement Assessment Test with question and answer method was administered to the students at the beginning and end of the application. These questions were the same questions asked to the experimental group. Interaction of groups with each other was limited. Students were informed about this and their consent was taken.At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels."
62355296|NCT05015738|EXPERIMENTAL|Diabetes Education supported by digital tools|The subjects included in the course content were given between 10:00-12:00 with the animation supported method, which lasted for 2 hours. The animations were created by the researchers to reflect all guidelines for diabetes. The scenario of the animation video was prepared in line with the training content. Storyboards in videos and animations were created with the collaboration of researchers and experts in their fields (software specialists, computer programmers). The animation video was voiced in Turkish by a professional actor. Animations are 2 minutes each and a total of 18 minutes long. The 'Kahoot' application, a Web 2.0 tool, was used to apply Diabetes Achievement Evaluation Test. At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels.
62355297|NCT03771443|EXPERIMENTAL|gluten free toothpaste|experimental gluten free toothpaste with natural ingredients prepared for the study to be used 3 times per day for six months
62355298|NCT06372197|EXPERIMENTAL|Intervention|This is an uncontrolled feasibility study with only one arm.
62517421|NCT06004778|ACTIVE_COMPARATOR|educational support|Training booklet will be provided. A total of 5 sessions of sleep training will be given by dividing them into groups of 30 minutes, 3 days a week for 2 weeks.
62517422|NCT02704234|EXPERIMENTAL|Active Acupuncture|Active Acupuncture 2 times per week for 5 weeks
62517423|NCT02704234|PLACEBO_COMPARATOR|Placebo|Placebo Acupuncture 2 times per week for 5 weeks
62517424|NCT03274622|EXPERIMENTAL|Impact Parent Training|Parents receive 22 1.5-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
62710621|NCT03641287|EXPERIMENTAL|Arm I (aerobic exercise)|Participants meet with exercise physiologist for 1, 60 minute session. Participants then receive individualized exercise prescription with goal of moderate aerobic exercise over 150 minutes per week at home for up to 24 weeks. Participants also receive telephone-based motivational support by exercise physiologist weekly for 24 weeks.
61974187|NCT02622516|ACTIVE_COMPARATOR|Intervention Group (IG)|Participants in the intervention group subjects (IG) will receive physiotherapy treatment in vestibular rehabilitation based on multisensory exercises consisting of the group of therapeutic proposals that stimulation of the vestibular, proprioceptive and visual associated with manual therapy treatment proposed by the techniques cervical global pompage and classic massage therapy on neck and shoulder girdle .
62710622|NCT03641287|ACTIVE_COMPARATOR|Arm II (habitual level of physical activity)|Participants maintain habitual levels of physical activity and receive general education material about ovarian cancer and survivorship for 24 weeks. After 24 weeks, participants are offered exercise intervention.
62710623|NCT01256255||influenza infection|Patients with the diagnosis of influenza infection by standard laboratory technique
62710624|NCT05739448|NO_INTERVENTION|control|
62355299|NCT05648981|EXPERIMENTAL|Test group|
62710625|NCT05739448|EXPERIMENTAL|fortification (FOR)|
61974188|NCT02622516|EXPERIMENTAL|Control Group (CG)|Participants in the control group subjects (CG) will receive physiotherapy treatment in vestibular rehabilitation based on Cawthorne and Cooksey Exercises, consisting of eye movements in different directions, slowly and quickly; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
61974189|NCT05843981|EXPERIMENTAL|Ks dental implant|Innovative dental implant with lasting, internal conical connection of 15° and strengthened implant walls.
61974190|NCT05843981|ACTIVE_COMPARATOR|TSIII dental implant|Standard dental implant with internal conical connection of 11°.
61974191|NCT02436889|EXPERIMENTAL|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
62710626|NCT05739448|EXPERIMENTAL|fortification + physical activity (FAP)|
62710627|NCT04415554||exposure to aminoglicosides|preterm receiving aminoglycosides
62710628|NCT04415554||non exposure to aminoglycosides|preterm not receiving aminoglycosides
62710629|NCT04212663|PLACEBO_COMPARATOR|control|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release
61974192|NCT02436889|ACTIVE_COMPARATOR|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
61974193|NCT04432662|ACTIVE_COMPARATOR|Darbepoetin Alpha|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
62147936|NCT06313632|EXPERIMENTAL|ESP with Bupivacaine Group|Erector spinae plane block with bupivacaine.
62147937|NCT06313632|SHAM_COMPARATOR|ESP with Placebo|Erector spinae plane injection with a placebo (normal saline).
62147938|NCT04890457|EXPERIMENTAL|Tragus then earlobe stimulation|
62710630|NCT04212663|EXPERIMENTAL|experiment|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release+ The tendon release of musculi tibialis posterior
62147939|NCT04890457|EXPERIMENTAL|Earlobe then tragus stimulation|
62147940|NCT00532350|EXPERIMENTAL|1|QAT370
62147941|NCT00532350|PLACEBO_COMPARATOR|2|Placebo
62147942|NCT00532350|ACTIVE_COMPARATOR|3|Tiotropium
62147943|NCT00953355|EXPERIMENTAL|Folate|Folate plus metformin
62147944|NCT00953355|PLACEBO_COMPARATOR|Placebo|Placebo plus metformin
62710631|NCT04972279|EXPERIMENTAL|Aggressive adaptation strategy|Participants receive up to 6 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
61974194|NCT04432662|NO_INTERVENTION|Standard of care|Standard of care: Cooling only
61974195|NCT05340868|EXPERIMENTAL|Semaglutide (oral)|In this study, each participant will receive a regimen of oral semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for a duration of twelve weeks. The dosage will begin at 3 mg/day for weeks 1-2, gradually increasing to 7 mg/day for weeks 3-4, 14 mg/day for weeks 5-6, 28 mg/day for weeks 7-8, and finally, to 42 mg/day for the last four weeks (weeks 9-12).
62147945|NCT04976764||liver cirrhosis with cirrhotic cardiomyopathy|
62147946|NCT04976764||liver cirrhosis without cirrhotic cardiomyopathy|
62147947|NCT02797743||Whole blood from all ages and gender|- Ages from 0 to Adults (18 yrs of age or older)
62147948|NCT00074425|EXPERIMENTAL|1|BufferGel
62147949|NCT00074425|EXPERIMENTAL|2|Pro 2000/5 Gel (P)
62147950|NCT00074425|PLACEBO_COMPARATOR|3|Placeo Gel
62147951|NCT00074425|NO_INTERVENTION|4|
62147952|NCT01218594|EXPERIMENTAL|Endostatin combine CCRT|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
62147953|NCT05227898|ACTIVE_COMPARATOR|Attune™|Attune™ is a completely digital therapeutic intervention.
62147954|NCT05227898|ACTIVE_COMPARATOR|Cerena™|Cerena™ is a completely digital therapeutic intervention.
62147955|NCT00969007|EXPERIMENTAL|Lifestyle counseling|
62147956|NCT04638049|ACTIVE_COMPARATOR|Prostate (Bed) only RadioTherapy (PBRT)|Primary, adjuvant or salvage RT of the prostate (bed) without RT of the pelvic nodal regions in the small pelvis, according to local hospital guidelines and protocols.
62147957|NCT04638049|ACTIVE_COMPARATOR|Whole Pelvis RadioTherapy (WPRT)|Primary, adjuvant or salvage RT of the pelvic nodal regions in the small pelvis with possible additional RT of the prostate (bed), according to local hospital guidelines and protocols.
62147958|NCT03674788||TAVI|Transcatheter Aortic Valve Implantation
62355300|NCT05648981|ACTIVE_COMPARATOR|Control group|
62517425|NCT03274622|PLACEBO_COMPARATOR|No Impact|No parent coaching is provided
62147959|NCT03674788||TMVI|Transcatheter Mitral Valve Intervention
62147960|NCT03674788||TTVI|Transcatheter Tricuspid Valve Intervention
62517426|NCT04910516|NO_INTERVENTION|Control Group|The nurses in the control group were informed about the purpose of working in a quiet room. STAI-D, STAI-S, SUD, P19-S scales were filled face-to-face by the investigator after their informed consent was obtained. The scales were filled again by the researcher after a break of 7 (seven) days.
62539496|NCT06625632|ACTIVE_COMPARATOR|Antiemetic drug + Vitamin B6 + Home care advice|It will be consisted of 25 pregnant women who will receive antiemetic drugs (ondansetron 4mg every 12 hours, vitamin B6 (50 mg, once daily), and home care advice only for 5 days.
61974196|NCT03156673|EXPERIMENTAL|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
61974197|NCT00703989|EXPERIMENTAL|I|Patients with Type 1 diabetes
61974198|NCT00703989|NO_INTERVENTION|II|Age-matched male subjects without Type 1 diabetes
61974199|NCT00941473|ACTIVE_COMPARATOR|Epidural Steriod Injection|This study focuses on the changes in bone mineral density over time of the cohort previously described in the inclusion criteria (post-menopausal white women)
61974200|NCT03440710|EXPERIMENTAL|with BET|with BET and Tympanoplast
61974201|NCT03440710|OTHER|without BET|with Tympanoplast only
62147961|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
62147962|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
62147963|NCT03849937|EXPERIMENTAL|Intervention|Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
62147964|NCT03849937|ACTIVE_COMPARATOR|Waitlist Control|After the intervention group takes the training, the waitlist control group will crossover and take the training.
62147965|NCT01379885|ACTIVE_COMPARATOR|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
62147966|NCT01379885|EXPERIMENTAL|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
62147967|NCT04093609||cases|
62355301|NCT03798587||OS patients|"Patients with age ≥18 years that were/can be recruited within the IRCCS Istituto Ortopedico Galeazzi BioBanca (ethical committee approval n. 29/INT/2017).~Patients with age \<18 years: will be additionally recruited besides the IRCCS Istituto Ortopedico Galeazzi BioBanca.~The target group corresponds to patients hospitalized at Istituto Ortopedico Galeazzi, undergoing surgical eradication of primary osteosarcoma.~Patients will be considered eligible for enrollment in the study if able to sign the consent to the procedure after appropriate information from the reference surgeon or signed by parents or legal guardian after appropriate information from the reference surgeon (if age \<18).~Inclusion Criteria:~* Indication for primary OS eradication surgery~* Patients hospitalized in Istituto Ortopedico Galeazzi~Exclusion criteria:~-Patients not able to sign the Informed Consent."
61974202|NCT03498690|ACTIVE_COMPARATOR|Integrative|
61974203|NCT03498690|ACTIVE_COMPARATOR|Role Specific|
61974204|NCT03498690|ACTIVE_COMPARATOR|Consecutive|
61974205|NCT03038334|EXPERIMENTAL|Magnesium sulfate|All participants will apply magnesium sulfate transdermally a total of 250mg equivalent to 2 mEq every four hours per day for 90 days.
61974206|NCT00432471|EXPERIMENTAL|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
61974207|NCT02245490|EXPERIMENTAL|Tamsulosin|
61974208|NCT02245490|PLACEBO_COMPARATOR|Placebo|
61974209|NCT00105482|EXPERIMENTAL|Naltrexone, Transdermal Nicotine|Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
62355302|NCT01814826|EXPERIMENTAL|MLN4924 and Azacitidine|
62355303|NCT02660866|PLACEBO_COMPARATOR|SMT+APT+Placebo|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents \[angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs\] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (\>5 days of prior use) aspirin therapy."
61974210|NCT00105482|PLACEBO_COMPARATOR|Placebo Naltrexone, Transdermal Nicotine|Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
61974211|NCT01053728|EXPERIMENTAL|Cohort 1 : SAR161271 0.3 U/kg|Cross-over design of four formulation of SAR161271 0.3U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
62147968|NCT04093609||control|
62147969|NCT04335149||COREVALVE|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a COREVALVE
62539497|NCT02944305||Patient with difficult intubation|Group 1: Patient undergoing endotracheal intubation with difficult intubation Group 2: Patient undergoing endotracheal intubation without difficult intubation
62147970|NCT04335149||EDWARDS|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a EDWARDS
62147971|NCT02680015|EXPERIMENTAL|Experimental Group|Immediate enrollment in the PEERS group.
61974212|NCT01053728|EXPERIMENTAL|Cohort 2 : SAR161271 0.6 U/kg|Cross-over design of four formulation of SAR161271 0.6U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
61974213|NCT01053728|EXPERIMENTAL|Cohort 3 : SAR161271 1.2 U/kg|Cross-over design of four formulation of SAR161271 1.2 U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
62710632|NCT04972279|EXPERIMENTAL|Moderate adaptation strategy|Participants receive up to 3 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected randomly from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
61974214|NCT02526472|EXPERIMENTAL|transabdominal US guidance (UGET)|ET under transabdominal US guidance (UGET)
61974215|NCT02526472|EXPERIMENTAL|TV-US ET guidance (mTVET)|ET after transvaginal US uterine measurement (mTVET)
62517427|NCT04910516|EXPERIMENTAL|Experiment Group|In order to avoid bias in the intervention applied in our study, the experimental group was started after the control group was finished. The participants were informed about the purpose of working face-to-face in a quiet room so that EFT, which will be applied online for 7 (seven) days by the researcher, can be applied effectively and accurately. STAI-D, STAI-S, SUD, P19-S scales were completed after their consent was obtained. The researcher, who has the EFT certificate, first showed the application steps on himself with the guidance of the EFT guideline, and ensured that the application steps were applied again simultaneously on both himself and the participant. After this application, it was provided to make EFT online for 7 (seven) days. STAI-D, STAI-S, SUD, P19-S scales were filled in after the last EFT application.
62517428|NCT01927354||Head and neck cancer|Subjects who suffer from oral cancer. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.
62517429|NCT01202877|EXPERIMENTAL|5-azacytidine + PKC412|5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
62517430|NCT04281394|EXPERIMENTAL|Robot assisted gait training|Robot assisted gait training(RAGT) group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks. SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements.
62517431|NCT04281394|ACTIVE_COMPARATOR|conventional physical training group|The conventional group underwent conventional physical therapy( even level gait training and range of motion exercises) twice a day, 5 times a week in 12 weeks.
62517432|NCT04470531|NO_INTERVENTION|Control|"Arm A :No Intervention/control: Standard treatment~1. Antibiotics for secondary bacterial infection as per institutional guidelines~2. Supplemental oxygen (to keep saturations between 90% to 96%)~3. Intravenous hydration (to maintain euvolumia)~4. Thrombo-prophylaxis as per local guidelines~5. Paracetamol (oral or I/V 1gram QDS as required or regular)~6. To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
62517433|NCT04470531|EXPERIMENTAL|intervention /experimental|"Arm B: Experimental Arm received oral co-trimoxazole + standard therapy~The following treatments are recommended as standard therapy:~1. Antibiotics for secondary bacterial infection as per institutional guidelines~2. Supplemental oxygen (to keep saturations between 90% to 96%)~3. Intravenous hydration (to maintain euvolumia)~4. Thrombo-prophylaxis as per local guidelines~5. Paracetamol (oral or I/V 1gram QDS as required or regular)~6. To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
62517434|NCT01731717|EXPERIMENTAL|Stepped care intervention (SCM)|"Patients within the stepped care intervention are screened by general physician using the PHQ-9 (inclusion criterion: \>4 points) and diagnosed according to International Classification of Diseases (ICD-10) criteria. Patients receive differentially intensive treatment according to depression severity.~Patients with mild depression receive:~Step I: Active monitoring or Step II: II.a. Bibliotherapy or II.b. Online self-help (Deprexis®) or II+: Telephone-based psychotherapy~Patients with moderate depression receive:~Step III: III.a. Outpatient psychotherapy or III.b. Psychopharmacological treatment~Patients with severe depression receive:~Step IV: Combined psychotherapy and psychopharmacological treatment, optionally in inpatient setting."
62517435|NCT01731717|ACTIVE_COMPARATOR|Control group: treatment as usual|Patients in the control group are screened by their general physician using the PHQ-D-9 depression scale. Patients included in the study then receive treatment as usual from general physician or other health service providers.
62517436|NCT05535439|EXPERIMENTAL|19 G EBUS-TBNA Needle|Mediastinal or Hilar Lymphadenopathy will be sampled by using 19 G EBUS-TBNA Needle
62517437|NCT05535439|EXPERIMENTAL|22 G EBUS-FNB Device|Mediastinal or Hilar Lymphadenopathy will be sampled by using 22 G EBUS-FNB Device
62517438|NCT02794857|EXPERIMENTAL|NP001|NP001 2 mg/kg by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
62517439|NCT02794857|PLACEBO_COMPARATOR|Placebo|Normal saline by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
62517440|NCT03596619|EXPERIMENTAL|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2).
61974216|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
61974217|NCT03194321|EXPERIMENTAL|Tacrolimus Extended-Release Arm|All patients will receive tacrolimus extended-release adjusted to target trough levels, mycophenolate mofetil or mycophenolate sodium, and prednisone per CSMC practice.
61974218|NCT01179854|EXPERIMENTAL|500 mg|Group of active treatment of Remegal 500 mg
61974219|NCT01179854|EXPERIMENTAL|Remegal 750 mg|Group of active treatment of Remegal 750 mg
61974220|NCT01179854|EXPERIMENTAL|Remegal 1000 mg|Group of active treatment of Remegal 1000 mg
61974221|NCT01179854|PLACEBO_COMPARATOR|Placebo|Placebo
61974222|NCT01324999|EXPERIMENTAL|Sarcoid Associated Pulm. Hypertension|Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.
61974223|NCT04497506|EXPERIMENTAL|Self-affirmation and Incremental theory of personality|1 hour Wise intervention (based on SA and ITP) consisting on several tasks to be completed online individually.
61974224|NCT04497506|OTHER|Standard preventive intervention|1 hour educational intervention (about stress management) consisting on several tasks to be completed online individually.
62147972|NCT02680015|NO_INTERVENTION|Waitlist Group|Research measures while waiting for PEERS; will receive PEERS within one year.
62710633|NCT06228950|EXPERIMENTAL|Intervention Group|A structured MBSR training for this study will be given to the intervention group of students with visual impairment. The intervention will include body scan, sitting meditation, yoga, breathing exercises, guided mindfulness, loving kindness, etc exercises to improve the emotional and behavioural problems of students with visual impairment.
62147973|NCT03713476|EXPERIMENTAL|Robot-assisted training|The participants will receive 20 minutes of robot assisted tenodesis-grip therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
62517441|NCT03596619|NO_INTERVENTION|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
62517442|NCT00156715|EXPERIMENTAL|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
62517443|NCT02664857|ACTIVE_COMPARATOR|vitamin D|After per orally vitamin D supplementation during 12 weeks, serum Vitamin D level will evaluate with laboratory testing. 600 IU vitamin D will apply to 30 subject during 12 weeks. At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
62517444|NCT02664857|SHAM_COMPARATOR|Placebo|Grup P will not take vitamin D during 12 weeks. This group just only will follow by researchers.At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
62517445|NCT05339646|EXPERIMENTAL|SSD8432 dose 1~7|Dose level 1 \~7 of SSD8432
62517446|NCT05339646|EXPERIMENTAL|SSD8432 dose 8~9|Dose level 8 \~9 of SSD8432
62517447|NCT05339646|EXPERIMENTAL|SSD8432 dose 10~12|Dose level 10 \~12 of SSD8432
62517448|NCT05339646|EXPERIMENTAL|SSD8432 dose 13|Dose level 13 of SSD8432
62147974|NCT03713476|ACTIVE_COMPARATOR|Traditional occupational therapy|The participants will receive 20 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
62517449|NCT05339646|EXPERIMENTAL|SSD8432 dose 14|Dose level 14 of SSD8432
62517450|NCT06264479||Trial Cohort|Patients with advanced or metastatic kidney cancer, due to start a new line of systemic therapy (targeted drug, immunotherapy, etc.)
62710634|NCT06228950|NO_INTERVENTION|Wait-list Control Group|The Wait-list control group will receive no intervention. This group will serve as a comparison group to evaluate the specific effect of the mindfulness based intervention.
62710635|NCT03213509||Perinatal Death With Pause Point(s) Observed, Intervention Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the intervention arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
62710636|NCT03213509||Perinatal Death With Pause Point(s) Observed, Control Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the control arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
62710637|NCT02299245|EXPERIMENTAL|randomised to rosuvastatin (20mg/d)|randomised to rosuvastatin (20mg/d)
62710638|NCT02299245|ACTIVE_COMPARATOR|randomised to rosuvastatin (10mg/d)|randomised to rosuvastatin (10mg/d)
62147975|NCT00428714|EXPERIMENTAL|Enzastaurin-Cohort 1|Chemo-naive participants who had androgen-independent prostate cancer with rising prostate-specific antigen (PSA) levels but no clinical or radiographic evidence of metastatic disease. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
62147976|NCT00428714|EXPERIMENTAL|Enzastaurin-Cohort 2|Participants with progressed, metastatic prostate cancer who had received prior treatment with a docetaxel-containing agent. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
62147977|NCT03393559|EXPERIMENTAL|Group L|leg elevation during the beach chair position
62517451|NCT01358552||Néevo®/NéevoDHA®|Subjects who have been prescribed Néevo/NéevoDHA® daily.
62517452|NCT05355038|EXPERIMENTAL|lifesyle modification|intervention group will take lifestyle modification protocol which composed of health teaching about low glycemic index diet, physical activity and self glucose monitoring
62517453|NCT05355038|NO_INTERVENTION|control group|routine care of the hospital
62517454|NCT03399240|EXPERIMENTAL|Vitastiq device|Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
62517455|NCT04192123|EXPERIMENTAL|Experimental|"All patients will receive an occlusive patch per test treatment as follows:~* Treatment 1: HM242-Solution~* Treatment 2: HM242-Gel~* Treatment 3: HM242-Solution and HM242-Gel~* Treatment 4: Irritant control (sodium lauryl sulfate (SLS))~* Treatment 5: Negative control"
62517456|NCT01673698|ACTIVE_COMPARATOR|ReShape Duo Balloon|ReShape Duo Balloon
62517457|NCT01673698|SHAM_COMPARATOR|Sham Comparator|Sham Comparator
62517458|NCT03801421|EXPERIMENTAL|Continous suture group|The surgical incision will be treated by mass continous suture with PDS.
62355304|NCT02660866|ACTIVE_COMPARATOR|SMT+APT+Vorapaxar|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents \[angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs\] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (\>5 days of prior use) aspirin therapy.~Vorapaxar: Vorapaxar 2.08mg/day"
62355305|NCT00648570|EXPERIMENTAL|1|Escitalopram Oxalate Tablets 20 mg
62517459|NCT03801421|ACTIVE_COMPARATOR|Control group|The surgical incision will be treated by interrupted suture with thread.
62517460|NCT01010126|EXPERIMENTAL|Treatment (temsirolimus, bevacizumab)|Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61974225|NCT02422511|ACTIVE_COMPARATOR|Well Baby Family History Only|Parents of newborns in well-baby units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
61974226|NCT02422511|EXPERIMENTAL|Well Baby Family History + Exome Sequencing|Parents of newborns in well-baby units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
62517461|NCT06357949|ACTIVE_COMPARATOR|High-intensity laser therapy group|High-intensity laser will be applied continuously to the gastrocnemius muscle for a total of 10 minutes with an energy density of 100 j/cm2, totaling 2500 j.
62710639|NCT04419246|ACTIVE_COMPARATOR|Group I|interscalene block + General anesthesia
61974227|NCT02422511|ACTIVE_COMPARATOR|ICU Baby Family History Only|Parents of newborns in intensive care units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
62147978|NCT03393559|NO_INTERVENTION|Group C|Patients' leg will be straightened without any intervention.
62147979|NCT04620642||Registry group|Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research
62355306|NCT00648570|ACTIVE_COMPARATOR|2|Lexapro® Tablets 20 mg
62355307|NCT00924729|ACTIVE_COMPARATOR|Moxifloxacin 0.5% ophthalmic solution|
62355308|NCT00924729|ACTIVE_COMPARATOR|Besifloxacin 0.6% ophthalmic suspension|
62355309|NCT06161857||Normal Hearing Group|Participants with hearing levels of 20dBHL or better at 6 and 8kHz frequencies of sound
62355310|NCT06161857||Mild Hearing Loss Group|Participants with hearing levels of 25-40dBHL at 6 and 8kHz frequencies of sound
62355311|NCT06161857||Moderate Hearing Loss Group|Participants with hearing levels of 45-70dBHL at 6 and 8kHz frequencies of sound
62355312|NCT06161857||Severe Hearing Loss Group|Participants with hearing levels of 75- 90dBHL at 6 and 8kHz frequencies of sound
62355313|NCT05652972|EXPERIMENTAL|Ketogenic diet|40 women which will follow the ketogenic diet with 1700 kcal daily for 8 weeks
62355314|NCT05652972|ACTIVE_COMPARATOR|Control diet|40 women which will follow the standard diet with 1700 kcal daily for 8 weeks
62355315|NCT00709124|EXPERIMENTAL|NMES|60 minute daily NMES sessions every day for the duration of subject's ICU stay.
62355316|NCT00709124|SHAM_COMPARATOR|Sham|60 minute sham sessions every day for the duration of subjects ICU stay. No voltage will be applied to those receiving sham sessions.
62355317|NCT06580860||PMNP-Healthy Norms|Healthy Norms
62355318|NCT06580860||PMNP-Subclinical high-risk|Subclinical high-risk
62355319|NCT06580860||PMNP-Schizophrenia and Psychosis|Schizophrenia and Psychosis patient
62355320|NCT06580860||PMNP-MDD|major depressive disorder patient
62355321|NCT06580860||PMNP-ASD|autism spectrum disorder patient
62355322|NCT06580860||PMNP-BD|bipolar disorder patient
62355323|NCT05113498|EXPERIMENTAL|(-)-Epicatechin|(-)-Epicatechin supplementation
62355324|NCT05738772||hcc group|The study group will include 45 patients with HCC on top of liver cirrhosis. All virus-related liver cirrhosis and all BCLC stages of HCC will be accepted. Verified presence of HCC, will be assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) or based on histological validation. In patients with presence of liver cirrhosis, non-invasive diagnosis of HCC is standard, when dynamic imaging shows typical diagnostic patterns as the combination of hypervascularity in late arterial phase and washout on portal venous and/or delayed phases
62355325|NCT05738772||LC group|Will include 45 patients diagnosed with liver cirrhosis on top of HCV or HBV with an absence of focal lesions on ultrasound screening as a control group. Cirrhosis will be determined according to clinical, serological, and radiological findings
62355326|NCT05082506|EXPERIMENTAL|Acupressure Group|Applicable to the acupressure group; Heart meridian 7th point (HT7), large intestine meridian 4th point (LI4) and pericardium 6th point (PC6), a total of three points will be applied. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Since the symmetry of the selected three different points on the other extremity will also be applied, a total of 12 minutes of compression will be applied to each point, provided that it is two minutes. Depending on the preparation and compression time on each point, the session duration of each patient will be approximately 16 minutes.
62355327|NCT05082506|PLACEBO_COMPARATOR|Sham Group|n the acupressure application to the Sham group, pressure will be exerted on the bone region where the meridians do not pass, parallel to the HT7, LI4, PC6 and points (approximately 1-1.5 cm away) (Figure 4). Before the application, the acupressure points will be heated for about 20 seconds and the tissue sensitivity will be reduced by rubbing and they will be made ready for the acupressure application. Afterwards, the acupressure points determined will be pressed with the thumb by the researcher with a lower intensity than the normal application pressure for two minutes. Similar to the acupressure group, the sham group will be applied to symmetrical points. In this direction, a session will last 16 minutes for each patient, as in the acupressure group, together with the duration of the pre-procedure preparation and applications.
62710640|NCT04419246|ACTIVE_COMPARATOR|Group T|Tranexamic acid +General anesthesia
62517462|NCT06357949|SHAM_COMPARATOR|Sham group|The same procedure will be followed, but sham laser will be applied at 0 j/cm2 for 10 minutes.
62517463|NCT04273919|SHAM_COMPARATOR|Mindfulness Mediation|Subjects will undergo virtual reality in a non-embodied (no first person bodily experience) program called Lumen, which was developed by Stanford University's Virtual Human Interaction Lab.
62517464|NCT04273919|EXPERIMENTAL|Graded Motor Imagery|The subjects will engage in 2 therapeutic modules intended to help them practice increasing range of motion safely, and using small movements of the lower back.
62517465|NCT00317642|EXPERIMENTAL|clofarabine (IV formulation) and cytarabine|"Participants received clofarabine (40 mg/m\^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m\^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)~Complete induction cycle = 5 consecutive days of treatment~Re-induction cycle = 5 consecutive days of treatment at the original or modified dose~Consolidation cycle = 4 consecutive days of treatment at the original or modified dose"
62517466|NCT00317642|EXPERIMENTAL|placebo and cytarabine|Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m\^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
62517467|NCT03971487|ACTIVE_COMPARATOR|Ocrelizumab|Two doses of 300 mg of ocrelizumab will be administered as an intravenous infusion two weeks apart.
62517468|NCT03971487|PLACEBO_COMPARATOR|Placebo|Two placebo intravenous infusions will be administered two weeks apart.
62517469|NCT04535752|EXPERIMENTAL|ANX009, Single Ascending Doses|Single dose of ANX009 with a 7-day follow-up before escalation to the next dose level.
62517470|NCT04535752|PLACEBO_COMPARATOR|Placebo, Single Ascending Doses|Single doses of matching placebo
62517471|NCT04535752|EXPERIMENTAL|ANX009, Multiple Ascending Doses|ANX009 once daily on Days 1-14
62517472|NCT04535752|PLACEBO_COMPARATOR|Placebo, Multiple doses|Matching placebo once daily on Days 1-14
62517473|NCT04386928||Elderly patients with hematological disease|older than 60 years who received hematopoietic stem cell transplantation (HSCT)
62517474|NCT04030494|OTHER|Blood pressure (BP)|Group for the validation of blood pressure measurement by the device
62517475|NCT04030494|OTHER|Atrial fibrillation (AF)|Group for the validation of detection of AF by the device
62517476|NCT04030494|OTHER|Valvular heart disease (VHD)|Group for the validation of detection of VHD by the device
62517477|NCT03220126|EXPERIMENTAL|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
62710641|NCT04419246|SHAM_COMPARATOR|Group S|General anesthesia
62710642|NCT04224519|EXPERIMENTAL|Batch 1 of sIPV|The first commercial batch of sIPV
61974228|NCT02422511|EXPERIMENTAL|ICU Baby Family History + Exome Sequencing|Parents of newborns in intensive care units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
62517478|NCT03220126|EXPERIMENTAL|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
62517479|NCT03220126|EXPERIMENTAL|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
62517480|NCT03220126|EXPERIMENTAL|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
62517481|NCT01056094|ACTIVE_COMPARATOR|20mg Lutein|Dietary Supplement: 20mg Lutein; daily supplementation 12 week
62517482|NCT01056094|ACTIVE_COMPARATOR|10mg Lutein|Dietary Supplement: 10mg Lutein; daily supplementation 12 week
62517483|NCT01056094|PLACEBO_COMPARATOR|0mg Lutein|Dietary Supplement: 0mg Lutein; daily supplementation 12 week
62517484|NCT02920463||Critically ill patients with infection|Critically ill adult patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
62517485|NCT06137157|EXPERIMENTAL|Internal controlled arm|ATR12-351 on left side of body, vehicle on right side of body in one group; vehicle on left side of body, ATR12-351 on right side of body.
62517486|NCT00731549|EXPERIMENTAL|1|Active Treatment of aripiprazole IM depot (300mg or 400mg)
61974229|NCT05627154|PLACEBO_COMPARATOR|Placebo only|Participants randomised to the Placebo condition will be taking a lactose placebo capsule daily for 14 days.
62355328|NCT05082506|NO_INTERVENTION|Control Group|Patients in the control group will not receive any intervention.
62517487|NCT03832738|EXPERIMENTAL|JTE-451 Dose 1|JTE-451 Tablets Dose 1 daily for 16 weeks.
62710643|NCT04224519|EXPERIMENTAL|Batch 2 of sIPV|The second commercial batch of sIPV
62710644|NCT04224519|EXPERIMENTAL|Batch 3 of sIPV|The third commercial batch of sIPV
61974230|NCT05627154|EXPERIMENTAL|Citalopram only|Participants randomised to the Citalopram only condition will be taking 20mg of citalopram in capsule form daily for 14 days.
62355329|NCT01331720||FSH:LH 1:1 - Treatment Group A|"Patients with a condition~LH (luteinizing hormone)"
62517488|NCT03832738|EXPERIMENTAL|JTE-451 Dose 2|JTE-451 Tablets Dose 2 daily for 16 weeks.
62517489|NCT03832738|PLACEBO_COMPARATOR|Placebo|Placebo Tablets daily for 16 weeks.
62517490|NCT06316713|EXPERIMENTAL|One MORE (Spanish Adaptation)|
62517491|NCT06316713|NO_INTERVENTION|Waitlist Control|
62517492|NCT06304935|OTHER|One Group of pt used one tonsillar bed (tested) side other tonsillar bed (control)|In the same Group one of tonsillar bed randamly injected with injectable platelet rich fibrin and other side as control and compare in post tonsillectomy healing, pain and hemostasis
62517493|NCT06139718|EXPERIMENTAL|ACT Guide Lite|Those randomly assigned to the ACT condition after completing baseline assessment will be automatically directed to the registration for ACT Guide Lite. Participants in the ACT condition will be asked to complete the intervention at that time, but they will have the option to take a break before starting. If an ACT participant does not complete the intervention, they will be prompted to login by a research assistant.
62539498|NCT01544179|EXPERIMENTAL|Gefitinib|Gefitinib and cisplatin plus pemetrexed combination chemotherapy
62539499|NCT01544179|PLACEBO_COMPARATOR|Placebo|Placebo and cisplatin plus pemetrexed combination chemotherapy.
62710645|NCT00462826|EXPERIMENTAL|Treatment (aflibercept)|Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62710646|NCT05751577|EXPERIMENTAL|EXPERIMENTAL ARM: TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery
61974231|NCT05627154|EXPERIMENTAL|Citalopram and Behavioural Activation|Participants randomised to the Citalopram only condition will be taking 20mg of citalopram in capsule form daily for 14 days. Over the two weeks of taking citalopram, they will also receive \~3h of behavioural activation therapy split into 3 sessions.
61974232|NCT06372860|ACTIVE_COMPARATOR|DPP + Breastfeeding (Tx1)|Patients randomized to Tx1 will receive education in the Diabetes Prevention Program (DPP) and intensive breastfeeding education and support. Ante- and postpartum education includes access to the mHealth app and individualized 1-on-1 health coaching. Phase I is delivered antepartum and includes: four (4) 1-hour DPP-based educational sessions and six (6) 20-minute educational videos on lactation. Phase II is delivered postpartum and includes: in-hospital lactation support and two (2) 1-hour DPP-based educational sessions. Participants will continue to receive individualized 1-on-1 health coaching through 3 months postpartum.
62710647|NCT05751577|ACTIVE_COMPARATOR|CONTROL ARM: TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
62710648|NCT06173869|EXPERIMENTAL|FE 999049|"The participants receive either low or high starting dose as appropriate according to Investigators Judgement.~10 or 15 µg"
61974233|NCT06372860|PLACEBO_COMPARATOR|Usual Care|Usual care is described as obstetrical care that pregnant women with normal BMI receive and that is provided by their provider. There will not be any antepartum education or 1-on-1 health coaching. Postpartum education will only include usual care in-hospital lactation support. There will not be any other education nor 1-on-1 support.
61974234|NCT00607412|EXPERIMENTAL|1|Present focused, integrated psychotherapy for PTSD and substance use disorders
61974235|NCT00607412|ACTIVE_COMPARATOR|2|Supportive therapy using 12-step model
61974236|NCT04496544||Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with drug-coated devices (drug-eluting stent ± drug-coated balloon, bare metal stent with drug-coated balloon, or drug-coated balloon alone)
61974237|NCT04496544||Non-Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with non-drug-coated devices (bare metal stent ± percutaneous transluminal balloon angioplasty or percutaneous transluminal balloon angioplasty alone)
61974238|NCT05971407|ACTIVE_COMPARATOR|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks.
61974239|NCT05971407|SHAM_COMPARATOR|Sham remote ischaemic preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks
62517494|NCT06139718|NO_INTERVENTION|Waitlist control|Participants assigned to the waitlist condition will be asked to simply wait to complete the scheduled 1-week and 1-month follow up assessments before accessing the intervention. After they complete the 1-month follow up assessment we will direct participants in the waitlist to access ACT Guide Lite, but at that point their participation in the study will be complete and we will not analyze their use of or responses to the program as part of the study aims.
62710649|NCT06173869|ACTIVE_COMPARATOR|GONAL-F|"The participants receive either low or high starting dose as appropriate according to Investigators Judgement.~150 or 225 IU."
62710650|NCT03822026|OTHER|patients with severe TBI|Patients with severe TBI enrolled in the study undergo an hyperventilation test, in which the alveolar ventilation is increased by a stepwise increase in tidal volumes and respiratory rate until a reduction of etCO2 of 0.7 kPa is achieved.
61974240|NCT05747781|ACTIVE_COMPARATOR|Pilot Phase|12 patients with glaumatous optic neuropathy
61974241|NCT05747781|PLACEBO_COMPARATOR|Validation Phase|66 patients with glaumatous optic neuropathy 12 subjects with no known visual impairment
61974242|NCT02978261|EXPERIMENTAL|PLB1001|There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
61974243|NCT03176329|OTHER|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
62355330|NCT01331720||FSH:LH 3:2 - Treatment Group B|Patients with a condition
62355331|NCT01331720||FSH:LH 3:1 - Treatment Group C|Patients with a condition
62355332|NCT01331720||FSH:LH 3:0 - Treatment Group D|Patients with a condition
62355333|NCT01331720||Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E|Patients with a condition
62355334|NCT04152642|ACTIVE_COMPARATOR|Marketed Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
62355335|NCT04152642|EXPERIMENTAL|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
62355336|NCT04152642|SHAM_COMPARATOR|Water/Negative Control|subjects will swallow 15 ml of water (on-site). Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after water intake (on-site) on Day 1 and Day 4.
62355337|NCT04376099||Exercise oximetry|Patients complaining claudication and referred for exercise diagnostic oximetry. Exercise oximetry are performed on treadmill (3.2km/h, 10% slope)
62355338|NCT04712357|PLACEBO_COMPARATOR|Placebo (Vitamin C)|Control placebo (Vitamin C - 500mg / day, for 10 days)
62355339|NCT04712357|ACTIVE_COMPARATOR|Tenofovir disoproxyl fumarate (TDF)|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)
62517495|NCT00922558|NO_INTERVENTION|normal children|Normal children ages 5-12 years.
62517496|NCT00922558|EXPERIMENTAL|postural control|
61974244|NCT03176329|OTHER|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
61974245|NCT02177305|EXPERIMENTAL|Tiotropium dose group 1|0.02 mcg tiotropium solution
61974246|NCT02177305|EXPERIMENTAL|Tiotropium dose group 2|0.04 mcg tiotropium solution
62517497|NCT04890080|EXPERIMENTAL|PR Group|Patients diagnosed with COPD according to GOLD and completed the 2-day / 8-week PR program
62710651|NCT01212900|EXPERIMENTAL|Imaging|Lipid targets assigned according to the severity of atherosclerotic plaque measured as wall volume in the common and internal carotid arteries by MRI
61974247|NCT02177305|EXPERIMENTAL|Tiotropium dose group 3|0.08 mcg tiotropium solution
61974248|NCT02177305|EXPERIMENTAL|Tiotropium dose group 4|0.16 mcg tiotropium solution
61974249|NCT02177305|EXPERIMENTAL|Tiotropium dose group 5|0.28 mcg tiotropium solution
61974250|NCT02177305|EXPERIMENTAL|Tiotropium dose group 6|0.40 mcg tiotropium solution
61974251|NCT00983021|EXPERIMENTAL|A|
61974252|NCT00983021|EXPERIMENTAL|B|
61974253|NCT00983021|ACTIVE_COMPARATOR|C|
61974254|NCT00983021|EXPERIMENTAL|D|
61974255|NCT01967121|EXPERIMENTAL|'Compex unit's Active Recovery® program'|The Compex electrical stimulation system utilized in this study is intended for external application with electrodes to create a muscular contraction and help enhance recovery after eccentric muscular activity.
62147980|NCT04852471|ACTIVE_COMPARATOR|Standard Post-Operative Counseling + FACT-G (Control Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. Patients will complete the Functional Assessment of Cancer Therapy - General (FACT-G).
62147981|NCT04852471|EXPERIMENTAL|Standard Post-Operative Counseling + PROM survey + FACT-G (Intervention Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. The intervention arm will receive and complete the Patient-Reported Outcome Measure (PROM) survey via the SMS text messaging service on a set schedule. Patients will complete the FACT-G.
62355340|NCT04712357|ACTIVE_COMPARATOR|TDF + FTC|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)
62355341|NCT02983799|EXPERIMENTAL|gBRCAm;|germline BRCA mutant
62355342|NCT02983799|EXPERIMENTAL|sBRCAm and germline BRCA wild type;|somatic BRCA mutant, germline BRCA wild type
62355343|NCT02983799|EXPERIMENTAL|myChoice® HRD positive and BRCAwt;|genomic instability positive and no BRCA mutation
62710652|NCT01212900|ACTIVE_COMPARATOR|Standard|Standardized statin therapy based on NCEP ATP IIIR guidelines, including clinical risk factors and blood lipid levels.
62710653|NCT04561856|ACTIVE_COMPARATOR|Group1|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume intravenously.
61974256|NCT01967121|OTHER|Ice application|A randomized pre and post-test research design will be used to compare three interventions (control, ice, compex) to alleviate the physical symptoms of delayed-onset muscle soreness (DOMS).
61974257|NCT01967121|NO_INTERVENTION|Control|This is a control group where subjects will not perform an intervention.
61974258|NCT01816633|EXPERIMENTAL|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive AutoloGel treatment.
61974259|NCT02056704|NO_INTERVENTION|Angiography|Evaluation by angiography only.
61974260|NCT02056704|EXPERIMENTAL|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
61974261|NCT00168688|ACTIVE_COMPARATOR|FeFol|Iron (60 mg) and folic acid (400 ug), standard of care
61974262|NCT00168688|EXPERIMENTAL|MN1|"1 RDA of 15 micronutrients, including iron (30 mg) and folic acid (400 ug)~Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg"
61974263|NCT00168688|EXPERIMENTAL|MN2|"2 RDA of 14 micronutrients including iron (30 mg) and folic acid (800 ug)~Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg"
61974264|NCT02569723|EXPERIMENTAL|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
61974265|NCT01617174||assessments completed by patients|"A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health \& Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing moderate or worse pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff."
61974266|NCT04334720||Observation group of positive F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
61974267|NCT04334720||Observation group of no abnormal changes in F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
61974268|NCT04334720||The control group|Corresponding to the observation group, the time, sequence and protocol were consistent
62355344|NCT02983799|EXPERIMENTAL|myChoice® HRD negative and BRCAwt|genomic instability negative and no BRCA mutation
62517498|NCT02011919|OTHER|Echopulse|Echopulse HIFU
61974269|NCT05004753|EXPERIMENTAL|Artemisinin 500mg|The dose regimen will be in cycles. In a cycle a subject will receive Artemisinin 500 mg capsule once daily plus SOC on Day 1 to Day 5 followed by 5 days off (no dosing of Artemisinin) or SOC alone. A subject can have a total of consecutive 3 cycles maximum. Here SOC is Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division)
61974270|NCT05004753|ACTIVE_COMPARATOR|Standard of Care|Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division) Mild Patients: HYDROXYCHLOROQUINE Moderate Patients: Dexamethasone - OD for 05
61974271|NCT00425451|EXPERIMENTAL|PerioChip Plus|
61974272|NCT00425451|EXPERIMENTAL|Flurbiprofen Chip|
61974273|NCT00425451|ACTIVE_COMPARATOR|PerioChip|
62710654|NCT04561856|ACTIVE_COMPARATOR|Group2|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume perinural plus 2 ml of normal saline intravenously.
62710655|NCT04561856|PLACEBO_COMPARATOR|Group3|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 2 ml of normal saline intravenously.
62147982|NCT03909100|EXPERIMENTAL|CoolSculpting® System|Participants received up to two CoolSculpting® treatment sessions for the abdomen, flanks or both 8 weeks apart. A treatment session was comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage. Up to 12 cycles per treatment session were performed at the investigator's discretion.
62355345|NCT03628521|OTHER|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
62517499|NCT01995721|EXPERIMENTAL|4-valent HPV vaccine|4-valent HPV vaccine administered in months 0., 2., 6.
62710656|NCT05598814|EXPERIMENTAL|Intervention group - FESS|Biologic treatment with Mepolizumab and functional endoscopic sinus surgery (FESS).
62710657|NCT05598814|ACTIVE_COMPARATOR|Control group - No-FESS|Biologic treatment with Mepolizumab
62710658|NCT04443114|OTHER|Early Arm|The early arm will receive the experimental organ donation workshop first, followed by the control workshop on end-of-life care.
62710659|NCT04443114|OTHER|Late Arm|The late arm will receive the control workshop on end-of-life care first, followed by the experimental organ donation workshop.
61974274|NCT00425451|PLACEBO_COMPARATOR|Placebo Chip|
61974275|NCT05368857|EXPERIMENTAL|Afamelanotide|
61974276|NCT00002925|ACTIVE_COMPARATOR|ADE|
61974277|NCT00002925|EXPERIMENTAL|ADEP|
61974278|NCT05184140|EXPERIMENTAL|Adnexal mass with high suspicion of malignancy|An ovarian lymphatic map will be performed in patients with adnexal masses suspected of malignancy. Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer confirmation including restaging surgeries.
61974279|NCT03852940|OTHER|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level \< 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
61974280|NCT03852940|OTHER|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
61974281|NCT05609240|ACTIVE_COMPARATOR|Standard treatment|Cefuroxime 1.5 grams intravenous Administered in the hour before surgery and then 4 hourly intra-operatively.
61974282|NCT05609240|ACTIVE_COMPARATOR|Intervention treatment|"Cefuroxime loading dose of 2332mg intravenous Administered in the hour before surgery.~Following the loading dose a renal function based dosing will be given as a continuous intravenous infusion throughout surgery, as below. Continuous infusion will continue for up to 6 hours when it will return to 4 hourly dosing of cefuroxime at 1.5 grams intravenously, if required.~Creatinine clearance (ml/min) and Cefuroxime:Dose per hour (mg/hr) 40-50ml/min=723mg/hr 50-60ml/min=867mg/hr 60-70ml/min=1011mg/hr 70-80ml/min=1155mg/hr \>80ml/min=1227mg/hr"
62355346|NCT03628521|OTHER|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
62517500|NCT05329298|EXPERIMENTAL|Phase I|"Patients will receive a single dose on Day 1, then after an 7-day wash-out period, repeated dosing, once daily will be initiated(Ia).~Patients receive BPI-361175 PO. Cycles repeat every 28 days(Ib)."
62517501|NCT05329298|EXPERIMENTAL|Phase II|Patients receive BPI-361175 based on RP2D.
62539500|NCT04460482|ACTIVE_COMPARATOR|NIRS-guided PCI|Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent
62710660|NCT03782415|EXPERIMENTAL|MN-166 and temozolomide|Part 1: Combination treatment of MN-166 60 mg/day (30 mg twice a day) for 28 days and temozolomide 150 mg/m² on Days 1-5 of 28-day cycle. Part 2: Open-label, fixed-dose MN-166 and temozolomide combination treatment for 6 cycles until disease progression, unacceptable tolerability and/or toxicity or loss of life.
61974283|NCT03590236|EXPERIMENTAL|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
61974284|NCT03590236|ACTIVE_COMPARATOR|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
62539501|NCT04460482|ACTIVE_COMPARATOR|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent
62539502|NCT01046786|ACTIVE_COMPARATOR|Group A|Intraspinal injection of 1.6 million cord blood mononuclear cell
61974285|NCT03590236|NO_INTERVENTION|Control group|Waiting list patients
61974286|NCT03933189|ACTIVE_COMPARATOR|Biomedical (BIOM) physical therapy|Six 60 minute PT sessions consisting of 15 minutes of education on topics such as ideal postural alignment (sitting, sleeping), maintenance of normal spinal curves, body mechanics, proper lifting techniques, home pain control via anti-inflammatory modalities such as ice; 15 minutes of manual therapy to region of pain (soft tissue and/or joint mobilization); 30 minutes of region specific exercises to address identified muscle imbalances -stretching and strengthening of the muscles local to the area of pain.
61974287|NCT03933189|ACTIVE_COMPARATOR|Biopsychosocial (BPS) physical therapy|"Six 60 minute PT sessions consisting of 15 minutes of pain neuro-science education, 15 minutes of Graded Motor Imagery (GMI) techniques, (a progressive program of visual and mental exercises consisting of laterality exercises, motor imagery and mirror therapy); 30 minutes of a general conditioning exercise program individualized for each participant based on initial examination findings and participant presentation consisting of:~A cardiovascular component which may include walking on a treadmill, stationary cycling, or a seated stepping machine.~A muscle strengthening component for extremities and trunk. A flexibility component for upper and lower extremity musculature."
61974288|NCT03495076|EXPERIMENTAL|Saline injection|In the saline condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline solution.
61974289|NCT03495076|SHAM_COMPARATOR|Sham injection|In the sham injection condition, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
61974290|NCT03495076|NO_INTERVENTION|Control|Participants in the control condition will not receive any kind of pain or pinprick sensation.
61974291|NCT06495164||Palbociclib + aromatase inhibitor (AI)|Oral palbociclib + AI combination treatment regimen as decided by physician
61974292|NCT06495164||Aromatase inhibitor (AI)|Oral AI treatment regimen as decided by physician
61974293|NCT06495164||Abemaciclib plus aromatase inhibitor (AI)|Oral abemaciclib plus AI treatment regimen as decided by physician
61974294|NCT06495164||Ribociclib plus aromatase inhibitor (AI)|Oral ribociclib plus AI as decided by physician
61974295|NCT03793231||Fungal Cases|Patients with confirmed invasive fungal infections according to internationally accepted criteria identified by active manual surveillance. Clinical data will be sent to fungalAi platform technology for disease classification.
61974296|NCT03793231||Control patients|Patients without invasive fungal infections.Clinical data will be sent to fungalAi platform technology for disease classification.
61974297|NCT04065906|EXPERIMENTAL|NIRS group|Children with ADHD, 12 sessions of NIRS feedback, for two sessions per week.
61974298|NCT04065906|OTHER|Drug group|Children with ADHD, 6 weeks' treatment of either methylphenidate or tomoxetine
61974299|NCT04065906|OTHER|Control group|Healthy children, 12 sessions of NIRS feedback, for two sessions per week.
61974300|NCT03724084|EXPERIMENTAL|Cohort I (higher and lowers dose pinometostat)|Patients receive higher dose pinometostat IV continuously on days 1-7 and lower dose pinometostrat IV continuously on days 8-35. Patients also receive daunorubicin hydrochloride IV over 10-30 minutes on days 8-10 and cytarabine IV continuously on days 8-14. Cycles repeat every 35 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve CR/CRi after treatment receive pinometostat IV continuously on days 1-28, daunorubicin hydrochloride IV over 10-30 minutes on days 1 and 2 and cytarabine IV continuously on days 1-5 in the absence of disease progression or unacceptable toxicity.
61974301|NCT03724084|EXPERIMENTAL|Cohort II (higher dose pinometostat)|Patients receive higher dose pinometostat intravenously (IV) continuously on days 1-35. Patients also receive daunorubicin hydrochloride IV over 10-30 minutes on days 8-10 and cytarabine IV continuously on days 8-14. Cycles repeat every 35 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve CR/CRi after treatment receive pinometostat IV continuously on days 1-28, daunorubicin hydrochloride IV over 10-30 minutes on days 1 and 2 and cytarabine IV continuously on days 1-5 in the absence of disease progression or unacceptable toxicity.
61974302|NCT03029377|EXPERIMENTAL|Chronic Fatigue Patients|Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
61974303|NCT03029377|ACTIVE_COMPARATOR|Healthy Controls|Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
61974304|NCT05201560|EXPERIMENTAL|Butorphanol tartrate|Butorphanol tartrate on the patients with mechanical ventilation
61974305|NCT05201560|ACTIVE_COMPARATOR|fentanyl|fentanyl on the patients with mechanical ventilation
61974306|NCT00527007|EXPERIMENTAL|A|
61974307|NCT00527007|NO_INTERVENTION|B|
61974308|NCT05528679|EXPERIMENTAL|Treatment group A|610 100 mg administered subcutaneously every 4 weeks
61974309|NCT05528679|EXPERIMENTAL|Treatment group B|610 300 mg administered subcutaneously every 4 weeks
61974310|NCT05528679|PLACEBO_COMPARATOR|placebo Arm Type：no inter|placebo administered subcutaneously every 4 weeks
61974311|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S1)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
61974312|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S2)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
61974313|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S3-1)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
61974314|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S3-2)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
61974315|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S4)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
62539503|NCT01046786|ACTIVE_COMPARATOR|Group B|Intraspinal injection of 3.2 million cord blood mononuclear cell
61974316|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S5)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
62517502|NCT06288191|EXPERIMENTAL|Neoadjuvant Treatment|Nivolumab and relatlimab will be administered in a fixed dose combination (FDC). The dose and dosing regimen for this study is nivolumab 480 mg and relatlimab 160 mg - 2 vials per infusion. All patients are scheduled to receive two doses of nivolumab and relatlimab FDC prior to surgery on days 1 and 29. Patients without a complete pathological response to neoadjuvant therapy may receive standard of care radiotherapy per multidisciplinary team meeting discussion.
62517503|NCT04415008|EXPERIMENTAL|treatment arm|prospective, open-label, multicenter,single arm
62517504|NCT04641793|EXPERIMENTAL|SCI|
62517505|NCT04641793|EXPERIMENTAL|STROKE|
62517506|NCT04641793|EXPERIMENTAL|UNIMPAIRED|
62517507|NCT03338842|EXPERIMENTAL|Distractor and Lower limb VR|The training sessions consist of Phase 1 (Distractor VR) in which patients will explore VR environments and Phase 2 (Lower limb VR) in which they will play games using their VR lower-limbs.
62517508|NCT02265341|EXPERIMENTAL|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62517509|NCT02732691|EXPERIMENTAL|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.
62517510|NCT01921465||multiparas having a planned cesarean section|elective cesarean section
62517511|NCT03325985|EXPERIMENTAL|Nurse-led telephonic case management|"* Telephonic nurses will contact patients within 72 hours of enrollment~* Patients will speak with the telephonic nurse over the phone once a week (or as often as needed) for a duration of 6 months."
62710661|NCT02563327|ACTIVE_COMPARATOR|Standard Therapy|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, \< 55kg 1000 mg, \>= 55-75 kg 1500 mg, \>75 kg 2000 mg; ethambutol, \< 55kg 800 mg, \>= 55-75 kg 1200 mg, \>75 kg 1600 mg."
61974317|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S6)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
62355347|NCT03628521|OTHER|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
62355348|NCT04347278||Patients receiving treatment for COVID19|
62355349|NCT02819349|EXPERIMENTAL|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. The intervention will include an online interface for clinicians and an automated text messaging program for patients. Firstly, patients and providers will meet in an intake session, to identify the patient's personal early warning signs from a pre-identified list. Using the online interface, providers will enter additional warning signs or personalize the wording of the messages as requested by the patient. The patient also will determine the threshold at which the provider will be alerted about a possible relapse and whether additional contact people should be alerted.
62355350|NCT02819349|NO_INTERVENTION|Treatment-As-Usual Control|The control group will be a treatment as usual comparison group. For the majority of individuals with schizophrenia/SAD in care at JHCPP, this involves meeting with their therapist every 2 to 4 weeks and meeting with their psychiatrist at least once every 90 days or more frequently as clinically indicated. All routine appointments are scheduled, but individuals can walk in or call if they do not feel well between sessions.
62355351|NCT01517412|EXPERIMENTAL|Lixisenatide Main Meal|"Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
62355352|NCT01517412|ACTIVE_COMPARATOR|Lixisenatide Breakfast|"Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
62355353|NCT03009812|ACTIVE_COMPARATOR|Group 1|26 subjects who are planned for transverse uterine incision
62355354|NCT03009812|ACTIVE_COMPARATOR|Group 2|26 subjects who are planned for longitudinal uterine incision
62355355|NCT03908905||Intervention|
62517512|NCT03325985|ACTIVE_COMPARATOR|Facilitated, outpatient specialty palliative care|"* Patients will be scheduled for their first in-person palliative care visit within two weeks of enrollment and then once a month for 6 months.~* Clinic visits will be scheduled the same day as other specialty appointments if possible"
62517513|NCT04925713|EXPERIMENTAL|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion|One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
62517514|NCT02470091|EXPERIMENTAL|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
61974318|NCT04481750|EXPERIMENTAL|A single dose MT-1186 (Part 1, Cohort S7)|Healthy Caucasian male subjects receive a single dose of MT-1186 or matching placebo.
61974319|NCT04481750|EXPERIMENTAL|Multiple doses MT-1186 (Part 2, Cohort M1)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo.
61974320|NCT04481750|EXPERIMENTAL|Multiple doses MT-1186 (Part 2, Cohort M2)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo
62517515|NCT01638650|EXPERIMENTAL|Single Arm|
62517516|NCT05783661|ACTIVE_COMPARATOR|Conventional antibiotic strategies|The control group will receive treatment according to the local guidelines of the Hospital Clinic de Barcelona.
62517517|NCT05783661|EXPERIMENTAL|Regimens guided by epidemiological surveillance|The experimental group will receive treatment to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
62517518|NCT00684567|EXPERIMENTAL|Single arm|It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.
62517519|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
62517520|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
62517521|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
62517522|NCT05698927|ACTIVE_COMPARATOR|Intrathecal Morphine Group|"Bilateral Erector Spinae Plane Block (with %0.25 bupivacaine, 20 ml for each side) and intravenous tramadol via Patient Controlled Analgesia device (5 mg/ml tramadol, bolus dose: 1ml, lock time: 20 minutes)~Comparing postoperative pain and opioid consumption in groups"
62517523|NCT05698927|ACTIVE_COMPARATOR|Bilateral Erector Spinae Plane Block Group|Intrathecal morphine (100mcg) and intravenous tramadol via Patient Controlled Analgesia device (5 mg/ml tramadol, bolus dose: 1ml, lock time: 20 minutes) Comparing postoperative pain and opioid consumption in groups
62517524|NCT00126126|EXPERIMENTAL|EBAR Program|Evidence Based Amputee Rehabilitation Program (rehabilitation program based on performance of the Amputee Mobility Predictor
62517525|NCT00126126|NO_INTERVENTION|Wait List Control|Wait List Control Group
62517526|NCT05114382|OTHER|A prospective, multi-center, open-label, single arm study|Patients undergoing assessment and ablation of cardiac arrhythmiast. who are scheduled for an electrophysiology (EP) procedure and meet all inclusion criteria will be enrolled in the study and undergo the EP procedure. Intracardiac signals will be passively recorded using the CathVision Cube® System in parallel with the commercial (CE marked) EP recording system for post procedure evaluation. The investigational device will not be used for direct clinical care decisions or therapy. The EP procedure will be guided by the study site Standards Of Care.
62517527|NCT04108247|EXPERIMENTAL|Abiraterone+SHR3162|
62517528|NCT06546007||Patient with early lung cancer|Patients with a diagnosis of lung cancer, planned for lung resection with curative intent.
61974321|NCT05124964||1|Patients with newly diagnosed primary intracranial germ cell tumors are scheduled for subsequent anti-tumor therapy.
61974322|NCT04684498|EXPERIMENTAL|Tamiflu (Oseltamivir Phosphate Capsules)|Standardized STEMI treatment + oseltamivir phosphate capsule (75mg, 2 times/day, 7days, oral)
61974323|NCT04684498|OTHER|no intervention|Standardized STEMI treatment + no intervention
61974324|NCT02880189|OTHER|Single|All subjects will be receiving the Orbera Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
61974325|NCT03372811|ACTIVE_COMPARATOR|TC cream (10%)|
61974326|NCT03372811|PLACEBO_COMPARATOR|Vehicle|
61974327|NCT05424042|EXPERIMENTAL|In-Person Caloric Restriction Arm|This group will undergo a 9-month behavioral diet intervention targeting a 20% reduction in caloric intake. During the first 6 months, participants will meet in-person one time each month individually and three times/month in a group setting with a dietitian and/or behavioral coach. During the remaining three months of intervention, there will be one group and one individual meeting each month. Participants will keep diet records using the Fitbit app on a tablet and weight using a BodyTrace™ smart scale that transmits data through a study-specific Companion App. Participants will use wrist-worn Fitbit step monitors to track their physical activity and receive feedback via the app, with a goal to promote movement across the day, continuously increasing their daily step count.
61974328|NCT05424042|EXPERIMENTAL|Remote Caloric Restriction Arm|This group will have a 20% reduction in caloric intake and meeting schedule, and physical activity goal similar to the In-Person group. However, the remote arm intervention will be delivered via video conferencing.
62355356|NCT04063072|NO_INTERVENTION|Usual care|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to current hospital clinical practice.
62355357|NCT04063072|EXPERIMENTAL|ERAS protocol|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to ERAS protocol.
62355358|NCT02322099|ACTIVE_COMPARATOR|Alendronate|Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
62355359|NCT02322099|PLACEBO_COMPARATOR|Placebo|Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
62355360|NCT00848445|EXPERIMENTAL|APP and VRR on|APP and VRR turned on at 2 week visit
62355361|NCT00848445|ACTIVE_COMPARATOR|APP and VRR off|APP and VRR turned off
62355362|NCT01600001|EXPERIMENTAL|Drug:KWA-0711 dose 1|
62355363|NCT01600001|EXPERIMENTAL|Drug:KWA-0711 dose 2|
62355364|NCT01600001|EXPERIMENTAL|Drug:KWA-0711 dose 3|
62355365|NCT01600001|EXPERIMENTAL|Drug:KWA-0711 dose 4|
62355366|NCT01600001|PLACEBO_COMPARATOR|Drug: Placebo|
62355367|NCT04809272|EXPERIMENTAL|ParentChat for parents of children ages 2-17|The ePLH parent support groups will be delivered over a 8 week period (i.e., 7-8 short online interactive group sessions, two per week). ePLH facilitators will moderate discussions around the parenting theme, support parents on an individual basis, and encourage them to apply the parenting skills at home. The facilitators will begin the next group engagement with a brief voice summary of the feedback and address possible solutions to 2-3 key challenges. Facilitators will also be provided with weekly supervision by an ePLH coach or trainer. A designated research assistant will provide parent support groups with needed technical support during the implementation - including IT-related support. Data bundles will be provided for internet access and to incentivise engagement.
62355368|NCT03514888|EXPERIMENTAL|HIPEC after Radical Cystectomy|After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
62355369|NCT03040817|EXPERIMENTAL|G-POEM|Each participant receive gastric peroral endoscopic pyloromyotomy (G-POEM).
62355370|NCT03040817|ACTIVE_COMPARATOR|Esomeprazole + Mosapride|Each participant receive Esomeprazole+ Mosapride. The dosages are：Nexium 40mg bid， Mosapride Citrate Tablets 5mg tid.
62355371|NCT02995213|EXPERIMENTAL|Feedback Intervention|
62355372|NCT00091962|EXPERIMENTAL|Depressed Intervention|Telephone-based, nurse-delivered Collaborative Care program for depression; Involving: Psychoeducation; workbook for depression self-care; initiation or adjustment of antidepressant pharmacotherapy prescribed under their PCPs' direction; referral to mental health specialist
62355373|NCT00091962|ACTIVE_COMPARATOR|Depressed Usual Care|"Usual care for depression; feedback of the depression finding by the study team"
62355374|NCT00091962|NO_INTERVENTION|Non-Depressed Control Group|Non-depressed control group
62517529|NCT06226194||Lleida|Saliva sample collection and questionnaire
62517530|NCT06226194||Barcelona|Saliva sample collection and questionnaire
62517531|NCT06226194||Madrid|Saliva sample collection and questionnaire
62517532|NCT06226194||Málaga|Saliva sample collection and questionnaire
62517533|NCT06226194||Santiago de Compostela|Saliva sample collection and questionnaire
62517534|NCT06226194||Pamplona|Saliva sample collection and questionnaire
62517535|NCT06226194||León|Saliva sample collection and questionnaire
62517536|NCT06226194||A Coruña|Saliva sample collection and questionnaire
62517537|NCT06226194||Mallorca|Saliva sample collection and questionnaire
62517538|NCT06226194||Tenerife|Saliva sample collection and questionnaire
62517539|NCT06226194||Las Palmas|Saliva sample collection and questionnaire
62517540|NCT04747704|EXPERIMENTAL|Intervention|Participants receiving Three-Principles Counseling
62517541|NCT03313648|EXPERIMENTAL|Laparoscopic Hepatectomy|Improvements in laparoscopic technology mean that LH now has superior short-term efficacy and similar long-term efficacy to open surgery , and LH has shown significant advantages in applications involving recurrent HCC.
62517542|NCT03313648|ACTIVE_COMPARATOR|Radiofrequency Ablation|With recent technological advances, RFA has become the most widely investigated new first-line therapeutic option for recurrent HCCs . Numerous large studies have demonstrated the advantages of RFA, which include its ease of use, safety, effectiveness, minimal invasiveness, and minimal morbidity and mortality .
62517543|NCT01981499|EXPERIMENTAL|Arm A1|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
61974329|NCT05424042|EXPERIMENTAL|Time-Restricted Eating Arm|This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake. During the first 6 months, participants will meet in-person once per month individually and three times per month in a group setting with a dietitian and/or behavioral coach. During the remaining 3 months of intervention, there will be one group and one individual meeting each month. Participants in TRE will be asked to log into the study-specific Companion App each day to document the beginning and end of their feeding cycles with timing of meals/snacks consumed. As in the CR arms, participants will use wrist-worn Fitbit step monitors to track their physical activity and receive feedback via the app, with a goal to promote movement across the day, increasing daily step count. Continuous glucose monitoring will be used at intervals to document glucose levels over a 7-10-day period.
62147983|NCT05114993|EXPERIMENTAL|Effects of donning a disposable surgical mask|"Participants will be observed and monitored without wearing a mask for a 5-minute control period. Measurements will include End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute without a mask x 5 minutes.~After 5 minutes, all study subjects will don the same model of disposable surgical mask. The same measurements will be taken, including End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute with a mask x 15 minutes."
62517544|NCT01981499|PLACEBO_COMPARATOR|Arm A2|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
62517545|NCT01981499|EXPERIMENTAL|Arm B1|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
62517546|NCT01981499|EXPERIMENTAL|Arm B2|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
62517547|NCT01981499|EXPERIMENTAL|Arm B3|Positive control to ensure histamine-induced wheal assay integrity
62147984|NCT00893100|EXPERIMENTAL|Diltiazem|
62517548|NCT01981499|EXPERIMENTAL|Arm B4|Placebo control
62517549|NCT04297995|EXPERIMENTAL|Part 1: HLX10 Plus HLX07 (stage 1L)|3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly
62517550|NCT04297995|EXPERIMENTAL|Part 1: HLX10 Plus HLX07 (Stage 1H)|3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly
62517551|NCT04297995|EXPERIMENTAL|Part 2: HLX10 Plus HLX07 Plus Chemotherapy|HLX10 (300 mg) Plus HLX07 (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.
62517552|NCT04297995|PLACEBO_COMPARATOR|Part 2: HLX10 Plus HLX07 Placebo Plus Chemotherapy|HLX10 (300 mg) Plus HLX07 Placebo (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.
62517553|NCT04294342|ACTIVE_COMPARATOR|Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program which consists of three blocks. All sessions include: Balance, Strength, power and break fall exercises. The intervention group i tested before and after the 10 week exercise.
62517554|NCT04294342|NO_INTERVENTION|Control Group|The subjects in the control group go about their normal life for 10 weeks without any intervention. The control group is tested before and after the 10 week period.
62517555|NCT01185028|EXPERIMENTAL|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
62517556|NCT00614926|EXPERIMENTAL|Modafinil|Eligible patients will be treated at baseline through Week 4. Those who choose to continue will have additional in-person visits at Weeks 8 and 12 visits (and Week 16 for those starting modafinil at Week 4).
62517557|NCT00614926|PLACEBO_COMPARATOR|Placebo|Sugar pill equivalent to the active comparator. Dosing schedule will be the same as the dosing schedule for Modafinil.
62517558|NCT01863693||Cohort|
62517559|NCT04553224|OTHER|All Subjects|Clinical and instrumental measurements
62147985|NCT05081726||Never had delirium|Older people recovering from hip fracture surgery who did not have postoperative delirium
62147986|NCT05081726||Recovered delirium|Older people recovering from hip fracture surgery who experienced delirium which has resolved
62147987|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
62517560|NCT03897647|EXPERIMENTAL|POCUS Patients|A bedside echocardiogram will be taken using a point-of-care pocket ultrasound (General Electric (GE) Vscan). Central venous pressure (right atrial pressure) and pulmonary capillary wedge pressure (left atrial pressure) will be collected from pulmonary artery catheters.
62517561|NCT02554734|EXPERIMENTAL|Levodopa standard carbidopa|Levodopa, carbidopa, ODM-104
62517562|NCT02554734|EXPERIMENTAL|Levodopa modified carbidopa|Levodopa, carbidopa, ODM-104
62517563|NCT02554734|ACTIVE_COMPARATOR|Stalevo|Levodopa, carbidopa, entacapone
62517564|NCT06409650|EXPERIMENTAL|Arm A|KX-826 2.5mg QD
62517565|NCT06409650|EXPERIMENTAL|Arm B|KX-826 2.5mg BID
62517566|NCT06409650|EXPERIMENTAL|Arm C|KX-826 5mg QD
62517567|NCT06409650|EXPERIMENTAL|Arm D|KX-826 5mg BID
62517568|NCT06409650|PLACEBO_COMPARATOR|Arm E|Matching placebo QD
62517569|NCT06409650|PLACEBO_COMPARATOR|Arm F|Matching placebo BID
62517570|NCT03311308|ACTIVE_COMPARATOR|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years; after the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
62517571|NCT03311308|EXPERIMENTAL|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, twice a day, for nine weeks; after the first three doses, pembrolizumab dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
62517572|NCT03018379||Assessment of body composition|The collection of the samples and the analyses were undertaken according to the guidelines of the International Atomic Energy Agency. In brief, after having emptied the bladder, each participant provided a predose saliva sample using a cotton ball.A 99.8 % deuterium dose of 0.5 g per kg body weight was given orally to the participant. The postdose sample was collected from 3h to 4h after the administration of the dose. The saliva samples were stored at 20°C until analysis by Fourier transform infrared spectroscopy (FTIR).
62147988|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
62517573|NCT03018379||Assessment of energy expenditure|"Each participant provided a predose urine sample. A dose of doubly labelled water 2.625 ml per kg body weight was given orally to the participant.~The post dose sample was collected at 3h to 4h , and on days 3, 7 and 14 after dosing. An aliquot of those samples were stored at 20°C in tightly sealed containers until analysis by isotope-ratio mass spectrometry (IRMS)."
62517574|NCT03018379||Assessment of physical activity|The participants were instructed to wear the accelerometer triaxial (GT3X+) attached to an elasticized belt around the waist, once they woke up until bed time at night for 7 consecutive days and to remove the accelerometer any time they were to perform activities that involve the use of water and when going to bed.
62517575|NCT02712801|EXPERIMENTAL|Intervention group|Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
62710662|NCT02563327|EXPERIMENTAL|Rifapentine-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, \< 55kg 1000 mg, \>= 55-75 kg 1500 mg, \>75 kg 2000 mg; ethambutol, \< 55kg 800 mg, \>= 55-75 kg 1200 mg, \>75 kg 1600 mg."
62517576|NCT02712801|ACTIVE_COMPARATOR|Control group|Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
62517577|NCT05043259|ACTIVE_COMPARATOR|Inactivated vaccine group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of inactivated SARS-CoV-2 vaccine
62517578|NCT05043259|EXPERIMENTAL|Low dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the low dose of aerosolized Ad5-nCoV.
62517579|NCT05043259|EXPERIMENTAL|High dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the high dose of aerosolized Ad5-nCoV.
62147989|NCT01603108|EXPERIMENTAL|Rifaximin Arm|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
62147990|NCT01603108|PLACEBO_COMPARATOR|Placebo Control Arm|Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
62147991|NCT05605132|EXPERIMENTAL|Proprioceptive Training Group|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~head relocation gaze stability eye follow saccadic eye movement head and eye coordination"
62355375|NCT00617838|ACTIVE_COMPARATOR|1|Optimization of gluten introduction by nutritional councelling
62355376|NCT00617838|NO_INTERVENTION|2|No specific nutritional councelling. Follow-up of gluten introduction
62517580|NCT03271606|EXPERIMENTAL|ERAS group|The patients in this group receive enhanced measures perioperatively
62517581|NCT03271606|ACTIVE_COMPARATOR|Traditional group|The patients in this group receive traditional measures perioperatively
62517582|NCT01993602|NO_INTERVENTION|Control group|no intervention was performed in this group during postoperative period,
62517583|NCT01993602|ACTIVE_COMPARATOR|volumetric incentive spirometry|patients performed breathing exercises using volumetric incentive spirometer during five postoperative days
62517584|NCT01993602|ACTIVE_COMPARATOR|Flow oriented incentive spirometry|patients performed breathing exercises using flow oriented incentive spirometer during five postoperative days
62517585|NCT01993602|ACTIVE_COMPARATOR|Deep breathing group|patients performed deep breathing exercises without any device during five postoperative days
62517586|NCT01993602|ACTIVE_COMPARATOR|Continuous positive airway pressure group|patients performed breathing exercises using continuous positive airway pressure group during five postoperative days
62355377|NCT03419910|EXPERIMENTAL|BMS-986165 and cyclosporine|BMS-986165 and cyclosporine administered orally
62517587|NCT01878721||Staphylococcus aureus bacteremia|PET/CT in patients with Staphylococcus aureus bacteremia
62517588|NCT01878721||Salmonella spp. bacteremia|PET/CT in patients with Salmonella spp. bacteremia
62517589|NCT01878721||Endocarditis|PET/CT in patients with infective endocarditis
62517590|NCT01878721||Pacemaker infection|PET/CT in patients with pacemaker infection
62517591|NCT01878721||Vasculitis|PET/CT in patients with vasculitis
62517592|NCT01805726|PLACEBO_COMPARATOR|Xylocain (C)|(C): Local anesthesia
62517593|NCT01805726|ACTIVE_COMPARATOR|Alfentanil Group + Xylocain (A)|Local anesthesia and Alfentanil
62517594|NCT01805726|ACTIVE_COMPARATOR|Dexmedetomidine Group + Xylocain (D)|Local anesthesia and dexmedetomidine
62517595|NCT06305520|EXPERIMENTAL|Investigational Medical Device|Application of the investigational medical device (SkinPlus-HYAL Implant Lidocaine)
62517596|NCT06305520|ACTIVE_COMPARATOR|Active Comparator Medical Device|Application of the control device (RESTYLANE Lidocaine)
62517597|NCT03811626|EXPERIMENTAL|Intervention|Patient who underwent cognitive-behavioral rehabilitation
62517598|NCT03811626|NO_INTERVENTION|Comparator|Patient with no specific management
62517599|NCT04292366|EXPERIMENTAL|Intervention arm I|pre-notification approximately ten days prior to intervention, invitation and one reminder (three-staged intervention)
62517600|NCT04292366|EXPERIMENTAL|Intervention arm II|invitation, one reminder after 45 days and a second reminder three months after invitation (three-staged invitation procedure)
62517601|NCT04292366|EXPERIMENTAL|Intervention arm III|pre-notification, invitation, reminder after 45 days and reminder after three months (four-staged invitation procedure)
62517602|NCT04292366|ACTIVE_COMPARATOR|Control group|invitation and one reminder after 45 days (usual care)
62517603|NCT05015335|EXPERIMENTAL|Adalimumab|Adalimumab administered subcutaneously at 40mg every 2 weeks
62517604|NCT05015335|ACTIVE_COMPARATOR|Methotrexate|Methotrexate given 10mg orally once a week.
62517605|NCT06337214|EXPERIMENTAL|Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy|"This study aims to evaluate whether the participation in Traditional Chinese Medicine (TCM) supportive therapy courses, specifically the Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy , can enhance the quality of life of breast cancer patients undergoing treatment, increase their understanding and satisfaction with TCM adjunctive treatments, and bolster their confidence in cancer recovery. Evaluations will be conducted using pre- and post-tests spaced 4 to 6 weeks apart, during which participants will be administered three questionnaires."
62517606|NCT03966859|PLACEBO_COMPARATOR|Placebo|Participants will receive lactose placebo tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
62517607|NCT03966859|EXPERIMENTAL|Atorvastatin|Participants will receive 20mg atorvastatin tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
62710663|NCT02563327|EXPERIMENTAL|Rifapentine- and Moxifloxacin-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, \< 55kg 1000 mg, \>= 55-75 kg 1500 mg, \>75 kg 2000 mg; moxifloxacin, 400 mg."
62710664|NCT01020357|ACTIVE_COMPARATOR|caffeine|
62355378|NCT00861588|EXPERIMENTAL|isoflavones|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
62517608|NCT00834899|EXPERIMENTAL|1|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
62710665|NCT01020357|PLACEBO_COMPARATOR|placebo|
62710666|NCT04667689|OTHER|CAMPFIRE Assessment|NIH Toolbox Cognitive Assessment and PROMIS Surveys
62710667|NCT00410579||Patients treated in NSABP R-02, R-03, C-05, C-06 or C-07|Study population to be interviewed comprises patients who were treated at least 5 years ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07
62355379|NCT00861588|PLACEBO_COMPARATOR|starch|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
62355380|NCT03129412|EXPERIMENTAL|Arm 1|4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.
62517609|NCT00834899|PLACEBO_COMPARATOR|2|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
62517610|NCT00705120|OTHER|1|
62517611|NCT00705120|OTHER|2|
62517612|NCT02804555|ACTIVE_COMPARATOR|Oxygen support|5 liter / minute oxygen has given to the mothers on face mask.
62710668|NCT00158678|ACTIVE_COMPARATOR|1|Conventional RT 70Gy + concomitant cisplatin
62710669|NCT00158678|EXPERIMENTAL|2|IMRT 75Gy + concomitant cisplatin
62517613|NCT02804555|NO_INTERVENTION|Room air|Oxygen support has not given to the mothers.
62517614|NCT05571267|EXPERIMENTAL|Zimura and Avastin|Participants receive three monthly Avastin treatments (Day 1, Month 1, and Month 2) followed by Zimura administered on the same day. All participants will receive treatment every 3 months for a total of 18 months. If there is a loss of visual acuity during the intervening visits, participants may be retreated with Avastin and Zimura.
62517615|NCT05571267|EXPERIMENTAL|Zimura and Lucentis|Participants receive three monthly Lucentis treatments (Day 1, Month 1, and Month 2) followed by Zimura administered on the same day. All participants will receive treatment every 3 months for a total of 18 months. If there is a loss of visual acuity during the intervening visits, participants may be retreated with Lucentis and Zimura.
62539504|NCT01046786|ACTIVE_COMPARATOR|Group C|Intraspinal injection of 6.4 million cord blood mononuclear cell
62517616|NCT05571267|EXPERIMENTAL|Zimura and Eylea|Participants receive three monthly Eylea treatments (Day 1, Month 1, and Month 2) followed by Zimura administered on the same day. All participants will receive treatment every 3 months for a total of 18 months. If there is a loss of visual acuity during the intervening visits, participants may be retreated with Eylea and Zimura.
62517617|NCT01965184|EXPERIMENTAL|Cognitive-Behavioral Therapy for Anger and Aggressive Behavior|CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
62517618|NCT01965184|ACTIVE_COMPARATOR|Supportive Psychotherapy (SPT)|SPT consists of 12 sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
62517619|NCT04799613|NO_INTERVENTION|Natural walking|
62517620|NCT04799613|EXPERIMENTAL|fast walking|
61974330|NCT04473014||Positive Mood|This group will be exposed to a positive mood induction prior to heat pain.
61974331|NCT04473014||Negative Mood|This group will be exposed to a negative mood induction prior to heat pain.
61974332|NCT04473014||Neutral Mood|This group will be exposed to a neutral mood induction prior to heat pain.
61974333|NCT00342433||Localized Prostate Cancer cases|Cases enrolled between Jan 2000 and Apr 2004 at five locations. Study subject eligibility: Age \>=18; scheduled for radical prostatectomy; and newly diagnosed with localized prostate cancer.
61974334|NCT00503802|ACTIVE_COMPARATOR|1|Active RF treatment
61974335|NCT00503802|SHAM_COMPARATOR|2|Sham RF treatment
61974336|NCT04378751|EXPERIMENTAL|Decision aid video|Participants receiving the intervention will complete a pretest, watch the decision aid video, and complete posttest via tablet computer facilitated by Patient Navigators.
61974337|NCT04378751|ACTIVE_COMPARATOR|Genetic counseling informational brochure|Participants receiving the control will complete pretest, review a genetic counseling brochure with the Patient Navigators, and complete posttest via tablet computer facilitated by a Patient Navigator.
61974338|NCT02560233|EXPERIMENTAL|Contingent|Contingent RT-fMRI-NF
61974339|NCT02560233|SHAM_COMPARATOR|Non-contingent|Sham RT-fMRI-NF
61974340|NCT06039826|EXPERIMENTAL|LY3437943 + Combined Oral Contraceptive (COC)|The COC ethinyl estradiol and drospirenone administered orally in combination with LY3437943 administered subcutaneously (SC).
62517621|NCT04799613|EXPERIMENTAL|normal walking passing through narrow pathway|
62517622|NCT04799613|EXPERIMENTAL|fast walking passing through narrow pathway|
62517623|NCT04799613|EXPERIMENTAL|Natural walking with dual task|
62517624|NCT04799613|EXPERIMENTAL|fast walking with dual task|
61974341|NCT06481514|ACTIVE_COMPARATOR|group A (FRI)|"The Fetal Reserve Index algorithm will be applied to the first group of patients. In in these patients the fetal reserve index will be calculated every 10 minutes.. For patients with abnormal FRI a 40 minute timer will be started within which it will be necessary to exit the red zone. If such patients will not be able to exit the red zone within 40 minutes, an additional timer will be started of 30 minutes within which the birth will be completed."
61974342|NCT06481514|ACTIVE_COMPARATOR|group B (No FRI)|The second group of patients will, however, be managed according to the usual protocols internal management.
62147992|NCT05605132|EXPERIMENTAL|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
62147993|NCT05605132|SHAM_COMPARATOR|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
62147994|NCT02243800|EXPERIMENTAL|cholecalciferol|One group will receive the study treatment: cholecalciferol One group will receive placebo
62147995|NCT02243800|PLACEBO_COMPARATOR|placebo|One group will receive the study treatment: cholecalciferol One group will receive placebo
62517625|NCT04799613|EXPERIMENTAL|Natural walking passing through narrow pathway and during cognitive dual task|
62517626|NCT04799613|EXPERIMENTAL|fast walking passing through narrow pathway and during cognitive dual task|
62517627|NCT04799613|EXPERIMENTAL|Natural walking reducing the best side|
62517628|NCT04799613|EXPERIMENTAL|fast walking reducing the best side|
62517629|NCT04799613|EXPERIMENTAL|Natural walking reducing the best side passing through narrow pathway|
62517630|NCT04799613|EXPERIMENTAL|fast walking reducing the best side passing through narrow pathway|
62517631|NCT04799613|EXPERIMENTAL|Natural walking reducing the best side with cognitive dual task|
62710670|NCT03218969|EXPERIMENTAL|Study period 1|"* Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by~* Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by~* Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3)."
61974343|NCT05827523|EXPERIMENTAL|HIPEC|Interval cytoreductive surgery with HIPEC
61974344|NCT05827523|NO_INTERVENTION|No HIPEC|Interval cytoreductive surgery without HIPEC
61974345|NCT03017950|EXPERIMENTAL|Part1 (A)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330~IPs for Period 2: CKD-330 + D086"
61974346|NCT03017950|EXPERIMENTAL|Part1 (B)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: CKD-330"
61974347|NCT03017950|EXPERIMENTAL|Part2 (A)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: D086~IPs for Period 2: CKD-330 + D086"
62517632|NCT04799613|EXPERIMENTAL|fast walking reducing the best side with cognitive dual task|
62517633|NCT04799613|EXPERIMENTAL|Natural walking reducing the best side passing through narrow pathway and during cognitive dual task|
62517634|NCT04799613|EXPERIMENTAL|fast walking reducing the best side passing through narrow pathway and during cognitive dual task|
62517635|NCT06063668||patients|SLE patients
62517636|NCT06063668||controls|healthy controls
62517637|NCT00207194|ACTIVE_COMPARATOR|Automated Telephone Program|The intervention was a totally automated, computer-based, interactive telephone counseling system called Telephone- Linked-Care, designed to monitor, educate, and counsel African-American adults with hypertension and to provide summary data regularly to the patient's primary care provider.
62517638|NCT00207194|PLACEBO_COMPARATOR|Health Behavior Education|The comparator group received health education relating to the management of hypertension. Members of this group also received standard primary medical care.
62517639|NCT06233578|EXPERIMENTAL|RADPAD|Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and a single RADPAD will be placed on the patient. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
62517640|NCT06233578|NO_INTERVENTION|No RADPAD|Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and no RADPAD will be used. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
62517641|NCT05876728||cases group|50 patient of histologically confirmed breast cancer
62517642|NCT05876728||control group|50 healthy volunteers with no clinical evidence of any neoplastic disorder
62517643|NCT02493920|EXPERIMENTAL|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room; the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
62517644|NCT02493920|NO_INTERVENTION|Control|Preterm infants will be assisted in the delivery room with a continuous positive airway pressure (CPAP) of 5 cmH2O with mask and the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
62517645|NCT03262727|EXPERIMENTAL|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
62517646|NCT03138824|EXPERIMENTAL|SPIES assisted TURBT|Storz Professional Image Enhancement System (SPIES) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
62517647|NCT03138824|EXPERIMENTAL|WLI assisted TURBT|White Light Imaging (WLI) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
62517648|NCT02705833||Population with R/M SCCHN|Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) patients diagnosed between 01July2013 and 30June2014, alive or deceased, at the time of data collection
62517649|NCT03269799|ACTIVE_COMPARATOR|test group|vitamin C 500 mg oral capsule
62517650|NCT03269799|PLACEBO_COMPARATOR|control group|placebo
62147996|NCT04377191|EXPERIMENTAL|VR 1 Group|In this group, participants received standard exercise and exergame training with Microsoft Xbox 360 Kinect for 2 days per week for 6 weeks.
62517651|NCT05574894|EXPERIMENTAL|GH group|Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
62517652|NCT05574894|ACTIVE_COMPARATOR|Control group|No Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
62517653|NCT02519621|ACTIVE_COMPARATOR|NPWT PRO without irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
62517654|NCT02519621|ACTIVE_COMPARATOR|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
62517655|NCT02519621|ACTIVE_COMPARATOR|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
62517656|NCT02130167|EXPERIMENTAL|0.01% Atropine|
62517657|NCT02130167|ACTIVE_COMPARATOR|0.05% Atropine|
61974348|NCT03017950|EXPERIMENTAL|Part2 (B)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: D086"
61974349|NCT03055351|NO_INTERVENTION|Control group|Participants will complete the outcome measures but will not receive any intervention.
61974350|NCT03055351|EXPERIMENTAL|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
61974351|NCT06371053|EXPERIMENTAL|the intervention group|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Community Intervention, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-20 minutes.
62517658|NCT04844021|EXPERIMENTAL|Nudge|"Clinics randomized to the Nudge condition will receive the EHR prompt only. The investigators will add default language to the standard Well Child Visit workflow to serve as a reminder and allow for tracking of S.A.F.E. Firearm implementation. The clinician will be asked to denote whether the program was delivered (e.g., whether conversation around firearm storage was conducted, whether cable firearm lock was offered) to the parent during the visit. This EHR prompt will remain turned on from active implementation through the sustainment period."
62539505|NCT01046786|ACTIVE_COMPARATOR|Group D|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone
62539506|NCT01046786|ACTIVE_COMPARATOR|Group E|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone plus 6 week course of oral lithium, titrated to maintain 0.6-1.0 mM serum level
62539507|NCT03067597|EXPERIMENTAL|Dinoprostone vaginal insert (DVI)|
62147997|NCT04377191|EXPERIMENTAL|VR 2 Group|In this group, participants received standard exercise and exergame training with ALDA balance gear for 2 days per week for 6 weeks.
61974352|NCT06371053|NO_INTERVENTION|the blank group|No intervention will be applied
61974353|NCT03628703|EXPERIMENTAL|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
61974354|NCT00804830|EXPERIMENTAL|chemotherapy|Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
62539508|NCT01269333|ACTIVE_COMPARATOR|fluvoxamine|
62147998|NCT04377191|ACTIVE_COMPARATOR|Control Group|In this group, participants received only standard exercise for 2 days per week for 6 weeks.
62147999|NCT03941509|NO_INTERVENTION|Control|All facilities will receive usual care during the control phase of the trial.
62148000|NCT03941509|EXPERIMENTAL|Antimicrobial stewardship|Implementation of the nurse-led bundled antimicrobial stewardship intervention
62148001|NCT03122548|EXPERIMENTAL|CRS-207 + Pembrolizumab|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units \[CFU\]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
62148002|NCT05825404|EXPERIMENTAL|Smart ambient bright light|The smart ambient bright light (SABL) intervention provides auto-controlled, consistent indoor lighting that incorporates natural daylight.
62355381|NCT04035265|ACTIVE_COMPARATOR|pain+ / synovitis +|SLE patients with inflammatory pain and synovitis determined by the practitioner during physical examination of radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP. Defining synovitis as pain and inflammation and/or deformity (present or existing over the past year) included in the clinical history
62355382|NCT04035265|ACTIVE_COMPARATOR|pain + / synovitis -|SLE patients with inflammatory pain without determined synovitis. Current (or over the past year) pain in radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP, with no synovitis
62355383|NCT04035265|ACTIVE_COMPARATOR|pain - / synovitis -|SLE patients without inflammatory pain with normal physical examination currently or over the past year
62355384|NCT04035265|PLACEBO_COMPARATOR|healthy|control patients (healthy participants: no pain, no SLE, no family affected by systemic inflammatory disease, a blood test with no elevation APR or autoimmunity +)
62355385|NCT02248857|NO_INTERVENTION|Usual Care|Employ the current standard of care. No intervention.
62355386|NCT02248857|EXPERIMENTAL|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.~1. Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~2. Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.~3. A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
62355387|NCT02248857|EXPERIMENTAL|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
62355388|NCT01692223||Unaffected Relatives|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
62355389|NCT01692223||Pts with history of cancer|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
62355390|NCT01692223||Participants whose genomes/exomes are not sequenced|We will also recruit an additional group of participants from the general public (with or without a cancer history) who have not had their genomes or exomes sequenced to participate in focus groups to inform us about their perceptions of the hypothetical utility of learning of incidental results from their genome or exomes. For our sampling purposes, this group of participants is referred to as the 'focus group participants (sample #3-hypothetical group)
62355391|NCT05102331|EXPERIMENTAL|Lavender Oil Aromatherapy Treatment Arm (LOA)|"Participants will complete baseline assessments including 20 minutes of questionnaires and vitals assessment, including EEG activity (baseline measured with Bispectral Index (BIS) device). Participants will be given a dental bib with three lavender oil drops and instructed to relax for 20 minutes. BP and a brief self-report measure will be obtained. BIS recordings will be collected continuously during study and biopsy.~At procedure, participants will continue to wear bib with drops. BIS machine will stay attached and recording. Participants will be asked to verbally report pain and anxiety on visual analogue scale between the bone marrow aspirate and biopsy. EEG and heart rate (HR) will be collected continuously. An event marker and notation will indicate times when participant does something that may influence EEG activity (e.g. speak, move, etc.) or diagnostic images are taken. At procedure end, BIS device will be removed, final questionnaires administered, and vitals measured."
62355392|NCT05102331|PLACEBO_COMPARATOR|Placebo Aromatherapy Control Arm (PA)|Participants assigned to PA Clinic staff will have the same procedures as listed in LOA arm except the oil used will be a refined jojoba oil which has no color or smell. The BMAB procedure will follow the SOC provided by the clinic. This includes warning participants of upcoming stimuli, encouraging patients to remain calm, and generally expressing empathy to participants. Participants in this group will receive the same collection of questionnaires before, during, and after the procedure as the LOA group. BP, HR, and EEG measurements will similarly be collected continuously before, during, and after the procedure.
62355393|NCT05466734|OTHER|Treatment RTRT (R: Cilostazol, T: PMR)|"Treatment R: One Cilostazol Tablet 100 mg at 08:00 and another at 20:00~Treatment T: Two PMR Tablet 135 mg at 08:00~Four-period dosing following the sequence of Treatment RTRT"
62539509|NCT01269333|EXPERIMENTAL|omeprazole|
62539510|NCT01269333|PLACEBO_COMPARATOR|placebo|
61974355|NCT05263323|EXPERIMENTAL|Experimental Group - Education Group|"Stage 1; In the intervention group, at the first stage, the data were filled with the data collection tools of the intervention group.~Stage 2; It was made two weeks after the first visit in stage 1. Patient education according to Neuman Systems Theory was given to the patients who participated in the study, who received hemodialysis treatment in the center determined as the intervention group. This training was applied in the form of one-on-one training by going to the homes of the patients on the day they did not go to dialysis, within the topics determined according to the theory.~Stage 3. It was done one month after the 2nd stage. Patient education according to Neuman Systems Theory was repeated to the patients, and a pre-prepared education guide called Let's Learn Hemodialysis was distributed and a question-answer evaluation was made.~Stage 4; It was done one month after the 3rd stage. The data of the intervention group were collected again with data collection tools."
62517659|NCT04844021|EXPERIMENTAL|Nudge+|This arm consists of Nudge as described above, as well as facilitation. Facilitation (i.e., external support delivered by health system employees not employed within the clinic site) will be offered for 12 months to each clinic, in keeping with other implementation trials. The investigators will use a train-the-trainer model to train facilitators at both health systems to ensure they achieve facilitator core competencies with an eye toward implementation of S.A.F.E. Firearm. The role of the facilitator is to engage with study clinics, to assist each clinic in setting change and performance goals around the implementation of S.A.F.E. Firearm, and to troubleshoot implementation barriers.
61974356|NCT05263323|ACTIVE_COMPARATOR|Control Group|"Data collection for individuals in the control group included two stages, one at the beginning and one at the end of the study.~The first stage was applied to the experimental group during the first stage. The data of the control group were collected with data collection tools.~The second stage was given to the experimental group during the fourth stage. In this visit, The data of the control group were collected again with data collection tools."
61974357|NCT04637789|OTHER|controlled group|
62517660|NCT03267420|EXPERIMENTAL|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
62517661|NCT03267420|ACTIVE_COMPARATOR|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
62517662|NCT03267420|ACTIVE_COMPARATOR|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
62517663|NCT04838028||Standard polypropylene mesh|Density \> 50 g/square meter
62517664|NCT04838028||Lightweight mesh|"* A mesh based on either polypropylene or polyester. Some variants contain purely 1 polymer. Others are composite, ie, contain also an absorbable material.~* The density \< 50 g/square meter (when applicable, after partial absorption)"
62517665|NCT04838028||Fixation with metal tacks|Non-absorbable metal staples or tacks
62517666|NCT04838028||Fixation with absorbable tacks|Absorbable synthetic staples or tacks
62517667|NCT04838028||Fibrin glue fixation|Biologic glue/sealant produced from human donor blood
62517668|NCT04838028||Non-fixation|Mesh is deployed without fixation
62517669|NCT04838028||3D mesh|"A polypropylene mesh with a preformed anatomic shape corresponding to the inner preperitoneal curvature of the groin.~The category does not differentiate between standard and lightweight variants."
62517670|NCT04838028||Progrip fixation|Absorbable (Velcro type of) microhooks. The particular meshes come with prefabricated Progrip microhooks. Progrip = Registered trademark.
62517671|NCT04838028||Polyester mesh|Polyester-based mesh. This category does not differentiate between standard and lightweight variants
62517672|NCT04142619|EXPERIMENTAL|Dose Escalation|Several tested doses of UCARTCS1A until the Maximum Tolerated Dose (MTD) is identified.
62517673|NCT04387734|EXPERIMENTAL|Ocrevus|
62517674|NCT04387734|ACTIVE_COMPARATOR|Other Disease Modifying Treatments|Other Disease Modifying Treatments will consist of FDA-approved injectable and oral medications for multiple sclerosis.
61974358|NCT04637789|EXPERIMENTAL|experimental group|
62517675|NCT06053762|EXPERIMENTAL|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes.
62517676|NCT06053762|OTHER|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
62710671|NCT03218969|EXPERIMENTAL|Study period 2|"* Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by~* Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by~* Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9)."
62710672|NCT01263119|EXPERIMENTAL|Warfarin, LY2216684 + Warfarin|Period 1: Single 10-milligram (mg) warfarin oral dose on Day 1; Washout Period of at least 14 days; Period 2: 18-mg LY2216684 oral dose, once daily on Days 1 to 12, with single 10-mg warfarin oral dose coadministered on Day 3.
62710673|NCT00740181|EXPERIMENTAL|Chemotherapy|Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
61974359|NCT03178864|EXPERIMENTAL|Rivaroxaban|Rivaroxaban
61974360|NCT03178864|ACTIVE_COMPARATOR|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
61974361|NCT01877499||optimization of HDF key parameters|The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).
61974362|NCT03409406|EXPERIMENTAL|Caregiver Intervention + ST Intervention|Parents/caregivers receive web-based tablet protocol containing sequenced communication information for working with their child at home in addition to the Standard of Care Intervention.
62517677|NCT01926275|EXPERIMENTAL|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
62517678|NCT01926275|ACTIVE_COMPARATOR|NPPV|noninvasive positive pressure ventilation
62517679|NCT01926275|ACTIVE_COMPARATOR|IMT|inspiratory muscle training
62517680|NCT01926275|PLACEBO_COMPARATOR|LTOT|Long time oxygen therapy
62517681|NCT06110247||Group R|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded. NIRS monitoring will be performed in addition to routine ASA monitoring. After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value. NIRS, pulse oximetry, and hemodynamic data will be recorded every 5 minutes until recovery from anesthesia just prior to induction. When comparing the NIRS values measured during follow-up with the baseline NIRS value, a decrease of 20% or more than 20% will be considered significant. Anesthesia and surgery times will also be recorded. Postoperative fever and the amount of irrigation fluid used during the surgical procedure will be recorded .
62517682|NCT06110247||Group U|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded. NIRS monitoring will be performed in addition to routine ASA monitoring. After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value. NIRS, pulse oximetry, and hemodynamic data will be recorded every 5 minutes until recovery from anesthesia just prior to induction. When comparing the NIRS values measured during follow-up with the baseline NIRS value, a decrease of 20% or more than 20% will be considered significant. Anesthesia and surgery times will also be recorded. Postoperative fever and the amount of irrigation fluid used during the surgical procedure will be recorded .
62517683|NCT06110247||Group H|The study involves continuous NIRS monitoring in addition to routine ASA monitoring. To establish the initial value of regional oxygen saturation (rSO2), renal NIRS probes will be positioned using ultrasonography, and an average of three measurements will be taken. Throughout the procedure, NIRS data, along with pulse oximetry and hemodynamic data, will be recorded at 5-minute intervals until the patient recovers from anesthesia just prior to induction. Significant changes in NIRS values will be determined if a decrease of 20% or more compared to the baseline measurement is observed. Anesthesia and surgery times will also be recorded.
62517684|NCT00369382|ACTIVE_COMPARATOR|1|Group 1: Continuation of CNI regimen
62517685|NCT00369382|EXPERIMENTAL|2|Group 2: (CNI-Free) Conversion to SRL-based regimen
62517686|NCT05519709||Asymptomatic Adolescent Tennis Players|Adolescent tennis players aged 7-17 years who have been actively attending tennis club for at least 1 year will be form adolescent tennis players groups. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. The assessment form, which includes demographic data such as, training duration(min/day), frequency (times/week) and sport age will record by asking the parents. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist.
62517687|NCT06425952||CMT patients|patients with sensory-motor genetic neuropathy
62517688|NCT06425952||Motor patients|Patients with motor genetic neuropathy
62517689|NCT06425952||Sensory patients|Patients with sensory neuropathy
62517690|NCT06425952||Myopathic patients|Patients with distal myopathy
62710674|NCT05903534|ACTIVE_COMPARATOR|Pediatric Endurance and Limb Strengthening Program (PEDALS) Group|In this group patients will performed pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention was performed 60 min per day, 3 times per week, for a total of 24 sessions, within a 8 week period. The longer session duration was designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program was performed prior to cycling.
61974363|NCT03409406|ACTIVE_COMPARATOR|ST Intervention|This intervention is the once monthly standard of care intervention 30-minutes speech therapy (ST) session that the child receives at the hospital.
61974364|NCT00759954|OTHER|1|Treatment A (test product) followed by Treatment B (reference product)
61974365|NCT00759954|OTHER|2|Treatment B (reference product) followed by Treatment A (test product)
61974366|NCT03229161|EXPERIMENTAL|IWT-group|The IWT-group follows the standardized GDM care program for GDM patients at OUH and is prescribed to a 6-week non-supervised IWT-program consisting of 3 IWT sessions per week of 40-50 minutes each.
61974367|NCT03229161|NO_INTERVENTION|Con-group|The con-group follows the standardized GDM care program for GDM patients at OUH
61974368|NCT00726804|OTHER|2|
61974369|NCT00996216|EXPERIMENTAL|Open-label eltrombopag|Open-label eltrombopag with dose titrations to support adequate platelet counts.
61974370|NCT00811538||1 1 (Liv*)|i.v. thrombolysis with rtPA
61974371|NCT00811538||2 (L*)|intraarterial thrombolysis
61974372|NCT03277105|EXPERIMENTAL|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
61974373|NCT03277105|ACTIVE_COMPARATOR|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
61974374|NCT00596570||1|Patient with atrial fibrillation who underwent PCI
61974375|NCT01577823|NO_INTERVENTION|No foley catheter|
61974376|NCT01577823|ACTIVE_COMPARATOR|Foley Catheter|
62517691|NCT01774175||Coolprep|A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
62517692|NCT01774175||Picolyte|Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
62517693|NCT05990842|EXPERIMENTAL|antibiotic prophylaxis|
62517694|NCT05990842|PLACEBO_COMPARATOR|placebo|
62517695|NCT06389916|EXPERIMENTAL|Euclid orthokeratology MAX (current design)|Euclid Orthokeratology (oprifocon A) Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.
62517696|NCT06389916|EXPERIMENTAL|Euclid orthokeratology MAX Phoenix (new design)|Euclid Orthokeratology (oprifocon A) Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.
62517697|NCT01763918|PLACEBO_COMPARATOR|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
62517698|NCT01763918|PLACEBO_COMPARATOR|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
62517699|NCT01763918|EXPERIMENTAL|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
62517700|NCT01763918|EXPERIMENTAL|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
62517701|NCT04685551|EXPERIMENTAL|Survivorship Management among African American and Latinx Cancer Dyads|"This arm will implement a one group pre-test and posttest design to improve health outcomes of African American and Latinx cancer survivors and caregivers in collaboration with health professional students trained as Cancer Survivorship and Caregiver Leaders Aimed for Minority Populations (CSC LAMPs)."
62517702|NCT03347513|EXPERIMENTAL|Eradication of H-pylori|"triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).~Followed by confirmation of eradication by repeating the H-pylori stool antigen test.~Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt."
62517703|NCT03347513|ACTIVE_COMPARATOR|No eradication of H-pylori|Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.
62517704|NCT01435226|ACTIVE_COMPARATOR|Arm 1|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV BID
62517705|NCT01435226|ACTIVE_COMPARATOR|Arm 2|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV placebo BID
62517706|NCT01435226|ACTIVE_COMPARATOR|Arm 3|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir placebo BID + RBV BID
62517707|NCT04828798|ACTIVE_COMPARATOR|Directional deep brain stimulation|Deep brain stimulation delivered in a directional manner within an axial plane
62517708|NCT04828798|ACTIVE_COMPARATOR|Nondirectional deep brain stimulation|Deep brain stimulation delivered in a nondirectional manner within an axial plane
62517709|NCT00799916|ACTIVE_COMPARATOR|Voluven|Resuscitation fluid: Voluven (R)
62517710|NCT00799916|ACTIVE_COMPARATOR|Saline|Resuscitation fluid: Saline solution
62710675|NCT05903534|ACTIVE_COMPARATOR|Lower Limb Strength Training Group|In this group patients will performed lower limb strengthening intervention was performed 3 times per week, for a total of 24 sessions, within a 8 week period using the functional strength training (for eccentric, concentric, and isometric contraction), plyometric exercises (including jumping), and balance training. Before each training session, there was a warm-up period with 5 to 10 minutes of dynamic activities (eg, jogging). After training, there was a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals, after each training session, there was a rest interval to prevent muscle fatigue and injury
61974377|NCT03348956|EXPERIMENTAL|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
61974378|NCT01431833|EXPERIMENTAL|Moderate hepatic|
61974379|NCT01431833|EXPERIMENTAL|Severe Hepatic|
62148003|NCT05825404|SHAM_COMPARATOR|Control|Usual light.
62148004|NCT05283876|ACTIVE_COMPARATOR|Active psoriasis|
62517711|NCT01208428|ACTIVE_COMPARATOR|Conventional cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy for the treatment of major depression
62517712|NCT01208428|EXPERIMENTAL|Religious cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy, but their religious beliefs will be utilized as a resource in the therapy
62517713|NCT04555278|EXPERIMENTAL|Active rTMS + Motor control exercises|Active (real) repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
62710676|NCT00138684|EXPERIMENTAL|Venesection therapy|
62710677|NCT00138684|NO_INTERVENTION|no venesection therapy|
62710678|NCT01766102|ACTIVE_COMPARATOR|Intra-operative Mammography|Intra-operative Specimen Mammography
62710679|NCT01766102|ACTIVE_COMPARATOR|Standard Mammography|Standard Specimen Mammography
62710680|NCT04348474|EXPERIMENTAL|HCQ + AZT|All patients included in the study will receive hydroxychloroquine (HCQ) 400 mg (00 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (AZT) (500 mg/ 5 days) on top of standard care.
61974380|NCT01431833|EXPERIMENTAL|Matched control|
62148005|NCT05283876|ACTIVE_COMPARATOR|Stable psoriasis|
62148006|NCT04027985|EXPERIMENTAL|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
62148007|NCT04027985|SHAM_COMPARATOR|Control group|the patients will receive sham KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
62517714|NCT04555278|SHAM_COMPARATOR|Sham rTMS + Motor control exercises|Sham repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
62517715|NCT04555278|EXPERIMENTAL|Active rTMS|Active (real) repetitive transcranial magnetic stimulation (20 minutes).
62517716|NCT04555278|SHAM_COMPARATOR|Sham rTMS|Sham repetitive transcranial magnetic stimulation (20 minutes).
62517717|NCT03420768|EXPERIMENTAL|Part 1 BMS-986263 45mg weekly|
62517718|NCT03420768|EXPERIMENTAL|Part 1 BMS-986263 90mg weekly|
62517719|NCT03420768|PLACEBO_COMPARATOR|Part 1 Placebo weekly|
62517720|NCT03420768|EXPERIMENTAL|Part 2 BMS-986263 45mg every 2 weeks|
62517721|NCT03420768|EXPERIMENTAL|Part 2 BMS-986263 90mg every 2 weeks|
62517722|NCT03420768|EXPERIMENTAL|Part 2 BMS-986263 90mg every 4 weeks|
62517723|NCT03420768|PLACEBO_COMPARATOR|Part 2 Placebo every 2 weeks|
62517724|NCT05829759|EXPERIMENTAL|Tele-B6|The tele-B6 intervention includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
62517725|NCT05829759|OTHER|Wait-list control -delayed intervention|Await-list control design to safeguard ethical treatment of participants by ensuring that a potentially impactful intervention will be available to all after a brief waiting period.
62710681|NCT02145936|EXPERIMENTAL|oleic acid diet|Participants are provided with meals enriched in oleic acid (18:1)
62710682|NCT02145936|EXPERIMENTAL|palmitic acid diet|Participants are provided with meals enriched in palmitic acid (18:0)
61974381|NCT01640145|PLACEBO_COMPARATOR|Carbohydrate|
61974382|NCT01640145|ACTIVE_COMPARATOR|Protein continous boluses|
62710683|NCT02145936|EXPERIMENTAL|stearic acid diet|Participants are provided with meals enriched in stearic acid (18:0)
62710684|NCT06278454|EXPERIMENTAL|NRT6008 Injection|In this study, participants shall receive NRT6008 injection in combination with chemotherapy.
62710685|NCT04577781|EXPERIMENTAL|GLPG3970|Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.
61974383|NCT01640145|ACTIVE_COMPARATOR|Protein 2 boluses|
61974384|NCT01548092|EXPERIMENTAL|Autologous SVF|Intralesional application
61974385|NCT04326348|EXPERIMENTAL|TQ05105 Tablet|TQ05105 tablet administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
61974386|NCT04087694|OTHER|Open|Open laminectomy and posterior stabilization with pedicle screws for symptomatic lumbar spine stenosis
61974387|NCT04087694|OTHER|Microscope|Microscopically done decompression of lumbar spine stenosis who are symptomatic
61974388|NCT02402439|EXPERIMENTAL|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
61974389|NCT00589563|EXPERIMENTAL|Fludarabine/Melphalan Conditioning|"Fludarabine/Melphalan Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
61974390|NCT00589563|EXPERIMENTAL|FTBI/Cytoxan Conditioning|FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
62148008|NCT04460066|EXPERIMENTAL|PD-L1 group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
61974391|NCT00589563|EXPERIMENTAL|FTBI/Etoposide Conditioning|"FTBI/Etoposide Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
61974392|NCT06369376|EXPERIMENTAL|All patients|
62517726|NCT02217696|EXPERIMENTAL|Computerized reading training first|Cross-over design: group first receives the intervention
62517727|NCT02217696|EXPERIMENTAL|Waiting Control First|Cross-over design: group first serves as waiting control
61974393|NCT04218305||The first group|Include One hundred patients with type 2 diabetes mellitus with average body mass index.
61974394|NCT04218305||The second group|Include One hundred patients whose body mass index is 30 or over without diabetes.
62517728|NCT02816502|EXPERIMENTAL|Stress Management Skill Building Program A|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
62517729|NCT02816502|ACTIVE_COMPARATOR|Stress Management Skill Building Program B|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
62517730|NCT04216615||patients with preoperative anxiety|
62517731|NCT04216615||patients without preoperative anxiety|
62517732|NCT05500573|EXPERIMENTAL|Sperm sorting|Selection of gender specific spermatozoa using a multilayer density gradient
62517733|NCT02777918|EXPERIMENTAL|Intervention|6 recipes will be sent by post every 2 weeks for a 12 week period. Dietary recommendations will also be provided at the start of the intervention period to increase the relevance of the recipes.
62517734|NCT02777918|NO_INTERVENTION|Control|Dietary recommendations will be provided at the start of the study period, such that the intervention regards the recipes, not the recommendations
62517735|NCT04259255||Edaravone (Radicava®/Radicava ORS®)|During an estimated 12-month period, eligible participants who are prescribed Edaravone within the approved indication will be invited to participate in the study.
62517736|NCT00922259|EXPERIMENTAL|H7N7 Vaccine|Participants will be administered two doses of the candidate live influenza A H7N7 vaccine
62517737|NCT05855616|EXPERIMENTAL|"Group chlorhexidine dressing"|CHG Chlorhexidine Gluconate dressing
62517738|NCT05855616|OTHER|"Group solution"|2% aqueous-based chlorhexidine solution and covering with a semi-permeable self-adhesive polyurethane dressing.
62517739|NCT02315066|EXPERIMENTAL|PF-04518600|OX40 agonist
62517740|NCT02315066|EXPERIMENTAL|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
62517741|NCT02602834|EXPERIMENTAL|HTx|Heart transplant recipients n=15
62517742|NCT02602834|ACTIVE_COMPARATOR|Control|Healthy controls n=5
62517743|NCT01045421|EXPERIMENTAL|MLN8237 (Alisertib)|MLN8237 administered as an enteric-coated tablet (ECT)
62517744|NCT05750147||Cardiomyopathies|"Approximately 1000 participants recruited prospectively from participating sites with a diagnosis of cardiomyopathy~Participants will provide biosamples and allow access to medical scans and records for health data collection"
62517745|NCT02505152|EXPERIMENTAL|Shunt|Perform percutaneous transhepatic intrahepatic portosystemic shunt
62517746|NCT03728023|EXPERIMENTAL|AZD4205|Single ascending dose: 5mg, 20mg, 50mg, 100mg, 150mg Multiple ascending dose: low, medium and high dose once daily X 14 days
62517747|NCT03728023|PLACEBO_COMPARATOR|Placebo|placebo single dose in SAD and once daily for 14 days
62517748|NCT00016276|EXPERIMENTAL|Arm I (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes, and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery, modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5 weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks. Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning on week 36 (day 254).
62517749|NCT00016276|EXPERIMENTAL|Arm II (chemoprotection, radiotherapy, surgery, trastuzumab)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
62517750|NCT00016276|EXPERIMENTAL|Arm III (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of radiotherapy.
62517751|NCT00016276|EXPERIMENTAL|Arm IV (chemoprotection, paclitaxel, surgery, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
62517752|NCT00016276|EXPERIMENTAL|Arm V (combination chemo, radiotherapy, long term trastuzumab)|Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
62517753|NCT00016276|EXPERIMENTAL|Arm VI (combination chemo, paclitaxel, surgery, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
62517754|NCT00016276|EXPERIMENTAL|Arm VII (combination chemo, monoclonal antibody, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
62517755|NCT00016276|EXPERIMENTAL|Arm VIII (combination chemotherapy, paclitaxel, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
62517756|NCT03383419|EXPERIMENTAL|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
62517757|NCT03580564|EXPERIMENTAL|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
62517758|NCT04645979||Participants|Participants who used betamethasone plus loratadine to treat allergic rhinitis within the previous two months.
62517759|NCT02199678|PLACEBO_COMPARATOR|Placebo|Placebo
62517760|NCT02199678|ACTIVE_COMPARATOR|ketamine 25 mg|ketamine
62517761|NCT02199678|ACTIVE_COMPARATOR|ketamine 35 mg|ketamine
62517762|NCT02199678|ACTIVE_COMPARATOR|ketamine 50 mg|ketamine
62148009|NCT04460066|PLACEBO_COMPARATOR|placebo group|All patients will receive 4 cycles of placebo ( IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
62517763|NCT04036149|EXPERIMENTAL|LUCIA|CT LUCIA 611P - Intraocular lens
62517764|NCT04036149|ACTIVE_COMPARATOR|ASPHINA|CT ASPHINA 409MP - Intraocular lens
62517765|NCT00412737|EXPERIMENTAL|Oseltamivir|
62517766|NCT00412737|PLACEBO_COMPARATOR|Placebo|
62517767|NCT02617524|EXPERIMENTAL|Valve Medical Dedicated Sheath|Valve Medical Dedicated Sheath version 00
62517768|NCT04803188|EXPERIMENTAL|A: patients will perform non-contrast MRI|A: 355 patients will perform non-contrast MRI regardless their serum PSA value
62148010|NCT01597882||Case managed patients|Patients aged 65 years and over receiving community case management.
62517769|NCT04803188|EXPERIMENTAL|B: patients will perform non-contrast MRI|B: 355 patients will perform non-contrast MRI when serum PSA value is increased (\>4 ng/ml or 2.5 ng/ml if positive family history)
62517770|NCT03319095|NO_INTERVENTION|Control|Control group: participants will receive only verbal instructions on PFM anatomy and function during the first assessment when women will be required to contract their pelvic floor muscle. The participants will have no contact with the service until the second assessment
62517771|NCT03319095|ACTIVE_COMPARATOR|Intervention|Intravaginal Electrical Nerve Stimulation: participants will be submitted to Intravaginal Electrical Nerve Stimulation
62517772|NCT02606526|EXPERIMENTAL|Intervention arm: BCG at birth|Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
62517773|NCT02606526|ACTIVE_COMPARATOR|Control arm: BCG at 14 weeks of age|Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
62517774|NCT03679273|EXPERIMENTAL|Abound supplement|The participant will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
62517775|NCT03679273|NO_INTERVENTION|Traditional supplement|The participant will take traditional diabetes-specific formula as provided by dietitians.
62517776|NCT03864042|EXPERIMENTAL|Arm 1 - CYP Probe Cocktail|"Patients will receive a single oral dose of the CYP Probe Cocktail on Day -7, Day 1, and Day 14:~* 25 mg losartan oral tablet~* 30 mg dextromethorphan oral capsule~* 50 mg caffeine oral liquid~* 20 mg omeprazole oral capsule~* 2 mg midazolam oral syrup~encorafenib/binimetinib continuous daily dosing starting Day 1:~* 450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~* 45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~All drugs will be taken within 10 minutes."
62517777|NCT03864042|EXPERIMENTAL|Arm 2 - Rosuvastatin and Bupropion|"Patients will receive a single oral dose of rosuvastatin and bupropion once on Day -7, Day 1 and Day 14:~* 10 mg rosuvastatin oral tablet~* 75 mg bupropion immediate release (IR) oral tablet~encorafenib/binimetinib continuous daily dosing starting Day 1:~* 450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~* 45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~All drugs will be taken within 10 minutes."
62517778|NCT03864042|EXPERIMENTAL|Arm 3 - Modafinil|"Patients will begin encorafenib/binimetinib continuous daily dosing starting Day 1:~* 450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~* 45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~then receive continuous treatment of modafinil on Day 15 through Day 21:~- 400 mg modafinil tablet once daily (QD)"
62517779|NCT05503251|EXPERIMENTAL|Arm I (neuropsychological evaluation)|Patients undergo neuropsychological evaluations with a certified neuropsychologist at baseline, 3 months, and 6 months.
62517780|NCT05503251|ACTIVE_COMPARATOR|Arm II (usual care)|Patients receive usual care.
62517781|NCT06037278|OTHER|MyPAO use|SIngle arm study, use of device
62517782|NCT01271179|ACTIVE_COMPARATOR|sequential perfusion|sequential perfusion of liver grafts with low-viscosity improved Ross solution and high-viscosity UW solution.
62517783|NCT01271179|PLACEBO_COMPARATOR|sole perfusion|sole perfusion of liver grafts with high-viscosity UW solution only
62517784|NCT00512837|ACTIVE_COMPARATOR|2|
62517785|NCT04818437|EXPERIMENTAL|Balance training|"Balance training~1. Trunk, head, and upper limbs rotation from kneeling.~2. Upper limbs flexion and extension with simultaneous head movement from kneeling.~3. Pelvic bridging followed by raising one lower limb and extending knee.~4. Lifting opposite upper and lower limbs from Quadruped position.~6-Heel and toe raises, alternate rising ofthe right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed"
62517786|NCT04818437|ACTIVE_COMPARATOR|Core stability exercise|"Core stability exercises:~1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing 6-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying."
62355394|NCT05466734|OTHER|Treatment TRTR (T: PMR, R: Cilostazol)|"Treatment R: One Cilostazol Tablet 100 mg at 08:00 and another at 20:00~Treatment T: Two PMR Tablet 135 mg at 08:00~Four-period dosing following the sequence of Treatment TRTR"
61974395|NCT04218305||The third group|Include One hundred type 2 diabetic obese patients whose body mass index is 30 or over.
61974396|NCT04218305||The fourth group|Include One hundred apparently healthy adult person as a control.
62355395|NCT01478295|EXPERIMENTAL|CuidaCare Intervention|Regular care in consultation or home and Structured nursing care (CuidaCare intervention): improved strategies for coping, health education on self-care and dependent care and emotional support. 10 visits are structured, with a periodicity of approximately 2 visits per month and last for 30 to 40 minutes each
61974397|NCT04894903|EXPERIMENTAL|Intervention|"Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention.~."
61974398|NCT04894903|NO_INTERVENTION|Usual Care|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care).
61974399|NCT02259582|PLACEBO_COMPARATOR|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
62355396|NCT01478295|ACTIVE_COMPARATOR|Control Group/Usual Care|Usual care in consultation or home, which is to respond to the specific demands of care of the caregiver, using the resources of the nursing discipline.
62355397|NCT05306184||ECT group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving ECT as treatment
62355398|NCT05306184||Medication group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving medication as treatment
62355399|NCT04048538|EXPERIMENTAL|Treatment Arm|Individuals who will receive access to the animated multimedia platform prior to their surgical procedure.
62355400|NCT04048538|ACTIVE_COMPARATOR|Control Arm|Individuals who will not receive access to the animated patient platform, and instead will receive the usual standard of care.
62355401|NCT01185704|EXPERIMENTAL|Day 1 protocol|
62355402|NCT01185704|EXPERIMENTAL|Day 7 protocol|
62355403|NCT02818413||U.S. Olympic Team and elite athletes|Biospecimens will be collected from and questionnaires will be administered to U.S. Olympic team members and other elite athletes
62355404|NCT01734096|ACTIVE_COMPARATOR|control group|healthy volunteer
62355405|NCT01734096|ACTIVE_COMPARATOR|obesity group|Patients with BMI \>30 Kg/m2
62355406|NCT01734096|ACTIVE_COMPARATOR|white coat hypertension group|Patients with office blood pressure \>140/90 mmHg and ambulatory daytime blood pressure \<135/85 mmHg
62355407|NCT01734096|ACTIVE_COMPARATOR|Resistant hypertension|Patients with ambulatory blood pressure \> 135/85 mm Hg (day) or \>120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking.
62355408|NCT00438919|EXPERIMENTAL|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
62355409|NCT04079387|EXPERIMENTAL|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°."
62355410|NCT04079387|ACTIVE_COMPARATOR|ENDOTRACHEAL TUBE ALONE|The control group consists in intubating the trachea with an endotracheal tube alone (i.e, without stylet).
62355411|NCT01109550||with biliary candidiasis|Patients with positive fungal cultures of bile samples.
62517787|NCT05888324||Patients with PDPH after epidural analgesia for labor, requiring BP|Patients with PDPH after epidural analgesia for labor, requiring BP
62517788|NCT02150772|OTHER|Shear Wave Elastography|All included patients have SWE performed
61974400|NCT02259582|ACTIVE_COMPARATOR|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
62517789|NCT01509482|EXPERIMENTAL|insulin resistance|unexplained oligospermia and azoospermia. Blood samples will be taken for hormonal and blood lipids analysis.
62517790|NCT01509482|ACTIVE_COMPARATOR|Fertile males|Healthy Men with proven fertility. Blood samples will be taken for hormonal and blood lipids analysis
61974401|NCT02259582|ACTIVE_COMPARATOR|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
61974402|NCT03404791|EXPERIMENTAL|Participants Ineligible for Radical Cystectomy|Participants will receive the TAR-200 transuretherally on Day 0 in to the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed on Day 21 via flexible or rigid cystoscopy. Participants will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Participants may undergo 21 day cycle every 3 months for a maximum of 3 cycles as maintenance (Up to 14 months). Each TAR-200 system will be removed at 21 days after insertion.
61974403|NCT03824912|EXPERIMENTAL|Test: Ketoconazole Cream 2%|Test: Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd)
61974404|NCT03824912|ACTIVE_COMPARATOR|Reference: Ketoconazole Cream 2%|Ketoconazole Cream 2% (G\&W Laboratories Inc.; Registrant: Teva Pharmaceuticals USA Inc.)
61974405|NCT03824912|PLACEBO_COMPARATOR|Placebo: Cream (Test vehicle)|Placebo Cream (Test vehicle) (Encube Ethicals Pvt Ltd)
62355412|NCT01109550||without biliary candidiasis|Patients with negative fungal cultures of bile samples.
62355413|NCT05152290|EXPERIMENTAL|Treatment Group (AlloRx)|intravenous infusion and intrathecal injection (total of 100 million cells)
62355414|NCT03439111|PLACEBO_COMPARATOR|Placebo|Intervention : Placebo + Standardized Lycium chinense Fruit Extract (LCF) capsules Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment 3 week wash-out Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment
62355415|NCT03439111|EXPERIMENTAL|Experimental|Intervention : Standardized Lycium chinense Fruit Extract (LCF) capsules + Placebo Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment 3 week wash-out Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment
61974406|NCT03294057|EXPERIMENTAL|ICT programs + Tele-coaching programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. And a trained nurse provides tele-coaching programs to subjects. After that, subjects will conduct self-management health care and tele-coaching programs for 12 weeks. After 3 months, they finish self-management ICT + coaching programs, and then they fill out the questionnaire.
61974407|NCT03294057|EXPERIMENTAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
62355416|NCT02407912|EXPERIMENTAL|Cisplatin|75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
62355417|NCT02407912|NO_INTERVENTION|Control|No intervention was applied.
62355418|NCT03745235|EXPERIMENTAL|"Mindfulness group"|
62355419|NCT03745235|OTHER|Control group|Treatment as Usual
62355420|NCT04902898|OTHER|Circumcision|Adult patients treated with circumcision
62355421|NCT04902898|ACTIVE_COMPARATOR|Circumcision with device|Adult patients treated with sterile single-use circular stapling device CIRCCURERII (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
62355422|NCT05438810|EXPERIMENTAL|FCN-437c+Fulvestrant ± Goserelin acetate|
62355423|NCT05438810|PLACEBO_COMPARATOR|Placebo+ Fulvestrant ± Goserelin acetate|
62355424|NCT00082043|EXPERIMENTAL|1|Dutasteride 2.5 mg by mouth daily for one month
62355425|NCT00082043|PLACEBO_COMPARATOR|2|Placebo oral capsule for two months
62355426|NCT01874119|EXPERIMENTAL|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
62355427|NCT01874119|PLACEBO_COMPARATOR|Placebo|During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
62355428|NCT02911818|ACTIVE_COMPARATOR|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
62355429|NCT02911818|ACTIVE_COMPARATOR|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
62355430|NCT02911818|ACTIVE_COMPARATOR|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
62355431|NCT02911818|ACTIVE_COMPARATOR|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
62355432|NCT02911818|ACTIVE_COMPARATOR|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
62355433|NCT04576247|EXPERIMENTAL|Combined aerobic and resistance exercise|12 weeks of supervised resistance exercise and unsupervised aerobic exercise.
62355434|NCT01274117|PLACEBO_COMPARATOR|One-stage transposition of the basilic vein|One-stage transposition of the basilic vein
62355435|NCT01274117|EXPERIMENTAL|Two-stage transposition of the basilic vein|Two-stage transposition of the basilic vein
62517791|NCT04966364|ACTIVE_COMPARATOR|patients with hypotension prediction index guided|Patients receiving hypotension prediction index guided. In this group, they will be alerted when the index exceeded 85 (range 0 to 100) indicating the later occurrence of MAP\< 65mmHg for at least minutes and a treatment protocol based on advanced hemodynamic parameters recommended vasopressor or inotrope, fluid administration, or observation.
62355436|NCT01055418|PLACEBO_COMPARATOR|placebo|
62355437|NCT01055418|EXPERIMENTAL|Vitamin C|
62355438|NCT01194869|EXPERIMENTAL|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
62355439|NCT02971527|EXPERIMENTAL|Oste-scan 500A-SONOST3000|In this group, the investigators will measure calcaneal bone strength index of each subject by experimental device firstly and then by control device.
62517792|NCT04966364|OTHER|patients without hypotension prediction index gudied|Patients will receive usual care during the operation without hypotension prediction index alerted.
62517793|NCT01944787|ACTIVE_COMPARATOR|Routine|IV Hydration at 125 cc hour
62517794|NCT01944787|EXPERIMENTAL|Intervention|IV Hydration at 250 cc hour
62517795|NCT05906199|EXPERIMENTAL|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
62517796|NCT05906199|ACTIVE_COMPARATOR|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
62355440|NCT02971527|EXPERIMENTAL|SONOST3000-Oste-scan 500A|In this group, the investigators will measure calcaneal bone strength index of each subject by control device firstly and then by experimental device.
62355441|NCT05016804|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
61974408|NCT03294057|ACTIVE_COMPARATOR|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
62148011|NCT05277454|EXPERIMENTAL|HMPL-653 open-label treatment arm|"Dose-escalation Stage:~Participants will be treated with escalating doses of HMPL-653 to determine the MTD and RP2D.~Dose-expansion Stage:~Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of HMPL-653 in TGCT and specific advanced solid tumors."
62355442|NCT03915912|EXPERIMENTAL|Mindfulness meditation|Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session. Patients will complete various Quality of Life questionnaires and distress measuring tools prior to initiating the mindfulness sessions, at the clinic visit following the mindfulness intervention, and \~2 months after completing the mindfulness intervention. Additionally, patients will be provided with supplemental materials including website references and guided audiotape meditations to guide their individual practice outside of the weekly guided sessions.
62355443|NCT01734707|ACTIVE_COMPARATOR|Allicor|Allicor 150 mg tablet by mouth two times a day
62517797|NCT05603455|EXPERIMENTAL|Bifidobacterium adolescentis group|Bifidobacterium adolescentis supplementation
62517798|NCT05603455|PLACEBO_COMPARATOR|Placebo group|Placebo supplementation
62517799|NCT04774341||CDSS (MedicBK) Analysis|
62517800|NCT04774341||Core Laboratory Analysis|
62517801|NCT05794724||Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.|
62517802|NCT05215613||Patients implanted with the Zimmer® Plates and Screws System|
61974409|NCT02554812|EXPERIMENTAL|Cohort A1|NSCLC patients treated with avelumab + utomilumab (Dose level 1)
61974410|NCT02554812|EXPERIMENTAL|Cohort A2|NSCLC patients treated with avelumab + utomilumab (Dose level 2)
61974411|NCT02554812|EXPERIMENTAL|Cohort A3|NSCLC patients treated with avelumab + utomilumab (Dose level 3)
62355444|NCT01734707|PLACEBO_COMPARATOR|Sugar pill|Placebo tablet 150 mg by mouth two times a day
62355445|NCT04238572|EXPERIMENTAL|Audiovisual distraction device|Audiovisual distraction device, analgesia nociception index monitoring, remifentanil added to local anesthesia technique
62355446|NCT04238572|ACTIVE_COMPARATOR|Active comparator group|Analgesia nociception index monitoring, remifentanil added to local anesthesia technique
62355447|NCT05542693|EXPERIMENTAL|RNA MCTI CIMATEC HDT 5µg|Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 5 µg of single-dose administration on day 1.
62517803|NCT06330532||Patients categorized as having no frailty on the frailty item, assessed by four domains|cognitive, emotional, physical, and nutritional.
62517804|NCT06330532||Patients exhibiting the early signs that may lead to frailty, assessed in four domains|cognitive, emotional, physical, and nutritional.
62517805|NCT06330532||Patients categorized as having frailty on the frailty item, assessed by four domains|cognitive, emotional, physical, and nutritional.
62517806|NCT04440449|EXPERIMENTAL|Behavioral Lifestyle Intervention|The participants will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
62517807|NCT04440449|OTHER|Group B control arm|Participants use the smart-phone app to record their daily diet and physical activity, with no group sessions.
62517808|NCT03511274|EXPERIMENTAL|Hygiene based educational film|Women randomised to receive the CMV educational intervention will fill in a questionnaire and view the film. The website will also contain interactive information about CMV and how to prevent it. After watching the film and reading the information, women will be asked to fill in a post-intervention questionnaire. The website will be accessible via the participants' own mobile device or computer or dedicated study tablets or computers on-site. Using a web-based intervention, we will be able to monitor use of the educational intervention and also collect data in real time.
62539511|NCT01397643|OTHER|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
62148012|NCT02364024||Arm A|Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells
62148013|NCT02364024||Arm B|Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells
62148014|NCT00591136|EXPERIMENTAL|Single Arm|
62148015|NCT00814749|ACTIVE_COMPARATOR|surgical therapy|
62539512|NCT01397643|OTHER|Operative|Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.
62517809|NCT03511274|NO_INTERVENTION|Treatment as usual (TAU)|Women who are randomised to the TAU group will also be asked to log-on the website. Instead of receiving specific information about prevention of CMV in pregnancy, they will receive information about routine antenatal immunisation. In the UK, the Department of Health recommends that all pregnant women should be offer immunisation against pertussis (whooping cough) and influenza (if pregnant during the influenza session). This will ensure that participants in the TAU arm of the study also derive benefit from the study.
62517810|NCT01988168|EXPERIMENTAL|Suture closure|Closure of skin with a running subcuticular, absorbable monofilament suture.
62517811|NCT01988168|ACTIVE_COMPARATOR|Staples closure|Closure of skin with stainless-steel surgical staples.
61974412|NCT02554812|EXPERIMENTAL|Cohort A4|Melanoma patients treated with avelumab +utomilumab
61974413|NCT02554812|EXPERIMENTAL|Cohort A5|SCCHN patients treated with avelumab + utomilumab
61974414|NCT02554812|EXPERIMENTAL|Cohort A6|TNBC patients treated with avelumab + utomilumab
61974415|NCT02554812|EXPERIMENTAL|Cohort A7|SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
61974416|NCT02554812|EXPERIMENTAL|Cohort A8|NSCLC first-line Stage IV treated with avelumab +PF-05082566
61974417|NCT02554812|EXPERIMENTAL|Combination B Dose Escalation|PF-04518600 + avelumab in selected tumor types
61974418|NCT02554812|EXPERIMENTAL|Combination B Expansion Cohorts|PF-04518600 + avelumab in selected tumor types
61974419|NCT02554812|EXPERIMENTAL|Combination C Dose escalation cohorts|PD 0360324 + avelumab in selected tumor types
62517812|NCT00655850|EXPERIMENTAL|Paclitaxel and Gemcitabine + Avastin|Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
62517813|NCT00782028|NO_INTERVENTION|Standard Care|No intervention consists of routine well child care
62517814|NCT00782028|OTHER|Centering parenting/Group well child care|
62517815|NCT02786719|EXPERIMENTAL|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
62148016|NCT00814749|ACTIVE_COMPARATOR|individual management|
62148017|NCT06470633|EXPERIMENTAL|HIFU+Adebrelimab+Chemotherapy|Induction phase: HIFU+Adebrelimab Neoadjuvant Therapy phase: Adebrelimab+ EC-T(Epirubicin + Cyclophosphamide → Docetaxel
62517816|NCT05064748|EXPERIMENTAL|Treatment Cohort|
62517817|NCT00567437|OTHER|A|10 patients with no aortic stenosis
62148018|NCT04948736|EXPERIMENTAL|Combined exercise nutrition intervention group|Customized exercise and nutrition intervention by underlying disease and functional state for 12 weeks during intervention period.
62148019|NCT04948736|ACTIVE_COMPARATOR|Conventional medial care group|Conventional medical care service for 12weeks during intervention period.
62517818|NCT00567437|OTHER|B|100 patients with asymptomatic AS
62517819|NCT01323452||Chronic HBV patients|Patients with chronic hepatitis B Treated for at least 3 months No HIV, HCV or HDV.
62517820|NCT04628104||COVID-19 patients presented with myocardial infarction|
62517821|NCT04628104||Non-COVID-19 patients presented with myocardial infarction|
62517822|NCT00344214|EXPERIMENTAL|1|Participants will receive the tri-focal cognitive behavioral therapy - social skills training counseling program
62517823|NCT00344214|ACTIVE_COMPARATOR|2|Participants will receive the standard care comparison condition
62517824|NCT03178916||Low risk pregnant women|evaluation of the efficacy of breastfeeding Low risk pregnant women
62517825|NCT03178916||high risk pregnant women|evaluation of the efficacy of breastfeeding high risk pregnant women
62517826|NCT01124708|PLACEBO_COMPARATOR|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
62517827|NCT01124708|ACTIVE_COMPARATOR|TC-5619|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, one capsule once daily p.o.
61974420|NCT02554812|EXPERIMENTAL|Combination C Dose expansion cohorts|PD 0360324 + aveluamb in selected tumor types
62517828|NCT05899322|EXPERIMENTAL|Primary Care Intervention for PTSD (PCIP) Spanish Speaking Adolescents and Families|This arm will receive the culturally adapted and translated PCIP intervention lasting from 1-3 weeks, and will complete baseline, post treatment, and 1-month follow up assessments.
61974421|NCT02554812|EXPERIMENTAL|Combination D Dose escalation cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
61974422|NCT02554812|EXPERIMENTAL|Combination D Dose expansion cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
61974423|NCT02554812|EXPERIMENTAL|Cohort A9|NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
61974424|NCT02554812|EXPERIMENTAL|Cohort A10|NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
61974425|NCT02554812|EXPERIMENTAL|Cohort F1|CMP-001 +avelumab in SCCHN
61974426|NCT02554812|EXPERIMENTAL|Cohort F2|CMP-001+avelumab+utomilumab in SCCHN
61974427|NCT02554812|EXPERIMENTAL|Cohort F3|CMP-001 +avelumab+PF-04518600 in SCCHN
61974428|NCT03222050|EXPERIMENTAL|electronic toy group|Distraction technique was given by electronic toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
61974429|NCT03222050|EXPERIMENTAL|key toy group|Distraction technique was given by key toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
62517829|NCT05899322|ACTIVE_COMPARATOR|Waitlist Treatment as Usual|Receive standard care treatment and will complete baseline, post treatment, and 1-month follow up assessments, and are offered translated and adapted PCIP treatment after conclusion of the study.
62517830|NCT03418987||Deformities of the spinal column|Patients with adolescent idiopathic scoliosis or adult degenerative scoliosis, treated or untreated.
62539513|NCT01658501|EXPERIMENTAL|Diet and Exercise|Diet and exercise only.
62539514|NCT01658501|EXPERIMENTAL|Metformin|Metformin only
62539515|NCT01658501|EXPERIMENTAL|Sulfonylurea|Sulfonylurea only
62517831|NCT00971737|ACTIVE_COMPARATOR|Cyclophosphamide and Vaccine only|Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
62517832|NCT00971737|EXPERIMENTAL|Cyclophosphamide, Vaccine and Trastuzumab|Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
62517833|NCT04375839|EXPERIMENTAL|Main treatment group|Zirconia implants will be placed in a prosthetically guided position in horizontally deficient ridges in main treatment group.
62517834|NCT04375839|ACTIVE_COMPARATOR|Control group|Titanium implants will be placed in a prosthetically guided position in horizontally deficient ridges in control group.
62517835|NCT05485220|EXPERIMENTAL|aerobic exercise group|the participants do aerobic training by an arm crank ergometer (Monark 881E Upper and Lower Body Ergometer)
62517836|NCT05485220|EXPERIMENTAL|High intensity interval training group|the participants do High intensity interval training by an arm crank ergometer (Monark 881E Upper and Lower Body Ergometer)
62517837|NCT05485220|NO_INTERVENTION|control group|the participants don't do any exercises
62517838|NCT03693534||Long Antagonist Protocol|Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.
62517839|NCT03693534||Long Agonist Protocol|Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.
62517840|NCT03794791||education|Education will be used to see whether or not improve the HCV screening and diagnosis in HBsAg(+) patients. Blood test ,HCV-RNA quantification test and HCV genotyping will be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
62517841|NCT03794791||no education|There is no education at all.Screening and diagnosis of HCV infection in HBsAg(+) patients are based on voluntary. Blood test ,HCV-RNA quantification test and HCV genotyping will still be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
62517842|NCT03093272|EXPERIMENTAL|ARN-509 Combined With Docetaxel|"* Apalutamide (ARN-509) will be taken orally at home daily~* Docetaxel will be administered every 3 weeks intravenously~* Prednisone will be taken orally twice daily~* Leuprolide Acetate will be administered at the specification of the physician"
62517843|NCT04873531|EXPERIMENTAL|Neostigmine|"For the Neostigmine (N) group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
62517844|NCT04873531|PLACEBO_COMPARATOR|Normal saline|"For the Normal saline (NS) group, normal saline with a same volume of the N group will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
62517845|NCT01091103|EXPERIMENTAL|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
62517846|NCT01800526|EXPERIMENTAL|Oral N-acetylcysteine (NAC)|Eligible subjects who did not participate in Intravenous NAC or subjects who are at least 4 weeks after participation in Intravenous NAC, will be given Oral NAC at a dose of 2400mg daily, in two equally divided doses, for 4 weeks. Subjects will have blood drawn prior to beginning the phase and weekly for 4 weeks. At each visit interim medical events and adverse events will be collected.
62517847|NCT01800526|EXPERIMENTAL|Intravenous N-acetylcysteine (NAC)|"For part 1, Eligible subjects who did not participate in Oral NAC or subjects at least 4 weeks after oral NAC will receive IV NAC 150 mg/kg over 8 hours. At least four weeks after the first infusion, the subject will receive IV NAC 300 mg/kg over 8 hours.~For part 2, Eligible subjects with sickle cell disease and hospitalization for VOC within the past 2 years, who now present in VOC will be enrolled. Subjects will receive IV NAC 75 mg/kg over 1 hour every 6 hours for 5 days or discharge, whichever occurs earlier."
61974430|NCT03222050|EXPERIMENTAL|Simple toy group|Distraction technique was given by simple toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
61974431|NCT03222050|NO_INTERVENTION|control group|Routine care was given during immunization and no intervention was given
61974432|NCT05219084|PLACEBO_COMPARATOR|placebo group|5ml of normal; saline-injected subcutaneously
62355448|NCT05542693|EXPERIMENTAL|RNA MCTI CIMATEC HDT 10µg|Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 10 µg of single-dose administration on day 1.
61974433|NCT05219084|ACTIVE_COMPARATOR|Hip denervatiopn|Hip denervation with lidocaine 2% to each genicular branch, 2ml at each point
61974434|NCT05219084|ACTIVE_COMPARATOR|Inra-articular hydration|10 ml of normal saline injected inside the hip under ultrasound guidance
62355449|NCT05542693|ACTIVE_COMPARATOR|Covishield® - AstraZeneca|Intramuscular injections of vaccine Covishield® - AstraZeneca at a usual dose of single-dose administration on day 1.
62355450|NCT05542693|ACTIVE_COMPARATOR|Comirnaty® - Pfizer|Intramuscular injections of vaccine Comirnaty® - Pfizer at a usual dose of single-dose administration on day 1.
62517848|NCT06126666|EXPERIMENTAL|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
62710686|NCT04577781|PLACEBO_COMPARATOR|Placebo|Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.
62710687|NCT06544070||Phase 1|"Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.0 x109/L who can be consented within 24 hours of the result.~Participants will donate one finger prick sample up to once per day to be tested on the Liberty device."
61974435|NCT05219084|ACTIVE_COMPARATOR|compined group|hip denervation and intra-articular hydration were conducted together in this group
62517849|NCT01360866|EXPERIMENTAL|OPC-34712 (Brexpiprazole) and Escitalopram|OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day
62517850|NCT01360866|EXPERIMENTAL|OPC-34712 and Fluoxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day
62517851|NCT01360866|EXPERIMENTAL|OPC-34712 and Paroxetine CR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day
62517852|NCT01360866|EXPERIMENTAL|OPC-34712 and Sertraline|OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day
62355451|NCT03509844|EXPERIMENTAL|Prolonged Exposure|Psychotherapy: 10 weeks, Prolonged Exposure (individual sessions) according to the manual developed by Foa et al., adapted for a residential care setting
62355452|NCT03509844|EXPERIMENTAL|STAIR|Psychotherapy: 10 weeks, Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting
62517853|NCT01360866|EXPERIMENTAL|OPC-34712 and Duloxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day
62517854|NCT01360866|EXPERIMENTAL|OPC-34712 and Venlafaxine XR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day
62517855|NCT01491035|EXPERIMENTAL|Cohort CC1, 6 children|
62517856|NCT01491035|EXPERIMENTAL|Cohort CC2, 6 children|
62517857|NCT01491035|EXPERIMENTAL|Cohort CC3, 6 children|
62517858|NCT01491035|EXPERIMENTAL|Cohort CC4, 6 children|
62517859|NCT01491035|EXPERIMENTAL|Cohort AC1, 6 adolescents|
62517860|NCT01491035|EXPERIMENTAL|Cohort AC2, 6 adolescents|
62517861|NCT01491035|EXPERIMENTAL|Cohort AC3, 6 adolescents|
62517862|NCT01491035|EXPERIMENTAL|Cohort AC4, 6 adolescents|
62517863|NCT04171713|EXPERIMENTAL|Grup 1|MBHP protocol + TAU
62517864|NCT04171713|EXPERIMENTAL|Grup 2|ABCT protocol + TAU
62517865|NCT04171713|ACTIVE_COMPARATOR|Grup 3|TAU
62517866|NCT01606852|NO_INTERVENTION|usual sedative practice|"Subjects will have usual care sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration."
62517867|NCT01606852|EXPERIMENTAL|Patient controlled sedation|Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
62148020|NCT04536766|EXPERIMENTAL|Enhanced Sleep Health Education|50 families will be randomly assigned to receive sleep health education delivered in two telephone sessions by Beds for Kids staff members, in addition to receiving the standard Beds for Kids program (bed, bedding, written sleep education materials). The first session will occur approximately 2-3 days before bed delivery. The second 15-20-minute session will occur approximately one week following bed delivery. Sleep health education training and supervision of Beds for Kids staff members will be provided by board-certified Behavioral Sleep Medicine providers. Sleep health information will be manualized and will consist of evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs.
62355453|NCT03509844|EXPERIMENTAL|STAIR/NT|Psychotherapy: 16 weeks, 10 weeks Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), followed by 6 weeks of Narrative Therapy (NT) (individual sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting.
62355454|NCT04429152|EXPERIMENTAL|Doravirine|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
62355455|NCT04868136|EXPERIMENTAL|Warm-up, then no warm-up|Participants' visit 2 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session. Participants' visit 3 consisted of the 30 minute exercise session without a warm-up.
62355456|NCT04868136|EXPERIMENTAL|No warm-up, then warm-up|Participants' visit 2 consisted of the 30 minute exercise session without a warm-up. Participants' visit 3 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session.
61974436|NCT01679977|ACTIVE_COMPARATOR|Legpress|"Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called swinging vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training."
62517868|NCT01351350|EXPERIMENTAL|MLN0128P 30 mg QW|MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517869|NCT01351350|EXPERIMENTAL|MLN0128P 40 mg QW|MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517870|NCT01351350|EXPERIMENTAL|MLN0128P 6 mg QD×3d QW|MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517871|NCT01351350|EXPERIMENTAL|MLN0128P 7 mg QD×3d QW|MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517872|NCT01351350|EXPERIMENTAL|MLN0128P 8 mg QD×3d QW|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517873|NCT01351350|EXPERIMENTAL|MLN0128P 9 mg QD×3d QW|MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517874|NCT01351350|EXPERIMENTAL|MLN0128P 10 mg QD×3d QW|MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517875|NCT01351350|EXPERIMENTAL|MLN0128P 7 mg QD×5d QW|MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
62517876|NCT01351350|EXPERIMENTAL|MLN0128P 8 mg QD×3d QW HER2-|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
62517877|NCT01351350|EXPERIMENTAL|MLN0128PH 8 mg QD×3d QW HER2+|MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
62517878|NCT01823276|ACTIVE_COMPARATOR|Tyrosine-Containing Bar|150 mg/kg dose of tyrosine per administration, administered twice
62517879|NCT01823276|PLACEBO_COMPARATOR|Placebo Bar|0 mg/kg dose of tyrosine per administration, administered twice
62517880|NCT03821363|EXPERIMENTAL|Low dose group|SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
62517881|NCT03821363|EXPERIMENTAL|Middle dose group|SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
62517882|NCT03821363|EXPERIMENTAL|High dose group|SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
62517883|NCT01834781|ACTIVE_COMPARATOR|Pulsed electromagnetic fields|Pulsed electromagnetic fields is applied transcranially 30 minutes twice a day for 7 days a week over 6 consecutive weeks
62517884|NCT01834781|PLACEBO_COMPARATOR|Wearing the inactive device|The inactive device is worn on the head for 30 minutes twice a day for 7 days a week over 6 consecutive weeks
61974437|NCT01679977|ACTIVE_COMPARATOR|E-Stim|ES training is performed with a custom-built battery-powered stimulator. The subject are seated over the edge of the therapeutic table with the trunk upright and lower legs freely swinging. Two conductive rubber electrodes covered by wet sponge are placed on the anterior thigh on each side of the body. The electrode pairs are connected to the independent channels of the stimulator and the left and the right thigh are stimulated in an alternative manner. Each repetition (i.e. ES evoked muscle contraction) is evoked by a 3.5 s train (60 Hz) of electrical pulses (rectangular, biphasic, width 0.6 ms). Consecutive contractions of the same thigh are separated by 4.5 s off intervals. Maximal tolerable intensity should be used and is monitored during the training sessions. In all the subjects this should induce a tetanic contraction of the stimulated muscles.
61974438|NCT01679977|NO_INTERVENTION|Control|This group only perform the same measurements as the intervention groups and lives their live as usual in between.
62517885|NCT01490866|EXPERIMENTAL|FOLFOX/bevacizumab and Axitinib|"Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC. (FOLFOX is a combination of 5-Fluorouracil, Leucovorin and Oxaliplatin.)~All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks). After 4 cycles, maintenance axitinib will be started."
62517886|NCT00892788|ACTIVE_COMPARATOR|A|Participants assigned to Group A will receive the LEARN (Lifestyle, Exercise, Attitudes, Relationships, Nutrition) Program weight loss manual and will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
62517887|NCT00892788|EXPERIMENTAL|B|Participants assigned to Group B will receive the LEARN manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
62517888|NCT02619448|EXPERIMENTAL|Chemotherapy with hypofractionated RT|Carboplatin AUC 2 + Paclitaxel 50 mg/m2 given weekly x 4 concurrently with radiation therapy (70 Gy in 20 fractions) over 4 weeks
62517889|NCT04180176|EXPERIMENTAL|All-Comer Cohort|Participants with mNSCLC or ES-SCLC will give blood samples at three separate timepoints for ctDNA profiling.
61974439|NCT06474585|ACTIVE_COMPARATOR|Sitting Group|Patients assigned the treatment molded in the unloaded condition (this is the routine clinical practice).
61974440|NCT06474585|EXPERIMENTAL|Weight-bearing Group|Patients assigned the treatment molded under load.
61974441|NCT02149004||Site Bonn|
61974442|NCT02149004||Site Heidelberg|
61974443|NCT02149004||Site Munich|
61974444|NCT02149004||Site Hamburg|
61974445|NCT02149004||Site Hannover|
61974446|NCT02149004||Site Cologne|
61974447|NCT02149004||Site Freiburg|
61974448|NCT02149004||Site Frankfurt|
61974449|NCT02149004||Site Essen|
61974450|NCT01170455|EXPERIMENTAL|Blind Intubation Device|
62517890|NCT04180176|EXPERIMENTAL|Front-line Immunotherapy Re-enrollment Cohort|Participants with mNSCLC or ES-SCLC that have received front-line treatment as defined by the protocol will give blood samples at three separate timepoints for ctDNA profiling.
62517891|NCT03351530||Pre-diabetes|
62517892|NCT03351530||Diabetes|
62517893|NCT03351530||Diabetes with periodontal disease|
62517894|NCT03351530||Periodontal patient|
62517895|NCT03351530||Healthy person|
62517896|NCT04142008|EXPERIMENTAL|Walk with Me app|
62517897|NCT05376618||stable COPD|
62517898|NCT05376618||Healthy|
62517899|NCT05210452|EXPERIMENTAL|Patients with alopecia receiving standard treatment and follicular stem cells|Patients with alopecia receiving standard treatment and autologous follicular stem cells
62517900|NCT05210452|ACTIVE_COMPARATOR|Patients with alopecia receiving standard treatment|Patients with alopecia receiving standard treatment
62517901|NCT04178031|EXPERIMENTAL|IUD insertion group|All participants will have IUD inserted and follow up for occurance of complications
62517902|NCT00269542|EXPERIMENTAL|1|
62517903|NCT00269542|PLACEBO_COMPARATOR|2|
62517904|NCT02605798|EXPERIMENTAL|T test|Test drug (Elbanovir)1 tablet contains 400 mg Sofosbuvir
62517905|NCT02605798|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
62517906|NCT02605798|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
62517907|NCT03307564|EXPERIMENTAL|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments
62517908|NCT04352608|EXPERIMENTAL|Emergency schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the emergency schedule
62517909|NCT04352608|EXPERIMENTAL|Emergency schedule & Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the emergency schedule
62517910|NCT04352608|PLACEBO_COMPARATOR|Emergency schedule &Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the emergency vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the emergency schedule
62517911|NCT04352608|EXPERIMENTAL|Routine schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the routine schedule
62517912|NCT04352608|EXPERIMENTAL|Routine schedule &Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the routine schedule
62517913|NCT04352608|PLACEBO_COMPARATOR|Routine schedule & Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the routine vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the routine schedule
62517914|NCT04352608|EXPERIMENTAL|Emergency schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
61974451|NCT01170455|ACTIVE_COMPARATOR|Direct laryngoscope|
61974452|NCT02707510|EXPERIMENTAL|Intervention Arm|Patients in the intervention group will be provided with all programmatic materials (including copies of power point presentations, copies of reading texts, and audio CDs) and classes will be held in group format, with a maximum of 9 participants per group. Classes will meet weekly, in a group, and at a set time. All classes will be facilitated jointly by the two Co-PIs. All participants will complete surveys before class, during class, at the end of class, 1 month after the end of class, 6 months after the end of class and 1 year after the end of the class. Additionally, those randomized to the intervention group will be asked to attend a 1 time focus group 1 week after the end of the class.
61974453|NCT02707510|NO_INTERVENTION|Control Arm|Patients in the control group will be asked to complete surveys at: baseline, 6 weeks after baseline (T1), and 1 month after T1. After T1, the control group will off study and will be permitted to attend the next available GRACE course.
62517915|NCT04352608|EXPERIMENTAL|Emergency schedule & Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
62517916|NCT04352608|PLACEBO_COMPARATOR|Emergency schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the emergency vaccination schedule
62517917|NCT04352608|EXPERIMENTAL|Routine schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
62517918|NCT04352608|EXPERIMENTAL|Routine schedule &Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
62517919|NCT04352608|PLACEBO_COMPARATOR|Routine schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the routine vaccination schedule
62517920|NCT04328519||patient(hospitalized)|patients who are admitted to the emergency department and hospitalized.
62517921|NCT04328519||control(not hospitalized)|patients who are admitted to the emergency department and not hospitalized.
62517922|NCT04718129|EXPERIMENTAL|Mindfulness|Internet-based, coached Mindfulness Program. Nine weekly coached sessions with practice exercises between sessions.
62539516|NCT01658501|EXPERIMENTAL|Metformin and Sulfonylurea|Metformin and Sulfonylurea combination therapy
61974454|NCT01891695|EXPERIMENTAL|Reduced Intensity Radiation|39.6 Gy radiation to clinically uninvolved cervical lymphatics
61974455|NCT00159536|EXPERIMENTAL|Metformin|Metformin 1000mg x 2 daily
61974456|NCT00159536|PLACEBO_COMPARATOR|placebo|Placebo x 2 daily
61974457|NCT03401424|EXPERIMENTAL|improved Warren-type style|Minimally invasive treatment improved Warren-type cholangiocarcinoma reconstruction is easy
61974458|NCT03401424|ACTIVE_COMPARATOR|Roux-en-Y style|Early open cholecystectomy reconstruction surgery using Roux-en-Y style
61974459|NCT06339723|EXPERIMENTAL|Experimental|Training Given with the Pecha Kucha Method
61974460|NCT06339723|NO_INTERVENTION|Control|No training was given on the Pecha Kucha Method
61974461|NCT02446990|EXPERIMENTAL|Ivabradine|
61974462|NCT02446990|PLACEBO_COMPARATOR|Placebo|
61974463|NCT05378815|EXPERIMENTAL|PRP group|"PRP will be prepared with The Regenkit BCT kit provided by the RegenLab laboratory. This is a 2B medical device with the CE mark. 5mL will be injected in knee under ultrasound guidance.~The PRP extracted using this kit is poor in leukocytes, has a platelet concentration multiplied by 1.6 on average compared to circulating blood and is not activated (P2Bbeta according to the PAW classification; 3B according to the Mishra's classification)."
61974464|NCT05378815|PLACEBO_COMPARATOR|Placebo group|5 mL of NaCl will be injected in knee under ultrasound guidance.
61974465|NCT01721616|ACTIVE_COMPARATOR|Cefazolin|single antibiotic
62517923|NCT04718129|NO_INTERVENTION|Control|Participants in this arm are randomly assigned to an assessment-only, no intervention control condition.
62517924|NCT06341049|ACTIVE_COMPARATOR|Group Intraperitoneal local anasthetic+ loal anesthetic wound infiltration|For Group Intraperitoneal local anasthetic+ loal anesthetic wound infiltration, after the birth of the newborn and placenta, the uterus is taken out and closed, the blood accumulated in the pelvis is carefully wiped with surgical towels, and after complete hemostasis is achieved, sterilely prepared 20 ml 0.5% bupivacaine + 20 ml 2% lidocaine +1 A total of 40 ml of solution containing 200,000 epinephrine will be given to the surgeon. 10 ml of this solution will be instilled into all four quadrants of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer will be sutured or left open, depending on the surgeon's preference. 10 ml will be infiltrated around the edges of the rectus aponeurosis, and the remaining 20 ml will be infiltrated subcutaneously into the wound area.
62517925|NCT06341049|ACTIVE_COMPARATOR|Group Morphine|Group Morphine will be given 11.2 mg hyperbaric bupivacaine + 15 µg fentanyl + 150 µg morphine into the spinal space.
62517926|NCT06341049|ACTIVE_COMPARATOR|Group Quadratus lumborum block|In Group Quadratus lumborum block, Quadratus lumborum block type I, a total of 40 ml of a solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200,000 epinephrine will be applied bilaterally under ultrasound guidance.
62517927|NCT00062751|EXPERIMENTAL|A|
62517928|NCT00062751|EXPERIMENTAL|B|
62517929|NCT00062751|ACTIVE_COMPARATOR|C|
62517930|NCT02826941|EXPERIMENTAL|Hypothermia|If randomized to hypothermia, plastic bags filled with ice wrapped in a washcloth were applied to the head and body for approximately 2 hours, then the infant was placed on an adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature to 33 ± 0.5 °C for 48 hours at the participating tertiary care center. Rewarming by 0.5°C per hour was begun after 48 hours of hypothermia.
62517931|NCT02826941|PLACEBO_COMPARATOR|Normothermia|If randomized to normothermia, rectal temperatures were maintained at 37 ± 0.5 °C per standard neonatal intensive care unit practice, using adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature of 37 ± 0.5 if baby was febrile.
62517932|NCT05025579|EXPERIMENTAL|Exercise group|Considering the protocol suggested in the literature and by examining exercise samples for geriatric individuals, an exercise protocol was created. The first week started with aerobic exercises with a total of 120 minutes, and the next week increased to 160 minutes . A 6-week exercise program was planned and applied 4 days a week in which the intensity was increased gradually. People 's heart rate, blood pressure and respiratory frequency exercise program implementation before and after was recorded in the evaluation form.
62517933|NCT03665948|EXPERIMENTAL|Ketogenic Diet (KD)|Group consuming very low carbohydrate ketogenic diet. The ketogenic diet model was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement up to 5% of energy from carbohydrates. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with fats (fats covered more than 75% of the daily energy requirement). Each of the subjects in this group received 10-day menus.
62517934|NCT03665948|ACTIVE_COMPARATOR|Low-Glycemic Index Diet (CHO-LGI)|Group consuming carbohydrate, low-glycemic index diet. The carbohydrate diet model with a low glycemic index was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement of 25% of fat. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with carbohydrates (carbohydrates covered about \~55% of the daily energy requirement). The glycemic index of individual meals as well as the daily diet was calculated in accordance with the appropriate recommendations. Each of the subjects in this group received 10-day menus.
62517935|NCT05793814|EXPERIMENTAL|Experimental: Limosilactobacillus Supplement|Capsules containing Probiotic taken daily for 6 month
62517936|NCT05793814|PLACEBO_COMPARATOR|Placebo|Capsules containing Microcrystalline cellulose, magnesium stearate taken Daily for 6 month
62517937|NCT02370914||Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a Sport Concussion Assessment Tool (SCAT) test.
62710688|NCT06544070||Phase 2|"Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.5 x109/L who can be consented within 24 hours of the result.~Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session."
62710689|NCT06544070||Phase 3|"Participants who are undergoing a routine venous draw as part of the standard of care as part of SACT toxicity monitoring.~Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session."
61974466|NCT01721616|ACTIVE_COMPARATOR|Cefazolin + Azitrhromycin|double antibiotic
61974467|NCT00699621|ACTIVE_COMPARATOR|1|Platelet transfusion
61974468|NCT00699621|NO_INTERVENTION|2|No platelet transfusion
61974469|NCT01120912|EXPERIMENTAL|Oral insulin and placebo|
61974470|NCT05899309||Liver cirrhosis with metabolic syndrome|Liver cirrhosis patients with metabolic syndrome on standard treatment
61974471|NCT05899309||Liver cirrhosis without metabolic syndrome|Liver cirrhosis patients without metabolic syndrome on standard treatment
61974472|NCT00901160||Surgical patients|Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay. This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
61974473|NCT04590261|OTHER|group 1|Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment
61974474|NCT04590261|OTHER|Group 2|Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, \> 5 L/mn Oxygen treatment
61974475|NCT04590261|OTHER|Group 3|Physician examination in the Pneumology ward, Cochin Hospital
61974476|NCT04590261|OTHER|Group 4|Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital
61974477|NCT04646798|ACTIVE_COMPARATOR|Hemi Arthroplasty (HA) of the elbow.|Hemi Arthroplasty (HA) of the elbow, where the surgeon replaces the bottom of the humerus bone at the elbow.
62355457|NCT02994381|EXPERIMENTAL|[14C]-RPC1063 Solution (0.1 g/mL)|1 mg; 10 mL \[14C\]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
62517938|NCT02370914||Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a Sport Concussion Assessment Tool (SCAT) test.
62517939|NCT01355354|EXPERIMENTAL|1|Digoxin
62517940|NCT01355354|EXPERIMENTAL|2|Fostamatinib
62517941|NCT00521274|EXPERIMENTAL|1|"Patients randomized to Arm 1 will receive treatment cycles of Docetaxel and vaccine.~PI relocated, data not available."
62517942|NCT00521274|ACTIVE_COMPARATOR|2|"Patients randomized to Arm 2 will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over).~PI relocated, data not available."
62517943|NCT05443269|EXPERIMENTAL|Jump Start Program|The intervention consists of following the Jump Start plan for 7 days
62517944|NCT02782091|EXPERIMENTAL|Schizophrenia Patient|
62517945|NCT02782091|EXPERIMENTAL|Control Subject|
62148021|NCT04536766|ACTIVE_COMPARATOR|Beds for Kids Standard Program|50 families will be randomly assigned to the standard Beds for Kids program, which includes a bed, bedding, and written sleep education materials.
62148022|NCT03566901|EXPERIMENTAL|Robot-Assisted Stair Climbing Training|Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
62517946|NCT04529226|EXPERIMENTAL|Clozapine|Pharmaceutical Form: Tablet Anatomical Therapeutic Chemical classification system (ATC Code): N: nervous system, N05: psycholeptic, N05A: antipsychotic, N05AH02: clozapine (N05AH02)
62517947|NCT04529226|ACTIVE_COMPARATOR|Control|Usual antipsychotic medication used in the treatment of treatment-resistant psychosis.
62517948|NCT05101993|EXPERIMENTAL|AtriClip group|
62517949|NCT02225665|EXPERIMENTAL|Cohort 1|
62517950|NCT02225665|EXPERIMENTAL|Cohort 2|
62517951|NCT05123313|NO_INTERVENTION|Control group|The control group will not receive a series of consultations with their general practitioner. Controls will receive baseline measurements and follow-up measurements 3 months and 6 months following baseline measurements.
62517952|NCT05123313|EXPERIMENTAL|Intervention group|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences. Interventions will receive baseline measurements and follow-up measurements 3 months and 6 months following baseline measurements.
62517953|NCT05483582|ACTIVE_COMPARATOR|classical electrical stimulation protocol (control group)|"* Apply 2-channel electrical stimulation device with protocol 1.~* It will simultaneously stimulate bilateral suprahyoid, bilateral thyrohyoid muscle with 2-channel electrical stimulation device.~* Basic intervention involves 600-900 minutes of electrical stimulation for 2 weeks. (based on 60 minutes per 1 time, applied 10 times(+5 times, within 1 week))~* With the consent of the patient, an additional evaluation is performed after additional 2 weeks of intervention, which is use as an exploratory indicator.~* After application of the device, we evaluate videofluoroscopic swallowing study(VFSS) for evaluation of swallowing function.~* In addition, we evaluate clinical questionnaires(FOIS, MDADI, Likert scale), nutritional status assessments(MNA-SF), and oral intake assessments.~* Also, we measure tongue strength through IOPI and body composition changes through Inbody."
62539517|NCT01658501|EXPERIMENTAL|PB1023|PB1023 weekly SC injection
61974478|NCT04646798|ACTIVE_COMPARATOR|Total Elbow Arthroplasty (TEA).|Total Elbow Arthroplasty (TEA), where the surgeon fits a new elbow joint replacing damaged parts of the humerus bone and forearm bone that it joins onto.
61974479|NCT04958005||Children with early chilhood caries|Early chilhood caries group
62148023|NCT03566901|ACTIVE_COMPARATOR|Conventional Physiotherapy|50 min of overground walking training and stair climbing up/down and lower limb mobilization and stretching exercise.
62355458|NCT05845489|EXPERIMENTAL|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
62355459|NCT05845489|ACTIVE_COMPARATOR|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
62355460|NCT01212198||Korean type 2 diabetic patients|
62355461|NCT01212198||Koreans at high risk for diabetes|
62539518|NCT01658501|PLACEBO_COMPARATOR|Placebo Comparator|Placebo (0.9% Sodium Chloride) weekly SC injection
62539519|NCT01658501|ACTIVE_COMPARATOR|Active Comparator|Active Comparator (Victoza) daily SC injection
62539520|NCT03429400|OTHER|Morphine Sulfate|oral morphine sulfate tablets oral morphine sulfate oral solution
62539521|NCT04430478|EXPERIMENTAL|Volume flow group|Consecutive patients undergoing sequential volume flow measurements using percutaneous DUS
61974480|NCT04958005||Without early chilhood caries|Control group
61974481|NCT02240160|EXPERIMENTAL|Sativex: acidic oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with Coca-Cola (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
61974482|NCT02240160|EXPERIMENTAL|Sativex: neutral oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with tap water (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
62148024|NCT01318850|EXPERIMENTAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes and Reeder, 2005)
62355462|NCT01212198||Korean gestational diabetic patients|
62355463|NCT01779596|EXPERIMENTAL|Bosentan|Single dose of Bosentan (125 mg)
62355464|NCT01779596|PLACEBO_COMPARATOR|Placebo|Single dose of placebo (125 mg)
62355465|NCT05008068|EXPERIMENTAL|PRF alone|
62355466|NCT05008068|ACTIVE_COMPARATOR|PRF in addition to Simvastatin|
62517954|NCT05483582|EXPERIMENTAL|revised sequential activation protocol (experimental group)|"* Apply 4-channel electrical stimulation device with protocol 2.~* It sequentially stimulates bilateral suprahyoid muscle(ch 1, ch 2), bilateral thyrohyoid muscle(ch 3), bilateral sternothyroid muscle(ch 4) with 4-channel electrical stimulation device.~* Basic intervention involves 600-900 minutes of electrical stimulation for 2 weeks. (based on 60 minutes per 1 time, applied 10 times(+5 times, within 1 week))~* With the consent of the patient, an additional evaluation is performed after additional 2 weeks of intervention, which is use as an exploratory indicator.~* After application of the device, we evaluate videofluoroscopic swallowing study(VFSS) for evaluation of swallowing function.~* In addition, we evaluate clinical questionnaires(FOIS, MDADI, Likert scale), nutritional status assessments(MNA-SF), and oral intake assessments.~* Also, we measure tongue strength through IOPI and body composition changes through Inbody."
61974483|NCT02240160|EXPERIMENTAL|Sativex: alkaline oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with milk of magnesia (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
62148025|NCT01318850|ACTIVE_COMPARATOR|Psychoeducation|Symptom Management Module from the University of California. Liberman \& Kopelowicz (1995)
62148026|NCT01318850|OTHER|Healthy Controls|Healthy controls
62355467|NCT00574444|EXPERIMENTAL|Procedure|Procedure/Surgery: transvaginal diagnostic peritoneoscopy For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
62355468|NCT03177785|EXPERIMENTAL|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
62355469|NCT03177785|NO_INTERVENTION|Control|Wait-list control
62355470|NCT03393689|EXPERIMENTAL|Angiogenesis PET/MR|One injection of the radioligand 68Ga-NODAGA-E\[c(RGDyK)\]2 followed by PET/MR
62355471|NCT06279663|ACTIVE_COMPARATOR|PCI|complete revascularization
62355472|NCT06279663|ACTIVE_COMPARATOR|CABG|
62355473|NCT01779648|ACTIVE_COMPARATOR|Simultaneous compression+Fixed refill time|Simultaneous bilateral compression with fixed venous refill time through the whole duration of pneumatic compression
62355474|NCT01779648|ACTIVE_COMPARATOR|Alternate compression+Adjusted refill time|alternate bilateral compression with adjusted venous refill time which would change several times during pneumatic compression
62355475|NCT00589433||1|
62355476|NCT05382988|EXPERIMENTAL|Experimental Group|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
62355477|NCT05382988|NO_INTERVENTION|Control Group|No additional intervention was performed
62355478|NCT02780596|EXPERIMENTAL|Items1;3|Caregiver is randomly assigned to receive screening items 1 and 3. Item 1: Does CHILD NAME often wake one or more times during the night? Item 3: Do you think CHILD NAME's sleep is a problem?
62355479|NCT02780596|EXPERIMENTAL|Items1;4|Caregiver is randomly assigned to receive screening items 1 and 4. Item 1: Does CHILD NAME often wake one or more times during the night? Item 4: Does you think CHILD NAME has a sleep problem?
62355480|NCT02780596|EXPERIMENTAL|Items1;5|Caregiver is randomly assigned to receive screening items 1 and 5. Item 1: Does CHILD NAME often wake one or more times during the night? Item 5: Do you have any concerns about CHILD NAME's sleep?
62355481|NCT02780596|EXPERIMENTAL|Items2;3|Caregiver is randomly assigned to receive screening items 2 and 3. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 3: Do you think CHILD NAME's sleep is a problem?
62355482|NCT02780596|EXPERIMENTAL|Items2;4|Caregiver is randomly assigned to receive screening items 2 and 4. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 4: Does you think CHILD NAME has a sleep problem?
62355483|NCT02780596|EXPERIMENTAL|Items2;5|Caregiver is randomly assigned to receive screening items 2 and 5. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 5: Do you have any concerns about CHILD NAME's sleep?
62355484|NCT02780596|EXPERIMENTAL|Items3;5|Caregiver is randomly assigned to receive screening items 3 and 5. Item 3: Do you think CHILD NAME's sleep is a problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
62355485|NCT02780596|EXPERIMENTAL|Items4;5|Caregiver is randomly assigned to receive screening items 4 and 5. Item 4: Does you think CHILD NAME has a sleep problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
62355486|NCT03846973|EXPERIMENTAL|Tranexamic acid|group-I will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes followed by an intravenous infusion of 1 g TXA to be given and completed over 8 h in the hospital
62355487|NCT03846973|PLACEBO_COMPARATOR|Placebo|group-II will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes but will receive placebo (normal saline) infusion to be given and completed over 8 h in the hospital
62355488|NCT03526315|ACTIVE_COMPARATOR|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
62355489|NCT03526315|ACTIVE_COMPARATOR|Fluoride toothpaste|Fluoride toothpaste
62355490|NCT03526315|ACTIVE_COMPARATOR|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
62355491|NCT04386083||COVID-19 patients with neurologic manifestations|Patients with confirmed COVID-19 disease who presented with neurological symptoms or new-onset neurological disorders/complications
62355492|NCT04386083||COVID-19 patients without neurologic manifestations|Patients with confirmed COVID-19 disease who did not present with neurological symptoms or new-onset neurological disorders/complications
62355493|NCT06446518|EXPERIMENTAL|VR intervention group|"On admission, patients are asked to fill out a STAI-T and-S anxiety inventory. Attending investigator will take vital parameters upon admission.~Patients are asked to use the VR headset a minimum of 1 hour before surgery. Participants are asked to fill out a STAI-S test in the operating room, where physiologic data is collected and timing and dose of medication administered. After surgery, during emergence physiologic data is collected, and attending anesthesiologist fills out the PAED score. Patients are encouraged to use the VR headset after surgery, any time when they feel comfortable.~Pain using an NRS scale, and vital parameters are monitored postoperative 1, 2, 3, 6, 12 hours (if patient is not sleeping) and in the morning following surgery at 6 and 9 am. A final STAI-S test is filled out by patients in the morning after surgery. Data regarding painkiller demand is collected after surgery."
62517955|NCT03352141|EXPERIMENTAL|Fat Reduction|The treatments are designed to see if the fat can be reduced along the jawline with Cryolipolysis.
62517956|NCT00765011|EXPERIMENTAL|Group A|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
62517957|NCT00765011|OTHER|Grupo B|Surgery
62517958|NCT03632967|EXPERIMENTAL|Device: TriCinch Coil System treatment|
62517959|NCT03894241|EXPERIMENTAL|Sedentary condition|
62517960|NCT03894241|EXPERIMENTAL|Moderate-intensity continuous training|
62517961|NCT03894241|EXPERIMENTAL|Cooperative-high-intensity interval training|
62517962|NCT03186703|EXPERIMENTAL|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
62517963|NCT03186703|NO_INTERVENTION|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
62517964|NCT04133246|OTHER|Group arm|Includes subjects enrolled in focus groups
62517965|NCT04133246|OTHER|Interview arm|Includes subjects with individual interviews
61974484|NCT02887521|EXPERIMENTAL|Pulmonary Rehabilitation (PR)|Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
62148027|NCT02367794|EXPERIMENTAL|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
62517966|NCT03715322|ACTIVE_COMPARATOR|tobramycin inhalation|300mg tobramycin dissolved in 5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
62517967|NCT03715322|PLACEBO_COMPARATOR|natural saline inhalation|5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
62517968|NCT03715322|OTHER|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
62517969|NCT03815968|EXPERIMENTAL|low sodium diet|women diagnosed with oligohydramnios designated for conservative management applying a low-salt diet.
62517970|NCT03815968|NO_INTERVENTION|regular diet|women diagnosed with oligohydramnios designated for conservative management applying a regular diet.
62517971|NCT05112419|EXPERIMENTAL|Cohort 1: Participants with moderate hepatic impairment and moderate renal impairment|Participants will receive a single oral dose of zibotentan under fasted conditions.
62517972|NCT05112419|EXPERIMENTAL|Cohort 2: Healthy participants|Participants will receive a single oral dose of zibotentan under fasted conditions.
62517973|NCT04107142|EXPERIMENTAL|CAR-T Cell Therapy Group|"One arm study consisting of 3 + 3 dose escalation study design ranging from 3 x 10\^8 - 3 x 10\^9 cells CAR-γδ T cell.~Each cycle of therapy will consist of 4 intravenous infusions, given 7 days apart."
62517974|NCT03744078|ACTIVE_COMPARATOR|PGE2 with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
62517975|NCT03744078|NO_INTERVENTION|PGE2 vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
62517976|NCT01378741|ACTIVE_COMPARATOR|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
62517977|NCT01378741|ACTIVE_COMPARATOR|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
62710690|NCT01688297|EXPERIMENTAL|Low Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
62710691|NCT01688297|PLACEBO_COMPARATOR|VXA Placebo Tablet|Oral tablets of the same size and number as the vaccine tablet doses. Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
62710692|NCT01688297|EXPERIMENTAL|Medium Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet
62517978|NCT00004135|EXPERIMENTAL|Arm A|Fludarabine 30 mg/m2/d x S days IVPB in 100 cc NS over 30 minutes on day -8, -7, -6, -S, and -4. Cyclophosphamide 2 gm/m2/d x 2 days IVPB in SOO cc DS W over I hour on day -3 and day-2. G-CSF (Neupogen®) administration 480 f!gld subcutaneously starting on day +5 (or first day of neutropenia if earlier)and continued until an ANC of 0.5 x 109/L is maintained for 3 consecutive days.
62517979|NCT04428099|EXPERIMENTAL|Intervention|Lifestyle change promotion program
62517980|NCT04428099|ACTIVE_COMPARATOR|Control 1|MBCT program
62517981|NCT04428099|PLACEBO_COMPARATOR|Control 2|Usual care
62539522|NCT05228028|EXPERIMENTAL|fascia iliaca compartement block [FICB] group|
62539523|NCT05228028|EXPERIMENTAL|quadratus lumborum block [QLB] group|
62539524|NCT01860677|ACTIVE_COMPARATOR|Active stimulation|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies. The device has been designated by the FDA to be minimally invasive and has FDA approval to be used to reduce symptoms associated with anxiety, depression, pain and insomnia. The unit is locked at the factory to deliver a maximal output of 4 mA of current and has a timer that prevents it from staying on longer than 20 minutes. Current will be limited to a maximum of 2 mA.
62517982|NCT03914235|EXPERIMENTAL|Tumescent anesthesia|A tumescent solution was prepared; consisting of 40 cc of 0.9% Saline Solution, 10 cc of 2% Lidocaine, 0.4 cc of Epinephrine (1: 1000) and 4 cc of 7.5% Sodium Bicarbonate. This solution was applied in the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc of tumescent solution was injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc of tumescent solution was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Subsequently, 20 minutes were waited for the epinephrine to cause vasoconstriction, and the asepsis of the limb was continued , sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
62517983|NCT03914235|ACTIVE_COMPARATOR|Local anesthesia with tourniquet.|"Lidocaine 1% was applied to the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc were injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Afterwards, a pneumatic tourniquet was placed at the level of the forearm at 250 mmHg after exsanguination with a bandage from Esmarch. The asepsis of the limb was continued, sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.~At the end of the surgical procedure, it was closed by planes, a soft bandage was placed, the tourniquet was removed and the patient was taken to recovery."
62517984|NCT03508687|EXPERIMENTAL|Group 1: 300 mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.
62517985|NCT03508687|EXPERIMENTAL|Group 2: 600mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.
62517986|NCT05329506||Supportive care patient population|Attitudes and Believes About Vaccinations, questionnaires
62517987|NCT00821002|EXPERIMENTAL|Plug placement|
62517988|NCT06181747|EXPERIMENTAL|ADHD group|Participants are required to engage in game training at home for 5 days per week, with each session lasting 20-25 minutes. The game is equipped with anti-addiction measures, limiting the maximum daily game time to 30 minutes. Participants will adjust their game training based on their own abilities, and as the training progresses, the game will adaptively adjust the difficulty level and change levels accordingly.
62517989|NCT06181747|EXPERIMENTAL|healthy control group|Participants are required to engage in game training at home for 5 days per week, with each session lasting 20-25 minutes. The game is equipped with anti-addiction measures, limiting the maximum daily game time to 30 minutes. Participants will adjust their game training based on their own abilities, and as the training progresses, the game will adaptively adjust the difficulty level and change levels accordingly.
62517990|NCT02549573|ACTIVE_COMPARATOR|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
62517991|NCT02549573|OTHER|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
62355494|NCT06446518|NO_INTERVENTION|Control group|"On admission, patients are asked to fill out a STAI-T and-S anxiety inventory. Attending investigator will take vital parameters upon admission.~Participants are asked to fill out a STAI-S test in the operating room, where physiologic data is collected and timing and dose of medication administered. After surgery, during emergence physiologic data is collected, and attending anesthesiologist fills out the PAED score.~Pain using an NRS scale, and vital parameters are monitored postoperative 1, 2, 3, 6, 12 hours (if patient is not sleeping) and in the morning following surgery at 6 and 9 am. A final STAI-S test is filled out by patients in the morning after surgery. Data regarding painkiller demand is collected after surgery."
62517992|NCT01727687|EXPERIMENTAL|Patients with Parkinson's disease|Using simulated traffic scene system to help patients with Parkinson's disease improve crossing road behaviors.
62517993|NCT02246868|EXPERIMENTAL|Optivate®|Optivate® (Human Coagulation Factor VIII)
62517994|NCT05457517|EXPERIMENTAL|YL-13027+Sintilimab|"YL-13027 tablets will be given daily for 21 days in 21-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the patient discontinues from the study treatment for other reasons.~Sindilizumab injection will be given 200mg every three weeks."
62517995|NCT03639974|ACTIVE_COMPARATOR|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
62710693|NCT01688297|EXPERIMENTAL|High Dose VXA-A1.1 Oral Vaccine|One dose of replication incompetent adenovirus given in an oral tablet dose. This dose was studied under protocol VXA02-003.
62710694|NCT02895217|EXPERIMENTAL|Cycling exercise in water|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
62710695|NCT02895217|EXPERIMENTAL|cycling exercise on dryland|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
62355495|NCT05955157|EXPERIMENTAL|Treatment Group|Receiving DC-CIK plus S1 maintenance treatment
62517996|NCT03639974|ACTIVE_COMPARATOR|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
62517997|NCT03639974|SHAM_COMPARATOR|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
62517998|NCT06302972|EXPERIMENTAL|IASTM and CCEP|"Instrument Assisted Soft Mobilization Technique; For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The CCEP will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
62517999|NCT06302972|ACTIVE_COMPARATOR|Comprehensive Corrective Exercise Program.Type|"The CCEP will be designed in three phases, including initial, improvement, and maintenance. Exercises are progressed in frequency and intensity during these phases, as long as the movements are performed in a good quality. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures. This goal was addressed in the improvement phase when necessary tissue adaptations occurred by increasing the load of exercises. In the maintenance phase, the participant continued to do the exercises and maintain the training adaptations for two weeks. The exercises will be the same as the improvement phase without any progression in intensity and frequency.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
62518000|NCT03507348|OTHER|Desensitization with Tocilizumab and rituximab (MFI >15000)|
62518001|NCT03507348|OTHER|Desensitization with Rituximab only (MFI<15000)|
62518002|NCT05982821||Training set|Patients with thyroid nodules underwent contrast-enhanced ultrasound and ultrasound-guided fine-needle aspiration during January 2018 and December 2020 in Sun Yat-sen Memorial Hospital Sun Yat-sen University.
62518003|NCT05982821||Internal test set|Patients with thyroid nodules underwent contrast-enhanced ultrasound and ultrasound-guided fine-needle aspiration during January 2021 and May 2023 in Sun Yat-sen Memorial Hospital Sun Yat-sen University.
62518004|NCT05982821||External test set|Patients with thyroid nodules underwent contrast-enhanced ultrasound and ultrasound-guided fine-needle aspiration during January 2022 and June 2023 in Houjie Hospital of Dongguan and Central People's Hospital of Zhanjiang.
62518005|NCT02459041||Pancreatic cancer|"Consecutively admitted patients with pancreatic cancer confirmed by EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
62518006|NCT02459041||Benign pancreatic masses|"Consecutively admitted patients with benign pancreatic masses with negative EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
62518007|NCT02459041||Malignant lymph nodes|"Consecutively admitted patients with malignant lymphnodes confirmed by EUS-guided FNA.~EG-EUS will be applied in all patients."
62518008|NCT02459041||Benign lymph nodes|"Consecutively admitted patients with benign lymphnodes with negative EUS-guided FNA.~EG-EUS will be applied in all patients."
62518009|NCT05338021|EXPERIMENTAL|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 20ml of normal saline was injected directly into the joint.
62518010|NCT05338021|EXPERIMENTAL|Intrawound Administration of Vancomycin combined with epsilon-aminocaproic acid (EACA)|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 4g (20ml) of epsilon-aminocaproic acid (EACA) was injected directly into the joint.
61974485|NCT02887521|ACTIVE_COMPARATOR|Standard of Care|Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
62148028|NCT02367794|EXPERIMENTAL|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
62355496|NCT05955157|ACTIVE_COMPARATOR|Control Group|Receiving S-1 maintenance treatment alone
62355497|NCT03549117|EXPERIMENTAL|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
62518011|NCT06493903|NO_INTERVENTION|Usual care|Participants in this group will not receive any intervention from the researchers. However, they will continue to receive their usual care from their healthcare providers.
62710696|NCT02672995|EXPERIMENTAL|Single arm dose-escalation|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5\~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5\~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.~Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
61974486|NCT05745350|EXPERIMENTAL|Treatment|
61974487|NCT01886040||cases with endometrial cancer|
61974488|NCT05529043|ACTIVE_COMPARATOR|MINISTOP app|Receives the MINISTOP app for 12-months.
61974489|NCT05529043|EXPERIMENTAL|MINISTOP Plus Program|Receives the MINISTOP app for 12-months and receives Community Group Mini.
62518012|NCT06493903|EXPERIMENTAL|Positive Minds Strong Joints|Participants in this group will receive an individual mental health intervention through a zoom video-call once a week for 10 weeks and a community-based group exercise intervention once a week for 10 weeks.
62518013|NCT05865977||the failure group|Re-intubation within 48 h after passing the SBT was defined as failed weaning.
62710697|NCT00730886|EXPERIMENTAL|1|Non-invasive procedure for fertility enhancement (i.e., ExAblate treatment)
62710698|NCT00730886|ACTIVE_COMPARATOR|2|Invasive surgical procedure for fertility enhancement (i.e., myomectomy)
61974490|NCT01577056|ACTIVE_COMPARATOR|Fish oil|
61974491|NCT01577056|PLACEBO_COMPARATOR|Placebo|FH subjects with standard treatment (statin treatment)
62518014|NCT05865977||the success group|Extubation and invasive mechanical ventilation was not needed within 48 h after extubation was defined as successful weaning.
62518015|NCT01487382||Insulin Aspart|
62518016|NCT01644136|EXPERIMENTAL|Supportive care (microsphere-mediated lymphocele prevention)|Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis.
62518017|NCT00988689|EXPERIMENTAL|Soup with no added starch|
62518018|NCT00988689|EXPERIMENTAL|Soup + 50 g of whole grain starch|
62518019|NCT00988689|EXPERIMENTAL|Soup + 50 g of high amylose corn starch|
62518020|NCT00988689|EXPERIMENTAL|Soup + 50 g of regular corn starch|
62518021|NCT00988689|EXPERIMENTAL|Soup + 50 g maltodextrin starch|
62518022|NCT04975321|ACTIVE_COMPARATOR|Nu Smile Zirconia crown|Anterior primary teeth which received a NuSmile zirconia crown as a final restoration
62518023|NCT04975321|ACTIVE_COMPARATOR|Nu Smile pre veneered crown|Anterior primary teeth which received a NuSmile pre veneered crown as a final restoration
61974492|NCT04498611|EXPERIMENTAL|breast DCIS patients|Breast DCIS patients who diagnosed by tissue biopsy except excisional biopsy before surgery, and who agreed to taking the breast MRI.
62148029|NCT02367794|ACTIVE_COMPARATOR|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
62518024|NCT04975321|ACTIVE_COMPARATOR|Composite strip crown|Anterior primary teeth which received a composite strip crown as a final restoration
62518025|NCT02760264|EXPERIMENTAL|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
62518026|NCT02760264|EXPERIMENTAL|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
62710699|NCT01526200||CEIOUS|One hundred and twenty-seven consecutive patients -77 males and 50 females, mean age of patients was 61 years (median 65 years; range 29-85 years)- underwent liver resection using intraoperative ultrasound and contrast-enhanced intraoperative ultrasound.
61974493|NCT01370174|ACTIVE_COMPARATOR|Induced Step Training (IST)|The IST group will receive waist-pulls in both the left and right lateral directions by a motorized pulling system to produce stepping.
61974494|NCT01370174|ACTIVE_COMPARATOR|Hip Strength Training (HST)|The HST group will have muscle strength training, to include hip abduction (AB) and adduction (AD) resistance exercises.
61974495|NCT01370174|ACTIVE_COMPARATOR|Combined Induced Step and Hip Strength Training|This training group consists of combined induced step training (IST) and hip AB-AD strength training (HST).
62518027|NCT02760264|EXPERIMENTAL|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
62518028|NCT02760264|EXPERIMENTAL|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
62518029|NCT06147726|ACTIVE_COMPARATOR|VR group|group to receive virtual reality supported upper extremity rehabilitation in addition to conventional physiotherapy
62710700|NCT04179617|EXPERIMENTAL|Preferred nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 5% nicotine content pod (their preferred pod)
62710701|NCT04179617|EXPERIMENTAL|Low nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 3% nicotine content pod (non-preferred pod)
61974496|NCT01370174|PLACEBO_COMPARATOR|Standard Flexibility and Relaxation (SFR)|The SFR group will perform a flexibility and relaxation program involving minimal-intensity exercises.
61974497|NCT00913003|PLACEBO_COMPARATOR|Placebo|Group B using saline as a placebo.
61974498|NCT00913003|ACTIVE_COMPARATOR|Lidocaine|Group A lidocaine infusion and bolus.
62148030|NCT04768569|ACTIVE_COMPARATOR|Zonisamide Pre-op + Placebo Post-op|For subjects randomized to zonisamide pre-op, the pre-op package will contain one zonisamide capsule (100 mg PO) and the post-op package will contain one placebo capsule that looks, smells, and tastes the same as zonisamide capsules.
62148031|NCT04768569|PLACEBO_COMPARATOR|Placebo Pre-op + Placebo Post-op|For the subjects randomized to placebo, both pre- and post-op packages will contain placebo capsules that looks, smells, and taste the same as zonisamide capsules.
62148032|NCT04768569|ACTIVE_COMPARATOR|Placebo Pre-op + Zonisamide Post-op|For subjects randomized to zonisamide post-op, the pre-op package will contain one placebo capsule and the post-op package will contain one zonisamide capsule (100 mg PO).
62518030|NCT06147726|ACTIVE_COMPARATOR|Control group|The group that will receive conventional physiotherapy for the total treatment time of the VR group
62518031|NCT01612416|SHAM_COMPARATOR|Normal subjects|
62518032|NCT01612416|ACTIVE_COMPARATOR|Primary open angle glaucoma|
62518033|NCT01612416|ACTIVE_COMPARATOR|Normal tension glaucoma|
62518034|NCT01570816|EXPERIMENTAL|Experimental|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures
62518035|NCT06236568|EXPERIMENTAL|Machine perfusion|The liver graft to be transplanted is treated with 90 minutes of D-HOPE machine perfusion
62518036|NCT06236568|ACTIVE_COMPARATOR|No machine perfusion|Standard liver transplantation
61974499|NCT02256228|ACTIVE_COMPARATOR|Group R|Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
62148033|NCT01720706|EXPERIMENTAL|Acute|The RFA Loosely wound thermal coil electrode will be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed group'. Energy will be delivered using the single timed heating cycle. Treatment will be monitored with B mode US. Once the cycle is completed, the probe will be removed and the planned surgery will continue with partial or radical nephrectomy.
62518037|NCT03878888|EXPERIMENTAL|Exparel use in TAP block|Exparel used in bilateral TAP block for open abdomen surgery
62518038|NCT03878888|NO_INTERVENTION|no TAP block|these patients, N=20, did not received a bilateral TAP block for postoperative pain control. Instead, pain control involves PO/IV pain medications
62518039|NCT04997395|EXPERIMENTAL|MediCabilis Cannabis sativa 50|"The medicinal cannabis used for this study is MediCabilis Cannabis sativa 50, a full spectrum CBD dominant plant based medicinal cannabis containing 50 mg/ml CBD and 2 mg/ml THC.~On commencing the oral medication, it will be titrated over a 2 week period to a dose of 1 ml twice a day (total dose 2 ml = 100 mg CBD and 4 mg THC). Participants will be given a written titration schedule at the initial clinic visit. There will be the potential for a further dose increase to a total dose of 3 ml per day (150 mg CBD and 6 mg THC) at the 1-month follow-up visit."
62518040|NCT05895721|NO_INTERVENTION|Control|Standard Of Care only
62518041|NCT05895721|OTHER|Intervention|Standard Of Care + VR Modules
62518042|NCT02030314|EXPERIMENTAL|chlorthalidone, resistant high blood pressure|if Furosemide dose is 40 mg per day, start Chlorthalidone 12.5 mg per day if Furosemide dose is 80 mg per day, start Chlorthalidone 25 mg per day
62518043|NCT02614313|ACTIVE_COMPARATOR|Fructose double-blind|Fructose during breath test, double-blind 35g
62518044|NCT02614313|ACTIVE_COMPARATOR|Fructose open|Fructose during breath test, open 35g
62518045|NCT02614313|PLACEBO_COMPARATOR|Sweet placebo double-blind|Assugrin during breath test double-blind
62518046|NCT02614313|PLACEBO_COMPARATOR|Neutral placebo double-blind|Water during breath test double-blind
61974500|NCT02256228|PLACEBO_COMPARATOR|Group P|Saline is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Saline would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
61974501|NCT01700725|EXPERIMENTAL|Nasal Irrigation - Saline|nasal irrigation using saline plus routine care for symptoms of CRS and fatigue
61974502|NCT01700725|EXPERIMENTAL|Nasal Irrigation - Xylitol|Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
61974503|NCT01700725|NO_INTERVENTION|Control Group|Control group subjects continue to use routine care only
61974504|NCT06087107|EXPERIMENTAL|High Intensity Spinal Decompression Exercises|Participants in this group will receive high intensity spinal decompression exercises
61974505|NCT06087107|ACTIVE_COMPARATOR|Eldoa|Participants in this group will receive Eldoa.
61974506|NCT01635192|ACTIVE_COMPARATOR|VSL#3|
62148034|NCT01720706|EXPERIMENTAL|Delayed|Using an electrically insulated 12ga introducer with trocar is inserted percutaneously into the renal tumor. The needle tip will be placed 20mm from the center of the target. The trocar is removed and co-axially (i.e. within the introducer), a core biopsy of the lesion is performed with a 14-18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode is then optimally positioned and locked into the introducer. On approximately day 6-10, a partial or radical nephrectomy will be performed in the usual way.
62518047|NCT03260075||ward cat|Patients and staff at wards that have a cat present
62518048|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
62518049|NCT01456091|EXPERIMENTAL|AIM 4 Teen Moms|
62518050|NCT01456091|NO_INTERVENTION|Control|
62518051|NCT02881164|EXPERIMENTAL|Low glycemic index breakfast|Low glycemic index breakfast (GI=45)
62518052|NCT02881164|ACTIVE_COMPARATOR|High glycemic index breakfast|High glycemic index breakfast (GI=80)
62518053|NCT05415020|ACTIVE_COMPARATOR|Virtual Therapy Group|
62518054|NCT05415020|SHAM_COMPARATOR|Attention Placebo Group|
62518055|NCT03465436|EXPERIMENTAL|100 milligrams (mg) Lasmiditan|A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
61974507|NCT01635192|PLACEBO_COMPARATOR|Inactive treatment|
62518056|NCT03465436|EXPERIMENTAL|400 mg Lasmiditan|A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
62518057|NCT03465436|PLACEBO_COMPARATOR|Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
62518058|NCT03465436|ACTIVE_COMPARATOR|Moxifloxacin|A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
62518059|NCT05116748||LuTx recipients|Lung Transplant recipients
62518060|NCT05116748||OLT recipients|Orthotopic Liver Transplant recipients
62518061|NCT01045915|EXPERIMENTAL|Plasmid AMEP electrotransfer|
62518062|NCT00680186|EXPERIMENTAL|Dabigatran etexilate (150mg bid)|Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
62518063|NCT00680186|ACTIVE_COMPARATOR|Warfarin (INR 2.0-3.0)|Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
62518064|NCT04631887|EXPERIMENTAL|Intervention Arm: Doing What Matters in Times of Stress: An Illustrated Guide|The intervention arm will receive the assigned intervention for five weeks. They will receive the intervention materials and will be called by psychologists three times (at the beginning, middle and end) during the intervention.
62710702|NCT01252680|EXPERIMENTAL|Group 1: Healive+Healive|75 subjects to receive two doses of Healive 6 months apart
62518065|NCT04631887|NO_INTERVENTION|Control Arm: Wait List|The control arm has no intervention. The participants in the control arm will receive the intervention after the post-assessments are completed.
62518066|NCT03331237|ACTIVE_COMPARATOR|LVS group|interscalene injection
62518067|NCT03331237|ACTIVE_COMPARATOR|ISO group|in this group all patients will receive ISO block.
62518068|NCT04209335|OTHER|healthy working age population|isometric core muscle endurance tests (McGill V-sit, Biering-Sorensen and sideplank)
62518069|NCT03648034|EXPERIMENTAL|ropivacaine|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.5% ropivacaine
62518070|NCT03648034|PLACEBO_COMPARATOR|saline|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.9% saline
62518071|NCT04375930|EXPERIMENTAL|Experimental|The patient will be trained with STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION. The patient will be follow up at 2nd, 6th and 12th weeks.
62518072|NCT04375930|ACTIVE_COMPARATOR|control|The patient will be trained only skills and discharge education. The patient will be follow up at 2nd, 6th and 12th weeks.
62518073|NCT04831086|EXPERIMENTAL|Intervention|"In the intervention arm, the management will be optimized according to the risk of the predictive model. The predictive model of intra-amniotic infection includes maternal C-reactive protein (CRP) (in mg/L) and amniotic fluid glucose (in mg/dL), and the predictive model of spontaneous preterm delivery within 7 days includes gestational age (in weeks), cervical length (in mm), amniotic fluid glucose (in mg/dL) and Interleukin (IL)-6 (in a log10 scale). High risk will be defined when the risk is \> 10% in the predictive model of spontaneous delivery in 7 days and \> 20% in the predictive model of intra-amniotic infection:~1. If low-risk: we will optimize the standard management reducing the dose of steroids (e.g not administering second doses), tocolysis duration and facilitating discharge home.~2. If high-risk: we will follow the standard management of each center and we will treat with antibiotics"
62518074|NCT04831086|NO_INTERVENTION|Control|In the control arm the standard management of each center will be followed regarding doses of steroids, duration of tocolysis or maternal stay length duration.
62518075|NCT01056640|EXPERIMENTAL|Home Telemonitoring|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line. This device has video monitoring which allows a real time face to face interaction with the provider. This allows for an individualized home care plan based upon multiple concerns which have not been adequately studied.
62518076|NCT01056640|ACTIVE_COMPARATOR|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required. It also includes home health care, timely post-hospital outpatient visits, a nurse generated phone call progress report within one business day of hospital dismissal, and standard clinic phone triage during business hours. It also involves a 24 hour nurse triage line for questions. Patients will be informed of the general options currently available to patients including the above as well as options for care in extended hours and at Mayo Express care.
62518077|NCT05195866|ACTIVE_COMPARATOR|Group A - CRP POCT|Participants assigned to Group A will take C-reactive protein (CRP) point of care test (POCT) during a check-up with their healthcare worker (HCW). The assistant investigator will attend the child's consultation with the local HCW and complete the case report form (CRF). Consequently, the CRP result will be recorded in the CRF, which will be the basis for choosing a treatment, depending on its result.
62518078|NCT05195866|NO_INTERVENTION|Group B - Usual care|HCWs will also consult children who have been randomised to Group B. The assistant investigator will complete the CRF for these children, but the CRP POCT will not test them. They will receive the treatment prescribed by the HCW as usual care
62518079|NCT04305379|EXPERIMENTAL|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction (Sling + Intussusception)
62518080|NCT04305379|ACTIVE_COMPARATOR|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction (Intussusception Only)
62518081|NCT01334710|EXPERIMENTAL|Sorafenib and OSI-906|This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients.
62518082|NCT01812135|EXPERIMENTAL|Group 1: 400U EV71 vaccine without adjuvant|60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
62518083|NCT01812135|EXPERIMENTAL|Group 2: 400U EV71 vaccine without adjuvant|60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
62518084|NCT01812135|EXPERIMENTAL|Group 3: 400U EV71 vaccine with adjuvant|60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
62518085|NCT02612220|EXPERIMENTAL|Experimental Group|Complete hemostasis will be achieved using BioFoam® Surgical Matrix
62518086|NCT02612220|ACTIVE_COMPARATOR|Control Group|Complete hemostasis will be achieved without the use of topical agents, using conservative hemostasis
62518087|NCT03898102|EXPERIMENTAL|Regorafenib treatment with Zn supplement|Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
62518088|NCT03898102|ACTIVE_COMPARATOR|Regorafenib treatment only|Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.
62518089|NCT03359824|OTHER|Exercise|Arm: Exercise: Combination of moderate intensity continuous training, high intensity interval training and endurance training 5 times per week for a total of 6 weeks. Out of 5 sessions three were supervised by trainer and two sessions were performed by subjects on their own.The duration of the exercise was increased progressively. The first two weeks was 30 minutes that increased to 45 minutes in the third and fourth week. It was 60 minutes for the last two weeks.
62148035|NCT00082966|EXPERIMENTAL|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
62518090|NCT05819671||Groupe(A)|Group (A)diabetics - g
62518091|NCT05819671||group(B)|group B normal is a normal control(non-diabetics)
62148036|NCT01903902|EXPERIMENTAL|Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter \> 2.25 mm and ≤ 2.75 mm)
62518092|NCT02655159||Abraxane® treatment in patients with metastatic breast cancer|Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.
62518093|NCT04086771|EXPERIMENTAL|Intervention Group (Navigation)|Participants will be contacted by CHAs by phone one week after giving informed consent and completion of the baseline survey. CHAs will contact participants once a week for up to 10 weeks (a maximum of 10 attempts or until a clinic appointment is made, whichever comes first). Using the TIMS© message library, the CHAs will engage participants in conversations about breast and cervical cancer screening and navigate the participants to overcome any barriers to screening and motivate them to make a clinic appointment. Personal messages from mothers to daughters and vice versa and screening reminder notecards will be sent at 12-months (T3). At 18-months (T4), CHAs will follow-up with navigation group participants who reported completing a mammogram during the navigation process. Screening completion will be measured by self-report and confirmed via medical record check.
62518094|NCT04086771|PLACEBO_COMPARATOR|Control Group (Information only)|Participants will be mailed an informational brochure on mammography and Pap testing one week after enrollment into the study. At 3-months post enrollment, CHAs will conduct a follow-up phone call with each participant to assess mammogram and/or Pap testing completion (primary outcomes). At 12-months (T3) post enrollment, CHAs will contact all control group participants by phone to confirm a scheduled appointment or screening completion. For those who completed a mammogram within the 12 months since enrollment, generic screening reminder notecards will be sent by mail. At 18-months (T4), CHAs will follow-up with those control group participants who reported scheduling a mammogram, Pap smear, or both at the 12-month (T3) time point.
62518095|NCT02572349|EXPERIMENTAL|IW-1701|Single Dose
62518096|NCT02572349|PLACEBO_COMPARATOR|Matching Placebo for IW-1701|Single Dose
62518097|NCT03165955|EXPERIMENTAL|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
62148037|NCT05972252|EXPERIMENTAL|Experimental Group|Patients with acute ischemic stroke will receive interventional procedure by the Cerebrovascular Interventional Procedural Control System.
62518098|NCT01778153|EXPERIMENTAL|Equinox Personal Coaching|Participants assigned the Coached group will receive up to 36 sessions about three times a week, consisting of both strength and aerobic exercises, through a program designed by Equinox Fitness Centers.
62518099|NCT01778153|NO_INTERVENTION|Self-directed exercise training|Participants in the Self-directed group will receive general exercise training advice as any member of the fitness club would, and will record the details of their exercise in log sheets. They will be asked to continue their usual exercise routine.
62518100|NCT02783430|EXPERIMENTAL|Milnacipran + Ketamine|Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
62518101|NCT02783430|ACTIVE_COMPARATOR|Milnacipran + Placebo|Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
62518102|NCT01918631|ACTIVE_COMPARATOR|Entecavir|Entecavir 0.5mg QD for 48 weeks
62518103|NCT01918631|ACTIVE_COMPARATOR|tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300mg QD for 48 weeks
62518104|NCT02164734|ACTIVE_COMPARATOR|Endotracheal intubation|Endotracheal intubation for surfactant administration, following remifentanil and atropine pre-medication
62518105|NCT02164734|EXPERIMENTAL|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
62518106|NCT04147988|OTHER|DONALD T list|adults on the DONALD T list seeking diagnostic advice on autism spectrum disorder or asperger's syndrome
62518107|NCT03153618|EXPERIMENTAL|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
62518108|NCT03153618|NO_INTERVENTION|Control|Current standard of care will be followed
62518109|NCT01064531||MIS Femoral Neck Stem|Subject will be randomized to either MIS or Synergy implant.
62518110|NCT01064531||Synergy Hip System|Subject will be randomized to either Synergy or MIS implant.
62518111|NCT03766490|EXPERIMENTAL|Anlotinib Hydrochloride plus gefitinib or icotinib|
62518112|NCT03662906|EXPERIMENTAL|Electroacupuncture|Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.30 mm in diameter, 75 mm in length or 0.40 mm diameter, 100 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
62518113|NCT03662906|SHAM_COMPARATOR|Sham electroacupuncture|Sham Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.20 mm in diameter, 25 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
62710703|NCT01252680|EXPERIMENTAL|Group 2: Healive+Havrix|75 subjects to receive one dose of Healive and another dose of Havrix 6 months apart
62710704|NCT01252680|EXPERIMENTAL|Group 3: Havrix+Havrix|75 subjects to receive two doses of Havrix 6 months apart
62355498|NCT03549117|PLACEBO_COMPARATOR|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH nasal strips placebo nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
62710705|NCT01252680|EXPERIMENTAL|Group 4: Havrix+Healive|75 subjects to receive one dose of Havrix and another dose of Healive 6 months apart
62710706|NCT05442645||Participants with AD|Male or female, 18 years or older at the baseline visit initiated treatment with dupilumab for AD, who are eligible for dupilumab reimbursement according to the country-specific prescribing information
62148038|NCT00655499|EXPERIMENTAL|Panitumumab + CPT11 (irinotecan hydrochloride)|1 cycle every 14 days (J1= J15)
62355499|NCT00971633|EXPERIMENTAL|1|Treatment Sequence A-B-C
62355500|NCT00971633|EXPERIMENTAL|2|Treatment Sequence B-C-A
62355501|NCT00971633|EXPERIMENTAL|3|Treatment Sequence C-A-B
62355502|NCT00971633|EXPERIMENTAL|4|Treatment Sequence A-C-B
62355503|NCT00971633|EXPERIMENTAL|5|Treatment Sequence B-A-C
62355504|NCT00971633|EXPERIMENTAL|6|Treatment Sequence C-B-A
62518114|NCT01996384|EXPERIMENTAL|Classical Acupuncture + Lidocaine|Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
62518115|NCT01996384|ACTIVE_COMPARATOR|Non-classical acupuncture + lidocaine|Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
62518116|NCT00190242|EXPERIMENTAL|group1:3 administrations of Havrix|group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24
62518117|NCT00190242|ACTIVE_COMPARATOR|group2: 2 administrations of Havrix|group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24
62148039|NCT02504762|EXPERIMENTAL|Treatment: HCR|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
62518118|NCT04689100|EXPERIMENTAL|Dose Escalation Cohort|"Monotherapy: Six dose levels of JMT101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of JMT101 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
62518119|NCT04689100|EXPERIMENTAL|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
62518120|NCT02307214|OTHER|Coronary X syndrome|BaroReflex Sensitivity, endothelial function measurement
62518121|NCT02307214|OTHER|Tako-tsubo cardiomyopathy|BaroReflex Sensitivity, endothelial function measurement
62518122|NCT02307214|OTHER|Healty Volunteers|BaroReflex Sensitivity, endothelial function measurement
62518123|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
62518124|NCT03201679||Patients without preoperative sepsis|
62518125|NCT05223491|EXPERIMENTAL|En Bloc|The bladder tumour will be resected en bloc and removed in total, if possible.
62518126|NCT05223491|ACTIVE_COMPARATOR|Conventional TURB|The bladder tumour will be removed by conventional piecemeal resection.
62518127|NCT05042934|EXPERIMENTAL|Treatment (lurbinectedin, fine-needle aspiration, irinotecan)|Patients receive lurbinectedin IV over 60 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo fine-needle aspiration on days 2-6 of cycle 1. Beginning in cycle 2, if the biopsy shows suppression of NR0B1, then patients receive irinotecan IV over 1 hour on the day of maximum NR0B1 suppression on cycle 2. If the duration of NR0B1 suppression from lurbinectedin alone exceeds 48 hours, or if the duration of NR0B1 suppression from lurbinectedin and irinotecan exceeds 48 hours and is longer than that seen with lurbinectedin alone, then patients may receive a second dose of irinotecan during the extended period of NR0B1 suppression.
62518128|NCT00926016|ACTIVE_COMPARATOR|pioglitazone|Treatment with pioglitazone 45 mg a day for 3 months
62710707|NCT02235324|EXPERIMENTAL|Treatment (ziv-aflibercept, leucovorin calcium, fluorouracil)|"PHASE I:~Patients receive ziv-aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients proceed to Phase II.~PHASE II:~Patients receive ziv-aflibercept IV over 1 hour, leucovorin calcium IV over 1 minute, and fluorouracil IV over 46 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
61974508|NCT02678845|EXPERIMENTAL|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
61974509|NCT02678845|NO_INTERVENTION|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
61974510|NCT01898611|ACTIVE_COMPARATOR|Ghrelin plus resistance training|Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
62518129|NCT00926016|NO_INTERVENTION|No intervention|Monitoring period without pioglitazone for 3 months
62518130|NCT01473121||Group 1|
62518131|NCT02046525|EXPERIMENTAL|Auto fecal microbitoa therapy|autologous fecal microbiota therapy
62518132|NCT02046525|PLACEBO_COMPARATOR|Saline enema|Saline enema
62518133|NCT00493246|EXPERIMENTAL|Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)|Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
62518134|NCT00493246|EXPERIMENTAL|Intravenous (IV) Acetaminophen 12.5 (mg/kg)|Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
61974511|NCT01898611|PLACEBO_COMPARATOR|Placebo plus resistance training|Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
61974512|NCT04997993|EXPERIMENTAL|Leflunomide|Leflunomide, 20-50mg PO daily
62148040|NCT02504762|ACTIVE_COMPARATOR|Control: Conventional CABG|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
62148041|NCT01402804||Stable CAD, ASA, NSAID|
62148042|NCT01402804||Stable CAD, ASA|
62148043|NCT04847180|EXPERIMENTAL|Instability shoulder group|Patients operated for an antero-inferior shoulder instability
62148044|NCT04847180|OTHER|Non instability shoulder group|Patients without shoulder instability, operated for another reason.
62518135|NCT01045031||Controls|"Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper (Krone) and one in an Austrian bicyclist journal (Bicyclist Sports). The controls were matched according to age, sex and years of education"
62518136|NCT01045031||marathon athletes|Runners participating in the 2008 Wachau half marathon (21,2 km) and the Vienna City marathon (42,5 km) as well as bicyclists participating at the Corinthian marathon (180km). Inclusion criteria:1) participation in at least one of these 3 marathons in the preceding two years,2)still in continuous training during the recruitment phase (at least 2 hours/week), 3) aged over 60. Exclusion criteria:(a) present or past exposure to neurotoxic substances (b) if they did not speak German as their native language (c) diseases that markedly affect CNS functions (d) manifest cardiovascular disease, (e) chronic alcoholism (daily alcohol intake \> 60 g or diagnosed history of alcoholism) and (f) unwillingness to give informed consent.
62518137|NCT00571194|OTHER|peritoneal dialysis (CCPD)|PK profile of pravastatin
62518138|NCT05221424|EXPERIMENTAL|Active Comparator|"MARS, PAIS-SR and Patient Information Form, containing data about the patient and the disease were applied to each patient in the experimental group during pretest. Then, the individual training was given to each patient by giving the Hypertension Training Booklet prepared in line with the Roy Adaptation Model. The training period lasted for averagely 45-50 minutes for each patient. After the training, the patients were called by phone at least once a week, every week for four weeks and reminder information was obtained and their follow-ups were made. One month after the training, post-test data were applied to the patients. In the posttest phase; MARS, PAIS-SR and the questions containing lifestyle changes were repeated and their follow-ups were then terminated."
62518139|NCT05221424|NO_INTERVENTION|No Intervention|• MARS, PAIS-SR and Patient Information Form containing data about the patient and the disease were applied to each patient in the control group in the pretest. Without giving any training to the patients in the control group, only the patients were called at least once a week, every week for four weeks and their health status was examined. One month after the collection of initial data, posttest data were applied to the patients. In the posttest phase; MARS, PAIS-SR and the questions containing lifestyle changes were repeated and then their follow-ups were terminated. After the follow-up, the training prepared in line with Roy Adaptation Model was applied to the voluntary patients and the training booklet was given to them.
62518140|NCT05106543|EXPERIMENTAL|kinesiologic tape|"first group of 20 people (experimental group) T max branded kinesiology tape was applied to both M. Quadriceps Femoris and M. Gastrocnemius muscles of the experimental group.~Timed get up and go test was applied to evaluate functionality. All evaluations were applied before taping, immediately after taping and 45 minutes after taping. Patients in both groups were asked not to have their tapes removed until the 4th day. Apart from routine physical therapy methods and taping, no other treatment was applied to the patients."
62518141|NCT05106543|PLACEBO_COMPARATOR|patch tape|"second group of 20 people (control group) Roll branded patch tape was applied to both M. Quadriceps Femoris and M. Gastrocnemius muscles of the control group.~Timed get up and go test was applied to evaluate functionality. All evaluations were applied to both groups before taping, immediately after taping and 45 minutes after taping. Patients in both groups were asked not to have their tapes removed until the 4th day. Apart from routine physical therapy methods and taping, no other treatment was applied to the patients."
62518142|NCT03643679|EXPERIMENTAL|Kwit smartphone app|This arm will receive the Kwit smartphone app.
62518143|NCT05023577|EXPERIMENTAL|CL group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levoflaxacin 0.5 g qd for 14 days
62518144|NCT05023577|EXPERIMENTAL|LM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levoflaxacin 0.5 g bid for 14 days
62518145|NCT05023577|ACTIVE_COMPARATOR|CM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
62148045|NCT01337752|EXPERIMENTAL|BHQ880 + bortezomib and dexamethasone|
62518146|NCT05955495|ACTIVE_COMPARATOR|Delayed feeding|
62518147|NCT05955495|EXPERIMENTAL|Early feeding|
62518148|NCT05907330|EXPERIMENTAL|CU104|CU104 100 mg three capsules a day .
62518149|NCT05907330|PLACEBO_COMPARATOR|Placebo|Placebo three capsules a day.
62518150|NCT06126965|EXPERIMENTAL|KX-826-0.5% BID|treatment dose group of 0.5% BID(0.5%)
62518151|NCT06126965|PLACEBO_COMPARATOR|Placebo|Placebo
62518152|NCT05964790|EXPERIMENTAL|HS-10380|Participants received HS-10380 tablet orally once daily for 28 days.
62518153|NCT05964790|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablet matching HS-10380 1.5mg tablet orally once daily for 28 days.
62518154|NCT02282995||•FDR-Relatives of FD patients|"Relatives of FD patients. Patients may bring at most two FDRs to participate in this study.~* Up to 20 ml of fasting blood sample will be collected~* Serology test of Hp status will be performed for healthy volunteers and all FDRs"
61974513|NCT04202692|EXPERIMENTAL|GERDOff Plus|Hyaluronic acid + chondroitin sulphate + magnesium trisilicate melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
62148046|NCT01337752|PLACEBO_COMPARATOR|BHQ880 Placebo + bortezomib and dexamethasone|
62148047|NCT05492513|EXPERIMENTAL|Grade 1 CI Therapy + Sensory Components|All participants will receive the Grade 1 CI Therapy + Sensory Components administered over a two-week period of time.
62148048|NCT06035354|EXPERIMENTAL|AK120 150 mg in phase Ib|subcutaneous injection once a week for 4 weeks.
62148049|NCT06035354|EXPERIMENTAL|AK120 300mg in phase Ib|subcutaneous injection once a week for 4 weeks.
62148050|NCT06035354|PLACEBO_COMPARATOR|Placebo Comparator: Placebo in phase Ib|subcutaneous injection once a week for 4 weeks.
62148051|NCT06035354|EXPERIMENTAL|AK120 150mg in phase II|subcutaneous injection every 2 weeks for 50 weeks.
62518155|NCT02282995||•FDC-Healthy control|"Healthy control. Controls who are self-referred to this study will be recruited.~* Up to 20 ml of fasting blood sample will be collected~* Fasting glucose test will be performed for FD patients~* Serology test of Hp status will be performed for healthy volunteers and all FDRs"
62518156|NCT02282995||•FD-Patients with FD|"Patients with FD. Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms suggestive of FGID will be invited to participate in this study.~* Up to 20 ml of fasting blood sample will be collected~* Fasting glucose test will be performed for FD patients"
62518157|NCT02282995||•FDCR-Relatives of healthy controls|"Relatives of healthy controls. Each participating control is required to bring at least one and up to two FDRs to participate in this study.~* Up to 20 ml of fasting blood sample will be collected~* Serology test of Hp status will be performed for healthy volunteers and all FDRs"
62518158|NCT02593227|EXPERIMENTAL|Low dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
62518159|NCT02593227|EXPERIMENTAL|High dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
62518160|NCT02593227|EXPERIMENTAL|Low dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
62518161|NCT02593227|EXPERIMENTAL|High dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
62518162|NCT01431352|EXPERIMENTAL|Letrozole+ Chinese herbal medicine granules|
62518163|NCT01431352|PLACEBO_COMPARATOR|Letrozole+ Chinese herbal medicine granules placebo|
62518164|NCT02513836|EXPERIMENTAL|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
62518165|NCT02513836|OTHER|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. They will repeat the questionnaire (POEM) after this education on opioid knowledge on the same day.
61974514|NCT04202692|PLACEBO_COMPARATOR|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period, patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
61974515|NCT01392976|EXPERIMENTAL|CO-1.01 Formulation B|
61974516|NCT01392976|ACTIVE_COMPARATOR|CO-1.01 Formulation A|
62710708|NCT05792748|ACTIVE_COMPARATOR|ZOE group|Pulp hemostasis achieved by a dry cotton pellet applied on the pulp, then the chamber was filled with reinforced zinc oxide eugenol (ZOE) directly over the pulp.
61974517|NCT04350840|EXPERIMENTAL|Feedback|Participating endoscopists will make high confidence diagnosis according to their judgment time
61974518|NCT00829946|EXPERIMENTAL|2|
61974519|NCT02192814|EXPERIMENTAL|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
61974520|NCT05701150||MIN Data Set|Patients who did not receive a targeted therapy based on NGS results (outside of a clinical trial)
61974521|NCT05701150||EXT Data Set|Patients who received a targeted therapy based on NGS results (outside of a clinical trial)
61974522|NCT02242409|EXPERIMENTAL|Gemcitabine/abraxane|Gemcitabine and Abraxane
62148052|NCT06035354|EXPERIMENTAL|AK120 300mg in phase II|subcutaneous injection every 2 weeks for 50 weeks.
62148053|NCT06035354|EXPERIMENTAL|AK120 450mg in phase II|subcutaneous injection every 2 weeks for 50 weeks.
62148054|NCT06035354|PLACEBO_COMPARATOR|Placebo Comparator: Placebo in phase II|subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 4 and Regimen 5, subcutaneous injection at week 16, after primary endpoint evaluation.
62148055|NCT06035354|EXPERIMENTAL|AK120 150mg in phase II extension|subcutaneous injection every 2 weeks for 14 weeks.
61974523|NCT01223989|EXPERIMENTAL|group bread|group who received an hypocaloric balanced diet including bread
61974524|NCT01223989|ACTIVE_COMPARATOR|group without bread|group who received a hypocaloric balanced diet with exclusion of bread
62148056|NCT06035354|EXPERIMENTAL|AK120 300mg in phase II extension|subcutaneous injection every 2 weeks for 14 weeks.
62148057|NCT06035354|EXPERIMENTAL|AK120 450mg in phase II extension|subcutaneous injection every 2 weeks for 14 weeks.
62148058|NCT00610961||Basiliximab (Simulect) Induction|Prospective group: patients are scheduled to receive a kidney transplant; and will receive Simulect®, Myfortic® and Prograf® with or without steroids according to routine care (Standard of Care).
61974525|NCT01551082||Outpatient chest tubes|All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device.
62148059|NCT00610961||Thymoglobulin Induction|Retrospective (historical or control) group: patients have already received a kidney transplant and were treated with Thymoglobulin®, Myfortic®, and Prograf® with or without steroids. This treatment was Standard of Care at a time of transplant.
62518166|NCT02987803|NO_INTERVENTION|Control Group|Participants in the control group will receive educational articles about obstetric hospitals. The articles will prompt the participant to look up hospitals in their geographic location. Participants will not know they are participating in a trial.
62518167|NCT02987803|EXPERIMENTAL|Data Group|"Participants in the intervention group will receive an educational module designed to support them in selecting a delivering hospital, which will include an educational video, articles, and a data tool with cesarean delivery rate data for hospitals in their geographic location.~Participants will not know they are participating in a trial."
62710709|NCT05792748|ACTIVE_COMPARATOR|FS group|Pulp hemostasis achieved by a wet cotton pellet impregnated with ferric sulphate (FS) applied on the pulp, then the chamber was filled with (ZOE) directly over the pulp.
61974526|NCT05205746|EXPERIMENTAL|Intramuscular|10 8.0 EID 50/dose intramuscular
62518168|NCT04293549||rhNGF group|Therapeutic contact lens use was discontinued during the duration of the study. Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment. Changes in the corneal epithelium and stroma were evaluated by slit lamp biomicroscopy and photo documentation of the cornea after fluorescein staining.
62518169|NCT04293549||control comparator group|control comparator group was matched for age and gender and underwent assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline.
62518170|NCT05998551|ACTIVE_COMPARATOR|Dexmedetomidine Group|participants will receive intrathecal injection of 5mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml contain 5μg dexmedetomidine(0.05ml dexmedetomidine in insulin syringe+ 0.95ml normal saline).
62518171|NCT05998551|ACTIVE_COMPARATOR|Fentanyl group|participants will receive intrathecal injection of 5 mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml contain 12.5μg fentanyl(0.25ml fentanyl in insulin syringe+ 0.75ml normal saline).
62518172|NCT05998551|ACTIVE_COMPARATOR|Control group|participants will receive intrathecal injection of 5mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml normal saline
62518173|NCT03521648||PAE|Men with BPH - LUTS BPE who have opted for PAE and have consented to take part in the Register Study.
62518174|NCT03521648||TURP|Men with BPH - LUTS BPE who have opted for TURP and have consented to take part in the Register Study.
62518175|NCT03521648||Other|Men with BPH - LUTS BPE who have opted for other treatment options (e.g., holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate) and have consented to take part in the Register Study.
62518176|NCT00986570|EXPERIMENTAL|Xeomin®|Botulinum Toxin A
62518177|NCT01452048||Obese Sedentary Adults, but otherwise healthy|
62518178|NCT03384017|EXPERIMENTAL|TSCS and gait training|
62518179|NCT03290287||New users of aclidinium bromide|This nested cohort will be composed of patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of aclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and aclidinium/formoterol)
62518180|NCT03290287||New users of other COPD medication|This nested cohort will include patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of other COPD medication: tiotropium, other LAMAs, LABA, LABA/ICS and LAMA/LABA.
62518181|NCT05491239|ACTIVE_COMPARATOR|Thoracic epidural analgesia|See intervention description
62518182|NCT05491239|EXPERIMENTAL|Continuous regional paravertebral block|See intervention description
62518183|NCT05491239|EXPERIMENTAL|Single shot intercostal nerve block|See intervention description
62518184|NCT05037786|ACTIVE_COMPARATOR|Powerpoint group|In the control group, there will be a face-to-face intervention of 15 minutes of education on pain explained by Verbal form with supporting Powerpoint presentation. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
62518185|NCT05037786|EXPERIMENTAL|Infographic group|In the intervention group, the same pain education will be carried out, explained verbally but with the support of an infographic instead of a Powerpoint. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
62518186|NCT03938129||Group 1|Pregnant women and their baby
62518187|NCT00769626|EXPERIMENTAL|Early Treatment|
62710710|NCT00048984||Basic science (biomarker analysis)|Patients undergo various specimen collections, including bone marrow aspirate, paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens. These specimens are collected before, during, and after any chemotherapy regimens, during follow-up, and at time of recurrence. Translocation studies are performed on specimens to identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined. Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase chain reaction.
62518188|NCT00769626|ACTIVE_COMPARATOR|Usual Care|
62518189|NCT06146439||Successful|Patients who do not need advanced respiratory support treatments (invasive and noninvasive mechanical ventilation)
62518190|NCT06146439||Failure|Patients who need advanced respiratory support treatments (invasive and noninvasive mechanical ventilation)
62518191|NCT05962450|EXPERIMENTAL|RPI group|Regorafenib + PD-1 + iNKT cells
62518192|NCT05962450|OTHER|RP group|Regorafenib + PD-1
62518193|NCT00567736|ACTIVE_COMPARATOR|1|Disci/Rhus toxicodendron comp.®
62518194|NCT00567736|PLACEBO_COMPARATOR|2|placebo solution
62518195|NCT00567736|NO_INTERVENTION|3|waiting list group
62518196|NCT02448849|EXPERIMENTAL|MSC recipients|The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.
61974527|NCT05205746|EXPERIMENTAL|Intranasal|10 8.0 EID 50/dose intranasal
62148060|NCT04705389|OTHER|Case group|Intervention only includes additional blood sampling at baseline and during follow up (5 samplings).
62518197|NCT02448849|PLACEBO_COMPARATOR|Placebo|The patients with nonunion fracture who underwent percutaneous injection of placebo.
62518198|NCT02582372|EXPERIMENTAL|dexmedetomidine|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge
62518199|NCT02582372|ACTIVE_COMPARATOR|fentanyl|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge
62518200|NCT01978210|EXPERIMENTAL|Wireless Moisture Pager|Parent(s) of subjects will participate in training and follow-up sessions in a manualized toilet training intervention for their child that incorporates use of a wireless moisture pager.
62710711|NCT02081586|EXPERIMENTAL|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
62518201|NCT01978210|ACTIVE_COMPARATOR|Standard Behavioral Treatment|Parent(s) of subjects will participate in training and follow-up sessions in a toilet training intervention for their child that incorporates use of the Autism Treatment Network's Toilet Training Tool Kit. The Tool Kit is a publication widely available to parents and clinicians that is designed to serve as an aid in the toilet training of children with autism. In this study, it is being used as a standard treatment control.
62518202|NCT02970435|EXPERIMENTAL|Video Discharge Instructions|These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
62518203|NCT02970435|ACTIVE_COMPARATOR|Verbal and Written Discharge Instructions|Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery
62518204|NCT05020249|EXPERIMENTAL|Bimekizumab arm|Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
62518205|NCT05020249|PLACEBO_COMPARATOR|Placebo arm|Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.
62518206|NCT01083017||chlorthalidone|
62518207|NCT01083017||motivational invervention|motivational interview(s) vs. repeated calls vs. no particular intervention
62518208|NCT01083017||standardized anti-hypertensive treatment|
62518209|NCT04877171|EXPERIMENTAL|telemedicine neurology consultation|Starting on day 12-14 post-discharge, participants will receive a phone call for a drug conciliation. Participants at 1-month post-discharge will receive a telemedicine consultation, another at 3 months and 6 months.
62518210|NCT04877171|ACTIVE_COMPARATOR|in-person neurology consultation|Starting at 1-month post-discharge, participants will attend an in-person neurology consultation and the following consultations depend on their physician's criteria until completed 6 months post-discharge.
62518211|NCT03265067|NO_INTERVENTION|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
62518212|NCT03265067|EXPERIMENTAL|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
62518213|NCT00845975|ACTIVE_COMPARATOR|Erchonia Hearing Lasers #1 & #2|"Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light."
62518214|NCT00845975|PLACEBO_COMPARATOR|Placebo Lasers|Inactive lasers that do not emit any therapeutic light.
62518215|NCT06026852|OTHER|Patients|Patients admitted to the ICU who are treated with piperacillin-tazobactam or meropenem.
62518216|NCT06026852|OTHER|Physicians|Physicians in training or consultants who care for patients that are included in the study.
62518217|NCT03142516|EXPERIMENTAL|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~* Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~* FOLFIRI~* Irinotecan: 150 mg/m2 as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle.~* Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~* 5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
62518218|NCT05495113|SHAM_COMPARATOR|Sham Stimulation|Sham Stimulation
62518219|NCT05495113|EXPERIMENTAL|Real Stimulation (Active)|transcranial Direct Current Stimulation (tDCS) application 5 \~7 days a week for 26 weeks
62518220|NCT02848066||Gastric Cancer patients|This arm is composed of the gastric cancer patients. It is perfomed a blood sampling to them after the research registration.
62518221|NCT02848066||Cancer-free healthy volunteers|This arm is composed of the cancer-free healthy volunteers. It is perfomed a blood sampling to them after the research registration.
62518222|NCT04851431|EXPERIMENTAL|One-to-One Peer Mentoring|Caregiver will be matched based on characteristics such as age, date of patient injury, level of patient injury, cause of patient injury, marital status, work status before and after patient injury, interests, and leisure activities. After participant is matched with a peer mentor, they will be required to have at least one weekly one-to-one interaction from time of match until 30 days post- discharge.
61974528|NCT05205746|OTHER|Intramuscular Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intramuscular After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
62518223|NCT04851431|ACTIVE_COMPARATOR|Usual Care|Participants received the usual discharge planning and family support services offered by the ABI program. These services include nurse instruction in care routines, case management support for discharge, peer support services, referral to family counseling and community services as indicated, and general information resources about brain injury. Participants in both the intervention and usual care groups also had access to the online peer support community created for ABI caregivers (facebook.com/shepherdbi.peers). In addition, usual care participants could request one-to-one visits with peer mentors and, indeed, most usual care participants received at least one peer mentoring visit.
62518224|NCT01492972|ACTIVE_COMPARATOR|Radiation Alone|Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
61974529|NCT05205746|OTHER|Intranasal Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intranasal After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
61974530|NCT02552563|NO_INTERVENTION|Usual Care|Standard care received by veterans in the Corporal Michael J. Crescenz VA Medical Center
62518225|NCT01492972|EXPERIMENTAL|Radiation + Androgen Suppression|Androgen Suppression Therapy x 6 months + Radiation
61974531|NCT02552563|ACTIVE_COMPARATOR|Dementia Care Management|CG education, continuous support, communication and coping skills training, and veteran monitoring, via CG report, of medication, symptoms, and service needs.
62148061|NCT04402476|EXPERIMENTAL|Device and Control|"Device:~Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, Tested for use with Chemotherapy Drugs.~Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive Control:~0.4% Sodium Lauryl Sulfate (SLS) Dose. 0.2 ml"
62148062|NCT02309294|EXPERIMENTAL|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
62148063|NCT03055988|EXPERIMENTAL|Tiotropium/Olodaterol Fixed Dose Combination|
62148064|NCT03055988|ACTIVE_COMPARATOR|Fluticasone Propionate + Salmeterol Fixed Dose Combination|
62148065|NCT05667441|ACTIVE_COMPARATOR|Standard recommendations|The first group (n=50) will receive standard care recommendations (according to Netherlands Scientific Society of Ophthalmology 2014, 'Richtlijn Leeftijdsgebonden Maculadegeneratie;): refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish; and recommendations for supplementation with antioxidants according an established formula.
62710712|NCT02081586|EXPERIMENTAL|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
62148066|NCT05667441|ACTIVE_COMPARATOR|Standard recommendations + Risk profiling|The second group (n=50) receives standard care plus personalized risk profiling. A risk scoring based on currently available literature for lifestyle and genetic risk will be used to determine personalized risks of conversion to late AMD. Individuals will be informed about their own risk profile and a personalized strategy will be communicated.
62355505|NCT05215314|EXPERIMENTAL|Healthy Minds Program (HMP)|Fully remote, 4-week meditation intervention
62355506|NCT05215314|NO_INTERVENTION|Waitlist Control|Control participants will not complete the Healthy Minds Program during the study, but can use it after they have completed the study
62355507|NCT05419414|ACTIVE_COMPARATOR|Adenomyosis|Patients who were diagnosed with adenomyosis according to pelvic MRI were examined with transvaginal ultrasound. Certain ultrasonographic features of adenomyosis ( asymmetrical uterine wall thickening, myometrial cysts, fan shaped lines and shadows, presence of irregular junctional zone, presence of clue sign, global enlargement) were recorded. Then the patients were examined with shear wave elastography. Maximum and minimum median shear wave values were recorded through the selected regions of interest.
62355508|NCT05419414|ACTIVE_COMPARATOR|Uterine Fibroid|Patients who were diagnosed with myoma uteri according to pelvic MRI were examined with transvaginal ultrasound. Then the patients were examined with shear wave elastography. Maximum and minimum median shear wave values were recorded through the selected regions of interest.
62355509|NCT00812240|EXPERIMENTAL|Masitinib (7.5)|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
62355510|NCT00812240|EXPERIMENTAL|Masitinib (6.0)|Participants receive masitinib (6.0 mg/kg/day), given orally twice daily
62355511|NCT00812240|ACTIVE_COMPARATOR|Active Comparator (7.5)|Participants receive imatinib at 400 or 600 mg per day
62355512|NCT00812240|ACTIVE_COMPARATOR|Active Comparator (6.0)|Participants receive imatinib at 400 or 600 mg per day
62355513|NCT03571217||Diabetic retinopathy cohort|
62355514|NCT03571217||Mild visual impairment cohort|
62355515|NCT00525785|EXPERIMENTAL|5-Fluorouracil + Folinic Acid + Oxaliplatin|"PreOp Chemotherapy: 2 cycles (each cycle consisting of 4 weeks or 2 treatments) of chemotherapy with oxaliplatin, folinic acid and infusional 5-FU (FOLFOX-48). Oxaliplatin 100 mg/m\^2 over 2 hours on day 1, folinic acid intravenous (IV) at 200 mg/m\^2 over 30 minutes on day 1, and 5-FU 2,200 mg/m\^2 over 48 hours as continuous infusion by outpatient pump starting on day 1. This therapy, FOLFOX-48 repeated every 2 weeks x 4 (8 weeks of induction chemotherapy).~PreOp Chemoradiotherapy begins 12 days after last dose of PreOp Chemo 5FU plus oxaliplatin; A total of 45 Gy (1.8 Gy fx/d) of radiotherapy concurrent to low-dose continuous infusion of 5-FU (300 mg/m\^2/d Monday through Friday) \& weekly oxaliplatin 45 mg/m\^2 over 2 hours for 5 weeks (oxaliplatin administered on the first day of radiation week).~Surgical resection 4-6 weeks after completion of chemoradiotherapy"
62355516|NCT06526806|EXPERIMENTAL|Experimental group|"Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified."
62355517|NCT06526806|NO_INTERVENTION|Control group|The learning topics of the pediatric emergency nursing course will be conveyed to students through face-to-face education supported by PowerPoint presentations and learning methods such as video, question-answer-discussion. Kahoot game strategy will not be applied to students in the control group.
62710713|NCT02081586|EXPERIMENTAL|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
62355518|NCT05532540||Liver transplant recipients|All adults enlisted for liver transplantation at Copenhagen University Hospital - Rigshospitalet (N = around 60 per year) will be invited to participate regardless of indication for liver transplantation. These participants are expected to undergo a liver transplantation and will continue in the study after the procedure.
62355519|NCT06295601|EXPERIMENTAL|Experimental group|Individuals will receive standard rehabilitation and telerehabilitation-based motor imagery and action observation therapy.
62355520|NCT06295601|EXPERIMENTAL|Control group|Individuals will receive standard rehabilitation.
62710714|NCT02081586|ACTIVE_COMPARATOR|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
62710715|NCT01092221|EXPERIMENTAL|Allopurinol|
61974532|NCT00438698|EXPERIMENTAL|Low Glycemic Index Diet|Diet with low glycemic index carbohydrates
61974533|NCT00438698|ACTIVE_COMPARATOR|High Fiber Diet|Diet with high cereal fibre choices
61974534|NCT00815945|EXPERIMENTAL|PegLiposomal Doxorubicin + Carboplatin|Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)
61974535|NCT00797030|ACTIVE_COMPARATOR|1|Ten HIV-positive-patients with dry eye diagnosis received sodium carboxymethylcellulose 0.5% drops (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) for six months.
61974536|NCT00797030|OTHER|2|Ten HIV-positive-patients with dry eye received sodium carboximethylcelullose 0.5% (1 drop 4 times per day) during six months
61974537|NCT05830292|EXPERIMENTAL|DRS in-vivo|Participants (patients undergoing GI cancer surgery) will have a DRS probe used on the in-vivo tissue for 5-10 minutes during a single operation
61974538|NCT04292860||Breast Cancer Pts|Post-operative (lumpectomy or mastectomy) female breast cancer patients who will receive radiation to the whole breast or chest wall and the regional nodes.
61974539|NCT03481036|ACTIVE_COMPARATOR|Non cirrhotic|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks Patients \< 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg), LDV (90 mg) and DCV (60 mg) per day
62710716|NCT01092221|PLACEBO_COMPARATOR|Placebo|
62710717|NCT02180789|EXPERIMENTAL|Harnalidge® OCAS®|
62518226|NCT00608192|ACTIVE_COMPARATOR|Testing, Education, & Counseling (TEC)|HIV and hepatitis screening is done on-site, but vaccination and medical care will be provided by off-site referral. HIV and Hepatitis, Testing, Education, \& Counseling (TEC) participants will receive standard HIV and hepatitis education \& counseling. TEC participants will not receive case management services.
62518227|NCT00608192|EXPERIMENTAL|Hepatitis Care Coordination (HCC)|Participants will receive on-site HIV and viral hepatitis screening. Hepatitis A and B combination vaccination will be provided on-site. Participants will receive on-site theory-based HIV and hepatitis education, counseling, and 6 months of case management to promote adherence to HIV and HCV evaluation.
61974540|NCT03481036|ACTIVE_COMPARATOR|Genotype 1,4,5 and 6 with cirrhosis|Sofosbuvir (SOF)+ Ledipasvir (LDV) for 12-weeks + weight based Ribavirin Patients \< 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and LDV (90 mg) per day
61974541|NCT03481036|ACTIVE_COMPARATOR|Genotype 2 and 3 with Cirrhosis|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks+ weight based Ribavirin Patients \< 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and DCV (60 mg) per day
61974542|NCT02626520|EXPERIMENTAL|Resectable, Low Risk|Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
61974543|NCT02626520|EXPERIMENTAL|Locally Advanced|Systemic chemotherapy followed by chemoradiation, followed by definitive surgery
61974544|NCT02355353|EXPERIMENTAL|Imaging arm|
61974545|NCT01244906|EXPERIMENTAL|Reduced Intensity Allogeneic Stem Cell Transplantation|All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
61974546|NCT03931291|EXPERIMENTAL|Experimental arm: APR-246 + azacitidine|APR-246 and azacitidine maintenance therapy will continue for a maximum of 12 cycles
61974547|NCT04339127||Cohort NMDARE-HSE|Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
62148067|NCT05667441|ACTIVE_COMPARATOR|Standard recommendations + Risk profiling + Additional coaching|The third group (n=50) receives standard care (see 1); personalized risk profiling (see 2); and coaching. A coach will employ behavioral change techniques (BCT) to enhance adherence using motivational interviews, feedback on behavior; and focus on the advantages of following recommendations.
62148068|NCT03430427||Community-Dwelling Older Adults|The group will consist of 240 community-dwelling older adults with a range of mobility function based on the short physical performance battery (SPPB).
62148069|NCT03682614|EXPERIMENTAL|HCG group|All patients will accept HCG 500IU intrauterine injection 2 days before blastocyte transfer
61974548|NCT04810845|EXPERIMENTAL|Patients undergoing coronary angiography with planned PCI|Patients with a known coronary artery disease admitted for elective coronary angiography with planned PCI would be enrolled
61974549|NCT01493206|EXPERIMENTAL|intraoperative radiotherapy|
62148070|NCT03682614|PLACEBO_COMPARATOR|control group|All patients will accept same dose of culture medium intrauterine injection 2 days before blastocyte transfer
62518228|NCT00979381||1|Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks
62710718|NCT03508050|EXPERIMENTAL|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
62710719|NCT03508050|NO_INTERVENTION|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
61974550|NCT02111850|EXPERIMENTAL|1/Phase I Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-Melanoma antigen family A, 3 (MAGE-A3)-DP4 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high-dose aldesleukin
61974551|NCT02111850|EXPERIMENTAL|2/Phase II Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-Melanoma antigen family A, 3 (MAGE-A3)-DP4 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high-dose aldesleukin
61974552|NCT01778881|EXPERIMENTAL|Massage + Exercise|Massage and stretching exercises
62148071|NCT06132009||Remission group|Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but were in remission during follow-up
62148072|NCT06132009||Recurrent group|Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but developed an endometrioma of at least 2 cm in size in a single ovary during follow-up.
62148073|NCT03696056|EXPERIMENTAL|Kirtan Kriya meditation|Participants will mediate for 12 minutes a day for 8 consecutive weeks.
62148074|NCT03696056|ACTIVE_COMPARATOR|Relaxing instrumental music|Participants will relax listening to music for 12 minutes a day for 8 consecutive weeks.
62148075|NCT02022293|ACTIVE_COMPARATOR|Atorvastatin|Patients will take atorvastatin 20mg per night, totally 2 years.
62710720|NCT01425814|EXPERIMENTAL|Arm #2|Single dose, double blind treatment period
62518229|NCT00979381||2|patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
62518230|NCT00979381||3|healthy volunteers
62518231|NCT01626963|EXPERIMENTAL|SPA|Single-port access surgery
62518232|NCT01626963|ACTIVE_COMPARATOR|CL|Conventional Laparoscopic access
62518233|NCT03201211|EXPERIMENTAL|10-10-10-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, PE-PilA and UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
62518234|NCT03201211|EXPERIMENTAL|10-10-3-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
61974553|NCT01778881|EXPERIMENTAL|Relaxation +Imagination|Relaxation and Imagination therapies
62148076|NCT02022293|PLACEBO_COMPARATOR|Placebo|Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.
62518235|NCT03201211|PLACEBO_COMPARATOR|PLACEBO|Subjects who received two doses of placebo (saline solution), administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974) and were enrolled in the study.
62518236|NCT02110017|OTHER|Patients with schizophrenia|"Twenty patients suffering from schizophrenia (DSM-IV-R), with medication and medical care. No recent relapse of the psychotic disease, nor change in medications.~No neurological comorbidity.~After anatomic scans, each subject will go through the fMRI social cognition task."
62518237|NCT02110017|OTHER|Healthy subjects|"Twenty healthy subjects (no mental or neurological disease)~After anatomic scans, each subject will go through the fMRI social cognition task."
62518238|NCT00002829|EXPERIMENTAL|Bone Marrow Transplantation|
62710721|NCT01425814|EXPERIMENTAL|Arm #3|Single dose, double blind treatment period
62710722|NCT01425814|EXPERIMENTAL|Arm #4|Single dose, double blind treatment period
62710723|NCT01425814|ACTIVE_COMPARATOR|Arm #5|Single dose, double blind treatment period
62710724|NCT01425814|PLACEBO_COMPARATOR|Arm #6|Single dose, double blind treatment period
62710725|NCT01425814|EXPERIMENTAL|Arm #1|Single dose, double blind treatment period
61974554|NCT01778881|EXPERIMENTAL|Dental treatment|Reconstruction with composite resin
61974555|NCT01778881|EXPERIMENTAL|Massage + Exercise + Relaxation + Imagination|Massage, stretching exercises, relaxation and imagination
61974556|NCT06030791||Group 1|All examinees will undergo ACL reconstruction using BTB graft. MRI scans of operated knee will be conducted at two time points: 4 weeks and 1 year after ACL reconstruction surgery.
61974557|NCT06030791||Group 2|All examinees will undergo ACL reconstruction using BTB graft. MRI scans of operated knee will be conducted at two time points: 4 weeks and 1 year after ACL reconstruction surgery.
62518239|NCT00932230|EXPERIMENTAL|Group 1|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
62518240|NCT04317599||Non interventional|All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
62518241|NCT02277704|PLACEBO_COMPARATOR|Placebo|"2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
62518242|NCT02277704|ACTIVE_COMPARATOR|TNX-102 SL, 2.8 mg|"1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
62518243|NCT02277704|ACTIVE_COMPARATOR|TNX-102 SL, 5.6 mg|"2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime."
62518244|NCT04300829|EXPERIMENTAL|Simple hygiene rules of the site + Cicaderma ointment|Hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and Cicaderma ointment application)
62518245|NCT04300829|ACTIVE_COMPARATOR|Preventive standard cares|Preventive standard cares of the site including hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and a maximum of one topical treatment
62539525|NCT01860677|PLACEBO_COMPARATOR|Sham stimulation|Participants are outfitted with a device that is identical to the Fisher Wallace Cranial Stimulator in appearance but does not deliver any current.
61974558|NCT00221598|EXPERIMENTAL|hemodialysis|
61974559|NCT01150981|EXPERIMENTAL|Rosiglitazone|One 8mg capsule daily for 6 weeks.
61974560|NCT01150981|PLACEBO_COMPARATOR|Placebo|One capsule daily for 6 weeks.
61974561|NCT01635413|EXPERIMENTAL|Arm I (strength training)|Patients attend strength training classes for 1 hour 2 days per week.
61974562|NCT01635413|EXPERIMENTAL|Arm II (tai chi)|Patients attend tai chi classes for 1 hour 2 days per week.
61974563|NCT01635413|ACTIVE_COMPARATOR|Arm III (control)|Patients attend supervised stretching and relaxation classes for 1 hour 2 days per week.
62710726|NCT01428791|ACTIVE_COMPARATOR|Generations older adult member program|Rush Generations is a membership program for older adults, providing chronic disease prevention and management through educational programming, civic engagement, and individual and family consultations with social work staff.
62710727|NCT01428791|EXPERIMENTAL|BRIGHTEN Heart Virtual Team|BRIGHTEN Heart provides older adults with an interdisciplinary team evaluation of physical and mental health and on-going support for mental health and health behavior change for a minimum of six months. The five core components of the BRIGHTEN intervention consist of: 1) Assessment; 2) Virtual team case review; 3) Patient centered action planning; 4) Plan implementation, and; 5) When indicated, short-term evidence-based geriatric specialty psychotherapy.
62710728|NCT01967745||laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars, placed in the periumbilical area, right midabdomen, and forceps.
62710729|NCT01967745||open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
62710730|NCT05532969||Observation group of newly diffuse astrocytoma patients with high-level psychological stress|The patients had high threshold levels of perceived psychological stress, fear, anxiety, and depression as assessed by psychologists
62710731|NCT05532969||Observation group of newly diffuse astrocytoma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
61974564|NCT00208611|EXPERIMENTAL|Open-Label Treatment|Levodopa-treated Parkinson's Disease subjects with vitamin B12 \< 200 pg/ml given oral vitamin B12 supplement
62518246|NCT06525922|EXPERIMENTAL|Center M Intervention|Data from participants in this arm will be compared across pre-intervention, post-intervention, and 6-weeks postpartum. All participants will receive the Center M intervention, which includes group-based Cognitive Behavioral Therapy (CBT) sessions and home practice materials.
62518247|NCT02769884|EXPERIMENTAL|MMPPC arm|Subjects in this arm will wear the experimental MMPPC algorithm artificial pancreas for 72 hours in a hotel/house setting. The study period will involve unannounced meals and exercise
62518248|NCT00770692|EXPERIMENTAL|Eszopiclone 1 mg- Elderly|
62518249|NCT00770692|EXPERIMENTAL|Eszopiclone 2 mg- Elderly|
62518250|NCT00770692|EXPERIMENTAL|Eszopiclone 2 mg- Non-elderly|
62518251|NCT00770692|EXPERIMENTAL|Eszopiclone 3 mg- Non-elderly|
62518252|NCT01715896|EXPERIMENTAL|Golimumab 50 mg alternating with Placebo|Participants received alternating doses of golimumab 50 milligram (mg) (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
62518253|NCT01715896|EXPERIMENTAL|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
62518254|NCT06615882|EXPERIMENTAL|Experimental|During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused
62518255|NCT04758663|EXPERIMENTAL|Declarative memory|Napping v. wake effect on declarative memory in habitual and non-habitual nappers.
62518256|NCT04758663|EXPERIMENTAL|Overnight Physiology|Napping v. wake effect on overnight physiology in habitual and non-habitual nappers.
62518257|NCT02228993||Awake Craniotomy|
62518258|NCT02228993||General Anesthesia Craniotomy|
62518259|NCT04199650||Mild ARDS|153mmHg\<PaO2/FiO2≤230mmHg
61974565|NCT03330769||Patients with active Psoriatic Arthritis|Patients with clinically diagnosed PsA with clinically active joint disease starting a new course of treatment.
61974566|NCT01546740||Glaucoma patients|all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma.
61974567|NCT02500888|EXPERIMENTAL|Treatment|Radiosurgery by linear accelerator.
62518260|NCT04199650||Moderate ARDS|76mmHg\<PaO2/FiO2≤153mmHg
62518261|NCT04199650||Severe ARDS|PaO2/FiO2≤76mmHg
62518262|NCT06224621|EXPERIMENTAL|Study group|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
62518263|NCT02728011|EXPERIMENTAL|Intervention|Scientific Brain Training (SBT)
62710732|NCT03767049||Lung transplant patients readmitted in ICU|
62710733|NCT04705805||Case|Patient presenting an olfactory dysfunction of any acquired aetiology that has been evolving for at least 3 months without total recovery.
61974568|NCT01541124|EXPERIMENTAL|Morphine, Pain intensity|For cancer pain treatment, World Health Organization recomends tritation of opioids associated with non steroidal antiinflamatory drugs. This study compares the analgesic effect with diferents dosages in 63 patients with cancer pain.
61974569|NCT00650624|ACTIVE_COMPARATOR|Arm 1|
61974570|NCT00650624|ACTIVE_COMPARATOR|Arm 2|
61974571|NCT00650624|ACTIVE_COMPARATOR|Arm 3|
61974572|NCT00650624|PLACEBO_COMPARATOR|Arm 4|
61974573|NCT02335294|EXPERIMENTAL|TRV130|
61974574|NCT02335294|ACTIVE_COMPARATOR|Morphine|
61974575|NCT02335294|PLACEBO_COMPARATOR|Placebo|
61974576|NCT01320085|EXPERIMENTAL|BRAFV600 mutant, 45mg bid MEK162|BRAFV600 mutant, 45mg bid MEK162
62518264|NCT02728011|PLACEBO_COMPARATOR|Controle|Tetris
62518265|NCT01300923|ACTIVE_COMPARATOR|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
62518266|NCT01300923|NO_INTERVENTION|Autism Spectrum Disorder|This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization.
62518267|NCT01004042|ACTIVE_COMPARATOR|Depressed subjects|Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
62518268|NCT01004042|ACTIVE_COMPARATOR|Non Depressed subjects|Subjects with no diagnosis of depression
62518269|NCT03511170|EXPERIMENTAL|alternative regiment|The first stage:XELOX chemotherapy and XELIRI chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage. The second stage: continue to apply another plan until there is progress or intolerance.
62518270|NCT03511170|PLACEBO_COMPARATOR|classical regiment|Use the XELOX chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI chemotherapy until there is progress or intolerance.
62518271|NCT03604341|EXPERIMENTAL|Gestational age up to 10w0d - Dronabinol|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
62518272|NCT03604341|PLACEBO_COMPARATOR|Gestational age up to 10w0d - Placebo|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
62518273|NCT05582252||Experimental group|Patients with ICD who received at least one electric shock in 6 months after ICD implantation
62518274|NCT05582252||Control Group|Patients with ICD who didnot received any electric shock in 6 months after ICD implantation
62518275|NCT05582252||Healthy Group|Healthy Volunteers This group will be used for related bioinformatic analysis (DATA analysis stage) but not in statistical analysis
62518276|NCT00781521|EXPERIMENTAL|1|Floxin otic solution twice a day for 7 days
62518277|NCT03777904||Children with high serum ferritin|Children with very high serum ferritin levels and confirmed iron toxicity will have a urine sample and blood sample drawn at the same time. Both samples will have ferritin levels and iron content measured and compared for correlation.
62710734|NCT04705805||Control|Patient with no sense of smell problems followed up in ENT for another pathology that does not affect the sense of smell
61974577|NCT01320085|EXPERIMENTAL|NRAS mutant, 45mg bid MEK162|NRAS mutant, 45mg bid MEK162
62518278|NCT01404871|ACTIVE_COMPARATOR|Randomization to ECIT or CMI|Randomized trial of clomipramine or escitalopram
62518279|NCT01404871|ACTIVE_COMPARATOR|Open label Duloxetine|Open label trial of duloxetine
62518280|NCT05542979|EXPERIMENTAL|HH-003 Group|
62518281|NCT05542979|PLACEBO_COMPARATOR|Placebo Group|
62518282|NCT03951584||ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study cohort. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset, to evaluate the damage and prognosis of vestibular function.
62518283|NCT05559112|EXPERIMENTAL|Mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily for 12 weeks.
62518284|NCT05559112|PLACEBO_COMPARATOR|No Mushrooms|This is a behavioral control where no change in Vitamin D status is expected to occur. Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily for 12 weeks.
61974578|NCT01320085|EXPERIMENTAL|BRAFV600 mutant, 60mg bid MEK162|BRAFV600 mutant, 60mg bid MEK162
61974579|NCT02154490||S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
61974580|NCT02154490||S1400A Arm II (CLOSED TO ACCRUAL 4/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
62518285|NCT00887328|EXPERIMENTAL|IV tPA|intravenous tissue plasminogen activator
62518286|NCT00887328|PLACEBO_COMPARATOR|Placebo|
62518287|NCT00998972|NO_INTERVENTION|control|control arm without any specific intervention
62518288|NCT00998972|EXPERIMENTAL|N-acetylcysteine|administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death
62518289|NCT03676751|ACTIVE_COMPARATOR|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
61974581|NCT02154490||S1400A Arm III (MEDI4736)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
62518290|NCT03676751|PLACEBO_COMPARATOR|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
62518291|NCT03077321|ACTIVE_COMPARATOR|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
62518292|NCT03077321|EXPERIMENTAL|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
62710735|NCT03559270|EXPERIMENTAL|Placebo/Baricitinib 2-milligram (mg)|Open-label 2 mg baricitinib administered orally once daily (QD) to participants who randomized to placebo in the originating study (JAIW).
62710736|NCT03559270|EXPERIMENTAL|Baricitinib 1-mg/Baricitinib 2-mg|Open-label 2 mg baricitinib administered orally QD to participants who randomized to 1 mg baricitinib in the originating study (JAIW).
62710737|NCT03559270|EXPERIMENTAL|Baricitinib 2-mg/Baricitinib 2-mg|Open-label 2 mg baricitinib administered orally QD to participants who randomized to 2 mg baricitinib in the originating study (JAIW).
62710738|NCT03559270|EXPERIMENTAL|Baricitinib 2-mg Open-Label Addendum|Participants were directly enrolled to receive open-label 2 mg baricitinib orally QD.
61974582|NCT02154490||S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62518293|NCT03077321|NO_INTERVENTION|Control|Wait list control
62518294|NCT00635830|EXPERIMENTAL|1|Open Label
62518295|NCT05306171|EXPERIMENTAL|Intervention group (I)|Online training for healthcare professionals which will follow a protocol made especially for this research. The online training is composed by 4 modules and each module has 3 meetings. Each meeting has 35 minutes long.
62518296|NCT05306171|NO_INTERVENTION|Control group (C)|No intervention. The control group will receive the intervention after study is completed.
62518297|NCT05861635|EXPERIMENTAL|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
62710739|NCT03857776|OTHER|Open dialogue about CAM|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
62710740|NCT03857776|OTHER|Standard care|Standard care including referral to a homepage about complementary alternative medicine
62518298|NCT03921151|OTHER|Cocaine-dependent|Participants who use and are dependent on cocaine
62518299|NCT03921151|OTHER|Non-drug using Healthy Controls|Participants who are not drug users
62518300|NCT01665924|EXPERIMENTAL|40-50 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
62518301|NCT01665924|EXPERIMENTAL|65-74 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
61974583|NCT02154490||S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
62355521|NCT01579552|EXPERIMENTAL|Intervention Group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
62355522|NCT01579552|ACTIVE_COMPARATOR|attention control group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
61974584|NCT02154490||S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61974585|NCT02154490||S1400C Arm I (palbociclib)|Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61974586|NCT02154490||S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
62710741|NCT04068922|EXPERIMENTAL|Resilience Intervention|Participants will initially complete a baseline assessment assessing study eligibility. The Resilience intervention consists of seven weekly 1.5-hour group sessions guided by trained clinicians. Due to the COVID-19 pandemic, these group session may be conducted through Zoom. Skills and content will be directed toward improving pain management by enhancing positive emotions, setting goals, learning to live a life according to one's values, and boosting self-confidence in one's ability to manage pain. Self-administered activities include the identification of personal strengths, pleasant activity scheduling, expressing gratitude, values clarification, mindfulness practice, goal setting, positive reappraisal, and noting positive events.
62710742|NCT02916264|ACTIVE_COMPARATOR|a scalp block|A standard scalp block ,with 0.5% bupivacaine total dose \< 3 mg/kg, is performed by an anesthesiologist.
61974587|NCT02154490||S1400C Arm III (palbociclib)|Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61974588|NCT02154490||S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61974589|NCT02154490||S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
61974590|NCT02154490||S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)|Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61974591|NCT02154490||S1400E Arm I (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
61974592|NCT02154490||S1400E Arm II (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
62710743|NCT02916264|NO_INTERVENTION|no scalp block|An anesthesiology will pretend to perform the scalp block,
62710744|NCT00865748|EXPERIMENTAL|A|Metformin HCl 500 mg tablets, single dose
62710745|NCT00865748|ACTIVE_COMPARATOR|B|CLUCOPHAGE® XR 500 mg tablets, single dose
62710746|NCT06426979|ACTIVE_COMPARATOR|Group LTZ-MTX|Letrozole and Methotrexate Therapy's Group
61974593|NCT02154490||S1400F (durvalumab, tremelimumab)|Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
61974594|NCT02154490||S1400G (talazoparib)|Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
61974595|NCT02154490||S1400I Arm I (nivolumab, ipilimumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62710747|NCT06426979|ACTIVE_COMPARATOR|Group MTX|Methotrexate Therapy's Group
62710748|NCT03040206||Nodal PTCL|"1. newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma \[ALCL\], anaplastic lymphoma kinase \[ALK\]-negative) between January 1, 2005 and Jun 30, 2016~2. initially treated with curative intent~3. Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment"
62710749|NCT01912014|EXPERIMENTAL|Psychosocial support and counselling|There is only one arm as this is a pilot and feasibility study.
62148077|NCT03658915||Osteoarthritis|"Thirty symptomatic knee with osteoarthritis will be recruited according to the following criteria:~INCLUSION CRITERIA:~1. Referred with a confirmed diagnosis of unilateral or bilateral OA of the knee based on the following criteria.~   1.1. Morning stiffness \< 30 minutes, 1.2. Crepitus on active knee movement. 1.3. Bony enlargement either palpable or visible in radiographs. 1.4. Bony tenderness.~2. Age 40-60 years old.~EXCLUSION CRITERIA:~1. Steroid injection within the past 2 months.~2. Presence of neurologic disorders.~3. Presence of of orthopedic diseases or trauma in the lower extremity or spine within the past year.~6. Severe pain with active movement 7. Poor memory or cognitive function"
62518302|NCT01665924|EXPERIMENTAL|75 years and older|GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
62518303|NCT02162355|EXPERIMENTAL|GLPG0634 in Japanese subjects|Per panel, 6 Japanese healthy subjects will receive one of the three doses (50 mg, 100 mg or 200 mg) of GLPG0634 as tablets once daily for 10 days
62518304|NCT02162355|PLACEBO_COMPARATOR|Placebo in Japanese healthy subjects|Per panel, 2 or 4 (last panel only) Japanese healthy subjects will receive placebo as tablets once daily for 10 days
62518305|NCT02162355|EXPERIMENTAL|GLPG0634 in Caucasian subjects|In the last panel, 6 Caucasian healthy subjects will receive one dose of GLPG0634 (200 mg) as tablets once daily for 10 days
62518306|NCT02162355|PLACEBO_COMPARATOR|Placebo in Caucasian healthy subjects|In the last panel, 4 Caucasian healthy subjects will receive receive placebo as tablets once daily for 10 days
62518307|NCT00350649|EXPERIMENTAL|1|manualized delivery of CBT by trained clinicians
62518308|NCT00350649|ACTIVE_COMPARATOR|2|CBT with Contingency Management reinforcement for attendance and completing homework (CBT+CM/adherence)
62518309|NCT00350649|EXPERIMENTAL|3|Contingency Management for abstinence alone (CM/abstinence)
62518310|NCT00350649|ACTIVE_COMPARATOR|4|Contingency Management integrated with CBT (CM/abstinence+CBT)
62148078|NCT03658915||Control|Thirty asymptomatic knee will be recruited for this study. Control group participants will be age-matched to the osteoarthritis group, and should have no pain or other relevant clinical symptoms in lower quadrant.
62148079|NCT00424502|EXPERIMENTAL|1|
62148080|NCT01344980|EXPERIMENTAL|Stainless steel MGH|Patients in this study arm will have their flexor tendon laceration repaired using stainless steel suture (size 3-0) in an MGH repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
62518311|NCT02676713|EXPERIMENTAL|TCM Sequential Treatment|"After conservative surgery, patients start to take pre-ovulation decoction for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found LUFS or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles.~Pre-ovulation decoction is HuoXueXiaoYi decoction, and post-ovulation decoction is BuShenZhuYun decoction. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~All drugs are tcm formula granules, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
62518312|NCT02676713|PLACEBO_COMPARATOR|Placebo|"After conservative surgery, patients start to take pre-ovulation decoction(placebo) for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found luteinized unruptured follicle syndrome (LUFS) or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction(placebo) for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~Pre-ovulation decoction and post-ovulation decoction is placebo, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
61974596|NCT02154490||S1400I Arm II (nivolumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62518313|NCT01400620|EXPERIMENTAL|Active oral rinse|Oral rinse containing botanical extracts
62518314|NCT01400620|PLACEBO_COMPARATOR|Placebo rinse|
62518315|NCT05275972|PLACEBO_COMPARATOR|DMEK plus topical placebo|
62518316|NCT05275972|EXPERIMENTAL|DSO plus topical ripasudil 0.4%|
61974597|NCT01621620|EXPERIMENTAL|yohimbin|
61974598|NCT03336047|ACTIVE_COMPARATOR|10,000 steps daily|Subjects will be encouraged to obtain 10 000 steps a day, monitored by a step counter (fit bit zip)
61974599|NCT03336047|EXPERIMENTAL|using personal activity intelligence|Subjects will be encouraged to obtain 100 PAI points per week, monitored by Mio Slice and the Mio Pai 2.0 smart phone application
61974600|NCT01260285|EXPERIMENTAL|Vardenafil|
61974601|NCT03198949|EXPERIMENTAL|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
61974602|NCT03198949|PLACEBO_COMPARATOR|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
62148081|NCT01344980|ACTIVE_COMPARATOR|Polypropylene DOLL|Patients in this study arm will have their flexor tendon laceration repaired using polypropylene suture (size 3-0) in a double-locking loop repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
62148082|NCT06282926||Group 1|Healthy adult volunteers
62148083|NCT06282926||Group 2|ACHD patients with repaired Tetralogy of Fallot and known moderate or severe pulmonary regurgitation
62148084|NCT05796141|EXPERIMENTAL|Condition 1|1) Core BWL Intervention
62518317|NCT02691741|EXPERIMENTAL|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
62518318|NCT02691741|ACTIVE_COMPARATOR|839MP|AT LISA® tri IOL, bilateral implantation
62518319|NCT02632734|EXPERIMENTAL|CoreBone Cone device|Experimental: CoreBone Cone device After extraction intervention will include the placement of CoreBone Cone device derived from coral that its dimensions is 4-5mm width and 8-10mm height. One cone for each extraction socket.Its advantage is that it fits well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month. We predict that CoreBone Cones are more effective than particulate device.
62518320|NCT02632734|EXPERIMENTAL|CoreBone 500 device|After extraction intervention will include the placement of CoreBone500 device derived from coral that is particulate. 0.3-0.5cc for each extraction socket.Its advantage is that it fills well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month.
62518321|NCT03349528|EXPERIMENTAL|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10\^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
62518322|NCT03349528|PLACEBO_COMPARATOR|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
62518323|NCT01425021||Total hip/knee joint revisions|All University of Utah orthopedic patients who have had total or partial joint arthroplasties at the time of revision surgery.
62518324|NCT05162651|ACTIVE_COMPARATOR|Contingency management group|Randomized to receive individual motivational interviewing therapy and contingency management
62518325|NCT05162651|OTHER|Control group|Randomized to receive individual motivational interviewing therapy alone
62518326|NCT03657108|EXPERIMENTAL|group 1 of 60 Gy dose|The first 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
62148085|NCT05796141|EXPERIMENTAL|Condition 2|1) Core BWL Intervention; 2) Home Environment Modifications
62148086|NCT05796141|EXPERIMENTAL|Condition 3|1) Core BWL Intervention; 2) Autonomy Support Training
62518327|NCT03657108|EXPERIMENTAL|group 2 of 60 Gy dose|The second 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
62518328|NCT03657108|EXPERIMENTAL|group 1 of 75 Gy dose|The third 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
62518329|NCT03657108|EXPERIMENTAL|group 2 of 75 Gy dose|The fourth 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
62518330|NCT05981248|EXPERIMENTAL|the MIED+TAU group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
62518331|NCT05981248|NO_INTERVENTION|the TAU-only group|treated as usual
62518332|NCT03892213|OTHER|Benznidazole and E1224|Benznidazole and E1224
62518333|NCT03984045|EXPERIMENTAL|SPG block|SPG block performed by using qtip applicator soaked in 2% lidocaine and placed posteriorly into nasal cavity where it dwells for up to 30 min
62710750|NCT01673126|ACTIVE_COMPARATOR|Anodal tDCS|Patients received anodal tDCS (on DLPF cortex) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised)
62148087|NCT05796141|EXPERIMENTAL|Condition 4|1) Core BWL Intervention; 2) Autonomy Support Training; 3) Home Environment Modifications
62148088|NCT05796141|EXPERIMENTAL|Condition 5|1) Core BWL Intervention; 2) Joint Feedback
62518334|NCT03984045|ACTIVE_COMPARATOR|Control|Delivered through IV access obtained in all patients.
62518335|NCT02710513|EXPERIMENTAL|Beta-glucans|2 months run-in period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of normal pasta) + 2 months intervention period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of functional pasta providing 3 g of beta-glucans/day)
62518336|NCT02213913|EXPERIMENTAL|Treatment (lenalidomide, DA-EPOCH-R)|"INDUCTION PHASE: Patients receive lenalidomide PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months."
62710751|NCT01673126|SHAM_COMPARATOR|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
61974603|NCT00851383|EXPERIMENTAL|Group A|Ad35-GRIN/ENV: 2x10\^9 vp
61974604|NCT00851383|EXPERIMENTAL|Group B|Ad35-GRIN/ENV: 2x10\^10 vp
62148089|NCT05796141|EXPERIMENTAL|Condition 6|1) Core BWL Intervention; 2) Joint Feedback; 3) Home Environment Modifications
62148090|NCT05796141|EXPERIMENTAL|Condition 7|1) Core BWL Intervention; 2) Joint Feedback; 3) Autonomy Support Training
62148091|NCT05796141|EXPERIMENTAL|Condition 8|1) Core BWL Intervention; 2) Joint Feedback; 3) Autonomy Support Training; 4) Home Environment Modifications
62148092|NCT05796141|EXPERIMENTAL|Condition 9|1) Core BWL Intervention; 2) Dyadic Action Planning
62518337|NCT02709486|EXPERIMENTAL|Low dose|Investigational product
62518338|NCT02709486|EXPERIMENTAL|High dose|Investigational product
62518339|NCT02709486|PLACEBO_COMPARATOR|Placebo|Investigational product
62539526|NCT05506995||Vitiligo vulgaris|A serial of vitiligo patients under treatment with UVB-NB
62710752|NCT06560333|EXPERIMENTAL|N0892|in the test group will be required to take 3 tablet of the test drug N0892. 3 tablets a day for 84 days +/- 4 days.
62710753|NCT06560333|ACTIVE_COMPARATOR|Forxiga® + Glifage XR® + Placebo of Januvia®|in the control group will be required to take 1 tablet of Forxiga® 10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia® 100mg. 3 tablets a day for 84 days +/- 4 days.
62518340|NCT05179694|EXPERIMENTAL|Local Anaesthetic Transperineal Prostate Biopsy (LATP)|"LATP prostate biopsy performed with an average of 12 biopsy cores in 6 sectors depending on prostate size, plus typically 4 target cores per MRI lesion, using an ultrasound probe-mounted LATP needle guidance device (e.g. the Precision-Point access system, or BK UA1232, or any other which is used in a virtually identical fashion)."
62518341|NCT05179694|ACTIVE_COMPARATOR|Transrrectal Ultrasound-guided Prostate Biopsy (TRUS)|TRUS prostate biopsy performed according to each hospital's standard practice, with an average of 12 biopsy cores, in two sectors with additional target pots (typically 4 target cores per MRI lesion).
62518342|NCT06139224|EXPERIMENTAL|HIV-infected ART-suppressed individuals with AUD|Only 10 HIV+ ART+,AUD + individuals will be invited to take part in a prebiotic sub study, which they will take a commercially available prebiotic (FOS) for 10 days
62518343|NCT06139224|EXPERIMENTAL|HIV-infected ART-suppressed individuals with no AUD|Only 10 HIV+ ART+,AUD - individuals will be invited to take part in a prebiotic sub study, which they will take a commercially available prebiotic (FOS) for 10 days
62518344|NCT00507546|EXPERIMENTAL|Ramelteon then placebo|8 mg nightly ramelteon for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of nightly placebo (cross-over)
62518345|NCT00507546|EXPERIMENTAL|Placebo then ramelteon|placebo nightly for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of 8 mg nightly ramelteon (cross-over)
62518346|NCT01510652|ACTIVE_COMPARATOR|Quad Group|Patients in the Quad group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
62518347|NCT01510652|ACTIVE_COMPARATOR|BiP Group|Patients in the BiP Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
62518348|NCT03177382|EXPERIMENTAL|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
62148093|NCT05796141|EXPERIMENTAL|Condition 10|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Home Environment Modifications
62518349|NCT03177382|ACTIVE_COMPARATOR|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
62518350|NCT04332848|EXPERIMENTAL|(B) Empirical therapy|choose antibiotics according to drug history
62518351|NCT04332848|ACTIVE_COMPARATOR|(A) Susceptibility testing guided therapy|choose antibiotics according to susceptibility testing
62518352|NCT05009966|EXPERIMENTAL|SYSA1801 for injection|"Stage I: Dose Escalation and dose expansion： Dose Escalation：SYSA1801 will be administered intravenously (IV) at different dose levels, including 0.5, 1, 2, 3, 4.5 and 6 mg/kg according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.5 and 1 mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (2, 3, 4.5 and 6 mg/kg).~Dose expansion: SYSA 1801 will be administered at up to dose levels which is equal or lower than MTD IV infusion. Each dose level contains no more than 12 subjects (including subjects in dose escalation) Stage II: Extension cohort This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma, pancreatic cancer or other solid cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of SYSA1801 for expansion will be derived from the RP2D determined during Stage I"
62518353|NCT02191475|ACTIVE_COMPARATOR|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy, dose of imipenem/cilastatin 500mg, IVdrip, 3\~4 times/d, or meropenem 1g, IVdrip, 3 times/d; vancomycin for 15mg/kg,2 times/d, or linezolid 300mg, IVdrip, 2 times/d; these drugs are required to state organ function in patients with drug doses adjustment, treatment for 3-5 days.
62710754|NCT06560333|ACTIVE_COMPARATOR|Januvia® + Glifage XR® + Placebo of Forxiga®|in the control group will be required to take 1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga® 100mg. 3 tablets a day for 84 days +/- 4 days.
62710755|NCT03778801||fibromyalgia syndrome|Thirty patients with a diagnosis of fibromyalgia syndrome according to the 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria and a disease duration of longer than three months
62710756|NCT03778801||chronic neck pain|30 patients with chronic neck pain lasting for more than three months and didn't meet 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria.
62710757|NCT03778801||healthy controls|30 healthy controls without pain or additional disease
62710758|NCT00529633|ACTIVE_COMPARATOR|Thalidomide|"1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~2. Serum C reactive protein level of ≥ 0.8 mg/dl~3. Serum albumin \< 3.8 g/dl (BCG)~4. Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide."
62710759|NCT00529633|PLACEBO_COMPARATOR|No Drug|"1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~2. Serum C reactive protein level of ≥ 0.8 mg/dl~3. Serum albumin \< 3.8 g/dl (BCG)~4. Patients will receive Placebo (Sugar pill) for a period of 24 weeks."
62148094|NCT05796141|EXPERIMENTAL|Condition 11|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Autonomy Support Training
61974605|NCT00851383|EXPERIMENTAL|Group C|Ad35-GRIN/ENV: 2x10\^11 vp
61974606|NCT00851383|EXPERIMENTAL|Group D|Ad35-GRIN at 1x10\^10 vp
62148095|NCT05796141|EXPERIMENTAL|Condition 12|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Autonomy Support Training 4) Home Environment Modifications
62148096|NCT05796141|EXPERIMENTAL|Condition 13|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback
62710760|NCT03262961|ACTIVE_COMPARATOR|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
62710761|NCT03262961|PLACEBO_COMPARATOR|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
62710762|NCT04857060|NO_INTERVENTION|Usual Care|Subjects in this arm do not meet with ACP Educator during their index hospitalization.
62710763|NCT04857060|EXPERIMENTAL|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
62710764|NCT04304560|PLACEBO_COMPARATOR|Control Group|Control group will receive the standard therapy for DM \& HFrEF and placebo.
62710765|NCT04304560|EXPERIMENTAL|Dapagliflozin|Intervention group will receive 10mg of Dapagliflozin (Forxiga) ® tablet and standard therapy for HFrEF.
62518354|NCT02191475|EXPERIMENTAL|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin / tazobactam (tazocin ®), with or without antifungal therapy, dose of tigecycline first dose 100 mg, 50 mg, every 12 hours, piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day, each time the infusion of 3 hours, treatment for 3-5 days.
62518355|NCT05506358|OTHER|1) HbSS; 2) HbAS; 3) HbS/β-thalassemia; 4)Hbβ/β-thalassemia; 5) HbA/β- thalassemia; 6) HbAA|"Around 20 participants each (in Nepal):~* with the homozygous form of sickle cell disease (HbSS)~* with the heterozygous form of sickle cell disease (HbAS)~* with the compound heterozygous form of sickle cell disease (HbS/β-thalassemia)~* with the carrier form of β-thalassemia (HbA/β-thalassemia)~* with the carrier form of β-thalassemia (HbA/β-thalassemia)~* without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc.~Around 30 participants each (in Canada):~* with the homozygous form of sickle cell disease (HbSS)~* with the heterozygous form of sickle cell disease (HbAS)~* without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc."
61974607|NCT01911689||acute pancreatitis|acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
61974608|NCT01911689||controlgroup|normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).
61974609|NCT01352689|EXPERIMENTAL|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
61974610|NCT01352689|EXPERIMENTAL|Free combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
61974611|NCT02601131||AML, ALL and MDS|Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
62148097|NCT05796141|EXPERIMENTAL|Condition 14|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback; 4) Home Environment Modifications
62148098|NCT05796141|EXPERIMENTAL|Condition 15|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback; 4) Autonomy Support Training
62148099|NCT05796141|EXPERIMENTAL|Condition 16|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback; 4) Autonomy Support Training; 5) Home Environment Modifications
62148100|NCT01247155||first day review|
62518356|NCT00426010|ACTIVE_COMPARATOR|1|overt then covert caffeine
62518357|NCT00426010|ACTIVE_COMPARATOR|2|covert then overt caffeine
62518358|NCT00426010|ACTIVE_COMPARATOR|3|overt then covert placebo
62518359|NCT00426010|ACTIVE_COMPARATOR|4|covert then overt placebo
61974612|NCT02601131||Autologous stem cell transplantation|Patients undergoing autologous stem cell transplantation
61974613|NCT02601131||Allogeneic stem cell transplantation|Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC)
61974614|NCT02601131||Platelet transfusion prophylaxis|Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture
62148101|NCT01247155||non-first day review|
62148102|NCT00738348|ACTIVE_COMPARATOR|2|250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
62148103|NCT00738348|PLACEBO_COMPARATOR|1|250mL of 5% glucose was injected though the vein at 10mL per an hour
62148104|NCT02236611|EXPERIMENTAL|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
62148105|NCT02236611|EXPERIMENTAL|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
62518360|NCT04529330||fractures with blister appeared|tibial plateau fractures with blister observed
62518361|NCT04529330||fractures without blister appeared|tibial plateau fractures without blister observed
62518362|NCT02139917|EXPERIMENTAL|Transitional Palliative Care|"Transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* home visit for spiritual support"
62518363|NCT02139917|NO_INTERVENTION|Customary care|"Customary care receive care :-~* hospital based medical follow up~* general nursing assessment and advice"
62518364|NCT00257920|ACTIVE_COMPARATOR|A|
62518365|NCT00257920|ACTIVE_COMPARATOR|B|
62518366|NCT04958382|EXPERIMENTAL|Ciprofol|
62518367|NCT04958382|PLACEBO_COMPARATOR|placebo|
62518368|NCT01706848|ACTIVE_COMPARATOR|Celotres|Scar halves randomized to treatment with device, opposite side treated per standard of care.
62518369|NCT01706848|ACTIVE_COMPARATOR|Standard surgical wound closure|Scar halves randomized to treatment with device, opposite side treated per standard of care.
62518370|NCT01554826|EXPERIMENTAL|Influenza Split Vaccine|7.5μg HA/strain/0.25ml/syringe
62518371|NCT01554826|ACTIVE_COMPARATOR|Inactivated Influenza Vaccine|7.5μg HA/strain/0.25ml/syringe
62518372|NCT01569776|EXPERIMENTAL|New Amino Acid formula|
62518373|NCT01569776|ACTIVE_COMPARATOR|Control formula|Commercially available Amino Acid infant formula
62518374|NCT01106521|EXPERIMENTAL|PBSI|PBSI is a form of accelerated partial breast irradiation involving the insertion of 103-palladium stranded seeds under ultra-sound guidance and light sedation after CT planning in lieu of whole breast adjuvant radiotherapy.
62518375|NCT01674647|EXPERIMENTAL|Rivaroxaban (Xarelto, BAY59-7939)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
62518376|NCT01674647|ACTIVE_COMPARATOR|Vitamin K antagonist (VKA)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
62518377|NCT04546893|EXPERIMENTAL|1904B CAR-T|Patients will be treated with CD19 CAR-T cells
62518378|NCT03252327|NO_INTERVENTION|routine care|Preterm infants in the control condition will receive only usual neonatal intensive care units (NICU) care
62518379|NCT03252327|EXPERIMENTAL|Multiple Sensory Integrations(1)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
62518380|NCT03252327|EXPERIMENTAL|Multiple Sensory Integrations(2)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
62518381|NCT03252327|EXPERIMENTAL|Multiple Sensory Integrations(3)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
62518382|NCT01859767|EXPERIMENTAL|[123I]MNI-672 SPECT|\[123I\]MNI-672 single photon emission tomography (SPECT)imaging
62518383|NCT04754334|PLACEBO_COMPARATOR|Placebo|placebo dosed QD
62518384|NCT04754334|EXPERIMENTAL|ORMD-0801|ORMD-0801 8 mg QD
62518385|NCT06271902|EXPERIMENTAL|Intervention group|Participants will be instructed to perform YoSO-IPP at a recommended frequency of two times per week for 12 weeks and attend an online 45-minute educational workshop in Week 1
62148106|NCT03294187|EXPERIMENTAL|Monitoring and Feedback|Subjects will use two wrist-worn wearables over a period of 6 weeks. Patients will receive multimodal (vibrotactile and visual) feedback.
62710766|NCT03398330|EXPERIMENTAL|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
62710767|NCT03398330|ACTIVE_COMPARATOR|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
62710768|NCT04009148||Successful Cascade Testing|Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.
62710769|NCT04009148||Relative Declines Genetic Testing|Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.
62148107|NCT03294187|PLACEBO_COMPARATOR|Monitoring|Study subjects will use identical devices over a period of 6 weeks. Patients will \*not\* receive multimodal feedback.
62518386|NCT06271902|ACTIVE_COMPARATOR|Control group|Participants will be instructed to perform the lower body stretching program at a recommended frequency of two times per week.
62710770|NCT06087380|EXPERIMENTAL|Arms and Interventions|The experimental group A total of 32 patients to undergo auricular acupuncture interventional
62710771|NCT06087380|OTHER|No Intervention: Control group:|The control group total 30 patients No interventions implemented
62148108|NCT02402270|EXPERIMENTAL|ECP-019 A (Group A)|
61974615|NCT02601131||Control|Patients with AML, ALL or MDS that have low PLC (10-20 billion/L) and is not relevant for platelet transfusion. Samples taken in the same manner as in the other groups. Control is needed to rule out other causes of variation of the PLC than the platelet transfusion and thereby strengthen the causality between a given transfusion and increased PLC.
61974616|NCT04544254|ACTIVE_COMPARATOR|Bilateral transversus thoracis muscle plane block|Regional block will be performed after induction of anesthesia by anesthesiologist on duty who is not part of investigators for this study. The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided
62148109|NCT02402270|EXPERIMENTAL|ECP-019 B (Group B)|
62148110|NCT02402270|EXPERIMENTAL|ECP-019 C (Group C)|
62148111|NCT02402270|ACTIVE_COMPARATOR|Group D|
62148112|NCT02402270|ACTIVE_COMPARATOR|Group E|
62148113|NCT03622957||Type 2 diabetes subjects|Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic
62518387|NCT04688580|EXPERIMENTAL|XW10172|
62518388|NCT03443193|EXPERIMENTAL|Linear training|Linear training consists to a progressive improvement of the training load during the 3 month-program.
62518389|NCT03443193|EXPERIMENTAL|Non-linear training|Non-linear training consists to an undulating progressive improvement of the training load during the 3 month-program.
62518390|NCT02726919|OTHER|Clobazam treatment|This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment
62518391|NCT01092078|EXPERIMENTAL|Motivational Interviewing|Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
62518392|NCT01092078|EXPERIMENTAL|Patient Navigation|Participants in the patient navigation arm will receive patient navigation for colonoscopy.
62518393|NCT01092078|EXPERIMENTAL|PLUS|Both patient navigation for colorectal cancer screening and motivational interviewing for blood pressure control
62518394|NCT06102408||Patients with only one etiological workup|patients who underwent only one set of exams for etiological investigations of uveitis
62518395|NCT06102408||Patients without diagnostic modification subsequently to the second etiological workup|Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was not modified by the second line investigations.
62518396|NCT06102408||Patients with diagnostic modification subsequently to the second etiological workup|Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was modified by the second line investigations.
62518397|NCT00952276|EXPERIMENTAL|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)
62518398|NCT00952276|EXPERIMENTAL|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)
62518399|NCT00952276|ACTIVE_COMPARATOR|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
62518400|NCT00952276|ACTIVE_COMPARATOR|A/H1N1 Vaccine Group 4|Participants will receive A/H1N1 vaccine formulation 4
62518401|NCT00952276|PLACEBO_COMPARATOR|Placebo Group 5|Participants will receive a placebo vaccine
62710772|NCT02286063|ACTIVE_COMPARATOR|ambulatory oxygen cylinders|Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
62710773|NCT02286063|NO_INTERVENTION|no oxygen cylinders|Subjects randomised to be on air for the first two weeks of the treatment period.
62710774|NCT00492453|ACTIVE_COMPARATOR|1|Laparoscopic cholecystectomy under spinal anesthesia
62710775|NCT00492453|ACTIVE_COMPARATOR|2|Laparoscopic cholecystectomy under general anesthesia
61974617|NCT04544254|PLACEBO_COMPARATOR|Control|Needle will be put in the superficial skin on the same area as transversus thoracis muscle plane block area without any drugs injected into the injection area
61974618|NCT01397474|NO_INTERVENTION|Control|The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume \> 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
62355523|NCT04213508|ACTIVE_COMPARATOR|Isotonic saline with frequency of 2 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
62355524|NCT04213508|ACTIVE_COMPARATOR|Hypertonic saline with frequency of 2 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
62355525|NCT04213508|ACTIVE_COMPARATOR|Isotonic saline with frequency of 5 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
62355526|NCT04213508|ACTIVE_COMPARATOR|Hypertonic saline with frequency of 5 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
62355527|NCT02656901|ACTIVE_COMPARATOR|Auto Total endovenous anesthesia|The closed loop delivering as already approved by ClinicalTrials.gov Identifier: NCT00392158
62355528|NCT02656901|SHAM_COMPARATOR|Manual Desflurane anesthesia|The anesthesia will be maintained with desflurane to target the BIS of 50.
62355529|NCT02656901|SHAM_COMPARATOR|Manual sevoflurane anesthesia|The anesthesia will be maintained with sevoflurane to target the BIS of 50.
62355530|NCT02656901|SHAM_COMPARATOR|Manual total endovenous anestesia|In ManualTIVA group, the anesthesia will be maintained with propofol to target the BIS of 50
62355531|NCT02501902|EXPERIMENTAL|Palbociclib + Nab-Paclitaxel|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
62355532|NCT01089816||All|Anyone presenting with influenza-like-illness
62518402|NCT03297671||Pregnant Women|2000 pregnant women from the communities in the catchment area of THQ Johi and DHQ Dadu. Rh negative women will receive two RhIg prophylaxis injections.
62518403|NCT03297671||Lady Health Visitors (LHVs)|3-5 LHVs who are full time employees at THQ Johi and DHQ Dadu. LHVs will perform ELDONCARD test and provide RhIg prophylaxis injections.
62518404|NCT02827890|EXPERIMENTAL|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Januvia Tab. 100mg)\*1T/day for 5 days, QD, PO.~Period 2: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)\*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
62518405|NCT02827890|EXPERIMENTAL|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)\*1T/day for 5 dyas, QD, PO.~Period 2: Treatment A(Januvia Tab. 100mg)\*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
62518406|NCT04209673||Transcutaneous nerve stimulation (TENS) patients|Patients who received a TENS unit after surgery
62518407|NCT04209673||No TENS|Historic controls- Patients who did not receive a TENS unit after surgery
62355533|NCT05507645|EXPERIMENTAL|rhPro-UK (35mg)|rhPro-UK: 35 mg (5 mg per vial, 7 vials in total) Dissolve 15mg (3 vials) of rhPro-UK in 10ml of saline and intravenous bolus within 3 minutes, and dissolve the remaining 20mg (4 vials) in 90ml of saline and intravenous drip within 30 minutes. (Note: after adding saline, overturn it gently once to twice, do not shake vigorously, so as to avoid foaming of the rhPro-UK solution and reduce the efficacy).
62355534|NCT05507645|ACTIVE_COMPARATOR|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators according to the 'Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018'.
62355535|NCT00865189|EXPERIMENTAL|Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)|In this arm, participants will undergo 3 phases of treatment. During the Phase 1, participants will receive induction chemotherapy with 6 two-week cycles of bevacizumab + Folfox-4 (5-FU + oxaliplatin + folinic acid) for 12 weeks followed by a treatment-free interval of 3 to 4 weeks. The Phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (intravenous \[IV\] infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy \[5-FU + radiotherapy\], with administration of bevacizumab every two weeks \[Cycles 1, 3 and 5\]) followed by a treatment-free interval of 6 to 8 weeks. The Phase 3 will be surgery involving a radical rectal excision using the total mesorectal excision (TME) technique.
62355536|NCT00865189|EXPERIMENTAL|Arm B (Bevacizumab, Chemoradiotherapy)|In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy \[5-FU + radiotherapy\], with administration of bevacizumab every two weeks \[Cycles 1, 3 and 5\]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.
62355537|NCT05579119|EXPERIMENTAL|Sitagliptin + glargine|Sitagliptin and glargine once daily + correction doses of lispro if needed.
62355538|NCT05579119|ACTIVE_COMPARATOR|Basal-plus|Glargine once daily plus correction doses of lispro if needed.
62355539|NCT03574415|EXPERIMENTAL|Japanese_DWP14012 Amg|DWP14012 Amg, tablets, orally, single and multiple administration
62355540|NCT03574415|EXPERIMENTAL|Japanese_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
62355541|NCT03574415|EXPERIMENTAL|Japanese_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
62355542|NCT03574415|EXPERIMENTAL|Caucasian_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
62355543|NCT03574415|EXPERIMENTAL|Caucasian_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
62355544|NCT03574415|EXPERIMENTAL|Korean_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
62355545|NCT03574415|EXPERIMENTAL|Korean_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
62355546|NCT03574415|PLACEBO_COMPARATOR|Placebo|DWP14012 placebo-matching tablets
62355547|NCT05724017|EXPERIMENTAL|Street Games Intervention Group|Street Games Intervention Group
62355548|NCT02333006|OTHER|Traumatic brain injury questionnaires|Traumatic brain injury patients with anosognosia will answer to quetionnaires about Anosognosia compare to the answer of participant without neurological deficits
62355549|NCT04896307||Physicians at The Ottawa Hospital|Online survey completed by physicians working at The Ottawa Hospital consisting of the 2-item Maslach Burnout Inventory, a Satisfaction Questionnaire and the 12-Item Participatory Management Leadership Score.
62355550|NCT03226561|ACTIVE_COMPARATOR|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
62355551|NCT03226561|NO_INTERVENTION|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
62355552|NCT03457480|EXPERIMENTAL|Prevention (text messages, computer messages)|"PHASE I: Participants attend focus group over 2 hours.~PHASE II: Participants receive 2 text messages per day for 30 days at baseline and after 3 months.~PHASE III: Participants read 64 computer messages with or without images over 30 minutes and have their facial expressions assessed."
62355553|NCT04991272|ACTIVE_COMPARATOR|warming group|Warming group patients are applied prewarming with bair-hugger (43'C)(warm touch, COVIDIEN, full body blanket) for 10 minutes in the preanesthetic unit prior to induction of anesthesia. During operation, prewarmed intravenous fluid which was stored in the warming cabinet for more than 8 hours is connected and infused. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
62355554|NCT04991272|NO_INTERVENTION|no warming group|No warming group patients are not applied prewarming devices. Intravenous fluid stored in room air is connected and infused during the operation. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
62355555|NCT04477915|EXPERIMENTAL|Core stabilization Exercise|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises. Exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
62355556|NCT04477915|EXPERIMENTAL|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles. exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
62355557|NCT04477915|NO_INTERVENTION|Control|Control Group
62355558|NCT03159013|OTHER|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
62355559|NCT03159013|OTHER|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
62355560|NCT02043236|ACTIVE_COMPARATOR|Healthy bones pamphlet, letter to GP|Strategy 1: Written educational material to patient and GP
62355561|NCT02043236|ACTIVE_COMPARATOR|Healthy bones pamphlet, Bone Health Care Coordinator|Strategy 2: Written educational material to patient and counseling from a Bone Health Care Coordinator
62355562|NCT02043236|NO_INTERVENTION|Usual care|Control group gets usual care from their oncologist.
62710776|NCT01349114|ACTIVE_COMPARATOR|aliskiren 300 mg once daily for 12 weeks|aliskiren 300 mg daily
62710777|NCT01349114|PLACEBO_COMPARATOR|Sugar pill/ placebo|Patients were double-blind placebo-controlled randomized to either aliskiren 300 mg once daily or sugar pill/ placebo
62710778|NCT02063256|ACTIVE_COMPARATOR|7 NUTS a day|the patients allocated to this arm will be instructed to supplement their diet with 7 nuts a day (whole shelled weight around 75 grams)
61974619|NCT01397474|EXPERIMENTAL|PPTFM|"The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a bad peripheral perfusion (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2."
62710779|NCT02063256|EXPERIMENTAL|Diet modification|the patients allocated to this arm will be instructed to modify their diet allowing more intake of PUFA rich food avoiding saturated fat rich food
62710780|NCT04999410|EXPERIMENTAL|Long-HITT|Long work bout durations (4 minutes) on cycle ergometers or home trainers
61974620|NCT00619801|PLACEBO_COMPARATOR|Placebo|
61974621|NCT00619801|EXPERIMENTAL|Levocetirizine|
61974622|NCT03386682|EXPERIMENTAL|ESTYME MATRIX|Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)
61974623|NCT03336333|EXPERIMENTAL|Cohort 1: Bendamustine + Rituximab|Participants will receive bendamustine plus rituximab for up to six 28-day cycles (Arm B)
62148114|NCT05185973|EXPERIMENTAL|"For-Baby powder supplement"|For-baby supplements provided as powder containing dry yeast powder, biovita mixed probiotics, synergy probiotics and other nutrients such as glucose, xylitol, chocolate powder, chocolate flavor powder, organic galactose oligosaccharide, chicory extract powder, vegetable Cream substitute, silicon dioxide, milk flavor powder, whole milk powder, zinc oxide, vitamin B12, vitamin B6, enzyme mixed preparation, vitamin C, organic alpha rice powder, folate 0.4mg, thiamine, leucin, isoleucin, valine, glutamine, and magnesium chloride.
62710781|NCT04999410|ACTIVE_COMPARATOR|Medium HIIT-L|Medium duration work bouts (2 minutes) with intensity matched to the Long-HITT intensity
62710782|NCT04999410|ACTIVE_COMPARATOR|Medium HIIT-H|Medium duration work bouts (2 minutes) with intensity at 30% of the difference between Wmax and mean TT power outputs
62710783|NCT04999410|ACTIVE_COMPARATOR|Short HIIT|Short duration work bouts (30 seconds) with intensity at 50% of the difference between Wmax and mean TT power outputs
62710784|NCT05231863||Observational Group|Patients receive TKIs after T-DM1 progression.
62710785|NCT02188329||Households with children under 13|Interviews were conducted with the parent or guardian of a child or children under age 13.
62710786|NCT02188329||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own.
62710787|NCT02188329||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
62710788|NCT02188329||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
62710789|NCT00806585|EXPERIMENTAL|MK-0736 0.5 mg|One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
62710790|NCT00806585|EXPERIMENTAL|MK-0736 2.0 mg|One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
62710791|NCT00806585|EXPERIMENTAL|MK-0736 8.0 mg|One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
62710792|NCT00806585|ACTIVE_COMPARATOR|HCTZ 12.5 mg → MK-0736 8.0 mg|one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks. Participant then switched to MK-0736 8.0 mg for 12 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
62710793|NCT00806585|PLACEBO_COMPARATOR|Placebo|One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)
62710794|NCT02590107|EXPERIMENTAL|Supportive care (Boost Plus, Pro-Stat 101)|Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.
61974624|NCT03336333|EXPERIMENTAL|Cohort 1: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm A)
61974625|NCT03336333|EXPERIMENTAL|Cohort 1a (China only): Bendamustine + Rituximab|Participants will receive bendamustine plus rituximab for up to six 28-day cycles (Arm B, China only)
61974626|NCT03336333|EXPERIMENTAL|Cohort 1a (China only): Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm A, China only)
62148115|NCT05185973|PLACEBO_COMPARATOR|Micronutrient powder|Micronutrient powder containing containing glucose 236.3mg, xylitol 150mg, chocolate powder 600mg, chocolate flavor powder 45mg, organic galactose oligosaccharide 60mg, chicory extract powder 60mg, vegetable Cream substitute 135mg, silicon dioxide 45mg, milk flavor powder 30mg, whole milk powder 75mg, zinc oxide 11.2mg, vitamin B12 2.6mg, vitamin B6 2mg, enzyme mixed preparation 2mg, vitamin C 1mg, organic alpha rice powder 1mg, folate 0.4mg, thiamine 0.5mg, and maltodextrin 1,541mg.
62518408|NCT03106558|ACTIVE_COMPARATOR|Manual instrument total knee replacement|
62710795|NCT00951392|EXPERIMENTAL|Problematic aging|
62710796|NCT00951392|EXPERIMENTAL|successful aging|
62710797|NCT03716648|ACTIVE_COMPARATOR|Subjective titration|After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
62710798|NCT03716648|EXPERIMENTAL|DISE-assisted titration|Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated.
62710799|NCT03716648|EXPERIMENTAL|PSG-guided titration|An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced.
62710800|NCT06324656|ACTIVE_COMPARATOR|Crystallized phenol|Crystallized phenol group: The patients will undergo to crystallized phenol application.
62518409|NCT03106558|ACTIVE_COMPARATOR|Robitic arm total knee replacement|
62518410|NCT05495373||healthy cases|healthy children at ages between 4-12
62518411|NCT02370225|EXPERIMENTAL|aerobic exercise|Subjects were submitted to a supervised walking, 3 times a week for 16 weeks.
62518412|NCT02370225|NO_INTERVENTION|no exercise|Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group.
62518413|NCT03642782|EXPERIMENTAL|early age of glaucoma or with important risk factors|All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
61974627|NCT03336333|EXPERIMENTAL|Cohort 2: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm C)
62148116|NCT04912765|EXPERIMENTAL|Neoantigen Dendritic Cell Vaccine and Nivolumab|"NA DC vaccine every 2 weeks at a dose of 3-5 million cells.~Adjuvant nivolumab every 2 weeks at 240mg when given concurrently with the vaccine; every 4 weeks at 480mg after vaccine treatment is completed for a total duration of 1 year."
62148117|NCT01275911|EXPERIMENTAL|Esmolol|
62148118|NCT01275911|ACTIVE_COMPARATOR|Remifentanil|
62518414|NCT06226922||PCIA-PONV Group|Patient-controlled intravenous analgesia (PCIA) will be used after surgery. Patients will receive dedicated follow-up. Routine bedside visits will be conducted twice daily after surgery to assess postoperative nausea and vomiting (PONV). The severity of nausea will be evaluated using the Visual Analogue Scale (VAS), where 0 indicates no nausea and vomiting, and 10 represents the most unbearable nausea and vomiting. When the PONV score is \>0 or vomiting occurs, it is defined as the PCIA-PONV group.
62518415|NCT06226922||None PCIA-PONV Group|Patient-controlled intravenous analgesia (PCIA) will be used after surgery. Patients will receive dedicated follow-up. Routine bedside visits will be conducted twice daily after surgery to assess postoperative nausea and vomiting (PONV). The severity of nausea will be evaluated using the Visual Analogue Scale (VAS), where 0 indicates no nausea and vomiting, and 10 represents the most unbearable nausea and vomiting. When the PONV score is 0, it is defined as the None PCIA-PONV Group.
62518416|NCT06140121|EXPERIMENTAL|Experimental: VRPT then Traditional PT|Participants will receive Virtual Reality assisted Physical Therapy sessions (VRPT) in the first Physical Therapy (PT) session and will receive traditional Physical Therapy sessions (standard care) in the second Physical Therapy session under the supervision of the accredited physical therapist.
62518417|NCT06140121|EXPERIMENTAL|Traditional PT then VRPT|Participants will receive traditional Physical Therapy (PT) sessions (standard care) in the first Physical Therapy session and receive Virtual Reality assisted Physical Therapy sessions (VRPT) in the second Physical Therapy session under the supervision of the accredited physical therapist.
62518418|NCT02059330|EXPERIMENTAL|Healthy Subjects of Japanese Descent|Enrolled Japanese subjects will receive four palbociclib single doses of differing dose amounts in fixed sequence over four treatment periods.
62518419|NCT02059330|EXPERIMENTAL|Healthy Non-Asian Subjects|Enrolled healthy non-Asian subjects will receive a single 125mg oral dose of palbociclib in a single treatment period.
62518420|NCT01139918||Cohort A|40 patients with moderate psoriatic arthritis and moderate psoriasis
62518421|NCT01139918||Cohort B|40 patients with mild psoriatic arthritis and moderate psoriasis
62518422|NCT01139918||Cohort C|40 patients with moderate psoriatic arthritis and mild psoriasis
62518423|NCT04016337|EXPERIMENTAL|Intervention with beverage added with sucralose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with sucralose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener sucralose was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
62518424|NCT04016337|EXPERIMENTAL|Intervention with beverage added with saccharose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with saccharose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener saccharose was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
62710801|NCT06324656|EXPERIMENTAL|Crystallized phenol + platelet rich plasma|Crystallized phenol + platelet rich plasma group. Alongside the crystallized phenol application + patients also will receive platelet rich plasma injections in the same session.
62710802|NCT05173090|ACTIVE_COMPARATOR|Ropivacaïne 0,5%|3 mg/kg of ropivacaine 0.5% sprayed into the abdominal cavity
62710803|NCT05173090|PLACEBO_COMPARATOR|NaCl 0,9%|NaCl 0,9% sprayed into the abdominal cavity
62148119|NCT05647538||control group|underwent normal cesarean section without Postpartum hemorrhage after delivery
61974628|NCT03336333|EXPERIMENTAL|Cohort 3: Venetoclax + Zanubrutinib|Approximately 110 participants, 50 without del17p and 60 with del\[17p\] or TP53 mutation will receive zanubrutinib plus venetoclax; Participants will also receive zanubrutinib starting on Cycle 1 Day 1 then daily for a minimum of 27 cycles, or until unacceptable toxicity or disease progression, whichever occurs first. Participants will receive venetoclax starting Cycle 4 Day 1 according to a 5-week dose-up schedule then daily until unacceptable toxicity, disease progression, or for a maximum of 24 cycles. Each cycle is 28 days. (Arm D)
62148120|NCT05647538||case group|cases underwent bilateral uterine artery ligation after Postpartum hemorrhage or Intrapartum hemorrhage after cesarean section.
61974629|NCT05299515|EXPERIMENTAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRS-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention.
62518425|NCT04016337|EXPERIMENTAL|Intervention with beverage added with stevia|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with stevia extract was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener stevia was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
62518426|NCT03912402|EXPERIMENTAL|BCD-100|BCD-100 mg/kg Q3W
61974630|NCT05299515|NO_INTERVENTION|Treatment As Usual|Participants in the TAU group will receive treatment as usual (weekly group and individual counseling with an addiction counselor in addition to referral to other available services in the community through study contact).
62518427|NCT03829358|EXPERIMENTAL|Probiotic|Lactobacillus plantarum IS-10506
62518428|NCT03829358|PLACEBO_COMPARATOR|Placebo|Placebo
62710804|NCT06297148|EXPERIMENTAL|Self-management|"The intervention will consist of 3-5 individual sessions over 12 weeks with a physiotherapist.~There will be 3 physiotherapists delivering the self-management intervention."
62710805|NCT06297148|ACTIVE_COMPARATOR|Usual care|Given standardized information at baseline and free to choose further treatment in primary care.
61974631|NCT02250365|EXPERIMENTAL|Continuous, suprasensory ESS|
61974632|NCT02250365|ACTIVE_COMPARATOR|Intermittent, suprasensory ESS|
61974633|NCT04154020|EXPERIMENTAL|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
61974634|NCT04154020|NO_INTERVENTION|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
61974635|NCT03544502|EXPERIMENTAL|Music group|Music group (group M, n=35) patients applied CD player. One CDs were prepared with 5 children's songs (classic music) for the study. CD player opened during anesthesia induction and continued until postoperative 15 minute
61974636|NCT03544502|EXPERIMENTAL|Silence group|"silence group (group S, n=35) patients received the independent anesthesiologist applied earplugs into the patients' ears during anesthesia induction and the earplugs were removed immediately before tracheal tube extubation.~During each measurement, noise level recordings were performed using CEL-480 Sound Level Meter Sonometre."
61974637|NCT03544502|PLACEBO_COMPARATOR|Noise group|"noise group (group N, n=35) patients were exposed to the ambient operating room noise.~Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.Postoperatively, Emergence delirium (ED) was assessed as a Pediatric Anesthesia Emergence Delirium (PAED) Score ≥ 10."
61974638|NCT00828607||liver mass|The group will comprise any patients with an unknown liver mass at the time of diagnostic imaging.
61974639|NCT03535103|EXPERIMENTAL|ARM A|Gonal-F®
61974640|NCT03535103|EXPERIMENTAL|ARM B|LM001
61974641|NCT04235049|NO_INTERVENTION|In prison treatment arm|Of patients who achieved SVR, 100 inmates will be enrolled for long-term monitoring for re-infection after they have completed treatment. Patients will be seen every 6 months to test for reinfection, however they will not be subject to any medical or behavioral interventions through the study team. Limited opioid agonist therapy may be available as per the standard practice of the DOC, however syringe exchange and other harm reduction services will not be accessible to inmates, per DOC policy.
61974642|NCT04235049|ACTIVE_COMPARATOR|Community Linkage - Rapid Initiation Arm|The rapid initiation group will receive HCV medication immediately upon release from prison/jail.
62710806|NCT01832610||HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
62710807|NCT02455739|EXPERIMENTAL|chewing gum positive|chewing gum group will chew gum
61974643|NCT04235049|ACTIVE_COMPARATOR|Community Linkage - Clinic-Based Initiation Arm|The group will receive medication after attending first ANCHOR clinic visit.
61974644|NCT04235049|NO_INTERVENTION|In prison - Retrospective Review|a retrospective review of de-identified available data provided by the DOC for all patients previously treated with DAAs through standard of care in the DOC will be reviewed for rates of SVR.
61974645|NCT01347450|EXPERIMENTAL|Cocoa, Placebo|
61974646|NCT05629624|EXPERIMENTAL|Chickpea based RUSF|Locally produced ready to use supplementary food (RUSF), 50 g/packet contains 204 kcal energy). Two packets of RUSF provided for consumption at a rate of 50-100 kcal/kg/day till the child's weight for height returns to normal (WHZ \>-1SD) or for maximum 3 months.
61974647|NCT05629624|EXPERIMENTAL|E-RUSF|Enhanced Ready to use therapeutic feeds (E-RUSF), 50-100 kcal/kg/d daily until for anthropometric recovery (WHZ \> - 1SD) is achieved or for maximum 3 months then E-SQLNS will be given till the end of 2 years follow-up.
61974648|NCT05629624|NO_INTERVENTION|Well-nourished children|Well-nourished children at 1 year of age (WLZ/WHZ score \>-1 SD). No nutritional or psychosocial intervention. Only follow-up.
62355563|NCT04859972||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County between 2015- 2019, identified by ICD-code K.58.
62518429|NCT03431974|EXPERIMENTAL|LD-Aminopterin oral capsule|LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).
62518430|NCT03431974|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).
62518431|NCT01010022|EXPERIMENTAL|1|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
62518432|NCT01010022|ACTIVE_COMPARATOR|2|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
62518433|NCT03250299|EXPERIMENTAL|Dose Finding|Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
62710808|NCT02455739|NO_INTERVENTION|chewing gum negative|chewing gum group will not chew gum
62710809|NCT00016354|EXPERIMENTAL|benzoylphenylurea|
61974649|NCT05629624|EXPERIMENTAL|Outcome reference group|3 year olds previously untreated MAM children (WHZ \<-2 and ≥-3 z-score, and/or MUAC \<12.5 and ≥11.5 cm) and free from any acute illness will be used as the outcome reference group.
62710810|NCT01813383||HLA-DR3-DQ2 patients|Patients with HLA-DR3-DQ2 haplotype
62710811|NCT01813383||HLA-DR7-DQ2 patients|Patients with HLA-DR7-DQ2 haplotype
61974650|NCT03316664|EXPERIMENTAL|INT|Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min.
61974651|NCT03316664|ACTIVE_COMPARATOR|IPT|Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min.
62518434|NCT05739968|ACTIVE_COMPARATOR|control group|Control Group: Usual care + oncology case manager (OCM) care, UC group or Control group
62518435|NCT05739968|EXPERIMENTAL|experimental group|The experimental group is Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care. Main contents of MAP are to (a) cope multi-domain of distress, and (b) develop an active life style to handle their life after cancer, including effective coping, relaxation, regular physical activities, and balance nutrition. Four face-to face interventions will be delivered, including: day before hospital discharge post-operation, before the last weekly instillations of induction therapy (around 6±2 weeks post operation), 2nd-time cystoscopy and before 1st maintenance therapy (around 3- month post operation) and 3rd-time cystoscopy which before the second cycle of maintenance therapy (around 6- month post operation) \[section 1-4\], respectively.
62518436|NCT06392204|EXPERIMENTAL|Custom made reduction guides and 3D grid plates|Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate
62518437|NCT06392204|ACTIVE_COMPARATOR|Stock titanium plates|Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
62518438|NCT00513552|EXPERIMENTAL|Antibiotics|Antibiotics
62518439|NCT05319834|ACTIVE_COMPARATOR|Progesterone with asprin|The included women will be randomly allocated to prophylactically receive either vaginal progesterone at a dose of 200 mg (prontogest 200mg every 12 hr) combined with oral aspirin at a dose of 100mg once daily both at the same time (group1),
62518440|NCT05319834|PLACEBO_COMPARATOR|Progesterone and placebo|vaginal progesterone (prontogest 200mg every 12 hr) and oral placebo (manufactured in a standard way to have the same size and shape of asprin tablet) also at the same time (group 2).
62710812|NCT05201651|EXPERIMENTAL|Creatine|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
61974652|NCT03316664|OTHER|CoC|COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes.
61974653|NCT03132376|EXPERIMENTAL|Breakfast Preload Drink|"Participants were given isovolumetric drinks, to consume in the morning after an overnight fast, followed by questionnaires asking throughout the day asking participants of their perceived hunger, fullness, desire to eat, and prospective food consumption, and if they would like to eat again. Four hours following consumption, they were given an ad libitum pasta meal to consume.~The drinks consisted of the following:~Water Preload Drink, Whey Protein Isolate Drink, Micellar Casein Protein Drink, Egg White Isolate Protein Drink, and Egg White Concentrate Protein Drink"
62518441|NCT01574664||Subjects scheduled to undergo lumpectomy|
62518442|NCT04275726|EXPERIMENTAL|Myval THV Series|"Myval THV Series will include Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site.~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
62518443|NCT04275726|ACTIVE_COMPARATOR|Contemporary Valves|"* Sapien THV Series will consist of Sapien 3/Sapien 3 Ultra THVs or any subsequent advanced version commercially available at the study site.~* Evolut THV Series will include Evolut R/Evolut PRO THVs or any subsequent advanced version commercially available at the study site.~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
62518444|NCT02114957|EXPERIMENTAL|study herb|
62518445|NCT02037165|EXPERIMENTAL|Test Treatment 1: BI 1026706|BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet
62518446|NCT02037165|EXPERIMENTAL|Test Treatment 2: BI 1026706|BI 1026706 and placebo tablet
62518447|NCT02037165|EXPERIMENTAL|Reference Treatment 1: BI 1026706|Matching placebo to BI 1026706 PfOS and placebo tablet
62518448|NCT02037165|EXPERIMENTAL|Reference Treatment 2: Celecoxib|Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
62518449|NCT02037165|EXPERIMENTAL|Reference Treatment 3: Pregabalin|Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
62518450|NCT05539976||Healthy participants who perform taste evaluations|A maximum of 10 healthy adult participants will complete a maximum of 30 taste assessment days, to evaluate the taste characteristics of iberdomide or mezigdomide on each taste assessment day.
62518451|NCT03512951|EXPERIMENTAL|Normal hearing|A control group including ten normal-hearing participants. These participants are recruited because they can be considered as a reference when compared to hearing-impaired patients. They usually provide homogeneous results that are expected to be significantly different than those obtained with hearing-impaired patients. In this study, normal-hearing participants are expected to provide better and more consistent performance of auditory distance estimation.
62518452|NCT03512951|EXPERIMENTAL|10 experienced hearing impaired|A group of ten (expected sample size) severe-to-profound hearing-impaired patients who have a past and/or present experience of more than 6 months with remote microphone systems. These patients are expected to be aware of the drawbacks of the current remote microphone technology with respect to sound localization, auditory distance estimation, and audio-visual fusion.
62710813|NCT05201651|PLACEBO_COMPARATOR|Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
62710814|NCT01617473|EXPERIMENTAL|procedure/surgery|transplant with G-CSF mobilized PBSCs
62710815|NCT01617473|NO_INTERVENTION|other|no intervention after transplant with mobilized BMPB
62710816|NCT01854684|EXPERIMENTAL|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
61974654|NCT02705495|ACTIVE_COMPARATOR|acupuncture|12 acupuncture treatments according to a standardized protocol, plus recommendation for use of cranberry products
61974655|NCT02705495|OTHER|Control|Recommendation for use of cranberry products only
61974656|NCT03858088||Training set|Cohort of consecutive liver transplants performed in 2016-2017 from 14 liver transplant centers in Italy
62518453|NCT03512951|EXPERIMENTAL|10 naive hearing impaired|A group of ten severe-to-profound hearing-impaired patients with no past or current experience with remote microphone systems. They are referred to as naïve patients. These patients must have similar profiles to the patients in the experienced group as regards the degree of hearing loss, origin of hearing loss (congenital, pre- or post-lingual disability), age, gender, and hearing aid technology. They will be selected and recruited on the basis of the patients included in experienced group
62518454|NCT01170910|OTHER|Static incubation|If conservation in static incubation (group 1) is chosen by random selection, the transplant should be carried out while keeping the cold ischemic time (CIT) as short as possible (preferably less than 18 hours). Keep in mind that for reasons of homogeneity for result analysis and for conservation quality, it is recommended that kidneys in group 1 be conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution.
61974657|NCT03858088||Validation set|Cohort of consecutive liver transplants performed in 2016-2017 from 2 liver transplant centers in the United Kingdom
61974658|NCT06506227|EXPERIMENTAL|according to the order of their visits then were assigned numbers|The patients were assigned numbers according to the order of their visits, and after obtaining informed consent, they were divided into a treatment group and a control group to conduct a prospective cohort study.
61974659|NCT06506227|EXPERIMENTAL|According to the order of their visits to the clinic, given the appropriate number,|According to the order of their visits to the clinic, given the appropriate number, divided into the test group and the control group, in strict accordance with the results of the group, the appropriate treatment and observation of the group, the teams of personnel and the implementation of clinical treatment should not be the same person.
61974660|NCT03012425|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Session 1- Review of initial sleep diary, formulation of impression of type/subtype of insomnia, determine modifiable factors, address immediate concerns about participation, discuss motivation \& compliance. Session 2- Review of sleep diary, present 4-P model of insomnia, prescribe Sleep Restriction \& Stimulus Control Therapy. Session 3- Review of sleep diary, continue with stimulus control \& sleep restriction procedures, review of sleep hygiene. Session 4- Review of sleep diary, continue with stimulus control \& sleep restriction procedures, introduce \& practice relaxation strategies. Session 5- Review of sleep diary, continue with stimulus control \& sleep restriction procedures, conduct cognitive therapy to address dysfunctional thoughts underlying insomnia. Session 6- Review of sleep diary, continue with stimulus control \& sleep restriction procedures Session 7- Review of sleep diary \& overall progress, discuss relapse prevention, further sleep restriction guidelines \& prophylaxis.
62148121|NCT06365892|EXPERIMENTAL|Open-label Placebo (COLP)|Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Each oral opioid dose is a 5mg Oxycodone tablet. Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
62148122|NCT06365892|EXPERIMENTAL|Treatment As Usual (TAU)|Treatment As Usual (TAU) subjects will receive equal access to opioid and non-opioid analgesics. The preferred oral opioid dose is a 5mg Oxycodone pill. Subjects will take a placebo with each oral opioid dose and additional three times per day beginning on POD 1.
62518455|NCT01170910|EXPERIMENTAL|Pulsatile perfusion|If conservation in a pulsatile perfusion machine (group 2) is chosen by random selection, the kidney will be placed in the perfusion machine within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
62710817|NCT02427490|ACTIVE_COMPARATOR|Unenhanced Monitoring|Family caregivers of cancer patients receiving outpatient palliative care will complete standardized questionnaires at the time of study enrollment and two, four, and eight weeks after study enrollment.
62710818|NCT02427490|EXPERIMENTAL|Problem-Solving Intervention|Family caregivers of cancer patients receiving outpatient palliative care will use videoconferencing tools to participate in three problem-solving sessions with a member of the research team.
62710819|NCT06518967||Open|Test analysis perfomed in open to train the artificial intelligence algorithm.
62710820|NCT06518967||Blind|Test analysis performed in blind to minimize biases when evaluating the predictive performance of the IVD under investigation.
61974661|NCT03012425|EXPERIMENTAL|Acupuncture|Session 1 - Detailed history and examination, introduction to acupuncture. Sessions 2 - 10 - Each session will begin with insertion and manipulation of needles, which will remain in place for 30 minutes.
61974662|NCT03042533|ACTIVE_COMPARATOR|Conventional Compression|Nail will be seated using conventional compression technique
61974663|NCT03042533|ACTIVE_COMPARATOR|Standard Backslapping|Nail will be seated using standard backslapping technique
61974664|NCT03042533|ACTIVE_COMPARATOR|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
61974665|NCT03798990||users of French roads|all road users circulating on French roads outside over-seas
61974666|NCT00608231|EXPERIMENTAL|PD-STN|Parkinson's Disease -- STN target
61974667|NCT00608231|EXPERIMENTAL|PD - GPi|Parkinson's Disease -- GPi target
61974668|NCT00608231|EXPERIMENTAL|ET - VIM|Essential Tremor -- VIM target
61974669|NCT00608231|EXPERIMENTAL|Dystonia - GPi|Dystonia -- GPi target
61974670|NCT00608231|PLACEBO_COMPARATOR|PD - STN Control|Parkinson's Disease -- STN target
62148123|NCT00458094|EXPERIMENTAL|1|Participants will receive the peer-supported physical activity intervention
62148124|NCT00458094|ACTIVE_COMPARATOR|2|Participants will receive physical activity without peer support
62148125|NCT02372318|EXPERIMENTAL|Nalmefene Challenge|Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
61974671|NCT00608231|PLACEBO_COMPARATOR|PD - GPi Control|Parkinson's Disease -- GPi target
61974672|NCT00608231|PLACEBO_COMPARATOR|ET - VIM Control|Essential Tremor -- VIM target
62710821|NCT02944890|EXPERIMENTAL|RESTORE DEB|Conduct Drug Eluting Balloon Catheters(RESTORE DEB）
62518456|NCT05101226|EXPERIMENTAL|Intervention in person|The participants in this group will receive 8 weeks of yoga classes, that they attend in person.
62518457|NCT05101226|EXPERIMENTAL|Intervention online|The participants in this group will receive 8 weeks of yoga classes, that they attend online via zoom.
62518458|NCT05101226|OTHER|Waiting list control in person|The waiting list control in person group will participate in person in the same yoga classes as the intervention in person group but only after the first group has finished the intervention
62518459|NCT05101226|OTHER|waiting list control online|The waiting list control online group will participate online in the same yoga classes as the intervention online group but only after the first group has finished the intervention
62518460|NCT00522340|EXPERIMENTAL|Aerobic Exercise Program|
62518461|NCT00522340|NO_INTERVENTION|Usual Care|
62518462|NCT01414049|EXPERIMENTAL|On-pump CABG|
62518463|NCT01414049|EXPERIMENTAL|Off-pump CABG|
62518464|NCT01252264||Individuals with craniofacial anomalies|Individuals who have a craniofacial anomaly (head, face, or eye disorder)
62518465|NCT01252264||Control Subjects|Family members of individuals with a craniofacial anomaly
62518466|NCT05378919|ACTIVE_COMPARATOR|Arm A (Control): Radiotherapy + fluorouracil|Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy) , then 6-8 weeks after chemoradiation, surgery, followed by adjuvant chemotherapy for 4-6 months, either Folfox4 or fluorouracil, depending on the center's choice.
62710822|NCT02944890|ACTIVE_COMPARATOR|SeQuent® Please|Conduct Drug Eluting Balloon Catheters(SeQuent® Please）
62518467|NCT05378919|EXPERIMENTAL|Arm B (Experimental): Chemotherapy with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4) regimen|"Neoadjuvant CT FOLFOX4, 8 cycles (ca. 4 months; each cycle = 2 weeks):~oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles)."
62710823|NCT03588702|EXPERIMENTAL|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
62518468|NCT04989777|NO_INTERVENTION|Control group|Patients with AMI and shock stage B were received Standardized treatment
62518469|NCT04989777|EXPERIMENTAL|IABP group|Patients with AMI and shock stage B were received Standardized treatment and IABP treatment
62518470|NCT02794259|EXPERIMENTAL|Anodal tDCS|Anodal stimulation during resting state fMRI
62518471|NCT02794259|EXPERIMENTAL|Cathodal tDCS|Cathodal stimulation during resting state fMRI
62518472|NCT02794259|SHAM_COMPARATOR|Sham tDCS|Sham stimulation during resting state fMRI
62518473|NCT01091272|EXPERIMENTAL|Cohort 1|Single dose 3 period interleaved cross-over with placebo substitution
62518474|NCT01091272|EXPERIMENTAL|Cohort 2|Single dose 4 period interleaved cross-over, placebo substitution, with food effect
62518475|NCT01091272|EXPERIMENTAL|Cohort 3|Single dose 4 period cross-over, placebo insertion, with food effect
62710824|NCT04201704|ACTIVE_COMPARATOR|Liberal IV Fluid|"* Maintenance fluid rate calculated by 4-2-1 formula for patients \<110kg: 4 mL/kg for first 0-10kg + 2 mL/kg for 11-20kg + 1 mL/kg for each kg \>20kg~* Patients \>110kg maintenance 150 mL/hr~* Bolus Criteria: change in 1 of: \>20% decrease in systolic blood pressure 50th percentile for age and sex, \>20% increase in heart rate over 50th percentile for age, base excess \> -5mmol/L, blood lactate \>2mmol/L, AND urine output (UO) \<1 mL/kg/hr if \<50kg or \<50 mL/hr if \>50kg~* If criteria met: bolus 20 mL/kg if \<50kg or 1 L if ≥50 kg~* For transfusion: give 10 mL/kg packed red blood cells, platelets, or fresh frozen plasma up to 250 mL. If \>25kg give 250 mL.~* Diuresis- after minimum 24hrs: if UO \<2 mL/kg/hr (or \<100 mL/hr if \>50 kg) continue maintenance rate and bolus per initial phase. If UO \>2 mL/kg/hr (or \>100 mL/hr if \>50kg), and lactate, systolic blood pressure, heart rate, creatinine are normal then lower IV fluid rate to ½ maintenance rate and then to keep vein open once on regular feeds"
61974673|NCT00608231|PLACEBO_COMPARATOR|Dystonia - GPi Control|Dystonia -- GPi target
62518476|NCT01091272|EXPERIMENTAL|Optional Cohort 4|Single dose 3 period cross-over with placebo substitution
62518477|NCT03870113|EXPERIMENTAL|Vaccinated group|Patients will be vaccinated with autologous mature dendritic cells-loaded with HPV 16/18 E6/E7, DC vaccine will be injected into the adjacent lymph-node 6 times, once a week.
62518478|NCT00196131|NO_INTERVENTION|0|
62518479|NCT00517959|EXPERIMENTAL|1|Stereotactic conformal radiotherapy (SCRT)
62518480|NCT00517959|OTHER|2|Conventional radiotherapy Patients in this arm will be treated with conventional radiotherapy techniques being used at the moment in the department. This involves patient being immobilised with a customised thermoplastic mask after which they will have a contrast enhanced planning CT scan. The radiation oncologist will draw the tumour on the appropriate CT slices and a margin of 1-2 cms grown for the planning target volume. Beam arrangement will be relatively simple and typically consist of 2-3 coplanar fields using 6 MV photons. Conventional planning optimisation will be carried out by the use of wedges, beam weightage and corner shields as appropriate. Radiotherapy doses, prescription and fractionation schedules will be identical to the SCRT arm
62518481|NCT01094249|EXPERIMENTAL|001|divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
62518482|NCT03632317|EXPERIMENTAL|Panobinostat and Everolimus|Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
62518483|NCT05240131|EXPERIMENTAL|Part A - GB1211 200 mg and 100 mg BID in combination with atezolizumab.|Part A of the study, open-label sentinel dosing will be undertaken to assess safety and tolerability of GB1211 at 200 mg and 100 mg BID in combination with atezolizumab.
62518484|NCT05240131|EXPERIMENTAL|Part B - GB1211 (200 or 100 mg BID) or Placebo in addition to atezolizumab|Part B of the study, GB1211 (200 or 100 mg BID to be selected from part A) in addition to atezolizumab, for 12 weeks
62518485|NCT05240131|EXPERIMENTAL|Part C - Extension of GB1211 (200 or 100 mg BID) or Placebo in addition to atezolizumab|"Extension of GB1211 in addition to atezolizumab until part B has been unblinded.~Extension of placebo in addition to atezolizumab until part B has been unblinded"
62518486|NCT03946020|ACTIVE_COMPARATOR|Augmentation with autologous bone + DBBM|A layer of autogenous bone chips was placed on the implant surface. On top of this a layer of DBBM (Bio-Oss™, Geistlich®, Wolhusen, Switserland) was placed, thereafter covered with a collagen membrane.
62518487|NCT03946020|EXPERIMENTAL|Augmentation with DBBM|A layer of DBBM was placed on the implant surface and thereafter covered with a collagen membrane. Care was taken to make both augmentations as comparable as possible by weighting the used amount of graft material.
62518488|NCT03131622|EXPERIMENTAL|Digital Therapeutics|Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
62518489|NCT03131622|NO_INTERVENTION|Control|
62518490|NCT01068379|EXPERIMENTAL|Cryopexy|the cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
62518491|NCT01068379|EXPERIMENTAL|laser photocoagulation 4 weeks after|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
62518492|NCT03353454|EXPERIMENTAL|Maralixibat (SHP625)|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) orally twice daily for 26 weeks.
62518493|NCT03353454|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
62518494|NCT04906317|ACTIVE_COMPARATOR|Sedation and Analgesia|0.05 mg/kg midazolam and 5mg dezocine iv infusion
62518495|NCT04906317|ACTIVE_COMPARATOR|Anesthesia|continuous 1.5mg/kg propofol iv infusion
62518496|NCT00916136|ACTIVE_COMPARATOR|Cutaneous Traction|Applied by using a strap on boot that attaches to the leg. A rope is attached to the boot. Weight is attached to the rope to use gravity to pull traction. The traction is left in place until patient is taken to surgery for reduction of the femur fracture.
62518497|NCT00916136|ACTIVE_COMPARATOR|Skeletal Traction|A small incision is made on the inside of the knee and a pin is surgically inserted through the bone. Weights are then attached that will pull traction on the broken femur. This traction pin will stay in until patient is taken to surgery for reduction of the femur fracture.
62518498|NCT04677855|EXPERIMENTAL|PCUR-101 Dose Escalation|PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
62148126|NCT02372318|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
62148127|NCT02695004|EXPERIMENTAL|Donepezil 35 mg|Donepezil 35 mg or placebo
62148128|NCT02695004|EXPERIMENTAL|Donepezil 70 mg|Donepezil 70 mg or placebo
62148129|NCT02695004|EXPERIMENTAL|Donepezil140 mg|Donepezil 140 mg or placebo
62518499|NCT04677855|EXPERIMENTAL|PCUR-101 Dose Expansion Cohort 1|PCUR-101 dosed orally once per day in 28 day cycles
62148130|NCT02695004|EXPERIMENTAL|Donepezil 210 mg|Donepezil 210 mg or placebo
62148131|NCT02695004|EXPERIMENTAL|Donepezil 280 mg|Donepezil 280 mg or placebo
62148132|NCT03810170|ACTIVE_COMPARATOR|control|control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
62148133|NCT03810170|EXPERIMENTAL|intervention|intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
62148134|NCT01760005|EXPERIMENTAL|Gantenerumab|This arm completed and is closed.
62518500|NCT04677855|EXPERIMENTAL|PCUR-101 Dose Expansion Cohort 2|PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
62518501|NCT04677855|EXPERIMENTAL|PCUR-101 Dose Expansion Cohort 3|PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles
62518502|NCT01129934|EXPERIMENTAL|Morphine-Promethazine|Pain relief by administration of morphine-promethazine combination
62518503|NCT01129934|ACTIVE_COMPARATOR|morphine|pain relief by administration of morphine
62518504|NCT00988936|EXPERIMENTAL|[F-18]RDG-K5|
62518505|NCT01221246|EXPERIMENTAL|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
62148135|NCT01760005|EXPERIMENTAL|Solanezumab|This arm completed and is closed.
62148136|NCT01760005|PLACEBO_COMPARATOR|Matching placebo (Gantenerumab)|This arm completed and is closed.
62148137|NCT01760005|PLACEBO_COMPARATOR|Matching Placebo (Solanezumab)|This arm completed and is closed.
62148138|NCT01760005|NO_INTERVENTION|Cognitive Run-in|
62148139|NCT01760005|ACTIVE_COMPARATOR|Gantenerumab Open Label Extension|Subcutaneously every 4 weeks at escalating doses
62518506|NCT01221246|PLACEBO_COMPARATOR|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.
62539527|NCT05372640|EXPERIMENTAL|Treatment (ZEN003694, abemaciclib)|Patients receive ZEN003694 PO QD on days 1-28 or 5 days on and 2 days off, and abemaciclib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo imaging evaluation, blood sample collection and tumor biopsy throughout the study.
62518507|NCT02317679|EXPERIMENTAL|Bosentan and laser|Patients with PWS resistant to PDL treatment will be included. A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject). The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
62148140|NCT01760005|EXPERIMENTAL|E2814 plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
62148141|NCT01760005|EXPERIMENTAL|Matching placebo (E2814) plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
62355564|NCT02760160|OTHER|Reconstituted grape powder|Open grape powder pouch and pour contents into volumetric measuring device. Add approximately 180 mL of water to container with grape powder. Stir for a minimum of 30 seconds and ingest.
62518508|NCT06406660|OTHER|Organoid-Guided therapy|All patients will be included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation and drug sensitivity tests.
62539528|NCT01182376|PLACEBO_COMPARATOR|Placebo|Half of the patients will be assigned placebo.
62539529|NCT01182376|EXPERIMENTAL|Multaq® (dronedarone)|Half of the patients will be prescribed dronedarone.
62355565|NCT05114148|EXPERIMENTAL|Holmium-166 radioembolization|Individualized holmium-166 radioembolization will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
62355566|NCT03174613|EXPERIMENTAL|LC51-0255|tablets, PO
62355567|NCT03174613|PLACEBO_COMPARATOR|Placebo|tablets, PO
62355568|NCT04696510||Chronic migraineurs|This group includes patients with chronic migraine.
62355569|NCT04696510||Control group|This group includes healthy subjects.
62355570|NCT04696510||Episodic migraineurs|This group includes patients with episodic migraine
62355571|NCT02238548|PLACEBO_COMPARATOR|Control group|Regular cholera vaccination
62355572|NCT02238548|EXPERIMENTAL|Milk bolus|Cholera vaccination - raw milk - bolus
62355573|NCT02238548|EXPERIMENTAL|Milk controlled|Cholera vaccination - raw milk - controlled intake
62355574|NCT04051476|EXPERIMENTAL|3-g footbath|Footbath with 3g ginger flour per liter of water
62355575|NCT04051476|EXPERIMENTAL|6-g footbath|Footbath with 6g ginger flour per liter of water
62355576|NCT04051476|EXPERIMENTAL|12-g footbath|Footbath with 12g ginger flour per liter of water
62355577|NCT04051476|PLACEBO_COMPARATOR|Warm water footbath|Footbath with warm water only
62355578|NCT05797363|EXPERIMENTAL|Experiment|Continuous midwifery support will be applied to the intervention group. The women included in the experimental group will be counseled on many issues such as nutrition, vaccinations, family planning, pregnancy follow-ups, normal birth and cesarean section surgery, coping with labor pain, puerperium process, baby care, starting from the pre-pregnancy period, during pregnancy, childbirth and postpartum periods.
62355579|NCT05797363|NO_INTERVENTION|Control Group|No action will be taken against this group.
62355580|NCT00561613|PLACEBO_COMPARATOR|1|SILCS with K-Y Jelly
62355581|NCT00561613|ACTIVE_COMPARATOR|2|SILCS with N-9
62539530|NCT03096912|EXPERIMENTAL|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
62539531|NCT00714610||1|Unilateral or bilateral large head metal on metal primary total hip arthroplasty
62355582|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
62355583|NCT06338046|ACTIVE_COMPARATOR|Sample A - Active treatment|28-day-treatment, with twice daily application (morning and evening) of a cosmetic formula containing NC65 - Vita D-Light at 0.5 %w/w. The cosmetic formula is a w/o emulsion done with cosmetic-grade ingredients according to GMP. The designed quantity to be applied on the face is approximately 2 mg.
62355584|NCT06338046|PLACEBO_COMPARATOR|Sample B - Placebo treatment|28-day-treatment, with twice daily application (morning and evening) of a cosmetic formula containing the same ingredient of the active treatment except for NC65 - Vita D-Light at 0.5 %w/w. The cosmetic formula is a w/o emulsion done with cosmetic-grade ingredients according to GMP. The designed quantity to be applied on the face is approximately 2 mg.
62355585|NCT02786108|EXPERIMENTAL|left gastric artery embolization|Patients undergoing left gastric artery embolization
62355586|NCT02786108|ACTIVE_COMPARATOR|healthy diet and exercise|Patients undergoing healthy diet and exercise
62355587|NCT02629614|EXPERIMENTAL|TAPS Stimulation|Temporal Afferent Patterned Stimulation (TAPS) is alternating bursts of TENS stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
62355588|NCT02629614|SHAM_COMPARATOR|Sham Stimulation|0 amplitude stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
62355589|NCT02945800|EXPERIMENTAL|Combination Therapy|Participants will receive nab-Paclitaxel and Gemcitabine on days 1, 8, and 15 of each 28 day cycle, for up to 12 cycles.
62355590|NCT03559192|PLACEBO_COMPARATOR|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
62148142|NCT00594282|EXPERIMENTAL|1|Enhanced Mammography (EM) - Women who are randomized to the Enhanced Mammography (EM) condition will receive a mammogram in which a MammoPad radiolucent breast plate cushion is used.
62355591|NCT03559192|EXPERIMENTAL|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2\*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
62355592|NCT03559192|PLACEBO_COMPARATOR|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
62355593|NCT03802656|EXPERIMENTAL|Anterior Vertebral Body Tethering|Subjects who will be undergoing the anterior vertebral body tethering surgery.
62355594|NCT00859807|EXPERIMENTAL|Sequence 1 (19 subjects)|"Period 1: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment.~Period 2: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis); reference treatment)."
62355595|NCT00859807|EXPERIMENTAL|Sequence 2 (19 subjects)|Period 1: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis Period 2: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment
62355596|NCT03939611|EXPERIMENTAL|Foot Reflexology Group|Foot reflexology was performed to the reflexology group infants. Foot reflexology application (FRA) involved relaxation for the first 3-5 minutes and the last 2 minutes; the remaining 12-15 minutes included stimulation of the brain and digestive system organs. To ensure relaxation, rotation was performed by using the thumbs of the hand under the feet, cephalocaudally. The session of FRA included stimulating the brain and medulla spinalis (2 min), the solar plexus (1min), the stomach (2min), the liver (2min), the pancreas (2min), the gallbladder (1min), and the ileocecal valve and intestine (5min) reflex points. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
62355597|NCT03939611|PLACEBO_COMPARATOR|Placebo Foot Reflexology Group|Placebo foot reflexology was performed to the placebo group infants. Placebo foot reflexology application (PFRA) was constrained to ineffective touch without any stimulation and pressure. The aim of the PFRA was to create only a touch effect. It was applied by patted the foot by using the thumbs of the hand, for 20 minutes with the same rotation and to the same points as FRA. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
62355598|NCT06131229|EXPERIMENTAL|Structured emotional education program (PEE)|A tutorial action focused on a structured program of emotional education with 20 activities divided into 5 blocks with specific objectives. The program involves 34 hours of group work, one per week in the tutoring hour, throughout the 23-24 school year.
62355599|NCT06131229|ACTIVE_COMPARATOR|Incidental tutorial action based on the school's regular curriculum (PCO)|An incidental tutorial action focused on the ordinary school curriculum for the 23-24 school year.
62355600|NCT05494983|OTHER|Session 1 : Peripheral Session (left) - session 2 Central Session (right)|"The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm.~The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
62355601|NCT05494983|OTHER|Session 1 : Peripheral Session (right) - session 2 Central Session (left)|"The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm.~The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
62355602|NCT05494983|OTHER|Session 1 : Central Session (left) - session 2 Peripheral Session (right)|"The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm.~The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
62355603|NCT05494983|OTHER|Session 1 : Central Session (right) - session 2 Peripheral Session (left)|"The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm.~The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
62518509|NCT02794935|EXPERIMENTAL|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
61974674|NCT02279901|NO_INTERVENTION|Traditional|Patients will attend a 1 hour OSA Class where OSA education is provided and home sleep testing is set up. These patients return the next day for individual appointments where study is scored and test results are discussed with patient. If study is consistent with OSA based on AHI4% at least 5/hour, patients undergo a 1 week autoCPAP trial. During this week, wireless remote monitoring is performed and troubleshooting is provided via telephone if problems with CPAP use are identified. The autoCPAP is returned during an individual visit, and CPAP is ordered for long-term use based on trial results and patient feedback. Patients are scheduled a 3 month follow-up appointment but are also instructed to call their sleep center case manager prior to that visit if there are problems with CPAP use.
62518510|NCT02794935|PLACEBO_COMPARATOR|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
62518511|NCT00682214|ACTIVE_COMPARATOR|A, Choelcalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
62518512|NCT00682214|PLACEBO_COMPARATOR|B, Lactose|
62518513|NCT01580657|EXPERIMENTAL|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
62518514|NCT01580657|EXPERIMENTAL|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
62518515|NCT01580657|EXPERIMENTAL|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
62518516|NCT01580657|ACTIVE_COMPARATOR|D. Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
62518517|NCT01580657|ACTIVE_COMPARATOR|E. General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
62539532|NCT04142112|EXPERIMENTAL|Ohana IVF Sperm Preparation Kit|Samples in the Ohana IVF Sperm Preparation Kit group will undergo product-specific multistep processing in the lab prior to insemination.
62148143|NCT00594282|NO_INTERVENTION|2|Routine Mammography (RM) - Women who are randomized to the Routine Mammography (RM) condition will obtain a routine, un-altered mammogram during which typical exam protocol will be followed and no radiolucent cushion is used.
62148144|NCT05904210||Patients treated by SEVENFACT®|"Patients that initiated treatment with SEVENFACT® in real-world clinical care in the USA will be eligible.~Data from eligible patients' medical charts, bleeding diaries, and medication logs will be extracted from the time of initiation of SEVENFACT® treatment and for each bleeding episode and surgery or invasive procedure requiring treatment with SEVENFACT® or for prophylaxis, up until the data collection at the investigational site."
62148145|NCT02332889|EXPERIMENTAL|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
62355604|NCT04263194|EXPERIMENTAL|Default Mode Network (DMN)|The treatment will consist in the individually tailored stimulation of a DMN node (i.e. left inferior parietal lobe).
62355605|NCT04263194|EXPERIMENTAL|Central Executive Network (CEN)|The treatment will consist in the individually tailored stimulation of a CEN node (i.e. left dorsolateral prefrontal cortex).
62355606|NCT04263194|PLACEBO_COMPARATOR|Placebo|The treatment will consist in targeting the upper part of the scalp (i.e. CZ) while using a sham rTMS coil.
62355607|NCT02972112|ACTIVE_COMPARATOR|Study group|will receive 2 sessions of 90 minutes each of a cognitive behavioral protocol for the treatment of Tokophobia administered by a CBT trained midwife.
62355608|NCT02972112|SHAM_COMPARATOR|Control group|will receive 2 sessions of a delivery preparation course (practice as usual).
62355609|NCT06453772||Patients undergoing liposuction|
62355610|NCT04491240|EXPERIMENTAL|EXO-1|Participants (n=10) in this group will receive standard therapy and exosomes of the first type.
62355611|NCT04491240|EXPERIMENTAL|EXO-2|Participants (n=10) in this group will receive standard therapy and exosomes of the second type.
62355612|NCT04491240|PLACEBO_COMPARATOR|Placebo|Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.
62355613|NCT05860998||Toxoplasmosis positive|Healthy students with RhD-Negative blood with Toxoplasma gondii IgG Antibodies
62518518|NCT01580657|ACTIVE_COMPARATOR|F. No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
62518519|NCT04403217|EXPERIMENTAL|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
62518520|NCT02743143|EXPERIMENTAL|Exercise therapy|High aerobic intensity training and maximal strength training 2 times per week in 1 year at the Hospital's Exercise Training Clinic. Patients receive comprehensive support from Trondheim municipal administration to facilitate adherence.
62518521|NCT02743143|ACTIVE_COMPARATOR|Follow-up care as usual|The usual care (UC) group will receive the usual physical activity offered by the primary health care system. UC includes the traditional physical activity advice from the Health Directorate. The UC group are invited to supervised exercise at the exercise training Clinic after 1 year.
62518522|NCT04457453|ACTIVE_COMPARATOR|control group|intubation with direct laryngoscope in sniffing position
62518523|NCT04457453|EXPERIMENTAL|direct laryngoscope in Trendelenburg and Sellick position|intubation with direct laryngoscope in Trendelenburg and Sellick position
62518524|NCT04457453|EXPERIMENTAL|video laryngoscope in Trendelenburg and Sellick position|intubation with video laryngoscope in Trendelenburg and Sellick position
62518525|NCT06108258||Oral iron|
61974675|NCT02279901|EXPERIMENTAL|Telemedicine Education Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are emailed a link to view the Emmi OSA program within 2 weeks prior to their initial OSA class. If the patient tests positive for OSA and agrees to an autoCPAP trial, the patient is emailed a link to view the Emmi CPAP program. These patients are also scheduled for a 3 month follow-up visit to check CPAP usage.
62148146|NCT01286311|EXPERIMENTAL|Direct-to-patient tailored cardiovascular risk message system|Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
62518526|NCT06108258||IV iron|
62518527|NCT05992376|ACTIVE_COMPARATOR|Intervention|
62518528|NCT05992376|NO_INTERVENTION|Control/No Intervention|
62518529|NCT02772094|EXPERIMENTAL|Single arm, open-label|"Experimental:~ADCTA-G total 10 doses, each dose (30+/-5 millions autologous dendritic cells plus 6+/-0.5 millions 100Gy-irradiated short-term cultured autologous GBM tumor cells) divided in 2 halves for subcutaneous injection into both axillar areas, in a course of 6 months (sequential series of weekly injections 4 times, bi-weekly injections twice; then monthly injections 4 times.~Experimental: ADCTA-G total 10 doses, each dose (similar fore-mentioned numbers of 5:1 ratio of autologous dendritic cells and irradiated short-term cultured autologous GBM tumor cells) divided into 2 injections administered subcutaneously in both axillar areas, in a course of 8 months (sequential series of bi-weekly injections 4 times, then monthly injections 6 times)."
62518530|NCT02377635|EXPERIMENTAL|Treatment|Drug: Anhydrous selenite (Se-77), single dose 0.8mg, orally administered as a 100 ml purified water solution
62518531|NCT02377635|PLACEBO_COMPARATOR|Control|Drug: Placebo sodium chloride (table salt), orally administered as a 100 ml purified water solution
62518532|NCT04810442|EXPERIMENTAL|Nap Group|This group will be involved with taking a nap in between the two scanning procedures.
62518533|NCT04810442|NO_INTERVENTION|No-Nap Group|This group will not be taking a nap in between the two scanning procedures, and instead will be silently watching a film for the 45 minute period.
62518534|NCT06426173|EXPERIMENTAL|Resistance Training Group|Patients will receive the standard treatment provided by the hospital inpatient unit alongside the resistance training program.
62148147|NCT01286311|NO_INTERVENTION|Control|
62148148|NCT03690466|EXPERIMENTAL|Study device treatment|Transcutaneous non-invasive ultrasound will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
62148149|NCT03690466|SHAM_COMPARATOR|Sham device treatment|Sham treatment will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
62518535|NCT06426173|ACTIVE_COMPARATOR|Standard Treatment Group|Patients will receive the standard treatment provided by the hospital inpatient unit.
62518536|NCT04977661|ACTIVE_COMPARATOR|Group1|Group I (n = 34) received 400 IU Vitamin E (Vitamin E 400 IU®, MEPACO Pharmaceutical Company, Sharqia, Egypt) twice daily for 3 month
62518537|NCT04977661|ACTIVE_COMPARATOR|Group2|Group II (n =34) received 250 mg Ursodeoxycholic acid (Ursofalk 250 mg®, MINAPHARM Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
62518538|NCT04977661|ACTIVE_COMPARATOR|Group3|Group III (n = 34) received 400 mg sustained release (SR) Film-Coated Tablets of pentoxifylline (Trental 400 mg®, SANOFI Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
62518539|NCT04272723||VMP members of the SFMV|VMP (vascular medicine physicians) members of the SFMV (French Society of Vascular Medicine )
62518540|NCT04272723||VMP registered as willing to do medical research|VMP (vascular medicine physicians) registered as willing to do medical research
62518541|NCT03582761|EXPERIMENTAL|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
62518542|NCT01752231||DCE-MRI (dynamic contrast-enhanced MRI)|Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
62518543|NCT03022669|EXPERIMENTAL|Text Message Group|"The TM group will use the VA Annie text messaging program to remind patients to take antiplatelet medications. The content for the text messages will be determined through preliminary focus groups that will be conducted prior to the RCT."
62518544|NCT03022669|EXPERIMENTAL|Application Group|"The App group will use a mobile application to remind patients to take antiplatelet medications. The commercially available mobile app will be selected by participants through preliminary focus groups that will be conducted prior to the RCT."
62518545|NCT03022669|EXPERIMENTAL|Website-Control|"The Website-Control group will will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an attention-control. The website will be offered to participants in all three groups. The 7 small steps to big changes are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking."
62518546|NCT04904159||Benign|Patients who have benign pathologies after thyroidectomy
62518547|NCT04904159||Malign|Patients who have malign pathologies after thyroidectomy
62518548|NCT05987917|EXPERIMENTAL|Group RF+USN|Subjects will be enrolled for an active treatment with BTL-785F (BTL-785-2 applicator) delivering radiofrequency (RF) and ultrasound (USN) for non-invasive facial rejuvenation
62518549|NCT05987917|EXPERIMENTAL|Group RF|Subjects will be enrolled for an active treatment with BTL-785F (BTL-785-2 applicator) delivering radiofrequency (RF) only for non-invasive facial rejuvenation
62518550|NCT05987917|EXPERIMENTAL|Control|Control subject will not receive treatment
62539533|NCT04142112|ACTIVE_COMPARATOR|Standard IVF Preparation Kit|Samples in the Standard IVF Sperm Preparation Kit group will undergo traditional processing in the lab prior to insemination.
62710825|NCT04201704|EXPERIMENTAL|Restricted IV Fluid|"* Maintenance fluid rate calculated by 70% of 4-2-1 formula if \<110 kg: 4 mL/kg for first 0-10 kg, + 2 mL/kg for 11-20 kg, + 1 mL/kg for every kg \>20 kg~* Patients \>110 kg: maintenance is 105 mL/hr~* If same bolus criteria met: 10 mL/kg for patients \<50kg, or 500 mL if ≥50 kg~* If meet transfusion criteria: transfuse 10 mL/kg with packed red blood cells, platelets, or fresh frozen plasma by weight up to 250 mL. Patients \>25 kg get 250 mL per transfusion~* Diuresis (after minimum 24 hrs): if UO \<1 mL/kg/hr (or \<50 mL/hr if \>50 kg) then continue IV fluids at maintenance rate and bolus as needed. If UO 1-2 mL/kg/hr (or 50-100 mL/hr if \>50 kg) then decrease IV rate to ½ maintenance rate. If UO \>2 mL/kg/hr (or \>100 mL/hr if \>50 kg), and Lactate, systolic blood pressure, heart rate, creatinine normal then reduce to keep vein open and consider Furosemide for goal UO \>2-4 mL/kg/hr (100-200 mL/hr if \>50 kg) until euvolemic"
62710826|NCT06118658|EXPERIMENTAL|Chemotherapy-sequential tislelizumab adjuvant therapy|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
62710827|NCT02470702|EXPERIMENTAL|Oritavancin|Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
61974676|NCT02279901|EXPERIMENTAL|Telemedicine IVR Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. Additionally, if CPAP is ordered for long-term therapy, the patient is enrolled into an IVR protocol that automatically analyzes the patient's CPAP use. If specific provider-defined thresholds are met, the platform will automatically deliver feedback messages to the patient (phone call, text messaging, or email) with the intention of encouraging better CPAP use. Patients are instructed to contact the sleep center for any issues with their therapy. This platform also includes a method for patients to track their own usage online. Automated messaging mechanism will be active for 3 months after CPAP is ordered, after which the messaging will stop. These patients are also scheduled for a 3 month follow-up visit.
61974677|NCT02279901|EXPERIMENTAL|Telemedicine Both Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are provided both Emmi education programs and IVR follow-up as previously outlined. These patients are also scheduled for a 3 month follow-up.
61974678|NCT03280420|ACTIVE_COMPARATOR|early catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 3 days.
61974679|NCT03280420|ACTIVE_COMPARATOR|late catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 7 days.
61974680|NCT02095587|EXPERIMENTAL|Mild Hepatic Impairment|
61974681|NCT02095587|EXPERIMENTAL|Moderate Hepatic Impairment|
61974682|NCT02095587|EXPERIMENTAL|Healthy Subjects|
61974683|NCT02095587|EXPERIMENTAL|Severe Hepatic Impairment|Optional arm based on results from Arms 1, 2, and 3
61974684|NCT01983982||Adjuvant chemotherapy|Subjects will undergo pain testing, then receive standard of care chemotherapy, and then undergo pain testing.
61974685|NCT04496154|EXPERIMENTAL|Omega-3 fatty acids|3 oral softgels (600 mg EPA and 300 mg DHA / softgel), Triple Strength Omega-3 from Webber Naturals
61974686|NCT05782608|ACTIVE_COMPARATOR|group (I)|
61974687|NCT05782608|ACTIVE_COMPARATOR|group (II)|
61974688|NCT00926276|ACTIVE_COMPARATOR|Surgical Treatment Group-Fundoplication|Re-evaluated 1 month post-op Re-evaluated 2 months post-op
62148150|NCT06498609|EXPERIMENTAL|Microosteoperforation|MOPs with leveling and alignment that will be performed tow time according to standardized protocol
61974689|NCT00926276|ACTIVE_COMPARATOR|Medical Therapy|Treated by primary clinician for GERD Re-evaluated 1 month Proceed to Fundoplication if GERD persist by pH-MII Re-evaluated at 2 months (1 month post-op) Worsening BPD will be given option of immediate surgery
62148151|NCT06498609|EXPERIMENTAL|Injectable platelet rich fibrin|i-PRF with leveling and alignment that will be performed tow time according to standardized protocol
62148152|NCT06498609|NO_INTERVENTION|control group|leveling and alignment that will be performed without any intervention
62355614|NCT05860998||Toxoplasmosis negative|Healthy students with RhD-Negative blood without Toxoplasma gondii IgG Antibodies
62355615|NCT03755999|EXPERIMENTAL|PIOMI treat group|Preterm infant receive oral massage using the premature infant oral motor intervention (PIOMI)
62355616|NCT03755999|NO_INTERVENTION|Routine care group|Preterm infant receive routine care of neonatal intensive care unit(NICU)
62355617|NCT02800772|EXPERIMENTAL|acetic acid|spray 50ml acetic acid to duodenal bulb
62355618|NCT02800772|PLACEBO_COMPARATOR|saline|spray 50ml saline to duodenal bulb
62355619|NCT05848076|EXPERIMENTAL|TNE with core stability|Group A (TNE WITH CORE STABILITY) on low back this McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explain the patient about their pain.The study participants will receive the total 18 session over 6 weeks period consider 3 treatment session per week
62518551|NCT05057026||Adult mental health support program|The investigators will evaluate the Impact of an Adult mental health support program on stigmatization and confidence of medical residents working with people with mental health concerns. The intervention will be delivered to approximately 30 residents from the University of Dalhousie family medicine residency program from the 2021-2022 academic year. The training will be delivered by resident groups. The first group will receive the PSP training October - November 2022. The second will receive the training November 2021 to February 2022. The third will take the training March to May 2022. Each group will include approximately 10 residents.
62518552|NCT02547766|EXPERIMENTAL|Anakinra Arm|All patients in this arm receive Anakinra in a pre-post design. That is, outcome markers are measured, the intervention (Anakinra) is applied, and the outcome markers are measured again at various intervals to determine effect.
62518553|NCT00658931|EXPERIMENTAL|Treatment|
62518554|NCT06208826|EXPERIMENTAL|Toripalimab|toripalimab, IV, 240mg, q3w, for 15 cycles
62518555|NCT06208826|ACTIVE_COMPARATOR|SOC CCRT or radiotherapy|Standard concurrent radiochemotherapy or postoperative radiotherapy
62518556|NCT02714231|EXPERIMENTAL|diclofenac|oral diclofuhenac sodium
62518557|NCT02714231|ACTIVE_COMPARATOR|hyoscine|oral hyoscine butyl bromide
62518558|NCT04032158|EXPERIMENTAL|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
62518559|NCT04032158|ACTIVE_COMPARATOR|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
62148153|NCT05247307|EXPERIMENTAL|Intervention|"Treatment in the intervention group:~Infusion of 300 cc of convalescent donor plasma from COVID 19, administered within more than 168 hours from the onset of symptoms Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
62518560|NCT02459145|ACTIVE_COMPARATOR|Graduated Exercise Protocol|Intervention involves exercise starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation. The exercise protocol includes treadmill speed and track minutes per lap conversion, rate of perceived exertion and talk test for each stage of exercise plus total time to execute for 5 days each week.
62518561|NCT02459145|OTHER|Rest followed by Protocol|No activity in weeks 1 - 8. In week 9 we will begin their intervention phase as described in graduated exercise protocol
62518562|NCT02813421|EXPERIMENTAL|CGM Informed|CGM data was available for use when determining starting insulin pump doses.
62518563|NCT02813421|NO_INTERVENTION|Control|CGM data will remain secure and not used. Starting insulin pump doses will be made by standard of care.
62518564|NCT00804141|EXPERIMENTAL|MOA-728 12 mg QD|Participants will receive MOA-728 12 milligrams (mg) SC once daily (QD) for 48 weeks. Dosing could be adjusted to an as needed (PRN) basis with a minimum 1 dose per week and maximum 1 dose per day.
62518565|NCT01040884|EXPERIMENTAL|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
62518566|NCT04936776||Text message 1|Text messaging frame = safety and cleanness of clinic site. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
62518567|NCT04936776||Text message 2|Text messaging frame = importance of vaccines. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
62148154|NCT05247307|ACTIVE_COMPARATOR|Control|"Treatment in the control group:~For the study to be blind, the infusion of non-convalescent donor plasma, obtained before the start of the epidemic, is required to guarantee the absence of anti-COVID antibodies in the plasma of the control group.~Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
62148155|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
62148156|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
62148157|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
62148158|NCT02752984||PICC insertion|Peripherally Inserted Central Catheter insertion
62148159|NCT01933100|EXPERIMENTAL|Brown Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
62518568|NCT04936776||No text message|No text sent.
62518569|NCT01953822||Cervarix vaccinated (exposed) female cohort|Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.
62518570|NCT01953822||Unexposed historical female cohort|Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
62518571|NCT01953822||Unexposed concurrent male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.
62518572|NCT01953822||Unexposed historical male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
62518573|NCT05920564|EXPERIMENTAL|Intervention group|
62518574|NCT05920564|ACTIVE_COMPARATOR|Control group|
62518575|NCT03261882||Foreign-born Mexican-Americans|
62518576|NCT03261882||US-born Mexican-Americans|
61974690|NCT01894451|EXPERIMENTAL|89Zr-bevacizumab-PET/CT Scan|"* 89Zr-bevacizumab-PET/CT will be performed at baseline, after 2 cycles of preoperative chemotherapy, and at the completion of preoperative chemotherapy.~* The 89Zr-bevacizumab-PET/CT imaging procedure is detailed in Appendix A and is briefly described below.~Participants will be injected with 1 mCi of 89Zr-bevacizumab intravenously and PET/CT images will be obtained at 3-4 days after 89Zr-bevacizumab administration to allow time for antibody accumulation in the tumor. Imaging will be performed on a Centers for Quantitative Imaging Excellence (CQIE) qualified PET/CT scanner at the Dana-Farber Cancer Institute. After the baseline scan, subsequent scans will be obtained on the same PET/CT scanner for an individual participant."
61974691|NCT06459908|EXPERIMENTAL|Robot-assisted group (RG)|Patients in group A will perform these exercises while Wearing robotic hand-training gloves. Group A will perform hand exercises with the help of robotic glove assistance for 3 times per day/ 4 times per week, 45 minutes per session for 6 consecutive weeks, Number of total sessions will be 72 .
61974692|NCT06459908|ACTIVE_COMPARATOR|conventional hand rehabilitation exercises|The control group will receive the same treatment as Robot Assisted group but without any robot-assisted device.Group B will perform hand exercises without the help of robotic glove for 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Number of total sessions will be 72 .
61974693|NCT00902369|EXPERIMENTAL|AK106-001616|
61974694|NCT00902369|PLACEBO_COMPARATOR|Placebo|Part1: AK106-001616 and Placebo
62518577|NCT03261882||non-Hispanic Whites|
61974695|NCT00902369|ACTIVE_COMPARATOR|Active comparator|Part2: AK106-001616 and Active comparator
61974696|NCT06101745|ACTIVE_COMPARATOR|Nizaracianine Triflutate Study Drug Arm|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0, 2.5 or 5.0mg depending on trial phase.
62518578|NCT03634345|EXPERIMENTAL|PF-04965842|investigational drug
62518579|NCT00609388|ACTIVE_COMPARATOR|A|Group A receives an intraportal Tacrolimus-infusion, ATG Induction, Tacrolimus and Steroids.
62518580|NCT00609388|PLACEBO_COMPARATOR|B|Group B receives a placebo-Saline solution (0.9%)-Infusion, ATG induction, Tacrolimus and Steroids.
62518581|NCT04948229||Control Group|This group will be included subjects who had no history or diagnosis of any disease, no infection history within last two weeks, no history of any particular medication, who were admitted to emergency department (ED) with complaints other than infectious issues, and who gave their written consent to participate in the study.
61974697|NCT06101745|PLACEBO_COMPARATOR|Sugar Comparator Arm|In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo.
62148160|NCT01933100|EXPERIMENTAL|Polished Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
62518582|NCT04948229||Moderate Disease Group|This group will be consisted of the patients whose diagnoses of moderate COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
62518583|NCT04948229||Severe/Critical Disease Group|This group will be consisted of the patients whose diagnoses of severe/critical COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
62148161|NCT01933100|EXPERIMENTAL|Wheat Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
62148162|NCT02791295|EXPERIMENTAL|Diet and physical activity program|Diet and physical activity program with individual coaching
62148163|NCT02791295|NO_INTERVENTION|control|standard care
62148164|NCT01933945||TACE + early Nexavar|Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not).
62518584|NCT03697330|ACTIVE_COMPARATOR|Ringer's lactate 18-20 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group L:will receive 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
62518585|NCT03697330|ACTIVE_COMPARATOR|Ringer's lactate 4-6 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group R: will receive 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
62518586|NCT00320567|EXPERIMENTAL|001|norgestimate/ethinyl estradiol
62518587|NCT03874494|EXPERIMENTAL|Brexpiprazole|2-4 mg/day, once daily for 6 weeks, oral administration
62518588|NCT03874494|ACTIVE_COMPARATOR|Aripiprazole|10-20 mg/day, once daily for 6 weeks, oral administration
62518589|NCT01991665|OTHER|Group A|Digital examination before instrumental delivery to determine fetal head station and position
62518590|NCT01991665|OTHER|Group B|Digital examination before instrumental delivery to determine fetal head station and position + sonography evaluation of fetal head position
62710828|NCT02470702|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
62518591|NCT02917226|EXPERIMENTAL|Clinical decision support and monitoring system|
62518592|NCT02917226|NO_INTERVENTION|Control Group|
62518593|NCT02332980|EXPERIMENTAL|Treatment (pembrolizumab, idelalisib, or ibrutinib)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients with CLL or CLL with Richter's transformation experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.~CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator."
62518594|NCT04477551|EXPERIMENTAL|Diode laser (device) with scaling and root planing|Diode laser (device) with conventional scaling and root planing
62518595|NCT04477551|ACTIVE_COMPARATOR|Conventional scaling and root planing|Conventional scaling and root planing
62518596|NCT00775684|EXPERIMENTAL|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
62518597|NCT00775684|EXPERIMENTAL|Sitagliptin|Sitagliptin (Januvia®)-100 mg by mouth every morning
62518598|NCT00775684|ACTIVE_COMPARATOR|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose \< 110mg/dl
62518599|NCT02596386||potassium level in saliva|Each willing participant will undergo Sialometry
62518600|NCT02596386||blood test|blood will be drawn from the dialysis connections for Biochemistry for potassium level evaluation
62518601|NCT05473819|EXPERIMENTAL|Buffered Anaesthetic solution|8.4% sodium bicarbonate will be added to the 4% articaine HCL with 1:1000000 epinephrine carpule in ratio 19:1 the Articaine to the Sodium bicarbonate
62518602|NCT05473819|ACTIVE_COMPARATOR|Conventional Anaesthetic solution|4% Articaine HCL with 1:1000000 epinephrine Anaesthetic carpule
62518603|NCT03036839|EXPERIMENTAL|LDV/SOF for 8 weeks|Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
62518604|NCT03036839|EXPERIMENTAL|LDV/SOF for 12 weeks|Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
62518605|NCT03036839|EXPERIMENTAL|LDV/SOF for 24 weeks|Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks
62518606|NCT04668976|EXPERIMENTAL|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
62518607|NCT01635062|EXPERIMENTAL|calcitriol|Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
62518608|NCT01635062|PLACEBO_COMPARATOR|placebo|Subjects will receive placebo for 3 weeks.
62518609|NCT02136563||Darbepoetin alfa|
62518610|NCT02443545|EXPERIMENTAL|Group 1: Deferiprone 3 years|Patients in this group are those who were randomized to the deferiprone arm in study LA38-0411, and hence will receive deferiprone for a total of 3 years (1 year in the initial study plus 2 years in the extension study).
61974698|NCT05329272|EXPERIMENTAL|The VR group: the Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
61974699|NCT05329272|NO_INTERVENTION|The control group|The control group received usual care.
61974700|NCT05744544||External Oblique Intercostal Block Group|Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after EOIB. (external oblique intercostal block)
61974701|NCT05744544||modified-TAPA block|Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after m-Tapa. (modified- thoracoabdominal nerves block through perichondrial approach)
62518611|NCT02443545|EXPERIMENTAL|Group 2: Deferiprone 2 years|Patients in this group are those who were randomized to the deferoxamine arm in study LA38-0411, and hence will receive deferiprone for 2 years (both of them in the extension study).
62518612|NCT03182894|EXPERIMENTAL|Epacadostat + Pembrolizumab + Azacitidine|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
62518613|NCT04068974|EXPERIMENTAL|Test group|Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
62518614|NCT04576182|EXPERIMENTAL|Supportive-Expressive|Participants will receive supportive-expressive treatment for 16 weeks.
62518615|NCT04576182|EXPERIMENTAL|Emotion-Focused|Participants will receive Emotion-Focused treatment for 16 weeks.
62518616|NCT02784782|EXPERIMENTAL|Orthesis|Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol Intervention: After fitting the patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes.
62518617|NCT02784782|ACTIVE_COMPARATOR|No Orthesis|"Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol.~Control: The patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes."
62518618|NCT01066949|ACTIVE_COMPARATOR|Support and discussion|The Support and Discussion protocol will consist of two integrated components: (a) brief educational materials presented at the start of each session, and (b) group leader facilitated discussion following presentation of the educational materials.
62539534|NCT04502420||Abdominal surgery|People who to be operated in the abdomen are investigated before and after surgery.
62518619|NCT01066949|EXPERIMENTAL|Behavioral Self management|Self-Regulation group sessions will be generally highly leader-directed though participants will be regularly encouraged to share their experiences dealing with the dialysis regimen. A consistent attempt will be made to focus all group discussion on self-regulatory principles as they relate to treatment adherence.Session material utilized by group-leaders will be highly structured and detailed across the seven sessions.
62518620|NCT03974750|EXPERIMENTAL|intervention|Training on the rehabilitation robot REAplan(R) to learn complex, coordinated bimanual movements
62518621|NCT03974750|ACTIVE_COMPARATOR|control intervention|Training on the rehabilitation robot REAplan(R) with simple movements
62518622|NCT02164630|EXPERIMENTAL|Hope Therapy|Patients assigned to this arm will receive Hope Therapy in three individual intervention sessions. Intervention will be administered by an experienced therapist.Training focuses on effective goal setting and augmenting hopeful thinking.
62518623|NCT02164630|OTHER|Pain Education|Patients assigned to this arm will receive Pain Education in three individual intervention sessions. Intervention will be administered by an experienced therapist. Training will focus on understanding TMD-related pain and learning pain management techniques.
62518624|NCT03822221|EXPERIMENTAL|SK20º|MVIC and NMES with hip at 85º and knee at 20º
62518625|NCT03822221|EXPERIMENTAL|SK60º|MVIC and NMES with hip at 85º and knee at 60º
62518626|NCT03822221|EXPERIMENTAL|LK20º|MVIC and NMES with hip at 0º and knee at 20º
62518627|NCT03822221|EXPERIMENTAL|LK60º|MVIC and NMES with hip at 0º and knee at 60º
62518628|NCT06358287|EXPERIMENTAL|Cryogenic Auriculotherapy Treatment|Compressed nitrogen is used to create a 'cryogenic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point. This will occur on each ear with the following points being targeted: Omega 2, Omega, spine location point, and 3 points of the pain pathway including the sensory master point (SMP), the master point of the reticule (MPR), and the thalamus (T) as well as the corpus callosum (CC) point, the amygdala, rhinencephalon, hippocampus, FSHLH, ACTH, anterior and posterior white commissure points, and the corresponding sympathetic sensory and motor nerve points.
62518629|NCT06020001|EXPERIMENTAL|AP203 mixture (RESCOVIN®) in capsule form|Patients with an increased incidence of upper respiratory tract infection
62518630|NCT06020001|EXPERIMENTAL|AP203 mixture (RESCOVIN®) in syrup form|Patients with an increased incidence of upper respiratory tract infection
62518631|NCT06020001|PLACEBO_COMPARATOR|Placebo|Patients with an increased incidence of upper respiratory tract infection
62518632|NCT05212064|SHAM_COMPARATOR|Nasal cannula group|Heated and humidified oxygen of 6 L/minute was supplied via an HFNC
62518633|NCT05212064|EXPERIMENTAL|High-flow nasal cannula (HFNC)|Heated and humidified oxygen of 40 L/minute was supplied via an HFNC
62518634|NCT01387763|ACTIVE_COMPARATOR|PegIntron <= 60 years|In patients \<= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
62518635|NCT01387763|ACTIVE_COMPARATOR|Pegasys <= 60 years|In patients \<= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
62518636|NCT01387763|ACTIVE_COMPARATOR|PegIntron > 60 years|In patients \< 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
62518637|NCT01387763|ACTIVE_COMPARATOR|Pegasys > 60 years|In patients \> 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
62518638|NCT01387763|ACTIVE_COMPARATOR|Hydroxyurea > 60 years|Capsule Hydrea 500-2000 mg orally QD or BID
62518639|NCT05863624|EXPERIMENTAL|Open hernioplasty|Open Lichtenstein hernia repair
62518640|NCT05863624|ACTIVE_COMPARATOR|TEP hernioplasty|totally endoscopic hernia repair (TEP)
62518641|NCT03394755|EXPERIMENTAL|9.45 x 10^7 Thrombosomes/kg|Cohort 1
61974702|NCT05360511|EXPERIMENTAL|Group A (Test group)|Group A (Test group): Twelve patients will be subjected to open flap debridement and application of particulate xenograft + erythropoietin gel.
61974703|NCT05360511|ACTIVE_COMPARATOR|Group B (Control group)|Group B (Control group): Twelve patients will be subjected to open flap debridement and application of particulate xenograft.
61974704|NCT01641770|EXPERIMENTAL|Dietary Counseling + ONS|
61974705|NCT01641770|ACTIVE_COMPARATOR|Dietary Counseling|
62518642|NCT03394755|EXPERIMENTAL|1.89 x 10^8 Thrombosomes/kg|Cohort 2
61974706|NCT03059654|ACTIVE_COMPARATOR|Ultrasound PCT|Ultrasound guide Percutaneous tracheostomy
61974707|NCT03059654|ACTIVE_COMPARATOR|Surgical tracheostomy|Surgical tracheostomy
61974708|NCT02076880|EXPERIMENTAL|Arm with caloric restriction|"Patients in this arm will have, during 7 days before surgery, a caloric restriction of 1000 kcal per day compared to the usual food intake. They will be hospitalized during this period.~Intervention: caloric restriction"
62518643|NCT03394755|EXPERIMENTAL|3.78 x10^8 Thrombosomes/kg|Cohort 3
62518644|NCT03708965|EXPERIMENTAL|JR-141|"Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.~During the study, the dose of all subjects will be switched to the selected one\*.~\* The dose was determined to be 2.0 mg/kg/week based on the safety and efficacy data of JR-141-BR21 study."
62518645|NCT03010982|EXPERIMENTAL|Tazemetostat and [14C] Tazemetostat|"* Tazemetostat 800 mg BID orally as tablets continuously starting on Day 1, with the exception of the morning dose on Day 16;~* A single IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of \[14C\] tazemetostat on Day 15;~* A single oral dose of 800 mg tazemetostat as a solution containing approximately 400 µCi (14.8 MBq) of \[14C\] tazemetostat on Day 16."
62518646|NCT01862393|EXPERIMENTAL|400 microseconds|Electrically-induced torque generated with stimulus phase duration set at 400 microseconds.
62518647|NCT01862393|EXPERIMENTAL|700 microseconds|Electrically-induced torque generated with stimulus phase duration set at 700 microseconds.
62518648|NCT01862393|EXPERIMENTAL|1000 microseconds|Electrically-induced torque generated with stimulus phase duration set at 1000 microseconds.
62518649|NCT06437418||Group I|Gallbladder dysfunction in pre-dialysis CKD patients.
62518650|NCT06437418||Group II|Gallbladder dysfunction in end stage CKD patients on dialysis.
62518651|NCT06437418||Control Group|Gallbladder dysfunction in normal renal function participants (control group).
62518652|NCT00812422|EXPERIMENTAL|Dexibuprofen 1|Dexibuprofen 2.5 or 5 mg/kg
62518653|NCT00812422|EXPERIMENTAL|Dexibuprofen 2|Dexibuprofen 3.5 or 7 mg/kg
62518654|NCT00812422|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 5 or 10 mg/kg
62518655|NCT03564301|ACTIVE_COMPARATOR|Metronidazole 250mg|Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
62518656|NCT03564301|PLACEBO_COMPARATOR|Placebo|Placebo: same shape, size and dosis as test
62518657|NCT02689245|EXPERIMENTAL|Tenofovir + Fecal Microbiota Transplantation (FMT)|
62518658|NCT02689245|ACTIVE_COMPARATOR|Tenofovir|
62518659|NCT03346252|EXPERIMENTAL|Botulinum Toxin type A|Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
62518660|NCT04943159|EXPERIMENTAL|Afamelanotide group A|
61974709|NCT02076880|EXPERIMENTAL|Arm without caloric restriction|"Patients in this arm will not have a caloric restriction before surgery.~Intervention: No caloric restriction"
62148165|NCT01933945||TACE without early Nexavar|Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time.
62148166|NCT02359929|EXPERIMENTAL|Dose Level 1: Infusion of MSCs|First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight
62518661|NCT04943159|EXPERIMENTAL|Afamelanotide group B|
61974710|NCT03033511|EXPERIMENTAL|Rovalpituzumab tesirine/dexamethasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
62518662|NCT06133803|EXPERIMENTAL|Treatment Arm|"Patients randomized to receive aspirin and Lovenox will begin taking one low dose 81mg aspirin and one 40mg injection of Lovenox daily, on the day of progesterone start."
62715103|NCT06157034|EXPERIMENTAL|T1|"* In the pursuit of scientific understanding, clinical studies play a pivotal role in evaluating the efficacy of treatments. One essential aspect is the inclusion of a placebo group, denoted as the T1 group in this study. Participants in this group will be administered inert material in the form of 100 mg capsules, serving as a baseline for comparison against the active treatment groups.~* Group Designation: T1 Placebo Group~  * Intervention: 100 mg capsule containing inert material~ * Dosage Frequency: Daily~ * Duration: 3 months~ * Number of Participants: 50 subjects~* Participants in the T1 Placebo Group are fully informed about the nature of the study, including the possibility of receiving a placebo.~* Informed consent is obtained from each participant, ensuring that they are aware of the study's objectives and the potential for receiving an inactive treatment."
61974711|NCT03033511|EXPERIMENTAL|Placebo|Placebo q6 wk; omitting every third cycle
61974712|NCT03922425|EXPERIMENTAL|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
62148167|NCT02359929|EXPERIMENTAL|Dose Level 2: Infusion of MSCs|Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight
62148168|NCT02359929|EXPERIMENTAL|Dose Level 3: Infusion of MSCs|Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight
62518663|NCT06133803|ACTIVE_COMPARATOR|Control Arm|This arm receives neither medication.
62518664|NCT01348984|ACTIVE_COMPARATOR|group 1|group 1 = transdermal fentanyl patch
62518665|NCT01348984|PLACEBO_COMPARATOR|group 2|placebo patch
62518666|NCT06345144||Undergraduate nursing students|
62518667|NCT06446141|EXPERIMENTAL|Group A|"The Osteopathic technique included:~Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed."
62518668|NCT06446141|ACTIVE_COMPARATOR|Group B|"I- Postural correction through correction of:~* Forward head~* Protracted shoulders~* Depressed shoulder.~II- Strengthen ex to:~* Shoulder girdle elevators and retractors.~* Cervical and dorsal extensors~* raising arms to reach full flexion and elevation. III- Restoration of normal mobility o Inhibition of muscle spasm especially scaleni and pectoral ms. by source of heat\& slow, sustain and self-stretching ex.~IV- Breathing ex: diaphragmatic breathing,."
62518669|NCT06278038|EXPERIMENTAL|Toludesvenlafaxine hydrochloride sustained-release tablets treatment group|
62518670|NCT06278038|ACTIVE_COMPARATOR|Venlafaxine hydrochloride sustained-release tablets treatment group|
62710829|NCT06490692|EXPERIMENTAL|Blood Flow Restriction Training Group|"The experimental group will undergo conventional physical therapy including ultrasound, stretching, icing, heat, and deep friction massage applied at the extensor origin. In addition, the experimental group will undergo blood flow restriction strength training including the following: the weight of the dumbbell should be between 20-40% of their 1 rep max. The exercises were targeting the extensor muscles, applied by extending the wrist while holding the dumbbel and exercises targeting the supinator's and pronators while the participants were holding the dumbbell with forearm in neutral position, and were asked to supinate or pronate their forearm.~The cuff will be placed proximally at the affected arm and inflated to achieve 40% limb occlusion depending on size attested using a a golden standard vascular dopler and all blood flow restriction activities were done with a licensed and experienced physical therapist."
62710830|NCT06490692|ACTIVE_COMPARATOR|Conventional Strength Training Group|The active comparator group will undergo the same interventions as the experimental group with the addition of conventional strength training including the same program as the experimental group but without blood flow restriction of any kind: the weight of the dumbbell should be between 20-40% of their 1 rep max. The exercises were targeting the extensor muscles, applied by extending the wrist while holding the dumbbell for 4 sets (35 repetitions, 15 repetitions,15 repetitions,15 repetitions) respectively, and exercises targeting the supinator's and pronators while the participants were holding the dumbbell with forearm in neutral position, and were asked to supinate or pronate their forearm.
61974713|NCT03922425|NO_INTERVENTION|Standard care|
61974714|NCT04949126||acute pain of pulpal origin|no intervention
61974715|NCT04949126||anxious group|no intervention
61974716|NCT06367790|EXPERIMENTAL|Experimental group|The intervention period will last 4 weeks, with a periodicity of 2 weekly sessions of 30 minutes each. All interventions will take place in the sports facilities of both clubs. The interventions will be carried out by the principal investigator of the study. The 10 players assigned to the experimental group will perform plyometric exercises and will undergo dry needling of the gastrocnemius (gastrocnemius muscle) and the control group (plyometric exercises and dry needling of the gastrocnemius muscle).
61974717|NCT06367790|ACTIVE_COMPARATOR|Control group|The 10 players assigned to the control group will perform plyometric exercises.
61974718|NCT00388271|ACTIVE_COMPARATOR|1|xatral
62355620|NCT05848076|ACTIVE_COMPARATOR|Core stability|McGill exercises for the low back. involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition. The researcher will reassess the patient. Post treatment patient will complete Numeric Pain Rating Scale (NPRs), range of motion (Goniometer and Oswestry disability index (ODI). All study participant will receive a total of 18 treatment sessions over a six-week period, which consisted of 03 treatment sessions per week.
62355621|NCT05163067|EXPERIMENTAL|Combined aerobic exercise and cognitive training program|
62355622|NCT05163067|NO_INTERVENTION|Standard health counseling at baseline|
62355623|NCT03661892|EXPERIMENTAL|Treatment (Syndros)|All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks).
62518671|NCT04236583|EXPERIMENTAL|Telehealth|Eligible patients will be given the option to consent to having one virtual visit with their primary care physician within four weeks after discharge from the hospital. Usual follow-up care will occur during this visit.
62710831|NCT02896946|EXPERIMENTAL|diffusion-weighted nuclear magnetic resonance imaging|detection of liver metastasis on diffusion-weighted nuclear magnetic resonance imaging in patients with potentially resectable pancreatic adenocarcinoma
62710832|NCT02840630|NO_INTERVENTION|Non-diabetic group|Non-diabetic volunteers will be recruited for baseline data. They will only be required to provide dried blood samples (DBS) samples and information at week 0. They have to collect finger prick DBS, weigh themselves and fill in food frequency questionnaire only at one time point.
61974719|NCT00388271|PLACEBO_COMPARATOR|2|standard treatment
61974720|NCT00709046|EXPERIMENTAL|1|High dose pantoprazole infusion
62148169|NCT04924166|PLACEBO_COMPARATOR|Placebo|matching capsule PO
62148170|NCT04924166|ACTIVE_COMPARATOR|HCORT|180 mg capsule PO
62148171|NCT00799409|EXPERIMENTAL|1|CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
62518672|NCT06051084|EXPERIMENTAL|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
62518673|NCT06051084|ACTIVE_COMPARATOR|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
62518674|NCT02588066|EXPERIMENTAL|Index test|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
62518675|NCT02588066|NO_INTERVENTION|Reference test|No Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
61974721|NCT00709046|ACTIVE_COMPARATOR|2|standard dose pantoprazole infusion
61974722|NCT05040841|EXPERIMENTAL|Condition 1|"Includes 1 intervention:~S2/Peer: Enhanced peer group support."
61974723|NCT05040841|EXPERIMENTAL|Condition 2|"Includes 1 intervention:~S1/Text: Weekly check-in text messages."
62355624|NCT00602511|ACTIVE_COMPARATOR|1|Bortezomib - dexamethasone
62355625|NCT00602511|EXPERIMENTAL|2|Thalidomide - dexamethasone
62355626|NCT00536848|EXPERIMENTAL|A|Metronidazole for 10 days, probiotics for 6 months
62355627|NCT00536848|PLACEBO_COMPARATOR|B|Metronidazole for 10 days, placebo for 6 months
62355628|NCT04754113|EXPERIMENTAL|prone position|patients from supine to prone for at least 3 hours than re-supine
62518676|NCT02133001|EXPERIMENTAL|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter \[mcl\] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
62518677|NCT02133001|PLACEBO_COMPARATOR|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
62518678|NCT01631526|EXPERIMENTAL|Vitamin D|vitamin D 20,000 IU per day for 2 weeks followed by 10,000 IU per day for a further 7 days
62518679|NCT05234320|EXPERIMENTAL|stage I- Healty|The first 2 patients in this stage will receive the vehicle treatment and will not undergo the first 24 hour hospitalization. The 3rd and 4th patients will receive a lower dose of 12.5 mg of the DP once daily for 7 days, and the first 24 hours will be hospitalized for the first 24 hours. The 5th patient will receive the 25 mg from the DP once daily for 7 days and will be hospitalized for the first 24 hours. The next 2 patients will receive the 25 mg dose and will not undergo the first 24 hour hospitalization. The next 3 patients will receive the optimal dose of 50 mg and will not undergo the first 24 hour hospitalization
62518680|NCT05234320|ACTIVE_COMPARATOR|Stage II- Placebo + SOC|This arm will be include 20 This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Placebo + standard of care
62518681|NCT05234320|ACTIVE_COMPARATOR|Stage II- DP low dose (25 mg) + SOC|This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Drug product low does(25 mg) + standard of care
62518682|NCT05234320|ACTIVE_COMPARATOR|Stage II- DP planned dose (50 mg) + SOC|This arm will be include 20 This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Drug product planned does(50 mg) + standard of care
62518683|NCT06233110|EXPERIMENTAL|Dose escalation phase: Dose level 0|Fostamatinib at dose level 0 (dose of 50mg QAM) in combination with standard of care ruxolitinib 10mg BID
62518684|NCT06233110|EXPERIMENTAL|Dose escalation phase: Dose level 1|Fostamatinib at dose level 1 (dose of 100mg QAM) in combination with standard of care ruxolitinib 10mg BID
62518685|NCT06233110|EXPERIMENTAL|Dose escalation phase: Dose level 2|Fostamatinib at dose level 2 (dose of 150mg QAM) in combination with standard of care ruxolitinib 10mg BID
62518686|NCT06233110|EXPERIMENTAL|Dose escalation phase: Dose level 3|Fostamatinib at dose level 3 (dose of 100mg BID) in combination with standard of care ruxolitinib 10mg BID
61974724|NCT05040841|EXPERIMENTAL|Condition 3|"Includes 1 intervention:~M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient."
61974725|NCT05040841|EXPERIMENTAL|Condition 4|"Includes 3 interventions:~M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
62148172|NCT00799409|EXPERIMENTAL|2|Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
62518687|NCT06233110|EXPERIMENTAL|Candidate Dose #1|In the safety expansion cohort, subjects will be randomized to one of two candidate doses of fostamatinib (identified from the dose escalation phase) in combination with ruxolitinib 10mg BID.
62518688|NCT06233110|EXPERIMENTAL|Candidate Dose #2|In the safety expansion cohort, subjects will be randomized to one of two candidate doses of fostamatinib (identified from the dose escalation phase) in combination with ruxolitinib 10mg BID.
62518689|NCT00856713|EXPERIMENTAL|1 YM|Healthy young males
62518690|NCT00856713|EXPERIMENTAL|2 EM|Healthy elderly males
62518691|NCT00856713|EXPERIMENTAL|3 YF|Healthy young females
62518692|NCT00856713|EXPERIMENTAL|4 EF|Healthy elderly females
62148173|NCT03833752|EXPERIMENTAL|Flexible Cystoscopy|Diagnostic flexible cystoscopy for the patients in this arm
62518693|NCT00856713|EXPERIMENTAL|5 CTP-A|Patients with hepatic cirrhosis CTP-class A
62518694|NCT00856713|EXPERIMENTAL|6 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
62518695|NCT01304758|EXPERIMENTAL|ExAblate Treatment|
62518696|NCT05500040||Patients with IBD - Crohn's Disease|
62710833|NCT02840630|NO_INTERVENTION|Diabetic control intervention group|The diabetic control group will provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16. This group will not be receiving tinned mackerel and will be asked to continue with their habitual diet and lifestyle.
62710834|NCT02840630|ACTIVE_COMPARATOR|Diabetic fish intervention group|This intervention group will receive two 125 g portion of tinned mackerel fish (containing 7.8 g n-3 LCPUFA) per week from week 0 until 16 and a mackerel recipe book each. They will be required to provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16.
62710835|NCT03028701|EXPERIMENTAL|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
62710836|NCT06300775|ACTIVE_COMPARATOR|Modified Hyrax|Appliance used for rapid maxillary expansion
62710837|NCT06300775|ACTIVE_COMPARATOR|Quad Helix|Appliance used for slow maxillary expansion
61974726|NCT05040841|EXPERIMENTAL|Condition 5|"Includes 1 intervention:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient."
61974727|NCT05040841|EXPERIMENTAL|Condition 6|"Includes 3 interventions:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
62148174|NCT03833752|ACTIVE_COMPARATOR|Rigid Cystoscopy|Diagnostic rigid cystoscopy is done for the patients in this arm
62518697|NCT05500040||Patients with IBD - Ulcerative Colitis|
62518698|NCT05462730|ACTIVE_COMPARATOR|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory damage following ST-segment elevation myocardial infarction. The infusion of methylprednisolone will be given in the pre-hospital setting prior to primary PCI.
62518699|NCT05462730|PLACEBO_COMPARATOR|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
62518700|NCT06167954|EXPERIMENTAL|EXPLORER|8 sessions with the robotics gait device in their homes and natural environment for all participants
62518701|NCT03712241|EXPERIMENTAL|Treatment A|K-285 dose/application method A
62518702|NCT03712241|EXPERIMENTAL|Treatment B|K-285 dose/application method B
62518703|NCT03712241|EXPERIMENTAL|Treatment C|K-285 dose/application method C
62518704|NCT03712241|ACTIVE_COMPARATOR|Treatment D|Indomethacin capsule
62518705|NCT05736536|EXPERIMENTAL|Intervention Group|This group will receive a package of health education modules through Chance2Act website in addition to the existing health education being offered in the health clinic.
62518706|NCT05736536|NO_INTERVENTION|Control Group|This group will receive the existing health education being offered in the health clinic.
61974728|NCT05040841|EXPERIMENTAL|Condition 7|"Includes 3 interventions:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support."
61974729|NCT05040841|EXPERIMENTAL|Condition 8|"Includes 3 interventions:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages."
61974730|NCT05040841|EXPERIMENTAL|Condition 9|"Includes 1 intervention:~M1/OTR: Outreach (OTR) to patient due to unsuppressed VL test result."
61974731|NCT05040841|EXPERIMENTAL|Condition 10|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
61974732|NCT05040841|EXPERIMENTAL|Condition 11|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support."
61974733|NCT05040841|EXPERIMENTAL|Condition 12|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages."
61974734|NCT05040841|EXPERIMENTAL|Condition 13|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S2/Peer: Enhanced peer group support."
61974735|NCT05040841|EXPERIMENTAL|Condition 14|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S1/Text: Weekly check-in text messages."
61974736|NCT05040841|EXPERIMENTAL|Condition 15|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient."
61974737|NCT05040841|EXPERIMENTAL|Condition 16|"Includes 5 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
61974738|NCT00508807|EXPERIMENTAL|RTA 402|5 mg PO daily x 21 days
61974739|NCT01312688|OTHER|Standard hemodynamic therapy|Standard hemodynamic therapy currently accepted in our ICU
61974740|NCT01312688|EXPERIMENTAL|Early Goal Directed Hemodynamic Therapy|Early Goal Directed Hemodynamic Therapy according to the Surviving Sepsis Campaign Guidelines
61974741|NCT05769881|ACTIVE_COMPARATOR|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
61974742|NCT05769881|ACTIVE_COMPARATOR|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access.
61974743|NCT04827550||STUDY GROUP|diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
61974744|NCT04827550||CONTROL GROUP|90 healthy volunteers
61974745|NCT06138301|EXPERIMENTAL|Experimental group|Patients with SI treated with CBT+CR
61974746|NCT06138301|ACTIVE_COMPARATOR|Control group|Patients with SI treated with CBT
61974747|NCT03283228||CD11b and CD56 markers|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
62355629|NCT05200429||Pre-Therapy Participants|All CF people with CF who do not have any known contraindications to CFTR modulator therapy and will be initiated on CFTR modulator therapy by their treating physician as part of clinical care are eligible and will be asked to participate in this study.
62355630|NCT01249963|EXPERIMENTAL|Experimental Group|Patients of this group will receive 400 ml per day of T-Diet plus Atémpero product during 28 days.
62518707|NCT03249740|EXPERIMENTAL|Experimental: Phase 1 - GB-102|Subjects will be assigned to 1 of 4 cohorts to receive a single intravitreal injection of up to 2.0 mg (50 μL) GB-102.
62518708|NCT03249740|EXPERIMENTAL|Experimental: Phase 2 - GB-102|Low dose or high dose injected every 6 months
62518709|NCT03249740|ACTIVE_COMPARATOR|Active Comparator: Phase 2 - Aflibercept|Aflibercept 2 mg injected every 2 months
62518710|NCT05237440|OTHER|All patients|Metabolic, hormonal and psychometric evaluations will be carried out during or after hospitalization inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out
62518711|NCT04054284|EXPERIMENTAL|Intervention|Herbal Tea Mixture is consisted of: Vaccinium myrtillus L. folium, Morus nigra L. folium, Phaseolus vulgaris L. pericarpium, Viscum album L. herba, Urtica dioica L. radix, Gentiana lutea L. radix, Taraxacum officinale W. radix, Cichorium intybus L. herba, Teucrium chamaedrys L. herba, Stevia rebaudiana folium.
62710838|NCT02520778|EXPERIMENTAL|Treatment (navitoclax, osimertinib)|Patients receive navitoclax PO QD on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
61974748|NCT03283228||Haematological parameters in cases of adult AML|Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
61974749|NCT01957644|EXPERIMENTAL|Schedule A|Volasertib (d1 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
61974750|NCT01957644|EXPERIMENTAL|Schedule B|Volasertib (d 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
61974751|NCT01957644|EXPERIMENTAL|Schedule C|Volasertib (d 1 and 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
61974752|NCT04608851|EXPERIMENTAL|Nissle group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral suspension containing 10 E8 CFU/ml of E coli Nissle. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
61974753|NCT04608851|PLACEBO_COMPARATOR|Control group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
61974754|NCT04734080|EXPERIMENTAL|Dronabinol|57 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of 5 mg of Dronabinol beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
61974755|NCT04734080|PLACEBO_COMPARATOR|Placebo|57 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of a non-active placebo pill beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
61974756|NCT01767779||seizure free infants with dx of TSC|infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC
61974757|NCT01767779||Parents or family guardian of cohort 1|Parent or family guardian of infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC.
61974758|NCT02908503|OTHER|1 x 2 inch PVA based film|1 x 2 inch polyvinyl acetate (PVA) based vaginal film
62518712|NCT04054284|ACTIVE_COMPARATOR|Control|Herbal Tea Mixture without antidiabetic properties is consisted of: Achillea millefolium L. herba, Teucrium montanum L. herba, Glechoma hederacea L. herba, Eupatorium cannabinum L. herba, Humulus lupulus L. lupulin, Artemisia absinthium L. herba, Salvia officinalis L.
62518713|NCT01490320|PLACEBO_COMPARATOR|Control|Parents in control group experienced a routine primary care visit.
61974759|NCT02908503|OTHER|2 x 2 inch PVA based film|2 x 2 inch polyvinyl acetate (PVA) based vaginal film
62518714|NCT01490320|EXPERIMENTAL|Handout intervention|"Caregivers assigned to the hand-out group were instructed to read the AAP hand-out Pulling the Plug On TV Violence. This 2 page hand-out emphasizes the negative effect that television has on children's behavior and makes recommendations about limiting media. The RA did not supervise the reading of the handout."
62518715|NCT01490320|EXPERIMENTAL|Multimedia intervention|"Caregivers assigned to the multimedia group were instructed to watch Recommendation 3: Decrease Exposure to Violence from the Play Nicely program, a 5 minute video in English and Spanish that teaches caregivers about the negative impact of violent media and instructs parents about the importance of limiting media. The intervention was presented to the parents on a mobile laptop computer."
61974760|NCT02908503|OTHER|1 x 2 cellulose based film|1 x 2 cellulose based vaginal film
62148175|NCT02216084|EXPERIMENTAL|Recombinant ADAMTS13|The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects\]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.
62148176|NCT00491400|ACTIVE_COMPARATOR|Fenofibrate First|Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
62148177|NCT00491400|ACTIVE_COMPARATOR|Atorvastatin First|Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second
62148178|NCT05770115|EXPERIMENTAL|Group A|vicryl 2/0
62148179|NCT05770115|ACTIVE_COMPARATOR|Group B|vicryl 1
62148180|NCT02570100|EXPERIMENTAL|Biological collection|Before, during and after their treatment by chemotherapy, patients will undergo laboratory examinations.
62148181|NCT04997798|EXPERIMENTAL|Dalpiciclib in combination with exemestane and trastuzumab plus pyrotinib|Patients are treated with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) for six cycles plus oral Dalpiciclib (125 mg QD x 21，Q4W) and Exemestane (25 mg po QD ）and oral pyrotinib (320 mg po QD) for 20 weeks.
62148182|NCT00074607|EXPERIMENTAL|Intrathecal gemcitabine administration|"Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.~Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.~Dose Levels and Dose Escalation:~Dose Level 1a: 5 mg~Dose Level 1b: 5 mg~Dose Level 2: 10 mg~Dose Level 3: 20 mg~Dose Level 4: 30 mg~Dose Level 5: 40 mg~Dose Level 6: 50 mg"
62148183|NCT05376839|EXPERIMENTAL|Group 1: Cedirogant|Participants will receive cedirogant once daily.
62148184|NCT05376839|EXPERIMENTAL|Group 2: Cedirogant|Participants will receive cedirogant once daily.
62518716|NCT01710436||Low dose - Wild genotype (LW)|75mg Qd \> 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
62518717|NCT01710436||Low dose - Variant genotype (LV)|75mg Qd \> 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
62518718|NCT01710436||High dose - Wild genotype (HW)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
62518719|NCT01710436||High dose - Variant genotype (HV)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
61974761|NCT02908503|OTHER|2 x 2 cellulose based film|2 x 2 cellulose based vaginal film
61974762|NCT03881592||R-Clb patients|Patients treated with the combination of Rituximab + chlorambucil
61974763|NCT03881592||R-B patients|Patients treated with the combination of Rituximab + bendamustine
61974764|NCT03881592||Obi-Clb patients|Patients treated with the combination of Obinutuzumab + chlorambucil
62518720|NCT03736759|EXPERIMENTAL|Exercise and vaccine in same arm|20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
62518721|NCT03736759|ACTIVE_COMPARATOR|Exercise and vaccine in different arms|20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
62518722|NCT03736759|NO_INTERVENTION|vaccine only|20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
62518723|NCT03109119|ACTIVE_COMPARATOR|Group S|These patients will be induced and maintained with sevoflurane during anaesthesia.
62518724|NCT03109119|SHAM_COMPARATOR|Group P|These patients will be induced and maintained with propofol during anaesthesia.
62518725|NCT05016622|EXPERIMENTAL|Booster dose|
62518726|NCT02972502|ACTIVE_COMPARATOR|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
62518727|NCT02972502|EXPERIMENTAL|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
62518728|NCT05715814|EXPERIMENTAL|Empagliflozin|
62518729|NCT03966391|EXPERIMENTAL|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/ fear/fainting mitigation interventions from CARD during vaccination)
62518730|NCT03966391|NO_INTERVENTION|Control (standard care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
62518731|NCT03580291|EXPERIMENTAL|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10\^6/kg body weight are suspended in 100ml saline and infused intravenously.~1. Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.~2. A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
62518732|NCT03580291|ACTIVE_COMPARATOR|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
62518733|NCT04627077||SIC drug therapy patients|Patients with a cancer diagnosis currently being treated at SIC clinic
62518734|NCT03244423|PLACEBO_COMPARATOR|Group 1|In control group will receive normal saline,
62518735|NCT03244423|ACTIVE_COMPARATOR|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
62518736|NCT03244423|ACTIVE_COMPARATOR|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
62518737|NCT03095898|EXPERIMENTAL|True Acupuncture|
62518738|NCT03095898|SHAM_COMPARATOR|Sham Acupuncture|
62518739|NCT03095898|NO_INTERVENTION|Control Group|
62518740|NCT06331858|ACTIVE_COMPARATOR|Study group|The study group received hip device-assisted concentric abductor strengthening (HDACAS) program in addition to knee device-assisted concentric flexor-extensor strengthening (KDACFES) program.
62355631|NCT01249963|ACTIVE_COMPARATOR|Control Diet|Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days.
62518741|NCT06331858|ACTIVE_COMPARATOR|Control group|The control group received only KDACFES program
62518742|NCT03284879||Patients with PsV and PsA treated with OTEZLA Tablets|Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets
62518743|NCT06015477|EXPERIMENTAL|ticagrelor monotherapy group|Ticagrelor monotherapy (starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.). After 1 month, continuation to ticagrelor monotherapy for 1 year.
62518744|NCT06015477|ACTIVE_COMPARATOR|Dual Antiplatelet Therapy group|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
62518745|NCT03887728||Artificial (HRT) Cycles|"1. Commence estradiol tablets (E2) 4mg from day 2 or 3 of period for 3 days~2. Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.~3. Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.~4. Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.~5. Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 10 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.~6. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily). Embryo transfer is scheduled 5 days following the initial initiation of progesterone"
62518746|NCT03887728||Spontaneous natural cycles|"1. Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.~2. Measurements of serum LH, estradiol and progesterone levels to determine ovulation.~3. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).~4. Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5nmol /L confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
61974765|NCT01336920|EXPERIMENTAL|Treatment (carfilzomib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62518747|NCT06357663|OTHER|SIMPLE FOLLOW UP GROUP|"Every subject who is accepted into the study, will receive prior to the inception of practice transmission of pure energy (blessing) and will be instructed on how to practice meditations with Tao Calligraphy.~Blood samples will be drawn at DAP accredited institution in British Columbia (Life Labs or Vancouver Coastal Health) and will be promptly sent by currier to Repeat Diagnostics, All participants will have blood samples drawn and Questionnaire filled at the entry time point (Time 0), at the end of 3 months (Time 1), and at the end of 9 months (Time 2)."
62518748|NCT06063759|OTHER|VitalDetectTM|Determination of microcirculating blood flow, glucose, SpO2, and heart rate.
62518749|NCT05083039||750 volunteers who will be vaccinated with the BiVac polio vaccine|Group 1 - 750 volunteers, Vaccine 0.2 ml, post-vaccination observation period of 12 months.
62518750|NCT05083039||750 volunteers who will be given a Placebo.|Group 2 - 750 volunteers, Vaccine 0.2ml, post-vaccination observation period of 12 months.
62518751|NCT02314572|OTHER|Single-arm|
62518752|NCT01956019|EXPERIMENTAL|MRI scanning|patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
62518753|NCT05695872|ACTIVE_COMPARATOR|subtarsal approach|
62518754|NCT05695872|ACTIVE_COMPARATOR|conventional transconjunctival approach|
62518755|NCT05695872|ACTIVE_COMPARATOR|transconjunctival approach with Y- modification|
62518756|NCT06348056|EXPERIMENTAL|Zinc Amino Acid|The zinc in the supplement is complexed with the amino acids lysine and glutamate.
62518757|NCT06348056|EXPERIMENTAL|Zinc Gluconate|The zinc in the supplement is complexed with gluconate.
62518758|NCT02416011|NO_INTERVENTION|Assessment Only (ASSESS)|Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time.
62518759|NCT02416011|ACTIVE_COMPARATOR|Generic Self-Help (GENERIC)|This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
62518760|NCT02416011|EXPERIMENTAL|Targeted Self-Help (eTARGET)|Participants in this condition will receive the intervention created as the product of Study I.
62518761|NCT00949689|EXPERIMENTAL|Cognitive Behavioral Therapy for insomnia and depression|cognitive behavioral therapy for insomnia followed by cognitive behavioral therapy for depression
62518762|NCT00949689|ACTIVE_COMPARATOR|contol|participants will receive sleep hygiene, time management techniques and cognitive therapy for depression
62518763|NCT01747122|EXPERIMENTAL|Wound catheter|Wound catheter
62518764|NCT01747122|ACTIVE_COMPARATOR|Epidural|Standard epidural, pre-operative insertion, to be run for 48 hours
62518765|NCT03992417||Participants with AD|Adult and adolescent participants with AD initiating treatment with Dupixent® for AD according to the country-specific prescribing information, as part of their usual care as determined by their physician
62518766|NCT04999033||Inpatient|This study is a cross-sectional study and no intervention will be involved
62518767|NCT06441461||Danish citizens|All citizens aged 0-25 years and all adults aged 18-67 years residing in Denmark in the period from 2000 to 2008.
62148185|NCT05376839|EXPERIMENTAL|Group 3: Cedirogant|Participants will receive cedirogant once daily.
62148186|NCT05376839|EXPERIMENTAL|Group 4: Cedirogant|Participants will receive cedirogant once daily.
62148187|NCT03068312|EXPERIMENTAL|Sequence 1: First Ivacaftor (IVA) Then Placebo|Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
62148188|NCT03068312|EXPERIMENTAL|Sequence 2: First Placebo Then IVA|Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
62518768|NCT04542850|OTHER|Moderate group and Severe Group|Moderate group and Severe group - . Both groups will be administered 5-aminolevulinic acid (5-ALA) is a natural delta amino acid widely present in nature that can be found in common food. 5-ALA combined with sodium ferrous citrate (SFC) produces the nutritional dietary supplement 5-ALA-Phosphate + SFC (5-ALA + SFC).
62518769|NCT04801667|EXPERIMENTAL|Coronavac vaccine|Kidney transplant recipients receiving the coronavac vaccine
62710839|NCT05036343|EXPERIMENTAL|InPen® and CGM, then standard of care and CGM|Adolescents and young adults (13-21 years) identified with having type 1 diabetes and currently receiving insulin injections with a continuous glucose monitor (CGM) will use the InPen® and CGM for the first 90 days then switch to standard of care with traditional insulin injections and CGM for 90 days.
62148189|NCT01721356||Healthy individuals|Healthy individuals ranging in age, race, ethnicity, socioeconomic status, and years of education
62148190|NCT05147155||Severe asthma patients|The sample will consist of 40 patients between 18 and 82 years of age with uncontrolled severe eosinophilic asthma despite receiving high dose ICS/LABA combination therapy who will receive mepolizumab, which will be administered as a 100-mg subcutaneous dose every four weeks
62148191|NCT05147155||Control group 1|Control group 1 will be a set of 50 healthy individuals matched for age and gender
62148192|NCT05147155||Control group 2|Control group 2 will be a set of 40 patients with severe well-controlled asthma requiring high dose ICS/LABA combination therapy from becoming uncontrolled, as previously defined, matched for age and gender.
62148193|NCT00128765|ACTIVE_COMPARATOR|usual care|usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
62148194|NCT00128765|EXPERIMENTAL|monitoring controls|regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
62148195|NCT00128765|EXPERIMENTAL|self-management|disease specific self-management program 'Living Well with COPD'
62710840|NCT05036343|EXPERIMENTAL|Standard of care and CGM, then InPen® and CGM|Adolescents and young adults (13-21 years) identified with having type 1 diabetes and currently receiving insulin injections with a continuous glucose monitor (CGM) will receive standard of care with traditional insulin injections and CGM for first 90 days then switch to the InPen® and CGM for 90 days.
62148196|NCT05893615|ACTIVE_COMPARATOR|CBT group|Patients in the CBT intervention group, who received CBT focused on anxiety symptoms in addition to their usual treatment, including 10 one-hour sessions spread over 10 weeks, and weekly homework guided by the therapist.
62518770|NCT02936687|EXPERIMENTAL|Metabolic Syndrome NOS Inhibition|Will occur over two separate study visits after screening. Eligible subjects with MetSyn will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
62518771|NCT02936687|EXPERIMENTAL|Metabolic Syndrome ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male subjects with MetSyn will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
62710841|NCT06563843||Performing VELYS robot-assisted TKA|Surgeons performing VELYS robot-assisted TKA
62710842|NCT06563843||Performing conventional TKA|Surgeons performing conventional TKA
62710843|NCT00946595|ACTIVE_COMPARATOR|efavirenz/emtricitabin/tenofovir|
62710844|NCT00946595|EXPERIMENTAL|lopinavir/ritonavir|
62148197|NCT05893615|NO_INTERVENTION|Treatment as usual (TAU) group|Patients in TAU group received optimal medical care according to the current clinical guidelines. Patients in the TAU group did not receive any psychotherapy.
62148198|NCT02638506|EXPERIMENTAL|Intranasal Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
62355632|NCT02425280|EXPERIMENTAL|Narrative Exposure Therapy|For the intervention group receiving Narrative Exposure Therapy treatment, the intervention will last for approximately three months and include 10-12 weekly sessions of 60-90 minutes. The course of the intervention will follow the NET manual (Schauer et al., 2011).
62355633|NCT02425280|ACTIVE_COMPARATOR|Treatment as Usual|For the TAU control group, participants will receive the usual care for posttraumatic stress symptoms currently offered by each unit.
62355634|NCT01619605|EXPERIMENTAL|Shrim|
62355635|NCT05178693|EXPERIMENTAL|Treatment|
62355636|NCT01001858|ACTIVE_COMPARATOR|Domiciliary group|In this group OSA diagnosis was performed at patient's home by mean of non-attended RP. All follow-up visits were conducted by a trained nurse in patient's home.
62355637|NCT01001858|ACTIVE_COMPARATOR|Hospital Group|In this group diagnosis was made by in-hospital PSG. Follow-up was performed at hospital by a specialist Physician
62355638|NCT01001858|ACTIVE_COMPARATOR|Mixed Group|In this group diagnosis was made by home RP, and follow-up at hospital
62355639|NCT05974007||Resectable stage I-III NSCLC|Patients with NSCLC patients receiving neoadjuvant therapy and undergoing surgeries. Resectability after neoadjuvant therapy is judged by the multidisciplinary team of thoracic surgeon, oncologist and radiation oncologist.
62355640|NCT01998399|EXPERIMENTAL|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
62355641|NCT01998399|PLACEBO_COMPARATOR|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
62355642|NCT02562950|EXPERIMENTAL|Midazolam and 500 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (250 mg b.i.d daily for 10 days) from Days 2 to 11.
62355643|NCT02562950|EXPERIMENTAL|Midazolam and 1000 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (500 mg b.i.d daily for 11 days) from Days 2 to 12.
62355644|NCT01250457|EXPERIMENTAL|Topical timolol|topical Timolol 0.5% solution applied twice daily
62355645|NCT01332019|EXPERIMENTAL|peginterferon beta-1a Q4W|125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
62355646|NCT01332019|EXPERIMENTAL|peginterferon beta-1a Q2W|125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
62355647|NCT02062398|EXPERIMENTAL|The Reprieve system implantation|The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
62355648|NCT06374862|EXPERIMENTAL|Interventional|This study is of an interventional nature, because the investigators want to objectively assess the impact of specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine.
62355649|NCT06374862|SHAM_COMPARATOR|control|This approach will help to determine whether there is spontaneous modulation of neuromuscular activity in the absence of intervention. Thus, the investigators can distinguish the effects of intervention from natural variations in the healthy subject.
62355650|NCT06374862|NO_INTERVENTION|no interventional|"A control group was also integrated to assess whether a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect. This approach will allow to disentangle the real effects of mobilization from those that could result from psychomotor responses"
62355651|NCT02747446|EXPERIMENTAL|Honey|added sugar: diet with 25% acacia honey
62355652|NCT02747446|EXPERIMENTAL|Fructose:glucose mixture|added sugar: Diet with 25% energy as a fructose:glucose mixture
62355653|NCT02747446|NO_INTERVENTION|control|no intervention: Diet with 45% starch and no honey or added sugars
62355654|NCT05750316|EXPERIMENTAL|Freeze dried cowpea leaves mixed in jam|6g of freeze-dried cowpea leaves (equivalent to one portion of vegetables) mixed with apricot jam and spread on bread.
62355655|NCT05750316|ACTIVE_COMPARATOR|Jam with green food colour|Apricot jam mixed with green colouring and spread on bread
62710845|NCT01574144||AVIVO™ PiiX Patch Monitor System|Heart failure patients monitored continuously for 30 days post-discharge.
62710846|NCT00523978|EXPERIMENTAL|Experimental|Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
62518772|NCT02936687|EXPERIMENTAL|Control NOS Inhibition|Will occur over two separate study visits after screening. Eligible control subjects will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
62518773|NCT02936687|EXPERIMENTAL|Control ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male control subjects will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
62518774|NCT05560789|EXPERIMENTAL|Participants with Post-bariatric Hypoglycemia Performing Structured Physical Activity|Individuals with a confirmed diagnosis of post-bariatric hypoglycemia will perform structured physical activity by cycling on a stationary bicycle ergometer or on a treadmill.
62518775|NCT03167593|PLACEBO_COMPARATOR|Control|Capsules containing 300 mg of maltodextrin.
62518776|NCT03167593|EXPERIMENTAL|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
62518777|NCT03806842|OTHER|Easytech group|patients who require a reverse total shoulder, meet the eligibility criteria and receive the Easytech Reversed Shoulder System
62518778|NCT03169920|ACTIVE_COMPARATOR|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
62518779|NCT03169920|ACTIVE_COMPARATOR|Control Group|Modified-Minimally Invasive Surgical Technique alone.
62518780|NCT06443788|OTHER|Pregnant women with history suggestive of PPROMs between 24 to 37 weeks' gestation|"Evaluation of amniotic fluid pooling via transperineal ultrasonography will be performed. Images will be captured in sagittal and transverse planes. Sagittal plane images will be captured with ultrasound probe placed in between labia major, parallel to their long axis. Transverse plane images will be captured with ultrasound probe placed on posterior fourchette, parallel to the plane of posterior.~Images will be evaluated for appearance of accumulated hypoechogenic fluid around cervix. Whenever collection is spotted, three largest dimensions of fluid will be measured (length, width, depth).~Fluid accumulations around the cervix that are clearly demarcated from surrounding tissues were considered positive.~Cervical length detected . Presenting part and cord prolapse"
62518781|NCT04013113|ACTIVE_COMPARATOR|Standard Medical Treatment|Group A will be given standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
62518782|NCT04013113|EXPERIMENTAL|Hemoadsorption plus standard medical therapy|
62518783|NCT04013113|EXPERIMENTAL|Plasma Exchange plus standard medical therapy|
62518784|NCT04667702||Patient Focused Interviews|
62518785|NCT04667702||Caregiver Focused Interviews|
62518786|NCT04667702||Healthcare Provider Focused Interviews|
62518787|NCT01200940|EXPERIMENTAL|Phase I - Low-dose sweetener|68 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
62518788|NCT01200940|EXPERIMENTAL|Phase I - Medium-dose sweetener|170 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
62518789|NCT01200940|PLACEBO_COMPARATOR|Phase I Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
62518790|NCT01200940|EXPERIMENTAL|Phase I- High-dose sweetener|250 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test.
62518791|NCT01200940|PLACEBO_COMPARATOR|Phase II - Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
62518792|NCT01200940|EXPERIMENTAL|Phase II - Diet Soda 1|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
62518793|NCT01200940|EXPERIMENTAL|Phase II - Diet Soda 2|less than or equal to 5 mg/kg sucralose, less than or equal to 50 mg/kg aspartame, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
62710847|NCT00523978|ACTIVE_COMPARATOR|Control|Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.
62710848|NCT01340456|EXPERIMENTAL|Rifampicin 10 mg QD|
62710849|NCT01340456|EXPERIMENTAL|Rifampicin 20 mg QD|
62710850|NCT01340456|EXPERIMENTAL|Rifampicin 100 mg QD|
62148199|NCT02638506|PLACEBO_COMPARATOR|Salinex|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
62518794|NCT01200940|EXPERIMENTAL|Phase II - Water with sucralose and acesulfame-potassium|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
62518795|NCT04158336|EXPERIMENTAL|Single Agent Dose Escalation|Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
62518796|NCT04158336|EXPERIMENTAL|Single Agent Food Effect Cohort|Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.
62518797|NCT04158336|EXPERIMENTAL|Single Agent Dose Expansion|Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.
62518798|NCT03078452|EXPERIMENTAL|Arm I (biopsy using power drill)|Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
62518799|NCT03078452|ACTIVE_COMPARATOR|Arm II (biopsy using Jamshidi needle)|Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
62518800|NCT02919826|EXPERIMENTAL|DBT Group|Adapted Dialectical Behaviour Therapy
62710851|NCT04546100|EXPERIMENTAL|Maternal-Infant Exercise Program|"In the postpartum period, give the intervention group Maternal-Infant Exercise Program and encourage them to do exercise. The Parent-Child Exercise Program can be divided into three stages. Videos will be provided in each stage. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
62148200|NCT03854734|NO_INTERVENTION|Usual Care|Educational emails about broad health topics to keep control group engaged
62148201|NCT03854734|ACTIVE_COMPARATOR|Multi-Component Intervention|(1) a community event to raise parental awareness of the importance of vaccination; (2) social marketing to target parents' attitudes and knowledge around vaccinations in the form of educational material
62148202|NCT01672684|EXPERIMENTAL|Arm I (experimental arm)|Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
62148203|NCT01672684|ACTIVE_COMPARATOR|Arm II (control arm)|Participants receive an educational workbook journal.
62148204|NCT02584257|PLACEBO_COMPARATOR|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols and one actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
62148205|NCT02584257|ACTIVE_COMPARATOR|90 mcg ProAir HFA|90 mcg of ProAir HFA: 1 actuation each from ProAir HFA inhalation aerosol and the placebo ProAir HFA inhalation aerosol and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
62148206|NCT02584257|ACTIVE_COMPARATOR|180 mcg ProAir HFA|180 mcg of ProAir HFA: 1 actuation each from 2 different ProAir HFA inhalation aerosols and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
62148207|NCT02584257|EXPERIMENTAL|90 mcg Lupin albuterol HFA MDI|90 mcg of Lupin albuterol HFA MDI product: 1 actuation each from the Lupin albuterol HFA MDI inhalation aerosol and the placebo Lupin albuterol HFA MDI inhalation aerosol and 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols
62148208|NCT02584257|EXPERIMENTAL|180 mcg Lupin albuterol HFA MDI|180 mcg of Lupin albuterol HFA MDI: 1 actuation each from 2 different Lupin albuterol HFA MDI inhalation aerosols and 1 actuation each from 2 different placebo ProAir HFA product inhalation aerosols
62148209|NCT06505993|EXPERIMENTAL|Health Communication|This intervention arm will include exclusively health communication messaging strategies that is both theory-based and community-targeted to encourage uptake of the COVID-19 vaccine delivered by trusted local communicators. Pre-identified theory-based components are attitudes, social norms, perceived behavioral control, response efficacy, and implementation intentions. The development process for the messaging will be based through a conjoint process of identification of theory- based determinants of decision-making relevant to the desired behavior change and a community-engaged process of identifying: a) community-specific messaging themes; b) trusted communicators within the target population; and c) community-specific messaging, imaging, and themes to achieve targeting.
62148210|NCT06505993|EXPERIMENTAL|Health Communication + Structural|This intervention arm will include the conditions outlined and included in the health communication arm, however, they will be coupled with a series of structural and/or environmental intervention strategies as well, which are targeted to facilitate vaccine accessibility and uptake among adults in the randomly assigned study counties.
62148211|NCT06505993|NO_INTERVENTION|Standard of Care|No study-specific intervention strategies (as outlined above) will be implemented in control counties at the time of the study period. Any ongoing and/or pre-existing efforts within the scope of the project's outcomes will continue as it would have i.e. a health department operating a health fair.
62148212|NCT03985566|EXPERIMENTAL|Fibre Grains|Fibre grains were used to partially replaced Jasmine white rice in this arm.
62148213|NCT03985566|PLACEBO_COMPARATOR|Jasmine white rice|Jasmine white rice is used as a control to compare the outcome.
62355656|NCT05966493|EXPERIMENTAL|NEXAGON® (lufepirsen ophthalmic gel) High Dose Concentration|Lufepirsen (High dose concentration) applied topically weekly for 4 to 8 weeks.
62518801|NCT02919826|NO_INTERVENTION|Control Arm|People in this group will receive treatment as usual
62518802|NCT03893734|ACTIVE_COMPARATOR|methadone group|Patients in this group will receive a syringe of methadone at the induction of anesthesia and a syringe of saline at the end of anesthesia.
62518803|NCT03893734|PLACEBO_COMPARATOR|hydromorphone group|Patients in this group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
62518804|NCT00821366|ACTIVE_COMPARATOR|1|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment only group
62148214|NCT02334605|OTHER|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
62518805|NCT00821366|ACTIVE_COMPARATOR|2|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment and ARV peer adherence support group
62518806|NCT00821366|ACTIVE_COMPARATOR|3|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment, ARV peer adherence support and nutritional support group
62518807|NCT00821366|NO_INTERVENTION|4|Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment - comparison/control group
62148215|NCT02334605|OTHER|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
62518808|NCT03496857|EXPERIMENTAL|Photobiomodulation analgesia|"LED therapy sessions will be held in the pre-labor room. The patient who will undergo analgesia and the professional responsible for placing the LED plate on the patient's back, between T10 and L2, will be present at the time of the intervention. The LED plate will be covered with clear disposable plastic (PVC) to avoid cross-contamination and ensure hygiene. During the interventions, the patient will be allowed to choose the position that is the most comfortable for her.~Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention."
62518809|NCT03496857|ACTIVE_COMPARATOR|bath therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
62710852|NCT04546100|PLACEBO_COMPARATOR|Regular postpartum exercise guidance|"Another group will receive Regular postpartum exercise guidance. The guidance includes chest exercises, neck exercises, leg exercises, hip exercises, abdominal exercises, vagina contraction exercises, and uterine contraction exercises, starting from the third day after delivery to one month after delivery. The detail information will refer to the General Hospital of Tri-Services Provided the postpartum health education manual-postpartum exercise (p.8-10)"
62355657|NCT05966493|PLACEBO_COMPARATOR|NEXAGON Vehicle (ophthalmic gel)|Vehicle applied topically weekly for 4 to 8 weeks.
62355658|NCT03384225|EXPERIMENTAL|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
62355659|NCT03384225|ACTIVE_COMPARATOR|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
62355660|NCT04354441|EXPERIMENTAL|hydroxychloroquine|10-day course of hydroxychloroquine 200 mg tablet twice a day. To be taken orally.
62355661|NCT04354441|PLACEBO_COMPARATOR|Placebo|An identical appearing placebo. To be taken orally twice a day for 10-days.
62355662|NCT04030897|ACTIVE_COMPARATOR|Online Programs + Information/Psychoeducation/Referral (IPR)|"Includes 2 online, one-session programs (one for youths; one for parents) and Primary Care-based IPR. The 30-min, self-administered YOUTH PROGRAM includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change. In the 15-min Qualtrics-based PARENT PROGRAM, parents read 2 scientific passages on (1) the notion that emotions are flexible in youth and adults, and (2) that failure promotes personal growth. After each passage, parents write a persuasive summary of its main arguments, directed to fellow parents who may benefit from the information."
62355663|NCT04030897|PLACEBO_COMPARATOR|Information/Psychoeducation/Referral (IPR; usual care control)|Information, Psychoeducation and Referral (IPR) represents usual care in the Stony Brook University Hospital's Pediatric Primary Care Division. Families of a youth with elevated MD symptoms during a PC visit receive a folder containing informational materials about the nature of depression and referrals to providers in their area. All families in this study will receive PC-based IPR.
62355664|NCT04179786|OTHER|Sci-B-Vac™|Single arm study in healthy volunteers who had never been vaccinated with any hepatitis B vaccine and who were seronegative for antibodies to HBsAg, HBc and HBs at baseline.
62355665|NCT00648661|EXPERIMENTAL|1|Escitalopram Oxalate Tablets 20 mg
62355666|NCT00648661|ACTIVE_COMPARATOR|2|Lexapro® Tablets 20 mg
62355667|NCT05588180|ACTIVE_COMPARATOR|Group (P)|Group (P) PPV guided group
62355668|NCT05588180|ACTIVE_COMPARATOR|Group (F)|Group (F) FVD/FAD ratio guided
62355669|NCT03487328|ACTIVE_COMPARATOR|Modified technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
62355670|NCT03487328|ACTIVE_COMPARATOR|Conventional technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
62355671|NCT02026518|EXPERIMENTAL|Soy|Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks
62355672|NCT02026518|EXPERIMENTAL|Soy- Cholecalciferol|Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks
62355673|NCT02026518|PLACEBO_COMPARATOR|Placebo|Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks
62355674|NCT02026518|EXPERIMENTAL|Cholecalciferol|Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks
62518810|NCT06490003||Chemotherapy response patients.|"Responders according to the response evaluation criteria in solid tumors (RECIST).~A panel of DNA methylation, whose specific methylation level is tested DNA from resection tissue with Methylation-specific PCR(MSP)"
62518811|NCT06490003||Chemotherapy non-response patients|"Responders according to the response evaluation criteria in solid tumors (RECIST).~A panel of DNA methylation, whose specific methylation level is tested DNA from resection tissue with Methylation-specific PCR(MSP)"
62518812|NCT00283413|EXPERIMENTAL|1|Symbiot Covered Stent System
62518813|NCT00283413|ACTIVE_COMPARATOR|2|Commercially available bare metal stent
62148216|NCT02334605|OTHER|capsaisin nasal spray|one puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
62710853|NCT01594242|EXPERIMENTAL|Autophagy Induction After Bortezomib|"Subjects will undergo a baseline bone marrow aspirate and biopsy (under sedation if preferred by the subject) and have baseline blood samples (and urine samples if clinically indicated for measurement of their myeloma).~The following week, subjects will undergo a second bone marrow aspirate and biopsy and have additional blood samples taken for research assays prior to starting therapy on treatment day 1 with bortezomib at the standard dose of 1.3 mg/m2. Subjects will receive a second dose of bortezomib on treatment day 4, followed by a third bone marrow aspirate and biopsy on treatment day 4 or 5, along with serial blood samples on treatment days 4 and 5. After completion of the week of study treatment, subjects may continue treatment with the bortezomib-containing regimen planned by their treating oncologist. Active study participation will end after the completion of the week of study treatment."
62710854|NCT02728024||A|Complete the questionnaires with personal aid
62148217|NCT05351697|EXPERIMENTAL|BR105|BR105 infusions will be administered weekly 21 days after the initial dose
62518814|NCT06203912|EXPERIMENTAL|Treatment (cyclophosphamide, dexamethasone, TiNK, isatuximab)|Patients receive cyclophosphamide IV on day 1, dexamethasone PO on days 1-4, TiNK IV on day 8, and isatuximab IV on days 8 and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy during screening and on study, as well as optionally during follow up. Patients undergo ECHO during screening and blood sample collection throughout the study.
62518815|NCT01973023||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
62518816|NCT02527018||Healthy Subjects|Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.
62518817|NCT02527018||Preeclamptic Subjects|Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.
62518818|NCT02463305|EXPERIMENTAL|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
62518819|NCT02463305|PLACEBO_COMPARATOR|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
62518820|NCT02463305|EXPERIMENTAL|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
62518821|NCT01588236|EXPERIMENTAL|high dose KYG0395|Patients received high dose KYG0395 capsule (tid)
62518822|NCT01588236|EXPERIMENTAL|lower dose KYG0395|Patients received lower dose KYG0395 capsule (bid)
62518823|NCT01588236|PLACEBO_COMPARATOR|placebo|Patients received placebo (tid)
62518824|NCT00795808|EXPERIMENTAL|BMI > 32|Women with BMI \> 32
62518825|NCT00795808|EXPERIMENTAL|BMI </= 32|Women with BMI \</= 32
62518826|NCT01994694||adults with ADHD|adults with ADHD, without neurological and psychiatric comorbidities
62518827|NCT01994694||controls|people without ADHD, with no neurological and psychiatric disorders
62518828|NCT04399876|EXPERIMENTAL|Surgery Cohort|"Participant eligibility for intervention and selection of lesion for device placement~- Surgery Cohort will undergo percutaneous placement of several microdevices in a selected tumor(s) prior to surgery. The microdevice in the surgery cohort will dwell in the tumor tissue for approximately 48 hours to allow time for tissue effects of the drugs in the microdevice reservoirs.~Placement of at least 1, and up to 6, microdevices depending on the number of lesions, size and accessibility~* Extirpative surgery will proceed according to standard-of-care procedures. The microdevice(s) will be removed surgically along with surrounding tumor tissue.~* Standard of care treatment and follow-up of clinical course"
62148218|NCT01375790|EXPERIMENTAL|Exercise with Whole-body vibration platform|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm). Training volume and intensity we will increase systematically over six weeks according to the overload principle.
62710855|NCT02728024||B|questionnaires are completed by patients alone
62148219|NCT01375790|ACTIVE_COMPARATOR|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli, during a six weeks training period (3sessions/week). Training volume and intensity we will increase systematically over six weeks according to the overload principle
62518829|NCT04399876|EXPERIMENTAL|Ex-Vivo Cohort|"Each participant will undergo a screening process to determine their eligibility for microdevice placement, consisting of the following items:~* Routine standard of care for radical prostatectomy.~* Placement of implantable microdevice with multiple miniature drug reservoirs but no drug in prostate that have been removed~* Ex vivo image guided removal using retrieval device~* Standard of Care Treatment and follow-up of clinical course"
62148220|NCT01135121||Weaning failure|
62148221|NCT01135121||Weaning succes|
62355675|NCT04733001|EXPERIMENTAL|HSG4112 Treatment Arm: Fasted|Single oral dosing of HSG4112 480 mg under fasted conditions
62518830|NCT00594646|OTHER|Group 1|TRUVADA
62518831|NCT01090375|EXPERIMENTAL|Exercise|
62518832|NCT01090375|PLACEBO_COMPARATOR|Non Exercise|
62518833|NCT02918747|EXPERIMENTAL|P-Gemoxd|"Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.~Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions."
62710856|NCT03497377|EXPERIMENTAL|18F-DCFPyL Injection & 18F-NaF|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose
62710857|NCT00734448|EXPERIMENTAL|A,1|Gestational diabetes patients who take myo-inositol
62710858|NCT00444106|EXPERIMENTAL|Artemether-lumefantrine (Coartem)|Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
62710859|NCT00444106|ACTIVE_COMPARATOR|Atovaquone-proguanil (Malarone)|Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
62710860|NCT00444106|ACTIVE_COMPARATOR|Artesunate-mefloquine|Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.
62710861|NCT04519970|ACTIVE_COMPARATOR|Highest Tier of Case Management (Piggyback) and Biktarvy|The most intensive tier of case management. Includes three appointment reminders; check ins twice per week; travel compensation; housing support; food insecurity support; follow ups for missed appointments and off pill counts; connections with substance use programs; meetings with the benefits department for health insurance needs; childcare support to make appointments; mental healthcare referrals; open pool appointments as back-up options in case of rescheduling needs; late doctor's appointments and prescription pick up for those working during the day; meetings with the health educators to discuss HIV and ART; and re-motivation of HIV treatment every 3 months.
62710862|NCT04519970|ACTIVE_COMPARATOR|Middle Tier of Case Management (Got Your Back) and Biktarvy|The middle tier (Got Your Back) will work closely with the CORE case managers to augment their work in housing support, transportation assistance, mental healthcare referrals, childcare assistance, substance use program referrals, food insecurity support and health insurance needs. The retention specialist will additionally provide this middle tier 2 reminders for appointments; check ins once per week; follow ups for missed appointments or off pill counts; support with scheduling appointments for limited availability; meetings with the health educators for information on HIV or ART; and re-motivation for treatment at the 6 and 9 month marks of participation.
62518834|NCT02918747|ACTIVE_COMPARATOR|P-CHOP|"Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1; Pegaspargase 2000U/m2 im，day 2 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.~IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions."
62518835|NCT05123677||Low Risk|These patients are screened to be low-risk for pre-eclampsia and fetal growth restriction by the guidelines set out by the National Institute for Health and Care Excellence; and the Royal College of Obstetricians \& Gynaecologists, respectively.
62518836|NCT05123677||High Risk|These patients are screened to be high-risk for pre-eclampsia and fetal growth restriction by the guidelines set out by the National Institute for Health and Care Excellence; and the Royal College of Obstetricians \& Gynaecologists, respectively.
62710863|NCT04519970|ACTIVE_COMPARATOR|Lowest Tier of Case Management (Backbone) and Biktarvy|The top tier (Backbone) will need the least amount of support and also have a CORE Center case manager for a majority of the support in housing, food, insurance, transportation, childcare, substance use, and mental healthcare. The retention specialist will still provide an appointment reminder; check ins every other week; text checkups after missed appointments or off pill counts; support with scheduling for appointments or prescription pick up for limited availability; and re-motivation of treatment for HIV at the 9 month mark of study participation.
62148222|NCT00500604|EXPERIMENTAL|A|"* period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~* period 2: One 150/12.5mg tablet every morning for 8 weeks.~* period 3: One 300/12.5mg tablet every morning for 8 weeks.~* period 4: Two 150/12.5mg tablets every morning for 8 weeks."
62148223|NCT00500604|ACTIVE_COMPARATOR|B|"* period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~* period 2: One 80/12.5mg tablet every morning for 8 weeks.~* period 3: One 160/12.5mg tablet every morning for 8 weeks.~* period 4: Two 80/12.5mg tablets every morning for 8 weeks."
62148224|NCT01835652|ACTIVE_COMPARATOR|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
62148225|NCT01835652|OTHER|Passive Exercise|Passive Exercise (stretching and balance based exercise)
62518837|NCT02560441|OTHER|chemotherapy followed by radiotherapy|Patients receive 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy followed by radiotherapy.
62518838|NCT02560441|OTHER|radiotherapy followed by chemotherapy|Patients receive radiotherapy followed by 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy.
62148226|NCT05995730|EXPERIMENTAL|Experimental group|Lavender inhalation will be administered to this group.
62148227|NCT05995730|PLACEBO_COMPARATOR|Placebo group|Olive oil will be administered to the placebo group.
62148228|NCT02504411|EXPERIMENTAL|Device Assisted Colonoscopy|"Device assisted colonoscopy (DAC) is a technique of attaching disposable devices like Endocuff or Transparent cap at tip of colonoscope to improve mucosal visualization and stability."
62148229|NCT02504411|ACTIVE_COMPARATOR|Standard Colonoscopy|Standard colonoscopy is the endoscopic examination of the large bowel and the distal part of the small bowel with a camera on a flexible tube passed through the anus.
62148230|NCT01567878||ankylosing spondylitis|It will be held ultrasound exam in enthesis and joints in patients with ankylosing spondylitis and healthy subjects
62148231|NCT01567878||Healthy pelople|It will be held ultrasound exam in enthesis and joints of healthy subjects
62148232|NCT02333565|EXPERIMENTAL|Combinaison everolimus and octreotide|
62148233|NCT03180476|EXPERIMENTAL|apatinib|apatinib,500mg,qd，28 day/cycle until the emergence of PD, death, intolerable toxicity
62148234|NCT06369844|EXPERIMENTAL|Intervention group|The group that received pediatric pressure injury education
62148235|NCT06369844|NO_INTERVENTION|Control group|The group that did not receive pediatric pressure injury education
62148236|NCT01079104|ACTIVE_COMPARATOR|Control|Standard Medical Therapy
62148237|NCT01079104|EXPERIMENTAL|Hepa Wash|"Treatment with the liver support system Hepa Wash"
62148238|NCT02309515|EXPERIMENTAL|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
62710864|NCT06338163|EXPERIMENTAL|Treatment|"Once a day starting 5 days before the operation:~Total body washing with usual soap/shampoo and single-use washcloths impregnated with a mix of Polihexanide, surfactants, and excipients.~Nasal cleaning 3 times a day with a Polihexanide Nasal Gel Oral gargles 3 times a day using 10 mL of a Polihexanide oral solution. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) of antiseptic solution will be performed using a 0.04% sterile Polihexanide solution. After the end of the application time, a subcutaneous swab for culture will be taken. Before standard (according to local center clinical practice) wound(s) dressing(s), a 3 mm-thick antiseptic gel (a combination comprised of 0.1 % Polihexanide and 0.1 % propyl betaine (surfactant) that is used for cleansing, moistening and decontamination of post-operative wounds) will be applied on any wound(s)."
62710865|NCT06338163|ACTIVE_COMPARATOR|Control|"Once a day starting 5 days before the operation:~Total body washing with usual soap/shampoo. No oral and nasal MDRO-decolonization will be performed. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) NS will be performed. After the end of the application time, a subcutaneous swab for culture will be taken. Finally, standard wound(s) dressing(s) (according to local center clinical practice) will be applied."
62710866|NCT02550002||Strict treatment regimen with aflibercept|Treatment intervals with aflibercept in the strict retinal fluid treatment regimen will be extended by two weeks only if no SRF in the central subfoveal field and no IRF can be detected SD-OCT examination.
61974766|NCT05725109||Before Period (1/16/2022 to 10/17/2022)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the before phase of this study. In the before phase, alerts identifying patients with active hepatitis C infection will NOT be disseminated to healthcare providers and clinic staff. Routine clinical care will be administered without knowledge of the intervention.
61974767|NCT05725109||After Period (1/16/2023 to 10/17/2023)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the after phase of this study. In the after phase, alerts identifying patients with active hepatitis C infection will be disseminated to healthcare providers and clinic staff.
61974768|NCT01949350|ACTIVE_COMPARATOR|Carbohydrate|CHO loaded test:
62355676|NCT04733001|EXPERIMENTAL|HSG4112 Treatment Arm: Low-Calorie Diet|Single oral dosing of HSG4112 480 mg under low-calorie (400-500 kcal with 100-125 kcal fat) diet conditions
62518839|NCT02560441|OTHER|IPGDP regimen chemotherapy|Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6. 6 cycles, every 3 weeks one cycle.
62518840|NCT02546843|EXPERIMENTAL|Group A|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).~maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.~Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered"
62518841|NCT02546843|ACTIVE_COMPARATOR|Group B|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.~Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.~Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher."
62518842|NCT06468293|NO_INTERVENTION|Control group|Non psychological support intervention
62518843|NCT06468293|OTHER|Intervention group|Psychological support intervention with scheduled appointment within the period of diagnostic assessment
62518844|NCT00572117|PLACEBO_COMPARATOR|Placebo (inert pill) Arm|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
62518845|NCT00572117|EXPERIMENTAL|Topiramate|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. The pills will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
62710867|NCT02550002||Relaxed treatment regimen with aflibercept|Treatment intervals with aflibercept in the relaxed retinal fluid treatment regimen will be extended by two weeks only if SRF in the central subfoveal field is ≤100 μm in a vertical extent and no IRF is detected on SD-OCT examination.
61974769|NCT01949350|ACTIVE_COMPARATOR|Carbohydrate protein|CHO-P loaded test:
61974770|NCT01949350|ACTIVE_COMPARATOR|Water|Starved as for surgery
61974771|NCT05062681|ACTIVE_COMPARATOR|Dexamethasone group|Patients will receive dexamethasone 8 mg q12hours
61974772|NCT05062681|EXPERIMENTAL|methylprednisolone group|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
61974773|NCT03593707|EXPERIMENTAL|Metformin Alone|Metformin alone
61974774|NCT03593707|EXPERIMENTAL|Metformin + PF-06865571|Co-administer metformin and PF-06865571
61974775|NCT04597827||Semantic dementia|Diagnosis of semantic dementia (revised criteria Moreaud et al., 2008; based on Neary et al., 1998)
61974776|NCT04597827||Alzheimer's disease|NIAAA 2011 criteria
61974777|NCT04597827||Control|MMSE above 27, no neurological or psychiatric disorder
62148239|NCT02309515|ACTIVE_COMPARATOR|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
62355677|NCT04733001|EXPERIMENTAL|HSG4112 Treatment Arm: High-Calorie Diet|Single oral dosing of HSG4112 480 mg under high-calorie (800-1000 kcal with 500-600 kcal fat) diet conditions
62355678|NCT05274828|EXPERIMENTAL|H7-Coil Deep TMS Treatment|H7-Coil Deep TMS Treatment
62518846|NCT02893995|EXPERIMENTAL|Slow Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.
62518847|NCT02893995|EXPERIMENTAL|Rapid Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 2.0 ng/kg/min with dose increments of 1-2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate should be increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min has been achieved the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a dose rate of at least 10, 20, 30 and 40 ng/kg/min by the end of Weeks 1, 4, 8 and 12, respectively.
62518848|NCT03757780||Pregnant ladies who are caffeine using|ladies who uses caffeine during pregnancy
62518849|NCT00679913|ACTIVE_COMPARATOR|1|standard pancreatoduodenectomy
62518850|NCT00679913|ACTIVE_COMPARATOR|2|extended pancreatoduodenectomy
62518851|NCT01568866|EXPERIMENTAL|Carfilzomib plus Dexamethasone|Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
62518852|NCT01568866|ACTIVE_COMPARATOR|Bortezomib plus Dexamethasone|Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
62518853|NCT02818387|ACTIVE_COMPARATOR|Group P|Induction with propofol bolus. Dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
62355679|NCT03434418|EXPERIMENTAL|osimertinib|
62518854|NCT02818387|ACTIVE_COMPARATOR|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
62518855|NCT02818387|ACTIVE_COMPARATOR|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by midazolam 0.015 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary."
62518856|NCT04572282|EXPERIMENTAL|Mentora|Remote symptoms monitoring with mobile app
62518857|NCT03476343|EXPERIMENTAL|MRI for Neonates|MRI
62518858|NCT01088282|ACTIVE_COMPARATOR|Implantation of difractive multifocal IOL|
62518859|NCT01088282|SHAM_COMPARATOR|Implantation of monofocal IOL|
62518860|NCT00975962|EXPERIMENTAL|Thrombolysis + Remote perconditioning|"Remote perconditioning (rIPerC) undertaken in ambulance on rute to hospital in case of suspected stroke.~The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC."
62518861|NCT00975962|ACTIVE_COMPARATOR|Thrombolysis|Thrombolysis without pretreatment with remote perconditioning
62518862|NCT05513287||Spinal anethesia|group number one which recive spinal anethesia in cesarean section in 2020 and 2021
62518863|NCT05513287||General anesthesia|Group number 2 which recive general anathesia in cesarean section in 2020 snd 2021
62355680|NCT05898750|EXPERIMENTAL|experimental group|
62355681|NCT05898750|NO_INTERVENTION|Control group|
62518864|NCT05315622|EXPERIMENTAL|Intervention|Bilateral vertebral manipulation of the T12-L1 vertebra
62518865|NCT05315622|PLACEBO_COMPARATOR|Placebo|Application of slight manual tension to the vertebra without reaching a manipulation thrust
62518866|NCT02516423|EXPERIMENTAL|ixazomib + lenalidomide + dexamethasone + zoledronic acid|Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
62518867|NCT02516423|ACTIVE_COMPARATOR|zoledronic acid|Patients receive zoledronic acid (dose based on creatinine clearance on day 1) IV on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
62518868|NCT01817465|EXPERIMENTAL|Motilione®|30 mg is administered with a tablet of placebo (Pantoline®)
62518869|NCT01817465|ACTIVE_COMPARATOR|Pantoline®|40mg is administered with a tablet of Motilitone®
62518870|NCT01817465|ACTIVE_COMPARATOR|Motilitone® and Pantoline®|Both drugs are administered at once
62518871|NCT01421342|ACTIVE_COMPARATOR|Switching: Bupropion-SR|Switching: Bupropion-SR
62518872|NCT01421342|ACTIVE_COMPARATOR|Augmenting: Antidepressant + Bupropion-SR|Augmenting: Antidepressant + Bupropion-SR
62518873|NCT01421342|ACTIVE_COMPARATOR|Augmenting: Antidepressant + Aripiprazole|Augmenting: Antidepressant + Aripiprazole
62355682|NCT03055572|EXPERIMENTAL|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
62518874|NCT01224028|EXPERIMENTAL|Tacrolimus group|
62518875|NCT01224028|PLACEBO_COMPARATOR|Placebo|
62355683|NCT03055572|ACTIVE_COMPARATOR|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
62355684|NCT03055572|NO_INTERVENTION|Control Group|The control group will continue the medical therapy prescribed by their provider.
62148240|NCT05777772|EXPERIMENTAL|Educational Intervention|Educational Intervention
62518876|NCT05678231|NO_INTERVENTION|Standard of Care|Patients will receive standard of care instructions rehabilitation instructions following total knee replacement.
62518877|NCT05678231|EXPERIMENTAL|Zero Degree Knee|Patients will receive the Zero Degree Knee device and instructions for use following total knee replacement.
62518878|NCT02780167|EXPERIMENTAL|Cohort 1|10 mg of PF-04965842 QD
62518879|NCT02780167|EXPERIMENTAL|Cohort 2|30 mg of PF-04965842 QD
62518880|NCT02780167|EXPERIMENTAL|Cohort 3|100 mg of PF-04965842 QD
62518881|NCT02780167|EXPERIMENTAL|Cohort 4|200 mg of PF-04965842 QD
62518882|NCT02780167|PLACEBO_COMPARATOR|Cohort 5|placebo QD
61974778|NCT02406482|EXPERIMENTAL|HIVRR + MF|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)) followed by financial literacy, micro-savings and vocational training (Behavioral: Microfinance intervention (MF)).
62148241|NCT00561249|EXPERIMENTAL|1|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo.
62148242|NCT00561249|NO_INTERVENTION|2|No intervention
62148243|NCT04495153|OTHER|Cohorts|"Cohort 1A and 1B - persistent but stable disease at least 18 weeks after starting ICI treatment~Cohort 2A and 2B - radiographic progressive disease at least 18 weeks after starting ICI treatment~Cohort 3 - refractory disease defined as progressed by imaging at least 9 weeks after starting ICI treatment (CLOSED TO ENROLLMENT)"
62355685|NCT03626740|EXPERIMENTAL|TheraCal|Indirect pulp capping with TheraCal
61974779|NCT02406482|ACTIVE_COMPARATOR|HIVRR only|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)).
62148244|NCT04555057|EXPERIMENTAL|Music therapy group|"One day before surgery, the participants of music therapy group choose the music they want to listen in the operating room. The total playing time of the selected music is recommended between 5 and 10 minutes.~On the day of surgery, after entering the operating room, listen to personally selected music through the speaker. After the music is over, start anesthesia induction."
61974780|NCT05244330||Partial vaccination|One dose of vaccine received at least 7 days prior to study enrollment
61974781|NCT05244330||Full vaccination|Two doses of COVID-19 vaccine received at least 7 days prior to study enrollment
61974782|NCT05244330||Unvaccinated|No dose of COVID-19 vaccine for at least 7 days prior to study enrollment
61974783|NCT06230081|ACTIVE_COMPARATOR|Block|"Hip Arthroplasty: Multimodal analgesic therapy + Ultrasound guided PENG block and Iliohypogastric block or LFCN-block.~Knee arthroplasty: Multimodal analgesic therapy + Ultrasound guided iPACK block, triple Genicular blocks, Vastus intermedius block, Adductor canal block and AFCN-block."
61974784|NCT06230081|NO_INTERVENTION|No block|"Hip Arthroplasty: Multimodal analgesic therapy~Knee Arthroplasty: Multimodal analgesic therapy + LIA"
61974785|NCT01018186|EXPERIMENTAL|Fluticasone furoate/GW642444|
62518883|NCT03959215|EXPERIMENTAL|Usual care + Back in the Game|Smartphone-delivered cognitive behavioural therapy to support confidence to return to sport + usual post-operative physiotherapy rehabilitation
62518884|NCT03959215|ACTIVE_COMPARATOR|Usual care|Usual post-operative physiotherapy rehabilitation
62518885|NCT05154058|ACTIVE_COMPARATOR|Control: electrocautery|Primary patients with Osteoarthritis (OA) undergoing Total Knee arthroplasty (TKA) will be randomly assigned into either the control or investigational group. The control arm of the study will undergo medial sub periosteal release with electrocautery.
61974786|NCT01018186|ACTIVE_COMPARATOR|Fluticasone propionate|
61974787|NCT00142584|EXPERIMENTAL|1-NEB|Nebivolol
62148245|NCT04555057|NO_INTERVENTION|Control group|The participants of control group wear earmuff to block noise after entering the operating room until induction of anesthesia. All other treatments proceed as conventional treatments.
62148246|NCT00299676||001|Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet
62148247|NCT03964974|EXPERIMENTAL|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|
62518886|NCT05154058|ACTIVE_COMPARATOR|Investigational: sharp dissection.|Primary patients with OA undergoing TKA will be randomly assigned into either the control or investigational group. The investigational arm will undergo medial sub periosteal release using sharp dissection.
61974788|NCT00142584|ACTIVE_COMPARATOR|2-MET|Metoprolol
61974789|NCT06152978|EXPERIMENTAL|Sintilimab plus chemotherapy|Sintilimab: 200mg; cisplatin: 75mg/m2, d1, routine hydration for 3 days; nab-paclitaxel: 260mg/m2, d1, every 3 weeks, 2-3 cycles.
62148248|NCT03964974|PLACEBO_COMPARATOR|Sleep Hygiene Education (SHE)|
62148249|NCT02577939|EXPERIMENTAL|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
62148250|NCT03108430||Inhalation pneumonia|
62148251|NCT03108430||Proven inhalations|
62148252|NCT03108430||Suspected inhalations (coma + anamnesis)|
62148253|NCT00610337|PLACEBO_COMPARATOR|1|
62148254|NCT00610337|EXPERIMENTAL|2|1mg Cethrin®
62518887|NCT06354491||Average or low BMI|Children with BMI under the 85th percentile for age and sex
62518888|NCT06354491||High BMI|Children with BMI in the 95th percentile or higher for age and sex
62518889|NCT00703508|EXPERIMENTAL|Metformin|Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
62518890|NCT01478282|ACTIVE_COMPARATOR|Rivaroxaban|Healthy donors subjected to 20mg/day for 5 days
62518891|NCT01478282|ACTIVE_COMPARATOR|Dabigatran|Healthy volunteers subjected to 150 mg/12hours for 5 days
62518892|NCT03347760|EXPERIMENTAL|Experimental arm|All included patients wil receive 68Ga-dotatoc-PET/CT suspected acute myocarditis in first and an other 68Ga-dotatoc-PET/CT 6 months later
62518893|NCT05916521|ACTIVE_COMPARATOR|Positive Control|2 brushings per day (AM and PM)
62518894|NCT05916521|SHAM_COMPARATOR|Negative Control|2 brushings per day (AM and PM)
62518895|NCT05916521|EXPERIMENTAL|Experimental Control|Brush with Positive control in the morning and negative control in the evening
62518896|NCT04614493|EXPERIMENTAL|Ultrasound experimental arm|Standard of Care + 15 Ultrasound BBB opening
62518897|NCT04614493|OTHER|Control arm|Standard of Care
62148255|NCT00610337|EXPERIMENTAL|3|3mg Cethrin®
62148256|NCT00610337|EXPERIMENTAL|4|6mg Cethrin®
62148257|NCT00610337|EXPERIMENTAL|5|12mg Cethrin®. Administration of this dose is dependent on data from lower doses.
62148258|NCT00610337|EXPERIMENTAL|6|18mg Cethrin®. Administration of this dose is dependent on data from lower doses.
62148259|NCT02445404|ACTIVE_COMPARATOR|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
62148260|NCT02445404|EXPERIMENTAL|Fractionated ICED|ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
62355686|NCT03626740|ACTIVE_COMPARATOR|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
62148261|NCT02459860|EXPERIMENTAL|Problem Solving Treatment|Problem Solving Treatment Individual, face-to-face PST sessions over a span of 8 weeks and 3 monthly booster sessions. The PST protocol is highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies.
62148262|NCT02459860|ACTIVE_COMPARATOR|Enhanced Usual Care|Enhanced Usual Care EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
62355687|NCT01812122|EXPERIMENTAL|Glimepiride|Starting with Glimepiride. After 3 month, switching to vildagliptin.
62355688|NCT01812122|EXPERIMENTAL|Vildagliptin|Starting with vildagliptin. After 3 month, switching to Glimepiride.
62355689|NCT04744610|OTHER|4-hour delayed radiographs|The follow-up radiographs was taken 4 h after the HSG operation.
62148263|NCT03795532|ACTIVE_COMPARATOR|Ultraslow shock wave lithotripsy (SWL)|SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).
62148264|NCT03795532|ACTIVE_COMPARATOR|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
62148265|NCT01228500|EXPERIMENTAL|Experimental Arm (Internal Control)|"One-half of ulcer receives negative pressure wound therapy~One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy"
62148266|NCT02589613|PLACEBO_COMPARATOR|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
62148267|NCT02589613|ACTIVE_COMPARATOR|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
62148268|NCT02589613|ACTIVE_COMPARATOR|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
62148269|NCT02601859|EXPERIMENTAL|Phase 3|Administration of Lithium to 11 individuals with MCI (non-randomised) for 9 weeks. Lithium dose escalates from 100mg to 200mg to 400mg, then a 3 week wash out period, total study duration 12 weeks. Blood samples taken at regular intervals throughout trial and analysed for GSK-3 enzyme activity in blood.
62148270|NCT04661774|OTHER|Sham massage before reflexology massage (RP)|Sham massage (MS) comparator will be realised before RP.
62148271|NCT04661774|OTHER|Reflexology massage (RP) before Sham massage|RP will be realized before Sham massage.
62355690|NCT05610722|OTHER|DreaMed Endo Digital|"At each visit, participants who use pump therapy will download their pump and glucose data (V1-V5) as they use to do at clinic visit. Participants who use MDI therapy will use the Endo.Digital App for insulin and glucose documentation and will upload data from their CGM/FGM or glucometer as they use to do at clinic visit.~In addition, participants will be offered to download data also at home in between study visits, every 3-6 weeks as they feel needed (Phone visits: P1-up to P8). Each time, optimization of pump settings or MDI will be done according to the downloaded data using the Endo.DigitalTM system. The device recommendations for insulin dosing adjustments and diabetes management tips will be reviewed by the treating physician. Each new treatment settings will be approved or edit by the study physician prior to implementation by the participant."
62355691|NCT01559714||Clinical HCM patients|Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC and ACCF/AHA guidelines
62355692|NCT01559714||Pre-clinical HCM patients|Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy
62710868|NCT02782910|EXPERIMENTAL|SBAA+|Upon exceeding pre defined SBAA-threshold limits during the randomisation phase the treating physician is alerted (+) to this signal and required to contact the patient so as to assess the current mental status and collaboratively discuss the potential need for medical/psychiatric treatment with the patient.
62148272|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
62148273|NCT00978718|PLACEBO_COMPARATOR|Arm I|Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
62148274|NCT00978718|EXPERIMENTAL|Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily|Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
62148275|NCT00978718|EXPERIMENTAL|Arm III: 400 μg Se as high-Se baker's yeast daily|Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
62148276|NCT02321956|EXPERIMENTAL|Ultrasound|Using ultrasound measurement of the subglottic area to choose endotracheal tube size
62148277|NCT02321956|NO_INTERVENTION|Formula|Using Cole's formula to choose endotracheal tube size
62148278|NCT06357455|EXPERIMENTAL|SAME™ Device group|SAME™ Autotransfusion Device that is being tested for recovery of platelets along with RBCs
62148279|NCT06357455|ACTIVE_COMPARATOR|Autolog™ Device group|Autolog™ standard autotransfusion device currently used at our institution
62148280|NCT02188459|ACTIVE_COMPARATOR|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
62148281|NCT02188459|PLACEBO_COMPARATOR|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
62148282|NCT04277494|EXPERIMENTAL|Clorethyl cold spray® (Vapocoolant spray)|"23 volunteer athletes who are studying at the Faculty of Health Sciences of Acıbadem University, between the ages of 18-23, with a subcutaneous fold thickness of the quadriceps muscle between 5 mm and 15 mm (Shadgan et al., 2015).~From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application."
62148283|NCT00578344|EXPERIMENTAL|Allogeneic BMT/SCT Transplant|"Busulfan, Campath 1H, Cyclophosphamide and MESNA:~Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.~Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10\^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest."
62148284|NCT06301620|EXPERIMENTAL|Routine rehabilitation treatment+Intra-articular Injection|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
62148285|NCT06301620|ACTIVE_COMPARATOR|Routine rehabilitation treatment|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
62148286|NCT03956407|ACTIVE_COMPARATOR|Active, subacute stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
62518898|NCT01745341||vitreoretinal surgery patients|Patients undergoing vitreoretinal surgery under monitored anesthesia care. They will be observed during surgery and no interventions will be administered.
62710869|NCT02782910|NO_INTERVENTION|SBAA|Continuous monitoring will occur analogous to SBAA+. Exceeding the pre defined SBAA-threshold will not result in any action taken.
62710870|NCT03515421|EXPERIMENTAL|Blood Glucose monitoring System (BGMS)|"Intervention: Blood Glucose monitoring Systems (BGMSs): Frazier 3 Verio and Frazier 3 UltraPLus.~Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)"
62148287|NCT03956407|SHAM_COMPARATOR|Sham, subacute stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
62148288|NCT03956407|ACTIVE_COMPARATOR|Active, chronic stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
62148289|NCT03956407|SHAM_COMPARATOR|Sham, chronic stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
62148290|NCT02159794|EXPERIMENTAL|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
62710871|NCT01784029|EXPERIMENTAL|Low Dose|"VItamin D3 1,000 IU~1 x day, 8 weeks"
62148291|NCT01056159|EXPERIMENTAL|Albuterol dry powder inhaler|The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler).
62148292|NCT01056159|ACTIVE_COMPARATOR|Albuterol HFA MDI|The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler).
62148293|NCT01419184|EXPERIMENTAL|Daptomycin|4 milligrams per kilogram (mg/kg) daptomycin administered intravenously (IV) once a day until end of antibiotic therapy for complicated skin and skin structure infections (cSSSI) or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
62148294|NCT01419184|ACTIVE_COMPARATOR|Vancomycin|Vancomycin was reconstituted per the manufacturer's instructions and was dosed per investigator's discretion and was administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occured first. Investigators treated participants according to their usual decision-making and discretion
62148295|NCT04195789||Sample population|Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.
62148296|NCT02439099||MDD|Currently unmedicated patients with a depressive episode in the context of unipolar major depression
62148297|NCT02439099||Control|Healthy Controls
62148298|NCT02439099||Alzheimer's Disease|Patients with Alzheimer's disease
62355693|NCT02245867|EXPERIMENTAL|Phase Ia|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks."
62518899|NCT01913236|EXPERIMENTAL|Implementation intervention|Tailored implementation intervention to address determinants of practice in primary care
62518900|NCT01913236|NO_INTERVENTION|Control|Treatment as usual provided by general practitioners to elderly patients with depression
62518901|NCT01842126|EXPERIMENTAL|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
62710872|NCT01784029|EXPERIMENTAL|Weekly High Dose|"Vitamin D3 50,000 IU~1x week, 8 weeks"
62710873|NCT01784029|EXPERIMENTAL|Daily High Dose|"Vitamin D3 5,000 IU~1x day, 8 weeks"
62710874|NCT04119713||Study Population|Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).
62710875|NCT03852030|EXPERIMENTAL|Mindfulness text/email message|"Weekly MBSR specific text or email messages related to course teachings were sent.~TYPES OF MESSAGES INCLUDED: Non-reaction; Non-Judgment; Awareness; Loving Kindness; Acceptance."
62710876|NCT03852030|PLACEBO_COMPARATOR|Health promotion text/email message|Weekly general/informational texts or emails about healthy living and lifestyle were sent. TYPES OF MESSAGES INCLUDED: Diet; Exercise; Sleep; Illness; Stress.
62710877|NCT03852030|NO_INTERVENTION|No text/email message|No texts or emails were sent. There are no examples or descriptions for these messages, because no messages were sent to this group.
62148299|NCT02439099||Alcoholism|Subjects with alcoholism
62355694|NCT02245867|EXPERIMENTAL|Phase Ib|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12."
62148300|NCT02439099||Schizophrenia|Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole
62148301|NCT01648114|NO_INTERVENTION|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
62518902|NCT01842126|EXPERIMENTAL|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
62148302|NCT01648114|EXPERIMENTAL|Antenatal Breastfeeding Intervention|Antenatal intervention group will receive usual care plus a 20 to 30-minute one-to-one educational intervention about breastfeeding.
62148303|NCT05967845|ACTIVE_COMPARATOR|Platelet rich fibrin augmented tympanoplasty|Platelet rich fibrin will be prepaired from the patient's own blood throud a centrifugation process and will be applied on the temproalis fascia graft to improve healing.
62518903|NCT01842126|EXPERIMENTAL|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
62518904|NCT01842126|EXPERIMENTAL|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
62148304|NCT05967845|ACTIVE_COMPARATOR|cartilage tympanoplasty|A piece of cartilage will be harvested from the concha and used as a graft for tympanoplasty
62518905|NCT02725775|ACTIVE_COMPARATOR|100% OJ|240ml 100% Florida Orange Juice consumed on a daily basis for 10 weeks.
62148305|NCT00135278|OTHER|CSF Drainage|
62148306|NCT00135278|OTHER|No CSF Drainage|
62148307|NCT02614157|EXPERIMENTAL|LLND+TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo lateral lymph node dissection and total mesorectal excision(LLND+TME)
62355695|NCT00179517|EXPERIMENTAL|depotestosterone plus anastrozole (T-A)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes an oral tablet of anastrozole 1 mg daily for the duration of the study. This group is referred to as the depotestosterone plus anastrozole (T-A) group.
62355696|NCT00179517|PLACEBO_COMPARATOR|depotestosterone plus placebo (T-P)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes 1 matching placebo oral tablet daily for the duration of the study. This group is referred to as the depotestosterone plus placebo (T-P) group.
62355697|NCT03255811|EXPERIMENTAL|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
62355698|NCT02980692|EXPERIMENTAL|SUNPG1623 dose I|low range dose
62355699|NCT02980692|EXPERIMENTAL|SUNPG1623 dose II|mid range dose
62518906|NCT02725775|PLACEBO_COMPARATOR|Equicaloric Orange Drink|An equicaloric placebo orange drink (containing equivalent dose of sucrose, glucose, fructose, vitamin C and citric acid for flavour) consumed daily for 10 weeks.
61974790|NCT06152978|ACTIVE_COMPARATOR|Chemotherapy|Cisplatin: 75mg/m2, d1, routine hydration for 3 days; nab-paclitaxel: 260mg/m2, d1, every 3 weeks, 2-3 cycles.
62148308|NCT02614157|NO_INTERVENTION|TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo total mesorectal excision (TME)solely, without LLND
62148309|NCT03187548|EXPERIMENTAL|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
62518907|NCT05749679|EXPERIMENTAL|Training|Physicians participating will receive training on renal failure in type 2 diabetes and on measures to reduce nephron loss
62518908|NCT05749679|SHAM_COMPARATOR|Routine care|
62710878|NCT01658059|EXPERIMENTAL|group 1|homeopathic remedy first , placebo second
62710879|NCT01658059|EXPERIMENTAL|group 2|placebo first, homeopathic remedy second
62710880|NCT03800355||Male breast cancer|The study target population is all cases of male breast cancer (MBC), diagnosed with invasive breast cancer between the years 2000 and 2019, and treated in the Medical Oncology Departments of participating sites.
62148310|NCT03191448|EXPERIMENTAL|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
61974791|NCT00005622|OTHER|Cy/TBI|cyclophosphamide and total body irradiation (TBI)
61974792|NCT03600610|EXPERIMENTAL|patient group|malnourished patients with anorexia nervosa gadolinium-enhanced cardiac MRI will be performed
61974793|NCT03600610|ACTIVE_COMPARATOR|control group|age- and sex- matched, normal weight, healthy volunteers gadolinium-enhanced cardiac MRI will be performed
62148311|NCT04994093||COLON CANCER|This cohort will consist of 100 patients with Colon Cancer.
62148312|NCT01269307|ACTIVE_COMPARATOR|1:1 ketamine - propofol mixture|
62148313|NCT01269307|ACTIVE_COMPARATOR|propofol|propofol
62148314|NCT05894291|EXPERIMENTAL|Swimmer Prone Position|
62148315|NCT05894291|ACTIVE_COMPARATOR|Prone position with arms alongside the body|
62148316|NCT01728298|ACTIVE_COMPARATOR|SLITone ULTRA low dose|SLITone ULTRA HDM immunotherapy
62148317|NCT01728298|ACTIVE_COMPARATOR|SLITone ULTRA medium dose|SLITone ULTRA HDM immunotherapy
62148318|NCT01728298|ACTIVE_COMPARATOR|SLITone ULTRA high dose|SLITone ULTRA HDM immunotherapy
62710881|NCT03982160|EXPERIMENTAL|L-arginine|Intravenous infusion of L-arginine (250-350 mg/kg) will be performed for 30 minutes.
62518909|NCT01742559|EXPERIMENTAL|Anterior middle superior alveolar|The AMSA technique was performed in the test group according to Friedman \& Hochman (1997). The needle was introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the periodontal procedure.
62518910|NCT01742559|ACTIVE_COMPARATOR|Supraperiosteal technique|The supraperiosteal technique at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the SRP procedure.
62518911|NCT01356784|EXPERIMENTAL|Tailored Physical Activity|
62518912|NCT01356784|ACTIVE_COMPARATOR|"Chronic Pain Self-management Programme"|
62518913|NCT01356784|OTHER|Health Counselling|
62518914|NCT04636242|EXPERIMENTAL|Group 1: Phototherapy Group|patient will be instructed to apply 5-aminolevulinic acid HCL topical solution to their shoulder prior to their surgery. 16 minutes before skin incision a blue light will be applied to the area of the shoulder where the 5-ALA was administered
62518915|NCT04636242|ACTIVE_COMPARATOR|Group 2: Control Group|patient will undergo standard of care surgery
62355700|NCT02980692|EXPERIMENTAL|SUNPG1623 dose III|mid range dose
62355701|NCT02980692|EXPERIMENTAL|SUNPG1623 dose IV|mid range dose to high dose
62355702|NCT02980692|PLACEBO_COMPARATOR|Placebo|mid range dose to high dose
62355703|NCT06342648|ACTIVE_COMPARATOR|Intracutaneous sterile water injection (ISWI)|Sterile water will be intramuscularly injected in the intracutaneous sterile water injection (ISWI) group (Group I) in a plane parallel to the posterior midline, adhering to a predetermined injection pattern from the level of the iliac crest to the last rib.
62355704|NCT06342648|ACTIVE_COMPARATOR|Intramuscular diclofenac sodium injection (DIC)|Diclofenac sodium injection intramuscularly (Group II): Diclofenac sodium injection intramuscularly (75 mg) will be given to 285 patients in total.
62355705|NCT05386264|EXPERIMENTAL|Expanded autologous T regulatory cells|This is an open-label, non-randomised interventional trial.
62355706|NCT04829942|EXPERIMENTAL|experimental|A 12-week training program will be applied to the experimental group. Pre-tests will be applied before the trainings begin, and height and weight measurement, nutrition, health perception and behavior scale and physical activity scale will be applied to the experimental group and the control group within the 3rd and 6th month after the training program begins. Scale applications will be applied within 2 days, taking into account the attention span of the students.
62355707|NCT04829942|NO_INTERVENTION|no intervention|Power point presentations will be given to the control group
62355708|NCT02911623|EXPERIMENTAL|Lithoplasty Treatment|Patients in this group will receive treatment with the Shockwave Lithoplasty® System which uses lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic peripheral arteries.
62355709|NCT00232505|EXPERIMENTAL|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.
62355710|NCT00232505|EXPERIMENTAL|Cetuximab and Carboplatin|Patients receive cetuximab as in arm I and carboplatin IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62355711|NCT05929638|EXPERIMENTAL|Experimental|Lavender oil in 15 ml opaque dark colored bottles closed with metal caps to prevent volatility to the venture group and 40 2×2 cotton pads were delivered. Patients were asked to apply lavender oil 30 minutes before going to bed. Deep breathing increases the concentration of aromatic substances in the body. The time it takes for essential oils to be absorbed into the blood circulatory system is about 30 minutes for complete absorption by the body. Information was given about dripping 3 drops of lavender oil on cotton pads and placing them 15-20 cm away from the pillow. Patients were told that they should apply lavender oil for 30 days and re-prepare the lavender oil dripped onto a new pad each night, and that the bedroom should be ventilated and free of different odors. A message was sent to the patients to remind them of the application on their phones for 30 days.
62355712|NCT05929638|NO_INTERVENTION|Control|No intervention will be applied to the control group.
62355713|NCT02823080|ACTIVE_COMPARATOR|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
62355714|NCT02823080|NO_INTERVENTION|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
62355715|NCT03148756|EXPERIMENTAL|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
62355716|NCT03148756|ACTIVE_COMPARATOR|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
62355717|NCT02771678||Asthma|All participants will have an asthma-related crisis event due to an asthma exacerbation that resulted in A\&E attendance and/or hospital admission.
62355718|NCT01136863|ACTIVE_COMPARATOR|felodipine group, active, pill|felodipine and HCTZ treatment group
62355719|NCT01136863|PLACEBO_COMPARATOR|placebo, no treatment, pill|placebo and HCTZ group
62355720|NCT04946162|EXPERIMENTAL|Tadalafil Group|Each patient will be given tadalafil 40 mg one time
62355721|NCT05553912|EXPERIMENTAL|QBSafe intervention|
62148319|NCT02099409|EXPERIMENTAL|Starting with FLORENCED2 followed by open loop|Start 2 Overnight periods with closed loop through FLORENCED2 Device , followed by 2 overnight periods with open loop.
62518916|NCT01112813|EXPERIMENTAL|Lithium|Lithium Carbonate, 0.4-0.8 mmol/L for 2 months
62518917|NCT05543330|EXPERIMENTAL|Experimental group|Pleural drainage and M701 infusion
62518918|NCT05543330|SHAM_COMPARATOR|Control group|Pleural drainage only or plus chemotherapy as investigator's choice.
62148320|NCT02099409|EXPERIMENTAL|Start open loop followed by FLORENCED2|Start with 2 overnight periods with open loop , followed by 2 overnight with closed loop FLORENCED2
62148321|NCT06153784|EXPERIMENTAL|Combination of hydroxyurea and thalidomide|Hydroxyurea was continued at a dose of 10-20 mg/kg/day for 6 months and then thalidomide was added orally at a dose of 2-5mg/kg/day.
62148322|NCT01999335|EXPERIMENTAL|Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
62148323|NCT01999335|EXPERIMENTAL|Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 2 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
62148324|NCT01999335|EXPERIMENTAL|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
62148325|NCT01999335|EXPERIMENTAL|Oprozomib 240 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
62148326|NCT01999335|EXPERIMENTAL|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone: Expansion Phase|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
62148327|NCT06434584||senior doctor group|
62148328|NCT06434584||junior doctor group|
62148329|NCT05819268|EXPERIMENTAL|ReACT Intervention|"During the initial visit participant will be randomized to either Retraining and Control Therapy (ReACT) or Competent Adulthood Transition with Cognitive Behavioral, Humanistic, and Interpersonal Training (CATCH-IT) intervention.~ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.~Participants will have 12 therapy sessions. The first session will be in-person which will last 2 hours and the subsequent 11 sessions will be conducted via video telehealth and each session will last 1 hour."
62148330|NCT05819268|ACTIVE_COMPARATOR|CATCH-IT Intervention|"During the initial visit participant will be randomized to either Retraining and Control Therapy (ReACT) or Competent Adulthood Transition with Cognitive Behavioral, Humanistic, and Interpersonal Training (CATCH-IT) intervention.~CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.~Participants will have 12 therapy sessions. The first session will be in-person which will last 2 hours and the subsequent 11 sessions will be conducted via video telehealth and each session will last 1 hour."
62148331|NCT04024982|OTHER|Lecture followed by Simulation|Subjects will undergo the lecture on TEE first followed by the simulation session.
62148332|NCT04024982|OTHER|Simulation followed by Lecture|Subjects will undergo the TEE simulation first followed by the lecture.
62148333|NCT05397509|EXPERIMENTAL|Olive Leaf Tea|Olive Leaf Tea
62148334|NCT05397509|PLACEBO_COMPARATOR|Placebo tea|Placebo tea
62148335|NCT04707820|EXPERIMENTAL|Patient group|- Patient with an acute SARS-CoV-2 infection, confirmed by PCR or typical CT images, requiring hospitalization in a COVID unit at Rouen University Hospital.
62148336|NCT04707820|NO_INTERVENTION|control group|- Rouen University Hospital staff free of any symptomatology compatible with an SARS-CoV-2 infection (fever, cough, fatigue, loss of taste, loss of smell) since February 1, 2020
62518919|NCT03197558|OTHER|Tube insertion using Tube Delivery System (TDS)|Active Tymbion iontophoresis and tube insertion using the TDS
62148337|NCT05904652|EXPERIMENTAL|SAFEx|Electrical Impedance Tomography recording is commenced 15 minutes prior to planned extubation. High Flow Nasal Therapy (HFNT) is commenced at least 10 minutes prior to planned extubation. At 5 minutes before extubation, the flow rate of HFNT should be established at 60 litres per min (or as high as can be tolerated by the participant) and the fraction of inspired oxygen (FiO2) set at 40 percent. Prior to extubation, endotracheal, infraglottic and supraglottic suctioning are performed. Then, the cuff is let down followed by immediate extubation with simultaneous application of HFNT. 10 minutes after extubation, the FiO2 is weaned in a protocolised manner to 21 percent - or as close to 21 percent as possible over 25 minutes. If the participant is safely weaned onto room air, the flow rate of HFNT is then reduced in a protocolised manner over 120 minutes: 60 minutes at 60 litres per minute (or the highest flow rate tolerated) and then 60 minutes at 30 Litres per minute.
62148338|NCT05904652|ACTIVE_COMPARATOR|Standard Care|Electrical Impedance Tomography recording commenced 15 minutes prior to planned extubation. Prior to extubation, endotracheal, infraglottic and supraglottic suctioning are performed. Then, the cuff is let down followed by immediate extubation on to low flow conventional oxygen with a fraction of inspired oxygen of up to 40 percent. Then, the participant is weaned at the discretion of their clinician over the next 2 hours and 35 minutes.
62148339|NCT03400007||Prolapse surgery|
62148340|NCT04202822|OTHER|Biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) at T0 and T24
62518920|NCT03415984||Exposed patients|Patients with Parkinson's disease treated with L-DOPA
62148341|NCT02070172||Cervicogenic Headache Group|This group of subjects is considered the symptomatic group. No intervention was provided in this study so there are no intervention groups.
62355722|NCT05553912|NO_INTERVENTION|usual care|
62355723|NCT05876104||Adult chronic pain patients|Adult chronic pain patients who harass pain clinic staff
62518921|NCT03415984||Non exposed patients|Patients with Parkinson's disease not treated with L-DOPA
62518922|NCT03627234|EXPERIMENTAL|Same Day Discharge|Same day discharge after hysterectomy is the standard of care at George Washington University Hospital.
62710882|NCT03982160|PLACEBO_COMPARATOR|Saline|Saline will be infused for 30 minutes
62518923|NCT03627234|EXPERIMENTAL|Overnight stay|Overnight stay is not the standard of care at George Washington University Hospital. It is being used as an experimental condition.
62148342|NCT02070172||Healthy, Asymptomatic Group|Subjects in this group had no headache symptoms. Their neck motion was compared to subjects in the headache group. No intervention was provided to subjects in either group for this study.
62518924|NCT02072824|EXPERIMENTAL|Study Drug Level 1|
62518925|NCT02072824|EXPERIMENTAL|Study Drug Level 2|
62518926|NCT02072824|PLACEBO_COMPARATOR|Placebo|
62518927|NCT03896984||Cohort_2LX|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as first liine (1L) after diagnosis of mCRPC who then received Ra-223 monotherapy as second line (2L) treatment
62518928|NCT03896984||Cohort_2LH|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as 1L after diagnosis of mCRPC who then received another NAH monotherapy (i.e., Abiraterone to Enzalutamide or Enzalutamide to Abiraterone) as 2L treatment. None of the patients had ever received Radium-223 dichloride
62518929|NCT02596321|EXPERIMENTAL|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
62148343|NCT02279732|EXPERIMENTAL|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
62355724|NCT05779605|EXPERIMENTAL|Home-based training|12 weeks of home-based exercise training using modern technology to transfer exercise data remotely. The participants receive a heart rate monitor and sensor. Three sessions per week will be performed (36 sessions overall).
62355725|NCT05779605|ACTIVE_COMPARATOR|Center-based training|12 weeks of centre-based exercise training under supervision physiotherapists specializing in exercise rehabilitation. The participants receive a heart rate monitor and sensor. The patients in the Center-based training group receive an individually tailored training program on a treadmill and a bicycle ergometer. Three sessions per week will be performed (36 sessions overall).
62355726|NCT04783220|EXPERIMENTAL|Intervention|The parents of babies in this group will receive an educational and intervention program
62355727|NCT04783220|NO_INTERVENTION|Control|The parents of babies in this group will receive the standard parent education and follow-up.
62355728|NCT00431821|OTHER|Arm 1|Home-based exercise prescriptions with weekly motivational telephone calls.
62355729|NCT00431821|OTHER|Arm 2|Stroke education program with matched attention phone calls
62355730|NCT03923439|EXPERIMENTAL|MRI protocol|For stroke patients, the follow-up MRI (named MRI-2) after successfully recanalized thanks to thrombectomy, intravenous thrombolysis or spontaneously, will be performed between 24h and 72h after recanalization on our new Canon 3T research magnet with high gradient system. Patients will be explored for a follow-up evaluation at 3 months with a final MRI (named MRI-3) that will be performed on the Canon 3T research magnet.
62355731|NCT04114539|EXPERIMENTAL|Ecopipam|
62355732|NCT06306924||Palliative radiation therapy|Subjects who are with metastatic cancer receive palliative radiation therapy.
62355733|NCT04869670|EXPERIMENTAL|G-POEM|
62355734|NCT04869670|SHAM_COMPARATOR|Sham procedure|
62355735|NCT01631240||Adults 18-39 years|Healthy adults aged 18-39 years
62355736|NCT02522572|EXPERIMENTAL|Group A|4 doses of plerixafor and plasmapheresis
62355737|NCT02522572|EXPERIMENTAL|Group B|4 doses of plerixafor, 1 dose of bortezomib, and plasmapheresis
62355738|NCT02522572|EXPERIMENTAL|Group C|6 doses of plerixafor, 2 doses of bortezomib, and plasmapheresis
62355739|NCT01374672||Correlative studies|DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.
62355740|NCT05550896||Mild to moderate AS|Patients with mild to moderate AS by echocardiography
62355741|NCT05550896||Controls|Age and sex match controls with no AS by echocardiography
62355742|NCT04020406||Antibacterial Activity of Urea|Activity of Urea Solution against Ocular Bacterial Isolates
62355743|NCT00293150|ACTIVE_COMPARATOR|Eplerenone|Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
62355744|NCT00293150|PLACEBO_COMPARATOR|Placebo|Placebo dosed daily
62355745|NCT02674165|EXPERIMENTAL|Intervention|"The pregnancy prevention intervention to be tested is an adaptation of Becoming a Responsible Teen (BART), an evidence-based (proven to work by research) HIV prevention curriculum designed primarily for African American adolescents, ages 14-18, in community-based settings.~The culturally-adapted version HART consists of nine sessions, lasting about 2 hours each, and includes interactive group discussions and role plays that are -performed by adolescents. Unlike BART, one PTSD awareness session has been added to address what happens to people who have been exposed to mental trauma and natural disasters."
62355746|NCT02674165|NO_INTERVENTION|Control or nutrition|Nutrition/fitness curriculum will teach students about ingredients in food that are good for the body and will keep it in good health
62355747|NCT05928676|EXPERIMENTAL|Vascanox® HP|
62355748|NCT03154307|EXPERIMENTAL|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
62355749|NCT03154307|EXPERIMENTAL|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
62355750|NCT03154307|SHAM_COMPARATOR|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
62518930|NCT02596321|PLACEBO_COMPARATOR|Placebo tablet|Placebo tablet
62518931|NCT00944112|EXPERIMENTAL|Restrictive RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70g/L with a target Hb concentration of 71-90g/L during the intervention period.
62355751|NCT03154307|EXPERIMENTAL|Short-term protocol|LF-rTMS intervention daily for up to 5 days in medically refractory status epilepticus participants only
62355752|NCT04183946|OTHER|Online Cognitive Behavioural Therapy|Screened participants diagnosed with minor to moderate anxiety and/or depression will receive online CBT therapy (8 interactive sessions) aiming to treat their symptomatology. Each session can be completed at one's own pace.
62518932|NCT00944112|EXPERIMENTAL|Liberal RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90g/L with a target Hb concentration of 91-110g/L during the intervention period.
62518933|NCT05011630||IAA group|Intraabdominal abscess (IAA) is defined as either a turbid discharge from the intraoperatively placed drain or a postoperative fluid collection managed by CT-guided placement of drains with documental bacteriological culture.
62518934|NCT05011630||Non-IAA group|No IAA formation
62710883|NCT06565273|EXPERIMENTAL|FBL-MTX|"* DMARD-naïve Patients: Patients will be administered an initial dose of FBL-MTX of 1 mg, by SC route. Subsequent doses will be titrated according to clinical response at intervals of 4 weeks, for 12 weeks. Maximum dosage will be 2.5 mg, every 2 weeks.~* Patients with an Inadequate Response or Intolerance to Oral MTX: Patients will be administered an initial dose of FBL-MTX 2.5 mg, by SC route. Subsequent doses will be titrated according to clinical response at intervals of 4 weeks, for 12 weeks. Maximum dosage will be 2.5 mg, every two weeks."
62710884|NCT05578014|EXPERIMENTAL|Group STD|"19 participant received sham acupuncture at EX-B2 T3 point in right side or acupuncture with tonyfying or dispersing manipulations at Dazhui point, corresponding to 3 times of acupuncture in 14 days, each time is 7 days aparts. In each time, temperature of skin surface at the acupuncture site, the neck and the face will be recorded.~Procedure/Surgery: Acupuncture with disposable acupuncture needles (the size of 0.30 x 25 mm) at EX-B2 T3 point in right side as sham acupoint in the first trial phase. We used the same type of acupuncture needles as aboved to acupuncture at Dazhui with tonifying manipulations in the second trial phase and with dispersing manipulatiuons in the third trial phase."
62355753|NCT03731338||Reassured and discharged|patients who are reassured and discharged after first attendance
62355754|NCT03731338||Further diagnostic testing|Patients who went on to have further diagnostic testing
62355755|NCT06028425|EXPERIMENTAL|LOXO-783 (Fasted State)|LOXO-783 administered orally to participants who are in fasted state
62355756|NCT06028425|EXPERIMENTAL|LOXO-783 (Fed State - Low Fat Meal)|LOXO-783 administered orally to participants who are on low fat meal
62355757|NCT06028425|EXPERIMENTAL|LOXO-783 (Fed State - High Fat Meal)|LOXO-783 administered orally to participants who are on high fat meal
62355758|NCT01255306||NO IOP|Patients without raised IOP
62355759|NCT01255306||RAISED IOP|Patients with raised IOP
62355760|NCT06087588|ACTIVE_COMPARATOR|sham PENG block|PENG block - 20ml 0,9% normal saline
62355761|NCT06087588|ACTIVE_COMPARATOR|PENG neurolysis|PENG neurolysis with 5ml 95% ethanol
62355762|NCT03284346|EXPERIMENTAL|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
62355763|NCT03284346|ACTIVE_COMPARATOR|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
62355764|NCT00156910|EXPERIMENTAL|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
62518935|NCT05897268|EXPERIMENTAL|Cryoablation combined with Tislelizumab and Lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab and Lenvatinib will be initiated on day 1 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62518936|NCT00234455|OTHER|1|stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group)
62355765|NCT00156910|PLACEBO_COMPARATOR|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
62355766|NCT01342952|EXPERIMENTAL|Ambrisentan|Open label, flexible dosing from 2.5 mg to 10 mg (not to exceed 0.25 mg/kg) per day
62518937|NCT00234455|OTHER|2|stents in both the main and side branches (stent/stent group)
62518938|NCT01145131|EXPERIMENTAL|Beef steak|
62518939|NCT01145131|EXPERIMENTAL|Minced beef|
62518940|NCT04478461|EXPERIMENTAL|MW11 injection|1, 3, 10 mg/kg and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W.
62518941|NCT05512520|EXPERIMENTAL|Concurrent Chemoradiotherapy group|After completion of 4 to 6 cycles of standard chemotherapy and anti-PD1, all patients will receive thoracic radiation therapy (RT) in the following scheme: 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks, and then followed by a maintenance treatment phase of anti-PD1 every 3 weeks.
62355767|NCT01188538|EXPERIMENTAL|Epiduo gel|"* Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.~* Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~* Duration of Treatment:12 weeks"
62355768|NCT01188538|ACTIVE_COMPARATOR|BPO gel|"* Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel.~* Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~* Duration of Treatment:12 weeks"
62355769|NCT04746209|EXPERIMENTAL|Alpha/beta T-cell and B-cell Depleted, Myeloablative HCT|Patients who are MRD Negative by Flow cytometry but are MRD Positive by High Throughput Sequencing, will receive a myeloablative conditioning regimen which includes total body irradiation (TBI) followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
62148344|NCT02279732|EXPERIMENTAL|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
62148345|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
62148346|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
62148347|NCT02024503||Experimental group|Hospitalized patients with acute stroke.
62148348|NCT02024503||Control group|Healthy Volunteers.
62148349|NCT04789174|ACTIVE_COMPARATOR|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
62355770|NCT04746209|EXPERIMENTAL|Alpha/beta T-cell and B-cell Depleted, Reduced Intensity HCT|Patients who are MRD Negative by Flow cytometry and are MRD Negative by High Throughput Sequencing, will receive a reduced intensity conditioning regimen followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
62518942|NCT05512520|NO_INTERVENTION|Control group|After completion of 4 to 6 cycles of standard chemotherapy and anti-PD1, patients will receive the maintenance treatment with anti-PD1 every 3 weeks.
62518943|NCT05796063|EXPERIMENTAL|Intervention|On postoperative day one, patients will be asked if they are having any GI symptoms. These are defined as presence of nausea, emesis, belching, and/or hiccups. In the intervention arm, clinicians will use the results of G-POCUS and presence/absence of GI symptoms to inform decision making according to one of two standardized algorithms.
62148350|NCT04789174|PLACEBO_COMPARATOR|Placebo|
62148351|NCT02086461|SHAM_COMPARATOR|15 mm Pyloric balloon dilatation.|During fluoroscopic control the pneumatic balloon is positioned of the pyloric sphincter and maintained there during the entire dilatation.
62148352|NCT02086461|ACTIVE_COMPARATOR|Pneumatic pyloric dilatation.|Endoscopy and 15 mm balloon dilatation is completed according to the same principle as active comparator arm.
62148353|NCT05799534|EXPERIMENTAL|Rehabilitation|The duration for 4-week, three sessions per week. Each session will last for 45-60 minutes
62148354|NCT06358794||Training cohort|2,438 patients diagnosed with NOA were included for model training and validation
62148355|NCT06358794||External validation cohort|174 participants from January 2023 to May 2023 were included as the external validation cohort for online platform
62148356|NCT02072109||Bolus feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
62148357|NCT02072109||Continuous feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
62148358|NCT05469516|EXPERIMENTAL|Ultherapy and Radiesse|"Delivered to the lower face areas as drawn using a single transducer with a focal depth of 1.5mm (following a previously published paper (Lowe, 2021) but with extension of the lower treatment area to the two-ruler width (Ulthera marking ruler) as treatment zones. Application will be delivered through a cross-hatching technique.~Immediately following MFU-V or up to a week after, diluted CaHA will be administered following the Global Consensus Guidelines published in 2018 by de Almeida et al as follows 1) 1 syringe or 1.5ml of CaHA diluted 1:1 with saline for a total of 3ml of solution or 1.5 diluted CaHA per side will be injected in the subdermal plane with a cannula using a retrograde fanning technique."
62148359|NCT04307056|EXPERIMENTAL|HIFU|Patients Treated with high intensity focused ultrasound (HIFU)
62355771|NCT00518843|EXPERIMENTAL|FBT-BN|Family-based treatment
62355772|NCT00518843|ACTIVE_COMPARATOR|SPT|Individual Supportive Psychotherapy
62518944|NCT05796063|NO_INTERVENTION|Control|On postoperative day one, patients will be asked if they are having any GI symptoms. These are defined as presence of nausea, emesis, belching, and/or hiccups. In the control arm, presence of GI symptoms will be assessed, and once of two standardized algorithms which are representative of the current standard of care for postoperative diet management.
62518945|NCT01641133|ACTIVE_COMPARATOR|Synflorix Group|Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
62518946|NCT01641133|EXPERIMENTAL|Prevnar 1 Group|Subjects who were primed with Prevnar 13 and Synflorix vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.
62518947|NCT01641133|EXPERIMENTAL|Prevnar 2 Group|Subjects who were primed with two doses of Prevnar 13 vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
62518948|NCT04368611|ACTIVE_COMPARATOR|fundus first cholecystectomy|start with fundus dissection then complete the dissection
62518949|NCT04368611|ACTIVE_COMPARATOR|Calot first dissection|start and complete the dissection by dissection of Calot triangle
62518950|NCT01795742|ACTIVE_COMPARATOR|Electric Nebulizer|Pulmo-Aide Model 5650D
62518951|NCT01795742|EXPERIMENTAL|Human-Powered Nebulizer|Human-Powered
62518952|NCT02350374|OTHER|carbohydrate counting|patients must fill their logbook during 28 days
62518953|NCT01701830||Case Group|Patients with chronic kidney disease of stage 3-4.
62518954|NCT01701830||Control group|30 healthy subject
62518955|NCT05715554|EXPERIMENTAL|Homeopathy Group|Individualized Homeopathy Treatment provided by homeopathic physicians
62518956|NCT05715554|NO_INTERVENTION|Standard Group|Usual care provided by primary care physicians were followed by patients in the standard group
62355773|NCT06392750||adjacent tissues|Paraffin tissue microarray slides prepared from normal tissue adjacent to tumor tissue removed during gastrectomy were retrieved from the biological sample library of the Northern Jiangsu People's Hospital.
62148360|NCT04307056|ACTIVE_COMPARATOR|Prostatectomy|Patients Treated by Radical Prostatectomy
62148361|NCT04249440||PST|patient accepts preoperative systemic treatment as upfront strategy
62148362|NCT04249440||upfront surgery|patient accepts upfront surgery and run postoperative systemic treatment
62148363|NCT04728191|EXPERIMENTAL|+ asthma + intervention|35 participants with asthma aged 10-17 years, randomized to physiotherapy. The intervention consists of 4 instruction lessons spread over 6 weeks. The participants are instructed in a daily ten-minute-program of breathing exercizes.
62148364|NCT04728191|ACTIVE_COMPARATOR|+ asthma - intervention|35 participants with asthma aged 10-17 years, randomized to standard care. Participants are getting advice about dysfunctional breathing by a physician or nurse in the outpatient clinic.
62148365|NCT04728191|EXPERIMENTAL|- asthma + intervention|35 participants without asthma aged 10-17 years, randomized to physiotherapy. The intervention consists of 4 instruction lessons spread over 6 weeks. The participants are instructed in a daily ten-minute-program of breathing exercizes.
62148366|NCT04728191|ACTIVE_COMPARATOR|- asthma - intervention|35 participants without asthma, which are randomized to standard care. Participants are getting advise about dysfunctional breathing by a physician or nurse in the outpatient clinic.
62148367|NCT01573559||ClearView/Predicate|
62148368|NCT02929758|ACTIVE_COMPARATOR|Control Initial Training Group|Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
62148369|NCT02929758|ACTIVE_COMPARATOR|Control Delayed Training Group|Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
62148370|NCT02929758|OTHER|PD Initial Training Group|PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
62518957|NCT04392284|EXPERIMENTAL|Diet Counseling|Delivery of nutrition counseling intervention to improve diet quality.
62518958|NCT04392284|EXPERIMENTAL|Exercise Counseling|Delivery of exercise counseling intervention to increase engagement in physical activity..
62148371|NCT02929758|OTHER|PD Delayed Training Group|PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
62148372|NCT01274507|OTHER|All participants|
62148373|NCT00980616|EXPERIMENTAL|Ropivacaine, serum, adrenalin|235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.
62148374|NCT00980616|NO_INTERVENTION|No infiltration|B: no infiltration
62148375|NCT01571947|ACTIVE_COMPARATOR|SFA|
62148376|NCT01571947|ACTIVE_COMPARATOR|MUFA|
62148377|NCT01571947|ACTIVE_COMPARATOR|PUFA|
62148378|NCT01571947|ACTIVE_COMPARATOR|CARB|
62148379|NCT00690079|EXPERIMENTAL|AZD1386|7 groups receiving a specified volume of the active component AZD1386 at different points of time.
62518959|NCT01675024|EXPERIMENTAL|Rotigotine, Period 1|In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
62518960|NCT01675024|EXPERIMENTAL|Rotigotine, Period 2|In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.
62518961|NCT04414436|EXPERIMENTAL|GYNEA- digital coping program|Participants randomized to this arm will receive active treatment after the inclusion
62148380|NCT00690079|PLACEBO_COMPARATOR|Placebo|7 groups receiving a specified volume of placebo at different points of time
62148381|NCT01111812||weight measurements|This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center.
62148382|NCT05559697|EXPERIMENTAL|Prospera Flex Incisional NPWT System|Sponsor incisional dressing connected to sponsor disposable negative pressure device placed on knee for seven days.
62148383|NCT05559697|ACTIVE_COMPARATOR|Prevena Incisional NPWT System|Market leader incisional NPWT system (includes the device and dressing) placed on opposite knee for seven days.
62148384|NCT05474950|EXPERIMENTAL|minocycline|
62148385|NCT03770897|EXPERIMENTAL|3D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed with 3d technology device by young surgeons, tutored by an expert assistant.
62148386|NCT03770897|ACTIVE_COMPARATOR|2D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed by young surgeons (tutored by an expert assistant) with the standard 2D viewing method.
62148387|NCT03102632|NO_INTERVENTION|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
62148388|NCT03102632|EXPERIMENTAL|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
62148389|NCT05694832|EXPERIMENTAL|Expressive writing weekly session|Weekly, 1-hour sessions of creative writing, discussion and social support, in a group setting via videoconference for a total of 4 sessions.
62148390|NCT02279485|EXPERIMENTAL|Perampanel - Group 1|"Treatment A: Single oral dose of a 12-mg perampanel tablet under fasted condition.~Treatment B: Single 12 mg dose of perampanel oral suspension under fasted condition.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment A or Treatment B. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
62148391|NCT02279485|EXPERIMENTAL|Perampanel - Group 2|"Treatment C: Single oral dose of a 12-mg perampanel tablet co-administered with high fat meal.~Treatment D: Single 12 mg dose of perampanel oral suspension co-administered with high fat meal.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment C or Treatment D. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
62518962|NCT04414436|NO_INTERVENTION|Waiting list|6 weeks waiting list before crossing over to GYNEA- digital coping program
62518963|NCT02159781|EXPERIMENTAL|periodontal treatmnent|
62518964|NCT03399318|EXPERIMENTAL|Aggressive Antipyretics|regardless of temperature, children allocated to this arm will receive acetaminophen (30 milligrams (mg)/ kilogram (kg) load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
62518965|NCT03399318|PLACEBO_COMPARATOR|Usual Care|will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
62518966|NCT02293291|ACTIVE_COMPARATOR|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
62518967|NCT02293291|PLACEBO_COMPARATOR|MIneral water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
62518968|NCT06525272|EXPERIMENTAL|Recombinant Human Chymotrypsin(OsrhCT)|"Recombinant Human Chymotrypsin (OsrhCT), freeze-dried powder, 4,000U/vial~Single Ascending Dose (SAD) Study:~20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.There are six dose groups (2000U, 4000U, 8000U, 12000U, 16000U, 20000U),each subject can only receive administration in one dose group, and repeated administration is not allowed.~Multiple Ascending Dose (MAD) Study:~20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.three dose groups (low, medium, and high) will be selected for multiple dosing. Each subject will receive only one dose group and no repeat dosing."
62518969|NCT06525272|PLACEBO_COMPARATOR|Placebo for Recombinant Human Chymotrypsin|"Placebo for Recombinant Human Chymotrypsin (OsrhCT), freeze-dried powder~Single Ascending Dose (SAD) Study:~20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.There are six dose groups ,each subject can only receive administration in one dose group, and repeated administration is not allowed.~Multiple Ascending Dose (MAD) Study:~20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.three dose groups (low, medium, and high) will be selected for multiple dosing. Each subject will receive only one dose group and no repeat dosing."
62518970|NCT00925301|EXPERIMENTAL|Migalastat|Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
62518971|NCT00925301|PLACEBO_COMPARATOR|Placebo|Placebo capsule taken orally QOD for 6 months.
62518972|NCT05009732|EXPERIMENTAL|Proxalutamide (GT0918) plus standard of care|Participants receive 300mg once daily orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
62518973|NCT05009732|PLACEBO_COMPARATOR|Placebo plus standard of care|Participants will receive placebo tablets matching Proxalutamide (GT0918) orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
62518974|NCT01227655|EXPERIMENTAL|BIA 9-1067 25 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
62518975|NCT01227655|EXPERIMENTAL|BIA 9-1067 50 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
62518976|NCT01227655|PLACEBO_COMPARATOR|Placebo|PLC, Placebo
62518977|NCT05852808|ACTIVE_COMPARATOR|Intra-articular steroid injections|The intra-articular steroid injections are the most common standard of care to treat the lower back pain resulting from FJA.
62518978|NCT05852808|EXPERIMENTAL|Low-dose radiation therapy|LDRT is commonly used as treatment for benign degenerative inflammatory disorders
62518979|NCT03458247|ACTIVE_COMPARATOR|Abiraterone acetate standard dose|1000 mg/day
62518980|NCT03458247|EXPERIMENTAL|Abiraterone acetate escalated dose|2000 mg/day
62518981|NCT02199015|EXPERIMENTAL|Spasticity, Cerebral Palsy|To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.
62518982|NCT03642522|EXPERIMENTAL|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
62518983|NCT04698772||Survey Packet 1 Group|"Patients who receive Packet 1 will be in group 1, or the treatment group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions \[age, sex, race, height, weight, etc.\], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2. The physician will be asked to administer a sub-dissociative dose of ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)."
62710885|NCT05578014|EXPERIMENTAL|Group TDS|"19 participant received acupuncture with tonyfying or dispersing manipulations at Dazhui or sham acupuncture at EX-B2 T3 point in right side, corresponding to 3 times of acupuncture in 14 days, each time is 7 days aparts. In each time, temperature of skin surface at the acupuncture site, the neck and the face will be recorded.~Procedure/Surgery: Acupuncture with disposable acupuncture needles (the size of 0.30 x 25 mm) at Dazhui with tonifying manipulations in the first trial phase and with dispersing manipulatiuons in the second trial phase. We used the same type of acupuncture needles as aboved to acupuncture at EX-B2 T3 point in right side as sham acupoint in the third trial phase."
62148392|NCT02766361|EXPERIMENTAL|Cognitive Behavioral Rehabilitation|12 sessions of new intervention of cognitive behavior therapy and cognitive rehabilitation
62148393|NCT02766361|ACTIVE_COMPARATOR|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
62148394|NCT05371899|OTHER|Chiauranib|Take 50 mg ChiauranibCioroni capsules orally on an empty stomach once a day, every day; except on the eighth day 8, when you start taking Cioroni capsules liquid, take a single oral dose of \~50 mg/about 100 Ci of \[14C\]Chiauranib suspensionCioroni solution once on an empty stomach.
62148395|NCT02067689|EXPERIMENTAL|Hemisphere Stimulation|Participants will receive 1mA vs. 2mA transcranial direct current stimulation of a) right and b) left brain structures (1x1 stimulation), and sham/placebo stimulation. A subset of participants will undergo right and left brain stimulation, but all will undergo sham stimulation.
62148396|NCT02067689|EXPERIMENTAL|Temporal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the temporal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left structures using 4x1 stimulation (e.g., 1mA left temporal, 1mA right temporal, sham; 2mA left temporal, 2mA right temporal, sham).
62148397|NCT02067689|EXPERIMENTAL|Frontal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the frontal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left frontal structures using 4x1 stimulation (e.g., 1mA left frontal, 1mA right frontal, sham; 2mA left frontal, 2mA right frontal, sham).
62518984|NCT04698772||Survey Packet 2 Group|"Patients who receive Packet 2 will be in group 2, or the control group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions \[age, sex, race, height, weight, etc.\], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2.The physician will be asked to administer morphine 4 mg IV push over 3-5 minutes for pain control."
62518985|NCT03326674|EXPERIMENTAL|Arm A: Tesetaxel (oral) and capecitabine (oral)|Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
62518986|NCT03326674|ACTIVE_COMPARATOR|Arm B: Capecitabine (oral)|Capecitabine (1,250 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
62518987|NCT00732420|EXPERIMENTAL|Treatment Arm A|Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.
62518988|NCT00732420|EXPERIMENTAL|Treatment Arm B|Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.
62518989|NCT01322126|EXPERIMENTAL|ultrasound ,without ultrasound|ultrasound group will be passed the neuraxial anesthesia with ultrasound,the secoud group will be passed the neuraxial anesthesia without ultrasound .
62518990|NCT00300326|NO_INTERVENTION|1|Using the same knee implant with a conventional surgical technique.
62518991|NCT00300326|ACTIVE_COMPARATOR|2|Using the same knee implant using a computer-assist surgery group is the comparator
62518992|NCT02226731|EXPERIMENTAL|Early Belfort-Dildy balloon device|
62518993|NCT02226731|OTHER|Late Belfort-Dildy balloon device|
62518994|NCT06390202||Uterine artery notch negative group|Pregnant women who did not have diastolic notching in uterine artery Doppler between the 11th and 14th weeks of pregnancy constituted the uterine artery notch negative group.
62518995|NCT06390202||Uterine artery notch positive group|Pregnant women with unilateral or bilateral diastolic notching detected in uterine artery Doppler between the 11th and 14th weeks of pregnancy formed the uterine artery notch positive group.
62148398|NCT02067689|EXPERIMENTAL|Parietal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the parietal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left parietal lobes using 4x1 stimulation (e.g., 1mA left parietal lobes, 1mA right parietal lobes, sham; 2mA parietal lobes, 2mA right parietal lobes, sham).
62148399|NCT02067689|EXPERIMENTAL|Supplementary Motor Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the Supplementary Motor Area at 1mA vs. 2mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left Supplementary Motor Area using 4x1 stimulation (e.g., 1mA left Supplementary Motor Area, 1mA right Supplementary Motor Area, sham; 2mA left Supplementary Motor Area, 2mA right Supplementary Motor Area, sham).
62518996|NCT03380559|EXPERIMENTAL|Group A : Association (botulinum toxin + corticoid)|
62518997|NCT03380559|PLACEBO_COMPARATOR|Group C : placebo of toxin + corticoid :|
62518998|NCT03380559|ACTIVE_COMPARATOR|Group T : botulinum toxin + placebo corticoid|
62518999|NCT01370213|EXPERIMENTAL|CD34 Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and filgrastim mobilized CD34+ selected peripheral blood stem cell graft from the same donor.
62519000|NCT01370213|EXPERIMENTAL|TCRα/β Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and same donor TCR α/β-depleted cells infusion.
62519001|NCT02776514|ACTIVE_COMPARATOR|Triamcort (1 ml, 40 mg/ml)|30 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)
62519002|NCT02776514|ACTIVE_COMPARATOR|Platelet-rich-plasma (PRP 3 ml)|30 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)
62519003|NCT02776514|ACTIVE_COMPARATOR|Suplasyn1-shot (60 mg/ ml)|30 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)
62519004|NCT02776514|PLACEBO_COMPARATOR|Placebo (Iopamiro 200)|30 patients receive intraarticular injection with contrast media only
62519005|NCT00586482|ACTIVE_COMPARATOR|Nicotine lozenge|"Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
62519006|NCT00586482|PLACEBO_COMPARATOR|Placebo lozenge|"Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
62519007|NCT00140660|EXPERIMENTAL|R-ACVBP|addition of rituximab to standard ACVBP chemotherapy
62519008|NCT00140660|NO_INTERVENTION|ACVBP|standard ACVBP chemotherapy
62519009|NCT00355472|EXPERIMENTAL|1|KW-0761
62519010|NCT00390130|ACTIVE_COMPARATOR|Pentacel|The subjects in this arm will be vaccinated with Pentacel
62519011|NCT00390130|ACTIVE_COMPARATOR|Prevnar|The subjects in this arm will be vaccinated with Prevnar
62519012|NCT03910660|OTHER|Phase 1b|"Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO:~If there are no DLTs, the dose of BXCL701 will be escalated to 0.6 mg in the next cohort.~If ≥1/3 of patients has a DLT in Cycle 1, either 3 patients (if 1 experience a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg dose.~At the 0.4mg dose:~If \<1/3 of the patients experience a DLT, consideration will be given to dose to 0.6 mg BXCL701 plus PEMBRO.~If 1/3 of the patients experience a DLT, the Phase 2a can commence. If \>1/3 of the patients experience a DLT, a discussion will be held as to how to proceed.~Following 0.6 mg dose. If there are no DLTs, the Phase 2a can commence. If ≥1/3 patients have a DLT in Cycle 1, after a discussion, 6 to 9 patients will be added at the 0.6 mg dose.~For this cohort of 6 to 9 patients:~If \</=1/3 of the patients experience a DLT, the Phase 2a can commence"
62519013|NCT03910660|OTHER|Phase 2a|After assessment of the safety and confirmation of the BXCL701/+PEMBRO dose schedule to be used in the subsequent stage, the Phase 2a will begin. Eligible patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
62519014|NCT03910660|OTHER|Phase 2b combination|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~• Combination therapy of BXCL701 on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 of every 21 days."
62519015|NCT03910660|OTHER|Phase 2b monotherapy|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~* Monotherapy BXCL701 on Days 1 to 14 of a 21-day cycle. Upon radiographic disease progression with monotherapy, crossover to combination treatment is allowed."
62519016|NCT00387920|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|"PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience."
62519017|NCT04808882|EXPERIMENTAL|Low dose prophylactic anticoagulation|LD-PA
62519018|NCT04808882|EXPERIMENTAL|High dose prophylactic anticoagulation|HD-PA
62519019|NCT04808882|EXPERIMENTAL|Therapeutic anticoagulation|TA
62519020|NCT05110807|EXPERIMENTAL|TQB3617|0.1mg, once daily, was used as the initial dose, and the medication stage was divided into single administration and continuous administration stages. The single administration was given once, and the continuous administration stage was entered 7 days after drug withdrawal. The drug was administered continuously until the disease progressed.
62519021|NCT02594371|EXPERIMENTAL|Oraxol (paclitaxel + HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
62519022|NCT02594371|ACTIVE_COMPARATOR|IV paclitaxel|IV paclitaxel - supplied as Taxol or generic
62519023|NCT01956448|EXPERIMENTAL|Drug eluting stent (BioMatrix Flex)|Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)
62519024|NCT01956448|EXPERIMENTAL|Drug eluting stent (Resolute Integrity)|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
62519025|NCT02024373|EXPERIMENTAL|Atorvastatin|atorvastatin：20 mg (every evening orally) for 8 weeks
62519026|NCT02024373|PLACEBO_COMPARATOR|placebo|placebo:20 mg (every evening orally) for 8 weeks
62519027|NCT03545191|EXPERIMENTAL|Daridorexant 25 mg|
62519028|NCT03545191|EXPERIMENTAL|Daridorexant 50 mg|
62519029|NCT03545191|PLACEBO_COMPARATOR|Placebo|
62519030|NCT00594620|EXPERIMENTAL|1|Subjects receive supplement
62519031|NCT00594620|PLACEBO_COMPARATOR|2|Subjects will receive placebo
62519032|NCT04289506||Community-acquired pneumonia (Sepsis)|Community-acquired pneumonia with organ dysfunction
62519033|NCT04289506||Abdominal sepsis|Abdominal infection due to peritoneal soiling, biliary infection, urinary tract infection leading to organ dysfunction
62519034|NCT04289506||Infection of unknown origin (Sepsis)|Infection of unknown origin of less than 72 hours duration, including bacteraemia with organ dysfunction
62519035|NCT04289506||Organ dysfunction related to non-infectious cause (SIRS)|Patients admitted to the ICU following out-of hospital cardiac arrest OR Patients admitted to the ICU following major trauma (ISS\>12) OR Patients admitted to the ICU following pancreatitis with organ dysfunction
62519036|NCT04289506||Healthy volunteers|Healthy volunteers
62148400|NCT02067689|EXPERIMENTAL|Brain Structure Interactions Group|This cohort will evaluate the interaction between frontal, parietal, temporal, and SMA regions in cognitive function. To accomplish this goal will require evaluation of change in cognitive and neurocognitive performance following transcranial direct current stimulation of different brain regions within the same subjects. For example, we will evaluate the contribution of frontal, SMA, and parietal regions by asking participants to undergo stimulation sessions at each of these sites, in addition to a sham session.
62148401|NCT05477407|EXPERIMENTAL|Pathogenesis study|This pathogenesis study aimed to evaluate potential changes in adipose tissue after switching from an INSTI-based regimen (RAL or DTG or BIC) to TDF/FTC/DOR.
62710886|NCT05578014|EXPERIMENTAL|Group DST|"19 participant received acupuncture with tonyfying or dispersing manipulations at Dazhui or sham acupuncture at EX-B2 T3 point in right side, corresponding to 3 times of acupuncture in 14 days, each time is 7 days aparts. In each time, temperature of skin surface at the acupuncture site, the neck and the face will be recorded.~Procedure/Surgery: Acupuncture with disposable acupuncture needles (the size of 0.30 x 25 mm) at Dazhui with tonifying manipulations in the first trial phase and with dispersing manipulatiuons in the second trial phase. We used the same type of acupuncture needles as aboved to acupuncture at EX-B2 T3 point in right side as sham acupoint in the third trial phase."
62519037|NCT01725919|EXPERIMENTAL|Immediate CI therapy|
62519038|NCT01725919|ACTIVE_COMPARATOR|Delayed CI therapy|
62710887|NCT03576235|EXPERIMENTAL|a treatment group|PG102P 1.5 g/day
62710888|NCT03576235|PLACEBO_COMPARATOR|a control group|placebo
62148402|NCT02539576|EXPERIMENTAL|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
62519039|NCT00734201|EXPERIMENTAL|1|Randomised to a parallel group comparison of either one of four doses of study drug (1mg, 2mg, 5mg, 25mg) or placebo. Dosed once daily for 28 days
62519040|NCT04471402||All subjects recruited|"All subjects recruited will be given 3mcg/kg intranasal Precedex through an atomiser, divided equally between two nostrils. They will be observed and sedation score will be recorded every 5 minutes according to the University of Michigan Sedation Scale (UMSS). Pulse oximetry and Blood pressure cuff will be applied whenever they accept these monitoring.~A buccal swab sample will be taken from all children and the identified genes will be analysed and compared between the different responders (fast, normal, slow or non-responders)."
62148403|NCT04806906|EXPERIMENTAL|CC-486|subjects will receive 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
62148404|NCT01047709|EXPERIMENTAL|positional therapy|Avoidance of supine positioning.
62519041|NCT05517161||Individuals with TBI|
62519042|NCT01955655|ACTIVE_COMPARATOR|Baclofen|The starting dose was 0.75 mg/kg in four divided doses daily and was cautiously increased at three-day intervals until crying subsided or symptoms of over dosage or side effects appeared. The usual maximum dose was two mg/kg in four divided doses daily.
62519043|NCT01955655|PLACEBO_COMPARATOR|placebo|Placebo contained fructose powder in equal quantity in packets mimicking those of Baclofen.
62519044|NCT00912093|PLACEBO_COMPARATOR|Placebo|Single subcutaneous injection of matching placebo
62519045|NCT00912093|EXPERIMENTAL|Icatibant|Single subcutaneous injection of icatibant, 30 mg
62519046|NCT04320979|EXPERIMENTAL|internal mammary nodal irradiation|chest wall and supraclavicular nodal+-axillary plus internal mammary nodal irradiation
62519047|NCT04320979|ACTIVE_COMPARATOR|no-internal mammary nodal irradiation|ipsilateral chest wall and supraclavicular +-axillary nodal irradiation
62519048|NCT05158218|ACTIVE_COMPARATOR|Cerebral Palsy Youth/Young Adults Physical Therapy|Baseline and 8 week assessments; 8 week gait therapy
62519049|NCT05158218|EXPERIMENTAL|Cerebral Palsy Youth/Young Adults Robotic Exoskeleton|Baseline and 8 week assessments; 8 week gait therapy using robotic exoskeleton
62519050|NCT00059787|EXPERIMENTAL|Paclitaxel, carboplatin, erlotinib|Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
62519051|NCT02941120||NOVOCART® Inject patients|Patients who where treated with NOVOCART® Inject autologous chondrocyte implantation in the knee joint.
62519052|NCT03351387||SPY Intra-operative Angiography|The SPY Fluorescent Imaging System
62519053|NCT00949455|EXPERIMENTAL|Arm I|Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
62519054|NCT00949455|PLACEBO_COMPARATOR|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
62710889|NCT01204788|EXPERIMENTAL|Arm 1 (Prophylactic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
62148405|NCT01047709|NO_INTERVENTION|Control|Position ad lib.
62148406|NCT03559296||Study Group|patients with postmastectomy lymphedema who will undergo ultrasonographic assessment of postmastectomy lymphedema and circumferential tape measurement of arm
62148407|NCT01234584|EXPERIMENTAL|Group A|23 implants using SPK Abutments
62148408|NCT01234584|ACTIVE_COMPARATOR|Group B|implants using CPK Abutments
62148409|NCT04328467|EXPERIMENTAL|Intervention Once Weekly|400 mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg weekly for the duration of follow up, up to 12 weeks
62519055|NCT01704430|EXPERIMENTAL|Glutamine|Oral/enteral glutamine 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
62519056|NCT01704430|PLACEBO_COMPARATOR|Maltodextrin|Oral/enteral maltodextrin 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
62710890|NCT01204788|EXPERIMENTAL|Arm 2 (Therapeutic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
62710891|NCT02541591|EXPERIMENTAL|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
62710892|NCT02541591|ACTIVE_COMPARATOR|Control|MAP\>65mmHg
62710893|NCT04844125|EXPERIMENTAL|SHR-1209|
62710894|NCT04844125|PLACEBO_COMPARATOR|SHR-1209 Placebo|
62710895|NCT05975242|EXPERIMENTAL|Interventional group|The interventional group will use the digital self-management smartphone application during the 12-week study period and will have access to 3 coaching sessions. The interventional group will be trained in the use of the app and receive education focused on self-monitoring blood glucose based on paired (before and 2 hours after a meal) blood glucose testing, which participants will conduct twice daily for 6 days once monthly for 3 months.
62710896|NCT05975242|NO_INTERVENTION|Control group|The control group will not have use of the digital self-management smartphone application during the 12-week study period and will not have access to 3 coaching sessions. No structured self-monitoring blood glucose testing will be done.
62710897|NCT05358002|ACTIVE_COMPARATOR|Frontalis sling|Connecting the frontalis muscle action with the tarsus of the upper eyelid with synthetic material PTFE ( gore-tex )
62710898|NCT05358002|EXPERIMENTAL|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
62710899|NCT03053128|EXPERIMENTAL|CSWT group|Patients in CSWT group will receive cardiac shock wave therapy for three moths, every first week of the month.
62710900|NCT03053128|SHAM_COMPARATOR|Sham CSWT group|Patients in sham CSWT group will receive sham cardiac shock wave, which segregated by an air-cushion.
62148410|NCT04328467|EXPERIMENTAL|Intervention Twice Weekly|400mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg twice weekly for the duration of follow up, up to 12 weeks
62148411|NCT04328467|PLACEBO_COMPARATOR|Control Group|Placebo 2 tabs once, followed by 2 tabs 6 to 8 hours later, thereafter two tabs weekly or twice weekly for the duration of follow up, up to 12 weeks
62148412|NCT04131556|EXPERIMENTAL|Part 1: Sequence ABC|Participants will receive 200 milligram (mg) of maribavir tablet orally (Sequence A) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
62148413|NCT04131556|EXPERIMENTAL|Part 1: Sequence BCA|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
62148414|NCT04131556|EXPERIMENTAL|Part 1: Sequence CAB|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
62148415|NCT04131556|EXPERIMENTAL|Part 1: Sequence CBA|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
62148416|NCT04131556|EXPERIMENTAL|Part 1: Sequence ACB|Participants will receive 200 mg of maribavir tablet orally (Sequence A) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
62148417|NCT04131556|EXPERIMENTAL|Part 1: Sequence BAC|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 and with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
62148418|NCT04131556|EXPERIMENTAL|Part 2: Sequence DEGF|Participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 1 followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 4 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 7 and then followed by participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
62355774|NCT06392750||tumor tissues|Paraffin tissue microarray slides prepared from tumor tissue removed during gastrectomy were retrieved from the biological sample library of the Northern Jiangsu People's Hospital.
62355775|NCT02581618|EXPERIMENTAL|Study group|"Remote ischemic preconditioning arm~Blood pressure cuff will be inflated up to 200 mmHg in the non-dominant arm for 5 minutes before guiding catheter engagement."
62519057|NCT03737318|EXPERIMENTAL|Group 1|Traditional articulation treatment
62519058|NCT03737318|EXPERIMENTAL|Group 2|Biofeedback--visual-acoustic
62519059|NCT03737318|EXPERIMENTAL|Group 3|Biofeedback-ultrasound
62519060|NCT03396237||Group A|Case group contain cases of unexplained infertility women
62710901|NCT03997032|EXPERIMENTAL|Patients with Diabetes|Patients with Type 1 or Type 2 Diabetes
62710902|NCT03260712|EXPERIMENTAL|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem \[25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle\] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
62710903|NCT02272127|EXPERIMENTAL|intercalated treatment|Patients will receive 4 cycles treatment: chemotherapy(day 1) plus intercalated icotinib(day 8-21) every 3 weeks, and then oral icotinib continuously for 2 years or until disease progression or unacceptable toxic effects
62710904|NCT02471144|EXPERIMENTAL|Secukinumab low dose|Secukinumab
62710905|NCT02471144|EXPERIMENTAL|Secukinumab high dose|Secukinumab
62710906|NCT02471144|PLACEBO_COMPARATOR|Placebo|Placebo
62710907|NCT02471144|ACTIVE_COMPARATOR|Etanercept Comparator|Etanercept
62710908|NCT03944850|EXPERIMENTAL|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
62519061|NCT03396237||Group B|Control group contain fertile pregnant women
62710909|NCT04516278|EXPERIMENTAL|Biological: bevacizumab|ONS-5010
62519062|NCT05768126|EXPERIMENTAL|Rivastigmine|Rivastigmine, transdermal administration with a dosage of 4.6 and 9.6mg. The patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
62710910|NCT05641610|EXPERIMENTAL|ZS801|Single intravenous (i.v.) infusion of ZS801 Intervention: Gene Therapy / Gene Transfer
62519063|NCT05768126|SHAM_COMPARATOR|Sham|Non-active patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
62148419|NCT04131556|EXPERIMENTAL|Part 2: Sequence EFDG|Participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 1 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 4 followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 7 and then followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
62519064|NCT00976794|EXPERIMENTAL|lithium plus carbamazepine|combination of the two drugs in standard dosage
62519065|NCT00976794|ACTIVE_COMPARATOR|lithium plus valproate|combination of the two drugs in standard dosage
62519066|NCT04731311|OTHER|Usability Evaluation of the BrightGo system|Participants with rate the device in each of 4 usability evaluation sessions.
62519067|NCT03656874|NO_INTERVENTION|Usual Care|Usual care, practitioners review clinical guidelines for tobacco during consent process.
62519068|NCT03656874|EXPERIMENTAL|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care.
62519069|NCT05266079|EXPERIMENTAL|Syndrome differentiation treatment(GMBHDHT, TWBXD,SG,LWDHP and EZP, YGP and LZP)|"Syndrome differentiation treatment group of participants will be given medication by syndrome differentiating from qualified TCM Practitioners. TCM Practitioners will base on the syndrome of the participants to evaluate and modify the prescription after each assessment.~1. Liver and Kidney Yin Deficiency syndrome use Gan Mai Bai He Di Hung Tang(GMBHDHT);~2. Non Interaction Between Heart and Kidney syndrome use Tian Wang Bu Xin Dan(TWBXD);~3. Liver Stagnation and Qi Stagnation syndrome use Shugan Granules(SG);~4. Kidney Yin Deficiency syndrome use Liu Wei Di Huang Pill and Er Zhi Pill(LWDHP and EZP) ;~5. Spleen and Kidney Yang Deficiency syndrome use You Gui pill and Li Zhong pill addition and subtraction(YGP and LZP).~Each dose will be prepackaged in two identical foil sachets. Participants will be instructed to drink one sachet of granules dissolved in 200 mL of warm water twice daily."
62148420|NCT04131556|EXPERIMENTAL|Part 2: Sequence FGED|Participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 1 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 4 followed by participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 7 and then followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
62519070|NCT05266079|EXPERIMENTAL|Fixed formula treatment|Fixed formula treatment Group will be given the standard formula Er-Xian decoction consisting of six herbs. The dosages of each herb were standardized according to the latest Chinese Medicine Recipe Dictionary (1997). The standard formula Er-Xian decoction are in the form of water-soluble granules. Each dose contains 11.8g and prepackaged in two identical foil sachets. Participants were instructed to drink one sachet of granules dissolved in 200 mL of warm water twice daily.
62519071|NCT06437665|EXPERIMENTAL|ADAS-integrated driver simulation training|The intervention administered in this study is ADAS-integrated driver simulation training. Participants in this arm will undergo training sessions using a high-fidelity driving simulator equipped with Lane Departure Warning (LDW), Cruise Control (CC), and Forward Proximity Warning (FPW) technologies. These technologies are designed to assist older drivers (≥65 years of age) in improving their driving performance and reducing critical driving errors. The training will simulate real-world driving scenarios to help participants become familiar with and effectively use these ADAS features.
62519072|NCT04107155|EXPERIMENTAL|Weight Management Program|Dietary Supplement: Saffron extract and Gynostemma extract with hesperidin and a handout with suggestions for healthy eating and overall health
62519073|NCT04107155|PLACEBO_COMPARATOR|Placebo|Placebo and handout with suggestions for healthy eating and overall health
62519074|NCT02407171|EXPERIMENTAL|Non Small Cell Lung Cancer, Phase I|Dose escalation cohort for patients with Non Small Cell Lung Cancer (NSCLC). The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
62519075|NCT02407171|EXPERIMENTAL|Non-Lung, Phase I|Dose escalation cohort for non lung cancer patients. The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
62710911|NCT05090787|EXPERIMENTAL|Investigational Device|Investigational mDCB00
62710912|NCT05090787|ACTIVE_COMPARATOR|Control Device|Control DCB00
61974794|NCT04775602|EXPERIMENTAL|18F-PSMA PET/CT|Patients with evidence of biochemical recurrence of prostate cancer radically treated, with negative results to traditional diagnostic methods or doubtful imaging of 18F- Fluoro Methyl Choline (18F-FMC) PET/CT will perform a 18F-PSMA PET/CT as a tool for searching and location of recurrence.
61974795|NCT06112782|OTHER|Keravive by Hydrafacial Treatment|Subjects will receive 3 in-office scalp Keravive by Hydrafacial treatments every 4 weeks in combination with daily application of Keravive Peptide Spray.
61974796|NCT01722071|PLACEBO_COMPARATOR|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
61974797|NCT01722071|EXPERIMENTAL|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
61974798|NCT06493721|EXPERIMENTAL|Clear aligner only|Clear aligner therapy group only
61974799|NCT06493721|EXPERIMENTAL|Low level laser|Clear aligner therapy with low level laser therapy
61974800|NCT02297074|EXPERIMENTAL|Ordinary White Bread|Ordinary white bread bread is characterised by a white crumb with regular soft alveoli and a slightly soft thin crust.
62519076|NCT02407171|EXPERIMENTAL|Melanoma Expansion Cohort|Phase 2a expansion cohort for patients with melanoma. Patients will be treated at the maximum tolerated dose discovered in phase I.
62519077|NCT02407171|EXPERIMENTAL|Non Small Cell Lung Cancer Expansion Cohort|Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
62519078|NCT04208126|ACTIVE_COMPARATOR|Early ECMO|ECMO is placed immediately after admission to the intensive care unit
62519079|NCT04208126|NO_INTERVENTION|Control|Conservative therapy unless failure of therapy.
62519080|NCT04223999|EXPERIMENTAL|Intervention|In this arm, trial participants receive the intervention that is being tested, skullremodeling surgery. This is in combination with tumor treating fields and best practice medical treatment.
62519081|NCT04223999|ACTIVE_COMPARATOR|Control|"In this arm, the trial participant receives tumor treating fields and best practice medical treatment.~This serves as an active comparative control arm to the intervention."
62710913|NCT01343212||newly diagnosed HCC|"* Subjects with newly diagnosed untreated hepatocellular carcinoma (HCC) will be enrolled.~* Subjects with the following conditions will be excluded:~liver cancer other than HCC, treated HCC, post major abdominal surgery, contraindications to liver tumor biopsy, contraindications to local percutaneous treatment of liver tumors, low quality ARFI measurement"
62710914|NCT00125788|EXPERIMENTAL|investigational product|L-glutamine
62710915|NCT00125788|PLACEBO_COMPARATOR|placebo|maltodextrin
62710916|NCT04232852|ACTIVE_COMPARATOR|Probiotics|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~This group will receive a probiotic mix, which will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule. During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
62710917|NCT04232852|PLACEBO_COMPARATOR|Placebo supplement|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~Patients of this group will receive an identical capsule of maltodextrin (placebo). During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
62710918|NCT05453214|EXPERIMENTAL|Fludrocortisone arm|10 hospitalised COVID-19 patients meeting inclusion criteria will receive fludrocortisone 0.1 mg tablets in addition to dexamethasone 6 mg / 24 hours and standard care
62355776|NCT02581618|NO_INTERVENTION|Control group|No intervention will be performed. Percutaneous coronary intervention will be performed without ischemic preconditioning.
62355777|NCT03412500|ACTIVE_COMPARATOR|Vancomycin trough concentration method|vancomycin dosage will be adjusted by the trough concentration method
62355778|NCT03412500|EXPERIMENTAL|Vancomycin equation-based method|vancomycin dosage will be adjusted by the equation-based method
62355779|NCT06100549||16 Healthy people|The volunteers will be healthy men and women aged 18 to 65 with a BMI between 18.5 and 30 kg/m2. Volunteers will provide a single stool sample to compare 16S rRNA gene sequencing results for gut microbiota between faeces processed from standard stool sample and those collected by the collection device (EXTEL HEMO AUTO MC Collection Picker) used in the Scottish Bowel Screening Programme.
62355780|NCT06100549||100 anonymised qFIT samples|To determine whether our carefully controlled conditions are replicated in the NHS setting, one hundred anonymised qFIT samples will be obtained from Chemical Pathology Aberdeen Royal Infirmary under NHS Grampian Biorepository ethical approval. Extracted DNA will be quantified by Qubit and run on an agarose gel to determine the intact nature of the DNA.
62519082|NCT04772391|OTHER|Exercise Treatment Group|Exercise Sessions
62519083|NCT05673213|NO_INTERVENTION|Routine 15º head raised prone position (control group)|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with routine 15º head raised prone position. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
62710919|NCT01119638|ACTIVE_COMPARATOR|Escitalopram Drug|"Drug:~Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion."
62355781|NCT02142504|EXPERIMENTAL|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
62355782|NCT02142504|EXPERIMENTAL|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
62355783|NCT02142504|PLACEBO_COMPARATOR|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
62355784|NCT03029897|EXPERIMENTAL|experimental|Patients are educated on the use of a mobile application to report adverse drug reactions
62355785|NCT03029897|NO_INTERVENTION|control|Patients are not educated on the use of a mobile application to report adverse drug reactions
62355786|NCT02284230|ACTIVE_COMPARATOR|Liraglutide treatment|Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
62148421|NCT04131556|EXPERIMENTAL|Part 2: Sequence GDFE|Participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 1 followed by participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 4 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 7 and then followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
62519084|NCT05673213|EXPERIMENTAL|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
62519085|NCT03282968|EXPERIMENTAL|Experimental|Regular neurophysiotherapy plus REWIRE exercises
62519086|NCT03282968|ACTIVE_COMPARATOR|Control|Regular neurophysiotherapy plus standing balance exercises
62148422|NCT04680988|EXPERIMENTAL|Doublet Arm|SHR-1210+SHR-1020
62519087|NCT06322394|EXPERIMENTAL|BXOS110 high-dose group|Name:BXOS110 Dosage form:injection Dosage:3.0 mg/kg, maximum dose not exceeding 300 mg Frequency:Frequency of injection is once Duration:10±1 min
62519088|NCT06322394|EXPERIMENTAL|BXOS110 low-dose group|Name:BXOS110 Dosage form:injection Dosage:2.0 mg/kg, maximum dose not exceeding 300 mg Frequency:Frequency of injection is once Duration:10±1 min
62519089|NCT06322394|PLACEBO_COMPARATOR|Placebo control group|Dosage:0 mg/kg Frequency:Frequency of injection is once Duration:10±1 min
62519090|NCT03255512|EXPERIMENTAL|Vericiguat + isosorbite mononitrate|"Subjects received Isosorbide mononitrate (ISMN) up-titration with 30 mg / 60 mg, about 7 days each,prior to start of vericiguat administration.~Then subjects received 2.5 mg vericiguat for about 14 days, followed by 5 mg vericiguat for about 14 days, followed by 10 mg vericiguat for about 14 days together 60 mg ISMN od on each day of vericiguat administration, taken 1 hour prior to vericiguat (in-house days) or together with vericiguat (out-patient days)."
62519091|NCT03255512|PLACEBO_COMPARATOR|Placebo + isosorbite mononitrate|"Subjects received Isosorbide mononitrate (ISMN) up-titration with 30 mg / 60 mg, about 7 days each, prior to start of placebo administration.~Then subjects received placebo matching 2.5 mg vericiguat for about 14 days, followed by placebo matching 5 mg vericiguat for about 14 days, followed by placebo matching 10 mg vericiguat for about 14 days together 60 mg ISMN od on each day of placebo administration, taken 1 hour prior to placebo (in-house days) or together with placebo (out-patient days)."
62519092|NCT02485002|ACTIVE_COMPARATOR|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
62519093|NCT02485002|EXPERIMENTAL|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
62519094|NCT05260164|EXPERIMENTAL|HIFEM+RF|"The subjects will be enrolled and assigned into one study arm and will be required to complete four (4) treatment visits.~Both flanks will be treated simultaneously with the BTL-899 device for 30 minutes per session."
62519095|NCT01795105||Aripiprazole (Abilify® Tablets/Abilify® ODT)|
62519096|NCT02165618|NO_INTERVENTION|GCT|In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
62519097|NCT02165618|ACTIVE_COMPARATOR|GCT-RASP|Medication review, based on but not limited to the RASP list
62148423|NCT04680988|EXPERIMENTAL|Single Arm|SHR-1210
62148424|NCT04680988|ACTIVE_COMPARATOR|Physician's choice chemotherapy|Albumin-bound paclitaxel injection or Pemetrexed disodium for injection or Gemcitabine for injection
62519098|NCT03257150|EXPERIMENTAL|Study Treatment|Single arm trial of irreversible electroporation using the NanoKnife system for locally advanced pancreatic ductal adenocarcinoma.
62519099|NCT00653484|EXPERIMENTAL|Physical Activity Only|Physical Activity
62519100|NCT00653484|EXPERIMENTAL|Dietary Energy Restriction|Energy restriction
62519101|NCT00653484|EXPERIMENTAL|Physical Activity+Dietary Energy Restriction|Physical Activity ad Energy Restriction
62710920|NCT01119638|ACTIVE_COMPARATOR|Risperidone Drug|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
62148425|NCT06308354||colorectal cancer|Colorectal cancer patients are enrolled when patients were underwent surgeries.
62519102|NCT03487848|EXPERIMENTAL|Daclatasvir with Sofosbuvir|Specified dose on specified days for specified duration
62710921|NCT05235165|EXPERIMENTAL|Arm A (thoracotomy)|Patients undergo open thoracic surgery (thoracotomy). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial.
62148426|NCT04083209|EXPERIMENTAL|Counseling group|"Patients randomized into the counseling group will be given a 1-2 minute presentation over the risks of opioid pain medications during their preoperative visit."
62148427|NCT04083209|NO_INTERVENTION|Control group|The control group will undergo the standard preoperative evaluation by the senior author without any additional formal opioid counseling.
62148428|NCT01208506|EXPERIMENTAL|Dose level 1|
62148429|NCT01208506|EXPERIMENTAL|Dose level 2|
62710922|NCT05235165|EXPERIMENTAL|Arm B (thoracoscopy)|Patients undergo thoracoscopy (video-assisted thoracoscopic surgery or VATS). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial.
62710923|NCT04284137|EXPERIMENTAL|Modified FE-SaLiR|FE-SaLiR is based on modified Ba Duan Jin and Wu Qin Xi exercises that include low to moderate intensity age-tailored activities targeting different parts of the body, integrating breathing and mindfulness. A trained Community Health Worker will serve as the class instructor.
62148430|NCT01208506|EXPERIMENTAL|Dose level 3|
62148431|NCT01208506|EXPERIMENTAL|Dose level 4|
62148432|NCT01208506|EXPERIMENTAL|Dose level 5|
62148433|NCT01208506|EXPERIMENTAL|Dose level 6|
62519103|NCT06273202|EXPERIMENTAL|Massage|Infants will be randomized to receive infant massage or not. Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
62519104|NCT06273202|NO_INTERVENTION|Control group (standard care)|Infants in this group will receive standard care.
62519105|NCT05361291|ACTIVE_COMPARATOR|Inferior Alveolar nerve block with 2% lidocaine with 1:80 000 epinephrine|An Inferior Alveolar nerve block was given with 2% lidocaine with 1:80 000 epinephrine
62519106|NCT05361291|EXPERIMENTAL|Inferior Alveolar nerve block with 2% lidocaine with 1:80 000 epinephrine with 2mg dexamethasone|An Inferior Alveolar nerve block was given with 2% lidocaine with 1:80 000 epinephrine mixed with 2mg dexamethasone
62519107|NCT05361291|EXPERIMENTAL|Inferior Alveolar nerve block with plain 2% lidocaine mixed with 2mg dexamethasone|An Inferior Alveolar nerve block was given with plain 2% lidocaine mixed with 2mg dexamethasone
62519108|NCT05628779|EXPERIMENTAL|Transcatheter Edge-to-Edge Repair (TEER) on top of the Standard Of Care (SOC)|Transcatheter Edge-to-Edge Repair (TEER) on top of the Standard Of Care (SOC)
62519109|NCT05628779|NO_INTERVENTION|Standard Of Care (SOC)|Patients will continue the SOC with heart failure medication following the European Society of Cardiology guideline 2021 recommendations (e.g. diuretics)
62519110|NCT05887349|OTHER|Control Group|The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects.
62519111|NCT05887349|EXPERIMENTAL|Intervention group|The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. Additionally, Robacado exercises (jaw exercises) will be given to the individuals in this group.
62519112|NCT04075019|EXPERIMENTAL|full intervention|students assigned to intervention classrooms in grades 1 through 4 and who remained in schools assigned to the intervention condition in grades 5 or 6
62519113|NCT04075019|EXPERIMENTAL|late intervention|students in intervention classrooms in grades 5 and 6 only
62519114|NCT04075019|EXPERIMENTAL|parent-training only|students whose parents were offered parent training only when their children were in grades 5 and 6 and no other intervention
62519115|NCT04075019|NO_INTERVENTION|control|students in schools assigned to receive no intervention in grades 5 and 6 and who were not in intervention classrooms in grades 1 through 4
62519116|NCT05714566||IBD|
62519117|NCT05714566||IBD+CDI|
62148434|NCT01208506|EXPERIMENTAL|Dose level 7|
62148435|NCT01208506|EXPERIMENTAL|Dose level 8|
62355787|NCT02284230|PLACEBO_COMPARATOR|Placebo treatment|Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.
62355788|NCT01149343|EXPERIMENTAL|GSK2302025A Cohort 1|Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
62355789|NCT01149343|EXPERIMENTAL|GSK2302025A Cohort 2|Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
62355790|NCT01149343|EXPERIMENTAL|GSK2302025A Cohort 3|Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
62355791|NCT01149343|EXPERIMENTAL|GSK2302025A Cohort 4|In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.
62355792|NCT02330913|EXPERIMENTAL|Intracorporeal esophagojejunostomy|Patient group with intracorporeal esophagojejunostomy with linear stapler
62355793|NCT01537094|ACTIVE_COMPARATOR|Vitamin C low dose|vitamin C 250 mg oral once daily
62355794|NCT01537094|ACTIVE_COMPARATOR|Vitamin C high dose|vitamin C 1,000 mg oral once daily
62355795|NCT01537094|PLACEBO_COMPARATOR|Placebo|Placebo oral once daily
62519118|NCT05714566||Health control|
62519119|NCT05811702|EXPERIMENTAL|High fat Ketogenic Diet (HFKD)|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD for 12 weeks. The weight will be measured weekly, body fat % and blood samples before and after 12 weeks of following HFKD.
62519120|NCT05811702|EXPERIMENTAL|low-fat diet (LFD|A randomised acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether LFD for 12 weeks. The weight will be measured weekly, body fat % and blood samples before and after 12 weeks of following LFD.
62148436|NCT03942107|ACTIVE_COMPARATOR|Group 1: RCT+post+core in 1 visit|the root canal treatment will be completed with 2Shape NiTi system as well as post and core application in the same visit prior to postoperative pain evaluation.
62148437|NCT03942107|ACTIVE_COMPARATOR|Group 2: after RCT, post and core in 2nd visit|after root canal treatment conducted with 2Shape NiTi system, the postoperative pain evaluation will be completed prior applying post and core for coronal restoration.
62519121|NCT00287859|EXPERIMENTAL|Escalating Cohorts|"Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD."
62519122|NCT04487743|EXPERIMENTAL|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
62519123|NCT04487743|PLACEBO_COMPARATOR|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
62519124|NCT00110695|EXPERIMENTAL|A|
62148438|NCT01631409||Cohort 0|"Cohort 0 is allocated for the following two patient groups:~1. The patients with suspicion of angina although in whom the thorough investigation has not revealed CHD and the pain syndrome has been received the extracardiac interpretation (e.g. vertebral osteochondrosis, left side humeroscapular periarthritis, herpes zoster, intercostal neuralgia Tietze syndrome etc.)~2. The patients with subclinical manifestation of coronary atherosclerosis without angina (Class 0 angina, here and further is according to the Canadian Cardiovascular Society Angina Classification). This subgroup of the patients is recommended the proper diet, life style modification, lipid targeting medications in some cases, and no antianginal treatment."
62519125|NCT01882920|EXPERIMENTAL|Goal directed therapy intravenous restricitve fluid protocol|
62519126|NCT01882920|ACTIVE_COMPARATOR|Control arm|
62519127|NCT03438227|EXPERIMENTAL|Intravenous iron dextran infusion|Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor \& Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
62519128|NCT03438227|ACTIVE_COMPARATOR|Oral ferrous sulfate supplementation|Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
62519129|NCT01701037|EXPERIMENTAL|Dabrafenib and Trametinib|Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
62519130|NCT02464826|EXPERIMENTAL|Edit arms|Nailprotex apply to the abnormal nail twice daily
62519131|NCT01901874|EXPERIMENTAL|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
62519132|NCT00859001|EXPERIMENTAL|FM+R|4 cycles of FM+R plus Zevalin
62519133|NCT05790954|EXPERIMENTAL|Guided imagery Group|
62519134|NCT05790954|NO_INTERVENTION|Control Group|
62519135|NCT00592202|EXPERIMENTAL|1|Adolescents between the ages 14 through 17 with a BMI of 40 or more or with a BMI of 35 or more and with an obesity related comorbidity will undergo placement of an adjustable gastric band
62519136|NCT02495181|SHAM_COMPARATOR|Aflibercept Monotherapy|IVT Aflibercept 2 mg + Sham PDT
62519137|NCT02495181|ACTIVE_COMPARATOR|Aflibercept + verteporfin PDT|IVT Aflibercept 2 mg + Verteporfin PDT
62519138|NCT03505814|EXPERIMENTAL|Optiflow Group|high flow (6l/min), humidified oxygen administred into nasal cannula for post-extubation new born ventilated patients.
62519139|NCT03505814|ACTIVE_COMPARATOR|Control Group|Conventional oxygen therapy for post extubation care
62519140|NCT04734119||Group A- same anesthesiologist|In Group A patients were evaluated preoperatively and anesthetized by the same anesthesiologist.
62519141|NCT04734119||Group B- different anesthesiologist|In Group B the preoperative assessment and actual anesthesia was performed by two different anesthesiologists
62519142|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
62519143|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
62519144|NCT02409394|EXPERIMENTAL|hetrombopag 7.5mg fasted to fed|Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.
62148439|NCT01631409||Cohort I|Represents patients with Class 1 angina, who receive OMT.
62519145|NCT02409394|EXPERIMENTAL|hetrombopag 7.5mg fed to fasted|Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.
62519146|NCT01559987|OTHER|Control|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
62519147|NCT01559987|OTHER|Test|MTB + Floss
62519148|NCT01559987|EXPERIMENTAL|MTB + Waterpik Ultra Water Flosser High|MTB + Waterpik Ultra Water Flosser High
62519149|NCT02048839||Radiel Intervention group and their children|Participated the Radiel- intervention study (2008-2011) in the Intervention group: Lifestyle counselling during and after pregnancy (up to 1 year post partum)
62519150|NCT02048839||Radiel Control Group with their children|Control group in the Radiel- intervention study.
62519151|NCT05748327|EXPERIMENTAL|Alcasite restorative material|
62519152|NCT05748327|ACTIVE_COMPARATOR|Bulk fill glass hybrid restorative material|
62519153|NCT04854564||End-stage liver disease (ESLD) patients|These potential liver transplant candidates are patients with end-stage liver disease (ESLD) who have been assigned to the liver transplant waitlist.
62519154|NCT04854564||Caregivers of potential liver transplant candidates|They are the primary caregivers for the patients.
62519155|NCT01252875|OTHER|LDL-C to100 mg/dL (+/-10 mg/dL)|"Target : 100 mg/dL (+/-10 mg/dL):~Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of 100 mg/dL(+/-10 mg/dL)."
62519156|NCT01252875|OTHER|LDL-C < 70 mg/dL|70 mg/dL: Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of less than 70 mg/dL.
62519157|NCT06489938|EXPERIMENTAL|Mirror therapy combined with the task-oriented approach (MTT)|Each participant will receive the mirror therapy combined with the task-oriented approach 90 minutes daily, three days per week for six weeks.
62710924|NCT04284137|EXPERIMENTAL|Unmodified Chinese Medicine Exercise|The Ba Duan Jin and Wu Qin Xi low- to moderate- intensity exercises published by the General Administration of Sport of China. A trained Community Health Worker will serve as the class instructor.
62519158|NCT06489938|EXPERIMENTAL|Mirror therapy combined with the impairment-oriented approach (MTI)|Each participant will receive the mirror therapy combined with the impairment-oriented approach 90 minutes daily, three days per week for six weeks.
62519159|NCT06489938|ACTIVE_COMPARATOR|Task-oriented rehabilitation program combined with impairment-oriented rehabilitation program (TI)|Each participant will receive the task-oriented rehabilitation program combined with the impairment-oriented rehabilitation program 90 minutes daily, three days per week for six weeks.
62519160|NCT01194973|EXPERIMENTAL|Eculizumab|
62519161|NCT04463498|EXPERIMENTAL|n=15, Sleep-school 8 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
62519162|NCT04463498|EXPERIMENTAL|n=15, Sleep-school 8 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
62519163|NCT04463498|ACTIVE_COMPARATOR|n=30 8-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
62519164|NCT00908921|EXPERIMENTAL|1|"The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) \>7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.~At every visit if FBG\<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.~Patients who have been on 4mg for 4 weeks and FBG\>11.0mmol/L at visit, another treatment can be added at the physician's discretion."
62519165|NCT03144817|NO_INTERVENTION|Control Group|
62519166|NCT03144817|EXPERIMENTAL|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
62519167|NCT01534637|EXPERIMENTAL|Treatment (antiemetic, chemotherapy, and radiation therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy once daily on days 1-5 for 5.5 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes once weekly and either fluorouracil IV continuously or capecitabine PO twice daily on days 1-5.~PROPHYLACTIC THERAPY: Beginning 1 hour before chemoradiotherapy, patients receive aprepitant PO on days 1-3. Treatment repeats every 7 days for 5.5 weeks in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION CHEMOTHERAPY: Two to four weeks after completion of chemoradiotherapy and prophylactic therapy, patients without disease progression or a declining performance status receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
62519168|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
62519169|NCT00446199|EXPERIMENTAL|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
62519170|NCT00446199|EXPERIMENTAL|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
62519171|NCT00446199|EXPERIMENTAL|Estradiol (E2 0.3mg)|One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
62519172|NCT00446199|PLACEBO_COMPARATOR|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
62519173|NCT02489604|EXPERIMENTAL|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE 25.9 GBq activity. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
62519174|NCT02489604|EXPERIMENTAL|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE 18.5 GBq activity. Total activity of 18.5 GBq 100 mCi for 5 cycles, every 6 ± 2 weeks (500 mCi)
62519175|NCT04131231|EXPERIMENTAL|microparticles packaging methotrexate (MPs-MTX) group|"Patients are first treated with microparticles packaging methotrexate (MPs-MTX) via intrapleural infusion four times on day5,6,7,8 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.~MPs-MTX: 5 U of MPs-MTX containing a total dose of more than 25μg of MTX dissolving in 50ml of physiological saline solution"
62519176|NCT04131231|ACTIVE_COMPARATOR|recombinant human interleukin-2(rhIL-2) group|"Patients are first treated with rhIL-2 via intrapleural infusion three times on day5,8,11 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.~rhIL-2: 2 million IU of rhIL-2 dissolving in 50ml of physiological saline solution"
62519177|NCT00765141||No treatment|
62519178|NCT00750022|EXPERIMENTAL|E1|
62710925|NCT04284137|ACTIVE_COMPARATOR|Active Control|The active control program is a health education program for attention control. The participants will learn knowledge and skills about healthy aging and nutrition in a group with hands-on activities.
62710926|NCT04505488|EXPERIMENTAL|Intervention Group|The intervention group will receive a parent manual, a resource packet, and 12 weekly sessions delivered by the clinician and peer leader.
62148440|NCT01631409||Cohort II|"Comprises the patients with Class 2-4 angina, they are on MAAMT. The cohort is further divided in two groups:~1. The patients for whom MAAMT is effective.~2. The patients for whom MAAMT is not effective or not sufficiently effective, although those patients have not received any invasive, surgical or CSWT interventions yet.~They are those patients who then form cohorts III-VI."
62519179|NCT00750022|ACTIVE_COMPARATOR|A1|
62710927|NCT04505488|NO_INTERVENTION|Control Group|The control group will receive a parent manual and a resource packet. Four phone check-ins will be conducted across 12-14 weeks to address questions by the research team.
62710928|NCT01788878|EXPERIMENTAL|Questionnaires|completion of questionnaires
62148441|NCT01631409||Cohort III|Consists of patients already received PCA. They also continue various MAAMT.
62519180|NCT02573935|EXPERIMENTAL|Clarithromycin|Clarithromycin combined with VCD induction therapy
62519181|NCT02573935|PLACEBO_COMPARATOR|Placebo|Placebo combined with VCD induction therapy
62519182|NCT04918303|EXPERIMENTAL|SKNA group|
62519183|NCT04695756||People who require liver transplant|We will compare the year before the beginning of the COVID-19 Pandemia with the period during the COVID-19 Pandemia.
62519184|NCT05897918|OTHER|single group|
62519185|NCT02441582|EXPERIMENTAL|Telemetry|In this group, participants will have a prehospital 12 lead ECG taken and sent through to the receiving facility.
62519186|NCT02441582|OTHER|Non-Telemetry|In this group, participants will have a prehospital 12 lead ECG taken which will not be sent through to the receiving facility.
62519187|NCT02055443||Holter monitor group|12-lead holter monitor application
62519188|NCT03227224|PLACEBO_COMPARATOR|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
62519189|NCT03227224|EXPERIMENTAL|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
62519190|NCT06052488|EXPERIMENTAL|Strength After Breast Cancer (SABC) Intervention|"Participants will undergo study procedures as outlined:~* Complete a baseline survey regarding exercise self-efficacy, physical activity level, quality of life, and fatigue~* Attend a 1-on-1 physical therapy evaluation and 4 group exercise sessions at MGH Waltham~* After completing the 4 exercise sessions, complete follow-up surveys including a program satisfaction survey~* At 1-month post-program, complete follow-up surveys and an individual, semi-structured interview with study staff to supply feedback about the program.~* At 3-months post-program, complete follow-up surveys"
62519191|NCT02396784||High risk|One parent has a BMI of greater than or equal to 28, or both parents have a BMI of greater than or equal to 24
62519192|NCT02396784||Normal risk|Both parents have a BMI of smaller than 24
62519193|NCT05802108|EXPERIMENTAL|Experimental Group|evolocumab combined with statins
62710929|NCT01115907|EXPERIMENTAL|Freedom SOLO stentless valve implant|Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
62710930|NCT05035888|ACTIVE_COMPARATOR|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
62710931|NCT05035888|EXPERIMENTAL|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
62148442|NCT01631409||Cohort IV|Includes the patients after CABG. They also are on various MAAMT.
62148443|NCT01631409||Cohort V|Incorporates the patients who have already underwent CSWT. They also receive individualized MAAMT.
62148444|NCT01631409||Cohort VI|"The cohort is composed of the patients who for various reasons have not been exposed to any intervention except MAAMT and continue to be on it.~The algorithm of the cohort formation is graphically demonstrated in the Diagram The logic tree of the cohort formation (see the link at the bottom of the protocol)."
62148445|NCT00362284|EXPERIMENTAL|NYUCI-AC group|Adult children in this arm received the NYUCI-AC intervention, which consisted of 6 individual and family counseling sessions, the offering of an adult child specific support group, and the provision of ad hoc, or ongoing, consultation throughout the duration of participation.
62519194|NCT05802108|OTHER|Control Group|statins only
62519195|NCT00906113|EXPERIMENTAL|Intra-arterial melphalan|The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
62519196|NCT03064438|EXPERIMENTAL|ACU-D1 Ointment|Twice-daily application of ACU-D1 ointment to the face for 12 weeks.
62148446|NCT00362284|NO_INTERVENTION|Usual care control|Adult children randomly assigned to the usual care control did not receive the NYUCI-AC intervention. If they were in crisis or required support, the NYUCI-AC counselors provided information and referral on an as-needed basis.
62519197|NCT03064438|PLACEBO_COMPARATOR|ACU-D1 Ointment Vehicle|Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.
62519198|NCT02087124|EXPERIMENTAL|0g whey protein|0g whey protein dissolved in 200 milliliter (mL) water.
62519199|NCT02087124|EXPERIMENTAL|10g whey protein|10g whey protein dissolved in 200 milliliter (mL) water.
62519200|NCT02087124|EXPERIMENTAL|20g whey protein|20g whey protein dissolved in 200 milliliter (mL) water.
62519201|NCT05396664|EXPERIMENTAL|Intervention|The ATWA LSE program will be implemented following a joint curricula development process with approval from the government in each of the three countries. The 'dose' of the intervention are once-weekly hour-long sessions for both in-school adolescents (session facilitated by teachers) and out-of-school adolescents (sessions facilitated by community leaders) over the course of the academic year (roughly 9 months), or roughly 30 sessions of exposure to the in-depth LSE curriculum.
62710932|NCT06528405|EXPERIMENTAL|SGLT2i|
62710933|NCT06528405|PLACEBO_COMPARATOR|Control|
62710934|NCT05767281||Children 3 years old|Epidemiological examination of children according to the WHO 2013 methodology, including only an examination of the oral cavity.
62710935|NCT05767281||Children 5-6 years old|Epidemiological examination of children according to the WHO 2013 methodology, including only an examination of the oral cavity.
62710936|NCT05767281||Children 7 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including only an examination of the oral cavity.
62710937|NCT05767281||Children 12 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
62148447|NCT03146026|NO_INTERVENTION|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
62519202|NCT05396664|NO_INTERVENTION|Control|"Control groups are comprised of adolescents (10-19) attending schools where the ATWA Life Skills Education (LSE) program has not been implemented, as well as out-of-school adolescents (10-19) who have not received the ATWA LSE program in their communities. Control groups receive standard of care educational opportunities. Standard of care in the case of this trial translate to the provision of standard Ministry of Education-sanctioned sexuality education, as already available in the adolescents' schools and communities."
62519203|NCT03338179|EXPERIMENTAL|Adult Patients|Schizophrenia patients aged between 18 and 45 years old
62519204|NCT03338179|EXPERIMENTAL|Aged Patients|Schizophrenia patients aged 59.5 years and above
62519205|NCT03338179|ACTIVE_COMPARATOR|Adult Controls|Controls aged between 18 and 45 years old
62519206|NCT03338179|ACTIVE_COMPARATOR|Aged Controls|Controls aged 59.5 years and above
62519207|NCT04076488|EXPERIMENTAL|Dividat FIT: Computer based exercise|Tablet based interactive physical training.
62710938|NCT05767281||Teenagers 15 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
62710939|NCT05767281||Teenagers 18 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
62710940|NCT03361878|ACTIVE_COMPARATOR|Metformin Tolerant|
62519208|NCT02307643|EXPERIMENTAL|Part 1|MT-1303 Low dose+Corticosteroid
62519209|NCT02307643|EXPERIMENTAL|Part 2-A|MT-1303 High dose+Corticosteroid
62519210|NCT02307643|EXPERIMENTAL|Part 2-B|MT-1303 Low dose+Corticosteroid+Immunosuppressant
62519211|NCT01475253|EXPERIMENTAL|Lidocaine Releasing Intravesical System|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
62519212|NCT01475253|PLACEBO_COMPARATOR|LiRIS containing inactive substance only|LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
62519213|NCT01475253|SHAM_COMPARATOR|Cystoscopy Procedure|No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.
62519214|NCT04773717|EXPERIMENTAL|Ascorbic acid|"Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours.~Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours."
62519215|NCT04773717|PLACEBO_COMPARATOR|Placebo|Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.
62519216|NCT05160467||Deresuscitation cohort|"Patients with fluid overload (defined by a cumulative fluid balance \> 5%), stable hemodynamic (defined by Norepinephrine equivalent \< 0.5µg/kg/min and nor clinical nor biological sign of hypoperfusion) and continuous renal replacement therapy. All these patients benefit in our service from a protocol directed, perfusion based deresuscitation strategy with a 2mL/kg/h net ultra filtration to induce negative fluid balance and correct fluid overload. If hypoperfusion occurs, the net ultra filtration is stopped; if pulmonary oedema or right ventricular dysfunction occurs, the net ultra filtration is set to 3mL/kg/h.~We carried out at day 0, 1,3 and 5 bio electrical impedance analysis with an eight polar multifrequency bio impedance monitor (InBody S10), and monitor cumulative fluid balance with our prescription software and daily weight assessment."
62519217|NCT01912638|EXPERIMENTAL|Implantation of Ologen in trabeculectomy|Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
62519218|NCT01912638|ACTIVE_COMPARATOR|Provisc in trabeculectomy|Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
62519219|NCT04130659|EXPERIMENTAL|MARIAL® and PPI; Follow-up period: MARIAL® alone|"Period 1, open comparative phase: MARIAL® and PPI administered from day 1 to day 28.~Period 2, open non comparative follow up: MARIAL® alone administered from day 29 to month 6."
62519220|NCT04130659|ACTIVE_COMPARATOR|PPI alone; Follow-up period: MARIAL® alone|"Period 1, open comparative phase: PPI alone administered from day 1 to day 28.~Period 2, open non comparative follow up: MARIAL® alone administered from day 29 to month 6."
62519221|NCT06122233|EXPERIMENTAL|REBUILD-SM Group|Participants randomised to REBUILD-SM will receive the self-management package as well as the RE-BUILD app. Structured self-management support via telephone or Zoom call will be provided 4 times during the 12-week intervention period.
62519222|NCT06122233|NO_INTERVENTION|Standard Care Group|In the control arm, participants will receive standard care and a reduced capability version of the RE-BUILD app to be used for data-capture only. They will also receive phone/Zoom calls at the same frequency during the 12-week intervention period, but no health advice will be given. After 26 weeks, participants in this group will receive access to the fully functional RE-BUILD app.
62519223|NCT01047020||ALL survivors|The study sample for this research will be recruited from participants in an institutionally funded cohort study, St. Jude Life, as well as from active ACT patients that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated group who were followed in the After Completion of Therapy Clinic until age 18 years and a minimum of 10 years after their treatment ended if they were older than age 11 at the end of therapy
62519224|NCT01047020||Comparison Group|Potentially eligible comparison group participants will be recruited from the parent, older sibling, relative or friend population who accompany the ACT patient for follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older) of children in remission, both from the active follow-up cohort (within five years of last treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete the same assessments that the ALL survivor participants will complete. Comparison group participants are frequency matched to potentially eligible participants by race/ethnicity (white, black, other) age group (18 to 29, 30-39, 40-49 years) and gender.
62519225|NCT05130138|EXPERIMENTAL|Pharmaceutical conciliation|Patients with Chronic Myeloid Leukemia taking TKI with a molecular response \< 4,5 Log will participate to pharmaceutical conciliation.
62519226|NCT05343052||Student Athlete|Student-athlete rostered on the varsity football team of participating institutions between 5/1/2022-6/30/2025 (study period)
62519227|NCT04818749|PLACEBO_COMPARATOR|Placebo|Participants allocated to this arm will have placebo administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
62519228|NCT04818749|ACTIVE_COMPARATOR|Dexamethasone 12 mg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
62519229|NCT04818749|EXPERIMENTAL|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and dexmedetomidine 1 mcg/kg administered intravenously after induction of general anaesthesia.
62519230|NCT02680418|EXPERIMENTAL|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
62519231|NCT02680418|EXPERIMENTAL|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
62519232|NCT02680418|EXPERIMENTAL|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
62519233|NCT02680418|EXPERIMENTAL|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
62519234|NCT02680418|EXPERIMENTAL|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
62710941|NCT03361878|ACTIVE_COMPARATOR|Metformin Intolerant|
62519235|NCT02680418|EXPERIMENTAL|Multiple dose|Repeat doses of FDL169 to be administered at a dose level to be determined
62519236|NCT02170948|EXPERIMENTAL|Dex 0.5|Ropivacaine and Lidocaine plus Dexmedetomidine (0.5mg/kg) plus Normal Saline
62519237|NCT02170948|EXPERIMENTAL|Dex 1.0|Ropivacaine and Lidocaine plus Dexmedetomidine (1.0mg/kg) plus Normal Saline
62519238|NCT04150198|EXPERIMENTAL|Patients with Alzheimer (<65 years) (AD-Y)|15 patients with a diagnostic of MA-J
62519239|NCT04150198|EXPERIMENTAL|Patients with posterior Cortical Atrophy (PCA)|15 patients with a diagnostic of PCA
62519240|NCT04150198|ACTIVE_COMPARATOR|Control|15 controls
62519241|NCT01843348|ACTIVE_COMPARATOR|TAC+MPA|
62519242|NCT01843348|EXPERIMENTAL|TAC+Certican|
62519243|NCT01843348|EXPERIMENTAL|CycA+Certican|
62519244|NCT04413136|EXPERIMENTAL|Web-ORLA|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.~The participant is presented with 3-5 word (level 1) or 8-10 word (level 2) sentences, depending upon the severity of the aphasia. Each sentence is chosen by the software program at random from a group of 150 sentences. The participant is instructed to look, listen, and point to words spoken by the virtual therapist, read highlighted words aloud, and then read the sentence aloud, both chorally with the virtual therapist and independently."
62519245|NCT04413136|PLACEBO_COMPARATOR|Control|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.~A commercially available game, Bejeweled 2, by PopCap. Participants use loaned 13-in laptop computers to access the Bejeweled interface, which displays an 8 X 8 grid of gems of varying shapes and colors. The objective is to match three gems of the same color and shape to score points and advance to more difficult levels."
62519246|NCT02009748|ACTIVE_COMPARATOR|Vitamin D supplementation|Colecalciferol 2.800 IU/day
62519247|NCT02009748|PLACEBO_COMPARATOR|Placebo|Vehicle (coconut oil)
62519248|NCT03144102|EXPERIMENTAL|VR-based motor rehabilitation with tDCS|
62519249|NCT03144102|ACTIVE_COMPARATOR|Occupational Therapy with tDCS|
62519250|NCT03144102|SHAM_COMPARATOR|VR-based motor rehabilitation with sham tDCS|
62519251|NCT03144102|SHAM_COMPARATOR|Occupational Therapy with sham tDCS|
62519252|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_1_YA|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 1 during Phase 1, at Day 1 and at Day 22.
62519253|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_2_YA|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 2 during Phase 1, at Day 1 and at Day 22.
62519254|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_3_YA|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 3 during Phase 1, at Day 1 and at Day 22.
62519255|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_4_YA|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 4 during Phase 1, at Day 1 and at Day 22.
62519256|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_5_YA|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 5 during Phase 1, at Day 1 and at Day 22.
62519257|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph1_YA|YA participants receive 2 doses of Placebo during Phase 1, at Day 1 and at Day 22.
62519258|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_1_OA|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 1 during Phase 1, at Day 1 and at Day 22.
62519259|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_2_OA|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 2 during Phase 1, at Day 1 and at Day 22.
62519260|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_3_OA|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 3 during Phase 1, at Day 1 and at Day 22.
62519261|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_4_OA|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 4 during Phase 1, at Day 1 and at Day 22.
62519262|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph1_5_OA|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 5 during Phase 1, at Day 1 and at Day 22.
62519263|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph1_OA|OA Adult participants receive 2 doses of Placebo during Phase 1, at Day 1 and at Day 22.
62519264|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_1_YA Part A|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 1 during Phase 2 Part A, at Day 1 and at Day 22.
62519265|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_2_YA Part A|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 2 during Phase 2 Part A, at Day 1 and at Day 22.
62519266|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_3_YA Part A|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 3 during Phase 2 Part A, at Day 1 and at Day 22.
62519267|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_4_YA Part A|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 4 during Phase 2 Part A, at Day 1 and at Day 22.
62519268|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_5_YA Part A|YA participants receive 2 doses of Flu Pandemic mRNA_Dose level 5 during Phase 2 Part A, at Day 1 and at Day 22.
62519269|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_YA Part A|YA participants receive 2 doses of Placebo during Phase 2 Part A, at Day 1 and at Day 22.
62519270|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_1_OA Part A|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 1 during Phase 2 Part A, at Day 1 and at Day 22.
62519271|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_2_OA Part A|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 2 during Phase 2 Part A, at Day 1 and at Day 22.
62519272|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_3_OA Part A|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 3 during Phase 2 Part A, at Day 1 and at Day 22.
62519273|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_4_OA Part A|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 4 during Phase 2 Part A, at Day 1 and at Day 22.
62519274|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_5_OA Part A|OA participants receive 2 doses of Flu Pandemic mRNA_Dose level 5 during Phase 2 Part A, at Day 1 and at Day 22.
62519275|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_OA Part A|OA participants receive 2 doses of Placebo during Phase 2 Part A, at Day 1 and at Day 22.
62519276|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_1_YA Part B (Scenario 1)|YA participants receive 1 dose of Flu Pandemic mRNA at a selected dose level 1 from the 5 dose levels tested during Phase 2 Part A administered in Phase 2 Part B, at Day 1.
62710942|NCT05321290|EXPERIMENTAL|Robotic Therapy Program|The intervention will consist of identification of 3-5 therapy goals using GAS (Turner-Stoke, 2009), joint planning with a therapist to achieve these goals during the program, and a robotic therapy plan. The robotic therapy plan will be negotiated with participants and consist of 3 sessions (about 1 h) per week for 8 weeks. The plan will detail the types of robotic activities (e.g. selection of interactive activities and games) to be completed by the participant. Homework relevant to participants' therapy goals will also be developed after each session. The intervention for each participant will be 24 robotic therapy sessions and 10 progress review sessions. The robotic system includes a tabletop 2-degree of freedom haptic robot that provides assisted and resisted shoulder and elbow movement therapy (Lu et. al, 2012). Interactive games are used with the system to engage and motivate participants to continue therapy.
62710943|NCT04127318|EXPERIMENTAL|Pedaling Group|During their 30 minute immunotherapy infusions, participants will pedal using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. A research personnel will monitor the patient's heart rate, blood pressure, and RPE at baseline and every 10 minutes throughout the pedaling session. Participants will also have treatment response biomarkers gathered at baseline and before and within 10 minutes of completing their first and fourth immunotherapy infusions. Lastly, participants will complete both a physical activity questionnaire and a quality of life questionnaire at baseline and following their fourth treatment.
62710944|NCT06645795|EXPERIMENTAL|robot assisted gait training plus conventional physical therapy|Participants will complete 8 weeks of intervention of robot assisted gait training plus conventional physical therapy.
62148448|NCT03146026|EXPERIMENTAL|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
62148449|NCT02745756|EXPERIMENTAL|Combined Cell Therapy|Hematopoietic progenitor cell (HPC) transplant (HPCT) with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
62519277|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_2_YA Part B (Scenario 1)|YA participants receive 1 dose of Flu Pandemic mRNA at a selected dose level 2 from the 5 dose levels tested during Phase 2 Part A administered in Phase 2 Part B, at Day 1.
62519278|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_YA Part B (Scenario 1)|YA participants receive 1 dose of Placebo during Phase 2 Part B, at Day 1.
62710945|NCT06645795|ACTIVE_COMPARATOR|Conventional physical therapy|Participants will complete 8 weeks of conventional therapy.
62710946|NCT04504955||Atopic Dermatitis|Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible
62710947|NCT06370390|EXPERIMENTAL|the intervention group|Patients in the intervention group received swallowing function training in community public spaces for 5 days every week for a 4-week period.
62710948|NCT06370390|NO_INTERVENTION|The control group|No intervention will be applied
62710949|NCT01876212|EXPERIMENTAL|Vaccine + dasatinib|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 2, day 1 (week 5).~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
62710950|NCT01876212|EXPERIMENTAL|Vaccine + dasatinib from cycle 1|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 1, day 1.~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
62710951|NCT01985230|EXPERIMENTAL|ReActiv8 Implant|
62710952|NCT01151657|PLACEBO_COMPARATOR|Placebo|Capsules containing maltodextrin.
62710953|NCT01151657|EXPERIMENTAL|Probiotics|Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
62710954|NCT06274658||Spinal Cord Injury|This group includes people with spinal cord injury and the level of injury is at the 6th thoracic vertebra or above.
62519279|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_1_OA Part B (Scenario 1)|OA participants receive 1 dose of Flu Pandemic mRNA at a selected dose level 1 from the 5 dose levels tested during Phase 2 Part A administered in Phase 2 Part B, at Day 1.
62519280|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_2_OA Part B (Scenario 1)|OA participants receive 1 dose of Flu Pandemic mRNA at a selected dose level 2 from the 5 dose levels tested during Phase 2 Part A administered in Phase 2 Part B, at Day 1.
62519281|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_OA Part B (Scenario 1)|OA participants receive 1 dose of Placebo during Phase 2 Part B, at Day 1.
62710955|NCT06274658||Non-injured Controls|This group includes age- and sex-matched non-injured control participants.
62148450|NCT01968824|NO_INTERVENTION|General Anesthesia|general anesthesia only
62148451|NCT01968824|EXPERIMENTAL|Brachial Plexus Nerve Block|brachial plexus nerve block
62148452|NCT03479892|EXPERIMENTAL|NNC0194-0499|Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
62148453|NCT03479892|PLACEBO_COMPARATOR|Placebo|Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
62148454|NCT01705366||Knee Arthroplasty|"Patients undergoing total knee arthroplasty. This may be Non-MAKO® Robot Assisted Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty or MAKO® Robot Assisted Medial and PF Knee Arthroplasty~The Non-MAKO® Robot Assisted Total Knee Arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System. The MAKO® Robot Assisted Arthroplasty uses the RESTORIS Multicompartmental Knee System ."
62148455|NCT04326894|EXPERIMENTAL|Methotrexate|25mg oral MTX tablets
62519282|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_6_YA Part B (Scenario 2/Segment 1)|YA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 6 during Phase 2 Part B, at Day 1.
62519283|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_7_YA Part B (Scenario 2/Segment 1)|YA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 7 during Phase 2 Part B, at Day 1.
62519284|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_YA Part B (Scenario 2/Segment 1)|YA participants receive 1 dose of Placebo during Phase 2 Part B, at Day 1.
62519285|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_6_OA Part B (Scenario 2/Segment 1)|OA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 6 during Phase 2 Part B, at Day 1.
62519286|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_7_OA Part B (Scenario 2/Segment 1)|OA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 7 during Phase 2 Part B, at Day 1.
62519287|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_OA Part B (Scenario 2/Segment 1)|OA participants receive 1 dose of Placebo during Phase 2 Part B, at Day 1.
62519288|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_6_YA Part B (Scenario 2/Segment 2)|YA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 6 during Phase 2 Part B, at Day 1.
62519289|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_7_YA Part B (Scenario 2/Segment 2)|YA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 7 in Phase 2 Part B, at Day 1.
62519290|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_YA Part B (Scenario 2/Segment 2)|YA participants receive 1 dose of Placebo in Phase 2 Part B, at Day 1.
62519291|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_6_OA Part B (Scenario 2/Segment 2)|OA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 6 in Phase 2 Part B, at Day 1.
62519292|NCT06382311|EXPERIMENTAL|Flu mRNA_Ph2_7_OA Part B (Scenario 2/Segment 2)|OA participants receive 1 dose of Flu Pandemic mRNA_ Dose level 7 in Phase 2 Part B, at Day 1.
62519293|NCT06382311|PLACEBO_COMPARATOR|Placebo_Ph2_OA Part B (Scenario 2/Segment 2)|OA participants receive 1 dose of Placebo in Phase 2 Part B, at Day 1.
62519294|NCT00106938|ACTIVE_COMPARATOR|1|"CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
62519295|NCT00106938|ACTIVE_COMPARATOR|2|"CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
62519296|NCT02213952|EXPERIMENTAL|Platelet-Rich Plasma|Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
62519297|NCT02213952|ACTIVE_COMPARATOR|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
62519298|NCT03655236|EXPERIMENTAL|K0706, low dose|
62519299|NCT03655236|EXPERIMENTAL|K0706, high dose|
62519300|NCT03655236|PLACEBO_COMPARATOR|Placebo|
62519301|NCT05790421|EXPERIMENTAL|Group A|Participants received foot muscle energy techniques and conventional physical therapy program for three sessions/week for 4 weeks, each lasting 30 min
62519302|NCT05790421|EXPERIMENTAL|Group B|Participants received conventional physical therapy program only for three sessions/week for 4 weeks, each lasting 30 min
62710956|NCT02455167|EXPERIMENTAL|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
62710957|NCT00127855|EXPERIMENTAL|MenHibrix Formulation 1 Group|Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
62710958|NCT00127855|EXPERIMENTAL|MenHibrix Formulation 2 Group|Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
62710959|NCT00127855|EXPERIMENTAL|MenHibrix Formulation 3 Group|Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
62519303|NCT00836329|EXPERIMENTAL|Intensive Glucose Management|Participants will receive intensive glucose management.
62519304|NCT00836329|ACTIVE_COMPARATOR|Traditional Glucose Management|Participants will receive a traditional method of glucose management.
62519305|NCT02234206|EXPERIMENTAL|Chandrakanthi choornam|"Chandrakanthi Choornam (CKC) - 12gm in milk~OD dose; Oral route~3 Months - duration~Intervention Drug: Chandrakanthi Choornam (CKC)"
62519306|NCT01757574|EXPERIMENTAL|Alemtuzumab|Open label study of alemtuzumab
62519307|NCT01264159|PLACEBO_COMPARATOR|Control|
62519308|NCT01264159|ACTIVE_COMPARATOR|Lung impedence-guided treatment|
62519309|NCT04544020||subjects|subjects with alcoholic hepatitis receiving NG feeding
62519310|NCT05609916|ACTIVE_COMPARATOR|Continued SRI|After post-phase I assessment, participants who are eligible will be randomized to 1) Continued SRI. For these participants, the medication (SRI) will be provided at a consistent dosage.
62519311|NCT05609916|PLACEBO_COMPARATOR|Discontinuation titration to placebo|After post-phase I assessment, participants who are eligible will be randomized to 2) Discontinuation titration to placebo. For these participants, the placebo substitution in an increasing proportion of capsules will be implemented until all drug is withdrawn.
62519312|NCT05609916|OTHER|Open label CBT|During Phase I, all participants will receive open label cognitive-behavioral therapy. Only those who achieve significant benefit will be able to most on to the post-phase I assessment, and then to the random assignment to Continued SRI or Discontinuation titration to placebo arms.
62519313|NCT01364324||Gastrectomy|Twenty gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
62519314|NCT01364324||Non-gastrectomy|Twenty non-gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
62519315|NCT03184220|EXPERIMENTAL|EXPERIMENTAL GROUP|"Patients who are pregnant, have pacemaker and those surgically operated cervical spine patients who have been treated with myofascial therapy a month earlier.~Multimodal physical therapy program includes:~Myofascial syndrome cervical therapy treatment."
62519316|NCT03184220|EXPERIMENTAL|CONTROL GROUP|"Multimodal physical therapy program includes:~* ultrasound therapy (US),~* transcutaneous electric nerve stimulation (TENS)~* massage."
62519317|NCT05302570|EXPERIMENTAL|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
62519318|NCT04400760|OTHER|DAPA Tx|This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.
62519319|NCT00784524|EXPERIMENTAL|LMI Vaccination + IL-2|Patients receiving allogeneic large multivalent immunogen breast cancer vaccine and aldesleukin.
62519320|NCT04356118|EXPERIMENTAL|Endostatin Therapy for NSCLC of LM|"Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer~Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.~intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.~Targeted drugs for non-small cell lung cancer:~EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs ."
62519321|NCT01685593|SHAM_COMPARATOR|regular bandage|no abdominal binder
62519322|NCT01685593|EXPERIMENTAL|abdominal binder|binder
62519323|NCT05797584|OTHER|EchocardiocolorDoppler|EchocardiocolorDoppler examination
62519324|NCT01254682|ACTIVE_COMPARATOR|Hyaluronic acid sodium salt (1%, 20mg/2ml)|
62710960|NCT00127855|ACTIVE_COMPARATOR|Menjugate Group|Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
62710961|NCT00127855|ACTIVE_COMPARATOR|ActHIB Group|Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
62710962|NCT02071901|EXPERIMENTAL|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine by mouth (PO) daily (QD) until platelet counts reach \>= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.
62710963|NCT03895073||healthy|healthy volunteers' replies to questionnaire
62148456|NCT04326894|PLACEBO_COMPARATOR|Placebo|25 mg/week placebo tablets
62148457|NCT05914532||group 1|healthy controls
62148458|NCT05914532||group 2|axial spondyloarthropathy
62148459|NCT02636114|ACTIVE_COMPARATOR|scaling and root planing|this was an international study in which scaling and root planing was done in systemically healthy patients patients with chronic periodontitis
62148460|NCT02636114|NO_INTERVENTION|control group|Scaling and planing was not done that no intervention is carried out in this group
62519325|NCT01254682|OTHER|Standard arthroscopic procedure|
62519326|NCT04010019|EXPERIMENTAL|Enhanced Facebook Condition|The enhanced Facebook group will be moderated by clinicians and offer psychosocial pain management techniques.
62519327|NCT04010019|ACTIVE_COMPARATOR|Control Facebook Condition|In the control condition, there will be no outside intervention; rather, the investigators will instruct participants to offer mutual support for the duration of the group and will not comment further.
62710964|NCT03895073||heart failure|heart failure patients' replies the questionnaire
62710965|NCT00375258|EXPERIMENTAL|1|Active
62710966|NCT00375258|PLACEBO_COMPARATOR|2|
62148461|NCT02393976|OTHER|CONTROL|STANDARD NUTRITION
62148462|NCT02393976|EXPERIMENTAL|IMMUNONUTRITION|INMUNONUTRITION
62148463|NCT05729126||active arm|participants responding to the questionnaire emailed.
62148464|NCT04094207|PLACEBO_COMPARATOR|Control group|Equivalent Placebo will be given
62148465|NCT04094207|EXPERIMENTAL|Pentoxifylline group|Pentoxifylline will be given orally at 800 mg a day for 8 weeks
62148466|NCT04237792|EXPERIMENTAL|dexmedetomidine low dose group|low dose of dexmedetomidine to be given
62148467|NCT04237792|EXPERIMENTAL|dexmedetomidine middle dose group|middle dose of dexmedetomidine to be given
62519328|NCT04133766|EXPERIMENTAL|Community-Based Nutrition Package|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
62519329|NCT04133766|NO_INTERVENTION|Standard of care|Current standard of existing community health services.
62519330|NCT01393457|ACTIVE_COMPARATOR|ldopa + ropinirole low dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d
62519331|NCT01393457|ACTIVE_COMPARATOR|ldopa + ropinirole high dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d
62519332|NCT01393457|ACTIVE_COMPARATOR|ldopa|levodopa/carbidopa 800/200 mg/d
62519333|NCT01393457|PLACEBO_COMPARATOR|placebo|Placebo
62519334|NCT03293173|EXPERIMENTAL|Group A|Biologically low risk group, R-CHOEP-14
62519335|NCT03293173|EXPERIMENTAL|Group B|Biologically high risk group, DA-EPOCH-R
62519336|NCT00428779|EXPERIMENTAL|1|patients running during 24 hours without sleep
62519337|NCT00428779|PLACEBO_COMPARATOR|2|patients without sleep during 24 hours
62519338|NCT00211965|EXPERIMENTAL|vaccine|single dose
62519339|NCT00211965|PLACEBO_COMPARATOR|placebo|single dose
62710967|NCT05344534|NO_INTERVENTION|Control|assessment only through online survey
62710968|NCT05344534|EXPERIMENTAL|LOCI|Leadership and Organizational Change for Implementation strategy
62355796|NCT04569799|OTHER|group-1|Following treatment, patients will receive their standard CT or MRI, as routinely ordered in the post-TACE setting. This imaging will be per standard protocol, as directed by hepatology or oncology services, often 2 to 4 months after the treatment. At the same visit, patients will also receive a one-time additional contrast-enhanced ultrasound (CEUS),
62355797|NCT02501837|EXPERIMENTAL|Oxytocin|24 IU Oxytocin (Syntocinon spray), intranasal application 30 min prior to the experiment
62355798|NCT02501837|PLACEBO_COMPARATOR|Placebo|Intranasal application, containing all ingredients except for the peptide, 3 puffs per nostril
62519340|NCT02777515|OTHER|Patients using electronic cigarette|The patients under the age of 35 followed at the consultation of rythmology for a cardiovascular assessment and already smoking the electronic cigarette and this since at least 1 month. The patient will receive a clinical examination, an electrocardiogram, a Holter-ECG and an echocardiogram before and after electronic cigarette consumption for 15 minutes.
62519341|NCT00750646||A|Subject's adherence to prescribed therapy will be monitored with an electronic compliance device.
62519342|NCT04339920||Chinese patients with clinical suspicious of prostate cancer|Chinese patients with clinical suspicious of prostate cancer, due to elevated serum PSA or abnormal digital rectal examination, will be recruited for the study from the Prince of Wales Hospital and North District Hospital.
62519343|NCT01405131|EXPERIMENTAL|methylprednisolone suspension|
62519344|NCT01405131|ACTIVE_COMPARATOR|methylprednisolone tablets|
62519345|NCT05397548||case|Gastric cancer cases from two medical centers in China
62519346|NCT05397548||control|Controls from two medical centers in China
62519347|NCT01397708|EXPERIMENTAL|INXN-1001 in combination with INXN-2001|Intratumoral injections of INXN-2001 (Ad-RTS-hIL-12) at a constant dose in combination with inter-cohort escalating doses of INXN-1001 (activator ligand).
62519348|NCT01838928|EXPERIMENTAL|Bupivacaine|
62519349|NCT02242318|EXPERIMENTAL|Telmisartan|low dose for two weeks, then up titration to high dose, once daily
62519350|NCT02242318|ACTIVE_COMPARATOR|Valsartan|low dose for two weeks, then up titration to high dose, once daily
62519351|NCT02242318|PLACEBO_COMPARATOR|Placebo|
62710969|NCT03405740|ACTIVE_COMPARATOR|Remote Patient Management|Patients will be followed by remote monitoring only.
62148468|NCT04237792|EXPERIMENTAL|dexmedetomidine high dose group|high dose of dexmedetomidine to be given
62355799|NCT04962672|EXPERIMENTAL|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide.
62355800|NCT04962672|ACTIVE_COMPARATOR|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group will received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide.
62710970|NCT03405740|PLACEBO_COMPARATOR|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
62710971|NCT06326021|EXPERIMENTAL|Autologous FL-33 CAR T|Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from patients.
62148469|NCT04389658||Asymptomatic population|Subjects who underwent PCR and ELISA tests for the diagnosis of COVID-19: mainly asymptomatic individuals from three main areas of Spain (Madrid, Barcelona and Valencia) with high impact of COVID-19 that have performed the PCR and ELISA test for the diagnosis of COVID-19 before initiating the work immediately after Spanish lockdown.
62519352|NCT01634282|EXPERIMENTAL|OPC-262|
62519353|NCT01192984|EXPERIMENTAL|KW-0761|
62710972|NCT06326021|EXPERIMENTAL|Prior-HSCT donor-derived FL-33 CAR T|Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from prior-HSCT donors.
62715104|NCT06157034|EXPERIMENTAL|T2|"* Zingiber officinale, commonly known as ginger, has been of interest for its potential health benefits.~* In this clinical study, the T2 treatment group is designated to receive Zingiber officinale powder.~* Intervention Details:~  * Group Designation: T2 Treatment Group~ * Intervention: Zingiber officinale powder~ * Dosage: 500 mg capsules~ * Dosage Frequency: Twice daily~ * Total Daily Dosage: 1000 mg~ * Administration Timing: After breakfast and dinner~ * Duration: 3 months~* Throughout the study duration, data will be systematically collected from participants in the T3 treatment group. This data may include subjective reports, clinical assessments, and laboratory analyses."
62519354|NCT01543555|EXPERIMENTAL|Atorvastatin active|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
62519355|NCT01543555|PLACEBO_COMPARATOR|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
62519356|NCT04656730|EXPERIMENTAL|Study 1: Experimental: Study 2: Experimental|Iberogast® (STW5) or Iberogast® N (STW5-II) 20 drops TID per 14 days
62519357|NCT04656730|PLACEBO_COMPARATOR|Study 1: Comparator Study 2: Comparator|Placebo 20 drops TID per 14 days
62519358|NCT05520593|EXPERIMENTAL|Complex Carbohydrate Drink Group|The patients will drink a 400ml drink that contains 50g of complex carbohydrates, 3 hours prior to the surgery. The drink will be given once at the preoperative holding area. Patients are not allowed to eat solid foods after 12am the morning of surgery and can only drink clear fluids up to 3 hours prior to the surgery.
62519359|NCT05520593|NO_INTERVENTION|No-Complex Carbohydrate Drink Group|These patients will follow normal institutional preoperative fluid management guidelines, this consist of no solid foods after 12am the morning of surgery. Patients are allowed to drink clear liquids (water, clear fruit juices, coffee) from 12am the morning of surgery up to 3 hours prior to the surgery.
62519360|NCT01615042|EXPERIMENTAL|Dose Escalation/High Dose Lenalidomide|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
62519361|NCT04647669|PLACEBO_COMPARATOR|Local Standard of Care|Local Standard of Care
62355801|NCT00516412|EXPERIMENTAL|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62355802|NCT00352313|EXPERIMENTAL|Phase I|Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
62355803|NCT00352313|EXPERIMENTAL|Phase II|Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62355804|NCT05163717|EXPERIMENTAL|INP105|POD-olanzapine (INP105), 5 mg, single dose, to be delivered to each participant
62355805|NCT05163717|PLACEBO_COMPARATOR|Placebo|POD-placebo, single dose, to be delivered to each participant
62355806|NCT04701047||pessary|Vaginal prolapse being treated by pessary
62355807|NCT04701047||surgery|Vaginal prolapse being treated by surgical repair
62355808|NCT01001728|ACTIVE_COMPARATOR|Prone Position|Patients will lie on their fronts on an in-house designed board comprising an arm positioning device registerable to the couch-top, together with a styrofoam/ memory foam mattress. The ipsilateral breast will drop through an aperture in the mattress. The distance from the nipple to the superior, inferior and lateral aspects of the aperture will be recorded along with the distance of the nipple from the couch-top. Arms will be extended as far as possible above the head and the position of the arm immobilisation handles recorded. The head will be turned to the contralateral side. The contralateral breast will be pulled laterally such that it is as flat as possible beneath the patient. Measurements will be taken in order to relate the position of the bi-lateral tattoos to the orthogonal lasers. A fourth tattoo will be marked on the patient's back in line with the A-P laser. The position will be reproduced at treatment using measurements from the tattoo to the laser.
62355809|NCT01001728|ACTIVE_COMPARATOR|Supine position|For the supine position, patients will be positioned on a customized supine breast board co-registerable to the couch-top to CT and the treatment machines. Arms will be placed above the head in supports. Arm and head position will be recorded along with the angle of the board (which is adjusted such that the sternum is parallel to the couch-top). Tattoos will be marked bi-laterally and medially in a defined relationship to orthogonal lasers. The position will be reproduced at treatment using the above measurements, tattoos and lasers.
62355810|NCT05308615|EXPERIMENTAL|Active (Investigational Product)|"Investigational (Active) product:~Rhea® Health Tone (1.8 mg of Gardenia jasminoides; 1.8 mg Commiphora myrrha oil; 1.8 mg Boswellia serrata oil; 1.8 mg Daucus carota oil; 1.8 mg of Foeniculum vulgarae oil and 0.99 mg of Olea europeae oil or Olive oil as a solvent.)~Regimen:~Subjects will receive Rhea® Health Tone 2 times supplementation 1 ml a day for 84 days"
62355811|NCT05308615|PLACEBO_COMPARATOR|Placebo (Control Product)|"Placebo (Control Product):~Using olive oil without the active ingredients contained in the Rhea® Health Tone test product.~Regimen:~Subjects will receive Placebo 2 times supplementation 1 ml a day for 84 days"
62355812|NCT04562545|ACTIVE_COMPARATOR|Maximum Bite Advancement|
62355813|NCT04562545|EXPERIMENTAL|Incremental Bite Advancement|
62355814|NCT01613001||DoD Beneficiaries|"Exclusion: Active Duty Air Force members with the following conditions will be excluded from the study:~* Documented preexisting musculoskeletal injury/disease before onset of obesity~* Hypothyroidism/Hyperthyroidism~* Hyperparathyroidism~* Osteopenia/Osteoporosis~* Nicotine dependence~* Alcohol dependence~* Eating disorders (anorexia nervosa, bulimia nervosa)~* Cancer requiring chemotherapy or radiation therapy~* Status-post gastrectomy~* Status-post bilateral oophorectomy~* Crohn's Disease~* Ulcerative Colitis~* Celiac Disease~* Cushing's Disease~* Prior to or during the study period, more than 6 months of taking proton pump inhibitors, medroxyprogesterone acetate, bisphosphonates, methotrexate, selective serotonin reuptake inhibitors, or inhaled/intranasal corticosteroids~* Prior to or during the study period, more than 1 month of taking fluoroquinolones, oral or intramuscular corticosteroids, oral or intramuscular testosterone, or leuprolide"
62355815|NCT02855242|OTHER|Intervention Program Group|Lifestyle Counseling
62355816|NCT02855242|ACTIVE_COMPARATOR|Controls Group|No lifestyle counseling
62355817|NCT03424317|ACTIVE_COMPARATOR|Sodium intake reduction and exercise|education of sodium intake reduction and regular exercise
62355818|NCT03424317|PLACEBO_COMPARATOR|Exercise|education of regular exercise only
62519362|NCT04647669|ACTIVE_COMPARATOR|Remdesivir|Remdesivir (daily infusion for 10 days)
62519363|NCT04647669|ACTIVE_COMPARATOR|Acalabrutinib|Acalabrutinib (orally twice daily for 10 days)
62519364|NCT04647669|ACTIVE_COMPARATOR|Interferon|Interferon β1a(daily injection for 6 days).
62519365|NCT00217269|EXPERIMENTAL|1|Endeavor Drug Eluting Stent
62519366|NCT00217269|ACTIVE_COMPARATOR|2|Taxus Drug Eluting Stent
62519367|NCT05397743|EXPERIMENTAL|Questionnaires|Questionnaires for global, psychological and visual Quality of Life (QoL)
62519368|NCT00293202|ACTIVE_COMPARATOR|Etanercept 25 mg|Etanercept 25 mg injection twice a week
62519369|NCT00293202|PLACEBO_COMPARATOR|Saline|Saline injection twice a week
62519370|NCT01453413|OTHER|People with type 2 diabetes|People with type 2 diabetes who were in attendance at a diabetes conference were asked for their perceived Blood Glucose (BG) value. Then, after staff measured BG on a Blood Glucose meter, subjects were informed of their BG value.
62519371|NCT05506722|ACTIVE_COMPARATOR|Testes shocker|This device is working and giving the electrical shocks regularly.
62519372|NCT05506722|PLACEBO_COMPARATOR|Fake Testes shocker|This device is not giving electricity but it is working with a red light, so the participants cannot suspect it.
62519373|NCT02573753|EXPERIMENTAL|sleep restriction|Sleep restriction
62519374|NCT02573753|NO_INTERVENTION|normal sleep|Normal sleep
62519375|NCT02573753|EXPERIMENTAL|weight gain|Weight gain
62519376|NCT05070702|EXPERIMENTAL|CT-1500 Active (SAD)|6 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of CT-1500 between 5 mg and 120 mg
62519377|NCT05070702|PLACEBO_COMPARATOR|Placebo (SAD)|2 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of matching placebo
62519378|NCT05070702|EXPERIMENTAL|CT-1500 Active (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of CT-1500 between 5 and 45 mg
62519379|NCT05070702|PLACEBO_COMPARATOR|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of matching placebo
62148470|NCT04598646|EXPERIMENTAL|Cario-Oncology Rehabilitation (CORE)|"CORE consists of exercise therapy, CVD risk factor management, and behavioural support for 3 months.~Exercise therapy: Staff will prescribe and deliver a standardized, yet individually tailored (based on CPET results), aerobic exercise programs consisting of two days of supervised, facility- and home-based high-intensity interval training (HIIT) and one day of supervised home-based moderate-intensity continuous training (MICT) per week. Exercise HRs and durations will be monitored using an accurate commercially available wrist-worn HR monitor and PA tracker.~CVD risk factor management: CVD risk factors will be assessed and treated according to Canadian guidelines.~Behavioural support: All participants will receive a planned sequence of educational and instructional material via email and ongoing PAYA-CS tailored education and peer support during the follow-up period using a peer support online system."
62519380|NCT03697265|EXPERIMENTAL|Sepranolone (UC1010) low dose|Sepranolone (UC1010) low dose administered subcutaneously (SC) during the luteal phase
62148471|NCT04598646|EXPERIMENTAL|Support|The Support group will receive the behavioural support only. The timing and nature of all education, information provided to Support participants will be identical to what is provided to CORE participants. All Support participants will receive the same wrist-worn HR monitor and PA tracker as the CORE participants and will be given the challenge of meeting and maintaining the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).
62148472|NCT00807599|EXPERIMENTAL|Stem cell transplant x 1 or x 2|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~* stem cell transplant right after collection~* continue lenalidomide and dexamethasone, saving stem cell transplant for a later time."
62519381|NCT03697265|EXPERIMENTAL|Sepranolone (UC1010) high dose|Sepranolone (UC1010) high dose administered subcutaneously (SC) during the luteal phase
62519382|NCT03697265|PLACEBO_COMPARATOR|Placebo|Placebo administered subcutaneously (SC) during the luteal phase
62519383|NCT05195749|EXPERIMENTAL|COVID-19 Patients|Moderate to severe COVID-19 patients receiving SOC and '005.
62519384|NCT05195749|PLACEBO_COMPARATOR|Control|Moderate to severe COVID-19 patients receiving SOC and placebo.
62519385|NCT04714970|EXPERIMENTAL|iTBS stimulation|The participants randomized into experimental group will receive iTBS stimulation of dlPFC 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
62519386|NCT04714970|SHAM_COMPARATOR|Sham stimulation|The participants randomized intoSham group will receive Sham stimulation, as the coil vertical to the brain surface, 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
62519387|NCT01144728|EXPERIMENTAL|Single arm Glimepiride+metformin|Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
62519388|NCT01079832|EXPERIMENTAL|Arm I: CyberKnife Radiosurgery|Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
62519389|NCT00331071||001|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE worn for 1 week and replaced for 3 consecutive weeks fourth week is patch free
62519390|NCT00331071||002|Monophasic or triphasic Oral contraceptive tablet 35 mcg EE for 21 consecutive days followed by no or drug-free tablet for 7 days
62519391|NCT02480582|EXPERIMENTAL|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
62710973|NCT03973957|ACTIVE_COMPARATOR|Control Arm|If undergoing talc slurry in the control arm, the patient will undergo IPC placement in the pulmonary procedure unit on day one of admission. The IPC will then be connected to a pleur-evac as standard of care protocol for chest tube drainage. At 1-2 hours post-IPC placement a chest x-ray will be obtained to assess for full lung re-expansion. If the lung does not fully expand the patient will be excluded from the study. Once full lung re-expansion has occurred, talc slurry will be ordered and the patient will be given 25 mcg of IV fentanyl. Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will be administered via the IPC. The patient will remain in the hospital, with continuous drainage measured daily for 2-5 days, depending on drainage of the effusion.
62519392|NCT02480582|EXPERIMENTAL|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
62519393|NCT02480582|EXPERIMENTAL|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
62519394|NCT02480582|EXPERIMENTAL|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\\kg).
62519395|NCT02480582|EXPERIMENTAL|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\\kg). Finally, after another washout period participants received no food.
62355819|NCT02620709|EXPERIMENTAL|Hula intervention|"Participants randomized to the intervention arm will receive the 6-month KaHOLO Program within 1 week of baseline data collection. The first 3 months of the KaHOLO was designed and standardized as a culturally-based PA, which includes 12 weeks of hula lessons. These hula lessons consist of two 60 minute classes per week over 12 weeks. Each hula lesson will consist of 15 participants, providing with the opportunity to engage in social support network.~The last three months of the program will be reduced to once a week sessions. One week will consist of hula lessons for 60 minutes. The remaining 3 weeks will consist of the intervention group meeting for 45 minutes with the community-peer educator."
62519396|NCT02480582|EXPERIMENTAL|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\\kg).
62519397|NCT00728442|EXPERIMENTAL|1|medical decision based on computerized guideline-based decision support system
62519398|NCT00728442|NO_INTERVENTION|2|
62519399|NCT04387682|OTHER|OSCC subjects with β-glucan supplement|Oral squamous cell carcinoma subjects with pre-surgical administration of whole glucan particle β-glucan
62519400|NCT04387682|NO_INTERVENTION|Healthy donors|healthy donors without pre-surgical administration of whole glucan particle β-glucan
62519401|NCT04387682|NO_INTERVENTION|OSCC subjects without β-glucan supplement|Oral squamous cell carcinoma subjects without pre-surgical administration of whole glucan particle β-glucan
62519402|NCT03344978|ACTIVE_COMPARATOR|Cardboard Cot Care|Stable infant will be nursed in a cardboard cot, lined with reflective film for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Incubator Care), and back for a total of 2 24-hour periods in each arm.
62519403|NCT03344978|PLACEBO_COMPARATOR|Incubator Care|Stable infant will be nursed in an incubator for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Cardboard Cot Care), and back for a total of 2 24-hour periods in each arm.
62519404|NCT01382251||Patient|Patients undergoing ambulatory surgery
62519405|NCT01382251||Caregiver|Spouse, family members, or friends identified as the patient's primary source of support in the community.
62148473|NCT00807599|EXPERIMENTAL|Continue lenalidomide and dexamethasone|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~* continue lenalidomide and dexamethasone~* saving stem cell transplant for a later time."
62519406|NCT05670782|EXPERIMENTAL|Part 1a: Cohort 1.1a Dose 400 mg|Healthy older adult participants will receive oral 400 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
62148474|NCT00799838|EXPERIMENTAL|Ketoprofen + Amoxicillin|Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
62148475|NCT00799838|PLACEBO_COMPARATOR|Amoxicillin|Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
62148476|NCT03885544|ACTIVE_COMPARATOR|Controlled lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet without red meat for 3 weeks.
62519407|NCT05670782|EXPERIMENTAL|Part 1a: Cohort 1.2a Dose 600 mg|Healthy older adult participants will receive oral 600 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
62519408|NCT05670782|EXPERIMENTAL|Part 1a: Cohort 1.3a Dose 800 mg|Healthy older adult participants will receive oral 800 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
62519409|NCT05670782|EXPERIMENTAL|Part 1b: Cohort 1.1b Dose 200 mg|Participants with Parkinson's disease will receive oral 200 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
62519410|NCT05670782|EXPERIMENTAL|Part 1b: Cohort 1.2b Dose 400 mg|Participants with Parkinson's disease will receive oral 400 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
62519411|NCT05670782|EXPERIMENTAL|Part 1b: Cohort 1.3b Dose 600 mg|Participants with Parkinson's disease will receive oral 600 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
62519412|NCT05670782|EXPERIMENTAL|Part 2: Cohort 2.1 Dose X|Participants with Parkinson's disease will receive oral doses of KM-819 (dose to be determined based on the findings from Part 1) or matching placebo once-daily for 730 days and will be allowed to take study intervention with or without fasting.
62519413|NCT05670782|EXPERIMENTAL|Part 2: Cohort 2.2 Dose Y|Participants with Parkinson's disease will receive oral doses of KM-819 (dose to be determined based on the findings from Part 1) or matching placebo once-daily for 730 days and will be allowed to take study intervention with or without fasting.
62519414|NCT05485519|EXPERIMENTAL|Dexmedetomidine (D)|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
62148477|NCT03885544|EXPERIMENTAL|Controlled unprocessed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with unprocessed red meat for 3 weeks.
62148478|NCT03885544|EXPERIMENTAL|Controlled processed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with processed red meat for 3 weeks.
62148479|NCT03772132|EXPERIMENTAL|Chemotherapy|The patients wil receive conventional chemotherapy FORFIRINOX
62148480|NCT05671549|ACTIVE_COMPARATOR|Chronic Closed-Lock|The participants will be enrolled in this group regarding the duration (longer than three months) of their symptoms. The allocated participants will undergo one session of the arthrocentesis procedure. The prefabricated occlusal stabilization splints will be applied. The participants' preoperative, postoperative immediate, and postoperative seventh-day pain intensities and maximum mouth-opening amounts will be recorded and analyzed.
62355820|NCT02620709|NO_INTERVENTION|Wait-List Control|After baseline data collection and education, participants randomized to the wait-list control arm will not receive the KaHOLO Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not receive the intervention for 6 months until after the intervention arm is completed and their 6 month follow-up data collection is completed. They will not receive any other intervention from us during the 6 month period but they will be instructed to continue with their routine medical care as usual.
62519415|NCT05485519|ACTIVE_COMPARATOR|Midazolam (M)|1 mcg/kg/minute. Up to a maximum of 5 mcg/kg/minute.
62519416|NCT01102569||Pancreatic cancer and Ashkenazi decent|Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.
62519417|NCT01846273|EXPERIMENTAL|Ranibizumab + vPDT|Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
62519418|NCT01846273|ACTIVE_COMPARATOR|Ranibizumab monotherapy|Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
62519419|NCT01484418|EXPERIMENTAL|A Exposure long|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
62519420|NCT01484418|EXPERIMENTAL|B Exposure short|See above exposure long. This treatment comprises 5 exposure sessions.
62519421|NCT01484418|ACTIVE_COMPARATOR|C Cognitive behavioural psychotherapy|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
62519422|NCT02969772|EXPERIMENTAL|Assessment of upper limb variables|Assessment of clinical variables of tetraplegics reach-and-grasp pattern
62519423|NCT02969772|EXPERIMENTAL|Training protocol|Training with electrical stimulation of upper limb
62519424|NCT05717582|EXPERIMENTAL|maximal-cytoreductive therapy|Patients with de novo mCSPC who achieve ≤10 oligopersistent metastases on PSMA PET CT after initial 3-month systemic treatment with apalutamide plus ADT will receive cytoreductive radical prostatectomy with/without PLND and metastasis-directed therapy with radiation.
62519425|NCT05703035|ACTIVE_COMPARATOR|waiting group during staple firing|In this group, the amount of bleeding, bleeding points, postoperative drain amount and laboratory values will be monitored during the operation.
62519426|NCT05703035|ACTIVE_COMPARATOR|staple firing group without waiting for a certain time|In this group, no further intervention will be made, and the same treatment will be given as the 1st group and comparison will be made.
62519427|NCT03621319|ACTIVE_COMPARATOR|Hybrid argon plasma ablation (HAPC)|Eligible participants will be randomized to receive ablation of dysplasia with Hybrid argon plasma coagulation (HAPC) after EMR of visible lesions (if present) has been performed as per standard of care.
62519428|NCT03621319|ACTIVE_COMPARATOR|Radiofrequency ablation (RFA)|Eligible participants will be randomized to receive treatment of dysplasia with RFA after EMR of visible lesions (if present) has been performed as per standard of care.
62519429|NCT01947231|EXPERIMENTAL|Global Postural Re-education|Global Postural Re-education is delivered in a single treatment session each week for nine weeks.
62355821|NCT04749576|ACTIVE_COMPARATOR|Low dose saffron|healthy, mild-moderate ulcerative colitis for low dose
62519430|NCT01947231|ACTIVE_COMPARATOR|Standard manual physical therapy|Standard manual physical therapy is delivered in a single treatment session each week for 9 weeks.
62519431|NCT03353623|EXPERIMENTAL|ISG-Group (Immediate Serious Game)|Children in the ISG-Group first participated in the VR-assisted rehabilitation, which consisted in 8 sessions with immersive virtual environment and wearable haptic devices, and were then crossed over and followed during an intended duration of 6 hours of conventional therapy.
62519432|NCT03353623|EXPERIMENTAL|DSG-Group (Delayed Serious Game)|Children from DSG-Group were followed during an intended duration of 6 hours of conventional therapy before receiving VR-assisted rehabilitation with immersive virtual environment and wearable haptic devices.
62355822|NCT04749576|ACTIVE_COMPARATOR|High dose Saffron|healthy, mild-moderate ulcerative colitis for high dose
62355823|NCT04749576|PLACEBO_COMPARATOR|Placebo|healthy, mild-moderate ulcerative colitis for placebo
62355824|NCT01854593|ACTIVE_COMPARATOR|Bevacizumab injection and vitrectomy|0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
62355825|NCT01854593|SHAM_COMPARATOR|Sham injection and vitrectomy|Sham injection one day before vitrectomy.
62355826|NCT01709214|EXPERIMENTAL|Cebranopadol (GRT6005) Low-Dose Range|Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, and once daily Placebo; oral administration for 15 weeks
62519433|NCT04133649|EXPERIMENTAL|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
62519434|NCT05364996||child with severe asthma|Child eligible for bronchial endoscopy with bronchoalveolar lavage (LBA) for assessment of severe asthma. The diagnosis of asthma being established by a pneumo-pediatrician in the presence of a history of respiratory symptoms such as wheezing, shortness of breath, chest tightness and coughing variable in time and intensity, associated with a variable limitation expiratory flows.
62519435|NCT03452774||Study Group|Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
62519436|NCT04900909||Aortic valve replacement with mechanical valves|
62519437|NCT04900909||Aortic valve replacement with bioprostheses|
62519438|NCT03814941||paper-based anesthesia record|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by paper-based documented anesthesia record."
62519439|NCT03814941||electronic documents|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by electric documented anesthesia record."
62519440|NCT05881902|EXPERIMENTAL|İntervention 1: Cancer awareness training based on the Health Belief Model|"Awareness training based on the Health Belief Model will be given to the participants in the Intervention 1 group during home visits in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made."
62519441|NCT05881902|EXPERIMENTAL|İntervention 2: Standart cancer education|Participants in the Intervention 2 group will be provided with the standard training applied at KETEM by the Ministry of Health on female cancers, which are frequently seen in physical women, during home visits. The training will be held in the form of power-point presentation, question and answer. For 3 months, intervention 2 groups will be applied to reinforce their awareness in standard education (sms reminder).
62519442|NCT04669717|ACTIVE_COMPARATOR|Amoxicilline and Metronidazole for 7 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 7 days~Systemic antibiotics after sub gingival mechanical debridement"
62519443|NCT04669717|ACTIVE_COMPARATOR|Amoxicilline and Metronidazole for 3 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 3 days~Systemic antibiotics after sub gingival mechanical debridement"
62519444|NCT04669717|ACTIVE_COMPARATOR|Azithromycine for 3 days|"Drug: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH~1/d 500mg for 3 days~Systemic antibiotics after sub gingival mechanical debridement"
62148481|NCT05671549|ACTIVE_COMPARATOR|Acute Closed-Lock|The participants will be enrolled in this group regarding the duration (shorter than three months) of their symptoms. The allocated participants will undergo one session of the arthrocentesis procedure. The prefabricated occlusal stabilization splints will be applied. The participants' preoperative, postoperative immediate, and postoperative seventh-day pain intensities and maximum mouth-opening amounts will be recorded and analyzed.
62148482|NCT05642806|EXPERIMENTAL|Mepolizumab|Mepolizumab (100 mg) subcutaneously every 4 weeks
62148483|NCT05642806|PLACEBO_COMPARATOR|Placebo|Placebo 100 mg subcutaneously every 4 weeks
62148484|NCT06428656|EXPERIMENTAL|Postbiotics supplementation|Supplementation of postbiotics for 4 weeks
62355827|NCT01709214|EXPERIMENTAL|Cebranopadol (GRT6005) High-Dose Range|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, and once daily Placebo; oral administration for 15 weeks
62355828|NCT01709214|PLACEBO_COMPARATOR|Placebo|Twice daily Placebo, oral administration for 15 weeks
62355829|NCT01709214|ACTIVE_COMPARATOR|Oxycodone CR|Twice daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams; oral administration for 15 weeks
62355830|NCT01369407||Enrolled Subjects|Enrolled subjects participate for up to 2 years
62355831|NCT00643357|EXPERIMENTAL|A|50% Oxygen/50% Nitrous oxide premix (Kalinox® 170 bar)
62355832|NCT00643357|PLACEBO_COMPARATOR|B|50%Oxygen/50% Nitrogen premix
62148485|NCT06428656|PLACEBO_COMPARATOR|Placebo supplementation|Supplementation of placebo for 4 weeks
62148486|NCT05630859|EXPERIMENTAL|Phase 1:1a Low dose Group|Participants randomized to the 1a Low dose Group receive 2 doses of NgG low dose investigational vaccine.
62148487|NCT05630859|PLACEBO_COMPARATOR|Phase 1:1b Placebo Group|Participants randomized to the 1b Placebo Group receive 2 doses of placebo.
62355833|NCT02168296|PLACEBO_COMPARATOR|No added Plant-based ingredient|No Plant-based ingredient added to starchy meal
62355834|NCT02168296|ACTIVE_COMPARATOR|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
62355835|NCT02168296|ACTIVE_COMPARATOR|High dose added to starchy meal|Plant-based ingredient in high dose added to starchy meal
62355836|NCT02168296|ACTIVE_COMPARATOR|Low dose added to liquid|Plant-based ingredient in low dose added to liquid
62355837|NCT02168296|ACTIVE_COMPARATOR|High dose added to liquid|Plant-based ingredient in high dose added to liquid
62355838|NCT00082329|EXPERIMENTAL|G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers|Participants received subcutaneous injection of G-CSF (10 mcg/kg/day) for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
62355839|NCT01228487||Acute knee pain|Patients with a history of knee pain \< 6 months. The radiologic and arthroscopic OA stadium is less or equal II°. n=20.
62355840|NCT01228487||Chronic knee pain|Clinical manifestation of knee joint OA, radiological and arthroscopic III° or more. n=20
62355841|NCT01228487||Control group|Patients coming for post- primary repair of the cruciate ligament, having no inflammation and no sign of OA. n=10
62355842|NCT04668092|EXPERIMENTAL|Functional dry needling|Functional dry needling for shortened hamstring muscle
62519445|NCT01183325|EXPERIMENTAL|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
62519446|NCT00207948||Therapeutic Dose Adjustment|To adjust the doses of medications to meet target therapeutic concentrations
62519447|NCT05575635|EXPERIMENTAL|fruquintinib + mFOLFOX6 + radiotherapy|fruquintinib + mFOLFOX6 + radiotherapy
62519448|NCT01157897|EXPERIMENTAL|Cohort 1: 15 μg VMP001|15ug VMP001 per vaccination on days -1 or 0, 28, and 84. P. vivax sporozoite challenge on day 98.
62519449|NCT01157897|EXPERIMENTAL|Cohort 2: 30 μg VMP001|30ug VMP001 per vaccination on days 14, 42, and 84. P. vivax sporozoite challenge on day 98.
62519450|NCT01157897|EXPERIMENTAL|Cohort 3: 60 μg VMP001|60ug VMP001 per vaccination on days 28, 56, and 84. P. vivax sporozoite challenge on day 98.
62519451|NCT01157897|OTHER|Control|No Vaccinations given for controls. P. vivax sporozoite challenge on day 98.
62519452|NCT00534794|EXPERIMENTAL|Elestat|
62519453|NCT00534794|ACTIVE_COMPARATOR|Pataday|
62519454|NCT03130114|PLACEBO_COMPARATOR|Control|Placebo mixture, 0.25 ml / kg / day
62148488|NCT05630859|EXPERIMENTAL|Phase 1: 2a Medium dose Group|Participants randomized to the 2a Medium dose Group receive 2 doses of NgG medium dose investigational vaccine.
62148489|NCT05630859|PLACEBO_COMPARATOR|Phase 1: 2b Placebo Group|Participants randomized to the 2b Placebo Group receive 2 doses of placebo.
62148490|NCT05630859|EXPERIMENTAL|Phase 1: 3a High dose Group|Participants randomized to the 3a High dose Group receive 2 doses of NgG high dose investigational vaccine.
62148491|NCT05630859|PLACEBO_COMPARATOR|Phase 1: 3b Placebo Group|Participants randomized to the 3b Placebo Group receive 2 doses of placebo.
62148492|NCT05630859|EXPERIMENTAL|Phase 2: 4a HTD Group|Participants randomized to the 4a highest tolerated dose (HTD) Group receive 2 doses of NgG highest tolerated dose selected from Phase 1.
62355843|NCT03073408|ACTIVE_COMPARATOR|1: Manual control group|The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
62355844|NCT03073408|EXPERIMENTAL|2: PI +Smith group|The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
62355845|NCT00430963|PLACEBO_COMPARATOR|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
62355846|NCT00430963|EXPERIMENTAL|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
62355847|NCT04294095|EXPERIMENTAL|Intervention|During the first four weeks of the MBMM+ program, participants will receive electronic informational handouts covering topics on weight management as well as the benefits and safety concerns related to prenatal physical activity. Starting week 5 of the 12-week intervention, participants will attend two in-person, group physical activity sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics. Sessions will be held on weekday evenings and weekend mornings as these times were preferred by pregnant women. Each session will include both didactic and experiential components to increase knowledge and skill building.
62519455|NCT03130114|EXPERIMENTAL|Azithromycin|Azithromycin mixture (40 mg / ml), 0.25 ml / kg / day
62519456|NCT05839535|ACTIVE_COMPARATOR|BDJ + real tDCS|
62519457|NCT05839535|ACTIVE_COMPARATOR|Exercise + real tDCS|
62519458|NCT05839535|ACTIVE_COMPARATOR|BDJ + sham tDCS|
62519459|NCT05839535|ACTIVE_COMPARATOR|Exercise + sham tDCS|
62519460|NCT05880121||systemic lupus erythematosus|Patients with SLE according to the 1997 ACR, 2012 SLICC or 2019 EULAR/ACR criteria will undergo MRI along with neuropsychological tests, rheumatological evaluation and blood sample collection at baseline and after at least 12 months or during a new neuropsychiatric manifestation. In case of existing MRI with compatible features, they will be used as baseline studies.
62519461|NCT05880121||healthy controls|Subjects with Charlson's Comorbidity Index=0 with no ongoing chronic therapy and no history of immune-mediated disease will undergo a single MRI study, along with neuropsychological tests and blood sample collection. In case of existing MRI with compatible features, no additional studies will be performed in this cohort.
62519462|NCT03500042|EXPERIMENTAL|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
62519463|NCT03500042|EXPERIMENTAL|normal respiratory muscle|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
62148493|NCT05630859|EXPERIMENTAL|Phase 2: 4b dose below HTD Group|Participants randomized to the 4b dose below HTD Group receive 2 doses of NgG dose below the highest tolerated dose selected from Phase 1.
62148494|NCT05630859|PLACEBO_COMPARATOR|Phase 2: 4c Placebo Group|Participants randomized to the 4c Placebo Group receive 2 doses of placebo.
62148495|NCT02696200|EXPERIMENTAL|Subjects Wearing the Q Collar|Subjects wearing the Q collar throughout the football season
62148496|NCT02696200|NO_INTERVENTION|Subjects Not Wearing the Q Collar|Control group of subjects not wearing the q collar
62148497|NCT01122134||20 adults with severe malaria|20 adult patients admitted with severe malaria
62148498|NCT01319032||I. Top-level swimmers|
62519464|NCT03913897|EXPERIMENTAL|virtual reality group|The children in the groups were distracted by virtual reality goggles 2 minutes before venipuncture, until the process was over.
62519465|NCT03913897|EXPERIMENTAL|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
62519466|NCT03913897|NO_INTERVENTION|control group|No intervention was made to children in the control group
62519467|NCT06194006|OTHER|Long term follow-up|"* Formalized and standardized follow-up~* Retrospective data collection~* Biological collections~* Biological collections's centralisation"
62148499|NCT01319032||II. Control|Other swimmers
62355848|NCT04294095|ACTIVE_COMPARATOR|Control|Electronic materials related to various prenatal topics including preparation for birth, birthing options, and responsive parenting will be distributed twice a week for the first 4-weeks of the program. Starting week 5 of the 12-week intervention, participants will attend two in-person, group sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics.
62355849|NCT05441540|EXPERIMENTAL|Treatment Group|Device will be fitted and worn up to two hours daily and participants will log changes in symptom intensity before and during device usage
62355850|NCT01299610|EXPERIMENTAL|GW870086 2.0% &amp; 0.2%|GW870086 2.0%, GW870086 0.2% \&amp; Placebo each applied to a separate specific lesion for 21±2 days.
62355851|NCT01299610|EXPERIMENTAL|GW870086 2.0% & FP 0.05%|GW870086 2.0%, FP 0.05% \&amp; Placebo each applied to a separate specific lesion for 21±2 days.
62355852|NCT01299610|EXPERIMENTAL|GW870086 0.2% & FP 0.05%|GW870086 0.2%, FP 0.05% \&amp; Placebo each applied to a separate specific lesion for 21±2 days.
62355853|NCT04913480|EXPERIMENTAL|Durvalumab and stereotactic body radiation therapy|"1. Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles, starting 1 week before commencement of stereotactic body radiation therapy~2. Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days"
62355854|NCT03763799|EXPERIMENTAL|multiplex PCR strategy|FilmArray® Pneumonia Panel plus
62355855|NCT03763799|ACTIVE_COMPARATOR|standard strategy|
62355856|NCT05420415||High-CSTME|Patients with high tumor microenvironment collagen signature
62355857|NCT05420415||Low-CSTME|Patients with low tumor microenvironment collagen signature
62355858|NCT00990249|EXPERIMENTAL|Busulfan + Clofarabine + Stem Cell Transplant|"Busulfan test dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.~Clofarabine 40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors.~Stem cell infusion on Day 0."
62355859|NCT01929213|EXPERIMENTAL|Udenafil|
62519468|NCT04463290||Knee Osteoarthritis Patients Group|Patients suffering from primary knee osteoarthritis
62519469|NCT04463290||Control Group|Healthy people without suffering from primary knee osteoarthritis
62519470|NCT06453512|OTHER|Main Study|Main Study which also involves the subgroup
62519471|NCT02276079|EXPERIMENTAL|mTBI Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily aerobic exercise intervention lasting 1-week.
62148500|NCT00651326|ACTIVE_COMPARATOR|Antiandrogen; LHRH; Docetaxel, Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel
62148501|NCT00651326|ACTIVE_COMPARATOR|Antiandrogen; LHRH; Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)
62148502|NCT04240197|SHAM_COMPARATOR|Standard Pressure Transducer|Epidural pressure waveforms will be measured by using a standard invasive monitor pressure transducer
62355860|NCT01929213|EXPERIMENTAL|Bosentan|
62355861|NCT01929213|EXPERIMENTAL|Udenafil/Bosentan|
62355862|NCT03932539||Twenty-five de-novo heart transplant recipients|Twenty-five de-novo heart transplant recipients will be enrolled, male and female, aging 18-70 years, receiving TAC in combination with steroids and antiproliferative drugs, either Everolimus or Sirolimus.
62519472|NCT02276079|EXPERIMENTAL|mTBI Non-Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily non-aerobic exercise intervention lasting 1-week.
62519473|NCT02276079|NO_INTERVENTION|Non-injured Reference Group|Non-injured, healthy participants will serve as a reference group for functional outcome measures.
62148503|NCT04240197|ACTIVE_COMPARATOR|CompuFlo|Epidural pressure waveforms will be measured by using the CompuFlo Instrument
62148504|NCT02394912|EXPERIMENTAL|Single-arm|
62148505|NCT01355809|ACTIVE_COMPARATOR|Inhalation Nitrogen/Oxygen|Nitrogen/Oxygen (65%/35%)
62148506|NCT01355809|EXPERIMENTAL|Inhalation Helium/Oxygen|Helium/Oxygen (65%/35%)
62148507|NCT01355809|EXPERIMENTAL|Inhalation gas|Medicinal oxygen 100% via NIV with FiO2 of 0.35
62148508|NCT01884207||orbital tumors|
62148509|NCT03838575|ACTIVE_COMPARATOR|A - NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
62519474|NCT03141879|EXPERIMENTAL|Physical Activity Intervention|HUR resistance training intervention
62519475|NCT03141879|NO_INTERVENTION|Regular care|(Wait-list control)
62519476|NCT03532633||23-27w|preterm infants 23+0-27+6SSW
62519477|NCT03532633||28-31w|preterm infants 28+0-31+6SSW
62519478|NCT03532633||32-34w|preterm infants 32+0 - 34+6SSW
62519479|NCT03532633||35-36w|preterm infants 35+0-36+6 SSW
62519480|NCT03532633||37-42w|term infants 37+0-42+6
62519481|NCT03827564|EXPERIMENTAL|ITN [TrueTear®] - Intranasal Application|Intranasal application of the ITN. Single application at application visit.
62148510|NCT03838575|ACTIVE_COMPARATOR|B - SKIN PREP|"Mechanism: A broad-spectrum antiseptic to clean and prepare the skin prior to surgery.~Supplier: BD"
62355863|NCT03838003|EXPERIMENTAL|Experimental: Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
62355864|NCT03838003|NO_INTERVENTION|No Intervention: Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
62355865|NCT02904187|OTHER|Profound deaf patients|Profound deaf patients with bilateral cochlear implants: Cortical brain activation pattern obtained by PET and EEG
62355866|NCT02904187|OTHER|Healthy volunteers|Healthy volunteers: Cortical brain activation pattern obtained by PET and EEG
62355867|NCT01768338|EXPERIMENTAL|Ofatumumab combined with SB-485232|Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
62355868|NCT02185248|NO_INTERVENTION|Control Group|General clinical counseling in regards to child's BMI category and necessary changes to diet and activity regimen.
62355869|NCT02185248|EXPERIMENTAL|Wellness Plan|Received a wellness action plan. The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
62355870|NCT03587584|EXPERIMENTAL|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
62355871|NCT03587584|ACTIVE_COMPARATOR|bupivacaine|These patients receive an interscalene block with bupivacaine.
62355872|NCT01679561|EXPERIMENTAL|intralipids|Two hundreds patients (group1) with abnormal NK activity results (NKa)will receive intralipids 20% i.v. (9 mg/mL total blood volume -corresponds to 2 mL of intralipids 20% diluted in 250 mL saline; or 18 mg/mL - corresponds to 4 mL of intralipids 20% diluted in 250 mL saline) infusions and their NKa will be tested periodically. The determination of NK cell function will be performed by flow cytometry using K562 cells as targets,then follow up of the patients by the Doppler of endometrial blood follow at the time of luteal phase,and the clinical pregnancy rate.Group(2)of 180 patients will receive placebo.
62355873|NCT03928860|EXPERIMENTAL|OMT Session and Doppler Ultrasonography|"OMT Session Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.~Doppler Ultrasonography Femoral artery diameter and flow evaluated by radiologist.~In the evaluation, the wall contour characteristics of the vessel to be examined were evaluated and the diameter was measured. Color doppler examination was performed to determine whether the vessel contained color filling, patency, flow direction and turbulence.~Peak systolic and end diastolic flow rates and flow pattern and flow rate were measured by spectral examination"
62355874|NCT00092677|EXPERIMENTAL|EZ/Simva 10/40 mg|Ezetimibe 10 mg + Simvastatin 40 mg
62355875|NCT00092677|PLACEBO_COMPARATOR|Placebo|
62355876|NCT04026763|EXPERIMENTAL|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as a US guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy guided prostate biopsy.
62355877|NCT02285712|NO_INTERVENTION|Classical method of peripheral venous catheterization|Classical method will be applied only on arm and forearm.
62355878|NCT02285712|EXPERIMENTAL|Ultrasound guided peripheral venous catheterization|Nurse will use a vascular ultrasound system to orient the catheter toward the peripheral vein. Ultrasound method will be applied only on arm and forearm.
62355879|NCT05806112|EXPERIMENTAL|Integrated Resiliency Training and Task Sharing|A multi-component intervention combining resiliency training and task sharing implemented at the site-level (microsystem).
62355880|NCT05806112|EXPERIMENTAL|Workplace Improvement Learning Collaborative|A workplace improvement learning collaborative implemented at the organization level (mesosystem).
62355881|NCT04229238||Home-dwelling older adults|Older adults (70 +) receiving regular health care from the home nursing service. Setting is two rural municipalities in southern Norway.
62355882|NCT06065904|EXPERIMENTAL|CP with recommended diet|CP children that will follow a recommended menu
62355883|NCT06065904|NO_INTERVENTION|CP with a standard of care nutritional menu|Children with CP that will not be advised on a specific menu
62355884|NCT06065904|EXPERIMENTAL|ASD with recommended diet|Children with ASD that will not be advised on a specific menu
62355885|NCT06065904|NO_INTERVENTION|ASD with a standard of care nutritional menu|Children with ASD that will not be advised on a specific menu
62148511|NCT03838575|OTHER|C - DRAPE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~Mechanism: A thin impregnated plastic sheet applied to the prepared skin prior to incision to maintain sterility.~Supplier: 3M Infection Prevention"
62355886|NCT01229891|PLACEBO_COMPARATOR|Plain yogurt drink|daily intake of two bottle (250 mL) plain yogurt drink
62355887|NCT01229891|EXPERIMENTAL|vitamin D-fortified yogurt drink|daily intake of two bottle yogurt drink fortified with 500 IU vitamin D/250 mL
62355888|NCT01229891|EXPERIMENTAL|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 mL
62355889|NCT03222622|EXPERIMENTAL|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
62355890|NCT03222622|EXPERIMENTAL|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
62355891|NCT03222622|EXPERIMENTAL|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
62355892|NCT03222622|PLACEBO_COMPARATOR|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
62148512|NCT03838575|ACTIVE_COMPARATOR|D - SPONGE|"Mechanism: Small absorbable sponges placed into the wound at the time of closure which deliver high concentrations of antibiotic locally to kill pathogens present that may go on to cause SSI.~Supplier: SERB"
62148513|NCT03838575|OTHER|E - SKIN PREP and DRAPE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~See descriptions in single arms (B \& C)"
62148514|NCT03838575|ACTIVE_COMPARATOR|F - SKIN PREP and SPONGE|See descriptions in single arms (B \& D)
62148515|NCT03838575|OTHER|G - DRAPE and SPONGE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~See descriptions in single arms (C \& D)"
62355893|NCT03379896||Sepsis|Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
62519482|NCT03827564|EXPERIMENTAL|ITN [TrueTear®] - Extranasal Application|Extranasal application of the ITN. Single application at application visit.
62355894|NCT03379896||Control|Age-matched healthy control
62355895|NCT02277340|EXPERIMENTAL|EAPA for Pilonidal Disease|The abbrevition EAPA is used to describe the study. The cohort of pilonidal disease patients treated who do not have an acute abscess or other problems like hydradenitis suppurativa, has been treated by endoscopy assisted fulguration of the inner surface and additional crystallized phenol application for further clean up of the remaining tissue as well as preventing bacterial growth.
62355896|NCT03098524|EXPERIMENTAL|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with 5 acts/minute, tidal volume = 3 ml/kg (ideal body weight) with positive end-expiratory pressure = 5 cmH2O
62355897|NCT03098524|PLACEBO_COMPARATOR|No ventilation (noV arm)|No mechanical ventilation during cardiopulmonary bypass.
62355898|NCT02064205|ACTIVE_COMPARATOR|polydextrose or glucose syrup at breakfast|Breakfast with pre-load four hours before lunch
62355899|NCT02064205|PLACEBO_COMPARATOR|Pre-load with yogurt and polydextrose or glucose later|Breakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
62355900|NCT02890732|EXPERIMENTAL|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
62355901|NCT01688440|EXPERIMENTAL|#1 Respiratory Care Solution|Low sodium physiologically based airway care solution.
62148516|NCT03838575|OTHER|H - SKIN PREP and DRAPE and SPONGE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~See descriptions in single arms (B, C \& D)"
62148517|NCT00753259|EXPERIMENTAL|AF Clinic|
62148518|NCT00753259|ACTIVE_COMPARATOR|Care as Usual|
62148519|NCT06144437||study group|All participants included will be in one study group.
62148520|NCT03973021|EXPERIMENTAL|VSEL Max|Each treatment: 120,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
62148521|NCT03973021|EXPERIMENTAL|VSEL Medium|Each treatment: 90,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
62148522|NCT03973021|EXPERIMENTAL|VSEL Mini|Each treatment: 60,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
62148523|NCT03973021|NO_INTERVENTION|Control|In this group, the patients will receive 20 mL platelet-rich plasma(PRP) treatment and as a control group.
62148524|NCT02042092|ACTIVE_COMPARATOR|Color Doppler Ultrasound (CDUS)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by color Doppler ultrasound
62355902|NCT05552859|EXPERIMENTAL|Gla-300 arm|Gla-300 will be administered once daily for 24 weeks
62355903|NCT05552859|ACTIVE_COMPARATOR|IDeg-100 arm|Ideg-100 will be administered once daily for 24 weeks
62355904|NCT02476344|EXPERIMENTAL|research arm|40 subjects will undergo the experiment protocol, total 3 days, each consisting different training exercises.
62355905|NCT01011218|EXPERIMENTAL|BBT-I + Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~Armodafinil 150 mg/day by mouth."
62355906|NCT01011218|EXPERIMENTAL|Behavioral placebo + Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~Armodafinil 150 mg/day by mouth."
62355907|NCT01011218|SHAM_COMPARATOR|BBT-I without Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~No pharmaceutical intervention."
62355908|NCT01011218|PLACEBO_COMPARATOR|Behavioral placebo without Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~No pharmaceutical intervention."
62355909|NCT03590704|EXPERIMENTAL|Intervention Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region. The bandage will not be applied on the scar. If there are any complications such as itching, redness, discomfort and / or others, the patients will remove the material at home and communicate on return to the institution. They will remain four days approximately for revaluation and intervention suspension.
62519483|NCT00753220|EXPERIMENTAL|VDC2008|Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10\^7, 7.5 x 10\^7, or 1.0 x 10\^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
62519484|NCT01555827|EXPERIMENTAL|Alzheimer Disease|
62519485|NCT01555827|ACTIVE_COMPARATOR|Control|
62519486|NCT02038231|EXPERIMENTAL|Parenting Mindfully Program|Mindfulness program for parents of adolescents provided for 2 hours once per week for 8 weeks.
62355910|NCT06068179|EXPERIMENTAL|intervention group|Mycophenolate Mofetil 0.5 twice daily for 12 months added to methimazole standard therapy.
62519487|NCT02038231|ACTIVE_COMPARATOR|Parent Education Program|Group for parents of adolescents providing handouts and brief education to parents on topics of adolescence, family relations, and risk behaviors. Group meets 3 times over the course of 8 weeks for about 15 minutes per meeting.
62519488|NCT01301508|EXPERIMENTAL|AN2898 ointment, 1%, vs. ointment vehicle|"AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
62519489|NCT01301508|EXPERIMENTAL|AN2728 ointment, 2%, vs. ointment vehicle|"AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
62355911|NCT06068179|ACTIVE_COMPARATOR|control group|Methimazole 15-30mg daily initially, then titrate to maintenance dose. Beta-blocker used when necessary.
62355912|NCT06056765|EXPERIMENTAL|ESWT group|"The therapy will be applied using a focused shock wave device (Minilith, Storz, Swiss) at the pulley of the first extensor channel under ultrasound guidance. Shock wave therapy will be performed with the patient's hand in intermediate between pronation and supination and will be administered once a week, for 3 sessions. For each treatment session, 2000 pulses will be applied with an energy flux density of 0.09 mJ/mm2 (between 0.05 and 0.12 mJ/mm2) and a frequency of 4 pulses per second (4 Hz). Gel will be used between the probe and the skin during applications to ensure conductivity. No local anesthetic will be used. Patients in both groups will be instructed to use a brace during the day for 4 weeks following recruitment."
62355913|NCT06056765|NO_INTERVENTION|Exercise group|Patients will perform exercises for 4 weeks following recruitment. Patients in this group will be taught home exercises to improve the dynamic stability of the thumb metacarpal trapezius joint. The patient is instructed to perform a flexion of the trapeziometacarpal. If the individual is able to complete 10 repetitions with good technique, resistance will be added manually or with rubber bands. If this exercise is painful, they are asked to return to active movement only. Patients in both groups will be instructed to use a brace during the day for 4 weeks following recruitment.
62355914|NCT05003141|EXPERIMENTAL|Single-arm, escalating dose levels|3 + 3 Phase 1 dose escalation design; sequential ascending dose levels.
62355915|NCT03958539|ACTIVE_COMPARATOR|Intervention arm|6 sites out of a total of 12 will act as the intervention sites. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to be provided with bespoke 3-D printed insoles.
62355916|NCT03958539|NO_INTERVENTION|Control|6 sites out of a total of 12 will act as the control sites providing standard care. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to standard care
62355917|NCT01057004||all patients|chronical heart failure and EF ≤ 40 %
62355918|NCT02963415|EXPERIMENTAL|Virtual Reality Cognitive Training|Exergame to stimulate cognition
62355919|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
62355920|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
62355921|NCT06495216|EXPERIMENTAL|Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator|Participants with paroxysmal atrial fibrillation (PAF) will undergo pulmonary vein (PV) ablation procedure with investigational system (pulsed field ablation balloon catheter used in combination with the TRUPULSE generator) until pulmonary vein isolation (PVI) is achieved and confirmed via entrance block. If PVI cannot be achieved with the investigational system, a commercially approved Biosense Webster (recommended) catheter and compatible commercially available generator can be used to complete the procedure.
62355922|NCT05367557||Group A|pneumoperitoneum pressure of 12 mmHg
62355923|NCT05367557||Group B|pneumoperitoneum pressure of 8 mmHg
62355924|NCT04384432|EXPERIMENTAL|Routine Physical Therapy with Thoracic mobility exercise|Combination of Routine Physical Therapy with Thoracic mobility exercise.
62355925|NCT04384432|ACTIVE_COMPARATOR|Routine Physical Therapy|Routine Physical Therapy exercise
62355926|NCT01544686|ACTIVE_COMPARATOR|3M™ Tegaderm CHG IV|Patients receive the 3M Tegaderm CHG IV securement dressing after placement of a central venous catheter.
62355927|NCT01544686|PLACEBO_COMPARATOR|3M™ Tegaderm™ Advanced IV'|Patients receive the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
62355928|NCT03600493|ACTIVE_COMPARATOR|Dexemetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
62355929|NCT03600493|ACTIVE_COMPARATOR|Lidocaine|Lidocaine prepared in a syringe with the same volume of Dexmedetomidine to assure blinding given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
62355930|NCT03983226|EXPERIMENTAL|Surgery|"Intervention:~Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib"
62519490|NCT04922684|ACTIVE_COMPARATOR|Lower austic sub-group|16 times of mimicking emotional expressions
62519491|NCT04922684|EXPERIMENTAL|Higher austic sub-group|16 times of mimicking emotional expressions
62519492|NCT06415266|EXPERIMENTAL|Patients receiving oncoSexology supportive care on proactive|Repeated assessment of the patient's needs in the field of oncosexology. Proposal of a personalized care plan to meet the various needs identified.
62519493|NCT06415266|OTHER|Patients receiving oncoSexology supportive care on request|One-off distribution of a flyer to the patient containing both general information on sexual health and contact telephone numbers and e-mail addresses for oncosexology help
62519494|NCT03235661|EXPERIMENTAL|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
62519495|NCT03235661|ACTIVE_COMPARATOR|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
62519496|NCT04337684||Historical Control|
62519497|NCT04337684||Treated with Copper Histidinate|
62519498|NCT00472797|ACTIVE_COMPARATOR|1|Rebif New Formulation - Non Titrated
62148525|NCT02042092|ACTIVE_COMPARATOR|Magnetic resonance angiography (MRA)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by Magnetic resonance angiography
62355931|NCT03983226|ACTIVE_COMPARATOR|No surgery|Intervention: Drug: Platinum-based chemotherapy and Niraparib
62355932|NCT04001309|EXPERIMENTAL|Infectious diseases physician led|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly~Also including standard of care~* infectious disease consultant on demand~* hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
62355933|NCT04001309|EXPERIMENTAL|Multiprofessional team|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention~Also including standard of care~* infectious disease consultant on demand~* hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
62355934|NCT03943446|PLACEBO_COMPARATOR|Placebo|TAK-018 placebo-matching tablets, orally, twice daily (BID) for up to 27.7 weeks.
62355935|NCT03943446|EXPERIMENTAL|TAK-018 0.30 g Low Dose|TAK-018 0.30 gram (g), tablets, orally, BID for up to 31.7 weeks.
62355936|NCT03943446|EXPERIMENTAL|TAK-018 1.5 g High Dose|TAK-018 1.5 g, tablets, orally, BID for up to 26.1 weeks.
62355937|NCT01860963|ACTIVE_COMPARATOR|IBD patients on immunosuppression|Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.
62355938|NCT01860963|ACTIVE_COMPARATOR|IBD patients off immunosuppressants|Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.
62355939|NCT01860963|ACTIVE_COMPARATOR|Healthy controls|Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.
62355940|NCT03407170|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
62355941|NCT03842215||silver hair people|Exam subject's physical function by a smart physical exam
62355942|NCT00540306||Diagnostic Tool|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
62355943|NCT05269472||Trigeminal Electrophysiology|
62355944|NCT05269472||Controls|
62355945|NCT04348539|EXPERIMENTAL|Balance training|The balance training consists of 3 moments: warm up, main and stretch. Warm-up with mobility exercises for major joints and large muscle groups. The main part will have eight exercise stations divided into: a) five balance exercises (dynamic and static with or without object balance) on a varied floor, b) three agility exercises, and a stretching of the worked muscle groups and a final relaxation.
62355946|NCT04348539|EXPERIMENTAL|Strength training|Muscle strength training will consist of 3 moments: warm up, main and stretch. Warm up with mobility exercises for the main joints and large muscle groups. The main part will include strength exercises with lower and upper limbs with two sets of 6-12 repetitions according to periodization, and a stretching of the muscle groups worked
62355947|NCT04348539|EXPERIMENTAL|Cardiorespiratory endurance training|The older people walking training consists of 3 moments: warm up, main and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed, then walk according to the training cycle, and then a stretching of the main muscle groups. Will be held, twice a week for 45 minutes each session. The training intensity will follow 60-110% of the volume of the 6-minute Test (6MWT) and the Borg Scale at moderate to difficult intervals. the training
62355948|NCT04348539|NO_INTERVENTION|Control group|control group: who will receive educational lectures on health, walking and aging.
62355949|NCT05554718|EXPERIMENTAL|App condition|All participants will receive access to the developed social anxiety disorder (SAD) treatment app for 12 weeks.
62355950|NCT05554718|EXPERIMENTAL|App with accompanying therapy sessions|In addition to being able to use the app to treat social anxiety over a 12-week period, participants will receive a total of 8 video therapy sessions based on cognitive behavioral therapy to accompany their use of the app.
62355951|NCT05554718|NO_INTERVENTION|Waitlist control condition|Delayed use of the mobile application after 12 weeks.
62355952|NCT03842956|ACTIVE_COMPARATOR|Primary wound healing|Primary woundclosure in Allgöwer suture technique
62355953|NCT03842956|NO_INTERVENTION|Secondary wound healing|no closure, open wound healing
62355954|NCT02669199|EXPERIMENTAL|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
62355955|NCT02628951|EXPERIMENTAL|Ramucirumab + Paclitaxel|"Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.~Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason."
62148526|NCT01333709|EXPERIMENTAL|Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy within 2-4 weeks after the end of the induction chemotherapy."
62355956|NCT06302998|EXPERIMENTAL|DEX-PRESSIN|This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
62355957|NCT06302998|ACTIVE_COMPARATOR|Standard-of-care group|This group will receive conventional treatment according to the Surviving Sepsis Campaign 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive dexmedetomidine.
62355958|NCT04688216||MDRO|
62355959|NCT04688216||Non-MDRO|
62355960|NCT01877941|ACTIVE_COMPARATOR|Cardiac output monitoring|Patients undergoing surgery who will have their cardiac output monitored by pulmonary artery catheter (PAC) and endotracheal cardiac output monitoring (ECOM) during surgery and during post-surgical recovery, will also have sensors placed on the arm, finger and leg to calculate pulse wave transit time (PWTT) using the estimated Continuous Cardiac Output system (ecCCO).
62355961|NCT05470712||Plasma from women with preeclampsia|Plasma collected from women who developed preeclampsia during pregnancy will be analyzed for mechanism of NETs formation.
62148527|NCT01333709|OTHER|Arm B: RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
62148528|NCT01333709|OTHER|Arm C: RCT Cap 50 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
62148529|NCT01333709|EXPERIMENTAL|Bras D: RCT Cap 60 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 60 grays (2Gy/day, 5 days a week, 6 weeks, boost 14 Gy)."
62355962|NCT05470712||Plasma from women with normal pregnancies|Plasma collected from women with normal pregnancies will be analyzed for mechanism of NETs formation.
62148530|NCT01273298|EXPERIMENTAL|Bisoprolol|
62355963|NCT02505594||OSA Group|Apnea-hypopnea index (AHI) ≥ 15 events/h
62519499|NCT00472797|ACTIVE_COMPARATOR|2|Rebif New Formulation - Titrated
62519500|NCT02865395|EXPERIMENTAL|Pre-operative Suppository|A B\&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
62148531|NCT01273298|PLACEBO_COMPARATOR|Sugar pill|
62148532|NCT01157195|ACTIVE_COMPARATOR|CI therapy|
62355964|NCT02505594||Control Group|Apnea-hypopnea index (AHI) \< 5 events/h
62148533|NCT01157195|EXPERIMENTAL|Tele-AutoCITE|AutoCITE stands for Automated Constraint Induced Therapy Extender.
62148534|NCT05119192||Veterans with Dysvascular Lower Limb Amputation|Self-report assessments, performance-based assessments, and optional individual interview with Veterans with dysvascular lower limb amputation.
62355965|NCT03097029|EXPERIMENTAL|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
62355966|NCT01340391|EXPERIMENTAL|splinting method|A new splinting method has been invented. This is a study using the splint / cast in treatment of distal radius fractures.
62355967|NCT00065442|PLACEBO_COMPARATOR|APC-Placebo|
62355968|NCT00065442|ACTIVE_COMPARATOR|Sipuleucel-T|
62355969|NCT00888615|EXPERIMENTAL|Treatment (paclitaxel, elesclomol sodium)|Patients receive paclitaxel IV over 1 hour and elesclomol sodium IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients who are currently on treatment must not be dosed with elesclomol sodium after 12/31/2015. All other study procedures, with the exception of elesclomol sodium administration and paclitaxel administration, should continue in accordance with protocol requirements. Any treatment given after 12/31/2015, including continuation of paclitaxel, will be considered off study.
62355970|NCT02877667|EXPERIMENTAL|Open label device treatment|Up to four passes with Q-Switched laser alternating with acoustic wave device
62519501|NCT02865395|ACTIVE_COMPARATOR|Post-operative Suppository|A B\&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
62148535|NCT06240351|EXPERIMENTAL|Baricitinib|All patients will be treated with the active product, Baricitinib. Each patient will take 4mg of Baricitinib daily for 36 weeks.
62148536|NCT03133572|EXPERIMENTAL|Supraglottic airway|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
62148537|NCT03133572|ACTIVE_COMPARATOR|Face-mask|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
62148538|NCT00519935|EXPERIMENTAL|Multisystemic Therapy|In-home, intensive family therapy
62148539|NCT00519935|NO_INTERVENTION|Standard Medical Care (TAU)|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
62148540|NCT04784988|EXPERIMENTAL|PROPEL-like arm|EHL-FVIII prophylaxis targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
62148541|NCT04784988|ACTIVE_COMPARATOR|Control arm|standard treatment with FVIII concentrate according to current guidelines
62148542|NCT04693637|EXPERIMENTAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
62148543|NCT00861874|EXPERIMENTAL|Treatment|
62148544|NCT01349998|EXPERIMENTAL|Safety Population|
62148545|NCT03396445|EXPERIMENTAL|Arm 1: Boserolimab|Participants receive escalating doses of boserolimab via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
62148546|NCT03396445|EXPERIMENTAL|Arm 2: Boserolimab + Pembrolizumab|Participants receive escalating doses of boserolimab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
62355971|NCT04145713|EXPERIMENTAL|Probiotic group|
62355972|NCT04145713|PLACEBO_COMPARATOR|Placebo group|
62355973|NCT03381209|EXPERIMENTAL|Group A|Sugammadex given in a dose of 2mg/kg based on ideal body weight
62355974|NCT03381209|EXPERIMENTAL|Group B|Sugammadex given in a dose of 2mg/kg based on adjusted body weight
62355975|NCT03381209|EXPERIMENTAL|Group C|Sugammadex given in a dose of 2mg/kg based on actual body weight
62355976|NCT02098057|PLACEBO_COMPARATOR|Placebo|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
62519502|NCT02865395|PLACEBO_COMPARATOR|Rectal Exam|Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.
62519503|NCT05460559|ACTIVE_COMPARATOR|Group A (p-PCNL) procedure|In lithotomy position, . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
62519504|NCT05460559|EXPERIMENTAL|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
62148547|NCT03396445|EXPERIMENTAL|Arm 3: Boserolimab + Pembrolizumab + Pemetrexed + Carboplatin|Participants receive boserolimab at the selected dose via IV infusion PLUS pembrolizumab 200 mg via IV infusion PLUS pemetrexed 500 mg/m\^2 via IV infusion PLUS carboplatin Area Under the Curve (AUC) 5 mg/mL/min via IV infusion, all given on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
62148548|NCT03396445|EXPERIMENTAL|Arm 4: Boserolimab + Pembrolizumab + Nab-paclitaxel|Participants receive boserolimab at the selected dose via IV infusion PLUS pembrolizumab via IV infusion PLUS nab-paclitaxel 100 mg/m\^2 via IV infusion. Boserolimab and pembrolizumab will be given on Day 1 of each 6-week cycle (Q6W). Nab-paclitaxel will be given on a 3-week on (Days 1, 8 and 15)/ 1-week off schedule every 28 days. Boserolimab and pembrolizumab will be given for up to a total of 18 cycles (approximately 2 years).
62148549|NCT03368274|EXPERIMENTAL|Signal arm study|Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.
62148550|NCT01477866|EXPERIMENTAL|citogenex|citogenex + conventional therapy
62148551|NCT01477866|ACTIVE_COMPARATOR|conventional therapy|conventional therapy
62148552|NCT01337388||Cohort|
62148553|NCT05208788||Renal transplant patients - group 1|Renal transplant patients with stable renal function parameters (mean SCr (or cystatin C) or mean eGFR based on creatinine and / or cystatin C defined as changes ≤ ±15 % for at least three consecutive ambulatory controls).
62148554|NCT05208788||renal transplant patients - group 2|Renal transplant recipients with stable renal function at inclusion, facing a pre-defined event during the course of the study. Pre-defined events are Acute Rejection (AR), viral transplant-associated infection (e.g. BKV), bacterial infection (febrile urinary tract infection (fUTI)), calcineurin-inhibitor (CNI) toxicity, and acute tubular necrosis (ATN).
62148555|NCT05208788||Patients with Chronic Kidney Disease Stage IV and V (CKD IV-V) - group 3|Patients with CKD IV-V (and maintained urine output, without renal replacement therapy and without pre-defined events).
62148556|NCT05208788||Healthy controls|Healthy children serve as control group
62148557|NCT04549688|EXPERIMENTAL|Focal therapy|
62355977|NCT02098057|ACTIVE_COMPARATOR|Gluten|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
62355978|NCT05976477|EXPERIMENTAL|Intervention|Patients randomized to intervention arm during the 12 weeks after randomization will receive on their smartphone and/or via e-mail, information materials such as videos, images and recipes for reminders specifically designed to make patients aware on the importance of reducing dietary salt intake and suggestions on how to do it. The educational interventions will be delivered once a week. The main objective of the educational interventions is to spread knowledge about the health risks of excessive salt intake, the actual amount of salt in food, measures to reduce salt intake (e.g. use spices, eat fresh fruits and vegetables, check food labels, gradually reduce the salt in favorite recipes, avoid putting salt and salty sauces on the table, etc.). The interventions, conceived with nutritionists, will be delivered once a week to the participants and to their caregivers and/or the closest family member, involved in the food shopping and the preparation of meals.
62355979|NCT05976477|NO_INTERVENTION|Control|Patients randomized to Control Group will only receive short tips on controlling blood pressure.
62355980|NCT03682939|EXPERIMENTAL|Single arm|Single arm, open-label, all participants will receive both Bexsero® (meningitis B vaccine) and Menveo® (meningitis ACWY vaccine) vaccines.
62355981|NCT02465242||NPi greather than 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi greater than 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
62355982|NCT02465242||NPi less than or equal to 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi less than or equal to 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
62355983|NCT02879370|EXPERIMENTAL|TICRANT|Transanal Inspection and management of low ColoRectal Anastomosis
62355984|NCT01022151|PLACEBO_COMPARATOR|Placebo [group P]|
62355985|NCT01022151|ACTIVE_COMPARATOR|Aminophylline 2 mg/Kg [group A2]|
62519505|NCT03746548|OTHER|CM-ADHEAR|First patients use the Contact Mini (conventional bone conduction device used with a soft band or headband) then ADHEAR (adhesive bone conduction device)
62519506|NCT03746548|OTHER|ADHEAR - CM|First patients use ADHEAR (adhesive bone conduction device) then CM (conventional bone conduction device used with a soft band or headband)
62148558|NCT02954783|EXPERIMENTAL|High Intensity Interval Training|The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
62148559|NCT02954783|ACTIVE_COMPARATOR|Usual Care Observational Control|Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
62148560|NCT05870995|EXPERIMENTAL|CLAGE-VEN-RIC-Conditioning|"Cladribine: 5mg/m2 day -21 to d -17 cytarabine: 1g/m2 day -21- to d -17 etoposide: 100mg/m2 day -17 to -15 venetoclax: 100mg day-21; 200mg day -20, 400mg day -19 to day-3 Fludarabine: 30mg/m2 day -7 to -3 Busulfan: 3.2mg/kg day -6 to -5 Melphalan: 50mg/m2 day -4 to -3. or Fludarabine 30mg/m2 day -7 to -3 Total marrow irradiation day-5 to -3 PBSC: day 0~Conditioning regimen cane delayed to in patients with ongoing active infection or work-up of donors after CLAGE-VEN chemotherapy based on clinicians' decision. Patients receiving all-HSCT in cytopenia are classified as sequential while patients with recovered CBC are considered as bridging transplantation."
62148561|NCT01186809|EXPERIMENTAL|Cytokine Induced Killer|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
62519507|NCT02646449|ACTIVE_COMPARATOR|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
62519508|NCT02646449|PLACEBO_COMPARATOR|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
62519509|NCT05638841||atrial fibrillation|After radiofrequency ablation of patients with atrial fibrillation
62519510|NCT04624347|EXPERIMENTAL|Acess to Videos and Movement curves|with caregivers' access to videos and movement curves (4 days)
62148562|NCT00837044|ACTIVE_COMPARATOR|1|Treximet, cognitive testing
62148563|NCT00837044|PLACEBO_COMPARATOR|2|Placebo, Cognitive testing
62148564|NCT05583656||Edwards Inspiris Resilia Valve|
62148565|NCT03223688|EXPERIMENTAL|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training. Said therapists assisted the caregivers in improving their nurturing and parenting skills with their children, as well as their techniques with regards to influencing them.
62148566|NCT03223688|EXPERIMENTAL|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
62148567|NCT03223688|ACTIVE_COMPARATOR|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
62148568|NCT04288388|EXPERIMENTAL|massage group|Immediately before the episiotomy repair was started (after exit of placenta and applying local anesthetic agent), women assigned to the study (massage) group were asked to place plastic gloves filled with ice pieces in the LI4 point on hand. This application was made for 5 minutes to the right hand and for 5 minutes to the left hand. The episiotomy was opened by the same midwife as all the women to the right mediolateral and repaired by the same midwife with the same technique and material.The ice massage was repeated until the episiotomy repair was over; total massage time and episiotomy repair time were recorded. Women were asked to mark the perceived pain level before the application and at the end of the application using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair).
62148569|NCT04288388|NO_INTERVENTION|Control group|I the control group women were not excluded from routine practice; women were asked to mark the perceived pain level before episiotomy repair begin and at the end the repair using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair) like the study (massage) group.
62355986|NCT01022151|ACTIVE_COMPARATOR|Aminophylline 3 mg/Kg [group A3]|
62355987|NCT01022151|ACTIVE_COMPARATOR|Aminophylline 4mg/Kg [group A4]|
62355988|NCT01022151|ACTIVE_COMPARATOR|Aminophylline 5 mg/Kg [group A5]|
62355989|NCT01022151|ACTIVE_COMPARATOR|Doxapram 1 mg/kg [group D]|
62519511|NCT04624347|NO_INTERVENTION|No Acess to Video and Movement curves|without caregivers' access to videos and movement (4 days)
62519512|NCT02306057||Pre BCPC|Children undergoing catheterization before Bidirectional CavoPulmonary Connection (BCPC) procedure
62519513|NCT02306057||BCPC surgery|Children undergoing surgical BCPC procedure
62519514|NCT02306057||Pre TCPC|Children undergoing catheterization before Total CavoPulmonary Connection (TCPC )procedure
62519515|NCT02306057||TCPC surgery|Children undergoing surgical TCPC procedure
62519516|NCT02224573|EXPERIMENTAL|GWP42003-P|
62519517|NCT04450849|EXPERIMENTAL|collagen membrane associated to anorganic bone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio) associated to anorganic bovine bone matrix + collagen (Bio-Oss® Collagen) . The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
62519518|NCT04450849|ACTIVE_COMPARATOR|collagen membrane alone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio). The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
62519519|NCT01000493|EXPERIMENTAL|Orvepitant 60 mg|60 mg/day
62519520|NCT01000493|PLACEBO_COMPARATOR|Placebo|
62519521|NCT05618535|SHAM_COMPARATOR|Zero position|All monitoring was done from 9 to 11 a.m., and the whole monitoring process was carried out in a specific and quiet environment at 20-24℃ to avoid other auditory and visual stimuli. After 10min of the relaxed supine position, the blood pressure, heart rate, and blood flow velocity of the middle cerebral artery were measured in the 0° position for 5min.
62519522|NCT05618535|EXPERIMENTAL|30 degrees position|Within 30 seconds after the 0° position measurement completion, the subjects were transferred to the 30° position and rested for 15 minutes under the 30° position. In other words, a washout period of 15 minutes was established between two measurements to ensure the stability of vital signs and avoid confounding effects. The blood pressure, heart rate, and blood flow velocity of the middle cerebral artery were measured again for 5 minutes after the vital signs were stable.
62519523|NCT02264093|EXPERIMENTAL|Talsaclidine with Propranol|
62519524|NCT02264093|ACTIVE_COMPARATOR|Propranolol|
62519525|NCT02264093|ACTIVE_COMPARATOR|Talsaclidine|
62355990|NCT01551472||3DKnee™ with e-plus Insert|Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
62355991|NCT01241656|EXPERIMENTAL|Mail DVD|
62355992|NCT01241656|EXPERIMENTAL|Invite to SMA to view and discuss DESI|
62355993|NCT01241656|EXPERIMENTAL|SMA and DVD|
62355994|NCT01241656|NO_INTERVENTION|Encouraged to talk to physician|
62355995|NCT01504971||Gastroesophageal reflux disease (GERD)|
62355996|NCT00878891|ACTIVE_COMPARATOR|1. Conventional glucose monitoring|Discontinuous glucose monitoring - GlucoDay Device with Continue record blinded
62519526|NCT02759770||ARDS|ARDS patients after cardiac surgery
62519527|NCT02759770||non-ARDS|non-ARDS patients after cardiac surgery
62519528|NCT02759770||propective group|patients of cardiac surgery including ARDS and non-ARDS patients
62355997|NCT00878891|EXPERIMENTAL|2. Conventional glucose monitoring + Glucoday|Continuous glucose monitoring - GlucoDay device with Continue record displayed
62355998|NCT01676441|EXPERIMENTAL|cellgram-spine|posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10\^7 and 3.2 X10\^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively
62355999|NCT01896739|EXPERIMENTAL|Experimental group with 0-2-4-6 schedule|HB at 0, Eutravac at 2-4-6
62356000|NCT01896739|ACTIVE_COMPARATOR|Active comparator group with 0-2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
62356001|NCT01896739|EXPERIMENTAL|Experimental group with 2-4-6 schedule|Eutravac at 2-4-6
62356002|NCT01896739|ACTIVE_COMPARATOR|Active comparator group with 2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
62356003|NCT04639908||barriers|find out what are the barriers
62356004|NCT04639908||facilitators|find out what are the facilitators
62356005|NCT04367792||Patients died with Covid-19 disease|Sample of patients died with Covid-19 disease and pulmonary disease
62356006|NCT04367792||Patients died with Covid-19 and cardiovascular disease|Sample of patients died with Covid-19 disease and pulmonary disease with clear cardiovascular involvement
62356007|NCT04367792||Patient died with myocarditis|Sample of patient died with different types of myocarditis without Covid-19 disease. These samples are used as control and are part of database of previously collected samples of CVPath Institute Inc.
62356008|NCT03118076|PLACEBO_COMPARATOR|Group R|Nerve blocks were administered with 0.3% ropivacaine without dexmedetomidine.
62356009|NCT03118076|EXPERIMENTAL|Group RD|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
62356010|NCT03182842|EXPERIMENTAL|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
62356011|NCT03182842|ACTIVE_COMPARATOR|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
62356012|NCT04530396|EXPERIMENTAL|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
62356013|NCT04530396|PLACEBO_COMPARATOR|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
62356014|NCT03461185|EXPERIMENTAL|EGFR-TKI plus anti-angiogenesis|EGFR-TKI(erlotinib or gefitinib) plus anti-angiogenesis(endostatin or apatinib or anlotinib)
62356015|NCT03461185|ACTIVE_COMPARATOR|EGFR-TKI|EGFR-TKI(erlotinib or gefitinib)
62356016|NCT01095341||THP|THP: patients undergoing parathyroidectomy according to tertiary hyperparathyroidism
62356017|NCT01095341||Other causes|patients with hyperthyroidism not caused by parathyroidectomy
62356018|NCT04969432|EXPERIMENTAL|Telerehabilitation|
62356019|NCT04969432|EXPERIMENTAL|Face-to-face|
62356020|NCT00456885|PLACEBO_COMPARATOR|Exenatide First|Started on Exenatide, 3 week washout, start placebo
62356021|NCT00456885|EXPERIMENTAL|Placebo First|Started on placebo, 3 week washout, start exenatide
62356022|NCT02966353|EXPERIMENTAL|All Subjects|10 mg BID (2 tablets of 5mg) was self-administered as starting dose for all patients. This dose was maintained for the first 12 weeks and titrated up thereafter unless they had met criteria for dose hold or dose reduction. Dose was to have been increased or decreased per standardized dosing paradigm and not to have exceeded 25 mg bid.
62519529|NCT04263428|EXPERIMENTAL|Irregular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights, including an adaptation night and a baseline night of 7.5 h time in bed (0:00-7:30). Afterwards, they are instructed to sleep in bed on a schedule alternated between 6 h, i.e. 1:30-7:30, and 9 h, i.e. 22:30-7:30).
62519530|NCT04263428|NO_INTERVENTION|Regular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights of 7.5 h time in bed (0:00-7:30).
62519531|NCT03314818||Ultrasound 3D Imaging|To investigate natural history of subclinical atherosclerosis as determined by 3D carotid ultrasound.
62519532|NCT04024293|EXPERIMENTAL|All participants|All patients will be follow the same procedures and be placed the investigational device
62519533|NCT00970008|ACTIVE_COMPARATOR|Massage 30 min - 2x wk for 4 wks & 1x wk for 4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
62519534|NCT00970008|ACTIVE_COMPARATOR|Massage 60 min - 2x wk for 4 wks & 1x wkly for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
62519535|NCT00970008|ACTIVE_COMPARATOR|Massage 30 min sessions - 1x/wk for 8wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
62148570|NCT05068232|EXPERIMENTAL|Participants With Extensive Small Cell Lung Cancer (All Participants)|"This arm will involve all participants in the study who have extensive small cell lung cancer that has not responded to previous treatments. All participants will receive the same treatment of study drugs and radiation treatment in cycles (a specific window of time).~You will receive up to four 21-day cycles of chemotherapy using carboplatin, etoposide and durvalumab (immunotherapy) as part of a standard care treatment plan recommended by your doctor. These drugs will be combined with ablative radiation treatment during the second cycle of chemotherapy.~After completing these four cycles of chemotherapy (with radiation treatment added in cycle 2), you will continue to receive a fixed dose of durvalumab until your cancer progresses, you experience serious side effects, you decide to no longer be part of the study or the study doctor request to take you off the study for medical reasons."
62148571|NCT05488990|EXPERIMENTAL|Single arm with several test fields|Altogether six test fields (two active formulations, their corresponding vehicles and two comparators) located on the torso, or the extremities were randomly assigned for treatments per subject.
62148572|NCT01945372|EXPERIMENTAL|EEG NeuroFeedback - real feedback|Thw women in the experimental group will receive accurate realtime feedback corresponding to their performance on the task.
62148573|NCT01945372|SHAM_COMPARATOR|EEG NeuroFeedback - sham feedback|The women in the sham group will receive neural feedback from another person in the study, thus unrelated to their mental practice
62148574|NCT02409407|EXPERIMENTAL|Oral Misoprostol|oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.
62148575|NCT02409407|EXPERIMENTAL|Vaginal Misoprostol|vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)
62148576|NCT02409407|PLACEBO_COMPARATOR|Placebo|oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.
62148577|NCT02377544|PLACEBO_COMPARATOR|Placebo|Saccharum lactis
62148578|NCT02377544|EXPERIMENTAL|Probiotic|Bifidobacterium animalis lactis
62148579|NCT05687214|EXPERIMENTAL|Experimental group|Each participant in the experimental group will receive eight weekly osteopathic manipulative treatments within eight weeks. Each treatment session will include several specific manipulations.
62356023|NCT03437213|EXPERIMENTAL|Total intravenous anesthesia group|propofol, and fentanyl-based regimen.
62519536|NCT00970008|ACTIVE_COMPARATOR|Massage 60 min sessions - 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
62519537|NCT00970008|NO_INTERVENTION|Usual Care Control|Continue on usual care for eight (8) week period.
62519538|NCT01633502|PLACEBO_COMPARATOR|Conventional circulatory support|Patients randomized to conventional circulatory support.
62519539|NCT01633502|ACTIVE_COMPARATOR|Impella|Patients randomized to Impella CP
62148580|NCT05687214|NO_INTERVENTION|Control Group|Participants in the control group will not receive any treatment.
62148581|NCT00224835|EXPERIMENTAL|1|Mindfulness Based Stress Reduction Class
62148582|NCT00224835|EXPERIMENTAL|2|Cardiac Education Class
62148583|NCT06380959|EXPERIMENTAL|Art Based Activity Group|The art-based activity module consists of 3 activities planned for 7 days.
62148584|NCT06380959|NO_INTERVENTION|Control Group|No intervention
62148585|NCT00476294||Group 1: G + Placebo|G-CSF plus Placebo Arm (G + Placebo)
62148586|NCT00476294||Group 2: G + AMD3100|G-CSF plus AMD3100 Arm (G + AMD3100)
62148587|NCT01840085|EXPERIMENTAL|0.03% DSC127 topical gel|
62148588|NCT04373291|ACTIVE_COMPARATOR|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
62148589|NCT04373291|PLACEBO_COMPARATOR|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine.
62148590|NCT04865744|ACTIVE_COMPARATOR|Oral semaglutide 7 mg|The semaglutide 7 mg tablet taken orally with upto120 ml of water.
62148591|NCT04865744|PLACEBO_COMPARATOR|Placebo|The placebo tablet taken orally with 120 ml of water.
62148592|NCT04865744|ACTIVE_COMPARATOR|Oral semaglutide 14 mg|The semaglutide 14 mg tablet taken with upto 120 ml of water.
62148593|NCT06456359|EXPERIMENTAL|Pasireotid treatment single arm|Adults receive 60 mg via intragluteal depot injection every 28±3 days, adolescents 60 mg (body surface area \[BSA\] \>1.6 m²) or 40 mg (BSA 1.1-1.6 m2) via intragluteal depot injection every 28±3 days.
62148594|NCT06001515|ACTIVE_COMPARATOR|Dual scan protocol|Two CBCT scans will be made.One while the patient wearing the radiographic stent and another CBCT for the radiographic stent alone.
62148595|NCT06001515|EXPERIMENTAL|Dual scan protocol +3D facial scan record|3D face scan record will be made plus Two CBCT scans. One while the patient wearing the radiographic stent and another CBCT for the radiographic stent alone.
62356024|NCT03437213|ACTIVE_COMPARATOR|Total intravenous plus block group|ultrasound guided paravertebral block before induction then propofol and fentanyl maintenance.
62356025|NCT04617899|EXPERIMENTAL|Novasight IVUS/OCT|A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter
62356026|NCT01767181|NO_INTERVENTION|A|Control group without intervention
62356027|NCT01767181|EXPERIMENTAL|B|Intensive light therapy during the first half of the night shift
62356028|NCT01767181|EXPERIMENTAL|C|Exercise before the beginning of the night shift
62356029|NCT01767181|EXPERIMENTAL|D|Exercise after the end of the night shift
62519540|NCT03804398|EXPERIMENTAL|optimal PEEP group|The study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained
62519541|NCT03804398|ACTIVE_COMPARATOR|PEEP level of 5 cmH2O group|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
62519542|NCT01299805|EXPERIMENTAL|Vortioxetine|Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.
62519543|NCT01299805|PLACEBO_COMPARATOR|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.
62519544|NCT03223948|ACTIVE_COMPARATOR|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
62519545|NCT03223948|ACTIVE_COMPARATOR|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
62519546|NCT03223948|ACTIVE_COMPARATOR|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
62519547|NCT00662181||H, NH|HIV positive patients with and without lipodystrophy
62519548|NCT05626699|OTHER|RT's in ICU|We will collect ventilator pressure, flow, volume, oxygen and breathing pattern data, etc, as well as arterial blood-gas exchange and hemodynamic data of adults attached to ventilators. the RRT's will treat patients as normal without the assistance of the RT Assistant for the pre-intervention phase and will be observed collecting the same data and performing patient care with the assistance of the RT Assistant during the intervention phase. The RRTs will then be given a likert scale questionnaire on the use of the RT Assistant.
62519549|NCT03088618|EXPERIMENTAL|Patients with septal deformity|To evaluate the safety and efficacy of surgical material for nasal septoplasty in septal deformity patients with nasal obstruction
62519550|NCT02621801|EXPERIMENTAL|Intervention|Stress Management and Resiliency Training for Residents (SMART-R)
62519551|NCT02621801|ACTIVE_COMPARATOR|Waitlist Control|The control group will receive the same intervention (SMART-R) after the experimental group.
62148596|NCT03713580|EXPERIMENTAL|Venetoclax+BEAM x 1 cycle prior to ASCT|"Venetoclax dose escalation cohorts + BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) begin with dose level 1 (800mg on Day -7 and Day -6). The dosing cohorts are escalated in a 3 + 3 design but with increasing duration instead of increasing dosage.~Carmustine 300 mg/m2 by IV over 2 hours on Day -7.~Etoposide 100 mg/m2 by IV over 6 hours daily for 4 consecutive days, Day-6 through Day-3.~Cytarabine 200 mg/m2 by IV over 2 hours every 12 hours for 3 consecutive days, Day-6 through Day-4.~Melphalan 140 mg/m2 by IV over 30 minutes or IV push once on Day -2.~Following V+BEAM therapy, participants will receive Autologous Stem Cell Transplant (ASCT): infusion of previously collected autologous stem cells and supportive care per institutional guidelines"
62148597|NCT02078518||Multiple Myeloma|Questionnaires will be given to patients for completion.
62148598|NCT00917098|EXPERIMENTAL|Behavior Therapy|Participants will receive behavior therapy during Phases 1 and 2.
62148599|NCT00917098|PLACEBO_COMPARATOR|Supportive Counseling|Participants will receive supportive counseling during Phase 1 and will not participate in Phase 2.
62148600|NCT03162614|ACTIVE_COMPARATOR|AduFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
62148601|NCT03162614|EXPERIMENTAL|2PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
62356030|NCT05803369|EXPERIMENTAL|Regulating Together (RT)|Participants will receive Regulating Together -the emotion dysregulation intervention
62148602|NCT03162614|EXPERIMENTAL|PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
62356031|NCT05803369|ACTIVE_COMPARATOR|Achieving Independence and Mastery in School (AIMS)|Participants will receive AIMS, the academic functioning/organizational skill intervention.
62356032|NCT05889351|PLACEBO_COMPARATOR|Placebo|Vehicle treatment
62356033|NCT05889351|ACTIVE_COMPARATOR|Cohort 1|For all subjects, the IMP was applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours). For subjects in Cohort 1, this was followed by 4 additional applications: on Day 1 at 12 hours, on Day 2 at 24 and 36 hours, and on Day 3 at 48 hours.
62519552|NCT04051684|EXPERIMENTAL|TAP, Bupivacaine|This group will receive general anesthesia and at the end of the operation, but still in the operating room, a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
62519553|NCT04051684|NO_INTERVENTION|No intervention|General anesthesia
62710974|NCT03973957|ACTIVE_COMPARATOR|Intervention Arm|"An indwelling pleural catheter (IPC) will be placed during this visit. After complete drainage of the effusion, a chest x-ray will be done to determine if full lung reexpansion occurs. If there is lack of full lung re-expansion the patient will be excluded from the study at this time. If full lung re-expansion is present, the patient will receive an intravenous line (IV) by our nursing staff for analgesia prior to talc administration and will be pre-treated with 25 mcg of IV fentanyl.~Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will then be administered through the IPC. The IPC will then be connected to a circuit that will consist of the IPC connected to a 4-liter fluid drainage collection bag via a one-way Heimlich valve (picture of set up included in additional documents)."
62710975|NCT00172809|ACTIVE_COMPARATOR|1|Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks
62710976|NCT00172809|ACTIVE_COMPARATOR|2|Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks
62148603|NCT03162614|EXPERIMENTAL|Adu2Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
62148604|NCT03162614|ACTIVE_COMPARATOR|Adu1Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
62148605|NCT03162614|OTHER|Control Group|Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.
62148606|NCT03609450|ACTIVE_COMPARATOR|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
62148607|NCT03609450|OTHER|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
62519554|NCT03982576|EXPERIMENTAL|CS Relapse Prevention|"Participants will receive 4 group sessions of a novel culturally specific, CBT-based intervention. They will also receive Path2Quit, a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Notably, CS relapse prevention will incorporate surface and deep structure elements,17 including race-matched interventionists, religion/spirituality, discussion of race-related stress, traditional values (e.g., collectivism), culturally specific recipes, etc.~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
62710977|NCT03098095|EXPERIMENTAL|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
62710978|NCT03098095|EXPERIMENTAL|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
62148608|NCT05352854|EXPERIMENTAL|Health control|emmetropia/low myopia (equivalent spherical lens \> -3.00d, astigmatism ≤ 1.5d), best corrected visual acuity ≥1.0
62148609|NCT05352854|EXPERIMENTAL|High myopia|Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm
62148610|NCT05352854|EXPERIMENTAL|Primary open angle glaucoma|emmetropia/low myopia (equivalent spherical lens \> -3.00d, astigmatism ≤ 1.5d), diagnosed as POAG
62148611|NCT05352854|EXPERIMENTAL|HM-POAG|Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm，diagnosed as POAG
62356034|NCT05889351|ACTIVE_COMPARATOR|Cohort 2|For all subjects, the IMP was applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours). For subjects in Cohort 2 the IMP was likewise applied 4 times during the 4 ½-hour period (on Day 1 at 0, 1 ½, 3 and 4½ hours), but was followed by 2 applications: on Day 1 at 12 hours and on Day 2 at 36 hours.
62356035|NCT02320968|EXPERIMENTAL|Patients with nocturnal extraesophageal reflux|This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.
62356036|NCT04702984|EXPERIMENTAL|LID021201|LID021201 contact lenses worn in both eyes for 7 days. Lenses will be removed nightly for cleaning and disinfection with OPTI-FREE multipurpose solution.
62356037|NCT00367432|EXPERIMENTAL|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
62356038|NCT05730374|NO_INTERVENTION|Control group|children with thalassemia will receive only routine care of hospital during blood transfusion.
62356039|NCT05730374|EXPERIMENTAL|Benson's Relaxation Group|children with thalassemia will receive Benson's relaxation intervention beside routine care of hospital during blood transfusion
62356040|NCT05730374|EXPERIMENTAL|Music Therapy Group|children with thalassemia will receive music therapy intervention beside routine care of hospital during blood transfusion.
62356041|NCT05934721||RA patients aged 70-90 years|Patients meeting inclusion/exclusion criteria will be recruited from rheumatology clinics and community sources.
62356042|NCT00975026|ACTIVE_COMPARATOR|Massages|Chair massage for 30 minutes once a week.
62356043|NCT00975026|ACTIVE_COMPARATOR|Massages + Stretches|Chair massage for 30 minutes once a week in addition to stretching exercises, to be done twice daily for 20 minutes.
62356044|NCT00975026|NO_INTERVENTION|No Intervention|
62356045|NCT01708616|PLACEBO_COMPARATOR|Placebo + risperidone|
62356046|NCT01708616|PLACEBO_COMPARATOR|Placebo +placebo|
62356047|NCT01708616|ACTIVE_COMPARATOR|RO5285119 + placebo|
62356048|NCT01708616|EXPERIMENTAL|RO5285119 + risperidone|
62356049|NCT01752725|EXPERIMENTAL|BiCision Arm|Coagulation with BiCision
62356050|NCT01752725|ACTIVE_COMPARATOR|Ultracision Arm|Coagulation with Ultracision
62356051|NCT02255617|EXPERIMENTAL|Fecal Microbiota Transplant|Single arm open label FMT administered at Week 0 by colonoscopy and at Weeks 1-4 by enema
62356052|NCT03689881|EXPERIMENTAL|Tomosynthesis|Tomosynthesis of SI joints
62356053|NCT00510484|EXPERIMENTAL|A|
62356054|NCT00510484|PLACEBO_COMPARATOR|B|
62356055|NCT01610206|ACTIVE_COMPARATOR|gemcitabine|
62356056|NCT01610206|EXPERIMENTAL|Gemcitabine + pazopanib|
62356057|NCT04866095|EXPERIMENTAL|Surgery|All patients, who have given their consent, aged over 18 years, with a sinus rhythm, requiring a surgical procedure that allows obtaining high quality transthoracic echocardiogram imaging without pain and discomfort.
62356058|NCT03700268|EXPERIMENTAL|Manual fitting|The patient is receiving the classical treatment : 10 sessions of 1 hour during one year where the clinician programs manually the Cochlear implant.
62356059|NCT03700268|EXPERIMENTAL|Artificial Intelligence|The patient is receiving the new treatment : 4 sessions of 1 hour during one year where the clinician programs the Cochlear implant with the FOX (Fitting to Outcome eXpert) software using artificial intelligence.
62356060|NCT00646113|EXPERIMENTAL|OsseoSpeed™ TX 3.0S (Dental implant)|OsseoSpeed™ TX 3.0S, Dental implants, 3.0 mm diameter, in lengths of 11, 13 and 15 mm
62356061|NCT00995579||Healthy college volunteers|
62356062|NCT02712281|EXPERIMENTAL|Autism MEAL Plan|Parents of eligible children who are randomized to the Autism Managing Eating Aversions and Limited variety (MEAL) Plan will participate in group-based parent training sessions (4 parents per group).
62356063|NCT02712281|ACTIVE_COMPARATOR|Parent Education|Parents of eligible children who are randomized to the Parent Education Arm will receive group-based parent education (PE). Each group includes 4 parents.
62148612|NCT02156180||Early stage oral cavity / oropharyngeal cancer|Exhaled breath
62148613|NCT05816707|OTHER|Control|extraction socket .
62148614|NCT05816707|ACTIVE_COMPARATOR|PRF Group|extraction socket and PRF
62148615|NCT05816707|ACTIVE_COMPARATOR|Curcuma Longa Group|Extraction Socket and Curcuma Longa
62519555|NCT03982576|ACTIVE_COMPARATOR|Standard Relapse Prevention|"Participants will receive 4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov. Participants will also receive SmokefreeTXT, the NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7.~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
62519556|NCT05530746||Control|Volunteers with no significant abnormalities on colonoscopy were given informed consent to obtain colon tissue biopsies and fecal specimens.
62710979|NCT03198390||Subjects with chronic skin conditions|Subjects with chronic skin conditions including but not limited to atopic dermatitis, contact dermatitis, hidradenitis suppurativa, and psoriasis
62710980|NCT03198390||Healthy subjects|
62519557|NCT05530746||Non-advanced adenoma|Patients with non-advanced adenoma were given informed consent to obtain colon tissue biopsies and fecal specimens.
62519558|NCT05530746||Advanced adenoma|Patients with advanced adenoma were given informed consent to obtain colon tissue biopsies and fecal specimens.
62519559|NCT05530746||Inflammatory bowel disease|Patients with inflammatory bowel disease were given informed consent to obtain colon tissue biopsies and fecal specimens.
62519560|NCT05530746||Colorectal cancer|Patients with colorectal cancer were given informed consent to obtain cancer tissue biopsies and fecal specimens.
62519561|NCT06331000||Adult patients with cystic fibrosis|
62519562|NCT06405698|EXPERIMENTAL|closure of the myelomeningocele defect by perforator flap.|fifteen patient with myelomeningocele defect
62519563|NCT06405698|EXPERIMENTAL|closure of the myelomeningocele defect by perforator plus flap .|fifteen patient with myelomeningocele defect
62519564|NCT01117337|NO_INTERVENTION|Mesh Non Fixation Group|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed by ant means
62519565|NCT04807751|EXPERIMENTAL|Delgocitinib cream 20 mg/g|topical occlusive administration
62519566|NCT04807751|PLACEBO_COMPARATOR|Delgocitinib cream vehicle|topical occlusive administration
62519567|NCT04807751|NO_INTERVENTION|Untreated skin|topical occlusive administration
62519568|NCT04004117|EXPERIMENTAL|Fentanyl s/l|Sublingual fentanyl will consist in liquid fentanyl at a concentration of 25 mcg/mL, with preparation by the pharmacist of pre-dosed syringes of 12,5 mcg (0,5 mL).
62710981|NCT05648708|ACTIVE_COMPARATOR|Group AS|The investigators will perform an adductor canal block and sciatic nerve block on that patient group for postoperative analgesia
62148616|NCT02637063|EXPERIMENTAL|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
62148617|NCT02637063|EXPERIMENTAL|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
62148618|NCT02637063|OTHER|Usual care|No intervention beyond the participants' personal medical care.
62148619|NCT01020578||Impaired glucose tolerance|Patients diagnosed with impaired glucose tolerance
62148620|NCT01020578||Control|Patients with normal blood glucose
62710982|NCT05648708|ACTIVE_COMPARATOR|Group FS|The investigators will perform femoral and sciatic nerve blocks on that patient group for postoperative analgesia
62710983|NCT06503731|EXPERIMENTAL|Treatment arm 1|Participants receiving Efgartigimod PH20 SC on top of optimized standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, and optionally steroids)
62710984|NCT06503731|EXPERIMENTAL|Treatment arm 2|Participants receiving Efgartigimod PH20 SC on top of optimized standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, and optionally steroids) up to week 24 followed by placebo PH20 SC on top of optimized standard background immunosuppression therapy from weeks 24 to 48
62710985|NCT06503731|PLACEBO_COMPARATOR|Treatment arm 3|Participants receiving Placebo PH20 SC on top of optimized standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, and optionally steroids)
62710986|NCT04582214|EXPERIMENTAL|OLE Therapy with The MetaNeb® System|Subjects in the active treatment group will receive OLE therapy with The MetaNeb® System following the labeled instructions for the device.
62710987|NCT04582214|NO_INTERVENTION|Control Group|The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.
62710988|NCT00730054|ACTIVE_COMPARATOR|1|Clonidine
62148621|NCT06269497|EXPERIMENTAL|Scaffold|After tooth extraction will one scaffold be placed in the extraction alveola, covered by a membrane and then covered by the gingival tissue.
62148622|NCT03692871|EXPERIMENTAL|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).
62519569|NCT04004117|PLACEBO_COMPARATOR|Placebo|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
62519570|NCT03340753|ACTIVE_COMPARATOR|KBP-5074 Capsule|KBP-5074 capsule, 0.5 mg or 1.0 mg, QD, single dose
62519571|NCT03340753|EXPERIMENTAL|KBP-5074 Tablet|KBP-5074 tablet, 0.5 mg or 1.0 mg, QD, single dose
62519572|NCT00306163|ACTIVE_COMPARATOR|1|Ciclesonide 160 µg
62519573|NCT00306163|ACTIVE_COMPARATOR|2|Fluticasone 100 µg
62710989|NCT00730054|ACTIVE_COMPARATOR|2|Remifentanil
62710990|NCT00730054|EXPERIMENTAL|4|Remifentanil+clonidine
62710991|NCT00730054|PLACEBO_COMPARATOR|3|Placebo
62710992|NCT03377660||Sandostatin|This cohort will be the group who are undergoing routine clinical treatment with a long-acting somatostatin analogue to minimise abnormal gut hormone signalling, and thus reduce early satiety.
62148623|NCT03692871|ACTIVE_COMPARATOR|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).
62148624|NCT05503407|EXPERIMENTAL|Baseline V-RESOLVE score-guided PCI|"Lesions with baseline V-RESOLVE \<14 scores would undergo either jailed wire technique or provisional two-stent strategy;~Lesions with baseline V-RESOLVE ≥14 scores would undergo either jailed balloon technique or elective two-stent strategy."
62148625|NCT05503407|PLACEBO_COMPARATOR|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
62148626|NCT03142932|ACTIVE_COMPARATOR|Control|A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute (NCI) 5 A's model.
62148627|NCT03142932|EXPERIMENTAL|COach2Quit|"A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute's 5 A's model.~Participants in the COach2Quit arm will be provided with an individualized carbon monoxide (iCO) monitor along with instructions on the use of the monitor and the COach2Quit application."
62148628|NCT01255800|EXPERIMENTAL|IPI-926 and Cetuximab|"* Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take the study drug by mouth every day."
62148629|NCT01489683|EXPERIMENTAL|control|3 ml of normal saline was instilled to larynx and trachea
62148630|NCT01489683|ACTIVE_COMPARATOR|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea before endotracheal intubation
62148631|NCT03701607||PD-L1|
62148632|NCT00651703|EXPERIMENTAL|1|
62519574|NCT05393505|EXPERIMENTAL|Fast-tRack Absolute Neutrophil Count (FRANC) Protocol|"Patient's blood sample will be expedited for complete blood count with differentials. Intravenous antibiotic is given depending on absolute neutrophil count. If neutropenia is present, broad-spectrum antibiotic (meropenem 1 g or levofloxacin 500 mg) will be given after septic workup within 1 hour of registration in emergency department before transfer to wards. If absent, antibiotic according to Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) with reference to previous bacterial sensitivity pattern, or amoxiclav 1.2 g if not specified, will be given. Other interventions are given according to clinical needs. The regimen is continued until clinicians recommend an alternative antimicrobial based on clinical grounds, or detection of other pathogens which indicate another antimicrobial."
62519575|NCT05393505|ACTIVE_COMPARATOR|Standard of Care|"The control group refers to the existing clinical pathway which guides management of adult patients with suspected NF in ED. Without information of absolute neutrophil count, Meropenem 1 g IV bolus (or Levofloxacin 500 mg IV infusion over 1 hour if Penicillin-allergic) will be given within 1 hour of ED registration after septic workup. Other interventions are given according to clinical needs.~Subsequent treatment in wards will be determined by doctor's clinical judgement, on a personalised basis. Each patient will be assessed by a parent team member. There is no standardised antibiotic de-escalation protocol in place, but it is a usual practice to continue Meropenem or Levofloxacin injections until clinical improvement, rising ANC, and negative culture results. After that it will be replaced with an antibiotic with a narrower spectrum, such as oral Amoxiclav, before discharge."
62519576|NCT00995085|EXPERIMENTAL|Metadoxine SR|Metadoxine is a pyrolate salt of Pyridoxine
62710993|NCT03377660||Mirtazapine|This cohort will be the group who are undergoing routine clinical treatment with a tetracyclic antidepressant to stimulate appetite.
62148633|NCT00651703|EXPERIMENTAL|2|
62148634|NCT00651703|EXPERIMENTAL|3|
62148635|NCT00651703|EXPERIMENTAL|4|
62148636|NCT05361356|EXPERIMENTAL|Experimental group, all volunteer will be scanned.|All participation accept Spectral CT scanning; No group;
62148637|NCT03597152|EXPERIMENTAL|Treatment|WelTract
62148638|NCT03597152|PLACEBO_COMPARATOR|Control|Inert Placebo
62148639|NCT01794273|EXPERIMENTAL|ephedrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
62148640|NCT01794273|EXPERIMENTAL|phenylephrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
62148641|NCT04117100||Endoscopic mucosal resection (EMR)|It has become the standard treatment for superficial tumors of the gastrointestinal tract, either flat or sessile: precancerous lesions and superficial cancers with no or low ganglionic risk. The pre-injection of physiological serum detaches the lesion from the deep plane and allows, with great security, the resection of the mucosa, muscularis mucosae with part of the submucosa, whatever the size and location of the lesion. Compared to other techniques, it allows a histological analysis which dictates the subsequent conduct and the possible need for a complementary surgery.
62148642|NCT04117100||Endoscopic mucosal dissection (ESD)|This technique uses submucosal injection and special knives to make a peri-lesional circumferential incision, followed by dissection through the submucosal sub-lesion.
62356064|NCT05343741||Helpseeking Ecuadorian adult and adolescent clients|The participants will be adolescent (11-17 years) and adult (\>18 years) clients presenting with common non-severe mental health problems who seek mental health services at the Centro de Psicología Aplicada. The CPA is an outpatient psychological service where students of the last semesters of the Clinical Psychology degree develop and practice their psychological care skills as co-therapists of professional clinical psychologists.
62148643|NCT04117100||Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC)|This is a mucosal thermo-destruction technique. It uses a generator that delivers a sinusoidal current of high frequency to a probe covered with bipolar electrodes in tight network ensuring a uniform diffusion of the thermal effect. The tissue penetration is superficial on 1mm, intended to eradicate the epithelium up to the muscularis mucosae. Circumferential or focal probes are used as a function of the length of the segment to be treated.
61974801|NCT02297074|EXPERIMENTAL|Precooked-Frozen White Bread|Precooked-Frozen white bread is characterized by white crumb with regular soft alveoli and bright crusty crust
62519577|NCT06248268||Suicide attempters|Patients with at least one previous suicide attempt
62519578|NCT06248268||Suicide ideators|Patients with suicidal thoughts, but no previous suicide attempt
62519579|NCT06248268||Clinical control group|Patients without suicidal behavior and thoughts
62519580|NCT06248268||Healthy controls|Healthy persons without suicidal behavior and thoughts
62519581|NCT06048289||Immunotherapy combined with chemotherapy|
62519582|NCT06616012|EXPERIMENTAL|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
62519583|NCT02261909||normal creatinine|pts receiving an iv-contrast enhanced CT with normal baseline renal function
62519584|NCT02261909||elevated creatinine|pts receiving an iv-contrast enhanced CT with abnormal baseline renal function
62356065|NCT05004350|EXPERIMENTAL|Encorafenib and cetuximab|"Safety Lead-in (SLI) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~Randomized (Phase II) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
62519585|NCT00621036|EXPERIMENTAL|methotrexate IV once every 2 weeks|
62519586|NCT03459352|EXPERIMENTAL|ePRO|There is no therapeutic intervention. Patients will use ePRO system to report systems. We will describe use in patients to determine compliance in reporting symptoms.
62519587|NCT05990582|EXPERIMENTAL|MLPTI Cohort|Group of 9 year old children born between 32 and 36 weeks of gestational age
62519588|NCT05990582|ACTIVE_COMPARATOR|Control cohort|Group of 9 year old children born at term
62519589|NCT00043537|EXPERIMENTAL|Social Effectiveness Therapy for Children|Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
62519590|NCT00043537|EXPERIMENTAL|Fluoxetine|Fluoxetine given in 10mg doses, up to 40 mg as tolerated
62519591|NCT00043537|PLACEBO_COMPARATOR|Pill placebo|"Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg."
62519592|NCT01218984|EXPERIMENTAL|Medisorb naltrexone 75 mg|
62519593|NCT01218984|EXPERIMENTAL|Medisorb naltrexone 150 mg|
62519594|NCT01218984|EXPERIMENTAL|Medisorb naltrexone 300 mg|
62519595|NCT01976013|OTHER|Coaguchek|infants will receive sequential coagulation checks
62519596|NCT05043064|ACTIVE_COMPARATOR|Experienced robotic cardiac surgeons|
62519597|NCT05043064|ACTIVE_COMPARATOR|Cardiac surgeons with limited robotic experience|
62519598|NCT05043064|ACTIVE_COMPARATOR|Non-cardiac surgeons with limited robotic experience|
62519599|NCT04757181|EXPERIMENTAL|IBD patients|IBD patients will be used as their own control. Participants will start the study in a baseline phase (4 weeks) and intervention phase (8 weeks)
62519600|NCT01088919|EXPERIMENTAL|Dosing Regimen 1|
62519601|NCT01088919|EXPERIMENTAL|Dosing Regimen 2|
62519602|NCT01088919|EXPERIMENTAL|Dosing Regimen 3|
62519603|NCT01088919|EXPERIMENTAL|Dosing Regimen 4|
62519604|NCT01369602|EXPERIMENTAL|healthy controls|healthy subjects (creatinine clearance \> 90 mL/min)
62519605|NCT01369602|EXPERIMENTAL|ESRD / severe renal insufficiency|Severe (creatinine clearance 15 to 29 mL/min) OR ESRD (creatinine clearnace \<15 mL/min OR requiring dialysis)
62519606|NCT01369602|EXPERIMENTAL|Moderate renal impairment|Moderate (creatinine clearance = 30 to 59 mL/min)
62519607|NCT01369602|EXPERIMENTAL|Mild renal impairment|Mild (creatinine clearance = 60 to 89 mL/min)
62519608|NCT05339269|EXPERIMENTAL|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
62519609|NCT03993249|OTHER|Chemoradiotherapy|standard of care chemo-radiotherapy
62519610|NCT03993249|EXPERIMENTAL|Combination|standard of care chemo-radiotherapy + Nivolumab
62519611|NCT00016718|EXPERIMENTAL|Age Group 1: 90 days to < 3 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
62519612|NCT00016718|EXPERIMENTAL|Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
62519613|NCT00016718|EXPERIMENTAL|Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
62519614|NCT05656079|EXPERIMENTAL|pegylated liposomal doxorubicin；cyclophosphamide；trastuzumab；pertuzumab ；docetaxel|"Pegylated liposomal doxorubicin 35 mg/m2, i.v. d1 +Cyclophosphamide 600 mg/m2 , i.v. d1 +Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg), i.v. d1+Pertuzumab (840 mg loading dose at first day only, then 420 mg), i.v. d1 ； q3w, for 4 cycles followed by Docetaxel 75mg/m2 , i.v. d1+ Pertuzumab 420 mg, i.v. d1+Trastuzumab 6 mg/kg, i.v. d1； q3w, for 4 cycles.~After the completion of adjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab combined with pertuzumab."
62519615|NCT05656079|ACTIVE_COMPARATOR|Epirubicin；cyclophosphamide f；docetaxel；trastuzumab；pertuzumab|"Epirubicin 90 mg/m2 , i.v. d1 +Cyclophosphamide 600 mg/m2 , i.v. d1； q3w, for 4 cycles followed by Docetaxel 75mg/m2 , i.v. d1+Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg), i.v. d1+Pertuzumab (840 mg loading dose at first day only, then 420 mg), i.v. d1； q3w, for 4 cycles.~After the completion of adjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab combined with pertuzumab."
62519616|NCT03021694|EXPERIMENTAL|Young Males Week 1|Six separate 3 x 14 \[condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)\] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
62519617|NCT03021694|EXPERIMENTAL|Young Males Week 3|Six separate 3 x 14 \[condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)\] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
62519618|NCT03021694|EXPERIMENTAL|Young Males Week 5|Six separate 3 x 14 \[condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)\] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
62519619|NCT02506608|EXPERIMENTAL|Operation of sensorized hand prosthesis|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in amputees:~* STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~* TIME 4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~* Sensorized hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~* Prosthetics sensorized hand for amputees DLR / HIT Hand II (Wessling Robotics)~* ODROID software integration within the afferent and efferent bi-directional control of the robotic hand"
62519620|NCT05760352|NO_INTERVENTION|Control group|Self-paced exercise
62519621|NCT05760352|EXPERIMENTAL|Intervention Group: eccentric cycling exercise|Received eccentric cycling exercise
62519622|NCT05760352|EXPERIMENTAL|Intervention Group: eccentric cycling exercise with helmet ventilation|Eccentric cycling exercise combined with helmet ventilation
62519623|NCT02795637|EXPERIMENTAL|dasotraline|dasotraline 8mg capsule/day
62519624|NCT05253274|EXPERIMENTAL|Virtual Reality application group|VR application will be applied to the experimental group during the emergency surgical intervention under local anesthesia.
62519625|NCT05253274|NO_INTERVENTION|Control|The patients in the control group routinely receives standard care in the emergency service. No application will be made to the control group.
62519626|NCT04719104|EXPERIMENTAL|Participating group of neonates|Participating group: Neonates that have had both a serum bilirubin measurement and transcutaneous measurement post phototherapy. This is a single arm study as we are only targeting one group of individuals with the intervention (transcutaneous bilirubin measurement). However, we will compare the serum bilirubin measurement to the transcutaneous measurement from the same neonate to determine if there is a clinically significant difference between the two measurements.
62519627|NCT02856009|EXPERIMENTAL|patient|
62519628|NCT05852795|EXPERIMENTAL|Experimental group|VR-based and audio-based mindfulness experience. Partecipants watch VR scenario and receive a guided mindfulness practice.
62519629|NCT05852795|OTHER|Control Group|VR-based mindfulness experience. Participants watch VR scenario without experiencing voice guided mindfulness practice.
62519630|NCT04888676|EXPERIMENTAL|Self- Adhesive Bulk fill Resin Composite ( Surefil one™ ,Dentsupply Sirona)|New Surefil one™ restorative Self-adhesive: no etching, bonding or cavity conditioning inserted in increments of up to 4 mm in thickness.
62519631|NCT04888676|ACTIVE_COMPARATOR|Bulkfill Resin Composite. (Tetric N-Ceram Bulk Fill )|after selective etching of enamel and bonding, the bulk-fill composite resins are inserted in increments of up to 4 mm in thickness.
62519632|NCT02373670|EXPERIMENTAL|Parent Mentor|Parent mentors using positive deviance findings to promote healthy behaviors
62519633|NCT02373670|ACTIVE_COMPARATOR|Education|Community health workers providing health education to promote healthy behaviors
62519634|NCT03166813|EXPERIMENTAL|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
62519635|NCT03166813|PLACEBO_COMPARATOR|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
62519636|NCT02948920|EXPERIMENTAL|Ephedrine|Intravenous 9 mg of ephedrine (3 ml) given at finishing local anesthetic administration for spinal anesthesia
62519637|NCT02948920|PLACEBO_COMPARATOR|NSS|Intravenous normal saline 3 ml given at finishing local anesthetic administration for spinal anesthesia
62519638|NCT00754013|ACTIVE_COMPARATOR|Donepezil|
62519639|NCT00754013|PLACEBO_COMPARATOR|Placebo|
62519640|NCT04194684|EXPERIMENTAL|Assigned Interventions|Nab-paclitaxel
62519641|NCT02677181|EXPERIMENTAL|ATG combined regimen|"ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1.5 mg/kg/d on day -5 and 3.5 mg/kg/d on day -4. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11."
62710994|NCT06173466|EXPERIMENTAL|Liposomal bupivacaine|Patients in the bupivacaine liposomal group were treated with liposome bupivacaine 133 mg under ultrasound-guided TPVB. And ultrasound-guided TPVB was performed at the right T7-8, T8-9, T9-10, and T10-11 paravertebral interval under left lateral decubitus position, with 7.5 ml of medication injected into each paravertebral interval, for a total of 30 ml.
62519642|NCT02677181|ACTIVE_COMPARATOR|no-ATG|regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
62519643|NCT04555304|EXPERIMENTAL|KH903 + Paclitaxel|IV KH903 4 mg/kg IV paclitaxel 80 mg/m²
62519644|NCT04555304|ACTIVE_COMPARATOR|Placebo + Paclitaxel|IV Placebo IV paclitaxel 80 mg/m²
62519645|NCT01124695|EXPERIMENTAL|Tamoxifen|Patients receive oral tamoxifen citrate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicities.
62519646|NCT02766426|OTHER|Lifestyle change intervention|Overweight/obese pregnant women enrolled in a healthy lifestyle change programm
62356066|NCT05004350|EXPERIMENTAL|Irinotecan and cetuximab or FOLFIRI and cetuximab|"Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles.~Irinotecan and cetuximab:~* irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks and~* cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~OR~FOLFIRI and cetuximab:~* irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks~* Folinic acid 400 mg/m² (120-minute infusion or to study site standards) or maximal dose tolerated in a prior regimen every 2 weeks~* 5-FU 400 mg/m² initial dose bolus (not to exceed 15 minutes), then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46 to 48 hours) continuous infusion or maximal dose tolerated in a prior regimen every 2 weeks and~* cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
62356067|NCT04686877|EXPERIMENTAL|STAPLE group|For patients in STAPLE group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided aspiration followed by urokinase clot irrigation (every 12 h for up to 5 days or until reduction of ICH to ≤10 mL). CT will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset. On the 1st, 3rd, 5th, and 7th day of post-operation, patients will be re-examined using CT. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
62356068|NCT04686877|NO_INTERVENTION|Conservative treatment group|We used the 2015 ASA/AHA and 2020 Chinese multidisciplinary expert consensus recommendations for treatment of spontaneous intracerebral hemorrhage, including a standard approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacological treatment of intracranial mass effect. Patients allocated to the standard medical care group had follow-up CT scans and other monitoring assessments on the same schedule as those in the STAPLE group. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
62356069|NCT00943254|EXPERIMENTAL|Arm 1|"Patients randomized to this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based and DVD materials"
62356070|NCT00943254|EXPERIMENTAL|Arm 2|"Patients in this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based material"
62356071|NCT00943254|NO_INTERVENTION|Arm 3|Patients randomized to control receive the diagnosis of individual cardiovascular risk factors with paper-based educational material
62356072|NCT03485222|EXPERIMENTAL|Empagliflozin|10mg once a day
62356073|NCT03485222|PLACEBO_COMPARATOR|Placebos|placebo once a day
62356074|NCT04381572||High fidelity simulation training|Group consisting of medical students scheduled to undergo high fidelity medical simulation as a part of standard scholastic program.
62356075|NCT00089102|EXPERIMENTAL|Gemcitabine + Irinotecan|
62356076|NCT00637377|ACTIVE_COMPARATOR|Ranibizumab 0.5mg Q4|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
62356077|NCT00637377|EXPERIMENTAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
62356078|NCT00637377|EXPERIMENTAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
62356079|NCT00637377|EXPERIMENTAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
62356080|NCT02103881|EXPERIMENTAL|Ketamine|Patients enrolled in this arm will be given 500 mg of intramuscular ketamine for their severe agitation they experience in the prehospital environment.
62356081|NCT02103881|EXPERIMENTAL|Haloperidol|Patients enrolled in this arm will be given 10 mg of intramuscular haloperidol for their severe agitation they experience in the prehospital environment.
62356082|NCT02818127|ACTIVE_COMPARATOR|normal coronary artery|coronary angiography will be performed by transfemoral or transradial route.
62356083|NCT02818127|ACTIVE_COMPARATOR|coronary slow flow|coronary angiography will be performed by transfemoral or transradial route.
62356084|NCT02818127|ACTIVE_COMPARATOR|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
62356085|NCT02818127|ACTIVE_COMPARATOR|non-obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
62356086|NCT02818127|ACTIVE_COMPARATOR|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
62356087|NCT00214487|EXPERIMENTAL|Bifocal Contact Lenses|Use of bifocal contact lenses to control the progression of myopia
62356088|NCT00214487|PLACEBO_COMPARATOR|Control|Single vision soft contact lenses
62356089|NCT04406012|ACTIVE_COMPARATOR|block group|Paravertebral group at Thoracic 9-10 vertebrae level with an in-plane technique advanced ultrasound guided 10 ml bupivacaine hydrochloride (Marcaine 0.5%, Astra Zeneca) in 20 ml volume was enjected in the paravertebral area with real-time visualisation It was observed that the local anesthetic drug spread on the pleura and the pleura was pushed. All blocks were performed by the same experienced anaesthesiologist.
62356090|NCT04406012|NO_INTERVENTION|Control group|Conventional analgesia methods were applied to the control group. Control group was relieved by dexketoprofen 50mg intravenously. If the patient was not relieved with dexketoprofen and VAS score \>4, tramadol 1 mg kg-1 was administered intravenously.
62356091|NCT01705587|EXPERIMENTAL|Immediate teriparatide|Open label teriparatide given immediately following surgical repair of fracture
62356092|NCT01705587|EXPERIMENTAL|Delayed teriparatide|Open label teriparatide given six months following surgical repair of fracture
62356093|NCT04475263||Carbon monoxide exposure|Confirmed exposure to carbon monoxide
62148644|NCT04117100||Per Oral Endoscopic Myotomy (POEM)|"This technique allows a myotomy on the 8 cm of the lower esophagus extended on the gastric side of the cardia, totally endoscopically, after having approached and tunneled the esophageal submucosa.~Less invasive, it gradually replaces the pneumatic dilatation and surgical myotomy of Heller.~It requires a general anesthesia, an expert operator and a trained nursing team, ESD instruments, carbone dioxide insufflation."
62710995|NCT06173466|ACTIVE_COMPARATOR|Standard bupivacaine combined with dexamethasone|Patients in the standard control group were treated with 0.5% bupivacaine hydrochloride 150 mg combined with dexamethasone 4 mg. the volume were expended to 30ml in both groups with normal saline. And ultrasound-guided TPVB was performed at the right T7-8, T8-9, T9-10, and T10-11 paravertebral interval under left lateral decubitus position, with 7.5 ml of medication injected into each paravertebral interval, for a total of 30 ml.
62519647|NCT00692146|EXPERIMENTAL|1|36 subjects receiving a specified volume of the active component AZD1386 in a single dose.
62519648|NCT00692146|PLACEBO_COMPARATOR|2|36 subjects receiving a specified volume of placebo in a single dose.
62519649|NCT02039414||Obese, Inactive|Pregnant women with a BMI≥30kg/m2 and sedentary lifestyle
62148645|NCT03116191|EXPERIMENTAL|SK-1404 high dose|
62148646|NCT03116191|EXPERIMENTAL|SK-1404 middle dose|
62519650|NCT02039414||Obese, Active|Pregnant women with a BMI≥30kg/m2 and exercising \>150min/week
62519651|NCT04674397||Test group|Living kidney donors
62710996|NCT02107885|EXPERIMENTAL|DS-1971|single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg.
62710997|NCT02107885|PLACEBO_COMPARATOR|placebo|placebo matching each of the DS-1971 dosages.
61974802|NCT02297074|EXPERIMENTAL|Candeal-flour White Bread|Candeal-flour white bread has a thick crust of between one and two millimetres, which is smooth and crisp, golden to light brown in colour and which tastes of toasted cereal. The crumb of the bread is white and its texture is smooth, spongy and consistent, with little regular alveolus and with an intense cereal aroma with a pleasant and slightly sweet taste
62148647|NCT03116191|EXPERIMENTAL|SK-1404 low dose|
62148648|NCT03116191|PLACEBO_COMPARATOR|Placebo|
62148649|NCT03114215|ACTIVE_COMPARATOR|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
62148650|NCT03114215|PLACEBO_COMPARATOR|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
62148651|NCT04827849|EXPERIMENTAL|Experiment group|The study group will be provided physical examination, pregnancy monitoring and training on transition to motherhood within the direction of nursing care based on Meleis's Transition Period Theory, in addition to the usual care provided by healthcare professionals.
62519652|NCT00283322||Medical ICU patients|Patients admitted to a medical intensive care unit
62519653|NCT00283322||Surgical ICU patients|Patients admitted to a surgical-trauma intensive care unit
62519654|NCT00283322||Neuro ICU patients|Patients admitted to a neuro-trauma intensive care unit
62519655|NCT01974024|EXPERIMENTAL|Methylprednisolone|Dexamethasone was replaced with methylprednisolone as an antiemetic.
62148652|NCT04827849|NO_INTERVENTION|Control group|The control group continued to receive the routine care
62148653|NCT04003558||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is a training cohort.
62148654|NCT04003558||Sun Yat-sen University Cancer Center|The cohort of Sun Yat-sen University Cancer Center is a validation cohort.
62148655|NCT04003558||Tungwah Hospital of Sun Yat-Sen University|The cohort of Tungwah Hospital of Sun Yat-Sen University is a validation cohort.
62519656|NCT01974024|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone was re-administered in the cycle.
62519657|NCT06028503|EXPERIMENTAL|Acceptance and Commitment Therapy + Continuous Glucose Monitoring + Lifestyle Education (ACT+CGM+LE)|Participants assigned to ACT+CGM+LE will have both of the above modules in addition to three ACT modules based on Gregg et al.8 and traditional ACT therapy19. Two facilitators will lead the ACT sessions: Dr. Marek or Dr. Ratcliff and one trained doctoral-level clinical psychology student under their direct supervision (i.e., one licensed provider paired with a student). We will run all sessions in a group format. Participants will be given breaks between modules and one long lunch break.
62519658|NCT06028503|EXPERIMENTAL|Continuous Glucose Monitoring + Lifestyle Education (CGM+LE)|Participants assigned to CGM+LE will attend the group LE workshop. CGM training will occur after the 5 hour lifestyle education delineated above (same content, but less informal discussion). This will include training on using blood glucose monitoring devices, setting up the App on the smartphone (including activating the hypoglycemic alarm) and how to apply the glucose sensors on the arm. If a sensor does fall off a participant, a member of the study team will provide a spare sensor to the participant. The glucose range for participants will be set at between 70 and 140 mg/dL, unless the study physician (Dr. Olaiya) determines otherwise. The CGM device will allow us to calculate the percentage of 'time in range' per day, peak glucose, nocturnal glucose and number of hypoglycemic events. The CGM training will be managed by Dr. Olaiya and/or Dr. Kelly, and a medical/dietetic students.
62710998|NCT02481557|EXPERIMENTAL|Oxalate Salt Solution|Professionally applied
62710999|NCT02481557|NO_INTERVENTION|No Treatment|No Treatment
62711000|NCT05466305|PLACEBO_COMPARATOR|Maxillary complete denture reinforced by chrome cobalt alloy|Completely edentulous patients treated by maxillary complete denture reinforced by chrome cobalt alloy
62148656|NCT04003558||Shunde hospital of southern medical university|The cohort of Shunde hospital of southern medical university is a validation cohort.
62148657|NCT01181232|EXPERIMENTAL|MR low-dose group|
62148658|NCT01181232|EXPERIMENTAL|MR high-dose group|
62148659|NCT01181232|ACTIVE_COMPARATOR|IR group|
62148660|NCT06216002|EXPERIMENTAL|TOF nerve stimulation|Patient receive TOF nerve stimulation in recovery room after surgery
62148661|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
61974803|NCT02297074|EXPERIMENTAL|Alfacar White Bread|Alfacar white bread is made according to its protected designation of origin and protected geographical indication (D.O. Alfacar, Granada, Spain). The bread has a creamy white, flexible and soft crumb, with many randomly scattered holes. The crust is medium-thick to thick, golden, slightly shiny and quite smooth
62148662|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
62148663|NCT00131404|PLACEBO_COMPARATOR|Phase A/B: Arm 1|"Phase A: Arm 1: MK0364 Pbo capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily."
62148664|NCT00131404|EXPERIMENTAL|Phase A/B: Arm 2|"Phase A: Arm 2: MK0364 2 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily."
62148665|NCT00131404|EXPERIMENTAL|Phase A/B: Arm 3|"Phase A: Arm 3: MK0364 4 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:~MK0364 4 mg capsule once daily."
62148666|NCT00131404|EXPERIMENTAL|Phase A/B: Arm 4|"Phase A: Arm 4: MK0364 6 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:~MK0364 6 mg capsule once daily."
62148667|NCT00131404|EXPERIMENTAL|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.
62148668|NCT03516877|EXPERIMENTAL|ESRT|"Volunteer surgery and anesthesia faculty from UCSF working at Parnassus Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Zuckerberg San Francisco General Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Mission Bay Hospital site and interested in training."
62148669|NCT00729547|PLACEBO_COMPARATOR|2|Psychotherapy placebo session
62711001|NCT05466305|EXPERIMENTAL|Maxillary complete denture reinforced by gold plated chrome cobalt alloy|Completely edentulous patients treated by maxillary complete denture reinforced by gold plated chrome cobalt alloy
62148670|NCT00729547|EXPERIMENTAL|1|Neurofeedback training which enhance left frontal alpha wave.
62148671|NCT03711279|EXPERIMENTAL|SHR-1210 plus Apatinib|
62148672|NCT03711279|ACTIVE_COMPARATOR|ADM plus IFO or IFO alone|
62148673|NCT01666821||early and intermediate-stage AMD|Follow-up observation was implemented in whose fundus examination show lesions in the early and intermediate-stage AMD
62356094|NCT06015568|EXPERIMENTAL|MCLA-129+ Befotertinib|Drug:MCLA-129 1500mg or 2000mg IV Q2W Other name:MCLA-129 Drug:Befotertinib (75 mg or 100 mg orally, once daily) Other name:D-0316
62356095|NCT00472017|EXPERIMENTAL|Pediatric Diffuse Brainstem Glioma Patients|Patients with newly diagnosed diffuse brainstem gliomas receive vandetanib.
61974804|NCT02297074|EXPERIMENTAL|Organic Wholemeal Bread|The Organic wholemeal bread only includes organic whole grain flours as the unique difference compared with the Ordinary bread. The resulting dark brown bread is characterized by compact crumb free of alveoli and hard thin crust
62356096|NCT03838367|EXPERIMENTAL|Phase I-Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
61974805|NCT02297074|ACTIVE_COMPARATOR|Glucose|Glucose is used to calculate glycemic index, glycemic load and insulinemic index
61974806|NCT01763216|EXPERIMENTAL|Road Tour|Road Tour was designed to improve the efficiency and accuracy of visual information processing and the ability to perform complex visual attention tasks. It focuses on improving the speed and accuracy with which users identify and locate visual information using a divided attention format. Over time, the difficulty and complexity of each task is systematically increased as users attain specified performance criteria. Difficulty is increased by reducing visual stimuli duration, adding visual distracters, increasing similarity between target and distracter stimuli, and presenting visual targets over a broader spatial expanse.
61974807|NCT01763216|SHAM_COMPARATOR|Boatload of Crosswords|Boatload of Crosswords offers the user a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also provides optional help features that the user may select, like filling in a letter or word to minimize frustration levels often associated with puzzle completion. Boatload of Crosswords was chosen for this study because it is computerized, it is very popular and easy to use, and many older adults enjoy doing crossword puzzles. Boatload of Crosswords, however, does not improve speed of processing because it does not focus on central discrimination and peripheral target location. Indeed, Boatload of Crosswords is not designed to train on any aspect of cognitive ability associated with visual speed of processing.
62356097|NCT03838367|EXPERIMENTAL|Phase I-Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
62711002|NCT01116284|EXPERIMENTAL|Revision of gastric bypass|A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.
62711003|NCT01265485|EXPERIMENTAL|treatment|
62711004|NCT05878574||LMWH group|Continuous use of low molecular weight heparin for more than 3 months during pregnancy preparation and during pregnancy with a history of more than 2 consecutive miscarriages before 28 weeks of gestation
61974808|NCT00525707|EXPERIMENTAL|1|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
61974809|NCT00525707|PLACEBO_COMPARATOR|2|
61974810|NCT02239757|EXPERIMENTAL|Right radial approach|Primary PCI performed through right radial approach.
61974811|NCT02239757|EXPERIMENTAL|Left radial approach|Primary PCI performed through left radial approach.
61974812|NCT01639651|ACTIVE_COMPARATOR|Control Group|
61974813|NCT01639651|EXPERIMENTAL|Mobilization Group|
61974814|NCT00763477|PLACEBO_COMPARATOR|saline injections|
61974815|NCT04434794|EXPERIMENTAL|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
61974816|NCT04434794|ACTIVE_COMPARATOR|control|standard treatment according to clinical protocols
61974817|NCT02759679|OTHER|Lung cancer|Patients with lung cancer
61974818|NCT02759679|OTHER|Controls|Controls being either healthy or having other lung disease
62148674|NCT01221532|EXPERIMENTAL|SHHE Peridischarge intervention|Patients receive the Support from Hospital to Home (SHHE) Peridischarge Intervention plus usual care
62519659|NCT06028503|ACTIVE_COMPARATOR|Lifestyle Education (LE)|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy.
62519660|NCT05730504|EXPERIMENTAL|Mobile app-based self-guided interventions|Participants have access to self-guided, app-based mobile psychological interventions grounded in Cognitive Behavioral Therapy, meditation, mindfulness, journaling, as well as audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
62519661|NCT05730504|NO_INTERVENTION|No interventions|Participants don't have access to app-based mobile psychological interventions
62519662|NCT00841360||HIV Positive|"Participant self-discloses as HIV positive.~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
62519663|NCT00841360||HIV Negative|"Participant self-discloses as HIV negative (based on receiving a negative HIV test within 12 months prior to study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
62148675|NCT01221532|NO_INTERVENTION|Usual Care|
62711005|NCT05878574||control group|No use of low molecular weight heparin during pregnancy preparation and throughout pregnancy and history of more than 2 consecutive miscarriages before 28 weeks of gestation
62148676|NCT00647465|ACTIVE_COMPARATOR|1|IFNalpha 2b
62148677|NCT00647465|PLACEBO_COMPARATOR|2|Placebo
62148678|NCT05534230|PLACEBO_COMPARATOR|Control Group|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
62519664|NCT00841360||HIV Status Unknown|"Participant self-discloses as HIV negative (no history of prior HIV testing, or HIV screening more than 12 months prior to date of study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
62519665|NCT00841360||Friendship Network Members|Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
62519666|NCT00831623|EXPERIMENTAL|Proton radiation therapy|Single arm
62519667|NCT01829919|EXPERIMENTAL|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate) Capsules taken orally with 240 mL of water for 20 days.
62519668|NCT04031612||Neoadjuvant Breast Cancer|Patients undergoing neoadjuvant therapy for breast cancer
62519669|NCT01408563|EXPERIMENTAL|Fludarabine/Melphalan/TBI|All patients receive same therapy
62148679|NCT05534230|ACTIVE_COMPARATOR|Dexmedotimidine Group|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
62148680|NCT06165978|EXPERIMENTAL|Physical activity coaching - Experimental group|The experimental group intervention consists of a 12-week physical activity coaching program informed by the literature (CRD42021253066). The intervention is conducted at participants' home or within the community, delivered remotely (mostly) and face-to-face, and encompasses several behaviour change components (mandatory: self-monitoring, goal setting/review, education, feedback, contact; optional: exercise, reports, support meeting, group activities).
62148681|NCT06165978|OTHER|Usual care - Control group|The control group intervention runs parallel to the experimental group for 12 weeks, conducted at participants' home or within the community, and consists of usual management (i.e., World Health Organization's recommendations for being physically active).
62148682|NCT04393571|EXPERIMENTAL|conventional follow up patients|
62148683|NCT04393571|EXPERIMENTAL|Mobile app follow up patients|
62148684|NCT01947491|EXPERIMENTAL|DFD01 Spray|DFD01 Spray twice daily for 28 days
62148685|NCT01947491|PLACEBO_COMPARATOR|Vehicle Spray|Vehicle Spray twice daily for 28 days
62148686|NCT01947491|ACTIVE_COMPARATOR|Comp01 Lotion|Comp01 Lotion twice daily for 14 days
62148687|NCT01947491|PLACEBO_COMPARATOR|Vehicle Lotion|Vehicle Lotion twice daily for 28 days
62148688|NCT01630486||glomerulonephritis|adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
62148689|NCT01630486||hypertensive nephropathy|adult CKD patients, whose underlying etiology is hypertensive nephropathy
62519670|NCT03477955|ACTIVE_COMPARATOR|Peek Group|Patients that received PEEK interspinous spacer
62519671|NCT03477955|ACTIVE_COMPARATOR|Silicon Group|Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer
62519672|NCT03477955|ACTIVE_COMPARATOR|Control Group|Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer
62519673|NCT03202901|EXPERIMENTAL|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
62519674|NCT03202901|PLACEBO_COMPARATOR|Placebo|"Yeast brew extract (200 mg)~Excipients:~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
62148690|NCT01630486||polycystic kidney disease|adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
62711006|NCT04518501|EXPERIMENTAL|study group|Fuzuloparib Capsules plus table Arsenic Trioxide po
62711007|NCT02639390|EXPERIMENTAL|Robotic|The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
62711008|NCT02639390|ACTIVE_COMPARATOR|Conventional|Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).
62148691|NCT01630486||diabetic nephropathy|adult CKD patients, whose underlying etiology is diabetic nephropathy
62148692|NCT00071500|EXPERIMENTAL|1|Participants will use MedSignals with all of its features
62519675|NCT01772264|EXPERIMENTAL|Arm A - active treatment|
62148693|NCT00071500|EXPERIMENTAL|2|Participants will use MedSignals with only alarm features
62148694|NCT00071500|NO_INTERVENTION|3|Participants will not use any device
62148695|NCT00879827|EXPERIMENTAL|Single Group|
62356098|NCT03838367|EXPERIMENTAL|Phase I-Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
62356099|NCT03838367|EXPERIMENTAL|Phase II- MTD to be established for the combination treatment|MTD PRO 140 SC + AUC 5 Carboplatin in 30 subjects
62356100|NCT02917629|EXPERIMENTAL|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 10-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
62356101|NCT02917629|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo PO QD daily for 10-21 days.
62356102|NCT01125618|EXPERIMENTAL|MVP village|Wealth stratified and randomly selected households residing in a village exposed to the Millennium Villages Project intervention (or health and development intervention package)
62356103|NCT01125618|ACTIVE_COMPARATOR|Comparison village|Villages receiving routine services through established programs
62356104|NCT03230513|ACTIVE_COMPARATOR|Self Epley Manoeuvre|Self Epley Manoeuvre.
62356105|NCT03230513|ACTIVE_COMPARATOR|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
62356106|NCT05031429|NO_INTERVENTION|Control - Standard Care|"* includes a minimum 12-hour feeding window for 7 days per week~* no caloric restriction will be used~* will wear a continuous glucose monitor"
62356107|NCT05031429|EXPERIMENTAL|Intervention - Time Limited Eating|"* includes an 8-hour feed/16-hour fast for 7 days per week~* will be instructed to consume all of their calories in the afternoon/evening period~* can consume non-caloric beverages (water, tea, coffee) during the fasting period~* will wear a continuous glucose monitor~* no caloric restriction will be used"
62356108|NCT02043184|ACTIVE_COMPARATOR|Standard Care 12 weeks|Standard care. Standard supportive care and Toolkit given at 12 weeks.
62356109|NCT02043184|EXPERIMENTAL|Standard Care 8 wks, Daily IVR 4 wks|Interactive Voice Response (IVR) Reminders Daily delivery for the last 4 weeks of the study.
62148696|NCT00681915|EXPERIMENTAL|1|
62148697|NCT04680598||high HBV-DNA group|patients with HBV-DNA \>500 IU/ml
62148698|NCT04680598||low HBV-DNA group|patients with HBV-DNA≤500 IU/ml
62148699|NCT04871555||mesio-temporal epilepsy|patients suffering from mesiotemporal epilepsy type
62148700|NCT04871555||basal temporal epilepsy|patients suffering from basal temporal epilepsy type
62356110|NCT02043184|EXPERIMENTAL|Daily IVR 8 weeks|Interactive Voice Response (IVR) Reminders daily for the first 8 weeks of the study.
62356111|NCT02043184|EXPERIMENTAL|Daily IVR 4 wk, Every other day IVR 4 wk|Interactive Voice Response (IVR) Reminders daily for the first 4 weeks of the study and every other day for weeks 4-8.
62356112|NCT06353360|EXPERIMENTAL|Tumor Treating Fields + Temozolomide + Tislelizumab|
62356113|NCT03722472|EXPERIMENTAL|Single-vial ID93 + GLA-SE|Single-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
62356114|NCT03722472|ACTIVE_COMPARATOR|Two-vial ID93 + GLA-SE|Two-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
62356115|NCT02572011|NO_INTERVENTION|Control|Participants in the control (CON) group will not complete any formalised balance training as part of the current study.
62356116|NCT02572011|EXPERIMENTAL|Experimental|Participants in the experimental group will complete the Home-based Games Console Balance Training intervention.
62356117|NCT02428673|OTHER|Load-measuring platform|A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
62356118|NCT02119468|EXPERIMENTAL|Treatment (3mg MLN9708)|Patients receive 3mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62356119|NCT02119468|EXPERIMENTAL|Treatment (4mg MLN9708)|Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62519676|NCT01772264|PLACEBO_COMPARATOR|Arm B - placebo|
62711009|NCT04790500|ACTIVE_COMPARATOR|Group A|mobilization technique
62148701|NCT04871555||temporal lateral epilepsy|patients suffering from temporal lateral epilepsy type
62148702|NCT04871555||operculo insular epilepsy|patients suffering from operculo insular epilepsy type
62148703|NCT04871555||temporo-insular epilepsy|patients suffering from temporo- insular epilepsy type
62148704|NCT04871555||healthy subjects|non epileptic patients
62148705|NCT02565589||ICU patient|Critically ill patients who were enrolled less than 24 hours after ICU admission.
62148706|NCT02565589||Control|Age-, sex-, and BMI-matched healthy subjects.
62148707|NCT01316913|EXPERIMENTAL|GSK573719/GW642444 125/25|125/25 mcg once-daily
62148708|NCT01316913|EXPERIMENTAL|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
62148709|NCT01316913|EXPERIMENTAL|GSK573719|125 mcg once-daily
62148710|NCT01316913|ACTIVE_COMPARATOR|tiotropium bromide|18 mcg once-daily
62356120|NCT06185413|EXPERIMENTAL|Intervention communities|A participatory system dynamics approach will be implemented by the municipal staff and research group.
62519677|NCT04946565||Sinopharm vaccine group|Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
62711010|NCT04790500|EXPERIMENTAL|Group B|muscle energy technique
62148711|NCT04493411|EXPERIMENTAL|Multiple Myeloma Patients|Patients with pathologically confirmed myeloma for cross-sectional study (detection) or scheduled to undergo induction therapy (or have gone 1-2 cycles of induction therapy), followed by either bone marrow transplantation or consolidation therapy for longitudinal study (therapy response assessment).
62356121|NCT06185413|NO_INTERVENTION|Comparison communities|No intervention will be applied, but according to the wait-list design, the participatory system dynamics approach will be implemented in the comparison community by the municipal staff after follow-up.
62356122|NCT04581863|ACTIVE_COMPARATOR|COVID Watch|COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
62356123|NCT04581863|EXPERIMENTAL|PCORI Pulse|This arm is COVID Watch + pulse oximeter device. Patients sent a pulse oximeter will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is \>3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
62356124|NCT05565014|EXPERIMENTAL|Virus Activated Killer immune Cells（VAK）|The VAK should be given once a week, three times a circle. The VAK could given 1 or 2 circle for each subject. The dosage of Pleural Effusion（more than 10\^5/kg cells in 30-50mL solvent） differs from Peritoneal Effusion（more than 10\^4/kg cells in 30-50mL solvent）
62356125|NCT05565014|PLACEBO_COMPARATOR|saline|50ml of saline was injected once a week,three times a circle.The saline could given 1 or 2 circle for each subject.
62356126|NCT02706119|EXPERIMENTAL|Glargine insulin|Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
62356127|NCT02706119|ACTIVE_COMPARATOR|Regular insulin|Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
62356128|NCT00260429|EXPERIMENTAL|AA4500 0.58 mg|
62356129|NCT00260429|PLACEBO_COMPARATOR|placebo|
62356130|NCT05193968|OTHER|Experimental: Healthy Women Volunteers|Hot Flash frequency will be assessed in the study subjects during a screening period. Participants can then chose to participate 1 or 2 study visits- Protocol 1: Microvascular function and/or Protocol 2: Autonomic function
62356131|NCT04501835||Cardiac implantable electronic device infections|Patients hospitalised in Nancy University Hospital for suspected cardiac implantable electronic device infections
62356132|NCT05690698|EXPERIMENTAL|Quatiapine group (n=50)|Quetiapine (25-50 mg/day) according to their symptoms of agitations.
62356133|NCT05690698|ACTIVE_COMPARATOR|Haloperidol group (n=50)|Haloperidol (1-2 mg/day) according to their symptoms of agitations.
62356134|NCT02131545|EXPERIMENTAL|Quetiapine|Quetiapine 25 mg
62356135|NCT02141217|ACTIVE_COMPARATOR|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
62356136|NCT02141217|ACTIVE_COMPARATOR|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
62356137|NCT01611766|EXPERIMENTAL|secondary cytoreductive surgery|SCR followed by chemotherapy
62356138|NCT01611766|ACTIVE_COMPARATOR|Salvage Chemotherapy|platinum-based chemotherapy
62356139|NCT02150213|EXPERIMENTAL|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
62356140|NCT01258517||group 1, group 2, group 3, group 4|administration of beractant with single lumen ET tube administration of poractant with single lumen ET tube administration of beractant with double lumen ET tube administration of poractant with double lumen ET tube
62148712|NCT00599196|EXPERIMENTAL|Rotigotine|Rotigotine
62148713|NCT04929509|EXPERIMENTAL|self-assembling peptide (P11-4)|"Curodont Repair; Credentis will be applied to the~white spot lesion at baseline."
62356141|NCT04857788|EXPERIMENTAL|Pandah Application only|Design is a controlled randomized Study with two parallel arms after randomization with a three months follow-up of the two arms that are (Group 1) Care as usual for patients in follow-up list; (Group 2) PANDAH App proposed alone with only 15-20 minutes setup with investigator at start-up (digital accompaniment only); Patients of the 2 groups will have a three months follow-up period before secondary evaluation and entering into the so-called extension period.
62356142|NCT04857788|NO_INTERVENTION|Care as usual|Design is one period of 3 months with 2 parallel groups (with or without application) following by extension period of 3 months with all subject accessing to the application.
62356143|NCT00776321|PLACEBO_COMPARATOR|1|
62356144|NCT00776321|EXPERIMENTAL|Eprotirome dose 1|
62356145|NCT00776321|EXPERIMENTAL|Eprotirome dose 2|
62356146|NCT03579225||MATRx plus test|
62356147|NCT03942237|EXPERIMENTAL|single-injection QLB (quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
62356148|NCT03942237|PLACEBO_COMPARATOR|Placebo control|Single-injection of QLB with NS is given preoperatively
62356149|NCT00067821||1/Patients|Must have a brain tumor, or residual abnormality that is measurable or evaluable on standard MRI or CT
62148714|NCT04929509|ACTIVE_COMPARATOR|nanosilver fluoride varnish|"(Study group) Nano-silver fluoride varnish will be applied to the~white spot lesion at baseline."
62519678|NCT02140307|EXPERIMENTAL|Meditation training, group format|"The course Relaxation Response-based Mental Health Promotion (publicly referred to as Open and Calm) is given in group format.~The intervention entails 9 courses (1 per week of 2.5 hrs), a course book (120 pages), audio support (6 guided meditative practices), access to a webpage with additional information, and the possibility of two personal sessions with the intervention instructor (a certified psychologist)."
62519679|NCT02140307|ACTIVE_COMPARATOR|Meditation training, individual format|"The course Relaxation Response-based Mental Health Promotion (Open and Calm) is given by the same instructor as for group formats using precisely the same material and methods, but in about 6-9 (as to each persons' individual needs and preferences) face-to-face meetings."
62519680|NCT02140307|NO_INTERVENTION|Wait-list control|This arm is an inactive wait-list control.
62519681|NCT06411340||Acute inflammatory cardiac disease|This registry aims to collate routinely collected clinical data on patients with acute cardiovascular diseases.
62519682|NCT06051383|EXPERIMENTAL|single group|"Research design:~Quasi-experimental, single group pre- posttest design was utilized in the study. all patients will be assessed for LUTS at base line then will be reassessed after three months.~Study variables:~The independent variable is self management intervention while the dependent variable is the severity of lower urinary tract symptoms."
62519683|NCT02844517|EXPERIMENTAL|Artificial Pancreas|The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
62519684|NCT01231750|ACTIVE_COMPARATOR|0.1% Capsaicin Cream|0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise
62519685|NCT01231750|PLACEBO_COMPARATOR|Placebo Cream|Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise
62519686|NCT00886041|OTHER|laparoscopy group|laparoscopy
62711011|NCT05381480|ACTIVE_COMPARATOR|In-home Preventive Health Visits by Advanced Practice Nurse|APRNs will perform in-home multidimensional health assessment with quarterly follow up visits to provide individualized patient education, negotiation of recommendations to maintain/improve health and wellness. All participants continue to receive care from their primary care provider and other community-based providers, although use might be modified. Throughout the intervention, participants are encouraged to take a primary role in the management of their own health. APRNs coach and guide the participant in navigating existing service providers as well as accessing and establishing new services. Having the program in-home promotes an atmosphere of shared decision-making, while allowing the nurse to observe the physical and social environment. Key to this model is identification of individual profiles of health strengths and health risks; recommendations and negotiation over priority health behavior change; and quarterly follow up.
62148715|NCT04929509|PLACEBO_COMPARATOR|sodium fluoride varnish|"(Control group) Fluoride varnish (Duraflor) will be applied to the~white spot lesion at baseline and 6 months follow up."
62148716|NCT03720249|EXPERIMENTAL|supplementation of compound nutrients|Betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc are provided as a 800mg tablet. And the tablet is orally taken once a day, four tablets at a time for 12 weeks.
62148717|NCT03720249|PLACEBO_COMPARATOR|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement.
62148718|NCT06229756||EDOF Toric|Patient submitted to bilateral implantation of Asqelio EDOF Toric IOL
62148719|NCT00351026|ACTIVE_COMPARATOR|1|25 HIV negative opiate dependent patients all treated with methadone
62148720|NCT00351026|ACTIVE_COMPARATOR|2|25 HIV positive opiate dependent patients all treated with methadone
62148721|NCT05435105|EXPERIMENTAL|Virtual Reality Group|Watching the cartoon by wearing virtual reality glass to the child during the peripheral intravenous catheterization
62148722|NCT05435105|EXPERIMENTAL|Local Cold-Vibration Group|The local cold-vibration device is placed 5 cm above the area just before peripheral intravenous catheterization
62148723|NCT05435105|NO_INTERVENTION|Control Group|Routine Care
62356150|NCT02312115|ACTIVE_COMPARATOR|Furosemide|Patients assigned to the furosemide infusion group will receive furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al. (2007) and the SPARK study protocol (Bagshaw et al. 2010). Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline reaching a concentration of 4 mg/mL. All medication and placebo bags will have no identifiers that show what type of drug is being administered, for blinding purposes. Medication and placebo bags will have randomly generated study identifier numbers. The protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the manufacturer.
62356151|NCT02312115|PLACEBO_COMPARATOR|Saline|All patients assigned to the saline group will receive saline that is equal in volume as compared to the treatment group. The amount of saline given to the patients in the placebo arm is so small that its effect on these patients is negligible. All other aspects of care for the enrolled patient will be managed per primary team and any consultants.
62356152|NCT04084405|EXPERIMENTAL|IMT group|Inspiratory muscle training + aerobic exercice
62356153|NCT04084405|ACTIVE_COMPARATOR|Control group|aerobic exercice
62519687|NCT00886041|ACTIVE_COMPARATOR|ovarian stimulation group|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
62519688|NCT04969861|EXPERIMENTAL|BEMPEG + Pembrolizumab|Bempegaldesleukin plus pembrolizumab every 3 weeks (q3w) for up to 35 cycles (approximately 2 years).
62519689|NCT04969861|ACTIVE_COMPARATOR|Pembrolizumab Monotherapy|Pembrolizumab monotherapy q3w for up to 35 cycles (approximately 2 years).
62519690|NCT01452594||Diphenylcyclopropenone|topical gel administration to skin
62519691|NCT04072276||EV71 Vaccine with Adjuvant AlPO4|EV71 Vaccine Produced in Vero Cells with Adjuvant AlPO4
62519692|NCT04072276||Adjuvant AlPO4|Placebo (Adjuvant AlPO4 only)
62519693|NCT00761449|EXPERIMENTAL|1|1. lenalidomide
62148724|NCT05295706|EXPERIMENTAL|Intervention Group|Participants in this group will complete the same measures as the control group, but will additionally be involved in a counterfactual intervention conducted by an advanced graduate student.
62148725|NCT05295706|NO_INTERVENTION|Control Group|Participants in this group will complete the same measures as the experimental group. Instead of being involved in a counterfactual intervention, participants will be asked about their intentions to complete future study components.
62148726|NCT00114452|ACTIVE_COMPARATOR|Provacel: Cohort 1|ex vivo cultured adult mesenchymal stem cells
62148727|NCT00114452|ACTIVE_COMPARATOR|Provacel: Cohort 2|ex vivo cultured adult mesenchymal stem cells
62519694|NCT02902718|EXPERIMENTAL|mē device|The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.
62148728|NCT00114452|ACTIVE_COMPARATOR|Provacel: Cohort 3|ex vivo cultured adult mesenchymal stem cells
62519695|NCT01949753|EXPERIMENTAL|Nutritional supplement Pregnenolone|Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.
62519696|NCT01949753|PLACEBO_COMPARATOR|Placebo|Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.
62519697|NCT06394726|ACTIVE_COMPARATOR|Aerobic Exercise Group|Aerobic Exercise Group For 3 months, participants will engage in a total of 150 minutes of exercise per week, either 30 minutes for 5 days a week or 50 minutes for 3 days a week.
62519698|NCT06394726|ACTIVE_COMPARATOR|Core Stabilization Exercise Group|Core Stabilization Exercise Group for 3 months, 2 sets of exercises, each comprising 10 repetitions per set.
62519699|NCT03065595|PLACEBO_COMPARATOR|Intervention|Ophicephalus striatus extract
62148729|NCT00114452|ACTIVE_COMPARATOR|Provacel: Cohort 4|ex vivo cultured adult mesenchymal stem cells
62148730|NCT00114452|PLACEBO_COMPARATOR|Placebo|ex vivo cultured adult mesenchymal stem cells
62148731|NCT03262714|EXPERIMENTAL|Dancing|Elderly women randomized to the dance intervention programme.
62148732|NCT03262714|EXPERIMENTAL|Walking|Elderly women randomized to the walking intervention programme.
62148733|NCT03262714|ACTIVE_COMPARATOR|Stretching|Elderly women randomized to the stretching intervention programme.
62148734|NCT01762397|EXPERIMENTAL|PMK-S005|
62148735|NCT03944889|PLACEBO_COMPARATOR|Placebo Topical|Placebo Cream, applied topically to trapezius muscle
62148736|NCT03944889|ACTIVE_COMPARATOR|Low Dose, Topical|Capsaicin Cream- low dosage, applied topically to trapezius
62148737|NCT03944889|ACTIVE_COMPARATOR|High Dose, Topical|Capsaicin Cream- higher dosage, applied topically to trapezius
62148738|NCT03944889|PLACEBO_COMPARATOR|Placebo, Intrafascial|Injection placebo(saline)- injected intrafascially into trapezius
62519700|NCT03065595|ACTIVE_COMPARATOR|Control|Placebo drug
62519701|NCT04815330||Patient dyspnea under veno-arterial extracorporeal circulation|"Relief of dyspnea will be carried out by the clinician in charge of the patient. He will have complete control of his behaviour. He will carry out this test according to the practices in force in the department.~If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.~In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved."
62148739|NCT03944889|ACTIVE_COMPARATOR|Low Dose, Intrafacial|Injection Capsaicin formulation low dose- injected intrafascially into trapezius
62148740|NCT03944889|ACTIVE_COMPARATOR|High Dose, Intrafascial|Injection Capsaicin formulation higher dose- injected intrafascially into trapezius
62148741|NCT03944889|PLACEBO_COMPARATOR|Placebo, Intramuscular|Injection placebo (saline) - injected intramuscularly into trapezius
62148742|NCT03944889|ACTIVE_COMPARATOR|Low Dose, Intramuscular|Injection Capsaicin formulation low dose - injected intramuscularly into trapezius
62148743|NCT03944889|ACTIVE_COMPARATOR|High Dose, Intramuscular|Injection Capsaicin formulation higher dose - injected intramuscularly into trapezius
62148744|NCT03286907|EXPERIMENTAL|Online videos|Participants will watch two online videos, complete a self-administered online tutorial, and receive reminders at Month 1, 2, 4, 6 \& 8
62148745|NCT03286907|EXPERIMENTAL|Online videos and MI|Participants will watch two online videos, complete a self-administered online tutorial, received motivational interviewing (MI), and receive reminders at Month 1, 2, 4, 6 \& 8
62148746|NCT03286907|ACTIVE_COMPARATOR|Control group|Participants will receive online messages about mental health problems and stress reduction exercises
62148747|NCT05722626|EXPERIMENTAL|Platelet-rich plasma|PRP manufactured by T_Biyoteknoloji LTD, Turkey
62148748|NCT05722626|PLACEBO_COMPARATOR|Normal Saline|NaCl 0.9%
62148749|NCT05051826|EXPERIMENTAL|1.Drag Umbrella 2. Hand Resistance 3.Resistance Suit|"1. In the water, a small umbrella is attached to the athlete to increase resistance.~2. In the water, increase resistance by increasing the area of the hand.~3. In the water, use swim shorts that increase resistance"
62148750|NCT05051826|EXPERIMENTAL|1 Resistance 2 Bands Swiss Ball 3 Medicine Ball 4 Pulley Pull|"1. On land, use a stretch rope to increase resistance.~2. On land, inflatable bouncy balls are used to increase strength.~3. On land, solid balls are used to increase strength.~4. On land, pulleys are used to increase resistance."
62148751|NCT06077305||Registry Study on Microcirculatory Disorders in Acute Ischemic Stroke|Establish a Chinese registry platform for microcirculatory disorders after acute ischemic stroke; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders after acute ischemic stroke.
62148752|NCT06077305||Registry Study on Microcirculatory Disorders in Ischemic Stroke during Recovery Period|Establish a national registry platform for microcirculatory disorders in ischemic stroke during recovery period; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders in ischemic stroke during recovery period.
62148753|NCT06077305||Registry Study on Microcirculatory Disorders in CSVD|Establish a national registry platform for microcirculatory disorders in CSVD; use this registry platform to record the prevalence, diagnosis and treatment information, and disease outcome of microcirculatory disorders in CSVD.
62148754|NCT05068050|EXPERIMENTAL|Experimental group|This arm will be provided by horse-assisted therapy interventions.
62148755|NCT05068050|ACTIVE_COMPARATOR|Control group|This arm will be provided by the physical exercise interventions.
62148756|NCT02040701||SDB group|
62148757|NCT02040701||Control group|
62148758|NCT02068157|EXPERIMENTAL|Treatment (porfimer sodium, image-guided I-PDT)|Patients receive porfimer sodium IV over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2.
62148759|NCT03792178|ACTIVE_COMPARATOR|Nano resin composite|are types of synthetic resins which are used in dentistry as restorative material or adhesives.
62148760|NCT03792178|EXPERIMENTAL|Bulk fill composite|Bulk- ll composites are claimed to be restorative materials used in deep preparations and effectively photoactivated in layers up to 4 mm.
62148761|NCT01095848|EXPERIMENTAL|0.25ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
62148762|NCT01095848|EXPERIMENTAL|1ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
62148763|NCT01297595|EXPERIMENTAL|crizotinib|
62148764|NCT05074212|EXPERIMENTAL|Complex Linear Closure|The study participant will receive two layers of sutures to close the wound.
62148765|NCT05074212|EXPERIMENTAL|Second Intention Healing|The study participant will not have any sutures placed.
62519702|NCT00192270|EXPERIMENTAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|All subjects were scheduled to receive 2 doses of CAIV-T.The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
62519703|NCT04189731||supra-scapular block|Patient will have a short ISB (between 2h and 4h) relayed by a supra-scapular block (SSB) long (72h) through the placement of a perineural catheter thus allowing a continuous diffusion of Naropein® by an elastomeric pump
62519704|NCT02522403|ACTIVE_COMPARATOR|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
62519705|NCT02522403|EXPERIMENTAL|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
62519706|NCT01405287|EXPERIMENTAL|Combo Stent|PTCA with Combo Stent
62356154|NCT00326157|EXPERIMENTAL|1|AmBisome® will be administered for a duration of 8 weeks
62356155|NCT04183387|EXPERIMENTAL|Simvastatin and standard treatment|40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis
62519707|NCT01405287|ACTIVE_COMPARATOR|Everolimus Eluting Stent (EES)|PTCA with DES (Everolimus Eluting Stent: Xience V or Promus)
62519708|NCT01478737|SHAM_COMPARATOR|Sham|Vitrectomy only
62148766|NCT02399241|EXPERIMENTAL|Remote telemonitoring of clinical data|Bluetooth enabled nebuliser device (I-neb) providing breathing parameters and adherence data.
62148767|NCT00644306|PLACEBO_COMPARATOR|A|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
62148768|NCT00644306|ACTIVE_COMPARATOR|B|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
62148769|NCT00001627||Group 1|Normal Volunteers and patients.
62148770|NCT00444743|ACTIVE_COMPARATOR|1|
62148771|NCT00444743|PLACEBO_COMPARATOR|2|
62148772|NCT01372475|ACTIVE_COMPARATOR|Hymovis Viscoelastic Hydrogel|Intra-articular Injection
62356156|NCT04183387|NO_INTERVENTION|standard treatment|conventional treatment of uveitis
62356157|NCT05276765|EXPERIMENTAL|CAD/CAM customized Socket Sealing Abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
62356158|NCT05276765|ACTIVE_COMPARATOR|Standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
62356159|NCT06377072|EXPERIMENTAL|Shenqi Sherong Pill|6g per bag
62148773|NCT01372475|PLACEBO_COMPARATOR|Placebo|Phosphate Buffered Saline Intra-articular Injection
62148774|NCT05364515|ACTIVE_COMPARATOR|Conventional treatment|0.05% Clobetasol propionate
62148775|NCT05364515|EXPERIMENTAL|PRGF|"0.05% Clobetasol propionate + PRGF~PRGF: 4 infiltrations (first two months) + topical administration (from third month)"
62148776|NCT03690609|ACTIVE_COMPARATOR|Nutraceutical intervention, 3 capsules daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 3 capsules daily in the morning.
62519709|NCT01478737|ACTIVE_COMPARATOR|Intravitreal Ozurdex|Intravitreal Ozurdex after vitrectomy
62519710|NCT02931045|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
62519711|NCT02931045|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
62148777|NCT03690609|ACTIVE_COMPARATOR|Nutraceutical intervention, 2 capsules twice daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 4 capsules daily: Two in the morning and two later in the day.
62519712|NCT02080832|EXPERIMENTAL|Medication (Citalopram 20mg)|Citalopram (20mg dose)
62148778|NCT00278499||1|Female sex workers
62519713|NCT02080832|PLACEBO_COMPARATOR|Placebo|
62519714|NCT02080832|EXPERIMENTAL|Medication (Citalopram 40mg)|Citalopram 40mg dose
62519715|NCT01685541|EXPERIMENTAL|Maximum AVS Content|AVS includes patient name, visit date, chief complaining, allergies, immunizations, vital signs, medications, problem list, lab order, physician contact information, referrals, instructions
62148779|NCT00278499||2|Female sex workers' clients (miners)
62148780|NCT00620139||A|Some patients presenting with suspicious lesions of the oropharynx or oral cavity will need to undergo transoral biopsy in the clinic to confirm the diagnosis of carcinoma. Of those patients who choose to participate in the study, an extra piece of tumor will be harvested for investigational purposes related to this trial.
62519716|NCT01685541|EXPERIMENTAL|Intermediate AVS content|AVS includes patient name, visit date, vital signs, medications, diagnosis, problem list, physician contact information, referrals, instructions
62519717|NCT01685541|EXPERIMENTAL|Minimum AVS content|AVS contains patient name, visit date, medications, diagnosis, physician contact information, referrals, instructions
62148781|NCT00861315|EXPERIMENTAL|Nebulized amikacin|Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely
62148782|NCT00861315|ACTIVE_COMPARATOR|Intravenous amikacin|
62519718|NCT01685541|ACTIVE_COMPARATOR|Control Group (Usual AVS)|Content differed by clinic site
62519719|NCT02041091|EXPERIMENTAL|Tabalumab Auto-Injector|Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
62519720|NCT02041091|EXPERIMENTAL|Tabalumab Prefilled Syringe|Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.
62519721|NCT04334655||Clinic 1|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
62519722|NCT04334655||Clinic 2|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
62519723|NCT04334655||Clinic 3|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
62148783|NCT05503485|EXPERIMENTAL|Existential group treatment|Participants who are randomized to the experimental condition will participate in an existential group treatment together with 3 to 6 other participants in seven group sessions of 90-120 minutes each for seven weeks.
62148784|NCT05503485|ACTIVE_COMPARATOR|Supportive telephone calls|Participants who are randomized to the control condition will receive brief supportive telephone calls once a week for 7 weeks.
62148785|NCT02315118|EXPERIMENTAL|T-cell therapy + Rituximab + IL-2|"Patients will undergo apheresis procedure and T cell expansion will be done in the laboratory. All patients will receive Rituximab on day -2 and IL-2 three times per week for one week starting on day -1 (dose 1 of 3). IL-2 dosing will be continued 3 times per week for one week (3 doses total).~On Day 0, T cell modification in the laboratory and T cell infusion in the patient will be done.~A disease status evaluation will be conducted approximately 4 weeks post-T cell infusion."
62148786|NCT04926259|EXPERIMENTAL|18F-T807, PET/CT|PET/CT perform after injecting 18F-T807
62148787|NCT01673256||SJM Confirm ICM Observational Group|
62148788|NCT06371950|EXPERIMENTAL|Probiotic DE111®|1 capsule of probiotic DE111® containing 5 billion CFU Bacillus subtilis, to be taken once daily starting 3 weeks prior to surgery until 6 weeks after surgery.
62148789|NCT06371950|PLACEBO_COMPARATOR|Placebo|1 capsule of placebo, to be taken once daily starting 3 weeks prior to surgery until 6 weeks after surgery.
62148790|NCT01869465|ACTIVE_COMPARATOR|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
62356160|NCT06377072|PLACEBO_COMPARATOR|Placebo|6g per bag
62356161|NCT04783870|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg PO QD
62356162|NCT04783870|PLACEBO_COMPARATOR|Control|Placebo PO QD
62356163|NCT00907972|EXPERIMENTAL|Vitamin D3 supplementation|1000 IU/day of Vitamin D3
62356164|NCT00907972|PLACEBO_COMPARATOR|Placebo|Placebo
62519724|NCT04334655||Clinic 4|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
62519725|NCT04556552|EXPERIMENTAL|Active non-invasive Vagal nerve stimulation (VNS)|Active non-invasive Vagal Nerve Stimulation (nVNS) with opioid cues.
62519726|NCT04556552|SHAM_COMPARATOR|Sham stimulation|Sham stimulation of vagus with opioid cues
62519727|NCT01389934|PLACEBO_COMPARATOR|Control|Women of this group be infused saline 2 ml / h for 48h.
62519728|NCT01389934|EXPERIMENTAL|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.
62148791|NCT01869465|EXPERIMENTAL|Snack arm|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
62519729|NCT04799652||Doctors within Belgian Hospitals|
62519730|NCT01148641||LNS-regular|Lipid-based nutrient supplement, regular (peanut) flavor
62519731|NCT01148641||LNS-cinnamon|Lipid-based nutrient supplement, cinnamon flavor
62519732|NCT00681759||1|Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro).
62519733|NCT00681759||2|420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA)
62519734|NCT00681759||3|Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms.
62519735|NCT01269281|EXPERIMENTAL|Sumatriptan Succinate tablets 100 mg|Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited
62519736|NCT01269281|ACTIVE_COMPARATOR|Imitrex 100 mg Tablets|Imitrex 100 mg Tablets of Glaxosmithkline
62519737|NCT02974036||Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
62519738|NCT05692076|EXPERIMENTAL|HVNI group|Patients will receive high velocity nasal insufflation therapy
62519739|NCT05692076|OTHER|Control group|Patient will receive conventional oxygen therapy via nasal prongs , normal oxygen mask or venturi mask
62519740|NCT04732364|PLACEBO_COMPARATOR|Group (C) (control group):|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
62148792|NCT02253966|ACTIVE_COMPARATOR|Methylprednisoloneacetate|"Administration of:~1 ml methylprednisoloneacetate 40 mg/ml 5 ml lidocaine 20 mg/ml 4 ml sodium chloride 9 mg/ml as a single intraarticular injection 7 days prior to surgery."
62519741|NCT04732364|ACTIVE_COMPARATOR|Group (D) (Dexmetonidine group):|Patient will receive 20ml 0.25% levobupivacaine + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5..
62519742|NCT04732364|ACTIVE_COMPARATOR|Group (M) (magnesium slphate group):|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5..
62519743|NCT01816815|EXPERIMENTAL|BAY1002670 [0.1mg]|0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
62519744|NCT01816815|EXPERIMENTAL|BAY1002670 [0.5mg]|0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
62519745|NCT01816815|EXPERIMENTAL|BAY1002670 [1.0mg]|1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
62519746|NCT01816815|EXPERIMENTAL|BAY1002670 [2.0mg]|2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
62519747|NCT01816815|EXPERIMENTAL|BAY1002670 [5.0mg]|5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
62519748|NCT01816815|PLACEBO_COMPARATOR|Placebo|Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
62519749|NCT01651546|OTHER|Cohort|Patients with dysvoiding function and chronic urinary retention, with an indication to CISC.
62519750|NCT00003621|EXPERIMENTAL|carmustine + etoposide + cisplatin + radiation therapy|Patients receive carmustine IV over 1 hour on days 1-3, oral etoposide on days 1-21 and 29-49, and cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 3 courses. Patients receive radiotherapy concurrently with the third course of chemotherapy. Quality of life is assessed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 3 months for 5 years and then annually thereafter.
62519751|NCT05555394|EXPERIMENTAL|Basic Body Awareness Therapy|the Basic Body Awareness Therapy is usual therapy of physiotherapy in mental health in nord europe. BBAT is based in twelve movements and massage that improve the movements quality of patient, also improves other movement qualities like biomechanical, physiologic, socio-cultural and existential
62519752|NCT05555394|ACTIVE_COMPARATOR|Stretching group|"Stretching exercise will be developed in control group in order to blind the intervention of interest. It will consist in analytic stretching of trunk, upper and lower limb.~It will last around 45 min twice a week during 12 weeks."
62519753|NCT03716076|EXPERIMENTAL|Participant receives 50 mcg of carbetocin post-delivery.|Participant receives 50 mcg of carbetocin post-delivery.
62148793|NCT02253966|PLACEBO_COMPARATOR|Sodium chloride|"Administration of:~5 ml lidocaine 20 mg/ml 5 ml sodium chloride 9 mg/ml as a singe intraarticular injection 7 days prior to surgery."
62148794|NCT05948995|NO_INTERVENTION|Conventional arm sling|Conventional arm sling Arm position : Internal rotation , Adduction
62711012|NCT05381480|ACTIVE_COMPARATOR|On-site Evidence-based Physical Activity, Health and Wellness Classes|Curriculum. There will be three categories of classes offered at sites randomized into this intervention. A physical activity class will be offered three times weekly, and will include elements of Tai Chi, fall prevention, and arthritis exercises. Class content/activity will be modified for all levels of ability. A class focused on mental health and functioning will be offered weekly, and include activities targeting depression prevention, memory enhancement, and engagement (e.g., life review, agile mind). There will also be offered a weekly multi-topic class with a repeating cycle of topics and instructors including medication management, computer literacy and electronic health records, etc.. Tenants will be engaged in choosing topics that reflect the group consensus on importance. Altogether, at each location there will be five scheduled class opportunities each week for tenants to choose among.
62711013|NCT05539651|EXPERIMENTAL|RBD5044 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD5044 on Day 1.
62148795|NCT05948995|EXPERIMENTAL|Abduction external rotational brace|Abduction external rotational brace Arm position : Abduction , External rotation
62148796|NCT05479565||50 pregnant women with patological OGTT|50 pregnant women with patological OGTT ( glucose load test) and after delivery - 50 women with GDM in previous pregnancy.
62519754|NCT03716076|EXPERIMENTAL|Participant receives 100 mcg of carbetocin post-delivery.|Participant receives 100 mcg of carbetocin post-delivery.
62519755|NCT00793026|EXPERIMENTAL|1|Dermacyd Breeze Pocket BR (Lactic Acid)
62519756|NCT03050918|ACTIVE_COMPARATOR|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
62519757|NCT03050918|NO_INTERVENTION|Usual Care Group (Control Arm)|Patients assigned to the control group receive standard discharge planning and follow-up per the usual care of their medical providers.
62711014|NCT05539651|EXPERIMENTAL|RBD5044 MAD experimental group|Subjects in MAD experimental groups will receive one subcutaneous injection of RBD5044 on Day 1 and another subcutaneous injection of RBD5044 on Day 29.
62711015|NCT05539651|PLACEBO_COMPARATOR|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
62711016|NCT05539651|PLACEBO_COMPARATOR|Placebo MAD group|Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 1 and another subcutaneous injection of placebo on Day 29.
62148797|NCT05479565||50 pregnant women with regular OGTT|50 pregnant women with regular OGTT ( glucose load test) and after delivery - 50 women without GDM in previous pregnancy
62356165|NCT06420999||Patients weaned from mechanical or non invasive ventilation|Adults admitted to ICU receiving either invasive mechanical ventilation for at least 48 hours, non-invasive ventilation or high-flow humidified oxygen therapy for at least 48 hours, and who have been weaned from ventilatory support within the last 24 hours.
62356166|NCT05463159|EXPERIMENTAL|Group A|participants in this group will be given with TENS to spastic Hams, Adductor and TA along with stretchings and ROM as baseline treatment
62356167|NCT05463159|ACTIVE_COMPARATOR|Group B|participants in this group will be given with TENS to opposite of spastic muscles, i.e. quards, abductor and dorsiflexors along with stretchings and ROM as baseline treatment
62356168|NCT05463159|ACTIVE_COMPARATOR|Group C|participants in this group will be given with TENS to both spastic muscles and opposite of spastic muscle along with stretchings and ROM as baseline treatment
62356169|NCT05463159|ACTIVE_COMPARATOR|Group D|participants in this group will be given with stretchings and ROM as baseline treatment
62356170|NCT04777604||Patients with resectable pancreatic cancer after neoadjuvant chemotherapy|
62356171|NCT00751179|ACTIVE_COMPARATOR|Rocuronium - Sugammadex|Rocuronium - Sugammadex 4.0 mg/kg
62519758|NCT05333237|EXPERIMENTAL|Sequence 123|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
62711017|NCT03671811|EXPERIMENTAL|Arm I (pterostilbene, megestrol acetate)|Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
62148798|NCT06510959|OTHER|Digital course|10-lesson weekly course taught by a peer on the use of smartphones and daily utility apps.
62148799|NCT06552351|EXPERIMENTAL|Needle-Free Jet Injection of 1 % lidocaine|"Device: Needle-Free Jet Injection The needle-free jet injection device delivers 1 % Lidocaine through high-pressure fluid without the use of a needle. This method aims to reduce the pain associated with needle-based anesthesia during infant lumbar punctures.~Other Names:~• Jet Injection Device, J-tip"
62356172|NCT00751179|ACTIVE_COMPARATOR|Succinylcholine|Succinylcholine 1.0 mg/kg
62711018|NCT03671811|EXPERIMENTAL|Arm II (megestrol acetate)|Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
62148800|NCT06552351|EXPERIMENTAL|Traditional needle infiltration of 1% lidocaine|"Traditional needle infiltration involves injecting 1% lidocaine with a needle to provide local anesthesia before an infant lumbar puncture. This method is the standard practice for pain management in such procedures.~Other Names:~• traditional needle infiltration of 1% lidocaine"
62148801|NCT03507504||care pathway with SCU-B|250 patients with dementia and behavioural and psychological symptoms of dementia (BPSD) followed up by six clinical centres with a Special Care Unit for BPSD (SCU-B)
62148802|NCT03507504||care pathway without SCU-B|250 patients with dementia and BPSD followed up by six clinical centres without SCU-B
62148803|NCT03593785|EXPERIMENTAL|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
62711019|NCT04490278|EXPERIMENTAL|Patients with PICS|
62711020|NCT05966480|EXPERIMENTAL|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
62711021|NCT05966480|EXPERIMENTAL|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
62148804|NCT03593785|EXPERIMENTAL|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
62148805|NCT03593785|EXPERIMENTAL|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
62356173|NCT06306326|EXPERIMENTAL|3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities|By performing autologous fat grafting surgery on 100 patients with craniofacial deformities that meet the research criteria, 3dMD technology will be used for facial three-dimensional scanning preoperatively, immediately postoperatively, and at six months postoperatively to obtain facial volume data. Then, through precise data analysis, we will calculate the fat absorption rate and study the effects of individual factors on treatment outcomes through correlation regression analysis.
62356174|NCT01071668||GEM-2 Cohort|Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
62519759|NCT05333237|EXPERIMENTAL|Sequence 132|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
62148806|NCT03593785|EXPERIMENTAL|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
62356175|NCT01003795||Promus|Patients treated with at least one Promus, everolimus-eluting, Stent
62356176|NCT05474469|EXPERIMENTAL|Diaphragmatic breathing in combination with abdominal muscle strengthening exercises|Exprimental Group ( Group A) will receive diaphragmatic breathing in combination with abdominal muscle strengthening exercises .12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
62356177|NCT05474469|ACTIVE_COMPARATOR|Diaphragmatic breathing Exercises only without abdominal muscle strengthening exercises|Active comparator (Group B) will receive diaphragmatic breathing only. 12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
62356178|NCT04883567||AI arm|AI would be used to assist the trainee endoscopist
62356179|NCT04883567||Non-AI arm|Trainee endoscopist would perform OGD as usual.
62356180|NCT03831737|EXPERIMENTAL|Group 1: In-Person|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will participate in in-person physical therapist-led instructional sessions three times per week. Each stretch will be performed twice, one on the left and one on the right. The therapist will describe what to do and briefly demonstrate each stretch. Stretches will be held for 45-60 seconds with therapist instructions and modification as needed based on subject technique."
62356181|NCT03831737|EXPERIMENTAL|Group 2: Video|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will complete sessions three times per week, led by a physical therapist and viewed remotely via pre-recorded video using a smartphone application."
62519760|NCT05333237|EXPERIMENTAL|Sequence 213|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
62711022|NCT05966480|EXPERIMENTAL|ESK-001 Dose Level 3|ESK-001 administered as an oral tablet
62148807|NCT03593785|EXPERIMENTAL|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
62148808|NCT01519882|PLACEBO_COMPARATOR|Placebo|Placebo Transdermal Patches
62356182|NCT04952051|EXPERIMENTAL|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
62356183|NCT04952051|ACTIVE_COMPARATOR|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
62711023|NCT05966480|PLACEBO_COMPARATOR|Placebo|Placebo administered as an oral tablet
62711024|NCT05072483||Healthy controls|Healthy controls for exploratory analyses, where the measurements were not commonly performed previously in other populations, for qualitative comparison with CADASIL population
62711025|NCT05072483||Subjects with CADASIL|Adult genetically-confirmed patients with a wider range of CADASIL disease duration and debility
62711026|NCT03025126|EXPERIMENTAL|HEAD Rehabilitation|rehabilitation with IT multimedial devices
62711027|NCT03025126|ACTIVE_COMPARATOR|Usual care program|usual care program
62148809|NCT01519882|EXPERIMENTAL|Rotigotine|Rotigotine Transdermal Patches
62148810|NCT02488798||postmenopausal bleeding group|"100 women with postmenopausal bleeding undergoing 2D greyscale vaginal ultrasound and 3D Endometrial power Doppler and the features were classified using six different vascular patterns described by IETA group including the following patterns; single dominant vessel without branching, with branching, multiple vessels with focal origin, with multifocal origin at the myometrium-endometrium junction, scattered vessels or circular flow (Kucur et al., 2013 ).~All patients then had Office hysteroscopy carried out in the outpatient clinic using vaginoscopic approach (Cooper et al., 2010). With endometrial samples from lesions or from the cavity for histopathological analysis."
62711028|NCT01031888|ACTIVE_COMPARATOR|1|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops
62148811|NCT01078051|ACTIVE_COMPARATOR|Optimal medical therapy|optimal medical therapy
62148812|NCT01078051|ACTIVE_COMPARATOR|drug-eluting stent|Cypher, xience, Endeavor, Taxus
62148813|NCT02340806|EXPERIMENTAL|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
62519761|NCT05333237|EXPERIMENTAL|Sequence 231|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
62148814|NCT02340806|EXPERIMENTAL|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
62148815|NCT02798653|EXPERIMENTAL|Choriomon®|subjects receive 1,500 IU of hCG (Choriomon®; IBSA) intramuscular (IM) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
62519762|NCT05333237|EXPERIMENTAL|Sequence 312|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
62519763|NCT05333237|EXPERIMENTAL|Sequence 321|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
62148816|NCT02798653|EXPERIMENTAL|Choriomon®+Endometrin ®|patients will receive 1,500 IU of hCG (Choriomon®; IBSA) (IM) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
62148817|NCT02798653|EXPERIMENTAL|Endometrin ®|patients will receive only Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
62519764|NCT06392763||KYMRIAH DLBCL|
62519765|NCT06392763||YESCARTA DLBCL|
62519766|NCT06392763||CAR-T DLBCL|
62519767|NCT06392763||KYMRIAH ALL|
62519768|NCT03574922|ACTIVE_COMPARATOR|Balance Exercises|Balance Exercises
62519769|NCT03574922|ACTIVE_COMPARATOR|Core Stabilization Exercises|Balance and core stabilization exercises
62519770|NCT03574922|NO_INTERVENTION|Control|Assessments only
62519771|NCT04252222|EXPERIMENTAL|VL3|Tracheal intubation with VL3 videolaryngoscope
62519772|NCT01021241|EXPERIMENTAL|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner
62519773|NCT03601546||Patients with HCV infection|
62519774|NCT03650959|EXPERIMENTAL|Faculty-led|
62519775|NCT03650959|EXPERIMENTAL|Peer tutor-led|
62148818|NCT05073393|EXPERIMENTAL|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
62148819|NCT05073393|PLACEBO_COMPARATOR|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
62148820|NCT02353507|ACTIVE_COMPARATOR|Opticell Ag+|Absorbent, antibacterial, barrier dressing
62148821|NCT02353507|ACTIVE_COMPARATOR|Aquacel Ag+|Absorbent, antibacterial, barrier dressing
62148822|NCT02915211|EXPERIMENTAL|Consumption of Keyo|Participants will consume their normal KD and take Keyo as advised by the lead dietitian.
62148823|NCT06452121||Diabetic patients|to know severity of coronary artery disease using Triglyceride glucose (TyG) index in diabetic patients comparing it with non diabetic
62148824|NCT06452121||Non diabetic patients|to know severity of coronary artery disease using Triglyceride glucose (TyG) index in non diabetic patients
62148825|NCT00635635|ACTIVE_COMPARATOR|1|Guided Imagery Audio
62148826|NCT00635635|ACTIVE_COMPARATOR|2|Music Audio
62519776|NCT03650959|EXPERIMENTAL|Computer augmented self-directed learning|
62519777|NCT06082674|EXPERIMENTAL|Vayu CPAP Group|The patients will be hooked to VAYu bCPAP
62519778|NCT06082674|ACTIVE_COMPARATOR|Mechanical Ventilator Driven CPAP|Patients will be hooked to Mechanical Ventilator Driven CPAP
62519779|NCT00673933|EXPERIMENTAL|1|PDT using MAL crem
62519780|NCT00673933|PLACEBO_COMPARATOR|2|PDT using Placebo cream
62519781|NCT02932020|EXPERIMENTAL|Group A|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection of (a) 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI~Visit: 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
62519782|NCT02932020|OTHER|Group B|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection 2mL 0.5% marcaine and 1mL and 1mL steroid (depomedrol 80mg/ml).~Visit 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
62519783|NCT03329807|EXPERIMENTAL|Experimental rTMS and conventional sensory therapy|"Device: Repetitive Transcranial Magnetic Stimulation (rTMS) The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.~Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week."
62711029|NCT01031888|ACTIVE_COMPARATOR|2|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops
62148827|NCT04090502|EXPERIMENTAL|Grupo A. Dry needling in Trigger point|Participants will be treated in the most hyperalgesic foci within the hamstring musculature.
62519784|NCT03329807|SHAM_COMPARATOR|Sham Comparator|"control The control group received rTMS sham stimulation (same area as the experimental group) in 10 sessions, 5 days per week, and Sham conventional sensory therapy in the paretic upper limb The sham stimulation will be applied so that it is perceived by the patient as real. Thus during the rTMS sessions the same procedures of the active rTMS sessions will be applied, however the stimulation will be performed with two coils: a coil coupled to the stimulator positioned away from the patient's scalp, yet not visible to the patient so that the patient Perceive only the characteristic sound of the stimulation, and the other coil, disconnected from the stimulator positioned on the volunteer's head.~For the SHAM group, all sensory therapy activities will be performed, however only with the non-affected member. Patients will be convinced that a transfer of skills from one member to another can occur through the connections between the hemispheres."
62519785|NCT03563846|EXPERIMENTAL|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
62519786|NCT03563846|EXPERIMENTAL|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
62519787|NCT04860596|EXPERIMENTAL|collaborative health management model program|nursing education and self care program
62519788|NCT04860596|NO_INTERVENTION|Routine care|Tranditional education program
62711030|NCT01031888|PLACEBO_COMPARATOR|3|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops
62711031|NCT01031888|PLACEBO_COMPARATOR|4|corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops
62711032|NCT05157360|EXPERIMENTAL|Treatment Arm|"Patients will be enrolled within 24 hours of diagnosis of sepsis related to a necrotizing soft-tissue infections (NSTI). HAT will be initiated within 4 hours of enrollment (thus treatment with HAT can occur no later than 28 hours from diagnosis).~Per Dr. Marik's original study, HAT consists of:~1. 1.5 g vitamin C every 6 hours for 4 days or until ICU discharge~2. 50 mg hydrocortisone every 6 hours for 7 days or until ICU discharge (followed by a taper over 3 days)~3. 200 mg thiamine every 12 hours for 4 days or until ICU discharge In our study, due to the prolonged ICU course typical of most patients with NSTIs, it is not felt feasible to continue indefinitely until ICU discharge. Thus, treatment will be continued for 4 to 7 days plus a 3 day taper (respectively) as above, with no plan for a longer duration of treatment."
62711033|NCT05157360|PLACEBO_COMPARATOR|Control Arm|The control arm will receive the same standard ICU care for NSTI but will not receive HAT. They will receive a placebo consisting of normal saline, indistinguishable to the treatment team (blinded) but known to the pharmacy team (unblinded to treatment and placebo groups). This is so that if the treatment team elects to give stress dose steroids, they can be administered without breaking protocol (i.e. if the patient is getting HAT, it includes steroids, so if the treating team wanted to start hydrocortisone - because they didn't know if the patient was on HAT or placebo and felt steroids were indicated - the pharmacist could ensure the patient was on steroids one way or another without unblinding the providers).
62148828|NCT04090502|PLACEBO_COMPARATOR|Grupo B. Dry needling in non-hyperalgesic areas|Participants will be treated in non-hyperalgesic areas within the hamstring muscles.
62148829|NCT01487460|EXPERIMENTAL|TAP311 in Healthy Volunteers|
62148830|NCT01487460|PLACEBO_COMPARATOR|Matching Placebo|Healthy Volunteers and Patients will be treated in Placebo group.
62148831|NCT01487460|EXPERIMENTAL|TAP311 and Simvastatin|
62148832|NCT01487460|EXPERIMENTAL|TAP311 in Patients|
62148833|NCT00655785|EXPERIMENTAL|Phase 1/2 study|
62148834|NCT02562274|PLACEBO_COMPARATOR|Placebo group|Subjects are received the placebo product which has same color and smell look like the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) treatments once daily for 8 weeks
62148835|NCT02562274|ACTIVE_COMPARATOR|MP 50 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 50 mg/day treatments once daily for 8 weeks
62148836|NCT02562274|ACTIVE_COMPARATOR|MP 1500 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 1500 mg/day treatments once daily for 8 weeks
62148837|NCT01745666|EXPERIMENTAL|patients with KCNQ1 or KCNH2 mutation|
62148838|NCT01745666|OTHER|patients WITHOUT KCNQ1 or KCNH2 mutation (control group)|
62148839|NCT02398955||Study cohort|All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent
62148840|NCT04848532|EXPERIMENTAL|Adolescent-specific behavioral weight loss treatment|
62148841|NCT04454112|EXPERIMENTAL|24-hour esophageal pH monitoring|24-hour esophageal pH monitoring was conducted using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands). This system consists of a portable data logger (MMS Investigation and Diagnostic Software®) and a disposable catheter which contains two pH electrodes (Unisensor, Attikon, Switzerland). Before recording, the pH electrode was calibrated in the special buffer solutions at pH values of 1 and 2.
62148842|NCT02732132|ACTIVE_COMPARATOR|Ketamine and Midazolam|ketamine 1 mg/kg midazolam 0.1 mg/kg
62148843|NCT02732132|EXPERIMENTAL|Propofol and Fentanyl|propofol 1 mg/kg fentanyl 1 mcg/kg
62148844|NCT02845609|EXPERIMENTAL|Intervention|Sialic acid-Extended release 2000 mg, three times per day (TID) for 3 months
62148845|NCT01444404|EXPERIMENTAL|Dose Expansion|The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
62148846|NCT01444404|EXPERIMENTAL|Dose Escalation|The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.
62148847|NCT01784809|EXPERIMENTAL|Multimedia HIV/STI prevention|Multimedia WORTH is a 4-session group based gender specific HIV and drug abuse prevention intervention.
62148848|NCT01784809|ACTIVE_COMPARATOR|Traditional HIV/STI prevention|Traditional WORTH is a 4-session group-based HIV/STI and drug abuse prevention intervention that covers the same content as Multimedia WORTH without the use of interactive videos, computerized assessments, and other audiovisual tools.
62519789|NCT02357342|EXPERIMENTAL|Sirolimus|Intravitreal Sirolimus
62519790|NCT02357342|ACTIVE_COMPARATOR|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
62519791|NCT06107478||Children ALL, 2-12 years old|Children with acute lymphoblastic leukemia (ALL) and in the induction phase of its treatment (at least one month post-diagnosis and up to 50 days post-diagnosis, i.e. until the first day of consolidation).
62519792|NCT06107478||Parents of children ALL|Parents of a patient with acute lymphoblastic leukemia (ALL) being in the induction phase of his treatment (at least one month post-diagnosis and up to 50 days post-diagnosis, i.e. until the first day of consolidation), 2 to 12 years of age at diagnosis and managed by a participating centre.
62519793|NCT04419623|EXPERIMENTAL|Dose Finding - 200mg BID|200mg TL-895 orally BID taken continuously in 7-day cycles for 2 - 4 cycles with SAT for COVID-19 (14 - 28 days of treatment).
62519794|NCT06221878||Laparoscopic Group|Individuals with a body mass index of ≥ 30 kg/m2 underwent laparoscopic surgery for primary stage I-III colorectal adenocarcinoma.
62519795|NCT06221878||Open Group|Individuals with a body mass index of ≥ 30 kg/m2 underwent open surgery for primary stage I-III colorectal adenocarcinoma.
62519796|NCT03840252|ACTIVE_COMPARATOR|PD patients: Parkinson's disease group|"Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
62519797|NCT03840252|ACTIVE_COMPARATOR|PSP patients|"Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of probable PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
62519798|NCT03840252|ACTIVE_COMPARATOR|HC: healthy control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
62519799|NCT04587102|ACTIVE_COMPARATOR|whole body viberation :group A|will receive low vibrational training in the form of whole body vibration for 8 weeks
62519800|NCT04587102|ACTIVE_COMPARATOR|control group (B)|control
62519801|NCT00136578|EXPERIMENTAL|Subjects receiving carboplatin and SB-715992|Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.
62519802|NCT05818748|EXPERIMENTAL|virtual reality distraction|watching the application by wearing virtual glasses to the child during the 1st, 2nd and 3rd days of chemotherapy treatment
62519803|NCT05818748|NO_INTERVENTION|control|no virtual reality distraction
62519804|NCT02446834|EXPERIMENTAL|intensive lifestyle intervention|3 months intensive lifestyle intervention, including low GI diet and exercise.
62519805|NCT02446834|EXPERIMENTAL|GLP-1 Receptor Agonists|3 months GLP-1 Receptor Agonists treatment
62519806|NCT02446834|EXPERIMENTAL|metformin|3 months metformin treatment
62519807|NCT02446834|EXPERIMENTAL|acarbose|3 months acarbose treatment
62519808|NCT00677079|EXPERIMENTAL|Iniparib|Iniparib, twice weekly on Days 1 and 4 of each week during 8-week cycles
62519809|NCT02984774|EXPERIMENTAL|Infertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
62519810|NCT02984774|EXPERIMENTAL|Fertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
62148849|NCT01784809|PLACEBO_COMPARATOR|Wellness Promotion|Wellness Promotion is a 4-session group based intervention that aims to improve diet, physical fitness and well-being which is designed as an attentional control condition.
62519811|NCT02984774|OTHER|Control|Ovarian tissue sampling, endometrial sampling from hysterectomy and oophorectomy pieces and peripheric blood sampling during intravenous catheterization during anesthesia.
62519812|NCT05862194||Lazertinib|
62148850|NCT01338532|ACTIVE_COMPARATOR|Supervised exercise + patient education|
62148851|NCT01338532|ACTIVE_COMPARATOR|Patient education|
62519813|NCT05862194||Platinum-based Chemotherapy|
62519814|NCT00038649|EXPERIMENTAL|Gleevec|Gleevec 400 mg orally twice daily.
62519815|NCT02603978|NO_INTERVENTION|Wait-list|This arm will receive no intervention for the first 6 months. At the conclusion of the 6-month period, this group will receive a brief alcohol intervention
62519816|NCT02603978|ACTIVE_COMPARATOR|Brief Alcohol Intervention|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing
62148852|NCT06205836|EXPERIMENTAL|Cohort A - Cemiplimab|
62148853|NCT06205836|EXPERIMENTAL|Cohort B - Cemiplimab with Fianlimab|
62519817|NCT02603978|ACTIVE_COMPARATOR|Bystander and Social Norms Intervention|This arm will receive a brief (2-hour) bystander and social norms intervention designed to increase healthy sexual behaviors
62519818|NCT02603978|ACTIVE_COMPARATOR|Combined Alcohol and Bystander Intervention|This arm will receive a combined (4-hour) alcohol and bystander/social norms intervention to target both alcohol and sexual behavior
62519819|NCT00908518||Total Intravenous Anesthesia|Propofol based anesthesia
62519820|NCT00908518||Inhaled anesthesia|Isoflurane based anesthesia
62519821|NCT05182619|ACTIVE_COMPARATOR|ultrasoung guided stellate block|stellate ganglion will have ultrasound-guided block via bupivacaine for sympathectomy and enhancement of cerebral blood flow
62519822|NCT05182619|ACTIVE_COMPARATOR|nimodipine infusion|intravenous nimodipine will be given for enhancement of cerebral blood flow
62711034|NCT05631444|PLACEBO_COMPARATOR|Placebo group|Placebo group (n=10), which consisted of 15 injections of 1 mL of vehicle (1 mL saline solution with 2% of autologous serum) on periadventitial arteries in one dose at day 0.
62148854|NCT01407874|EXPERIMENTAL|Placebo|Placebo + Allopurinol 200mg
62148855|NCT01407874|EXPERIMENTAL|Ulodesine (BCX4208) 5mg|BCX4208 5mg + Allopurinol 200 mg
62148856|NCT01407874|EXPERIMENTAL|Ulodesine (BCX4208) 10mg|BCX4208 10mg + Allopurinol 200mg
62519823|NCT05177562||PCOS|No intervention.
62519824|NCT05177562||PCOS surgery|No intervention
62519825|NCT05177562||Surgery control|No intervention
62519826|NCT05177562||IVF PCOS|No intervention
62519827|NCT05177562||IVF control|No intervention
62519828|NCT05177562||Investigations, fertility PCOS|No intervention
62519829|NCT05177562||Investigations, fertility control|No intervention
62519830|NCT05177562||Pregnancy - gestational diabetes mellitus|No intervention
62519831|NCT05177562||Pregnancy - Intrahepatic cholestasis of pregnancy|No intervention
62519832|NCT05177562||Pregnancy - control|No intervention
62711035|NCT05631444|EXPERIMENTAL|Auto-BM-MNC|Auto-BM-MNC (n=7) were obtained from diabetic patients. Fifteen injections of 7.197x106 ± 2.984x106 cells/mL each with 2% of autologous serum were periadventitial arteries administrated in one dose at day 0.
62148857|NCT04272385||Focus Group|Qualitative research done with a group of patients with TN. Patients will describe their experience of living with the disease and what outcomes of treatment they consider to be important.
62148858|NCT04272385||Delphi survey|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment in a 3 round Delphi survey.
62148859|NCT04272385||Consensus meeting|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment and finalise the COS for Trigeminal Neuralgia.
62356184|NCT04814472|EXPERIMENTAL|Oral Solution vs. Tablet Formulation|"There will be 3 treatments, each single dose administered based on the treatment sequence with at least a 3 day washout between treatments:~Treatment A: 750 mg BLD-0409 oral solution formulation (solution) under fasting conditions.~Treatment B: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fasting conditions.~Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fed conditions."
62356185|NCT04814472|EXPERIMENTAL|Tablet Formulation Dose Proportionality|"There will be 4 treatments, each single dose administered under fed conditions (standard meal) based on the treatment sequence with at least a 3 day washout between treatments:~Treatment A: 250 mg BLD-0409 tablet formulation (1 x 250 mg tablet).~Treatment B: 500 mg BLD-0409 tablet formulation (2 x 250 mg tablet).~Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablet).~Treatment D: 1000 mg BLD-0409 tablet formulation (4 x 250 mg tablet)."
62356186|NCT00033228|EXPERIMENTAL|Cohort 1|The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (\<33%) patients of a 6 patient cohort.
62356187|NCT00033228|EXPERIMENTAL|Cohort 2|The second cohort of 6 patients received 1000 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (\<33%) patients of a 6 patient cohort.
62356188|NCT00033228|EXPERIMENTAL|Cohort 3|The third cohort of 6 patients received 1500 ug of Synchrovax SEM plasmid DNA vaccine. The maximum tolerated dose (MTD) was to be determined by the observation of DLT at each dose group.
62356189|NCT03067194|ACTIVE_COMPARATOR|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
62356190|NCT03067194|ACTIVE_COMPARATOR|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
62356191|NCT00801138|PLACEBO_COMPARATOR|Group 1|Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
62356192|NCT00801138|PLACEBO_COMPARATOR|Group 2|Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
62356193|NCT00801138|ACTIVE_COMPARATOR|Group 3|Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
62356194|NCT00801138|ACTIVE_COMPARATOR|Group 4|Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).
62356195|NCT03052387|PLACEBO_COMPARATOR|control|"* Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.~* Buccal\& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.~* Decortication of the bone bed to increase the blood supply to the onlay graft.~* The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.~* Periosteal incisions are usually needed to allow tension free sutures.~* Vicryl 3/0 sutures for closer.~* augmentin 1g twice daily for 5 days.~* catflam 50g twice daily for 3 days"
62356196|NCT03052387|ACTIVE_COMPARATOR|Comparator|"* Crestal incision with labial flap reflected leaving the palatal tissues without elevation.~* Marking of the 3 bony cuts ( 2 vertical cuts \& 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.~* Drilling of pilot drill and first drill only.~* 3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.~* splitting osteotomes are used and mallet to complete the splitting of the bony segment.~* After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.~* The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.~* Drilling through the bony segment and the block graft.~* Immediate implant placement~chin graft block dental implants"
62356197|NCT03330600|EXPERIMENTAL|aquatic physicotherapy group|For the experimental group, we will associate kinesiotherapy with immersion in water.
62356198|NCT03330600|PLACEBO_COMPARATOR|immersion group|The control group will be submitted to immersion in the water, contained in flexion with the towel and maintaining the same care as the experimental one.
62356199|NCT03822702|NO_INTERVENTION|1st part:System development of Adult|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
62356200|NCT03822702|NO_INTERVENTION|1st part:System development of Child|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
62356201|NCT03822702|NO_INTERVENTION|2nd part:Handwriting Difficulty|No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour with sensors on the hand. A handwriting screening questionnaire shall be filled.
62711036|NCT05631444|EXPERIMENTAL|Allo-WJ-MSCs|Allo-WJ-MSCs (n=7) were obtained from culturing the WJ from healthy cordon umbilical donors unrelated to the patient. Fifteen injections of 1.333x106 cells/mL each with 5% of human serum albumin serum were periadventitial arteries administrated in one dose at day 0.
62148860|NCT04336709|ACTIVE_COMPARATOR|Calcipex II|Calcipex group Manufactures Nishika, Yamaguchi, Japan Color- White Formulation- Water based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Water-based calcium hydroxide paste without radio contrast agent (Barium Sulfate) Packaging- (1 syringe of Calcipex Plain II (1.8g), 2 needles of Nishika Spin with 2 needle caps) Storage requirement- Room temperature (1-30℃).
62148861|NCT04336709|ACTIVE_COMPARATOR|Metapex|Metapex group Manufactures- Meta Biomed, Korea Color- Yellow Formulation- Oil based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Premixed oil-based paste composed of Calcium Hydroxide with Iodoform and silicon oil Packaging-2.2g paste in 1 syringe. 20 disposable tips. 1 ring rotator for direction control of the tip Storage requirement- Room temperature (1-30℃).
62148862|NCT04130490||Eye with normal Anterior Segment|3 repeat measurements on each of the 3 investigational and reference devices
62148863|NCT04130490||Eye with cataract|3 repeat measurements on each of the 3 investigational and reference devices
62148864|NCT04130490||Eye with corneal abnormality|3 repeat measurements on each of the 3 investigational and reference devices
62148865|NCT04130490||Eye with status post-keratorefractive surgery|3 repeat measurements on each of the 3 investigational and reference devices
62148866|NCT04130490||Eye without a crystalline lens|3 repeat measurements on each of the 3 investigational and reference devices
62148867|NCT05662930||Hypertension + Diabetes Mellitus (HT+DM)|"Patients who fulfilled the following criteria were included in this group:~1. Using antihypertensive treatment for the last 3 months~2. Diagnosed with Type 2 Diabetes Mellitus and taking medication for at least 3 months~3. Being between the ages of 40-65~4. Being male~5. Having signed the informed consent form"
62148868|NCT05662930||Hypertension (HT)|"Patients who fulfilled the following criteria were included in this group:~1. Using antihypertensive treatment for the last 3 months~2. Being between the ages of 40-65~3. Being male~4. Having signed the informed consent form"
62148869|NCT00607607|EXPERIMENTAL|A|Ovarian Cancer Patients
62148870|NCT00607607|EXPERIMENTAL|B|Endometrial Cancer Patients
62356202|NCT03822702|EXPERIMENTAL|3rd part: Biofeedback Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Biofeedback Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
62148871|NCT03949257|EXPERIMENTAL|colonic TET and FMT|gut microbiota will be collected through the colonic TET after FMT
62148872|NCT03137446|NO_INTERVENTION|Usual Care|Participants randomized to the usual care resuscitation strategy will receive an initial 30 ml/kg bolus and then IV fluids as needed and without limit as well as IV vasopressors to maintain a MAP\>65, determined by the primary care team for the duration of the study.
62148873|NCT03137446|EXPERIMENTAL|Restrictive Care|Participants randomized to the restrictive fluid resuscitation strategy will be LIMITED to 60 ml/kg (up to 6000 ml) of IV fluids as initial resuscitation followed by administration of IV vasopressors to maintain a MAP\>65 mm Hg for the first 72 hours of care. The intervention is defined as capping the total allowed IVF administered. After 72 hours the participants are eligible for IV fluids as determined by the primary care team.
62148874|NCT02368652|EXPERIMENTAL|CC 16mg|Candesartan ceilexetil 16mg, once a day for 8 weeks
62148875|NCT02368652|EXPERIMENTAL|AML 10mg / CC 16mg|Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
62356203|NCT03822702|EXPERIMENTAL|3rd part: Motor Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Motor Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
62356204|NCT03822702|NO_INTERVENTION|3rd part:Control Group|"No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~The same procedure will be ask to do again about one and a half month later."
62356205|NCT01803711|EXPERIMENTAL|Desvenlafaxine + Omega 3 FA supplement|Desvenlafaxine 50mg/day \& Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
62356206|NCT01803711|ACTIVE_COMPARATOR|Desvenlafaxine + Placebo (for Omega 3 FA supplement)|Desvenlafaxine 50mg/day \& Placebo (for Omega 3 FA supplement) over a 12 week period
62356207|NCT04980898|EXPERIMENTAL|Electrical stimulation wound management system|Two daily electrostimulation sessions using the WoundEL® device on wound two for 30 minutes at an adjustable intensity, between 5 and 42 milliampere and chosen by the patient.
62356208|NCT04980898|ACTIVE_COMPARATOR|Standard of care|Use of dressings appropriate to the stage of healing according to French recommendations for the management of leg ulcers.
62356209|NCT01652937|PLACEBO_COMPARATOR|Placebo + Background Therapy|Background therapy including DMARD(s) approved by protocol
62356210|NCT01652937|EXPERIMENTAL|BIIB057 Dose 1 + Background Therapy|Background therapy including DMARD(s) approved by protocol
62356211|NCT01652937|EXPERIMENTAL|BIIB057 Dose 2 + Background Therapy|Background therapy including DMARD(s) approved by protocol
62356212|NCT01652937|EXPERIMENTAL|BIIB057 Dose 3 + Background Therapy|Background therapy including DMARD(s) approved by protocol
62356213|NCT06402903||Observacional group|The data will be collected in April 2024 at the Physical Medicine and Rehabilitation Service of the Central University Hospital of Asturias (HUCA), belonging to Health Area IV of the Health Service of the Principality of Asturias.
62356214|NCT02418767|EXPERIMENTAL|Low dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
62711037|NCT06119217|EXPERIMENTAL|Arm 1|TTX-030 plus nab-paclitaxel and gemcitabine
62711038|NCT06119217|EXPERIMENTAL|Arm 2|TTX-030 plus budigalimab plus nab-paclitaxel and gemcitabine
62711039|NCT06119217|ACTIVE_COMPARATOR|Arm 3|Nab-Paclitaxel and gemcitabine
62519833|NCT02422914|EXPERIMENTAL|Nicotine|Smoking cessation program TFC and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (with nicotine) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
62519834|NCT02422914|PLACEBO_COMPARATOR|Nicotine-free|Smoking cessation program TFC-free and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (nicotine-free) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity trackerand ad-hoc items.
62519835|NCT02422914|ACTIVE_COMPARATOR|No-cig|Smoking cessation program and activity tracker. Three months low intensity counselling at distance program;subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
62519836|NCT06158074|EXPERIMENTAL|EPNS group|
62519837|NCT06158074|ACTIVE_COMPARATOR|SNM group|
62519838|NCT04798235|EXPERIMENTAL|TSHA-101|Subjects who will receive one-time intrathecal TSHA-101, brain volume based sliding scale for dosage
62519839|NCT03237533|ACTIVE_COMPARATOR|Study Group|in this group patients will be treated with Dexamethasone local application
62519840|NCT03237533|ACTIVE_COMPARATOR|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
62148876|NCT04916704||CMV seropositive|New diagnosis of AAV as evidenced by relevant biopsy and / or clinical diagnosis in the context of a positive ANCA antibody OR major relapse of previously diagnosed AAV that requires re-induction of remission treatment with intravenous rituximab or cyclophosphamide together with high dose oral corticosteroids. CMV IgG positive.
62148877|NCT04916704||CMV seronegative|New diagnosis of AAV as evidenced by relevant biopsy and / or clinical diagnosis in the context of a positive ANCA antibody OR major relapse of previously diagnosed AAV that requires re-induction of remission treatment with intravenous rituximab or cyclophosphamide together with high dose oral corticosteroids. CMV IgG positive. CMV IgG negative.
62148878|NCT03055598|EXPERIMENTAL|Ferric Citrate|Ferric Citrate (Auryxia) will be dosed initially at 2 tablets three times a day (with meals).
62148879|NCT02795741|EXPERIMENTAL|Cooling Bolero|All participants will use the Cooling Bolero for one month
62148880|NCT02312544|ACTIVE_COMPARATOR|OTX-TP treatment|OTX-TP (sustained release travoprost, 0.36 mg) to be used in this trial with placebo drops administered separately
62148881|NCT02312544|ACTIVE_COMPARATOR|Timolol control|Timolol Maleate Ophthalmic Solution, 0.5% dosed twice daily (BID) in the presence of a placebo vehicle punctum plug (PV).
62148882|NCT03595670||experimental group|"• Patients diagnosed bipolar in mania, depression or euthymic phases according DSM-IV critiera by psychiatrist~standardized questionnaires and interview will be performed"
62148883|NCT02689011|EXPERIMENTAL|Group F|Femoral nerve Block Group
62148884|NCT02689011|ACTIVE_COMPARATOR|Group E|Epidural Group
62148885|NCT05756569|EXPERIMENTAL|Treatment (enfortumab vedotin, pembrolizumab)|Patients receive enfortumab vedotin IV and pembrolizumab IV on study. Patients also undergo CT scan or MRI, and collection of blood throughout the trial.
62148886|NCT03450811|ACTIVE_COMPARATOR|Study group|The patients underwent elective open or laparoscopic inguinal hernia repair at a general surgery clinic.
62148887|NCT03450811|NO_INTERVENTION|Control group|patients who were admitted to the outpatient clinics with various diseases or healthy persons
62148888|NCT04918394||Asthma patients unexposed to mold / moisture|No mold / moisture exposure is defined by a negative response to all of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
62148889|NCT04918394||Asthma patients exposed to mold / moisture|Mold / moisture exposure is defined by a positive response to at least one of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
62148890|NCT00712179||Stroke Survivors|Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.
62148891|NCT01303744|EXPERIMENTAL|CHF 5074 1x|oral tablet, multidose
62148892|NCT01303744|EXPERIMENTAL|CHF 5074 2x|oral tablet, multidose
62519841|NCT04221607|EXPERIMENTAL|Feasibility|Sensate Focus Exercises aim to help couples be more present with one another through talking and through touch.
62519842|NCT05709483|EXPERIMENTAL|Women with prior history of preeclampsia who received aspirin in subsequent gestation|Single-dose of enteric-coated 81 mg aspirin
62519843|NCT05709483|NO_INTERVENTION|Healthy volunteers|In this group, no aspirin will be given, as blood draw will not be performed at all among the healthy volunteers. The group of healthy volunteers will serve only for the SNP assay development.
62519844|NCT03367325|EXPERIMENTAL|CDS-NVAF benefiting group|CDS-NVAF = Clinical decision support (CDS) tool for improving the adequacy of the anticoagulant therapy adequacy in non-valvular atrial fibrillation (NVAF)
62519845|NCT03367325|NO_INTERVENTION|CDS-NVAF not-benefiting group|
62519846|NCT02595008|EXPERIMENTAL|DSXS topical product|treatment with DSXS twice daily for 28 days
62519847|NCT06178159|EXPERIMENTAL|Disitamab Vedotin + Pertuzumab|Disitamab Vedotin With Pertuzumab arm
62519848|NCT06178159|EXPERIMENTAL|Disitamab Vedotin + Toripalimab+ Pertuzumab|Disitamab Vedotin+ Toripalimab with Pertuzumab arm
62519849|NCT03832699|EXPERIMENTAL|Oral progesterone|
62519850|NCT03832699|ACTIVE_COMPARATOR|Vaginal progesterone|
62519851|NCT03425279|EXPERIMENTAL|BA3011|"Phase 1: All patients will receive BA3011, CAB-AXL-ADC.~Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor."
62519852|NCT03425279|EXPERIMENTAL|Combination Therapy|Phase 2: BA3011 in combination with PD-1 inhibitor.
62519853|NCT04462471|EXPERIMENTAL|Participants with thyroid cancer|Eligible participants will have a diagnosis of BRAF mutant RAIR thyroid cancer
62519854|NCT02629913|EXPERIMENTAL|Intervention|mementor somnium
62519855|NCT02629913|OTHER|Waitlist|
62519856|NCT03605251|EXPERIMENTAL|TAS5315 low dose group|TAS5315 low dose and Methotrexate as specified
62519857|NCT03605251|EXPERIMENTAL|TAS5315 high dose group|TAS5315 high dose and Methotrexate as specified
62519858|NCT03605251|PLACEBO_COMPARATOR|Placebo group|Placebo and Methotrexate as specified
62148893|NCT01303744|EXPERIMENTAL|CHF 5074 3x|oral tablet, multidose
62148894|NCT01303744|PLACEBO_COMPARATOR|Placebo|placebo, oral tablet, multidose
62711040|NCT05419245||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
62711041|NCT05419245||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
62148895|NCT05672485|EXPERIMENTAL|Patients diagnosed with prostate cancer|
62711042|NCT05419245||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
62148896|NCT00955565|EXPERIMENTAL|Navigated|
62711043|NCT05419245||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
62711044|NCT05419245||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
62711045|NCT05419245||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and spine curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
62711046|NCT00831389|EXPERIMENTAL|Closed Loop (CL) Phase|Closed Loop (CL) Phase
62711047|NCT00831389|NO_INTERVENTION|Standard of Care (OL) Phase|Standard of Care (OL) Phase or Open Loop Phase
62711048|NCT01968343|EXPERIMENTAL|Group cognitive-behavioral therapy|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group cognitive-behavioral therapy.
62519859|NCT01425723|EXPERIMENTAL|On-Demand|The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
62711049|NCT01968343|ACTIVE_COMPARATOR|Group supportive therapy (control)|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group supportive therapy (control).
62711050|NCT02588014||Schizophrenia|Individuals with schizophrenia
62711051|NCT02588014||Control|Neurotypical individuals
62711052|NCT06004622|NO_INTERVENTION|control group|The control group receives care according to the standard intensive care unit nursing guidelines.
62711053|NCT06004622|EXPERIMENTAL|experimental group|The experimental group, in addition to following the standard guidelines, undergoes two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasts approximately 20 minutes. Both groups complete three questionnaires during the study period. Furthermore, after the study concludes, the experimental group participates in an interview lasting approximately 15 minutes before returning home.
62148897|NCT00955565|ACTIVE_COMPARATOR|Conventional|
62148898|NCT05073822|OTHER|standard of care Immunosuppression (SOC-IS) therapy|"serum tacrolimus level : target tacrolimus levels 8-12ng/ml in the first 3 months target tacrolimus levels 6-8ng/ml in months 4-12 target tacrolimus level 4-8ng/ml after the 1st year~Mycophenolate mofetil dose :~2g/day for 1 month 1.5mg/day between months 2-12~1g/day after the 1st year"
62148899|NCT05073822|OTHER|minimised immunosuppression (Min-IS) therapy|"serum tacrolimus level : target tacrolimus levels 6-8ng/ml for first 3 months target tacrolimus levels 4-8ng/ml in months 4-12.~Mycophenolate mofetil dose:~1.5g/day in the first month~1g/day until 1 year post-transplantation"
62148900|NCT02345551|EXPERIMENTAL|Exercise|The behaviour change intervention to promote an increase in moderate-vigorous physical activity (to meet the cancer prevention guidelines of 150 min/week) will be guided by the Health Action Process Approach (HAPA) model. This model aims to promote behaviour change through increasing self-efficacy for intention, planning and maintenance of physical activity. As a compliment to the behavioural counseling sessions, participants will be asked to track their physical activity using the FitBit, a wrist-worn activity monitor (www.fitbit.com) which monitors step counts, distance covered, and active minutes and also tracks sleep. The FitBit synchronizes wirelessly to the participants' computer and/or smartphones, thus minimizing the need for daily data entry tracking by participants.
62148901|NCT03738592|EXPERIMENTAL|cochlear implant children|18 cochlear implant children wil include in this study
62148902|NCT03738592|OTHER|normal hearing children|18 normal hearing children wil include in this study
62148903|NCT01799603|EXPERIMENTAL|TMC435 in fasted then fed condition|Participants under fasting condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fed condition of second treatment period (after washout period of 9 days, between the two treatment periods).
62519860|NCT01425723|EXPERIMENTAL|Prophylaxis|Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.
62519861|NCT01034787|EXPERIMENTAL|Open Label CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity.
62519862|NCT02516904|EXPERIMENTAL|CD101 IV|single intravenous infusion ascending dose
62519863|NCT02516904|PLACEBO_COMPARATOR|Placebo|normal saline
62519864|NCT00877357|EXPERIMENTAL|Shan 5 Lot No 1|
62519865|NCT00877357|EXPERIMENTAL|Shan 5 Lot No 2|
62519866|NCT00877357|EXPERIMENTAL|Shan 5 Lot No 3|
62519867|NCT00788502|EXPERIMENTAL|Healing Touch|Healing Touch (HT) is a gentle form of energy balancing work that promotes relaxation. Subjects in this arm will receive three one-hour sessions of Healing Touch during the first two weeks of their IVF cycle.
62519868|NCT00788502|EXPERIMENTAL|Desensitization Therapy|Desensitization Therapy is a quasi-desensitization procedure where subjects meet with a therapist and generate a list of stressful thoughts and a list of neutral thoughts. Subjects in this arm will receive three one-hour sessions of Desensitization Therapy during the first two weeks of their IVF cycle.
62519869|NCT00788502|NO_INTERVENTION|Standard Care|Subjects in this arm will receive no therapeutic intervention.
62519870|NCT02191007|EXPERIMENTAL|Calcipotriol/Betamethasone and Calcipotriol|Calcipotriol/Betamethasone ointment 1/d for 4 weeks; Calcipotriol ointment bid for 6 weeks on-demand treatment period;
62519871|NCT02191007|SHAM_COMPARATOR|Calcipotriol/Betamethasone and urea cream|alcipotriol/Betamethasone ointment 1/d for 4 weeks , urea cream 1/d for 6 weeks on-demand treatment period
62519872|NCT02191007|ACTIVE_COMPARATOR|Calcipotriol/Betamethasone|Calcipotriol/Betamethasone ointment 1/d for 4 weeks, Calcipotriol/Betamethasone ointment 1/d for 6 weeks on-demand treatment period
62519873|NCT04153019|OTHER|Cancer cachexia|Psycho-educational session: 3 weekly face-to-face consultations between a dyads (patients-caregivers) and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
62519874|NCT04808830||Pulmonary arterial hypertension|Adult patients with pulmonary arterial hypertension
62519875|NCT03026972|EXPERIMENTAL|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
62519876|NCT03026972|EXPERIMENTAL|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
62519877|NCT03026972|EXPERIMENTAL|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
62519878|NCT03026972|EXPERIMENTAL|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
62519879|NCT04792359|EXPERIMENTAL|Equinometer|Measurement with Equinometer
62519880|NCT01524913|EXPERIMENTAL|Hyaluronic acid|
62519881|NCT01524913|ACTIVE_COMPARATOR|Corticosteroid|
62519882|NCT01524913|PLACEBO_COMPARATOR|Saline|
62519883|NCT04390906||All participants|Participants will receive standard of care partial brain radiation therapy at discretion of their radiation oncologist
62519884|NCT00999180|ACTIVE_COMPARATOR|Btx-A and Kinesiotherapy|The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
62519885|NCT00999180|PLACEBO_COMPARATOR|Saline and Kinesiotherapy|The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
62519886|NCT03786133||type 2 diabetics|Analysis of microbiological tests in chronic periodontitis patients with type 2 diabetes mellitus
62148904|NCT01799603|EXPERIMENTAL|TMC435 in fed then fasted condition|Participants under fed condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fasting condition of second treatment period (after washout period of 9 days, between the two treatment periods).
62519887|NCT03786133||non-diabetics|Analysis of microbiological tests in chronic periodontitis patients without type 2 diabetes mellitus
62519888|NCT04793074|EXPERIMENTAL|Transforming nanoparticle dressing|Patients in the treatment group (n=30) had transforming nanoparticle dressing
62519889|NCT04793074|ACTIVE_COMPARATOR|Conventional compression dressing|The control group (n=30) received conventional compression dressing.
62519890|NCT03345394|ACTIVE_COMPARATOR|Standard Treatment|12 weeks of standard treatment offered by Unidade Recomeço Helvétia treatment program
62519891|NCT03345394|EXPERIMENTAL|Contingency Management|12 weeks of standard treatment offered at Unidade Recomeço Helvétia treatment program associated with Contingency Management
62519892|NCT06455436|ACTIVE_COMPARATOR|Control group|Will receive standard healing abutments
62519893|NCT06455436|EXPERIMENTAL|Individualized healing abutment group|Will receive individualized healing abutments
62519894|NCT02050425|ACTIVE_COMPARATOR|Therapeutic CPAP|Patients continue therapeutic continuous positive airway pressure (CPAP).
62519895|NCT02050425|PLACEBO_COMPARATOR|Subtherapeutic CPAP|Placebo-CPAP device delivering subtherapeutic pressure for two weeks.
62519896|NCT03962582|EXPERIMENTAL|Supportive Back Comparison|Motion Concepts matrx back to be attached to individual's wheelchair in place of the individual's back. It will be adjusted for size and to support the spinal curves as compared to a fabric back
62519897|NCT03602040|EXPERIMENTAL|PISICC group|Psychoeducational intervention
62519898|NCT06383871|EXPERIMENTAL|HRS-7058|
62711054|NCT02199041|EXPERIMENTAL|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.~Cells for infusion are prepared using the CliniMACS System."
62148905|NCT05569382|ACTIVE_COMPARATOR|Verapamil|
62148906|NCT05569382|ACTIVE_COMPARATOR|Bisoprolol|
62148907|NCT05569382|PLACEBO_COMPARATOR|Placebo|
62148908|NCT03185793|PLACEBO_COMPARATOR|Placebo|placebo for 5 weeks
62148909|NCT03185793|EXPERIMENTAL|2.5mg SHR4640|SHR4640 for 5 weeks
62148910|NCT03185793|EXPERIMENTAL|5mg SHR4640|SHR4640 for 5 weeks
62148911|NCT03185793|EXPERIMENTAL|10mg SHR4640|SHR4640 for 5 weeks
62148912|NCT03185793|ACTIVE_COMPARATOR|50mg benzbromarone|Benzbromarone for 5 weeks
62148913|NCT00836537|EXPERIMENTAL|1|
62148914|NCT00836537|ACTIVE_COMPARATOR|2|
62356215|NCT02418767|EXPERIMENTAL|Mid dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
62356216|NCT02418767|EXPERIMENTAL|High dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
62356217|NCT03950999|EXPERIMENTAL|Study arm|Each subject underwent baseline assessment of pain reporting accuracy (FAST). Thereafter, the placebo response was assessed using tonic heat stimuli delivered at fixed temperature of 44, 46.5, and 48°C which evoke mild, moderate and severe pain sensations (in accordance). The stimuli were given in a pseudo-random order twice, once before receiving the placebo pill (a sugar pill) and once after, maintaining the same order as before.
62356218|NCT06580470|EXPERIMENTAL|Tailored CBT-Meno|Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
62356219|NCT01184456|EXPERIMENTAL|GanedenBC30, GBI-30, PTA-6086|
62356220|NCT01184456|PLACEBO_COMPARATOR|Placebo|
62356221|NCT03012282|EXPERIMENTAL|Diagnostic (CT perfusion sequence)|Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.
62356222|NCT01357889|ACTIVE_COMPARATOR|process 2 albiglutide|albiglutide 30mg from process 2 drug substance
62356223|NCT01357889|ACTIVE_COMPARATOR|process 3 albiglutide|albiglutide 30mg from process 3 drug substance
62356224|NCT03239639|EXPERIMENTAL|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
62519899|NCT05775822|OTHER|Single arm study|After signing the informed consent form, patients who meet all eligibility criteria will be enrolled in the Study. After execution of the CT scan the patient will be contacted to discuss the CT scan result. In case of high calcium score values, patients will be performing a cardiological medical examination, ECG, and further diagnostic investigations, as clinically indicated
62519900|NCT06071819||Generalized Anxiety Disorder (GAD)|Patients affected by GAD
62519901|NCT06071819||Panic Disorder (PD)|Patients affected by Panic Disorder
62519902|NCT06181799||Experimental group|The group is planned to include 31 people with myocardial perfusion defect on the stress computed tomography myocardial perfusion Imaging (by using contrast enhanced multi-slice spiral computed tomography (CE-MSCT) using adenosine triphosphate (ATP)).
62148915|NCT06318377|EXPERIMENTAL|Peanut Consumption|Peanuts are rich in polyphenols and also have anti-inflammatory and antioxidant properties.
62148916|NCT06318377|NO_INTERVENTION|Non-peanut consumption|The non-peanut consumption will simply not be consuming any additional supplements in their diet
62519903|NCT06181799||Control group|The group is planned to include 49 people without myocardial perfusion defect on the stress computed tomography myocardial perfusion imaging (by using contrast enhanced multi-slice spiral computed tomography (CE-MSCT) using adenosine triphosphate (ATP)).
62148917|NCT01008787|NO_INTERVENTION|Focus Group|Qualitative interviews examining social support for PA conducted with African American (AA) women recruited from Wheeler Avenue Baptist Church located in Houston used to design Culturally-Appropriate Peer-based Motivational Interviewing (CAPMI) intervention.
62148918|NCT01008787|ACTIVE_COMPARATOR|Intervention Group 1|CAPMI Intervention: Training + Weekly Partner Questionnaire + Interview + PA Newsletter
62148919|NCT01008787|ACTIVE_COMPARATOR|Intervention Group 2|Interview + PA Newsletter
62148920|NCT02346357|ACTIVE_COMPARATOR|Obturator nerve block|Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%
62148921|NCT02346357|PLACEBO_COMPARATOR|Sham block|Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.
62148922|NCT04271865|OTHER|therapy induced anemia for HCV treated patients|"Four types of interventions:~* Educational to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits~* Provision of Dates : Dates fruit intake for all the anaemic patients~* Recipe book~* Model kitchen for all patients having Hemoglobin lower than normal hemoglobin levels; less than 13.2 grams (g) of hemoglobin per deciliter (dL) of blood for men and less than 11.6 for women."
62356225|NCT03239639|SHAM_COMPARATOR|Wait list control|The intervention is not provided.
62356226|NCT04575831|EXPERIMENTAL|Intervention|The intervention arm will receive a 12-week multimodal intervention featuring exercise, nutrition, and palliative symptom management.
62356227|NCT02666508|ACTIVE_COMPARATOR|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
62356228|NCT02666508|ACTIVE_COMPARATOR|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
62356229|NCT01939964|ACTIVE_COMPARATOR|Activation Mist|Liquid mist preparation to be sprayed topically on wrinkle areas
62356230|NCT01939964|PLACEBO_COMPARATOR|Placebo|sugar pill
62356231|NCT03555071|EXPERIMENTAL|Experimental Group1|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
62519904|NCT03780946||Magnetic group|Magnetic anastomosis for pancreaticojejunostomy
62519905|NCT03780946||Control group|Traditional hand-sewn for pancreaticojejunostomy
62519906|NCT02939014|EXPERIMENTAL|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
62519907|NCT02053129|OTHER|HIV negative pregnant women|Pregnant women who are HIV negative attending their first ANC visit
62519908|NCT02053129|OTHER|HIV positive pregnant women|Pregnant women who are HIV positive accessing antenatal care.
62519909|NCT02867475|OTHER|A|Physical activity motivation
62519910|NCT04061642|EXPERIMENTAL|Clinical Decision Aid|
62519911|NCT01713426|EXPERIMENTAL|Qutenza|Cutaneous patch
62519912|NCT01713426|ACTIVE_COMPARATOR|Pregabalin|Oral capsule
62519913|NCT01164410||Pediatric Colonoscopy|Patients undergoing colonoscopy in the Department of Pediatric Gastroenterology at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.
62519914|NCT05513586|EXPERIMENTAL|TAK-771|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive SC infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution.
62519915|NCT02494934|EXPERIMENTAL|Cognitive-behavioural therapy|Eight sessions of psychotherapy incorporating cognitive-behavioural and sex therapy interventions.
62519916|NCT02494934|EXPERIMENTAL|physical therapy|Eight sessions of physical therapy targeting the pelvic floor muscles.
62519917|NCT06300788|EXPERIMENTAL|CKD group|Patient with chronic kidney disease
62519918|NCT06300788|EXPERIMENTAL|Dialysis group|Dialysis patients (hemodialysis or peritoneal dialysis)
62519919|NCT06300788|EXPERIMENTAL|kidney transplant group|Kidney transplant patients
62519920|NCT06300788|ACTIVE_COMPARATOR|Control group|Control group of patients with normal renal function
62519921|NCT02546362|EXPERIMENTAL|Cefaly active device|12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)
62519922|NCT00361114|ACTIVE_COMPARATOR|A|SP in symptomatic children aged 6-59 months
62519923|NCT00361114|EXPERIMENTAL|B|SP to asymptomatic infected children aged 2-10 months
62519924|NCT00361114|EXPERIMENTAL|C|Chlorproguanil/dapsone in symptomatic 6-59 month old children
62519925|NCT05203666||degenerative lumbar spinal stenosis|All patients treated in 2019 with a percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
62356232|NCT03555071|EXPERIMENTAL|Experimental Group2|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
62519926|NCT00635115|EXPERIMENTAL|1|
62519927|NCT00635115|ACTIVE_COMPARATOR|2|
62356233|NCT03555071|EXPERIMENTAL|Experimental Group3|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
62519928|NCT02381626|EXPERIMENTAL|Intervention Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
62519929|NCT02381626|EXPERIMENTAL|Wait-list Control Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. The Wait-list Control Group drivers will not receive a HEPA air purifier at this time, but will also have the air monitoring and biological parameters repeated for another 2 weeks. At the end of the 1 month period of measurements for both groups of drivers, the Wait-list drivers will then receive a HEPA air purifier, so that they may also potentially benefit from the intervention being tested in this study, but no further measurements will be taken.
62519930|NCT03126357|EXPERIMENTAL|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62519931|NCT03126357|EXPERIMENTAL|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62519932|NCT03126357|EXPERIMENTAL|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62356234|NCT03555071|ACTIVE_COMPARATOR|Control Group|"The control vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at trial-scale.~Intervention: Live attenuated varicella vaccine manufactured at trial-scale"
62356235|NCT05049343|EXPERIMENTAL|SAGE-904 then Placebo|SAGE-904 in combination with ketamine, followed by a washout period, followed by placebo in combination with ketamine.
62356236|NCT05049343|PLACEBO_COMPARATOR|Placebo then SAGE-904|Placebo in combination with ketamine, followed by a washout period, followed by SAGE-904 in combination with ketamine.
62356237|NCT01082367|EXPERIMENTAL|TOBI (tobramycin inhaled solution)/Placebo|Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
62356238|NCT01082367|PLACEBO_COMPARATOR|Placebo/TOBI|Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).
62519933|NCT03126357|EXPERIMENTAL|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62519934|NCT03126357|EXPERIMENTAL|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62148923|NCT05015842|EXPERIMENTAL|Kinesio Tapping plus Conventional Physical Therapy - Experimental Group|"Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).~The KT was applied to the back once a week with a treatment duration of 2 weeks. Each KT was applied for continuous three days and the next KT was applied after a break of two days. Each participant in the experimental group was assessed for any allergy reaction of the skin to KT."
62148924|NCT05015842|OTHER|Conventional Physical Therapy alone - Control Group|Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).
62148925|NCT05409170||pre-covid group|Each surgical procedure was considered an independent event. , the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
62148926|NCT05409170||covid group|Each surgical procedure was considered an independent event. , the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
62148927|NCT03093064|EXPERIMENTAL|Patient Group: Natalizumab|Natalizumab 300mg, intravenous, once monthly, total of 3 doses
62519935|NCT03126357|EXPERIMENTAL|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62148928|NCT03093064|PLACEBO_COMPARATOR|Patient Group: Placebo|Saline, intravenous, once monthly, total of 3 doses
62519936|NCT03126357|EXPERIMENTAL|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62519937|NCT03126357|EXPERIMENTAL|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62519938|NCT03126357|EXPERIMENTAL|Product usage order BACED|Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62519939|NCT03126357|EXPERIMENTAL|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
62148929|NCT02290548|EXPERIMENTAL|high flow nasal cannula|High flow nasal cannula immediately use after extubation
62148930|NCT02290548|PLACEBO_COMPARATOR|stanrd oxygen therapy|Oxygen cannula or mask after extubation
62148931|NCT03967197|EXPERIMENTAL|Lidocaine|Patients randomized to the lidocaine intervention will receive 2 sprays of lidocaine hydrochloride 10% in each nostril 3-5 minutes before their test.
62148932|NCT03967197|PLACEBO_COMPARATOR|Placebo (Saline)|Patients randomized to placebo will receive 2 sprays of physiological saline in each nostril 3-5 minutes before their test.
62148933|NCT03064256|EXPERIMENTAL|Physical training program|"Intervention participants are submitted to supervised aerobic physical training at the predetermined intensity, which is composed of three weekly sessions, lasting one hour, over a period of 12 weeks.~All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise."
62519940|NCT05970419|EXPERIMENTAL|High power laser acupuncture group|This group will receive high power laser acupuncture (HPLA) +conventional therapy
62711055|NCT01517984|EXPERIMENTAL|Tacrolimus (CNI) Withdrawal|"Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal."
62711056|NCT01517984|ACTIVE_COMPARATOR|Standard Immunosuppressive Therapy|"Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur."
62148934|NCT03064256|NO_INTERVENTION|Control Group|Control participants receive routine outpatient care for a 12-week period.
62148935|NCT03731741|EXPERIMENTAL|treatment group|Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk).
62148936|NCT03731741|NO_INTERVENTION|control group|Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes.
62148937|NCT03150589|EXPERIMENTAL|SB11 (Proposed ranibizumab biosimilar)|
62148938|NCT03150589|ACTIVE_COMPARATOR|Lucentis (ranibizumab)|
62148939|NCT03265132|EXPERIMENTAL|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
62148940|NCT03265132|PLACEBO_COMPARATOR|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
62148941|NCT05148052|EXPERIMENTAL|Conventional therapy first|Group receiving conventional occupational therapy first and then virtual reality exergames.
62519941|NCT05970419|ACTIVE_COMPARATOR|Conventional treatment group|This group will receive sham laser and The first line of chronic nonspecific low back pain treatment is the conventional treatment.
62711057|NCT06095037|EXPERIMENTAL|Intervention|Mindful yoga
62148942|NCT05148052|EXPERIMENTAL|Virtual reality first|Group receiving virtual reality exergames with virtual reality first and then conventional occupational therapy.
62519942|NCT02002000|EXPERIMENTAL|vitamin D|Patients receiving 3 doses of vitamin D (cholecalciferol)
62519943|NCT02002000|EXPERIMENTAL|Placebo|Patients receiving 3 doses of placebo according to the same schedule as experimental arm
62519944|NCT04226235|EXPERIMENTAL|1-hour vinyasa yoga session|One hour of vinyasa yoga was completed by all participants while following a DVD.
62519945|NCT01516866||Cohort A: Microtubule directed chemotherapy treatment|Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
62519946|NCT01516866||Cohort B: AR-directed therapy|Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks. A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
62519947|NCT01970865|EXPERIMENTAL|PF-06463922|
62148943|NCT03070548|EXPERIMENTAL|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
62519948|NCT01970865|OTHER|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
62148944|NCT02132039|ACTIVE_COMPARATOR|12-step sitting Tai Chi Chuan|The intervention is a simplified Tai Chi Chuan exercise, which consists of 12 steps, including weight shifting in different sitting positions, trunk and upper limb movements, and alternate thigh lift in a smooth and coordinated manner.
62519949|NCT01211704|PLACEBO_COMPARATOR|Placebo, Counceling|Placebo
62519950|NCT01211704|EXPERIMENTAL|Paliperidone Palmitate|Paliperidone Palmitate
62519951|NCT05223257|EXPERIMENTAL|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
62519952|NCT05223257|NO_INTERVENTION|Control group|"Children will continue standard care for 8 weeks~Subject allocated to standard care group will have to continue what they normally do; they (if \> 13 years) or their parents will have to fill a diary in which they will write the rehabilitative activities they do, specifying their intensity and whether these activities are more focused on the lower limbs or upper limbs."
62519953|NCT03485638||Cetuximab administration|
62519954|NCT03052413|ACTIVE_COMPARATOR|Active|
62519955|NCT03052413|PLACEBO_COMPARATOR|Placebo|
62519956|NCT03325972|EXPERIMENTAL|IV dexmedetomidine|Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
62519957|NCT03325972|PLACEBO_COMPARATOR|Placebo|saline placebo
62519958|NCT05334355||Positive Family History of Hypertension|Young normotensive generally healthy adult with one or more biological parents with diagnosed hypertension.
62519959|NCT05334355||Negative Family History of Hypertension|Young normotensive generally healthy adult with no biological parent with diagnosed hypertension.
62519960|NCT04439084||Chronic Liver Disease Group|COVID-19 patients with Chronic Liver Disease.
62519961|NCT04439084||Control Group|COVID-19 patients without Chronic Liver Disease.
62519962|NCT02964819|ACTIVE_COMPARATOR|exercise group|Manual cervical traction, Myofascial release of upper trapezius muscle, 3 sets of 1 minute;Sleeper's stretch, during 3 series of 30 seconds,Punch exercise, Knee push-up plus, Prone V-raise exercise (arms abducted at 120°), rotador cuff exercise (internal rotation), rotador cuff exercise (external rotation), Rotation on the wall using a ball (internal rotation), Rotation on the wall using a ball (external rotation).
62711058|NCT06095037|ACTIVE_COMPARATOR|Control|Psychoeducation
62519963|NCT02964819|EXPERIMENTAL|exercise + Interferential current group|Addition to the exercise protocol performed in the exercise group the interferential current. Four self-adhesive electrodes (8x5 cm), two upper and two lower ones (forming a square) will be placed around the center of the shoulder. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (swing pattern), 100 Hz Frequency modulation amplitude (AMF), 50 Hz (sweep frequency), automatic vector mode, With intensity at the motor threshold of sensation, with duration of 50 minutes.
62519964|NCT02964819|PLACEBO_COMPARATOR|exercise + US group|In addition to the exercise protocol performed in the exercise group, an ultrasound device will be used. The appliance will be used off, without any individual participant having knowledge. For this, the individual will be asked to position himself in the dorsal position on the stretcher, the therapist will perform the application of the transducer head, with gel on its surface, in the anterolateral region of the affected shoulder.
62519965|NCT04700280|EXPERIMENTAL|GLPG3970|Participants will receive GLPG3970 400 milligrams (mg) (2 \*200 mg tablet), orally, once daily for 12 weeks.
62519966|NCT04700280|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to GLPG3970 tablet, orally, once daily for 12 weeks.
62519967|NCT02562482|EXPERIMENTAL|Group 1: VRC-CHKVLP059-00-VP 20 mcg|Group 1 subjects were randomized to receive two intramuscular (IM) injections of CHIKV VLP vaccine (VRC-CHKVLP059-00-VP) at Day 0 and Day 28 (+14 days) at a dose of 20 micrograms (mcg).
62519968|NCT02562482|PLACEBO_COMPARATOR|Group 2: Placebo (VRC-PBSPLA043-00-VP)|Group 2 subjects were randomized to receive two intramuscular (IM) injections of Phosphate Buffered Saline (VRC-PBSPLA043-00-VP) placebo at Day 0 and Day 28 (+14 days).
62711059|NCT06343805|EXPERIMENTAL|Cohort 1|Dose A of AJ1-11095 taken orally by patients.
62148945|NCT02132039|PLACEBO_COMPARATOR|Control|We provide participants in the control group with a level of social contact equivalent to the intervention group, which comprises structured conversations on topic other than physical activity.
62519969|NCT04471038|EXPERIMENTAL|Cohort 1|1 mg/mL SAB-176 in normal (0.9%) Saline; concentration 1 mg/mL (0.1%)
62519970|NCT04471038|EXPERIMENTAL|Cohort 2|10 mg/kgSAB-176 in normal (0.9%) Saline; concentration 4 mg/mL (0.4%)
62711060|NCT06343805|EXPERIMENTAL|Cohort 2|Dose B of AJ1-11095 taken orally by patients.
62148946|NCT04008953||Sixteen patients having end stage renal disease|Intravascular volume assessment in 16 pediatric patients under going renal transplant surgery using ultrasonography, CVP and echocardiography
62148947|NCT03351504|NO_INTERVENTION|Control (usual lighting)|Participants will continue to use their usual lighting sources.
62148948|NCT03351504|EXPERIMENTAL|Intervention (solar lighting)|Participants will receive an indoor solar lighting system
62711061|NCT06343805|EXPERIMENTAL|Cohort 3|Dose C of AJ1-11095 taken orally by patients.
62711062|NCT06343805|EXPERIMENTAL|Cohort 4|Dose D of AJ1-11095 taken orally by patients.
62711063|NCT06343805|EXPERIMENTAL|Cohort 5|Dose E of AJ1-11095 taken orally by patients.
62519971|NCT04471038|EXPERIMENTAL|Cohort 3|25 mg/kgSAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
62148949|NCT03382704||Patients undergoing biopsy|Patients undergoing biopsy (incisional or excisional) of peri-ocular lesions. Pre-operative examination for presence or absence of lanugo hairs
62356239|NCT04869176|EXPERIMENTAL|On Caffeine, maintenance dose|During receiving maintenance dose of 5 mg/kg caffeine citrate (i.e. 2,5 mg/kg caffeine) in the form of solution, orally or intravenously, Holter electrocardiogram and vital functions were monitored for 40 minutes.
62711064|NCT06343805|EXPERIMENTAL|Dose Expansion Cohort 1|Candidate RP2D of AJ1-11095 taken orally by patients.
62519972|NCT04471038|EXPERIMENTAL|Cohort 4|50 mg/kg SAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
62711065|NCT06343805|EXPERIMENTAL|Dose Expansion Cohort 2|Alternative candidate RP2D of AJ1-11095 taken orally by patients.
62711066|NCT05511779|EXPERIMENTAL|Dose Escalation Phase: Cohort 1: BCV 0.3 mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
62148950|NCT06134193|EXPERIMENTAL|HAIC, surufatinib and tislelizumab|
62148951|NCT02764905||intensive cognitive-physical rehabilitation group|will include a 2 phase multi-disciplinary intervention. The 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies
62148952|NCT01353872|EXPERIMENTAL|Sports Drinks|3 drinks : Nutrattente (before each match) / Nutraperf (during each match) / Nutrarecup (after each match)
62148953|NCT01353872|PLACEBO_COMPARATOR|Placebo|3 drinks : Nutrattente placebo (before each match) / Nutraperf placebo(during each match) / Nutrarecup placebo (after each match)
62148954|NCT05813990|OTHER|Pediatric patient with conductive hearing loss|All pediatric patients aged below 18 years old will subjected to reconstructive ear surgery (ossiculoplasty)
62148955|NCT06506357|EXPERIMENTAL|Probiotic Supplement Group|Participants in this group will receive the Good Girl Probiotics supplement.
62148956|NCT00585793||PEPFAR 1|
62148957|NCT00378898|ACTIVE_COMPARATOR|EGD with proximal BRAVO capsule|Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
62356240|NCT04869176|EXPERIMENTAL|Off caffeine|100 hours after caffeine withdrawal Holter electrocardiogram and vital functions were monitored for 40 minutes.
62519973|NCT04471038|PLACEBO_COMPARATOR|Cohort 5|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
62519974|NCT03364166|ACTIVE_COMPARATOR|buccinator muscle excision with skin|surgical excision of the buccinator muscle with the skin in buccal squamous cell carcinoma and neck dissection also done
62711067|NCT05511779|EXPERIMENTAL|Dose Escalation Phase: Cohort 2: BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
62711068|NCT05511779|EXPERIMENTAL|Expansion Phase: BCV Recommended dosage regimen in the Dose Escalation Phase|BCV: Recommended dosage administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
62148958|NCT00378898|SHAM_COMPARATOR|EGD with sham BRAVO capsule placement|Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
62148959|NCT05841342||Healthy Control|Healthy male or female aged 2-80 years with negative EBV-DNA quantitative test results within the last week.
62148960|NCT05841342||CAEBV or EBV-HLH Patients|"Patients aged 2-80 years who fulfilled the diagnostic criteria for CAEBV or EBV-HLH.~The diagnostic criteria for CAEBV as defined in the recently revised World Health Organization classification include persistent IM-like symptoms for more than three months, increased EBV DNA (\>10\^2.5 copies/mg) in peripheral blood, histological evidence of organ disease, and EBV RNA or viral protein in affected tissues.~Patients diagnosed with EBV-HLH must meet five of the following eight HLH-2004 diagnostic criteria:~1. temperature 38.5 ℃ and above;~2. splenomegaly;~3. two or three lines of hemocytopenia, i.e. hemoglobin (HB) \<90 g/L, platelets (PLT) \<100 × 10\^9/L or neutrophils (N) \<1 × 10\^9/L;~4. triacylglycerol (TG) ≥ 3 mmol/ L or fibrinogen (Fbg) \<1.5 g/L;~5. serum ferritin (SF) ≥ 500 mg/L;~6. phagocytosis found in bone marrow, spleen, liver or lymph nodes;~7. soluble CD25 (sCD25) ≥ 2400 U/mL;~8. low or absent natural killer (NK) cell activity."
62711069|NCT00987350|ACTIVE_COMPARATOR|Trivalent influenza vaccine by needle and syringe|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the standard needle and syringe method
62711070|NCT00987350|EXPERIMENTAL|Trivalent influenza vaccine by jet injection|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the experimental method of jet injection
62356241|NCT00562016|EXPERIMENTAL|IMPELLA LP 2.5|
62356242|NCT00562016|ACTIVE_COMPARATOR|IABP Intra-aortic balloon pump|
62356243|NCT04394143|EXPERIMENTAL|AD128|The study specific intervention includes per oral administration of two capsules of AD128, once daily, just before lights out, for 7 days.
62356244|NCT04394143|PLACEBO_COMPARATOR|placebo|Two placebo capsules (Mannitol) will be administered for the control intervention once daily, just before light outs, for one week.
62356245|NCT02474823|OTHER|Sleep Apnea assessment|all participants are in the same arm \& undergo the same assessments: PSG, HST, ESAP
62356246|NCT02111512|OTHER|Egg allergic children|Children with a physician diagnosis of egg allergy will be recruited to receive the intranasal LAIV as part of a safety surveillance study
62519975|NCT03364166|ACTIVE_COMPARATOR|buccinator muscle excision without skin|surgical excision the buccinator muscle without the skin in buccal squamous cell carcinoma and neck dissection also done.
62519976|NCT06310928|EXPERIMENTAL|Thermal Blanket Intervention Group|After the informed consent form is signed by the patients, general body warming of the patient will be provided with the hot air blowing system after surgery. In the 30th minute of the active heating method, a thermal blanket will be applied to the treated area (extremity) of the patient. The first 24 hours after the application; Pain will be evaluated every hour for the first 8 hours, every 2 hours for the second 8 hours, every 4 hours for the last 8 hours with the VAS Pain Scale and circulation with the Neurovascular Diagnosis Form. Mobilization of the patient for the first time in the 8th hour and for the second time in the 24th hour will be evaluated with the Patient and Observer Mobility Scale. Pain and neurovascular evaluation will be performed every 12 hours on the second postoperative day. Mobility will be assessed for the third time on the second postoperative day.
62356247|NCT04018703|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine will be used for perioperative sedation.
62356248|NCT04018703|EXPERIMENTAL|Midazolam|Midazolam will be used for perioperative sedation.
62356249|NCT02000557||Class II Malocclusion|
62356250|NCT04600843|EXPERIMENTAL|Physical therapy with Patient education|Treated with proper physical therapy treatment protocol according to patient presenting condition and patient education manual
62356251|NCT04600843|EXPERIMENTAL|Physical Therapy without patient Education|Treated with proper physical therapy treatment protocol according to patient presenting condition
62356252|NCT00961662|EXPERIMENTAL|2.5 active|2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
62356253|NCT00961662|ACTIVE_COMPARATOR|5.0 mid dose|5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
62356254|NCT00961662|ACTIVE_COMPARATOR|7.5 high dose|7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
62356255|NCT01432093|ACTIVE_COMPARATOR|Intensive glycemic management|Multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
62356256|NCT01432093|ACTIVE_COMPARATOR|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
62356257|NCT03120364|EXPERIMENTAL|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
62356258|NCT03120364|ACTIVE_COMPARATOR|Zostavax|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
62356259|NCT04902768||Adults with congenital heart disease|
62356260|NCT04406389|ACTIVE_COMPARATOR|Intermediate Dose Prophylaxis|"Subjects will receive one of the following interventions, at their physician's discretion:~* Enoxaparin 0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min~* Enoxaparin 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 mL/min~* If patient develops acute kidney injury: unfractionated heparin 7,500 units subcutaneously every 8 hours.~* Fondaparinux (if history of heparin-inducted thrombocytopenia \[HIT\]) 2.5 mg daily subcutaneously"
62356261|NCT04406389|EXPERIMENTAL|Therapeutic Dose Anticoagulation|"Subjects will receive one of the following interventions, at their physician's discretion:~* Unfractionated heparin (UFH) to target anti-Xa level 0.3 -0.7 IU/mL or activated partial thromboplastin time (aPTT) (according to institutional protocol).~* Enoxaparin 1 mg/kg subcutaneously every 12 hours~* Argatroban (if heparin-induced thrombocytopenia \[HIT\]), dosed according to institutional protocol.~* Fondaparinux (if HIT and creatinine clearance greater than or equal to 50 ml/min) dosed by weight:~  * ≥100 kg: 10 mg daily~ * \<100 kg but ≥50 kg: 7.5 mg daily~ * \<50 kg: 5 mg daily"
62356262|NCT06449846||Patient with hepatocellular carcinoma|Patient with hepatocellular carcinoma who can undergo radical resection
62356263|NCT06180668||Trauma Laparotomy Patients|Patients of all ages who present to hospital with a blunt or penetrating injury and undergo a trauma laparotomy within 5 days of presentation to the treating centre
62356264|NCT01585493|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual
62356265|NCT01585493|ACTIVE_COMPARATOR|Care coordinator|
62356266|NCT01585493|EXPERIMENTAL|CHANGE|
62356267|NCT04735965|EXPERIMENTAL|Dexmedetomidine group|
62356268|NCT04735965|ACTIVE_COMPARATOR|Meperidine group|
62356269|NCT04735965|PLACEBO_COMPARATOR|Control group|
62356270|NCT04853589|ACTIVE_COMPARATOR|Hyaluronic acid|hyaluronic acid gel application
62356271|NCT04853589|ACTIVE_COMPARATOR|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier
62356272|NCT04853589|NO_INTERVENTION|Standard treatment|standard treatment (i.e., blood clot only)
62356273|NCT02494219|EXPERIMENTAL|Rapid Immunochromatographic Streptococcal test|Throat swabbing by two port germ Amines agar (copan) swabs,the swabs were randomly labeled as swab A and swab B.Swab A was processed for rapid streptococcal test and swab B was processed for culture in Colombia blood agar.All patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.
62356274|NCT03621306||Men and women aged 18+|Men and women over the age of 18
62356275|NCT02219711|EXPERIMENTAL|MGCD516|MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles
62356276|NCT00531492|EXPERIMENTAL|A|
62356277|NCT00531492|ACTIVE_COMPARATOR|B|
62356278|NCT01781871|EXPERIMENTAL|Prevenar13|68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured
62356279|NCT01781871|ACTIVE_COMPARATOR|Pneumovax|68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group
62711071|NCT06041321|EXPERIMENTAL|Reparel Sleeve|"Device size(s): Small, medium, large, x-large Device model(s): Reparel Leg Sleeve (full length) Description of each component: Fabric garment constructed of 41% Polyester embedded with a proprietary non-metal semiconductive nano-sized material, 13% Polyester, 27% Nylon, and 19% Lycra-Spandex. The top cuff of the garment has silicone grips to keep the garment from sliding down.~501k exempt: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=FQL Company Name: Challenger Health, LLC (dba Reparel) FDA Registration Number: 3012651665 Device Listing Number: D269770 Product Classification: Class I Medical Device, 510(k) exempt Product Code: FQL, Stocking/Medical Support"
62711072|NCT06041321|PLACEBO_COMPARATOR|Placebo Sleeve|Device size(s): Small, medium, large, x-large Device model(s): Generic Black Leg Sleeve Supplier: Jupin Group Co., Ltd. Description of each component: Fabric garment constructed of 80% polyester and 20% lycra
62711073|NCT01359956|EXPERIMENTAL|A1|combination chemotherapy without interferon
62356280|NCT01781871|EXPERIMENTAL|liver Prevenar13|30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.
62356281|NCT01781871|ACTIVE_COMPARATOR|liver Pneumovax|30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.
62356282|NCT04749563|ACTIVE_COMPARATOR|Active|IGC AD1
62356283|NCT04749563|PLACEBO_COMPARATOR|Placebo|IGC AD1 Placebo
62356284|NCT03299309|EXPERIMENTAL|PEP-CMV|Cytomegalovirus (CMV)-specific peptide vaccine (PEP-CMV)
62356285|NCT00852319|EXPERIMENTAL|Central Mississippi group|Participants from central Mississippi are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
62356286|NCT00852319|EXPERIMENTAL|Mississippi Delta group|Participants from 18 counties of the Mississippi delta are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
62356287|NCT00973622|EXPERIMENTAL|Smokers|Healthy adult smokers aged 19-55 who are not currently interested in quitting smoking.
62356288|NCT00973622|EXPERIMENTAL|Non-smokers|Healthy adult non-smokers aged 19-55
62356289|NCT01771367|ACTIVE_COMPARATOR|Fluad|Participants receive one dose of Fluad vaccine.
62356290|NCT01771367|ACTIVE_COMPARATOR|Agrippal|Participants receive one dose of Agrippal vaccine.
62356291|NCT01771367|PLACEBO_COMPARATOR|Placebo|Participants receive one dose of saline placebo.
62356292|NCT06403813|SHAM_COMPARATOR|Control|Participating schools will be randomly assigned to one of the 4 study arms. Neither the parent or adolescents in the control schools will receive the intervention. Families from the control schools will be given the option to use any other version of Toolkit after completion of the Time 2 post-intervention data collection.
62356293|NCT06403813|EXPERIMENTAL|mSELY-A intervention|Participating schools will be randomly assigned to one of the 4 study arms. Only the adolescents from the mSELY-A-alone schools will receive the mSELY-A intervention. Families from these mSELY-A-alone schools will be given the option to use any other version of Toolkit after completion of the Time 2 post-intervention data collection.
62356294|NCT06403813|EXPERIMENTAL|mSELY-P intervention|Participating schools will be randomly assigned to one of the 4 study arms. Only the parents from the mSELY-P-alone schools will receive the mSELY-P intervention. Families from these mSELY-P-alone schools will be given the option to use any other version of Toolkit after completion of the Time 2 post-intervention data collection.
62356295|NCT06403813|EXPERIMENTAL|mSELY-A and mSELY-P intervention|Participating schools will be randomly assigned to one of the 4 study arms. Both parent and adolescent participants from the mSELY-A+P intervention schools will receive the mSELY-A and mSELY-P intervention.
62356296|NCT02843919|OTHER|Healthy volunteers|Adults healthy volunteers
62356297|NCT02832518||patients under hemodialysis|
62356298|NCT06236308|EXPERIMENTAL|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. 10 mg of TTAX03 in a 0.5 mL solution of sterile, preservative-free 0.9% NaCl (saline).
62356299|NCT06236308|EXPERIMENTAL|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. 25 mg TTAX03 in a 0.5 mL saline solution; or 0.5 mL of saline alone.
62519977|NCT06310928|NO_INTERVENTION|Control Group|After the informed consent form was signed by the patients who agreed to participate in the study before the application and who met the inclusion criteria, respectively;The vital signs of patients admitted to the intensive care unit after surgery will be stabilized.The patient's general warming of the body will be ensured with the hot air blowing system (Forced-air), which is an active heating method.Afterwards, the treated extremity will be wrapped with cotton alban, which is a routine application.Tests will be performed to the participants in the control group at the same time as in the experimental group.
62519978|NCT00819975|ACTIVE_COMPARATOR|Casein|
62519979|NCT00819975|ACTIVE_COMPARATOR|Whey Isolate|
62519980|NCT00819975|ACTIVE_COMPARATOR|Whey Hydrolysate|
62519981|NCT00819975|ACTIVE_COMPARATOR|Alphalact-Albumin|
62711074|NCT01359956|EXPERIMENTAL|A2|combination chemotherapy with interferon
62711075|NCT01359956|ACTIVE_COMPARATOR|B1|single agent dacarbazine without interferon
62711076|NCT01359956|EXPERIMENTAL|B2|single agent dacarbazine plus interferon
62711077|NCT06315933||Unexposed|Children unexposed to general anesthesia before school age (\<=6y)
62711078|NCT06315933||Singly exposed|Children singly exposed to general anesthesia before school age (\<=6y)
62711079|NCT06315933||Multiply exposed|Children multiply exposed to general anesthesia before school age (\<=6y)
62711080|NCT05716945|EXPERIMENTAL|Intervention STEP I (Year 1 after DMEK)|
62711081|NCT05716945|ACTIVE_COMPARATOR|Control STEP I (Year 1 after DMEK)|
62148961|NCT04885140|EXPERIMENTAL|Feedback-based health education health education and Routine health education|"Feedback-based health education:(1) Implementation of the feedback method includes information transmission, patient feedback, clarification and correction, and confirmation of understanding.① One day before surgery: Health education team members provided bedside one-on-one education for patients, 15-20 min per session, twice a day.~② One week after surgery: One-on-one education on rehabilitation exercise was conducted for the patients by the health education team members, 15-20 min per session, twice a day.~③ Two to four weeks after surgery: The health education group members guided the patients through functional rehabilitation exercises via WeChat. Each intervention lasted 20-30 min. The patients interacted once through WeChatB1, and their questions were answered at any time.~④ Five to 12 weeks after surgery: The health education group members guided patients through the functional rehabilitation exercises via WeChat."
62148962|NCT04885140|EXPERIMENTAL|Routine health education|"Routine health education:~Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method."
62148963|NCT03848962||Subjects for observational study|Various conditions \& healthy subjects
62148964|NCT02016365|EXPERIMENTAL|Doxycycline and UDCA|Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)
62519982|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
62356300|NCT06236308|PLACEBO_COMPARATOR|Saline Control|0.5 mL of saline alone
62356301|NCT05185817|EXPERIMENTAL|vaccine|Patients who are a candidate for HSCT within the the Hematology, Oncology, and Stem Cell Transplantation Research Center of Shariaty Hospital, and agree to be vaccinated with an approved vaccine against the COVID-19 virus.
62711082|NCT05716945|EXPERIMENTAL|Intervention STEP II (Year 2 after DMEK)|
62148965|NCT00392652|EXPERIMENTAL|Arm I (low-dose oral diindolylmethane)|Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.
62148966|NCT00392652|EXPERIMENTAL|Arm II (high-dose oral diinolylmethane)|Participants receive high-dose oral BR-DIM twice daily for 4 weeks.
62356302|NCT01307553||PCS Group|
62356303|NCT01320956|EXPERIMENTAL|Hypnosis|"Pre operative nurse consultation and Hypnosis:~will have hypnosis"
62356304|NCT01320956|ACTIVE_COMPARATOR|Control|"Pre operative nurse consultation:~usual nurse consultation without hypnosis"
62356305|NCT01277471|EXPERIMENTAL|Arm A: 6 and 2 meals/day|6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
62356306|NCT01277471|ACTIVE_COMPARATOR|Arm B: 2 and 6 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
62356307|NCT01422512|EXPERIMENTAL|cell culture derived TIV|single dose of cell culture derived seasonal trivalent influenza vaccine (TIV)
62356308|NCT02504177|EXPERIMENTAL|The group of keep medication NOAC|The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation
62356309|NCT02504177|ACTIVE_COMPARATOR|The group of stop medication NOAC 1 day|The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation
62356310|NCT00272545|EXPERIMENTAL|1|Participants will receive the normalization of eating program
62356311|NCT00272545|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual
62356312|NCT05224440|EXPERIMENTAL|Sponsorship Initiative|TSMV receives a VA certified and volunteer sponsor (1-on-1) approximately 6 months prior to military discharge. Sponsorship continues for approximately 6 months after military discharge.
62711083|NCT05716945|ACTIVE_COMPARATOR|Control STEP II (Year 2 after DMEK)|
62356313|NCT05224440|NO_INTERVENTION|Transition as Usual|TSMVs transition to civilian life as usual.
62356314|NCT01254578|EXPERIMENTAL|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo blood and bone marrow biopsies and aspirate collection at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies. Buccal swab samples are also collected at baseline and analyzed for genetic polymorphisms."
62356315|NCT04671069|EXPERIMENTAL|MGL-3196 100 mg tablet plus Clopidogrel 75 mg tablet|
62356316|NCT01386957||Study group|children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.
62356317|NCT03841526|EXPERIMENTAL|CRC Phase: Glucagon RTU With Insulin Pump Reduction|CRC Phase: 2-arm randomized double-blind crossover, Glucagon RTU Injection 30 microliters of 0.15 mg injection with 50% reduction in the insulin pump
62356318|NCT03841526|PLACEBO_COMPARATOR|CRC Phase: Vehicle for Glucagon RTU With Insulin Pump Reduction|CRC Phase: 2-arm randomized double-blind crossover, Vehicle for Glucagon RTU Injection 30 microliters vehicle with 50% reduction in the insulin pump
62519983|NCT00652028|OTHER|Group 1|Dose level 1
62519984|NCT00652028|OTHER|Group 2|Dose level 2
62519985|NCT00652028|OTHER|Group 3|Dose level 3
62519986|NCT00652028|OTHER|Group 4|Dose level 4
62711084|NCT00525421|EXPERIMENTAL|Curcumin|Curcumin C3 Complex
62711085|NCT00525421|PLACEBO_COMPARATOR|Placebo|Placebo
62711086|NCT05415904||HANTA-NE|All adult patient hospitalized for hantavirus infection between 01/01/2013 and 31/12/2022 in North Eastern France
62711087|NCT03198156|EXPERIMENTAL|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes daily for 4 sessions
62711088|NCT03198156|SHAM_COMPARATOR|Sham stimulation|Sham stimulation sessions will be for 30 minutes daily for each of the 4 sessions; however, active stimulation for this arm of the study is only for 30 seconds; yet, will be applied at the same intensity as the Active arm of the study, albeit for only 30 seconds.
62148967|NCT05779696||Group 1|We will recruit a diverse range of participants to take part and therefore have a limited inclusion/exclusion criteria. Participants must be over 18 years old and be able to a computer/mobile device to access the survey or video conference software (Zoom, as used by the Centre of Ethnic Health Research). Participants can come from a range of cultural communities and religious groups. Participants do not need to have any prior knowledge to participate in the virtual focus groups or the survey.
62148968|NCT06177561|EXPERIMENTAL|LPE group|"1. Serum DSA positive: MFI ≥ 2000；Between the ages of 18 and 65, male and female are not limited；Planned to undergo allo-HSCT , with an estimated survival time of\>3 months and an ECOG physical fitness score of 0-2；Normal renal function (BUN, Cr ≤ 1.5 times the upper limit of normal value, Ccr\>80ml/min)~2. Normal liver function (defined as ALT and AST ≤ 1.5 times the upper limit of normal~3. TBiL ≤ 1.5 times the upper limit of normal)~4. ECG did not indicate any AMI, arrhythmia, or IAVB~5. No CI (defined as LVEF ≥ 50%, normal MYO and BNP)~6. Non active RHD~7. Chest X-ray or physical examination did not indicate cardiac dilatation~8. Normal lung function (defined as FEV1, FVC, DLCO ≥ 60% predicted value)."
62148969|NCT03874949|ACTIVE_COMPARATOR|SEALITE Regular|zinc oxide eugenol sealer
62519987|NCT04722601|EXPERIMENTAL|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 / Starting Dose|"Phase 1/the dose-finding arm of this study will use three dose levels (a starting dose, second dose and highest dose) of the venetoclax, CC-486 and obinutuzumab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to groups 2 and 3 to take higher doses until the safest/ most tolerable dose is found.~Group 1/ Dose Level 1:~Participants in group 1 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at a starting dose used in previous human studies. Participants in this group will receive:~* Venetoclax:~  400 mg on days 1-28~* CC-486:~  200 mg on days 1-14~* Obinutuzumab:~  1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
62519988|NCT04722601|EXPERIMENTAL|Phase 2 (Efficacy Arm/ Expansion Cohort)|Participants in this arm will help test the efficacy of the three-drug regimen and dose established in the phase 1 of the study. Participants will take two drugs (venetoclax and CC-48) used in the same three-drug regimen during the first phase of this study. These two drugs will be paired together by themselves and given to participants in the expansion cohort before obinutuzumab (a third drug) is added during cycle 4 of treatment.
62519989|NCT04722601|EXPERIMENTAL|Phase 1(Dose-Finding Arm): Group 2 - Dose Level 2 /Second Dose|"Participants in group 2 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the second highest dose (dose level 2) set by doctors leading the study. Participants in this group will receive:~* Venetoclax:~  600 mg on days 1-28~* CC-486:~  200 mg on days 1-14~* Obinutuzumab:~  1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
62519990|NCT04722601|EXPERIMENTAL|Phase 1 (Dose-Finding Arm) - Group 3 - Dose Level 3/ Highest Dose|"Participants in group 3 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the highest dose (dose level 3) set by doctors leading the study. Participants in this group will receive:~* Venetoclax:~  800 mg on days 1-28~* CC-486:~  200 mg on days 1-14~* Obinutuzumab:~  1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
62519991|NCT04722601|EXPERIMENTAL|Phase 1 (Dose-Finding Arm) - Group 4 - Lower Dose Level 1|"Participants in this group will received a lower dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:~* Venetoclax:~  400 mg on days 1-28~* CC-486:~  150 mg on days 1-14~* Obinutuzumab:~  1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
62519992|NCT04722601|EXPERIMENTAL|Phase 1 (Dose-Finding Arm) - Group 5 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:~* Venetoclax:~  400 mg on days 1-10 only~* CC-486:~  150 mg on days 1-14~* Obinutuzumab:~  1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
62519993|NCT04232241|ACTIVE_COMPARATOR|Treatment A|Allogeneic stem cell transplantation from 10/10 HLA matched unrelated donor
62519994|NCT04232241|EXPERIMENTAL|Treatment B|Allogeneic stem cell transplantation from haploidentical donor
62519995|NCT00653991|EXPERIMENTAL|SOLVE-IT|Participants will receive the intervention SOLVE-IT. The SOLVE-IT intervention is a videogame designed to optimize self-regulation, reduce shame, and reduce risky choices for young men who have sex with men (YMSM).
62519996|NCT00653991|ACTIVE_COMPARATOR|Waitlist Control|Participants will receive the intervention, SOLVE-IT, a video game designed to optimize self-regulation reduce shame, and reduce risky sexual choices for YMSM, after a 6-month waitlist period.
62519997|NCT02664818||Heart failure|Hospitalized patients with primary discharge diagnosis of heart failure and who were aged 18 years or older.
62519998|NCT05609123||Brain dead organ donors|Patients with clinically proven bain death were assigned to the paraclinical confirmatory investigation of the brain death and subsequently accepted into the transplantation program.
62148970|NCT03874949|EXPERIMENTAL|SEALITE Ultra|zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)
62519999|NCT02217631|EXPERIMENTAL|BI 653048 BS H3PO4|dose escalation
62520000|NCT02217631|ACTIVE_COMPARATOR|Prednisolone low dose|
62520001|NCT02217631|ACTIVE_COMPARATOR|Prednisolone high dose|
62520002|NCT02217631|PLACEBO_COMPARATOR|Placebo|
62148971|NCT02160600|EXPERIMENTAL|split bolus|Patients will undergo diagnostic Split bolus DECT scan
62148972|NCT02160600|EXPERIMENTAL|Standard|Patients will undergo routine multiphase diagnostic CT
62148973|NCT01488084|EXPERIMENTAL|"Pedicled no-touch SVG harvesting"|Saphenous vein harvested with a pedicle of surrounding fat and distension with heparinized blood at arterial pressure. No manual distention.
62148974|NCT01488084|ACTIVE_COMPARATOR|Conventional open SVG harvesting|Saphenous vein is harvested with an open technique, stripped of adventitia, and manually distended with crystalloid solution.
62520003|NCT03401450|ACTIVE_COMPARATOR|ACB within true AC with bupivacaine|The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine
62520004|NCT03401450|ACTIVE_COMPARATOR|ACB proximal to true AC with bupivacaine|The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine
62520005|NCT03017118|EXPERIMENTAL|Turmeric|Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
62520006|NCT03017118|PLACEBO_COMPARATOR|Control|Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.
62520007|NCT02158611|OTHER|Lifestyle counseling|
62520008|NCT00695435|EXPERIMENTAL|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
62520009|NCT00695435|ACTIVE_COMPARATOR|TOBREX® Ophthalmic Solution|TOBREX® Ophthalmic Solution
62520010|NCT00695435|ACTIVE_COMPARATOR|TOBRADEX® Ophthalmic Suspension|TOBRADEX® Ophthalmic Suspension
62520011|NCT05102136|EXPERIMENTAL|Intravenous Cohorts|Randomized 6:2 to REGN9933 or placebo
62148975|NCT01853384|EXPERIMENTAL|HP802-247 plus compression therapy|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
62356319|NCT03841526|EXPERIMENTAL|Outpatient Phase: Glucagon RTU With Insulin Pump Reduction|Outpatient Phase: 3-arm randomized comparison (2-arm double-blind, 1-arm open-label), Glucagon RTU Injection 30 microliters of 0.15 mg injection with 50% reduction in the insulin pump (double-blind arm)
62520012|NCT05102136|EXPERIMENTAL|Subcutaneous Cohorts|Randomized 6:2 to REGN9933 or placebo
62520013|NCT03639259||Post-stroke fatigue|Participants fulfilling criteria for presence of fatigue after cerebral stroke
62520014|NCT02620215|EXPERIMENTAL|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
62520015|NCT02620215|ACTIVE_COMPARATOR|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
62520016|NCT04481178||patients with nevus of Ota|patients with nevus of Ota who had been treated with laser at Siriraj hospital
62520017|NCT01832675|ACTIVE_COMPARATOR|Bupivacaine lozenge|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
62520018|NCT01832675|ACTIVE_COMPARATOR|Xylocain, cutaneous spray, solution|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
62520019|NCT02269878||people with MPM with Thymine/Thymine,Thymine/cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
62148976|NCT01853384|PLACEBO_COMPARATOR|HP802-247 Vehicle plus compression therapy|fibrinogen solution \& thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.
62148977|NCT03744052|EXPERIMENTAL|Adult Participants|Messages regarding physical activity will be texted to participants.
62148978|NCT05621902|EXPERIMENTAL|Weekly symptom monitoring|Web-based weekly symptom monitoring in addition to standard follow-up
62148979|NCT05621902|NO_INTERVENTION|Standard care|Standard follow-up according to guidelines
62148980|NCT05608772|ACTIVE_COMPARATOR|RYGB procedure arm 1|After failed sleeve, the patients will get a revisional procedure. The RYGB
62148981|NCT05608772|ACTIVE_COMPARATOR|OAGB procedure arm 2|After failed sleeve, the patients will get a revisional procedure. The OAGB
62356320|NCT03841526|PLACEBO_COMPARATOR|Outpatient Phase: Vehicle for Glucagon RTU With Insulin Pump Reduction|Outpatient Phase: 3-arm randomized comparison (2-arm double-blind, 1-arm open-label), Vehicle for Glucagon RTU Injection 30 microliters vehicle with 50% reduction in the insulin pump (double-blind arm)
62356321|NCT03841526|EXPERIMENTAL|Outpatient Phase: Glucagon RTU Without Insulin Pump Reduction|Outpatient Phase: 3-arm randomized comparison (2-arm double-blind, 1-arm open-label), Glucagon RTU Injection 30 microliters of 0.15 mg injection without a reduction in the insulin pump (open-label arm)
62356322|NCT02251158|EXPERIMENTAL|TPV/r with food|Tipranavir/Ritonavir paediatric/oral solution
62520020|NCT02269878||people with MPM, Cytosine/Cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
62520021|NCT05053347|EXPERIMENTAL|Flaxseed oil|Flaxseed oil capsule, 5g/d(ALA2.5g/d)
62520022|NCT05053347|PLACEBO_COMPARATOR|Corn oil|Corn oil capsule, 5g/d
62520023|NCT05417360|EXPERIMENTAL|Akkermansia muciniphila (A. muciniphila)|After an 8-week low caloric diet (LCD, \~800kcal), participants who have successfully lost 8% of their body weight who are randomized to the intervention group, will receive pasteurized A. muciniphila.
62520024|NCT05417360|PLACEBO_COMPARATOR|Placebo|After an 8-week low caloric diet (LCD, \~800kcal), participants who have successfully lost 8% of their body weight who are randomized to the control group, will receive a placebo.
62520025|NCT01539993||1|
62520026|NCT02867657|EXPERIMENTAL|Mindfulness in nature|A five day mindfulness retreat in nature
62520027|NCT02867657|ACTIVE_COMPARATOR|Mindfulness indoor|A five day mindfulness retreat indoor
62520028|NCT02867657|NO_INTERVENTION|Wait list control|A wait list control group, that 6 months later is offered a two-day mindfulness retreat in nature
62520029|NCT05068375||Thrombotic group|Non-critically COVID-19 patients with unusual thrombotic events
62520030|NCT05068375||Non-thrombotic group|Non-critically COVID-19 patients without thrombotic events
62520031|NCT06457737|EXPERIMENTAL|Preheated resin composite (IPS Empress Direct) group|Endodontically treated teeth will be prepared to receive partial coverage ceramic restorations that will be luted with preheated composite.
62520032|NCT06457737|EXPERIMENTAL|Dual-cure adhesive resin cement (Bisco Duo-Link Universal) group|Endodontically treated teeth will be prepared to receive partial coverage ceramic restorations that will be luted with dual-cure adhesive resin cement.
62520033|NCT04918641||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral, and imaging measures.
62148982|NCT05608772|ACTIVE_COMPARATOR|SADI-S procedure arm 3|After failed sleeve, the patients will get a revisional procedure. The SADI-S
62148983|NCT01078272|EXPERIMENTAL|Remote Ischemic Preconditioning (RIPC)|Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
62520034|NCT00563680|EXPERIMENTAL|Exploratory Cohort|If a total of two or more responses (partial and complete) in EFTs/DSRCTs are documented in this or the ongoing phase 1 study (20050118), then the study will allow enrollment of up to 10 additional EFT/DSRCT subjects who have been exposed to prior anti-IGF-1R targeting therapy.
62520035|NCT00563680|EXPERIMENTAL|Main Cohort|Subjects with relapsed Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have not received prior anti-IGF-1R therapy will receive AMG 479 at 12mg/kg.
62520036|NCT03376542|EXPERIMENTAL|Cardiopulmonary exercise testing|All patients included in the study will perform cardiopulmonary exercise testing prior to surgery
62520037|NCT05993715|EXPERIMENTAL|Nitrate supplementation|2 × 70 mL/day shots of concentrate nitrae-rich (\~12.8 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
62520038|NCT05993715|PLACEBO_COMPARATOR|Placebo supplementation|2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
62520039|NCT01939041|EXPERIMENTAL|Robot-assisted therapy with InMotion3 (IMT)|We will use the InMotion3 Wrist Robot (Figure 1) for the IMT group. During the InMotion3 therapy (IMT) session, participants will receive 5-minute of muscle tone normalization preparation and passive range of motion, then a 70-minute robot-assisted training followed by a 15-minute functional training. During the robot-assisted training, only the paretic hand will be trained and the participant will rest the forearm and hand on a cradle and the wrist and hand in a fixed positions. During the practice, a visual display will provide online visual feedback of accuracy and coordination success. And summary scores regarding movement accuracy and movement smoothness will be shown on the display periodically. After each IMT session, a 15 min functional task practice will be provided as described in the previous paragraph.
62520040|NCT01939041|EXPERIMENTAL|Robot-assisted therapy with Bi-Manu-Track (BMT)|During the Bi-Manu-Track training (BMT), participant will use both nonparetic and paretic hands. Participants will receive 5-munite of muscle tone normalization preparation and passive range of motion, then will practice about 5-minute in Mode 1, 25-minute in Mode 2, and 5-minute in Mode 3 in wrist and forearm respectively. The training repetitions of each mode fall within the range of the protocols used in previous studies which would not cause adverse events (Hesse et al., 2005). The total minutes of each robot-assisted will be 70 minutes. After each BMT session, a 15 min functional task practice will be provided based on the same principles as the one in the IMT group.
62520041|NCT01939041|ACTIVE_COMPARATOR|Control intervention group (CI)|The control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
62520042|NCT01403753||Non-clinical sample of children|
62520043|NCT04073628|ACTIVE_COMPARATOR|Active Lighting intervention|The active lighting intervention will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, the intervention will allow us to: (1) use a light source that will stimulate the circadian system and (2) provide the participants with options as to how the light treatment will be delivered
62520044|NCT04073628|PLACEBO_COMPARATOR|Control Lighting Intervention|The control lighting intervention will consist of low levels of a warm light source designed not to impact the circadian system.
62711089|NCT03589274|EXPERIMENTAL|I-FS-CBT|In I-FS-CBT each participant saw a therapist weekly. The first session was 90 minutes long, and subsequent sessions were 60 minutes long. The I-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care.
62711090|NCT03589274|EXPERIMENTAL|G-FS-CBT|The G-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care. The session organization was modified for a closed group format. The group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence.
62711091|NCT00875914|EXPERIMENTAL|Manually guided|Treatment with manually guided RF-catheter
62711092|NCT00875914|EXPERIMENTAL|Magnetically navigated|Treatment with magnetically navigated RF-catheter.
62148984|NCT01078272|PLACEBO_COMPARATOR|Sham Remote Ischemic Preconditioning|Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.
62148985|NCT03097549|EXPERIMENTAL|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
62148986|NCT03097549|OTHER|Tät®II Information app|"Information only.~."
62356323|NCT02251158|EXPERIMENTAL|TPV/r|Tipranavir/Ritonavir paediatric/oral solution
62356324|NCT02251158|ACTIVE_COMPARATOR|TPV/r capsules|
62356325|NCT02711605|EXPERIMENTAL|Unilateral UltraShape treatment|One side of the chest (left or right breast) will be treated with the UltraShape focused ultrasound device, while the opposite will serve as an untreated control.
62356326|NCT02711605|EXPERIMENTAL|Bilateral UltraShape treatment|Both sides of the chest (right and left breasts) will be treated with the UltraShape focused ultrasound device.
62356327|NCT02264171|EXPERIMENTAL|Ketoconazole + Tamsulosin HCl|Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
62356328|NCT02264171|ACTIVE_COMPARATOR|Tamsulosin HCl|Tamsulosin HCl given at day 1
62356329|NCT01541111|OTHER|Magnesiun, pain relief, sugar pills|Magnesiun 75mg po each 12h pain relief Sugar pills po each 12h
62356330|NCT00756704|NO_INTERVENTION|Baseline Period|
62356331|NCT00756704|EXPERIMENTAL|Intervention Period|
62356332|NCT03094611|EXPERIMENTAL|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.
62356333|NCT03491930|EXPERIMENTAL|Interventional Cohort|"VA MOVE! Coach app: Weight loss using the VA MOVE! Coach weight loss app which presents positive feedback, education in nutrition and portion sizes, coping mechanisms, charts and graphs. App will be used for three months.~Telephone Coaching: Weekly phone coaching will provide further support and assist with problem solving and goal setting for a three month period.~Standard of care for weight loss (the 2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
62356334|NCT03491930|ACTIVE_COMPARATOR|Control Cohort|"Standard of care for weight loss (2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
62356335|NCT04231032|ACTIVE_COMPARATOR|Active ventricular pacing|Asynchronous dual chamber pacing (DOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)
62356336|NCT04231032|PLACEBO_COMPARATOR|Back-up ventricular pacing|Asynchronous atrial pacing with intrinsic ventricular activation (AOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)
62356337|NCT01765946|EXPERIMENTAL|Metformin|Metformin tablets 500 mg tid for 2 months
62356338|NCT01765946|PLACEBO_COMPARATOR|Placebo|Placebo tables tid for 2 months
62356339|NCT03080467||Suture|Wound repair with suture
62356340|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
62356341|NCT05072756||Gynecologists|Brazilian gynecologists who agreed to participate and answered the questionnaire
62356342|NCT02942706|EXPERIMENTAL|Cet maintenance|Cetuximab maintenance treatment following induction treatment
62356343|NCT02942706|ACTIVE_COMPARATOR|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
62356344|NCT05851794|ACTIVE_COMPARATOR|endomanometric laparoscopic Nissen fundoplication|use endomanometry and endoscope during laparoscopic Nissen fundoplication
62356345|NCT05851794|ACTIVE_COMPARATOR|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication only
62356346|NCT05985070|EXPERIMENTAL|Intervention Arm 1|Subjects in this arm will receive an oral 30mg elemental iron supplement as Ferric pyrophate, twice daily, for 6 weeks.
62356347|NCT05985070|EXPERIMENTAL|Intervention Arm 2|Subjects in this arm will receive an oral 30mg elemental iron supplement as Sodium Ferric pyrophate, twice daily, for 6 weeks.
62356348|NCT05985070|ACTIVE_COMPARATOR|Interventional Arm 3|Subjects in this arm will receive an oral 30mg elemental iron supplement as Ferric maltose, twice daily, for 6 weeks.
62356349|NCT02854007||Coronary stenosis treated with Absorb|Patients with ischemic heart disease who have undergone percutaneous coronary revascularization with Absorb according to standard clinical practice. One thousand revascularized patients will be recruited at 40 siteS.
62356350|NCT06109519|ACTIVE_COMPARATOR|Group I|patients who would be delivered a mandibular implant overdenture using conventional locator attachments.
62356351|NCT06109519|ACTIVE_COMPARATOR|Group II (study)|patients who would be delivered mandibular implant overdenture using Locator RTX attachments
62356352|NCT01972854|EXPERIMENTAL|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
62356353|NCT01972854|PLACEBO_COMPARATOR|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
62356354|NCT00418730|EXPERIMENTAL|1|
62711093|NCT06547736|EXPERIMENTAL|Arm A|For SHR-A2102 monotherapy or combination therapy with HRS-4642, for advanced or metastatic pancreatic cancer.
62356355|NCT00418730|ACTIVE_COMPARATOR|2|
62356356|NCT00418730|PLACEBO_COMPARATOR|3|
62356357|NCT02581124|EXPERIMENTAL|Experimental: JTZ-951 and Lapatinib|Tablets; JTZ-951, single dose on non-dialysis Days 1 and 5; Lapatinib, single dose on non-dialysis Day 5
62356358|NCT00881790||Fluoride application|
62356359|NCT00661570|EXPERIMENTAL|Early feasability arm|
62356360|NCT01577784|EXPERIMENTAL|Pazopanib|800 mg / day of pazopanib in monotherapy
62356361|NCT04693520|EXPERIMENTAL|Active treatment|ALZ-801 265 mg tablets once daily for two weeks and twice daily thereafter
62356362|NCT04992546|EXPERIMENTAL|SAR444727 5% BID per lesion|During the double-blinded period, 2 target lesions per participant (with difference no greater than 1 point in total sign scores \[TSS\]) were randomized in 1:1 ratio to receive either SAR44727 Gel 5 percent (%) or matching placebo (i.e., each participant was treated with both SAR444727 5% BID and placebo in parallel). During open-label period, participants applied SAR444727 Gel, 5% twice daily (BID) to the all atopic dermatitis (AD)-affected areas, except the scalp, palms, soles and genitals through Days 15 to 42.
62356363|NCT04992546|PLACEBO_COMPARATOR|Placebo then SAR444727 5% BID per lesion|Multiple topical doses of placebo for 14 days, and PRN473 (SAR444727) for 28 days
62520045|NCT05765136||Close collaboration group|Preterm infants born in hospitals where the Close Collaboration with Parents training program has been successfully implemented
62520046|NCT05765136||Single-family room group|Preterm infants born in hospitals that have implemented an architectural change to single-family room design
62520047|NCT05765136||Control group|Preterm infants born in hospitals that have not gone through any of the two aforementioned interventions (single-family room architecture or Close Collaboration with Parents training program)
62520048|NCT02442583|NO_INTERVENTION|Arm 1: Phase 1, Step 1|In this part, 15 early stage colorectal cancer survivors will fill out surveys and have a recorded phone interview regarding their physical activity and sedentary behaviors, to inform the creation of a brochure about sedentary behaviors.
62356364|NCT02479438||Diagnosed with GERD|Collect data on GERD patients
62356365|NCT04297410|EXPERIMENTAL|Neoadjuvant LuPSMA|
62356366|NCT04110184||active systemic lupus erythematosus|
62356367|NCT04110184||inactive systemic lupus erythematosus|
62520049|NCT02442583|NO_INTERVENTION|Arm 2: Phase 1, Step 2|5 early stage colorectal cancer survivors will have recorded telephone interviews to provide feedback about the brochure.
62148987|NCT04483102|EXPERIMENTAL|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. NMP of the donated declined liver utilizing the OrganOx® metra device. NMP involves (warm) machine perfusion with oxygenated blood at normal body temperature. During NMP, the device also allows for ongoing assessment of donor liver function and further viability assessment to help determine suitability of the organ for transplant.
62520050|NCT02442583|EXPERIMENTAL|Arm 3: Phase 2|15 early stage colorectal cancer survivors will complete a baseline survey about sedentary behaviors, then wear an Actigraph device and self-report their sedentary activities for one week. They will receive feedback regarding their activity, and one month after receiving the feedback will participate in a phone survey regarding use of the brochure, physical activity and sedentary behaviors.
62148988|NCT04483102|ACTIVE_COMPARATOR|Standard cold preservation of liver|This group will receive liver transplant using the standard method of preservation. There will be 3 comparison groups: one local comparison group and two comparison groups from the national UNOS data.
62148989|NCT00520663|EXPERIMENTAL|Healthy male subjects|Each subject will receive a single oral dose of 14C-SB649868 (containing approximately 70 microcuries of radiocarbon and 30 milligrams of SB649868).
62148990|NCT04927715||Diseased|Females with peripartum cardiomyopathy
62148991|NCT04927715||Control|Healthy females
62148992|NCT02936544|EXPERIMENTAL|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62148993|NCT02205255|EXPERIMENTAL|Azithromycin|N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
62148994|NCT02205255|PLACEBO_COMPARATOR|Placebo|N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
62148995|NCT05585398|EXPERIMENTAL|LMRC (left with micro-/right with conv- needle)|
62356368|NCT03447821|ACTIVE_COMPARATOR|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
62356369|NCT03447821|ACTIVE_COMPARATOR|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
62356370|NCT03447821|ACTIVE_COMPARATOR|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
62356371|NCT00724815|EXPERIMENTAL|Sumatriptan|NP101 - sumatriptan iontophoretic transdermal patch
62356372|NCT00724815|PLACEBO_COMPARATOR|Placebo|Placebo iontophoretic transdermal patch
62356373|NCT04679558|ACTIVE_COMPARATOR|Comparator|Preventive protocol
62356374|NCT04679558|EXPERIMENTAL|Intervention|Adding chlorhexidine to the preventive protocol
62356375|NCT02091947|EXPERIMENTAL|experimental group|Real FMS, 5 Hz, 20 minutes per day, for 10 weekdays.
62356376|NCT02091947|SHAM_COMPARATOR|sham group|sham FMS, 5 Hz, 20 min per day, for 10 weekdays.
62356377|NCT01672528||Cardiac arrhythmia patients|Patients with cardiac arrhythmias consented to and awaiting a cardiac ablation procedure or post ablation.
62356378|NCT00344760|ACTIVE_COMPARATOR|Standard Treatment|Efavirenz 600mg once daily, Lamivudine 300mg once daily and Tenofovir 300mg once daily
62356379|NCT00344760|EXPERIMENTAL|Standard Treatment Plus Enfuvirtide|Efavirenz 600mg once daily, Lamivudine 300mg once daily, Tenofovir 300mg once daily and enfuvirtide 90mg subcutaneously twice a day until the viral load is less than 50copies for 2 consecutive visits or 12 weeks (whichever comes first).
62356380|NCT01601704|EXPERIMENTAL|NB32|
62356381|NCT01601704|PLACEBO_COMPARATOR|PBO|
62711094|NCT06547736|EXPERIMENTAL|Arm B|For SHR-A1904 monotherapy or combination therapy with HRS-4642, for advanced or metastatic pancreatic cancer.
62356382|NCT03371251|EXPERIMENTAL|Phase 1b: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
62356383|NCT03371251|PLACEBO_COMPARATOR|Phase 1b: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
62356384|NCT03371251|EXPERIMENTAL|Phase 2: BOS161721|Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
62520051|NCT02553902|ACTIVE_COMPARATOR|Combination therapy|"Sleep Position Trainer + Mandibular Advancement device combination The SPT is a sensor that measures the sleeping position, and gives the user feedback about wrong positions with a soft vibration. A user is then able to react to the signal and turn into a non-supine position. To stimulate compliance, information is provided about nightly behaviour, implicating a learning pattern by viewing the data on a home computer.~MRA or oral appliances (OA) works by advancing the mandible and its attached soft tissue structures forward they aim to increase upper airway size."
61974819|NCT00112593|EXPERIMENTAL|Treatment (allogeneic hematopoietic stem cell transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD."
62520052|NCT02553902|ACTIVE_COMPARATOR|CPAPContinuous positive airway pressure|Continuous positive airway pressure (CPAP) functions as a pneumatic splint to maintain upper airway patency. Possible side effect can be related to the interface, pressure and negative social factors.
62520053|NCT01933464|EXPERIMENTAL|Cromolyn|Subjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.
62520054|NCT01933464|PLACEBO_COMPARATOR|Vehicle|Participants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.
62520055|NCT02771795||Herceptin (trastuzumab)|Intravenous administration
62520056|NCT02771795||SB3 (proposed trastuzumab biosimilar)|Intravenous administration
62520057|NCT02933762|EXPERIMENTAL|Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])|Healthy elderly participants will receive single dose of 30mg JNJ-54175446.
62148996|NCT05585398|EXPERIMENTAL|RMLC (right with micro-/left with conv- needle)|
62148997|NCT05585398|EXPERIMENTAL|LCRM (left with conv-/ right with micro-needles)|
62520058|NCT02933762|EXPERIMENTAL|Part 1: Cohort A1 (JNJ-54175446 100mg)|Healthy elderly participants will receive single dose of 100mg JNJ-54175446.
62520059|NCT02933762|EXPERIMENTAL|Part 1: Cohort A1 (JNJ-54175446 300mg)|Healthy elderly participants will receive single dose of 300mg JNJ-54175446.
62520060|NCT02933762|EXPERIMENTAL|Part 1: Cohort A1 (Placebo)|Healthy elderly participants will receive single dose of placebo.
62148998|NCT05585398|EXPERIMENTAL|RCLM (right with conv-/left with micro-needles)|
62148999|NCT00003167|EXPERIMENTAL|Treatment (adenovirus p53)|"Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade 3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences grade 3 toxicity, an additional 3 patients are treated at that dose level and dose escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients receive Ad-p53 at the MTD on days 1-4 and 8-11."
62149000|NCT02160301|EXPERIMENTAL|Multimodal pain control|Oxycodone 5-15mg PO q4hrs prn pre- and post-op, Acetaminophen 1000mg IV once pre-op, Acetaminophen 1000mg PO q8hrs pre-op and x2 weeks post op, prn thereafter, Gabapentin 100mg/200mg PO a8hrs pre-op and x2 weeks post op, Dexamethasone 8mg IV once intra-op, Celecoxib 400mg PO once pre-op.
62149001|NCT02160301|ACTIVE_COMPARATOR|Standard pain control|Oxycodone 5-15mg PO q4hrs prn, Acetaminophen 1000mg PO q8hrs prn.
62520061|NCT02933762|EXPERIMENTAL|Part 1: Cohort A2 (JNJ-54175446 D1 mg)|Healthy elderly participants will receive an additional dose D1 mg \[less than or equal to (\<=) 600 mg\] of JNJ-54175446, to be determined.
62520062|NCT02933762|EXPERIMENTAL|Part 1: Cohort A3 (JNJ-54175446 D2 mg)|Healthy young participants will receive a single dose D2 mg (\<= 600 mg) of JNJ-54175446, to be determined.
62520063|NCT02933762|EXPERIMENTAL|Part 1: Cohort A3 (Placebo)|Healthy young participants will receive a single dose of placebo.
62520064|NCT02933762|EXPERIMENTAL|Part 2: Cohort B1 (JNJ-54175446 D3 mg)|Healthy elderly participants will receive multiple dose levels D3 mg (\<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
62520065|NCT02933762|EXPERIMENTAL|Part 2: Cohort B1 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1.
62520066|NCT02933762|EXPERIMENTAL|Part 2: Cohort B2 (JNJ-54175446 D4 mg)|Healthy elderly participants will receive multiple dose levels D4 mg (\<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
62520067|NCT02933762|EXPERIMENTAL|Part 2: Cohort B2 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
62520068|NCT02933762|EXPERIMENTAL|Part 2: Cohort B3 (JNJ-54175446 D5 mg)|Healthy elderly participants will receive multiple dose levels D5 mg (\<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
62520069|NCT02933762|EXPERIMENTAL|Part 2: Cohort B3 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
62520070|NCT03660436|EXPERIMENTAL|BMS-986165 + MMF|Oral administration
62520071|NCT00788229|EXPERIMENTAL|1. Study Drugs|
62520072|NCT00788229|EXPERIMENTAL|2. Study Drug|
62520073|NCT00788229|EXPERIMENTAL|3. Study Drug|
62520074|NCT00788229|PLACEBO_COMPARATOR|4. Placebo|
62520075|NCT04346966|EXPERIMENTAL|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
62520076|NCT04346966|NO_INTERVENTION|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
62520077|NCT01938404||Octaplas|Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
62520078|NCT01938404||standard plasma products|Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
62711095|NCT06547736|EXPERIMENTAL|Arm C|For SHR-A1811 monotherapy or combination therapy with HRS-4642, for advanced or metastatic pancreatic cancer.
62711096|NCT05927987|EXPERIMENTAL|Problem Management Plus and care-as-usual|The five sessions of PM+ will be delivered by trained master students in clinical psychology on an individual basis. Care-as-usual will not be withheld.
62711097|NCT05927987|NO_INTERVENTION|Care-as-usual|Care-as-usual includes all social, health, and mental health services already available for individuals detained in Dutch prisons.
62356385|NCT03371251|PLACEBO_COMPARATOR|Phase 2: Placebo|Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
62356386|NCT03256409|EXPERIMENTAL|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
62711098|NCT05719116|EXPERIMENTAL|Physical exercise for participants with psychotic disorder|Participants with a psychotic disorder will exercise in a group supervised by a physiotherapist for 16 weeks, three times a week.
62711099|NCT05719116|ACTIVE_COMPARATOR|Physical exercise for participants with psychiatric disorder, but not psychotic disorder|Participants with a psychiatric disorder will exercise in a group supervised by a physiotherapist for 16 weeks, three times a week.
62711100|NCT01434004|EXPERIMENTAL|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
62711101|NCT01434004|NO_INTERVENTION|Control group|Usual care (watchful waiting).
62711102|NCT03430167|OTHER|Group I - Formal Therapy|Supervised physical therapy will be ordered 2 times/week initially for 6 weeks and then tailored to a minimum of 1 visit/week based upon the individual progress of each patient. Home exercises will be provided to the patient by the therapist to be performed daily. Supervised physical therapy will be discontinued once the patient demonstrates independence with the final phase of rehabilitation, which represents the graduated strengthening program.
62711103|NCT03430167|OTHER|Group II - Home Therapy|In the study group all patients will be instructed in a standardized fashion regarding a home exercise program. This program will involve a standardized a set of five exercises. These exercises will be reviewed with patients in clinic in a standardized fashion and patients will be provided with an instructive hand-out.
62711104|NCT00735657|ACTIVE_COMPARATOR|Group 1|Control
62711105|NCT00735657|ACTIVE_COMPARATOR|Group 2|Block with short needle
62149002|NCT04130282|EXPERIMENTAL|Group 1|8 volunteers receiving 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
62149003|NCT01180959|EXPERIMENTAL|Erlotinib + Bevacizumab|Erlotinib 150 mg by mouth once a day. Bevacizumab 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes.
62149004|NCT03340922|EXPERIMENTAL|Automatic annotation of LAT (WF-method)|The annotation of LAT in each acquired point will be automatically performed using the LAT annotation tool integrated into CARTO navigation system, called Wavefront (WF). Automatic annotation of LAT performed by the CARTO system uses the maximum negative slope of the distal U-EGM to set the timing of the mapping annotation, displayed on the corresponding B-EGM. Additionally, the automatic annotation of LAT will be aided by an ECG recognition pattern algorithm (included in the last version of CARTO), which is intended to avoid wrong annotation of ventricular complexes other than the clinical PVC.
62149005|NCT03340922|ACTIVE_COMPARATOR|Manual annotation of LAT (M-method)|A detailed electrocardiogram (ECG)-gated activation map of the chamber of interest will be acquired using the CARTO navigation system. An experienced electrophysiologist will perform the annotation of LAT in each acquired point. The LAT will be measured from the onset of B-EGM (earliest positive or negative deflection) of the distal dipole of the mapping catheter to the defined reference. The use of the U-EGM as a guidance to identify the real onset of B-EGM will be decided under electrophysiologist criteria.
62149006|NCT03190148|OTHER|Pregnant women with RYGB-operation|Pregnant women with a history of RYGB-Operation were investigated.
62149007|NCT03190148|OTHER|Normal weight pregnant women|Normal weight pregnant women were investigated.
62149008|NCT03190148|OTHER|Obese Pregnant women|Obese pregnant women were investigated.
62149009|NCT03917186|ACTIVE_COMPARATOR|Group sevoflurane|Administration under labelling conditions
62149010|NCT03917186|EXPERIMENTAL|Group desflurane|Administration under labelling conditions
62149011|NCT01613599||Rituximab|Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4 years.
62149012|NCT05766202|OTHER|Pilot intervention for multiparas with fear of childbirth|A group intervention with four meetings and one telephone call.
62149013|NCT03080350|EXPERIMENTAL|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
62149014|NCT03080350|ACTIVE_COMPARATOR|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
62711106|NCT02900430||Patients without antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
62711107|NCT02900430||Patients with antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
62356387|NCT03256409|EXPERIMENTAL|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
62711108|NCT00490581|EXPERIMENTAL|Study group|These patients are assigned to the intervention of early supportive housing with case management integrated into the medical system. These subjects are offerred respite care/interim housing upon discharge from enrolling hospitalizations, followed by stable housing within 90 days. They have a case manager at each stage (hospital, respite/interim housing, and stable housing)
62711109|NCT00490581|NO_INTERVENTION|Usual Care|These patients receive usual social services for hospital discharge planning.
62520079|NCT04686838|EXPERIMENTAL|READyR II A|Continuous monitoring will be conducted and analyzed for anomaly detection. Participants in this arm will receive contact phone call when a potential change in care needs is indicated by an anomaly.
62520080|NCT04686838|ACTIVE_COMPARATOR|READyR II B (comparison)|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content. Standard educational content will instead be shared over the phone.
62520081|NCT04816630||CBC-Diff Monocyte Volume Width Distribution|Monocyte Distribution Width \[MDW\] is part of the CBC with Differential. No intervention
62520082|NCT01739296|EXPERIMENTAL|Wedge|Lateral wedge insole with subtalar strapping Use of lateral wedge insoles with subtalar strapping for 5 to 10 hours daily
62711110|NCT03708367|EXPERIMENTAL|Study Group: LipiFlow Treatment at PreOp|Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
62356388|NCT04099706|EXPERIMENTAL|Intervention - Fat grafting|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the intervention group, the fat will be purified using decanting and injected into the painful areas of skin.
62356389|NCT04099706|SHAM_COMPARATOR|Control - Saline|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the control group, the fat will be discarded and saline will be injected into the painful areas of skin.
62356390|NCT01013493||myopic|
62356391|NCT01013493||non myope-healthy|
62356392|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
62356393|NCT03406364|EXPERIMENTAL|MG005|Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib\[8:00 AM (±2 hours)\] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib\[8:00 AM (±2 hours)\] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib\[8:00 AM (±2 hours); 8:00 PM (±2 hours)\]
62356394|NCT04140604|EXPERIMENTAL|Lactobacillus salivarius AP-32|A 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Lactobacillus salivarius AP-32 and maltodextrin.
62356395|NCT04140604|EXPERIMENTAL|Bifidobacterium animalis subsp. lactis CP-9|A 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Bifidobacterium animalis subsp. lactis CP-9 and maltodextrin.
62356396|NCT04140604|PLACEBO_COMPARATOR|Placebo|The placebo composition and appearance are the same as probiotic capsules, but does not contain live bacteria.
62356397|NCT05021796||Nurses|"Including criteria: (1) registered nurses, (2) nurses undergoing a training for asthma telecounseling, (3) age 21 or more.~Excluding criteria: (1) nurses with previous training for asthma counseling, (2) nurses who do not take care of patients with asthma, (3) Pregnant women"
62356398|NCT00962754|NO_INTERVENTION|physician insight fluid balance|physician has insight in fluid balance chart, this is standard practice
62356399|NCT00962754|EXPERIMENTAL|fluid balance data masked to physician|physician no insight in the fluid balance chart
62520083|NCT01739296|SHAM_COMPARATOR|Neutral|Neutral insole with subtalar strapping (sham) Use of neutral insoles with subtalar strapping for 5 to 10 hours daily
62711111|NCT03708367|OTHER|Control Group|Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
62711112|NCT03965845|EXPERIMENTAL|Cohort 1: Telaglenastat 600 mg and Palbociclib 75 mg|
62711113|NCT03965845|EXPERIMENTAL|Cohort 2: Telaglenastat 800 mg and Palbociclib 75 mg|
62711114|NCT03965845|EXPERIMENTAL|Cohort 3: Telaglenastat 800 mg and Palbociclib 100 mg|
61974820|NCT03773679|EXPERIMENTAL|Exercise Group|"Daily exercise program involved Range of Motion (ROM) exercises against extremity resistances and extension and flexion in upper and lower extremities. Exercises were implemented on wrists, elbows, shoulders, ankles, knees, and hip joints of the infants by the same researcher (YSE). The daily exercise program was repeated 5-8 times, 1 session/day (a similar time of the day), for 30 days. Each session continued for 7-10 minutes."
62520084|NCT03045471||R-EPOCH|
62520085|NCT03045471||R-CHOP|
62520086|NCT06097793|EXPERIMENTAL|KSD-101|Biological: Dendritic Cell Vaccine（Autologous monocyte-derived DCs pulsed with EBV Multi-antigen).
62520087|NCT00657228|PLACEBO_COMPARATOR|2|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) plus an equal volume bolus of normal saline after the first doses are administered.
62520088|NCT00657228|EXPERIMENTAL|1|Standard therapy plus a one-time bolus of heparin at 80 U/kg (maximum dose of 10,000 Units) given immediately after the first doses of standard treatment.
62520089|NCT01857960||Adolescents|Acne survey among Mexican adolescents
62520090|NCT02375919|NO_INTERVENTION|Control|Emergency physician will assess low risk patients for PE with conventional strategy, using D-Dimer testing with subsequent CTPA if positive
62711115|NCT03965845|EXPERIMENTAL|Cohort 3: Telaglenastat 800 mg and Palbociclib 125 mg|
62711116|NCT03965845|EXPERIMENTAL|Part 2: Expansion|The recommended phase 2 dose (RP2D) determined from Part 1 will be the treatment for all cohorts in expansion Part 2.
62711117|NCT01846026|EXPERIMENTAL|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule~1 capsule per week"
62149015|NCT02172898||Heavily Drinking Controls|Heavy alcohol drinking will be defined as \> 40 grams per day on average in women and \> 60 grams per day on average in men for a minimum of 6 months and within the 6 weeks prior to study enrollment. Heavy drinkers, who have just become abstinent within prior 2 weeks, including those we convince to seek treatment as part of the recruiting process, are eligible for enrollment. Control subjects must meet the following criteria: (1) AST, ALT, and total bilirubin levels must be within normal range; (2) no prior history of known alcoholic liver disease; and (3) absence of hepatosplenomegaly (from physical examination or radiographic imaging) or stigmata of liver disease.
62711118|NCT01846026|PLACEBO_COMPARATOR|Placebo|capsule with peanut oil
62711119|NCT06718322|EXPERIMENTAL|Local implementation teams|The local implementation teams for this study, referred to as the implementers of the Primary Cancer Prevention Implementation Toolkit (PCP-IT), are the primary users of the toolkit and play a central role in tailoring and implementing cancer prevention interventions. Each team is responsible for selecting and adapting the intervention to meet local needs and developing a tailored implementation plan. Each team is led by an implementation lead, who directly oversees the implementation process and ensures the team effectively uses the PCP-IT to guide their work. In some cases, the implementation lead may also serve as the implementation coordinator. The coordinator's role is to provide higher-level oversight and may involve coordinating multiple implementation teams across various locations, such as hospitals, or focusing on a single team at one site.
62711120|NCT06563960|OTHER|intervention|patients who drank carbonated water.
62149016|NCT02172898||Subjects with AH|Diagnosis of AH will be established on published criteria based on history of heavy alcohol consumption (defined as \> 40 grams per day on average in women and \> 60 grams per day on average for men for a minimum of 6 months and within the 6 weeks prior to study enrollment), clinical evaluation and appropriate laboratory testing (as defined as total bilirubin \> 2 mg/dL and AST \> 50 U/L). When diagnosis of AH remains in question, a liver biopsy (if clinically feasible and subject has no contraindications) will be required. We plan to enroll patients with AH in special population infected with hepatitis B (HBV), hepatitis C (HCV), or HIV.
61974821|NCT03773679|NO_INTERVENTION|Control Group|The preterm infants in the control group did not receive the daily exercise program, only the standard clinical routine.
62149017|NCT04373772|EXPERIMENTAL|abdominal massage group|the abdominal massage group received a total of 30 minutes of massage, 15 minutes every morning and evening, until the first defecation.
62149018|NCT04373772|NO_INTERVENTION|control group|Routine care for the control group
62149019|NCT02709044|EXPERIMENTAL|Ringer lactate 20 mL/kg|This group of subjects will receive a bolus of 20 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
61974822|NCT06234657|EXPERIMENTAL|Telerehabilitation for stroke patient|
62520091|NCT02375919|OTHER|Intervention|PERC based Strategy : Emergency physician will assess low risk patients for PE first with calculation of PERC score. If all PERC criteria are negative, then no further testing for PE is recommended. If at least one criterion is positive, then the patient undergoes D-Dimer testing with subsequent CTPA if positive
62711121|NCT01511133||HRV Group|Subjects received two or three doses of HRV in previous studies.
62711122|NCT01511133||Placebo Group|Subjects received two or three doses of placebo in previous studies.
62711123|NCT05956002|EXPERIMENTAL|Sequence 1|Single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference) followed by single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1) followed by single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2) followed by single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3) followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
62711124|NCT05956002|EXPERIMENTAL|Sequence 2|Single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1) followed by single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3) followed by single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference) followed by single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2) followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
62711125|NCT05956002|EXPERIMENTAL|Sequence 3|Single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2). Followed by single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference).followed by single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1) Followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
62711126|NCT05956002|EXPERIMENTAL|Sequence 4|Single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1). Followed by single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
62711127|NCT05862688||Infection|patients with infection
62711128|NCT05862688||non-infection|patients without infection
62711129|NCT06124222|ACTIVE_COMPARATOR|Group A|Patients who have not received RT in their oncologic treatment (non-irradiated).
62711130|NCT06124222|EXPERIMENTAL|Group B|Patients who have received RT in their oncologic treatment (irradiated).
62149020|NCT02709044|EXPERIMENTAL|Ringer lactate 40 ml/kg|This group of subjects will receive a bolus of 40 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
62520092|NCT01289444|ACTIVE_COMPARATOR|Healthy Living Control|"Session 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered, with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~Session 3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides. The Administered by the trained RA-Control to prevent contamination with the FACE condition."
62520093|NCT01289444|EXPERIMENTAL|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
62520094|NCT04455178|EXPERIMENTAL|Spironolactone|Spironolactone 20mg once daily
62520095|NCT04455178|ACTIVE_COMPARATOR|Indapamide|Indapamide 1.5mg once daily
62520096|NCT02943967|ACTIVE_COMPARATOR|CXL + PRK group|"Corneal cross-linking surgery is perfomed in one eye : deepithelization of the cornea and instillation of 0,1% riboflavin (ophthalmos - Brazil) for 30 minutes and UVA for irradiated for 30 minutes with ultraviolet-A of 365nm light with an irradiance of 3 mW/cm2 using Xlink (Opto - São Carlos) Photorefractive keratotomy will be perfomed in the same eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
62356400|NCT05128526|EXPERIMENTAL|Short foot exercise without respiratory exercises|"The participant will place by the researcher in the standing position so that the width between both feet will equal the width of the pelvis and the second toe will align with the patella. During the Short Foot Exercise, the participant will ask to position the spine straight, maintain the pelvis in a neutral position, and place the centerline of the body. The starting position will be set by the researcher under the same conditions as the midway between the feet. The subjects will give feedback from the researchers to assist in the maintenance of accurate body alignment. SFE, only in a standing position.~The participants will keep in contact with the fibular head of the target bar to maintain a constant position during Short Foot Exercises. Afterward, surface EMG measurements will be taken from the same muscle groups for 10 seconds during the foot shortening exercises while without breathing."
62356401|NCT05128526|EXPERIMENTAL|Short Foot Exercise With Respiratory Exercise|The participants will keep in contact with the fibular head of the target bar to maintain a constant position during Short Foot Exercises. Afterward, surface EMG measurements will be taken from the same muscle groups for 10 seconds during the foot shortening exercises while with breathing.
62356402|NCT00781872|EXPERIMENTAL|Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously|Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments
62356403|NCT04401904|EXPERIMENTAL|Dapagliflozin|10 participants with pre-diabetes will be randomized to the experimental group to receive dapagliflozin 10mg by mouth daily for 12 weeks.
62356404|NCT04401904|OTHER|Nutritional Counseling|10 participants with pre-diabetes will be randomized to receive nutritional counseling weekly for 12 weeks
62356405|NCT03747991||Control Infants|Infants ages 2 months to 12 months who are not on H2RA medication.
62356406|NCT03747991||Treated Infants|Infants ages 2 months to 12 months who are taking H2RA medication.
62356407|NCT03612947|ACTIVE_COMPARATOR|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4.
62356408|NCT03612947|PLACEBO_COMPARATOR|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
62356409|NCT03118453|EXPERIMENTAL|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
62356410|NCT03118453|ACTIVE_COMPARATOR|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
62356411|NCT03731546|NO_INTERVENTION|Group A|Placental insufficiency and ICC : Immediate cord clamping after delivery of the fetus in preterm infants with placental insufficiency
62356412|NCT03731546|ACTIVE_COMPARATOR|Group B|Placental insufficiency and DCC: Cord clamping 60 seconds after delivery of fetus in preterm infants with placental insufficiency
62356413|NCT03731546|ACTIVE_COMPARATOR|Group C|Normal placenta with DCC:Cord clamping 60 seconds after delivery of fetus in preterm infants without placental insufficiency
62356414|NCT05856669|EXPERIMENTAL|Single subject case study|
62356415|NCT03406715|EXPERIMENTAL|Combination Immunotherapy Plus Vaccine|Combination immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC). Induction Immunotherapy, followed by Maintenance Immunotherapy and potentially Retreatment. During retreatment, participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone every three weeks for a maximum of one additional year.
62356416|NCT01808404|EXPERIMENTAL|Web-Based Guided Self-Help|The study is an open trial and all participants will be assigned to the same intervention arm.
61974823|NCT01414075|EXPERIMENTAL|Arm A + E (Participants on HD): Roxadustat Only, No Iron|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally 3 times weekly (TIW) for 12 weeks.
62149021|NCT05688891|EXPERIMENTAL|Virtual reality|"Before the procedure, Visual Analogue Scale-VAS, Spielberger State and Trait Anxiety Inventory, Burn-Specific Pain Anxiety Scale were filled in.5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Video monitoring with Virtual Reality continued throughout the entire dressing.This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings.After the procedure, the scales were filled again."
62149022|NCT05688891|EXPERIMENTAL|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings.After the procedure, the scales were filled again."
62520097|NCT02943967|ACTIVE_COMPARATOR|PRK group|"Photorefractive keratotomy will be perfomed in the fellow eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
62520098|NCT02058082|ACTIVE_COMPARATOR|ejaculated sperm|Intracytoplasmic sperm injection (ICSI) cycles using ejaculated sperm
62520099|NCT02058082|ACTIVE_COMPARATOR|testicular extracted sperm|Intracytoplasmic sperm injection (ICSI) cycles using testicular extracted sperm
62520100|NCT02823483|EXPERIMENTAL|Arm 1|All subjects are patched.
62520101|NCT01174082|EXPERIMENTAL|KLH Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
62520102|NCT01174082|EXPERIMENTAL|KLH-id Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
62520103|NCT01174082|EXPERIMENTAL|KLH Vaccine (Donor)|Donor Group 1: (non-specific vaccination) vaccinated with KLH only vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
62520104|NCT01174082|EXPERIMENTAL|Vaccine KLH-id (Donor)|Donor Group 2: (myeloma specific vaccination) vaccinated with KLH-id vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collections.
62520105|NCT06206083||Patients with EC endometroid|Patients with EC endometroid subtype and peripheral blood, treated during 2015-2019 at the INCan.
62520106|NCT03867955||Patients who have a neurosurgical intervention|Patients who have a neurosurgical intervention will be included. They will have a collection of datas.
62520107|NCT02221037|EXPERIMENTAL|GSK2862277|GSK2862277 will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will undergo either ventilated or collapsed lung BAL procedure. Regular assessments will be conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
62520108|NCT02221037|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will be undergo either ventilated or collapsed lung BAL procedure. Regular assessments will conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
62520109|NCT02439671|EXPERIMENTAL|Immediate intervention|Participant assigned to McGill Transition Support Program in next available session
62520110|NCT02439671|NO_INTERVENTION|Waiting List control|Participant assigned to waiting list for one session prior to receiving McGill Transition Support Program in following session
62149023|NCT05688891|NO_INTERVENTION|Control|"During the burn dressing procedure, no intervention method was used, and routine treatment and care interventions were continued.This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
62149024|NCT06422715||patients with histological diagnosis of PTLD|patients with histological diagnosis obtained from a biopsy sample in 10 years' time frame (from 01/01/2011 to 31/12/2021) of PTLD (from allogeneic transplantation (both SOT and HSCT))
62149025|NCT04901585||Totally intracorporeal distal gastrectomy|All patients who underwent minimally invasive distal gastrectomy with intracorporeal anastomosis for gastric cancer
62149026|NCT03345979|EXPERIMENTAL|Treatment Group 1|Regular injections
62149027|NCT03345979|ACTIVE_COMPARATOR|Treatment Group 2|Regular injections
62149028|NCT01000649|EXPERIMENTAL|FE 202158 1.25|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 1.25 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
62149029|NCT01000649|EXPERIMENTAL|FE 202158 2.5|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 2.5 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
62356417|NCT05446194|EXPERIMENTAL|Investigational Treatment 1|Investigational treatment stimulation pattern 1
62520111|NCT02192008|ACTIVE_COMPARATOR|Part A|Cohort naive to typhoidal Salmonella challenged with either S. Typhi or S. Paratyphi
62520112|NCT02192008|ACTIVE_COMPARATOR|Part B|Cohort previously challenged with S. Typhi or Paratyphi re-challenged with either S. Typhi or S. Paratyphi.
62520113|NCT02071953|EXPERIMENTAL|Adhesive without acid pretreatment|Experimental adhesive w/out phosphoric acid in post. rest.
62520114|NCT02071953|ACTIVE_COMPARATOR|Adhesive with acid pretreatment|Experimental adhesive with phosphoric acid in post. rest.
62149030|NCT01000649|EXPERIMENTAL|FE 202158 3.75|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 3.75 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
62149031|NCT01000649|PLACEBO_COMPARATOR|PLCBO|Patients in the arm received an intravenous infusion for up to 7 days of placebo.
62149032|NCT02671266|EXPERIMENTAL|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
62149033|NCT02671266|EXPERIMENTAL|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
62520115|NCT02527499|EXPERIMENTAL|ROCBT group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (\>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Ride-On Cars with Bimanual Training Program (ROCBT) group.
62520116|NCT02527499|ACTIVE_COMPARATOR|Early Mobility Training group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (\>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Early Mobility Training Program group.
62520117|NCT02527499|ACTIVE_COMPARATOR|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (\>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Regular Therapy Program group.
62520118|NCT04431882|EXPERIMENTAL|optic nerve sheath fenestration|Leukemic patients mainly those suffering from acute lymphoblastic leukemia.
62520119|NCT05450328|PLACEBO_COMPARATOR|Normal Saline|The control group will receive a saline solution (8mL) as a placebo, before CPB start.
62520120|NCT05450328|ACTIVE_COMPARATOR|Combination of inhaled Epoprostenol and Milrinone|The experimental group will receive simultaneously 4mg of Milrinone (1mg/mL, 4mL) and 60 mcg of Epoprostenol (15 mcg/mL, 4mL) before CPB initiation.
62520121|NCT01078129|ACTIVE_COMPARATOR|behavior therapy - CRT|behavior program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions) by means REHACOM® software
62149034|NCT03605147|EXPERIMENTAL|CaHMB|CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
62149035|NCT03605147|ACTIVE_COMPARATOR|Control|Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
62520122|NCT01078129|SHAM_COMPARATOR|non-CRT|no intervention
62711131|NCT03378102|EXPERIMENTAL|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|"Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. The donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion and infused within 4 hours as a bolus on day 0.~Subjects will receive virus-specific, antigen selected T cells within a targeted range of 1 x 10\^3- 2 x 10\^5 per kg of recipient weight."
62149036|NCT01431118|ACTIVE_COMPARATOR|sports intervention male|male athletes of the german national dragon boat team
62149037|NCT01431118|ACTIVE_COMPARATOR|sports intervention women|women athletes of the german national dragon boat team
62149038|NCT04150016|EXPERIMENTAL|Firehawk implantation|22 subjects will be enrolled to receive Firehawk™ sirolimus target-eluting stent(s).
62149039|NCT04150016|ACTIVE_COMPARATOR|XIENCE implantation|22 subjects will be enrolled to receive XIENCE™ everolimus target-eluting stent(s).
62520123|NCT03799991|EXPERIMENTAL|Vestibular therapy|Vestibular therapy (Vestibular physical therapy) entails an 8-week course of exercises delivered by a physical therapist designed to improve vestibular function.
62711132|NCT06389175|EXPERIMENTAL|Patients suffering from MDD|All participants will receive tVNS and sham stimulation in a randomized order.
62149040|NCT03610620|EXPERIMENTAL|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
62149041|NCT04097509|EXPERIMENTAL|autologous fibrin glue (AFG) group|In the test groups, polymerized AFG was applied to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
62356418|NCT05446194|EXPERIMENTAL|Investigational Treatment 2|Investigational treatment stimulation pattern 2
62520124|NCT03799991|ACTIVE_COMPARATOR|Active control|"The active control regimen consists of eye movement exercises (e.g. smooth pursuit eye movements) and also general conditioning exercises (e.g. range of motion exercises, lifting light weights with the arms and legs). This regimen is vestibular neutral in that head movements which specifically challenge the vestibular system are avoided."
62520125|NCT04048941|EXPERIMENTAL|Verum Acupuncture with Movement|Verum acupuncture along radial side of 2nd metacarpal, following by active movement of previously painful body part x 10 minutes.
62520126|NCT04048941|ACTIVE_COMPARATOR|Verum Acupuncture without Movement|Verum acupuncture along radial side of 2nd metacarpal, following by laying on examination table x 10 minutes.
62520127|NCT04048941|SHAM_COMPARATOR|Control Acupuncture with Movement|Sham/control acupuncture at acupoint LI4, following by active movement of previously painful body part x 10 minutes.
62711133|NCT06389175|EXPERIMENTAL|Healthy controls (HC)|All participants will receive tVNS and sham stimulation in a randomized order.
62711134|NCT06715228|EXPERIMENTAL|group I|in this group, patients (n=20) with obstructive sleep apnea will participate and will administer six cycles of 5-min shitali respiratory pranayama exercise rehabilitation training (the rehabilitation will be repeated or applied at morning, afternoon, and also at evening) for 12 week as a daily performance,
62356419|NCT01629979|EXPERIMENTAL|A: Grafting of autologous epidermal harvested cells and UVB|"Grafting with epidermal cells: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
62520128|NCT03334721|EXPERIMENTAL|Gabapentin, Then Placebo Oral Capsule|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
62520129|NCT03334721|EXPERIMENTAL|Placebo Oral Capsule, Then Gabapentin|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of Gabapentin medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
62520130|NCT03748355|OTHER|Pharmacogenetic Analysis|A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
62520131|NCT01332578|EXPERIMENTAL|Test Product|Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
62520132|NCT01332578|ACTIVE_COMPARATOR|Paracetamol tablet|Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
62711135|NCT06715228|NO_INTERVENTION|Group II|in this group, patients (n=20) with obstructive sleep apnea will participate and will act as control group. In this group, no intervention will be applied
62149042|NCT04097509|EXPERIMENTAL|injectable platelet rich fibrin (i-PRF) group|In the test groups, polymerized i-PRF was applied to the donor area. Donor palate was closed with sterile aluminum foil and periodontal pack.
62149043|NCT04097509|PLACEBO_COMPARATOR|Control Group|In the control group, only moist sterile tamponade was applied following graft removal to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
62149044|NCT02558205||CT Perfusion and PET/CT|Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
62149045|NCT01073761|EXPERIMENTAL|Everybody|All Subjects will receive the same intervention
62356420|NCT01629979|ACTIVE_COMPARATOR|UVB treatment|UVB treatment twice a week during 3months
62356421|NCT05839847|EXPERIMENTAL|NPU|Participant will be presented with a series of images (cues) and sounds. Three conditions will occur - a no shock (N), predictable shock (P), and unpredictable shock (U). In P, shocks will only occur with the cue. In U, shocks will happen at any time. Participants will be told which condition they are in throughout the task. Startle sounds will occur throughout. 3 Study visits will occur - identical conditions for the participant, testing 2 brain regions and 1 sham visit.
62356422|NCT05839847|EXPERIMENTAL|NPU-c|Participants will be presented with a moving line. When the line reaches a certain point - an event will occur. This event will either be a painful shock or a monetary reward. Startle sounds will occur throughout. 3 study visits will occur - identical conditions for the participant, testing 2 brain regions and 1 sham visit.
62356423|NCT03126279||Preoperative Chronic Knee OA Patients|Patients will be recruited from orthopaedic preoperative clinics from those awaiting total knee replacement surgery.
62356424|NCT03126279||Healthy Volunteers|Healthy volunteers will be recruited that are aged match to our OA patient cohort so meaningful comparisons regarding brain activity and pain sensitisation characteristics can be assessed.
62356425|NCT04146337|EXPERIMENTAL|Fecal microbiota transplantation (FMT)|FMT regimen: Patients will be given capsulized FMT 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
62356426|NCT04146337|NO_INTERVENTION|Control|Routine follow-up
62356427|NCT04101734||Double Lumen Endotracheal Tube|Group of patients intubated with Double Lumen Endotracheal Tube.
62520133|NCT01834430|EXPERIMENTAL|EN group|The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 \~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 \~ 80 ml/h. On the third day, tube feeding utilized 1500 \~ 2000 ml with the speed of 100 \~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
62520134|NCT01834430|NO_INTERVENTION|parenteral nutrient group|
62711136|NCT03175029|EXPERIMENTAL|TAC-302|
62711137|NCT03175029|PLACEBO_COMPARATOR|Placebo|
62711138|NCT03186638|EXPERIMENTAL|Arm I (ibuprofen)|Patients receive ibuprofen PO BID for 6 weeks.
62711139|NCT03186638|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for 6 weeks.
62149046|NCT04472715|EXPERIMENTAL|follicular unit extraction|extraction of hair follicle unit from donar area and tranplant it into recepient bald area
62149047|NCT04472715|EXPERIMENTAL|foolicular unit extraction and platelet rich plasma|the same procedure mentioned above coupled with session of platelet rich plasma before and after transplantation
62149048|NCT03950661|EXPERIMENTAL|Forest|"Each subject is exposed to a 50 minute walk in a green location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
62711140|NCT04328389|PLACEBO_COMPARATOR|Placebo Comparator: electric toothbrush|Participats will be instructed to used electric toothbrush for home supragingival plaque removal
62520135|NCT01570348|EXPERIMENTAL|Treatment (allogeneic BMT)|"CONDITIONING THERAPY: Patients receive fludarabine phosphate IV over 30-60 minutes QD on days -6 to -2 and cyclophosphamide IV over 1-2 hours QD on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo donor BMT on day 0.~IMMUNOSUPPRESSIVE THERAPY: Patients receive high-dose cyclophosphamide IV over 1-2 hours QD on days 3-4, tacrolimus IV daily or PO BID on days 5-180 with taper to day 365, and mycophenolate acid enteric coated or mycophenolate mofetil PO TID on days 0-35."
62520136|NCT00292188|EXPERIMENTAL|Active|
62520137|NCT00292188|PLACEBO_COMPARATOR|Placebo|
62520138|NCT03145831|EXPERIMENTAL|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
62520139|NCT05651555|EXPERIMENTAL|N arm|
62520140|NCT05651555|ACTIVE_COMPARATOR|Control group|
62520141|NCT00663832|EXPERIMENTAL|LBH589|
62520142|NCT01713231|ACTIVE_COMPARATOR|standard-dose vitamin D|one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
62520143|NCT01713231|EXPERIMENTAL|high-dose vitamin D|One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
62520144|NCT01829087|EXPERIMENTAL|Botox injection|
62520145|NCT01829087|PLACEBO_COMPARATOR|Control|
62149049|NCT03950661|EXPERIMENTAL|Urban|"Each subject is exposed to a 50 minute walk in a gray location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
62520146|NCT01649466|EXPERIMENTAL|Vildagliptin|Patients randomized to the vildagliptin group will receive 50mg vildagliptin once daily add-on to their current glimepiride monotherapy for 24 weeks. No dose titrations are permitted during the study.
62520147|NCT01649466|ACTIVE_COMPARATOR|Protaphane|Patients randomized to the Protaphane group will receive a individualized dose of Protaphane once daily as bedtime dose. The Protaphane dose will be titrated within the first 4 weeks to reach fasting plasma glucose values below 100 mg/dl.
62520148|NCT05841290|EXPERIMENTAL|Group (1) Resin Based Sealer intervention|evaluate the incidence and intensity of post-operative pain after obturation using resin based sealers.
62520149|NCT05841290|EXPERIMENTAL|Group (2) Silicone Based Sealer intervention|evaluate the incidence and intensity of post-operative pain after obturation using sillicon based sealers.
62149050|NCT01955499|EXPERIMENTAL|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO on days 1-21 and ibrutinib PO on days 1-28 (days 2-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT or PET/CT throughout the study. Patients may undergo bone marrow biopsy and aspiration and MRI as clinically indicated.
62149051|NCT01197924||healthy volonteer children|paired for the sex and the age
62149052|NCT01197924||older children followed for a médulloblastome cérébelleux|children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
62149053|NCT00047385|EXPERIMENTAL|Low-Dose CT|
62149054|NCT00047385|EXPERIMENTAL|Chest X-ray|
62149055|NCT00564798||1|Study Group
62149056|NCT00564798||2|Control Group
61974824|NCT01414075|EXPERIMENTAL|Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
62149057|NCT06405906|EXPERIMENTAL|Biliary Colic Group - Non-operative Treatment - RADIGAL1|Patients presenting with biliary colic and treated non-operatively will be randomly assigned to receive fat-free diet or balanced WHO diet for 3 months.
62149058|NCT06405906|EXPERIMENTAL|Cholecystitis Group - Non-operative Treatment - RADIGAL1|Patients presenting with acute cholecystitis and treated non-operatively will be randomly assigned to receive fat-free diet or balanced WHO diet for 3 months.
62149059|NCT06405906|EXPERIMENTAL|Biliary Colic Group - Cholecystectomy - RADIGAL2|Patients undergoing cholecystectomy due to biliary colic will be randomly assigned to receive fat-free diet or balanced diet for 3 months.
62149060|NCT06405906|EXPERIMENTAL|Cholecystitis Group - Cholecystectomy - RADIGAL2|Patients undergoing cholecystectomy due to acute cholecystitis will be randomly assigned to receive fat-free diet or balanced diet for 3 months.
62520150|NCT05147038|EXPERIMENTAL|Intervention group|Participants allocated into the intervention group will be coached for 12 weeks by a tele-coaching mobile App containing tips for PA increase and for number of steps recording (visual feedback for the patient).
62520151|NCT05147038|NO_INTERVENTION|Control group|Participants in the control group will receive usual care (including regular visits) together with the educational information.
62520152|NCT05628519|EXPERIMENTAL|Captain Sonar|Participants will receive a training by a game session at Captain SonarTM of 60 min (including 15 min of presentation and prize in hand of the game) against a standardized investigator team
62520153|NCT05628519|PLACEBO_COMPARATOR|Placebo Monopoly|"The control group participants will benefit from a 60 min session to play a Placebo game: monopoly"
62520154|NCT04171557||Patients with diabetes at the baseline assessement in EPIC|Self-reported and confirmed diabetes (validated by a second source (at least 1), including repeated self-report, contact with physician, linkage to register later point, intake of diabetes medicine, registration of diabetic chiropody, baseline glycated hemoglobin\>=6.0%, five annual blood glucose measurements or two blood glucose measurements per year for five consecutive years) cases were included in the analyses. No information is available to distinguish between type 1 and type 2 diabetes across the population but type 1 is rare by comparison.
62520155|NCT01701869||NTHi positive|No intervention, this is an observational study
62520156|NCT01701869||NTHi negative|No intervention, this is an observational study
62520157|NCT01701869||Healthy Control|No intervention, this is an observational study
62520158|NCT05841446|EXPERIMENTAL|Test/reference|Subjects first receive a single-dose of 2.5mg test apixaban tablet (T, produced by Disha Pharmaceutical Group Co., Ltd. China) in the first treatment period and to receive the reference (R, Bristol-Myers Squibb Manufacturing Company,USA )in the second treatment period.
62520159|NCT05841446|EXPERIMENTAL|Reference/test|Subjects first receive a single-dose of 2.5mg reference apixaban tablet (R, Bristol-Myers Squibb Manufacturing Company, USA )in the first treatment period and to receive test tablet (T, produced by Disha Pharmaceutical Group Co., Ltd. China) in the second treatment period.
62520160|NCT03977831|ACTIVE_COMPARATOR|Open Radical Cystectomy (ORC)|Open radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an iliac conduit urinary diversion is performed.
62520161|NCT03977831|ACTIVE_COMPARATOR|Robot-assisted Radical Cystectomy (iRARC)|Robot-assisted radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an intracorporeal iliac conduit urinary diversion is performed.
62520162|NCT06205472|EXPERIMENTAL|Adjuvant SIB radiotherapy|Adjuvant integrated boost radiotherapy following narrow-margin hepatectomy in patients with HCC.
62520163|NCT01769274|EXPERIMENTAL|PF-05089771 1600 mg|
62520164|NCT01769274|PLACEBO_COMPARATOR|Placebo comparator: matching placebo|Single oral dose of placebo for PF-05089771 1600 mg
62520165|NCT00441350|ACTIVE_COMPARATOR|OM 40|Olmesartanmedoxomil (OM)40 mg tablets.
62520166|NCT00441350|EXPERIMENTAL|OM/HCTZ 40/12.5|Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.
62520167|NCT03521063|EXPERIMENTAL|Poractant alfa/budesonide|A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal
62520168|NCT03521063|ACTIVE_COMPARATOR|Poractant alfa/saline|A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal
62520169|NCT03132194|EXPERIMENTAL|DPSG 7.5%|"DPSG 7.5% (Taro Pharmaceuticals USA)~Topical, twice daily on the face for 84 days."
62520170|NCT03132194|PLACEBO_COMPARATOR|Vehicle Gel|"Placebo product (Taro Pharmaceuticals Inc.)~Topical, twice daily on the face for 84 days."
62520171|NCT03132194|ACTIVE_COMPARATOR|Aczone|"dapsone 7.5~Topical, twice daily on the face for 84 days."
62520172|NCT01764295|EXPERIMENTAL|DWJ1276|Once daily, administered orally, 8 week
62520173|NCT01764295|ACTIVE_COMPARATOR|Olmesartan|Once daily, administered orally, 8 week
62520174|NCT01764295|ACTIVE_COMPARATOR|Rosuvastatin|Once daily, administered orally, 8 week
62520175|NCT01764295|PLACEBO_COMPARATOR|Placebo|Once daily, administered orally, 8 week
62520176|NCT02834806|EXPERIMENTAL|BioNIR drug eluting stent system|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
62520177|NCT06502197|EXPERIMENTAL|Short-term (4 weeks) Silastic Stenting|
62520178|NCT06502197|EXPERIMENTAL|Long-term (12 weeks) Silastic Stenting|
62520179|NCT02701231|SHAM_COMPARATOR|Sham control|Subjects will receive one cycle of treatment of sham low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
62520180|NCT02701231|EXPERIMENTAL|Low-frequency Rotating Magnetic Therapy|Subjects will receive one cycle of treatment of low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
62520181|NCT00949611|EXPERIMENTAL|FRAX + Decision Aid|
62520182|NCT00949611|NO_INTERVENTION|Usual care|
62520183|NCT00949611|EXPERIMENTAL|FRAX estimated fracture risk|
62520184|NCT04013945|ACTIVE_COMPARATOR|Superba Boost capsules|1000 mg krill oil concentrate per capsule
62520185|NCT04013945|PLACEBO_COMPARATOR|Placebo capsules|1000 mg capsule composed of mixed vegetable oil.
62520186|NCT02947074|NO_INTERVENTION|Control|Waiting list
62520187|NCT02947074|EXPERIMENTAL|Yoga Meditation|Previously naive to yoga and meditation, subjects will receive 2 30min yoga meditation classes for 8 weeks.
61974825|NCT01414075|EXPERIMENTAL|Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with approximately 60 mg IV iron (ferric gluconate complex in sucrose injection \[for example, Ferrlecit®\] or equivalent) once a week for 12 weeks.
62520188|NCT02109536||Staff Gastroenterologists.|Staff Gastroenterologists ability to recognize loops will be assessed using an magnetic endoscopic imager.
62520189|NCT04102631|EXPERIMENTAL|exposed group|patients will receive colonoscopy with assistance of Endo.Angel
62520190|NCT04102631|SHAM_COMPARATOR|non-exposed group|patients will receive colonoscopy without assistance of Endo.Angel
62520191|NCT02147249|EXPERIMENTAL|erythema migrans patients treated with antibiotics|adult patients with erythema migrans will be treated with oral antibiotics
62520192|NCT03396666|EXPERIMENTAL|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
62520193|NCT03396666|NO_INTERVENTION|No intervention|Regular follow-up with advice on physical activity and nutrition
62520194|NCT02013375|EXPERIMENTAL|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
62520195|NCT04294420|EXPERIMENTAL|Patient education program|Patient education program
62520196|NCT01861444||Cohort|
62520197|NCT01660334||Voriconazole|Subjects who are treated with voriconazole
62520198|NCT00556023|EXPERIMENTAL|CP-675,206 and gemcitabine|
62520199|NCT01917864|EXPERIMENTAL|iPad Application|Student participants will use specialized iPad software under the supervision of a speech-language pathologist over the course of 12 months, approximately one session per week, one hour per session.
62520200|NCT00632086|EXPERIMENTAL|1|Single oral dose of 325 mg aspirin administered as PA32540
62520201|NCT00632086|EXPERIMENTAL|2|aspirin core
62520202|NCT00632086|ACTIVE_COMPARATOR|3|active
62520203|NCT03504280|ACTIVE_COMPARATOR|high dose IM|cholecalciferol 600,000 IU given intramuscularly
62520204|NCT03504280|ACTIVE_COMPARATOR|high dose oral|cholecalciferol 600,000 IU given orally
62520205|NCT03504280|ACTIVE_COMPARATOR|low dose oral|cholecalciferol 400,000 IU given orally in 2 divided doses given monthly for 2 consecutive months followed by daily maintenance dose of 1000 IU
61974826|NCT01414075|EXPERIMENTAL|Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on PD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
61974827|NCT00638768|ACTIVE_COMPARATOR|Physiotherapy|Including 10 individual visits with a physiotherapist and home exercises
61974828|NCT00638768|NO_INTERVENTION|2|Usual care
62520206|NCT05143151|EXPERIMENTAL|Treatment group|CD276 targeted chimeric antigen receptor cells treatment
62520207|NCT05435339|EXPERIMENTAL|GEN1053 Monotherapy|
62520208|NCT03817801|EXPERIMENTAL|non-slip element (NSE) predilation|In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.
62520209|NCT03817801|ACTIVE_COMPARATOR|non-compliant (NC) balloon predilation|In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.
62520210|NCT05262036|EXPERIMENTAL|Anti-aging Supplement|Mixture (powder) of vitamins and nutrients
62520211|NCT05262036|PLACEBO_COMPARATOR|Placebo excipients|All excipients in powder WITHOUT vitamins and nutrients
62149061|NCT04218877||Children with atopic dermatitis|Children 1-3 years old with atopic dermatitis
62149062|NCT04218877||Children without atopic dermatitis|
62520212|NCT00787579|ACTIVE_COMPARATOR|Bifocal spectacles|
62520213|NCT00787579|ACTIVE_COMPARATOR|Prismatic bifocals|
62520214|NCT00787579|NO_INTERVENTION|Single vision spectacles|
62520215|NCT01222390|EXPERIMENTAL|Contour Profile Tissue Exander|Patients undergoing breast reconstruction using a Contour Profile Tissue Expander (CPX3).
62520216|NCT06371144|EXPERIMENTAL|Paracetamol group|Receive intravenous paracetamol intrapartum as labour analgesia
62520217|NCT06371144|ACTIVE_COMPARATOR|Tramadol group|Receive intramuscular tramadol intrapartum as labour analgesia
62520218|NCT00506818|ACTIVE_COMPARATOR|2|Intensive risk factor intervention
62520219|NCT03992794||Total patients|Consecutive patients presenting to the ED with either a suspected or documented infection in which blood samples were taken during routine. An extra blood sample was taken to measure PCT \& MR-proADM using the Samsung IB10 point of care assay.
62520220|NCT04091958|EXPERIMENTAL|Post-tumourectomy reconstruction with myo-glandular flap.|Standard tumourectomy followed by reconstruction with myo-glandular flap.
62520221|NCT06000735|EXPERIMENTAL|7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2|All participants will go through the same intervention described above.
62520222|NCT01934738|EXPERIMENTAL|Group 1: Cohort 1|
62520223|NCT01934738|EXPERIMENTAL|Group 1: Cohort 2|
62520224|NCT01934738|EXPERIMENTAL|Group 1: Cohort 3|
61974829|NCT04767204|EXPERIMENTAL|Peer support service|Peer support workers co-lead and assist workplace problem-solving and care skills training in an extended vocational rehabilitation program
61974830|NCT03785431|EXPERIMENTAL|Intervention|Patient diagnosed with ST elevation myocardial infarction will undergo bioresorbable stent deployment in culprit lesion.
62149063|NCT04218877||Children with genetic predisposition|Children with genetic predisposition to atopic dermatitis, but without manifestations
62149064|NCT03788811||Control subjects|Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder, recurrent mood disorder or have not met criteria for a major depression episode in the last 12 months according to DSM-V criteria.
62149065|NCT03788811||Patients with schizophrenia (SZ)|Patient with a diagnosis of schizophrenia for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
62520225|NCT01934738|EXPERIMENTAL|Group 2: Cohort 4|
62520226|NCT01934738|EXPERIMENTAL|Group 1: Cohort 5|
62520227|NCT01934738|EXPERIMENTAL|Group 2: Cohort 6|
62520228|NCT03677791|EXPERIMENTAL|Virtual 360° intervention|counselling in the virtual 360° environment and also counselling in accordance with current practice
62520229|NCT03677791|ACTIVE_COMPARATOR|Control group|counselling in accordance with current practice
62520230|NCT06354855|ACTIVE_COMPARATOR|Group is doing breathing exercises while watching videos|Abdominal breathing exercise group .The group, which receives abdominal breathing exercise training, will perform video-assisted breathing exercises for 30 minutes a day.
62520231|NCT06354855|ACTIVE_COMPARATOR|Medium pace walking group|Medium pace walking group .Control group will walk at a moderate pace for 30 minutes daily.
62520232|NCT04259138|OTHER|Symptomatic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission.
62520233|NCT04259138|OTHER|Symptomatic and endoscopic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission.
62520234|NCT04259138|OTHER|Symptomatic, endoscopic and histological remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission plus histological remission.
62520235|NCT03955471|EXPERIMENTAL|Niraparib+Dostarlimab (TSR-042)|Participants with body weight ≥77 kilogram (kg) and platelet count ≥150,000/microliter (μL) at baseline were administered Niraparib 300 milligram (mg) once daily (QD) and participants with body weight \<77 kg or platelet count \<150,000/μL at baseline were administered Niraparib 200 mg QD. Niraparib was administered continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) was administered as an intravenous (IV) infusion of 500 mg once every three weeks (Q3W) from Cycle 1 Day 1 through Cycle 4. Beginning at Cycle 5, Dostarlimab (TSR-042) was administered via an IV infusion of 1000 mg on Day 1 of each 6-week cycle until PD or toxicity, up to 27 months.
62520236|NCT00789763|EXPERIMENTAL|Sorafenib + gemcitabine + radiotherapy|
62520237|NCT01402180|EXPERIMENTAL|A|Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation
62520238|NCT01402180|ACTIVE_COMPARATOR|B|Patients randomized in Arm B will receive chemoradiation only
62711141|NCT04328389|EXPERIMENTAL|Professional oral hygiene|Full-Mouth professional oral hygiene consisting in scaling and root planing, four quadrants in one session.
62711142|NCT05645757|EXPERIMENTAL|Cohort 1|WCK 6777 (Ertapenem 1 g combined with Zidebactam 1 g) or placebo administered by 100 ml of intravenous infusion (IV) for 30 (±5) minutes once daily for 7 days. N= 8
62520239|NCT03531801||Recovered fracture group|The interventions will be conducted on both groups, on two experimental (approximately 45 minutes per session) sessions separated by 24 hours.Pressure algometry consists of measuring pressure pain thresholds at three bilateral muscle sites.Mapping referred pain areas consists of recording on an electronic body chart the area of pain induced by 60s pressure stimulation at 1.2 times the force needed to reach the pressure pain threshold, exerted on the extensor carpi radialis and the infraspinatus muscles.As group-differences can be attenuated at baseline but emerge on a sensitized (exercise-induced soreness) state, these procedures are performed at baseline and 24 hours after evoking exercise-induced muscle soreness. For further clarification see our recent publication PMID:29608510
62520240|NCT03531801||Control group|This group will receive the same intervention than the recovered fracture group
62520241|NCT02254018|EXPERIMENTAL|bivatuzumab mertansine|single dose escalation
62520242|NCT04497675||Can't fell bitterness|"1. The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.~2. Record whether the subject feels bitterness, if not, let the subject puts on the hood, carry out the fitness test again and record the results."
62520243|NCT04497675||Can fell bitterness|"1. The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.~2. If the subject feels bitterness, stick the adhesive strip on the upper edge of the subject's mask and perform the direct spray test again. Record whether the subject feels bitterness, if not, ask the subject to put on the hood, carry out the fitness test again and record it. If there is a feeling, ask the subject to change to a medical surgical mask and put an adhesive strip on the upper edge of the mask, then conduct the direct spray test again, and record the test results."
62520244|NCT01083810||therapy-naive|Patients who had not received prior antiretroviral drug therapy
62520245|NCT01083810||pre-treated|Patients that had previously received antiretroviral therapy, but are protease inhibitor naive
62520246|NCT01083810||non-B|Patients infected with non-B subtypes of HIV-1
62520247|NCT05683327|ACTIVE_COMPARATOR|Hyaluronic Acid 150 mg|Take 150 mg/day of hyaluronic acid.
62520248|NCT05683327|ACTIVE_COMPARATOR|Hyaluronic Acid 80 mg|Take 80 mg/day of hyaluronic acid.
62520249|NCT05683327|PLACEBO_COMPARATOR|Placebo|Take 0 mg/day of hyaluronic acid.
61974831|NCT02762682||CASES OF ITS AND PRE ITS|"1. Either sex, age less than 3 years~2. Clinical diagnosis of Infantile Tremor Syndrome as evidenced by the following features:~\[Developmental delay or regression WITH history of exclusive or predominant breast feeding WITH two or more of the following; skin pigmentation, hair depigmentation, tremors\] ITS:1 and 2 plus tremors PreITS:1 and 2 without tremors"
62520250|NCT04729647|OTHER|Axillary Lymph Node Metastasis|
62711143|NCT05645757|EXPERIMENTAL|Cohort 2|Ertapenem 2 g or placebo administered by 250 ml of intravenous infusion (IV) for 1 hour once daily for 7 days. N=8
62149066|NCT03788811||Patients with bipolar disorder Type I (BP1)|Patient with a diagnosis of bipolar disorder Type 1 for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
62149067|NCT01623609|EXPERIMENTAL|A|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fasted conditions
62149068|NCT01623609|EXPERIMENTAL|B|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fed conditions
62149069|NCT01623609|EXPERIMENTAL|C|Naloxegol film-coated IR tablet 25 mg Phase III formulation under fasted conditions
62149070|NCT01009359|EXPERIMENTAL|Arm 1|
62356428|NCT04101734||Double Lumen Video Endotracheal Tube|Group of patients intubated with Double Lumen Video Endotracheal Tube.
62356429|NCT03358498||β-thalassemia group|"SICT It is a questionnaire to assess patient satisfaction with ICT regimens. It comprises 19 items assessing four domains: perceived effectiveness of ICT (PE), burden of ICT (BD), acceptance of ICT (AC), and side effects of ICT (SE). Patients rate all items on scale from 1 very dissatisfied to 5 very satisfied.~Lab methods :~1. full history and thorough clinical evaluation.~2. . Complete blood count. .3- Serum ferritin .~4-Renal function tests. 5-liver function tests."
62520251|NCT02030483|EXPERIMENTAL|All Subjects|Palbociclib (PD 0332991) will be given at a prespecified dose by cohort orally on days 1-14 of a 28-day cycle. For cycle 1 only, PD 0332991 will start on Day 0. Lenalidomide (Revlimid®) will be given at a prespecified dose by cohort orally on days 8-21 of a 28-day cycle (or days 1-21 as defined by dose cohort level). Dexamethasone (Decadron®) will be given orally at a dose of 20 mg on days 1, 8, 15, and 22 of a 28-day cycle. For cycle 1 only, the dexamethasone will be omitted on Day 1.
62356430|NCT06054503|EXPERIMENTAL|prototype of sensor|The patient is his own control
62356431|NCT06054503|ACTIVE_COMPARATOR|ventilator|The patient is his own control
62356432|NCT01163019||Chest pain|Patients who present to the emergency department with a chief complaint of chest pain and have a moderate pre-test probability for an acute coronary syndrome
62520252|NCT01432574|EXPERIMENTAL|Gardasil Vaccine|Vaccine Administration: A total of 3 injections (shots) at 3 separate visits.
61974832|NCT02762682||HEALTHY CONTROLS|Developmentally normal child not suffering from any acute or chronic neurological illness
61974833|NCT00533845|EXPERIMENTAL|On-Q pain pump|Bupivacaine
61974834|NCT00533845|PLACEBO_COMPARATOR|Placebo/control|Saline
62149071|NCT01009359|EXPERIMENTAL|Arm 2|
62149072|NCT01009359|EXPERIMENTAL|Arm 3|
62520253|NCT03031665||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
62520254|NCT03031665||Remitted MDD|Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
62520255|NCT03031665||Control Subjects|Subjects who have no history of clinical depression or other psychological disorder.
62711144|NCT05645757|EXPERIMENTAL|Cohort 3|Zidebactam 2 g administered by 250 ml of intravenous infusion (IV) for 1 hour,once daily,for 7 days. N=6
62711145|NCT05645757|EXPERIMENTAL|Cohort 4|WCK 6777 (Ertapenem 2 g combined with Zidebactam 2 g) or placebo administered by 250 ml of intravenous infusion (IV) for 1 hour, once daily, for 7 days. N=8
62711146|NCT05645757|EXPERIMENTAL|Cohort 5|Ertapenem 3 g or placebo administered by 250 ml of intravenous infusion (IV) for 2 hours, once daily, for 7 days. N=8
62520256|NCT03627741|EXPERIMENTAL|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
62520257|NCT04788160|EXPERIMENTAL|Cervical SNAGs along with conventional therapy|patient will receive Cervical SNAGs along with conventional therapy (Group A)
62149073|NCT02791204||Participants with PAD|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
62520258|NCT04788160|OTHER|Conventional Therapy|patient will receive only conventional therapy (Group B)
62520259|NCT04126616|EXPERIMENTAL|patients with COPD and PH|
62520260|NCT04126616|ACTIVE_COMPARATOR|patients with COPD without PH|
62520261|NCT04126616|ACTIVE_COMPARATOR|healthy subjects|
62520262|NCT02650401|ACTIVE_COMPARATOR|Extracranial solid tumors harboring NTRK1/2/3,|"Arm closed for further enrollment~ROS1, ALK non-gene fusion molecular alterations~Oral entrectinib (RXDX-101)"
62520263|NCT02650401|ACTIVE_COMPARATOR|CNS tumors harboring- NTRK1/2/3, ROS1, ALK|"Arm closed for further enrollment~molecular alterations, including gene fusions~Oral entrectinib (RXDX-101)"
62520264|NCT02650401|ACTIVE_COMPARATOR|Neuroblastoma|"Arm closed for further enrollment~Oral entrectinib (RXDX-101)"
62149074|NCT02791204||Controls|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
62520265|NCT02650401|ACTIVE_COMPARATOR|Non-neuroblastoma, extracranial solid tumors|"Arm closed for further enrollment~harboring - NTRK1/2/3, ROS1, ALK gene fusions~Oral entrectinib (RXDX-101)"
62520266|NCT02650401|ACTIVE_COMPARATOR|Any participant unable to swallow capsules|"Arm closed for further enrollment~Any participant who otherwise meet all other eligibility criteria~Oral entrectinib (RXDX-101)"
62520267|NCT02650401|ACTIVE_COMPARATOR|Expansion: CNS tumors harboring NTRK1/2/3, ROS1|"gene fusions~Oral entrectinib (RXDX-101)"
62520268|NCT02650401|ACTIVE_COMPARATOR|Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1|"NTRK 1,2,3 and ROS1 fusions~Oral entrectinib (RXDX-101)"
62520269|NCT06105320|ACTIVE_COMPARATOR|1: LCHF-HCLF|"LCHF (12 weeks) followed by HCLF (12 weeks) with immediate contrast (no wash-out period)"
62520270|NCT06105320|ACTIVE_COMPARATOR|2: HCLF-LCHF|"HCLF (12 weeks) followed by LCHF (12 weeks) with immediate contrast (no wash-out period)"
62520271|NCT03175289|ACTIVE_COMPARATOR|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
62520272|NCT03175289|EXPERIMENTAL|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
62520273|NCT00161382|EXPERIMENTAL|Intervention Group|HIV, STD, and pregnancy prevention curriculum
62520274|NCT00161382|EXPERIMENTAL|Control Group|Standard sexual education curriculum
62520275|NCT01311557|EXPERIMENTAL|Adacel Vaccine Group 1|Participants enrolled at 10 to \< 11 years of age
62149075|NCT02983721|ACTIVE_COMPARATOR|Transfemoral|in case of transfemoral approach our preference was to use right femoral route. The groin was prepared and draped and the site was punctured for femoral access after anesthetizing the skin with 2-4 ml of 1% lignocaine. Once the femoral puncture was done 6F sheath of Cordis variety was introduced and 6F Judkins, catheter was introduced and it was guided under fluoroscopic guidance through the aortic route.
62356433|NCT05918588|EXPERIMENTAL|Cohort 1|500 mg KD025 or placebo once daily (QD) for 7 days
62356434|NCT05918588|EXPERIMENTAL|Cohort 2|800 mg KD025 or placebo QD for 7 days
62356435|NCT05918588|EXPERIMENTAL|Cohort 3|500 mg KD025 or placebo twice daily (BID) for 7 days
62356436|NCT05918588|EXPERIMENTAL|Cohort 4|1000 mg KD025 or placebo QD for 7 days
62356437|NCT00807014|EXPERIMENTAL|Duac Gel|Duac Gel
62356438|NCT00807014|ACTIVE_COMPARATOR|Differin gel|Differin gel
62520276|NCT01311557|EXPERIMENTAL|Adacel Vaccine Group 2|Participants enrolled at 11 to \< 12 years of age
62520277|NCT06127914|EXPERIMENTAL|LEIFc Intervention|There is only 1 arm of this study. All participants will receive the LEIFc intervention.
62520278|NCT01187121||Experimental|Those persons randomized to the Decide Your Time program.
62520279|NCT01187121||Standard Pracitice|Those persons randomized to the standard probationary practice condition.
62520280|NCT03795831||Cohort|Adult patients, undergoing surgery requiring general anesthesia, planned to be monitored with a system that accurately measures and stores the intra-arterial waveform.
62520281|NCT02427295|EXPERIMENTAL|Group 2: Surgery + Medical treatment|"MRI : residual tumor 6 months post-op : IGF-1 \>600 ng/ml~medical treatment : Sandostatin (Octreotide Acetate)"
62520282|NCT02427295|NO_INTERVENTION|Group 3 : Rescue group|If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)
62520283|NCT02427295|NO_INTERVENTION|Gruop1 : Surgery only group|"MRI : without residual tumor 6months post-operation~and IGF-1 \<600ng/ml"
62520284|NCT05033912|EXPERIMENTAL|Treatment Sequence 1|Subjects will receive daily doses of matching placebo for CST-2032 and CST-107 on Day 1, 1mg CST-2032 \& 3mg CST-107 on Day 2, 3mg CST-2032 \& 3mg CST-107 on Day 3, \& 9mg CST-2032 and 3mg CST-107 on Day 4.
62711147|NCT05645757|EXPERIMENTAL|Cohort 6|Zidebactam 3 g administered by 250 ml of intravenous infusion (IV) for 2 hours, once daily, for 7 days. N=6
62520285|NCT05033912|EXPERIMENTAL|Treatment Sequence 2|Subjects will receive daily doses of 1mg CST-2032 \& 3mg CST-107 on Day 1, 3mg CST-2032 \& 3mg CST-107 on Day 2, \& 9mg CST-2032 and 3mg CST-107 on Day 3, and matching placebo for CST-2032 and CST-107 on Day 4.
62520286|NCT05033912|EXPERIMENTAL|Treatment Sequence 3|Subjects will receive daily doses of 3mg CST-2032 \& 3mg CST-107 on Day 1, \& 9mg CST-2032 and 3mg CST-107 on Day 2, matching placebo for CST-2032 and CST-107 on Day 3, and 1mg CST-2032 \& 3mg CST-107 on Day 4.
62520287|NCT05033912|EXPERIMENTAL|Treatment Sequence 4|Subjects will receive daily doses of 9mg CST-2032 and 3mg CST-107 on Day 1, matching placebo for CST-2032 and CST-107 on Day 2, 1mg CST-2032 \& 3mg CST-107 on Day 3, and 3mg CST-2032 \& 3mg CST-107 on Day 4.
62520288|NCT04154150|EXPERIMENTAL|Ketamine + Cognitive Training|
62520289|NCT04154150|SHAM_COMPARATOR|Ketamine + Sham Training|
62711148|NCT05645757|EXPERIMENTAL|Cohort 7|WCK 6777 (Ertapenem 3 g combined with Zidebactam 3 g) or placebo administered by 250 ml of intravenous infusion (IV) for 2 hours, once daily, for 7 days. N=8
62149076|NCT02983721|ACTIVE_COMPARATOR|Transradial|Our preference was to use the right radial and right femoral routes as they are nearest to operator while facing cardiac monitors, in our hospital. For the radial approach, the wrist was sterilized and draped in usual fashion. Hyperextension over an arm board was done and skin over the puncture site was anesthetized with 2 - 3 ml of 1% lignocaine. A small scaled incision was performed 1 cm proximal to styloid process of radius where arterial pulse was best felt. The radial artery was punctured with a 21 G needle and 6 F sheath (Cardis, Terumo) were introduced into the artery, using Seldinger technique. All patients received verapamil (5mg) to reduce radial artery spasm. Heparin (weight adjusted) was used only in PCIs to prevent artery occlusion and not in elective diagnostic coronary studies. Long 0.038 Terumo guide wire was used under fluoroscopic guidance.
62149077|NCT06305078|EXPERIMENTAL|Intervention|All will choose one of five medication experiment options to complete.
62711149|NCT01887717|EXPERIMENTAL|TheraSphere|Participants will receive TheraSphere at a dose consistent with the approved product label to the treated lobe of the liver. TheraSphere will be administered through the hepatic artery. The target dose will be 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% will be permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere will be permitted if a treatable progression is detected during follow-up evaluations. Any re-treatment will take place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants can receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations will be permitted.
62149078|NCT02992145||Case group: This group will include forty (40) preeclampt|
62149079|NCT02992145||Control group: This group will include forty (40) normoten|
62149080|NCT01394835|EXPERIMENTAL|Alpha -1 Antitrypsin|
62149081|NCT00916110|EXPERIMENTAL|1.5mgSC|ATN-103
62149082|NCT00916110|EXPERIMENTAL|4mgSC|ATN-103
62149083|NCT00916110|EXPERIMENTAL|10mgSC|ATN-103
62149084|NCT00916110|EXPERIMENTAL|25mgSC|ATN-103
62149085|NCT00916110|EXPERIMENTAL|25mgIV|ATN-103
62149086|NCT00916110|EXPERIMENTAL|50mgSC|ATN-103
62149087|NCT00916110|EXPERIMENTAL|100mgSC|ATN-103
62149088|NCT00916110|EXPERIMENTAL|200mgSC|ATN-103
62149089|NCT00916110|EXPERIMENTAL|200mgIV|ATN-103
62149090|NCT05025813|EXPERIMENTAL|Arm A|"Neoadjuvant Pembrolizumab 4 cycles, 200mg IV Q3W followed by interval restaging:~If restaging imaging positive will have Radical Neck Resection followed by Pembrolizumab 17 cycles, 200mg IV Q3W +/- External Beam Radiotherapy (if \>10% viable tumour cells at resection) If restaging imaging negative will have Mapping biopsy. If biopsy positive will proceed to Radical Neck dissection followed by Pembrolizumab 17 cycles 200mg IV, Q3W If biopsy negative will proceed to Pembrolizumab 17 cycles 200mg IV, Q3W"
62149091|NCT01553617|EXPERIMENTAL|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
62149092|NCT01553617|ACTIVE_COMPARATOR|Human serum albumin|Human serum albumin (HSA 50g/L)
62149093|NCT03868774|ACTIVE_COMPARATOR|rTMS standard|Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)
62149094|NCT03868774|ACTIVE_COMPARATOR|rTMS accelerated model|Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)
62149095|NCT05488509|EXPERIMENTAL|20mg THC|Participants will inhale vapor from .17 grams of cannabis containing 11.86% THC (20mg THC total).
62149096|NCT05488509|EXPERIMENTAL|40mg THC|Participants will inhale vapor from .34 grams of cannabis containing 11.86% THC (40mg THC total).
62149097|NCT05488509|PLACEBO_COMPARATOR|Placebo|Participants will inhale vapor from a placebo product.
62149098|NCT02502136|EXPERIMENTAL|CO2 in sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with sedation
62149099|NCT02502136|PLACEBO_COMPARATOR|Air in sedated colonoscopy|Room air insufflation during colonoscopy with sedation
62149100|NCT02502136|EXPERIMENTAL|CO2 in mild sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with mild sedation
62149101|NCT02502136|PLACEBO_COMPARATOR|Air in deep sedated colonoscopy|Room air insufflation during colonoscopy with deep sedation
62149102|NCT02502136|EXPERIMENTAL|CO2 in sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with sedation
62520290|NCT04750135|PLACEBO_COMPARATOR|Control group|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
62520291|NCT04750135|EXPERIMENTAL|Metformin group|participants will receive 500 mg Metformin TID for 8 consecutive weeks in addition to the standard therapy
62520292|NCT03376620|SHAM_COMPARATOR|10% Urea cream|Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
62520293|NCT03376620|ACTIVE_COMPARATOR|Active cream with 1,4 diaminobutane|Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
62520294|NCT03648242|EXPERIMENTAL|Interruptive Clinical Decision Support|
62520295|NCT06333223|EXPERIMENTAL|Mixture of (Poly)phenols and a probiotic supplement|This is a Mixture of (Poly)phenols and a probiotic supplement
62520296|NCT06333223|PLACEBO_COMPARATOR|(Poly)phenols and maltodextrin|This is a mixture of (Poly)phenols and maltodextrin (placebo comparator)
62149103|NCT02502136|PLACEBO_COMPARATOR|Air in sedated panendoscopy|Room air insufflation during panendoscopy with sedation
62149104|NCT02502136|EXPERIMENTAL|CO2 in mild sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with mild sedation
62149105|NCT02502136|PLACEBO_COMPARATOR|Air in deep sedated panendoscopy|Room air insufflation during panendoscopy with deep sedation
62520297|NCT03755479||Single Arm Group|Patient on multiple daily injections will start Hybrid Closed Loop System Insulin Pump Minimed 670G
62149106|NCT04108858|EXPERIMENTAL|Phase I, Phase II Arm I (copanlisib, trastuzumab, pertuzumab)|Patients receive copanlisib IV over 60 minutes on days 1 and 8. Patients also receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62149107|NCT04108858|ACTIVE_COMPARATOR|Phase II Arm II (trastuzumab, pertuzumab)|Patients receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62711150|NCT01887717|ACTIVE_COMPARATOR|Sorafenib|Participants will receive sorafenib, oral tablets, 400 milligrams (mg) twice daily in accordance with the package insert. Treatment is to continue until the participant is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity will be allowed.
62149108|NCT05596916|EXPERIMENTAL|High frequency of stretching exercise|Axio scapular muscle stretching exercises will be applied for 5 days a week during 6 weeks
62149109|NCT05596916|ACTIVE_COMPARATOR|Low frequency of stretching exercise|Axio scapular muscle stretching exercises will be applied for 3 days a week during 6 weeks
62149110|NCT00637663|EXPERIMENTAL|A|entecavir 0.5 mg QD
62149111|NCT00637663|ACTIVE_COMPARATOR|B|lamivudine 100 mg QD
62149112|NCT05135234|EXPERIMENTAL|Muscular Exercise|Increased level of low effort muscular activity
62149113|NCT02941744|EXPERIMENTAL|IpNiv|low fixed dose ipilimumab plus low fixed dose nivolumab
62149114|NCT04675268|EXPERIMENTAL|7 night home oximetry|Patients will undergo 7 nights home monitoring with oximetry.
62356439|NCT04578119|NO_INTERVENTION|Conventional Intubating Technique|'Conventional technique' means that endotracheal intubation is performed with the videolayngoscope blade lifting up the epiglottis.
62356440|NCT04578119|EXPERIMENTAL|Sliding Intubating Technique|'Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
62356441|NCT02954302|EXPERIMENTAL|PrPD with RGA|Patients who will undergo PrPD with proximal Roux-en-y gastrojejunal anastomosis.
62356442|NCT02954302|EXPERIMENTAL|conventional PrPD|Patients who will undergo conventional PrPD.
62356443|NCT02644837|ACTIVE_COMPARATOR|i-Gel and AuraGain|"In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.~Interventions with both devices will be~1. Insertion of the laryngeal mask airway~2. Assessment of ease of insertion~3. Ability to perform positive pressure ventilation~4. Measurement of OLP~5. Fibreoptic assessment with Ambu A-scope~6. Ability to insert nasogastric tube~7. Record number of manipulations~8. An assessment of device related trauma"
62356444|NCT02644837|ACTIVE_COMPARATOR|AuraGain and i-Gel|"In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.~Interventions with both devices will be~1. Insertion of the laryngeal mask airway~2. Assessment of ease of insertion~3. Ability to perform positive pressure ventilation~4. Measurement of OLP~5. Fibreoptic assessment with Ambu A-scope~6. Ability to insert nasogastric tube~7. Record number of manipulations~8. An assessment of device related trauma"
62356445|NCT01329289|EXPERIMENTAL|SOM230 with Bortezomib and Dexamethasone|
62356446|NCT02907086||colorectal cancer|
62356447|NCT02907086||melanoma|
62356448|NCT03973203|EXPERIMENTAL|Niacin in controls|The arm includes healthy controls supplemented with niacin.
62356449|NCT03973203|EXPERIMENTAL|Niacin in mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
62356450|NCT00032617|ACTIVE_COMPARATOR|1|Prolonged Exposure
62356451|NCT00032617|ACTIVE_COMPARATOR|2|Present Centered Therapy
62356452|NCT01223326|EXPERIMENTAL|N-acetylcysteine|Intravenous N-acetylcysteine
62356453|NCT01223326|PLACEBO_COMPARATOR|Placebo|Placebo
62356454|NCT03446989|EXPERIMENTAL|Case management|Those who did not agree to participate in the NLCM were enrolled into the control group and received the standard care: visits to their RA physicians on a regular basis with health education administered by a ward nurse during each visit. The education sessions lasted for approximately 15 minutes and consisted of consultation about disease symptoms, related treatments, and disease management.
62520298|NCT04586153|EXPERIMENTAL|Meplzaumb|This arm is combined with 3 groups, low dose, middle dose, and high dose. Low dose group: First dose: 0.12 mg/kg - Day 1; second dose: control - Day 8 Middle dose group: First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8 High dose group: First dose: 0.3 mg/kg - Day 1; second dose: 0.3 mg/kg - Day 8
62520299|NCT04586153|PLACEBO_COMPARATOR|Placebo|First dose: control - Day 1; second dose: control - Day 8
62356455|NCT01867866|EXPERIMENTAL|TAS-102|
62356456|NCT01867866|EXPERIMENTAL|FTD (Trifluridine)|
62356457|NCT05994963|EXPERIMENTAL|Part 1 Treatment A|4 capsules of sisunatovir in fasted state
62356458|NCT05994963|EXPERIMENTAL|Part 1 Treatment B|2 tablets of sisunatovir in fasted state
62356459|NCT05994963|EXPERIMENTAL|Part 1 Treatment C|2 tablets of sisunatovir with a high-fat meal
62356460|NCT05994963|EXPERIMENTAL|Part 2 Treatment B|2 tablets of sisunatovir in fasted sate
62520300|NCT06091748|EXPERIMENTAL|PET/CT imaging with 68Ga-DOTATOC|
62356461|NCT05994963|EXPERIMENTAL|Part 2 Treatment D|2 tablets of sisunatovir with a low-fat meal
62356462|NCT01422772|EXPERIMENTAL|Cohort I|0.5mg/1mL of VM202RY was intramuscularly injected into 4 sites
62356463|NCT01422772|EXPERIMENTAL|Cohort II|1mg/2mL of VM202RY was intramuscularly injected into 8 sites
62356464|NCT01422772|EXPERIMENTAL|Cohort III|2mg/4mL of VM202RY was intramuscularly injected into 8 sites
62356465|NCT06561438|NO_INTERVENTION|Control Arm|The patient will not be administered with any drug/placebo before the surgery
62356466|NCT06561438|EXPERIMENTAL|Intervention arm|20 mg oral vortioxetine tablet 2 hours before the procedure
62356467|NCT01263093|EXPERIMENTAL|Clopidogrel First, Then LY2216684 + Clopidogrel|"Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1).~Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
62356468|NCT01263093|EXPERIMENTAL|LY2216684 + Clopidogrel First, Then Clopidogrel|"Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
62356469|NCT01472991|EXPERIMENTAL|TC-5619-238 (25mg)|TC-5619-238 25 mg will be provided as hard gelatin capsules
62356470|NCT01472991|PLACEBO_COMPARATOR|Placebo|Placebo will be provided as hard gelatin capsules similar to TC-5619-238
62356471|NCT01472991|EXPERIMENTAL|TC-5619-238 (5 mg)|TC-5619-238 5 mg will be provided as hard gelatin capsules.
62356472|NCT00994162|EXPERIMENTAL|Negative Pressure Wound Therapy|Application of NPWT therapy to the wound
62356473|NCT02174861|EXPERIMENTAL|Erenumab|Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.
62356474|NCT05325398|ACTIVE_COMPARATOR|patients with NAFLD|17 patients will receive molecular hydrogen
62356475|NCT05325398|PLACEBO_COMPARATOR|probands in the control group|13 probands in the control group who will receive placebo.
62356476|NCT06164613|EXPERIMENTAL|Intervention|1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
62356477|NCT06164613|PLACEBO_COMPARATOR|Placebo|400 mg orally of canola oil per day for 21-28 days
62356478|NCT01431261|ACTIVE_COMPARATOR|Pain Management + Training|Education in pain management strategies and treatment sessions including instructions in neck exercises and aerobic training
62356479|NCT01431261|ACTIVE_COMPARATOR|Pain Management|Education in pain management strategies
62356480|NCT02899624|EXPERIMENTAL|Bicuspid aortic valve (BAV)|patient with bicuspid aortic valve
62356481|NCT02899624|ACTIVE_COMPARATOR|healthy subjects related patients with BAV|healthy control, related to patient with bicuspid aortic valve, at the 1st, 2nd or 3rd degree
62356482|NCT02899624|ACTIVE_COMPARATOR|Tricuspid aortic valve (TAV)|patient with aortic stenosis on tricuspid valve
62356483|NCT06359704|EXPERIMENTAL|COPE program|a 6-week Caregivers Of dementia Processing Emotions (COPE) program using the integrative therapy to reduce EE (primary outcome) in family caregiver of PLwD to alleviate the caregivers' depression, improve social dynamic with the PLwD, and mitigate the perceived stress from BPSD (secondary outcomes)
62356484|NCT06359704|NO_INTERVENTION|Waitlist control|Participants in the waitlist control group, in comparison to those in the intervention group who receive treatment immediately, are placed on a waiting list and receive the same set of intervention sessions after the formal trial. This approach ensures participants have equal opportunity to receive treatment while strengthening the study's validity and overall quality by maximally controlling for potential confounding variables and biases
62356485|NCT01297426||Group 1|Lean and obese, diabetic and non diabetics
62356486|NCT06124885|EXPERIMENTAL|AKI risk screening using RenaFAST POCT test kits|All consenting patients will have a real-time biomarker analysis done at 5 time-points during their course of drug therapy using the renaFAST kits.
62356487|NCT03689868|EXPERIMENTAL|Virtual Reality|
62356488|NCT03689868|NO_INTERVENTION|Control|
62356489|NCT03753815|ACTIVE_COMPARATOR|19G FNA needle|Patients referred for EUS-guided tissue acquisition of AIP
62356490|NCT03753815|ACTIVE_COMPARATOR|20G FNB needle|Patients referred for EUS-guided tissue acquisition of AIP
62520301|NCT01520974|ACTIVE_COMPARATOR|Probiotic tablet|
62520302|NCT01520974|PLACEBO_COMPARATOR|Placebo tablet|Comparison tablet without the probiotic bacteria
62520303|NCT03937128|EXPERIMENTAL|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
62520304|NCT03937128|ACTIVE_COMPARATOR|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
62356491|NCT00313248|EXPERIMENTAL|Arm 1|
62356492|NCT00313248|EXPERIMENTAL|Arm 2|
62356493|NCT00158223|PLACEBO_COMPARATOR|placebo|Participants will receive encapsulated placebo made to match active drug
62356494|NCT00158223|EXPERIMENTAL|pimozide|Participants will receive pimozide flexible dosing
62356495|NCT02591888|ACTIVE_COMPARATOR|Liposomal bupivacaine|Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
62356496|NCT02591888|PLACEBO_COMPARATOR|Placebo|Subjects in this arm will received the placebo - normal saline 30 mL.
62356497|NCT00415519|EXPERIMENTAL|1|
62356498|NCT00415519|PLACEBO_COMPARATOR|2|
62520305|NCT04054128|EXPERIMENTAL|Sodium bicarbonate catheter lock group (SBCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with sodium bicarbonate 7.5% Injection.
62520306|NCT04054128|ACTIVE_COMPARATOR|Heparin catheter lock group (HCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with heparin, 1000 Units/mL injectable solution
62520307|NCT00773942|NO_INTERVENTION|Usual care|Study subjects receive usual care, without the intervention.
62711151|NCT03201120|EXPERIMENTAL|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
62149115|NCT01596985|EXPERIMENTAL|Ablation using the PlasmaJet system|"Origin of cyst invagination is identified after lysis of adhesions between ovary and adjacent broad ligament, leading to characteristic chocolate fluid evacuation. Surgeon then attempts to turn cyst completely inside out via original invagination site of diameter averaging 1 to 2cm. Ablation of cyst's inner surface is performed using the PlasmaJet system in coagulation mode set at 40, at distance averaging 5mm from tip of handpiece, and with exposure time limited to 1 to 2s on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and corresponding peritoneal implants on adjacent broad ligament. When cyst reversion is not feasible, surgeon progressively exposes cyst interior to guide plasma beam at an angle perpendicular to the inner surface."
62520308|NCT00773942|EXPERIMENTAL|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
62520309|NCT00773942|EXPERIMENTAL|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and a brief chart synopsis including patient medical history, medication history, and relevant laboratory information.
62711152|NCT03201120|EXPERIMENTAL|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
62711153|NCT02180828|EXPERIMENTAL|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
62711154|NCT02180828|ACTIVE_COMPARATOR|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
62711155|NCT04256525|EXPERIMENTAL|Aspirin 100mg|
62711156|NCT04256525|EXPERIMENTAL|rivaroxaban 10mg|
62711157|NCT04256525|EXPERIMENTAL|low molecule heparin|
62711158|NCT04256525|NO_INTERVENTION|Reference|mechanical prophylaxis
62520310|NCT01071447|ACTIVE_COMPARATOR|Rheumatologist-led clinic|Rheumatologist-led clinic: The subjects are seeing a rheumatologist after six months and after 12-months of intervention and have the possibility to contact the rheumatology clinic
62711159|NCT04655157|EXPERIMENTAL|Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumab|Patients will be treated with 300mg encorafenib and 3mg/kg nivolumab and 1 mg/kg ipilimumab (triple therapy).
62711160|NCT04655157|EXPERIMENTAL|Phase 1 (cohort 2): 450mg encorafenib + 45mg binimetinib + 3mg/kg nivolumab + 1mg/kg ipilimumab|Patients will be treated with 450mg encorafenib, 45mg binimetinib, 3mg/kg nivolumab and 1mg/kg ipilimumab (quadruple therapy).
62711161|NCT05024513|EXPERIMENTAL|BD-HAIC (Biliary drainage & HAIC)|The patients enrolled in this arm would receive external percutaneous biliary drainage plus 3Cir-OFF hepatic arterial infusion chemotherapy （HAIC）with oxaliplatin and 5-fluorouracil.
62711162|NCT05024513|ACTIVE_COMPARATOR|BD-BSC (Biliary Drainage & Best supportive care)|The patients enrolled in this arm would receive biliary drainage, biliary stents,or biliary stents with Iodine-125 seed strands, plus best supportive care.
62711163|NCT06410209|EXPERIMENTAL|Stage 1 (Fitbit, interview)|Patients wear a Fitbit physical activity tracker daily, set physical activity goals, receive text messages, and view private social media peer support group content over 7-10 days once every 3 months. Patients also wear a research grade activity measuring device over 1-3 days and participate in a one-on-one interview once every 3 months for 9 months.
61974835|NCT03725696||Observational group|Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.
61974836|NCT03326258|EXPERIMENTAL|Treatment (glembatumumab vedotin, nivolumab, ipilimumab)|Patients receive glembatumumab vedotin IV over 90 minutes and nivolumab IV over 60 minutes on day 8 of course 1 and on day 1 of subsequent courses. Patients in melanoma expanded cohort also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 21 days for 4 courses in the absence of disease progression or unaccepted toxicity and courses with glembatumumab vedotin and nivolumab repeat every 21 days in the absence of disease progression or unaccepted toxicity.
61974837|NCT03393741||Taxane (nab-paclitaxel or paclitaxel)|"Up to 10 participants will be enrolled on the Taxane arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
61974838|NCT03393741||Eribulin|"Up to 5 participants will be enrolled on the Eribulin arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
62520311|NCT01071447|EXPERIMENTAL|Nurse-led clinic|The subjects are seeing a rheumatology nurse after six months and a rheumatologist after 12 months of intervention and have the possibility to contact the rheumatology nurse during the intervention.
62520312|NCT01565265|ACTIVE_COMPARATOR|GnRH agonist long protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with decapeptyl, which will be administered from the midluteal phase of the preceding menstrual cycle up to ovulation induction.
62520313|NCT01565265|EXPERIMENTAL|antagonist protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with Cetrotide, which will be administered from the day six up to ovulation induction.
62520314|NCT02287129|EXPERIMENTAL|Non-Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Carboplatin Paclitaxel Radiation Biopsy
62520315|NCT02287129|ACTIVE_COMPARATOR|Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Biopsy
62520316|NCT03112980|EXPERIMENTAL|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.
62520317|NCT03112980|ACTIVE_COMPARATOR|Surgical aortic valve replacement|Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.
62520318|NCT06094452|EXPERIMENTAL|Computerized Cognitive Training|Adaptive computerized cognitive training program (www.66nao.com) and the intensity is at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks.
62520319|NCT06094452|ACTIVE_COMPARATOR|Treatment As Usual|Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet.
62520320|NCT05050695||Subjects with unilateral chronic low back pain|Subjects with low back pain for more than 3 months on one side of the spine
62520321|NCT05050695||Healthy subjects|Subjects without a history of low back pain
62520322|NCT06032455||Families receiving standard MST|Families in which the adolescent and/or parent(s) has/have an ID receiving standard MST treatment
61974839|NCT03393741||Vinorelbine|"Up to 5 participants will be enrolled on the Vinorelbine arm. TThe dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
62149116|NCT01596985|ACTIVE_COMPARATOR|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
62520323|NCT06032455||Families receiving MST-ID|Families in which the adolescent and/or parent(s) has/have an ID receiving MST-ID treatment
62520324|NCT02265172|EXPERIMENTAL|Physiotherapy screening|"Screening consisted of a 60-min appointment including assessment, diagnosis and management. The patients received advice regarding ergonomics, exercises and/or treatment when needed. Management options were;~* Referral for orthopaedic surgeon consultation.~* Referral back to the patient's General Practitioner.~* Referral for further investigation.~* Referral to the physiotherapy or the occupational therapy clinic."
62520325|NCT02265172|ACTIVE_COMPARATOR|Standard practice (orthopaedic surgeon)|"Appointment was 15 min, including assessment, diagnosis and management. The patients received advice, prescriptions or injections when needed. Management options were;~* Referral for orthopaedic intervention.~* Referral back to the patient's General Practitioner.~* Referral for further investigation.~* Referral to the physiotherapy or the occupational therapy clinic."
62520326|NCT03977701|EXPERIMENTAL|Mono-morphemic Singleton PD|Speech sound treatment on mono-morphemic singleton consonants for children with PD.
62520327|NCT03977701|EXPERIMENTAL|Mono-morphemic Singleton PD-SLI|Speech sound treatment on mono-morphemic singleton consonants for children with PD-SLI.
62520328|NCT03977701|EXPERIMENTAL|Mono-morphemic Cluster PD|Speech sound treatment on mono-morphemic consonant clusters for children with PD.
62520329|NCT03977701|EXPERIMENTAL|Mono-morphemic Cluster PD-SLI|Speech sound treatment on mono-morphemic consonant clusters for children with PD-SLI.
62520330|NCT03977701|EXPERIMENTAL|Bi-morphemic Singleton PD|Treatment on singletons in bi-morphemic contexts for children with PD.
62711164|NCT06410209|EXPERIMENTAL|Stage 2, Group I (Fitbit, goal setting, peer support)|"INTENSIVE PHASE: Patients wear a Fitbit physical activity tracker daily and receive weekly reminders to wear the Fitbit for 12 weeks. Patients attend weekly goal setting sessions, receive individualized physical activity goals, view and post private social media peer support group content 2-3 times weekly, and receive badges for 12 weeks.~MAINTENANCE PHASE: Patients wear a Fitbit physical activity tracker daily and set their own physical activity goals weekly for 4 weeks. Patients also receive access to the social media account and post content for 4 weeks."
62520331|NCT03977701|EXPERIMENTAL|Bi-morphemic Singleton PD-SLI|Treatment on singletons in bi-morphemic contexts for children with PD-SLI.
62520332|NCT03977701|EXPERIMENTAL|Bi-morphemic Cluster PD|Treatment on bi-morphemic consonant clusters for children with PD.
62520333|NCT03977701|EXPERIMENTAL|Bi-morphemic Cluster PD-SLI|Treatment on bi-morphemic consonant clusters for children with PD-SLI.
62520334|NCT03977701|EXPERIMENTAL|Bi-morphemic Singleton SLI|Treatment on singletons in bi-morphemic contexts for children with SLI.
62520335|NCT03977701|EXPERIMENTAL|Bi-morphemic Cluster SLI|Treatment on bi-morphemic consonant clusters for children with SLI.
61974840|NCT03393741||Ixabepilone|"Up to 5 participants will be enrolled on the Ixabepilone arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
62520336|NCT02545855|EXPERIMENTAL|Arm A (myAIRVO2® + HOT, HOT)|Subjects will receive the myAIRVO2® therapy plus HOT for week 1-6 and HOT only for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
62520337|NCT02545855|EXPERIMENTAL|Arm B (HOT, myAIRVO2® + HOT)|Subjects will receive HOT only for week 1-6 and the myAIRVO2® therapy plus HOT for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
62520338|NCT05880836|EXPERIMENTAL|Path A (vibrating mesh nebulizer (VMN) with the high flow nasal cannula)|Enrolled patients will receive two standard forms of inhaled medications as ordered by the physician. Patients will be randomized into two paths of the cross over study. There will be no blinding involved in this randomization. Path A will have medications delivered trans-nasally in line via the vibrating mesh nebulizer (VMN) with the high flow nasal cannula followed by standard jet nebulization (SJN) with face mask at the next time of medication dosing 3-6 hours later.
62520339|NCT05880836|ACTIVE_COMPARATOR|Path B (standard jet nebulization (SJN) with face mask)|Path B will receive standard jet nebulization without HFNC followed by the trans-nasal in line nebulization via the HFNC. Patients agreed to enroll in day 2 of the trial will have their clinical path alternated in attempt to control for diurnal variability. All patients will also receive as-needed nebulized treatments as well as usual supportive care provided by respiratory therapists. As needed therapy will be delivered via the method of the current arm of the study they are in, and the washout period will subsequently reset.
62520340|NCT03074396|OTHER|before and after use of program|one arm (10 patients and 4 physicians) before and after use of dialysisNet (for doctors) and Avatar Beans (for patients)
62520341|NCT05587335|EXPERIMENTAL|In person|Couples will be assigned into in person relationship intervention.
62520342|NCT05587335|EXPERIMENTAL|Online|Couples will be assigned into online relationship intervention.
62520343|NCT01310673|ACTIVE_COMPARATOR|Allopurinol|
62520344|NCT01310673|PLACEBO_COMPARATOR|Placebo|
62520345|NCT06331741|OTHER|The 1st group|ACL reconstruction + collagen membrane
62520346|NCT06331741|OTHER|The 2nd group|ACL reconstruction (control)
62520347|NCT06331741|OTHER|The 3rd group|Hallux Rigidus + collagen membrane
62520348|NCT02778503|ACTIVE_COMPARATOR|High Cost|Restoration using a high-cost glass ionomer cement.
62520349|NCT02778503|EXPERIMENTAL|Low Cost|Restoration using a low-cost glass ionomer cement.
62711165|NCT06410209|ACTIVE_COMPARATOR|Stage 2, Group II (Fitbit)|Patients wear a Fitbit physical activity tracker daily for 12 weeks.
62711166|NCT01885988|ACTIVE_COMPARATOR|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
62149117|NCT04577326|EXPERIMENTAL|Engineered Autologous T Cells|Following eligibility screening and enrollment, patients will undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMCs), to enable generation of M28z1XXPD1DNR. Following successful M28z1XXPD1DNR CAR T-cell manufacturing, patients will be reevaluated for eligibility. A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m2 will be administered 2-7 days before the infusion. A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. All patients will be monitored in the hospital for a minimum of 48 h following the administration of CAR T cells.
62520350|NCT01207999||Group A|Subjects diagnosed with invasive cervical cancer
62520351|NCT02434224|EXPERIMENTAL|music therapy|two to three sessions per week: The therapist will stay with one hand on the infants' chest (or back) in order to continuously assess the infants' breathing pattern. Based on and oriented towards the assessed breathing pattern, the infants' behavioral state, facial and gestural expression, the therapist transforms the infants' rhythms and subtle expressions into infant-directed improvised humming.
62520352|NCT02434224|NO_INTERVENTION|control|standard care
62520353|NCT01147978|EXPERIMENTAL|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
62520354|NCT01147978|NO_INTERVENTION|Usual Procedure|Usual discharge procedure from the ICU
62711167|NCT01885988|PLACEBO_COMPARATOR|Sugar pill|Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
62711168|NCT05965310|NO_INTERVENTION|Standard Post-Operative Rehabilitation|No intervention, patients will receive the standard level of care.
62711169|NCT05965310|ACTIVE_COMPARATOR|Virtual Psychological Intervention|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
62149118|NCT02129751|EXPERIMENTAL|bupropion hydrobromide|study drug
62149119|NCT02129751|PLACEBO_COMPARATOR|placebo|placebo
62149120|NCT02734706|EXPERIMENTAL|LRC™ capsule|
62149121|NCT02734706|PLACEBO_COMPARATOR|Placebo capsule|
62149122|NCT02198898|NO_INTERVENTION|GUARDIX|no guadix
62149123|NCT02198898|EXPERIMENTAL|guadix|guadix treatment
62149124|NCT04685395|ACTIVE_COMPARATOR|Benzydamine hydrochloride|"group I ( benzdymine HCL ); subject will be instructed to use Benzydamine hydrochloride gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dose :5 ml every time dosage form ; mouth wash"
62149125|NCT04685395|ACTIVE_COMPARATOR|Rebamipide|"group II ( rebamipide) :subject will be instructed to use Rebamipide gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dosage form ; mouth wash"
62149126|NCT01905566|ACTIVE_COMPARATOR|Clopidogrel|clopidogrel: 75mg once a day
62149127|NCT01905566|EXPERIMENTAL|Ticagrelor|ticagrelor: 90mg twice a day
61974841|NCT03393741||Control Arm|"Up to 10 participants will be enrolled on the control arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
61974842|NCT04874727||Study Population|The five or six individual patients enrolled are the members of the sole group, the study population. These individuals all have been diagnosed with obstructive sleep apnea and have take a Cone-beam CT scan with and without the new bite technique.
61974843|NCT03428789||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction with additional sensory nerve coaptation.
62520355|NCT06346002|EXPERIMENTAL|Mindfulness-based condition|Classes assigned to this condition received the mindfulness-based intervention. The MBI program implemented comprised ten weekly sessions. Activities were drawn from the Mission Méditation program, a MBI intervention specifically tailored for elementary school children. Activities comprised in this intervention encompassed formal (e.g., body scan, sitting, and breathing meditation) and informal meditations (e.g., mindful eating, listening, and touching, mindful walking), as well as positive psychology exercises (e.g., taking care of oneself, gratitude). The weekly sessions, lasting 45 to 60 minutes each, were delivered in a group format by the teachers themselves, in their classroom.
62520356|NCT06346002|NO_INTERVENTION|Wait-list control|Placed on waitlist and then offered the intervention once the data collection phase was over.
62520357|NCT03174106|EXPERIMENTAL|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
62520358|NCT03174106|NO_INTERVENTION|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
62520359|NCT02247219|EXPERIMENTAL|Intervention|'Counselling and education individually and in groups'
61974844|NCT03428789||Non-innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction without sensory nerve coaptation.
61974845|NCT01373801|ACTIVE_COMPARATOR|Control|
62520360|NCT02247219|OTHER|Waiting list control|The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
62520361|NCT02251119|EXPERIMENTAL|TPV|"Administration of LOP on days 1, 9 and 22~Administration of TPV on days 4-9~Administration of TPV/RTV on days 12-22"
62520362|NCT02251119|EXPERIMENTAL|RTV|"Administration of LOP on days 1, 9 and 22~Administration of RTV on days 4-9~Administration of TPV/RTV on days 12-22"
62520363|NCT05404074|EXPERIMENTAL|Cobitolimod 500mg|2-3 single doses of rectal cobitolimod (500mg/50ml) over 3-6 weeks
62520364|NCT03575871|EXPERIMENTAL|PF-04965842 100 mg|
61974846|NCT01373801|EXPERIMENTAL|GuardaCare|
61974847|NCT01676389|EXPERIMENTAL|OMM Hands-On Treatment|The Osteopathic Manual Medicine (OMM) Hands-On Treatment group will be receiving an osteopathic structural exam along with 7 gentle, non-thrusting techniques during each treatment session that lasts 20-30 minutes. The Sham treatment group will be receiving only an osteopathic structural exam that will be slowed down in order to be a similar duration to the full treatment group session (approximately 20-30 minutes).
62149128|NCT03917732|EXPERIMENTAL|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
62149129|NCT03917732|ACTIVE_COMPARATOR|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
62149130|NCT03871075|EXPERIMENTAL|IPC + exercise|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy.
62149131|NCT03871075|EXPERIMENTAL|"IPC + no exercise control"|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
62520365|NCT03575871|EXPERIMENTAL|PF-04965842 200 mg|
62520366|NCT03575871|PLACEBO_COMPARATOR|Placebo|
62711170|NCT06382051|OTHER|PEST Screening group|"When visiting their dermatologists, all eligible patients with moderate-to-severe plaque psoriasis (PsO) eligible for treatment with biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) will be screened for psoriatic arthritis (PsA) using PEST+pictures+2, a variation of the PEST screening tool.~The PEST+pictures+2 is made up of 3 components:~1. Psoriasis Epidemiology Screening Tool (PEST) consisting of 5 simple questions~2. PEST+2 refers to the PEST modified with two additional questions (Do you have morning stiffness that lasts for more than one (1) hour? Do you wake up at night because of low back or buttock pain?), AND~3. PEST+pictures which provides an opportunity for patients to modify their answers to PEST questions 1, 3, and 5 by presenting them with pictures of swollen joints, fingernail pitting, and swollen fingers and toes."
62149132|NCT03871075|ACTIVE_COMPARATOR|sham control + exercise|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy.
62149133|NCT03871075|ACTIVE_COMPARATOR|"sham control + no exercise control"|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
62149134|NCT03500406|SHAM_COMPARATOR|Group 1 - Control|No treatment will be administered and men will not have to delay their IPP procedure
62356499|NCT02375984|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
62356500|NCT01147406|EXPERIMENTAL|Active|N6022
62356501|NCT01147406|PLACEBO_COMPARATOR|Placebo|Placebo
62520367|NCT04451603||Surgical resection|
62711171|NCT02795039|EXPERIMENTAL|Fulvestrant 50mg/mL (Fresenius Kabi)|5 mL intramuscular injection
62356502|NCT03768895||MRI group|The criteria for patient inclusion were: Age \> 18 years old, who had realised a pelvis MRI for any cause at MRI Center. Exclusion criteria included age \< 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
62356503|NCT04559269||Cohort 1|Cohort of 98 patients suffering from sleep disorders hospitalized between September 2017 and January 2019 in the Sleep Medicine Center of the Croix Rousse Hospital (Lyon) for objective sleepiness evaluation with polysomnography and MWT.
62520368|NCT04451603||Y-90 therapy|
62520369|NCT04451603||Systemic Therapy|
62520370|NCT03023514|EXPERIMENTAL|ALA + P|Oral alpha-lipoic acid + vaginal Progesterone
62520371|NCT03023514|ACTIVE_COMPARATOR|P|vaginal Progesterone
62520372|NCT05335993|EXPERIMENTAL|Combination of Oregovomab and Niraparib|"* Niraparib (300/200 mg) will be administered orally once daily.~* Oregovomab (2 mg) will be administered via IV infusion on Day 1 of Week 1, Week 4, Week 7, Week 12, and Week 20."
62711172|NCT02795039|ACTIVE_COMPARATOR|Fulvestrant 50 mg/mL (Faslodex®)|5 mL intramuscular injection
62711173|NCT01039389|EXPERIMENTAL|Collateral promotion; PCI after 6 months|
62711174|NCT01039389|EXPERIMENTAL|Collateral promotion; PCI at baseline|
62711175|NCT04486040|ACTIVE_COMPARATOR|Drainage group|Patients with drainage after hip revision arthroplasty
62711176|NCT04486040|ACTIVE_COMPARATOR|No-drainage group|Patients without drainage after hip revision arthroplasty
62711177|NCT00105625||Group 1|
61974848|NCT01676389|PLACEBO_COMPARATOR|Sham OMM|Sham Osteopathic Manual Medicine (OMM)
61974849|NCT02103764|EXPERIMENTAL|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
61974850|NCT02103764|ACTIVE_COMPARATOR|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
61974851|NCT05409573|EXPERIMENTAL|monitoring of the expired oxygen fraction|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)"
61974852|NCT03484481||1;Oral nutritional support (ONS)|patients ongoing hemodialysis who received only oral nutritional support (Nutrena) and refused intradialytic parenteral nutrition; n: 14
61974853|NCT03484481||2; Intradialytic Parenteral Nutrition|patients ongoing hemodialysis who received only Intradialytic Parenteral Nutrition (Kabiven central) and refused parenteral nutrition; n: 14
61974854|NCT03484481||group 3; combination group|patients ongoing hemodialysis received both ONS and Intradialytic Parenteral Nutrition NS; n: 10
61974855|NCT03484481||group 4; dietetic support group;|patients ongoing hemodialysis who refused all types of nutritional support and only followed by counselling, n: 18
61974856|NCT00115687|PLACEBO_COMPARATOR|A|placebo
61974857|NCT00115687|EXPERIMENTAL|B|2 mg nicotine gum
61974858|NCT01286012|ACTIVE_COMPARATOR|SFP in liquid bicarbonate|
61974859|NCT01286012|PLACEBO_COMPARATOR|Placebo: Conventional Liquid Bicarbonate|Control concentrate lacking SFP does not contain SFP (total iron = 0)
61974860|NCT05322304|EXPERIMENTAL|almond|dietary intervention with almonds ()20% of energy)
61974861|NCT05322304|NO_INTERVENTION|Control|usual diet and lifestyle
61974862|NCT00989794|EXPERIMENTAL|GelrinC|GelrinC one step implantation to the femoral condyle lesion
61974863|NCT01821521|EXPERIMENTAL|AGSPT_L20|tablet, q.d.
61974864|NCT01821521|ACTIVE_COMPARATOR|Pantoloc 40mg|tablet, q.d.
62520373|NCT05044884|EXPERIMENTAL|Otago exercise group|"The Otago exercise group will practice the Otago exercise protocol which includes strength and balance exercises along with pulmonary rehabilitation.~* 3 times per week for 8 weeks.~* Each session will be of 60 minutes~* Total number of sessions: 24"
62520374|NCT05044884|ACTIVE_COMPARATOR|Circuit training group|"The Circuit training group will practice balance exercises including Stance exercise, Functional strength exercise, Transition exercise and Gait training along with pulmonary rehabilitation.~* 3 times per week for 8 weeks.~* Each session will be of 60 minutes~* Total number of sessions: 24"
62520375|NCT00855803|EXPERIMENTAL|Radiation followed by Vertebroplasty|"Intervention:~This study is one arm. All patients will undergo radiotherapy followed by vertebroplasty. Patients who had prior radiotherapy will undergo 5 fractions of stereotactic body radiotherapy (SBRT) over 30-90 minutes each. Patients has no prior radiotherapy will undergo 1 fraction of SBRT over 30-90 minutes. The full patient population will then undergo vertebroplasty\*.~\*Vertebroplasty may not be possible for certain patients due to tumor location or safety. In such cases, patients will omit the vertebroplasty but receive all other protocol care and follow-up."
62520376|NCT03477019|EXPERIMENTAL|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
62149135|NCT03500406|EXPERIMENTAL|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
62149136|NCT00734682|EXPERIMENTAL|Nanoliposomal CPT-11|All patients are treated with nanoliposomal CPT-11
62149137|NCT05158426||propofol susceptibility group|patients undergoing gastrointestinal endoscopy
62149138|NCT02924051|EXPERIMENTAL|Motivational Interview (MI)|Intervention group participants receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families, along with monthly motivational interviewing conducted by a trained registered nurse
62520377|NCT03477019|OTHER|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
62520378|NCT03477019|EXPERIMENTAL|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
61974865|NCT05513079|NO_INTERVENTION|Control group|"Individuals in the control group agreed to participate in the study after being explained about the research.~Verbal and written consent will be obtained from individuals who do so. Initial interview with individuals who agreed to participate in the study Introductory Information Form, Trait Anxiety Scale, Dermatological Quality of Life Scale, Urticaria Activity Score will be applied. Patients in this group have routine chronic No application will be made other than the treatment of urticaria. 5 months after the pre-test Trait State Anxiety Scale, Dermatological Quality of Life Scale, Urticaria Activity Score will be applied. After the study is completed, individuals in the control group can also request it.~counseling will be provided."
62149139|NCT02924051|ACTIVE_COMPARATOR|Cooking Skills/Nutritional Education|Participants in this arm receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families.
62149140|NCT03590496|ACTIVE_COMPARATOR|Arm 1|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.
62149141|NCT03590496|PLACEBO_COMPARATOR|Arm 2|31 patients will be treated with placebo capsules (twice a day) for 8 weeks.
62149142|NCT01672242|EXPERIMENTAL|HFNC|High Flow Nasal Cannula (HFNC) oxygen.
62520379|NCT03477019|OTHER|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
62520380|NCT05028231||Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|
62520381|NCT05622136|EXPERIMENTAL|Regorafenib|"Cycles 1 and 2:~* Week 1: 80mg/day~* Week 2: 120mg/day~* Week 3: 160mg/day~* Week 4: off-treatment Cycles 3 on (up to treatment discontinuation)~* Weeks 1 to 3: Maximum dose tolerated daily, defined as the highest dose at which the patient had no adverse events grade ≥3 by CTCAE version 5.0 during cycles 1 and 2.~* Week 4: off treatment~* Dose adjustments may be required. Appendix 11.1 guide dose adjustments. Individual decisions at the occurrence of particular adverse events may be discussed individually within the study team and investigators.~Treatment will be administered until any of the following events occur:~* Both radiological and clinical progression according to definition of mRECIST or clinical deterioration that prevents treatment continuation according to the judgment of the attending physician~* Limiting toxicity as defined by a grade 3 adverse event that does not resolve to grade \< 3 within 7 days; adverse event grade 4 or 5.~* Subject decision."
62520382|NCT05613517||Healthy individual|Healthy individual without eye disorder.
62520383|NCT03673319|EXPERIMENTAL|Positive expectative|"Participants in the positive expectation group will be told that DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
62520384|NCT03673319|EXPERIMENTAL|Neutral expectatives|"Participants in the neutral expectation group will be told that DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
62520385|NCT02919241|EXPERIMENTAL|Diagnostic interview|Intervention for this group include diagnostic interview. Oral health Impact Profile (OHIP 14) and Spielberg State and Trait Anxiety (STAI-1) questionnaires and behaviour analyses are used in diagnostic interview.
62520386|NCT02919241|EXPERIMENTAL|Combined interview and treatment|Intervention for this group include both the diagnostic interview and one session treatment.
62520387|NCT00145639|OTHER|1|
62520388|NCT03218891|EXPERIMENTAL|Clinical treatment physical training|"Patients with optimized clinical treatment group that will do physical training for 12 weeks. They will do the tests in moment 1 and after 3 mounths.~The intervention is the Cardiac Rehabilitation."
62149143|NCT01672242|EXPERIMENTAL|CPAP|Continuous Positive Airway Pressure (CPAP)
62520389|NCT03218891|NO_INTERVENTION|Optimized clinical treatment|Patients with optimized clinical treatment group that will not do physical training.They will do the tests in moment 1 and after 3 mounths.
62520390|NCT03218891|NO_INTERVENTION|Coronary insufficiency without angina|Group with coronary insufficiency without angina and will not do physical training. They will do the tests only one moment.
62520391|NCT03218891|NO_INTERVENTION|Normal healthy subjects|Group normal healthy subjects, without coronary injuries, diabetes, hypertension and another chronic disease. These group have be sedentary and will not do physical training. They will do the tests only one moment.
62149144|NCT06073587||ION-682884-CS2 Scintigraphy Subset|Participants randomized in ION-682884-CS2 (NCT04136171) study to receive either eplontersen or placebo with baseline scintigraphy scan with planar and single-photon emission computerized tomography (SPECT) or SPECT with computed tomography (SPECT/CT) images will undergo an optional scintigraphy scan at Weeks 25 or 37, Week 97, and an additional scan at Week 140.
62149145|NCT03711058|EXPERIMENTAL|Phase I - Copanlisib and Nivolumab (De-Escalation)|
62149146|NCT03711058|EXPERIMENTAL|Phase II /Arm A-P13K mutation/Copanlisib and Nivolumab|
62149147|NCT03711058|EXPERIMENTAL|Phase II/Arm B -P13K wild type /Copanlisib and Nivolumab|
62149148|NCT04153357|ACTIVE_COMPARATOR|intubation time airtraq|intubation time of Airtraq
62356504|NCT06468111|ACTIVE_COMPARATOR|Control group|The control group underwent a blood and dental extraction will be performed according to the usual protocol of the health center.
62520392|NCT02101242||Orthopedic surgery of the shoulder|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to beach chair position.
62520393|NCT02101242||Gynecological, urological or general surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to Trendelenburg position.
62520394|NCT02101242||Cardiac surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (heart-lung machine).
62520395|NCT05637437|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive the usual care of the hospital.
62520396|NCT05637437|EXPERIMENTAL|Intervention Group|Participants in the intervention group will receive a peer supported diabetes self-care intervention through digital media
62520397|NCT02384252||obese patients|patients with BMI \> 30
62520398|NCT02384252||no obese patients|norma weight patient (BMI\<25) overweight patients ( 25\< BMI \>30)
61974866|NCT05513079|EXPERIMENTAL|Intervention Group|Positive psychotherapy counseling sessions, specialist psychiatry who completed positive psychotherapy training will be done by the nurse. The first one face-to-face with each individual in the intervention group. A total of 8 sessions will be held, theothers being online. Audio and video with attendees Other sessions will be completed through a program that allows sharing (WhatsAap, zoom etc.). Each session will be applied once a week, lasting 45-50 minutes. Interviews with individuals No audio or video recording will be taken during the recording.
61974867|NCT05230225|EXPERIMENTAL|Notification Letter Arm|Providers that will receive an electronic Physician Notification Letter.
62711178|NCT03577899|EXPERIMENTAL|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
62711179|NCT03577899|EXPERIMENTAL|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
62149149|NCT04153357|ACTIVE_COMPARATOR|intubation time of c-mac|intubation time of c-mac
62356505|NCT06468111|EXPERIMENTAL|experimental group|"The experimental group underwent a blood and dental extraction will be performed according to the usual protocol of the health center, the same as control group, and in addition dog-assisted therapy will be performed.~Intervention (with the additional assistance of the therapy dog). Includes AAT with 10 minutes of pre-procedure interaction with the therapy dog, extraction performed with the therapy dog, and 5 minutes of post-procedure interaction."
62356506|NCT04942119|NO_INTERVENTION|Routine standard care group|This group will continue to receive the usual recommended care provided in the clinic and usual follow-up appointment as well as clinical assessment. Any required nutrition education by the dietitian or medication counseling will be provided at any visit or when requested.
62520399|NCT04936828|EXPERIMENTAL|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
62149150|NCT03200574|OTHER|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
62149151|NCT04788407|EXPERIMENTAL|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID.
62149152|NCT04788407|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo TID.
62149153|NCT03456856|EXPERIMENTAL|Ivabradine|The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise. Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
62149154|NCT00539955|OTHER|1|Standard 40 hour state-mandated batterer intervention
62520400|NCT04936828|NO_INTERVENTION|Control group|Receive general mental health information through instant message.
62711180|NCT03577899|ACTIVE_COMPARATOR|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
61974868|NCT05230225|NO_INTERVENTION|Control Group|Providers that will not be contacted.
62149155|NCT00539955|OTHER|2|Brief alcohol intervention combined with standard batterer intervention
62149156|NCT05828407||Cohort|"Population:~Critically ill patient with:~* cardio circulatory insufficiency as defined by vasopressor requirement and at least one of the following criteria: arterial lactate \>2mmol/L ; capillary refill time \>3s ; mottling score \>1 ; diuresis \<0,5mL/h for more than 6hours~* diameter of inferior vena cava \>20mm~Protocol:~Administration of a fluid challenge (4mL/kg of Ringer Lactate) over 5 to 10 min.~Point of care ultrasound evaluation of portal vein pulsatility index and Vexus criteria before and after the fluid challenge ; fluid challenge induced cardiac index variations estimated by pulse contour analysis"
62149157|NCT00910962|EXPERIMENTAL|Treatment A|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
62149158|NCT00910962|EXPERIMENTAL|Treatment B|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
62711181|NCT01415752|EXPERIMENTAL|Arm A|Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm E.
62539535|NCT05097794|EXPERIMENTAL|Sequence BR1015-1/BR1015-2/BR1015-1 + BR1015-2|"A total of 32 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(BR1015-1, BR1015-2, BR1015-1 + BR1015-2) assigned to one sequence group in Period 1, Period 2, and Period 3.~* Period 1(BR1015-1): BR1015-1(Fimasartan 60mg) - 1 tablet QD, five-day repeated-dose~* Period 2(BR1015-2): BR1015-2(Indapamide 1.5mg) - 1 tablet QD, five-day repeated-dose~* Period 3(BR1015-1 + BR1015-2): BR1015-1 (Fimasartan 60mg) 1 tablet + BR1015-2 (Indapamide 1.5mg) 1 tablet QD, five-day repeated-dose~* Washout period between Period 1 and Period 2: five days~* Washout period between Period 2 and Period 3: two days"
62149159|NCT00910962|PLACEBO_COMPARATOR|Treatment C|Placebo twice daily for 12 weeks
62149160|NCT05197452|EXPERIMENTAL|COVID-19 Testing|COVID-19 antigen and PCR Testing
61974869|NCT01928524|EXPERIMENTAL|DOS2W Dose level 1A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
61974870|NCT01928524|EXPERIMENTAL|DOS2W Dose level 2A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
61974871|NCT01928524|EXPERIMENTAL|DOS2W Dose level 3A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
61974872|NCT01928524|EXPERIMENTAL|DOS2W Dose level 4A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
62149161|NCT00615368|PLACEBO_COMPARATOR|Placebo|Isotonic NaCl, intravenously injection
62149162|NCT00615368|EXPERIMENTAL|Active|Epoetin alfa, injected
62149163|NCT05178706||non-operative conservative treatment|"9 individuals diagnosed with FSHD who have not undergone unilateral or bilateral surgery who meet the inclusion criteria.~application of determined outcome scales and rehabilitation program on patients"
61974873|NCT01928524|EXPERIMENTAL|DOS3W Dose level 1B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
62149164|NCT05178706||scapulothoracic arthrodesis|"9 individuals diagnosed with FSHD who have undergone bilateral surgery who meet the inclusion criteria.~application of determined outcome scales and rehabilitation program on patients"
62711182|NCT01415752|EXPERIMENTAL|Arm B|Patients receive induction therapy comprising bortezomib IV subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm F.
62711183|NCT01415752|EXPERIMENTAL|Arm C|Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm G.
61974874|NCT01928524|EXPERIMENTAL|DOS3W Dose level 2B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
61974875|NCT01928524|EXPERIMENTAL|DOS3W Dose level 3B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
62149165|NCT05178706||healthy control|18 participants for measuring the normative datas; application of determined outcome scales
62149166|NCT04892251|EXPERIMENTAL|MORE+KAP|8 weeks of Mindfulness-Oriented Recovery Enhancement plus two ketamine assisted psychotherapy sessions
62149167|NCT04892251|ACTIVE_COMPARATOR|MORE|8 weeks of Mindfulness-Oriented Recovery Enhancement
62149168|NCT02646098|ACTIVE_COMPARATOR|CD34+ cell selection|CD34+ cell selection applying CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany)
62149169|NCT02646098|NO_INTERVENTION|No CD34+ cell selection|No CD34+ cell selection
62149170|NCT02851498|EXPERIMENTAL|Novel high-protein pasta and cereal|High-protein pasta (orzo and fusilli) enriched with gluten and egg white protein (%energy: 27/30/43 for protein/fat/carbohydrate) and high-protein flaked breakfast cereal enriched with gluten (%energy: 30/35/35 for protein/fat/carbohydrate) were manufactured by Zone Inc.(Boston, MA). The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as control meals.
62149171|NCT02851498|SHAM_COMPARATOR|Control pasta and cereal|Commercial gluten-free pasta (Barcilla orzo and fusilli; %energy: 13/24/63 for protein/fat/carbohydrate) and commercial flaked cereal (Post Honey Bunches of Oats; %energy: 6/18/76 for protein/fat/carbohydrate) were used as the control foods. The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as experimental foods.
62149172|NCT01856062|EXPERIMENTAL|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
62711184|NCT01415752|EXPERIMENTAL|Arm D|Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
62149173|NCT01856062|PLACEBO_COMPARATOR|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
62149174|NCT06204653|EXPERIMENTAL|High-flow nasal oxygenation group (HFNO group)|
62149175|NCT06204653|ACTIVE_COMPARATOR|Facemask ventilation group (MV group)|
62149176|NCT04546555|PLACEBO_COMPARATOR|No pacing|
62149177|NCT04546555|EXPERIMENTAL|Bachmann's bundle pacing|
62149178|NCT04546555|EXPERIMENTAL|Bachmann's bundle and His bundle pacing|
62149179|NCT04546555|EXPERIMENTAL|Bachmann's bundle, His bundle and nocturnal pacing|
62149180|NCT00643409|EXPERIMENTAL|1|
62149181|NCT00643409|EXPERIMENTAL|2|
62149182|NCT01008917|EXPERIMENTAL|single treatment-non randomized study|Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
62149183|NCT02243449|ACTIVE_COMPARATOR|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
62149184|NCT02243449|EXPERIMENTAL|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
62149185|NCT01204502|EXPERIMENTAL|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg"
62149186|NCT00446095|EXPERIMENTAL|fostamatinib|
62149187|NCT06477549|EXPERIMENTAL|FluBeBu conditioning|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days;Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +20: ruxolitinib 5 mg tid per os; Days +21 through 150: ruxolitinib 5 mg bid per os.
62520401|NCT02296684|EXPERIMENTAL|Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475|"* MK-3475 will be given intravenously once approximately 2-3 weeks prior to standard of care surgery.~* Adjuvant therapy will be dictated by surgical pathology and occurs after standard of care surgery and will consist of:~  * risk-based intensity modulated radiation therapy consisting of 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)once-daily fraction size (total of 30 fractions)~ * optional image-guided radiation therapy~ * risk-based cisplatin administered intravenously on Days 1, 22, and 43 of treatment course~ * MK-3475 will be given intravenously once every 3 weeks for a maximum of 6 doses if participant is considered high-risk based surgical pathology from standard of care surgery. These doses of MK-3475 will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
61974876|NCT01359657|EXPERIMENTAL|Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone|
61974877|NCT01359657|EXPERIMENTAL|Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone|
61974878|NCT02425046|EXPERIMENTAL|health coaching and community screening|Family Health Coaching and community benefits screening
62149188|NCT06477549|ACTIVE_COMPARATOR|FluBeRux conditioning|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -2: ruxolitinib 5 mg tid per os; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +20: ruxolitinib 5 mg tid per os; Days +21 through 150: ruxolitinib 5 mg bid per os.
62149189|NCT06451159|EXPERIMENTAL|Dosing Cohort #1: KYV-101 CAR+ T -- 0.33 ×10^8 cells|Five participants will be enrolled at the lower dose (0.33 ×10\^8 cells). Once safety and tolerability are adequately assessed, treatment will proceed to the higher dose level.
62149190|NCT06451159|EXPERIMENTAL|Dosing Cohort #2: KYV-101 CAR+ T -- 1×10^8 cells|An additional five participants are planned for enrollment at the higher dose level (1×10\^8 cells).
62149191|NCT03733951|EXPERIMENTAL|KN046|
62149192|NCT01455948|ACTIVE_COMPARATOR|Balloon Sinuplasty™ System|
62149193|NCT01455948|ACTIVE_COMPARATOR|Functional Endoscopic Sinus Surgery|
62149194|NCT04834830||Patients with pleural effusion|In patients with pleural effusion and indication for diagnostic and/or therapeutic procedures (thoracocentesis, drainage of fluid, indwelling pleural catheter (IPC) management, and/or video-assisted thoracoscopic surgery), pleural fluid will be examined for various cytokines and PD1-lymphoctyes.
61974879|NCT02425046|OTHER|community screening|community benefits screening only
62149195|NCT02166684|EXPERIMENTAL|Do-it-yourself devices|All subjects will use do-it-yourself devices for self-monitoring health parameters
62149196|NCT05026541|SHAM_COMPARATOR|Nap Practitioners|This is an observational arm of regular nappers. Individuals that take naps at least two times a week will be invited to undergo all of the study procedures for one weekend of data collection.
62149197|NCT05026541|ACTIVE_COMPARATOR|Shoonya Meditators|This is intervention arm. Participants will learn and practice the fifteen minute shoonya meditation - described as a process of conscious non-doing- and shakti chalana kriya, which is a set of breathing exercises designed as a preparatory practice to shoonya meditation. Participants will practice shoonya meditation twice a day for two months. A weekend of data collection will happen at baseline and two months after they learn the practice.
62149198|NCT05026541|NO_INTERVENTION|Control Meditators|Control subjects will be individuals that have learned the prerequisite meditation to Shoonya meditation. This meditation is called Shambhavi Mahamudra Kriya. Control subjects will not learn Shoonya meditation while they are participating in the study. One weekend of data collection will occur at baseline.
62149199|NCT01497184|EXPERIMENTAL|DLI (Adults)|Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
61974880|NCT02729844||Neolifes Heart|All premature infants, admitted at the neonatal intensive care unit (NICU) of the University Medical Centre Groningen, born \<30 weeks or birth weight \< 1000 gram, who participate in NeolifeS
62149200|NCT01497184|EXPERIMENTAL|DLI any time|Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
62149201|NCT01497184|EXPERIMENTAL|DLI Pediatrics|Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
61974881|NCT02792933|ACTIVE_COMPARATOR|air in epidural space|When the ALOR epidural localization technique will be used, an intermittent pressure with fast movements will be exerted on the plunger of the syringe while the Tuohy needle will be inserted until loss of resistance was felt.
61974882|NCT02792933|EXPERIMENTAL|saline in epidural space|When the SLOR technique is used, a continuous pressure will be exerted on the plunger of the Tuohy needle until loss of resistance was felt.
61974883|NCT05981144||Experimental|Patients with heart failure without significant stenosis of the major epicardial coronary artery and reduced left ventricular ejection fraction below 40%
61974884|NCT00814528|EXPERIMENTAL|1|"Application of 5-ALA PDT to some lesions on skin with Blue U light source (417 nm)."
61974885|NCT00814528|EXPERIMENTAL|2|5-FU, Imiquimod or treatment with cryotherapy to lesions on the skin.
62149202|NCT01497184|EXPERIMENTAL|DLI - Haplo-Identical Family Donor|Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
62520402|NCT02296684|EXPERIMENTAL|Cohort 2: Neoadjuvant MK-3475|-MK-3475 will be given once intravenously and then given again 21 days after dose 1 (14-24 days before standard of care surgery)
62520403|NCT06360068|EXPERIMENTAL|Sulfasalazine group|
62520404|NCT01741779|EXPERIMENTAL|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
62520405|NCT01741779|NO_INTERVENTION|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
62520406|NCT01741779|EXPERIMENTAL|Whole body vibration training & diet|Lower-body exercise training on a vibration platform and diet
62520407|NCT01741779|EXPERIMENTAL|Whole body vibration training|Lower-body exercises 3 times per wk for 12 wk in a vibration platform
62520408|NCT03666481|EXPERIMENTAL|MPAI group|Patients in this group participated in a 6-months Motivational Physical Activity Intervention (MPAI) to explore its effects on different variables related to PA levels and psychosocial aspects of life of bariatric patients. Concretely, the fundamental goals of the MPAI group were three: to increase the self-determined forms of motivation of the patients towards exercise or reduce those related to non-self-determined motivation; to improve post-operative levels of PA with respect to pre-operative levels, and; transfer the benefits of the intervention on different variables related to the perceived health-related quality of life.
62520409|NCT03666481|NO_INTERVENTION|Control group|Patients in this group did not participate in any intervention, but the same measurements were made in them as in the MPAI group in the same temporal spaces.
62520410|NCT06482671|ACTIVE_COMPARATOR|Rikkunshito|Rikkunshito (TJ-43) Route of administration: P.O.; dose: 2.5 grams 3 times per day. Needs to be dissolved in about 30 ml of lukewarm water 30 minutes prior to the meal and swallowed as a single dose over approximately one minute at most.
62520411|NCT06482671|PLACEBO_COMPARATOR|Placebo|Placebo Route of administration: P.O.; dose: 2.5 grams 3 times per day Needs to be dissolved in about 30 ml of lukewarm water 30 minutes prior to the meal and swallowed as a single dose over approximately one minute at most.
62520412|NCT02030548||acute CABG|patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy
62520413|NCT02939950|EXPERIMENTAL|Bausch + Lomb Samfilcon A Soft Contact Lens|Participants will wear Bausch + Lomb samfilcon A soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
62520414|NCT02939950|ACTIVE_COMPARATOR|Bausch + Lomb Pure Vision Soft Contact Lens|Participants will wear Bausch + Lomb pure vision soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
62520415|NCT04476628|OTHER|Budesonide 5MR then 1MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.~1. st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~2. nd time period: 5MR administration method once daily for 8 weeks in duration.~3. rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~4. th time period: 1MR administration method once daily for 8 weeks in duration."
62520416|NCT04476628|OTHER|Budesonide 1MR then 5MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.~1. st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~2. nd time period: 1MR administration method once daily for 8 weeks in duration.~3. rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~4. th time period: 5MR administration method once daily for 8 weeks in duration."
62520417|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
62711185|NCT01415752|EXPERIMENTAL|Arm E|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62711186|NCT01415752|EXPERIMENTAL|Arm F|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62149203|NCT00442507|EXPERIMENTAL|1|Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects.
62149204|NCT00502684|EXPERIMENTAL|1|Peri-operative etodolac and propranolol as described in protocol
62149205|NCT00502684|PLACEBO_COMPARATOR|2|peri-operative placebo as described in protocol
62149206|NCT02003872|EXPERIMENTAL|Spattz 3 intragastric balloon|obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon
62520418|NCT03587155||Control|Embryo or infant without ASNS mutation.
62520419|NCT05032313||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for hematological disorders.
62711187|NCT01415752|EXPERIMENTAL|Arm G|Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62149207|NCT03644082|EXPERIMENTAL|Epilepsy Patients|
62149208|NCT02000752|EXPERIMENTAL|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
62149209|NCT02000752|SHAM_COMPARATOR|Sham acupuncture|Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.
62356507|NCT04942119|EXPERIMENTAL|Multifactorial intervention group|"1. Correction of magnesium and/or potassium levels, and correction of the underlying disease, if possible by a endocrinologist.~2. Education at each follow-up visit by a specialized dietitian, reinforcing optimal diet and exercise, with pre-\& post-nutrition and physical activity assessment using the validated revised summary of diabetes self-care activities (SDSCA) scale.~3. Medication reconciliation and counseling, online post adherence questionnaire and confirm adherence by fixed medication possession ratio (FMPR) approach."
62149210|NCT05647759|EXPERIMENTAL|HEART Camp Connect|Participants will have access to a virtual exercise platform or membership to a medical exercise facility. Participants will meet with a virtual exercise coach via zoom on a weekly basis.
62356508|NCT01269047|EXPERIMENTAL|Pramlintide + Insulin Group|These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
62356509|NCT01269047|EXPERIMENTAL|Exenatide + Insulin Group|This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
62356510|NCT01269047|ACTIVE_COMPARATOR|Insulin monotherapy|This group will be on their regular insulin therapy.
62356511|NCT03886441|EXPERIMENTAL|Prevention group|Participants inhaled beclomethasone propionate aerosol daily during chest radical radiotherapy (total dose 60GY).
62356512|NCT03886441|NO_INTERVENTION|Traditional therapy group|Participants were not given daily inhalation of beclomethasone propionate when undergoing radical chest radiotherapy (total dose 60GY).
62356513|NCT05993000|EXPERIMENTAL|Grup 1(Music + mobilization + exercise was applied)|In this group, hot packs and TENS (Transcutaneous Electrical Nerve Stimulation) were applied to the patients simultaneously, while they were listening to 432 hertz frequency music through headphones. Subsequently, shoulder mobilization was applied in appropriate positions. The exercises were conducted by the physiotherapist during the session and the manageable exercises were given to the patients as a home program.
62356514|NCT05993000|EXPERIMENTAL|Grup 2 ( music + exercise)|In this group, hot packs and TENS (Transcutaneous Electrical Nerve Stimulation) were applied to the patients simultaneously, while they were listening to 432 hertz frequency music through headphones. The exercises were conducted by the physiotherapist during the session and the manageable exercises were given to the patients as a home program.
62356515|NCT05993000|ACTIVE_COMPARATOR|Grup 3 (mobilization + exercise)|After applying hot packs and TENS(Transcutaneous Electrical Nerve Stimulation) to the patients, shoulder mobilization was performed in suitable positions.The exercises were conducted by the physiotherapist during the session and the manageable exercises were given to the patients as a home program.
62356516|NCT05993000|ACTIVE_COMPARATOR|Grup 4 (exercise)|After the application of hot packs and TENS (Transcutaneous Electrical Nerve Stimulation) to the patients, the physiotherapist administered specific exercises during the session. Additionally, customized exercises were prescribed as a home program for the patients to continue their rehabilitation outside of the clinic setting.
62356517|NCT04559087|EXPERIMENTAL|Natural Orifice Specimen Extraction Surgery|
62356518|NCT04559087|SHAM_COMPARATOR|Conventional laparoscopy|
62356519|NCT06376838|EXPERIMENTAL|DLMR01|"* one side crow's feet~* Single dose"
62356520|NCT06376838|ACTIVE_COMPARATOR|Rejuran|"* one side crow's feet~* Single Dose"
62356521|NCT00436982|ACTIVE_COMPARATOR|Cemented Triathlon total knee system|The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
62356522|NCT00436982|ACTIVE_COMPARATOR|Cemented Duracon total knee system|The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
62356523|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
62356524|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
62356525|NCT02789826|EXPERIMENTAL|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic Gastrectomy' group will undergo laparoscopic gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
62356526|NCT02789826|ACTIVE_COMPARATOR|Open gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive gastrectomy via laparotomy. This group is considered the control group
62356527|NCT05445882|EXPERIMENTAL|Arm 1|N-803 + BN-Brachyury (+ bintrafusp alfa if progression beyond 12 weeks)
62356528|NCT05445882|EXPERIMENTAL|Arm 2|N-803 (+ BN-Brachyury + bintrafusp alfa if progression beyond 12 weeks)
62356529|NCT05445882|EXPERIMENTAL|Arm 3|N-803 + bintrafusp alfa (+ BN-Brachyury if progression beyond 12 weeks)
62356530|NCT01937624||Diagnostic ultrasound and radiographic imaging|- The diagnostic musculoskeletal ultrasound and x-rays will both be used to image bones in perpendicular and orthogonal planes over the distal radius visualizing the physis.
62356531|NCT06013267|EXPERIMENTAL|experimental group|"The experimental group will receive a four-week CTAR exercise protocol  and routine dysphagia care."
62356532|NCT06013267|NO_INTERVENTION|control group|The control group will only receive routine dysphagia care.
62356533|NCT01495923|EXPERIMENTAL|Epidural steroids|Injection of steroids into the epidural space
62356534|NCT01495923|ACTIVE_COMPARATOR|Gabapentin|Titration of gabapentin to effect
62356535|NCT04169113|ACTIVE_COMPARATOR|Group 1 - Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
62149211|NCT03964779||Anovulatory women|40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility
62149212|NCT03964779||Tubal factor women|40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility
62149213|NCT03964779||male factor couple|40 women with exclusive male factor of infertility and will be used as a control group
62711188|NCT01415752|EXPERIMENTAL|Arm H|Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
62149214|NCT03678688|ACTIVE_COMPARATOR|Stage 1: RHEZ|Participants received a single dose of RHEZ (each tablet containing 150 milligrams (mg) rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, once daily (QD) from Day 1 through Day 20.
62149215|NCT03678688|EXPERIMENTAL|Stage 1: 10 mg OPC-167832|Participants received OPC-167832, 10 mg, orally, QD, from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
62356536|NCT04169113|ACTIVE_COMPARATOR|Group 2 - Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
62356537|NCT02513771|ACTIVE_COMPARATOR|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
62711189|NCT03560492|EXPERIMENTAL|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
62711190|NCT03560492|ACTIVE_COMPARATOR|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
62356538|NCT02513771|PLACEBO_COMPARATOR|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
62356539|NCT02397590|OTHER|A Group|Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
62711191|NCT06230809|EXPERIMENTAL|Intervention|
62711192|NCT06230809|NO_INTERVENTION|Waitlist|Waitlist, participants will be included after 8 weeks.
62711193|NCT04696146|EXPERIMENTAL|Berinert|Berinert 500 units
62711194|NCT04696146|PLACEBO_COMPARATOR|Placebo|Normal Saline in identical volume to Berinert
62711195|NCT02483364|EXPERIMENTAL|Experimental|HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)
62711196|NCT03183310|ACTIVE_COMPARATOR|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
62711197|NCT03183310|PLACEBO_COMPARATOR|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
62711198|NCT06205693|ACTIVE_COMPARATOR|Stent|Placement of biodegradable stent intraoperatively.
62711199|NCT06205693|NO_INTERVENTION|No stent|Control group. No placement of stent.
62711200|NCT04272697||Heterozygous Familial Hypercholesterolaemia|Adults and children with Heterozygous Familial Hypercholesterolaemia.
62149216|NCT03678688|EXPERIMENTAL|Stage 1: 30 mg OPC-167832|Participants received OPC-167832, 30 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
62149217|NCT03678688|EXPERIMENTAL|Stage 1: 90 mg OPC-167832|Participants received OPC-167832, 90 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
62149218|NCT03678688|EXPERIMENTAL|Stage 1: 3 mg OPC-167832|Participants received OPC-167832, 3 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
62711201|NCT04272697||Homozygous Familial Hypercholesterolaemia|Adults and children with Homozygous Familial Hypercholesterolaemia
62149219|NCT03678688|EXPERIMENTAL|Stage 2: 30 mg OPC-167832 + 300 mg Delamanid|Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
62356540|NCT02397590|OTHER|B Group|Fimasartan (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days)
62711202|NCT04272697||Unaffected (non-FH) relatives of FH individuals|Adults and children with unaffected (non-FH) relatives of FH individuals
62711203|NCT05007964|EXPERIMENTAL|Spatz4 subjects|Subjects will be studied in an open label multi-center center study which will examine the usability of the adjustment process and success of the process. .
62711204|NCT03580044|EXPERIMENTAL|ATM- AVI Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm|
62149220|NCT03678688|EXPERIMENTAL|Stage 2: 30 mg OPC-167832 + 400 mg Bedaquiline (BDQ)|Participants received OPC-167832, 30 mg, in combination with BDQ, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, QD, orally from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
62356541|NCT02397590|OTHER|C Group|Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
62356542|NCT02397590|OTHER|D Group|Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
62356543|NCT02397590|OTHER|E Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days)
62356544|NCT02397590|OTHER|F Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
62356545|NCT01639391|EXPERIMENTAL|patients|
62356546|NCT00830115||Pantoprazole|All patients enrolled
62711205|NCT03580044|ACTIVE_COMPARATOR|Best Available Therapy (BAT) Comparator Treatment Arm|
62711206|NCT01198587|EXPERIMENTAL|Outpatient Zinc Sulfate|Zinc Sulfate
62711207|NCT01198587|EXPERIMENTAL|Inpatient Zinc Sulfate|Zinc Sulfate
62711208|NCT01198587|PLACEBO_COMPARATOR|Outpatient Placebo|Placebo oral capsule
62520420|NCT05702879||Ulcerative colitis patients|Patients with a flare of ulcerative colitis who meet the inclusion criteria. 120 patients will be included.
62520421|NCT05702879||Controls|For each patient, enrollment of a healthy control individual who shares the same living conditions (e.g., spouse or roommate) is attempted
62520422|NCT03324321|EXPERIMENTAL|Hyperventilation Protocol|This will involve sustained periods of 90-seconds of hyperventilation at two levels (-5mmHg and -10mmHg below baseline EtCO2) to a maximum lower level threshold of EtCO2 24mmHg/CBFV 33cm/s regulated using a metronome. Two-minute washout periods of normal respiration will be allowed between successive measurements. Each incremental reduction in pCO2 will be repeated on two occasions during the same session. Further assessments will be conducted 10-14 days following baseline assessments.
62520423|NCT00103038|EXPERIMENTAL|Diagnostic (ferumoxytol, gadolinium, DCE-MRI, DSC-MRI)|"Study patients: adult patients with high grade primary malignant brain tumors or with known or suspected brain metastases from histologically confirmed primary cancer~Study procedures: patients will receive IV ferumoxytol (maximum dose 4 mg/kg, over at least 15 minutes) beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients will also undergo MRI without contrast at baseline (before and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.~3 Tesla Magnetic Resonance Imaging: Undergo 3T MRI~Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DCE-MRI~Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DSC-MRI~Ferumoxytol: Given IV~Gadolinium: Given IV~MRI-Based Angiogram: Undergo MRA"
62520424|NCT04793035|EXPERIMENTAL|Enrolled patients|Single-arm study for enrolled GERD patients to be treated with an Omega-Cuff device
62520425|NCT02243293|EXPERIMENTAL|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
62520426|NCT02243293|EXPERIMENTAL|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520427|NCT02243293|EXPERIMENTAL|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520428|NCT02243293|EXPERIMENTAL|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
62520429|NCT02243293|EXPERIMENTAL|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520430|NCT02243293|EXPERIMENTAL|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
62711209|NCT01198587|PLACEBO_COMPARATOR|Inpatient Placebo|Placebo oral capsule
62149221|NCT03678688|EXPERIMENTAL|Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ|Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg and BDQ, 400 mg, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, orally, QD from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
62149222|NCT03678688|ACTIVE_COMPARATOR|Stage 2: RHEZ|Participants received a single dose of RHEZ (each tablet containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, QD, from Day 1 through Day 20.
62149223|NCT05866432|EXPERIMENTAL|Datopotamab-deruxtecan|Datopotamab-deruxtecan (DS-1062a) 6.0 mg/kg body weight i.v. on day 1 once every three weeks
62149224|NCT02054208|EXPERIMENTAL|NEUROSTEM (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
62149225|NCT02054208|EXPERIMENTAL|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10\^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
62149226|NCT02054208|PLACEBO_COMPARATOR|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
62356547|NCT04505878|EXPERIMENTAL|Vitamin C Arm|Ascorbic Acid will be administered at a dose of 1500 mg in 100 mL of saline over 30 minutes intravenously once every 6 hours for a total of 72 hours
61974886|NCT03763123|EXPERIMENTAL|Sevacizumab +Chemotherapy Combined chemotherapy drug including|Investigators selected single-agent chemotherapy on an individual patient basis from the following options, with appropriate premedication according to local standards: paclitaxel 80mg/m2 intravenously (IV)on days 1, 8, 15, and 22 every 4 weeks; or topotecan 4 mg/m2 IV on days 1, 8, and 15 every 4 weeks.
61974887|NCT03378362|EXPERIMENTAL|Partial denervation of the wrist joint|Patients will be operated with a partial denervation of the wrist through a single dorsal approach.
61974888|NCT02293408||Component 1|Component 1 involved an evaluation of the clinical characteristics of MPS IIIB in participants based on a retrospective chart review to collect information on demographics, clinical history, diagnostic tests, treatments, clinical chemistry and hematology test results, physical examination findings, anthropometric data, radiology results, and supportive interventions performed over a period of up to 6 weeks.
62356548|NCT02884856||Females observers (F)|those with female gender characteristics
62356549|NCT02884856||Male observers (M)|those with male gender characteristics
62356550|NCT05564442|ACTIVE_COMPARATOR|Group I: Children received 20% benzocaine gel|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
62356551|NCT05564442|ACTIVE_COMPARATOR|Group II: Children received TENS stimuli|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
62356552|NCT05564442|ACTIVE_COMPARATOR|Group III: Children received EMLA gel.|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
62356553|NCT05564442|ACTIVE_COMPARATOR|Group IV: Children received ice application at injection site|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
62149227|NCT04020172|EXPERIMENTAL|Dobutamine + Goal-Directed Fluid Therapy|All patients will receive a baseline infusion of Ringer's lactate at 2 ml/kg/h to satisfy maintenance fluid requirements. The intervention will commence at anesthesia induction and continue for up to 4 hours postoperatively. In addition to maintenance fluids, patients will receive 250 ml fluid challenges with crystalloid as required until they are no longer fluid responsive. The absence of fluid responsiveness will be defined as the absence of a sustained rise in stroke volume index of at least 10% for 20 minutes or more, at which point, the patient will be considered fluid optimized. At this point, a low-dose dobutamine infusion at a fixed rate (2.5 μg/kg/min) will be commenced and maintained until 4 hours postoperatively. The infusion rate will be halved and/or discontinued if the patient develops tachycardia (heart rate ≥ 100 bpm) for more than 30 minutes despite adequate anesthesia/analgesia and fluid status.
62520431|NCT02243293|EXPERIMENTAL|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520432|NCT02243293|EXPERIMENTAL|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520433|NCT02243293|EXPERIMENTAL|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520434|NCT02243293|EXPERIMENTAL|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520435|NCT02243293|EXPERIMENTAL|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
62520436|NCT02243293|EXPERIMENTAL|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
62149228|NCT04020172|NO_INTERVENTION|Standard of care|Patients in the control group will also receive a baseline infusion of Ringer's lactate at 2 ml/kg/h to satisfy maintenance fluid requirements, which will be commenced upon admission to the operating room. The anesthetic management will otherwise be according to standard practice. No specific cardiac output monitoring device will be used to guide fluid therapy. Likewise, perioperative dobutamine will not be used unless clinically indicated to improve cardiac function.
62149229|NCT05697536|EXPERIMENTAL|Pilates training|Group A will receive Pilates training. The treatment will be given with the frequency of 3 times per week for 8 weeks. Treatment sessions will be of 45 minutes with short resting intervals.
62520437|NCT02243293|EXPERIMENTAL|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
62711210|NCT03719014|EXPERIMENTAL|NovaCross|the NovaCross is a guidewire positioning and support micro-catheter for improving chronic total occlusion (CTO) crossability. The NovaCross gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extandable segment, both at its distal tip.
62711211|NCT03044444|EXPERIMENTAL|high dose citrus extract|this group will receive a high dose (500mg/day) of the citrus extract for 8 weeks
62149230|NCT05697536|EXPERIMENTAL|Aerobic exercise|Group B will receive aerobic exercise plan. The frequency of treatment will be as same as that of Pilates exercise program i.e. 3 times a week for 8 weeks. Treatment sessions will be of 45 minutes with short resting intervals.
62149231|NCT01130298|EXPERIMENTAL|1|
62356554|NCT02035579|EXPERIMENTAL|Aerobic Training Intervention|Children with PCS who are eligible for the study will be randomized to a progressive, sub-symptom exacerbation, cycling aerobic training intervention or stretching comparison intervention. Children with PCS that meet criteria for the intervention trial will complete a baseline evaluation followed by a one week run-in-period (week 0-1) prior to their first intervention visit. After the initial intervention visit, weekly visits will be completed for at least 6 additional weeks (i.e., at least 6 weeks of aerobic training). An individualized home exercise program 5-6 days per week will also be developed. Children will be provided with a home stationary cycle to complete the home program.
62520438|NCT02243293|EXPERIMENTAL|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
62149232|NCT02390778|EXPERIMENTAL|Debrief Group|The debrief group participated in 3 consecutive face-to-face group debriefing sessions lasting 1.5-2 hrs each. Each session started with a fun ice-breaker to create a relaxed atmosphere and group cohesion. Session 1 focused on encouraging group participation, discussing primary trauma encountered and emotional reactions to these stories. Session 2 connected current experiences with the group members' own trauma histories and life experiences. The last session focussed on societal and community responses to violence, and employing personal agency to find constructive ways to address violence in communities.
62520439|NCT02243293|EXPERIMENTAL|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
62711212|NCT03044444|EXPERIMENTAL|low dose citrus extract|this group will receive a low dose (400mg/day) of the citrus extract for 8 weeks
62711213|NCT03044444|PLACEBO_COMPARATOR|placebo|this group will receive a placebo (500mg maltodextrin per day) for 8 weeks
62711214|NCT06089993|EXPERIMENTAL|Exercise|Resistance exercise involves 4 exercises (bench pull, bench press, leg extension and unilateral leg press), that are performed at 75% of maximum, determined from 3-RM test.
62711215|NCT06089993|EXPERIMENTAL|Rest|One hour rest.
62711216|NCT02749747|ACTIVE_COMPARATOR|Sulpiride use|50mg sulpiride once a day use for 60 days
62711217|NCT02749747|PLACEBO_COMPARATOR|Placebo|50mg placebo once a day use for 60 days
62711218|NCT02736071|ACTIVE_COMPARATOR|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
62149233|NCT02390778|PLACEBO_COMPARATOR|Control Group|The control group was assigned to a leisure activity (film showing), for every session of debriefing undergone by the intervention group. The films were chosen for their light-hearted uplifting content and presented as a fun and relaxing activity.
62149234|NCT02219607||epidural|
62149235|NCT02219607||general anesthesia|
62520440|NCT02243293|EXPERIMENTAL|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
62520441|NCT02243293|EXPERIMENTAL|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
61974889|NCT02293408||Component 2|Component 2 involved a longitudinal evaluation of the course of disease progression in a subset of participants considered to be at risk of rapid disease progression, who, after completing Component 1, were to be prospectively followed for a period of at least 1 year (Longitudinal Follow-Up) and up to 3 years total (Extended Follow-Up).
61974890|NCT06439992||Healthy participants|"Healthy participants with normal cognition will be recruited and receive the following interventions:~Drug: \[18F\]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET-certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: \[11C\]-Pittsburgh Compound (\[11C\]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET-certified professional will prepare and administer the \[11C\]-PIB tracer. Participants will receive the PIB injection followed by a 10 ml 0.9% sodium chloride (normal saline) flush."
62149236|NCT05641220||Biopsy|Newly diagnosed elderly (\>70 years of age) glioblastoma patients who undergo biopsy
62356555|NCT02035579|EXPERIMENTAL|Stretching Intervention|Children in the stretching intervention will complete a series of full body stretches of the shoulders, arms, chest, back, legs, and feet 5-6 days per week and will return weekly to review the stretching program. The minimum duration of the stretching intervention will also be 6 weeks
62356556|NCT04879784||Stored antenatal sera|Antenatal sera from women booking for antenatal care at six centres in England
62356557|NCT02012881|EXPERIMENTAL|Physical activity intervention|60 minutes of physical activity on every school day
62356558|NCT02012881|ACTIVE_COMPARATOR|Control|Usual practice
62356559|NCT06199505|EXPERIMENTAL|GZR101|GZR101 injection s.c., once daily, treat-to-target dose
62356560|NCT06199505|ACTIVE_COMPARATOR|insulin degludec/insulin aspart,|insulin degludec/insulin aspart injection s.c., once or twice daily, treat-to-target dose
62356561|NCT05752071|EXPERIMENTAL|Treatment group|A pace lead is mounted on the stomach, and exteriorized trough the skin and connected to an external pacemaker. The pacemaker is set to the following settings: 10,5 Volt, 14 hz, 330 Micro sec, Cycling 5 seconds off 0,1 sec on. The pacemaker is turned on.
62356562|NCT05752071|SHAM_COMPARATOR|Control group|A pace lead is mounted on the stomach, and exteriorized trough the skin and connected to an external pacemaker. The pacemaker is turned off.
62356563|NCT00444964|EXPERIMENTAL|Primary Cohort|Nutropin AQ
62356564|NCT03620435|EXPERIMENTAL|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
62149237|NCT05641220||Resection|Newly diagnosed elderly (\>70 years of age) glioblastoma patients who undergo resection
62356565|NCT01938001|EXPERIMENTAL|Rituximab and Lenalidomide|Participants received rituximab 375 mg/m\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
62356566|NCT01938001|ACTIVE_COMPARATOR|Rituximab and Placebo|Participants received riituximab 375 mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.
62520442|NCT02243293|EXPERIMENTAL|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
62520443|NCT02243293|EXPERIMENTAL|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
62356567|NCT02522650|EXPERIMENTAL|Amiloride Phase|Subject receives 5mg of Amiloride twice daily for 8 weeks.
62356568|NCT02522650|ACTIVE_COMPARATOR|Triamterene Phase|Subject receives 50mg of Triamterene twice daily for 8 weeks.
62356569|NCT02522650|NO_INTERVENTION|Washout Phase|Subject does not take any study medication for 4 weeks
62356570|NCT01645865||Control|
62520444|NCT02243293|EXPERIMENTAL|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
62520445|NCT02243293|EXPERIMENTAL|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
62520446|NCT02243293|EXPERIMENTAL|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
62520447|NCT01438255||Alvesco|
62356571|NCT01645865||Intervention|
62356572|NCT00989612|EXPERIMENTAL|GSK2340274A GROUP|Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
62356573|NCT04189991|ACTIVE_COMPARATOR|Manual then automated oxygen titration|First will be performed the manual oxygen titration and then the automatic oxygen titration.
62520448|NCT04274023|EXPERIMENTAL|TSR-042 arm|TSR-042 at a dose of 500 mg in IV infusion (given over t30-minutes) every 21 days for the first 4 doses, followed by 1.000 mg on day 1 of every 42 day.
62520449|NCT06398613|NO_INTERVENTION|RALP + ePLND Arm A|RALP + ePLND with no preoperative PSMA PET/CT
62520450|NCT06398613|EXPERIMENTAL|PrePSMA Arm B|Patients examined with PSMA PET/CT preoperatively and treated with RALP + ePLND if PSMA is positive. If PSMA PET/CT is negative, only RALP will be done
62711219|NCT02736071|ACTIVE_COMPARATOR|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
62711220|NCT02736071|PLACEBO_COMPARATOR|Placebo|Women will receive an oral placebo similar to Tramadol and an oral placebo similar to Celecoxib 2 hours before the procedure
62711221|NCT06631638|OTHER|EMPHASYS Cup with VHN|EMPHASYS Cup with Non-Invasive Navigation
62711222|NCT06027606|EXPERIMENTAL|Salbutamol|Participants are healthy and between the ages of 18-40 years old
62711223|NCT06027606|EXPERIMENTAL|Budesonide-formoterol|Participants are healthy and between the ages of 18-40 years old
62520451|NCT05160753|EXPERIMENTAL|gastric function preserving surgery combined with resection of the anterior lymphatic drainage area.|"1. Steps of sentinel lymph node dissection Indocyanine green (ICG) tracing of anterior lymph nodes. ICG injection: A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method. 0.5 mL was injected at each site, and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.~2. Intraoperative and postoperative pathological examination Intraoperative histological examination of lymph nodes collected from the anterior lymph node pool was performed, If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed. After surgery, anterior lymph nodes that proved to be tumor-free on intraoperative frozen section examination were reevaluated."
62520452|NCT05160753|ACTIVE_COMPARATOR|Patients in the control group will undergo standard laparoscopic gastrectomy|Patients in the control group will undergo standard laparoscopic gastrectomy (laparoscopic distal gastrectomy with simultaneous D1+ lymph node dissection).
62711224|NCT06027606|SHAM_COMPARATOR|Placebo|Participants are healthy and between the ages of 18-40 years old
62149238|NCT01785056|EXPERIMENTAL|Privigen|Privigen is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Subjects will be given 2 g/kg/month of IVIGfor 6 months. Each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
62149239|NCT01785056|PLACEBO_COMPARATOR|Placebo (Albuminar-5)|Albuminar-5 is a sterile solution of albumin obtained from large pools of adult human venous plasma and used as the placebo in this study. Albuminar-5 will be administered by the intravenous route and each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
62149240|NCT01742494|ACTIVE_COMPARATOR|Water-jet POEM|POEM were performed by the use of Erbe Hybrid knife (WJ group)
62356574|NCT04189991|ACTIVE_COMPARATOR|Automatic then manual oxygen titration|First will be performed the automatic oxygen titration and then the manual oxygen titration.
62356575|NCT05135351|EXPERIMENTAL|Treatment|resistant starch
62149241|NCT01742494|ACTIVE_COMPARATOR|Conventional POEM|POEM were performed by the conventional technique using injection and triangle tip knife (C group).
62356576|NCT05135351|PLACEBO_COMPARATOR|Placebo|maltodextrin
62356577|NCT02718027||Participants with Alport Syndrome|Participants diagnosed with Alport syndrome aged between 2 months and 50 years
62356578|NCT01674192|EXPERIMENTAL|prucalopride|single dose of 2 mg prucalopride
62356579|NCT04868227|EXPERIMENTAL|INTERVENTION STUDY|TREATED WITH 3200IU FULTIUM VITAMIN D3
62356580|NCT03771690|NO_INTERVENTION|Control 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
62356581|NCT03771690|NO_INTERVENTION|Control 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
62356582|NCT03771690|EXPERIMENTAL|Standardised meal 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
62356583|NCT03771690|EXPERIMENTAL|Standardised meal 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
62356584|NCT01659268|EXPERIMENTAL|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
62356585|NCT01659268|OTHER|Exhibition-dialogued class|Students will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, each subgroup composed of 4-5 students will go to the and practical activity in skill lab using the low-fidelity mannequin for 35 minutes.
62356586|NCT02773056|ACTIVE_COMPARATOR|Socket 1 (Ischial Ramus Containment)|This arm included unilateral transfemoral amputees who were assessed while using the Ischial Ramus Containment socket.
62356587|NCT02773056|ACTIVE_COMPARATOR|Socket 2 (Dynamic Socket IRC)|This arm included unilateral transfemoral amputees who were assessed while using the Dynamic Socket Ischial Ramus Containment socket.
62356588|NCT02773056|ACTIVE_COMPARATOR|Socket 3 (Sub-Ischial Interface)|This arm included unilateral transfemoral amputees who were assessed while using the Sub-Ischial Interface socket.
62356589|NCT01350713|EXPERIMENTAL|povidone iodine|
62356590|NCT01350713|ACTIVE_COMPARATOR|cold water|treatment by cold water after burn
62356591|NCT06527261||Acute Sessions|Observed sessions for patients who are in the acute inpatient setting. Each session will include a patient and a clinician
62356592|NCT06527261||Subacute Sessions|Observed sessions for patients who are in the subacute inpatient setting. Each session will include a patient and a clinician
62356593|NCT04679441|ACTIVE_COMPARATOR|Healthy individuals Skills training only|These participants will receive CFSAT training only (n = 60). They will train for 24 hours over 12 weeks.
62356594|NCT04679441|EXPERIMENTAL|MCI, Skills training only|These participants will receive 24 hours of CFSAT training over 12 weeks following the same training protocol as the NC sample.
62356595|NCT04679441|EXPERIMENTAL|MCI, Combined treatment|Participants assigned to this condition will initially train for 3 weeks @ 60 minutes twice per week on CT (Posit Science). Participants will train 90 minutes on Double Decision and 30 minutes on Hawkeye. They can train on Hawkeye in 15- minute increments and intersperse it within the Double Decision training. They will then train CFSAT for 9 weeks at the recommended dosage. Each task will be trained twice before advancing to the next task
62356596|NCT02690324|EXPERIMENTAL|Major depressive disorder|DSM-5 major depressive disorder HAMD-17 \> 16
62356597|NCT02690324|ACTIVE_COMPARATOR|panic disorder|DSM-5 panic disorder PDSS\>7
62356598|NCT02690324|ACTIVE_COMPARATOR|normal control|age \>20, healthy adults HAMD-17\<17 PDSS\<7
62356599|NCT01118715|EXPERIMENTAL|Compression glove|Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
62711225|NCT06477198|ACTIVE_COMPARATOR|Group QLB = QLB group|Posterior QLB will be performed
62520453|NCT03274713|EXPERIMENTAL|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
62520454|NCT03274713|EXPERIMENTAL|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
62520455|NCT02221908||Patients brought to Hahnemann Hospital ED|
62711226|NCT06477198|ACTIVE_COMPARATOR|Group ESPB = ESPB Group|Lumbar ESPB will be performed
62520456|NCT00393224||cohort|hospital based family cohort
62520457|NCT01274806|NO_INTERVENTION|Usual care|
62711227|NCT05678946||Integrated face-to-face rehabilitation and telerehabilitation|Participation in integrated face-to-face rehabilitation and telerehabilitation services for family caregivers organized by the Social Insurance Institution of Finland (Kela)
61974891|NCT06439992||Participants with mild cognitive impairment|"Participants with mild cognitive impairment will be recruited and receive the following interventions:~Drug: \[18F\]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET-certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: \[11C\]-Pittsburgh Compound (\[11C\]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET-certified professional will prepare and administer the \[11C\]-PIB tracer. Participants will receive the PIB injection followed by a 10 ml 0.9% sodium chloride (normal saline) flush."
62149242|NCT00972920|ACTIVE_COMPARATOR|Blind TAP block|"TAP block technique as first described by McDonnell. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Identification of triangle of Petit just above iliac crest and between external oblique and latissimus dorsi muscles. Insertion of regional anaesthesia needle perpendicular to skin, and its advancement until sensation of two 'pops' indicating advancement of needle through both external oblique and internal oblique muscle layers.~After confirmation of negative aspiration the local anaesthetic is injected slowly, (1mg/kg of levobupivacaine), concentration 2.5 mg/mL. Repeat procedure bilaterally (to a maximum dose of 2mg/kg of levobupivacaine)."
62149243|NCT00972920|ACTIVE_COMPARATOR|Ultrasound-guided TAP block|"Technique as described by Hebbard. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Ultrasound probe covered with sterile sheath.~Identification of triangle of Petit with USS probe perpendicular to skin. Insertion of regional anaesthesia needle transversely to the probe, using in-plane (IP) technique, moving posteriorly. Advancement of the needle under ultrasound control until its tip is located between internal oblique and transversus abdominis muscle layers."
62149244|NCT00725972|EXPERIMENTAL|Augmented Oxygen Delivery Group|"Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.~Intervention: Augment O2 Delivery by hemodynamic protocol. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)"
62149245|NCT00725972|SHAM_COMPARATOR|Control|Patients having the same types of surgery but receiving usual anesthetic care. Intervention: High Risk Surgery. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)
62356600|NCT01118715|NO_INTERVENTION|Control|Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.
62356601|NCT04568187|ACTIVE_COMPARATOR|cryolipolysis machine on Left inner thigh|Zeltiq machine as intervention procedure was carried out on left inner thigh (treated side) for 1 hour through cool sculpting procedure with CIF (Cooling Intensity Factor: -73 mW/cm2).
62356602|NCT04568187|SHAM_COMPARATOR|radiofrequency on right thigh|The radio frequency method was applied on right thigh (control side) as sham procedure for 30 minutes through 3000 Hz- amplitude modulated frequency at once.
62356603|NCT01913197|EXPERIMENTAL|Pre-implant MRI images and planning|
62520458|NCT01274806|EXPERIMENTAL|Physical therapy|
62520459|NCT03035552|EXPERIMENTAL|Treatment prior to surgery|Infants randomized to receive the pacifier activated music player and mother's voice treatment prior to surgery for 5 sessions, and mother's voice playing freely post surgery.
62520460|NCT03035552|EXPERIMENTAL|Treatment post surgery|Infants randomized to receive the mother's voice playing freely prior to surgery,and pacifier activated music player and mother's voice treatment post surgery for 5 sessions.
62520461|NCT02980302|OTHER|Patient|
62711228|NCT05678946||Social Holidays|Participation in face-to-face Social Holidays for family caregivers organized by Maaseudun Terveys- ja Lomahuolto (MTLH), a non-profit organization
62711229|NCT05678946||Face-to-face rehabilitation|Participation in face-to-face rehabilitation services for family caregivers and the care recipients organized by Kela
61974892|NCT03453307||Group-1|NSCLC patients receiving chemotherapy or target therapy treatment.
62520462|NCT02980302|OTHER|Asymptomatic carrier|Father of the patient : asymptomatic carrier of the same mutation
62520463|NCT02980302|OTHER|Two control patients|
62711230|NCT01960491|EXPERIMENTAL|Device Closure of Atrial Septal Defect|
62711231|NCT01276704|EXPERIMENTAL|flaxseed lignan, SDG|Secoisolariciresinol diglycoside
62711232|NCT01276704|PLACEBO_COMPARATOR|Placebo|Matched Placebo
62711233|NCT04079660||Surgical patients|Diabetic patients scheduled to undergo non-cardiac surgery
62711234|NCT00286637||Cross-Sectional Study|Subjects will undergo a comprehensive ocular examination at every visit. Frequency of the visits is dictated by the treating physician, disregarding participation in the study. In glaucoma clinic patients are typically scheduled for visits every six months, and the frequency of visits varies according to clinical severity in the retina clinic. No additional research visits are required beyond the clinically dictated schedule.
62520464|NCT02749292|ACTIVE_COMPARATOR|B cell reconstitution|Subjects will not receive their regularly-scheduled every-six-month dose of rituximab and will instead receive rituximab 1000 mg IV x 1 dose once peripheral B cells return ( ≥ 10 B cells/mm3). This cycle will then re-start. Subjects will be seen in clinic every three months. Patients will continue to be dosed with rituximab each time the B cell count rises to 10 cells/mm3. In the unique scenario that the B cells are detectable, but less than the threshold of 10 cells/mm3, subjects will be asked to return in 6 weeks for repeat B cell testing.
62520465|NCT02749292|ACTIVE_COMPARATOR|Serologic ANCA flare|Subjects will not receive regularly scheduled every six-month doses of rituximab (1000mg IV) and will instead be seen in clinic for ANCA titer monitoring every 3 months. Re-dosing will occur upon a significant ANCA titer increase. For MPO, a significant rise will be defined as a 5-fold rise in ANCA titer and a level greater than 4 times the cutoff value for the assay. For PR3, a significant rise will be defined as a 4-fold rise in ANCA titer to a level at least twofold above the cutoff for the assay. Subjects who sustain a significant increase in ANCA titer will receive rituximab 1000mg IV x 2 doses, spaced \~2-3 weeks apart. If the ANCA titer remains two-fold above baseline and above a specified threshold (the cutoff value of the assay for PR3 and 4 times the cutoff value for MPO) , subjects will continue to receive rituximab 1000mg IV every 6 months for a maximum of 2 doses, at which time a new baseline ANCA titer will be established and the cycle will re-start.
61974893|NCT04235270|EXPERIMENTAL|Group 1 (Bioequivalence Part)|Participants will receive Treatment A (single oral dose of an fixed dose combination \[FDC\] of macitentan/tadalafil \[10 milligram \[mg\]/40 mg\] in fasted conditions \[test\]) or Treatment B (single oral dose of a free combination of 10 mg macitentan and 40 mg tadalafil in fasted conditions \[reference\]) on Day 1 of Treatment Period 1 followed by Treatment B or Treatment A on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
62356604|NCT04241146|ACTIVE_COMPARATOR|Standard Blind Technique of Tube placement|FDA approved technique of enteral nutrition tube placement
62356605|NCT04241146|ACTIVE_COMPARATOR|CORTRAK enteral access system (CEAS) placement|An electromagnetic device used to enable enteral nutrition tube placement
62356606|NCT00888069|EXPERIMENTAL|Low Dose CTAP101 Capsules|CTAP101 Capsules, 450 mcg dose
62356607|NCT00888069|EXPERIMENTAL|High Dose CTAP101 Capsules|CTAP101 Capsules, 900 mcg dose
62356608|NCT00888069|EXPERIMENTAL|CTAP101 Injection|IV injection, 448 mcg dose
62356609|NCT00801892|ACTIVE_COMPARATOR|1 subjects treated with CPAP|Continuous Positive Airway Pressure treatment (CPAP)
62356610|NCT00801892|SHAM_COMPARATOR|2 subjects treated with sham-CPAP|Sham Continuous Positive Airway Pressure treatment (sham-CPAP)
62356611|NCT00503737|ACTIVE_COMPARATOR|Colorectal Cancer Screening Toolkit|Toolbox includes tools and guides designed increase screening by primary care physicians
62356612|NCT00503737|NO_INTERVENTION|Standard of Care Colorectal Cancer Screening|Primary Care physician will screen for colorectal cancer as per his/her standard practice
62356613|NCT03909672|EXPERIMENTAL|Cupping therapy with 2 suctions|Participants in the intervention group will receive the application of cupping therapy with two acrylic type 1 cups with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally. This group will consist of the application of windsheets with 2 suctions for 10 minutes, once a week, for 10 weeks. The cups shall be secured by means of elastic bands.
62356614|NCT03909672|PLACEBO_COMPARATOR|Cupping Therapy sham|"The placebo group will receive the application of cupping therapy with 2 cups of acrylic type size 1 with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of applying the sham winds for 10 minutes, once a week for 10 weeks.~However, the cups will be made with small holes \<2 mm in diameter to release the negative pressure in seconds. The cups will also be fixed by means of elastic bands."
62356615|NCT04103775|EXPERIMENTAL|Cognitive Remediation|Cognitive Remediation comprises of six exercises supplied by BrainHQ by Posit Science Corporation: Sound Sweeps (targets auditory processing speed): Two successive frequency-modulated tone sweeps are presented and participants indicate whether the frequency increased or decreased within each tone: Fine Tuning (targets auditory perception and processing speed): Participants indicate which one of two confusable syllables were presented; Syllable Stacks (targets auditory memory); Users report the order of presented syllables in a serial memory span task; Memory Grid (targets auditory memory); Participants match identical cards representing syllables; To do List Training (targets auditory memory): Participants see a g rid of everyday items (e.g., plant, carrots, shovel) and select the items in accordance with spoken instructions; Rhythm Recall (target auditory memory): Participants recreate auditory melodies
62356616|NCT04103775|ACTIVE_COMPARATOR|Active Control|Active Control Comprises six exercises also supplied by Post Science Corporation: A Maze Race, Reversi, Bricks Breaking Hex, Word Search II, Bricks Squasher II, and CircloO. These are all common computer games freely offered online.
62356617|NCT00571688|EXPERIMENTAL|Risperdal Consta|Risperdal Consta injection in conjunction with existing treatment
62356618|NCT00571688|ACTIVE_COMPARATOR|Treatment As Usual|Clinician and patient decide upon treatment, as in a non-research clinical setting. The only treatment exclusion is any form of risperidone.
62356619|NCT04724512|ACTIVE_COMPARATOR|polypropylene|patients randomised to receive polypropylene sutures.
62356620|NCT04724512|ACTIVE_COMPARATOR|polyglactin|patients randomised to receive polyglactin sutures.
62356621|NCT05382962|EXPERIMENTAL|Intervention: iCanCope Post-Op App|Adolescents randomized to the intervention group will receive the iCanCope PostOp app, in addition to usual care. Both groups will complete measures at pre-operative appointments following consent and randomization (6-8 weeks prior to surgery, T0), at 1-week pre-op (T1), 2-week post-op, (T2) and 4-week post-op (T3), and 12-week post-op (T4).
62356622|NCT05382962|NO_INTERVENTION|Control: Usual Care|Adolescents randomized to the control group will receive usual care. Both groups will complete measures at pre-operative appointments following consent and randomization (6-8 weeks prior to surgery, T0), at 1-week pre-op (T1), 2-week post-op, (T2) and 4-week post-op (T3), and 12-week post-op (T4).
62356623|NCT05982834|EXPERIMENTAL|Disitamab Vedotin combined with fruquintinib and Tislelizumab|
62149246|NCT03737110|EXPERIMENTAL|Rilonacept|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to double-blinded administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL \[either on the same day or separated by no more than 7 days\]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept \[or 4.4 mg/kg for pediatric participants\]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
62356624|NCT00716339|ACTIVE_COMPARATOR|1|motivated
62711235|NCT00286637||Longitudinal Study|Subjects will undergo a comprehensive ocular examination at every visit. Frequency of the visits is dictated by the treating physician, disregarding participation in the study. In glaucoma clinic patients are typically scheduled for visits every six months, and the frequency of visits varies according to clinical severity in the retina clinic. No additional research visits are required beyond the clinically dictated schedule.
61974894|NCT04235270|EXPERIMENTAL|Group 2 (Food-effect Part)|Participants will receive Treatment C (single oral dose of an FDC of macitentan/tadalafil \[10 mg/40 mg\] in fed conditions \[test\]) or Treatment D (single oral dose of an FDC of macitentan/tadalafil (10 mg/40 mg) in fasted conditions \[reference\]) on Day 1 of Treatment Period 1 followed by Treatment D or Treatment C on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
61974895|NCT06108791|ACTIVE_COMPARATOR|HIGH FIO2|will include 50 patients: each one will receive intraoperatively a high concentration of oxygen (80% oxygen + 20% air), following extubation, high-concentration oxygen supplementation will be maintained and given through non-rebreathing face mask with a reservoir at 10 L/min for 2 h.
61974896|NCT06108791|PLACEBO_COMPARATOR|LOW FIO2|will include 50 patients: each one will receive intraoperatively standard concentration oxygen (33% oxygen + 66% air) followed by oxygen supplementation through the standard Venturi face mask of 30%
61974897|NCT06371118|ACTIVE_COMPARATOR|Control group|An invitation to attend a cervical cancer screening in a clinical setting will be sent by post to the woman's address.
61974898|NCT06371118|EXPERIMENTAL|Intervention 1 (directly mailed group)|The HPV self-sampling test will be sent by post directly to the woman's address.
62149247|NCT03737110|PLACEBO_COMPARATOR|Placebo|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to placebo SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL \[either on the same day or separated by no more than 7 days\]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept \[or 4.4 mg/kg for pediatric participants\]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
62149248|NCT04159545||Participants treated with DAAs|"Participants identified through the standard pathway of care as receiving Direct-Acting Antiviral (DAA) drugs to treat chronic hepatitis C with a history of problematic substance use.~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
62356625|NCT00716339|NO_INTERVENTION|2|control
62356626|NCT00535691|ACTIVE_COMPARATOR|1|Tacrolimus ointment 0.03% once daily, placebo once daily
62356627|NCT00535691|ACTIVE_COMPARATOR|2|Tacrolimus ointment 0.03% twice daily
62356628|NCT01072968|EXPERIMENTAL|BF2.649|BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
62356629|NCT01072968|PLACEBO_COMPARATOR|Placebo|Capsules of placebo containing lactose with low, medium and high dosage
62356630|NCT05461183||Readmission/ SMM post-delivery discharge|All women aged 15-49 who were readmitted up to six weeks post-delivery discharge and/or experienced at least one SMM event up to six weeks post-delivery
62356631|NCT05461183||De novo readmission/ SMM post-delivery discharge|All women aged 15-49 who were readmitted up to six weeks post-delivery discharge and/or experienced at least one SMM event post-delivery, excluding those who experienced a SMM in the two months before delivery or during delivery hospitalization
61974899|NCT06371118|EXPERIMENTAL|Intervention 2 (opt-in group)|The HPV self-sampling test will be sent by post directly to the woman's address after a opt-in procedure.
61974900|NCT01569490|EXPERIMENTAL|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
61974901|NCT01569490|ACTIVE_COMPARATOR|Attendance incentive|Incentives for only attending the biochemical verification visits
61974902|NCT03059498|ACTIVE_COMPARATOR|unilateral PECS block patients|unilateral PECS I and II block using bupivacaine
61974903|NCT03059498|ACTIVE_COMPARATOR|bilateral PECS block patients|bilateral PECS I and II block using bupivacaine
61974904|NCT02630550||Aortic Aneurysm Repair|The impact of large abdominal retractors and an abdominal aortic cross-clamp on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
61974905|NCT02630550||Femoral Endarterectomy|The impact of the clamping of a large peripheral arterial vessel on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
62356632|NCT05461183||No post-delivery discharge readmission/ SMM at any time (CONTROL)|All women aged 15-49 who did not experience post-delivery discharge readmission and/or SMM at any time
62356633|NCT00546234|ACTIVE_COMPARATOR|1|
62356634|NCT00546234|ACTIVE_COMPARATOR|2|
62356635|NCT01467661|EXPERIMENTAL|SPD422 (anagrelide hydrochloride)|
62356636|NCT04643665||No grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having not a grade 3 Pulmonary graft dysfunction at postoperative day 3
62356637|NCT04643665||Grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having a grade 3 Pulmonary graft dysfunction at postoperative day 3
62711236|NCT00286637||Reproducibility Study|Subjects willing to participate in the reproducibility arm of the project will undergo the same comprehensive ocular examination as in the longitudinal and cross-sectional study arms. However, OCT scanning will be repeated up to five times within a single visit. The participants will be requested to repeat the visual field and OCT scanning in up to 5 additional independent visits within a month to minimize the possibility that an actual change in ocular structures has occurred. Duration of each additional visit will be up to 45 minutes.
62711237|NCT00286637||Alzheimer's Disease (AD) Sub-Study|Participants with AD or mild cognitive impairment (MCI) undergo the same comprehensive ocular examination as in the longitudinal and cross-sectional study arms.
61974906|NCT02388945|EXPERIMENTAL|A APDGroup|PDGO APD machines used in the PD patients for 8 weeks
62356638|NCT01223040|EXPERIMENTAL|SYSTANE® Balance Lubricant Eye Drops|SYSTANE Balance Lubricant Eye Drops dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
62356639|NCT03601793|EXPERIMENTAL|Internet intervention with assistance|This arm is given access to the internet intervention Alcohol Help Center with email assistance from a health educator during the first two weeks after randomization.
62711238|NCT01935388|EXPERIMENTAL|Common canister|Use of a single MDI (instead of assigning each patient an individual MDI) for multiple mechanically ventilated patients. Inhalers will undergo a stringent cleaning protocol between administrations and storage.
62711239|NCT01935388|NO_INTERVENTION|Control|Each patient will be assigned an individual inhaler as per standard of care practice.
62711240|NCT05685303|EXPERIMENTAL|Treatment|Subjects randomized to the treatment arm will undergo cardiac imaging, femoral vein access and receive the Alleviant ALV1 System device procedure.
62711241|NCT05685303|SHAM_COMPARATOR|Control|Subjects randomized to the control arm will undergo cardiac imaging and sheath placement in femoral vein.
62711242|NCT00619996|EXPERIMENTAL|1|
61974907|NCT02388945|ACTIVE_COMPARATOR|B CAPDGroup|CAPD used in the PD Patients for 8 weeks
61974908|NCT04404751|ACTIVE_COMPARATOR|Arm 1|
61974909|NCT04404751|ACTIVE_COMPARATOR|Arm 2|
61974910|NCT04404751|SHAM_COMPARATOR|Arm 3|
61974911|NCT01793675||haploidentical transplant|transplant with haploidentical donor
61974912|NCT03107325|OTHER|F-18 FDG|Only patients scheduled for a whole body PET scan will be eligible. Subjects of all ages will be imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
61974913|NCT06357598|EXPERIMENTAL|Experimental Group|Participants receive 2-4 cycles of Tislelizumab combined with chemotherapy treatment during preoperative period, every 3 weeks for 4 cycles at most.
61974914|NCT01573572|EXPERIMENTAL|Intravitreal Injections of Macugen|
61974915|NCT04387851||Placebo|Placebo effects are defined as the positive effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have positive effects.
61974916|NCT04387851||Nocebo|Nocebo effects are defined as the negative effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have negative effects.
61974917|NCT05677750||newly diagnosed aplastic anemia, ITP, AIHA, Evan syndrome|"40 patients with newly diagnosed aplastic anemia, ITP, AIHA, Evan syndrome. aged one year and older attending Pediatric Hematology Unit at Children University Hospital in Assiut Univesity will undergo the following:~1. History\& Physical Examination:~   History and physical findings will be recorded on a standard data collection sheet.~2. Bone marrow aspirate and biopsy:~3. CD 55, CD 59 Flowcytometric markers:~4. PCR for COVID-19\& Antibody for COVID-19~5. Biologic (Lab) tests:~Venous blood samples were obtained for:~* CBC with reticulocytic count and differential~* Platelet lymphocyte ratio\&neutrophil lymphocyte ratio~* Coagulation profile with PT, PC, INR, PTT~* Inflammatory markers(ESR,CRP)~* Serum ferritin, fibrinogin, D-dimer,."
61974918|NCT02326025|EXPERIMENTAL|Part A|"Doxorubicin Alone: On Cycle 1, Day 1, participants received 75 milligram/square meter (mg/m2) of doxorubicin intravenously (IV).~Olaratumab Alone: On Cycle 1, Day 10, participants received 15 milligram/kilogram (mg/kg) of olaratumab IV.~Olaratumab + Doxorubicin: For Cycles 2 to 8, participants received 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, IV and 75 mg/m2 of doxorubicin IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onward, until discontinuation criteria are met."
61974919|NCT02326025|EXPERIMENTAL|Part B|"Doxorubicin Alone: On Cycle 1, Day 1, participants received doxorubicin 75 mg/m2 IV~Olaratumab Alone: On Cycle 1, Day 10, participants received 20 mg/kg of olaratumab IV.~Olaratumab + Doxorubicin:~For Cycle 2, participants received 20 mg of olaratumab on Days 1 and 8 of each 21-day cycle, IV. On Day 1 of Cycle 2, doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~For Cycles 3 - 8, Day 1 and 8, olaratumab 15 mg/kg was administered and on Day 1 doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onwards, until discontinuation criteria are met."
61974920|NCT00040664|EXPERIMENTAL|2 to 5 years (FPV/RTV)|Two to five years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
61974921|NCT00040664|EXPERIMENTAL|6 to 11 years (FPV/RTV)|Six to twelve years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
61974922|NCT00040664|EXPERIMENTAL|12 to 18 years (FPV/RTV)|Twelve to Eighteen years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
62356640|NCT03601793|ACTIVE_COMPARATOR|Internet intervention without assistance|This arm is given access to the internet intervention Alcohol Help Center without any assistance from a health educator.
62520466|NCT01277718|EXPERIMENTAL|Treatment A first, then Treatment B, followed by Treatment C|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.
62520467|NCT01277718|EXPERIMENTAL|Treatment A first, then Treatment C, followed by Treatment B|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.
62520468|NCT00992368|ACTIVE_COMPARATOR|reduction mammaplasty|submitted to surgery
62520469|NCT00992368|NO_INTERVENTION|not reduction mammaplasty|not submitted to surgery
62520470|NCT02156141|EXPERIMENTAL|Supervised high intensity training|"8 weeks of supervised high intensity training, 10 minutes, 3 times a week (once a week supervised) on a cycle ergometer followed by 8 weeks of unsupervised optional training.~Participants: Patients with Kennedy's disease or healthy control subjects (individually matched with patients).~Participants: Patients with Kennedys disease and healthy control subjects."
62520471|NCT02156141|EXPERIMENTAL|Unsupervised High intensity training|"8 week control period with no training followed by 8 weeks of unsupervised high intensity training on a cycle ergometer.~Participants: Patients with Kennedy's disease."
62520472|NCT02467608|EXPERIMENTAL|Isoniazid with HUEXC030 and RZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 \[H\], rifampin \[R\], pyrazinamide \[Z\] and ethambutol \[E\]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin \[R\]: 450\~600mg daily, pyrazinamide \[Z\]; 1000\~2000mg daily and ethambutol \[E\]: 800-1600mg daily)"
62149249|NCT04159545||Control Group|"Participants identified through the standard pathway of care as having HCV positive antibodies who spontaneously clear the infection.~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
62149250|NCT01037868|EXPERIMENTAL|Supportive SMS messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
62520473|NCT02467608|OTHER|Isoniazid|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid \[H\], rifampin \[R\], pyrazinamide \[Z\] and ethambutol \[E\]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid (H):300mg daily, rifampin \[R\]: 450\~600mg daily, pyrazinamide \[Z\]; 1000\~2000mg daily and ethambutol \[E\]: 800-1600mg daily)"
61974923|NCT00075179|EXPERIMENTAL|Nesiritide|Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
62520474|NCT02575612|EXPERIMENTAL|vacuum-assisted biopy|All patients enrolled in this study received a vacuum-assisted biopsy before surgery.
61974924|NCT00450450|EXPERIMENTAL|Arm I|Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.
61974925|NCT00450450|ACTIVE_COMPARATOR|Arm II|Patients undergo conventional allogeneic bone marrow transplantation on day 0.
61974926|NCT04413409|EXPERIMENTAL|surgical group|The metastatic sites are firstly treated by surgery then followed by systemic treatment
61974927|NCT04413409|NO_INTERVENTION|systemic group|After confirmation of puncture, receive systemic treatment
62149251|NCT01037868|NO_INTERVENTION|No supportive SMS text message|Patients in the non-intervention group would also receive text messages once every fortnight thanking them for participating in the study and a monthly phone call which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
62149252|NCT03349944|ACTIVE_COMPARATOR|Moderate intensity training|Moderate continuous exercise three times pr. week for 50 min.
61974928|NCT01545986|EXPERIMENTAL|High Velocity Exercise|The high velocity exercise group performed the concentric contraction phase of resisted exercise in one second or less. This group performed sit to stand exercise, walking, curbs, and stairs as fast as was comfortable without an increased limp. Other exercises were performed at the participant preferred rate.
62520475|NCT05978908|EXPERIMENTAL|SAD study in Healthy adult participants|A total of 24 healthy adult participants will be enrolled, and then sequentially allocate to 3 planned dose cohorts (A1-A3): 4 mg, 8 mg and 16 mg, respectively.
62520476|NCT05978908|PLACEBO_COMPARATOR|Placebo|Placebo
62520477|NCT02916693|EXPERIMENTAL|Mirabegron|Participants take 25- 50mg oral Mirabegron tablets daily for 12 weeks,
62520478|NCT04870723|EXPERIMENTAL|Immediate|Behavioral: Motivational interviewing (MI)-based peer counseling: MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness.
62520479|NCT04870723|OTHER|Waitlist|"Behavioral: Motivational interviewing (MI)-based peer counseling: After the immediate group completes the intervention, the waitlist group will receive the intervention.~MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness."
62520480|NCT02775136|EXPERIMENTAL|HS-1000 recording|Non-invasive measurements duration with HS-1000 device will be for at least 30 minutes and up to 1 hour of aggregate recording either continuously in the event the patient's clinical condition allows it or in separate recording iterations in the event patient's condition will not allow continuous recording. For each patient, there may be several monitoring intervals from three times a day and up to as long as the patient undergoes brain monitoring, per the discretion of the investigator, patient and/or family members.
62520481|NCT05529472|EXPERIMENTAL|Peripheral Orbital Atherectomy System (OAS)|Treatment with Cardiovascular Systems, Inc. (CSI) Orbital Atherectomy System (OAS) followed by Percutaneous Old Balloon Angioplasty (POBA) pre-dilation and Medtronic IN.PACT™ Admiral™ Drug Coated Balloon (DCB)
62520482|NCT03823235|EXPERIMENTAL|Culture of human embryo in non-humidified incubator|Embryo culture after in vitro fertilization in incubator with no humidity
62520483|NCT03823235|NO_INTERVENTION|Culture of human embryo in humidified incubator|Embryo culture after in vitro fertilization in incubator with humidity
62520484|NCT01904006|EXPERIMENTAL|New Culture Condition|Intervention group embryos cultured grouped under low oxygen tension in benchtop incubators.
61974929|NCT01545986|ACTIVE_COMPARATOR|Low Velocity exercise|The low velocity exercise group performed the concentric contraction phase of resisted exercise in two seconds. This group performed sit to stand exercise, walking, curbs, stairs, and other exercises at the participant preferred rate.
62356641|NCT06051851|EXPERIMENTAL|Trial group|penpulimab in combination with anlotinib and AG regimen in the first-line treatment of advanced metastatic pancreatic cancer
62356642|NCT06051851|ACTIVE_COMPARATOR|Control group|AG regimen in the first-line treatment of advanced metastatic pancreatic cancer
62356643|NCT03815812|EXPERIMENTAL|IBI306|Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
62356644|NCT03815812|PLACEBO_COMPARATOR|placebo|Participants received matching placebo dose regimen by subcutaneous injection.
62356645|NCT01667458||Cohort|
62356646|NCT01451398|EXPERIMENTAL|TI inhalation powder|Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
62356647|NCT01451398|PLACEBO_COMPARATOR|Technosphere powder|Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
62356648|NCT06185478|EXPERIMENTAL|Imaging|
62356649|NCT00268463|ACTIVE_COMPARATOR|Arm 1: Capecitabine + Oxaliplatin|Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
62356650|NCT00268463|EXPERIMENTAL|Arm 2: Floxuridine + Oxaliplatin + Capecitabine|Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
62356651|NCT04521920|EXPERIMENTAL|Medication and telemedicine follow up|All participants are provided with Suboxone and/or PrEP and follow up visits will be conducted via telemedicine
62520485|NCT01904006|ACTIVE_COMPARATOR|Standard Culture Condition|Control group embryos cultured individually under atmospheric oxygen tension in large-box incubators.
62520486|NCT02274207|EXPERIMENTAL|silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
62520487|NCT02274207|ACTIVE_COMPARATOR|non-silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
62520488|NCT05449509||High-SYNTAX score patients|
62520489|NCT05449509||Intermediate/low-SYNTAX score patients|
62520490|NCT04464993|EXPERIMENTAL|CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app and a Fitbit watch to use throughout the 16-week intervention.The Fitbit will provide device-based behavioral feedback through the StandUPTV self-monitoring component. SST feedback will be Self-monitoring will provide passive and objective feedback regarding SST behaviors and MVPA drawn from Fitbit and SCREENTIME sources. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
62520491|NCT04464993|EXPERIMENTAL|CORE + text|CORE components + The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV app) that will provide simple adaptive content based upon length of most recent SST bout and time of day. These prompts will specifically target outcome expectations around SST and MVPA.
61974930|NCT03792282|EXPERIMENTAL|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
62356652|NCT01699646|ACTIVE_COMPARATOR|CTG + FBS|intrapartum surveillance with CTG+FBS
62356653|NCT01699646|ACTIVE_COMPARATOR|Neoventa S 21 ST-ANalysis of fetal heart|intrapartum surveillance with CTG + STAN
62520492|NCT04464993|EXPERIMENTAL|CORE + Lockout|CORE components + Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided with a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
62520493|NCT04464993|ACTIVE_COMPARATOR|CORE + Earn|CORE components + the investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
62520494|NCT04464993|ACTIVE_COMPARATOR|CORE + Text + Earn|"Intervention components will be delivered as described in simpler factorial conditions.~App shows progress toward SST goal or if goal is exceeded. Can earn additional SST through exercise based on 3:1 ratio , simple adaptive content (by SST bout, time of day). Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation."
62520495|NCT04464993|ACTIVE_COMPARATOR|CORE + Text + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Simple adaptive content (by SST bout, time of day)."
62520496|NCT04464993|ACTIVE_COMPARATOR|CORE + Earn + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio."
62711243|NCT05489471||Adult Chest Radiographs|All chest X-rays for patients over 16 years from either a GP referral or performed in the Emergency department (ED) of the acute hospital, which includes Accident and Emergency attendances and in-patient studies.
62149253|NCT03349944|EXPERIMENTAL|High intensity training|High intensity interval training three times pr. week for 15 min.
62356654|NCT03097718||Non-specific low back pain|Individuals with recurrent non-specific low back pain
62356655|NCT03097718||Healthy control subjects|Healthy individuals without low back pain
62356656|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
62356657|NCT03162029||control group|CBCT imaging of medically-free participants
62356658|NCT04319406|EXPERIMENTAL|PROLOTHERAPY|Prolotherapy will be performed with 12.5 % Dextrose into superior joint space of involved TMJ
62356659|NCT04319406|ACTIVE_COMPARATOR|DRY NEEDLING|Dry needling will be performed into superior joint space of involved TMJ
62356660|NCT03039738|ACTIVE_COMPARATOR|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
62356661|NCT03039738|EXPERIMENTAL|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
62356662|NCT02692313|PLACEBO_COMPARATOR|Saline infusion|Hyperinsulinemic euglycemic glucose clamp with saline infusion
62356663|NCT02692313|EXPERIMENTAL|Epinephrine infusion-0.015ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
62356664|NCT02692313|EXPERIMENTAL|Epinephrine infusion-0.03 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
62356665|NCT02692313|EXPERIMENTAL|Epinephrine infusion-0.06 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
62356666|NCT04377672|EXPERIMENTAL|Anti- SARS-CoV-2 Plasma|Human Convalescent Plasma
61974931|NCT03792282|ACTIVE_COMPARATOR|Usual care|Participants in this group will receive a general lifestyle counseling.
61974932|NCT06090279|EXPERIMENTAL|OmniFlow Breathing Therapy BioFeeback System|This system is a FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab.
61974933|NCT01881776|ACTIVE_COMPARATOR|Single ISB (SISB) group|Patients in this group received single injection (SISB) interscalene brachial plexus block
61974934|NCT01881776|ACTIVE_COMPARATOR|Continuous ISB (CISB) group|Patients in this group received continuous (CISB) interscalene brachial plexus block
61974935|NCT01881776|NO_INTERVENTION|General anesthesia (GA) group|Patients in this group received general anesthesia (GA)
61974936|NCT03629067|EXPERIMENTAL|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)~There will be a 14 washout of days between the each period."
61974937|NCT03629067|EXPERIMENTAL|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
62149254|NCT00525122||1|Patients with hyperthyroidism who are will be treated with radioactive iodine.
62356667|NCT00927719||ACAM2000® vaccinia vaccine Cohort|Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.
62356668|NCT05281848|ACTIVE_COMPARATOR|Smoker-Periodontitis; Non-surgical periodontal treatment|
62356669|NCT05281848|ACTIVE_COMPARATOR|Nonsmoker-Periodontitis;Non-surgical periodontal treatment|
62356670|NCT05281848|NO_INTERVENTION|Healthy|
62356671|NCT02667457|EXPERIMENTAL|CAD Participants|Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an intraveneous (IV) catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
62356672|NCT02667457|EXPERIMENTAL|Healthy Participants|Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
62356673|NCT00562640|EXPERIMENTAL|WT1-Specific T Cells|This is a phase I dose escalating trial designed to identify tolerable, clinically active doses of Wilms' tumor gene (WT1) peptide sensitized T cells when administered alone or with nonmyelosuppressive chemotherapy in patients with recurrent or persistent, evaluable WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas.
62520497|NCT04464993|ACTIVE_COMPARATOR|CORE + Earn + Lockout + Text|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio). Simple adaptive content (by SST bout, time of day)."
62356674|NCT04975672|EXPERIMENTAL|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances|The participant will receive a session of myofunctional therapy every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system.
62356675|NCT04975672|EXPERIMENTAL|Group 2, without myofunctional therapy and SN1 functional orthopedic appliances.|Once the investigation is finished, the patient will decide whether or not to perform myofunctional therapy one every month, for 9 months.
62520498|NCT04691180|EXPERIMENTAL|Cohort 1|BRII-196 and BRII-198 dose level 1 or placebo
62520499|NCT04691180|EXPERIMENTAL|Cohort 2|BRII-196 and BRII-198 dose level 2 or placebo
62520500|NCT04231734|EXPERIMENTAL|All Subjects|Low tumor burden, treatment-naïve MCL
62520501|NCT00584441||1|Women with pre-menstrual asthma (PMA): As defined by a 20% or more fall in PEFR and / or change by 20% or more of daily symptom score.
62520502|NCT00584441||2|Women without pre-menstrual asthma
62520503|NCT00584441||3|Women on oral contraceptives
62520504|NCT01099059|ACTIVE_COMPARATOR|Ritalin|receive ritalin depending on weight
62520505|NCT01099059|EXPERIMENTAL|Amantadine|100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for \>30 Kg)
62520506|NCT05120323|EXPERIMENTAL|vDOT Intervention Group|The VDot group will submit videos via app to Emocha to have their inhaler technique graded to assess their inhaler technique.
62520507|NCT05120323|NO_INTERVENTION|Standard Asthma Care Group|Participants in the standard asthma care group will receive standard of care asthma education conducted by a respiratory therapist in the specialty clinics at Arkansas Children's Hospital at the baseline visit. Education will include standard of care instruction on the participant's prescribed asthma medications, how to use an asthma action plan, as well as training and demonstration of proper inhaler technique. They will not have any additional study activities until the 3-month visit. They will be instructed to take their medications as prescribed.
62520508|NCT02426047|EXPERIMENTAL|Modified Atkins diet plus betaquik®|Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).
62520509|NCT03277209|EXPERIMENTAL|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
62520510|NCT02316249|ACTIVE_COMPARATOR|Gellhorn Pessary|Patients who are fitted with a Gellhorn pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
62520511|NCT02316249|ACTIVE_COMPARATOR|Ring with Support Pessary|Patients who are fitted with a Ring with Support Pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
62520512|NCT02621034|EXPERIMENTAL|Control|K-file hand instrumentation
62520513|NCT02621034|EXPERIMENTAL|Reciproc|rotary reciprocating protocol
62520514|NCT02621034|EXPERIMENTAL|One shape|one shape continuous rotation protocol
62520515|NCT02969993|EXPERIMENTAL|Questionnaire|Questionnaire to previously operated patients
62520516|NCT01748331|OTHER|Strict fluid restriction < 1 L/day|20 patients will be randomized to strict fluid restriction \< 1 L/day
61974938|NCT03629067|EXPERIMENTAL|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
61974939|NCT05294445|ACTIVE_COMPARATOR|Group1: Cryo-AF-Ablation|Patients randomized in the Cryo-AF-Ablation group should receive the cryo AF ablation within 21 days from baseline.
62520517|NCT01748331|OTHER|Moderate fluid restriction < 2.5 L/day|20 patients will be randomized to moderate fluid restriction \< 2.5 L/day
62520518|NCT02384694|EXPERIMENTAL|Intervention|Zumba dance intervention
61974940|NCT05294445|NO_INTERVENTION|Group 2: Usual care|Patients randomized in the usual care group should start or maintain on AAD therapy within 21 days from baseline, based on decision of the investigator according to current ESC Guidelines.
61974941|NCT06295263||Parkinson Disease group|100 patients with primary Parkinson's disease were included, mainly from outpatient clinics and wards of the Parkinson's Disease and Movement Disorders Center. Inclusion criteria: patients with primary Parkinson's disease, based on the 2015 MDS Parkinson's disease diagnostic criteria. Exclusion criteria: ① patients suffering from other central nervous system diseases, such as cerebrovascular disease, traumatic brain injury, central system inflammatory diseases, intracranial tumors and postoperative neurosurgery; ② patients with various types of cognitive disorders (MMSE score \<24); ③ severe psychiatric disorders that are difficult to cooperate.
61974942|NCT06295263||Alzheimer Disease group|One hundred patients with Alzheimer's disease were included, mainly from geriatric neurology outpatient clinics and wards (F5A \& F6A). Inclusion criteria: patients with Alzheimer's disease, meeting the IWG-2 clinical diagnostic criteria as the basis. Exclusion criteria: ① patients suffering from other central nervous system diseases, such as cerebrovascular disease, traumatic brain injury, central system inflammatory diseases, intracranial tumors and postoperative neurosurgery; ② severe psychiatric illnesses that are difficult to cooperate with.
61974943|NCT06295263||Nervous System Diseases group|Neurodegenerative diseases (non-PD non-AD) group 100: source neurology outpatient clinic visits, exclusion criteria: ① patients suffering from other central nervous system diseases, such as cerebrovascular disease, traumatic brain injury, central system inflammatory diseases, intracranial tumors and neurosurgery postoperative; ② severe psychiatric diseases difficult to cooperate with the person.
62520519|NCT01546935|EXPERIMENTAL|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
62520520|NCT02014077|ACTIVE_COMPARATOR|Thoracostomy Tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube for traumatic haemothorax
62520521|NCT02014077|ACTIVE_COMPARATOR|VATS|patients selected for VATS after failure of first thoracostomy tube drainage of traumatic haemothorax will undergo a Video-Assisted Thoracoscopic clearance of the persistent/retained haemothorax
62149255|NCT04898582|OTHER|20 women 20-60 years old with sensitive skin and persistent centrofacial erythema of rosacea|"The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions. The subjects were allowed to use their habitual foundation and makeup products on the whole face.~The side of application of the product M89 Probiotic Fractions (right or left side of the face) was randomized among the subjects.~The assignment of subject number and subsequent placement on the randomization chart were made in order of appearance at the study centre on the first day."
62149256|NCT01651507||HLP|Patients with pulmonary LCH from eight teaching hospitals evaluated between June 1989 and February 2005 were considered for this study, if they were followed for at least 6 months and evaluated by ≥ 2 lung HRCT and lung function tests at the same time or within a 2 months period
62356676|NCT05320380|EXPERIMENTAL|Cohort 1 (IMGN632)|Patients receive IMGN632 IV on days 1 and 22. Treatment repeats every 42 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62356677|NCT05320380|EXPERIMENTAL|Cohort 2 (IMGN632, CPX-351, ITT, fludarabine, cytarabine)|"CYCLE 1: Patients receive IMGN632 IV on days 1 and 22 and CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients with CNS1 also receive ITT consisting of methotrexate IT, hydrocortisone or prednisolone IT, and cytarabine IT on day 0 of cycle 1 (NOTE: Patients who received IT cytarabine or ITT at time of diagnostic LP do not need to repeat ITT on day 0 if given within 7 days of starting protocol therapy). Patients with CNS2 receive ITT QW until the CSF is clear for a maximum of 6 ITT treatments in the absence of disease progression or unacceptable toxicity.~CYCLE 2: Patients receive ITT on day 0, IMGN632 IV on days 1 and 22, fludarabine IV over 30 minutes QD on days 1-5, and cytarabine IV over 1-3 hours QD on days 1-5 in the absence of disease progression or unacceptable toxicity."
62356678|NCT05320380|ACTIVE_COMPARATOR|Cohort 3, Arm A (CPX-351, fludarabine, cytarabine)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 of cycle 1 in the absence of disease progression or unacceptable toxicity. Patients then receive fludarabine IV over 30 minutes QD on days 1-5 of cycle 2 and cytarabine IV over 1-3 hours QD on days 1-5 of cycle 2 in the absence of disease progression or unacceptable toxicity.
62356679|NCT05320380|EXPERIMENTAL|Cohort 3, Arm B (CPX-351, fludarabine, cytarabine, IMGN632)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 of cycle 1 and IMGN632 IV on days 1 and 22 of cycle 1 in the absence of disease progression or unacceptable toxicity. Patients then receive fludarabine IV over 30 minutes QD on days 1-5 of cycle 2, cytarabine IV over 1-3 hours QD on days 1-5 of cycle 2, and IMGN632 IV on days 1 and 22 of cycle 2 in the absence of disease progression or unacceptable toxicity.
62356680|NCT01231607|ACTIVE_COMPARATOR|1mg Finasteride|1mg finasteride active plus dutasteride placebo, by mouth once daily
62356681|NCT01231607|ACTIVE_COMPARATOR|0.02mg Dutasteride|0.02mg dutasteride active plus finasteride placebo, by mouth once daily
62356682|NCT01231607|ACTIVE_COMPARATOR|0.1mg Dutasteride|0.1mg dutasteride active plus finasteride placebo, by mouth once daily
62356683|NCT01231607|ACTIVE_COMPARATOR|0.5mg Dutasteride|0.5mg dutasteride active plus finasteride placebo, by mouth once daily
62356684|NCT01231607|PLACEBO_COMPARATOR|Placebo|1mg finasteride placebo plus dutasteride placebo, by mouth once daily
62356685|NCT02285504|EXPERIMENTAL|SAGE-547|Participants received SAGE-547 intravenous injection over 60 hours (including 12-hour titration infusion of 21.5 micrograms per kilogram per hour \[mcg/kg/hr\] \[4 hrs\], 43 mcg/kg/hr \[4 hrs\] and 64.5 mcg/kg/hr \[4 hrs\] on Day 1, followed by 13 to 48 hrs \[36 hrs\] maintenance infusion of 86 mcg/kg/hr from Day 1 to 3, followed by a 12-hr taper infusion of 64.5 mcg/kg/hr \[49 - 52 hrs\], 43 mcg/kg/hr \[53 - 56 hrs\] and 21.5 mcg/kg/hr \[57 - 60 hrs\] on Day 3).
62356686|NCT02898142|EXPERIMENTAL|Isolated HTG without metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
62356687|NCT02898142|EXPERIMENTAL|HTG with metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
62356688|NCT03368599|EXPERIMENTAL|Bronchoscope guide group|DLT is advanced into the main bronchus through the guide of fiberoptic bronchoscope (Bronchoscope guided advancement).
62356689|NCT03368599|ACTIVE_COMPARATOR|Conventional group|DLT is advanced blindly to the main bronchus level (Conventional advancement).
62356690|NCT04041141||Oral Cancer|Patients receiving curative radiation treatment for an oral cancer.
62356691|NCT05797194||POD group|Patients were considered to surfer from postoperative delirium by a positive Confusion Assessment Method (CAM) questionnaire after surgery.
62356692|NCT05797194||No-POD group|Patients did not surfer from postoperative delirium by a positive CAM questionnaire after surgery.
62356693|NCT05611515||TORS|Patients operated by Trans-oral Robotic Surgery (TORS)
62356694|NCT05611515||TLM|Patients operated by Trans-oral Laser Microsurgery (TLM)
62356695|NCT05611515||IMRT|Patients treated by Intensity Modulated Radiation Therapy (IMRT)
62520522|NCT04235452||Epileptic myoclonus|Juvenile Myoclonic Epilepsy and Progressive Myoclonic Epilepsy
62520523|NCT04235452||Non-epileptic myoclonus (secondary)|Post hypoxic myoclonus, Post ischemic stroke myoclonus, Hepatic, Chronic kidney disease, and Drug induced myoclonus
62520524|NCT01138111|EXPERIMENTAL|Arm 1|
62711244|NCT04464668||Wave 1 Only: Clinics using CARES Intervention|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics to implement the Colorectal Cancer Awareness, Research, Education \& Screening (CARES) intervention.
62356696|NCT06058936|EXPERIMENTAL|virtual reality|"The patients in this group are under exercise training and pneumatic pressure followed by Pablo©Handle training for 45 minutes per week for 8 week~-Pablo©Handle training One-dimensional therapy games using five games are available for Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Apple hunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week"
62356697|NCT06058936|ACTIVE_COMPARATOR|regular exercises|"The patients in this group will receive exercise training and pneumatic pressure only for 30 min3 times per week for 8 week~* Exercise training will be done by the following exercise for 15 min3 times per week for 8 week~* Intermittent Compression Therapy Parameters: using the (Care Pump expert 8)~* Pressure. 60 mmHg, Direction. Distal to proximal, Speed 4 to 5, for 15 min /3 times per week for 8 week"
62356698|NCT04928391|EXPERIMENTAL|Group D|Dexmedetomidine IV at the end of surgery
62356699|NCT04928391|EXPERIMENTAL|Group N|Nalbuphine IV at the end of surgery
62356700|NCT04928391|PLACEBO_COMPARATOR|Group C|Same volume of saline placebo IV at the end of surgery
62356701|NCT01934933|ACTIVE_COMPARATOR|celebrex|celebrex capsule, 0.2 gram bid, 52 weeks
62356702|NCT01934933|ACTIVE_COMPARATOR|Enbrel|etanercept injection, 25mg per injection, 50mg/week, 52 weeks
62356703|NCT01934933|ACTIVE_COMPARATOR|Enbrel plus Celebrex|50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks
62356704|NCT04078529|EXPERIMENTAL|Intervention group|This group will complete a 5 day falls prevention training programme, followed by a 12 week home exercise programme, then a repeat 5 day training intervention.
62356705|NCT04078529|ACTIVE_COMPARATOR|Comparison group[|This group will complete the home exercise programme only.
62356706|NCT02617017|EXPERIMENTAL|Buspirone|
62356707|NCT02617017|PLACEBO_COMPARATOR|Placebo|
62356708|NCT05097833|EXPERIMENTAL|Enhanced Treatment Group|Randomized group of participants receiving an enhanced Fatherhood FIRE program.
62356709|NCT05097833|ACTIVE_COMPARATOR|Control Group|Randomized group of participants receiving the 'services as usual' Fatherhood program.
62356710|NCT01871207||Diabetic patients|Diabetic patients who underwent vitrectomy for Proliferative Diabetic Retinopathy
62356711|NCT01871207||Non-diabetic patients|Non-diabetic patients who underwent vitrectomy for macular hole or pucker
62356712|NCT05871372|EXPERIMENTAL|Depression Cohort|
62356713|NCT05871372|EXPERIMENTAL|Epilepsy Cohort|
62356714|NCT05054179|EXPERIMENTAL|Intervention Group|The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side of the sternum, followed by infusion of 3 mL/h for 48 hours.
62356715|NCT05054179|PLACEBO_COMPARATOR|Placebo group|The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side of the sternum, followed by infusion of 3 mL/h of normal saline for 48 hours.
62356716|NCT05884281|ACTIVE_COMPARATOR|Intervention|
62356717|NCT05884281|PLACEBO_COMPARATOR|Control|
62356718|NCT03917225|EXPERIMENTAL|MIN-102|MIN-102 (5-\[\[4-\[2-\[5-(1-Hydroxyethyl)-2-pyridinyl\]ethoxy\]phenyl\]methyl\]-2,4-thiazolidinedione hydrochloride (1:1)). Dosing is once daily at approximately the same time each morning throughout the entire treatment phase (48 weeks).
62356719|NCT03917225|PLACEBO_COMPARATOR|Placebo|Matches MIN-102 visually and by taste. Dosing is once daily at approximately the same time each morning throughout the entire treatment phase (48 weeks).
62149257|NCT01970878|EXPERIMENTAL|GFF MDI (PT003)|
62149258|NCT01970878|EXPERIMENTAL|GP MDI (PT001)|
62356720|NCT02245802||Low risk group|CU Prediction model \< 3
62356721|NCT02245802||High risk group|CU Prediction model \>=3
62356722|NCT04159818|EXPERIMENTAL|Control group|no induction treatment, nivolumab 240 mg flat-dose, every 2 weeks
62149259|NCT01970878|EXPERIMENTAL|FF MDI (PT005)|
62149260|NCT01970878|ACTIVE_COMPARATOR|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
62356723|NCT04159818|EXPERIMENTAL|Cisplatin induction|Cisplatin 40mg/m2, weekly for two weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
62356724|NCT04159818|EXPERIMENTAL|Low dose doxorubicin induction|Low dose doxorubicin 15mg flat dose, weekly for 8 weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
62356725|NCT05247385|ACTIVE_COMPARATOR|Prasugrel group|"Prasugrel (60mg loading dose, followed by 10 mg QD for 15 days)~+ Ticagrelor placebo (Placebo loading dose followed by two pills a day)"
62356726|NCT05247385|ACTIVE_COMPARATOR|Ticagrelor group|"Ticagrelor (180mg loading dose, followed by 90 mg BID)~+ Prasugrel placebo (Placebo loading dose followed by one pill a day)"
62356727|NCT05227209|EXPERIMENTAL|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
62356728|NCT00003203|EXPERIMENTAL|Newly diagnosed cerebral PNET with histologic verification|Begin therapy within 31 days of surgery. Radiation therapy will be given in standard fractions along with filgrastim. The craniospinal axis will be treated first. Patients will receive carboplatin at 35 mg/m2/day IV over 15-20 minutes Monday through Friday, 1-4 hours prior to radiation for 6 weeks (total of 30 doses). Vincristine sulfate 1.5 mg/m2 IV will be given weekly x 6. Following radiation, patients will receive Maintenance chemotherapy. Patients enrolled prior to Amendment #5 will receive six cycles of cyclophosphamide and vincristine (Regimen A). Patients enrolled after Amendment #5 will receive six cycles of cyclophosphamide, vincristine sulfate and cisplatin (Regimen B).
62356729|NCT01563107|EXPERIMENTAL|High Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
62520525|NCT02218619|EXPERIMENTAL|Taurourodeoxycholic Acid (TUDCA)|TUDCA 1750 mg/day x 12 months
62711245|NCT04464668||Wave 1 Only: Control Clinics|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics as control (usual care) clinics.
62711246|NCT04464668||All Clinics|For Wave 2, the 7 clinics in the control group will roll out as intervention clinic, thus, all 14 clinics will be exposed to the intervention by year 2.
62520526|NCT02218619|PLACEBO_COMPARATOR|Sugar pill (placebo)|Placebo at same dose, frequency, and duration as experimental treatment
62149261|NCT05172232||Primary care patients with melanoma suspicious skin lesion(s)|Patients seeking primary care, having one or more skin lesion that the primary care physician cannot by certainty can rule out as being a possible melanoma.
62149262|NCT04235998||Systematic lung ultrasound|Patients with unilateral pleural effusion of unknown course
62149263|NCT02434991|EXPERIMENTAL|Barostat|The barostat (a thin tube, with a deflated balloon attached at the end) will be placed through your mouth down your esophagus (swallowing tube) to where your stomach and esophagus meet. The 10-cm long balloon will then be inflated with step by step pressure increases of 4mmHg for 30 seconds each to a maximum pressure of 50mmHg. The patient will rate discomfort during each step of inflation
62149264|NCT03637075|PLACEBO_COMPARATOR|Placebo|Intranasal placebo administration
62520527|NCT04449757|EXPERIMENTAL|bicarbonated ringer's solution|We apply bicarbonated ringer's solution as resuscitation fluid to patients with septic shock.
62520528|NCT04449757|EXPERIMENTAL|lactated ringer's solution|We apply lactated ringer's solution as resuscitation fluid to patients with septic shock.
62520529|NCT04919941|EXPERIMENTAL|Decision aid|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
62520530|NCT04919941|NO_INTERVENTION|Control|Did not receive the decision aid.
62520531|NCT00007579||1|
62520532|NCT01366378|EXPERIMENTAL|Arm 1|methylnaltrexone (MNTX)
62520533|NCT03715998|EXPERIMENTAL|Group 1: firibastat 100 mg|Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.
62520534|NCT03715998|EXPERIMENTAL|Group 2: firibastat 500 mg|Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.
62520535|NCT03715998|ACTIVE_COMPARATOR|Group 3: ramipril 5 mg|Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.
62520536|NCT00206492|EXPERIMENTAL|Iressa and Tamoxifen|Iressa and Tamoxifen
61974944|NCT06295263||Healthy geriatric group|Healthy elderly control 80 people, from peer attendees and health checkup centers. Inclusion criteria: ① Voluntary participation in this study and signing of informed consent; ② Age and gender matched with the patients in the case group; Exclusion criteria: ① Previous history of chronic diseases related to the study subjects, such as cerebrovascular disease, traumatic brain injury, inflammatory diseases of the central system, intracranial tumors and neurosurgery, etc.; ② Patients with various types of cognitive disorders (MMSE scores \<24); ③ Those with poor adherence.
62149265|NCT03637075|ACTIVE_COMPARATOR|Intranasal insulin|Intranasal insulin administration
62149266|NCT06195449|EXPERIMENTAL|Alkasite restorative material in primary molar|ARM 1 : ALKASITE RESTORATIVE MATERIAL( INTERVENTION)
62149267|NCT06195449|ACTIVE_COMPARATOR|Glass Ionomer Cement in primary molar|ARM2: Glass Ionomer Cement(CONTROL)
62149268|NCT04938453|EXPERIMENTAL|nintedanib 4 X 25 mg (T) then nintedanib 1 X 100 mg (R))|first test (T), then reference (R) treatment
62149269|NCT04938453|EXPERIMENTAL|nintedanib 1 X 100 mg (R) then nintedanib 4 X 25 mg (T)|first reference (R), then test (T) treatment
61974945|NCT06295263||Healthy Adults Group|Young healthy controls 80 people, from peer attendees and health screening centers. Inclusion criteria: ① Voluntary participation in the study and signing of informed consent; ② Gender matched with the patients in the case group, age \<60 years; Exclusion criteria: ① History of chronic diseases related to the study subjects, such as cerebrovascular disease, traumatic brain injury, inflammatory diseases of the central system, intracranial tumors and neurosurgery, etc.; ② With various types of cognitive disorders (MMSE scores \<24); ③ Poor adherence to the study. Poor adherence.
61974946|NCT06061965|EXPERIMENTAL|Web-based resilience-building|The web-based resilience-building intervention will be implemented on a website and consist of (1) assessments to help participants (a) understand their coping strategies and (b) appraise their beliefs, values, and goals about advance care planning and (2) 6 weekly modules.
62149270|NCT02282215|EXPERIMENTAL|CLT-008 low dose with G-CSF|Dose escalation
62520537|NCT02216019||study cohort|Patient undergoing planned heart surgery with cardiopulmonary bypass
62520538|NCT05441995|EXPERIMENTAL|Cryotherapy|
62149271|NCT02282215|EXPERIMENTAL|CLT-008 high dose with G-CSF|Dose escalation
62149272|NCT02282215|EXPERIMENTAL|CLT-008 with G-CSF|Randomized
62149273|NCT02282215|ACTIVE_COMPARATOR|G-CSF|Randomized
62149274|NCT03626376|PLACEBO_COMPARATOR|Control|suppressive antiviral treatment
62149275|NCT03626376|ACTIVE_COMPARATOR|Study Arm|oral acyclovir or oral valacyclovir
62520539|NCT05441995|ACTIVE_COMPARATOR|Inferior alveolar nerve block|
62520540|NCT03176459|EXPERIMENTAL|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
62520541|NCT03176459|ACTIVE_COMPARATOR|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
62149276|NCT05890404|EXPERIMENTAL|Materials Only|The Materials Only arm will have access to a digital suite of online training materials for LGBTQ-Affirmative CBT prepared by the research team.
62356730|NCT01563107|EXPERIMENTAL|Low Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
62356731|NCT05239312||Patients with prosthetic joint infection|
62356732|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
62520542|NCT01032772|EXPERIMENTAL|CHOICES Plus Intervention|A two session intervention utilizing a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, and smoking. The interventions will (a) provide norms-based-but personalized-feedback, (b) encourage attendance at a contraceptive counseling visit, (c) encourage participation in the smoking cessation program, (c) increase motivation to change each of the target behaviors, (d) decrease temptation to engage in risk behaviors, (e) increase confidence to avoid risk behaviors, and (f) develop a personalized, tailored change plan.
62149277|NCT05890404|EXPERIMENTAL|Direct Training|In addition to receiving access to the online training materials, the Direct Training arm will receive 12 weekly 1-hour live webinars on delivering LGBTQ-affirmative CBT led by our four expert trainers.
62149278|NCT05890404|EXPERIMENTAL|Local Supervision|In addition to receiving the online training materials and live webinars, the Local Supervision arm will receive guidance from an on-site clinical supervisor, who will be nominated by the center director as someone with substantial CBT experience.
62149279|NCT05888740|EXPERIMENTAL|TUS Therapy|These subjects will undergo treatments with the Vibrato Sleeve TUS device.
62149280|NCT01052272|ACTIVE_COMPARATOR|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
62520543|NCT01032772|ACTIVE_COMPARATOR|Information|Women in the information condition receive advice and educational material from the research assistant about women's health and related referrals.
62520544|NCT02810821||female, premenopause|Women with regular menstrual cycles in normal range (22-35 days) for the previous three cycles.
62149281|NCT01052272|ACTIVE_COMPARATOR|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
61974947|NCT04593563|EXPERIMENTAL|Psilocybin 25mg|Psilocybin 25mg Single does with supportive conditions.
62356733|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
62356734|NCT04516577||Shanghai Pulmonary Hospital|Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.
61974948|NCT00311610|EXPERIMENTAL|SN-38 liposome|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months for up to 3 years."
62520545|NCT02810821||female, perimenopause|Peri-menopause was defined as the presence of menses within the past 3 months with a decrease in cycle predictability in the year preceding examination or 3-11 months of amenorrhea. To investigate the association between serum FSH and cholesterol levels independent of E2, we further selected peri-menopausal subjects with the presence of menses within the past 3 months with a decrease in cycle predictability in the year preceding examination because their E2 levels have been reported to be similar to those in pre-menopause.
62520546|NCT02810821||Serum FSH level Quartile 1|Serum FSH level: \<6.95 mIU/mL
62520547|NCT02810821||Serum FSH level Quartile 2|Serum FSH level: 6.95-10.87 mIU/mL
62520548|NCT02810821||Serum FSH level Quartile 3|Serum FSH level: 10.88-25.45 mIU/mL
62520549|NCT02810821||Serum FSH level Quartile 4|Serum FSH level: \>25.45 mIU/mL
61974949|NCT00864045|EXPERIMENTAL|Sertindole|
61974950|NCT00864045|ACTIVE_COMPARATOR|Olanzapine|
62149282|NCT01052272|ACTIVE_COMPARATOR|Ramipril and Allopurinol|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. It is anticipated that the starting dose of each drug will be initiated in hospital and that the second dose will be implemented prior to discharge from the hospital. The starting dose of Allopurinol is 300 mg daily.
61974951|NCT05922150|EXPERIMENTAL|LLLT and ozone group|administered of low level laser therapy and ozone gel after extraction of impacted mandibular third molar
61974952|NCT05922150|EXPERIMENTAL|LLLT group|administered of low level laser therapy after extraction of impacted mandibular third molar
61974953|NCT05922150|EXPERIMENTAL|ozone group|administered of low ozone gel after extraction of impacted mandibular third molar
61974954|NCT05922150|NO_INTERVENTION|control group|routinely extraction of impacted mandibular third molar
61974955|NCT02045368|EXPERIMENTAL|Subject Treatment with IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
61974956|NCT05991076||Activate Bailando Dance Program|The Activate Bailando program is a 6-week dance-focused exercise program that focuses on balance and social connectedness for community-dwelling Spanish-speaking older adults.
61974957|NCT03306680|EXPERIMENTAL|Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0|"Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy~Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy~Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy"
61974958|NCT00467259|PLACEBO_COMPARATOR|Placebo|28 cm² Placebo patch
62149283|NCT01052272|ACTIVE_COMPARATOR|Candesartan cilexetil and Allopurinol|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. The starting dose of Allopurinol is 300 mg daily.
62356735|NCT04516577||Peking Union Medical College Hospital|Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.
62356736|NCT04516577||Nanjing Drum Tower Hospital|The Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital has been focusing on the research of rare pulmonary diseases for many years.
62520550|NCT02658513||All Patients|"All patients will undergo both of the following interventions:~Lancet blood sampling Standard intravenous blood sampling"
62520551|NCT00650442|EXPERIMENTAL|1|Estradiol Transdermal System Placebo - Alternate Adhesive
62520552|NCT00650442|PLACEBO_COMPARATOR|2|Estradiol Transdermal System Placebo - Current Adhesive
62520553|NCT01583218|EXPERIMENTAL|Betrixaban|Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
62520554|NCT01583218|ACTIVE_COMPARATOR|Enoxaparin|Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
62520555|NCT04337619|EXPERIMENTAL|Standard Behavioral Weight Loss Treatment|
62520556|NCT04337619|EXPERIMENTAL|Behavioral + Mindful Acceptance|
62520557|NCT04337619|EXPERIMENTAL|Behavioral + Values|
62520558|NCT04337619|EXPERIMENTAL|Behavioral + Mindful Awareness|
62520559|NCT04337619|EXPERIMENTAL|Behavioral + Acceptance + Values|
62149284|NCT01005914|EXPERIMENTAL|Group 1|"Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3~Drug:cytarabine Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4~Drug:dexamethasone Day 1-4; 11-14: 40 mg daily~Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours~Drug:imatinib mesylate 600 mg/day~Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion~Drug: methylprednisolone Day 1-3: 50mg IV BID~Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV~Drug: vincristine sulfate Day 4 \& 11: 2 mg IV"
62356737|NCT01800851|EXPERIMENTAL|no weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
62356738|NCT01800851|EXPERIMENTAL|weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
62356739|NCT01800851|OTHER|lean body mass|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
61974959|NCT00467259|EXPERIMENTAL|Testosterone|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
62356740|NCT00987090|ACTIVE_COMPARATOR|Alzheimer Disease|subjects who have developed symptoms of Alzheimer Disease aged from 45 to 85 years old
62356741|NCT00987090|PLACEBO_COMPARATOR|Control|subjects without symptoms of Alzheimer Disease aged from 45 to 85 years old.
62356742|NCT02905916|EXPERIMENTAL|PEG-rhG-CSF|
62356743|NCT05659667||Stroke|Case group: 50 adults (between 18 and 70 years old) in chronic phase of stroke (\> 6 months from stroke), in possession of driving license and having to have driven in the three months before stroke.
62356744|NCT05659667||Healthy adults|50 healthy adults with the same age as case group, match up in driving experience, age, sex and educational level with the group of people with stroke, and driver´s license in validity.
62356745|NCT04142385||Observational (health information collection)|Participants receive a questionnaire, undergo a targeted physical and anal clinical exam, undergo blood collection and urethral swab for STIs, and a penile skin cell and anal swab for cytology and HPV DNA at months 0, 6, and 12. Participants also undergo HRA and penile clinical exam at month 12.
62356746|NCT03043807|EXPERIMENTAL|chemohormonal and definitive therapy after prostatectomy|(1st) Systemic chemo-hormonal therapy with up to 6-months (\~24 weeks) of adjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
62356747|NCT01135017|EXPERIMENTAL|Dronedarone|Dronedarone 400 mg twice a day for 12 weeks
62356748|NCT01135017|PLACEBO_COMPARATOR|Placebo|Placebo (for Dronedarone) twice a day for 12 weeks
62356749|NCT03443895|ACTIVE_COMPARATOR|Experimental: AEF0117|Subjects in cohorts 1 through 3 receive active treatments. Subjects in Cohorts 1 through 3 will receive a single dose of 0.6, 2 and 6mg respectively of AEF0117 on Day 1 to Day 7.
62356750|NCT03443895|PLACEBO_COMPARATOR|Placebo|Subjects in Cohorts1 through 3 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
62356751|NCT05060796|EXPERIMENTAL|EGFR CAR-T|Group: 3 dose levels
62356752|NCT01425229||Bosentan|Haplotypes of CYP2C9 and OATP1B1 characterisation of CYP2C9 (CYP2C9\*2 (rs1799853), CYP2C9\*3 (rs1057910)) and OATP1B1 (SLCO1B1\*15 (rs2306283, rs4149056))
62356753|NCT04670224|EXPERIMENTAL|QLB technique|
62356754|NCT04670224|ACTIVE_COMPARATOR|Intravenous anesthesia without QLB|
62356755|NCT05334550|EXPERIMENTAL|Intervention group|Allocated to intervention group through randomization process.
62520560|NCT04337619|EXPERIMENTAL|Behavioral + Acceptance + Awareness|
62520561|NCT04337619|EXPERIMENTAL|Behavioral + Values + Awareness|
62520562|NCT04337619|EXPERIMENTAL|Behavioral + Acceptance + Values + Awareness|
62356756|NCT05334550|NO_INTERVENTION|Control group|Allocated to control group through randomization process.
62520563|NCT03664895|NO_INTERVENTION|observation arm(TMX, MDR≥5%)|keep go on TMX
62520564|NCT03664895|NO_INTERVENTION|control arm(TMX, MDR<5%)|keep go on TMX
61974960|NCT02677142|ACTIVE_COMPARATOR|Attention Control Group (CG)|Behavioural: CG: Social Skills Activities: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific social skill and activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
62356757|NCT03310580|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
62356758|NCT03310580|EXPERIMENTAL|AR-13324 Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
62520565|NCT03664895|ACTIVE_COMPARATOR|OFS add arm(TMX + OFS, MDR<5%)|OFS add on to TMX
62520566|NCT04476966|EXPERIMENTAL|T test|Test drug (Bladogra)1 extended release tablet contains 25 mg Mirabegron
62520567|NCT04476966|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (first dose)
62520568|NCT04476966|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (second dose)
62520569|NCT01030341|EXPERIMENTAL|CGMS and insulin pump|Continuous glucose monitoring in conjunction with insulin pump
62520570|NCT05410158|OTHER|Pecs block group|"The Pecs block will be performed while the patient in the supine position with the ipsilateral upper limb abducted 90 degree with an 80 mm 21 G needle (Pajunk®SonoPlex Stim cannula U.S.A) using linear array ultrasound probe of high frequency (Sonosite®, Inc. U.S.A) starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line .~Patients will be given ultrasound guided, modified Pecs block with 30 mL of 0.25% bupivacaine hydrochloride (Markyrene ®Sigma Tec, Egypt) plus ketamine hydrochloride (1 mg/kg) (Ketamine® Sigma-Tec, Egypt) injected between the pectoralis minor and the serratus anterior muscles , and skin incision will be performed 15 minutes after the block was given."
62711247|NCT05276674||ZNN Bactiguard Retrograde Femoral Nail|Patients implanted with a ZNN Bactiguard Retrograde Femoral Nail for fixing and stabilizing a femoral fracture.
62711248|NCT06037564|EXPERIMENTAL|Intervention|Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
61974961|NCT02677142|EXPERIMENTAL|Experimental Group (EG)|Behavioral: Structured social skills training program, SSIP. Participants in this arm will experience an 8-week manualized intervention program that addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion). Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
61974962|NCT01586390|EXPERIMENTAL|MOK|Adjustable and removable brace made out of Softcast material
62149285|NCT05765526|EXPERIMENTAL|The scalp of discomfort or itching and one treatment|Participants with discomfort or itching scalp who will receive one treatment with the device and complete the questionnaire.
62356759|NCT03310580|PLACEBO_COMPARATOR|Placebo Comparator|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
62520571|NCT05410158|OTHER|Topical instillation group:|After surgical hemostasis before wound closure Patients will receive 1 mg/kg ketamine hydrochloride plus 30 mL of 0.25% bupivacaine hydrochloride which will be put in asterile syringe and irrigated onto the surgical field at the end of surgery .
62520572|NCT02431819|EXPERIMENTAL|contention socks|Patients wear evolutive contention socks during 15 days.
62520573|NCT03032861|EXPERIMENTAL|Orange juice|Ten women will consume 100% orange juice (300 mL/day) during 60 days.
61974963|NCT01586390|ACTIVE_COMPARATOR|WRAP|Softcast ankle cast
62520574|NCT05495984|EXPERIMENTAL|Primary Objective: Event-Related Potentials (ERPs)|Use ERPs elicited by unknown infant face and cry stimuli to determine whether neural markers translate to maternal mentalization in mothers with opioid use disorder (OUD) at 4-12 months postpartum
62520575|NCT05495984|EXPERIMENTAL|Secondary Objective: ERPs + Mothering from the Inside Out (MIO)|Use Event-Related Potentials (ERPs) elicited by unknown infant face and cry stimuli to determine whether neural response changes with participation in an evidence-based parenting intervention designed specifically for mothers with OUD: Mothering from the Inside Out (MIO).
62520576|NCT01672970||Cohort|
62520577|NCT01069952|EXPERIMENTAL|Active DBS|Participants will receive deep brain stimulation.
62520578|NCT06491160||Attention Deficit Hyperactivity Disorder|"Subjects eligible for enrolment in this study must the following criteria:~1. meet current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for ADHD as a primary diagnosis as assessed by the Structured Clinical Interview for DSM Disorders (SCID) and the Structured Clinical Interview for DSM Personality Disorders (SCID-PD)~2. between 18 and 45 years, inclusive~3. BIS-11 score of ≥ 70"
62711249|NCT06037564|NO_INTERVENTION|Control|"Participants randomized to the control arm will continue to take their fully suppressive ART at baseline. The following selection of treatment combinations could be encountered in the control group (among others):~* Once-daily co-formulated elvitegravir 150 mg, cobicistat 150 mg, tenofovir alafenamide 10 mg, emtricitabine 200 mg (Genvoya®) and darunavir 800 mg (e.g. Darunavir Mylan®)~* Once-daily co-formulated darunavir 800 mg, cobicistat 150 mg, tenofovir alafenamide 10 mg, emtricitabine 200 mg (Symtuza ®) and DTG 50 mg (Tivicay ®)~* Once-daily DTG 50 mg (Tivicay®), darunavir 800 mg (e.g. Darunavir Mylan®), and ritonavir 100 mg (Norvir®)~* Etravirine 200 mg twice daily (Intelence®), raltegravir 400 mg twice daily (Isentress®),darunavir 800 mg once daily (e.g. Darunvair Mylan®) and ritonavir 100 mg once daily (Norvir®)"
62711250|NCT02203643|EXPERIMENTAL|CCyd|"Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
61974964|NCT04792164|EXPERIMENTAL|The experimental group will receive US guided nerve block|The experimental group will receive US guided nerve block by lidocaine before open inguinal hernia repair.
61974965|NCT04792164|OTHER|The control group will receive usual infiltration|The control group will receive usual infiltration by lidocaine before open inguinal hernia repair.
61974966|NCT03041545||Fitbit|All participants will be asked to wear the Fitbit as much as possible and to sync it at least once a week, from one week prior to start of chemotherapy treatment to six months after ending chemotherapy.
61974967|NCT01390311|ACTIVE_COMPARATOR|Control Cohort|"1. Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~2. DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and \~1 x 106/kg for match unrelated donors based on recipient weight~3. No Azacitidine will be given"
61974968|NCT01390311|EXPERIMENTAL|Cohort 1 (Starting Dose)|"1. Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~2. DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and \~1 x 106/kg for match unrelated donors based on recipient weight~3. Azacitidine 45 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
61974969|NCT01390311|EXPERIMENTAL|Cohort 2|"1. Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~2. DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and \~1 x 106/kg for match unrelated donors based on recipient weight~3. Azacitidine 75 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
61974970|NCT02625272|EXPERIMENTAL|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
62520579|NCT06491160||Borderline Personality Disorder|"Subjects eligible for enrolment in this study must meet all of the following criteria:~1. meet current DSM-5 criteria for BPD as a primary diagnosis as assessed by SCID and SCID-PD~2. between 18 and 45 years, inclusive~3. BIS-11 score of ≥ 70"
62520580|NCT02469779|EXPERIMENTAL|ASPIRE Group|Participants complete baseline survey. Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
61974971|NCT02625272|NO_INTERVENTION|Group B|novel laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were divided at the beginning of the operation intracorporeally.
62356760|NCT05159362|EXPERIMENTAL|OARSCM|After successful completion of usability testing (Patients: n=12, Providers: n=4), a proof-of-concept field test was completed. OARSCM patients (n = 11) received TAU procedures during enrollment (SBIRT for opioid use disorder and a warm handoff to outpatient MOUD treatment). TAU outpatient MOUD treatment consists of urine toxicology (Utox) screening, group/individual therapy, and MOUD prescription. Treatment visits are typically weekly in weeks 1-4 and taper over time. Patients earned chances for prizes, for targeted behaviors, which escalated for each targeted behavior in a row, with reset criteria. For scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with each targeted behavior in a row up to a max of 10 draws/targeted behavior. There are 18 targeted behaviors during the 4-week field test (schedule intake, complete intake, 4 opioid-negative Utox/week plus bonuses for cocaine-negative Utox, and 4 therapy/week).
62356761|NCT00686010|PLACEBO_COMPARATOR|1|Placebo
62356762|NCT00686010|EXPERIMENTAL|2|JTT-705 300mg
62356763|NCT00686010|EXPERIMENTAL|3|JTT-705 600mg
62356764|NCT00686010|EXPERIMENTAL|4|JTT-705 900mg
62356765|NCT00612989|EXPERIMENTAL|1|Schedule 1
62356766|NCT00612989|EXPERIMENTAL|2|Schedule 2
62356767|NCT00612989|EXPERIMENTAL|3|Schedule 2, Neulasta-supported
62356768|NCT04718584|EXPERIMENTAL|Experimental Arms|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
62356769|NCT02216890|EXPERIMENTAL|SGN-CD70A|
62356770|NCT05849896|EXPERIMENTAL|Static contractions in healthy volunteers|Acquisition of HD SEMG signals of an upper limb muscle and a lower limb muscle while the participant executes simple static exercises.
62356771|NCT05849896|EXPERIMENTAL|Dynamic contractions in healthy volunteers|Acquisition of HD SEMG signals of a leg muscle while the participant executes simple dynamic exercises.This arm will recruited recreationally active or athletic volunteers, preferably between 18 and 20 years
62356772|NCT05849896|EXPERIMENTAL|Static contractions in post-stroke patients|Acquisition of HD SEMG signals of a lower limb muscle while the participant executes simple static exercises.
62356773|NCT05982639|OTHER|one-lung ventilation|Usual care. One lung ventilation will be provided using a Carleans type double lumen orotracheal tube.
62356774|NCT05982639|EXPERIMENTAL|two-lung ventilation and use of pneumothorax with CO2.|Two lung ventilation will be provided using a single lumen orotracheal tube and CO2-induced pneumothorax
62356775|NCT05005091|ACTIVE_COMPARATOR|oral carbohydrate|the patients drunk oral carbohydrate two hours ago preoperatively
62356776|NCT05005091|NO_INTERVENTION|no oral carbohydrate|the patients did not drink oral carbohydrate preoperatively
62356777|NCT02165345|EXPERIMENTAL|Tocilizumab|Participants will receive tocilizumab until the commercial availability of the drug or up to 5 years, whichever is earlier.
62356778|NCT00702910|EXPERIMENTAL|GW642444M/lactose|GW642444M/lactose 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
62356779|NCT00702910|EXPERIMENTAL|GW642444M/MgSt|GW642444M/MgSt 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
62356780|NCT00702910|PLACEBO_COMPARATOR|Placebo|Placebo containing lactose, single inhaled dose for two days treatment in each treatment sequence (crossover design)
62356781|NCT01929707|EXPERIMENTAL|LY3050258|Single escalating dose of LY3050258 (2 milligram \[mg\] up to 200 mg) administered in up to two of two periods.
62356782|NCT01929707|PLACEBO_COMPARATOR|Placebo|Single dose of placebo matching LY3050258 administered in up to one of two periods.
62356783|NCT04095442|ACTIVE_COMPARATOR|Cepacol|
62356784|NCT04095442|SHAM_COMPARATOR|Tom's Natural Mouthwash|
62356785|NCT01612442|EXPERIMENTAL|Integrated education|
61974972|NCT02625272|NO_INTERVENTION|Group C|the traditional laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer.
62356786|NCT01612442|NO_INTERVENTION|Control|
62356787|NCT01612442|EXPERIMENTAL|Nutrition education|
62356788|NCT01769495|NO_INTERVENTION|Control|Standard post ED care
62356789|NCT01769495|EXPERIMENTAL|2-3 day return appointment|Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge.
62356790|NCT03205982|SHAM_COMPARATOR|Control|WiseApp that delivers fitness reminders
62356791|NCT03205982|EXPERIMENTAL|Intervention|WiseApp that delivers medication adherence reminders
62356792|NCT04777474|EXPERIMENTAL|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy
62356793|NCT00702728|EXPERIMENTAL|1|Furosemide and matched saline hydration by RenalGuard system
62356794|NCT00702728|ACTIVE_COMPARATOR|2|Standard IV saline infusion
62356795|NCT02467855||Cross-Sectional Cohort|Participants receiving standard of care for hypertension with well-controlled hypertension will participate in 1 visit.
62356796|NCT02467855||Longitudinal Cohort|Participants receiving standard of care for hypertension with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks.
62356797|NCT00780507||1|Patients are in a state of remission
62356798|NCT00780507||2|Patients are in a flare
62356799|NCT04167514|EXPERIMENTAL|AAT|Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration
62356800|NCT04167514|PLACEBO_COMPARATOR|Placebo|Albumin solution administered intravenously
62711251|NCT02203643|EXPERIMENTAL|CRd|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
62711252|NCT02203643|EXPERIMENTAL|CRd long treatment|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. Stem cells collection will be performed. Carfilzomib Lenalidomide and Dexamethasone administered for 8 28-day cycles.~After that all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
62356801|NCT00435994|OTHER|Infants with viral lower respiratory infections|Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
62356802|NCT00435994|OTHER|Healthy Control|Healthy infants between the ages of 2-24 month
62356803|NCT00435994|OTHER|Bronchiolitis-Nasal wash only|Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only
62520581|NCT02469779|ACTIVE_COMPARATOR|Control Group|Participants complete baseline survey. Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
62520582|NCT00366041|EXPERIMENTAL|Cellularised LG002|Cellularised LG002
62520583|NCT00366041|EXPERIMENTAL|UnCellularised LG002|UnCellularised LG002
62520584|NCT06223217||Experiment group|Patients who undergoing endoluminal treatment for lower extremity peripheral arterial disease will complete the Modified version of the VascuQoL scale, the Chinese version of the VascuQoL scale, EQ-5D-5L Scale and the ABI test according to follow-up plan.
62520585|NCT00649727|EXPERIMENTAL|1|Oxybutynin Chloride ER Tablets 10 mg
62356804|NCT01984736|EXPERIMENTAL|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
62356805|NCT02718391|EXPERIMENTAL|Arm A: Autologous Dendritic Cell vaccine|Daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days starting from the second day after each vaccine dose. Vaccine doses will be given intradermally in two sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis.The first dose (WK1) will consist of freshly prepared vaccine, whereas for all the further doses cryopreserved aliquots will be utilized. The remaining 5 doses will be administered every 4 weeks to complete six months of therapy (six vaccines).
62356806|NCT02718391|NO_INTERVENTION|Arm B: follow up|Arm B: Patients will undergo laboratory and clinical assessment, tumor re-staging, blood collection for immunological biomarkers every 12 weeks until relapse.
62356807|NCT03459404||Sufentanil NanoTab PCA System/15 mcg|"Drug: Sufentanil 15 mcg~Unless contraindicated patients also received around the clock regimen of NSAIDS (ketoprofen 200 mg/day) and acetaminophen (1000 mg every 8 hours)."
62356808|NCT06261242|EXPERIMENTAL|Intervention|Tripod-Fix will be used to treat osteoporotic vertebral compression fractures.
62356809|NCT06309004||DGBI individuals|Individuals with clinically meaningful symptom levels of DGBI, and anxiety and/or depression
62356810|NCT06309004||Healthcare professionals|Healthcare professionals (ACT therapists, health psychologists, physicians, nurses, and dietitians working with people with DGBI)
62356811|NCT04328012|EXPERIMENTAL|Losartan|losartan 25 mg po QD X 14 days
62356812|NCT04328012|PLACEBO_COMPARATOR|Placebo|placebo QD X 14 days
62356813|NCT03457766|EXPERIMENTAL|Patients with skin lesions|Using HIFU in identification of safety margins of lesions clinically apparent locally malignant, or malignant
62356814|NCT01154595|ACTIVE_COMPARATOR|Food-for-Training component|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
62356815|NCT01154595|EXPERIMENTAL|Food-for-Training + RUF (Plumpy Doz(r))|"Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.~In addition, a blanket supplementation with 47g RUF (Plumpy Doz(r)) per day per child is provided."
62356816|NCT06107036|EXPERIMENTAL|Treatment 1 (L - low)|Treatment with low dose BI 1015550
62356817|NCT06107036|EXPERIMENTAL|Treatment 2 (H - high)|High dose treatment with BI 1015550
62356818|NCT06107036|ACTIVE_COMPARATOR|Treatment 3 (M - moxifloxacin)|Treatment with moxifloxacin
62520586|NCT00649727|ACTIVE_COMPARATOR|2|Ditropan XL® Tablets 10 mg
62520587|NCT00773695|ACTIVE_COMPARATOR|Chemotherapy|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.
62520588|NCT00773695|EXPERIMENTAL|Chemotherapy and Bevacizumab|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
62711253|NCT01906268|EXPERIMENTAL|TAU + ABMT active|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - active"
62711254|NCT01906268|SHAM_COMPARATOR|TAU + AMBT placebo|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - placebo (sham)"
62711255|NCT06476678||Treatment arm|Patients who were deemed eligible and signed the consent will undergo the removal of their esophageal precancerous lesion utilizing the novel bipolar knife during their endoscopic submucosal dissection (ESD).
62711256|NCT04841408|EXPERIMENTAL|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
62711257|NCT01990742|EXPERIMENTAL|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention homes.
62711258|NCT01990742|NO_INTERVENTION|Standard care|Usual care will be provided to residents in the control homes.
62149286|NCT06207006|EXPERIMENTAL|eConquerFear-HK|Participants in the eConquerFear-HK intervention group will receive six online modules with each containing educational text, illustrative graphics, interactive exercises, and brief videos. Every module will teach a specific topic, such as self-examination and medical surveillance, values-based goal setting, attention training, detached mindfulness, worry management and treatment summary and relapse prevention.
62149287|NCT06207006|ACTIVE_COMPARATOR|Basic Cancer Care|Participants in the control group will receive six videos, which were designed to provide comprehensive lifestyle guidance (e.g., relaxation techniques, diet and physical activity advices) to help with survivors' maintenance of health in long-term.
62149288|NCT03388957|EXPERIMENTAL|Propranolol|Patients in this group will be given Propranolol 0.5 mg/Kg orally.
62149289|NCT03388957|EXPERIMENTAL|Midazolam|Patients in this group will be given Midazolam 0.5 mg/Kg orally.
62149290|NCT03388957|EXPERIMENTAL|Propranolol and Midazolam|Patients in this group will be given Propranolol and Midazolam with a dose of 0.5 mg/Kg orally for each drug.
62149291|NCT05484297|EXPERIMENTAL|Treatment|Participants in the treatment arm will receive the intervention post cards
62711259|NCT04101097||training group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
62149292|NCT05484297|SHAM_COMPARATOR|Control|Participants in the control arm will receive the control post cards
62149293|NCT06093490||Absence Seizure|Age 4-12, Typical Absence Seizure captured during hyperventilation
62149294|NCT06093490||Control Group|Age 4-12, Control Group without seizure activity during hyperventilation
62149295|NCT03794388|EXPERIMENTAL|Arm CAPSAICINE topical|"Application of capsaicin patches at 8% on the painful area~1 to 2 patches will be administered during the consultation. If necessary, a second application will be realized 3 months later."
62356819|NCT06107036|PLACEBO_COMPARATOR|Treatment 4 (P1 and P2 - placebo)|Treatment with placebo matching BI 105550 in two different periods: P1 and P2
62711260|NCT04101097||validation group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
62149296|NCT03794388|ACTIVE_COMPARATOR|Arm PREGABALINE|"Pregabalin tablets will be initiated at a dose of 50 mg / day taken in 2 doses Depending on the tolerance, the dose will be increased to 100 mg / day and then to 150 mg / day to reach a maximum dose of 600 mg / day.~An interval of 3 to 7 days must be observed between each dose increase."
62149297|NCT02823340|EXPERIMENTAL|Fractional Microneedle Radiofrequency Treatment|Fractional Microneedle Radiofrequency Treatment
62711261|NCT02346669|ACTIVE_COMPARATOR|FMT from a lean donor+ high fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~1. at time 0~2. after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
62711262|NCT02346669|SHAM_COMPARATOR|FMT from a lean donor+ sham diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~1. at time 0~2. after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
62149298|NCT02283086|NO_INTERVENTION|Control|
62149299|NCT02283086|EXPERIMENTAL|Intervention|The intervention consisted of quarterly performance feedback reports sent via e-mail.
62149300|NCT02320097|OTHER|Foot pressure measurement|"The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
62149301|NCT02051218|ACTIVE_COMPARATOR|Arm A (standard arm)|Denosumab 120mg (XGEVA®) sc. q4w
62149302|NCT02051218|EXPERIMENTAL|Arm B (reduced arm)|Denosumab 120mg (XGEVA®) sc. q4w \[weeks 1, 5, 9\] followed by Denosumab 120mg (XGEVA®) sc. q12w \[weeks 13, 25, ...\]
62149303|NCT04514978|EXPERIMENTAL|Blood donation and transfusion|Donation and reinfusion of 1 unit whole blood and 130 mL packed red blood cells, respectively. Blood samples were collected at 8 weeks prior to donation for 12 subjects and 2 weeks prior to donation by 12 subjects. Blood samples were collected 3, 7, 14, 21, and 28 days after donation and 3, 6, 24 hours and 2, 3 and 6 days after reinfusion of blood.
62149304|NCT04514978|NO_INTERVENTION|Control group|Blood samples collected with same frequency as described in the intervention arm.
62149305|NCT06230588|EXPERIMENTAL|TQH3906 capsule|TQH3906 capsule for oral administration as a single or multiple dose for 7days.
62149306|NCT06230588|PLACEBO_COMPARATOR|TQH3906 placebo capsule|TQH3906 placebo capsule for oral administration as single dose or multiple dose for 7days.
62149307|NCT05588739|EXPERIMENTAL|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxation, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
62356820|NCT00755872|EXPERIMENTAL|1|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
62356821|NCT00755872|EXPERIMENTAL|2|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
62356822|NCT00755872|EXPERIMENTAL|3|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
61974973|NCT00734903|EXPERIMENTAL|A Woman's Path to Recovery (WPR)|A gender-focused approach to addiction recovery
61974974|NCT00734903|ACTIVE_COMPARATOR|12-Step Facilitation (TSF)|An evidence-based, non-gender-focused approach to addiction recovery
62520589|NCT00773695|ACTIVE_COMPARATOR|Endocrine Therapy|Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.
62520590|NCT00773695|EXPERIMENTAL|Endocrine Therapy and Bevacizumab|Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.
62520591|NCT03911921|EXPERIMENTAL|RSYYT decoction|RSYYT decoction Compound granules of traditional Chinese medicine
62520592|NCT03911921|EXPERIMENTAL|Astragalus membranaceus|one herb decoction Compound granules of one herb (Astragalus membranaceus)
62520593|NCT03071328|EXPERIMENTAL|Bone metastatic site|
62520594|NCT03071328|EXPERIMENTAL|Liver metastatic site|
62520595|NCT03071328|EXPERIMENTAL|Lymph node metastatic site|
62520596|NCT03071328|EXPERIMENTAL|Soft tissue metastatic site|
61974975|NCT00372112|ACTIVE_COMPARATOR|100 mcg GW642444H|Twice daily in the morning.
61974976|NCT00372112|ACTIVE_COMPARATOR|400 mcg GW642444H|Twice daily in the morning.
61974977|NCT00372112|ACTIVE_COMPARATOR|50 mcg salmeterol|Twice daily.
61974978|NCT00372112|PLACEBO_COMPARATOR|placebo|Twice daily
61974979|NCT04827927|EXPERIMENTAL|INTELLiVENT-ASV|Use of INTELLiVENT-ASV during 3 hours with 30 minutes wash-out time before.
61974980|NCT04827927|ACTIVE_COMPARATOR|Conventional Ventilation|Use of conventional ventilation during 3 hours with 30 minutes wash-out time before.
62520597|NCT04979273|ACTIVE_COMPARATOR|Control Group|Patients within control group will be given adrenaline 1:20.000 injection, followed by thermocoagulation or hemoclip
62520598|NCT04979273|EXPERIMENTAL|Dextrose group|Patients within this group will be given adrenaline 1:20.000 injection, followed by dextrose 40% spray
62520599|NCT03392493|EXPERIMENTAL|Group A|In the phase 1 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week); In the phase 2 :12 training sessions of Standard treatment only. (60 minutes a time, 2 times a week)
62520600|NCT03392493|ACTIVE_COMPARATOR|Group B|In the phase 1 :12 training sessions of Standard treatment only(60 minutes a time, 2 times a week) ; In the phase 2 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
61974981|NCT00722033|OTHER|A|\< 30 weeks of gestation
61974982|NCT00512993|ACTIVE_COMPARATOR|Treatment|Patients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
61974983|NCT00512993|NO_INTERVENTION|Observation|Patients will be under observation and receive standard endocrine, radiologic and trastuzumab treatment, respectively
61974984|NCT02345382|EXPERIMENTAL|20 mg BAY1143572|Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
61974985|NCT02345382|EXPERIMENTAL|40 mg BAY1143572|Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
62520601|NCT04004143||Cross-sectional|a cross-sectional study.
62520602|NCT05077436|EXPERIMENTAL|Sequence 1|"Participants receive a single dose of study drug, every 4 days:~* Day 1: Participants in fasted state receive Vamifeport Formulation 1~* Day 5: Participants in fed state receive Vamifeport Formulation 1~* Day 9: Participants in fed state receive Vamifeport Formulation 2~* Day 13: Participants in fasted state receive Vamifeport Formulation 2"
62520603|NCT05077436|EXPERIMENTAL|Sequence 2|"Participants receive a single dose of study drug, every 4 days:~* Day 1: Participants in fed state receive Vamifeport Formulation 1~* Day 5: Participants in fasted state receive Vamifeport Formulation 2~* Day 9: Participants in fasted state receive Vamifeport Formulation 1~* Day 13: Participants in fed state receive Vamifeport Formulation 2"
62520604|NCT05077436|EXPERIMENTAL|Sequence 3|"Participants receive a single dose of study drug, every 4 days:~* Day 1: Participants in fasted state receive Vamifeport Formulation 2~* Day 5: Participants in fed state receive Vamifeport Formulation 2~* Day 9: Participants in fed state receive Vamifeport Formulation 1~* Day 13: Participants in fasted state receive Vamifeport Formulation 1"
62520605|NCT05077436|EXPERIMENTAL|Sequence 4|"Participants receive a single dose of study drug, every 4 days:~* Day 1: Participants in fed state receive Vamifeport Formulation 2~* Day 5: Participants in fasted state receive Vamifeport Formulation 1~* Day 9: Participants in fasted state receive Vamifeport Formulation 2~* Day 13: Participants in fed state receive Vamifeport Formulation 1"
62520606|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
62520607|NCT03166553|EXPERIMENTAL|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
62711263|NCT02346669|ACTIVE_COMPARATOR|FMT from lean donor+ low fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~1. at time 0~2. after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
61974986|NCT02345382|EXPERIMENTAL|80 mg BAY1143572|Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
61974987|NCT02345382|EXPERIMENTAL|120 mg BAY1143572|Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
61974988|NCT02345382|EXPERIMENTAL|160 mg BAY1143572|Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
62520608|NCT03166553|NO_INTERVENTION|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
62520609|NCT01499680||NV in XLIF|This group will have the XLIF procedure done using NV.
62520610|NCT00254852|ACTIVE_COMPARATOR|O|This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
62520611|NCT00254852|ACTIVE_COMPARATOR|A|This treatment arm includes autograft harvested from local bone and / or the iliac crest.
62520612|NCT00222352||central laboratory cTnI test|Control Group
62520613|NCT00222352||Point of Care cTnL testing|Experimental Group
62520614|NCT06073535|EXPERIMENTAL|i-PRF|i-PRF will be used after the extraction of the third molar to reduce postoperative complications (swelling, pain) and wound healing.
62711264|NCT05201131||Rezum procedure|
62149308|NCT05588739|NO_INTERVENTION|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
62149309|NCT05165420||RV4941A arm|RV4941A study product is applied twice a day (morning and evening) on the face, neck and eye contour during the whole study.
62149310|NCT05498051|EXPERIMENTAL|Sentinel lymph node detection after submucosal bevacizumab-800CW injection|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
62149311|NCT00655824|EXPERIMENTAL|Ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
62149312|NCT00995683|EXPERIMENTAL|half sodium lactate|infusion of 0.5 ml/kg/day during 48 hours
62520615|NCT06073535|ACTIVE_COMPARATOR|Spontaneous healing|After the extraction of the lower third molar the socket will be left to heal spontaneously.
61974989|NCT02345382|EXPERIMENTAL|200 mg BAY1143572|Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
62149313|NCT00995683|ACTIVE_COMPARATOR|isotonic sodium chloride|infusion of 0.5 ml/kg during 48 hours
62149314|NCT00362219|PLACEBO_COMPARATOR|Placebo|Gel with no active ingredient
62149315|NCT00362219|ACTIVE_COMPARATOR|Morphine .25 mg|Gel with 0.25 mg morphine per 100cm2 square of wound
62711265|NCT01424800|EXPERIMENTAL|change in blood pressure and blood flow|34 patients will form the experimental group, in which changes of blood pressure and blood flow will be induced and monitored.
62711266|NCT02359656|OTHER|non operative treatment|specif non operative treatment protocol
62711267|NCT02359656|OTHER|operative treatment|dorsal atlanto-axial C1-C2 Arthrodesis
62149316|NCT00362219|ACTIVE_COMPARATOR|Morphine - .75 mg.|Gel with 0.75 mg morphine per 100cm2 square of wound.
62149317|NCT00362219|ACTIVE_COMPARATOR|Morphine 1.25 mg.|Gel with 1.25 mg morphine per 100cm2 square of wound.
62149318|NCT05424328|EXPERIMENTAL|Study Group: ALTF with preoperative virtual planning|Subjects will receive ALTF( Anterolateral thigh flap) with preoperative virtual planning
62149319|NCT05424328|ACTIVE_COMPARATOR|Control Group: ALTF with conventional method|Subjects will receive ALTF (Anterolateral thigh flap) with conventional method
62149320|NCT03938207||Dry eye syndrome|Dry eye syndrome patients were extracted from Taiwan Biobank.
62149321|NCT03938207||Health subjects|Health subjects were extracted from Taiwan Biobank.
62149322|NCT03938207||Sjögren's syndrome|Sjogren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
62149323|NCT03938207||other inflammation disease|Other inflammation disease were extracted from Taiwan Biobank.
62520616|NCT01237353|EXPERIMENTAL|betaine hydrochloride and rabeprazole|
62149324|NCT01124942|EXPERIMENTAL|MGuard|MGuard net protective stent, investigational device
62149325|NCT01124942|ACTIVE_COMPARATOR|BMS plus thrombectomy|Bare-metal stent plus manual thrombectomy device
62149326|NCT04918719|EXPERIMENTAL|NAC arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine (NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.~The dosing of NAC will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours."
62520617|NCT02071849|EXPERIMENTAL|Aortic Valve Repair|Implantation of HAART 200 Aortic Valve Annuloplasty Device for bicuspid aortic valve reconstruction
62520618|NCT06131827|EXPERIMENTAL|Neural mobilization|Neural mobilization technique will be perormed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval for rest between each set for 4 days weekly for Six week.
62711268|NCT06716476|ACTIVE_COMPARATOR|Treatment with Vitamin D|RA Patients with Vitamin D
62711269|NCT06716476|NO_INTERVENTION|No treatment with Vitamin D|RA Patients without Vitamin D
62711270|NCT03030378|EXPERIMENTAL|Treatment (recombinant interleukin-12, pembrolizumab)|Patients receive recombinant interleukin-12 SC on days 2, 5, 9, and 12 and pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of subsequent cycles. Treatment continues for 28 days for cycle 1 and repeats every 21 days for subsequent cycles for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patient then receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, PET, and MRI, as well as collection of blood during screening, on study, and during follow-up. Patients also undergo a tumor biopsy during screening and on study.
62149327|NCT04918719|PLACEBO_COMPARATOR|Placebo arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine(NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.~The placebo will consist of a 5% Dextrose in Water (D5W) instead of NAC (dosage and timings are the same as the NAC arm)."
62149328|NCT04995198||Participants with at least one germline pathogenic/likely pathogenic variant|
62520619|NCT06131827|EXPERIMENTAL|Task based activities|Task based activities consisted of different type of task which will be performed with the doasage of 45 minutes per session 5 days weekly for 6 weeks.
62520620|NCT02609412|EXPERIMENTAL|Static compression of LMTRP|static compression of most sensitive LMTRP with the foam roll for 90 seconds
62520621|NCT02609412|EXPERIMENTAL|Dynamic self-myofascial release of calf|dynamic self-myofascial release rolling back and forth on the entire calf for 90 seconds with the foam roll
62711271|NCT01220661|EXPERIMENTAL|One dose|One dose prophylactic antibiotic
62711272|NCT02526784|ACTIVE_COMPARATOR|Injection A|Degarelix s.c. standard injections
62520622|NCT02609412|PLACEBO_COMPARATOR|Placebo laser acupuncture of LMTRP|placebo laser acupuncture applied on most sensitive LMTRP of the calf, light and acoustic sounds provided, but laser remains switched off, 90 seconds
61974990|NCT02345382|EXPERIMENTAL|240 mg BAY1143572|Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
61974991|NCT01549093|EXPERIMENTAL|Endostar -Continued Pumping into+GC|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
61974992|NCT01549093|ACTIVE_COMPARATOR|Endostar -injecting into +GC|Endostar that is injecting into vein with Gemcitabine -Carboplatin
61974993|NCT01549093|ACTIVE_COMPARATOR|GC|Gemcitabine -Carboplatin
62711273|NCT02526784|EXPERIMENTAL|Injection B|Degarelix s.c. optimised injections
61974994|NCT04941001|ACTIVE_COMPARATOR|Healthcare professional using ReferID Tool in primary care|The asthma review will be undertaken by a healthcare professional with the use of the ReferID tool in primary care
62356823|NCT00755872|EXPERIMENTAL|4|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
62356824|NCT04226287|EXPERIMENTAL|Monterey Pneumatic Compression Device|All participants will receive treatment with the Monterey investigational pneumatic compression device
62356825|NCT06085287|EXPERIMENTAL|CAU+EMT groups|CAU+EMT group will continue their current interventions and medications as usual. The existing interventions and medications will be recorded and serve as covariates included in outcome analysis. Besides, CAU+EMT group will receive a total of 30 sessions of EMT within 12 weeks (2 - 3 sessions/week).
62356826|NCT06085287|NO_INTERVENTION|CAU Group|CAU group will continue their current interventions and medications as usual. The existing interventions and medications will be recorded and serve as covariates included in outcome analysis.Those who are initially assigned to CAU group will receive EMT for 12 weeks after they complete the trial. The post-trial treatment will serve as a compensation for their participation.
62356827|NCT06210438|EXPERIMENTAL|SHR-A1921 + Bevacizumab|
62356828|NCT01153906||Exposed cohort|Females 9-25 years of age, who received at least one dose of Cervarix® as part of their routine health care.
62356829|NCT01153906||Unexposed cohort|Females 9-25 years of age, who did not receive Cervarix®
62356830|NCT05366257||CAR-T: Inpatient (IP) Cohort|Patients received CAR-T infusion in IP setting
62356831|NCT05366257||CAR-T: Outpatient (OP) Cohort|Patients received CAR-T infusion in OP setting
62356832|NCT05366257||Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
62356833|NCT05167721|ACTIVE_COMPARATOR|Arm 1|25 million mesenchymal stem cells administered intrathecally every 3 months for 4 injections
62356834|NCT05167721|ACTIVE_COMPARATOR|Arm 2|25 million mesenchymal stem cells administered intrathecally every 6 months for 2 injections (placebo injections at 3 month and 9 month timepoints)
62356835|NCT05167721|PLACEBO_COMPARATOR|Arm 3|Placebo (lactated Ringer's) administered intrathecally every 3 months for 4 injections
62356836|NCT02759562|EXPERIMENTAL|Andecaliximab 600 mg (Part 1)|Andecaliximab 600 mg weekly for 8 weeks
62356837|NCT02759562|PLACEBO_COMPARATOR|Placebo (Part 1)|Placebo weekly for 8 weeks
62356838|NCT02759562|EXPERIMENTAL|Andecaliximab 300 mg (Part 2)|Andecaliximab 300 mg weekly for 8 weeks
62356839|NCT02759562|EXPERIMENTAL|Andecaliximab 150 mg (Part 2)|Andecaliximab 150 mg + placebo weekly for 8 weeks
62356840|NCT02759562|PLACEBO_COMPARATOR|Placebo (Part 2)|Placebo weekly for 8 weeks
62356841|NCT02759562|EXPERIMENTAL|Open-Label Extension|(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
62356842|NCT06130410||COMIRNATY intramuscular injection for 6 months to 4 years old (monovalent, omicron XBB.1.5.)|
62520623|NCT03971149|EXPERIMENTAL|Behavorial intervention|
62520624|NCT04724434||Study group|Patients with positive test for SARS-CoV-2 by PCR
62520625|NCT04724434||Control group|Patients with negative SARS-CoV-2 antibody test
62520626|NCT03785535|EXPERIMENTAL|Actual treatment|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (2-90 Hz), low intensity and long daily duration (3h).
62520627|NCT03785535|SHAM_COMPARATOR|Sham|Sham treatment will be applied using identical instruments and with power and duration programmed identically. However, in this case, the output will not be the signal activating the vibration motors, but rather an electrical signal turning on an incorporated pilot light indicating that the (simulated) treatment was operating
62520628|NCT04690036|EXPERIMENTAL|one group|All patients encountered EBV reactivation after allo-HCT could be enrolled in this study, there was only one group of treatment.
62520629|NCT02701413|EXPERIMENTAL|ApexM Device|The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
62711274|NCT02526784|EXPERIMENTAL|Injection C|Degarelix i.m. injections
61974995|NCT04941001|NO_INTERVENTION|Usual care in primary care|A cohort of patients will be recruited who continue to receive usual care in primary care
62356843|NCT00702247|EXPERIMENTAL|1|
62356844|NCT04787211|EXPERIMENTAL|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
62356845|NCT04787211|EXPERIMENTAL|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
62356846|NCT04787211|EXPERIMENTAL|Placebo in adult subjects with mild-moderate COVID-19|
62356847|NCT01670136|NO_INTERVENTION|sildenafil, standard of care|Infants receiving sildenafil as standard of care
62356848|NCT01670136|OTHER|sildenafil administered for study|1 dose of sildenafil administered for study
62356849|NCT05148169|ACTIVE_COMPARATOR|SSRI group|One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
62520630|NCT02701413|SHAM_COMPARATOR|Sham Device|The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.
62520631|NCT02998450|EXPERIMENTAL|Cohort 1|"4 Subjects will receive a single low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
62520632|NCT02998450|EXPERIMENTAL|Cohort 2|"4 Subjects will receive a single low-mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
62520633|NCT02998450|EXPERIMENTAL|Cohort 3|"4 Subjects will receive a single mid-low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
62520634|NCT02998450|EXPERIMENTAL|Cohort 4|"4 Subjects will receive a single mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
62356850|NCT05148169|EXPERIMENTAL|SSRI plus Sulforaphane group|"One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
62356851|NCT05148169|NO_INTERVENTION|Healthy control group|No intervention is given.
62356852|NCT06168825||Black and African American Women diagnosed with Cancer|Participants who have completed primary treatment (completed chemotherapy and/or radiation and/or surgery) are eligible to participate in the study
62356853|NCT02538367|EXPERIMENTAL|YH12852 IR 0.05mg|Once daily
62356854|NCT02538367|EXPERIMENTAL|YH12852 IR 0.1mg|Once daily
62356855|NCT02538367|EXPERIMENTAL|YH12852 IR 0.3mg|Once daily
62356856|NCT02538367|EXPERIMENTAL|YH12852 IR 0.5mg|Once daily
62356857|NCT02538367|EXPERIMENTAL|YH12852 IR 1mg|Once daily
62356858|NCT02538367|EXPERIMENTAL|YH12852 IR 2mg|Once daily
62356859|NCT02538367|EXPERIMENTAL|YH12852 IR 3mg|Once daily
62356860|NCT02538367|EXPERIMENTAL|YH12852 DR1 0.5mg|Once daily
62356861|NCT02538367|EXPERIMENTAL|YH12852 DR1 1mg|Once daily
62356862|NCT02538367|EXPERIMENTAL|YH12852 DR1 2mg|Once daily
62356863|NCT02538367|EXPERIMENTAL|YH12852 DR1 4mg|Once daily
62356864|NCT02538367|EXPERIMENTAL|YH12852 DR2 8mg|Once daily
62356865|NCT02538367|ACTIVE_COMPARATOR|Prucalopride 2mg|Once daily
62356866|NCT02538367|PLACEBO_COMPARATOR|Placebo|Once daily
62356867|NCT04108819|EXPERIMENTAL|Ketogenic Diet|Participants will receive the ketogenic diet.
62356868|NCT03396926|EXPERIMENTAL|Treatment (pembrolizumab, bevacizumab, capecitabine)|Patients receive pembrolizumab IV over 30 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62356869|NCT03923075|ACTIVE_COMPARATOR|Dexmedetomidine|"Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution \[that corresponds to the volume (ml) calculated by the type body weight (Kg)/4 or body weight (Kg) X 0.25.~THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
62356870|NCT03923075|PLACEBO_COMPARATOR|0.9 % saline|"Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: body weight (Kg)/4 or body weight (Kg) X 0.25 THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
62356871|NCT06104319|EXPERIMENTAL|GSK4532990 Dose 1|Participants will receive GSK4532990 Dose 1
62356872|NCT06104319|EXPERIMENTAL|GSK4532990 Dose 2|Participants will receive GSK4532990 Dose 2
62356873|NCT06104319|EXPERIMENTAL|GSK4532990 Dose 3|Participants will receive GSK4532990 Dose 3
62356874|NCT06104319|EXPERIMENTAL|GSK4532990 Dose 4|Participants will receive GSK4532990 Dose 4
62520635|NCT02998450|EXPERIMENTAL|Cohort 5|"4 Subjects will receive a single mid-high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
62520636|NCT02998450|EXPERIMENTAL|Cohort 6|"4 Subjects will receive a single high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
62520637|NCT04715360|OTHER|Control|Only received standard medication (avigan) for severe COVID-19 management
62520638|NCT04715360|EXPERIMENTAL|PRP Group|received standard medication (avigan) for severe COVID-19 management and autologous activated platelet-rich plasma transfusion
62520639|NCT03322384|EXPERIMENTAL|Experimental|All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.
62356875|NCT04532073|EXPERIMENTAL|Eurythmy therapy exercises|As part of the ENTAiER trial: In group sessions á 5 patients with a qualified therapist: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by an eurythmy manual and an exercise video. This supplements the regular care.
62149329|NCT04995198||Participants with at least one variant of uncertain significance|
62356876|NCT04532073|EXPERIMENTAL|Tai Chi exercises|As part of the ENTAiER trial:In group sessions of 5 patients each with a qualified teacher: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by a Tai Chi Manual and an exercise video. This complements the regular care
62520640|NCT02604472||CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
62520641|NCT02604472||IC+CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
62520642|NCT02334865|EXPERIMENTAL|Group A (vaccine and week-4 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
62520643|NCT02334865|EXPERIMENTAL|Group B (vaccine and week-0 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 4, 6, 8, and 10 for up to 4 doses and then receive a booster in week 16. Beginning in week 0, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
62520644|NCT00674401|ACTIVE_COMPARATOR|1|"In patients with paroxysmal atrial fibrillation: Empirical pulmonary vein antrum circumferential isolation.~In patients with persistent atrial fibrillation: Empirical circumferential PV antrum isolation w/out roof line."
62520645|NCT00674401|ACTIVE_COMPARATOR|2|"In patients with paroxysmal atrial fibrillation: High frequency sites ablation in the LA.~In patients with persistent atrial fibrillation: A combined approach involving pulmonary vein antrum isolation w/out roof line and high frequency sites ablation"
62520646|NCT04802707|EXPERIMENTAL|dC/dT100-400 Arm|Children \& Adult (0-60 Y), who takes the investigational product deoxynucleosides pyrimidine (mix of deoxycytidine and deoxythymidine), following the protocol.
62520647|NCT02978924|ACTIVE_COMPARATOR|Cathodal tsDCS|20 min of active treatment
62520648|NCT02978924|SHAM_COMPARATOR|Sham tsDCS|20 min of sham treatment
62520649|NCT02429141|EXPERIMENTAL|US-guided periarterial techique|Axillary brachial plexus block by an ultrasound-guided periarterial technique
62520650|NCT02429141|EXPERIMENTAL|US-guided multi-injection technique|Ultrasound-guided multi-injection perineural technique for axillary brachial plexus
62711275|NCT02433964|EXPERIMENTAL|LED group|Treated by a device LED - LED: power 60mW, 627nm wavelength ± 10nm and 1,3cm2 beam output. The energy density used was 10J / cm2 with time of 2 minutes and 47 seconds per flash of the beam, which is unique for each ten points in the lateral region of the ankle edema. The volunteers underwent previous cleaning application points with cotton soaked in 70% alcohol, positioned for high stretcher in the supine position and wearing goggles. The LED was applied in a timely manner, wherein the skin contact surfasse at an angle of 90 °, the ten points were irradiated in a 1cm2 area selected by a single investigator. One session was performed every 24 hours for six consecutive days. Ice applications were made associated with semi-rigid compression bandage, with the patient lying supine and the affected limb in elevation under a foam wedge in the same period.
62520651|NCT03692143||teriparatide group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide
62520652|NCT03692143||PVP group plus alendronate|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with vertebroplasty. Then alendronate was prescribed.
62520653|NCT03692143||teriparatide and PVP group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide after vertebroplasty
62149330|NCT01049152||nondiabetic patients|nondiabetic patients with ESRD undergone hemodialysis
62356877|NCT04532073|ACTIVE_COMPARATOR|Standard Care Only|"As part of the ENTAiER trial:Brochure with detailed description of various evidence-based measures for fall prevention, prepared for the specific age group (https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf)~- Recommendation to visit the family doctor and discuss fall prophylaxis with her"
62356878|NCT03965871|EXPERIMENTAL|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62520654|NCT06036888||thoracobrachial outlet syndrome|"Patient :~* adult~* with thoraco-brachial outlet syndrome~* who has participated to DEFILE-QoL study in 2016~* who accept to participate and is able to complete questionaries"
62520655|NCT03347552|EXPERIMENTAL|Active Treatment|Participants in the active arm will be enrolled in the HOME Program.
62520656|NCT03347552|NO_INTERVENTION|E-CARE|"Receiving enhanced care as usual. Participants at these sites are described as receiving enhanced care as usual or E-CARE because they will be recruited, enrolled and complete baseline and follow-up assessments in addition to care as usual."
62520657|NCT01824134|ACTIVE_COMPARATOR|Klean & Klear|aloe vera gel
62149331|NCT01049152||diabetic patients|diabetic patients with ESRD undergone hemodialysis
62149332|NCT02089906||Chinese Elderly|multi-center cross-sectional study
62149333|NCT03367299|EXPERIMENTAL|Chemotherapy + Blinatumomab|Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
62149334|NCT05924113|EXPERIMENTAL|Post-Lung Transplant|Subjects that received a single or double lung transplants at Mayo Clinic Florida from 1/1/2020 to the present will participate in open sessions of Latin Dance over a 12-week period.
62149335|NCT03918005|EXPERIMENTAL|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
62520658|NCT01824134|ACTIVE_COMPARATOR|The Skin Gel|aloe vera gel
62520659|NCT00952549|EXPERIMENTAL|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
62520660|NCT04595916|EXPERIMENTAL|Polyene Phosphatidylcholine|
62520661|NCT04595916|ACTIVE_COMPARATOR|Magnesium Isoglycyrrhizinate|
62520662|NCT04029987|ACTIVE_COMPARATOR|Trans Muscular Quadratus Lumborum fascial plane Block|"In group (Trans Muscular Quadratus Lumborum Block),will undergo ultrasound guided trans-muscular quadratus lamborum block as follows:~A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoas Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
61974996|NCT04387175|EXPERIMENTAL|Carriere Motion 3D Class III Appliance|
62520663|NCT04029987|ACTIVE_COMPARATOR|Intra Muscular Quadratus Lumborum fascial plane Block|"In group Intra Muscular Quadratus Lumborum Block ,will undergo ultrasound guided intra-muscular quadratus lamborum (QL) block as follows:~A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
62520664|NCT04029987|PLACEBO_COMPARATOR|group c → control|group c → control ,will receive conventional analgesia in the form of paracetamol with 15 mg\\ k.g every 6 hours, and naluphin 0.1 mg \\kg on demands
62520665|NCT02882685|ACTIVE_COMPARATOR|RYGB|Roux-en-Y gastric bypass
62149336|NCT03918005|ACTIVE_COMPARATOR|High glycemic load diet|Foods with high glycemic index or glycemic load (white rice, white bread, corn flakes, mashed potatoes, orange juice, banana, persimmon, grape, raisins, honey, sugar)
62520666|NCT02882685|ACTIVE_COMPARATOR|SAGB|Single anastomosis gastric bypass
62520667|NCT05940623|ACTIVE_COMPARATOR|Management Paradigm I: Standard care and home IOP telemonitoring with smart phone-based intervention|Eligible patients randomized to Management Paradigm I will be provided with an iCare Home and instructed to measure and upload 6 IOP measurements weekly (2 days a week, 1 measurement in the early morning (5 am to 9 am), 1 during the mid-day (12 pm to 4 pm) and 1 in the evening (7 pm to 11pm)) to a secure server via iCare. Patients will be treated with topical prostaglandin analogue after baseline IOP measurements. A text message will be sent to the patient's smart phone to (1) inform whether the treatment goal is achieved over the past 4 weeks (i.e., ≥75% of the self- measured IOP measurements are below the target IOP) and (2) remind adherence to medications. The patients will need to reply via a text message reporting how many times eyedrops are missed over the past 4 weeks. A nurse will phone the patient if a reply message is not received or the number of home IOP measurements is less than 20 over the past 4 weeks.
62520668|NCT05940623|NO_INTERVENTION|Management paradigm II: Standard care and smart phone-based intervention|Patients will be treated with a topical prostaglandin analogue after baseline IOP measurements (described below). Additional treatment will be provided in the following order: carbonic anhydrase inhibitor, brimonidine, beta blocker, and selective laser trabeculoplasty (SLT) when the target IOP is not achieved. Fixed combination will be given whenever possible to improve adherence. Similar to Management Paradigm I, smart phone-based intervention includes (1) a text message from the investigators to inform whether the target pressure is attained (with reference to the latest clinic GAT measurement) and remind medication adherence every 4 weeks and (2) a reply message from the patients regarding how many times eyedrops are missed over the past 4 weeks.
62520669|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
62520670|NCT04887233|EXPERIMENTAL|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
62520671|NCT04887233|PLACEBO_COMPARATOR|Placebo nasal spray|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
62520672|NCT00833352|EXPERIMENTAL|1|Right ventricular lead located in Mid Septum
62520673|NCT00833352|ACTIVE_COMPARATOR|2|Right ventricular lead located in Apex
62520674|NCT02149121|EXPERIMENTAL|CT-P10|rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
62520675|NCT02149121|ACTIVE_COMPARATOR|Rituxan|US-licensed referece product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
62520676|NCT02149121|ACTIVE_COMPARATOR|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
62520677|NCT04277871|EXPERIMENTAL|The intervention group|The intervention group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The intervention group attended on-site group practice sections and performed individual home-based practice.
62520678|NCT04277871|ACTIVE_COMPARATOR|The comparison group|The comparison group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The comparison group performed individual home-based practice only.
62520679|NCT05624827|EXPERIMENTAL|Women with CIN 2 and under 36 years old|We will analyze patients under 36 years old (≤ 35) with histological confirmed CIN 2 lesions and without any additional risk factors.
62520680|NCT04842500|EXPERIMENTAL|"Cheap Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
62149337|NCT01735214||Patients with POAG or OHT|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
62149338|NCT00482911|EXPERIMENTAL|Cohort 1-lenalidomide & cyclophosphamide|Participants first started on 2 Interventions (Dose A-QD) in Cycle 1, with 10 mg Lenalidomide (Len) once daily and 50 mg Cyclophosphamide (Cyc) once daily; 25 mg Sunitinib (Sun) was added once daily as a 3rd Intervention (Dose B-QD) from Cycle 2 onwards. Doses were adjusted in subsequent cycles depending on toxicity, including incremental step downs to 5/25/12.5 mg Len/Cyc/Sun once daily (Dose C-QD) or once every other day (Dose C-QOD).
62149339|NCT00482911|EXPERIMENTAL|Cohort 2-sunitinib & cyclophosphamide|2 participants started Cycle 1 with Dose B as described above and had adjusted-dosing as described for Cohort 1. The remaining 7 participants began Cycle 1 with 10 mg Len, 25 mg Cyc and 12.5 mg Sun once daily (Dose D-QD). Doses were adjusted in subsequent cycles depending on toxicity, including step up to 10/50/12.5 mg Len/Cyc/Sun once daily (Dose E-QD) and step down to Dose D once every other day (Dose D-QOD).
62149340|NCT05750719||Women with early triple negative breast cancer who received neoadjuvant chemotherapy.|
62711276|NCT02433964|PLACEBO_COMPARATOR|Placebo group|Both volunteers LED group and the placebo group were treated with the same procedure, with the LED device in the placebo group remained off.
62520681|NCT04842500|EXPERIMENTAL|"Cheap Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
62520682|NCT04842500|EXPERIMENTAL|"Expensive Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
62520683|NCT04842500|EXPERIMENTAL|"Expensive Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
62520684|NCT04135196|EXPERIMENTAL|Low Magnitude|voluntary forearm compression by leaning onto the palm of the hand with low target strain
62520685|NCT04135196|EXPERIMENTAL|High Magnitude|voluntary forearm compression by leaning onto the palm of the hand with high target strain
62520686|NCT04135196|EXPERIMENTAL|Low Rate|"voluntary forearm compression by leaning onto the palm of the hand with low strain rate (task performed slowly and evenly)"
62520687|NCT04135196|EXPERIMENTAL|High Rate|"voluntary forearm compression by leaning onto the palm of the hand with high strain rate (task performed as quickly as possible, with a bump)"
62520688|NCT04135196|NO_INTERVENTION|Control|observation only
62149341|NCT05927259|ACTIVE_COMPARATOR|study group|Patients who will receive (conventional treatment of acute organophosphorus poisoning plus NAC)
62520689|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
62520690|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
62520691|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
62520692|NCT02957188||Young|Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
62520693|NCT02957188||Elderly|Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
62711277|NCT03501628|PLACEBO_COMPARATOR|Placebo|"2 servings daily~Serving information:~* 204 kcal~* 2.8 g fat~* 44.4 g carbohydrate~* 0.4 g protein (0 g L-leucine)"
62711278|NCT03501628|EXPERIMENTAL|L-leucine + maltodextrin|"2 servings daily~Serving information:~* 200 kcal~* 2.0 g fat~* 43.1 g carbohydrate~* 2.8 g protein (2.8 g L-leucine)"
62711279|NCT03501628|EXPERIMENTAL|Whey protein concentrate|"2 servings daily~Serving information:~* 184 kcal~* 3.5 g fat~* 12 g carbohydrate~* 26.3 g protein (2.8 g L-leucine)"
62711280|NCT03501628|EXPERIMENTAL|Hydrolyzed whey protein concentrate|"2 servings daily~Serving information:~* 192 kcal~* 4.6 g fat~* 12.2 g carbohydrate~* 25.4 g protein (2.9 g L-leucine)"
62149342|NCT05927259|OTHER|control group|Patients who will receive conventional treatment only
62149343|NCT05038202|EXPERIMENTAL|Bencycloquidium Bromide|Bencycloquidium Bromide Nasal Spray (90μg per spray)：1 spray on each nostril, 4times per day, continuous treatment for 4 weeks (28days).
62149344|NCT05038202|ACTIVE_COMPARATOR|Mometasone Furoate Aqueous|Mometasone Furoate Aqueous Nasal Spray (50μg per spray)：2 sprays on each nostril, 1 time per day, continuous treatment for 4 weeks (28days).
62356879|NCT03965871|EXPERIMENTAL|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62356880|NCT03965871|EXPERIMENTAL|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62356881|NCT03965871|PLACEBO_COMPARATOR|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
62520694|NCT02132754|EXPERIMENTAL|MK-4166 0.0015 mg|Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520695|NCT02132754|EXPERIMENTAL|MK-4166 0.0045 mg|Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520696|NCT02132754|EXPERIMENTAL|MK-4166 0.014 mg|Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520697|NCT02132754|EXPERIMENTAL|MK-4166 0.04 mg|Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520698|NCT02132754|EXPERIMENTAL|MK-4166 0.12 mg|Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520699|NCT02132754|EXPERIMENTAL|MK-4166 0.37 mg|Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520700|NCT02132754|EXPERIMENTAL|MK-4166 1.1 mg|Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520701|NCT02132754|EXPERIMENTAL|MK-4166 3.3 mg|Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520702|NCT02132754|EXPERIMENTAL|MK-4166 10 mg|Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520703|NCT02132754|EXPERIMENTAL|MK-4166 30 mg|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520704|NCT02132754|EXPERIMENTAL|MK-4166 42 mg|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520705|NCT02132754|EXPERIMENTAL|MK-4166 59 mg|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520706|NCT02132754|EXPERIMENTAL|MK-4166 82 mg|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520707|NCT02132754|EXPERIMENTAL|MK-4166 120 mg|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520708|NCT02132754|EXPERIMENTAL|MK-4166 170 mg|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62711281|NCT03501628|EXPERIMENTAL|Soy protein concentrate|"2 servings daily~Serving information:~* 266 kcal~* 4.5 g fat~* 17.2 g carbohydrate~* 39.2 g protein (2.9 g L-leucine)"
62711282|NCT01819740||patients with suspected prostate cancer|
62520709|NCT02132754|EXPERIMENTAL|MK-4166 240 mg|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520710|NCT02132754|EXPERIMENTAL|MK-4166 340 mg|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520711|NCT02132754|EXPERIMENTAL|MK-4166 480 mg|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520712|NCT02132754|EXPERIMENTAL|MK-4166 670 mg|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520713|NCT02132754|EXPERIMENTAL|MK-4166 900 mg|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
62520714|NCT02132754|EXPERIMENTAL|MK-4166 1.1 mg + Pembro|Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520715|NCT02132754|EXPERIMENTAL|MK-4166 3.3 mg + Pembro|Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520716|NCT02132754|EXPERIMENTAL|MK-4166 10 mg + Pembro|Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
61974997|NCT04387175|ACTIVE_COMPARATOR|Facial mask|
62711283|NCT00586157|ACTIVE_COMPARATOR|Methylphenidate Transdermal System (MTS)|
62711284|NCT00586157|PLACEBO_COMPARATOR|Placebo|
62356882|NCT00364819|EXPERIMENTAL|1|rituximab 1000 mg IV on days 1 and 15, given over 5 - 6 hours
62356883|NCT05572788|ACTIVE_COMPARATOR|Rectal Indomethacin|Patients assigned to the Indomethacin group will receive100 mg of indomethacin administered per rectal route (two tablets of 50 mg indomethacin suppositories)
62711285|NCT06433583|EXPERIMENTAL|transcutaneous auricular vagal nerve stimulation (taVNS) treatment|
62711286|NCT05603260|OTHER|Meta-cognitive imagery rescripting techniques (M-Int)|"These techniques are developed to reduce the power of an image by changing how the client responds to an image by shifting attention away from it, or by doing something that reinforces that it is just an image and not real."
61974998|NCT01365234|EXPERIMENTAL|20066 Lead|Non-randomized study. Intervention: Device: Pacing Lead
61974999|NCT04756843|EXPERIMENTAL|Early treatment|Treatment started in the early mixed dentition phase
61975000|NCT04756843|EXPERIMENTAL|Late treatment|Treatment started in the late mixed dentition phase
62356884|NCT05572788|PLACEBO_COMPARATOR|Placebo|Patients assigned to the Placebo group will receive two glycerin suppositories.
62356885|NCT02500368|EXPERIMENTAL|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
62356886|NCT02500368|ACTIVE_COMPARATOR|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
62356887|NCT01753830|EXPERIMENTAL|Durolane|Single intraarticular injection of Durolane
62356888|NCT01753830|PLACEBO_COMPARATOR|PBS|Single intraarticular injection of PBS
62356889|NCT00860119|EXPERIMENTAL|Sublingual tablet|Test treatment
62356890|NCT00860119|EXPERIMENTAL|Oral tablet|Reference treatment
62356891|NCT05848180|EXPERIMENTAL|Iinterventional group|Ankle proprioceptive and balance training 3 days a week for 8 weeks.
62356892|NCT05848180|ACTIVE_COMPARATOR|control group|Balance training 3 days a week for 8 weeks.
62356893|NCT01354613|EXPERIMENTAL|HFpEF|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF \> 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will receive amlodipine, oral administration for a period of 12 weeks.
62356894|NCT01354613|EXPERIMENTAL|Pulmonary Disease|20 patients with pulmonary disease and no clinical evidence of cardiovascular disease
62356895|NCT01354613|EXPERIMENTAL|LVH/HTN|20 subjects with known left ventricular hypertrophy and clinically diagnosed hypertension without the diagnosis of heart failure.
62356896|NCT01354613|PLACEBO_COMPARATOR|HFpEF placebo|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF \> 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will be administered a placebo for a period of 12 weeks.
62356897|NCT05439018|EXPERIMENTAL|Integrated Neuromuscular Inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique )
62356898|NCT05439018|ACTIVE_COMPARATOR|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
62520717|NCT02132754|EXPERIMENTAL|MK-4166 30 mg + Pembro|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520718|NCT02132754|EXPERIMENTAL|MK-4166 42 mg + Pembro|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520719|NCT02132754|EXPERIMENTAL|MK-4166 59 mg + Pembro|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520720|NCT02132754|EXPERIMENTAL|MK-4166 82 mg + Pembro|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520721|NCT02132754|EXPERIMENTAL|MK-4166 120 mg + Pembro|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520722|NCT02132754|EXPERIMENTAL|MK-4166 170 mg + Pembro|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520723|NCT02132754|EXPERIMENTAL|MK-4166 240 mg + Pembro|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
61975001|NCT03119194|EXPERIMENTAL|Reguimen A - [14C]-BIA 9-1067|"100 mg \[14C\]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.~Single dose administration on a single occasion."
61975002|NCT05728450|EXPERIMENTAL|Study group|This group includes 15 burned patients who will receive laser puncture for one month (3 times/week) in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment.
61975003|NCT05728450|NO_INTERVENTION|Control group|This group includes 15 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
62520724|NCT02132754|EXPERIMENTAL|MK-4166 340 mg + Pembro|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
61975004|NCT04756791|ACTIVE_COMPARATOR|Local infiltration anesthesia|Patients will receive local infiltration anesthesia with ropivacaine placed by surgeon.
61975005|NCT04756791|EXPERIMENTAL|Serratus anterior plane block|Patients receive a SAPB with ropivacaine placed by anesthesiologist.
62520725|NCT02132754|EXPERIMENTAL|MK-4166 480 mg + Pembro|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
61975006|NCT06379477|ACTIVE_COMPARATOR|Corneal refractive surgery|Among patients scheduled for cataract surgery, Group I; will undergo Corneal refractive surgery to correct any post-operative refractive surprises.
61975007|NCT06379477|ACTIVE_COMPARATOR|IOL exchange|Among patients scheduled for cataract surgery, Group II; will undergo IOL exchange to correct any post-operative refractive surprises.
61975008|NCT06379477|ACTIVE_COMPARATOR|Piggyback sulcus IOL|Among patients scheduled for cataract surgery, Group III; will undergo Piggyback sulcus IOL to correct any post-operative refractive surprises.
61975009|NCT04421729|ACTIVE_COMPARATOR|Savvy Caregiver Program|Savvy Caregiver Program, 6 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
62520726|NCT02132754|EXPERIMENTAL|MK-4166 670 mg + Pembro|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
61975010|NCT04421729|ACTIVE_COMPARATOR|Savvy Express|Savvy Express, 3 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
62520727|NCT02132754|EXPERIMENTAL|MK-4166 900 mg + Pembro|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
62520728|NCT04912882||Training Group|Training group including about 500 patients that be using to building the prognosis model
62356899|NCT06151860|EXPERIMENTAL|Static stretching|A equipment (Ladder Barrel), used in Pilates sessions, will help with the movement. To stretch the knee flexor muscles, the participant, standing, will place the dominant lower limb on the equipment and keep the other on the ground, remaining with both knees extended. The trunk will be flexed forward within the maximum range of movement achieved by the participant, until discomfort occurs in the posterior region of the thigh, but not pain. To stretch the knee extensor muscles, the participant, standing, will position the back of the foot of the dominant lower limb on the equipment and keep the other limb with the foot flat on the ground. The glute of the dominant lower limb will meet the heel of the same limb, until there is discomfort, but not pain. In both stretches, the position will be maintained for 30 seconds, followed by an equal rest time. Three series of stretching will be performed for the knee flexor muscles and then another three series for the extensor muscles.
62520729|NCT04912882||Validation Group|Validation group including about another 500 patients that be using to validating the prognosis model
62520730|NCT04019184|EXPERIMENTAL|Glutamine group|Intravenous infusion of 0.5 g/kg body weight (2.5 ml/kg body weight) L-alanyl-Lglutamine over 12 h after randomization
62520731|NCT04019184|PLACEBO_COMPARATOR|Control group|Intravenous infusion of 2.5 ml/kg body weight sodium chloride 0.9 % over 12 h after randomization
62520732|NCT03776292||supine position group= Group (S)|1st group of 20 patients will undergo urinary bladder cystectomy and orthotopic urinary diversion lying supine with ring abdominal retractors
62520733|NCT03776292||lateral position group = Group (L)|2nd group of 20 patients will undergo surgical open nephrectomy lying lateral position with self retaining abdominal retractors
62520734|NCT03221348|EXPERIMENTAL|Open label treatment|Study drug (CHO-H01) administered on Day 1 of 28 day cycles up to 6 cycles total.
62520735|NCT06067321|ACTIVE_COMPARATOR|4 hours formula feed|Parents asked to offer formula feed 4 hours prior to anticipated procedure start
62520736|NCT06067321|ACTIVE_COMPARATOR|6 hour formula feed|Parents asked to offer formula 6 hours prior to anticipated procedure start
62520737|NCT04111848|EXPERIMENTAL|ketamine group : group (k)|-Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour
61975011|NCT00555321|EXPERIMENTAL|Group 1: Basiliximab+Belatacept (MI) + MMF|
61975012|NCT00555321|EXPERIMENTAL|Group 2: Belatacept (MI) + MMF|
61975013|NCT00555321|EXPERIMENTAL|Group 3: Belatacept Less Intensive (LI) + MMF|
61975014|NCT00555321|OTHER|Group 4: Tacrolimus + MMF|Other
61975015|NCT00555321|ACTIVE_COMPARATOR|Group 5: Tacrolimus|
61975016|NCT03965910|OTHER|group 1|Group 1:Early rehabilitation
61975017|NCT03965910|OTHER|group 2|Group 2:Late rehabilitation
61975018|NCT02140229|ACTIVE_COMPARATOR|Usual care|Usual care and follow-up every 3 months
61975019|NCT02140229|EXPERIMENTAL|US-driven therapy|Clinical evaluation according to DAS28 + US every 3 months
61975020|NCT02140229|ACTIVE_COMPARATOR|ACR/EULAR remission criteria-driven therapy|Clinical evaluation according to DAS28 + ACR/EULAR remission criteria every 3 months
61975021|NCT05047510|EXPERIMENTAL|Anti-GPC3-IRDye800CW Intraoperative Fluorescence|The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
61975022|NCT00939250|EXPERIMENTAL|Diabetes and depression intervention|Measurement based care for diabetes and depression, disease self management for diabetes and depression
62520738|NCT04111848|EXPERIMENTAL|ketamine and magnesium group: group (KM)|- Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
62520739|NCT03016221|EXPERIMENTAL|Axanova hot gel|Intervention: Axanova hot gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
61975023|NCT00939250|ACTIVE_COMPARATOR|Diabetes intervention|Measurement based care for diabetes, disease self management for diabetes
62711287|NCT05603260|OTHER|Imagery rescripting techniques (ImRs)|These techniques are developed to update imagery appraisals, by for example adding a helpful other to the image or by imagining the scene from another perspective.
62711288|NCT05603260|OTHER|Promoting positive imagery de novo|These involve creating a new stand-alone positive imagery to help a client to increase his ability to self-soothe and reduce fear.
62711289|NCT05603260|OTHER|Visuospatial working memory tasks|These tasks are also known as imagery competing tasks (such as Tetris) and are used to directly target imagery using a tax visuospatial working memory task to reduce the frequency of intrusive imagery.
62356900|NCT06151860|EXPERIMENTAL|Pilates stretching|The protocol will be the same as the Static stretching Group, with the exception of maintaining the static position during the exercise. To do this, when stretching the knee flexor muscles, the trunk will perform continuous flexion movements until the point of muscular discomfort, followed by the extension movement, until an upright posture, continuously. On the other hand, when stretching the knee extensor muscles, the gluteal muscle of the dominant lower limb will meet the heel of the same limb, until there is discomfort, followed by the movement away, continuously.
62356901|NCT06151860|NO_INTERVENTION|Control|
62356902|NCT00206011|EXPERIMENTAL|1|
62356903|NCT00206011|OTHER|2|
62356904|NCT02414971||Men with prostate cancer|men over 18 years of age diagnosed with prostate cancer receiving external beam radiation
62356905|NCT04313088|OTHER|Experimental Group A|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group A will take eluxadoline 100mg by mouth twice for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take matching placebo by mouth twice daily. Each participant in Group A will take 42 days of eluxadoline 100mg twice daily followed by 42 days of placebo over the course the study.
62356906|NCT04313088|OTHER|Experimental Group B|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group B will take placebo by mouth twice daily for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take eluxadoline 100mg by mouth twice daily. Each participant in Group B will take 42 days of placebo followed by 42 days of eluxadoline 100mg twice daily over the course the study.
62356907|NCT05127291|EXPERIMENTAL|Study Group|Patients with type 2 diabetes mellitus
62356908|NCT05127291|OTHER|Control Group|People without type 2 diabetes and prediabetes
62356909|NCT03025893|EXPERIMENTAL|Sunitinib|Patients in this experimental arm will receive sunitinib in a high-dose, intermittent schedule.
62356910|NCT03025893|ACTIVE_COMPARATOR|Lomustine|Patients in this control arm will receive lomustine, currently used as second-line treatment in the case of recurrence.
62356911|NCT01535768|EXPERIMENTAL|Intervention Group|Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
62356912|NCT01535768|NO_INTERVENTION|Control Group|"Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates.~(If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)"
62356913|NCT03906175|EXPERIMENTAL|Whole-body hyperthermia|Whole-body hyperthermia will be applied 2 times during 4 weeks. At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
62520740|NCT03016221|NO_INTERVENTION|Axanova hot gel control|No product application. The contralateral lumbar back side acts as a Axanova hot gel control.
61975024|NCT03804879|EXPERIMENTAL|LMB763|50 mg LMB763 (two LMB763 25 mg capsules) were orally administered once daily for 24 weeks in addition to SoC.
61975025|NCT03804879|PLACEBO_COMPARATOR|Placebo|Placebo was orally administered once daily for 24 weeks in addition to SoC.
61975026|NCT06455371|NO_INTERVENTION|Control|Current clinical practise. Levothyroxine dose is calculated based on weight and adjusted according to TSH-level at 6-8 week intervals until biochemical target is reached
62356914|NCT03906175|NO_INTERVENTION|Wait list|Participants will wait for 6 weeks (primary outcome assessment point). They will then receive the same treatment procedure as the experimental group. They will also be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
62356915|NCT02197598|EXPERIMENTAL|Selincro® (nalmefene) 18 mg, tablets|One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.
62356916|NCT02527187|EXPERIMENTAL|Allergic patients to birch pollen|"Allergic patients already diagnosed to be true allergic to birch pollen.~A mean wheal diameter \>3 mm obtained in a prick test with histamine dihydrochloride 10 mg/ml.Also presence of serum specific IgE and clinical history of symptomatology related to exposure to birch pollen.~Patients of both gender aged from 5 up to 70 years."
62149345|NCT05038202|EXPERIMENTAL|Bencycloquidium Bromide with Mometasone Furoate Aqueous|Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray: For Bencycloquidium Bromide Nasal Spray(90μg per spray), 1 spray on each nostril, 4times per day. For Mometasone Furoate Aqueous Nasal Spray (50μg per spray), 2 sprays on each nostril, 1 time per day. If there is an overlap between the two drugs, use Bencycloquidium Bromide Nasal Spray first, and then mometasone furoate nasal spray should be used after an interval of more than 30 minutes.
62520741|NCT03016221|EXPERIMENTAL|Axanova activ gel|Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
61975027|NCT06455371|EXPERIMENTAL|DST 1|Levothyroxine dose is calculated using the current version of the decision support tool based on 4 blood samples.
61975028|NCT06455371|EXPERIMENTAL|DST 2|Levothyroxine dose is calculated using an improved mathematical model in the decision support tool based on 4 blood samples.
62520742|NCT03016221|NO_INTERVENTION|Axanova activ gel control|No product application. The contralateral lumbar back side acts as a Axanova activ gel control.
61975029|NCT06455371|EXPERIMENTAL|DST 3|Levothyroxine dose is calculated using an improved mathematical model in the decision support tool based on 2 blood samples.
61975030|NCT01988792|ACTIVE_COMPARATOR|Fortification at 20 ml/kg/day feeding volume|Human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 20 ml/kg/day.
62711290|NCT01880957|OTHER|Lithium|Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
61975031|NCT01988792|ACTIVE_COMPARATOR|Fortification at 100 ml/kg/day feeding volume|human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 100 ml/kg/day.
62149346|NCT04552015|OTHER|volunteers|two different types of diagnostic tools (TST vs microneedle) will be used to screen for latent TB infection
62149347|NCT04920799|ACTIVE_COMPARATOR|Nitrate rich beetroot juice|
62149348|NCT04920799|PLACEBO_COMPARATOR|Nitrate depleted beetroot juice|
62149349|NCT00555932|ACTIVE_COMPARATOR|1|The research head ultrasound (HUS) will be performed at the bedside in the Neonatal Unit. The ultrasound examination will be performed within 10 hours time window of the MR and or CT study.
62149350|NCT00523900|EXPERIMENTAL|Experimental|Malnourished adults who will be given a dietary supplement.
62149351|NCT05168280|ACTIVE_COMPARATOR|DEX group|The DEX group patients will be received dexmedetomidine intraoperatively.
62149352|NCT05168280|PLACEBO_COMPARATOR|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively.
62149353|NCT03335059|EXPERIMENTAL|Synergo® RITE + MMC|Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
62149354|NCT00780793|ACTIVE_COMPARATOR|1-M : Maintenance|Usual care
62149355|NCT00780793|EXPERIMENTAL|2 -S : Spacing of TNF-blocker injections|Spacing of TNF-blocker injections
62149356|NCT04635657||Meningioma Group|This group will include all patients in the study, regardless of location (frontal or temporal lobe) or surgical approach (endoscopic endonasal or craniotomy). Fifty patients will be included in the cohort
61975032|NCT01972503|EXPERIMENTAL|ARM A|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6.
62149357|NCT03136159|EXPERIMENTAL|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
61975033|NCT01972503|ACTIVE_COMPARATOR|ARM B|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone.
61975034|NCT03695107||XBDP1-|
61975035|NCT03695107||XBDP2-|
61975036|NCT05256160|EXPERIMENTAL|CVS subjects|Subjects diagnosed with Cyclic Vomiting Syndrome (CVS)
62149358|NCT05013398|EXPERIMENTAL|The Together Webinar Programme (TTP-Webinar)|Participants receive the six weekly session TTP-Webinar intervention.
62149359|NCT05013398|NO_INTERVENTION|Waitlist condition|Participants do not receive any intervention as part of waitlist condition. Note: Following the collection of measures at the follow-up time point, participants assigned to the waitlist condition were offered four TTP-Webinar groups to sign up to.
62149360|NCT00825318|EXPERIMENTAL|Daily ultrafiltration|During the treatment phase of the study, the subject will undergo ultrafiltration 6 times a week and hemodialysis 2 times a week.
62149361|NCT03410420|ACTIVE_COMPARATOR|Non aneurysmal|Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
62520743|NCT03016221|EXPERIMENTAL|Perskindol Dolo Gel|Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
62520744|NCT03016221|NO_INTERVENTION|Perskindol Dolo Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Dolo Gel control.
61975037|NCT05256160|ACTIVE_COMPARATOR|healthy, non-CVS subjects|Subjects not diagnosed with CVS
61975038|NCT04723745||VTRACTS|We will target post-9/11 Veterans with TBI or blast exposure who self-report ongoing post-concussive neurobehavioral symptoms, but V-TRACTS will be open to all post-9/11 Veterans irrespective of any diagnoses.
62149362|NCT03410420|EXPERIMENTAL|Aneurysmal|Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
62149363|NCT06505525|EXPERIMENTAL|Anatomical ACL reconstruction combined with extra-articular reconstruction with ALL|Anatomical ACL reconstruction combined with extra-articular reinforcement reconstruction with ALL
62520745|NCT03016221|EXPERIMENTAL|Perskindol Classic Gel|Intervention: Perskindol Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
62520746|NCT03016221|NO_INTERVENTION|Perskindol Classic Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Classic Gel control.
62520747|NCT03016221|EXPERIMENTAL|Perskindol Cool Kühl-Gel|Intervention: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
62520748|NCT03016221|NO_INTERVENTION|Perskindol Cool Kühl-Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Cool Kühl-Gel control.
62149364|NCT06505525|ACTIVE_COMPARATOR|Isolated intra-articular anatomical ACL reconstruction|Isolated intra-articular anatomical ACL reconstruction
62520749|NCT03016221|EXPERIMENTAL|Dolor-X Hot Gel|Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
62520750|NCT03016221|NO_INTERVENTION|Dolor-X Hot Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Hot Gel control.
62520751|NCT03016221|EXPERIMENTAL|Dolor-X Classic Gel|Intervention: Dolor-X Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
62520752|NCT03016221|NO_INTERVENTION|Dolor-X Classic Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Classic Gel control.
62520753|NCT03016221|EXPERIMENTAL|Dolor-X Cool Gel|Intervention: Dolor-X Cool Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
62520754|NCT03016221|NO_INTERVENTION|Dolor-X Cool Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Cool Gel control.
62149365|NCT04946734|EXPERIMENTAL|Test Arm|Device PFO closure
62149366|NCT04946734|OTHER|Control Arm|Drugs only
62356917|NCT02527187|EXPERIMENTAL|Non-allergic patients to birch pollen|"Patients already diagnosed to be true non-allergic to birch pollen.~Non clinical history of symptomatology related to the exposure to birch pollen. Previous skin prick test negative and absence or undetectable serum specific IgE to Betula verrucosa~Patients of both gender aged from 5 up to 70 years."
62356918|NCT03214328||Determination of causes of fetal death|Both the extensive and selective protocols will be applied to each case of IUFD recruited, so that each case will serve as its own control. For each case, determination of cause from either protocol will be performed in a blind manner with respect to the other protocol.
62356919|NCT02992301|EXPERIMENTAL|Open Label|All enrolled patients will receive open label Praluent (Alirocumab).
62356920|NCT02617576||Flavored contrast|This group of patients will have the choice to flavor their contrast.
62356921|NCT02617576||Unflavored contrast|This group of patients will drink the contrast without flavoring.
62356922|NCT05048199|EXPERIMENTAL|pressure regulated volume-controlled mode of ventilation (PRVC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
62356923|NCT05048199|ACTIVE_COMPARATOR|volume-controlled mode of ventilation (VC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
62520755|NCT05684471|ACTIVE_COMPARATOR|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients randomized to receive suprainguinal fascia iliaca block
62520756|NCT05684471|ACTIVE_COMPARATOR|Ultrasound Guided Anterior quadratus lumborum block|Patients randomized to receive anterior quadratus lumborum block
62520757|NCT02756247|EXPERIMENTAL|Buparlisib and Ibrutinib|"This is a two stage protocol comprised of a single institution phase Ib dose escalation trial. The first stage is a standard 3+3 phase I dose escalation trial to assess the safety of buparlisib and ibrutinib. The second stage is a single center expansion cohort in MCL, FL and DLBCL respectively evaluating the efficacy of buparlisib and ibrutinib combination.~Treatment will be with ibrutinib orally daily and buparlisib orally daily. A cycle is defined as 4 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death with a maximum duration for 36 cycles, not exceeding 36 months on therapy."
62520758|NCT03631082|EXPERIMENTAL|Slump stretching group|"Slump stretching will be performed with the patient in the long sitting position. The position will be held for 30 seconds. A total of 5 repetitions will be completed.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, and quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
62520759|NCT03631082|ACTIVE_COMPARATOR|Lumbar mobilization group|"Maitland Grade 1 - 2 Posterior to anterior lumbar spine mobilization will be applied for 30 - 45 seconds for all segments through L1 to L5 at rate of 1 oscillation per 2 seconds.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
62149367|NCT05145348||Down syndrome, adults|Adults and adolescents with Down syndrome \>16 years old.
62149368|NCT05145348||Healthy control, adults|Healthy adults and adolescents without Down syndrome \> 16 years old. Without any significant comorbidities.
62520760|NCT03192865||diaphragmatic paralysis/paresis group|"Diaphragmatic paralysis can be associated with regional anesthesia procedure in arthroscopic shoulder surgery as phrenic nerve is close to the brachial plexus.~Diaphragmatic paralysis will be defined using ultrasounds."
62520761|NCT03192865||No diaphragmatic paralysis/paresis group|Some strategies of peripheral nerve block are able to spare diaphragmatic paralysis.
62711291|NCT01880957|OTHER|Lamotrigine|Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
62711292|NCT00678704|PLACEBO_COMPARATOR|Arm 3|
62520762|NCT04801953|ACTIVE_COMPARATOR|Nimodipine|During surgery a nimodipine soaked gel foam pad is administered to the cranial nerves VII and VIII
62520763|NCT04801953|PLACEBO_COMPARATOR|Placebo|During surgery a sodium chloride soaked gel foam pad is administered to the cranial nerves VII and VIII
62520764|NCT02881060|ACTIVE_COMPARATOR|Ethanol|Drinking a cocktail of ethanol (0.8 g ethanol per kg body weight), diet lemonade and water of 1:1:1 (volume distribution).
62520765|NCT02881060|PLACEBO_COMPARATOR|Non-ethanol|Drinking a cocktail of diet lemonade and water of 1:2 (volume distribution).
62520766|NCT02623049||octogenarians patients - Apixaban|octogenarians patients who will be treated with Apixaban
62520767|NCT02623049||younger than 70 years patients - Apixaba|younger than 70 years patients who will be treated with Apixaba
62711293|NCT00678704|EXPERIMENTAL|Arm 1|
62149369|NCT05145348||Down syndrome, children|Children with Down syndrome \< 16 years old.
62149370|NCT05145348||Healthy control, children|Healthy children without Down syndrome \< 16 years old. Without any significant comorbidities.
62520768|NCT02623049||octogenarians patients - Rivaroxaban|octogenarians patients who will be treated with Rivaroxaban
62149371|NCT02356874|EXPERIMENTAL|Exercise group|Exercise
62520769|NCT02623049||younger than 70 years patients - Rivaroxaban|younger than 70 years patients who will be treated with Rivaroxaban
62520770|NCT02623049||octogenarians patients - Dabigatran|octogenarians patients who will be treated with Dabigatran
62149372|NCT02356874|NO_INTERVENTION|Control group|Participants in the control group will be asked to continue their usual physical activity habits
62149373|NCT01145313||Patients diagnosed with Major Depressive Disorder|Patients diagnosed with MDD who are treated with antidepressants and subsequently augment with atypical antipsychotic therapy.
62520771|NCT02623049||younger than 70 years patients - Dabigatran|younger than 70 years patients who will be treated with Dabigatran
62711294|NCT00678704|EXPERIMENTAL|Arm 2|
62711295|NCT06710080|EXPERIMENTAL|Treatment|Participants randomized to this arm will receive Vascepa for 6 months.
62711296|NCT06710080|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will receive placebo for 6 months.
62711297|NCT03984279||Sequentiel group (SEQ)|
62711298|NCT03984279||Siral group (SPI)|
62711299|NCT05853601|EXPERIMENTAL|Single Dose Theophylline|Single dose of theophylline or aminophylline (5mg/kg IV) given within 18 hours after birth
62711300|NCT05853601|EXPERIMENTAL|Repeat Dose Theophylline|Loading dose of theophylline or aminophylline (5mg/kg IV) given within 18 hours of birth, with two subsequent doses (1.2 mg/kg IV) given at 12 and 24 hours after the loading dose
62711301|NCT05853601|NO_INTERVENTION|Standard treatment|Infants cared for according to standard practice.
62711302|NCT04964947|EXPERIMENTAL|Tobramycin Treatment Group|Participants in this group receive a local aqueous tobramycin injection (2mg/mL) plus standard of care treatment.
62711303|NCT04964947|NO_INTERVENTION|Standard of Care Treatment Group|Participants in this group receive standard of care treatment.
62149374|NCT04374981|EXPERIMENTAL|Celecoxib|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of celecoxib tablets (100mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
62520772|NCT01426035|EXPERIMENTAL|GROUP 1|
62520773|NCT01426035|ACTIVE_COMPARATOR|GROUP 2|
62520774|NCT00208117|ACTIVE_COMPARATOR|1|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
62520775|NCT00208117|PLACEBO_COMPARATOR|2|To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
62711304|NCT04807738|ACTIVE_COMPARATOR|"Neuroproprioceptive facilitation and inhibition"|"ARM 1 - Neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT), with former positive probative evidence on MS and are recommended for MS intervention."
62715105|NCT06157034|EXPERIMENTAL|T3|"* Carum carvi, L, commonly known as caraway, is a botanical with a rich history of traditional use. In this clinical study, a treatment group, denoted as T3, is established to investigate the effects of encapsulated Carum carvi, L powder in alleviating the gastrointestinal disturbances among TB patients.~* Intervention Details:~  * Generic Name: Carum carvi, L powder~ * Dosage Form: Encapsulated~ * Dosage: 1 g per capsule~ * Frequency: Twice daily~ * Total Daily Dosage: 2 g/day~ * Administration Timing: After breakfast and dinner~ * Duration of Treatment: 3 months~* Throughout the study duration, data will be systematically collected from participants in the T3 treatment group. This data may include subjective reports, clinical assessments, and laboratory analyses."
62520776|NCT06139393|EXPERIMENTAL|Treatment group A: HR091506 tablets + placebo of febuxostat tablets|
62520777|NCT06139393|ACTIVE_COMPARATOR|Treatment group B: febuxostat tablets + placebo of HR091506 tablets|
62520778|NCT03510182|EXPERIMENTAL|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
62520779|NCT04219735|EXPERIMENTAL|Minocycline|Minocycline 100 mg BID
62520780|NCT04219735|PLACEBO_COMPARATOR|Placebo|Placebo capsules identical to experimental arm
62520781|NCT02733081|NO_INTERVENTION|Arm 1: Traditional IUD Insertion|Standard IUD insertion according to package insert. Bimanual pelvic exam to assess uterine size and position will be performed. Uterine sound will be used to measure depth of uterus prior to insertion.
62520782|NCT02733081|EXPERIMENTAL|Arm 2: Simplified IUD Insertion|Simplified, investigational IUD insertion performed. No bimanual pelvic exam or uterine sounding.
62149375|NCT04374981|EXPERIMENTAL|Montelukast|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of Montelukast tablets (10mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
62149376|NCT04221711|EXPERIMENTAL|Repetitive pulsed magnetic stimulation|Patients randomized in this group will receive rPMS (80 milliTesla ; 2 Hertz; OMNITRON® promed; Healthfactories Holding GmbH) three times a week for a total of 12 weeks. Thereby they will be lying in a prone position or sitting for 20 minutes with the magnet coil positioned over the mid-portion of the affected Achilles tendon (manufactures instruction).
62149377|NCT04221711|ACTIVE_COMPARATOR|Eccentric Calf Muscle Training for Achilles Tendinopathy|Two types of eccentric exercises will be used. The calf muscle will be eccentrically loaded both with the knee straight and with the knee bent. Each of the two exercises will include an increasing number of repetitions (1. Week, 2-3 weeks, 4-12 weeks) done in 3 sets (e.g. 3x15, 3x20, 3x30 repetitions). The patients will be informed that muscle soreness during the first 1 to 2 weeks of training was to be expected. Patients will receive a visual exercise protocol.
62149378|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
62149379|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
62149380|NCT02382172|EXPERIMENTAL|Social Cognition and Interaction Training for Autism (SCIT-A)|The measures the investigators are giving assess participants' initial level of social deficits and the extent to which the therapy did or did not help their social skills. The research team will compare the level of difficulty that participants first reported with their subjective evaluation of their experience in the group sessions to determine whether the program is clinically useful for further development. The investigators will also have the participants complete eye tracking paradigms to assess possible changes in social functioning after completing the Social Cognition and Interaction Training for Autism (SCIT-A) program.
62356924|NCT03104985|ACTIVE_COMPARATOR|Conventional treatment|"Conventional treatment only.~* An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2~* Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.~* Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
62356925|NCT03104985|EXPERIMENTAL|Conventional therapy and combined LLLT|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:~1. - 365-405nm, power 1-2mW, exposure 2 min;~2. - 520-525nm, 1-2mW, 5 min;~3. - 365-405nm, 1-2mW, 2 min;~4. - 520-525nm, 1-2mW, 5 min;~5. - 365-405nm, 1-2mW, 2 min;~6. - 520-525nm, 1-2mW, 5 min;~7. - 365-405nm, 1-2mW, 2 min;~8. - 520-525nm, 1-2mW, 5 min;~9. - 365-405nm, 1-2mW, 2 min;~10. - 520-525nm, 1-2mW, 5 min;~11. - 365-405nm, 1-2mW, 2 min;~12. - 520-525nm, 1-2mW, 5 min"
62520783|NCT03767855|EXPERIMENTAL|CK-3773274 for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274
62520784|NCT03767855|PLACEBO_COMPARATOR|Placebo for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo
62520785|NCT03767855|EXPERIMENTAL|CK-3773274 for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274
62520786|NCT03767855|PLACEBO_COMPARATOR|Placebo for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo
62520787|NCT03767855|EXPERIMENTAL|CK-3773274 for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274
62520788|NCT03767855|PLACEBO_COMPARATOR|Placebo for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo
62520789|NCT03767855|EXPERIMENTAL|Food Effect|Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion
62520790|NCT03767855|EXPERIMENTAL|Relative Bioavailability|Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.
62520791|NCT01363804|EXPERIMENTAL|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
62520792|NCT04870450||Healthcare professionals|No intervention. Gathering data on their experiences of using video diaries.
62520793|NCT04870450||Family members of ICU patients|No intervention. Gathering data on their experiences of using video diaries.
62520794|NCT02872792|EXPERIMENTAL|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer in addition of Standard physiotherapy during sepsis for patient with sepsis in ICU
61975039|NCT05403177||MOHCCN-O|Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.
61975040|NCT01534871|EXPERIMENTAL|Exercise|Subjects enrolled in the exercise arm will receive the study intervention.
62149381|NCT02382172|OTHER|Treatment As Usual (TAU)|Continuation of services being given upon study entry.
61975041|NCT01534871|NO_INTERVENTION|Control|Subjects in the control arm will receive standard of care (e.g. medication and medical supervision) for rheumatoid arthritis. These subjects will not participate in the exercise intervention.
62520795|NCT02872792|ACTIVE_COMPARATOR|Standard physiotherapy|Standard physiotherapy during sepsis for patient with sepsis in ICU
62520796|NCT01936519|ACTIVE_COMPARATOR|Calcineurin Inhibitor with Mycophenolic Acid|Calcineurin inhibitor immunosuppression with mycophenolic acid
62520797|NCT01936519|EXPERIMENTAL|Everolimus with Mycophenolic Acid|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
62520798|NCT03475264||Healthy|Healthy Participants
62711305|NCT04807738|EXPERIMENTAL|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"ARM 2. Experimental group, neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) through virtual reality and software inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). We believe that the VR environment might lead to better results due to greater motivation effect, novelty effect, entertainment effect, as well as activating the reward system. We believe the VR might enhance the activation of mirror neurons, it might also activate proprioception. The present physiotherapist is to ensure proper execution of the tasks. The correlation of the two arms of the study should indicate, whether virtual reality and the software used are as effective, or more effective in sustaining the hand motor function and axial stability, than traditionally led therapy."
62711306|NCT03976336|EXPERIMENTAL|Berberine|
62711307|NCT03976336|PLACEBO_COMPARATOR|Identical Placebo|
62149382|NCT04995315||PK Deficiency Diagnosed Participants|Participants will receive online user access to the CBB. Participants will complete 2 CBB assessments on Study Day 0 and Study Day 90.
62149383|NCT03146845|EXPERIMENTAL|ALLEVYN Life Non-Bordered|Foam Dressing
62149384|NCT03146845|OTHER|Standard care|Standard care dressing
62149385|NCT01196364|EXPERIMENTAL|Sedentary activity, noncaloric beverage|
62149386|NCT01196364|EXPERIMENTAL|Sedentary activity, glucose beverage|
62149387|NCT01196364|EXPERIMENTAL|Exercise activity, noncaloric beverage|
62149388|NCT01196364|EXPERIMENTAL|Exercise activity, glucose beverage|
62149389|NCT03339544|EXPERIMENTAL|Celebrex premedication|Celebrex is a NSAID with selective COX-2 inhibition properties, is given as an intervention to assess the pain
62149390|NCT03339544|PLACEBO_COMPARATOR|Placebo tablets|placebo tablets to compare the efficacy of Celebrex on the intra-operative and post-operative pain accompanying endodontic treatment of teeth with irreversible pulpits
62149391|NCT01230970|EXPERIMENTAL|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
62149392|NCT06309862||Patients with skin cancer eligible for dual ICI treatment.|
62149393|NCT00125723|NO_INTERVENTION|No Intervention|
62149394|NCT00125723|OTHER|Intervention|PI Discretion
62149395|NCT04038190|EXPERIMENTAL|Behavioral Activation Course|Behavioral activation course condition administered in a college freshman orientation seminar
62149396|NCT04038190|NO_INTERVENTION|Standard Orientation Course|Standard freshman orientation seminar course condition
62149397|NCT00853606|EXPERIMENTAL|avanafil|
61975042|NCT04758754|EXPERIMENTAL|Single leg knee extension training (SLKE)|Active 8-week training involving lower limbs. SLKE participants will be involved in a 8-week aerobic training protocol involving the knee extensor muscles. The training will be held on an Anderson and Saltin ergometer, 3 times per week, with a single session duration of 33.3 min. Total weekly duration: 100 min.
62149398|NCT03160976|NO_INTERVENTION|Control Group|Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
62149399|NCT03160976|ACTIVE_COMPARATOR|Intervention Group|A single 50 minutes session of cold exposure with a cryolipolysis device. The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
62149400|NCT01219127|EXPERIMENTAL|Derma-PACE|Pre-treatment evaluations include complete history and physical examination, chemistry and coagulation profiles, detailed past surgical and medical treatments. The local findings of the ulcer are quantitatively assessed using the S(AD) SAD classification (6) including photo-documentation for the size, shape and configuration of the ulcer
62149401|NCT04084262||All Study Participants|Phantom® Intramedullary Nail combined with a supinating reduction technique
62149402|NCT00987272|EXPERIMENTAL|Pataday+Pataday Vehicle|Olopatadine Hydrochloride Ophthalmic Solution 0.2%, 1 drop in 1 eye and Olopatadine 0.2% Vehicle in the contralateral eye
62520799|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
62520800|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
62520801|NCT04790123|SHAM_COMPARATOR|Control group|
62520802|NCT04790123|EXPERIMENTAL|Experimental group|
62520803|NCT04079127||Patients suffering from severe hip pain and disability|Patients in need of a total hip arthroplasty.
62520804|NCT03852459|EXPERIMENTAL|Active Arm|S-Ibuprofen Topical Gel 5%
62520805|NCT03852459|PLACEBO_COMPARATOR|Placebo Arm|Vehicle Topical Gel
62520806|NCT05077371|EXPERIMENTAL|Experimental group 1|newly diagnosed breast cancer patients receiving the peer support program at the beginning of their medical treatment.
62520807|NCT05077371|EXPERIMENTAL|Experimental group 2|newly diagnosed breast cancer patients receiving the social peer support program at the end of their medical treatment.
62520808|NCT01706874||Periodontal prophylaxis|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.
62520809|NCT01706874||Control|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients
62520810|NCT00569790|EXPERIMENTAL|1|S-1, Irinotecan, Bevacizumab
62520811|NCT04435106||Opaganib + Standard of Care|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
62520812|NCT04435106||Standard of Care|Study participants received Standard of Care
62520813|NCT01197417|EXPERIMENTAL|Magnesium group|Intravenous Magnesium Sulfate
62520814|NCT01197417|PLACEBO_COMPARATOR|Placebo group|Normal Saline placebo
62520815|NCT02387593|EXPERIMENTAL|colonoscopy with endocuff|To the usual colonoscopy will place a endocuff at the tip of the colonoscope
62520816|NCT02387593|NO_INTERVENTION|standard colonoscopy without endocuff|Routine colonoscopy without endocuff
62520817|NCT04439773|PLACEBO_COMPARATOR|control group|the control group will be given the same volume of saline as the experimental group
62149403|NCT00987272|ACTIVE_COMPARATOR|Patanol+Patanol Vehicle|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, 1 drop in 1 eye and Olopatadine 0.1% Vehicle in the contralateral eye
62149404|NCT03142867||Control|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The control group will be made of individuals who do not meet the qualifications for a liver biopsy."
62520818|NCT04439773|EXPERIMENTAL|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
62520819|NCT01057381|ACTIVE_COMPARATOR|Dexmedetomidine 0.75 mcg/kg|Intraoperative administration for analgesia.
62711308|NCT05300477|EXPERIMENTAL|Acetazolamide|Acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
62711309|NCT05300477|EXPERIMENTAL|Erythropoietin and Acetazolamide|Erythropoietin (subcutaneously) 50 IU /kg three times a week for 4 weeks. After the 4 week Erythropoietin, acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
62711310|NCT06529432|EXPERIMENTAL|Bupivacaine Liposome Injection|
62711311|NCT06529432|ACTIVE_COMPARATOR|Bupivacaine Hydrochloride Injection|
62711312|NCT03081689|EXPERIMENTAL|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
62711313|NCT06297876|EXPERIMENTAL|Storytelling|Participants will view short video narratives of community members speaking about why they chose to get vaccinated against Coronavirus Disease of 2019 (COVID-19) and how they overcame hesitancy. Participants will also view the informational videos described below.
62711314|NCT06297876|OTHER|Learn More|Participants will view short informational videos that provide factual information on the COVID-19 vaccines.
62711315|NCT03440385|EXPERIMENTAL|Administration of oral Ozanimod|
62711316|NCT03440385|PLACEBO_COMPARATOR|Administration of Placebo|
62149405|NCT03142867||NAFLD|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD."
62520820|NCT01057381|ACTIVE_COMPARATOR|Dexmedetomidine 1mcg/kg|Intra-operative administration of dexmedetomidine 1 mcg/kg for analgesia
62520821|NCT01057381|ACTIVE_COMPARATOR|Morphine 50 mcg/kg|Intra-operative administration of morphine 50 mcg/kg for analgesia
62711317|NCT06712602|EXPERIMENTAL|PT150 with alcohol consumption then stress|Following at least five days of maintenance on a randomized dose of PT150, participants will complete an experimental alcohol administration session. No less than 24 hours later, participants will then complete an experimental stress induction session.
62520822|NCT01057381|ACTIVE_COMPARATOR|Morphine 100mcg/kg|Intra-operative administration of morphine 100mcg/kg for analgesia
62520823|NCT05752565|OTHER|patients with severe HA under FVIII concentrates prophylaxis|patients with severe HA under FVIII concentrates prophylaxis
62711318|NCT06712602|EXPERIMENTAL|PT150 with stress then alcohol consumption|Following at least five days of maintenance on a randomized dose of PT150, participants will complete an experimental session involving stress induction. No less than 24 hours later, participants will then complete an experimental alcohol administration session.
62711319|NCT02468830|EXPERIMENTAL|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
62149406|NCT03142867||NASH|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH."
62520824|NCT01681966|EXPERIMENTAL|Application of PRF110- oily solution|Post operative application of new extended release PRF110- oily solution (Ropivacaine)
62520825|NCT03093818|EXPERIMENTAL|Pharmacogenomic testing arm|"4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a Safety-Code card containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions."
62520826|NCT03093818|NO_INTERVENTION|Standard of care arm|"4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock Safety-Code card, which does not contain personal pharmacogenomics results."
62520827|NCT04612517|EXPERIMENTAL|ZP7570|Four ascending doses of ZP7570
62711320|NCT06717880|EXPERIMENTAL|IBI363 combined with Bevacizumab|IBI363 Combined with Bevacizumab in Subjects with Advanced Colorectal Cancer
62711321|NCT01464879|EXPERIMENTAL|Testosterone 2.50 mL (hand)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
62520828|NCT04612517|PLACEBO_COMPARATOR|Placebo|Corresponding volume of placebo
62520829|NCT03867799|EXPERIMENTAL|Nivolumab and Relatlimab|Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks
62520830|NCT01882179|PLACEBO_COMPARATOR|Placebo|Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
61975043|NCT04758754|ACTIVE_COMPARATOR|Passive static stretching training (PST)|Passive 8-week training involving lower limbs. PST participants will be involved in a 8-week passive static training training involving the knee extensor muscles. The training will have a frequency of 5 times per week, with a single duration of 20 min. Total weekly duration: 100 min
61975044|NCT04758754|NO_INTERVENTION|Control (CTRL)|CTRL will not receive any intervention.
62149407|NCT05346588|ACTIVE_COMPARATOR|Propofol total intravenous anesthesia (TIVA)|No administration of inhaled agent.
62520831|NCT01882179|ACTIVE_COMPARATOR|Mineralocorticoid receptor antagonist|"1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible~In case the LVEF \<40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines."
62520832|NCT02496819|EXPERIMENTAL|Metacognitive self-regulated learning intervention|It involves training of daily tasks using a self-correct strategy. Participants' performance will be video-taped and they will then watch the video playback for reflection and self-correction under the guidance of the occupational therapist.
62520833|NCT02496819|EXPERIMENTAL|Sensory Integration intervention|It involves active, fun physical activity completing 8 stations of activities involving tactile, proprioceptive and vestibular tasks. Frequent breaks will be given to avoid exhaustion and fatigue throughout the activities.
62520834|NCT02496819|ACTIVE_COMPARATOR|Activity-Based Intervention|It provides constructional, drawing and crafts activity. Participants are guided to complete these tasks
62520835|NCT01762124|EXPERIMENTAL|Native Outflow Tract TPV|Implantation of the Native Outflow Tract TPV
62149408|NCT05346588|ACTIVE_COMPARATOR|Inhaled volatile general anesthesia|Must administer inhaled agent.
62520836|NCT04731402|EXPERIMENTAL|Acupressure|Acupressure group Acupressure application will be applied twice a week, 24 times in total in 12 weeks. Each acupressure point will be massaged for 30 seconds to provide circulation before compression. After the massage, pressures will be applied consecutively for 90 seconds. The session duration for each woman will be 8 minutes in total, with 2 minutes for each point in each attempt.
62520837|NCT04731402|EXPERIMENTAL|Laughter Yoga|Laughter Yoga group Laughter yoga sessions begin with gentle warm-up techniques that include stretching and stretching movements, songs, applause, and body movements. Therapy sessions are between 30-45 minutes.8 sessions of laughter yoga will be done once a week.
62520838|NCT04731402|EXPERIMENTAL|mindfulness stress reduction program|mindfulness stress reduction program mindfulness stress reduction program consists of 8 weeks. each week is 2.5 hours. each week has a different theme. There is a 6-hour silence day in the 6th week of the program.
62520839|NCT04731402|NO_INTERVENTION|Control Group|INTERVENTION NOT IMPLEMENTED
62520840|NCT03074539|ACTIVE_COMPARATOR|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
62520841|NCT03074539|ACTIVE_COMPARATOR|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
62149409|NCT04220983|OTHER|MR-Guided Prostate SBRT|
62520842|NCT03074539|ACTIVE_COMPARATOR|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
62520843|NCT03828448|EXPERIMENTAL|Ublituximab + Umbralisib|Participants were administered ublituximab, 900 milligrams (mg), intravenous (IV) infusion through Cycles 1-6, Cycles 9 and 12. Participants also received umbralisib, 800 mg, oral tablet, daily through Cycles 1-24. 1 Cycle = 28 days.
62149410|NCT06092177|EXPERIMENTAL|Test group|The group will include patients who undergo periodontal surgery with virtual reality distraction
62520844|NCT00273741|EXPERIMENTAL|1|methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
62520845|NCT00273741|PLACEBO_COMPARATOR|2|placebo capsules
62149411|NCT06092177|EXPERIMENTAL|Control group|The group will include patients who undergo periodontal surgery without virtual reality distraction
62149412|NCT05575687|OTHER|Water|Ingestion of 500 ml of mineral water
62149413|NCT05575687|OTHER|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
62149414|NCT05575687|OTHER|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
62149415|NCT05575687|OTHER|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
62711322|NCT01464879|EXPERIMENTAL|Testosterone 1.25 mL (applicator)|Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.
62520846|NCT04027374||Fetal surgery group|Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0.
62520847|NCT04027374||Glucocorticoid control group|Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
62520848|NCT04027374||Healthy controls|Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1.
62520849|NCT05959434|EXPERIMENTAL|Integrated Cognitive Processing Therapy and Relapse Prevention (CPT+RP)|Participants will receive 12, 90-minute individual sessions of CPT+RP delivered twice-weekly. We will offer some flexibility (e.g., due to illness or scheduling conflicts) and allow up to 9 weeks to complete all 12 sessions if needed. During CPT+RP, patients receive psychoeducation pertaining to the interconnectedness of AUD and PTSD and learn techniques to identify and manage triggers for alcohol use, cope with cravings, address problem thoughts about drinking, and enhance social support. These skills address core functional outcomes relevant to addiction, including executive functioning, incentive salience, and negative emotionality. The PTSD treatment component of CPT+RP reduces PTSD symptoms via identifying and targeting maladaptive trauma-related cognitions, beliefs, and Stuck Points via cognitive restructuring exercises, such as Socratic questioning. RP skills are integrated within each session.
62711323|NCT01464879|EXPERIMENTAL|Testosterone 2.50 mL (applicator)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
62711324|NCT01464879|EXPERIMENTAL|Testosterone 3.75 mL (applicator)|Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.
62356926|NCT01743170|NO_INTERVENTION|Control group|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
62356927|NCT01743170|EXPERIMENTAL|Intervention group|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
62711325|NCT03181867|EXPERIMENTAL|1/Localized High Risk|18F-DCFPyL PET/CT imaging, unlabeled PSMA-11 (optional) and possible prostatectomy
62711326|NCT03181867|EXPERIMENTAL|2/biochemical recurrence (bcr)|18F-DCFPyL PET/CT imaging, unlabeled PSMA-11 (optional)
62711327|NCT05185843|EXPERIMENTAL|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 209 weeks.
62711328|NCT04960670||Dyads|Mother/infant pairs will be evaluated for anthropometric parameters, prenatal (dietary/lifestyle maternal factors)/postnatal determinants (type of feeding, sleep patterns, speed of growth) before discharge and after different follow-up after birth. Infant urinary and stool samples will be collected and stored. The infant adiposity rebound will be monitored.
62711329|NCT05053191|EXPERIMENTAL|Nurses|MSKCC day-shift nurses (Clinical Nurse I to IV) assigned to the GI inpatient unit (MH16) at the time of study, all of whom provide initial and ongoing assessment of patients' physical, psychosocial, cultural and informational needs
62711330|NCT03768323|NO_INTERVENTION|Control|No airtime incentive was given for completing the survey
62711331|NCT03768323|EXPERIMENTAL|1X incentive|1X airtime incentive
62356928|NCT05089448|ACTIVE_COMPARATOR|The morning dosing group|After randomization, subjects will take alisartan 120 mg (Salubris, Shenzhen, China) once daily at 6:00-10:00. After 8 weeks of treatment, if the 24-hour ambulatory systolic BP remained ≥ 130 mmHg, alisartan will be doubled to 240mg. After 16 weeks of treatment, if the 24-hour ambulatory systolic BP remained ≥ 130 mmHg, amlodipine besylate 2.5 mg (Dawnrays, Suzhou, China) once daily will be added. The whole treatment duration will last for 24 weeks.
62356929|NCT05089448|EXPERIMENTAL|The bedtime dosing group|After randomization, subjects will take alisartan 120 mg once daily at 20:00-24:00. The follow-up plan is the same as the morning dosing group.
62356930|NCT05535764|EXPERIMENTAL|Treatment: All Patients|A 3+3 dose de-escalation design will be used to determine the recommended phase 2 dose,while ensuring the safety and tolerability of the treatment. In this trial, the dose determined to be the maximum tolerated dose will be the recommended phase 2 dose and will be utilized in the cohort expansion.
62356931|NCT06313853|EXPERIMENTAL|COACH-Cog Intervention|Oncology clinician intervention components: 1) a brief training video, 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments. Patient/Care partner dyad intervention components: 1) Communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
62711332|NCT03768323|EXPERIMENTAL|2X incentive|2X airtime incentive
62356932|NCT06313853|NO_INTERVENTION|Usual Care|Usual Care
62711333|NCT03754322|ACTIVE_COMPARATOR|Standard of care|One third of individuals get allocated to the standard of care arm. At each antenatal visit as per Ethiopian guidelines, pregnant women enrolled in the study will be submitted to the standard of care for malaria in pregnancy. If the pregnant mothers are symptomatic for malaria, they receive microscopy (blood smear for Plasmodium detection) and then are treated with anti-malarial therapy if microscopy is positive for Plasmodium. If it is negative they receive no treatment. If they are asymptomatic, they do not receive any further investigations or treatment in relation to malaria.
62711334|NCT03754322|EXPERIMENTAL|Intervention arm|The remaining two-thirds of participants will be actively screened (symptomatic and asymptomatic) for Plasmodium infection at each antenatal visit, using both LAMP and conventional techniques (microscopy and RDT). If either is positive, participants will be treated with antimalarial therapy according to Ethiopian Ministry of Health guidelines. If both are negative then they receive no treatment.
62356933|NCT03226548|EXPERIMENTAL|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
62520850|NCT05959434|ACTIVE_COMPARATOR|Relapse Prevention (RP)|Participants will receive 12, 90-minute individual sessions of RP delivered twice-weekly as consistent with the experimental condition. The RP manual is adapted from the NIAAA Project MATCH Cognitive-Behavioral Coping Skills Therapy Manual and has been used in prior NIH-funded trials of integrated, trauma-focused treatment. Session topics include, for example, Triggers for Alcohol Use, Coping with Cravings and Urges to Drink (e.g., avoid alcohol cues, distracting activities, talk to friends/family, urge surfing), Managing Thoughts about Alcohol and Drinking by challenging and changing thoughts, Planning for Emergencies and Coping with a Lapse, Drink Refusal Skills, Increasing Pleasant Activities and Enhancing Social Support.
62520851|NCT06125496||Female|Forty one females with CLBP between the ages of 20-60 participated in the study. Pain management strategies were determined by Pain Coping Questionnaire (PCQ). Tampa Scale for Kinesiophobia for perception of kinesiophobia, Oswestry Disability Index for disability due to pain and International Physical Activity Questionnaire-Short Form (IPAQ-SF) for the physical activity level were used.
61975045|NCT03453944|EXPERIMENTAL|VF03-K active stimulation|NMES applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
61975046|NCT03453944|SHAM_COMPARATOR|VF03-K sham stimulation|Sham stimulation applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Sham stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
62520852|NCT06125496||Male|Forty one males with CLBP between the ages of 20-60 participated in the study. Pain management strategies were determined by Pain Coping Questionnaire (PCQ). Tampa Scale for Kinesiophobia for perception of kinesiophobia, Oswestry Disability Index for disability due to pain and International Physical Activity Questionnaire-Short Form (IPAQ-SF) for the physical activity level were used.
62149416|NCT05575687|OTHER|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
62520853|NCT06196021|ACTIVE_COMPARATOR|Grup 1 quadriceps strengthening exercises|"The patients in group 1 received Quadriceps strengthening exercises with isokinetic dynamometer device. Strengthening exercises were applied to the Quadriceps muscle group by the physiotherapist for 4 weeks, 3 days a week, 30 minutes a day, for a total of 12 sessions.~All patients received patient education and intra-articular hyaluronic acid injection (once a week, 3 times in total) into the symptomatic knee.~Patient education: Just before the start of treatment, an education program consisting of general information about their disease, daily activity modifications and knee joint protection principles was applied by the physician to the patients within a period of approximately 10-15 minutes."
62520854|NCT06196021|ACTIVE_COMPARATOR|Grup 2 a home exercise program|"The patients in group 2 received a home exercise program. A home exercise program consisting of knee joint range of motion, quadriceps adjustment, and strengthening exercises for abductor and adductor muscle groups was demonstrated by the physiotherapist.They were asked to do the exercises 5 days a week, 2 times a day, with 10 repetitions. Patients were called every 15 days and asked to continue their home exercise program.~All patients received patient education and intra-articular hyaluronic acid injection (once a week, 3 times in total) into the symptomatic knee.~Patient education: Just before the start of treatment, an education program consisting of general information about their disease, daily activity modifications and knee joint protection principles was applied by the physician to the patients within a period of approximately 10-15 minutes."
62711335|NCT02383316|EXPERIMENTAL|Noonan Syndrome Children|"Children with Noonan Syndrome will be compared with age- and sex-matched healthy children. We hypothesize than Noonan Syndrome children have an increased insulin sensitivity compared to GHD children.~Study parameters will be collected including: clinical measurements (height, weight, body mass index, waist circumference, and blood pressure), glucose and insulin levels at baseline and after an oral glucose tolerance test (OGTT), body composition measured by dual-energy x-ray absorptiometry (DXA)."
62711336|NCT00095550|EXPERIMENTAL|A1|
62711337|NCT00095550|ACTIVE_COMPARATOR|A2|
62711338|NCT00095550|ACTIVE_COMPARATOR|A3|
62711339|NCT00444314|EXPERIMENTAL|A|
62711340|NCT00444314|EXPERIMENTAL|B|
62711341|NCT03567694|EXPERIMENTAL|Single Ascending Dose and Food effect|This is the SAD / Food effect arm. For SAD, a total of 80 subjects will be enrolled into 8 groups of 10 subjects each; within each group, 8 will receive HA115 at a single ascending dose 10, 25, 50, 100, 200, 400, 800, 1200 mg, and 2 subjects will be placebo control. For food effect study,10 participants will be administered HA115 at a single dose to be selected based on SAD results.
62711342|NCT03567694|EXPERIMENTAL|Multiple Ascending Dose|For the MAD portion, 3 dose levels will be selected based on SAD results.
62149417|NCT05575687|OTHER|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
62149418|NCT05528809|EXPERIMENTAL|Experimental group|Patients with Gougerot-Sjögren's syndrome meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
62149419|NCT05528809|ACTIVE_COMPARATOR|Positive control group|Patients with diffuse systemic scleroderma meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
62149420|NCT00001397||1|treated according to the guidelines of standard medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
62149421|NCT06301048||Pancreatic Stenting Group|performed pancreatic duct stent placement after endoscopic papillectomy
62149422|NCT06301048||Non-Pancreatic Stenting Group|have not performed pancreatic duct stent placement after endoscopic papillectomy
62149423|NCT06301048||Biliary Stenting Group|performed common bile duct stent placement after endoscopic papillectomy
61975047|NCT04022772|EXPERIMENTAL|GROUP I (PACK Health program)|Patients participate in PACK Health program consisting of weekly contact with an assigned health coach via text message, phone call, and email for 3 months. After 3 months, patients continue to be contacted by the health coach at least once monthly for an additional 3 months.
62149424|NCT06301048||Non-Biliary Stenting Group|have not performed common bile duct stent placement after endoscopic papillectomy
62149425|NCT00916656|EXPERIMENTAL|Prospective Arm|
62149426|NCT00916656|OTHER|Historical Control|
62356934|NCT03226548|NO_INTERVENTION|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
62711343|NCT00743470|EXPERIMENTAL|A, B|Group 1 receives regimen A and B. A: Healthy volunteers, receiving one 150 mg rifabutin QD alone. B: Healthy volunteers, receiving 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
62149427|NCT00704340|EXPERIMENTAL|1|"DuraSeal Dural Sealant System - FDA Approved Device:~The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel."
62356935|NCT06396455|EXPERIMENTAL|interscalene block group|patients received an ultrasound guided interscalene approach of brachial plexus plane block
62356936|NCT06396455|EXPERIMENTAL|suprascapular nerve block group|patients received ultrasound guided suprascapular nerve block.
62520855|NCT06196021|PLACEBO_COMPARATOR|Grup 3 did not receive exercise|"The patients in group 3 did not receive an exercise program.~All patients received patient education and intra-articular hyaluronic acid injection (once a week, 3 times in total) into the symptomatic knee.~Patient education: Just before the start of treatment, an education program consisting of general information about their disease, daily activity modifications and knee joint protection principles was applied by the physician to the patients within a period of approximately 10-15 minutes."
62520856|NCT00560937|ACTIVE_COMPARATOR|1|Pregnenolone
62520857|NCT00560937|PLACEBO_COMPARATOR|2|Placebo
62356937|NCT00886106|EXPERIMENTAL|1|Remifentanil
62520858|NCT04917718|EXPERIMENTAL|Extended Release Tacrolimus|All participants who consent to the study will be in this group.
62520859|NCT02268266|OTHER|Single-arm study|Early mobilization of patients after stroke or spinal cord injury. Monitoring of vital parameters during mobilization of healthy subjects
62356938|NCT00886106|ACTIVE_COMPARATOR|2|Midazolam
62520860|NCT01414751|ACTIVE_COMPARATOR|Absolute risk reduction information|Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
62520861|NCT01414751|ACTIVE_COMPARATOR|Prolongation of life information|Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
62520862|NCT04211142|ACTIVE_COMPARATOR|Laparoscopic repair|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)
62520863|NCT04211142|ACTIVE_COMPARATOR|Open repair|Open Inguinal Hernia Repair (Lichtenstein repair)
62711344|NCT00743470|EXPERIMENTAL|C|Group 2 receives regimen C. C: 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
61975048|NCT04022772|ACTIVE_COMPARATOR|GROUP II (standard of care)|Patients receive standard of care support services over 6 months.
62356939|NCT01886885||MBCPM|There is just one group of participants of no more than 20 people.
62356940|NCT05875246|NO_INTERVENTION|Group 1|Does not receive a micro-intervention
62356941|NCT05875246|EXPERIMENTAL|Group 2|Receives brief messages for stress reduction.
62356942|NCT05875246|EXPERIMENTAL|Group 3|Directed to the app to listen to a stress reduction audio activity.
62356943|NCT06394557|ACTIVE_COMPARATOR|Bleaching 7 days interval|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 7 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
62356944|NCT06394557|EXPERIMENTAL|Bleaching 2 days interval|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 2 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
62356945|NCT00438464|EXPERIMENTAL|Arm I (Finasteride)|Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
62520864|NCT02577341|EXPERIMENTAL|Nimotuzumab|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin, and concurrent weekly Nimotuzumab.
62520865|NCT02577341|ACTIVE_COMPARATOR|Control|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin.
62520866|NCT02138942|EXPERIMENTAL|The study population|"See inclusion/exclusion criteria.~Intervention: LIR"
62520867|NCT00390702|EXPERIMENTAL|VSD occluder|transcatheter implantation of a VSD occluder (Nitinol coil)
62520868|NCT05695092|EXPERIMENTAL|Experimental group|PMR session will be provided a night before competition
62520869|NCT05695092|SHAM_COMPARATOR|Control group|Simple ROM for upper limbs and lower limbs
62520870|NCT02957266|ACTIVE_COMPARATOR|Classical treatment|Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.
62520871|NCT02957266|EXPERIMENTAL|GemInterBraVMAT|"Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.~PIK3CA, KRAS, BRAF and RRM1 mutations rates."
62520872|NCT04971213|ACTIVE_COMPARATOR|Non Invasive Ventilation|Bilevel non-invasive ventilation. Support pressure will be set to obtain a 6-8 mL/kg of predicted body weight PEEP will be set within 5-10 cmH2O and FiO2 for a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure) All settings will be adjusted according tolerance of the patient.
62520873|NCT04971213|EXPERIMENTAL|High-flow nasal cannula heated and humidified oxygen|"Flow will be set at 60 L/min and ajusted according the tolerance of the patient.~FiO2 will be set according a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure)"
62520874|NCT04921124|EXPERIMENTAL|Treatment|"Teriparatide, 20 µg Subcutaneous (S/C) per day.~Two doses in total."
62520875|NCT03314662|EXPERIMENTAL|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
62149428|NCT00704340|ACTIVE_COMPARATOR|2|"Standard of Care (control):~Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator."
62520876|NCT03314662|EXPERIMENTAL|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
62520877|NCT03314662|EXPERIMENTAL|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
62520878|NCT04785508|EXPERIMENTAL|treated group|neuromuscolar tape application
61975049|NCT05431452|NO_INTERVENTION|Group 1 (Control Group)|"There is no non-pharmacological method applied during routine heel blood collection in the clinic where the research will be conducted. No intervention will be applied to this group within the scope of the research. In order to minimize the risk of aspiration during the procedure, the head of the bed in the incubator will be elevated at a 45-degree angle. The 1st minute before the procedure, the 1st minute and the 2nd minute during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
62149429|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
62520879|NCT04785508|ACTIVE_COMPARATOR|control group|antigravity position
62520880|NCT00930254|EXPERIMENTAL|Ultrasound|Vascular puncture guided by vascular ultrasound
62520881|NCT02033330|ACTIVE_COMPARATOR|phenolics form orange peel, type 1|1 dose of 500 mg of phenolics from orange peel, orally ingested
62520882|NCT02033330|ACTIVE_COMPARATOR|phenolics from orange peel, type 2|1 dose of 500 mg of phenolics from orange peel, orally ingested
62520883|NCT02033330|EXPERIMENTAL|phenolics from orange peel, type 3|1 dose of 500 mg of phenolics from orange peel, orally ingested
62520884|NCT03295695|EXPERIMENTAL|Cardiac Imaging - All Participants|Study agent: 2-deoxy-2-\[18F\]fluoro-D-glucose (FDG). Fluoro-D-glucose-positron Emission Tomography: Participants will undergo a PET-CT scan with Fluoro-D-glucose-labeled (FDG-labeled) red blood cells (RBCs) within 2 weeks of obtaining an echocardiogram prior to start of chemotherapy. A repeat FDG-RBC PET-CT scan will be completed within two weeks of obtaining their follow-up echocardiogram to determine post-therapy cardiac ejection fraction. If the participant has an echocardiogram obtained prior to completion of chemotherapy, an attempt will be made to obtain a FDG-RBC PET-CT scan within two weeks of the echocardiogram.
62711345|NCT05003193|EXPERIMENTAL|Using a pedometer|The pedometer will be given to the intervention group to evaluate the activity level and to encourage a walk , it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days.
62711346|NCT05003193|NO_INTERVENTION|Not using a pedometer|The control group will not be given a pedometer.Patients in the control group will only be instructed to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days.
62149430|NCT03111706||Intact scar|women with intact scar detected during cesarean section
62149431|NCT00876005|ACTIVE_COMPARATOR|1|80% oxygen during cesarean section
62149432|NCT00876005|ACTIVE_COMPARATOR|2|30% oxygen during cesarean section
62149433|NCT06129981|EXPERIMENTAL|Imaginary exposure therapy augmented by vocal feedback in patients fulfilling the criteria for PTSD|
62149434|NCT03265756||Healthy children|250 3D facial images of healthy children under 5yrs of age in the Democratic Republic of Congo (DRC).
62520885|NCT01435187||Infant Pulmonary Function Testing (iPFT)|A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.
62520886|NCT05895734|EXPERIMENTAL|Powerball|Rehabilitation using the Powerball system
62520887|NCT05895734|ACTIVE_COMPARATOR|Conventional treatment|Rehabilitation by conventional treatment
62149435|NCT03265756||Suspected Pneumonia|50 young children (under 5 yrs) in hospital/clinics in Butembo DRC with suspected pneumonia
62149436|NCT04190485|EXPERIMENTAL|Placebo and GMNL-143 Probiotic Toothpastes|Subjects will receive placebo and GMNL-143 probiotic toothpastes.
62149437|NCT04190485|EXPERIMENTAL|Placebo and GMNL-464 Probiotic Toothpastes|Subjects will receive placebo and GMNL-464 probiotic toothpastes.
62520888|NCT03516084|EXPERIMENTAL|ZL-2306(nirapairb)|
62520889|NCT03516084|PLACEBO_COMPARATOR|Placebo|
62520890|NCT03994549|ACTIVE_COMPARATOR|ZP7570|Single subcutaneous injection
62149438|NCT04501744|EXPERIMENTAL|M701|Patients will undergo a 2-week screening period and a 4-week core treatment period, and eligible patients who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
62149439|NCT00989755|EXPERIMENTAL|Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)|Clinics in this group receive Fax to Quit materials and in person training from a Regional Outreach Specialist (ROS). The ROS also provides on-going training/technical assistance and performance feedback.
62149440|NCT00989755|PLACEBO_COMPARATOR|Fax to Quit alone|Clinics in this group receive Fax to Quit materials and can download materials from a website.
62149441|NCT05588388|EXPERIMENTAL|Experimental Treatment|"1. Induction (ABCE): Atezolizumab 1200 mg, Bevacizumab 15 mg/kg, Carboplatin AUC5, Etoposide 100 mg/m2, given IV Q3weeks~2. Maintenance (AB): Atezolizumab 1200 mg and Bevacizumab 15 mg/kg given IV Q3weeks for 1 year, or until disease progression, or unacceptable toxicity"
62356946|NCT00438464|PLACEBO_COMPARATOR|Arm II (Placebo)|Placebo once daily for 4-6 weeks, then undergo prostatectomy.
62520891|NCT03994549|PLACEBO_COMPARATOR|Placebo|Single subcutaneous injection
62520892|NCT04214717|EXPERIMENTAL|Combination of DC-CIK with chemotherapy group|Patients will receive DC-CIK treatments combined with Chemotherapy .
62520893|NCT04214717|ACTIVE_COMPARATOR|Chemotherapy group|Patients will only receive Chemotherapy.
62711347|NCT04034888|EXPERIMENTAL|Home Exercise Program (HEX)|Customized home exercise program
62711348|NCT04341623|OTHER|Control Group|All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis
62711349|NCT04341623|OTHER|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence.
62149442|NCT02435485|EXPERIMENTAL|spondylolisthesis with balance training|Intervention: 1. Biodex balance training including weight shift training and random control training, 2. Regular rehabilitation including core spinal stabilization exercise.
62149443|NCT02435485|ACTIVE_COMPARATOR|spondylolisthesis, no balance training|Intervention: Regular rehabilitation including core spinal stabilization exercise
62149444|NCT02435485|ACTIVE_COMPARATOR|lumbar spondylitis|Intervention: Regular rehabilitation including core spinal stabilization exercise
62149445|NCT03615833|EXPERIMENTAL|Patients with Vitamin D deficiency|Patients with Vitamin D deficiency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
62149446|NCT01199185|ACTIVE_COMPARATOR|Tobacco Quitline Group|
62149447|NCT01199185|EXPERIMENTAL|Tobacco Quitline plus Interactive Technology Group|
62149448|NCT01867307|EXPERIMENTAL|Healthy Controls|healthy controls
62149449|NCT01867307|EXPERIMENTAL|Patients|patients with type 2 diabetes mellitus
62149450|NCT02237937|EXPERIMENTAL|Normal dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~* paroxetine \< 40 mg/d~* sertraline \< 100 mg/d~* citalopram \< 40 mg/d~* escitalopram \< 20 mg/d~* venlafaxine \< 225 mg/d~* amitriptyline \< 150 mg/d~* amitriptylinoxide \< 150 mg/d~* nortriptyline \< 150 mg/d~* trimipramine \< 150 mg/d"
62149451|NCT02237937|EXPERIMENTAL|High dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~* paroxetine \< 80 mg/d~* sertraline \< 200 mg/d~* citalopram \< 80 mg/d~* escitalopram \< 40 mg/d~* venlafaxine \< 450 mg/d~* amitriptyline \< 300 mg/d~* amitriptylinoxide \< 300 mg/d~* nortriptyline \< 300 mg/d~* trimipramine \< 300 mg/d"
62356947|NCT01914783|EXPERIMENTAL|ultrafine particles|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
62356948|NCT01914783|ACTIVE_COMPARATOR|ultrafine particles and ozone|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.Ozone is generated from medical oxygen in order to maintain a concentration of 250 ppb.
62520894|NCT03212521|EXPERIMENTAL|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 weeks.
62520895|NCT02870400|EXPERIMENTAL|REGN2477|Cohorts 1 - 5 will receive REGN2477
62711350|NCT04341623|OTHER|GPSkin group|The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily.
62711351|NCT05040776|OTHER|Active|Frunexian infusion 0.6 mg/kg/hr or 1 mg/kg/hr. 0.6 mg/kg/hr dose will be completed first.
62711352|NCT05040776|ACTIVE_COMPARATOR|Institutional Standard|Clinician's choice of prophylaxis strategy
62149452|NCT05448521||Low lactate|Patients with a low lactate level defined by logistic regression analysis.
62149453|NCT05448521||High lactate|Patients with a high lactate level defined by logistic regression analysis.
62149454|NCT04317430|ACTIVE_COMPARATOR|Treatment group|Niclosamide tablets 1 gram once daily
62149455|NCT04317430|PLACEBO_COMPARATOR|Control group|Lactose tablets
62149456|NCT05703659|EXPERIMENTAL|HMO consuming bacteria|Infants will given a daily HMO consuming probiotic (B. infantis) for four weeks
62149457|NCT05703659|EXPERIMENTAL|Non-HMO consuming bacteria|Infants will be given a daily non-HMO consuming probiotic (L. reuteri) for four weeks
62520896|NCT02870400|EXPERIMENTAL|Placebo|Cohorts 1 - 5 will receive placebo
62520897|NCT04572594||Inflammatory myofibroblastic tumor|tissue of Inflammatory myofibroblastic tumor lession
62520898|NCT04781036|NO_INTERVENTION|Normal feet|"* Swab their feet to analyze foot microbiome via 16s DNA sequencing~* Collect their socks to analyze metabolomics via gas chromatography"
62711353|NCT01968122||aggressive medical treatment|administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for more than 5d before the operation (but Clopidogrel of loading dose 200mg in case of emergency operation for TIA); administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for 90d and subsequent monoclonal antibody after the operation; control the primary risk factors (e.g. hypertension and high LDL); control the secondary risk factors (e.g. diabetes, blood lipid of not high LDL, smoking, obesity and hypomotility); and intervene the life style. Primary risk factors: target systolic pressure of \<140mmHg (or \<130mmHg in the diabetes patients); and LDL \<70mg/dl (1.81mmol/L) or drop by 50%.
62711354|NCT02797821|EXPERIMENTAL|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
62711355|NCT02797821|EXPERIMENTAL|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
62711356|NCT02797821|EXPERIMENTAL|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
62711357|NCT01713439|EXPERIMENTAL|Injection of allogeneic neuroblastoma cells|Retrovirally transduced allogeneic neuroblastoma cell lines secreting the human interleukin-2 and lymphotactin genes are frozen and, when needed, are thawed, mixed and irradiated. Relapsed or refractory patients are then treated with a course of four injections of their gene-modified tumor cells according to the following schedule: The first two injections will be given at week 1 and week 2. Patients will then have a two-week rest and the remaining two injections will be given at week 4 and week 5. A complete evaluation for evidence of toxicity and response will be performed at week 8 after a 3 week rest. At the 8 week evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
62149458|NCT03883724|EXPERIMENTAL|Brief behavioral treatment for insomnia|This group will undergo behavioral intervention proven to improve sleep among older adults: brief behavioral treatment for insomnia
62149459|NCT03883724|OTHER|Information-only control|This group is called information-only control. They will be provided sleep-related information. They will also view a video content of which overlap substantially with BBTI but without individualized behavioral instructions.
62149460|NCT05485025|EXPERIMENTAL|Tai chi training plus group activity|"Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.~Group activity: a organizer will lead the subjects to participate in group activities, once per quarter."
62149461|NCT05485025|EXPERIMENTAL|Only group activity|Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
62149462|NCT04955054||control|patients without coronary artery disease
62149463|NCT04955054||UAP|patients without unstable angina pectoris
62520899|NCT04781036|EXPERIMENTAL|Foot odor without pitted keratolysis|"* Swab their feet to analyze foot microbiome via 16s DNA sequencing~* Collect their socks to analyze metabolomics via gas chromatography~* Apply 4% chlorhexidine for 2 weeks~* Re-evaluate their feet at time of treatment finish and 1 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~* The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
62520900|NCT04781036|EXPERIMENTAL|Foot odor with pitted keratolysis|"* Swab their feet to analyze foot microbiome via 16s DNA sequencing~* Collect their socks to analyze metabolomics via gas chromatography~* Apply 4% chlorhexidine for 2 weeks~* Re-evaluate their feet at time of treatment finish and 1 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~* The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
62520901|NCT06129344|EXPERIMENTAL|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group: Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
62520902|NCT06129344|EXPERIMENTAL|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
62520903|NCT00792727|EXPERIMENTAL|Ketoprofen Patch|Treatment with experimental drug
62711358|NCT02096107|ACTIVE_COMPARATOR|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
62711359|NCT02096107|OTHER|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
62711360|NCT04784156||All study patients|"All study patients will be in one group.~Interventions:~Procedure: Subtalar (Talocalcaneal) arthrodesis Device: DynaNail Mini"
62711361|NCT06644378|EXPERIMENTAL|Part A: [14C]-LY3866288|Single dose of \[¹⁴C\]-LY3866288 administered orally.
62711362|NCT06644378|EXPERIMENTAL|Part B: LY3866288 + [14C]-LY3866288|Single dose of LY3866288 administered orally followed by a single dose of \[¹⁴C\]-LY3866288 administered intravenously (IV).
62149464|NCT04955054||AMI|patients with acute myocardial infarction
62711363|NCT01246882|EXPERIMENTAL|Augmented activity feedback|Feedback three times per week about 10-m walking speed, plus amount and types of physical activity measured using wireless bilateral ankle sensors that detect bouts of walking and cycling speed, duration, and distance.
62149465|NCT04396938|EXPERIMENTAL|Lamotrigine|Single dose of Lamotrigine (300mg - capsule). In healthy volunteers.
62149466|NCT04396938|PLACEBO_COMPARATOR|Placebo|Placebo capsule: identical appearance to experimental capsule. In healthy volunteers.
62149467|NCT01702259|EXPERIMENTAL|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
62149468|NCT01702259|SHAM_COMPARATOR|Placebo device|Inactive Erchonia GLS device
62149469|NCT00546156|ACTIVE_COMPARATOR|HR+, HER2-|Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
62149470|NCT00546156|ACTIVE_COMPARATOR|Triple Negative Breast Cancer Cohort|Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
62149471|NCT02680145|EXPERIMENTAL|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
62149472|NCT02798016|EXPERIMENTAL|Platelet-Rich Plasma alone|The scars will be injected with Platelet-Rich Plasma alone.
62149473|NCT02798016|ACTIVE_COMPARATOR|Platelet-Rich Plasma with micro-needling|The scars will be dealt with using micro-needling as well as injecting Platelet-Rich Plasma
62149474|NCT01045057|EXPERIMENTAL|Puncture Set and Flexible Protector|Provox Vega Puncture Set is used to create the primary puncture and insert the prosthesis during total laryngectomy
62520904|NCT00792727|PLACEBO_COMPARATOR|Placebo Patch|Treatment with placebo drug
62711364|NCT01246882|ACTIVE_COMPARATOR|speed-only feedback|Feedback three times per week about overground walking speed over 10 meters.
62711365|NCT01132859||1|Volunteers of 18 years of age or older willing to donate blood and tissue specimens and participate in imaging studies to evaluate the components of the immune system
62711366|NCT04817189|EXPERIMENTAL|NEPA (300mg netupitant/0.5mg palonosetron) + Dexamethasone 8 mg|"Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Dexamethasone (8 mg) will be administered on Day 1 of each cycle."
62711367|NCT04817189|ACTIVE_COMPARATOR|Standard of care + Dexamethasone 8 mg|"Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy and one of the 5-HT3-RAs recommended by European Society for Medical Oncology (ESMO) and Multinational Association of Supportive Care in Cancer (MASCC) guidelines (standard of care), i.e. either:~Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)"
62149475|NCT05005351|ACTIVE_COMPARATOR|Digital Acceptance and Commitment Therapy (ACT)|
62149476|NCT05005351|ACTIVE_COMPARATOR|Digital Symptom Tracker|
62149477|NCT02877524|EXPERIMENTAL|Adaptive support ventilation|Adaptive support ventilation during NIV for acute exacerbation of COPD
62149478|NCT02877524|ACTIVE_COMPARATOR|Pressure support ventilation|Pressure support ventilation during NIV for acute exacerbation of COPD
62149479|NCT00540566||Optical Biopsy|Optical Biopsy imaging
62149480|NCT05731206|EXPERIMENTAL|hydrolized protein formula|hydrolysed protein formula
62149481|NCT05731206|PLACEBO_COMPARATOR|Control formula|commercially available hypoallergenic infant formula
62149482|NCT02789488|OTHER|Furocyst|Furocyst one caps BID
62149483|NCT01564472||PSG Scoring|Retrospective, de-identified PSG studies will be collected and scored by registered polysomnogrpahy technicians. The manually scored studies will be compared to the automatic scoring performed by the new Sleepware Software G3 Autoscoring Algorithm.
62149484|NCT06461585|EXPERIMENTAL|Sprint interval training exercise|Group A the Interventional group will receive SIT . Group A will perform SIT 3 times a week for 30-second sprints on a cycle ergometer with 4 minutes of rest between each sprint, complete session will be for 30 -40 minutes.
62149485|NCT06461585|EXPERIMENTAL|Arabic exercises|Group B will receive the aerobic exercise. Group B will perform the aerobic exercise for 30-40 minutes of moderate-intensity continuous exercise on a treadmill and stationary cycle
62149486|NCT03630549|ACTIVE_COMPARATOR|Standard of Care|"1. Offer of home-based same-day ART initiation~2. Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~3. No SMS intervention"
62149487|NCT03630549|EXPERIMENTAL|Village-based ART refill|"1. Offer of home-based same-day ART initiation~2. Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home\* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~   \*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)~3. Offer of Individually customized SMS~   * Monthly reminder SMS: to pick up ART~  * SMS communicating VL result"
62149488|NCT00488267|EXPERIMENTAL|Thermoprofen|ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery \[CHADD™\] patch)
62149489|NCT00488267|PLACEBO_COMPARATOR|Placebo Matrix|Placebo matrix with CHADD patch.
62149490|NCT00488267|PLACEBO_COMPARATOR|Ketoprofen matrix/placebo CHADD|Ketoprofen matrix with placebo CHADD patch (no heat)
62520905|NCT02227654|EXPERIMENTAL|Abnormal Ovarian Ultrasound|Abnormal Ovarian Ultrasound
62711368|NCT06586398|ACTIVE_COMPARATOR|active rTMS|The rTMS magnet will be set to active stimulation without the knowledge of treating doctors or research team. Only one technician will know the randomization list assignment and will adjust the settings. rTMS treatment will include rTMS to the left dorsolateral prefrontal cortex (DLPFC), followed by rTMS to left primary motor cortex (M1).
62711369|NCT06586398|SHAM_COMPARATOR|Sham rTMS|The rTMS magnet will be set to sham stimulation without the knowledge of the treating doctors or the research team.
62149491|NCT05380115|EXPERIMENTAL|CBT|All subjects enrolled received CBT for 10 weeks.
62149492|NCT01777932||Cohort|
62149493|NCT03234010|EXPERIMENTAL|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
62149494|NCT03234010|EXPERIMENTAL|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
62149495|NCT03234010|EXPERIMENTAL|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
62149496|NCT03234010|EXPERIMENTAL|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
62149497|NCT03608436|EXPERIMENTAL|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
62149498|NCT03608436|ACTIVE_COMPARATOR|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
62520906|NCT01299649||Non-contrast echocardiography|Non-contrast echocardiography
62520907|NCT01299649||Contrast Echocardiography|Contrast Echocardiography
62520908|NCT01797484|ACTIVE_COMPARATOR|Ranolazine|Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
62520909|NCT01797484|NO_INTERVENTION|No additional medication|No additional medication - control group
62520910|NCT02510014|EXPERIMENTAL|Roll-over Subjects|Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
62520911|NCT02510014|EXPERIMENTAL|De Novo Subjects|Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.
62520912|NCT04420338|EXPERIMENTAL|Chronic hemodialysis patients|
62520913|NCT04420338|EXPERIMENTAL|Caregivers of chronic hemodialysis patients|
62520914|NCT02399098|EXPERIMENTAL|External focus group|This group will be given instructions on how to focus on the external cue relevant to the task (e.g., focus on the center of the dart board).
62520915|NCT02399098|EXPERIMENTAL|Internal focus group|This group will be instructed how to focus on the arm movements (e.g., feel the bend in your elbow).
62520916|NCT02399098|NO_INTERVENTION|Control|This group will be given general instructions on throwing techniques (e.g., hold the dart with four fingers and make sure it is in a stable position) but no attentional focus instructions will be given.
62520917|NCT04132401|EXPERIMENTAL|family medicine physicians|Retina reading
62520918|NCT04132401|EXPERIMENTAL|retina specialists|Retina reading (gold standard)
62520919|NCT05160714|EXPERIMENTAL|Adaptive SBRT Boost|Dose-escalated SBRT boost to an ADC-based high risk subvolume in HNC
62520920|NCT00852566|ACTIVE_COMPARATOR|Imatinib|Standard treatment Imatinib 400mg OD
62520921|NCT00852566|EXPERIMENTAL|dasatinib|Dasatinib 100mg OD
62520922|NCT04718194|EXPERIMENTAL|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
62520923|NCT04718194|PLACEBO_COMPARATOR|Self-monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
62149499|NCT02538094|SHAM_COMPARATOR|Sham Stimulation First|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS first and then Anodal Stimulation second.
62149500|NCT02538094|EXPERIMENTAL|Anodal Stimulation First|Transcranial direct current stimulation using Anodal stimulation first over the area of interest and then Sham Stimulation second.
62149501|NCT03600207|ACTIVE_COMPARATOR|Control group -complex training|complex training
62149502|NCT03600207|ACTIVE_COMPARATOR|Experimental group -diaphragm training|diaphragm training
62520924|NCT04300413|EXPERIMENTAL|High-Intensity Rehabilitation plus Mobility (HeRo)|The HeRo group will receive a behavior-change intervention based in the principals of behavioral economics to improve mobility. Physical and occupational therapists have been trained to deliver a high-intensity, functional intervention as the standard of care in this skilled nursing facility.
62520925|NCT05477160|EXPERIMENTAL|STAR-0215 Dose 1|Participants will be randomized to receive STAR-0215 or placebo.
62149503|NCT04150809||Patients|Patients who have been diagnosed with ALS.
62149504|NCT06231680|EXPERIMENTAL|Prevention Cohort 1 Group A|Camrelizumab + chemotherapy+Thalidomide(50mg)
62149505|NCT06231680|EXPERIMENTAL|Prevention Cohort 1 Group B|Camrelizumab + chemotherapy+Thalidomide(100mg)
62149506|NCT06231680|EXPERIMENTAL|Treatment Cohort 2 Group A|Thalidomide(100mg)
62149507|NCT06231680|EXPERIMENTAL|Treatment Cohort 2 Group B|Thalidomide(200mg)
62149508|NCT05570227|EXPERIMENTAL|[U-13C]Glucose Infusion|A 13.3% solution of sterile, pyrogen-free \[U-13C\]glucose in sterile water will be infused intravenously rapidly over 10 minutes to a total dose of 8 grams (bolus dose). Then the infusion will change to a rate of 4 grams/ hour. The infusion will continue until the time of tumour excision or biopsy, planned 2-3 hours.
62149509|NCT05570227|NO_INTERVENTION|No [U-13C]Glucose Infusion|Blood and tissue samples to be collected for translational research studies, no other additional intervention.
62149510|NCT01854866|EXPERIMENTAL|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
62149511|NCT00837291|EXPERIMENTAL|CF101 1 mg BID|
62149512|NCT00837291|PLACEBO_COMPARATOR|Placebo|Placebo tablets BID
62149513|NCT01697826|ACTIVE_COMPARATOR|ClinSupV3 -soft gelatin capsule|Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days
62149514|NCT01697826|ACTIVE_COMPARATOR|ClinSupV3ER- Extended release tablet|ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.
62149515|NCT00195819|EXPERIMENTAL|Adalimumab|
62520926|NCT05477160|EXPERIMENTAL|STAR-0215 Dose 2|Participants will be randomized to receive STAR-0215 or placebo.
62520927|NCT05477160|EXPERIMENTAL|STAR-0215 Dose 3|Participants will be randomized to receive STAR-0215 or placebo.
62520928|NCT05477160|EXPERIMENTAL|STAR-0215 Dose 4|Participants will be randomized to receive STAR-0215 or placebo.
62520929|NCT05477160|EXPERIMENTAL|STAR-0215 Dose 5|Participants will be randomized to receive STAR-0215 or placebo.
62520930|NCT01521065|EXPERIMENTAL|16 Gy IRay|16 Gy IRay + PRN Lucentis®
62520931|NCT02349620|ACTIVE_COMPARATOR|A:partialy edutolus patients|In this group surface treated implant with PRF will be inserted.Immediately after the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequency analysis (RFA), using the smart peg type 1, then stability will be measured every 2 weeks up to 3 months .Bone height will be measured in mesial and distal side immediately after placement and in months 3 and 6 with Intra Oral Peri Apical xray (IOPA x-ray)
62520932|NCT02349620|PLACEBO_COMPARATOR|B: partialy edutolus patients|In this group implant with out PRF will be inserted.Immediately after the surgery the implant stability will be measured with the Osstell mentor to verify the resonance frequence analysis (RFA ), using the smartpeg type 1, then stability will be measured every 2 weeks up to 3 months. Bone height was measured in mesial and distal side immediately after placement and in months 3 and 6 with IOPA xray
62520933|NCT00841906|OTHER|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
62520934|NCT00841906|OTHER|Alice PDx with written and verbal instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
62520935|NCT01385306|EXPERIMENTAL|AlphaCore System|non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System
62149516|NCT00195819|PLACEBO_COMPARATOR|Placebo|
62149517|NCT02206867|EXPERIMENTAL|LBAL|Developed by LG Life Sciences
62149518|NCT02206867|ACTIVE_COMPARATOR|Humira®|Abbvie
62149519|NCT04027452|EXPERIMENTAL|Traumatic memory reactivation|Audio recording of traumatic memory that triggers symptoms of PTSD, anxiety, depression, played before each ECT treatment.
62149520|NCT04027452|PLACEBO_COMPARATOR|Neutral memory reactivation|Audio recording of neutral (non-traumatic) memory played before each ECT treatment.
62149521|NCT01494766|OTHER|Tyrosine|"Dietary Supplement: L-Tyrosine~Other Names:~NOW Brand L-Tyrosine 750 mg Tablets~-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study."
62711370|NCT05730842|EXPERIMENTAL|Part A - AME|Evaluation of absorption, metabolism, excretion and pharmacokinetics of a single oral dose of radiolabeled EDG-5506 in healthy male volunteers
62711371|NCT05730842|EXPERIMENTAL|Part B - aBA|Evaluation of bioavailability of a single oral dose of EDG-5506 followed by a single intravenous dose of radiolabeled EDG-5506 in healthy male volunteers
62711372|NCT05271357|EXPERIMENTAL|Bilateral|Theta burst stimulation (TBS)
62149522|NCT05631236|PLACEBO_COMPARATOR|BLT control|Bright light glasses that emit a non-therapeutic blue light.
62149523|NCT05631236|ACTIVE_COMPARATOR|BLT intervention|Bright light glasses that emit a more intense therapeutic blue light.
62149524|NCT01368484|PLACEBO_COMPARATOR|Sunflower oil|
62149525|NCT01368484|EXPERIMENTAL|Docosahexanoic acid|
62149526|NCT01622049||TTTS treatment method|This is an observational trial. Patients who meet eligibility criteria and give written informed consent will have SLPCV. All subjects will receive ongoing standard-of-care prenatal care for the duration of their pregnancy from their referring perinatologist or obstetrician.
62149527|NCT00982527|PLACEBO_COMPARATOR|Placebo|Saline blinded infusion
62149528|NCT00982527|ACTIVE_COMPARATOR|Fenoldopam|Drug infusion
62149529|NCT00838409||1|
62149530|NCT01890954|ACTIVE_COMPARATOR|DiAs-closed-loop system|eight hours using Closed Loop Control (DiAs) under both, miss insulin bolus for 30 grams of carbohydrates snack or under bolus for an 80 grams of carbohydrates lunch
62149531|NCT01890954|NO_INTERVENTION|Sensor Augmented Pump|8 hours observational under both, missed insulin bolus for 30 gr carbohydrates snack and under bolus for an 80 gr carbohydrates lunch. Sensor augmented pump used the patients own insulin settings (basal rate, meal boluses and correction boluses) and a CGM provided by the study team to be used during admission. No DiAs use during this admission.
62149532|NCT00234676|EXPERIMENTAL|1|Premarin
62149533|NCT01483885|EXPERIMENTAL|TENS 4Hz|
62149534|NCT01483885|EXPERIMENTAL|Interferential Current 4Hz|
62149535|NCT01483885|PLACEBO_COMPARATOR|TENS|
62149536|NCT01483885|PLACEBO_COMPARATOR|Interferential Current|
62149537|NCT01483885|EXPERIMENTAL|Manual Acupuncture|
62149538|NCT01483885|EXPERIMENTAL|TENS 100 Hz|
62149539|NCT01483885|EXPERIMENTAL|Interferential Current 100Hz|
62149540|NCT05386537|EXPERIMENTAL|MyoPro-VR/HM group|Receive 18 sessions (in 6 weeks) of wrist/hand/UE rehabilitation using the MyoPro wearable robotic orthosis combined with VR-video games and Haptics.
62149541|NCT05386537|ACTIVE_COMPARATOR|MyoPro group|Receive 18 sessions (in 6 weeks) of wrist/hand/UE rehabilitation using the MyoPro wearable robotic orthosis only.
62149542|NCT05386537|ACTIVE_COMPARATOR|VR/HM group|Receive 18 sessions (in 6 weeks) of wrist/hand/UE rehabilitation using VR-video games only.
62149543|NCT05386537|OTHER|control|Receive 18 sessions (in 6 weeks) of conventional UE therapy at a rehabilitation facility.
62149544|NCT01729767|EXPERIMENTAL|Acyclovir|Acyclovir 400 mg tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
62149545|NCT01729767|PLACEBO_COMPARATOR|Placebo|Placebo tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
62149546|NCT03346590|ACTIVE_COMPARATOR|16 patients with active RA|"Women over 18 years old with proven active (DAS28 \>3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.~Covered by social security. Capable of giving informed consent and acceding to the requirements of the study. For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders."
61975050|NCT05431452|EXPERIMENTAL|Group 2 (Breast milk)|"2 minutes before the procedure, the bedside of the baby will be raised at an angle of 45 degrees and 2 ml of breast milk will be given by the research clinic nurse with the help of a sterile injector, provided that each baby will be their own breast milk. Heel blood collection will be performed 2 minutes after breast milk is given. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
62149547|NCT03346590|SHAM_COMPARATOR|8 Healthy volunteers (control group)|Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (\<25; 25-30; \>30).
62711373|NCT05271357|ACTIVE_COMPARATOR|Unilateral|Theta burst stimulation (TBS)
62149548|NCT01459952|EXPERIMENTAL|Rose hip Liquid|20 ml Rose hip Liquid BID
62149549|NCT01459952|PLACEBO_COMPARATOR|Placebo|20 ml placebo liquid BID
62149550|NCT02254902|EXPERIMENTAL|Physical Activity|Participants in the Physical Activity intervention arm of the study receive culturally-modified, materials through participation in 12 weekly 1-.5-hour sessions focused on increasing daily step counts and bouts of moderate intensity physical activity. The group sessions include participation in different forms of physical activity as well as group discussions on the barriers and opportunities for increasing physical activity in daily life.
62149551|NCT02254902|NO_INTERVENTION|Wait List Control|Participants in the Wait List Control will be offered the program after a 3-month wait period. While waiting for the program, participants are offered to attend monthly sessions on various wellness and prevention topics.
62711374|NCT00897026||Group 1|Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
62149552|NCT06352307||Right ventricular ACM group|The patients mainly had right ventricular enlargement and right ventricular fibrous adipose tissue replacement, and were diagnosed with right ventricular ACM.
62149553|NCT06352307||Left ventricular ACM group|The patients mainly had left ventricular enlargement and left ventricular fibroadipose tissue replacement, and were diagnosed with left ventricular ACM.
61975051|NCT05431452|EXPERIMENTAL|Group 3 (Supine Fetal Position)|"This method is a lower form of the method of taking the baby into the nest and is defined as the process of keeping the baby's upper and lower extremities flexed by hand, and taking the body into a closed position close to the midline. While applying this method, the baby can be placed in a lateral, supine or prone position (Neto et al., 2020).~In our research, according to the literature, the baby will be placed in the fetal position 3 minutes before the procedure, and the baby will be kept in the fetal position for 3 minutes after the procedure. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
62149554|NCT06352307||Biventricular ACM group|The patients mainly had biventricular enlargement and fibroadipose tissue replacement, and were diagnosed with biventricular ventricular ACM.
62149555|NCT01049490|ACTIVE_COMPARATOR|Intramuscular|15 mcg H1N1 vaccine delivered via intramuscular injection (control)
62149556|NCT01049490|ACTIVE_COMPARATOR|Intradermal|Intradermal: H1N1 vaccine delivered via intradermal injection: Experimental
62356949|NCT01914783|PLACEBO_COMPARATOR|clean air|Subjects will be exposed to clean air for three hours in an exposure chamber controlled for temperature, humidity, and gas/particle composition. During that time they will perform intermittent bicycle ergometer training for 15 minutes alternating with 15 minutes rest. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. The blood pressure will be measured in time intervals of 15 minutes.
62356950|NCT06174961|EXPERIMENTAL|Unfractionated heparin + No exercise|15,000 units of unfractionated heparin will be administered in the thigh. No exercise will be performed afterwards.
62149557|NCT02180932|EXPERIMENTAL|periodontal disease|Saliva samples
62149558|NCT00515242|EXPERIMENTAL|1|Therapeutic massage
62149559|NCT00515242|ACTIVE_COMPARATOR|2|Thermotherapy
62149560|NCT00515242|PLACEBO_COMPARATOR|3|Relaxation
62356951|NCT06174961|EXPERIMENTAL|Unfractionated heparin + Double-legged cycle ergometer exercise|15,000 units of unfractionated heparin will be administered in the thigh. Double-legged cycle ergometer exercise will be performed for 1 hour afterwards
62356952|NCT06174961|EXPERIMENTAL|Unfractionated heparin + Single-legged ipsilateral cycle ergometer exercise|15,000 units of unfractionated heparin will be administered in the thigh. Single-legged cycle ergometer exercise in leg where unfractionated heparin injection is given will be performed for 1 hour afterwards
62356953|NCT06174961|EXPERIMENTAL|Unfractionated heparin + Single-legged contralateral cycle ergometer exercise|15,000 units of unfractionated heparin will be administered in the thigh. Single-legged cycle ergometer exercise in contralateral leg to where unfractionated heparin injection is given will be performed for 1 hour afterwards
62356954|NCT01167153|EXPERIMENTAL|Valsartan/amlodipine|Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
62356955|NCT01167153|ACTIVE_COMPARATOR|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
62356956|NCT03682406|EXPERIMENTAL|CAMS-G|CAMS-G is an group-based adaptation of the Collaborative Assessment and Management of Suicidality (CAMS) that has been developed to address perceived burdensomeness and thwarted belongingness, two drivers of suicide risk. Ongoing assessment and treatment planning are completed using the CAMS Suicide Status Form in the group modality, with involvement from group members and group facilitators. Driver-focused intervention strategies and group process also occur in the group based upon the unique needs of the group members. Groups are 90-minutes in length and occur on a weekly basis.
62356957|NCT03682406|OTHER|Care as Usual|Care as usual includes access to all existing forms of treatment that currently exist at the Robley Rex VAMC and affiliated CBOCs, such as individual and group psychotherapy, suicide prevention programming and case management, psychiatric care, social work services, and substance use disorder counseling. We will essentially track the control condition over time as they engage in the typical services provided to suicidal Veterans through the Robley Rex VAMC. The CAMS-G study participants will have access to the same services delivered as part of care as usual, with the only difference being their participation in the CAMS-G treatment for suicidality.
62356958|NCT03558971|EXPERIMENTAL|Patient self-administration of cortisol|Intervention is patient self-administration of cortisol.
62356959|NCT01001234|EXPERIMENTAL|Stage 1: rizatriptan|
62356960|NCT01001234|PLACEBO_COMPARATOR|Stage 1: placebo|
62356961|NCT01001234|EXPERIMENTAL|Stage 2: rizatriptan|
62356962|NCT01001234|PLACEBO_COMPARATOR|Stage 2: placebo|
62356963|NCT03617913|EXPERIMENTAL|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
62149561|NCT02099058|EXPERIMENTAL|Monotherapy Telisotuzumab vedotin (21-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
62149562|NCT02099058|EXPERIMENTAL|Monotherapy Telisotuzumab vedotin(28-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
62149563|NCT02099058|EXPERIMENTAL|Monotherapy Expansion Cohort|Telisotuzumab vedotin will be administered every 14 days on a 28-day dosing cycle.
62149564|NCT02099058|EXPERIMENTAL|Arm A (Telisotuzumab vedotin plus Erlotinib)|Telisotuzumab vedotin to be evaluated with Erlotinib.
62149565|NCT02099058|EXPERIMENTAL|Arm D (Telisotuzumab vedotin plus Nivolumab)|Telisotuzumab vedotin to be evaluated with Nivolumab.
62149566|NCT02099058|EXPERIMENTAL|Arm E (Telisotuzumab vedotin plus Osimertinib)|Telisotuzumab vedotin to be evaluated with Osimertinib.
61975052|NCT05431452|EXPERIMENTAL|Group 4 (Kangaroo maternal care)|"10 minutes before the procedure, the mother will be placed on the mother's chest at an angle of 60 degrees, with only the diaper left under the baby in the baby adjustment room, in a way that it will contact the mother's chest directly from skin to skin. In order not to lower the newborn's body temperature, a thin blanket will be covered on his back and the mother will be asked to gently soothe the baby's movements by wrapping her hands around the newborn's back. The mother will be instructed not to make additional movements such as stroking, talking, feeding and shaking her baby. After 10 minutes of kangaroo mother care, heel blood collection will be performed and after the procedure, kangaroo mother care will continue for 2 more minutes. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
61975053|NCT05431452|EXPERIMENTAL|Group 5 (Supine Fetal position + Breast milk)|"The head of the baby's bed is elevated to a 45-degree angle and before the procedure, 2 ml of breast milk will be given with the help of a sterile injector by the research clinical nurse, on the condition that each baby has its own breast milk, and then the baby will be placed in the fetal position (Shah et al., 2012; Shukla et al. , 2018). After the baby is held in the fetal position for 3 minutes, heel blood sampling will be performed. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form. In line with the literature recommendations, the baby will be supported in the fetal position for 3 minutes after the procedure (Axelin et al. 2006; Cignacco et al. 2010; Obeidat et al. 2009; Çağlayan and Balci, 2014)."
62149567|NCT04943640|EXPERIMENTAL|kinesio taping|"The patient was advised to clean the skin with alcohol and shave the hairy areas. The standing patient was asked to take off high heels if he/she was wearing them.~The paravertebral technique was used with 5 cm x 5 m kinesio tape material. While the patient was standing in an upright position, two longitudinal pieces were cut by taking the tape and slightly rolling its corners. The patient was asked to lean forward. The lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. The patient was asked to do a slight rotation to the left, and while in this position, the tape was attached to T11-T12 without stretching at all. Kinesio tape was attached to the opposite side of the vertebrae with the same procedure."
62356964|NCT01010854|EXPERIMENTAL|VPA FEC100|Valproic Acid with FEC100
62356965|NCT05845307|EXPERIMENTAL|Control Group|Participants you will be randomly assigned to either receive the study drug or be in a control group.
62356966|NCT05845307|EXPERIMENTAL|TTI-101|Participants you will be randomly assigned to either receive the study drug or be in a control group.
62356967|NCT03094819|NO_INTERVENTION|Group 1|Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
62356968|NCT03094819|EXPERIMENTAL|Financial Incentive|Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
62356969|NCT03094819|EXPERIMENTAL|Retinal Care DR|Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
62356970|NCT05294341|ACTIVE_COMPARATOR|Drug 1|"Half of the subjects will be assigned 0.35mg norethindrone pills daily for 7 days.~The other half of the subjects will be 5mg norethindrone acetate pills daily for 7 days."
62356971|NCT05294341|ACTIVE_COMPARATOR|Drug 2|"Half of the subjects will be assigned 5mg norethindrone acetate pills daily for 7 days.~The other half of the subjects will be 0.35mg norethindrone pills daily for 7 days."
62356972|NCT03883490||Bicuspid Aortic valve|Patients with a bicuspid aortic valve
62356973|NCT03883490||Tri-leaflet Aortic valve|Patients with a tri-leaflet aortic valve
62356974|NCT02633046|OTHER|Acthar Gel|Acthar Gel, 1 mL (80 U) by subcutaneous injection (SC) 3x/week will be administered to all participants from Week 0 to 50. Tapering of dose to 1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 2x/week it must remain at this level. Participants unable to tolerate 1 mL SC 2x/week will be discontinued. All participants will have an End of Study/Early Termination Visit 4 weeks after discontinuing Investigational Medicinal Product (IMP).
62356975|NCT02879981||Pediatric Participants With Acute Bronchitis|Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to Balsamic Bactrim as per the local label will be observed for safety.
62356976|NCT03616847|EXPERIMENTAL|Standard care|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will remain inflated until the wound is closed.
62711375|NCT04268238|EXPERIMENTAL|Control group|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate). Afterwards, this group will receive no treatment. Instead of the sealant, water will be used and the laser will remain with power 0W, that is, there will be no light emission, giving the group the characteristic of the control group, no treatment.
62356977|NCT03616847|EXPERIMENTAL|Tourniquet release|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will be removed. There will be a five minute delay before the wound is closed.
62356978|NCT01902537||Participants With Constipation|Participants with constipation receiving prucalopride will be observed for for the health related quality of life (QoL).
62356979|NCT05190744|EXPERIMENTAL|Polyuric subjects with Hereditary Nephrogenic Diabetes Insipidus|Polyuric subjects with hereditary nephrogenic diabetes insipidus with loss of function of arginine vasopressin receptor 2 (AVPR2) or aquaporin 2 (AQP2) will be treated with PB
62356980|NCT05190744|EXPERIMENTAL|Polyuric subjects with Autosomal Dominant Polycystic Kidney Disease treated with Tolvaptan|Polyuric subjects with autosomal dominant polycystic kidney disease on chronic tolvaptan treatment will be treated with PB
62149568|NCT04943640|EXPERIMENTAL|rigid taping|The patient was asked to lean forward, and 5 cm x 5 m rigid tape material was used in the right paravertebral region. When bonding the tape, first, the lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. Then, the patient was asked to do a slight rotation to the left, and while in this position, the hypoallergenic tape (beta fix) was applied with no tension \[23\]. Then, rigid tape was applied upward onto the paravertebral muscles. The left paravertebral region was taped with the same procedure as the right paravertebral region .
62149569|NCT04943640|PLACEBO_COMPARATOR|placebo taping groups|"Placebo taping was applied to patients in this group using betafix, an elastic stabilization tape, as material. A straight line of betafix was applied to the non-painful scapular inferior alignment of the spine, right and left, while the patient was standing upright.~Treatment with taping was administered to all groups every 2 days by the same physiotherapist ."
62711376|NCT04268238|EXPERIMENTAL|Sealant group|In this group, besides the instructions described in the control group, the teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal (sealant) for 5 seconds to the tooth surface and light curing for 20 seconds.
62149570|NCT06510972|EXPERIMENTAL|Strategy for continuing to take oral supplements|Patients will be able to ingest any type of liquid or solid food orally, at any frequency and in any quantity they wish, according to their tolerance, with paramedical assistance if necessary. The necessary treatments will be administered orally. The patient may benefit from a glucosed intake at the discretion of the practitioner in charge of the patient. The patient will benefit from regular mouth care. Intravenous and oral fluids will be quantified.
62149571|NCT06510972|ACTIVE_COMPARATOR|Fasting strategy|The patient will not be able to ingest liquids or solid foods. The patient will be given glucose or parenteral nutrition at the discretion of the practitioner in charge of the patient. The patient will receive regular mouth care. Oral treatments that are essential and have no parenteral alternative may be administered under paramedical supervision.
62149572|NCT04482556|OTHER|Q-NRG+ Indirect Calorimetry Device|Q-NRG+ device will be compared to current V(max) device in each enrolled patient in subsequent, alternating fashion.
62149573|NCT04482556|OTHER|V(max) Encore Indirect Calorimetry Device|V(max) Encore device, currently institution's standard device, will be compared to Q-NRG+ device in each enrolled patient in subsequent, alternating fashion.
62149574|NCT01924585||Frail patient|Patients will be stratified into groups frail and non-frail based on pre-operative frailty and disability.
62149575|NCT01331174|EXPERIMENTAL|High dose PSW groups|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W. These settings were based on the fact that applications with mean power below 20W minimize the thermal effects
62149576|NCT01331174|PLACEBO_COMPARATOR|Placebo|A placebo group was also established, in which the PSW device was turned on but kept in stand-by mode during 19 minutes without any electrical current being applied in the patients
62149577|NCT01331174|NO_INTERVENTION|Control|The control group was composed of patients that were not submitted to any form of treatment and all patients were instructed to maintain their daily activities
62356981|NCT05190744|EXPERIMENTAL|Polyuric subject secondary to lithium administration|Polyuric subject post lithium administration will receive PB
62356982|NCT03865238|EXPERIMENTAL|EV71vac|
61975054|NCT05431452|EXPERIMENTAL|Group 6 (Kangaroo care + Breast milk)|"The head of the baby's bed will be raised at an angle of 45 degrees and before the procedure, 2 ml of breast milk will be given by the research clinical nurse with the help of a sterile injector, provided that each baby is breast milk, and then the mother will be in direct skin-to-skin contact with the mother's breast, with only the diaper under the baby in the baby adaptation room. It will be placed on the mother's chest at an angle of 60 degrees. The mother will be instructed not to make additional movements such as stroking, talking, feeding and shaking her baby. After 10 minutes of kangaroo mother care, heel blood collection will be performed and after the procedure, kangaroo mother care will continue for 2 more minutes. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
61975055|NCT00396591|EXPERIMENTAL|Aflibercept|Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
62149578|NCT03936699|EXPERIMENTAL|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
62149579|NCT03936699|ACTIVE_COMPARATOR|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
62356983|NCT03865238|PLACEBO_COMPARATOR|Placebo|
62356984|NCT01799421||Non-haematologic cancer|
62356985|NCT02176304|ACTIVE_COMPARATOR|Suprapatellar Knee Injection Site|Patients will be injected specified dose of lidocaine and depomedrol through suprapatellar-lateral knee entry site.
61975056|NCT01349803|EXPERIMENTAL|PT005 MDI|PT005 MDI
62356986|NCT02176304|ACTIVE_COMPARATOR|Anterolateral knee injection|Patients will be injected specified dose of lidocaine and depomedrol through anterolateral knee entry site.
62356987|NCT00805922||A|
61975057|NCT01349803|EXPERIMENTAL|PT001 MDI|PT001 MDI
62356988|NCT03536650|EXPERIMENTAL|DMR procedure|
61975058|NCT01349803|EXPERIMENTAL|PT003 MDI|PT003 MDI
61975059|NCT01349803|ACTIVE_COMPARATOR|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
61975060|NCT05248191|EXPERIMENTAL|Capsule fecal microbiota material (cap-FMT)|Participants will receive colonoscopy at day 0 and week 8 and receive cap-FMT orally for five days post-colonoscopy. Stool swabs and samples will be collected regularly.
61975061|NCT05248191|ACTIVE_COMPARATOR|Colonoscopic fecal microbiota material (colo-FMT) plus placebo|Participants will receive colonoscopy at day 0 and week 8 and receive a placebo orally for five days post-colonoscopy. During the first colonoscopy, colo-FMT will be administered. Stool swabs and samples will be collected regularly.
62149580|NCT02514824|EXPERIMENTAL|Dose Level 1: MLN01283 3 mg (Phase 1)|"Phase 1 dose level 1 participants receive MLN01283 3 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62149581|NCT02514824|EXPERIMENTAL|Dose Level 2: MLN01283 4 mg (Phase 1)|"Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62149582|NCT02514824|EXPERIMENTAL|Dose Level 3: MLN01283 5 mg (Phase 1)|"Phase 1 dose level 3 participants receive MLN01283 5 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62356989|NCT01438307|EXPERIMENTAL|Schedule A|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
62149583|NCT02514824|EXPERIMENTAL|MLN01283 RP2D (Phase 2)|"Phase 2 participants receive MLN01283 at the recommended phase 2 dose (RP2D) orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
62356990|NCT01438307|EXPERIMENTAL|Schedule B|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
62356991|NCT01303458|EXPERIMENTAL|Intervention arm|Study subjects will receive the Basic Needs Surveillance (BNS) intervention.
62356992|NCT01303458|NO_INTERVENTION|Control arm|Study subjects in the control arm will receive the standard of care.
62356993|NCT00989404|EXPERIMENTAL|Period|10 mg BID Zanamivir or placebo for 5 days
62356994|NCT01092026|EXPERIMENTAL|cord blood transplant|Eligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
62356995|NCT03096444|EXPERIMENTAL|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
62356996|NCT03096444|EXPERIMENTAL|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
62356997|NCT03096444|EXPERIMENTAL|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
62356998|NCT03096444|EXPERIMENTAL|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
62356999|NCT03096444|PLACEBO_COMPARATOR|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
62357000|NCT05915325|EXPERIMENTAL|Physical training|Supervised patient-tailored intensity-modulated physical training
62357001|NCT06079034||Venovenous ECMO|
62357002|NCT06079034||Venoarterial ECMO|
62357003|NCT01287598|EXPERIMENTAL|Arm 1|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam
62357004|NCT01287598|EXPERIMENTAL|Arm 2|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
62357005|NCT02061748||dabigatran|
62357006|NCT02061748||warfarin|
62357007|NCT04339322||Patients with Covid-19|Patients with clinical presentation and confirmed as Covid-19 according to the definition of Egyptian Ministry of Health
62357008|NCT00091026|EXPERIMENTAL|Arm I (cetuximab, gemcitabine hydrochloride, bevacizumab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22; gemcitabine IV over 30 minutes on days 1, 8, and 15; and bevacizumab IV over 30-90 minutes on days 1 and 15.
62357009|NCT00091026|EXPERIMENTAL|Arm II (gemcitabine hydrochloride, bevacizumab, erlotinib)|Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26.
62357010|NCT04138212|ACTIVE_COMPARATOR|Chemotherapy group|Patients in this group will receive neoadjuvant chemotherapy.
62357011|NCT04138212|EXPERIMENTAL|Chemoradiation group|Patients in this group will receive neoadjuvant chemoradiation therapy.
62357012|NCT03714009|ACTIVE_COMPARATOR|Fasting group|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. They should take adequate water and non calorie beverages intake daily (2-3 liters)"
62357013|NCT03714009|OTHER|Non fasting group|no fasting, patients will have usual balanced diet as 3 meals and 2 snacks all over the day. They should take adequate water and non calorie beverages intake daily (2-3 liters)
62357014|NCT03519399||Cases and Controls|"Cases - Pregnant women with ICP defined as pruritus in pregnancy in association with raised serum bile acids (using hospital threshold for diagnosis), and in the absence of an alternative cause.~Controls - Pregnant women not affected by ICP, or other liver, cardiac or hypertensive disorders."
61975062|NCT05534386|EXPERIMENTAL|First stage intervention: Cancer survivorship care intervention (CSCI)|Patients randomized to the CSCI will attend a 120-minutes survivorship clinic in which each participant will be assessed by members a multidisciplinary team comprising a registered nurse, a dietitian, an exercise physiologist and a psychologist/counsellor. During the visit, participants will receive a personalized (1) treatment summary, (2) assessment and recommendation on managing physical and psychological symptoms, (3) assessment and recommendation on dietary advice, (4) assessment and recommendation on physical activity, and (5) advice on managing potential psychosocial issues. While this is a multidisciplinary clinic, the nurse will be the core facilitator who will give a summary of health assessment report including personalized healthy lifestyle advice and action plan to each participant at the end of the visit.
61975063|NCT05534386|ACTIVE_COMPARATOR|First stage intervention: Control intervention|Patients randomized to the control group will be given a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations. Each pamphlet addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer recurrence) observed in Hong Kong cancer survivors, plus two on lifestyle recommendations (physical activity and healthy diet). All pamphlets are developed based on the self-management framework.
61975064|NCT05534386|EXPERIMENTAL|Second stage intervention: Step-up targeted personalized intervention|The step-up targeted personalized intervention will adopt a multi-disciplinary approach but place more emphasis on coaching to enhance patient' skills to manage their symptom burden and weight control.
61975065|NCT05534386|ACTIVE_COMPARATOR|Second stage intervention: Control intervention|Patients randomized to the control arm at the re-assessment at 4-months post-baseline will continue in the trial as usual (i.e. those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlets).
61975066|NCT03131050|EXPERIMENTAL|High-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
62149584|NCT00799331|EXPERIMENTAL|A|AZD5985
62149585|NCT00799331|EXPERIMENTAL|B|placebo
62149586|NCT05751733|EXPERIMENTAL|Experimental group|Subjects received Apatinib mesylate
62357015|NCT02600494|EXPERIMENTAL|40 mg ITI-007 (Lumateperone)|40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
62357016|NCT02600494|EXPERIMENTAL|60 mg ITI-007 (Lumateperone)|60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
62149587|NCT05751733|ACTIVE_COMPARATOR|Control group|Subjects received TKI second-line therapy such as Sunitinib, Imatinib plus, Dasatinib, and Reveratinib.
62149588|NCT01181115|EXPERIMENTAL|Active treatment|Interferon treatment for MS
62357017|NCT02600494|PLACEBO_COMPARATOR|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
62357018|NCT04939779|EXPERIMENTAL|Group A|Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
62357019|NCT04939779|EXPERIMENTAL|Group B|Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
62357020|NCT02708992|EXPERIMENTAL|Cefixime/Azithromycin|Eight participants will receive three oral doses of 800 mg cefixime (q 8 hours) on Day 1, followed by three oral doses of 800 mg cefixime (q 8 hours)+ one oral dose of 1000 mg azithromycin (with first dose of cefixime) on day 10
62357021|NCT00175162|ACTIVE_COMPARATOR|Osteopal G bone cement|
62357022|NCT00175162|ACTIVE_COMPARATOR|Refobacin-Palacos R bone cement|
62357023|NCT03357666|EXPERIMENTAL|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
62357024|NCT03357666|EXPERIMENTAL|HUDC_VT(Glucose 400mg/Sodium chloride 200mg)|Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
62357025|NCT03357666|EXPERIMENTAL|HUDC_VT(Glucose 400mg)|Glucose 400mg, once a day, two tablets at a time for 7 days
62357026|NCT03357666|EXPERIMENTAL|HUDC_VT(Sodium chloride 200mg)|Sodium chloride 200mg, once a day, two tablets at a time for 7 days
62357027|NCT03357666|PLACEBO_COMPARATOR|Placebo|Placebo, once a day, two tablets at a time for 7 days
62357028|NCT04282070|EXPERIMENTAL|SHR-1701 (Arm A)|SHR-1701 for R/M NPC failure after platinum-based chemotherapy
62357029|NCT04282070|EXPERIMENTAL|SHR-1701 (Arm B)|SHR-1701 for R/M NPC failure after anti PD-1/PD-L1 antibody therapy
62149589|NCT06445140|EXPERIMENTAL|Observation phase and Intervention phase|"This study is divided into two distinct parts (phase):~- A first observational part, already carried out, with the specific aim of assessing the relationship between motivation and behavior, for physical activity and nutrition.~The observational part enabled us to observe the relevant motivational levers for developing the second part of the study, the interventional part.~- The specific aim of the second, interventional part, in which we are inviting you to take part, is to improve physical activity and nutrition behaviours through the implementation of a behavioural intervention\*."
62149590|NCT00559572|EXPERIMENTAL|1|Exercise information group
62149591|NCT00559572|ACTIVE_COMPARATOR|2|General health information group
62357030|NCT04282070|EXPERIMENTAL|SHR-1701 plus Gemcitabine and Cisplatin (Arm C)|SHR-1701+Gemcitabine+Cisplatin for first line treatment of R/M NPC
62357031|NCT04282070|EXPERIMENTAL|SHR-1701 plus Albumin Paclitaxel (Arm D)|SHR-1701+Albumin Paclitaxel for R/M NPC failure after first line anti PD-1/PD-L1 antibody therapy
62357032|NCT01367860|ACTIVE_COMPARATOR|OMicro|This group will be formed by randomization, which gets out surgery to open microdiscectomy
62357033|NCT01367860|EXPERIMENTAL|SJet|This group will be formed by randomization, and receive the discectomy procedure addressed by the technique of Percutaneous Diskectomy SpineJet
62357034|NCT03274180|EXPERIMENTAL|Nursing consultation|travel preventive consultation was performed by nurse
62357035|NCT03274180|NO_INTERVENTION|Medical consultation|travel preventive consultation was performed by a doctor
62357036|NCT00610285||non-invasive immobilization system|This is a feasibility study to evaluate the accuracy of an alternative, non-invasive immobilization system in combination with image guided patient setup for SRS treatments. The aim is to determine whether or not the non-invasive system can provide comparable accuracy as the conventional invasive head ring system. If successful, patient discomfort can be significantly reduced for such treatments.
61975067|NCT03131050|EXPERIMENTAL|Low-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) QD; placebo (1 ml saline, i.m.) QD; escitalopram （10 mg/d p.o.）QD
61975068|NCT03131050|PLACEBO_COMPARATOR|Placebo add-on therapy|Placebo (1 ml saline, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
61975069|NCT01917474|EXPERIMENTAL|Group A: Low-lipid diet|"Lifestyle counseling At the end of this run-in period all patients will be randomly attributed to one of the following two dietary regimens. Those in the experimental groupwill be given a low lipid diet with a lipid content \< 20% of the total daily energy intake with the following composition:~Proteins (g) 77 (15% total energy intake) Lipids (g) 48 (22% total energy intake) Saturated (g) 9 (4% total energy intake) Monounsaturated (g) 31 (14% total energy intake) Polyunsaturated (g) 8 (4% total energy intake) Carbohydrates (g) 330 (63% total energy intake) Cholesterol (mg) 117 Fibres (g) 32 Total Energy (kcal) 1977"
62520936|NCT02106650|EXPERIMENTAL|Folotyn and Leucovorin|"Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment).~Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.~Folic acid and Vitamin B12 is given prior to initiation of Folotyn."
62520937|NCT04891965|EXPERIMENTAL|ART24 (Cohort A)|In Cohort A, subjects will receive ART24 or placebo daily for 7 days
62520938|NCT04891965|PLACEBO_COMPARATOR|Placebo (Cohort A)|In Cohort A, subjects will receive ART24 or placebo daily for 7 days
61975070|NCT01917474|ACTIVE_COMPARATOR|normal lipid diet|"Patients in the active comparator will be given a diet with normal lipid intake and the following composition:~Proteins (g) 75 (15% total energy intake) Lipids (g) 67 (29% total energy intake) Saturated (g) 14 (6% total energy intake) Monounsaturated (g) 43 (19% total energy intake) Polyunsaturated (g) 10 (4% total energy intake) Carbohydrates (g) 307 (56% total energy intake) Cholesterol (mg) 128 Fibres (g) 32 Total Energy (kcal) 2048 lipid intake between 25-30% of the total daily energy intake."
62520939|NCT04891965|EXPERIMENTAL|ART24 (Cohort B)|In Cohort B, subjects will receive ART24 or placebo daily for 28 days
62520940|NCT04891965|PLACEBO_COMPARATOR|Placebo (Cohort B)|In Cohort B, subjects will receive ART24 or placebo daily for 28 days
62520941|NCT03236142|ACTIVE_COMPARATOR|Standard Duodenal Switch (DS)|
62520942|NCT03236142|EXPERIMENTAL|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
62520943|NCT01861236||Advanced Prostate Cancer|Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
62520944|NCT04177563|EXPERIMENTAL|a group of ten students with high physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
62520945|NCT04177563|EXPERIMENTAL|a group of eight students with moderate physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
62520946|NCT06359860|EXPERIMENTAL|ST-1898 Phase Ib|Dose Escalation: Subjects will be administered orally at 140mg, 160mg, 180mg, 220mg, QD during the study, until disease progression or intolerable toxicity.
62520947|NCT06359860|EXPERIMENTAL|ST-1898 Phase II|Dose Expansion: Subjects with unresectable or metastatic melanoma will be administered orally at recommended phase II dose from phase Ib once daily during the study, until disease progression or intolerable toxicity.
62520948|NCT04560465|EXPERIMENTAL|group A: Cases that had tranexamic acid infusion|Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour
62520949|NCT04560465|PLACEBO_COMPARATOR|Group B: Control|control were given perioperative placebo at the rate of 100mls per hour
62520950|NCT05086718|OTHER|AB Gap Closure|Air Bone gap closure following surgery will be considered as successful outcome
62520951|NCT04999930|EXPERIMENTAL|Group A|with aerochamber
62520952|NCT04999930|EXPERIMENTAL|Group B|without aerochamber
62520953|NCT06337825||40 patients with primary hyperparathyroidism|patients undergoing parathyroidectomy for primary hyperparathyroidism
62520954|NCT06337825||40 patients with multinodular goiters|patients undergoing thyroidectomy for multinodular goiter
62520955|NCT05094752|EXPERIMENTAL|Intervention group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
62520956|NCT05094752|SHAM_COMPARATOR|Control group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
62520957|NCT05290324|EXPERIMENTAL|MIdazolam Group|Following surgery Immediately after shifting in ICU, midazolam infusion were administered as 0.25 mg/kg/min.
62520958|NCT05290324|NO_INTERVENTION|Propofol Group|Following surgery after Immediately shifting in ICU propofol infusion was started at 10µg/kg/min.
61975071|NCT05156489|EXPERIMENTAL|Fractionated Laser|
61975072|NCT04080817|EXPERIMENTAL|Neolexon Therapy|
61975073|NCT04080817|ACTIVE_COMPARATOR|Standard logopedic therapy|
61975074|NCT00874965|ACTIVE_COMPARATOR|ES|Electrostimulation
61975075|NCT00874965|PLACEBO_COMPARATOR|Sham ES|Sham stimulation
61975076|NCT05982392|ACTIVE_COMPARATOR|Tramadol|Group A will receive premedication of Oral tramadol 100mg,
61975077|NCT05982392|ACTIVE_COMPARATOR|Naproxen Sodium|Group B will receive premedication of oral naproxen sodium 550mg.
61975078|NCT05982392|PLACEBO_COMPARATOR|Placebo|Group C, will be the control group and no active preoperative medication will be given to these patients.
61975079|NCT03740958|EXPERIMENTAL|Argatroban combined with rt-PA|Drug: Argatroban combined with rt-PA Argatroban as a 100 ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
62520959|NCT05536726|EXPERIMENTAL|608 160 mg W0+80 mg Q2W+80 mg Q4W|Participants will receive starting dose of 160 milligrams (mg) 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period (12 weeks). During the maintenance period, participants will receive 80mg 608 once every four weeks (Q4W).
62149592|NCT03995394|EXPERIMENTAL|Positive Reinforcement Group|"In the intervention group, participants will receive two text messages weekly. The first text message will ask if participants completed the recommended activity. If the participants respond yes, the participant will receive a positive reinforcement response. If the participants respond no, the participant will receive a text message stating, Thank you for your response."
62520960|NCT05536726|EXPERIMENTAL|608 160 mg Q4W+160 mg Q8W|Participants will receive 160mg 608 once every four weeks (Q4W) by subcutaneous injection during induction period (12 weeks) followed by 160mg 608 once every eight weeks (Q8W) during maintenance period.
61975080|NCT03740958|ACTIVE_COMPARATOR|rt-PA|Drug: rt-PA Intravenous throbolysis with 0.9mg/kg rtPA.
61975081|NCT05625672|EXPERIMENTAL|Intervention|Five modules of training on hemovigilance were given in 5 hours. A pre-test was applied at the beginning of the training. The final test was done at the end of the training. One month later, the same test was applied again to measure the permanence of the training.
61975082|NCT05625672|NO_INTERVENTION|Control|No training was provided. Only the pretest was administered one week after the posttest.
61975083|NCT02385045|PLACEBO_COMPARATOR|Narrow band imaging|Narrow band imaging function (Olympus endoscopes)
61975084|NCT02385045|EXPERIMENTAL|i-scan imaging|i-scan imaging (Pentax endoscopes)
62149593|NCT03995394|NO_INTERVENTION|Control Group|"For the control group, participants will receive two text messages weekly. The first text message will ask if the participants completed the recommended activity. When the participant responds, the participant will receive a second text message stating, Thanks for your response."
62357037|NCT02790294|EXPERIMENTAL|Postoperative Magnetic Resonance Imaging|Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.
62357038|NCT01545713||Renal Transplant Recipients|Patients undergoing living-donor kidney transplant at NMH who have a positive XM-One AbSorber® positive test result.
62357039|NCT04480541|EXPERIMENTAL|Roadmap 2.0 + Fitbit Charge 3|"* Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.~* Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep."
62357040|NCT01053702|EXPERIMENTAL|Dose 1|R475
62357041|NCT01053702|EXPERIMENTAL|Dose 2|R475
62357042|NCT01053702|PLACEBO_COMPARATOR|Dose 3|Placebo to match R475 dose
62357043|NCT05252923|EXPERIMENTAL|Sulodexide|Standard treatment plus oral sulodexide
62357044|NCT05252923|NO_INTERVENTION|Control|Standard treatment only
62357045|NCT04811001|EXPERIMENTAL|Arm A (Osimertinib->Dacomitinib)|"Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal.~At treatment discontinuation patients maintaining the original EGFR mutation will switch to Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal."
62357046|NCT04811001|EXPERIMENTAL|Arm B (Dacomitinib->Osimertinib)|"Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal.~At treatment discontinuation, patients harboring the EGFR-T790M will receive Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal."
62357047|NCT01809678|EXPERIMENTAL|Smoking Cessation plus Yoga|Twice weekly, 1-hour yoga classes delivered for 8 weeks combined with once-weekly, 1-hour cognitive-behavioral smoking cessation classes.
62357048|NCT01809678|ACTIVE_COMPARATOR|Smoking Cessation plus Wellness|Twice-weekly, 1-hour Wellness classes given on a variety of health topics twice weekly to match schedule of the yoga classes, plus 1-hour per week of cognitive-behavioral smoking cessation
62357049|NCT04169685||with dexmedetomidine|Drugs provided moderate sedation during procedure including dexmedetomidine
61975085|NCT01000441|ACTIVE_COMPARATOR|arm 1 (2d anti-TNF):|infliximab, etanercept, adalimumab
62357050|NCT04169685||without dexmedetomidine|Drugs provided moderate sedation during procedure without dexmedetomidine
62357051|NCT04714723|ACTIVE_COMPARATOR|Programmed smartphone intervention group|Subjects will receive programmed-smartphone lifestyle intervention
61975086|NCT01000441|ACTIVE_COMPARATOR|arm 2 (other biotherapy)|abatacept, rituximab or tocilizumab
61975087|NCT03251066|OTHER|Test group|Proponent Nasal Spray Medical device
62149594|NCT04288869||Interventional radiology or surgery under general anesthesia|Monitoring of patients (mean arterial blood pressure, Transcranial Doppler , bispectral index, near infrared spectroscopy) who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anaesthesia during the interventional neuroradiology or orthopedic surgery in adults .
62149595|NCT03132636|EXPERIMENTAL|Group 1- metastatic BCC|Administration of cemiplimab in accordance with protocol dosing regimen
62357052|NCT04714723|EXPERIMENTAL|Programmed smartphone plus dietitian intervention group|Subjects will receive programmed-smartphone plus dietitian lifestyle intervention
62357053|NCT00947843|PLACEBO_COMPARATOR|aspirin+placebo|aspirin protect (Bayer) 100mg + placebo clopidogrel 75mg for 1mo
62357054|NCT00947843|ACTIVE_COMPARATOR|aspirin+pregrel|pregrel is a generic brand name of clopidogrel
62357055|NCT00947843|ACTIVE_COMPARATOR|Aspirin+Plavix|plavix is a original brand name of clopidogrel
62357056|NCT04661852|EXPERIMENTAL|CABOZANTINIB WITH TOPOTECAN-CYCLOPHOSPHAMIDE|"Participants will be accrued to dose levels in cohorts of 3 using the 3 + 3 design with a combination of cabozantinib, topotecan and cyclophosphamide.~* Each study treatment cycle lasts 21 days.~* Participants may receive up to 17 cycles.~* Participants will be assigned a specific dose and schedule of the study drugs determined when enrolled in the study."
62520961|NCT05536726|PLACEBO_COMPARATOR|Placebo|Participants will receive Placebo by subcutaneous injection during induction period and then, will be re-randomized to either receive starting dose of 160mg 608 at week 12 followed by 80mg 608 once every four weeks (Q4W) or 160mg 608 once every eight weeks (Q8W) during maintenance period.
61975088|NCT03010163|ACTIVE_COMPARATOR|Health Fair + Pedometer|Participants will get free weight, height, waist, and blood pressure testing at health fairs stationed at NYC taxi garage bases and airport taxi holding lots. Health fair staff will follow up with participants who need to see a doctor due to a high blood pressure reading or other unusual result that needs a physician follow-up. All participants will be given a pedometer with instructions on how to use it to track their daily step counts. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
61975089|NCT03010163|EXPERIMENTAL|Health Fair, Pedometer + Text Messaging|In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
61975090|NCT03010163|EXPERIMENTAL|Health Fair, Pedometer, Social Network Support|Each participant in this group will receive the health fair services with general follow-up along with a pedometer with instructions on how to use the device to track daily step counts. Additionally, participants in this group will be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given a social network guide to train their family and/or friends on how to best motivate the participants . Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
62149596|NCT03132636|EXPERIMENTAL|Group 2 - unresectable locally advanced BCC|Administration of cemiplimab in accordance with protocol dosing regimen
62149597|NCT05770492||Epithelial Basement Membrane Dystrophy|Patients with epithelial basement membrane dystrophy
62149598|NCT05770492||Healthy|Patients/Subjects without corneal pathologies
62149599|NCT05097105||urilogic patients|
62149600|NCT02799849|OTHER|Narcoleptic patients|
62149601|NCT02799849|OTHER|hypersomnic patients|
62520962|NCT00965055|PLACEBO_COMPARATOR|Atorvastatin|
62520963|NCT00965055|EXPERIMENTAL|Atorvastatin/Ezetimibe|
62520964|NCT01983319|EXPERIMENTAL|CIMT + active anodal tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving active anodal transcranial Direct Current Stimulation 1,5 mA for 30 min.
62520965|NCT01983319|SHAM_COMPARATOR|CIMT + sham tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving sham transcranial Direct Current Stimulation
62520966|NCT01983319|NO_INTERVENTION|Healthy control subjects|20 healthy age-matched control subjects will undergo MRI spectroscopy of the brain.
62520967|NCT03276780|EXPERIMENTAL|In vivo|Will receive 4 types of short-acting NRT medication to use in combination with the nicotine patch in each counseling session for four sessions. At the fifth session, participants will select their short acting NRT to use with the patch to make a cessation attempt.
62520968|NCT03276780|ACTIVE_COMPARATOR|Standard of care|Will receive 4 sessions of behavioral counseling around their smoking. At the fifth session, participants will select their short-acting NRT to use with the nicotine patch based on a product description of each product to make a cessation attempt.
62520969|NCT03082664|NO_INTERVENTION|Standard dressing|Standard dressing will be applied after C-section.
62520970|NCT03082664|EXPERIMENTAL|PICO dressing|Device: PICO Single Use Negative Pressure Wound Therapy
62520971|NCT03967587|EXPERIMENTAL|Neosense Umbilical Catheter|
62520972|NCT02006368|EXPERIMENTAL|Storage Age|
62520973|NCT04390321|EXPERIMENTAL|Down Syndrome LLMcare|Individuals with Down Syndrome which are able to execute the LLMcare physical and cognitive training intervention
62520974|NCT00676325|ACTIVE_COMPARATOR|1|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction were eligible for participation.traditional colporrhaphy in this group.
62520975|NCT00676325|ACTIVE_COMPARATOR|2|The NAZCA TC™ POP REPAIR SYSTEM (polypropylene mesh repair),promedon™ , cordoba, argentina, is used to repair anterior vaginal prolapse by a transobturator and pre pubic approach . Helical needles are used to anchor graft to the pelvic sidewall at two points transobturator, the other two arms pre pubic needles is used. We designed this randomized control trial to compare the anatomic success rates, effect on quality of life and sexual symptom scores, and rates of adverse events of the procedure with polypropylene mesh with that of anterior colporrhaphy, with planned follow-up of 1 years.
62520976|NCT02872363|NO_INTERVENTION|Control|The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment.
62520977|NCT02872363|EXPERIMENTAL|Intervention A - Behavioural Regulation|Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
62520978|NCT02872363|EXPERIMENTAL|Intervention B - Priority|Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
62520979|NCT03891017|EXPERIMENTAL|vacuum casting|Vacuum casting will be performed using the Ottobock vacuum casting system. For our vacuum casting procedures, we will be following the protocols outlined in the Harmony Fabrication Quick Guide
62520980|NCT03891017|ACTIVE_COMPARATOR|hydrostatic casting|For the aqua casting system, we will be using an in-house manufactured device. This device will be created following guidelines from the PCAST Technical Manual
62520981|NCT01458106|EXPERIMENTAL|All participants|"PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated."
62520982|NCT01855048|EXPERIMENTAL|N-Rephasin® SAL200|N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
62520983|NCT01855048|PLACEBO_COMPARATOR|INT200-Placebo|Placebo
62357057|NCT03429322|EXPERIMENTAL|Medical Care and Resource Facilitation|All intervention components will be delivered remotely: there will be no face-to-face interaction with the participants. The intervention is comprised of the clinical, educational, and supportive services of Mayo's Brain Rehabilitation Clinic integrated with the MN BIA RF program.
62149602|NCT02757378|EXPERIMENTAL|Neuroplasticity Education Group|Patients who receive manual physical therapy treatment with a neuroplasticity explanation of the basis for the technique
62149603|NCT02757378|ACTIVE_COMPARATOR|Biomechanical Education Group|Patients who receive manual physical therapy treatment with a traditional, biomechanical explanation of the basis for the technique
62357058|NCT03429322|ACTIVE_COMPARATOR|Usual care|Individuals with TBI, their family members and PCPs assigned to the usual care group will receive care and provide services as usual in their communities. Individuals with TBI assigned to the usual care group will receive RF as routinely provided by MN BIA.
62357059|NCT05445141|EXPERIMENTAL|Intervention|Parents included in the intervention group will be offered to participate in four meetings that are taking place during four weeks time. The focus of the meetings is on how to promote parent-infant relationship. The theoretical base is positive developmental psychology including research on attachment, parenting and co-parenting, emotional regulation, and observational learning/role models. Roleplays, video-clips, discussions, and individual reflections are used to empower families during the sessions. Parents are encouraged to try the content with their child between the sessions and will be provided a printed material.
62520984|NCT03361384|EXPERIMENTAL|Alcohol condition|The amount of alcohol received in the alcohol condition will be determined by an algorithm developed by Curtin (Curtin, 2000). Participants in the alcohol condition will receive a dose of alcohol (target BAC = .08%), administered in a chilled beverage of 80-proof vodka mixed with tonic water and lime juice in a 1:4 ratio.
62520985|NCT03361384|PLACEBO_COMPARATOR|Placebo condition|Placebo participants will receive tonic water and lime juice served to enhance alcohol cues in an amount comparable to the amount that they would have received if assigned to the alcohol condition.
62520986|NCT03361384|NO_INTERVENTION|Control (water)|Participants in the water control condition will receive a glass of chilled water in volume of liquid comparable to the amount that they would have received if assigned to the alcohol or placebo condition.
62520987|NCT02252653||Familial Amyloidotic Cardiomyopathy (FAC)|
62520988|NCT05934617||Foch hospital|Lung recipients from Foch hospital, Suresnes, France
62520989|NCT05934617||Bichat hospital|Lung recipients from Bichat hospital, Paris, France
62520990|NCT05934617||Nantes hospital|Lung recipients from Nantes hospital, Nantes, France
62520991|NCT05934617||San Antonio center|Lung recipients from Pulmonary hypertension center, San Antonio, Texas, US
62520992|NCT05934617||Marie-Lannelongue hospital|Lung recipients from Marie-Lannelongue hospital, Le Plessis-Robinson, France
62520993|NCT05934617||Bordeaux hospital|Lung recipients from Bordeaux hospital, Nantes, France
62520994|NCT05934617||Marseille hospital|Lung recipients from Marseille hospital, Marseille, France
62520995|NCT05934617||Toulouse hospital|Lung recipients from Toulouse hospital, Toulouse, France
62520996|NCT05934617||Strasbourg hospital|Lung recipients from Strasbourg hospital, Strasbourg, France
62520997|NCT05934617||Grenoble hospital|Lung recipients from Grenoble hospital, Grenoble, France
62520998|NCT05934617||Cochin hospital|Lung recipients from Strasbourg hospital, Paris, France
62357060|NCT05445141|SHAM_COMPARATOR|Control|Parents in the control group will via a web-based portal be able to view four pre-recorded lectures during four weeks. The lectures will be around 10 minutes long and have a content similar to the group meetings that are offered to the intervention group but more superficial and without printed material and reflection practices.
62357061|NCT02521857|EXPERIMENTAL|ALKS 5461|Sublingual tablet
62357062|NCT06263660|ACTIVE_COMPARATOR|Keto-like supplement|Participants will receive standardized 9.25g stick packs of the keto-like supplement. The study participants will take one of these stick packs dissolved in water three times a day (morning, noon, and evening) for 8 weeks.
62357063|NCT06263660|PLACEBO_COMPARATOR|Placebo|Participants will receive standardized 9.25g stick packs of placebo. The study participants will take one of these stick packs dissolved in water three times a day (morning, noon, and evening) for 8 weeks.
62357064|NCT00616291|EXPERIMENTAL|Group I|MHC Class I binding peptide at 1000 mcg
62357065|NCT00616291|EXPERIMENTAL|Group II|MHC Class II binding peptide at 1000 mcg
62357066|NCT00616291|EXPERIMENTAL|Group III|Combination MHC Class I and II binding peptide at 1000 mcg each
62357067|NCT03751423|ACTIVE_COMPARATOR|PO Morphine & IV Placebo|One third of study participants will be randomized to this local standard of care arm.
62357068|NCT03751423|ACTIVE_COMPARATOR|IV Fentanyl & PO Placebo|One third of study participants will be randomized to this current gold standard of care arm.
62357069|NCT03751423|EXPERIMENTAL|IV Ketamine & PO Placebo|One third of study participants will be randomized to this experimental arm.
62357070|NCT05906992|EXPERIMENTAL|CT-P53|CT-P53(Ocrelizumab)
62357071|NCT05906992|ACTIVE_COMPARATOR|US-Ocrevus|US-licensed Ocrevus(Ocrelizumab)
62357072|NCT05906992|ACTIVE_COMPARATOR|EU-Ocrevus|EU-approved Ocrevus(Ocrelizumab)
62520999|NCT05934617||Hospital center Mayenne North|Lung recipients from Hospital center Mayenne North, Mayenne, France
61976389|NCT05822531|EXPERIMENTAL|Maternal Cardiovascular health (CVH) Intervention|The pilot maternal CVH intervention will be delivered by NFP partners starting as early as NFP program enrollment in the first trimester after confirmation of a viable pregnancy and no later than the 28th week of pregnancy and will continue up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long (weekly visits for the first month following enrollment followed by twice monthly visits until delivery). The pilot study will include an enhanced behavioral component target decreased sedentary time and increase physical activity and utilizing a technology/monitoring component. All women be monitored using a wrist-worn actigraphy device to record daily activity, intermittent home blood pressure self-monitoring, intermittent home weight self-monitoring, and carbon monoxide monitoring administered by the NFP nurse.
62357073|NCT00461422|EXPERIMENTAL|1|Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
62521000|NCT05089695|EXPERIMENTAL|Helmet Noninvasive ventilation (NIV)|"Patients in helmet noninvasive ventilation group will receive continuous helmet pressure support ventilation for at least 16 hours/day in the first 2 calendar days. Dedicated helmets for noninvasive ventilation will be applied and size will be chosen according to patient's neck circumference.~Each patient will be connected to a mechanical ventilator ventilator through a bitube circuit with no humidification.~The ventilator will be set in PSV-NIV mode, with the following suggested settings \[34-38\]:~1. initial pressure support=12 cmH2O and adequate to permit a peak inspiratory flow of 100 l/min;~2. positive end-expiratory pressure=12 cmH2O.~3. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~4. Inspiratory flow trigger = 2 l/min or according to the practice of each institution;~5. fastest pressurization time;~6. expiratory trigger: 10-50% of the maximum inspiratory flow, eventually modified to avoid double triggering;~7. maximum inspiratory time 1.2 second."
62521001|NCT05089695|EXPERIMENTAL|Helmet continuous airway pressure (CPAP)|"Patients in CPAP group will receive continuous helmet CPAP for at least 16 hours/day in the first 2 calendar days. Continuous CPAP without interruptions will be strongly encouraged in the first 48 hours of treatment. Dedicated helmets for noninvasive ventilation will be applied and size will be chosen according to patient's neck circumference.~Treatment will be delivered through a high-flow generator. The following settings will be applied:~1. Continuous air flow\>45 l/min.~2. Bi-tube circuit with no humidification, Y-piece with heat and moisture exchanger, or active heating and humidification with humidification chamber temperature set at 31 °C, 34 °C or 37 °C according to patients' comfort.~3. Expiratory positive end-expiratory pressure valve set to achieve PEEP=12 cmH2O.~4. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%."
62357074|NCT00461422|NO_INTERVENTION|2|Standard Flexible antagonist protocol
62357075|NCT05541523|EXPERIMENTAL|cognitive behavioural therapy|
62357076|NCT05541523|EXPERIMENTAL|mindfulness-based therapy|
62357077|NCT01994317|ACTIVE_COMPARATOR|Standard sedation dose|IV sedation dose calculated using current standard of care
62521002|NCT05089695|ACTIVE_COMPARATOR|High-flow nasal oxygen|"Initial set flow will be 50-60 l/min and flows will be decreased. in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber will be set at 31 °C, 34 °C or 37 °C according to patient's comfort. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~Weaning the patient from high-flow will be considered only after 48 hours from enrolment and will be discouraged until the patients is considered for ICU discharge."
62521003|NCT04313049|ACTIVE_COMPARATOR|Motor control|
62521004|NCT04313049|EXPERIMENTAL|Vocal control|
62521005|NCT03347136|ACTIVE_COMPARATOR|Newborns with CPAP support|Newborn with mild to moderate respiratory distress randomly allocated to CPAP arm. CPAP started with Positive End Expiatory Pressure(PEEEP) 05 and increased up to PEEP 09 according to the severity of baby's condition.
62711377|NCT04268238|EXPERIMENTAL|Low Level Laser Group|In this group, besides the instructions described in the control group, volunteers will receive irradiation with AsGaAl laser, wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, energy density of 35 J/cm2 (considering a spot size of 0.028 cm2 of this equipment), the dose will be 1 J per point. The irradiation will be performed at a cervical, an apical point and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
62357078|NCT01994317|EXPERIMENTAL|Algorithm|IV sedation dose calculated by study algorithm
62357079|NCT00714298|OTHER|1|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. Treating physicians, biologist physician will be blinded to the results of the markers.
62357080|NCT01322451|EXPERIMENTAL|Single oral dose, single capsule|
62357081|NCT01322451|EXPERIMENTAL|Single oral dose, two capsules|
62521006|NCT03347136|EXPERIMENTAL|Newborns with NIPPV support|Newborn with mild to moderate respiratory distress randomly allocated to NIPPV arm. NIPPV started with Intermittent Mandatory Ventilation rate 30, Peak Inspiratory Pressure 20 and PEEP 5.Increased the settings according to the severity of baby's condition
62711378|NCT04268238|EXPERIMENTAL|Low Level Laser + Sealant Group|In this group, patients will receive the treatments described in Control group, Sealant group and Low Level Laser Group.
62357082|NCT02024841|EXPERIMENTAL|Intraperitoneal docetaxel|"Intraperitoneal docetaxel in 1litre normal saline infused over 1 hour on day 1 every 3 weeks:~- Level I: 40mg/m2; Level II: 50mg/m2; Level III: 60mg/m2~Intravenous cisplatin: 60mg/m2 on day 1 every 3 weeks~Oral TS-ONE: 40-60mg twice daily on day 1 -14 every 3 weeks"
62357083|NCT06063512|EXPERIMENTAL|Group A (sweet orange oil group)|Aromatherapy with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes.
62357084|NCT06063512|NO_INTERVENTION|For Group B (Control Group)|No aromatherapy inhalation
62357085|NCT06057610|EXPERIMENTAL|Treatment group A: SHR-A1811 Injection|
62357086|NCT06057610|EXPERIMENTAL|Treatment group B: SHR-A1811 Injection and Pertuzumab Injection|
62711379|NCT06140693|EXPERIMENTAL|Experimental group|All participants will perform all 5 exercise protocols (reduced-exertion high-intensity exercise, sprint interval exercise, below ventilatory threshold continuous exercise, at ventilatory threshold continuous exercise, and above ventilatory threshold continuous exercise) to determine the effect of intensity and duration of exercise on affective valence and felt-arousal, which will be measured using the feeling scale and felt-arousal scale respectively. Remembered enjoyment will be recorded using the physical activity enjoyment scale (PACES) 10 min post exercise.
62711380|NCT05552365|EXPERIMENTAL|Active Intervention|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder.
62711381|NCT05552365|OTHER|Treatment as Usual|Participants are re-directed to mental health support services. All participants given a mental health brochure which has contact details of mental health services for children.
62149604|NCT01535352|EXPERIMENTAL|Internet-facilitated CBT|Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
62149605|NCT01535352|ACTIVE_COMPARATOR|Coach-facilitated Treatment as Usual|Participants in the FUC condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
62711382|NCT05879978|EXPERIMENTAL|obrixtamig + ezabenlimab treatment group|Successive cohorts of patients will receive increasing doses of obrixtamig in combination with ezabenlimab until the maximum tolerated dose (MTD) is reached, or upon decision of Dose Escalation Committee (DEC).
62711383|NCT06062303|NO_INTERVENTION|Compartor arm|- Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, HR (heart rate) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
62711384|NCT06062303|ACTIVE_COMPARATOR|Capillary-refill time and phenotyping group|"Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If \<40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If \<50 mmHg NE will be increased for MAP \>65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m.~If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo.~Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring."
62711385|NCT03253081|ACTIVE_COMPARATOR|PARENT focused intervention|The PF condition will consist of a 90-minute parent group session twice per week. The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent.
62357087|NCT06057610|ACTIVE_COMPARATOR|Treatment group C: Trastuzumab Injection, Pertuzumab Injection and Docetaxel Injection|
62521007|NCT03757273|EXPERIMENTAL|FFF with CAD/CAM customized cutting guide|Mandibular reconstruction using free fibular flap with CAD/CAM customized osteotomy guide.
62521008|NCT03757273|ACTIVE_COMPARATOR|FFF without customized cutting guide|Mandibular reconstruction using free fibular flap without customized osteotomy guide. CAD/CAM 3D model for mandible will be used.
62711386|NCT03253081|ACTIVE_COMPARATOR|CHILD focused intervention|In the CF condition both parent and child will attend the 90-minute session twice weekly. The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist.
62711387|NCT05321563|NO_INTERVENTION|Observation Phase|Schools will continue to apply their standard disciplinary response to school-based substance use infractions during the 'unexposed' study period.
62711388|NCT05321563|EXPERIMENTAL|Intervention Phase|Schools will have the opportunity to deliver the iDECIDE curriculum in lieu of or as part of the standard disciplinary response to school-based substance use infractions during the 'exposed' study period.
62711389|NCT01924780|ACTIVE_COMPARATOR|NEMOS device stimulation 10 minutes|Subject will be stimulated in the cymba concha with a vibro-tactile mechanical device for 10 minutes
62711390|NCT01924780|ACTIVE_COMPARATOR|NEMOS device 60 minutes stimulation|Subjects will be stimulated in the cymba concha with a vibro-tactile mechanical device for 60 minutes
62357088|NCT02141113|ACTIVE_COMPARATOR|Guanfacine Hydrocholride|"1. mg Guanfacine Hydrochloride (orally, QD)~2. mg Guanfacine Hydrochloride (orally, QD)~3. mg Guanfacine Hydrochloride (orally, QD)~4. mg Guanfacine Hydrochloride (orally, QD)~5. mg Guanfacine Hydrochloride (orally, QD)~6. mg Guanfacine Hydrochloride (orally, QD)"
62357089|NCT02141113|PLACEBO_COMPARATOR|Sugar Pill Guanfacine Hydrocholride|"1. mg Guanfacine Hydrochloride (orally, QD)~2. mg Guanfacine Hydrochloride (orally, QD)~3. mg Guanfacine Hydrochloride (orally, QD)~4. mg Guanfacine Hydrochloride (orally, QD)~5. mg Guanfacine Hydrochloride (orally, QD)~6. mg Guanfacine Hydrochloride (orally, QD)"
62521009|NCT00492765|EXPERIMENTAL|1|interferon beta-1a and Simvastatin
62521010|NCT00492765|PLACEBO_COMPARATOR|2|Interferon beta-1a and Placebo
62521011|NCT05729919|EXPERIMENTAL|Free gingival graft|Free gingival technique will be done
62521012|NCT01261741|EXPERIMENTAL|Memantine|
62521013|NCT01261741|PLACEBO_COMPARATOR|Placebo|
62149606|NCT04482413|EXPERIMENTAL|Treatment|Treatment group will be administered via intravenously AstroStem which consists of two syringes and each syringe contains 2.0 x 10\^8 cells / 20 mL of saline with 30% auto-serum.
62149607|NCT04482413|PLACEBO_COMPARATOR|Placebo Control|Placebo control group will receive AstroStem Placebo.
62149608|NCT02137785|EXPERIMENTAL|ALA|
62521014|NCT05101369|EXPERIMENTAL|INCB086550|Participants will be administered INCB086550 orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
62521015|NCT04799678||Participants|Current user of the Smart Asthma app
62521016|NCT03043560|EXPERIMENTAL|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
62521017|NCT03043560|PLACEBO_COMPARATOR|Placebo|Participants will receive treatment with a matching placebo pill.
62521018|NCT03444272|EXPERIMENTAL|Hepatitis C Treatment|HCV Treatment (Sofosbuvir and Daklatasuvir)
62521019|NCT03444272|NO_INTERVENTION|Supportive treatment|supportive liver therapy
62711391|NCT01924780|SHAM_COMPARATOR|Sham 10 minutes|10 minutes of t-VNS stimulation by rotating the NEMOS ear electrode 180 degrees within the pinna, which will position the electrode on the earlobe
62711392|NCT05136170|EXPERIMENTAL|Cenegermin|One drop of cenegermin 20 mcg/mL (rhNGF 20 mcg/mL), in the pharmaceutical form of ophthalmic sterile solution, was instilled in both eyes three times daily (TID), every six hours.
62711393|NCT05136170|PLACEBO_COMPARATOR|Vehicle|In this arm one drop of vehicle was instilled in both eyes TID for 28 consecutive days.
62711394|NCT02398214|EXPERIMENTAL|Sleep hygiene & standard care|Participants receive a light, activity, and sleep training (LAST) intervention consists of behavioral and educational strategies for increasing light exposure and physical activity to minimize sleep disturbance.
62711395|NCT02398214|NO_INTERVENTION|Standard care|Participants receive usual care.
62711396|NCT03643835|EXPERIMENTAL|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
62711397|NCT03643835|ACTIVE_COMPARATOR|Forearm Ice Towels|Participants, following exercise-induced hyperthermia, will be cooled using forearm ice towels. Cotton-blend towels will be doused in ice-water and then wrapped around participant's forearms (elbow to wrist). The towels will be rotated (re-wetted) every 2 minutes)
62149609|NCT02137785|PLACEBO_COMPARATOR|Vehicle|
62149610|NCT04803734|EXPERIMENTAL|Test Group|Albuterol Sulfate inhalation aerosol
62149611|NCT04803734|ACTIVE_COMPARATOR|Reference Group|Proair HFA (albuterol sulfate) Inhalation Aerosol
62149612|NCT04997408|ACTIVE_COMPARATOR|Study Arm|Mobile device-assisted rehabilitation
62149613|NCT04997408|ACTIVE_COMPARATOR|Control Arm|In-person therapist-supervised rehabilitation
62149614|NCT01209156|EXPERIMENTAL|Assess [18F] PBR111 and PET imaging|Evaluation of PET imaging with \[18F\]PBR111 in HV and AD subjects (Proof of Mechanism)
62357090|NCT05897060|EXPERIMENTAL|Patients undergoing TAVI procedure|The study is interventional and consists of a single group of patients undergoing a Transcatheter Aortic Valve Implantation (TAVI), receiving in addition to the usual treatment, an optical fiber placed retrograde in the jugular bulb, in order to record the values of SJVO2 every second.
62357091|NCT01895712||Orsiro|
62357092|NCT05924516|NO_INTERVENTION|Control Group|Control Group: Standard Treatment
62357093|NCT05924516|EXPERIMENTAL|Experimental Group|Experimental Group: Standard Treatment + Adhera® Fatigue Digital Program
62357094|NCT01395641|EXPERIMENTAL|Gene therapy|Intracerebral infusion of AAV2-hAADC viral vector will be performed
62357095|NCT03588611|EXPERIMENTAL|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
62357096|NCT03588611|ACTIVE_COMPARATOR|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
62521020|NCT02780427|ACTIVE_COMPARATOR|1-6 months (Group 1)|
62521021|NCT02780427|ACTIVE_COMPARATOR|7-12 months (Group 2)|
62521022|NCT02780427|ACTIVE_COMPARATOR|13-18 months (Group 3)|
62521023|NCT02780427|ACTIVE_COMPARATOR|19-24 months (Group 4)|
62149615|NCT03390166|ACTIVE_COMPARATOR|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
62149616|NCT03390166|ACTIVE_COMPARATOR|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
62521024|NCT04527328|EXPERIMENTAL|AKST1210|The AKST1210 column will be connected to the dialysis circuit during each dialysis session.
62521025|NCT04527328|SHAM_COMPARATOR|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
62521026|NCT05335213||Participants with cirrhosis and urinary tract infections|"Participants collect urine and fecal specimens at first two days when they admit to hospital, after 7-10 days and last two days hospital treatment and during episodes of complications (variceal bleeding, hepatic coma, hepatorenal syndrome).~Urine samples take from patients via clean catch if the patient not have a catheter placed, otherwise take from urinary catheters if present. Straight catheterization utilize if the patient unable to void and doesn't have a catheter placed.~Fecal specimens collect using a toilet specimen collection kit. Clinical, standart laboratory and cultural test, molecular genetic methods, using 16S rRNA gene sequencing of the V4-V5 hypervariable region be administered."
62521027|NCT05335213||Participants with cirrhosis without urinary tract infections|"Participants ask to collect urine and fecal specimens at first two days when they admit to hospital, after 7-10 days and last two days hospital treatment and during episodes of complications (variceal bleeding, hepatic coma, hepatorenal syndrome).~Urine samples take from patients via clean catch if the patient not have a catheter placed, otherwise take from urinary catheters if present. Straight catheterization utilize if the patient unable to void and doesn't have a catheter placed.~Fecal specimens collect using a toilet specimen collection kit. Clinical, standart laboratory and cultural test, molecular genetic methods, using 16S rRNA gene sequencing of the V4-V5 hypervariable region be administered."
62521028|NCT04322149|EXPERIMENTAL|AT-1501|4 sequential dose cohorts
62521029|NCT01906086|EXPERIMENTAL|legume consumption|legume consumption, 4 servings per week, for 6 weeks
62521030|NCT01906086|ACTIVE_COMPARATOR|healthy dietary recommendations|no nutritional intervention
62521031|NCT01626521||COPD Exacerbation|Patients admitted to hospital with COPD exacerbation
62521032|NCT01598519|EXPERIMENTAL|study group|1500 students are randomized to receive a universal suicide intervention apart from usual school psychology classes. Furthermore, high risk of suicidal students screened in study group will receive an indicated suicide intervention in addition to usual school psychology classes.
62521033|NCT01598519|NO_INTERVENTION|control group|1500 students are randomized to receive usual school psychology classes. High risk of suicidal students screened in control group will receive usual psychology classes.
62521034|NCT05166681|ACTIVE_COMPARATOR|control group|cases allocated to that arm are those cases having their surgical wound closure by the traditional techniques involving subcutaneous layer closure as one or more raws of sutures and then skin layer closure
62521035|NCT05166681|EXPERIMENTAL|Single layer wound closure group|cases allocated to that group are those having their surgical wound closure with the new technique involving part of the subcutaneous layer and the subdermal layer
62521036|NCT02790307|EXPERIMENTAL|Daily stimulation (30mins/day)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
62521037|NCT02790307|EXPERIMENTAL|Weekly stimulation (30mins/week)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
62521038|NCT04551911|EXPERIMENTAL|Rayaldee|Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed. Patients were to remain fasted for at least 3 hours after administration of study drug.
62521039|NCT04551911|PLACEBO_COMPARATOR|Placebo|Subjects will be instructed to take a loading dose of 10 capsules (0 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed. Patients were to remain fasted for at least 3 hours after administration of study drug.
62521040|NCT05703243||Active|Newly diagnosed cancer patients.
62521041|NCT05703243||Control|Historically diagnosed cancer patients.
62521042|NCT00922987||Lyrica|Adult patients with partial seizures (type of epilepsy). Inclusion criteria according to Summary of Product Characteristics
62521043|NCT00117403|EXPERIMENTAL|1|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals
62521044|NCT00117403|EXPERIMENTAL|2|CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals
62521045|NCT00117403|PLACEBO_COMPARATOR|3|two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals
62521046|NCT05532579|EXPERIMENTAL|Invasive Physiotherapy|
62521047|NCT05532579|PLACEBO_COMPARATOR|Sham Group|
62521048|NCT00313443|EXPERIMENTAL|Amiodarone, long-term|Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings
62521049|NCT05476614|EXPERIMENTAL|Social robot-instructed yoga group|A socially assistive robot will be programmed to instruct 10-14 yoga postures for a group of 20-25 older adults. The yoga session will also include meditation and centering exercises.
62521050|NCT05476614|ACTIVE_COMPARATOR|Human-instructed yoga group|A human yoga instructor will lead 10-14 yoga postures for a group of 20-25 older adults. The yoga session will also include meditation and centering exercises.
62521051|NCT03022474|EXPERIMENTAL|Intervention group|
62521052|NCT03022474|NO_INTERVENTION|Control group|
62521053|NCT01900496|EXPERIMENTAL|Brentuximab vedotin & Rituximab|"Brentuximab vedotin:~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a \~ 1 year total course of therapy."
62521054|NCT03188718|OTHER|WatchPAT Intervention|Wearing the WatchPAT device simultaneously while receiving a clinically indicated sleep study (polysomnogram).
62521055|NCT05192759|EXPERIMENTAL|TBS Group|Participants will receive active transcranial magnetic stimulation (TMS) daily for 1 week
62521056|NCT00869024|EXPERIMENTAL|Stem Cell therapy|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
62521057|NCT00869024|PLACEBO_COMPARATOR|Placebo|Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
62521058|NCT03822364|EXPERIMENTAL|A-1 (009-1 -> active comparator)|Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)
62521059|NCT03822364|EXPERIMENTAL|A-2 (active comparator -> 009-1)|Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)
62521060|NCT03822364|EXPERIMENTAL|B-1a (009-2)|Part B, Arm 1 (Inhaled apomorphine, Dose 2)
62521061|NCT03822364|PLACEBO_COMPARATOR|B-1p (009-0)|Part B, Arm 1 (Inhaled placebo)
62711398|NCT03643835|NO_INTERVENTION|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
62711399|NCT01019265|EXPERIMENTAL|Norspan patch (Buprenorphine TDS)|
62711400|NCT01019265|ACTIVE_COMPARATOR|TramadolSR tab (Tridol SR tab)|
62711401|NCT04843631|EXPERIMENTAL|Arm A: BFI-751|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL BFI-751
62357097|NCT03588611|ACTIVE_COMPARATOR|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR \<60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
62357098|NCT03588611|EXPERIMENTAL|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR \<60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
62357099|NCT03013257|EXPERIMENTAL|High Intensity Focused Ultrasound|Try to use the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the relapsed Graves' disease
62521062|NCT03822364|ACTIVE_COMPARATOR|B-2a (009-3)|Part B, Arm 2 (Inhaled apomorphine, Dose 3)
62521063|NCT03822364|PLACEBO_COMPARATOR|B-2p (009-0)|Part B, Arm 2 (Inhaled placebo)
62521064|NCT03822364|EXPERIMENTAL|B-3a (009-4)|Part B, Arm 3 (Inhaled apomorphine, Dose 4)
62711402|NCT04843631|ACTIVE_COMPARATOR|Arm B: EU-STELARA®|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL EU- STELARA®
62711403|NCT04843631|ACTIVE_COMPARATOR|Arm C: US-STELARA®.|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL US- STELARA®
62357100|NCT03013257|NO_INTERVENTION|Fixed-dose radioiodine-131|Using the traditional treatment, fixed-dose radioiodine-131, to treat the relapsed Graves' disease
62357101|NCT00211874|EXPERIMENTAL|Nurse-management|nurse-led intervention focused on specific management problems
62357102|NCT00211874|NO_INTERVENTION|Usual Care|Usual care as control group
62357103|NCT00930709|ACTIVE_COMPARATOR|Active strength training and stretching|Active strength training and stretching
62357104|NCT00930709|ACTIVE_COMPARATOR|Botulinum toxin type A injections|Botulinum toxin type A injections
62357105|NCT05569564|EXPERIMENTAL|Osseodensification with ridge splitting|Ridge splitting followed by osseodensification using osseodensifying burs .
62357106|NCT05569564|ACTIVE_COMPARATOR|Osseodensification|osseodensification will be performed using osseodensifying burs.
62357107|NCT03029676|EXPERIMENTAL|Group B|spinal anesthesia premedication with benzodiazepine and opioid
62357108|NCT03029676|ACTIVE_COMPARATOR|Group K|spinal anesthesia premedication with opioid
62357109|NCT05226351|ACTIVE_COMPARATOR|Dronabinol PTSD|Donabinol before cognitve testing - PTSD patients
62357110|NCT05226351|ACTIVE_COMPARATOR|Dronabinol healthy controls|Donabinol before cognitve testing - healthy controls
62711404|NCT03339596|EXPERIMENTAL|Erythropoietin|4 intravenous infusions of recombinant human erythropoietin (EPO)
62711405|NCT03339596|PLACEBO_COMPARATOR|Saline|4 intravenous infusions of saline (1 ml NaCl)
62711406|NCT02918448|EXPERIMENTAL|Taining group|training group that performed the resistance program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. Participants of the TG performed 3 sets of 10-15 repetition maximums. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise
62711407|NCT02918448|NO_INTERVENTION|control group|control group that did not perform any type of physical exercise
62521065|NCT03822364|PLACEBO_COMPARATOR|B-3p (009-0)|Part B, Arm 3 (Inhaled placebo)
62357111|NCT05226351|PLACEBO_COMPARATOR|Placebo PTSD|Placebo before cognitve testing - PTSD patients
62357112|NCT05226351|PLACEBO_COMPARATOR|Placebo healthy controls|Placebo before cognitve testing - healthy controls
62357113|NCT01716026|ACTIVE_COMPARATOR|3 Month Load with 9 month p.r.n.|3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit
62357114|NCT01716026|EXPERIMENTAL|Single Dose Load Phase|Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol
62357115|NCT03203590|ACTIVE_COMPARATOR|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
62357116|NCT03203590|EXPERIMENTAL|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
62357117|NCT05399108|EXPERIMENTAL|The Novel Lateral Approach|In this arm, the catheterization of the internal jugular vein is done with ultrasound guidance displaying the vein on its short axis using a lateral approach and in-plane technique. The catheterization is done according to the newest international recommendations for good clinical practice.
62357118|NCT05399108|ACTIVE_COMPARATOR|The Conventional Approach|In this group catheterization of the jugular internal vein is done by conventional approach with ultrasound guidance using displaying on its short axis and using the out-of-plane technique.
62357119|NCT00563368|EXPERIMENTAL|VI-0521 Top|VI-0521; high dose phentermine/topiramate
62357120|NCT00563368|EXPERIMENTAL|VI-0521 Mid|VI-0521; mid dose phentermine/topiramate
62357121|NCT00563368|ACTIVE_COMPARATOR|TPM 46|mid dose topiramate
62357122|NCT00563368|ACTIVE_COMPARATOR|TPM 92|high dose topiramate
62357123|NCT00563368|ACTIVE_COMPARATOR|PHEN 7.5|mid dose phentermine
62357124|NCT00563368|ACTIVE_COMPARATOR|PHEN 15|high dose phentermine
62521066|NCT03822364|EXPERIMENTAL|C-1a (009-3)|Part C, Arm 1 (Inhaled apomorphine, Dose 3)
62521067|NCT03822364|PLACEBO_COMPARATOR|C-1p (009-0)|Part C, Arm 1 (Inhaled placebo)
62521068|NCT03822364|EXPERIMENTAL|C-2a (009-4)|Part C, Arm 2 (Inhaled apomorphine, Dose 4)
62711408|NCT03136120||Subjects with suspected fibrotic ILD|Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.
62711409|NCT03540680|OTHER|Term newborns (≥37GA)|Blood punction on the cordon
62357125|NCT00563368|PLACEBO_COMPARATOR|Placebo|
62357126|NCT03082417|NO_INTERVENTION|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
62357127|NCT03082417|EXPERIMENTAL|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
62357128|NCT03082417|NO_INTERVENTION|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
62357129|NCT02186756|EXPERIMENTAL|EMG-Biofeedback and Usual Care|"Patients in the intervention group started EMG-biofeedback training within three days after inclusion. In total 14 sessions of EMG-biofeedback training were applied. They started with three sessions of therapy in week 1-3 and had one session per week in week 4-8.~Patients were encouraged to do a home exercise program, in which they consciously relaxed the muscle analogously to the biofeedback session for about 15 minutes per day. Additionally, they should try to apply the techniques in stressful situations, for example appointments at the dentist's."
62357130|NCT02186756|NO_INTERVENTION|Usual care|The patients in the control group had only two encounters with the therapist in the eight week interval. At these encounters pain was assessed by a visual analogue scale and their trapezius muscle activity was measured during 5 minutes analogously to the intervention group. However, afterwards they did not continue with muscle straining and relaxation.
62357131|NCT06508437|ACTIVE_COMPARATOR|"Immediate Vaccination Group"|At the inclusion visit (D0), a dose of influenza vaccine will be administered.
62357132|NCT06508437|NO_INTERVENTION|"Follow-up vaccination group"|At the inclusion visit (D0), no immediate influenza vaccination (which will be administered one month later at the follow-up visit).
62357133|NCT06025617|EXPERIMENTAL|Intervention arm|Patients referred by their GP under suspicion of suffering from FSD are randomized to the intervention arm.
62357134|NCT06025617|ACTIVE_COMPARATOR|Control arm|"Patients referred by their GP under suspicion of suffering from FSD are randomized to Diagnostic as usual in the control arm."
62357135|NCT04759313|EXPERIMENTAL|Imagenarrative treatment group|INI Sessions: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
62357136|NCT04759313|EXPERIMENTAL|Wait List Control Group|In weeks 6 through 10, the same program will be delivered to the wait list control group.
62357137|NCT05172531|EXPERIMENTAL|test group|Participants in the test group received Cisatracurium Besilate 0.12mg/kg/hr Continuous infusion During intubation
62357138|NCT05172531|SHAM_COMPARATOR|control group|Participants in the control group received saline 0.12ml/kg/hr Continuous infusion During intubation
62357139|NCT05377307||Group A|After completion or early withdraw from the treatment protocol, patients will be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.
62357140|NCT05377307||Group B|Some patients may require joining other Pell's gene-edited immune cell therapy study during participating in this long-term follow-up study. For such case, the patient could be enrolled into the new treatment protocol. Meanwhile, the patient can be remaining in this long-term follow-up protocol as an inactive participant.
62357141|NCT01683084|ACTIVE_COMPARATOR|Telmisartan|One 40mg telmisartan pill given once daily for 24 months
62357142|NCT01683084|PLACEBO_COMPARATOR|Placebo|One 40mg placebo pill given once daily for 24 months
62357143|NCT02755142|ACTIVE_COMPARATOR|Dose level 1|0,2 mg/Kg
62357144|NCT02755142|ACTIVE_COMPARATOR|Dose level 2|2,0 mg/Kg
62357145|NCT02755142|ACTIVE_COMPARATOR|Dose level 3|20 mg/Kg
62357146|NCT04454580||treated patients|hypomethylating agent (azacitidine or decitabine) in combination with venetoclax
62357147|NCT00925145||1|
62711410|NCT03540680|OTHER|Premature newborns|Blood punction on the cordon
62711411|NCT03540680|OTHER|Child between 7 and 15 years old with BPD|Blood punction
62357148|NCT06017778|EXPERIMENTAL|whole body viberation group|
62357149|NCT06017778|ACTIVE_COMPARATOR|control group|
62357150|NCT01162304|ACTIVE_COMPARATOR|ER Oxycodone vs IR Oxycodone|"Extended release Oxycodone to assess pain relief adverse effects, treatment satisfaction and impact of treatment on health related quality of life.~IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every four hours"
62149617|NCT04251988|NO_INTERVENTION|Standard of Care (No VR) Randomization|Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.
62357151|NCT02126670|PLACEBO_COMPARATOR|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
62521069|NCT03822364|PLACEBO_COMPARATOR|C-2p (009-0)|Part C, Arm 2 (Inhaled placebo)
62711412|NCT03540680|OTHER|Child between 7 and 15 years old without BPD|Blood punction
62521070|NCT03822364|EXPERIMENTAL|C-3a (009-5)|Part C, Arm 3 (Inhaled apomorphine, Dose 5)
62521071|NCT03822364|PLACEBO_COMPARATOR|C-3p (009-0)|Part C, Arm 3 (Inhaled placebo)
62711413|NCT06715813|ACTIVE_COMPARATOR|pelvic floor strengthening group|"Group A that is the control group will includes pelvic floor strengthening exercises. given three times a week on alternate days and session will be given for 4 weeks (protocol) and the retention effect will be given for 8 weeks. Each session will be performed at a moderate intensity , indicated by sustained contractions for 5 seconds initially and then progresively increased to 10 seconds overtime.~pelvic floor strengtheing exercises includes :~1. breathing exercises,~2. kegels exercises~3. bridging exercises~4. squatting~5. Elevator exercises"
62711414|NCT06715813|EXPERIMENTAL|PFMS + Transversus abdominal strengthening|group B includes interventional group which includes core stabilization exercises for 2 weeks like stomach hallowing , dead bugs and pelvic tilt exercises and after 2 weeks dead bug progression, planks and pelvic floor strengthening exercises.
62711415|NCT03564236|ACTIVE_COMPARATOR|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:~* oral prednisolone 40 mg/day for 5 days;~* antibiotics prescribed according to the following criteria: fever (body temperature \> 38.5 degrees Celsius), elevated C-reactive protein (CRP) \>50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 \<30% of predicted;~* high dose inhaled corticosteroids, beta-agonists and or anticholinergics.~* Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
62711416|NCT03564236|EXPERIMENTAL|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:~* nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.~* During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.~* After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
62711417|NCT06657001||GI Disorders|Inflammatory Bowel Disease, Irritable Bowel Syndrome, Crohn's Disease, Celiac Disease, Diarrhea, Constipation
62711418|NCT03062943|EXPERIMENTAL|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
62711419|NCT06149169|EXPERIMENTAL|Relma-cel|The PK, safety and efficacy of Relma-cel will be evaluated in 1 x 10\^8 CAR+T cells dose level
62357152|NCT02126670|ACTIVE_COMPARATOR|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
62521072|NCT01698775|EXPERIMENTAL|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
62521073|NCT01698775|ACTIVE_COMPARATOR|Placebo to omarigliptin (Phase A) → Glipizide (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
62521074|NCT02581878|EXPERIMENTAL|Cohort 1a|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate \[ACC\]).
62521075|NCT02581878|EXPERIMENTAL|Cohort 1b|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).
62521076|NCT02581878|EXPERIMENTAL|Cohort 2|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).
62711420|NCT04221893|EXPERIMENTAL|Radiation therapy (RT)|Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity. Target prescription dose will be 30 Gy in 5 fractions and each treatment site (up to 5) will undergo standard Department-approved treatment planning, quality-assurance, and delivery protocols
62711421|NCT05442736|ACTIVE_COMPARATOR|Free drug|Free drug incorporated in in situ gels
62711422|NCT05442736|ACTIVE_COMPARATOR|drug entrapped in nanoparticles|drug entrapped in nanoparticles then incorporated in in situ gels
62149618|NCT04251988|EXPERIMENTAL|VR Randomization|Patients will receive virtual reality in addition to standard of care.
62149619|NCT03342261||HCV patients with mixed cryoglobulinemia|HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents
62357153|NCT02126670|ACTIVE_COMPARATOR|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
62357154|NCT02126670|OTHER|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
62521077|NCT02581878|EXPERIMENTAL|Cohort 3|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).
62521078|NCT02581878|EXPERIMENTAL|Cohort 4|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).
62521079|NCT00831636|EXPERIMENTAL|Open label CP-4055|Phase I: Dose escalation Phase II: Fixed dose
62711423|NCT03992950|EXPERIMENTAL|Cricoid pressure|Cricoid pressure is applied in the anesthetized state and during video laryngoscopy
62711424|NCT03992950|EXPERIMENTAL|Paratracheal pressure|Paratracheal pressure is applied in the anesthetized state and during video laryngoscopy
62149620|NCT01499979|NO_INTERVENTION|Vascular inflow occlusion|Patients that will receive intermittent vascular inflow occlusion, the standard method for vascular occlusion at our institution, during liver resection.
62149621|NCT01499979|EXPERIMENTAL|Hypothermic perfusion|Patients will receive in situ hypothermic perfusion of the future remnant liver during liver resection.
62149622|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
62149623|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
62149624|NCT02426931|EXPERIMENTAL|tf-URS|Participants in tf-URS group undergo ureteroscopy using the tip-flexible ureterorenoscope.
62149625|NCT02426931|ACTIVE_COMPARATOR|f-URS|Participants in f-URS group undergo ureteroscopy using the classic flexible ureteroscope.
62149626|NCT00486304|EXPERIMENTAL|Antioxidant-deficient diet (ADD)|
62149627|NCT00486304|PLACEBO_COMPARATOR|Placebo|
62149628|NCT06390449|EXPERIMENTAL|Experimental|"Kahoot application, which is in the digital test category as a Web 2.0 tool, will be applied after teaching the basic principles and practices in nursing course for 6 weeks. After the applications are completed, the personal information form and the Web Pedagogical Content Knowledge Scale will be applied again to both groups."
62149629|NCT06390449|NO_INTERVENTION|Control|"The students in the control group will be taught only basic principles and practices in nursing for 6 weeks. The study will be carried out without using the WEB 2.0 tool. After the applications are completed, the personal information form and the Web Pedagogical Content Knowledge Scale will be applied again to both groups."
62149630|NCT05440240|ACTIVE_COMPARATOR|Corticosteroid injection|Percutaneous needle fasciotomy with corticosteroid injection
62149631|NCT05440240|PLACEBO_COMPARATOR|Saline injection|Percutaneous needle fasciotomy with saline injection
62149632|NCT05556304|OTHER|assessment in the 8th month of pregnancy and during delivery|The study design includes a consultation during pregnancy between 36 and 38 weeks of gestation and an assessment in the delivery room during childbirth
62149633|NCT01061580|EXPERIMENTAL|CABG plus BMAC Injection|Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
62711425|NCT02659085|ACTIVE_COMPARATOR|Electroconvulsive Therapy (ECT)|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly. Each participating clinic decides for each patient whether the treatment is given uni- or bilateral, as well as the exact stimulation parameters. Choice of anesthetic drug (e.g. thiopental of propofol) and muscle relaxant is done by local anesthesiologist. The procedure differs in no way from how a given patient would have been treated if he or she were not included in the study.
62149634|NCT03661398|EXPERIMENTAL|Transcatheter Mitral Valve Replacement|Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System
62149635|NCT02065609|EXPERIMENTAL|Cohort 1|89Zr-Trastuzumab Human Dosimetry and Safety
62149636|NCT02065609|EXPERIMENTAL|Cohort 2: Lesion Detection and Safety|HER2 Positive Lesion Detection and Safety
62149637|NCT06441357||Patients with preinvasive lung adenocarcinomas|preinvasive lung adenocarcinomas include atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA)
62149638|NCT06441357||Patients with invasive lung adenocarcinomas|invasive adenocarcinoma(IAC)
62149639|NCT05484336|EXPERIMENTAL|Glucose as reference food|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
62149640|NCT05484336|EXPERIMENTAL|Glucose beverage containing 4 g spirulina|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
62149641|NCT05484336|EXPERIMENTAL|Glucose beverage containing 6 g spirulina|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
62149642|NCT05484336|EXPERIMENTAL|Glucose beverage containing 8 g spirulina|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
62149643|NCT01868230|EXPERIMENTAL|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
62711426|NCT02659085|EXPERIMENTAL|Ketamine IV Infusion|Ketamin intra venous infusions of racemic ketamine (0.5mg/kg), delivered over a period of 40 minutes thrice weekly, as ECT (Monday, Wednesday and Friday).
62711427|NCT00897884|EXPERIMENTAL|Metformin|Patients will take metformin three times a day for two to three weeks prior surgery.
62149644|NCT01868230|NO_INTERVENTION|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
62149645|NCT03605420|EXPERIMENTAL|Experimental group|Receiving one family visit prior to hospital admission
62149646|NCT03605420|NO_INTERVENTION|Control group|Without receiving one family visit prior to hospital admission
62149647|NCT06486233||Observe the patient with early percutaneous coronary intervention|Elderly patients with non-ST-segment elevation acute coronary syndrome receive early percutaneous coronary intervention (\< 24 hours after diagnosis).
62149648|NCT06486233||Observe the patient with late percutaneous coronary intervention|Elderly patients with non-ST elevation acute coronary syndrome undergoing late percutaneous coronary intervention (≥ 24 hours after diagnosis)
62149649|NCT01918033|EXPERIMENTAL|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
62149650|NCT01918033|EXPERIMENTAL|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
62149651|NCT01918033|PLACEBO_COMPARATOR|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
62149652|NCT04090476|EXPERIMENTAL|BIG for Life Exercise Group|This arm includes the entire cohort enrolled who will participate in the three times a week one hour community exercise group for a total of 8 weeks
62149653|NCT05237869|SHAM_COMPARATOR|Physical Therapy|For patients enrolled in the control group, the participants will undergo calibration of the Delfi Personalized Tourniquet System to measure limb occlusion pressure and will wear the cuff during completion of the exercises with minimal inflation (approximately 5%), to hold the cuff in place during treatment. This will act as a sham.
62149654|NCT05237869|ACTIVE_COMPARATOR|Blood Flow Restricted Physical Therapy|Physical therapy assisted by blood flow restriction per standard physical therapy protocol.
62149655|NCT05991518|EXPERIMENTAL|Phase Ia - Dose escalation|To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and/or recommended phase II dose (RP2D) of intravenous IAH0968 in combination with the GC regimen for adult patients with HER2-positive advanced solid tumors who have failed standard treatment.
62149656|NCT05991518|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage|The RP2D determined from the Phase Ib study is used as the first-line treatment for HER2-positive advanced or metastatic biliary tract cancer (BTC) patients who have not received prior systemic therapy. The efficacy of IAH0968 in combination with the GC regimen is compared to the efficacy of placebo in combination with the GC regimen based on the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, using the objective remission rate (ORR) as the evaluation criteria.
62149657|NCT00310609|EXPERIMENTAL|Arm 1|
62149658|NCT02356198|ACTIVE_COMPARATOR|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
62149659|NCT02356198|ACTIVE_COMPARATOR|Intrathecal opioid (IT)|single injection intrathecal hydromorphone analgesia given preoperatively
62149660|NCT04002349|PLACEBO_COMPARATOR|A: Placebo group|Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning
62149661|NCT04002349|EXPERIMENTAL|B: Budesonide Nasal Spray (Rhinocort)|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning
62149662|NCT04002349|EXPERIMENTAL|C: Levocabastine Nasal Spray (Livostine)|Treated by Levocabastine(Livostinet, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
62149663|NCT04002349|EXPERIMENTAL|D: Combined Treatment|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
62149664|NCT06509594|ACTIVE_COMPARATOR|Group A will be treated with Scapular Stabilization Exercises along with hot pack;|Participants in the exercise group performed three scapular stabilization exercises at 3 sets of 10 repetitions, holding 10 seconds per one repetition, 5 days per week for 4 weeks under supervision. The exercises included:
62149665|NCT06509594|ACTIVE_COMPARATOR|Group B will be treated with Eccentric Muscle Energy Technique along with hot pack.|Eccentric muscle energy technique was applied to subjects' cervical spine. The Cervical spine was brought to the barrier of motion in each plane i.e. Flexion/extension, lateral bending and rotation. Then subjects were asked to push their heads into the direction opposite that of the barrier. The therapist provided Isometric resistance for 7-10 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch. Three to five repetitions were performed(2). We will apply protocol for 4 weeks 20 Sessions (5 sessions in a week) and 10 sec rest between each segment with 3-5 time's repetition than their will 7-10 sec Isometric contraction followed by 5 sec relaxation than 30 sec hold for MET stretch.
62149666|NCT03762278|EXPERIMENTAL|Immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the uni-laterally immobilised leg.
62149667|NCT03762278|ACTIVE_COMPARATOR|Non-immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the non-immobilised leg.
62149668|NCT03762278|PLACEBO_COMPARATOR|Immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the uni-laterally immobilised leg.
62149669|NCT03762278|PLACEBO_COMPARATOR|Non-immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the non-immobilised leg.
62149670|NCT01850342|EXPERIMENTAL|Fat micrograft enhanced with ADRC|
62521080|NCT02919813|ACTIVE_COMPARATOR|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
62521081|NCT02919813|ACTIVE_COMPARATOR|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
62521082|NCT01828944|ACTIVE_COMPARATOR|Extra virgin olive oil|Extra virgin olive oil
62521083|NCT01828944|EXPERIMENTAL|Enriched extra virgin olive oil|Enriched extra virgin olive oil
62149671|NCT04511286|EXPERIMENTAL|Internet-delivered exposure-based treatment|Eight weeks of therapist-guided exposure-based treatment delivered via the Internet.
62149672|NCT01475110||Study cohort group|"Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.~Adult pts treated with Nilotinib as second line therapy after Dasatinib."
62149673|NCT01319344|EXPERIMENTAL|Eplerenone|
62149674|NCT06231667|EXPERIMENTAL|Education|The health literacy training was implemented in a total of 4 sessions, each session lasting 30 minutes, with an interval of one week. Various teaching methods and techniques were used in the trainings.
62149675|NCT06231667|NO_INTERVENTION|Control|
62149676|NCT02562612|EXPERIMENTAL|SM-88|SM-88 multiple ascending doses
62357155|NCT04664140|EXPERIMENTAL|QFR-based virtual PCI|"Before starting PCI, the operator must acquire QFR angiographic projections after nitroglycerin administration at 15 frames/second. Angiographic projections should be at least 25 apart, aiming for minimal vessel foreshortening and minimal vessel overlap. In agreement with previous studies, operators follow a table of recommended projection angles. Afterwards, online QFR analysis must be performed. The tool residual vessel QFR should be used to anticipate the result of stenting (virtual PCI) by placing the proximal (p) and distal (d) marker in order to obtain a post-PCI QFR ≥0.90. then, the operator has to implant one or more stents following the pre-PCI plan and utilizing the QFR and angio to place the stent(s) according to the virtual PCI plan. Post-dilation with non-compliant (NC) balloon is strongly suggested. Blinded QFR projections must be obtained after PCI."
62711428|NCT03586973|EXPERIMENTAL|Cohort A: Cabozantinib 60 mg|Participants who have received first/second line anticancer therapy with sorafenib were assigned to Cohort A and received cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state, up to approximately 2 years.
62711429|NCT03586973|EXPERIMENTAL|Cohort B: Cabozantinib 60 mg|Participants who did not receive first/second line anticancer therapy with sorafenib were assigned to Cohort B and received cabozantinib 60 mg, tablet orally, once daily in the fasted state, up to approximately 2 years.
62149677|NCT03049332|EXPERIMENTAL|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
62149678|NCT01498614|EXPERIMENTAL|Affect school|Affect school is an educational intervention which includes 8 group sessions followed by 10 individual meetings with therapist
62357156|NCT04664140|ACTIVE_COMPARATOR|Angiography-based PCI|Invasive coronary angiography and PCI are performed following best local practices. Post-dilation with a noncompliant balloon is strongly suggested. Blinded QFR projections must be obtained before and after PCI.
62357157|NCT05215119||Immediate|NC endometrial preparation will start immediately after blastocyst cryopreservation confirmation.
62357158|NCT05215119||Delayed|NC endometrial preparation will start on day 1 of the patient's 2nd menstruation after the oocyte retrieval cycle menstruation or in a subsequent cycle.
62357159|NCT01266408||DRSP/EE/metafolin|Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin
62357160|NCT01266408||Other OC users|Women using oral contraceptives containing other estrogen/progestogen combinations
62357161|NCT02399904|EXPERIMENTAL|1|
62357162|NCT03734562|EXPERIMENTAL|Ablation|Substrate-based radiofrequency catheter ablation
62357163|NCT03734562|ACTIVE_COMPARATOR|Antiarrhythmic drug therapy|Antiarrhythmic drug therapy; amiodarone or sotalol
62357164|NCT01148693|ACTIVE_COMPARATOR|gentamicin|adding 10mg gentamicin to every 10 ml of contrast media
62357165|NCT01148693|PLACEBO_COMPARATOR|Placebo|Identical placebo
62521084|NCT01828944|PLACEBO_COMPARATOR|refined olive oil|refined olive oil
62521085|NCT00541164|EXPERIMENTAL|1|300 mg CoQ10 chewable wafer twice a day
62521086|NCT00541164|PLACEBO_COMPARATOR|2|Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
62521087|NCT00551382|EXPERIMENTAL|A|
62521088|NCT00551382|PLACEBO_COMPARATOR|B|
62521089|NCT03036553||Chronic musculoskeletal pain|"(i) men / women over the age of 18 (ii) participants with musculoskeletal pain (pain intensity of 3 or more on a numerical scale of pain 0-10) will be included in this study, among all of the following conditions: pain around the axial skeleton (neck, lower back And / or pelvis) or peripheral joints (shoulder, elbow, wrist, knee and / or ankle). We included people with clinical diagnoses of chronic pain (shoulder pain, neck pain, whiplash disorder, temporomandibular joint disorders, pelvic pain syndrome, ankle pain and epicondylalgia), non-specific low back pain, fibromyalgia, chronic fatigue syndrome and those with a radiological diagnosis of osteoarthritis.~(iii) duration of symptoms: more than 3 months."
62521090|NCT02884323|EXPERIMENTAL|geko device arm|
62521091|NCT00832221|ACTIVE_COMPARATOR|1|
62521092|NCT00832221|ACTIVE_COMPARATOR|2|
62521093|NCT05362721||Pressure-volume loop catheter|
62521094|NCT00711841|PLACEBO_COMPARATOR|saline solution|Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours
62521095|NCT00711841|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
62711430|NCT02185300|EXPERIMENTAL|Sequence ABCDE|Subject will be administered treatments in the sequence ABCDE where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 minutes(mins), re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 minutes, re-dispersed, and then taken by subject
62521096|NCT02290275|PLACEBO_COMPARATOR|Placebo|The subjects in this arm will receive 20 grams of a placebo (maltodextrin) for 1 week and then 5 grams of placebo (maltodextrin) for 11 weeks in addition to their regular diets.
62711431|NCT02185300|EXPERIMENTAL|Sequence BCDEA|Subject will be administered treatments in the sequence BCDEA where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
62711432|NCT02185300|EXPERIMENTAL|Sequence CDEAB|Subject will be administered treatments in the sequence CDEAB where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
62711433|NCT02185300|EXPERIMENTAL|Sequence DEABC|Subject will be administered treatments in the sequence DEABC where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
62711434|NCT02185300|EXPERIMENTAL|Sequence EABCD|Subject will be administered treatments in the sequence EABCD where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
62711435|NCT04255771|EXPERIMENTAL|Effect of adjuvant chemotherapy on pTanyN0M0 UTUC with LVI|This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+) patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma, respectively.
62711436|NCT04255771|PLACEBO_COMPARATOR|Effect of placebo on pTanyN0M0 UTUC with lymphatic invasion|As a control, this clinical trial also set up a placebo control group. The effect of adjuvant chemotherapy was obtained by random grouping and comparing the effects of patients in the experimental group and the control group.
62711437|NCT05544721|ACTIVE_COMPARATOR|Paravertebral block pre procedure|Subjects will receive a preoperative paravertebral block only
62711438|NCT05544721|ACTIVE_COMPARATOR|Paravertebral block pre and post procedure|Subjects will receive one paravertebral block, administered preoperatively and one paravertebral block, administered on postoperative day 1
62711439|NCT06310382|EXPERIMENTAL|GH55 GROUP|
62711440|NCT01402310||Women attending antenatal clinic|Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation.
62521097|NCT02290275|EXPERIMENTAL|Creatine|The subjects in this arm will receive 20 grams of creatine for 1 week and then 5 grams of creatine for 11 weeks in addition to their regular diets.
62711441|NCT04863794|EXPERIMENTAL|RO7248824|In Part 1 of the study RO7248824 and \[89Zr\]-labeled RO7248824 will be administered as a single bolus IT injection following a standard IT Administration procedure. In Part 2 of the study, it is planned to test up to 3 additional IT procedures. This part is tentative with regard to its conduct and the number of procedures that may be tested.
62711442|NCT05219643|EXPERIMENTAL|NAVA|Received NAVA.
62711443|NCT05219643|ACTIVE_COMPARATOR|PSV|Received PSV.
62711444|NCT05635006||Training group|70% of the participants were randomly divided into training groups to train the learning performance of the machine
62521098|NCT02290275|EXPERIMENTAL|Walking Exercise|The subjects in this arm will receive a walking exercise program on a motorized treadmill where they will walk for 30 minutes at 3.1 mph, 3 days per week for 12 weeks.
62711445|NCT05635006||Validation group|15% of the participants were randomly divided into validation groups to enhance the learning performance of the machine and avoid over fitting
62711446|NCT05635006||Test group|15% of the participants were randomly divided into test groups to test the learning performance of the machine and draw research conclusions
62149679|NCT01498614|ACTIVE_COMPARATOR|Basal body awareness|Basal body awareness is an educational method with 9 group sessions followed by 6 individual meetings
62149680|NCT04851782|EXPERIMENTAL|Braun Infusomat Pump and ivEAD tubing|ivEAD tubing
62521099|NCT06339320|OTHER|ESG Procedure|Endoscopic Sleeve Gastroplasty for patients with obesity using the Apollo OverStitch endoscopic suturing device.
62521100|NCT03814330|PLACEBO_COMPARATOR|Sedation/Analgesia|Patients with applied sedation analgesia will perform State-Trait Anxiety Inventory and Quality of Recovery Score
62521101|NCT03814330|ACTIVE_COMPARATOR|Laryngeal Mask Airway|Patients with applied Laryngeal Mask Airway will perform State-Trait Anxiety Inventory and Quality of Recovery Score
62149681|NCT04851782|NO_INTERVENTION|Braun Infusomat Pump and standard tubing|Standard tubing
62149682|NCT04851782|EXPERIMENTAL|Standard pump and ivEAD tubing|ivEAD tubing
62149683|NCT04851782|NO_INTERVENTION|Standard infusion pump and standard tubing|Standard tubing
62521102|NCT01782508|EXPERIMENTAL|imatinib|Participants will take 400mg tablets once daily for one year
62521103|NCT01782508|ACTIVE_COMPARATOR|inteferon|Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
61976390|NCT05412654|EXPERIMENTAL|High potassium water|All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The intervention group will receive high potassium water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.
62149684|NCT06360276|EXPERIMENTAL|Seated Exercises|Women practiced seated exercises
62521104|NCT01888575||Aspirin discontinuers; Aspirin non-discontinuers|Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
62521105|NCT01888575||Drug|PPI continuous use; No PPI use
62521106|NCT02504346|EXPERIMENTAL|Treatment|Non-randomized trial, all patients receive therapy - singel-arm
62521107|NCT00513682|EXPERIMENTAL|Ultrase® MT20|
62521108|NCT04597489||Angiography + FFR|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
62521109|NCT04597489||Angiography only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
62521110|NCT04597489||Subgroup ACS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with ACS."
62521111|NCT04597489||Subgroup CCS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with CCS."
62521112|NCT04597489||Subgroup revascularization|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing revascularization after an angiography (with or without FFR) during the index hospital stay."
62521113|NCT04597489||Subgroup optimal medical therapy|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing optimal medical therapy after an angiography (with or without FFR) during the index hospital stay."
62357166|NCT02661464|EXPERIMENTAL|Exposed to Ad26.ZEBOV and/or MVA-BN Filo|Safety Data will be collected from participants who received Ad26.ZEBOV and/or MVA-BN-Filo in Phase 1, 2 or 3 clinical studies in 6-month intervals up to 60 months after prime vaccination, including the duration in the participant's original study (Cohort 1). Female participants who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV will be followed to the end of their pregnancy for pregnancy outcomes (Cohort 2). After the end of pregnancy, female participants will continue to be followed in Cohort 1. Safety Data for live born children to female participants will be followed up to 60 months after birth (Cohort 3).
62357167|NCT01110226|EXPERIMENTAL|Period 1: KML001 15mg plus Cisplatin 75mg/m2|KML001 15 mg orally daily days 1-14 with cisplatin IV on day1
62357168|NCT01110226|EXPERIMENTAL|Period 2: KML001 17.5mg plus Cisplatin 75mg/m2|KML001 17.5 mg orally daily days 1-14 with cisplatin IV on day1
62357169|NCT01110226|EXPERIMENTAL|Period 3: KML001 20mg plus Cisplatin 75mg/m2|KML001 20 mg orally daily days 1-14 with cisplatin IV on day1
62357170|NCT00885885|EXPERIMENTAL|1|Panitumumab+FOLFOX 4
62357171|NCT00885885|EXPERIMENTAL|2|Panitumumab+FOLFIRI
62521114|NCT06157762|EXPERIMENTAL|ESPB performed by surgeon|The transverse process of the vertebra will be observed by the surgeon intraoperatively. Local anesthetic medication will be applied between the transverse process and the ESP muscle group.
62521115|NCT06157762|ACTIVE_COMPARATOR|Erector spinae plane block|The ultrasound-guided erector spinae plane block will be applied preoperatively.
62357172|NCT04539925||Industrial area|
62357173|NCT04539925||Non-industrial area|
62357174|NCT05106335|EXPERIMENTAL|Treatment Arm A|camrelizumab + famitinib
62357175|NCT05106335|EXPERIMENTAL|Treatment Arm C|famitinib
62357176|NCT05106335|ACTIVE_COMPARATOR|Treatment Arm B|docetaxel
62357177|NCT00045630|EXPERIMENTAL|Gemcitabine, Paclitaxel, Carboplatin|Gemcitabine, Paclitaxel, Carboplatin followed by surgery
62357178|NCT06528808|EXPERIMENTAL|İntervention group (n:40)|Women in the intervention group will undergo a simulator breast cancer awareness application in simple reality.
62357179|NCT06528808|NO_INTERVENTION|Control group (n:40)|Control group women will receive 2 hours of theoretical training.
62357180|NCT02023112|EXPERIMENTAL|ABT-450/r/ABT-267 plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
62357181|NCT02023112|EXPERIMENTAL|ABT-450/r/ABT-267 plus RBV for 16 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
62521116|NCT04681040||UrBMC19 Group (International Cooperative Group)|The examination of urine for mild pre-diagnosed COVID-19 cases are conducted to evaluate the risk classification and detect the effectiveness of early intervention by COVID-19 treatment such as dexamethasone, chloroquine, remdesivir, ivermectin, actemra, and so forth within the period of 14 days after starting the intervention.
62521117|NCT03181321|EXPERIMENTAL|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
62521118|NCT03181321|NO_INTERVENTION|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
62521119|NCT05957419|EXPERIMENTAL|Hypertrophic Obstructive Cardiomyopathy|Transapical beating-heart septal myectomy for the patient with hypertrophic obstructive cardiomyopathy.
62521120|NCT04212533|ACTIVE_COMPARATOR|supplementation arm|43 patients undergoing total thyroidectomy received 40000 IU vit D and once before operation and 500mg calcium tab 4 times in the day before surgery
62521121|NCT04212533|ACTIVE_COMPARATOR|non-supplementation arm|43 patients undergoing total thyroidectomy received rice starch tablets /6 hrs in the day before surgery
62521122|NCT03082170|OTHER|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
62521123|NCT03082170|EXPERIMENTAL|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
62521124|NCT02130076||Stop|Patients with stable RA stopping TNF inhibition
62521125|NCT02130076||Continue|Patients with stable RA continuing TNFi therapy
62521126|NCT01362465|EXPERIMENTAL|Cardiac Resynchronization Therapy (CRT)|Implanting device to measure delays between paced chambers in heart failure patients.
62521127|NCT04516408|EXPERIMENTAL|Recombinant zoster vaccine|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the vaccine 2 months apart.
62521128|NCT04516408|PLACEBO_COMPARATOR|Placebo|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the placebo (sterilized water) 2 months apart.
62521129|NCT05144347|EXPERIMENTAL|XL114 Dose-Escalation Cohorts|Subjects (Cohort A1-An) will accrue in cohorts of 3-12 subjects in a i3+3 design.
62521130|NCT05144347|EXPERIMENTAL|XL114 Expansion Cohorts|The recommended dose from the Dose-Escalation stage, will be used in subjects with activated B-cell-like diffuse large B-cell lymphoma \[ABC-DLBCL\] (Cohort B), mantle cell lymphoma \[MCL\] (Cohort C), chronic lymphocytic leukemia \[CLL\]/small lymphocytic lymphoma \[SLL\] (Cohort D). Subjects will also be enrolled in a Biomarker cohort (Cohort E).
62521131|NCT05226559|ACTIVE_COMPARATOR|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
62521132|NCT05226559|NO_INTERVENTION|Usual care|Standard pharmacological treatment alone
62521133|NCT02615171|ACTIVE_COMPARATOR|Comprehensive Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
62521134|NCT02615171|ACTIVE_COMPARATOR|Simple Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
62711447|NCT00874601|EXPERIMENTAL|valsartan group|The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
61976391|NCT05412654|PLACEBO_COMPARATOR|Low potassium control water|All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The control group will receive regular bottled mineral water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.
62149685|NCT06360276|EXPERIMENTAL|Psychoeducational Rehabilitation|Women received psychological rehabilitation
62521135|NCT05372874||Healthy voluntaries control group (Group 1)|
62521136|NCT05372874||sofosbuvir/daclatasvir treated group (group 2)|
61976392|NCT05281991||Patients who had an epidural placed for labour|Patients who had an epidural placed for labour may take part. Study procedures will take place after delivery and prior to removal of the epidural catheter.
62149686|NCT06360276|ACTIVE_COMPARATOR|Routine Care|Women received routine health education in the unit
62149687|NCT00788606|EXPERIMENTAL|bevacizumab and Rituximab|This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
62149688|NCT00729794|EXPERIMENTAL|Study Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
62521137|NCT05372874||sofosbuvir /daclatasvir/ ribavirin treated group (group 3)|
62521138|NCT03045237|EXPERIMENTAL|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
62521139|NCT03045237|NO_INTERVENTION|Control Group|The control group has the basic information through health professionals.
62711448|NCT00874601|NO_INTERVENTION|control group|Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
62711449|NCT01985789|ACTIVE_COMPARATOR|diphenhydramine|50mg dose given as two 25mg capsules
62711450|NCT01985789|ACTIVE_COMPARATOR|cetirizine|10mg dose given as 1 10mg capsule and 1 placebo capsule
62711451|NCT01985789|ACTIVE_COMPARATOR|desloratadine|5mg dose given as 1 5mg capsule and 1 placebo capsule
62711452|NCT01985789|PLACEBO_COMPARATOR|placebo|given as 2 placebo capsules
62711453|NCT00822302|PLACEBO_COMPARATOR|1.Saline Infusion|Patients randomised to this arm will receive an infusion of saline
62149689|NCT00729794|PLACEBO_COMPARATOR|Control Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
62149690|NCT02932124||1|manual chest compressions
62711454|NCT00822302|ACTIVE_COMPARATOR|2.recHDL|Patients randomised to the active comparator arm of the study will receive 40mg/kg reconstituted High density lipoproteins (lot nos 05422-00006) over a period of 4 hours, 24 hours prior to carotid endarterectomy.
62149691|NCT02932124||2|mechanical chest compression
61976393|NCT04480437|EXPERIMENTAL|Study Intervention|mp-BUS data collection
62149692|NCT01567007|NO_INTERVENTION|control|session of 15-20 minutes duration. It took place guidelines on physical activity, delivering a manual with general information about physical activity
62149693|NCT01567007|EXPERIMENTAL|Individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise steps. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
62149694|NCT01567007|EXPERIMENTAL|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices.
62149695|NCT01567007|EXPERIMENTAL|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill
62149696|NCT01020097|OTHER|Arm I|Patients undergo fluorine F-18 EF5 positron emission tomography imaging. Scana are performed 180 minutes following injection.
62149697|NCT01110096|EXPERIMENTAL|Group A - family camp|Obese families participate in a two week camp with two years follow-up.
62357182|NCT04306978|ACTIVE_COMPARATOR|CareLink Express RM system|Patients in the remote monitoring (RM) group will undergo the implantation of Ensura DR MRI SureScan pacing system. Patients in the RM group should visit the main follow-up clinic 12 weeks after discharge, and then the device data will be remotely transmitted to the CareLink Express Network at least once in 3 months. Research personnel will contact patients by telephone once in 6 months. If participants indicate they have experienced a study outcome event (corresponding to the study endpoints), the event will be recorded. If remote transmission or telephone call data require to make clinical decision an in-hospital visit will be induced.
62357183|NCT04306978|ACTIVE_COMPARATOR|Standard follow-up|Patients in the control group will receive Adapta DR pacing system without remote monitoring using. All patients from the control group should have the first in-hospital visit 12 weeks after pacemaker implantation. Then, the follow-up will be provided according to the standard guidelines
62357184|NCT01637818|OTHER|Lichtenstein's Operation|
62357185|NCT01637818|OTHER|Mesh Plug Repair|
62357186|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
62357187|NCT04570514||Obesity|Patients with Obesity. BMI\>=25
62711455|NCT04293562|EXPERIMENTAL|Arm A High Risk Group|Arm A High Risk Group: See Detailed Description.
62711456|NCT04293562|EXPERIMENTAL|Arm A Low Risk Group 1|Arm A Low Risk Group 1: See Detailed Description.
62149698|NCT01110096|OTHER|Group B - family lifestyle school|Families participate in a four day practical course about lifestyle.
62149699|NCT01862159||Operated patients|Patients undergoing laparoscopic gastric bypass surgery between 1st of May 2007 until 30th of september 2012
62357188|NCT04570514||Non-Obesity|Patients without Obesity. BMI\<25
62357189|NCT00167362|EXPERIMENTAL|1|Participants will receive cognitive enhancement therapy
62357190|NCT00167362|PLACEBO_COMPARATOR|2|Participants will receive enriched supportive therapy
62149700|NCT06401590||POSITIVE CASES|
62149701|NCT06401590||NEGATIVE CASES|
62149702|NCT00659373|ACTIVE_COMPARATOR|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
62149703|NCT00659373|EXPERIMENTAL|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
62149704|NCT00659373|EXPERIMENTAL|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
62149705|NCT05188378|EXPERIMENTAL|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
62149706|NCT05188378|ACTIVE_COMPARATOR|EU-approved RoActemra|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
62149707|NCT02291406|ACTIVE_COMPARATOR|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
62149708|NCT02291406|ACTIVE_COMPARATOR|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
62357191|NCT03048942|EXPERIMENTAL|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
62357192|NCT03048942|ACTIVE_COMPARATOR|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
62711457|NCT04293562|EXPERIMENTAL|Arm A Low Risk Group 2|Arm A Low Risk Group 2: See Detailed Description.
62711458|NCT04293562|EXPERIMENTAL|Arm AC High Risk Group|Arm AC High Risk Group: See Detailed Description.
62711459|NCT04293562|EXPERIMENTAL|Arm AC Low Risk Group 2|Arm AC Low Risk Group 2: See Detailed Description.
62711460|NCT04293562|EXPERIMENTAL|Arm AD High Risk Group|Arm AD High Risk Group: See Detailed Description.
62711461|NCT04293562|EXPERIMENTAL|Arm AD Low Risk Group 2|Arm AD Low Risk Group 2: See Detailed Description.
62711462|NCT04293562|EXPERIMENTAL|Arm B High Risk Group|Arm B High Risk Group: See Detailed Description.
62711463|NCT04293562|EXPERIMENTAL|Arm B Low Risk Group 1|Arm B Low Risk Group 1: See Detailed Description.
62711464|NCT04293562|EXPERIMENTAL|Arm B Low Risk Group 2|Arm B Low Risk Group 2: See Detailed Description.
62711465|NCT04293562|EXPERIMENTAL|Arm BC High Risk Group|Arm BC High Risk Group: See Detailed Description.
62149709|NCT02673359|ACTIVE_COMPARATOR|Progesterone group|Vaginal progesterone suppositories will be given
62149710|NCT02673359|ACTIVE_COMPARATOR|Cerclage group|Cervical cerclage will be performed.
62357193|NCT03895970|EXPERIMENTAL|Lenvatinib plus Pembrolizumab|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.~Pembrolizumab is a recombinant anti-human PD-1 monoclonal antibody."
62521140|NCT04625322|NO_INTERVENTION|Referral to outpatient specialty for HCV care|Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
62521141|NCT04625322|EXPERIMENTAL|Receive HCV care during inpatient admission by a hospitalist|CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred. An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive. Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay. At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
62521142|NCT00614809|EXPERIMENTAL|1|non-randomized open-label uncontrolled phase II trial
62711466|NCT04293562|EXPERIMENTAL|Arm BC Low Risk Group 2|Arm BC Low Risk Group 2: See Detailed Description.
62711467|NCT04293562|EXPERIMENTAL|Arm BD High Risk Group|Arm BD High Risk Group: See Detailed Description.
62149711|NCT03266419|EXPERIMENTAL|Deep NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
62149712|NCT03266419|ACTIVE_COMPARATOR|Moderate NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
62711468|NCT04293562|EXPERIMENTAL|Arm BD Low Risk Group 2|Arm BD Low Risk Group 2: See Detailed Description.
62711469|NCT06393751|EXPERIMENTAL|Phase I (paclitaxel, tolinapant, bevacizumab)|Patients receive paclitaxel IV on days 1, 8 and 15, bevacizumab IV on days 1 and 15, and ASTX660 PO on days 1-7 and 15-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
62711470|NCT06393751|ACTIVE_COMPARATOR|Phase II, Arm I (paclitaxel, bevacizumab)|Patients receive paclitaxel IV on days 1, 8, and 15 of each cycle. Patients may also receive bevacizumab IV on days 1 and 15 of each cycle per provider. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
61976394|NCT02668133|ACTIVE_COMPARATOR|lipid-based nutrient supplement SQ-LNS|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day) 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
62149713|NCT00803985|ACTIVE_COMPARATOR|Lichtenstein|Open operation with onlay light weight polypropylene mesh
62149714|NCT00803985|ACTIVE_COMPARATOR|Total Extraperitoneal repair (TEP)|Laparoscopic operation with preperitoneal nonfixated mesh
62149715|NCT06003244|ACTIVE_COMPARATOR|Ambient air|Patient will perform tests on ambient air at 2840 m
62149716|NCT06003244|EXPERIMENTAL|SOT via nasal canula|Supplemental oxygen therapy (SOT) at 3l/min will be provided via a nasal cannula from a small oxygen bottle carried on the back according to standard care
62149717|NCT04781868|EXPERIMENTAL|Multi-nutrient supplement|
62149718|NCT04781868|PLACEBO_COMPARATOR|Placebo supplement|
62149719|NCT06208605|EXPERIMENTAL|Transdiagnostic Network Informed Personalized Treatment|Participants will receive 1 session of education about the treatment after completing Phase I of the study (two weeks of ecological momentary assessment). Participants will then complete 10 sessions of personalized treatment for eating disorders based on their ecological momentary assessment surveys. Participants will complete one session of relapse prevention at the end.
62149720|NCT06208605|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Eating Disorders|Participants will receive 1 session of education about the treatment after completing Phase I of the study (two weeks of ecological momentary assessment). Participants will then complete 10 sessions of Enhanced Cognitive Behavioral Therapy for Eating Disorders (CBT-E. Participants will complete one session of relapse prevention at the end.
62149721|NCT00926094||1|
62149722|NCT00926094||2|
62357194|NCT00105755|OTHER|Arm 1|
62357195|NCT04213937|EXPERIMENTAL|nab-paclitaxel|nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles
62357196|NCT04213937|ACTIVE_COMPARATOR|Topotecan|Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
62149723|NCT03110809|PLACEBO_COMPARATOR|BAT Positive Placebo|Participants will be confirmed positive for BAT activity, but on Placebo
62149724|NCT03110809|PLACEBO_COMPARATOR|BAT Negative Placebo|Participants will be confirmed negative for BAT activity, but on Placebo
62149725|NCT03110809|EXPERIMENTAL|BAT Positive Capsinoid|Participants will be confirmed positive for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
62149726|NCT03110809|EXPERIMENTAL|BAT Negative Capsinoid|Participants will be confirmed negative for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
62149727|NCT01342497|EXPERIMENTAL|BBR-012|
62149728|NCT01342497|PLACEBO_COMPARATOR|Placebo|
62149729|NCT01567150|ACTIVE_COMPARATOR|novel dressing|Treatment with novel dressing
62149730|NCT01567150|NO_INTERVENTION|Control|Control is treatment without novel dressing
62357197|NCT01619475||Prospective|Individuals approved as liver donors and recipients shortly Pre-donation/Pre-transplant at the study sites.
62149731|NCT04003792|EXPERIMENTAL|single arm prospective trial|
62521143|NCT04486755|EXPERIMENTAL|Dose Level 1|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 20 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
62521144|NCT04486755|EXPERIMENTAL|Dose Level 2|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 16 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
62521145|NCT04486755|EXPERIMENTAL|Dose Level 3|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
62521146|NCT02566993|EXPERIMENTAL|Experimental Arm|Lurbinectedin (PM01183) / Doxorubicin
62521147|NCT02566993|ACTIVE_COMPARATOR|Control Arm 1|CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
62521148|NCT02566993|ACTIVE_COMPARATOR|Control Arm 2|Topotecan
62521149|NCT02782494||Dialysis group|Patient receiving long term dialysis
61975091|NCT03010163|EXPERIMENTAL|Health Fair, Pedometer, Text Msg, Social Network Support|Participants in this group will receive the health fair service with general follow-up, along with a pedometer with instructions on how to use the device to track daily step counts. Participants will also receive daily healthy living advice through encouraging text messages about walking through text messages sent by our staff to participants' cellular phones. Participants will also be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given tools to train their family and/or friends on how to best motivate the drivers. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
61975092|NCT00788151|EXPERIMENTAL|CYD Dengue vaccine group|Participants received three injections of the CYD Dengue vaccine at 0, 6, and 12 months. Participants were followed for 6 months after the last vaccination (up to 18 months).
61975093|NCT00788151|PLACEBO_COMPARATOR|Control group|Participants received two injections of placebo, and one injection of pneumococcal polysaccharide vaccine (Pneumo23®) at 0, 6, and 12 months, respectively. Participants were followed for 6 months after the last vaccination (up to 18 months).
62149732|NCT01995981||Advanced soft tissue sarcoma patients|Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment.
62149733|NCT05837806|EXPERIMENTAL|tislelizumab+disitamab-vedotin|
62149734|NCT03125148|ACTIVE_COMPARATOR|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
62521150|NCT01176643|ACTIVE_COMPARATOR|standard care plus yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
62521151|NCT01176643|NO_INTERVENTION|Standard care|
62521152|NCT06216743|EXPERIMENTAL|Imaging cohort|Patients participating in pilot study who will receive an additional MRI-scan, cineMRI and cineCT scan.
62521153|NCT02199054|PLACEBO_COMPARATOR|Run-in Intervention|Control wheat pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of control wheat pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
62521154|NCT02199054|ACTIVE_COMPARATOR|Wheat-Safflower Oil Arm|Wheat-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of wheat-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
62521155|NCT02199054|ACTIVE_COMPARATOR|Soy-Safflower Oil Arm|Soy-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of soy-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
62521156|NCT04988152|EXPERIMENTAL|Part 1 Sotrovimab intravenous infusion, single dose|
62521157|NCT04988152|PLACEBO_COMPARATOR|Part 1 Volume-matched placebo, intravenous infusion|
62521158|NCT04988152|EXPERIMENTAL|Part 2 Sotrovimab intramuscular injection, single dose|
62521159|NCT04988152|PLACEBO_COMPARATOR|Part 2 Volume-matched placebo, intramuscular injection|
62521160|NCT00974948|ACTIVE_COMPARATOR|Neurolysis|Patients will undergo EUS followed by EUS-guided, bilateral neurolysis with bupivicaine and absolute alcohol.
62521161|NCT00974948|NO_INTERVENTION|Conventional therapy|EUS will be performed with no celiac plexus neurolysis.
62521162|NCT04102241|PLACEBO_COMPARATOR|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
62521163|NCT04102241|EXPERIMENTAL|15mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 15mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 15mg of Hemay005.
62521164|NCT04102241|EXPERIMENTAL|30mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 30mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
62521165|NCT04102241|EXPERIMENTAL|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
62521166|NCT03398629||IUGR group|Estimated fetal weight below10th percentile for gestational age associated with Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)\>95th percentile).
61975094|NCT03649464|EXPERIMENTAL|OKN-007|Oral OKN-007
62149735|NCT03125148|EXPERIMENTAL|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
62149736|NCT01572805|ACTIVE_COMPARATOR|melatonin 3mg|
62357198|NCT01619475||Long-Term Follow-up|"Donors and recipients enrolled in the original A2ALL Cohort study.~Donors and LDLT recipients whose donation/transplant occurred during the period of time that began with the end of enrollment into the original Cohort study (Aug. 31, 2009) and ended with the opening of the enrollment in the current core protocol; this is referred to as the Gap Era.~LDLT recipients and donors who were not in the original Cohort study or from the Gap Era will enter the study at time proximate to time of living donation."
62357199|NCT01619475||HCV-Infected Liver Transplant Recipients|Male and female HCV-infected adult liver transplant recipients from those enrolled in the A2ALL-1 Cohort study and from those concurrently transplanted at the new A2ALL-2 centers (University of Toronto, University of Pittsburgh, Lahey Clinic).
62149737|NCT01572805|ACTIVE_COMPARATOR|melatonin 6mg|
62357200|NCT03261063|EXPERIMENTAL|Evera Implanted Group|
62357201|NCT03246555|EXPERIMENTAL|Fimasartan or Fimasartan/Hydrochlorothiazide|
62357202|NCT03246555|ACTIVE_COMPARATOR|Perindopril or Perindopril/Indapamide|
62357203|NCT05766293|ACTIVE_COMPARATOR|Shockwave treated group|Effect of Extracorporeal shockwaves on Fibroblast cell proliferation and cell viability
62357204|NCT05766293|PLACEBO_COMPARATOR|No shockwave group|Fibroblast cell lines assessed for proliferative rate and viability without shockwave exposure.
62357205|NCT04977973|EXPERIMENTAL|Intervention group: Body Image|Participants will complete a 9-day self-guided programme on body image delivered via a mobile phone application with daily exercises informed by cognitive-behavioural and self-compassion principles.
62357206|NCT04977973|ACTIVE_COMPARATOR|Control group|Participants will complete a 9-day self-guided programme on cooperation delivered via a mobile phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
62357207|NCT02238288|ACTIVE_COMPARATOR|aminocaproic acid|Crushed tablets inserted in the dental socket post-extraction
62357208|NCT02238288|OTHER|Routine care after dental extraction|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
62357209|NCT03869671|EXPERIMENTAL|PrEP uptake/adherence intervention|A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
62357210|NCT03869671|ACTIVE_COMPARATOR|Harm reduction standard of care|Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
62357211|NCT02564029|EXPERIMENTAL|PF-06372865 dose level 1|17.5 milligram (mg) single dose
61975095|NCT01819402|ACTIVE_COMPARATOR|Active Comparator: 1|up to 30 mg pioglitazone, tablet, orally, once daily
62357212|NCT02564029|EXPERIMENTAL|PF-06372865 dose level 2|52.5 mg single dose
62357213|NCT02564029|PLACEBO_COMPARATOR|Placebo|Single dose
62357214|NCT02564029|ACTIVE_COMPARATOR|Lorazepam|2mg single dose
62357215|NCT01618526|ACTIVE_COMPARATOR|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch
62521167|NCT03398629||Structural anomaly group|Fetus/neonates/infants who are diagnosed as congenital malformations, deformations, disruptions, dysplasias by ultrasound.
62521168|NCT03398629||Chromosomal anomaly group|Fetus/neonates/infants diagnosed by genetic amniocentesis or chorionic villus sampling for increased risk for fetal aneuploidy or fluorescence in situ hybridization.
62521169|NCT01727986|EXPERIMENTAL|RoActemra/Actemra|
62521170|NCT00438477|EXPERIMENTAL|Injection Methods|One injection site with radioactive tracer intraparenchymal/peritumoral (around the tumor), and other subareolar (around the nipple)
61975096|NCT01819402|SHAM_COMPARATOR|Sham Comparator: 1|up to 4 mg/day glimepiride, tablet, orally, once daily
61975097|NCT06166498|ACTIVE_COMPARATOR|Sulphadoxine-pyrimethamine (SP)|Children in the SP group will receive a 7-day course of placebo artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed by the standard of care, 5 doses of SP.
61975098|NCT06166498|ACTIVE_COMPARATOR|Artesunate monotherapy (AS)|Children in the AS group will receive a 7-day course of 7-day course of active artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed by placebo SP.
61975099|NCT01791829||Luminal A with other Clinical Criteria|BCS postulated to be at low risk for IBTR following Endocrine Therapy
62149738|NCT01572805|PLACEBO_COMPARATOR|placebo|
62149739|NCT05253092|OTHER|Virtual mindfulness meditation|
62357216|NCT01618526|PLACEBO_COMPARATOR|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.
62357217|NCT04911829|ACTIVE_COMPARATOR|Inpatient treatment|High intensity high dosage inpatient short-term psychodynamic psychotherapy
62357218|NCT04911829|EXPERIMENTAL|Outpatient treatment|Low dosage outpatient short-term psychodynamic psychotherapy
62357219|NCT02899741|EXPERIMENTAL|Omega-3|One group of this study. Omega-3 will be administered for thee months.
62357220|NCT06219668|ACTIVE_COMPARATOR|omentopexy with LSG|We performed omentopexy on staple line after LSG
62357221|NCT06219668|ACTIVE_COMPARATOR|Clips with LSG|we performed Clips on staple line after LSG
62357222|NCT04991064|OTHER|AB arm|participants allocated to this arm receive treatment A first, followed by treatment B.
62357223|NCT04991064|OTHER|BA arm|participants allocated to this arm receive treatment B first, followed by treatment A.
62357224|NCT01090869|ACTIVE_COMPARATOR|Physical training, unchanged diet|Daily endurance training equivalent to 600 kcal/day and unchanged habitual diet
62357225|NCT01090869|ACTIVE_COMPARATOR|Physical training, increased diet|Daily endurance training equivalent to 600 kcal/day, and increased diet by 600 kcal/day.
62357226|NCT01090869|ACTIVE_COMPARATOR|Diet, unchanged physical activity|Energy-reduced diet by 600 kcal/day, and unchanged sedentary lifestyle
62357227|NCT01090869|NO_INTERVENTION|Control|Unchanged sedentary lifestyle and diet
62521171|NCT02350634|EXPERIMENTAL|Autopsy Cohort|End-of-life subjects (life expectancy \< 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of 18F-AV-1451.
62149740|NCT03044652|EXPERIMENTAL|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
61976395|NCT02668133|EXPERIMENTAL|lipid-based nutrient supplement SQ-LNS with phytase|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS added during manufacturing 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
62149741|NCT03044652|ACTIVE_COMPARATOR|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
62149742|NCT03000725|ACTIVE_COMPARATOR|UPLIFT|Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is a home-based intervention that teaches cognitive and mindfulness skills to people with epilepsy by phone to reduce their depression and improve quality of life (QOL).
62149743|NCT03000725|ACTIVE_COMPARATOR|USUAL CARE|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
62149744|NCT06099444|ACTIVE_COMPARATOR|Conventional High Intensity Gait Training|Participants in the conventional high-intensity gait training group will undergo gait training on a treadmill. Each session will consist of between 30-60 minutes of walking targeted to reach a high intensity, as measured via heart rate and Borg rating of perceived exertion. This may also include inclined walking, walking with an ankle weight, backwards walking, sidestepping, and/or obstacle walking.
62149745|NCT06099444|EXPERIMENTAL|Standard FES to the Tibialis Anterior (TA)|Participants in the standard FES gait training group will receive FES applied to the TA muscle/peroneal nerve on his/her more affected leg. FES strategically stimulates the TA/peroneal nerve at specific phases of the gait cycle identified by internal inertial measurement units (IMUs).
62357228|NCT06202339|EXPERIMENTAL|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
62357229|NCT05134636|EXPERIMENTAL|Treatment Arm|For patients in the intervention arm, symptoms and laboratory results will be assessed using the text-based e-triage 96 hours prior to their intended infusion date. The e-triage will consist of a standardized questionnaire and algorithm to evaluate symptoms and laboratory values. Patients with acceptable labs and minimal or no symptoms can opt to proceed directly to their immunotherapy infusion without an in-person office assessment.
62357230|NCT05134636|NO_INTERVENTION|Usual Care|Patients in the usual care arm will receive standard of care symptom monitoring including an in-person office assessment prior to their scheduled immunotherapy infusion.
62357231|NCT02626364|EXPERIMENTAL|Treatment|crenolanib 100mg PO TID
62357232|NCT05425095|EXPERIMENTAL|Buteyko Breathing Technique|Group A
62357233|NCT05425095|EXPERIMENTAL|Corpse-Pose Technique|Group B
62357234|NCT00779311|EXPERIMENTAL|Experimenal|All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle. Sorafenib will be administered daily throughout treatment beginning on day 1
62357235|NCT03886922|ACTIVE_COMPARATOR|Glibenclamide and Levcromakalim|Participants will receive levcromakalim infusion after glibenclamide administration
62357236|NCT03886922|ACTIVE_COMPARATOR|Glibenclamide and Saline|Participants will receive placebo infusion after glibenclamide administration
62357237|NCT03886922|SHAM_COMPARATOR|Placebo|Participants will receive placebo infusion after placebo administration.
62357238|NCT03886922|ACTIVE_COMPARATOR|Levcromakalim and Glibenclamide|Participants will receive levcromakalim infusion before glibenclamide administration.
62357239|NCT03886922|ACTIVE_COMPARATOR|Levcromakalim and Placebo|Participants will receive levcromakalim infusion before placebo administration.
62357240|NCT05959304||brolucizumab 6 mg|brolucizumab 6 mg intravitreal injection
62357241|NCT05500183|EXPERIMENTAL|PA + CA|a cognitively enriched walking program (Physical Activity (PA)+Cognitive Activity (CA)
62357242|NCT05500183|ACTIVE_COMPARATOR|PA only|a walking program without cognitive enrichment (Physical Activity (PA) only)
62357243|NCT05500183|NO_INTERVENTION|control|a passive control group (CG). The passive CG will receive no intervention program.
62357244|NCT05656287|EXPERIMENTAL|Arm A|(Arm A): For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if \>90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if \>90% medication adherence.
62357245|NCT05656287|EXPERIMENTAL|Arm B|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders.
62357246|NCT05656287|EXPERIMENTAL|Arm C- Control|Participants (54) in the Control (Arm C) will not receive SMS reminders or mobile money
62357247|NCT03488238|EXPERIMENTAL|ORi sensor|All subjects are enrolled in the test group and receive an ORi sensor during their scheduled, general surgery procedure
62357248|NCT05226897|EXPERIMENTAL|Test|Take YYC405-T and Metformin≥1000mg, Dapagliflozin 10mg
62357249|NCT05226897|PLACEBO_COMPARATOR|Placebo control|Take YYC405-T Placebo and Metformin≥1000mg, Dapagliflozin 10mg
62521172|NCT01801683|OTHER|Intervention: PEARLS (evidence based reports)|Intervention was modified academic detailing method, performed by sixth-year medical students/academic detailers.Each mentor chose two patients from real life who represented diagnostic, therapeutic or prognostic challenge. The students formed an answerable question, using PICO, and wrote report according to PEARLS.
61976396|NCT01564797|ACTIVE_COMPARATOR|Education Intervention|A series of 5 home-based lay health educator-led education sessions (Home Health Parties (HHP)), to educate a Hispanic population about diabetes, management of diabetes, and diet and exercise
62357250|NCT02483455|EXPERIMENTAL|ALC-919 Topical Solution|ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts
62357251|NCT02483455|PLACEBO_COMPARATOR|Vehicle-Control Topical Solution|Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts
62521173|NCT01801683|NO_INTERVENTION|Control group of GPs|GPs not mentors who do not receive academic detailing intervention using PICO/PEARLS.
62521174|NCT04375852|EXPERIMENTAL|1|consecutive cases diagnosed with APS-1associated keratitis
62521175|NCT06461481||Core center|In addition to clinical assessment, MRI examinations will be optionally conducted in patients from core center at baseline and in month 12 and 24. Measurement parameters from clinical MRI examinations (lesion load) are also taken into account from the other study centers. In addition to that, patients from core center will undergo an Optical coherence tomography (OCT) measurement.
62357252|NCT00422903|PLACEBO_COMPARATOR|Letrozole plus placebo|Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery
62357253|NCT00422903|EXPERIMENTAL|Letrozole plus lapatininb|Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
62521176|NCT06461481||Extended cohort|Clinical assessment will be conducted in patients from extended cohort at baseline and in month 6, 12, 18 and 24.
62521177|NCT01314378|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy|
62521178|NCT01314378|EXPERIMENTAL|Mindfulness Training|
62521179|NCT05747521|EXPERIMENTAL|Anrotinib hydrochloride combined with adriamycin|Anrotinib hydrochloride combined with adriamycin neoadjuvant therapy for patients with high-grade soft tissue sarcoma
62149746|NCT06099444|EXPERIMENTAL|Synergy-Based Multichannel FES (MFES)|Participants in the synergy-based MFES gait training group will receive FES applied to muscles of the affected lower limb. These muscles may include the TA, gastrocnemius medialis, gastrocnemius lateralis, soleus, rectus femoris, vastus medialis, vastus lateralis, semitendinosus, biceps femoris, gluteus medius, and adductor longus. FES will be applied to each muscle with an activation pattern that is derived from extracted healthy muscle synergies that are scaled to fit the patient's gait cycle.
62149747|NCT06099444|EXPERIMENTAL|Muscle Synergy Visual Biofeedback|Participants in the muscle synergy visual biofeedback group will wear bipolar EMG sensors on the muscles of interest. In real time, muscle synergies will be extracted and the similarity of affected synergies to healthy synergies will be displayed on a screen. Patients in this group will be instructed to try to increase the similarity score of the affected synergies and the healthy synergies. No electrical stimulation will be provided in this group.
62521180|NCT00553592|EXPERIMENTAL|Drug|Bicifadine
62521181|NCT00553592|EXPERIMENTAL|Drug: 2|Bicifadine
62521182|NCT00553592|PLACEBO_COMPARATOR|Control|Placebo of Bicifadine
62521183|NCT00454519|EXPERIMENTAL|A|cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
62149748|NCT06099444|EXPERIMENTAL|Synergy-Based Multichannel (MFES) + Muscle Synergy Visual Biofeedback|Participants in the group will receive a combination of the synergy-based MFES and muscle synergy visual biofeedback interventions. Because EMG cannot be recorded while FES is being applied in a continuous fashion, this method will alternate between providing sensory feedback (FES) and visual feedback of the muscle synergies.
62357254|NCT03983213||Pat. after mpfl reconstruction|All 45 subjects operated with mpfl reconstruction included to chek-up after follow-up.
62357255|NCT03326869|EXPERIMENTAL|Delayed|"Intervention: Raindrop Near Vision Inlay~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
62357256|NCT03326869|ACTIVE_COMPARATOR|Non-Delayed|"Intervention: Raindrop Near Vision Inlay~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
62357257|NCT03202745|NO_INTERVENTION|Control|The control arm will not receive any communications as a result of this study.
62357258|NCT03202745|EXPERIMENTAL|Patient Consequences|The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
62357259|NCT03202745|EXPERIMENTAL|Prescriber Consequences|The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
62357260|NCT00860990||1|SCI or disabled
62357261|NCT00860990||2|Able-bodied
62521184|NCT00454519|ACTIVE_COMPARATOR|B|cytoreductive surgery alone, postoperative chemotherapy.
62521185|NCT01683890||Simple hysterectomy group|Patients will undergo simple hysterectomy due to benign uterine disease.
62521186|NCT05032521|ACTIVE_COMPARATOR|standard practice|
62357262|NCT06387030|EXPERIMENTAL|Patient with suspicion of eosinophilic esophagitis|Patients will benefit from blood, urine and stool sampling, esophageal brushing, and additional esophageal biopsies.
62357263|NCT04896190|EXPERIMENTAL|Experimental group|Before the evaluation of EMG amplitude on dynamic balance position, the Q angle was measured in supine and standing positions. The EMG signals collected by measuring the muscle activation of the Vastus Medialis and Vastus Lateralis during dynamic balance position on the ProKin device were recorded. Q angle evaluations, static and dynamic balance and functional status of all participants were evaluated.
62357264|NCT06024694||patients diagnosed with PMLBL|Patients whose diagnosis met the histological criteria of PMLBL according WHO classification with a diagnosis of CNS involvement at relapse/progression
62521187|NCT05032521|EXPERIMENTAL|algorithm|
62521188|NCT00444457|EXPERIMENTAL|1|
62521189|NCT00444457|EXPERIMENTAL|2|
62521190|NCT00444457|EXPERIMENTAL|3|
62521191|NCT00444457|ACTIVE_COMPARATOR|4|
61976397|NCT01564797|NO_INTERVENTION|Control Arm|A delayed intervention where the intervention was delivered after the hA1c level was measured for the second time (3 months after the baseline measurement)
62521192|NCT03528785|EXPERIMENTAL|Single Arm|All patients will receive a treatment scheme of Irinotecan Liposomal Injection \[Onivyde\], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.
62521193|NCT01827124|EXPERIMENTAL|carbetocin and placebo|100microgram carbetocin IV and 1cc normal saline(placebo)infusion
62521194|NCT01827124|EXPERIMENTAL|oxytocin and placebo|20Interntional unit oxytocin infusion and 1cc normal saline IV
62521195|NCT04627480|EXPERIMENTAL|Experiment Arm|Active Fisher Wallace device for full 8 weeks
62521196|NCT04627480|SHAM_COMPARATOR|Sham Arm|Sham Fisher Wallace device for 4 weeks, then cross over at 4 weeks to active device.
61975100|NCT05570565|EXPERIMENTAL|Erector spinae plane group|"The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear ultrasound transducer will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 20 mL of local anesthestic mixture of 0.25% bupivacaine and 1%lidocaine adrenaline (1;200000) will be injected. The procedure will be repeated following the same steps on the other side.~The surgical intervention will be then allowed 20 minutes after finishing the block procedure"
61975101|NCT05570565|ACTIVE_COMPARATOR|local field block|For the preincisional local field block, a 23-gauge needle is used to infiltrate 20mL of local anesthestic mixture of 0.25% bupivacaine and 1%lidocaine adrenaline (1;200000) will be injected in the subcutaneous space and in the paravertebral muscles on each side of the spinous processes of the presumed surgical approach.
61975102|NCT04534023|EXPERIMENTAL|trial group|
61975103|NCT04534023|PLACEBO_COMPARATOR|control group|
62149749|NCT05205213||lateral retromuscular preperitoneal group|All patients undergoing open lateral retromuscular preperitoneal repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
62521197|NCT03236948|EXPERIMENTAL|WfWI Intervention|Women receive the WfWI intervention. This comprises of three main components. First, a social empowerment and health intervention. Second a livelihood strengthening intervention, including numeracy training, and vocational training. Third, a cash transfer conditional on attendance at the intervention to cover costs of attendance and provide start-up capital. The intervention is delivered over 12 months.
62521198|NCT03236948|NO_INTERVENTION|Control|
62521199|NCT05253924||Preterm children (PT)|gestational age at birth \<37
62521200|NCT05253924||Full-term children (FT)|gestational age at birth ≥ 37 weeks
62521201|NCT04963595|EXPERIMENTAL|Pyrotinib and Vinorelbine with Inetetamab|
62521202|NCT04963595|EXPERIMENTAL|Pyrotinib and Vinorelbine without Inetetamab|
62521203|NCT01940328||Decompensated CHF|patients with acute pulmonary congestion or pulmonary edema
62521204|NCT01940328||Compensated CHF|patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion
62521205|NCT01940328||Non CHF patients|patients without CHF and without uncontrolled hypertension.
62521206|NCT00969319||Group 1|
62521207|NCT05346783|EXPERIMENTAL|TJO-083 [Part 2]|1 drop 3 times a day
62521208|NCT05346783|PLACEBO_COMPARATOR|Placebo of TJO-083 [Part 2]|1 drop 6 times a day
62149750|NCT05205213||Reverse TAR group|All patients undergoing open reverse TAR repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
62149751|NCT04389788|ACTIVE_COMPARATOR|Rt Eye|The right eye of the patients received carboxy therapy for 6 sessions every 2 weeks. The used device is locally manufactured by a national company for esthetic and dermatological devices. Carbon dioxide gas was subcutaneously injected at the lateral one-third of each eye lid (5 cc gas in each puff according to standardized flowmetry) using insulin syringe. Compression of the injected area will be avoided to prevent rapid leakage of the gas.
62357265|NCT00605072|EXPERIMENTAL|Candesartan|Angiotensin Receptor Blocker
62357266|NCT00605072|EXPERIMENTAL|Lisinopril|Angiotensin-Converting Enzyme (ACE) Inhibitor
62357267|NCT00605072|ACTIVE_COMPARATOR|HCTZ|Hydrochlorothiazide (diuretic)
62357268|NCT02629328|OTHER|CardioCel|Treatment with CardioCel implant
62357269|NCT01618422|SHAM_COMPARATOR|Directly Observed Therapy (DOTS)|The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
62357270|NCT01618422|ACTIVE_COMPARATOR|Directly Observed Therapy (DOTS) plus|The DOTS-Plus strategy (the strategy to be tested) includes additional measures including continuous drug resistance surveillance, culture, drug susceptibility testing for TB patients, and tailoring of individual drug regimen through the use of first and second-line drugs.
62357271|NCT02573337|EXPERIMENTAL|Intradermal injection|Emervel Classic Lidocaine and/or Emervel Deep Lidocaine
62357272|NCT06291467|EXPERIMENTAL|Suicide attempters|patients hospitalized for suicide attempt within the last 72 hours
62357273|NCT06291467|ACTIVE_COMPARATOR|Affective controls|patients hospitalized for current major depressive episode according to DSM-5 criteria and without any lifetime history of suicide attempt
62357274|NCT05953207|EXPERIMENTAL|Medical hypnosis (HYP)|3 medical hypnosis interventions
62357275|NCT05953207|ACTIVE_COMPARATOR|Standard Of Care (SOC)|3 standard of care quality and sleep safety interventions
62521209|NCT05346783|ACTIVE_COMPARATOR|Diquas-s Ophthalmic solution 3% 0.4mL [Part 2]|1 drop 6 times a day
62521210|NCT03966482|EXPERIMENTAL|Group before-after|Speech therapy with Semiocluded vocal tract exercise.
62521211|NCT01293760|OTHER|6 weeks interval insertion|IUD is inserted 6 weeks following c-section delivery of baby and placenta
62521212|NCT01293760|EXPERIMENTAL|Immediate insertion|IUD is inserted immediately following c-section delivery of baby and placenta
62521213|NCT03043118|EXPERIMENTAL|Variety|Children receive three servings of vegetables each prepared with a different herb and spice blend.
62521214|NCT03043118|NO_INTERVENTION|No Variety - Control|Children receive three servings of vegetables each prepared with the same herb and spice blend.
62521215|NCT02104336|EXPERIMENTAL|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
62521216|NCT05173038||second ejaculate group|
62521217|NCT05173038||first ejaculate group|
62521218|NCT03824990|NO_INTERVENTION|Before-intervention phase|All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.
62521219|NCT03824990|EXPERIMENTAL|Intervention phase|All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.
61975104|NCT04492839|EXPERIMENTAL|Intestial adsorbent arm|This is a single arm study, all participants will receive the class IIa intestinal adsorbent medical device
61975105|NCT05773287|EXPERIMENTAL|Targeted Health Coaching Group|
61975106|NCT05773287|PLACEBO_COMPARATOR|Standard Care Group|
61975107|NCT00758212|EXPERIMENTAL|A|The experimental group will consist of HIV/AIDS patients(approx.50) who volunteer to receive a reduced dose Influenza vaccine using mesotherapy as a mode of injecting the vaccine intradermally.
61975108|NCT04447261|EXPERIMENTAL|BI 1356225|
62521220|NCT03824990|EXPERIMENTAL|Sustainability intervention phase|All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
62521221|NCT03184259|EXPERIMENTAL|Robotic ankle system|Subjects will wear the Ankle Robot during 20-session gait training, power assistance will be provided from the motor to the ankle joint.
62521222|NCT03184259|EXPERIMENTAL|Robotic knee system|Subjects will wear the Knee Robot during 20-session gait training, power assistance will be provided from the motor to the knee joint.
62521223|NCT03184259|PLACEBO_COMPARATOR|Ankle Sham group|Subjects will wear the Ankle Robot during 20-session gait training, but no power assistance will be provided from the motor to the ankle joint.
62521224|NCT03184259|PLACEBO_COMPARATOR|Knee Sham group|Subjects will wear the Knee Robot during 20-session gait training, but no power assistance will be provided from the motor to the knee joint.
62521225|NCT03184259|NO_INTERVENTION|Health Control|Healthy subjects will wear the Ankle Robot and/or Knee Robot during walking tasks (with or without power assistance), to collect control data for investigating if there are any effects of the robotic assistance on normal gait pattern.
62521226|NCT01750619||Mucosal tumors of the colon|Patients who received endoscopic treatment for noninvasive mucosal tumors of the colon.
62521227|NCT01750619||Nonampullary tumors of the duodenum|Patients who received endoscopic treatment for noninvasive mucosal tumors of the duodenum.
62521228|NCT01750619||Ampullary tumors|Patients who received endoscopic treatment for noninvasive ampullary tumors.
62521229|NCT03095573|EXPERIMENTAL|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
62521230|NCT03095573|ACTIVE_COMPARATOR|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
62149752|NCT04389788|ACTIVE_COMPARATOR|Lt Eye|The left eye of the same patients received microneedling with topical glutathione for 6 sessions every 2 weeks. Microneedling was done with Derma pen which is automatic and rechargeable device (vibrating frequency : 6500-10000 r/m , vibration speed level 5 , model :Ultima A6 , company : Dr ,pen and country : Korea). Needle length is adjustable from 0.25 mm to 0,5 mm.Needles number : 36 .Then, Patient was subjected to topical glutathione about 0.25 ml (vial : 600mg/5ml).
62357276|NCT06426498|EXPERIMENTAL|tFUS over V1|All subjects will get tFUS, open label
62357277|NCT01664819|ACTIVE_COMPARATOR|Antioxidant supplementation|Randomized to receive antioxidant supplementation (vitamin C, 500 mg; beta carotene, 15 mg; and alpha-tocopherol, 400 IU) three times per week for five years.
62357278|NCT01664819|PLACEBO_COMPARATOR|Placebo|Randomized to receive placebo three times per week for five years
62357279|NCT00810810|ACTIVE_COMPARATOR|1|Blood components with no additional treatment
62357280|NCT00810810|EXPERIMENTAL|2|Blood components leukoreduced
62357281|NCT00810810|EXPERIMENTAL|3|Blood components leukoreduced and irradiated
62357282|NCT03263741|EXPERIMENTAL|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 135 mg/m2, iv, 3h, at D1 ; S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
62357283|NCT00055575|EXPERIMENTAL|Depressed Patients with Major Depression DIsorder|
62357284|NCT00055575|EXPERIMENTAL|Depressed Patients with Bipolar Disorder|
62357285|NCT00055575|EXPERIMENTAL|Healthy Control|
62357286|NCT02722629|EXPERIMENTAL|Aspiration in COPD patients|All COPD patient will be evaluated systematically by FEESST (Flexible Endoscopic Evaluation of Swallowing with Sensory Testing) with direct evaluation of aspiration by direct observation.
62521231|NCT05875922|EXPERIMENTAL|IOL implantation experimental|Experimental arm: Premium monofocal intraocular lens.
62521232|NCT05875922|ACTIVE_COMPARATOR|IOL implantation active comparator|Comparator arm: EDOF intraocular lens.
62521233|NCT00377507|EXPERIMENTAL|catechin|mask containing catechins
62149753|NCT02239614|EXPERIMENTAL|Group 1: LAV (T=0), PIV (T=28)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 28 of the study."
62357287|NCT00747539||1|This group will be composed of 165 HCV-infected people who are not also HIV infected.
62357288|NCT00747539||2|This group will be composed of 165 HCV-infected people who are also HIV infected.
62521234|NCT05012865||Patients with metastatic renal cell carcinoma|Patients with metastatic renal cell carcinoma
62521235|NCT00351598||1|Patients with loco-regional, NSCLC treated by definitive radiotherapy.
62521236|NCT01393184|EXPERIMENTAL|Radiotherapy + Nimotuzumab|"1. Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy \& CTV 60 Gy/33F~2. Nimotuzumab (Nimo) weekly Nimo (200 mg) × 8, started 1 w before RT"
62521237|NCT01393184|ACTIVE_COMPARATOR|Radiotherapy (RT)|Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy \& CTV 60 Gy/33F
62521238|NCT01530594|ACTIVE_COMPARATOR|Lenalidomide|Lenalidomide/Low dose Dex (LLD)
62521239|NCT01530594|EXPERIMENTAL|Bortezomib/Lenalidomide|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
62521240|NCT05748119|PLACEBO_COMPARATOR|A1a Placebo|Single Sentinel Placebo Comparator for 20 mg Dose of MEB-1170
62521241|NCT05748119|EXPERIMENTAL|A1a MEB-1170|Single MEB-1170 Sentinel 20 mg Dose
62521242|NCT05748119|PLACEBO_COMPARATOR|A1b Placebo|Single Placebo comparator for 20 mg dose cohort of MEB-1170
62521243|NCT05748119|EXPERIMENTAL|A1b MEB-1170|Single MEB-1170 20 mg dose cohort
62521244|NCT05748119|PLACEBO_COMPARATOR|A2a Placebo|Single Sentinel Placebo Comparator for 60 mg Dose of MEB-1170
62521245|NCT05748119|EXPERIMENTAL|A2a MEB-1170|Single MEB-1170 Sentinel 60 mg Dose
62521246|NCT05748119|PLACEBO_COMPARATOR|A2b Placebo|Single Placebo comparator for 60 mg dose cohort of MEB-1170
62521247|NCT05748119|EXPERIMENTAL|A2b MEB-1170|Single MEB-1170 60 mg dose cohort
62521248|NCT05748119|PLACEBO_COMPARATOR|A3a Placebo|Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170
61975109|NCT04447261|PLACEBO_COMPARATOR|Placebo|
61975110|NCT05808491|NO_INTERVENTION|control|provide usual care, which includes patient education sheets and medical treatment covered by National Health Insurance regulations
61975111|NCT05808491|EXPERIMENTAL|intervention|provide a resilience intervention by teaching participants how to assess their level of resilience and how to minimize their level of stress. Other objectives include to enhance coping, to control belief, and to manage skills through role-play, group discussion, and individual practice.
62521249|NCT05748119|EXPERIMENTAL|A3a MEB-1170|Single MEB-1170 Sentinel 120 mg Dose
62521250|NCT05748119|PLACEBO_COMPARATOR|A3b Placebo|Single Placebo comparator for 120 mg dose cohort of MEB-1170
62521251|NCT05748119|EXPERIMENTAL|A3b MEB-1170|Single MEB-1170 120 mg dose cohort
62521252|NCT05748119|PLACEBO_COMPARATOR|A4a Placebo|Single Sentinel Placebo Comparator for 200 mg Dose of MEB-1170
62521253|NCT05748119|EXPERIMENTAL|A4a MEB-1170|Single MEB-1170 Sentinel 200 mg Dose
62521254|NCT05748119|PLACEBO_COMPARATOR|A4b Placebo|Single Placebo comparator for 200 mg dose cohort of MEB-1170
62521255|NCT05748119|PLACEBO_COMPARATOR|A4b MEB-1170|Single MEB-1170 200 mg dose cohort
62521256|NCT05748119|PLACEBO_COMPARATOR|A5a Placebo|Single Sentinel Placebo Comparator for 400 mg Dose of MEB-1170
62521257|NCT05748119|EXPERIMENTAL|A5a MEB-1170|Single MEB-1170 Sentinel 400 mg Dose
62521258|NCT05748119|PLACEBO_COMPARATOR|A5b Placebo|Single Placebo comparator for 400 mg dose cohort of MEB-1170
62521259|NCT05748119|EXPERIMENTAL|A5b MEB-1170|Single MEB-1170 400 mg dose cohort
62521260|NCT05748119|PLACEBO_COMPARATOR|B1 Placebo|MAD Placebo 60 mg comparator cohort of MEB-1170
62521261|NCT05748119|EXPERIMENTAL|B1 MEB-1170|MAD 60 mg MEB-1170 cohort
62521262|NCT05748119|PLACEBO_COMPARATOR|B2 Placebo|MAD Placebo 100 mg comparator cohort of MEB-1170
62521263|NCT05748119|EXPERIMENTAL|B2 MEB-1170|MAD 100 mg MEB-1170 cohort
62521264|NCT05748119|PLACEBO_COMPARATOR|B3 Placebo|MAD Placebo 200 mg comparator cohort of MEB-1170
62521265|NCT05748119|EXPERIMENTAL|B3 MEB-1170|MAD 200 mg MEB-1170 cohort
62521266|NCT05748119|PLACEBO_COMPARATOR|B4 Placebo|MAD Placebo 400 mg comparator cohort of MEB-1170
62521267|NCT05748119|EXPERIMENTAL|B4 MEB-1170|MAD 400 mg MEB-1170 cohort
62521268|NCT05748119|PLACEBO_COMPARATOR|A3a Placebo Fed State|Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170 in Fed State
62521269|NCT05748119|EXPERIMENTAL|A3a MEB-1170 Fed State|Single Sentinel 120 mg Dose of MEB-1170 in Fed State
62521270|NCT05748119|PLACEBO_COMPARATOR|A3b Placebo Fed State|Single Placebo comparator for 120 mg dose cohort of MEB-1170 in Fed State
62521271|NCT05748119|EXPERIMENTAL|A3b MEB-1170 Fed State|Single MEB-1170 120 mg dose cohort in Fed State
62521272|NCT06205433|EXPERIMENTAL|IHSS Basic Training|Individuals in the treatment group will be invited to participate in CCA's IHSS Basic training program. The program is a 30 hour online course for IHSS providers, which teaches fundamental caregiving skills. Training includes personal care, infection control, nutrition and body mechanics, medication adherence, and home safety.
62521273|NCT06205433|NO_INTERVENTION|Control|No intervention is delivered to the control group. The control group will be unable to access CCA's training programs for two years following random assignment.
62521274|NCT03501836|EXPERIMENTAL|Rapid Rhythm Handheld 8-lead ECG Device|Participants will have measurements taken with the 8 lead ECG system, which will be compared to the conventional standard care 12 lead ECG.
62521275|NCT05222542||Patients after aneurysmal subarachnoid hemorrhage|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
62521276|NCT04284514|EXPERIMENTAL|AKB-9778 Ophthalmic Solution|Up to 4 daily dose levels of AKB-9778 Ophthalmic Solution will be evaluated. Doses will be administered in both eyes daily for 7 days.
62521277|NCT04284514|PLACEBO_COMPARATOR|Vehicle Control Ophthalmic Solution|Matched vehicle-control ophthalmic solution will be administered in both eyes daily for 7 days.
62521278|NCT04178265|EXPERIMENTAL|Electroacupuncture group|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of three times per week for four weeks, for a total of twelve times.~Acupoint selection: needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints."
62521279|NCT04178265|NO_INTERVENTION|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of three times per week for four weeks, for a total of twelve times.
62521280|NCT02439203|EXPERIMENTAL|JM-010|JM-010
62521281|NCT02439203|PLACEBO_COMPARATOR|Placebo|Placebo
62521282|NCT04960306|ACTIVE_COMPARATOR|Fecal filtrate transplantation|Patients randomized to the fecal filtrate transplantation group
62521283|NCT04960306|ACTIVE_COMPARATOR|Conventional fecal microbiota transplantation|Patients randomized to the conventional fecal microbiota transplantation group
62521284|NCT01720199|EXPERIMENTAL|Intervention group|Preadolescents allocated to the Diario della Salute (DDS) intervention.
62521285|NCT01720199|NO_INTERVENTION|Control group|
62521286|NCT01846117|ACTIVE_COMPARATOR|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
62521287|NCT01846117|PLACEBO_COMPARATOR|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
62149754|NCT02239614|EXPERIMENTAL|Group 2: PIV (T=0), LAV (T=28)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 28 of the study."
62149755|NCT02239614|EXPERIMENTAL|Group 3: LAV (T=0), PIV (T=180)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 180 of the study."
62149756|NCT02239614|EXPERIMENTAL|Group 4: PIV (T=0), LAV (T=180)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 180 of the study."
62521288|NCT01543659|EXPERIMENTAL|89Zr-DFO-huJ591|Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan up to 4 weeks prior to registration are not required to repeat the FDG PET scan on study.
62521289|NCT06153654||Obese|Obese participants with BMI \>30
62711471|NCT06393751|EXPERIMENTAL|Phase II, Arm II (paclitaxel, tolinapant, bevacizumab)|Patients receive paclitaxel IV on days 1, 8, and 15 and ASTX660 PO on days 1-7 and 15-21 of each cycle. Patients may also receive bevacizumab IV on days 1 and 15 of each cycle per provider. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
62711472|NCT02930148|EXPERIMENTAL|Intervention|Participants will be provided with a smart phone (android, version 5.0), two smart garments, a smart garment sensor and an activity bracelet will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The smart phones will have all apps of the PEGASO ecosystem installed.
61975112|NCT06037434||Modified Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).
62149757|NCT03315338|EXPERIMENTAL|SAD Part 1 Active Cohort A|CORT118335, 25 mg
62149758|NCT03315338|PLACEBO_COMPARATOR|SAD Part 1 Placebo oral capsule Cohort A|
62149759|NCT03315338|EXPERIMENTAL|SAD Part 1 Active Cohort B|CORT118335, 75mg
62149760|NCT03315338|PLACEBO_COMPARATOR|SAD Part 1 Placebo Cohort B|
62149761|NCT03315338|EXPERIMENTAL|SAD Part 1 Active Cohort C|CORT118335, 225mg
62357289|NCT05964504||Initial Cohort|Up to 12 participants at each evaluation timepoint (approximately every 3-6 months to follow standard of care visits) will have up to 40 mL of blood drawn and distributed into 8 cell-free DNA Streck tubes, for plasma isolation, cell free DNA extraction, and ctDNA analysis. Blood for ctDNA analysis will be collected within +/- 14 days of whole body imaging studies which will occur when patients are scheduled for standard of care whole body imaging.
62357290|NCT05032417|ACTIVE_COMPARATOR|EBNPG knowledge-focused training (knowledge-only group)|The knowledge-focused training includes didactic information about the content of the EBNPG related to nutrition care for individuals on dialysis. This training contains information that is typically shared with RDNs when an EBNPG is released, and in this instance, includes a free webinar developed by the Academy and NKF that provides an overview of EBNPGs, as well as a presentation of the specific EBNPG developed.
62357291|NCT05032417|EXPERIMENTAL|EBNPG knowledge-focused training plus an implementation toolkit (comprehensive group)|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
62357292|NCT02757092|EXPERIMENTAL|Home-based rehabilitation program|0-2 weeks,1. aerobic exercise intensity was targeted to reach 10-11 points of perceived exercise (RPE) scale 2. raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min 3.walked at a comfortable speed for 15 min twice per day.4. Triflo-II was performed 8-10 times per hour. inspiratory muscle training with the initial pressure set at 25%-30% of the maximum inspiratory pressure.3-6 weeks, aerobic exercise reach 12-15 points on the RPE scale. upper-limb resistance exercise (raising of a 250-cc water bottle) and lower-limb stepping for 20 min per day , walking exercise for a total of 30 min. Triflo-II was performed 8-10 times per hour, and train the inspiratory muscle with the pressure intensity adjusted to more than 5% of that in the first stage.
62521290|NCT06153654||Lean|Lean participants with a BMI \<25
62149762|NCT03315338|PLACEBO_COMPARATOR|SAD Part 1 Placebo Cohort C|
62521291|NCT06153654||Bariatric|Participants with scheduled bariatric surgery.
62521292|NCT03114696|EXPERIMENTAL|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
62521293|NCT03114696|PLACEBO_COMPARATOR|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
62521294|NCT00073021|ACTIVE_COMPARATOR|Asacol 2.4 g/day|Asacol (2.4 g/day)
62521295|NCT00073021|EXPERIMENTAL|Asacol 4.8 g/day|Asacol (4.8 g/day)
62521296|NCT06070987|EXPERIMENTAL|BoNT-A injection and robot therapy|Training session included 40 minutes Robotic Therapy, the group will receive 2 sessions per week, for 12 weeks.
62711473|NCT02930148|NO_INTERVENTION|Comparative|Participants will be asked to continue their routine daily physical and educational activities related to leading a healthy lifestyle.
62711474|NCT04330976|EXPERIMENTAL|Nutrition and physical activity intervention|
62711475|NCT04330976|OTHER|Control|
62149763|NCT03315338|EXPERIMENTAL|SAD Part 1 Active Cohort D|CORT118335, 675mg
62711476|NCT05221892|EXPERIMENTAL|Test combination|Gamma-aminobutyric acid tartrate 100mg, glutamic acid 100mg, dibasic calcium phosphate 50mg, thiamine nitrate 25mg, pyridoxine hydrochloride 10mg and cyanocobalamin 5mcg
62711477|NCT05221892|ACTIVE_COMPARATOR|Comparative medication|Ginger extract 160mg (8mg gingerols)
62521297|NCT06070987|EXPERIMENTAL|None BoNT-A injection and robot therapy|Training session included 40 minutes Robotic Therapy, the group will receive 2 sessions per week, for 12 weeks.
62521298|NCT01144364|EXPERIMENTAL|1|
62521299|NCT05015920|EXPERIMENTAL|Mobilization,harvest,transduction,conditioning,treatment,engraftment|Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.
62521300|NCT03621007||POMC deficiency obesity|
62521301|NCT03621007||LEPR deficiency obesity|
61975113|NCT06037434||the Traditional Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).
61975114|NCT02604108|EXPERIMENTAL|Physical Exercise|Physical Exercise: Participants will receive training and health messages on positive psychology and healthy living style focusing on physical activity.
61975115|NCT02604108|EXPERIMENTAL|Healthy Diet|Healthy Diet: Participants will receive training and health messages on positive psychology and healthy living style focusing on healthy diet.
61975116|NCT03221400|EXPERIMENTAL|Phase 1a PEN-866 Sodium (Single Agent)|Dose escalation of PEN-866 Sodium administered intravenously
61975117|NCT03221400|EXPERIMENTAL|Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid|Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
61975118|NCT03221400|EXPERIMENTAL|Phase 2a PEN-866 Sodium (Single Agent)|Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
62357293|NCT02757092|ACTIVE_COMPARATOR|standard care|control group accept the pulmonary rehabilitation (breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day and without home based pulmonary rehabilitation.
62357294|NCT02031588||Ceftriaxone|Patients receiving a C3G (ceftriaxone) during the hospitalization.
62357295|NCT02031588||Ceftriaxone + Fluoroquinolone|ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
62357296|NCT02031588||Fluoroquinolones|fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
62357297|NCT02031588||Reference|"A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
62357298|NCT04606641|EXPERIMENTAL|Goal specific functional tasks with mirror therapy):|"The session will be performed thrice in a week for total of 4 weeks. Each session will last for 20 minutes. Mirror therapy procedure and functional tasks will be explained to the patient before the start of treatment.~In this group, a mirror will be placed in the sagittal plane of the patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror"
61975119|NCT03221400|EXPERIMENTAL|Phase 1b PEN-866 Sodium + Niraparib|Dose escalation of intravenous administration of PEN-866 Sodium in combination with niraparib
62521302|NCT03621007||PCSK1 deficiency obesity|
62521303|NCT06436352|EXPERIMENTAL|Group I: cases with capsulotomy during fixation|before fixation, We perform a guide wire insertion passing anterior to the Greater Trochanter and the neck is done. then passing a pointed Schanz 5 or 6mm ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.
62521304|NCT06436352|ACTIVE_COMPARATOR|Group II: cases without capsulotomy during fixation|we fix the fracture without capsulotomy
62521305|NCT01565772|EXPERIMENTAL|Radiation, Chemotherapy and Surgery|Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.
62521306|NCT01893645||Pregnant women|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
62521307|NCT03647046|EXPERIMENTAL|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
62521308|NCT01974908|EXPERIMENTAL|Ventricular Tachycardia (VT)|Patients with VT will undergo a clinically indicated ablation of their VT
61975120|NCT05543876|EXPERIMENTAL|intervention group|group watching video with virtual reality glasses
61975121|NCT05543876|NO_INTERVENTION|control group|without any intervention
62149764|NCT03315338|PLACEBO_COMPARATOR|SAD Part 1 Placebo Cohort D|
62149765|NCT03315338|EXPERIMENTAL|SAD Part 2 Active Cohort A, Fasting|CORT118335, 600mg, is supplied as capsules for oral dosing given after an overnight fast
62521309|NCT00932945|EXPERIMENTAL|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Treatment duration: 21 consecutive days
62521310|NCT00896324|ACTIVE_COMPARATOR|Cognitive Rehabilitation (Breast Cancer(BC) with chemotherapy)|Cognitive rehabilitation is a very low-risk method of treatment for cognitive deficits that involves restoring impaired function and/or training the individual to compensate for the area of deficit. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
62521311|NCT00896324|ACTIVE_COMPARATOR|Active Neurofeedback (BC pre-chemotherapy)|"In active Neurofeedback session subjects will be trained to increase brain activation in regions associated with executive function (EF) function deficits (as determined by neuroimaging measures) by viewing their own brain activation in real-time. The dose will be 2-3 sessions, each lasting approximately 30 minutes."
62711478|NCT06082453|EXPERIMENTAL|Molecular testing for detection of T. pallidum and use of CDC guidelines for diagnosis of syphilis|
62711479|NCT03302767|EXPERIMENTAL|Psychological and Social Consultation|Psychological and Social Consultation
62149766|NCT03315338|EXPERIMENTAL|SAD Part 2 Active Cohort A, Fed|CORT118335, 600mg, is supplied as capsules for oral dosing given after a high-fat breakfast
62521312|NCT00896324|SHAM_COMPARATOR|Neurofeedback placebo (Sham) (BC pre-chemotherapy)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
62521313|NCT02182128|EXPERIMENTAL|BIBF 1120|
62521314|NCT04629859|EXPERIMENTAL|study arm|dento skeletal class III patients will undergo a mandibular setback surgery and maxillary advancement
62521315|NCT04629859|EXPERIMENTAL|controlled arm|dento skeletal class III patients will undergo a mandibular setback surgery
61975122|NCT05590754||Experimental Group|8 participants (4 males, 25.5±4.4 years, 63.5±10.6 kg, 163.2±5.6 cm)
62521316|NCT00077584|EXPERIMENTAL|Bosentan|The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
62521317|NCT00077584|PLACEBO_COMPARATOR|Placebo|The patients received the matching placebo for 24 weeks
61975123|NCT05590754||Observational Group|8 participants (3 males, 27.0±2.0 years, 68.4±11.8 kg, 176.5±10.9 cm
61975124|NCT01384968|EXPERIMENTAL|Beetroot juice|beetroot juice (170 mL, 8 mmol nitrate)
62521318|NCT05905263|EXPERIMENTAL|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are in the application, the interface will be introduced through the images projected to the computer simultaneously.
62521319|NCT02921126||High Dose Group|Apixaban - 10 mg/day Rivaroxaban - 20 mg/day Dabigatran - 300 mg/day
62521320|NCT02921126||Low Dose Group|Apixaban - 5 mg/day Rivaroxaban - 15 mg/day Dabigatran - 220 mg/day
62521321|NCT02921126||Other Dose Group|Invalid Doses / Off-Label
62521322|NCT03896464|ACTIVE_COMPARATOR|Soft-tissue hamstring|All patients in the study will undergo arthroscopic-assisted, single-bundle, complete transphyseal, anatomic primary ACL reconstruction at the discretion of the surgeon, considering the individual patient's age, physeal status, and anticipated years of growth remaining to skeletal maturity. Patients in this arm will undergo soft-tissue autograft reconstruction using hamstrings (i.e. semitendinosus and/or gracilis) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
62711480|NCT06329219|EXPERIMENTAL|Radiation|Participants in the intervention group each receive a hyperthermia device for water-filtered Infrared-A radiation.
62711481|NCT06329219|NO_INTERVENTION|Waiting list|Participants in the control group initially receive no therapeutic intervention, but can receive it after the study's last visit for 3 months.
62711482|NCT05669222|EXPERIMENTAL|FAST Guided Strategy (μQFR+RWS)|"1. μQFR is measured in all non-infarct related arteries containing any non-culprit lesion with visually-assessed DS% ≥50% and ≤90% with RVD ≥2.5 mm.~   1. μQFR ≤0.80: PCI~  2. RWS ≥13%: PCI~  3. μQFR \>0.80 and RWS \<13%: Deferral~  4. DS% \>90%: PCI without the need of μQFR or RWS~2. For all patients undergoing PCI, post-PCI μQFR measurement is recommended; if μQFR \<0.90, if the reason is obvious post-dilation with a non-compliant balloon or bail-out stenting should be considered; if the reason is not obvious intravascular imaging should be considered."
62711483|NCT05669222|SHAM_COMPARATOR|Standard Treatment Strategy|"1. PCI should be performed of all non-culprit lesions with visual DS% ≥70% in all non-infarct related arteries with RVD ≥2.5 mm;~2. For a non-culprit lesion with visually DS% 50-70%, PCI can be performed if FFR ≤0.80 or iFR ≤0.89."
61975125|NCT01384968|PLACEBO_COMPARATOR|Nitrate-depleted beetroot juice|140 mL ...0 nitrate. Beetroot juice
62149767|NCT03315338|PLACEBO_COMPARATOR|SAD Part 2 Placebo PD Effect Cohort B|
62149768|NCT03315338|EXPERIMENTAL|SAD Part 2 Active PD Effect Cohort B: 630mg of CORT118335|
61975126|NCT03927131|EXPERIMENTAL|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
61975127|NCT03927131|ACTIVE_COMPARATOR|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
61975128|NCT03927131|ACTIVE_COMPARATOR|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
61975129|NCT03927131|EXPERIMENTAL|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
62149769|NCT03315338|EXPERIMENTAL|SAD Part 2 Active PD Effect Cohort B: 675mg of CORT118335|
62149770|NCT03315338|EXPERIMENTAL|MAD Part 3 Active Cohort A|CORT118335, 375mg qd for 14 days
61975130|NCT03927131|EXPERIMENTAL|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
62149771|NCT03315338|PLACEBO_COMPARATOR|MAD Part 3 Placebo Cohort A|Placebo qd for 14 days
62149772|NCT03315338|EXPERIMENTAL|SAD Part 4 Active Cohort A|CORT118335, 100mg
62149773|NCT03315338|PLACEBO_COMPARATOR|SAD Part 4 Placebo Cohort A|
62149774|NCT03315338|EXPERIMENTAL|SAD Part 4 Active Cohort B|CORT118335, 300mg
61975131|NCT03927131|EXPERIMENTAL|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
61975132|NCT01905657|EXPERIMENTAL|Pembrolizumab 2 mg/kg|Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
61975133|NCT01905657|EXPERIMENTAL|Pembrolizumab 10 mg/kg|Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
61975134|NCT01905657|ACTIVE_COMPARATOR|Docetaxel 75 mg/m^2|Participants received docetaxel 75 mg/m\^2 IV over 1 hour Q3W for up to 2 years.
61975135|NCT01810354|EXPERIMENTAL|Two grams cefazolin|Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
62149775|NCT03315338|PLACEBO_COMPARATOR|SAD Part 4 Placebo Cohort B|
62149776|NCT03315338|EXPERIMENTAL|SAD Part 4 Active Cohort C, Fasting|CORT118335, 900mg is supplied as suspension for oral dosing given after an overnight fast
62521323|NCT03896464|ACTIVE_COMPARATOR|Quadriceps tendon|Patients in this arm will undergo soft-tissue autograft reconstruction using all-soft-tissue quadriceps (i.e. full or partial thickness) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
62521324|NCT05675241||Functional Dental Implant|An implant restored with a prothesis and in function for a minimum of one year.
62521325|NCT02480218||Tamoxifen|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed tamoxifen.
61975136|NCT01810354|ACTIVE_COMPARATOR|Three grams cefazolin|Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
62521326|NCT02480218||Aromatase Inhibitors|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed aromatase inhibitors.
62521327|NCT03653494|EXPERIMENTAL|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
62521328|NCT03653494|ACTIVE_COMPARATOR|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
61975137|NCT00764153|OTHER|Internal fixation|Closed reduction and internal fixation with two parallel screws (Olmed)
62521329|NCT03596736|EXPERIMENTAL|Elbow Hemiarthroplasty|
62521330|NCT03596736|ACTIVE_COMPARATOR|Total Elbow Arthroplasty|
62521331|NCT00809159|EXPERIMENTAL|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
62521332|NCT00809159|PLACEBO_COMPARATOR|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose
62521333|NCT00809159|EXPERIMENTAL|Parts 1 and 2 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
62521334|NCT00809159|EXPERIMENTAL|Part 1 and 2 - AIN457 0.1 mg/kg|AIN457A 0.1 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
62521335|NCT00809159|EXPERIMENTAL|Part 1 and 2 - AIN457 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
62521336|NCT02044549|ACTIVE_COMPARATOR|carbetocin|single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
62521337|NCT02044549|ACTIVE_COMPARATOR|Syntometrine|Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
62521338|NCT03149458|EXPERIMENTAL|Dance group|dance program for 8 one-hour sessions.
62521339|NCT03149458|ACTIVE_COMPARATOR|control group|upper limb rehabilitation for 8 one-hour sessions.
62521340|NCT03866915||Patients undergoing elective surgery|All patients older than 18 years undergoing elective surgery that receive a preoperative visit by anesthesiologists in which Aortic pulse wave velocity measurement and the 6 minutes walking test (6MWT) is carried out
62521341|NCT03946254|EXPERIMENTAL|Intervention|THE EXPERIMENTAL GROUP WILL DEVELOP 20 WEEKS OF TRAINING TO IMPROVE THE MUSCLE CAPACITY. FOR THIS, FORCE EXERCISES WILL BE DEVELOPED IN GUIDED MACHINES.
62521342|NCT03946254|EXPERIMENTAL|Control|THE CONTROL GROUP WILL DEVELOP 20 WEEKS OF BALANCE AND BREATHING EXERCISES.
61975138|NCT00764153|OTHER|Bipolar hemiarthroplasty|Hemiarthroplasty with Charnley/ Hastings prosthesis
61975139|NCT05482763||Patients with onychomycosis|All patients with clinical suspicion of onychomycosis at the Tor Vergata Polyclinic center will be enrolled according to the inclusion and exclusion criteria of the study. After signing the informed consent, the subjects will be subjected to scraping or clipping of the nail unit affected by the disease. The collected material will be stored in a sterile container to be sent to the Microbiology laboratory.
61975140|NCT01059825|PLACEBO_COMPARATOR|Placebo|Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
61975141|NCT01059825|EXPERIMENTAL|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
61975142|NCT01059825|EXPERIMENTAL|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
61975143|NCT01059825|EXPERIMENTAL|Ertugliflozin 10 mg|Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
61975144|NCT01059825|EXPERIMENTAL|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
61975145|NCT01059825|ACTIVE_COMPARATOR|Sitagliptin 100 mg|Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
62711484|NCT03545672||PBC group|Patients have a definite PBC diagnosis.
62521343|NCT03968198|EXPERIMENTAL|ASC (Adipose-derived Stem/Stroma Cells)|Patients administrated with autologous ASC in their ischemic inferiors limbs
61975146|NCT02988531|EXPERIMENTAL|PET/MR|Participants to have PET/MR scan
62149777|NCT03315338|EXPERIMENTAL|SAD Part 4 Active Cohort C, Fed|CORT118335, 900mg is supplied as suspension for oral dosing given after a high-fat breakfast
62521344|NCT04529447||Patient satisfaction survey|Jaseng Hospital of Korean medicine conducted a pen and paper survey on patient satisfaction with regard to its COVID-19 response in inpatients hospitalized and outpatients visiting during March 23-25, 2020.
62521345|NCT03022058|EXPERIMENTAL|Patients with type 1 diabetes mellitus|
62521346|NCT01700426|ACTIVE_COMPARATOR|iron|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
62711485|NCT03545672||Control group|The healthy volunteers.
62711486|NCT04400825|EXPERIMENTAL|Dry needling|Dry needling of 3 active MTrPs at most.
62711487|NCT04400825|ACTIVE_COMPARATOR|Stretching|Stretching of the main hip flexors (rectus femoris, iliopsoas and tensor fasciae latae)
62711488|NCT05595928||Supine|supine
62521347|NCT01700426|ACTIVE_COMPARATOR|iron 2|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
62521348|NCT03858218||Pediatric cancer survivors group|Childhood cancer survivors refers to those who have completed cancer treatment for at least six months, the pediatric cancer survivors must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese.This group will be required to fill in the questionnaires set.
62711489|NCT05595928||15° left-lateral tilt position|15° left-lateral tilt position.
62711490|NCT05595928||30° left-lateral tilt position.|30° left-lateral tilt position.
62711491|NCT04027296||suspected COPD|Patients aged ≥ 35yo and ≥10Pack.Year
62357299|NCT04606641|ACTIVE_COMPARATOR|Goal specific functional tasks without mirror therapy|"Session will be performed thrice in a week for total 4 weeks. Each session will last for 20 minutes.~The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks as mentioned in the table below Functional tasks will be same in both groups"
62357300|NCT03111342|EXPERIMENTAL|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
62711492|NCT05838742|EXPERIMENTAL|GSK3858279 Dose 1|Participants will receive GSK3858279 dose 1.
62711493|NCT05838742|EXPERIMENTAL|GSK3858279 Dose 2|Participants will receive GSK3858279 dose 2.
62711494|NCT05838742|EXPERIMENTAL|GSK3858279 Dose 3|Participants will receive GSK3858279 dose 3.
62711495|NCT05838742|EXPERIMENTAL|GSK3858279 Dose 4|Participants will receive GSK3858279 dose 4.
62711496|NCT05838742|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62711497|NCT02146443|ACTIVE_COMPARATOR|Baseline|Completion of the star shaped manual dexterity test, five rounds clockwise and five rounds counter clockwise without any intervention. Time and number of errors are recorded. Measurement of static arm strength with the stretched arm test. test subject is asked to hold a 2.5 kg weight in stretched arm for as long as possible. Maximum endurance time is recorded.
62149778|NCT03315338|PLACEBO_COMPARATOR|SAD Part 4 Placebo Cohort C, Fasting|Supplied as suspension for oral dosing given after an overnight fast
62357301|NCT03111342|SHAM_COMPARATOR|Dry-needling|A placement of thin needle into the cervix without substance injection
62357302|NCT03111342|NO_INTERVENTION|No intervention|No intervention for pain relief prior to LNG-IUS insertion
62357303|NCT02474914|ACTIVE_COMPARATOR|Octreotide|Enrolled patients will be randomized to either the octreotide (sandostatin ) or the placebo group. The randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . Patients in the octreotide group will receive sandostatin 100ug SC every 8 hours daily staring from the day of operation to the postoperative day 7. Patients in the placebo group will receive saline administered in a similar manner.
62711498|NCT02146443|ACTIVE_COMPARATOR|Fatigue|Prior to completion of the star shaped manual dexterity test, the test subject is asked to stand up still and hold a 2.5-kg weight with the dominant arm fully extended as long as possible without moving. Maximum endurance time is recorded. After this, the test subject completes the the star shaped manual dexterity test and time and number of errors are recorded.
62711499|NCT02146443|ACTIVE_COMPARATOR|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test. Completion time and number of errors are recorded.
62711500|NCT02146443|ACTIVE_COMPARATOR|Fatigue and Stress|The test subject will be fatigued prior to the test (as detailed in the fatigue arm), and asked to identify cards during completion of the star shaped manual dexterity test (as detailed in the stress arm). Completion time and number of errors are recorded.
62711501|NCT01163188||Proband|Very low birth weight children (\< 32 weeks of gestation) and/ or Very preterm children (\< 1500 g birthweight) of the Bavarian Longitudinal Study
62711502|NCT01163188||Controls|Term born children of the Bavarian Longitudinal Study
62149779|NCT03315338|PLACEBO_COMPARATOR|SAD Part 4 Placebo Cohort C, Fed|Supplied as suspension for oral dosing given after a high-fat breakfast
62357304|NCT02474914|PLACEBO_COMPARATOR|Placebo|pancreaticoduodenectomy without octreotide postoperative
62357305|NCT05966246|EXPERIMENTAL|Prucalopride succinate group|Taking prucalopride succinate from the first day to the fifth day after surgery.
62357306|NCT05966246|PLACEBO_COMPARATOR|Control (mosapride citrate) group|Taking mosapride citrate from the first day to the fifth day after surgery.
62521349|NCT03858218||Healthy children group|Healthy children must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese. This group will be required to fill in the questionnaires set.
62711503|NCT01331759|EXPERIMENTAL|Immediate Neuropattern™|The experimental group will undergo Neuropattern™ stress diagnostics immediately after inclusion in the study.
62711504|NCT01331759|PLACEBO_COMPARATOR|Later Neuropattern™|The control group will undergo Neuropattern™ stress diagnostics three months after inclusion in the study.
62149780|NCT03315338|EXPERIMENTAL|SAD Part 4 Active Cohort Part D|CORT118335, 1500mg
62521350|NCT02003911|EXPERIMENTAL|Azithromycin suspension|"Azithromycin suspension at 10mg/kg/dose (max 500mg)~Once daily for 3 days"
62521351|NCT02003911|PLACEBO_COMPARATOR|Placebo suspension|"Same volume as active drug~Once daily for 3 days"
62149781|NCT03315338|PLACEBO_COMPARATOR|SAD Part 4 Placebo Cohort D|
62149782|NCT03315338|EXPERIMENTAL|MAD Part 5 Active Cohort A|CORT118335, 150mg
62149783|NCT03315338|PLACEBO_COMPARATOR|MAD Part 5 Placebo Cohort A|
62357307|NCT05563051|OTHER|Interventional treatment|Open label
62357308|NCT05322915|EXPERIMENTAL|dance group|The dance group, each patient received a goal-oriented line dancing program.
62521352|NCT02744131|ACTIVE_COMPARATOR|OCP|Arm 1: oral contraceptive pill, combination pill of ethyl estradiol 20 micro gram with Cyproterone acetate.
62521353|NCT02744131|ACTIVE_COMPARATOR|Metformin|Arm 2: Metformin . Oral insulin sensitising drug in the dose of 1500gms daily.
62521354|NCT00911807|EXPERIMENTAL|Cerebrolysin + donepezil|
62521355|NCT00911807|EXPERIMENTAL|Cerebrolysin + placebo|
62357309|NCT05322915|NO_INTERVENTION|control|The control group did not receive any treatment program during this period.
62521356|NCT00911807|ACTIVE_COMPARATOR|Donepezil + placebo|
62149784|NCT03315338|EXPERIMENTAL|MAD Part 5 Active Cohort B|CORT118335, dose to be determined
62521357|NCT01089621|EXPERIMENTAL|Duloxetine|
62521358|NCT00389831|PLACEBO_COMPARATOR|Placebo|Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
62357310|NCT04629638||covid -19 positive pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth.
62357311|NCT04629638||covid -19 negative pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-negative pregnant women in the 3rd month after birth.
62521359|NCT00389831|EXPERIMENTAL|Rotigotine Nasal Spray|Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
62521360|NCT05173246|EXPERIMENTAL|JS001 Combined With TP|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with nab-paclitaxel and cisplatin or carboplatin for injection
62521361|NCT01239979||Stable, Unstable , control|
62357312|NCT02358564|ACTIVE_COMPARATOR|Healthy Volunteers|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
62357313|NCT02358564|EXPERIMENTAL|Irritable Bowel Syndrome Patients|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
62357314|NCT01804114|ACTIVE_COMPARATOR|Local anesthetic continuous infusion|Pain management following hernia repair
62149785|NCT03315338|PLACEBO_COMPARATOR|MAD Part 5 Placebo Cohort B|
62357315|NCT01804114|PLACEBO_COMPARATOR|Placebo continuous infusion|Placebo pain management following hernia repair
62357316|NCT00870038|EXPERIMENTAL|1|Paclitaxel eluting balloon (Elutax) + Genous stent
62357317|NCT00870038|EXPERIMENTAL|2|Uncoated balloon + Genous stent
62357318|NCT00870038|ACTIVE_COMPARATOR|3|Drug eluting stent (Taxus stent)
62357319|NCT02045251|EXPERIMENTAL|Interventional Arm|This arm will have 100 patients receiving the proposed Pylera based regimen for 10 days.
62357320|NCT04322162|EXPERIMENTAL|Active implementation - Wave 1 (First and Second Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites. Active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves two phases at each of the 6 sites: a variable number of 7-month data periods during baseline period (three 7-month periods for Wave 1 sites, four 7-month data periods for Wave 2 sites, five 7-month data periods for Wave 3 sites), three 7-month data periods in active implementation phase for each wave. Wave 1 and Wave 2 sites will also each have one 7-month period of sustainability. The stepped-wedge design allows for 6 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 21 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on six different cross-sectional samples. Investigators will have repeated information on each site. Arm 1 corresponds to Wave 1."
62357321|NCT04322162|EXPERIMENTAL|Active implementation - Wave 2 (Third and Fourth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites. Active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves two phases at each of the 6 sites: a variable number of 7-month data periods during baseline period (three 7-month periods for Wave 1 sites, four 7-month data periods for Wave 2 sites, five 7-month data periods for Wave 3 sites), three 7-month data periods in active implementation phase for each wave. Wave 1 and Wave 2 sites will also each have one 7-month period of sustainability. The stepped-wedge design allows for 6 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 21 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on six different cross-sectional samples. Investigators will have repeated information on each site. Arm 2 corresponds to Wave 2."
62521362|NCT01530763|EXPERIMENTAL|Ceftaroline fosamil|
62521363|NCT01530763|ACTIVE_COMPARATOR|Ceftriaxone|
62521364|NCT03316378|EXPERIMENTAL|Group with Achilles Tendinopathy|Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
62521365|NCT03316378|NO_INTERVENTION|Group without Achilles Tendinopathy|The control group did not receive an injection between test repetitions
62521366|NCT06357793||fibromyalgia|The revised 2016 American College of Rheumatology (ACR) FM diagnostic criteria going to be use to diagnose FM participants group. Their relatives will fill out the WPAI:GH Questionnaire and World Health Organization Quality of Life (WHOQOL).
62521367|NCT06357793||control|Healthy participants' relatives will fill out the WPAI:GH Questionnaire and World Health Organization Quality of Life (WHOQOL).
62521368|NCT06011616|EXPERIMENTAL|interventional group|"Superficial and Deep Sensory training: 5 sets of 9 min, 3 times a week for 8 weeks.~Motor training: 5 sets of 9 min, 3 times a week for 8 weeks. Conventional therapy: 30 min, 3 days for 8 weeks"
62521369|NCT06011616|ACTIVE_COMPARATOR|control group|Motor training: 5 sets of 9 min, 3 times a week for 8 weeks. Conventional therapy: 30 min, 3 days for 8 weeks
62521370|NCT02280226|EXPERIMENTAL|Deliberate Apnea Group|Subjects undergo maximum apnea.
62521371|NCT03626506|EXPERIMENTAL|spironolactone|Subjects will take spironolactone 20\~40mg once daily on top of amlodipine 5\~10mg once daily.
62149786|NCT03315338|EXPERIMENTAL|MAD Part 5 Active Cohort C|CORT118335, dose to be determined
62149787|NCT03315338|PLACEBO_COMPARATOR|MAD Part 5 Placebo Cohort C|
62149788|NCT01995292|EXPERIMENTAL|bronchoscope|Patients will receive local anaesthetics via the working channel of the bronchoscope.
62149789|NCT01995292|EXPERIMENTAL|Enk Fiberoptic Atomizer|Patients will receive local anaesthetics for the awake fiberoptic intubation via the Enk Fiberoptic Atomizer.
62521372|NCT03626506|ACTIVE_COMPARATOR|indapamide|Subjects will take indapamide 1.5\~3.0mg once daily on top of amlodipine 5\~10mg once daily.
62521373|NCT01674413|PLACEBO_COMPARATOR|Placebo/Step-Down|1 syringe of placebo SC q 2 weeks.
62521374|NCT01674413|ACTIVE_COMPARATOR|PRNLOAD Arm|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38)
62521375|NCT01674413|ACTIVE_COMPARATOR|Maintenance Arm|Adalimumab 40 mg q 2 weeks.
62521376|NCT00433316|EXPERIMENTAL|study|Receiving 10ml of 1% ropivacaine
62521377|NCT00433316|PLACEBO_COMPARATOR|Control|Receiving 10ml of saline
62521378|NCT05367414|EXPERIMENTAL|aromatherapy|In addition to routine medical treatment, massage with diluted tea tree oil was applied to the individuals in this group.
62521379|NCT05367414|PLACEBO_COMPARATOR|placebo|Individuals in this group were provided massage with sweet almond oil in addition to routine medical treatment.
62149790|NCT01411657|EXPERIMENTAL|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye
62149791|NCT01967394|EXPERIMENTAL|Intervention County|Use of internet based social marketing intervention
62521380|NCT05367414|NO_INTERVENTION|control|Individuals in this group received only routine medical treatment.
62149792|NCT01967394|PLACEBO_COMPARATOR|Control County|No use of social media
62521381|NCT02599259|EXPERIMENTAL|1. Monitored (M+)|Group receiving treatment as usual (TAU) and using the AiCure platform for monitoring and intervention platform on a mobile device being tested when taking their daily anticoagulation medication.
62521382|NCT02599259|NO_INTERVENTION|Unmonitored (M-)|No Intervention. Group receiving TAU and not issued mobile device with the AiCure platform.
62521383|NCT05461118|EXPERIMENTAL|Treatment group|Consented subjects will undergo osteotomies for their resective and reconstructive procedures using mixed reality adjuncts (Magic Leap ®, Microsoft Hololens ®) to commercially available navigation platforms (BrainLAB ®).
61975147|NCT01716351|EXPERIMENTAL|Adapted Yoga Intervention Group|Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.
61975148|NCT01716351|NO_INTERVENTION|Control|Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.
62521384|NCT03907800|EXPERIMENTAL|Nab-paclitaxel + Carboplatin ± Herceptin|
62521385|NCT04764955|PLACEBO_COMPARATOR|Group A (Placebo)|Prenatal Period 0 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
61975149|NCT01991028|EXPERIMENTAL|Radiolabelled OligoG CF-5/20 DPI|Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
61975150|NCT01991028|ACTIVE_COMPARATOR|Radiolabelled OligoG CF-5/20 6% Solution|Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
62521386|NCT04764955|EXPERIMENTAL|Group B (4200:0 IU/week)|Prenatal Period 4200 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
61975151|NCT02826707|EXPERIMENTAL|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
62521387|NCT04764955|EXPERIMENTAL|16800:0 IU/week|Prenatal Period 16800 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
62521388|NCT04764955|EXPERIMENTAL|28000:0 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
62521389|NCT04764955|EXPERIMENTAL|28000:28000 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 28000 IU/week (delivery-6 months postpartum)
62521390|NCT01957228|EXPERIMENTAL|bone biopsies|
62521391|NCT02099604|EXPERIMENTAL|Vitamin D|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
62149793|NCT02630186|EXPERIMENTAL|Single Arm Rociletinib and MPDL3280A|Specific doses of rociletinib, taken continuously BID, will be administered in combination with a fixed dose of MPDL3280A, given intravenously on Day 1 of each 21-day cycle.
62149794|NCT05421572||Single Group Assignment|Adults with health check-ups at multiple health examination centers across China
62149795|NCT00590759|OTHER|GORE TAG® Thoracic Endoprosthesis|
62149796|NCT02817386||POD and Non-POD;|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The assessment of post deliriu (POD) was performed once per day between 8:00 AM to 10:00 AM. Patient notes were not reviewed for episodes of delirium which could occur outside the time of assessment. The clinical research assistants who performed the delirium assessments in this study had good training and went through quality control procedures. We used state-of-the-art delirium detection methods, which tend to report a higher incidence of delirium. The interview included the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS).
62521392|NCT02099604|NO_INTERVENTION|Standard of Care|Pegylated Interferon Alpha 2b + Ribavirin
62521393|NCT02516410|EXPERIMENTAL|VX-661/IVA|VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
62521394|NCT02516410|PLACEBO_COMPARATOR|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
61975152|NCT02826707|NO_INTERVENTION|Control group|Pragmatic no-contact control group
62521395|NCT05278572|EXPERIMENTAL|Group|Intervention consists of a psychotherapy trial using cognitive-behavioral stress management/expressive supportive therapy to target depression among HIV-positive older women. Dosage: 8 sessions. Frequency: weekly. Duration: 8 weeks.
62521396|NCT05518266|ACTIVE_COMPARATOR|US-guided post-incisional PIFB|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of the sternum after skin closure under ultrasound guidance
62521397|NCT05518266|ACTIVE_COMPARATOR|Surgeon-delivered post-incisional parasternal block|Just before wiring the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
62521398|NCT00569413||1|Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
62149797|NCT03507179|PLACEBO_COMPARATOR|conventional dentures|a complete denture made through conventional processing technique
61975153|NCT04867850|ACTIVE_COMPARATOR|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice. Usual care for clinicians includes a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm.
61975154|NCT04867850|EXPERIMENTAL|Clinician Nudge|Clinicians receive a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm as well as performance feedback compared to peers.
61975155|NCT04867850|EXPERIMENTAL|Patient Nudge|Patients receive a nudge consisting of a normalizing message prompting patients to complete an electronic questionnaire designed to prime patients towards having an SIC.
62149798|NCT03507179|ACTIVE_COMPARATOR|3d printed dentures|a complete denture made through 3D printing
61975156|NCT04867850|EXPERIMENTAL|Clinician and Patient Nudge|Both strategies described above will be used.
61975157|NCT02118389|EXPERIMENTAL|Glucerna,Meal Replacement|Glucerna 52g instead of night meal 5weeks
61975158|NCT06504758|EXPERIMENTAL|Study Group|12 young adults patients diagnosed with asthma.
62521399|NCT00569413||2|20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
62521400|NCT05974917||Group 1|with 'Serious Game' to support the asthma treatment plan
62521401|NCT05974917||Group 2|without 'Serious Game' and will follow the standard treatment plan
62521402|NCT03344926|EXPERIMENTAL|ACTsmart|ACT treatment via a smart phone application
62149799|NCT02196610||HEALTHY SUBJECTS group|A group of 20 healthy staff volunteers identified from the Division of Nephrology, Dept. of Medicine and the Kidney Research Centre at the Ottawa Hospital Research Institute will be invited to participate. Measurements of arterial stiffness will be performed by Applanation tonometry. Healthy status will be defined by a self-reporting questionnaire obtained over the phone prior to enrolment and 2 subsequent non-invasive measurements of arterial blood pressure (BP) prior to testing. Subjects will be included if diastolic BP is ≤ 90 mm Hg and systolic BP ≤ 140 mm Hg on 2 consecutive measurements.
62521403|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
62521404|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
62711505|NCT06718686|PLACEBO_COMPARATOR|Placebo|Patients will be given placebo and actual drug sequentially with the order hidden
62711506|NCT06718686|EXPERIMENTAL|Rifaximin SSD 40mg IR BID|Patients will be given placebo and actual drug sequentially with the order hidden
62711507|NCT03773809|PLACEBO_COMPARATOR|Group A0|Vitamin D3 deficient ACO patients with placebo at day 0.
62711508|NCT03773809|PLACEBO_COMPARATOR|Group A90|Vitamin D3 deficient ACO patients with placebo at day 90.
62149800|NCT02196610||END-STAGE RENAL DISEASE (ESRD) group|A group of 20 patients with stage 5 Chronic Kidney Disease (estimated glomerular filtration rate \<15 ml/min/m2), who attend chronic hemodialysis treatments at The Ottawa Hospital (TOH) will be invited to participate. Measurements of arterial stiffness will be performed in this group by Applanation tonometry.
62149801|NCT04463004|ACTIVE_COMPARATOR|Intervention|Treatment infusion
62711509|NCT03773809|ACTIVE_COMPARATOR|Group B0|Vitamin D3 deficient ACO patients with vitamin D3 at day 0.
62149802|NCT04463004|PLACEBO_COMPARATOR|Control|Placebo infusion
62149803|NCT01763307|EXPERIMENTAL|RECONVAL CREAM|half face treated with RECONVAL CREAM
62357322|NCT04322162|EXPERIMENTAL|Active implementation - Wave 3 (Fifth and Sixth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites. Active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves two phases at each of the 6 sites: a variable number of 7-month data periods during baseline period (three 7-month periods for Wave 1 sites, four 7-month data periods for Wave 2 sites, five 7-month data periods for Wave 3 sites), three 7-month data periods in active implementation phase for each wave. Wave 1 and Wave 2 sites will also each have one 7-month period of sustainability. The stepped-wedge design allows for 6 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 21 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on six different cross-sectional samples. Investigators will have repeated information on each site. Arm 3 corresponds to Wave 3."
62521405|NCT01138826|ACTIVE_COMPARATOR|treatment A - reference w/ water|
62521406|NCT01138826|EXPERIMENTAL|Treatment B - ODT (test) w/ water|
62521407|NCT01138826|EXPERIMENTAL|Treatment C - ODT (test) w/o water|
62711510|NCT03773809|ACTIVE_COMPARATOR|Group B90|Vitamin D3 deficient ACO patients with vitamin D3 at day 90.
62521408|NCT05649735|EXPERIMENTAL|GROUP A- LOGUSGYN/CANDIDEP vaginal ovules,|At baseline, eligible and PAP test negative patients were randomly assigned to receive LOGUSGYN/CANDIDEP vaginal ovules treatment for 10 consecutive days.
62521409|NCT05649735|EXPERIMENTAL|GROUP B- LOGUSGYN/CANDIDEP lavander|At baseline, eligible and PAP test negative patients were randomly assigned to receive LOGUSGYN/CANDIDEP lavender treatment for 10 consecutive days.
62521410|NCT05649735|PLACEBO_COMPARATOR|GROUP C- vaginal irrigation with sterile saline AELAV PURLING|At the baseline visit, eligible and PAP test negative patients were randomly assigned to receive the vaginal irrigation with sterile saline AELAV PURLING treatment for 10 consecutive days.
62149804|NCT01763307|PLACEBO_COMPARATOR|PLACEBO|half face treated with PLACEBO cream
62149805|NCT05396885|EXPERIMENTAL|anitocabtagene-autoleucel|Single dose of 115±10 x 10e-6 CAR+ anitocabtagene-autoleucel cells infused intravenously
62149806|NCT04842006|EXPERIMENTAL|TNT + precision|
62149807|NCT04842006|ACTIVE_COMPARATOR|Conventional|
62149808|NCT00971555||Late preterm|Late preterm infants admitted to the NICU
62711511|NCT01295710|ACTIVE_COMPARATOR|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
62711512|NCT01295710|PLACEBO_COMPARATOR|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
62711513|NCT01034722||Western Diet|Volunteer mothers with western diet.
62711514|NCT01034722||Vegetarians|volunteer mothers with vegetarians diet
62711515|NCT01034722||Bedouins|Volunteer mothers who are Bedouins
62711516|NCT03166748|ACTIVE_COMPARATOR|MTA pulpotomy|mineral trioxide aggregates (MTA) is accepted as an optimum material for use in vital pulp therapy of permanent teeth
62711517|NCT03166748|EXPERIMENTAL|Potassium Nitrate in Polycarboxylate cement|Potassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol \[ZOE\]) It reduced pain following full crown preparation.
62149809|NCT05749120|EXPERIMENTAL|Superficial temporal recipient vessels (group A)|Participants in whom superficial temporal vessels were used as the recipient vessels.
62149810|NCT05749120|ACTIVE_COMPARATOR|Cervical recipient vessels (group B)|Participants in whom cervical vessels were used as the recipient vessels.
62149811|NCT04949113|EXPERIMENTAL|A: Neoadjuvant|"2 cycles of neoadjuvant ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by a total lymph node dissection (TLND) and if applicable, resection of in-transit metastases.~Patients with a pathologic partial or non-response in arm A will also receive adjuvant nivolumab 480 mg every 4 weeks 11 cycles. In case of BRAF V600E/K mutation-positivity, patients will be treated with adjuvant dabrafenib plus trametinib for 46 weeks instead."
62149812|NCT04949113|ACTIVE_COMPARATOR|B: Adjuvant|Standard upfront total lymph node dissection (TLND) and if applicable, resection of in-transit metastases followed by 12 cycles adjuvant nivolumab 480 mg every 4 weeks
62149813|NCT02944981|EXPERIMENTAL|Gabapentin|Patient receiving oral gabapentin 600 mg preoperatively
62149814|NCT02944981|PLACEBO_COMPARATOR|Placebo|Patient receiving oral placebo tablet preoperatively
62149815|NCT01858688|EXPERIMENTAL|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
62149816|NCT06306937||Periodontitis|Individuals diagnosed with periodontitis based on established clinical criteria. This group will include participants who exhibit signs and symptoms of periodontal disease, such as probing depth, clinical attachment loss, and bleeding on probing.
62357323|NCT05242978|EXPERIMENTAL|Impact of GT, coffee, OJ, PGJ, milk, SSB on exercise induced oxidative stress&inflammation|single consumption of one cup of green tea (GT), coffee, orange juice (OJ), pomegranate juice (PGJ), milk and sugar sweetened beverage (SSB) 2 hours prior to a 30-min- HIIT resistance circuit exercise in healthy human subjects
62357324|NCT05242978|EXPERIMENTAL|Impact of choc, bcc, fl-oil, blueb., r&w bread on exercise induced oxidative stress&inflammation|single consumption of one proportion of dark chocolate (choc), broccoli (bcc), flaxseed oil, blueberries, white bread and whole grain bread (r = refined \& w = whole grain) 2 hours prior to a 30-min-HIIT resistance circuit exercise in healthy human subjects
62357325|NCT05242978|EXPERIMENTAL|Impact of r&p meat, cheese, eggs, tofu, salmon, on exercise induced oxidative stress&inflammation|single consumption of one proportion of red meat (r meat), full fat cheese, eggs, tofu, salmon and processed meat (p meat) 2 hours prior to a 30-min- HIIT resistance circuit exercise in healthy human subjects
62357326|NCT03217201|EXPERIMENTAL|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
62357327|NCT03217201|ACTIVE_COMPARATOR|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
62357328|NCT03217201|EXPERIMENTAL|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
62357329|NCT03217201|ACTIVE_COMPARATOR|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
62357330|NCT05453006|EXPERIMENTAL|Intervention|At the three intervention clinics, clinic providers or staff will offer women the option to perform HPV self-sampling as an alternative to cervical cancer screening by a clinician.
62357331|NCT05453006|NO_INTERVENTION|Control|Control clinics will have passive participation and their only involvement will be that data will be pulled from these clinics. Women in the control clinics will be offered usual care cervical cancer screening by a clinician. The research team will not have any contact with women in the control clinics.
62357332|NCT05633680||Breast cancer group|Breast cancer is finally determined through breast puncture biopsy or excisional tissue biopsy and sent for pathological diagnosis
62357333|NCT05633680||Non-breast cancer group|By breast puncture biopsy or excisional tissue biopsy and sent to pathology for final determination of benign tumor. and healthy women
62357334|NCT05484427|EXPERIMENTAL|Telemedicine arm|Participants in this arm will be follow up by telemedicine control (via emails) instead of regular controls. They will upload the data from their devices (pump, CGM) to cloud system on their own. All instructions what to change they will recive by email only.
62357335|NCT05484427|NO_INTERVENTION|Outpatient clinic meetings arm|Participants in this arm will normally come for the regular meetings with their diabetologist to the outpatient clinic.
62357336|NCT03926338|EXPERIMENTAL|Neoadjuvant treatment with PD-1 blockade plus COX-2 inhibitor|Toripalimab plus celecoxib
62357337|NCT03926338|EXPERIMENTAL|Neoadjuvant treatment with PD-1 blockade|Toripalimab monotherapy
62357338|NCT04355026|EXPERIMENTAL|hydroxychloroquine and bromhexine|Bromhexine 16 mg TID + hydroxychloroquine 200 mg BID
61975159|NCT01250262|ACTIVE_COMPARATOR|Standard care|Subjects will receive normal medical care and follow up during the four month study period if assigned to this group.
62149817|NCT06306937||Control|Individuals without any signs or history of periodontal disease. This group will consist of participants who do not have clinically diagnosed periodontitis and serve as the healthy control group for comparison with the periodontitis group.
62149818|NCT03137849|ACTIVE_COMPARATOR|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
62357339|NCT04355026|ACTIVE_COMPARATOR|hydroxychloroquine alone|hydroxychloroquine 200 mg BID
62357340|NCT05371938|EXPERIMENTAL|Volar Locking Plate|Surgery with volar locking plate
62357341|NCT05371938|ACTIVE_COMPARATOR|External fixation|Surgery with external fixation
62357342|NCT05186012|EXPERIMENTAL|Arm A (Single agent)|
62357343|NCT05186012|EXPERIMENTAL|Arm B (combo)|
62521411|NCT05649735|EXPERIMENTAL|GROUP D- Patients pap test positive|Patients eligible at baseline and PAP test positive will be assigned to GROUP D and treated for 10 days with sterile saline-based vaginal irrigation (Placebo/control group) AELAV PURLING- Subsequently after the initial 10-day treatment they will be randomised into two further groups, E and F, and treated for 30 days with: GROUP E- LOGUSGYN/CANDIDEP vaginal ova, GROUP F- LOGUSGYN/CANDIDEP vaginal ova, + LOGUSGYN/CANDIDEP lavage, and treated for 30 days with: GROUP E- LOGUSGYN/CANDIDEP vaginal ova, GROUP F- LOGUSGYN/CANDIDEP vaginal ova, + LOGUSGYN/CANDIDEP douche
61975160|NCT01250262|ACTIVE_COMPARATOR|Isolated Lumbar Resistance Exercise Program|Lumbar extension exercise protocol to increase strength and reduce pain.
61975161|NCT01250262|ACTIVE_COMPARATOR|Total Body Resistance Exercise Program|Training protocol for 1 set for each exercise: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl
62711518|NCT05899829|EXPERIMENTAL|Part 1: Camlipixant 50 mg + Rifampin 600 mg|Participants will receive a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There will be a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.
62149819|NCT03137849|ACTIVE_COMPARATOR|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
62149820|NCT03137849|ACTIVE_COMPARATOR|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
62357344|NCT03824535|EXPERIMENTAL|Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)|Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
62357345|NCT01400074|ACTIVE_COMPARATOR|Nilotinib|400 mg twice daily
62357346|NCT01400074|ACTIVE_COMPARATOR|Imatinib|400 mg twice daily
62357347|NCT01924962|NO_INTERVENTION|medical therapy|patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
62357348|NCT01924962|ACTIVE_COMPARATOR|revascularisation|revascularisation and stent-implantation of chronic occluded coronary artery
62357349|NCT04114344|ACTIVE_COMPARATOR|TAPP (Trans Abdominal PrePeritoneal)|Trans Abdominal PrePeritoneal approach to inguinal hernia repair
62357350|NCT04114344|EXPERIMENTAL|TEP (Totally Extra Peritoneal)|Totally Extra Peritoneal approach to inguinal hernia repair
62357351|NCT01917708|EXPERIMENTAL|Abatacept|4 doses of abatacept 10 mg/kg/dose will be given on days -1, +5, +14, and +28.
62357352|NCT01807767|EXPERIMENTAL|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
62357353|NCT01807767|OTHER|Myfortic and Tacrolimus|Normal Care: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
62357354|NCT06185608|EXPERIMENTAL|0.25% ropivacaine group|This group will receive a total of 15 mL of 0.25% ropivacaine.
62357355|NCT06185608|ACTIVE_COMPARATOR|0.5% ropivacaine group|This group will receive a total of 15 mL of 0.5% ropivacaine.
62357356|NCT06185608|EXPERIMENTAL|1% ropivacaine group|This group will receive a total of 15 mL of 1% ropivacaine.
62357357|NCT02361619|EXPERIMENTAL|1|
62357358|NCT02567357|ACTIVE_COMPARATOR|Visual Scheduling|A caregiver training package on the use of a pictorial (visual) schedule to illustrate each day's expected activities to a child. Caregivers will be trained to ensure that activities occur as described in the schedule as far as possible, thus the expected mechanism of action is the reduction of (unexpected change) antecedents of children's temper outbursts.
62357359|NCT02567357|EXPERIMENTAL|Signalling change|A caregiver training package where parents are taught to present a distinctive visual-verbal cue to a child whenever they become aware that a change will take place in the child's usual/expected activities. Caregivers will be trained to only ever present to cue if they can be sure that a change to the child's routine or plan will occur, thus the expected mechanism of action is the child's learned association between the presentation of the cue and the subsequent occurrence of a change to their expectations. Signalled changes will therefore be more predictable for the child, and should therefore be easier for them to deal with.
62357360|NCT05376527|EXPERIMENTAL|VV-GMCSF-Lact|Double Recombinant Vaccinia Virus VV-GMCSF-Lact
62357361|NCT03870009|EXPERIMENTAL|ARDS patients|All the patients will be evaluated with the same procedure, as the study relates to evaluation of the diagnostic performance of a semi-automated method to detect cyclic hyperinflation on CT scan
62357362|NCT04612803||IBS-D + dermatographism|IBS-D patients with dermatographism. Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
62357363|NCT01999907|PLACEBO_COMPARATOR|Placebo|bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
62521412|NCT01829113|EXPERIMENTAL|OGX-427|Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
61975162|NCT03898050|EXPERIMENTAL|A-P|Anterior - Posterior pad placement
62149821|NCT03137849|ACTIVE_COMPARATOR|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
62149822|NCT04226118|NO_INTERVENTION|Control Group|Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
62149823|NCT04226118|EXPERIMENTAL|Experimental Group|Patients who have a peripheral venous access by a procedure using a Vein Illumination System.
62149824|NCT04738149|EXPERIMENTAL|Area 1: Excimer laser, bimatoprost, and microneedling|
62149825|NCT04738149|ACTIVE_COMPARATOR|Area 2: Excimer laser|
62149826|NCT05020067|EXPERIMENTAL|SPLS-IMRT|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%
62521413|NCT01829113|PLACEBO_COMPARATOR|Placebo|Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
62149827|NCT05020067|NO_INTERVENTION|C-IMRT|The entire parotid gland was delineated as an OAR, and V36 (the percentage volume receiving 36 Gy or more) in the entire parotid gland was constrained to be less than 40%
62149828|NCT01137682|EXPERIMENTAL|Pasireotide LAR 40 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
62149829|NCT01137682|EXPERIMENTAL|Pasireotide LAR 60 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
62149830|NCT01137682|ACTIVE_COMPARATOR|Control arm (octreotide or lanreotide)|"If a patient is randomized to the open label arm the investigator will either:~* be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or~* continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations."
62521414|NCT04293978|EXPERIMENTAL|Virtual Reality relaxation|Participants may request to use the application at any time during their stay at the ward, as many times as they wish. Participants sign in using an anonymous study ID and sessions (and outcomes) are automatically logged by the device to this ID.
61975163|NCT03898050|EXPERIMENTAL|A-L|Anterior - Lateral pad placement
62149831|NCT05146635|ACTIVE_COMPARATOR|Intravesical immunotherapy (BCG) group|
62521415|NCT06186102|ACTIVE_COMPARATOR|Spermidine|Spermidine will be given orally as capsules of cellulose with spermidine (24 mg/day) and rice flour.
62149832|NCT05146635|ACTIVE_COMPARATOR|Intravesical chemotherapy (Epirubicin) group|
62149833|NCT05729386|EXPERIMENTAL|GC2129A + Reference drugs|Period 1: GC2129A, Period 2: Individual Components
62149834|NCT05729386|EXPERIMENTAL|Reference drugs + GC2129A|Period 1: Individual Components, Period 2: GC2129A
62521416|NCT06186102|PLACEBO_COMPARATOR|Placebo|Placebo will be given orally as capsules of cellulose and rice flour (same size and visual appearance as spermidine capsules)
62711519|NCT05899829|EXPERIMENTAL|Part 2: Camlipixant 50 mg + Rabeprazole 20 mg|Participants will receive a single oral dose of camlipixant 50 mg tablet on Day 1, followed by repeat oral doses of 20 mg rabeprazole enteric-coated tablets, once daily (QD) from Days 4 to 11, with co-administration of a single oral dose of 50 mg camlipixant tablet with rabeprazole enteric-coated tablet on Day 10. There will be a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rabeprazole on Day 4
62149835|NCT06149299|PLACEBO_COMPARATOR|interfascial plane group|injection into inferfascial plane
62149836|NCT06149299|EXPERIMENTAL|intramuscular group|injection into obliqus capitis inferior muscle
62357364|NCT01999907|ACTIVE_COMPARATOR|Vitamin D|Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
62357365|NCT01009918|EXPERIMENTAL|Arm I lisinopril|Patients receive oral lisinopril once daily.
62357366|NCT01009918|EXPERIMENTAL|Arm II Coreg CR®|Patients receive oral Coreg CR® once daily.
61975164|NCT05432414|EXPERIMENTAL|Pomalidomide, Bortezomib and Dexamethasone (PVD)|Each cycle is 21 days, after 2 cycles, patients who reached MR continued treatment for 2 cycles, 4 cycles in total. Subsequent treatment regimens after 4 cycles of induction therapy were determined by the investigator.
61975165|NCT05432414|ACTIVE_COMPARATOR|Bortezomib and Dexamethasone (VD)|Each cycle is 21 days, after 2 cycles, patients who reached MR continued treatment for 2 cycles, 4 cycles in total. Subsequent treatment regimens after 4 cycles of induction therapy were determined by the investigator.
62149837|NCT00641537|PLACEBO_COMPARATOR|Cladribine Low/Placebo (LLPP)|
62149838|NCT00641537|PLACEBO_COMPARATOR|Cladribine High Dose/Placebo (HLPP)|
62149839|NCT00641537|EXPERIMENTAL|Cladribine Low/Low Dose (LLLL)|
62149840|NCT00641537|EXPERIMENTAL|Cladribine High/Low Dose (HLLL)|
62149841|NCT00641537|EXPERIMENTAL|Placebo/Cladribine Low Dose (PPLL)|
62149842|NCT00641537|NO_INTERVENTION|Placebo/No Treatment|
62149843|NCT00641537|NO_INTERVENTION|Cladribine 3.5 mg/kg/No Treatment|Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
62149844|NCT00641537|NO_INTERVENTION|Cladribine 5.25 mg/kg/No Treatment|Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
62357367|NCT01009918|PLACEBO_COMPARATOR|Arm III placebo|Patients receive oral placebo once daily.
62149845|NCT03977805|EXPERIMENTAL|Hetrombopag Olamine|Hetrombopag Olamine (5 mg, 100 uCi)
62149846|NCT04265235|EXPERIMENTAL|Home-based Exercise Program|12-weeks, remotely monitored home-based exercise program consisting or aerobic and resistance exercise
62149847|NCT04704856|ACTIVE_COMPARATOR|Interventiongroup|Interventiongroup, undergo supervised exercise for the first 6 weeks.
62149848|NCT04704856|NO_INTERVENTION|Controlgroup|Controlgroup, do not undergo supervised exercise for the first 6 weeks (possibility to undergo supervised exercise after 6 weeks).
62521417|NCT03507478|EXPERIMENTAL|BPI1000013|Subjects suffering from pain associated with plantar fasciitis or general heel pain
62521418|NCT01631513|EXPERIMENTAL|Nucynta ER|Nucynta ER will be 100 to 250 mg every 12 hours
62521419|NCT04968860||Study group|Composed of children/adolescent individuals who have a definitive diagnosis of lymphoid leukemia or acute myeloid leukemia, who will be invited to participate in the research, regardless of race or gender.
62521420|NCT04968860||Control group|The control group is going to consist of healthy children/adolescent individuals, non-syndromic, without history of cancer, matched by age and gender in relation to the study group, who have not used antibiotics 48 hours before or in the day of evaluation.
62521421|NCT05732896|NO_INTERVENTION|control group|standard care group
62521422|NCT05732896|ACTIVE_COMPARATOR|study group|NOL guided group
62711520|NCT02543775|EXPERIMENTAL|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
62711521|NCT05547672|EXPERIMENTAL|UroMems artificial urinary sphincter|"Male adults (18+) with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency.~Intervention: device (UroMems artificial urinary sphincter)"
62711522|NCT01480778|EXPERIMENTAL|LNG+EE2|pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
62149849|NCT05862402|EXPERIMENTAL|Intervention group|Dose antibiotics adjusted by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
62149850|NCT05862402|NO_INTERVENTION|Control group|Dose antibiotics from standard care
62149851|NCT01581099||Clinical treatment|Diabetic individuals refractory to medical treatment kept under clinical treatment guidelines and lifestyle
62149852|NCT01581099||Surgery|Diabetic individuals refractory to conservative clinical treatment subject to Digestive Adaptations III Surgery.
62149853|NCT01581099||Control|Healthy individuals (normal weight and no cardiovascular risk factors) will be used to evaluate the behavior incretin hormones in healthy individuals, serving as a benchmark to analyze the results obtained in other groups.
62149854|NCT05888844|EXPERIMENTAL|Part 1: INCB099280 Dose 1|Participants will receive INCB099280 dose 1 twice daily (BID) for up to 2 years.
62149855|NCT05888844|EXPERIMENTAL|Part 1: INCB099280 Dose 2|Participants will receive INCB099280 dose 2 twice daily (BID) for up to 2 years.
62711523|NCT01480778|ACTIVE_COMPARATOR|Nordette|pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
62711524|NCT03549520|EXPERIMENTAL|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of the contrast agent.
62711525|NCT03781414|ACTIVE_COMPARATOR|TAC Control|Tacrolimus (TAC) + Mycophenolate mofetil (MMF) + Corticosteroids (CS) up to End of Study (EOS). Initial TAC target trough were between 5-15 ng/mL during the run-in period. From randomization onwards, the TAC levels were adjusted as per local label.
62711526|NCT03781414|EXPERIMENTAL|CFZ533 600 mg regimen|Loading doses of 30 mg/kg IV on Day 8 (with +/- 2 days window), and 15 mg/kg IV on Day 15. The subcutaneous (SC) administration of 600 mg (2 injections of 2 mL CFZ533 at 150 mg/mL) every 2 weeks started on Day 29, in combination with MMF and CS up to EOS.
62711527|NCT03781414|EXPERIMENTAL|CFZ533 300 mg regimen|Single loading dose of 30 mg/kg IV on Day 8 (with +/- 2 days window). The SC administration of 300 mg (1 injection of 2 mL CFZ533 at 150 mg/mL) every 2 weeks started on Day 29, in combination with MMF and CS up to EOS.
62711528|NCT05384314||COPD|Patients admitted with COPD as the primary admission.
62149856|NCT05888844|EXPERIMENTAL|Part 1: INCB099280 Dose 3|Participants will receive INCB099280 dose 3 twice daily (BID) for up to 2 years.
62149857|NCT05888844|EXPERIMENTAL|Part 2: INCB099280 Dose selected from Part 1|Participants will receive INCB099280 dose selected from Part 1 twice daily (BID) for up to 2 years.
62149858|NCT00668057|EXPERIMENTAL|Arm 1|
62711529|NCT05384314||Respiratory Compromised General|Patients admitted with Pneumonia, COPD, COVID, to be included
62149859|NCT00668057|EXPERIMENTAL|Arm 2|
62149860|NCT00668057|EXPERIMENTAL|Arm 3|
62149861|NCT00668057|PLACEBO_COMPARATOR|Arm 4|
62357368|NCT02427100|NO_INTERVENTION|Control Group|Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
62357369|NCT02427100|ACTIVE_COMPARATOR|Intervention Group|Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.
62357370|NCT01040845|EXPERIMENTAL|Oral Contraceptive with Colchicine then Placebo|
61975166|NCT05070598|EXPERIMENTAL|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab Q3W d1 Pyrotinib d1-21 Nab-paclitaxel Q3W d1 Tegafur d1-14
61975167|NCT03807869|EXPERIMENTAL|coexisting glaucoma and cataract|Patients with coexisting glaucoma and cataract qualified to combined glaucoma surgery
62149862|NCT00668057|PLACEBO_COMPARATOR|Arm 5|
62149863|NCT00668057|PLACEBO_COMPARATOR|Arm 6|
62149864|NCT04669366||Patients in Sweden with metastatic renal cell carcinoma|The cohort of patients with metastatic renal cell carcinoma in Sweden
62149865|NCT02095145|EXPERIMENTAL|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
62149866|NCT02095145|PLACEBO_COMPARATOR|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
62149867|NCT00110032|EXPERIMENTAL|Group 1 (fluorine F 18 EF5, PET)|Patients receive fluorine F 18 EF5 (\^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
62149868|NCT00110032|EXPERIMENTAL|Group 2 (EF5, PET)|Patients receive nonradioactive EF5 IV over 1-2½ hours followed by \^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
62149869|NCT00110032|EXPERIMENTAL|Group 3 (EF5, PET)|Patients receive nonradioactive EF5 and \^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.
62149870|NCT04775732|EXPERIMENTAL|ultra proactive arm|
62149871|NCT04775732|ACTIVE_COMPARATOR|reactive arm|
62149872|NCT05939505|EXPERIMENTAL|Su Jok Therapy Group|Su jok Therapy According to Sujok therapy, sujok therapy will be applied 14 times with an interval of one day with Mexican bean seeds on the points representing the kidney.
62357371|NCT01040845|PLACEBO_COMPARATOR|Oral Contraceptive with Placebo then Colchicine|
62357372|NCT04630964|EXPERIMENTAL|psilocybin|25 mg Single Oral Dose
61975168|NCT03681392|EXPERIMENTAL|Once daily then twice daily|One 6.5 cc scoop of S4S once a day for 7 days, then one 6.5 cc scoop of S4S twice a day for 7 days
61975169|NCT03681392|EXPERIMENTAL|Twice daily then once daily|One 6.5 cc scoop of S4S twice a day for 7 days, then one 6.5 cc scoop of S4S once a day for 7 days
61975170|NCT02278198|EXPERIMENTAL|Differentiated Thyroid Cancer|"All patients will receive one extra imaging scan with I-123 in addition to their routine care as described above. This research portion of their care will be similar to the scan that they undergo for the I-123 planning scan that is already a part of their routine care. The research study, which will be performed in the middle of the patient's normal standard of care treatment, will take 4 days.~On days 1 and 2, all patients will receive a intramuscular injection of rhTSH (Thyrogen).~On day 3, all patients will be given 3 mCi of I-123 in the form of a pill to take by mouth.~On day 4, all patients will receive a I-123 Whole Body Imaging Scan and a thyroid camera scan of the neck and thigh."
61975171|NCT00479661|EXPERIMENTAL|1|Dexmedetomidine
62357373|NCT04630964|ACTIVE_COMPARATOR|placebo|100 mg Single Oral Dose
62357374|NCT03287869|EXPERIMENTAL|Brexpiprazole|Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
62711530|NCT06639633|OTHER|3D Printed Model Group Enlarged %100|carpal bone models printed on a 3D resin printer and enlarged by 100% will be used for students' anatomy practical training. Each student will examine the models with direct manipulation for 15 minutes after the theoretical lecture.
62711531|NCT06639633|OTHER|3D Printed Model Group Enlarged %50|carpal bone models printed on a 3D resin printer and enlarged by 50% will be used for students' anatomy practical training. Each student will examine the models with direct manipulation for 15 minutes after the theoretical lecture.
62711532|NCT06639633|ACTIVE_COMPARATOR|Control Group|Standard carpal bone models will be used for student's anatomical practical training. Each student will examine the models with direct manipulation for 15 minutes after the theoretical lecture.
62357375|NCT06300346|ACTIVE_COMPARATOR|propofol|30 Patients will receive propofol as equal volumes of both 1% of propofol 10mg/ml and0.9% normal saline will be drawn in a 20-ml syringe before spinal puncture.
62357376|NCT06300346|ACTIVE_COMPARATOR|pregabalin|30 Patients will receive three capsules of pregabalin 100 mg once one hour before the surgical incision.
62357377|NCT06300346|ACTIVE_COMPARATOR|ondansetron|30 Patients will receive 4 mg ondansetron in 10 ml saline intravenously 5 min before spinal puncture.
62357378|NCT03115788|ACTIVE_COMPARATOR|No Intervention Game play|The person will be instructed how to hold the iPad and how to play the game.
62357379|NCT03115788|EXPERIMENTAL|Thermal pain and ipad performance|Interventions: Cold induced pain and heat induced pain. The whole group gets thermal heat (n=40) and half (n=20) get cold water foot immersion and half (n=20) get body temperature foot emersion. The person will be instructed how to hold the iPad and how to play the game. The person will then be allowed to play the game until the number of trials is completed or until the person no longer wishes to play.
62357380|NCT01522443|EXPERIMENTAL|Cabozantinib|"Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.~There will be a maximum of 10 infusions for mitoxantrone placebo."
62357381|NCT01522443|ACTIVE_COMPARATOR|Mitoxantrone/prednisone|"Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.~There will be a maximum of 10 infusions for mitoxantrone."
62357382|NCT04376515|EXPERIMENTAL|HOPE Intervention|HOPE peer-led intervention
62357383|NCT04376515|NO_INTERVENTION|Control|Control group- online community without peer leaders
61975172|NCT00479661|ACTIVE_COMPARATOR|2|Propofol
62521423|NCT05036395|EXPERIMENTAL|The neonates evaluated by the routine assessment protocol and AI-assisted cEEG Diagnostic tool|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol and AI assisted cEEG diagnostic tool in real time during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
62711533|NCT04325308|EXPERIMENTAL|Protein-enriched human milk diet|Infants in this group will receive protein-enriched expressed human milk or donor human milk during the first 2 weeks after birth.
62711534|NCT04325308|ACTIVE_COMPARATOR|Usual human milk diet|Infants in this group will receive either expressed human milk or donor human milk during the first 2 weeks after birth.
62711535|NCT06707922|NO_INTERVENTION|Cohort 1|Participants who have achieved functional cure at the time of completion of TB1901IFN will be included and followed up for 5 years without any intervention.
62357384|NCT02077946||Liraglutide / Sitagliptin|
62521424|NCT05036395|ACTIVE_COMPARATOR|The neonates evaluated by the routine assessment protocol|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
62521425|NCT00324311|EXPERIMENTAL|DGD|
62521426|NCT00324311|ACTIVE_COMPARATOR|SOC|
62521427|NCT04056975|EXPERIMENTAL|single arm|A-319 dosage: 0.05, 0.15, 0.03, 0.06, 0.12, 0.18, 0.24 μg/kg
62521428|NCT04325152|EXPERIMENTAL|FCSEMS+Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. One to two centimeters of distal end of FCSEMS was left outside of the papilla and the stent was released. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
62521429|NCT04325152|SHAM_COMPARATOR|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
62521430|NCT03998579|EXPERIMENTAL|Individualized exercise|The intervention group get a referral to physiotherapist in Primary Health Care in Stockholm County Council, close to where they live. Within the third week after discharge, the patients begin twelve weeks of biweekly exercise. The physical exercise is individually targeted aerobic and strength exercises, based on international recommendations for persons with cancer disease. The program is approved by resposible surgeons.
62521431|NCT03998579|ACTIVE_COMPARATOR|Active control group|Oral and written information of a home-based exercise programme and information of supportive techniques to improve physical activity
62149873|NCT05939505|PLACEBO_COMPARATOR|placebo group|Instead of the Mexican bean seed used in Sujok therapy, plastic beans will be applied 14 times with an interval of one day.
62149874|NCT05939505|ACTIVE_COMPARATOR|Control group|Routine applications will be made in the Dialysis Unit.
62149875|NCT05574309|SHAM_COMPARATOR|Fallers|population of patients who have fallen from the clinical gerontology department of the CHU of Saint-Etienne and from the PROOF cohort and subjects of the Office Stéphanois pour les Ainés (OSAP)
62521432|NCT01095679|EXPERIMENTAL|Baclofen|
62521433|NCT01095679|PLACEBO_COMPARATOR|Placebo|Placebo
62521434|NCT01899365||Multifaceted|"* brief structured interview with the physician about pneumococcal risk and vaccination,~* information sheet delivered to patients with explanation about risk and benefit of APV,~* letter given to patient for his/her general practitioner stating that the patient is at-risk for pneumococcal infection and could benefit of APV,~* 3 SMS every 2 weeks to remind patients talking of pneumococcal risk with general practitioner."
62711536|NCT06707922|EXPERIMENTAL|Cohort 2|Participants with S antigen decrease≥1log and the S antigen level \<100IU/ml at enrollment, or who with S antigen decrease ≥1.5log and the S antigen level \<1500IU/ml after TB1901IFN treatment, will initially treated with 72-week pulse treatment of peginterferon in combination with TAF, and then followed up to 5 years.
62711537|NCT06707922|NO_INTERVENTION|Cohort 3|Except for those who already enrollment in Cohort 2, Participants with functional cure achievement will enroll in Cohort 3, and follow-up for 5 years without any study intervention.
62711538|NCT06120244||Healthy Volunteers|Healthy volunteers aged 18 years and older
62711539|NCT01912235|ACTIVE_COMPARATOR|Test Study 1: 2-15N glutamine|To determine the contributions make by glutamine to the provision of nitrogen for ornithine, citrulline and arginine syntesis in adults.
62711540|NCT01912235|ACTIVE_COMPARATOR|Test Study 2: 15N2 arginine &15N proline|administration of 15N2 arginine \&15N proline to measure arginine and proline flux
62711541|NCT01912235|ACTIVE_COMPARATOR|Study Test 3: 1-13C glutamine|to determine to contribution of glutamine to the carbon skeleton of ornithine, citrulline and arginine in adults.
62711542|NCT04594746|EXPERIMENTAL|Oral Amiodarone|Amiodarone hydrochloride 2000 mg
62711543|NCT04594746|PLACEBO_COMPARATOR|Placebo|Oral placebo
62149876|NCT05574309|OTHER|non fallers|population of patients who did not fall from the clinical gerontology department of the CHU of Saint-Etienne and from the PROOF cohort and subjects of the Office Stéphanois pour les Ainés (OSAP)
62149877|NCT05878106|NO_INTERVENTION|Control Group|They receive physical activity and nutrition recommendations.
62149878|NCT05878106|EXPERIMENTAL|Resistance training group|They will perform resistance training and placebo in the supplementation.
62149879|NCT05878106|EXPERIMENTAL|Resistance training and creatine supplementation group|They will perform the same resistance training and will also receive creatine supplementation
62149880|NCT02471872|EXPERIMENTAL|Air Pollution Education|Students are presented with a one-hour interactive information session about air pollution and the environment.
62711544|NCT05111756||Unit A|Staff at first phase units, receiving Braining, physical exercise
62711545|NCT05111756||Unit B|Staff at second phase units, receiving Braining, physical exercise
62711546|NCT05027828||patients using olaparib only|
62711547|NCT05027828||patients using olaparib combined with bevacizumab|
62711548|NCT01137890|EXPERIMENTAL|Zonisamide|Participants administered blind capsules containing either placebo or zonisamide.
62711549|NCT01137890|PLACEBO_COMPARATOR|Placebo|Participants administered only placebo capsules containing lactose.
62711550|NCT04946630|EXPERIMENTAL|Seretide Evohaler forte according to SmPc|Single dose inhalation of fluticasone propionate/salmeterol 250 µg/25 µg administered via the Evohaler in accordance with instruction in the SmPC for Seretide Evohaler forte.
62149881|NCT02471872|PLACEBO_COMPARATOR|Non-Air Pollution Education|Students are presented with a one-hour interactive information session about vaccines.
62149882|NCT05673109|EXPERIMENTAL|AC176|Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
62149883|NCT01670877|EXPERIMENTAL|Part I: Neratinib Only|-Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62149884|NCT01670877|EXPERIMENTAL|Part II: Neratinib Only (ER-)|-Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62521435|NCT01899365||Control|"* information sheet delivered to patients with explanation about the aim of the study,~* brief interview with the physician about study."
62521436|NCT03592342|PLACEBO_COMPARATOR|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
62521437|NCT03592342|EXPERIMENTAL|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
62521438|NCT03592342|EXPERIMENTAL|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
62521439|NCT03592342|EXPERIMENTAL|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
62521440|NCT03520868||Coumadin|Coumadin patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 70 U/kg
62521441|NCT03520868||Dabigatran|Dabigatran patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
62521442|NCT03520868||Rivaroxiban|Rivaroxiban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
62521443|NCT03520868||Apixaban|Apixaban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 10 U/kg
62149885|NCT01670877|EXPERIMENTAL|Part II: Neratinib + Fulvestrant (ER+, fulvestrant-naive)|-Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62149886|NCT01670877|EXPERIMENTAL|Part II: Neratinib + Fulvestrant (ER+. prior fulvestrant-tx)|-Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62711551|NCT04946630|EXPERIMENTAL|Whole lung exposure|Single dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for whole lung exposure. The entire 300 mL aerosol volume produced by the single dose from the inhaler will be inhaled at a flow rate in accordance with instructions for the Evohaler.
62357385|NCT02407314|SHAM_COMPARATOR|Aspirin only|Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
62521444|NCT04335175||Tourette Syndrome|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
62521445|NCT04335175||Obsessive Compulsive Disorder|Individuals previously diagnosed with obsessive compulsive disorder (OCD). Participants must be 18 years of age or older.
62521446|NCT04335175||Healthy Controls|Individuals with no past or current neurologic or psychiatric illness. Participants must be 18 years of age or older.
62149887|NCT01670877|EXPERIMENTAL|Crossover: Neratinib + Trastuzumab|-If a participant experiences disease progression during Part I or Part II following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days. Patients will continue to receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks.
62149888|NCT01670877|EXPERIMENTAL|Crossover: Neratinib + Fulvestrant + Trastuzumab|-If a participant experiences disease progression during Part I or Part II following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days. Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks.
62521447|NCT03407521|ACTIVE_COMPARATOR|study group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once
62711552|NCT04946630|EXPERIMENTAL|Alveolar bolus/ Breath hold exposures|A subdivided dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for six repetitive 70 mL Alveolar bolus/ Breath hold exposures. Each 70 mL bolus will be extracted from a freshly generated volume of 300 mL aerosol produced by actuation of a single dose from the inhaler.
62149889|NCT03020433|ACTIVE_COMPARATOR|rTMS Contralesional M1 Inhibition|
62357386|NCT02407314|EXPERIMENTAL|Aspirin + Ticagrelor|ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
62357387|NCT03990090|EXPERIMENTAL|TG103|Escalating doses of TG103 administered subcutaneously (SC) once in healthy participants.
62357388|NCT03990090|PLACEBO_COMPARATOR|Placebo|Placebo administered SC once in healthy participants.
62357389|NCT03764579|ACTIVE_COMPARATOR|sleep and diet intervention|
62357390|NCT03764579|ACTIVE_COMPARATOR|diet intervention|
62357391|NCT04335708|EXPERIMENTAL|Intervention|Daily consumption of 5 mL of edible gel with intracellular content of Lactobacillus casei CRL-431 during 30-d
62357392|NCT04335708|PLACEBO_COMPARATOR|Placebo|Daily consumption of 5 mL of edible gel without intracellular content of Lactobacillus casei CRL-431 during 30-d
62357393|NCT06308146|EXPERIMENTAL|Probiotic, Bacillus subtilis|Bacillus subtilis ATCC 122264; One capsule per day with a larger meal; providing 5 billion CFU for 8 weeks.
62357394|NCT06308146|PLACEBO_COMPARATOR|Placebo|Placebo; matched the test product in colour, size, smell and texture and contained only the excipients (maltodextrin and hydroxypropylmethylcellulose); one capsule per day with a larger meal, for 8 weeks.
62357395|NCT02169713|EXPERIMENTAL|Treatment Sequence 1|Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron
62357396|NCT02169713|EXPERIMENTAL|Treatment Sequence 2|Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)
62521448|NCT03407521|PLACEBO_COMPARATOR|control group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo
62521449|NCT04665206|EXPERIMENTAL|VT3989 Dose Escalation|VT3989 dosed orally in 21 or 28 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase
62521450|NCT04665206|EXPERIMENTAL|Dose Expansion|VT3989 dosed in 21 or 28 day cycles in patients with refractory metastatic solid tumors or mesothelioma, with or without NF2 mutant tumors.
62149890|NCT03020433|ACTIVE_COMPARATOR|rTMS Contralesional PMC facilitation|
62149891|NCT03020433|ACTIVE_COMPARATOR|rTMS Ipsilesional PMC facilitation|
62149892|NCT03020433|SHAM_COMPARATOR|rTMS Sham at Ipsilesional M1|
62357397|NCT05251298|ACTIVE_COMPARATOR|Intervention group|Patients in the intervention group come from the same region (Münsterland) and will undergo therapies coordinated through the online platform.
62357398|NCT05251298|NO_INTERVENTION|Control group|Patients in the control group will undergo their usual therapies as prescribed by their neurologists.
62357399|NCT05726448|EXPERIMENTAL|Telehealth solution|Telehealth solution offered
62357400|NCT05726448|NO_INTERVENTION|Usual care|Control
62521451|NCT01582984|ACTIVE_COMPARATOR|iMedConsentTM and customized written handout group|iMedConsentTM and a customized written handout
62521452|NCT01582984|EXPERIMENTAL|iMedConsentTM, handout, and standard video g|iMedConsentTM, handout, and standard AAOS video
62357401|NCT05320328||1|The study group (A) will receive radio frequency ablation followed by uncovered Self expandable metal stent/Plastic stent placement (one or more)at same procedure.
62521453|NCT01582984|EXPERIMENTAL|iMedConsentTM, handout, video, and formal education|iMedConsentTM, the handout, the video, and a formal education session
62521454|NCT01155401||1|Patients with acute upper gastrointestinal bleeding
62521455|NCT04320550||abdominal pain|one group of children complaining of recurrent abdominal pain
62521456|NCT01509521|ACTIVE_COMPARATOR|Ephedrine|
62521457|NCT01509521|ACTIVE_COMPARATOR|Phenylephrine|
62521458|NCT01946074|EXPERIMENTAL|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
62521459|NCT01946074|EXPERIMENTAL|Cohort A|ABT-165 plus paclitaxel
62521460|NCT01946074|EXPERIMENTAL|Cohort B|ABT-165 plus FOLFIRI
62521461|NCT01946074|EXPERIMENTAL|Cohort C|ABT-165 plus ABBV-181
62521462|NCT01946074|EXPERIMENTAL|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
62711553|NCT04946630|EXPERIMENTAL|Bronchial bolus/ Breath hold exposures|A subdivided dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for six repetitive 70 mL Bronchial bolus/ Breath hold exposures. Each 70 mL bolus will be extracted from a freshly generated volume of 300 mL aerosol produced by actuation of a single dose from the inhaler.
62711554|NCT01429688|EXPERIMENTAL|DP-R202|Multiple oral administration for 3 days
62711555|NCT01429688|ACTIVE_COMPARATOR|Anplag|Multiple oral administration for 3days
62149893|NCT03830320|ACTIVE_COMPARATOR|Healthy Volunteers|Twenty (20) healthy adult subjects will be injected with \[64Cu\]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
62149894|NCT03830320|EXPERIMENTAL|Atrial Fibrillation Patients|Thirty-five (35) patients with LAA thrombus documented by TEE will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care. Thirty-five (35) patients with atrial fibrillation and negative TEE will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus. Forty (40) patients with atrial fibrillation who are scheduled for TEE in the upcoming 14 days will be injected with \[64Cu\]FBP8 and imaged for LAA thrombus.
62149895|NCT03830320|EXPERIMENTAL|COVID-19 Patients|Thirty (30) COVID-19 patients will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.
62149896|NCT03830320|EXPERIMENTAL|Cancer Patients|Thirty (30) cancer patients will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.
62149897|NCT03830320|EXPERIMENTAL|Other Thrombotic Condition Patients|Fifty (50) patients with other thrombotic conditions will be injected with \[64Cu\]FBP8 and imaged for thrombi in the body.
62149898|NCT05771688|EXPERIMENTAL|FETO therapy|FETO therapy
62357402|NCT05320328||2|The control group (B) will receive uncovered Self expandable metal stent / Plastic stent (one or more) placement.
62357403|NCT02339857||No-touch vein grafts to LAD|
62521463|NCT00845234|NO_INTERVENTION|Standard of Care Group|Received the current standard of care as operationally defined by the investigators- Q\&A session + Video
62521464|NCT00845234|EXPERIMENTAL|Intervention Group|Intervention group- Patients will receive the brief educational CBT intervention + video and Q\&A session
62521465|NCT03338348|OTHER|Azacitidine + Vosaroxin|"Cycle 1-8:~Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Vosaroxin: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .~Patients who have completed 8 cycles of azacitidine and vosaroxin are scheduled to maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
62521466|NCT00775541|EXPERIMENTAL|Vitamin C|2 gms vitamin C
62521467|NCT02714933|EXPERIMENTAL|MRI sequence Advanced ZTE|
62521468|NCT05515016|OTHER|A surgical technique for double chin treatment and chin advancement|the same surgical technique was performed on 10 participants with their consent. Subplatysmal fat, of the submental region, was dissected from the subcutaneous plan and the platysma muscle, then elevated as a flap to be plicated and turned, then fixed on the muscular layer of the chin. This technique provides both double chin treatment and chin advancement. It improves the profile of the face.
62521469|NCT00990587|EXPERIMENTAL|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
62521470|NCT02593513|EXPERIMENTAL|Daifert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
62521471|NCT02593513|OTHER|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
62521472|NCT01121341|EXPERIMENTAL|EVOH|Procedure: Endoscopic vein with an open CO2 system harvesting
62521473|NCT01121341|ACTIVE_COMPARATOR|OVH|Procedure: Conventional vein harvesting
62521474|NCT03421366||Cystic Fibrosis on Posaconazole|"* Able to provide written informed consent~* Greater than 18 years of age or older~* Have a diagnosis of cystic fibrosis~* No known azole hypersensitivity~* To commence as part of their standard of care the newer modified release oral formulation of posaconazole to treat Aspergillus~* Able to provide a pre-treatment sputum collected for fungal culture as part of standard of care~* Have been prescribed a loading dose of 300mg bd for 1 day of the modified release posaconazole tablet followed by 300mg daily."
62521475|NCT04979884|EXPERIMENTAL|cyclosporine|patients will receive cyclosporine + (standard care treatment (± anticoagulant± antibiotic± antipyretic± steroid) according to Alexandria university hospitals protocol )
62711556|NCT05299164|EXPERIMENTAL|Liposomal mitoxantrone hydrochloride 16 mg/m^2 (with a caret included)|
62711557|NCT05299164|EXPERIMENTAL|Liposomal mitoxantrone hydrochloride 18 mg/m^2 (with a caret included)|
62711558|NCT05299164|EXPERIMENTAL|Liposomal mitoxantrone hydrochloride 20 mg/m^2 (with a caret included)|
62711559|NCT05299164|EXPERIMENTAL|Liposomal mitoxantrone hydrochloride 22 mg/m^2 (with a caret included)|
62149899|NCT04468191|EXPERIMENTAL|Experimental, then sham|Patients with ALS in the experimental, then sham arm will undergo an expiratory muscle strength training (EMST) session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 0% resistance.
62521476|NCT04979884|ACTIVE_COMPARATOR|Standard of care treatment|patients will receive standard treatment (antiviral ± anticoagulant± antibiotic± antipyretic± steroid± interleukin ) according to Alexandria university hospitals protocol.
62521477|NCT00749281||1|Patients with angiographically confirmed significant CAD
61975173|NCT04271605|EXPERIMENTAL|behavior intervention and pharmacological therapy|"* For participants with abnormal biochemical markers, pharmacological therapy and diet modification are applied.~* Dietary education on phosphorus additives is applied specifically for retention of phosphorus or high serum phosphorus level.~* Exercise for bone and cardiovascular health.~* Osteoporosis medications are initiated according to the reimbursed criteria of National Health Insurance, otherwise medications are used with non-insurance payment."
61975174|NCT02104700|ACTIVE_COMPARATOR|Rilpivirine/Emtricitabine/Tenofovir|"Immediate switch: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
61975175|NCT02104700|ACTIVE_COMPARATOR|Nevirapine/Lamivudine/ plus other NNRTI|"Delayed switch: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
61975176|NCT00345254|EXPERIMENTAL|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
61975177|NCT00345254|NO_INTERVENTION|Untouched cord|The cord was untouched after delivery of the anterior shoulder and prior to extraction of the body.
62149900|NCT04468191|EXPERIMENTAL|Sham, then experimental|Patients with ALS in the sham, then experimental arm will undergo an expiratory muscle strength training (EMST) session with a device set to 0% resistance during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment.
62521478|NCT00749281||2|Patients without significant CAD
62521479|NCT03722355|ACTIVE_COMPARATOR|Arm 1: Conventional RT + Carmustine|Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles
62521480|NCT03722355|EXPERIMENTAL|Arm 2: Hyperfractionated RT + Carmustine|Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles
62149901|NCT03543332||Cardiac arrest|
62149902|NCT03543332||Myocardial infarction|Myocardial infarction without cardiac arrest
62149903|NCT04150965|ACTIVE_COMPARATOR|Arm A - Elotuzumab|Patients receive Elotuzumab in combination with pomalidomide and dexamethasone. Arm A begings in Phase 2 portion.
62521481|NCT03581071|EXPERIMENTAL|Step1:1mg in non-dialysis subject|
62149904|NCT04150965|EXPERIMENTAL|Arm B - Anti LAG-3 Single Agent|Patients receive Anti-LAG-3 as a single agent for 1 Cycle in Phase 1 portion.
62357404|NCT04273009|ACTIVE_COMPARATOR|Renew Anal Insert|The device is intended for self-insertion through the anal canal aided by a fingertip applicator.
62521482|NCT03581071|EXPERIMENTAL|Step2-1:1mg in hemodialysis subjects|
62521483|NCT03581071|EXPERIMENTAL|Step2-2:6mg in non-dialysis subject|
62521484|NCT03581071|EXPERIMENTAL|Step3-1:11㎎ in hemodialysis subjects|
62521485|NCT03581071|EXPERIMENTAL|Step3-2:11㎎ in non-dialysis subject|
62521486|NCT02630836|EXPERIMENTAL|XCEL-MT-OSTEO-BETA|Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing
62521487|NCT02630836|OTHER|Standard treatment|Standard surgical treatment with isolated endomedullary nailing
62521488|NCT06616948|EXPERIMENTAL|Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
62521489|NCT06616948|NO_INTERVENTION|Normal care control|Participants assigned to the normal care control will receive no intervention for the first 6-months then cross over to the cycling intervention.
62521490|NCT06616948|EXPERIMENTAL|Biweekly health coach|Following completion of the 6-month cycling intervention, participants will receive a call every 2-weeks to discuss ongoing maintenance efforts.
62521491|NCT06616948|ACTIVE_COMPARATOR|No health coach|Following the conclusion of the 6-month cycling session, participants will be contacted monthly to record falls. No discussion of ongoing exercise will occur
62521492|NCT02914236|EXPERIMENTAL|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
62521493|NCT02343757|OTHER|PET/CT vs. PET/MRI|"Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1."
62521494|NCT04039386|EXPERIMENTAL|Cell Phone Based Cognitive Based Therapy|Young adults with hip pain
62521495|NCT04039386|PLACEBO_COMPARATOR|Placebo|Young adults with hip pain
62521496|NCT05344651|ACTIVE_COMPARATOR|Baerveldt glaucoma drainage device|
62521497|NCT05344651|EXPERIMENTAL|Paul glaucoma drainage device|
62521498|NCT05720975||Experimental: iNstroke|Study device
62521499|NCT03342599|EXPERIMENTAL|GNC Alpha Lipoic Acid Supplement|600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
62521500|NCT03342599|PLACEBO_COMPARATOR|Cellulose Fiber Placebo|600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks
62521501|NCT00851643|ACTIVE_COMPARATOR|qHPV (GARDASIL™) - Phase A Control|Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.
62521502|NCT00851643|EXPERIMENTAL|Octavalent HPV with 15 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg AAHS and 15 mcg IMX.
61975178|NCT05992610|EXPERIMENTAL|Chemotherapy (Ch)+ Radiotherapy (RT)|"Induction phase:~Chemotherapy based on carboplatin 6 AUC (area under the curve) + paclitaxel 75 mg/m2 carboplatin 6 AUC 30-minute infusion on D: 1 (maximum carboplatin dose is 700 mg) paclitaxel 75 mg/m2 1-hour infusion on D: 1, 8, 15~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
61975179|NCT04811391||Vaccinated participants|Participants who have received 2 doses of the pfizer Covid-19 vaccine or 1 or dose of the Astra Zeneca Covid-19 Vaccine
61975180|NCT04811391||Unvaccinated participants|Have not received any doses of any form of COVID-19 vaccine
62521503|NCT00851643|EXPERIMENTAL|Octavalent HPV with 30 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX.
62521504|NCT00851643|ACTIVE_COMPARATOR|qHPV (GARDASIL™) - Phase B Control|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 60 mcg IMX / AAHS and Octavalent HPV with 120 mcg IMX / AAHS during Phase B.
62521505|NCT00851643|EXPERIMENTAL|Octavalent HPV with 60 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX.
62521506|NCT00851643|EXPERIMENTAL|Octavalent HPV with 120 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX.
62521507|NCT04343703|EXPERIMENTAL|Telephone-based management|Telephone-based management will consist of a three-phase intervention: 1) An initial 15-20 min call at 1 week of enrollment in which the cases manager introduces him/herself, and does a short assessment of the current suicide risk, 2) A 5-10 min telephone follow-up at 1, 3, 6, 9 and 12 months, 3) If suicide risk is detected, a 15-45 min crisis intervention call will be done, tailored to the participant's characteristics and context. If deemed necessary, an emergency face-to-face appointment will be scheduled. At each phone call information regarding the current treatment, adherence to mental health services, and current life stressors will be collected.
62521508|NCT04343703|EXPERIMENTAL|iFightDepression for Suicide|The iFightDepression-Survive (iFD-S) program is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iFD tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. To that end, the expertise of a panel of mental health experts in suicide and cognitive-behavioral interventions will be asked. The iFD-S also provides telephone guidance (2h per participant) during the use of the program.
62521509|NCT04343703|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual. TaU will consist of any routine procedures applied at each participating site.
62521510|NCT04343703|EXPERIMENTAL|Self Awareness of Mental Health|The Self Awareness of Mental Health (SAM) is an adaptation of the Youth Awareness of Mental Health program, originally developed for the Saving and Empowering Young Lives in Europe (SEYLE) study. The SAM aims to raise mental health awareness about risk and protective factors associated with suicide, provide knowledge about depression and anxiety, and enhance the skills needed to cope with adverse life events and suicidal behavior. The intervention is delivered by trained clinical psychologists in five, 45-60 minutes, face-to-face sessions.
62521511|NCT03113448|ACTIVE_COMPARATOR|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
62521512|NCT03113448|PLACEBO_COMPARATOR|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
62711560|NCT06605209|EXPERIMENTAL|Peripheral Balloon-Expandable Covered Stent System Group|"This arm of the study involves the use of the Peripheral Balloon-Expandable Covered Stent System. The intervention consists of implanting this stent system into the common and/or external iliac arteries of participants who have been diagnosed with stenosis and/or occlusion. The stent system is designed to be balloon-expandable and covered, providing a means to treat arterial blockages.~Participants in this arm will undergo the stent implantation procedure, followed by scheduled follow-up visits at discharge, and at 1, 6, 12, 24, and 36 months post-procedure. During these visits, the safety and effectiveness of the stent system will be assessed based on predefined performance goals, including clinical outcomes and any adverse events related to the stent."
62711561|NCT05526417|EXPERIMENTAL|Arm I (prehabilitation physical therapy)|Patients perform personalized prehabilitation physical therapy exercises BID 5 days per week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery, attend telemedicine visits with a physical therapist once a week for 9 weeks, and receive educational materials. Patients undergo MRI and CT at week 9.
62521513|NCT03542084|EXPERIMENTAL|Intervention: Unsolicited e-consult|The PCP of intervention arm patients will receive an unsolicited e-consult by an endocrinologist offering clinical guidance on how to optimize the patients' glycemic control
62521514|NCT03542084|NO_INTERVENTION|Control|Control arm patients will receive usual care
62521515|NCT01744119||Abdominal Aortic Aneurysm|
62521516|NCT04184661||hypophosphatemic rickets patients|30 hypophosphatemic rickets patients older than 2 years will be included in this study
62521517|NCT04184661||controls patients|10 controls patients from pediatric nephrology unit without hypophosphatemic rickets, older than 2 years will be included in this study
62149905|NCT04150965|EXPERIMENTAL|Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-LAG-3 in combination with pomalidomide and dexamethasone.
62357405|NCT04273009|ACTIVE_COMPARATOR|Percutaneous tibial nerve stimulation|A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points.
62357406|NCT00079820|EXPERIMENTAL|A|MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112
62357407|NCT00079820|EXPERIMENTAL|B|MVA3000 Smallpox vaccine (1x10-8) with no Challenge
62357408|NCT00079820|PLACEBO_COMPARATOR|C|Placebo
62357409|NCT00079820|EXPERIMENTAL|D|MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112
62357410|NCT00079820|EXPERIMENTAL|E|MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112
62357411|NCT02907671|ACTIVE_COMPARATOR|Group A|carpal tunnel corticoanesthetic injection between the flexor tendons
62357412|NCT02907671|ACTIVE_COMPARATOR|Group B|carpal tunnel corticoanesthetic injection next to the median nerve with hydrodissection
62357413|NCT01878097|EXPERIMENTAL|Green Dot Bystander Training|Green Dot intervention
62521518|NCT03143478|EXPERIMENTAL|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
62521519|NCT06138119|EXPERIMENTAL|Female anesthesiologists in the experimental group|Stereotype threat manipulation will be performed on the female anesthesiologist in the experimental group just before they are taken into the testing room.
62521520|NCT06138119|NO_INTERVENTION|Female anesthesiologists in the control group|The female anesthesiologists in the control group will not be given any prior information.
62521521|NCT06138119|EXPERIMENTAL|Male anesthesiologist in the experimental group|Stereotype threat manipulation will be performed on the male anesthesiologist in the experimental group just before they are taken into the testing room.
62521522|NCT06138119|NO_INTERVENTION|Male anesthesiologist in the control group|The male anesthesiologists in the control group will not be given any prior information.
62521523|NCT06222541|EXPERIMENTAL|"Nudge Web-Based Supermarket"|"Participants will be asked to simulate one grocery shopping trip in a web-based supermarket and to select three unique beverages for their household that their child would drink.~Participants randomized to the nudge web-based supermarket will view beverages in descending order of healthfulness (i.e., the healthiest beverages will appear at the top of the screen), view a store landing page promoting the healthiest beverages with a health message, and be offered healthier swaps for sugary drinks at point-of-selection (i.e., immediately after selecting an item to be added to their shopping cart)."
62711562|NCT05526417|ACTIVE_COMPARATOR|Arm II (educational materials)|Patients receive educational materials and attend a telemedicine visit with a research assistant once a week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery. Patients undergo MRI and CT at week 9.
62711563|NCT05504122|ACTIVE_COMPARATOR|Laparoscopic Totally Extraperitoneal (TEP)|Patients who underwent Laparoscopic Totally Extraperitoneal (TEP) will be included in this group.
62711564|NCT05504122|PLACEBO_COMPARATOR|Open tension-free mesh repair technique (Lichtenstein)|Patients with open tension-free inguinal hernia(Lichtenstein) repair will be included in this group.
62149906|NCT04150965|EXPERIMENTAL|Arm C - Anti-TIGIT Single Agent|Patients receive Anti-TIGIT as a single agent for 1 Cycle in Phase 1 portion.
62149907|NCT04150965|EXPERIMENTAL|ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-TIGIT in combination with pomalidomide and dexamethasone.
62149908|NCT04658888|EXPERIMENTAL|Modified letter with self-sampling request card|This group will receive a modified letter telling the participant they are out of date with their cervical cancer screening. They will also receive information on the self-sampling kit and will be provided a card that they can send back to the study team in order to have a kit sent to their house. The kit will include a pre-paid mailer so that it can be sent back to the lab for testing. The result will then be shared with the participant.
62357414|NCT01878097|ACTIVE_COMPARATOR|Control|Awareness Eduation
62357415|NCT03107598|EXPERIMENTAL|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
62357416|NCT03107598|PLACEBO_COMPARATOR|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
62357417|NCT03466307||Group A|Thirty patients with nocturnal shoulder pain
62357418|NCT03466307||Group B|Thirty patients without nocturnal shoulder pain
62357419|NCT03466307||Group C|Healthy controls
62357420|NCT04712487||Routine discectomy|Patients undergoing routine spine surgery due to degenerative disease of the spine
62357421|NCT03248050|EXPERIMENTAL|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
62357422|NCT03248050|NO_INTERVENTION|Control pharmacy|
62357423|NCT02646150||critical limb ischemia|
62521524|NCT06222541|NO_INTERVENTION|Standard Web-Based Supermarket|"Participants will be asked to simulate one grocery shopping trip in a web-based supermarket and to select three unique beverages for their household that their child would drink.~Participants randomized to the standard web-based supermarket will not receive any nudges related to health."
62711565|NCT01042314|EXPERIMENTAL|Donepezil and BMS-708163|
62711566|NCT00688597|EXPERIMENTAL|Cohort 1|Regimen 1: Low-dose duvoglustat (2.5 grams \[g\]) once a day (QD) for 3 days, followed by no drug for 4 days, for 11 weeks.
62521525|NCT02514161|ACTIVE_COMPARATOR|Inspiratory Muscle Training Group (IMT)|"The IMT program consisted of supervised and domiciliary exercises.~1. - The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 4 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~   * First week: 30% Maximum Inspiratory Pressure (MIP)~  * Second week: 40% MIP~  * Third week: 50% MIP~  * Fourth week: 60% MIP~2. - The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen"
62521526|NCT02514161|EXPERIMENTAL|IMT + Manual Therapy and Motor Control Exercises|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~1. - MT:~   * Upper cervical region mobilization in flexion~  * Lower cervical postero-anterior mobilization + maintained traction~  * Costovertebral joint postero-anterior mobilization~  * Thoracic vertebral posteroanterior mobilization~  * Thrust dorsal~2. - MCE:~   * Isometric contraction of the deep neck flexors.~  * Isometric contraction of the neck extensors.~  * Neural self-mobilization.~  * Cervical retraction with theraband.~  * Sphinx.~  * Scapular adduction exercises in prone.~  * Scapular adduction exercises in sitting position with theraband."
62521527|NCT00705692|EXPERIMENTAL|Levamisole|Two 50 mg levamisole tablets daily, six days before and six days after Td vaccination.
62521528|NCT00705692|PLACEBO_COMPARATOR|Placebo|Two placebo tablets daily, six days before and six days after Td vaccination.
62521529|NCT03336957|EXPERIMENTAL|Pregnant group|Test group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
62521530|NCT03336957|ACTIVE_COMPARATOR|Non-Pregnant|Control group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
62521531|NCT01940497|EXPERIMENTAL|Trastuzumab (Vial)|Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy \[consisting of doxorubicin, paclitaxel or docetaxel\] and 14 cycles administered alone).
62521532|NCT01940497|EXPERIMENTAL|Trastuzumab (SID)|Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy \[consisting of doxorubicin, paclitaxel or docetaxel\] and 14 cycles administered alone).
62521533|NCT01528020|EXPERIMENTAL|Dialectical Behavior Therapy|
62521534|NCT01528020|ACTIVE_COMPARATOR|Inidividual and Group Supportive Therapy|
61975181|NCT01922206|NO_INTERVENTION|Wait-list Control|Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.
61975182|NCT01922206|EXPERIMENTAL|TRACK Intervention|3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
62521535|NCT01929031|OTHER|Caffeine-Ibuprofen|Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator
62521536|NCT01929031|OTHER|Placebo-Ibuprofen/Caffeine|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental
62521537|NCT01929031|OTHER|Ibuprofen/Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental
62149909|NCT04658888|NO_INTERVENTION|Standard letter|Participants will receive a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
62149910|NCT02378376|EXPERIMENTAL|Wheat derived fiber fraction 1|Arabinoxylan oligosaccharides
62149911|NCT02378376|EXPERIMENTAL|Wheat derived fiber fraction 2|Dietary fiber enriched bran
62149912|NCT03030365||Healthy Controls|"Age matched controls for the various clinical groups will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi (millicurie) of 18F (fluorodeoxyglucose) -FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
62149913|NCT03030365||Amnestic Mild cognitive impaired|"Patients diagnosed with mild cognitive impairment, exhibiting impairment mostly in memory that is significant but does not interfere with everyday activities.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
62149914|NCT03030365||Alzheimer's disease patients|"Patients exhibiting significant loss of intellectual ability that interferes with everyday functioning that meet Alzheimer's pattern of decline, and following exclusion of alternative neurodegenerative, cerebrovascular, and metabolic etiologies.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
62149915|NCT03441256|EXPERIMENTAL|Intervention|All participant in the intervention group will undergo the LION procedure and subsequent neurostimulation.
62711567|NCT00688597|EXPERIMENTAL|Cohort 2|Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks.
62711568|NCT00688597|EXPERIMENTAL|Cohort 3|Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks.
61975183|NCT01107041|EXPERIMENTAL|Mobilyze!|
62149916|NCT03441256|ACTIVE_COMPARATOR|Control|All participants in the control group will be issued with a device for neuromuscular electrical stimulation.
62711569|NCT00617864|EXPERIMENTAL|1|Group will receive infusion of human albumin
62149917|NCT05550441|PLACEBO_COMPARATOR|Placebo group|
62149918|NCT05550441|EXPERIMENTAL|Dapagliflozin group|
62149919|NCT06363604|EXPERIMENTAL|VOMEI + PVI + linear ablation of mitral isthmus + PWI|Acquisition of left atrial posterior wall isolation by linear ablation of LA roof and bottom line, in addition to routine strategy with vein of Marshall ethanol infusion, isolation of bilateral pulmonary veins and linear ablation of mitral isthmus.
62149920|NCT06363604|ACTIVE_COMPARATOR|VOMEI + PVI + linear ablation of mitral isthmus|Routine strategy with vein of Marshall ethanol infusion, isolation of bilateral pulmonary veins and linear ablation of mitral isthmus. Left atrial posterior wall not isolated.
62521538|NCT01929031|OTHER|Ibuprofen-Ibuprofen|Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator
62521539|NCT01929031|OTHER|Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental
62521540|NCT01929031|OTHER|Placebo-Ibuprofen|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator
62521541|NCT05121844|EXPERIMENTAL|Signos digital health app and CGM|For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.
61975184|NCT01096225||vaccinated group|
61975185|NCT01645696|EXPERIMENTAL|BD Continuous Glucose Monitor (CGM) with outer layer|A subcutaneous glucose binding protein sensing device to continuously monitor glucose in diabetics.
61975186|NCT01645696|EXPERIMENTAL|BD CGM without outer layer|A continuous glucose binding protein sensing device used to monitor glucose in Diabetics
62521542|NCT04093869|EXPERIMENTAL|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX intervention will consist of 12, 30 minute weekly sessions conducted by a respiratory therapist knowledgeable about lung transplantation and trained in motivational interviewing, Cognitive Behavioral Therapy (CBT), and exercise therapy.
62521543|NCT04093869|EXPERIMENTAL|Standard of Care plus Education (SOC-ED)|The SOC-ED intervention will consist of 12, 30 minute weekly sessions conducted by a health educator knowledgeable about transplantation and skilled in educational instruction.
62521544|NCT03805308|NO_INTERVENTION|Medical Management|Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
62149921|NCT00787475|EXPERIMENTAL|1|CHW intervention
62149922|NCT00787475|NO_INTERVENTION|2|Enhanced usual care (brochure mailings)
62521545|NCT03805308|EXPERIMENTAL|Intra-arterial Therapy|For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
62521546|NCT04859036||Transchateter VSD closure group|VSD cases treated with transcatheter closure method.
61975187|NCT01645696|ACTIVE_COMPARATOR|Medtronic iPro 2 Professional CGM|Commercial glucose oxidase continuous glucose monitor
61975188|NCT05087784|EXPERIMENTAL|Intervention:|Complex, technology supported survivorship intervention using wearable devices for patients, supportive patient apps and physician apps for risk prediction. Increased Cardio-oncology visits assigned to risk patients as predicted by the app.
61975189|NCT05087784|NO_INTERVENTION|Control arm:|Wearable device for patients together with a basic patient app providing feedback on the wearable device records and patient information material.
62149923|NCT06310707|EXPERIMENTAL|ePatch® Extended Wear Holter (EWH) Arm|Participants will undergo long-term continuous ambulatory ECG recording of 7-day duration
62149924|NCT06310707|NO_INTERVENTION|Standard of Care|Participants will undergo 24 hours of continuous ECG recording.
62149925|NCT03302091|EXPERIMENTAL|BI 1467335 Normal (R)|Participants with normal renal function.
61975190|NCT05762094||CAR-R|Patients with impaired renal function (eGFR \< 60ml/min/1.73m2) treated by carbapenem
61975191|NCT05762094||CAR-L|Patients with liver cirrhosis or impaired liver function (Child-Pugh grade B or C) treated by carbapenem
61975192|NCT05762094||CAR-LR|Patients with co-morbidity of both liver cirrhosis or impaired liver function (Child-Pugh grade B or C) and impaired renal function (eGFR \< 60ml/min/1.73m2) treated by carbapenem
61975193|NCT05762094||CAR-N|Patients with normal liver function or renal function treated by carbapenem
61975194|NCT00111592|ACTIVE_COMPARATOR|1|current usual care
62149926|NCT03302091|EXPERIMENTAL|BI 1467335 Moderate (T)|Participants with moderate renal impairment.
62149927|NCT01368874|ACTIVE_COMPARATOR|Group A|Ulthera® System treatment of the submental and submandibular regions at two treatment depths, and the lower neck region at one treatment depth.
62149928|NCT01368874|ACTIVE_COMPARATOR|Group B|Ulthera® System treatment of skin above the jawline, as well as the submental, submandibular and lower neck regions.
62357424|NCT01047046||SNM device placement|Patients who have undergone a placement of a SNM device to treat refractory OAB. A retrospective chart review will be performed on all patients who underwent a one or two-stage placement of an SNM device, which includes an implantable pulse generator (IPG), for refractory urge incontinence and urgency frequency symptoms. The patients will be those of Dr. Karen Noblett, having their device placed after 2001.
62357425|NCT04643795|EXPERIMENTAL|40 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
62521547|NCT04859036||Control group|Healty children
62521548|NCT03008239|EXPERIMENTAL|FiberSense sensor|"Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks.~In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subject."
62521549|NCT01949948|ACTIVE_COMPARATOR|Tenecteplase|0.4 mg/kg single bolus intravenously
62521550|NCT01949948|ACTIVE_COMPARATOR|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
62521551|NCT03544879|EXPERIMENTAL|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
62711570|NCT00617864|PLACEBO_COMPARATOR|2|Group will receive infusion of saline
61975195|NCT00111592|EXPERIMENTAL|2|treatment protocol with clear indications for therapy
61975196|NCT06507592|OTHER|Fixed Appliances (FA)|13 patients with fixed appliances, between 10 and 18 years of age, with good oral hygiene and without gingival inflammation, has been recruited
61975197|NCT06507592|OTHER|Clear Aligners (CA)|13 patients with clear aligners, between 10 and 18 years of age, with good oral hygiene and without gingival inflammation, has been recruited
62521552|NCT03544879|ACTIVE_COMPARATOR|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
62521553|NCT02337049||Previously early onset preeclampsia|Women with a history of early onset preeclampsia 10 years ago
61975198|NCT00776347|EXPERIMENTAL|donepezil|
61975199|NCT06125353|ACTIVE_COMPARATOR|intervention group|Participants in the Intervention group consumed one melatonin tablet per day, containing 1mg of melatonin, for a total of three months.
61975200|NCT06125353|NO_INTERVENTION|placebo group|Participants in this group were instructed to consume one placebo tablet (with water) every day for a total of three months. Melatonin and placebo tablets were of similar physical and sensory properties.
61975201|NCT00844051|NO_INTERVENTION|No Intervention|No school-based influenza vaccination program
62521554|NCT02337049||Previously late onset preeclampsia|Women with a history of late onset preeclampsia 10 years ago
61975202|NCT00844051|ACTIVE_COMPARATOR|Intervention|School-based Influenza Vaccination Program
61975203|NCT03562481|EXPERIMENTAL|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
61975204|NCT03562481|EXPERIMENTAL|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
62521555|NCT02337049||Previously normotensive pregnancy|Women with a history of normotensive pregnancies 10 years ago
61975205|NCT02147340||Heart failure patients with ICD|Heart failure patients with ICD and RPM system equipped with sensors for the measurement of weight and pressure
62711571|NCT06715748|PLACEBO_COMPARATOR|PLACEBO|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
62149929|NCT01368874|ACTIVE_COMPARATOR|Group C|Ulthera® System treatment of the submental, submandibular, and the lower neck regions at two treatment depths.
62149930|NCT02099188|EXPERIMENTAL|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~* Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~* Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~* 5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma.~* Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~* Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w . Second cycle and every other cycle~* Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~* Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Intestinal Type Adenocarcinoma with functional p53.~* Leucovorin\* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w.~* Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~* 5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by radiotherapy"
61975206|NCT05745779||Gingivitis|0% interdental bone loss
61975207|NCT05745779||Stage 1 periodontitis|0-15% interdental bone loss
61975208|NCT05745779||Stage 2 Periodontitis|15-33% interdental bone loss
62521556|NCT01255735||Vocal nodules|Two groups of children who are hoarse and have vocal nodules will be examined to see whether voice therapy is effective as a treatment strategy
62521557|NCT02311920|EXPERIMENTAL|Arm I (temozolomide and ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
61975209|NCT05745779||Stage 3 Periodontitis|\>33% interdental bone loss with potential for additional tooth loss
61975210|NCT05745779||Stage 4 Periodontitis|\>%33 interdental bone loss with potantial for loss of dentition
62521558|NCT02311920|EXPERIMENTAL|Arm II (temozolomide and nivolumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes once every 2 weeks for 16 weeks and then once every 2 weeks for 48 weeks in the absence unacceptable toxicity.
62711572|NCT06715748|ACTIVE_COMPARATOR|Keton|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
62711573|NCT05739266||Before step test|"Before step test.~-Participants record their before-step-test voice."
62711574|NCT05739266||After step test|"After step test.~-Participants record their after-step-test voice."
61975211|NCT02496533|NO_INTERVENTION|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
62149931|NCT02633085||Fixed Bearing or Mobile Bearing UKA|
62149932|NCT01811615|ACTIVE_COMPARATOR|toothbrushing plus rinsing|0.06% CHX + 0.025% NaF plus toothbrushing and alcohol-containing mouth rinsing
62149933|NCT01811615|EXPERIMENTAL|alcohol-free experimental mouth rinse|0.06% CHX + 0.025% NaF plus toothbrushing
62149934|NCT01811615|EXPERIMENTAL|toothbrushing and rinsing|0.06% CHX + 0.03% CPC + 0.025% NaF, alcohol-free, mouth rinsing
62149935|NCT01811615|NO_INTERVENTION|toothbrushing alone|negative control
62149936|NCT06509555||PCR|
62149937|NCT06509555||non-PCR|
62521559|NCT02311920|EXPERIMENTAL|Arm III (temozolomide, nivolumab, ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and nivolumab IV over 60 minutes once every 2 weeks for 64 weeks in the absence unacceptable toxicity.
61975212|NCT02496533|EXPERIMENTAL|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
61975213|NCT06337331|EXPERIMENTAL|High-dose Chemotherapy + Mismatched Allogeneic Stem Cell Transplant|
61975214|NCT04533698||Resternotomy|
61975215|NCT04533698||No resternotomy|
62711575|NCT01680211|EXPERIMENTAL|Salacia bark extract (SR-B-01) and TLC|Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)
61975216|NCT03009435|EXPERIMENTAL|prophylactic manual rotation|"Only obstetricians will participate in the study. Manual rotation is performed at full dilatation.The technique employed will be at the discretion of the operator performing the procedure :~* Tarnier and Chantreuil technique~* or SOGC technique"
61975217|NCT03009435|NO_INTERVENTION|expectative management|Expectative management . No manual rotation
61975218|NCT04014842|OTHER|RapidShock|Patients receiving xseries device with rapid shock enabled
61975219|NCT02700815|EXPERIMENTAL|Diclofenac and capsaicin|Fixed dose combination
62521560|NCT03425487|EXPERIMENTAL|MBSR+TAU|Mindfulness based Intervention (MBSR) + Usual specialized treatment in mental health. MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
62711576|NCT01680211|EXPERIMENTAL|Sesame seeds extract (SI-S-01) and TLC|Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)
62711577|NCT01680211|EXPERIMENTAL|Salacia leaf extract (SR-L-01) and TLC|Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)
62711578|NCT01680211|PLACEBO_COMPARATOR|Placebo and TLC|Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)
62711579|NCT02008617|ACTIVE_COMPARATOR|Study Drug|Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)
62711580|NCT02008617|SHAM_COMPARATOR|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
62149938|NCT03492853||patients with AMD|150 patients with age related macular degeneration more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
62149939|NCT03492853||control group|150 patients in control group without the clinical signs of the disease more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
62149940|NCT06358599||Neoadjuvant chemotherapy prior to radical cystectomy|
62149941|NCT06358599||radical cystectomy directly|
62149942|NCT05087407|EXPERIMENTAL|decomprssion and drainage seton|
62711581|NCT03012750|EXPERIMENTAL|foot perfusion|intravenous application of indocyanine green in patients receiving tibial Bypass surgery
62711582|NCT05905562|EXPERIMENTAL|Spinal mobilization and core stabilization exercises group:|will have core muscle activation exercises along with lumber spine joint mobilization along with TENS and Ultrasound for 12 weeks and 3 sessions per week
62711583|NCT05905562|ACTIVE_COMPARATOR|Spinal mobilization techniques group|will have lumber spine joint mobilization along with TENS and Ultrasound duration of 12 weeks with 3 sessions per week.
61975220|NCT02700815|ACTIVE_COMPARATOR|Diclofenac|
61975221|NCT02700815|ACTIVE_COMPARATOR|Capsaicin|
61975222|NCT02700815|PLACEBO_COMPARATOR|Placebo|
61975223|NCT05299125|EXPERIMENTAL|Single Arm: Therapy consisting of lazertinib plus amivantamab plus chemotherapy|"CYCLE 1 (21-day cycle)~Amivantamab 1400 mg (1750 mg if body weight is \>80 kg) IV once weekly + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1~CYCLE 2 (21-day cycle)~Amivantamab 1400 mg (1750 mg if body weight is \>80 kg) IV on day 1 + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1~MAINTENANCE CYCLES 3 + (21-day cycle)~Amivantamab 1750 mg (2100 mg if body weight is \>80 kg) IV on day 1 + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1"
61975224|NCT02145364|EXPERIMENTAL|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
61975225|NCT00951808|ACTIVE_COMPARATOR|Blood Transfusion Trial Cohort|Twenty participants will receive a blood transfusion while in the hospital.
61975226|NCT00951808|ACTIVE_COMPARATOR|Standard Care Trial Cohort|Twenty participants will not receive a blood transfusion and will receive standard care.
61975227|NCT00951808|ACTIVE_COMPARATOR|Standard Care Observational Cohort|Approximately 300 participants who are ineligible for or decline the blood transfusion part of the study will participate in the observational portion of the study and receive standard care.
61975228|NCT01752907|EXPERIMENTAL|General Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a general chemotherapy side effects education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
62149943|NCT05087407|ACTIVE_COMPARATOR|Cutting seton|
62149944|NCT01693471||SEARCH Study Group|
62149945|NCT02991118|EXPERIMENTAL|bempedoic acid|bempedoic acid 180 mg/day
62149946|NCT02991118|PLACEBO_COMPARATOR|Placebo|Placebo control
62149947|NCT03482102|EXPERIMENTAL|Tremelimumab + Durvalumab + Radiation|"* Durvalumab via IV infusion every 28 days for up to 4 doses/cycles~* Tremelimumab via IV infusion every 28 days for up to 4 doses/cycles, and then continue durvalumab monotherapy every 4 weeks starting on Week 16 for up to 8 months.~* Radiation therapy will only be given during cycle 2"
62357426|NCT04643795|EXPERIMENTAL|60 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
62357427|NCT04643795|EXPERIMENTAL|80 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
62149948|NCT01682928|ACTIVE_COMPARATOR|IV/Oral Hydration and Bedrest|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs"
62149949|NCT01682928|ACTIVE_COMPARATOR|Hydrotherapy Group|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
62149950|NCT03686345|EXPERIMENTAL|Core binding factor acute myeloid leukemia (CBF-AML)|Patients must have an unequivocal diagnosis of de novo-CBFL, prior to start midostaurin, documented by rearrangement of Core Binding Factor (CBF) genes, namely AML1-ETO and CBFB-MYH11. The experimental arm involves the administration of Midostaurin orally 50 mg (two 25 mg tablets) twice a day, from the end of induction chemotherapy, for 14 days. Patients should take Midostaurin at approximately 12 hours intervals. During all consolidation cycles, Midostaurin 50 mg (two 25 mg tablets) is administered orally twice a day, on days 8-21. Patients in complete remission after 3 cycles of remission consolidation therapy, will receive Midostaurin continuation therapy for 12 months. Midostaurin 50 mg (two 25 mg tablets) will be given orally twice a day for 12 months.
62149951|NCT03028805|NO_INTERVENTION|Usual care and order set A|Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
62357428|NCT04643795|EXPERIMENTAL|100 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
62357429|NCT04291924||Ablebodied individuals|
62357430|NCT04291924||Spinal Cord Injured Individuals|
62357431|NCT01271413|EXPERIMENTAL|Adaptive cognitively stimulating activities|
62357432|NCT01271413|ACTIVE_COMPARATOR|Non-adaptive cognitively stimulating activities|
62357433|NCT01091051|ACTIVE_COMPARATOR|Ustekinumab|Ustekinumab S/C 45mg or 90mg depending on patient's weight or placebo injection. 10 with PPPP and 10 with PPP will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
62357434|NCT01091051|PLACEBO_COMPARATOR|Placebo|Placebo S/C (Sodium Chloride). 10 with PPPP and 10 with PPP will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
62357435|NCT01170221|EXPERIMENTAL|TR-701 FA|TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
62357436|NCT01170221|ACTIVE_COMPARATOR|Linezolid|Linezolid 600 mg tablets oral twice a day for 10 days
62357437|NCT05247541|ACTIVE_COMPARATOR|Healthy Participants|
62357438|NCT05247541|EXPERIMENTAL|Study participants|
62357439|NCT03509623|EXPERIMENTAL|Blood coagulation and aflibercept|Blood sampling through direct peripheral venous puncture will be collected from treatment naive patients commencing treatment with intravitreal injections of aflibercept for neovascular AMD before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection. Blood coagulation parameters will be evaluated at each timepoint.
62357440|NCT03729661|EXPERIMENTAL|Breath hold|Patients who receive a breathhold CT- and treatment
62357441|NCT02178072|OTHER|HPV positive|HPV positive patients
62357442|NCT02178072|OTHER|HPV negative|HPV negative patients
62357443|NCT04900207||Observed Group|Participants will be enrolled in the study at the time of their first-trimester screen (10w3d-13w6d weeks of gestation) to the time of their delivery. Collection of first-trimester 3D-volume ultrasound imaging to measure the placental volume, blood flow, and vascularity and maternal serum markers will occur over a 6-12 months period. Collection of descriptive and pregnancy outcome information will be obtained from the electronic medical records will continue through their pregnancy episode (typical 9 months).
62357444|NCT01782924|EXPERIMENTAL|KHK4827 140mg SC|
62357445|NCT01782924|EXPERIMENTAL|KHK4827 210mg SC|
62357446|NCT05816291|PLACEBO_COMPARATOR|Placebo|14 days of supplementation placebo (maltodextrin)
62357447|NCT05816291|EXPERIMENTAL|Veillonella atypica FB004|14 days of supplementation 1 x 109CFU dose Veillonella atypica FB004
62357448|NCT03864536|NO_INTERVENTION|No-contact control|No-contact control
62357449|NCT03864536|ACTIVE_COMPARATOR|Psychoeducation control|Receives general psychoeducation on dementia prevalence, prognosis, and risk factors,
62357450|NCT03864536|EXPERIMENTAL|Psychoeducation + CogRx|Receives same general psychoeducation on dementia and will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
62357451|NCT00925691|ACTIVE_COMPARATOR|APICAL|implantation at the apex
62357452|NCT00925691|EXPERIMENTAL|SEPTAL|implantation at the interventricular septum
62357453|NCT06413368|OTHER|treatment arm|within - subjects study
62521561|NCT03425487|EXPERIMENTAL|ABCT+TAU|Compassion based Intervention (ABCT) + Usual specialized treatment in mental health. ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
62521562|NCT03425487|ACTIVE_COMPARATOR|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
62357454|NCT05340101|EXPERIMENTAL|experimental group|This group will practiced progressive muscle relaxation exercise
62357455|NCT05340101|NO_INTERVENTION|control group|This group will not practiced progressive muscle relaxation exercise
62149952|NCT03028805|ACTIVE_COMPARATOR|Usual care and order set B|Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
62521563|NCT02397005|ACTIVE_COMPARATOR|ZL-2102|Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg
62149953|NCT03028805|ACTIVE_COMPARATOR|Automatic inclusion and order set A|COPD order set is automatically included in admission orders as a static list.
62521564|NCT02397005|PLACEBO_COMPARATOR|Placebo|Placebo matching ZL-2102
62521565|NCT04097171|EXPERIMENTAL|High Carbohydrate Diet|Participants will consume a high carbohydrate diet (65-75% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
62521566|NCT04097171|EXPERIMENTAL|Ketogenic Diet|Participants will consume a low carbohydrate diet (\<5-10% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
62521567|NCT05507762|EXPERIMENTAL|Experimental|MSCs Participants will receive antiviral drug, anti-fibrotic drugs and UC-MSCs
62521568|NCT05507762|PLACEBO_COMPARATOR|Comparator|Comparator participants will receive antiviral drug, anti-fibrotic drugs and saline solution
62521569|NCT04694326||Inpatients|Patients who were inpatients of units other than internal medicine services and internal medicine side-branch services
62711584|NCT06333496|EXPERIMENTAL|GLP-1 Booster|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
62711585|NCT01923636|OTHER|detection of CMV|Cohort of neonates less than 1 month with congenital CMV infection at birth objectified by the detection of CMV in a urine sample, in saliva or blood (fresh or Guthrie card) obtained in the first 10 days life
62521570|NCT02138292|EXPERIMENTAL|Trametinib (2mg)/Digoxin (0.25mg)|"1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8-week cycle, duration of treatment can last from 8 to 104 weeks."
62521571|NCT02524587|ACTIVE_COMPARATOR|acetabular polyethylene vitamys®|acetabular polyethylene vitamys®
62521572|NCT02524587|ACTIVE_COMPARATOR|standard polyethylene acetabular irradiated at 3 Mrad|standard polyethylene acetabular irradiated at 3 Mrad
62521573|NCT00667082|EXPERIMENTAL|NPI-0052 + Vorinostat Dose-Escalation|4 dose-escalation cohorts
62521574|NCT03924011|SHAM_COMPARATOR|Control group|Receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
62521575|NCT03924011|EXPERIMENTAL|Treatment group|Receives PBMT (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
62521576|NCT00836017||BOTOX®|Patients received BOTOX® (onabotulinumtoxinA) treatment as standard of care in clinical practice as prescribed by the physician. No intervention was administered as part of the study.
62711586|NCT01385579|NO_INTERVENTION|usual care|Patients assigned to the usual care arm may be referred for colorectal cancer screening by their providers per usual health center protocol and practice. They receive no additional outreach by the preventive care care manager.
62149954|NCT03028805|ACTIVE_COMPARATOR|Automatic inclusion and order set B|COPD order set is automatically included in admission orders as a dynamic and end user tested version.
62149955|NCT02751294|EXPERIMENTAL|TQ Control+ TQ SIL|Subjects received TQ Control product (2 tablets) and 30 mg TQ SIL solution orally with water after a meal.
62149956|NCT02751294|EXPERIMENTAL|TQ X + TQ SIL|Subjects received 2 tablets of Tafenoquine dissolution profile X and 30 mg TQ SIL solution orally with water after a meal.
62149957|NCT02451072|EXPERIMENTAL|Placebo, LSD, Ketanserin/LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject
62149958|NCT02648555|NO_INTERVENTION|Standard follow-up (controls)|Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine.
62149959|NCT02648555|EXPERIMENTAL|W+D protocol (lifestyle intervention)|Daily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine
62521577|NCT05312242|ACTIVE_COMPARATOR|IFA + Standard of Care|Iron and Folic Acid (IFA) tablets dispensed 30 tablets at a time + standard of care \[Represents standard of care comparison\]
62521578|NCT05312242|EXPERIMENTAL|MMS 30 + novel counseling|MMS dispensed 30 tablets at a time (MMS 30) with novel counseling
62521579|NCT05312242|EXPERIMENTAL|MMS 180 + novel counseling|MMS dispensed 180 tablets at a time (MMS 30) with novel counseling
62521580|NCT02677649|ACTIVE_COMPARATOR|cranberry|30 grams/day freeze dried whole cranberry powder added to a basal diet comprising meats, dairy products, simple sugars, and stevia
62521581|NCT02677649|PLACEBO_COMPARATOR|placebo|30 grams/day placebo powder \[made with maltodextrin (CPC Maltrin M-180), citric acid, artificial cranberry flavor (Lorann oils), fructose, red color (Lorann oils), and grape shade\] added to a basal diet comprising meats, dairy products, simple sugars, and stevia
62521582|NCT04633421|EXPERIMENTAL|PRECISe protocol EN (8g protein/100kcal)|Enteral (EN) feed with 8 grams protein per 100 kcal (2.0 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
62521583|NCT04633421|ACTIVE_COMPARATOR|PRECISe protocol EN (5g protein/100kcal)|Enteral (EN) feed with 5 grams protein per 100 kcal (1.3 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
62521584|NCT01023295|PLACEBO_COMPARATOR|Placebo|single dose
62521585|NCT01023295|EXPERIMENTAL|15 mg/m^2|15 mg/m\^2 fosbretabulin, single dose
62521586|NCT01023295|EXPERIMENTAL|25 mg/m^2|25 mg/m\^2 fosbretabulin, single dose
62521587|NCT01023295|EXPERIMENTAL|35 mg/m^2|35 mg/m\^2 fosbretabulin, single dose
62521588|NCT01023295|EXPERIMENTAL|45 mg/m^2|45 mg/m\^2 fosbretabulin, single dose
62521589|NCT02707861|EXPERIMENTAL|Cohort 1|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~OR~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~Administered for 48 weeks, or until ibalizumab becomes commercially available"
62521590|NCT02707861|EXPERIMENTAL|Cohort 2|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for qualifying patients who have never received ibalizumab~Administered for 48 weeks, or until ibalizumab becomes commercially available"
62149960|NCT01141257|EXPERIMENTAL|Angiocal®|Angiocal®
62521591|NCT00206830|NO_INTERVENTION|Control-Blinded from Results|
62521592|NCT00206830|EXPERIMENTAL|Access to Results|
62521593|NCT05622292|NO_INTERVENTION|Control|Subjects in the control group will receive education on the day of enrolment in NCCHK. Subjects are instructed to take medications and conduct hospital visits as usual.
62521594|NCT05622292|EXPERIMENTAL|I-Care|"Subjects will be instructed to download the HARKIT I-Care app from the google play store on their smartphones. Then, they will be guided to create an account and explained how to use the application, including how to log their progress (laboratory parameters and exercise tracking) and how to see messages from their physician. All follow-ups regarding treatment progress, education, and reminders will be done through the app. Patients are directed to conduct hospital visits once per month, where patients will be prescribed cardiovascular medications according to their current condition."
62521595|NCT02836834|EXPERIMENTAL|Dose Escalation Cohort|JS001
61975229|NCT01752907|EXPERIMENTAL|Bone Pain Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a bone pain education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
61975230|NCT01347008|ACTIVE_COMPARATOR|Sildenafil citrate|Oral Sildenafil citrate, 50mg, b.i.d.
61975231|NCT01347008|PLACEBO_COMPARATOR|Sugar pill|Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.
61975232|NCT02502643|EXPERIMENTAL|OK-432 pleurodesis|Picibanil ( OK-432 ) ,OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci; UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO, LTD; JAPAN).
62521596|NCT02836834|EXPERIMENTAL|Expanded cohort 1|The subjects of expanded cohort 1 will use repeated doses every 2 weeks like multiple dose cohorts
62521597|NCT02836834|EXPERIMENTAL|Expanded cohort 2|The subjects of expanded cohort 2 will use repeated doses every 2 weeks like multiple dose cohorts
62521598|NCT03653052|EXPERIMENTAL|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
62521599|NCT05183295|EXPERIMENTAL|Experimental: Nonessential Amino Acid Restriction (NEAAR) Medical Food|All subjects will receive NEAAR medical food
62521600|NCT04407078|EXPERIMENTAL|Sugammadex group|Sugammadex group receives the intravenous sugammadex of 2 mg/kg.
62521601|NCT04407078|PLACEBO_COMPARATOR|Neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
62521602|NCT06091852|EXPERIMENTAL|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
62357456|NCT03235726|EXPERIMENTAL|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
62521603|NCT02736682|EXPERIMENTAL|Single dose antibiotic|2g of intra venous Ceftriaxone and 500 mgs Intra venous metronidazole is administered to the mothers as a Single dose pre-operative30-60 minutes before surgery.
62521604|NCT02736682|ACTIVE_COMPARATOR|multiple dose antibiotic.|Multiple doses of IV Ceftriaxone 1g and metronidazole 500mgs given to the mother during surgery there after Ceftriaxone 1g every day for 3 days and IV metronidazole 500 mgs every 8 hours for 3 days.
62521605|NCT04235699|EXPERIMENTAL|Ketogenic Diet|This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood \[3-OHB\] ≥0.5 mM.
62521606|NCT04235699|EXPERIMENTAL|Low-fat mixed Diet|This arm will be provided food consisting of \~25% fat, and the remaining calories from carbohydrate (\~55% after accounting for protein at \~20%).
62521607|NCT05953857||Untreated|Not treated with TKI
62521608|NCT05953857||Treated|Treated with TKI
62521609|NCT03238976|EXPERIMENTAL|Nature sounds exposure|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~Patients in the nature sounds group will be exposed to continuous nature sounds during the core needle biopsy (CNB) procedure.~The CNB procedure will continue as planned with nature sounds playing instead of the supportive dialogue. All sounds will be played out of a speaker situated in the corner of the room."
62521610|NCT03238976|NO_INTERVENTION|Standard care (supportive dialogue)|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~The CNB procedure will continue as planned with supportive dialogue which will be played out of a speaker situated in the corner of the room. This group follows the current standard of care."
62521611|NCT04761705|EXPERIMENTAL|Randomized Part 2, Arm 1|Dose 1 selected in Part I
62521612|NCT04761705|EXPERIMENTAL|Randomized Part 2, Arm 2|Dose 2 selected in Part I
61975233|NCT02502643|ACTIVE_COMPARATOR|normal saline pleurodesis|(Normal Saline),Isotonic Sodium Chloride Solution
61975234|NCT02653391|EXPERIMENTAL|Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
62357457|NCT03235726|PLACEBO_COMPARATOR|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
62521613|NCT04761705|ACTIVE_COMPARATOR|Randomized Part 2, Arm 3|
62521614|NCT05600205|EXPERIMENTAL|GOAL!|Combined Support for the Ambulatory Lifestyle Intervention
62521615|NCT05600205|NO_INTERVENTION|Control group|Care and counseling as usual (matched for gender, age and diagnosis)
62521616|NCT01664221|EXPERIMENTAL|Eritromax|Eritromax (Epoetin alfa) intravenous administration, dose: 100 IU/kg
62521617|NCT01664221|ACTIVE_COMPARATOR|Eprex|Eprex (Epoetin alfa) intravenous administration: 100 IU/kg
62357458|NCT03235726|EXPERIMENTAL|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
62521618|NCT04219683|EXPERIMENTAL|Patient with resected Mandible|Patient with resected mandible who is candidate for free fibula flap
62521619|NCT02349971|EXPERIMENTAL|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
62521620|NCT03668821||Carotid Artery Disease|Patients with Carotid Artery Disease. Quality of life and frailty questionnaires
61975235|NCT02653391|EXPERIMENTAL|Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
62357459|NCT03235726|PLACEBO_COMPARATOR|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
62357460|NCT03235726|NO_INTERVENTION|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
62357461|NCT03235726|EXPERIMENTAL|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
62357462|NCT03235726|PLACEBO_COMPARATOR|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
62357463|NCT03235726|EXPERIMENTAL|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
62357464|NCT03235726|PLACEBO_COMPARATOR|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
62357465|NCT03019705||Participants|Individuals with pathological health anxiety
62357466|NCT03900741|EXPERIMENTAL|Submerged healing|Bone regeneration of peri-implantitis defects following a submerged healing
62357467|NCT03900741|ACTIVE_COMPARATOR|Non-submerged healing|Bone regeneration of peri-implantitis defects following a non-submerged healing
62357468|NCT05744323|EXPERIMENTAL|Experimental group|The experimental group will engage in functional training
62357469|NCT05744323|NO_INTERVENTION|Control group|the control group will follow the state-mandated physical education curriculum.
62357470|NCT03980626|EXPERIMENTAL|Walking Intervention|Walking participants will engage in the 3-times weekly walking program for 12 weeks.
62357471|NCT03980626|NO_INTERVENTION|Usual Care|Usual care participants will be offered two personalized exercise sessions with a trained exercise specialist after all post-intervention data have been collected.
61975236|NCT02653391|PLACEBO_COMPARATOR|Placebo A|Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
61975237|NCT02653391|PLACEBO_COMPARATOR|Part B Placebo|Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
61975238|NCT01489592|EXPERIMENTAL|curcumin|oral administration of 6g of curcumin
62521621|NCT03668821||Aneurysmal Disease|Patients with Aneurysmal Disease. Quality of life and frailty questionnaires
62521622|NCT03668821||Peripheral Artery Disease|Patients with Peripheral Artery Disease. Quality of life and frailty questionnaires
62357472|NCT05189132||Test Group|Adult patients diagnosed with Alzheimer's disease
62357473|NCT05189132||Control Group|The control group will consist of patients who attend consultations at the Faculty of Dentistry of the University of Lisbon, matched for age, gender and other confounding factors, such as smoking and systemic diseases (diabetes).
62357474|NCT05316480|EXPERIMENTAL|Nimotuzumab|nimotuzumab 200mg/week
62357475|NCT04131985|EXPERIMENTAL|Erector spina block|"After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).~All anesthesia procedure will be the same as control group"
62357476|NCT04131985|NO_INTERVENTION|Control|There were no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1-2μg/kg, propofol 2 - 4 mg/kg and rocuronium 0.6 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCO2≈ 35-40 mmHg. Anesthesia was maintained using remifentanil 0.05-0.1 mcg/kg/min and propofol 80-100 mcg/kg/min via total intravenous micro pump until the surgery was completed. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria.Tramadol 100 mg i.v. will be used before 15 min end of surgery and 20 mL of 25% bupivacaine will be infiltrated to the trochar sites at the end of the surgery. Patient control analgesia device will administer all patients.
62357477|NCT04026971|EXPERIMENTAL|Phone Application Supported Nutrition Education|Classic nutrition training and diet list is provided. Then notification was sent to obese patients for 3 months by phone application named 'MotiVe'
62357478|NCT04026971|OTHER|Classical Nutrition Education|Classic nutrition training and diet list is provided.
62357479|NCT00879983|OTHER|Group 1|Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
61975239|NCT01489592|PLACEBO_COMPARATOR|placebo|oral administration of 12 sugar pill
61975240|NCT01023750||Fenofibrate|
61975241|NCT05990972|EXPERIMENTAL|FMT group|
61975242|NCT01721330|ACTIVE_COMPARATOR|Naltrexone|Active Naltrexone administered twice daily up to a maximum total dose of 100mg/day.
61975243|NCT01721330|PLACEBO_COMPARATOR|Placebo|Naltrexone-masked placebo administered twice daily up to a maximum total dose of 100mg/day.
61975244|NCT03662685|ACTIVE_COMPARATOR|Goeckerman Therapy|Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
61975245|NCT03662685|ACTIVE_COMPARATOR|Phototherapy Only|Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
62357480|NCT00879983|OTHER|Group 2|Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
62357481|NCT00388167||1|Caspofungin
62521623|NCT06428435||Ibis|Tested with Ibis technology
62521624|NCT06428435||Optonet|Tested with Optonet Technology
61975246|NCT03662685|ACTIVE_COMPARATOR|Crude Coal Tar Only|Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
62711587|NCT01385579|EXPERIMENTAL|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit
62711588|NCT06527807||ASPP|Patients with acute stroke in pregnancy or puerperium
62711589|NCT06527807||Pregnant/Puerperal Non-Stroke|Pregnant or puerperal participants without any history of stroke
62711590|NCT06527807||Non-Pregnant Stroke|Non-pregnant or non-puerperal participants with a recent acute stroke event
62149961|NCT04697615||Algometry|In the test stage, pain threshold evaluations were started through the algometer in a randomized manner by two different examiners trained and experienced in the application of the test, following the same order of evaluation of the muscles (middle deltoid, upper trapezius, pectoralis major, biceps brachii , triceps, lumbar multifidus, rectus femoris, biceps femoris, tibialis anterior and soleus, bilaterally), with an interval between each assessment of five minutes in which the participants remained at rest. After the interval described, the retest stage was initiated, which had the same procedures as the test stage.
62149962|NCT06113393|NO_INTERVENTION|control group|Hold enteral feeding when GRV reaches 200 mL(current standard)
62357482|NCT06271694|OTHER|Standard Vestibular Rehabilitation|All participants will receive standard vestibular rehabilitation
62357483|NCT04833868|EXPERIMENTAL|hippotherapy combined with Schroth Exercise|received hippotherapy combined with Schroth Exercise hippotherapy session for 30 minutes of walking and sitting trot training, 15 sessions split into 2 phases over ten weeks in addition to 60-minute session Schroth's intervention, 3 times/ week for 10 weeks
62357484|NCT04833868|ACTIVE_COMPARATOR|Schroth Exercise|received Schroth's intervention for a 60-minute session, 3 times/ week for 10 weeks
62357485|NCT00869219|ACTIVE_COMPARATOR|Nevanac|
62357486|NCT00869219|ACTIVE_COMPARATOR|Acular LS|
62357487|NCT01455415|EXPERIMENTAL|1: Pregabalin|
62357488|NCT01455415|PLACEBO_COMPARATOR|2: Placebo|
62357489|NCT06380790|OTHER|Control|Placebo laser-aided csf
62357490|NCT06380790|OTHER|Intervention|Laser-aided csf before leveling and alignment
62357491|NCT03079245|OTHER|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
62357492|NCT03079245|OTHER|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
62357493|NCT03079245|OTHER|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
62357494|NCT03079245|NO_INTERVENTION|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
62149963|NCT06113393|EXPERIMENTAL|study group|Hold enteral feeding when GRV reaches 300 mL(current standard)
62149964|NCT05466630|OTHER|participant|All eligible participants will undergo 5 serological field tests for HAT and a malaria test. Those testing positive in at least 1 serological field test will undergo parasitology to confirm HAT and immunological and molecular laboratory tests
62149965|NCT01941576|EXPERIMENTAL|rhBNP Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
62357495|NCT01599702|EXPERIMENTAL|Group A Monofer|Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
62357496|NCT01599702|EXPERIMENTAL|Group B Monofer|Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg.. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
62357497|NCT04208646|EXPERIMENTAL|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
62357498|NCT04208646|EXPERIMENTAL|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells high-dose group
62357499|NCT04208646|PLACEBO_COMPARATOR|No mesenchymal progenitor cells|No mesenchymal progenitor cells
62357500|NCT05453448|EXPERIMENTAL|tenofovir alafenamide|tenofovir alafenamide,Gilead Sciences,capsule,25 mg,once a day,Continuous use for 48 weeks.
61975247|NCT04832672||The upfront radiotherapy group|
61975248|NCT04832672||The upfront targeted-therapy group|
61975249|NCT01692327|OTHER|Obese Group|Obese group with fat overload intake.
61975250|NCT01692327|OTHER|Control Group|Control Group + fat overload intake
61975251|NCT01692327|OTHER|Glucose Intolerance|glucose intolerance + fat overload intake
61975252|NCT03902197|EXPERIMENTAL|CD19 hsCAR-T|This cohort will be administrated by T cells transduced with lentivirus vectors expressing CD19 hsCAR
61975253|NCT02678260|EXPERIMENTAL|PDR001|PDR001 will be administered i.v. every two weeks until a patient experiences unacceptable toxicity, progressive disease as per irRC and/or treatment is discontinued at the discretion of the investigator or the patient. The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and evaluations, a treatment cycle will consist of 28 days. During the study, cohorts of patients will be treated with PDR001 until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
62357501|NCT05453448|EXPERIMENTAL|entecavir|entecavir,Fujian cosunter pharmaceutical co.LTD,capsule,0.5mg,once a day,Continuous use for 48 weeks.
62357502|NCT00606528||Group A|patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy
62357503|NCT00606528||Group B|Healthy volunteers willing to donate blood on 2 separate occasions
62357504|NCT01799304|EXPERIMENTAL|no distractor control group|postural control and locomotion of CP children without attentional distractor and without additional cognitive task (control condition)
61975254|NCT00989339|EXPERIMENTAL|Twenty-four Hour TPN and Saline Infusion|Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.
61975255|NCT00849810|EXPERIMENTAL|Metoprolol to nebivolol|metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
62357505|NCT01799304|EXPERIMENTAL|visual and sound attentional distractors|postural control and locomotion of CP children with visual and sound attentional distractors (video film).
62357506|NCT01799304|EXPERIMENTAL|sound attentional distractor alone|postural control and locomotion of CP children with sound attentional distractor alone (sound track of the video film).
62357507|NCT01799304|EXPERIMENTAL|additional cognitive task|postural control and locomotion of CP children with an additional cognitive task (adapted Stroop task with animals)
62357508|NCT05687708|EXPERIMENTAL|Non-Nutritive Sucking|Non-Nutritive Sucking
62711591|NCT06264167|EXPERIMENTAL|Participants with normal/negative baseline groin ultrasounds|Interventional Treatment: serial high-resolution bilateral groin ultrasound surveillance in conjunction with clinical examinations every 2 months (n=13).
62711592|NCT06264167|NO_INTERVENTION|Participants with normal/negative baseline groin ultrasounds - Standard Care|Standard Treatment: receive upfront full groin LND or sentinel node biopsy (SNB) based on clinician choice (according to local clinical practice management guidelines).
62711593|NCT06264167|NO_INTERVENTION|Participants with suspicious/indeterminate baseline groin ultrasound|Participants with suspicious/indeterminate baseline groin ultrasound (third group) will receive an upfront full groin LND or SNB, consistent with the current standard treatment, according to local clinical practice management guidelines.
62711594|NCT04637529|EXPERIMENTAL|S (+) - Ibuprofen|S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.
62711595|NCT04637529|ACTIVE_COMPARATOR|Ibuvix® - ibuprofen|Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.
62357509|NCT05687708|NO_INTERVENTION|Control|routine treatment
62357510|NCT00168909|EXPERIMENTAL|1|alfacalcidol 1µg/d
62357511|NCT00168909|PLACEBO_COMPARATOR|2|placebo
62357512|NCT03532776|EXPERIMENTAL|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
62357513|NCT03532776|ACTIVE_COMPARATOR|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
62357514|NCT03532776|PLACEBO_COMPARATOR|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
62357515|NCT00474825|ACTIVE_COMPARATOR|1|Hyperbaric Oxygen twice weekly (Monday \& Friday) with Radiation and Chemotherapy
62357516|NCT00474825|ACTIVE_COMPARATOR|2|Hyperbaric Oxygen three times per week (Monday, Wednesday \& Friday) with Radiation and Chemotherapy.
62357517|NCT00474825|ACTIVE_COMPARATOR|3|Hyperbaric Oxygen Five times per week (Monday through Friday) with Radiation and Chemotherapy
62357518|NCT02354092|SHAM_COMPARATOR|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include~* Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~* Local anesthetic for tenaculum placement~* Sham Paracervical Block done with capped spinal needle~* osmotic dilators placed in the usual fashion~* postprocedural assessment"
62357519|NCT02354092|EXPERIMENTAL|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include~* Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~* Local anesthetic for tenaculum placement~* 18 ml 1% buffered lidocaine Paracervical Block~* osmotic dilators placed in the usual fashion~* postprocedural assessment"
62521625|NCT04026685|ACTIVE_COMPARATOR|Phenylephrine infusion only|Phenylephrine infusion only
61975256|NCT03033381|ACTIVE_COMPARATOR|operated side testis|Operated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
62149966|NCT01941576|PLACEBO_COMPARATOR|Placebo Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
62357520|NCT00456833|EXPERIMENTAL|RAD 5mg/day + erlotinib|
62357521|NCT00456833|ACTIVE_COMPARATOR|erlotinib 150mg/day|
62357522|NCT01328197|EXPERIMENTAL|Treovance|
61975257|NCT03033381|SHAM_COMPARATOR|Contralateral testis|Nonoperated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
61975258|NCT04521075|EXPERIMENTAL|Treatment Arm|Combination treatment: anti PD1 + FMT by capsules
62357523|NCT00358501|EXPERIMENTAL|Defibrotide|Defibrotide treatment
62357524|NCT00358501|NO_INTERVENTION|Historical Control|Historical control group
62357525|NCT03212807|EXPERIMENTAL|Investigational|Durvalumab + Lenalidomide
62357526|NCT00145912|EXPERIMENTAL|Intrinsic Motivation|PCP motivational interview + Internet program
62357527|NCT00145912|ACTIVE_COMPARATOR|Extrinsic Motivation|PCP breif advice + Internet Program
61976398|NCT02557646||Pegasys + Copegus|Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.
61976399|NCT00481000|NO_INTERVENTION|1|Waitlist; Treatment as usual
62357528|NCT04625361|EXPERIMENTAL|Single dose of HEC122505MsOH Tablets（pilot trial arm）|Healthy subjects receive single dose of tablets HEC122505MsOH
62357529|NCT04625361|EXPERIMENTAL|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）|Healthy subjects receive single dose of HEC122505MsOH or matching placebo
62149967|NCT05884515|OTHER|PCR comparator|Another molecular test like PCR will be done to confirm the positive and negative antigen test
62149968|NCT02151084|EXPERIMENTAL|Arm A (Continuous Dosing)|"Run-In: Selumetinib, orally, BID for 7 days (Day -7 to Day -1)~On treatment: Selumetinib, orally, BID from Day 1-21 of every 28 day cycle. Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
62149969|NCT02151084|EXPERIMENTAL|Arm B (Sequential Dosing)|"Run-In: Selumetinib, orally, BID for 5 days (Day -7 to Day -3) with 2 days washout~On treatment: Selumetinib, orally, BID from Day 1-5 and 8-19 of every 28 day cycle.~Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
62149970|NCT02151084|EXPERIMENTAL|Arm C (Standard Care)|Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.
62149971|NCT04235920||Impaired Cognition|First group was cognitively impaired test with MoCA score of 25 or less.
62149972|NCT04235920||Preserved cognition|The second group was cognitively preserved with MoCA score of higher than 25.
62149973|NCT05596006|EXPERIMENTAL|ASIMOMMY®|"Experimental:~2 capsules of ASIMOMMY, orally one times daily from days 1 to 7"
62149974|NCT05596006|ACTIVE_COMPARATOR|Domperidone|Domperidone capsule, one capsule, orally three times daily from days 1 to 7
62149975|NCT05596006|PLACEBO_COMPARATOR|Placebo|Identical 2 capsules of placeb, orally one times daily from days 1 to 7
62149976|NCT04658784|EXPERIMENTAL|Intervention|Receives posterior colporrhaphy closure using standardized technique with 2-0 V-Loc 90TM, Medtronic
61975259|NCT03031977|EXPERIMENTAL|visceral mobilization|Conventional physical therapy and visceral mobilization. The experimental group was also submitted to mobilization of the ascending colon, descending colon, sigmoid colon and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual.
61975260|NCT03031977|SHAM_COMPARATOR|sham mobilization|Conventional physical therapy and sham mobilization. In the control group, sham mobilization was performed, which consisted of superficial contact with no pressure on the abdominal region corresponding to the loops of the large intestine.
61975261|NCT05421234|ACTIVE_COMPARATOR|infertile men with post-COVID-19 (vaccinated or without vaccination)|15 infertile men with post-COVID-19 (vaccinated or without vaccination)
61975262|NCT05421234|ACTIVE_COMPARATOR|infertile men without post-COVID-19 (vaccinated or without vaccination)|15 infertile men without post-COVID-19 (vaccinated or without vaccination)
61975263|NCT05421234|ACTIVE_COMPARATOR|Control: 15 healthy men volunteers (no COVID-19, no other pathologies)|15 healthy men volunteers (no COVID-19, no other pathologies) as control group
61975264|NCT02300584|EXPERIMENTAL|Prototype Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
61975265|NCT02300584|EXPERIMENTAL|Field Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Based on the feedback from the prototype program, the videos may vary. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
61975266|NCT02041286|EXPERIMENTAL|Intended Users of the Monitoring System|"Subjects with diabetes use the Karajishi Contour Investigational BG Monitoring System with no training. The criteria for the intended use population:~1. At least 60% of subjects will be younger than age 65~2. At least 10% of subjects will have type 1 diabetes"
61975267|NCT05459324|EXPERIMENTAL|Study Group|Twenty-four patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
61975268|NCT04811625|OTHER|PL-ASA capsule, then EC-ASA tablet|PL-ASA capsule 81 mg, then crossover to EC-ASA tablet 81 mg
61975269|NCT04811625|ACTIVE_COMPARATOR|EC-ASA tablet, then PL-ASA capsule|EC-ASA tablet 81 mg, then crossover to PL-ASA capsule 81 mg
61975270|NCT02058576|EXPERIMENTAL|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination) in period 2 orally once daily under fed condition.
61975271|NCT02058576|EXPERIMENTAL|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fed condition.
61975272|NCT02985554|EXPERIMENTAL|Nivolumab|Nivolumab will be administrated intravenously. Standard dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
61975273|NCT03789045||Obese men and women|Metabolic thresholds and fat oxidation points relationship in Obese males and females, age 18-60y, body fat \> 30%
61975274|NCT03789045||Male and female athletes|Metabolic thresholds and fat oxidation points relationship in Athletic males and females, age 18-60y.
62149977|NCT04658784|ACTIVE_COMPARATOR|Control|Receives posterior colporrhaphy closure using standardized technique with conventional 2-0 PDS® Ethicon
62149978|NCT00909909|ACTIVE_COMPARATOR|A|3DCRT/IMRT lumpectomy bed boost followed by accelerated whole breast irradiation (AWBI)
62149979|NCT00909909|ACTIVE_COMPARATOR|B|Accelerated whole breast irradiation (AWBI) followed by 3DCRT/IMRT lumpectomy bed boost
62149980|NCT02369328|EXPERIMENTAL|multimodal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for patients whom suffering stroke
62149981|NCT02369328|ACTIVE_COMPARATOR|multimocal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for healthy subjects
62357530|NCT04625361|EXPERIMENTAL|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
62149982|NCT06046807||35mmHg ECS|Subjects with first proximal DVT allocated to wear 35 mmHg elastic compression stockings (ECS) for 2 years during the CELEST RCT
62149983|NCT06046807||25mmHg ECS|Subjects with first proximal DVT allocated to wear 25 mmHg elastic compression stockings (ECS) for 2 years during the CELEST RCT
62149984|NCT02782260|EXPERIMENTAL|Active|"Dipyridamole eye drops 8.48 mg in 100ml~1 drop three times a day for 1 year"
61975275|NCT03789045||Sedentary females and males|Metabolic thresholds and fat oxidation points relationship in Sedentary females and males, age 18-60y,
62521626|NCT04026685|ACTIVE_COMPARATOR|Phenylephrine infusion and Ringer-Acetate bolus|Phenylephrine infusion and Ringer-Acetate bolus
62521627|NCT02944942||Postoperative nausea and vomiting|Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting
62521628|NCT02072148|EXPERIMENTAL|Low Risk Group I|"Group I:~* Complete resection (margins: tonsil \>1mm, tongue \>3mm, pT1-2, pN0-2B),~* No LVI, no PNI, \<3 positive nodes.~* No ECS, No matted or Level \>III,"
62149985|NCT02782260|PLACEBO_COMPARATOR|Placebo|"Fluorescein in Active Vehicle~1 drop three times a day for 1 year"
62149986|NCT03605082|EXPERIMENTAL|UCB0107|Subjects will be randomized to receive a predefined dosage of UCB0107 in order to maintain the blinding.
62149987|NCT03605082|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized and receive a placebo in order to maintain the blinding.
62149988|NCT01656512|ACTIVE_COMPARATOR|Arm ( A)|Arm ( A) : patients will receive calcium \& vitamin D
62357531|NCT04625361|EXPERIMENTAL|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
62357532|NCT04625361|EXPERIMENTAL|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
62357533|NCT04625361|EXPERIMENTAL|Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
62521629|NCT02072148|EXPERIMENTAL|Intermediate Risk Group II|"Group II~* Complete resection (margins: tonsil \<1mm, tongue \<1mm, pT1-2, pN0-2B),~* +LVI, +PNI, \<3 positive nodes. ≤1mm ECS."
62521630|NCT02072148|EXPERIMENTAL|High Risk Group IIIA|"* 3+ nodes, no ECS \> 1mm~* Contralateral or supraclavicular nodes"
62521631|NCT02072148|EXPERIMENTAL|High Risk Group IIIB|"* Incomplete surgical resection with + surgical margins~* ≥ 1 mm ECS~* Matted nodes"
62149989|NCT01656512|EXPERIMENTAL|Arm (B)|we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
62149990|NCT05432518|EXPERIMENTAL|Treatment|"Patients will receive one of the 5 study drugs based on their recurrent tumor mutation profile and their recurrent organoid response to these drugs:~1. Afatinib~2. Dasatinib~3. Palbociclib~4. Everolimus~5. Olaparib"
62149991|NCT01083706|EXPERIMENTAL|Treatment (chemotherapy)|Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62149992|NCT03270384|EXPERIMENTAL|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
62149993|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
62149994|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
61975276|NCT05451160|EXPERIMENTAL|Steep Pulse Therapy System|
62149995|NCT02027584||preterm infant|gestational age at birth \< 37 weeks
62149996|NCT02027584||term infant|gestational age at birth \>36 weeks
62149997|NCT03927794|EXPERIMENTAL|Self-Assembling Peptide P11-4|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed at baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.~Then they will receive the intervention by the self-Assembling Peptide P11-4 at Day 0 and will be followed up at 3 months, 6 months and 1 year."
62357534|NCT04625361|EXPERIMENTAL|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
62357535|NCT04625361|EXPERIMENTAL|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
61975277|NCT05451160|ACTIVE_COMPARATOR|RF Ablation System|
61975278|NCT03331419||Males with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
61975279|NCT03331419||Females with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
62149998|NCT03927794|ACTIVE_COMPARATOR|5% Fluoride Varnish|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed as baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.~Then they will receive Topical Fluoride Varnish at Day 0 and will be followed up at 3 months, 6 months and 1 year."
62357536|NCT04625361|EXPERIMENTAL|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
62357537|NCT04625361|EXPERIMENTAL|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
62149999|NCT03556410|PLACEBO_COMPARATOR|sleep|Subject will undergo 5 days of shortened sleep and then 2 days of ad libitum sleep.
62521632|NCT05045352|ACTIVE_COMPARATOR|Echogenic needle|venous access performed under ultrasound guidance with echogenic needles
62521633|NCT05045352|NO_INTERVENTION|Non-Echogenic needles|venous access performed under ultrasound guidance with non-echogenic needles
62521634|NCT01458821|EXPERIMENTAL|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
62521635|NCT01458821|NO_INTERVENTION|No treatment|Subject will make no changes in their usual daily routine. No intervention. Will repeat all study procedures at end of 8 weeks.
62521636|NCT06296654|EXPERIMENTAL|Empowerment-Based Interventions (EBI)|The EBI was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions.
62521637|NCT06296654|ACTIVE_COMPARATOR|standard health education|Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
62521638|NCT05017974|EXPERIMENTAL|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement (MBSR+PS)|The study intervention is standard mindfulness-based stress reduction (MBSR), which will be delivered through 8 weekly 2.5-hour sessions via video conferencing to groups of 20-30 pregnant and non-pregnant people. MBSR also consists of a 2.5-hour orientation session, a 30-minute private interview with the instructor, and an all-day retreat, all conducted via video conferencing. The supplemental prenatal sleep content will be delivered through 6-8 30-minute sessions via video conferencing either individually or to small groups, and draws material from mindfulness-based therapy for insomnia, mindfulness-based childbirth and parenting program, and cognitive behavior therapy for prenatal insomnia.
62521639|NCT05017974|OTHER|Treatment as Usual|The control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy, with the exception of asking participants to refrain from participating in non-study mindfulness practice. Use of non-study treatment will be tracked.
62521640|NCT02413931||Patients with MDR-TB|Patients with multidrug-resistant tuberculosis admitted for treatment at the Marius Nasta Institute will be included
62521641|NCT02988869|EXPERIMENTAL|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
62521642|NCT02988869|ACTIVE_COMPARATOR|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
62521643|NCT02988869|ACTIVE_COMPARATOR|Tiotropium + Formoterol|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
62711596|NCT05099263|EXPERIMENTAL|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will undergo bilateral treatment of the nasal airway in a single study procedure session. Each side of the nose will be treated as follows:~• Two (2) to six (6) nonoverlapping applications of RF energy are performed at the SSB per nostril.~The default treatment settings will be used for the study: temperature 60 C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (36 months)."
62711597|NCT04372914|EXPERIMENTAL|BRB Lozenges|Oral lozenges that contain 1 gram of BRB freeze-dried powder
62711598|NCT05029752|OTHER|Vendys II Device|Your participation in this study will be over after your blood vessel health is measured 1 time with the Vendys II device
62711599|NCT03479983|EXPERIMENTAL|AMX160|500 mg (one capsule) x 2 times daily for 90 days
62711600|NCT03479983|PLACEBO_COMPARATOR|Placebo|500mg (one capsule) x 2 times daily for 90 days.
62711601|NCT05485558|PLACEBO_COMPARATOR|Control group|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
62711602|NCT05485558|ACTIVE_COMPARATOR|N-acetyl cysteine group|15 patients will receive 10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
62711603|NCT05485558|ACTIVE_COMPARATOR|N-actyl cysteine group|15 patients will receive 40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
62711604|NCT00278161|EXPERIMENTAL|R-HiCy|Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.
62711605|NCT06400667|EXPERIMENTAL|Healthy subjects|Subjects without upper limb disease
61975280|NCT05975515|ACTIVE_COMPARATOR|immediate implant placement with bone grafts till crest|Group1 (control group): immediate implant placement with bone grafts till crest and customized healing abutment.
62150000|NCT03556410|EXPERIMENTAL|sleep+exercise|Subject will undergo 5 days of shortened sleep but also have 45 min of moderate exercise/day and then 2 days of ad libitum sleep
62150001|NCT00861991|EXPERIMENTAL|Perspective taking intervention|Students were given an instruction to take the perspectives of their standardized patients
62150002|NCT00861991|ACTIVE_COMPARATOR|Control|Students given standard instructions
62150003|NCT00952640|ACTIVE_COMPARATOR|vitamin A directly post-partum|200.000 IU of vitamin A within 3 days of delivery
62521644|NCT02523196|OTHER|(HVPG) and HepQuant-SHUNT (HQ-Shunt)|"Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.~Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices."
62521645|NCT04810520||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
62521646|NCT04810520||Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed without tele-supervision.
62521647|NCT01684436|EXPERIMENTAL|Punctal plug|Punctal plugs inserted into the study eye on Day 1.
62150004|NCT00952640|EXPERIMENTAL|vitamin A delayed|200.000 IU vitamin A 6 weeks post-partum
62150005|NCT00211926|EXPERIMENTAL|StaphVAX|
62521648|NCT02031016|ACTIVE_COMPARATOR|Fentanyl|"fentanyl bolus injections on an as needed base, next to the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
62521649|NCT02031016|ACTIVE_COMPARATOR|Remifentanil|remifentanil, starting with 0.15 ug/Ideal Body Weight(IBW)(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
62521650|NCT01071148||Subgroup 1: Age < 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
62711606|NCT06400667|EXPERIMENTAL|Pathological subjects|Subjects with a brain injury like cerebral phalsy or acquired brain injury
62711607|NCT03870048|EXPERIMENTAL|All Study Participants/tDCS or SHAM|"tDCS Block: The participant will receive tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.~Sham block: Identical to the tDCS block, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes."
62711608|NCT04120870|ACTIVE_COMPARATOR|Etomidate|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
62711609|NCT04120870|EXPERIMENTAL|Ketamine|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
62711610|NCT04919512|EXPERIMENTAL|Cohort 1: TAR-200 + Cetrelimab|Participants will receive TAR-200 in combination with cetrelimab.
62711611|NCT04919512|EXPERIMENTAL|Cohort 2: Cetrelimab|Participants will receive cetrelimab.
62711612|NCT04289480||ENTERPRISE 2 group|"The study population enrolled for this clinical study is aneurysm patients who need stent-assisted coiling treatment, using ENTERPRISE 2 device."
62711613|NCT01889914|EXPERIMENTAL|continuous infusion of insulin by pump|"in this arm called continuous infusion of insulin with a pump the patient receive continuous rapid insulin (APIDRA ®)with an external pump.~An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin)"
62711614|NCT01889914|EXPERIMENTAL|discontinuous insulin multiple injections|"An arm called  intensification of the multiple daily injections : the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®).~An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment"
62711615|NCT01421056|EXPERIMENTAL|CHF 5074 1x|oral tablet, multidose
62711616|NCT01421056|EXPERIMENTAL|CHF 5074 2x|oral tablet, multidose
62711617|NCT01421056|EXPERIMENTAL|CHF 5074 3x|oral tablet, multidose
62711618|NCT06710925|EXPERIMENTAL|TNM001|
62711619|NCT06710925|PLACEBO_COMPARATOR|Placebo|
62150006|NCT00211926|PLACEBO_COMPARATOR|Placebo|
62150007|NCT01083966|EXPERIMENTAL|Avastin|IA Avastin
62150008|NCT05584748|EXPERIMENTAL|Simulation group|During anodal stimulation, the participants will receive 1.5 mA of constant current over the site for 20 min, with a 15-second ramp up and scale down at the beginning and the end of the procedure.
62150009|NCT05584748|SHAM_COMPARATOR|Sham group|In the sham stimulation condition, the current will only be administered during the first 30 seconds and last 30 seconds of the 20-minute window.
62150010|NCT04152824|EXPERIMENTAL|Leader Intervention|Leaders in the intervention group will go through the Resilience-Supportive Leadership Training (RESULT)
62150011|NCT04152824|NO_INTERVENTION|Control Group|Leaders in the control group will be usual practice
62150012|NCT04321109|EXPERIMENTAL|Collagen cone|Collagen matrix
62150013|NCT04321109|ACTIVE_COMPARATOR|Allograft|mineralized corticocancellous allograft
62150014|NCT05211726|EXPERIMENTAL|Low Added Sugar Diet|Subjects will be provided with a diet that is low in added sugars.
62150015|NCT05211726|EXPERIMENTAL|High Added Sugar Diet|Subjects will be provided with a diet that is high in added sugars.
62150016|NCT01106807|EXPERIMENTAL|CD07223 1.5% gel|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
62150017|NCT01106807|EXPERIMENTAL|CD07223 0.5% gel|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
61975281|NCT05975515|EXPERIMENTAL|immediate implant placement with customized healing abutment|Group 2 (intervention 1 group): Immediate implant placement with CTG and customized healing abutment.
61975282|NCT05975515|EXPERIMENTAL|immediate implant placement with CTG and customized healing abutment.|Group 3 (intervention 2 group): immediate implant placement with customized healing abutment
61975283|NCT02632955|EXPERIMENTAL|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
61975284|NCT02632955|SHAM_COMPARATOR|Regular Angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
61975285|NCT00989014|EXPERIMENTAL|CD07805/47 0.5% Topical Gel|0.5% Topical Gel
61975286|NCT00989014|EXPERIMENTAL|CD07805/47 0.18% Topical Gel|0.18% Topical Gel
62150018|NCT01106807|ACTIVE_COMPARATOR|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces
62150019|NCT04698694|EXPERIMENTAL|Subjects treated with Cliniporator® using a voltage amplitude of 40 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 40 V.
62150020|NCT04698694|EXPERIMENTAL|Subjects treated with Cliniporator® using a voltage amplitude of 60 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 60 V.
62150021|NCT02527694|EXPERIMENTAL|Flexible EMS Stretcher Cart Group|Patients in this group will be transported on the new flexible EMS stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
62711620|NCT05457595|EXPERIMENTAL|carbon ion radiotherapy|All enrolled subjects will undergo carbon ion radiation therapy. Patients affected by pelvic recurrence of gynecological neoplasia, already undergone to radiotherapy on pelvis, will be enrolled in the study.
62711621|NCT06677892||All Participants|Participants with post-transplant CMV infection and/or disease that are refractory or intolerant to one or more prior therapies, who have undergone a solid organ transplant/ hematopoietic stem-cell transplantation (SOT/HSCT) and are treated with maribavir for the first time and in line with the Belgian reimbursement criteria, data will be collected and observed prospectively for up to 2 years.
62711622|NCT04350684|EXPERIMENTAL|Umifenovir|Umifenovir + Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
62150022|NCT02527694|NO_INTERVENTION|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
62150023|NCT02709200||Dexmedetomidine|Patients that received dexmedetomidine during open heart surgery.
62150024|NCT02709200||No dexmedetomidine|Patients that didn't receive dexmedetomidine during open heart surgery.
62711623|NCT04350684|ACTIVE_COMPARATOR|Control|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
62711624|NCT02675829|EXPERIMENTAL|Cohort 1: Lung cancers, HER2 mutant|
62711625|NCT02675829|EXPERIMENTAL|Cohort 2: Lung cancers, HER2 amplified|
62150025|NCT02731066|EXPERIMENTAL|High pro, carbo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
62150026|NCT02731066|EXPERIMENTAL|Standard pro, carbo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
62150027|NCT02731066|EXPERIMENTAL|High pro, placebo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
62711626|NCT02675829|EXPERIMENTAL|Cohort 3: Colorectal cancers|
62711627|NCT02675829|EXPERIMENTAL|Cohort 4: Endometrial cancers|
62150028|NCT02731066|EXPERIMENTAL|Standard pro, placebo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
62150029|NCT05389202|EXPERIMENTAL|Patients benefitting from a perfusion CT scan before embolization|Prostatic perfusion parameters seem to be correlated with the effectiveness of embolization. Studying these prostatic perfusion parameters in perfusion CT and evaluating the prostatic Iodine load in dual energy CT will make it possible to better select responder patients.
62150030|NCT03648749|EXPERIMENTAL|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided
62150031|NCT06030739|NO_INTERVENTION|Usual Care|No letter
62150032|NCT06030739|EXPERIMENTAL|Standard Letter|This group will receive a standard letter on the benefits of influenza vaccination without behavioral economic enhancement
62150033|NCT06030739|EXPERIMENTAL|Repeated Letter|The standard letter sent out two times instead of once
62150034|NCT06030739|EXPERIMENTAL|Cardiovascular Gain-Framing Letter|Text added to the standard letter highlighting potential cardiovascular benefits of influenza vaccination
62150035|NCT06030739|EXPERIMENTAL|Respiratory Gain-Framing Letter|Text added to the standard letter highlighting potential respiratory disease-related benefits of influenza vaccination
62150036|NCT06030739|EXPERIMENTAL|Implementation Intention Prompt Letter|Implementation intention prompt added to the standard letter
62150037|NCT06030739|EXPERIMENTAL|Loss-Framing Letter|Text added to the standard letter highlighting potential risks of not receiving influenza vaccination
62357538|NCT02645591|EXPERIMENTAL|Nerve Sparing RARP + AmnioFix®|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.
62357539|NCT02645591|ACTIVE_COMPARATOR|Nerve Sparing RARP|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)
62711628|NCT02675829|EXPERIMENTAL|Cohort 5: Salivary gland cancers|
62711629|NCT02675829|EXPERIMENTAL|Cohort 6: Other solid cancers|
62711630|NCT05365776|EXPERIMENTAL|Arm 1: Graded Exposure Therapy|
62711631|NCT05365776|ACTIVE_COMPARATOR|Arm 2: Prescribed Aerobic Exercise|
62711632|NCT05365776|ACTIVE_COMPARATOR|Arm 3: Enhanced usual care|
62711633|NCT05210725|EXPERIMENTAL|Stable coronary artery disease|Patients with stable coronary artery disease with an indication for single antiplatelet therapy according to international (ESC) guidelines, with a high cardiovascular risk.
62711634|NCT02605902|ACTIVE_COMPARATOR|iCBIT|internet-delivered Comprehensive Behavioral Intervention for Tics (iCBIT) consisting of psychoeducation, habit reversal training (HRT), function-based assessment and intervention, and relaxation training
62711635|NCT02605902|PLACEBO_COMPARATOR|Control intervention/reference test|internet-delivered psychoeducation and relaxation training.
62711636|NCT02605902|ACTIVE_COMPARATOR|face-to-face CBIT-treatment|face-to-face CBIT-treatment
62711637|NCT01987076|ACTIVE_COMPARATOR|Corticosteroids per os: Prednisone + Emollient|
62711638|NCT01987076|EXPERIMENTAL|Topical corticosteroid: Clobetasol + Emollient|
62711639|NCT03333603|EXPERIMENTAL|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
62150038|NCT05123755|ACTIVE_COMPARATOR|AV-001 Injection with standard of care (SOC).|A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3 and to be determined (TBD) in cohort 4. The dose for cohort 4 will be determined by the Data Safety Monitoring Board (DSMB) based on emerging data from cohorts 1, 2 and 3.
62150039|NCT05123755|PLACEBO_COMPARATOR|AV-001 Placebo Injection with standard of care (SOC).|A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).
62150040|NCT05080348|ACTIVE_COMPARATOR|Ropivacaine iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.25% Ropivacaine with 1:400,000 epinephrine in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
62711640|NCT03700177|ACTIVE_COMPARATOR|ropivacaine + dexamethasone|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).
62711641|NCT03700177|PLACEBO_COMPARATOR|ropivacaine + placebo|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml placebo (NaCl 0,9%).
62711642|NCT05141695|EXPERIMENTAL|therapeutic group|therapeutic repetitive peripheral magnetic stimulation
62711643|NCT05141695|SHAM_COMPARATOR|sham group|sham repetitive peripheral magnetic stimulation
62711644|NCT06719336|EXPERIMENTAL|Addition of thoracic consolidation radiotherapy to the maintenance therapy with PD-L1 inhibitor|
62711645|NCT06719336|ACTIVE_COMPARATOR|Maintenance therapy with PD-L1 inhibitor|
62711646|NCT04088903|EXPERIMENTAL|Daratumumab infusion|"* Participants will receive an intravenous infusion of daratumumab weekly for 8 doses and then every other week for 2 doses.~* For this dose-escalation study, the initial patients will receive a 2 mg/kg dose of daratumumab. In subsequent patients, the dose will be uptitrated to 16 mg/kg as tolerated.~* Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
62711647|NCT04582591|EXPERIMENTAL|Cannabidiol|Patients will receive cannabidiol in conjunction with their standard chemotherapy treatment
62150041|NCT05080348|SHAM_COMPARATOR|Normal Saline iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.9% Normal Saline in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
62150042|NCT02407899|EXPERIMENTAL|Metformin (and insulin) + saxagliptin|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5mg/d and Metformin 1.5g/d (and insulin at individual dose) for 104-week.
62150043|NCT02407899|EXPERIMENTAL|Metformin(insulin)+saxagliptin +vitamin D3|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5 mg/d, vitamin D drop 2000IU/d, Metformin 1.5g/d (and insulin at individual dose) for 104-week.
62150044|NCT02407899|ACTIVE_COMPARATOR|Metformin (and insulin)|Patients who have diagnosed LADA are assigned to receive Metformin 1.5g/d(and insulin at individual dose) for 104-week.
62150045|NCT02064933||Retrospective Cohort (Longitudinal Analysis)|Participants with WAS treated at consortium centers since 1990 who have received transplant (Stratum A) or gene therapy (Stratum B)
62357540|NCT02964988|EXPERIMENTAL|uPAR PET/CT|Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
62357541|NCT02268071|EXPERIMENTAL|Hypertensive patients|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
62357542|NCT02097485|ACTIVE_COMPARATOR|Abametapir Lotion 0.74% w/w|Topically administered to hair and scalp for 10 minutes application.
62357543|NCT02097485|PLACEBO_COMPARATOR|Vehicle Lotion|Administered to scalp and hair for 10 minutes application.
62357544|NCT05989295|PLACEBO_COMPARATOR|Placebo group|2.0 g maltodextrin /sachet； Take one sachet a day before meals. Dilute in water； Store in a cool, dry place without sun exposure.
62521651|NCT01071148||Subgroup 2: 42 > Age ≥ 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
62711648|NCT02449525|EXPERIMENTAL|perfusion of flaps by a bypass system|Support of perfusion of microvascular free flaps until ingrowth of vessels from the wound bed has taken place. The System works with a pressure controlled bypass to ensure low grade perfusion.
62711649|NCT02499744|ACTIVE_COMPARATOR|HHFNC|HHFNC is provided nasal cannula. Ventilator settings:fraction of inspired oxygen (FiO2):21-40%,flow:2-8(litre,L)/min,to maintain arterial blood hemoglobin oxygen saturation ( SaO2) at 90-95% The weaning process is left to the discretion of the attending physician.,when FiO2: 25%,flow:2(litre,L)/min.
62711650|NCT02499744|ACTIVE_COMPARATOR|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP):6cm H2O,R:30 per minute .
62711651|NCT00618761|EXPERIMENTAL|1|kidney-pancreas recipients
62711652|NCT00618761|ACTIVE_COMPARATOR|2|kidney recipients
61975287|NCT00989014|EXPERIMENTAL|CD07805/47 0.07% Topical Gel|0.07% Topical Gel
62711653|NCT00618761|ACTIVE_COMPARATOR|3|healthy controls
62711654|NCT00618761|ACTIVE_COMPARATOR|4|beta-cell recipients
62711655|NCT06716892||Healthy|Healthy adult volunteers. Exclusion criteria: Chronical abuse of alcohol and nicotine, pregnancy and breastfeeding, ink / tattoo in the areas of interest (upper back, distal forearm, upper and lower leg)
62711656|NCT06716892||Head and neck cancer patients.|Patients with histopathological diagnosed head and neck cancer.
61975288|NCT00989014|PLACEBO_COMPARATOR|CD07805/47 Vehicle Topical Gel|Vehicle Topical Gel
61975289|NCT00387439|EXPERIMENTAL|standard medical treatment|standard medical treatment
61975290|NCT00387439|EXPERIMENTAL|standard medical treatment + anoperineal physiotherapy|standard medical treatment + anoperineal physiotherapy
62711657|NCT05619393|EXPERIMENTAL|Mobilie Bi-planar X-ray Imaging system|
62521652|NCT05987462|EXPERIMENTAL|Green Walk group|Patients who were admitted to the Cardiology Outpatient Clinic of Y State Hospital and passed the 6MWT conducted by the cardiology physician were eligible for participation in the green walk group. Following the physician's examination at the Cardiology Outpatient Clinic, the researcher conducted face-to-face interviews with the patients in a private room. During these interviews, the patients were administered the Structured Patient Information Form, Blood Lipids and BMI Monitoring Form, the Brief IPQ, and the MIDAS, and the collected data were recorded on the respective forms. Then, the researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups.
62521653|NCT05987462|NO_INTERVENTION|Control group|"Patients who were admitted to the Cardiology Outpatient Clinic of X State Hospital and passed the 6MWT conducted by the cardiology physician were enrolled in the control group. Upon their visit to the outpatient clinic, the patients in this group underwent a face-to-face interview, during which they were administered the Structured Patient Information Form, the Blood Lipids and BMI Monitoring Form, the Brief-IPQ, and the MIDAS as pretests. . The patients in the control group continued with their routine daily activities. No specific intervention or additional measures were implemented by the investigator in this group. Furthermore, a follow-up Blood Lipids and BMI Monitoring Form was administered to the patients during their visit to the Cardiology Outpatient Clinic in the middle of the study (6th week). At the end of the 12-week period, the patients in the control group underwent a posttest."
62521654|NCT03077906||Existing gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who already had a disabling gastroœsophageal reflux resistant to medical treatment in pre-op, and lost it in post-op."
62521655|NCT03077906||De novo gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who developped gastroœsophageal reflux de novo."
62521656|NCT01254474|EXPERIMENTAL|MAP 4 procedure|Assess MAP 4 mapping capabilities in cardiac chambers in patients suffering from regular or fibrillating tachycardia's
61975291|NCT05061810|EXPERIMENTAL|Group A: Arm 1|Arm 1, group A will receive standard respiratory outpatient care such as routine virtual visits to the respiratory clinic at 6 and 12 months along with the use of a smartphone app self-management programme with follow up monthly phone calls. They will be asked to use the spirobank spirometer (measures lung function, FEVI), pulse oximeter (measures oxygen saturations, SP02) and input the dyspnoea score (m MRC), step count and view the educational videos on the app twice a week for twelve months. The smartphone app self-management programme will prompt the patient once a week to remind them to input their data. Furthermore, they will receive motivational messages weekly via the app. At the routine visits they will complete questionnaires on engagement, quality of life, m MRC scale and self-efficacy at these visits over the phone. They will inform the research team of self-reported GP visits or hospital admissions due to an exacerbation of COPD.
61976400|NCT05152901|ACTIVE_COMPARATOR|EpiPen ®.|Dosage Form- Intra muscularly (IM), Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via IM on day, Visit 2.
62521657|NCT05579574|EXPERIMENTAL|BMS-986322 and Loestrin|Loestrin, then progress to combination
62521658|NCT05834530|NO_INTERVENTION|Conventional Complete Denture|
62521659|NCT05834530|EXPERIMENTAL|3 D printed Complete Denture|
62521660|NCT00232271|ACTIVE_COMPARATOR|clexane|patients received clexane
62521661|NCT00232271|NO_INTERVENTION|non clexane|no clexane given
62521662|NCT05334264|EXPERIMENTAL|Group A|cervical cerclage between 14 and 20 weeks will be done by one of the three authors. McDonald cervical cerclage.
62521663|NCT05334264|NO_INTERVENTION|Group B|Routine antenatal care without cerclage
62521664|NCT01869478|ACTIVE_COMPARATOR|Intravenous Thrombolysis|0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
62521665|NCT01869478|ACTIVE_COMPARATOR|Endovascular Arterial Reperfusion|Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.
62521666|NCT05161650|EXPERIMENTAL|Ketone monoester (3-OHB)|
62521667|NCT05161650|EXPERIMENTAL|Isocaloric placebo|
62521668|NCT03801941|EXPERIMENTAL|Group A|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with the ATLAS Device at the 4th day and without the device at the 5th day of a 4 weeks rehabilitation program.
62521669|NCT03801941|EXPERIMENTAL|Group B|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without the ATLAS Device at the 4th day and with the device at the 5th day of a 4 weeks rehabilitation program.
62521670|NCT02286219|EXPERIMENTAL|FS102|Dose escalation of either weekly or Q3W of FS102
62521671|NCT02126930|ACTIVE_COMPARATOR|Routine care|"The patients in this receive routine care.~Intervention: Routine care"
62521672|NCT02126930|EXPERIMENTAL|Pharma consult|"The patients in this arm will have a pharmaceutical consult upon hospital discharge.~Intervention: Pharma consult"
62521673|NCT03898674|EXPERIMENTAL|GDT feasibility|Patients undergoing microcirculatory goal directed therapy
62521674|NCT05857826|EXPERIMENTAL|soft tissue release with vaginal dilators|Group A will receive soft tissue release with vaginal diltors. Soft tissue release consists of myofacial release and deep intervaginal massage.Triggers points can be released vaginally or rectally they are so painfyul on palpation deep massage of pelvic floor muscle
62521675|NCT05857826|ACTIVE_COMPARATOR|soft tissue release only|will receive only soft tissue release using trigger point release vaginally or rectally and deep intervaginal massage
62711658|NCT06338111||1|09.11.2020-01.08.2021, patients with sepsis and septic shock
62711659|NCT06338111||2|13.07.2022-04.12.2022, patients with sepsis and septic shock
62711660|NCT04242147|EXPERIMENTAL|Bi-weekly Monotherapy Dose Escalation (Q2W)|KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).
62711661|NCT04242147|EXPERIMENTAL|Weekly Monotherapy Dose Escalation (Q1W)|KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW) for 6 weeks and then every 2 week-dosing.
62521676|NCT01251978|ACTIVE_COMPARATOR|High dose Ranibizumab|6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
62521677|NCT01251978|ACTIVE_COMPARATOR|Standard Dose Ranibizumab|6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
62357545|NCT05989295|ACTIVE_COMPARATOR|Probiotic group|(2B CFU/sachet) Lactobacillus rhamnosus LRa05 and maltodextrin Take one sachet a day before meals. Dilute in water； Store in a cool, dry place without sun exposure.
62357546|NCT06259045||Advanced heart failure|Patients enrolled will all have advanced heart failure, defined by a set criteria
62521678|NCT00762931|EXPERIMENTAL|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation, all subjects will receive active treatment
61976401|NCT05152901|EXPERIMENTAL|Epinephrine (0.3mg)|Dosage Form- Inhaled, Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via inhalation on day 2 of Visit 2.
61976402|NCT05152901|EXPERIMENTAL|Epinephrine (1.3mg)|Dosage Form- Inhaled, Dosage- 1.3mg, Dosage Frequency and Duration- Single dose of 1.3mg epinephrine via inhalation on Visit 3.
62357547|NCT03380338|EXPERIMENTAL|Exercise program|Twice weekly exercise program, combined aerobic and strenght training
62521679|NCT02608970|EXPERIMENTAL|BMS-986177|BMS-986177 specified dose on specified days
62357548|NCT06527625|EXPERIMENTAL|Arts group|A 9-week Cultural Art Program
62521680|NCT02608970|OTHER|Placebo|Placebo specified dose on specified days
62521681|NCT00973765|ACTIVE_COMPARATOR|bactrim DS (800/160) 2 pills po BID x 7 days|active comparator
62521682|NCT00973765|PLACEBO_COMPARATOR|Matched placebo 2 pills po BID x 7 days|placebo
62521683|NCT04511052|EXPERIMENTAL|Carotenoid + Probiotic|"Carotenoid: 1 capsule daily of a mixed carotenoid (\~ 20 mg total carotenoids) supplement~Probiotic: 1 capsule daily containing 10 x 10\^9 CFU of a proprietary strain~Total duration: 10 weeks"
62357549|NCT06527625|ACTIVE_COMPARATOR|Waitlist control|Treatment as usual
62521684|NCT04511052|PLACEBO_COMPARATOR|Carotenoid + Placebo|"Carotenoid: 1 capsule daily of a mixed carotenoid (\~ 20 mg total carotenoids) supplement~Placebo: 1 capsule daily containing the same carrier material of the probiotic, that is also similar in size, shape, and taste.~Total duration: 10 weeks"
62521685|NCT04171024|SHAM_COMPARATOR|Sham Group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.~Transcutaneous electrical stimulation settings: Frequency (2 hertz); wave length (300 µs);"
62521686|NCT04171024|EXPERIMENTAL|Transcutaneous diaphragm electrical stimulation group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.~Transcutaneous electrical stimulation settings: Frequency (35 hertz); wave length (300 µs); Intensity to achieve a visual contraction"
62521687|NCT02287493||Meropenem|Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.
62521688|NCT02287493||Ceftazidim|Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.
62521689|NCT01957566|EXPERIMENTAL|APS|
62521690|NCT05545761|EXPERIMENTAL|intervention group|music will be played to the intervention group. They will be asked to listen to the Hüseyni makam for at least 15 minutes at 11.00 in the morning, 5 times a week for 5 weeks, and to listen to the Zirgüle makam for at least 15 minutes at 20.00 on the same day.
62521691|NCT05545761|NO_INTERVENTION|control group|group that does not listen to music and is not interfered with
62711662|NCT04242147|EXPERIMENTAL|Dose Expansion|KD033 (SAR445710) will be administered at recommended dose/schedule for expansion
62357550|NCT00978224|EXPERIMENTAL|A|Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
62521692|NCT02196740|ACTIVE_COMPARATOR|creosote|Creosote ，once，three weeks Triple Antibiotic Paste ，none
62711663|NCT03700229|EXPERIMENTAL|Bortezomib +Rituximab|Bortezomib +Rituximab
62711664|NCT03586947|EXPERIMENTAL|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
62711665|NCT03586947|NO_INTERVENTION|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
62521693|NCT02196740|EXPERIMENTAL|Triple Antibiotic Paste|Triple Antibiotic Paste,once,three weeks creosote,none
62521694|NCT02667288|EXPERIMENTAL|A-101 Solution|A-101 Solution 40% administered once
62521695|NCT01408095|EXPERIMENTAL|LY2608204|80 to 400 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. The starting dose level depends on the participant's HbA1c level measured at Screening. Administered orally, daily for 12 weeks
62521696|NCT01408095|ACTIVE_COMPARATOR|Glimepiride|1 to 6 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. Administered orally, daily for 12 weeks
62521697|NCT05058534||Very preterm infants born between November 30, 2018 and November 30, 2019|Infants born between November 30, 2018 - November 30, 2019, before implementation of the new multiperfusion neonatal system
62521698|NCT05058534||Very preterm infants born between December 1st, 2019 and December 31st, 2022|Infants born between January 1rst, 2019 - December 31st, 2022, after implementation of the new multiperfusion neonatal system
62711666|NCT05638074||With cervical facet tropism|
62711667|NCT05638074||Without cervical facet tropism|
62711668|NCT01510574|ACTIVE_COMPARATOR|misoprostol|3 tablets of 200mcg misoprostol self-administered following home birth, taken orally immediately after delivery of baby
62711669|NCT01510574|PLACEBO_COMPARATOR|placebo|3 tablets of placebo resembling misoprostol self-administered following home birth, taken orally immediately after delivery of baby
62711670|NCT01146145|EXPERIMENTAL|treatment|intravenous morphine titration combined to ketamine
62711671|NCT01146145|PLACEBO_COMPARATOR|placebo|morphine titration alone
62711672|NCT01138410|EXPERIMENTAL|SCIB1|
62711673|NCT01917318|EXPERIMENTAL|Iloperidone / Placebo|During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
62150046|NCT02064933||Prospective Cohort (Longitudinal Analysis)|Participants treated at consortium centers since 1990 who will receive transplant (Stratum A) or gene therapy (Stratum B)
62150047|NCT02064933||Cross-Sectional Cohort (Cross-sectional Analysis)|Living participants with WAS who have received transplant (Stratum A) or gene therapy (Stratum B) at Consortium Centers 1990-Present And \>= 2 Years Post-Transplant
62150048|NCT02596737|OTHER|workers|"Workers will fulfil a visual analog scale of Well-being regarding 3 main categories: Physically, Mentally, At Work."
62150049|NCT04867772|OTHER|Usual Care|Participants will receive the care that would usually be received in the local hospital setting. this has been determined as between 1 and 6 sessions of physiotherapy
62150050|NCT04867772|EXPERIMENTAL|Intervention|Participants will receive a home based rehabilitation programme with 1-7 sessions of physiotherapy delivered over 12 weeks.
62711674|NCT01917318|EXPERIMENTAL|Placebo / Iloperidone|During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.
62711675|NCT03582176|PLACEBO_COMPARATOR|Lactose Placebo|Lactose Placebo by mouth twice per day
62711676|NCT03582176|ACTIVE_COMPARATOR|Ketotifen Fumarate - 2mg|Ketotifen Fumarate 2 mg by mouth twice per day
62711677|NCT03582176|ACTIVE_COMPARATOR|Ketotifen Fumarate - 5mg|Ketotifen Fumarate 5 mg by mouth twice per day
62357551|NCT00978224|PLACEBO_COMPARATOR|B|Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
62711678|NCT02866747|ACTIVE_COMPARATOR|Arm A: radiation therapy alone|Hypofractionated stereotactic radiation therapy (hFSRT) 24 Gray (Gy), 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 of the radiotherapy (RT), Day 3 RT and Day 5 RT.
62711679|NCT02866747|EXPERIMENTAL|Arm B: combined treatment|"hFSRT 24 Gy, 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 RT, Day 3 RT and Day 5 RT, combined with Durvalumab infusion: first administration of Durvalumab\* on Day 5 RT (i.e. the same day after the last fraction of radiation, corresponding to the Day 1 for Durvalumab treatment) and then administration of Durvalumab 1500 milligrams (mg) every four weeks.~\* Dosing 750 mg or 1500 mg, according to the recommended combination schema determined in phase I."
62711680|NCT04190368|OTHER|Team Clinic Care: No VTC Groups|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient and yearly team visit as needed~• Providers will utilize a patient centered care approach to conducting appointments"
62357552|NCT01797315|ACTIVE_COMPARATOR|Sirolimus|Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
62711681|NCT04190368|OTHER|Team Clinic: Virtual Team Clinic Group|"Participants will be invited to participate in online/virtual thematic group sessions led by Team Clinic group facilitators (e.g., RD, SW, RN) aimed at improving glycemic control and treatment adherence, increasing social supports and diabetes care satisfaction, and aid in the transition from caregiver led treatment to self care.~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
62711682|NCT04190368|OTHER|Standard Care: No VTC Groups|Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).
62711683|NCT04190368|OTHER|Standard Care: Virtual Team Clinic|"Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
62357553|NCT01797315|NO_INTERVENTION|Standard therapy|Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.
62711684|NCT03170440|EXPERIMENTAL|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
62711685|NCT03170440|ACTIVE_COMPARATOR|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
62150051|NCT03841994||Preterm infant cohort|Preterm infants who were born \<28 weeks of gestational age
62150052|NCT05207397||Healthy Control|Lactate clamp: After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. The investigator will then administer priming doses of 57.5 mg \[3-13C\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[3-13C\]lactate at 10 mg/min and D2-glucose at 2 mg/min. Along with the continuous isotope infusion the investigator will begin infusion of the Na-lactate at approximately 2.6mg/kg·min. Based upon readings from blood samples during the infusion, this rate will be adjusted as needed to maintain the target lactate concentration of approximately 4-5 mM. Blood samples will be drawn at 10, 20, 30, 45, 60, 75, 90 and 120 minutes, while breath samples will be collected at 60, 75, 90 and 120 minutes.
62357554|NCT02729805|PLACEBO_COMPARATOR|Saline|A syringe of 50 ml 0.9% normal saline will be prepared as placebo for infusion and a syringe of 10ml 0.9% normal saline for bolus injection.
62357555|NCT02729805|ACTIVE_COMPARATOR|Ketamine 0.5mg/kg|A bolus injection of intravenous ketamine at a dose of 0.5mg/kg during anaesthetic induction before skin incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation.
62357556|NCT02729805|EXPERIMENTAL|Ketamine 0.75mg/kg|A bolus injection of intravenous ketamine at a dose of 0.75mg/kg during anaesthetic induction before skin incision followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation.
62357557|NCT03014921|PLACEBO_COMPARATOR|placebo injection group|saline solution injection as placebo
62357558|NCT03014921|ACTIVE_COMPARATOR|iron injection group|iron injection
62711686|NCT05964894|EXPERIMENTAL|Ergonomic training group|The ergonomic training group received a 12-week ergonomic training program.
62711687|NCT05964894|NO_INTERVENTION|No training group|The no training group did not receive any training program.
62150053|NCT05207397||Mild Cognitive Impairment|Lactate clamp: After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. The investigator will then administer priming doses of 57.5 mg \[3-13C\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[3-13C\]lactate at 10 mg/min and D2-glucose at 2 mg/min. Along with the continuous isotope infusion the investigator will begin infusion of the Na-lactate at approximately 2.6mg/kg·min. Based upon readings from blood samples during the infusion, this rate will be adjusted as needed to maintain the target lactate concentration of approximately 4-5 mM. Blood samples will be drawn at 10, 20, 30, 45, 60, 75, 90 and 120 minutes, while breath samples will be collected at 60, 75, 90 and 120 minutes.
62150054|NCT06169566|ACTIVE_COMPARATOR|Intervention|synbiotics
62521699|NCT03458637|EXPERIMENTAL|LITE Program with usual care.|LITE Program with usual care. LITE program involves four x 180 min weekly sessions, followed by three x 90 min monthly sessions, for adolescents and parents. The key aspects covered in the LITE program are in keeping with Health Promotion Board guidelines for the management of overweight and obesity and include healthy food choices and eating patterns, increasing physical activity and reducing sedentary behavior. The parenting aspects aim to support and increase parental capacity to implement and maintain the lifestyle changes.
62521700|NCT03458637|ACTIVE_COMPARATOR|Usual Care|Usual care consisting of Weight management clinic consultation at baseline randomization, 3 and 6 months post randomization in a tertiary setting in KK Hospital. Duration of treatment is 6 months. Qualified pediatrician, trained in screening for causes and medical complications of obesity in children, runs the weight management clinic and review the participant at each visit. Optional physical activity, dietary consultation at each weight management clinic visit.
62521701|NCT02697773|PLACEBO_COMPARATOR|Placebo|placebo administered subcutaneously at day 0 and week 8
62521702|NCT02697773|EXPERIMENTAL|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
61975292|NCT05061810|EXPERIMENTAL|Group B: Arm 2|Those allocated to the intervention groups B will receive standard respiratory outpatient care such as routine virtual visits at 6 and 12 months to the respiratory outpatient clinic along with the use of a smartphone app self-management programme. They will be asked to use the spirobank spirometer (measures lung function, FEV1), pulse oximeter (measures oxygen saturations, SP02) and input the dyspnoea score (m MRC), their step count and view the educational videos on the app twice a week for twelve months. The smartphone app self-management programme will prompt the patient once a week to remind them to input their data. Furthermore, they will receive motivational messages weekly via the app. At the routine visits they will complete questionnaires on engagement, quality of life, m MRC scale and self-efficacy at these visits over the phone. They will inform the research team of self-reported GP visits or hospital admissions due to an exacerbation of COPD.
62150055|NCT06169566|PLACEBO_COMPARATOR|non-intervention|placebo
62150056|NCT04951791|EXPERIMENTAL|treatment|patients will receive intravenous infusion of SMOFlipid 20%
62150057|NCT04951791|PLACEBO_COMPARATOR|control|patients will receive intravenous infusion of normal saline 0.9%
62521703|NCT02697773|EXPERIMENTAL|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
62150058|NCT01297088|EXPERIMENTAL|Arm 1|
62150059|NCT05051072|OTHER|MRI in morphological sequence, diffusion tensor and resting functional|"* standard anatomical sequences T1, FLAIR (Fluid Attenuated Inversion Recovery), TOF(Time-of-flight MR angiography) , DRIVE, sequence centered on the V after injection of gadolinated contrast product as part of routine care,~* diffusion tensor sequence (DTI)"
62150060|NCT01529866|EXPERIMENTAL|New abutment connection implant|Implant with new abutment connection
62150061|NCT01529866|ACTIVE_COMPARATOR|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
62150062|NCT01333215||Group 1|Depressed older suicide non-attempters
62150063|NCT01333215||Group 2|Depressed older suicide attempters
62150064|NCT01211015||Control group|healthy control group
62150065|NCT01211015||Disease group|asthma, COPD, ILD, lung malignancy
62150066|NCT04998266|EXPERIMENTAL|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
62521704|NCT00626717|EXPERIMENTAL|1|
62521705|NCT00626717|SHAM_COMPARATOR|2|
62521706|NCT01566864|EXPERIMENTAL|Behavioral: Improve clinic based measurement of blood pressur|
62521707|NCT01566864|EXPERIMENTAL|Behavioral: Provider education system to promote patient-cent|
62521708|NCT01566864|EXPERIMENTAL|Behavioral: Introduce care management system in clinics|
62521709|NCT06000917|EXPERIMENTAL|pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel|"Pyrotinib tablets: 320mg qd, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration"
62521710|NCT06138470|ACTIVE_COMPARATOR|Saffron extract|
62521711|NCT06138470|ACTIVE_COMPARATOR|Scutellaria baicalensis extract|
62521712|NCT06138470|ACTIVE_COMPARATOR|Saffron and Scutellaria baicalensis extract|
62521713|NCT06138470|PLACEBO_COMPARATOR|Placebo (maltodextrin)|
62521714|NCT02312713|ACTIVE_COMPARATOR|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
62711688|NCT00946933|PLACEBO_COMPARATOR|Placebo|0.025 g/kg/day of NaCl (sodium chloride)
62711689|NCT00946933|ACTIVE_COMPARATOR|High salt diet|0.2 g/kg/day of NH4Cl (ammonium chloride)
62521715|NCT02312713|EXPERIMENTAL|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
62357559|NCT05960513|EXPERIMENTAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Participants will receive three weekly online instructions (90 minutes each) by trained instructors in addition to standard care. Weekly 60 minutes follow-ups will include 10 minutes of breathing exercises followed by 33 minutes of guided meditation practice, and then focus on participants' experiences with breathing exercise followed by meditation during the week, additional observations, and a review of relevant knowledge to support their home practice.
62357560|NCT05960513|NO_INTERVENTION|No Intervention|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
62357561|NCT04813302|EXPERIMENTAL|Gingival recession treatment|Gingival recession treatment by means of a coronally advanced flap and a connective tissue graft
62357562|NCT00132314|EXPERIMENTAL|Arm 1|long-acting injectable risperidone
62357563|NCT00132314|ACTIVE_COMPARATOR|Arm 2|oral antipsychotic medication
62357564|NCT04105647|EXPERIMENTAL|Experimental group|Patients in the experimental group will receive a face-to-face group session and a package of healthy lifestyle instant messages, including lifestyle-integrated exercise and physical activity.
62357565|NCT04105647|PLACEBO_COMPARATOR|Control group|The control group will receive a face-to-face group session and a package of healthy lifestyle instant messages, but not related to lifestyle-integrated exercise and physical activity.
62357566|NCT00961441|EXPERIMENTAL|Children 12-16 years old|
62357567|NCT00961441|EXPERIMENTAL|Adults 18-55 years old|
62357568|NCT02575677||Parturients with oxycodone|Parturients who were given oxycodone
62357569|NCT03808428|EXPERIMENTAL|Ankle Group|Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm.
62357570|NCT06011980|EXPERIMENTAL|Group A|Participants in this group will take growth inhibitors for 5 days after endoscopic treatment.
62357571|NCT06011980|NO_INTERVENTION|Group B|Participants in this group will not take growth inhibitor treatment after endoscopic treatment.
62357572|NCT01746914||Lung transplantated patients|Patients undergone lung transplantation
62357573|NCT00861380|EXPERIMENTAL|10Pn3+1-6W- 6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
62357574|NCT00861380|EXPERIMENTAL|10Pn2+1-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
62357575|NCT00861380|ACTIVE_COMPARATOR|Ctrl-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
62357576|NCT00861380|EXPERIMENTAL|10Pn7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
62357577|NCT00861380|ACTIVE_COMPARATOR|Ctrl7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
61976403|NCT05152901|EXPERIMENTAL|Epinephrine (4mg)|Dosage Form- Inhaled, Dosage-4mg, Dosage Frequency and Duration- Single dose of 4mg epinephrine via inhalation on Visit 4.
62521716|NCT02312713|NO_INTERVENTION|Wait list control|no intervention
62150067|NCT04998266|ACTIVE_COMPARATOR|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
62150068|NCT05858606|EXPERIMENTAL|200 patients with idiopathic short stature,|200 patients with apparently idiopathic short stature,
62521717|NCT01648504|EXPERIMENTAL|Intervention with eGuide to colonoscopy|The investigators will prospectively enroll and follow patients who receive the eGuide to Colonoscopy and determine benefit and satisfaction with the intervention as part of a pilot study.
61975293|NCT05061810|ACTIVE_COMPARATOR|Group C: Arm 3 Control group|Participants in group C the control group will receive standard outpatient respiratory care which involves attending the routine visits as outlined above and informing the research team of an GP visits and or hospital admissions relating to an exacerbation of COPD. They will complete questionnaires on quality of life, m MRC scale and self-efficacy at these visits over the phone.
62521718|NCT01797835|PLACEBO_COMPARATOR|Usual Care|Youth in usual care will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. They will also receive an informational brochure.
62521719|NCT01797835|EXPERIMENTAL|CHAT brief MI intervention|Youth in CHAT will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. In addition, these youth will CHAT. CHAT is a brief motivational intervention that takes places in the primary care setting. It is a 15-20 minute intervention for adolescents age 12-18 focused on discussing alcohol and drug use. They will also receive a booster call one month later to check in on how they are doing.
61975294|NCT02967497|NO_INTERVENTION|Blank|No intervention, just observation.
62521720|NCT06307782|EXPERIMENTAL|Total Hip Arthroplasty, whey protein intake,|"In the ERAS (Enhanced Recovery After Surgery) protocol, preoperative oral carbohydrate intake must be at least 45 g. While preparing the whey mixture, 60 grams of whey powder will be mixed into 600ml bottled water to obtain a mixture worth 200 kcal. Whey will be prepared and given by the researcher at the bedside in room air using bottled water.~In this study, by scanning the literature (13) and taking expert opinion (dietitian, anesthesiologist, orthopedic doctor), the individuals in the intervention group were given 6 hours after the surgery. It is planned to drink 600ml oral whey powder water first."
62521721|NCT06307782|ACTIVE_COMPARATOR|Total Hip Arthroplasty, water intake|600ml of water will be given 6 hours before the surgery.
62521722|NCT02232464||ADHD group|Adults with clinical diagnosis of ADHD according to the DSM-IV criteria
61975295|NCT02967497|EXPERIMENTAL|YQ1 group|Cisplatin-based chemotherapy + YQ1
61976404|NCT03438175|NO_INTERVENTION|Control|Families of Critically Ill will be informed about patients'clinical status only by oral communication during daily family meeting
62357578|NCT00861380|EXPERIMENTAL|10Pn12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
62357579|NCT00861380|ACTIVE_COMPARATOR|Ctrl12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
62521723|NCT02232464||Control group|Age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD
62711690|NCT03817398|EXPERIMENTAL|Basic Science (stop taking TKI, biospecimen collection)|Patients stop taking TKI medication within 10 days after enrollment. Patients undergo peripheral blood collection to monitor loss of MMR every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Patients who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.
62521724|NCT06026111|EXPERIMENTAL|High-Intensity Interval Training (HIIT)|Patients in the HIIT group will perform alternating vigorous-intensity and recovery aerobic exercise intervals on a provided home stationary bike. The HIIT protocol consists of alternating a high-intensity exercise phase (1 min at 65-90% of workload corresponding to VO2peak) and a recovery phase (1 min at 30%), and the high-intensity and recovery intervals will be repeated 5-10 times in each session.
62521725|NCT06026111|EXPERIMENTAL|Moderate-Intensity Continuous Training (MICT)|The MICT group will perform an aerobic exercise at a continuous intensity in each session on a stationary bike. Similar to HIIT, the intensity will be progressed (47.5-60%). The total work of MICT is equalized with HIIT for training volume and frequency to compare the differences exerted from different intensities and energy expenditure.
62521726|NCT06026111|NO_INTERVENTION|Usual Care (UC)|Participants will be asked to maintain their baseline exercise behavior and will be offered to participate in the HIIT exercise program upon the completion of post-intervention assessments after the initial 12 weeks.
62521727|NCT06312514|EXPERIMENTAL|Intervention Arm|Participants will be young gay, bisexual and all other men who have sex men (YGBMSM) and providers from healthcare institutions working with (YGBMSM) who will receive the LAFIYA intervention.
62521728|NCT06312514|EXPERIMENTAL|Waitlist control group.|Control arm for comparison who will receive the intervention after the intervention group
62521729|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
62521730|NCT06045819||Patients with composite complete remission|Patients in composite complete remission following the first cycle of venetoclax (400 mg/day, orally, after a ramp-up phase of the first 3 days) + azacytidine (75mg/m²,intravenous, at the start of each cycle from day 1 to day 7)
62521731|NCT06045819||Patients without composite complete remission|Patients not in composite complete remission following the first cycle of venetoclax (400 mg/day, orally, after a ramp-up phase of the first 3 days) + azacytidine (75mg/m²,intravenous, at the start of each cycle from day 1 to day 7)
62711691|NCT05181488|EXPERIMENTAL|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
62711692|NCT04826198|EXPERIMENTAL|AsiDNA in addition to Niraparib|Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
62521732|NCT02963311|EXPERIMENTAL|ALN-PCSSC|300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by \>70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
62521733|NCT05645770||coronary artery disease|
62357580|NCT01285063|EXPERIMENTAL|physical activiy & nutrition|"25 kindergarten children in the ages of 4-6 who defined as suffering from overweigh (BMI percentage 85-95) or obesity (above BMI percentage 95).~Non-generalization criteria: children who suffer from obesity due to organic disease or children who take medicine which may influence body weight (e.g., steroids) will be excluded from the research."
62357581|NCT05306353|PLACEBO_COMPARATOR|VIB4920 Placebo with TNFi|Participants will receive VIB4920 placebo in a blinded fashion intravenously at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period VIB4920 placebo consists of 0.9% normal saline in 250mL bags.
61975296|NCT05605314||pSS-DED|DED patients who visited the dry eye clinic of Peking University Third Hospital from 2021 to May 2028. The pSS-DED patients further accepted the diagnosis of rheumatology department. All enrolled DED participants met the criterion of TFOS DEWS II Definition and Classification Report and pSS-DED group also met 2016ACR/EULAR pSS diagnosis and classification consensus.
61975297|NCT05605314||nss-DED|DED patients who visited the dry eye clinic of Peking University Third Hospital from 2021 to May 2028.
62521734|NCT05645770||control|
62521735|NCT03110601|ACTIVE_COMPARATOR|Control - Conventional SCS|Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
62521736|NCT03110601|NO_INTERVENTION|Washout Period|1 day where no stimulation is provided
61975298|NCT02654483|EXPERIMENTAL|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
61975299|NCT02654483|PLACEBO_COMPARATOR|Placebo|Placebo tablets to be taken daily by mouth for 56 days
62521737|NCT03110601|EXPERIMENTAL|Test - Stimgenics SCS|Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
62521738|NCT03848169|EXPERIMENTAL|Experimental group|Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.
62711693|NCT03732469|EXPERIMENTAL|Fentanyl/propofol + acetaminophen|In addition to the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol, one dose of 1300 mg of solid base rectal acetaminophen suppository (2 suppositories) will be administered at the end of oocyte retrieval.
62711694|NCT03732469|ACTIVE_COMPARATOR|Fentanyl/propofol only|Participants in this arm will receive the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol.
62711695|NCT04065321||Control group|250 patients will be assigned into control group.
62357582|NCT05306353|EXPERIMENTAL|VIB4920 with TNFi|Participants will receive VIB4920 in a blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period
62357583|NCT05306353|EXPERIMENTAL|VIB4920 without TNFi|Participants will stop TNFi after randomization to this arm, and receive VIB4920 in an evaluator-blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 while maintaining all other background disease-modifying RA therapy (e.g., methotrexate, hydroxychloroquine, etc.) through the study period. This arm is evaluator blinded (not aware of treatment status), with the participant aware of treatment status but evaluator is not, due to not using a TNFi placebo for this study
62357584|NCT01236794|EXPERIMENTAL|Lifestyle and Exercise Intervention|
62357585|NCT02876679|EXPERIMENTAL|Cyclophosphamide|50mg/Kg/day cyclophosphamide (day +3 and +4)
62357586|NCT02876679|ACTIVE_COMPARATOR|Anti-Thymocyte Globulin|2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)
62357587|NCT03998904|EXPERIMENTAL|Muscle preservation|Muscle preservation for hamsting graft
62357588|NCT03998904|ACTIVE_COMPARATOR|None preservation|No muscle preservation for hamstring graft
62357589|NCT05244538|EXPERIMENTAL|Virtual Reality Distraction|In the experimental group, patients will benefit from a 20-minute VR. Patients will watch a forest walk in virtual reality while listening to narrations designed to induce relaxation and meditation. If the oocyte retrieval was not completed within 20 minutes, patients will watch the same VR program again.The TCI remifentanil and propofol will be connected to the infusion but will be stopped and titrated if discomfort.
62711696|NCT04065321||Trial group|250 patients will be assigned into trial group.
62711697|NCT01225952|EXPERIMENTAL|Crystalens AO|Bausch \& Lomb silicone multi-piece accommodating IOL is a modified plate haptic lens
62711698|NCT01225952|ACTIVE_COMPARATOR|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
62711699|NCT01225952|ACTIVE_COMPARATOR|AMO Tecnis Multifocal|A foldable hydrophobic acrylic IOL,(Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL
62711700|NCT04052373|EXPERIMENTAL|Peri-implantitis treatment with implantoplasty|Open flap debridement with implantoplasty treatment
62711701|NCT04052373|ACTIVE_COMPARATOR|Peri-implantitis treatment without implantoplasty|Open flap debridement withput implantoplasty treatment
61975300|NCT04891783||50 patients diagnosed as AS|50 patients diagnosed as AS according to 1984 modified New York criteria of AS .including radiographic and non-radiographic AS according to ASAS criteria these patients will undergo carotid ultrasound examination
61975301|NCT04891783||30 patients with psoriatic arthritis|30 patients with psoriatic arthritis who will be diagnosed according to the Classification Criteria of Psoriatic Arthritis (CASPAR) study these patients will undergo carotid ultrasound examination
62357590|NCT05244538|ACTIVE_COMPARATOR|Sedation group|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml.~The concentration of propofol will be adjusted by an effect concentration of 0.5 ug/ml with a maximum of 1.5 ug/ml, in this case according to a 5-point scale~1. fully awake and oriented~2. drowsy~3. eyes closed, responds quickly to verbal commands~4. eyes closed, aroused only by mild physical stimulation~5. eyes closed, not aroused by mild physical stimulation) A sedation score of 3 will be the target throughout the procedure."
62711702|NCT06304857|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg tablet orally once daily for 12 months
62711703|NCT06304857|PLACEBO_COMPARATOR|Placebo|Placebo tablet matching dapagliflozin orally once daily for 12 months
62711704|NCT02259114|EXPERIMENTAL|Continuous Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
62711705|NCT02259114|EXPERIMENTAL|Days 1-7 Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
62357591|NCT01213264||Spontaneous NMB reversal|Participants whose reversal from NMB is spontaneous (no reversal agent used)
62357592|NCT01213264||NMB reversal with sugammadex|Participants who are administered sugammadex for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
62357593|NCT01213264||NMB reversal with other agents|Participants who are administered any other agent (other than sugammadex) for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
62357594|NCT04714489||experimental group|
62357595|NCT05976932||treatment group|After enrollment, patients will receive standard treatment (pegylated liposomal doxorubicin) and follow-up strategy. Peripheral blood samples will be collected from all patients before treatment and 3 weeks after the first cycle of treatment，If necessary, Peripheral blood samples also be collected after 2 cycles of treatment.
62357596|NCT05578768||training phase|The study procedures for both cohorts are the same.
62357597|NCT05578768||validation phase|The study procedures for both cohorts are the same.
62357598|NCT02284022||Brain Computer Interface|Patients will test the brain computer interface system
62357599|NCT00139841|EXPERIMENTAL|1|bendamustine
62357600|NCT02836132|ACTIVE_COMPARATOR|Weight Watchers Online|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform.
62357601|NCT02836132|EXPERIMENTAL|Weight Watchers Online + Experience Success|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform. They will also receive 6 months of no-cost access to the Experience Success online platform, with 4 virtual reality scenarios for training in behavioral weight loss skills.
62357602|NCT01536652||BIAsp 30 users|
62357603|NCT04890106|EXPERIMENTAL|Bimatoprost 0.01% Ophthalmic Solution|"Bimatoprost Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Mankind Pharma Limited, India.~Intervention Drug: Test - Bimatoprost 0.01% Ophthalmic Solution"
62357604|NCT04890106|ACTIVE_COMPARATOR|LUMIGAN® 0.01% Ophthalmic Solution|"LUMIGAN® ( Contains Bimatoprost) Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Allergan, Inc.,~Intervention Drug: Reference - Bimatoprost 0.01% Ophthalmic Solution"
62357605|NCT03792165|EXPERIMENTAL|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
62711706|NCT06639464|EXPERIMENTAL|Semaglutide|This arm will receive semaglutide (n=23). All participants will initially receive 0.25mg for 4 weeks, and then as tolerated dose will be increased to 0.5mg for 4 weeks. Then as tolerated, the dose will be increased to 1.0mg for 4 weeks.
62711707|NCT06639464|PLACEBO_COMPARATOR|Placebo|This arm will receive saline placebo (n=23).
62711708|NCT00759343||Control Group|"The control subjects of this study will be asked to undergo renal ultrasound examination, if available, or will be asked to complete a disease history form to determine the presence or lack of a kidney stone. Urine and serum will then be taken for storage until further analysis.~Controls will be asked to undergo a screening renal ultrasound to ensure they are stone free, this will take approximately 45 minutes. If the controls are asked to complete the history form, this will not take more than 20 minutes. They will also give a blood and urine sample during this time to bring the total extra time up to at most 60 minutes for controls."
62357606|NCT03792165|ACTIVE_COMPARATOR|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
62357607|NCT04116216|ACTIVE_COMPARATOR|High frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
62357608|NCT04116216|ACTIVE_COMPARATOR|Low frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
62357609|NCT04116216|SHAM_COMPARATOR|Sham rTMS + physical therapy|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
62357610|NCT00498225|EXPERIMENTAL|1|Gemcitabine plus TS-1
62357611|NCT00498225|EXPERIMENTAL|2|TS-1
62357612|NCT00498225|ACTIVE_COMPARATOR|3|Gemcitabine
62711709|NCT00759343||Stone Group|"The stone group will undergo standard diagnostic procedures for their condition and recovery process. Serum and urine for storage and analysis will be taken prior to stone treatment and 6 weeks following stone treatment. This will allow for the determination of differences in a stone patient's protein profile while they have their stone and after they are stone free. All patients will be required to have a stone patient metabolic evaluation which includes serum and urine testing. The analysis will focus on the serum and urine sample that they provide.~The stone patient will be asked to undergo one extra tube of blood during their preoperative assessment which should only add a few seconds to their visit."
62711710|NCT02096978|EXPERIMENTAL|Osteotome preparation|Procedure/Surgery: Preparing the osteotomy to accept a standard implant device
62711711|NCT02096978|ACTIVE_COMPARATOR|Drill preparation|Preparing the osteotomy to accept a standard implant device
62521739|NCT03848169|SHAM_COMPARATOR|Control Group|Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.
62521740|NCT01784666|EXPERIMENTAL|Isradipine-Isradipine|Subjects will receive isradipine in phase 1 (4 weeks) and phase 2 (4 weeks)
62711712|NCT02979587|OTHER|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
62711713|NCT05067101|EXPERIMENTAL|Capsule Sparing Cystectomy|Patients undergoing transurethral resection and enucleation of the prostate before laparoscopic cystectomy
62711714|NCT05067101|PLACEBO_COMPARATOR|Conventional Radical Cystoprostatectomy|Patients undergoing conventional radical cystoprostatectomy
62711715|NCT03200470||Suspected PJI|
62711716|NCT06490146||Study group|premenopausal women without vasomotor symptoms (VMS)
62711717|NCT05849129|EXPERIMENTAL|Intravenous Vitamin C|1g/kg IVC administered twice weekly for 6 months.
62711718|NCT05849129|PLACEBO_COMPARATOR|Normal Saline|Equivalent volume normal saline administered twice weekly for 6 months.
62711719|NCT00153660|ACTIVE_COMPARATOR|NSAID #1|Celecoxib and Naproxen Placebo
62711720|NCT00153660|ACTIVE_COMPARATOR|NSAID #2|Naproxen and Celecoxib Placebo
62711721|NCT00269581|OTHER|1|Educational CD-Rom
62711722|NCT00269581|EXPERIMENTAL|2|Headstrong CD-rom
62711723|NCT00481936|EXPERIMENTAL|Dose Escalating|"Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met.~Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33."
62150069|NCT03054506|EXPERIMENTAL|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
62150070|NCT03054506|ACTIVE_COMPARATOR|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
61975302|NCT04891783||40 healthy controls|healthy controls will undergo carotid ultrasound examination
62150071|NCT03054506|PLACEBO_COMPARATOR|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
62150072|NCT06372899|EXPERIMENTAL|ECIGS|Participants randomized to ECIGS will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study-provided e-cigarette device. Participants will be able to choose between Tobacco, Menthol, Watermelon, and Blueberry flavored nicotine pods. They will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
62357613|NCT00884221|EXPERIMENTAL|Highly Purified Menotrophin|
62357614|NCT00884221|ACTIVE_COMPARATOR|Recombinant FSH|
62357615|NCT01496170|EXPERIMENTAL|Treatment A: MK-8931 12 mg|Participants receiving 12 mg MK-8931 for 7 days
62521741|NCT01784666|EXPERIMENTAL|Placebo -> Isradipine|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the next 4 weeks
62521742|NCT01784666|PLACEBO_COMPARATOR|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the subsequent 4 weeks
62521743|NCT01908218||ULBT group|344 adult patients undergoing general anesthesia with orotracheal intubation
62711724|NCT01465009|EXPERIMENTAL|Arm 1|
62711725|NCT01465009|ACTIVE_COMPARATOR|Arm 2|
62711726|NCT01465009|PLACEBO_COMPARATOR|Arm 3|
62711727|NCT03913351|EXPERIMENTAL|Lifestyle modification program|The dietary intervention program will be scheduled for 12 months, and conducted by a dietitian.The program aims to increase energy expenditure and reduce caloric intake, with an emphasis on long-term lifestyle and behavioural change. An exercise instructor will provide advice on physical activity. A mobile tracking device to monitor calories expenditure will be provided to each participant during they study period to encourage physical activity.
62711728|NCT03913351|NO_INTERVENTION|Control|standard care of treatment, as in routine clinical practice
62711729|NCT00640302||PIPET A|Patients presenting at study sites with the recognised clinical case definition for pandemic influenza (to be distributed by State and Commonwealth Departments of Health when first clinical case occurs) will be eligible to be enrolled on the study. Informed consent to participate in the study will be sought including parental/guardian consent for minors and presumed consent for adults who are incapacitated (consistent with NHMRC requirements).
62150073|NCT06372899|EXPERIMENTAL|ONPS|Participants randomized to ONPS will be provided with oral nicotine pouches and be instructed to switch from smoking combustible cigarettes to using only the study-provided nicotine pouches. Participants will be able to choose between Original, Mint, Berry, and Citrus flavored nicotine pouches. They will receive their supply of nicotine pouches in 7-day increments, based on baseline smoking behavior.
62150074|NCT04985903|EXPERIMENTAL|Intervention|Clinicians in the intervention arm will receive a tailored communication training on smoking cessation skills and a general lecture on smoking cessation.
62150075|NCT04985903|ACTIVE_COMPARATOR|Control|Clinicians in the control arm will be asked to attend a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
62150076|NCT06463626||CDKi cohort|Adult women with HR-positive and HER-2-negative advanced breast cancer who started first- or second-line treatment with CDKi 4/6 (ribociclib or palbociclib).
62150077|NCT05255744|EXPERIMENTAL|Whitsundays nasal mask|Participants will be asked to take home the investigational mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
62711730|NCT05047042|EXPERIMENTAL|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The intervention will take place in participants' homes, at times convenient for the participant. Programming will be administered virtually through the University of Alberta's Cancer Rehabilitation Clinic, which is fully equipped for virtual delivery of services. The study intervention will be tailored to the individual with respect to their baseline strength, symptom profile and prior experience with exercise. Pre- and post-testing will be done virtually. The mode, intensity and duration of each exercise session will be based on the participant's baseline fitness and status that day. Variations on each exercise will be provided to ensure an appropriate movement and intensity and to allow for individual prescription. Resistance bands will be used to provide resistance during strengthening and balance retraining exercises. The interactive group class will be led virtually by an exercise or rehabilitation specialist.
62521744|NCT06072495|EXPERIMENTAL|child with operated isolated labial cleft|
62711731|NCT02320656|EXPERIMENTAL|Acute leukemia/myelodysplastic or myeloproliferative disease|
62711732|NCT05950841|EXPERIMENTAL|Low dose IHAT|IHAT in capsule form and carob flour in capsule form - taken as 1 x 100mg IHAT capsule (equiv 30mg iron) in the morning with water and 1 x placebo capsule in the evening with water
62150078|NCT05255744|ACTIVE_COMPARATOR|AirFit N30i Quiet mask|Participants will be asked to take home the comparator mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
62150079|NCT01799005|ACTIVE_COMPARATOR|flavanol rich intervention|Ingestion of 410mg flavanols twice a day for 30 days
62711733|NCT05950841|EXPERIMENTAL|High dose IHAT|IHAT in capsule form - taken as 2 x 100mg (equiv 60mg iron) daily with water (1 in the morning and 1 in the evening)
62711734|NCT05950841|PLACEBO_COMPARATOR|Carob flour|Carob flour in capsule form - taken as 2 x capsules daily with water (1 in the morning and 1 in the evening)
62711735|NCT00714948|EXPERIMENTAL|1|This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.
62150080|NCT01799005|PLACEBO_COMPARATOR|flavanol free intervention|Ingestion of a macro and micro nutrients matched flavanol free drink
62357616|NCT01496170|EXPERIMENTAL|Treatment B: MK-8931 40 mg|Participants receiving MK-8931 40 mg for 7 days
62357617|NCT01496170|PLACEBO_COMPARATOR|Treatment C: Placebo matching MK-8931 12 mg or 40 mg|Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
62711736|NCT00655096||Affected participants|Adults and children with either diagnosed or un-diagnosed ocular conditions.
62711737|NCT00655096||Disease free control|Adults and children without any ocular disorders.
62711738|NCT00655096||Unaffected relative|Unaffected first degree relative of a genetic ocular disease participant.
62711739|NCT02919592|EXPERIMENTAL|Primary Breast Augmentation|Participants who meet the requirements for primary breast augmentation (have not had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
62711740|NCT02919592|EXPERIMENTAL|Revision Breast Augmentation|Participants who meet the requirements for revision breast augmentation (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast implants
62711741|NCT02919592|EXPERIMENTAL|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
62150081|NCT01444365|EXPERIMENTAL|ABT-652 NSAID|ABT-652 capsules -2 ABT-652 capsules twice daily (add-on) NSAID - as prescribed
62357618|NCT01496170|EXPERIMENTAL|Treatment D: MK-8931 60 mg|Participant receiving MK-8931 60 mg for 7 days
62357619|NCT01496170|PLACEBO_COMPARATOR|Treatment E: Placebo matching MK-8931 60 mg|Participants receiving placebo matching MK-8931 60 mg for 7 days
62357620|NCT02186457|EXPERIMENTAL|Polymyxin B in Normal Saline|Polymyxin B (500,000 U) in 1 liter of 0.9% Normal Saline
62150082|NCT01444365|PLACEBO_COMPARATOR|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID - as prescribed
62150083|NCT00848094|OTHER|arm 1|Arm I: tumor diameter more than 5 cm and less than 10 cm.
62150084|NCT00848094|OTHER|arm 2|Arm II: tumor diameter no less than 10 cm.
62150085|NCT03032965|EXPERIMENTAL|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
62150086|NCT03032965|OTHER|Isoproterenol|This group will not receive adenosine during the procedure.
62150087|NCT02871245|ACTIVE_COMPARATOR|Comparator Group|Patients received gastrointestinal neoplasms laparoscopic surgery but no acupuncture therapy.
62357621|NCT02186457|PLACEBO_COMPARATOR|Placebo: Normal Saline|0.9 % Normal Saline
62357622|NCT05666570||Avelle NPWT|Avelle Negative Pressure Wound Therapy administered as indicated by the IFU.
62357623|NCT02232594||chronic obstructive respiratory tract disease patients|
62521745|NCT06072495|EXPERIMENTAL|child with isolated operated velopalatal cleft with severe VPI ( IIB//IIM) and normal velum anatomy|
62521746|NCT06072495|EXPERIMENTAL|child with isolated operated velopalatal cleft with soft VPI (I/I-II) and abnormal velum anatomy|
62521747|NCT06072495|EXPERIMENTAL|child with isolated operated velopalatal cleft with normal anatomy and soft VPI|
62521748|NCT02811263|ACTIVE_COMPARATOR|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)
62521749|NCT02811263|PLACEBO_COMPARATOR|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age
62521750|NCT03274882|EXPERIMENTAL|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio of 1:0.5) was administered at 35 mg/m²/dose orally twice a day, within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period. This treatment cycle was repeated every 4 weeks until treatment withdrawal criteria are met.
62521751|NCT00818129|EXPERIMENTAL|1|
62711742|NCT02919592|EXPERIMENTAL|Revision Breast Reconstruction|Participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
62711743|NCT02919592|ACTIVE_COMPARATOR|Other Aesthetic Surgery|Participants who meet the requirements for other aesthetic surgery procedures, which may not include silicone implants (breast or otherwise)
62357624|NCT03508284||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
62521752|NCT00818129|PLACEBO_COMPARATOR|2|
62711744|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
62711745|NCT03733327|EXPERIMENTAL|BUCYE|For PCNSL patients undergoing auto-HSCT，BUCYE conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/ day on days -3 and -2.
62711746|NCT04268914|NO_INTERVENTION|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for IV placement and induction of anesthesia. Current standard of care practices at CHLA for outpatient surgery induction will include the following steps. Children may receive midazolam, parental presence during induction and any other intervention or medication chosen by the HCP. The research team will have no input to the decision regarding the use of any therapy.
62357625|NCT03508284||Healthy group|Healthy individuals without chronic disease
62357626|NCT01171287|EXPERIMENTAL|Aircast Walker|Automobile driving with an Aircast Walker applied to each participant's right lower extremity
62357627|NCT01171287|EXPERIMENTAL|Walking cast|Automobile driving with a walking cast applied to each participant's right lower extremity
62357628|NCT01171287|ACTIVE_COMPARATOR|Running shoe|Automobile driving with a running shoe applied to each participant's right lower extremity
62357629|NCT06193694|NO_INTERVENTION|Receive wellness materials|Control group - 50% of the study early career pediatric surgeon population will be randomized to the control group in a 1:1 manner after baseline burnout data is obtained. 33% of the coaches who volunteer will also be randomized to a control group in a 1:2 manner after baseline burnout data is obtained.
62357630|NCT06193694|EXPERIMENTAL|Formal Coaching|Study group - 50% of the study population will be randomized to the intervention or coaching group in a 1:1 manner after baseline burnout data is obtained. Similarly, 67% of the coaches who volunteer will be randomized to the intervention or coaching group in a 2:1 manner after baseline burnout data is obtained.
61975303|NCT04803357|EXPERIMENTAL|Blinded Continuous Glucose Monitoring Devise|If you are in the control group, you will wear a continuous glucose monitor with the read out screen covered so you can not see your continuous glucose level. You will be taught how to test your blood sugar by pricking your finger and using a standard blood glucose meter as per the standard of care used by your provider in the obstetrics clinic.
61975304|NCT02417974|EXPERIMENTAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
61975305|NCT02417974|NO_INTERVENTION|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
61975306|NCT05489055|EXPERIMENTAL|BBT-CM (basic body temperature) group|BBT-CM (basic body temperature) group received contrast media warmed to body temperature (37°C\[99°F\]) before coronary CTA.
61975307|NCT05489055|ACTIVE_COMPARATOR|RT-CM (room temperature) group|RT-CM (room temperature) group received contrast media at room temperature (\~23°C \[\~73°F\]) before coronary CTA.
61975308|NCT01949168|ACTIVE_COMPARATOR|Boceprevir triple therapy with 5-day lead in|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) for 5 days, followed by boceprevir plus • Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection plus • Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy (week 5 from baseline), and maintain an undetectable plasma HCV RNA at week 20 of triple therapy (week 21 from baseline), treatment will stop at week 25. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 23 weeks (stopping at week 48).
61975309|NCT01949168|ACTIVE_COMPARATOR|Boceprevir triple therapy|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) plus Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy, and maintain an undetectable plasma HCV RNA at week 20 of triple therapy, treatment will stop at week 24. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 24 weeks (stopping at week 48).
62357631|NCT03310437||Primary PCI|In primary PCI we use arterial sheath , wires ,heparin ,intracoronary stents
62357632|NCT03310437||Thrombolytic|In patients recieving thrombolytics they continue on LWMH for 72h ,plus aspirin , clopedogril , BB, statins
62357633|NCT01613508|ACTIVE_COMPARATOR|Direct Anterior Approach|An oblique incision is made over the anterior margin of the tensor muscle. The fascia of the tensor muscle is identified and incised. The muscle is swept digitally laterally and a retractor is placed over the superior aspect of the femoral neck. The hip capsule is then incised and retracted.
61975310|NCT01949168|ACTIVE_COMPARATOR|Standard of Care|48 weeks of Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg by mouth daily (200mg tablets)
61975311|NCT04032314||Healthy controls - cross-sectional project design|
61975312|NCT04032314||Patients - cross-sectional project design|
62521753|NCT06224712|EXPERIMENTAL|Arogya Sangama Intervention|"The villages in the service area of both the intervention and control PHC-HWCs will be selected randomly, weighted by population size (PPS). There are two different population groups that are being examined to get a comprehensive picture of primary health services.~Group 1: To assess the impact of the intervention in improving the coverage and utilisation of antenatal and post-natal services, a cross-sectional sample of 1680 women, 840 in each arm, in the age group of 18-49 years who delivered in the last 12 months will be interviewed in the baseline and similarly in the endline.~Group 2: To estimate the effect of the intervention on improving the access to screening and management of NCDs among diabetic and hypertensives, a cross-sectional sample of 200 persons in the age group of 30 years and above from each arm will be interviewed in the baseline and similarly in the endline. Hence in each round the total sample will be 400."
62150088|NCT02871245|EXPERIMENTAL|Acupuncture Therapy Group|Patients received gastrointestinal neoplasms laparoscopic surgery and acupuncture therapy. Finish surgery up to 24 hours electricity acupuncture treatment, treatment 1 times a day, every time lasted 30 minutes, 5 days in a row
62357634|NCT01613508|ACTIVE_COMPARATOR|Mini-Posterior Approach|The surgical approach involved a 7 to 9.5 cm incision along the posterior aspect of the femur starting at the tip of the greater trochanter and proceeding distally. The fascia of the gluteus maximus was split, and blunt dissection revealed the underlying abductor and external rotator musculature. The external rotators an the hip capsule were incised and preserved as one layer, with an attempt being made to preserve the insertion of the quadratus femoris on the femur. The hip was dislocated posteriorly and the femoral neck was cut in accordance with the preoperative plan.
62521754|NCT06224712|NO_INTERVENTION|Control|Same inclusion criteria as above, without Arogya Sangama intervention.
62521755|NCT06221553|EXPERIMENTAL|Locoregional delivery of B7H3/IL-7Ra CAR T cell in DIPG|"Patients with DIPG for whom CAR T cells will be delivered into the ventricular system~Interventions:~Biological: Autologous B7H3-specific chimeric antigen receptor (CAR) T cell with additional of IL-7Ra signaling domain Dose level: 1x10e7 CAR T cell, 3x10e7 CAR T cell, 10x10e7 CAR T cell"
62521756|NCT00899470|EXPERIMENTAL|S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)|Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M \[fasted\]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M \[fed\]) followed by S/M under fasting conditions (S/M \[fasted\]) followed by S + M under fed conditions (S + M \[fed\])
62521757|NCT00899470|EXPERIMENTAL|S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)|Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
62711747|NCT04268914|EXPERIMENTAL|VR Randomization|When a child is assigned to the VR condition s/he will have the added component of VR distraction during pre-surgical preparation. Children in the VR condition will interact with an immersive 3D virtual environment presented via a HMD (head-mounted display), a helmet with computer screens for each eye. This study will use two HMDs at two possible time points: (1) Prior to and during IV placement, participants will play using the Oculus Go; (2) Prior to and during anesthesia induction, participants will play using the Mira Prism.
62711748|NCT06211712|EXPERIMENTAL|Human Urinary Kallidinogenase|
62711749|NCT06211712|PLACEBO_COMPARATOR|Placebo|
62357635|NCT02379312|ACTIVE_COMPARATOR|Very low energy aerated beverage|Very low energy aerated beverage
62357636|NCT02379312|ACTIVE_COMPARATOR|Normal energy aerated beverage 1|Normal energy aerated beverage 1
62357637|NCT02379312|ACTIVE_COMPARATOR|Normal energy aerated beverage 2|Normal energy aerated beverage 2
62711750|NCT01077063|ACTIVE_COMPARATOR|paracentesis|cutting and draining procedure for malignant ascites
62711751|NCT01077063|ACTIVE_COMPARATOR|Pleurx catheter|a catheter drainage system the subject uses himself/herself.
62711752|NCT01682330||Fitness|
62711753|NCT01682330||Whole-body vibration|
62711754|NCT01682330||Control|
62711755|NCT03622047|EXPERIMENTAL|dexmedetomidine ropivacaine|Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
62711756|NCT03622047|EXPERIMENTAL|sufentanil ropivacaine|compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.
61975313|NCT04032314||Patients - longitudinal project design|
61975314|NCT05678894|EXPERIMENTAL|femoro-acetabular impingement|symptomatic patients with femoro-acetabular impingement
61975315|NCT05678894|OTHER|Healthy volunteers|Healthy volunteers
61975316|NCT05039151||septic shock|50 patients with a diagnosis of septic shock established within 24 hours of admission with oedemas
61975317|NCT05039151||control|35 non-septic patients with oedema from another cause
62150089|NCT02958553|OTHER|emPOWER Ankle (powered prosthesis)|The subject's own passive prosthesis will be used as a baseline and crossed over after the emPOWER has been worn 3-4 months. Then the passive foot will be crossed back to the emPOWER for a final series of tests.
62150090|NCT03528915||Prophylaxis group|Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
62150091|NCT03528915||no-antibiotic group|Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
62357638|NCT02379312|ACTIVE_COMPARATOR|Normal energy aerated beverage 3|Normal energy aerated beverage 3
62357639|NCT04030949||Ateendes STD clinics Östergötland physician appointment|"Attendees with an appointment to a physician (if she has symptoms or if she wishes a gynecological exam).~The exam starts with an Abbot multi-collect swab taken from the anal verge, at the opening of the anal canal.~A pediatric proctoscope (a proctoscope designed and manufactured to examine children) is used for sampling the rectal specimens using an Abbot multi-collect swab and a standard Sigma swab of Sigma virocult, followed by vaginal speculum exam. Firstly samples from the lateral fornix for wet smear are collected, secondly a swab for methylene-blue staining from the endocervical orifice followed by two Abbot multi-collect swabs for chlamydia/gonorrhoea and M.genitalium respectively from the orifice, the portio and the vaginal wall and one standard Sigma swab of Sigma virocult from the same areas. Lastly a sample is collected from the distal urethra and stained with methylene blue."
62150092|NCT05458466|EXPERIMENTAL|Pilates training Group|The Pilates Training program consisted of warm-up, work-out and cool-down sections. For the warm-up section, breathing, standing roll down, and spine twist exercises were selected; for the work-out section, the hundred, shoulder bridge, scissors, swimming, and quadruped exercises, and for cool-down section, torso twist, cat-camel, and standing stretches. The Pilates Training progression was achieved by increasing the number of repetitions of the selected exercises and adding some equipment (balls, foam rollers) to challenge postural stability. In the first five sessions, after each exercise was performed for six to eight repetitions, the number of repetitions was increased to 10-12. Moreover, the environment where the training took place was carefully arranged according to the needs of children with autism.
62150093|NCT05458466|EXPERIMENTAL|Aerobic Training Group|Each training session consisted of a 20-minutes treadmill workout (using the motorized Ultıma Ac 3500 treadmill) followed by 20-minutes bicycle workout (Voit Yellow Collection 112u exercie bike). The intensity of training, which began at 50% to 60% of maximum heart rate (HR), was increased each week so that by week five, the children were at 75% to 80% maximum HR. The maximum HR, as recommended for children, was calculated using the formula 208 - 0.7 x (age) (Mahon et al., 2010). To ensure that the exercise intensity remained in the target HR zone during training, the child's HR was continuously monitored from the used treadmill and exercise bike monitors.
62521758|NCT00899470|EXPERIMENTAL|S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)|Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
62521759|NCT00899470|EXPERIMENTAL|S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)|Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)
62521760|NCT05033366||Proov test strip users that record results with the Proov app|Participants using Proov test strips along with the Proov app who have logged at least one complete cycle will be asked to complete an online survey about fertility test results and current/previous pregnancy status. They will also be asked cycle history (irregular vs regular, cycle length), fertility testing (partners semen analysis results, AMH level, HSG results), possible fertility medications taken or prescribed, age, race, smoking status, and BMI.
62521761|NCT03605654|EXPERIMENTAL|Investigational Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
62521762|NCT03605654|ACTIVE_COMPARATOR|Active Control Arm|Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study
62150094|NCT02501369|EXPERIMENTAL|Self-directed Teen Triple P|"Self-directed Teen Triple P is a behaviourally based parenting intervention that parents follow at home using a workbook. It is based upon social learning theory principles and is used to help parents build upon their existing skills and information to practice positive parenting. Key skills promoted include: Increasing positive parent-teenager interactions, increase desirable behaviour, teach new behaviours and skills, and manage problem behaviour.~As this is a case series design participants will act as their own controls and so there are no other arms to the study."
62150095|NCT00709787||Hypertensive Subjects undergoing primary prevention|
62150096|NCT01544894|ACTIVE_COMPARATOR|raloxifene|60 mg/d for one year.
62521763|NCT03605654|EXPERIMENTAL|Non-Randomized Exploratory Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
62521764|NCT00531141||A|examination twice by examiner 1
62711757|NCT03622047|EXPERIMENTAL|No analgesia labor|Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
62711758|NCT05564637|OTHER|Healthy Volunteers|Healthy volunteers will undergo RHC while exercising and an optional muscle biopsy.
62521765|NCT00531141||B|examination first by examiner 1 thereafter by examiner 2
62521766|NCT00531141||C|examination first by examiner 2 thereafter by examiner 1
61975318|NCT06157814|EXPERIMENTAL|STOMA Care|Patients and the caregivers accessing the full MORE program on the secured Website. The patients and caregivers will be instructed on how to complete the 1 week (or upon discharge) and 4 week surveys via REDCap or through the RC. This group has additional requirements in the 4-week survey to assess the helpfulness of the Stoma Care app.
62521767|NCT00531141||D|examination performed twice by examiner 2
62521768|NCT03792360|EXPERIMENTAL|Single Arm|
62521769|NCT00666848|PLACEBO_COMPARATOR|2 (enalapril 5mg)|Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .
62521770|NCT00666848|PLACEBO_COMPARATOR|1 (placebo)|Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.
62521771|NCT00666848|PLACEBO_COMPARATOR|3 (enalapril 10mg)|Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.
62521772|NCT05215080|EXPERIMENTAL|Treatment group|Group of infants aged 6-7 months that given organic formula milk three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
62521773|NCT02824471||Minor SCD Group, Ages 12-17|No Intervention. Use of discarded blood/tissue only
62521774|NCT02824471||Adult SCD. Ages 18+|No Intervention. Use of discarded blood/tissue only
62521775|NCT02859948|EXPERIMENTAL|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
62521776|NCT06367595|ACTIVE_COMPARATOR|intrathecal|"will include 30 patients who will receive~* Intrathecal hyperbaric bupivacaine 0.5 % 20 mg in 4 ml plus magnesium sulfate 30 mg of 0.5 ml volume.~* 250 ml of isotonic saline infusion over 15 minutes immediately before spinal anesthesia, then 250 ml of isotonic saline infusion over 2 hours."
62521777|NCT06367595|ACTIVE_COMPARATOR|intravenous|"will include 30 patients who will receive~- 30 mg/kg magnesium sulfate at a concentration of 100 mg/ml (regarding the ideal body weight) in 250 ml of isotonic saline infusion over 15 minutes immediately before spinal anesthesia (intrathecal hyperbaric bupivacaine 0.5 % 20 mg in 4 ml plus 0.5 ml of isotonic saline), and then 10 mg/kg/h magnesium sulfate in 250 ml isotonic saline infusion over 2 hours."
62521778|NCT06367595|PLACEBO_COMPARATOR|placebo|"will include 30 patients who will receive~* intrathecal hyperbaric bupivacaine 0.5 % 20 mg in 4 ml plus 0.5 ml of isotonic saline.~* 250 ml of isotonic saline infusion over 15 minutes immediately before spinal anesthesia then 250 ml of isotonic saline infusion over 2 hours."
62521779|NCT02610387|ACTIVE_COMPARATOR|Arm 1:tDCS|Transcranial direct current stimulation (tDCS) Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days
62521780|NCT02610387|SHAM_COMPARATOR|Arm 2: Sham tDCS|Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days
62521781|NCT05456711||knee osteoarthritis|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
62521782|NCT05456711||healthy control|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
61975319|NCT06157814|ACTIVE_COMPARATOR|Usual Care|Patients and caregivers will NOT be given access to the web-based app and outpatient clinic will provide ostomy care if requested by all patients with ostomies per their regular care.
62521783|NCT02639052|EXPERIMENTAL|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
62521784|NCT02639052|PLACEBO_COMPARATOR|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
62521785|NCT04629261|EXPERIMENTAL|Users with no incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will not receive a discount fee for enrollment.
62521786|NCT04629261|EXPERIMENTAL|Users with incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will do receive a discount fee for enrollment.
62521787|NCT04629261|NO_INTERVENTION|Non-users|Participants with an age range similar to the intervention groups, who work or lives nearby ECOBICI's bicycle station, that are not enrolled in the ECOBICI program or in a health related program (ex. reducing weight).
62521788|NCT01915719|EXPERIMENTAL|Early non invasive ventilation|Early non invasive ventilation
62521789|NCT01915719|ACTIVE_COMPARATOR|Oxygen therapy only|Oxygen therapy only
62521790|NCT04568031|ACTIVE_COMPARATOR|Part I|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
62521791|NCT04568031|PLACEBO_COMPARATOR|Part II|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
62521792|NCT05291455|EXPERIMENTAL|Lacosamide|Lacosamide will be given.
62521793|NCT05291455|ACTIVE_COMPARATOR|Phenobarbitone|Phenobarbital will be given
62521794|NCT00532935|EXPERIMENTAL|1|Sitagliptin phosphate (+) metformin hydrochloride
62521795|NCT00532935|ACTIVE_COMPARATOR|2|pioglitazone
62521796|NCT02993770|EXPERIMENTAL|Endoscopic DCR|Endoscopic DCR will be performed by a single ophthalmic plastic surgeon expert in endoscopic surgery (F.P.) with a modified powered endonasal endoscopic technique described by Wormold.
61975320|NCT04326231|EXPERIMENTAL|Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
62521797|NCT02993770|ACTIVE_COMPARATOR|External DCR|External DCR will be performed in a conventional mannervia a nasal side straight skin incision 1 cm medial to medial canthal area, 1 cm long, then orbicularis oculi muscle will be separated using blunt dissection to expose the periosteum overlying and medial to the anterior lacrimal crest
62711759|NCT05564637|EXPERIMENTAL|PAH-ILD Patients|Patients diagnosed with PAH-ILD will undergo RHC while exercising, receive inhaled treprostinil, and undergo an optional muscle biopsy.
62521798|NCT04445779|EXPERIMENTAL|CoQ10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in the form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before the surgical procedure.
62521799|NCT04445779|PLACEBO_COMPARATOR|Placebo|Patients will receive per-orally placebo in three divided doses.
48850461|NCT06676150||Human Papillomavirus|The goal of this study is to prove that a self-collected sample might be as accurate as a clinician-collected sample collected during a visit to the doctor. In the initial part of the study, also known as the pilot phase, a limited number of participants may participate to understand the best way to get the study started and collect and process the specimens. These participants may only participate in some, but not all activities as discussed below.
62521800|NCT06264245||High exposure to compressed sound|
62521801|NCT06264245||Moderate or limited exposure to compressed sound|
62521802|NCT01700049|EXPERIMENTAL|Open Label oral vismodegib|This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
62521803|NCT04281979|EXPERIMENTAL|Study Agent|
62521804|NCT04281979|PLACEBO_COMPARATOR|Placebo|
62521805|NCT04719234|OTHER|lung ultrasound|lung ultrasonography protocol will be applied.
62521806|NCT03297528|EXPERIMENTAL|study group|Participants receive chemotherapy and donor lymphocyte infusions based on the state GvHD, even the participants have a negative result of minimal residual disease (MRD). If the participants have no GvHD,they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD.
62521807|NCT03297528|NO_INTERVENTION|control group|Participants don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD,in dispite of whether or not GvHD.
62711760|NCT00401076|EXPERIMENTAL|1|
62711761|NCT05233397|EXPERIMENTAL|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
62711762|NCT01591629|PLACEBO_COMPARATOR|Placebo and Placebo|
62357640|NCT04030949||Ateendes STD clinics Östergötland, nurse appointment|"The participant collects the rectal sample for chlamydia and gonorrhea (Abbot multi-collect swab) first and is instructed to try not to touch the perianal/perineal areas. Then the vaginal samples for chlamydia/gonorrhoea and M.genitalium are collected.~There is a group of women who have been tested positive for chlamydia by self-collected vaginal swab which is sent to the patient by mail. Those are requested to attend the STD-clinic for partner tracing and are offered antibiotic treatment with doxycycline. Those accepting to participate in the study will answer the study questions and will be tested again and a nurse will collect firstly an Abbot multi-collect swab from the anal verge, at the opening of the anal canal and then two rectal swabs using a pediatric proctoscope (one Abbot multi-collect and one standard Sigma swab of Sigma virocult) and the participant will self-collect a new vaginal sample for chlamydia/gonorrhea and one for M.genitalium (two Abbot multi-collect swabs)"
62150097|NCT01544894|ACTIVE_COMPARATOR|strontium ranelate|2 g/d for one year.
62357641|NCT04030949||Ateendes STD clinics Östergötland+Jönköping partner chlamydia|"Women attending the STD clinics because of a verified chlamydia infection of their current partner. This group of patients is examined and tested by a nurse or doctor before doxycycline treatment is offered.~Those accepting to participate in the study answer the questions about the experience of receptive anal sex and fellatio (and condom use) during the last 12 months and even additional questions regarding fellatio and whether it happened that a male partner ejaculated in oral cavity of the participant.~The first sample is an Abbot multi-collect swab taken from the anal verge and the anal canal and two more swabs are taken under the use of a pediatric proctoscope: one Abbot multi-collect and one standard Sigma swab of Sigma virocult and finally vaginal samples are collected (one Abbot multi-collect and one standard Sigma swab of Sigma virocult)"
62357642|NCT06260904|ACTIVE_COMPARATOR|Prednisolone and Methotrexate (Control Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) and Methotrexate 15 mg weekly for 12 weeks.
62357643|NCT06260904|EXPERIMENTAL|Prednisolone and Apremilast (Test Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) and Apremilast 30 mg twice daily for 12 weeks.
62357644|NCT03742206|EXPERIMENTAL|Parasacral|Parasacral Transcutaneous Electrical Stimulation Group: participants in this group will receive two self-adhesive electrodes and will be instructed to position them in the sacral region. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
62357645|NCT03742206|ACTIVE_COMPARATOR|Posterior Tibial Nerve|Transcutaneous Posterior Tibial Nerve Stimulation Group: participants in this group will receive a neoprene ankle brace that will be connected to the electrostimulator. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
62357646|NCT05516160|EXPERIMENTAL|multifocal lens|examination of dysphotopsia
62357647|NCT05516160|ACTIVE_COMPARATOR|control group|examination of dysphotopsia
62357648|NCT04329000|EXPERIMENTAL|On-demand PPI therapy|The patients in this group were advised to take PPI for 8 weeks continuously, followed by on-demand PPI therapy for the following 40 weeks.
62357649|NCT04329000|ACTIVE_COMPARATOR|Continuous PPI therapy|The patients in this group were advised to take PPI QD continuously for 48 weeks.
62357650|NCT03634917|ACTIVE_COMPARATOR|Acamprosate|"1 capsule with Acamprosate calcium~* oral use~* 3 times / day (morning, noon, evening)~* 666 mg per capsule~* 14 - 19 days"
62357651|NCT03634917|ACTIVE_COMPARATOR|Calcium Carbonate|"1 capsule with Calcium Carbonate~* oral use~* 3 times / day (morning, noon, evening)~* 1500 mg Calcium Carbonate (= 600 mg Calcium 2+)~* 14 - 19 days"
62357652|NCT03634917|PLACEBO_COMPARATOR|Placebo|"1 capsule placebo,~* oral use~* 3 times / day (morning, noon, evening)~* 14 - 19 days"
62357653|NCT01378299|EXPERIMENTAL|Arm 1: Testosterone Cypionate|All patients who qualify for the study will receive testosterone cypionate
62357654|NCT04582604|EXPERIMENTAL|Ruxolitinib combined with Decitabine|Ruxolitinib and Decitabine conditioning regimen All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Decitabine. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid \[p.o.\], days -15 to -10, diminishing to day -1), decitabine (20 mg/m2/day, days -15 to -10), cytarabine (4 g/m2/day, days -10 to -9 (for unrelated donors or haploidentical donors; and 4 g/m2/day, days -9 for sibling donors)), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4);carmustine(BCNU)(250mg/m2/day, day -3),
62357655|NCT02902822|ACTIVE_COMPARATOR|Screening|This arm includes all subjects randomized to regular dermatological follow-up visits on annual basis.
62357656|NCT02902822|EXPERIMENTAL|Tele-dermatology|This arm includes all subjects randomized to the use of a tele-dermatology system for the evaluation of newly onset non-widespread skin lesions.
62521808|NCT02478320|EXPERIMENTAL|Ilorasertib (ABT-348)|"Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.~Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle."
62711763|NCT01591629|EXPERIMENTAL|Active Naloxone and Placebo|
62711764|NCT01591629|PLACEBO_COMPARATOR|Placebo and Active Delta-9-THC|
62711765|NCT01591629|EXPERIMENTAL|Active Naloxone and Active Delta-9-THC|
62711766|NCT05308121||First trimester pregnant women (first pregnancy)|This group will consist of women in the first trimester of pregnancy. Pregnant women will be evaluated 2 points of the Achilles Tendon
62711767|NCT05308121||Second trimester pregnant women (first pregnancy)|This group will consist of women in the second trimester of pregnancy. Pregnant women will be evaluated 2 points of the Achilles Tendon
62711768|NCT05308121||Third trimester pregnant women (first pregnancy)|This group will consist of women in the third trimester of pregnancy. Pregnant women will be evaluated 2 points of the Achilles Tendon
62150098|NCT02973932|EXPERIMENTAL|Internet-based psychotherapy|
62150099|NCT05764395|EXPERIMENTAL|Treatment (Rigosertib, pembrolizumab)|Patients receive rigosertib PO plus pembrolizumab IV throughout the study. Patients undergo CT or MRI and blood sample collection at screening and on study, and may also undergo tissue biopsy at screening and on study.
62150100|NCT04338568|ACTIVE_COMPARATOR|LUS observer 1|The subject will undergo a Lung Ultrasound by observer nr 1
62150101|NCT04338568|ACTIVE_COMPARATOR|LUS observer 2|The subject will undergo a Lung Ultrasound by observer nr 2
62521809|NCT01828710|SHAM_COMPARATOR|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
62150102|NCT04890626|EXPERIMENTAL|Main randomization.Arm: Emtricitabine / Tenofovir disoproxil fumarate|Emtricitabine / Tenofovir disoproxil fumarate
62150103|NCT04890626|NO_INTERVENTION|Main randomization.Arm: No treatment|No treatment
62150104|NCT04890626|OTHER|Rescue randomization: Arm: Dexamethasone + Baricitinib|Rescue randomization: patients with oxygen requirements, O2 Sat \<95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
62150105|NCT04890626|OTHER|Rescue randomization: Arm: Dexamethasone|Rescue randomization: patients with oxygen requirements, O2 Sat \<95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
62150106|NCT00703092|EXPERIMENTAL|Fiber-Stat|2 tablespoons daily
62150107|NCT05454332|EXPERIMENTAL|Early Caffeine Group|Group administering caffeine in the first 2 hours of life. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day.
62521810|NCT01828710|ACTIVE_COMPARATOR|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
62521811|NCT01828710|PLACEBO_COMPARATOR|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
62357657|NCT04682678|SHAM_COMPARATOR|OFF STIM|without stimulation
62357658|NCT04682678|ACTIVE_COMPARATOR|ON STIM|stimulation with the most effective parameters
62521812|NCT01484184|ACTIVE_COMPARATOR|buspirone or levodopa/carbidopa|Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.
62711769|NCT02699229||Malignant|Tissue sample
62711770|NCT02699229||Benign|Tissue sample
62711771|NCT02699229||Normal|Tissue Sample
62357659|NCT03543527||Takayashu|
62357660|NCT05800509|EXPERIMENTAL|Experimental Group|"The participants and their partners will receive structured questionnaires respectively at 22nd and 35th week of pregnancy, and 3rd month and 6th month after delivery. The context of questionnaire includes basic information (age, level of education and occupation of the participant and her partner, household income, and status of marriage), marriage satisfaction, obstetrics and gynecological history (history of abortion, intended pregnancy , and artificial insemination), psychiatric history, family history of diabetes mellitus, height, pre-pregnancy weight, sleeping status, and basic knowledge of gestational diabetes mellitus.~A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners."
62357661|NCT05800509|SHAM_COMPARATOR|Controlled group|"The participants and their partners will receive structured questionnaires respectively at 22nd and 35th week of pregnancy, and 3rd month and 6th month after delivery. The context of questionnaire includes basic information (age, level of education and occupation of the participant and her partner, household income, and status of marriage), marriage satisfaction, obstetrics and gynecological history (history of abortion, intended pregnancy , and artificial insemination), psychiatric history, family history of diabetes mellitus, height, pre-pregnancy weight, sleeping status, and basic knowledge of gestational diabetes mellitus.~A website of health education about gestational diabetes mellitus for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners."
62357662|NCT02077842|EXPERIMENTAL|Nasal CPAP|The experimental group will receive nasal continuous positive airway pressure at 10cmH20 for one hour in the Post Anesthetic Care Unit.
62357663|NCT02077842|ACTIVE_COMPARATOR|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
62521813|NCT01484184|PLACEBO_COMPARATOR|Placebo|First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.
62711772|NCT06398873||CRSsNP|
62711773|NCT06398873||CRSwNP|Dupilumab
62711774|NCT04698304||Group A：TASC C lesion group|Multiple stenoses or occlusions totaling \>15cm or recurrent stenoses or occlusions that need treatment after endovascular interventions (300 cases)
61975321|NCT03180151|NO_INTERVENTION|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
62150108|NCT05454332|ACTIVE_COMPARATOR|Control Group|Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day.
62150109|NCT04779463||Mechanical Ventilated patients|All patients are invasively mechanically ventilated at least 24 hours, and are clinically stable as ready to undergo a spontaneous breathing trial.
62150110|NCT02802111|EXPERIMENTAL|Albuterol 5 mg first, then levalbuterol 2.5 mg|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
62150111|NCT02802111|EXPERIMENTAL|Levalbuterol 2.5 mg first, then albuterol 5 mg|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
62150112|NCT00838045|EXPERIMENTAL|Akreos TL intraocular lens|Bausch \& Lomb Akreos TL intraocular lens
62150113|NCT06041438|EXPERIMENTAL|BI 1584862 alone (Reference R) - BI 1584862 + itraconazole (Test T)|
62711775|NCT04698304||Group B：TASC D lesion with common femoral artery involved|Chronic total occlusions \>20cm with common femoral artery involved (100 cases)
62711776|NCT04698304||Group C：TASC D lesion with proximal popliteal artery involved|Chronic total occlusions \>20cm with proximal popliteal artery involved (300 cases)
62711777|NCT04698304||Group D：TASC D lesion with distal popliteal artery involved|Chronic total occlusions \>20cm with distal popliteal artery involved (200 cases)
62711778|NCT04698304||Group E：TASC D lesion with popliteal artery and proximal trifurcation vessels involved|Chronic total occlusion of popliteal artery (P1-3 segment) with proximal trifurcation vessels involved (100 cases)
62150114|NCT03430440|EXPERIMENTAL|CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button.
62357664|NCT05153447|EXPERIMENTAL|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
62357665|NCT05153447|ACTIVE_COMPARATOR|Usual Care|Participants randomized to the usual care arm will receive standard of care.
62357666|NCT06081699|EXPERIMENTAL|Single Ascending Doses Cohort 1|TNP-2198 Capsules 50mg
62357667|NCT06081699|EXPERIMENTAL|Single Ascending Doses Cohort 2|TNP-2198 Capsules 100mg
62357668|NCT06081699|EXPERIMENTAL|Single Ascending Doses Cohort 3|TNP-2198 Capsules 200mg
62357669|NCT06081699|EXPERIMENTAL|Single Ascending Doses Cohort 4|TNP-2198 Capsules 400mg
62357670|NCT06081699|EXPERIMENTAL|Single Ascending Doses Cohort 5|TNP-2198 Capsules 600mg
62357671|NCT06081699|EXPERIMENTAL|Single Ascending Doses Cohort 6|TNP-2198 Capsules 800mg
62357672|NCT06081699|EXPERIMENTAL|Single Ascending Doses Cohort 7|TNP-2198 Capsules 1000mg
62357673|NCT06081699|EXPERIMENTAL|Food Effect Cohort 8|TNP-2198 Capsules 200mg
62357674|NCT06081699|PLACEBO_COMPARATOR|Placebo Cohort 9|Placebo
62357675|NCT00980434||1|patients with neurological symptoms
62357676|NCT00980434||2|patients without neurological symptoms
62357677|NCT04742972|EXPERIMENTAL|SABR|
62357678|NCT04742972|PLACEBO_COMPARATOR|SOC|
62357679|NCT01883804|EXPERIMENTAL|Study group|All participants selected to continue with Methyldopa administration.
62357680|NCT02670850|NO_INTERVENTION|Control group|Patients received only routine hospital care
62357681|NCT02670850|EXPERIMENTAL|Intervention group|Patients received regular hospital routine care and model-based intervention program
62357682|NCT04463446|EXPERIMENTAL|The app arm|Use of CHD app
62357683|NCT04463446|ACTIVE_COMPARATOR|Nurse-led intervention arm|Nurse-led intervention
62357684|NCT02915068|NO_INTERVENTION|Control|Physicians do not receive focused education and training on patient-centered communication with the EHR
62357685|NCT02915068|EXPERIMENTAL|EHR-PACE|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
62711779|NCT00176748|EXPERIMENTAL|1|
61975322|NCT03180151|EXPERIMENTAL|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
61975323|NCT01988805||Blood Draw|Normal healthy individuals will be consented and their blood drawn at the time of their visit.
62711780|NCT05544253|EXPERIMENTAL|HIPEC group|
62711781|NCT05544253|NO_INTERVENTION|non-HIPEC group|
62357686|NCT01082978|EXPERIMENTAL|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
62357687|NCT01082978|EXPERIMENTAL|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
62357688|NCT01082978|NO_INTERVENTION|Usual standard of care|Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.
62357689|NCT00396825|EXPERIMENTAL|Active treatment|Subjects randomized to this arm will receive the Family Caregiver Kit composed of the Williams LifeSkills Family Caregiver Video and Workbook and will also receive telephone coaching
62357690|NCT00396825|NO_INTERVENTION|Control|Subjects randomized to this arm will receive no intervention and serve as wait list controls. They will undergo the same evaluations as the Intervention arm subjects at comparable times. In a crossover design, once subjects have finished serving as controls, they will be given the video, workbook, and telephone calls from a social worker and tested one more time.
62357691|NCT02794623|EXPERIMENTAL|Cochlear Implant Recipients|
62357692|NCT04539691|EXPERIMENTAL|Magnet group|"Women wearing magnet~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
62357693|NCT04539691|SHAM_COMPARATOR|Sham group|"Women wearing sham~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
62711782|NCT05568329|EXPERIMENTAL|Hearing Aid Signal Processing|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
62521814|NCT04798365|EXPERIMENTAL|Intervention group|The main components of the intervention are 1) two sessions of voluntary continuing medical education on the urinary tract infection program in each LTCF for physicians and nursing staff, 2) distribution of educations materials such as written guidelines on antibiotic prescribing including a smart phone friendly version, 3) implementation of the project homepage as a platform to distribute guidelines and educational videos and to enable physicians to ask questions which will be answered by an infectious disease physician.
62521815|NCT04798365|NO_INTERVENTION|Control group|No intervention until end of the stuy.
62521816|NCT01301235||Subjects with mitochondrial disease|
62521817|NCT01264042|EXPERIMENTAL|FeSo4|
62521818|NCT00825136|ACTIVE_COMPARATOR|relaxation|The patients of this arm practice on-line muscle relaxation for 8 weeks.
62521819|NCT00825136|EXPERIMENTAL|relaxation & biofeedback|The patients of this arm practice on-line muscle relaxation plus finger temperature biofeedback for 8 weeks.
62521820|NCT04306237|EXPERIMENTAL|IMB-1018972|Participants will receive IMB-1018972 (200 mg) MR tablets twice daily for 16 weeks
62521821|NCT04306237|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo tablets twice daily for 16 weeks
62521822|NCT03052322|EXPERIMENTAL|MSB11022|
62521823|NCT03052322|ACTIVE_COMPARATOR|EU-Humira|
62521824|NCT02340845|ACTIVE_COMPARATOR|Bromalian 10 mg/kg/day|The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
62150115|NCT03430440|ACTIVE_COMPARATOR|Conventional mode|The conventional mode in which only the basal infusion rate is set to be fixed.
62521825|NCT02340845|ACTIVE_COMPARATOR|Bromalian 50mg/kg/day|The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
62521826|NCT03735134|ACTIVE_COMPARATOR|Control Group|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
62521827|NCT03735134|ACTIVE_COMPARATOR|Early colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
62521828|NCT03735134|ACTIVE_COMPARATOR|Late colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
62521829|NCT00443768||1|
62521830|NCT00443768||2|
62521831|NCT02238626|PLACEBO_COMPARATOR|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets plus 50 mg riluzole by mouth twice daily for 6 months.
62521832|NCT02238626|EXPERIMENTAL|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day plus 50 mg riluzole 2 times a day by mouth for 6 months.
62521833|NCT04906252||Ventricular Fibrillation|Patients presenting to the Emergency Department after out of hospital cardiac arrest demonstrating Ventricular Fibrillation (Vfib) Cardiac Arrest or Patients demonstrating Vfib during cardiac arrest.
62711783|NCT00461708|EXPERIMENTAL|Rash, Grade <2|Participants with a rash graded less than (\<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m\^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
62521834|NCT04906252||PEA|Patients presenting to the Emergency Department after out of hospital cardiac arrest demonstrating Pulseless Electrical Activity (PEA) Cardiac Arrest. Patients demonstrating PEA during cardiac arrest
62521835|NCT04906252||Asystole Cardiac Arrest|Patients presenting to the Emergency Department after out of hospital cardiac arrest demonstrating Asystolic Cardiac Arrest. Patients demonstrating Asystole during cardiac arrest
62521836|NCT03533257|ACTIVE_COMPARATOR|Active (AMX0035)|AMX0035--a combination of TUDCA and Phenylbutyrate
62521837|NCT03533257|PLACEBO_COMPARATOR|Placebo|Taste-matched Placebo
62521838|NCT01918826|ACTIVE_COMPARATOR|TENS active|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE
62521839|NCT01918826|PLACEBO_COMPARATOR|TENS placebo|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO
62521840|NCT03983694||BabyLux device|Cerebral haemodynamics of neonates undergoing erythrocyte transfusion according to the local clinical guidelines are monitored with BabyLux device before and after transfusion and with traditional NIRS during itself.
62521841|NCT03015727|EXPERIMENTAL|IC+RT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2. And then radiation using IMRT/TOMO without concurrent chemotherapy.
62521842|NCT03015727|ACTIVE_COMPARATOR|IC+CCRT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2.And then chemoradiation using IMRT/TOMO with 2 cycles of cisplatin concurrent chemotherapy at 100mg/m2.
62521843|NCT04324593|EXPERIMENTAL|IV line with an attached Deltran BP transducer|After device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test. At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
62521844|NCT06033365|EXPERIMENTAL|Intervention|Dedicated care navigator to address social support needs
62521845|NCT06033365|NO_INTERVENTION|Usual care|Standard of care.
62521846|NCT04597398||Group A|A total of 39 patients underwent the procedure prior to June 2019
62521847|NCT04597398||Group B|11 patients underwent the procedure as of June 2019
62150116|NCT02124044|EXPERIMENTAL|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
62150117|NCT02124044|EXPERIMENTAL|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
62521848|NCT05060432|EXPERIMENTAL|Part 1A - EOS-448 + pembrolizumab|Participants will receive EOS-448 and pembrolizumab at every cycle
62521849|NCT05060432|EXPERIMENTAL|Part 1B - EOS-448 + inupadenant|Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis
62521850|NCT05060432|EXPERIMENTAL|Part 1C - EOS-448 + inupadenant|Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis
62150118|NCT05521256|EXPERIMENTAL|NNC0113-6856 (Oral Cohort)|Participants will receive single oral dose of NNC0113-6856 tablets in dose escalated manner.
62150119|NCT05521256|PLACEBO_COMPARATOR|Placebo|Participants will receive single oral dose of placebo (NNC0113-6856) tablets in dose escalated manner.
62521851|NCT05060432|EXPERIMENTAL|Part 1D - EOS-448 + dostarlimab|Participants will receive EOS-448 and dostarlimab at every cycle
62521852|NCT05060432|EXPERIMENTAL|Part 1E - inupadenant HCl + dostarlimab|Participants will receive dostarlimab at every cycle and inupadenant on an ongoing basis
62521853|NCT05060432|EXPERIMENTAL|Part 1F - EOS-448 + dostarlimab + inupadenant HC|Participants will receive EOS-448 and dostarlimab at every cycle and inupadenant on an ongoing basis
62521854|NCT05060432|EXPERIMENTAL|Part 1G - EOS-448 + dostarlimab + chemotherapies|Participants with 1L mNSCLC will receive EOS-448 and dostarlimab and chemotherapies at every cycle
62521855|NCT05060432|EXPERIMENTAL|Part 2C - EOS-448 + dostarlimab|Participants with 1L mHNSCC CPS ≥ 20 will receive EOS-448 and dostarlimab at every cycle
62521856|NCT05060432|EXPERIMENTAL|Part 2D - EOS-448 + dostarlimab|Participants with 1L mHNSCC 1 \< CPS \< 20 will receive EOS-448 and dostarlimab at every cycle
62711784|NCT00461708|EXPERIMENTAL|Rash, Grade ≥2|Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m\^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
62521857|NCT00709436|EXPERIMENTAL|1|PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.
62521858|NCT00709436|PLACEBO_COMPARATOR|2|Placebo at time 0 and specified time points thereafter.
62521859|NCT03578237|EXPERIMENTAL|Treatment (active cryoneurolysis)|Receiving active cryoneurolysis
62521860|NCT03578237|SHAM_COMPARATOR|Sham|Receiving sham cryoneurolysis procedure
62711785|NCT06345404|EXPERIMENTAL|Soquelitinib Dose Escalation|Participants will receive soquelitinib tablets orally at one of four dose levels (100 mg twice daily, 200 mg once daily, 200 mg twice daily, 400 mg once daily) for 28 days
62711786|NCT06345404|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo tablets orally once daily or twice daily for 28 days
62150120|NCT05521256|EXPERIMENTAL|NNC0113-6856 (i.v. Cohort)|Participants will receive single dose of 1.5 milligrams (mg) NNC0113-6856 intravenously (i.v.).
62150121|NCT03982797|EXPERIMENTAL|treated with IMUNO BCG Moreau RJ adjuvant.|
62150122|NCT06244914|EXPERIMENTAL|tDCS + taVNS|tDCS + taVNS will be applied before rehabilitation.
62150123|NCT06244914|ACTIVE_COMPARATOR|tDCS + sham-taVNS|tDCS + sham-taVNS will be applied before rehabilitation.
62150124|NCT06244914|ACTIVE_COMPARATOR|sham-tDCS + taVNS|sham-tDCS + taVNS will be applied before rehabilitation.
62150125|NCT06244914|SHAM_COMPARATOR|sham-tDCS + sham-taVNS|sham-tDCS + sham-taVNS will be applied before rehabilitation.
62150126|NCT01505309|EXPERIMENTAL|Stent Graft|TEVAR procedure using devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
62150127|NCT06364514|EXPERIMENTAL|Intervention Group|"Patients will be started on antibiotics for treatment of pneumonia per usual care by their medical provider team. The research team will monitor enrolled patients daily for markers of their clinical status (caregiver assessment of respiratory status, supplemental oxygen/respiratory support, presence of fever). Once the patient has been clinically stable x48 hours, antibiotics will be discontinued."
62150128|NCT00458783|ACTIVE_COMPARATOR|Prolonged RBC storage|Transfusion with oldest available matching RBCs.
62150129|NCT00458783|ACTIVE_COMPARATOR|Short RBC storage|Transfusion with youngest available matching RBCs.
62150130|NCT00213759|ACTIVE_COMPARATOR|groupe filigrastin|
62150131|NCT00213759|PLACEBO_COMPARATOR|groupe placebo|
62521861|NCT04094948|EXPERIMENTAL|clenbuterol|The initial dose of clenbuterol will be 40 mcg per oral each morning for one week, followed by 40 mcg twice per day (BID) for the next 5 weeks until Week 6. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5 weeks until the Week 12 visit. If 80 mcg BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
62521862|NCT04094948|PLACEBO_COMPARATOR|placebo|Initially, one capsule each morning for one week, followed by one capsule BID for the next 5 weeks until Week 6. If tolerated, the dose will be increased to two capsules each morning and 1 capsule each evening for one week, followed by two capsules BID for the next 5 weeks until the Week 12 visit. If two capsules BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
62521863|NCT05373121|EXPERIMENTAL|Intervention condition - signposting to online peer support|The intervention group will be sent a list of online peer support signposting groups and forums to engage with, which will be adapted depending on what health conditions their child has. They will be asked to keep a weekly engagement log for three months.
62521864|NCT05373121|NO_INTERVENTION|Waitlist condition|The waitlist group will be informed that they will be contacted again in three months, after which, the waitlist will be sent the signposting resources.
62521865|NCT01746264|EXPERIMENTAL|Vitamin D3|Vitamin D3 supplementation at 100,000 IU once a month for 3 months
62521866|NCT03508414|EXPERIMENTAL|Ketogenic diet|
62521867|NCT03508414|EXPERIMENTAL|Intermittent therapeutical fasting|
62150132|NCT01221402|EXPERIMENTAL|Extended-release niacin|
62150133|NCT01221402|PLACEBO_COMPARATOR|Placebo|
62150134|NCT00149409|PLACEBO_COMPARATOR|Placebo|4 gelatine capsules/d
62521868|NCT03508414|ACTIVE_COMPARATOR|Control group|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
62521869|NCT00629265|ACTIVE_COMPARATOR|Active NMES + Swallowing Exercise|Active Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
62521870|NCT00629265|SHAM_COMPARATOR|Sham NMES + Swallowing Exercise|Sham (inactive) Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
62521871|NCT00644449|EXPERIMENTAL|1|
62521872|NCT00644449|EXPERIMENTAL|2|
62521873|NCT02733562||Binge eaters|Classificated preoperatively
62521874|NCT02733562||Volume eaters|Classificated preoperatively
62521875|NCT02733562||sweet eaters|Classificated preoperatively
62521876|NCT02733562||snack eaters|Classificated preoperatively
62521877|NCT02613325|EXPERIMENTAL|Arm 1: fPAM imaging & Single cell PAM imaging|"* fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.~* When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.~* Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.~* To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged"
62711787|NCT05364814||Obese Group|A single sample group . Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks.Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks. At the end of each week, food consumption records and scales were applied. During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet was started and the same procedures were repeated.During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet (with the addition of probiotic yogurt) was changed and the same procedures were repeated.
62711788|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
62711789|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
62711790|NCT00570843|ACTIVE_COMPARATOR|1.|
62711791|NCT00570843|PLACEBO_COMPARATOR|2.|
62150135|NCT00149409|ACTIVE_COMPARATOR|1g/d Omacor|
62150136|NCT00149409|ACTIVE_COMPARATOR|4g/d Omacor|
62521878|NCT03504995|EXPERIMENTAL|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
62521879|NCT06362382|EXPERIMENTAL|tele-rehabilitation training group|"During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle ofstandardized training.~After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily training sessions and intensive supervision and management by the online community at least once a week."
62521880|NCT06362382|ACTIVE_COMPARATOR|control group|"During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times).~After discharge from the hospital, the control group followed their daily routine."
62521881|NCT01194336||Huperzine A: 100 ug|
62521882|NCT01194336||Huperzine A: 200 ug|
62521883|NCT01194336||Donepezil: 2.5 mg|
62521884|NCT01194336||Donepezil: 5 mg|
62521885|NCT01194336||Galantamine: 4 mg|
62521886|NCT01194336||Galantamine: 8 mg|
62521887|NCT01194336||Placebo|
62521888|NCT05166954||LSG group|Laparoscopic sleeve gastrectomy (LSG) performed as a treatment for obesity
62521889|NCT05166954||RYGB group|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity
62521890|NCT01916746|EXPERIMENTAL|transvaginal resection of pregnancy tissue|
62521891|NCT06182904||1|Management of pilon fractures with fibula fixation
62521892|NCT06182904||2|Management of pilon fracture without fibula fixation
62150137|NCT01697605|EXPERIMENTAL|BGJ398|Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
62150138|NCT03610685|PLACEBO_COMPARATOR|Placebo|Participants will be given 2 weeks of placebo treatment. The placebo capsules will be taken once a day orally. The daily dose of placebo treatment will match the Prednisone dose for each participant.
62150139|NCT03610685|ACTIVE_COMPARATOR|Prednisolone|Participants will be given 2 weeks of prednisolone treatment. This is administered orally once a day. The daily dose is calculated according to 0.5mg/kg with a maximum dose of 40mg per day.
62150140|NCT00655213|ACTIVE_COMPARATOR|1|AAISafeR mode programming
62150141|NCT00655213|ACTIVE_COMPARATOR|2|DDD with long AV Delay programming
62150142|NCT00655213|ACTIVE_COMPARATOR|3|DDDAMC mode programming
62521893|NCT04473521|NO_INTERVENTION|No Adhesive|No adhesive will be applied.
62521894|NCT04473521|ACTIVE_COMPARATOR|Super Poligrip Free (SPF)|The denture adhesive of 1.00grams (g) +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilised using this adhesive up to 2 times (maximum \[max\] 3 adhesive applications per day) at examiner's discretion.
62521895|NCT04473521|EXPERIMENTAL|Investigational Adhesive|The denture adhesive of 1.00g +/- 0.05g will be applied only to the maxillary denture only in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
62150143|NCT00655213|OTHER|4|AAISafer mode programming in non randomized patients
62357694|NCT03620253|EXPERIMENTAL|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
62357695|NCT03620253|PLACEBO_COMPARATOR|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
62521896|NCT04473521|EXPERIMENTAL|Investigational Adhesive + Hot drink|The denture adhesive of 1.00g +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Hot drinks will be provided within 1 hour of completing lunch and dinner and must be consumed within 30 minutes. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
62521897|NCT05690087|EXPERIMENTAL|Lidocaine group|Intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation.
61975324|NCT00052208|EXPERIMENTAL|Treatment (gefitinib, radiation therapy)|Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
61975325|NCT01324336||4-17 years, receiving 6-MP|
62521898|NCT05690087|PLACEBO_COMPARATOR|Control group|Intravenous sodium chloride 0.9% solution volume matched in bolus and infusion.
62521899|NCT04859842|ACTIVE_COMPARATOR|Pulse Electromagnetic Field Group|Pulse Electromagnetic Field Therapy (PEMF) will be applied to patients' low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to PEMF therapy.
62521900|NCT04859842|ACTIVE_COMPARATOR|Interferential Current Group|Interferential current will be applied to patients' low back pain region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to Interferential current.
62521901|NCT04859842|SHAM_COMPARATOR|Sham Group|Sham electrodes will be placed on the low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to sham therapy.
62521902|NCT06288022|EXPERIMENTAL|total tubeless mini-PCNL|When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
62521903|NCT06288022|ACTIVE_COMPARATOR|tubeless mini-PCNL|When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
62150144|NCT04330612|NO_INTERVENTION|Control|In the control pathway, the surgeons communicated with the family only once near the completion of the procedure.
62521904|NCT02799030|PLACEBO_COMPARATOR|BF-200 ALA 0%|Topical application of matched placebo gel without containing 5-ALA. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
62521905|NCT02799030|EXPERIMENTAL|BF-200 ALA 1%|Topical application of BF-200 ALA gel containing 0.78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
62521906|NCT02799030|EXPERIMENTAL|BF-200 ALA 3%|Topical application of BF-200 ALA gel containing 3.8 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
62521907|NCT02799030|EXPERIMENTAL|BF-200 ALA 10%|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
62521908|NCT02453906|EXPERIMENTAL|healthy subjects|they receive XNKQ acupuncture, as well as control 1, control 2, and control 3 in a randomized order.
62521909|NCT02043613|ACTIVE_COMPARATOR|Exercise in standard room|"Intervention: Exercise~Patients exercise in standard physical surroundings. The room is marked by years of use. The room is placed in the basement, has artificial lighting, poor acoustics and bare concrete walls."
62521910|NCT02043613|EXPERIMENTAL|Exercise in a contexually enhanced room|"Intervention: Exercise + contextually enhanced physical surroundings~Patients exercise in a contextually enhanced room. The room has both artificial lighting and daylight, view of a recreational park, better acoustics, decorations among other factors, which may cause or enhance the context effect."
62521911|NCT02043613|NO_INTERVENTION|Waiting list|Patients on waiting list are included, baseline tested and placed on a waiting-list for a 8 week period and tested at 8 weeks follow-up. The group is representative of the natural cause of disease.
62711792|NCT02971501|EXPERIMENTAL|Arm I (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, tumor biopsy and blood sample collection throughout the study.
62521912|NCT03734211|EXPERIMENTAL|Evolocumab|Evolocumab (Repatha®) will be administered subcutaneously once monthly in the abdomen, thigh, or upper arm for the duration of the treatment period (one year). The 420 mg evolocumab/placebo will be administered by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
62711793|NCT02971501|EXPERIMENTAL|Arm II (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, tumor biopsy and blood sample collection throughout the study.
62521913|NCT03734211|PLACEBO_COMPARATOR|Placebo|The placebo is presented in an identical prefilled autoinjector. It is supplied as a sterile, single-use, preservative-free solution for subcutaneous injection in a disposable, spring-based prefilled autoinjector. The prefilled autoinjector contains a 1.0 mL deliverable volume of 1.1% (w/v) sodium carboxymethylcellulose, 250 mM proline, 10 mM acetate, and 0.01% (w/v) polysorbate 80, pH 5.0.
62521914|NCT03424512|EXPERIMENTAL|Group Metacognitive Therapy|Group metacognitive therapy (MCT) is a brief psychological intervention designed to be delivered in small groups of 4-8 patients over a course of six, 90 minute sessions conducted on a weekly basis
62521915|NCT01286389|ACTIVE_COMPARATOR|Conventional medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
62521916|NCT01286389|EXPERIMENTAL|caloric restriction +medical care|Nutritional counseling individually and in groups, aiming to promote weight loss (10% of body weight) through caloric restriction, +Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise)
62521917|NCT04722159||Treatment resistent hypertensives, treated with renal denervation|Patients having undergone renal denervation and fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP \>140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
62521918|NCT04722159||Treatment resistent hypertensives, conservatively treated|Patients fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP \>140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
62521919|NCT03124862|EXPERIMENTAL|Test group|The subjects will be enrolled into the test group and will receive ARM sensor.
62521920|NCT01799317|ACTIVE_COMPARATOR|Treatment with vitamin D2|Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
62521921|NCT01799317|NO_INTERVENTION|Standard of Care|Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
62521922|NCT02816866|EXPERIMENTAL|empowered primary care model|"patients receive an individualized prescription for survivorship care prepared by a cancer survivor specialist to be implemented by the primary care doctor"
62521923|NCT02816866|EXPERIMENTAL|specialty survivor clinic|patient attends a specialty survivor clinic at Yale for survivorship care
62521924|NCT05800899|ACTIVE_COMPARATOR|Brief Motivational Interviewing|
62521925|NCT05800899|EXPERIMENTAL|Culturally Adaptation Brief Motivational Interviewing|
62521926|NCT03026855|EXPERIMENTAL|Autologous PRP Gel and PRP Injection|Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
62521927|NCT02304991|EXPERIMENTAL|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
61975326|NCT05931159|EXPERIMENTAL|Abdominal Hypopressive Training|The Abdominal hypopressive Exercises along with home plan based on conventional exercises.
62711794|NCT02301897|PLACEBO_COMPARATOR|Placebo|Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
62711795|NCT02301897|EXPERIMENTAL|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
62711796|NCT02301897|EXPERIMENTAL|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
62711797|NCT05067335|EXPERIMENTAL|Romosozumab|Subjects randomized to this arm will receive romosozumab during all treatment Periods.
62711798|NCT05067335|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind-Placebo controlled Period and romosozumab during the Open-Label treatment Period
62711799|NCT05016635||Sub-arachnoid Hemorrhage Patients|
62150145|NCT04330612|EXPERIMENTAL|Intervention|In the intervention group, the families received additional standardized electronic updates via pagers.
62150146|NCT01482325|EXPERIMENTAL|Subjects requiring blood pressure monitoring|Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring
62150147|NCT03086226|EXPERIMENTAL|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
62357696|NCT05185284|EXPERIMENTAL|Favipiravir (Areplivir)|Arm 1 (n=106) receives the study drug Areplivir for parenteral administration as follows: Day 1 1600 mg 2 times a day, Day 2-10 800 mg 2 times a day. Administration will be done intravenously by drip infusion for 2 hours. The course of treatment is 10 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient.
62521928|NCT02304991|PLACEBO_COMPARATOR|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
62521929|NCT05479799||Anemia group|anemia was diagnosed with a hemoglobin level of less than 11.0 g/dl
62521930|NCT05479799||Non-anemia group|Normal hemoglobin was diagnosed with a hemoglobin level of more than 11.0 g/dl
62711800|NCT05663060|EXPERIMENTAL|Probiotic|Probiotic
62711801|NCT05792020|EXPERIMENTAL|Excitatory tFUS parameters effect on Motor Evoked Potentials|All participants will receive three sessions of Focused Ultrasound Stimulation to their motor hotspot. This stimulation cycle will operate at a 50% duty cycle.
61975327|NCT05931159|ACTIVE_COMPARATOR|Conventional Physical therapy for DrA|Draw-in maneuver in supine, quarduped, prone lying, bent leg fall outs, curl ups, and front and side planks.
62150148|NCT03086226|EXPERIMENTAL|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
62150149|NCT03086226|ACTIVE_COMPARATOR|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
62150150|NCT05575349|EXPERIMENTAL|Mandala coloring group|Mandala painting will be applied to climacteric women with anxiety.
62150151|NCT05575349|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms
62150152|NCT01960972|EXPERIMENTAL|Salt substitute|"As described by Brown, in a stepped wedge design, an intervention is rolled-out sequentially to the trial participants (either as individuals or clusters of individuals) over a number of time periods. The order in which the different individuals or clusters receive the intervention is determined at random and, by the end of the random allocation, all individuals or groups will have received the intervention. Stepped wedge designs incorporate data collection at each point where a new group (step) receives the intervention.~Thus, the salt substitute will be implemented in each cluster (village) in a randomized fashion. Not arms are needed since the 6 randomly-selected villages will be implemented in some moment of the protocol."
62150153|NCT05569343||Textbook outcome group|Achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
62150154|NCT05569343||Non-Textbook outcome group|Not achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
62150155|NCT00486954|EXPERIMENTAL|Paclitaxel plus Lapatinib|6 pills of lapatinib at 250 mg each once daily and infusion of paclitaxel at 80 mglm2 weekly
62150156|NCT00486954|ACTIVE_COMPARATOR|Paclitaxel alone|Infusion of paclitaxel at 80 mglm2 weekly
62150157|NCT06275802|EXPERIMENTAL|Intervention schools (educated about nutrition)|The research will be conducted in six high schools, three of which are intervention schools . Schools in the district will be divided into 3 layers as 1- Anatolian High Schools, 2- Technical and Vocational High Schools, 3- Imam Hatip High Schools.
62150158|NCT06275802|SHAM_COMPARATOR|Control schools (non-educated about nutrition)|The research will be conducted in six high schools, three of which are control schools. Schools in the district will be divided into 3 layers as 1- Anatolian High Schools, 2- Technical and Vocational High Schools, 3- Imam Hatip High Schools, and a control school will be determined from each layer by means of a random numbers table
62150159|NCT01533194|EXPERIMENTAL|Treatment (wild-type reovirus)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62150160|NCT05912049|EXPERIMENTAL|9MW3811 Injection|single dose escalation for experimental drug
62150161|NCT05912049|PLACEBO_COMPARATOR|Placebo|matching placebo administration for control
61976405|NCT03438175|EXPERIMENTAL|Intervention|Families of critically ill patients will receive during the first ICU day of their loved one a brochure presenting the ICU and inviting them to visit a website specifically created for this project: www.intensiva.it Moreover, in the waiting room of the ICU will be placed 8 posters to improve comprehension and to legitimize emotions.
62150162|NCT04078217|EXPERIMENTAL|Jintronix|Jintronix Rehabilitation System uses Microsoft Kinect cameras to track patient's movements in 3D during exercises. They are programmed as games that are visualized on a TV and for which performance feedback is provided to the participant. Individualized asynchronous supervised home-base exercise program using the Jintronix System, 3 times/week for 12 weeks (36 sessions). A trained kinesiologist will install the system and supervise the exercise program, in person and remotely.
62711802|NCT05792020|EXPERIMENTAL|Inhibitory tFUS parameters effect of Motor Evoked Potentials|All participants will receive three sessions of Focused Ultrasound Stimulation to their motor hotspot. This stimulation cycle will operate at a 5% duty cycle
62711803|NCT05792020|SHAM_COMPARATOR|Sham tFUS parameters effect of Motor Evoked Potentials|All participants will receive three sessions of Focused Ultrasound Stimulation to their motor hotspot. This stimulation cycle will utilize an air-filled spacer to block stimulation from reaching the brain
62150163|NCT04078217|ACTIVE_COMPARATOR|Control|Participants in this group will follow an individualized non-supervised home-based exercise program (booklet format). The exercise program will include 3 sessions per week for 12 consecutive weeks, as for Jintronix group. Actually, all movements of the booklet program are selected to match the exercise-games of the technology (similar movement, muscles engagement, etc.). A trained kinesiologist will explain and supervise the exercise program for the first sessions. The communication frequence will be the same as the Jintronix group.
62150164|NCT00308308|EXPERIMENTAL|1|Technosphere Insulin
62150165|NCT00308308|ACTIVE_COMPARATOR|2|Rapid-acting analogue insulin plus basal insulin glargine
62150166|NCT01680432|EXPERIMENTAL|Probiotic cheese|The group received, for 30 days, was instructed to eat 30 g/day of probiotic fresh cheese enriched with Bifidobacterium lactis Bi-07.
62150167|NCT01680432|PLACEBO_COMPARATOR|Regular Cheese|The group placebo received, for 30 days, was instructed to consume 30g/day of regular fresh cheese.
62150168|NCT01685476|OTHER|Intracranial pressure|
62150169|NCT06100354||Preference study|Patients answering the questionnaire with choice sets
62150170|NCT02135315|EXPERIMENTAL|intensive controle group|The end point in this group was to maintain the systolic blood pressure (SBP) between 110 and 120 mmHg using continuous intravenous Isosorbide Dinitrate perfusion, and Labetalol if needed.
62150171|NCT02135315|ACTIVE_COMPARATOR|standard control group|The end point in these group was to maintain the systolic blood pressure under 140 mmHg using continuous intravenous Isosorbide Dinitrate perfusion, and Labetalol if needed.
62357697|NCT05185284|ACTIVE_COMPARATOR|Standard of care|"Arm 2 (n=108) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site. Might include Favipiravir tab, Remdesivir or other recommended schemes.~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
62357698|NCT04203940|ACTIVE_COMPARATOR|Cyanoacrylate|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue (Histoacryl®).
62521931|NCT05465642||Drug-induced liver injury|history of taking hepatotoxic drugs, liver injury.
62521932|NCT05465642||Healthy control|no liver disease or other disease
62521933|NCT00599898|EXPERIMENTAL|1|
62521934|NCT00599898|EXPERIMENTAL|2|
62521935|NCT02922101|EXPERIMENTAL|Audit and Feedback with toolbox|Access to an online dashboard that provides insight into clinical performance on quality indicators for pain management; including a quality improvement toolbox to facilitate planning and executing actions. Participating ICUs will receive one educational outreach visit and brief monthly telephone calls.
62711804|NCT02209467|NO_INTERVENTION|Group balance training late start|Participants randomized to late start act as No intervention group during the study period.
62711805|NCT02209467|EXPERIMENTAL|Group balance training early start|Group balance training focusing on core stability exercises 2 times per week for 7 weeks and 2 home training sessions per weeks.
62711806|NCT04219410||Cases|Patients who underwent minimally invasive esophagectomy with this novel procedure at Kaiser Permanente, Northern California, Oakland Medical Center
62521936|NCT02922101|ACTIVE_COMPARATOR|Audit and Feedback without toolbox|Same intervention, but without access to the quality improvement toolbox.
62521937|NCT05562908|ACTIVE_COMPARATOR|Pedicled|Harvesting of LIMA with its surrounding tissue: fascia, veins, etc
62521938|NCT05562908|ACTIVE_COMPARATOR|Surgical skeletonised|"Harvesting of LIMA in a naked fashion where you dissect the artery free of the surrounding tissue."
62521939|NCT05562908|ACTIVE_COMPARATOR|Skeletonised with Thunderbeat|Same as Surgical skeletonised but instead of closing the side branches with clips a surgical tool is used for coagulation of the side-branches.
62521940|NCT05499780|EXPERIMENTAL|Group A: treatment with Sentinox performed 3 times/day for 21 days|treatment with Investigational Medical Device (IMD) performed 3 times/day for 21 days at 8 am, 2 pm and 8 pm
62521941|NCT05499780|NO_INTERVENTION|Group B:no Sentinox treatment|
62521942|NCT00975286|EXPERIMENTAL|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
62521943|NCT00975286|PLACEBO_COMPARATOR|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
62711807|NCT02951780|EXPERIMENTAL|LY3185643|LY3185643 administered subcutaneous (SC)
62357699|NCT04203940|ACTIVE_COMPARATOR|Suture|mesh fixation was done with polypropylene 2/0 sutures
62150172|NCT02110407|SHAM_COMPARATOR|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
62711808|NCT02951780|EXPERIMENTAL|rGlucagon|rGlucagon administered subcutaneous (SC)
62150173|NCT02110407|EXPERIMENTAL|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
62150174|NCT06037044|EXPERIMENTAL|Sensory integration therapy for balance and gait|Sensory integration walking pathway with obstacles x 10 and standing on one leg with eyes open and eyes closed 5-10 sec
62357700|NCT01488409|EXPERIMENTAL|Acipimox|Treatment with the study drug Acipimox
62357701|NCT01488409|PLACEBO_COMPARATOR|Placebo|Treatment with Placebo control.
62357702|NCT04466072||High Ventricular Arrhythmia burden group|"Inclusion criteria for all groups:~* age \>18 years-old~* competent and willing to provide consent~* presence of implantable cardioverter-defibrillator~* diagnosis of cardiomyopathy~* left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment~Inclusion criteria for high ventricular arrhythmia burden group:~• at least one episode of sustained VT/VF or VT/VF requiring ICD therapies within the preceding 3 months as assessed on device interrogation at the time of study enrollment~Both groups will have stool sample collected for microbial analysis. This is anticipated twice for the high ventricular arrhythmia (VA) burden group. Once at the time of diagnosis of VA and later after the clinically indicated treatment for the VA."
62357703|NCT04466072||Control group|"Inclusion criteria for all groups:~* age \>18 years-old~* competent and willing to provide consent~* presence of implantable cardioverter-defibrillator~* diagnosis of cardiomyopathy~* left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment~Inclusion criteria for control group:~• no VT/VF on device interrogation for a period of at least 3 months preceding study enrollment~Both groups will have stool sample collected for microbial analysis. This is anticipated only once for the control group."
62357704|NCT05432024||Radiofrequency ablation, High power, short duration|Radiofrequency ablation is an ablation modality that uses radiofrequency energy to create ablation lesions through heat. Patients that are scheduled for pulmonary vein isolation using radiofrequency ablation will be consented for study participation.
62357705|NCT05432024||Ultra-low temperature cryo ablation|Ultra-low temperature cryo ablation is an ablation modality that uses nitrogen near its liquid-vapor critical point to create ablation lesions through ultra-low temperatures. Patients that are scheduled for pulmonary vein isolation using ultra-low temperature cryo ablation will be consented for study participation.
62357706|NCT05432024||Pulsed field ablation|Pulsed field ablation is an ablation modality that uses short lived electrical fields to create ablation lesions through irreversible electroporation. Patients that are scheduled for pulmonary vein isolation using pulsed field ablation will be consented for study participation.
62357707|NCT05569616|EXPERIMENTAL|Hand massage group|Based on the hand massage procedure, hand massage with baby oil will be applied for 20 minutes, three times a week (12 times in total) for 4 weeks.
62357708|NCT05569616|EXPERIMENTAL|Play activity group|It will be played in groups of two for one hour once a week. The application will take 4 weeks.
62521944|NCT00862017|EXPERIMENTAL|MSG|Subjects receive a 6-d supplementation of MSG and are studied on the 7th day in the postprandial period following a standard meal ingestion with 2g MSG
62521945|NCT00862017|PLACEBO_COMPARATOR|Control|
62521946|NCT01802749|ACTIVE_COMPARATOR|chemotherapy|"Combination chemotherapy with ONE of the following regimens:~* PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;~* GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;~* PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days."
62711809|NCT04378153||Master Study Run-in|Participants enrolled in the run-in phase of the master protocol.
62711810|NCT06474871|EXPERIMENTAL|Non-immersive VR-based training (VR)|VR training focuses on enhancing executive processes but uses digital VR devices. During a VR session, the patient sits in front of the device and actively interacts with it, under the supervision of the therapist. The device contains many different exercises and for each of them the therapist can modify the virtual task scenario, increasing/decreasing its difficulty, creating a stimulating learning context in which the exercises are neither too easy nor too difficult. The exercises are divided into specific sub-domains, and include orientation, attentional processes, memory, and visual-executive functions.
62521947|NCT01802749|EXPERIMENTAL|Chemotherapy and bevacizumab|"Combination chemotherapy AND bevacizumab with ONE of the following regimens:~* PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC 5 on day 1 every 4 weeks and Bevacizumab 10 mg/kg i.v. on Day 1 every 2 weeks;~* GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks;L~* PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks.~Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn."
62521948|NCT04610463|OTHER|Standard|Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
62521949|NCT05211999|EXPERIMENTAL|Precede-Proceed Model Based Simulation Experience|
61975328|NCT04478474||Eligible|Retrospective chart review of all pediatric patients who underwent allogeneic stem cell transplant between June 29, 2011 and December 31, 2019 at Westchester Medical Center (WMC). Children, adolescent, and young adult patients, ages 0-≤26 years, who have received an allogeneic stem cell transplantation on the pediatric bone marrow transplant service including matched unrelated donor, matched sibling donor, haploidentical donor, umbilical cord donor, who received ganciclovir prophylaxis for ≥14 days.
62521950|NCT05211999|NO_INTERVENTION|Control Group|
62521951|NCT01758055|EXPERIMENTAL|Autologous MSCs transplantation|intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once
62521952|NCT02941276|EXPERIMENTAL|Group A|Active electrostimulator device (intra-oral active second generation Saliwell GenNarino) (Saliwell Ltd., Harutzim, Israel)
62711811|NCT06474871|ACTIVE_COMPARATOR|Traditional cognitive training (TCT)|the standard treatment focused on executive processes and was based on a face-to-face approach between the therapist and the patient using paper and pencil tools and other traditional materials. The training of the executive abilities is carried out by working on categorization, planning, association processes, analogical reasoning, problem solving and coping strategies to simulate problematic situations, tailored on patients' deficits, in a protected context, thanks to interaction with the cognitive therapist according to a holistic-integrated approach.
61975329|NCT00707668||Control|Chung-ju cohort populations aged over 30 year-old
62150175|NCT06037044|ACTIVE_COMPARATOR|Traditional Physiotherapy for balance and gait|Walking pathway with obstacles x 10 and standing on one leg with eyes open 5-10 sec
62357709|NCT05569616|NO_INTERVENTION|Control group|These elderly people in the control group will benefit from the standard care practices offered in the institution, and no intervention will be given to these elderly people by the researcher.
62357710|NCT01894763|ACTIVE_COMPARATOR|Small-diameter stent|Placement of a 23 mm self-expandable metal stent
62357711|NCT01894763|ACTIVE_COMPARATOR|Large-diameter stent|Placement of a 28-mm self-expandable metal stent
62357712|NCT06326671|EXPERIMENTAL|Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 mcg)|The subjects randomly received single oral inhalation dose of Tiotropium bromide inhaling powder generic product.
62357713|NCT06326671|ACTIVE_COMPARATOR|Reference Product (Spiriva®Handihaler®, Strength: 18 mcg)|The subjects randomly received single oral inhalation dose of the reference listed drug (RLD) Spiriva®Handihaler®.
62357714|NCT02379611|ACTIVE_COMPARATOR|normally hearing children|
62357715|NCT02379611|EXPERIMENTAL|Congenital profound deaf children|
62357716|NCT04841694|EXPERIMENTAL|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day
62357717|NCT02581670|EXPERIMENTAL|Oligometastatic breast cancer patients|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.
62357718|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
62357719|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
62357720|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
62357721|NCT05376995|EXPERIMENTAL|Graston technique.|The Graston Technique is a form of manual therapy known as soft-tissue instrument-assisted mobilization
62357722|NCT05376995|EXPERIMENTAL|muscle energy technique|Muscle Energy Technique (MET), uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle
62357723|NCT00093756|EXPERIMENTAL|Treatment (bortezomib, paclitaxel, carboplatin)|"PHASE I: Cohorts of 3-6 patients receive escalating doses of study medications until the maximum tolerated dose (MTD) is determined. PHASE II: Patients receive as in phase I at the MTD. Patients also undergo radiotherapy as in phase I.~3-dimensional conformal radiation therapy bortezomib: Given IV paclitaxel: Given IV carboplatin: Given IV"
62357724|NCT01126502|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive alvespimycin hydrochloride IV over 60 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62357725|NCT04018586|EXPERIMENTAL|Heat and Vacuum|AVACEN 100 device applies heat and vacuum to hand
62521953|NCT02941276|SHAM_COMPARATOR|Group B|Sham electrostimulator device (intra-oral sham second generation Saliwell GenNarino) (Saliwell Ltd., Harutzim, Israel)
61975330|NCT00676351|OTHER|A|body plethysmography Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
61975331|NCT06466109|EXPERIMENTAL|intervention group|Patients and their parents will interact with the social robot PARO separately and together in each 30-minute course every two weeks for four courses.
62711812|NCT00796458|ACTIVE_COMPARATOR|Arm I|Patients continue to receive LHRH-A therapy until disease progression.
62357726|NCT04018586|ACTIVE_COMPARATOR|Heat Only|AVACEN 100 device with heat only
62357727|NCT04018586|SHAM_COMPARATOR|Sham|AVACEN 100 device with neither heat nor vacuum
62357728|NCT02932644||Rheumatoid arthritis patients|Participants in the original, parental trial
62357729|NCT03162393||group 1|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve
62150176|NCT00787176|ACTIVE_COMPARATOR|Group A|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient is positioned for epidural placement. Oxytocin management continued as per protocol.
62150177|NCT00787176|EXPERIMENTAL|Group B|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
62150178|NCT00787176|ACTIVE_COMPARATOR|Group C|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
62150179|NCT00787176|EXPERIMENTAL|Group D|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
62150180|NCT03675789||STEMI|50 STEMI patients treated with standard therapy undergoing to primary percutaneous coronary internention (PPCI). Thromboaspiration will be performed whenever possible (when the anatomy of the coronary artery - curve and size- allowed it) in all patients with a TIMI Flow 0 and in all patients with a visible thrombus if TIMI Flow was 1 or more.
62150181|NCT03675789||Stable angina|50 stable angina (SA) patients on standard therapy, undergoing to intracoronary blood aspiration during elective diagnostic and/or interventional coronary procedure, matched for age, sex and comorbidities with the 50 STEMI patients.
62150182|NCT03675789||Controls|50 outpatients without coronary heart disease, matched for age gender and comorbidities like diabetes and hypertension with the 50 STEMI patients. Peripheral blood samples will be collected during routine patient monitoring.
62150183|NCT05020236|EXPERIMENTAL|Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab|
62150184|NCT05020236|EXPERIMENTAL|Part 2 Randomized Arm A: Elranatamab|
62150185|NCT05020236|EXPERIMENTAL|Part 2 Randomized Arm B: Elranatamab + Daratumumab|
62150186|NCT05020236|ACTIVE_COMPARATOR|Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone|
62150187|NCT05304676|EXPERIMENTAL|KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation. Children will be treated for 3 days a week over 4 weeks.
62150188|NCT05304676|ACTIVE_COMPARATOR|Conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
62150189|NCT06118008|EXPERIMENTAL|HS-20094 5mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
62150190|NCT06118008|EXPERIMENTAL|HS-20094 10mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
62150191|NCT06118008|EXPERIMENTAL|HS-20094 15mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
62150192|NCT06118008|EXPERIMENTAL|HS-20094 20mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
62150193|NCT03367416||Intervention|This study will test the NIATx model, an evidence-based behavioral intervention for implementing organizational change and quality improvement in community based health settings with a high proportion of underserved individuals. The goal of the study will be to use the model to identify and implement organizational changes in dental practices that will improve the no-show rate in underserved populations.
62150194|NCT03960645|EXPERIMENTAL|B/F/TAF|Pregnant women participants will receive fixed dose combination (FDC) tablet of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for up to 38 weeks (from the second or third trimesters of pregnancy, depending on enrollment, through 12 weeks post-partum).
62357730|NCT03162393||group 2|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve
62357731|NCT03162393||group 3|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
62357732|NCT03162393||group 4|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
62357733|NCT03162393||group 5|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and triceps branch
62357734|NCT03162393||group 6|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve and radial nerve; contralateral C7 nerve transfer to median nerve and triceps branch
62357735|NCT00832312|EXPERIMENTAL|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml) injected into the knee joint
62357736|NCT00832312|PLACEBO_COMPARATOR|Saline|Injection of 1cc of saline into the knee joint
62357737|NCT01141127|ACTIVE_COMPARATOR|INTERMITENT ADMINISTRATION|Administration of 10 mg/kg of Tranexamic Acid at the beginning ,the middle and at the end of the intervention
62357738|NCT01141127|EXPERIMENTAL|continuous administration of Tranexamic Acid|Administration of 10 mg /Kg of Tranexamic Acid at the beginning in the priming pump and continuous infusion of 1 mg/KG of Tranexamic Acid until the end of the intervention
62357739|NCT00744848|ACTIVE_COMPARATOR|Bupivacaine HCl|"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
62357740|NCT00744848|OTHER|SKY0402|"300 mg SKY0402 in a 40-mL injection volume.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
62357741|NCT06345599|EXPERIMENTAL|Experimental group|Radiotherapy、Immunotherapy、Chemotherapy
62711813|NCT00796458|EXPERIMENTAL|Arm II|Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62711814|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
61975332|NCT04435860||Ankylosing Spondylitis|Patients with ankylosing spondylitis meeting the inclusion and exclusion criteria
61975333|NCT04435860||Healthy Controls|Healthy individuals meeting the exclusion criteria
62711815|NCT02411461||Healthy siblings|Control group
62711816|NCT02411461||Obese patients|Control group
62357742|NCT02249208|ACTIVE_COMPARATOR|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.
62150195|NCT03960645|NO_INTERVENTION|Neonates|Neonates who will be born to women participants in the study will be followed from birth up to 8 weeks of age after obtaining consent from the parent or legal guardian. None of the neonates that participate in the study will be treated with the study drug.
62150196|NCT01448928||Group 1|
62357743|NCT02249208|EXPERIMENTAL|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.
62357744|NCT02249208|EXPERIMENTAL|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.
62357745|NCT06025903||Primary Progressive multiple sclerosis|patients affected by primary progressive multiple sclerosis
62357746|NCT06025903||Relapsing Remitting multiple sclerosis|patients affected by primary progressive multiple sclerosis
62357747|NCT03498118|EXPERIMENTAL|Transversus Abdominis Plane Block group|after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
62357748|NCT03498118|ACTIVE_COMPARATOR|Wound Infiltration group|at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure
62357749|NCT01433120|EXPERIMENTAL|Probiotic L. casei F19|
62357750|NCT01433120|EXPERIMENTAL|Flax seed fibres|
62357751|NCT01433120|PLACEBO_COMPARATOR|Placebo|
62357752|NCT00984529||1|Cardiologist´s office patients
62150197|NCT03136861|EXPERIMENTAL|Secukinumab 150 mg (Group A)|Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
62357753|NCT03347240|ACTIVE_COMPARATOR|Brain lesioning group|Stereotactic lesioning of the thalamus or gloves pallidus
62357754|NCT03347240|ACTIVE_COMPARATOR|Combined rhizotomy group|Combined anterior and posterior lumbosacral rhizotomy
62357755|NCT03347240|ACTIVE_COMPARATOR|Deep brain stimulation group|Bilateral globus pallidus internus deep brain stimulation
62357756|NCT03347240|ACTIVE_COMPARATOR|Intra-thecal Baclofen infusion therapy|Intra-thecal infusion pump
62357757|NCT00510068|EXPERIMENTAL|Everolimus 10 mg/day|Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
62357758|NCT00510068|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
62357759|NCT01062009|NO_INTERVENTION|Control group|No intervention
62357760|NCT01062009|ACTIVE_COMPARATOR|Low dose group|250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
62357761|NCT01062009|ACTIVE_COMPARATOR|Medium dose group|500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
62357762|NCT01062009|ACTIVE_COMPARATOR|High dose group|750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
62357763|NCT05771506||COPD Group|Balance assessment, Pulmonary function test, Respiratory muscle strength test, Peripheral muscle strength test, 6-minute walk test, Cognitive assessment
62357764|NCT05771506||Control Group|Balance assessment, Pulmonary function test, Respiratory muscle strength test, Peripheral muscle strength test, 6-minute walk test, Cognitive assessment
62357765|NCT02313922|EXPERIMENTAL|etanercept combined with methotrexate|patients treated with etanercept combined with methotrexate
62357766|NCT02313922|EXPERIMENTAL|etanercept as monotherapy|patients treated with etanercept combined with placebo
62357767|NCT02740218||Psoriasis patients|Single cohort of psoriasis patients treated with OTEZLA (apremilast)
62357768|NCT02833519|NO_INTERVENTION|control group|Standard care, mentally vulnerable women
62357769|NCT02833519|ACTIVE_COMPARATOR|group exercise|Supervised Group training
62357770|NCT02771457|EXPERIMENTAL|Infliximab at weeks 0,2, and 6|In this arm subjects will receive re-induction treatment of infliximab at weeks 0,2, and 6.
62357771|NCT02771457|EXPERIMENTAL|Infliximab at weeks 0,4, and 8|In this arm subjects will receive re-induction treatment of infliximab at weeks 0, 4, and 8
62357772|NCT02771457|ACTIVE_COMPARATOR|Infliximab at weeks 0, and 8|In this arm subjects will not be randomized. They will receive re-induction therapy weeks 0 and 8.
62357773|NCT03405155|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62357774|NCT01570608|ACTIVE_COMPARATOR|monotherapy arm|patients receiving 3 initial Ranibizumab injections, thereafter as needed
62357775|NCT01570608|ACTIVE_COMPARATOR|combined treatment arm|
62357776|NCT03527316|EXPERIMENTAL|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
62357777|NCT03527316|EXPERIMENTAL|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
62357778|NCT02847845|EXPERIMENTAL|Red ginseng powder capsule|People in this group take a red ginseng powder capsule.
62357779|NCT02847845|PLACEBO_COMPARATOR|Placebo powder capsule|People in this group take a placebo powder capsule.
62357780|NCT04467164|EXPERIMENTAL|Exhalatory-gated tVNS|exhalatory-gated tVNS on the left auricle
62357781|NCT04467164|ACTIVE_COMPARATOR|Inhalatory-gated tVNS|inhalatory-gated tVNS on the left auricle
62521954|NCT01366092|EXPERIMENTAL|Interleukin-2|Each study participant will receive daily subcutaneous IL-2 (1 x 106 IU/m2/day) for self-administration for 12 weeks, followed by a 4-week hiatus. IL-2 will be typically administered on an outpatient basis. After completing the 16 week study (12 weeks of IL-2 study treatment and a mandatory 4 weeks off-IL-2), patients experiencing clinical benefit (complete or partial response; as well as minor response not meeting NIH criteria for partial response) with an acceptable toxicity profile will be permitted to continue extended-duration treatment indefinitely at the discretion of the treating physician.
62711817|NCT01918189|EXPERIMENTAL|10 week Pain EASE access|behavioral pain self-management intervention (Pain EASE) delivered via the Internet
62150198|NCT03136861|PLACEBO_COMPARATOR|Placebo (Group B)|Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
62521955|NCT03647683|EXPERIMENTAL|Self-Compassion|After pretreatment heat pain assessment, participants are introduced to the concept of self-compassion. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily self-compassion audio-interventions. Afterwards, the follow-up pain assessment is conducted.
62521956|NCT03647683|EXPERIMENTAL|Acceptance|After pretreatment heat pain assessment, participants are introduced to the concept of acceptance. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily acceptance audio-interventions. Afterwards, the follow-up pain assessment is conducted.
62521957|NCT03647683|EXPERIMENTAL|Distraction|After pretreatment heat pain assessment, participants are introduced to the concept of distraction. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily distraction audio-interventions. Afterwards, the follow-up pain assessment is conducted.
62521958|NCT05541991|EXPERIMENTAL|Single dose product|A single dose coated tablet with standardised rhubarb extract is administrated daily in the evening during 30days
62521959|NCT05541991|EXPERIMENTAL|Double dose product|A double dose coated tablet with standardised rhubarb extract is administrated daily in the evening during 30days
62521960|NCT05541991|PLACEBO_COMPARATOR|placebo product|A placebo coated tablet without active is administrated daily in the evening during 30days
62711818|NCT04744584||Patients with medication reconciliation|Patient with medication reconciliation during 1st hospitalization
62711819|NCT04744584||Patients without medication reconciliation|Patient without medication reconciliation (MR) at 1st hospitalization but with retrospective MR at the next one (3 to 6 months after)
62711820|NCT04915716||healthy pregnant woman|healthy pregnant woman
62711821|NCT04915716||pregnant women with GDM|pregnant women with gestational diabetes mellitus
62711822|NCT04885959|NO_INTERVENTION|Usual diet|In the pilot study among healthy volunteers, participant need to maintain their habitual diet for 4 weeks. Meanwhile, in the large-scale study among pregnant women, participants are subjected to receive general dietary advice for healthy pregnancy from attended nurses or physician during their antenatal visits.
62711823|NCT04885959|EXPERIMENTAL|Traditional Asian Diet|"Participants will receive dietary intervention on a traditional Asian diet which diet consists of high fiber, moderate protein, and low fat and with the inclusion of local probiotics and prebiotics food sources which are known to enhance gut health by fostering the gut colonization of beneficial bacteria and promoting the production of SCFA.~During the pilot phase the diet is given for four weeks. Meanwhile, the intervention among pregnant mothers, the intervention is given for 20 weeks considering the nature of the availability of pregnant mothers being recruited where most of them (low risk pregnancy) were given their first clinic appointment at 16 weeks of gestational age."
62150199|NCT03136861|ACTIVE_COMPARATOR|Arm A1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
62150200|NCT03136861|ACTIVE_COMPARATOR|Arm A2|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
62150201|NCT03136861|ACTIVE_COMPARATOR|Arm A3|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
62150202|NCT03136861|ACTIVE_COMPARATOR|Arm B1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
62711824|NCT02022540|EXPERIMENTAL|Stage 1 - Group 1|Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
62711825|NCT02022540|EXPERIMENTAL|Stage 1 - Group 2|Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
62150203|NCT03136861|ACTIVE_COMPARATOR|Arm B2|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
62150204|NCT03015688||knee OA|OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded：the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
62711826|NCT02022540|EXPERIMENTAL|Stage 1- Group 3|Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
62521961|NCT04796779|EXPERIMENTAL|CLC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the intervention group will use the Tandem t:slim X2 with Control-IQ Technology v1.0 during the first 13 weeks of the study (RCT phase, weeks 1-13) and then use Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 for the remaining 13 weeks of the study (extension phase, weeks 14-26).
62711827|NCT02022540|EXPERIMENTAL|Stage 1- Group 4|Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
62711828|NCT02022540|EXPERIMENTAL|Stage 1 - Group 5|Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
62711829|NCT02022540|EXPERIMENTAL|Stage 2|Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks
62711830|NCT03655847|EXPERIMENTAL|Dexmedetomidine|Drug: Dexmedetomidine dexmedetomidine, 0.1ug/kg up or down Other Name: precedex
62521962|NCT04796779|ACTIVE_COMPARATOR|SC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the SC group will use their existing insulin therapy in conjunction with study Dexcom G6 CGM during the first 13 weeks of the study (RCT phase, weeks 1-13). The SC group will then transition to using the Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 and study Dexcom G6 CGM for the remaining 13 weeks of the study (weeks 14-26).
62521963|NCT01923623|EXPERIMENTAL|Block|Popliteal and saphenous Block with Ropivacaine
62150205|NCT03015688||Control|"no often have pain, aching or stiffness in your Left/right knee during last month,no Left/right knee trauma history,no histories of glucocorticoid and/or sterol hormones normal knee X-ray images,"
62150206|NCT02064686|NO_INTERVENTION|TAE|
62150207|NCT00439218|EXPERIMENTAL|Subject Enrollments|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
62521964|NCT01923623|PLACEBO_COMPARATOR|NaCl|
62521965|NCT01101204|ACTIVE_COMPARATOR|M1000 S10 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
62521966|NCT01101204|ACTIVE_COMPARATOR|M1000 S10 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
62521967|NCT01101204|ACTIVE_COMPARATOR|M1000 S40 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
62521968|NCT01101204|ACTIVE_COMPARATOR|M1000 S40 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
62150208|NCT04677309||Lung resection less than lobectomy|participants scheduled for lung resection that is less than lobectomy
62150209|NCT04677309||Lung resection equal to or greater than lobectomy|participants scheduled for lung resection that is equal to or greater than lobectomy
62150210|NCT04166084|ACTIVE_COMPARATOR|Control Group|Patients in this group will receive active ROM exercises, 10 repeats X 3 times a day, 5 days a week for 6 weeks. All exercises will be performed at home .
62150211|NCT04166084|EXPERIMENTAL|Training group|I addition to active ROM exercises, patients in this group will also receive trunk stabilization exercises training for 45 minutes, 2 times a week for 6 weeks. All exercises sessions will be supervised by a physiotherapist in a clinic per week.
62150212|NCT02260726|EXPERIMENTAL|Surgical group|Subjects already scheduled to undergo surgical correction of a symptomatic cam-type hip impingement deformity. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound investigation prior to surgery.
62150213|NCT02260726|OTHER|Control|Asymptomatic subjects with normal hip morphometry, as determined by MRI. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound imaging.
62150214|NCT06248255|EXPERIMENTAL|Intervention arm|Single arm study, all participants get pads applied to their forearms
62150215|NCT05600439|EXPERIMENTAL|Experimental GP|CareME Program. Group attachment-based intervention program developed for improving relational abilities in professional caregivers working in Youth Residential Care (YRC) settings.
62521969|NCT01101204|ACTIVE_COMPARATOR|M2500 S10 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
62521970|NCT01101204|ACTIVE_COMPARATOR|M2500 S10 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
62521971|NCT01101204|ACTIVE_COMPARATOR|M2500 S40 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
62521972|NCT01101204|ACTIVE_COMPARATOR|M2500 S40 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
62521973|NCT01101204|PLACEBO_COMPARATOR|Therapeutic Lifestyle Change|Only therapeutic lifestyle change
61975334|NCT06477458||Single inspiratory phase cohort|Patients in this cohort undergo single inspiratory phase CT and pulmonary function tests preoperatively.
62521974|NCT03161964|EXPERIMENTAL|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
62521975|NCT03161964|EXPERIMENTAL|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
62521976|NCT04813315|EXPERIMENTAL|Kendall exercise|Experimental group 1 got this intervention containing Kendall exercise for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
62521977|NCT04813315|EXPERIMENTAL|Gong's mobilization|Experimental group 1 got this intervention containing Gong's mobilization for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
62521978|NCT02019212||MPI Perfusion Imaging|Clinical patients who have undergone myocardial perfusion imaging with 99mTc
62521979|NCT04732936|EXPERIMENTAL|Device Usability|Device usability and safety will be evaluated.
62521980|NCT04732936|EXPERIMENTAL|Preliminary Efficacy|Preliminary treatment efficacy will be evaluated.
62521981|NCT03330782|EXPERIMENTAL|Elderly|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.
62521982|NCT03330782|ACTIVE_COMPARATOR|Adult|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.
62521983|NCT00732433|EXPERIMENTAL|digital mammogram|"Digital mammography is a non-invasive imaging technique to obtain an x-ray image of the breast.~Two-view digital mammogram of the breast with a lesion that has been recommended for biopsy during the subject's regular clinical care. The digital mammogram is then analyzed by a computer program."
62521984|NCT03493776|ACTIVE_COMPARATOR|Pre-Transplant Group|VZV Subunit vaccine will be administered
62521985|NCT03493776|EXPERIMENTAL|Post-Transplant Group|VZV Subunit vaccine will be administered
62521986|NCT04422119|EXPERIMENTAL|Multi-layer foam dressing|Patients in experimental group will receive the application of a multi-layer foam dressing with Safetac in surgical wound
62521987|NCT04422119|ACTIVE_COMPARATOR|Usual care|Patients in control group will receive standard treatment with povidone-iodine and a gauze dressing with plaster.
62521988|NCT02701166|EXPERIMENTAL|Bezafibrate|Bezalip retard 400mg tablet
61975335|NCT06477458||Respiratory dual-phase cohort|Patients in this cohort undergo respiratory dual-phase CT and pulmonary function tests preoperatively.
61975336|NCT00927784|SHAM_COMPARATOR|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media alone (placebo).
61975337|NCT00927784|EXPERIMENTAL|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs in sequential cohorts.
61975338|NCT00902005||Rheumatic patients|"Three groups:~RA patients: 30 starting on Methotrexate, 30 starting on combination of Methotrexate and TNFalpha inhibitor.~PSA patients: 20 starting on Methotrexate, 20 starting on combination of Methotrexate and TNFalpha inhibitor.~AS patients: 20 starting on TNFalpha inhibitor"
61975339|NCT03124433|EXPERIMENTAL|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
61975340|NCT05982626|EXPERIMENTAL|68Ga/131I-SGMIB-ZT-199|68Ga/131I-SGMIB-ZT-199, single dose
61975341|NCT01991067|ACTIVE_COMPARATOR|HSCT patients / TBE virus vaccine|Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
62521989|NCT02701166|PLACEBO_COMPARATOR|Placebo|Placebo 400mg tablet
62521990|NCT03801538|EXPERIMENTAL|PEG-IFN group|"patients were treated with NAs once a day and PEG-IFN once a week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.~①If the decrease of HBsAg is more than 50%. NAs was stopped. PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.~②If the decrease of HBsAg is less than 50%.NAs and PEG-IFN was extended to week 24. Then, If the decrease of HBsAg is more than 50%. NAs was stopped, PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96. If the decrease of HBsAg is less than 50%. PEG-IFN was stopped, patients were treated with NAs once a day and then followed up for 48 weeks."
62521991|NCT03801538|OTHER|NAs group|CHB patients do not need to change their NAs treatment.
62521992|NCT01684163|PLACEBO_COMPARATOR|Placebo injection|Normal saline
62521993|NCT01684163|EXPERIMENTAL|GLYX-13, 5 mg/kg|Low dose of GLYX-13
62521994|NCT01684163|EXPERIMENTAL|GLYX-13, 10 mg/kg|High dose of GLYX-13
62150216|NCT05600439|NO_INTERVENTION|Control GP|The control group had no intervention assigned.
62521995|NCT06127368|EXPERIMENTAL|GB-5001A|GB-5001 Suspension for IM/SC injection at three doses(low, intermediate, high) The cohort is determined through random allocation.
62150217|NCT03229291|EXPERIMENTAL|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
62521996|NCT06127368|EXPERIMENTAL|GB-5001D|GB-5001 Suspension for SC injection at three doses(low, intermediate, high) The cohort is determined through random allocation.
62521997|NCT06127368|ACTIVE_COMPARATOR|Oral cohort|Aricept® tablet. The cohort is determined through random allocation.
62521998|NCT02631018|EXPERIMENTAL|Physical Activity Enhanced Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations. This arm, uniquely, will receive a culturally based physical activity component.
62150218|NCT03229291|EXPERIMENTAL|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
62150219|NCT03229291|EXPERIMENTAL|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
61975342|NCT01991067|ACTIVE_COMPARATOR|healthy volunteers / TBE virus vaccine|Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
62521999|NCT02631018|ACTIVE_COMPARATOR|Standard Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations.
62522000|NCT02563717|ACTIVE_COMPARATOR|Reference Device: T-piece System|
62522001|NCT02563717|ACTIVE_COMPARATOR|Investigational Device: The New System|
62522002|NCT03273491|EXPERIMENTAL|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
61975343|NCT03912766||Transurethral Prostatectomy|male patients undergoing transurethral prostatectomy (TURP) for benign prostatic hyperplasia, routine surgical removal using resectoscope
62150220|NCT03229291|PLACEBO_COMPARATOR|Vehicle|Vehicle solution applied once per day for 14 days
62150221|NCT00983294|ACTIVE_COMPARATOR|Colchicine alone|baseline colchicine pharmacokinetics
62150222|NCT00983294|EXPERIMENTAL|Colchicine with steady-state Azithromycin|colchicine pharmacokinetics in presence of steady-state azithromycin
62150223|NCT00813709|ACTIVE_COMPARATOR|RNF 44 mcg thrice weekly|
62150224|NCT00813709|ACTIVE_COMPARATOR|RNF 44 mcg once weekly and placebo|
62150225|NCT00813709|ACTIVE_COMPARATOR|Placebo/RNF 44 mcg thrice weekly|
61975344|NCT03552653|EXPERIMENTAL|Vitafusion Extra Strength Vitamin D3 Gummy|Single oral dose of gummy vitamin D3 to monitor vitamin D blood levels
61975345|NCT03552653|ACTIVE_COMPARATOR|Nature Made Vitamin D3 Tablet|Single oral dose of tablet vitamin D3 to monitor vitamin D blood levels
62150226|NCT01924117|NO_INTERVENTION|Linear Array HPV Genotyping assay|Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
62150227|NCT03530644|EXPERIMENTAL|RSP-14|"Comparative study of two Investigational Medical Devices (WM3.4NR and P0.1)~Optical data will be obtained from T1D over a dynamic glycemic range. Data will be paired with references."
62150228|NCT03443206|EXPERIMENTAL|Intervention|This condition will include access to a website that includes a social component, in addition to psychoeducation and access to resources.
62150229|NCT03443206|ACTIVE_COMPARATOR|Control|This condition will include access to a website that includes psychoeducation and access to resources.
62150230|NCT01282645||PSI in PEEK|All study subjects have received a Patient Specific Implant (PSI) made of PEEK to repair a cranial defect
62357782|NCT00816855|OTHER|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
62357783|NCT03748342|NO_INTERVENTION|Standard Endotracheal Tube|
62357784|NCT03748342|ACTIVE_COMPARATOR|Second-Generation LMA|
62357785|NCT04645823|ACTIVE_COMPARATOR|Spinal fentanyl|Using a combined spinal epidural technique a single dose of 20 µg of fentanyl diluted into 2 ml with NaCl 0.9 % will be injected into the CSF at lower lumbar interspace. An epidural catheter is left in place for subsequent analgesic doses.
62357786|NCT04645823|EXPERIMENTAL|Epidural lidocaine and fentanyl|Using a catheter in the epidural space in the lower lumbar interspace a single dose of lidocaine (80 mg) and fentanyl (100 µg) is given. The epidural catheter is left in place for subsequent analgesic doses.
62357787|NCT05158530|EXPERIMENTAL|Interventional Group|Pulmonary exercises + Aerobic training, 40%-60% intensity 3 days/ week for 4 weeks
62357788|NCT05158530|PLACEBO_COMPARATOR|Control group|Pulmonary exercises, 3 sessions per week and 3-5 repetitions in a session for 4 weeks.
62150231|NCT05702788|EXPERIMENTAL|Jaktinib 75mg BID|Jaktinib 75mg BID
62150232|NCT05702788|EXPERIMENTAL|Jaktinib 100mg BID|Jaktinib 100mg BID
62150233|NCT05702788|PLACEBO_COMPARATOR|Placebo|Placebo
62357789|NCT02639403|EXPERIMENTAL|RT for Obstructing Rectal Cancer|Conformal three-dimensional RT was planned (3D-RT) in patients with obstructing rectal cancer not amenable for curative resection
62357790|NCT03418064|EXPERIMENTAL|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
62357791|NCT03418064|ACTIVE_COMPARATOR|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
62357792|NCT01998152|EXPERIMENTAL|Nutritional counseling|Individualized nutritional counselling by a registered dietitian
62357793|NCT01998152|NO_INTERVENTION|No intervention|Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.
62357794|NCT06034912|EXPERIMENTAL|Low-Intensity Red Light Therapy|Intervention method：Daily wearing myopia frame glasses (optical monofocal lenses) and Low-Intensity Red Light therapy during the study to control myopia.
62357795|NCT06034912|NO_INTERVENTION|Control group|Intervention method: Daily wearing myopia frame glasses (optical monofocal lenses) during the study, no other treatment is used to control myopia.
62357796|NCT03611049|PLACEBO_COMPARATOR|Low dose Vitamin D intervention|intervention includes 800 IU Vitamin D3 replacement
62357797|NCT03611049|ACTIVE_COMPARATOR|High dose Vitamin D intervention|Intervention includes 5000 IU Vitamin D3 replacement
62357798|NCT02590419|NO_INTERVENTION|Control Group|Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits.
62357799|NCT02590419|EXPERIMENTAL|Treatment Arm|Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort.
62150234|NCT05116306|EXPERIMENTAL|hyaluronic acid group|study group
62150235|NCT05116306|OTHER|propylene glycol group|control group
62150236|NCT04896567|EXPERIMENTAL|Intervention|Patients will have kidney biopsy designated for cell isolation and culture.
62150237|NCT04070937||study group|all patients at least 18 years of age who present bilateral vestibulopathy on vestibular investigations according to the Barany criteria
62150238|NCT04070937||control group|DFNA9 patients carrying the p.P51S mutation in COCH gene presenting bilateral vestibulopathy according to the Barany criteria
62150239|NCT02439892|EXPERIMENTAL|Early rehabilitation|Exercise and nutrition during radiotherapy: Physical exercise, nutritional advice and oral nutritional supplements.
62522003|NCT03273491|ACTIVE_COMPARATOR|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
62522004|NCT05882916|EXPERIMENTAL|HIV self-test secondary distribution|The investigators will provide women who sell sex enrolled in the study with multiple World Health Organization (WHO) and Kenya-approved oral fluid-based HIV self-test kits. Participants will be counseled to secondarily distribute self-tests to their male transactional sex partners. Self-test kits will contain instructions for use and tailored information on clinic locations and hours within the cluster, the benefits of early ART use, and the availability and benefits of PrEP.
62522005|NCT00578981|EXPERIMENTAL|Arm 1|
62522006|NCT00578981|NO_INTERVENTION|Arm 2|
62522007|NCT02244918|ACTIVE_COMPARATOR|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
62522008|NCT02244918|EXPERIMENTAL|Counseling Plus NRT|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy(NRT) (like the patch, gum or lozenge) of their choice.
62150240|NCT02439892|ACTIVE_COMPARATOR|Late rehabilitation|Multidimensional rehabilitation after radiotherapy: Physical exercise, nutritional advice, oral nutritional supplements and patient education
62150241|NCT01507142||cART-unresponsive AIDS|HIV-positive, AIDS diagnosis, cART for \>18 months, \<200 CD4 Tcells/mm3 and Viral Load \>5000 copies/ml
62150242|NCT01507142||cART-responsive AIDS|HIV-positive, AIDS diagnosis, cART for \>18 months, \>350 CD4 Tcells/mm3 and Viral Load\<50 copies/ml
62522009|NCT01717430||Corticosteroid injection|Consecutive patients receiving initial or repeated sacroiliac joint or single or multi-level epidural corticosteroid injections as part of their management plan for SI joint, neck, back, or radicular pain. Injections will be performed using 0.5 mL bupivacaine 0.25% and 15 mg dexamethasone sodium phosphate.
62522010|NCT03150823|EXPERIMENTAL|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
62522011|NCT03150823|EXPERIMENTAL|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
62522012|NCT03150823|SHAM_COMPARATOR|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
62150243|NCT01507142||Acute or early HIV infection|Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease
62150244|NCT01507142||HIV-negative Hepatitis B|Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load
62150245|NCT04433052|EXPERIMENTAL|Personalised prevention program (PPP)|Participants will be invited to return to the study site six times over a three year period to receive lifestyle coaching and exercise prescriptions. Eupropean Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications. Participants will also receive pharmaceutical treatment according to the ESC guideline for chronic coronary syndromes.
62150246|NCT04433052|NO_INTERVENTION|Usual care (UC)|"Participants will be referred back to usual care provided by their treating physicians. It is anticipated that physicians will treat these participants according to local usual medical practices. Patients randomized to UC group will not receive any treatment recommendations nor restrictions by the study investigators or nurses.~Randomized UC patients are invited to site visits twice over a three year period."
62150247|NCT02647411||Projeto Boa Visão|Review of records between 1995 and 2000, in totality of 16.806 patients between 2 and 40 years old
62150248|NCT02647411||Projeto Olhar Brasil|Review of records between March and September 2014, in totality of 163 patients between 6 and 18 years old
62150249|NCT05344209|EXPERIMENTAL|anti-PD-1/PD-L1 treatment + UV1 vaccination|anti-PD-1/PD-L1 treatment + UV1 vaccination (and sagramostim)
62150250|NCT05344209|OTHER|anti-PD-1/PD-L1 treatment|anti-PD-1/PD-L1 treatment
62522013|NCT03704402||alcohol policy group|High schools that introduced the policy
62150251|NCT04411771|EXPERIMENTAL|Extended Assessment - Given shCBT|"The extended assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).~In the primary analysis, only patients given shCBT are included"
62150252|NCT04411771|ACTIVE_COMPARATOR|Screening Assessment - Suitable for shCBT but given BI|"The screening assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.~In the primary anaysis, only patients suited for shCBT are included, as decided from an algorithm based on data from their screening."
62522014|NCT03704402||control group|High schools that did not introduce the policy
62522015|NCT05767606|ACTIVE_COMPARATOR|NVX arm|NVX plus placebo
62522016|NCT05767606|ACTIVE_COMPARATOR|PCV20 arm|PCV20 (Apexxnar®) plus placebo
62522017|NCT05767606|EXPERIMENTAL|Combination arm|NVX plus PCV20
62522018|NCT05767606|PLACEBO_COMPARATOR|Placebo arm|Placebo (normal saline) plus placebo
61975346|NCT03807063|EXPERIMENTAL|Treatment (rivogenlecleucel)|Each subject may receive up to 3 IV infusions of rivogenlecleucel at intervals no less than 28 days apart. Subjects who meet protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia or encephalopathy will be treated with rimiducid infusion(s).
61975347|NCT00638378|EXPERIMENTAL|Ruxolitinib|Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
62150253|NCT04411771|EXPERIMENTAL|Extended Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomized to Extended Assessment are included, regardless of if they start shCBT or BI"
62150254|NCT04411771|ACTIVE_COMPARATOR|Screening Assessment - All patients|"Same as the other arm marked as Active comparator, but for the purpose of a secondary analysis all patients randomized to Screening Assessment are included, regardless of if they are suiteble for shCBT or not."
62357800|NCT04488081|ACTIVE_COMPARATOR|Control/Backbone - Remdesivir and Dexamethasone (CLOSED)|"Participants randomized to the backbone control will be given standard of care (supportive care for ARDS, including remdesivir and, if needed, lung protective ventilation). Because dexamethasone was shown to have benefit in at least one large randomized clinical trial, patients in the backbone control arm should receive dexamethasone for a total of 10 days during the hospitalization or until or hospital discharge.~Remdesivir (intravenous): 200-mg loading dose on day 1, followed by a daily maintenance dose of 100-mg on days 2 through 10.~Dexamethasone (intravenous): 6 mg intravenous or oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable."
62357801|NCT04488081|EXPERIMENTAL|Imatinib + Standard of Care (CLOSED)|Subjects will be administered standard of care + 800 mg imatinib on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
62357802|NCT04488081|EXPERIMENTAL|Cenicriviroc + Standard of Care (CLOSED)|Subjects administered standard of care + cenicriviroc orally , loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
62357803|NCT04488081|EXPERIMENTAL|Icatibant + Standard of Care (CLOSED)|Subjects administered standard of care + icatibant subcutaneously, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
62357804|NCT04488081|EXPERIMENTAL|Apremilast + Standard of Care (CLOSED)|Subjects administered standard of care + apremilast orally , 30 mg bid × 14 days.
62357805|NCT04488081|EXPERIMENTAL|Dornase + Standard of Care (CLOSED)|"For Non-intubated subjects: Subjects administered standard of care + dornase, 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: Subjects administered standard of care + dornase, 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
62150255|NCT03823703|EXPERIMENTAL|Miricorilant- 900 mg|Participants received 900 mg miricorilant (6 miricorilant tablets of 150 mg) orally once daily.
62150256|NCT03823703|EXPERIMENTAL|Miricorilant- 600 mg|Participants received 600 mg miricorilant (4 miricorilant tablets of 150 mg and 2 placebo tablets) orally once daily.
62150257|NCT03823703|PLACEBO_COMPARATOR|Placebo|Participants received 6 placebo tablets orally once daily.
62150258|NCT05120674|ACTIVE_COMPARATOR|CPT+CBT-I (usual care)|Veterans in this group completed the inpatient unit's existing Cognitive Processing Therapy (CPT) group based protocol. Furthermore, veterans in this group will also complete the inpatient unit's existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group based protocol.
62357806|NCT04488081|EXPERIMENTAL|Celecoxib/famotidine + Standard of Care (CLOSED)|"Subjects administered standard of care + celecoxib/famotidine orally .~Celecoxib, oral: 400 mg BID for 7 days.~Famotidine, oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days."
62357807|NCT04488081|EXPERIMENTAL|IC14 + Standard of Care (CLOSED)|Subjects administered standard of care + IC14 intravenously , 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
62357808|NCT04488081|EXPERIMENTAL|Narsoplimab + Standard of Care (CLOSED)|Subjects administered standard of care + narsoplimab dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
62357809|NCT04488081|EXPERIMENTAL|Aviptadil + Standard of Care (CLOSED)|Subjects administered standard of care + aviptadil (inhalation via nebulizer), 100 µg three times (TID) daily for a maximum of 14 days
62357810|NCT04488081|EXPERIMENTAL|Cyproheptadine + Standard of Care (CLOSED)|Subjects administered standard of care + cyproheptadine via 4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days.
62357811|NCT04488081|EXPERIMENTAL|Cyclosporine + Standard of Care (CLOSED)|Subjects administered standard of care + modified cyclosporine at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
62357812|NCT04488081|EXPERIMENTAL|Imatinib (PENDING ACTIVATION)|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
62357813|NCT06277583|EXPERIMENTAL|Urban Care farming Intervention|This intervention group of participants will receive the experimental urban care farming treatment.
62357814|NCT06277583|OTHER|Waitlist control|Waitlist control group consists of participants who do not receive the experimental treatment, but who are put on a waiting list to receive the intervention after the active treatment group does.
62357815|NCT00976729|PLACEBO_COMPARATOR|Placebo i.v.|
62357816|NCT00976729|EXPERIMENTAL|0.03 mg/kg i.v.|
62357817|NCT00976729|EXPERIMENTAL|0.09 mg/kg i.v.|
62357818|NCT00976729|EXPERIMENTAL|0.25 mg/kg i.v.|
62357819|NCT00976729|EXPERIMENTAL|0.5 mg/kg i.v.|
62357820|NCT00976729|EXPERIMENTAL|1.0 mg/kg i.v.|
62357821|NCT00976729|EXPERIMENTAL|2.0 mg/kg i.v.|
62357822|NCT00976729|PLACEBO_COMPARATOR|Placebo s.c.|
62357823|NCT00976729|EXPERIMENTAL|0.25 mg/kg s.c.|
62357824|NCT00976729|EXPERIMENTAL|0.5 mg/kg s.c.|
62522019|NCT03683524|EXPERIMENTAL|Experimental group|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
61975348|NCT01516320|EXPERIMENTAL|Gastric Bypass (GBP) Subjects|Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.
62522020|NCT03683524|ACTIVE_COMPARATOR|Control group|continuation of their current stable ART
62522021|NCT01027741|EXPERIMENTAL|Phone Referral|Participants receive phone referral to cancer control and prevention services.
62522022|NCT01027741|EXPERIMENTAL|Tailored Cancer Communication|Participants will receive phone referral to cancer control and prevention services as well as tailored materials in the mail.
62522023|NCT01027741|EXPERIMENTAL|Cancer Control Navigator|Participants will receive phone referral to cancer control and prevention services as well as a personal cancer control navigator.
62522024|NCT01027741|NO_INTERVENTION|Control|Participants receive only recommendation to talk to health care professional.
62522025|NCT01946360|NO_INTERVENTION|ACLF and Acute Liver Failure (ALF)..|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
62522026|NCT06453239||40 adults categorized as MASLD patients|
62522027|NCT06453239||40 adults of non-MASLD (controls)|
62522028|NCT03606421||Arm A|Patients in Arm A will be treated with stereotactic radiosurgery (SRS) which is a modern method of treating brain lesions that delivers a high amount of radiation to a small volume of the brain affected by a tumour; and is the standard of care for patients with a limited number of brain metastases.
62522029|NCT03606421||Arm B.|Patients in Arm B will be treated with whole brain radiotherapy, due to the number of lesions in their brain.
62522030|NCT01576874|EXPERIMENTAL|oxytocin|Participants will be administered 40 IUs of oxytocin nasal spray at one study visit.
62522031|NCT01576874|PLACEBO_COMPARATOR|placebo|Participants will be administered 40 IUs of placebo nasal spray at one study visit.
61975349|NCT01516320|ACTIVE_COMPARATOR|Laparoscopic adjustable gastric banding (LAGB) Subjects|Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.
61975350|NCT01516320|ACTIVE_COMPARATOR|Vertical Sleeve Gastrectomy (VSG) Subjects|Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.
61975351|NCT01910610|EXPERIMENTAL|STRATEGY A|FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
62522032|NCT02218112||OB - Bariatric surgery (gastric bypass)|Obese patients who will undergo a bariatric surgery (gastric bypass)
62522033|NCT02218112||OB- Control group|Obese patients who will not undergo surgery - Control group
61975352|NCT01910610|EXPERIMENTAL|STRATEGY B|OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
62522034|NCT03667014|EXPERIMENTAL|Dupilumab treatment|30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).
62522035|NCT01252719|EXPERIMENTAL|Single-Dose IV Oritavancin Diphosphate|
62522036|NCT01252719|ACTIVE_COMPARATOR|IV Vancomycin|
62522037|NCT06231719|EXPERIMENTAL|Anti-D Immunglobulin Injection with Cold Spray|Using cold spray before the Anti-D immunoglobulin injection
62522038|NCT06231719|EXPERIMENTAL|Anti-D Immunglobulin Injection with Manuel Pressure|Apply Manuel pressure before the Anti-D immunoglobulin injection
62522039|NCT06231719|PLACEBO_COMPARATOR|Standard Anti-D Immunoglobulin Injection|Standard procedure for Anti-D immunglobulin injection
62522040|NCT03421808|EXPERIMENTAL|SYNC TMS|Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
62522041|NCT03421808|ACTIVE_COMPARATOR|Non-Sync TMS|Patients will receive daily left prefrontal transcranial Magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will NOT be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm. This is the way conventional TMS is delivered now and is FDA approved.
62522042|NCT06417138||Rheumatoid arthritis patients receiving biological DMARDs or targeted synthetic DMARDs|"It will be a multicenter study. The data will be obtained primarily from Rheumatoid Arthritis Saudi Database (RASD). We will also include RA patients from other centers who are not part of the registry if they are providing minimum of 12 months follow up with at least 3 documented visits of these patients to health care facilities following treat to target approach or preferably treat to work approach."
62522043|NCT04124666|EXPERIMENTAL|Granulocytes infusion only|Fresh, non-irradiated granulocytes from ABO, Rh, CMV compatible, unrelated donors; bioactivity of anti-cancer ability meets the criteria.
62522044|NCT03721536|ACTIVE_COMPARATOR|low-flow anesthesia|Patients in low-flow anesthesia receive a fresh gas flow of 4 L/min for the first 10 minutes and were then maintain with a fresh gas flow of 0.75 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
62522045|NCT03721536|ACTIVE_COMPARATOR|normal-flow anesthesia|Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
62522046|NCT03639519|EXPERIMENTAL|Ascorbic acid|Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
62711831|NCT01179815||1|Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
62711832|NCT01218269|OTHER|no arms|all patients will receive the treatment - there is only one arms
62150259|NCT05120674|ACTIVE_COMPARATOR|CPT+ CBT-I + ERRT|Veterans in this group completed the CPT and CBT-I protocols augmented by the ERRT. ERRT therapy focuses on treating the posttrauma nightmares and does these via sleep hygiene, nightmare rescription, and exposure.
62150260|NCT05120674|EXPERIMENTAL|CPT+ CBT-I + ERRT + NAP|Veterans in this group will complete the CPT+CBT-I+ERRT protocol augmented by auditory stimulation (NAP). Exposure stimulation includes playing a rhythmic tone at 40-60hz (commonly referred to as pink noise) throughout the ERRT session and during the presleep exposure portion of ERRT. During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device (DREEM, 2013).
62711833|NCT03254121||Patients with SVR and developed HCC|HCV patients with SVR and developed HCC plus available tissue from HCC
62150261|NCT02602691|ACTIVE_COMPARATOR|Endomyocardial biopsy|Systematic endomyocardial biopsies performed according to a planned monitoring schedule in usual care for patients with a heart transplantation.
62150262|NCT02602691|EXPERIMENTAL|AlloMap® test|Noninvasive gene expression profiling blood test (AlloMap®) performed instead of endomyocardial biopsies when planned in the monitoring schedule for patients with a heart transplantation.
62357825|NCT05289154|EXPERIMENTAL|self- applied acupressure plus Qigong plus advice literature|"daily 20 min of self- applied acupressure over 8 weeks on acupuncture points Yintang, LI4, Pe6, ST36, SP6 and depending on further symptoms plus DU23/24 in hyposmia, LU7 in dyspnoea, GB34 in pain conditions, GB20 in headache OR Anmian in sleeping disorders.~The 16 sessions of 45 min Qigong course over 8 weeks will contain live online guided exercises with breathing, stretching and tapping of meridians and exercises such as the crane exercise."
62357826|NCT05289154|ACTIVE_COMPARATOR|advice literature|advice literature contains naturopathic remedies such as application of massage-oils, use of herbal teas, meditation techniques, breathing exercises for reconvalescence after COVID19.
62357827|NCT03876145|EXPERIMENTAL|Minimal ovarian stimulation with rec-FSH|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 International Unit (IU) Gonal-f (Follitropin alfa, Merck Serono, Germany) after the seventh day.
62150263|NCT05871905|EXPERIMENTAL|TY-9591|TY-9591
62150264|NCT00488969|ACTIVE_COMPARATOR|Modified-release morphine then Placebo|up to a ceiling dose of 120 mg
62357828|NCT03876145|EXPERIMENTAL|Minimal ovarian stimulation with HMG|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) after the seventh day.
62357829|NCT03876145|NO_INTERVENTION|Mild ovarian stimulation with rec-FSH|The group of mild ovarian stimulation that will receive 150 IU Gonal-f (Follitropin alfa, Merck Serono, Germany) daily from Day 3 of the menstrual cycle.
62357830|NCT03876145|NO_INTERVENTION|Mild ovarian stimulation with HMG|The group of mild ovarian stimulation that will receive 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) daily from Day 3 of the menstrual cycle.
62357831|NCT05941663|EXPERIMENTAL|SLAactive|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® surface
62150265|NCT00488969|PLACEBO_COMPARATOR|Placebo then modified-release morphine|Matching placebo
62150266|NCT05792852|EXPERIMENTAL|ENGAGE|ENGAGE uses social learning, guided problem-solving and applied skill training to promote social participation among people with disabilities within the context of the COVID-19 pandemic. This is a group intervention using a self-management framework.
62150267|NCT05990556|EXPERIMENTAL|interventional procedure to block bilateral meningeal blood supply|
62150268|NCT02873897|OTHER|"Group meals on wheels at home"|
62357832|NCT05941663|ACTIVE_COMPARATOR|SLA|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLA® surface
62357833|NCT03820726|EXPERIMENTAL|Nintedanib|Patients taking 150 milligram (mg) bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib 150 mg bid in this extension trial. Patients taking 100 mg bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib in this extension trial either at 100 mg bid or at an increased dose of 150 mg bid at the discretion of the investigator orally as soft gelatine capsule, twice daily (bid), together with a glass of water (\~250 mL), in a dose interval of 12 hours. With an optional dose reduction to 100 mg bid temporarily or permanently to manage adverse events (AEs). The treatment had a duration of 96 weeks or until nintedanib was made available to the patients outside of the clinical trial. Treatment was stopped if any reason for withdrawal was met.
62357834|NCT01293084|EXPERIMENTAL|7% saline|5 mL of 7% saline was inhaled once over a 20 minute period.
62357835|NCT01293084|PLACEBO_COMPARATOR|0.12% saline|5mL 0.12% saline inhaled once during 20 minutes
62357836|NCT04048629|EXPERIMENTAL|Point-of-care (POC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At POC facilities, at the first antenatal visit (ANC1), all women enrolled in the intervention cohort will have a blood sample collected for VL which will be tested onsite using an existing POC device. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
62357837|NCT04048629|ACTIVE_COMPARATOR|Standard of care (SOC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At SOC facilities, at ANC1, all women enrolled in the intervention cohort will have a blood sample collected for VL which will be sent to centralized labs for testing. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
62357838|NCT05859360||Trained CP|Adolescents and young adults with CP who have continued their regular training after completing the pilot study.
62357839|NCT05859360||Untrained CP|Adolescents and young adults with CP who have not continued their regular training after completing the pilot study.
62357840|NCT05859360||Trained Peers|Healthy peers who perform high-intensity strength training on a regular basis.
62357841|NCT05859360||Untrained Peers|Healthy peers who do not perform high-intensity strength training on a regular basis.
62150269|NCT02873897|OTHER|"Group residents of old people's homes - EHPAD"|
62357842|NCT03372564|EXPERIMENTAL|Hip Capsule Repair|Patients in the intervention group (Hip capsule repair) will undergo initial diagnostic arthroscopy of the hip. Two to three standard portals (anterolateral, mid anterior, distal antero-lateral, posterolateral) will be used during the entire procedure to assess and treat the patient. After establishing standard portals, an interportal capsulotomy is completed to allow for complete evaluation of the central compartment of the hip. In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl). Three to four simples sutures will be placed and tied using arthroscopic technique.
62357843|NCT03372564|NO_INTERVENTION|No Hip Capsule Repair (Control)|Patients in the control group (no hip capsule repair) have the same portals utilized and will have the same interportal capsulotomy performed. They will have all central and peripheral compartment pathologies addressed in the same way that the study group does. At the conclusion of the case, the hip capsule will be left open and not repaired.
62357844|NCT03422640|EXPERIMENTAL|Treatment arm with apremilast|Open label arm treating frontal fibrosing alopecia with apremilast
62711834|NCT02894411||No ocular motility disorders|Patients without ocular motility disorders, with normal orbital and brain MRI.
62711835|NCT02894411||superior oblique muscle palsy|Clinical features compatible with unilateral paralysis of the SO muscle Atrophy of the SO muscle on the orbital MRI without other orbital or cerebral anomaly
62711836|NCT02236676|ACTIVE_COMPARATOR|Nap after rehearsal trials|A 30-minute daytime nap after training
61975353|NCT03489720|EXPERIMENTAL|Arm A: Exercise intervention then usual exercise program|8 weeks of exercise intervention followed by 8 weeks of usual exercise program
61975354|NCT03489720|ACTIVE_COMPARATOR|Arm B: Usual Exercise Program then exercise intervention|8 weeks of usual exercise program followed by 8 weeks of exercise intervention
61975355|NCT04049123|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|15 units (U) Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.
61975356|NCT04049123|EXPERIMENTAL|LY900014|7 U, and 15 U LY900014 administered once, SC, in two of three study periods.
61975357|NCT00166114|ACTIVE_COMPARATOR|Escitalopram|
62711837|NCT02236676|PLACEBO_COMPARATOR|Resting while awake|Placebo condition of 30 minutes between training and retesting in which the half hour is spent resting awake in bed.
62711838|NCT03555058|OTHER|High risk- TDM|Treatment escalation per TDM and physician's decision.
62711839|NCT03555058|NO_INTERVENTION|High risk- Follow Up|Patients randomized to this arm will keep with the follow-up regime. Treatment escalation will occur only upon worsening of symptoms.
62711840|NCT03555058|NO_INTERVENTION|Low risk|Control group. Patients will be assigned to this group based on VCE results and will not undergo randomization.
62711841|NCT03728933|EXPERIMENTAL|2 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
62150270|NCT03311997|NO_INTERVENTION|Non-operative treatment|Active rehabilitation program
62150271|NCT03311997|ACTIVE_COMPARATOR|Operative treatment|Surgical reattachment of hamstring tendons using suture anchors followed by active rehabilitation program
62150272|NCT06030037|EXPERIMENTAL|R-FMT + pembrolizumab/lenvatinib (Arm A)|"* Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity as described).~* Lenvatinib will be administered at 20 mg daily.~* R-FMT (induction) will be administered at C1D1 and C4D1 via colonoscopy.~* R-FMT (maintenance) will be repeated every 9 weeks starting with C4D1 via sigmodoscopy."
61975358|NCT00166114|ACTIVE_COMPARATOR|Desipramine|
62150273|NCT06030037|ACTIVE_COMPARATOR|pembrolizumab/lenvatinib (Arm B)|"* Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity as described).~* Lenvatinib will be administered at 20 mg daily."
62150274|NCT03406390||primary pterygium|Observe the contrast sensitivity of primary pterygium patients and healthy control by quick CSF methods, and the pterygium group would achieve the pterygium surgery by the same surgeon (Jin Yuan) and then be performed the contrast sensitivity test on the 1st, 3rd and 6th month postoperatively.
62150275|NCT03948958|EXPERIMENTAL|TIVAD evaluation|TIVAD evaluation at port removal evaluation of catheter function, visualization of catheter tip, presence of thrombus material and sleeve and any device damage during linogram (contrast injection via TIVAD), tip and chamber content microbiological culture, macroscopic catheter and port chamber evaluation PROM: patient reported outcome measurements regarding TIVAD insertion, presence and removal
62150276|NCT00831194|EXPERIMENTAL|Diet plan and PDA|
61975359|NCT02749981||Cefazolin|patients receiving cefazolin as part of routine clinical care
62357845|NCT03673956|EXPERIMENTAL|Mupirocin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Mupirocin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
62357846|NCT03673956|EXPERIMENTAL|Tobramycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Tobramycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
61975360|NCT01183897|EXPERIMENTAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II study of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response in of primary refractory neuroblastoma in bone marrow (i.e., incomplete response to standard treatment).
61975361|NCT03847454|EXPERIMENTAL|Intervention REACH group|The intervention REACH consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity. The participants will receive 30 min training every day during 3 weeks. 3 times a week the standard training will be replaced with the intervention. The training is conducted/ supervised by a physiotherapist.
62711842|NCT03728933|EXPERIMENTAL|3 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine (1 mg/24 h patch + 2 mg/24 patch at the same time), which is the assigned dose level throughout the 12-week Maintenance Period.
62150277|NCT06511180||Children <12 years who are eligible for TPT - HHC|No intervention. Clinic record review: Data will be retrospectively abstracted from routine medical files using a standardised data collection tool that will document TPT uptake and outcomes
62357847|NCT03673956|EXPERIMENTAL|Levofloxacin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Levofloxacin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
61975362|NCT03847454|ACTIVE_COMPARATOR|Control group (Standard of care)|The participants will receive the standard of care as intervention which consists of 30 min training every day during 3 weeks. The training is conducted by a physiotherapist.
62711843|NCT03728933|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
62711844|NCT03929692|OTHER|Intervention Group|Intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects.
62150278|NCT06511180||Policy makers/Program managers|No intervention. Qualitative study: We will recruit a purposive sample of policy makers, healthcare workers and caregivers who will be interviewed to evaluate buy-in and explore their insights and experiences on the different TPT regimens and formulations.
62357848|NCT03673956|EXPERIMENTAL|Vancomycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Vancomycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
62357849|NCT04202978|EXPERIMENTAL|Camrelizumab+ Apatinib +XELOX +RFA|Camrelizumab combined with Apatinib 、XELOX 、RFA in the treatment of liver metastases of colorectal cancer
62357850|NCT01711541|EXPERIMENTAL|Arm I (veliparib, combination chemotherapy)|Patients receive veliparib PO BID on days 1-7, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then continue on to concomitant chemoradiotherapy.
62357851|NCT01711541|EXPERIMENTAL|Arm II (placebo, combination chemotherapy)|Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
62357852|NCT02290340|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo intramuscularly.
62357853|NCT02290340|EXPERIMENTAL|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
62357854|NCT02290340|EXPERIMENTAL|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
62357855|NCT02290340|EXPERIMENTAL|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
62357856|NCT06270563|ACTIVE_COMPARATOR|Group A|They received postural advice and traditional exercise treatment (stretching and strengthening exercises) for 3 times per week for 12 weeks.
62357857|NCT06270563|EXPERIMENTAL|Group B|They received postural advice, traditional exercise treatment (stretching and strengthening exercises), and scapular stabilization exercises 3 times per week for 12 weeks.
62357858|NCT06270563|EXPERIMENTAL|Group C|They received postural advice, traditional exercise treatment (stretching and strengthening exercises), and high intensity laser therapy 3 times per week for 12 weeks.
62357859|NCT01229514||Exposure to anesthesia|
62357860|NCT01229514||Normal controls|
62357861|NCT02796612|ACTIVE_COMPARATOR|No intervention|Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
62357862|NCT02796612|EXPERIMENTAL|Intervention group|"Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.~Additionally, delivery of a take-home brochure to the patients during the first visit is planned. The biopsy is explained to the patient and performed by a psychological trained physician. Patient care by a psychologically trained physician is performed in the sense that patients are informed about their biopsy result by a specifically trained physician."
62357863|NCT03525457|EXPERIMENTAL|Experimental|Non surgical periodontal therapy
62357864|NCT03276572|EXPERIMENTAL|All Subjects|A single dose of 225Ac-J591 will be given to subjects with documented progressive metastatic CRPC.
62150279|NCT06511180||Healthcare Workers|No intervention. Qualitative study: We will recruit a purposive sample of policy makers, healthcare workers and caregivers who will be interviewed to evaluate buy-in and explore their insights and experiences on the different TPT regimens and formulations.
62357865|NCT01997697|EXPERIMENTAL|Patients with obesity|behavior change program among patients with obesity
62711845|NCT03929692|OTHER|Control Group|Adolescents of same age as intervention group at follow-up examination that did not participate in health promotion program.
62357866|NCT02840526|EXPERIMENTAL|PVB group|Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
62522047|NCT03639519|PLACEBO_COMPARATOR|Placebo group|will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.
62522048|NCT03234894|OTHER|SiteSeal Endovascular|"After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.~There is a secondary metric as to patient reported pain on a 1-10scale."
62522049|NCT01703936|EXPERIMENTAL|agricultural training program|Three to four month residential agriculture and life skills training program.
62711846|NCT01935947|EXPERIMENTAL|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62711847|NCT01935947|EXPERIMENTAL|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
62711848|NCT01935947|ACTIVE_COMPARATOR|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
62522050|NCT01703936|NO_INTERVENTION|Control group|
62150280|NCT06511180||Caregivers|No intervention. Qualitative study: We will recruit a purposive sample of policy makers, healthcare workers and caregivers who will be interviewed to evaluate buy-in and explore their insights and experiences on the different TPT regimens and formulations.
62150281|NCT06511180||Pharmacy managers/pharmacists|No intervention. Clinic assessment: We will assess provider barriers and facilitators to prescribing the new dispersible 3HP (single dispersible formulations of isoniazid and rifapentine) through a survey tool which will collect information on the flow of TPT from national supply to the clinic and dispensing to the child.
62522051|NCT03385941||Osteoporotic|Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score \<-2.0 at any site and/or history of fragility fracture
62150282|NCT06511180||Procurement managers/Supply managers|No intervention. Clinic assessment: We will assess provider barriers and facilitators to prescribing the new dispersible 3HP (single dispersible formulations of isoniazid and rifapentine) through a survey tool which will collect information on the flow of TPT from national supply to the clinic and dispensing to the child.
62150283|NCT02135666|EXPERIMENTAL|2-dose Primed Group|Adolescent subjects in this group received 2 doses of Twinrix Adult (720/20) (licensed as Ambirix in the EU) according to a 0, 6 months schedule in the primary study HAB-084 (208127/084).
62522052|NCT03385941||Non-osteoporotic|Female, 27-40 years of age, no established history of osteoporosis
62150284|NCT02135666|EXPERIMENTAL|3-dose Primed Group|Adolescent subjects in this group received 3 doses of Twinrix Junior (360/10) according to a 0, 1, 6 months schedule in the primary study HAB-084 (208127/084).
62522053|NCT04355663|EXPERIMENTAL|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
62711849|NCT02177383|EXPERIMENTAL|Docosahexaenoic acid|1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek) provides 1.14 g DHA/daily
62711850|NCT02177383|PLACEBO_COMPARATOR|Olive oil|1 liter/day of placebo beverage (containing 0.8% olive oil)
62150285|NCT05328817|EXPERIMENTAL|Erythromycin|Receive 1) erythromycin 250 mg iv every 6 hours for 48 hours followed by 333 mg orally (pills) every 8 hours for 5 days
62711851|NCT04670861|EXPERIMENTAL|experimental group|Upper extremity Biodex balance training program three times/week for eight weeks in addition to regular weightlifting training exercises
62150286|NCT05328817|EXPERIMENTAL|Azithromycin|Receive azithromycin 500 mg iv daily for 48 hours followed by 500 mg orally (pills) for 5 days.
62150287|NCT02192632|EXPERIMENTAL|Epiduo- dermatologist's detailed instruction|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into detailed instruction for application of epiduo from dermatologist
62150288|NCT02192632|EXPERIMENTAL|Epiduo- drug insert only gruop|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into drug insert only group
62711852|NCT04670861|ACTIVE_COMPARATOR|control group|regular weightlifting training exercises
62711853|NCT04692389|EXPERIMENTAL|Jalosome® Soothing gel|"The medical device will be applied by the patient himself, after appropriate training carried out by the nurse, twice a day, in the quantity necessary to cover the lesion (0.2g of gel /16 cm2 of skin (one spray), repeated as many times as necessary to cover the entire lesion). The treatment will last 8 weeks.~The medical device will be delivered in the quantity strictly necessary to carry out the therapies between visits, in order to monitor its use. Patients will be seen weekly by the nurse, in order to ensure the best continuity of care and promote adherence to the study. Patients will be asked to keep a weekly diary, in which they will report their level of pain, analgesic therapy and medication. Nurses will be available for telephone counselling, if necessary."
62150289|NCT02192632|PLACEBO_COMPARATOR|BPO group|After randomly assigned to side of BPO application, patients apply BPO during 12 week
62150290|NCT05455632||Group1:PORT|Oral squamous cell carcinoma (OSCC) patients received neoadjuvant therapy, surgery, and postoperative radiotherapy.
62150291|NCT05455632||Group2:non-PORT|Oral squamous cell carcinoma (OSCC) patients received neoadjuvant therapy and surgery, without postoperative radiotherapy
62522054|NCT04355663|EXPERIMENTAL|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
62522055|NCT04355663|EXPERIMENTAL|Functional electric stimulation|Functional electric stimulation in the postural corrected position was developed at our workplace. Participants first underwent individual two-hour session consisting of postural correction using MPAT and the device (The WalkAide® System, Innovative Neurotronics Inc., 4999 Aircenter Circle, Suite 103 Reno, NV 89502, USA) programming (28). Patients received the device to use as much as they felt they were able to during their normal daily living activities thereafter.
62522056|NCT03001219|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
62522057|NCT03001219|EXPERIMENTAL|Part 1: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
62522058|NCT03001219|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
62522059|NCT03001219|EXPERIMENTAL|Part 2: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
61976406|NCT05253170|EXPERIMENTAL|Hypofractionation|"For the cumulative total dose of 39-45.9 Gy to the chest wall, a daily dose of 2.5-3.0 Gy is administered 13-17 fractions.~* Should be started within 3 months of completion of mastectomy or chemotherapy.~* Clinical target volume (CTV) may include regional lymph nodes.~* If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines."
62150292|NCT01737398|ACTIVE_COMPARATOR|Inotersen|300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
62522060|NCT03001219|PLACEBO_COMPARATOR|Part 3: Placebo|"Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
62522061|NCT03001219|EXPERIMENTAL|Part 3: RO7123520|"Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
62522062|NCT02443415||Healthy Controls|Non-diabetic subjects
62522063|NCT02443415||Diabetics without DKA|Diabetic subjects (recent(\< 1 year) diagnosis of diabetes) without a history of diabetic ketoacidosis (DKA)
62150293|NCT01737398|ACTIVE_COMPARATOR|Placebo|Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks
62522064|NCT02443415||First episode of DKA|Diabetic subjects that just had their primary event of diabetic ketoacidosis (DKA)
62522065|NCT02443415||Three or more DKA episodes|Diabetic subjects who have had three or more diabetic ketoacidosis (DKA) episodes
62522066|NCT03762499|ACTIVE_COMPARATOR|Prospective participants|250 participants will be recruited prospectively during the hypertension clinic, where a full set of data will be collected from each participant as part of their standard hypertension clinical service. An additional echocardiography scan will be performed for this cohort by the study team, if the scan has not been performed as a part of the clinical care service
62522067|NCT03762499|NO_INTERVENTION|Retrospective participants|500 participants will be recruited retrospectively, and no additional echocardiography scan will be required for them.
62150294|NCT01491815|ACTIVE_COMPARATOR|Active conventional therapy (ACT)|Non-biological DMARD's: Methotrexate plus steroids or Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids
62711854|NCT01991860|EXPERIMENTAL|APD421|APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
62711855|NCT01991860|PLACEBO_COMPARATOR|Placebo|Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia
62711856|NCT06446570|EXPERIMENTAL|Durvalumab, tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
62522068|NCT00511992|EXPERIMENTAL|Avastin|
62522069|NCT04333472|EXPERIMENTAL|Piclidenoson|Piclidenoson 2 mg every 12 hours orally added to standard of care
62522070|NCT04333472|PLACEBO_COMPARATOR|Placebo|Placebo every 12 hours orally added to standard of care
62522071|NCT00687310|OTHER|1|Educational Intervention At the initial visit (Visit 1), patients in the educational intervention group will complete a short Needs Assessment Questionnaire to help the investigator/nurse determine which section(s) of the tailored patient education booklet to give to, educate, and provide instruction on to the patient. This may, at the discretion of the investigator, include providing their patient with a peak flow meter and instructions on its use.Visit 2 will be scheduled for 1-month after the Visit 1 for the education intervention group. All educational materials provided at Visit 1 will be reviewed with the patient at Visit 2. The investigator/nurse will reassess the patient's use of the Turbuhaler® and asthma treatment plan. Patients will also be asked about any adverse events that may have occurred since Visit 1 and/or are observed at Visit 2. Once Visit 2 is completed with the patient, the investigator/nurse will complete the Educator Satisfaction Questionnaire.
62522072|NCT05332782||M-TEER|Patients with primary mitral regurgitation undergoing mitral valve transcatheter edge-to-edge repair.
62522073|NCT03885882|EXPERIMENTAL|Cohort 1: E0302 Sustained Release (SR1) 1500 mcg|Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.
62522074|NCT03885882|EXPERIMENTAL|Cohort 2: E0302 Sustained Release (SR3) 1500 mcg|Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.
62711857|NCT05089292|EXPERIMENTAL|Chinese Immigrants|NYC Chinese immigrants provided with narrative breast health education
62150295|NCT01491815|ACTIVE_COMPARATOR|Biologic agent 1|Cimzia: Certolizumab-pegol plus Methotrexate and steroids
62150296|NCT01491815|ACTIVE_COMPARATOR|Biologic agent 2|Orencia: Abatacept plus Methotrexate and steroids
62711858|NCT01846702|PLACEBO_COMPARATOR|Placebo|Single dose of placebo matching LY3084077 administered subcutaneously (SC).
62711859|NCT01846702|EXPERIMENTAL|LY3084077|Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC.
62711860|NCT02450825|OTHER|Mechanically ventilated patients|Mechanically ventilated patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 and Day 2 to 4. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
62711861|NCT02450825|OTHER|Spontaneously breathing patients|Spontaneously breathing patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 only. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
62711862|NCT01573117|ACTIVE_COMPARATOR|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
62711863|NCT01573117|ACTIVE_COMPARATOR|RhinoChill|Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)
62150297|NCT01491815|ACTIVE_COMPARATOR|Biologic agent 3|RoActemra: Tocilizumab plus Methotrexate and steroids
62711864|NCT02870426||Group 1A:|Donors after brainstem death (DBDs) undergoing solid organ donation
62711865|NCT02870426||Group 1B:|Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
62150298|NCT05260437|EXPERIMENTAL|CV2CoV Dose Cohort 1 (Group 1a 2μg)|Participants received 2 μg CV2CoV intramuscularly.
62150299|NCT05260437|EXPERIMENTAL|CV2CoV Dose Cohort 1 (Group 1b 4μg)|Participants received 4 μg CV2CoV intramuscularly.
62150300|NCT05260437|EXPERIMENTAL|CV2CoV Dose Cohort 2 (8 μg)|Participants received 8 μg CV2CoV intramuscularly.
62150301|NCT05260437|EXPERIMENTAL|CV2CoV Dose Cohort 3 (12 μg)|Participants received 12 μg CV2CoV intramuscularly.
62150302|NCT05260437|EXPERIMENTAL|CV2CoV Dose Cohort 4 (16 μg)|Participants received 16 μg CV2CoV intramuscularly.
62150303|NCT05260437|EXPERIMENTAL|CV2CoV Dose Cohort 5 (20 μg)|Participants were scheduled to receive 20 μg CV2CoV Intramuscularly, but there were no participants enrolled in this group, and hence, there was no vaccine administered in this study group.
62150304|NCT01450774|EXPERIMENTAL|CHF 1535 50/6µg|
62150305|NCT01450774|ACTIVE_COMPARATOR|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|
62150306|NCT02330900|NO_INTERVENTION|Study group|Evaluation of interference
62357867|NCT02840526|OTHER|GEN group|Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
62357868|NCT04628273||radiolucent stone group|
62357869|NCT04628273||radiopaque stone group|
62357870|NCT02023268|EXPERIMENTAL|T2762|
62357871|NCT02023268|ACTIVE_COMPARATOR|Vismed®|
62357872|NCT01256983|EXPERIMENTAL|Bright Light Therapy|Bright Light Therapy with 10000 lux beginning at day 21 until day 42
62357873|NCT01256983|OTHER|Wait-list intervention|Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
62357874|NCT00391807|EXPERIMENTAL|study drug|Norethindrone/Ethinyl Estradiol
62357875|NCT03902041||Treatment Group|The patients will receive Eltrombopag treatment after transplantation at d1.
62357876|NCT03902041||Control Group|The patients will not receive Eltrombopag treatment after transplantation.
62357877|NCT02859987|ACTIVE_COMPARATOR|Landmark Technique|Blinded method for catheter placement
62357878|NCT02859987|EXPERIMENTAL|Ultrasound-guided Technique|Use sonography for catheter placement
62357879|NCT02915991||All patients|This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.
62357880|NCT00690417|PLACEBO_COMPARATOR|1|
62357881|NCT00690417|ACTIVE_COMPARATOR|2. 2500 IU vitamin D in a food preparation|Daily ingestion of 2500 IU vitamin D in a food preparation.
62357882|NCT03760276|EXPERIMENTAL|Voriconazole TBD mg tablet orally, every 12 hours for 7 days|
62357883|NCT02627833||Subject Group|Patients suffering from Bronchiolitis Obliterans
62357884|NCT02627833||Control Group|Age and sex matched control group
62357885|NCT01192204|ACTIVE_COMPARATOR|10% FBR containing bioadhesive gel|Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site
62357886|NCT01192204|PLACEBO_COMPARATOR|Placebo Gel|Color/consistency matched placebo (no black raspberry) gel
62357887|NCT00891761|ACTIVE_COMPARATOR|Active Comparator|Patients receive IV casopitant (active), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
62357888|NCT00891761|PLACEBO_COMPARATOR|Placebo Comparator|Patients receive IV casopitant (placebo), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
62357889|NCT06146842|ACTIVE_COMPARATOR|DPE Group|Subjects will receive an epidural catheter via a dural puncture epidural technique.
62357890|NCT06146842|ACTIVE_COMPARATOR|EPL Group|Subjects will receive an epidural catheter via a traditional epidural technique.
62357891|NCT02274415|EXPERIMENTAL|PCV vaccine following by the PSV vaccine|Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
62357892|NCT02274415|ACTIVE_COMPARATOR|vaccine Pneumo 23|Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
62357893|NCT02970396|ACTIVE_COMPARATOR|SMART Intervention|Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio.
62357894|NCT02970396|ACTIVE_COMPARATOR|Wait-list|Participants assigned to the wait-list will start the SMART intervention 6 months following randomization.
62357895|NCT00621088|ACTIVE_COMPARATOR|Intertan|
62357896|NCT04774614|EXPERIMENTAL|VITA ENAMIC multiColor anterior laminate veneers|
62711866|NCT02870426||Group 2:|Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
62150307|NCT02813304|EXPERIMENTAL|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction (see Table 1). In a sitting position (with folded towel between body and arm), participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand (the uninvolved side) will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force; practice during the meeting with the treating physiotherapist using EMG recording) over five seconds.
62150308|NCT02813304|ACTIVE_COMPARATOR|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap and a towel cloth. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
62357897|NCT04774614|ACTIVE_COMPARATOR|IPS e.max CAD anterior laminate veneers|
62357898|NCT06530108|EXPERIMENTAL|Experimental: Intervention Group|PLISSIT model-based sexual health education will be provided to the intervention group, and the clinical procedure will be applied to the control group. The Sexual Attitude Scale during Pregnancy and the Female Sexual Distress Scale will be administered simultaneously. Four weeks after the training, the FSFI application and the Sexual Attitude Scale during Pregnancy and the Female Sexual Distress Scale will be administered again
62357899|NCT06530108|PLACEBO_COMPARATOR|Kontrol Group|The clinical procedure will be applied to the control group
62357900|NCT05222295|EXPERIMENTAL|Supervised Pulmonary Telerehabilitation Group|Three times a week for 8 weeks, a supervised and standardized pulmonary rehabilitation program will be applied in the form of telerehabilitation with simultaneous video conference method, accompanied by a specialist physiotherapist, while the patients are at home.
62357901|NCT05222295|EXPERIMENTAL|Cognitive Telerehabilitation Group|Motor imagery + action observation methods will be applied. In therapy, a video recording of each exercise in the supervised telerehabilitation group will be sent to the patients by the physiotherapist in accordance with the number of repetitions. At the end of the session, the cognitive telerehabilitation group will be asked to actively do the breathing exercises and active breathing techniques cycle in the supervised telerehabilitation group as well as to imagine with the instructions in the video recording, and commands will be given accordingly.
62357902|NCT01062919|EXPERIMENTAL|Epidural analgesia group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
62357903|NCT01062919|EXPERIMENTAL|Wound Group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
62357904|NCT06117917|EXPERIMENTAL|S-ketamine and pregabalin|
62357905|NCT06117917|PLACEBO_COMPARATOR|Normal saline and placebo capsule|
62357906|NCT06388135|EXPERIMENTAL|Serplulimab，nab-paclitaxel，Cisplatin|Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle
62357907|NCT06388135|SHAM_COMPARATOR|nab-paclitaxel，Cisplatin|Cisplatin (60-75 mg/m2) and nab-paclitaxel (135 mg/m2) given intravenously at the beginning of every 3-week cycle.
62357908|NCT00812604|EXPERIMENTAL|Ping On Ointment|Ping On Ointment
62357909|NCT00812604|PLACEBO_COMPARATOR|Vaseline|Vaseline with minor trace of Ping On ointment to give medicinal smell
62357910|NCT00471003||Arm 1|
62357911|NCT01907776|EXPERIMENTAL|ME1100|ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
62357912|NCT01907776|PLACEBO_COMPARATOR|Placebo|ME1100 placebo inhalation solution
62357913|NCT05601908|EXPERIMENTAL|VR Relaxation|a 5-week course of 20-min sessions of VR relaxation
62357914|NCT01549457|NO_INTERVENTION|Non-intervention|Participants will only receive standard of care
62357915|NCT01549457|EXPERIMENTAL|Cell phone intervention arm|Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH or 4 months of RIF) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH or months of RIF) without weekly SMS text messages via mobile phone.
62357916|NCT06508177||Interfascial plane blocks|Patients who are preferred to apply interfascial plane blocks as part of multimodal analgesia in the postoperative analgesia plan will be evaluated in this group.
62357917|NCT06508177||Control|Multimodal analgesia plans that does not include interfascial plane blocks
62357918|NCT05834101|EXPERIMENTAL|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
62357919|NCT05834101|EXPERIMENTAL|Dynamic Stretching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
62522075|NCT03885882|EXPERIMENTAL|Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg|Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
62522076|NCT03885882|EXPERIMENTAL|Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg|Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
62522077|NCT00865618|EXPERIMENTAL|1|Eplerenone 50mg Tablets
62522078|NCT00865618|ACTIVE_COMPARATOR|2|INSPRA 50mg Tablets
62522079|NCT01382082||subjects with breast cancer|
62522080|NCT01382082||subjects with lymphoma|
62522081|NCT01382082||subjects without cancer|
62522082|NCT03880799|EXPERIMENTAL|Mindfulness Intervention|Newly diagnosed breast cancer patients who undergo a mindfulness session before their surgical appointment.
61975363|NCT06219057|EXPERIMENTAL|Intervention|"Group of adolescents living in residential youth care. Participants selection will take as inclusion criteria: age (between 14 and 18 years old) and being placed in residential care at least for 1-month (allowing for an adjustment period); as exclusion criteria: a) cognitive impairment; b) psychotic symptoms; d) remaining in residential care less than 9-months, considering the study's length. They will be asked to fill in the self-report protocol at 3 different time points (baseline, post-test and 6-month follow-up).~Intervention comprises the psychological intervention program The Wise Adolescent, twenty individual psychotherapeutic sessions based on Compassion Focused Therapy."
62150309|NCT02544191|EXPERIMENTAL|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
62522083|NCT04910659|ACTIVE_COMPARATOR|acupuncture|Group1, laser acupuncture was applied to each of the previously described P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds
62522084|NCT04910659|SHAM_COMPARATOR|false acupuncture|P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds while laser acupuncture closed
62522085|NCT01699763|EXPERIMENTAL|Subjects with and without Diabetes|All testing and lancing were performed by the study staff; Subjects with and without Diabetes did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using three Blood Glucose Monitoring Systems (BGMS): Contour® NEXT LINK BGMS; OneTouch® UltraLink® BGMS; Nova Max Link® BGMS.
62522086|NCT00054041|EXPERIMENTAL|Arm I (HspE7)|Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
62522087|NCT00054041|EXPERIMENTAL|Arm II (control)|Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
62522088|NCT00104091|EXPERIMENTAL|1|40 mL of TP-38 at a 100 nanograms/mL concentration
62522089|NCT04712149|EXPERIMENTAL|intervention arm|In the intervention arm, 15 patients will receive a weekly questionnaire. Alerts will be sent to the multidisciplinary care team, who will undertake follow-up actions. In the control arm, 15 patients will receive the standard care pathway without weekly questionnaire and without automatic alerts to the care team. The standard care pathways and the care team are the same in both groups. In this pilot study, the weekly follow-up will be evaluated by a validation questionnaire, semi-structured interviews with patients and the care team, and workload registration of the care team during a six-month period.
62522090|NCT04712149|NO_INTERVENTION|Control arm|
62522091|NCT05801653|EXPERIMENTAL|Oat meal 1|The test portion is based on 30 gram available carbohydrates with added x amount oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
62522092|NCT05801653|EXPERIMENTAL|Oat meal 2|The test portion is based on 30 gram available carbohydrates with added y amount of oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
62522093|NCT05801653|EXPERIMENTAL|Oat meal 3|The test portion is based on 30 gram available carbohydrates with added z amount of oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
62522094|NCT05801653|PLACEBO_COMPARATOR|Reference|The test portion is based on 30 gram available carbohydrates without added oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
62522095|NCT05288036|EXPERIMENTAL|Proprioceptive Neuromuscular Rehabilitation group|PNF techniques; It is based on facilitating the responses of neuromuscular mechanisms by stimulating proprioceptors. It is a method used to improve active movement ability by increasing muscle strength, to increase muscle endurance, to improve stabilization at the point where the technique is applied within the movement pattern.
62522096|NCT05288036|EXPERIMENTAL|Progressive Resistance Exercise Group|Progressive resistance training (PRT) is a method for increasing muscle strength and endurance based on the determination of the amount of resistance appropriate for the individual. Free weights and resistance machines are used in the practice of this technique.To facilitate continued adaptation, training intensity (i.e. load) and training volume (i.e. number of sets) are progressively increased, and exercises are adjusted as indicated throughout the training regimen, to attenuate the onset of a plateau in physiological adaptation.
62522097|NCT05288036|ACTIVE_COMPARATOR|Control Group|This group was created to determine the amount of self-healing of the disease in the process. The approach was taken in a way that did not affect the outcome measures.
62522098|NCT05499013|EXPERIMENTAL|Phase 1 open-label SLN124|SLN124 for subcutaneous (s.c.) injection
62522099|NCT05499013|EXPERIMENTAL|Phase 2 Blinded SLN124|SLN124 for subcutaneous (s.c.) injection
62522100|NCT05499013|PLACEBO_COMPARATOR|Phase 2 Blinded Placebo|Sodium chloride for s.c. injection
62711867|NCT04541667|ACTIVE_COMPARATOR|Air for luminal inflation|Patients randomized into this arm will have luminal inflation using air.
62711868|NCT04541667|ACTIVE_COMPARATOR|Carbon Dioxide for luminal inflation|Patients randomized into this arm will have luminal inflation using carbon dioxide.
62522101|NCT04414839|ACTIVE_COMPARATOR|Digital Intubation (Two-finger)|
62522102|NCT04414839|ACTIVE_COMPARATOR|Video Laryngoscopy|
62711869|NCT02834819|EXPERIMENTAL|Hypertonic Saline|Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed.
62711870|NCT02834819|NO_INTERVENTION|No treatment|"Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed."
61975364|NCT06219057|NO_INTERVENTION|Care as Usual|"Group of adolescents living in residential youth care. Participants selection will take as inclusion criteria: age (between 14 and 18 years old) and being placed in residential care at least for 1-month (allowing for an adjustment period); as exclusion criteria: a) cognitive impairment; b) psychotic symptoms; d) remaining in residential care less than 9-months, considering the study's length. They will be asked to fill in the self-report protocol at 3 different time points (baseline, post-test and 6-month follow-up).~Participants in the control group will receive care as usual (TAU). There will be no restrictions on the care that can be provided and it may comprise no treatment or, instead, referral to a variety of health care professionals (e.g. psychologist, psychiatrist) with diverse dosage. TAU will be recorded in terms of timing and nature of any intervention received."
61975365|NCT04671225|EXPERIMENTAL|Intervention - Psychoeducation at the referral hospital|Intervention: Manual-structured group psychoeducation.
62711871|NCT05464602|EXPERIMENTAL|Intervention group Lavender|Each patient in this group received inhalation aromatherapy of lavender oil.
62711872|NCT05464602|EXPERIMENTAL|Intervention group Geranium|Each patient in this group received inhalation aromatherapy of geranium oil.
62711873|NCT05464602|NO_INTERVENTION|Control group|Each patient in this group did not receive any additional treatment.
62711874|NCT04244734|ACTIVE_COMPARATOR|Group 1|The control group receives regular treatment in the ICU, which includes muscle strengthening exercises, passive/assisted or active mobilizations, and respiratory physiotherapy with breathing muscle strengthening in a medium load (initially at 40% load from results in MIP).
62357920|NCT02842788||ARDS patients receiving invasive mechanical ventilation in ICU|"1. ARDS criteria (Berlin definition) fulfilled the day of the study, whatever the ARDS stage. The onset of ARDS could have been established at any time between ICU admission and study day but ARDS criteria must be still present the day of the study. The ARDS criteria are listed below~   * Within 1 week of a known clinical insult or new or worsening respiratory symptoms~  * Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules~  * Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present~2. PaO2/FIO2 ≤ 300 with Positive end-expiratory pressure (PEEP) ≥ 5 cmH2O~3. Age ≥ 18 years~4. Intubated or tracheotomized and mechanically ventilated"
62357921|NCT02468141|EXPERIMENTAL|SJDBT group|Herbal medicine
62150310|NCT02741557|EXPERIMENTAL|DTG/RPV FDC-DTG plus RPV|Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 2 under fed state.
62150311|NCT02741557|EXPERIMENTAL|DTG plus RPV-DTG/RPV FDC|Subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 2 under fed state.
62150312|NCT04867044||STUDY GROUP|patient diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
62150313|NCT04867044||CONTROL GROUP|healthy women volunteers
62357922|NCT02468141|PLACEBO_COMPARATOR|Placebo|Placebo control
61975366|NCT04671225|OTHER|Waiting list - at the referral hospital|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
61975367|NCT04684355|NO_INTERVENTION|Standard-of-care group|Participants in this group received their colonoscopic and pathological diagnosis simultaneously at next clinical visit, which arranged in 1 to 2 weeks later.
61975368|NCT04684355|EXPERIMENTAL|Intervention group|Participants in this group received their colonoscopic diagnosis right after they awake from general anesthesia, and then received pathological diagnosis at next clinical visit, which arranged in 1 to 2 weeks later.
62150314|NCT02204202||Grade A0|Double-lung transplant recipients with no evidence of rejection who undergo both \[18F\]FDG and \[18F\]ISO-1 PET imaging scans
62150315|NCT02204202||Grades A2-3|Double-lung transplant recipients with mild to moderate rejection who undergo both \[18F\]FDG and \[18F\]ISO-1 PET imaging scans
62357923|NCT02281344|EXPERIMENTAL|Cohort 1|Cohort 1 will receive a single dose of 20mg MMV390048.
62357924|NCT03770195||Abdominoplasty Patients|Patients undergoing full abdominoplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
62357925|NCT03058848|EXPERIMENTAL|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
62357926|NCT03688685|EXPERIMENTAL|Open-label study of CAD-1883|Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET
62357927|NCT03791268||Group A|Gastric Cancer Patients who underwent Chemotherapy and will have gastric cancer surgery.
62357928|NCT02783417|EXPERIMENTAL|Training with vascular occlusion|Strength Training: intensity of 30% of 1RM, with vascular occlusion pressure in members.
62357929|NCT02783417|EXPERIMENTAL|Traditional strength training|Strength Training: intensity of 80% of 1RM, without vascular occlusion pressure in members
62357930|NCT02783417|NO_INTERVENTION|Control|Subject untrained.
62357931|NCT03911869|EXPERIMENTAL|Standard Dose Arm|"Patients in the standard-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.~* 450 mg encorafenib orally once a day (QD)~* 45 mg binimetinib orally twice a day (BID)~Patients who are able to tolerate the standard dose during the first 4 weeks of treatment (Cycle 1) should be dose-escalated to 600 mg encorafenib QD plus 45 mg binimetinib BID provided they meet protocol-defined criteria."
62522103|NCT00560430|ACTIVE_COMPARATOR|T1|Telmisartan 80 mg/d
62522104|NCT00560430|ACTIVE_COMPARATOR|T2|Telmisartan 160 mg/d
62522105|NCT00560430|PLACEBO_COMPARATOR|P|placebo
62522106|NCT02341950|EXPERIMENTAL|SCI Hard|This arm plays the SCI HARD game
62522107|NCT02341950|NO_INTERVENTION|Control|Plays an alternate, publicly available game
62522108|NCT04146363|PLACEBO_COMPARATOR|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50."
62522109|NCT04146363|EXPERIMENTAL|Lebrikizumab 250 Q2W|"Induction Period (Baseline-Week 16):~500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection Q2W until Week 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18."
62522110|NCT04146363|EXPERIMENTAL|Lebrikizumab 250 Q4W|"Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.~One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two placebo injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~Two placebo injections on Week 18"
62522111|NCT04146363|EXPERIMENTAL|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):~Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.~For participants who received placebo in the Induction Period, the loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the loading dose blind, for participants who received Lebrikizumab in the Induction Period, the loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16. One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.~For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm."
62522112|NCT04309552|EXPERIMENTAL|High Grade Glioma (HGG)|Thirty newly diagnosed treatment-naïve subjects with suspected HGG based on clinical presentation and MRI findings and undergoing surgical planning will be accrued in this study.
62522113|NCT00683982|ACTIVE_COMPARATOR|1|This group will receive oral nitazoxanide preparation
62522114|NCT00683982|ACTIVE_COMPARATOR|2|This group will receive a mix combination of probiotics
62522115|NCT00683982|PLACEBO_COMPARATOR|3|This is the control group receiving only oral or systemic hydration solutions
62522116|NCT04689763|EXPERIMENTAL|Lifestyle Redesign Training|The participants will receive a total of 12 training sessions, and each session will contain 120 minutes of training.
62522117|NCT00952536|ACTIVE_COMPARATOR|Triple therapy|Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule (test group 1)
62150316|NCT05557695||Group 1|Patients with chronic lymphocytic leukaemia treated with acalabrutinib in first line
62150317|NCT04139486|EXPERIMENTAL|combined EMBOTRAP II or III and Contact Aspiration|
62150318|NCT04139486|ACTIVE_COMPARATOR|Contact Aspiration alone|
62150319|NCT05177432|EXPERIMENTAL|QPOP-based drug screen assay using patient tumour-derived organoids|"Patients with Histological confirmed breast carcinoma of any subtype (any estrogen receptor, progesterone receptor and HER2 receptor status) with at least 1 tumour lesion (primary or metastatic) amendable to fresh biopsy and measurable based on RECIST 1.1 criteria will undergo biopsy to obtain a sample of cancer tissue that will be used to generate Patient Derived Organoids (PDOs).~Patients' cells will be subjected to testing with 10-12 anti-cancer drugs and a table for treatment sensitivity to each drug will be derived after 8 to 12 weeks of treatment in the laboratory. Results will be reviewed at an expert panel discussion to decide on the most suitable anti-cancer drug treatment"
62150320|NCT05727111|EXPERIMENTAL|HABIT-ILE therapy at home with a HABIT-ILE follow-up at home|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of HABIT-ILE follow-up at home
62150321|NCT05727111|EXPERIMENTAL|HABIT-ILE therapy at home followed by usual care|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of usual care
62522118|NCT00952536|ACTIVE_COMPARATOR|Dual Therapy|Juice Plus+ with 2 vegetable \& 2 fruit \& 2 placebo capsule (test group 2)
62522119|NCT00952536|PLACEBO_COMPARATOR|Control|Daily Placebo in the form of 6 capsules (control group)
62522120|NCT02091323|EXPERIMENTAL|BMI<28kg/m2|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI\<28kg/m2 group.
61975369|NCT03626922|EXPERIMENTAL|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
62150322|NCT05727111|ACTIVE_COMPARATOR|Classic HABIT-ILE therapy followed by usual care|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of usual care
62150323|NCT05727111|ACTIVE_COMPARATOR|Classic HABIT-ILE therapy with HABIT-ILE follow-up at home|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of HABIT-ILE follow-up at home
62150324|NCT06192459|EXPERIMENTAL|Modality physical therapy vs combined therapy|Participants in this are will receive one month of modality physical therapy followed by one month of modality therapy combined muscle strengthening and joint mobility training.
62150325|NCT06192459|EXPERIMENTAL|Combined therapy vs modality physical therapy|Participants in this are will receive one month of modality therapy combined muscle strengthening and joint mobility training followed by one month of modality physical therapy.
62150326|NCT02959411|EXPERIMENTAL|Tolvaptan|Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
62150327|NCT02959411|ACTIVE_COMPARATOR|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients with acute decompensated heart failure
62522121|NCT02091323|OTHER|control|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI\>28kg/m2 group as well.
62150328|NCT06065930||Obese insulin-sensitive subjects (Ob-IS)|Obese Insulin Sensitive subjects (BMI \> 30 kg/m2, fasting insulin \< 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
62150329|NCT06065930||Obese insulin-resistant subjects (Ob-IR)|Obese Insulin Resistant subjects (BMI \> 30 kg/m2, fasting insulin \> 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
62150330|NCT06065930||Lean healthy controls (Lean)|Lean healthy controls (BMI \< 25 kg/m2, fasting insulin \< 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
62150331|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
62150332|NCT01127737|PLACEBO_COMPARATOR|Control|
62150333|NCT01127737|ACTIVE_COMPARATOR|Intervention|Educational intervention consisting of a mnemonic and a workbook used by kidney transplant recipients (KTRs) to assist with early detection of SCCs.
62150334|NCT04927468|EXPERIMENTAL|supramaximal rectus recession|supramaximal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
62357932|NCT03911869|EXPERIMENTAL|High Dose Arm|"Patients in the high-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.~* 300 mg encorafenib orally twice a day (BID)~* 45 mg binimetinib orally twice a day (BID)"
62357933|NCT00858936|EXPERIMENTAL|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
62150335|NCT04927468|ACTIVE_COMPARATOR|normal rectus recession|normal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
62150336|NCT01690000|ACTIVE_COMPARATOR|Melatonin1|1 mg melatonin nightly
62150337|NCT01690000|ACTIVE_COMPARATOR|Melatonin3|3 mg melatonin given nightly
62150338|NCT01690000|ACTIVE_COMPARATOR|Placebo|Identical placebo given nightly
62150339|NCT05543005|EXPERIMENTAL|experimental group|maternal voice
62150340|NCT05543005|NO_INTERVENTION|control group|no maternal voice
62150341|NCT06462248|EXPERIMENTAL|single arm|Single arm open labelled phase 2 study
62357934|NCT00858936|PLACEBO_COMPARATOR|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
62357935|NCT02856906|EXPERIMENTAL|Occlusal adjustment group|Patients in this group will receive treatment of occlusal adjustment based on the clinical and lab examination results.
62357936|NCT01002742|EXPERIMENTAL|Placebo|Corticosteroids with placebo
62357937|NCT01002742|EXPERIMENTAL|Mycophenolate Mofetil|Corticosteroids with Mycophenolate Mofetil
62150342|NCT03971344||Family members of newborns extremely premature|Parents and siblings (if any) of infants born at 30 weeks gestational age or less, or with a birthweight less than 1500 grams.
62150343|NCT03971344||Family members of new pediatric oncology patients|Parents and siblings (if any) of patients with new onset (not relapses) pediatric oncologic diagnoses including liquid, solid, and brain cancer.
62150344|NCT03971344||Family members of critical congenital heart defect patients|Parents and siblings (if any) of newborns with critical congenital heart defects who typically undergo surgery by 12 months of life.
62150345|NCT03971344||Family members of children with severe neurological impairment|Parents and siblings (if any) of patients with severe neurologic impairments, associated with substantial functional impairment, relentless progressive deterioration, or substantially shortened life-spans.
62150346|NCT04919668|SHAM_COMPARATOR|Low budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
62150347|NCT04919668|ACTIVE_COMPARATOR|High budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
62357938|NCT04970849||one group that is IBD endoscopist who perform the endoscopy for IBD patients|Complete the questionnaire online
62357939|NCT05903950|ACTIVE_COMPARATOR|Active mode|In home use of portable air cleaners with a High Efficiency Particulate Air (HEPA) filter for 4 weeks.
62357940|NCT05903950|SHAM_COMPARATOR|Sham mode|In home use of portable air cleaners without a High Efficiency Particulate Air (HEPA) filter for 4 weeks.
62357941|NCT01069367|EXPERIMENTAL|Arm:1|
62357942|NCT06456138|EXPERIMENTAL|Trametinib + Anlotinib + Tislelizumab|"In Phase I, there are four treatment arms: anlotinib (6 mg) plus trametinib (1 mg) plus tislelizumab (200 mg, Q3W),~anlotinib (6 mg) plus trametinib (2 mg) plus tislelizumab (200 mg, Q3W),~anlotinib (8 mg) plus trametinib (1 mg) plus tislelizumab (200 mg, Q3W),~and anlotinib (8 mg) plus trametinib (2 mg) plus tislelizumab (200 mg, Q3W).~In Phase II, there is one treatment arm including trametinib (RP2D) plus anlotinib (RP2D) plus tislelizumab (200 mg, Q3W)."
62357943|NCT06425263|EXPERIMENTAL|injection with adipose tissue|"After standard arthrocentesis of the temporomandibular joint~* Direct access to the buccal fat pad, is found at distobuccal depth of the maxillary tuberosity.~* It may be dissected during the resection an upper mucosal incision posterior to the second molar~* After a single scissor stab through the periosteum the (BFP)extrude into the operative site.~* Closure of the flap by suitable suture.~* Collection of lipids then manually manipulated with two syringes connecting together and pushing the lipids against each other to receive the injectable amount of micro fragmented adipose tissue ."
62150348|NCT04919668|ACTIVE_COMPARATOR|Low budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
62150349|NCT04919668|ACTIVE_COMPARATOR|High budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
62711875|NCT04244734|EXPERIMENTAL|Group 2|The experimental group receives a new early rehabilitation program based on a patient's in-bed cycling that allows controlled and adapted training to the patient's situation, along with coordinated exercise with neuromuscular electrostimulation and respiratory physiotherapy with breathing muscle strengthening in a high load (initially at 60% load from results in MIP).
62150350|NCT02393456|EXPERIMENTAL|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
62150351|NCT02393456|PLACEBO_COMPARATOR|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
62150352|NCT06299748||Retrospective Pregnancy|woman is no longer pregnant at time of study enrollment but was exposed to efgartigimod any time within 25 days prior to conception or any time during pregnancy
61975370|NCT03626922|EXPERIMENTAL|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
62150353|NCT06299748||Prospective Pregnancy|woman is pregnant or breastfeeding at time of study enrollment.
62711876|NCT03199833|EXPERIMENTAL|Arms|RETRAINER-S2 \& Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S2 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62150354|NCT03742297|ACTIVE_COMPARATOR|VMP x 9 + Lenalidomida-dexamethasone x 9|Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose
62150355|NCT03742297|EXPERIMENTAL|Carfilzomib-lenalidomida-dexamethasone regimen|carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 \& 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 \& 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 \& 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle
62150356|NCT03742297|EXPERIMENTAL|Carfilzomib-lenalidomida-dexamethason with daratumumab|Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 \& 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 \& 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 \& 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22. Daratumumab 1800mg SC Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18
62150357|NCT05008003|ACTIVE_COMPARATOR|Standard of care|This arm will receive the standard of care as per the hospital guidelines.
62357944|NCT06425263|ACTIVE_COMPARATOR|injection with hyaluronic acids|"Arthrocentesis of the superior joint compartment was performed in all patients under local anesthesia using the technique described by Nitzan et al.~Another 19-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL saline solution, allowing a free flow through the first needle.~On termination of procedure, 2 mL commercially available hyaluronic injected into the superior compartment."
62357945|NCT01105780|EXPERIMENTAL|001|JNJ-41443532 250mg tablet once daily for 1 day
62357946|NCT01105780|PLACEBO_COMPARATOR|002|Placebo Matching placebo
62150358|NCT05008003|EXPERIMENTAL|Investigational treatment|This arm will receive vitamin D3 supplement as add-on to the standard of care.
62150359|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 1 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62150360|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 2 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62150361|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 3 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62150362|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 4 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62357947|NCT04271670|EXPERIMENTAL|Warm water footbath with ginger powder|Footbath with ginger powder with a maximum duration of 20 minutes.
62357948|NCT04271670|EXPERIMENTAL|Warm water footbath with mustard powder|Footbath with mustard powder with a maximum duration of 20 minutes.
62357949|NCT04271670|ACTIVE_COMPARATOR|Warm water only footbath|Warm water only footbath with a maximum duration of 20 minutes.
62357950|NCT04232787||Case|Thai patients with diagnosed Brugada syndrome by confirmed Brugada type 1 ECG.
62357951|NCT04232787||Control|Healthy volunteers without Brugada marker from ECG.
62357952|NCT01630941|ACTIVE_COMPARATOR|Denosumab|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
62357953|NCT01630941|PLACEBO_COMPARATOR|saline|1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
62357954|NCT01874873|EXPERIMENTAL|Anlotinib|
62357955|NCT02592668|EXPERIMENTAL|Active stimulation|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function. The total estimated time for the intervention is 66 weeks.
62357956|NCT05687916|EXPERIMENTAL|TAK-861 Dose 1|TAK-861 dose 1, orally for 8 weeks.
62357957|NCT05687916|EXPERIMENTAL|TAK-861 Dose 2|TAK-861 dose 2, orally for 8 weeks.
62357958|NCT05687916|PLACEBO_COMPARATOR|Placebo|TAK-861 matching placebo tablets, orally for 8 weeks.
62357959|NCT02938546|ACTIVE_COMPARATOR|before therapy|18F-FDG PET/CT performed before therapy
62357960|NCT02938546|EXPERIMENTAL|3 days after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy
62522122|NCT01563419|NO_INTERVENTION|Control|dialing up the selected dose of insulin pens without an indicator magnifying window
61975371|NCT04083170|EXPERIMENTAL|Regimen A (fludarabine, cyclophosphamide, TBI, dilanubcel)|Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
62357961|NCT02938546|EXPERIMENTAL|longer time after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy
62357962|NCT00228943|EXPERIMENTAL|Acute tryptophan depletion|Full-strength tryptophan depletion
62357963|NCT00228943|ACTIVE_COMPARATOR|Control|Half-strength tryptophan depletion drink used as a control
62357964|NCT01281189|EXPERIMENTAL|Dexpramipexole|
62357965|NCT01281189|PLACEBO_COMPARATOR|Placebo|
62357966|NCT00282867|ACTIVE_COMPARATOR|tight control group|target glucose level 70-110 mg/dL
62357967|NCT00282867|ACTIVE_COMPARATOR|loose control group|target glucose level 70 - 200 mg/dL
62357968|NCT00282867|ACTIVE_COMPARATOR|usual care group|target level 70 - 300 mg/dL
62357969|NCT00951769||Control,|Control
62357970|NCT00951769||DAS: Difficult Airway Society, UK|DAS difficult airway algorithm
62357971|NCT00951769||Australian|Australian difficult airway algorithm
62357972|NCT06310837|EXPERIMENTAL|ADA+MMF group|Adalimumab biosimilars with immunosuppressants therapy
62357973|NCT06310837|ACTIVE_COMPARATOR|Corticosteroids+MMF group|Corticosteroids with immunosuppressive therapy；
62357974|NCT03375138|EXPERIMENTAL|Process E PPQ belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
62357975|NCT03375138|EXPERIMENTAL|Process C belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
62357976|NCT00435357|EXPERIMENTAL|mobile-bearing TKA|
62357977|NCT00435357|ACTIVE_COMPARATOR|fixed- bearing TKA|
62357978|NCT01732107|EXPERIMENTAL|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
62357979|NCT05277116|EXPERIMENTAL|Participants receiving a Genome Informed Risk Assessment (GIRA)|All participants and their health care providers will receive a Genome Informed Risk Assessment (GIRA) report.
62357980|NCT05630560||Psychologists in Danish private practice|All psychologists with a Danish university degree in psychology who have registered themselves as seeing clients in private practice (app. 1,750) have been invited to participate in the study. Thus, the sample of psychologists consists of psychologists employed in the Danish practice sector, where clients obtain a refund of 60% of the psychologist's salary, as well as psychologists working privately without any reimbursement of their salaries. Each psychologist enrolled in the study has agreed to aim to recruit no less than 10 clients each for the study. We aim to include 100 psychologists, which will yield a sample of 1,000 clients beginning therapy.
62357981|NCT01306032|EXPERIMENTAL|Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
62357982|NCT01306032|EXPERIMENTAL|Triple-negative Breast Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
62357983|NCT01306032|EXPERIMENTAL|BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
62357984|NCT01306032|EXPERIMENTAL|BRCA- positive Ovarian Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
62357985|NCT01306032|EXPERIMENTAL|Non-Hodgkin's: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
62357986|NCT01306032|EXPERIMENTAL|Non-Hodgkin's: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
62357987|NCT06360471||Fertility preservation|patients who choose fertility preservation
62357988|NCT06360471||Observation|patients who choose observation
62357989|NCT05690672|ACTIVE_COMPARATOR|3D-CAM screening|
62357990|NCT05690672|ACTIVE_COMPARATOR|4AT screening|
62357991|NCT00819104|EXPERIMENTAL|1|FDC of Metoprolol XL 50mg + Amlodipine 5mg
62357992|NCT00819104|EXPERIMENTAL|2|FDC of Metoprolol XL 25mg + Amlodipine 2.5mg
62357993|NCT00819104|ACTIVE_COMPARATOR|3|Extended release Metoprolol succinate
62357994|NCT00819104|ACTIVE_COMPARATOR|4|Extended release Metoprolol succinate
62357995|NCT00819104|ACTIVE_COMPARATOR|5|Amlodipine 5mg in immediate release formulation
62357996|NCT05599412||Korean patients with Metastatic ALK+ Non small cell lung cancer|
62357997|NCT03991182|EXPERIMENTAL|Community-based parenting group|The community-based parenting group will include 39 health zones and 585 caregiver-child dyads
62357998|NCT03991182|ACTIVE_COMPARATOR|Control group|The control group will include 39 health zones and 585 caregiver-child dyads
62357999|NCT04508062|ACTIVE_COMPARATOR|pectopexy group|this group will only have pectopexy operation
62358000|NCT04508062|ACTIVE_COMPARATOR|Pectopexy and uterosacral ligaments plication group|this group will have pectopexy operation with bilateral uterosacral ligaments plication
62358001|NCT01296698|PLACEBO_COMPARATOR|Placebo|0 mg Oral NRT, up to 4 times per hour for 12 weeks
62358002|NCT01296698|EXPERIMENTAL|Nicotine|1 mg Oral NRT, up to 4 times per hour for 12 weeks
62358003|NCT01875913|EXPERIMENTAL|Standard Message|Participants will receive email messages that encourage them to complete their VHR.
62358004|NCT01875913|EXPERIMENTAL|Curiosity Message|"Participants receive email messages containing curiosity-inducing questions. The messages tell the participants that they will receive the answer to the question after they complete their VHR."
62358005|NCT06380764|ACTIVE_COMPARATOR|First line Group|
62358006|NCT06380764|ACTIVE_COMPARATOR|Second line Group|
62358007|NCT06380764|ACTIVE_COMPARATOR|Third line Group|
62358008|NCT06380764|PLACEBO_COMPARATOR|Placebo Group|
61975372|NCT04083170|EXPERIMENTAL|Regimen B (anticancer drugs, TBI, dilanubicel)|Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
61975373|NCT03275051|EXPERIMENTAL|All subjects|Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study. Subjects received OTL-300 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
61975374|NCT06151795|EXPERIMENTAL|XTR006|Single dose 8.0-10.0 mCi intravenous injection of XTR006
62358009|NCT04016688|ACTIVE_COMPARATOR|ES Erector Spinae Plane Block|"bilateral ESP block at the level of T9 by a linear ultrasound (US) transducer (Phillips Saronno Italy) placed vertically 3cm lateral to the midline to visualize the back muscles superior to the transverse process.~A 22-G short bevel needle (spinocan, B.Braun, melsungen AG, Germany) will be inserted in cranial-caudal direction until it make contact with the transverse process. Confirmation of the correct position of the tip of the needle is by injection of 1 ml saline causing hydrodisscetion between the erector spinae muscle and the transverse process. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected.The same procedure is done on the other side of the back."
62358010|NCT04016688|ACTIVE_COMPARATOR|TAP Transversus Abdominis Plane Block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
62150363|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 5a SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62358011|NCT06020573|OTHER|Intraoperative detection of light signals during electrosurgical breast cancer resection|Participants undergo electrosurgical breast cancer resection while light signals are detected intraoperatively
62358012|NCT02191280|EXPERIMENTAL|Antistax®, low dose|
61975375|NCT01549444||Group 1|Babies of mothers that have diabetes and/or hypertension and babies that are small for dates
61975376|NCT01549444||Group 2|Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age
61975377|NCT05350150|EXPERIMENTAL|Auricular Vagal Nerve Stimulation|Patients will undergo a standard EPS with 4 catheters. Following the standard EPS, patients will be hooked up a Parasym device to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve, EPS will be repeated.
61975378|NCT02012998|EXPERIMENTAL|HBVAXPRO Challenge dose|HBVAXPRO 5µg
61975379|NCT05945693|PLACEBO_COMPARATOR|Placebo control|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule.
62150364|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 5b SAD|Participants will receive SC injection of AZD1163 on Day 1.
62150365|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 6 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62358013|NCT02191280|EXPERIMENTAL|Antistax®, high dose|
62358014|NCT02191280|PLACEBO_COMPARATOR|Placebo|
62358015|NCT06046547|EXPERIMENTAL|Pulmonary rehabilitation with palliative care education|The experimental group will participate in PR with palliative care education.
62358016|NCT06046547|ACTIVE_COMPARATOR|Pulmonary rehabilitation|The control group will participate in traditional PR.
62358017|NCT03743207|EXPERIMENTAL|Room temperature|All of the infants in neonatal intensive care units are used to be fed with milk at 22-24°C which is close to room temperature.
62358018|NCT03743207|EXPERIMENTAL|Warmer temperature|The investigators decided to feed the infants in this group with warmer milk at to examine the effects of feeding temperature.
62358019|NCT00243685|EXPERIMENTAL|II and III|
62358020|NCT03179930|EXPERIMENTAL|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
62358021|NCT03351478|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
62358022|NCT03351478|ACTIVE_COMPARATOR|Empagliflozin 25 mg|Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
62358023|NCT03351478|PLACEBO_COMPARATOR|Placebo|Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
62358024|NCT00898989||Inclusion Body Myositis|
62358025|NCT00898989||Control|
62358026|NCT02867722|EXPERIMENTAL|Daylight PDT|Patients will receive daylight-PDT treatment (aminolevulinic acid)
62358027|NCT00432913|ACTIVE_COMPARATOR|1g EPA per day|
62358028|NCT00432913|ACTIVE_COMPARATOR|2g EPA per day|
62358029|NCT00432913|PLACEBO_COMPARATOR|Placebo|
62358030|NCT04197024|EXPERIMENTAL|Traditional exercise capacity test|Patients of the Ministry of the Interior and Administration hospital in Głuchołazy with a diagnosed disease unit of Chronic Obstructive Pulmonary Disease (COPD).
62358031|NCT04197024|EXPERIMENTAL|Immersive virtual reality exercise capacity test|Healthy volunteers, Students of Department of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
62358032|NCT02527941|EXPERIMENTAL|metronidazole|50 women who test negative for HIV and classical sexually transmitted infections but test positive for Bacterial Vaginosis will be treated with metronidazole at a dosage of 400mg/dose, 3 doses per day, for 7 days (as per Kenyan National Guidelines).
62358033|NCT04766983||VAP - BAL positive|Clinically suspected VAP, microbiologically confirmed by BAL
62150366|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 7 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62150367|NCT06103877|ACTIVE_COMPARATOR|Part 1 Cohort 8 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
62150368|NCT06103877|PLACEBO_COMPARATOR|Part 1 pooled Placebo SAD IV|Participants will receive matching IV infusion of placebo on Day 1.
62150369|NCT06103877|PLACEBO_COMPARATOR|Part 1 pooled Placebo SAD SC|Participants will receive matching SC injection of placebo on Day 1.
62150370|NCT06103877|ACTIVE_COMPARATOR|Part 2 Cohort 1 MAD (Japanese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
62150371|NCT06103877|ACTIVE_COMPARATOR|Part 2 Cohort 2 MAD (Japanese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
62150372|NCT06103877|ACTIVE_COMPARATOR|Part 2 Cohort 1 MAD (Chinese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
62150373|NCT06103877|ACTIVE_COMPARATOR|Part 2 Cohort 2 MAD (Chinese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
62150374|NCT06103877|PLACEBO_COMPARATOR|Part 2 Placebo MAD (Japanese participants)|Participants will receive matching SC injection of placebo on Days 1 and 15.
62150375|NCT06103877|PLACEBO_COMPARATOR|Part 2 Placebo MAD (Chinese participants)|Participants will receive matching SC injection of placebo on Days 1 and 15.
62150376|NCT01502839||OEF/OIF Veterans|Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
62150377|NCT06019767|EXPERIMENTAL|Cognitive Processing Therapy (CPT)|Groups of 6-8 receive CPT to treat PTSD
62150378|NCT00762866||MDD|Unipolar Major Depressive Disorder, any subtype
62150379|NCT00762866||Bipolar|Bipolar I or II Disorder or Bipolar Disorder NOS
62150380|NCT00762866||Psychosis|Psychotic Disorder including Schizophrenia, Schizoaffective, Schizophreniform, Brief Psychotic Disorder, and Psychotic Disorder NOS
62150381|NCT02412540|NO_INTERVENTION|Weight Loss Surgery|Adolescents who will have Weight Loss Surgery and had biopsy-confirmed NASH. The Weight Loss Surgery is not part of the study. The investigators are following the adolescents after the surgery.
62150382|NCT02412540|EXPERIMENTAL|Comprehensive Lifestyle Intervention|Comprehensive Lifestyle Intervention - Dietary, activity and behavioral interventions. Adolescents who have biopsy-confirmed NASH and wish to participate in a Comprehensive Lifestyle Intervention (26+ contact hours) including individual meetings with a study dietitian, group nutrition classes, behavior management modules and physical activity goals.
62150383|NCT00078832|EXPERIMENTAL|anastrozole|anastrozole 1mg
62150384|NCT00078832|PLACEBO_COMPARATOR|placebo|anastrozole 1mg PLACEBO
62150385|NCT06500403||Patients who have received platinum-based chemotherapy for organ tumors|
62150386|NCT00937014|ACTIVE_COMPARATOR|Standard infant formula|
62150387|NCT00937014|EXPERIMENTAL|Test formula|
62150388|NCT06506409|ACTIVE_COMPARATOR|Group 1: Smart-Video Based Game Therapy Group|The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. The selected games focus on balance, coordination and weight transfer.
62150389|NCT06506409|ACTIVE_COMPARATOR|Otago Based Structured Exercise Group|Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions of movements at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.
62150390|NCT06506409|ACTIVE_COMPARATOR|Control group|A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
62150391|NCT01431157|ACTIVE_COMPARATOR|Nasal oxygen|Nocturnal nasal oxygen
62150392|NCT01431157|PLACEBO_COMPARATOR|No nasal oxygen|
62150393|NCT00687297|ACTIVE_COMPARATOR|Vandetanib Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, vandetanib maintenance daily until progression.
62358034|NCT04766983||VAP - BAL negative|Clinically suspected VAP, not microbiologically confirmed by BAL
62150394|NCT00687297|PLACEBO_COMPARATOR|Placebo Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, placebo maintenance daily until progression.
62150395|NCT02203799|EXPERIMENTAL|Peanut Oral Immunotherapy (POIT)|The peanut OIT is taken in the form of peanut flour. It will be given in small cups containing the amount of flour that needs to be eaten for one dose. One dose should be taken per day.
62150396|NCT02174978|EXPERIMENTAL|Group 1: 10 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
62358035|NCT04766983||NO VAP|No clinically suspected VAP during mechanical ventilation
62358036|NCT00721617|ACTIVE_COMPARATOR|Obese subjects|Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
62358037|NCT00721617|ACTIVE_COMPARATOR|Lean subjects|Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
62358038|NCT02858102|ACTIVE_COMPARATOR|Active treatment group|Physical activity program: 36 sessions of physical activity lasting between 30-60 minutes for 12 weeks, three days per week.
62358039|NCT02858102|NO_INTERVENTION|Control group|No physical activity program
62522123|NCT01563419|EXPERIMENTAL|Magnifier|dialing up the selected dose of insulin pens clipped on an indicator magnifying window
62522124|NCT01687582|EXPERIMENTAL|GLP-1 analog|Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
62358040|NCT03720301|EXPERIMENTAL|Treatment|Study arm who will receive pre operative and intraoperative treatments intended to effect POST severity.
62358041|NCT03720301|SHAM_COMPARATOR|Sham|Sham are who will receive a preoperative treatment not intended to effect POST outcomes.
62358042|NCT02762799|EXPERIMENTAL|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
62358043|NCT02762799|EXPERIMENTAL|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
62358044|NCT02762799|EXPERIMENTAL|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
62358045|NCT02762799|EXPERIMENTAL|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
62358046|NCT03524911|EXPERIMENTAL|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
62358047|NCT00606853|EXPERIMENTAL|1|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
62358048|NCT00606853|EXPERIMENTAL|2|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $560 in prizes and twice-weekly breath and urine samples.
62358049|NCT00606853|EXPERIMENTAL|3|Standard Treatment plus prize contingency management for attendance with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
62358050|NCT00606853|NO_INTERVENTION|4|Standard Treatment
62358051|NCT03514004|EXPERIMENTAL|Intervention|"The ICT-based intervention is known as Project Clan. Each participant randomized to the intervention group will have access to the web platform and mobile applications of Project Clan - a virtual community that seeks to promote adolescent mental health and wellbeing as students interact, express themselves, and resolve concerns, with the support of peers and mental health professionals. During the three-month intervention, participants will have complete anonymity, unless trained psychologists supervising the platform as community counselors identify behaviors associated with suicide risk and proceed to follow an established emergency protocol. The counselors will be available to answer community questions and provide support on an individual basis."
62358052|NCT03514004|NO_INTERVENTION|Control|Participants in the control group will also be assigned a username and password to access the website, but they will be met with a user interface that only displays a space to answer the corresponding assessments. In addition to the introductory presentation, they will be given a brochure with information regarding adolescent suicide and wellbeing and tips with regard to seeking help and assisting others. This will include the contact information for a telephone hotline, to ensure they can receive professional help if needed.
62358053|NCT03156855|EXPERIMENTAL|sequential therapy for 14 days (S14)|14 day sequential therapy
62358054|NCT03156855|ACTIVE_COMPARATOR|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
62358055|NCT00717002||1|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
62358056|NCT00717002||2|Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
62358057|NCT02855112|NO_INTERVENTION|Control|A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.
62358058|NCT02855112|EXPERIMENTAL|Adipose derived Mesenchymal Stem cell|A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks.
62358059|NCT06134869|OTHER|Patients requiring horizontal bone augmentation in the posterior mandible|
62358060|NCT01376362|EXPERIMENTAL|Interferon gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
62358061|NCT03990259||Male|The male individuals of the study population
62358062|NCT03990259||Female|The female individuals of the study population
62358063|NCT03949998|EXPERIMENTAL|Dry Needling|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals.
62358064|NCT03949998|ACTIVE_COMPARATOR|Dry Needling + Manual Therapy|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals IN ADDITION TO manual therapy of the above muscles and/or cervical joint traction and/or mobilization as indicated.
62358065|NCT03949998|ACTIVE_COMPARATOR|Manual Therapy|Participants will receive manual therapy of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals and/or cervical joint traction and/or mobilization as indicated.
62358066|NCT02685787|EXPERIMENTAL|Psychosocial Intervention|Every caregiver in this arm will be assigned to a permanent counselor.
62358067|NCT02685787|ACTIVE_COMPARATOR|Educational Intervention on AD|The caregiver enrolled in this arm will not be assigned to a counselor but will participate to group sessions on AD education.
62358068|NCT04323423|NO_INTERVENTION|Control (CON)|1) Condition A (CON): This will be the control condition. It will consist of uninterrupted sitting from 8 am until 7 pm, only rising from the chair to void.
62522125|NCT01408628|EXPERIMENTAL|Internet Insulin Education|"Single arm study; intervention represented by subjects' participation in 4 synchronous (live) interactive Internet classes."
62522126|NCT02672202|ACTIVE_COMPARATOR|Duloxetine|Treatment
62522127|NCT02672202|ACTIVE_COMPARATOR|Pregabalin|Treatment
62522128|NCT02672202|PLACEBO_COMPARATOR|Placebo|
62522129|NCT03304028|OTHER|Refusal Group|"Refusal Questionnaires Intervention:~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal."
62150397|NCT02174978|EXPERIMENTAL|Group 2: 30 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24. On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
62522130|NCT03304028|OTHER|Interventionnal Group|Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews
62522131|NCT02182791|EXPERIMENTAL|Nevirapine tablets|"once a day (q.d.) Day 2-15,~twice a day (b.i.d.) Study day 16-30"
62711877|NCT03199833|ACTIVE_COMPARATOR|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
62711878|NCT04259593|EXPERIMENTAL|Exercise Training Group|Exercise training group performed three weekly sessions for 16 weeks. This program consisted of moderate intensity aerobic, resistance, balance, and stretching exercises. The duration of every exercise session was 35 minutes during the first week and 65 minutes from the second week onward.
62150398|NCT02174978|OTHER|Infectivity control|Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
62150399|NCT02765867|EXPERIMENTAL|RBP-6000|A single dose of RBP-6000 will be administered on Study Day 1
62150400|NCT02055079|EXPERIMENTAL|Sirolimus|Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months.
62150401|NCT02055079|PLACEBO_COMPARATOR|Placebo|Fixed oral dose of placebo (blinded) once weekly for 24 months.
62522132|NCT02182791|ACTIVE_COMPARATOR|EE/NET tablets|Single dose on Study Day 0 and 30
62522133|NCT00262041|EXPERIMENTAL|MenACWY-CRM(Ad+)|Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
62522134|NCT00262041|EXPERIMENTAL|MenACWY-CRM(Ad-)|Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
62522135|NCT00262041|ACTIVE_COMPARATOR|MenACWY- PS|Subjects received one single dose of the polysaccharide vaccine.
62522136|NCT02328742||No intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to not have an intracavitary pathology. (The first 20 such patients will be retained in this group.)~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Telephone call"
62522137|NCT02328742||Synechia|"During the first diagnostic hysteroscopy, patients in this group are found to have synechia.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
62711879|NCT04259593|NO_INTERVENTION|Control Group|The control group received usual lymphoma care
62711880|NCT01606150|ACTIVE_COMPARATOR|Subcutaneous Lidocaine|0.1 ml/kg of 1% Lidocaine
62711881|NCT01606150|ACTIVE_COMPARATOR|Topical Lidocaine|LMX-4, 1 gram placed over lumbar puncture needle insertion site 30 minutes prior to the procedure
62522138|NCT02328742||Intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to have an intracavitary pathology.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
62522139|NCT03499002|EXPERIMENTAL|Simulation Lab|
62522140|NCT03499002|EXPERIMENTAL|ER in situ Simulation|
62522141|NCT00607152|EXPERIMENTAL|1|IV infusion at a dose level of 0.20mg/kg per day
62522142|NCT00607152|ACTIVE_COMPARATOR|2|100mg tablets, administered orally, according to standard medical practice
62522143|NCT00225121|EXPERIMENTAL|1|open label single arm trial
62711882|NCT02332811|EXPERIMENTAL|CKD patients not on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
62711883|NCT02332811|EXPERIMENTAL|CKD patients not on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
62711884|NCT02332811|EXPERIMENTAL|CKD patients on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
62150402|NCT05814809|EXPERIMENTAL|Sequence A|R → Washout period(7days) → T
62150403|NCT05814809|EXPERIMENTAL|Sequence B|T → Washout period(7days) → R
62150404|NCT02040038|EXPERIMENTAL|LIVE Arm|Participation in 3D virtual environment for DSMT/S for a period of 12 months.
62150405|NCT02040038|ACTIVE_COMPARATOR|Website|Participation in 2D website for DSMT/S for a period of 12 months.
62150406|NCT05360537|EXPERIMENTAL|patients treated with Insulin Degludec/Liraglutide|Diabetes therapy with Insulin Degludec/Liraglutide and various combinations of metformin, repaglinide, sulfonylureas.
62150407|NCT05360537|ACTIVE_COMPARATOR|patients treated with Insulin regime Basal Bolus|Diabetes therapy with the combination of a single administration of glargine insulin and three administration of Aspart Insulin.
62150408|NCT01029704|EXPERIMENTAL|EGT0001442|
62150409|NCT01029704|PLACEBO_COMPARATOR|Placebo|
62150410|NCT03630653|EXPERIMENTAL|Sentinel LN in breast cancer recurrence|"Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND."
62150411|NCT01500070|EXPERIMENTAL|Drug-eluting stent|Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
62522144|NCT04866277|EXPERIMENTAL|Intervention|"Women who present at least one of the four risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will be eligible to receive the intervention. The intervention will be the activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study. All pregnant women referred by the STOP LBW project would have access to consultations or other health activities, such as counselling and group meetings, within a maximum of seven days, in reference services available in each metropolitan area. The activation of the fast-track referral will be the responsibility of the doctor/nurse who applies the questionnaires to identify the risk factors. The intervention ends with childbirth, abortion or if the participant decides to abandon the study."
62522145|NCT04866277|NO_INTERVENTION|Standard of care|Women who present at least one of the risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will receive the standard of care currently existing in each PHCU. The standard of care varies across the various PHCU and may include several approaches: routine screening with care by the antenatal care provider; routine screening with referral to other health professional in the same health unit; and routine screening with referral to other health services, with the time elapsed for consultation depending on the health resources available in each area. In each PHCU, different standards of care may exist for each of the four risk factors.
62522146|NCT00618930|EXPERIMENTAL|1|
62522147|NCT00618930|ACTIVE_COMPARATOR|2|Use of Fleet
62522148|NCT02548312|EXPERIMENTAL|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
62522149|NCT02548312|EXPERIMENTAL|Review 1- competing interest statement 2|Variations of financial competing interest statements.
62522150|NCT02548312|EXPERIMENTAL|Review 1- competing interest statement 3|Variations of financial competing interest statements.
62522151|NCT02548312|EXPERIMENTAL|Review 1- competing interest statement 4|Variations of financial competing interest statements.
62522152|NCT02548312|EXPERIMENTAL|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
62522153|NCT02548312|EXPERIMENTAL|Review 2- competing interest statement 2|Variations of financial competing interest statements.
62522154|NCT02548312|EXPERIMENTAL|Review 2- competing interest statement 3|Variations of financial competing interest statements.
62522155|NCT02548312|EXPERIMENTAL|Review 2- competing interest statement 4|Variations of financial competing interest statements.
61975380|NCT05945693|ACTIVE_COMPARATOR|Placebo and aerobic exercise|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule and will perform aerobic type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day.
61975381|NCT05945693|EXPERIMENTAL|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA.
62522156|NCT02083237|ACTIVE_COMPARATOR|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
62522157|NCT02083237|NO_INTERVENTION|Waitlist Control|Due to the heavy demand for this clinical program, there is a naturally-occurring waitlist of approximately 3 months. Control participants are assessed during this period.
62522158|NCT06309446|EXPERIMENTAL|Zoralan Wound|"At the beginning of the study, two small, superficial, abrasive wounds (approximately 1.2 cm in diameter) were induced on one volar forearm of each subject with a minimum distance of 5 cm between the wounds, using a sterile surgical hand brush.~One wound is treated with the medical device by a study nurse and covered with standard semi-occlusive wound plaster (Hansaplast Sensitive wound plaster. Topical application of appoximately 0.2g per test field (approx. 1.2cm in diameter each) once daily during a 12-day treatment period (11 treatments)."
62522159|NCT06309446|NO_INTERVENTION|No treatment|"At the beginning of the study, two small, superficial, abrasive wounds (approximately 1.2 cm in diameter) were induced on one volar forearm of each subject with a minimum distance of 5 cm between the wounds, using a sterile surgical hand brush.~One wound is not treated but covered with standard semi-occlusive wound plaster (Hansaplast Sensitive wound plaster. Covering happens once daily during a 12-day treatment period (11 treatments)."
62522160|NCT05019820|ACTIVE_COMPARATOR|Sarcopenia and osteoarthritis group|Women aged 45-65 years diagnosed with sarcopenia and knee osteoarthritis
62522161|NCT05019820|OTHER|Without osteoarthritis and sarcopenia group|Women aged 45-65 years without a diagnosis of knee osteoarthritis and sarcopenia
62522162|NCT02070302|ACTIVE_COMPARATOR|Botulinum Toxin Type A|After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
62522163|NCT02070302|PLACEBO_COMPARATOR|Placebo|.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
62522164|NCT04508036||Study Group|Premature newborns born before 32nd gestational week and weighing less than 1500 grams.
62522165|NCT05445726|ACTIVE_COMPARATOR|Healthy|Generally healthy participants that are able to participate in study procedures (i.e. laying down, sitting up, shaving chest hair for ECG/Test device placement if needed).
62522166|NCT05445726|ACTIVE_COMPARATOR|Atrial Fibrillation Diagnosis|Participants with a diagnosis of atrial fibrillation that are able to participate in study procedures (i.e. laying down, sitting up, shaving chest hair for ECG/Test device placement if needed).
62522167|NCT05391334||Usual Care|Contact mat (CareMat®) for bed-exit detection in combination with Qumea fall detection.
62522168|NCT05391334||Intervention|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
62522169|NCT01427842|EXPERIMENTAL|DEVINE vancomycin regimen|This is the intervention arm and will be the pharmacokinetically derived vancomycin dosing regimen.
62711885|NCT02332811|EXPERIMENTAL|CKD patients on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
62358069|NCT04323423|EXPERIMENTAL|one 10 minute bout - (LONG)|will consist of completing one 10-minute bout of light intensity walking (RPE 6-9) 30 minutes post-prandial. Participants will rise from their seated position to walk \~10 metres to a treadmill to perform this bout. The participant will repeat this after lunch and dinner, for an accumulated total of 30 minutes of light walking.
62711886|NCT00916227|EXPERIMENTAL|ARRY-614|
62711887|NCT00060944|EXPERIMENTAL|Yondelis weekly schedule|Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
62358070|NCT04323423|EXPERIMENTAL|four 2.5 minute bouts SHORT|will consist of interrupting sitting with four 2.5-minute bouts of light walking at 30 minutes, 60 minutes, 90 minutes and 120 minutes post-prandial. Participants will rise from their seated position to walk \~10 metres to a treadmill to perform these bouts. The participant will repeat this after breakfast, lunch and dinner for an accumulated total of 30 minutes of light walking.
61975382|NCT05945693|EXPERIMENTAL|Omega-3 and aerobic exercise|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA and will perform aerobic type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day.
62150412|NCT04140526|EXPERIMENTAL|ONC-392 Treatment as single agent|"The Part A study will test ONC-392 intravenous (IV) infusion up to five predefined dose levels from 0.1 mg/kg to 10 mg/kg ONC-392 as monotherapy every 21 days (Q3W). The Part A study will determine the maximal tolerable dose (MTD) and the recommended Phase 2 dose in monotherapy (RP2D-M).~In Part C, Arms A-C, I-N monotherapy expansion cohorts will further assess the safety and efficacy of ONC-392 in different dose levels as monotherapy in pancreatic cancer, triple negative breast cancer, non small cell lung cancer with driver mutations, PD-1 resistant non small cell lung cancer, PD-1 resistant melanoma, head and neck cancer, ovarian cancer, renal cell carcinoma and other solid tumors.~Part D is a Phase II study on recurrent and/or metastatic adenoid cystic carcinoma."
62358071|NCT04639843|EXPERIMENTAL|1- Experimental Treatment: Dose Escalation|Duvelisib (PO BID) at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of C1 and days 1-14 of all other cycles of each 21- day cycle (max 8 cycles) with CC-486 (5-azacitidine) (PO) at 300mg/day on days 1-10, romidepsin at 12mg/m2 (IV) on Days 1 and 8 of each cycle and doxorubicin (IV) at 25 mg/ m2 on Day 1 of cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy), to determine RP2D of duvelisib and doxorubicin
61975383|NCT00176826|EXPERIMENTAL|Intent-To-Treat|Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
61975384|NCT04566224|EXPERIMENTAL|Macintosh 2 group|Using Macintosh size 2 blade for direct laryngoscope intubation according to randomization
62358072|NCT04639843|EXPERIMENTAL|2 - Experimental Treatment: Dose Expansion|Duvelisib (PO BID) at RP2D on days -14 to 14 of C1 and days 1-14 of all other 21-day cycle (max 8 cycles) with CC-486 (5-azacitidine) at 300mg/day (PO) on days 1-10, romidepsin at 12mg/m2 (IV) on days 1 and 8 of each cycle, and doxorubicin at 25 mg/m2 on day 1 of Cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy
62358073|NCT01989819||patients with Sjögren's syndrome|A skin biopsy will be performed in patients
62358074|NCT01989819||control group|A skin biopsy will be performed in control group
62358075|NCT01989819||non auto-immune small fiber neuropathies|
62358076|NCT05315141||Xiangya Hospital|
62358077|NCT05315141||The Second Xiangya Hospital|
62358078|NCT05315141||The Third Xiangya Hospital|
62358079|NCT05315141||Hunan Provincial People's Hospital|
62358080|NCT05315141||Xiangtan Central Hospital|
62358081|NCT06376929|ACTIVE_COMPARATOR|oral carbohydrate group|
62358082|NCT06376929|PLACEBO_COMPARATOR|control group|
62358083|NCT04874844|OTHER|Test drug group|Phase II Dose Addition Stage JY025 12MG / KG and 16mg / kg Q3W Givenate Combined EGFRTKI (Gifan Totibi 250mg or Erlotini 150mg) QD scheme, 6 cases of each dose group in group (Gifanibini 3 cases of Erlotini); 1 or 2 doses of JY025 in dose expansion phase Q3W administration combined with EGFR-TKI (50mg or Ellotini 150mg) QD scheme, each dose group 6 Examples of subjects (3 cases of Gifeng Tinib and Ellotini).
62358084|NCT04874844|ACTIVE_COMPARATOR|Group type|Phase III 396 patient JY025 injection and placebo combined with Notes Totibi / Erlotini (Gifeng Totibi 250mg or Erlotini 150mg) Q3W QD treatment group is randomly packet in 1: 1 ratio (in each group) Gifanibi and Erlotini are 2: 1)
62358085|NCT04396288|EXPERIMENTAL|Healthy volunteers|
62358086|NCT02596685|EXPERIMENTAL|Arm A (electronic-cigarette)|"Patients receive nicotine-free and flavor-free electronic cigarettes and instructed to use them BID over a 2 hour period for 4 weeks.~Patients undergo a second bronchoscopy during week 5."
62358087|NCT02596685|EXPERIMENTAL|Arm B (control)|"Patients receive no intervention.~Patients undergo a second bronchoscopy during week 5."
62358088|NCT02596685|EXPERIMENTAL|Arm I (bronchoscopy of the left lung)|Patients undergo bronchoscopy of the left lung over 30-60 minutes.
62358089|NCT02596685|EXPERIMENTAL|Arm II (bronchoscopy of the right lung)|Patients undergo bronchoscopy of the right lung over 30-60 minutes.
62358090|NCT02918656|EXPERIMENTAL|Infographics|Infographic presentation of health information
62358091|NCT02918656|ACTIVE_COMPARATOR|Plain Language Summary|PLS presentation of health information
62358092|NCT02918656|ACTIVE_COMPARATOR|Scientific abstract|Scientific abstract presentation of health information
62358093|NCT00789295|ACTIVE_COMPARATOR|Mediterranean diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%)
62358094|NCT00789295|ACTIVE_COMPARATOR|Low-Carbohydrates diet|Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)
62358095|NCT01195194|EXPERIMENTAL|A- negative pre-transplant ELISPOT|Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml (immunoassay) in the first 3 months, followed by trough levels of 5-10 ng/ml.
62358096|NCT01195194|EXPERIMENTAL|B- Positive pre-transplant ELISPOT|Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml the first 3 months, followed by trough levels of 5-10 ng/ml until the end of the study.
62358097|NCT01248403|ACTIVE_COMPARATOR|paclitaxel + placebo|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ Placebo (2 tablets / day) d1-d28"
62358098|NCT01248403|EXPERIMENTAL|paclitaxel + RAD001|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ RAD001 10mg (2 x5 mg tablets / day) d1-d28"
62358099|NCT02916810|ACTIVE_COMPARATOR|Active rTMS stimulation|
62358100|NCT02916810|SHAM_COMPARATOR|Sham rTMS stimulation|
62358101|NCT05098418||2015|total number of poisoned patients in 2015, including their demographic data
62358102|NCT05098418||2016|total number of poisoned patients in 2016, including their demographic data
62358103|NCT05098418||2017|total number of poisoned patients in 2017, including their demographic data
62358104|NCT05098418||2018|total number of poisoned patients in 2018, including their demographic data
62358105|NCT05098418||2019|total number of poisoned patients in 2019, including their demographic data
62358106|NCT06218199|ACTIVE_COMPARATOR|Diuretic protocol|"If asymptomatic at time of HeartLogic(HL) alert, will add or increase diuretic based on current medications.~If currently taking ≤ 20 mg. furosemide, begin furosemide 40mg orally daily until recovery from alert or re-alert. If currently taking ≥ 40mg furosemide begin torsemide 20 mg orally daily or bumetanide 1 mg orally daily. If patient unable to obtain torsemide or bumetanide double furosemide daily dose (maximum 480mg daily).~If currently taking ≥ 20mg torsemide or ≥ 1mg bumetanide, double daily dose. Recheck HeartLogic index 7 days following initiation of diuretic protocol. If patient recovers from alert consider reducing dose or stopping diuretic. If HeartLogic index is lower but still in alert continue current diuretic dose. If HeartLogic index is the same or higher double diuretic dose and/or add metolazone 2.5mg for 1-2 days."
62358107|NCT06218199|ACTIVE_COMPARATOR|Afterload reduction protocol|"If asymptomatic at time of HL alert, increase afterload reduction drugs based on current medications.~If on Sacubitril/valsartan, double the dose. If on maximum Sacubitril/valsartan, add Hydralazine 10mg and Isordil10 mg both three times a day. If on Angiotensin Receptor Blocker (ARB) at low dose (less than or equal to Valsartan 160mg daily or equivalent) then stop ARB and start sacubitril/valsartan 24-26mg twice a day. If on ARB at high dose (greater than Valsartan 160mg daily or equivalent) then immediately stop ARB and start Sacubitril/valsartan 49-51mg twice a day. If on Angiotensin-converting enzyme (ACE) inhibitor at low dose (less than or equal to 10mg daily or equivalent) then immediately stop ACE inhibitor and start Sacubitril/valsartan 24-26mg twice a day after 48hours. If on ACE inhibitor at high dose (greater than Enalapril 10mg daily or equivalent) stop ACE inhibitor and start Sacubitril/valsartan 49-51mg twice a day after 48hours. Cut diuretic in half for all."
62358108|NCT06218199|NO_INTERVENTION|Observation protocol|Standard therapy offered until development of symptoms of heart failure decompensation occurs. Patients will be monitored until out of alert and at 30, 60, and 90 days.
62358109|NCT02452710|EXPERIMENTAL|Open-Label Placebo|- Placebo Tablets-Twice a day for 3-4 weeks
62358110|NCT02452710|NO_INTERVENTION|NT-Control|- No Placebo Tablets
62358111|NCT03363919|ACTIVE_COMPARATOR|1 Hz left prefrontal rTMS|36 sessions of 1 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 continuous pulses.
62358112|NCT03363919|ACTIVE_COMPARATOR|10 Hz left prefrontal rTMS|36 sessions of 10 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 pulses with 4 seconds on and 36 seconds off.
62358113|NCT05081817||ICU|ICU patients on insulin drip
62358114|NCT04443296|EXPERIMENTAL|CCRT+TIL|Cisplatin based concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
62358115|NCT02562989|EXPERIMENTAL|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of \~185 megabecquerel (MBq) \[18F\]MK-6240 in Part 1 of the study
62358116|NCT02562989|EXPERIMENTAL|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of \~160 MBq \[18F\]MK-6240, in Part 2 of the study
61975385|NCT04566224|ACTIVE_COMPARATOR|Macintosh 3 group|Using Macintosh size 3 blade for direct laryngoscope intubation according to randomization
62358117|NCT02562989|EXPERIMENTAL|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of \~160 MBq \[18F\]MK-6240 in Part 2 of the study
62358118|NCT00578604||Patients with a diabetic wound|Patients with a diabetic wound
62358119|NCT00578604||Control|Patients without a diabetic wound
62358120|NCT02260895|NO_INTERVENTION|Control|Standard 2-hour 75-gram oral glucose tolerance test
62358121|NCT02260895|EXPERIMENTAL|Almond Pre-test snack|1/2 ounce (14 g) almond snack 30 minutes prior to a 2-hour 75-gram oral glucose tolerance test
62358122|NCT00623285|EXPERIMENTAL|Group 1|
62358123|NCT00623285|PLACEBO_COMPARATOR|Group 2|
62358124|NCT00654953|PLACEBO_COMPARATOR|1|Placebo capsules
62358125|NCT00654953|EXPERIMENTAL|2|sertraline (200 mg/day)
62358126|NCT00654953|EXPERIMENTAL|3|sertraline (200 mg/day) plus gabapentin (1,200 mg/day)
62358127|NCT03410134|EXPERIMENTAL|NeoMTA|Vital pulp therapy with NeoMTA
62358128|NCT02091921|EXPERIMENTAL|Experimental|All subjects will receive Ticagrelor.
62358129|NCT05007223||1. Experimental: doxycycline|Given doxycycline and assessment of skin
62358130|NCT05007223||2. No Intervention: Healthy Controls|Control subjects to assess if there is baseline difference in the skin microbiome
62358131|NCT05090683|EXPERIMENTAL|Mind-body mobile application|Participants are asked to engage with a user-guided mobile application (app) that employs mind-based techniques that include: expressive writing, meditation, cognitive behavioural therapy, and pain education. The app also includes access to podcasts that focus on pain counselling and pain education.
62358132|NCT05090683|NO_INTERVENTION|Control|Participants are asked to continue with usual care for pain treatments. They are asked not to start any new forms of treatment.
62358133|NCT01186003|NO_INTERVENTION|Standard insulin drip therapy|
62358134|NCT01186003|ACTIVE_COMPARATOR|Insulin drip and Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
62358135|NCT05216913||Endometrial cancer survivors|
62358136|NCT00220584|EXPERIMENTAL|Open donepezil|open donepezil
62358137|NCT02048267||Alcoholic|
62711888|NCT00060944|EXPERIMENTAL|Yondelis once every 3 weeks schedule|Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.
62711889|NCT02827721||COPD|Patients with known or suspected COPD Patients with known or suspected obstructive ventilation disorder
62358138|NCT02048267||Non alcoholic|
62711890|NCT02827721||pulmonary healthy controls|Patients without known or suspected pulmonary disease
62711891|NCT00706147|PLACEBO_COMPARATOR|1|
62711892|NCT00706147|ACTIVE_COMPARATOR|2|
61975386|NCT02341053|OTHER|Load-measuring platform|"Load-sensing platform A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will gradually increase their duration of standing by up to 75% after the baseline phase."
61975387|NCT04216017|PLACEBO_COMPARATOR|Controls|Patients receiving lidocaine
61975388|NCT04216017|ACTIVE_COMPARATOR|Cases|Patients receiving Kenalog
61975389|NCT04814433|EXPERIMENTAL|Topical lidocaine and bupivacaine alone|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
61975390|NCT04814433|EXPERIMENTAL|Topical lidocaine and bupivacaine with thrombin|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
62358139|NCT04101669|EXPERIMENTAL|RESET|Patients in ARM 1, will receive an upper endoscopy and will be treated with the RESET Liner
62358140|NCT04101669|SHAM_COMPARATOR|Sham|Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the RESET Liner.
62358141|NCT04075539|EXPERIMENTAL|Home-based cycling program associated to usual care|
62358142|NCT04075539|OTHER|Outpatient physiotherapy|
62358143|NCT06184542|EXPERIMENTAL|Intervention (Children aged 6 years, one-dose)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in Children aged 6 years on Day 0
62358144|NCT06184542|ACTIVE_COMPARATOR|DT Control (Children aged 6 years, one-dose)|Diphtheria-Tetanus Combined Vaccine in Children aged 6 years on Day 0
62358145|NCT06184542|EXPERIMENTAL|Intervention (Toddlers aged 18-24 months, one-dose)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in toddlers aged 18-24 months on Day 0
62358146|NCT06184542|ACTIVE_COMPARATOR|DTaP Control (Toddlers aged 18-24 months, one-dose)|Diphtheria-Tetanus-acellular Pertussis Vaccine in toddlers aged 18-24 months on Day 0
62358147|NCT06184542|ACTIVE_COMPARATOR|PENTAXIM Control (Toddlers aged 18-24 months, one-dose)|PENTAXIM (DTaP-IPV-Hib) Vaccine in toddlers aged 18-24 months on Day 0
62358148|NCT06184542|EXPERIMENTAL|Intervention (Infants aged 3 months, three-dose)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in infants aged 3 months on an M3-M4-M5 immunization schedule
62358149|NCT06184542|ACTIVE_COMPARATOR|DTaP Control (Infants aged 3 months, three-dose)|Diphtheria-Tetanus-acellular Pertussis Vaccine in infants aged 3 months on an M3-M4-M5 immunization schedule
62358150|NCT06184542|ACTIVE_COMPARATOR|PENTAXIM Control (Infants aged 3 months, three-dose)|PENTAXIM (DTaP-IPV-Hib) Vaccine infants aged 3 months on an M3-M4-M5 immunization schedule
62358151|NCT06184542|EXPERIMENTAL|Intervention (Infants aged 2 months, three-dose, 2-3-4)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in infants aged 2 months on an M2-M3-M4 immunization schedule
62358152|NCT06184542|EXPERIMENTAL|Intervention (Infants aged 2 months, three-dose, 2-4-6)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in infants aged 2 months on an M2-M4-M6 immunization schedule
62358153|NCT06184542|ACTIVE_COMPARATOR|PENTAXIM Control (Infants aged 2 months, three-dose)|PENTAXIM (DTaP-IPV-Hib) Vaccine infants aged 2 months on an M2-M3-M4 immunization schedule
62358154|NCT04411706|EXPERIMENTAL|Sintilimab+Apatinib+Capecitabine|=Drug: Sintilimab（i.v）+apatinib（p.o）+capecitabine（p.o）
62358155|NCT04635891||MOVE FSHD Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits will occur per standard of care and are anticipated to occur at least once a year.
62358156|NCT00654212|ACTIVE_COMPARATOR|1|endoluminal stenting followed by laparoscopic resection (endo-laparoscopic limb, the study group)
62358157|NCT00654212|OTHER|2|emergency open surgery (open limb, the control group)
62358158|NCT03001323|EXPERIMENTAL|Degludec|Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.
62358159|NCT03001323|ACTIVE_COMPARATOR|Standard long-acting|Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR \<30 ml/hr.
62711893|NCT00960089|EXPERIMENTAL|LIQUICURE|Medical Device
62711894|NCT05857397||Patients treated within the EAPs with niraparib for ovarian cancer|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
62711895|NCT05863455|EXPERIMENTAL|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation.
62711896|NCT05863455|ACTIVE_COMPARATOR|control|Intravenous injection of an equivalent volume of saline before radial artery cannulation.
62711897|NCT02045602|EXPERIMENTAL|Part I: Dose Escalation, Single Agent|Single intravenous injection of VCN-01 oncolytic adenovirus
62711898|NCT02045602|EXPERIMENTAL|Part II: Dose Escalation, Combination|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
62711899|NCT02045602|EXPERIMENTAL|"Part III: Dose Escalation, Combination, delayed schedule"|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
62711900|NCT05338138||the standard blind technique for Central venous catheter insertion into the internal jugular vein.|using the blind experience based technique without imaging guidance
62711901|NCT05338138||ultrasound guided technique for Central venous catheter insertion into the internal jugular vein.|using real time ulrasound guidance
62711902|NCT02950337|EXPERIMENTAL|Group 1: Peripherally Located Tumors|Peripherally Located Tumors - SBRT
62711903|NCT02950337|EXPERIMENTAL|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Peripherally Located Chest Wall Adjacent Tumors - SBRT
62522170|NCT03096847|EXPERIMENTAL|ribociclib + letrozole cohort A|"ribociclib + letrozole cohort A - postmenopausal women, or men; naïve.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily."
62522171|NCT03096847|EXPERIMENTAL|ribociclib + letrozole cohort B1|"ribociclib + letrozole cohort B1 - premenopausal women or perimenopausal women; naïve~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
62522172|NCT03096847|EXPERIMENTAL|ribociclib + letrozole cohort B2|"ribociclib + letrozole cohort B2 - premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
62522173|NCT02334111|NO_INTERVENTION|(Control)|Patients will receive standard of care
62522174|NCT02334111|EXPERIMENTAL|(Intervention)|Patients will receive RESPECT-Plus intervention
62522175|NCT01095042|EXPERIMENTAL|Control group|30 Asymptomatic Healthy Volunteers Intervention : Observation of emotional behavior in asymptomatic healthy volunteers subjected to stress.
62522176|NCT01095042|EXPERIMENTAL|Experimental group|"Persons reached by digestive pathologies (SII or IBD). Group SII : 30 patients Group IBD: 60 patients (30 patients RCH and 30 patients CD)~Intervention : Observation of emotional behavior in person affected by digestive pathologies subjected to stress."
62522177|NCT00562770|ACTIVE_COMPARATOR|1|Valacyclovir
62522178|NCT00562770|ACTIVE_COMPARATOR|2|Valganciclovir
62522179|NCT02470793|ACTIVE_COMPARATOR|DSAEK group|Subjects operated of Descemet Stripping Automated Endothelial Keratoplasty.
62522180|NCT02470793|EXPERIMENTAL|DMEK group|Subjects operated of Descemet Membrane Endothelial Keratoplasty.
62522181|NCT01714375|ACTIVE_COMPARATOR|QuietDose device VOLUNTARY|"This group of employees will voluntarily use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
62522182|NCT01714375|NO_INTERVENTION|No QuietDose device|"This group of employees will not use the QuietDose units and maintain use of their regular hearing protection which may be either ear plugs or ear muffs."
62711904|NCT02950337|EXPERIMENTAL|Group 3: Centrally Located Tumors|Centrally Located Tumors - SBRT
62711905|NCT01623063|EXPERIMENTAL|Infertile|patients from our human reproduction center
62522183|NCT01714375|ACTIVE_COMPARATOR|QuietDose Device REQUIRED|"This group of employees will be required to use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
62522184|NCT05415774|ACTIVE_COMPARATOR|S Stimulation|Standard STN DBS defined as high frequency at 130Hz stimulation
62522185|NCT05415774|EXPERIMENTAL|C1 Stimulation|Combined high frequency stimulation of the STN and SNr using an interleaved pulses at 125Hz
62522186|NCT05415774|EXPERIMENTAL|C2 Stimulation|Combined low frequency stimulation of the SNr at 60Hz and high frequency stimulation of the STN
62522187|NCT01591889|ACTIVE_COMPARATOR|tindamax|500 mg tablet
62522188|NCT01591889|ACTIVE_COMPARATOR|tinidazole|500 mg tablet
62522189|NCT02138136|EXPERIMENTAL|Lubiprostone|"Participants receive lubiprostone twice daily~Participants must have completed the entire 12-week treatment period during the preceding study. Those who received 12 mcg twice daily (BID) continued to receive 12 mcg, those who received 24 mcg BID continued with that dose.Those of the placebo arm in the previous study weighing less than 50 kg received 12 mcg BID and over 50 kg received 24 mcg BID during this study."
62522190|NCT02979236||STEMI treated with STENTYS Xposition S|Patients 18 years of age and older presenting with symptoms consistent with a ST-Elevation Myocardial Infarction (STEMI) lasting ≤12 hrs in duration, with ≥2 mm of ST-segment elevation in ≥2 contiguous leads, treated with primary stent implantation (Xposition S planned per operator's assessment).
62522191|NCT02017730|EXPERIMENTAL|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of \[11C\]BMT-136088
62522192|NCT02017730|EXPERIMENTAL|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of \[11C\]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of \[11C\]BMT-136088
62522193|NCT02017730|EXPERIMENTAL|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of \[11C\]BMT-136088
62711906|NCT01623063|ACTIVE_COMPARATOR|Fertile|patients with comproved fertility
62711907|NCT05104827|EXPERIMENTAL|Healthcare providers|Healthcare providers employed in COVID-19 departments are referred to integrative oncology-trained practitioners for an evaluation of their two main concerns, followed by a 30-minute individually tailored integrative care.
62711908|NCT01205516|EXPERIMENTAL|Methadone|
62711909|NCT01205516|ACTIVE_COMPARATOR|Controlled Release Morphine|Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
62711910|NCT02536664||First-line Stratum|Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
62711911|NCT02536664||Relapsed/Refractory Stratum|Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
62711912|NCT04161664|EXPERIMENTAL|neo adjuvant Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
62711913|NCT00876941|EXPERIMENTAL|Standard Brief Intervention|
62711914|NCT00876941|EXPERIMENTAL|Enhanced Brief Intervention|
62711915|NCT00876941|ACTIVE_COMPARATOR|Control|
62711916|NCT04033458|EXPERIMENTAL|Treatment Sequence ABECD|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B), then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and, then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711917|NCT04033458|EXPERIMENTAL|Treatment Sequence BCADE|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and, then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711918|NCT04033458|EXPERIMENTAL|Treatment Sequence CDBEA|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then, JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then, JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711919|NCT04033458|EXPERIMENTAL|Treatment Sequence DECAB|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regiment 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711920|NCT04033458|EXPERIMENTAL|Treatment Sequence EADBC|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then, JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711921|NCT04033458|EXPERIMENTAL|Treatment Sequence DCEBA|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62358160|NCT06506838|EXPERIMENTAL|Intervention Group|For patients with the soft tissue sarcoma, the treatment regimen includes doxorubicin monotherapy with neoadjuvant and adjuvant chemotherapy cycles, alongside anlotinib and stereotactic body radiation therapy before surgery, followed by radical resection.
61975391|NCT04814433|EXPERIMENTAL|Topical lidocaine and bupivacaine with thrombin and tranexamic acid|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
62358161|NCT04356209|EXPERIMENTAL|EXPERIMENTAL GROUP|ePRO intervention + PRAVASTATINE treatment
62358162|NCT04356209|OTHER|CONTROL GROUP|PRAVASTATINE treatment ( without ePRO)
62358163|NCT03671772||FDRs of idiopathic RBD patients|First-degree relatives of idiopathic RBD patients
62358164|NCT03671772||FDRs of controls|First-degree relatives of controls
62358165|NCT01485432||P group|Group P: Fluid Management according to measurements with PiCCO®
62358166|NCT01485432||C group|Group C: Conventional fluid management
62358167|NCT02820441|EXPERIMENTAL|ZOPICLONE|Zopiclone 3.5 mg capsule by mouth daily for 2 weeks
62358168|NCT02820441|PLACEBO_COMPARATOR|PLACEBO|Placebo 3.5 mg capsule by mouth daily for 2 weeks
62358169|NCT01466478|EXPERIMENTAL|LEO 29102 plus calcipotriol|
62358170|NCT03141892||Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
62358171|NCT05073627|NO_INTERVENTION|Baseline|The investigators measure the baseline of dicloxacillin and the probe drug dabigatran etexilate.
62522194|NCT02017730|EXPERIMENTAL|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with \[11C\]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
61975392|NCT04814433|EXPERIMENTAL|Topical lidocaine and bupivacaine with thrombin and aminocaproic acid|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid
61975393|NCT01401270|NO_INTERVENTION|Treatment Group A|Standard Care
61975394|NCT01401270|EXPERIMENTAL|Treatment Group B|100% probability of winning a prize with each draw and has 3 prize categories
61975395|NCT01401270|EXPERIMENTAL|Treatment Group C|31% probability of winning and has 3 prize categories
62358172|NCT05073627|EXPERIMENTAL|Dicloxacillin treatment|The investigators measure the concentration of dicloxacillin after 9 and 27 days and the concentration of dabigatran after 10 and 28 days of continuously taking dicloxacillin.
62358173|NCT03667508|EXPERIMENTAL|Rapid Maxillary Expansion|Patients will undergo Rapid Maxillary Expansion using a rapid maxillary expanding device, i.e. a Hyrax expander (modified by McNamra).
62358174|NCT03667508|ACTIVE_COMPARATOR|Slow Maxillary Expansion|Patients will undergo Slow Maxillary Expansion using a slow maxillary expanding device, i.e. a removable appliance with a central screw.
62358175|NCT02648243|NO_INTERVENTION|Control|Patients will receive routine discharge instructions and medication information by the nurses and treating physicians at hospital discharge: Patients will not have any contact with the clinical pharmacists.
62358176|NCT02648243|NO_INTERVENTION|Pharmacist delivered usual care at discharge|Patients will receive the usual counseling at discharge by the clinical pharmacists.
62358177|NCT02648243|EXPERIMENTAL|structured intervention at discharge and tailored follow up|The pharmacist will deliver a structured personalized discharge intervention in addition to 2 follow-up session (around 30 minutes each session) at 4 weeks of discharge and 8 weeks of discharge.
62522195|NCT04948580|EXPERIMENTAL|ICC-T|5.5 days with 8 hours of training for teachers aiming at changing attitudes towards violence and equipping teachers with non-violent discipline strategies
62522196|NCT04948580|NO_INTERVENTION|Monitoring condition|No intervention
62711922|NCT04033458|EXPERIMENTAL|Treatment Sequence EDACB|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711923|NCT04033458|EXPERIMENTAL|Treatment Sequence AEBDC|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and then JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711924|NCT04033458|EXPERIMENTAL|Treatment Sequence BACED|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711925|NCT04033458|EXPERIMENTAL|Treatment Sequence CBDAE|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
62711926|NCT02835690|EXPERIMENTAL|Pembrolizumab 2 mg/kg|Participants will receive pembrolizumab 2 mg/kg administered intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62711927|NCT02835690|EXPERIMENTAL|Pembrolizumab 10 mg/kg|Participants will receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62711928|NCT02835690|EXPERIMENTAL|Pembrolizumab 200 mg Fixed Dose|Participants will receive pembrolizumab 200 mg fixed dose administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
62711929|NCT00716274|EXPERIMENTAL|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
62711930|NCT00716274|PLACEBO_COMPARATOR|Placebo|Placebo will be packaged in the same way as active comparator to enforce double-blind study design
62711931|NCT03525509|EXPERIMENTAL|Epidural methadone|A single 4mg epidural bolus of methadone hydrochloride
62711932|NCT03525509|ACTIVE_COMPARATOR|Epidural morphine|A single 4mg epidural bolus of morphine sulfate
62358178|NCT04154917|EXPERIMENTAL|Experimental|HOME will be delivered by a community-based OT, who will be involved in the hospital discharge planning, trained by the PI. The HOME intervention comprises 4 phases: Phase 1 (in hospital): The clinician will focus on building a rapport with the patient and family members. Information will be gathered about the participant's home environment and functional ability. Phase 2 (± 5 days prior to expected discharge): Clinician will conduct a pre-discharge home assessment with patient and family to evaluate the environment, identify potential problems, and suggest appropriate ways to address them. Phase 3 (\<1 week after discharge): Post-discharge home assessment will be conducted to provide additional in-home training and follow up on any of the patient's unmet needs. Phase 4 (2-4 weeks post-discharge): Follow-up telephone calls will be made to provide ongoing support to participant and family and encourage self-problem solving and independence.
62711933|NCT03218865|EXPERIMENTAL|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
62711934|NCT03218865|ACTIVE_COMPARATOR|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
62711935|NCT01729039|EXPERIMENTAL|gaze stability|standard balance rehabilitation plus vestibular-specific exercises
62358179|NCT04154917|NO_INTERVENTION|Usual care|Usual care group will receive the customary discharge planning assessment by a different clinician (OT). During this assessment, according to usual care, information regarding the participants' ability to perform activities of daily living and regarding their home environment is gathered and used to plan for discharge. Usual care group will not receive an OT home assessment as this is not part of usual care. If the clinician identifies a potential need for assistive equipment and home modification needs, patients will be referred to community-based homecare services as is the current practice, and a home visit may be performed following discharge, typically after an lengthy wait (weeks, months) for service.
62522197|NCT02409602||Women with BIIAL|Women who underwent bilateral internal iliac artery ligation due to postpartum hemorrhage within last 2 months
61975396|NCT01401270|EXPERIMENTAL|Treatment Group D|100% probability of winning and has 7 prize categories
61975397|NCT01401270|EXPERIMENTAL|Treatment Group E|31% probability of winning and has 7 prize categories
62522198|NCT02409602||Healthy puerperal women|Age-matched healthy puerperal women who delivered within last 2 months
62711936|NCT01729039|PLACEBO_COMPARATOR|control|standard balance rehabilitation plus placebo eye exercises
62711937|NCT06341894|EXPERIMENTAL|Treatment|Dalpiciclib and endocrine therapy
62150413|NCT04140526|EXPERIMENTAL|ONC-392 in combination with pembrolizumab|"The Part B1 study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of pembrolizumab. The dose for pembrolizumab will be fixed at 200mg/cycle dosed every 21 days (Q3W).~The Part B1 will start at one level below RP2D-M dose for ONC-392 and 200mg of pembrolizumab. When 2 DLTs occur before 6 patients are enrolled, the ONC-392 dose will be decreased to the next dose level until ≤ 1/6 patients treated at that dose develops a DLT. This dose level will be designated RP2D-C.~In Part C, the expansion cohorts Arm D to G will assess the safety and efficacy of ONC-392 in different dose levels and Pembrolizumab combination therapy in non small cell lung cancer, and metastatic melanoma."
62150414|NCT04140526|EXPERIMENTAL|ONC-392 and docetaxel|Part E Arm O will test ONC-392 in combination with docetaxel, IV infusion, Q3W, in PD-1 resistant NSCLC patients.
62150415|NCT05224245|EXPERIMENTAL|Single arm: ACURATE Prime XL Transfemoral Aortic Valve System|Subjects who provide written informed consent, meet all eligibility criteria, and are approved by the Case Review Committee (CRC) will be implanted with ACURATE Prime XL Transfemoral Aortic Valve using iSLEEVE, ACURATE Prime XL Delivery System and ACURATE Prime XL Loading kit
62150416|NCT02065297||Horton's disease|
61975398|NCT01401270|EXPERIMENTAL|Treatment Group F|usual prize contingency management with a 50% probability of winning from 3 prize categories
61975399|NCT00278655|EXPERIMENTAL|Hematopoietic stem cell transplantation|All participants will undergo hematopoietic stem cell transplantation after receiving conditioning regimen.
62150417|NCT02065297||Infectious disease|
62150418|NCT02065297||Neoplasia|
62150419|NCT02065297||Control|
62150420|NCT04179526|EXPERIMENTAL|Transdiagnostic Internet-delivered REBT|Protocol is based on Rational Emotive Therapy (Ellis, 1962, 1994), structured in 8 modules delivered over 6 weeks (Module 1- Introduction and psychoeducation about emotions, Module 2 - Psychoeducation anxiety and depression, Module 3 - Relaxation, Module 4 - Negative patterns of thinking and cognitive restructuring, Module 5 - Problem solving, Module 6 - Exposure and Behavioral activation, Module 7 - Positive emotions and Module 8 - Gaining maintenance)
62150421|NCT04179526|NO_INTERVENTION|Waitlist|Participants in the control group will complete pre-treatment and post-treatment assessments. After participants in the experimental group complete post-treatment assessment, they will receive the intervention.
62150422|NCT05670561|EXPERIMENTAL|Esketamine-PCIA(patient controlled intravenous analgesia)|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.
62150423|NCT05670561|ACTIVE_COMPARATOR|Sufentanil-PCIA(patient controlled intravenous analgesia)|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.
62522199|NCT03977974|EXPERIMENTAL|LY3526318 - Part A|LY3526318 administered orally once.
62522200|NCT03977974|PLACEBO_COMPARATOR|Placebo - Part A|Placebo administered orally once.
62150424|NCT00691340||1|Control 1 (young subjects)
62522201|NCT03977974|EXPERIMENTAL|LY3526318 - Part B|LY3526318 administered once orally on consecutive days.
62522202|NCT03977974|PLACEBO_COMPARATOR|Placebo - Part B|Placebo administered once orally on consecutive days.
62522203|NCT05199766|EXPERIMENTAL|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks, in case of discontinuation due to patient's wishes and/or adverse event above grade 2 : 1000mg during 14 days then complete discontinuation if no resolution. In case of sudden discontinuation a therapeutic phlebotomy will be authorized.
62522204|NCT04323020|EXPERIMENTAL|Comatose cardiac arrest patients|Comatose cardiac arrest patients will be undergoing CT perfusion test
62150425|NCT00691340||2|Control 2 (old subjects)
62150426|NCT00691340||3|Glaucoma patients
62150427|NCT00691340||4|Alzheimer patients
62150428|NCT06413888|ACTIVE_COMPARATOR|Group A ( No NGT)|
62150429|NCT06413888|ACTIVE_COMPARATOR|Group B (NGT Retained)|
62150430|NCT00691691|EXPERIMENTAL|1|Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
62150431|NCT00824850|EXPERIMENTAL|1|Subjects received Prevnar in study D118-P8
62150432|NCT00824850|EXPERIMENTAL|2|Subjects received MnCC in study D118-P8
62150433|NCT01714908|EXPERIMENTAL|Erlotinib w Concurrent Radiotherapy|erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.
62150434|NCT01714908|ACTIVE_COMPARATOR|etoposide/cis-platin (EP) w Concurrent Radiotherapy|etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.
62522205|NCT06088849|OTHER|Lactating mothers taking ACE-inhibitors|Lactating mothers who are breastfeeding their infant (0-6 months) while taking ACE-inhibitors.
62522206|NCT02537847|EXPERIMENTAL|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
62522207|NCT02537847|ACTIVE_COMPARATOR|control group|Intervention was prescribed ertapenem for patients.
62711938|NCT05702307|EXPERIMENTAL|Glucose as reference food|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61975400|NCT01808053||Healthy older and independently living adults|The BodyGuardian remote health monitoring system will used by healthy older and independently living adults
62522208|NCT06141824|EXPERIMENTAL|Subject Self-Collection and Specimen Testing|"A subject's participation in this study will consist of one study visit. The subject self-collects a nasal swab sample according to Lucira COVID- 19 \& Flu Test instructions and runs test according to QRI.~Following the Lucira COVID-19 \& Flu Test self-collection will be an additional swab collection for reference method testing. One (1) additional NS specimen will be collected by the healthcare professional, prepared in Transport Medium, and sent to the reference laboratory."
62522209|NCT05018520|EXPERIMENTAL|4RCHOP+4R|Four Courses of R-CHOP Plus Four Courses of Rituximab
62522210|NCT05018520|EXPERIMENTAL|6RCHOP+2R|Six Courses of R-CHOP Plus Two Courses of Rituximab
62522211|NCT02405949||T2D 40%EWL|15 pacients who had type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
62522212|NCT02405949||nonT2D40%EWL|15 pacients without type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
62522213|NCT02405949||T2D75%EWL|35 pacients who had type 2 diabetes befor bariatric surgery and presented with more than 75% of the excess weight loss after 12 month from surgery.
62522214|NCT02405949||nonT2D75%EWL|35 pacients without type 2 diabetes befor bariatric surgery and who presented with more than 75% of the excess weight loss after 12 month from surgery.
62522215|NCT06492200|EXPERIMENTAL|Intervention Group|
62522216|NCT06492200|NO_INTERVENTION|Control Group|
62522217|NCT03915665|ACTIVE_COMPARATOR|Standard treatment|Manual treatment One application of Chlorhexidine 1% gel
62522218|NCT03915665|EXPERIMENTAL|Comprehensive treatment|Supragingival biofilm removal with Erythritol air-powder Submucosal biofilm removal with Erythritol air-powder (30%-60% power)
62522219|NCT02025751|EXPERIMENTAL|Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
62522220|NCT02025751|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
62522221|NCT04736563|EXPERIMENTAL|patients with painful arthritis of the knee|Administration of joints and muscle gel Puressentiel containing of 14 essential oils
62522222|NCT03248453|EXPERIMENTAL|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
62522223|NCT03248453|NO_INTERVENTION|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
62150435|NCT03152214|EXPERIMENTAL|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:~* 1 session of exercise counseling~* 3 weekly 25-minute sessions of vigorous intensity aerobic exercise~* 1 weekly Team RWB event~* 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
62150436|NCT03152214|ACTIVE_COMPARATOR|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:~* 1 weekly Team RWB event~* 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
62150437|NCT03152214|NO_INTERVENTION|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:~• 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
62522224|NCT05855486|EXPERIMENTAL|Eyedrops treatment arm|
62522225|NCT05689593|ACTIVE_COMPARATOR|Low-intensity ESWT Group|low intensity extracorporeal shock wave therapy will be applied to patients shoulder, also patients will receive a conventional therapy program consisting of hotpack and exercises
62522226|NCT05689593|ACTIVE_COMPARATOR|Low-intensity laser Group|low intensity laser will be applied to patients shoulder, also patients will receive a conventional therapy program consisting of hotpack and exercises
62522227|NCT05689593|OTHER|Conventional Control Group|patients will receive a conventional therapy program consisting of hotpack and exercises
62522228|NCT02249676|EXPERIMENTAL|Autologous mesenchymal stem cells group|"Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .~MSC a day-case 2·0×106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v."
62522229|NCT02249676|PLACEBO_COMPARATOR|Control group|Patients with progressive and refractory NMO treated with regular methods
62522230|NCT03185403|ACTIVE_COMPARATOR|continous paravertebral block|"echoguided thoracic continous paravertebral block was placed before the surgery.~A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required."
62522231|NCT03185403|ACTIVE_COMPARATOR|continous Thoracic epidural block|thoracic epidural catheter was inserted before the surgery. A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required.
62522232|NCT02719106||Ultimaster stent|
61975401|NCT05079295||Group 1|Patients taking anticoagulants or antithrombotics
62522233|NCT05200962|EXPERIMENTAL|Active tDCS group|The experimental arm receives real (or active) electrical stimulation for 20 minutes
61975402|NCT05079295||Group 2|Controls
62522234|NCT05200962|SHAM_COMPARATOR|sham tDCS group|The sham arm receives sham (or no real) intervention in which stimulation lasts for 30 seconds and ends afterward.
62522235|NCT03325400|OTHER|Non-fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
62711939|NCT05702307|EXPERIMENTAL|Tagliatelle Control|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62150438|NCT01575704|EXPERIMENTAL|Sport|
62150439|NCT01575704|OTHER|Control|
62522236|NCT03325400|ACTIVE_COMPARATOR|Fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
62522237|NCT01181271|EXPERIMENTAL|Autologous then Allogeneic transplant|"All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.~Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.~Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD)."
62522238|NCT05713552|EXPERIMENTAL|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear two different study lenses, one at a time, over two wear periods (test then control) with a washout period of 15 minutes between wears. During each wear period the lenses will be worn bilaterally for at least one hour in-office.
62711940|NCT05702307|EXPERIMENTAL|5% sunflower tagliatelle|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
61975403|NCT01116869||MBC patients|300 MBC patients, each of whom will provide a series of at least 3 blood draws (baseline, 3-4 weeks and 6-8 weeks after the initiation of the systemic therapy) for CTC analysis, will be enrolled. All MBC patients will be followed for a maximum of 36 months for disease progression and survival.
61975404|NCT01116869||Benign disease volunteers|100 Benign disease volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
61975405|NCT01116869||Healthy volunteers|100 Healthy volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
62150440|NCT02264847|ACTIVE_COMPARATOR|Clomiphene citrate plus hCG|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response could be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size . Women will receive 5,000 IU human chorionic gonadotrophin trigger in the morning between 9 and 10 a.m. and the couple will be advised to have intercourse the following night, about 36 hours later.
62150441|NCT02264847|ACTIVE_COMPARATOR|Clomiphene Citrate alone|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response will be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size , the women will be advised to have intercourse frequently over the next few days.
62150442|NCT06245564|EXPERIMENTAL|Cream application|This subproject will be conducted in two sessions one week apart. Each session will last approximately 3 hours. In each forearm of the participant, two 4x4 cm areas will be selected as Area of Interest (AOI). In these selected areas, the four different creams will be applied in a randomized position for 1½ hours. After the cream removal, itch will be induced using histamine in one session and cowhage in the other session (the order of histamine and cowhage will be randomized). During the application of the substances, the itch/pain elicited will be monitored for 10 minutes using a VAS (Visual analog scale). After the removal of the substances, measurements of SBP, TP, MEI, MPT, MPS, and thermal sensitivity will be conducted.
62150443|NCT04755309|EXPERIMENTAL|Typical development infants - experimental|Children without familial risk for language disorders, who participate to the rhythmic intervention.
62150444|NCT04755309|NO_INTERVENTION|Typical development infants - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
62150445|NCT04755309|ACTIVE_COMPARATOR|Typical development infants - control|Children without familial risk for language disorders, who are exposed to passive auditory stimulation.
61975406|NCT01539356||preterm infants|"preterm infants receiving blood transfusion~preterm infants with neonatal sepsis."
61975407|NCT05916391|EXPERIMENTAL|FT003 Dose 1|Low dose of FT-003
61975408|NCT05916391|EXPERIMENTAL|FT003 Dose 2|Mid dose of FT-003
61975409|NCT05916391|EXPERIMENTAL|FT003 Dose 3|High dose of FT-003
61975410|NCT03905746||acute decompensation group|patients admitted within 48 hours for acute decompensation of cirrhosis, with or without evidence of sepsis
61975411|NCT03905746||Pathological control group|patients with Chronic Liver Disease (CLD), also named stable cirrhotic patients, without any admission in the last 6 months for an acute event
62711941|NCT05702307|EXPERIMENTAL|16% sunflower tagliatelle|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62711942|NCT05702307|EXPERIMENTAL|16% sunflower penne|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62522239|NCT05713552|EXPERIMENTAL|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear two different study lenses, one at a time, over two wear periods (control then test) with a washout period of 15 minutes between wears. During each wear period the lenses will be worn bilaterally for at least one hour in-office.
62522240|NCT02792959|EXPERIMENTAL|Functional imaging|A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
62522241|NCT00223353||Lower Limb Amputee|
62522242|NCT00223353||Amputee and Normals and Clinical Case Study|"Amputee:~Lower limb below/above knee amputee~Normals:~Health adult~Clinical Case Study:~Individual case studies"
62522243|NCT00996931|EXPERIMENTAL|Lenalidomide|
62522244|NCT04131049|EXPERIMENTAL|Carbohydrate Counting|The insulin doses of the breakfasts were calculated according to carbohydrate counting.
62522245|NCT04131049|EXPERIMENTAL|Food Insulin Index|The insulin doses of the breakfasts were calculated according to food insulin index.
62522246|NCT01159782|OTHER|Asthma, Healthy|Asthmatics or Healthy Volunteers
62522247|NCT05356143|OTHER|Sequence 1|Subjects will take comparator and active drug at different study periods Treatment sequence AAB
62522248|NCT05356143|OTHER|Sequence 2|Treatment sequence ABA
62522249|NCT05356143|OTHER|Sequence 3|Treatment sequence BAA
62522250|NCT04698148||CDI patients|Patients with Clostridium Difficile Infection
62522251|NCT04698148||MDRO patients|Patients with Multi Drug Resistant Organisms infection
62522252|NCT04698148||IBD patients|Patients with Chronic Inflammatory Bowel Disease
62522253|NCT04698148||IBS patients|Patients with Irritable Bowel Syndrome
62522254|NCT04698148||Hepatic Encephalopathy patients|Patients with Hepatic Encephalopathy
62150446|NCT04755309|EXPERIMENTAL|Infants at familial risk - experimental|Children with familial risk for language disorders, who participate to the rhythmic intervention.
62522255|NCT04698148||healthy volunteers|healthy volunteers
62522256|NCT03418506|EXPERIMENTAL|Intervention|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
62150447|NCT04755309|NO_INTERVENTION|Infants at familial risk - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
62150448|NCT05326685|EXPERIMENTAL|Intervention|video with korotkoff sounds
62150449|NCT05326685|NO_INTERVENTION|Control|standart practice
62150450|NCT05205083|EXPERIMENTAL|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
62150451|NCT05272202|EXPERIMENTAL|Median nerve stimulation|
62150452|NCT06517576|EXPERIMENTAL|Remote patient monitoring and automated patient engagement system with blood glucose monitors|Participants in this group will receive blood glucose monitors and will check their blood glucose daily with monitoring through a digital platform and provided health coaching.
62150453|NCT06517576|EXPERIMENTAL|Self-monitoring program with continuous glucose monitors|Participants in this group will receive continuous glucose monitors and will self monitor their blood glucose measurements with support by their care team.
62522257|NCT03418506|NO_INTERVENTION|Control|No specific education will be given to the control group.
62522258|NCT03421782|EXPERIMENTAL|Exercise - Arm I|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks.
62522259|NCT03421782|EXPERIMENTAL|Exercise plus PROSPECT Cognitive Behavior Therapy (CBT)|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks. Patients also undergo PROSPECT internet-based CBT intervention over 12 weeks.
62522260|NCT00608517|EXPERIMENTAL|Pediatric Myeloablative conditioning|Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
62711943|NCT05702307|EXPERIMENTAL|16% sunflower fusilli|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
62711944|NCT02951260|EXPERIMENTAL|Metformin|17 days metformin treatment
62711945|NCT02951260|PLACEBO_COMPARATOR|Placebo|17 days placebo treatment
62711946|NCT01114984||10% after breast biopsy|Incidence Post-operative pain after breast surgery.
62711947|NCT01114984||20% after lumpectomy|Incidence Post-operative pain after breast surgery
62711948|NCT01114984||30% after simple mastectomy|Incidence Post-operative pain after breast surgery
62150454|NCT06517576|ACTIVE_COMPARATOR|Usual care group receiving standard care|Participants in this group will receive standard care for diabetes.
61975412|NCT06347536|EXPERIMENTAL|Supported Rescue Pack Arm|All patients in the SRP arm will receive 1) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan, with patients asked to press the telephone keys 0-9 depending on the answer to the questions. Any patient that has required the use of their rescue pack within 90 days of discharge, will be re-issued with a rescue pack by the central study team and will be sent to the patient home.
61975413|NCT06347536|NO_INTERVENTION|No Rescue Pack Arm|In this arm, patients will be randomised to receive no rescue packs on discharge. We will very carefully characterise the support provided to people in this arm, upon discharge from hospital, including any access to rescue packs in the community (which we will report, but not modify).
62522261|NCT00608517|EXPERIMENTAL|Adult Myeloablative conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
62522262|NCT00608517|EXPERIMENTAL|Reduced-intensity conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
62522263|NCT01021982||Glaucoma|Glaucoma Patients with visual field defects
62522264|NCT01021982||Retinitis Pigmentosa|Retinitis Pigmentosa Patients with visual field defects
62522265|NCT02799238|ACTIVE_COMPARATOR|Radiotherapy in combination with Temozolomide (TMZ)|radiotherapy combined with TMZ treatment followed by adjuvant TMZ
62522266|NCT02799238|EXPERIMENTAL|ALECSAT + Radiotherapy in combination with TMZ|3 doses of ALECSAT /4 weeks followed by ALECSAT every 3 months
61975414|NCT03021265||T80/A5/H12.5 FDC|Patients with hypertension
62150455|NCT04112563|ACTIVE_COMPARATOR|WLI-LCI group|a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI
62711949|NCT01114984||50% after mastectomy with reconstruction|Incidence Post-operative pain after breast surgery
62711950|NCT01114984||50% after radical mastectomy|Incidence Post-operative pain after breast surgery
62150456|NCT04112563|ACTIVE_COMPARATOR|LCI-WLI group|a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)
62150457|NCT02789514||children|Investigators give observation to the patients who need esophagogastroduodenoscopic procedures.
62150458|NCT06134557||flow diverter stents|single flow diverter(FD) stents or flow diverter assisted coil
62150459|NCT06134557||conventional stents|stent-alone or overlapping stent treatment ,stent-assisted coiling techniques
62150460|NCT02174146|OTHER|non-surgical therapy|non-surgical periodontal therapy with ultrasonic scalers and periodontal curettes
62150461|NCT02826954||COPD patients|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
62522267|NCT00321737|EXPERIMENTAL|Dexlansoprazole MR 30 mg QD|
62522268|NCT00321737|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62522269|NCT00321737|PLACEBO_COMPARATOR|Placebo|
62522270|NCT06180317|EXPERIMENTAL|Virtual reality group|Virtual reality to be applied to women undergoing endometrial biopsy.
62522271|NCT06180317|NO_INTERVENTION|Control group|Participants in this group will consist of people who do not routinely do any practive on their own to reduce anxiety and pain during endometrial biopsy.
62711951|NCT01114984||50% after radi mastectomy+reconstruction|Incidence Post-operative pain after breast surgery after radical mastectomy with reconstruction
62711952|NCT01114984||40% after cosmetic augmentation|Incidence Post-operative pain after breast surgery
62711953|NCT01114984||40% after breast reduction|Incidence Post-operative pain after breast surgery
62711954|NCT03189732|EXPERIMENTAL|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
62711955|NCT03189732|ACTIVE_COMPARATOR|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
62711956|NCT03189732|ACTIVE_COMPARATOR|No metformin + exercise|60min physical exercise without pretreatment of metformin
62711957|NCT01326442|EXPERIMENTAL|diet only|low glycemic index diet, calorie restricted with exercise 3 times per week.
62711958|NCT01326442|ACTIVE_COMPARATOR|supplemented|2000 IU vitamin D3 plus 1.8 g EPA + DHA
62522272|NCT06414460|EXPERIMENTAL|Part 1 Dose Escalation|Patients will receive ISM3412 once daily in sequential cohorts of increasing doses.
62522273|NCT06414460|EXPERIMENTAL|Part 2 Dose Selection Optimization|Participants will be randomized to receive one of the two selected dose levels of ISM3412 once daily determined by Study Review Committee.
62522274|NCT04397445|EXPERIMENTAL|Ranitidine and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of ranitidine (300 mg) plus low nitrite/NDMA meals (noncured-meats diet)
62522275|NCT04397445|PLACEBO_COMPARATOR|Placebo and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of placebo plus low nitrite/NDMA meals (noncured-meats diet)
62522276|NCT04397445|EXPERIMENTAL|Ranitidine and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of ranitidine (300 mg) plus high nitrite/NDMA meals (cured-meats diet)
62522277|NCT04397445|PLACEBO_COMPARATOR|Placebo and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of placebo plus high nitrite/NDMA meals (cured-meats diet)
62522278|NCT03918109|EXPERIMENTAL|OTO-313|
62522279|NCT03918109|PLACEBO_COMPARATOR|Placebo|
62150462|NCT02826954||Healthy subjects|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
62522280|NCT03987594|PLACEBO_COMPARATOR|TUF|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
61975415|NCT01148940||White women with Hb AA|White pregnant and postpartum women with Hb AA
61975416|NCT01148940||Black women with Hb AA|Black pregnant and postpartum women with HbAA
61975417|NCT01148940||Black women with Sickle Trait|Black pregnant and postpartum women with HbAS
62522281|NCT03987594|EXPERIMENTAL|TUF+HD|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
62522282|NCT05814003|EXPERIMENTAL|hydroxylate flavones|flavonoids mainly derived from citrus peel and have numerous strong biological activities, including anti-inflammatory , antioxidant , antimicrobial , and anticancer
62522283|NCT05814003|ACTIVE_COMPARATOR|alveogyl|ALVOGYL is a brown fibrous paste which contains per 100 g the following active ingredients : 25.70 g of butamben, 15.80 g of iodoform and 13.70 g of eugenol.
62522284|NCT05814003|PLACEBO_COMPARATOR|stent|acrylic resin material used to cover denuded soft tissues
62522285|NCT05742698|ACTIVE_COMPARATOR|Nabilone|"Weeks 1-2 Nabilone and placebo will be taken orally by the patient as per the schedule provided by the research team. All patients will start with one 0.5mg capsule per day, taken before bed for the first week and then increase administration to the 1mg capsule taken before bed for the second week.~Weeks 3-4 Two weeks after the start of the trial patients and study partners will attend an in person or remote Interim Assessment. If remission is not achieved and no clinically significant adverse drug reactions are reported then the dose schedule will increase to 2 capsules per day (2mg/day), 1 capsule in the morning and 1 before bed.~Weeks 5-6 Four weeks after the start of the trial there will be a second in person or remote Interim Assessment identical to the first. If remission of agitation has not been achieved and no adverse drug reactions are reported the dose schedule will increase to 4 tablets per day (4mg/day), with 2 tablets in the morning and 2 before bed."
62522286|NCT05742698|PLACEBO_COMPARATOR|Placebo|"Weeks 1 and 2 Participants will receive one capsule per day to be taken orally before bedtime.~Weeks 3-4 Participants will receive 2 capsules per day, one in the morning and one before bedtime.~Weeks 5-6 Participants will receive 2 capsules per day, one in the morning and one before bedtime.~The placebo dosing regimen is designed to be as similar as possible to the nabilone dosing regime, including using identical capsules."
62522287|NCT04899193|EXPERIMENTAL|Sequence 1: First Reference, Then Test 1, Then Test 2|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
62522288|NCT04899193|EXPERIMENTAL|Sequence 2: First Test 1, Then Test 2, Then Reference|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
62150463|NCT01759966||Heart transplant recipients|Patients receiving orthotopic heart transplant in the enrollment period
62522289|NCT04899193|EXPERIMENTAL|Sequence 3: First Test 2, Then Reference, Then Test 1|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
62522290|NCT04899193|EXPERIMENTAL|Sequence 4: First Reference, Then Test 2, Then Test 1|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
62522291|NCT04899193|EXPERIMENTAL|Sequence 5: First Test 1, Then Reference, Then Test 2|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
62711959|NCT04700150|EXPERIMENTAL|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
62711960|NCT04700150|PLACEBO_COMPARATOR|Control group B|2 tai chi session per week during 2 month (M2 to M4)
61975418|NCT06370832|EXPERIMENTAL|IMT and exercise training group|Participants in the IMT and exercise training group will perform twice daily 30-breath IMT sessions and exercise training sessions three times per week as part of their usual care during the pre-lung transplant phase. The exercise training is comprised of aerobic, resistance and flexibility training.
61975419|NCT06370832|NO_INTERVENTION|Usual care group|Participants in the usual care group will take part in the standard of care rehabilitation program provided during the waitlist phase prior to the transplant. Exercise training is performed at least three times per week for the duration of the waitlist period. The exercise training includes a combination of supervised in-person visits and home-based training that incorporates aerobic, resistance and flexibility training.
62150464|NCT01759966||Healthy controls|Healthy control subjects, having the same age and sex distribution as the heart transplant recipients
62358180|NCT02681718|EXPERIMENTAL|Community Health Worker education|During a six-month intervention period, the CHWs will conduct six home-based visitations and provide individualized diabetes education using an intensive diabetes lifestyle curriculum called Diabetes Learning Circle (DLC), developed and used by the Sinai Diabetes Education Program. At each visit, lasting for approximately one hour, the participants will be motivated to set SMART behavioral goals for diabetes self-management. At each visit after the initial visit, CHWs will follow-up with each participant to check their progress on their behavioral SMART goals. In addition, the CHWs will conduct intermittent phone calls (at least one monthly) and home visits as needed.
62358181|NCT02681718|EXPERIMENTAL|Cell phone text messaging|The participants in the text messaging group will receive weekly text messages through CareMessage. Each participant will receive 3-4 text messages per week for 6 months.
62358182|NCT02681718|NO_INTERVENTION|Control|The participants in the control group will receive education as determined by the hospital's diabetes educator, dietitian, physician, or the participant's managed care provider. No additional education will be provided by the research team.
62358183|NCT02773368|EXPERIMENTAL|IDegLira|
62358184|NCT02773368|ACTIVE_COMPARATOR|IGlar|
62358185|NCT02335203|EXPERIMENTAL|Depot medroxyprogesterone acetate|Women randomized to receive one intramuscular injection of 400mg depot medroxyprogesterone acetate prior to hysterectomy.
62358186|NCT02335203|PLACEBO_COMPARATOR|Placebo injection|Women randomized to receive one intramuscular injection of 1mL normal saline prior to hysterectomy.
62358187|NCT06094972|EXPERIMENTAL|TAU + A-CRA|"TAU: Interventions and treatments usually offered and delivered in institutional care. See below for examples.~12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Examples of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to meet youth individual goals and needs."
62358188|NCT06094972|ACTIVE_COMPARATOR|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
62358189|NCT01410162|ACTIVE_COMPARATOR|Advagraf|
62358190|NCT01410162|ACTIVE_COMPARATOR|Prograf|
62358191|NCT03954249|EXPERIMENTAL|Erector Spinae nerve block group|Receive multimodal analgesia and in addition erector spinae plane block
62358192|NCT03954249|ACTIVE_COMPARATOR|Multimodal Analgesia group|Receive standard multimodal analgesia
62358193|NCT05340491|EXPERIMENTAL|Chemoradiotherapy+anti-PD-1|Patients in this arm will receive three cycles of GP chemotherapy plus PD-1 antibody, then receive IMRT and PD-1 antibody maintenance for eight cycles.
62358194|NCT05340491|ACTIVE_COMPARATOR|Chemoradiotherapy|Patients in this arm will receive three cycles of GP chemotherapy, then receive IMRT.
62358195|NCT04667052|EXPERIMENTAL|JNJ 64304500: Reference|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 reference formulation.
62358196|NCT04667052|EXPERIMENTAL|JNJ 64304500: Test|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 test formulation.
62358197|NCT01525056|OTHER|imaging with ct, mri and pet scans|ct,mri and pet scans pre and post radiation
62711961|NCT02553629|ACTIVE_COMPARATOR|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
62711962|NCT02553629|EXPERIMENTAL|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
62358198|NCT01039818|ACTIVE_COMPARATOR|Radiodine-200µCi|A subgroup of patients with Graves' Disease and goiter ≥48ml treated with 200µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU, from a randomized controlled trial run at our institution between February 1997 and March 2000, serves as a historical control.
62358199|NCT01039818|EXPERIMENTAL|Radiodine-250µCi|Patients with Graves' Disease and goiter ≥48ml, prospectively assigned to receive 250 µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU.
62358200|NCT02089321||Patients with Low Back Pain|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years Currently seeking, but not yet initiated, treatment from a health care professional (PT, MD, DO, DC) for a chief complaint of pain between the level of the twelfth thoracic vertebrae and the coccyx Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~Signs of neurological impairment including diminished myotatic reflex, sensory impairment or strength deficits in a myotomal pattern No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
62358201|NCT02089321||Healthy Controls|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years No LBP episodes requiring clinical care by a health professional and/or greater than 3 days absence from work/school/recreation within the previous 5 years Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
62358202|NCT01721512||Breast-fed infants|80 infants of mothers who plan to exclusively breastfeed for at least 6 months.
62358203|NCT01721512||Formula-fed infants|"1. Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.~2. Mother consents to her infant receiving trial infant formula for 12 months"
62358204|NCT05430672|OTHER|Subjects with aortic dissection|Subjects receive endovascular treatment.
62358205|NCT03145597|EXPERIMENTAL|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
61975420|NCT00820157|ACTIVE_COMPARATOR|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE
61975421|NCT00820157|EXPERIMENTAL|TACE|TACE alone
62522292|NCT04899193|EXPERIMENTAL|Sequence 6: First Test 2, Then Test 1, Then Reference|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
62522293|NCT03346070|EXPERIMENTAL|Sugammadex 2 mg/kg ABW|Following administration of NMBA, participants received a single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
61975422|NCT03141242|ACTIVE_COMPARATOR|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
61975423|NCT03141242|PLACEBO_COMPARATOR|Mailed Resources|Participants will receive printed advance care planning resources by mail.
62522294|NCT03346070|EXPERIMENTAL|Sugammadex 2 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 2 mg/kg as determined utilizing participant IBW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
62522295|NCT03346070|EXPERIMENTAL|Sugammadex 4 mg/kg ABW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant ABW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
62522296|NCT03346070|EXPERIMENTAL|Sugammadex 4 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant IBW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
62522297|NCT03346070|ACTIVE_COMPARATOR|Neostigmine/Glycopyrrolate|Following administration of NMBA, participants received a single i.v. bolus containing both Neostigmine (50 µg/kg; up to 5 mg maximum dose) and Glycopyrrolate (10 µg/kg; up to 1 mg maximum dose) as determined utilizing participant ABW. Neostigmine/Glycopyrrolate was used for reversal of moderate NMB. Active comparator treatment for reversal for deep NMB was not available.
62522298|NCT04440319|EXPERIMENTAL|Intervention groups (4 PHC/clinics)|Intervention group are individual with T2DM who will receive DM nutrition counseling at selected Public Health Care (PHC). There are 75 subjects in Intervention group at selected 2 districts by randomly and 4 PHC which is selected based on cluster. DM nutrition counseling will be delivered by a selected nutritionist at each PHC. Nutritionist will educate the subjects following DM nutrition education module properly. DM nutrition education will be delivered for 3 months and 30 minutes for each meeting.
62522299|NCT04440319|EXPERIMENTAL|Control groups (4 PHC/clinics)|As the same with intervention group, the control group will have 75 subjects but at the different districts and PHC to avoid contaminant. Control group will follow conventional DM nutrition education. Therefore, there is a selected nutritionists will deliver DM counseling at each PHC.
62522300|NCT01475084|EXPERIMENTAL|Cryobiopsy, forceps biopsy|"Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation.~Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps."
62522301|NCT03971266|EXPERIMENTAL|Prevention (Fitbit, PRO diary)|Patients participant in movement assessment during 2 clinical trial visits. Patients also wear a Fitbit to track movements and complete a smartphone based PRO diary over 5-10 minutes to measure physical function, fatigue, sleep disturbance, social isolation, appetite, and body weight for up to 180 days.
62522302|NCT01386684||Patients with Prostate Cancer|Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
61975424|NCT04379882|EXPERIMENTAL|Digital sedation|30 minutes Silva module
62522303|NCT05697055|EXPERIMENTAL|Azvudine|
61975425|NCT03327298|OTHER|accuracy of pedicle screw insertion|postoperative CT lumbar spine axial and sagittal views.
61975426|NCT03959566|ACTIVE_COMPARATOR|Arm 1 (U0)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~* 400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~* 200 mg Delamanid orally in two daily doses of 100 mg.~* 400 mg Moxifloxacin orally once daily"
61975427|NCT03959566|EXPERIMENTAL|Arm 2 (U600)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~* 400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~* 200 mg Delamanid orally in two daily doses of 100 mg.~* 400 mg Moxifloxacin orally once daily~* 600 mg Sutezolid orally once daily"
61975428|NCT03959566|EXPERIMENTAL|Arm 3 (U1200)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~* 400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~* 200 mg Delamanid orally in two daily doses of 100 mg.~* 400 mg Moxifloxacin orally once daily~* 1200 mg Sutezolid orally once daily"
61975429|NCT03959566|EXPERIMENTAL|Arm 4 (U600BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~* 400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~* 200 mg Delamanid orally in two daily doses of 100 mg.~* 400 mg Moxifloxacin orally once daily~* 600 mg Sutezolid orally twice daily"
61975430|NCT03959566|EXPERIMENTAL|Arm 5 (U800BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~* 400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~* 200 mg Delamanid orally in two daily doses of 100 mg.~* 400 mg Moxifloxacin orally once daily~* 800 mg Sutezolid orally twice daily~* 2 mg Midazolam orally once per day on day-1 and day 14"
62711963|NCT05702034|EXPERIMENTAL|Milvexian|Participants after an acute ischemic stroke or high-risk transient ischemic attack (TIA) who are receiving antiplatelet therapy standard-of-care (SAPT \[single antiplatelet therapy\] or DAPT \[dual antiplatelet therapy\]) will receive milvexian 25 milligrams (mg), orally, twice daily.
61975431|NCT02315781|ACTIVE_COMPARATOR|Active tDCS|active tDCS will be used on half of the study participants
61975432|NCT02315781|SHAM_COMPARATOR|Sham tDCS|Sham tDCS will be used on half of the study participants
61975433|NCT04075565|ACTIVE_COMPARATOR|Simulated altitude|The participants are exposed to simulated altitude in a normobaric situation.
62150465|NCT03072706|ACTIVE_COMPARATOR|Standard group|2D X-ray templating technology
62522304|NCT05697055|ACTIVE_COMPARATOR|Nirmatrelvir-Ritonavir|
62711964|NCT05702034|PLACEBO_COMPARATOR|Placebo|Participants after an acute ischemic stroke or high-risk TIA who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) will receive placebo orally twice daily.
62711965|NCT00928967||Group 1|
62711966|NCT01018602|ACTIVE_COMPARATOR|vildagliptin|
62711967|NCT01018602|PLACEBO_COMPARATOR|inactive pill without active agent|participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
62711968|NCT02018120|ACTIVE_COMPARATOR|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
62150466|NCT03072706|EXPERIMENTAL|Corin OPS™|Corin Optimised Positioning System (OPS) Dynamic Hip Analysis
62150467|NCT01084772|OTHER|VISIONAIRE Instrumentation|TKA with VISIONAIRE instrumentation
61975434|NCT04075565|EXPERIMENTAL|Terrestrial altitude|The participants are exposed to terrestrial altitude in a hypobaric situation.
61975435|NCT04075565|NO_INTERVENTION|Control|the participants are exposed to a normoxic and normobaric environment.
62150468|NCT01084772|OTHER|Standard Instrumentation|TKA with standard instrumentation
62358206|NCT03145597|EXPERIMENTAL|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
62358207|NCT00705848||1|10 patients with tracheobronchomalacia
62358208|NCT00705848||2|10 patients with tracheal stenosis
61975436|NCT01804374|EXPERIMENTAL|sorafenib and everolimus|This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
61975437|NCT00717340|EXPERIMENTAL|tivozanib (AV-951) + paclitaxel|
62358209|NCT00705848||3|10 patients with normal airways (no known airway diseases)
62358210|NCT00291499|ACTIVE_COMPARATOR|Chondroitin 4&6 sulfate (Condrosulf)|
62358211|NCT00291499|PLACEBO_COMPARATOR|placebo|
62358212|NCT00601146|EXPERIMENTAL|Low-dose Chest CT screening|Annual low-dose Chest CT screening
62358213|NCT01376245|EXPERIMENTAL|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
62358214|NCT01376245|PLACEBO_COMPARATOR|placebo|matching placebo
62358215|NCT05625633|EXPERIMENTAL|HPV Vaccine|0.5-mL suspension of 9-valent Gardasil vaccine administered as intramuscular injection at weeks 0, 4, and 20
62358216|NCT05625633|PLACEBO_COMPARATOR|Placebo|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
62358217|NCT01009021|OTHER|Placebo first (scheme 2)|scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode \[placebo treatment episode (PTE)\] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode \[diclofenac treatment episode (DTE)\] to the left eye
62358218|NCT01009021|OTHER|Diclofenac first (scheme 1)|scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode \[diclofenac treatment episode (DTE)\] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode \[placebo treatment episode (PTE)\] to the left eye
62358219|NCT00511849|EXPERIMENTAL|1|
62358220|NCT01463657|EXPERIMENTAL|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
62358221|NCT01463657|ACTIVE_COMPARATOR|Juvéderm® Ultra Plus|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
62358222|NCT01626534|ACTIVE_COMPARATOR|clopidogrel group|
62358223|NCT01626534|EXPERIMENTAL|tricagrelor group|
62358224|NCT05446623|ACTIVE_COMPARATOR|Opioid free anesthesia (OFA)|The patients included in the OFA group will receive a bolus of Dexmedetomidine at the beginning of the surgery.
62358225|NCT05446623|SHAM_COMPARATOR|anesthesia with opioid (OA)|The one in the OA group will be given a bolus of Sufentanil before and during the surgery. When the specific sequence will be completed, the care of all the patient will return to usual.
62358226|NCT06006442||DHMC Ambulatory EEG Patients|Dartmouth Hitchcock Medical Center (DHMC) patients aged 21 years or older who already have planned ambulatory EEG study ordered and admit to vaping.
62358227|NCT01347632|OTHER|BV pre treatment|Open Label Study. All participants had BV and took metronidazole 500 mg po BID for 7 days.
62358228|NCT01155193||Palivizumab|Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season.
62358229|NCT02533778|EXPERIMENTAL|Interventional mechanical thrombectomy|Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours
62358230|NCT04088708|EXPERIMENTAL|Aerobic Exercise Training|Progressive aerobic exercise training sessions supervised by exercise specialists who have experience training cancer survivors.
62358231|NCT04088708|ACTIVE_COMPARATOR|Attention Control|The non-aerobic exercise attention control condition will control for the effects of attention with flexibility/toning activities.
62358232|NCT04165733||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
62358233|NCT05100108|NO_INTERVENTION|Control group|They will be on a waiting list. They will be assessed before and after the 8 week program but will not take part in it.
62358234|NCT05100108|EXPERIMENTAL|Experimental group|Participants in this group will take part in the 8 sessions of dog-assisted therapy. They will be assessed before and after the 8 week program.
62711969|NCT02018120|EXPERIMENTAL|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
62150469|NCT04540926|EXPERIMENTAL|COVID-19 Pneumonia control group|COVID-19 pneumonia patients with standar treatment: enoxaparin 0.5 mg/kg S.C. once, Clarithromycin 500 mg twice an metylprednisolone 0.5 mg/kg once endovenous.
62150470|NCT04388748|EXPERIMENTAL|SMART-D Intervention Group|Subjects will participate in Stress Management and Resiliency Training for Depression (SMART-D) therapy as well as treatment as usual which consists of any ongoing medication or psychotherapy based treatments that are currently in place.
62150471|NCT04388748|NO_INTERVENTION|Standard of Care Group|Treatment as usual will consist of any ongoing medication or psychotherapy based treatments that are currently in place.
62522305|NCT01851018|EXPERIMENTAL|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
62522306|NCT01851018|ACTIVE_COMPARATOR|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
62150472|NCT04555226|ACTIVE_COMPARATOR|Standard treatment group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
62150473|NCT04555226|EXPERIMENTAL|Experimental group|Open/minimally invasive pelvic and para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
62150474|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
62522307|NCT03642626||ARM A: Refractory/relapsed B-cell acute lymphoblastic leukemia (ALL)|
62522308|NCT03642626||ARM B: Yescarta for Refractory diffuse large B cell lymphoma (DLBCL)|
62522309|NCT03642626||ARM C: Kymriah for Refractory diffuse large B cell lymphoma (DLBCL)|
62522310|NCT03642626||Arm D: Tecartus CAR-T product for Mantle Cell Leukemia (MCL)|
62522311|NCT03642626||Arm E: Breyanzi for relapsed or refractory large B-cell lymphoma (RLBCL)|
62522312|NCT03642626||Arm F: Abecma for relapsed or refractory multiple myeloma|
62522313|NCT03642626||Arm G: Tecartus B-cell acute lymphoblastic leukemia (ALL)|
62522314|NCT04603911|ACTIVE_COMPARATOR|Control|Control arm will receive standard of care solution for the ESPB block
62522315|NCT04603911|ACTIVE_COMPARATOR|Liposomal Bupivicaine|Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block
62150475|NCT06312592|EXPERIMENTAL|Intervention group|Receives the Entrepreneurship School with Gender Lens intervention. Participants receive a general training with six modules focused on business modeling and female empowerment for the participants. It is targeted for women who are forcibly displaced people, including refugees, and who are survivors or at risk of Sexual or Gender Based Violence. Each women entrepreneur, participates in individual mentoring sessions to build their business plan after the training and receives $800 start-up capital for their business plan. For at least a year, entrepreneurs will have a follow-up to promote their business scale up, including how to formalize their business in the market, how to define new strategies, and how to answer to the market's evolving requirements. Additionally, the participants receive an extensive training in gender aspects that have been identified as relevant to promote women's empowerment. The intervention also includes mental health content.
62150476|NCT06312592|NO_INTERVENTION|Control group|Does not receive the Entrepreneurship School with Gender Lens intervention the Entrepreneurship School with Gender Lens intervention
62150477|NCT01198314|EXPERIMENTAL|LT, withdrawal of immunosuppression|
62150478|NCT01198314|ACTIVE_COMPARATOR|LT, maintenance of immunosuppression|
62522316|NCT06425770|ACTIVE_COMPARATOR|conventional cast|conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
62522317|NCT06425770|EXPERIMENTAL|indirect digital impression and 3D printed cast|the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration
62522318|NCT06425770|EXPERIMENTAL|direct digital impression|the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration
62522319|NCT04487002|EXPERIMENTAL|group A|underwent localized resection
62522320|NCT03413137|ACTIVE_COMPARATOR|Arm A|A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy
62522321|NCT03413137|ACTIVE_COMPARATOR|Arm B|A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy
62522322|NCT00408564|EXPERIMENTAL|Gemcitabine,Oxaliplatin and Cetuximab|"Gemcitabine will be given on day 1 of every 2 week cycle. Oxaliplatin will be given day 2 of every 2 week cycle. Cetuximab will be given every week for 12 weeks.~After chemotherapy, patient will be assessed for resectability. Patients will have either surgery or daily radiation and capceitabine Monday-Friday for a total of 5 and a half weeks."
62711970|NCT03259295|EXPERIMENTAL|Skin tag removal initial visit plus follow-up|Removal of skin tags 1 cm or less using Digiclamp and follow-up 2-3 months after skin tag removal to assess functionality and effectiveness of the device.
62711971|NCT06161584||Observation|
62150479|NCT01602302|EXPERIMENTAL|single arm ( bDMARD withdrawal )|single arm (bDMARD withdrawal)
62150480|NCT00299507|EXPERIMENTAL|15 mg Anecortave Acetate, 3 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months).
62522323|NCT00378716|ACTIVE_COMPARATOR|Group 1|5-FU + Leucovorin
62522324|NCT00378716|EXPERIMENTAL|Group 2|Uracil/Ftorarur + leucovorin
62522325|NCT03541863||Endocrine therapy|use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus
62522326|NCT03541863||Chemotherapy|use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based
62522327|NCT02119117|PLACEBO_COMPARATOR|sugar pill|Group 2 will receive a placebo of CoQ10
62522328|NCT02119117|EXPERIMENTAL|CoQ10|Patients will be divided into 2 groups. Group 1 will be treated with an oral supplement, 125 mg/twice daily of CoQ10 (NeoQ10, Theralogix, Rockville, Maryland, USA) for 3 months prior to IVF. This dosage will equate to a Cmax of 6.89 ug/ml (Liu and Artmann, 2009).
62522329|NCT03218163|EXPERIMENTAL|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
62522330|NCT06303713|EXPERIMENTAL|Phase 1A: Dose Escalation|"Participants will be enrolled in a 3+3 dose escalation design to establish a maximum tolerated dose (MTD) of carboplatin, starting at Dose Level 1 and escalating to Dose Level 2 or 3.~* Baseline visit.~* Day 1 of Cycles 3 and 5: Tumor assessment radiologic scans.~* Cycle 1 through End of Treatment:~  * Days 1 and 22 of 42-day cycle: Predetermined dose of carboplatin every 3 weeks for a maximum of up to 6 cycles.~ * Day 2 of 42-day cycle: Predetermined dose of 177Lu-PSMA-617 every 6 weeks for a maximum of up to 6 cycles.~* End of treatment visit.~* Follow up visits in-office or via telephone. If 0 out of 3 participants experience a dose-limiting toxicity (DLT), the study will proceed to the next dose level. If 1 or more participants experience a DLT, this dose level is declared the MTD and study will not proceed to expansion. If 1 out of 6 participants at the highest dose level experience DLTs, this is the recommended Phase 1B dose."
61975438|NCT06293807|EXPERIMENTAL|Treatment group Xylocaine|Participants have been scheduled to receive an area of gum surgery to treat periodontal (gum) disease in their mouth while under intravenous (IV) conscious sedation. The study drug is administered after surgery.
61975439|NCT06293807|EXPERIMENTAL|Treatment group Bupivicaine|Participants have been scheduled to receive an area of gum surgery to treat periodontal (gum) disease in their mouth while under intravenous (IV) conscious sedation. The study drug is administered after surgery.
62150481|NCT00299507|EXPERIMENTAL|15 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
62150482|NCT00299507|EXPERIMENTAL|30 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
61975440|NCT06293807|PLACEBO_COMPARATOR|Placebo control group|Participants have been scheduled to receive an area of gum surgery to treat periodontal (gum) disease in their mouth while under intravenous (IV) conscious sedation. The study drug is administered after surgery.
62522331|NCT06303713|EXPERIMENTAL|Phase 1B: Dose Expansion|"19 additional participants will be enrolled at the RP2D of carboplatin and will complete:~* Baseline visit.~* Day 1 of Cycles 3 and 5: Tumor assessment radiologic scans.~* Tumor biopsy at baseline and at 12 weeks.~* Cycle 1 through End of Treatment:~  * Days 1 and 22 of 42 day cycle: Predetermined dose of carboplatin every 3 weeks for a maximum of up to 6 cycles.~ * Day 2 of 42 day cycle: Predetermined dose of 177Lu-PSMA-617 every 6 weeks for a maximum of up to 6 cycles.~* End of treatment visit.~* Follow up visits in-office or via telephone."
61975441|NCT04085068||Study group (group A):|15 women take cranioscaral treatment
61975442|NCT04085068||control group (group B):|shame group
62150483|NCT00299507|SHAM_COMPARATOR|Anecortave Acetate Vehicle|One 0.5 mL sham injection of Anecortave Acetate Vehicle at 6 month intervals (3, 9, 15, 21 months).
62150484|NCT00296309|ACTIVE_COMPARATOR|1|
62150485|NCT00296309|EXPERIMENTAL|2|
62150486|NCT01762982|EXPERIMENTAL|Test|Benzalkonium chloride (0.13%) Disinfectant Spray water
62150487|NCT01762982|ACTIVE_COMPARATOR|Positive Control|Sodium lauryl sulfate (SLS) (0.3% weight by weight \[w/w\]) water solution
62150488|NCT01762982|PLACEBO_COMPARATOR|Negative Control 1|Normal saline water (0.9% weight by volume \[w/v\])
62150489|NCT01762982|PLACEBO_COMPARATOR|Negative Control 2|Empty Finn Chamber
62150490|NCT02125292|EXPERIMENTAL|Mesalamine (Vanilla Yogurt)|One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
62522332|NCT01669473|EXPERIMENTAL|Intervention Arm|"EHR Based Strategy to promote Safe and Appropriate Drug Use~Patients randomized to the intervention arm will be given (3) print tools to assist in safe and appropriate medication use. These include a Medreview, Medsheet,and Medlist."
62522333|NCT01669473|NO_INTERVENTION|Standard Care Arm|The control group will receive regular standard care at the Clinic. They will not receive any print tools.
62150491|NCT02125292|EXPERIMENTAL|Mesalamine (Applesauce)|One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
62150492|NCT02125292|EXPERIMENTAL|Mesalamine (Dosing Cup)|One 500mg capsule contents emptied into a dosing cup and taken with water
62150493|NCT05474326|EXPERIMENTAL|pregnant women with idiopathic oligohydramnios|women with singleton pregnancy between 32-41 weeks oligohydramnios diagnosed by ultrasound by the amniotic fluid index (AFI) method oligohydramnios is diagnosed if AFI index is less than 5 cm
62150494|NCT04976946||Urologists|Local and international consultant Urologists and accredited Urology trainees.
62358235|NCT00443846|EXPERIMENTAL|Group 1: Concomitant Administration|Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
62150495|NCT04976946||Anaesthetists|Local and international consultant anaesthetists. Critical care physicians who are primarily Urological anaesthetists or have experience in complication reporting will be targeted.
62150496|NCT04976946||ICU specialists|Local and international consultant ICU specialists. Critical care physicians who are primarily Urological focused or have experience in complication reporting will be targeted.
62358236|NCT00443846|ACTIVE_COMPARATOR|Group 2: Sequential Administration|Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.
62358237|NCT03010267|EXPERIMENTAL|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
62358238|NCT03010267|EXPERIMENTAL|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
61975443|NCT00452010|EXPERIMENTAL|1|transcutaneous electrical nerve stimulation
62358239|NCT03549429|EXPERIMENTAL|TegadermTM on R eye, EyeGard® on L eye|Patients will get TegadermTM on Right eye, EyeGard® on Left eye
62358240|NCT03549429|EXPERIMENTAL|TegadermTM on L eye, EyeGard® on R eye|Patients will get TegadermTM on Left eye, EyeGard® on Right eye
62358241|NCT01879813|ACTIVE_COMPARATOR|Phospholipid drink|Participants will consume a phospholipid drink daily for 6 weeks
62358242|NCT01879813|PLACEBO_COMPARATOR|Placebo milk drink|Participants will consume a placebo drink (no added phospholipids) daily for 6 weeks
62358243|NCT00790127|PLACEBO_COMPARATOR|Placebo|Placebo
62358244|NCT00790127|EXPERIMENTAL|HQK-1001|HQK-1001
62358245|NCT02301754|EXPERIMENTAL|INVAC-1|"INVAC-1 at escalating doses of 100, 400 and 800 µg will be given as a single agent by intradermal injection (Q 4 weeks x 3 cycles), always combined with electroporation.~Each patient will receive 3 cycles, unless motivated treatment interruption."
62358246|NCT01856842|ACTIVE_COMPARATOR|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
62358247|NCT01856842|ACTIVE_COMPARATOR|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
62358248|NCT03351010|EXPERIMENTAL|Mindfulness|Receiving education program and mindfulness training
62358249|NCT03351010|ACTIVE_COMPARATOR|Control|Receiving education program
62358250|NCT04112771||Penehyclidine group|Penehyclindine hydrochloride was administered before anesthesia induction.
62358251|NCT04112771||Placebo group|Penehyclindine hydrochloride was not administered before anesthesia induction.
62358252|NCT00888680|EXPERIMENTAL|BGC20-1531 200 mg|
62358253|NCT00888680|EXPERIMENTAL|BGC20-1531 400mg|
62358254|NCT00888680|PLACEBO_COMPARATOR|Lactose|
62358255|NCT00689169|EXPERIMENTAL|Experimental|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
62358256|NCT03030768||HIV-1 serodiscordant couples|Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
62358257|NCT03286296|EXPERIMENTAL|LZM009|
62358258|NCT01599806|EXPERIMENTAL|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
62358259|NCT01599806|ACTIVE_COMPARATOR|Doripenem|IV treatment
62358260|NCT03228394|EXPERIMENTAL|Ganaxolone|Intravenous
62358261|NCT03228394|PLACEBO_COMPARATOR|Placebo|Intravenous
62358262|NCT02490943|ACTIVE_COMPARATOR|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
62358263|NCT02490943|ACTIVE_COMPARATOR|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
62358264|NCT02490943|NO_INTERVENTION|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
62358265|NCT01231126|PLACEBO_COMPARATOR|spontaneous vaginal deliveries|
62358266|NCT01231126|PLACEBO_COMPARATOR|elective caesarians|
62358267|NCT01231126|EXPERIMENTAL|induced vaginal delivery by misoprostol|
62358268|NCT01231126|EXPERIMENTAL|caesarians section with induction attempt|
62358269|NCT02538939|EXPERIMENTAL|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
62358270|NCT05644808||Non-small Cell Lung Cancer|
62358271|NCT02384304|EXPERIMENTAL|Choice|A self help program consisting of 8 modules. Patients will have access to therapist support through either messages or chat sessions
62358272|NCT02384304|EXPERIMENTAL|Messages|A self help program consisting of 8 modules. Patients will have access to therapist support through messages
62358273|NCT02384304|ACTIVE_COMPARATOR|Self help|A relapse intervention program consisting of 8 modules. Patients will have no access to therapist support
62358274|NCT05191732|EXPERIMENTAL|PRP augmentation ACL reconstruction group|Platelet-rich plasma (PRP) (Dosage form: APA-15)
62358275|NCT05191732|EXPERIMENTAL|PRP+BMC augmentation ACL reconstruction group|Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
62358276|NCT05191732|NO_INTERVENTION|Traditional ACL reconstruction group|No intervention
62358277|NCT00665678|EXPERIMENTAL|1|paroxetine
62358278|NCT00665678|PLACEBO_COMPARATOR|2|placebo
62358279|NCT06409611|EXPERIMENTAL|neuromuscular electrical stimulation (NMES)|For the NMES group, NMES therapy will be performed for 1 hour, once a day and for 10 days. Using the following parameters: Biphasic and symmetrical rectangular pulse, with a frequency of 50Hz, pulse width of 500μs, ON time of 10 seconds, OFF time of 15 seconds, 3 seconds of rise time and 2 seconds of descent time. The intensity is increased to the point that there is complete muscle contraction, visible or palpable. The maximum intensity will be 120 mA.
62522334|NCT03533374||Patients with epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
62711972|NCT05375422|EXPERIMENTAL|SARAH group|The SARAH group will receive an exercise book containing 7 mobility exercises and 4 strength exercises that are performed using elastic materials that provide progressive degrees of resistance to movement. Patients will be guided in person by a trained professional, so that they are carried out without their presence, in the home environment, daily and monitored at periodically scheduled meetings. A total of 4 face-to-face meetings will be held during the 3-month follow-up. The SARAH group and the control group will receive information related to joint protection, use of splints, assistive devices and other general advice, as needed, will receive some booklets to reinforce the guidelines. The program will last 12 weeks, with 4 face-to-face meetings lasting 40 minutes and monitored in periodically scheduled meetings.
62711973|NCT05375422|ACTIVE_COMPARATOR|Control group|"Control group will receive information related to joint protection, use of splints, assistive devices and other general advice, as needed, will receive some booklets to reinforce the guidelines.~After 12 weeks, the control group will also be invited to perform the SARAH protocol exercises."
62522335|NCT03533374||Patients with non-epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
62522336|NCT03118570|EXPERIMENTAL|Setrusumab 20 mg/kg (Blinded)|Setrusumab 20 mg/kg intravenous (IV) infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
62522337|NCT03118570|EXPERIMENTAL|Setrusumab 8 mg/kg (Blinded)|Setrusumab 8 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
62522338|NCT03118570|EXPERIMENTAL|Setrusumab 2 mg/kg (Blinded)|Setrusumab 2 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
62522339|NCT03118570|EXPERIMENTAL|Setrusumab 20 mg/kg (Open-Label)|Setrusumab 20 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
62522340|NCT03118570|PLACEBO_COMPARATOR|Placebo|Placebo IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
62522341|NCT04901013|ACTIVE_COMPARATOR|Affinity plus SOC|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM). Affinity is human allograft tissue that is regulated as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) as defined by FDA 21 CFR Part 1271. Affinity may be applied as a wound covering to partial- and full-thickness acute and chronic wounds
62522342|NCT04901013|NO_INTERVENTION|Standard of Care (SOC)|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
62522343|NCT02664233|EXPERIMENTAL|Connected group|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
62522344|NCT02664233|NO_INTERVENTION|Usual diabetes education and care|Participants will receive standard diabetes education and care; each of the recruiting clinics offers diabetes self-management education programs.
62522345|NCT03725865|EXPERIMENTAL|iNSC treatment group|
62522346|NCT01298713|ACTIVE_COMPARATOR|A|Tamoxifen 20mg/d
62522347|NCT01298713|EXPERIMENTAL|B|Tamoxifen 20mg/d + RAD001 10mg/d
62522348|NCT00725114|ACTIVE_COMPARATOR|Tetrodotoxin|
62522349|NCT00725114|PLACEBO_COMPARATOR|Sugar injection|
62522350|NCT01617694|EXPERIMENTAL|group R|continuation of remifentanil target controlled infusion (TCI) at effect-site concentration of 2 ng/ml during anesthetic recovery until extubation.
62522351|NCT01617694|ACTIVE_COMPARATOR|group D|remifentanil TCI discontinuation and dexmedetomidine 0.5 mg/kg intravenous injection before 10 min of the end of surgery
62522352|NCT02692729|EXPERIMENTAL|supraumbilical transverse|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis. Above the panniculus, the fatty tissues are not particularly thick. A transverse opening of the aponeurosis and of the parietal peritoneum was done. Then the approach to the lower uterine segment was easy. A Ricard retractor was put in place.
61975444|NCT00452010|PLACEBO_COMPARATOR|2|No transcutaneous electrical nerve stimulation
61975445|NCT02751996|ACTIVE_COMPARATOR|Part A Cohort 1: 25mg SB 9200|Part A Cohort 1: 25mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
61975446|NCT02751996|PLACEBO_COMPARATOR|Part A Cohort 1: 25mg Placebo|Part A Cohort 1: 25mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
61975447|NCT02751996|ACTIVE_COMPARATOR|Part A Cohort 2: 50mg SB 9200|Part A Cohort 2: 50mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
61975448|NCT02751996|PLACEBO_COMPARATOR|Part A Cohort 2: 50mg Placebo|Part A Cohort 2: 50mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
61975449|NCT02751996|ACTIVE_COMPARATOR|Part A Cohort 3: 100mg SB 9200|Part A Cohort 3: 100mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
62522353|NCT02692729|ACTIVE_COMPARATOR|pfannenstiel|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
62522354|NCT03649412|EXPERIMENTAL|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).
62522355|NCT03649412|EXPERIMENTAL|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
61975450|NCT02751996|PLACEBO_COMPARATOR|Part A Cohort 3: 100mg Placebo|Part A Cohort 3: 100mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
62150497|NCT01884571|EXPERIMENTAL|Immunosuppression Regimen|Basiliximab Methylprednisolone Prednisone Tacrolimus Mycophenolate mofetil
62150498|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
62358280|NCT06409611|ACTIVE_COMPARATOR|Placebo|This group will perform conventional physiotherapy according to institutional protocol. Rehabilitation was oriented towards achieving daily motor milestones (sitting on the edge of the bed, sitting in an armchair, getting up and walking) according to the CPAx scale. The same electrostimulation device will be installed, but it will not be turned on.
62358281|NCT05220371|EXPERIMENTAL|Collagen|15g of collagen peptides ingested daily
62358282|NCT05220371|PLACEBO_COMPARATOR|Placebo|15g of Placebo ingested daily
62358283|NCT00944216|EXPERIMENTAL|Salkera Emollient Foam Treatment|All participants will receive this intervention.
62358284|NCT02267369|ACTIVE_COMPARATOR|Basic fitness program|The control condition provides study participants with online tools for enrolling in offline fitness workshops offered by the university's recreation department and recording their progress in the program. All fitness workshops are pre-programmed in an online calendar. Upon clicking a workshop, participants can read a detailed description and register for it directly on the calendar. The registration then triggers a confirmation email sent to the participant immediately and a reminder email 12 hours before the workshop starts. In addition, an online tracking tool is built that participants can use to keep a daily journal of their health activities and fitness status.
62358285|NCT02267369|EXPERIMENTAL|Media-assisted fitness program|"The media condition evaluates the effects of informational and motivational messages on physical activity by supplementing the basic program tools with promotional media, including: high arousal videos encouraging physical activity, real-time email notifications about upcoming fitness workshops, and informational graphics with exercise tips and motivational messages. In the media condition, participants receive two videos on the website and one informational graphic that encourage physical activity on a weekly basis."
62358286|NCT02267369|EXPERIMENTAL|Social network-assisted fitness program|"The social condition, by contrast, omits the media content. Instead, the basic program is supplemented with a network of four to six anonymous health peers, composed of other participants of the program. Within the program website, each participant is able to see their peers' basic profile information, as well as information about their peers' progress in the program, and real-time notifications about their peers' completion of program activities. These networks do not provide any added incentives or additional content to promote physical activity, nor can participants directly communicate with, or message their peers through the website."
62358287|NCT02227472||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study will complete evaluation of cognitive and pre-academic skills, and parent questionnaires.
62358288|NCT05380713|EXPERIMENTAL|Radiation+Drug (Arm A)|sub-ablative radiation plus low dose cyclophosphamide followed by surgery and adjuvant immunotherapy
62358289|NCT05380713|EXPERIMENTAL|Radiation alone (Arm B)|sub-ablative radiation alone followed by surgery and adjuvant immunotherapy
62358290|NCT06145893|EXPERIMENTAL|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 40 weeks.
62358291|NCT06145893|EXPERIMENTAL|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 40 weeks.
62358292|NCT06145893|PLACEBO_COMPARATOR|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 40 weeks.
62358293|NCT00900445||Basic science (pharmacokinetics)|Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.
62358294|NCT01985971|EXPERIMENTAL|EF5|
62358295|NCT06347783||Child/parent dyad|Study group will consist of 40 participant dyads - a pediatric patient with type 1 diabetes and one of their caregivers. At the beginning of the study, the patient's treatment should consist of multiple daily insulin injections and a continuous glucose monitor, and during this time, sleep will be evaluated through a FitBit and surveys. Then patient will be started on an insulin pump of their choice (Omnipod 5, Tandem, etc), and sleep will be re-evaluated 1-2 months after pump initiation.
62358296|NCT03521661||Kyphoplasty|Patients underwent kyphoplasty with an intravertebral expander
62358297|NCT03446001|EXPERIMENTAL|TRx0237 16 mg/day|
62358298|NCT03446001|PLACEBO_COMPARATOR|Placebo|
62358299|NCT03446001|EXPERIMENTAL|TRx0237 8 mg/day|
62358300|NCT00841269|EXPERIMENTAL|Uridine|Uridine 500 mg by mouth twice daily for 6 weeks
62358301|NCT00841269|NO_INTERVENTION|Healthy Comparison|Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
62358302|NCT03249948|NO_INTERVENTION|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
62358303|NCT03249948|OTHER|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
62358304|NCT03249948|OTHER|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
62522356|NCT02310282||Telemedicine|In-hospital telemedicine by a stroke expert aiming to assess stroke severity using the Unassisted TeleStroke Scale.
62522357|NCT03336320|EXPERIMENTAL|Multidomain Intervention Group|Home-based multidomain intervention composed of nutritional counselling, exercise (balance, gait, , and cognitive training provided using ICT solutions. A web platform, containing information, questionnaires, videos, games, and tests related to each one of the three components of the multidomain intervention will be made available to participants in this group.
62522358|NCT03336320|ACTIVE_COMPARATOR|Control Group|"Participants from CG will also be equipped with wrist worn accelerometers (that will record daily activity data continuously) but contrary to MIG, participants won't have access to the password encrypted application, and therefore, to the multidomain intervention. However, they will be able to access the study website with overall information on the eMIND study and links to the website of health authorities (such as http://www.mangerbouger.fr/PNNS or the World Health Organization http://www.who.int/topics/ageing/fr/) regarding healthy ageing topics. Plus, in order to control for the social aspect of MIG, participants in CG will receive monthly phone calls from the research team."
62522359|NCT03667079|EXPERIMENTAL|Integrated|Intervention 'integrated delivery of deworming and vaccination' will be delivered to this arm of the study
62522360|NCT03667079|ACTIVE_COMPARATOR|Deworming only|Intervention 'Mass deworming only' will be delivered to villages in this arm of the study
62522361|NCT03667079|ACTIVE_COMPARATOR|Rabies vaccination only|Villages assigned to this arm received mass vaccination of dogs against rabies only
62522362|NCT04583020|EXPERIMENTAL|Neoadjuvant PD-1 inhibitor|Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.
62522363|NCT03525418|EXPERIMENTAL|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
62522364|NCT03525418|EXPERIMENTAL|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
62522365|NCT03525418|NO_INTERVENTION|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
62522366|NCT04975074|EXPERIMENTAL|Anemia Correction Group|Continue to take the current medication orally at the current dose
62522367|NCT04975074|EXPERIMENTAL|Anemia uncorrected group|Continue to take the current medication orally at the current dose
62522368|NCT03412812|EXPERIMENTAL|Dose Escalated 5 Fraction Stereotactic Radiosurgery|Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.
62522369|NCT04158960|NO_INTERVENTION|Control|Control period; no equine-assisted activities or brain-building activities occurred
62522370|NCT04158960|ACTIVE_COMPARATOR|Equine-assisted activities period|Period in which only equine-assisted activities were performed
62522371|NCT04158960|NO_INTERVENTION|Washout|Washout period; no equine-assisted activities or brain-building activities occurred
62522372|NCT04158960|EXPERIMENTAL|GaitWay period|Period in which both equine-assisted activities and brain-building activities were performed
62522373|NCT02448121|EXPERIMENTAL|Autologous bone marrow stem cell graft|Autologous bone marrow stem cell implantation
62711974|NCT03985735||Group good sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are more than six hours."
62522374|NCT03195036|NO_INTERVENTION|Control|The control group of women/children dyads who consent and are patients at the control clinics will not have any exposure to ECD programming.
62522375|NCT03195036|EXPERIMENTAL|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation.
62522376|NCT04209205|EXPERIMENTAL|AIN457 6 mg/kg - 3 mg/kg i.v.|AIN457 6 mg/kg i.v. infusion at baseline, followed by AIN457 3 mg/kg i.v. infusion every 4 weeks starting at Week 4 through Week 48 (exposure through Week 52).
62522377|NCT04209205|PLACEBO_COMPARATOR|Placebo|Matching placebo from baseline to Week 16 and switch to AIN457 3mg/kg i.v. infusion every 4 weeks through Week 48 (exposure through Week 52).
62522378|NCT05943119|EXPERIMENTAL|Experimental group: Radiotherapy in painting dose on histoscannographic mapping|
62522379|NCT05943119|ACTIVE_COMPARATOR|Control group: standard pan-sinus Radiotherapy|
62522380|NCT01956695|EXPERIMENTAL|Lenalidomide & Rituximab|"Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.~Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
62711975|NCT03985735||Group poor sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are less than two hours."
62711976|NCT00578097|EXPERIMENTAL|A - 125 units|
62711977|NCT00578097|EXPERIMENTAL|B - 250 units|
61975451|NCT02751996|ACTIVE_COMPARATOR|Part A Cohort 4: 200mg SB 9200|Part A Cohort 4: 200mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
62711978|NCT00578097|EXPERIMENTAL|C - 500 units|
62711979|NCT00578097|PLACEBO_COMPARATOR|D|
62711980|NCT06716619|EXPERIMENTAL|Exploration of the dosage range and Expansion phase|"In the exploration dosage range phase, the safety data accumulated from the trial will be used to evaluate whether the safety of TAL-T cell therapy meets the requirements and decide whether to terminate the study. Exploration of the dosage range is divided into three dose phases, and the upper limit of the maximum dose is constantly expanded.~After completion of exploration study, three types of preferred tumor will be choosed by sponsor. During the expansion phase, the actual number of participants in each cohort may be adjusted based on the obtained trial results to further evaluate the safety, tolerability, and efficacy of TAL-T cell infusion."
62711981|NCT03916146|EXPERIMENTAL|Behavioral Parent Training|
62711982|NCT03916146|NO_INTERVENTION|Control|
62711983|NCT00544206|EXPERIMENTAL|#1|Diabetes specific enteral feeding product
62711984|NCT00544206|ACTIVE_COMPARATOR|#2|Standard enteral feeding product
62711985|NCT05962944||Laboratory testing|Slides reviewed in the laboratory to test the platform for suitability prior to involving patients
62711986|NCT05962944||Remote ROSE on the same site as the laboratory|The next phase will involve remote ROSE being performed on the same site as the laboratory in an ultrasound room located on the Royal Cornwall Hospitals Truro site.
62358305|NCT00699309||Taperloc® Microplasty™ Hip System|
62358306|NCT01115088|EXPERIMENTAL|Aspartame|Food or beverages containing Aspartame in comparison to Stevia or Sucrose
62358307|NCT01115088|EXPERIMENTAL|Sucrose|Food or beverages containing Sucrose in comparison to Aspartame or Stevia
62358308|NCT01115088|EXPERIMENTAL|Stevia|Food or beverages containing Stevia in comparison to Aspartame or Sucrose
62358309|NCT04507178|NO_INTERVENTION|prophylactic dose LMWH|Patients assigned to the control group will receive standard care according to current protocol with a prophylactic dose of LMWH (nadroparin once daily 2850 AxaIE subcutaneously) starting within 24 hours after coiling, continued until discharge or when mobilized for at least six hours a day.
62358310|NCT04507178|ACTIVE_COMPARATOR|therapeutic dose LMWH|In the intervention group, the standard prophylactic dose will be replaced by a higher dose of LMWH (nadroparin; twice daily 5700 IE) starting within 24 hours after coiling and continued for 21 days after initial SAH. After this, patients will continue with standard care (prophylactic dose until discharge or when mobilized for more than six hours per day).
62358311|NCT03337425|EXPERIMENTAL|psychoeducational groups|Psychoeducational group therapy and standard treatment (ADHD treatment as usual)
62358312|NCT03337425|ACTIVE_COMPARATOR|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
62358313|NCT02030587|EXPERIMENTAL|Radiofrequency Ablation|Radiofrequency Ablation
62358314|NCT02030587|ACTIVE_COMPARATOR|Laparoscopic Adrenalectomy|Laparoscopic Adrenalectomy
62358315|NCT01982526||Endmetrioma surgery|
62358316|NCT05839288||PyroHC|Patients used pyrotinib (Pyro) plus trastuzumab (H) and chemotherapy (C) as treatment for metastatic breast cancer.
62358317|NCT05340062||pediatric patients with ICP device|"In children requiring ICP, TCD and ONSD will be measured:~* within 30 minutes before to the placement of the ICP (if possiblel)~* at least twice a day after placement of the invasive ICP for the first 48 hours~Each measurement will include:~* The measure of the invasive ICP~* Calculation of invasive CPP (invasive MAP-invasive ICP)~* TCD: FVs, FVd, FVm, from which the nCPP will be obtained with the formula FVdICP. The nICP will be obtained from invasive MAP minus nCPP.~* The measurement of the nICP ONSD (2) for a total of 2 measurements preferably from the side where the invasive ICP device is positioned.~Measurements (TCD and ONSD) will be done by two operators blinded by each other in order to evaluate the inter-operator variability"
62358318|NCT02969694||Patients who use psychostimulants products in sexual contexts|"Patients who come to the CSAPA at the Croix-Rousse Hospital, Lyon France following the use of psychostimulants products in sexual contexts.These patients come for an addictologique support.~The patients will answer to the G-STAT questionnaire."
62358319|NCT03986242|EXPERIMENTAL|static stretchin|Static extremity muscles of the lower extremities, including: gluteal muscles (major muscle group: gluteus maximus), anterior thigh muscles (strand rectus, medial femoral muscle, lateral femoral muscle, medial femoral muscle), posterior thigh muscles (main muscle) Group: semimembranosus, semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). 4 groups per muscle group, 30 seconds/group
62358320|NCT03986242|EXPERIMENTAL|non- vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each leg of each pair performs 30 seconds/group for a total of 4 groups for a total time of 20 minutes.
62358321|NCT03986242|EXPERIMENTAL|Vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each muscle group of each foot performs 30 seconds/group, a total of 4 groups, the vibration frequency is 28 Hz, and the total time is 20 minutes.
62358322|NCT03854851|EXPERIMENTAL|NALDEBAIN|In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery.
62358323|NCT03854851|ACTIVE_COMPARATOR|MORPHINE|In group MORPHINE, subjects will receive morphine as needed after surgery.
62358324|NCT02481596|EXPERIMENTAL|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
62358325|NCT02481596|EXPERIMENTAL|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
62358326|NCT02481596|ACTIVE_COMPARATOR|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
62358327|NCT01045928|EXPERIMENTAL|Arm I|Patients receive oral lenalidomide once daily on days 1-21 and rituximab IV on day 1of courses 1, 3, 5, 7, 9, and 11.
62358328|NCT01887756|EXPERIMENTAL|Single arm study|The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.
62358329|NCT06047106|EXPERIMENTAL|Living kidney donor|Patient eligible for living kidney donation with eGFR \> 60 ml/min/1.73m²
62358330|NCT06047106|EXPERIMENTAL|Recipient of kidney transplant from living donor|Patient with end-stage chronic kidney failure awaiting kidney transplant from living donor
62358331|NCT03177967|EXPERIMENTAL|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
62358332|NCT03177967|EXPERIMENTAL|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
62358333|NCT03177967|ACTIVE_COMPARATOR|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia~Interventions: Psychoeducative advice to improve sleep"
62358334|NCT06229483|EXPERIMENTAL|Tranexamic Acid|Participants will be randomized in a 1:1 ratio to receive tranexamic acid 20 mg/kg IV bolus or identical volume of placebo 0.9 % NaCl within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, or identical volume of placebo 0.9 % NaCl, for the duration of surgery. Treatment is blinded.
62358335|NCT06229483|PLACEBO_COMPARATOR|Matching Placebo|Participants will be randomized in a 1:1 ratio to receive tranexamic acid 20 mg/kg IV bolus or identical volume of placebo 0.9 % NaCl within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, or identical volume of placebo 0.9 % NaCl, for the duration of surgery. Treatment is blinded.
62358336|NCT05676801|EXPERIMENTAL|PDT group|PDT with 5% topical methyl aminolevulinate (MAL) before skin antisepsis
62358337|NCT01100645|EXPERIMENTAL|Test|Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)
62358338|NCT01100645|PLACEBO_COMPARATOR|Placebo|Excipient
62358339|NCT03970707|EXPERIMENTAL|Small Number of Players training protocol A|Small Sided Game: 4 vs 4
62358340|NCT03970707|EXPERIMENTAL|Large Number of Players training protocol B|Small Sided Game: 8 vs 8
62358341|NCT03970707|NO_INTERVENTION|Control|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
62358342|NCT05355935|EXPERIMENTAL|Part 1: Treatment Dose 1|Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 1 or placebo, once on Day 1.
62358343|NCT05355935|EXPERIMENTAL|Part 1: Treatment Dose 2|Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 2 or placebo, once on Day 1.
62358344|NCT05355935|EXPERIMENTAL|Part 2|Participants will be randomized to 1 of 4 treatment sequences (ABCD, BDAC, CADB, DCBA).
62358345|NCT02901340||Borderline isolated oligohydramnios|"Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index\>5.0 and ≤8.0cm.~The borderline idiopathic isolated oligohydramnios group was formed of the patients who meets the inclusion criteria and between 34-37 weeks gestation (n:40)"
62358346|NCT02901340||Control group|The control group was formed of the patients who had normal amniotic volume and 34-37 weeks gestation who meets the inclusion criteria (n:100)
62358347|NCT02460978|EXPERIMENTAL|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
62358348|NCT02460978|EXPERIMENTAL|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
62358349|NCT02460978|PLACEBO_COMPARATOR|Placebo|Placebo tablet orally, once daily for 52 weeks
62358350|NCT00708903|EXPERIMENTAL|1|HKI-272
62358351|NCT00708903|PLACEBO_COMPARATOR|2|Placebo
62358352|NCT00708903|ACTIVE_COMPARATOR|3|Moxifloxacin
62358353|NCT01746810|EXPERIMENTAL|Stereotactic Body RT and IRGA|Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.
62358354|NCT06045728|ACTIVE_COMPARATOR|group 1 telerehabilitation group|subjects in this group will receive telerehabilitation sessions through online video programs (including Pilates exercise and diet) 3 times per week for 12 weeks. Outcome measures will be evaluated at baseline and after 12 weeks
62358355|NCT06045728|OTHER|group 2 control group|subjects in this group will be informed about the importance of Pilates exercise and diet for one session only. subjects will be asked to apply the exercise at home 3 times per week for 12 weeks and diet. Outcome measures will be evaluated at baseline and after 12 weeks
62358356|NCT01273987|EXPERIMENTAL|neobladder with round lig|ileal neobladder suspened with round ligament
62358357|NCT01273987|NO_INTERVENTION|standard neobladder|conventional standard neobladder
62522381|NCT04831372|ACTIVE_COMPARATOR|On Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.~The control group will be using the first method, which is the on-table method, which uses a specialized surgical table, called a traction table. This table involves placing both feet in specialized boots that are then hooked up to the table, and allows for positioning of the operative leg with aid of the table.~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
62522382|NCT04831372|EXPERIMENTAL|Off Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.~The experimental group will be using the second method, which is the off-table method. In this method the patient is placed on a standard operating room table and the operative leg is manually positioned by the surgeon during the procedure . This obviates the need for the additional staff members or purchase of a specialized table.~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
62522383|NCT05417503|EXPERIMENTAL|bi-level|
62522384|NCT05417503|PLACEBO_COMPARATOR|placebo|
62522385|NCT05467046||AD-patients|
62522386|NCT05255926|EXPERIMENTAL|68Ga-pentixafor and 18F-FDG PET/CT|Investigators recruit patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies. Then patients undergo 68Ga-pentixafor and 18F-FDG PET/CT imaging in one week.
62522387|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
62522388|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
62522389|NCT06240715|ACTIVE_COMPARATOR|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for early cord clamping (ECC).
62522390|NCT06240715|NO_INTERVENTION|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
62522391|NCT01215513|EXPERIMENTAL|Degarelix|
62522392|NCT04312269|EXPERIMENTAL|All phase TMR|TMR during every stage of sleep
62522393|NCT04312269|EXPERIMENTAL|Slow-wave sleep (SWS) only TMR|TMR during slow-wave sleep only
62522394|NCT04312269|EXPERIMENTAL|Reduced frequency TMR|TMR during only subset of sessions
62522395|NCT04312269|SHAM_COMPARATOR|Sham TMR|Patients receive no TMR
62522396|NCT06434922|EXPERIMENTAL|Prevention Strategies|Groups received the prevention strategies to prevent the recurrence of DFU's
62522397|NCT06434922|OTHER|Standard Strategies|Groups received the standard strategies to prevent the recurrence of DFU's
62522398|NCT05820867|ACTIVE_COMPARATOR|Single-session arm|
62522399|NCT05820867|ACTIVE_COMPARATOR|Two-session arm|
62522400|NCT03251274|EXPERIMENTAL|machine bathing group|structured machine bathing for 20-min duration at evening.
62522401|NCT03251274|ACTIVE_COMPARATOR|traditional bathing group|traditional bathing at evening.
62522402|NCT03533127|EXPERIMENTAL|LY01008+Carboplatin/Paclitaxel|Drug: LY01008 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
62522403|NCT03533127|EXPERIMENTAL|Bevacizumab + Carboplatin/Paclitaxel|Drug: Bevacizumab Bevacizumab 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
62522404|NCT05307887|EXPERIMENTAL|Virtual Reality Technology|Group receiving virtual reality technology in addition to standard therapy
62522405|NCT05307887|NO_INTERVENTION|Standard Therapy Control Group|
62711987|NCT05962944||Remote ROSE at a site external to the laboratory|Phase 3 will involved remote ROSE being performed on a different site to the laboratory. The ultrasound room at The Royal Cornwall Hospital's Camborne and Redruth site.
62711988|NCT02228057||operated group|all patients who had upper extremity artery surgery at least 6 months ago
61975452|NCT02751996|PLACEBO_COMPARATOR|Part A Cohort 4: 200mg Placebo|Part A Cohort 4: 200mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
62522406|NCT05619055||neonate with necrotizing enterocolitis|premature infants diagnosed as necrotizing enterocolitis
62522407|NCT05619055||neonate without necrotizing enterocolitis|premature infants without necrotizing enterocolitis
62522408|NCT05369468|PLACEBO_COMPARATOR|group 1|Group 1: will receive bilateral ESP block with injection of 20 ml of 0.25% Bupivacaine in each site of injection .
62522409|NCT05369468|EXPERIMENTAL|group 2|Group 2: will receive bilateral ESP block with injection of 18ml of 0.25% Bupivacaine plus 2ml dexmedetomidine 0.5 ug /kg in each site of injection .
62522410|NCT05289128|EXPERIMENTAL|Experimental Group/ Active HD-tDCS|Patients randomly enrolled in this group will receive 10 sessions of anodal HD-tDCS stimulation on cortical representation zone of left diaphragmatic motor cortex associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
62522411|NCT05289128|SHAM_COMPARATOR|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
62522412|NCT01372241|EXPERIMENTAL|Early Intervention|This group served as the treatment group for analysis of the primary outcome.
62522413|NCT01372241|NO_INTERVENTION|Delayed Intervention|This group served as a wait-list control group, eventually receiving the intervention after the treatment group completed the intervention and the primary outcomes were assessed for both groups.
62522414|NCT02053675|OTHER|Vasopressin|
62522415|NCT05314894|EXPERIMENTAL|initiative group|The first session will be right after the pre-test, the second session will be 15 days after the first session, and the last session will be 15 days after the second session. After the training is over, a total of 40 messages will be sent to the students in the initiative group, taking into account the factors that affect, strengthen and activate the main communication via the WhatsApp program.
62522416|NCT05314894|NO_INTERVENTION|control group|No intervention will be made
62522417|NCT00435396|EXPERIMENTAL|Group A|
62522418|NCT01193738|ACTIVE_COMPARATOR|active osteopathic compression|osteopathic compression of Pterygopalatine node
62522419|NCT01193738|PLACEBO_COMPARATOR|placebo osteopathic compression|placebo osteopathic compression
62522420|NCT03795714||Intravascular Imaging and Physiologic Assessment|330 patients with suspected ischemic heart disease and who underwent IVUS or OCT assessment and invasive physiologic assessment.
62522421|NCT05492370|EXPERIMENTAL|EpiCor|500 mg EpiCor given as two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
62522422|NCT05492370|PLACEBO_COMPARATOR|Placebo|Two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
62522423|NCT00105573|EXPERIMENTAL|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy for depression.
62522424|NCT00105573|EXPERIMENTAL|Interpersonal psychotherapy/child-parent psychotherapy|Participants will receive interpersonal psychotherapy for depression plus 1 year of in-home, child-parent psychotherapy.
62522425|NCT00105573|ACTIVE_COMPARATOR|Enhanced community standard|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
61975453|NCT02751996|ACTIVE_COMPARATOR|Part B: SB 9200 with tenofovir|Part B: SB 9200 selected dose from Part A administered in combination with tenofovir 300 mg qd. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
61975454|NCT02751996|ACTIVE_COMPARATOR|Part B: Tenofovir 300 mg|Part B: Tenofovir 300 mg qd monotherapy. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
62522426|NCT04125121|ACTIVE_COMPARATOR|Sevoflurane-Propofol|"Session one: Sevoflurane as maintenance anaesthetic during general anaesthesia.~Session two: Propofol as maintenance anaesthetic during general anaesthesia."
62522427|NCT04125121|ACTIVE_COMPARATOR|Propofol-Sevoflurane|"Session one: Propofol as maintenance anaesthetic during general anaesthesia.~Session two: Sevoflurane as maintenance anaesthetic during general anaesthesia."
62522428|NCT03928314|EXPERIMENTAL|Dose Escalation (Part I)|ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.
62522429|NCT03928314|EXPERIMENTAL|Dose Expansion (Part II)|RP2D dose
62522430|NCT04570397|EXPERIMENTAL|Interventional arm|ravulizumab
62522431|NCT04570397|NO_INTERVENTION|Control arm|patients in this arm will recieve standard care
62522432|NCT04158661||Tmin-group|"* confirmed seropositive ocular or generalized MG \[detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin\] or seronegative ocular or generalized MG~* age ≥ 18 years~* thymectomy ≥ three years"
62522433|NCT04158661||T0-group|"* confirmed seropositive ocular or generalized MG \[detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin\] or seronegative ocular or generalized MG~* a very long disease history OR~* age ≥ 18 years~* rejecting a thymectomy or have contraindications for thymectomy"
62522434|NCT04158661||"MGTX-group (historical control group)"|"from MGTX-trial (Randomized Trial of Thymectomy in Myasthenia Gravis)"
62522435|NCT03185013|EXPERIMENTAL|VGX-3100 + EP|Participants received three IM injections of 6 milligram (mg) (in 1 milliliter \[mL\]) VGX-3100 followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
62522436|NCT03185013|PLACEBO_COMPARATOR|Placebo + EP|Participants received three IM injections of 1 mL VGX-3100 matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
62522437|NCT01298401|EXPERIMENTAL|Arm A|Dose level -1A (Ganitumab 6 mg/kg, Capecitabine 825mg/m2)
62522438|NCT01298401|EXPERIMENTAL|Arm B|Dose level 1A (Ganitumab 12 mg/kg, Capecitabine 825mg/m2)
62522439|NCT01298401|EXPERIMENTAL|Arm C|Dose level 2A (Ganitumab 20 mg/kg, Capecitabine 825mg/m2)
62522440|NCT01298401|EXPERIMENTAL|Arm D|Dose level -1B (Ganitumab 6 mg/kg, Capecitabine 625mg/m2)
62522441|NCT01298401|EXPERIMENTAL|Arm E|Dose level 1B (Ganitumab 12 mg/kg, Capecitabine 625mg/m2)
62522442|NCT01298401|EXPERIMENTAL|Arm F|Dose level 2B (Ganitumab 20 mg/kg, Capecitabine 625mg/m2)
62358358|NCT00033371|ACTIVE_COMPARATOR|Arm I: Celecoxib and Placebo|Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
61975455|NCT06366568|EXPERIMENTAL|Group 1|toothpaste and gum product, brushing 2x a day for 2 minutes followed by gum product application
61975456|NCT06366568|PLACEBO_COMPARATOR|Group 2|toothpaste , brushing 2x a day for 2 minutes
61975457|NCT02956265|EXPERIMENTAL|Patients - Suffering from carcinomatous or polymorphous skin|
61975458|NCT01409564|EXPERIMENTAL|Cilostazol|Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
61975459|NCT01409564|PLACEBO_COMPARATOR|Placebo|Placebo group means dementia patients group receiving donepezil with placebo.
62358359|NCT00033371|EXPERIMENTAL|Arm II: Celecoxib and Eflornithine|Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m\^2/day rounded down to the nearest 250 mg dose. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
62358360|NCT01277913|EXPERIMENTAL|Vitamin D 1000 IU|vitamin D will be given 1000 IU for 12 months
62358361|NCT01277913|ACTIVE_COMPARATOR|Vitamin D 500IU|vitamin D 500 IU will be given for 12 months once daily
62358362|NCT01425853|EXPERIMENTAL|Chondroitin/Glucosamine (Droglican)|"Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.~Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX."
62358363|NCT01425853|ACTIVE_COMPARATOR|Celecoxib|Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
62358364|NCT05285267|ACTIVE_COMPARATOR|Parent-Child Activities|"Families assigned to the active control group will participate in weekly parent-child open house where the parents will be permitted to meet with other parents in the meeting room and the children will be invited to attend an open gym. There will be no formal curriculum for the parent meetings, but the facilitator will be available to inform the parents of community resources (e.g., mentorship programs) and a resources table will be made available of community activities and referrals in the same manner as the other two groups."
62358365|NCT05285267|EXPERIMENTAL|Nurturing Fathers|The Nurturing Fathers program (Perlman, 2021) is an adaptation of the Nurturing Parent program. It is a 13-week program that covers the role of fathers, the importance of nurturance rather than fear in fathering, how to effectively play and discipline a child, how to build relationships with the child and co-parent, and it ends with a graduate ceremony. For the present study, consistent with a prevention approach, the investigators will modify the Nurturing Fathers program to focus on the content directly related to parenting skills. The investigators will implement an eight-week program, which is consistent with the duration of prior, successfully attended father-focused interventions (e.g., Fabiano et al., 2009).
62358366|NCT05285267|EXPERIMENTAL|Nurturing Fathers + COACHES|The Nurturing Fathers program described above will be implemented as described. For the last 45 minutes of the sessions, fathers will join the child activity group and participate in shared parent-child activities consistent with the COACHES model. For the present study, several adaptations to the clinic-based COACHES program will be made, similar to those successfully deployed in our preliminary study in Head Start preschool settings (Caserta, Fabiano, et al., 2018). The investigators will use the Nurturing Fathers curriculum as the substantive content for each meeting, and then use the parent-child interactions within recreational sports as the forum for practicing skills.
62358367|NCT04451291|EXPERIMENTAL|Decidual Stromal Cells (DSC)|Participants will receive one dose of DSC at 1x10\^6/kg. A second dose may be given sometime between Day 5 and Day 8 if the participant's condition improves.
62358368|NCT06258863||inframammary fold incision|A total mastectomy was performed using an inframammary fold incision
62358369|NCT06258863||lateral chest wall incision|A longitudinal incision was made in the lateral chest wall for a total mastectomy
62358370|NCT06258863||circumareolar incision|A total mastectomy was performed with an arc-shaped incision around the areola without limiting the distance to the nipple
62358371|NCT06258863||radial incision|A total mastectomy was performed with a radial incision around the nipple
62358372|NCT00143988||Treadmill Test exertion females|
62358373|NCT00143988||Treadmill test exertion males|
62358374|NCT00143988||Sexual activity exertion females|
62358375|NCT00143988||Sexual activity exertion males|
62358376|NCT00981747|EXPERIMENTAL|All study participants|Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).
62358377|NCT05656391|ACTIVE_COMPARATOR|Treatment bread|Dietary treatment consisted of daily consumption of 200 grams of bread produced following traditional breadmaking techniques
62358378|NCT05656391|PLACEBO_COMPARATOR|Control bread|Dietary treatment consisted of daily consumption of 200 grams of bread produced following modern breadmaking techniques
62358379|NCT04969211|EXPERIMENTAL|Sequence A: VHX-896 then iloperidone|
62358380|NCT04969211|EXPERIMENTAL|Sequence B: Iloperidone then VHX-896|
62358381|NCT00979108|ACTIVE_COMPARATOR|Standard exercise|Subjects will be instructed in neck and postural exercises.
62358382|NCT00979108|EXPERIMENTAL|Over-door traction and exercise.|Subjects will receive traction utilizing an over-the-door traction unit in addition to neck and postural exercises.
62358383|NCT00979108|EXPERIMENTAL|Mechanical traction and exercise|Mechanical cervical traction will be utilized in addition to neck and postural exercises.
62358384|NCT00607126|EXPERIMENTAL|1|locomotor training using body weight support on a treadmill, using robotic device to provide locomotor training. Locomotor training will be done using the Lokomat device. the patient is suspended over a treadmill while their legs are in the Lokomat, which moves the legs on the treadmill.
62358385|NCT00607126|ACTIVE_COMPARATOR|2|resistive training using weights and therabands
62358386|NCT04239170|EXPERIMENTAL|Camrelizumab(SHR-1210) Combined With GEMOX|
62358387|NCT02582931|EXPERIMENTAL|Arm 1: MRI-guided SBRT|"* Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~* Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV.~* All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site"
62711989|NCT03943277||patient with infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:~A group with an inflammatory syndrome and infection; infection being defined as:~1. Viral infection confirmed by nasopharynx swab for: influenza, RSV, parainfluenza, rhinovirusses, coronavirusses.~2. Bacterial infection confirmed with positive blood culture, positive articular punction, positive expectorations, pneumonia on chest radiograph, or infection documented by abdominal imagery (CT or echo), a positive urine culture with a confirmed pyelonephritis with a renal echography or a DMSA scintigraphy or specific clinical symptoms for pyelonephritis and positive hemoculture. A positive urine culture alone is not considered as urine infection because of the high prevalence of asymptomatic bacteriuria in geriatric patients."
62522443|NCT03301532|EXPERIMENTAL|Patients on a ketogenic diet|This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.
62150499|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
62150500|NCT05615337|EXPERIMENTAL|Mindfulness-based stress reduction - MBSR|Traditional MBSR curriculum
62150501|NCT05615337|ACTIVE_COMPARATOR|Health Promotion Program - HPP|the HPP has the same structure of MBSR, but training different components, not including mindfulness practice.
62522444|NCT03375294|EXPERIMENTAL|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
62711990|NCT03943277||patient without infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:~=\> B) A group with inflammatory syndrome and inflammatory diseases without infection: defined as:~1. Confirmed pulmonary embolism (PE) by CT or ventilation-perfusion scintigraphy~2. Microcrystalline arthritis diagnosed by articular punction~3. Crush syndrome or rhabdomyolyses defined by history of a fall and raised creatine kinase in blood sample."
62711991|NCT02464982||Women with 1 year non-invasive technology areola tattoo|Women with 1 year non-invasive technology areola tattoo realized in standard care as part of 1 breast mammary reconstruction following an operated breast cancer
62150502|NCT01836523|EXPERIMENTAL|Liraglutide 0.6 mg + insulin|
62150503|NCT01836523|EXPERIMENTAL|Liraglutide 1.2 mg + insulin|
62150504|NCT01836523|EXPERIMENTAL|Liraglutide 1.8 mg + insulin|
62150505|NCT01836523|PLACEBO_COMPARATOR|Liraglutide placebo 0.6 mg + insulin|
62150506|NCT01836523|PLACEBO_COMPARATOR|Liraglutide placebo 1.2 mg + insulin|
62150507|NCT01836523|PLACEBO_COMPARATOR|Liraglutide placebo 1.8 mg + insulin|
62150508|NCT00786188|EXPERIMENTAL|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
62150509|NCT00786188|PLACEBO_COMPARATOR|Placebo - Sugar Pill|Eligible subjects will be randomized to receive a sugar pill.
62150510|NCT02372799|EXPERIMENTAL|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
62150511|NCT02372799|PLACEBO_COMPARATOR|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
62150512|NCT02372799|ACTIVE_COMPARATOR|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
62522445|NCT03165877|EXPERIMENTAL|Low-glycemic index|Low-glycemic index lunches and dinners (\<55%)
62711992|NCT01731561|EXPERIMENTAL|Rituximab infusion according biological parameters|Rituximab infusion based on ANCA and CD19 lymphocytes
62711993|NCT01731561|ACTIVE_COMPARATOR|Systematic rituximab infusion|Semestrial rituximab infusion until 18 months
62711994|NCT02622269|EXPERIMENTAL|Patient-regulated compression|Patient-regulated compression device
62522446|NCT03165877|ACTIVE_COMPARATOR|Control|Medium/high glycemic index lunches and dinners (\>60%)
62150513|NCT05281081|ACTIVE_COMPARATOR|levobupivacaine with morphine|30 patients will have intraperitoneal instillation of levobupivacaine with added morphine at the end of laparoscopic cholecystectomy operation
62150514|NCT05281081|EXPERIMENTAL|levobupivacaine with magnesium sulfate|30 patients will have intraperitoneal instillation of levobupivacaine with added magnesium sulfate at the end of laparoscopic cholecystectomy operation
62150515|NCT04131036||Arm A|Male patients with severe Hemophilia A who use prophylaxis with IV factor VIII concentrate with intended trough \>1%.
62150516|NCT04131036||Arm B|Male patients with severe Hemophilia A who use prophylaxis with SQ emicizumab.
62150517|NCT02773082|EXPERIMENTAL|Reclaim™ DBS Therapy|"Procedure:~The DBS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region. This is performed by a neurosurgeon skilled in this technique, as the same procedure is routinely performed in patients with other diseases (using other brain targets)."
62150518|NCT00493688||Cardiopulmonary Exercise Testing (CPET)|
62522447|NCT00534014|PLACEBO_COMPARATOR|A|0 mg of Vitamin C
62522448|NCT00534014|ACTIVE_COMPARATOR|B|250 mg Vitamin C
62522449|NCT00534014|ACTIVE_COMPARATOR|C|500 mg Vitamin C
62522450|NCT00534014|ACTIVE_COMPARATOR|D|1000 mg Vitamin C
62522451|NCT02691793|EXPERIMENTAL|sunitinib|sunitinib 50 mg will be administered orally daily
62522452|NCT00311311|ACTIVE_COMPARATOR|1|Tacrolimus + MMF + Steroids
62522453|NCT00311311|EXPERIMENTAL|2|Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
62711995|NCT02622269|ACTIVE_COMPARATOR|Standard compression|Standard compression device
62150519|NCT02489357|EXPERIMENTAL|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
62150520|NCT00551421|EXPERIMENTAL|Arm I|"Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I)."
62150521|NCT06177821|EXPERIMENTAL|Group A, 5 seconds|Patients with benign prostatic hyperplasia featuring a small median lobe enlargement will be allocated to the 5-second Rezum therapy group.
62150522|NCT06177821|EXPERIMENTAL|Group B, 9 seconds|Patients with benign prostatic hyperplasia featuring a big prominent median lobe enlargement will be allocated to the 9-second Rezum therapy group.
62711996|NCT01093131|ACTIVE_COMPARATOR|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
62711997|NCT01093131|ACTIVE_COMPARATOR|Intravenous hydration and sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
62150523|NCT03488498||Receiving NSAID medication|Receiving NSAID medication
62150524|NCT03488498||Receiving NSAID medication and weight bath therapy,|
62150525|NCT03488498||Receiving weight bath therapy,|
62150526|NCT03233542|EXPERIMENTAL|Panic Disorder: CBT|Participants with Panic Disorder randomized to this arm will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
62150527|NCT03233542|NO_INTERVENTION|Panic Disorder: Waiting list|After the pre-treatment testing session, participants with Panic Disorder randomized to this arm will wait a length of time equivalent to that for the pre/post-treatment duration for the Panic Disorder: Cognitive Behaviour Therapy arm (approx. 3 months), before returning to the post-treatment assessment. After completing all the study procedures, participants in this arm receive also the manualised Cognitive Behaviour Therapy treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
62150528|NCT03233542|OTHER|Anxious Control Group: CBT|All participants in the Anxious Control Group will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for their diagnosed anxiety disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
62150529|NCT03693989|EXPERIMENTAL|PRO-145.|Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
62150530|NCT03693989|ACTIVE_COMPARATOR|Prednefrin|Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
62150531|NCT01894503|EXPERIMENTAL|S8 Sinus Implant|Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
62150532|NCT04740541|EXPERIMENTAL|Threonine Requirement in CD Patients|Males aged 18 - 49 with stable Crohn's disease will be seen for pre-study They will be studied up to 5 times for different levels of threonine intakes.
62150533|NCT05733494||Patients with neurodegenerative disease|Patients with neurodegenerative disease
62150534|NCT05438875|ACTIVE_COMPARATOR|Eltrombopag|The initial dose of eltrombopag was 50 mg/time, once a day. According to the clinical standard of eltrombopag dose adjustment in the research protocol set by the research group, the dose was increased when the platelet count was lower than 5×109/L. The highest is 75mg/d, if the dose is higher than 200×109/L, the dose is reduced. When the dose is higher than 400×109/L, the drug is temporarily discontinued, and the drug is repeated according to the platelet count. The treatment course is 12 weeks.
62150535|NCT05438875|EXPERIMENTAL|ATRA and Eltrombopag|ATRA 10 mg, 2 times a day, orally; The initial dose of eltrombopag was 50 mg/time, once a day. According to the clinical standard of eltrombopag dose adjustment in the research protocol set by the research group, the dose was increased when the platelet count was lower than 5×109/L. The maximum dose is 75 mg/d, the dose is reduced if it is higher than 200×109/L, and the drug is temporarily discontinued when it is higher than 400×109/L, and the drug is repeated according to the platelet count. The treatment course is 12 weeks.
62150536|NCT03072810|EXPERIMENTAL|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
62150537|NCT03072810|OTHER|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
62150538|NCT04613284|EXPERIMENTAL|Endostar combined Radiation|
62150539|NCT03019289|EXPERIMENTAL|pridopidine|Pridopidine (TV-7820) capsules
62150540|NCT01929902||Surgical Patients|
62150541|NCT01778803|EXPERIMENTAL|defactinib (VS-6063) plus paclitaxel|Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
62150542|NCT04158206|EXPERIMENTAL|Maternal voice|The mother's voice recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group were explored maternal voice, which start from 3 minutes before the procedure, once a day and for three consecutive days.And then recorded the process by the camera, uploaded to YouTube within 24 hours and sent to their mother.
62150543|NCT04158206|NO_INTERVENTION|control group|When the premature infants undergoing heel lance procedure, the control group were under routine care.And then recorded the process by the camera for three consecutive days, uploaded to YouTube within 24 hours and sent to their mother.
62150544|NCT04454723|EXPERIMENTAL|Tranfusions and blood collection|"Patients enrolled will receive one unit each of blood and/or platelet transfusions once a week based on trigger symptoms of anemia and/or thrombocytopenia, along with blood sample collections.~Data on patient demographics, disease, and length of hospice stay will also be collected."
62150545|NCT03953079|EXPERIMENTAL|GB-102 1 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 1 mg in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
62711998|NCT01093131|ACTIVE_COMPARATOR|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
62150546|NCT03953079|EXPERIMENTAL|GB-102 2 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 2 mg in the study eye at Baseline, intravitreal (IVT) GB-102 1 mg at Month 6 and sham at Months 2, 4, 8 and 10.
62150547|NCT03953079|ACTIVE_COMPARATOR|Aflibercept 2 mg|Participants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.
62150548|NCT02840045|EXPERIMENTAL|Alzheimer patients|Cerebral measurements from high-density electroencephalography are recorded in Alzheimer patients. The same protocol is applied in the 3 arms
62711999|NCT01093131|ACTIVE_COMPARATOR|Oral hydration and oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
62712000|NCT03687281||Male patients living with HIV and having sex with men|Male patients living with HIV and having sex with men followed at Universitary Hospital Center of Reunion Island
62150549|NCT02840045|EXPERIMENTAL|patients with a depressive disorder|Cerebral measurements from high-density electroencephalography are recorded in patients with a depressive disorder. The same protocol is applied in the 3 arms
62358388|NCT03083275|EXPERIMENTAL|Resistance Training|
62358389|NCT03083275|NO_INTERVENTION|Control|
62358390|NCT02147509|EXPERIMENTAL|Severe dry eye|"1. 0.02% Fm, SH~2. 0.02% Fm, SH, AS~3. 0.02% Fm, SH, 0.05% CsA~4. 0.02% Fm, SH, tBCL (0.05% CsA: 0.05% cyclosporin A; tBCL: therapeutic bandage contact lenses; 0.02% Fm: 0.02% Fluorometholone; AS: Autologous Serum; SH: Sodium Hyaluronate)"
62712001|NCT03401294|OTHER|Single arm|FOLFOXIRI and Bevacizumab
62712002|NCT03314428|EXPERIMENTAL|Gait retraining|Runners will be taught how to modify their running gait through multiple laboratory sessions and in-field training.
62712003|NCT06717334||Patients undergoing Lung cancer screening|All patients will undergo prospective LDCT imaging annually. At baseline and Year 1, patients will also undergo biospecimen collection for post-hoc ctDNA analysis.
62712004|NCT01882465|OTHER|etafilcon A/2-HEMA, EGDMA/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
62712005|NCT01882465|OTHER|etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
61975460|NCT01979484|EXPERIMENTAL|PPI-668 capsule followed by tablet|On day 1 two 100 mg PPI-668 capsules will be administered; on day 8 one 200 mg PPI-668 tablet will be administered
61975461|NCT01979484|EXPERIMENTAL|PPI-668 tablet followed by capsule|On day 1 one 200 mg PPI-668 tablet will be administered; on day 8 two 100 mg PPI-668 capsules will be administered
61975462|NCT02055690|EXPERIMENTAL|Phase Ib/II: Fosbretabulin & Pazopanib|"Phase Ib:~Fosbretabulin and Pazopanib in combination. Fosbreatabulin dose will be in the range of 45mg/m2- 60 mg/m2 delivered by infusion every week for 3 weeks of a 4 week cycle until disease progression. Pazopanib will be either 600 mg or 800mg taken orally each day of 28 day cycle until disease progression.~The phase II dose of both drugs will be determined by the Phase Ib component which is a dose finding exercise.~Phase II:~Fosbretabulin and Pazopanib in combination. Fosbretabulin 54mg/m2 delivered by infusion every week for 3 weeks of a 4 week for 28 day cycle until disease progression. Pazopanib 600mg taken orally each day for 28 day cycle until disease progression"
61975463|NCT02055690|ACTIVE_COMPARATOR|Phase II: Pazopanib|Pazopanib 800mg taken orally each day of 28 day cycle until disease progression
61975464|NCT01523574|PLACEBO_COMPARATOR|Control Group|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
61975465|NCT01523574|EXPERIMENTAL|Vitamin e|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
61975466|NCT01829230|EXPERIMENTAL|Test lens C|Test lens C from previous study
61975467|NCT01829230|ACTIVE_COMPARATOR|Test lens A|Test lens A from previous study
61975468|NCT06228547||POI|Woman aged 18 years and older, diagnosed with POI following ESHRE 2016 criteria
61975469|NCT02086994|ACTIVE_COMPARATOR|cabetocin|a single dose of carbetocin (100 μg in 1 mL ampoule, Pabal) given intravenously after delivery of anterior shoulder
61975470|NCT02086994|ACTIVE_COMPARATOR|misoprostol|misoprostol (600 μg, 3 tables) sublingually after the delivery of the anterior shoulder of the baby.
61975471|NCT04396431|OTHER|2|The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy.
61975472|NCT02152839|EXPERIMENTAL|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
61975473|NCT02152839|EXPERIMENTAL|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
61975474|NCT02014896||Ischemic Stroke|"Ischemic stroke subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
61975475|NCT02014896||TIA (Transient Ischemic Attack)|"TIA subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
61975476|NCT02014896||Non-Ischemic TNE|"Non-Ischemic Transient Neurological Event (TNE) subjects will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department or hospital.~Biomarker blood draw"
61975477|NCT02014896||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn within 8 hours of arrival to the Emergency Department or hospital. Control group matched with ischemic stroke and TIA subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
61975478|NCT05265000|EXPERIMENTAL|tSpinalStim|Individuals in this arm will receive spinal cord stimulation
62358391|NCT03034057|OTHER|sayana press|single arm
62358392|NCT02195609|OTHER|Omega-3|600 mg (EPA, DHA and Omega-3) twice a day
62358393|NCT02195609|OTHER|Soy Isoflavones|54.4mg oral twice a day
62358394|NCT01084330|EXPERIMENTAL|AUY922|
62358395|NCT01084330|ACTIVE_COMPARATOR|Docetaxel or Irinotecan|
62358396|NCT03690947|EXPERIMENTAL|Combination Therapy Group|
62150550|NCT02840045|ACTIVE_COMPARATOR|Healthy controls|Cerebral measurements from high-density electroencephalography are recorded in healthy controls
62150551|NCT04725032|EXPERIMENTAL|sevoflurane-propofol balanced anesthesia|
62150552|NCT04725032|ACTIVE_COMPARATOR|propofol-based total intravenous anesthesia|
62150553|NCT01532609|EXPERIMENTAL|Intervention|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
62150554|NCT01532609|NO_INTERVENTION|Standard care|No additional training or service is provided for standard care group service providers or clients.
62150555|NCT06509230||mild fibrosis|S0-1
62150556|NCT06509230||significant liver fibrosis|S2
62150557|NCT06509230||Advanced liver fibrosis|S3-4
62150558|NCT02613052|PLACEBO_COMPARATOR|Agitated Normal Saline|Agitated saline is the current standard of care contrast agent used for bubble studies. 10 mL of agitated normal saline will be used for the bubble study.
62150559|NCT02613052|ACTIVE_COMPARATOR|Albumin only|10 mL of agitated 5% albumin will be used for the bubbly study.
62150560|NCT02613052|EXPERIMENTAL|Albumin and Propofol|7 mL of 5% albumin and 3 mL of propofol (10 mg/mL) will be agitated together and used for the bubble study.
62150561|NCT01997866|OTHER|Patients with Congestive Heart Failure|"STOP-BANG Scoring Model~Polysomnogram Sleep Study"
62150562|NCT05851157|EXPERIMENTAL|VX-548|Participants will be randomized to receive a single dose of VX-548 in 1 of 6 treatment sequences with 3 dosing periods to assess different fed conditions and timing of meal administration on the PK of VX 548. There will be a 14 day washout period between each dosing period.
62150563|NCT04804202|OTHER|Virtual Reality|This is a single arm study in which all participants will execute the same tasks over two sessions.
62150564|NCT01157624|ACTIVE_COMPARATOR|oxygen|
62150565|NCT01157624|PLACEBO_COMPARATOR|air supplement|
62150566|NCT00667953|EXPERIMENTAL|Arm A:|Temozolomide plus imatinib
62150567|NCT00871715|EXPERIMENTAL|ASAP|A focused, intense, evidence-based, upper extremity rehabilitation program, administered during the early post-acute outpatient interval. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence.
62150568|NCT00871715|ACTIVE_COMPARATOR|DEUCC|Dose-equivalent usual and customary arm therapy administered early post-acutely in the outpatient setting. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
62358397|NCT03690947|ACTIVE_COMPARATOR|Intravitreal Ranibizumab Group|
62358398|NCT01548417|ACTIVE_COMPARATOR|Korlym (mifepristone)|600 mg daily taken orally for one week
62358399|NCT01548417|PLACEBO_COMPARATOR|Sugar Pill|placebo pill daily taken orally for one week
62358400|NCT01866345|ACTIVE_COMPARATOR|Conventional orthodontic treatment|conventional orthodontic treatment in the mandibular anterior region
62358401|NCT01866345|EXPERIMENTAL|Surgically facilitated Orthodontics|Surgically facilitated Orthodontic treatment in the mandibular anterior region
62358402|NCT03466112|EXPERIMENTAL|endurance training|endurance training with stationary bicycles
62358403|NCT03466112|ACTIVE_COMPARATOR|balance and tone program|flexibility, core strength, balance, relaxation
62358404|NCT03904784||School withdrawal teenagers|The study is based on questionnaries, interview with teenagers and/or their familly
62358405|NCT06527209|ACTIVE_COMPARATOR|Sequence AB|Participants receive 350 g of a coffee and agave inulin-based beverage (A) at the fasting state 30 minutes before breakfast for two weeks, and after a two-week washout period, they will receive 350 g of a control beverage (B) at the fasting state, 30 minutes before breakfast for two weeks.
62358406|NCT06527209|ACTIVE_COMPARATOR|Sequence BA|Participants receive 350 g of a control beverage (B) at the fasting state 30 minutes before breakfast for two weeks, and after a two-week washout period, they will receive 350 g of a coffee and agave inulin-based beverage (A) at the fasting state, 30 minutes before breakfast for two weeks.
62358407|NCT05241665||Group 1|
62358408|NCT05241665||Group 2|
62358409|NCT04443842|EXPERIMENTAL|Intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentive, social incentives and weekly feedback on performance for 6 months.
62358410|NCT04443842|NO_INTERVENTION|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
62358411|NCT03529929|EXPERIMENTAL|Methylprednisolone|"Methylprednisolone glucocorticoid Medrol Dose Pack~Medrol is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively)."
62358412|NCT02015806|EXPERIMENTAL|All meds but depression, 1x daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
62358413|NCT02015806|EXPERIMENTAL|All meds but depression, 1x daily use, Take-N-Slide|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
62358414|NCT02015806|EXPERIMENTAL|All meds but depression, 1x daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
62358415|NCT02015806|NO_INTERVENTION|All meds but depression, 1x daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
62522454|NCT04149886|EXPERIMENTAL|Ablation group(Ablation+pacemaker)|"The cardioneuroablation will be performed under conscious sedation. After 3-dimensional endocardial surface of the LA and pulmonary veins have been constructed by Ensite system, the GP sites can be located in LA；High frequecy stimulation（HFS）will be used to conform if there is a positive vagal response at each GP site. The upper limits of power and temperature will be set to 30-40 W and 43-60°C, respectively. And if no vagal response been induced during ablation, radiofrequency will be delivered for 30 seconds and stopped in this site. The end point of the ablation procedure will be that no vagal response could be induced by repeat HFS.~After ablation of GPs, the participants will receive permanent pacemaker implantation(see arm of control group)."
62522455|NCT04149886|SHAM_COMPARATOR|Control group(only pacemaker)|The control group only treated with permanent pacemaker without cardioneuroablation.The participants will receive permanent pacemaker implantation, the pacemaker placement will be done in accordance with standards at each center. All implanted pacemakers are provided two manufacturers (St. Jude Medical or Medtronics), His bundle pacing will be recommended in patients with a LVEF between 35%-45%. After placement of permanent pacemaker, the participants will be followed-up at 1 week, 3,6,12 months. After the permanent pacemaker implantation, the rate response function should be turned off and low pacing rate should be set at 60bpm uniformly in all the eligible participants.
62522456|NCT00838708|PLACEBO_COMPARATOR|Vehicle cream|
62522457|NCT00838708|EXPERIMENTAL|SRD174 Cream|
62522458|NCT05889234||Modified electroconvulsive therapy group|The adolescent MDD receiving modified electroconvulsive therapy and conventional medication.
62522459|NCT05889234||Non-modified electroconvulsive therapy group|The adolescent MDD receiving only conventional medication.
62522460|NCT05889234||Healthy controls group|Healthy adolescents.
62522461|NCT02088190||Age group 1|Age \> 60 years old
62522462|NCT02088190||Age group 2|Age \< 60 years old
62522463|NCT01153230||poisoned patient|after patients died the pathological findings evaluated with autopsy
62522464|NCT01616953|EXPERIMENTAL|Ixmyelocel-T|iliac bone marrow aspirates are expanded ex vivo to enrich for adult multipotent cells (ixmyelocel-T) capable of regenerating bone and blood vessels and reducing inflammation. Following cell expansion, autologous ixmyelocel-T is then packaged and can be used as an autologous graft for treatment of bone defects.
62522465|NCT01616953|ACTIVE_COMPARATOR|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
62522466|NCT03119506||Long Recess Duration/Before Lunch|
62522467|NCT03119506||Short Recess Duration/Before Lunch|
62522468|NCT03119506||Long Recess Duration/After Lunch|
62522469|NCT03119506||Short Recess Duration/After Lunch|
62712006|NCT01882465|OTHER|2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
62522470|NCT04993677|EXPERIMENTAL|Melanoma Arm|SEA-CD40 + pembrolizumab
62522471|NCT04993677|EXPERIMENTAL|NSCLC Arm|SEA-CD40 + pembrolizumab + pemetrexed + carboplatin
62712007|NCT01882465|OTHER|2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
62712008|NCT01882465|OTHER|hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
62150569|NCT00871715|OTHER|UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group with treatment dose administered in accordance with usual and customary practices.
62150570|NCT02991573|ACTIVE_COMPARATOR|existing adhesive (control)|control adhesive
62522472|NCT06148571||Prospective LBBAP-HF cohort|Patient who underwent attempted left bundle branch area pacing using Biotronik Selectra 3D sheath and stylet driven lead (Solia S60, Biotronik).
62522473|NCT06148571||Retrospective LBBAP-HF cohort|Patients who underwent attempted left bundle branch area pacing using Biotronik Selectra 3D and Solia S60 lead prior to prospective enrollment.
62522474|NCT05824741|EXPERIMENTAL|Intervention|All participants will be enrolled into the intervention arm of this pilot study.
62522475|NCT00794391|EXPERIMENTAL|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
62522476|NCT00794391|ACTIVE_COMPARATOR|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
62522477|NCT05964192|EXPERIMENTAL|Treatment resistant major depressed inpatients (TRDs)|
62522478|NCT01462318|EXPERIMENTAL|DAC HYP|"DAC HYP 150 mg by a subcutaneous (SC) injection using the pre-filled syringe (PFS) every 4 weeks for 24 weeks followed by a 20-week washout period. After completion of the washout period, participants may resume monthly DAC HYP 150 mg using the PFS for up to 3 additional years.~Participants in the TP-DI sub-study will receive probe-drug cocktail administration at Weeks 43 and 53. The probe-drug cocktail consists of oral midazolam 5 mg, caffeine 200 mg, S-warfarin 10 mg, vitamin K 10 mg, omeprazole 40 mg, and dextromethorphan 30 mg. The oral vitamin K is used to counteract warfarin's anticoagula nt effect prophylactically."
62522479|NCT02801084|EXPERIMENTAL|Float|One arm only: restricted environmental stimulation
62712009|NCT01882465|OTHER|hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
62522480|NCT04078438|EXPERIMENTAL|neurofeedback augmentation group|The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol was determined considering the patient's main symptoms. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.
62522481|NCT04078438|ACTIVE_COMPARATOR|medication-only (treatment as usual, TAU) group|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.
62522482|NCT04078438|NO_INTERVENTION|healthy controls|The healthy controls provided blood samples using the same procedure at baseline only.
62522483|NCT00631852|EXPERIMENTAL|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
62522484|NCT05372783|EXPERIMENTAL|STI-9199|4 mg, 10 mg or 20 mg STI-9199 administered intranasally
62522485|NCT05372783|PLACEBO_COMPARATOR|Placebo|Placebo administered intranasally
62522486|NCT03256084|EXPERIMENTAL|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
62522487|NCT05051202|EXPERIMENTAL|25g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 25 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
62712010|NCT01194362||45 specimens collected from BAV patients|
62712011|NCT01194362||45 specimens collected from TAV patients|
62522488|NCT05051202|ACTIVE_COMPARATOR|25g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 25 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
62522489|NCT05051202|EXPERIMENTAL|35g Sugars From Fiber per day|Administered in 50 g Flapjack containing 35 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
62522490|NCT05051202|ACTIVE_COMPARATOR|35g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 35 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
62522491|NCT05051202|EXPERIMENTAL|45g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 45 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
62712012|NCT01194362||15 specimens collected from CABG pts|
62712013|NCT03425955|EXPERIMENTAL|GROUP 1|Normotypic or overweight subjects with rounded, oval or squared face (aged 35-50 years)
62712014|NCT03425955|EXPERIMENTAL|GROUP 2|"Thin subjects with oval or triangular face and sagging skin (aged 45-60 years)"
61975479|NCT06441344|EXPERIMENTAL|platinum+etoposide → toripalimab plus anlotinib|The experimental group was given etoposide (100 mg/m2) d1-3+carboplatin (AUC 5 d1)/cisplatin (25 mg/m2)d1-3 Chemotherapy regimen, for patients who have received 4-6 cycles chemotherapy sessions (including PR, CR, SD), they will enter the maintenance treatment phase and receive an oral dose of 12 mg of anlotinib (d1-14) combined with intravenous infusion of toripalimab 240mg for maintenance treatment until progress or intolerable adverse reactions occur or died for other illnesses
61975480|NCT06441344|ACTIVE_COMPARATOR|platinum+etoposide+ toripalimab → toripalimab|The control group was given etoposide (100 mg/m2) d1-3+carboplatin (AUC 5) d1/cisplatin (25mg/m2)+and toripalimab (240 mg) ,for patients who have received 4-6 cycles chemotherapy sessions (including PR, CR, SD), they will enter the maintenance treatment phase and receive maintenance treatment with toripalimab 240 mg d1 until progress or intolerable adverse reactions occur or died for other illnesses
61975481|NCT05036434|EXPERIMENTAL|Treatment arm|Pembrolizumab 200mg q 3wks IV / Lenvatinib 20mg daily once PO q 3wks
61975482|NCT05111158||50 eyes of 25 SLE patients with renal affection (Lupus nephritis).|mfERG
61975483|NCT05111158||50 eyes of 25 SLE patients without renal affection|mfERG
61975484|NCT00490854|EXPERIMENTAL|1|
61975485|NCT00490854|EXPERIMENTAL|2|
61975486|NCT02511184|EXPERIMENTAL|Dose finding and dose expansion phases|Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
61975487|NCT02857933|OTHER|Frequency Level 1 - Daily Therapy|Level 1 daily physical therapy is 2 hours of one-on-one physical therapy per day for 20 straight weekdays
61975488|NCT02857933|OTHER|Frequency Level 2 - Intermediate Therapy|Level 2 intermediate physical therapy is 2 hours of therapy per day 3 days per week for 6.6 weeks
61975489|NCT02857933|OTHER|Frequency Level 3 - Usual Therapy|Level 3 usual weekly physical therapy is 2 hours of therapy one day per week for 20 weeks.
62712015|NCT01486888|EXPERIMENTAL|Formulation A|
62712016|NCT01486888|ACTIVE_COMPARATOR|Formulation B|
61976407|NCT05253170|ACTIVE_COMPARATOR|Conventional Fractionation|"For the cumulative total dose of 45-50.4 Gy to the chest wall, a daily dose of 1.8-2.0 Gy is administered 23-28 fractions.~* Should be started within 3 months of completion of mastectomy or chemotherapy.~* Clinical target volume (CTV) may include regional lymph nodes.~* If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines."
62150571|NCT02991573|EXPERIMENTAL|new adhesive: technique 1|Prime \& Bond Universal: technique 1
62712017|NCT02499614|EXPERIMENTAL|Patients with MET amplification or MET exon 14 mutation|Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
62712018|NCT02499614|EXPERIMENTAL|Patients with ROS1 translocation|Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
62712019|NCT06368648||Patients receiving invasive ICP and ABP monitoring as their standard of care|Patients who are receiving invasive Intracranial Pressure (ICP) monitoring and invasive Arterial Blood Pressure (ABP) monitoring as per standard practice will serve as their own controls.
62712020|NCT04858581|OTHER|Healthcare workers who had a diagnosis confirmed by a nasopharyngeal RT-PCR test with SARS-CoV-2|Survey, RT-PCR test and blood test.
62358416|NCT02015806|EXPERIMENTAL|All meds but depression, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
62358417|NCT02015806|EXPERIMENTAL|All meds but depression, ≥1 med >1 daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
62358418|NCT02015806|NO_INTERVENTION|All meds but depression, ≥1 med >1 daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
62358419|NCT02015806|EXPERIMENTAL|Only depression meds, 1x daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
62358420|NCT02015806|EXPERIMENTAL|Only depression meds, 1x daily use, Take-N-Slide|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
62358421|NCT02015806|EXPERIMENTAL|Only depression meds, 1x daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
62358422|NCT02015806|NO_INTERVENTION|Only depression meds, 1x daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
62358423|NCT02015806|EXPERIMENTAL|Only depression meds, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
62358424|NCT02015806|EXPERIMENTAL|Only depression meds, ≥1 med >1 daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
62358425|NCT02015806|NO_INTERVENTION|Only depression meds, ≥1 med >1 daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
62358426|NCT05286996|EXPERIMENTAL|Iovera|Cryoneurolysis + standard of care: Usual intervention plus pre-operation Iovera treatment. Patients will receive local anaesthesia unilaterally to the affected knee prior to the treatment and then the anesthesiologist will administer the freezing cold therapy (Iovera device) to the affected knee.
62358427|NCT05286996|PLACEBO_COMPARATOR|Placebo|Placebo: Usual intervention plus pre-operation placebo. The placebo group will receive short-acting local anaesthesia injection unilaterally to the affected knee.
62358428|NCT01192841|NO_INTERVENTION|White coat group|Participants continued their regular practice of wearing their physician white coat.
62358429|NCT01192841|EXPERIMENTAL|Uniform group|Participants were given a clean uniform (scrubs) at the beginning of the day.
62358430|NCT00695500|EXPERIMENTAL|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
62150572|NCT02991573|EXPERIMENTAL|new adhesive: technique 2|Prime \& Bond Universal: technique 2
62150573|NCT00579306||SPS3 patient cohort|All SPS3 patients who participate in Baseline and 1-Year F/U blood draw
62358431|NCT00695500|PLACEBO_COMPARATOR|Placebo|Placebo tablets, 0 mg per day for 3 weeks
62358432|NCT04008199|NO_INTERVENTION|Control|Control group will not receive any intervention. Households in this group will only be surveyed.
62358433|NCT04008199|EXPERIMENTAL|Treatment|Treatment group will receive an invitation to join Super Abbu in addition to identical surveys to those in the control group.
62358434|NCT01731405||Formats A,B,C; medicines Ritalin, Morphine Sulfate, Aranesp|All patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
62358435|NCT01731405||There is not another group|
62358436|NCT02923310|EXPERIMENTAL|Osteoarthrits G II and III|Group of treatment
62358437|NCT02923310|EXPERIMENTAL|Osteoarthrits GIV|Group of treatment
62358438|NCT03199508|EXPERIMENTAL|the 3-day voiding diary group|The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
62358439|NCT03199508|ACTIVE_COMPARATOR|the 7-day voiding diary group|The 7-day voiding diary group is as the control group in which several centers use the 7-day voiding diary by cluster randomization. The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights. The 3-day voiding diary group is the experimental group in which several centers use the 3-day voiding diary by cluster randomization.
62522492|NCT05051202|ACTIVE_COMPARATOR|45g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 45 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
62522493|NCT00046631||Adolescent girls|Chosen from 6 schools in 6 cities
62522494|NCT03138447|EXPERIMENTAL|Prospective Cohort|
62150574|NCT00811239|OTHER|control group|As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
62150575|NCT00811239|ACTIVE_COMPARATOR|antivenom group|The patients included during the third year (2006) were treated with antivenom therapy and supportive care.
62150576|NCT06500546|OTHER|Adhesion Strategies|Four non-carious cervical lesions from patients will be separated into four groups according to differnet adhesion strategies
62150577|NCT06500546|OTHER|Different procedure|All lesions to which adhesives are applied according to different adhesion strategies will be restored with the same type of composite material.
62150578|NCT06505577||Breast cancer surgery group|This cohort includes all patients undergoing breast cancer surgery who are enrolled in the study.
62150579|NCT01727167|PLACEBO_COMPARATOR|Control Group|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
62150580|NCT01727167|EXPERIMENTAL|CO group|This group will breath 200 ppm of CO for one hour per day over the course of the three days immediately prior to surgery.
62150581|NCT01214070|ACTIVE_COMPARATOR|Arm 1|Group 1 - Combination Treatment
62150582|NCT01214070|ACTIVE_COMPARATOR|Arm 2|Group 2 - Combination Treatment
62522495|NCT03138447|NO_INTERVENTION|Retrospective Cohort|
62522496|NCT00000607|EXPERIMENTAL|Left ventricular assist device|Subjects received Thermo Cardiosystems, Inc. (TCI) vented electric (VE) left ventricular assist device (LVAD) and were followed for at least two years
62522497|NCT00000607|ACTIVE_COMPARATOR|Optimal medical therapy|Subjects received optimal medical therapy (OMM) and were followed for at least two years
62522498|NCT01131572|OTHER|N-acetylcysteine|open label treatment. Each subject receives N-acetylcysteine.
62522499|NCT01472328|EXPERIMENTAL|Hyperbaric oxygen therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
62522500|NCT01472328|SHAM_COMPARATOR|Hyperbaric room air|Effect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
62522501|NCT05701644|EXPERIMENTAL|C1K 150mg|Subcutaneous Administration C1K 150mg single or multi dose
62150583|NCT01214070|ACTIVE_COMPARATOR|Arm 3|Group 3 - Combination Treatment
62150584|NCT01214070|ACTIVE_COMPARATOR|Arm 4|Group 4 - Combination Treatment
62150585|NCT01214070|ACTIVE_COMPARATOR|Arm 5|Group 5 - Monotherapy Treatment
62150586|NCT01214070|ACTIVE_COMPARATOR|Arm 6|Group 6 - Monotherapy Treatment
62150587|NCT01214070|ACTIVE_COMPARATOR|Arm 7|Group 7 - Monotherapy Treatment
62150588|NCT00768755|EXPERIMENTAL|I|Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
62150589|NCT00768755|EXPERIMENTAL|II|Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
62150590|NCT00768755|ACTIVE_COMPARATOR|III|pemetrexed and cisplatin
62150591|NCT00768755|EXPERIMENTAL|IV|Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
62150592|NCT00768755|ACTIVE_COMPARATOR|V|pemetrexed and cisplatin
62150593|NCT01296100|EXPERIMENTAL|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
62150594|NCT01296100|EXPERIMENTAL|Lifestyle counseling (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
62150595|NCT00754325|ACTIVE_COMPARATOR|Arm 1 (Dasatinib +Fulvestrant)|
62150596|NCT00754325|ACTIVE_COMPARATOR|Arm 2 (Fulvestrant)|
62150597|NCT00638456|ACTIVE_COMPARATOR|1|oral viscous budesonide plus Prevacid
62150598|NCT00638456|PLACEBO_COMPARATOR|2|placebo plus Prevacid
62150599|NCT04633200|EXPERIMENTAL|Intervention|Participants in the intervention arm will receive a mobile app to support their daily PrEP adherence.
62150600|NCT04633200|NO_INTERVENTION|Control|Participants in the control group will receive a 2-page PrEP patient education document based information about PrEP from on the CDC website.
62522502|NCT05701644|EXPERIMENTAL|C1K 300mg or placebo|Subcutaneous Administration C1K 300mg or placebo single or multi dose
62522503|NCT05701644|EXPERIMENTAL|C1K 600mg or placebo|Subcutaneous Administration C1K 600mg or placebo single or multi dose
62522504|NCT05701644|EXPERIMENTAL|C1K 900mg or placebo|Subcutaneous Administration C1K 900mg or placebo single or multi dose
62522505|NCT05701644|EXPERIMENTAL|C1K 1200mg or placebo|Subcutaneous Administration C1K 1200mg or placebo single or multi dose
62522506|NCT06214533|EXPERIMENTAL|Never block|"Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug.~The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.~Intervention: Drug: 20 mL of 0.5% Ropivacaine"
62522507|NCT06214533|PLACEBO_COMPARATOR|Placebo block|"Patients in the control arm will undergo the celiac plexus block procedure as well. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.~Intervention: Drug: 20 mL of 0.9% normal saline"
62522508|NCT03054259|EXPERIMENTAL|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
62522509|NCT03054259|PLACEBO_COMPARATOR|Control|2 x 100mg methylprednisolone plus placebo
62522510|NCT02214368|EXPERIMENTAL|NIV bundle group|early use of NIV, and combination fiberoptic bronchoscopy and sedation
62150601|NCT01549951|EXPERIMENTAL|Orteronel+Prednisone|
62150602|NCT02833948|ACTIVE_COMPARATOR|ASA + Clopidogrel|ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
62150603|NCT02833948|EXPERIMENTAL|Rivaroxaban + ASA|Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
62150604|NCT02162394||Referred for Holter monitoring|
62150605|NCT03556332|EXPERIMENTAL|Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab & HCT|After receiving four 28-day cycles of Dara-CRd, eligible patients will then undergo HCT with high dose melphalan conditioning. Sixty to ninety days after HCT, patients will receive another 4 cycles of Dara-CRd.
62150606|NCT01713491||Cognitively normal|Patients with IQCODE score of 52 or less
62150607|NCT01713491||Cognitively impaired - no dementia|IQCODE score 53 - 63
62150608|NCT01713491||Demented|IQCODE score 64 or more
62150609|NCT01466569|EXPERIMENTAL|AbGn-7 phase 1a cohort 1|
62150610|NCT01466569|EXPERIMENTAL|AbGn-7 phase 1a cohort 2|
62358440|NCT04833920|ACTIVE_COMPARATOR|active tDCS|tDCS targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days
62358441|NCT04833920|SHAM_COMPARATOR|sham tDCS|tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds
62150611|NCT01466569|EXPERIMENTAL|AbGn-7 phase 1a cohort 3|
62150612|NCT01466569|EXPERIMENTAL|AbGn-7 phase 1b cohort 1|
62150613|NCT01466569|EXPERIMENTAL|AbGn-7 phase 1b cohort 2|
62150614|NCT01189552|ACTIVE_COMPARATOR|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
62358442|NCT01816256|OTHER|Screening tests|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
62358443|NCT01444898|EXPERIMENTAL|Exenatide|All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
62358444|NCT03936270|EXPERIMENTAL|Palbociclib 125mg + Letrozole 2.5mg|Palbociclib 125mg per day, administered orally in 4-week cycles (3 weeks of treatment followed by 1 week off) PLUS Letrozole 2.5mg per day administered orally (continuous treatment).
62358445|NCT01679522|EXPERIMENTAL|Single-port surgery group|Single-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
62358446|NCT01679522|ACTIVE_COMPARATOR|Four-port surgery group|Four-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
62358447|NCT00830154|EXPERIMENTAL|1|0.30 mg pagoclone BID
62358448|NCT00830154|EXPERIMENTAL|2|0.60 mg pagoclone BID
62358449|NCT00830154|PLACEBO_COMPARATOR|3|placebo
62358450|NCT04150354|EXPERIMENTAL|Participants allocated to Cogito Companion|Participants will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators.
62358451|NCT04458363|EXPERIMENTAL|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria) convalescent plasma will be administered
62358452|NCT03954379|ACTIVE_COMPARATOR|Group C ( Comparator Group )|Standard of care: Adductor Canal Block(ACB), Spinal Anesthesia (SA) and Peri-op Pain management
62358453|NCT03954379|EXPERIMENTAL|Group S ( Study Group )|iPACK and multi-modal analgesic regimen
62358454|NCT00367029|ACTIVE_COMPARATOR|1|Print-based, individually tailored motivational program
62358455|NCT00367029|EXPERIMENTAL|2|Enhanced version of the print-based, individually tailored motivational program
62358456|NCT00810589|EXPERIMENTAL|1|
62358457|NCT00810589|ACTIVE_COMPARATOR|2|
62358458|NCT05141734||BPPV (benign paroxysmal positional vertigo)|VOR gains were measured by vHIT in both the study group and the control group. The SPV values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
62358459|NCT05141734||Control|VOR gains were measured by vHIT in both the study group and the control group. The SPV values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
62358460|NCT01665768|EXPERIMENTAL|Everolimus and Rituximab|Everolimus daily for one year and IV rituximab four times during that year.
62358461|NCT02673723|EXPERIMENTAL|Dezocine|Dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
62358462|NCT02673723|PLACEBO_COMPARATOR|Controlled|The same amount of saline is given for 10 seconds after surface anesthesia
62358463|NCT05426018|EXPERIMENTAL|SY-009 -1|0.5mg tid
62358464|NCT05426018|EXPERIMENTAL|SY-009-2|1.0mg tid
62358465|NCT05426018|EXPERIMENTAL|SY-009-3|1.5mg tid
62358466|NCT05426018|PLACEBO_COMPARATOR|Placebo|tid
62358467|NCT06386211|EXPERIMENTAL|Treatment Sequence Group 1|
62358468|NCT06386211|EXPERIMENTAL|Treatment Sequence Group 2|
62358469|NCT02171949|NO_INTERVENTION|Control group|
62358470|NCT02171949|ACTIVE_COMPARATOR|Bone marrow mononuclear cell therapy|
62358471|NCT02931526||Group CRRT|Patients who need to treat with tigecycline for bacterial infection, have renal insufficiency and have to treat with CRRT
62358472|NCT02931526||Group non-CRRT|Patients who need to treat with tigecycline for bacterial infection, have normal renal function in ICU and have no need to treat with CRRT
62358473|NCT03162341|EXPERIMENTAL|UltraSonography and DECT|"UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.~Those are interventions that are not part of the standard care of the patients."
62358474|NCT00496613||1|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with a combination of chemotherapy and hormonal therapy, matched on age and education
62358475|NCT00496613||2|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with hormonal therapy only matched on age and education
62358476|NCT00496613||3|Healthy women matched on age and education
62358477|NCT01383187|EXPERIMENTAL|DE graft and PRP concentrate|Patients enrolled in this arm receive the innovative treatment methods consisting of application of DE graft together with PRP concentrate.
62358478|NCT01383187|ACTIVE_COMPARATOR|Standard treatment group|PAtients included into this arm will receive a standard treatment for deep-burn injuries, i.e. DE graft without the application of the PRP concentrate.
62358479|NCT03872193|EXPERIMENTAL|Physio Therapy|We intervention this group some routine exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees.
62358480|NCT03872193|EXPERIMENTAL|Virtual Reality|This group had physical therapy program plus virtual reality exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees. And virtual reality exercises were done for this group. Skiing,kayak, football,rafting and jumping activities were done in this exerciese.
62358481|NCT05193877|ACTIVE_COMPARATOR|treatment with autologous bone marrow aspirate concentrate|autologous bone marrow aspirate is taken under local anesthesia to be centrifuged and the concentrate given intra articularly in knee joint
62358482|NCT05193877|SHAM_COMPARATOR|control|control group given analgesics only
62358483|NCT01253187|EXPERIMENTAL|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|single oral administration of 1 film-coated SHT00186D tablet (YAZ), containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)
62358484|NCT01253187|EXPERIMENTAL|EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532B tablet, containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium \[MTHF-Ca\])
62358485|NCT01253187|EXPERIMENTAL|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated SHT04532C tablet, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium \[MTHF-Ca\])
62358486|NCT01146548|EXPERIMENTAL|the fluoxetine group|Multiple System Atrophy's patients with fluoxétine
62358487|NCT01146548|PLACEBO_COMPARATOR|the placebo group|Multiple System Atrophy's patients with placebo
62358488|NCT01620450|EXPERIMENTAL|NN2000|
62358489|NCT01620450|ACTIVE_COMPARATOR|NN-X14|
62358490|NCT02846051|OTHER|intensive sport practice|"intensive sport practice~1. the subject must practice for more than six months a drive of at least 8 hours / week, intense, above the ventilatory threshold, or 60-70% of maximum consumption oxygen or 70-80% of maximum heart rate, ie beyond a moderate slowdown. If stopping the intensive sport practice, the duration of the stop at the time of the study should be less practice time.~2. volunteers,~3. from 18 to 80 years,~4. free to consent.~5. covered by social security.~6. reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
62358491|NCT02846051|OTHER|control group|"\&) Volunteers who do not have intensive sport practice as it is defined in the group intensive sport practice 2) from 18 to 80 years, 3) free to consent. 4) covered by social security. 5) reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
62358492|NCT00672295|EXPERIMENTAL|Dasatinib, paclitaxel,and carboplatin|Combination of dasatinib, paclitaxel,and carboplatin
62358493|NCT01792297|EXPERIMENTAL|Bovine Colostrum|60 g/d bovine colostrum in powder form to be mixed with drinks. The dose will be spread out 3 times per day (20 g per dose)
62358494|NCT01792297|ACTIVE_COMPARATOR|Whey protein|60 g/d whey protein powder mixed into drinks. It is to be divided into 3 daily doses (20 g per dose)
62358495|NCT03419000|EXPERIMENTAL|Patient|Patients suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification and undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure
62358496|NCT03419000|ACTIVE_COMPARATOR|healthy volunteers|Adult (≥ 18 years) Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders
62358497|NCT01875510|ACTIVE_COMPARATOR|Fish-oil emulsions|Fish-oil emulsions:Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
62358498|NCT01875510|PLACEBO_COMPARATOR|soybean-oil emulsion|Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg
62358499|NCT05444413|EXPERIMENTAL|ultrasound-guided platelet rich plasma nerve block combined with drugs|selected patients were treated by the ultrasound-guided platelet rich plasma nerve block once a week for the 4 consecutive weeks while they were given the regular medicine which are taking pregabalin and amitriptyline hydrochloride orally, and the dosage shall be increased or decreased according to the patient's condition.
62358500|NCT04503863|EXPERIMENTAL|Experimental 1|Single administration of middle dose NPC-22
62358501|NCT04503863|EXPERIMENTAL|Experimental 2|Single administration of high dose NPC-22
62358502|NCT04503863|PLACEBO_COMPARATOR|Experimental 3|Single administration of placebo dose NPC-22
62358503|NCT00630240||1|only one arm for study
62358504|NCT00663468||A|
62358505|NCT05351463|OTHER|one arm study|in each case one site was assigned as control site and one site was assigned as test site.
62358506|NCT00351819|ACTIVE_COMPARATOR|Androgel (testosterone gel)|Testosterone replacement therapy
62358507|NCT00351819|PLACEBO_COMPARATOR|Placebo|Placebo gel
62712021|NCT01737892|EXPERIMENTAL|Arm T-Epinephrine Inhalation Aerosol HFA|Experimental arm utilizing Epinephrine HFA-MDI (E004)
62150615|NCT01189552|PLACEBO_COMPARATOR|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
62712022|NCT01737892|ACTIVE_COMPARATOR|Arm C-Epinephrine Inhalation Aerosol CFC|Active comparator arm utilizing Epinephrine CFC-MDI
62150616|NCT02358304|ACTIVE_COMPARATOR|a:Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received nasal spray calcitonin 200 IU/ day for 3 months after surgical curettage was done.
62150617|NCT02358304|PLACEBO_COMPARATOR|b; Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups . second group received placebo after surgical curettage for 3 months
62150618|NCT01230359|EXPERIMENTAL|Vitamin B6 and magnesium|
62150619|NCT01230359|PLACEBO_COMPARATOR|Tang powder group|
62150620|NCT02362789|EXPERIMENTAL|Secukinumab|300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
62358508|NCT04598711|EXPERIMENTAL|Remote Limb Ischemic Conditioning (RLIC)|"RLIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 200 mmHg on the more involved thigh. RLIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RLIC is performed on visits 1-14.~Interventions:~* Behavioral: RLIC~* Behavioral: Muscle power training~* Behavioral: Balance training~* Behavioral: Treadmill training"
62358509|NCT04598711|SHAM_COMPARATOR|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved thigh. Sham involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. Sham conditioning is performed on visits 1-14.~Interventions:~* Behavioral: RLIC~* Behavioral: Muscle power training~* Behavioral: Balance training~* Behavioral: Treadmill training"
62358510|NCT01319019|EXPERIMENTAL|GSK961081 100 mcg QD|
62358511|NCT01319019|EXPERIMENTAL|GSK961081 100mcg BD|
62358512|NCT01319019|EXPERIMENTAL|GSK961081 200mcg QD|
62358513|NCT01319019|EXPERIMENTAL|GSK961081 400mcg QD|
62358514|NCT01319019|EXPERIMENTAL|GSK961081 400mcg BD|
62358515|NCT01319019|EXPERIMENTAL|GSK961081 800mcg QD|
62358516|NCT01319019|ACTIVE_COMPARATOR|Salmeterol 50mcg BD|
62358517|NCT01319019|PLACEBO_COMPARATOR|Placebo|
62358518|NCT04436588||DDX3X|DDX3X
62358519|NCT00716326|ACTIVE_COMPARATOR|1|Subjects in this study arm will receive active treatment with Cefar TENS device which delivers therapeutic electrical currents 2-3x over sensory threshold in the area of pain.
62150621|NCT02362789|PLACEBO_COMPARATOR|Placebo|Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28
62150622|NCT01065779||FOSAMAX PLUS or FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg/2800 IU) or FOSAMAX PLUS D (70 mg/5600 IU).
62150623|NCT06402292|EXPERIMENTAL|PATIENTS WITH FRACTURE-RELATED INFECTION (FRI GROUP)|USE OF LOCAL ANTIBIOTICS WITH PEROSSAL
62150624|NCT02355106|EXPERIMENTAL|Treatment|Atrial flutter Ablation
62150625|NCT01425398|EXPERIMENTAL|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
62358520|NCT00716326|PLACEBO_COMPARATOR|2|Subjects in this study arm will receive placebo treatment with manipulated Cefar TENS device which delivers electrical currents just below sensory threshold in the area of pain.
62358521|NCT02702947|EXPERIMENTAL|Prunus Domestica|Prunus domestica extract capsules, 100mg, BD
62358522|NCT01469091|ACTIVE_COMPARATOR|Smoking intervention, Nicotine replacement therapy.|
62358523|NCT01469091|NO_INTERVENTION|Controlgroup|
62358524|NCT05236959|EXPERIMENTAL|Mindfulness-Based Cognitive Therapy|A group-based treatment combining intensive training in mindfulness mediation and elements of cognitive therapy (see further above).
62358525|NCT05236959|OTHER|Treatment as Usual|Participants in this group continue with their usual care and follow the regimes suggested by their GP or mental health professionals (see further above).
62358526|NCT01513863|EXPERIMENTAL|Metronidazole Topical Gel 1%|
62358527|NCT01513863|ACTIVE_COMPARATOR|Metronidazole Topical Gel 1% (Metrogel )|
62358528|NCT01513863|PLACEBO_COMPARATOR|Placebo|
62358529|NCT04154657|EXPERIMENTAL|biventricular conductance catheter|patients with indication for invasive assessment receive right and left heart catheter and parallel biventricular conductance catheter at rest and stress
62358530|NCT02597491|ACTIVE_COMPARATOR|4 wk assessment + TLC monthly|4 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
62358531|NCT02597491|ACTIVE_COMPARATOR|4 week assessment + TLC quarterly|4 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
62358532|NCT02597491|ACTIVE_COMPARATOR|4 week assessment +TLC + MTM|4 week assessment, 4 weeks counseling, NRT, medication management (nonresponders)
62358533|NCT02597491|ACTIVE_COMPARATOR|8 week assessment + TLC monthly|8 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
62150626|NCT01425398|PLACEBO_COMPARATOR|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5
62150627|NCT02341222|EXPERIMENTAL|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
62150628|NCT02341222|ACTIVE_COMPARATOR|PR (parietene) mesh device|A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
62150629|NCT03695185|EXPERIMENTAL|Ravagalimab 600 mg/300 mg|Participants received ravagalimab 600 mg intravenous (IV) at Week 0 followed by ravagalimab 300 mg subcutaneously (SC) at Weeks 2, 4, 6, 8, and 10 in a 12-week Induction Period. Participants who achieved clinical response per partial adapted Mayo score at Week 12 of the Induction Period entered the Maintenance Period to receive ravagalimab 300 mg SC every other week (EOW) from Week 12 through Week 102.
62150630|NCT02399072||Geographic Atrophy Participants|Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.
62150631|NCT02002689|EXPERIMENTAL|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
62150632|NCT01109979|ACTIVE_COMPARATOR|Estradiol+MPA|
62522511|NCT02214368|OTHER|Conventional treatment group|standard supplemental oxygen, and conventional application of noninvasive ventilation.
62150633|NCT01109979|ACTIVE_COMPARATOR|Estradiol+DRSP|
62150634|NCT02144194|EXPERIMENTAL|Maintenance treatment|"Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Followed by:~Oral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue"
62150635|NCT02144194|EXPERIMENTAL|Observation arm|"Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Patients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel"
62150636|NCT04432415|EXPERIMENTAL|Group Silver Diamine Fluoride|Participants receive Annual applications of 38% SDF solution and semestral applications of artificial saliva and a personalized dental health education program.
62150637|NCT04432415|EXPERIMENTAL|Group Sodium Fluoride Varnish|Participants receive semestral applications of Sodium Varnish Fluoride and a personalized dental health education program.
62150638|NCT04432415|PLACEBO_COMPARATOR|Placebo|Participants receive semestral apllications of artificial saliva and a personalized dental health education program.
62150639|NCT01329107|NO_INTERVENTION|No intervention|Standard Care
62150640|NCT01329107|EXPERIMENTAL|Multimodal intervention|Intervention group will be assigned to specific decribed multimodal intervention
62150641|NCT02359071||Handovers with lower durations|equal or lower than 20 minutes
62150642|NCT02359071||handovers with higher durations|Higher than 20 minutes
62150643|NCT02481011||users|patients on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
62150644|NCT02481011||non-users|patients not on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
62150645|NCT01366352|EXPERIMENTAL|Arm 1|MNTX tablet
62150646|NCT01366352|EXPERIMENTAL|Arm 2|MNTX tablet
62150647|NCT03060785|EXPERIMENTAL|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
62150648|NCT03060785|ACTIVE_COMPARATOR|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
62150649|NCT01584167|ACTIVE_COMPARATOR|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
62150650|NCT01584167|ACTIVE_COMPARATOR|EMCOOLS Flex.Pads|Passive surface cooling with 10 EMCOOLS Flex.Pads (Emergency Medical Cooling Systems AG, Wien, Austria)
62150651|NCT02404298|EXPERIMENTAL|IVIg|
62358534|NCT02597491|ACTIVE_COMPARATOR|8 week assessment + TLC quarterly|8 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
62358535|NCT02597491|ACTIVE_COMPARATOR|8 week assessment + TLC + MTM|8 week assessment, 8 weeks counseling, NRT, medication management (nonresponders)
62358536|NCT01125293|EXPERIMENTAL|Phase I Stage A Level 1|"Combination of everolimus \& rituximab for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
62358537|NCT01125293|EXPERIMENTAL|Phase I Stage A Level 2|"Combination of everolimus \& rituximab for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
62712023|NCT04142489|OTHER|UV and biopsy|"Minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= 6.4 photoproducts, and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure."
62712024|NCT03265184|EXPERIMENTAL|intervention group|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
62712025|NCT03265184|PLACEBO_COMPARATOR|placebo group|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
62358538|NCT01125293|EXPERIMENTAL|Phase I Stage B Level 1|"Combination of everolimus \& rituximab with bortezomib for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m\^2: Given intravenously on days 1, 8 and 15 of every cycle (1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
62358539|NCT01125293|EXPERIMENTAL|Phase I Stage B Level 2|"Combination of everolimus \& rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m\^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
62712026|NCT05181345||Normal sleep first|"The night before the first heat exposure, the participants will have a normal night at home.~The night before the second heat exposure, the participants sleep will be restricted to 3 hours in bed."
62712027|NCT05181345||Reduced sleep first|"The night before the first heat exposure, the participants sleep will be restricted to 3 hours in bed.~The night before the second heat exposure, the participants will have a normal night at home."
62712028|NCT06143189|OTHER|Control Group (CG)|Control Group participants were exposed to the normal hosting conditions of the hospital when receiving the usual chemotherapy treatment in ambulatory hospital setting.
62358540|NCT01125293|EXPERIMENTAL|Phase I Dose Expansion|"Combination of everolimus \& rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m\^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
62358541|NCT01125293|EXPERIMENTAL|Phase II|"Combination of everolimus \& rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m\^2: Given intravenously on days 1, 8 and 15 of every cycle~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
62358542|NCT06436209|EXPERIMENTAL|Multitask Practice|
62358543|NCT06436209|ACTIVE_COMPARATOR|Single Task Practice|
62358544|NCT03984838|EXPERIMENTAL|Subjects receiving Dolutegravir and Rilpivirine FDC|Subjects will receive Dolutegravir/Rilpivirine 50mg/25mg fixed dose combination (FDC) tablet as a single oral dose in a fed state.
62358545|NCT02006498|EXPERIMENTAL|Sillymarin|Active component study medication
62358546|NCT02006498|PLACEBO_COMPARATOR|Placebo|Placebo capsules
62358547|NCT01250652|ACTIVE_COMPARATOR|Levocetirizine|24 patients will received 20 mg Levocetirizine daily
62358548|NCT01250652|EXPERIMENTAL|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
62358549|NCT00425100|EXPERIMENTAL|Open Label-fesoterodine|Single treatment study arm.
62358550|NCT02333669||Control group|The control blood samples, which were collected from healthy neonatal umbilical cord blood, were obtained from the maternity ward of 80 hospitals in Chongqing and nearby areas
62358551|NCT02333669||RDS group|Newborns with RDS were consecutively recruited for this study from the neonatal intensive care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China, a tertiary care facility
62358552|NCT05444933||Sequencing post-cabozantinib|Participants treated by cabozantinib and who received another systemic therapy post-cabozantinib.
62358553|NCT05444933||Long responders|Participants treated by cabozantinib and who had a disease controlled (CR, PR or SDi during \> 12 months after cabozantinib initiation with or without additional local treatment).
62358554|NCT05444933||Non-responders|Participants treated by cabozantinib and who had a progressive disease less than 3 months after cabozantinib treatment initiation.
62358555|NCT05444933||Cabozantinib & rechallenge|Participants treated by cabozantinib who received systemic therapy and/or had prolonged treatment-free interval (≥ 12 weeks) between two cabozantinib treatment periods. Participants with at least one cabozantinib rechallenge could be included in this subgroup.
62358556|NCT05444933||Cabozantinib & therapeutic schedules|Participants treated by cabozantinib and who needed 1/ a dose increase following disease progression and/or a prior reduction, Or 2/ had any dose reduction/dose interruption of cabozantinib (schedule adaptation).
62358557|NCT05444933||Cabozantinib & local treatment|Participants treated by cabozantinib and who needed concomitant local treatment (LT) by surgery or radiotherapy
62358558|NCT05444933||Cabozantinib & elderly patients|Participants treated by cabozantinib and aged ≥ 75 years
62358559|NCT05735613|EXPERIMENTAL|Osteotome crestal sinus lifting|Full thickness flap elevated, then elevation of sinus floor by Osteotome, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device then flap sutured. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
62712029|NCT06143189|EXPERIMENTAL|Experimental Group (EG)|Experimental Group participants were exposed to the Hospital Clowns intervention plus the normal hosting conditions of the hospital when receiving the usual chemotherapy treatment in ambulatory hospital setting.
62712030|NCT04907630|EXPERIMENTAL|intervention group-antenatal education of health literacy (HL-AE)|It is the group that is given antenatal education based on improving health literacy (HL-AE).
62712031|NCT04907630|EXPERIMENTAL|intervention group-Antenatal Education (AE)|It is the group that gives antenatal education (AE)
62712032|NCT04907630|EXPERIMENTAL|Control group|No Intervention
62150652|NCT03462966|EXPERIMENTAL|Therapeutic|40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.
62150653|NCT06324097||colorectal lesion|
62150654|NCT03442998|OTHER|Suburban|Study participants will wall on a suburban sidewalk setting for 50 minutes.
62150655|NCT03442998|OTHER|Nature|Study participants will wall on a nature path setting for 50 minutes.
62150656|NCT02006641|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to 10 mg Donepezil
62150657|NCT02006641|EXPERIMENTAL|Idalopirdine 10 mg|Idalopirdine adjunct to 10 mg Donepezil
62150658|NCT02006641|EXPERIMENTAL|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
62358560|NCT05735613|EXPERIMENTAL|osseodensification crestal sinus lifting|Full thickness flap elevated, then elevation of sinus floor by Densah burs, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device then flap sutured. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
62150659|NCT05899348|EXPERIMENTAL|iTEST|
62150660|NCT06278194|OTHER|Patients treated with gasserian ganglion RFT for trigeminal neuralgia|In patients who have undergone radiofrequency thermocoagulation (RFT) of the gasserian ganglion for the treatment of trigeminal neuralgia, the thickness of the masseter muscle will be measured bilaterally, free and contracted, by ultrasound on the day of the procedure (just before the procedure) and at 1 and 3 months after the procedure.
62150661|NCT01415206|EXPERIMENTAL|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
62358561|NCT05735613|EXPERIMENTAL|peizoelectric crestal sinus lifting|Full thickness flap elevated, then elevation of sinus floor through piezoelectric surgery via intralift kit, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device, followed by flap suturing. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
62358562|NCT02670018|ACTIVE_COMPARATOR|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg \* 2 tablets
62358563|NCT02670018|EXPERIMENTAL|C|Combination of gemigliptin 25mg/metformin HCl extended release 1000mg \* 2 tablets
62358564|NCT04191213|EXPERIMENTAL|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks
62358565|NCT04191213|PLACEBO_COMPARATOR|Control group|This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age \& two-gram-dose for children above 5 years of age
62358566|NCT05143567|EXPERIMENTAL|patients with COVID-19 without thrombotic complications|Group I: 50 patients with confirmed coronavirus infection without thrombotic complications
62358567|NCT05143567|EXPERIMENTAL|patients with COVID-19 and VTE who received pharmacological prophylaxis of VTE|Group II: 50 patients with confirmed coronavirus infection with thrombotic complications confirmed by ultrasonography with pharmacological prophylaxis of VTE
62358568|NCT05143567|EXPERIMENTAL|patients with COVID-19 and VTE who received pharmacomechanical prophylaxis of VTE|Group III: 50 patients with confirmed coronavirus infection with ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities using pharmacomechanical prophylaxis of VTE.
62358569|NCT04572581|EXPERIMENTAL|Exclusively Human Milk Diet|This group will receive human milk only. If the mother is not producing enough breast milk, this group will receive donor milk supplementation.
62358570|NCT04572581|NO_INTERVENTION|Formula-based Diet|If the mother is not producing enough breast milk, this group will receive formula supplementation (the standard of care).
62358571|NCT03365947|EXPERIMENTAL|ARO-HBV 35 mg|Single dose of ARO-HBV 35 mg subcutaneous (sc) injection in normal healthy volunteers
62358572|NCT03365947|EXPERIMENTAL|ARO-HBV 100 mg|Single dose of ARO-HBV 100 mg sc injection in normal healthy volunteers
62358573|NCT03365947|EXPERIMENTAL|ARO-HBV 200 mg|Single dose of ARO-HBV 200 mg sc injection in normal healthy volunteers
62358574|NCT03365947|EXPERIMENTAL|ARO-HBV 300 mg|Single dose of ARO-HBV 300 mg sc injection in normal healthy volunteers
62358575|NCT03365947|EXPERIMENTAL|ARO-HBV 400 mg|Single dose of ARO-HBV 400 mg sc injection in normal healthy volunteers
62358576|NCT03365947|PLACEBO_COMPARATOR|Placebo|Sterile normal saline (0.9% NaCl) sc injection in normal healthy volunteers
62358577|NCT03365947|EXPERIMENTAL|ARO-HBV 25 mg, Q28D|ARO-HBV 25 mg sc injection every 28 days (Q28D) in participants with chronic hepatitis B
62712033|NCT04675827|EXPERIMENTAL|RCB = 0|"Treatment administration: adjuvant pertuzumab + trastuzumab (P+T) fixed dose combination (FDC) SC for 14 cycles.~Sub-study: 121 of the subjects who achieved a pCR (thus assigned to continue treatment with P+T FDC SC) will be randomised at a 1:1 ratio to receive 3 cycles of P+T FDC SC in the hospital, followed by 3 cycles in another setting outside the hospital, or to the same treatment starting with 3 cycles outside the hospital followed by 3 cycles in the hospital (treatment cross-over period). After the first 6 cycles of adjuvant treatment, subjects will be asked to choose between continuing treatment (for the remaining 8 cycles, for a total of 14 cycles) within or outside the hospital, according to their preference (treatment continuation period). Subjects can request to change from outside the hospital to in the hospital administration (and vice-versa) at any moment during the treatment continuation period, but not in the treatment cross-over period."
62522512|NCT04262661|EXPERIMENTAL|NNC0472-0147 Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147.
62712034|NCT04675827|EXPERIMENTAL|RCB > 0|Treatment administration:adjuvant T-DM1 for 14 cycles. In subjects whose residual invasive disease is classified per Residual Cancer Burden (RCB) score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.
62712035|NCT04015804|OTHER|Clinical database|
62712036|NCT00285779|PLACEBO_COMPARATOR|Placebo injection|patients receive normal saline injection twice weekly for weeks 1-12
62712037|NCT00285779|EXPERIMENTAL|Etanercept|patients receive etanercept injection twice weekly for weeks 1-12.
62712038|NCT02328872|EXPERIMENTAL|Intervention (HPV Arm)|"Molecular testing for HPV with partial genotyping for types 16/18, with referral of the HPV16/18-positive group for diagnostic evaluation, and secondary randomisation of women testing positive for other oncogenic HPV infection (not 16/18), to either image-read cytology screening or dual-stained (DS) cytology testing with p16/Ki67 - the HPV arm. Screening performed 5 yearly."
62712039|NCT02328872|ACTIVE_COMPARATOR|Control (LBC Arm)|"Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the LBC arm. Screening performed 2.5 yearly."
62712040|NCT05811325|EXPERIMENTAL|kinesio taping without craniosacral therapy|This group received Kinesio taping for improvement in pain,disability and quality of life.
62712041|NCT05811325|ACTIVE_COMPARATOR|kinesio taping group with craniosacral therapy|Group received kinesio Taping with craniosacral therapy for improvement in pain,disability and quality of life.
62712042|NCT05752500|EXPERIMENTAL|BASM + PA Coaching|Brief Advice and Self-Monitoring Physical Activity Coaching
62712043|NCT05752500|EXPERIMENTAL|BASM + CB-PA|Brief Advice and Self-Monitoring Cognitive-Behavioral Intervention to Increase Physical Activity
62712044|NCT05752500|EXPERIMENTAL|BASM + SS-PA|Brief Advice and Self-Monitoring Social support for Physical Activity
62712045|NCT05752500|EXPERIMENTAL|BASM + PA Coaching + CB-PA|Brief Advice and Self-Monitoring Physical Activity Coaching Cognitive-Behavioral Intervention to Increase Physical Activity
62712046|NCT05752500|EXPERIMENTAL|BASM + PA Coaching + SS-PA|Brief Advice and Self-Monitoring Physical Activity Coaching Social support for Physical Activity
62150662|NCT01415206|OTHER|Usual Care|Participants in the usual care condition will complete the core assessments and the Staging Health Risk Assessment (S-HRA) online at baseline, 3, 6, 12, and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
62358578|NCT03365947|EXPERIMENTAL|ARO-HBV 50 mg Q28D|ARO-HBV 50 mg sc injection Q28D in participants with chronic hepatitis B
62358579|NCT03365947|EXPERIMENTAL|ARO-HBV 100 mg Q28D|ARO-HBV 100 mg sc injection Q28D in participants with chronic hepatitis B
62358580|NCT03365947|EXPERIMENTAL|ARO-HBV 200 mg Q28D|ARO-HBV 200 mg sc injection Q28D in participants with chronic hepatitis B
62358581|NCT03365947|EXPERIMENTAL|ARO-HBV 300 mg Q28D|ARO-HBV 300 mg sc injection Q28D in participants with chronic hepatitis B
62358582|NCT03365947|EXPERIMENTAL|ARO-HBV 400 mg Q28D|ARO-HBV 400 mg sc injection Q28D in participants with chronic hepatitis B
62358583|NCT03365947|EXPERIMENTAL|ARO-HBV 100 mg Q14D|ARO-HBV 100 mg sc injection every 14 days (Q14D) in participants with chronic hepatitis B
62358584|NCT03365947|EXPERIMENTAL|ARO-HBV 100 mg Q7D|ARO-HBV 100 mg sc injection every 7 days (Q7D) in participants with chronic hepatitis B
62358585|NCT03365947|EXPERIMENTAL|ARO-HBV 300 mg, Q28D, HBeAg+/ Trt Naïve|ARO-HBV 300 mg sc injection Q28D in hepatitis B e antigen positive/treatment naïve (HBeAg+/Trt Naïve) participants with chronic hepatitis B
62358586|NCT03365947|EXPERIMENTAL|ARO-HBV 300 mg, Q28D, HBeAg+/ NUC|ARO-HBV 300 mg sc injection Q28D in HBeAg+/nucleotide or nucleoside analog treated (HBeAg+/NUC) participants with chronic hepatitis B
62358587|NCT03365947|EXPERIMENTAL|ARO-HBV 200 mg, Q7D|ARO-HBV 200 mg sc injection Q7D in participants with chronic hepatitis B
62358588|NCT03365947|EXPERIMENTAL|ARO-HBV 300 mg, Q7D|ARO-HBV 300 mg sc injection Q7D in participants with chronic hepatitis B
62358589|NCT03365947|EXPERIMENTAL|ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg|ARO-HBV 200 mg sc injection Q28D plus JNJ-56136379 250 mg in participants with chronic hepatitis B
62358590|NCT04379609||Employees and students|The control group was selected from among the employees and students of the faculty of dentistry to represent the general population without any temporomandibular disorder (TMD).
62358591|NCT04379609||Patients|Patients who were referred to the Ondokuz Mayıs University Faculty of Dentistry Department of Prosthodontics with a complaint of pain in the chewing muscles were enrolled in this study.
62358592|NCT01494987|EXPERIMENTAL|Ranolazine+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24.~Participants will be required to maintain their diet and exercise regimen."
62712047|NCT05752500|EXPERIMENTAL|BASM + CB-PA + SS-PA|Brief Advice and Self-Monitoring Cognitive-Behavioral Intervention to Increase Physical Activity Social support for Physical Activity
62150663|NCT01135719|ACTIVE_COMPARATOR|Wavefront guided LASIK/PRK|Wavefront-guided LASIK/PRK
62358593|NCT01494987|PLACEBO_COMPARATOR|Placebo+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks.~Participants will be required to maintain their diet and exercise regimen."
62712048|NCT05752500|EXPERIMENTAL|BASM + PA Coaching + CB-PA + SS-PA|Brief Advice and Self-Monitoring Physical Activity Coaching Cognitive-Behavioral Intervention to Increase Physical Activity Social support for Physical Activity
62712049|NCT05752500|OTHER|BASM|Brief Advice and Self-Monitoring
62712050|NCT06280209|EXPERIMENTAL|Cohort 1A|Cohort 1A will consist of both a single ascending dose (SAD) part and a multiple ascending dose (MAD). BMN 351 will be administered once every 2 weeks during the SAD portion of the study for up to 8 weeks and once weekly during the MAD portion for up to 56 weeks.
62150664|NCT01135719|ACTIVE_COMPARATOR|Wavefront optimized LASIK/PRK|Wavefornt optimized LASIK/PRK
62150665|NCT03547206|EXPERIMENTAL|RPh201 Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
62150666|NCT03547206|PLACEBO_COMPARATOR|Placebo Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
62358594|NCT01789658|EXPERIMENTAL|Cryotherapy|Cryotherapy during conditioning treatment with chemotherapy prior to HSCT
62358595|NCT01789658|NO_INTERVENTION|Control|Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT
62358596|NCT01718964|OTHER|A|Cortisol 20 mg /Placebo Mannitol
62358597|NCT01718964|OTHER|B|Placebo Mannitol/Cortisol 20mg
62358598|NCT03383627|EXPERIMENTAL|Continuous glucose monitoring|"* If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.~* There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.~* Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
62358599|NCT03776097||Defect Fill.|Observational study of the patients that were treated with biomaterials at the surgery in the previous study
62358600|NCT03776097||No defect Fill.observational|Observational study of the patients that were not treated with biomaterials at the surgery of te previous study
62358601|NCT05753007|EXPERIMENTAL|Cannabidiol (CBD) Solution Plus Standard of Care (SOC)|Full-spectrum, hemp-derived, ultra-high CBD solution administered for 8 weeks along with standard of care treatment
62358602|NCT05753007|PLACEBO_COMPARATOR|Placebo|Placebo solution administered for 8 weeks along with standard of care treatment
62358603|NCT02472015|NO_INTERVENTION|normal care|patients who will have normal care
62358604|NCT02472015|EXPERIMENTAL|telemedicine|patients who will have telemedicine
62358605|NCT05525832|EXPERIMENTAL|Normal saline group|Patients that will receive normal saline 0.9% solution for nasopharyngeal wash
62358606|NCT05525832|NO_INTERVENTION|control group|Patients that will not perform nasopharyngeal washes
62358607|NCT03579030|EXPERIMENTAL|Single Dose of RTA 1701 or Placebo|"RTA 1701 capsules or placebo taken orally in a single dose.~Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo"
62358608|NCT03579030|EXPERIMENTAL|Multiple Dose of RTA 1701 or Placebo|"RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks.~Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo"
62358609|NCT04163055|NO_INTERVENTION|Standard of Care|Wounds will be assessed using the Clinical Signs and Symptoms Checklist (CSSC). After initial assessment, a white-light (WL) photo will be taken of the wound. The wound bed will be prepared as indicated by clinical staff based on standard of care (SoC), including irrigation and debridement. A second WL image will be taken and a swab/biopsy will be obtained from the wound. Wounds will be dressed based on SoC.
62358610|NCT04163055|EXPERIMENTAL|Autofluorescence guided Standard of Care|Wounds will be assessed by autofluorescence (AF)-guided SoC. A baseline WL and AF photo will be taken of the wound. AF images will guide SoC including targeted debridement of areas of bacterial growth (AF+) and targeted sampling in areas of residual bacterial growth post-debridement. If no bacterial AF is detected, sample will be obtained from the wound center by curettage technique. If AF is detected, AF-guided debridement will be repeated and additional images will be obtained until 1) no AF is detected or 2) further debridement is not medically advised. After wound bed preparation, a second set of WL and AF images will be taken. Wounds will be dressed as per SoC. At all visits, samples will be sent for microbiology analysis. At 6- and 12-week visits (or any other scheduled visits in between), microbiology reports will be shared with clinicians if they were not collected outside of SoC.
62358611|NCT05385575|EXPERIMENTAL|Cohort 1|Participant will receive 0.1mg of single dose by subcutaneous injection of KN056
62358612|NCT05385575|EXPERIMENTAL|Cohort 2|Participant will receive 0.3mg of single dose by subcutaneous injection of KN056
62712051|NCT06280209|EXPERIMENTAL|Cohort 1B|BMN 351 low dose will be administered once weekly for up to 48 weeks
62150667|NCT03547206|EXPERIMENTAL|RPh201 Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
62150668|NCT03547206|PLACEBO_COMPARATOR|Placebo Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the vehicle control.
62522513|NCT04262661|PLACEBO_COMPARATOR|Placebo Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo.
62358613|NCT05385575|EXPERIMENTAL|Cohort 3|Participant will receive 1.0mg of single dose by subcutaneous injection of KN056 or placebo
62522514|NCT04262661|EXPERIMENTAL|NNC0472-0147 Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days
62712052|NCT06280209|EXPERIMENTAL|Cohort 2|BMN 351 medium dose will be administered once weekly for up to 48 weeks
62358614|NCT05385575|EXPERIMENTAL|Cohort 4|Participant will receive 3.0mg single subcutaneous dose of KN056 or placebo
62358615|NCT05385575|EXPERIMENTAL|Cohort 5|Participant will receive 6.0mg of single dose by subcutaneous injection of KN056 or placebo
62358616|NCT05385575|EXPERIMENTAL|Cohort 6|Participant will receive 12.0mg of single dose by subcutaneous injection of KN056 or placebo
62712053|NCT06280209|EXPERIMENTAL|Cohort 3|BMN 351 high dose will be administered once weekly for up to 48 weeks
62712054|NCT01877304|EXPERIMENTAL|AKITA with program central deposition|Nebulization for central deposition
62712055|NCT01877304|ACTIVE_COMPARATOR|AKITA with program for peripheral deposition|Nebulization for peripheral deposition
62712056|NCT05910658|OTHER|Intervention Group|Participants will receive the CRUSH Curriculum
62712057|NCT02286895|ACTIVE_COMPARATOR|Group A (without rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).
62712058|NCT02286895|EXPERIMENTAL|Group B (with rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).
62712059|NCT00723567||Affected Group|Family members of northern European descent in which members have different erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.
62712060|NCT00842621||1|Pediatric participants with severe sickle cell disease (HbSS or Hb S/β°-thalassemia) who are not receiving treatment, e.g., hydroxyurea or chronic transfusions
62150669|NCT05391867|EXPERIMENTAL|Lenvatinib group (Group-A)|Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Lenvatinib. Cap. Lenvatinib will be given at doses of 4 mg 12 hourly.
61976408|NCT03274401|ACTIVE_COMPARATOR|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
62150670|NCT05391867|EXPERIMENTAL|Sorafenib group (Group-B)|Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Sorafenib. Tab. Sorafenib will be given at doses of 200 mg 12 hourly.
62150671|NCT05325983|EXPERIMENTAL|lemonade ice cubes|10 ml lemonade ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
62358617|NCT05385575|EXPERIMENTAL|Cohort 7|Participant will receive 18.0mg of single dose by subcutaneous injection of KN056 or placebo
62358618|NCT02994095|EXPERIMENTAL|Single intervention arm|Trained CHAs in Motivational Interviewing in pilot study
62358619|NCT06372808|EXPERIMENTAL|Training Group|"The training group will receive a carefully designed plyometric training program by a qualified and experienced physiotherapist. This program will be implemented twice a week for eight weeks, with the number of sets and repetitions of the exercises adjusted weekly to ensure a progressive and safe training regimen. Evaluations will be conducted at the beginning and end of the eight weeks to assess the effects of the plyometric training.~Plyometric training program:~* Vertical jumps~* Tuck jumps~* Two-legged broad jumps~* One-legged bounding~* Depth jumps from a 40 cm height~Rest intervals between repetitions and sets were set at 15-30 seconds. A 20-minute warm-up period before the program and a 20-minute cool-down period afterwards were planned."
62358620|NCT06372808|EXPERIMENTAL|Control Group|The control group will continue their regular training program without additional interventions. The routine training program for the control group includes basic strength training (weightlifting exercises), cardiovascular training (biking, running, sprint training, jogging), technical and tactical training, and match-style wrestling. Evaluations will be conducted at the beginning and end of the eight weeks.
62358621|NCT03242590|EXPERIMENTAL|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
62358622|NCT06077201|NO_INTERVENTION|Control|Standard of care course for an individual not participating in center based cardiac rehabilitation. AHA Life's Essential 8 Fact Sheets are provided to promote healthy living.
62358623|NCT06077201|EXPERIMENTAL|HBCR hands-off|Home-based cardiac rehabilitation with mobile application + AHA Life's Essential 8 sheets.
62358624|NCT06077201|EXPERIMENTAL|HBCR interactive|Home-based cardiac rehabilitation with mobile application and periodic video calls with exercise physiologist + AHA Life's Essential 8 sheets.
62358625|NCT06046365||mastectomy|Expected to include female patients who are undergoing breast cancer resection surgery or those who have already undergone breast resection surgery for breast cancer.
62358626|NCT03736811|ACTIVE_COMPARATOR|Absorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyglactin 910 \[Vicryl\] or polydioxanone \[PDS II\] sutures.
62358627|NCT03736811|EXPERIMENTAL|Nonabsorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyester \[Ethibond Excel\] or polypropylene \[Prolene\] sutures.
62358628|NCT06305026||RA patients with concomitant fibromyalgia|
62358629|NCT06305026||RA patients without concomitant fibromyalgia|
62358630|NCT03300219|EXPERIMENTAL|telerehabilitation|Telerehabilitation refers to the use of technologies to provide rehabilitation services to people in their homes. The intervention will be performed by real-time video-conferencing using an iPad® and Skype™, a software program that allows video calls over the Internet
62358631|NCT03161782|EXPERIMENTAL|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
62358632|NCT03161782|EXPERIMENTAL|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
62358633|NCT01494415|EXPERIMENTAL|chemoradiotherapy|This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
62712061|NCT00842621||2|Pediatric participants with other forms of SCD or severe sickle cell disease patients (HbSS or Hb S/β°-thalassemia) being treated with hydroxyurea or chronic transfusions
62712062|NCT00842621||3|Pediatric and adult participants with other non-sickling hematological disorders
62150672|NCT05325983|PLACEBO_COMPARATOR|water ice cubes|10 ml water ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
62150673|NCT03052517|EXPERIMENTAL|QAW039 150mg|QAW039 Dose 1 once daily
62358634|NCT05869786|EXPERIMENTAL|Virtual Reality Group|Participants in both groups will receive a conventional rehabilitation program. Participants in the virtual reality group will receive virtual reality-mediated upper extremity rehabilitation for 3 weeks, 5 sessions per week, each session lasting 30 minutes (450 minutes in total). In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves. 3 different games will be intervened for 10 minutes each, totaling 30 minutes per day.
62358635|NCT05869786|ACTIVE_COMPARATOR|Control Group|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist. Participants in both groups will receive a conventional rehabilitation program.
62358636|NCT06170281|ACTIVE_COMPARATOR|Random - ME|participants will be randomized to an intervention involving regular mealtime and regular timed exercise
62712063|NCT05441514|EXPERIMENTAL|Treatment (cobimetinib, enasidenib mesylate)|Patients receive cobimetinib PO QD on days 1-21 and enasidenib mesylate PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
62712064|NCT04986631|EXPERIMENTAL|Topiramate|Individuals will receive 75 mg of topiramate daily. The dose will start at 25 mg daily for the first week. The second week participants will receive 50 mg daily. Starting at week 3 participants will take 75 mg daily.
62712065|NCT04256850|EXPERIMENTAL|Acceptance and Commitment Therapy (ACT)|Focuses on addressing cognitive and emotional barriers to successful weight loss maintenance.
62150674|NCT03052517|EXPERIMENTAL|QAW039 450 mg|QAW039 Dose 2 once daily
62150675|NCT03052517|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62358637|NCT06170281|ACTIVE_COMPARATOR|Random - MS|participants will be randomized to an intervention involving regular mealtime and regular sleep
62358638|NCT06170281|ACTIVE_COMPARATOR|Random - SE|participants will be randomized to an intervention involving regular sleep and regular timed exercise
62358639|NCT06170281|ACTIVE_COMPARATOR|Choice - ME|this arm belongs to participants who choose the intervention involving regular mealtime and regular timed exercise
62150676|NCT05504447|EXPERIMENTAL|"Rong-Yang Zhengyifang tea bag"|"1. Inclusion criteria:~   Aged over 20 years old, according to the guidelines of the Epidemic Command Center, during home isolation and self-epidemic prevention or home quarantine, use a household novel coronavirus antigen rapid screening reagent to test positive, and after the medical staff confirms the relevant symptoms or the PCR test is positive, it is determined to be mild. Those who were diagnosed with severe disease and who did not use antiviral drugs were given tea immediately.~2. Exclusion criteria:~(1)Patient characteristics: excluded under 20 years of age, incapacity, pregnancy or lactation women (2)Disease characteristics: Western medicine has clearly diagnosed mental diseases (3)Environmental characteristics: Other conditions that prevent the patient from cooperating. If you feel unwell after screening not to sign the subject's consent form, etc."
62150677|NCT05504447|PLACEBO_COMPARATOR|placebo tea bag|The appearance is exactly the same as the Zhengyifang tea bag, and the ingredient is oolong tea
62150678|NCT01470209|EXPERIMENTAL|Combination of BKM120 and everolimus|
62150679|NCT02976272||patients with myeloma multiple|
62150680|NCT06506552|EXPERIMENTAL|Inferior mesenteric artery preservation|Performing colorectal resection for diverticular disease the IMA was preserved ligating the sigmoids arteries close to colonic wall.
62150681|NCT06506552|ACTIVE_COMPARATOR|Inferior mesenteric ligation|Performing colorectal resection the IMA was sectioned just below the origin of left colic artery.
62358640|NCT06170281|ACTIVE_COMPARATOR|Choice - MS|this arm belongs to participants who choose the intervention involving regular mealtime and regular sleep
62358641|NCT06170281|ACTIVE_COMPARATOR|Choice - SE|this arm belongs to participants who choose the intervention involving regular sleep and regular timed exercise
62358642|NCT06300567||patients with unconcluded diagnosis for cystic fibrosis|"1. symptomatic patientscarrying 2 variants of CFTR, including at least 1 non CF causing~2. patients not concluded at neonatal screening of Cystic Fibrosis"
62358643|NCT01858896|ACTIVE_COMPARATOR|Glucagon-Like Peptide -1 (GLP-1) infusion|Infusion of GLP-1 during experimental period
62358644|NCT01858896|PLACEBO_COMPARATOR|Saline Infusion|Saline infusion during experimental period
62358645|NCT02067533|EXPERIMENTAL|flexion position|
62358646|NCT02067533|EXPERIMENTAL|extension position|
62358647|NCT03061812|EXPERIMENTAL|Rovalpituzumab tesirine|"Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted.~Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered."
62358648|NCT03061812|ACTIVE_COMPARATOR|Topotecan|Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m\^2 on Days 1 to 5 of each 21-day cycle.
62358649|NCT05438251|EXPERIMENTAL|Diabetic Foot Ulcers (TEXAS 3A, 3B)|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks"
62358650|NCT02267278|EXPERIMENTAL|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
62358651|NCT03810521|EXPERIMENTAL|CLT low-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
62150682|NCT03847545|EXPERIMENTAL|Intervention|The participants receive Fampridine treatment (10 mg x 2 daily) for 14 days. They are testet prior to treatment and following the 14 days of treatment.
62150683|NCT05606796|EXPERIMENTAL|Preserved latanoprost|"Benzalkonium chloride (BAK) preserved latanoprost 0.005%.~1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure."
62150684|NCT05606796|EXPERIMENTAL|Preservative-free latanoprost|"Preservative-free (Benzalkonium chloride-free) latanoprost 0.005%.~1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure."
62712066|NCT04256850|EXPERIMENTAL|Self-Regulation (SR)|Focuses on using self-monitoring and self-reinforcement techniques to improve weight loss maintenance.
62150685|NCT01307306|EXPERIMENTAL|Metformin|
62150686|NCT01307306|EXPERIMENTAL|Insulin|
62150687|NCT01307306|NO_INTERVENTION|Control|
62150688|NCT06052943|EXPERIMENTAL|Health without Barriers/ Salud Sin Barreras|Health Without Barriers/Salud Sin Barreras is 12-session community-delivered, family-based lifestyle intervention to reduction the risk of for chronic diseases (i.e., T2D) in adolescence and to improve whole family health and wellness. The program is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2 hour nutrition/cooking sessions through Cooking Matters and 6 weekly 2 hour Multidisciplinary Sessions that include parent education, a teen and sibling (ages 6-10 years) group physical fitness class, preschool curriculum for children 2-5 years of age, and a teen mindfulness curriculum called Learning 2 BREATHE. Health Without Barriers/Salud Sin Barreras has been tailored for adolescents at risk for depression and chronic diseases (i.e., T2D) in Southwest Colorado based on community input.
62150689|NCT04131855|ACTIVE_COMPARATOR|Pumice prophylaxis.|Will receive pumice prophylaxis in a slurry of plain pumice and water for 5 seconds per tooth using a rubber cup in a slow contra-angle handpiece. The teeth involved will then be washed and dried prior to using the self etch primer.
62150690|NCT04131855|EXPERIMENTAL|No pumice prophylaxis.|Will not receive pumice prophylaxis. Teeth will be washed and dried before using the self etch primer.
62358652|NCT03810521|EXPERIMENTAL|CLT medium-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
62358653|NCT03810521|EXPERIMENTAL|CLT high-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
62358654|NCT06214624|EXPERIMENTAL|12-week of aerobic high-intensity interval training (HIIT) exercise program|
62358655|NCT06214624|EXPERIMENTAL|12-week aerobic HIIT plus resistance exercise program|
61976409|NCT03274401|NO_INTERVENTION|Control Arm|Standard of care
62358656|NCT06214624|NO_INTERVENTION|Usual care, Wait-list control group|The control group (as well as the 2 intervention groups) will be treated as usual in outpatient Phase III, which in Spain includes periodic medical revisions and medication control. In addition, for the control group, we will apply the wait-list strategy providing the supervised exercise program once all data collection for pre- and post-intervention assessment points have been finished.
62358657|NCT00954057|EXPERIMENTAL|LIPO-102|Intraorbital Injection
62358658|NCT00954057|PLACEBO_COMPARATOR|Placebo|Intraorbital Injection
62358659|NCT00442260|EXPERIMENTAL|Abraxane dose escalation + fixed dose DOXIL|Limited dose-escalation study of Abraxane and fixed dose of DOXIL in order to identify correct dose and side effect profile of the combination.
62358660|NCT00561587|ACTIVE_COMPARATOR|1|
62358661|NCT00561587|NO_INTERVENTION|2|
62358662|NCT04831567|EXPERIMENTAL|Interventional|The participants will be submitted to metaiodobenzylguanidine 4 doses of 7.400 Mbq (million of Becquerels) (200 mCi). Each dose will be repeated with a minimum interval of 60 days.
62358663|NCT02562261||Healthy|
62358664|NCT02562261||Uncomplicated Infection|Showing signs of infection as defined by International Sepsis Definitions Conference 2003
62358665|NCT02562261||Sepsis|"Sepsis is defined as systemic inflammatory response syndrome (i.e. presence of two or more of the following~1. Temperature of \<36 °C (96.8 °F) or \>38 °C (100.4 °F)~2. Heart rate \>90bpm~3. Respiratory rate \>20/min or PaCO2\<32 mmHg (4.3 kPa)~4. WBC \<4x109/L (\<4000/mm³), \>12x109/L (\>12,000/mm³), or 10% bands in response to an infectious process.."
62358666|NCT02562261||Severe Sepsis/Septic Shock|Severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion \[manifesting as hypotension, elevated lactate (serum lactate 2 times the upper limit of normal), or decreased urine output (urine output \< 0.5 ml/kg/hr)\] Septic shock is defined as severe sepsis plus persistently low blood pressure (\< 5th percentile for age or systolic blood pressure \< 2 standard deviations below normal for age) following the administration of intravenous fluids.
62358667|NCT01565811||Hepatic pedicle lymph node Involvement|Intervention Type: perihepatic lymphadenectomy(surgical procedure)
62358668|NCT04257604||Perampanel|Participants with partial-onset seizures, with or without secondary generalization will receive perampanel tablets as add-on therapy according to the approved summary of product characteristics (SmPC) after the baseline visit as part of the clinical practice and will be observed after 3 months (visit 1), 6 months (visit 2), and 12 months (final visit).
62358669|NCT05824455|EXPERIMENTAL|JS109 combination with irinotecan|
62358670|NCT02576925||Eligible patients|Adults having had a transient diplopia during the last 8 days.
62358671|NCT04968353|ACTIVE_COMPARATOR|Incisally-beveled|Use of incisally-beveled attachment to extrude lateral incisor
62358672|NCT04968353|ACTIVE_COMPARATOR|Gingivally-beveled|Use of gingivally-beveled attachment to extrude lateral incisor
62358673|NCT04968353|ACTIVE_COMPARATOR|Optimized|Use of optimized attachment to extrude lateral incisor
62358674|NCT04968353|ACTIVE_COMPARATOR|Horizontal|Use of horizontal (unbeveled) attachment to extrude lateral incisor
62358675|NCT06165523|PLACEBO_COMPARATOR|Water|Water
62358676|NCT06165523|EXPERIMENTAL|Flavored Kefir|1% Lowfat Kefir manufactured by Lifeway Kefir and containing 18 g of CHO, 10 g of protein, and 2 g of fat
62358677|NCT06165523|ACTIVE_COMPARATOR|Flavored Milk|1% Lowfat Milk manufactured by Prairie Farms and containing 24 g of CHO, 8 g of protein, and 2.5 g of fat
62712067|NCT05784857|OTHER|No Intervention and Touch Group|"Each intubated infant will be follewed up during 3 aspiration procedures. Different touching techniques will be used for preterm infants in each aspiration application.~The first aspiration procedure will be performed without intervention. During the second aspiration procedure, yakson touch will be applied.Third aspiration procedure, gentle human touch will be applied."
62712068|NCT00152126|OTHER|1|
62712069|NCT02569853|EXPERIMENTAL|DFN-11|DFN-11 active injection upon occurrence of migraine
62522515|NCT04262661|ACTIVE_COMPARATOR|Insulin glargine Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days.
62522516|NCT02485730||Adult children of AD patient|Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.
62522517|NCT00973518||Alzheimer's Disease subjects|Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
62522518|NCT00973518||Healthy Control subjects|Age \& gender-matched subjects determined to be healthy.
62522519|NCT04076670|NO_INTERVENTION|Control group|Group pf participants that received usual psychological attention.
62522520|NCT04076670|EXPERIMENTAL|Experimental group|Group of participants that received usual psychological attention plus the structured psychological intervention prosed in the study.
62522521|NCT01457261|EXPERIMENTAL|Partical size 1|Monodisperse particle delivered with radiolabel
62712070|NCT02569853|PLACEBO_COMPARATOR|Placebo|Placebo injection upon occurrence of migraine
62712071|NCT03892317|OTHER|Medication adherence interventions|Pharmacist led medication adherence interventions which will be tailored to individual patient need
62712072|NCT02004301|EXPERIMENTAL|Radiolabelled T4 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 4 h radiolabelled with 4 MBq 99mTc
62712073|NCT02004301|EXPERIMENTAL|Radiolabelled T6 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 6 h radiolabelled with 4 MBq 99mTc
62712074|NCT05109793||Cohort|Late infantile or juvenile onset for GM1 or GM2 Gangliosidosis. The study anticipates to include a total of approximately 35 patients.
62712075|NCT04194424|EXPERIMENTAL|Multidisciplinary program|Multidisciplinary weight loss program
62150691|NCT00184444|EXPERIMENTAL|Hypoxic Interval training|4 x 4 minutes interval training with 100% oxygenated air
62150692|NCT00184444|EXPERIMENTAL|Normoxic interval training|4 x 4 minutes interval training in normoxic air
62150693|NCT04931966|ACTIVE_COMPARATOR|Group A|Adductor canal block
62150694|NCT04931966|ACTIVE_COMPARATOR|Group B|Adductor canal block plus IPACK
62150695|NCT04931966|ACTIVE_COMPARATOR|Group C|Adductor canal block plus PAI
62150696|NCT00330499|EXPERIMENTAL|A|Synchronous chemo / radiation therapy
62150697|NCT00330499|ACTIVE_COMPARATOR|B|Radiation Alone
62150698|NCT05159427|EXPERIMENTAL|G.I Intubation|Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 20% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
62522522|NCT01457261|EXPERIMENTAL|Particle size 2|Monodisperse particle delivered with radiolabel
62522523|NCT01457261|EXPERIMENTAL|Nebulised salbutamol|Polydisperse particle via a nebuliser
62522524|NCT01457261|EXPERIMENTAL|Salbutamol MDI|Unlabelled salbutamol via a metered dose inhaler
62522525|NCT02140866|EXPERIMENTAL|Hand Exercise|The intervention group will receive an exercise program for the hand/arm in combination with a compensatory intervention program (CIP).
62522526|NCT02140866|ACTIVE_COMPARATOR|Compensatory Intervention Program (CIP)|The control group will receive the Compensatory Intervention Program (CIP) only.
62712076|NCT04194424|OTHER|Control|Standard care
62712077|NCT05000710|EXPERIMENTAL|study arm|"Study treatments include:~Durvalumab at D1 and q4w + Tremelimumab at C1D1 and C4D1. Radiotherapy 11 fractions (start at D21)."
62712078|NCT01750853|EXPERIMENTAL|Group 1|"Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally."
62712079|NCT01750853|EXPERIMENTAL|Group 2|"Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally."
62712080|NCT01750853|EXPERIMENTAL|Group 3|"Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period)."
62150699|NCT05159427|EXPERIMENTAL|No G.I Intubation|Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 20% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water.
62150700|NCT05934175|EXPERIMENTAL|Intensive treatment with prolonged exposure|Intensive prolonged exposure delivered for five consecutive days comprising nine individual sessions and five group sessions followed by three individual session one, two and four weeks afterwards.
62150701|NCT05934175|ACTIVE_COMPARATOR|Weekly delivered prolonged exposure|15 weekly delivered, individual prolonged exposure sessions (gold standard treatment)
62150702|NCT03165305|EXPERIMENTAL|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
62150703|NCT03165305|NO_INTERVENTION|No Intervention group|Includes routine neonatal care in the delivery room
62522527|NCT01997229|EXPERIMENTAL|Eculizumab|Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
62150704|NCT03051074|EXPERIMENTAL|Floating|The participant will float supine in water with a high concentration of Epsom salt for up to 90 minutes on three separate occasions
62712081|NCT06004232|EXPERIMENTAL|PRY-D intervention|Participants in the intervention group will complete 8 prenatal yoga sessions (1x/week) in a virtual group format. The first session will be in person, in which they will meet the instructor, connect with one another through brief introductions, receive their yoga practice materials, practice basic yoga poses, and be given the schedule for the remaining sessions, including virtual access links (e.g., Webex).
62712082|NCT06004232|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Participants in the the TAU group will receive routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
62150705|NCT03051074|ACTIVE_COMPARATOR|Comparison condition|The participant will watch a relaxing 90 minute film as a comparison condition
62712083|NCT02804620|EXPERIMENTAL|PLEASED|The PLEASED intervention arm will receive peer leader who is patients with diabetes that has been gone through our trainings. Also, they will receive three free health screenings (baseline, 3 months, 12 months) and monetary compensation for their time and effort.
62358678|NCT04429321|EXPERIMENTAL|Ipilimumab +Nivolumab with Embolization|"Patients initiate ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 480mg flat dose IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities.~Patients will receive 2 cycles of systemic therapy followed by embolization of their primary tumor or metastatic lesion(s) and continue systemic therapy subsequently."
62150706|NCT00783146|EXPERIMENTAL|1|desloratadine
62150707|NCT00783146|ACTIVE_COMPARATOR|2|fexofenadine
62150708|NCT00783146|PLACEBO_COMPARATOR|3|placebo
62150709|NCT00639418||Participants 6 to 23 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 6 to 23 months of age
62358679|NCT02465255|EXPERIMENTAL|Ketorolac|Ketorolac 0.5 mg/kg administrated by sublingual route
62358680|NCT02465255|ACTIVE_COMPARATOR|Tramadol|Tramadol 2.0 mg/kg administrated by sublingual route
62358681|NCT02465255|ACTIVE_COMPARATOR|Acetaminophen (paracetamol)|Acetaminophen (paracetamol) 20.0 mg/kg administrated by sublingual route
62150710|NCT00639418||Participants 24 to 59 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 24 to 59 months of age
62358682|NCT05523804||interval cytoreductive surgery|women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) cytoreductive surgery
62358683|NCT05523804||delayed cytoreductive surgery|women with stage III-IV ovarian cancer, undergoing delayed (\>5 cycles of chemotherapy) cytoreductive surgery
62358684|NCT05523804||no surgery|women with stage III-IV ovarian cancer, undergoing \>5 cycles of chemotherapy alone (no cytoreductive surgery)
62358685|NCT02613702|EXPERIMENTAL|Modified Free Gingival Graft|Twenty patients will receive the modified free gingival graft technique at the inferior incisors area. In this technique, the graft is covered by a flap, similarly to what is done in a connective tissue graft surgery.
62358686|NCT02613702|ACTIVE_COMPARATOR|Original Free Gingival Graft technique|Twenty patients will receive the original technique of free gingival graft at the inferior incisors area.
62358687|NCT05837325||Study Group|
62358688|NCT05837325||Out of Study Group|
62358689|NCT02088541|EXPERIMENTAL|Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)|Participants under protocol versions (PV) less than (\<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m\^2 (milligrams per square meter) (60 to 120 mg based on body surface area \[BSA\]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
62358690|NCT02088541|EXPERIMENTAL|Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)|Participants under PV \< 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m\^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
62358691|NCT02088541|EXPERIMENTAL|Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)|Participants under PV \>= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m\^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
62358692|NCT02088541|ACTIVE_COMPARATOR|Physician's Choice 1 (PV <5)|Participants under PV \< 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
62358693|NCT02088541|ACTIVE_COMPARATOR|Physician's Choice 2 (PV >=5)|Participants under PV \>= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
62358694|NCT03175562|EXPERIMENTAL|Test product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
62358695|NCT03175562|OTHER|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
62358696|NCT04698512||Arteriovenous Fistuloplasty with MagicTouch™ Balloon|Patients above the age of 21 that have undergone AVF / AVG fistuloplasty with MagicTouch™ at Singapore General Hospital will be included in the study and followed up post-op for 12 months. Patients will be treated and followed-up following standard clinical care pathways.
62358697|NCT05452109|EXPERIMENTAL|Blood Flow Restriction + Classical Training|
62358698|NCT05452109|EXPERIMENTAL|Classical Training Alone|
62358699|NCT02394418|ACTIVE_COMPARATOR|Sevoflurane|Treatment of delirium by inhaled sevoflurane
62358700|NCT02394418|ACTIVE_COMPARATOR|Propofol|Treatment of delirium by propofol i.v. infusion
62358701|NCT02394418|ACTIVE_COMPARATOR|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
62358702|NCT03958318|EXPERIMENTAL|Exercise|Multi-modal exercise program
62712084|NCT02804620|NO_INTERVENTION|Wait List|The wait list will receive three free health screening (at baseline, 3months, 12 months) and monetary compensation for their time and effort.
62358703|NCT03958318|EXPERIMENTAL|Exercise plus nutritional suplementation|Multi-modal exercise program plus nutritional suplementation
62712085|NCT05423184|ACTIVE_COMPARATOR|Exercise Therapy For Lower Extremities|Participants will treated exercises with focused on lower extremities especilly knee joint and muscles. Exercise program continue for 18 sessions with 3 times a week and 6 week duration. Exercises are; straight leg raise, assisted squat, lunge. All sessions supervised by a physiotherapist with synchron tele-rehabilitation.
62712086|NCT05423184|EXPERIMENTAL|Exercise Therapy For Myofascial Chains|"Participants will treated exercises with focused on whole body especilly myofascial chains.~Exercise program continue for 18 sessions with 3 times a week and 6 week duration. Exercises are; straight leg raise, assisted squat, lunge with upper extremities and whole body participation. All sessions supervised by a physiotherapist with synchron tele-rehabilitation."
62712087|NCT05423184|NO_INTERVENTION|Control Group|Participants will do any exercises. They will join only assessment sessions.
62712088|NCT02070653|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor 90 mg tablets twice daily for 12 months.
62712089|NCT02070653|PLACEBO_COMPARATOR|Placebo|Ticagrelor-placebo tablets twice daily for 12 months.
62358704|NCT03958318|NO_INTERVENTION|Control|No interventions
62358705|NCT06216197|OTHER|The FENT Group|Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
62358706|NCT06216197|OTHER|The DEX Group|The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
62358707|NCT02971293|EXPERIMENTAL|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
62358708|NCT02971293|PLACEBO_COMPARATOR|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
62358709|NCT02971293|EXPERIMENTAL|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
62358710|NCT05433636|EXPERIMENTAL|Body Scan Practice|
62358711|NCT05433636|EXPERIMENTAL|Mindful Breathing Practice|
62358712|NCT05433636|EXPERIMENTAL|Mindfulness of Discomfort Practice|
62358713|NCT05433636|EXPERIMENTAL|Mindful Savoring Practice|
62358714|NCT05433636|ACTIVE_COMPARATOR|Integrative Health Recording|
62358715|NCT04296916|EXPERIMENTAL|Intervention arm|medical reduction of IOP by eyedrops
62358716|NCT04296916|NO_INTERVENTION|control arm|follow up without medication
62358717|NCT02979444|EXPERIMENTAL|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
62358718|NCT02979444|EXPERIMENTAL|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
62358719|NCT02979444|NO_INTERVENTION|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
62358720|NCT05190536|EXPERIMENTAL|Experimental: Patients in Group 1 undergo Ho:YAG laser|
62358721|NCT05190536|EXPERIMENTAL|Experimental: Patients in Group 2 undergo TFL|
62358722|NCT00756678|ACTIVE_COMPARATOR|1|Carboxymethylcellulose and Glycerin
62358723|NCT00756678|ACTIVE_COMPARATOR|2|Polyethylene glycol 400
62358724|NCT04020276|EXPERIMENTAL|MRI-Guided SBRT Dose Escalation|"Treatment on MRI Linac with SBRT in 5 fractions with adaptive planning, maximum dose 80 Gy~Dose Escalation Bowel Pathway, V34 \< 0.5cc Dose Escalation Liver Pathway, 700 cc \< 16 Gy~Subsequent Phase 1B: CRC only for Safety and Local Control, dosage informed by Phase 1A"
62358725|NCT04489537|EXPERIMENTAL|MarzAA|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route, administered on-demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis
62358726|NCT04489537|ACTIVE_COMPARATOR|Standard of Care|Standard of care administered on-demand during bleeding episodes
62358727|NCT01804491||Control group|Healthy age matched control subjects
62358728|NCT01804491||Cheilectomy prospective group|"Patients with hallux rigidus treated by the surgery type cheilectomy"
62358729|NCT01804491||Arthrodesis prospective group|"Patients with hallux rigidus treated by the type of surgery arthrodesis"
62358730|NCT01804491||Mixed prospective group|"Patients with hallux rigidus treated by other type of surgery: Arthoplasty, joint resection (Keller-Brandes technique)"
62358731|NCT01804491||Cheilectomy retrospective group|Patients after cheilectomy due to hallux rigidus
62358732|NCT01804491||Arthrodesis retrospective group|Patients after arthrodesis of the metatarsophalageal joint due to hallux rigidus
62358733|NCT01804491||Mixed retrospective group|Patients after other types of surgery due to hallux rigidus: arthroplasty or resection of the first metatarso-phalangeal joint
62358734|NCT05955430|EXPERIMENTAL|Exercise, education and PENS|Patients will receive eight face-to-face sessions of therapeutic exercise, four sessions of pain education and eight sessions of percutaneous electrical stimulation (PENS).
62358735|NCT05955430|ACTIVE_COMPARATOR|Exercise, education and TENS|Patients will receive eight face-to-face sessions of therapeutic exercise, four sessions of pain education and eight sessions of transcutaneous electrical stimulation (TENS).
62358736|NCT05955430|PLACEBO_COMPARATOR|Exercise, education and placebo stimulation|Patients will receive eight face-to-face sessions of therapeutic exercise, four sessions of pain education and eight sessions of placebo stimulation.
62358737|NCT02979366|EXPERIMENTAL|S64315 (also referred as MIK665) administered once a week|
62358738|NCT02979366|EXPERIMENTAL|S64315 (also referred as MIK665) administered twice a week|
62712090|NCT00904371||Patients with arterial hypertention|
62150711|NCT00639418||Participants 5 to 8 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 5 to 8 years of age
62150712|NCT00639418||Participants 9 to 17 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 9 to 17 years of age
62150713|NCT00652600|EXPERIMENTAL|A|Subjects received Par formulated product under fed conditions
62150714|NCT00652600|ACTIVE_COMPARATOR|B|Subjects received Wyeth Pharmaceuticals formulated product under fed conditions
62150715|NCT02926118|EXPERIMENTAL|Low glycemic load|Low glycemic load
62358739|NCT03822338|EXPERIMENTAL|Pneumoperitoneum preconditioning group|Participant assigned to the this group will receive a treatment consisting of three cycles of 5 min insufflation (intra-abdominal pressure at 15 mmHg) and 5 min desufflation, after complete anesthesia and successfully implanting the veress.
62150716|NCT02926118|EXPERIMENTAL|High glycemic load|High glycemic load
62150717|NCT04709185|EXPERIMENTAL|AVS after 1mg DST|Patients divided into AVS after 1mg DST group need to oral 1mg dexamethasone the night before AVS
62358740|NCT03822338|SHAM_COMPARATOR|Control group|Participants in the control group will receive the same placement of the veress but without insufﬂation and subsequent desufﬂation.
62150718|NCT04709185|PLACEBO_COMPARATOR|AVS after placebo|Patients divided into AVS after placebo group need to oral placebo the night before AVS
62150719|NCT06486428||SCLC (de novo)|Blood collection, survey (baseline and Month 4)
62150720|NCT06486428||SCLC (transformed)|Blood collection, survey (baseline and Month 4)
62150721|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
62358741|NCT00735761|EXPERIMENTAL|1|ME-609 (5% acyclovir and 1% hydrocortisone)
62358742|NCT00735761|ACTIVE_COMPARATOR|2|Acyclovir in ME-609 vehicle (5% acyclovir)
62358743|NCT04989881|EXPERIMENTAL|Da Vinci Simulator|Participants will undergo a single session of training using the da Vinci Simulator
61976410|NCT01453257|EXPERIMENTAL|Chemotherapy treatment|Tailored chemotherapy by Therapeutic Targets
61976411|NCT03483883|EXPERIMENTAL|Single Arm|
62358744|NCT04989881|ACTIVE_COMPARATOR|Laparascopic training box|Participants will undergo a single session of training using a laparoscopic training box
62358745|NCT04095468||Resectable rectal cancer|
62358746|NCT04095468||Rectal cancer with threatened mesorectal fascia|
62358747|NCT01992666|EXPERIMENTAL|Blood sampling|
62358748|NCT04277832||single arm|Group of psoriasis patients will select randomly. All selected psoriasis patients will be consulted to a physician experienced in rheumatology and all of patients will fill TUPAST and TOPAS 2 forms.
62358749|NCT04511078|EXPERIMENTAL|Panitumumab-IRDye800|50 mg infusion of panitumumab-IRDye800 given over 60 minutes
62358750|NCT04839393|EXPERIMENTAL|Part A - Sequence 1|Treatment A - PF-06882961 single dose followed by Treatment B - PF-06882961 single dose and PF-06865571 single dose
62358751|NCT04839393|EXPERIMENTAL|Part A - Sequence 2|Treatment B - PF-06882961 single dose and PF-06865571 single dose followed by Treatment A - PF-06882961 single dose
62358752|NCT04839393|EXPERIMENTAL|Part B|Period 1: PF-06865571 single dose, Period 2: PF-06882961 twice daily dose titration, Period 3: PF-06865571 single dose and PF-06882961 twice daily dosing, Period 4: PF-06865571 twice daily dosing and PF-06882961 twice daily dosing
62358753|NCT04104295|EXPERIMENTAL|Ultrasound following X-ray|An ultrasound scan of the abdomen within 2 hours of the routine X-ray will be performed by a physician blinded to the X-ray results.
62358754|NCT04285710|OTHER|Control|Subjects enrolled in the subject group will receive standard care treatment for infected diabetic wounds, including debridement surgery and wound dressings. However, in order to maintain consistency with the phototherapy arm, subjects within the control group will visit the clinic twice a week, with the first visit being for the debridement surgery, and the second visit being for clinical wound dressing redressing.
62712091|NCT05188989|EXPERIMENTAL|TPN171H 2.5mg group|
62712092|NCT05188989|EXPERIMENTAL|TPN171H 5mg group|
61976412|NCT02313181|EXPERIMENTAL|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
62150722|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
62150723|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
62150724|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
62150725|NCT04119947|EXPERIMENTAL|SY-009 dose 1|A single dose of SY-009 (0.5-40mg) taken orally.
62358755|NCT04285710|EXPERIMENTAL|Phototherapy|For this intervention therapy, subjects enrolled in the experimental group will still receive standard care treatment for infected diabetic wounds. However, experiment group subjects will receive phototherapy treatments alongside standard care. A mobile pulsed laser device will be utilized to apply nanosecond pulsed 410 nm light onto both the cellulitis afflicted regions and open wound portions of a patient's infected diabetic ulcer wound twice a week over the course of the 3 month study. The device will be designed and produced by the Ji Xin Cheng Lab located at the Boston University Charles River Campus. Phototherapy sessions will occur twice a week, with the first session occurring after debridement surgery, and the second session occurring later in the week during clinical wound dressing redressing.
62712093|NCT05188989|EXPERIMENTAL|TPN171H 10mg group|
62712094|NCT05188989|PLACEBO_COMPARATOR|Placebo group|
61976413|NCT02313181|OTHER|Standard Care|Continue exclusive breastfeeding unless otherwise instructed by a health care provider
61976414|NCT03578289|EXPERIMENTAL|Experimental Group (telemental health_|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
61976415|NCT03578289|EXPERIMENTAL|Waiting Control Group (usual care)|Participants randomly assigned to the control group will receive routine care for three months followed by the 8-week CBT intervention
62358756|NCT01592006|EXPERIMENTAL|HCV, LT, Pegasys, ribavirin, telaprevir|Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir
62358757|NCT06527859||control group|healthy pregnancy women
62150726|NCT04119947|EXPERIMENTAL|SY-009 dose 2|A single dose of SY-009 (0.5-40mg) taken orally.
62150727|NCT04119947|EXPERIMENTAL|SY-009 dose 3|A single dose of SY-009 (0.5-40mg) taken orally.
62150728|NCT04119947|EXPERIMENTAL|SY-009 dose 4|A single dose of SY-009 (0.5-40mg) taken orally.
62150729|NCT04119947|EXPERIMENTAL|SY-009 dose 5|A single dose of SY-009 (0.5-40mg) taken orally.
62150730|NCT04119947|EXPERIMENTAL|SY-009 dose 6|A single dose of SY-009 (0.5-40mg) taken orally.
62150731|NCT04119947|PLACEBO_COMPARATOR|SY-009 matching placebo|from 2-40mg
62150732|NCT01256359|EXPERIMENTAL|Docetaxel and AZD6244|Docetaxel with AZD6244
62150733|NCT01256359|EXPERIMENTAL|Docetaxel and Placebo|Docetaxel without AZD6244
62150734|NCT00321672|EXPERIMENTAL|NGX-4010, 60 minutes|
62150735|NCT00321672|EXPERIMENTAL|NGX-4010, 30 minutes|
62150736|NCT00321672|OTHER|0.04% conc. capsaicin patch, 60 min.|
62150737|NCT00321672|OTHER|0.04% conc. capsaicin patch, 30 min.|
62150738|NCT02790788|EXPERIMENTAL|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
62358758|NCT06527859||disease group|pregnant women with normal-high TSH and positive TPOAb in the first half of pregnancy
62358759|NCT03044470|EXPERIMENTAL|Cold saline|Saline stored at 4 degrees centigrade
62358760|NCT03044470|EXPERIMENTAL|Normal Saline|Saline stored at room temperature
62358761|NCT04340960|NO_INTERVENTION|Control Group|"The control group will not be monitored with continuity of care. After this period, 30-day emergency department visits will be measured and compared between the two groups, along with 30-day readmission rates, in-hospital length of stay, mortality, quality of recovery 40 item scale (QoR-40), European Quality of Life 5 Dimensions (EQ5D), patient satisfaction score, and societal and hospital cost.~No intervention will be administered."
62358762|NCT04340960|EXPERIMENTAL|Home Monitoring Group|At the time of hospital discharge, the control group will be discharged without receipt of home monitoring, and the intervention group will receive a home monitoring kit with (NIBP (non-invasive blood pressure) and SPO2 (pulse oximetry) with instructions on how to use these devices. Patients in the intervention groups will receive digital communication for four weeks and have their NIBP, HR (heart rate), SPO2 and pain scores evaluated twice a day for two weeks.
62358763|NCT01317693|EXPERIMENTAL|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
62358764|NCT01262599|SHAM_COMPARATOR|Sham PEMF Device|Patients will receive inactive device
62358765|NCT01262599|ACTIVE_COMPARATOR|PEMF Device|Patients will receive Ivivi Torino II PEMF Device
62358766|NCT06378060|EXPERIMENTAL|Experimental group|
62358767|NCT01090102|EXPERIMENTAL|Mesalamine|
62358768|NCT01090102|PLACEBO_COMPARATOR|Placebo|
62358769|NCT00868335|ACTIVE_COMPARATOR|1|Anterior cervical discectomy, no disc prosthesis
62358770|NCT00868335|EXPERIMENTAL|2|Anterior cervical discectomy, with disc prosthesis
62358771|NCT03717116||control-normocalcemia group|
62358772|NCT03717116||hypocalcemia group|
62358773|NCT05434104|EXPERIMENTAL|Lactoferrin intervention group|Women will be given bovine lactoferrin 300mg vaginal pessaries to insert every evening for the first 21 days of the study \[25\].
62358774|NCT05434104|ACTIVE_COMPARATOR|Usual care control - standard oral antibiotics/antifungals|Control women with BV will be given oral metronidazole 400mg twice daily for five days (and routine advice about avoiding alcohol). Control women with candida will be given a fluconazole 150mg capsule to take orally the same day.
62358775|NCT00192595|ACTIVE_COMPARATOR|Arm 1:|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
62358776|NCT00192595|EXPERIMENTAL|Arm 2|Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)
62358777|NCT00192595|EXPERIMENTAL|Amr 3|Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)
62358778|NCT03527771|NO_INTERVENTION|unassisted CPR|unassisted CPR
62358779|NCT03527771|ACTIVE_COMPARATOR|T-CPR|telephone assisted CPR according to ERC Guidelines 2015
62358780|NCT03527771|EXPERIMENTAL|V-CPR|video-assisted CPR according to ERC Guidelines 2015
62358781|NCT01061567||Male and female patients with Parkinson's disease|
62358782|NCT00649168|EXPERIMENTAL|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
62358783|NCT00649168|ACTIVE_COMPARATOR|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
62358784|NCT00703170|EXPERIMENTAL|Dose Level 1 (original)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 30 mg/m2 once every 4 weeks"
62358785|NCT00703170|EXPERIMENTAL|Dose Level 1 (revised)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
62358786|NCT00703170|EXPERIMENTAL|Dose Level 2|"Temsirolimus IV 25 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
62358787|NCT00762268|EXPERIMENTAL|SAMe|"SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
62358788|NCT00762268|PLACEBO_COMPARATOR|placebo|"Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day rest-period, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period."
62358789|NCT04734769||Cycles of embryo transfer from patients with at least one euploid embryo (no rebiopsy group)|Collect retrospectively clinical data on reproductive outcomes
62712095|NCT00140140|EXPERIMENTAL|Part 1: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m\^2 ABI-007, followed by an infusion of 15 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.
62712096|NCT00140140|EXPERIMENTAL|Part 2: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m\^2 ABI-007, followed by an infusion of 15 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
62712097|NCT00140140|EXPERIMENTAL|Part 2: 90 mg ABI-007 + 20 mg vinorelbine|Weekly intravenous infusion of 90 mg/m\^2 ABI-007, followed by an infusion of 20 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
62712098|NCT05238116|EXPERIMENTAL|PC945|PC945 dose, administered via nebulizer, twice daily
62358790|NCT04734769||Rebiopsy group:|Collect retrospectively clinical data on reproductive outcomes
62358791|NCT02189070||Responders|Responding participants
62358792|NCT02189070||Non-responders|Non-responding participants
62358793|NCT01616784|ACTIVE_COMPARATOR|Multiple daily injections plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
62358794|NCT01616784|EXPERIMENTAL|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
62358795|NCT00778726|EXPERIMENTAL|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets of Ranbaxy
62358796|NCT00778726|ACTIVE_COMPARATOR|2|Lotensin® HCT tablets
62358797|NCT00322179||Obese|
62358798|NCT00322179||Non-Obese|
62358799|NCT03733457|EXPERIMENTAL|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
62358800|NCT02778945|EXPERIMENTAL|Group D (Deep NMB group)|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
62358801|NCT02778945|ACTIVE_COMPARATOR|Group I (Intermediate NMB group)|Use NMB as conventional clinical usage Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
62358802|NCT04408170||Work Stream A|Patients that are recruited in hospital with either query COVID-19 or who have tested positive for COVID-19.
62358803|NCT04408170||Work Stream B|Known COVID-positive and/or COVID-negative community testing
62358804|NCT04408170||Work Stream C|Undifferentiated community testing
62358805|NCT06333236|EXPERIMENTAL|Group KRON|Active Treatment: Kron® (300ml) oral solution containing citicoline free acid 40 mg/ml; nicotinamide 15 mg/ml. In addition to the IOP-lowering medications, Kron will be administered at a dosage of 10 ml in the morning. To each patient will be given two bottles during the baseline visit and will be asked to return them at the end of the study (3 month) for the compliance assessment.
62358806|NCT06333236|NO_INTERVENTION|Control Group|No interviention in addition to the IOP-lowering medications.
62358807|NCT05710770|ACTIVE_COMPARATOR|Immunoadsorption|"Immunoadsorption will be conducted with the TheraSorb LIFE 21 apheresis system in combination with the TheraSorb-Ig omni 5 adsorber over a period of 9-12 days: each participant will receive five immunoadsorption cycles treating 2.0 - 2.5 patient's plasma volumes every other day. Initial pilot studies have demonstrated this dose finding to be effective and well tolerated (Scheibenbogen et al., 2018; Tolle et al., 2020). The immunoapheresis material will be provided by the Miltenyi company at the beginning of the study.~Concerning the high effectiveness of immunoadsorption therapy in patients with other neuroimmunological diseases and the invasiveness of a sham-apheresis, a 2:1 randomization was chosen in order to ensure that more patients will receive a verum IA treatment."
62358808|NCT05710770|SHAM_COMPARATOR|Sham-apheresis|To have identical conditions to the immunoadsorption, sham apheresis will also be conducted with the TheraSorb LIFE 21 apheresis system over a period of 9-12 days: each participant will receive five sham cycles. For the sham apheresis, a TheraSorb LIFE 21 unit with blocked Ig adsorbers and without regeneration of the adsorbers during the treatment will be used, ensuring that the patient and the investigator are blinded. The study nurses applying the treatment (a specific person only in charge of the patient during the treatment) cannot be blinded.
62358809|NCT03848715|EXPERIMENTAL|Endotoxin|Endotoxin 0.8 ng/kg body weight; 1 infusion
62358810|NCT03848715|PLACEBO_COMPARATOR|Placebo|same volume of 0.9% saline
62358811|NCT05944159|EXPERIMENTAL|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
62358812|NCT05944159|OTHER|Control Group|Control group (n=20) was received routin medication therapy was applied. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
62358813|NCT05221255|SHAM_COMPARATOR|Sham Therapy|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation plus non-real magnetic stimulation.
62358814|NCT05221255|EXPERIMENTAL|Spinal magnetic stimulation|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation followed by real spinal magnetic stimulation.
62358815|NCT02198989|EXPERIMENTAL|peer support and yoga music therapy|"Patients in the group will receive peer support and yoga music therapy before bed.~Patients in the group will received the group education courses and clinical medical therapy."
62358816|NCT02198989|NO_INTERVENTION|Control group|Patients in the group will received the group education courses and clinical medical therapy.
62358817|NCT04562532|EXPERIMENTAL|Firehawk group|Participants implant Firehawk stent(s)
62358818|NCT04562532|ACTIVE_COMPARATOR|2nd generation DES|Participants implant Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific), or Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic), or Sirolimus eluting stents (Orsiro- Biotronik)
62712099|NCT05238116|PLACEBO_COMPARATOR|Placebo|PC945-placebo administered via nebulizer, twice daily
62358819|NCT00991224|EXPERIMENTAL|Arm 1|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir \>200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
62358820|NCT00991224|EXPERIMENTAL|Arm 2|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir \>200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
62712100|NCT04349683|EXPERIMENTAL|Experimental group|basic treatment combined with Jinshuibao
62712101|NCT04349683|PLACEBO_COMPARATOR|Control group|basic treatment and placebo
62712102|NCT06078566|EXPERIMENTAL|AUR-201|AUR-201
62712103|NCT02196532||migraine group|Patients with migraine
62712104|NCT02196532||healthy control|Sex- and agematched healthy subjects
62712105|NCT05732038|EXPERIMENTAL|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to practice 10 minutes per day for 12 weeks. The first four weeks will be prescribed. Weeks 5-12 will allow full access to the app's library.
62712106|NCT05732038|EXPERIMENTAL|Wellness App (WA)|Participants in the WA group will be asked to listen to the app content for 10 minutes per day for the entire 12 weeks.
62712107|NCT06449651|ACTIVE_COMPARATOR|Nipocalimab|Maternal participants will receive nipocalimab Intravenously (IV).
62712108|NCT06449651|PLACEBO_COMPARATOR|Placebo|Maternal participants will receive placebo IV.
62358821|NCT00991224|EXPERIMENTAL|Arm 3|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir \>200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
62358822|NCT00991224|EXPERIMENTAL|Arm 4|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of \>200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
62358823|NCT01825226|EXPERIMENTAL|Program participation|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
62358824|NCT01825226|NO_INTERVENTION|Control|
62358825|NCT03835013|PLACEBO_COMPARATOR|Part A - Infusion A|"1. 60 minute intravenous infusion of 0.9% saline~   Followed by:~2. 60 minute intravenous infusion of 0.9% saline"
62358826|NCT03835013|ACTIVE_COMPARATOR|Part A - Infusion B|"1. 60 minute intravenous infusion of glucagon 25ng/kg/min and 0.9% saline.~   Followed by:~2. 60 minute infusion of glucagon 50ng/kg/min and 0.9% saline"
62358827|NCT03835013|ACTIVE_COMPARATOR|Part B - Infusion A|A 60 minute intravenous infusion of 0.9% saline
62358828|NCT03835013|ACTIVE_COMPARATOR|Part B - Infusion B|A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes followed by 25ng/min) and 0.9% saline
62358829|NCT03835013|ACTIVE_COMPARATOR|Part B - Infusion C|A 60 minute intravenous infusion of glucagon (25ng/kg/min) and 0.9% saline
62358830|NCT03835013|ACTIVE_COMPARATOR|Part B - Infusion D|A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes then 25ng/min) and glucagon (25ng/kg/min)
62358831|NCT02053558|PLACEBO_COMPARATOR|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
62358832|NCT02053558|ACTIVE_COMPARATOR|TAP BLOCK with ropivacaine|TAP block will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
62358833|NCT04213183||development dataset 01|Slit-lamp and retinal fundus images collected from Department of Hepatobiliary Surgery of the Third Affiliated Hospital of Sun Yat-sen University.
62358834|NCT04213183||development dataset 02|Slit-lamp and retinal fundus images collected from Affiliated Huadu Hospital of Southern Medical University.
62358835|NCT04213183||development dataset 03|Slit-lamp and retinal fundus images collected from Nantian Medical Centre of Aikang Health Care.
62358836|NCT04213183||test dataset 01|Slit-lamp and retinal fundus images collected from Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University.
62358837|NCT04213183||test dataset 02|Slit-lamp and retinal fundus images collected from Huanshidong Medical Centre of Aikang Health Care.
62358838|NCT00868543|ACTIVE_COMPARATOR|Long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)\>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with long (150 cm) alimentary Roux limb
62358839|NCT00868543|ACTIVE_COMPARATOR|Very long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)\>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with very long (250 cm) alimentary Roux limb
62358840|NCT04907422||CXPA group|carcinoma ex pleomorphic adenoma of major and minor salivary glands.
62358841|NCT04907422||PA group|Benign pleomorphic adenoma of major and minor salivary glands.
62358842|NCT04907422||Control group|normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.
62358843|NCT04231513|EXPERIMENTAL|SAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
62358844|NCT04231513|EXPERIMENTAL|SAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
62358845|NCT04231513|EXPERIMENTAL|SAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
62358846|NCT04231513|EXPERIMENTAL|SAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
62522528|NCT01997229|PLACEBO_COMPARATOR|Placebo|Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
62522529|NCT05422430|SHAM_COMPARATOR|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
62712109|NCT01706484|EXPERIMENTAL|80 mg BNO 1016 und placebo|2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily
62150739|NCT02790788|PLACEBO_COMPARATOR|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
62522530|NCT05422430|EXPERIMENTAL|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
62522531|NCT03841890|EXPERIMENTAL|Intubation with the Clarus Video System as a video stylet|
62522532|NCT03841890|EXPERIMENTAL|Intubation with the Clarus Video System as a lightwand|
62522533|NCT03841890|ACTIVE_COMPARATOR|Intubation with direct laryngoscope|
62522534|NCT00564226|EXPERIMENTAL|SSR240600C Dose Level 1|
62522535|NCT00564226|EXPERIMENTAL|SSR240600C Dose Level 2|
62522536|NCT00564226|EXPERIMENTAL|SSR240600C Dose Level 3|dose level 3
62522537|NCT00564226|ACTIVE_COMPARATOR|Tolterodine|
62522538|NCT00564226|PLACEBO_COMPARATOR|Placebo|
62522539|NCT03633448|EXPERIMENTAL|Mucinex® 1 x 200 mg (10 mL)|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
62522540|NCT03633448|EXPERIMENTAL|Mucinex® 1 x 400 mg (20 mL)|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
62522541|NCT05968534|OTHER|MOSAIC Plus|This is a single-arm open-trial to evaluate and refine the feasibility and acceptability of training and recruitment methods. Data from this phase will be used to refine and inform study procedures for the subsequent RCT.
62522542|NCT06213714|EXPERIMENTAL|5G Tele-Robotic-Assisted PCI|VRS100 Robotic Console System, was developed by Shenzhen Raysight Intelligent Medical Technology Co., Ltd., will be used for 5G Tele-Robotic-Assisted Percutaneous Coronary Intervention in this study.
62522543|NCT01856036|EXPERIMENTAL|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
62522544|NCT05777759|EXPERIMENTAL|New Dermal Filler for indication: Restylane Lyft with Lidocaine|hyaluronic acid dermal filler
62522545|NCT05777759|ACTIVE_COMPARATOR|Active Comparator: FDA approved Dermal Filler: Juvederm Voluma XC|hyaluronic acid dermal filler
62150740|NCT05637684|EXPERIMENTAL|low intensity pulsed ultrasound group|low intensity pulsed ultrasound application The following parameters will be used: intensity of 0.3 W/cm2 at a 1megahertz frequency for 20 minutes and pulsed (20%) ultrasound waves and conventional physical therapy program will be used for this group in a form of wrist hand Splint ,Medical Massage (effleurage),Passive stretching for wrist flexor, Carpal mobilization and Strengthening exercise
62522546|NCT05953766|EXPERIMENTAL|Presacral Nerve Block|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml instilled in the presacral space
62522547|NCT05953766|SHAM_COMPARATOR|Sham Block|20mL of normal saline (sham block) instilled in the presacral space
62522548|NCT03330912|EXPERIMENTAL|Seat Height Intervention|"Randomly assigned 5 wheelchair seat heights ranging from very low (2 below) to very high (2 above) the lower leg length of the participant."
62522549|NCT04243408|EXPERIMENTAL|group 1|
62522550|NCT04243408|PLACEBO_COMPARATOR|group 2|
62522551|NCT03407430|EXPERIMENTAL|Pregabalin, then Placebo|"Pregabalin in cycle 1; placebo in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg twice a day (BID) for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities \>Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
62522552|NCT03407430|EXPERIMENTAL|Placebo, then Pregabalin|"Placebo in cycle 1; pregabalin in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg BID for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities \>Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
62522553|NCT01690221|EXPERIMENTAL|VEN 307|diltiazem hydrochloride 2% cream
62712110|NCT01706484|EXPERIMENTAL|160 mg BNO 1016|2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily
62150741|NCT05637684|SHAM_COMPARATOR|control group|conventional physical therapy program will be used for this group in a form of wrist hand Splint ,Medical Massage (effleurage),Passive stretching for wrist flexor, Carpal mobilization and Strengthening exercise
62522554|NCT01690221|PLACEBO_COMPARATOR|Placebo|Placebo Cream
62522555|NCT03831763|ACTIVE_COMPARATOR|ColdZyme|
62522556|NCT03831763|NO_INTERVENTION|Optional care only|
62522557|NCT02724865|ACTIVE_COMPARATOR|Oral appliance therapy; Somnodent®|Somnodent is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
62522558|NCT02724865|ACTIVE_COMPARATOR|Oral appliance therapy; Herbst®|Herbst is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
62712111|NCT01706484|PLACEBO_COMPARATOR|placebo|2 tablets (each without BNO 1016) by mouth 3 times daily
62712112|NCT05786287||Conditioned Medium (CM)|2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell injected into peribulbar
62150742|NCT05539118|EXPERIMENTAL|Recombinant human interferon α1b + toripalimab + anlotinib hydrochloride|Recombinant human interferon α1b administered 600μg every other day. Toripalimab administered 240mg intravenously every three weeks. Anlotinib hydrochloride given 12mg or 10mg or 8mg orally (Daily for two weeks continuously, followed by one week of rest). A recommended phase II dose (RP2D) of anlotinib hydrochloride will be determined.
62150743|NCT02138838|ACTIVE_COMPARATOR|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
62150744|NCT02138838|EXPERIMENTAL|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
62150745|NCT00635609|EXPERIMENTAL|Doxycycline hyclate (Doryx)|
62358847|NCT04231513|EXPERIMENTAL|SAD, Cohort 5: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
62150746|NCT00635609|ACTIVE_COMPARATOR|Doxycycline hyclate|
62150747|NCT05493488|ACTIVE_COMPARATOR|DBI-001 Gel|Topical application of DBI-001 Gel on foot/feet affected with tinea pedis
62358848|NCT04231513|EXPERIMENTAL|MAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
62358849|NCT04231513|EXPERIMENTAL|MAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
62358850|NCT04231513|EXPERIMENTAL|MAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
62358851|NCT04231513|EXPERIMENTAL|MAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
62358852|NCT06357884|EXPERIMENTAL|Callus debridement|Callus debridement which aligns with routine clinical practice of the Princess Margaret Hospital Podiatry Department.
62358853|NCT00611611||1|SLE
62358854|NCT00611611||2|healthy controls
62358855|NCT00055848||Group 1|"Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.~A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.~Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment."
62358856|NCT03684941|EXPERIMENTAL|Treatment Period One|LoFric, hydrophilic urinary catheter for single use. The study device is based on commercially available hydrophilic urinary catheters for intermittent catheterization, but with a different coating process than the comparator. Treatment Period One will last 1 week.
62358857|NCT03684941|ACTIVE_COMPARATOR|Treatment Period Two|CE-marked LoFric®, hydrophilic urinary catheter for single use. The comparator product is today commercially available and produced by WHC. Treatment Period Two will last 1 week.
62358858|NCT02708615|OTHER|Vertical rotation|Vertical insertion and 90 degree rotation of speculum in vagina
62358859|NCT02708615|OTHER|Straight horizontal insertion|Straight horizontal insertion of speculum with no rotation in vagina
62358860|NCT06249009|ACTIVE_COMPARATOR|CPAP-first group|After a wash out of 15 minutes with conventional oxygen therapy, CPAP with a Positive End -Expiratory Pressure of 7 cmH2O will be introduced, with an inspiratory oxygen fraction required for an oxygen saturation of 94%, during 30 minutes. The collection of EAdi min/max will be done every minutes over 30min as well as the collection of HR, Respiratory rate (RR), SpO2, while TCPCO2, distress respiratory score and pain score will be taken at M0 and M30.
62358861|NCT06249009|ACTIVE_COMPARATOR|HFNC-first group|"After a wash out of 15 minutes with conventional oxygenotherapy, increasing flow rates for up to 2 hours according to the following augmentation:~* Initiation at a flow rate of 2 L/kg/min with FiO2 required to achieve SpO2≥94% (increase FiO2 if reliable SpO2 signal \<94% for 1 minute) for 30min.~* Increase to 3 L/kg/min after the first 30min of ventilation and repeat the previously described experimental scheme.~* Further increase to 4 L/kg/min after 30min of ventilation and repetition of the experimental scheme (if weight \< 16 kg).~* Last increase to 5 L/kg/min after 30 min of ventilation and repetition of the experimental scheme (if weight \< 13 kg).~The collection of EAdi min/max will be done every minutes over 30min as well as the collection of HR, RR, SpO2, while TCPCO2, distress respiratory score and pain score will be taken at M0 and M30."
62358862|NCT01851863|ACTIVE_COMPARATOR|Flupentixol-Melitracen(psychological and GI) + Omeprazole|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
62358863|NCT01851863|ACTIVE_COMPARATOR|Flupentixol-Melitracen(psychological) + Omeprazole|The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
62358864|NCT01851863|ACTIVE_COMPARATOR|Flupentixol-Melitracen(without explanation) + Omeprazole|In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
62358865|NCT01851863|ACTIVE_COMPARATOR|proton pump inhibitor|Prescribe Omeprazole.
62358866|NCT02588560||HCV lymphoma patients with chemotherapy|Lymphoma patients who are positive for anti-HCV and are planning to receive chemotherapy for lymphoma
62358867|NCT06383689|EXPERIMENTAL|Seizure placebo pill (PCB-S)|Patients assigned to this condition receive a covered placebo pill (1-0-1) on a daily basis with the indication of possible acceleration of the occurrence of an epileptic seizure (which then allows to conclude V-EEG monitoring faster)
62358868|NCT06383689|EXPERIMENTAL|Well-being placebo pill (PCB-W)|Patients assigned to this condition receive a covered placebo pill (1-0-1) on a daily basis with the indication of possible improvement of emotional well-being during the demanding V-EEG monitoring procedure
62150748|NCT05493488|ACTIVE_COMPARATOR|DBI-002 Gel|Topical application of DBI-002 Gel on foot/feet affected with tinea pedis
62358869|NCT06383689|NO_INTERVENTION|No pill (control)|Patients assigned to this condition receive no study pill but are asked to fill-in all questionnaires and diaries like patients in the two active arms
62358870|NCT00929045|EXPERIMENTAL|Growth Hormone|
62358871|NCT03168555|EXPERIMENTAL|Intervention|chenodeoxycholic acid 1250mg po.
62358872|NCT05800834|EXPERIMENTAL|Morphine sulfate|Topical morphine with hydrogel base.
62358873|NCT05800834|ACTIVE_COMPARATOR|Lidocaine Hcl 2% jelly|2% lidocaine jelly
62358874|NCT05832099||Radiation|Conformal focal-brain irradiation using modern radiotherapeutic techniques (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
62358875|NCT05359809|EXPERIMENTAL|Grasping Palmar Reflex|
62358876|NCT05359809|NO_INTERVENTION|Control|
62358877|NCT02220361|PLACEBO_COMPARATOR|placebo group|received 20 ml intravenous physiological saline
62358878|NCT02220361|EXPERIMENTAL|low dose dexmedetomidine group|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
62358879|NCT02220361|EXPERIMENTAL|hemabate+high dose dexmedetomidine group|received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
62358880|NCT02193672|EXPERIMENTAL|PET/CT + [18F]Fluciclatide|"At baseline: Participants have PET/CT imaging within 7 days prior to initiation of chemotherapy treatment. Participants monitored at 24 hours post scan via telephone.~On treatment: Participants have PET/CT imaging at end of the first cycle and prior to the initiation of the second cycle of chemotherapy. Participants assessed at 24 hours post scan via telephone call.~Baseline and on treatment PET/CT imaging performed with agent \[18F\] Fluciclatide."
62358881|NCT02293824||Premature infants|Premature infants \<29 weeks birth gestational age receiving caffeine per standard of care for the prevention or treatment of apnea of prematurity.
62358882|NCT01306851|ACTIVE_COMPARATOR|Fibrin glue|
62358883|NCT00355134|EXPERIMENTAL|Fingolimod 1.25 mg|"Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day."
62358884|NCT00355134|EXPERIMENTAL|Fingolimod 0.5 mg|Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
62358885|NCT00355134|EXPERIMENTAL|Placebo|"Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day."
62358886|NCT01207284|EXPERIMENTAL|Physical Therapy|Foot and ankle passive and active stretching, muscle strengthening, proprioception training and gait training.
62358887|NCT01207284|NO_INTERVENTION|Control|
62358888|NCT00656084|EXPERIMENTAL|Experimental arm|Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
62358889|NCT04905823||Type 1 diabetes patients|Patients with type 1 diabetes
62358890|NCT04905823||Non-diabetic subjects|Subjects in whom diabetes has not been diagnosed
62358891|NCT04905823||Type 2 diabetes patients|Patients with type 2 diabetes
62358892|NCT06344871|EXPERIMENTAL|NeuroLF Scan|Scan on the NeuroLF PET system.
62358893|NCT06344871|ACTIVE_COMPARATOR|Comparator Scan|Scan on a conventional clinical PET system.
62358894|NCT00002707|EXPERIMENTAL|Group 2|doxorubicin and cyclophosphamide plus Taxotere prior to surgery plus tamoxifen
62150749|NCT05493488|PLACEBO_COMPARATOR|Aqueous Gel|Topical application of Aqueous Gel on foot/feet affected with tinea pedis
62358895|NCT00002707|EXPERIMENTAL|Group 3|doxorubicin and cyclophosphamide followed by surgery followed by taxotere plus tamoxifen
62358896|NCT00002707|ACTIVE_COMPARATOR|Group 1|doxorubicin and cyclophosphamide plus tamoxifen
62358897|NCT01423955|PLACEBO_COMPARATOR|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
62358898|NCT01423955|EXPERIMENTAL|Erythropoietin|• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.
62358899|NCT01256203|EXPERIMENTAL|Sunscreen|Solar Protection Formula SPF® 60 will be applied on the skin of each subject. Applications will be followed by photobiological testings to assess skin protection.
62358900|NCT02785146|EXPERIMENTAL|mFOLFOX6 + Huaier Granule|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ). Huaier Granule will be administrated from the first cycle of chemotherapy until 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
62358901|NCT02785146|ACTIVE_COMPARATOR|mFOLFOX6|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ).
62358902|NCT06343025|EXPERIMENTAL|Pilates Group|Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises. In addition, Diet will be recommended by the doctor as routine treatment.
62358903|NCT06343025|EXPERIMENTAL|Tai Chi Group|Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises. In addition, Diet will be recommended by the doctor as routine treatment.
62150750|NCT05637944||intubated within day 7th|patients needing oro-tracheal intubation within day 7th from admission.
62712113|NCT05786287||UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension injected into peribulbar
62150751|NCT05637944||non intubated within day 7th|patients not requiring intubation within day 7th from admission
62150752|NCT02926313|NO_INTERVENTION|Existing Seating conditions|This group of participants received the standard care - they continue to sit in the seating system (chair and cushion) as provided by the nursing home facility staff; selected from whatever seats the facility had available.
62150753|NCT02926313|EXPERIMENTAL|Individualized Seating provision|This group of participants were provided with a seating system that was specifically configured to match their individual postural care needs.
62150754|NCT03006393|EXPERIMENTAL|Infliximab|Participants randomized to the infliximab group will receive one infusion of infliximab at 5mg/kg body weight.
62150755|NCT03006393|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo group will receive one placebo infusion.
62150756|NCT00854594|NO_INTERVENTION|Control|Control sites will receive the baseline measures pre and post. These sites will receive traditional diabetes education, which includes teleconsultation.
62150757|NCT00854594|EXPERIMENTAL|ReSPECT Intervention|Intervention sites will receive baseline measures pre and post, but also in-depth Shared Medical Appointments (SMA)(The Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT) intervention) and at 15 months SMA video conferences. At the end of the 18 months the randomly selected patients and providers will be asked to take part in a qualitative interview.
62150758|NCT02580227|ACTIVE_COMPARATOR|Tranexamic Acid|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
62150759|NCT02580227|PLACEBO_COMPARATOR|Placebo|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
62150760|NCT05870761|EXPERIMENTAL|Treatment (dostarlimab, niraparib)|Patients receive dostarlimab IV and niraparib PO on study. Patients also undergo MRI/CT and collection of blood samples throughout the trial.
62358904|NCT06343025|NO_INTERVENTION|Control Group|The control group will not be given any training. Diet and brisk walking 3 days a week will be recommended by the doctor as routine treatment for the control group.
62358905|NCT03810378|EXPERIMENTAL|Mediterranean Diet (Med-Plus)|Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
62150761|NCT03345706|EXPERIMENTAL|Selective cerebral hypothermia|Selective cerebral hypothermia
62150762|NCT03345706|ACTIVE_COMPARATOR|Regular hypothermia|Regular hypothermia
62150763|NCT02168855|ACTIVE_COMPARATOR|Active nicotine gum|
62150764|NCT02168855|PLACEBO_COMPARATOR|Inactive gum|
62150765|NCT01427400|EXPERIMENTAL|Expander Placement, Botulinum Toxin-A|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
62150766|NCT01427400|PLACEBO_COMPARATOR|Tissue expander Placement WITH Saline|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
62150767|NCT01586416|EXPERIMENTAL|Behavioral Intervention|Brief behavioral intervention on 2-3 sessions of tailored cognitive-behavioral therapy to support chemotherapy adherence and well-being of patients completing chemotherapy for colon cancer.
62150768|NCT03353285||Group I|Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)
62150769|NCT03353285||Group II|Group II= egg retrieved in the 1st-2nd flush
62150770|NCT03353285||Group III|Group III= egg retrieved in the 3rd-5th flush
62150771|NCT03507699|EXPERIMENTAL|Immunotherapy alone|Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
62150772|NCT03507699|EXPERIMENTAL|Combined radiotherapy and immunotherapy|"Liver radiation therapy: three treatments to one liver metastasis, administered on alternate days.~Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg."
62150773|NCT02815865|ACTIVE_COMPARATOR|Foley catheter and pitocin|Intervention: Foley catheter and pitocin Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
62150774|NCT02815865|ACTIVE_COMPARATOR|Foley catheter and dinoprostone|Intervention: Foley catheter and dinoprostone Foley catheter will be inserted through the cervix and inflated with 80 ml saline dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
62150775|NCT02815865|ACTIVE_COMPARATOR|Dinoprostone|Intervention: Dinoprostone 3 mg will be inserted to the posterior fornix
62150776|NCT06098833|ACTIVE_COMPARATOR|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
62358906|NCT03810378|EXPERIMENTAL|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.
62358907|NCT02959112|ACTIVE_COMPARATOR|Epinephrine sprayed on the papilla and rectal indomethacin|Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
62358908|NCT02959112|PLACEBO_COMPARATOR|Sterile water sprayed on the papilla and rectal indomethacin|10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
62522559|NCT05500716|EXPERIMENTAL|Auricular Non-Invasive Vagus Nerve Stimulation+Traditional Rehabilitation Program|"* Auricular Non-Invasive Vagus Nerve Stimulation~* Deep Friction Massage~* Myofascial Trigger Point Compression Therapy~* Temporomandibular Joint Mobilization~* Rocabado Exercises~* Muscle-Energy Techniques"
62150777|NCT06098833|PLACEBO_COMPARATOR|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
62358909|NCT00431496|EXPERIMENTAL|Cinacalcet|Cinacalcet was administered orally at a starting dose of 30 mg/day for 23 weeks. Possible sequential doses during the study were 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet occurred if the intact parathyroid hormone (iPTH) level from the previous study visit was \> 31.8 pmol/L (300 pg/mL) unless the participant had either reached the maximum dose (180 mg/day), the serum corrected total calcium was \< 2.1 mmol/L (8.4 mg/dL), or the participant experienced an adverse event that precluded a dose increase.
62150778|NCT04788810|EXPERIMENTAL|Oral route|Volunteers receiving d12-Cl2BPA via oral route
62150779|NCT04788810|EXPERIMENTAL|Dermal route|Volunteers receiving d12-Cl2BPA via oral route
62150780|NCT04712032|EXPERIMENTAL|Image Guided Bowel Anastomosis group|ICG-guided perfusion assessment
62150781|NCT04712032|NO_INTERVENTION|Conventional Bowel Anastomosis group|conventional perfusion assessment
62150782|NCT03784222|EXPERIMENTAL|treatment group|188 first episode schizophrenia patients, receiving blonanserin treatment, 60 of the patients receive MRI and serum BDNF test
62358910|NCT06403293|EXPERIMENTAL|AH Plus-NA|AH Plus was mixed according to the manufacturer's instructions. The R40 gutta-percha (VDW) was coated with the sealer and inserted into the canal, and the root canals were filled using the single cone technique (SCT). The sealer was not activated.
62358911|NCT06403293|EXPERIMENTAL|AH Plus- EA|An EA 25/04 tip was coated with AH Plus and activated in the root canals for 10 seconds. Then, the R40 gutta-percha was coated with the sealer and inserted into the canal, and the root canals were filled using SCT.
62358912|NCT06403293|EXPERIMENTAL|BC-NA|The ready-to-use EndoSequence BC was injected into the root canals and no activation was performed. Then, the R40 gutta-percha was inserted into the canali and the root canals were filled using SCT.
62358913|NCT06403293|EXPERIMENTAL|BC-EA|EndoSequence BC was injected into the root canals. An EA 25/04 tip was inserted 2 mm beyond the WL and activated for 10 s. Then, the R40 gutta-percha was inserted into the canal and the root canals were filled using SCT.
62358914|NCT04086602|EXPERIMENTAL|Single Ascending Dose|Once daily oral IZD334 or Placebo
62358915|NCT04086602|EXPERIMENTAL|Multiple Ascending Dose|Once or twice daily oral IZD334 or Placebo
62358916|NCT05450744|EXPERIMENTAL|131I-TLX101 + standard of care|
62358917|NCT02456792|ACTIVE_COMPARATOR|IVF group|Women will undergo one full IVF cycle
62358918|NCT02456792|ACTIVE_COMPARATOR|LOD group|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
62358919|NCT03108625|EXPERIMENTAL|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
62358920|NCT06456515|EXPERIMENTAL|Regorafenib and Sintilimab in combination with electroacupuncture|
62358921|NCT02808507|EXPERIMENTAL|Facility-based screening|This strategy will be implemented at all clinics (n=28) within this arm for 18 months. Study staff will encourage providers at each of the clinics to screen all consenting patients attending the clinic, regardless of the original reason for clinic presentation. Upon presenting for care (e.g., while waiting for their healthcare provider), patients will be informed about the study and screened for cough of any duration, fever, weight loss, or night sweats. Participants who are symptomatic and provide a sputum specimen (according to the clinic standard of care) will be given a study flyer informing them that they may be contacted by study staff, and a brief summary of the study. Per standard of care, all sputum samples will be sent to the local National Health Laboratory Service laboratory for Xpert testing.
62358922|NCT02808507|EXPERIMENTAL|Contact screening|"This arm is comprised of two sub-arms:~In the household contact screening sub-arm, a mobile field team visits the household of each consenting newly diagnosed pulmonary TB index case. Each visit consists of a household census, consent of all eligible household members for TB screening, administration of a brief questionnaire, sputum collection for testing with Xpert Mycobacterium tuberculosis (MTB)/rifampin (RIF) and the offer of HIV testing.~In the incentive-based contact screening sub-arm, all consenting newly diagnosed active TB cases are provided with 10 coupons for free TB screening to give to close contacts. When a contact presents at clinic with a coupon, they and the index case each receive a small amount of money. If the contact is diagnosed with active TB and starts treatment, the index case receives an additional larger amount of money. Each contact receives a brief questionnaire, TB symptom screen, optional HIV testing, and sputum sample collection for Xpert MTB/RIF."
62358923|NCT01213914|EXPERIMENTAL|High-volume hemofiltration at 70ml/kg/hr|Paired randomization into four groups via central randomization center. Group 1: age 18-65 and \<40%TBSA Group 2: age 18-65 and \>40%TBSA Group 3: age \>65 and \<40%TBSA Group 4: age \>65 and \>40%TBSA
62358924|NCT01213914|ACTIVE_COMPARATOR|Control group|Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.
62358925|NCT02533687|ACTIVE_COMPARATOR|Bipolar TURP-1|Transurethral resection of prostate (TURP) with bipolar resectoscope (Gyrus brand)
62358926|NCT02533687|ACTIVE_COMPARATOR|Bipolar TURP-2|TURP with bipolar resectoscope (Olympus brand)
62358927|NCT02533687|ACTIVE_COMPARATOR|Monopolar TURP|TURP with monopolar resectoscope (Karl Storz brand)
62150783|NCT03784222|OTHER|control group|60 subjects without schizophrenia, only receiving MRI and/or serum BDNF
62150784|NCT04347148|EXPERIMENTAL|SNAGs treatment|cervicogenic patients will undergo SNAGs treatment. Based on personal history, the offending active cervical movement (i.e. the movement predominantly causing dizziness) will be identified and treatment direction will be determined. As suggested, the active movement to most likely cause dizziness is cervical extension, though also rotation or flexion will be shown to provoke it. With the participant in an upright sitting position, a skilled physiotherapist (blinded to the allocation) will apply a sustained passive accessory movement (glide) while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing their symptoms. This procedure will be repeated six times.
62522560|NCT05500716|ACTIVE_COMPARATOR|Traditional Rehabilitation Program|"* Deep Friction Massage~* Myofascial Trigger Point Compression Therapy~* Temporomandibular Joint Mobilization~* Rocabado Exercises~* Muscle-Energy Techniques"
62522561|NCT03660241|EXPERIMENTAL|PF-04965842|PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor
62522562|NCT05780021|NO_INTERVENTION|Standard arm|The patients will have the usual care
62522563|NCT05780021|EXPERIMENTAL|Motivational Support Program Emotiv|The patients will have the motivational support program
62522564|NCT02494817|PLACEBO_COMPARATOR|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
62522565|NCT02494817|ACTIVE_COMPARATOR|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
62522566|NCT01140490|NO_INTERVENTION|Sub-total Parathyroidectomy|
62522567|NCT02907788||Cystic Fibrosis patients|Patient with cystic fibrosis diagnosed by Heel-prick screening
62522568|NCT02907788||non-CF patients|Children who undergo bronchoscopy for another reason, without CF: eg gastro-esophageal reflux.
62522569|NCT00683267|EXPERIMENTAL|1|Study treatment, 4975, is instilled directly into surgical site
62522570|NCT00683267|PLACEBO_COMPARATOR|2|Placebo is instilled directly into surgical site
62522571|NCT05983913|EXPERIMENTAL|cognitive-motor training group|Participants will receive 50 minutes of cognitive-motor training twice per week for 6 weeks. The cognitive-motor training program uses a wearable sensor-based interactive system to perform cognitive tasks in a large space without the constraints of physical movement. Participants wear a wearable sensor-based device on their dominant arm or leg and use an interactive system to perform cognitive-motor tasks.
62522572|NCT05983913|EXPERIMENTAL|cognition training group|Participants will receive 50 minutes of cognitive training twice a week for 6 weeks. The cognitive training program will be delivered in booklet form, and participants will perform the cognitive tasks of the cognitive-motor training in a seated position with no physical movement.
62522573|NCT05396131|ACTIVE_COMPARATOR|Collateral Ventilation Negative|Collateral Ventilation Negative participants will have endobronchial valve implant
62522574|NCT05396131|EXPERIMENTAL|Collateral Ventilation Positive|Collateral Ventilation Positive participants will have the lung sealant applied and the endobronchial valve implant
62522575|NCT01131793|EXPERIMENTAL|RF Guidewire|
62712114|NCT05786287||UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension injected into peribulbar
62712115|NCT05947006|ACTIVE_COMPARATOR|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure
62712116|NCT05947006|EXPERIMENTAL|CONSULFE Consultation|Patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE)
62712117|NCT03419494||VDCLD regimen containing PLD|PLD 36mg/㎡.d d1、d15，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
62712118|NCT03419494||VDCLD regimen containing DNR|DNR 45mg/㎡.d d1～3，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
62522576|NCT06332001||Experimental Group|Patients in this group receive the music and interaction interventions
62522577|NCT06332001||Control Group|Patients in this group receive a standard care condition (no music)
62712119|NCT05228418|EXPERIMENTAL|Participant|All participants who meet inclusion criteria will be offered oral naltrexone in the ED, a bridge prescription for oral naltrexone, and be referred to outpatient MAT clinic where participants will be offered monthly IM naltrexone injections.
62712120|NCT04250701||Dyslexia (D)|
62712121|NCT04250701||Intellectual Disability (ID)|
62712122|NCT04250701||Control (C)|
62522578|NCT05120102|EXPERIMENTAL|Experimental side of the arch|The right or left side of the patients maxillary arch selected by randomization
62522579|NCT05120102|NO_INTERVENTION|Placebo side of the arch|The right or left side of the patients maxillary arch selected by randomization
62522580|NCT03690882||Cases of unclassified acute cervical pain|
62522581|NCT03762551|EXPERIMENTAL|vitiligo|assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB
62522582|NCT03762551|ACTIVE_COMPARATOR|psoriasis|assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB
62522583|NCT03762551|OTHER|controls|assess the level of JAK1 in controls
62522584|NCT00399971|EXPERIMENTAL|Hemathera|Patients will receive cell-based immunotherapy.
62522585|NCT03196414|EXPERIMENTAL|CART-138/BCMA/19/more|
62522586|NCT01742780|ACTIVE_COMPARATOR|Standard Vidacare Site Identification Method|Palpate up the proximal humerus towards the anterior shoulder just above the surgical neck, to the greater tubercle of the proximal humerus. Insert the needle set perpendicular to skin with a slight downward angle at the most prominent aspect of greater tubercle to establish proximal humerus intraosseous vascular access.
62712123|NCT00104702|EXPERIMENTAL|Concentrated and Focalized Radiotherapy|
62712124|NCT06469801|EXPERIMENTAL|Portable MRI Arm|All subjects enrolled will be assigned to Arm 1
62150785|NCT04347148|PLACEBO_COMPARATOR|Detuned Laser|cervicogenic patients will receive a sham treatment, carried out by the another skilled therapist (blinded to the allocation) and consisting in exposition to a detuned laser. A laser - deactivated by the manufacturer in order to produce no effective emission - will appear to operate normally, emitting a light signal and a beeping sound. Such procedure - which was shown to not activate somatosensory receptors and to have a very strong placebo effect - will be used for six applications, lasting 20 seconds, on various sites on the upper cervical spine, at a distance of 0.5-1cm from the skin.
62150786|NCT02644980|EXPERIMENTAL|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
62712125|NCT06487520|EXPERIMENTAL|group watching hot environment image|"A virtual reality headset was placed on the heads of the individuals included in the intervention group one minute before the procedure and a cold environment image called Peaceful mountain snow was shown. By starting the image before the procedure, the individual was prevented from seeing the needle and blood. At the end of the procedure, the tourniquet and needle were removed and the virtual reality headset was removed from the individual's head and the displayed image was terminated."
62712126|NCT06487520|PLACEBO_COMPARATOR|group watching cold environment image|"A virtual reality headset was placed on the heads of the individuals in the placebo group one minute before the procedure and a warm environment image called Deep space relaxation was shown. By starting the image before the procedure, the individual was prevented from seeing the needle and blood. At the end of the procedure, the tourniquet and needle were removed and the virtual reality headset was removed from the individual's head and the image shown was terminated"
62712127|NCT06487520|NO_INTERVENTION|The control group|No intervention was performed on the control group before the peripheral intravenous catheterization procedure, and the standard peripheral intravenous catheterization procedure was performed.
62712128|NCT02862574|EXPERIMENTAL|Andecaliximab 300 mg|Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
62150787|NCT02644980|EXPERIMENTAL|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
62712129|NCT02862574|EXPERIMENTAL|Andecaliximab 150 mg|Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
62712130|NCT02862574|PLACEBO_COMPARATOR|Placebo|Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
62712131|NCT02862574|EXPERIMENTAL|Open-Label Extension|On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
62712132|NCT04052009|EXPERIMENTAL|CT - Group|The conventional training consists of gait training during walking over ground. It includes the standard interventions therapists apply during training over ground. The aim is to achieve as many steps as possible. Three training sessions per week of intensive over ground therapy are planned, and twice a week a therapy with focus of attention isn't walking.
62712133|NCT04052009|ACTIVE_COMPARATOR|EET - Group|In the end-effector-based training participants undergo gait training in the end-effector device lyra (THERA-trainer). The principle of an end-effector is that the movement is induced at the level of participants feet. Furthermore, participants wear a harness attached to the end-effector lyra for safety purpose and for weight support. Three training sessions per week of intensive over lyra therapy are planned, and twice a week a therapy with focus of attention isn't walking
62358928|NCT01766219|EXPERIMENTAL|Arm 1: (6,8-bis[benzylthio]octanoic acid) 2,300 mg/m²|"Participants will not be treated with CPI-613 during pre-Cycle 1 and will only be treated with 3 weeks on/1 week off at 2,300 mg/m² as a starting dose. If none of these 3 participants develop a dose-limiting toxicity through Cycle 1, the dose for the 3-weeks-on-1-week-off treatment cycles will be 3,000 mg/m² in all subsequent participants in this trial.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
62150788|NCT02673866|EXPERIMENTAL|DS-1971a 400 mg TID|DS-1971a 400 mg three times per day (TID)
62150789|NCT02673866|EXPERIMENTAL|DS1971a 400 mg BID|DS1971a 400 mg twice per day (BID)
62150790|NCT02673866|EXPERIMENTAL|DS1971a 100 mg BID|DS1971a 100 mg BID
62358929|NCT01766219|EXPERIMENTAL|Arm 2: (6,8-bis[benzylthio]octanoic acid) 1,200/3,00 mg/m²|"Participants will received pre-cycle 1 week dose at 1200 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
62150791|NCT02673866|PLACEBO_COMPARATOR|Placebo|Placebo
62150792|NCT02673866|ACTIVE_COMPARATOR|Pregabalin|Pregabalin
62150793|NCT05605158|ACTIVE_COMPARATOR|Group 1 (Pioglitazone group; n=28)|Non-diabetic patients with non-alcoholic steatohepatitis will receive 30mg/day pioglitazone for 24 weeks.
62522587|NCT01742780|ACTIVE_COMPARATOR|Saussy Site Identification Method|Palpate the proximal humerus to locate the intertubercular groove; rotate the forearm medially and laterally to isolate the groove. Move one finger breadth laterally from the groove to the greater tubercle. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
62150794|NCT05605158|ACTIVE_COMPARATOR|Group 2 (Empagliflozin group; n=28)|Non-diabetic patients with non-alcoholic steatohepatitis will receive 10mg/day empagliflozin for 24 weeks.
62712134|NCT04052009|ACTIVE_COMPARATOR|CETcomb:|The group with the combined training receives 5 sessions of CT and EET each. The pattern of series per week is always either two sessions of CT with one session of EET or vice versa.
62712135|NCT02566863|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine, 1 mcg/kg over 10 minutes, followed by a maintenance infusion, given to achieve sedation for eye surgery procedure
62712136|NCT06282341|ACTIVE_COMPARATOR|MARASIM|During visit 2, road runners will take part in a simulated marathon race on a treadmill.
62712137|NCT06282341|ACTIVE_COMPARATOR|TRAILSIM|During visit 2, trail runners will take part in a simulated trail race on a treadmill.
62712138|NCT06282341|ACTIVE_COMPARATOR|TRAILNAT|During visit 2, trail runners will take part in a real trail race in the nature.
62150795|NCT01049854|EXPERIMENTAL|Thiotepa/Cyclophosphamide/ATG|Full intensity with TBI
62150796|NCT01049854|EXPERIMENTAL|Busulfan/Melphalan/ATG|Full intensity without TBI
62712139|NCT02141321|EXPERIMENTAL|Misoprostol|Women will receive two sub lingual tablets each containing 200 micro gram misoprostol (Misotac), receiving a total dose of 400 micro grams. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
62712140|NCT02141321|PLACEBO_COMPARATOR|Placebo|Women will receive two sub lingual placebo tablets which will be similar in size, color, odor and shape to the misoprostol tablets. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
62712141|NCT04089410|ACTIVE_COMPARATOR|Hyperthermic Fitness Treatment|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the HFT.
62712142|NCT04089410|PLACEBO_COMPARATOR|Attenuated heating|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the placebo-HFT.
62712143|NCT00276419|EXPERIMENTAL|Placebo First, then Diclofenac (Arm A)|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks, then compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks.
62712144|NCT00276419|EXPERIMENTAL|Diclofenac First, then Placebo (Arm B)|Compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks, then placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks.
62712145|NCT01510093|OTHER|Insulin Aspart without glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
62712146|NCT01510093|OTHER|Insulin Aspart with glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
62712147|NCT02411409|EXPERIMENTAL|Intervention group|This group of patients receives the HealtheRx.
62712148|NCT02411409|NO_INTERVENTION|Control group|This group of patients does not receive the HealtheRx
62712149|NCT03868358|ACTIVE_COMPARATOR|Real Stimulation|Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
62712150|NCT03868358|PLACEBO_COMPARATOR|Sham Stimulation|Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
62712151|NCT05239078|ACTIVE_COMPARATOR|Inferior Alveolar nerve block with 2% lidocaine with epinephrine|An inferior alveolar nerve block was given with 2% lidocaine with epinephrine
62150797|NCT01049854|EXPERIMENTAL|Busulfan/Fludarabine/Alemtuzumab|Reduced Intensity Chemotherapy
62150798|NCT01049854|EXPERIMENTAL|Fludarabine/Cyclophosphamide/ATG|Reduced Intensity Chemotherapy for Fanconi Anemia
62150799|NCT04830345|EXPERIMENTAL|ATGC-100 100U|ATGC-100 will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
62150800|NCT04830345|ACTIVE_COMPARATOR|Botox 100U|Botox inj. will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
62150801|NCT05670457|NO_INTERVENTION|Control group|this group will include 22 patients who will receive anti peptic ulcer only for 2 months.
62358930|NCT01766219|EXPERIMENTAL|Arm 3 (6,8-bis[benzylthio]octanoic acid) 600/3,000 mg/m²|"Participants will received pre-cycle 1 week dose at 600 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
62150802|NCT05670457|ACTIVE_COMPARATOR|Diosmin group|this group will include 22 patients who will receive anti peptic ulcer and diosmin 500 mg twice daily for 2 months.
62150803|NCT00605605|EXPERIMENTAL|1|
62150804|NCT00674037|EXPERIMENTAL|inclusion with financial motivation|75 euros for each patient included
62712152|NCT05239078|EXPERIMENTAL|Inferior Alveolar nerve block with 4% articaine with epinephrine|An inferior alveolar nerve block was given with 4% articaine with epinephrine
62712153|NCT05239078|EXPERIMENTAL|Inferior Alveolar nerve block with 3% plain mepivacaine|An inferior alveolar nerve block was given with 3% plain mepivacaine
62712154|NCT04678401|EXPERIMENTAL|IS-FREE TREG CRAFT_ENGINEERED HaploHCT for relapsed/refractory AML or MDS EB-2 (Closed to Accrual)|"Please note that this arm is closed due to meeting accrual goal as of June 2024.~After meeting eligibility criteria and being enrolled, patients will receive:~Day -15 to -6 prior to hematopoietic stem cell transplant (HSCT), preparatory regimen of radiation and chemotherapy: Total Myeloid and Lymphoid Irradiation (TMLI): Days -15 to -11 prior to HSCT; - Chemotherapy (infusion): Day -10 to day -6 prior to HSCT: Fludarabine (all days), Thiotepa (days -10 and -9) and Cyclophosphamide and Mesna (days -8 and -7)~Day -4 prior to (HSCT), a Treg-enriched donor cell infusion and graft vs host disease (GVHD) assessment~Day -1 prior to (HSCT), a unmodified donor T Cell infusion and (GVHD) assessment~Day of (day 0) (HSCT), CD34+ Haplo Peripheral Blood Stem Cell Infusion/Transplant and (GVHD) assessment~Days 30, 60,100, 180, 365 post hematopoietic stem cell transplant (HSCT), participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD)"
62150805|NCT00674037|NO_INTERVENTION|no incentive|no incentive
62150806|NCT02304289|EXPERIMENTAL|Oral Artesunate|The first patient will receive 200 mg Artesunate once-daily for 14 days. If no dose-limiting toxicity (DLT) is observed after 14 days, the next patient will start at a daily dose of 300 mg Artesunate. If no DLT is observed after 14 days, a cohort of 3 patients will receive 400 mg once-daily for 14 days. For each subsequent cohort of 3 patients 200 mg will be added to the dose, until the maximum tolerated dose (MTD) is determined.
62150807|NCT00000250|ACTIVE_COMPARATOR|Lukewarm water|Subjects will immerse forearm in lukewarm water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
62150808|NCT00000250|ACTIVE_COMPARATOR|Ice cold water|Subjects will immerse forearm in ice cold water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
62150809|NCT04447898|EXPERIMENTAL|Low dose|10 μg + Montanide™ ISA 51 VG
62150810|NCT04447898|EXPERIMENTAL|High dose|50 μg + Montanide™ ISA 51 VG
62150811|NCT04856098|EXPERIMENTAL|Part 1 Ultibro Breezhaler 2 capsules, Batch A|
62150812|NCT04856098|EXPERIMENTAL|Part 1 Ultibro Breezhaler 2 capsules with charcoal, Batch A|
62150813|NCT04856098|EXPERIMENTAL|Part 1 Ultibro Breezhaler 1 capsule, Batch A|
62150814|NCT04856098|EXPERIMENTAL|Part 2 Ultibro Breezhaler 2 capsules, Batch A|
62150815|NCT04856098|EXPERIMENTAL|Part 2 Ultibro Breezhaler 2 capsules, Batch B|
62150816|NCT00269815|EXPERIMENTAL|001|methylphenidate HCl
62150817|NCT04917185|EXPERIMENTAL|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
62150818|NCT04917185|NO_INTERVENTION|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
62150819|NCT02551705|EXPERIMENTAL|functional Imaging mutation carrier|Premanifest mutation carrier, behavioral and neural emotional memory processing
62150820|NCT02551705|ACTIVE_COMPARATOR|functional Imaging non-carrier|non-carrier family member, behavioral and neural emotional memory processing
62150821|NCT01906905|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation|Active TMS (1)
62150822|NCT01906905|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation 2|Active TMS (2)
62150823|NCT01906905|ACTIVE_COMPARATOR|Transcranial Magnetic Stimulation 3|Active TMS (3)
62150824|NCT01428583|EXPERIMENTAL|oxycodone HCl and naltrexone HCl extended-release capsules|
62150825|NCT05033756|EXPERIMENTAL|Pembrolizumab / Olaparib|All eligible participants according to the definition of cohorts 1-3 will receive pembrolizumab i.v. 200 mg q3w in combination with olaparib tablets 300 mg twice daily (total dose 600 mg per day).
62150826|NCT00929526|EXPERIMENTAL|Cervarix Group|subjects received 3 doses of Cervarix™ vaccine in primary vaccination study NCT00316693.
62150827|NCT00929526|PLACEBO_COMPARATOR|Aimmugen Group|subjects received 3 doses of Aimmugen ™ vaccine in primary vaccination study NCT00316693.
62150828|NCT05175794||Cohort 1|Participants that test positive for Mycobacterium tuberculosis (M.tb) with rifampicin resistance will be enrolled in Cohort 1 (n=880).
62150829|NCT05175794||Cohort 2|Participants that test positive for M.tb that are rifampicin susceptible with isoniazid mono-resistance will be enrolled in Cohort 2 (n=400).
62150830|NCT06086548||cases|patients with molecular diagnosis of facioscapulohumeral dystrophy
62150831|NCT06086548||controls|healthy volunteers
62150832|NCT04062578|EXPERIMENTAL|CD Oliver|Female first team players of the club that plays in the National Second Division league.
62150833|NCT04062578|ACTIVE_COMPARATOR|SD Huesca|Female first team players who play in the Aragonese Territorial First league
62150834|NCT06430086|EXPERIMENTAL|Walnut - washout - HCHS|"Participants will consume 3 servings/day of walnuts (3 oz/d) over 4 days and have a washout for 2-3 weeks then crossover to consume 3 equicaloric servings of a HCHS food over 4 days.~Over each 4-day period, participants will sleep and eat at home for the first 3 days and will be admitted to the Inpatient Clinical Research Resource of the Irving Institute for Clinical and Translational Research of CUIMC on day 4 for in-depth profiling circadian physiology. Participants will be discharged on the morning of day 5."
62358931|NCT02052141|EXPERIMENTAL|500/1000|500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
62358932|NCT02052141|EXPERIMENTAL|1000/500|1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks
62358933|NCT04860011|EXPERIMENTAL|SGLT2i|Sodium-glucose Co-transporter-2 inhibitors
62358934|NCT04860011|EXPERIMENTAL|Thiazide|Thiazide or thiazide like diuretic
62358935|NCT03879993|EXPERIMENTAL|Exercise group|Exercise group was resistance training three times per week, during 45 to 60 minutes per day. Training program was composed by bench press, leg press 45°, lat pulldown, knee extension, dumbbell lateral raise, horizontal leg curl, triceps pulldown, seated calf raise, biceps curls and abdominal. Participants should complete 3 series with 8-12 repetitions of each exercise, which was supervised by trained research personnel. There were 60 seconds of interval between series and exercises were separated by a 120 seconds recovery period.
62358936|NCT03879993|NO_INTERVENTION|Control group|Control group was not do any exercise during intervention period. Participants was asked to keep their habitual routine until finish the final evaluations.
62358937|NCT02691364||Healthy|Healthy women
62358938|NCT02691364||Preeclamptic|Pregnant women with preeclampsia
62358939|NCT00086736|EXPERIMENTAL|Arm I|Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
62358940|NCT00086736|EXPERIMENTAL|Arm II|Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
62358941|NCT00086736|EXPERIMENTAL|Arm III|Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
62358942|NCT00086736|EXPERIMENTAL|Arm IV|Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
62358943|NCT03327519|EXPERIMENTAL|SHUTi|Self-guided, automated, interactive, and tailored web-based program
62712155|NCT04678401|EXPERIMENTAL|IS-FREE TREG CRAFT_ENGINEERED HaploHCT for Ultra high-risk AML or MDS with mutated TP53|"After meeting eligibility criteria and being enrolled, patients will receive:~Day -15 to -6 prior to hematopoietic stem cell transplant (HSCT), preparatory regimen of radiation and chemotherapy: Total Myeloid and Lymphoid Irradiation (TMLI): Days -15 to -11 prior to HSCT; - Chemotherapy (infusion): Day -10 to day -6 prior to HSCT: Fludarabine (all days), Thiotepa (days -10 and -9) and Cyclophosphamide and Mesna (days -8 and -7)~Day -4 prior to (HSCT), a Treg-enriched donor cell infusion and graft vs host disease (GVHD) assessment~Day -1 prior to (HSCT), a unmodified donor T Cell infusion and (GVHD) assessment~Day of (day 0) (HSCT), CD34+ Haplo Peripheral Blood Stem Cell Infusion/Transplant and (GVHD) assessment~Days 30, 60,100, 180, 365 post hematopoietic stem cell transplant (HSCT), participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD)"
62712156|NCT03545048|EXPERIMENTAL|Intervention arm|"Interventional groups will have an assessment session with the experienced staff and NRS, QST, WOMAC, MSK-HQ, 30CST, TUG, PSQI, MSK-USS, urine and blood samples will be taken at baseline. Those who consent for aspiration of synovial fluid will go through the USGA procedure.~Interventional group will shortly after that receive a link via email, which will be used to log-in to Joint Academy online portal. After log-in has been achieved, the intervention starts. It consist of a 6-week internet-based physical therapy program. Interventional group will be given actigraphy device (a device to monitor sleeping pattern) which is CE marked. Therefore, their sleeping pattern can be recorded quantitatively.~Once exercises programme is finished in six weeks, the participants will fill in the same questionnaire and perform the physical tests, to enable evaluation."
62712157|NCT03545048|NO_INTERVENTION|Control arm|Control group will continue with their routine self-management which is offered in the community setup. They will be assessed on NRS, QST, WOMAC, MSK-HQ, PSQI, 30CST, TUG, isometric muscles strengthen of quadriceps, MSK-USS, muscle mass of vastus lateralis, urine and blood samples at baseline. Control group will also get the actigraphy to monitor sleeping pattern of that group. They will be re-assessed after six weeks on the primary objective measures to see if they have made any difference by following self-management strategies in the community.
62712158|NCT04863430|EXPERIMENTAL|Apatinib with chemotherapy|Apatinib with oxaliplatin and S-1 treatment
62712159|NCT03331380|OTHER|Group A|Group A includes 600 healthy adult volunteers of both sexes with-out known cardiovascular disease
62150835|NCT06430086|EXPERIMENTAL|HCHS - washout - Walnut|"Participants will consume 3 equicaloric servings of a HCHS food over 4 days and have a washout for 2-3 weeks then crossover to consume 3 servings/day of walnuts (3 oz/d) for 4 days.~Over each 4-day period, participants will sleep and eat at home for the first 3 days and will be admitted to the Inpatient Clinical Research Resource of the Irving Institute for Clinical and Translational Research of CUIMC on day 4 for in-depth profiling circadian physiology. Participants will be discharged on the morning of day 5."
62150836|NCT05830032|EXPERIMENTAL|Soluble Corn fibre|Soluble corn fibre (SCF) (15g fibre/day)
62150837|NCT05830032|EXPERIMENTAL|Inulin|Inulin (In) (15g fibre/day)
62712160|NCT03331380|OTHER|Group B|Group B includes 500 adult subjects of both sexes with known sta-ble cardiovascular disease including adults with stable coronary artery disease after myocardial infarction; adults with heart failure and reduced left ventricular systolic function; adults with pulmonary artery hypertension; adults with congenital heart disease including cardiac shunts; adults with valvular heart disease including aortic stenosis, mitral regurgitation, and tricuspid regurgitation; and adults with metallic cardiovascular implants (such as coronary and peripheral artery stents) known to be safe for CMR at 1.5T
62712161|NCT03331380|OTHER|Group C|Group C includes 500 adult subjects of both sexes with known non-cardiovascular disease
62712162|NCT04848506|EXPERIMENTAL|Aficamten up to 20 mg|Patients in this arm take daily dose of aficamten. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.
62712163|NCT00871026|EXPERIMENTAL|1|CAD/CAM group, customized archwires
62712164|NCT00871026|ACTIVE_COMPARATOR|2|prefabricated archwires (superelastic)
62712165|NCT05753176|EXPERIMENTAL|Online 1-Day CBT-Based Workshop|Participants assigned to the treatment arm will attend a day long CBT-based workshop delivered online by two trained facilitators in addition to receiving usual care.
62712166|NCT05753176|NO_INTERVENTION|Treatment as Usual|Participants assigned to the control arm will continue to receive standard prenatal care from their healthcare providers.
62712167|NCT05835843||Cohort 1: ≥0.5 to <5% BSA affected|Approximately 10 subjects with psoriatic plaques covering at least 0.5% but less than 5% of their body surface area
62150838|NCT05830032|EXPERIMENTAL|Soluble corn fibre and inulin|SCF + In (15g/day fibre)
62150839|NCT05830032|PLACEBO_COMPARATOR|Control (Maltodextrin)|Control (Maltodextrin) (0g fibre)
62150840|NCT05508477|EXPERIMENTAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Study product are provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given twice with 28 days interval.
62150841|NCT05508477|ACTIVE_COMPARATOR|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine is CoronaVac Bio Farma vaccine, supplied by Ministry of Health of Indonesia, in the form of two doses vial. The vaccine will be given twice with 28 days interval.
62150842|NCT01252537||Initiation of antituberculosis therapy|Patients initiating treatment for tuberculosis with and without HIV co-infection in primary health care centres in Ethiopia
62150843|NCT02123667||Asthmatic patients|asthmatic patients 18 to 65
62150844|NCT02123667||Healthy volunteers|Volunteers 18 to 65
62150845|NCT03224988||Normal Adults|
62150846|NCT03224988||MCI Adults|
62150847|NCT01456156|EXPERIMENTAL|hepatectomy plus radiotherapy|
62358944|NCT03327519|EXPERIMENTAL|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
62358945|NCT02349737||Electromagnetic Interference|
62358946|NCT04348994|EXPERIMENTAL|Laser therapy|Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
62358947|NCT04836507|EXPERIMENTAL|CRC01|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CRC01.
62358948|NCT01223768|EXPERIMENTAL|Acetyl-L-carnitine|
62358949|NCT01223768|PLACEBO_COMPARATOR|placebo|
62712168|NCT05835843||Cohort 2: ≥5 to <10% BSA affected|Approximately 10 subjects with psoriatic plaques covering at least 5% but less than 10% of their body surface area
62712169|NCT05835843||Cohort 3: ≥10% BSA affected|Approximately 10 subjects with psoriatic plaques covering at least 10% of their body surface area
62712170|NCT01480102|PLACEBO_COMPARATOR|Group B- No Block|Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
62712171|NCT01480102|ACTIVE_COMPARATOR|Group A- Paravertebral block|Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
62150848|NCT03730727|ACTIVE_COMPARATOR|Control|A liquid meal replacement shake containing 500 kcal (55% kcals from carb, 30% fat, 15% protein) will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Two-hours after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises \[10 squats, 10 push-ups, 10 lunges, 10 sit-ups\]).
62150849|NCT03730727|EXPERIMENTAL|Immediate prior to meal|At approx. 8 am following an 8-10 hour overnight fast, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises \[10 squats, 10 push-ups, 10 lunges, 10 sit-ups\]). Immediately after completion of this bout, a liquid meal replacement shake containing 500 kcal will be administered. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion.
62150850|NCT03730727|EXPERIMENTAL|Immediate post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Immediately after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises \[10 squats, 10 push-ups, 10 lunges, 10 sit-ups\]).
62150851|NCT03730727|EXPERIMENTAL|30-minutes post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Thirty-minutes after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self selected brisk pace on a treadmill, or 3-sets of circuit-exercises \[10 squats, 10 push-ups, 10 lunges, 10 sit-ups\]).
62150852|NCT03741621|EXPERIMENTAL|High Viscosity|viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
62150853|NCT03741621|EXPERIMENTAL|Medium Viscosity|Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
62150854|NCT03741621|EXPERIMENTAL|Low Viscosity|Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
62150855|NCT02056847|ACTIVE_COMPARATOR|Pitavastatin calcium 4mg|Pitavastatin calcium (LIVALO®) 4mg, once a day
62358950|NCT04202276|OTHER|Patients with GERD|The data of Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire to be performed in children and adolescents with GERD.
62358951|NCT04202276|OTHER|Control group|The same examinations as in experimental group are to be performed in patients of the control group (no GERD according to the results of the examination): Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire.
62358952|NCT04687007|EXPERIMENTAL|SMART-ALD - Experimental group (EG)|Participants will receive 12 months of SMART-ALD intervention
62358953|NCT04687007|OTHER|Waiting List - Control group (CG)|Participants will receive 6 months of SMART-ALD after a 6-months waiting period
62358954|NCT05188599||Amputee patients|age between 18-65 years, (b) time after amputation ≥ 6 months, (c) unilateral or bilateral amputation above the ankle level
62150856|NCT02056847|ACTIVE_COMPARATOR|Pitavastatin calcium 2mg|Pitavastatin calcium (LIVALO®) 2mg, once a day
62150857|NCT05058157|ACTIVE_COMPARATOR|Ketone Precursor Formula 1|Formula 1 (in each cycle, up to 4 formula will be tested) Ketone precursors formula (powder to reconstitute in drinking water, or in a ready-to-drink format).
62150858|NCT05058157|ACTIVE_COMPARATOR|Ketone Precursor Formula 2|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format).
62150859|NCT05058157|ACTIVE_COMPARATOR|Ketone Precursor Formula 3|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format)
62150860|NCT05058157|ACTIVE_COMPARATOR|Ketone Precursor Formula 4|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format), or placebo
62150861|NCT01747538|PLACEBO_COMPARATOR|Placebo|
62150862|NCT01747538|EXPERIMENTAL|Dose 1 gevokizumab|
62150863|NCT01747538|EXPERIMENTAL|Dose 2 gevokizumab|
62150864|NCT05579717|EXPERIMENTAL|Equine Assisted Learning group|Participants in this group will receive 16 sessions of Equine Assisted Learning (EAL), facilitated by a trained clinician at Cartier Farms.
62522588|NCT01742780|ACTIVE_COMPARATOR|Campbell Site Identification Method|"With the fingers on both hands fully extended similar to a karate chop, place one hand into the anterior joint space (acromioclavicular joint) of the patient. Place the second karate chop hand along the midline of the patient's lateral shoulder; touch the pinkie fingers over the superior aspect of the patient's shoulder. Overlap the thumbs on the patient's shoulder, which will be at the most prominent aspect of the greater tubercle. Insert the needle set perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
62712172|NCT01321814|EXPERIMENTAL|Cognitive behavioural therapy (CBT)|Patients receiving 6 sessions of CBT conducted by a licensed psychologist. Sessions include psychoeducation, exposure treatment, behavioral activation and applied relaxation.
62712173|NCT01321814|NO_INTERVENTION|Waiting list|Patient waits for CBT treatment for 6 months.
62712174|NCT06717386|OTHER|bladder epithpidius complex|diagonal pelvic osteotomy in bladder exstrophy
62712175|NCT06717386|OTHER|bladder exstrophy|horizontal pelvic osteotomy
62712176|NCT04608708||Group 1. Periapical Cemento-Osseous Dysplasia|In Periapical Cemento-Osseous Dysplasia , the lower anterior teeth are usually affected. In these lesions, normal bone is replaced by fibrous tissue that contains amorphous vascularised calcifications. In the early stage, it can mimic a periapical lesion, but it is usually associated with vital teeth, without any clinical complaint, and it requires no intervention. Histopathologically, the lesion is similar to fibrous dysplasia and ossifying fibroma.
62712177|NCT04608708||Group 2. Focal Cemento-Osseous Dysplasia|It occurs in a single area of the posterior teeth. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
62150865|NCT05579717|NO_INTERVENTION|Waitlist control group|Participants in the waitlist control group will not receive EAL for the duration of the study.
62150866|NCT04378036|ACTIVE_COMPARATOR|Neurodevelopmental Therapy Group|The number of participants in this group is 30. All participants were included in the rehabilitation program using only the Neurodevelopmental Therapy approach for 16 sessions (8 weeks x 2 days x 45 minutes).
62712178|NCT04608708||Grup 3. Florid Cemento-Osseous Dysplasia|When the lesions involve two or more quadrants of the jaw, it is defined as Florid Cemento-Osseous Dysplasia. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
62150867|NCT04378036|ACTIVE_COMPARATOR|Hippotherapy Simulator Group|The same participants were taken into a rehabilitation program in which 16 sessions (8 weeks x 2 days a week) the Hippotherapy Simulator device (30 minutes) and Neurodevelopmental Therapy (NDT) (15 minutes) (HS + NDT method) were used together.
62150868|NCT06451107|EXPERIMENTAL|strength training and static stretching|The intervention will consist of a strength training program for the neck and shoulder muscles combined with static stretching of the neck.
62712179|NCT00005835|EXPERIMENTAL|Single Group|
62712180|NCT02007941|EXPERIMENTAL|End Stage Renal Disease(ESRD)|"CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
62712181|NCT02007941|ACTIVE_COMPARATOR|normal renal function|"CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
62712182|NCT02007941|EXPERIMENTAL|Mild renal impairment|CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.
62150869|NCT06451107|ACTIVE_COMPARATOR|strength training|The comparison group will only perform strength training.
62150870|NCT02077374|EXPERIMENTAL|IDN-6556|IDN-6556 capsules, 25 mg BID
62712183|NCT05317130||This is an observational study.|The cohort will consist of elite Para athletes (athletes with an impairment).
62712184|NCT00442702|EXPERIMENTAL|Mircera|Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
62712185|NCT00442702|ACTIVE_COMPARATOR|Darbepoetin alfa|Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
62712186|NCT02457338|EXPERIMENTAL|Supplement Group|This group will receive probiotic B. infantis supplementation, plus standard care and lactation consultation.
62712187|NCT02457338|NO_INTERVENTION|Control Group|This group will receive standard care plus lactation consultation only.
62712188|NCT00818194|EXPERIMENTAL|A. tacrolimus first|Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
62712189|NCT00818194|EXPERIMENTAL|B. cyclosporine first|Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
62150871|NCT02077374|PLACEBO_COMPARATOR|Placebo|Placebo BID
62712190|NCT06712342|EXPERIMENTAL|NEG|Upper Extremity Focused Neuromuscular Exercise Training
62150872|NCT03677167|EXPERIMENTAL|walking on a treadmill barefoot group|26 Patients in this group will walk barefoot on the treadmill and will be asked to walk barefoot at home and report the time of barefoot walking at home
62712191|NCT06712342|ACTIVE_COMPARATOR|CEG|Traditional Upper Extremity Exercise Training
62712192|NCT06712342|NO_INTERVENTION|CG|Control Group
62712193|NCT04971577|PLACEBO_COMPARATOR|Control arm|
62712194|NCT04971577|EXPERIMENTAL|Treatment arm|
62150873|NCT03677167|ACTIVE_COMPARATOR|Walking on a treadmill with shoes group|26 Patients in this group will walk with shoes on the treadmill
62150874|NCT06237621||People at risk of PAD|
62150875|NCT04737993|ACTIVE_COMPARATOR|prf shoulder joint|pulsed rf stimulation of joint capsel and prf stimlation of subscapular nerve
62150876|NCT04737993|ACTIVE_COMPARATOR|prf subscapular nerve|pulsed RF stimulation of subscapular nerve
62150877|NCT04737993|ACTIVE_COMPARATOR|subscapular nerve block|lidocain injection of subscapular nerve
62150878|NCT00884676|EXPERIMENTAL|Schedule A|Schedule A: Ixabepilone - Weekly for 3 weeks each cycle (Days 1, 8 and 15) For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1
62150879|NCT00884676|EXPERIMENTAL|Schedule B|Ixabepilone - Day 1 of each 3-week cycle For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1.
62150880|NCT06404983|EXPERIMENTAL|Opioid Free Anaesthesia (OFA group)|Patients are randomly allocated to receive non-opioid anaesthesia. Intraoperative analgesia will be achieved by continuous intravenous administration of a mixture of dexmedetomidine, ketamine, and lidocaine.
62150881|NCT06404983|ACTIVE_COMPARATOR|Conventional general anaesthesia (CGA group)|Patients are randomly allocated to receive conventional general anaesthesia with intraoperative use of opioids at the discretion of the attending anaesthesiologist.
62712195|NCT02932410|EXPERIMENTAL|Macitentan|Macitentan is administered once daily via oral route. Children less than (\<) 2 years old (y.o.) will be assigned as a cohort to the macitentan group without randomization. The dose will be adjusted to the participant's age (for those \< 2 y.o.) or to the participant's body weight (for those greater than or equal to (\>=) 2 y.o.). single-arm extension period (SAEP) will start at end of core period (EOCP) visit and ends at end of study (EOS) visit.
62712196|NCT02932410|OTHER|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with pulmonary arterial hypertension (PAH) non-specific treatment and/or up to two PAH-specific medications excluding macitentan and intravenous/subcutaneous (IV/SC) prostanoids.
62712197|NCT05173597||Patients receiving treatment with Follitropin-delta|The included patients are adult women from the routine clinical care settings with indication for ovarian stimulation with follitropin delta in a GnRH-antagonist protocol who are making a first treatment attempt IVF or ICSI. This study is intended to be conducted in non-vulnerable population. No vulnerable subjects will be enrolled in the study.
62358955|NCT02050906|EXPERIMENTAL|Arm I (diet and exercise intervention)|"EXERCISE COMPONENT: Patients undergo 1 hour of monitored intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.~BEHAVIORAL ACTIVITY COUNSELING: Patients undergo behavioral activity counseling in small group sessions over 20 minutes once weekly during months 1-2 and individualized activity counseling via telephone calls over 20 minutes every 2 weeks for 3 months. Counseling will include questionnaire administration.~BEHAVIORAL DIETARY INTERVENTION: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3."
62358956|NCT02050906|ACTIVE_COMPARATOR|Arm II (standard of care)|TELEPHONE BASED COUNSELING: Patients receive standard care and educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines. Patients also receive phone calls over 20 minutes every 2 weeks for 3 months focusing on routine prostate cancer self-management. After 3 months, patients have the option to undergo 2 supervised exercise training and dietary counseling sessions. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
62358957|NCT05706961|EXPERIMENTAL|Power Walking|
62358958|NCT05706961|ACTIVE_COMPARATOR|Standardized Outpatient Cardiac Rehabilitation|
62358959|NCT02010814||PCOS|"Women fulfilling at least two of the three Rotterdam criteria for PCOS, including~* Irregular menstrual cycle~* Clinical/biochemical hyperandrogenemia~* Polycystic ovaries"
62358960|NCT05685719|EXPERIMENTAL|Part 1: TR|Subjects will take a single dose of test product 200mg/capsule on Day 1 of the study, then reference product 100mg/capsule on Day 8 of the study.
62358961|NCT05685719|EXPERIMENTAL|Part 1: RT|Subjects will take a single dose of reference product 100mg/capsule on Day 1 of the study, then test product 200mg/capsule on Day 8 of the study.
62358962|NCT05685719|EXPERIMENTAL|Part 1: Group 1|Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 200mg of itraconazole, q.d, for 6 consecutive days (Day 4 to Day 9). The 5th dose (Day 8) of itraconazole will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
62358963|NCT05685719|EXPERIMENTAL|Part 1: Group 2|Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 600mg of rifampin, q.d, for 9 consecutive days (Day 4 to Day 12). The 8th dose (Day 11) of rifampin will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
62358964|NCT04840368|EXPERIMENTAL|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
62358965|NCT04840368|ACTIVE_COMPARATOR|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min, and a cool down of 10 min (muscle stretching and relaxation). They will be performed individually, outside, at a self-selected intensity, with no supervision.
62358966|NCT05185648|EXPERIMENTAL|post-training scores|evaluating qualities of trauma care after standard trauma traning
62358967|NCT05151224||Breast cancer patients eligible to neoadjuvant systemic therapy|Invasive breast cancer, age are 18 years or more, from stage IIB to stage IIIC, all subtypes are included, either HR (ER, PR) positive or negative, HER2 positive or negative, eligible to neoadjuvant systemic therapy.
62358968|NCT02969538|OTHER|Total etching time|Dentin etching (35% phosphoric acid) by time recommend by manufacturer (15 seconds)
62358969|NCT02969538|EXPERIMENTAL|Half-reduced etching time|Dentin etching (35% phosphoric acid) by 7 seconds
62358970|NCT02701179|ACTIVE_COMPARATOR|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
62358971|NCT02701179|ACTIVE_COMPARATOR|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
62358972|NCT05466071||TAF group|Patients who take TAF during pregnancy.
62358973|NCT05466071||TDF group|Patients who take TDF during pregnancy.
62358974|NCT01708707|ACTIVE_COMPARATOR|Oral morphine sulfate|Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine
62358975|NCT01708707|EXPERIMENTAL|Buprenorphine|Sublingual Buprenorphine 15.9 µg/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome
62358976|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
62358977|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
62358978|NCT00782301|ACTIVE_COMPARATOR|Maraviroc|
62358979|NCT00782301|ACTIVE_COMPARATOR|Etravirine|
62712198|NCT01746290|EXPERIMENTAL|PulsePoint notification|Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
62712199|NCT01746290|NO_INTERVENTION|Usual Care|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures but no PulsePoint notification will be sent to nearby PulsePoint users.
62712200|NCT05776758|EXPERIMENTAL|NAC+RC|cisplatin-based neoadjuvant chemotherapy plus radical cystectomy
62150882|NCT00003599|EXPERIMENTAL|Arm I|Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)
62150883|NCT00003599|EXPERIMENTAL|Arm II|Isotretinoin orally plus AT placebo orally daily (arm II).
62712201|NCT05776758|ACTIVE_COMPARATOR|RC alone|radical cystectomy alone
62522589|NCT01742780|ACTIVE_COMPARATOR|Davlantes Site Identification Method|"Using one hand, place the thumb on the acromioclavicular joint in the natural recess or pocket between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
62712202|NCT05471375||Stroke|For this cohort, individuals who have experienced a stroke will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
62712203|NCT05471375||Parkinsons Disease|For this cohort, individuals who have been diagnosed with Parkinsons Disease will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
62712204|NCT05471375||Lower Limb Amputation|For this cohort, individuals who have experienced a lower limb amputation will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
62712205|NCT05471375||Healthy Control|For this cohort, individuals who have no significant neurologic or orthopedic injuries will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
62712206|NCT03007147|EXPERIMENTAL|Arm A (imatinib mesylate, EsPhALL chemotherapy)|See Detailed Description
62150884|NCT04313985|ACTIVE_COMPARATOR|Electrical Stimulation First, then Sham Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
62150885|NCT04313985|SHAM_COMPARATOR|Sham Electrical Stimulation First, then Electrical Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
62150886|NCT04582994||Young participants|"30 young participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:~1. Day 1. Beta tACS (22Hz)~2. Day 2. Alpha tACS (10 Hz)~3. Day 3. Sham tACS"
62150887|NCT04582994||Old participants|"30 old participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:~1. Day 1. Beta tACS (22Hz)~2. Day 2. Alpha tACS (10 Hz)~3. Day 3. Sham tACS"
62150888|NCT03853889|ACTIVE_COMPARATOR|preepidural ONSD|The diameter of the optic nerve sheath to be measured(ONSD) with the help of ultrasonography before epidural anesthesia(pre epidural ONSD). The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
62150889|NCT03853889|EXPERIMENTAL|post epidural ONSD|The diameter of the optic nerve sheath to be measured with the help of ultrasonography Immediately after epidural anesthesia(post epidural ONSD) (T1), 15 minutes (T2), 30 min (T3), 60. min (T4) epidural anesthesia. The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
62712207|NCT03007147|EXPERIMENTAL|Arm B (imatinib mesylate, COG/BFM chemotherapy)|See Detailed Description.
62712208|NCT03007147|EXPERIMENTAL|Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)|See Detailed Description
62150890|NCT00985088|EXPERIMENTAL|GSK2340274A F1_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
62522590|NCT06213870||MRI group|"MRI Images were acquired on a 3T Siemens Prisma scanner (Siemens AG, Munich, Germany).Image sequences and typical parameter ranges were diffusion tensor imaging (repetition time \[TR\], 5200ms; echo time \[TE\], 80 ms; 4mm slice thickness; 40 slices) by using SE-EPI sequence; T1 imaging (TR, 240 ms; TE, 2.47 ms; 5 mm slice thickness; 17 slices) by using SE sequence;T2 imaging (TR, 4480 ms; TE, 99 ms; 4 mm slice thickness; 24 slices) by using FSE sequence; FLAIR imaging (TR, 8500 ms; TE, 95 ms; 5 mm slice thickness; 21 slices) by using IR sequence; time-of-flight magnetic resonance angiography images (TR, 20 ms; TE, 3 ms; 0.55 mm slice thickness; 40 slices) by using 3D-TOF sequence;~In the MRI group, patients with FVH-DWI mismatch were considered to have EVT indications and were treated with EVT, while patients without FVH-DWI mismatch were treated with medication."
62522591|NCT06213870||Perfusion group|"The protocol of CT Perfusion was as follows: 100 mm coverage in the z-axis, tube voltage, 80 kV; tube current, 120 mA; section thickness, 5 mm. Twenty-four consecutive spiral acquisitions with 0.28 seconds of rotation time and 1.70 seconds of inter scan delay time were performed.~Patients in the perfusion group were treated with EVT when there exist perfusion mismatch(defined as regional cerebral blood flow (\<30%) was \< 70 ml with mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 ml), and were treated with medication when there was no perfusion mismatch."
62522592|NCT02254369|EXPERIMENTAL|Cohort 1- GC021109|single dose, 0.0014 mg/kg GC021109
62522593|NCT02254369|EXPERIMENTAL|Cohort 2- GC021109|single dose, 0.014 mg/kg GC021109
62150891|NCT00985088|EXPERIMENTAL|GSK2340274A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
62522594|NCT02254369|EXPERIMENTAL|Cohort 3-GC021109|single dose, 0.14 mg/kg GC021109
62522595|NCT02254369|EXPERIMENTAL|Cohort 4- GC021109|single dose, 1.4 mg/kg GC021109 subjects will receive GC021109 under fasting then under fed conditions separated by a washout of 14 (± 1) days after the first dose.
62150892|NCT00985088|EXPERIMENTAL|GSK2340274A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
62150893|NCT00985088|EXPERIMENTAL|GSK2340274A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
62150894|NCT00985088|EXPERIMENTAL|GSK2340273A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
62150895|NCT00985088|EXPERIMENTAL|GSK2340273A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
62150896|NCT00985088|EXPERIMENTAL|GSK2340273A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. Subjects above (\>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm.
62150897|NCT00985088|EXPERIMENTAL|GSK2340273A F3_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
62150898|NCT01765855|EXPERIMENTAL|Single Arm Oral Betrixaban|
62150899|NCT03490500||S100B protein dosage|Biological
62150900|NCT02763657|EXPERIMENTAL|Brain activity during reasoning|
62150901|NCT01049698|ACTIVE_COMPARATOR|1. Resistance Training|3 d/wk resistance training
62150902|NCT01049698|EXPERIMENTAL|2. Resistance Training + Diet|Resistance training plus caloric restriction
62522596|NCT02254369|EXPERIMENTAL|Cohort 5- GC021109|single dose, 4.2 mg/kg GC021109
62522597|NCT02254369|PLACEBO_COMPARATOR|Cohort 1- placebo|single dose, 0.0014 mg/kg matching placebo
62522598|NCT02254369|PLACEBO_COMPARATOR|Cohort 2- placebo|single dose, 0.014 mg/kg matching placebo
62522599|NCT02254369|PLACEBO_COMPARATOR|Cohort 3- placebo|single dose, 0.14 mg/kg matching placebo
62522600|NCT02254369|PLACEBO_COMPARATOR|Cohort 4- placebo|single dose, 1.4 mg/kg subjects will receive matching placebo under fasting then under fed conditions separated by a washout of 14 (+/- 1) days after the first dose.
62522601|NCT02254369|PLACEBO_COMPARATOR|Cohort 5- placebo|single dose, 4.2 mg/kg matching placebo
62522602|NCT01908790||Heart Failure Patients|Acute and chronic heart failure patients already receiving right heart catheterization (RHC) as part of their usual care
62522603|NCT01338987|ACTIVE_COMPARATOR|Arm1 First Transplt/males/leuprolide/+/-FLT Imaging|"Males randomized to leuprolide for first transplant.~\[18F\]fluorothymidine (FLT) imaging"
62522604|NCT01338987|ACTIVE_COMPARATOR|Arm2 First Transplt/males/No Leuprolide/+/- FLT Imaging|"Males not receiving leuprolide for first transplant~\[18F\]fluorothymidine (FLT) imaging"
62712209|NCT03548129|ACTIVE_COMPARATOR|Fosfomycin group (FG)|"Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.~The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.~Response to treatment will be assessed by post-treatment urine culture."
62358980|NCT04429412|EXPERIMENTAL|Metacognitive Training (MCT+)|"MCT+ combines the process-oriented approach of metacognitive group training with elements of individual cognitive-behavioral therapy.~The metacognitive training program is comprised of 10 modules targeting common cognitive errors in schizophrenia. (Moritz et al, 2013).~The modules are: 1:Therapeutic alliance, 2: Introducyion to MCT+, 3:Disease model, 4: Attributional style, 5: Decision making, 6: Changing beliefs, 7: Empathizing, 8: Memory, 9: Depression and self-steem, 10: Relapse prevention.~The treatment consist of 10 weekly sessions of 45-60 minutes."
62358981|NCT04429412|NO_INTERVENTION|TAU|Treatment as usual.
62358982|NCT04586296|EXPERIMENTAL|Telemedicine Group|Group that will be receiving the telemedicine intervention in addition to the standard of care post-op.
62358983|NCT04586296|NO_INTERVENTION|Standard Treatment|Patients will be receiving the standard of care, post op visits at 2, 6, and 12 weeks.
62358984|NCT03380000|ACTIVE_COMPARATOR|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
62358985|NCT03380000|PLACEBO_COMPARATOR|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
62358986|NCT04266158|ACTIVE_COMPARATOR|MyoPro 2 Motion-G-orthosis-None|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
62358987|NCT04266158|ACTIVE_COMPARATOR|Comfy Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
62358988|NCT04266158|ACTIVE_COMPARATOR|No Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
62358989|NCT06402786|EXPERIMENTAL|Kitea ICP Sensor|At the same time as this surgery, the Kitea Sensor will be placed in the brain near the shunt. Participants will be asked to make measurements of their brain pressure at home using the Kitea ICP System for the next 3 months. Aside from the placement of the Kitea Sensor and home measurements of ICP using the Kitea ICP system, all clinical interventions will be standard of care.
62358990|NCT03385408|EXPERIMENTAL|HILT group|High-intensity laser therapy application through HIRO 3.0 device
62358991|NCT03385408|SHAM_COMPARATOR|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
62358992|NCT05764876|ACTIVE_COMPARATOR|Azithromycin|Participants in the control arm will receive standard treatment for yaws which azithromycin .
62358993|NCT05764876|EXPERIMENTAL|Linezolid|Participants in the experimental arm will receive oral linezolid treatment.
62358994|NCT03707262|EXPERIMENTAL|Donor CD34+ and CD3+ cell infusion|"The investigational products are (1) an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells (≥ 5 million cells per kilogram) followed by (2) an infusion of CD3+ cells (5 million cells per kilogram) from an HLA-identical sibling living donor.~The cells are infused around Day 11 post-transplant after the following pre-conditioning regimen:~1. 5 doses of rATG (1.5 mg/kg IV per day for 5 days, starting on the day of transplant)~2. 10 doses of TLI (120 centigray \[cGY\] x 10 fractions, starting the day after transplant)"
62358995|NCT04909216|EXPERIMENTAL|Mindful Attention Workshop|50 participants will be randomized to the Mindful Attention Training (MAT) workshop. The 90-minute workshop will be conducted in group, online format.
62358996|NCT04909216|NO_INTERVENTION|Waitlist Control|"50 participants will be randomized to the waitlist control condition (as usual condition)."
62358997|NCT02313415|EXPERIMENTAL|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions
62358998|NCT01773798|EXPERIMENTAL|IDegAsp 15|
62358999|NCT01773798|EXPERIMENTAL|IDegAsp|
62359000|NCT01773798|EXPERIMENTAL|IDeg|
62359001|NCT01773798|ACTIVE_COMPARATOR|IAsp|
62712210|NCT03548129|ACTIVE_COMPARATOR|Culture specific group (CG):|"Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.~Response to treatment will be assessed by post-treatment urine culture."
62712211|NCT05262569||ileus group|Patients developed postoperative ileus
62712212|NCT05262569||control group|Patients did not develop postoperative ileus
62712213|NCT06590038|EXPERIMENTAL|Psychotherapy Arm|
62359002|NCT01773798|EXPERIMENTAL|IDeg + IAsp|
62359003|NCT04147507|EXPERIMENTAL|Music Therapy|
62359004|NCT04147507|OTHER|Control|Life style Modification.
62359005|NCT00379236|EXPERIMENTAL|EUFLEXXA™ Double-blind|Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
62359006|NCT00379236|PLACEBO_COMPARATOR|Placebo Double-blind|Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
62150903|NCT00063089|EXPERIMENTAL|altastaph|S. aureus Immune Globulin Intravenous (Human) 5%
62150904|NCT00063089|PLACEBO_COMPARATOR|Placebo|0.45% Normal Saline
62150905|NCT01109277||Healthy term and late-preterm neonates|
62150906|NCT00489554|EXPERIMENTAL|Synflorix Vaccine Group|Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
62150907|NCT03105960|EXPERIMENTAL|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
62150908|NCT03105960|ACTIVE_COMPARATOR|chlorhexidine mouthwash|"chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash~."
62150909|NCT01662713|EXPERIMENTAL|NMSC Imaging|Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
62150910|NCT03890653|EXPERIMENTAL|Performance-Based Financing|At least one primary healthcare centre per ward and one General Hospital per selected LGA (in 50% of LGAs in each of the 3 states) and one secondary hospital per State will be contracted by the State Primary Health Care Development Agency ) , to deliver specified services at an agreed price. Selection of which services to focus on is based on priorities identified by the Federal Government of Nigeria and the states in 2010-2015. Initial prices for each service were based on shadow prices of providing the service and have been adjusted based on implementation experience.
62150911|NCT03890653|EXPERIMENTAL|Decentralized Facility Financing|In the other half of the LGA's in each treated state, at least one facility per ward will receive Decentralized Facility Financing (DFF) or equivalent financing that is not be linked to any service delivery targets. These payments would be made on a quarterly basis.
62150912|NCT03890653|NO_INTERVENTION|Control|This is a pure control arm with no additional interventions.
62150913|NCT06390345|ACTIVE_COMPARATOR|FOCuSEd Intervention|Participants randomized to the intervention will receive an integrated telehealth-delivered intervention composed of a self-directed lifestyle program and supervised pulmonary rehabilitation.
62359007|NCT00379236|EXPERIMENTAL|EUFLEXXA™ Open Label|All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.
62359008|NCT05284357||Group 1: Subjects implanted with HUMELOCK I & II® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~97 patients were identified who could be included in this cohort in 11 investigational centers.~subjects implanted in 2011 to 2013"
62359009|NCT05284357||Group 2: Subjects implanted with HUMELOCK II® Reversible System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~Number of patient to be determined following patients files in 4 investigational centers.~subjects implanted in 2011 to 2013"
62359010|NCT05284357||Group 3: Subjects implanted with HUMELOCK Reversed® Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~154 patients were identified who could be included in this cohort in 5 investigational centers.~subjects implanted in 2012 and 2013"
62359011|NCT05284357||Group 4: Subjects implanted with EASYTECH® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~66 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
62359012|NCT05284357||Group 5: Subjects implanted with EASYTECH® Reversed System (Primary intention)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~7 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
62359013|NCT05284357||Group 6:Subjects implanted with EASYTECH® Reversible System (Revision of Easytech Anatomic)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~the number of subjects will depend of revised subjects primary implanted with Easytech Anatomic® along the dedicated period subjects implanted in 2013 to 2014"
62359014|NCT05284357||Group 7: Subjects implanted with HUMERIS® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~11 patients were identified who could be included in this cohort in 3 investigational centers Subjects implanted in 2014 to 2015"
62359015|NCT05284357||Group 8: Subjects implanted with HUMERIS® Reversible Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~72 patients were identified who could be included in this cohort in 2 investigational centers Subjects implanted in 2014 to 2015"
62359016|NCT04106973||Pleural mesothelioma|Participants with all types of histologically identified pleural mesothelioma prior to, subsequent to,or concurrent with treatment.
62359017|NCT04106973||Asbestos exposed without pleural mesothelioma|Participants with asbestos exposure radiographically confirmed by the presence of bilateral pleural plaques or bilateral pleural thickening and without presence of pleural mesothelioma.
62359018|NCT01158066|NO_INTERVENTION|CT cardiac|the patient will undergo cardiac CT
62359019|NCT06317220|EXPERIMENTAL|Vedolizumab 300mg|"* Dose: 300mg~* Administration: Intravenous (IV)~* Frequency: Weeks 0, 2, 6, and then every 8 weeks~* Duration: 54 weeks (1 year)"
62359020|NCT03465384|ACTIVE_COMPARATOR|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
62359021|NCT03465384|EXPERIMENTAL|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
62359022|NCT02117804||High ESDP Score|Patients with 10 or greater score on the Early Screen for Discharge Planning at the time of admission.
62359023|NCT02117804||Low ESDP Score|Patients with 9 or lower score on the Early Screen for Discharge Planning at the time of admission.
62359024|NCT04000022||Non-Treatment Resistant Patients|
62712214|NCT01182350|EXPERIMENTAL|radiation + bevacizumab|"Cohort 1: MGMT-/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles"
62712215|NCT01182350|EXPERIMENTAL|radiation + bevacizumab + erlotinib|"Cohort 2: MGMT-/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
62150914|NCT06390345|ACTIVE_COMPARATOR|Usual Care- Enhanced|"For participants in the enhanced usual care group, study staff will prompt the patient's primary care provider to refer them to existing weight loss management and pulmonary rehabilitation programs."
62150915|NCT02009332|EXPERIMENTAL|Phase 1: ABI-009 100 mg/week|Phase 1, Cohort 1: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
62712216|NCT01182350|EXPERIMENTAL|radiation + bevacizumab + temozolomide|"Cohort 3. MGMT+/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Temozolomide: Administered orally at 90 mg/m2/day continuously during radiation therapy, held through the interim period and then 200 mg/m2/day for 5 days for up to 10 maintenance cycles"
62712217|NCT01182350|EXPERIMENTAL|radiation + bevacizumab + erlotinib + temozolomide|"Cohort 4. MGMT+/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
62712218|NCT03478605|EXPERIMENTAL|Olanzapine|Olanzapine 5 mg/day p.o. d 0-4 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d.; IM or P.O. d 2-4;
62712219|NCT03478605|ACTIVE_COMPARATOR|Aprepitant|Aprepitant 125 mg p.o d 1 + 80 mg p.o d 2,3 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d. IM or P.O. d 2-4;
62712220|NCT06375681|ACTIVE_COMPARATOR|Short Testing Group|Participants will go through 2 assessment sessions over 2-3 days (\~75 minutes each), followed by 1 session of 75 minutes about 2 weeks later, 2 further sessions (\~45 minutes) over 2-3 days about 2 weeks after this session, and finally another 2 sessions (\~45 minutes) 3 days to 2 weeks after that session. All the sessions will take place in the lab.
62150916|NCT02009332|EXPERIMENTAL|Phase 1: ABI-009 200 mg/week|Phase 1, Cohort 2: ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
62150917|NCT02009332|EXPERIMENTAL|Phase 1: ABI-009 100 mg 2×/week|Phase 1, Cohort 2b: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, twice per week (total dose 200 mg per week) for 6 weeks
62150918|NCT02009332|EXPERIMENTAL|Phase 1: ABI-009 300 mg/week|Phase 1, Cohort 3: ABI-009 injectable suspension, 300 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
62150919|NCT02009332|EXPERIMENTAL|Phase 1: ABI-009 400 mg/week|Phase 1, Cohort 4: ABI-009 injectable suspension, 400 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
62150920|NCT02009332|EXPERIMENTAL|Phase 2: ABI-009 400 mg/week + Gemcitabine 2000 mg/week|ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 1 hour, once per week for 6 weeks; Gemcitabine, 2000 mg in 100 mL saline, administered intravesically after voiding of ABI-009 and retained for 1 hour, once per week for 6 weeks
62150921|NCT01607320|EXPERIMENTAL|Raloxifene|3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
62359025|NCT04000022||Treatment-Resistant Patients|The group of patients from NCT03944213
62150922|NCT01607320|ACTIVE_COMPARATOR|Clomiphene|3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7
62150923|NCT02815800|EXPERIMENTAL|ETHNODYNE VISIO|Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease
62150924|NCT05804357|ACTIVE_COMPARATOR|Exercise Group|In our study, stabilization exercises were applied to the patients in the exercise group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Stabilization exercises: It is an approach that is combined with diaphragmatic breathing and activates the passive. The stabilization exercise program was applied in three phases and was progressed in line with the developments in the patients
62522605|NCT01338987|EXPERIMENTAL|Arm3 First Transplt/females/leuprolide+/- FLT Imaging|"Females receiving leuprolide for first transplant.~\[18F\]fluorothymidine (FLT) imaging"
62522606|NCT01338987|EXPERIMENTAL|Arm4-Second Transplt/leuprolide and FLT Imaging|Second transplant with leuprolide and \[18F\]fluorothymidine (FLT) imaging
62522607|NCT01338987|NO_INTERVENTION|Healthy Volunteer - Arm 5|Healthy Volunteer
62522608|NCT03970486|ACTIVE_COMPARATOR|Needle Manipulation|Participant will receive dry needling intervention with manipulation.
62522609|NCT03970486|ACTIVE_COMPARATOR|In Situ|Participant will receive dry needling intervention without manipulation.
62150925|NCT05804357|EXPERIMENTAL|Manual Therapy Group|In our study, stabilization exercises and spinal mobilization practices were performed to the patients in the manual therapy group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Mobilization applications were applied at Maitland IV degree as standard.Three mobilization methods were applied Anterior-Posterior Lumbal Spinal Mobilization Lumbal Spinal Rotational Mobilization Joint Mobilization in Lumbal Flexion Position
62150926|NCT05647642||low dose midazolam|0,025 mg/kg Midazolam
62150927|NCT05647642||high dose midazolam|0,05 mg/kg Midazolam
62150928|NCT05647642||low dose dexmedetothymidine|0.5 mg/kg dexmedetothymidine 10 minute infusion
62150929|NCT05647642||high dose dexmedetothymidine|1mg/kg dexmedetothymidine 10 minute infusion
62150930|NCT02428595|EXPERIMENTAL|Treatment|Eclipse™ System
62150931|NCT01019226||cardiac MRI|Ischemic cardiomyopathy, non ischemic cardiomyopathy, myocarditis, cardiomyopathy
62150932|NCT05298540|EXPERIMENTAL|Home-based computerised cognitive training|Participants will be asked to complete 40 sessions (20 minutes / day, 5 days / week) of cognitive training over the 8-week intervention period (this will be assessed using automated data reports of user activity generated in collaboration with BrainHQ). Training will commence one week postoperatively to avoid the effects of sedatives, postoperative pain, sleep deprivation, and patient fatigue, and to improve adherence
62712221|NCT06375681|ACTIVE_COMPARATOR|Long Testing Group|Participants will go through 2 assessment sessions over 2-3 days (75 minutes each), followed by 10 sessions of cognitive tasks over 2 weeks in-lab or at-home, 1 session of 75 minutes about 2 weeks later, another 10 sessions of cognitive tasks over 2 weeks in-lab or at-home, then 2 sessions (\~45 minutes) over 2-3 days about 2 weeks after this session, and finally another 2 sessions (\~45 minutes) 3 days to 2 weeks after that session. Unless otherwise specified, all the sessions will take place in the lab.
62522610|NCT02880657|EXPERIMENTAL|SODB®-physical training|This arm receives daily two capsules of SODB® 40mg containing 560 UI of superoxide dismutase, associated with standardized physical training
62522611|NCT02880657|EXPERIMENTAL|Placebo-physical training|This arm receives daily two capsules of Placebo containing excipients only, associated with standardized physical training
62522612|NCT04208074|EXPERIMENTAL|Exercise|Four months of muscle resistance training (exercise) designed to increase muscle mass and strength. The exercise protocol includes four different lifts with weights including, squats, bench press, dead lift and overhead press. The weights for each lift will be optimized for each participant and increased as the participant adapts to the exercise routine.
62522613|NCT03012672|EXPERIMENTAL|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62522614|NCT03012672|EXPERIMENTAL|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
62522615|NCT02466230|EXPERIMENTAL|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
62522616|NCT06124274|EXPERIMENTAL|Mid-Follicular Phase|7-11 days after onset of menses.
62522617|NCT06124274|EXPERIMENTAL|Mid-Luteal Phase|5-9 days after ovulation (as confirmed with ovulation test kits).
62522618|NCT06124274|EXPERIMENTAL|Active pill phase|10-20 days after starting new pill cycle.
62522619|NCT06124274|EXPERIMENTAL|Withdrawal phase|48hrs after last pill (during placebo pill phase).
62522620|NCT01474902|EXPERIMENTAL|Treatment group|"The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or~1 mg/kg/dose SC q12h for patients \> 2 months old~Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn."
62150933|NCT04749329|NO_INTERVENTION|Control Group|no mesh was used for end colostomy fashions
62150934|NCT04749329|EXPERIMENTAL|Mesh Group|Mesh of Bio A was used for end colostomy fashions
62150935|NCT01841385|EXPERIMENTAL|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
62150936|NCT01841385|NO_INTERVENTION|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
62150937|NCT04529200|EXPERIMENTAL|1. Comprehensive fall prevention protocol group (CARE)|every week protocol change for every patient according to 1 repetition maximum
62150938|NCT04529200|ACTIVE_COMPARATOR|2. Conventional balance training group|conventional protocol commonly used for rehabilitation
62150939|NCT02917759||Hepatocellular cancer|Surgical waste tissue will be collected after removal of a liver tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
62150940|NCT02917759||Cholangiocarcinoma|Surgical waste tissue will be collected after removal of a biliary tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
62150941|NCT00534677|ACTIVE_COMPARATOR|A|
62150942|NCT00534677|ACTIVE_COMPARATOR|B|
62150943|NCT02627794|EXPERIMENTAL|Silastic Silicone & Restora™ Steroid eluting spacer|"Silastic Silicone spacers are actively being used as the standard of care.~Restora™ Steroid eluting spacer (experimental).~Each nostril will receive one each of above spacers."
62150944|NCT01990794||Study Volunteers|"Volunteers (males and females) were instructed to take the cobalt dietary supplement in the morning according to the manufacturer's label, which suggested a serving of 1 mg cobalt (\~2 mL) daily in water or juice as maintenance. Dietary supplementation lasted for approximately three months."
62150945|NCT03096132|ACTIVE_COMPARATOR|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
62150946|NCT03096132|EXPERIMENTAL|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
62150947|NCT02560155|NO_INTERVENTION|Nose-SA-carriers control|Control Group, no intervention
62712222|NCT00561990|ACTIVE_COMPARATOR|Nimotuzumab|Nimotuzumab
62712223|NCT00561990|PLACEBO_COMPARATOR|Placebo|Placebo
62712224|NCT04662164|PLACEBO_COMPARATOR|placebo|control
62712225|NCT04662164|ACTIVE_COMPARATOR|4.2mg hepalatide|low dose
62712226|NCT04662164|ACTIVE_COMPARATOR|6.3mg hepalatide|middle dose
62712227|NCT04662164|ACTIVE_COMPARATOR|8.4mg hepalatide|high dose
62712228|NCT06324032||Patients with subepithelial gastrointestinal tumors|Patients with subepithelial gastrointestinal tumors
62712229|NCT06194799|EXPERIMENTAL|ACP-204|ACP-204 30mg or 60mg
62712230|NCT00001204||1|Longitudinal sequential cardiologic studies utilizing noninvasive techniques in homozygous patients with well-characterized LDL receptor defects
62712231|NCT02903472||Acute to first year after SCI|Individuals sustained SCI within a 1-year period
62712232|NCT02903472||Chronic|Individuals sustained SCI more than1 year ago
62150948|NCT02560155|ACTIVE_COMPARATOR|Nose-SA-carriers decolonized|"Chlorhexidine sol 4%; Mupirocin 2% nasal ointement~1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively"
62150949|NCT02560155|NO_INTERVENTION|Non-nose-SA-carriers control|Control Group, no intervention
62150950|NCT02560155|ACTIVE_COMPARATOR|Non-nose-carriers decolonized|Chlorhexidine sol 4% shower, daily for 5 days preoperatively
62150951|NCT06233149|EXPERIMENTAL|Sequence 1-Esomeprazole magnesium dihydrate test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
62150952|NCT06233149|EXPERIMENTAL|Sequence 2-Esomeprazole magnesium dihydrate product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
62150953|NCT03500276|EXPERIMENTAL|Yoga program|"12 weeks of Yoga in daily life practice, 2x weekly for 90 minutes including physical exercises (asanas), breathing exercises (pranayama), relaxation and meditation exercises."
62150954|NCT03500276|ACTIVE_COMPARATOR|Arthritis-education control|12 weeks of arthritis - education classes, consisting of 1x weekly sessions for 120 minutes including lectures on arthritis and related issues followed by group discussion.
62150955|NCT03380676||Oromandibular dystonia group|Patients with idiopathic oromandibular dystonia, either focal or associated to other dystonic features including generalized dystonia
62712233|NCT06446492|EXPERIMENTAL|Video-enhanced approach to consent|The research team will introduce themselves and ask the parents to watch an informational video explaining the ViDES study on an iPad while they stay in the room with the parents. After viewing the video, the team will answer any questions and provide written consent and enough time to decide whether to participate in the study. The research team will also provide a QR code that grants parents/guardians access to the video on their own device at any time. This allows them to pause, rewind, and revisit the information.
62150956|NCT03380676||Healthy subjects|Healthy subjects (normal neurological examination), each being age-matched to a subjet of the oromandibular dystonia group
62150957|NCT04301752||Neurobrucellosis|Brucellosis associated with neuropsychiatric manifestations
62150958|NCT04301752||Non-neurobrucellosis|Brucellosis not associated with neuropsychiatric manifestations
62150959|NCT02578004||100 patients suffering from pressure ulcer|100 subjects were having at least one wound of pressure ulcer (74 men and 26 women) middle-aged (55.5±20 years) and were recruited from many services of three University Regional hospitals of Tunisia.
62522621|NCT01474902|NO_INTERVENTION|No-treatment|
62522622|NCT03602443|EXPERIMENTAL|Experimental|This group will receive the LSVT(R)BIG Intervention first (4 weeks) and then cross over to the Waitlist Control (no intervention for 4 weeks).
62712234|NCT06446492|ACTIVE_COMPARATOR|Usual care approach to consent|The research team will present a detailed explanation of the ViDES study, answer questions, provide written consent, and provide enough time to decide on participation or not in the study.
62712235|NCT02947984|EXPERIMENTAL|Standard Treatment|Standard radiation therapy: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week.
62712236|NCT02947984|EXPERIMENTAL|Higher Dose Treatment|63 CGE in 35 treatments of 1.8 CGE given once a day, for five days of each week.
62712237|NCT04464980|EXPERIMENTAL|Retention: SL-BUP standard dose + MM|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62712238|NCT04464980|EXPERIMENTAL|Retention: SL-BUP high dose + MM|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62712239|NCT04464980|EXPERIMENTAL|Retention: XR-BUP + MM|Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62522623|NCT03602443|OTHER|Waitlist Control|This group will receive the Waitlist Control (4 weeks) and then cross over to receive the LSVT(R)BIG Intervention (4 weeks).
62522624|NCT01401257|EXPERIMENTAL|PXT3003 Low dose|Oral Liquid formulation, 1/100, bid, 12 months
62522625|NCT01401257|EXPERIMENTAL|PXT3003 Intermediate dose|Oral Liquid formulation, 1/50, bid, 12 months
62522626|NCT01401257|EXPERIMENTAL|PXT3003 High dose|Oral Liquid formulation, 1/10, bid, 12 months
62522627|NCT01401257|PLACEBO_COMPARATOR|Placebo|Oral Liquid formulation, bid, 12 months
62522628|NCT06225557|EXPERIMENTAL|ERAS society guidlines|The ERAS society guidelines for elective cesarean section will be followed.
62522629|NCT06225557|EXPERIMENTAL|Traditional methods|Traditional methods in postoperative care for elective cesarean section will be followed.
62522630|NCT03265613|EXPERIMENTAL|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
62522631|NCT06289803|EXPERIMENTAL|patients who accept the scan of pCLE|
62522632|NCT06411587||Patients with stroke|Patients with a chronic stroke and spasticity in the ankle flexors muscles.
62522633|NCT06411587||Patients without stroke|Patients without stroke were matched with those with stroke based on age and sex.
62522634|NCT05080647|ACTIVE_COMPARATOR|Mightier Child Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more play each week) for the 8-week duration. Parents in the Child Play condition will be advised specifically to not play Mightier for the 8-week duration of the study.
62522635|NCT05080647|EXPERIMENTAL|Mightier Child and Parent Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration. Additionally, parents in the Child and Parent Play condition will be encouraged to play Mightier games at least once a week (totalling 15 minutes or more of play each week) for the 8-week duration.
62522636|NCT00286819|EXPERIMENTAL|the FEC75 regimen|"Arm A: the FEC75 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles."
62522637|NCT00286819|EXPERIMENTAL|FEC90 regimen|"Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle."
62522638|NCT06412588|ACTIVE_COMPARATOR|Group A Bismuth quadruple|Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth, treatment course 14 days
62522639|NCT06412588|EXPERIMENTAL|Group B Amoxicillin Dual therapy|Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid , treatment course 14 days
62522640|NCT06412588|EXPERIMENTAL|Group C doxycycline Dual therapy|Vonoprazan 20 mg, bid +doxycycline 0.1 g, bid，treatment course 14 days
62522641|NCT03722095|ACTIVE_COMPARATOR|active tDCS + active iTBS|Participants will receive 20 minutes of active tDCS, during the last 7 minutes active iTBS will be applied.
62522642|NCT03722095|SHAM_COMPARATOR|sham tDCS + active iTBS|Participants will receive 20 minutes of sham tDCS, during the last 7 minutes active iTBS will be applied.
62522643|NCT00472121||1: AMG|
62522644|NCT00472121||2: MMG|
62522645|NCT02857738|EXPERIMENTAL|SPF evaluation|Subjects with Good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
62522646|NCT00888459|ACTIVE_COMPARATOR|active|Self-help counseling material and 4 mg nicotine lozenges
62712240|NCT04464980|EXPERIMENTAL|Retention: XR-NTX + MM|Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62150960|NCT02578004||213 healthy subjects|213 healthy subjects (125 men and 88 women) middle-aged (51.5±17 years). Although, healthy individuals, were included as controls, followed in the outpatient services of the University Hospital Farhat Hached and they considered clinically free of pressure ulcer and tissue necrosis.
62150961|NCT04594876|OTHER|Flouroscopic guidance Cervical Epidural injection|Group (P) flouroscopic guidance cervical epidural injection
62522647|NCT00888459|PLACEBO_COMPARATOR|2|self help counseling material and placebo nicotine lozenges
62522648|NCT02900963|OTHER|Nutrition state determination|"Determination of nutritional state and inflammatory status:~weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight"
62522649|NCT05266820|EXPERIMENTAL|TAS-102+Thalidomide|Thalidomide 100mg PO BID+TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
62522650|NCT05266820|ACTIVE_COMPARATOR|TAS-102|TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
62522651|NCT05733520|EXPERIMENTAL|Brain CareNotes App|
62522652|NCT05733520|ACTIVE_COMPARATOR|Attention Control App|
62522653|NCT04872972|OTHER|Before/After|Before and after simulation; Institutional faculty and facilities
62522654|NCT06052865|EXPERIMENTAL|Exposed: High neurological risk|25 very preterm infants with advanced neurological injury
62522655|NCT06052865|EXPERIMENTAL|Exposed: Low neurological risk|25 very preterm infants with low/no neurological injury
62522656|NCT06052865|OTHER|Reference/ Standard of care|25 very preterm infants with no study exposure/ standard of care
62522657|NCT03480438|EXPERIMENTAL|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day."
62522658|NCT00953108|EXPERIMENTAL|quetiapine|
62522659|NCT00953108|ACTIVE_COMPARATOR|escitalopram|
62712241|NCT04464980|EXPERIMENTAL|Retention: SL-BUP standard dose + MMR|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.
62712242|NCT04464980|EXPERIMENTAL|Retention: SL-BUP high dose + MMR|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
62150962|NCT04594876|OTHER|Flouroscopic guidance cervical facet injection|Group (F) Flouroscopic guidance cervical facet injection
62150963|NCT01048385|EXPERIMENTAL|CoQ10|This group will be treated concomitantly with Coenzyme Q10
62150964|NCT01048385|PLACEBO_COMPARATOR|Control|Treated with capsules containing the vehicle.
62712243|NCT04464980|EXPERIMENTAL|Retention: XR-BUP + MMR|Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
62712244|NCT04464980|EXPERIMENTAL|Retention: XR-NTX + MMR|Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
62712245|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue SL-BUP with SL-BUP + MM|Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62712246|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue SL-BUP with XR-BUP + MM|Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62712247|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue XR-BUP with XR-BUP + MM|Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62712248|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue XR-NTX with XR-NTX + MM|Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
62150965|NCT02705729|ACTIVE_COMPARATOR|Ketac Universal|Simplified glass ionomer tooth filling
62150966|NCT02705729|ACTIVE_COMPARATOR|Ketac Molar Quick|Glass ionomer tooth filling
62150967|NCT03531892|EXPERIMENTAL|AJM300 960mg/dose|Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
62712249|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue SL-BUP with SL-BUP + MMD|Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
62712250|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue SL-BUP with XR-BUP + MMD|Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
62150968|NCT03531892|PLACEBO_COMPARATOR|Placebo|Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.
62150969|NCT01754389|ACTIVE_COMPARATOR|Arm A (Standard of Care)|Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
62150970|NCT01754389|EXPERIMENTAL|Arm B (Experimental)|Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
62150971|NCT01754389|EXPERIMENTAL|Arm C (Experimental)|Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
62150972|NCT01580436|EXPERIMENTAL|Tricuspid Valve Annuloplasty|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to concomitant tricuspid valve annuloplasty.
62150973|NCT01580436|NO_INTERVENTION|Conservative arm|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to mitral valve surgery without concomitant tricuspid valve annuloplasty.
62150974|NCT06084988|EXPERIMENTAL|MSC Intervention Group|Participants will receive one dose (50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution (sodium chloride supplemented with human serum albumin) to be given via ultrasound-guided intra-articular injection of human allogeneic bone marrow-derived mesenchymal stromal cell product StromaForte. All patients will be observed for at least 2 hours post-injection at the study site. Both active monitoring and spontaneous reporting will be used.
62150975|NCT01632085|OTHER|Group SU (Single use or Laryngobloc ®) ®)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Laryngobloc ®.
62150976|NCT01632085|OTHER|Group R (Reusable handle)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Disposable Metal Blade.
62150977|NCT01753674|EXPERIMENTAL|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
62712251|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue XR-BUP with XR-BUP + MMD|Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
62712252|NCT04464980|EXPERIMENTAL|Discontinuation: Discontinue XR-NTX with XR-NTX + MMD|Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
62712253|NCT05242289|ACTIVE_COMPARATOR|Treated|"Treatment using the medical cytokine adsorption device in conjunction with lung transplantation"
62712254|NCT05242289|NO_INTERVENTION|Non-treated|No additional treatment in conjunction with lung transplantation
62712255|NCT04826380|OTHER|Trapeziectomy|Simple trapeziectomy for treating CMC I arthritis
62712256|NCT04826380|NO_INTERVENTION|Conservative|Conservative measures (e.g. splint, NSAID, activation modification) for treating CMC I arthritis
62712257|NCT04650581|EXPERIMENTAL|Ipatasertib + Fulvestrant|
62712258|NCT04650581|PLACEBO_COMPARATOR|Placebo|
62150978|NCT01753674|PLACEBO_COMPARATOR|Placebo|Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
62150979|NCT00164021||Cystic Fibrosis|Patients with cystic fibrosis
62150980|NCT00164021||Control|
62150981|NCT02102698|EXPERIMENTAL|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1/D5 receptor family that is being studied as a treatment for Tourette's Syndrome
62150982|NCT02102698|PLACEBO_COMPARATOR|Placebo|Placebo is the inactive comparator
62150983|NCT01979783||LBP|group of subjects with low back pain
62150984|NCT01979783||nonLBP|group without low back pain
62712259|NCT03941132|EXPERIMENTAL|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.~Total of 11 visits"
62150985|NCT02520336|EXPERIMENTAL|active management|Laboratoy test request given postpartum with phone reminder prior to test
62150986|NCT02520336|NO_INTERVENTION|Routine care|
62712260|NCT03941132|PLACEBO_COMPARATOR|Saline Solution - Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.~Total of 11 visits"
62712261|NCT03849209|EXPERIMENTAL|Stylet Slow-Pull Technique group|In patients randomized to the stylet slow-pull techniques an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
62712262|NCT03849209|ACTIVE_COMPARATOR|Standard Suction Technique group|In patients randomized to the standard suction technique an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed with the use of a 10-mL suction syringe.
62150987|NCT01838603||Interventional pain management patients|Patients passed through interventional pain management program
62150988|NCT00350129||1|healthy vasospastic subjects
62150989|NCT00350129||2|healthy non-vasospastic subjects
62150990|NCT00774592|EXPERIMENTAL|1|Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
62150991|NCT00774592|EXPERIMENTAL|2|FOYC plus Goal For It (GFI)
62150992|NCT00774592|ACTIVE_COMPARATOR|3|Wonderous Wetlands plus GFI
62150993|NCT00774592|EXPERIMENTAL|Grade 10-BFOOY+CImPACT|Youth receives HIV intervention; parents receive parental monitoring intervention
62150994|NCT00774592|EXPERIMENTAL|Grade 10 BFOOY+GFI|Youth receive HIV prevention intervention and parents receive attention control intervention on career planning
62150995|NCT00774592|EXPERIMENTAL|BFOOYand no parent intervention|Youth receive HIV prevention intervention; parents receive no intervention
62359026|NCT02057068|EXPERIMENTAL|SLEEP-E Dyads Intervention|"SLEEP-E Dyads Six-Week Tele-Health Intervention~1. . Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.~2. . Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.~3. . Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).~4. . SLEEP-E Dyads book~5. . Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching"
62712263|NCT03984825|EXPERIMENTAL|Portia followed by Portia co-administered with GSK3640254|Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.
62712264|NCT02981628|EXPERIMENTAL|Cohort I (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, 8, and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. (COMPLETE)
62522660|NCT04860765||TPVR|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
62712265|NCT02981628|EXPERIMENTAL|Cohort II (inotuzumab ozogamicin, mBFM chemotherapy)|See Detailed Description
62712266|NCT00002529|EXPERIMENTAL|AC with concurrent tamoxifen|AC for 4 cycles with concurrent tamoxifen for 5 years
62712267|NCT00002529|EXPERIMENTAL|AC followed by tamoxifen|AC for 4 cycles followed by tamoxifen to 5 years from randomization.
62150996|NCT00774592|PLACEBO_COMPARATOR|Health and FAmily life|Youth receive standard of care (current curriculum); parents receive no intervention
62150997|NCT03620474|EXPERIMENTAL|PRI-724|"Dose: 140, 280, 380 mg / m 2/4 hr~Administration method:~【Phase I Phase】 (Level 1) 140 mg / m 2/4 hr (Level 2) 280 mg / m 2/4 hr (Level 3) 380 mg / m 2/4 hr Twice weekly, continuous 4-hour intravenous administration (tolerance of administration time: ± 15 minutes). This is one cycle and 12 cycles (12 weeks in total) are carried out. However, in Phase I phase, single dose is administered on Day - 7 (tolerance: - 7 days).~【Phase IIa phase】 Continuous intravenous administration for 4 hours twice a week at the recommended dose determined in Phase I. This is one cycle and 12 cycles (12 weeks in total) are carried out."
62150998|NCT03477799|ACTIVE_COMPARATOR|Active|anodal stimulation over the right dlPFC
62150999|NCT03477799|PLACEBO_COMPARATOR|Sham|sham stimulation over the right dlPFC
62151000|NCT02733484|EXPERIMENTAL|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
62151001|NCT02733484|PLACEBO_COMPARATOR|Placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
62151002|NCT06366659||ICP patients|None intervention
62151003|NCT06366659||Healthy pregnant women|None intervention
62151004|NCT03541369|EXPERIMENTAL|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
62151005|NCT03541369|EXPERIMENTAL|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
62151006|NCT01187888|ACTIVE_COMPARATOR|Rasagiline|
62151007|NCT01187888|PLACEBO_COMPARATOR|Sugar pill|
62151008|NCT04645849||"Cohort A or End of treatment"|16 patients recruited at the end of breast cancer treatment and followed during 9 months
62151009|NCT04645849||"Cohort B or Diagnosis"|Patients recruited at breast cancer before any treatment: one blood sample to provide comparative values.
62359027|NCT02057068|NO_INTERVENTION|Usual Care Group|During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.
62359028|NCT00294827|EXPERIMENTAL|Liver transplantation|
62151010|NCT02560961|EXPERIMENTAL|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase \[1\] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
62151011|NCT02560961|PLACEBO_COMPARATOR|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase \[1\] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
62151012|NCT01019135|ACTIVE_COMPARATOR|Women-Only Cardiac Rehabilitation|The women-only CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format, wherein participants engage in on-site female-only group exercise sessions, as well as female-only group education sessions.
62151013|NCT01019135|ACTIVE_COMPARATOR|Co-ed Cardiac Rehabilitation|The traditional hospital-based co-ed CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format.
62151014|NCT01019135|ACTIVE_COMPARATOR|Home-Based Cardiac Rehabilitation|In the monitored home-based programs, patients attend an intake appointment where an exercise test is performed as the basis for exercise prescription. Patients are given written guidelines for aerobic conditioning based on their treadmill test. Patients are cautioned about symptoms, and taught how to check their heart rate during walking sessions. Patients are provided with reading materials regarding CVD, risk factors and lifestyle modification. These are discussed with an allied health professional from the home-based CR program by telephone during weekly scheduled telephone calls.
62151015|NCT05686837||People infected with NTM isolates identified in a cluster|All people with CF infected with NTM respiratory isolated identified in a cluster based on whole genome sequencing of the core genome will undergo epidemiologic investigation and home of residence watersheds will be mapped.
62359029|NCT06310070|EXPERIMENTAL|Receiving 3D Personalized Ostomy Appliance|The personalized ostomy appliances are designed based off of a 3D scan. We will scan your ostomy to create a 3D picture in the computer system that is an exact copy of your ostomy using plastic. We then apply computer aided design (CAD) tools to modify your normal ostomy baseplates.
62712268|NCT00002529|EXPERIMENTAL|Tamoxifen alone|Tamoxifen alone for 5 years.
62712269|NCT00002529|EXPERIMENTAL|AC with concurrent toremifene|AC for 4 cycles with concurrent toremifene for 5 years.
62151016|NCT05686837||People infected with NTM isolates not identified in a cluster|All people with CF infected with NTM respiratory isolated not identified in a cluster based on whole genome sequencing of the core genome will undergo epidemiologic investigation and home of residence watersheds will be mapped.
62151017|NCT06499116|EXPERIMENTAL|Topiramate|25-100 mg/12h, V.O., during 12 weeks
62151018|NCT06499116|EXPERIMENTAL|Flunarizine|2,5-10 mg/24h, V.O., during 12 weeks
62151019|NCT06499116|EXPERIMENTAL|Amitriptyline|10-75 mg/24h, V.O., during 12 weeks
62151020|NCT06499116|ACTIVE_COMPARATOR|Propranolol|20-120 mg/12h, V.O., during 12 weeks
62151021|NCT03560206|EXPERIMENTAL|Family SWaP intervention|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
62151022|NCT03560206|ACTIVE_COMPARATOR|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
62151023|NCT06372600|EXPERIMENTAL|Extracorporeal shock wave therapy group|In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
62151024|NCT06372600|EXPERIMENTAL|Platelet-rich plasma group|Autologous Platelet-rich plasma injection was performed under ultrasound guidance
62151025|NCT06372600|EXPERIMENTAL|Extracorporeal shock wave therapy+Platelet-rich plasma group|Extracorporeal shock wave therapy followed by Platelet-rich plasma injection
62151026|NCT04050514|EXPERIMENTAL|H-MAD, hinge system according to Herbst|"Patients with snoring and OSAS. Therapy with MAD type H-MAD with lateral hinges according to Herbst.~Bite elevation 2 mm interocclusal distance with a lower jaw advancement of 5 mm"
62359030|NCT05106595||Traditional Occupational Therapy|participants receiving traditional occupational therapy treatments and interventions provided in the inpatient rehabilitation setting. This includes, but is not limited to , therapeutic activity, therapeutic exercise, neuromuscular re-education. This group is retrospectively collected, and will not include participants who had access to the BAT.
62522661|NCT05125380|ACTIVE_COMPARATOR|1- Triage arm for HPV pos women|HPV positive women
62712270|NCT00002529|EXPERIMENTAL|AC followed by toremifene|AC for 4 cycles followed by toremifene to 5 years from randomization.
62712271|NCT00002529|EXPERIMENTAL|Toremifene alone|Toremifene alone for 5 years.
62712272|NCT03784248||asymptomatic carrier|
62712273|NCT03784248||uninfected subjects|
62712274|NCT02229617|ACTIVE_COMPARATOR|Injectable testosterone|We will take a group of transgender males, already on a stable dosage of intramuscular testosterone, and then using their same type and dosage, switch them to the subcutaneous injection route. Weekly trough (just before their weekly injection) levels of total serum testosterone will be taken to compare the steady states of those two injection routes.
62151027|NCT04050514|ACTIVE_COMPARATOR|F-MAD, SomnoDent Fusion|Patients with snoring and OSAS,Fusion MAD with sliding side wings (F-MAD). Bite elevation 5 mm interocclusal distance with a lower jaw advancement of 5 mm
62359031|NCT05106595||Bimanual Arm Trainer|Participants who are prospectively enrolled, who are appropriate for BAT use. Participants will receive additional traditional occupational therapy interventions, as deemed appropriate by treating therapists.
62359032|NCT02275910|EXPERIMENTAL|E7090 Arm|Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
62359033|NCT01917240|EXPERIMENTAL|Monophasic Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media \& the other half in sequential media. All embryos will undergo CCS \& the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
62359034|NCT01917240|PLACEBO_COMPARATOR|Sequential Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media \& the other half in sequential media. All embryos will undergo CCS \& the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
62359035|NCT06090448|OTHER|University of Bath - Clinical group 1|Participants will be Assistive Technology Users (clinical group 1) and the study will be conducted remotely at their homes. The device will be sent via post to their address.
62359036|NCT06090448|OTHER|Portsmouth Hospital Unit (PHU) - Clinical groups 2,3 & 4|"Three clinical groups will be recruited in Arm 2: 40 with mild-to-moderate motor neurodisabilities without communication assistive technology needs, 40 healthy participants and 20 who do not have the ability to ear rumble.~Participants will be required to attend two in-person visits at the Queen Alexandra Hospital at the beginning and end of the study. This is in addition to completing the home procedure using the Earswitch device at home."
62359037|NCT04716478||Patient in need of endodontic care|
62359038|NCT04589962||Percutaneous Group|
62359039|NCT04589962||Surgical Group|
62359040|NCT01785108|ACTIVE_COMPARATOR|GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen|"* GAD-Alum (Diamyd) 20 µg given twice with one month interval~* Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450~* Ibuprofen, 400 mg/day, from Day 1 to Day 90"
62359041|NCT01785108|ACTIVE_COMPARATOR|GAD-Alum (Diamyd) 20µg and Vitamin D|"* GAD-Alum (Diamyd) 20 µg given twice with one month interval~* Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
62359042|NCT01785108|ACTIVE_COMPARATOR|GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D|"* GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval~* Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
62359043|NCT01785108|PLACEBO_COMPARATOR|Placebo|
62359044|NCT05195268|ACTIVE_COMPARATOR|Group 1 - PVI + PWI|These patients will receive pulmonary vein isolation and posterior wall isolation.
62359045|NCT05195268|OTHER|Group 2 - PVI only|These patients will receive pulmonary vein isolation only.
62359046|NCT00933192||Group 1: young healthy patients|
62359047|NCT00933192||Group 2: old healthy patients|
62359048|NCT05187585|SHAM_COMPARATOR|radiograph interpretation without the support of the RAYVOLVE app|
62359049|NCT05187585|EXPERIMENTAL|radiograph interpretation with the support of the RAYVOLVE app|
62359050|NCT01170312|ACTIVE_COMPARATOR|Autologous conditioned plasma|
62359051|NCT01170312|PLACEBO_COMPARATOR|Normal saline|
62359052|NCT01879254||DBS for OCD|
62359053|NCT03137017|EXPERIMENTAL|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
62359054|NCT03137017|EXPERIMENTAL|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
62359055|NCT03137017|ACTIVE_COMPARATOR|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
62359056|NCT03137017|ACTIVE_COMPARATOR|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
62359057|NCT04324788||Group 1|"Transtibial amputation~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
62151028|NCT00487240|EXPERIMENTAL|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension twice daily
62151029|NCT00487240|ACTIVE_COMPARATOR|Detemir|Insulin Levemir (detemir) subcutaneous (SC) twice daily.
62151030|NCT06301945||Patients with TET|"Patients diagnosed with the following TET subtypes:~* Thymoma Type A~* Thymoma Type AB~* Thymoma Type B1~* Thymoma Type B2~* Thymoma Type B3~* Thymic Carcinoma"
62151031|NCT06301945||Recurrence|Patients with thymic epithelial tumors who have experienced recurrence.
62151032|NCT02652845|EXPERIMENTAL|Intervention-Wellness Engagement Program|"The group assigned to the intervention arm will receive treatment as described below for a twelve week period:~Weekly lessons related to healthy eating and physical activity Biweekly check-in calls with a trained peer support coach Access to neighborhood wide physical activity and nutritional education events"
62151033|NCT02652845|NO_INTERVENTION|Delayed treatment control group|The delayed treatment control group will not receive the intervention for measurement purposes; however the intervention as described will be administered to this group upon conclusion of the 12 week period for the intervention group.
62151034|NCT06469931|EXPERIMENTAL|Ozone therapy group|In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
62151035|NCT06469931|EXPERIMENTAL|Extracorporeal shock wave therapy group|Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercisess for wrist and hand and splinting.
62151036|NCT06369532|ACTIVE_COMPARATOR|Active tDCS group|Patients will receive active tDCS during the therapy.
62151037|NCT06369532|SHAM_COMPARATOR|Sham tDCS group|Patients will receive sham tDCS during the therapy.
62151038|NCT00911638|EXPERIMENTAL|1: Patient decision aid|Patient decision aid focused on treatment options for osteoarthritis of the hip or knee and preference report for surgeons. The patient decision aid used is from the Informed Medical Decisions Foundation
62712275|NCT01255280|ACTIVE_COMPARATOR|Information, Motivation, Behavioral skills|The comparison condition will only receive the two IMB risk reduction sessions. The intervention will begin with modules that focus directly with sexual risk reduction practices. It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits. This session will also involve a Q\&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information). The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
62151039|NCT00911638|ACTIVE_COMPARATOR|2: Usual care|Usual patient educational resources for patients undergoing hip or knee replacement surgery.
62151040|NCT02315014|EXPERIMENTAL|whey protein|whey protein micelles
62151041|NCT02315014|PLACEBO_COMPARATOR|placebo|calorie-free placebo
62151042|NCT03799809|ACTIVE_COMPARATOR|Voriconazole|Will receive 400 mg of Intrabronchial Voriconazole every week for 4 weeks along with standard medical therapy.
62151043|NCT03799809|NO_INTERVENTION|Control|Will receive standard medical therapy alone (hemostatics, anti-tussive and others as deemed appropriate by treating physician)
62151044|NCT03220815|EXPERIMENTAL|Biologic drilling drilling at low speed|
62359058|NCT04324788||Group 2|"Transfemoral amputation~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
62359059|NCT03989856|EXPERIMENTAL|Suturing group|"The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.~The running suture starting from central area, around the ovarian hilus to peripheral tissue, will be performed with intraovarian knots to re-approximate the edges to achieve satisfying hemostasis. Knots will not be detectable on the ovarian surface for prevention of adhesion. Mean time for hemostasis of ovary was recorded in a form. The cyst wall will be removed from the abdomen by means of an endobag. All resected cyst walls will be sent to the pathology laboratory, to confirm the histopathology of endometriosis."
62359060|NCT03989856|ACTIVE_COMPARATOR|Bipolar group|In bipolar coagulation group, after stripping the ovarian cyst wall, bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). In laparoscopic suturing group, no bipolar coagulation will be performed during or after stripping the ovarian cyst wall.
62359061|NCT06154499||Patients referred to the Urology Department who need to undergo radical prostatectomy surgery|
62359062|NCT02025829||Clinically Stable|Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D
62151045|NCT03220815|ACTIVE_COMPARATOR|conventional drilling drilling at high speed|
62151046|NCT01115309|OTHER|XprESS Balloon Device|Sinus dilation
62151047|NCT01480258|EXPERIMENTAL|PR5I|"Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age \[subset 1\] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age \[subset 2\]).~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
62151048|NCT01480258|ACTIVE_COMPARATOR|INFANRIX™ hexa|"Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age \[subset 1\] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age \[subset 2\]).~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
62151049|NCT05755178|EXPERIMENTAL|Musical group intervention|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
62359063|NCT02025829||Exacerbation|Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del
62359064|NCT04301583|ACTIVE_COMPARATOR|Procyanidin B2 enriched cocoa|Participants receiving cocoa capsules
62359065|NCT04301583|PLACEBO_COMPARATOR|Placebo group|Participants maltodextrin capsules
62359066|NCT01053403|ACTIVE_COMPARATOR|MDMA|
62359067|NCT01181310|EXPERIMENTAL|A, B, D, E, C|Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.
62359068|NCT01181310|EXPERIMENTAL|B, C, E, A, D|Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.
62359069|NCT01181310|EXPERIMENTAL|C, D, A, B, E|Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.
62522662|NCT05125380|EXPERIMENTAL|2- Triage arm for HPV pos women|HPV positive women
62522663|NCT05476107|EXPERIMENTAL|AMT-126|oral AMT-126
62522664|NCT05476107|PLACEBO_COMPARATOR|Placebo|oral placebo
62522665|NCT05476107|OTHER|Radioactive Tablet (Part 2 only)|oral radioactive tablet for scintigraphic analysis
62359070|NCT01181310|EXPERIMENTAL|D, E, B, C, A|Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.
62712276|NCT01255280|EXPERIMENTAL|Behavioral Activation Therapy and Risk Reduction Counseling|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions-1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention. Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
62712277|NCT04117633|ACTIVE_COMPARATOR|Mesh Rectopexy|Using Laparoscopy
62712278|NCT04117633|ACTIVE_COMPARATOR|Suture Rectopexy|Using Laparoscopy
62712279|NCT01968928||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients.
62712280|NCT01968928||normal|specimens come from normal bladder urothelial carcinoma patients.
62359071|NCT01181310|EXPERIMENTAL|E, A, C, D, B|Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.
62359072|NCT01181310|EXPERIMENTAL|A, C, B, E, D|Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.
62359073|NCT01181310|EXPERIMENTAL|B, D, C, A, E|Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.
62359074|NCT01181310|EXPERIMENTAL|C, E, D, B, A|Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.
62359075|NCT01181310|EXPERIMENTAL|D, A, E, C, B|Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.
62359076|NCT01181310|EXPERIMENTAL|E, B, A, D, C|Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.
62359077|NCT00416312||Conventional & Patient-Specific Dosimetry|Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
62359078|NCT02326389|EXPERIMENTAL|Exercise and Cognitive Remediation|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down. The experimental group will participate in the exercise intervention as well as cognitive remediation.
62359079|NCT02326389|ACTIVE_COMPARATOR|Cognitive Remediation Only|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
62359080|NCT01961089|EXPERIMENTAL|Normal|Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
62359081|NCT01961089|ACTIVE_COMPARATOR|Mild Cataract|Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
62359082|NCT01961089|EXPERIMENTAL|Severe cataract|Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
62359083|NCT04698681||Biomarker Screening|Patients with stage IV nonsquamous NSCLC not previously treated with systemic therapy for metastatic disease and who meet all of study inclusion criteria and none of the exclusion criteria.
62359084|NCT04820153|OTHER|Study Participants|Study participants will participate in both the Physical Activity Monitoring Device intervention and the Lifestyle Redesign Coaching intervention simultaneously. Both interventions are complementary to one another.
62359085|NCT04944381|EXPERIMENTAL|SARS-Cov-2 mRNA vaccine immunization group|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd.
62359086|NCT04944381|EXPERIMENTAL|Inactivated SARS-Cov-2 vaccine immunization group|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
62359087|NCT04018612|ACTIVE_COMPARATOR|High Dose Acetaminophen|High Dose Acetaminophen Post Op
62359088|NCT04018612|ACTIVE_COMPARATOR|Low Dose Acetaminophen|Low Dose Acetaminophen Post Op
62359089|NCT04018612|PLACEBO_COMPARATOR|Placebo|Placebo Post Op
62359090|NCT03884023||AD group|Alzheimer's disease
62359091|NCT03884023||aMCI group|Amnestic Mild Cognitive(MCI) impairment due to Alzheimer's disease
62359092|NCT03884023||NC group|Normal Control
62359093|NCT04463225|OTHER|Intervention condition|Participants assigned to the intervention condition will be invited to engage with an internet-based intervention three times during the course of the study.
62359094|NCT04463225|NO_INTERVENTION|Control|The control group will not be offered the internet-based intervention.
62359095|NCT06059092|EXPERIMENTAL|Adapt Module|Module targeting reactive adaptation processes
62359096|NCT06059092|EXPERIMENTAL|Engage Module|Module targeting proactive adaptation processes
62359097|NCT06059092|EXPERIMENTAL|Interact Module|Module targeting interpersonal adaptation processes
62359098|NCT06059092|PLACEBO_COMPARATOR|Control group|Sessions targeting cognitive functions
62359099|NCT03242161|EXPERIMENTAL|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
62359100|NCT00927758|ACTIVE_COMPARATOR|Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
62359101|NCT00927758|ACTIVE_COMPARATOR|Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
62151050|NCT01357902|EXPERIMENTAL|Lamictal|Chinese healthy male subjects were randomized to receive single dose of either 5 mg lamotrigine dispersible/chewable tablets or 25mg compressed/standard tablets.
62151051|NCT05694286|EXPERIMENTAL|Infraorbital Filler|Receives 1-2mL injection of approved filler in infraorbital region
62151052|NCT03542695|EXPERIMENTAL|Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)|Participants receive 64Cu-DOTA-alendronate IV and undergo PET/CT imaging 60 minutes after injection. Participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team.
62359102|NCT00927758|ACTIVE_COMPARATOR|Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
62712281|NCT01968928||non-tumoral|specimens come from non-tumoral patients.
62712282|NCT06330701|EXPERIMENTAL|Robotic mini-Percutaneous Nephrolithotomy (PCNL)|"Participants with kidney stones will be enrolled for a robotic-assisted mini-percutaneous nephrolithotomy procedure using the MONARCH Platform, Urology for removal of kidney stones. The MONARCH Platform, Urology enables electro-mechanical articulation and precise control of a flexible ureteroscope and/or a flexible mini-PCNL suction catheter (catheter) for visualization and access to the urinary tract for diagnostic and therapeutic procedures."
62712283|NCT02152189||Screening population|
62712284|NCT01589614|EXPERIMENTAL|PH-797804 6 mg|Subjects will receive a single 6 mg dose in the fed state
62151053|NCT05210985||premature babies|Fifty infants between 4-18 months with a history of premature birth and with the consent of their parents will be included in the study. Babies with the chromosomal anomalies, serious congenital problems, and whose parents are not willing to work will not be included in the study.
62151054|NCT05484921||traumatic brain injury group|(1) age 18-80 years, (2) admission due to isolated head injury, (3) unconsciousness at the time of injury. Isolated head trauma was defined as CT scan-confirmed brain injury without other major extracranial injuries, such as pelvis fractures, femur fractures, and severe invasive abdominal or thoracic injuries. Other exclusion criteria for patients were infection within the most recent month, previous head trauma, neurological diseases including ischemic and hemorrhagic stroke, use of antiplatelet or anticoagulant medications, and other prior systemic diseases including uremia, liver cirrhosis, malignancy, chronic heart disease, and chronic lung disease.
62359103|NCT00927758|ACTIVE_COMPARATOR|Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
62712285|NCT01589614|EXPERIMENTAL|PH-797804 6 mg + erythromycin 800 mg|Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
62359104|NCT00927758|ACTIVE_COMPARATOR|Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
62359105|NCT00927758|ACTIVE_COMPARATOR|Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
62151055|NCT03950609|EXPERIMENTAL|Treatment (lenvatinib, everolimus)|Patients receive lenvatinib PO daily and everolimus PO daily on days 1-28. Treatments repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62151056|NCT01072552||Treated|Palivizumab treated
62151057|NCT01072552||Untreated|Palivizumab untreated
62359106|NCT03126578|EXPERIMENTAL|All subjects|"Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12.~Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731."
62359107|NCT01459770|ACTIVE_COMPARATOR|control|"usual care for hospital discharge:~1. CKD group~2. ESRD group"
62359108|NCT01459770|ACTIVE_COMPARATOR|intervention|"pharmacist administered medication information transfer intervention~1. CKD group~2. ESRD group"
62359109|NCT01228188|EXPERIMENTAL|Idiopathic Full Thickness Macular Hole|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
62359110|NCT03825510|EXPERIMENTAL|Treatment Arm|
62359111|NCT05133336|EXPERIMENTAL|Saroglitazar Magnesium 2 mg|Subjects who received Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast are switched to Saroglitazar Magnesium 1 mg for remaining of the treatment period
62359112|NCT05133336|EXPERIMENTAL|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
62359113|NCT05133336|PLACEBO_COMPARATOR|Placebo|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
62359114|NCT03067480|EXPERIMENTAL|3-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
62151058|NCT06505356|EXPERIMENTAL|Patients with diagnosed prostate cancer after TRUS prostate biopsy|Prostate Biopsy Procedure (TRUS-guided): Preparation: Explain procedure, obtain consent. Administer antibiotics, discontinue blood thinners. No bowel prep needed. Procedure: Position: Patient lies on side or in lithotomy position. Anesthesia: Apply local anesthetic. Insert ultrasound probe into rectum to visualize prostate. Guide needle into prostate using ultrasound. Take 10-12 tissue samples. Post-procedure: Monitor for complications. Continue antibiotics, drink fluids, avoid strenuous activity. Side Effects: Minor blood in urine, semen, or rectum, resolving in days to weeks. Follow-up: Discuss results within a week. Expected result: confirmation of prostate cancer.
62151059|NCT06505356|EXPERIMENTAL|Patients without a prostate cancer diagnosis after TRUS prostate biopsy|Experimental: Patients without a prostate cancer diagnosis after TRUS biopsy. Prostate Biopsy (TRUS-guided). Preparation: Explain procedure, benefits, and risks; obtain consent. Administer antibiotics; discontinue blood thinners. No bowel prep. Procedure: Patient lies on their side or in lithotomy position. Apply local anesthetic. Insert lubricated ultrasound probe into rectum. Guide thin needle into prostate using ultrasound. Take 10-12 tissue samples. Post-procedure: Monitor for complications. Continue antibiotics, drink fluids, avoid strenuous activity, monitor for complications. Minor blood in urine, semen, or rectum may occur, resolving in days to weeks. Follow-up: Discuss biopsy results within a week. Expected result: Absence of prostate cancer.
62151060|NCT02196259|EXPERIMENTAL|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
62151061|NCT02196259|EXPERIMENTAL|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
62151062|NCT02196259|EXPERIMENTAL|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
62151063|NCT00490906||1|Patients receive Copaxone
62151064|NCT00490906||2|Patients receive interferons
62151065|NCT01299285|EXPERIMENTAL|LY3009104|Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
62151066|NCT05766566||Cohort|"Will be enrolled patients referring to the Department of General Surgery of the IRCCS Saverio de Bellis - Castellana Grotte (BA) Italy, affected by perianal fistulas from Crohn's disease."
62151067|NCT00572715||Observation|"Inclusion criteria - Families of infants (birthweight \>1500g) be asked to participate in the study.~Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded"
62151068|NCT03903978|EXPERIMENTAL|CORE condition|CORE is a 6-week web-based prevention programme whose main objective is to teach coping skills and strategies to cope with stressful everyday situations in order to improve resilience, promote self-efficacy and increase well-being. The intervention consists of 6 interactive modules designed for weekly sessions and organized in 6 dimensions: autonomy, self-acceptance, environmental mastery, purpose in life, positive relationships, and personal growth. Each module includes exercises to practice the proposed skills. The program includes multimedia elements: videos, audios, vignettes, images.
62151069|NCT03903978|ACTIVE_COMPARATOR|Healthy lifestyle|This program will provide information to promote a healthy lifestyle, on issues related to physical and mental health and physical activity, as well as diet and sleep management. The components of psychoeducation are based on the intervention protocol for depression (Castro, et al. 2015) based on low intensity psychological intervention models for mild or moderate depressive symptoms in primary care (Garcia-Herrera et al 2011; NICE, 2009; Nieuwsma et al 2012).
62712286|NCT02286609|EXPERIMENTAL|Hepatic Impairment|Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) will receive one 18 mg dose of deflazacort
62522666|NCT02895815|EXPERIMENTAL|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 microliter (mcL) given by subretinal delivery system.
62712287|NCT02286609|EXPERIMENTAL|Healthy Volunteer|Eight (8) healthy subjects. Subjects will be matched for age \[± 15 years\], BMI \[± 15 %\], and gender \[1:1\] to the subjects in the moderate hepatic impaired cohort; will receive 18 mg dose of deflazacort
62151070|NCT03903978|NO_INTERVENTION|Waiting List Control|Participants assigned to the Waiting List control group will be evaluated and monitored at the start of the study, 4 weeks, 8 weeks and follow-ups at 3 months. After the last follow-up evaluation, they will be given access to CORE training.
62151071|NCT01134159||Xience V|Those who have only received a Xience V stent
62151072|NCT01134159||Taxus Liberte|Those who have received only a Taxus Liberte stent
62151073|NCT01779245|PLACEBO_COMPARATOR|Control|A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
62151074|NCT01779245|EXPERIMENTAL|High-Calcium|A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
62151075|NCT02058992||Ramelteon 8 mg administered orally once daily|
62151076|NCT03730038|EXPERIMENTAL|Pitavastatin treatment|Treatment of pitavastatin 4 mg qd for 12 weeks
62151077|NCT03730038|ACTIVE_COMPARATOR|Life-style modification|
62359115|NCT03067480|EXPERIMENTAL|6-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
62359116|NCT04516655|EXPERIMENTAL|C-R-MTX|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles
62359117|NCT02680392|EXPERIMENTAL|Pulsed and Continuous Radiofrequency|In this group of patients undergoing total knee arthroplasty (allocation of patients is randomized), Pulsed radiofrequency (PRF) is applied to the saphenous nerve of the knee, associated to Continuous Radiofrequency (TRF) applied to the genicular nerves of the knee . A sham catheter is inserted in the mid-tigh to simulate a continuous adductor canal block, and connected to an infusion of normal saline (assessor and patient blinded to the treatment)
62151078|NCT05264714|EXPERIMENTAL|Cluster Headache Subjects|Subjects with cluster headaches will track their headaches for a one-week baseline headache diary. After establishing the baseline headache frequency, severity, and abortive medicine use, subjects will be asked to start their first dose of rimegepant with their next moderate to severe cluster headache.
62151079|NCT01619007||Group 1|
62151080|NCT01619007||Group 2|
62151081|NCT05790759|EXPERIMENTAL|PD patients|See inclusion criteria in the right section. See procedures in the the right section.
62151082|NCT02066636|EXPERIMENTAL|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
62151083|NCT02066636|EXPERIMENTAL|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until 1 year (52 weeks).~Discontinue treatment and at progression, retreatment allowed"
62522667|NCT02895815|EXPERIMENTAL|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system.
62522668|NCT02895815|NO_INTERVENTION|Control Group|Participants will undergo observations without surgery.
62522669|NCT03262506|EXPERIMENTAL|Cognitive Training|
62522670|NCT02824718|EXPERIMENTAL|rh PTH(1-34)|40 µg/day rhPTH(1-34) (teriparatide or FORSTEO® 20 µg twice daily) over 7 to 8 weeks (52±3 days).
62712288|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
62712289|NCT00968409|OTHER|FFNP-PET/CT Imaging|All subjects will receive an injection of F-18-FFNP followed by PET/CT imaging, laboratory testing and safety testing.
62151084|NCT02637089||PD-non-MCI|Patients with Parkinson's disease, no mild cognitive impairment
62151085|NCT02637089||PD-MCI|Patients with Parkinson's disease with mild cognitive impairment
62151086|NCT02637089||MCI (non-PD-MCI)|Patients with mild cognitive impairment, no Parkinson's disease
62151087|NCT02637089||HC (non-PD-non-MCI)|Healthy Controls (age-matched to patients)
62151088|NCT05054751|EXPERIMENTAL|GB491+ Fulvestrant|
62151089|NCT05054751|PLACEBO_COMPARATOR|Placebo+Fulvestrant|
62151090|NCT01958346|SHAM_COMPARATOR|Fiberoptic Intubation Alone|Intubation with fiberoptic scope assistance
62151091|NCT01958346|EXPERIMENTAL|Fiberoptic Intubation with lingual traction|Intubation with fiberoptic scope assistance and lingual traction maneuver provided by a second anesthesiologist
62151092|NCT00986505|EXPERIMENTAL|Lidocaine|Comparison between intravenous lidocaine and saline infusion
62151093|NCT05884567|EXPERIMENTAL|experimental|neck isometric exercises will be administered at for 4 weeks and will be evaluuated at baseline, 2nd and after 4 weeks of interventions
62151094|NCT05884567|ACTIVE_COMPARATOR|control|cervical mobilization will be administered at for 4 weeks and will be evaluuated at baseline, 2nd and after 4 weeks of interventions
62151095|NCT02790645|OTHER|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
62151096|NCT02790645|OTHER|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
62712290|NCT01926860|EXPERIMENTAL|Study group - Prevenar®13 and Hepatitis A vaccines|Study group (group 1) - Prevenar®13 and Hepatitis A: one dose of each vaccine administered on Day 0
62151097|NCT02790645|OTHER|Group 1b. Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
62151098|NCT02790645|OTHER|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months).
62151099|NCT04981431|EXPERIMENTAL|Elinzanetant single dose step 1|Each participant will receive a single oral dose of elinzanetant or placebo.
62151100|NCT04981431|EXPERIMENTAL|Elinzanetant single dose step 2|Each participant will receive a single oral dose of elinzanetant or placebo.
62151101|NCT04981431|EXPERIMENTAL|Elinzanetant single dose step 3|Each participant will receive a single oral dose of elinzanetant or placebo.
62151102|NCT04981431|EXPERIMENTAL|Elinzanetant single dose step 4|Each participant will receive a single oral dose of elinzanetant or placebo.
62151103|NCT04981431|EXPERIMENTAL|Elinzanetant single dose step 6|Each participant will receive a single oral dose of elinzanetant or placebo.
62151104|NCT04981431|EXPERIMENTAL|Elinzanetant multiple dose step 5|Each participant will receive multiple doses of elinzanetant or placebo administered once a day for 7 consecutive days.
62151105|NCT05545800|EXPERIMENTAL|metformin+empagliflozin+insulin glargine|metformin+empagliflozin+insulin glargine
62151106|NCT05545800|EXPERIMENTAL|IDegLira|IDegLira
62522671|NCT02824718|ACTIVE_COMPARATOR|Thiazide + potassium sparing diuretic|hydrochlorothiazide 25 mg/day (ESIDREX®) + amiloride 5 mg/day (MODAMIDE®) + 0.5 µg/day alfacalcidol (ALFACALCIDOL®) over 7 to 8 weeks (52±3 days).
62522672|NCT05799027|EXPERIMENTAL|Raman spectrum analysis|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
62522673|NCT01122290||negative emotion|Children experienced induction of mild negative emotion through a jigsaw with a missing piece (negative emotion group)
62522674|NCT01122290||neutral emotion|Vs. Same task with No missing piece (neutral emotion).
62522675|NCT01687348|EXPERIMENTAL|lidocaine|lidocaine traitment
62522676|NCT04554797|EXPERIMENTAL|Regional Hypothermia group|
62522677|NCT04554797|NO_INTERVENTION|Control group|
62522678|NCT03298295|EXPERIMENTAL|Insertion of Insulin Infusion Catheters|Non-diabetic patients scheduled for abdominoplasty will be inserted continuous subcutaneous insulin infusion (CSII) catheters of two different materials into the part of the abdomen which will be removed during surgery.
62522679|NCT05291832|EXPERIMENTAL|Brain.fm Music|Music with rhythmic amplitude modulation designed to drive neural oscillations.
62522680|NCT05291832|ACTIVE_COMPARATOR|Spectrally-matched Noise|Noise shaped to have the same frequency spectrum (i.e., input level across the cochlea) as the Music condition.
62522681|NCT04878614|ACTIVE_COMPARATOR|Standard Levothyroxine Management|Participants will continue with the same regimen
62522682|NCT04878614|EXPERIMENTAL|Liquid Levothyroxine Management|Participants will be treated with dose equivalent regimen through enteral feeding tube
62522683|NCT04472247||Critical Care Patients|Critical care patients requiring mechanical ventilation via an endotracheal tube, with invasive hemodynamic monitoring via an arterial line, and receiving intravenous sedation by continuous infusion (propofol, midazolam).
62522684|NCT02954926|EXPERIMENTAL|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
62522685|NCT02954926|NO_INTERVENTION|Control|No intervention
62522686|NCT01081314|EXPERIMENTAL|Standard DBT + PTSD Protocol|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team) plus a modified version of Prolonged Exposure therapy for PTSD.
62522687|NCT01081314|ACTIVE_COMPARATOR|Standard DBT|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
62522688|NCT01229644|EXPERIMENTAL|Cohort A|Adult newly diagnosed glioma (both low and high grade) patients, who are able to to take Crenolanib (CP-868,596) for at least 3 days prior to surgical resection.
62522689|NCT01229644|EXPERIMENTAL|Cohort B|Adult patients with recurrent high grade glioma, including patients treated with bevacizumab. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
62522690|NCT01229644|EXPERIMENTAL|Cohort C|Adult patients with biopsy proven low grade glioma who have residual measurable disease. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
62522691|NCT02450708|EXPERIMENTAL|For patients with 1 HLA-compatible donor for URD HCT|For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.
62522692|NCT02450708|EXPERIMENTAL|For patients with >1 HLA-compatible donor for URD HCT|For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.
62522693|NCT02501434|NO_INTERVENTION|Control|Standard of Care
62522694|NCT02501434|EXPERIMENTAL|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
62522695|NCT01300052|EXPERIMENTAL|AN2728 ointment, 2%|AN2728 ointment, 2%
62522696|NCT01300052|PLACEBO_COMPARATOR|Ointment Vehicle|Ointment Vehicle
62522697|NCT02686203|EXPERIMENTAL|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment."
62522698|NCT04082728|ACTIVE_COMPARATOR|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
62522699|NCT04082728|PLACEBO_COMPARATOR|Placebo|Patients in the experimental group will be instructed to take a placebo orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
62522700|NCT02581163||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
62522701|NCT01679587|EXPERIMENTAL|Molidustat, 80 mg|Subjects received a single oral dose of 80 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
62522702|NCT01679587|EXPERIMENTAL|Molidustat, 120 mg|Subjects received a single oral dose of 120 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
62522703|NCT01679587|EXPERIMENTAL|Molidustat, 40 mg|Subjects received a single oral dose of 40 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
62522704|NCT01679587|EXPERIMENTAL|Molidustat, 160 mg|Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
62522705|NCT04099979||Psoriasis patients|Patients who have been diagnosed with Psoriasis
62522706|NCT01302613|OTHER|arm one|RT + Chemo + surgery
62522707|NCT06277141|EXPERIMENTAL|Standard message|standard message reminder to screen for breast cancer.
62522708|NCT06277141|EXPERIMENTAL|Radiology Booking Site Link|Message with an online link to a radiology practice booking site.
62522709|NCT06277141|EXPERIMENTAL|Radiology practice telephone numbers|Message with a list and telephone numbers of radiology practices.
62522710|NCT06277141|NO_INTERVENTION|Control - no message|Participants will not receive any messaging regarding mammography.
62522711|NCT06277141|EXPERIMENTAL|Radiology booking site link and telephone numbers.|Message with a direct online link to a radiology practice booking site and telephone numbers of radiology practices.
62522712|NCT03880760|EXPERIMENTAL|Probiotics capsule|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
62522713|NCT03880760|PLACEBO_COMPARATOR|Placebo capsule|Taking 1 placebo capsule twice a day before meals for six months.
62522714|NCT00301847|EXPERIMENTAL|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62712291|NCT01926860|ACTIVE_COMPARATOR|Pneumococcal conjugate vaccine -Control group - Prevenar®13|PCV -Control group (group 2) - Prevenar®13: one vaccine injection administered on Day 0
62712292|NCT01926860|ACTIVE_COMPARATOR|HepA -Control group - Hepatitis A vaccine|HepA -Control group (group 3) - Hepatitis A vaccine: one vaccine injection administered on Day 0
62522715|NCT05834166|EXPERIMENTAL|Upper back strengthening and Postural correction:|Group A performed exercises for 3 weeks. Participants performed upper back strengthening exercises and postural correction exercises for 10 to 15 minutes per session. All exercises were performed for 3 sessions per week for a period of 4 weeks. The re-assessment will be done at the 6th and 9th visits.
62522716|NCT05834166|NO_INTERVENTION|Control group:|Group B: Group B will receive no intervention. Baseline treatment will include soft tissue mobilization, chest muscle stretch, trunk muscle stretch, and diaphragmatic breathing exercises for all patients
62522717|NCT04498741|EXPERIMENTAL|EDP-938 and tacrolimus interaction (Part 1)|
62522718|NCT04498741|EXPERIMENTAL|EDP-938 and dabigatran interaction (Part 2)|
62522719|NCT04498741|EXPERIMENTAL|EDP-938 and rosuvastatin interaction (Part 3)|
62522720|NCT04498741|EXPERIMENTAL|EDP-938 and midazolam interaction (Part 4)|
62522721|NCT01835379|EXPERIMENTAL|Oasis|Oasis
62522722|NCT01835379|OTHER|Standard|Standard Care
62522723|NCT03021252|EXPERIMENTAL|High intensity IEMT|Inspiratory and expiratory muscle training + standard swallow therapy.
62522724|NCT03021252|SHAM_COMPARATOR|Sham IEMT|Sham inspiratory and expiratory muscle training + standard swallow therapy
62522725|NCT05544565|EXPERIMENTAL|Experimental group: Discontinuation of treatment|For patients randomized in the experimental group, the patient receives 3-day IV therapy and the treatment is interrupted.
62522726|NCT05544565|OTHER|Control group: Usual practice|For patients randomized in the control group, the treatment for acute pyelonephritis is based on the attending clinician's practice and according to the usual practice: 3-day IV therapy followed by a 7-day oral antibiotic therapy.
62522727|NCT01621191|EXPERIMENTAL|60 mg Duloxetine|Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
62522728|NCT06231953||Cancer patients|Patients who have diagnosed as invasive cancers
62522729|NCT06231953||Healthy volunteers|Subjects who have done cancer screening tests
62522730|NCT04254835|EXPERIMENTAL|intervention group|Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will applied to this group once at the beginning of the study.Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.
62151107|NCT05545800|ACTIVE_COMPARATOR|premixed insulin analogues|premixed insulin analogues
62151108|NCT01578629|ACTIVE_COMPARATOR|Healthy Volunteers|Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.
62151109|NCT01578629|ACTIVE_COMPARATOR|Hyperlipidemic|hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.
62522731|NCT04254835|ACTIVE_COMPARATOR|control group|"Varnish containing Fluoride (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein). will applied to this group once at the beginning of the study.~Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks."
62522732|NCT03483207|EXPERIMENTAL|MVT with anticoagulation therapy(heparin &warfarin)|patients with confirmed diagnosis of acute MVT on CT scan but having no signs of peritonitis or established CT signs of gangrene will be treated conservatively with anticoagulation(heparin \&warfarin) while other cases will be for surgical management and not included in the study.
62522733|NCT03483207|EXPERIMENTAL|MVT with failure of anticoagulation therapy(heparin &warfarin)|patients who underwent conservative therapy with anticoagulation (heparin \&warfarin) but showed no improvement .
62522734|NCT05991830||Older adults > 60 years|
62522735|NCT01825122|PLACEBO_COMPARATOR|Placebo|placebo
62522736|NCT01825122|EXPERIMENTAL|Active, nadolol|Active
62522737|NCT00857792|OTHER|Open Label|
62522738|NCT02103270|PLACEBO_COMPARATOR|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
62522739|NCT02103270|ACTIVE_COMPARATOR|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria \[i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC\] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
62522740|NCT02103270|ACTIVE_COMPARATOR|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
62522741|NCT04795908|EXPERIMENTAL|Active rTMS Group|Patients will be seated in a comfortable reclined chair. The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% resting motor threshold (RMT). The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10 minute break in between each session.
62522742|NCT06213467|EXPERIMENTAL|A and B|Each patient in which two implants have already been inserted are exposed, the first implant expose by using traditional methods , the second one expose by using diode laser 940nm .
62151110|NCT05928754|EXPERIMENTAL|Uveitis Patients|"Uveitis Patients: intermediate, posterior or panuveitis noninfectious uveitis with Inflammatory activity requiring treatment with either one or more of the following:~1. Systemic corticosteroids or periocular or intravitreal injections of corticosteroids~2. Immunosuppressants: methotrexate, azathioprine, ciclosporine....~3. Biotherapy: infliximab, adalimumab, tocilizumab"
62151111|NCT05928754|ACTIVE_COMPARATOR|Control Patients|scheduled for cataract or vitreoretinal surgery
62151112|NCT03887611||thyroid nodules|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of thyroid surgery or thyroid biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
62151113|NCT03447912|EXPERIMENTAL|Intervention Condition|Fourteen communities will be assigned to the intervention.
62712293|NCT05290532|OTHER|Individualized exercise training|Exercise training. Individual program training 2 days per week during 4 week, after one week of discharge
62712294|NCT05290532|NO_INTERVENTION|No Intervention: Control|Usual care including rehabilitation when necessary
62712295|NCT01082302|ACTIVE_COMPARATOR|oral intake of green tea beverage|Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
62712296|NCT01082302|EXPERIMENTAL|Polyphenon E 15% ointment|3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
62712297|NCT00366457|OTHER|Gemcitabine, Bevacizumab and Erlotinib|single-arm, no masking
62712298|NCT04615819|EXPERIMENTAL|Arm 1|KTFT
62712299|NCT04615819|EXPERIMENTAL|Arm 2|PN
62151114|NCT03447912|NO_INTERVENTION|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
62151115|NCT00237926|EXPERIMENTAL|1|aerobic exercise
62359118|NCT02680392|ACTIVE_COMPARATOR|Continuous adductor canal block|"Continuous Adductor Canal Block~Continuous adductor canal block is performed in this group of patients, with a catheter infusing ropivacaine 0.2% in the first 48 hours after surgery.~The solutions bags are labelled in order to make assessor and patients, blinded to the treatment (Ropivacaine vs Normal Saline)"
62151116|NCT00237926|EXPERIMENTAL|2|Resistance Training
62151117|NCT05234489|ACTIVE_COMPARATOR|Low Dosage Group|This group will receive the lower dose (75mg) of the investigational product.
62151118|NCT05234489|ACTIVE_COMPARATOR|High Dosage Group|This group will receive the higher dose (150mg) of the investigational product.
62151119|NCT04436549||Patients with varicose veins|Patients with varicose veins and eligible to receive open surgery (stab avulsion of varicose veins) as routinely care.
62151120|NCT01303822|EXPERIMENTAL|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
62359119|NCT05742841|EXPERIMENTAL|EMERALD protocol|1) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED
62359120|NCT02283957|EXPERIMENTAL|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
62359121|NCT02283957|EXPERIMENTAL|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
62359122|NCT02283957|PLACEBO_COMPARATOR|2 mL injection of placebo|Single dose, 2 mL
62359123|NCT02283957|EXPERIMENTAL|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
62359124|NCT02197897|EXPERIMENTAL|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
62359125|NCT00432211|PLACEBO_COMPARATOR|1|Complete Scar Excision
62359126|NCT00432211|PLACEBO_COMPARATOR|2|Staged Excision of scar
62359127|NCT03063853|OTHER|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
62359128|NCT03063853|OTHER|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
62359129|NCT04924010|ACTIVE_COMPARATOR|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy (CBT) is a talking therapy that can help patients manage problems by changing the way they think and behave. It's most commonly used to treat anxiety, depression and chronic pain conditions.
62359130|NCT04924010|PLACEBO_COMPARATOR|Education and Mindfulness|Education and mindfulness therapy refers to lessons on techniques to calm the mind and body - can reduce the negative effects of stress
62359131|NCT02099487|EXPERIMENTAL|Radiation|To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
62359132|NCT03115125|OTHER|Adult patients with severe sepsis|
62359133|NCT00966069|ACTIVE_COMPARATOR|Healthcare worker visit|"Healthcare worker performs home visit when study child has acute respiratory illness to collect a respiratory swab (nasopharyngeal swab).~At the healthcare worker home visit, the HCW will collect the nasopharyngeal swab, and a parent will collect an anterior nasal swab. The HCW swab is to be returned immediately to the laboratory, and the parent collected swab was placed in a post box for return to the laboratory by surface mail."
62359134|NCT00966069|EXPERIMENTAL|Parent collection|Home collection of respiratory swab (anterior nose) and mailed return when study subject has an acute respiratory illness.
62359135|NCT03725293|ACTIVE_COMPARATOR|Angiodynamics BioFlo Midline Catheter|Placement of clinically indicated Angiodynamics BioFlo midline catheter.
62359136|NCT03725293|ACTIVE_COMPARATOR|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
62359137|NCT04447924|PLACEBO_COMPARATOR|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
62359138|NCT04447924|EXPERIMENTAL|Bif195 arm|Active trial product with minimum 15 billion CFU daily dose
62359139|NCT00802867|EXPERIMENTAL|1|Subjects in Study 494-01 and Study 494-03 who had received 4 doses of Pentacel™ vaccine.
62359140|NCT02650895|EXPERIMENTAL|Efprezimod alfa|Single dose of efprezimod alfa is administrated as intravenous infusion in one hour. There are 5 dose cohorts, 10mg, 30mg, 60mg, 120mg, 240mg. Each cohort has 6 subjects in efprezimod alfa and 2 subject in placebo.
62359141|NCT02650895|PLACEBO_COMPARATOR|Saline|Single dose of 100 ml normal saline is administrated as intravenous infusion in one hour.
62359142|NCT03086538|EXPERIMENTAL|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
62359143|NCT04298931||Patients undergoing open abdominal surgery|
62359144|NCT06067308|EXPERIMENTAL|to assess the sensitivity and accuracy of YEARS score in the diagnosis of PE.|50 patients with suspected PE were evaluated in Chest Department at faculty of medicine, Kasr Al-Ainy Hospital. At the beginning, clinical evaluation using YEARS score was done; subsequently for definitive diagnosis, computed tomography pulmonary angiography was performed in all cases as a reference method.
62359145|NCT01999023|NO_INTERVENTION|Observational group|No intervention
62359146|NCT01999023|EXPERIMENTAL|Dietary supplement|Low protein formula formula (28.5 g) twice a day
62522743|NCT02205502|EXPERIMENTAL|Lidocaine|"Proper amount of lidocaine will be injected lacerated wound.~* dosage form: fluid~* dosage: not exceeding 1mg/kg~* frequency: once~* duration: n/a"
62522744|NCT02205502|PLACEBO_COMPARATOR|Normal saline|Normal saline will be used as a placebo for lidocaine
62522745|NCT01692314|EXPERIMENTAL|Obese adolescents is being compared to control ones|Patients underwent to resistance training, three times a week, during three months.
62522746|NCT01467206|EXPERIMENTAL|Long term follow up program|
62522747|NCT01467206|ACTIVE_COMPARATOR|Standard care|
62522748|NCT01007747|EXPERIMENTAL|Geranium oil|
62522749|NCT01594450|EXPERIMENTAL|biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
62522750|NCT01594450|ACTIVE_COMPARATOR|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization.
62522751|NCT06041841|EXPERIMENTAL|POMC/PCSK1/LEPR cohort|LB54640 once daily by oral administration
62151121|NCT05363397|EXPERIMENTAL|TBO-309 30mg (25% of target dose)|"Following randomisation, 30mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~* 20% of the dose will be administered as a bolus over approximately one minute; then~* the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
62522752|NCT05958706||patients with manifest heart failure|patients with manifest heart failure and T2DM or patients with manifest heart failure without T2DM
62522753|NCT05958706||patients with terminal heart failure|patients with terminal heart failure and T2DM or patients with terminal heart failure without T2DM
62522754|NCT05958706||patients after heart transplantation|patients after heart transplantation and T2DM or patients after heart transplantation without T2DM
62522755|NCT04706923|EXPERIMENTAL|BCV 0.2mg/kg BIW|BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours
62522756|NCT04706923|EXPERIMENTAL|BCV 0.3mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours
62522757|NCT04706923|EXPERIMENTAL|BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours
62151122|NCT05363397|EXPERIMENTAL|TBO-309 60mg (50% of target dose)|"Following randomisation, 60mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~* 20% of the dose will be administered as a bolus over approximately one minute; then~* the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
62151123|NCT05363397|EXPERIMENTAL|TBO-309 120mg (100% of target dose)|"Following randomisation, 120mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~* 20% of the dose will be administered as a bolus over approximately one minute; then~* the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
62522758|NCT04706923|EXPERIMENTAL|BCV 0.4 mg/kg QW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours
62522759|NCT00669071|ACTIVE_COMPARATOR|IPL / Tri-Luma® Cream|
62522760|NCT00669071|ACTIVE_COMPARATOR|IPL/Cetaphil® Moisturizing Cream as Inactive Control|
62522761|NCT04310839||outpatient left laparoscopic colectomy|Left laparoscopic laparoscopic colectomy patient managed on an outpatient basis
62522762|NCT04188314|EXPERIMENTAL|Desflurane Interventional Group|"The intervention group will receive desflurane for maintenance of anaesthesia. Standard protocols for induction and maintenance of anaesthesia will be followed, as discussed with Prof. F. Puehringer, an international expert in the field of desflurane use. A detailed leaflet describing the protocol has been developed, which will be handed to the treating anaesthetist on the day of surgery.~After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the desflurane vaporiser is opened to 12%. This is maintained until 1MAC is reached. The fresh gas flow will then be turned down to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand."
62522763|NCT04188314|ACTIVE_COMPARATOR|Isoflurane Control Group|The control group will receive Isoflurane for maintenance of anesthesia. After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the Isoflurane vaporiser is opened and adjusted to attain 1MAC. Once 1MAC is attained, the fresh gas flow will be reduced to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser will be adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand.
62522764|NCT01423136||Routine postop care + Holter Monitoring|With sham remote ECG ST Monitoring
62522765|NCT01423136||Routine postop care + Holter + remote ECG monitoring|
62522766|NCT01470612|EXPERIMENTAL|CP-690,550 5 mg BID|5 mg BID
62522767|NCT01470612|EXPERIMENTAL|CP-690,550 10 mg BID|10 mg BID
62522768|NCT01224938||Asthma patients|Asthmatics of all classes of severity will be included.
62712300|NCT00672997|EXPERIMENTAL|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
62522769|NCT01224938||Healthy control population|A healthy control population will be included to compare with the asthmatics.
62522770|NCT03985787|EXPERIMENTAL|All Participants|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
62522771|NCT01859806|ACTIVE_COMPARATOR|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
62151124|NCT05363397|EXPERIMENTAL|TBO-309 180mg (150% of target dose)|"Following randomisation, 180mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~* 20% of the dose will be administered as a bolus over approximately one minute; then~* the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
62151125|NCT02964793|EXPERIMENTAL|Intervention group|The intervention consists in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines
62151126|NCT02964793|NO_INTERVENTION|Control group|In the control arm women will benefit from the current routine screening practice for growth failure. The management of pregnancies will remain unchanged. Consultants will be free to monitor growth according to their usual practice. In each maternity unit in the control arm, an information session will be organized on site but its content will be limited to the rational, the objectives of the trial and the study logistics.
62151127|NCT00721734|EXPERIMENTAL|Carfilzomib|"Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.~If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles."
62151128|NCT04476524||Study Arm|Patients who present with AF as the primary diagnosis to the ER will have their chart reviewed
62151129|NCT04476524||Historical Cohort|Historical control arm will be selected from chart review of emergency department prior to the commencement of this study after propensity matching with age and sex.
62151130|NCT00329914|PLACEBO_COMPARATOR|Placebo|
62151131|NCT00329914|ACTIVE_COMPARATOR|Progesterone|
62151132|NCT06418919|EXPERIMENTAL|RFA treatment|
62359147|NCT00469209|ACTIVE_COMPARATOR|No Bortezomib|Arm 1: Melphalan 100 mg/m\^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
62712301|NCT00672997|ACTIVE_COMPARATOR|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
62151133|NCT06073470||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
62151134|NCT06073470||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
62151135|NCT05719909|EXPERIMENTAL|Cognitive Training|8 sessions of web-based cognitive training
62151136|NCT05719909|SHAM_COMPARATOR|Sham Training|8 sessions of web-based sham training
62151137|NCT01366976|PLACEBO_COMPARATOR|Placebo|
62151138|NCT01366976|ACTIVE_COMPARATOR|Acetaminophen|Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period
62151139|NCT04235894||Patients undergoing GI endoscopy at Osijek University Hospital|Observational study. A total of 130 consecutive patients undergoing gastrointestinal endoscopy were included. The anesthesia was provided with propofol, starting with 0,5 mg/kg, and titrated until a patient was unresponsive to painful stimuli and maintaining spontaneous breathing. The blood pressure, pulse and Bispectral index values were measured in 6 defined points. On the emergence from anesthesia, the patient's facial expression was rated numerically by the investigator.
62151140|NCT02232997|ACTIVE_COMPARATOR|Standard Hydration|Standard long-term hydration, i.e. hydrated with normal saline 12 hours before and 12 hours after coronary intervention at a rate of 1 ml/kg/h
62151141|NCT02232997|ACTIVE_COMPARATOR|Simplified Hydration|Rapid short-term hydration, i.e. hydrated with normal saline from 1 hour before to 4 hours after coronary intervention at a rate of 3 ml/kg/h
62359148|NCT00469209|ACTIVE_COMPARATOR|Bortezomib 1.0 mg/m^2|Arm 2: Bortezomib (Level 1) 1.0 mg/m\^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m\^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
62359149|NCT00469209|ACTIVE_COMPARATOR|Bortezomib 1.5 mg/m^2|Arm 3: Bortezomib (Level 2) 1.5 mg/m\^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
62359150|NCT01209975||untreated glaucoma patients|We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.
62359151|NCT00683813|NO_INTERVENTION|UC|usual care
62359152|NCT00683813|EXPERIMENTAL|vCRP|
62359153|NCT04636320|EXPERIMENTAL|Patient group COVID-19|120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization
62712302|NCT01597817|ACTIVE_COMPARATOR|chitosan coated textile|Chitosan coated cotton long sleeved t-shirts and pants.
62151142|NCT02486939|EXPERIMENTAL|CHS-0214|CHS-0214 50 mg weekly
62151143|NCT04267952|EXPERIMENTAL|first group|Hand hygiene intervention program prepared by using planned behavior theory will be applied to the students in this group.
62151144|NCT04267952|ACTIVE_COMPARATOR|second group|Students in this group will be given classic hand hygiene training
62151145|NCT01896609|EXPERIMENTAL|Arm 1 (Standard therpy)|"Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:~* Reiferon Retard® 160 µg /week subcutaneous injection.~* Ribavirin in a dose of 13 mg/kg/day orally"
62151146|NCT01896609|EXPERIMENTAL|Arm 2 ( Xerovirinc)|"Arm 2 : Subjects randomized to this arm will be receiving the following medications for 48 weeks;~* Reiferon Retard® 160 µg /week subcutaneous injection~* Ribavirin in a dose of 13 mg/kg/day orally~* Xerovirinc® 500mg twice daily orally."
62359154|NCT04636320|ACTIVE_COMPARATOR|Healthy volunteer group|120 healthy volunteers. Age- and sex-matched controls
62359155|NCT04745078|ACTIVE_COMPARATOR|Carboxy30|carboxy30
62359156|NCT04745078|ACTIVE_COMPARATOR|Carboxy60|carboxy60
62359157|NCT03194620|PLACEBO_COMPARATOR|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
62359158|NCT03194620|EXPERIMENTAL|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
62712303|NCT01597817|PLACEBO_COMPARATOR|chitosan free cotton textile|Chitosan free cotton long sleeved t-shirts and pants.
62712304|NCT01603654|EXPERIMENTAL|sodium picosulphate/magnesium citrate|
62712305|NCT01603654|ACTIVE_COMPARATOR|low-volume PEG -ascorbic acid|
62151147|NCT01896609|EXPERIMENTAL|Arm 3 ( Bon one )|"Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:~* Bon-One ® 0.5 µg daily orally~* Reiferon Retard® 160 µg /week subcutaneous injection~* Ribavirin in a dose of 13 mg/kg/day orally~* Xerovirinc® 500mg twice daily orally."
62151148|NCT03949959|EXPERIMENTAL|Physiotherapy (PRPt)|The 6-week exercise program (2 sessions in each of weeks 1-4 and 1 session in each of weeks 5 and 6) will comprise specific individually-tailored exercises to improve the movement and control of the neck and shoulder girdle. The exercises will be of a low load nature and designed to be pain free. At the same time, the physiotherapist will provide pragmatic multimodal physiotherapy to facilitate ability to pursue exercises and guide the participant's return to normal activities. This specific treatment program has been described in detail (Jull et al., 2008; Ritchie et al., 2015b) and focuses on activating and improving the coordination and endurance capacity of the neck flexor, extensor and scapular muscles in specific exercises and functional tasks. Participants will also perform the exercises at home, once per day. Written and illustrated exercise instructions will be provided. The exercise program follows Australian guidelines for the management of chronic whiplash (TRACsa, 2008).
62151149|NCT03949959|NO_INTERVENTION|Wait and See (PRPu)|"Individuals randomized to usual care will be provided with an advice booklet Whiplash Injury Recovery: A Self Help Guide (MAIC, Qld, 2nd edition). It provides information about whiplash; assurance about prognosis; advice to stay active and resume working as well as information on correct posture; pictorial descriptions of specific exercises for the neck and upper limbs and information on resuming functional daily activities. The booklet is based on the recommendations of the current Australian Guidelines for Whiplash Management (SIRA, 2014).~Usual care involves a 'wait and see' approach (in combination with provision of home exercises) and will include weekly review appointments with a medical doctor, primarily to review the information in the booklet and progress the 'general' exercises and activity recommendations within the booklet. No hands-on physiotherapy will be provided. Education regarding PRP and associated healing cycles will also be provided during this time period."
62151150|NCT06179485||Comparator: Ketamine Group|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation.
62359159|NCT03194620|EXPERIMENTAL|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
62359160|NCT03194620|EXPERIMENTAL|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin-3-O-gallate (EGCG)
62359161|NCT03194620|EXPERIMENTAL|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin-3-O-gallate (ECG)
62359162|NCT03194620|ACTIVE_COMPARATOR|(-)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin (EC)
62359163|NCT03194620|EXPERIMENTAL|(-)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin (EGC)
62359164|NCT03194620|EXPERIMENTAL|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
62359165|NCT05552807|EXPERIMENTAL|Cohort 1 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who had failed previous platinum-based therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed consent, death, or loss of visit
62359166|NCT05552807|EXPERIMENTAL|Cohort 2-1 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who had failed previous platinum-based and immune checkpoint inhibitor therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
62359167|NCT05552807|EXPERIMENTAL|Cohort 2-2 SCT200+paclitaxel/docetaxel|SCT200+paclitaxel/docetaxel was given to patients who had failed previous platinum-based and immune checkpoint inhibitor therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; paclitaxel was 80mg/m\^2/QW by intravenous infusion; docetaxel was 75mg/m\^2/Q3W. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
62359168|NCT05552807|EXPERIMENTAL|Cohort 3 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who have not received prior systemic chemotherapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
62359169|NCT04499846||Diabetic patients following education|Patients will followed an educational intervention about physiopathology of diabetes and mechanisms of action of statins. A questionnaire will allow to measure compliance to the treatment.
62359170|NCT04914767|EXPERIMENTAL|Nigella|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
62359171|NCT04914767|PLACEBO_COMPARATOR|Placebo Group|"The patient will also receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
62359172|NCT02858284|EXPERIMENTAL|TUG Device|1 time external application - device powered on
62359173|NCT02858284|SHAM_COMPARATOR|Sham|1 time external application - device powered off
62359174|NCT01742091|EXPERIMENTAL|180 mg LY2541546 SC Q4W|180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
62359175|NCT01742091|EXPERIMENTAL|270 mg LY2541546 SC Q2W|270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks.
62151151|NCT06179485||Comparator: Etomidate Group|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation.
62151152|NCT02913300|ACTIVE_COMPARATOR|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
62151153|NCT02913300|ACTIVE_COMPARATOR|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
62151154|NCT01363128|EXPERIMENTAL|Treatment (hyper-CVAD, ofatumumab)|"COURSES 1, 3, 5, 7: Patients receive hyper-CVAD comprising cyclophosphamide IV over 3 hours every 12 hours on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 15 minutes on days 4 and 11; and dexamethasone IV over 30 minutes or PO QD on days 1-4 and 11-14. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 11 of courses 1 and 3.~COURSES 2, 4, 6, 8: Patients receive high-dose methotrexate IV over 2 hours and then over 22 hours on day 1 and cytarabine IV over 2 hours every 12 hours on days 2-3. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 8 of courses 2 and 4.~Treatment repeats every 21-28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may receive maintenance therapy for an additional 30 months."
62151155|NCT03811665|EXPERIMENTAL|Stereotactic body radiation therapy (SBRT)|
62151156|NCT03811665|ACTIVE_COMPARATOR|Radiofrequency Ablation (RFA)|
62151157|NCT00525616|EXPERIMENTAL|Rituximab|Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .
62151158|NCT01513005|EXPERIMENTAL|Laparoscopic Sleeve Gastrectomy|
62151159|NCT04093115|EXPERIMENTAL|CX1106|CX1106 740 mg/m2 as a 24-hour continuous infusion for 5 days every 3 weeks (3 weeks/cycle, 4-6 cycles)
62151160|NCT04327089|EXPERIMENTAL|Part 1- Cohort 1|Single oral dose of 400 mg Setanaxib administered as 1x400 mg tablet in fasting conditions.
62151161|NCT04327089|EXPERIMENTAL|Part 1- Cohort 2|Single oral dose of 800 mg Setanaxib administered as 2x400 mg tablet in fasting conditions.
62151162|NCT04327089|EXPERIMENTAL|Part 1- Cohort 3|Single oral dose of 1200 mg Setanaxib administered as 3x400 mg tablet in fasting conditions.
62151163|NCT04327089|EXPERIMENTAL|Part 1- Cohort 4|Single oral dose of 1600 mg Setanaxib administered as 4x400 mg tablet in fasting conditions.
62151164|NCT04327089|EXPERIMENTAL|Part 2- Cohort 5|Repeated 10-Day dosing of 1200mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 1x400mg tablet in the evening in fedding conditions.
62359176|NCT01742091|EXPERIMENTAL|270 mg LY2541546 SC Q4W|270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
62151165|NCT04327089|EXPERIMENTAL|Part 2- Cohort 6|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions.
62151166|NCT04327089|EXPERIMENTAL|Cohort 7|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions. Additionnaly, this cohort includes the evaluation of potential Drug-Drug interactions with CYPs and transporters.
62151167|NCT06432036|EXPERIMENTAL|Treatment (radioembolization, TheraSphere)|Patients undergo radioembolization with TheraSphere given intra-arterially. Patients undergo angiogram during screening, SPECT scan on study and CT scan and blood sample collection throughout the study.
62151168|NCT05859659||Molecular pathology of glioma positive|
62151169|NCT05859659||Molecular pathology of glioma negative|
62151170|NCT03037021||SCD Adult Patients|Focus group or individual interview and survey
62151171|NCT03037021||SCD Adolescent Patients|Focus group or individual interview and survey
62151172|NCT03037021||SCD Healthcare Providers|Focus group or individual interview and survey
62151173|NCT03037021||Parents of SCD Adolescents|Focus group or individual interview and survey
62151174|NCT02706483|EXPERIMENTAL|Plecanatide|Plecanatide 6.0 mg tablets
62151175|NCT00748891|EXPERIMENTAL|1|Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression
62151176|NCT03784898|OTHER|Participants Diagnosed With ITP|Participants with RMS who developed ITP after Lemtrada treatment were included in this study and provided blood samples for future genetic testing and biomarker analysis.
62151177|NCT00516399|EXPERIMENTAL|I:|povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
62151178|NCT00516399|ACTIVE_COMPARATOR|II|natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.
62151179|NCT00696241|EXPERIMENTAL|Azilsartan Medoxomil 20 mg QD|
62151180|NCT00696241|EXPERIMENTAL|Azilsartan Medoxomil 40 mg QD|
62359177|NCT01742091|EXPERIMENTAL|540 mg LY2541546 IV Q4W|540 mg administered intravenous (IV) once every 4 weeks (Q4W) for 8 weeks. Placebo administered IV at Weeks 2 and 6 to maintain the blind.
62151181|NCT00696241|EXPERIMENTAL|Azilsartan Medoxomil 80 mg QD|
62151182|NCT00696241|ACTIVE_COMPARATOR|Olmesartan 40 mg QD|
62151183|NCT00696241|PLACEBO_COMPARATOR|Placebo QD|
62359178|NCT01742091|EXPERIMENTAL|750 mg LY2541546 IV Q2W|750 mg administered (IV) once every 2 weeks (Q2W) for 8 weeks.
62359179|NCT01742091|PLACEBO_COMPARATOR|Placebo Q2W|Placebo administered IV or SC once every 2 weeks for 8 weeks.
62359180|NCT00389441|EXPERIMENTAL|A|
62359181|NCT00701103|EXPERIMENTAL|Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
62359182|NCT00701103|EXPERIMENTAL|Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
62359183|NCT00701103|EXPERIMENTAL|Dalotuzumab 5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
62359184|NCT00701103|EXPERIMENTAL|Dalotuzumab 10 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
62359185|NCT00701103|EXPERIMENTAL|Dalotuzumab 10 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
62359186|NCT00701103|EXPERIMENTAL|Dalotuzumab 15 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
62359187|NCT00701103|EXPERIMENTAL|Dalotuzumab 15 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
62359188|NCT00701103|EXPERIMENTAL|Dalotuzumab 20 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
62151184|NCT01629420|EXPERIMENTAL|Drug:KLH-2109 lower dose|
62359189|NCT00701103|EXPERIMENTAL|Dalotuzumab 20 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
62359190|NCT00701103|EXPERIMENTAL|Dalotuzumab 20 mg/kg Q2W (20 mg/mL)|Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
62359191|NCT00701103|EXPERIMENTAL|Dalotuzumab 30 mg/kg Q3W (20 mg/mL)|Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).
62359192|NCT01937481|EXPERIMENTAL|Nutrition and Physical Activity|The Food Friends programs
62359193|NCT01937481|NO_INTERVENTION|Control|Control group
62359194|NCT01729663|ACTIVE_COMPARATOR|Interferon alpha 2 b|Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks and then 5 MU (3t/w) for 23 months.
62359195|NCT01729663|EXPERIMENTAL|CSF470 vaccine, BCG, Molgramostim|"CSF470 vaccine, BCG, Molgramostim~CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.~Each vaccine consist of a mixture of 17,6.106 melanoma cells , from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rhGM-CSF (Molgramostim 400 µg, fractionated in four days doses) will be used."
62359196|NCT04402619|EXPERIMENTAL|Online CBT|Ten modules with minimum therapist guidance
62359197|NCT02219217|EXPERIMENTAL|No arms|All participants will be administered Tivicay® (dolutegravir 50 mg once daily) for 10 days, then will undergo a nine-day wash out period and then take Stribild® (245 mg of tenofovir disoproxil, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.
62359198|NCT02693327||Mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
62151185|NCT01629420|EXPERIMENTAL|Drug:KLH-2109 higher dose|
62151186|NCT01583959|ACTIVE_COMPARATOR|Folic acid 30 mg per week|Patients will be administered 5 mg folic acid for 6 days a week, no tablet on the day they take methotrexate (5 mg x 6 days = 30 mg per week)
62151187|NCT01583959|ACTIVE_COMPARATOR|Folic acid 10 mg|Patients will be given folic acid 5 mg for two days per week and placebo tablets for four days a week, no tablet on the day they take methotrexate (Folic acid 5mg x 2 days = 10mg per week)
62359199|NCT02693327||Non-mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
62359200|NCT02343419|EXPERIMENTAL|Bronchial challenge test|Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
62359201|NCT00750178|EXPERIMENTAL|A|MK0683
62359202|NCT03395223|EXPERIMENTAL|ProvayBlue (Methylene Blue) arm|"Methylene Blue 0.5% will be administered.~1 mg/kg will be administered intravenously over 5-30 minutes. If methemoglobin level remains above 30% or if clinical symptoms persist, give a repeat dose of up to 1 mg/kg one hour after the first dose."
62359203|NCT01484561|ACTIVE_COMPARATOR|Sequence 1|
62359204|NCT01484561|PLACEBO_COMPARATOR|Sequence 2|
62359205|NCT03625089|ACTIVE_COMPARATOR|Group 1 - FRS arm|Both group will participate in the nurse-led programme on CV risk screening and carotid ultrasound for carotid plaque assessment. Subjects in group 1 will initiate Atorvastatin treatment (20mg daily per oral) if their Framingham Risk Score \>10%
62359206|NCT03625089|EXPERIMENTAL|Group 2 USG arm|Subjects in group 2 will initiate Atorvastatin treatment (20mg daily per oral) if they had carotid plaque upon carotid ultrasound findings..
62359207|NCT02988492|OTHER|MRI perfusion imaging|MRI screening will be performed as per standard-of-care by the MRI technologist staff. Imaging will be performed with 1.5 T or 3 T systems (Magnetom Vision; Siemens, Erlangen, Germany) using a multisection, single shot, spin echo, echo planer imaging sequence. Diffusion gradients will be applied in each of the x, y and z directions with three b values (0, 500 and 1000 s/mm2). Imaging parameters include a TE of 94 ms, field of view of 23 cm, matrix of 128 and section thickness of 5.5 mm for the 1.5 T system and a TE of 83 ms, field of view of 23 cm, matrix of 128 and section thickness of 3 mm for the 3 T system. Conventional spin echo imaging also will be performed at each examination under T1 and T2 weighted conditions, with a fluid attenuated inversion recovery sequence and Time-of-flight MRA of the Circle-of-Willis.
62359208|NCT02518776|OTHER|Neuropsychological tests|
62359209|NCT04694716||Covid-19 group (Group I)|Patients diagnosed with Covid-19 will be enrolled in this group.
62359210|NCT04694716||Control group (Group II)|Healthy individuals will be enrolled in this group.
62359211|NCT05512312|ACTIVE_COMPARATOR|Test Group|Eight patients indicated for ECL were treated using digitally assisted crown lengthening utilizing 3D printed surgical stents.
62359212|NCT05512312|ACTIVE_COMPARATOR|Control Group|Eight patients indicated for ECL were managed by conventional crown lengthening.
62359213|NCT02798562|EXPERIMENTAL|Native and dynamic contrast-enhanced CT|Patients will undergo a native high-resolution and a dynamic contrast-enhanced CT, both sides respectively.
62359214|NCT05820009|EXPERIMENTAL|GORE® VIABIL® Biliary Endoprosthesis|GORE® VIABIL® Biliary Endoprosthesis
62359215|NCT01660776||DLBCL (diffuse large B-cell lymphoma)|DLBCL (diffuse large B-cell lymphoma)
62359216|NCT01660776||Hodgkin's lymphoma|Hodgkin's lymphoma
62359217|NCT01660776||metastatic breast cancer|metastatic breast cancer or with lymph node involvement
62359218|NCT01660776||immune thrombocytopenia (ITP)|immune thrombocytopenia (ITP)
62359219|NCT01660776||healthy volunteers|healthy volunteers
62359220|NCT01660776||non-small cell lung cancer|non-small cell lung cancer
62359221|NCT00446758|EXPERIMENTAL|Zinc|zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children \< 12 mo)
62359222|NCT00446758|PLACEBO_COMPARATOR|Placebo|
62359223|NCT04390789|EXPERIMENTAL|single visit retreatment|nonsurgical root canal retreatment will be carried out in single visit.
62359224|NCT04390789|ACTIVE_COMPARATOR|multi visit retreatment|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
62359225|NCT05768542|ACTIVE_COMPARATOR|Takotsubo Control|Patients with Takotsubo receiving betablockade
62359226|NCT05768542|PLACEBO_COMPARATOR|Takotsubo Intervention|Patients with Takotsubo receiving placebo
62359227|NCT05768542|NO_INTERVENTION|Control|Control subjects
62522772|NCT01859806|ACTIVE_COMPARATOR|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
62522773|NCT00283491|ACTIVE_COMPARATOR|A|
62522774|NCT00283491|PLACEBO_COMPARATOR|B|
62522775|NCT05723068||Patients with chronic hepatitis D|
62522776|NCT01006941|EXPERIMENTAL|Trichuris suis ova|
62522777|NCT02814435||Patients|Patients with inherited retinal degeneration will answer two questionnaires and undergo a computerised contrast sensitivity function test.
62522778|NCT02814435||Normal controls|Normal controls recruited by advertising will answer two questionnaires and undergo a computerised test that assess contrast sensitivity function.
62522779|NCT06163599|EXPERIMENTAL|Telenovela Arm|The UP telenovela (which is the experimental treatment arm) constitutes of nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the UP, and completing worksheets relating to the weekly therapy sessions.
62712306|NCT06102395|EXPERIMENTAL|Pembrolizumab combined with standard chemotherapy|Patients receive pembrolizumab 200mg, IV, on day1 of Q3W; plus platinum (cisplatin 75 mg/m\^2, IV, day 1 of Q3W or carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W or nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W); plus other chemotherapy（nab-paclitaxel 260 mg/m\^2, IV, day 1 of Q3W or docetaxel 75 mg/m\^2, IV, day 1 of Q3W or liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W or fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W）; total 2 cycle
62712307|NCT06102395|ACTIVE_COMPARATOR|Standard chemotherapy|Patients receive platinum (cisplatin 75 mg/m\^2, IV, day 1 of Q3W or carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W or nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W); plus other chemotherapy（nab-paclitaxel 260 mg/m\^2, IV, day 1 of Q3W or docetaxel 75 mg/m\^2, IV, day 1 of Q3W or liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W or fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W）; total 2 cycle
62712308|NCT02916485|EXPERIMENTAL|Bioresorbable scaffold|Percutaneous coronary intervention (PCI) with a sirolimus-eluting resorbable coronary magnesium scaffold
62712309|NCT02205424||Ischaemic stroke patients|Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).
62712310|NCT02205424||Healthy control participants|People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.
62712311|NCT00633126|EXPERIMENTAL|A|ceftaroline
62712312|NCT04242069|EXPERIMENTAL|Intervention|Healthy for my Baby Intervention
62712313|NCT04242069|OTHER|Control|Usual care
62151188|NCT01382706|EXPERIMENTAL|Treatment|Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.
62151189|NCT00391066|ACTIVE_COMPARATOR|1|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
62151190|NCT00391066|EXPERIMENTAL|2|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
62522780|NCT06259136|EXPERIMENTAL|Pal-Cycles Intervention|The patients in the intervention arm will be exposed to the Pal-Cycles intervention.
62522781|NCT06259136|NO_INTERVENTION|Care as usual|The patients included in this intervention will be given care as usual.
62522782|NCT01805830|EXPERIMENTAL|MP513 group|
62522783|NCT01805830|PLACEBO_COMPARATOR|Placebo group|
62151191|NCT04853654|EXPERIMENTAL|Selective training|selective training on lower extremity for 3 days/week
62151192|NCT04853654|EXPERIMENTAL|Downhill walking|downhill walking training on the treadmill for 2 days/week
62151193|NCT04853654|EXPERIMENTAL|Uphill walking|uphill walking training on the treadmill for 2 days/week
62151194|NCT04725266|EXPERIMENTAL|family-based intervention plus routine care|This group of participants including drug abusers and their families will be receiving family-based intervention which is a well-designed intervention with group sessions and routine care provided by professional social workers in local social service center.
62151195|NCT04725266|ACTIVE_COMPARATOR|routine care|The group of participants will receive routine care which is widely used in social service providers and mainly includes individual counselling service for drug abusers.
62151196|NCT04323800|EXPERIMENTAL|High titer anti-SARS-CoV-2 plasma|Participants with High titer anti-SARS-CoV-2 plasma.
62522784|NCT01948570||not in therapy (GROUP 1)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0).
62522785|NCT01948570||in therapy (GROUP 2)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study
62522786|NCT04815421|EXPERIMENTAL|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The therapy duration was 6 days.
62522787|NCT04815421|EXPERIMENTAL|the meridian group|Patients in the meridian group were treated with dredging the same side Hand yang meridian techniques
62151197|NCT04323800|ACTIVE_COMPARATOR|SARS-CoV-2 non-immune plasma|Participants with SARS-CoV-2 non-immune plasma.
62151198|NCT01892007|EXPERIMENTAL|Cogmed RM (adaptive)|Online training intervention: An adaptive version of Cogmed RM working memory training. Task difficulty (number of to-be-remembered items) increases based on individual performance, in order to maintain average daily performance levels of approximately 60% of trials correct. Participants complete 35-45 minutes of active training per day, 5 days a week for 5 weeks.
62151199|NCT01892007|PLACEBO_COMPARATOR|Cogmed RM (non-adaptive, placebo)|Online training intervention: A non-adaptive placebo version of Cogmed RM working memory training. Tasks are fixed at a low-difficulty practice level (three to-be-remembered items) and do not increase in difficulty over the course of the intervention. Participants complete 35-45 minutes of active placebo training per day, 5 days a week for 5 weeks.
62151200|NCT03433885||Progressors|Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
62151201|NCT03433885||Nonprogressor|Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
62151202|NCT04301999|ACTIVE_COMPARATOR|PDT group|Patients in PDT group underwnt PDT
62151203|NCT04301999|EXPERIMENTAL|RFA group|Patients in RFA group underwent RFA
62151204|NCT03674476|EXPERIMENTAL|Mild Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
62151205|NCT03674476|EXPERIMENTAL|Moderate Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
62151206|NCT03674476|EXPERIMENTAL|Severe Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
62151207|NCT03674476|OTHER|Normal|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
62151208|NCT06080087|EXPERIMENTAL|Intervention|Intervention group will receive access to the I-TEAM
62151209|NCT06080087|NO_INTERVENTION|Waitlist control|Waitlist control group will not receive access to the I-TEAM until the Intervention group has completed the 8-week intervention.
62151210|NCT06399939|EXPERIMENTAL|Nap|Naps are promoted
62151211|NCT06399939|EXPERIMENTAL|Wake (non-nap)|Wake is promoted
62151212|NCT04261309||Elderly with back pain in primary healthcare|Consecutive women and men 55 years of age or older who seek primary care (GP, physiotherapist or chiropractor) with a new episode of back pain (preceded by 6 months without visiting a primary care provider for similar complaints)
62151213|NCT01246635|EXPERIMENTAL|TRUFIT CB with accelerated rehab.|
62151214|NCT01246635|EXPERIMENTAL|TRUFIT CB with standard rehab.|
62151215|NCT01246635|ACTIVE_COMPARATOR|• Microfracture with rehabilitation|
62151216|NCT00978159|ACTIVE_COMPARATOR|esomeprazole|esomeprazole 20 mg
62151217|NCT00978159|ACTIVE_COMPARATOR|Famotidine|famotidine 40 mg
62151218|NCT00919698||Sedated mechanically ventilated patients|
62151219|NCT05798598|ACTIVE_COMPARATOR|GIP - Face-to-face intervention group|Participants in the scientific writing face-to-face training course.
62151220|NCT05798598|ACTIVE_COMPARATOR|GIO: Online intervention group|Participants in the scientific writing online training course.
62151221|NCT05798598|NO_INTERVENTION|GIC: Control intervention group|Participants in other face-to-face training courses not related to scientific writing.
62151222|NCT06356883|EXPERIMENTAL|IA Carboplatin + IA Caelyx|Participants will be treated with IA carboplatin + IA liposomal doxorubicin on each cycle (4-6 weeks), for up to 12 cycles.
62151223|NCT06356883|EXPERIMENTAL|IA Carboplatin + IA Etoposide Phosphate|Participants will be treated with IA carboplatin + IA etoposide phosphate on each cycle (4-6 weeks), for up to 12 cycles.
62151224|NCT01378884|EXPERIMENTAL|Domeperidone|Patients to receive Domperidone for treatment of Gastroparesis
62151225|NCT05959902|ACTIVE_COMPARATOR|Forward Walking|"This study ARM will receive following treatment in home program after mesenchymal stem cell treatment.~• Forward Walking"
62151226|NCT05959902|EXPERIMENTAL|Physiotherapy|"This study ARM will be receiving following physiotherapy exercises for knee osteoarthritis after mesenchymal stem cell therapy.~* Isometric quadriceps exercise~* Straight leg raising (SLR) exercise~* Isometric hip adduction exercise~* Terminal knee extension exercise~* Semi wall squat exercise~* Quadriceps drill exercise"
62151227|NCT01244997|EXPERIMENTAL|Immediate implant placement|This arm is an immediate placement of a dental implant following tooth extraction.
62151228|NCT01244997|ACTIVE_COMPARATOR|Delayed Implant|This is the traditional method for implants. This arm will be done following a healing of the area.
62151229|NCT05923788|OTHER|Fabry disease|
62151230|NCT05923788|OTHER|Patients undergoing renal functional exploration|Patients undergoing renal functional exploration for a reason other than Fabry disease, amyloidosis, hemochromatosis
62151231|NCT01636726||Patients with AMI|All patients of the study population with a record/diagnosis of AMI during the study period
62151232|NCT01636726||Patients without AMI|All patients of the study population without a record/diagnosis of AMI during the study period
62359228|NCT01574937|EXPERIMENTAL|Treatment Arm|Cabozantinib and abiraterone
62359229|NCT06410469||33 patients operated with rug wave|Group1
62359230|NCT06410469||32 patients who underwent surgery using conventional colporrhaphy.|Group 2
62359231|NCT05211609|EXPERIMENTAL|Plasmatic 3-O-Methyldopa Level|Prevalence of High Plasmatic 3-O-Methyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency (Aromatic L-Amino Acid Decarboxylase)
62359232|NCT06517303||retrospective study|Retrospective study of two data warehouses and the Delphi method
62522788|NCT04515537||conventional therapy plus AFA|Patient using conventional therapy plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
62522789|NCT04515537||conventional therapy plus SVF|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue, evaluted for period of 6 months
61975490|NCT05778747|EXPERIMENTAL|Intervention|A total of 20 patients with HF and 20 caregivers (n= 40) who have at least mild depressive symptoms (Patient Health Questionnaire 9 \[PHQ-9\] score = 5) will be randomly assigned to the intervention or usual care group stratified by patient and caregiver groups (Figure 1). Only participants in the intervention will be asked to attend the 12-week sessions (two sessions per week; a total of 24 sessions in 12 weeks) via video conferencing (i.e., ZOOM). The short-term intervention efficacy will be assessed at the following week of the completion of 12-weeks sessions. Primary psychological outcomes include depressive symptoms, anxiety, stress, and quality of life. Primary physical outcomes include physical activity level, sleep quality, and perceived symptoms.
61975491|NCT05778747|NO_INTERVENTION|Usual Care|Participants in the usual care group will also receive the printed information and links to the AHA's Life's Simple 7 program without explicit skills and training, including education and stress management. We will encourage stress management by watching and practicing yoga programs by providing a yoga mat.
62151233|NCT04720209|EXPERIMENTAL|Circuit-style aerobic and resistance Exercise(CARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months.~-16 weeks of circuit-style aerobic and resistance exercise"
62151234|NCT04720209|EXPERIMENTAL|Traditional Aerobic Resistance Exercise (TARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months~- 16 weeks of traditional aerobic and resistance exercise"
62359233|NCT03558009||Participants with abdominal pain attacks|Participants experiencing recurrent abdominal pain attacks without a clear etiolgy aged between 2-60 years
62359234|NCT05109078|EXPERIMENTAL|[14C]- Rongliflozin|Patients will receive single dose of \[14C\]- Rongliflozin (Suspension, 50mg/100μCi)
62359235|NCT02382653|OTHER|oral perixicam|50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
61975492|NCT03232047|EXPERIMENTAL|Combined cognitive training|The training is combined executive function and memory training. The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
61975493|NCT03232047|NO_INTERVENTION|Waiting-list group|Participants in the control condition will conduct the same training as the intervention group after a 26-week waiting period. During the 26-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
61975494|NCT00782223||1|Hip X-rays DDH
61975495|NCT00782223||2|Hip X-rays, CP
61975496|NCT00782223||3|Long standing lower Limb X-rays
61975497|NCT00782223||4|Scoliosis, AP X-rays
61975498|NCT00782223||5|Scoliosis Lateral X-rays
62359236|NCT02382653|NO_INTERVENTION|oral fentanyl|50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
62359237|NCT05968716|NO_INTERVENTION|Control (pre-implementation) arm|"Caregivers recruited from the pediatric hospital ward before the social needs screening and intervention protocol is implemented will compose the control group or pre-implementation group."
62359238|NCT05968716|EXPERIMENTAL|Intervention (post-implementation) arm|"Caregivers recruited from the pediatric hospital ward after the social needs screening and intervention protocol is implemented will compose the intervention group or post-implementation group."
62359239|NCT03281408||Suspected OSA Patients Undergoing Knee or Hip Arthroplasty|These 100 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered. Troponin testing will be done post-op with other routine blood work.
62359240|NCT04132648|EXPERIMENTAL|Curcumin|Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials
62359241|NCT04132648|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
62359242|NCT05564208|EXPERIMENTAL|Elafibranor Fasting then Elafibranor fed|Participants will receive Elafibranor 80 mg in Fasting State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fed State on Day 1 of Period 2.
62359243|NCT05564208|EXPERIMENTAL|Elafibranor Fed then Elafibranor fasting|Participants will receive Elafibranor 80 mg in Fed State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fasting State on Day 1 of Period 2.
62359244|NCT03320538|EXPERIMENTAL|Hou Gu Mi Xi|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
62359245|NCT03320538|EXPERIMENTAL|Hou Gu Mi Xi + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (once 10 mg, once a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
62522790|NCT04515537||conventional therapy plus SVF and AFA|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
62522791|NCT03200691|EXPERIMENTAL|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.~SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.~After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
62712314|NCT05213806|ACTIVE_COMPARATOR|Withholding feeds around transfusion|All enteral feeds will be discontinued (the infant will be placed nil by mouth) for 4 hours prior to packed red cell transfusion, during the transfusion and until 4 hours post transfusion. During this period, hydration and blood glucose will be maintained according to local practice, commonly by providing parenteral nutrition or intravenous dextrose. Four hours after the red cell transfusion has finished, feeds will be recommenced to how they were being received prior to the decision to transfuse. This duration of withholding feeds will follow the approach used in other trials and observational studies, and identified as the most acceptable in a survey of UK neonatal units. It gives time for milk in the small bowel to transit into the large bowel before the transfusion and for the circulation to stabilize after the transfusion before milk feeds given into the stomach pass through into the small intestine.
62151235|NCT04720209|ACTIVE_COMPARATOR|Home-Based Stretching|"Attention Control for 16 weeks home-based stretching~-structured home-based stretching program, participants will be asked to maintain their current activity level for the 4-month study duration, and will be offered the CARE program upon study completion"
62522792|NCT00944268|EXPERIMENTAL|Liquid and solid|
62522793|NCT02624726|EXPERIMENTAL|FOLFIRI/Aflibercept|5 Fluorouracil/Leucovorin/Irinotecan/Aflibercept
62151236|NCT01446640|EXPERIMENTAL|MSC|Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.
62522794|NCT00940836|ACTIVE_COMPARATOR|Resfenol|"Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
62522795|NCT00940836|PLACEBO_COMPARATOR|Placebo|"Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
62151237|NCT05232357|EXPERIMENTAL|Endoscopic nerve staining|Methylene blue (MB) solution was used as nerve staining agent. Routine endoscopic submucosal injection of MB solution for mucosal nerve staining was used to identify and evaluate the neural architecture and special morphology of normal gastrointestinal mucosa, adenoma and malignant lesions.
62151238|NCT01422265||Cohort|
62151239|NCT06157684|EXPERIMENTAL|Postprandial Ambulation|Participants are counseled to walk for 20 minutes within 2 hours following meals daily.
62522796|NCT05142371|EXPERIMENTAL|Arm A (home-based exercise program)|Patients undergo home-based exercise program 3 times per week for 8 weeks. Patients complete questionnaires at baseline (before 1 week) and at weeks 9 and 17.
62712315|NCT05213806|ACTIVE_COMPARATOR|Continuing feeds around transfusion|Enteral feeds will continue to be given prior, during and after the packed red cell transfusion, in the manner in which they were being given prior to the decision to transfuse. Infants will remain allocated to the same care pathway until 34(+6) weeks(+days) gestational age.
62151240|NCT06157684|NO_INTERVENTION|Routine exercise counseling|Participants are counseled on routine ADA recommendations for 30 minutes of low-impact exercise 5 times a week
62151241|NCT03266432|OTHER|60 pregnant women|60 pregnant women diagnosed with placenta previa will take from them 3 blood samples : one pre intervention and two samples postintervention
62151242|NCT04266821|EXPERIMENTAL|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
62522797|NCT05142371|ACTIVE_COMPARATOR|Arm B (current activities)|Patients complete questionnaires at baseline and at week 9 and 17. Patients continue maintaining current activities of daily living and do not participate in any exercise program. Patients may then participate in home-based exercise program 3 times per week for 8 weeks.
62522798|NCT03982563|EXPERIMENTAL|Growth Mindset|
61975499|NCT02845453|EXPERIMENTAL|Quetiapine|Quetiapine
61975500|NCT02845453|PLACEBO_COMPARATOR|Placebo|Placebo
62522799|NCT03982563|EXPERIMENTAL|Gratitude|
62522800|NCT03982563|EXPERIMENTAL|Behavioral Activation|
62522801|NCT03982563|SHAM_COMPARATOR|Study Skills|
62522802|NCT01806038|EXPERIMENTAL|RPh Counseling + Outpatient Dispensing|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist.
61975501|NCT03855280|EXPERIMENTAL|APVO101|APVO101: 35 - 75 IU/kg; twice weekly
61975502|NCT01709591|NO_INTERVENTION|No Prenatal education|These subjects will be randomized to receive routine prenatal epidural class (control group).
62151243|NCT04266821|NO_INTERVENTION|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
62151244|NCT06425289||Experimental: Corrective strategy|"Procedure: Fluid balance negativation~During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion."
62359246|NCT03320538|PLACEBO_COMPARATOR|Placebo + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Placebo of Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (10 mg/d, qd).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
62359247|NCT03320538|PLACEBO_COMPARATOR|Placebo|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive placebo of Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
62712316|NCT04272164|ACTIVE_COMPARATOR|technical taekwondo training|Light jogging,running, Stretching exercises,Pushups and sit ups, Punches,Kicks
62712317|NCT04272164|EXPERIMENTAL|weighted rope taekwondo training|weighted rope jump training along with tachnical taekwando training
62712318|NCT05361174|EXPERIMENTAL|Cohort 1|Participants with unresectable or metastatic melanoma
62712319|NCT05361174|EXPERIMENTAL|Cohort 2|Participants with Stage III or IV non-small-cell lung cancer
62712320|NCT06716125|EXPERIMENTAL|group I|This group (n =20 for the group) will administer low calorie diet for 12 weeks plus additionally administering supervised walking training aerobic training for 45 minutes 3 times per week for 12 weeks.
62359248|NCT01468493||steroid-sensitive FSGS|
62359249|NCT01468493||steroid-dependent and resistant FSGS|
61975503|NCT01709591|ACTIVE_COMPARATOR|Receives Prenatal Education|Subjects randomized to this group will receive educational video addressing the cultural and perceptions regarding the myths on epidural in either English or Spanish (Keeping an Open Mind: choices in Labor Anaglesia: an educational produce of the Society for Obstetric Anesthesia and perinatology)
62359250|NCT01468493||Healthy volunteers|
62359251|NCT02383264||feeding intolerance|Development of feeding intolerance, defined as enteral feeding withholding for at least 1 day due to the onset ofgastrointestinal clinical symptoms
62359252|NCT02383264||normal feeding tolerance|no evidence of feeding intolerance during the hospitalization
62359253|NCT00054444|EXPERIMENTAL|Treatment (topotecan hydrochloride, radiation, cisplatin)|Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive cisplatin IV and topotecan IV over 30 minutes once weekly for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
62359254|NCT02954445|EXPERIMENTAL|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-BCMA-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62359255|NCT00331955|EXPERIMENTAL|Treatment (vorinostat, doxorubicin hydrochloride)|Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.
61975504|NCT03559257|EXPERIMENTAL|Galcanezumab|Galcanezumab administered subcutaneously (SC).
61975505|NCT03559257|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
61975506|NCT05947812|EXPERIMENTAL|Tafenoquine|Tafenoquine two tablets 1x/day on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery
62359256|NCT01221818|EXPERIMENTAL|1|
62359257|NCT01221818|EXPERIMENTAL|2|
62359258|NCT01221818|EXPERIMENTAL|3|
62359259|NCT01221818|EXPERIMENTAL|4|
62359260|NCT01221818|EXPERIMENTAL|5|
62359261|NCT01221818|EXPERIMENTAL|6|
62359262|NCT00978679|EXPERIMENTAL|Orthokeratology|Myopic children wearing orthokeratology at night will be the study group
62359263|NCT00978679|OTHER|Others|Myopic children wearing single-vision spectacles in the daytime will serve as control group
62359264|NCT00909519|ACTIVE_COMPARATOR|naproxen|
62359265|NCT00909519|EXPERIMENTAL|naproxcinod|
62359266|NCT00909519|PLACEBO_COMPARATOR|placebo|
62359267|NCT03379376|EXPERIMENTAL|Supportive Care (eMMB)|Participants receive a self-directed 20-minute eMMB video and are instructed to practice eMMB at least once before surgery and daily for 2 weeks after surgery. Participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible.
62359268|NCT01952704|EXPERIMENTAL|Aerobic exercise|30 minutes x 3 times/week x 12 weeks of stationery cycling
62359269|NCT01952704|PLACEBO_COMPARATOR|Non-aerobic exercise|30 minutes x 3 times/week x 12 weeks of gentle non-aerobic stretching
62359270|NCT02467023|EXPERIMENTAL|effective muscle stimulation group|Subjects in this arm will be in the study for up to 28 days or until discharge from the ICU. They will receive lower extremity muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength, muscle biopsy with muscle biopsy medication fentanyl, muscle biopsy medication versed, muscle biopsy medication lidocaine, and blood and urine sampling.
62359271|NCT02467023|ACTIVE_COMPARATOR|ineffective muscle stimulation group|Subjects assigned to this arm will be studied for up to 28 days or until discharge and will receive a sham muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength blood and urine samples, and a muscle biopsy sample with muscle biopsy medication fentanyl, muscle biopsy medication versed, and muscle biopsy medication lidocaine.
62359272|NCT00979719|EXPERIMENTAL|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
62151245|NCT06425289||Other: Stabilizing strategy In the control group, all patients will have a UFnet 2 ml settled|"Procedure: Body weight Stabilization~During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure (variation \>5%), the UF net can be increased to 1,5 ml/kg/h.~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min."
62359273|NCT00979719|PLACEBO_COMPARATOR|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, \& Fuchs, 2007) Göhner, W. \& Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.
62359274|NCT00979719|NO_INTERVENTION|Passive Control Group (PCG)|patients are asked to answer the questionnaires only
62359275|NCT01063218|OTHER|Emollient|Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day
62359276|NCT03366818|EXPERIMENTAL|thrombectomy|thrombectomy by Versi system
61975507|NCT05947812|PLACEBO_COMPARATOR|Placebo|Placebo two tablets 1x/day on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery
61975508|NCT04688710|ACTIVE_COMPARATOR|Self-Hypnosis (HYP)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Self-Hypnosis. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
62359277|NCT02923648||Very/extremely prematurely born with BPD|Very/extremely prematurely born (gestational age \[GA\]\< 32 weeks) with bronchopulmonary dysplasia (BPD) as defined by Jobe and Bancalari 2001, age 18-23 years
62359278|NCT02923648||Very/extremely prematurely born without BPD|Very/extremely prematurely born (GA\< 32 weeks) without BPD in the neonatal period, age 18-23 years
62359279|NCT02923648||Asthma full-term control group|Subjects with mild atopic asthma, born at term (GA\> 37 weeks), age 18-23 years
62359280|NCT02923648||Healthy full-term control group|Healthy participants, born at term (GA\>37 weeks), age 18-23 years
62359281|NCT04935970||patients with peripherial vestibular disorder|Forty patients with BPPV, vestibular neuritis or another peripherial vestibular disorder
62359282|NCT04935970||patients with central vestibular disorder|Forty patients vestibular disorder of central origin
62359283|NCT04935970||healthy controls|twenty healthy control without balance problems
62359284|NCT00796003|EXPERIMENTAL|Phase I: JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
62359285|NCT00796003|EXPERIMENTAL|Phase I: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
62359286|NCT00796003|EXPERIMENTAL|Phase II: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles
62359287|NCT01268943|EXPERIMENTAL|1000mg|capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
62359288|NCT01268943|EXPERIMENTAL|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
62359289|NCT01268943|EXPERIMENTAL|1400mg|capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
62359290|NCT01268943|EXPERIMENTAL|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
62359291|NCT03454204||Pharmacokinetic|Establish a pharmacokinetic relationship between plasma concentration and the effect of norepinephrine in patients under concentration-target intravenous anesthesia by identifying significant covariates during general anesthesia.
62359292|NCT04083118||Bicuspid aortic valve|80 patients with bicuspid aortic valve with or without an aortic aneurysm
62359293|NCT04083118||controls|20 healthy volunteer controls age and sex matched to 20 of the bicuspid aortic valve patients
62359294|NCT02560493|NO_INTERVENTION|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
62359295|NCT02560493|EXPERIMENTAL|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
62359296|NCT00003613|EXPERIMENTAL|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62359297|NCT06280612|EXPERIMENTAL|Live Cat Group|"Before starting the study, the Structured Patient Information Form, Edmonton Symptom Diagnosis Scale, and Oxford Happiness Scale Short Form were applied to the patients. Then, the researcher gave the patients face-to-face, individual information about hand hygiene after contact with a live cat for approximately 15 minutes in the waiting room and offered them a Live Cat Information Brochure. Patients were then asked to spend 20 minutes with a pet at home twice a week for 12 weeks. Edmonton Symptom Diagnosis Scale and Oxford Happiness Scale Short Form were applied to this group of patients three times: before, at the 6th week, and at the end of the 12th week of the study."
62359298|NCT06280612|EXPERIMENTAL|Robotic Cat Group|"Before starting the study, the Structured Patient Information Form, Edmonton Symptom Diagnosis Scale, and Oxford Happiness Scale Short Form were applied to the patients. Then, the researcher gave the patients face-to-face information about the robotic cat Silver and its use for approximately 15 minutes in the waiting room and offered them a Robotic Cat Information Brochure. In each pet therapy application, patients' hand hygiene and cleaning of the Robotic Cat was provided, the robot cat was given to the patients."
62359299|NCT06280612|NO_INTERVENTION|Control Group|"Before starting the study, the Structured Patient Information Form, Edmonton Symptom Diagnosis Scale, and Oxford Happiness Scale Short Form were applied to the patients. Treatment was given to this group of patients only after informing them about the study, and the patients were followed for only three months. Edmonton Symptom Diagnosis Scale and Oxford Happiness Scale Short FormS were applied to the patients three times: before, at the 6th week, and the end of the 12th week of the research."
62522803|NCT01806038|ACTIVE_COMPARATOR|Routine Med Dispensing + Counseling|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
61975509|NCT04688710|ACTIVE_COMPARATOR|Mindfulness Meditation (MM)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Mindfulness Meditation. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
61975510|NCT04688710|NO_INTERVENTION|Treatment as Usual (TAU)|Participants will not receive treatment from the study during the treatment phase. Participants will continue to receive their normal care outside of the study for MS and fatigue. Participants will have the option to access either the Self-Hypnosis or Mindfulness Meditation treatment after all study assessments have been completed.
62151246|NCT03274648|EXPERIMENTAL|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
62151247|NCT03274648|EXPERIMENTAL|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
62151248|NCT03274648|ACTIVE_COMPARATOR|Habitual diet|habitual diet without supplementation
61975511|NCT02118844|ACTIVE_COMPARATOR|Moderate rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain moderate neuromuscular blockade (TOF-count 2-4) during gastrojejunal anastomosis
62151249|NCT03803657||Neonates|Neonates 0-28 days
62151250|NCT03803657||Infant|29 days to 1 year
62151251|NCT03803657||Child|\>1 year and \<10 kg
62151252|NCT02542332|ACTIVE_COMPARATOR|With Data|Participants received statistical data about lung cancer screening
62151253|NCT02542332|NO_INTERVENTION|Without Data|Participants had no statistical data on lung cancer screening
62151254|NCT03275467|EXPERIMENTAL|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
62151255|NCT00257894|EXPERIMENTAL|Baclofen condition|Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
62151256|NCT00257894|PLACEBO_COMPARATOR|Placebo condition|Placebo capsules identical to active medication, 3/day for 12 days.
62151257|NCT04089202|ACTIVE_COMPARATOR|In-person visit arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to an in-person visit with an Endocrinologist. This is currently the standard of care for patients referred for diabetes specialty care.~Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.~Surveys will be administered to measure patient burden and self efficacy."
62151258|NCT04089202|EXPERIMENTAL|Freestyle Libre sensor arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to have the Freestyle Libre Pro continuous glucose monitor (CGM) placed at their primary care clinic. The data collected from the diagnostic CGM will be utilized in conjunction with diet, exercise and medication logs provided by the patient and information from the patient's electronic medical record to complete an eConsult with treatment recommendations. Implementation of these recommendations will be per the primary care provider's discretion in conjunction with conversation with the patient in follow up visits.~Surveys will be administered to measure patient burden and self efficacy."
62151259|NCT02518399|EXPERIMENTAL|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
62359300|NCT00541736|EXPERIMENTAL|Patients|GTN-infusion
62359301|NCT00541736|ACTIVE_COMPARATOR|Controls|GTN-infusion
62359302|NCT01962857|EXPERIMENTAL|Exercise|4 week supervised high-intensity shuttle running intervention, with 3 sessions per week (12 sessions in total)
62359303|NCT01962857|NO_INTERVENTION|Control|No intervention - participants maintain usual lifestyle
62359304|NCT02657187|EXPERIMENTAL|rocuronium 1|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).
62359305|NCT02657187|EXPERIMENTAL|rocuronium 2|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).
62359306|NCT02657187|EXPERIMENTAL|rocuronium 3|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).
61975512|NCT02118844|EXPERIMENTAL|deep rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain deep neuromuscular blockade (here defined as a Posttetanic Count 1 - 5) during gastrojejunal anastomosis
61975513|NCT05248022|EXPERIMENTAL|Combination Treatment Group|Drug-eluting Beads Bronchial Arterial Chemoembolization combined with Programmed Cell Death Protein 1 Inhibitor was used for treatment.
61975514|NCT05248022|ACTIVE_COMPARATOR|Single Treatment Group|Only receive drug-eluting beads bronchial arterial chemoembolization treatment.
61975515|NCT03447990|OTHER|Part 1/SAD and Part 2/MAD - drug|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
62359307|NCT02657187|EXPERIMENTAL|rocuronium 4|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).
62359308|NCT03447119|EXPERIMENTAL|Living Well with a Disability|The parents will work together with the project directors to deliver the adapted curriculum to participating families. With bi-weekly meetings for 10 weeks between parent facilitators and family participants in the home or another desired location. The project directors have already participated in the facilitator training and will serve as mentors to newly trained facilitators. At the end of the online training session, the parent facilitators will be equipped to successfully implement the Living Well curriculum.
61975516|NCT03447990|OTHER|Part 1/SAD and Part 2/MAD - placebo|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
62359309|NCT03753204|EXPERIMENTAL|Weinberger protocol|During the Weinberger protocol, salt loading will be achieved by the combination of a high-salt diet (isocaloric, 160 mEq Na and 70 mEq K), and an infusion of 2L of saline (300 mEq Na+). Patients will have free access to water but their food will be limited to that provided by the protocol. Salt depletion will be accomplished by administering an isocaloric diet containing 10 mEq Na and 70 mEq K and continued unlimited water intake. At 8 am, 12 noon and 4 pm, subjects will be given 40 mg of furosemide or lasix orally.
62359310|NCT04373213||Pleth variability index|Patients undergoing fluid management with Pleth variability index
62712321|NCT06716125|ACTIVE_COMPARATOR|Group II|this group (n =20 for the group) will administer low calorie diet for 12 weeks
62712322|NCT03780257|EXPERIMENTAL|QR-421a|Single dose administration
62712323|NCT03780257|SHAM_COMPARATOR|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
62712324|NCT04456907|EXPERIMENTAL|PPR group|Receive PRP injection
62712325|NCT04456907|SHAM_COMPARATOR|Saline group|Receive saline injection
62712326|NCT06625242|EXPERIMENTAL|Filgotinib Maleate 100 or 200 milligram|
62712327|NCT05617326|EXPERIMENTAL|screening by a GP|Each patient in this group will have a screening for AAA performed by a trained general practitioner
62712328|NCT05617326|OTHER|screening by a radiologist (conventional)|Each patient in this group will have AAA screening performed by a radiologist
62712329|NCT02412670|EXPERIMENTAL|Arm A (methotrexate, vinblastine, doxorubicin, cisplatin)|Patients receive methotrexate IV over 2-3 minutes, vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1. Pegfilgrastim at 6 mg is given once 24-48 hours after completion of chemotherapy. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
62712330|NCT02412670|EXPERIMENTAL|Arm B (gemcitabine, carboplatin)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
62712331|NCT03323164|ACTIVE_COMPARATOR|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
62712332|NCT03323164|ACTIVE_COMPARATOR|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
62712333|NCT02213250|EXPERIMENTAL|BeneFIX|
62712334|NCT02114086||breast cancer|observation of intraoperative radiotherapy
62712335|NCT05177250|OTHER|Case group|50 cases with type 2 DM.
62712336|NCT05177250|OTHER|Control group|50 subjects not diabetics.
62359311|NCT04373213||hemodynamic|Patients undergoing fluid management with hemodynamic findings
62359312|NCT01745913|EXPERIMENTAL|Haplo-Cord SCT|The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
62359313|NCT01745913|ACTIVE_COMPARATOR|UCB SCT|For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
62359314|NCT02347852||Physical activity / Cohort 1|The non influenced and non triggered habitual physical activity of patients will be assessed by pedometer and physical activity questionnaire. The study population will consist of patients with metastatic CRC (mCRC) who are included in the NIS CORRELATE, have been previously treated with other approved regimens for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label prior to and independent of the inclusion into this observational study.
62359315|NCT05229991|EXPERIMENTAL|Intervention Group|Lonafarnib 50mg co-administered with ritonavir 200 mg
62359316|NCT00250081|ACTIVE_COMPARATOR|Therapy Group|Therapy only
62359317|NCT00250081|ACTIVE_COMPARATOR|Surgery Group|surgical intervention
62359318|NCT00250081|ACTIVE_COMPARATOR|Botox Injections|botulinum toxin
62359319|NCT01567423|EXPERIMENTAL|Artesunate and Amodiaquine (ASAQ)|children receiving fixed-dose combination of artesunate and amodiaquine
62359320|NCT01567423|ACTIVE_COMPARATOR|Arthemeter and Lumefantrine (AL)|children receiving fixed-dose combination of arthemeter and lumefantrine
62359321|NCT04989088|EXPERIMENTAL|Left theta/beta and right beta/theta NF training|
62359322|NCT04989088|PLACEBO_COMPARATOR|Sham NF training|
62359323|NCT04580160|EXPERIMENTAL|Duo Venous Stent System Implantation|
62359324|NCT00723671|EXPERIMENTAL|metabolic peaks|
62359325|NCT04591145||Observational group|Patients received bowel preparation and colonoscopy. The withdrawal phase video was saved and their lesions detection was record.
62359326|NCT04450641|EXPERIMENTAL|Treatment|Treatment group used GuessWhat during the 4 week intervention period.
62359327|NCT04450641|OTHER|Control|Participants in control group received standard treatment as usual.
62359328|NCT02194556|EXPERIMENTAL|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
62359329|NCT02194556|ACTIVE_COMPARATOR|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib (125 mg three times per day) as maintenance treatment until disease progression or intolerable toxicity.
62712337|NCT03571490|ACTIVE_COMPARATOR|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
62712338|NCT03571490|PLACEBO_COMPARATOR|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
62712339|NCT04470024|EXPERIMENTAL|Arm 1|Vax + delayed anti-PD-1
62151260|NCT02518399|SHAM_COMPARATOR|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
62151261|NCT03788226|EXPERIMENTAL|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
62151262|NCT03788226|ACTIVE_COMPARATOR|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
62151263|NCT02704156|EXPERIMENTAL|SBRT plus Pembrolizumab and Trametinib|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
62359330|NCT04394689|ACTIVE_COMPARATOR|MRV-SC|A standard, single dose of Measles Rubella vaccine delivered subcutaneously with a needle and syringe
62359331|NCT04394689|EXPERIMENTAL|MRV-MNP|A single dose of Measles Rubella vaccine delivered intradermally with a microneedle patch
62712340|NCT04470024|EXPERIMENTAL|Arm 2 (CLOSED TO ENROLLMENT)|Vax + anti-GITR + delayed anti-PD-1
62712341|NCT01131052|ACTIVE_COMPARATOR|BASAL PLUS|Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed
62712342|NCT01131052|ACTIVE_COMPARATOR|sliding scale regular insulin (SSRI)|Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed
62712343|NCT00313560|EXPERIMENTAL|Erlotinib and EBRT after pancreatectomy|"Adjuvant treatment with erlotinib 100 mg plus Capecitabine 800 mg/m2 PO BID (5 days on/ 2 days off regimen) and External Beam Radiation Therapy (EBRT) at doses of 50.4 Gy in 28 fractions after pancreatectomy (Dosing for capecitabine and erlotinib was amended after considering the toxicity profile of the first 6 patients).~Approximately 4-8 weeks after the conclusion of chemoradiation, it is recommended patients will continue treatment with 4 cycles of gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg."
62712344|NCT01889693||acute coronary syndrome|patients with acute myocardial infarction and unstable angina
62712345|NCT01889693||chronic stable angina|patients with chronic stable angina
62712346|NCT01889693||control|control subjects without coronary artery disease
62712347|NCT03763578|EXPERIMENTAL|Licorice|licorice is one of the natural products that is listed by the Food and Drug Administration (FDA) as GRAS (generally regarded as safe) when used as food flavoring and sweetening agent which has an antimicrobial, anti-inflammatory and antiviral activity.
62712348|NCT03763578|ACTIVE_COMPARATOR|Chlorhexidine|"The gold standard of oral therapeutics is Chlorhexidine due to its prolonged broad- spectrum antimicrobial effect."
62712349|NCT03763578|NO_INTERVENTION|Control Group|Participants in this group will follow only the standard preventive measures which is brushing twice a day after breakfast and before bed time and daily flossing interdentally before bed time. (No Mouthwash is used)
62712350|NCT03198871|EXPERIMENTAL|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
62712351|NCT03198871|PLACEBO_COMPARATOR|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
62712352|NCT01227057|EXPERIMENTAL|Arm 1: Cognitive Rehabilitation|Cognitive rehabilitation and exposure therapy for hoarding
62712353|NCT01227057|ACTIVE_COMPARATOR|Arm 2: Case Management|Case management
62712354|NCT05558384|EXPERIMENTAL|Aerobic exercise|15-week standardized aerobic exercise intervention
62712355|NCT06174675|ACTIVE_COMPARATOR|Study group|"patients will receive combined bilateral infraorbital and infratrochlear nerve block.~20 patients"
61975517|NCT00731289|EXPERIMENTAL|1|single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
61975518|NCT00731289|ACTIVE_COMPARATOR|2|single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
61975519|NCT05339854||ECPR survivor|Adult patient who survived therapy-refractory cardiac arrest with extracorporeal cardiopulmonary resuscitation (ECPR).
61975520|NCT01103011|EXPERIMENTAL|ND0611 dose 1, ND0611 dose 2, placebo|
62712356|NCT06174675|NO_INTERVENTION|control group|"patients will not receive the block and will receive intravenous analgesia according to standard protocol.~20 patients."
61975521|NCT04017585|ACTIVE_COMPARATOR|patients with IBS treated with gluten|patients receiving gluten
61975522|NCT04017585|PLACEBO_COMPARATOR|patients with IBS treated with placebo|patients receiving placebo
61975523|NCT04160208||IUI - Insemination|Males of couples undergoing their first IUI treatment
61975524|NCT04160208||IVF - In vitro fertilisation|Males of couples undergoing their first IVF treatment. Including males of couples who have had previous IUI treatments.
61975525|NCT04160208||ICSI - Micro Insemination|Males of couples undergoing their first ICSI treatment. Including males of couples who have had previous IUI treatments.
61975526|NCT05620563|EXPERIMENTAL|45 mg LY3857210|Participants received 45 milligram (mg) LY3857210 orally once daily for up to 8 weeks.
61975527|NCT05620563|PLACEBO_COMPARATOR|Placebo|Participants received placebo orally once daily for up to 8 weeks.
62712357|NCT04565457|EXPERIMENTAL|Participants Scanned|All participants will be scanned with a CBCT system equipped with 2D antiscatter grid technology, referred to as research CBCT. Each participant will also be scanned with a standard clinical CBCT as part of their standard clinical care, which will serve as the baseline, or control.
62712358|NCT05481736|EXPERIMENTAL|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
62359332|NCT00480207|EXPERIMENTAL|omega-3, folic acid, vitB12|folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
62359333|NCT00480207|EXPERIMENTAL|omega-3, folic acid placebo, vit B12|omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
62359334|NCT00480207|EXPERIMENTAL|omega-3 placebo, folic acid, vit B12|folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
62359335|NCT00480207|EXPERIMENTAL|omega-3 placebo, folic acid placebo, vit B12|omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
62359336|NCT03230721|ACTIVE_COMPARATOR|ThuLEP group|Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
62359337|NCT03230721|ACTIVE_COMPARATOR|Monopolar enucleation group|Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
62359338|NCT03230721|ACTIVE_COMPARATOR|HoLEP group|Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
62359339|NCT05625646||Course participants|Participants will be enrolled in a quality assurance program with an online multiple-choice quiz including still-pictures and video sequences of 10 application specific POCUS examinations. Through 15-20 questions, the quiz tests participants (1) knowledge about indications for performing POCUS examinations, (2) applied knowledge of ultrasound equipment, (3) ability to optimize images, (4) ability to recognize and present structures, (5) ability to interpret images, (6) ability to describe and document findings and (7) medical decision-making. Following the quiz, the participants are offered guidance to improve their performance.
62359340|NCT01477138||DDD(R)|SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.
62359341|NCT01477138||AAI(R)<=>DDD(R)|SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum
62359342|NCT03874195|ACTIVE_COMPARATOR|Control|"Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care - www.palliativedoctors.org; getpalliativecare.org; and Wikipedia Palliative Care https://en.wikipedia.org/wiki/Palliative care)."
62359343|NCT03874195|EXPERIMENTAL|Intervention|Intervention Arm subjects will receive access to PCforMe.
62359344|NCT05260606||Patients with NSCLC who will have FDG PET/CT before and during ICI Tx|There is no difference from the treatment schedule performed in usual clinical setting except for an additional F-18 FDG PET/CT scan. Detailed plan of ICI treatment and patient management (dose, administration date, treatment period, and follow-up) follows the standard protocol of our institution in this study.
62359345|NCT05500560||COVID-19|Patients admitted to our hospital due to COVID-19
62359346|NCT05500560||Controls|Healthy volunteers matched for age, sex and cardiovascular risk factors.
62359347|NCT03638115|EXPERIMENTAL|VaSecure™ Drug Coated PTA Balloon Catheter|
62359348|NCT05702398|EXPERIMENTAL|Vitamin A & Nicotinamide|1,000 μg retinyl palmitate and 500 mg NAM twice a day
62359349|NCT05702398|PLACEBO_COMPARATOR|Placebo|Identical placebo pills twice a day
62359350|NCT05745025|EXPERIMENTAL|rTMS and Rehabilitation|Subjects in this arm will get rTMS to the contralateral motor cortex and best practice rehabilitation.
62359351|NCT05745025|SHAM_COMPARATOR|Sham rTMS and Rehabilitation|Subjects in this arm will get sham rTMS to the contralateral motor cortex and best practice rehabilitation.
62359352|NCT02109068|ACTIVE_COMPARATOR|In-Person Counseling|Participants randomized to in-person counseling will meet via in-person or via telephone (but at least 3 of the 11 sessions must be in person) weekly for month 1, then every other week for months 2, and 3, and then monthly for months 4-6 at Yale University. The meetings will last 30 minutes. Participants will turn in their diet and exercise logs and also be weighed. A lesson will then be discussed (see above for content).
62359353|NCT02109068|ACTIVE_COMPARATOR|Telephone-based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs. Every four weeks, participants will return, via stamped, addressed envelopes, the logs to the study office.
62359354|NCT02109068|NO_INTERVENTION|Usual Care|Immediately after randomization, participants in the Usual Care Group will be provided written information that emphasizes the importance of a healthy lifestyle. Usual care participants will be encouraged to follow the American Cancer Society (ACS) nutrition and physical activity guidelines. Upon completion of the study (at 6 months), usual care participants will be offered all the educational material, as well as an in-person or telephone counseling session.
62359355|NCT00647972|EXPERIMENTAL|1|Olanzapine Tablets 20 mg
62359356|NCT00647972|ACTIVE_COMPARATOR|2|Zyprexa® Tablets 20 mg
62359357|NCT05782374||Patients diagnosed with r/r PCNSL|Adult patients diagnosed with relapsed or refractory PCNSL who in the period between August 2020 and May 2022 were candidates for treatment with ibrutinib alone or in combination with R-CHOP or R-CHOP like (in compassionate use, or off- label).
62359358|NCT01015820|EXPERIMENTAL|Cancer group|Participants in this group had pathologically confirmed pancreatic adenocarcinoma. They received an EGD with EUS. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
62359359|NCT01015820|OTHER|Control group|Participants in this group were without pancreatic adenocarcinoma. Participants in the control group received an EGD with EUS for the indication of abdominal pain. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
62359360|NCT01283867|EXPERIMENTAL|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
62359361|NCT01283867|ACTIVE_COMPARATOR|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
62712359|NCT05481736|ACTIVE_COMPARATOR|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin
62712360|NCT06361537|EXPERIMENTAL|OCTA-C1-INH|OCTA-C1-INH injection, 20IU/kg BW after first qualifying attack. Treatment to be administered to blinded as well as open-label subjects.
62359362|NCT03846167||FTT PET/CT|"The imaging procedure may include one or both of the following imaging sessions; 1) a 45- 60 minute dynamic scan, starting at approximately the same time as the injection and/or 2) a skull base to mid-thigh scan starting approximately 60 minutes post injection of \[18F\]FTT.~Participants will be asked to complete the following research procedures: \[18F\]FTT PET/CT scan before surgery or treatment \[18F\]FTT PET/CT scan after you start treatment (optional)"
62359363|NCT05166395|EXPERIMENTAL|Er:YAG laser Group|The study is a split-scar model. Participants will have half of their lesion receive a total of three sessions using 2940 nm Er:YAG laser spaced over a 4-week study participation interval.
62359364|NCT05166395|NO_INTERVENTION|Control (No Intervention) Group|The study is a split-scar model. Participants will serve as their own control and have half of their lesion receive no intervention.
62359365|NCT03796884|EXPERIMENTAL|Arm I (linaclotide)|Patients receive linaclotide PO daily on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
62359366|NCT03796884|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
62712361|NCT06361537|PLACEBO_COMPARATOR|Placebo|0.1 mL/kg BW 0.9% sodium chloride solution injection after first qualifying attack. Only blinded subjects to receive.
62359367|NCT01535612|EXPERIMENTAL|PaQ™ insulin infusion device|PaQ™ insulin infusion device which delivers rapid acting insulin.
62359368|NCT01037972||Whole body vibration|
62359369|NCT01037972||Conventional physiotherapy|
62359370|NCT00719537|PLACEBO_COMPARATOR|Aspirin plus Placebo Oral Tablet|Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
62359371|NCT00719537|ACTIVE_COMPARATOR|Aspirin plus Progesterone|Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day
62359372|NCT05182424|EXPERIMENTAL|Myndlift BPT Immediate Treatment|After the completion of consent, a battery of baseline assessments will be completed by the parent. Children will not be involved in the study assessment or interventions-only parents/caregivers. Parent(s) will be emailed baseline and post-treatment assessment surveys through Qualtrics to complete. Following completion of baseline assessment, study staff will meet with the parent via Zoom to review any questions with the consent and review and discuss questions/issues with the baseline assessment. Following completion of the post-treatment assessment, study staff will meet with the parent via Zoom to review and discuss questions/issues with the post-treatment assessment. Following this review, the post-treatment interview will be completed. Having study staff present has been found useful by parents should they have any questions or concerns about items on surveys.
62359373|NCT05182424|OTHER|Waitlist Control Group|Following completion of consent and baseline assessment, parent participants randomly assigned to the waitlist condition will be requested to wait for a period of 12 weeks before accessing the program, modules, and receiving therapist support. They will be required to answer the time 2 (at 12 weeks following completion of the baseline assessment) assessment prior to starting the process. The time 2 assessment for the waitlist condition is identical to the post-treatment assessment for participants in the Myndlift BPT group except that questions related to experience with Myndlift BPT will not be included.
62359374|NCT01841294|EXPERIMENTAL|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
62359375|NCT01841294|PLACEBO_COMPARATOR|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
62359376|NCT01391338|EXPERIMENTAL|Lowest dose ASP3652 twice daily|
62359377|NCT01391338|EXPERIMENTAL|Low dose ASP3652 twice daily|
62359378|NCT01391338|EXPERIMENTAL|Medium dose ASP3652 twice daily|
62359379|NCT01391338|EXPERIMENTAL|High dose ASP3652 once daily|
62359380|NCT01391338|EXPERIMENTAL|High dose ASP3652 twice daily|
62359381|NCT01391338|PLACEBO_COMPARATOR|Placebo|
62359382|NCT03184116|EXPERIMENTAL|Individual intervention|Individual intervention using cognitive-behavioral principles
62359383|NCT03184116|NO_INTERVENTION|Control|No additional intervention
62359384|NCT04090580|EXPERIMENTAL|Daily dosage of dapagliflozin and metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 10 mg dapagliflozin and 2000 mg metformin for 12 weeks
62359385|NCT04090580|EXPERIMENTAL|Daily dosage of metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 2000 mg metformin for 12 weeks
62359386|NCT01864317|EXPERIMENTAL|Primary Open Angle Glaucoma|30 patients with primary open angle glaucoma
62359387|NCT01864317|EXPERIMENTAL|Normal Tension Glaucoma|30 patients with normal tension glaucoma
62359388|NCT01864317|EXPERIMENTAL|Ocular Hypertension|30 patients with ocular hypertension
62359389|NCT01864317|OTHER|Healthy subjects|30 healthy control subjects
62359390|NCT03290170|EXPERIMENTAL|Measured resection technique|Measured resection surgical technique
62359391|NCT03290170|EXPERIMENTAL|Gap Balancing Technique|Gap Balancing surgical technique
62359392|NCT04665713||Normal|children whose BMI are in the normal range(From P5 to P85)
62359393|NCT04665713||Overweight|children whose BMI are above the normal range(over P85)
62359394|NCT04813978|NO_INTERVENTION|Group B (control)|Head phone will be placed and music will not be played, will get normal nursing care
62359395|NCT04813978|EXPERIMENTAL|Group A (music intervention)|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
62359396|NCT03855241|ACTIVE_COMPARATOR|Informational Sheet|Persons picking up an opioid prescription will receive an informational sheet that describes how to properly dispose of leftover opioid medications
62359397|NCT03855241|ACTIVE_COMPARATOR|Drug Disposal Kit|Persons picking up an opioid prescription will receive a drug disposal kit (DisposeRx Drug Disposal kit) and instructions on how to use it
62522804|NCT01946776|OTHER|Reveal XT|People with drug-resistant epilepsy whose heart rhythm will be monitored continuously for 2 years using Reveal XT, an implantable heart rate monitor.
62712362|NCT01803633|EXPERIMENTAL|Cheese|Cheese sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain medium cheddar cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, high oleic sunflower oil, high polyunsaturated fatty acids (PUFA) sunflower oil, and canola oil.
62359398|NCT03855241|NO_INTERVENTION|No intervention|Persons picking up an opioid prescription will receive no additional information or materials on disposal.
62359399|NCT03148587|EXPERIMENTAL|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
62359400|NCT03148587|EXPERIMENTAL|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
62359401|NCT03583788|EXPERIMENTAL|Hypnotherapy group|The intervention consisted of individual hypnotherapy of 5 hourly sessions (60 minutes) over 5 weeks, a total of five hours. The hypnotherapy treatment method was Erickson's (permissive) hypnosis (17). It began with a conversation about patient's past life events, present situation, alcohol problem and his or her thoughts about it. The hypnotherapy Group did not receive any treatment of motivational interviewing.
62359402|NCT03583788|ACTIVE_COMPARATOR|Motivational interviewing group|The comparator patient group received individual therapy as motivational interviewing (MI) for 5 hourly sessions over 5 weeks, a total of five hours. The patients in the experimental group did not receive this.
62359403|NCT05913518|EXPERIMENTAL|Active neurofeedback group|
62359404|NCT05913518|PLACEBO_COMPARATOR|Placebo feedback group|
62359405|NCT05913518|NO_INTERVENTION|Control group|
62359406|NCT02122926|EXPERIMENTAL|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge."
62151264|NCT02704156|ACTIVE_COMPARATOR|SBRT plus Gemcitabine|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
62151265|NCT03006718|EXPERIMENTAL|Patients|"Participants must have SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSOArab), within the age range of 8 - 21 years, and be admitted to the hospital for vaso-occlusive crisis (VOE)-related pain. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study.~All participants will use the PROMIS for Pain Management App over 5 consecutive weeks (starting at hospital discharge)."
62151266|NCT06236204|EXPERIMENTAL|Arthroscopic Scapholunate Ligament Reconstruction|Experimental: patients with dynamic scapholunate instability wrist arthroscopy: bone-tendon reconstruction of the volar and dorsal part of the scapholunate complex
62359407|NCT02122926|NO_INTERVENTION|Usual Care|Patients in the control arm of this study receive usual care.
62359408|NCT00334646|EXPERIMENTAL|Arm A|cyclophosphamide + dexamethasone + ondansetron
62359409|NCT00334646|EXPERIMENTAL|Arm B|cyclophosphamide + dexamethasone + ondansetron + GW679769
62359410|NCT01002404|ACTIVE_COMPARATOR|angled tipped guide wire|angled tipped guide wire used to deep biliary cannulation
62359411|NCT01002404|ACTIVE_COMPARATOR|straight tipped guidewire|straight guide wire used to deep biliary cannulation
62359412|NCT03114423|EXPERIMENTAL|Treatment As Usual + Treatment with EMDR|
62359413|NCT03114423|SHAM_COMPARATOR|Treatment As Usual + Cognitive Training|
62359414|NCT00555282|EXPERIMENTAL|1|coated central venous catheter
62359415|NCT00555282|ACTIVE_COMPARATOR|2|standard central venous catheter
62359416|NCT06364384|EXPERIMENTAL|PD-1 + CRT|Patients from experimental group are underwent treatment together with PD-1 monoclonal antibody and radical CRT
62359417|NCT04819581|EXPERIMENTAL|SP-103 (1 topical system)|One topical system applied to the skin on the back for 12 hours.
62359418|NCT04819581|EXPERIMENTAL|SP-103 (2 topical systems)|Two topical systems applied to the skin on the back for 12 hours.
62359419|NCT04819581|EXPERIMENTAL|SP-103 (3 topical systems)|Three topical systems applied to the skin on the back for 12 hours.
62359420|NCT04819581|ACTIVE_COMPARATOR|ZTlido|Three topical systems applied to the skin on the back for 12 hours.
62359421|NCT04252248|EXPERIMENTAL|Stratum 1|Patients having received standard, definitive chemoradiotherapy according to current, national guidelines with curative intent and being at high risk for disease recurrence (patients are considered at high risk if they display a positive nodal status of their cancer (anogenital HPV-induced tumor) or if the tumor is locally advanced and/or if they display a positive nodal status with extracapsular extension (head and neck HPV-induced tumor). Study therapy (as additional therapy to standard chemoradiation) will start after a time interval of 6-8 weeks after finishing chemoradiotherapy
62359422|NCT04252248|EXPERIMENTAL|Stratum 2|"Patients with non-curative and progressive disease having received all standard, national approved systemic therapies (according to current, national guidelines with regard to the specific tumor entity), and/or presently not eligible for a respective therapy, and/or refused respective therapy. Study treatment thereby represents a potential palliative, last-line systemic therapy option (late salvage)."
62359423|NCT02841592|ACTIVE_COMPARATOR|Non-rebreather|This group will have a non-rebreather mask applied to the face and they will receive the flush rate oxygen intervention
62151267|NCT01020435|ACTIVE_COMPARATOR|Spinal Manipulation High Velocity|This non-rotary upper cervical procedure uses an impulse thrust with a controlled depth (high velocity). The participant's head is supported by a specially designed cushion and the doctor usually approaches the participant from in front of his or her head to contact soft tissue over the atlas transverse process, posterior to the lateral mass or occasionally on the C2 lamina or spinous process, with the pisiform process of one hand. The thrust is delivered by a contraction of the triceps muscles of both arms, which straightens the arms and applies the thrust to the participant.
62151268|NCT01020435|PLACEBO_COMPARATOR|Sham Spinal Manipulation|The sham assessment procedures will be similar to the active group. It has been developed and validated by Vernon et al.
62151269|NCT01916109|EXPERIMENTAL|Gemcitabine, Carboplatin, and Panitumumab (GCaP)|Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.
62151270|NCT02860949|EXPERIMENTAL|LAI with PCI|Local anesthetic infiltration with posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area, Lateral gutter area and Posterior capsular area)
62151271|NCT02860949|ACTIVE_COMPARATOR|LAI without PCI|Local anesthetic infiltration without posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area and Lateral gutter area)
62151272|NCT01670526|EXPERIMENTAL|Rivastigmine|Rivastigmine transdermal patch
62151273|NCT01670526|PLACEBO_COMPARATOR|Placebo|Placebo
62151274|NCT01383785|ACTIVE_COMPARATOR|GROUP A|Intracoronary full bolus dose of abciximab proximal to thrombus occlusion
62151275|NCT01383785|EXPERIMENTAL|GROUP B|Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter
62151276|NCT01383785|EXPERIMENTAL|GROUP C|Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter
62151277|NCT03071523|EXPERIMENTAL|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
62151278|NCT03071523|ACTIVE_COMPARATOR|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
62151279|NCT02007070|EXPERIMENTAL|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.
62151280|NCT01966679|ACTIVE_COMPARATOR|Double-blind (active versus placebo)|AZD7325 versus placebo
62151281|NCT01966679|PLACEBO_COMPARATOR|Placebo|
62151282|NCT04933474|EXPERIMENTAL|painTRAINER (2D mHealth intervention)|Participants will use one of the most widely-validated mHealth interventions for pain management called painTRAINER®, which is a standardized, 56-day program delivering skills training and Cognitive behavioral therapy (CBT)-related treatments through daily virtual experiences.
62151283|NCT04933474|EXPERIMENTAL|Skills-based VR Therapy|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
62359424|NCT02841592|ACTIVE_COMPARATOR|Bag-valve-mask|With each inspiration from the subject, the ventilation bag will be gently squeezed to provide positive pressure and augment the amount of oxygen that is received by the subject for each breath. This group will receive the flush rate oxygen with assist intervention.
62359425|NCT01052181|EXPERIMENTAL|Vitamin D supplementation|Cholecalciferol sachets 120,000 IU monthly for 12 months
62359426|NCT01052181|PLACEBO_COMPARATOR|placebo|placebo with same taste, color, odor
62359427|NCT01373918|EXPERIMENTAL|low dose intravenous fat emulsion|Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
62359428|NCT01373918|ACTIVE_COMPARATOR|standard dose intravenous fat emulsion|Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
62359429|NCT05293171|EXPERIMENTAL|1.25 mg/kg BL-8040 + BL-8040-matching placebo administered via SC injection (Therapeutic)|1.25 mg/kg BL-8040 + BL-8040-matching placebo administered via SC injection (Therapeutic)
62359430|NCT05293171|EXPERIMENTAL|2 mg/kg BL-8040 administered via SC injection (Supratherapeutic)|2 mg/kg BL-8040 administered via SC injection (Supratherapeutic)
62359431|NCT05293171|PLACEBO_COMPARATOR|BL-8040-matching placebo administered via SC injection|BL-8040-matching placebo administered via SC injection
62359432|NCT05293171|ACTIVE_COMPARATOR|400 mg moxifloxacin (1 x 400 mg tablet) administered orally|400 mg moxifloxacin (1 x 400 mg tablet) administered orally
62359433|NCT04042038|EXPERIMENTAL|CBT|Intensive CBT (20 sessions in 1 month)
62359434|NCT04042038|NO_INTERVENTION|Waiting-list|Waiting-list
62359435|NCT03825172||Group I|Caudal Epidural Ultrasonography will be performed in patients aged between 1-24 months
62359436|NCT03825172||Group II|Caudal Epidural Ultrasonography will be performed in patients aged between 25-48 months
62359437|NCT03825172||Group III|Caudal Epidural Ultrasonography will be performed in patients aged between 49-84 months
62359438|NCT04198519|ACTIVE_COMPARATOR|Poor Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Poor cardiovascular health is considered for two or less metrics.
62712363|NCT01803633|ACTIVE_COMPARATOR|Vegan cheese|Non-dairy cheese alternative sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain vegan cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, cream of tartar, high oleic sunflower oil, high PUFA sunflower oil, and palm oil.
62712364|NCT06216574|EXPERIMENTAL|SHINE 1|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62151284|NCT02010684|NO_INTERVENTION|Wait-listed Control Group|Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider. The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening. The research team will also attach a list of local mental health service providers to the letter. The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
62151285|NCT02010684|EXPERIMENTAL|Empowerment and CBT Classes|"Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change experiments designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis."
62151286|NCT02779972||60's decade|60's decade Echo stress test
62151287|NCT02779972||70's decade|70's decade Echo stress test
62151288|NCT02779972||80's decade|80's decade Echo stress test
62151289|NCT02588521|EXPERIMENTAL|AL-794|AL-794 administered orally in a suspension
62151290|NCT02588521|PLACEBO_COMPARATOR|Vehicle|Suspension vehicle alone
62151291|NCT05334433|EXPERIMENTAL|Local anesthesia injection with the comfort in jet (Needless system)|A needle-less injection approach will be used to administer the local anesthetic solution
62151292|NCT05334433|ACTIVE_COMPARATOR|Local anesthesia injection with needle injection (conventional technique).|A conventional aspirating syringe fitted with 27-gauge long needles will be used to administer the local anesthetic solution.
62151293|NCT04584736|EXPERIMENTAL|Livalo 2mg, Ezetrol 10mg|Pitavastatin 2mg, Ezetimibe 10mg
62359439|NCT04198519|ACTIVE_COMPARATOR|Ideal-intermediate Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Ideal cardiovascular health is considered for those with five or more metrics within this qualification, and intermediate for the presence of three or four metrics.
62359440|NCT05390307|EXPERIMENTAL|GLP1RA alone|Participants in the GLP1RA will be prescribed either Liraglutide 3.0mg or Semaglutide 1.0mg, whichever is licensed and available locally. The dose and titration will follow the usual clinical practice. The treatment will continue for 6 months.
62359441|NCT05390307|EXPERIMENTAL|SGLT2i alone|Participants in the SGLT2i group will be prescribed dapagliflozin 5-10mg once daily for 6 months.
62151294|NCT04584736|ACTIVE_COMPARATOR|Livalo 2mg|Pitavastatin 2mg
62151295|NCT04584736|EXPERIMENTAL|Livalo 4mg, Ezetrol 10mg|Pitavastatin 4mg, Ezetimibe 10mg
62151296|NCT04584736|ACTIVE_COMPARATOR|Livalo 4mg|Pitavastatin 4mg
62151297|NCT05347849|EXPERIMENTAL|BPL-003 arm|
62151298|NCT05347849|PLACEBO_COMPARATOR|Placebo arm|
62151299|NCT04012242||NAFLD patients who are scheduled for liver biopsy|
62151300|NCT03531242|EXPERIMENTAL|Cohort A: Initial Non-responders to VEE TC-83 vaccinations|Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, to be administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area.
62359442|NCT05390307|EXPERIMENTAL|GLP1RA/SGLT2i combination|Participants in the combination GLP1RA and SGLT2i group will be prescribed liraglutide 3mg once daily or semaglutide1mg once weekly subcutaneous injection plus dapagliflozin 5-10mg for 6 months.
62359443|NCT05390307|EXPERIMENTAL|GLP1RA/SGLT2i combination with intensive lifestyle changes|Participants in the combination GLP1RA and SGLT2i and intensive weight loss groupwill be prescribed liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus dapagliflozin 5-10mg together with an intensive dietary and lifestyle approach for 6 months. This typically involves dietary advice to reduce energy intake (and may includea period of partial or total meal replacement), accompanied -if available -by a physical activity programme, both supported by behavioural change techniqueswith regular professional contacts.
62359444|NCT05390307|EXPERIMENTAL|Usual Care|Participants in the usual care arm will follow the best medical care by following the international guidelines for 6 months. This usually involves diet and exercise advice.
62359445|NCT04698109||recurrent cervicovaginitis|patients with recurrent cervicovaginitis
61975528|NCT06136702|ACTIVE_COMPARATOR|Educational session and follow-up assessment|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake
62359446|NCT04698109||endometriosis|patients with endometriosis
62359447|NCT04698109||repeated implantation failures|patients with repeated implantation failures
62359448|NCT04698109||healthy volunteers|healthy volunteers
62359449|NCT01770041||Liver resection group|Patients undergoing liver resection and receiving paracetamol (observation of routine administration)
62359450|NCT02096042|EXPERIMENTAL|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
62359451|NCT02096042|EXPERIMENTAL|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
62359452|NCT02307318|OTHER|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
62359453|NCT05323487|ACTIVE_COMPARATOR|Bumetanide 10 mg|Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
62359454|NCT05323487|ACTIVE_COMPARATOR|Bumetanide 5 mg|5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
62359455|NCT05323487|ACTIVE_COMPARATOR|Bumetanide 2.5 mg|2.5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
62359456|NCT05323487|ACTIVE_COMPARATOR|Bumetanide 1.25 mg|1.25 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
62359457|NCT04709718||churgery of geant liver hemangioma|
62359458|NCT04460248|EXPERIMENTAL|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|
62359459|NCT03670901|EXPERIMENTAL|JHL1101|375 mg/m2 of JHL1101 is given intravenously on D1 of each cycle
62359460|NCT03670901|ACTIVE_COMPARATOR|MabThera|375 mg/m2 of Rituximab is given intravenously on D1 of each cycle
62359461|NCT02904525|EXPERIMENTAL|7T MRI + high resolution spectroscopy|Next to routine imaging, patients undergo an additional 7 tesla MRI for high resolution spectroscopy
62359462|NCT03000686|EXPERIMENTAL|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
62359463|NCT03000686|EXPERIMENTAL|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
62359464|NCT02726126||C group, (n=25)|C group, (n=25) each patient received transdermal placebo patch
62359465|NCT02726126||TDF group, (n=25)|TDF group, (n=25) each patient received transdermal therapeutic system-fentanyl 50μg/h
62359466|NCT02726126||TDM group, (n=25)|TDM group, (n=25) each patient received transdermal therapeutic system containing 7 mg of melatonin
62359467|NCT00592436||1|
62359468|NCT02182180||Protocol participants|All participants enrolled on the protocol
62359469|NCT02591043|OTHER|Follow-up|Patients have not received a structured follow up examination or evaluation of outcome after surgery. Therefore this study aims at conducting a follow up examination regarding functional outcome, pain and radiologic healing in these patients.
62359470|NCT01896661|EXPERIMENTAL|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
62359471|NCT01896661|ACTIVE_COMPARATOR|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
62359472|NCT04521309|NO_INTERVENTION|Control|Standard care only n = 10 patients.
62359473|NCT04521309|EXPERIMENTAL|IVIG dose: 0.15 g/kg|Standard Care + Single dose of 0.20 g/Kg anti-COVID-19 IVIG (experimental drug prepared at DUHS) n= 10 patients
62359474|NCT04521309|EXPERIMENTAL|IVIG dose: 0.20 g/kg|Standard Care + Single dose of 0.25 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
62359475|NCT04521309|EXPERIMENTAL|IVIG dose: 0.25 g/kg|Standard Care + Single dose of 0.30 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
62359476|NCT04521309|EXPERIMENTAL|IVIG dose: 0.30 g/kg|Standard Care + Single dose of 0.35 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
62359477|NCT03347006|PLACEBO_COMPARATOR|Placebo|Placebo control
62359478|NCT03347006|EXPERIMENTAL|Dose 1|1.5 g of omega-3 supplement
62359479|NCT03347006|EXPERIMENTAL|Dose 2|3.0 g of omega-3 supplement
62359480|NCT03347006|EXPERIMENTAL|Dose 3|4.5 g of omega-3 supplement
62359481|NCT02352103|ACTIVE_COMPARATOR|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
62359482|NCT02352103|EXPERIMENTAL|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
62359483|NCT03091595|EXPERIMENTAL|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
62359484|NCT03091595|ACTIVE_COMPARATOR|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
62522805|NCT04765527|EXPERIMENTAL|Turmeric|Dietary supplement, Turmeric Strength for Joint, containing turmeric root extract (with 350 mg curcumin), black pepper extract, boswellia gum resin extract, devil's claw root extract, and ginger root; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
62712365|NCT06216574|EXPERIMENTAL|SHINE 2|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
62151301|NCT03531242|EXPERIMENTAL|Cohort B: Responders to TC-83 or previous C-84 vaccinations|"Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
62151302|NCT00941447|EXPERIMENTAL|Self-Regulation|Self Regulation Arm focuses on increasing participants self-monitoring blood glucose (SMBG) AND awareness of self-regulatory approaches to managing diabetes.
62151303|NCT00941447|EXPERIMENTAL|Self-Monitoring|Self-Monitoring Arm focuses on increasing participants self-monitoring blood glucose (SMBG) and providing nutrition education ONLY.
62151304|NCT01762839|EXPERIMENTAL|Oritavancin|Single-dose intravenous (IV) oritavancin diphosphate
62522806|NCT04765527|PLACEBO_COMPARATOR|Placebo|Placebo tablets; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
62522807|NCT03185234|ACTIVE_COMPARATOR|Real tDCS|Anodal tDCS at an intensity of 2 mA is applied for 10 minutes at a time on 5 consecutive days. The anodal electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere, the cathodal electrode is located supraorbital on the right side. Motor tasks are performed before and after the stimulation.
62522808|NCT03185234|SHAM_COMPARATOR|Sham tDCS|Sham stimulation is applied for 10 minutes at a time on 5 consecutive days. One electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere and a second electrode supraorbital on the right side. Motor tasks are performed before and after the stimulation.
62522809|NCT00102687|EXPERIMENTAL|Aza-5|Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days on a 28 day cycle.
62522810|NCT00102687|EXPERIMENTAL|Aza-5-2-2|Azacitidine administered subcutaneously at 75mg/m\^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.
62522811|NCT00102687|EXPERIMENTAL|Aza-5-2-5|Azacitidine administered subcutaneously at 50mg/m\^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.
62522812|NCT00102687|EXPERIMENTAL|Maintenance Aza 5 days q 4 weeks|Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days every 4 weeks.
62359485|NCT05848973|ACTIVE_COMPARATOR|Healthy diet|The study participants randomized to this arm will be given advice about consuming a healthy diet, i.e. a diet rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; and moderate in red meat and dairy products. The participants will receive 8 weekly, one hour group sessions delivered by trained nutritionists.
62712366|NCT06216574|EXPERIMENTAL|SHINE 3|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62359486|NCT05848973|ACTIVE_COMPARATOR|Mindfulness-based cognitive therapy (MBCT)|The study participants randomized to this arm will be taught the purpose and application of MBCT, namely to modify cognitive and effective processes in the management of depressive symptoms as well as relapse prevention among those with residual depressive symptoms. It is a structured 8-weeks' intervention program delivered in groups, with an all-day practice session around week six and regular reunion sessions thereafter.
62359487|NCT05848973|ACTIVE_COMPARATOR|Healthy diet and MBCT combined|The study participants randomized to this arm will receive both the healthy diet intervention and the MBCT intervention
62151305|NCT01762839|PLACEBO_COMPARATOR|Placebo|Single-dose IV placebo
62151306|NCT01762839|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin tablet
62151307|NCT05757674||Patients|Patients
62151308|NCT05757674||Control|Control
62359488|NCT05848973|NO_INTERVENTION|Control|No particular intervention will be provided to the control group.
62359489|NCT01042938|ACTIVE_COMPARATOR|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks).
62359490|NCT01042938|PLACEBO_COMPARATOR|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks).
62359491|NCT03004976|EXPERIMENTAL|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
62359492|NCT03004976|PLACEBO_COMPARATOR|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
62151309|NCT02817360|EXPERIMENTAL|Intensive therapy|RAS-antagonist and beta-blocker up-to maximal dosages as permitted and tolerated and following national guidelines.
62151310|NCT02817360|OTHER|Conventional therapy|No RAS-antagonist and beta-blocker or at stable dose as per study entrance. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase.
62151311|NCT03132571|EXPERIMENTAL|Naltrexone with Bupropion|Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
62151312|NCT03132571|PLACEBO_COMPARATOR|Placebo with Bupropion|Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
62151313|NCT04281355|EXPERIMENTAL|Randomisation A - Intervention|In pathologically node-negative patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, no regional radiotherapy is given and no axillary lymph node dissection are performed.
62151314|NCT04281355|EXPERIMENTAL|Randomisation B - Intervention|In pathologically node-positive patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, full axillary and regional radiotherapy is given but no axillary lymph node dissection performed.
62151315|NCT01537497|EXPERIMENTAL|100 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
62151316|NCT01537497|EXPERIMENTAL|250 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
62151317|NCT01537497|EXPERIMENTAL|600 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
62151318|NCT01537497|PLACEBO_COMPARATOR|Placebo|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
62522813|NCT00102687|EXPERIMENTAL|Maintenance Aza 5 days q 6 weeks|Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days every 6 weeks.
62522814|NCT01151956||actinic keratosis patients|patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
62522815|NCT03659474|EXPERIMENTAL|cryotherapy by compression|maximum dynamic intermittent compression, programmed to maintain a temperature at 1 ° C
62522816|NCT03659474|EXPERIMENTAL|ice pack|the ankle joint was surrounded by three plastic bags containing crushed ice.
62522817|NCT03659474|EXPERIMENTAL|cold water immersion|articulation of the ankle submerged in cold water at approximately 10 ° C, being controlled by the thermal camera.
62522818|NCT03053336|EXPERIMENTAL|App-technology group|"Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which steps are automatically measured and laboratory values from blood sampling within primary care will be shown.~Intervention: App-technology to increase physical activity"
62522819|NCT03053336|NO_INTERVENTION|Control group|The control group will receive standard care
62522820|NCT04754126|EXPERIMENTAL|Intervention Group|Educators and students complete a baseline survey. Educators will implement 6 lessons, each 45 minutes, in the classroom. Educators are free to choose the time between lessons, so some can implement all in one week, others can choose to implement once per week. Educators are given a maximum of 6 weeks to implement the curriculum. Educators and students complete a post-program survey. Students complete a 6- and 12-month follow-up survey.
62522821|NCT04754126|NO_INTERVENTION|Control Group|This group will only complete online surveys that match the time when intervention group is complete the surveys. There is a baseline survey and then a post-survey 6 weeks later for both educators and students. Additionally, students will complete a 6- and 12-month follow-up survey.
62522822|NCT02809170|ACTIVE_COMPARATOR|Arginine|Endothelial function will be assessed before and after arginine supplementation
62522823|NCT02809170|ACTIVE_COMPARATOR|Citrulline|Endothelial function will be assessed before and after citrulline supplementation
62522824|NCT02674230||Extreme obesity|BMI ≥35kg/m2
62522825|NCT02674230||Obesity|BMI 24-34.9kg/m2
62522826|NCT02674230||Normal subjects|BMI \<24kg/m2. No systemic disease, including hypertension, diabetes, liver cirrhosis, chronic kidney disease, and psychiatric disease.
62522827|NCT02127775|EXPERIMENTAL|Sequence B|Day 1: Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)
62522828|NCT02127775|EXPERIMENTAL|Sequence A|Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)
62151319|NCT06128915|EXPERIMENTAL|Vaccination with Prevnar.|Intramuscular vaccination with Prevnar 20
62151320|NCT01792505|EXPERIMENTAL|Biological/Vaccine|
62151321|NCT03038490|EXPERIMENTAL|Study group|The treatment group would be given 2 Sackets of an oral mixture of arginine, glutamine and HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral feeding.
62151322|NCT03038490|NO_INTERVENTION|Control group|All patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. During the study period, vitamin C and zinc supplement would not be given.
62151323|NCT02234999|EXPERIMENTAL|3mg [14C]-CC-122 (Single Dose)|Single oral capsule of 3mg \[14C\]-CC-122. given as a suspension under fasting conditions on Day 1
62522829|NCT06055036|EXPERIMENTAL|Black Impact Intervention|Black Impact Intervention
62522830|NCT06055036|NO_INTERVENTION|Black Impact Waitlist Control|Usual Care
62522831|NCT01304693|EXPERIMENTAL|ESBA1008|ESBA1008 solution, single intravitreal injection
62522832|NCT01304693|ACTIVE_COMPARATOR|LUCENTIS|Ranibizumab 0.5 mg, single intravitreal injection
62522833|NCT06285968|EXPERIMENTAL|Multidimensional Sleep Health Promotion Intervention|"Participants randomized to the intervention arm will receive:~1. A multi-component multidimensional sleep health promotion intervention that includes virtual sleep health and sleep hygiene education, personalized feedback and establishment of a sleep health plan, behavioral coaching, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.~2. Cardiovascular health education materials based on the American Heart Association's Life's Essential 8 framework."
62522834|NCT06285968|NO_INTERVENTION|Standard of care|Participants randomized to the control arm will receive standard American Heart Association Life's Essential 8 cardiovascular health education materials.
62522835|NCT01064323|OTHER|Intermittent leg compression|Intermittent leg compression daily for 3 hrs a day for 4 weeks
62522836|NCT03763760|EXPERIMENTAL|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
62522837|NCT03763760|ACTIVE_COMPARATOR|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
62522838|NCT00941057|EXPERIMENTAL|Estradiol + dienogest + levomefolate|Treatment A
62522839|NCT00941057|ACTIVE_COMPARATOR|Estradiol + dienogest|Treatment B
62522840|NCT00941057|ACTIVE_COMPARATOR|Levomefolate|Treatment C
62522841|NCT03286478|EXPERIMENTAL|Mindfulness|Mindfulness-based body image intervention
62522842|NCT03286478|EXPERIMENTAL|Dissonance|Cognitive dissonance-based body image intervention
62522843|NCT03286478|EXPERIMENTAL|Confident Me|Dove Confident Me body image intervention
62522844|NCT03286478|NO_INTERVENTION|Control|Classes as usual, assessment-only control group.
62522845|NCT05487079||Diabetic|"Diabetes will be defined as below (any or combination):~1. 2h-OGTT: ≥ 11.1 mmol/L~2. FPG (fasting plasma glucose): ≥ 7.0 mmol/L~3. HbA1c; ≥ 48 mmol/mol (6.5%)"
62522846|NCT05487079||Pre-Diabetic|"Prediabetes will be defined as as below (any or combination)~1. 2h-OGTT is between 140 and 199 mg/dL (7.8-11.0 mmol/L)~2. FPG values is between 100 and 125 mg/dL (5.6-6.9 mmol/L)~3. HbA1c is between 42 and 47 mmol/mol (6.0 - 6.4%)"
62522847|NCT05487079||Non-Diabetics|"Normal glucose tolerance (NGT)~1. 2h-OGTT; \< 140 mg/dL (7.8 mmol/L).~2. FPG; \< 100 mg/dL (5.6 mmol/L) and~3. HbA1c; \< 42 mmol/mol"
62522848|NCT03433716|EXPERIMENTAL|PNM group|Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
62522849|NCT03433716|NO_INTERVENTION|Control group|the subects of the control group received no any treatment
62522850|NCT04309214|EXPERIMENTAL|MCT fats|MCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption.
62522851|NCT01222286|EXPERIMENTAL|IPH2101 0.2 mg/kg|0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
62522852|NCT01222286|EXPERIMENTAL|IPH2101 2 mg/kg|2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
62522853|NCT03970837|EXPERIMENTAL|GSK3196165 90mg + csDMARD (Global Cohort)|Participants in Global Cohort received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARD).
62522854|NCT03970837|EXPERIMENTAL|GSK3196165 150mg + csDMARD (Global Cohort)|Participants in Global Cohort received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with csDMARD.
62712367|NCT06216574|EXPERIMENTAL|SHINE 4|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician."
62522855|NCT03970837|ACTIVE_COMPARATOR|Tofacitinib 5mg + csDMARD (Global Cohort)|Participants in Global Cohort received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with csDMARD plus placebo injection weekly to maintain the blind for 52 weeks.
62522856|NCT03970837|PLACEBO_COMPARATOR|Placebo + csDMARD and GSK3196165 90mg + csDMARD (Global Cohort)|Participants in Global Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
62522857|NCT03970837|PLACEBO_COMPARATOR|Placebo +csDMARD and GSK3196165 150mg +csDMARD (Global Cohort)|Participants in Global Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
62522858|NCT03970837|PLACEBO_COMPARATOR|Placebo +csDMARD and Tofacitinib 5mg +csDMARD (Global Cohort)|Participants in Global Cohort received Placebo capsule BID in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with csDMARD plus placebo injection to maintain the blind for 52 weeks.
62522859|NCT03970837|EXPERIMENTAL|GSK3196165 90mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with csDMARD.
62522860|NCT03970837|EXPERIMENTAL|GSK3196165 150mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with csDMARD.
62522861|NCT03970837|ACTIVE_COMPARATOR|Tofacitinib 5mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with csDMARD plus placebo injection weekly to maintain the blind for 52 weeks.
62522862|NCT03970837|PLACEBO_COMPARATOR|Placebo + csDMARD and GSK3196165 90mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
62522863|NCT03970837|PLACEBO_COMPARATOR|Placebo + csDMARD and GSK3196165 150mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
62151324|NCT04478409||Children or adult with Familial Mediterranean fever|"Considering 5 clearly pathogenic (homozygous) genotypes, 15 possibly pathogenic genotypes (5 pathogenic mutations in the heterozygous state, 10 possibly pathogenic mutations in the homozygous or heterozygous state), a number of 80 patients will be necessary to cover the correlation analysis genotype / phenotype.~The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients."
62522864|NCT03970837|PLACEBO_COMPARATOR|Placebo + csDMARD and Tofacitinib 5mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Placebo capsule BID in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with csDMARD plus placebo injection to maintain the blind for 52 weeks.
62522865|NCT05270200|EXPERIMENTAL|Azacitidine combined with Chidamide|Patients will recieve six courses of azacitidine 100mg through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time patients will recieve oral chidamide 5mg per day for no more than 2 years.
62522866|NCT00384176|ACTIVE_COMPARATOR|1|Bevacizumab + FOLFOX
62522867|NCT00384176|EXPERIMENTAL|2|Cediranib + FOLFOX
62522868|NCT05884879||Tinnitus group|"* Adults, i.e. 18-69 year old;~* Pure tone average \<35 dB HL (0.5, 1, 2, 4 kHz);~* Proficient and native speaker of Dutch language;~* Severe unilateral or bilateral tinnitus disorder (TQ \> 46)."
62522869|NCT05884879||Control group|"* Adults, i.e. 18-69 year old;~* Pure tone average \<35 dB HL (0.5, 1, 2, 4 kHz);~* Proficient and native speaker of Dutch language;~* No tinnitus."
62522870|NCT04594174||Responders|
62522871|NCT04594174||Non responders|
62522872|NCT05161806|EXPERIMENTAL|SOK583A1 (40 mg/mL)|participants received a single dose of 2 mg SOK583 in 0.05 mL (40 mg/mL) and completed the study
62522873|NCT06299852|EXPERIMENTAL|Prospective group: STR + trastuzumab emtansine 24 hours after the STR|STR + trastuzumab emtansine. Patients included in the study will will undergo SRT for up to 2 cycles, depending on the location of the irradiated focus, followed by administration of trastuzumab emtansine at a dose of 3.6 mcg/kg once every 3 weeks, up to 4 total cycles. Targeted therapy with trastuzumab emtansine should commence 24 hours after the completion of SRT.
62151325|NCT04478409||Healthy blood donor|Healthy blood donor
62151326|NCT01504984|EXPERIMENTAL|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
62151327|NCT01504984|ACTIVE_COMPARATOR|Glivec film coated tab 4T(400mg)|100mg/tablet, po, 4 tablets once daily for period I\&II D1(crossover)
62151328|NCT02128893|EXPERIMENTAL|Isavuconazole alone|Isavuconazole three times a day on Days 1 and 2 and once a day on Days 3, 4, and 5
62151329|NCT02128893|EXPERIMENTAL|Isavuconazole and Esomeprazole|Esomeprazole daily for 10 days starting on Day 1 and isavuconazole three times a day on Days 6 and 7 and once a day on Days 8, 9, and 10
62151330|NCT03611985|EXPERIMENTAL|Epidiferphane + taxane chemotherapy|
62151331|NCT02717208|ACTIVE_COMPARATOR|HL036 0.5mg/ml|Administration : 2 times per day for one day
62522874|NCT06299852|NO_INTERVENTION|Retrospective group: STR + trastuzumab emtansine > 24 hours after the STR|Patients with oligometastatic HER2+ breast cancer who were treated with trastuzumab-emtansine and who had a history of SRT. Retrospectively, using CT and MRI data, the dynamics of the process will be evaluated according to the RECIST 1.1. Based on the data of the medical documentation of patients, the main statistical indicators will be calculated.
62522875|NCT04376528|EXPERIMENTAL|Cyclosporin A|
62522876|NCT04376528|ACTIVE_COMPARATOR|Mycophenolate Mofetil|
62522877|NCT02363608||standard post surgery care|An initial cohort of consecutive patients admitted to the 15th floor of the hospital on a Monday or Tuesday will form the usual care control arm of the study. Once this cohort is completed, the Caring Canines program will start.
62522878|NCT02363608||Caring Canines program|Once the standard of care cohort is completed, the Caring Canines program will start making visits on the 15th floor and a second cohort of consecutive patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.
62522879|NCT02363608||staff canine-assisted|For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
62522880|NCT02758522|ACTIVE_COMPARATOR|Once-daily insulin|60% of total dose of insulin as NPH insulin in the once-daily regimen was administered subcutaneously before breakfast. Also, 40% in rapid insulin before meals (every 8 hours).
62151332|NCT02717208|ACTIVE_COMPARATOR|HL036 5mg/ml|Administration : 2 times per day for one day
62151333|NCT06307574|EXPERIMENTAL|bpMedManage-S|Intervention group will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. They will complete immediate outcomes assessment 4 weeks after the beginning of the intervention and follow-up outcomes 12 weeks after the beginning of intervention.
62151334|NCT06307574|ACTIVE_COMPARATOR|bpMedManage-P|Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on the education portal. They will complete immediate outcomes assessment 4 weeks after the beginning of the intervention and follow-up outcomes 12 weeks after the beginning of intervention.
62151335|NCT02138201||control|individuals with normal bladder function
62151336|NCT02138201||neurogenic bladder|individuals suffering from neurogenic lower urinary tract dysfunction
62151337|NCT02813174|EXPERIMENTAL|Automated online Compassionate Mind Training|
62151338|NCT06131957|EXPERIMENTAL|Fluoride varnish with SBGC|This group will receive applications of fluoride varnish (containing 5% NaF) with 7.5% SBGC every 3 months for 36 months.
62151339|NCT06131957|ACTIVE_COMPARATOR|Fluoride varnish without SBGC|This group will receive 5% NaF varnish with SBGC every 3 months for 36 months.
62151340|NCT02225288|EXPERIMENTAL|Group A|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group A: 48 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications \[applying in the morning and removing next morning\])
62522881|NCT02758522|ACTIVE_COMPARATOR|Twice-daily insulin|60% of total dose of insulin as NPH insulin in the twice-daily regimen it was given before breakfast and before dinner. Also, 40% in rapid insulin before meals (every 8 hours).
62522882|NCT02758522|ACTIVE_COMPARATOR|Triple-daily insulin|60% of total dose of insulin as NPH insulin in the triple daily regimen it was administered before each meal. Also, 40% in rapid insulin before meals (every 8 hours).
62712368|NCT06216574|EXPERIMENTAL|SHINE 5|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62712369|NCT06216574|EXPERIMENTAL|SHINE 6|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
62522883|NCT03772431|EXPERIMENTAL|Male Informational|Male voice, informational introduction
62522884|NCT03772431|EXPERIMENTAL|Male Motivational|Male voice, motivational introduction
62522885|NCT03772431|EXPERIMENTAL|Female Informational|Female voice, informational introduction
62522886|NCT03772431|EXPERIMENTAL|Female Motivational|Female voice, motivational introduction
62151341|NCT02225288|EXPERIMENTAL|Group B|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group B: 72 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications \[applying in the morning and removing next morning\])
62151342|NCT02225288|EXPERIMENTAL|Group C|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group C: 96 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications \[applying in the morning and removing next morning\])
62151343|NCT02225288|EXPERIMENTAL|Group D|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group D: 120 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications \[applying in the morning and removing next morning\])
62151344|NCT00722865|OTHER|Avastin (Bevacizumab)|single-arm, open-label
62151345|NCT04048226|PLACEBO_COMPARATOR|Control group|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
62151346|NCT04048226|EXPERIMENTAL|Dexmedetomidine-Ketamine group|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
62151347|NCT05636345|EXPERIMENTAL|Intervention group|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
62522887|NCT00010608|EXPERIMENTAL|Transcendental Meditation program|A mental technique for stress reduction which is natural, easy and effortless and is practiced sitting in a chair with eyes closed for 20 minutes twice a day.
62522888|NCT00010608|ACTIVE_COMPARATOR|Health Education|A lifestyle modification program for improving diet, exercise, salt intake and substance use.
62522889|NCT04691310|ACTIVE_COMPARATOR|Kinesio taping study|Kinesio tex gold tape was applied to neck localised lymphedema as stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
62522890|NCT04691310|SHAM_COMPARATOR|Kinesio taping sham|Kinesio tex gold tape was applied to neck localised lymphedema as no-stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
62522891|NCT04158349|EXPERIMENTAL|Dose Level 0|Dose Level 0: 85 mg/m2 Oxaliplatin IP every 2 weeks
62522892|NCT04158349|EXPERIMENTAL|Dose Level 1|Dose Level 1: 95 mg/m2 Oxaliplatin IP every 2 weeks
62522893|NCT04158349|EXPERIMENTAL|Dose Level 2|Dose Level 2: 105 mg/m2 Oxaliplation IP every 2 weeks
62522894|NCT02219971|EXPERIMENTAL|Kukoamine B Mesilate 0.005mg/kg|Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
62522895|NCT02219971|EXPERIMENTAL|Kukoamine B Mesilate 0.02mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
62522896|NCT02219971|EXPERIMENTAL|Kukoamine B Mesilate 0.04mg/kg +Placebo|"Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
62522897|NCT02219971|EXPERIMENTAL|Kukoamine B Mesilate 0.08mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
62522898|NCT02219971|EXPERIMENTAL|Kukoamine B Mesilate 0.12mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
62522899|NCT02219971|EXPERIMENTAL|Kukoamine B Mesilate 0.24mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
62522900|NCT02219971|EXPERIMENTAL|Kukoamine B Mesilate 0.48mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
62522901|NCT04912336||VV-ECMO|Patients supported because of respiratory failure by Veno-Venous Extra Corporeal Membrane Oxygenator.
62522902|NCT04912336||VA-ECMO|Patients supported because of circulatory failure by Veno-Arterial Extra Corporeal Membrane Oxygenator.
62522903|NCT00307034|EXPERIMENTAL|2-dose group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
62522904|NCT00307034|EXPERIMENTAL|Comparator group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-3-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
62522905|NCT05665920|ACTIVE_COMPARATOR|Standard Whole breast Radiotherapy|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
62522906|NCT05665920|EXPERIMENTAL|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated radiation: Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
62522907|NCT00112346|ACTIVE_COMPARATOR|A|
62522908|NCT00112346|ACTIVE_COMPARATOR|B|
62522909|NCT00982449|ACTIVE_COMPARATOR|4 mCi of I-FIAU|GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-4.
62522910|NCT00982449|ACTIVE_COMPARATOR|2 mCi of I-FIAU|GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-2.
62522911|NCT00759902|OTHER|1|Treatment A (test product) followed by Treatment B (reference product)
62522912|NCT00759902|OTHER|2|Treatment B (reference product) followed by Treatment A (test product)
62522913|NCT03695861|EXPERIMENTAL|Whole-body 18F-FDG PET-CT scan|
62522914|NCT05726175|EXPERIMENTAL|RC48 and AK105|Disitamab Vedotin(RC48) combined with Penpulimab(AK105) as neoadjuvant therapy
62522915|NCT03680287|ACTIVE_COMPARATOR|Uninterrupted Sleep|Participants will be permitted to sleep without interruption for 8 hours.
62522916|NCT03680287|EXPERIMENTAL|Sleep Disruption|Participants will be repeatedly awakened throughout the night according to a standardized protocol.
62522917|NCT03875937|EXPERIMENTAL|Tranexamic acid 1 gram intramuscularly|Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.
62522918|NCT03764436|EXPERIMENTAL|LEAPS-NCHD Program - Group 1|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
62522919|NCT03764436|EXPERIMENTAL|LEAPS-NCHD Program - Group 2|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
62522920|NCT03764436|EXPERIMENTAL|LEAPS-NCHD Program - Group 3|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
62522921|NCT01479257||Bilingual Latinos|Bilingual Houston area Latinos surveyed for 7 continuous days with objective and subjective assessments using accelerometer and smart phone.
62522922|NCT05046665|OTHER|Administration of 89Zr-Girentuximab|Administration of 89Zr-Girentuximab as per protocol
62522923|NCT01908413|EXPERIMENTAL|CUDC-427|
61975529|NCT06136702|EXPERIMENTAL|Educational session, self-sampling and follow-up assessment|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. In addition, women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site. The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time.
62522924|NCT04670666|EXPERIMENTAL|MADALENA|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association, oral;~1 tablet empagliflozin + linagliptin association placebo, oral;~1 tablet metformin placebo, oral."
62522925|NCT04670666|ACTIVE_COMPARATOR|Metformin + empagliflozin + linagliptin|"The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association placebo, oral;~1 tablet empagliflozin + linagliptin association, oral;~1 tablet metformin, oral."
62522926|NCT01576094|ACTIVE_COMPARATOR|Milrinone|Milrinone (MR) lactate 1 mg/ml: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission; dose 3, after 2 hours of stability with dose 2, and maintained up to 48 hours. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
62522927|NCT01576094|ACTIVE_COMPARATOR|Levosimendan|
62522928|NCT02592109|EXPERIMENTAL|Enhanced Counseling using CFR based on LP|"The counseling will be done by individual face-to-face communications. The intervention's arm will get a counseling with an additional of 7-day cycle with adequate n-3 and optimal n-3/6 ratio for complementary feeding menu obtained from linear programming formulation.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet; definition, function, and source of omega-3; example of menu that contains adequate omega-3. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
62522929|NCT02592109|ACTIVE_COMPARATOR|General CFR Counseling|"The control's arm will get general counseling combining balance diet and IYCF principal, which already been used by Ministry of Health, with additional of 7-day cycle menu guidance modified from existing or available menu which can be downloaded for public on Ministry of Health official website.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet based on Ministry of Health's Recommendation, and example of balanced diet menu. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
62522930|NCT05726760||Study group - Parturients having spinal anaesthesia|ASA 1 and 2 full term (37-42 weeks), parturients with singleton pregnancy, normal placental position, scheduled for category 4 LSCS under 'single-shot' spinal anaesthesia will be recruited. The investigators intend to recruit 60 parturients. The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. A patient information leaflet will be provided for the parturients.
62522931|NCT05726760||Control group - Parturients not having spinal anaesthesia|6 parturients will be recruited as a control group. ASA 1 and 2 full term (37-42 weeks), parturients with singleton pregnancy, normal placental position, scheduled for category 4 LSCS under 'single-shot' spinal anaesthesia will be recruited.
62522932|NCT02377063|OTHER|pressed juice 6 bottles|Subjects will consume pressed juice daily for 3 days.
62522933|NCT03102593|EXPERIMENTAL|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
62522934|NCT03102593|EXPERIMENTAL|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
62522935|NCT03102593|PLACEBO_COMPARATOR|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
62522936|NCT05927831|EXPERIMENTAL|Grape seed extract|grape seed extract with 95% proanthocyanins will be applied topically to the hypersensitive dentin area for 10 minutes, followed by rinsing with water.
62522937|NCT05927831|EXPERIMENTAL|Low-level laser therapy|The low-level laser diode treatment of 810 nm will be performed using a commercially available diode laser device. The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode starting at a distance of 5-6 mm away from the hypersensitive tooth area and slowly approaching within a distance of 2-3mm in a scanning motion covering the entire hypersensitive tooth area for a period of 30 seconds to 1 minute.
62522938|NCT05927831|EXPERIMENTAL|Combination of low-level laser therapy and grape seed extract|Grape seed extract will be applied topically to the hypersensitive dentin area for 10 minutes, followed by low-level laser diode treatment.
62522939|NCT02776579|EXPERIMENTAL|Girls-only resistance training|8 weeks of 2-3x/week girls-only resistance training class with a female strength and conditioning specialist.
62522940|NCT02776579|NO_INTERVENTION|No resistance training|8 weeks of usual activity.
62522941|NCT04378517|OTHER|ADHD FAM-SOTC support: A Pilot Study|"Phase-I, a pilot study to evaluate the feasibility of offering a 5-week intervention for families of adolescents diagnosed with ADHD at BUGL. The outcome helps to determining the feasibility of subjecting the intervention to a more rigour and a more expensive and time-consuming RCT.~Phase-II and III are an RCTs to determine the benefit of a FAM-SOTC intervention: Is there a significant difference in the impact of FAM-SOTC intervention:~From caregiver's perspective (phase II) on the experience of support for, family functioning, believes, coping patterns, general well-being, parental adaptation and parental assessment of ADHD symptoms and adolescent developmental disruptive behaviour, compared to caregivers receiving delayed treatment?~From adolescents' perspective (Phase-III) in the assessment of adolescents own self-awareness and self-esteem, after their parents receive FAM-SOTC intervention, compared to a group of adolescents where caregivers receive delayed treatment?"
62522942|NCT01359644|EXPERIMENTAL|Treatment A: PSI-7977 + Daclatasvir|Genotype 1a or 1b
62522943|NCT01359644|EXPERIMENTAL|Treatment B: PSI-7977 + Daclatasvir|Genotype 2 or 3
62522944|NCT01359644|EXPERIMENTAL|Treatment C: PSI-7977 + Daclatasvir|Genotype 1a or 1b
62522945|NCT01359644|EXPERIMENTAL|Treatment D: PSI-7977 + Daclatasvir|Genotype 2 or 3
62522946|NCT01359644|EXPERIMENTAL|Treatment E: PSI-7977 + Daclatasvir + Ribavirin|Genotype 1a or 1b
62522947|NCT01359644|EXPERIMENTAL|Treatment F: PSI-7977 + Daclatasvir+ Ribavirin|Genotype 2 or 3
62522948|NCT01359644|EXPERIMENTAL|Treatment G: PSI-7977 + Daclatasvir|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
62522949|NCT01359644|EXPERIMENTAL|Treatment H: PSI-7977 + BMS-790052 + Ribavirin|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
62522950|NCT01359644|EXPERIMENTAL|Treatment I: PSI-7977 + Daclatasvir|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
62522951|NCT01359644|EXPERIMENTAL|Treatment J: PSI-7977 + Daclatasvir + Ribavirin|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
62522952|NCT04857463|EXPERIMENTAL|Nutritional supplement drink|Nutritional supplement, this group receives a nutritional supplement for a period of 12 weeks.
62522953|NCT04857463|PLACEBO_COMPARATOR|Nutritional education|Qualified clinical dietitians provide regular nutrition education and ensure the effectiveness of nutrition education
62151348|NCT00828178|ACTIVE_COMPARATOR|Omega-3|3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery
62151349|NCT00828178|PLACEBO_COMPARATOR|corn starch|corn starch; flow-mediated dilation of the brachial artery
62151350|NCT03971539|PLACEBO_COMPARATOR|SRD part: Placebo|Single rising dose (SRD) part: Placebo film-coated tablet matching BI 894416 taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
62712370|NCT06216574|EXPERIMENTAL|SHINE 7|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62712371|NCT06216574|EXPERIMENTAL|SHINE 8|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids."
62712372|NCT06216574|EXPERIMENTAL|SHINE 9|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62151351|NCT03971539|EXPERIMENTAL|SRD part: 75 mg BI 894416|Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
62522954|NCT04857463|NO_INTERVENTION|Healthy control|No intervention was done to this group, only blood collection, physical performance and anthropometric assessment were done.
62522955|NCT05019625||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
62522956|NCT05019625||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
62151352|NCT03971539|EXPERIMENTAL|SRD part: 125 mg BI 894416|Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
62522957|NCT05019625||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
62522958|NCT05019625||Ultrasound and myography testing|We will ask eligible volunteers to provide a single urine sample, a single blood draw, and undergo ultrasound and electrical impedance myography studies once.
62151353|NCT03971539|EXPERIMENTAL|SRD part: 170 mg BI 894416|Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
62522959|NCT04934150|ACTIVE_COMPARATOR|M1 stimulation|10 Hz stimulation of left motor area
62151354|NCT03971539|PLACEBO_COMPARATOR|MRD part: Placebo|Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
62151355|NCT03971539|EXPERIMENTAL|MRD part: 10 mg BI 894416|Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
62522960|NCT04934150|ACTIVE_COMPARATOR|DLPFC stimulation|5 Hz stimulation of left dorsolateral prefrontal cortex
62522961|NCT04934150|SHAM_COMPARATOR|Sham TMS|Sham TMS over the left M1 area
62522962|NCT04341376|EXPERIMENTAL|Enhanced First Connections|Enhanced First Connections is a short-term risk assessment and response home visiting referral program. The goal of Enhanced First Connections is to identify family needs and link families to community resources, including evidence based home visiting models. Enhanced First Connections includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation. Women who enroll in Enhanced First Connections are expected to receive between four and eight home visits before being referred to other community resources.
62522963|NCT04341376|NO_INTERVENTION|Treatment as Usual|Women who receive Treatment as Usual will follow the usual course of clinical care throughout their pregnancy and into the postpartum period, and will be eligible for the typical array of community services that may be offered to them.
62522964|NCT01374139|EXPERIMENTAL|Cohort 1|
62522965|NCT01374139|EXPERIMENTAL|Cohort 2|
62522966|NCT02795377||male subjects with arterial hypertension|Measurements will be taken at baseline.
62522967|NCT02795377||male subjects without arterial hypertension and no CAD|Measurements will be taken at baseline.
62522968|NCT02795377||male subjects with hypertensive crises|Measurements will be taken before and after 4 hours and normalization of arterial blood pressure by urapidil.
62522969|NCT02795377||male subjects with stable CAD|Measurements will be taken before and after transfemoral coronary diagnostic angiography.
62522970|NCT04606836|EXPERIMENTAL|Prospective Cases|These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).
62522971|NCT04606836|NO_INTERVENTION|Retrospective Controls|Controls will be gathered retrospectively from chart reviews where patient did not receive a intercostal nerve blocker bilaterally.
62522972|NCT04883970|EXPERIMENTAL|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 124I-18B10(10L) PET/CT scans
62151356|NCT03971539|EXPERIMENTAL|MRD part: 25 mg BI 894416|Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
62151357|NCT03971539|EXPERIMENTAL|MRD part: 50 mg BI 894416|Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
62151358|NCT03971539|EXPERIMENTAL|MRD part: 60 mg BI 894416|Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
62522973|NCT02244879|PLACEBO_COMPARATOR|placebo|In this arm, 64 patients will receive a tablet of placebo once/day for 6 months
62522974|NCT02244879|EXPERIMENTAL|resveratrol 40|In this arm, 64 patients will receive a tablet of 40mg resveratrol once/day for 6 months
62522975|NCT02244879|EXPERIMENTAL|resveratrol 500|In this arm, 64 patients will receive a tablet of 500 mg resveratrol once/day for 6 months
62522976|NCT05558995|EXPERIMENTAL|MDD patient|Male and female participants (N=10) with ages between 18 and 50 have a confirmed diagnosis of major depressive episode, are experiencing a current episode (following DSM-5 criteria),
62522977|NCT03903458|EXPERIMENTAL|Tinostamustine and Nivolumab|Experimental drug combination arm
62522978|NCT02671240||- Patients with behavioral addiction|
62522979|NCT02671240||- Patients with no behavioral addiction|
62522980|NCT02429934|ACTIVE_COMPARATOR|Abatacept also known as Orencia also known as CTLA4Ig|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
62522981|NCT02429934|PLACEBO_COMPARATOR|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks
62522982|NCT03056261|EXPERIMENTAL|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
62522983|NCT03056261|PLACEBO_COMPARATOR|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
62712373|NCT06216574|EXPERIMENTAL|SHINE 10|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
62522984|NCT06428630|EXPERIMENTAL|Investigative group- Those with OLP|The investigative will apply the dexamethasone oral rinse 0.5 mg/5ml treatment. The oral rinse is considered a topical rinse because it is confined to the oral cavity (topical) and not swallowed. Subjects will be reminded by the study team via a phone call a few days before their visit that they must not drink water or eat at least 60 min before their visit. Once we get to the stage of the rinse, we will first their oral cavity with gauze. Then, we will instruct the subject to Rinse their mouth with 0.5mg/5ml dexamethasone for 2 min, then spit into a provided plastic cup the oral rinse. This will then be discarded down the drain.
62522985|NCT06428630|ACTIVE_COMPARATOR|Control 1 - 5 minute rinse|The first control group will apply the dexamethasone oral rinse 0.5 mg/5ml treatment. The oral rinse is considered a topical rinse because it is confined to the oral cavity (topical) and not swallowed. Subjects will be reminded by the study team via a phone call a few days before their visit that they must not drink water or eat at least 60 min before their visit. Once we get to the stage of the rinse, we will first their oral cavity with gauze. Then, we will instruct the subject to Rinse their mouth with 0.5mg/5ml dexamethasone for 5 min, then spit into a provided plastic cup the oral rinse. This will then be discarded down the drain.
62522986|NCT06428630|ACTIVE_COMPARATOR|Control 2- 2 minute rinse|The second control group will apply the dexamethasone oral rinse 0.5 mg/5ml treatment. The oral rinse is considered a topical rinse because it is confined to the oral cavity (topical) and not swallowed. Subjects will be reminded by the study team via a phone call a few days before their visit that they must not drink water or eat at least 60 min before their visit. Once we get to the stage of the rinse, we will first their oral cavity with gauze. Then, we will instruct the subject to Rinse their mouth with 0.5mg/5ml dexamethasone for 2 min, then spit into a provided plastic cup the oral rinse. This will then be discarded down the drain.
62522987|NCT02418143||Implantable electronic device placement|CorMatrix CanGaroo ECM envelope for an implantable electronic device placement following a battery change out or upgrade.
62522988|NCT03356028|OTHER|impacted by the attack of 14 July 2016|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire following the mass trauma of 14 July 2016 in Nice on a sample of exposed pediatric population
62151359|NCT02070276|NO_INTERVENTION|Standard Clinical Practice|"This arm is considered the current clinical standard for spinal anesthesia; its used as a control sample and statistical reference. During the induction phase the patient is fitted with a non-invasive blood pressure monitoring, three-lead ECG, pulse oximetry and peripheral intravenous device. The pressure control is set as the standard every 5 minutes until the procedure under spinal anesthesia, the cuff pressure is placed on the arm that is going to be on top during spinal anesthesia.~Data is recorded and vital signs of the patient and is put an infusion of crystalloid (0.9% NaCl or Ringer's acetate) with administration of 500 ml during the entire procedure until the beginning of the operation."
62151360|NCT02070276|EXPERIMENTAL|Trans-thoracic echocardiography|"In addition to the current clinical standard (arm A of the study) a trans-thoracic echocardiography is performed with the aim of assessing patient's volume status, identifying if he is responsive to fluid and could benefit from their administration. The echocardiography is performed with the subcostal projection to assess the size of the abdominal inferior vena cava and its collapsing during breathing.~According to different pre-established parameters, the patient is defined as unresponsive to fluids or responsive. If it's not responsive, he proceed to spinal anesthesia. Otherwise investigators proceed to the administration of crystalloid (NaCl 0.9% or Hartmann's solution second clinical evaluation) and at the end he's rerun an echocardiographic assessment."
62522989|NCT03356028|OTHER|control group|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire of children controls
62522990|NCT06211153||Asciminib|
62522991|NCT01046799|EXPERIMENTAL|Entecavir|
62522992|NCT01946191|EXPERIMENTAL|Coaching Group|"* 24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts~* Online self-monitoring~* Real-time updates to primary care physicians"
62522993|NCT01946191|ACTIVE_COMPARATOR|Tracking Group|-Online self-monitoring
62522994|NCT02689063|EXPERIMENTAL|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
62522995|NCT02689063|ACTIVE_COMPARATOR|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
62151361|NCT02070276|EXPERIMENTAL|Passive Leg Raising Test|"In addition to the arm A of the study, is performed a measurement of end-tidal CO2 (EtCO2) by trans-nasal canula with a patient positioned in semi-recumbent position. After, investigators run the Passive Leg Raising Test (PLRT): the position of the bed is changed in such manner to bring the trunk from 45° to 0° and accordingly the legs from 0° to 45°. Measurements are performed before and during the maneuver : an etCO2 increasing more than 12% from baseline was interpreted as fluid-responsive.~If the patient is not responsive to fluids, the patient is moving to the spinal anesthesia. If the patient is responsive investigators proceed to bolus administration, the patient returns to the initial PLRT position and is run again the PLRT until the patient is no longer responsive to fluids."
62522996|NCT02689063|ACTIVE_COMPARATOR|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
62522997|NCT02689063|PLACEBO_COMPARATOR|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
62522998|NCT04920916|EXPERIMENTAL|Dupilimab|Dupilimab: 600 mg, given as two 300 mg subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
62522999|NCT04920916|PLACEBO_COMPARATOR|Placebo|Normal saline will be given as two one mL subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (1 mL) will be given on days 14 and 28.
62523000|NCT00974961|ACTIVE_COMPARATOR|Levobupivacaine|Lumbar puncture with Levobupivacaine for spinal anesthesia
62523001|NCT00974961|ACTIVE_COMPARATOR|Bupivacaine|Lumbar puncture with Bupivacaine for spinal anesthesia
62151362|NCT02917148||aGVHD|Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.
62151363|NCT02917148||non aGVHD|Patients who undergo allogeneic transplant but do not develop aGVHD.
62151364|NCT03432871|EXPERIMENTAL|Nicotinamide Riboside|"This is an open-label experimental medicine study.~All subjects will receive the same dosage of the supplement Nicotinamide Riboside."
62523002|NCT05865080|ACTIVE_COMPARATOR|group K|group K (63 patients): Received 0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution,
62523003|NCT05865080|PLACEBO_COMPARATOR|group C|group C (Controlled) (63 patients): Received 10 ml of normal saline followed by infusion of 0.1 ml/kg/hr. as 20 ml solution.
62523004|NCT02726893||patients undergoing colonoscopy|patients undergoing colonoscopy were observed in terms of the bowel preparation quality which is measured by Boston Bowel Preparation Scale (BBPS).
62523005|NCT04204759|EXPERIMENTAL|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the ventromedial prefrontal cortex and one cathodal electrode (35cm2) will be placed over the occipital cortex. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 30 seconds at the beginning and end of the stimulation period.
62523006|NCT04204759|SHAM_COMPARATOR|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
61975530|NCT01214356|PLACEBO_COMPARATOR|Lower Dose Vitamin D|Vitamin D3 supplementation of 400 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
62523007|NCT02337140|EXPERIMENTAL|Pacemaker|Patient who have been implanted with a pacemaker after TAVI
62523008|NCT02337140|ACTIVE_COMPARATOR|No Pacemaker|Patient who have not been implanted with a pacemaker after TAVI
62523009|NCT02283164|EXPERIMENTAL|Treatment|Hazardous materials online education and study feedback
62523010|NCT02283164|ACTIVE_COMPARATOR|Control then treatment|Hazardous materials online education and study feedback
61975531|NCT01214356|ACTIVE_COMPARATOR|Higher Dose Vitamin D|Vitamin D3 supplementation of 4000 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
62523011|NCT03898921|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to \<15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
62523012|NCT03898921|ACTIVE_COMPARATOR|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
62523013|NCT00391079|EXPERIMENTAL|A|
62523014|NCT00391079|PLACEBO_COMPARATOR|B|
62523015|NCT00774696|EXPERIMENTAL|1|Clarithromycin 500 mg Tablets
62523016|NCT00774696|ACTIVE_COMPARATOR|2|BIAXIN® 500 mg tablets
62151365|NCT03147586|ACTIVE_COMPARATOR|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
62712374|NCT06216574|EXPERIMENTAL|SHINE 11|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62712375|NCT06216574|EXPERIMENTAL|SHINE 12|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy -NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician."
62151366|NCT03147586|PLACEBO_COMPARATOR|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
62151367|NCT05576701|EXPERIMENTAL|Laughter Therapy|Laughter therapy consists of group-based interventions that include yoga breathing exercises and stillness. Laughter education is a form of exercise with gratuitous laughter and childlike play. Laughter therapy practices consist of four steps. These; warming exercises, deep exercises, playing childlike games and entertainment (eg greeting laughter, lion laughter, milk waving sounds, quiet laughter, etc.). Laughter therapy sessions in the study were carried out for 4 weeks and three times a week. Laughter therapy has been applied by researchers who have a leader certificate.
62151368|NCT05576701|ACTIVE_COMPARATOR|Control|"The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. The patients were followed for four weeks. Before the study, data collection tools were applied to the patients. Again, after the study started and the study ended, all other data collection tools were applied, except the Patient Information Form."
62523017|NCT05791682|ACTIVE_COMPARATOR|MICROFILLED RESIN SEALANT|-Microfilled rein sealant (fissurit FX) after etching, washing, drying, sealant was gradually applied along the fissure of first permanent molar, Immediately light cured for 20 sec
62523018|NCT05791682|ACTIVE_COMPARATOR|NANOFILLED RESIN SEALANT|Nanofilled resin sealant (Grandioseal) after etching, washing, drying, sealant was gradually applied along the fissure. Immediately light cured for 20 sec.
62523019|NCT05791682|ACTIVE_COMPARATOR|FLOWABLE COMPOSITE|Flowable composite (Te-Econom Flow) after etching, washing, drying, adhesive was applied and dried under gentle air flow for 2-3 sec and was light cured. A uniform layer of flowable composite was applied and light cure for 20 sec.
62523020|NCT05791682|ACTIVE_COMPARATOR|UNFILLED RESIN SEALANT|Unfilled resin sealant (clinpro) after etching, washing, drying, sealant will be gradually applied along the fissure. Immediately light cure for 20 sec.
61975532|NCT03487757|ACTIVE_COMPARATOR|Control Group|After recording the demographic and clinical information at the beginning of the study and after 8 weeks, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They won't receive any intervention by this time. At the end of 8 weeks, they may be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training.
62523021|NCT04658836|EXPERIMENTAL|Triamcinolone application|Patients will recieve intratympanic triamcinolone acetonide 24h before vestibular schwannoma surgery
62523022|NCT00750308|ACTIVE_COMPARATOR|tadalafil, ramapril, combo, placebo|placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks
62523023|NCT00750308|ACTIVE_COMPARATOR|ramipril, tadalafil, placebo, combo|placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks
62523024|NCT00750308|ACTIVE_COMPARATOR|combo, placebo, tadalafil, ramipril|ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks
62523025|NCT00750308|ACTIVE_COMPARATOR|placebo, combo, ramipril, tadalafil|placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks
62523026|NCT00750308|ACTIVE_COMPARATOR|tadalafil, placebo, ramipril, combo|placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks
62523027|NCT00750308|ACTIVE_COMPARATOR|ramipril, combo, tadalfil, placebo|placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks
62523028|NCT00750308|ACTIVE_COMPARATOR|combo, ramipril, placebo, tadalafil|ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks
62712376|NCT06216574|EXPERIMENTAL|SHINE 13|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62151369|NCT03226600|ACTIVE_COMPARATOR|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
62712377|NCT06216574|EXPERIMENTAL|SHINE 14|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
62712378|NCT06216574|EXPERIMENTAL|SHINE 15|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
62523029|NCT00750308|ACTIVE_COMPARATOR|placebo, tadalafil, combo, ramipril|placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks
62712379|NCT06216574|EXPERIMENTAL|SHINE 16|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy."
62712380|NCT00414375|ACTIVE_COMPARATOR|1|Drainage with interval appendectomy
62712381|NCT00414375|EXPERIMENTAL|2|appendectomy on presentation
62151370|NCT03226600|EXPERIMENTAL|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
62523030|NCT00750308|ACTIVE_COMPARATOR|tadalafil, combo, placebo, ramipril|placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks
62523031|NCT00750308|ACTIVE_COMPARATOR|ramipril, placebo, combo, tadalafil|placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks
62523032|NCT00750308|ACTIVE_COMPARATOR|combo, tadalafil, ramipril, placebo|ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks
62523033|NCT00750308|ACTIVE_COMPARATOR|placebo, ramipril, tadalafil, combo|placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks
62523034|NCT03846713|ACTIVE_COMPARATOR|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
62523035|NCT03846713|EXPERIMENTAL|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
62523036|NCT03438396|EXPERIMENTAL|Single arm|tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)
62523037|NCT02362984|PLACEBO_COMPARATOR|Control Group|Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
62523038|NCT02362984|EXPERIMENTAL|DLBS1033 Group|DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period
62523039|NCT05886452||DT1fA contact lenses|Subjects fitted with DT1fA contact lenses
62523040|NCT02906241|EXPERIMENTAL|Patients--Intervention|Patients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
62523041|NCT02906241|NO_INTERVENTION|Patients--Usual Care|Patients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
62523042|NCT02906241|OTHER|Physicians|Physicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
62523043|NCT03679052|ACTIVE_COMPARATOR|Group I (Mirtazapine group): (n=100)|
62712382|NCT05401838|EXPERIMENTAL|G-BCBT|68 active duty service member participants assigned to G-BCBT will undergo 12 group therapy sessions scheduled on a weekly basis.
62151371|NCT05763823|EXPERIMENTAL|Letermovir|Chinese HSCT recipients will receive 240 mg \[for participants on Cyclosporin A (CsA)\] or 480 mg (for participants not on CsA) Letermovir orally or IV once daily through week 14 (\~100 days) post-transplant.
62151372|NCT04251455||TMJ disease/disorder characterisation|Patients with the diagnosis disc displacement without reduction (DDwoR), or disc displacement with reduction (DDwR), or osteoarthritis (OA), or chronic inflammatory arthritis (CIA) were designated to TMJ surgery. According to the Swedish national guidelines on TMJ surgery DDwoR, OA, and CIA patients had arthroscopy and DDwR had discectomy.
62523044|NCT03679052|ACTIVE_COMPARATOR|Group II (Clonidine group): (n=100)|
62523045|NCT03679052|PLACEBO_COMPARATOR|Group III (Control group): (n=100)|
62151373|NCT06562881|EXPERIMENTAL|Scheduling Navigation|Participants will be assigned to a scheduler.
62712383|NCT05401838|ACTIVE_COMPARATOR|DBT|68 active duty service member participants in the DBT condition will receive 24 weekly group therapy sessions each lasting 90 minutes.
62151374|NCT06562881|ACTIVE_COMPARATOR|Without Scheduling Navigation|Participants will not be assigned to a scheduler.
62151375|NCT02450084|EXPERIMENTAL|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl 800 µg for 48 hours postoperatively.
62151376|NCT02450084|SHAM_COMPARATOR|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl 800µg for 48 hours postoperatively.
62151377|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
62523046|NCT01534923||Pts having colorectal cancer screening|The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).
62523047|NCT05134896|EXPERIMENTAL|normal healthy group|Spatial light modulator
62523048|NCT01460901|EXPERIMENTAL|GD2 CAR modified Tri-virus CTL infusion|A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant.
62523049|NCT00940797|EXPERIMENTAL|DMMET-01|
62523050|NCT00940797|PLACEBO_COMPARATOR|Control|
62523051|NCT04336124|EXPERIMENTAL|CVM-1118 ER|Dose escalation (escalation from 400, 600, 800 to 1200 mg of CVM-1118 ER Capsule)
62523052|NCT02017860|EXPERIMENTAL|Everolimus|Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.
62523053|NCT01176214|EXPERIMENTAL|early tracheostomy|see study description
62523054|NCT01176214|ACTIVE_COMPARATOR|late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
62523055|NCT03343613|EXPERIMENTAL|LY3381916 Escalation|LY3381916 administered orally.
62523056|NCT03343613|EXPERIMENTAL|LY3381916 + LY3300054 Escalation|LY3381916 administered orally and LY3300054 administered intravenously (IV).
62523057|NCT03343613|EXPERIMENTAL|LY3381916 Expansion|LY3381916 administered orally.
62712384|NCT05024552|EXPERIMENTAL|Dose Escalation Arm|"Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy. The induction and reinduction dose of Vyxeos is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion.~Dose level 1: Vyxeos + 120 mg Gilertinib~In the event of a dose-limiting toxicity (DLT) at the initial dose level, a dose level minus (-) 1 is permitted Dose Level -1: Vyxeos + 80 mg Gilertinib"
62712385|NCT05024552|EXPERIMENTAL|Dose Expansion Arm|Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy in the dose determined in the dose escalation arm.
62151378|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
62151379|NCT01775657|EXPERIMENTAL|Air leak present - Analogue|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, air leak present.
62523058|NCT03343613|EXPERIMENTAL|LY3381916 + LY3300054 Expansion B1|"Metastatic triple negative breast cancer (TNBC)~LY3381916 administered orally and LY3300054 administered IV."
62523059|NCT03343613|EXPERIMENTAL|LY3381916 + LY3300054 Expansion B2|"Metastatic non-small cell lung cancer (NSCLC)~LY3381916 administered orally and LY3300054 administered IV."
62523060|NCT03343613|EXPERIMENTAL|LY3381916 + LY3300054 Expansion B3|"Metastatic clear cell carcinoma renal cell carcinoma (RCC)~LY3381916 administered orally and LY3300054 administered IV."
62523061|NCT01955213||Morphine Sulphate|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
62523062|NCT01955213||Fentanyl|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
62523063|NCT01955213||Oxycodone|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
62712386|NCT06314009||Normal Weight|Body Mass Index (BMI) 18.5-24.9 kg/m\^2
62151380|NCT01775657|ACTIVE_COMPARATOR|Air leak absent - Analogue (Pleur Evac)|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, no air leak present
62151381|NCT01775657|EXPERIMENTAL|Air leak present - Digital (Thopaz)|Patients with an air leak present, randomized to Thopaz (digital drainage) monitoring system.
62151382|NCT01775657|ACTIVE_COMPARATOR|Air leak absent - Digital (Thopaz)|Patients randomized to digital system, no air leak present.
62151383|NCT06225323|EXPERIMENTAL|Lidocaine group|Patients will receive Lidocaine infusion for 6 hours
62151384|NCT06225323|PLACEBO_COMPARATOR|Control group|Patients will receive normal saline infusion for 6 hours
62523064|NCT05136118|ACTIVE_COMPARATOR|Group MS|The modified surgeon assisted approach for TAPB Before the closure of the peritoneum, TAPB will be performed; at the level of the umbilicus 8 to 10cms from the midline bilaterally. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin slightly directed towards the ipsilateral anterior superior iliac spine. After feeling the 2 pops of the external and the internal oblique aponeurosis by the anesthesiologist, the surgeon will confirm proper needle placement by his hand inside the abdominal cavity. The LA will be injected after negative aspiration and a bleb will be palpated by the surgeon as the injection continues. The same procedure will be repeated on the other side.
62523065|NCT05136118|ACTIVE_COMPARATOR|Group US|The ultra-sound guided approach for TAPB. After abdominal wall closure, the linear probe of the ultra- sound will be placed perpendicular to the skin at the mid-axillary line between the iliac crest and the costal margin; the TAP will be located between the internal oblique and the transversus abdominis muscle. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin and the 2 pops of the external and the internal oblique aponeurosis will be also felt. The LA will be injected after negative aspiration and its spread in the plane will be observed. The same procedure will be repeated on the other side.
62523066|NCT05625087|EXPERIMENTAL|ALPELISIB ARM|Oral alpelisib (300 mg daily, in 28-day cycle) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice
62523067|NCT05625087|ACTIVE_COMPARATOR|RIBOCICLIB ARM|Oral ribociclib (600 mg daily, 3 weeks on, then 1 week off treatment in 28-day cycles) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice.
62523068|NCT01618188|EXPERIMENTAL|Formulation A|
62523069|NCT01618188|EXPERIMENTAL|Formulation B|
62523070|NCT01618188|ACTIVE_COMPARATOR|Insulin Aspart|
62523071|NCT01330420|EXPERIMENTAL|Relaxation Response Resiliency Program for Depression|"The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients."
62523072|NCT01739920|EXPERIMENTAL|Povidone-iodine|1 drop of povidone-iodine 5% will be instilled at time zero, 20-minute and 28-minute study period.
62523073|NCT01739920|ACTIVE_COMPARATOR|Povidone-iodine and Saline Solution|1 drop of saline solution 0.9% will be instilled at time zero and 20-minute. At 28-minute will be instilled 1 drop of Povidone-iodine 5%.
62523074|NCT06236932|ACTIVE_COMPARATOR|Mediterranean diet group|At baseline (T0), all patients will be subjected to anthropometric determinations, including body weight and height for BMI calculation, body composition by mean of DXA Scan, blood, serum and urine collection, oral cavity swab and stool sampling. Patients will undergo a session of behavioural dietary counselling by which patients will be educated to adhere to a hypocaloric MD for the first 12w (T1).
62523075|NCT06236932|ACTIVE_COMPARATOR|Mediterranean diet plus melatonin group|After the first 12 w of the study (T2), all patients will continue a hypocaloric MD adding the supplementation with 1mg/die of melatonin before bedtime for other 12w.
62523076|NCT04126421|ACTIVE_COMPARATOR|E1 Vitamin E infused HXLPE|E1 Vitamin E infused highly cross-linked polyethylene (HXLPE)
62523077|NCT04126421|ACTIVE_COMPARATOR|Marathon HXLPE|Marathon highly cross-linked polyethylene (HXLPE)
62523078|NCT05403736|EXPERIMENTAL|CARMA|Cardiac Aggressive Risk MitigAtion plan with biosensor monitoring
62523079|NCT04322578|EXPERIMENTAL|Cohort A: Target Therapy Group.|Patients with MET exon 14 skipping will be treated with First line crizotinib or savolitinib and other MET TKIs.
62523080|NCT04322578|EXPERIMENTAL|Cohort B: Chemotherapy or Chemotherapy plus immune checkpoint inhibitor|Patients with MET exon 14 skipping will be treated with chemotherapy.
62523081|NCT04166513|EXPERIMENTAL|Targeted tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions before.
62523082|NCT04166513|ACTIVE_COMPARATOR|Active Control tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with active control tDCS for 10 therapy sessions.
62523083|NCT04166513|EXPERIMENTAL|Targeted tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions.
62523084|NCT04166513|ACTIVE_COMPARATOR|Active Control tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with active control tDCS for 10 therapy sessions.
62523085|NCT01698437|OTHER|Transcranial MR-Guided Focused Ultrasound for Brain Tumors|
62523086|NCT02526511|EXPERIMENTAL|Diagnostic (pMRI)|Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.
62523087|NCT02932228|EXPERIMENTAL|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
62523088|NCT02932228|NO_INTERVENTION|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
62523089|NCT01524250|EXPERIMENTAL|oral prednisone|1250mg oral prednisone daily for 3 days
62523090|NCT01524250|ACTIVE_COMPARATOR|IV methylprednisolone|1000mg IV methylprednisolone daily for 3 days
62712387|NCT06314009||Obese|Pre-pregnancy Body Mass Index (BMI) ≥ 30.0 kg/m\^2
62151385|NCT02039401|EXPERIMENTAL|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
62523091|NCT03096275|EXPERIMENTAL|MMF+MTX+Glucocorticoids|Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.
62151386|NCT05431322|EXPERIMENTAL|Total intravenous anesthesia (TIVA) + Dexmedetomidine|Total intravenous anesthetic drug is propofol. Dexmedetomidine is infused continuously.
62523092|NCT03096275|ACTIVE_COMPARATOR|CYC/AZA+Glucocoticoids|Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks
62523093|NCT04665375|EXPERIMENTAL|DOR/3TC/TDF|100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)
62523094|NCT06091228|NO_INTERVENTION|Control- No tongue scraping full length of study|Oral hygiene instructions before and after non-surgical treatment without inclusion of tongue scraper
62523095|NCT06091228|EXPERIMENTAL|Test 1 - tongue scraping full length of study|Oral hygiene instructions before and after non-surgical treatment with inclusion of tongue scraper
62523096|NCT06091228|EXPERIMENTAL|Test 2 - tongue scraping only after non-surgical therapy|Oral hygiene instructions before and after non-surgical treatment with inclusion of tongue scraper only after treatment
62523097|NCT04701515||Retrospective Cohort|Review electronic medical records of de-identified patients that tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until December 2022
62523098|NCT00570882|ACTIVE_COMPARATOR|Sunitinib 4/2|Sunitinib 50 mg PO 4-week on and 2-week off
62523099|NCT00570882|EXPERIMENTAL|Sunitinib 2/1|Sunitinib 50 mg PO 2-week on 1-week off
62523100|NCT04952077|EXPERIMENTAL|Experimental|
62523101|NCT03828136|EXPERIMENTAL|ACDF with Novum Vitrium® Cervical Interbody Device|A resorbable cervical interbody cage.
62523102|NCT03828136|ACTIVE_COMPARATOR|ACDF with Allograft|Structural allograft made from structural corticocancellous allograft bone.
62523103|NCT01347866|EXPERIMENTAL|Arm D: PF-05212384 + PD-0325901|
62523104|NCT01347866|EXPERIMENTAL|Arm C: PF-05212384 + irinotecan|
62523105|NCT00074737|ACTIVE_COMPARATOR|cenersen, idarubicin|cenersen, idarubicin, no cytarabine
62523106|NCT00074737|ACTIVE_COMPARATOR|cenersen, idarubicin, cytarabine|cenersen, idarubicin, standard dose cytarabine
62523107|NCT00074737|ACTIVE_COMPARATOR|cenersen, idarubicin, HDAC|cenersen, idarubicin, HDAC (high dose cytarabine)
62523108|NCT03772366||Antivitamin K|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Fluindione
62712388|NCT02877017|NO_INTERVENTION|Pre-intervention arm|This arm is the pre-intervention arm of parents and providers before the family safety reporting bundle has been implemented.
62712389|NCT02877017|EXPERIMENTAL|Post-intervention arm|This arm is the post-intervention arm of parents and providers after the family safety reporting bundle has been implemented on the study units.
61975533|NCT03487757|EXPERIMENTAL|Training Group|After recording the demographic and clinical information at the beginning of the study, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They will be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training. After the eight week training program the evaluations will be repeated.
62151387|NCT05431322|NO_INTERVENTION|Total intravenous anesthesia (TIVA)|Total intravenous anesthetic drug is propofol. The ordinary pain is controlled mainly by opioids.
62151388|NCT04534699|EXPERIMENTAL|Hepatic Impaired|KBP-5074 0.5mg tablet orally, Single dose
62523109|NCT03772366||Rivaroxaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Rivaroxaban
62523110|NCT03772366||Apixaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Apixaban
61975534|NCT04704167|ACTIVE_COMPARATOR|3D titanium mesh tray|3D titanium mesh tray as a method of fixation for double-barrel vascularized fibula
62523111|NCT03772366||Control|Women in childbearing age with superficial venous insufficiency without treatment oral anticoagulant or antiplatelet.
62523112|NCT00326287|EXPERIMENTAL|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
62523113|NCT00326287|ACTIVE_COMPARATOR|Ceftriaxone with or without Linezolid|Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d
62523114|NCT04328571|EXPERIMENTAL|OLE enzymatically treated|Participants will receive 1 capsule of OLE enzymatically treated + 1 stick of maltodextrin each day in the morning for 21 days
62523115|NCT04328571|EXPERIMENTAL|OLE + probiotic|Participants will receive 1 capsule of OLE + 1 stick of probiotic each day in the morning for 21 days
62523116|NCT04328571|ACTIVE_COMPARATOR|OLE|Participants will receive 1 capsule of OLE + 1 stick of maltodextrin each day in the morning for 21 days
62523117|NCT02099695|ACTIVE_COMPARATOR|Oxybutynin Chloride|"* Tablet~* Dose 5,0 or 10 mg/ day"
62523118|NCT02099695|PLACEBO_COMPARATOR|Placebo|- Tablet
62523119|NCT01206621||ED patients presenting with dyspnea|
62523120|NCT05000970|EXPERIMENTAL|TRIO PLUS tablet and nurse at day 3|Virtual nurse encounter at 3 days
62523121|NCT05000970|EXPERIMENTAL|TRIO PLUS Tablet and nurse at day 3 and 7|Virtual nurse encounter at 3 days and 7 days
62523122|NCT05000970|PLACEBO_COMPARATOR|TRIO PLUS Group|No encounter
62712390|NCT00512070|EXPERIMENTAL|IIA (0.3mg day melatonin)|0.3mg day melatonin
62712391|NCT00512070|EXPERIMENTAL|IIB (3.0 mg/day melatonin)|3.0 mg/day melatonin
61975535|NCT04704167|EXPERIMENTAL|3D titanium miniplate|3D titanium miniplate as a method of fixation for double-barrel vascularized fibula
62151389|NCT04534699|EXPERIMENTAL|Matched-control Healthy|KBP-5074 0.5mg tablet orally, Single dose
62151390|NCT06034977|PLACEBO_COMPARATOR|Lenvatinib|Advanced HCC patients treated by Lenvatinib.
62151391|NCT06034977|EXPERIMENTAL|Lenvatinib + ADI-PEG20|Advanced HCC patients treated by Lenvatinib + ADI-PEG20.
62523123|NCT00141986|EXPERIMENTAL|Vitamin D-higher dose|Vitamin D 2000 IU per os once daily
62523124|NCT00141986|ACTIVE_COMPARATOR|Vitamin D-lower dose|Vitamin D 400 IU per os once daily
62151392|NCT05352555|EXPERIMENTAL|Robotic Maneuvering System (RMS)|"BPPV subtype diagnosis and corresponding treatment will be performed using automated RMS chair and recorded with video frenzel goggle.~In cases of posterior canal involvement, Epley's maneuver will be used for canalithiasis and cupulolithiasis. Semont maneuver will be used as a second-line treatment for cupulolithiasis, in cases of initial failure.~In cases of horizontal canal involvement, Barbecue (Lempert) maneuver will be used. If canalithiasis or cupulolithiasis is diagnosed, Gufoni's maneuver will be performed.~In cases of anterior canal involvement, Yacovino's maneuver will be used."
62523125|NCT02341833|ACTIVE_COMPARATOR|Sevoflurane|1 MAC of sevoflurane for 15 minutes before organs procurement.
62523126|NCT02341833|NO_INTERVENTION|No intervention|No volatile anesthetics during organs procurement
62523127|NCT05843799|EXPERIMENTAL|ILB-202|ILB-202 exosome with Clinical grade normal saline (0.9% sodium chloride for intravenous injection)
62151393|NCT05352555|ACTIVE_COMPARATOR|Canalith Reposition Maneuver|"BPPV subtype diagnosis and corresponding treatment will be performed with manual repositioning maneuvers and recorded with video frenzel goggle.~In cases of posterior canal involvement, Epley's maneuver will be used. In cases of horizontal canal involvement, Log roll maneuver will be used. In cases of anterior canal involvement, Yacovino's maneuver will be used."
62151394|NCT00454922|ACTIVE_COMPARATOR|1|education
62523128|NCT05843799|PLACEBO_COMPARATOR|Placebo|Clinical grade normal saline (0.9% sodium chloride for intravenous injection)
62523129|NCT02680431||Neurofibromatosis 1|10 mL venous blood sample taken from patients with type 1 neurofibromatosis
62523130|NCT02680431||Control|10 mL venous blood sample taken from age- and gender-matched healthy controls
62523131|NCT01833533|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
62523132|NCT01833533|EXPERIMENTAL|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
62523133|NCT03522571|EXPERIMENTAL|Patients with altered passive eruption - APE|3 teeth of the patients with altered passive eruption that will undergo to experimental gingivitis
62523134|NCT03522571|ACTIVE_COMPARATOR|Patients with normal gingival anatomy - Non APE|3 teeth of the patients with normal gingival anatomy that will undergo to experimental gingivitis
62523135|NCT04254939|EXPERIMENTAL|CS3007(BLU-285)|
62151395|NCT00454922|PLACEBO_COMPARATOR|2|standard of care
62151396|NCT04506047||Acute Myocardial Infarction|Consecutive patients with acute myocardial infarction
62151397|NCT01466556||Obese children|
62523136|NCT02145026|EXPERIMENTAL|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (\>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (\</=) 10 g/dL; if the hemoglobin level increases less than (\<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases \>/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
62523137|NCT05701137|EXPERIMENTAL|EMDR-RTE|Eye movement desensitization and reprocessing in its recent traumatic episode version.
62712392|NCT06718556|EXPERIMENTAL|Virtual reality group|"The intervention procedure was planned to consist of 8 weeks, 3 days a week and 45-minute sessions in total.~In this intervention group, a virtual reality intervention was applied in addition to the client-centered intervention applied to both groups."
62151398|NCT02176694|NO_INTERVENTION|Standard Care|Aside from the asthma education provided at enrollment and placement of the SmartInhaler (i.e.,electronic monitoring device), adolescents will continue to receive usual care through their primary care providers.
62151399|NCT02176694|EXPERIMENTAL|Text Messaging|A technology based system which allows adolescents to compose, schedule and send one-time or recurring text messages to their own cell phones.
62151400|NCT04425837|ACTIVE_COMPARATOR|Standard care alone|
62523138|NCT05701137|ACTIVE_COMPARATOR|TAU|Usual treatment by a psychologist.
62523139|NCT02035839|OTHER|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
62523140|NCT02035839|OTHER|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
62523141|NCT02035839|OTHER|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
62523142|NCT01613950|EXPERIMENTAL|BYL719 + AUY922|Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
62523143|NCT02196519|EXPERIMENTAL|Test|All test arm subjects received Sylys Surgical sealant around anastomotic junction after closure.
62523144|NCT04583748|EXPERIMENTAL|Sahaj Samadhi Meditation|Participants randomized to the Sahaj Samadhi Meditation (SSM) arm will undergo SSM training in groups of 10. SSM will be delivered virtually using the Cisco WebEx platform by trained, certified non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
62712393|NCT06718556|EXPERIMENTAL|Control group|Client-centered intervention procedure was applied to the control group. The intervention procedure was planned to consist of 8 weeks, 3 days a week and 45-minute sessions in total.
62712394|NCT06586281|EXPERIMENTAL|psoriatic arthritis patients|Adults with active PsA and diagnosed NAFLD
61975536|NCT00911495|EXPERIMENTAL|GMI-1070|
62151401|NCT04425837|EXPERIMENTAL|SARS-CoV-2 convalescent plasma treatment plus standard care|
61975537|NCT01868685|PLACEBO_COMPARATOR|Placebo|
61975538|NCT01868685|EXPERIMENTAL|BYM338|
62523145|NCT04583748|ACTIVE_COMPARATOR|Health Enhancement Program|Participants randomized to the Health Enhancement Program (HEP) arm will undergo HEP training in groups of 10. HEP will be delivered virtually using the Cisco WebEx platform by trained non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
62523146|NCT04583748|NO_INTERVENTION|Treatment as Usual|Participants randomized to the Treatment as Usual (TAU) arm will continue to receive their treatment as usual. The usual standard of care for irreversible age-related vision patients includes no active treatment since eye surgeons have done all that could possibly be done to restore vision.
62523147|NCT00862238|EXPERIMENTAL|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
62523148|NCT00862238|OTHER|Health Promotion|4-session education offering basic information about the prevention of hepatitis A, B \& C
62151402|NCT02822703|EXPERIMENTAL|Active 20Hz|The rTMS device used in this study is the Mastim Super Rapid2 Stimulator with a 70mm Double Air Film Coil. Guidelines indicate that the maximum safe duration of a single train of 20Hz at 110% of the Motor Threshold (MT) is 1.6 seconds. In this study, the stimulator and the coils will be used to stimulate neurons in the left dorsolateral prefrontal cortex (DLPFC), the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment in depression, in order to examine the feasibility of testing this intervention for efficacy in the treatment of tobacco dependence.
62151403|NCT02822703|SHAM_COMPARATOR|Sham|The rTMS sham coil used in this study is manufactured by Magstim and currently classified as an investigational device. There is no intention to treat or prevent a disease and/or alter a function in the body with the sham stimulation provided by the sham coil. In this project, the sham coil will be placed in the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment for depression.
62151404|NCT04749797|PLACEBO_COMPARATOR|Saline group|The surgeon will administer injectable saline as a cranial block. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
62523149|NCT04016792|PLACEBO_COMPARATOR|Placebo|Placebo qd
62151405|NCT04749797|ACTIVE_COMPARATOR|Bupivacaine|The surgeon will administer bupivacaine as a cranial block. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
62151406|NCT04749797|EXPERIMENTAL|Liposomal Bupivacaine|The surgeon will administer Exparel (liposomal bupivacine) as a cranial block. 20 mL of Exparel will be diluted with saline to constitute 60 mL total. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
62523150|NCT04016792|EXPERIMENTAL|SPN-812|200 mg SPN-812
61975539|NCT00705081||Not previously treated|subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy
62151407|NCT06498232|EXPERIMENTAL|Group I- Active Video Based Group|Participants will play progressive, configured games with Nintendo Wii, supervised by a physiotherapist, 2 days a week for 12 weeks, for a total of 24 sessions. The game schedule will be divided into 4 phases: 1-3, 4-6, 7-9, and 10-12 weeks. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of balance and sports games, and 5 minutes of cool-down.
62151408|NCT06498232|EXPERIMENTAL|Group II- Exercise Group|Participants will be included in a total of 24 sessions of progressive, configured exercise program, supervised by a physiotherapist, 2 days a week for 12 weeks. The exercise program will be divided into 4 phases: 1-3, 4-6, 7-9, and 10-12 weeks. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of stabilization, strengthening, and balance exercises, and 5 minutes of cool-down.
62151409|NCT06498232|OTHER|Group III- Control Group|Participants in the control group will be placed on a waiting list for 12 weeks. Participants in the control group will be given a 30-minute spine protection principles training and the things to pay attention to will be explained. Participants will not receive any exercise intervention for 12 weeks and will be able to continue their routine physical activities.
62151410|NCT01142063||Treatment A (Reference fasted)|Treatment A (Reference fasted): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fasted condition.
62151411|NCT01142063||Treatment B (Test fasted)|Treatment B (Test fasted): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fasted condition.
62151412|NCT01142063||Treatment C (Reference fed)|Treatment C (Reference fed): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fed condition.
62151413|NCT01142063||Treatment D (Test fed)|Treatment D (Test fed): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fed condition.
62151414|NCT01324089|ACTIVE_COMPARATOR|Arm 1|Resveratrol 2.5 grams x 1 dose
62523151|NCT02353052||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
62523152|NCT02353052||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
62151415|NCT01324089|EXPERIMENTAL|Arm 2|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
62151416|NCT01324089|OTHER|Arm 3|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
62151417|NCT04353856||twin pregnancy|Women followed for a twin pregnancy
62151418|NCT01120457|EXPERIMENTAL|Arm 1: Dose Escalation and Expansion cohort (AML Patients)|"Dose Escalation: BMS-936564 0.3-10 mg/kg solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)~Dose Expansion: BMS-936564 maximum tolerated dose (MTD) based on dose escalation, solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)"
62151419|NCT01120457|EXPERIMENTAL|Arm 2: Dose Expansion cohort (DLBCL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
62523153|NCT01709279|OTHER|adipose tissue derived stromal cells|
62523154|NCT04696107|EXPERIMENTAL|Intervention Group|Standard pharmacological treatment aimed at controlling mCNCP with four-week face to face psychoeducational intervention.
62523155|NCT04696107|NO_INTERVENTION|Control Group|Standard pharmacological treatment aimed at controlling mCNCP without psychoeducational intervention.
62523156|NCT01009671|EXPERIMENTAL|ART 44|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
62523157|NCT01009671|ACTIVE_COMPARATOR|ART 50|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
62712395|NCT05318508||patients with low back pain|
62712396|NCT05318508||patients without low back pain|
62712397|NCT02161536|EXPERIMENTAL|Motus CleanC System|Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
62712398|NCT02161536|EXPERIMENTAL|Motus Cleansing System Rev 2.5|Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
62712399|NCT02161536|EXPERIMENTAL|Motus Cleansing System Rev 3.0|Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
62712400|NCT02479191||Female (Treatment Group)|Device: Ovation Abdominal Stent Graft Platform
62712401|NCT02479191||Male (Control Group)|Device: Ovation Abdominal Stent Graft Platform
62712402|NCT02493764|EXPERIMENTAL|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
61975540|NCT00705081||Previously treated with statin|subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy
61975541|NCT02120729|NO_INTERVENTION|Standard of Care|Patients assigned to standard-of-care pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription and psychotropic therapy follows the institutional norm.
61975542|NCT02120729|ACTIVE_COMPARATOR|Genotype-guided Care|Patients assigned to genetically-guided pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription as part of psychotropic therapy.
61975543|NCT05624203|EXPERIMENTAL|Extracorporeal cardiac shock wave therapy was performed（ECSW）|Patients with acute ST-segment elevation myocardial infarction who underwent Percutaneous coronary intervention (PCI) were treated with extracorporeal cardiac shock wave therapy 2-3 days after operation. The duration of treatment was 3 months, and 9 treatments were completed within 3 months as a course. One week of treatment was followed by a 3-week rest in each month. CSWT was performed three times in each treatment week, respectively on the 1st, 3rd, and 5th day of the treatment week, for a total of 3 months.
61975544|NCT05624203|NO_INTERVENTION|Extracorporeal cardiac shock wave therapy was not performed（NO ECSW）|Patients with acute ST-segment elevation myocardial infarction undergoing Percutaneous coronary intervention (PCI) are not treated with extracorporeal cardiac shock wave
61975545|NCT04669483||Intervention group (post-interruption)|Patients receive evidence-based informed consent forms for total knee arthroplasty and related anaesthesia procedures
61975546|NCT04669483||Control group (pre-interruption)|Patients receive standard consent forms (of the study centre) for total knee arthroplasty and related anaesthesia procedures
61975547|NCT01396720|ACTIVE_COMPARATOR|fluvoxamine|
61975548|NCT01396720|ACTIVE_COMPARATOR|citalopharm|
61975549|NCT02010554|ACTIVE_COMPARATOR|Brief Education|Patients receive a brief educational packet along with treatment as usual
61975550|NCT02010554|EXPERIMENTAL|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
61975551|NCT00680043|EXPERIMENTAL|Peginesatide 0.04 mg/kg|
61975552|NCT00680043|EXPERIMENTAL|Peginesatide 0.08 mg/kg|
61975553|NCT00680043|ACTIVE_COMPARATOR|Epoetin Alfa|
61975554|NCT04734444|EXPERIMENTAL|SonoClear acoustic coupling fluid (ACF) mimicking brain tissue|SonoClear
61975555|NCT04043091|EXPERIMENTAL|percutaneous coronary intervention|stable obstructive coronary artery disease (coronary artery stenosis \>70%) - percutaneous coronary intervention performed in all diseased segments until 300 mL of contrast reached; preferably with drug eluting stents; along with standard medical therapy
61975556|NCT04043091|NO_INTERVENTION|standard of care|stable obstructive coronary artery disease (coronary artery stenosis \>70%) - no intervention (revascularization), just standard medical therapy
61975557|NCT02408458|OTHER|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of ventral hernia.
61975558|NCT02990091|EXPERIMENTAL|1,000mg/day n-3 HUFA|Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.
61975559|NCT02990091|EXPERIMENTAL|4,000 mg/day n-3 HUFA|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
61975560|NCT02990091|PLACEBO_COMPARATOR|1 capsule safflower seed oil|Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
61975561|NCT02990091|PLACEBO_COMPARATOR|4 capsules safflower seed oil|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
61975562|NCT02567942|OTHER|propofol group|The patient who anesthetized by using propofol.
61975563|NCT02567942|OTHER|sevoflurane group|The patient who anesthetized by using propofol.
62523158|NCT06456944|EXPERIMENTAL|selected rehabilitation program|involves 24 patients and will be given the selected rehabilitation program involving (self-stretching exercise, mobilization of the ankle and subtalar, rigid tape and unilateral heel raising exercise 3 times per week for 8 weeks.
62523159|NCT06456944|EXPERIMENTAL|traditional program|involves 24 patients and will be given the traditional program involving (self-stretching exercise, mobilization of the ankle and subtalar, plantar fascial release and ultrasonic therapy 3 times per week for 8 weeks.
62523160|NCT05879198|EXPERIMENTAL|Single-Arm|All participants in this phase of the project will receive the active working memory training intervention (15, 20-30-minute computer-based training sessions over the course of 5 to 7 weeks). Additionally, key stakeholders will be asked to participate in a qualitative interview following the intervention to refine future models of intervention delivery in traditionally underserved communities.
62523161|NCT06406517|ACTIVE_COMPARATOR|Gadobenate dimeglumine 0.15 mmol/kg (standard of care)|
62523162|NCT06406517|EXPERIMENTAL|Gadopiclenol 0.075 mmol/kg|
62523163|NCT06406517|EXPERIMENTAL|Gadopiclenol 0.10 mmol/kg|
62523164|NCT06406517|EXPERIMENTAL|Gadopiclenol 0.15 mmol/kg|
62523165|NCT01045993|ACTIVE_COMPARATOR|1|Heat device
62523166|NCT01045993|SHAM_COMPARATOR|2|Placebo arm
62712403|NCT02493764|ACTIVE_COMPARATOR|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
62712404|NCT05179876|EXPERIMENTAL|Macitentan|Participants who have completed a parent study, benefit from their study intervention maintenance and have no adequate alternative local treatment option will be enrolled in this study and will continue to receive study drug macitentan orally during the course of the study. For adult participants study visits will be scheduled every 6 months and for pediatric participants study visits will be scheduled every 3 months. The study includes on-site visits to collect efficacy and safety information until participant discontinuation/withdrawal, or the respective study intervention is made commercially available in the country/territory or an equivalent approved therapy becomes available, or the sponsor decides to terminate the study prematurely.
62151420|NCT01120457|EXPERIMENTAL|Arm 3: Dose Expansion cohort (CLL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
62151421|NCT01120457|EXPERIMENTAL|Arm 4: Dose Expansion cohort (FL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
62151422|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
62151423|NCT00996242|EXPERIMENTAL|L-lysine|
62151424|NCT04253951|EXPERIMENTAL|LUS-monitored management (LUS-m)|In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0). At any time point, they will undergo at least one LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities.
62151425|NCT04253951|SHAM_COMPARATOR|Standard care management (SC-m)|Sham protocol with LUS performed at the same timepoints. LUS results in the SC-m group will be available only at the time of data analyses for comparison by investigators. They will not be used for clinical decisions.
62151426|NCT01509183|ACTIVE_COMPARATOR|Intervention Group|Intervention group (IG) participants received access to and feedback from the Propeller Health System (formerly Asthmapolis System).
62151427|NCT01509183|NO_INTERVENTION|Control Group|Control group (CG) participants were outfitted with sensors from the Propeller Health System, but did not receive feedback.
62151428|NCT03455140|EXPERIMENTAL|Group 1 - Leukaemia|PEG- BCT-100 in patients with Leukaemia Starting dose 1600U/Kg IV infusion weekly
62151429|NCT03455140|EXPERIMENTAL|Group 2 - Neuroblastoma|PEG- BCT-100 in patients with Neuroblastoma Starting dose 1600U/Kg IV infusion weekly
62151430|NCT03455140|EXPERIMENTAL|Group 3 - Sarcomas|PEG- BCT-100 in patients with Sarcomas Starting dose 1600U/Kg IV infusion weekly
62151431|NCT03455140|EXPERIMENTAL|Group 4 - High Grade Glioma|PEG- BCT-100 in patients with High Grade Gliomas Starting dose 1600U/Kg IV infusion weekly
62151432|NCT01313663|EXPERIMENTAL|Pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
62523167|NCT01045993|ACTIVE_COMPARATOR|3|Marketed analgesic
62523168|NCT01045993|PLACEBO_COMPARATOR|4|(Oral) Placebo comparator
62151433|NCT01313663|ACTIVE_COMPARATOR|Pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
62523169|NCT01762826||Placebo control|Diet pills of 400 mcg of acid folic daily
62523170|NCT01762826||D-chiro-inositol / Myo-inositol|Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily
62523171|NCT01762826||D-chiro-inositol|Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily
62523172|NCT01762826||Myo-inositol|Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily
62523173|NCT00238875|EXPERIMENTAL|1|Procedure/Surgery: stereotactic body radiation therapy
62523174|NCT05886439|EXPERIMENTAL|LK101 injection combined with pembrolizumab|patients with locally advanced or metastastic (stage IIIB-IV) NSCLC and received ≤3 lines systemtic therapy. eligible subjects will receive LK101 injection and pembrolizumab treatment.
62523175|NCT05886439|EXPERIMENTAL|LK101 injection combined with durvalumab|patients with extensive SCLC who failed with at least first-line standard therapy. eligible subjects will receive LK101 injection and durvalumab treatment.
62523176|NCT01117766|ACTIVE_COMPARATOR|Active drug|
62523177|NCT01117766|PLACEBO_COMPARATOR|Placebo|
62523178|NCT00375570|EXPERIMENTAL|1|ME-609
62523179|NCT00937820|EXPERIMENTAL|YM150 group|
62712405|NCT05179876|EXPERIMENTAL|Selexipag|Participants who have completed a parent study, benefit from their study intervention maintenance and have no adequate alternative local treatment option will be enrolled in this study and will continue to receive study drug selexipag orally during the course of the study. Study visits are scheduled every 6 months to collect efficacy and safety information until participant discontinuation/withdrawal, or the respective study intervention is made commercially available in the country/territory or an equivalent approved therapy becomes available, or the sponsor decides to terminate the study prematurely.
62712406|NCT05179876|EXPERIMENTAL|Macitentan/Tadalafil FDC|Participants who have completed a parent study, benefit from their study intervention maintenance and have no adequate alternative local treatment option will be enrolled in this study and will continue to receive drug Macitentan and Tadalafil fixed dose combination (FDC) orally during the course of the study. Study visits are scheduled every 6 months to collect efficacy and safety information until participant discontinuation/withdrawal, or the respective study intervention is made commercially available in the country/territory or an equivalent approved therapy becomes available, or the sponsor decides to terminate the study prematurely.
62151434|NCT06244563|EXPERIMENTAL|Face mask with Hybrid-Hyrax and Alt-RAMEC procedure|The experimental group was comprised of 15 patients submitted to the alternate rapid maxillary expansion and constriction (alt-RAMEC) procedure for expansion protocol with a hybrid-hyrax expander as anchorage in the maxillary arch. The Face mask was used.
62151435|NCT06244563|EXPERIMENTAL|Face mask with Bonded RME and Alt-RAMEC procedure|The experimental group was comprised of 15 patients submitted to the alt-RAMEC procedure for expansion protocol with a bonded RME as anchorage in the maxillary arch. The Face mask was used.
62523180|NCT02041936|EXPERIMENTAL|NanoKnife IRE System|
62712407|NCT02167321|ACTIVE_COMPARATOR|Arm A|"Arm A; standard neoadjuvant chemoradiotherapy group~fluoropyrimidine based concurrent chemoradiotherapy-\> TME -\> adjuvant chemotherapy (Low risk: fluoropyrimidine-based chemotherapy, High risk: FOLFOX)"
62151436|NCT06244563|EXPERIMENTAL|Face mask with Hybrid-Hyrax and routine protocol|The experimental group was comprised of 15 patients submitted to routine palatal expansion procedure (routine) with a hybrid-hyrax expander as anchorage in the maxillary arch. The Face mask was used.
62151437|NCT06244563|ACTIVE_COMPARATOR|Face mask with Bonded RME and routine protocol|The active comparator group was comprised of 15 patients who submitted to the routine expansion procedure with a bonded RME as anchorage in the maxillary arch. The Face mask was used.
62523181|NCT06309277|EXPERIMENTAL|Active|GM-1020 (oral)
62523182|NCT06309277|PLACEBO_COMPARATOR|Placebo|Placebo (oral)
62523183|NCT05763706|EXPERIMENTAL|Experimental: PBM1 group|The patients allocated to the first PBM-group will receive twelve PBM sessions of 6 J/cm² over six weeks (2x/week).
62712408|NCT02167321|EXPERIMENTAL|Arm B|"Arm B : adjuvant FOLFOX group~Total mesorectal excision (TME) --\> 12 cycles of FOLFOX every 2 weeks (or Total mesorectal excision (TME) --\> Concurrent chemoradiotherapy + 12 cycles of FOLFOX every 2 weeks)"
62712409|NCT00677794|ACTIVE_COMPARATOR|1|Clear fluids only after lunch.
62151438|NCT02271906|EXPERIMENTAL|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
62151439|NCT06344481|EXPERIMENTAL|Hyalex Cartilage System|Implantation of Hyalex Cartilage Knee Implant
62151440|NCT02748200|EXPERIMENTAL|external beam radiotherapy: Dose level 1|57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks)
62151441|NCT02748200|EXPERIMENTAL|external beam radiotherapy: dose level 2|60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks)
62151442|NCT02748200|EXPERIMENTAL|external beam radiotherapy: dose level 3|62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks)
62523184|NCT05763706|EXPERIMENTAL|Experimental: PBM2 group|The patients allocated to the second PBM-group will receive twelve PBM sessions of 8 J/cm² over six weeks (2x/week).
62712410|NCT00677794|ACTIVE_COMPARATOR|2|Two sachets of picosalax the evening prior to Video Capsule Endoscopy (VCE).
62151443|NCT01302106|EXPERIMENTAL|Arm 1|Clofarabine combined with low dose Ara-C
62151444|NCT00670488|EXPERIMENTAL|MK-2206 30 mg QOD|Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
62151445|NCT00670488|EXPERIMENTAL|MK-2206 60 mg QOD|Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
62151446|NCT00670488|EXPERIMENTAL|MK-2206 75 mg QOD|Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
62151447|NCT00670488|EXPERIMENTAL|MK-2206 90 mg QOD|Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
62151448|NCT00670488|EXPERIMENTAL|MK-2206 90 mg QW|Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
62523185|NCT04899817|ACTIVE_COMPARATOR|Group G|will receive granisteron 1mg after induction of general anesthesia
62523186|NCT04899817|PLACEBO_COMPARATOR|Group C|Will receive metoclopramide 10 mg after induction of general anesthesia
62523187|NCT00605865||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
62523188|NCT04892797||Covid-19+|Hospitalized patients with Covid-19 infection confirmed by PCR test
62523189|NCT05333484|EXPERIMENTAL|Pilates Intervention Group|12-week programed Pilates intervention
62151449|NCT00670488|EXPERIMENTAL|MK-2206 135 mg QW|Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.
62151450|NCT00670488|EXPERIMENTAL|MK-2206 200 mg QW|Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.
62151451|NCT00670488|EXPERIMENTAL|MK-2206 300 mg QW|Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
62151452|NCT00670488|EXPERIMENTAL|MK-2206 250 mg QW|Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.
62151453|NCT00670488|EXPERIMENTAL|MK-2206 150 mg QW|Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.
62523190|NCT05333484|NO_INTERVENTION|Control Group|maintenance of normal lifestyle in control group
62523191|NCT05296382|EXPERIMENTAL|Crushed Tebipenem Tablet with Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through. Subjects will also receive concurrent enteral tube feeds (feeds run for 2h before dose and 4h post-dose).
62523192|NCT05296382|EXPERIMENTAL|Whole Tebipenem Tablet|Tebipenem tablet will be swallowed whole without crushing.
62151454|NCT05121285|EXPERIMENTAL|Contrast fluid by lower GI endoscopy and enema with and without positioning|There is a washout period of at least four weeks between the two interventions (delivery by lower GI endoscopy and enema)
62523193|NCT05296382|EXPERIMENTAL|Crushed Tebipenem Tablet without Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through.
62523194|NCT03083821|EXPERIMENTAL|Arm A|
62523195|NCT00136318|ACTIVE_COMPARATOR|Escitalopram|After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
62523196|NCT00136318|PLACEBO_COMPARATOR|Placebo|After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
62712411|NCT00677794|ACTIVE_COMPARATOR|3|Polyethylene glycol, 2 liters the evening prior to Video Capsule Endoscopy (VCE).
62712412|NCT06712017||adult HCC patients treated with yttrium90|
62712413|NCT01332981||Cohort|
62712414|NCT03139448|ACTIVE_COMPARATOR|Oxygen via nasal cannula (Standard of Care)|The anesthesia provider will supply oxygen via nasal cannula at oxygen flow rates as per standard of care routine at Vanderbilt University Medical Center.
62712415|NCT03139448|EXPERIMENTAL|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
62712416|NCT06186609|EXPERIMENTAL|Experiment Arm|PD-1 inhibitor combined with radiotherapy
62712417|NCT05980130|EXPERIMENTAL|RFCBT|This is a single subject design study. Thus, all participants receive Rumination-Focused Cognitive Behavior Therapy
62712418|NCT06561347|EXPERIMENTAL|Zanubrutinib + Bendamustine + Rituximab|"Zanubrutinib will be taken orally once daily on days 1-28 of cycles 1-15.~Bendamustine will be given by intravenous infusion over about 10 to 60 minutes on days 1 and 2 of cycles 1 to 4.~Rituximab will be given by intravenous infusion over about 30 minutes on day 1 of cycles 1 to 4.~Drug diaries will be provided to participants to document information about the study treatment being taken."
62712419|NCT02911727|EXPERIMENTAL|Fast-track discharge|Intention to discharge within 28 hours after elective cesarean section including a home visit by a nurse or midwife from the postnatal ward.
62712420|NCT02911727|NO_INTERVENTION|Standard discharge|Discharge at least 48 hours after elective cesarean section.
62712421|NCT06639438||Group 1- Patients with Opioid Use Disorder (OUD)|Participants in this group will be diagnosed with OUD, defined by cognitive, behavioral, and physiological symptoms indicating using opioids despite significant opioid-related problems.
62712422|NCT06639438||Group 2- Patients who are engaged in long-term opioid therapy (LTOT) for chronic pain|Participants in this group will be engaged in long-term opioid therapy (LTOT) for chronic pain management under medical supervision, without exhibiting the problematic behaviors or experiencing the significant impairment or distress outlined in the OUD criteria.
61975564|NCT01847157|EXPERIMENTAL|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
61975565|NCT01847157|SHAM_COMPARATOR|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
61975566|NCT03235076|EXPERIMENTAL|Subjects with mild renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
61975567|NCT03235076|EXPERIMENTAL|Subjects with moderate renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
61975568|NCT03235076|EXPERIMENTAL|Subjects with severe renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
61975569|NCT03235076|EXPERIMENTAL|Matched healthy subject group|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
61975570|NCT04034381||Port-au-Prince metropolitan area|
61975571|NCT04034381||Other urban areas|
61975572|NCT04034381||Rural areas|
61975573|NCT03235154|OTHER|Treatment Arm|In this open label, single arm study, all subjects will receive the intervention as prescribed by psychiatrists in the office based opiate addition treatment program.
61975574|NCT03791476|PLACEBO_COMPARATOR|Control Group|Intervention is saline solution placebo (0.9% Sodium Chloride IV to equal volume of investigational arm: intraoperatively, and then every 12 hours x 2 = total of 3 doses)
62712423|NCT06639438||Group 3- Patients with chronic pain but no (or minimal) opioid use|Participants in this group will have chronic pain but no (or minimal) opioid use where chronic pain is defined as pain that lasts more than three months or beyond the expected period of healing but opioid use is \< 20MME with \<3 weeks of duration.
62712424|NCT06639438||Group 4- Patients without chronic pain|Participants in this group will not suffer from chronic pain but choose to undergo spine surgery due to structural abnormalities or conditions that could potentially lead to pain, neurological issues, or other significant health problems
62712425|NCT06018987|EXPERIMENTAL|Cohort 1: Treatment Group|Participants will receive subdermal injection of HAC20L to the nasolabial folds on Day 1 followed by an optional touch-up treatment on Day 30 if applicable. Participants will then be eligible to receive optional repeat treatment at Month 12 if applicable.
62712426|NCT06018987|OTHER|Cohort 1: Control Group|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
62523197|NCT03589235|EXPERIMENTAL|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be used in both donor and receiving sites after a free gingival graft.
62523198|NCT03589235|EXPERIMENTAL|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be used in both donor and receiving sites after a free gingival graft.
62151455|NCT00952523|EXPERIMENTAL|Tretinoin & Adapalene-Benzoyl Peroxide|Tretinoin and Adapalene-Benzoyl Peroxide facial gels applied once daily in a split face model
62151456|NCT04410445|EXPERIMENTAL|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Arm A: Participants will receive bempegaldesleukin (NKTR-214) IV in combination with nivolumab every 3 weeks.
62151457|NCT04410445|ACTIVE_COMPARATOR|Nivolumab|Arm B: Participants will receive nivolumab IV alone every 4 weeks.
62151458|NCT02487680|EXPERIMENTAL|Breakfast meal|A breakfast like meal will be provided together with a drink to overnight fasted subjects
62151459|NCT02487680|EXPERIMENTAL|Lunch meal|A lunch like meal will be provided together with a drink to overnight fasted subjects
62151460|NCT03022825|EXPERIMENTAL|BCG+N-803|
62151461|NCT02819609||Myomectomy|Women with uterine fibroids who underwent myomectomy as their index procedure as part of their routine clinical care
62151462|NCT02819609||Endometrial ablation|Women with uterine fibroids who underwent endometrial ablation as their index procedure as part of their routine clinical care
62151463|NCT02819609||Uterine artery embolization|Women with uterine fibroids who underwent uterine artery embolization as their index procedure as part of their routine clinical care
62151464|NCT02819609||MRI-guided focused ultrasound ablation|Women with uterine fibroids who underwent MRI-guided focused ultrasound ablation as their index procedure as part of their routine clinical care
62151465|NCT01817894|OTHER|split-face eflornithin vs. no treatment|Eflornithine cream 11.5 W/W% applied twice daily to one side of the face for six months
62151466|NCT05645445|NO_INTERVENTION|control group|The routine ESWL procedure will be applied. Pre-procedural anxieties will be evaluated with the State-Trait Anxiety Inventory-State Anxiety Scale. After the ESWL procedure, their anxiety will be re-evaluated with the same scale, and their pain will also be evaluated with the Visual Analog Scale.
62151467|NCT05645445|EXPERIMENTAL|virtual reality group|The pre-procedure anxiety of the patients who will use virtual reality glasses during the ESWL process will be evaluated with the State-Trait Anxiety Inventory-State Anxiety Score. After the ESWL procedure, their anxiety will be re-evaluated with the same scale and in addition to the pain, the pain will be evaluated with the Visual Analog Scale.
62151468|NCT05996900|ACTIVE_COMPARATOR|TBS via direct electrical stimulation|
62151469|NCT05996900|ACTIVE_COMPARATOR|TBS via transcranial magnetic stimulation|
62151470|NCT05996900|SHAM_COMPARATOR|Sham TBS via direct electrical stimulation|
62151471|NCT05996900|SHAM_COMPARATOR|Sham TBS via transcranial magnetic stimulation|
62151472|NCT03489356|EXPERIMENTAL|Intervention|Addressing Behavior Change (ABC) intervention delivery method
62151473|NCT03489356|NO_INTERVENTION|Control|Control
62151474|NCT03390998||Peripartum SCAD|Female patients who experienced any SCAD event that occurred during pregnancy or up to 1 year post-delivery
62151475|NCT03390998||Non-peripartum SCAD|Female patients who experienced any SCAD with event onset outside of the pregnancy period
62151476|NCT03033667|EXPERIMENTAL|Glucose group (G group)|patients received 500 cc of glucose 10% that containing 50 g of glucose and provides patients with 200 Kcal with 556 mosmoles/L.
62151477|NCT03033667|EXPERIMENTAL|Lipid Group (L group)|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid and provides patients with 200 Kcal with osmolarity of 380 mosmoles /L.
62151478|NCT03033667|EXPERIMENTAL|Control Group (C group)|patients was fasting overnight from 11 pm till 9 am except for clear fluids that was allowed till 5 am.
62523199|NCT01727882|EXPERIMENTAL|Daily Assessments & Brief Feedback|Daily assessments during 30 days after parole and a feedback intervention based on these daily assessments.
62523200|NCT01727882|ACTIVE_COMPARATOR|Daily assessments|Daily assessments during 30 days after parole.
62523201|NCT02148861|EXPERIMENTAL|Insulin 287 + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
62523202|NCT02148861|ACTIVE_COMPARATOR|Insulin degludec + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
62523203|NCT02310646|ACTIVE_COMPARATOR|Treatment group 1|Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
62523204|NCT02310646|ACTIVE_COMPARATOR|Treatment group 2|Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
62151479|NCT02743039|EXPERIMENTAL|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
62151480|NCT02743039|NO_INTERVENTION|Control Standard of CAP|No assignment to participate in the CareerAdvance® program, but given community referrals and resources
62151481|NCT00713466||1|all third year medical students entering their pediatric clerkship at the Medical College of Wisconsin
62151482|NCT05922774||Group 1|Patients with recurrent BPPV
62151483|NCT05922774||Group 2|Patients with non recurrent BPPV
62151484|NCT05922774||Group 3|Healthy controls
62151485|NCT05341700|EXPERIMENTAL|Endurance and Jumping Exercises|5 days of endurance treadmill running and 5 sets of 10 jumping exercises
62151486|NCT05341700|ACTIVE_COMPARATOR|Endurance Exercise Only|5 days of endurance treadmill running
62151487|NCT04466735|EXPERIMENTAL|Active group|Participants will be on the active intervention for 6 months
62151488|NCT04466735|PLACEBO_COMPARATOR|Placebo Group|Participants will be on the placebo intervention for 6 months
62151489|NCT04466735|ACTIVE_COMPARATOR|Open phase on active product|At the end of the 6-month randomized controlled phase, participants will be unblinded and invited to continue on the active product for an additional 3 months.
62523205|NCT05480592|EXPERIMENTAL|Single Ascending Dose (SAD)|Subjects in cohorts 1-6 will receive oral administration of single dose of HS-10380 tablets or matching placebo.
62523206|NCT05480592|PLACEBO_COMPARATOR|Multiple Ascending Dose (MAD)|Subjects in cohorts 7 will receive oral administration of 7 dose of HS-10380 tablets or matching placebo.
62151490|NCT02134782|EXPERIMENTAL|Individualized Yoga Intervention Group|Yoga will be administered individually by a trained yoga instructor, and offered daily for 21 days (5 days per week or 15 days in total). There will be a common structure for all sessions that will include relaxation and breathing exercises. Additional poses focused on strength, flexibility, and balance will be incorporated at low, moderate or high intensity levels based upon the wishes and abilities of the child and parent and the judgment of the yoga instructor. The target intensity will be documented and may change with each yoga session. Each yoga session will vary in duration between 15 and 45 minutes. Modifications will be made to accommodate devices such as central venous lines, particularly if accessed. For children who are in isolation, the research team will follow hospital policies and procedures.
62151491|NCT02134782|ACTIVE_COMPARATOR|iPad Activity Control Group|For those randomized to the control group, visits by the same yoga instructors will occur at the same schedule as the yoga intervention. Contact will be offered daily (5 days per week) for 21 days. The yoga instructor will offer games, music, movies or books on a study-supplied iPad. The instructor will offer to interact with the child (for example, read to, or play games with the child) for a maximum of 45 minutes (the maximum length of yoga sessions). This approach will allow us to control for contact frequency and the individual providing contact, and consequently, to better measure the independent effect of yoga. These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities.
62523207|NCT01047930|OTHER|AM-Ex; PM-Ex; C|within subject design, with each participant receiving all three conditions
62151492|NCT05832970|EXPERIMENTAL|Hand cooling|Records will be taken for Baseline electromyography, Heart rate, H-reflex, and T-reflex measurements before, during, and at 0, 3, 6, 9, 12, and 15. minutes before applying 2-4 degrees Celsius cold to the back of the hand in this group.
62151493|NCT05735379|EXPERIMENTAL|Deprescribing anticholinergic and sedative medications|Deprescribing plan targeting a reduction in drug burden index score of ≥ 0.5
62151494|NCT06519448|EXPERIMENTAL|NASH|Patients with histological proven NASH (either diabetics and non-diabetics).
62151495|NCT01845337|ACTIVE_COMPARATOR|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
61975575|NCT03791476|EXPERIMENTAL|rhC1INH|Intervention is rhC1INH 100 U/kg intraoperative followed by 50 U/kg every 12 hours x 2 = total of 3 doses (200 U/kg)
62151496|NCT01845337|ACTIVE_COMPARATOR|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
62151497|NCT01845337|ACTIVE_COMPARATOR|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA \< 1.5 m2), 45 mg (BSA 1. 5 to \< 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
62151498|NCT01845337|ACTIVE_COMPARATOR|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA \< 1.5 m2), 40mg (BSA 1.5 to \< 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA \>1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
62151499|NCT05692245|ACTIVE_COMPARATOR|Ondansetron|ondansetron 4 mg intravenous, given once after initiation of anesthesia
62151500|NCT05692245|ACTIVE_COMPARATOR|Dexamethasone|dexamethasone 8 mg intravenous, given once after initiation of anesthesia
62151501|NCT05197179|OTHER|Single-dose A|A single dose A of FB2001 or placebo will be administered by intravenous (IV) infusion
62151502|NCT05197179|OTHER|Single-dose B|A single dose B of FB2001 or placebo will be administered by intravenous (IV) infusion
62151503|NCT05197179|OTHER|Multiple-dose A|Dose A of FB2001 or placebo will be administered by intravenous (IV) infusion once daily for 5 consecutive days
62523208|NCT02796131|EXPERIMENTAL|30 mg bid|30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).
62523209|NCT02796131|EXPERIMENTAL|30 mg tid|30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).
62523210|NCT02796131|EXPERIMENTAL|60 mg bid|60 mg of RDX5791 administered two times daily (120 mg total dose/day).
61975576|NCT05342259|ACTIVE_COMPARATOR|dorsal penile block patients|
61975577|NCT05342259|ACTIVE_COMPARATOR|caudal block patients|
62151504|NCT05197179|OTHER|Multiple-dose B|Dose B of FB2001 or placebo will be administered by intravenous (IV) infusion twice daily for 5.5 consecutive days
62151505|NCT05197179|OTHER|Single-dose C|A single dose C of FB2001 or placebo will be administered by intravenous (IV) infusion
62151506|NCT03819543|EXPERIMENTAL|Transcranial Direct Current Stimulation|
62151507|NCT01114685|ACTIVE_COMPARATOR|Effects of taking AlgaeCal-1|Following a bone health plan with Algae-cal-1 supplement
62523211|NCT02796131|EXPERIMENTAL|15 mg bid|15 mg of RDX5791 administered two times daily (30 mg total dose/day).
61975578|NCT05342259|ACTIVE_COMPARATOR|combined block patients|
61975579|NCT01057654|EXPERIMENTAL|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
61975580|NCT01057654|ACTIVE_COMPARATOR|Pravastatin|Pravastatin 40 mg per day
62523212|NCT02796131|EXPERIMENTAL|30 mg QD|30 mg of RDX5791 administered once daily (30 mg total dose/day).
62523213|NCT02796131|EXPERIMENTAL|Escalating dose bid|15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.
62523214|NCT02796131|EXPERIMENTAL|30 mg bid with psyllium|30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).
62523215|NCT05954182|EXPERIMENTAL|Cognitive Intervention|Participants in this group will receive weekly, live, virtual group sessions for 12 weeks
62523216|NCT05954182|NO_INTERVENTION|Control|Participants in this group will NOT receive the group sessions
62523217|NCT04714229|EXPERIMENTAL|EuMCV4|Healthy adults received 0.5mL single intramuscular dose on Day 0.
62523218|NCT04714229|ACTIVE_COMPARATOR|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
62151508|NCT01114685|ACTIVE_COMPARATOR|Effects of taking AlgaeCal-2|Following a bone-health plan while consuming AlgaeCal 2
62712427|NCT06018987|EXPERIMENTAL|Cohort 2: Treatment Group|Participants will receive subdermal injection of HAC20L to the nasolabial folds on Day 1 followed by an optional touch-up treatment on Day 30 if applicable. Participants will then be eligible to receive optional repeat treatment at Month 12 if applicable.
62712428|NCT06018987|OTHER|Cohort 2: Control Group|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
62712429|NCT00639457|EXPERIMENTAL|Pioglitazone|Pioglitazone (Actos; 30mg/day) for 16 weeks.
62712430|NCT00639457|ACTIVE_COMPARATOR|Pioglitazone + Exercise training|Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.
62151509|NCT04434872|ACTIVE_COMPARATOR|FMT from a healthy donor|"Patients will undergo FMT 4 times during the study:~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:~1. A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.~2. Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
62151510|NCT04434872|PLACEBO_COMPARATOR|FMT from a self donated stool sample|"Patients will undergo FMT 4 times during the study:~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:~1. A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.~2. Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
62151511|NCT00863902|EXPERIMENTAL|Cetirizine Hydrochloride|Cetirizine Hydrochloride 10 mg tablets, single dose
62151512|NCT00863902|ACTIVE_COMPARATOR|Zyrtec|Zyrtec® 10 mg tablets, single dose
62151513|NCT02593552|EXPERIMENTAL|Video camera|DriveCam video event recorder with counseling feedback
62523219|NCT01714349|EXPERIMENTAL|Nerve Transfer|Surgical - Nerve transfers for patients with stable cervical spinal cord injuries
62523220|NCT04601038|OTHER|MCI|Individuals with mild cognitive impairment due to Alzheimer's disease
62523221|NCT04601038|OTHER|Cognitively Normal|Individuals who are cognitively normal but who are at risk for Alzheimer's disease
62523222|NCT00085774|EXPERIMENTAL|Albuterol HFA BOI|
62151514|NCT05658094|EXPERIMENTAL|Exosome|Exosome (100e10 particle) injections with an interval of 14 days during two months.
62151515|NCT04263688||Immunotherapy effective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
62523223|NCT00085774|EXPERIMENTAL|Albuterol HFA MDI|
62523224|NCT00085774|PLACEBO_COMPARATOR|Placebo|
62523225|NCT06251596||Patients with ovulatory cycles|Patients with ovulatory cycles
62523226|NCT06251596||Patients with artificial cycles|Patients with artificial cycles
62523227|NCT02483832|ACTIVE_COMPARATOR|Gain-frame|This group will receive messages about the benefits of colorectal cancer screening.
62523228|NCT02483832|ACTIVE_COMPARATOR|Loss-frame|This group will receive messages about the disadvantages of not getting colorectal cancer screening.
62523229|NCT04463303||group 1|patient who will develop weaning induced pulmonary adema
62523230|NCT04463303||group 2|patient who will nor develop weaning induced pulmonary adema
62523231|NCT04950959||All subjects|Subjects undergoing CT-guided, minimally invasive percutaneous procedures in an interventional radiology setting
62523232|NCT05056610|EXPERIMENTAL|Patients with IBS or FI|Food antigens are added to duodenal mucosa during CLE
62523233|NCT05056610|EXPERIMENTAL|healthy controls|Food antigens are added to duodenal mucosa during CLE
62523234|NCT01862315|EXPERIMENTAL|No prior chemo or responded/stable with prior chemo|All patients receive HAI FUDR (\[0.12 mg/kg/day kg 30\] / pump flow rate)\& dexamethasone ({1 mg/m2/day30} pump flow rate) on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) \& Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 \& 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, \& then every 2 weeks thereafter. Clinical MRI examinations of the abdomen \& pelvis are obtained at baseline following surgery, prior to treatment initiation \& 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 \& 9 thereafter A non-contrast CT of chest, abdomen \& pelvis will also be obtained as part of routine clinical care.
62712431|NCT05796752|EXPERIMENTAL|Memantine and Behavioral Therapy|All subjects will receive 8-weeks of memantine treatment (10mg po qday for the first two weeks, then 20 mg po qday for the remaining six weeks). After the 8-weeks of memantine treatment, the dose will be discontinued. Then, after a 4-week washout period, all subjects will receive 8-weeks of ComB therapy. Therapy will be once a week for 30 minutes. After the 8-weeks of ComB treatment, the therapy will be discontinued.
62712432|NCT06073678|EXPERIMENTAL|Photobiomodulation|Red laser irradiation on palate wound at the day of the surgery and after 2, 4 and 6 days postoperatively. Protection of wound with surgical dressing during 7 days.
62712433|NCT06073678|ACTIVE_COMPARATOR|Control|Protection of wound with surgical dressing during 7 days.
62712434|NCT05020574|EXPERIMENTAL|Cohort A: Standard antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - Prescribed standard postoperative antibiotics to take for at least 7 days post-operatively
62712435|NCT05020574|NO_INTERVENTION|Cohort B: No antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - No antibiotics post-operatively, unless patient develops clinical evidence of infection
61975581|NCT00819221|EXPERIMENTAL|1|
61975582|NCT04667767|EXPERIMENTAL|Intervention|"In addition to the national standard outpatient treatment for uncomplicated severe acute malnutrition, caregivers of participants will receive a WASH kit containing a plastic container, a supply of Aquatabs® (effervescent chlorine tablets), and training in their use and associated hygiene practices."
62151516|NCT04263688||Immunotherapy Ineffective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
62151517|NCT06413459||CF patients with chronic M. abscessus infection|
62151518|NCT06413459||CF patients with M. abscessus pulmonary disease|
62151519|NCT06413459||CF patients with no history of M. abscessus infection|
62151520|NCT06413459||Healty Controls|
62151521|NCT01930188|EXPERIMENTAL|Semaglutide 0.5 mg + sitagliptin placebo|
62151522|NCT01930188|EXPERIMENTAL|Semaglutide 1.0 mg + sitagliptin placebo|
62151523|NCT01930188|ACTIVE_COMPARATOR|Sitagliptin 100 mg + semaglutide placebo 1.0 mg|
62151524|NCT01930188|ACTIVE_COMPARATOR|Sitagliptin 100 mg + semaglutide placebo 0.5 mg|
62523235|NCT01862315|EXPERIMENTAL|patients who have failed systemic therapy|All patients receive HAI FUDR (\[0.12 mg/kg/day kg 30\] / pump flow rate)\& dexamethasone ({1 mg/m2/day 30}/ pump flow rate) on day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) \& Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 \& 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, \& then every 2 weeks thereafter. Clinical MRI examinations of the abdomen \& pelvis are obtained at baseline following surgery, prior to treatment initiation \& 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 \& 9 thereafter A non-contrast CT of chest, abdomen \& pelvis will also be obtained as part of routine clinical care.
62523236|NCT01862315|EXPERIMENTAL|pts who have had prior oxaliplatin & have existing neuropathy|All patients receive will receive gemcitabine alone with HAI FUDR/Dex Gemcitabine (800 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
62151525|NCT02338999|EXPERIMENTAL|Pioglitazone, then placebo|Treatment with pioglitazone up to 45 mg orally daily for three months. Followed by a two-month washout period before cross over to placebo orally daily for three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
62523237|NCT00588640|EXPERIMENTAL|Phase I, Group|This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.
62523238|NCT00588640|EXPERIMENTAL|Phase II, Group I|patients receiving around the clock opioid therapy-No patients were accrued to this group
62523239|NCT00588640|EXPERIMENTAL|Phase II, Group II|patients not receiving around the clock opioid therapy.No patients were accrued to this group
62523240|NCT05468788|EXPERIMENTAL|Integrative Community Therapy (ICT) Intervention Arm|Participants will perform scenes related to having a chronic medical condition and they will be guided through conversations about their feelings and coping methods.
62523241|NCT05468788|SHAM_COMPARATOR|Improvisational Theatre Arm|Participants will perform generic improvisational theatre with no instruction on feelings or coping methods.
62523242|NCT02524717|EXPERIMENTAL|JNJ-56021927|Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
62523243|NCT00725530|ACTIVE_COMPARATOR|balafilcon A / etafilcon A|Balafilcon A worn first, with etafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
62523244|NCT00725530|ACTIVE_COMPARATOR|etafilcon A / balafilcon A|Etafilcon A worn first, with balafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
62523245|NCT03602963||Dexcom G5 mobile CGM system|Children (6 to 18 years) with type 1 diabetes mellitus treated with insulin injections and wearing a FreeStyle Libre Flash glucose sensor that will switch to the Dexcom G5 mobile glucose monitoring system.
62151526|NCT02338999|EXPERIMENTAL|Placebo, then Pioglitazone|Treatment with placebo orally daily for three months. Followed by a two-month washout period before cross over to pioglitazone up to 45 mg daily orally for an additional three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
62523246|NCT02882672|EXPERIMENTAL|Experimental|experimental group did 8 weeks exercise training
62523247|NCT02882672|EXPERIMENTAL|Control|Control group did not do any exercise training.
62523248|NCT01753336|EXPERIMENTAL|Dysport®|Dysport®, up to 500 units (U)/vial using 2mL dilution
62523249|NCT03947736||patients with positive HER2 amplification|
62151527|NCT03783936|OTHER|Induction and Maintenance|"Cycles 1-9; Induction; Cycle = 14 days~mFOLFOX6~* oxaliplatin 85 mg/m2 IV Day 1 and~* leucovorin 400 mg/m2 IV Day 1 and~* 5 fluorouracil 400 mg/m2 IV bolus and 2400 mg/m2 IV over 46 hours Day 1 and~Trastuzumab 6 mg/kg IV loading dose C1D1 then Trastuzumab 4 mg/kg IV Day 1 and~Avelumab 800 mg IV Day 1~Cycles 10 and subsequent; Maintenance; Cycle = 14 days~Trastuzumab 4 mg/kg Day 1 and Avelumab 800 mg Day 1"
62151528|NCT02441829|EXPERIMENTAL|Mild Renal Impairment (CLcr 60-89 mL/min)|Participants with mild renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
62151529|NCT02441829|EXPERIMENTAL|Moderate Renal Impairment (CLcr 30-59 mL/min)|Participants with moderate impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
62151530|NCT02441829|EXPERIMENTAL|Severe Renal Impairment (CLcr 15-29 mL/min)|Participants with severe renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
62523250|NCT03947736||patients with negative HER2 amplification|
62523251|NCT00472836|EXPERIMENTAL|Normal renal function|
62523252|NCT00472836|EXPERIMENTAL|Severe renal impairment|
62151531|NCT01514773||ICD placement|Those subjects who have an ICD.
62712436|NCT05109741|EXPERIMENTAL|Internet-based Psychodynamic Therapy|"This is a 10-week treatment based on the psychodynamic SUBGAP model (Seeing, Understanding, Breaking, and Guarding Against Patterns) by Farrell Silverberg (2005). The treatment has been evaluated in two previous randomized controlled trials.~Silverberg, F. (2005). Make the leap: A practical guide to breaking the patterns that hold you back. Da Capo Press.~Andersson, G., Paxling, B., Roch-Norlund, P., Östman, G., Norgren, A., Almlöv, J., ... \& Silverberg, F. (2012). Internet-based psychodynamic versus cognitive behavioral guided self-help for generalized anxiety disorder: a randomized controlled trial. Psychotherapy and psychosomatics, 81(6), 344-355.~Johansson, R., Ekbladh, S., Hebert, A., Lindström, M., Möller, S., Petitt, E., ... \& Andersson, G. (2012). Psychodynamic guided self-help for adult depression through the internet: a randomised controlled trial. PloS one, 7(5), e38021."
62712437|NCT05109741|ACTIVE_COMPARATOR|Internet-based Behavioral Activation|"This 10-week treatment is based on the BATD-R (Behavioral Activation Treatment for Depression - Revised) treatment by Lejuez and others (2011).~Lejuez, C. W., Hopko, D. R., Acierno, R., Daughters, S. B., \& Pagoto, S. L. (2011). Ten year revision of the brief behavioral activation treatment for depression: revised treatment manual. Behavior modification, 35(2), 111-161."
62712438|NCT05109741|NO_INTERVENTION|Waiting-list|Participants will be in a 10-week waiting period.
62712439|NCT00982384|EXPERIMENTAL|Disease management|Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
62712440|NCT00982384|ACTIVE_COMPARATOR|Best care|Best care according to clinical guidelines for COPD patients
62712441|NCT04156139|ACTIVE_COMPARATOR|Control group|NPPV treatment for patients will be performed for patients immediately after extubation in control group.
62151532|NCT01514773||No ICD placement|Those subjects who have not had an ICD placed.
62151533|NCT01054118|EXPERIMENTAL|001|JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
62151534|NCT01054118|ACTIVE_COMPARATOR|002|Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
62151535|NCT01054118|EXPERIMENTAL|003|JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
62151536|NCT01054118|PLACEBO_COMPARATOR|004|Placebo Placebo suspension and placebo capsule administered as single doses
62712442|NCT04156139|EXPERIMENTAL|intervention group|HFNC treatment will be performed for patients immediately after extubation in the intervention group.
62712443|NCT01603017|PLACEBO_COMPARATOR|Placebo - no therapy|Patients who were blinded but did not receive therapy
62151537|NCT03865732|PLACEBO_COMPARATOR|Placebo|placebo suspension 3x's /day for 17 weeks
62151538|NCT03865732|EXPERIMENTAL|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
62151539|NCT02267109|EXPERIMENTAL|2.5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 2.5 x 10(10):
62151540|NCT02267109|EXPERIMENTAL|5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 5 x 10(10):
62712444|NCT01603017|EXPERIMENTAL|MRI therapy|Patients receiving MRI therapy but blinded to it
62712445|NCT05881798||Patients indicated for the placement of a Celect Platinum Vena Cava Filter|Patients indicated for the placement of a Celect Platinum Vena Cava Filter
62712446|NCT05558111||Patients with orthotopic neobladder|Patients with orthotopic neobladder who met the inclusion criteria will be enrolled.Inclusion criteria :(1) being right-handed;(2) 3 months or more after operation;(3) No contraindications to fMIR examination;(4)Does not meet the relevant exclusion criteria.
62151541|NCT02267109|EXPERIMENTAL|1.0 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(10):
62151542|NCT02267109|EXPERIMENTAL|1.0 x 10(11) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(11):
62712447|NCT01306695|EXPERIMENTAL|NYUCI|New York University Caregiver Intervention (NYUCI) in addition to community-based case management using community health workers: The first component consists of two individual and four family counseling sessions that include relatives suggested by the caregiver.
62151543|NCT02267109|EXPERIMENTAL|Booster-MVA-BN® Filo or saline placebo|MVA-BN® Filo or saline placebo
62151544|NCT01220999|EXPERIMENTAL|Cohort 1|Subjects received an initial loading dose of 111\^In-CS-1008 (0.2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111\^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
62151545|NCT01220999|EXPERIMENTAL|Cohort 2|Subjects received an initial loading dose of 111\^In-CS-1008 (1 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111\^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
62151546|NCT01220999|EXPERIMENTAL|Cohort 3|Subjects received an initial loading dose of 111\^In-CS-1008 (2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111\^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
62151547|NCT01220999|EXPERIMENTAL|Cohort 4|Subjects received an initial loading dose of 111\^In-CS-1008 (4 mg/kg) on Day 1, CS-1008 (4 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111\^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
62151548|NCT01220999|EXPERIMENTAL|Cohort 5|Subjects received an initial loading dose of 111\^In-CS-1008 (6 mg/kg) on Day 1, CS-1008 (2 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111\^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
62523253|NCT03582280|EXPERIMENTAL|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:~1. Amor powder, each eppendorf contains 200mg Calcium~2. Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
62523254|NCT03001752|ACTIVE_COMPARATOR|Open flap immediate implant|Open flap immediate implant insertion, without bone grafting
62523255|NCT03001752|ACTIVE_COMPARATOR|Open flap immediate implant and bone grafting|Open flap immediate implant insertion and bone grafting
62523256|NCT03001752|ACTIVE_COMPARATOR|Flapless immediate implant|Immediate implant insertion without opening flap of inserting bone grafting
62151549|NCT01758068|EXPERIMENTAL|Coconut Oil Application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
62523257|NCT03263039|OTHER|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
62523258|NCT04430855|EXPERIMENTAL|Upadacitinib 30 mg|Participants will receive 30 mg upadacitinib orally once a day for 12 weeks (Period 1) followed by 30 mg upadacitinib orally once a day for 36 weeks (Period 2).
62523259|NCT04430855|EXPERIMENTAL|Placebo followed by Upadacitinib 15 mg|Participants will receive matching placebo orally once a day for 12 weeks (Period 1) followed by 15 mg upadacitinib orally once a day for 36 weeks (Period 2).
62523260|NCT03486054|EXPERIMENTAL|Experimental Arm A|Whole blood treated with amustaline and glutathione, a pathogen reduction technology (PRT), ordered and administered to study patients by their treating physicians
62523261|NCT03486054|ACTIVE_COMPARATOR|Control Arm B|Standard of Care (either red blood cells or whole blood)
62523262|NCT05228496|EXPERIMENTAL|Tislelizumab combined with Sitravatinib|
62523263|NCT05366465||SMA adult patients|
62523264|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
62523265|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
62523266|NCT02876926|EXPERIMENTAL|"Enhanced home-based testing"|"These participants will download a study-specific smartphone app (eTEST), and receive home-based HIV test kits in the mail every 3 months. These kits will have been fit with sensors that enable remote detection of when the kit was opened. Qualified HIV test counselors (QHTC) will then follow up with these participants within 24 hours of receiving notification that the test has been opened to conduct routine counseling, offer referrals for other services, and connect those with reactive results with follow-up care."
62523267|NCT02876926|ACTIVE_COMPARATOR|Home-based testing alone|These participants will receive a typical home-based test for HIV in the mail every 3 months, but no phone-based follow-up will be provided.
62523268|NCT02876926|SHAM_COMPARATOR|Reminders for clinic-based testing|Participants in this condition will receive a letter in the mail every 3 months reminding them to be tested at a local clinic for free.
62523269|NCT01844999|OTHER|Usual patient education + standard educational websites|
62523270|NCT01844999|EXPERIMENTAL|Usual patient education + P3P decision support website|
62523271|NCT02622113|EXPERIMENTAL|Canagliflozin (TA-7284) ＋insulin|
62523272|NCT01072266|EXPERIMENTAL|INCB028060|Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
62523273|NCT01163448|EXPERIMENTAL|High-Dose Single-Fraction Image-Guided Radiotherapy|This will assess the feasibility and safety of this approach in men at high-risk for extraprostatic prostate cancer undergoing RP. This initial trial has been designed in a manner intended to emphasize patient comfort and safety.
62523274|NCT05414292|EXPERIMENTAL|Drug group|Will take 1mg Rapamune (sirolimus) in oral tablet form daily for 16 weeks.
62523275|NCT05414292|PLACEBO_COMPARATOR|Placebo group|Will take a placebo tablet (lactose) daily for 16 weeks
62523276|NCT05337774|EXPERIMENTAL|Blast-related mTBI group|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy (\[18F\]PI-2620), and amyloid (\[18F\]florbetaben).
62523277|NCT05337774|EXPERIMENTAL|mTBI not blast-related (control group 1)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy (\[18F\]PI-2620), and amyloid (\[18F\]florbetaben).
62523278|NCT05337774|EXPERIMENTAL|no history of TBI (control group 2)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy (\[18F\]PI-2620), and amyloid (\[18F\]florbetaben).
62523279|NCT06218264|ACTIVE_COMPARATOR|FullAA|Amino acid drink containing all amino acids
62523280|NCT06218264|ACTIVE_COMPARATOR|NoBCAA|Amino acid drink containing all amino acids except for BCAAs.
62523281|NCT00891371|EXPERIMENTAL|lanreotide (Autogel formulation) Autogel 120mg|lanreotide (Autogel formulation) Autogel 120mg
62523282|NCT04566705||Women with uterine rupture|Women with uterine rupture
62523283|NCT04566705||Women without uterine rupture|Women without uterine rupture
62523284|NCT03613116|EXPERIMENTAL|High Dose Vitamin D3|Receives 4000 IU daily Vitamin D3 tablets.
62523285|NCT03613116|ACTIVE_COMPARATOR|Standard Dose Vitamin D3|Receives 600 IU Vitamin D3 tablets.
62523286|NCT02765217|EXPERIMENTAL|Study group 1|"Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).~Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days."
62523287|NCT02765217|PLACEBO_COMPARATOR|Study group 2|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.
62523288|NCT02765217|EXPERIMENTAL|Study group 3|Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.
62712448|NCT01306695|OTHER|CHW Intervention|Community-based case management using community health workers (CHWs): The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6.
62523289|NCT02765217|PLACEBO_COMPARATOR|Study group 4|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.
62523290|NCT03986450|ACTIVE_COMPARATOR|ERAS group|Patients in this group will receive ERAS protocol preoperatively, perioperatively and postoperatively.
62523291|NCT03986450|NO_INTERVENTION|Control|This group of patients will not receive ERAS care and will undergo a standard laparoscopic hysterectomy.
62523292|NCT00853086||A|
62523293|NCT04669470|ACTIVE_COMPARATOR|Group with adjustable IGB|
62523294|NCT04669470|ACTIVE_COMPARATOR|Group with nin-adjustable IGB|
62523295|NCT03731221|EXPERIMENTAL|Bupi HCl plus liposomal bupi|PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine
62712449|NCT06406933||new-pSS|Newly diagnosed primary Sjögren's syndrome patients
62523296|NCT03731221|ACTIVE_COMPARATOR|Bupi HCl plus saline|PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline
62523297|NCT02546349|EXPERIMENTAL|high eNO: ICS/LABA|patients with eNO \>=23.5 ppb, receive inhaled corticosteroid (ICS)/long-acting beta2 agonist (ICS/LABA) of fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid.
62523298|NCT02546349|ACTIVE_COMPARATOR|high eNO: LAMA|patients with eNO \>=23.5 ppb, receive long acting muscarinic antagonist (LAMA) of tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
62712450|NCT06406933||Sjögren's syndrome|Patients diagnosed with Sjögren's syndrome and who have undergone treatment: Need to undergo major illness card registration.
61975583|NCT04667767|ACTIVE_COMPARATOR|Control|National standard outpatient treatment for uncomplicated severe acute malnutrition
61975584|NCT05841251|ACTIVE_COMPARATOR|phenylephrine|phenylephrine-soaked pack will be applied after induction of surgery and intubation.
62151550|NCT01758068|NO_INTERVENTION|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
62523299|NCT02546349|EXPERIMENTAL|Low eNO: ICS/LABA|patients with eNO \< 23.5 ppb, receive fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid
62523300|NCT02546349|ACTIVE_COMPARATOR|Low eNO: LAMA|patients with eNO \< 23.5 ppb, receive tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
62523301|NCT01176110|EXPERIMENTAL|thermal management with LMA PerfecTemp™|
62523302|NCT01176110|ACTIVE_COMPARATOR|no specific thermal management|
62523303|NCT03252418|EXPERIMENTAL|ascorbic acid|injection of 1 ml intamucosal ascorbic acid 3 times with 1 week interval
62523304|NCT03252418|EXPERIMENTAL|diode laser|photothermolysis by diode laser in one session
62523305|NCT00946348|EXPERIMENTAL|Dronabinol|Dronabinol 10mg or 15 mg
62523306|NCT00946348|ACTIVE_COMPARATOR|Cannabis|Cannabis cigarette
62523307|NCT00640536||1|Newly diagnosed obstructive sleep apnea patients without systemic and pulmonary arterial hypertension
62523308|NCT00640536||2|Age, sex and and body mass index-matched matched healthy subjects
62523309|NCT03325465|EXPERIMENTAL|Pembrolizumab and epacadostat|"Patients will receive neoadjuvant immunotherapy either with anti-PD-1 (pembrolizumab) alone or anti-PD-1 in combination with IDO1 inhibition (epacadostat). Patients will receive Pembrolizumab every 3 weeks over a period of 8 weeks as well as epacadostat starting on day 1 for the duration of pembrolizumab treatment.~All patients will undergo baseline biopsy (mandatory, sampling ≥ 4 areas to represent the tumor), as well as baseline imaging (and for exploratory analysis collection of blood for baseline ctDNA testing and TCR analysis)."
62523310|NCT05379855|EXPERIMENTAL|0.05% atropine group|Subjects received 0.05% atropine eye drops (0.1% sodium hyaluronate as a solution) both eyes once every night. Eye drops are prepackaged with identical eye drops bottle, pasted with number and shelf life, and stored in 4℃.
62523311|NCT05379855|PLACEBO_COMPARATOR|placebo group|Subjects of the control group received placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) both eyes once every night. Eye drops are prepackaged with identical eye drops bottle, pasted with number and shelf life, and stored in 4℃.
61975585|NCT05841251|ACTIVE_COMPARATOR|tranexamic acid|Single intravenous dose of tranexamic acid 15 mg/kg will be given in 100 mL normal saline over 10 minutes.
61975586|NCT04219332|EXPERIMENTAL|Subserosal injection of indocyanine green tracer group|Subserosal injection of indocyanine green, with a concentration of 0.5 mg /ml, 6 points along the lesser and greater curvature of the stomach, 1.5 ml for each point.
61975587|NCT04219332|ACTIVE_COMPARATOR|Submucosal injection of indocyanine green tracer group|Submucosal injection of indocyanine green, with a concentration of 1.25mg /ml, four points around the primary tumor, each point 0.5 ml.
61975588|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
61975589|NCT03845907|ACTIVE_COMPARATOR|Imagio Gen 1B|Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe
61975590|NCT03845907|ACTIVE_COMPARATOR|Imagio Gen 1|Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System
61975591|NCT01751867|EXPERIMENTAL|3-Day Dose schedule|Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days. Cycles will be repeated every 6 weeks.
61975592|NCT01751867|EXPERIMENTAL|5-Day Dose schedule|Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days. Cycles will be repeated every 4 weeks.
61975593|NCT02738151|EXPERIMENTAL|Toujeo|Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
61975594|NCT02738151|ACTIVE_COMPARATOR|Tresiba|Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
62523312|NCT05379855|EXPERIMENTAL|0.01% atropine group|Subjects received 0.01% atropine eye drops (0.1% sodium hyaluronate as a solution) both eyes once every night. Eye drops are prepackaged with identical eye drops bottle, pasted with number and shelf life, and stored in 4℃.
62523313|NCT06422390||PRP Injection|Adult patients with symptomatic partial rotator cuff tear of one rotator cuff tendon diagnosed on imaging with MRI or ultrasound.
62523314|NCT06422390||Placebo|Adult patients with symptomatic partial rotator cuff tear of one rotator cuff tendon diagnosed on imaging with MRI or ultrasound.
62523315|NCT00760201||1|Hospital executives, physician administrators and hospital legal counsel
62523316|NCT04775420||Group 1|Ascetic patients without spontaneous bacterial peritonitis
62151551|NCT01098292||Healthy Control|"Healthy Control participants do not suffer from any Urological Chronic Pelvic Pain Syndromes or from the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
62151552|NCT01098292||Positive Control|"Positive Control participants do not suffer from any Urological Pelvic Pain Syndromes like Interstitial Cystitis and/or Chronic Prostatitis. However Positive Controls have a history of one of the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
62523317|NCT04775420||Group 2|Ascetic patients with spontaneous bacterial peritonitis
62523318|NCT05566964||ME&MGopen|Use of ME\&MGopen mobile app, at home for 12 months
62523319|NCT03122340|PLACEBO_COMPARATOR|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
62523320|NCT03122340|EXPERIMENTAL|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
62523321|NCT02876380||Prospective cohort|These are women who are currently pregnant and who have a LQTS mutation. This also includes women whose partner/father of the baby has a LQTS mutation. If the father of the child has the LQTS mutation, the father will also be enrolled.
62523322|NCT02876380||Retrospective cohort|In this cohort the investigators will collect information about previous pregnancies affected by the LQTS mutation. Parents may enroll in both retrospective and prospective cohorts
62523323|NCT05296486|EXPERIMENTAL|phacovitrectomy surgery with silicone oil tamponade|patients who had phacovitrectomy surgery with silicone oil tamponade.The patients diagnosed cataract The patients' ages are over 50.
62523324|NCT05296486|EXPERIMENTAL|phacovitrectomy surgery with gas tamponade|patients who had phacovitrectomy surgery with gas tamponade.The patients diagnosed cataract The patients' ages are over 50.
62523325|NCT05296486|EXPERIMENTAL|phacovitrectomy surgery with balanced saline solution tamponade|patients who had phacovitrectomy surgery with balanced saline solution tamponade.The patients diagnosed cataract The patients' ages are over 50.
62523326|NCT05296486|EXPERIMENTAL|phacoemulsifacation surgery without vitrectomy|patients who had phacoemulsifacation surgery without vitrectomy.The patients diagnosed cataract The patients' ages are over 50.
62523327|NCT03672305|OTHER|c-Met/PD-L1 CAR-T cells treating group|Intervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 \* 10\^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.
62523328|NCT03961022|ACTIVE_COMPARATOR|ReWin(d)|Subjects have to take ReWin(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
62523329|NCT03961022|PLACEBO_COMPARATOR|placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
62523330|NCT02788149|EXPERIMENTAL|STUDY GROUP|Model development group: This group will get Ultrasound of neck exam followed by polysomnography. We will use this group to identify the ultrasonographic parameters that have strong association of predicting obstructive sleep apnea. We will use these these predictors to estimate the patient's probability of severe OSA, which then will be used to test the receiver operating characteristic (ROC) curve of diagnosing severe OSA. The optimal cut-off value of the ROC curve will be defined as the one with the least (1 - sensitivity)2+ (1- specificity)2 in the model-development group. This formula will then tested in the validation group.
62523331|NCT02788149|ACTIVE_COMPARATOR|validation group|One third patients in the cohort will be randomly assigned to this group. This group will get ultrasound of neck exam followed by polysomnography. The predictors will be tested in his group.
62151553|NCT02881086|OTHER|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
62151554|NCT02881086|OTHER|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
62151555|NCT02881086|ACTIVE_COMPARATOR|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
62523332|NCT02756936|EXPERIMENTAL|A Test|Test drug (Daclatasvir zeta)1 tablet contains 60 mg Daclatasvir
62523333|NCT02756936|ACTIVE_COMPARATOR|B Reference|Reference drug (Clatazev)) 1 tablet contains 60 mg Daclatasvir
62523334|NCT00546572|EXPERIMENTAL|1|Receives 13vPnC at year 0 and 13vPnC at year 1
62523335|NCT00546572|ACTIVE_COMPARATOR|2|Receives 23vPS at year 0 and 13vPnC at year 1
62712451|NCT06406933||dry eye|Those with symptoms of dry eyes (such as a sensation of foreign bodies in the eyes, sensitivity to light, tearing, etc.) but without symptoms of dry mouth (such as frequent drinking of water).
62151556|NCT02881086|EXPERIMENTAL|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
62712452|NCT06406933||normal|Those without symptoms of dry eyes or dry mouth.
62151557|NCT02881086|OTHER|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
62151558|NCT02881086|OTHER|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
62151559|NCT02881086|OTHER|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
62523336|NCT02721836|EXPERIMENTAL|Yoga|12 week yoga course, two times a week 75 minutes each time
62151560|NCT02881086|ACTIVE_COMPARATOR|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
62523337|NCT02721836|ACTIVE_COMPARATOR|Nutrition|3 counselling sessions within 12 weeks
62523338|NCT02860442|EXPERIMENTAL|Smartphone brief intervention (SP-BI)|
62523339|NCT02860442|PLACEBO_COMPARATOR|Enhanced Usual Care (EUC)|
62151561|NCT02881086|EXPERIMENTAL|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
62151562|NCT04270032||malignant group|women with malignant lesions confirmed by pathology
62151563|NCT04270032||benign group|women with benign lesions confirmed by pathology or stable in follow-up \> 2 years
62151564|NCT04270032||normal group|women have normal images with follow up \> 2 years
62151565|NCT05578807|EXPERIMENTAL|Total tubeless percutaneous nephrolithotomy without reverse insertion of a ureteral catheter|In total tubeless percutaneous nephrolithotomy surgery, there is no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no need to change the position, and no need to re-sterilize and lay towels.
62151566|NCT05578807|NO_INTERVENTION|Conventional total tubeless percutaneous nephrolithotomy|In total tubeless percutaneous nephrolithotomy surgery, there is reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, need to change the position, and need to re-sterilize and lay towels.
62151567|NCT06279416||grup-1: awake nasal fiberoptic intubation|awake nasal fiberoptic intubation
62151568|NCT06279416||grup-2: awake intubation with laryngeal mask airway-mediated aintree catheter|awake intubation with laryngeal mask airway-mediated aintree catheter
62151569|NCT06279416||grup-3: awake intubation with videolaryngoscopy|awake intubation with videolaryngoscopy
62151570|NCT01555307|EXPERIMENTAL|Balance group|Typical plus balance exercises
62523340|NCT01618136|EXPERIMENTAL|E7449|
62151571|NCT01555307|OTHER|Typical group|Typical exercises
62151572|NCT05995691|EXPERIMENTAL|ABP 501|Participants will receive a single dose of ABP 501
62151573|NCT05995691|ACTIVE_COMPARATOR|Adalimumab|Participants will receive a single dose of adalimumab
62151574|NCT02142270||Victims of cardiac arrest, either SCD or aborted SCA|
62151575|NCT02142270||Premature death|"All residents of districts of interest will be surveyed during 3 years. premature deaths occurring in residents of districts of interest will be checked for past medical history, circumstances of death, and autopsy report (if possible). Investigators will also analyze the employment of resuscitation attempts during the timeframe of sudden cardiac arrest (SCA) in various patient populations throughout African countries.~The arm group of the study is every resident of the district of interest"
62151576|NCT05914285|PLACEBO_COMPARATOR|Control group|Normal saline
62151577|NCT05914285|EXPERIMENTAL|Salbutamol group|Salbutamol + normal saline
62151578|NCT01005602|EXPERIMENTAL|Digoxin Dosing per Nomogram|Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
62151579|NCT01005602|OTHER|Standard Digoxin Dosing|This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.
62151580|NCT04417309|EXPERIMENTAL|Moderate Intensity Exercise|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
62523341|NCT01618136|ACTIVE_COMPARATOR|E7449 plus TMZ|
62523342|NCT01618136|ACTIVE_COMPARATOR|E7449 plus carboplatin and paclitaxel|
62523343|NCT02185313|EXPERIMENTAL|gaze holding|
62151581|NCT04417309|ACTIVE_COMPARATOR|Control|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
62151582|NCT04317937|EXPERIMENTAL|Jaw Movement Group|"A: Jaw opening-closing movements~* Active jaw movements~* Active neck exercises~B: Isometric strengthening exercises (Same as control group) C: Postural Advice and Home Exercise Program with Dairy (Same as control group)"
62523344|NCT04673513|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy will be provided as described in Beck et al. (1979) and Beck (2011), with adaptations for the treatment of comorbid personality disorders as described in Beck et al. (2015).
62523345|NCT04673513|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy - Skill enhanced (CBT-SE)|This condition includes a variation of CBT (as provided in the other condition) with special emphasis on helping clients to develop the skills of CBT.
62523346|NCT04978064|EXPERIMENTAL|Intervention group|Behavioral e-health psychological counselling
62523347|NCT04978064|OTHER|Control group|Usual care (delayed behavioral e-health psychological counselling)
62523348|NCT03512262|EXPERIMENTAL|Abaloparatide|Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.
62523349|NCT03512262|PLACEBO_COMPARATOR|Placebo|Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.
62523350|NCT04765774|EXPERIMENTAL|The Effect of Expressive Touch Applied After Lumbar Disc Herniation Surgery|Expressive touch reduces pain and keeps vital signs and NIRS values within normal limits by touching the arms and hands of the patients through energy transfer.
62151583|NCT04317937|ACTIVE_COMPARATOR|Exercise therapy|"A: Active neck exercises Active neck exercises Active jaw movements (Active Jaw movement will not be perform in this group) B: Isometric strengthening exercises C: Postural Advice and Home Exercise Program with Dairy i: Postural Advise ii: Home Exercise Program (unsupervised) iii: Home Dairy~Frequency and Duration of Treatment Non-specific Chronic Neck Pain (more than 3 months history of pain)~Initial Assessment (week 1) 60 minutes First treatment session (week1) 40 minutes~* 3 treatment sessions per week (week- 2) 40 minutes~* 3 treatment sessions per week (week- 3) 40 minutes~* 3 treatment sessions per week (week- 4) 40 minutes~* 3 treatment sessions per week (week- 5) 40 minutes~* Last treatment session (week 6) 40 minutes~* Final Assessment (week 6) 60 minutes"
62523351|NCT04765774|EXPERIMENTAL|The Effect of Music Applied After Lumbar Disc Herniation Surgery|Patients listening to music are distracted and their pain is reduced, vital signs and NIRS values are kept within normal limits.
62523352|NCT04765774|NO_INTERVENTION|Pain, vital signs and NIRS values of patients after lumbar disc hernia surgery|No intervention is applied to the patients in this group and the effectiveness of the interventions used on the patients in the other group is measured.
62523353|NCT00486018|SHAM_COMPARATOR|Sham injection|
62523354|NCT00486018|EXPERIMENTAL|Ranibizumab injection 0.3 mg|
62523355|NCT00486018|EXPERIMENTAL|Ranibizumab injection 0.5 mg|
62523356|NCT02199340|EXPERIMENTAL|Cystic fibrosis|"* iStep exercise test~* CPET exercise test"
62523357|NCT02199340|ACTIVE_COMPARATOR|Healthy control|- iStep exercise test
62523358|NCT03335605||Antibody deficiency (CVID)|Subjects with antibody deficiency (CVID)
62523359|NCT03335605||Healthy controls|Age and gender-matched control subjects
62523360|NCT02296853|EXPERIMENTAL|Severe Hepatic Impairment Group|Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.
62523361|NCT02296853|ACTIVE_COMPARATOR|Matched Normal Hepatic Function Group|Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.
62523362|NCT03923530|EXPERIMENTAL|Eplerenone|Eplerenone 50 mg daily, administered orally for 8 weeks.
62523363|NCT01953939|EXPERIMENTAL|Prosthetic Limb Users|Single lower limb amputees who are wearing their artificial limb all day and are using them outdoors for the majority of the time will be enrolled into this reliability study.
62523364|NCT03499418||newborns with TTN|Group of late preterm and full-term newborns with TTN evaluated by modified Silverman scale
62523365|NCT03499418||newborns with PPHN|Group of late preterm and full-term newborns with respiratory failure with PPHN evaluated by echocardiography
62523366|NCT01452711|EXPERIMENTAL|TAK-438 20 mg QD|
62523367|NCT01452711|ACTIVE_COMPARATOR|Lansoprazole 30 mg QD|
62523368|NCT03680859||Diabetic|Participants with a primary etiology of diabetic gastroparesis
62523369|NCT03680859||Idiopathic|Participants with a primary etiology of idiopathic gastroparesis
62151584|NCT01184027||G-tube/swallowing intervention|patients will receive G-tube/nutritional and swallowing intervention. As per patient needs
62151585|NCT01184027||G-tube/swallowing counseling|G-tube/ad lib dietary and swallowing counseling. Current standard of care.
62151586|NCT01184027||nutrition/swallowing intervention|Patients will receive active nutrition and swallowing intervention based on patients caloric and swallowing needs.
62151587|NCT01184027||nutrition/swallowing counseling|Patients will have ad lib dietary intake with general nutrition and swallowing counseling.
62151588|NCT03511781|EXPERIMENTAL|Single Arm study|Hypofractionated Radiotherapy Schedule of 35 GY in 10 fractions is being administered in advanced Incurable Breast Cancer for female patients
62151589|NCT05842330|EXPERIMENTAL|Pharmaceutical intervention (OROS-MPH)|Participants will receive OROS-MPH (Concerta® available in Switzerland as first-line treatment for ADHD). Dosages will be defined according to the Swiss Compendium. The psychiatrist (blinded during detention) will start with the smallest dosage (18 mg, Concerta®). The treatment will be monitored weekly the first month, and then monthly. The pharmacy of the Geneva University Hospitals will be in charge of over-encapsulating medications.
62151590|NCT05842330|PLACEBO_COMPARATOR|Placebo|
62523370|NCT03680859||Post-fundoplication|Participants with a primary etiology of post-Nissen fundoplication gastroparesis
62523371|NCT03680859||Diabetic with Normal Emptying|Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying
62151591|NCT01655082|EXPERIMENTAL|V0116|One patch per day (during 24 hours) for 21 days
62523372|NCT03680859||Idiopathic with Normal Emptying|Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying
62523373|NCT03680859||Post-fundoplication with Normal Emptying|Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying
62523374|NCT03055663|EXPERIMENTAL|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
62523375|NCT03055663|ACTIVE_COMPARATOR|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
62523376|NCT04393766|EXPERIMENTAL|normal saline|
62523377|NCT04393766|PLACEBO_COMPARATOR|non normal saline|
62523378|NCT02960061|EXPERIMENTAL|HIPEC|After receiving neoadjuvant chemotherapy and D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy is conducted,4 catheters are placed in 4 position in the peritoneal cavity: ① under the left diaphragm ② hepatorenal recess ③ left pelvis ④ right pelvis.catheters, all four tubes are connected to the perfusion device.Perfusion prescription: cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2 start within 24-48 hours after cycle 1, dosage of paclitaxel adjust to 100mg/ m2, the rest of the same. A total of two cycle is administered, routine adjuvant chemotherapy using SOX (oxaliplatin plus S-1 capsule)or XELOX regimens follows within 4-6 weeks.
62523379|NCT02960061|SHAM_COMPARATOR|controlled group|After receiving neoadjuvant chemotherapy and D2 radical resection, patients receive peritoneal lavage with 3000ml distilled water.Adjuvant chemotherapy using SOX or XELOX regimens is administered as routine within 4-6 weeks.
62523380|NCT04944719||chronically ill adult patients colonized by streptococcus pneumoniae|At baseline, adult patients with chronic disease who are colonized with Streptococcus pneumoniae will be identified. Then, after determining the colonized subjects, monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be taken to determine colonization by other serotypes or resolution of colonization status in these patients.
62523381|NCT04944719||chronically ill adult patients not colonized by streptococcus pneumoniae|Subjects who are not colonized with S. pneumoniae will be followed by monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be collected every six months to determine colonization during the follow-up time in the study.
62523382|NCT05476653|EXPERIMENTAL|MRI exam|"Patients will be asked to perform a pulmonary MRI in addition to the usual chest CT can.~The chest CT scan will be performed according to the usual protocol of standard practices. No difference is expected for this research protocol."
62712453|NCT02217969|EXPERIMENTAL|Electronic alert to SLUScore increase|Patients whose anesthesia care team members are receiving alerts to increments in their SLUScore (progressive hypotensive exposures) are anticipated to be given interventions aimed at minimizing further hypotensive exposures. The decision of whether or not to intervene as well as the type(s) of interventions will be at the sole discretion of the patient's anesthesia care team
62151592|NCT01655082|ACTIVE_COMPARATOR|Reference|One patch per day (during 24 hours) for 21 days
62151593|NCT04863365|PLACEBO_COMPARATOR|Placebo treatment|A matching placebo ophthalmic solution, TID
62151594|NCT04863365|EXPERIMENTAL|PHP-201 treatment|PHP-201 0.5% ophthalmic solution, TID
62151595|NCT05141409||CAD-A|
62151596|NCT05141409||CAD-B|
62151597|NCT02296307||DOvEE Participants|"All symptomatic women who are eligible for participation in the DOvEE trial receive the same interventions:~Blood test: CA-125 biomarker at day 1 and week 6-8. Second Test: Transvaginal Ultrasound at day 1. Follow-up Phone Call: Confirms continuing health 6 months after last visit."
62151598|NCT05954247|EXPERIMENTAL|Intervention: DWJ1543|
62151599|NCT05954247|EXPERIMENTAL|Intervention: DWC202216|
62151600|NCT04209322|EXPERIMENTAL|Pulsed Radiofrequency|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. PRF treatment was administered at 5 Hz and a 2 ms pulsed width for 10 minutes at 45V under the constraint that the electrode tip temperature not exceed 42°C. Finally, patients received 1mL lidocaine 20mg/mL mixed with 2mL dexamethasone 10mg/mL.
62151601|NCT04209322|ACTIVE_COMPARATOR|Transforaminal Epidural Steroid Injection|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. After 10 minutes await (as per pRF), patients received 1mL lidocaine 20mg/mL mixed with 2mL dexamethasone 10mg/mL.
62151602|NCT03840447|EXPERIMENTAL|Chronic Disease Self-Management programme|
62151603|NCT02090205|PLACEBO_COMPARATOR|Non-ventilation during CPB|This group of patients will not be ventilated during the cardio-pulmonary bypass. They will be disconnected from the respirator.
62151604|NCT02090205|EXPERIMENTAL|Ventilation with CPAP|This group will receive a ventilation with CPAP (at least 5 cmH2O) and FiO2 50%-80%
62151605|NCT02090205|EXPERIMENTAL|Ventilation with 5 act/minute|This group will receive 5 respiratory acts/minute. Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
62151606|NCT04721600|EXPERIMENTAL|treatment|Subjects aged 35-75, healthy adults with visible signs of aging, seeking skin laxity treatments. three treatments
62151607|NCT03312621|EXPERIMENTAL|Intervention|The intervention group received all aspects of enhanced usual care but was also assigned a healthcare transition nurse who coordinated the delivery of specific intervention services. These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
62151608|NCT03312621|NO_INTERVENTION|Control|The control group received enhanced usual care which provides standardized healthcare transition-specific written information including a written transition policy, as well as insurance and guardianship information. Participants were also provided with a transition readiness assessment and entered into a healthcare transition registry to facilitate tracking and communication.
62151609|NCT01910194|OTHER|Lyxumia|4 weeks Luxumia plus another 4 weeks combination
62151610|NCT01910194|OTHER|Lantus|4 weeks Lantus plus another 4 weeks combination
62151611|NCT01071317|EXPERIMENTAL|Comprehensive care|Reinforcement of diagnosis, education, medications, and referral
62523383|NCT00871741|EXPERIMENTAL|GSK2202083A GROUP|Subjects in this group were to receive three doses of GSK2202083A vaccine at 3, 5 and 11 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
62151612|NCT01071317|ACTIVE_COMPARATOR|Typical care|Usual care
62151613|NCT04115670|EXPERIMENTAL|specific intervention (experimental)|Specific intervention (experimental). The intervention group will carry out 3 sessions of specific pain education + 15 sessions of physical training.
62151614|NCT04115670|ACTIVE_COMPARATOR|control group (no intervention)|NO intervention
62151615|NCT02163850|EXPERIMENTAL|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
62151616|NCT02163850|ACTIVE_COMPARATOR|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
62151617|NCT04703114|EXPERIMENTAL|Symptomatic|40 symptomatic patients to COVID-19 infection
62151618|NCT04703114|EXPERIMENTAL|Asymptomatic|40 asymptomatic patients to COVID-19 infection
62523384|NCT00871741|ACTIVE_COMPARATOR|INFANRIX + MENJUGATE GROUP|Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
62523385|NCT03532113|EXPERIMENTAL|Updating|The Updating intervention aims to improve the ability to monitor and quickly add or delete of content of working memory.
62712454|NCT02217969|NO_INTERVENTION|Control (no alert)|Routine anesthesia care at the discretion of the anesthesia care team
62712455|NCT04410861|ACTIVE_COMPARATOR|Minimal Micropulse Arm|"Wavelength 810 577 Power 0.75 W 0.15 W DC 5% 5% Spot size 125um 100um Duration 0.3 sec 0.3 sec Number of spots 100-120 100-120~."
62151619|NCT01155843||Asthmatic, chronic stress|
62151620|NCT01155843||Asthmatic, non-stress|
62151621|NCT01381198|ACTIVE_COMPARATOR|Distal rectus femoris transfer|Single-event multilevel surgery with a concomitant distal rectus femoris transfer
62523386|NCT03532113|EXPERIMENTAL|Inhibition|The Inhibition intervention aims to improve the ability to supersede responses that are prepotent or automatic for a given situation.
62523387|NCT03532113|ACTIVE_COMPARATOR|General Knowledge|The General knowledge intervention allows the learning of information on various topics. It does not involve attentional control but semantic knowledge.
62523388|NCT03734666|EXPERIMENTAL|Mindfulness Based Relapse Prevention|Participants will receive Mindfulness Based Relapse Prevention (MBRP), an existing substance use treatment, which has been modified to focus explicitly on smoking cessation and reduced alcohol use, creating Mindfulness Based Relapse Prevention - Smoking and Alcohol (MBRP-SA).
62523389|NCT03734666|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|Participants will receive Cognitive Behavioral Therapy (CBT) a well-established and commonly used treatment for substance abuse behaviors that utilizes problem solving and coping skills.
62712456|NCT04410861|EXPERIMENTAL|Panmacular Micropulse Arm|Wavelength 810 577 Power 1.7 W 0.425 W DC 5% 5% Spot size 500um 500um Duration 0.3 sec 0.3 sec Number of spots 400-450 400-450
62151622|NCT01381198|NO_INTERVENTION|No distal rectus femoris transfer|Single-event multilevel surgery without distal rectus femoris transfer
62151623|NCT02074384|OTHER|Continuous Glucose Monitoring|Participants will wear Continuous Glucose Monitoring for two weeks.
62151624|NCT02074384|OTHER|Self Monitoring Blood Glucose|Participants will self test for two weeks.
62151625|NCT02074384|OTHER|Clinicians|Clinicians completing study visits.
62151626|NCT01790542|OTHER|A|Iron fortified cereal
62151627|NCT01790542|OTHER|B|Iron fortified cereal with fruit
62151628|NCT01790542|OTHER|C|Meat
62151629|NCT04475406|SHAM_COMPARATOR|Control group|Standard implant, intra-bone length ≥8 mm (30 implants)
62712457|NCT04196530|EXPERIMENTAL|Dose Escalation of BDB001 with atezolizumab|"This part of the study will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of BDB001 with atezolizumab is reached."
62151630|NCT04475406|ACTIVE_COMPARATOR|Test group|Extra Short implant, intra-bone length ≤6 mm (30 implants)
62151631|NCT00650169|EXPERIMENTAL|1|Clopidogrel Bisulfate Tablets 75 mg
62151632|NCT00650169|ACTIVE_COMPARATOR|2|Plavix® Tablets 75 mg
62151633|NCT02799537|EXPERIMENTAL|Intervention|Participants in the intervention arm complete the Stanford letter advance directive
62151634|NCT02799537|ACTIVE_COMPARATOR|Control|Participants in the control arm complete the California state traditional advance directive
62151635|NCT00913055|EXPERIMENTAL|One hydrated 84mg Octreotide implant|hydrated implant
62151636|NCT00913055|EXPERIMENTAL|One non-hydrated 84mg Octreotide implant|
62151637|NCT02033174|OTHER|Sugar water first, then alcohol|8 participants have received oral fat diet plus water with sugar (equivalent caloric intakes as sugar with water in the control group). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and a daily total amount of 16 g/m2 of alcohol, of different beverages (red wine, vodka, brandy or rum)
62151638|NCT02033174|OTHER|Alcohol first then sugar water|8 participants have received oral fat diet plus alcoholic beverages (a daily total amount of 16 g/m2 of alcohol, of different beverages : red wine, vodka, brandy or rum). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and water with sugar (equivalent caloric intakes as sugar with water in the control group).
62151639|NCT01434732|EXPERIMENTAL|Umbilical Cord Milking|Umbilical Cord Milking involved milking the umbilical cord at birth.
62523390|NCT02107326|EXPERIMENTAL|Webdia Software use|Use of Webdia Software during 3 months by the patient. Monthly review of blood glucose values by the medical team and automatic adjustment of insulin doses by the team.
62151640|NCT01434732|ACTIVE_COMPARATOR|Immediate Cord Clamping|Umbilical cord is clamped soon after birth without any milking of the cord.
62151641|NCT03340662|EXPERIMENTAL|CC-122 Alone under fasted conditions|Single oral dose of 3 mg CC-122 administered alone under fasted conditions
62151642|NCT03340662|EXPERIMENTAL|CC-122 plus Itraconazole|Single oral dose of 3 mg CC-122 alone and with multiple doses of itraconazole.
62151643|NCT03340662|EXPERIMENTAL|CC-122 plus Fluvoxamine|Single oral dose of 3 mg CC-122 alone and with multiple doses of fluvoxamine.
62151644|NCT03340662|EXPERIMENTAL|CC-122 plus Rifampin|Single oral dose of 3 mg CC-122 alone and with multiple doses of rifampin
62151645|NCT02535585|ACTIVE_COMPARATOR|knotted anchors|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
62151646|NCT02535585|ACTIVE_COMPARATOR|knotless anchors|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
62151647|NCT02430909|PLACEBO_COMPARATOR|CZP / CZP + PBO / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+Placebo from Week 8 to Week 18"
62151648|NCT02430909|EXPERIMENTAL|CZP / CZP + UCB4940 / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+ UCB4940 from Week 8 until Week 18"
62151649|NCT02430909|OTHER|CZP / CZP/ CZP|Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two Weeks) until Week 30
62151650|NCT00930397||Low risk women|Women without any personal risk.
62151651|NCT00930397||High risk women|Women at high risk for pre-eclampsia with personal of pre-eclampsia and/or IUGR in a previous pregnancy, diabetes, auto-immune syndrome such as lupus, hypertension, renal insufficiency and anti-phospholipid.
62523391|NCT02107326|NO_INTERVENTION|Observation|No use of the software. No intervention.
62523392|NCT05566548||Group of patients with liver cirrhosis and ACLF|"This group will include patients with diagnosed liver cirrhosis regardless of the cause hospitalized and/or presenting to the emergency department for possible ACLF.~With any etiology of liver cirrhosis including alcoholic liver disease (ALD), chronic hepatitis C virus (HCV), metabolism associated fatty liver disease (MAFLD) and autoimmune liver diseases."
62151652|NCT05964309|EXPERIMENTAL|Supine group(Control group)|Supine group (flat head position- n=28) during pre-oxygenation patients will be in supine position
62151653|NCT05964309|EXPERIMENTAL|sitting group|Sitting position (90 degree head up position- n=28) during pre-oxygenation patients will be in 90 degree head up position
62151654|NCT06123936|EXPERIMENTAL|Experimental group|"GPs selected at random in the intervention arm Recall will recall their patients to be vaccinated via the recall module integrated into their Eo medical software"
62523393|NCT05566548||Group of patients with liver cirrhosis compensated|"This group will include patients with diagnosed liver cirrhosis, any etiology of liver cirrhosis including alcoholic liver disease (ALD), chronic hepatitis C virus (HCV), metabolism associated fatty liver disease (MAFLD) and autoimmune liver diseases.~No previous episodes of ACLF and at the time of admission."
62523394|NCT05566548||Group of healthy people|People who do not have any acute or chronic degenerative disease. Participation on a voluntary basis.
62523395|NCT05566548||Group of patients with liver cirrhosis and hepatic encephalopathy|This group will include patients with diagnosed liver cirrhosis who develop hepatic encephalopathy graded according to West Haven.
62151655|NCT06123936|NO_INTERVENTION|No intervention group|"GPs in the usual care or control arm will not recall their patients to be vaccinated. GPs with their medical software.~They will worked as usual."
62151656|NCT03293043|EXPERIMENTAL|Experimental Group|After initial screening, appropriately obtained informed consent and confirmation of eligibility at time of transplant, those recipients (a total of 12 subjects) who agree to continue as participants will receive reconditioned marginal lungs should the lungs on the device meet acceptable criteria to proceed with clinical transplantation.
62151657|NCT01668394|ACTIVE_COMPARATOR|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
62151658|NCT01668394|PLACEBO_COMPARATOR|Control arm|Usual care. Teaching style: deductive.
62151659|NCT06554509|EXPERIMENTAL|Treatment group A：SHR-1819 injection dose 1|
62151660|NCT06554509|EXPERIMENTAL|Treatment group B：SHR-1819 injection dose 2|
62151661|NCT06554509|EXPERIMENTAL|Treatment group C：SHR-1819 injection dose 3|
62151662|NCT06554509|PLACEBO_COMPARATOR|Treatment group D：placebo|
62523396|NCT05921513|PLACEBO_COMPARATOR|NC Group|This group is provided normal saline mouth-rinse to rinse 2 times per day along with placebo gel to be applied 2 times and placebo oral spray.
62523397|NCT05921513|EXPERIMENTAL|S Group|This group is provided StellaLife Oral Care kit's mouth-rinse, gel and spray 2 times per day.
62523398|NCT05921513|ACTIVE_COMPARATOR|C Group|This group is provided chlorhexidine mouth-rinse and placebo gel and spray 2 times per day.
62523399|NCT01297374|EXPERIMENTAL|dietetic counseling|
62523400|NCT01297374|EXPERIMENTAL|physical activities|
62523401|NCT01297374|EXPERIMENTAL|Lifestyle counseling|
62523402|NCT04078880|EXPERIMENTAL|Intervention (group A)|Patients who are subjected to the intervention, being iron plus ascorbic acid, other than the standard of care.
62523403|NCT04078880|NO_INTERVENTION|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
62523404|NCT06469489||Liver Disease patients undergoing Trans-Jugular Liver Biopsy|
62523405|NCT05241717|EXPERIMENTAL|Intervention arm|All study participants will be given the intervention
62523406|NCT00468728|ACTIVE_COMPARATOR|1|Vancomycin
62523407|NCT00468728|EXPERIMENTAL|2|PAR-101/OPT-80
62523408|NCT05727917|EXPERIMENTAL|hetrombopag group (Experimental group)|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response (CR, platelet count ≥50×109/L for 3 consecutive days without platelet transfusions for 7 consecutive days). The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
62523409|NCT05727917|PLACEBO_COMPARATOR|Control group|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days.
62523410|NCT01242930|EXPERIMENTAL|Imetelstat (7.5 mg/kg)|Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
62523411|NCT01242930|EXPERIMENTAL|Imetelstat (9.4 mg/kg)|Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
62523412|NCT04622397|ACTIVE_COMPARATOR|Group T (tranexamic acid),n=15|Group T: tranexamic acid 10 mg/kg will be injected locally
62523413|NCT04622397|PLACEBO_COMPARATOR|Group S (saline) (n=15)|Group S saline will be injected
62523414|NCT03493542|EXPERIMENTAL|Chinese Girls Aged 9 to 19 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
62523415|NCT03493542|ACTIVE_COMPARATOR|Chinese Young Women Aged 20 to 26 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
62523416|NCT01699386|ACTIVE_COMPARATOR|Control Study Formula|protein hydrolysate formula
62523417|NCT01699386|EXPERIMENTAL|Experimental Study Formula|free-amino acid-based medical food
62523418|NCT05667350||Cancer arm|Baseline blood samples will be collected from participants newly diagnosed with biliary tract cancer.
62523419|NCT05667350||Benign disease arm|Baseline blood samples will be collected from participants newly diagnosed with benign biliary tract diseases.
62151663|NCT03897491|EXPERIMENTAL|Interstitial photodynamic therapy|20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.
62151664|NCT04848740|OTHER|FRESH CORNEAL LENTICULE IMPLANTATION|"The aim in our study is to describe the importance of stroma as criteria of corneal thickness at implanting human fresh corneal lenticule in progressive corneal disease.~We have conclude that every biomechanical instability of corneal stroma function(abnormal increase collagen activity,decrease proteinase inhibitors,excessive premature keratocyte apoptosis) describe the role of stroma in corneal thickness."
62523420|NCT06164314|EXPERIMENTAL|Dex group|Subjects assigned to Dex group will receive a continuous dexmedetomidine infusion (0.4 ug/kg/h) after anesthesia induction until dural closure, and then received an intravenous analgesia pump with dexmedetomidine(0.08ug/kg/h), sufentanil and antiemetic until 48 hours postoperatively
62523421|NCT06164314|PLACEBO_COMPARATOR|Placebo group|Subjects in the Placebo group were given comparable volumes of normal saline during the surgery, and intravenous analgesia pump also contains sufentanil and antiemetic, but no dexmedetomidine used until 48 hours postoperatively.
62523422|NCT02304458|EXPERIMENTAL|Treatment (nivolumab, ipilimumab)|See Detailed Description
62523423|NCT03979820|EXPERIMENTAL|10 mg BI 1467335/10 mg BI 1467335 + Tyramine|
62523424|NCT03979820|EXPERIMENTAL|15 mg BI 1467335/15 mg BI 1467335 + Tyramine|
62523425|NCT03979820|ACTIVE_COMPARATOR|Phenelzine/Phenelzine + Tyramine|
62523426|NCT03979820|PLACEBO_COMPARATOR|Placebo/Placebo + Tyramine|
62523427|NCT00878514|EXPERIMENTAL|Alprazolam|Alprazolam 1 mg tablet
62523428|NCT00878514|ACTIVE_COMPARATOR|Xanax|Xanax 1 mg tablet
62523429|NCT01168765|EXPERIMENTAL|Intervention group|This is the promotora plus group that will receive the TSSC newsletter and exposure to the media campaign but will also receive monthly visits by promotoras/lay health workers who will review the monthly newsletter with participants, emphasize role model stories, and discuss physical activity and healthful food choices using motivational interviewing strategies.
62523430|NCT01168765|OTHER|Control group|TSSC Media Campaign only participants who will receive a newsletter and the same exposure to the media campaign intervention as other community members not enrolled in the behavioral intervention.
62523431|NCT03856684|ACTIVE_COMPARATOR|Self-sampling kit sent at home|Sending of a vaginal self-sampling kit at home
62523432|NCT03856684|EXPERIMENTAL|Self-sampling kit sent at home + SMS reminder|"Sending of a vaginal self-sampling kit at home + a SMS reminder is sent if the woman do not (in 2 months) :~* perform a pap smear~* or send her vaginal self-sample to the laboratory~* or contact the screening center to inform to an exclusion reason"
62523433|NCT03856684|EXPERIMENTAL|"Letter offering a self-sampling kit on request+ SMS reminder"|"Sending of letter offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us.~If they do ask for the kit, one kit is sending to their home.~For these women, a SMS reminder is sent if the woman do not (in 2 months) :~* perform a pap smear~* or send her vaginal self-sample to the laboratory~* or contact the screening center to inform to an exclusion reason"
62523434|NCT03856684|EXPERIMENTAL|"SMS offering a self-sampling kit on request+ SMS reminder"|"Sending of SMS offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us.~If they do ask for the kit, one kit is sending to their home.~For these women, a SMS reminder is sent if the woman do not (in 2 months) :~* perform a pap smear~* or send her vaginal self-sample to the laboratory~* or contact the screening center to inform to an exclusion reason"
62523435|NCT05732974||Resected early stage non small cell lung cancer|Early stage (IA-IIIA) resectable non small cell lung cancer patients receiving surgery
62523436|NCT02581007|EXPERIMENTAL|Reduced-Intensity Mismatched Transplant|Fludarabine, Melphalan \& Post-transplant cyclophosphamide
62523437|NCT04514965||PBC patients offered bezafibrate treatment|"All patients started on bezafibrate treatment are offered inclusion in the study.~First visit is before start of treatment. Afterwards patients will be seen at 4 weeks, 6 months, 1 year, 2 years and 3 years after inclusion.~At all visits blood samples will be taken and liver stiffness will be measured using FibroScan. Further, they will be asked about pruritus."
62523438|NCT01475006|EXPERIMENTAL|Part I Dose Exploration|Pre-specified nominal doses are proposed in the dose exploration. Intermediate doses may also be used if required based on the CRM design.
62523439|NCT01475006|EXPERIMENTAL|Part II Dose Expansion|Dose selected from Part 1 dose exploration
62523440|NCT02668926|EXPERIMENTAL|Lisdexamfetamine, d-amphetamine, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
62523441|NCT02668926|EXPERIMENTAL|d-amphetamine, Placebo, Lisdexamfetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
62523442|NCT02668926|EXPERIMENTAL|Placebo, Lisdexamfetamine, d-amphetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
62523443|NCT01859130|OTHER|Persona TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
62523444|NCT04707976|EXPERIMENTAL|Navina Smart|An electronic medical device to perform transanal irrigation. Treatment period 8 weeks.
62523445|NCT04707976|ACTIVE_COMPARATOR|Standard Bowel Care|Supportive bowel care without using irrigation.
62523446|NCT03660358|EXPERIMENTAL|Kinesiotape|Kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
62523447|NCT03660358|NO_INTERVENTION|Control|No kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
62523448|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
62523449|NCT03869203|EXPERIMENTAL|Enhanced recovery after surgery (ERAS) patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the ERAS perioperative care.
62523450|NCT03869203|NO_INTERVENTION|Control patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the traditional perioperative care.
62523451|NCT03525730|NO_INTERVENTION|Control|This group receives no intervention.
62523452|NCT03525730|EXPERIMENTAL|Valproic acid|This group receives valproic acid (enteric) for 14 days.
62523453|NCT03525730|EXPERIMENTAL|Pyrimethamine|This group receives pyrimethamine for 14 days.
62523454|NCT03525730|EXPERIMENTAL|Valproic acid and Pyrimethamine|This group receives valproic acid and pyrimethamine for 14 days.
62523455|NCT01880125|OTHER|Group A|Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state
62151665|NCT02142569|ACTIVE_COMPARATOR|Chinese Red Yeast Rice (CRYR)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 Sugar Pill/Placebo capsules for 12 weeks.
62151666|NCT02142569|ACTIVE_COMPARATOR|Tocotrienol-enriched Fraction of Palm Oil (TRF)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 TRF and 2 Sugar Pill/Placebo capsules for 12 weeks.
62151667|NCT02142569|ACTIVE_COMPARATOR|CRYR + TRF|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF + CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 TRF capsules for 12 weeks.
62151668|NCT02142569|PLACEBO_COMPARATOR|Sugar Pill|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the placebo (sugar pill) arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 4 placebo tablets for 12 weeks. Additionally during a two-week run-in period, subjects will be asked to follow the American Heart Association Step 1 dietary regimen and to take a placebo capsule daily to determine their ability to comply with the diet and a pill regimen.
62151669|NCT02190656||Anterior resection|Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery
62151670|NCT05258929||Hematological patients who underwent allograft|Patients who underwent allograft and then relapsed
62523456|NCT01880125|OTHER|Group B|Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state
62523457|NCT04167176|ACTIVE_COMPARATOR|Erector spinae plane block|ultrasound guided ESP Block after anaesthesia induction
62523458|NCT04167176|ACTIVE_COMPARATOR|Port site infiltration technique|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of Local anesthetic (LA) mixture that will be divided equally between port sites
62523459|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
62523460|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
62151671|NCT04768556|EXPERIMENTAL|ADHD group|ADHD group: 20 participants having received a positive diagnosis of ADHD
62151672|NCT04768556|OTHER|Control group 1|Control group 1: 20 participants having received a negative diagnosis of ADHD
62151673|NCT04768556|OTHER|Control group 2|Control group 2: 20 participants as healthy volunteers
62151674|NCT05830422||Good neurological outcome|Patients who showed good neurological outcomes with CPC scores of 1-2 at discharge
62151675|NCT05065840|EXPERIMENTAL|4 Pillars Program|Patients at study clinics who consent to have their HPV vaccination history verified with the Georgia Registry of Immunization Transactions and Services (GRITS).
62151676|NCT05065840|NO_INTERVENTION|Adjacent time-period Control Group|The background HPV update rate among PLWH will be obtained by using the electronic medical record (EMR) and GRITS to identify HPV vaccination uptake 18 months prior to the intervention. These data are collected retrospectively and no study participants are prospectively assigned to this study arm.
62151677|NCT00488605|ACTIVE_COMPARATOR|Treatment Arm A|
62151678|NCT00488605|EXPERIMENTAL|Treatment Arm B|
62151679|NCT04970459||Patients with Marfan syndrome or related syndromes|Children aged at least 3 years old or adult with Marfan syndrome or related syndromes
62151680|NCT01852175|ACTIVE_COMPARATOR|Prasugrel|Prasugrel 60mg loading dose and 10 mg maintenance dose
62151681|NCT01852175|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
62151682|NCT01274156|ACTIVE_COMPARATOR|shock wave treatment|
62523461|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
62523462|NCT03610568|EXPERIMENTAL|Growing up GREAT! Intervention|
62523463|NCT03610568|NO_INTERVENTION|Control|
62523464|NCT01029158|EXPERIMENTAL|1a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
62523465|NCT01029158|EXPERIMENTAL|1b|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
62523466|NCT01029158|EXPERIMENTAL|1c|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
62151683|NCT01274156|SHAM_COMPARATOR|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
62151684|NCT01681511|EXPERIMENTAL|ICET™ TIC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
62523467|NCT01029158|EXPERIMENTAL|1d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
62523468|NCT01029158|EXPERIMENTAL|2a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
62523469|NCT01029158|EXPERIMENTAL|2b|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
62151685|NCT01681511|ACTIVE_COMPARATOR|BARD® LUBRI-SIL® IC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
62151686|NCT03706872|EXPERIMENTAL|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care.
62151687|NCT03706872|NO_INTERVENTION|Control Group|Provision of usual prenatal care
62523470|NCT01029158|EXPERIMENTAL|2c|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
62523471|NCT01029158|EXPERIMENTAL|2d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).
62523472|NCT02384941|PLACEBO_COMPARATOR|Placebo|Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
62523473|NCT02384941|EXPERIMENTAL|Sotagliflozin 200 milligrams (mg)|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
62523474|NCT02384941|EXPERIMENTAL|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.
62523475|NCT05515393|EXPERIMENTAL|XY03-EA Tablet (300mg group)|XY03-EA 150 mg/tablet, 2 tablets，three times a day； XY03-EA Placebo 150 mg/tablet, 2 tablets，three times a day； For 90 days, continuous administration Other Name: low dose
62523476|NCT05515393|EXPERIMENTAL|XY03-EA Tablet (600mg group)|XY03-EA 150 mg/tablet, 4 tablets ,three times a day, For 90 days, continuous administration Other Name:high dose
62523477|NCT05515393|PLACEBO_COMPARATOR|XY03-EA Placebo Tablet|XY03-EA Placebo Tablet 150 mg/tablet, 4 tablets,three times a day, For 90 days, continuous administration Other Name: placebo
62523478|NCT01703884|EXPERIMENTAL|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively.
62523479|NCT01703884|NO_INTERVENTION|SP|At ANC and labor wards for women in the control area, there will be no change from routine approaches.
62523480|NCT01598350|EXPERIMENTAL|Orthotic|Orthotic Use
62523481|NCT03457649|ACTIVE_COMPARATOR|ARGX-113|SAD and MAD with test product at different increasing doses
62523482|NCT03457649|PLACEBO_COMPARATOR|Placebo|SAD and MAD with placebo at different increasing doses
62151688|NCT02319707|EXPERIMENTAL|Intramuscular treatment:IV|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
62523483|NCT04860050|EXPERIMENTAL|TPG|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 24 weeks
62523484|NCT04860050|PLACEBO_COMPARATOR|Control|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (colored acacia gum) product during 24 weeks
62523485|NCT01370135|EXPERIMENTAL|Lucentis (Ranibizumab)|
62523486|NCT03822507|EXPERIMENTAL|KHK7580 1mg-12mg|
62523487|NCT03822507|ACTIVE_COMPARATOR|Cinacalcet 25mg-100mg|
62523488|NCT05614557|NO_INTERVENTION|Control|
62523489|NCT05614557|EXPERIMENTAL|Formulation 1|
62523490|NCT05614557|EXPERIMENTAL|Formulation 2|
62523491|NCT04764656||Brolucizumab|Naïve (Patients being the first time treated) and pre-treated patients
62523492|NCT05149443|EXPERIMENTAL|Effectiveness of the Move it, Move ID app|All participants will receive the Move it, Move ID app.
62523493|NCT05006872|EXPERIMENTAL|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
62523494|NCT05006872|NO_INTERVENTION|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
62523495|NCT06034561|EXPERIMENTAL|Bortezomib|"Patients with refractory or relapsed acute lymphoblastic leukemia will receive one-two courses of salvage regimen composed by:~* Bortezomib 1.3 mg/m2 I.V. D1,D4,D8,D11;~* Vincristine 1.5 mg/m2 I.V. (maximum at 2 mg) - D1, D8,D15,D22;~* Doxorubicin 60 mg/m2 I.V. - D1;~* Peg-asparaginase 2000 IU/m2 I.V. - D4 and D18;~* Dexamethasone 20 mg/m2 P.O. or I.V. (divided BID) - D1-D5 and D15-D19~* Intrathecal chemotherapy: methotrexate 12 mg + dexamethasone 2 mg."
62523496|NCT02073877||Controls - Holgers 0 & 1|
62523497|NCT02073877||Cases - Holgers >1 (active peri-implant dermatitis)|
62523498|NCT01295866||nasal nitric oxide, atypy status|
62523499|NCT03657212|ACTIVE_COMPARATOR|Nap/5mg Zolpidem|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
62712458|NCT04196530|EXPERIMENTAL|Dose Expansion of BDB001 with atezolizumab|"At the end of the dose escalation part of the study, the BDB001 dose to be used in combination with atezolizumab in the expansion part of the study will be established after thorough review of all available safety, preliminary efficacy, PK and PD data.~A biologically active dose will be selected that is either the MTD, if one was established in the escalation part, or an RP2D if no MTD was established. Approximately 20 additional subjects will initially be enrolled in the dose expansion part."
62712459|NCT03839914|ACTIVE_COMPARATOR|Intervention - Vancomycin|Intervention: 1g vancomycin powder locally applied to the deep wound and subcutaneous layer prior to closure.
62712460|NCT03839914|NO_INTERVENTION|Control - No vancomycin application|No intervention, control group All other wound closure procedure and wound care and monitoring are the same
62712461|NCT05962021|EXPERIMENTAL|19DEL cohort|Patients who participated in the trial with EGFR 19DEL mutation will be included in this arm.
62523500|NCT03657212|PLACEBO_COMPARATOR|Nap/Placebo|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
62523501|NCT05982730|EXPERIMENTAL|PD - individuals with Parkinson Disease, either male or female|Individuals, aged 50-85, with a clinical diagnosis of idiopathic Parkinson Disease, either male or female, with moderate disease stage presenting balance alterations (Hoehn or Yahr stage III)
62523502|NCT01562340|ACTIVE_COMPARATOR|Pomegranate fruit extract|
62523503|NCT01562340|ACTIVE_COMPARATOR|Pomegranate juice|
62523504|NCT02920918|ACTIVE_COMPARATOR|Canagliflozin|Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.
62523505|NCT02920918|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.
62523506|NCT06387459|EXPERIMENTAL|Knee Extensor Muscle-Mimicking Orthosis|This arm involves participants wearing a novel, lightweight fabric-type orthosis designed to mimic the function of knee extensor muscles through embedded shape-memory alloys. This intervention aims to support the knee joint during gait, enhancing stability and mobility for elderly individuals with compromised muscle function.
62523507|NCT03440541|EXPERIMENTAL|treated|Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
62523508|NCT02773459|EXPERIMENTAL|Phase 1 part|to assess the maximal tolerated dose (MTD) of MEK162+Capecitabine combination
62523509|NCT02773459|EXPERIMENTAL|Expansion part|to assess the efficacy (PFS) of MEK162+Capecitabine combination
62151689|NCT02319707|EXPERIMENTAL|Combined treatment:IV+IM|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
62151690|NCT02319707|ACTIVE_COMPARATOR|The control group|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
62151691|NCT02207140|EXPERIMENTAL|probiotic|HOWARU Restore
62151692|NCT02207140|PLACEBO_COMPARATOR|placebo|microcrystalline cellulose
62151693|NCT03800771|EXPERIMENTAL|Practice dual-task tests|"The study consists to practice these dual-task tests with a new device which name is Cycléo BRAU that allows to the patients to achieve carefully an attentional task: cycle. Results will be compared tothe results obsvered during the routine GAITRITE analysis ( a validated tool for elderly patients and gait analysis)."
62151694|NCT01959009|EXPERIMENTAL|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~* Frequency 3 breaths/min~* Ti = 1s~* Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP\*Tinsp+PEEP\*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
62151695|NCT01959009|EXPERIMENTAL|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~* Frequency 3 breaths/min~* Ti = 1s~* Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP\*Tinsp+PEEP\*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
62151696|NCT02674399|EXPERIMENTAL|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
62151697|NCT02674399|ACTIVE_COMPARATOR|Synvisc-One|hyaluronic acid
62523510|NCT02593448|ACTIVE_COMPARATOR|Propofol|"General anaesthesia with Propofol use. Maintenance of anaesthesia in group P will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
62523511|NCT02593448|EXPERIMENTAL|Sevoflurane|"General anaesthesia with sevoflurane use. Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
62523512|NCT01256723||J-LESSON Central committee|
62523513|NCT03474432|OTHER|Optical Coherence Tomography|Patients who have undergone clinically-indicated PCI of LM where OCT was performed as part of the routine index procedure will be approached for the study and enrolled if eligible.
62523514|NCT02038465|OTHER|patient|Complete questionary remembering the day
62712462|NCT05962021|EXPERIMENTAL|L858R cohort|Patients who participated in the trial with EGFR L858R mutation will be included in this arm
62523515|NCT02038465|OTHER|healthy volunteers|- Complete questionary, remembering the day
61975595|NCT01941901|EXPERIMENTAL|Calcium electroporation|"The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
62523516|NCT02021370|EXPERIMENTAL|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
62523517|NCT02021370|EXPERIMENTAL|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
62523518|NCT02021370|EXPERIMENTAL|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
62523519|NCT02021370|EXPERIMENTAL|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
62523520|NCT02021370|EXPERIMENTAL|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
62523521|NCT02021370|PLACEBO_COMPARATOR|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
62523522|NCT00942695|OTHER|base|average American diet without pistachios
62523523|NCT00942695|ACTIVE_COMPARATOR|1.5PD|average American diet plus 1.5 oz per day pistachios
62523524|NCT00942695|ACTIVE_COMPARATOR|3.0PD|average American diet plus 3.0 oz per day pistachios
62523525|NCT03524183|ACTIVE_COMPARATOR|Control|The children will receive the standard of care at their respective afterschool programs. As with the treatment group, all children will be asked to wear their Fitbits for one year following the intervention period, for the mid- and long-term follow up. Fitbit data will be recorded tracked year-round through the automated Fitbit data syncing stations at the afterschool program site. All participants will be assessed for PA and psychosocial variables at the same four measurement points for the treatment group.
62523526|NCT03524183|EXPERIMENTAL|Treatment|The virtual pet functions as a personalized fitness buddy to encourage children to set and meet physical activity goals, promote physical activity self-efficacy, and foster mutually supportive relationships among children, parents, and the virtual pet. Concurrently, the kiosk sends a text message to parents on the child's physical activity progress. Parents are then able to send words of encouragement and communicate with their children via the kiosk, using the text messaging feature of their mobile phones. Parents will also receive text messages from the kiosk with a security code to access a website that provides detailed records of the child's physical activity over time. Participants will be assessed for post-treatment measurements immediately after 3 months, 6 months after, and 12 months after the intervention.
62523527|NCT02327741|EXPERIMENTAL|plavix long term|taking plavix more than 12 months
62523528|NCT02327741|ACTIVE_COMPARATOR|plavix short term|taking plavix less than 12 months
62523529|NCT01884922|EXPERIMENTAL|Dose escalation|"Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested~Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle."
62523530|NCT03182582|ACTIVE_COMPARATOR|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
62523531|NCT03182582|ACTIVE_COMPARATOR|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
62151698|NCT02562521|EXPERIMENTAL|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy \[NRT\] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
62523532|NCT04626752|EXPERIMENTAL|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) Multiple Myeloma (MM)
62712463|NCT04983043|EXPERIMENTAL|Low dose group|Low dose QiShen YiQi Dripping Pills, 3 bags, take orally after meals, 3 times a day
61975596|NCT01941901|ACTIVE_COMPARATOR|Electrochemotherapy with bleomycin|"The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
62151699|NCT02562521|NO_INTERVENTION|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
62523533|NCT04058574|ACTIVE_COMPARATOR|ACL|"Intervention Group ACL: 30 patient, athletes, with ACL deficiency candidate to a surgical ACL reconstruction"
62712464|NCT04983043|EXPERIMENTAL|High dose group|High dose QiShen YiQi Dripping Pills, 3 bags, take orally after meals, 3 times a day
62712465|NCT04983043|PLACEBO_COMPARATOR|Placebo group|QiShen YiQi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day
62712466|NCT02351089|PLACEBO_COMPARATOR|Placebo|capsules containing corn starch
61975597|NCT00529542|EXPERIMENTAL|Atorvastatin|
61975598|NCT00529542|PLACEBO_COMPARATOR|Placebo|
61975599|NCT01974245|PLACEBO_COMPARATOR|Placebo|100 drops/week for 12 weeks
61975600|NCT01974245|ACTIVE_COMPARATOR|Cholecalciferol|Drug: Cholecalciferol - 100,000 IU/week
62151700|NCT06026462||Asthma with frequent acute exacerbations phenotype|Asthma with frequent acute exacerbations phenotype was defined as having at least two acute attacks in the past 12 months.
62151701|NCT06026462||Asthma with Intermittent acute exacerbations phenotype|Asthma with Intermittent acute exacerbations phenotype was defined as having less than or equal to one acute attacks in the past 12 months.
62151702|NCT01558726|EXPERIMENTAL|Case management|
62523534|NCT04058574|PLACEBO_COMPARATOR|Control|Control Group: 15 healthy volunteers, athletes.
62523535|NCT03134443|ACTIVE_COMPARATOR|Experimental group|Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
62523536|NCT03134443|PLACEBO_COMPARATOR|control group|Xiyanping injection simulation(andrographolide sulfonate simulation) 10-20ml/d, The treatment method is the same as the experimental group.
62523537|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
62523538|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
62523539|NCT00999648|EXPERIMENTAL|Manual therapy|Myofascial trigger point pressure release
62523540|NCT00999648|PLACEBO_COMPARATOR|Control|Placebo myofascial trigger point pressure release
62523541|NCT06133075|ACTIVE_COMPARATOR|50 mg group|Ten patients will receive 50 mg mirabegron for 8 weeks.
62523542|NCT06133075|ACTIVE_COMPARATOR|25 mg group|Ten patients will receive 25 mg mirabegron for 8 weeks.
62523543|NCT00605735|EXPERIMENTAL|A1|
62523544|NCT00605735|PLACEBO_COMPARATOR|P1|
62523545|NCT04299451|EXPERIMENTAL|Open dialogue about CAM (ODC-COC)|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
62523546|NCT04299451|NO_INTERVENTION|Standard care|Standard care including referral to a homepage about complementary alternative medicine
62523547|NCT00960830|PLACEBO_COMPARATOR|mirtazapine|
62523548|NCT00960830|PLACEBO_COMPARATOR|mirtazapine, sugar pill|
62523549|NCT03485053|EXPERIMENTAL|IOP Injection / MPB-1514|Administered IV infusion
62523550|NCT01565616|EXPERIMENTAL|Bone Marrow Transplant Recipients|Adults with sickle cell disease undergoing a bone marrow transplant from an HLA-identical sibling donor or an unrelated HLA-matched donor.
62523551|NCT04331444|EXPERIMENTAL|Group A, CGM|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group A (intervention) will, in similarity to the HCPs, receive a CGM-education and training session led by the study investigator and will be interactive and hands-on, using case studies. The training session will include spoken and written instructions on how to insert and wear the CGM device and how to interpret the CGM information to better understand the relation between participants blood glucose and their diabetes self-management."
62523552|NCT04331444|EXPERIMENTAL|Group B, CGM + peer-support|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin plus 3 sessions of peer-support in groups of 6 participants.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group B (intervention incl. peer-support) will, in similarity to group A, receive a CGM-education and training session. The training and CGM-course for participants in group B are similar to the course for group A with the addition of three peer-support sessions. The approach will be participatory and adaptable to allow flexibility in the content of the peer-support sessions and involving customized use of participatory methods i.e. dialogue tools and exercises."
62523553|NCT04331444|ACTIVE_COMPARATOR|Group C, SMBG|"Standard self-monitoring of blood glucose according to standard guidelines, in 12 months.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly."
62523554|NCT03358784||PHILOS Plate|three or four-part fractures of proximal humerus treated with internal fixation
62523555|NCT03358784||Hemi-shoulder arthroplasty|three or four-part fractures of proximal humerus treated with hemi-shoulder arthroplasty
62523556|NCT05980286|EXPERIMENTAL|Piano Improvisation|This intervention will involve group piano improvisation training sessions once a week for 12 weeks, in addition to daily in-home practice for 4-5 days.
61975601|NCT06203860|ACTIVE_COMPARATOR|The Cardio-Metabolic Clinic|Comprising specialized, multidisciplinary management of diabetes and cardiovascular disease in a Cardio-Metabolic Clinic.
61975602|NCT06203860|NO_INTERVENTION|Usual Care|Involving collaboration between the general practitioner, and/or the endocrinology outpatient clinic, and/or cardiology outpatient clinic.
62523557|NCT05980286|ACTIVE_COMPARATOR|Music Listening|The music listening condition will involve group music listening sessions (led by a trained instructor) once a week for 12 weeks and daily in-home music listening practice.
62523558|NCT05054218||Participants who receive 3rd dose of mRNA-1273 SARS-CoV-2 vaccine|Cancer patients who have already received their 1st and 2nd doses of mRNA-1273 SARS-CoV-2 vaccine will receive a 3rd dose of the vaccine. The volume of vaccine injected will be 0.5 mL, containing a 100-μg dose of mRNA-1273.
62523559|NCT02512536|EXPERIMENTAL|Experimental|"Intervention:~Subjects receiving a single ultrasound scan guided injection of Botulinum Toxin type A into the supraspinatus muscle belly.~Drug: Dysport 300 units im. One single injection over course of study."
62523560|NCT02151812|EXPERIMENTAL|Agent Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion
62523561|NCT02151812|ACTIVE_COMPARATOR|SeQuent Please Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single SeQuent(R) Please balloon that completely covers the restenotic lesion
62523562|NCT05258331|EXPERIMENTAL|Single Arm|CT303
62523563|NCT01093664|EXPERIMENTAL|AFFITOPE AD02|
62523564|NCT01303705|EXPERIMENTAL|Cyclophosphamide - Cohort 1|Cyclophosphamide 300 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
62523565|NCT01303705|EXPERIMENTAL|Cyclophosphamide - Cohort 2|Cyclophosphamide 600 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
62523566|NCT01303705|EXPERIMENTAL|Cyclophosphamide - Cohort 3|Cyclophosphamide 900 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
62523567|NCT04572126|EXPERIMENTAL|Mindfulness Group|Participants in the mindfulness group will receive mindfulness based instructions.
62523568|NCT04572126|ACTIVE_COMPARATOR|Control Group|Participants in the control group will receive instructions to cope with cravings how they normally would.
62523569|NCT01389947||Extracorporeal circulation|Patients who have coronary artery bypass graft performed under extracorporeal circulation
62523570|NCT01389947||Heart beating group|Patients who have a coronary artery bypass graft without extracorporeal circulation
62523571|NCT01016093|EXPERIMENTAL|Intervention|Patients in this arm received zoledronic acid.
62523572|NCT01016093|PLACEBO_COMPARATOR|Control|Patients in this arm received placebo as control group
62523573|NCT00448136|EXPERIMENTAL|1|
62523574|NCT00448136|EXPERIMENTAL|2|
62523575|NCT00767065|ACTIVE_COMPARATOR|Cardiac Computed Tomography (CCT)|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. CCT will be available Monday to Friday from 9am until 5pm. Patients will be entered into the study provided CCT can be undertaken within 24 hours of troponin result. Therefore, the only period during which a patient will be ineligible for inclusion will be between 5pm on a Friday and 9am the following Sunday. Studies will be reported at CWH by one of 2 experienced radiologists trained in CCT and results passed to the referring team on the same day.
62151703|NCT01558726|ACTIVE_COMPARATOR|Usual treatment|Usual treatment of the CAPSad
62523576|NCT00767065|ACTIVE_COMPARATOR|Standard Care Arm|Patients randomised to the standard care arm will undergo further care as dictated by the responsible clinician. Except for CCT, all standard investigations will be available to the responsible clinician and may be used at their discretion. CCT does not form part of current in-patient management at our hospital.
62523577|NCT06456437||Post-ischemic adaptation to combined endovascular therapy|
62523578|NCT06456437||Endovascular therapy alone|
62523579|NCT03591939||1|cases of Diabetic type two nephropathy
62523580|NCT03591939||2|controls of normal subjects
62523581|NCT01630681|EXPERIMENTAL|Internet-based stepped care|Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
62523582|NCT01630681|NO_INTERVENTION|Standard care|
62523583|NCT05707143|ACTIVE_COMPARATOR|home based stabilization exercises|knee rolls, the cat, spine curl, bridging, single knee to chest, pelvic tilt
61975603|NCT03297996||SIT|Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)
62151704|NCT04874142|EXPERIMENTAL|A Group|Two cohort, single sequence
62151705|NCT04874142|EXPERIMENTAL|B Group|Two cohort, single sequence
62151706|NCT02399111|NO_INTERVENTION|Not obese:BMI<30; Standard Care|Standard Wound Care
62523584|NCT05707143|EXPERIMENTAL|kegel exercises|kegel exercises
62523585|NCT06168435|NO_INTERVENTION|Pre-implementation|Outcomes collected in patient populations prior to roll-out of the eIMPAQc
62523586|NCT06168435|EXPERIMENTAL|Post-implementation|Outcomes collected in patient populations after roll-out of eIMPAQc
62523587|NCT03873636|EXPERIMENTAL|Active Stimulation|Active stimulation of targeted brain regions involved in task-switching and dual-tasking.
62523588|NCT03873636|SHAM_COMPARATOR|Sham Stimulation|Sham stimulation of targeted brain regions involved in task-switching and dual-tasking.
62151707|NCT02399111|NO_INTERVENTION|Obese:BMI≥30; Standard Care|Standard Wound Care
62523589|NCT02310243|EXPERIMENTAL|Palbociclib|"Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.~phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest."
62523590|NCT03203135|EXPERIMENTAL|Intervention Group|
62523591|NCT03203135|NO_INTERVENTION|Control Group|
62523592|NCT00885014|EXPERIMENTAL|CBT|Telephone cognitive-behavioral therapy
62523593|NCT00885014|ACTIVE_COMPARATOR|TAU|Treatment as usual through the Employees Assistance Program
62523594|NCT05771675|EXPERIMENTAL|Simvastatin|Participants receive Simvastatin 40mg capsule once daily for 6 months.
62523595|NCT05771675|PLACEBO_COMPARATOR|Placebo|Participants receive Placebo capsule matching Simvastatin once daily for 6 months.
62523596|NCT06341387||Lung cancer patients|Age 50-80 years Diagnosis of early stage of lung cancer No previous chemo or radiotherapy for lung cancer No previous malignancies within last 5 years No abuse of alcohol (no more than 1 litre of wine for day). No patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study Signed Informed Consent Completed questionnaire
62523597|NCT06341387||High Risk-Healthy Subjects|Age 50-80 years high risk individuals (heavy smokers, subjects with pulmonary disease non-cancer related or with a familiar history of lung cancer disease) Recent (within 6 months) negative Chest X-ray or CT scan No previous malignancies within last 5 years No patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study Signed Informed Consent Completed questionnaire
62523598|NCT04116853|EXPERIMENTAL|ADAPTIVE Extended-Care Group|"Participants randomized to the ADAPTIVE extended-care program will receive extended-care intervention phone delivered only if either 1) an algorithm developed by our study team detects that a participant is at high risk for weight regain or 2) the participant self-initiates a request for a session."
61975604|NCT03297996||NYU|New York University (NYU) Human Microbiome and Colorectal Tumor study
61975605|NCT00284661|EXPERIMENTAL|FAST FIX|Inetrvention is Fast Fix repair of meniscal tear
62151708|NCT02399111|OTHER|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
62712467|NCT02351089|ACTIVE_COMPARATOR|Probiotic low dose|capsules containing probiotic powder and corn starch
62151709|NCT02399111|OTHER|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
62151710|NCT01584999|ACTIVE_COMPARATOR|Fresh not-leukocyte-reduced RBCs|
62151711|NCT01584999|ACTIVE_COMPARATOR|Fresh RBCs leukocyte-reduced|
62712468|NCT02351089|ACTIVE_COMPARATOR|Probiotic high dose|capsules containing probiotic powder and corn starch
62151712|NCT01584999|ACTIVE_COMPARATOR|RBCs with storage longer than 15 days|
62151713|NCT00346398|EXPERIMENTAL|Oral mucosal immunoprophylaxis (OMIP)|Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
62523599|NCT04116853|ACTIVE_COMPARATOR|STATIC Extended-Care Group|Participants randomized to the STATIC extended-care program will receive the extended-care intervention phone calls on a fixed, once-per-month schedule (the schedule currently used in gold-standard weight maintenance programs).
62151714|NCT00346398|PLACEBO_COMPARATOR|Placebo|Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
62151715|NCT06034145||Asthma|Asthma according to Gina Guidelines
62151716|NCT03860129|OTHER|ISO|Drug name: Isoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (0.5 Vol%)
62151717|NCT03860129|OTHER|SEVO|Drug name: Sevoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (1.0 Vol%)
62523600|NCT00289874|EXPERIMENTAL|1|montelukast
62523601|NCT00289874|PLACEBO_COMPARATOR|2|placebo
62523602|NCT05964712||Population # 1|De novo patients with acromegaly, diagnosed according to Endocrine Society guidelines, aged equal or above 18 years old
62151718|NCT03860129|OTHER|DES|Drug name: Desflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (3.0 Vol%)
62151719|NCT03770429|EXPERIMENTAL|AZD6738|Patients will receive AZD6738 orally on a 28-day cycle
62151720|NCT06593691|ACTIVE_COMPARATOR|Conventional treatment group|In conventional treatment, Hot Pack, TENS, therapeutic ultrasound and exercise program will be given by the hospital staff.
62523603|NCT05964712||Population # 2|Acromegalic patients with different disease status (active disease despite ongoing therapies, controlled disease under medical therapy, and disease remission), aged equal or above 18 years old
61975606|NCT00284661|EXPERIMENTAL|Meniscal suturing|Intervention is Standard suturing of meniscal tear
62151721|NCT06593691|EXPERIMENTAL|Conventional treatment + Multiwave Locked System Laser treatment group|Multiwave-locked system laser treatment will be applied by the hospital staff to the group in addition to conventional treatment.
62151722|NCT06313268||Test group|Bevacizumab (Effivia®)
62151723|NCT01029639|NO_INTERVENTION|Treatment|Diabetic patients will complete hypoglycemia unawareness questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on low blood sugar incidences reported by subjects requiring heath care intervention other than by the subject themselves.
62151724|NCT01029639|EXPERIMENTAL|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
62151725|NCT03511495||Keratoconic Patients|
62151726|NCT00947895|ACTIVE_COMPARATOR|Methylprednisolone|Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
62151727|NCT00947895|ACTIVE_COMPARATOR|ACTH|Intramuscular (IM) ACTH 80 mg/day for 5 days.
62523604|NCT01103622|EXPERIMENTAL|1|twice daily Day 1 to Day 7; digoxin on day 4
62523605|NCT01103622|PLACEBO_COMPARATOR|2|twice daily Day 1 to Day 7; digoxin on day 4.
62523606|NCT06165666|EXPERIMENTAL|intervention group (EG)|The participants will receive as a therapeutic approach 3 physical therapy sessions/week of 40' duration, for 10 weeks.
62151728|NCT04111991|ACTIVE_COMPARATOR|Usual Care|Usual care in the NCH Complex Concussion Clinic
62523607|NCT06165666|ACTIVE_COMPARATOR|control group (CG)|The participants will receive as a therapeutic approach 3 physical therapy sessions/week of 40' duration, for 10 weeks.
62523608|NCT00003093|EXPERIMENTAL|Treatment|See detailed description.
62523609|NCT04161014|OTHER|Treatment Arm|Nintedanib 150mg twice daily for 3 years
62523610|NCT02451098|EXPERIMENTAL|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe10mg will be administered (Duration 8 weeks)
61975607|NCT05877781|ACTIVE_COMPARATOR|PEA + participant ON-PPI|Patiënts that on baseline take daily PPI treatment are randomized in the ON-PPI PEA arm or ON-PPI placebo arm
62523611|NCT02451098|ACTIVE_COMPARATOR|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, placebo will be administered (Duration 8 weeks)
62712469|NCT00271544|EXPERIMENTAL|4196 Lead|Non-randomized study.
62712470|NCT03005340|ACTIVE_COMPARATOR|Group A|Period 1: Bazedoxifene 20 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
62712471|NCT03005340|ACTIVE_COMPARATOR|Group B|Period 1: Bazedoxifene 20 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Cholecalciferol granule 10 mg
62151729|NCT04111991|EXPERIMENTAL|Usual Care + C-STEP|Usual care in the NCH Complex Concussion Clinic, plus 4 weekly sessions of C-STEP
62151730|NCT03864237|EXPERIMENTAL|Alcohol texts|Participants assigned to this arm will receive a text message each day for 10 weeks, containing factual information about campus drinking norms.
62151731|NCT03864237|PLACEBO_COMPARATOR|Attention control|"Participants assigned to this arm will receive a text message each day for 10 weeks, containing this day in history facts."
62151732|NCT02742805|EXPERIMENTAL|High Dose Vitamin D|Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.
62151733|NCT02742805|ACTIVE_COMPARATOR|Low Dose Vitamin D|Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.
62523612|NCT02451098|EXPERIMENTAL|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe10mg will be administered (Duration 8 weeks)
62523613|NCT02451098|ACTIVE_COMPARATOR|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, placebo will be administered (Duration 8 weeks)
62523614|NCT02451098|EXPERIMENTAL|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe10mg will be administered (Duration 8 weeks)
62523615|NCT02451098|ACTIVE_COMPARATOR|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, placebo will be administered (Duration 8 weeks)
62523616|NCT05483803|EXPERIMENTAL|Qualitative sub-study 1 group|One group of caregivers (n = 20) will engage with the digital health solution during 1 month.
62523617|NCT05483803|EXPERIMENTAL|Quantitative sub-study 2 group|A different group of caregivers (n = 80) will engage with the digital health solution during 3 months.
62523618|NCT01759017||Infliximab responders|Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
62151734|NCT05052398|ACTIVE_COMPARATOR|PSP NEURO SERUM|Active arm in which 26 patients will receive PSP NEURO SERUM in their hands three times a day for 28 days. Each application will consist of 1 g of PSP NEURO SERUM.
62151735|NCT05052398|PLACEBO_COMPARATOR|Placebo of PSP NEURO SERUM|Placebo arm in which 26 patients will receive Placebo PSP NEURO SERUM (same ingredients as PSP NEURO SERUM except for the active ingredient that is replace with water) in their hands three times a day for 28 days. Each application will consist of 1 g of Placebo PSP NEURO SERUM.
62523619|NCT01759017||Infliximab non-responders|Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery
62523620|NCT03287973|ACTIVE_COMPARATOR|Lifestyle modification program group|Patients with apnea-hypopnea index (AHI) ≥ 15/hr on home sleep study will participate in a dietitian-led lifestyle modification program (LMP) for 6 months. Patients will attend dietary consultation weekly in the first 4 months, and then monthly in the following two months.
62523621|NCT03287973|OTHER|CPAP group|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
62523622|NCT05410366||Emergency department (ED) patients|Adult emergency department patients presenting with a chief complaint of 1) low back pain, 2) headache, or 3) minor head injury.
62523623|NCT04727437|ACTIVE_COMPARATOR|Control|Full dose anticoagulation treatment as standard care for at least 3 months.
62523624|NCT04727437|EXPERIMENTAL|Intervention|Withholding anticoagulation for Isolated Sub-Segmental Pulmonary Embolism (ISSPE) for at least 3 months.
62523625|NCT01956617|OTHER|injection volume|block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively
62523626|NCT02262793|EXPERIMENTAL|telmisartan and ASA/ER-DP (concomitant)|
62523627|NCT02262793|ACTIVE_COMPARATOR|ASA/ER-DP alone|
62523628|NCT02262793|EXPERIMENTAL|telmisartan and ASA/ER-DP (consecutively)|
62523629|NCT02262793|ACTIVE_COMPARATOR|telmisartan|
62523630|NCT04511221|PLACEBO_COMPARATOR|Placebo|15 mg capsule containing rice maltodextrin and medium chain coconut triglycerides
62523631|NCT04511221|ACTIVE_COMPARATOR|Bifidobacterium animals subsp. lactis BL04|15 mg capsule containing 1x 10\^9 CFU Bifidobacterium animals subsp. lactis BL04 with rice maltodextrin and medium chain coconut triglycerides as a filler material
62523632|NCT04511221|EXPERIMENTAL|Bifidobacterium animals subsp. lactis BL04+PreforPro|15 mg capsule containing 1x 10\^9 CFU Bifidobacterium animals subsp. lactis BL04 and 1x10\^6 PFU of PreforPro (Commercial phage preparation) with rice maltodextrin and medium chain coconut triglycerides as a filler material
62523633|NCT00633516||Medical tool|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
62523634|NCT01193036||Interview|
62523635|NCT01193036||Symptom Inventory Assessment|
62523636|NCT06323486|OTHER|absTBS-sham treatment sequence arm|Those assigned to the accelerated bilateral sequential theta burst stimulation (absTBS)-sham arm shall receive the blinded active absTBS treatment at Week 1. At Week 3, they shall receive the blinded sham treatment.
62523637|NCT06323486|OTHER|Sham-absTBS treatment sequence arm|In the sham-absTBS arm, the blinded sham treatment shall be administered at Week 1. The blinded active absTBS treatment shall be given at Week 3.
62523638|NCT05046639|EXPERIMENTAL|Treatment group 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
62523639|NCT05046639|PLACEBO_COMPARATOR|Sham preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
62523640|NCT00107549|EXPERIMENTAL|1|All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine
62523641|NCT01112943|EXPERIMENTAL|Acupuncture|Acupuncture on predefined points once a week for 20 minutes over the seven week pulmonary rehabilitation course
62523642|NCT01112943|ACTIVE_COMPARATOR|Pulmonary Rehabilitation|A seven week exercise and educational class run twice a week using international guidelines.
62523643|NCT01112943|NO_INTERVENTION|Control|Three assessments over the same time frame of three months but without intervention
62523644|NCT00777413|EXPERIMENTAL|1|Minocycline 100 mg tablets of Ranbaxy
62151736|NCT00552461|EXPERIMENTAL|1|
62151737|NCT01890278|ACTIVE_COMPARATOR|Whole Brain IMRT|Whole brain radiation therapy delivered via IMRT (37.5 Gy to brain tumor, 30 Gy to the uninvolved brain in 15 fractions), mean dose of less than 18 Gy to scalp.
62151738|NCT01890278|ACTIVE_COMPARATOR|Conventional whole brain RT|Conventional whole brain radiation therapy (37.5 Gy to the brain tumors and uninvolved brain in 15 fractions).
62523645|NCT00777413|ACTIVE_COMPARATOR|2|Minocin 100mg tablets
62523646|NCT06048666|EXPERIMENTAL|Intra ovarian by platelet rich plasma|intra-ovarian injection of autologous platelet rich plasma 3 months after the PRP injection,they will undergo assisted reproductive therapy with antagonist protocol followed by a dose of 450 units of FSH (Gonal F)
62523647|NCT06048666|NO_INTERVENTION|control|they will undergo ICSI trial with antagonist protocol followed by a dose of 450 units of FSH (Gonal F)
62523648|NCT05657236|OTHER|control group|
62523649|NCT05657236|EXPERIMENTAL|Experimental group|
62523650|NCT02647593||gallstone hepatitis group,|gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis),
62523651|NCT02647593||control group|control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase)
62712472|NCT03005340|ACTIVE_COMPARATOR|Group C|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
62712473|NCT03005340|ACTIVE_COMPARATOR|Group D|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
62523652|NCT03589521|EXPERIMENTAL|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
62523653|NCT04785859||Moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, with the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
62523654|NCT04785859||no moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, without the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
62523655|NCT05881226||Patients admitted to hospital/emergency department with neurological diseases|All clinical data, laboratory data and imaging data of patients at baseline and follow-up were collected, as well as blood and tissue samples that did not affect the diagnosis and treatment of patients after obtaining the consent of patients at different time points in the acute and chronic phases.
62523656|NCT05655247|EXPERIMENTAL|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|
62523657|NCT05655247|ACTIVE_COMPARATOR|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|Modified Coronally Advanced Tunnel (MCAT)
62523658|NCT01481324||Functioning Pressure Sensor Group|This group will have a functioning pressure sensor placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
62523659|NCT01481324||Non-Functioning Pressure Sensor Group|This group will have a non-functioning pressure sensor (a placebo) placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
62523660|NCT01481324||No Sensor Group|This group will not have a pressure sensor placed on the foot ankle orthosis.
62523661|NCT01804218|PLACEBO_COMPARATOR|Placebo|Placebo
62523662|NCT01804218|EXPERIMENTAL|Active, nadolol|Active
62523663|NCT01363427||Crohn's disease|Patients with initially diagnosed Crohn's disease
62523664|NCT02288390|ACTIVE_COMPARATOR|Miswak (Sewak)|Miswak (sewak) oral care applied 4 hourly for oral care in mechanically ventilated patients.
62523665|NCT02288390|ACTIVE_COMPARATOR|Chlorhexidine/ toothbrush|Chlorhexidine 0.12 % plus toothbrushing oral care applied 4 hourly for oral care in mechanically ventilated patients.
62523666|NCT05696795|EXPERIMENTAL|Abrocitinib 200 mg daily|6 months of treatment with abrocitinib 200 mg daily
62523667|NCT01108666|EXPERIMENTAL|Proton RT and Nelfinavir|
62523668|NCT01642199|ACTIVE_COMPARATOR|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|
62523669|NCT01642199|ACTIVE_COMPARATOR|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|
62523670|NCT01642199|ACTIVE_COMPARATOR|Reduced Intensity Behavioral Weight Loss|
62523671|NCT05579483|EXPERIMENTAL|Predicted responders with prebiotics|Predicted responders, which are defined as UC patients having a relative abundance of Bacteroidetes \<=10% in their feces, will receive 6 grams of prebiotics per day.
62523672|NCT05579483|PLACEBO_COMPARATOR|Predicted responders with placebo|Predicted responders, which are defined as UC patients having a relative abundance of Bacteroidetes \<=10% in their feces, will receive 6 grams of placebo per day.
62523673|NCT05579483|EXPERIMENTAL|Predicted non-responders with prebiotics|Predicted non-responders, which are defined as UC patients having a relative abundance of Bacteroidetes \>=15% in their feces, will receive 6 grams of prebiotics per day.
62523674|NCT05579483|PLACEBO_COMPARATOR|Predicted non-responders with placebo|Predicted non-responders, which are defined as UC patients having a relative abundance of Bacteroidetes \>=15% in their feces, will receive 6 grams of placebo per day.
62523675|NCT01769339|EXPERIMENTAL|Miconazole plus Hydrocortisone|
62523676|NCT04001920|EXPERIMENTAL|Training program|12-week strength and endurance training program
62523677|NCT01939925|EXPERIMENTAL|New plain language summary format|New plain language summary format of a Cochrane systematic review
62712474|NCT03005340|ACTIVE_COMPARATOR|Group E|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
62712475|NCT03005340|ACTIVE_COMPARATOR|Group F|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Cholecalciferol granule 10 mg
62712476|NCT00716820||SUNITINIB MALATE|Patients taking Sutent.
62523678|NCT01939925|ACTIVE_COMPARATOR|Current plain language summary format|Plain Language Summary format for the public currently in use in Cochrane systematic reviews
62523679|NCT06534528|EXPERIMENTAL|Dose escalation|Four different doses were set, and three subjects in each dose plan received human umbilical cord mesenchymal stem cell injection successively. Each subject received a single dose of 6.0\*10\^6, 3.0\*10\^7,6.0\*10\^7, and 9.0\*10\^7 cells / person.
62523680|NCT01941940|EXPERIMENTAL|Tocilizumab|Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
62523681|NCT02934763|PLACEBO_COMPARATOR|Placebo|Saline solution by target controlled infusion
62523682|NCT02934763|ACTIVE_COMPARATOR|Propranolol at 5ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
62523683|NCT02934763|ACTIVE_COMPARATOR|Propranolol at 15ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
62712477|NCT01363960||neonates with retinopathy of prematurity|"all neonates meet the criteria:~1. a BW of less than 1501 gram (g)~2. born at a GA of 34 weeks (wk) or less and~3. selected infants with an unstable clinical course were included"
62712478|NCT05010590|ACTIVE_COMPARATOR|Romosozumab and denosumab|
62712479|NCT05010590|ACTIVE_COMPARATOR|Romosozumab|
62523684|NCT02706782|EXPERIMENTAL|TAI-meso-CART|A single dose of meso-CART cells will be administered by vascular interventional mediated as one dose infusions. The dose is 1-10x106/kg meso-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. Patients will undergo cannula--DSA radiography--CAR-T cells perfusion. The cells perfusion process would lasts 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
62523685|NCT02115217|EXPERIMENTAL|Leukotape K, basketball training|Use of Leukotape K to ensure stability of the ankle in basketball players
62523686|NCT02115217|PLACEBO_COMPARATOR|Sham, basketball training|Use of sham tape
62523687|NCT01415219|ACTIVE_COMPARATOR|active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
62523688|NCT01415219|NO_INTERVENTION|conventional care|community based physiotherapy
62523689|NCT01672944|EXPERIMENTAL|TBCCN-developed educational materials|"Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled Biobanking Hope for a Cancer Cure, and Spanish kit is entitled Biobanco: Una esperanza de cura para el cancer."
62523690|NCT01672944|OTHER|Control Group|"Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled Providing your Tissue for Research: What you need to Know, Spanish brochure is entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
62523691|NCT01989338||Hallux valgus patients|Females patients with hallux valgus asses for pain, function, and quality of life
62523692|NCT01439230|EXPERIMENTAL|Investigational Test Product|Donepezil 10 mg Tablets
62523693|NCT01439230|ACTIVE_COMPARATOR|Reference Listed Drug|Aricept® 10 mg Tablets
62523694|NCT04671030|EXPERIMENTAL|Treatment group|Subjects are screened by criteria, intravenous and transdermal iontophoresis then undergo the study during which they will be administered the placebo alternating with real drug without being aware of which is being given.
62523695|NCT04671030|PLACEBO_COMPARATOR|Placebo group|Placebo will be given without the subject being aware of the time in advance.
62523696|NCT03916523|EXPERIMENTAL|Group A|Infants in the group receive CPAP for respiratory support in the delivery room. In addition, they receive a total of 15 sustained lung inflations in the first 96 hours of life; 6 in the first day, 3 in the second day, 3 in the third day and 3 in the forth day of life.
62523697|NCT03916523|EXPERIMENTAL|Group B|Infants in the group receive CPAP for respiratory support in the delivery room. No sustained lung inflation will be applied.
62523698|NCT03916523|ACTIVE_COMPARATOR|Group C|Infants in this group are intubated in the delivery room and supported with mechanical ventilation.
62523699|NCT03820934|OTHER|Patients undergoing Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these test. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
62151739|NCT01986348|EXPERIMENTAL|Arm A: Selinexor 60 mg and Surgery|Participants who required surgery received up to 3 doses of oral selinexor tablets 60 milligrams (mg) twice weekly (BIW) on Day 1, Day 3 and between 2 and 48 hours prior to surgery, subsequently underwent surgery for resection of their tumor and resumed selinexor tablets 60 mg BIW after recovery, during Week 1 to 4 of each 4-week cycle, until progression of disease (PD) or development of unacceptable toxicities.
62151740|NCT01986348|EXPERIMENTAL|Arm B: Selinexor 50 mg/m^2|Participants who were not eligible for surgery received selinexor tablets 50 mg per square meter (mg/m\^2) BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
62151741|NCT01986348|EXPERIMENTAL|Arm C: Selinexor 60 mg|Participants who were not eligible for surgery received selinexor tablets 60 mg BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
62523700|NCT01491230||25 autologous/25 allogeneic patients|
62523701|NCT00074776|EXPERIMENTAL|1 Lithium|
62523702|NCT00074776|EXPERIMENTAL|2 Lamotrigine|
62523703|NCT03335293|PLACEBO_COMPARATOR|Placebo|normal saline vehicle added to subarachnoid block
62523704|NCT03335293|EXPERIMENTAL|100 mcg epinephrine|100 mcg epinephrine added to subarachnoid block
62523705|NCT03335293|EXPERIMENTAL|200 mcg epinephrine|200 mcg epinephrine added to subarachnoid block
62523706|NCT00045175|EXPERIMENTAL|UCN-01 in combination with topotecan|
62523707|NCT02681224|ACTIVE_COMPARATOR|Active Product with Occlusion|TR987 Gel with Silon Bandage
62523708|NCT02681224|ACTIVE_COMPARATOR|Active Product without Occlusion|TR987 without Silon Bandage
62523709|NCT02681224|PLACEBO_COMPARATOR|Placebo Gel with Occlusion|Placebo Gel with Silon Bandage
62523710|NCT02681224|PLACEBO_COMPARATOR|Placebo Gel without Occlusion|Placebo Gel without Silon Bandage
61975608|NCT05877781|PLACEBO_COMPARATOR|Placebo + Participant ON-PPI|Patiënts that on baseline take daily PPI treatment are randomized in the ON-PPI PEA arm or ON-PPI placebo arm
62523711|NCT01125020|ACTIVE_COMPARATOR|gemcitabine and oxaliplatin|
62523712|NCT01125020|ACTIVE_COMPARATOR|doxorubicin, 5-Fu and cisplatin|
62523713|NCT01544738|EXPERIMENTAL|Aponeurotic stimulation group|The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the trunk and upper limb muscles.
62523714|NCT01544738|ACTIVE_COMPARATOR|Placebo stimulation group|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the Aponeurotic stimulation group.
62523715|NCT02995876|NO_INTERVENTION|Zirconia and E-max Press|The first design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press.
62523716|NCT02995876|EXPERIMENTAL|Zirconia and E-max Press and Glaze|The second design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with a glaze layer to improve adhesion.
62523717|NCT02995876|EXPERIMENTAL|Zirconia and E-max Press twice|The third design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with an E-max Press layer to improve adhesion.
62523718|NCT01565850|EXPERIMENTAL|D/C/F/TAF|D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
62523719|NCT01565850|ACTIVE_COMPARATOR|DRV+COBI+FTC/TDF|DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
62523720|NCT05243186|EXPERIMENTAL|MPH walking|The participants will be instructed to work while taking Methylphenidate and walking on a treadmill workstation
62523721|NCT05243186|PLACEBO_COMPARATOR|MPH sitting|The participants will be instructed to work while taking Methylphenidate and sitting at a desk
62523722|NCT05243186|PLACEBO_COMPARATOR|No MPH walking|The participants will be instructed to work without taking Methylphenidate while walking on a treadmill workstation
62523723|NCT05243186|PLACEBO_COMPARATOR|No MPH sitting|The participants will be instructed to work without taking Methylphenidate while sitting at a desk
62523724|NCT01876550|EXPERIMENTAL|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)
62523725|NCT01876550|ACTIVE_COMPARATOR|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)
62523726|NCT01876550|PLACEBO_COMPARATOR|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.)
62523727|NCT00921089||Hemodialysis group|End stage renal disease patients aged lower than 70 years, treated for more than 6 months with hemodialysis
62523728|NCT00921089||Control group|Normotensive healthy controls
62523729|NCT01200264|EXPERIMENTAL|apremilast for all subjects|
62523730|NCT01884428|EXPERIMENTAL|Panobinostat + IGEV|Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)
62712480|NCT03655067|EXPERIMENTAL|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
62712481|NCT03655067|NO_INTERVENTION|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
62712482|NCT04562415|ACTIVE_COMPARATOR|Active rTMS group|chronic ischemic stroke patients receiving active low frequency repetitive transcranial magnetic stimulation therapy and physical therapy
62712483|NCT04562415|ACTIVE_COMPARATOR|Active cTBS group|chronic ischemic stroke patients receiving active continuous theta burst stimulation therapy and physical therapy
62523731|NCT04327856||Cataract surgery group|Patients which were administrated to the Ophthalmology Clinic Medical University of Bialystok due to scheduled cataract removal surgery
62523732|NCT05124197||Cohort of ICU patients with COVID-19 related ARDS requiring at least one extended PP session|patients with COVID-19 related ARDS requiring prone position because of profound hypoxemia were applied the investigators' strategy to extend duration of prone position: after being turned prone, they spent at least two complete nights in prone position before being turned to supine position
62523733|NCT05224284|OTHER|BPA level|BPA (Bisfenol A) in blood and ejaculate samples
62523734|NCT04660890|EXPERIMENTAL|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants will receive all 3 doses of ALXN2050 in a multiple-ascending fashion over 3 periods:~Treatment A (Period 1): ALXN2050 Dose 120 milligrams (mg) and moxifloxacin-matching placebo.~Treatment B (Period 2): ALXN2050 Dose 240 mg and moxifloxacin-matching placebo.~Treatment C (Period 3): ALXN2050 Dose 360 mg and moxifloxacin-matching placebo."
62712484|NCT04562415|SHAM_COMPARATOR|Sham cTBS group|chronic ischemic stroke patients receiving sham continuous theta burst stimulation therapy and physical therapy
62712485|NCT04951531|EXPERIMENTAL|BPTB double-bundle allograft group|The patient underwent arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
62712486|NCT04951531|ACTIVE_COMPARATOR|BPTB single-bundle allograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
62712487|NCT04951531|ACTIVE_COMPARATOR|BPTB single-bundle autograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
62712488|NCT01076010|EXPERIMENTAL|Sorafenib crossover to tivozanib.|The subjects who failed sorafenib (had Response Evaluation Criteria in Solid Tumors \[RECIST\] - defined progressive disease) on the parent protocol AV-951-09-301 will be offered tivozanib hydrochloride on Protocol AV- 951-09-902.
62712489|NCT01076010|EXPERIMENTAL|First line tivozanib.|The subjects who were randomized to tivozanib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability in Protocol AV-951-09-301.
61975609|NCT05877781|ACTIVE_COMPARATOR|PEA + participant OFF-PPI|Patiënts that do not take PPI at baseline are randomized in the OFF-PPI PEA arm or OFF-PPI placebo arm
61975610|NCT05877781|PLACEBO_COMPARATOR|Placebo + participant OFF-PPI|Patiënts that do not take PPI at baseline are randomized in the OFF-PPI PEA arm or OFF-PPI placebo arm
62151742|NCT01986348|EXPERIMENTAL|Arm D: Selinexor 80 mg|Participants who were not eligible for surgery received selinexor tablets 80 mg once weekly (QW) during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
62523735|NCT04660890|PLACEBO_COMPARATOR|Control Arm (DEF)|"Treatment Sequence DEF - Participants will receive ALXN2050-matching placebo over 3 periods:~Treatment D (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.~Treatment E (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin.~Treatment F (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin-matching placebo."
62523736|NCT04660890|PLACEBO_COMPARATOR|Control Arm (GHI)|"Treatment Sequence GHI - Participants will receive ALXN2050-matching placebo over 3 periods:~Treatment G (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin.~Treatment H (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.~Treatment I (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin."
62523737|NCT04976998||patients|those with symptoms of CTS
62523738|NCT04976998||control group|normal people those with no symptoms of CTS
62523739|NCT00931268|OTHER|Macrolane VRF 30|Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.
62523740|NCT04375865|EXPERIMENTAL|Treatment A|Period1: Celecoxib 200mg Period2: Tramadol 150mg Period3: Celecoxib 200mg + Tramadol 150mg
62523741|NCT04375865|EXPERIMENTAL|Treatment B|Period1: Celecoxib 200mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Tramadol 150mg
62712490|NCT01076010|ACTIVE_COMPARATOR|First line sorafenib.|The subjects who were randomized to sorafenib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability were to be offered long-term access to sorafenib.
62523742|NCT04375865|EXPERIMENTAL|Treatment C|Period1: Tramadol 150mg Period2: Celecoxib 200mg Period3: Celecoxib 200mg + Tramadol 150mg
62523743|NCT04375865|EXPERIMENTAL|Treatment D|Period1: Tramadol 150mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Celecoxib 200mg
62523744|NCT04375865|EXPERIMENTAL|Treatment E|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Celecoxib 200mg Period3: Tramadol 150mg
62523745|NCT04375865|ACTIVE_COMPARATOR|Treatment F|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Tramadol 150mg Period3: Celecoxib 200mg
62523746|NCT04569448|EXPERIMENTAL|Patient|Individuals diagnosed with Bipolar Disorder Type I or Type II and suffering a major depressive episode who will receive an adjunctive and variable dose of Brexpiprazole treatment
62712491|NCT05364450|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|The EUC group will meet for a single 90-minute coaching session via Zoom Health.
62523747|NCT03250949|NO_INTERVENTION|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
62712492|NCT05364450|ACTIVE_COMPARATOR|Acceptance Commitment Therapy (ACT)|The ACT group will meet for 90-minute sessions via Zoom Health weekly for 6 weeks.
62712493|NCT05364450|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|The CBT group will meet for 90-minute sessions via Zoom Health weekly for 6 weeks.
62712494|NCT00839969|SHAM_COMPARATOR|Cystoscopy alone|Women in this arm will undergo saline cystoscopy under general anaesthesia only.
62523748|NCT03250949|EXPERIMENTAL|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
62523749|NCT01903603||Healthy Children|Inclusion criteria for healthy children were as follows: ages of 4-20 y/o ; good cognition and cooperation; and healthy children.
62523750|NCT01903603||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 4-20 years old.
62523751|NCT04549935|ACTIVE_COMPARATOR|Group A Dextenza|Drug: Dextenza 0.4mg Opthalmic Insert The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion, The attributes of the insert reduce risks for improper corticosteriod tapering and unwanted peaks and troughs in drug concentration.
62523752|NCT04549935|ACTIVE_COMPARATOR|Group B Topical Prednisolone|Drug: Topical Prednisolone Standard of care topical drop treatment
62523753|NCT02643017|PLACEBO_COMPARATOR|normal saline|
62523754|NCT02643017|EXPERIMENTAL|Dex|
62523755|NCT04111406|OTHER|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
62523756|NCT04111406|EXPERIMENTAL|Protocol based|Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based
62523757|NCT01550744|EXPERIMENTAL|Group 1: Approved q12w maintenance regimen|Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
62523758|NCT01550744|EXPERIMENTAL|Group 2: Subject-tailored fixed-interval maintenance regimen|Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.
62523759|NCT01294475|EXPERIMENTAL|Cell Phone Enhanced Parent Training|Cell phones will be provided to mothers participating in Planned Activities Training.
62523760|NCT02927977|ACTIVE_COMPARATOR|Control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
62523761|NCT02927977|EXPERIMENTAL|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks. Participants will receive 4-6 treatments during 4 weeks.
62523762|NCT06227156|EXPERIMENTAL|Disitamab Vedotin|Disitamab Vedotin Q2W arm
62523763|NCT01930318|PLACEBO_COMPARATOR|PCA,Placebo,Placebo|PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery
62712495|NCT00839969|ACTIVE_COMPARATOR|Cystoscopy and urethral dilatation|Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
62712496|NCT02210078|EXPERIMENTAL|Treatment (allogeneic CMV-specific cytotoxic T-lymphocytes)|Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes IV. Patients with partial response, stable disease, or progressive disease may receive an additional dose of allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes at a minimum of 2 weeks from the first infusion.
62712497|NCT03454789|ACTIVE_COMPARATOR|LB Group|Ultrasound-guided brachial plexus block for LB Group (15 ml lidocaine 1% + 15 ml bupivacaine 0.5%)
62523764|NCT01930318|PLACEBO_COMPARATOR|PCA,placebo,tramadol|PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery
62523765|NCT01930318|EXPERIMENTAL|PCA,parecoxib,placebo|PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery
62523766|NCT01930318|EXPERIMENTAL|PCA,parecoxib,celecoxib|PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery
62523767|NCT02993315|EXPERIMENTAL|nDC vaccination arm|Patients in the nDC vaccination arm will receive a maximum of 3 cycles each consisting of 3 nDC injections intranodally (3-8x10\^6 nDC).
62523768|NCT02993315|PLACEBO_COMPARATOR|placebo arm|Patients will receive a maximum of 3 cycles each consisting of 3 placebo injections intranodally.
62523769|NCT06301061|EXPERIMENTAL|Patients treated with Focal Microvibration|Patients will be treated with focal microvibration through the application on the skin of four devices for 6 hours/day every day except thursady and Sunday.
62523770|NCT06301061|SHAM_COMPARATOR|Patients treated with a Sham device|Patients will be treated with four sham device which will be attached on the skin for 6 hours/day every day except thursady and Sunday.
62523771|NCT06301061|ACTIVE_COMPARATOR|Patients treated with standard pharmacological approach|Patients will be treated with standard pharmacological therapy
62523772|NCT03880773|EXPERIMENTAL|Stapler|
62523773|NCT03880773|ACTIVE_COMPARATOR|ultrasonic shears|
62151743|NCT02166723||CRYOABLATION|Cryoballoon ablation will be applied to all patients with persistent atrial fibrillation. It consists on applying the Arctic Front Cryoballoon to the pulmonary veins and freezing the antrum. In addition debulking of the atrial roof will be performed by a single application of the cryoballoon to the left and right roof, the septal wall and the lateral ridge wall.
62523774|NCT03876977|NO_INTERVENTION|Non-invasive|Neuropathic drugs Pudendal infiltration
62523775|NCT03876977|EXPERIMENTAL|Robotic laparoscopic decompression|Robotic laparoscopic decompression of pudendal nerve entrapment.
62523776|NCT02901613|NO_INTERVENTION|Retrospective|Standard dry sterile dressing
62523777|NCT02901613|EXPERIMENTAL|Prospective|Negative-pressure wound therapy
62523778|NCT04226573||Low anxiety, Middle and High anxiety|State Trait Anxiety İndex Scale: Values of less than 60, Low anxiety State Trait Anxiety İndex Scale: Values above 60, Middle and High anxiety
62523779|NCT03736213|EXPERIMENTAL|Visual-acoustic biofeedback|Visual-acoustic biofeedback treatment targeting /r/ distortions.
62523780|NCT03736213|EXPERIMENTAL|Ultrasound biofeedback|Ultrasound biofeedback treatment targeting /r/ distortions.
62523781|NCT05426304|EXPERIMENTAL|Agomelatine|The Agomelatine group will be received agomelatine (25 mg/day) for 180 days.
62523782|NCT05426304|PLACEBO_COMPARATOR|Placebo|The Placebo group will be received placebo (25 mg/day) for 180 days.
62523783|NCT00537927|ACTIVE_COMPARATOR|0|fixation of mesh with a single crown of tacks and absorbable sutures
62523784|NCT00537927|ACTIVE_COMPARATOR|1|fixation of mesh with a double crown of tacks and no sutures
62523785|NCT00537927|ACTIVE_COMPARATOR|2|fixation of mesh with a single crown of tacks and non-absorbable sutures
62523786|NCT02246439|EXPERIMENTAL|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
62523787|NCT02246439|PLACEBO_COMPARATOR|Placebo|Placebo
62523788|NCT01739621|EXPERIMENTAL|Proellex 12 mg|Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months
62523789|NCT01739621|EXPERIMENTAL|Proellex 24 mg|Telapristone acetate, 1 vaginally inserted capsule, twice a day, for 4 months
62523790|NCT00608153||1|Patient with essential hypertension under treatment with candesartan or candesartan HCT
62523791|NCT01892657|EXPERIMENTAL|Facial Moisturizer with SPF 50+|All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
62523792|NCT02923882|EXPERIMENTAL|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
62523793|NCT02923882|NO_INTERVENTION|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
62523794|NCT05789719|EXPERIMENTAL|autoSTEM-OA 400|400x10\^6 autologous MSC(AT)s in autologous fat
62151744|NCT01579955||eptacog alpha users|
62151745|NCT00070642|EXPERIMENTAL|CPG 7909 Injection plus chemotherapy|CPG 7909 Injection plus DTIC
62523795|NCT05789719|EXPERIMENTAL|alloSTEM-OA 400|400x10\^6 allogeneic MSC(AT)s in autologous fat
62523796|NCT05789719|EXPERIMENTAL|autoSTEM-OA 800|800x10\^6 autologous MSC(AT)s in autologous fat
62523797|NCT05789719|EXPERIMENTAL|alloSTEM-OA 800|800x10\^6 allogeneic MSC(AT)s in autologous fat
62523798|NCT05789719|EXPERIMENTAL|autoSTEM-OA 1600|1600x10\^6 autologous MSC(AT)s in autologous fat
62523799|NCT05789719|EXPERIMENTAL|alloSTEM-OA 1600|1600x10\^6 allogeneic MSC(AT)s in autologous fat
62523800|NCT02715206|EXPERIMENTAL|Control|middle schools not receiving keepin' it REAL; continue their own programs if any.
62523801|NCT02715206|EXPERIMENTAL|keepin' it REAL classic|middle schools will implement keepin' it REAL classic drug prevention curriculum
62523802|NCT02715206|EXPERIMENTAL|keepin' it REAL rural|middle schools will implement the keepin' it REAL rural curriculum
62523803|NCT01138865|OTHER|1|Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
62523804|NCT01138865|OTHER|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
62523805|NCT03373136|EXPERIMENTAL|Cold snaring|Polypectomy will be done without electrocautery
62523806|NCT03373136|ACTIVE_COMPARATOR|Hot snaring|Polypectomy will be performed with electrocautery
62523807|NCT02567318|EXPERIMENTAL|MRI-scan|All study participants will complete a MRI-scan of the brain
62523808|NCT02880020|EXPERIMENTAL|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62523809|NCT02880020|EXPERIMENTAL|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes every 6 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62523810|NCT01389466|EXPERIMENTAL|MG1109 - Step 1|
62523811|NCT01389466|PLACEBO_COMPARATOR|Normal Saline - Step 1|
62523812|NCT01389466|EXPERIMENTAL|MG1109 - Step 2|
62523813|NCT03729076|EXPERIMENTAL|Crystalloid|Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.
62523814|NCT03729076|ACTIVE_COMPARATOR|Colloid|Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.
62523815|NCT05072197|EXPERIMENTAL|Mobile device application group|routine care and mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment
62523816|NCT05072197|NO_INTERVENTION|control group|routine care for breast cancer women during their chemotherapy treatment
62523817|NCT02666352|EXPERIMENTAL|Moderate HI Participants|On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
62523818|NCT02666352|EXPERIMENTAL|Severe HI Participants|On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
62712498|NCT03454789|ACTIVE_COMPARATOR|BS Group|Ultrasound-guided brachial plexus block for BS Group (20 ml bupivacaine 0.5% + 10 ml normal saline)
62523819|NCT02666352|EXPERIMENTAL|Healthy Participants|On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
62523820|NCT05841082||CAD|The investigators recruited all consecutive end-stage renal disease patients requiring dialysis who had significant coronary artery disease, defined as 50% or greater stenosis in any of three main coronary arteries or left main coronary artery on visual assessment of the coronary angiogram
62523821|NCT00622466|EXPERIMENTAL|Sorfenib + Paclitaxel|Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
62523822|NCT05222503|ACTIVE_COMPARATOR|Control group: Medial off-loader brace and home exercise program|The subject will receive a traditional medial off-loader brace and a take-home, self-guided exercise program. The subject will be instructed how to wear the brace. The subject will be instructed to incrementally increase wear time of the brace in the first week to get accustomed to the brace to reach a minimum of 6 hours per day after the first week.
62712499|NCT03454789|ACTIVE_COMPARATOR|LS Group|Ultrasound-guided brachial plexus block for LS Group (20 ml lidocaine 1% + 10 ml normal saline)
62523823|NCT05222503|EXPERIMENTAL|2. Intervention group: Medial off-loader brace with OPUM Digital Knee and Remote Patient Monitoring|"The same off-loader brace as above but with the ODK sensor will be provided. The subject will be instructed how to wear the brace and sensor. The patient will be instructed to incrementally increase wear time in the first week to get accustomed to the brace to reach a minimum of 6 hours per day after the first week. Using the sensor they will be able to keep track of their exercise frequency, range of motion (ROM), and kinematics in the OPUM app on their mobile phone. Education/resources will also be provided to the subjects via modules in the mobile app. The subjects will be instructed how to use the app as well.~Patients data will be monitored remotely for 20mins per patient per month in the sensor group. Programs will be updated as necessary based on data."
62712500|NCT03454789|ACTIVE_COMPARATOR|BL Group|and Ultrasound-guided brachial plexus block for BL Group (20 ml bupivacaine 0.5% + 10 ml lidocaine 1%)
62712501|NCT03190122|ACTIVE_COMPARATOR|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
62712502|NCT03190122|EXPERIMENTAL|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
62712503|NCT00967616|ACTIVE_COMPARATOR|FOLFIRI|"Participants who received irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). FOLFIRI was administered by intravenous (IV) injection once every 2 weeks. The FOLFIRI regimen consisted of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
62523824|NCT01383421||Participants With RA Receiving Adalimumab|"Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.~All participants were offered to participate in the PSP while treated with ADA for their RA."
62712504|NCT00967616|EXPERIMENTAL|CS7017+FOLFIRI|"Participants who received CS7017 plus irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). Two CS-7017 tablets were administered by mouth (PO) twice a day (BID) every 12 hours. FOLFIRI was administered IV once every 2 weeks. The FOLFIRI regimen consisted of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
62523825|NCT02229448||IgG4 UKN diagnosis|who ever been found with IgG4 sub class in blood sample or in his byposy
62523826|NCT03698266|OTHER|All Enrolled Patients|Receive needle knife fistulotomy as a starting technique to gain access to the biliary system
62523827|NCT03476122||Disease Group|The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
62523828|NCT03476122||Control Group|The control group will receive Colonoscopy
62712505|NCT03537638|EXPERIMENTAL|Multicomponent Intervention|Rheumatologist and internist receive a multicomponent intervention
62712506|NCT03537638|NO_INTERVENTION|Control|Rheumatologist and internist provide the usual care
62712507|NCT02916316||Chemo immunotherapy|All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
62712508|NCT00986882|EXPERIMENTAL|SAF312A (2 doses in part B; 5 - 6 doses in part C)|
62712509|NCT00986882|PLACEBO_COMPARATOR|Placebo|
62712510|NCT00986882|ACTIVE_COMPARATOR|Ibuprofen|
62712511|NCT05805163|ACTIVE_COMPARATOR|Control|Participants will be mailed a standard COVID-19 home-based test kit.
62712512|NCT05805163|EXPERIMENTAL|Intervention|Participants will be mailed a standard COVID-19 home-based test plus the FABI culturally sensitive COVID-19 educational pamphlet.
61975611|NCT04112836||Normal nutritional status|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of 24-30 points.
62523829|NCT01969292|EXPERIMENTAL|Colometer|Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
62523830|NCT01969292|SHAM_COMPARATOR|Sham Software|An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
62523831|NCT01969292|NO_INTERVENTION|Control|Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.
62523832|NCT03983252|EXPERIMENTAL|Relapsing Remitting Multiple Sclerosis starting Alemtuzumab|"Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (defined by International Panel Criteria), age 18-60 years, enrolled to start treatment with alemtuzumab.~Subjects will undergo \[F-18\]PBR06 PET scans at baseline, 6 months and 18 months."
62523833|NCT02058212|PLACEBO_COMPARATOR|no antioxidant , ROS , pregnancy outcome|no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF
61975612|NCT04112836||Malnourished|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of fewer than 17 points.
62523834|NCT02058212|ACTIVE_COMPARATOR|antioxidant , ROS , pregnancy outcome|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)
62523835|NCT03514654|ACTIVE_COMPARATOR|Mastectomy +/- reconstruction|Either a simple mastectomy or skin sparing mastectomy technique will be used. Women in this arm will be offered either immediate or delayed breast reconstruction according to standard practice. Reconstructions will be followed by chemotherapy and/or endocrine therapy as determined by local clinicians . Chest wall and/or regional nodal radiotherapy will be prescribed according to local centre policy.
62523836|NCT03514654|ACTIVE_COMPARATOR|Therapeutic Mammoplasty|"Therapeutic Mammoplasty (TM) comprises well-established surgical techniques involving volume displacement using breast reduction techniques, or volume replacement to maximize the volume of tissue that can be excised resulting in effective local control whilst maximizing cosmetic outcomes. This group will either have one disease site lumpectomy in the case of multifocal tumours or distant disease site lumpectomies in multicentric cancers."
62151746|NCT00070642|ACTIVE_COMPARATOR|Chemotherapy alone|dacarbazine
62523837|NCT05376852|EXPERIMENTAL|treatment group|Based decitabine and olverembatinib（HQP1351)chemotherapy
62523838|NCT06166316|ACTIVE_COMPARATOR|lateral incisor group|patients having mandibular two implants in lateral incisor positions.
62523839|NCT06166316|ACTIVE_COMPARATOR|canine group|patients having mandibular two implants in the canine positions.
62523840|NCT06166316|ACTIVE_COMPARATOR|premolar group|patients having mandibular two implants in the premolar positions.
62523841|NCT02031952|EXPERIMENTAL|hepatectomy combined lymphadenectomy|hepatectomy combined lymphadenectomy
62151747|NCT00070642|EXPERIMENTAL|CPG 7909 Injection 10 mg|
62151748|NCT00070642|EXPERIMENTAL|CPG 7909 Injection 40 mg|
62151749|NCT01817491|ACTIVE_COMPARATOR|Reduced Fat Vegan Diet|Plant based diet with as few added oils and fats as possible.
62523842|NCT02031952|ACTIVE_COMPARATOR|hepatectomy|hepatectomy alone
62523843|NCT04691050|OTHER|OrthoMta (BioMTA)|OrthoMTA was applied in primary molars without successors
62523844|NCT01059266|ACTIVE_COMPARATOR|conventional regimen of PURETHAL Grasses|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16)."
62523845|NCT01059266|EXPERIMENTAL|rush regimen of PURETHAL Grasses|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)~Maintenance treatment:~3 monthly doses of 0.5 ml (week 7, 11, 15)."
62523846|NCT03566264||Participants hospitalized with ADHF|
62523847|NCT00770536|EXPERIMENTAL|Part 1|In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy \[(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)\].
62523848|NCT00770536|EXPERIMENTAL|Part 2|The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
62523849|NCT01659736|EXPERIMENTAL|TMS Therapy|TMS treatment
62523850|NCT01659736|SHAM_COMPARATOR|TMS-Sham|This is a sham TMS condition
62523851|NCT04751084|ACTIVE_COMPARATOR|treatment group|20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer
62523852|NCT04751084|PLACEBO_COMPARATOR|control group|2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer
62523853|NCT04593017|EXPERIMENTAL|Active Probiotic|Probiotic contain active microorganism
61975613|NCT05872672|ACTIVE_COMPARATOR|Sleep Program|
61975614|NCT05872672|OTHER|Waitlist|
61975615|NCT01858090|PLACEBO_COMPARATOR|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
61975616|NCT01858090|ACTIVE_COMPARATOR|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
61975617|NCT01858090|ACTIVE_COMPARATOR|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
62151750|NCT01817491|ACTIVE_COMPARATOR|American Heart Association Diet|Diet emphasizing fruits, vegetables and whole grains but also low fat dairy, low fat meat and fish.
62151751|NCT05534776||First Scoring Session|Participants whose de-identified photos will be printed in the first booklet for the first scoring session.
62151752|NCT05534776||Second Scoring Session|Participants whose de-identified photos will be printed in the second booklet for the second scoring session.
62523854|NCT04593017|PLACEBO_COMPARATOR|Placebo Probiotic|Probiotic with no active microorganism
62151753|NCT04470089|EXPERIMENTAL|Myramistin 0.005%|
62151754|NCT04470089|EXPERIMENTAL|Myramistin 0.01%|
62151755|NCT04470089|EXPERIMENTAL|Myramistin 0.02%|
62151756|NCT04470089|PLACEBO_COMPARATOR|Placebo|
62151757|NCT04557566|ACTIVE_COMPARATOR|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
62151758|NCT04557566|NO_INTERVENTION|Control|Wait list control
62151759|NCT04207372|EXPERIMENTAL|Whey protein isolate|
62151760|NCT04207372|EXPERIMENTAL|Zein|
62151761|NCT04207372|PLACEBO_COMPARATOR|Protein-free|
62151762|NCT01204879|ACTIVE_COMPARATOR|CM for general activities|Standard care plus individual contingency management session for general activities
62523855|NCT00249691|EXPERIMENTAL|Topiramate|
62523856|NCT00249691|PLACEBO_COMPARATOR|Placebo|
62523857|NCT05314114|EXPERIMENTAL|No Axillary Surgery|No axillary surgery including SLNB
62523858|NCT04796636|EXPERIMENTAL|Intermediate dose|"Sodium ascorbate (vitamin C) is provided by the manufacturer (Orthomolecular Medisearch Laboratory P/L, Braeside, Victoria, Australia) as 30 grams in 100 ml.~* 30 gram load over 2 hours (T = 0 - 2 hours)~* 30 gram infusion over 6 hours (T = 2-8 hours) which will be repeated at 14, 26 and 38 hours"
62523859|NCT04796636|EXPERIMENTAL|High dose|"Sodium ascorbate (vitamin C) is provided by the manufacturer (Orthomolecular Medisearch Laboratory P/L, Braeside, Victoria, Australia) as 30 grams in 100 ml.~* 30 gram load over 2 hours (T = 0 - 2 hours)~* 60 gram infusion over 6 hours (T = 2-8 hours) which will be repeated at 14, 26 and 38 hours"
62712513|NCT03669887|EXPERIMENTAL|Lifestyle Modification Program|Women randomised into the intervention group received the 1-year lifestyle modification program.
62712514|NCT03669887|NO_INTERVENTION|Control|Women randomised into the control arm received standard postnatal care.
61975618|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
62523860|NCT04796636|NO_INTERVENTION|Usual care|Usual care for septic shock. No vitamin C will be given
62523861|NCT05873361||Adult patients with a papillary microcarcinoma asymptomatic|Adult patients who have had a papillary microcarcinoma asymptomatic and who are followed.
62523862|NCT02819141|NO_INTERVENTION|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
62523863|NCT02819141|EXPERIMENTAL|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
62151763|NCT01204879|EXPERIMENTAL|CM for exercise-related activities|Standard care plus individual contingency management session for physical activities
62151764|NCT00632736|ACTIVE_COMPARATOR|Ropinirole XL (formerly CR)|Ropinirole XL (formerly CR)
62523864|NCT03231319|ACTIVE_COMPARATOR|fascia iliaca compartment block+ IV-PCA|
62151765|NCT06443099|EXPERIMENTAL|shotblocker group|It is a C-shaped plastic tool with small blunt protrusions on one side that contact the skin. It does not have any side effects. The protruding surface of the ShotBlocker is pressed against the skin during injection and the injection is performed through the opening. It is thought to provide pain control as an application of gate control theory. In addition to the IM injection application procedure, after the skin is cleaned in the patient group, the protruding part of the ShotBlocker (Bionix, Press Firmly, USA) will be placed in contact with the skin. The ShotBlocker will be pressed firmly against the skin and the injection will be made through the central opening of the ShotBlocker. Once the injection is complete, the ShotBlocker will be removed from the skin.
62523865|NCT03231319|ACTIVE_COMPARATOR|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
62523866|NCT03231319|PLACEBO_COMPARATOR|IV PCA only|
62523867|NCT03014336|NO_INTERVENTION|Control|Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
62523868|NCT03014336|EXPERIMENTAL|memsorb|Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
62523869|NCT02405663|EXPERIMENTAL|manual removal group|Group will be assigned for manual removal of the placenta as the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby by caesarean section
62523870|NCT02405663|EXPERIMENTAL|cord traction group|Group will be assigned for controlled cord traction as the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery after the delivery of the baby by caesarean section
62523871|NCT00166270|EXPERIMENTAL|1|
62523872|NCT02658565|NO_INTERVENTION|Low-risk for nodal involvement|No lymphadenectomy recommended
62523873|NCT02658565|EXPERIMENTAL|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
62523874|NCT04977063|OTHER|SmartPill and Atmo capsule|The SmartPill and Atmo gas capsule will be tested simultaneously. This will allow the ability of the Atmo gas capsule to measure gastrointestinal transit time to be compared to the SmartPill. The order of swallowing will be randomised using a computer-generated list. The two capsules will be swallowed within 5 minutes of each other
62523875|NCT01527617|ACTIVE_COMPARATOR|Cranberry beverage|
62523876|NCT01527617|PLACEBO_COMPARATOR|Non-cranberry beverage|
62523877|NCT05250674||Adult women with indication for a breast biopsy procedure after an abnormal CEM or MRI examination.|Adult women presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination and no clear ultrasound or mammography correlation.
62523878|NCT00003034|EXPERIMENTAL|Arm I|Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.
62523879|NCT00003034|EXPERIMENTAL|Arm II|Patients receive doxorubicin as in arm I for up to 6 courses.
62523880|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
62523881|NCT03564041|EXPERIMENTAL|Sahaj Samadhi Meditation (SSM)|SSM will be taught to participants over 4 consecutive days, for 2 hours each day. Participants will initially learn about the nature of meditation and will be taken through a guided meditation. Afterwards, participants will undergo training which includes understanding the nature of the mind and the thoughts arising from it, guided meditation by the instructor, and a discussion of what is correct and incorrect meditation. Follow-ups will be conducted once every week for the following 11 weeks, each including guided meditation. Participants will be encouraged to practice the meditation at home for 20 minutes per session and will be given weekly practice logs to complete.
62712515|NCT03243721|EXPERIMENTAL|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
62712516|NCT03243721|EXPERIMENTAL|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
62712517|NCT03573492|ACTIVE_COMPARATOR|In-Person Education by Ultrasonographer|In-person education of the DVT scanning technique by an RDMS-certified ultrasonographer
62712518|NCT03573492|ACTIVE_COMPARATOR|Online Education (EM Sono)|Online lectures of DVT scanning technique by an Emergency Ultrasound fellowship director
62712519|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Previous tooth extraction|Patient with osteoporosis - antiresorptive treatment \> 4 years who have had previous tooth extraction without development of MRONJ
62712520|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Previous resection|Patient with osteoporosis - antiresorptive treatment \> 4 years who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
62523882|NCT03564041|OTHER|Health Enhancement Program (HEP)|"Arm type: Active control group~HEP controls for several non-specific factors found in a meditation group such as Sahaj Samadhi, including: group support and morale, behavioral activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP has been tailored to be structurally equivalent to a SSM intervention, with similar-sized groups, meeting for 4 days for 2 hours, and then a one-hour follow up session weekly for the subsequent 11 weeks, and completing the same amount of home practice (20 minutes twice daily, every day), and will be asked to complete weekly practice logs."
62523883|NCT02812979|EXPERIMENTAL|Airvo2 with Aerogen Solo|"AIRVOTM2 will be set to deliver air (21% oxygen concentration ) at a rate of 30 L / min at 100 % relative humidity at 37 ° C.~Nebulization of salbutamol will be effected by means of a nebulizer to the vibrating screen (Aerogen® Solo, Aerogen , Galway, Ireland ) which is a nebulizing device for single use, commonly used in invasive and non invasive mechanical ventilation.~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
62523884|NCT02812979|ACTIVE_COMPARATOR|Mask|"During nebulization in the usual way ( oral facial mask ) , it will be used a pneumatic nebulizer powered by a 6 L / min air flow rate ( usual method ).~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
62523885|NCT02812979|PLACEBO_COMPARATOR|arm control Airvo2 without nebulization of salbutamol|control procedure is to be placed under humidified high flow nasal alone
62523886|NCT04014855|ACTIVE_COMPARATOR|obese children 1|iron supplementation
62523887|NCT04014855|ACTIVE_COMPARATOR|obese children 2|lactoferrin supplementation
62523888|NCT00944749|EXPERIMENTAL|Single Arm|
62523889|NCT00115297|EXPERIMENTAL|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
62523890|NCT00115297|PLACEBO_COMPARATOR|Placebo|Participants who are 2 to 3 years old received 5-mg montelukast placebo tablets and participants who are 12 months to 2 years old received 4-mg montelukast placebo granules.
62523891|NCT04191798|EXPERIMENTAL|KinexConnect|Rehab at Home Patients
62523892|NCT04191798|ACTIVE_COMPARATOR|Outpatient PT|In-person PT patients
62523893|NCT02011750|EXPERIMENTAL|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
62523894|NCT02011750|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
62523895|NCT00557076|EXPERIMENTAL|Familiar Auditory Sensory Training|FAST is a standardized passive auditory stimulation protocol. The patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. The FAST protocol is provided on compact discs (CDs), using portable players and noise cancelling headphones, while patients were awake (ie, eyes open). Speakers were used for one patient not tolerating his headphones. The CDs were identical according to track duration, labeling, and administration procedures.
62523896|NCT00557076|SHAM_COMPARATOR|Sham Auditory Sensory Training|Placebo protocol is silence. Patients receive sham protocols for 10 minutes 4 times per day, with at least 2 hours in between, for 6 weeks.
62523897|NCT00620659|EXPERIMENTAL|1|Arm 1: Treatment period 1: MK0249; Treatment period 2: Placebo; Treatment period 3: modafinil
62523898|NCT00620659|EXPERIMENTAL|2|Arm 2: Treatment period 1: Placebo; Treatment period 2: modafinil; Treatment period 3: MK0249
62523899|NCT00620659|EXPERIMENTAL|3|Arm 3: Treatment period 1: modafinil; Treatment period 2: MK0249; Treatment period 3: Placebo
62523900|NCT00620659|EXPERIMENTAL|4|Arm 4: Treatment period 1: MK0249; Treatment period 2: modafinil; Treatment period 3: Placebo
62523901|NCT00620659|EXPERIMENTAL|5|Arm 5: Treatment period 1: Placebo; Treatment period 2: MK0249; Treatment period 3: modafinil
62523902|NCT00620659|EXPERIMENTAL|6|Arm 6: Treatment period 1: modafinil; Treatment period 2: Placebo; Treatment period 3: MK0249
62151766|NCT06443099|EXPERIMENTAL|Cold needle group|In addition to the IM injection procedure, a cold needle tip will be used in the needle tip changing procedure step. For this, before the application, the 25 Gauge orange syringe tip will be placed in a cold thermos and kept at 0-2 degrees Celsius with ice batteries. The appropriate temperature range will be checked with a digital thermometer.
62151767|NCT06443099|NO_INTERVENTION|Control group|Applications will be carried out according to the IM injection application protocol. Identifying the deltoid region. Clean the area around the injection site (five cm) with 70% disposable alcohol cotton in circular motions, wait for the alcohol to dry in the area (5 seconds). Injecting the drug every 10 sec/ml. 10 seconds before withdrawing the needle. wait. Retracting the needle straight and steady at the angle at which the tissue was entered.
62523903|NCT05925504|EXPERIMENTAL|Luspatercept|open-label, single-arm
62523904|NCT01447836||Sepsis|Sepsis patients who are admitted to SICU of our clinical center.
62523905|NCT01447836||Control|Postoperative patients who underwent abdominal surgery and then was directly transferred to SICU of our clinical center.
62523906|NCT00115557|EXPERIMENTAL|1|Performance feedback, academic detailing, practice facilitation, IT support
62523907|NCT00115557|ACTIVE_COMPARATOR|2|Performance feedback only
62523908|NCT04416620|ACTIVE_COMPARATOR|The active group of Syria|"Participants in the active group received the 'pharmacist standard counseling' plus the 'pharmaceutical care service' designed by the research group. Both services were delivered by one female clinical pharmacist who has a Master's degree in pharmaceutical sciences, 5-year work experience in community pharmacies, and comprehensive knowledge of PCOS. The time it took to deliver the counseling and education to each participant in the active group was formally assessed. This time assessment excluded data collection and questionnaire filling time (which was planned to take around 15 min).~Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise."
62151768|NCT04876430|EXPERIMENTAL|Meropenem plus Best Available Therapy plus|"Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~1. Polymyxin B or colistimethate;~2. Amikacin or gentamicin;~3. Tigecycline;~4. Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
62151769|NCT04876430|NO_INTERVENTION|Best Available Therapy|"The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~1. Polymyxin B or colistimethate;~2. Amikacin or gentamicin;~3. Tigecycline;~4. Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
62523909|NCT04416620|NO_INTERVENTION|The control group of Syria|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
62523910|NCT04416620|ACTIVE_COMPARATOR|The active group of Jordan|Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise.
62523911|NCT04416620|NO_INTERVENTION|The control group of Jordan|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
62523912|NCT02410356|EXPERIMENTAL|TV-1106|TV-1106 to be injected once weekly.
62523913|NCT02410356|ACTIVE_COMPARATOR|dGH|dGH to be given as daily injections.
62523914|NCT00571285|PLACEBO_COMPARATOR|Placebo|Placebo capsule once a week and 600 IU vitamin D daily for 26 weeks
62523915|NCT00571285|EXPERIMENTAL|Vitamin D|50K IU vitamin D3 (high dose) weekly plus 600 IU Vitamin D3 capsule daily for 26 weeks
62523916|NCT04787393||LOVE-HF-2 Participants|"Participants will have the Heartfelt device as well as a set of weighing scales installed at home.~Alerts will be raised for the patient to be seen at home or in clinic by clinician ( the clinician will be blinded to the type of alert). During this face-to-face encounter, the clinician will perform a detailed oedema assessment (recording pitting depth, time of recovery, height oedema, overall grading), ankle circumference measurement, weight measurements, and echo (Left ventricular ejection fraction, Left atrial volumes, inferior vena cava diameter, Diastolic function (E/A, E/E'), TAPSE and TR jet velocity + visually estimated mitral and tricuspid regurgitation)."
62523917|NCT02439749|EXPERIMENTAL|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
62523918|NCT02439749|SHAM_COMPARATOR|Sham Procedure|Renal angiography
62523919|NCT02715934|EXPERIMENTAL|Glucose to Goal|Three diabetes educators will be assigned to the Glucose to Goal/experimental arm. The educators will each identify two primary care practices of mid to large size to participate in the Glucose to Goal intervention. Patients will not be formally recruited or enrolled. Rather, information documented in the electronic medical record system will be extracted to evaluate patient-level outcomes. Based on a random sampling of mid to large size primary care practices in study communities, an estimated 2,200 patients with diabetes per study group will meet eligibility criteria for DSME referral.
62523920|NCT02715934|OTHER|Control Group|Two usual care diabetes educators will each identify three primary care practices of mid to large size to include in the control arm and participate in the usual care intervention. Uneven group assignment accounts for the amount of time (one day equivalent/per week) that the intervention diabetes educators will devote to each primary care practice versus the full-time availability of the usual care diabetes educators to see patients at the outpatient, hospital-based program. Like the experimental arm, an estimated 2,200 patients with diabetes will meet eligibility criteria for DSME referral. Patients will not be formally recruited or enrolled into the control arm; data will be extracted from the electronic medical record system to evaluate patient-level outcomes.
62523921|NCT05550883|EXPERIMENTAL|Group A (aerobic exercise group)|aerobic exercise training for 45 minutes, three sessions per week for 6 weeks.
62712521|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Simultaneously with resection|Patient with osteoporosis - antiresorptive treatment \> 4 years with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
62712522|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Previous tooth extraction|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ
62712523|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Previous resection|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
62712524|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Simultaneously with resection|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
62151770|NCT01214109|EXPERIMENTAL|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
62712525|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Previous tooth extraction|Cancer patient treated with high dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ
62712526|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Previous resection|Cancer patient treated with high dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
62712527|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Simultaneously with resection|Cancer patients (breast, prostate or multiple myeloma) treated with high dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
62712528|NCT01561833|EXPERIMENTAL|Sorafenib|Sorafenib, 400 mg PO twice daily
62712529|NCT05324241|EXPERIMENTAL|Microencapsulated fat stomach|Participants will consume a drink containing 400kcal of microencapsulated fat that will be released in the stomach.
62712530|NCT05324241|EXPERIMENTAL|Microencapsulated fat intestine|Participants will consume a drink containing 400kcal of microencapsulated fat that will be released in the intestine.
62712531|NCT05542888|EXPERIMENTAL|Experimental group|Postural education Hot pack(10 min) Antenatal exercises(i.e. deep breathing(5 min), stretching(5 min), kegel exercises(5 min), Mitchells physiologic relaxation technique(10 min) and walk(10 min) Sacro iliac joint mobilization(5 min) Total duration:50 min/session
62712532|NCT05542888|ACTIVE_COMPARATOR|Control group|Postural education Hot pack(10 min) Antenatal exercises(i.e.deep breathing(5 min), stretching(5 min), kegel exercises(5 min), Mitchells physiologic relaxation technique(10 min) and walk(10 min) Total duration:45 min/session
62712533|NCT02838667|NO_INTERVENTION|Standard of Care|If participants are randomized into the non-intervention group, the participants' information during the study period will be collected. Participants will be managed by a care provider as per the standard of care. Participants may receive nephrology consultation as indicated clinically.
62151771|NCT01214109|ACTIVE_COMPARATOR|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
62151772|NCT00658632|EXPERIMENTAL|1|
62151773|NCT00658632|ACTIVE_COMPARATOR|2|
62523922|NCT05550883|ACTIVE_COMPARATOR|Group B (Medications group)|The patients in this group did not receive treatment program. just received their medical treatment tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers over the period of 6 weeks.
62523923|NCT04982874|EXPERIMENTAL|Furosemide 40 mg tablet|volunteers received Furosemide 40 mg tablet with 240 mL of water
62151774|NCT00511316|EXPERIMENTAL|Drug|20 mg montelukast daily for 6 months
62151775|NCT00511316|PLACEBO_COMPARATOR|Placebo|20 mg daily placebo
62523924|NCT04982874|ACTIVE_COMPARATOR|Lasix® 40 mg Tablet|volunteers received Lasix® 40 mg tablet with 240 mL of water
61975619|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
62151776|NCT01078402||Single patients group: RA, PsA and AS|Single patients group with: Active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)
62151777|NCT01722097|ACTIVE_COMPARATOR|Deep neuromuscular blockade|Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
62151778|NCT01722097|PLACEBO_COMPARATOR|Moderate neuromuscular blockade|Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron
62151779|NCT00545909|EXPERIMENTAL|1|
62151780|NCT00545909|ACTIVE_COMPARATOR|2|
62151781|NCT04017299|ACTIVE_COMPARATOR|Virtual reality with computer graphics|Use of Virtual reality with computer graphics
62151782|NCT04017299|ACTIVE_COMPARATOR|Virtual reality with real movies|Use of Virtual reality with real movies
62151783|NCT04017299|ACTIVE_COMPARATOR|Music therapy (dedicated device and music scores)|Use of music therapy (dedicated device and music scores)
62151784|NCT04017299|OTHER|Usual device (TV radio)|usual distraction : watching TV
62523925|NCT01346774|EXPERIMENTAL|Cranberry powder capsules|"TheraCran® cranberry: based upon proanthocyanidin content, the four cranberry capsules are equivalent to two 8-ounce servings of cranberry juice.~Participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food."
62523926|NCT01346774|PLACEBO_COMPARATOR|Placebo capsules|Placebo: participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.
62523927|NCT03302312||Participants|Service members who received at least one SGB study procedure as part of the clinical effectiveness trial during the three months prior to qualitative data collection or service members who received at least one SGB for PTSD symptoms at a study site in the three months prior to qualitative data collection.
62523928|NCT03302312||Providers|Behavioral Health or other (e.g., Family Medicine) clinicians who have referred or could potentially have referred service members for SGB for PTSD symptoms, as well as physicians who provide SGBs.
62523929|NCT04874636|EXPERIMENTAL|600 Milligram (mg) LY3556050|Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
62523930|NCT04874636|PLACEBO_COMPARATOR|Placebo|Participants received placebo BID every 12 hours for up to 8 weeks.
62523931|NCT05757882|ACTIVE_COMPARATOR|4H|Participants who are following the standard fasting time (4 hours).
61975620|NCT05450341|EXPERIMENTAL|Right frontal 1 Hz rTMS|"Low-frequency (1 Hz) inhibitory rTMS will be administered to right inferior frontal gyrus with the following parameters:~Frequency: 1 Hz Stimulation site: Right IFG (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)"
62151785|NCT02939742|EXPERIMENTAL|Betamethasone|Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
62151786|NCT02939742|PLACEBO_COMPARATOR|Saline Placebo|Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
62151787|NCT01260883|EXPERIMENTAL|ketorolac 1 mg/kg|ketorolac 1 mg/kg iv given by 10 min infusion
62151788|NCT01260883|ACTIVE_COMPARATOR|ketorolac 0.5 mg/kg|ketorolac 0.5 mg/kg iv given by 10 min infusion
62151789|NCT01260883|SHAM_COMPARATOR|placebo|placebo group received D5W 10 min infusion
62523932|NCT05757882|EXPERIMENTAL|2H|Participants who are following minimized fasting time (2 hours)
62523933|NCT04465630|OTHER|Pseudophakic eyes with Open Angle Glaucoma|Eligible subjects enrolled in the trial will receive surgery for Open Angle Glaucoma using the OMNI® Surgical System.
62523934|NCT01173471|EXPERIMENTAL|1) AZD4017|Europe: 200 mg AZD4017
62523935|NCT01173471|PLACEBO_COMPARATOR|2) Placebo|Europe: placebo
62523936|NCT01173471|EXPERIMENTAL|3) AZD4017|USA: 800 mg AZD4017
62523937|NCT01173471|PLACEBO_COMPARATOR|4) Placebo|USA: placebo
62523938|NCT04993300|EXPERIMENTAL|transcranial magnetic stimulation (TMS)|This arm constitute of methamphetamine users who undergone abstinent period
62151790|NCT03606863|EXPERIMENTAL|Perioperative peripheral parenteral nutrition|Perioperative peripheral parenteral nutrition during 4 days
62523939|NCT00054548|EXPERIMENTAL|Treatment (oblimersen sodium, paclitaxel)|"Patients receive oblimersen IV continuously on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~An additional cohort of 12-15 patients receives treatment as above with oblimersen at the MTD."
62523940|NCT05697926||Experiment|The excess tumor tissue from patients following surgical resection will be collected for further analysis.
62151791|NCT03606863|NO_INTERVENTION|Standard fluid therapy|Standard fluid therap
62151792|NCT03271359|EXPERIMENTAL|Eye movement desensitization and reprocessing (EMDR) arm|
62151793|NCT03271359|EXPERIMENTAL|Progressive counting (PC) arm|
62151794|NCT04891978|EXPERIMENTAL|AIRQ, Asthma Checklist, and PRECISION Program|All participants in the trial will be given the behavioral interventions which include the AIRQ tool, the Asthma Checklist tool, and the PRECISION program educational resources.
62151795|NCT02792738|EXPERIMENTAL|hypnosis, visual distraction|"This is a crossover study in which each subject will be exposed to a 5 min phase of hypnotic suggestion and visual distraction.~For hypnotic suggestion, subject will be invited to experience a pleasant memory . Indirect and permissive suggestion will be used.~For visual distraction, subject will be watching the movie la marche des empereurs"
62151796|NCT00831571||All Participants|Patients receiving Oxaliplatin
62151797|NCT00831571||Desensitization|Patients that have experienced a moderate to severe hypersensitivity reaction to oxaliplatin
62151798|NCT01700699||Sorafenib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sorafenib
62151799|NCT01700699||Axitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Axitinib
62151800|NCT01700699||Pazopanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Pazopanib
62151801|NCT01700699||TKI|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with different type of tyrosine kinase inhibitor
62523941|NCT02010788||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
62523942|NCT01745211|EXPERIMENTAL|755nm Alexandrite laser with array handpiece|Device: 755nm Alexandrite laser with array handpiece
62523943|NCT01791231|EXPERIMENTAL|Radiolabeled 14C-canagliflozin|Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.
62523944|NCT02043665|EXPERIMENTAL|CVA21/pembrolizumab|CVA21/pembrolizumab
62523945|NCT01646047|EXPERIMENTAL|supplement - no retinopathy|subjects receiving active supplement and with no retinopathy based on clinical examination
62523946|NCT01646047|PLACEBO_COMPARATOR|placebo - no retinopathy|patients receiving placebo and who have no diabetic retinopathy based on clinical examination
62523947|NCT01646047|EXPERIMENTAL|supplement - retinopathy|patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
62523948|NCT01646047|PLACEBO_COMPARATOR|placebo - retinopathy|patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
62712534|NCT02838667|EXPERIMENTAL|Standard of Care plus Nephrology Care|If participants are randomized into the intervention group, participants' information will be checked by the study investigators daily for 7 days (2 days pre-op and 5 days post-op). When appropriate, investigators may give suggestions to minimize the participants' risk(s) for AKI. Participant's primary care providers may take the suggestions into consideration. Participants' primary care providers are not obligated to carry out the suggestions that are given.
62712535|NCT03743493||Prevalence numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017)
62712536|NCT03743493||Prevalence denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017)
62712537|NCT03743493||Guideline A numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
62712538|NCT03743493||Guideline A denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
62151802|NCT01700699||Motesanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Motesanib
62151803|NCT01700699||Sunitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sunitinib
62151804|NCT01612897|EXPERIMENTAL|Computer based reminders to MD|Children in this arm attend a clinic that is randomly assigned to receive physician alerts to screen appropriate children for autism.
62151805|NCT01612897|NO_INTERVENTION|Usual care arm|Children in this are receive usual care from a clinic randomly chosen to serve as a control.
62151806|NCT00990314|EXPERIMENTAL|B.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, B.I.D (twice a day dosing)
62151807|NCT00990314|EXPERIMENTAL|Q.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, q.i.d (four times a day dosing)
62523949|NCT04746300||Group 1: no sequencing|Participants in this group, for which DNA sequencing could not be reported due to a variety of (quality/technical) reasons, will be treated with standard of care therapy. This group is therefore comparable to patients treated outside the Radboudumc.
62523950|NCT04746300||Group 2: no druggable aberration|Participants in this group received a DNA sequencing report identifying no biomarkers to which a logical treatment option can be connected. These participants will also receive standard of care therapy.
62151808|NCT02262988|EXPERIMENTAL|Tourniquet used with intramedullary rod|Patients will undergo a total knee replacement with a tourniquet and intramedullary rod.
62151809|NCT02262988|EXPERIMENTAL|No tourniquet with intramedullary rod|Patients will undergo a total knee replacement without a tourniquet and with an intramedullary rod.
62523951|NCT04746300||Group 3: allocated to personalized treatment|Participants in this group received a DNA sequencing report which identified presence of a biomarker allowing the participant to be treated with a personalized therapy. This therapy could range from immunotherapy, or PARP inhibitors, to other medication.
62523952|NCT03095313|EXPERIMENTAL|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
62523953|NCT00766935||1 - lymphoedema group|Females with previously diagnosed unilateral Lymphoedema of the arm, who have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy.
62523954|NCT00766935||2 - healthy individuals|Healthy females aged between 18-75 years chosen randomly from the population of Queensland, Australia.
62523955|NCT06148064|EXPERIMENTAL|Collaplug application with low level laser application.|
62523956|NCT06148064|ACTIVE_COMPARATOR|Collaplug application|
62523957|NCT02551666|ACTIVE_COMPARATOR|Tai Chi exercise intervention|Participants will perform 30-minute Tai Chi sessions (Yang Short form) 3 times a week for 4 weeks.
62523958|NCT02551666|EXPERIMENTAL|Balance recovery training|Participants will practice balance recovery on a modified treadmill for approximately 30-minutes per session, 3 sessions a week for 4 weeks.
62523959|NCT02836626|EXPERIMENTAL|Deep Fascial Mobilization|
62523960|NCT02836626|EXPERIMENTAL|Superficial Fascial Mobilization|
62523961|NCT01870882|ACTIVE_COMPARATOR|Retraining|Using the PED, participants repeatedly complete a version of attentional bias task that orients their attention away from drug-related cues.
62523962|NCT01870882|SHAM_COMPARATOR|Control|Using the PED, participants repeatedly complete versions of the attentional bias task in which their attention is oriented toward and away from drug-related cues on an equal number of trials.
62523963|NCT00423319|ACTIVE_COMPARATOR|Apixaban, 2.5 mg BID plus placebo|Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
62523964|NCT00423319|EXPERIMENTAL|Enoxaparin, 40 mg QD plus placebo|Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
62712539|NCT03743493||Guideline B numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO inpatient cancer diagnosis OR cancer procedure in the year prior to the index event
62712540|NCT03743493||Guideline B denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO in-patient cancer diagnosis OR cancer procedure in the year prior to the index event
62712541|NCT01544673|ACTIVE_COMPARATOR|Arm A|
62712542|NCT01544673|PLACEBO_COMPARATOR|Arm B|
62712543|NCT04108273|EXPERIMENTAL|No-Wait|Participants with organizational skill difficulties to undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
62712544|NCT04108273|ACTIVE_COMPARATOR|Waitlist|Participants with organizational skill difficulties to undergo two magnetic resonance imaging (MRI) sessions: one 12 weeks prior to OST treatment and one \~12 weeks after their first scan and before proceeding to OST.
62712545|NCT04811690|EXPERIMENTAL|claim and imagery|control condition (status quo) showing a front-of-package (FOP) vitamin C claim and fruit imagery on all fruit-flavored drinks.
62523965|NCT02606175|OTHER|Admitted for renal transplantation|"Patients who are hospitalised on the abdominal transplantation surgery ward at the University Hospitals of Leuven (UZLeuven) and undergo a kidney transplantation during this hospitalisation.~Intervention: taking questionnaires and tests at predefined timepoints:~* at discharge: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~* 1 month after kidney transplantation: BAASIS, medication knowledge test~* 3 months after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test~* 1 year after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~* 2 years after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire"
62523966|NCT05232084|ACTIVE_COMPARATOR|Group 30 = 30 ml of Erector spinae plane block group|In group 30 ml, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
62523967|NCT05232084|ACTIVE_COMPARATOR|Group 20 = 20 ml of Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
62523968|NCT03593811|ACTIVE_COMPARATOR|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
62523969|NCT03593811|ACTIVE_COMPARATOR|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
62523970|NCT03593811|ACTIVE_COMPARATOR|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
62523971|NCT03593811|ACTIVE_COMPARATOR|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
62523972|NCT03593811|ACTIVE_COMPARATOR|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 4mg or 8mg dependent upon age disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine 4mg twice a day.
62523973|NCT05937321|EXPERIMENTAL|Intervention Group- Virtual with Dyad Follow + Share plus|The Share plus intervention is a behavioral intervention administered by a certified diabetes education and care specialist (CDCES) using telehealth. Share plus consists of three educational sessions to facilitate dyads' success in data sharing glucose levels. The Share plus intervention has five major components that are delivered using techniques of motivational interviewing: 1) shared appraisal, 2) communication strategies, 3) problem-solving strategies, 4) action planning and, 5) re-evaluating, practicing, and advancing.
62523974|NCT05937321|ACTIVE_COMPARATOR|Control Group- Virtual with Dyad Follow + Diabetes Self-Management Education|Participants will receive diabetes self-management education using the Association of Diabetes Care and Education Specialists 7 education curriculum (ADCES7).
62523975|NCT00939120|EXPERIMENTAL|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
62523976|NCT00939120|PLACEBO_COMPARATOR|placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
62712546|NCT04811690|EXPERIMENTAL|imagery only|FOP fruit imagery on all fruit-flavored drinks, no vitamin C claim on drinks high in added sugars (\>=20 %DV)
62712547|NCT04811690|EXPERIMENTAL|claim only|FOP vitamin C claim on all fruit-flavored drinks, no fruit imagery on drinks high in added sugars
62712548|NCT04811690|EXPERIMENTAL|no claim or imagery|No FOP vitamin C claim or fruit imagery on drinks high in added sugars
62712549|NCT04811690|EXPERIMENTAL|claim, imagery, and % juice disclosure|FOP fruit imagery, vitamin C claim, and % juice disclosure on all fruit-flavored drinks
62151810|NCT02262988|EXPERIMENTAL|Tourniquet without intramedullary rod|Patients will undergo a total knee replacement with a tourniquet and without an intramedullary rod.
62151811|NCT02262988|EXPERIMENTAL|No tourniquet without intramedullary rod|Patients will undergo a total knee replacement without a tourniquet nor an intramedullary rod.
62151812|NCT03799588|EXPERIMENTAL|Biphasic Chest Cuirass Arm|This is the only arm in the study and all patients will receive negative pressure ventilation via the biphasic chest cuirass.
62151813|NCT01970527|EXPERIMENTAL|Treatment (stereotactic body radiotherapy, ipilimumab)|Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
62151814|NCT04805008|EXPERIMENTAL|Intervention|Lactation cookies
62151815|NCT04805008|PLACEBO_COMPARATOR|Control|Control cookies
62151816|NCT00942266|EXPERIMENTAL|Arm I|Patients receive low-dose oral vorinostat once daily on days 1-3, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV over 46 hours on days 2 and 3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
62151817|NCT00942266|EXPERIMENTAL|Arm II|Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
62523977|NCT00752960||A|Patients receiving olanzapine
62523978|NCT00752960||B|patients receiving risperidone
62523979|NCT00752960||C|Patients receiving quetiapine
62151818|NCT03430518|EXPERIMENTAL|Her2-negative Metastatic Breast Ca and Recurrent Ovarian Ca|Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian cancer
62151819|NCT06343636|EXPERIMENTAL|Single and Multiple Ascending Dose|Ascending single doses and multiple doses for healthy volunteers.
62151820|NCT06343636|PLACEBO_COMPARATOR|Placebo|Matching placebo
62523980|NCT00752960||D|Patients receiving aripiprazole
62523981|NCT00752960||E|patients receiving ziprasidone
62523982|NCT04969718|EXPERIMENTAL|LEADS Plus educational posters|A total of six group sessions with students using presentations and videos.
62523983|NCT04969718|EXPERIMENTAL|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers (teachers). This includes both presentations and videos.
62523984|NCT04969718|EXPERIMENTAL|Screening by Professionals programme Plus educational posters|This is an indicated or selective intervention by health professionals who will review assessments (done using structured questionnaires) and refer students where necessary.
62151821|NCT06343636|EXPERIMENTAL|Alzheimer's Disease|Single Dose Open-label
62151822|NCT05752084||group 1|the group that develops Nis during the study
62151823|NCT05752084||group 2|the group doesn't develop NIs
62151824|NCT00091572|EXPERIMENTAL|A|"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (7 days on / 7 days off continuously)"
62151825|NCT00091572|ACTIVE_COMPARATOR|B|dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks
62523985|NCT04969718|ACTIVE_COMPARATOR|Educational poster|The control group will be exposed to the six educational posters.
62523986|NCT04969718|EXPERIMENTAL|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents). This includes both presentations and videos.
62523987|NCT04060342|EXPERIMENTAL|Phase 1: Regimen A - GB1275 monotherapy|GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).
62523988|NCT04060342|EXPERIMENTAL|Phase 1: Regimen B - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab dose escalation and expansion:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
62523989|NCT04060342|EXPERIMENTAL|Phase 1: Regimen C - GB1275 with Standard of Care (SOC)|"GB1275 with SOC dose escalation:~GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)"
62523990|NCT04060342|EXPERIMENTAL|Phase 2: Cohort 1 - GB1275 with SOC|"GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:~GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI."
62523991|NCT04060342|EXPERIMENTAL|Phase 2: Cohort 2 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
62523992|NCT04060342|EXPERIMENTAL|Phase 2: Cohort 3 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
61975621|NCT05450341|ACTIVE_COMPARATOR|Right temporal 1 Hz rTMS|"Low-frequency (1 Hz) inhibitory rTMS will be administered to right posterior superior temporal gyrus with the following parameters:~Frequency: 1 Hz Stimulation site: Right posterior superior temporal gyrus (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)"
62151826|NCT01314482|EXPERIMENTAL|Minocycline|
62523993|NCT03733210|EXPERIMENTAL|Tumor-negative Lymph Nodes (by 18F-FDG scan)|Participants whose lymph nodes are negative for cancer
62523994|NCT03733210|EXPERIMENTAL|Tumor-positive Lymph Nodes (by 18F-FDG scan)|Participants whose lymph nodes are positive for cancer.
62523995|NCT04273581|PLACEBO_COMPARATOR|Control group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. placebo：100mg/d，qn，for 14 days.
62523996|NCT04273581|EXPERIMENTAL|Thalidomide group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. thalidomide：100mg/d，qn，for 14 days.
62523997|NCT02917330|EXPERIMENTAL|Strength and stretching intervention|Treatment as usual + a strength and stretching intervention together with a physiotherapist
62523998|NCT02917330|NO_INTERVENTION|Control group|Treatment as usual
62712550|NCT04811690|EXPERIMENTAL|claim, imagery, and added sugar warning|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning on drinks high in added sugar
62151827|NCT06275841|EXPERIMENTAL|vepdegestrant with or without esomeprazole|vepdegestrant administered as a single dose in Period 1 and Period 2. Esomeprazole administered once a day for 5 days in Period 2
62151828|NCT04236297|OTHER|Modified Bite Block|Patients undergoing transesophageal echocardiogram under sedation or general anesthesia during which a modified bite block is used
62151829|NCT04884256|PLACEBO_COMPARATOR|CBT-004|
62151830|NCT04884256|EXPERIMENTAL|0.05% CBT-004|
62151831|NCT04884256|EXPERIMENTAL|0.075% CBT-004|
62151832|NCT04707599|NO_INTERVENTION|OFF intervention|No reminder plus (telephone reminder from therapist) but standard test message reminder (SMS) from second admission
62151833|NCT04707599|EXPERIMENTAL|ON intervention|Reminder plus (telephone reminder from therapist) AND standard test message reminder (SMS) from second admission
62151834|NCT01450891||total patient group|all new consecutive patients of the participating memory clinics who are suspected of having a primary neurodegenerative disease, meaning that all patients with subjective as well as objective memory complaints are included
62151835|NCT02875730|EXPERIMENTAL|CMRI Pulse Sequence|Patients will have late gadolinium cardiac magnetic resonance images of the individual pulmonary veins acquired with the standard and the cylindrical navigator preparatory pulse sequences for comparison.
62712551|NCT04811690|EXPERIMENTAL|claim, imagery, and added sugar warning with teaspoons of added sugar disclosure|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning with teaspoons of added sugar disclosure on drinks high in added sugar
62151836|NCT02332824|PLACEBO_COMPARATOR|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
62712552|NCT01101529|PLACEBO_COMPARATOR|Standard antiemetic therapy plus placebo|Standard anti-emetic prophylaxis consisting of 1/dexamethasone 6 mg daily during the chemotherapy days and 2/tropisetron (Navoban)5 mg daily during chemotherapy and 2 days after
62151837|NCT02332824|EXPERIMENTAL|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
62523999|NCT02252159||Cohort A|"Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:~1. Watchful waiting (with or without aspirin)\*, or~2. Phlebotomy (PHL) alone (with or without aspirin)\* - or~3. HU alone (without concomitant PHL, with or without aspirin).~(\*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea \[HU\] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)"
62524000|NCT02252159||Cohort B|"Patients with clinically overt PV, with one or more of the following disease characteristics:~1. Treatment with HU and PHL in combination or~2. Treatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or~3. A history of thrombosis (venous or arterial) or~4. A history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or~5. Presence of documented splenomegaly (clinically assessed by palpation) or~6. Presence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)~   1. Tiredness~  2. Difficulty sleeping~  3. Itching~  4. Muscle aches and/or bone pain~  5. Night sweats~  6. Sweats while awake~  7. Other"
62524001|NCT05056766||single group assignement|
62524002|NCT04064814|ACTIVE_COMPARATOR|Flunarizine|flunarizine will be prescribed at a dose of 5mg once daily , orally for 12 weeks
62524003|NCT04064814|EXPERIMENTAL|Alpha Lipoic Acid|Alpha Lipoic Acid will be prescribed at a dose of 300mg once daily,orally for 12 weeks
62524004|NCT04064619|ACTIVE_COMPARATOR|sudden stopping|patients were followed up after 1 and 3 months from stopping the drug,
62524005|NCT04064619|EXPERIMENTAL|Weaning|patients were followed up after 1and 3 months from the end of gradual weaning
62524006|NCT01268605|ACTIVE_COMPARATOR|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
62524007|NCT01268605|ACTIVE_COMPARATOR|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
62524008|NCT05507593|EXPERIMENTAL|Group A|Patients of group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment.
62151838|NCT02332824|EXPERIMENTAL|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
62524009|NCT05507593|EXPERIMENTAL|Group B|Patients of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment.
62524010|NCT05507593|EXPERIMENTAL|Group C|Patients of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
62524011|NCT03362918|NO_INTERVENTION|Control Group|"Participants randomized to the control group will continue with their usual level of physical activity. They will track their menstrual cycles and perform daily ovulation tests.~Once all post-intervention assessments are complete, they will have the option to begin an exercise program with three supervised sessions of either high-intensity interval training or continuous aerobic exercise training free of charge. They will be given a Polar heart rate (HR) monitor as a gift for their participation in the study."
62524012|NCT03362918|EXPERIMENTAL|High-Intensity Interval Training|Participants randomized to this group will complete three high intensity interval training sessions per week, two of which will be supervised. They will exercise for a total of 30 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool-down.
62524013|NCT03362918|EXPERIMENTAL|Continuous Aerobic Exercise Training|Participants randomized to this group will complete three continuous aerobic training sessions per week, two of which will be supervised. They will exercise for a total of 50 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool down.
62524014|NCT06219590|ACTIVE_COMPARATOR|Study group (A)|"* 40 patients with type 2 diabetes mellitus clinically proved peripheral neuropathy.~* Both groups were received conventional medical treatment and healthy diet.~* Group A was received iontophoresis by acetylcholine with (15) min for three sessions per week for four weeks."
62524015|NCT06219590|SHAM_COMPARATOR|Control group (B)|"* 40 patients with asymptomatic type 2 diabetes mellitus, both groups were selected from south valley university hospitals.~* Both groups were received conventional medical treatment and healthy diet.~* Group (B) was received shame iontophoresis with (15) min for three sessions per week for four weeks."
62524016|NCT05770505|EXPERIMENTAL|Supervised exercise|
62524017|NCT05770505|NO_INTERVENTION|Control group|
62712553|NCT01101529|EXPERIMENTAL|aprepitant (Emend)|Aprepitant given orally 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after as an addition to standard antiemetic therapy as in the placebo arm.
62524018|NCT02442674|ACTIVE_COMPARATOR|Tolvaptan|Tolvaptan (3.75 mg, 7.5 mg, 15 mg, 30 mg, 60 mg dose daily depending on age and weight)
61975622|NCT05142865|EXPERIMENTAL|Camrelizumab+ Chemotherapy+Apatinib|Induction stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1) or Cisplatin(25mg/m2，continuously on Day 1, 2 and 3) Q3W for 4-6 cycles; Maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
62524019|NCT02442674|PLACEBO_COMPARATOR|Placebo|Placebo tablet matching active drug
62524020|NCT01593241|EXPERIMENTAL|Carboplatin|
62524021|NCT03359577|EXPERIMENTAL|Psorax35|Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid. Dose: 10 capsules of 590 mg. Route of administration: oral.
62524022|NCT03359577|PLACEBO_COMPARATOR|MCT oil|Placebo capsules containing coconut oil high in caprylic acid C8:0 and capric acid C10:0 (Medium Chain triglycerides (MCT) oil). Dose: 10 capsules of 590 mg: Route of administration: oral.
62524023|NCT04149795||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
62524024|NCT05676086|EXPERIMENTAL|indoor light intervention|Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home
62524025|NCT05676086|ACTIVE_COMPARATOR|control group|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only
62524026|NCT00222989|OTHER|no label study|1
62524027|NCT03008486|ACTIVE_COMPARATOR|DOC - real|Spastic patients with disorders of consciousness receiving the real soft splint
62524028|NCT03008486|PLACEBO_COMPARATOR|DOC - placebo|Spastic patients with disorders of consciousness receiving the placebo soft splint
62524029|NCT03008486|ACTIVE_COMPARATOR|Stroke - real|Spastic patients stroke receiving the real soft splint
62524030|NCT03008486|PLACEBO_COMPARATOR|Stroke - placebo|Spastic patients stroke receiving the placebo soft splint
62524031|NCT04247152|OTHER|Intraoperative Aberrometry vs Preoperative Biometry|Retrospective view of existing chart data.
62524032|NCT03676517|EXPERIMENTAL|Preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
62524033|NCT05816369|EXPERIMENTAL|Taste preferences of five ONS flavors|Taste session with corresponding questionnaires
62524034|NCT03161548|EXPERIMENTAL|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
62524035|NCT01850095|ACTIVE_COMPARATOR|treatment 1|topical acid azelaic, used 2 times a day for 6 months
62524036|NCT01850095|ACTIVE_COMPARATOR|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
62524037|NCT01850095|NO_INTERVENTION|control|control group ( only take biopsies and blood samples )
62524038|NCT00681707||1|Hypertension patients recovering from stroke
62524039|NCT05236920|NO_INTERVENTION|Standard Care|Participants randomized to this arm will receive standard care for cardiac arrest, which consists of advanced cardiovascular life support (ACLS)
62524040|NCT05236920|EXPERIMENTAL|Standard Care Plus Intervention|Participants randomized to this arm will receive standard care for cardiac arrest, which consists of advanced cardiovascular life support (ACLS) plus the study intervention
62524041|NCT04684303|EXPERIMENTAL|Lumbar medial branch RF neurotomy|Procedure lumbar medial branch RF neurotomy By raising the temperature of the tip of the electrode to 85 C for 120 seconds. RF generator. Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be \> 4 )
62524042|NCT04684303|EXPERIMENTAL|Lumbar medial branch cryoablation|"Procedure lumbar medial branch cryoablation Decreasing the temperature of the electrode to - 85 C for 120 seconds in two cycles.~Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be =/\> 4 )"
62524043|NCT05847439|EXPERIMENTAL|[14C]BMS-986419|
62524044|NCT01963130||drug (metformin and gliclazide)|The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
62524045|NCT01963130||drug (metformin, gliclazide and vildagliptin)|The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
62524046|NCT00797329||observation|adult men with alcohol and polydrug use according to DSM-IV criteria, hospitalized in maximum security department between 2002 - 2008
62524047|NCT05757323|EXPERIMENTAL|test formula|hydrolysed protein-based infant formula
62524048|NCT05757323|ACTIVE_COMPARATOR|control formula|standard intact protein-based formula
62524049|NCT05777161|EXPERIMENTAL|Parent Coached Exposure Therapy-Individual (PCET-I) Group|Subjects will receive six to 14 weekly sessions of individual Parent Coached Exposure Therapy
62524050|NCT05777161|ACTIVE_COMPARATOR|Traditional Cognitive Behavior Therapy (CBT) Group|Subjects will receive 6 to 14 weekly sessions of individual Cognitive Behavioral Therapy
62524051|NCT05777161|EXPERIMENTAL|Parent Coached Exposure Therapy-5day Intensive (PCET-5day) Group (removed from study)|Subjects will receive 5 day (nine sessions) of group-based Parent Coached Exposure Therapy delivered within a span of five days (Monday through Friday), followed by 5 weeks of self-care
62524052|NCT00362921|EXPERIMENTAL|Gliadel wafers in combination with O6-benzylguanine|
62524053|NCT03072199|EXPERIMENTAL|Rituximab|
62524054|NCT05434377|ACTIVE_COMPARATOR|Vitamin D supplementation using titration regimen|"Patients will receive ergocalciferol orally depending on serum 25(OH)D level as described~* serum 25(OH)D \< 5 ng/ml --\> receive ergocalciferol 50,000 IU/week for 3 months followed by 50,000 IU monthly for 3 months~* serum 25(OH)D 5-15 ng/ml--\> receive ergocalciferol 50,000 IU/week for 1 month followed by 50,000 IU monthly for 5 months~* serum 25(OH)D 16-30 ng/ml--\> receive ergocalciferol 50,000 IU monthly for 6 months"
62524055|NCT05434377|EXPERIMENTAL|Vitamin D supplementation using fixed dose regimen|Patients will receive ergocalciferol 20,000 unit orally per week for 6 months.
62524056|NCT03179163|NO_INTERVENTION|Normotensive|Blood Pressure \<120/80 mmHg
62151839|NCT02332824|EXPERIMENTAL|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
62524057|NCT03179163|EXPERIMENTAL|Hypertensive - ACE inhibitor with sulfahydrl donor (ACEi +SH)|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and \<160/110 mmHg
62151840|NCT02332824|EXPERIMENTAL|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
62712554|NCT06113757|EXPERIMENTAL|Dr.Biolyse|When you join the Dr. Biolyse® Therapy Group, you will be given electrical signal therapy with the Dr. Biolyse® device. Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. The treatment protocol to be applied to DBTG patients consists of device therapy and daily fluid support therapy. No medication or different device applications are performed.
62524058|NCT03179163|EXPERIMENTAL|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and \<160/110 mmHg
62524059|NCT03179163|ACTIVE_COMPARATOR|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and \<160/110 mmHg
62712555|NCT06113757|EXPERIMENTAL|Kontrol|In the CG patients, who constitute the Comparison Group, the same non-drug fluid support therapy applied in device therapy will be repeated (isotonic, isolated 500 ml). As both groups of patients will receive fluid support therapy, the impact of the device on the disease will be observed with monitored parameters.
62712556|NCT05325203|EXPERIMENTAL|JS002 150mg Q2W for 24 weeks|40 patients will be enrolled in this arm
62712557|NCT05325203|PLACEBO_COMPARATOR|placebo 150mg Q2W for 24 weeks|20 patients will be enrolled in this arm
62712558|NCT05325203|EXPERIMENTAL|JS002 450mg Q4W for 24 weeks|40 patients will be enrolled in this arm
62712559|NCT05325203|PLACEBO_COMPARATOR|placebo 450mg Q4W for 24 weeks|20 patients will be enrolled in this arm
62712560|NCT01798797||no treatment|non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months
62524060|NCT00000396|EXPERIMENTAL|1|Education in Arthritis Self-Help Course
61975623|NCT01490476|EXPERIMENTAL|RAD001|Patient with Neurofibromatosis Type 2 and Vestibular Schwannoma treated with RAD001.
62524061|NCT03906162|EXPERIMENTAL|Motivational interviewing|Experimental content + base intervention
62524062|NCT03906162|ACTIVE_COMPARATOR|Control intervention|Base intervention
62712561|NCT04136145|EXPERIMENTAL|Belimumab SC|Subjects will be administered a single dose of belimumab 200 mg via the SC route. The dose will be administered in the front of the thigh via auto-injector device.
62712562|NCT04136145|EXPERIMENTAL|Belimumab IV|Subjects will be administered a single dose of belimumab 200 mg via the IV route administered over approximately 1 hour.
62712563|NCT06509373|EXPERIMENTAL|ACPVoice Intervention|Community-dwelling persons living with cognitive impairment aged 65 and older with known or probable mild cognitive impairment or dementia or elevated eRADAR score (with decision-making capacity), who are affiliated with the Atrium-Wake Forest Baptist Health , have a primary care physician at one of the participating sites, and have an active patient portal account.
62712564|NCT06509373|ACTIVE_COMPARATOR|Standard of Care|Community-dwelling persons living with cognitive impairment aged 65 and older with known or probable mild cognitive impairment or dementia or elevated eRADAR score (with decision-making capacity), who are affiliated with the Atrium-Wake Forest Baptist Health, have a primary care physician within the Atrium-Wake Forest Baptist Health Network, and have an active patient portal account.
62712565|NCT00744614||1|Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation
62712566|NCT01943760|ACTIVE_COMPARATOR|tramadol wound infiltration|2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously
62712567|NCT01943760|EXPERIMENTAL|tramadol intravenous administration|2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration
62712568|NCT05849597|EXPERIMENTAL|Dexmedetomidine|Evaluate the effects of dexmedetomidine for sedation of patients in the intensive care unit after open heart surgery
62712569|NCT05849597|ACTIVE_COMPARATOR|Propofol|Compare the clinical outcomes of the experimental group with the standard of care, i.e. sedation with propofol
62712570|NCT02588885|EXPERIMENTAL|Trauma-sensitive Care|Participants will attend 7, one-hour psychotherapy sessions, which will be concurrent with trauma-sensitive care at physical therapy appointments.
62712571|NCT02363530|EXPERIMENTAL|HPMC group|Patients use the intervention Hydroxypropyl ethylcellulose (HPMC) 2% gel during the cataract surgery.
62712572|NCT02363530|PLACEBO_COMPARATOR|BSS group|Patients use balanced salt solution (BSS) during the cataract surgery.
62151841|NCT02332824|ACTIVE_COMPARATOR|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
62151842|NCT06598891|EXPERIMENTAL|PD APA training group|Weight shift training and APA feedback.
62151843|NCT06598891|EXPERIMENTAL|PD PAS group|Using PAS to regulate brain plasticity
62151844|NCT01030263|EXPERIMENTAL|CEM|Biopsies obtained with fluorescence-aided confocal endomicroscopy.
62151845|NCT01030263|OTHER|RFQ|Random four-quadrant biopsies.
62151846|NCT06500910|EXPERIMENTAL|Exercise Training|10 weeks of exercise training
62151847|NCT06500910|NO_INTERVENTION|Control Group|Control group receiving age appropriate physical activity and life style recommendations as of current guidelines.
62712573|NCT06400784|ACTIVE_COMPARATOR|Conventional HF medications plus ISDN & HYD|Will administer Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) on top of conventional heart failure medications.
62712574|NCT06400784|PLACEBO_COMPARATOR|Conventional HF medications plus placebo|We will administer placebo on top of conventional heart failure medications
62712575|NCT02078869|ACTIVE_COMPARATOR|intramuscular Progesterone in oil|50mg of intramuscular Progesterone injection will be administered once daily for 6 days including the day of embryo transfer
62712576|NCT02078869|ACTIVE_COMPARATOR|vaginal progesterone suppositories|200mg of progesterone suppositories will be administered 3 times a day for 6 days including the day of embryo transfer
62524063|NCT04560348|EXPERIMENTAL|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program An 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure games, and one adventure day camp (2 sessions). One session per week, 3 hours for each session. A variety of cognitive behavioral skills are taught in lectures and these skills are practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. The adventure training includes a day adventure camp and five 40-minute adventure games in the beginning of each workshop. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework are used in the intervention program.
62524064|NCT03437915|EXPERIMENTAL|Treatment Arm|28.5 Gy delivered in 5 daily fractions then 4-12 weeks post NIBB, surgery via partial mastectomy
62524065|NCT04905849|EXPERIMENTAL|Adaptive Cognitive Control Trainer (ACCT)|There are three modules within the game, each training a different aspect of cognitive control (attention, goal management, working memory): a visual search task for attention abilities, a spatial span task for working memory, and a task switching paradigm for goal management abilities. There are also 3 different levels of difficulty associated with each module; advancing to the next level delivers an advanced challenge that enhances the difficulty in performing the given cognitive task. Participants advance to the next level of difficulty following 6 training sessions occurring over 2 weeks, with the total training experience being 6 weeks of training (3 days/week), with each training session lasting 36 minutes (not including self-paced breaks).
62712577|NCT05193006||peritoneal malignant mesothelioma of grade 1|peritoneal malignant mesothelioma of grade 1
62151848|NCT00512902|EXPERIMENTAL|Group 1|SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.
62712578|NCT05193006||peritoneal malignant mesothelioma of grade 2|peritoneal malignant mesothelioma of grade 2
62712579|NCT05193006||peritoneal malignant mesothelioma of grade 3|peritoneal malignant mesothelioma of grade 3
62712580|NCT05395936|EXPERIMENTAL|Intraoperative Data Collection Arm|Participants scheduled for mastectomy with or without breast reconstruction during the course of their breast surgery treatment will have breast skin temperatures taken using a myocardial probe in different anatomical breast areas at multiple time points during the surgery.
62712581|NCT04815863||Elderly|Over 60 years old
62151849|NCT03155035|EXPERIMENTAL|Intervention|Albendazole 200 mg 2 tablets single dose
62151850|NCT03155035|PLACEBO_COMPARATOR|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
62151851|NCT05781932|EXPERIMENTAL|Histoacryl medical tissue glue|specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4\[(toluene)amino\]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)
62151852|NCT02547506||Parkinson Disease (Boxing)|Individuals with Parkinson Disease who participate in boxing on a regular basis
62151853|NCT02547506||Parkinson Disease (Group Exercise)|Individuals with Parkinson Disease who participate in group exercise other than boxing on a regular basis
62151854|NCT02547506||Healthy Controls|Individuals without disability who participate in group exercise other than boxing on a regular basis
62151855|NCT02064335|EXPERIMENTAL|Intervention group|"Physical activity coaching: Participants will be coached by a professional physical activity coach through individual and group sessions.~Intake: This talk (1 hour) is the start of the coaching. A physical activity plan will be set up, according to the needs and possibilities of the participant. Activities in leisure time and daily physical activity will be included.~Group sessions: During 5 weeks and one time a week, the subjects will take part in the exercise lessons. About 5 subjects will be in one group and all sessions are supervised by a professional physical activity coach. Activities are walking, Nordic walking and conditional fitness.~Evaluation: After the 5 weeks of group sessions, an evaluation moment will take place between each participant and the physical activity coach. The physical activity plan will be refined."
62151856|NCT02064335|NO_INTERVENTION|Control group|The control group will operate as a waiting group. It means that in the first 6 months of the project, the subjects of the control group will only be measured and will not receive any intervention.
62712582|NCT04815863||Non-Elderly|Under 60 years old
62712583|NCT00841139|EXPERIMENTAL|Perhexiline|perhexiline 100mg bd for 1 month duration
62712584|NCT00841139|PLACEBO_COMPARATOR|Placebo|placebo one tablet bd for 1 month duration
62712585|NCT03085680|EXPERIMENTAL|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
62712586|NCT03085680|PLACEBO_COMPARATOR|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
62151857|NCT04119700|ACTIVE_COMPARATOR|Muco-muscular endorectal advancement flap|After fistulectomy a muco-muscular endorectal advancement flap is mobilised and fixed to anoderma
62151858|NCT04119700|EXPERIMENTAL|Primary sphincter reconstruction|After fistulectomy the defect in anal sphincters is closed
62151859|NCT06241183|ACTIVE_COMPARATOR|Intravenous Famotidine|Patients in this group will receive 20 mg of intravenous famotidine.
62151860|NCT06241183|ACTIVE_COMPARATOR|Oral Maalox|Patients in the group will receive 30 ml of oral Maalox/ Mylanta.
62151861|NCT04446949||Undocumented migrants|
62151862|NCT04446949||Immigrants with Norwegian ID|
62151863|NCT04446949||Norwegian residents|
62151864|NCT00769197||1|Children with birth/time of neurologic insult less than 28 weeks of gestation
62151865|NCT00769197||2|Children with birth/time of neurologic insult at more than 28 weeks of gestation
62712587|NCT06325787|ACTIVE_COMPARATOR|lobectomy|thyroid lobectomy, is recommended as first-line treatment for papillary thyroid micraocarcinima
62712588|NCT06325787|EXPERIMENTAL|image-guided thermal ablation|radiofrequency ablation or microwave ablation
62151866|NCT05125549|EXPERIMENTAL|Treatment A|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)
62151867|NCT05125549|ACTIVE_COMPARATOR|Treatment B|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
62151868|NCT01000207|EXPERIMENTAL|1|Dose ranging
62151869|NCT01000207|EXPERIMENTAL|2|Dose ranging
62151870|NCT00537914|EXPERIMENTAL|Omnitrope|All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
62151871|NCT03311802||1|
62151872|NCT03374423|ACTIVE_COMPARATOR|intercostal nerve group|pulsed radiofrequency on intercostal nerves (2-5)
62524066|NCT04905849|ACTIVE_COMPARATOR|Active Control Group|An active control application will be used for this arm. The total training experience here will also be for 6 weeks (3 days/week), with each training session lasting \~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.
62524067|NCT05589519|EXPERIMENTAL|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition for the rehabilitation of the partial edentulous.
62524068|NCT03118388|EXPERIMENTAL|36 SEI youth|36 homeless youth (ages 16-24) randomized to the SEI intervention
62524069|NCT03118388|EXPERIMENTAL|36 IPS youth|36 homeless youth (ages 16-24) randomized to the IPS intervention
62524070|NCT03063762|EXPERIMENTAL|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
62524071|NCT03063762|EXPERIMENTAL|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
62524072|NCT03063762|EXPERIMENTAL|Extension Part (Arm A): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
62712589|NCT02007304|EXPERIMENTAL|Herbs|participants assigned to experimental arm will take 300mg panax ginseng and 300mg salvia miltiorrhiza extracts in capsules for 12 weeks along with eccentric exercise training
62712590|NCT02007304|PLACEBO_COMPARATOR|Placebo|parcipants in this group will take placebo capsule containing microcrystalline cellulose
62712591|NCT01599039||breast cancer patients with SN|1. Breast cancer patients with sentinel node biopsy (n=25)
62712592|NCT01599039||breast cancer patients with AD|2. Breast cancer patients with axillary dissection (n=25)
62712593|NCT01599039||colo-rectal patients|3. Colo-rectal patients as control group (n=25)
62151873|NCT03374423|ACTIVE_COMPARATOR|dorsal root ganglion group|pulsed radiofrequency on dorsal root ganglion (2-5)
62151874|NCT05214092|EXPERIMENTAL|Neurosurgical Patients|Patient participants with previously excised tissue within Heschl's gyrus (as dictated by clinical care)
62151875|NCT05687825||Clinically relevant postoperative pancreatic fistula|patients who developed clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
62151876|NCT05687825||No clinically relevant postoperative pancreatic fistula|patients who did not develop clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
62151877|NCT00139360|EXPERIMENTAL|1|Active drug
62151878|NCT03481153|PLACEBO_COMPARATOR|Sham tDCS|Participants will be participate in a 20-minute sham tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex. Sham stimulation will be applied.
62151879|NCT03481153|ACTIVE_COMPARATOR|tDCS|Participants will participate in a 20-minute tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex.
62151880|NCT04023266|EXPERIMENTAL|Intravenous N-Acetylcysteine arm|On arrival at the recruiting hospital, eligible and consenting STEMI patients randomly allocated to the experimental arm would be administered an intravenous N-Acetylcysteine bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours.
62151881|NCT04023266|NO_INTERVENTION|Control arm|Patients randomized to this arm would receive no experimental therapies and would continue to receive all standard guideline recommended medical therapies and interventions.
62151882|NCT05757934||Group A|vapers, who are ex-smokers.
62151883|NCT05757934||Group B|vapers with no previous smoking experience.
62151884|NCT05757934||Group C|vapers, who are dual users (i.e., those who vape and smoke).
62151885|NCT05757934||Group D|ex-smokers who don't vape.
62151886|NCT02313194|EXPERIMENTAL|Stimulation|Determine if epidural stimulation can improve motor function.
62151887|NCT01366053||Prostate Cancer|Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.
62151888|NCT06360367|ACTIVE_COMPARATOR|usual HI-FLY curriculum (HI-FLY)|The HI-FLY curriculum includes 6 lessons of 1-2 hours each, over 6 weeks. Lesson topics include 1) safe food handling, 2) vegetables and fruits, 3) more meals at home, 4) a food guide, 5) move more every day, and 6) re-think your drink.
62712594|NCT05971095|EXPERIMENTAL|Neuromodulation group|"The maximum isometric contraction force of the quadriceps will be measured prior to the neuromodulation program using a hand dynamometer.~The percutaneous neuromodulation program will begin using the EPTE® Bipolar System device. The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts.~The low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to.~The surgical intervention will be carried out by subarachnoid block with local anesthetic in accordance with the usual practice.~After its completion, a single injection block of the femoral nerve will be performed with a long-acting local anesthetic , a regional anesthesia technique included in routine clinical practice."
62151889|NCT06360367|EXPERIMENTAL|HI-FLY integrated with the PortionSize Ed app (HI-FLY + PSEd).|Participants will receive HI-FLY usual care and be provided with the PortionSize Ed mobile app for the entire study.
62524073|NCT03063762|EXPERIMENTAL|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
62524074|NCT03063762|EXPERIMENTAL|Extension Part (Arm C): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
62524075|NCT03063762|EXPERIMENTAL|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: Arm D is closed for future enrollment"
62524076|NCT03858166|ACTIVE_COMPARATOR|Standard group|6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy.
62524077|NCT03858166|EXPERIMENTAL|Adjusted group|6mg PEG-rhG-CSF was administrated subcutaneously when ANC \< 1000/mm3 after chemotherapy.
62524078|NCT00776165|EXPERIMENTAL|1|Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
62524079|NCT00776165|ACTIVE_COMPARATOR|2|Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
62524080|NCT05892146|EXPERIMENTAL|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
62524081|NCT05892146|NO_INTERVENTION|Conventional therapy|No intervention
62524082|NCT05892146|NO_INTERVENTION|Global longitudinal strain (GLS) function decreased >15%, No intervention|With the value of GLS function via echocardiography study decreased \>15%, No intervention
62524083|NCT05892146|EXPERIMENTAL|GLS function descending >15%, Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
62524084|NCT01775436|ACTIVE_COMPARATOR|Healthy Living Control|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
62524085|NCT01775436|EXPERIMENTAL|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
62524086|NCT00168311|EXPERIMENTAL|Active Treatment|Bilateral high frequency (10 Hertz) rTMS
62524087|NCT00168311|SHAM_COMPARATOR|Sham rTMS|Bilateral Sham rTMS
62524088|NCT06150456|EXPERIMENTAL|Experimental: Group 1|15 patients who will only have their first teeth or second molars extracted.
62524089|NCT06150456|EXPERIMENTAL|Experimental: Group 2|15 patients who will have only their first or second molars extracted and will receive infrared laser treatment
62524090|NCT06150456|EXPERIMENTAL|Experimental: Group 3|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial
62524091|NCT06150456|EXPERIMENTAL|Experimental: Group 4|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial and infrared laser treatment
61975624|NCT01365325|EXPERIMENTAL|handled echocardiography|home monitoring care program based on clinical and electrocardiographic evaluations and periodical handled echocardiographic examinations
61975625|NCT01365325|ACTIVE_COMPARATOR|home monitoring program|home monitoring care program based on clinical and electrocardiographic evaluations
62151890|NCT01780272|OTHER|Normoglycaemia followed by hypoglycaemia|
62151891|NCT01780272|OTHER|Hypoglycaemia followed by normoglycaemia|
62712595|NCT05971095|NO_INTERVENTION|Control group|The neuromodulation program will not be carried out. Only the maximum contraction force of the quadriceps prior to subarachnoid block will be measured. After the intervention, the femoral nerve block will be performed following the usual clinical practice.
62712596|NCT00938301|ACTIVE_COMPARATOR|Treatment|2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
62712597|NCT00938301|PLACEBO_COMPARATOR|Placebo|2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
62151892|NCT01865695|PLACEBO_COMPARATOR|Placebo|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
62151893|NCT01865695|ACTIVE_COMPARATOR|Creon|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
62712598|NCT03652155||Orthognathic Surgery Patients|The study cohort will be patients undergoing orthognathic surgery for correction of an existing dentofacial deformity.
62712599|NCT02937155||Vaccinated|Patients who have received the HPV vaccine.
62712600|NCT02937155||Vaccine Naive|Patients who have not received the HPV vaccine.
62712601|NCT03547427|EXPERIMENTAL|Insulin hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
62712602|NCT03547427|ACTIVE_COMPARATOR|Insulin hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
62712603|NCT03547427|EXPERIMENTAL|Exercise hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
62712604|NCT03547427|ACTIVE_COMPARATOR|Exercise hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia' ). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
62151894|NCT03052998|ACTIVE_COMPARATOR|Ivermectin|Ivermectin and anti-epileptic treatment
62151895|NCT03052998|NO_INTERVENTION|no treatment|only anti-epileptic treatment
62151896|NCT02584426|EXPERIMENTAL|Cefazolin Treatment|Subjects will receive antibiotic treatment with phonophoresis (i.e., hypodermoclysis) during test 1, and will be given standard of care for 8 weeks.
62151897|NCT02584426|NO_INTERVENTION|Standard of Care Control|Subjects will not receive intervention and will receive standard of care for 8 weeks.
62712605|NCT04313465|NO_INTERVENTION|Control (Routine Care)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a cardiac troponin blood test upon admission to the Emergency Department. Participants will then have a repeat cardiac troponin blood test in 3 hours.
62712606|NCT04313465|EXPERIMENTAL|Intervention (Immediate Discharge)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a troponin blood test upon admission to the Emergency Department. Participants will then be discharged.
62712607|NCT00077974|EXPERIMENTAL|1|
62712608|NCT00057161|OTHER|Arm 1|
62712609|NCT05187299|EXPERIMENTAL|Group with an observation tool|In this group (OT +), each student will complete an observer tool each time another dyad is performing
62712610|NCT05187299|NO_INTERVENTION|Group without observation tool|In this group (OT-), the student will not use the observer tool and will observe other students without any physical support.
62151898|NCT03721159||Group I|30 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease.
62151899|NCT03721159||Group II|30 Generalized chronic periodontitis subjects without coronary heart disease.
62151900|NCT03721159||Group III|30 Systemically healthy patients with no chronic periodontitis or coronary heart disease.
62151901|NCT02474004|EXPERIMENTAL|medial meniscus repair|patients receiving medial meniscus repair
62151902|NCT02474004|ACTIVE_COMPARATOR|medial partial meniscectomy|patients having medial partial meniscectomy
62151903|NCT03814226|EXPERIMENTAL|PACAP-38 infusion|According to main hypothesis PACAP-38 is expected to induce headache. PACAP-38 causes marked vasodilation visible to investigator. PACAP38 (10 pmol/kg/min) is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
62524092|NCT01736436|EXPERIMENTAL|100 mg APG101 weekly over 12 weeks|Single arm open label study. Patient receive 100 mg APG101 i.v. weekly over 12 weeks with a 6 monthly follow-up phase
62524093|NCT04434664|ACTIVE_COMPARATOR|Amlodipine besylate|Initial dose 5mg (1 capsule) daily, titrated up to 10mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
62151904|NCT03814226|ACTIVE_COMPARATOR|VIP infusion|According to main hypothesis VIP is not expected to induce headache. VIP also causes marked vasodilation visible to investigator, which is why VIP is chosen as an active comparator. VIP (10 pmol/kg/min) is infused over 20 minutes. VIP is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
62712611|NCT06078826|EXPERIMENTAL|passive music therapy group|"Intubated patients on mechanical ventilator hospitalized in the 3rd Stage Intensive Care Unit will be included in the intervention group 48 hours after admission. The data of the individuals will be collected by face-to-face interview method in the Ramsey Sedation Scale, Patient Identification Form, Patient Follow-up Form, Behavioral Pain Scale to determine the level of pain, and Facial Anxiety Scale to determine the level of anxiety at the first interview.~Before the tracheal aspiration procedure, passive music therapy will be applied for 30 minutes and throughout the aspiration, and during this application, music will be continued for approximately two more minutes (15 seconds of first aspiration, 30 seconds of break, 15 seconds of second aspiration) during both aspirations. Patient Follow-up Form, Behavioral Pain Scale and Face Anxiety Scale will be filled again during and after tracheal aspiration (30 minutes later)."
62151905|NCT00239642|EXPERIMENTAL|Venofer (0.5 mg/kg)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
62151906|NCT00239642|EXPERIMENTAL|Venofer (1.0 mg/kg)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
62151907|NCT00239642|EXPERIMENTAL|Venofer (2.0 mg/kg)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
62151908|NCT01113697||Clinical Investigator Collaborative (CIC) Asthma study cohort|Participants will be healthy volunteer research subjects with allergic asthma who will have an allergen inhalation challenge at CIC sites across Canada.
62151909|NCT01113697||Western Red Cedar Asthma study cohort|Participants will be volunteer research subjects with Western Red Cedar asthma, who will have a plicatic acid inhalation challenge at The Lung Centre at Vancouver General Hospital.
62151910|NCT01113697||Environmental Exposure Unit (EEU), Kingston General Hospital|Subjects will be over 19 years of age so that they qualify for studies involving allergen challenge.
62151911|NCT06332118|EXPERIMENTAL|ice massage group|Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
62151912|NCT01190124||CohortHIV|Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.
62151913|NCT04979702|ACTIVE_COMPARATOR|Active Control|Patients will have access to our online exercise resources throughout the 12-week intervention.
62151914|NCT04979702|EXPERIMENTAL|Experimental: mHealth technology assisted exercise counselling (mHealth)|Participants will complete a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
62524094|NCT04434664|ACTIVE_COMPARATOR|Metoprolol succinate|Initial dose 100mg (1 capsule) daily, titrated up to 200mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
62524095|NCT02664363|EXPERIMENTAL|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10\^6/kg, #2: 1.5 x 10\^7/kg, #3: 4.5 x 10\^7/kg, and #4: 1.5 x 10\^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
61975626|NCT03679650|EXPERIMENTAL|AML Patient who are undergoing allogeneic transplantation|"* Patients will be vaccinated with DC/AML fusion cells~* Four days of GM-CSF given subcutaneously at the site of vaccination~* Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine~* Patients will be treated with 5 days of decitabine in the post-transplant setting"
62151915|NCT04267523|EXPERIMENTAL|Web-based parenting intervention|Families randomized to this intervention group will receive a self-administered web-based parenting intervention. Parents have access to a weekly 6-modules parenting intervention.
62151916|NCT04267523|ACTIVE_COMPARATOR|Face-to-face parenting intervention|Families randomized to this intervention group will receive a face-to-face group parenting intervention. Groups will meet weekly for 120 minutes for 4 weeks.
62151917|NCT02411175|EXPERIMENTAL|20% Ethanol|20% ethanol will be medicated with the individualised homeopathic remedy as determined by the researcher and administered as drops. The potency, dose and frequency of the medicated 20% ethanol drops will be determined for each prescription, in accordance with the laws that govern homeopathic prescribing.
62151918|NCT01051648|EXPERIMENTAL|Triamcinolone acetenoide|Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery
62524096|NCT04757701||General dentists and dental hygienists in North Carolina|This objective will be met by administering a quantitative survey to active and licensed NC dentists and dental hygienists.
62524097|NCT04757701||Directors of Service-Learning Centers and their partnering FQHCs|This objective will be met by conducting qualitative assessments with ECU's SoDM's CSLCs and their partnering community clinic/FQHCs. The investigators will interview the Directors of the eight existing CSLCs and focus groups with clinical staff at each CSLC. In collaboration with the Directors of the CSLCs, the investigators will identify key stakeholders in the co-located/partnering medical clinics, and conduct interviews with the administrators and focus groups with medical clinic staff.
62524098|NCT03861793|EXPERIMENTAL|ALKS 4230|Administered via SC injection once every 7 days or once every 21 days at escalating doses
62712612|NCT06078826|EXPERIMENTAL|foot massage group|"Intubated patients on mechanical ventilator hospitalized in the 3rd Stage Intensive Care Unit will be included in the intervention group 48 hours after admission. The data of the individuals will be collected by face-to-face interview method in the Ramsey Sedation Scale, Patient Identification Form, Patient Follow-up Form, Behavioral Pain Scale to determine the level of pain, and Facial Anxiety Scale to determine the level of anxiety at the first interview.~Foot massage will be applied for 30 minutes before the tracheal aspiration process and throughout the aspiration, and the music will be continued for approximately two more minutes (15 seconds of first aspiration, 30 seconds of break, 15 seconds of second aspiration) during both aspirations. Patient Follow-up Form, Behavioral Pain Scale and Face Anxiety Scale will be filled again during and after tracheal aspiration (30 minutes later)."
62712613|NCT06078826|NO_INTERVENTION|control group|"No intervention will be made to the control group, and the routine care practice of the clinic will be applied. Ramsey Sedation Scale, Patient Identification Form, Patient Follow-up Form, Behavioral Pain Scale to determine pain level, Behavioral Pain Scale to determine the level of anxiety, at the first interview 48 hours after hospitalization in intubated patients hospitalized in the 3rd Stage Intensive Care Unit. Data will be collected by face-to-face interview method, Face Anxiety Scale. Hemodynamic parameters will be recorded. Patient Follow-up Form, Behavioral Pain Scale and Face Anxiety Scale will be filled again during and after tracheal aspiration (30 minutes later)."
62151919|NCT05228834|EXPERIMENTAL|Active Drug|Voxelotor 1500mg or equivalent daily as a tablet or powder for oral suspension
62712614|NCT03722810|ACTIVE_COMPARATOR|Active comparator: patient interview|This intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.
62712615|NCT03722810|SHAM_COMPARATOR|Sham comparator: document|In this intervention, the student's allocated GP teacher will give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher.
62712616|NCT04256447||Sixty-eight children and adolescents with type 1 diabetes|Sixty-eight children and adolescents aged between 4 and 18 years with type 1 diabetes. Patients with celiac disease, thyroid disease, other autoimmune diseases, concurrent illness, patients with diabetic nephropathy, other renal disease and in therapy with natriuretic drugs were excluded.
62712617|NCT06524544|ACTIVE_COMPARATOR|Arm I (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additional undergo blood sample collection, and CT or MRI throughout the study.
62712618|NCT06524544|EXPERIMENTAL|Arm II (pembrolizumab, sacituzumab govitecan)|Patients receive pembrolizumab IV over 30 minutes on day 1 and sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additional undergo blood sample collection, and CT or MRI throughout the study.
62712619|NCT02589821|EXPERIMENTAL|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
62712620|NCT02589821|PLACEBO_COMPARATOR|Placebo|Placebo 300 mg, orally, once daily (QD)
62712621|NCT03586960|EXPERIMENTAL|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
62712622|NCT06064487|EXPERIMENTAL|septic AKI patients|80 patients with sepsis associated AKI stage 1 or 2 according to KDIGO definition
62712623|NCT04088396|EXPERIMENTAL|Cohort 1 Baricitinib|Baricitinib given orally.
62151920|NCT05228834|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62151921|NCT04019925|OTHER|ADM/MDM hip prosthesis|Type of prosthesis participant received.
62151922|NCT01372917||Allomax|The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction.
62151923|NCT01386632|ACTIVE_COMPARATOR|DCA (dichloroacetate) Treatment|DCA orally 12.5mg/kg or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
62151924|NCT01386632|PLACEBO_COMPARATOR|Placebo|Placebo orally or per G-tube BID for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
62151925|NCT06509191|EXPERIMENTAL|Melatonin 5mg/day|"Intervention group 1: Melatonin 5mg/day~* Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission.(20)~* The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water."
62151926|NCT06509191|EXPERIMENTAL|Melatonin 8 mg/day|"Intervention group 2:Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission.(20)~• The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water."
62151927|NCT06509191|PLACEBO_COMPARATOR|Placebo|"* Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission. (20)~* The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water."
62151928|NCT02245620|EXPERIMENTAL|Elamipretide|Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
62151929|NCT02245620|PLACEBO_COMPARATOR|Placebo|Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
62151930|NCT02032004|EXPERIMENTAL|Allogeneic Mesenchymal Precursor Cells|Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
62712624|NCT04088396|ACTIVE_COMPARATOR|Cohort 1 Tocilizumab|Tocilizumab given Subcutaneously (SC).
62524099|NCT03861793|EXPERIMENTAL|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via SC injection once every 7 or 21 days at escalating doses or at the recommended phase 2 dose and schedule; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label. In December 2020, an RP2D of 3 mg with an administration schedule of q7d was determined for SC ALKS 4230.
62712625|NCT04088396|EXPERIMENTAL|Cohort 2 Baricitinib|Baricitinib given orally.
62712626|NCT01882816|EXPERIMENTAL|IMRT and doxorubicin|All patients will undergo radiation treatments using IMRT with concurrent low-dose radiosensitizing doxorubicin at 10 mg/m2 will be administered.
62712627|NCT06240650|EXPERIMENTAL|modified Health- Dx™ (mHDx) study capsule|
62712628|NCT06240650|OTHER|modified Health- Dx™ (mHDx) control capsule|
62712629|NCT01150292|EXPERIMENTAL|DHA - Sunflower oil|400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
62712630|NCT01150292|EXPERIMENTAL|Sunflower oil - DHA|Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
62712631|NCT06483399||Low [index] group|The patients were grouped according to the cut-off value of each index, and the patients whose index value was lower than the cut-off value were classified as the Low \[index\] group.
62151931|NCT02032004|SHAM_COMPARATOR|Control Treatment|Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
62151932|NCT03166605|NO_INTERVENTION|Control|"First group: Control~Follow the current standard protocol used at Albany Medical Center that includes:~* Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~* Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~* Return to clinic (RTC) 8 hours after to remove equipment~* Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period"
62151933|NCT03166605|SHAM_COMPARATOR|Sham|"* Receive 3 ml simethicone 20 minutes prior to capsule swallowing~* Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~* Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~* Return to clinic (RTC) 8 hours after to remove equipment~* Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
62151934|NCT03166605|EXPERIMENTAL|Experiment|"* Receive 3 ml simethicone 20 minutes prior to capsule swallowing.~* Receive 3 ml simethicone 1 hours after capsule swallowing~* Receive 1.5 ml simethicone 2 hours after capsule swallowing~* Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids~* Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~* Return to clinic (RTC) 8 hours after to remove equipment~* Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
62151935|NCT06398015|EXPERIMENTAL|rHat-group|Surgical reconstruction of hip abductor tendon tear
62151936|NCT06398015|SHAM_COMPARATOR|SHAM-group|Sham surgery of hip abductor tendon tear
62151937|NCT05871502|EXPERIMENTAL|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days).
62524100|NCT00359242|EXPERIMENTAL|1|Soothing and Calming instructions given at 2 weeks of life
62712632|NCT06483399||High [index] group|The patients were grouped according to the cut-off value of each index, and the patients whose index value was higher than the cut-off value were classified as the High \[index\] group.
62524101|NCT00359242|EXPERIMENTAL|2|Repeated food exposure instructions given between 4 and 6 months of life
62524102|NCT00359242|EXPERIMENTAL|3|Receive both interventions: Soothing and Calming and Repeated food exposure
62524103|NCT00359242|NO_INTERVENTION|4|Group receiving neither of the interventions.
62712633|NCT03564886|EXPERIMENTAL|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
62524104|NCT03580122|EXPERIMENTAL|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
62524105|NCT04613674|EXPERIMENTAL|Arm A|
62524106|NCT04613674|EXPERIMENTAL|Arm B|
62524107|NCT00753818|EXPERIMENTAL|1|
62524108|NCT00753818|EXPERIMENTAL|2|
62524109|NCT00753818|EXPERIMENTAL|3|
62524110|NCT00753818|OTHER|4|Control
62524111|NCT02312063|EXPERIMENTAL|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
62712634|NCT03564886|PLACEBO_COMPARATOR|Normal Saline|Lactate Ringer's (LR, 273mOsm/L) is commonly used at our facility as our isotonic standard irrigation solution and will serve as the control to be evaluated against a hyperosmolar (1.9%, 600mOsm) solution.
62712635|NCT06628843||Before|twin deliveries after 34 wks 2017 january-2020 December (Pescara), and 2020 January-2022 June (Florence)
62712636|NCT06628843||After|twin deliveries after 34 wks January 2021-december 2024 (Pescara), and July 2022-December 2024
62712637|NCT00926614|EXPERIMENTAL|Pioglitizone and Atorvastatin|Pioglitazone and Atorvastatin added to standard of care Pegasys and weight based ribavirin
62712638|NCT02128737|NO_INTERVENTION|Control|10 hours time-in-bed all nights of study
62712639|NCT02128737|EXPERIMENTAL|1 Recovery Night|2 baseline nights, five nights sleep restriction, 1 recovery night, five nights sleep restriction, 4 recovery nights
61975627|NCT03679650|EXPERIMENTAL|AML Patient who are undergoing transplantation|"* Patients will be vaccinated with DC/AML fusion cells~* Four days of GM-CSF given subcutaneously at the site of vaccination~* Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine"
62524112|NCT02312063|ACTIVE_COMPARATOR|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
62524113|NCT04838236|EXPERIMENTAL|MASP app + NRT|MASP is an intervention designed to assist African American smokers with anxiety sensitivity quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal.
62151938|NCT05778253||Patients with lung Squamous Cell Carcinoma receiving neoadjuvant chemoimmunotherapy|
62151939|NCT01554332|ACTIVE_COMPARATOR|Active stimulation|
62712640|NCT02128737|EXPERIMENTAL|3 Recovery Nights|2 baseline nights, five nights sleep restriction, 3 recovery nights, five nights sleep restriction, 2 recovery nights
62712641|NCT02128737|EXPERIMENTAL|5 Recovery Nights|2 baseline nights, five nights sleep restriction, 5 recovery nights, five nights sleep restriction, 1 recovery nights
62712642|NCT05901610|OTHER|EFT and LIFU|Participants will generate positive future events they are looking forward to at several time points in the future (e.g., 2 weeks, 1 month, 3 months, 1 year, and 5 years). During the LIFU condition, participants will have an ultrasound transducer placed on their head, where brief ultrasound pulses are delivered to the desired brain area using the imaging collected during visit 1. A small amount of ultrasound gel will be placed on the face of the single-element focused ultrasound transducer. The transducer will then be fitted on the scalp over the desired brain area and held in place with a mechanical arm. Brief pulses (0.2 to 2 seconds; duty cycle 10 - 70%; pulse repetition frequency 100 - 1000 Hz) of low-intensity (\< 50 W/cm2 Isppa), sub-thermal ultrasound (0.3 - 0.5 MHz) will be delivered in order to determine the area of activation, as well as the patterns of brain activity generated.
62712643|NCT05901610|OTHER|EFT and Sham LIFU|Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). During Sham LIFU, the device will be set up identically as in real LIFU. However, the device will be turned off.
62712644|NCT05901610|OTHER|CET ad LIFU|Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). During the LIFU condition, participants will have an ultrasound transducer placed on their head, where brief ultrasound pulses are delivered to the desired brain area using the imaging collected during visit 1.
62712645|NCT01499537|ACTIVE_COMPARATOR|Percutaneous Drainage|Percutaneous Transhepatic Biliary Drainage (PTBD)
62712646|NCT01499537|EXPERIMENTAL|EUS-guided drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
62712647|NCT03156218|EXPERIMENTAL|Without ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio \> 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
62712648|NCT03156218|EXPERIMENTAL|With mild to moderate ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio \> 100 and \< 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
62712649|NCT00710593|ACTIVE_COMPARATOR|A: HAART naive or no HAART in past 6 months|Participants who are ART naïve or, if ART-exposed, have not received highly active antiretroviral therapy (HAART) for at least the six months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
62151940|NCT01554332|SHAM_COMPARATOR|Sham stimulation|
62151941|NCT02764320|ACTIVE_COMPARATOR|Discontinuation|Migraine prophylactic therapy will be initiated or optimized with the immediate discontinuation of the overused medication(s)
62151942|NCT02764320|ACTIVE_COMPARATOR|Preventive Therapy Only|Migraine prophylactic therapy will be initiated or optimized without the early discontinuation of the overused medication(s)
62151943|NCT01653392||Anthrax Vaccine Adsorbed|Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry.
62151944|NCT02749253|EXPERIMENTAL|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
61975628|NCT03791840||Ultrasound evaluation|Eligible patients undergo lymph node biopsy or lymph node dissection. Before surgery, the status of axillary lymph node status was evaluated using ultrasound. After surgery, all lymph node specimens would be collected and be assessed using ultrasound in a special evaluation system in vitro.
62151945|NCT02776124|EXPERIMENTAL|ONS group|Individualized dietary counseling+ONS(Healing elements)during CRT Interventions: (Healing elements)
62151946|NCT02776124|NO_INTERVENTION|control group|Individualized dietary counseling during CRT
62151947|NCT06506175|EXPERIMENTAL|Treatment group A：Different fasting time、dosing conditions and timing|
62151948|NCT06506175|EXPERIMENTAL|Treatment group B：Different fasting time、dosing conditions and timing|
61975629|NCT00837304||UC|Patients with known ulcerative colitis
62524114|NCT04838236|OTHER|QuitGuide app + NRT|The QuitGuide app is a standard of care app that allows users to track their nicotine cravings, and provides users with motivational messages.
62524115|NCT03827616|ACTIVE_COMPARATOR|2,5 Gy|hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula\> 15% or N1) 28 x 1,8 Gy - 50,4 Gy).
62151949|NCT06506175|EXPERIMENTAL|Treatment group C：Different fasting time、dosing conditions and timing|
62151950|NCT06506175|EXPERIMENTAL|Treatment group D：Different fasting time、dosing conditions and timing|
62151951|NCT06506175|EXPERIMENTAL|Treatment group E：Different fasting time、dosing conditions and timing|
62151952|NCT06506175|EXPERIMENTAL|Treatment group F：Different fasting time、dosing conditions and timing|
62151953|NCT06506175|EXPERIMENTAL|Treatment group G：Fed conditions|
62151954|NCT06506175|EXPERIMENTAL|Treatment group H：Fasting conditions|
62151955|NCT06500195||SCREWS|The SCREWS group of patients operated on with the use of only transpedicular screws.
62151956|NCT06500195||HYBRID|The HYBRID group of patients whose corrections were performed using the hybrid instrumentation system (screws and bands).
62151957|NCT05979766|ACTIVE_COMPARATOR|Manual lymphatic drainage vs marian clark drainage|Effect of Marian Clark drainage and manual lymphatic drainage in women suffering from pelvic congestion syndrome
62151958|NCT05979766|ACTIVE_COMPARATOR|Manual lymphatic drainage versus marian clark drainage|Effect of Marian Clark drainage and manual lymphatic drainage in women suffering from pelvic congestion syndrome
62524116|NCT03827616|ACTIVE_COMPARATOR|3 Gy|hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula\> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).
62524117|NCT01362127|ACTIVE_COMPARATOR|Radiochemotherapy|Arm I: Radiochemotherapy + Surgery
62524118|NCT01362127|ACTIVE_COMPARATOR|Chemotherapy|Arm II: Chemotherapy + surgery
62524119|NCT01601366|EXPERIMENTAL|LNG-IUS (Mirena)|"Group I the LNG-IUS group where they will have a LNG IUS (mirena) inserted for them"
62524120|NCT01601366|ACTIVE_COMPARATOR|Combined oral contraceptives|"Group II COCs group where they will receive low dose combined oral contraceptive pills for 6 months"
62524121|NCT04739696|NO_INTERVENTION|Caregiver Control|biomarker analysis; questionnaire administration; survey administration; treatment as usual
62524122|NCT04739696|EXPERIMENTAL|Caregiver Intervention|biomarker analysis; questionnaire administration; survey administration; PsychoEducation Paced Respiration and Relaxation (PEPRR), which includes virtual one-on-one psychoeducation and stress management intervention.
62524123|NCT04739696|EXPERIMENTAL|Caregiver Self-Directed|biomarker analysis; questionnaire administration; survey administration; Pep-Pal web-accessible video modules of the psychoeducation and stress management intervention.
62524124|NCT06352229|EXPERIMENTAL|Playful Learning in Infancy Program|Playful Learning in Infancy Program plus postnatal care as usual
62524125|NCT06352229|ACTIVE_COMPARATOR|Care As Usual|Postnatal care as usual
62524126|NCT02993692|OTHER|fiberoptic bronchoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about fiberoptic bronchoscopy.
62524127|NCT02993692|OTHER|direct laryngoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about direct laryngoscopy.
62524128|NCT01764282|EXPERIMENTAL|Intervention|comprehensive intervention components
62524129|NCT01764282|NO_INTERVENTION|Usual|According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.
62524130|NCT05253365|EXPERIMENTAL|Memory Support System participants|
62524131|NCT05167604||MRD-positive Cohort|ctDNA positivity in pretreatment and posttreatment plasma samples was defined by accessing the presence of one or more mutations identified in match tumor samples. A mutation was considered present when at least one consensus read contained the mutation and passed the local polishing pipeline. The MRD positive cohort was randomly divided into two groups, one group for interventional treatment and the other group for observation.
62524132|NCT05167604||MRD-negative Cohort|ctDNA negative in pretreatment and posttreatment plasma samples was defined by accessing the presence of no mutation identified in match tumor samples. According to the clinical prognostic characteristics of the MRD negative group, the clinician decides to observe or treat.
62524133|NCT00367003|EXPERIMENTAL|Deep Brain Stimulation|Participants with treatment resistant depression will have a device implanted for deep brain stimulation.
62524134|NCT01207505|EXPERIMENTAL|Enchancing Emotion Regulation|12 week group 3 week modules: 1) Mindfulness 2) Emotion Regulation 3) Distress Tolerance
62524135|NCT01553279|EXPERIMENTAL|V419 and MCC-TT|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-TT (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of a measles, mumps, and rubella (MMR) vaccine (at 12 months of age).
62151959|NCT05126537||Health volunteers|Health volunteers as control group
62151960|NCT05126537||ICU non-sepsis patients|ICU non-sepsis patients as control group
62151961|NCT05126537||Sepsis patients|Sepsis patients as study group
62151962|NCT00952003|EXPERIMENTAL|interventional arm|Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination therapy cycles Bevacizumab will be continued until progression.
62524136|NCT01553279|EXPERIMENTAL|V419 and MCC-CRM|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-CRM (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of an MMR vaccine (at 12 months of age).
62524137|NCT06456619|ACTIVE_COMPARATOR|Composite resin (Filtek Z250, 3M ESPE)|A pretreatment protocol including sodium hypochlorite and ortho-phosphoric acid was applied to the tooth surface. Then, the tooth was restored with a composite resin material (Filtek Z250, 3M ESPE). This protocol is a clinically approved way for restoring hypomineralized teeth.
62524138|NCT06456619|EXPERIMENTAL|CAD-CAM supported (Cerasmart, GC Dental)|The preparation was completed by making bevels on the enamel surfaces. Then, an intraoral impression was taken to sent to the laboratory for manufacturing CAD-CAM-supported restoration with a nanohybrid ceramic material (Cerasmart, GC Dental). CAD-CAM supported restorations can be done by using a lot of restorative blocks by milling them. In this study, we preferred using resin-based blocks (Cerasmart, GC Dental) to compare with the control group.
62524139|NCT04205396|EXPERIMENTAL|Written emotional disclosure|
62524140|NCT04205396|EXPERIMENTAL|Resilience training|
62524141|NCT04205396|OTHER|Control arm|
62151963|NCT01861041|EXPERIMENTAL|Heavy Bupivacain, Local anesthetic, Amp|Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml
62151964|NCT01861041|ACTIVE_COMPARATOR|Isobaric spinal, Local anesthetic, Amp|7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml
62151965|NCT02648841|ACTIVE_COMPARATOR|Adjuvant Chemotherapy|The interventions of adjuvant chemotherapy group is 8 cycles of SOX(S-1+Oxaliplatin) chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
62524142|NCT01787539|EXPERIMENTAL|Complete Perioperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery with the same regimen as in the preoperative part."
62524143|NCT01787539|NO_INTERVENTION|Preoperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Patients with tumor regression grade 0, 1, 2 randomized to preoperative chemotherapy will not undergo postoperative chemotherapy and will be followed-up."
62712650|NCT00710593|ACTIVE_COMPARATOR|B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months|Participants who have been receiving highly active antiretroviral therapy (HAART) for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads \< 400 copies/ml on two previous clinical visits within the 6 months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
62712651|NCT03121521|EXPERIMENTAL|melatonin|Melatonin 10mg/d p.o.
62712652|NCT03121521|PLACEBO_COMPARATOR|placebo|placebo 10mg/d p.o.
62712653|NCT05130073||Observational (PET/CT, medical data review, follow-up)|Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients' medical records are received. Patients are followed up for 5 years.
62712654|NCT01161771||Patients with cataract and corneal astigmatism|Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
62151966|NCT02648841|EXPERIMENTAL|Adjuvant Chemo-radiotherapy|The interventions of adjuvant chemo-radiotherapy group is concurrent chemo-radiotherapy to be give after 4-6 cycles of chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral. Six cycles of SOX chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
62151967|NCT03734432|EXPERIMENTAL|Patients|IGAR-Breast TeleOp
62151968|NCT05437328|EXPERIMENTAL|bi-4SCAR-GD2/CD56 T Cell Therapy for GD2 and/or CD56 positive tumor|
62524144|NCT05380076|EXPERIMENTAL|Mindfulness|Mindfulness meditation video before the circuit
62524145|NCT05380076|EXPERIMENTAL|Mobilization of inner resources|Standardised video before the circuit
62524146|NCT05380076|EXPERIMENTAL|Biofeedback|Cardiac biofeedback before the circuit
62524147|NCT05380076|SHAM_COMPARATOR|Control|Standardised video before the circuit
62524148|NCT01376193||Subjects prescribed naratriptan tablets|Subjects with migraine headache prescribed naratriptan tablets during study period
62524149|NCT01718470|ACTIVE_COMPARATOR|Endotracheal tube|At the end of surgery, emerge from anesthesia with the ETT still in place
62712655|NCT03796910|EXPERIMENTAL|SPR720 for SAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
62712656|NCT03796910|PLACEBO_COMPARATOR|Placebo for SAD|2 out of 8 subjects per cohort will be randomized to receive placebo
62151969|NCT02128269|EXPERIMENTAL|ALXN1007- Open label study|ALXN1007
62712657|NCT03796910|EXPERIMENTAL|SPR720 for MAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
62712658|NCT03796910|PLACEBO_COMPARATOR|Placebo for MAD|2 out of 8 subjects per cohort will be randomized to receive placebo
62151970|NCT04155814|EXPERIMENTAL|Iron Sucrose Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
62524150|NCT01718470|ACTIVE_COMPARATOR|Laryngeal mask|At the end of surgery,emerge from anesthesia after ETT had been replaced by an LMA.
62524151|NCT02192749|EXPERIMENTAL|Umbilical cord mesenchymal stem cells|
62151971|NCT04155814|ACTIVE_COMPARATOR|Venofer Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
62151972|NCT04806659|EXPERIMENTAL|SH1573 Capsules|SH1573 capsules administered orally. Multiple doses will be administered by effiacy and safety to determine the RP2D.
62151973|NCT04376788|EXPERIMENTAL|Exchange transfusion|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
62524152|NCT03436914|EXPERIMENTAL|PPI|Esomezol®
62151974|NCT04376788|EXPERIMENTAL|Methylene blue with plasma|Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
62151975|NCT04376788|EXPERIMENTAL|Exchange transfusion and methylene blue with plasma|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
62524153|NCT05970445||Patients with enlarged vestibular aqueduct|This study will analyze the SLC26A4 mutation, and audiological and imaging characteristics of PS/NSEVA to summarize the clinical manifestations of PS/NSEVA patients. The study also will analyze the effects of SLC26A4 mutation and inner ear imaging on the degree of hearing loss in PS/NSEVA patients to provide predictive measures for the genetic diagnosis and clinical phenotype of PS/NSEVA. Finally, the effects of sex and age on the degree of hearing loss in patients with PS/NSEVA will be analyzed to provide insight on PS/NSEVA pathogenesis.
62524154|NCT04216758|EXPERIMENTAL|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m\^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m\^2 on days 1, 8, and 15
62712659|NCT05932485|EXPERIMENTAL|Left stellate ganglion block|Left stellate ganglion block under ultrasound guidance was administered with 0.375% Ropivacaine hydrochloride 5 ml
62712660|NCT05932485|NO_INTERVENTION|Control|do nothing
62712661|NCT01663792|PLACEBO_COMPARATOR|Placebo|5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
62712662|NCT01663792|EXPERIMENTAL|Seaweed|Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
62712663|NCT01663792|PLACEBO_COMPARATOR|Placebo2|5 g/d placebo in 10 500-mg capsules for one month
62712664|NCT02297412|EXPERIMENTAL|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62524155|NCT04216758|EXPERIMENTAL|tegafur + gemcitabine|gemcitabine at 1000 mg/m\^2 on days 1, 8, and 15; tegafur: Body surface area \< 1.25 m\^2, 60 mg/d; Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d; Body surface area ≥ 1.5 m\^2, 100 mg/d; Oral (po), Bid, D1-21
62151976|NCT01000935|ACTIVE_COMPARATOR|Platelet Rich Plasma|The platelet concentrate extracted from patient's own blood (PRP) will be applied to the surgical site after completion of the repair.
62524156|NCT03651466|EXPERIMENTAL|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
62524157|NCT03651466|EXPERIMENTAL|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
62524158|NCT03651466|EXPERIMENTAL|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
62524159|NCT03651466|EXPERIMENTAL|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
62524160|NCT03651466|EXPERIMENTAL|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
62524161|NCT03651466|EXPERIMENTAL|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
62524162|NCT04009538|EXPERIMENTAL|COPD patients participated PR program|COPD patients participated first and second PR program
62524163|NCT02126774||focal epilepsy|observational study
62524164|NCT04805918|EXPERIMENTAL|VIPP-SD (Video-feedback Intervention to Promote Positive Parenting and Sensitive Discipline).|The VIPP-SD includes seven sessions of 1½-2 hours each with an 2-4 weeks interval VIPP-SD is delivered by a VIPP-SD trained pedagogue and takes place in the family home and the targeted parent and child are videotaped during daily interactions. The intervener studies the video and prepares feedback. During the sessions, the intervener and parent review the video together and the intervener provides their feedback according to the VIPP-SD protocol.
62524165|NCT04805918|ACTIVE_COMPARATOR|Care as ususl|The existing standard practices for parents of 2-6 year old children identified to be at risk for developing externalizing problems in the participating municipalities will be the active control condition. These vary in content and duration in the municipalities. Likewise, CAU may change during the project period. The exact content and duration of CAU interventions as well as participants' adherence to treatment will be described as precisely as possible.
62524166|NCT06248658||Inpatient cohort|Patients who were admitted to hospital for any cardiac diagnosis (ICD-10 codes I00-I99), with CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis. Index event is the earliest hospitalization for any cardiac diagnosis during which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis).
62524167|NCT06248658||Outpatient cohort|Patients who had an outpatient visit for any cardiac diagnosis (ICD-10 codes I00-I99), with: 1) CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis at the same visit. Index event is the earliest outpatient visit to a general practitioner or cardiologist for any cardiac diagnosis for which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF of stage 2a or higher and/or FC II and higher (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis).
62524168|NCT05611450|PLACEBO_COMPARATOR|routine care|
62524169|NCT05611450|EXPERIMENTAL|lung cancer self-management|
62524170|NCT02299817|ACTIVE_COMPARATOR|Denosumab|Patients will receive a dose of 60 mg denosumab (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
62524171|NCT02299817|PLACEBO_COMPARATOR|Placebo|Patients will receive a dose of placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
62524172|NCT04231942|EXPERIMENTAL|Group 1 (experimental): continuous using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS (at least 8 hours per day) for both lower extremities every day for 12 months, while change of GCS for the new one should be carried out at 6 months or early in case of stocking deterioration;"
62524173|NCT04231942|EXPERIMENTAL|Group 2 (experimental): intermittent using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS on both limbs during physical activity and long stasis events: any kind of sport activities, air travel of any duration, traveling on vehicles for more than 4 hours, walking for more than 2 hours, standing work for more than 4 hours) for 12 months, while change of GCS for the new one should be carried in case of stocking deterioration;"
62151977|NCT01000935|NO_INTERVENTION|Surgical repair (standard-of-care)|Patients will have a rotator cuff repair without the PRP application.
62712665|NCT02297412|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62712666|NCT06356155|EXPERIMENTAL|Combination Therapy|"Enfortumab vedotin 1.25 mg/kg IV on Days 1 and 8 and Pembrolizumab 200 mg IV on Day 1 (every 21 days for 4 cycles)~Definitive surgery (radical nephroureterectomy RNU or distal ureterectomy per treating urologist)~Pembrolizumab 200 mg IV on day 1 (every 21 days for up to 13 cycles) after surgery"
62712667|NCT02108886|EXPERIMENTAL|Montelukast|Intervention group
62712668|NCT02108886|PLACEBO_COMPARATOR|Placebo|Placebo
62712669|NCT05469178|EXPERIMENTAL|Phase 1b Cohort 1: Bemcentinib Dose 1|Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 1 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
62712670|NCT05469178|EXPERIMENTAL|Phase 1b Cohort 2: Bemcentinib Dose 2|Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 2 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
62712671|NCT05469178|EXPERIMENTAL|Phase 1b Cohort 3: Bemcentinib Dose 3|Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 3 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
62151978|NCT01973361|EXPERIMENTAL|Ultrasound debridement|Participants receiving ultrasound assisted debridement in addition to best practice wound care.
62151979|NCT01973361|ACTIVE_COMPARATOR|Best Practice wound care|Participants receiving best practice wound care alone
62712672|NCT05469178|EXPERIMENTAL|Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)|Participants with previously untreated advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC having a serine/threonine kinase 11 (STK11) mutation as identified by Next Generation Sequencing (NGS) and without actionable mutations will receive bemcentinib, at RP2D identified in Phase 1b, once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
62151980|NCT06252454|EXPERIMENTAL|Furosemide|Subjects will inhale once 40 mg of furosemide for 23 minutes, next they will be monitored for an hour and then cross over will take place, the subjects will inhale placebo - saline for 23 minutes and another hour of monitoring and observation will take place. Lastly all subject will be given levodropropizine 1 ml (60mg) with last hour of monitoring and observation
62712673|NCT04108650|EXPERIMENTAL|Fit & Strong! group|The experimental group (23 participants) was enrolled in the intervention, the Fit \& Strong! program. The program consists in 24 sessions each divided in two parts. The first part is the exercise component (60 minutes) and the second is the educational component (30 minutes). The program was provided in two classes, the first class took place from October to December 2017 and the second class took place from October to November 2018. The experimental group was enrolled in the intervention (8 weeks).
62151981|NCT06252454|PLACEBO_COMPARATOR|Placebo|Subjects will inhale once placebo - saline for 23 minutes, next they will be monitored for an hour and then cross over will take place, the subjects will inhale 40 mg of furosemide for 23 minutes and another hour of monitoring and observation will take place. Lastly all subject will be given levodropropizine 1 ml (60mg) with last hour of monitoring and observation
62151982|NCT05905068|ACTIVE_COMPARATOR|Cohort 1 will be 25 mg RN0191 (or placebo)|
62151983|NCT05905068|ACTIVE_COMPARATOR|Cohort 1 will be 100 mg RN0191 (or placebo)|
62151984|NCT05905068|ACTIVE_COMPARATOR|Cohort 1 will be 300 mg RN0191 (or placebo)|
62151985|NCT05905068|ACTIVE_COMPARATOR|Cohort 1 will be 500 mg RN0191 (or placebo)|
62151986|NCT05124210|EXPERIMENTAL|Cohort A: Sotrovimab Intravenous (IV) (6 to less than [<] 12 years)|Participants in the age group 6 to \< 12 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1
62151987|NCT05124210|EXPERIMENTAL|Cohort A: Sotrovimab Intravenous (IV) (12 to less than [<] 18 years)|Participants in the age group 12 to \< 18 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1
62151988|NCT02131454|EXPERIMENTAL|Education and Inhalation technique training|Training in technique of drug inhalation in asthma and COPD patients and education about the role of inhalation therapy in the course of the disease.
62151989|NCT02131454|NO_INTERVENTION|Education|Basic education about asthma and COPD.
62151990|NCT06253962||carotid atherosclerosis|
62151991|NCT06253962||without carotid atherosclerosis|
62151992|NCT04856384|EXPERIMENTAL|persons with Multiple Sclerosis|
62151993|NCT04856384|EXPERIMENTAL|Healthy controls|
62151994|NCT05898789|EXPERIMENTAL|CaRE@Home intervention|
62151995|NCT05898789|NO_INTERVENTION|Usual Care group|
62151996|NCT03258788||Non-Small Cell Lung Cancer|Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.
62151997|NCT02855762|OTHER|Dietary Intervention Group|Subject will be guided to eat a high polyunsaturated fatty acid diet.
62151998|NCT02078999||Control Grup|"* Daily clinical data collection~* Quantitative tracheal aspirates (QTA) every 3 days~* Deep freeze serum samples for posterior analysis every day (two aliquots).~* In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
62151999|NCT02078999||Patients with pulmonary infection|"* Daily clinical data collection~* Quantitative tracheal aspirates (QTA) every 3 days~* Deep freeze serum samples for posterior analysis every day (two aliquots).~* In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
62712674|NCT04108650|NO_INTERVENTION|Control group|To participants in the control group (8 participants) were offered the possibility of enrolling in the program the following year after posttest measurement for both the intervention and control groups was complete.
62712675|NCT05129956|EXPERIMENTAL|therapy group|
62524174|NCT04231942|NO_INTERVENTION|Group 3 (control): no use of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~The use of GCS will be possible on-demand when symptoms or risk factors appear after appropriate coordination with the Investigator"
62712676|NCT05669365|EXPERIMENTAL|Care Ecosystem|Patient and caregiver dyads receive the Care Ecosystem intervention
62152000|NCT02078999||Patients with extrapulmonary infection|"* Daily clinical data collection~* Quantitative tracheal aspirates (QTA) every 3 days~* Deep freeze serum samples for posterior analysis every day (two aliquots).~* In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
62712677|NCT04001400|EXPERIMENTAL|High-dose rabeprazole|Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
62712678|NCT04001400|ACTIVE_COMPARATOR|Standard-dose rabeprazole|Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks
62712679|NCT01370148|EXPERIMENTAL|Subjects with severe hepatic impairment|
62712680|NCT01370148|ACTIVE_COMPARATOR|Subjects with normal hepatic function|
62712681|NCT02760914||Coronary heart disease|Patients with coronary heart disease undergoing planned coronary artery bypass surgery
62152001|NCT00512265|ACTIVE_COMPARATOR|1|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
62712682|NCT01615783||Medicaid beneficiaries|Medicaid beneficiaries with at least one medical or pharmacy claim during each year in the identification period (2004-2006)
62712683|NCT02622789||Controls|Age-matched Healthy Controls
62712684|NCT02622789||General Exercises|Low Back Pain Participants Receiving General Exercises
62712685|NCT02622789||Pilates Exercises|Low Back Pain Participants Receiving Pilates Exercises
62712686|NCT03533582|ACTIVE_COMPARATOR|Group A1 (WDF)|Patients undergo observation. Patients may optionally undergo blood sample collection on study.
62712687|NCT03533582|EXPERIMENTAL|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally undergo blood sample collection on study.
62712688|NCT03533582|EXPERIMENTAL|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity. Patients may optionally undergo blood sample collection on study.
62712689|NCT03533582|EXPERIMENTAL|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (2 pre-surgery, 4 post-surgery) in the absence of disease progression or unacceptable toxicity. Patients may optionally undergo blood sample collection on study.
62712690|NCT03533582|EXPERIMENTAL|GROUP B2 ARM I|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 total cycles (4 pre-surgery, 2 post-surgery). After cycle 4, patients undergo surgery, then continue with 2 additional cycles of cisplatin. Patients may optionally undergo blood sample collection on study.
62152002|NCT00512265|PLACEBO_COMPARATOR|2|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
62152003|NCT02418286||Low Back Pain Participant Registry|Patients with low back pain in traditional Korean medicine rehabilitation clinic
62152004|NCT01381549|EXPERIMENTAL|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
62152005|NCT01381549|EXPERIMENTAL|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
62524175|NCT05813288|EXPERIMENTAL|150 mg BID|Dexpramipexole 150 mg oral tablet taken twice a day
62712691|NCT03533582|EXPERIMENTAL|GROUP B2 ARM II|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 total cycles. Patients may optionally undergo blood sample collection on study.
62712692|NCT03533582|EXPERIMENTAL|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4. Patients may optionally undergo blood sample collection on study.
62712693|NCT03533582|EXPERIMENTAL|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4. Patients may optionally undergo blood sample collection on study.
62712694|NCT03533582|EXPERIMENTAL|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9 during cycles 1 and 2 and days 1 and 2 during cycle 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients may optionally undergo blood sample collection on study."
62152006|NCT01381549|ACTIVE_COMPARATOR|imipenem-cilastatin|500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
62524176|NCT05813288|EXPERIMENTAL|75 mg BID|Dexpramipexole 75 mg oral tablet taken twice a day
62524177|NCT05813288|PLACEBO_COMPARATOR|Placebo|Placebo oral tablet taken twice a day
62152007|NCT05344742|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection and Capecitabine|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection and capecitabine followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 18 mg/m\^2, and then the dose will be sequentially escalated to 24 mg/m\^2 and 30 mg/m\^2. The frequency of administration will be once every three weeks. The fixed dose of capecitabine will be set as 1000 mg/m\^2, twice daily, from day 1 to day 14. Every 3 weeks will be set as a treatment cycle, and the administration of drugs is planned for 6 cycles.~Dose-expansion phase: one dose cohort will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection and capecitabine, and the administration of drugs is planned for 6 cycles."
62712695|NCT03533582|EXPERIMENTAL|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5, and carboplatin over 1 hour and etoposide IV over 2 hours on day 1 and 2 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients may optionally undergo blood sample collection on study."
62712696|NCT03533582|EXPERIMENTAL|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients may optionally undergo blood sample collection on study."
62712697|NCT03533582|ACTIVE_COMPARATOR|GROUP E1|Patients undergo observation only. Patients may optionally undergo blood sample collection on study.
62524178|NCT02400671|EXPERIMENTAL|Two-way SMS|Participants will receive weekly push SMS messaging with a questions and have the ability to text back to the study nurse
62524179|NCT02400671|EXPERIMENTAL|One-Way SMS|Participants will receive weekly push SMS messaging
62152008|NCT05344742|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection and albumin-paclitaxel|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection and albumin-paclitaxel followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 18 mg/m\^2, and then the dose is sequentially escalated to 24 mg/m\^2 and 30 mg/m\^2. The frequency of administration will be once every three weeks. The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks. Every 3 weeks will be set as a treatment cycle, and the administration of drugs is planned for 6 cycles.~Dose-expansion phase: one dose cohort will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection and albumin-paclitaxel, and the administration of drugs is planned for 6 cycles."
62152009|NCT00115167|EXPERIMENTAL|Darbepoetin alfa|
62152010|NCT00115167|PLACEBO_COMPARATOR|Placebo|
62152011|NCT04850092||Non-hypotensive|Mean blood pressure is maintained after positional change from supine to prone.
62152012|NCT04850092||Hypotensive|Mean blood pressure decrease \< 20% after positional change from supine to prone.
62152013|NCT01164176|EXPERIMENTAL|RAD001 group|
62152014|NCT04883515|EXPERIMENTAL|Oral glutamine supplementation|patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks
62152015|NCT04883515|ACTIVE_COMPARATOR|Oral protein powder supplementation|patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks
62152016|NCT04518865|EXPERIMENTAL|pre-pubertal group.|The patients were allocated into the pre-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS II and CVMS III
62524180|NCT02400671|NO_INTERVENTION|Control|Participants will receive standard of care (no intervention)
62524181|NCT01917448|SHAM_COMPARATOR|Control|The skin will be injected with local anesthetic without spinal block
62524182|NCT01917448|ACTIVE_COMPARATOR|Spinal morphine|0.15 mg spinal morphine
62524183|NCT02497313|PLACEBO_COMPARATOR|Placebo+Placebo|Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.
62524184|NCT02497313|ACTIVE_COMPARATOR|Placebo+Cholecystokinin|Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.
62524185|NCT02497313|ACTIVE_COMPARATOR|Metformin+Placebo|Oral ingestion of metformin combined with intravenous infusion of isotonic saline.
62524186|NCT02497313|ACTIVE_COMPARATOR|Metformin+Cholecystokinin|Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.
62524187|NCT01765582|EXPERIMENTAL|Arm A: Concurrent FOLFOXIRI + Bevacizumab|Participants will receive concurrent FOLFOXIRI along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4 month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
62524188|NCT01765582|EXPERIMENTAL|Arm B: Sequential FOLFOXIRI + Bevacizumab|Participants will receive alternating 4-week administrations of FOLFOX/bevacizumab and folinic acid (leucovorin), 5-FU, and irinotecan (FOLFIRI) /Bevacizumab with a treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
62524189|NCT01765582|EXPERIMENTAL|Arm C: FOLFOX + Bevacizumab|Participants will receive FOLFOX along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
62524190|NCT03178526|ACTIVE_COMPARATOR|levostatin gel|levostatin gel 1.2% topical gel was put into teh periodontal pocket using an insulin syringe
62524191|NCT03178526|PLACEBO_COMPARATOR|placebo gel|placebo gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
62524192|NCT01409057||No heart lung machine|Coronary-artery-disease
62524193|NCT01409057||Heart lung machine|Coronary artery disease
62524194|NCT05480826|OTHER|Patients|"Subject suffering from (according to DSM IV criteria)~* bipolar disorder~* unipolar depression~* schizophrenia~* autism spectrum disorder~Collection of hair follicle cells"
62524195|NCT05480826|OTHER|Relatives|"Relatives of enrolled patients suffering from psychiatric disorder.~* test to detect psychiatric disorders~* blood or saliva sampling for genomic DNA extraction~* Collection of hair follicle cells"
62524196|NCT02047175|EXPERIMENTAL|A(Telmisartan/S-Amlodipine)|"A(Telmisartan/S-Amlodipine)~: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
62524197|NCT02047175|EXPERIMENTAL|B(Rosuvastatin)|"B(Rosuvastatin)~: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
62524198|NCT02831959|EXPERIMENTAL|NovoTTF-200M device|"NovoTTF-200M device Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-200M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head.~The treatment enables the patient to maintain regular daily routine."
62712698|NCT03533582|EXPERIMENTAL|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally undergo blood sample collection on study.
62712699|NCT03533582|EXPERIMENTAL|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 cycles of the treatment. Patients may optionally undergo blood sample collection on study.
62712700|NCT03533582|EXPERIMENTAL|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of cycles 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of cycles 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 cycles of the treatment. Patients may optionally undergo blood sample collection on study.
62712701|NCT03681756|NO_INTERVENTION|Group 1|Participants will receive an in-person session and an activity monitor
62524199|NCT02831959|ACTIVE_COMPARATOR|Best Standard of Care|Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
62524200|NCT02006628|ACTIVE_COMPARATOR|GWP42003 1000 milligrams (mg)/day|Participants received GWP42003 (100 mg/milliliter \[mL\]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
62524201|NCT02006628|PLACEBO_COMPARATOR|Placebo|Participants received placebo (0 mL cannabidiol \[CBD\]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
62524202|NCT04978116|EXPERIMENTAL|Chest X-Ray (CXR)|Only CXR (image and standardized report) will be available to the clinician in charge of the patient (standard of care). LDCT and LUS will be performed but not available (clinician will be blinded to LDCT and LUS).
62524203|NCT04978116|EXPERIMENTAL|Low-dose CT scan (LDCT)|Only LDCT (image and standardized report) will be available to the clinician (first intervention arm). CXR and LUS will be performed but not available (clinician will be blinded to CXR and LUS).
62524204|NCT04978116|EXPERIMENTAL|Lung ultrasonography (LUS)|Only LUS (image and standardized report) will be available to the clinician (second intervention arm). CXR and LDCT will be performed but not available (clinician will be blinded to CXR and LDCT).
62712702|NCT03681756|EXPERIMENTAL|Group 2|Participants will receive an in-person session, an activity monitor, and social support through BAND
62524205|NCT01558297|EXPERIMENTAL|Motivational Interviewing|
62524206|NCT01558297|ACTIVE_COMPARATOR|Nutritional Counseling|
62524207|NCT01558297|ACTIVE_COMPARATOR|Treatment as usual|
62524208|NCT02133586|PLACEBO_COMPARATOR|Clean Air - O3|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
62524209|NCT02133586|EXPERIMENTAL|NO2-O3|"Day #1: Two-hour exposure to 500ppb nitrogen dioxide with intermittent exercise.~Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
62524210|NCT02133586|PLACEBO_COMPARATOR|Clean Air - NO2|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
62524211|NCT02133586|EXPERIMENTAL|O3 - NO2|"Day #1: Two-hour exposure to 300ppb ozone with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
62152017|NCT04518865|EXPERIMENTAL|post-pubertal group|The patients were allocated into the post-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS V and CVMS IV
62712703|NCT06387082|EXPERIMENTAL|50mg QD|"The starting dose of 50 mg QD will be escalated using the accelerated titration design in the first enrolled subject.~If no DLT is observed and no Grade 2 or higher investigational product-related adverse events occur during the DLT observation period at the dose 50mg QD, the dose can be escalated to 100 mg QD, and the mTPI-2 design will be used for dose escalation.~The dose will be escalated based on available efficacy and safety data in conjunction with preclinical Pharmacodynamics, Pharmacokinetic (PK) and Pharmacodynamics (PD) data."
62712704|NCT06387082|EXPERIMENTAL|100mg QD|"If no DLT is observed and no Grade 2 or higher investigational product-related adverse events occur during the DLT observation period at the dose 50mg QD, the dose can be escalated to 100 mg QD, and the mTPI-2 design will be used for dose escalation.~Three patients will be enrolled first at this dose level. When all patients treated at one dose level complete the DLT evaluation, if more than one patient is undergoing screening when the last patient in this cohort (i.e., the third patient) starts treatment, a maximum of 3 patients can be enrolled in this cohort based on the assessment conducted by the sponsor and investigator.~The dose will be escalated based on available efficacy and safety data in conjunction with preclinical pharmacodynamics, PK and PD data."
62712705|NCT06387082|EXPERIMENTAL|200mg QD|"If no DLT is observed during the DLT observation period at the dose 100mg QD, the dose can be escalated to 200 mg QD, and the mTPI-2 design will be used for dose escalation.~Three patients will be enrolled first at each dose level. When all patients treated at one dose level complete the DLT evaluation, additional 3 patients will be enrolled in the next cohort treated at the determined dose level following the rules. If more than one patient is undergoing screening when the last patient in this cohort (i.e., the third patient) starts treatment, a maximum of 3 patients can be enrolled in this cohort based on the assessment conducted by the sponsor and investigator.~The dose will be escalated based on available efficacy and safety data in conjunction with preclinical pharmacodynamics, PK and PD data."
62712706|NCT06387082|EXPERIMENTAL|300mg QD|"If no DLT is observed during the DLT observation period at the dose 200mg QD, the dose can be escalated to 300 mg QD and the mTPI-2 design will be used for dose escalation.~Three patients will be enrolled first at each dose level. When all patients treated at one dose level complete the DLT evaluation, additional 3 patients will be enrolled in the next cohort treated at the determined dose level following the rules. If more than one patient is undergoing screening when the last patient in this cohort (i.e., the third patient) starts treatment, a maximum of 3 patients can be enrolled in this cohort based on the assessment conducted by the sponsor and investigator.~The dose will be escalated based on available efficacy and safety data in conjunction with preclinical pharmacodynamics, PK and PD data."
62524212|NCT01722565|EXPERIMENTAL|Mesh Group|Patients receiving conventional sigmoid end colostomy plus a preperitoneal lightweight mesh Physiomesh® by laparoscopic procedure
62524213|NCT01722565|NO_INTERVENTION|Control Group|Patients receiving conventional sigmoid end colostomy by laparoscopic procedure, without mesh
62152018|NCT00749827|ACTIVE_COMPARATOR|1|Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours
62152019|NCT00749827|ACTIVE_COMPARATOR|2|Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
62152020|NCT02858206|EXPERIMENTAL|Neoadjuvant nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
62152021|NCT02858206|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
62152022|NCT02858206|EXPERIMENTAL|Radical nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
62524214|NCT03403166||DASH diet|The DASH diet consisted of a high intake of fruits, vegetables, and low-fat dairy products. It included a wide range of sources of protein, such as meat, fish, poultry, nuts, and beans. Sugar-sweetened beverages, desserts, and red meat were restricted. In terms of nutrients, the DASH diet had a high amount of fiber and protein; low amounts of saturated fat, total fat, and cholesterol; and intake of potassium, magnesium, and calcium at levels close to the 75th percentile of U.S. consumption.
62524215|NCT03403166||Fruits and vegetables diet|Potassium and magnesium intake was similar to the 75th percentile of U.S. consumption. Fiber intake was high. The fruits and vegetables diet consisted of more fruits and vegetables and fewer snacks and desserts than the control diet, but otherwise was similar to the control diet.
62524216|NCT03403166||Control diet|For the control diet, macronutrient intake was similar to average U.S. consumption and intake of potassium, magnesium, and calcium were similar to the 25th percentile of U.S. consumption. Sodium intake was approximately 3 g/day in each diet.
62524217|NCT02244736||Controls|Subjects with no family history of diabetes mellitus and normal OGTT
62712707|NCT06387082|EXPERIMENTAL|400mg QD|"If no DLT is observed during the DLT observation period at the dose 300mg QD, the dose can be escalated to 400 mg QD and the mTPI-2 design will be used for dose escalation.~Three patients will be enrolled first at each dose level. When all patients treated at one dose level complete the DLT evaluation, additional 3 patients will be enrolled in the next cohort treated at the determined dose level following the rules. If more than one patient is undergoing screening when the last patient in this cohort (i.e., the third patient) starts treatment, a maximum of 3 patients can be enrolled in this cohort based on the assessment conducted by the sponsor and investigator.~The dose will be escalated based on available efficacy and safety data in conjunction with preclinical pharmacodynamics, PK and PD data."
62152023|NCT02858206|ACTIVE_COMPARATOR|Radical chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
62152024|NCT00423215||Patients with Type II diabetes|
62152025|NCT06094439||good or poor embryo quality|morphological evaluation will be performed by an expert embryologist to confirm poor and good embryo quality
62152026|NCT06094439||metabolomics profiles|metabolomics profiles will be performed by a Metabolomics core facility
62524218|NCT02244736||Relatives|First-degree relatives of patients with diabetes mellitus and normal OGTT
62524219|NCT02244736||Diabetics|Subjects with abnormal OGTT
62524220|NCT00598624|EXPERIMENTAL|A|
62524221|NCT01922167|EXPERIMENTAL|Leucine|2.5 g doses of leucine isolate three times per day (7.5 g total) of leucine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
62524222|NCT01922167|PLACEBO_COMPARATOR|Alanine|2.5 g doses of alanine isolate three times per day (7.5 g total) of alanine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
62524223|NCT03040323|EXPERIMENTAL|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
62524224|NCT03040323|PLACEBO_COMPARATOR|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
62524225|NCT01077882|PLACEBO_COMPARATOR|current therapy|
62524226|NCT01077882|EXPERIMENTAL|current therapy with educational program|
62524227|NCT05632341|EXPERIMENTAL|GCWB1176|1 capsule once a day
62524228|NCT05632341|ACTIVE_COMPARATOR|Placebo|1 capsule once a day
62524229|NCT03642353|EXPERIMENTAL|G1: Triclosan/health children|Children from health parents will use the triclosan toothpaste for 45 days.
62524230|NCT03642353|PLACEBO_COMPARATOR|G2: Placebo/health children|Children from health parents will use the placebo toothpaste for 45 days.
62524231|NCT03642353|EXPERIMENTAL|G3: Triclosan/GAP children|Children from GAP parents will use the triclosan toothpaste for 45 days.
62524232|NCT03642353|PLACEBO_COMPARATOR|G4: Placebo/GAP children|Children from GAP parents will use the placebo toothpaste for 45 days.
62524233|NCT03045159|EXPERIMENTAL|Strong Families|parenting program
62524234|NCT03045159|ACTIVE_COMPARATOR|Strong Parents|self-care program
62152027|NCT03204773||HSP patients|Patients with hereditary spastic paraplegia regardless of their genetic mutation
62152028|NCT03204773||Healthy controls|healthy controls (spouses, relatives, or other healthy controls)
62524235|NCT04180553|EXPERIMENTAL|Point-Of-Care Ultrasound Guided Resuscitation|Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission.Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and IVC study performed post-operatively in PACU, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two. Based on ultrasound findings, their fluid resuscitation will be guided to a fluid liberal or fluid restrictive strategy at the time of each assessment.
62524236|NCT04180553|ACTIVE_COMPARATOR|Usual Care|The comparator arm in this trial is randomization to usual care. Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria
62524237|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
62524238|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
62524239|NCT05389982|PLACEBO_COMPARATOR|Standard Care|
62524240|NCT05389982|ACTIVE_COMPARATOR|standard care + mHealth (GetWell)|
62524241|NCT05389982|ACTIVE_COMPARATOR|mHealth (GetWell)|
62524242|NCT03340571||Alzheimer's Patients|
62524243|NCT03340571||Healthy Volunteers|
62524244|NCT00817076|EXPERIMENTAL|1|
62524245|NCT05318209|EXPERIMENTAL|Study grou[p|Closed-chain shoulder girdle scapular depression exercise
62524246|NCT05318209|ACTIVE_COMPARATOR|control group|Shoulder girdle depression against manual resistance exercise
62524247|NCT03912441|EXPERIMENTAL|BCD-147 Monotherapy Dose Level 1|
62524248|NCT03912441|EXPERIMENTAL|BCD-147 Monotherapy Dose Level 2|
62524249|NCT03912441|EXPERIMENTAL|BCD-147 Monotherapy Dose Level 3|
62524250|NCT03912441|EXPERIMENTAL|BCD-147 Monotherapy Dose Level 4|
62524251|NCT02379286||14 to 17 years old French teenager|14 to 17 years old French teenager representative of French population from whom parental consent to particpare to the study has been given
62524252|NCT04683419|EXPERIMENTAL|Patients with pleural effusion of Undetermined etiology|Patients with undiagnosed exudative pleural effusion will undergo modified pleural cryobiopsies and conventional pleural forceps biopsies in the same settings
62524253|NCT05304611|EXPERIMENTAL|Adult Dose-escalation study: Arm 1: 300 mg of L9LS|Adult participants receive single dose of 300 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns dosing begins for arm 2.
62712708|NCT05831943||Renal CT evaluation|Patients who are planned kidney contrast enhanced CT scan
62712709|NCT06101810|EXPERIMENTAL|COMET (Korrelboom)|Korrelbooms' Competitive Memory Training (2011) (abbreviated COMET) is a cognitive behavioral therapy based on counter-conditioning. It uses positive self-verbalizations, imagination, posture and facial expression and music in a protocolized intervention consisting of 8 weekly group sessions of 90 minutes. For this study the protocol is extended with 1 session, to 9 sessions, in concertation with the author.
62712710|NCT06101810|EXPERIMENTAL|CBT (De Neef)|"The cognitive behavioural protocol by De Neef (2010; 2018) has not been specifically named but is commonly referred to as 'the whitebook method' or 'cognitive behavioral therapy' (CBT). For convenience, this intervention will be addressed to as CBT in the current study.~This intervention relies heavily on positive data logging to specifically focus on evidence that is contradictory to the negative core belief. Patients keep a positive data log (the 'whitebook') to write down positive events and positive qualities of themselves to achieve cognitive bias modification. They also receive psycho-education and practice on alternative behavior such as receiving compliments (which is also regarded as exposure), lowering perfectionist behavior and receiving criticism. In this protocolized intervention patients receive 9 to 11 weekly group sessions of 90 minutes. for this study a version of the protocol with 9 sessions is used."
62524254|NCT05304611|EXPERIMENTAL|Adult Dose-escalation study: Arm 2: 600 mg of L9LS|Adult participants receive single dose of 600 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns dosing begins for arm 3.
62524255|NCT05304611|EXPERIMENTAL|Adult Dose-escalation study: Arm 3: 20 mg/kg of L9LS|Adult participants receive highest single dose of 20 mg/kg IV of L9LS intravenously. Once subjects reach day 7 post-administration without safety concerns dosing begins for pediatric subjects dose escalation arm 1.
62524256|NCT05304611|EXPERIMENTAL|Pediatric Dose-escalation study: Arm 1: 150 mg of L9LS|Pediatric subjects age 6-10 years receive single dose of 150 mg L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns, dosing begins for arm 2.
62524257|NCT05304611|EXPERIMENTAL|Pediatric Dose-escalation study: Arm 2: 300 mg of L9LS|Pediatric subjects age 6-10 years receive single dose of 300 mg L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns, dosing begins for the pediatric efficacy study arms.
62524258|NCT05304611|PLACEBO_COMPARATOR|Pediatric Dose-escalation study: Arm 3: Placebo|Pediatric subjects age 6-10 receive single dose placebo of normal saline subcutaneously for comparison.
62524259|NCT05304611|EXPERIMENTAL|Pediatric Efficacy study: Arm 1: 150 mg of L9LS|Pediatric subjects age 6-10 receive single dose of 150 mg L9LS subcutaneously.
62524260|NCT05304611|EXPERIMENTAL|Pediatric Efficacy study: Arm 2: 300 mg of L9LS|Pediatric subjects age 6-10 receive single dose of 300 mg L9LS subcutaneously.
62152029|NCT00785031|ACTIVE_COMPARATOR|internet based intervention|
62712711|NCT04260958|EXPERIMENTAL|Intervention center|Patients at intervention centers will be offered remote video exCR (first-hand option), usual care centre-based exCR or a combination. The exercise program (remote/centre-based) will be standardized and performed for totally 60 minutes, 2 times a week for 3 months. Exercise will be individually prescribed and progressed by physiotherapists in accordance with guidelines. Patients will also be asked to perform one additional session of at least 30 min aerobic exercise per week, at intensity level 13-15 according to Borg RPE-scale.
62712712|NCT04260958|NO_INTERVENTION|Control|At control centers, patients will be offered usual care centre-based exCR only. Patients will also be asked to perform one additional session of at least 30 min aerobic exercise per week, at intensity level 13-15 according to Borg RPE-scale.
62152030|NCT00785031|NO_INTERVENTION|usual care|Patients receive their usual care from their specialist or general practitioner.
62524261|NCT05304611|PLACEBO_COMPARATOR|Pediatric Efficacy study: Arm 3: Placebo|Pediatric subjects age 6-10 receive single dose placebo of normal saline subcutaneously.
62152031|NCT02470312||CRT|Patients who are undergoing CRT implantation utilizing MediGuide system and tools
62152032|NCT02470312||EP|Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools
62152033|NCT05815459||Clinical Cases|Participants wear OCOsense during mood induction tasks tracking hedonic, self-reflective and autobiographical processes respectively. Participants also wear OCOsense whilst engaging in simple physical activities.
62524262|NCT00577902||Observational|This is an observational study
62524263|NCT01124357|ACTIVE_COMPARATOR|novasure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
62524264|NCT01124357|OTHER|thermachoice|ThermachoiceTM III thermal balloon ablation
62524265|NCT05884242|EXPERIMENTAL|Active Arm: Adalimumab + Lipopolysaccharide (LPS) Challenge|Healthy participants will receive adalimumab subcutaneous (SC) injections via prefilled syringe or prefilled pen on Day 1, followed by the LPS intravenous (IV) injection challenge on Day 6.
62524266|NCT05884242|EXPERIMENTAL|Control Arm: LPS Challenge|Participants will receive LPS IV injection on Day 6. No study interaction will be administered.
62524267|NCT05991128|EXPERIMENTAL|Ferric derisomaltose|"Iron to be administered as ferric derisomaltose.~The treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value.~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb \<10 g/dL, dosage according to body weight is as follows:~Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg.~Infused over a minimum of 15mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg"
62152034|NCT05815459||Control Cases|Participants wear OCOsense during mood induction tasks tracking hedonic, self-reflective and autobiographical processes respectively. Participants also wear OCOsense whilst engaging in simple physical activities.
62152035|NCT02923349|EXPERIMENTAL|INCAGN01949|
62152036|NCT01195584||BMI < 25|Body Mass Index (WHO) established by WHO. BMI \< 25 has been defined as 'normal weight'.
62152037|NCT01195584||25 >= BMI < 30|Body Mass Index (WHO) established by WHO. BMI \>= 25 and \< 30 has been defined as 'overweight'.
62524268|NCT05991128|PLACEBO_COMPARATOR|Placebo|Participants in this arm will receive normal saline 0.9% in analogy to treatment arm.
62524269|NCT04310956|EXPERIMENTAL|Y-Knot group|Patients use Y-Knot all-suture anchor
62524270|NCT04310956|ACTIVE_COMPARATOR|Biocomposite suture anchor|Patients use Biocomposite suture anchor
62712713|NCT05557877|EXPERIMENTAL|Prevention (low-dose aspirin)|"Patients undergo standard of care breast biopsy for assessment of abnormalities seen on imaging, as well as collection of blood during screening. If cancer is found, patient is taken off study and treatment options are discussed with treating physician.~Patients without a cancer finding on biopsy then receive low-dose aspirin by mouth daily for 42-65 days and undergo collection of blood on study. Patients may undergo ultrasound guided breast biopsy as clinically indicated."
62712714|NCT05940350|EXPERIMENTAL|Intervention group|A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10.
62712715|NCT05940350|NO_INTERVENTION|Control group|"The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months"
62524271|NCT05792124|EXPERIMENTAL|ESP BLOCK|
62524272|NCT05792124|ACTIVE_COMPARATOR|RLB BLOCK|
62712716|NCT01658046|EXPERIMENTAL|NMES group|10 weeks neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
62524273|NCT01320748|EXPERIMENTAL|Dual Processing|
62524274|NCT01320748|ACTIVE_COMPARATOR|Relapse Prevention|
62524275|NCT04680234|ACTIVE_COMPARATOR|Cryotherapy group|Patients underwent superficial cryotherapy using dimethyl ether and propane (DMEP) at -57C very 2 weeks for maximum six sessions
62524276|NCT04680234|ACTIVE_COMPARATOR|Microneedling group|Patients underwent microneedling 2 weeks for maximum six sessions
62524277|NCT04076384|EXPERIMENTAL|Team-based consultations|Guided Self-Determination
62524278|NCT04076384|EXPERIMENTAL|Standard care|Standard consultation
62524279|NCT04797520|OTHER|Treatment|All participants will have placement of ETT confirmed using both Core stethoscope and point-of-care ultrasound
62712717|NCT01658046|SHAM_COMPARATOR|Control group|10 weeks sham neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
62712718|NCT06099769|EXPERIMENTAL|Enzalutamide|Enzalutamide 160 mg/day, continuous daily dosing in a 21-day cycle
62712719|NCT06099769|EXPERIMENTAL|Enzalutamide with Mifepristone|Enzalutamide 120mg/day and mifepristone 300mg/day, continuous daily dosing in a 21-day cycle
62712720|NCT06099769|ACTIVE_COMPARATOR|Chemotherapy:Carboplatin, Paclitaxel, Eribulin or Capecitabine (TPC)|"The treating physician must select from one of the following regimens.~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle~Patients randomized to TPC may be offered crossover to enzalutamide plus mifepristone treatment at the time of disease progression if they continue to meet eligibility criteria."
62524280|NCT03659461|EXPERIMENTAL|low GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
62524281|NCT03659461|ACTIVE_COMPARATOR|normal GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin ( Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
62524282|NCT01440439|ACTIVE_COMPARATOR|Insulin detemir|Metabolism during and after submaximal exercise during treatment with insulin detemir
62524283|NCT01440439|ACTIVE_COMPARATOR|Insulin glargine|Metabolism during and after submaximal exercise during treatment with insulin glargine
62524284|NCT02575274|EXPERIMENTAL|JHS COL-HAP91 + JHS HAP-91|Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed.
62524285|NCT02575274|OTHER|surgical and mechanical debridement|Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed.
62524286|NCT01868711|ACTIVE_COMPARATOR|*Cognitive behavior therapy|Depressed patients will receive 12 virtual sessions of cognitive behavior therapy (CBT) for depression. CBT Includes behavior activation, correcting distorted thoughts, and other tools to reduce symptoms.
62524287|NCT01868711|OTHER|Supportive psychotherapy|Supportive psychotherapy aims to strengthen the patient's ability to cope effectively with various life stressors. Specifically, in our study, supportive psychotherapy will be geared towards reducing or alleviating symptoms of depression. The sessions will be administered virtually.
62524288|NCT02063243|OTHER|keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
62524289|NCT06428318|ACTIVE_COMPARATOR|Group A: Routine Conventional Methods|Patients subjected to Routine sputum culture Conventional Methods
62524290|NCT06428318|ACTIVE_COMPARATOR|GroupB: BioFire Pneumonia Panel (BFPP).|Patients subjected to BioFire Pneumonia Panel (BFPP
62524291|NCT04704635||Ischemic stroke/TIA|Patients with ischemic stroke or transient ischemic attack
62524292|NCT01403974|EXPERIMENTAL|Monotherapy|BI 836845 dose escalation, infusion, once every week, monotherapy
62712721|NCT05602194|EXPERIMENTAL|Arm A (levocarnitine, standard of care chemotherapy)|Patients receive levocarnitine PO or IV prior to standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
62712722|NCT05602194|ACTIVE_COMPARATOR|Arm B (standard of care chemotherapy)|Patients receive standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
62524293|NCT05783648||Before TXA recommendations|All patients operated between october 1st, 2021 and december 31st 2021, that means before the publication of the POISE-3 trial and the recommendations on the use of tranexamic acid.
62524294|NCT05783648||After TXA recommendations|All patients operated between october 1st, 2022 and december 31st 2022, that means after the publication of the POISE-3 trial and the recommendations on the use of tranexamic acid.
62524295|NCT05087862|ACTIVE_COMPARATOR|Pericapsular nerve group block|Twenty milliliters of bupivacaine 0.5% (100 milligrams) with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle. Additionally, ketorolac 30 mg will be administered intravenously.
62524296|NCT05087862|EXPERIMENTAL|Periarticular local anesthetic infiltration|Sixty milliliters of 0.25% bupivacaine (150 milligrams), 5ug/mL epinephrine, and ketorolac 30 mg will be deposited at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
62524297|NCT01951885|ACTIVE_COMPARATOR|Group A (tacrolimus, methotrexate)|Participants receive tacrolimus IV over 24 hours beginning on day -1 (or tacrolimus orally beginning on day -3) and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.
62524298|NCT01951885|EXPERIMENTAL|Group B (tacrolimus, methotrexate, mycophenolate mofetil)|Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).
62524299|NCT04783974||Patients assuming SSRI|Patients treated with dental implants and assuming selective serotonin reuptake inhibitors
62524300|NCT04783974||Patients assuming PPI|Patients treated with dental implants and assuming proton pump blockers
62524301|NCT04783974||Patients assuming Anti-inflammatory drugs|Patients treated with dental implants and assuming anti-inflammatory drugs
62524302|NCT04783974||Patients assuming Anti-hypertensive drugs|Patients treated with dental implants and assuming anti-hypertensive drugs
62524303|NCT04783974||Control group - Patients not assuming the studied drugs|Patients treated with dental implants and not assuming any of the following drugs: selective serotonin reuptake inhibitors, proton pump blockers, anti-inflammatory drugs, anti-hypertensive drugs
62524304|NCT06110728|EXPERIMENTAL|Habit Change|Participants randomly assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Outside of using the app, participants will not be asked to engage in any additional activities beyond those typically engaged in for behavioral health treatment (e.g., completion of mental and behavioral health outcome measures).
62524305|NCT06110728|NO_INTERVENTION|Treatment as Usual|Participants in the TAU arm will continue to engage in their behavioral health treatment as usual and will not be provided access to the habit change app.
62524306|NCT02068521|EXPERIMENTAL|Treatment naive subjects with GHD|Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.
62524307|NCT02068521|EXPERIMENTAL|Subjects who have completed a somavaratan study|All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.
62524308|NCT03561441|ACTIVE_COMPARATOR|Tailored standard hydration|Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
62524309|NCT03561441|EXPERIMENTAL|Tailored aggressive hydration|Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
62524310|NCT01668693|ACTIVE_COMPARATOR|RIF ERA Receptive 1|"With the receptive results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis."
62524311|NCT01668693|EXPERIMENTAL|RIF ERA Non Receptive|"The Non Receptive results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the Receptive daignosis. A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool."
62524312|NCT02980874|EXPERIMENTAL|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
62524313|NCT02980874|ACTIVE_COMPARATOR|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
62524314|NCT05985733||Study group|patients who applied to our clinic with complaint of pain in TMJ region subjects who had RDC/TMD type II disorder
62524315|NCT05985733||Control group|age and sex matched healthy volunteers
62524316|NCT00474851|EXPERIMENTAL|Norethindrone acetate + estrogens|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
62712723|NCT05602194|EXPERIMENTAL|Arm C (rescue levocarnitine)|Patients in Arms A and B who develop conjugated hyperbilirubinemia \> 3 mg/dL during induction may receive levocarnitine rescue PO or IV supplementation until resolution of conjugated hyperbilirubinemia =\< 3 mg/dL (or start of consolidation or the next treatment phase, whichever occurs first).
62712724|NCT06581042||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
62712725|NCT05160415|EXPERIMENTAL|Treatment|Drug: Sevasemten
62712726|NCT01641575|EXPERIMENTAL|CO-1.01 and Cisplatin|
62524317|NCT00474851|PLACEBO_COMPARATOR|norethindrone acetate + placebo|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.
62524318|NCT02198326|EXPERIMENTAL|BIBN 4096 BS - in single rising doses|
62712727|NCT02307630|EXPERIMENTAL|PET Imaging using 124I-Humanized 3F8|124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
62712728|NCT05826600|EXPERIMENTAL|OMX-0407 - Escalation Phase|"A starting daily dose of 20 mg OMX-0407 per participant split into twice daily 10 mg.~Dose escalation will be determined by the safety monitoring committee. Dose for expansion will be determined by the safety monitoring committee."
62712729|NCT05826600|EXPERIMENTAL|OMX-0407 - Expansion Phase (Phase Ib)|A dose of 100 mg OMX-0407 will be orally administered twice daily.
62712730|NCT03037398|ACTIVE_COMPARATOR|Novel Arm|Programming completed by a novel method
62524319|NCT02198326|PLACEBO_COMPARATOR|Placebo|
62524320|NCT02685202|EXPERIMENTAL|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
62524321|NCT06394674|EXPERIMENTAL|Group A: Furmonertinib 160mg QD|Furmonertinib (AST2818) 160mg QD. All patients enrolled into this group will receive furmonertinib 160mg daily.
62712731|NCT03037398|OTHER|Standard of Care Arm|Programming completed as Standard of care
62712732|NCT06050980|EXPERIMENTAL|Phase Ia(Part A): HSK40118 as monotherapy|Phase 1a(Part A): dose escalation of HSK40118 as monotherapy at various dose levels
62712733|NCT06050980|EXPERIMENTAL|Phase Ia(Part B): HSK40118 as monotherapy|Phase 1a(Part B): dose extention of HSK40118 as monotherapy at certain dose levels
62524322|NCT06394674|EXPERIMENTAL|Group B: Furmonertinib 240mg QD|Furmonertinib (AST2818) 240mg QD. All patients enrolled into this group will receive furmonertinib 240mg daily.
62524323|NCT01524965|EXPERIMENTAL|Immediate mobilisation|
62524324|NCT01524965|ACTIVE_COMPARATOR|Standard mobilisation|
62524325|NCT00535587|EXPERIMENTAL|1|
62524326|NCT00535587|EXPERIMENTAL|2|
62524327|NCT00535587|EXPERIMENTAL|3|
62524328|NCT00535587|EXPERIMENTAL|4|
62524329|NCT02660528|EXPERIMENTAL|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
62524330|NCT03272841||Transplant recipients|Renal, heart, lung, liver, small bowel, pancreas or combined transplant recipients
62524331|NCT01923441||Highschool athletes|
62524332|NCT01923441||midschool athletes|
62524333|NCT04154306|PLACEBO_COMPARATOR|Placebo|
62524334|NCT04154306|EXPERIMENTAL|Red clover|
62524335|NCT04129320|EXPERIMENTAL|Experimental Arm 1|Enoblituzumab plus MGA012
62712734|NCT06050980|EXPERIMENTAL|Phase Ib: HSK40118 as monotherapy|Phase 1b: dose expansion for HSK40118 as monotherapy at a dose determined during Phase 1 in patients with previous treatment with 3rd-generation EGFR-TKI
62712735|NCT05695976||Pilot|"The first 20 patients accrued to this study will be assayed to validate the performance of the assays developed by Personalis. This pilot sub-study will be analyzed in a blinded manner without clinical information."
62712736|NCT05695976||Full Study|"The remaining 80 patients accrued to this study (after the initial 20 patients accrue to the Pilot cohort)."
62712737|NCT01645176|EXPERIMENTAL|Hydroxychloroquine/Atorvastatin open label|
62152038|NCT01195584||BMI >= 30|Body Mass Index (WHO) established by WHO. BMI \> 30 has been defined as 'obese'.
62152039|NCT01843920|ACTIVE_COMPARATOR|Post surgery without glaucoma drops|This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade) and only uses the standard post-operative topical drops.
62524336|NCT04129320|EXPERIMENTAL|Experimental Arm 2|Enoblituzumab plus MGD013
62524337|NCT00539357|EXPERIMENTAL|1|All patients self-administered stimulation for 60 consecutive minutes each day. Participants self-administered the treatment for a period of 6 weeks, 7 days a week between the hours of 15:00 and 19:00. Assessments took place every 2 weeks during the treatment period.
62524338|NCT05944120|EXPERIMENTAL|Crisis Intervention Cart|To determine if a Crisis Intervention Cart filled with evidence-based stress-reducing interventions does reduce stress experienced during a shift.
62524339|NCT00704730|EXPERIMENTAL|1|
62524340|NCT00704730|PLACEBO_COMPARATOR|2|
62524341|NCT04309253|OTHER|PMPBB3|"1. Primary endpoint(s):~   A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.~2. Secondary endpoints:~A. To correlate vascular burden, \[18F\]AV45 and \[18F\]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, \[18F\]AV45 and \[18F\]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
62524342|NCT04309253|OTHER|AV45|"1. Primary endpoint(s):~   A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.~2. Secondary endpoints:~A. To correlate vascular burden, \[18F\]AV45 and \[18F\]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, \[18F\]AV45 and \[18F\]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
62524343|NCT01211782|EXPERIMENTAL|AC-1204|
62524344|NCT01211782|PLACEBO_COMPARATOR|Placebo|
62712738|NCT06204484|ACTIVE_COMPARATOR|MRD-negative standard adjuvant therapy|In MRD-negative standard therapy groups, patients will receive 3-month capecitabine and oxaliplatin (CAPEOX) therapy.
62712739|NCT06204484|EXPERIMENTAL|MRD-negative deferred adjuvant therapy|In MRD- deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
62524345|NCT04553861||Healthy subjects|Healthy subjects without blood pressure difference on both arm
62524346|NCT04669535|EXPERIMENTAL|AXO-AAV-GM2|AXO-AAV-GM2 infusion
62524347|NCT03483168|EXPERIMENTAL|Culturally sensitive pain education|
62524348|NCT03483168|ACTIVE_COMPARATOR|Standard pain education|
62524349|NCT04341649|ACTIVE_COMPARATOR|Head massage by therapist|Head massage therapist will practice massage covering the scalp, front head, occipital area and neck.
62524350|NCT04341649|ACTIVE_COMPARATOR|Helmet massage BREO|Breo helmet will be installed for massaging the head at different defined places.
62524351|NCT04341649|ACTIVE_COMPARATOR|Low Laser Therapy|Laser light can penetrate the skin and stimulate the nervous connections. The investigators will use a laser pen (Min Sheng).
62524352|NCT04341649|ACTIVE_COMPARATOR|Sham Low Laser Therapy|The investigators will use the same laser pen, but without laser beam.
62524353|NCT04341649|ACTIVE_COMPARATOR|TENS ear stimulation|The investigators will use the (Hwato) device that provides electrical pulse at various frequency and intensity. This TENS device is a prototype modified for ear stimulation.
62524354|NCT04341649|ACTIVE_COMPARATOR|Deep and Slow breathing|This intervention is guided by an app that leads to a full respiratory.
62524355|NCT04341649|SHAM_COMPARATOR|Relaxed Reading time|Participants will read the newspaper in a quiet environment.
62524356|NCT05225974|EXPERIMENTAL|Liraglutide injection|
62152040|NCT01843920|EXPERIMENTAL|Post surgery with glaucoma drops|This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.
62152041|NCT04820088|EXPERIMENTAL|Intervention Arm|The educational intervention will be TTACS, the training program with simulated roleplays. Each participant will be asked to schedule 10 hours of time to utilize the simulation. In order to ensure all participants adhere to the minimum intervention requirements, each will be asked to schedule training time with a member of the research team. Participants will attend an initial training session where each participant will receive a short orientation about the product and its capabilities. Participants will attend an initial training session at one of two sites Psychology Department at Towson University or SIMmersion's office in Columbia, MD based on participant preference. Subsequent training sessions may be completed at Towson, SIMmersion or can be completed individually. Participants will receive confirmation emails the day before a scheduled session and a phone call to reschedule any missed sessions.
62524357|NCT05225974|ACTIVE_COMPARATOR|Liraglutide injection(Victoza®)|
62524358|NCT04941339|EXPERIMENTAL|MRG002|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG002 on Day 1 of every 3 weeks (21-day cycle).
62524359|NCT04648124||Patients for whom there is no planned implant surgery|
62524360|NCT04648124||Patients for whom implantation surgery is planned|
62524361|NCT04648124||case|
62524362|NCT04232813|ACTIVE_COMPARATOR|Estradiol 10 micrograms vaginal tablets|One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
62524363|NCT04232813|ACTIVE_COMPARATOR|Promestriene 10mg./g vaginal cream|One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
62712740|NCT06204484|ACTIVE_COMPARATOR|MRD-positive standard adjuvant therapy|In MRD-positive standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
62524364|NCT06363786|EXPERIMENTAL|Test patches|Application of test patches. Each subject wear both low pH formula patches (intervention) and control patches without formula.
62524365|NCT05120206|ACTIVE_COMPARATOR|Cigarette smokers with periodontitis|Periodontal therapy in cigarette smokers
62524366|NCT05120206|ACTIVE_COMPARATOR|Non-smokers with periodontitis|Periodontal therapy in non-smokers
62524367|NCT01377675||Usual curriculum education program|Third year internal medicine residents
62524368|NCT05663450||patients with direct R0 (in primary intraoperative pathology consultation)|patients undergoing (sub)total gastrectomy for gastric or GEJ adenocarcinoma with R0 without further resection (direct R0)
62524369|NCT05663450||patients with converted R0 (in second intraoperative pathology consultation)|patients undergoing (sub)total gastrectomy for gastric or GEJ adenocarcinoma with R0 after positive IOC and extension of resection (converted R0)
62524370|NCT05663450||patients with remaining R1 (after final intraoperative pathology consultation)|patients undergoing (sub)total gastrectomy for gastric or GEJ adenocarcinoma with R1 resection.
62524371|NCT02428686|EXPERIMENTAL|epoetin beta|
62524372|NCT00361335|EXPERIMENTAL|Group I: 2mg/kg Golimumab + MTX|Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
62524373|NCT00361335|EXPERIMENTAL|Group II: 2mg/kg Golimumab only|IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
62712741|NCT06204484|EXPERIMENTAL|MRD-positive intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month modified folinic acid, fluorouracil, oxaliplatin and irinotecan (mFOLFOXIRI) intensive therapy, instead of the CAPEOX standard adjuvant therapy.
62712742|NCT05613816||Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
62524374|NCT00361335|EXPERIMENTAL|Group III: 4mg/kg Golimumab + MTX|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
62524375|NCT00361335|EXPERIMENTAL|Group IV: 4mg/kg Golimumab only|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
62524376|NCT00361335|PLACEBO_COMPARATOR|Group V: IV Placebo + MTX|IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
62524377|NCT05855083|EXPERIMENTAL|Narsoplimab single arm-treatment|Narsoplimab 4 mg/kg
62524378|NCT01775969|NO_INTERVENTION|Standard of Care|Written discharge instructions only
62524379|NCT01775969|EXPERIMENTAL|Text Message|Written discharge instructions plus a text message with antibiotic prescription instructions
62712743|NCT04225858|EXPERIMENTAL|Omission of sentinel lymph node biopsy|No surgical axillary staging (i.e. sentinel lymph node biopsy) will be performed.
62524380|NCT01775969|EXPERIMENTAL|Voicemail|Written discharge instructions plus a voicemail with antibiotic prescription instructions
62524381|NCT01344174|OTHER|glucocorticoids treatment|
62524382|NCT06360315|EXPERIMENTAL|Incentive letter for pneumococcal vaccination to the patient and to the GP|
62524383|NCT06360315|NO_INTERVENTION|No letter sent|
62524384|NCT00532818|PLACEBO_COMPARATOR|1|
62524385|NCT00532818|EXPERIMENTAL|2|
62524386|NCT04542265|EXPERIMENTAL|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
62524387|NCT04542265|EXPERIMENTAL|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
62524388|NCT04542265|EXPERIMENTAL|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil A + vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
62524389|NCT04542265|PLACEBO_COMPARATOR|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
62524390|NCT01693627|ACTIVE_COMPARATOR|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
62524391|NCT01693627|ACTIVE_COMPARATOR|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
62524392|NCT01693627|ACTIVE_COMPARATOR|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
62524393|NCT01693627|ACTIVE_COMPARATOR|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
62524394|NCT00679536|EXPERIMENTAL|A|All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)
62524395|NCT01598441|EXPERIMENTAL|iloprost|Iloprost nebuliser solution 500 ng/kg inhaled
62712744|NCT05740514|EXPERIMENTAL|Twelve-week Exercise|Study participants will participate in an exercise program consisting of aerobic and resistance exercise. This arm will last twelve weeks.
62712745|NCT05740514|EXPERIMENTAL|One-week Detraining|Study participants will undergo unilateral knee immobilization for a one-week period.
62524396|NCT01598441|PLACEBO_COMPARATOR|distilled water|aerosolized distilled water 1-2 ml
62524397|NCT02511899|ACTIVE_COMPARATOR|Mango fruit powder 100mg|Mango fruit powder 100mg
62524398|NCT02511899|ACTIVE_COMPARATOR|Mango fruit powder 300mg|Mango fruit powder 300mg
62712746|NCT05740514|EXPERIMENTAL|Four-week Re-training|Study participants will once again participate in an exercise program consisting of aerobic and resistance exercise. This arm will last four weeks.
62712747|NCT06262659||group fistula|"Preoperative age, gender, weight, height, body mass index, diabetes mellitus, hypertension, asthma, smoking status, postoperative chest pain, intraoperative AVF flow, AVF depth, AVF vascular diameter, and postoperative 6th-week Doppler ultrasonography measurements of AVF flow, AVF depth, and AVF vascular diameter will be recorded for the patients included in the study. Maturation assessment will be made based on these results.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated."
62712748|NCT02189109|EXPERIMENTAL|Dose Escalation|NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide. 0.05-0.35cc/kg.
62712749|NCT00613106|EXPERIMENTAL|HZT-501|HZT-501: ibuprofen 800mg/famotidine 26.6mg
62524399|NCT01157780|EXPERIMENTAL|fish oil|When a subject develops PNALD (three consecutive direct bilirubin concentrations \> 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
62524400|NCT01157780|NO_INTERVENTION|standard of care|When a subject develops PNALD (three consecutive direct bilirubin concentrations \> 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
62524401|NCT02989168|EXPERIMENTAL|GBT440 900 mg Dose|"Part A, 900 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
62524402|NCT02989168|EXPERIMENTAL|GBT440 1500 mg Dose|"Part B , 1500 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
62524403|NCT03481062||Neutral|
62524404|NCT03481062||abduction|
62524405|NCT03481062||pad|
62524406|NCT03481062||combination|
62524407|NCT01031953|EXPERIMENTAL|Fosaprepitant|
62524408|NCT05682846|EXPERIMENTAL|Intervention group|"Optimization of serum phosphorus to ≥ 3.5 and ≤ 4.5 mg/dL (Average 4mg/dL) using Sodium glycerophosphate pentahydrate solution.~Sodium glycerophosphate pentahydrate 20ml solution (20 mmol glycerophosphate) dose will be given once daily till the target serum phosphorus level is achieved."
62524409|NCT05682846|NO_INTERVENTION|Control group|Maintaining serum phosphorus level at ≥ 2.5 and \< 3.5 mg/dL.
62524410|NCT06395779|EXPERIMENTAL|Neuromuscular Exercise Group|NE (Neuromuscular Exercise) group will participate in a 12-week exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns.
62524411|NCT06395779|EXPERIMENTAL|Dance Therapy Group|DT (Dance Therapy) Group will participate in 12-week dance training by a dance instructor. In dance therapy practices, simple and selected basic movements are appropriate to the level of the participants
62524412|NCT05787054|ACTIVE_COMPARATOR|Single scan|Normal screening at 28-32 weeks as currently recommended
62524413|NCT05787054|EXPERIMENTAL|Longitudinal scan|Early and late ultrasound screening with a scan at 35-37 weeks to detect late iugr
62524414|NCT01429051|EXPERIMENTAL|Intranasal Fentanyl Spray (INFS)|All participants were step-wise titrated to an effective dose of 50, 100, 200 or 400 μg INFS in the Titration Phase (I). Participants titrated to 200 or 400 μg INFS in the Titration Phase were randomized to an 8-spray sequence in the Efficacy Phase (II); 6 BTP episodes were treated with 400 μg INFS and 2 BTP episodes with placebo in a random sequence. Participants entered the Tolerability Phase (III) either directly from the Titration Phase (with an effective dose of 50 or 100 μg) or from the Efficacy Phase (400 μg) and continued with this specific dose, unless adjustment was needed, for a total treatment time of 12 weeks.
62524415|NCT01742520|ACTIVE_COMPARATOR|Formula or Breast Milk|Breast milk or formula prior to every painful procedure.
62524416|NCT01742520|ACTIVE_COMPARATOR|Multiple doses of sucrose|Infants in this group will be treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure
62524417|NCT00251719|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62524418|NCT00251719|EXPERIMENTAL|Dexlansoprazole MR 90 mg QD|
62524419|NCT00251719|ACTIVE_COMPARATOR|Lansoprazole 30 mg QD|
62524420|NCT02662166|EXPERIMENTAL|MRI and biomarkers in bladder cancer|Utilization of MR-imaging and biomarkers to stage bladder cancer and in estimation of chemosensitivity
62524421|NCT02996760|EXPERIMENTAL|Endometrium with less than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~Less than 5mm despite 10 days with standard doses of estrogen"
62524422|NCT02996760|NO_INTERVENTION|Endometrium with more than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~More than 5mm despite 10 days with standard doses of estrogen"
62524423|NCT03022708|EXPERIMENTAL|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:~* Tetralogy of Fallot~* Truncus Arteriosus~* Pulmonary Atresia~* Transposition of Great Arteries with Ventricular Septal Defect~* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~In addition, the PV conduit can be used for the following indications:~* replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).~* Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
62524424|NCT04887246||UNISALUD population|Refers to all affiliated members or beneficiaries of the UNISALUD entity, who got any of tthe COVID-19 vaccines available in Colombia
62524425|NCT01969448|ACTIVE_COMPARATOR|Inframammary Fold Incision Cohort|"* Inframammary fold incision which is in the crease under the breast.~* Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~  * Intraoperatively prior to mastectomy~ * At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~ * Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
62712750|NCT00613106|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 800mg
62712751|NCT01470157|EXPERIMENTAL|Ketamine|Oral Ketamine in addition to oral midazolam
62712752|NCT01470157|PLACEBO_COMPARATOR|Placebo|Normal saline (placebo) in addition to oral midazolam
62712753|NCT05446714|ACTIVE_COMPARATOR|conventional hyrax|CH 4 BANDS for expansion of maxilla and observation improvement of the air way
62712754|NCT05446714|ACTIVE_COMPARATOR|Hybrid hyrax|HH 2 BANDS for expansion of maxilla and observation improvement of the air way
62524426|NCT01969448|ACTIVE_COMPARATOR|Lateral Radial Incision Cohort|"* Lateral radial incision~* Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~  * Intraoperatively prior to mastectomy~ * At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~ * Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
62524427|NCT01969448|OTHER|Non-Randomized Cohort|"* Patients in which the surgeon feels that for oncologic reasons must have a specific incision (either inframammary fold or lateral radial incision) and cannot be randomized due to concerns of compromising clinical care but otherwise meet the inclusion and exclusion criteria will be offered participation as part of a non-randomized cohort.~* Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~  * Intraoperatively prior to mastectomy~ * At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~ * Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
62524428|NCT05994820|NO_INTERVENTION|Control|These participants receive no intervention. No chatbot messaging. Usual care.
62524429|NCT05994820|EXPERIMENTAL|Vaccine Campaign|These participants will receive the Happy Baby Programme messages through a WhatsApp Chatbot. All messages will be narrowly focused on vaccine promotion.
62524430|NCT05994820|EXPERIMENTAL|Vaccine++ Campaign|These participants will receive the Happy Baby Programme messages through a WhatsApp Chatbot. All messages will promote vaccines in conjunction with other health-promotion activities (e.g. nutrition, breastfeeding, etc.).
62524431|NCT00031122||SBRR|Families with a child/pregnancy affected with spina bifida or anencephaly
62524432|NCT02139124|PLACEBO_COMPARATOR|Placebo|Placebo Arm
62524433|NCT02139124|EXPERIMENTAL|PRC-063 25 mg|PRC-063 25 mg
62524434|NCT02139124|ACTIVE_COMPARATOR|PRC-063 45 mg|PRC-063 45 mg
62524435|NCT02139124|ACTIVE_COMPARATOR|PRC-063 70 mg|PRC-063 70 mg
62524436|NCT02139124|ACTIVE_COMPARATOR|PRC-063 100 mg|PRC-063 100 mg
62524437|NCT00186043|EXPERIMENTAL|Quetiapine/Seroquel|Quetiapine/Seroquel up to 800 mg/day
62524438|NCT00186043|PLACEBO_COMPARATOR|Placebo|Placebo
62524439|NCT01775865|EXPERIMENTAL|Salsalate|Salsalate capsule 1.5 g/day twice per day by mouth for 4 weeks
62524440|NCT01775865|PLACEBO_COMPARATOR|Placebo|Placebo capsule twice per day by mouth for 4 weeks
62524441|NCT01775865|NO_INTERVENTION|Young Control|No intervention; Baseline measurements only
62524442|NCT02494102|PLACEBO_COMPARATOR|Placebo|Administered Placebo day of surgery immediately prior to general anesthesia and surgery
62524443|NCT02494102|ACTIVE_COMPARATOR|Intervention|Administered Modafinil 200mg day of surgery prior to general anesthesia and surgery
62524444|NCT02925806||ER/LA opioids included in the class REMS|
62524445|NCT02925806||IR Opioids|
62524446|NCT02925806||Celecoxib|
62524447|NCT02925806||Benzodiazepines|
62524448|NCT03119974|OTHER|Tpo-RA discontinuation|
62524449|NCT03597360|EXPERIMENTAL|CT scan subjects|Three participants with severe Alzheimer's dementia will be studied
62524450|NCT01691820|EXPERIMENTAL|Group S+|Cytomegalovirus (CMV) seropositive subjects aged between 10-17 years at enrollment in the study.
62524451|NCT01691820|EXPERIMENTAL|Group S-|Cytomegalovirus (CMV) seronegative subjects aged between 10-17 years at enrollment in the study.
62712755|NCT05446714|ACTIVE_COMPARATOR|Maxillary skeletal expander|MSE 2 BANDS AND 4 for expansion of maxilla and observation improvement of the air way
62524452|NCT01691820|EXPERIMENTAL|Missing serostatus Group|Subjects with no confirmed serostatus, aged between 10-17 years at enrollment in the study.
62524453|NCT06332287|EXPERIMENTAL|Trilaciclib+Pemetrexed|Patients were treated with Trilaciclib (240mg/m2, administered within 4 hours before each chemotherapy,Q3W) and pemetrexed (30mg,Q3W) until disease progression as assessed by the investigator according to RECIST 1.1 criteria or withdrawal or discontinuation criteria were met.
62524454|NCT06197958|EXPERIMENTAL|eccentric exercises|Group A: Group A will receive 3 sets of eccentric exercises with 10 RM (repetition maximum) in six sessions.
62712756|NCT06089083||Newly diagnosed gynecologic cancer|Participants will undergo physical function assessments, complete surveys, and medical records every 3 months +/- 4 weeks prior to standard of care surgery (outside of this protocol). After surgery subjects will be followed for at least 3 months +/- 4 weeks for up to one year after diagnosis. Medical record reviews will occur periodically to examine for long-term follow up oncologic outcomes of progression free survival, overall survival, and chemotherapy delays for up to 10 years after enrollment.
62524455|NCT06197958|EXPERIMENTAL|concentric exercises|Group B: Group B will receive 3 sets of concentric exercises with 10 RM in six sessions
62524456|NCT00531349|ACTIVE_COMPARATOR|A|General anesthesia and opioid analgesia for the treatment of pain after surgery.
62524457|NCT00531349|ACTIVE_COMPARATOR|B|Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.
62524458|NCT02556372|EXPERIMENTAL|JKB-122|AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal
62524459|NCT02756026|EXPERIMENTAL|Micronutrient supplementation|"On day 3, all mothers are given a commercial multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).~On day 4, all mothers are given two commercial multiple micronutrient supplements (Nutri-Fem) manufactured by Thorne, containing twice the Recommended Dietary Intake (RDA)."
62712757|NCT00240877|EXPERIMENTAL|1|Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
62712758|NCT00240877|PLACEBO_COMPARATOR|2|Placebo
62712759|NCT02972996|EXPERIMENTAL|Blueberry|22 g freeze-dried blueberries
62712760|NCT02972996|PLACEBO_COMPARATOR|Placebo|22 g placebo
62524460|NCT03748849||Low back pain group|Males and females who have had low back pain lasting between 12 weeks - 5 years without any other health problems (physical or psychological). Following baseline measurements, all subjects are offered individualized physiotherapy. The interventions mainly consist of exercises targeting their functional limitations. These are supplemented by a thorough explanation of their pain condition. This is done within the boundaries of the current understanding of musculoskeletal pain. This is supplemented with encouragement to do regular exercise and with manual therapy if needed/indicated.
62524461|NCT03748849||Control group|"Healthy males and females who have no current musculoskeletal pain problem (specific to the low back and/or in general). Likewise, they cannot have a previous history of on-going musculoskeletal pain. On-going pain is defined as a condition that limited their function for 3 months or more.~Participants in the control group take part in the baseline measurement and then another measurement after 6-8 weeks"
62712761|NCT04843059|OTHER|the resident memory T-cell infiltrate in perilesional vitiligo skin|"To compare the resident memory T-cell infiltrate in perilesional vitiligo skin after 6 months of treatment with OMP and UVB, between three groups of patients suffering from non-segmental vitiligo, using flow cytometric analysis.~* First group will include patients with a long-lasting disease (more than 2 years) and no new or growing lesions for at least 2 years: Old vitiligo with Old lesions~* The second group will include patients with a long-lasting disease (more than 2 years) and with at least one new lesion developed in the last 6 months: Old vitiligo with new lesions~* The third one will include patients developing, for the first-time, vitiligo lesions with all the lesions no older than 6 months: New vitiligo"
62712762|NCT03248323||pre-con|
62712763|NCT01416025|EXPERIMENTAL|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
62152042|NCT04820088|NO_INTERVENTION|Contro Arm|Students randomized to the control group will be given an electronic copy of the Guidelines for Psychological Practice with Transgender and Gender Non-Conforming People (APA, 2015) and asked to take notes in the pdf document. The amount of time students spend on the document and note-taking will be recorded and notes will be analyzed for content. As an incentive, the participants in the control group will be given access to TTACS after they complete the post-intervention assessment.
62152043|NCT01372800||volunteer|
62152044|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp \>20mm
62152045|NCT02556697|EXPERIMENTAL|patients with a suspicion of emphysema|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of emphysema
62152046|NCT02556697|EXPERIMENTAL|patients with a suspicion of scleroderma|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of sclerodermia
62152047|NCT04401943|EXPERIMENTAL|Fatigue intervention|the Fatigue intervention is a 6 week intervention delivered using video teleconferencing
62152048|NCT02045914|NO_INTERVENTION|control group|the patients who have no intervention with calcium ionophore during ICSI cycle
62152049|NCT02045914|EXPERIMENTAL|calcium ionophore|the patients whose oocytes are incubated with calcium ionophore solution during ICSI cycle
62152050|NCT05962099||NAFLD|
62152051|NCT05962099||Controls (non-NAFLD)|
62152052|NCT00644501|EXPERIMENTAL|1|
62152053|NCT06505096||Orthokeratology group|-0.5D\~+0.0D
62152054|NCT06505096||myopia group|SE lens less than -0.5D
62152055|NCT06505096||hyperopia group|SE more than +0.5D
62152056|NCT01990183|EXPERIMENTAL|CareToy|CareToy intervention
62152057|NCT01990183|OTHER|Standard Care|Standard Care
62152058|NCT00603798|ACTIVE_COMPARATOR|3.75% imiquimod cream|
62152059|NCT00603798|ACTIVE_COMPARATOR|2.5% imiquimod cream|
62152060|NCT00603798|PLACEBO_COMPARATOR|Placebo cream|
62152061|NCT01231074|EXPERIMENTAL|Psychotropic/metformin (PIW)|"Inclusion Criteria:Psychotropic/metformin (PIW) Cohort: Children aged 10-17 years on psychotropic\* medication with reported weight gain defined by 1 of the following: 1. \>5% weight increase from the start of medication to 3 months on medication 2. Crossing into the 95th percentile for BMI 3. Crossing into the 85-95th percentile plus one obesity related complication~* The subject will have to be on one of these medications in addition to the criteria above to be eligible for the study: haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, fluphenazine, loxapine, mesoridazine, thiothixene or trifluoperazine"
62152062|NCT01231074|EXPERIMENTAL|Obese/metformin (OME)|Obese/metformin (OME) cohort: Children 10-17 years old with BMI \>95th percentile and fasting insulin level\>21.7U/L
62152063|NCT03137459|EXPERIMENTAL|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
62152064|NCT03137459|ACTIVE_COMPARATOR|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
62152065|NCT01633359|EXPERIMENTAL|Intensive statin|"1. Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~2. All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~3. the Intensive Atorvastatin protocol indicates that 80mg Atorvastatin will be administrated before CAG, and then are followed with 20mg Atorvastatin during the entire study period."
62152066|NCT01633359|EXPERIMENTAL|Routine statin|"1. Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~2. All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~3. the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period."
62152067|NCT03779945|ACTIVE_COMPARATOR|posteriolateral lumbar fusion +bone graft+ PRP|the addition of autologous platelet rich plasma to the bone graft
62152068|NCT03779945|ACTIVE_COMPARATOR|posteriolateral lumbar fusion+bone graft only|posteriolateral lumbar fusion with adding autologus bone graft alone posteriolateral lumbar fusion only
62152069|NCT01260259|EXPERIMENTAL|Remote Ischemic Preconditioning (RIPC)|
62152070|NCT01260259|SHAM_COMPARATOR|Control|
62152071|NCT06129188|EXPERIMENTAL|Remimazolam|2.5-5 mg IV remimazolam will be administered no more frequently than every 2 minutes for the duration of the TEE procedure.
62712764|NCT01416025|NO_INTERVENTION|Standard dosing|Standard doses of voriconazole will be used
62152072|NCT06129188|ACTIVE_COMPARATOR|Propofol|Standard-of-care IV propofol administration will be administered at the discretion of the anesthesia team caring for the patient for the duration of the TEE procedure
62152073|NCT03989609|EXPERIMENTAL|Dexmedetomidine Group|patients will receive dexmedetomidine as sedative
62152074|NCT03989609|ACTIVE_COMPARATOR|Midazolam|patients will receive midazolam as sedative
62152075|NCT00992745|EXPERIMENTAL|Previous ProstaScint®|Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
62524462|NCT06219993||RKPE group|"1. Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis by Da Vinci robot.~2. The Roux-en-Y jejunojejunostomy reconstruction was fashioned extracorporeally through the umbilical incision.~3. With Da Vinci robotic electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot.~4. Last, an end-to-side hepaticojejunostomy was conducted with one-layer continuous 5-0 PDS sutures posteriorly and anteriorly. A drainage tube was left under the liver, and the incision was closed."
62524463|NCT06219993||OKPE group|"1. The Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, cholangiography were observed to confirm the BA diagnosis by conventional open surgery.~2. The Roux-en-Y jejunojejunostomy reconstruction by hand-sewn anastomosis.~3. Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).~4. Last, an end-to-side hepaticojejunostomy was conducted with one-layer interrupt 5-0 PDS sutures posteriorly and anteriorly. A drainage tube was left under the liver, and the incision was closed."
62152076|NCT00992745|EXPERIMENTAL|No Previous ProstaScint®|Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
62152077|NCT01328756|EXPERIMENTAL|Lisdexamfetamine Dimesylate|
62524464|NCT02777957||mPAP ≥ 25 mmHg|mean pulmonary artery pressure (mPAP) ≥ 25 mmHg (37 patients)
62524465|NCT02777957||mPAP < 25 mmHg|mean pulmonary artery pressure (mPAP) \< 25 mmHg (28 patients).
62524466|NCT05876455|ACTIVE_COMPARATOR|Control group|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
62712765|NCT05244161|NO_INTERVENTION|Radio messaging (RM)|Radio messaging only (RM)
62712766|NCT05244161|ACTIVE_COMPARATOR|RM, Video job aids, Early Childhood Development program (RMV-ECD)|Radio messaging, short video job aids primarily for CHW use, and the UNICEF Care for Childhood Development program (RMV-ECD)
62712767|NCT03810976|EXPERIMENTAL|eribulin+gemcitabine|The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
62712768|NCT05298475|EXPERIMENTAL|Statin-only group|The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn).
62712769|NCT05298475|EXPERIMENTAL|Low-dose PCSK9 inhibitor group|The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn) and 1 injection of PCSK9 inhibitor once a month SC.
62152078|NCT05230394|EXPERIMENTAL|Level 1 In Lab Polysomnography|
62152079|NCT05230394|EXPERIMENTAL|Level 2 In Home Polysomnography|
62152080|NCT04221321|PLACEBO_COMPARATOR|Atorvastatin 40 mg|Oral administration of Atorvastatin 40 mg tablet once daily for 7 days
62712770|NCT05298475|EXPERIMENTAL|Normal-dose PCSK9 inhibitor group|The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn) and 1 injection of PCSK9 inhibitor twice a month SC.
62152081|NCT04221321|EXPERIMENTAL|Atorvastatin 40 mg + Tegoprazan 50 mg|Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days
62152082|NCT04221321|ACTIVE_COMPARATOR|Atorvastatin 40 mg + RAPA114|Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days
62152083|NCT02607956|EXPERIMENTAL|B/F/TAF|B/F/TAF + DTG + F/TAF placebo administered without regard to food for at least 144 weeks.
62152084|NCT02607956|ACTIVE_COMPARATOR|DTG + F/TAF|DTG + F/TAF+ B/F/TAF placebo administered without regard to food for at least 144 weeks.
62152085|NCT02607956|EXPERIMENTAL|Open-label Phase B/F/TAF from B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
62152086|NCT02607956|EXPERIMENTAL|Open-label Phase B/F/TAF from DTG + F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
62712771|NCT02261961|EXPERIMENTAL|Nutritional Supplement|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
62152087|NCT06160453|EXPERIMENTAL|Stroke with upper limb monoparesis or hemiparesis|Patients from Greece, 18 y.o. or older, suffering from chronic stroke and motor disability
62152088|NCT06160453|EXPERIMENTAL|Stroke with monoplegia or hemiplegia|Patients from Greece, 18 y.o. or older, suffering from chronic stroke and motor disability
62152089|NCT06160453|ACTIVE_COMPARATOR|Healthy Participants|Healthy participants, age and sex matched to the participants in the other arms
62152090|NCT04221165|ACTIVE_COMPARATOR|Opioid Analgesia|Opioids will be prescribed as per institutional standards. Examples of opioids are morphine and hydromorphone.
62152091|NCT04221165|EXPERIMENTAL|Multimodal Analgesia|Pregabalin (50 mg to 300 mg, oral, twice daily), acetaminophen (1000 mg, oral, 3 times per day), naproxen 250 mg to 500 mg, oral, twice daily), and pantoprazole magnesium (40 mg, oral, daily)
62152092|NCT03660527||6-17 year old|
62152093|NCT03660527||18-44 year old|
62524467|NCT05876455|ACTIVE_COMPARATOR|Test Group|Experimental sites designated to receive minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
62524468|NCT03055442||Follicular Fluids|Follicular fluids obtained by 8 oocyte donors
62524469|NCT00362479|EXPERIMENTAL|1|
62524470|NCT01195272|EXPERIMENTAL|Single Arm|
62152094|NCT03660527||45-59 year old|
62152095|NCT03660527||above 60 year old|
62524471|NCT02440568|EXPERIMENTAL|Cohort 1: Omacetaxine at Dose level at 0.625mg/m^2|Patients will receive Omacetaxine at Dose level 0.625mg/m\^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
62152096|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
62152097|NCT03301597|OTHER|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
62152098|NCT03301597|EXPERIMENTAL|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
62152099|NCT03301597|EXPERIMENTAL|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
62152100|NCT03301597|EXPERIMENTAL|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
62152101|NCT06462378|EXPERIMENTAL|Proton therapy|Proton therapy
62152102|NCT04769921||All-on-4 TiUltra and Xeal|Patients rehabilitated in the edentulous maxilla or mandible with an implant supported prosthesis through the All-on-4 Concept (2 anterior implants in the axial position and 2 posterior implants inserted with distal tilting). The implants used will be NobelParallel Conical Connection, with TiUltra surface. The abutments used will be Multi-unit abutments of internal connection with Xeal surface. The immediate prosthesis will be a high-density acrylic and 4 titanium cylinders. The definitive prosthesis will be a Titanium infrastructure with acrylic resin artificial gingiva and either acrylic or ceramic crowns.
62152103|NCT05773872|EXPERIMENTAL|NT1|type 1 narcolepsy
62152104|NCT05773872|EXPERIMENTAL|NT2|type 2 narcolepsy
62152105|NCT05773872|ACTIVE_COMPARATOR|HSI|idiopathic hypersomnia
62524472|NCT02440568|EXPERIMENTAL|Cohort 2: Omacetaxine at Dose level at 1.25mg/m^|Patients will receive Omacetaxine at Dose level 1.25mg/m\^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
62524473|NCT02440568|EXPERIMENTAL|Cohort 3: Omacetaxine at Dose level at 2.0mg/m^|Patients will receive Omacetaxine at Dose level 2.0mg/m\^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
62524474|NCT02440568|EXPERIMENTAL|Cohort 4: Omacetaxine at Dose level at 3.0mg/m^|Patients will receive Omacetaxine at Dose level 3.0mg/m\^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
62152106|NCT03958266||MyIBD Care - Study Group|Will have traditional face to face outpatient contacts replaced with a novel mobile phone application supported via a digital clinician portal
62152107|NCT06390176|PLACEBO_COMPARATOR|Control group|Placebo-containing tablets
62712772|NCT02261961|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
62524475|NCT02676362|EXPERIMENTAL|the first day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 5., 10., 30.
62524476|NCT02676362|EXPERIMENTAL|the 2nd day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 10., 30., 5.
62524477|NCT02676362|EXPERIMENTAL|the 3rd day|Gingival crevicular fluid collection with filter paper the length of sampling time in second: 30., 5., 10.
62712773|NCT06120322||Ulcerative Colitis (UC)|Patients will be enrolled in all the centers participating in this study: Ospedale San Raffaele - Milano, Ospedale Casa Sollievo della Sofferenza - Foggia and Azienda Ospedaliera San Camillo Forlanini - Roma as follows: 100 UC patients at OSR, 75 at San Camillo Hospital and 75 at CSS
62712774|NCT06120322||Diabetes Type 1 (T1D)|50 new onset T1D patients recruited and enrolled at OSR
62712775|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
62712776|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
62712777|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
62712778|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
62712779|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
62712780|NCT05829876|EXPERIMENTAL|HF-ECG guided LV pacing site optimisation|Participants will have the left ventricular pacing site programmed based on the results of HF-ECG mapping to locate the area of latest activation and best pattern of paced resynchronisation.
62712781|NCT05829876|ACTIVE_COMPARATOR|Q-LV guided LV pacing site optimisation|Participants will have the left ventricular pacing site programmed based on the results of Q-LV measurement to locate the area of latest activation. This is the standard of care method for pacing site optimisation.
62712782|NCT03735732||weight status|
62712783|NCT03735732||mindset|
62712784|NCT04031729|EXPERIMENTAL|Aspirin|Low-dose (81mg) aspirin tablets
62712785|NCT04031729|PLACEBO_COMPARATOR|Placebo|Placebo tablets
62712786|NCT04391920||COVID-19 ICU Patients|
62524478|NCT06414278||Observational|Patients complete SALSA assessment and ICE assessments on study. Patients also have their medical records reviewed on study.
62524479|NCT04436978|ACTIVE_COMPARATOR|First month DAPT|"30-day DAPT (aspirin + P2Y12 inhibitor). After 30 days all patients will be treated with edoxaban and P2Y12 inhibitor.~Selection of P2Y12 inhibitor is at the discretion of the treating physician, depending on both bleeding and ischemic risk. Dosage of aspirin and P2Y12 inhibitor is according to local guidelines.~NOAC of choice will be edoxaban. Patients will be treated with the recommended dose of 60mg once daily or the reduced dose of 30mg once daily."
62524480|NCT04436978|ACTIVE_COMPARATOR|Guideline-directed therapy|"Standard guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients). After 30 days all patients will be treated with edoxaban and P2Y12 inhibitor.~Selection of P2Y12 inhibitor is at the discretion of the treating physician, depending on both bleeding and ischemic risk. Dosage of aspirin and P2Y12 inhibitor is according to local guidelines.~NOAC of choice will be edoxaban. Patients will be treated with the recommended dose of 60mg once daily or the reduced dose of 30mg once daily."
62524481|NCT01258166||Tramuatic ulnar translocation|Patients who suffered a traumatic ulnar translocation following injury.
62712787|NCT00658268|EXPERIMENTAL|1|
62712788|NCT00658268|PLACEBO_COMPARATOR|2|
62152108|NCT06390176|EXPERIMENTAL|Experimental group|Lactobacillus rhamnosus GG (LGG)
62152109|NCT06134232|EXPERIMENTAL|Booster Arm|"Experimental: Treatment Group: Single Infusion of Sipuleucel-T (Booster) Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion.~Subjects randomized to sipuleucel-T arm will receive 1 infusion of sipuleucel-T 6-9 months after receiving commercial Provenge. These subjects will be followed as described in the schedule of events."
62524482|NCT05438407|EXPERIMENTAL|Leniolisib|Leniolisib - Film Coated Tablets Leniolisib tablets in 10 and 30 mg strengths administered orally BID by body weight for 12 weeks for Part I and for 1 year for Part II.
62524483|NCT02245061|EXPERIMENTAL|paired pulses cortical electrical stimulation|
62524484|NCT02806258|ACTIVE_COMPARATOR|Arm A|6-8 cycles of Primary systemic therapy using anthracycline and/or taxane based regimens, according to their physician's preference and center policy
62524485|NCT02806258|EXPERIMENTAL|Arm B|The patients will receive 3D conformal or other modality (eg IMRT, VMAT) APBI during their PST sequence. APBI will be planned sequentially between the Primary systemic therapy cycles, 2 weeks after the 3rd/6 or the 4th/8 cycle of PST.
62524486|NCT01087671|OTHER|Open-lable study with one arm|
62524487|NCT04597294|EXPERIMENTAL|Perioperative FLOT + prophylactic HIPEC + surgery|After 4 doses of preoperative FLOT chemotherapy diagnostic laparoscopy will be performed - patients without distant metastases will be randomised, in those randomised to experimental arm HIPEC with irinotecan will be performed (a dose of 300 mg/m2 body surface area will be administered over 45 minutes at a temperature of 42 degrees Celsius)
62712789|NCT00823173|EXPERIMENTAL|Topical ESBA105|ESBA105 applied as eye drops
62712790|NCT05795907|EXPERIMENTAL|SAR443820|Single dose oral ascending dose (parts 1a and 1b) and multiple ascending oral dose (part 2) of SAR443820
62712791|NCT05795907|PLACEBO_COMPARATOR|Placebo|Single dose oral ascending dose (part 1a) and multiple ascending oral dose (part 2) of matching placebo
62712792|NCT01246960|EXPERIMENTAL|Ramucirumab|"* Oxaliplatin 85 milligrams per square meter (mg/m\^2) given on Day 1 of a 2-week cycle~* Leucovorin 400 mg/m\^2 given on Day 1 of a 2-week cycle~* 5-Fluorouracil (5-FU) 400 mg/m\^2 bolus given on Day 1 of a 2-week cycle~* 5-FU 2400 mg/m\^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~* Ramucirumab 8 milligrams per kilogram (mg/kg) given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
62712793|NCT01246960|PLACEBO_COMPARATOR|Placebo|"* Oxaliplatin 85 mg/m\^2 given on Day 1 of a 2-week cycle~* Leucovorin 400 mg/m\^2 given on Day 1 of a 2-week cycle~* 5-FU 400 mg/m\^2 bolus given on Day 1 of a 2-week cycle~* 5-FU 2400 mg/m\^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~* Placebo given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
62712794|NCT06351618||Elite female ice hockey players in Sweden|
62712795|NCT01855893|EXPERIMENTAL|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
62712796|NCT01855893|OTHER|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
62524488|NCT04597294|ACTIVE_COMPARATOR|Perioperative FLOT + surgery|Standard treatment regimen for advanced gastric cancer
62524489|NCT01311349||1|A listing of all isolates meeting the inclusion criteria will be maintained.
62712797|NCT01877174||MICHI(TM) NPS+f|Patients routinely treated with the CE marked MICHI(TM) NPS+f System
62712798|NCT05969951||New scoring mode group|Patients were evaluated for VTE risk in the perioperative period using a new scoring system
62712799|NCT05969951||Caprini group|Patients were evaluated for VTE risk in the perioperative period using Caprini scoring system
62712800|NCT01378143|EXPERIMENTAL|OCZ103-OS, mFOLFOX6 or FOLFIRI|OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
62712801|NCT05597176|EXPERIMENTAL|Spinal Cord Injury Exercise Group|Participants will exercise at home 3-5 times per week under supervision via teleconference. Participants will be part of this group for 18-20 weeks.
62524490|NCT06242002|EXPERIMENTAL|Experimental group|"For patients participating to the clinical trial, the sensor will be positioned at the end of the procedure, under the surgical dressing, at ankle level.~This dressing is a definitive dressing which is only removed during the post-operative consultation on day 8, during which the sensor will be removed.~During this 7 days, data from the sensor will be collected every 4 hours."
62712802|NCT05407701|EXPERIMENTAL|Cranberry|100% juice active: water, cranberry juice concentrate.
62524491|NCT03760614|EXPERIMENTAL|Entinostat + FOLFOX|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. Entinostat dose will vary between 2mg and 5mg depending on time of enrollment and observed toxicities. Dosing will begin at 3mg.
62524492|NCT03732261|EXPERIMENTAL|Intervention|Intervention Group: Women randomized to the intervention group will be given a 3month membership to a community based exercise program, a pedometer and individual dietary recommendations. They will be asked to attend a minimum of three 45 minute to 60 minute exercise sessions per week but no more than five and will gradually build to walk 10,000 steps per day. Childcare and breastfeeding support will be provided. Trained research assistants will lead all group sessions. Weekly workout volume will be calculated and weekly steps will be monitored by research assistants. For the dietary intervention, the women will be provided 6oz of plain yogurt fortified with vitamin D post workout for the 12-week intervention. If any yogurt is out of date (expired), we will dispose of the expired yogurt. Weekly monitoring for the consumption of the yogurt and energy intake will be conducted by face-to-face or telephone interviews by research assistants.
62712803|NCT05407701|PLACEBO_COMPARATOR|Placebo|100% juice placebo: water, fructose, dextrose, citric acid, malic acid, natural flavors, pectin, cherry colorant, sucralose.
62712804|NCT05217173|EXPERIMENTAL|Intervention group|"Rehabilitation service that will be provided remotely through information and communication technologies. It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks.~The content of the rehabilitation program will consist of e modules: 1) Information module on the disease and self-care, 2) Exercise module (Stretching, strengthening and proprioception)."
62712805|NCT05217173|NO_INTERVENTION|Control group|Care service that is carried out by the Family Physician. The medical care that the patient with an ankle sprain will carry out with the Family Physician of the assigned office; Medical care will consist of the approach that the Doctor considers appropriate for the patient. The follow-up and time of disability will be the responsibility of the Physician in question
62712806|NCT06484075|NO_INTERVENTION|Non treatment|Healthy Volunteers will receive two PET scans and one MRI session without any treatment.
62712807|NCT06484075|PLACEBO_COMPARATOR|Placebo|AUD subjects randomized to receive placebo for up to 4 weeks during inpatient treatment.
62712808|NCT06484075|ACTIVE_COMPARATOR|Suvorexant|AUD subjects randomized to receive Suvorexant (20 mg po) for up to 4 weeks during inpatient treatment.
62712809|NCT03023345|EXPERIMENTAL|Microwave|Microwave trans rectal focal treatment
62712810|NCT03763747|EXPERIMENTAL|Scoreflex NC Scoring PTCA Catheter|Single arm with investigational Scoreflex NC Scoring PTCA catheters
62712811|NCT06185452|ACTIVE_COMPARATOR|Hospital Group|Administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg in the hospital (standard of care)
62712812|NCT06185452|EXPERIMENTAL|Outpatient Group|Out-of-hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long -acting Rekambys (rilpivirine) 900 mg
62712813|NCT00852111||Patients|Prostate cancer patients
62524493|NCT03732261|NO_INTERVENTION|Control|Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
62524494|NCT05723679|EXPERIMENTAL|HeO2 gas mixture, then Room air gas mixture|Participant will be randomized to each intervention on separate days (Study visit 3 and 4) in this cross-over trial. Participants that receive HeO2 first will then receive the room air gas mixture. At least 24 hours will separate each visit.
62524495|NCT05723679|EXPERIMENTAL|Room air gas mixture, then HeO2 gas mixture|Participant will be randomized to each intervention on separate days (Study visit 3 and 4) in this cross-over trial. Participants that receive Room air first will then receive the HeO2 mixture. At least 24 hours will separate each visit.
62524496|NCT00173537|OTHER|other|
62524497|NCT03036241|EXPERIMENTAL|Drug-eluting balloon|
62524498|NCT03036241|ACTIVE_COMPARATOR|Conventional angioplasty|
62524499|NCT03898830|EXPERIMENTAL|eon™ FR 1064 nm device|Patient will be treated with the eon™ FR 1064 nm device
62152110|NCT06134232|NO_INTERVENTION|No Booster|No Intervention: Control Arm Subjects randomized to the control arm after receiving commercial Provenge will be followed as described in the schedule of events.
62712814|NCT01892566|NO_INTERVENTION|Usual care for COPD|Usual care for AECOPD in the JHHCC consists of patient-initiated contact with the clinic for change in respiratory symptoms. Participants will be asked to complete a weekly symptom diary assessment which will be returned to the study staff at every 3-month visits. Participants contacting research staff with a worsening in respiratory symptoms will be referred to their assigned clinical providers.
62152111|NCT01189045|EXPERIMENTAL|Aerobic Program|The Aerobic Program will be the Experimental arm of this trial, where a structured, progressive aerobic exercise will be conducted in a class format
62524500|NCT01507974|NO_INTERVENTION|control arm|The women in this arm will not receive preventive antibiotic treatment after delivery
62524501|NCT01507974|ACTIVE_COMPARATOR|preventive antibiotic treatment|The women in this arm will receive preventive antibiotic treatment after the delivery to 6 weeks
62524502|NCT04746911|EXPERIMENTAL|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
62524503|NCT04002505|EXPERIMENTAL|Head Injury Subject|Subjects that present to the Emergency Department with a blunt head injury within the past 24 hours, determined to be low risk by the Canadian CT Head Rules (CCHR), and are being considered for a head CT by the treating provider will use the shared decision making tool Concussion and Brain Bleed app (CBC) with their clinician
62524504|NCT01411865|EXPERIMENTAL|Intervention|
62524505|NCT01411865|OTHER|Control|
62524506|NCT02214784|ACTIVE_COMPARATOR|Active Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30minutes over 12 weeks.
62152112|NCT01189045|ACTIVE_COMPARATOR|Balance and Flexibility Program|The Balance and Flexibility Program will be a non-aerobic intervention that will act as an Active Comparator. Stretching, balance exercises, yoga- or Tai Chi-style classes will be conducted.
62524507|NCT02214784|PLACEBO_COMPARATOR|Modified Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30 minutes over 12 weeks.
62524508|NCT01244061|EXPERIMENTAL|Varenicline|
62524509|NCT01244061|PLACEBO_COMPARATOR|Placebo|
62524510|NCT04134923||[11C] Pittsburgh Compound-B (PIB)|Using \[11C\] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.
62524511|NCT01586403|EXPERIMENTAL|Dose 1|Subjects in cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight
62152113|NCT05244954|EXPERIMENTAL|Intermittent Screening and Treatment (IST)|Students will be screened for infection using a higher sensitivity malaria rapid diagnostic test and treated if positive. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
62152114|NCT05244954|EXPERIMENTAL|Intermittent Preventive Treatment (IPT)|All students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
62152115|NCT05244954|NO_INTERVENTION|Control|Students will not receive preventive treatment.
62524512|NCT01586403|EXPERIMENTAL|Dose 2|cohort 2 will receive 7.5 x 106 TIL 1383I TCR transduced T cells per kg body weight.
62524513|NCT01586403|EXPERIMENTAL|Dose 3|Subjects in cohort 3 will receive 2.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
62524514|NCT01586403|EXPERIMENTAL|Dose 4|Subjects will then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
62524515|NCT00545207|EXPERIMENTAL|1|
62524516|NCT00545207|PLACEBO_COMPARATOR|2|
62524517|NCT05227612|EXPERIMENTAL|Psilocybin + CBT|All participants will receive 12 sessions of cognitive-behavioral therapy (CBT) along with two psilocybin-drug sessions -- the first following the third CBT session (10mg of psilocybin, taken orally) and the second following the sixth CBT session (25mg of psilocybin, taken orally).
62524518|NCT01587937|EXPERIMENTAL|Antibiotic stewardship intervention|Audit-and-feedback intervention to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antimicrobial
62152116|NCT04316494|EXPERIMENTAL|Hydroxychloroquine|"Patients will be receive 400mg of Hydroxychloroquine (2 x 200mg) to take daily for 52 weeks. Hydroxychloroquine will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing \<50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
62524519|NCT01587937|NO_INTERVENTION|Control|The pre-intervention period will serve as the control period on each medical and surgical service. The cross-over is uni-directional from control to intervention; all services receive the intervention by the end of the study. This is a stepped wedge design. The order of roll-out is randomized.
62712815|NCT01892566|EXPERIMENTAL|mHealth Intervention|For the mHealth intervention, investigators will use of the eResearch Technology, Inc system (ERT®; Philadelphia, PA) for home-based monitoring of spirometry and respiratory symptoms. In conjunction, wireless sensor-based inhalers will monitor the frequency of rescue inhaler use (Asthmapolis®; Madison, WI). As well, on a daily basis, participants in the early identification group will complete eight respiratory symptom questions from the COPD Assessment Test (CAT). Participants' short acting beta-agonist inhaler use will be monitored by an Asthmapolis Spiroscout Inhaler Tracker. Based on participant responses, flags or electronic notifications can be generated. Based on severity of symptoms and guidelines for recommended care, participants will be instructed to self-manage by optimizing inhaler use (if symptoms are mild) or present for an acute care visit at JHHCC if necessary.
62712816|NCT02226302||Female Group 2|Females with BMI \>30 kg/m2 who are having a hysterectomy for benign conditions
62712817|NCT02226302||Females Group 1|Females with BMI \<30 kg/m2 who are having a hysterectomy for benign conditions
62712818|NCT02226302||Males|2 males with BMI \<30 kg/m2 and 2 males with BMI \>30 kg/m2
62152117|NCT04316494|PLACEBO_COMPARATOR|Placebo|"Patients will be receive 400mg of Placebo (2 x 200mg) to take daily for 52 weeks. Placebo will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing \<50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
62152118|NCT03874091|ACTIVE_COMPARATOR|GA group|Patients will receive general anaesthesia for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
62152119|NCT03874091|EXPERIMENTAL|ESP group|Patients will receive general anaesthesia with bilateral ESP block for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
62152120|NCT03757767|EXPERIMENTAL|Intervention arm|Fasting for 26-hours.
62152121|NCT01821040|EXPERIMENTAL|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
62152122|NCT01821040|ACTIVE_COMPARATOR|Prednisone IR|Prednisone IR 15mg daily start dose (immediate release) administered in the morning
62152123|NCT06210555||Living kidney donors|Living kidney donors
62152124|NCT06210555||Transplant recipients|Recipients of kidneys from living donors
62152125|NCT06210555||Healthy controls|Age- and sex matched healthy controls (Living kidney donors)
62152126|NCT00873626|ACTIVE_COMPARATOR|1|fluoroquinolones 5 days
62152127|NCT00873626|ACTIVE_COMPARATOR|2|fluoroquinolones 10 days
62712819|NCT04781582|ACTIVE_COMPARATOR|Lung volume reduction surgery arm|Bilateral videothoracoscopic lung volume reduction surgery by wedge resection. Unilateral procedures are possible in case of severe adhesions or intraoperative instability. In these cases a staged approach with contralateral LVRS within 3 months is possible.
62712820|NCT04781582|ACTIVE_COMPARATOR|Bronchoscopic lung volume reduction arm|Primarily unilateral bronchoscopic lung volume reduction by endobronchial valves. If a bilateral procedure is feasible it must be performed within 3 months after the first intervention.
62712821|NCT00651222||1|All deceased patients who underwent brachytherapy at Chicago Prostate Center between 10/14/1997 and 6/15/2007
62712822|NCT04043286|NO_INTERVENTION|Control group|Split mouth: Healing abutments are connected on the implants on the day of surgery, which will be subjected to multiple disconnection and reconnection during the study
62712823|NCT04043286|EXPERIMENTAL|Test group|Split mouth: Definitive abutments connected to the implants on the day of surgery. No disconnection or reconnection during the prosthetic phase
62712824|NCT03954431||Dedicated breast computed tomography (BCT)|All subjects will undergo bilateral breast CT (BCT) imaging exam.
62712825|NCT06482567|EXPERIMENTAL|iCOVER|Individuals randomized to the iCOVER arm will be approached by a trained RA who will obtain assent and perform the iCOVER intervention. After completing the iCOVER protocol, the unblinded RA will leave, and a blinded outcome assessor will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
62152128|NCT01724905|EXPERIMENTAL|Modified Stop Light Diet|
62152129|NCT01724905|ACTIVE_COMPARATOR|Recommended Care for Weight Reduction|
62152130|NCT01644604|EXPERIMENTAL|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
62152131|NCT01644604|NO_INTERVENTION|Control Group|Subjects are maintained on baseline anti-hypertensive medications
62152132|NCT04501588|EXPERIMENTAL|Parent Learning Style 1|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
62152133|NCT04501588|EXPERIMENTAL|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
62152134|NCT04501588|ACTIVE_COMPARATOR|Learning Style 1 (Parent)|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
62152135|NCT04501588|ACTIVE_COMPARATOR|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
62152136|NCT01542502|EXPERIMENTAL|Anakinra|Treatment with daily subcutaneous injections of Anakinra 100 mg
62152137|NCT01542502|PLACEBO_COMPARATOR|Placebo|Treatment with daily subcutaneous injection of placebo
62712826|NCT06482567|ACTIVE_COMPARATOR|Physical Presence with Reassurance|A research assistant (RA) will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
62524520|NCT03439852|EXPERIMENTAL|Light to Moderate Physical Activity/Sedentary behavior|The telephone counseling plus group cohesion intervention is designed to increase Light-to-Moderate intensity physical activity (LMPA) and reduce Sedentary time (ST). The 12-wk intervention includes group discussions during 3 regular monthly club meetings when clubs' accumulated milestones for LMPA/ST min/wk will be identified and future cumulative club goals for PA/ST set. In addition, each member will receive 12 weekly personalized phone calls from health coaches who will use motivational interviewing to set individualized LMPA/ST goals setting, reduce barriers, and facilitate social support for LMPA/ST change.
62524521|NCT03439852|NO_INTERVENTION|Delayed Treatment/Healthy Aging|Delayed Treatment (DT) / Healthy Aging materials Condition is for 12 weeks and participants receive 12 phone calls using a previously developed contact-matched protocol that uses mailed healthy aging information and telephone calls to assess symptom ratings. After the initial 12 weeks they then receive the LMPA/ST intervention
62152138|NCT02107976|EXPERIMENTAL|Stage 1|Inpatient admission to NIH CC, consisting of euglycemic period with serial blood and urine sampling followed by hyperglycemic period (induced with high-carbohydrate diet; diabetic subjects only) with serial blood and urine sampling.
62524522|NCT00231257|EXPERIMENTAL|1|Cypher Bx Velocity
62152139|NCT02107976|EXPERIMENTAL|Stage 2|Inpatient admission to NIH CC after at least 8 weeks of vitamin C and vitamin E supplementation. Testing periods include: euglycemic period with serial blood and urine sampling followed by hyperglycemic period (induced with high-carbohydrate diet; diabetic subjects only) with serial blood and urine sampling.
61975630|NCT03643640|EXPERIMENTAL|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
62152140|NCT04299009|EXPERIMENTAL|Retimer bright light therapy glasses|active bright light therapy in the green/blue spectrum range
62152141|NCT04299009|SHAM_COMPARATOR|sham-Retimer bright light therapy glasses|bright light therapy with light in the red spectrum (not active)
62152142|NCT03841253|EXPERIMENTAL|Observation Phase|A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
62152143|NCT03841253|EXPERIMENTAL|Treatment Phase|If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.
62152144|NCT04543188|EXPERIMENTAL|PF-07284890 (Part A monotherapy)|Monotherapy dose escalation of PF-07284890
62152145|NCT04543188|EXPERIMENTAL|PF-07284890+binimetinib (Part A combo-therapy)|Combination dose escalation of PF-07284890 + binimetinib
62152146|NCT04543188|EXPERIMENTAL|Expansion Phase (Part B, Cohort 1)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
62152147|NCT04543188|EXPERIMENTAL|Expansion Phase (Part B, Cohort 2)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
62152148|NCT04543188|EXPERIMENTAL|Expansion Phase (Part B, Cohort 3)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with asymptomatic brain involvement, and prior BRAF inhibitor utilization
62152149|NCT04543188|EXPERIMENTAL|Expansion Phase (Part B, Cohort 4)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with symptomatic brain involvement, and prior BRAF inhibitor utilization
62152150|NCT04543188|EXPERIMENTAL|Expansion Phase (Part B Cohort 5)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors
62152151|NCT04543188|EXPERIMENTAL|Expansion Phase Drug-Drug Interaction Substudy (Part B Optional Cohort 6)|PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor
62152152|NCT04543188|EXPERIMENTAL|Expansion Phase (Part B Optional Cohort 7)|PF-07284890 (at the recommended dose for expansion when administered with food) plus binimetinib in participants with BRAF V600 solid tumor
62524523|NCT00231257|ACTIVE_COMPARATOR|2|Brachytherapy
62524524|NCT02273336||Ancillary-Correlative (comprehensive genomic analysis)|Tissue and blood samples are analyzed via next generation sequencing and whole exome sequencing.
62524525|NCT02802618|EXPERIMENTAL|Interactive 3D visualization technique|"The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with 3D technique.~Patients randomized into education by 3D technique."
62524526|NCT02802618|NO_INTERVENTION|Conventional technique|The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with conventional technique. Patients randomized into education by conventional technique.
62524527|NCT01179126|EXPERIMENTAL|complete multivessel revascularization|
62524528|NCT01179126|ACTIVE_COMPARATOR|stress echo guided revascularization|
62524529|NCT02575976|EXPERIMENTAL|comprehensive CR|education and exercise-based cardiac rehabilitation
62524530|NCT02575976|ACTIVE_COMPARATOR|exercise-based CR|Exercise-based cardiac rehabilitation
62524531|NCT02575976|OTHER|wait list control|no cardiac rehabilitation
62524532|NCT01679106|PLACEBO_COMPARATOR|Fentanyl IV PCA and placebo TAP catheter|Patients will receive Fentanyl IV PCA and placebo TAP catheter.
62524533|NCT01679106|ACTIVE_COMPARATOR|TAP catheter with continuous infusion of Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.
62152153|NCT01945086|EXPERIMENTAL|Ustekinumab 45 mg|
62524534|NCT02823860|OTHER|Biospecimens and Quality of Life (QoL)|Only if patient's consent is obtained, biospecimens, including tumor and/or peripheral blood are collected.
62524535|NCT00741936|EXPERIMENTAL|MaZiRenWan (MZRW)|MZRW granule, 7.5g/sachet
62524536|NCT00741936|PLACEBO_COMPARATOR|Placebo|Placebo granule, 7.5g/sachet
62524537|NCT00229736|EXPERIMENTAL|AAV-hAADC-2 (9x10^10 vector genomes)|
62524538|NCT00229736|EXPERIMENTAL|AAV-hAADC-2 (3x10^11 vector genomes)|
62524539|NCT02804230|EXPERIMENTAL|Exablate Neuro System Treatment|MR-Guided Focused Ultrasound will be used to ablate epileptic foci up to 8 cm3 in size.
62524540|NCT01509742|EXPERIMENTAL|NNC 90-1170|
62524541|NCT01509742|PLACEBO_COMPARATOR|Placebo|
62524542|NCT01508754|ACTIVE_COMPARATOR|CPAP|Treatment with Continuous Positive Airway Pressure
62524543|NCT01508754|NO_INTERVENTION|Control|Usual anti-hypertensive treatment without CPAP treatment
62524544|NCT04601298||AUS|
62524545|NCT04601298||FLUS|
62524546|NCT03340870|EXPERIMENTAL|Sonazoid™ 0.12 microliter (µl)|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight.
62152154|NCT01945086|EXPERIMENTAL|Ustekinumab 90 mg|
62152155|NCT01945086|PLACEBO_COMPARATOR|Placebo|
62152156|NCT03746015|EXPERIMENTAL|TDV: Flavivirus-naïve|Tetravalent Dengue Vaccine (TDV) 0.5 mL, subcutaneous (SC) injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
62152157|NCT03746015|EXPERIMENTAL|TDV: DENV Immune: DENV-1 Positive|"TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).~Participants with serology consistent with primary infection by wild type dengue virus serotype-1 (DENV-1) were included in this group."
62152158|NCT03746015|EXPERIMENTAL|TDV: DENV Immune: DENV-3 Positive|"TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).~Participants with serology consistent with primary infection by DENV-3 were included in this group."
62152159|NCT03345407|PLACEBO_COMPARATOR|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
62152160|NCT03345407|EXPERIMENTAL|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
62152161|NCT03345407|EXPERIMENTAL|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
62524547|NCT03340870|EXPERIMENTAL|Sonazoid™ 0.60 µl|Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight.
62524548|NCT02273687|EXPERIMENTAL|Prognostic study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Intervention: Diaphragmatic ultrasound"
62524549|NCT02251873|EXPERIMENTAL|TPV + RTV (low dose)+ ddI|
62524550|NCT02251873|EXPERIMENTAL|TPV+ RTV (high dose)+ ddI|
62152162|NCT03345407|EXPERIMENTAL|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
62152163|NCT03345407|EXPERIMENTAL|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
62524551|NCT02123212|EXPERIMENTAL|Mt. Sinai|Cluster randomization with EHR Alert intervention
62524552|NCT02123212|EXPERIMENTAL|Henry Ford Health System|Simple randomization with mailer intervention
62524553|NCT02123212|EXPERIMENTAL|University of Alabama, Birmingham|Crossover randomization with in-person recruitment intervention
62524554|NCT05055895||early onset deliryum on dementia|It was earlier than The median time of onset of delirium superimposed dementia
62524555|NCT05055895||Delirium on dementia (normal)|It was equal or later than The median time of onset of delirium superimposed dementia
62524556|NCT03146182|NO_INTERVENTION|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
62524557|NCT03146182|EXPERIMENTAL|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
62524558|NCT03146182|EXPERIMENTAL|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
62524559|NCT01272362|EXPERIMENTAL|Indacaterol|
62524560|NCT03893474|OTHER|Control Arm|All investigations are the same in both arms, but patients within this arm will be seen in the hospital as per standard practice.
62524561|NCT03893474|OTHER|Study Arm|All investigations are the same in both arms, but patients within this arm will be seen in a community optometrist practice.
62524562|NCT00914459|OTHER|Moroctocog alfa (AF-CC)|Open Label
62712827|NCT06482567|NO_INTERVENTION|Usual Care|Individuals randomized to usual care will not be approached by research staff until the immediate post-intervention assessment timepoint, at which point a blinded member of the research team will begin the immediate post-intervention assessment.
62712828|NCT03168139|EXPERIMENTAL|Olaptesed pegol + Pembrolizumab|
62524563|NCT03173053|ACTIVE_COMPARATOR|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
62712829|NCT01893710||Control|'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.
62524564|NCT03173053|ACTIVE_COMPARATOR|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
62524565|NCT04631523||IGD Group|The eligibility criteria were for IGD group as follows: being male in age between 10-18 years old; having accepted the research on a voluntary basis and signed the informed consent and being diagnosed with IGD according to DSM-5. Healthy adolescents in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
62524566|NCT04631523||Healthy Group|The eligibility criteria were for healthy group as follows: being male in age between 10-18 years old and having accepted the research on a voluntary basis and signed the informed consent. The adolescents with IGD in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
62524567|NCT05104463|EXPERIMENTAL|CST-2032 (3mg)/CST-107 (3mg) to Placebo|Subjects will receive daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.
62524568|NCT05104463|EXPERIMENTAL|Placebo to CST-2032 (3mg)/CST-107 (3mg)|Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days.
62524569|NCT05104463|EXPERIMENTAL|CST-2032 (6mg)/CST-107 (3mg) to Placebo|Subjects will receive daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.
62524570|NCT05104463|EXPERIMENTAL|Placebo to CST-2032 (6mg)/CST-107 (3mg)|Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days.
62524571|NCT05717855|OTHER|Screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia
62524572|NCT02302859|EXPERIMENTAL|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.~Participants complete saliva cotinine test 3 months after intervention."
62712830|NCT01893710||chronic kidney disease|Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)
62712831|NCT01893710||Peritoneal dialysis|Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.
62712832|NCT01893710||Post PD and with functioning graft|Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.
62712833|NCT02345733|EXPERIMENTAL|Ulcerative Colitis Diet|Patients will receive a structured novel diet termed the UCD for 6 weeks, and those in remission at week 6 will receive the step down diet for another 6 weeks.
62712834|NCT02345733|EXPERIMENTAL|Antibiotic Treatment|This antibiotic treatment will be given as an open label for patients who refuse diet therapy or for patients who show no improvement by week 3 , deteriorate by week 6, or patients who are not in full remission by week 6 will receive a 14 day course of antibiotics as previously described by Kato and colleagues.
62712835|NCT01816295|PLACEBO_COMPARATOR|Placebo Solution|Placebo Solution applied topically once daily for 12 weeks.
62712836|NCT01816295|EXPERIMENTAL|Testosterone Solution|Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.
62712837|NCT05949879|EXPERIMENTAL|Pecan LOW|Participants are given pecans and instructed on how to substitute study foods into their diet to maintain caloric balance.
62712838|NCT05949879|EXPERIMENTAL|Pecan MID|Participants are given pecans and instructed on how to substitute study foods into their diet to maintain caloric balance.
62712839|NCT05949879|EXPERIMENTAL|Pecan HIGH|Participants are given pecans and instructed on how to substitute study foods into their diet to maintain caloric balance.
62712840|NCT05949879|EXPERIMENTAL|CONTROL|Participants are asked to maintain their current habitual diet and avoid any tree nut/peanut consumption for the entire 28-day intervention period.
62712841|NCT05818644||Conservative treatment|
61975631|NCT03643640|ACTIVE_COMPARATOR|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
61975632|NCT03140384|ACTIVE_COMPARATOR|Administration of oral Misoprostol|
62524573|NCT02302859|EXPERIMENTAL|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.~Participants complete saliva cotinine test 3 months after intervention."
62524574|NCT01959035|EXPERIMENTAL|Aripiprazole once-monthly|
62524575|NCT01599130|ACTIVE_COMPARATOR|entecavir|patients continue to use entecavir
62524576|NCT01599130|EXPERIMENTAL|peg-interferon|patients switch to sequential peg-interferon α-2a
62524577|NCT02479373|EXPERIMENTAL|Resistance Exercise (RE)|Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
62524578|NCT02479373|OTHER|Control Group (CG)|Those assigned to the CG will complete baseline and post-testing assessments and will also be given JIA educational materials, including physical activity and exercise recommendations from the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness (COSMF).
62524579|NCT03187366|NO_INTERVENTION|Status quo|Status quo pesticide use
62524580|NCT03187366|ACTIVE_COMPARATOR|Low risk|Villages shifted to low risk pesticides that don't kill prawns
62524581|NCT03187366|EXPERIMENTAL|No agrochemicals|Villages that eliminate agrochemicals
62524582|NCT04461119|EXPERIMENTAL|Evenamide 7.5 mg bid|Evenamide capsules 7.5 mg BID for a total of 28 dosing days
62524583|NCT04461119|EXPERIMENTAL|Evenamide 15 mg bid|Evenamide capsules 15.0 mg BID for a total of 28 dosing days
62524584|NCT04461119|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules BID for a total of 28 dosing days
62524585|NCT00759239|EXPERIMENTAL|1|One drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 am and 1 drop of Timolol vehicle as placebo in each eye at 9 pm for 12 weeks.
62524586|NCT00759239|EXPERIMENTAL|2|One drop of Timolol vehicle as placebo in each eye at 9 am and one drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 pm for 12 weeks.
62712842|NCT05818644||Surgical revascularization|
62712843|NCT05818644||Endovascular revascularization|
62712844|NCT05818644||Re-transplantation|
62712845|NCT04358406|PLACEBO_COMPARATOR|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
62712846|NCT04358406|ACTIVE_COMPARATOR|Rhu-pGSN|Recombinant human plasma gelsolin reconstituted for slow bolus injection.
62712847|NCT03223753|ACTIVE_COMPARATOR|Arm I (tracking device, limited version of device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the limited version of device app/website to get basic information related to their physical activity for 6 months.
62712848|NCT03223753|EXPERIMENTAL|Arm II (tracking device, interactive-reward based device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the full version of the interactive-reward based device app/website to see their activity, earn activity points, see other's activity, and interact with other patients for 6 months.
62712849|NCT06486909||aSAH Patients|Patients with an acute ruptured intracranial aneurysm.
61975633|NCT03140384|ACTIVE_COMPARATOR|Administration of Misoprostol vaginally|
61975634|NCT03140384|ACTIVE_COMPARATOR|Administration of buccal Misoprostol|
61975635|NCT03362398|ACTIVE_COMPARATOR|Omarigliptin|Drug: Omarigliptin 25 mg
61975636|NCT03362398|ACTIVE_COMPARATOR|Trelagliptin|Drug: Trelagliptin 100 mg
61975637|NCT00421538|ACTIVE_COMPARATOR|LMWH|Therapeutic dose of Nadroparin
61975638|NCT00421538|PLACEBO_COMPARATOR|Placebo|Injectable placebo
62524587|NCT00856973|EXPERIMENTAL|Low dose eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
62524588|NCT00856973|EXPERIMENTAL|High dose eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
62524589|NCT00856973|PLACEBO_COMPARATOR|Placebo|Placebo 6-17 years
62524590|NCT02838511||Non-cardiac surgery|Hopkins Frailty Score (HFS) or Modified Frailty Index (MFI) will be obtained during during pre anesthesia evaluation
62524591|NCT03261765||Multiple repeat cesarean (four or more)|
62524592|NCT03261765||Fewer repeat cesarean (two-three)|
62524593|NCT03490448|OTHER|intervention group|aerobic exercise and appropriate caloric control
62524594|NCT02635217|EXPERIMENTAL|Group A1|EGD performed before the Colonoscopy with Carbon Dioxide insufflation.
62524595|NCT02635217|EXPERIMENTAL|Group A2|EGD performed before the Colonoscopy with room air insufflation.
62524596|NCT02635217|EXPERIMENTAL|Group B1|Colonoscopy performed before the EGD with Carbon Dioxide insufflation.
62524597|NCT02635217|EXPERIMENTAL|Group B2|Colonoscopy performed before the EGD with room air insufflation.
62524598|NCT02441244|EXPERIMENTAL|Probiotic Group|Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
62524599|NCT02441244|PLACEBO_COMPARATOR|Placebo Group|Placebo comparator group
62524600|NCT05384717|EXPERIMENTAL|Fidget group|Participants in the experimental fidget group select a fidget from 4 options: fidget spinner, stress ball, pop-it, or fidget cube
62524601|NCT05384717|PLACEBO_COMPARATOR|Control group|No fidget choice provided
62524602|NCT01732484|OTHER|iMics1 NY-60|eyes with implantation of iMics1 NY-60 IOL
62524603|NCT01732484|OTHER|AcrySof SN60WF|eyes with implantation of AcrySof SN60WF IOL
62712850|NCT06311760|EXPERIMENTAL|AZD0292 Dose 1|Participants will receive single dose of AZD0292 dose 1 as IV infusion on Day 1.
62712851|NCT06311760|EXPERIMENTAL|AZD0292 Dose 2|Participants will receive single dose of AZD0292 dose 2 as IV infusion on Day 1.
62524604|NCT02647736|EXPERIMENTAL|Copeptin values in normo- to hyperosmolar states|
62524605|NCT02791893|EXPERIMENTAL|VNS device|Vagus Nerve Stimulation (VNS) hand held device - subjects to utilize the VNS hand held device for 20 weeks total, putting it on the skin overlying the vagus nerve in their neck and then turning it on for 120 second periods three times a day. The device is programmed to deliver only 6 bouts of stimulation per day - one to each side of the neck three times a day
62524606|NCT02791893|PLACEBO_COMPARATOR|Inactive device|Inactive hand held device - subjects to utilize the inactive device for 10 weeks and then will receive the VNS device for the next 10 weeks.
62524607|NCT03465917|EXPERIMENTAL|Renal Denervation|Renal denervation using the Peregrine Catheter for extravascular administration of ethanol
62524608|NCT01150617|ACTIVE_COMPARATOR|long-acting insulin plus analogues|three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.
62524609|NCT01150617|ACTIVE_COMPARATOR|long-acting insulin and oral agents|treatment will be once-daily long-acting insulin and oral antidiabetic agents
62524610|NCT05355714|EXPERIMENTAL|Sofwave|
62524611|NCT05355714|OTHER|Ultherapy|
62524612|NCT02093221|EXPERIMENTAL|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
62152164|NCT03345407|EXPERIMENTAL|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
62152165|NCT00872339||transfusion-dependant|People with transfusion-dependant thalassemia who received at least 8 transfusions in the past year.
62524613|NCT02093221|EXPERIMENTAL|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
62524614|NCT02093221|PLACEBO_COMPARATOR|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
62524615|NCT02093221|EXPERIMENTAL|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
62524616|NCT02093221|EXPERIMENTAL|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
62524617|NCT02093221|PLACEBO_COMPARATOR|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
62712852|NCT06311760|EXPERIMENTAL|AZD0292 Dose 3|Participants will receive single dose of AZD0292 dose 3 as IV infusion on Day 1.
62712853|NCT06311760|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to AZD0292 as IV infusion on Day 1.
62712854|NCT00671086|EXPERIMENTAL|Ramelteon 8 mg QD|
62712855|NCT00671086|EXPERIMENTAL|Ramelteon 16 mg QD|
62712856|NCT03789708|EXPERIMENTAL|A|Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.
62712857|NCT03789708|PLACEBO_COMPARATOR|B|Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.
62712858|NCT03789708|EXPERIMENTAL|C|Patients will receive 20 g of Gum Arabic supplementation daily for four weeks
62152166|NCT00872339||non-transfusion-dependant|People with non-transfusion-dependant thalassemia who received no transfusions in the past year.
62152167|NCT00872339||intermittently transfused|Intermittently transfused patients- individuals who received at least one but fewer than eight transfusions in the last year
62712859|NCT03789708|EXPERIMENTAL|D|Patients will receive 40 g of Gum Arabic supplementation daily for four weeks
62152168|NCT02979678|EXPERIMENTAL|Questionnaire|Breast cancer
62152169|NCT03206398|OTHER|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
62152170|NCT05303324|EXPERIMENTAL|Sequence 1 (AB)|"Participants received ALXN1840 once in each Period as a single oral dose under fasted conditions as follows:~Period 1: ALXN1840 as a single EC tablet (Treatment A, reference). Period 2: ALXN1840 as three EC tablets (Treatment B, test).~Participants were discharged following the 240-hour post-dose procedures (approximately 10 days after dosing in each period) unless it was medically necessary to extend the confinement.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62524618|NCT01684137|ACTIVE_COMPARATOR|Joalis Bambi Bronchi & Joalis Bambi Analerg|10 days, 2 times per day 2,5/5 ml
62524619|NCT01684137|PLACEBO_COMPARATOR|Placebo & Placebo|10 days, 2 times per day 2,5/5 ml
62712860|NCT00328172|PLACEBO_COMPARATOR|Placebo|Placebo tablets matching BI 1356
62712861|NCT00328172|EXPERIMENTAL|BI 1356 0.5 mg|BI 1356 dose 1 once daily
62712862|NCT00328172|EXPERIMENTAL|BI 1356 2.5 mg|BI 1356 dose 2 once daily
62712863|NCT00328172|EXPERIMENTAL|BI 1356 5.0 mg|BI 1356 dose 3 once daily
62712864|NCT00328172|ACTIVE_COMPARATOR|Metformin|Metformin
62524620|NCT04599127|EXPERIMENTAL|Mobilization with movement|Mobilization with movement on the shoulder abduction and external rotation
62524621|NCT04599127|PLACEBO_COMPARATOR|Conventional physical therapy|Postural correction exercise and muscle strengthening of the rotator cuff muscle and surrounding muscle on the subacromial region
62524622|NCT04519034||Audit 1|All vitamin D results performed since January 2020 (N= \~15000) together with age, weight and height if available, ethnicity and other relevant laboratory markers (Ca, adjusted calcium, PTH, Mg, phosphate, liver and renal profile, Covid-19 screening, CRP, Haematinics, FBC)
62524623|NCT04519034||Audit 2|All Covid-19 screening results together with vitamin D, ethnicity, age, weight, height, length of stay in hospital including ICU (if applicable), type of illness, recovered or not, associated health conditions, CRP, Ferritin, Haematinics, vitamin A and E, procalcitonin, LDH, INR, fibrinogen, FBC, D-dimers, CK, Troponin-T, cytokines, renal function and electrolytes from patients tested at GSTT NHS Trust.
62524624|NCT04049617|EXPERIMENTAL|Cohort 1: Evixapodlin 400 mg (Phase 1)|Participants will receive Evixapodlin 400 mg once daily for 21 days of each cycle.
62712865|NCT00598507|EXPERIMENTAL|Chemotherapy - ZK-EPO|ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m\^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.
62712866|NCT06432465|ACTIVE_COMPARATOR|active tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
61975639|NCT02424747||De Novo Acute Kidney Injury|Patients who developed Acute Kidney Injury during intensive care admission and not previously diagnosed with chronic kidney disease or end stage renal disease.
61975640|NCT02424747||No Acute Kidney Injury.|Intensive care patients not diagnosed with acute kidney Injury during admission and not previously diagnosed with Chronic Kidney Disease or End Stage Renal Disease.
62712867|NCT06432465|SHAM_COMPARATOR|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
62712868|NCT03340714||Device Feasibility (ADAMM)|Patients wear the Automated Device for Asthma Monitoring and Management (ADAMM) from the time of computed tomography (CT) simulation for radiation therapy (RT) planning throughout the entire RT course and for 4 weeks post-RT
62152171|NCT05303324|EXPERIMENTAL|Sequence 2 (BA)|"Participants received ALXN1840 once in each Period as a single oral dose under fasted conditions as follows:~Period 1: ALXN1840 as three EC tablets (Treatment B, test). Period 2: ALXN1840 as a single EC tablet (Treatment A, reference).~Participants were discharged following the 240-hour post-dose procedures (approximately 10 days after dosing in each period) unless it was medically necessary to extend the confinement.~There was a washout period of at least 14 days between each ALXN1840 dosing."
62712869|NCT06176209||Post traumatic neck pain (i.e. whiplash)|"To be considered eligible for inclusion participants must meet the following criteria:~Inclusion criteria: 18-60 years of age, post-traumatic neck pain of a musculoskeletal nature without fractures or slippage of vertebrae acquired within the last 72 hours in connection an accident. Participants must be able to read and speak Danish.~Exclusion criteria: Previous pain discomfort after similar accidents, existing chronic back pain at the time of the accident, diagnosed with concussion after the accident, suspected or known spinal pathology, including confirmed fracture or slippage of vertebrae at the time of the accident, previous back or neck surgery, spinal cord injuries, severe psychiatric history (e.g., schizophrenia and depression), trauma patients or existing rheumatological or neurological disorders."
62152172|NCT01681563|EXPERIMENTAL|Pentostatin/Cyclophosphamide/Ofatumumab|Subjects will receive up to 6 cycles of pentostatin, cyclophosphamide, and ofatumumab given every 21 days (+/- 4 days).
62524625|NCT04049617|EXPERIMENTAL|Cohort 2: Evixapodlin 700 mg (Phase 1)|Participants will receive Evixapodlin 700 mg once daily for 21 days of each cycle.
62712870|NCT01900366||Obese subjects for fat biopsy|10 patients recruited during fat biopsies for sample collection
61975641|NCT04963933|EXPERIMENTAL|Patients treated with the device|Patients treated with the Nautilus will be followed up
62152173|NCT05513027|EXPERIMENTAL|Augmented Whole-body Scanning via Magnifying PET (AWSM-PET)|All enrolled subjects will undergo SOC PET/CT scan with an AWSM PET device positioned at the far end of the Biograph Vision PET/CT scanner. The patient will receive injection of the PET radiopharmaceutical according to the SOC PET/CT protocol dosing schedule. The entire study will require approximately 2 ½ - 3 hours (from the time patient arrives to the completion of the scan).
62152174|NCT00827294|EXPERIMENTAL|Self-delivered mirror therapy|All participants were directed to self-deliver mirror therapy for 20 minutes per day.
62152175|NCT02194907|ACTIVE_COMPARATOR|Anterior insula cortex activation|Participants will receive training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain, while thinking of and viewing emotional faces, scenes, and text.
62152176|NCT02194907|ACTIVE_COMPARATOR|Primary auditory cortex activation|Participants will have training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain while thinking of and viewing emotional faces, scenes, and text.
62152177|NCT04515576|EXPERIMENTAL|LY3493269|LY3493269 administered Subcutaneous (SC).
62152178|NCT04515576|ACTIVE_COMPARATOR|Dulaglutide|Dulaglutide administered SC.
62152179|NCT04515576|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
62152180|NCT01034813||Burn Range of motion|burn patients with hypertropic scar
62152181|NCT01034813||control range of motion|control subjects without scaring
62152182|NCT05473117||Patient Group|A single cohort consisting of 230 patients referred for CT Coronary Angiography (CCTA) at risk of coronary artery disease. All patients will undergo both CCTA and CMRA
62152183|NCT03030651|EXPERIMENTAL|Breastfeeding Education and Support|Pregnant women in the intervention arm will receive breastfeeding education and support intervention for nine months starting in their third trimester
62152184|NCT03030651|NO_INTERVENTION|Usual or routine care|Pregnant women in the intervention arm will continue to receive the usual/routine care.
62152185|NCT03110783|NO_INTERVENTION|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
62152186|NCT03110783|EXPERIMENTAL|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
62524626|NCT04049617|EXPERIMENTAL|Cohort 3: Evixapodlin 1000 mg (Phase 1)|Participants will receive Evixapodlin 1000 mg once daily for 21 days of each cycle.
62524627|NCT04049617|EXPERIMENTAL|Cohort 4: Evixapodlin 1500 mg (Phase 1)|Participants will receive Evixapodlin 1500 mg once daily for 21 days of each cycle.
61975642|NCT03382938|ACTIVE_COMPARATOR|Dexmedetomidine|Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
61975643|NCT03382938|ACTIVE_COMPARATOR|Ropivacaine|Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
62152187|NCT04674605||ocular myasthenia gravis|
62152188|NCT04674605||generalized myasthenia gravis|
62524628|NCT04049617|EXPERIMENTAL|Cohort 5: Evixapodlin 1000 mg (Phase 1)|Participants are planned to receive Evixapodlin 1000 mg twice daily (BID) for 21 days of each cycle.
62712871|NCT01900366||Lean controls for fat biopsy|5 Lean controls will be recruited
62524629|NCT04049617|EXPERIMENTAL|Cohort 1 Substudy: Evixapodlin 400 mg (Phase 1)|Participants will receive Evixapodlin 400 mg once daily for 21 days of each cycle.
61975644|NCT03382938|ACTIVE_COMPARATOR|Dexmedetomidine - Ropivacaine|Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
62524630|NCT04049617|EXPERIMENTAL|Cohort 2 Substudy: Evixapodlin 700 mg (Phase 1)|Participants are planned to receive Evixapodlin 700 mg once daily for 21 days of each cycle.
62524631|NCT04049617|EXPERIMENTAL|Cohort 3 Substudy: Evixapodlin 1000 mg (Phase 1)|Participants will receive Evixapodlin 1000 mg once daily for 21 days of each cycle.
62524632|NCT04049617|EXPERIMENTAL|Dose Expansion (Phase 2)|Dose expansion is planned to begin when the recommended Phase 2 dose (RP2D) will be determined.
62524633|NCT00794976|EXPERIMENTAL|1|Dexamethasone Iontophoretic Patch (low dose)
62524634|NCT00794976|EXPERIMENTAL|2|Dexamethasone Iontophoretic Patch (high dose)
62524635|NCT00794976|EXPERIMENTAL|3|Dexamethasone Passive Patch
62524636|NCT00794976|PLACEBO_COMPARATOR|4|Placebo Patch
62524637|NCT05862636||Mindfulness centre for general public|Mindfulness course attenders at a mindfulness centre that offers mindfulness trainings for the general public. Participants are thus not selected based on any complaints they may have.
62524638|NCT05862636||Stress clinic|Mindfulness course attenders at a stress clinic associated with a hospital that offers mindfulness courses for participants with mild complaints, such as stress or worry.
62524639|NCT05862636||Mood Disorders Centre|Mindfulness course attenders at a mood disorders centre that offers mindfulness courses for participants with a history of depression and for staff of the public sector such as health care, social care, or police forces.
62524640|NCT01031966|ACTIVE_COMPARATOR|H1N1sw monovalent vaccine|
62524641|NCT01031966|EXPERIMENTAL|Thymosin alpha 1 3.2mg|
62524642|NCT01031966|EXPERIMENTAL|Thymosin alpha 1 6.4 mg|
62524643|NCT00621049|EXPERIMENTAL|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|
62524644|NCT00621049|ACTIVE_COMPARATOR|Docetaxel and Carboplatin|
62524645|NCT03285789|EXPERIMENTAL|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
62524646|NCT03285789|EXPERIMENTAL|Dyslexics with normal visual attention span|
62152189|NCT02488733|EXPERIMENTAL|Laparoscopic Sleeve Gastrectomy (LSG)|In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
62152190|NCT02488733|OTHER|Conventional medical therapy (CMT)|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
62152191|NCT03956927||patients|Insulin-dependent diabetic patients who have participated in a full TPE program (3 sessions)
62152192|NCT02162823||Pancreatic cancer|Patients with pancreatic cancer and age\&sex-matched controls without any cancer from a distinct population area (district of Stockholm). Patients with pancreatic cancer will be subjected to pancreatic surgery
62152193|NCT03761199|EXPERIMENTAL|a group of patients with AD|15 people with clinically diagnosed atopic dermatitis (AD), established on the basis of criteria Hanifin and Rajka
62152194|NCT03761199|OTHER|control group|15 healthy persons which will form the control group
62152195|NCT05758532|ACTIVE_COMPARATOR|C.C. : Both MMR doses given on current schedule (9 months and 12 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~* 9 months (= current Swiss schedule)~* 12 months, concomitant with other vaccines (= current Swiss schedule)"
62524647|NCT03285789|ACTIVE_COMPARATOR|controls|
62524648|NCT02991430|ACTIVE_COMPARATOR|active|active neuromodulation
62524649|NCT02991430|PLACEBO_COMPARATOR|placebo|placebo neuromodulation
62152196|NCT05758532|EXPERIMENTAL|M.C. : 1st MMR on modified schedule (6 months) and 2nd MMR on current schedule (12 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~* 6 months (= modified schedule)~* 12 months, concomitant with other vaccines (= current Swiss schedule)"
62524650|NCT00197392|EXPERIMENTAL|Bactiseal TM EVD|Bactiseal External Ventricular Drainage System.
62524651|NCT00197392|ACTIVE_COMPARATOR|Standard EVD Catheter|Standard External Ventricular Device system
62524652|NCT05320341||TIVA group|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
62524653|NCT05320341||SEVO group|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
62524654|NCT00727948|EXPERIMENTAL|receive aspirin|
62524655|NCT00593788||1|Normal-hearing adults between 18 and 31 years of age.
62524656|NCT00523965|EXPERIMENTAL|A|AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8
62524657|NCT00523965|EXPERIMENTAL|B|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
62524658|NCT00523965|EXPERIMENTAL|C|oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
62524659|NCT00523965|ACTIVE_COMPARATOR|D|amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions
62524660|NCT01610739|OTHER|Median nerve perfusion|Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
62524661|NCT02579161|ACTIVE_COMPARATOR|Antibiotics for a 24 hour period|"Antibiotics for a 24 hour period~Intervention drug to be determined based on patient history etc."
62524662|NCT02579161|ACTIVE_COMPARATOR|Continued antibiotics|"Continued antibiotics until the removal of any external catheters~Intervention drug to be determined based on patient history etc."
62524663|NCT02775474|EXPERIMENTAL|Methadone|Methadone used as anesthesia opioid: induction with 0,15 mg / kg intravenous methadone. Boluses of 0,05 mg / kg intravenous methadone as needed intraoperatively
62524664|NCT02775474|ACTIVE_COMPARATOR|Fentanyl|Fentanyl used as anesthesia opioid: induction with 6 mcg / kg intravenous fentanyl. Boluses of 2 mug / kg intravenous fentanyl as needed intraoperatively
62524665|NCT05690126|ACTIVE_COMPARATOR|Saffron extract|"Daily, two dietary supplements (Saffron extract) will be taken orally with water, the first one at breakfast and the second one at dinner.~Dietary supplements in capsule form"
62712872|NCT01195454|EXPERIMENTAL|Insulin glargine / New insulin glargine formulation|"* Period 1: Insulin glargine~* Period 2: New insulin glargine formulation~* Period 3: New insulin glargine formulation~* Period 4: New insulin glargine formulation~Duration of treatment: 1 day at each period"
62712873|NCT02647684|EXPERIMENTAL|Self- Direced Triple P|Self-directed Triple P workbook to be completed over 10 weeks. Over the course of the workbook parents will think about the changes they would like to make to their child's behaviour. They are taught strategies to enhance their relationship with their child, and promote desirable behaviours. They learn about options for managing problem behaviours and have the opportunity to decide if they would like to use any of these approaches with their child in a clear and consistent way. Parents have practice period to use the approaches they have learnt in weeks 1-3. By the end of week 6 they will have had practice in using their chosen positive parenting approaches, learnt to set goals and monitor their own behaviour when using these strategies. The final weeks aim to help parents identify times when the strategies may not be working and provide survival tips on what to do at these times.
62712874|NCT01999192|EXPERIMENTAL|Dose Level 1 Tregalizumab|25mg Tregalizumab s.c. weekly
62712875|NCT01999192|EXPERIMENTAL|Dose Level 2 Tregalizumab|100mg Tregalizumab s.c. weekly
62712876|NCT01999192|EXPERIMENTAL|Dose Level 3 Tregalizumab|200mg Tregalizumab s.c. weekly
62712877|NCT01999192|PLACEBO_COMPARATOR|Placebo|Placebo s.c. weekly
62712878|NCT03493646|ACTIVE_COMPARATOR|Azacitidine|6 cycles of azacitidine (28 day cycle)
62712879|NCT03493646|EXPERIMENTAL|CC 486|6 cycles CC 486 (28 day cycle)
62712880|NCT00840333|EXPERIMENTAL|1|CF PATIENTS 6-11 YEARS OF AGE
62712881|NCT00840333|EXPERIMENTAL|2|CF PATIENTS 12-16 YEARS OF AGE
62524666|NCT05690126|PLACEBO_COMPARATOR|Placebo|"Daily, two dietary supplements (Maltodextrin) will be taken orally with water, the first one at breakfast and the second at dinner.~Dietary supplements in capsule form"
62524667|NCT04338217|EXPERIMENTAL|Bionator|The modified Bionator was used to correct the open bite malocclusion. Patients were asked to wear the appliance every day.
62524668|NCT04338217|ACTIVE_COMPARATOR|Removable Appliance with Posterior Bite Planes|A removable appliance with poster bite planes was used to correct the open bite malocclusion. Patients were asked to wear this appliance full time expect eating times.
62524669|NCT03073395|EXPERIMENTAL|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug \[68Ga\]P16-093 in patients with a history of histologically confirmed cancer.
62524670|NCT03073395|EXPERIMENTAL|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug \[68Ga\]P16-093
62524671|NCT04053465|EXPERIMENTAL|Exercise in heat group|Exercise in a hot environment
62524672|NCT04053465|PLACEBO_COMPARATOR|Exercise in cool group|Exercise in a cool environment
62524673|NCT02479542|ACTIVE_COMPARATOR|Standard Gauze Dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
62712882|NCT05424601|EXPERIMENTAL|Rethink game plus PsyPills|Rethink game followed by PsyPills
62712883|NCT05424601|EXPERIMENTAL|Rethink Game|Rethink game only
62712884|NCT05424601|NO_INTERVENTION|Control|Control group
62524674|NCT02479542|EXPERIMENTAL|WiCare NPWT dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the WiCare NPWT Dressing Arm, a saline moistened sterile gauze will be packed into the wound and then the WiCare dressing and wound pump will be placed on the wound. The dressing will be changed, measured and photodocumented every 72 hours with the Wound Zoom system.
62524675|NCT04453098|EXPERIMENTAL|Re group|high-Resistance-moderate-endurance, participants performed 10 repetitions at 70% of one maximal repetition in resistance and 30% of VO2-peak for endurance training
62524676|NCT04453098|EXPERIMENTAL|rE group|moderate-resistance (30%) - high-Endurance (70%)
62524677|NCT04453098|EXPERIMENTAL|re group|moderate-resistance (30%) - moderate-endurance (30%).
62524678|NCT04453098|NO_INTERVENTION|control group|no intervention
62524679|NCT01629966|PLACEBO_COMPARATOR|Placebo|Dose-matched placebo one per day, oral administration
62524680|NCT01629966|EXPERIMENTAL|Vilazadone 20mg|Vilazodone 20mg once per day, oral administration.
62524681|NCT01629966|EXPERIMENTAL|Vilazodone 40mg|Vilazodone 40mg once per day, oral administration
62524682|NCT05753761|EXPERIMENTAL|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS)|Additional to usual care, the experimental arm will undergo a theory-based behaviour change intervention to improve stepping time relative to reducing sedentary behaviour.
62524683|NCT05753761|ACTIVE_COMPARATOR|Usual care:|The control arm program will consist of usual inpatient care including therapeutic mobilization by the physical therapy team and general mobilization, as tolerated, by the nursing team.
62524684|NCT03095118|EXPERIMENTAL|Daratumumab|Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
62524685|NCT01764230|EXPERIMENTAL|case group|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
62524686|NCT01764230|NO_INTERVENTION|control group|no intervention
62524687|NCT01466452|ACTIVE_COMPARATOR|Aspirin 100|
62524688|NCT01466452|ACTIVE_COMPARATOR|Aspirin 200|
62524689|NCT01466452|ACTIVE_COMPARATOR|Aspirin 100 x 2|
62524690|NCT01602965|EXPERIMENTAL|counseling monthly phone calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviours that need to be changed, problem-solving as to how to make the changes and physical activity levels.
62712885|NCT04273360|ACTIVE_COMPARATOR|Systematic use group|
62712886|NCT04273360|EXPERIMENTAL|Restrictive use group|
62712887|NCT02040714||Nonoperative management between ages 6-8 in early stage|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
62712888|NCT02040714||Operative management between age 6-8 in early stage|Operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the early stage of the disease process
62524691|NCT01602965|ACTIVE_COMPARATOR|self help informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies.
62524692|NCT02278419|EXPERIMENTAL|Group A1|Participants without cirrhosis will receive simeprevir 150 milligram (mg) capsule along with sofosbuvir 400 mg tablet, orally, once daily for 8 weeks.
62712889|NCT02040714||Nonoperative management between age 8-11 in early stage|Patients who do not undergo some form of containment surgery because of medical, social, or other reasons will receive no surgical treatment.
62712890|NCT02040714||Operative containment with short-term non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11 in developed countries, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 weeks of non-weight bearing on the operated leg."
62712891|NCT02040714||Operative containment with prolonged non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 months of non-weight bearing on the operated leg."
62712892|NCT02040714||Operative containment for over 11 age group|Patients presenting over age 11 may receive multiple drilling and be non weight bearing for up to 6 months according to the treating physician's preference. Patients with application of fixator (arthrodiastasis) will be studied in this cohort arm as well, which typically involved 3-4 months followed by 8-12 weeks of non-weight bearing after fixator removal. Other surgical techniques may be included, however these are the most common for this age group.
62712893|NCT02040714||Nonoperative management in over 11 age group|Patients will be non-weight bearing and receive physical therapy according to the physician preferences.
62712894|NCT02040714||Nonoperative management in 1-6 age group|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
62712895|NCT02040714||Operative management in 1-6 age group|The choice of osteotomy management with containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
62524693|NCT02278419|EXPERIMENTAL|Group A2|Participants without cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
62524694|NCT02278419|EXPERIMENTAL|Group B|Participants with cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
62712896|NCT02040714||Late Stage Bracing group|Patients presenting with \<= 20 degrees of abduction on a maximum abduction x-ray treated with bracing who also present in the late stages of the disease (Waldenstrom Stage IIb or IIIa).The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
62712897|NCT02040714||Late Stage Symptomatic treatment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated symptomatically. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
62712898|NCT02040714||Late Stage Surgical Containment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated with surgical containment. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
62524695|NCT04957420||Neupro gruop|Patients using Neupro according to the standard clinical practice of therapists
62524696|NCT02991170|ACTIVE_COMPARATOR|control group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
62524697|NCT02991170|EXPERIMENTAL|interventional group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
62524698|NCT01763749|EXPERIMENTAL|Closone|75mg/100mg per day, 4weeks, PO
62524699|NCT01763749|ACTIVE_COMPARATOR|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
62524700|NCT00798187||Homogeneous Support Group|
62524701|NCT00798187||Heterogeneous Support Group One|
62524702|NCT00798187||Heterogeneous Support Group Two|
62524703|NCT01077466|EXPERIMENTAL|Natalizumab|24 patients: 12 with secondary progressive multiple sclerosis 12 with primary progressive multiple sclerosis
62524704|NCT01962181|ACTIVE_COMPARATOR|Ritalin|Ritalin treatment at different doses
62524705|NCT01962181|PLACEBO_COMPARATOR|Placebo|Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
62524706|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
62524707|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
62524708|NCT03278002||Group/Cohort Information|This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
62524709|NCT00212576|EXPERIMENTAL|Building Blocks (0-3)|"Randomized at birth to receive Building Blocks Project from birth through 3 years of age.~Note: This arm not followed past 3 years of age; NOT re-randomized to any group at age 3."
62712899|NCT04594187|EXPERIMENTAL|Group I (immunotherapy, radiation therapy)|Within 12 weeks of SLNB, patients start nodal radiation therapy (30 Gy in 5 treatments over 2-2.5 weeks). Immunotherapy planned to begin at any time after SLNB.
62712900|NCT04594187|ACTIVE_COMPARATOR|Group II (immunotherapy)|Patients planned to undergo immunotherapy.
62712901|NCT06060210|PLACEBO_COMPARATOR|Group A|50-ml volume of normal saline
62712902|NCT06060210|ACTIVE_COMPARATOR|Group B|50-ml volumes, and the ketamine concentration is 1 mg/ml
62712903|NCT03721822|EXPERIMENTAL|Traditional Cigarette Smokers|Reported current cigarette smoking of at least 5 cigarettes per day, 5 days per week for the past 1 year with no history of e-cigarette use (cannabis or nicotine) during the 30 days prior to study enrollment
62712904|NCT03721822|EXPERIMENTAL|Non-Smokers|Reported non-smoking history or \< 100 lifetime cigarettes, \< 100 e-cigarette use episodes and \< 100 lifetime cannabis use episodes
62524710|NCT00212576|EXPERIMENTAL|VIP (0-3), VIP (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
62712905|NCT03721822|EXPERIMENTAL|Nicotine Vapers|Reported current e-cigarette use of nicotine at least 5 days per week for the past year with no current combustible cigarette use, cannabis vaping or cannabis smoking during the 30 days prior to study enrollment
62712906|NCT03721822|EXPERIMENTAL|Cannabis Vapers|Reported current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking or nicotine vaping during the 30 days prior to study enrollment
62712907|NCT03721822|EXPERIMENTAL|Dual Smokers/Vapers|Reported current e-cigarette use of cannabis and/or nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 days prior to study enrollment
62712908|NCT06327711|ACTIVE_COMPARATOR|CHO Blend|Group will consume a ready to feed CHO blend beverage
62712909|NCT06327711|EXPERIMENTAL|CHO Blend plus AN100|Group will consume a ready to feed CHO plus AN100 beverage
62712910|NCT06234982||2-3 years of age|2-3 years of age
62712911|NCT06234982||4-6 years of age|4-6 years of age
62712912|NCT06234982||7-10 years of age|7-10 years of age
62712913|NCT02160821|EXPERIMENTAL|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block TAPB Ultrasound guided TAPB
62712914|NCT02160821|EXPERIMENTAL|Caudal Epidural Block|Caudal Epidural Block Caudal Block Neuraxial Block Ultrasound Guided Caudal Block
62712915|NCT03528902|EXPERIMENTAL|Tamoxifen|20 mg po TID for 24 weeks
62152197|NCT05758532|EXPERIMENTAL|C. M. : 1st MMR on current schedule (9 months) and 2nd MMR on modified schedule (13 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~* 9 months (= current Swiss schedule)~* 13 months, distant from other vaccines (= modified schedule)"
62152198|NCT05758532|EXPERIMENTAL|M.M. : Both MMR doses given on modified schedule (6 months and 13 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~* 6 months (= modified schedule)~* 13 months, distant from other vaccines (= modified schedule)"
62152199|NCT05028257|EXPERIMENTAL|COVID-19 Vaccinated Patients|
62524711|NCT00212576|EXPERIMENTAL|VIP (0-3), Control (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive care as usual (control) from 3-5 years of age."
62712916|NCT03528902|PLACEBO_COMPARATOR|Placebo|Placebo arm
62712917|NCT06322134||Fatal drowning|Prehospital mortality following a drowning incident, defined as a dichotomous variable (dead or alive) evaluated at case termination. Patients admitted to the hospital with cardiac arrest were considered fatal drowning incidents in this study.
62712918|NCT06322134||Non-fatal drowning|Drowning incidents where the patient had spontaneous circulation at hospital admission.
62152200|NCT04562883|EXPERIMENTAL|Single Culture|"Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the washing dish containing Maturation Medium and wash them thoroughly. Then transfer COCs one by one to the Culture dish with Maturation Medium."
62152201|NCT04562883|EXPERIMENTAL|Group Culture|"Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the washing dish containing Maturation Medium (Group Culture) by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the IVM dish with Maturation Medium (Group Culture)."
62712919|NCT04551495|EXPERIMENTAL|Single Arm|Subjects will receive four 28-day cycles of letrozole 2.5 mg daily in combination with entrectinib 600 mg daily. Pre-menopausal women will receive goserelin 3.6 mg every 28 days.
62712920|NCT04574856|EXPERIMENTAL|Patients with Newly Diagnosed Glioblastoma|Patients will receive dose-intensified, adaptive photon radiation therapy
62712921|NCT06717711|EXPERIMENTAL|PDE5i + LiESWT|Patients receiving LiESWT plus early introduction of PDE5i
61975645|NCT03382938|PLACEBO_COMPARATOR|0.9 % saline|Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration
62524712|NCT00212576|EXPERIMENTAL|Control (0-3), VIP (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
62712922|NCT06717711|ACTIVE_COMPARATOR|PDE5i alone|Control group, patients receiving PDE5i alone
62712923|NCT03108196|EXPERIMENTAL|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
62712924|NCT03108196|EXPERIMENTAL|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
62712925|NCT05266547||OCT guided group|
62712926|NCT05266547||angiography guided group|
62712927|NCT03949023||Standard of Care Cerebral Angiogram Group|Participants undergoing a standard of care cerebral angiogram.
62712928|NCT06719479|EXPERIMENTAL|Cohort 1|In Phase II，the patients will receive the combined treatment of IAE0972（7.5 mg/kg、10 mg/kg、15 mg/kg、20 mg/kg）+ Methotrexate（Chemotherapy chosen by doctors）. Every 21 days is defined as a treatment cycle.
62712929|NCT06719479|EXPERIMENTAL|Cohort 2|In Phase II，the patients will receive the combined treatment of IAE0972（7.5 mg/kg、10 mg/kg、15 mg/kg、20 mg/kg）+ Docetaxel（Chemotherapy chosen by doctors）. Every 21 days is defined as a treatment cycle.
62712930|NCT06719479|EXPERIMENTAL|Cohort 3|In Phase II，the patients will receive the combined treatment of IAE0972（7.5 mg/kg、10 mg/kg、15 mg/kg、20 mg/kg）+ Gemcitabine（Chemotherapy chosen by doctors）. Every 21 days is defined as a treatment cycle.
62712931|NCT06719479|EXPERIMENTAL|Cohort 4|In Phase II，the patients will receive the combined treatment of IAE0972（7.5 mg/kg、10 mg/kg、15 mg/kg、20 mg/kg）+ Taxanes （Chemotherapy chosen by doctors）. Every 21 days is defined as a treatment cycle.
62712932|NCT06719479|EXPERIMENTAL|Cohort 5|In Phase II，the patients will receive the combined treatment of IAE0972（7.5 mg/kg、10 mg/kg、15 mg/kg、20 mg/kg）+ Capecitabine（Chemotherapy chosen by doctors）. Every 21 days is defined as a treatment cycle.
62712933|NCT05579652||Patients with open abdomen|All non-pregnant adults with an open abdomen who are consentable or who have a legally authorized representative will have the tension on each side of their abdominal wall measured using a tensiometer at each abdominal exploration
62712934|NCT03261921|ACTIVE_COMPARATOR|Dexamethasone group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + (0.1 mg/kg dexamethazone) caudally.
62712935|NCT03261921|ACTIVE_COMPARATOR|Dexmedetomidine group|In this group the Patients received 0.5 ml/kg of bupivacaine 0.25% + dexmedetomidine(1 mu/kg) caudally.
62712936|NCT03261921|ACTIVE_COMPARATOR|Combination group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + dexamethasone(0.1mg/kg) and dexmedetomidine (1 mu/kg) caudally.
62712937|NCT05455320|EXPERIMENTAL|Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP)|Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
62712938|NCT05455320|EXPERIMENTAL|Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd)|Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
62712939|NCT05455320|EXPERIMENTAL|Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D)|Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
62712940|NCT05968846|EXPERIMENTAL|Patients will receive a single IV injection of 124I-AT-01 radiotracer and PET/CT imaging|"124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is an iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging. The peptide binds many forms of amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.~124I-AT-01 has been evaluated previously in an open-label Phase 1/2 clinical trial, AMY1001, performed at the University of Tennessee Medical Center (IND# 132282; NCT T03678259).~In this repeat imaging study, patients previously enrolled in the AMY1001 study, in whom positive PET/CT imaging findings were observed will undergo repeat imaging to assess changes in radiotracer uptake in the liver, spleen, heart and kidneys."
62712941|NCT04996667|ACTIVE_COMPARATOR|Interventional Radiology Arm (Invasive Cohort)|"Interventional radiology (IR) will perform a right heart catheterization (RHC) as part of a planned IR procedure.~Bedside apical 4 chamber view (RV:LV ratio) will be recorded using an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform.~The Butterfly iQ+ (one possible ultrasound device which may be used) is a single-probe, whole-body ultrasound device.~After initial measurements, inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The same measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
62712942|NCT04996667|ACTIVE_COMPARATOR|Non-intervention Arm (Non-invasive Cohort)|Vitals including O2 amount and modality, blood pressure, pressor name, dose, and rate will be recorded. If the patient is intubated, the name, dose, and rate of sedation and analgesia will be recorded. If the patient is not intubated, name and dose amount of sedation will be recorded. Arterial blood gas will be obtained if an A-line is placed. Bedside apical 4 chamber view will be recorded (RV:LV ratio) with an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. This data will be obtained before, during iNO administration, and after iNO has been withheld for 2 minutes.
62712943|NCT04538157|EXPERIMENTAL|Comprehensive Geriatric Assessment|Specialist co-ordinated care (known as comprehensive geriatric assessment, or CGA) was developed to address medical, social, mental health, and physical needs with the help of a skilled multi-disciplinary team.
62712944|NCT04538157|NO_INTERVENTION|Usual Care|Usual Care
62712945|NCT05041985|EXPERIMENTAL|group A (the Test group)|arm which received Diazepam 5 mg therapy for 7 days after whiplash
62712946|NCT05041985|NO_INTERVENTION|group B (the control group)|a group which did not receive Diazepam 5 mg therapy
62712947|NCT06464770|EXPERIMENTAL|Randomization Option 1|Right shoulder, Test Group ; Left shoulder, Control Group
62152202|NCT01062165|EXPERIMENTAL|Capsofungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
62152203|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
61975646|NCT03861715||Single Dose antagonist Degarelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.
61975647|NCT03861715||Multidose antagonist Ganirelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.
61975648|NCT05534750|EXPERIMENTAL|Tedizolid arm|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
62152204|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
62524713|NCT00212576|NO_INTERVENTION|Control (0-3), Control (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive receive care as usual (control) from 3-5 years of age."
62524714|NCT03854786|ACTIVE_COMPARATOR|Oxyjun|Oxyjun- 400 mg OD after breakfast
62524715|NCT03854786|PLACEBO_COMPARATOR|Methyl Crystalline Cellulose|Methyl Crystalline Cellulose- 400 mg OD after breakfast
62524716|NCT04866849||STUDY GROUP|"patient diagnosed with bruxism The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
62712948|NCT06464770|EXPERIMENTAL|Randomization Option 2|Right shoulder, Control Group ; Left shoulder, Test Group
62712949|NCT04864392|EXPERIMENTAL|LNA043 Dosing Regimen A|LNA043 injection to the knee with dosing regimen A
62712950|NCT04864392|EXPERIMENTAL|LNA043 Dosing Regimen B|LNA04 injection to the knee with dosing regimen B
62712951|NCT04864392|EXPERIMENTAL|LNA043 Dosing Regimen C|LNA043 injection to the knee with dosing regimen C
62712952|NCT04864392|EXPERIMENTAL|LNA043 Dosing Regimen D|LNA043 injection to the knee with dosing regimen D
62152205|NCT02214095|ACTIVE_COMPARATOR|glucosamine sulphate capsules|500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy.
62524717|NCT04866849||CONTROL GROUP|healthy volunteers
62524718|NCT03145402|EXPERIMENTAL|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
62524719|NCT03145402|PLACEBO_COMPARATOR|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
62524720|NCT05963191|EXPERIMENTAL|CAD-EYE group: Colorectal cancer screening with CAD EYE colonoscopy|The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on (device with CE mark). When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately.
62524721|NCT05963191|NO_INTERVENTION|CE group : Colorectal cancer screening with indigo carmine chromo colonoscopy|The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. In the CE group, descent is performed under white light with indigo carmin chromoendoscopy (0.4%) applied through a catheter spray. When polyps are detected, they are rigorously described and histological prediction of the endoscopist reported.
62524722|NCT01700166|EXPERIMENTAL|Biologic; Cord Blood Stem Cells; Intravenous injection|Autologous Human Umbilical Cord Blood derived Stem Cell injection
62524723|NCT04190030|EXPERIMENTAL|Mindfulness|
62524724|NCT04190030|ACTIVE_COMPARATOR|Cognitive reappraisal|
62524725|NCT04238832|ACTIVE_COMPARATOR|Free Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and free base nicotine e-liquid to sample for one week.
62524726|NCT04238832|ACTIVE_COMPARATOR|Salt Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and salt base nicotine e-liquid to sample for one week.
62712953|NCT04864392|PLACEBO_COMPARATOR|Placebo|Injection to the knee
62712954|NCT06446128|EXPERIMENTAL|CD19/CD20/BCMA CAR T therapy|"The safety and tolerability of BZE2204 will be assessed in a 1+1+1+3 and 3+3 dose escalation approach in different B-cell non-hodgkin lymphoma"
62712955|NCT04585750|EXPERIMENTAL|Phase 1 Monotherapy Dose Escalation|Multiple dose levels of daily oral PC14586 (INN: rezatapopt) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 (INN: rezatapopt) to recommend a Phase 2 dose (RP2D).
62152206|NCT02214095|PLACEBO_COMPARATOR|lactose capsules|lactose capsules three times daily for 3 months
62524727|NCT00467636|EXPERIMENTAL|Insulin Glulisine|Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose \< 4 mmol/l.
62524728|NCT00467636|ACTIVE_COMPARATOR|2|Blood glucose monitoring for comparison with treatment arm (1)
62524729|NCT05054322|NO_INTERVENTION|Standard Care|Participants will be monitored via video call twice a day without any specific drugs.
62524730|NCT05054322|EXPERIMENTAL|Fluticasone propionate with spacer|Fluticasone propionate 125 mcg with spacer, 4 puffs, twice a day, added to standard care
62524731|NCT01651143|EXPERIMENTAL|SAR100842|"Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
62524732|NCT01651143|PLACEBO_COMPARATOR|Placebo|"Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
62524733|NCT00713999|EXPERIMENTAL|STI/PZQ 1|Baseline and post-treatment follow-up (anti-STI and praziquantel Rx)
62524734|NCT03380533|ACTIVE_COMPARATOR|Buprenorphine Patch|"Buprenorphine 10mg Patch + Placebo Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
62524735|NCT03380533|ACTIVE_COMPARATOR|Tramadol Tablet|"Placebo Patch + Tramadol 50mg Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
62524736|NCT03531190|EXPERIMENTAL|Nutritional supplement (Protein + MIX)|Patients are given: Nutritional Supplement of protein 2-3 times a day + MIX once daily for 35 days
62524737|NCT03531190|ACTIVE_COMPARATOR|Nutritional supplement (Protein)|Nutritional Supplement of protein as needed 2-3 times a day for 35 days
62524738|NCT02420418|ACTIVE_COMPARATOR|NAC ( baseline )and 12 week|"subjects with tobacco use disorder (TUD) and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo at baseline for a period of 12 weeks The participants with TUD (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be asses laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
62712956|NCT04585750|EXPERIMENTAL|Phase 1b Combination Therapy Dose Escalation, Part 1|Multiple dose levels of daily oral PC14586 (INN: rezatapopt) in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab.
62712957|NCT04585750|EXPERIMENTAL|Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients|Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients.
62152207|NCT06010173|EXPERIMENTAL|Adult cohort|Each of 2 MRI visits will consist of gadopiclenol injection or comparator injection and MRI procedure (administered in a randomized, blinded and cross-over design). Gadopiclenol and comparator will be injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and may vary depending on scanned organ/region and age of patients.
62152208|NCT06010173|EXPERIMENTAL|Pediatric cohort|Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector.
62152209|NCT06010173|EXPERIMENTAL|Pediatric PK cohort|Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. In addition a total of 3 blood samples per patient will be taken post-injection for PK analysis over the period of 8 hours post-injection.
62152210|NCT05861232|EXPERIMENTAL|Experimental|informative animation, anxiety and fear
62152211|NCT05861232|NO_INTERVENTION|No Intervention|Control not anxiety and fear
62152212|NCT06505863||taTME|Patients who underwent transanal total mesorectal excision with anastomosis for primary rectal cancer UICC stage I to III
62152213|NCT06505863||abTME|Patients who underwent laparoscopic, robotic, or open total mesorectal excision with anastomosis for primary rectal cancer UICC stage I to III
62152214|NCT02270502||Adult patients on the SICU|Adult patients on the surgical intensive care unit (SICU), within 72 hours of admission to the SICU and until SICU discharge. Ultrasound Philips CX50, Frailty Index questionnaire and muscle strength tests.
62152215|NCT03544047|EXPERIMENTAL|Experimental arm|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
62152216|NCT00869609|ACTIVE_COMPARATOR|GLB Traditional Maintenance (TM)|Group Lifestyle Balance (GLB) program Traditional Maintenance: After completion of the GLB 12 core sessions, participants who are randomly assigned to GLB program Traditional Maintenance (TM) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions.
62152217|NCT00869609|ACTIVE_COMPARATOR|GLB-Carb-focused Maintenance (CF)|Group Lifestyle Balance (GLB) program Carb-focused Maintenance: After completion of the GLB 12 core sessions, participants randomly assigned to GLB Carb-focused Maintenance (CF) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information regarding healthy carbohydrate intake and hunger management.
62152218|NCT01330953|PLACEBO_COMPARATOR|Placebo|Single intravenous placebo dose.
62524739|NCT02420418|PLACEBO_COMPARATOR|placebo ( baseline ) and 12 week|"subjects with tobacco use disorders (TUD and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo for a period of 12 weeks.~The participants with TUD and bipolar disorders (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be assessed laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
62524740|NCT01463436|EXPERIMENTAL|soy isoflavone 100 mg|the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
62524741|NCT01463436|PLACEBO_COMPARATOR|calcium carbonate 500 mg|The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
62152219|NCT01330953|EXPERIMENTAL|30 mg LY2928057 (Cohort 1)|Day 1: single 30-milligram (mg) LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 30-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 30-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 30 mg LY2928057.
62152220|NCT01330953|EXPERIMENTAL|100 mg LY2928057 (Cohort 2)|Day 1: single 100-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 100-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 100-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 100 mg LY2928057.
62152221|NCT01330953|EXPERIMENTAL|300 mg LY2928057 (Cohort 3)|Day 1: single 300-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 300-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 300-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 300 mg LY2928057.
62524742|NCT04298645|EXPERIMENTAL|High GI carbs breakfast / dinner|Participants will receive a meal rich in high GI carbohydrates for breakfast (day 5) first. After the wash-out day (day 6), the identical meal will be provided for dinner (day 7).
62524743|NCT04298645|EXPERIMENTAL|High GI carbs dinner / breakfast|Participants will receive a meal rich in high GI carbohydrates for dinner (day 5) first. After the wash-out day (day 6), the same meal will be provided for breakfast (day 7).
62524744|NCT02702713|ACTIVE_COMPARATOR|Dairy BEF + egg placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Dairy BEF + 1 portion of Egg placebo + 1 portion of Bakery placebo
62152222|NCT01330953|EXPERIMENTAL|1000 mg LY2928057 (Cohort 4)|Day 1: single 1000-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 1000-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 1000-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 1000 mg LY2928057.
62152223|NCT04515550||Huntington's disease (HD)|people with HD
62152224|NCT04515550||Controls without HD|people without HD
62152225|NCT06368388||Phage treated group|Solely depending on the susceptibility of the isolates against the available phages (phagogram) the CBL will decide if the patient can be included in the phage treated group or the control group. Patients in the phage treated group will receive phage therapy according to the medical indication (local for musculoskeletal infections, hidradenitis suppurativa and CRS, through inhalation for pulmonary infections, intravenous for sepsis) on top of (surgical/antimicrobial) standard treatment.
62152226|NCT06368388||Control group|Patients for whom the isolated pathogens are not susceptible to the available phages are included in the control group. These patients receive standard (non-curative) surgical/antimicrobial treatment.
62152227|NCT00936819|PLACEBO_COMPARATOR|Plasma-Lyte A and 25% autologous plasma|
62152228|NCT00936819|EXPERIMENTAL|Autologous EPCs|
62152229|NCT00936819|EXPERIMENTAL|Autologous EPCs Transfected with human eNOS|
62152230|NCT06341309|EXPERIMENTAL|irinotecan liposome injection combined with bevacizumab|Patients will be treated with irinotecan liposome injection combined with bevacizumab. Treatment until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
62152231|NCT06139835|ACTIVE_COMPARATOR|Control|Individuals randomly assigned to the control arm where they brushed their teeth with a popular toothpaste (crest) in the morning and before bed. This routine was repeated daily for 4 weeks.
62152232|NCT06139835|EXPERIMENTAL|Tartarase brushing|In the morning, this group brushed with Tartarase for 30 seconds, spit, but did not rinse and repeated the process. In 30 minutes they brushed with Crest. They repeated this routine before bed. This routine was repeated daily for 4 weeks.
62152233|NCT06139835|EXPERIMENTAL|Tartarase tray|In the morning this group brushed with Tartarase for 30 seconds, filled a dental tray with Tartarase and applied it to the 6 lower front teeth and left it for 30 minutes, spit but did not rinse then brushed with Tartarase for another 30 seconds, spit, but did not rinse. In 30 minutes they brushed with Crest. Before bed they brushed with Crest alone. This routine was repeated daily for 4 weeks.
62152234|NCT02374372|ACTIVE_COMPARATOR|conventional hemodialysis|conventional hemodialysis
62152235|NCT02374372|ACTIVE_COMPARATOR|hemodiafiltration On-line|hemodiafiltration On-line
62524745|NCT02702713|ACTIVE_COMPARATOR|Egg BEF + dairy placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg BEF + 1 portion of Dairy placebo + 1 portion of Bakery placebo
62524746|NCT02702713|ACTIVE_COMPARATOR|Bakery BEF + dairy placebo + egg placebo|200 subjects consuming every day for 12 weeks: 1 portion of Bakery BEF + 1 portion of Dairy placebo + 1 portion of Egg placebo
62524747|NCT02702713|PLACEBO_COMPARATOR|All placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg placebo + 1 portion of Dairy placebo + 1 portion of Bakery placebo
62712958|NCT04585750|EXPERIMENTAL|Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients|Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients.
62152236|NCT03471117|ACTIVE_COMPARATOR|Pioglitazone|The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg/day. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg/day. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.
62152237|NCT03471117|PLACEBO_COMPARATOR|Placebo|Placebo pills are made of avicel microcrystalline cellulose and magnesium stearate, which are inactive ingredients in the Pioglitazone pills. The placebo pills will be of similar color and appearance as the Pioglitazone pills
62152238|NCT06534918|EXPERIMENTAL|Low Complexity Group|Participants in this group will receive the low complexity intervention for up to eight (8) weeks.
62152239|NCT06534918|EXPERIMENTAL|Moderate Complexity Group|Participants in this group will receive the moderate complexity intervention for up to eight (8) weeks.
62152240|NCT06534918|EXPERIMENTAL|High Complexity Group|Participants in this group will receive the high complexity intervention for up to eight (8) weeks.
62152241|NCT06534918|NO_INTERVENTION|Control Group|Participants randomized to this arm will receive routine care and will not receive any study materials until the end of the study at 24 weeks.
62152242|NCT02815345|EXPERIMENTAL|Measure of the nasal cavity|"The nasal cavity of all the included neonates will be measured using rhinometry during their hospitalization every weeks. So one to 8 measurement will be performed for each neonates.~Some included neonates will also have rhinomanometry measurements."
62152243|NCT03979352|ACTIVE_COMPARATOR|Empagliflozin arm|"Participant will be treated by empagliflozin for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the placebo arm.~Participant and research staff is blinded to arm assignment."
62524748|NCT04524052|EXPERIMENTAL|cohort 1 (144 mg)|Arms (both) 0.1 mL/site\*2 sites Hips (both) 0.2 mL/site\*2 sites
62524749|NCT04524052|EXPERIMENTAL|cohort 2 (432 mg)|Arms (both) 0.3 mL/site \*2 sites Hips (both) 0.6 mL/site\*2 sites
62524750|NCT04524052|EXPERIMENTAL|cohort 3 (960 mg)|Arms (both) 0.8 mL/site\*2 sites Hips (both) 1.2 mL/site\*2 sites
62524751|NCT04524052|EXPERIMENTAL|cohort 4 (1200 mg)|Arms (both) 1.0 mL/site \*2 sites Hips (both) 1.5 mL/site\*2 sites
62524752|NCT02654171|EXPERIMENTAL|AK0529|Subjects will receive single or multiple doses of AK0529 at different dose levels within different cohorts.
62712959|NCT04585750|EXPERIMENTAL|Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
62524753|NCT02654171|PLACEBO_COMPARATOR|Placebo|Patients who are randomized to the control arm within each cohort will receive the corresponding placebo to AK0529.
62524754|NCT06292884||CTD affected individuals|Individuals with genetic diagnosis of CTD.
62712960|NCT04585750|EXPERIMENTAL|Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
62712961|NCT04585750|EXPERIMENTAL|Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
62712962|NCT04585750|EXPERIMENTAL|Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
62712963|NCT04585750|EXPERIMENTAL|Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
62712964|NCT06368401|EXPERIMENTAL|Implant|Participants who pass all screening criteria will undergo a percutaneous procedure for the implantation of a permanent tricuspid repair device. Participants will be followed for 1 year to evaluate the safety and feasibility of the Versa System procedure and the Versa Tricuspid Repair Implant.
62712965|NCT06154603||Oesophageal perforation|Adult patients (at least 18 years of age) with an oesophageal perforation, treated for it at a Swedish hospital between 2005-2023.
62524755|NCT06292884||GAMT-D affected individuals|Individuals with genetic diagnosis of GAMT-D.
62524756|NCT06292884||Neurotypical controls|Healthy volunteers without known health or medical issues.
62524757|NCT02416024||No Refractory hypotension group|Patient who did not require more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia.
62524758|NCT02416024||Control|Patient who required more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia
62524759|NCT06074484|EXPERIMENTAL|RC48-ADC +AK104|Participants received 4 preoperative cycles of RC48-ADC（2.0 mg/kg，Q2W） plus AK104（6.0 mg/kg，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，Q3W）and 6 cycles of postoperative RC48-ADC（2 mg/kg，Q3W）
62524760|NCT02728752|PLACEBO_COMPARATOR|Placebo|Subjects randomized to placebo will receive 4 infusions of placebo every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to Octagam 10%. After response assessment at Week 16, all subjects with no confirmed deterioration and subjects switched to Octagam 10% due to confirmed deterioration but without further confirmed deterioration during the First Period will continue to receive 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to placebo and switched to Octagam 10% due to confirmed deterioration, who deteriorate also during Octagam 10% treatment at 2 consecutive visits will drop-out after response assessment at Week 16 and will not enter the Extension Period.
62524761|NCT02728752|EXPERIMENTAL|Octagam10%|Subjects randomized to Octagam will receive 4 infusions of 2.0 g/kg Octagam 10% every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to the alternate treatment. After response assessment at Week 16, all subjects with no confirmed deterioration during the First Period will continue receiving 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to Octagam and switched to the alternate treatment due to confirmed deterioration will drop-out after response assessment at Week 16 and will not enter the Extension Period.
62524762|NCT05965531|EXPERIMENTAL|Neoadjuvant chemo-radiotherapy with TAS-102|The patients in this group will all receive neoadjuvant treatment consisting of intensity-modulated radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102). Then the ones evaluated to have a possibility of R0 resection will receive radical surgery, followed by 6 cycles of adjuvant XELOX (capecitabine plus oxaliplatin) chemotherapy.
62524763|NCT05387707|EXPERIMENTAL|Difelikefalin 0.25 mg tablets plus TCS cream|Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
62524764|NCT05387707|EXPERIMENTAL|Difelikefalin 0.5 mg tablets plus TCS cream|Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
62524765|NCT05387707|ACTIVE_COMPARATOR|Placebo tablets plus TCS cream|Oral placebo tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
62524766|NCT05387707|PLACEBO_COMPARATOR|Placebo tablets plus Vehicle cream (Part A only)|Oral placebo tablets administered twice daily. Vehicle cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
61975649|NCT05534750|EXPERIMENTAL|Linezolid arm|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
62524767|NCT03195777|EXPERIMENTAL|Single Arm: Observation after Imaging|This is a single-arm study, where subjects will be monitored for development of PTS after baseline non-invasive imaging with FDG PET/CT. The experimental interventIon is the PET/CT imaging.
62524768|NCT00642694|EXPERIMENTAL|1|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)
62152244|NCT03979352|PLACEBO_COMPARATOR|Placebo arm|"Participant will take placebo for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the empagliflozin arm.~Participant and research staff is blinded to arm assignment."
62152245|NCT06318572|EXPERIMENTAL|Psychological intervention|
62152246|NCT06318572|PLACEBO_COMPARATOR|Placebo|
62152247|NCT02919059|EXPERIMENTAL|Dapagliflozin 10 mg|Dapagliflozin 10 mg once daily during 24 weeks
62152248|NCT02919059|ACTIVE_COMPARATOR|Glimepiride 4 mg|Glimepiride 4 mg once daily during 24 weeks
62152249|NCT02378584|OTHER|natural cycle|Ultrasound controls and endocrine blood test to asses the day of ovulation for embryo transfer
62152250|NCT02378584|ACTIVE_COMPARATOR|hormonal cycle|Ultrasound controls and endocrine blood test to asses the endometrium thickness for embryo transfer
62152251|NCT01645241|EXPERIMENTAL|Lutheal phase ovarian stimulation|Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
62524769|NCT00642694|PLACEBO_COMPARATOR|2|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)
62524770|NCT03562741|EXPERIMENTAL|Fecal Microbiota Transplantation|Subjects receive intervention of stool transplanted to the colon via colonoscopy.
62524771|NCT02622451|OTHER|Youth Behavioral Intervention|Teen Intervene
62524772|NCT02622451|OTHER|Parent Education|Everyday Parenting
62524773|NCT00816361|EXPERIMENTAL|MEDI-573 0.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 0.5 milligram per kilogram (mg/kg) as a 60-minute intravenous (IV) infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62524774|NCT00816361|EXPERIMENTAL|MEDI-573 1.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 1.5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62152252|NCT06226116|EXPERIMENTAL|socket preservation with autologous dentin|
62524775|NCT00816361|EXPERIMENTAL|MEDI-573 5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62524776|NCT00816361|EXPERIMENTAL|MEDI-573 10 mg/Kg QWk Dose Escalation|Participants received MEDI-573 10 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62152253|NCT06226116|PLACEBO_COMPARATOR|extract teeth socket|only stabilized blood clot
62152254|NCT00547456|OTHER|Decrease in oxygen level when sleeping|Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
62152255|NCT04101188|EXPERIMENTAL|Moderate Potassium/Low Sodium|Subjects will be provided with a diet that is moderate in potassium and low in sodium.
62152256|NCT04101188|EXPERIMENTAL|Moderate Potassium/High Sodium|Subjects will be provided with a diet that is moderate in potassium and high in sodium.
62152257|NCT04101188|EXPERIMENTAL|High Potassium/High Sodium|Subjects will be provided with a diet that is high in both potassium and sodium.
62152258|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
62524777|NCT00816361|EXPERIMENTAL|MEDI-573 15 mg/Kg QWk Dose Escalation|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62152259|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
62152260|NCT03949478|PLACEBO_COMPARATOR|Placebo|Patients will receive placebo for at least five days prior to the first blood flow study. They will continue to receive placebo until the baseline study is obtained after the postictal study has been completed.
62152261|NCT03949478|EXPERIMENTAL|Ibuprofen|Patients will receive ibuprofen 400 mg by mouth three times a day (po tid) for at least five days prior to the first blood flow study. They will continue to receive ibuprofen until the baseline study is obtained after the postictal study has been completed.
62524778|NCT00816361|EXPERIMENTAL|MEDI-573 30 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 30 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62524779|NCT00816361|EXPERIMENTAL|MEDI-573 45 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 45 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62524780|NCT00816361|EXPERIMENTAL|MEDI-573 5 mg/Kg QWk Dose Expansion|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62524781|NCT00816361|EXPERIMENTAL|MEDI-573 15 mg/Kg QWk Dose Expansion|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
62524782|NCT03936673|EXPERIMENTAL|atrophic kidney|Patients diagnosed with unilateral obstructed kidney with RRF 10% or less underwent application of percutaneous nephrostomy tube on affected side.
62524783|NCT01744093|ACTIVE_COMPARATOR|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
62524784|NCT01744093|PLACEBO_COMPARATOR|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
62524785|NCT05966220|OTHER|Total hip arthroplasty (THA) and Revision THA|Patients will be monitored for up to 15 years postoperatively.
62524786|NCT05966220|OTHER|Traumatology: femoral neck Total hip arthroplasty or hemiarthroplasty|Patients will be monitored for up to 10 years postoperatively.
62152262|NCT03949478|EXPERIMENTAL|Nifedipine|Patients will receive nifedipine 10 mg po tid for 2 days, then 20 mg po tid, thereafter for at least five days prior to the first blood flow study. They will continue to receive nifedipine until the baseline study is obtained after the postictal study has been completed.
62524787|NCT03819621|EXPERIMENTAL|OCULAR PROSTHESIS MOTILITY|All participants ocular prosthesis motility will be measured using the mediGrid app, Image J software in comparison to the ruler as a gold standard.
62712966|NCT06154603||Gastric perforation|Adult patients (at least 18 years of age) with a gastric perforation, treated for it at a Swedish hospital between 2005-2023.
62524788|NCT03120533|EXPERIMENTAL|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
62152263|NCT01728090|EXPERIMENTAL|Hand sanitizer|"Intervention classrooms received alcohol-based hand sanitizer and a programme educational.~Characteristics of the hydroalcoholic gel (ALCO ALOE GEL): chlorhexidine digluconate at 20% solution, phenoxyethanol 1%, benzalkonium chloride 0.%. aloe Barbadensis 5%, Renat ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 65 - 70% degrees, pondus Hydrogenium (pH) = 7-7,5."
62152264|NCT01728090|NO_INTERVENTION|Control|No hand sanitizer or educational programme were used
62152265|NCT03260452|EXPERIMENTAL|Patients|'Abdominal subcutaneous biopsies and Blood test'
62152266|NCT02446015|EXPERIMENTAL|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
62524789|NCT03120533|PLACEBO_COMPARATOR|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
62524790|NCT01785121|ACTIVE_COMPARATOR|Control Group|Patients who are randomized to the MSO group will get a protocoled exercise advice from a member of the HF team (nurse, cardiologist or physiotherapist). During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their current activity.
62524791|NCT01785121|EXPERIMENTAL|Wii Group|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
62524792|NCT03776253|EXPERIMENTAL|Supportive care (CFS)|"Patients attend CFS psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. Patients also complete home practice assignments comprising attention training technique and mindfulness practice after each session.~Patients complete self-report questionnaires at baseline (T1), 8 weeks (T2) and 12 weeks (T3)."
62524793|NCT04971265|EXPERIMENTAL|Low SES/High Supports|"Participants assigned to the Low SES/High Supports arm will see the Low SES/High Supports intervention"
62524794|NCT04971265|EXPERIMENTAL|Low SES/Low Supports|"Participants assigned to the Low SES/Low Supports arm will see the Low SES/Low Supports intervention"
62524795|NCT04971265|EXPERIMENTAL|High SES/High Supports|"Participants assigned to the High SES/High Supports arm will see the High SES/High Supports intervention"
62524796|NCT04971265|EXPERIMENTAL|High SES/Low Supports|"Participants assigned to the Low SES/High Supports arm will see the High SES/Low Supports intervention"
62524797|NCT00343239|EXPERIMENTAL|Docetaxel/Cisplatin/Fluorouracil (DCF)|DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability
62524798|NCT03265366|EXPERIMENTAL|ABPA|15 patients with ABPA
62524799|NCT03265366|ACTIVE_COMPARATOR|Severe asthma|12 patients with severe asthma
62524800|NCT04003584||Minimally Invasive Cardiac Bypass patients|
62524801|NCT04003584||Traditional Sternotomy Cardiac Bypass patients|
62524802|NCT02983136|EXPERIMENTAL|Study site|The study arm will consist of managers and staff at at the operating department of a University hospital in western Sweden' The intervention is based on partnership, dialogue and inter-professional learning
62524803|NCT02983136|NO_INTERVENTION|Control site|The Control arm will consist of managers and staff at at the operating department of a University hospital in south Sweden
62524804|NCT00251225|EXPERIMENTAL|Hormone Refractory Prostate Cancer|Gleevec + Docetaxel: Daily Oral Gleevec in Combination with Every-Three-Week Intravenous Docetaxel
62712967|NCT06154603||Small intestinal perforation|Adult patients (at least 18 years of age) with a small intestinal perforation, treated for it at a Swedish hospital between 2005-2023.
62152267|NCT02446015|ACTIVE_COMPARATOR|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
62152268|NCT02301286|EXPERIMENTAL|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
62152269|NCT02301286|PLACEBO_COMPARATOR|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
62152270|NCT06395207|EXPERIMENTAL|Optimized standard of care for CCM plus ProCCM|ProCCM will be implemented for two months near the start of the transmission season, and the existing program will be supplemented to ensure that HTR CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed.
62152271|NCT06395207|ACTIVE_COMPARATOR|Standard of care|As in arm 1 without ProCCM
62524805|NCT02583893|EXPERIMENTAL|Sirolimus, MEC chemotherapy|Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
62524806|NCT01036490|NO_INTERVENTION|Control|Control group
62524807|NCT01036490|EXPERIMENTAL|Exercise|Exercise Group
62524808|NCT03003273|EXPERIMENTAL|arm (A) - stoppage of antibiotics|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
62712968|NCT05500989||Short track controls|"Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies).~Follow up roughly 18 months postpartum."
62524809|NCT03003273|ACTIVE_COMPARATOR|arm (B) - oral antibiotics till ANC ≥ 500|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.
62524810|NCT05627167|EXPERIMENTAL|Daytime Cyclic enteral nutrition|Patients receive continuous isocaloric enteral feeding for 10 hours during the day (e.g. 08:00 to 18:00) via nasal or oro-gastric tube
62524811|NCT05627167|ACTIVE_COMPARATOR|Continuous enteral nutrition|Patients receive isocaloric enteral feeding continuously 24 hours a day via nasal or oro-gastric tube
62152272|NCT06395207|NO_INTERVENTION|Routine implementation (control)|No changes (business as usual) to iCCM, SBCC and stock management.
62152273|NCT03153423|OTHER|Basic intermittent exotropia patients|
62152274|NCT01787409|EXPERIMENTAL|Treatment (cholecalciferol)|Vitamin D sufficient patients receive no intervention. Vitamin D insufficient patients receive cholecalciferol PO once weekly for 12 weeks and then once monthly for a total of 36 months.
62152275|NCT02097316|EXPERIMENTAL|JewelPump|JewelPump for the first treatment period followed by the usual pump for the second treatment period
62152276|NCT02097316|ACTIVE_COMPARATOR|Usual insulin pump|Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump.
62152277|NCT04604717|EXPERIMENTAL|Pulmonary rehabilitation|8 weeks of pulmonary rehabilitation (twice weekly training) Exercise and education sessions accompanied by home exercise program
62152278|NCT04604717|NO_INTERVENTION|Control group|Usual medical treatment for 8 week period
62152279|NCT03437655|ACTIVE_COMPARATOR|Zinc oxide and eugenol|Temporary direct restoration with zinc oxide and eugenol.
62524812|NCT03250676|EXPERIMENTAL|H3B-6545 Arm 1: Dose escalation|
62524813|NCT03250676|EXPERIMENTAL|H3B-6545 Arm 2: Phase 2|
62524814|NCT03795896|EXPERIMENTAL|Optic nerve sheath diameter|The intracranial pressure will be measured by optic nerve sheath diameter while the patient in supine position with 30 -degree bed position .The linear probe in the two -dimensional mode will be placed gently on the upper eyelid without pressure .In linear horizontal orientation for both right and left optic nerve sheath will be measured
62524815|NCT02996045|EXPERIMENTAL|Treatment|Clinical Decision Support (CDS)
62524816|NCT02996045|NO_INTERVENTION|Control|Will not receive Clinical Decision Support (CDS)
62524817|NCT06224322||Cerebral Palsy Patients Parent|Parents of patients who underwent knee and hip surgery for cerebral palsy
62524818|NCT00003851|ACTIVE_COMPARATOR|Nutritional Arm|Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
62152280|NCT03437655|ACTIVE_COMPARATOR|Mineral trioxide aggregate|Temporary direct restoration with Mineral trioxide aggregate.
62152281|NCT01667159|EXPERIMENTAL|Integrated Cognitive Behavioral Therapy|Adolescents and their parent(s) will receive integrated cognitive behavioral therapy.
62152282|NCT01667159|ACTIVE_COMPARATOR|Standard Care|Adolescents and their parent(s) will receive treatment as usual through a community intensive outpatient program.
62152283|NCT02073214|EXPERIMENTAL|Probiotic|"Single dose of probiotic, was administered enterally twice daily with food (in the morning and in the evening). The first dose of probiotic was administered within the first 48 hours after birth. The probiotic administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the probiotic. If the probiotic was discontinued for more than 7 days, the patient was withdrawn from the study."
62524819|NCT00003851|ACTIVE_COMPARATOR|Chemotherapy Arm|Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy. Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
62152284|NCT02073214|PLACEBO_COMPARATOR|Placebo|"Single dose of placebo was administered enterally twice daily with food (in the morning and in the evening). The first dose of placebo was administered within the first 48 hours after birth. The placebo administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the placebo. If the placebo was discontinued for more than 7 days, the patient was withdrawn from the study."
62152285|NCT02499809|EXPERIMENTAL|Passive|Passive recovery
62152286|NCT02499809|EXPERIMENTAL|Vibration|Vibration recovery
62152287|NCT03791190|ACTIVE_COMPARATOR|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
62152288|NCT03791190|EXPERIMENTAL|Regional citrate anticoagulation|"Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.~Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.~Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level."
62152289|NCT00704548|ACTIVE_COMPARATOR|1|Simvastatin 40 mg
62152290|NCT00704548|PLACEBO_COMPARATOR|2|
62524820|NCT01398943|EXPERIMENTAL|COPD Patients|"Patients with COPD~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
62524821|NCT01398943|EXPERIMENTAL|Controls|"Healthy age- and sex- matched controls~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
62152291|NCT03155399|EXPERIMENTAL|Proprioceptive based training (PBT)|The treatment will last one hour and will be divided as follows: 2 proprioceptive based stimulation sessions per 3 minutes for each movement, with a rest of 2 minutes between each session. Every patient will receive 15 treatments, 5 days a week, for 3 weeks.
62524822|NCT05259878||Control|A Control group of students at CFB Borden will be recruited to complete questionnaires.
62152292|NCT03155399|OTHER|Conventional neuromotor treatment (CNT)|The CNT group will be treated for one hour daily by means of a CNT programme. The treatment will last 3 weeks.
62524823|NCT05259878||Patients with chronic pain|Patients are active service members, ranging from the age of 18-60 years old, referred primarily from the National Capital Region, CFB Petawawa, CFB Kingston, and CFB Trenton for consultation and management
62524824|NCT02929446|EXPERIMENTAL|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
62524825|NCT02929446|NO_INTERVENTION|Control|No mobilisation or breathing exercises until discharge or maximum 6 hours
62524826|NCT02929446|EXPERIMENTAL|Mobilisation and breathing exercises (PEP)|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
62524827|NCT04190849||Non-alcoholic fatty liver disease patients|Children (\<18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.
62524828|NCT03181698||first group|patients with more than one episodes of mania
62524829|NCT03181698||second group|sex-matched and age- matched healthy controls
62524830|NCT02914093|EXPERIMENTAL|IMT-feasibility|Single arm intervention
62524831|NCT04646486|EXPERIMENTAL|Intervention - Video debriefing|Baseline period (year 1): Standard practice. Intervention period (year 2-3): All teams will be assigned to video debriefing.
62524832|NCT05372133|EXPERIMENTAL|Split Script|Participants will receive four doses initially, with opportunity to obtain four additional doses if required
62524833|NCT06141161||group A,|group A (controlled bronchial asthma patients)
62524834|NCT06141161||group B|group B(uncontrolled bronchial asthma patients)
62524835|NCT05568693|EXPERIMENTAL|mRNA-enhanced immunoem|1 dose of 0.3 ml of mRNA vaccine
62524836|NCT01870245|EXPERIMENTAL|ACHN-975|
62152293|NCT06220578||candidates seeking corneal refractive surgery|Persons from both sexes between 18 and 45 years seeking corneal refractive surgery
62152294|NCT04405180|EXPERIMENTAL|20 mg Sodium Nitrite TID Arm|Subject is to receive active study drug three times per day during treatment (12 weeks +/- 5 days) period and then after the treatment period (up to 16 weeks total).
62152295|NCT04405180|PLACEBO_COMPARATOR|Placebo Control Arm|Subject is to receive placebo three times per day during treatment period (12 weeks +/- 5 days) and then after the treatment testing period (up to 16 weeks total).
62152296|NCT05514678|EXPERIMENTAL|Cognitive Stimulation Therapy|In the 2nd, 3rd, 4th, 6th, 7th and 8th weeks, IPT implementation twice a week, as two themes, for 7 weeks, with each session of 45 minutes.
62152297|NCT05514678|EXPERIMENTAL|CST nonpharmacological intervention|Individuals in the control group will be given two sessions in the 2nd week, and they will continue their daily lives in the following weeks.
62152298|NCT05910788|ACTIVE_COMPARATOR|HFNC|The intervention group will receive HFNC therapy at induction of anesthesia. The intervention group will receive oxygen by 100% HFNC with a flow of 40 L.min-1 being increased to 70 L.min-1 during the period of apnea. A rapid sequence of orotracheal intubation will be performed, considering the time of apnea the moment of disappearance of the capnography line until the first ventilation after tube placement.
62152299|NCT05910788|NO_INTERVENTION|Convencional oxygen therapy|Control group will receive conventional oxygen therapy by mask facial, with 100% oxygen and flow of 10 L.min-1.After surgery, patients who are extubated in the operating room or in theintensive care unit, will remain in the control and intervention groups and will receive therapy for conventional oxygen or HFNC, respectively.
62524837|NCT01870245|PLACEBO_COMPARATOR|Placebo|
62524838|NCT03340064|EXPERIMENTAL|Levetiracetam|"Subjects aged 1 month to \<6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to \<6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to \<4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day.~At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to \<6 months or by LEV 20 mg/kg/day for subjects aged 6 months to \<4 years at 2-week intervals to 0 mg/kg/day."
62524839|NCT03560349|EXPERIMENTAL|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
62524840|NCT03560349|PLACEBO_COMPARATOR|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
62524841|NCT02161120|ACTIVE_COMPARATOR|Traditional rye bread|As part of habitual diet participants are expected to consume 100-200 grams of traditional Finnish rye bread daily
62524842|NCT02161120|EXPERIMENTAL|Low-FODMAP rye bread|As part of habitual diet participants are expected to consume 100-200 grams of low-FODMAP rye bread daily
62712969|NCT05500989||Short track early PE with IUGR|"These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
62712970|NCT05500989||Short track early PE without IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
62712971|NCT05500989||Short track late PE with IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
62152300|NCT02626494|EXPERIMENTAL|Cocaine Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
62524843|NCT02681146|EXPERIMENTAL|Group1|Educational advice + physiotherapist treatment
62524844|NCT02681146|EXPERIMENTAL|Group2|Educational advice + physiotherapist treatment
62524845|NCT02681146|EXPERIMENTAL|Group3|Educational advice + physiotherapist treatment
62524846|NCT02681146|EXPERIMENTAL|Group4|Educational advice + physiotherapist treatment
62524847|NCT02681146|EXPERIMENTAL|Group5|Educational advice + physiotherapist treatment
62524848|NCT02681146|EXPERIMENTAL|Group6|Educational advice + physiotherapist treatment
62524849|NCT02681146|EXPERIMENTAL|Group7|Educational advice + physiotherapist treatment
62524850|NCT02681146|EXPERIMENTAL|Group8|Educational advice + physiotherapist treatment
62524851|NCT06051565|EXPERIMENTAL|Polysaccharide superparamagnetic iron oxide injection|Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3 mg/kg dose
62524852|NCT00735917|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62524853|NCT05079386|EXPERIMENTAL|New Voice Prosthesis|Patients will use the New Voice Prosthesis for two weeks to investigate short term feasibility and explore limitations and advantages. If the patient wishes to leave the New Voice Prosthesis in situ, this will be allowed under the condition that the subject agrees to remain in the study and report (adverse) events on an ongoing basis, until the device is removed after a maximum of 12 months.
62524854|NCT01547364|PLACEBO_COMPARATOR|Caudal Saline|
62524855|NCT01547364|ACTIVE_COMPARATOR|Caudal Dextrose|
62524856|NCT03242460|EXPERIMENTAL|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
62524857|NCT05387174|EXPERIMENTAL|Experimental group nursing intervention with technological support|Experimental group composed of 40 with the same characteristics as above and attending the San Antonio de Pichincha Health Center, this group will additionally receive a nursing intervention of 3 months, to reduce the risk factors of MS and improve the quality of life related to health. The nursing intervention with web application support will consist of three elements: Individual face-to-face individual Nursing Counseling, Group Education and Physical Activity sessions through virtual platform.
62152301|NCT02626494|ACTIVE_COMPARATOR|Healthy Control Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
62152302|NCT00624377||COPD patients|
62152303|NCT02684136|EXPERIMENTAL|suvorexant|9 nights of 20 mg suvorexant
62712972|NCT05500989||Short track late PE without IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
62712973|NCT05500989||Long term follow up track cases|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE \< 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
62152304|NCT02684136|PLACEBO_COMPARATOR|placebo|9 nights placebo
62152305|NCT01707563|OTHER|Marfan patients|Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
62712974|NCT06717633|NO_INTERVENTION|Control|Control group only receives a daily exercise program, including knee joint range of motion, stretching, and strengthening exercises.
62152306|NCT01707563|OTHER|control patients|Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
62152307|NCT02995447||epilepsy patients|The group consists of patients with therapy refractory epilepsy, in which intracerebral electrodes were implanted to locate the seizure origin and to determine whether the patients are eligible for epilepsy surgery. In an observational study, differences between surface and intracerebral EEG are recorded.
62152308|NCT00805441|PLACEBO_COMPARATOR|Placebo|
62152309|NCT00805441|EXPERIMENTAL|LY686017|
62152310|NCT02868983|EXPERIMENTAL|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
62152311|NCT02868983|NO_INTERVENTION|Co-Location|A Behavioral Health Clinician (BHC) such as a psychologist or counselor is housed in or near the primary care practice.
62152312|NCT05873296|EXPERIMENTAL|Health Education|Group of women being treated for breast cancer
62524858|NCT05387174|NO_INTERVENTION|Group compared regular care at the MSP Health Center|Comparison group composed of 40 women in the climacteric stage between 40 and 59 years old who have two risk factors of MS (abdominal obesity and arterial hypertension), who go to the Health Center of the People's Committee, to the group of the Hypertensive Program that receive the usual attention of the Institution on group talks, health fairs based on general topics of the disease.
62524859|NCT05533398|EXPERIMENTAL|Stress ball use|They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work.
62524860|NCT05533398|NO_INTERVENTION|Control group|During the control condition, patients received standard care and did not use stress ball.
62524861|NCT05090228||PVR/PPVI|Adult patients with congenital heart disease (GUCH) undergoing pulmonary valve replacement (PVR) or percutaneous pulmonary valve insertion (PPVI).
62524862|NCT01296659|EXPERIMENTAL|AIM Arm|Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)
62152313|NCT05873296|NO_INTERVENTION|usual care|Group of women who will remain in usual care
62152314|NCT03337022|EXPERIMENTAL|CC-90006; Dose level 1|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
62152315|NCT03337022|EXPERIMENTAL|CC-90006; Dose level 2|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
62152316|NCT03337022|EXPERIMENTAL|CC-90006; Dose level 3|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
62152317|NCT03337022|EXPERIMENTAL|CC-90006; Dose level 4|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
62152318|NCT03337022|PLACEBO_COMPARATOR|Placebo|Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29.
62524863|NCT01296659|EXPERIMENTAL|TG Arm|Ridaforolimus combined with docetaxel and gemcitabine (TG)
62524864|NCT02158312|EXPERIMENTAL|transcranial direct current stimulation|bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, for 20 minutes
62524865|NCT02158312|PLACEBO_COMPARATOR|sham stimulation|same as the experimental stimulation condition but only for 2 minutes
62524866|NCT03075319|EXPERIMENTAL|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
62524867|NCT03075319|ACTIVE_COMPARATOR|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
62712975|NCT06717633|EXPERIMENTAL|ESWT|The ESWT will be administered using an ESWT device (Modus ESWT Compact Model-Portable) once weekly over three consecutive weeks, resulting in a total of three sessions. A radial shockwave mode was chosen for the therapy. During each session, participants will receive 3000 pulses at an 12-Hz frequency and pneumatic pressure of 2.5 bars
62712976|NCT06717633|EXPERIMENTAL|LLLT|The MLS (Multiwave Locked System) laser is a specific type of low-level laser therapy (LLLT) that combines two different wavelengths of light-typically 808 nm (near-infrared) and 905 nm (mid-infrared)-to produce therapeutic effects. These wavelengths are delivered simultaneously in a synchronized manner, which is intended to enhance the overall effectiveness of the treatment. LLLT will be conducted with the laser device (MLS Laser M6 Robotic Multiwave Lock System, Asalaser, Italy) with the use of protective goggles, and the treatment parameters were set as follows: 100% power, 3 Joules per treatment spot with 904 nm wavelength, and a treatment area of 20 cm². The LLLT will be applied to five points on the anterior part of the joint space, with each point treated for 3 minutes, totaling 15 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
62152319|NCT02392507|EXPERIMENTAL|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg\*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.~Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).~Participants may continue to receive treatment until discontinuation criteria are met."
62152320|NCT00606788|ACTIVE_COMPARATOR|AW|Patients received computer-driven protocolized weaning (= Automated Weaning)
62524868|NCT02121275||Laparoscopic surgery|Patients undergoing laparoscopic surgery under general anaesthesia, patients undergo ultrasound of the lungs and electric impedance tomography at 4 times during anaesthesia
62152321|NCT00606788|ACTIVE_COMPARATOR|CW|Patients received physician-directed non-protocolized weaning (= Conventional Weaning)
62524869|NCT02302521||Healthy Younger Adults|Age: 20-30. Gender: male or female. No neurological conditions.
62524870|NCT02302521||Healthy Older Adults|Age: 50-70. Gender: male or female. No neurological conditions.
62152322|NCT02211872|EXPERIMENTAL|Treatment A|BI 2536 BS single rising dose
62524871|NCT02302521||Parkinson's disease|Gender: male or female. Tremor dominant Parkinson's disease.
62524872|NCT02302521||Healthy Children|Age: 4-8. Gender:male or female. No neurological conditions.
62152323|NCT02211872|EXPERIMENTAL|Treatment B|BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
62524873|NCT05717504|ACTIVE_COMPARATOR|Disclosure|Group A (disclosure arm): patients and physicians will be informed about all AF episodes identified on ILR lasting for ≥6 minutes.
62524874|NCT05717504|ACTIVE_COMPARATOR|Non-Disclosure|Group B (non-disclosure arm): patients and physicians will be only informed about AF episodes identified on ILR lasting for ≥24h. This longer threshold is selected because of its association with increased risk of systemic embolism.
62524875|NCT05565339||1|"Total Ossicular Replacement Prostheses:~The primary objective for the total ossicular replacement prostheses was to achieve an ABG ≤ 20 dB by at least 25 % of the patients after the PMEI implantation"
62524876|NCT05565339||2|"Partial Ossicular Replacement Prostheses:~The primary objective for the partial ossicular replacement prostheses was to achieve an ABG ≤ 20 dB by at least 53.8 % of the patients after the PMEI implantation."
62524877|NCT05565339||3|"Stapesplasty Prostheses:~The primary objective for the stapes prostheses was to achieve an ABG ≤ 20 dB by at least 86 % of the patients after the PMEI implantation."
62712977|NCT06717633|EXPERIMENTAL|PEMF|For PEMF, the applicator of the device (Easy QS Magnetotherapy Portable Magnetotherapy Medical Device, Asalaser, Italy) will be positioned to target the medial and lateral aspects of the knee. The treatment parameters were defined as follows: rectangular field shape, 30 Hz frequency, 10 mT intensity, and a duration of 20 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
62712978|NCT02031302||Lotus Valve|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
62152324|NCT01596465|ACTIVE_COMPARATOR|Control|Control arm
62152325|NCT01596465|ACTIVE_COMPARATOR|Intervention|Intervention arm
62524878|NCT01350843|EXPERIMENTAL|Orange Juice|Juice high in flavonoids
62524879|NCT01350843|PLACEBO_COMPARATOR|Orange Drink|Sugars matched, low flavonoids orange drink
62524880|NCT06290518|EXPERIMENTAL|Probiotic group|All women in the probiotic group consume (oral route) a daily capsule with \~50 mg of freeze-dried probiotic (9.5 log10 CFU of L. salivarius CECT5713; excipient: maltodextrin) during the 6 months prior to the fertility treatment and during the first IVF cycle (estimated 1-2 months). In case of pregnancy, the woman will continue the treatment until 12 weeks of gestation.
62524881|NCT06290518|PLACEBO_COMPARATOR|Placebo group|All women in the placebo group consume (oral route) a daily capsule with \~50 mg of maltodextrin during the 6 months prior to the fertility treatment and during the first IVF cycle (estimated 1-2 months). In case of pregnancy, the woman will continue the treatment until 12 weeks of gestation.
62524882|NCT01019473|EXPERIMENTAL|AFQ056A|
62524883|NCT01019473|PLACEBO_COMPARATOR|Placebo|
62524884|NCT06024083|NO_INTERVENTION|Assessment only|Daily assessment of emotion regulation and self-efficacy variables.
62524885|NCT06024083|EXPERIMENTAL|Acceptance-oriented skills followed by change-oriented skills|Administration of acceptance-oriented skills videos first followed by change-oriented skills videos.
62152326|NCT06419257|EXPERIMENTAL|VRDS users|Individuals who would use the VRDS
62152327|NCT04766996|EXPERIMENTAL|Prospective cases undergoing non-opioid drug regimen|Prospective study participants undergoing unilateral total hip replacement surgery and non-opioid drug regimen perioperatively
62152328|NCT04766996|NO_INTERVENTION|Retrospective control underwent opioid drug regimen|Retrospective controls that underwent unilateral total hip replacement surgery and used opioid drug regimen perioperatively
62152329|NCT04766996|NO_INTERVENTION|Professional Staff|Staff that participate in the implementation of the opioid free surgical protocol will be completing team assessment surveys seeking their opinion about interprofessional teamwork and communication.
62524886|NCT06024083|EXPERIMENTAL|Change-oriented skills followed by acceptance-oriented skills|Administration of change-oriented skills videos first followed by acceptance-oriented skills videos.
62152330|NCT01711788|EXPERIMENTAL|Intrabone umbilical cord blood tranplant|Intrabone infusion of umbilical cord blood stem cells
62152331|NCT04828915||Training cohort|Randomly selection of 80% of the study population. The machine learning algorithm is trained on this dataset
62152332|NCT04828915||Validation cohort|Randomly selection of 20% of the study population. The machine learning algorithm which was trained on the basis of the training data cohort is validated on the validation cohort.
62152333|NCT00915915|EXPERIMENTAL|Arm 1|
62524887|NCT01649271|EXPERIMENTAL|Phase Ia, group 1|afatinib escalating dose with 3-weekly trastuzumab
62524888|NCT01649271|EXPERIMENTAL|Phase Ia, group 2|afatinib at MTD dose with weekly trastuzumab
62524889|NCT01649271|EXPERIMENTAL|Phase Ib|afatinib at MTD level with 3-weekly trastuzumab
62524890|NCT02015689|EXPERIMENTAL|Benefits to Child|CDC VIS + message emphasizing benefits of MMR vaccine to child
62524891|NCT02015689|ACTIVE_COMPARATOR|CDC VIS|CDC Vaccine Information Statement (VIS)
62524892|NCT02015689|EXPERIMENTAL|Benefits to Society|CDC VIS + message emphasizing benefits of MMR vaccine to society
62524893|NCT02015689|EXPERIMENTAL|Benefits to Child and Society|CDC VIS + message emphasizing benefits of MMR vaccine to both child and to society
62524894|NCT01388166||Patients with COPD|
62524895|NCT04163978|EXPERIMENTAL|Nitric oxide releasing solution (NOSi)|DailyTopical sinus irrigation delivery of 240mL NOSi
62524896|NCT04163978|ACTIVE_COMPARATOR|Budesonide -saline|Daily Topical sinus irrigation delivery of 240 mL of 1 mg Budesonide-saline
62524897|NCT02890836||Pregnant women with pre-existing diabetes|Inclusion of 400 women is anticipated.
62524898|NCT02890836||Healthy pregnant women|Inclusion of 100 women is anticipated
62524899|NCT00431275|EXPERIMENTAL|Commercial Formulation|Commercial Formulation
62524900|NCT00431275|EXPERIMENTAL|Current Formulation|Current Formulation
62524901|NCT05342415|ACTIVE_COMPARATOR|Internally Focused|Focusing on the muscles that reveal the movement.
62524902|NCT05342415|EXPERIMENTAL|Externally Focused|Focusing on the result of the movement.
62524903|NCT00062010|EXPERIMENTAL|IFN-alpha, 13-CRA, paclitaxel|Interferon alpha: 6 million U/m2 on days 1 and 2 of each week for 6 weeks of an 8-week cycle 13-cis-retinoic acid: 1 mg/kg on days 1 and 2 of each week for 6 weeks of an 8-week cycle Paclitaxel: 75 mg/m2 on day 2 of each week for 6 weeks of an 8-week cycle
62524904|NCT02916017||Participants receiving adalimumab|Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
62524905|NCT00468078|EXPERIMENTAL|A|Parkinson's disease
62524906|NCT00468078|ACTIVE_COMPARATOR|B|ET+Normal
62524907|NCT05215717|EXPERIMENTAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
62524908|NCT05215717|ACTIVE_COMPARATOR|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
62524909|NCT01303536|EXPERIMENTAL|obsessive compulsive disorder|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
62524910|NCT05865808|EXPERIMENTAL|Cervical spine mobilization|Subjects in this group will be treated with headache SNAGs
62524911|NCT05865808|ACTIVE_COMPARATOR|Rocabado 6x6 exercises|Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique.
62152334|NCT00915915|EXPERIMENTAL|Arm 2|
62152335|NCT03688087|PLACEBO_COMPARATOR|placebo|"Smartphone application placebo"
62152336|NCT03688087|ACTIVE_COMPARATOR|"Bouge"|"Smartphone equipped with the application Bouge"
62152337|NCT04249700|EXPERIMENTAL|Whole-body Hyperthermia (WBH)|All participants receive WBH for 80-110 minutes in the Curve Sauna Dome infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
62152338|NCT01196286|EXPERIMENTAL|MFG and CR|Subjects provided with both multifamily psychoeducation (MFG) and cognitive remediation (CR)
62524912|NCT04841018|EXPERIMENTAL|Control|Higher dose of dexamethasone (0.5mg/kg) that is known to enhance the analgesic quality of caudal block from previous study
62524913|NCT04841018|EXPERIMENTAL|Dexamethasone|Lower, antiemetic dose of dexamethasone (0.15mg/kg)
62524914|NCT05986812||Normal subjects|
62524915|NCT05986812||Diseased subjects|
62524916|NCT05369286|EXPERIMENTAL|dose level 1 of max-40279 combined dose level 1 of toripalimab|"MAX-40279-01 and toripalimab"
62524917|NCT05369286|EXPERIMENTAL|dose level 2 of max-40279 combined dose level 1 of toripalimab|"MAX-40279-01 and toripalimab"
62524918|NCT05369286|EXPERIMENTAL|dose level 2 of max-40279 combined dose level 2 of toripalimab|"MAX-40279-01 and toripalimab"
62524919|NCT05369286|EXPERIMENTAL|dose level 3 of max-40279 combined dose level 2 of toripalimab|"MAX-40279-01 and toripalimab"
62524920|NCT05369286|EXPERIMENTAL|recommend dose of max-40279 combined recommend dose level of toripalimab|"MAX-40279-01 and toripalimab"
62524921|NCT04738682|ACTIVE_COMPARATOR|Group 1 (Digital -> Conventional)|Patients allocated to Group 1 (Digital -\> Conventional) will undergo three days of digital dietary registration, using mobile devices, followed by three days of conventional dietary registration, using pen and paper.
62712979|NCT02031302||Lotus with Depth Guard|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.
62152339|NCT01196286|ACTIVE_COMPARATOR|MFG|Subjects provided with only multifamily group psychoeducation (MFG)
62712980|NCT05178784||Active Stimulation|Adults exposed to active external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
62152340|NCT02106325|EXPERIMENTAL|Ketamine|IV Ketamine .25mg/kg
62152341|NCT02106325|PLACEBO_COMPARATOR|Diphenhydramine|25mg Diphenhydramine
62712981|NCT05178784||Sham Stimulation|Adults exposed to sham external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
62712982|NCT06607523|NO_INTERVENTION|Community Controls|Community Control subjects will not receive intervention.
62152342|NCT01634295|EXPERIMENTAL|CKD-828 2.5/40, 2.5/80, 5/80mg|
62152343|NCT01634295|ACTIVE_COMPARATOR|S-Amlodipine 2.5, 5mg|
62152344|NCT02382640|EXPERIMENTAL|Sequence 1: ABDC|Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
62152345|NCT02382640|EXPERIMENTAL|Sequence 2: DACB|Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
62152346|NCT02382640|EXPERIMENTAL|Sequence 3: CDBA|Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
62152347|NCT02382640|EXPERIMENTAL|Sequence 4: BCAD|Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
62152348|NCT01420198|EXPERIMENTAL|Lifestyle intervention|Lifestyle intervention: 500 participants from Iraq with obesity and/or prediabetes (impaired fasting glucose) and we expect to recruit 308 participants. Half of them will be randomized to lifestyle intervention i.e. group counseling and physical activity during a period of 1 year. An equal amount of controls will have treatment as usual. Every third month blood tests and a physical exam will be conducted in the intervention group.
62152349|NCT01420198|NO_INTERVENTION|Controls|Controls have treatment as usual. Every third month blood tests and a physical exam will be conducted in the control group.
62152350|NCT00201825|EXPERIMENTAL|Docetaxel and Capecitabine|
62152351|NCT05629806|ACTIVE_COMPARATOR|Metformin plus pioglitazone|
62152352|NCT05629806|ACTIVE_COMPARATOR|Acarbose|
62152353|NCT03875729|EXPERIMENTAL|Teplizumab|"Teplizumab was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days.~Each course included:~* Day 1: 106 μg/m\^2~* Day 2: 425 μg/m\^2~* Days 3-12: 850 μg/m\^2 Total per course: 9.0 mg/m\^2 The doses of study drug were calculated based on the participant's body surface area (BSA) measured on the first day of each treatment course."
62712983|NCT06607523|NO_INTERVENTION|Brain Injury Patients - no intervention|Brain injury patients receiving residential standard of care post-acute neurorehabilitation.
62712984|NCT06607523|ACTIVE_COMPARATOR|Brain Injury Patients - inulin intervention|Brain injury patients receiving residential standard of care post-acute neurorehabilitation plus 42 days of daily oral inulin supplementation (4g 2x daily).
62712985|NCT05309616|EXPERIMENTAL|Talz|All participants receive Talz
62712986|NCT05476081||Patients (single cohort study)|Patients presenting with a mild-to-moderate ischemic stroke or high risk TIA
62712987|NCT06715670|EXPERIMENTAL|Treatment sequence ABCD: Zibotentan|Participants will receive single dose of Zibotentan in 4 occassions with first Treatment A, followed by Treatment B, Treatment C and then Treatment D with each dose separated by 3 washout periods.
62712988|NCT06715670|EXPERIMENTAL|Treatment sequence BDAC: Zibotentan|Participants will receive single dose of Zibotentan in 4 occassions with first Treatment B, followed by Treatment D, Treatment A and then Treatment C with each dose separated by 3 washout periods
62712989|NCT06715670|EXPERIMENTAL|Treatment sequence CADB: Zibotentan|Participants will receive single dose of Zibotentan in 4 occassions with first Treatment C, followed by Treatment A, Treatment D and then Treatment B with each dose separated by 3 washout periods.
62524922|NCT04738682|ACTIVE_COMPARATOR|Group 2 - (Conventional -> Digital)|Patients allocated to Group 2 - (Conventional -\> Digital) will undergo the exact opposite sequence, commencing with three days of conventional dietary registration, using pen and paper, followed by three days of digital dietary registration, using mobile devices.
62524923|NCT03898895|EXPERIMENTAL|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic function. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
62524924|NCT01902628||Participants with CKD|This single cohort included participants with CKD not receiving dialysis (Stages 3 and 4), with renal anemia, treated with MIRCERA according to usual clinical practice.
62524925|NCT05986331|EXPERIMENTAL|BCD-201 group|BCD-201 200 mg as a 30-minute intravenous infusion once every 3 weeks
62524926|NCT05986331|ACTIVE_COMPARATOR|Keytruda|Keytruda 200 mg as a 30-minute intravenous infusion once every 3 weeks
62524927|NCT00723645||PEG IFN alfa-2b + RBV|Adult participants with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response prior to the study. Participants received no treatment during this study.
62712990|NCT06715670|EXPERIMENTAL|Treatment sequence DCBA: Zibotentan|Participants will receive single dose of Zibotentan in 4 occassions with first Treatment D, followed by Treatment C, Treatment B and then Treatment A with each dose separated by 3 washout periods.
62524928|NCT05743231|ACTIVE_COMPARATOR|interpectoral area block + serratus anterior area block group (IPSA)|Interpectoral plane block + serratus anterior plane block will be performed randomly on the participants.
62524929|NCT05743231|ACTIVE_COMPARATOR|erector spinae group (ES)|Erector spinae block will be performed randomly on the participants
62524930|NCT02772952|OTHER|Control Group|a control group whose intervention will be to review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
62712991|NCT06122610|EXPERIMENTAL|Participants treated with Lutathera|
62152354|NCT03875729|PLACEBO_COMPARATOR|Placebo|"Placebo was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days.~The placebo solution consisted of the same formulation as the study drug but without teplizumab. Placebo was administered in the same dose volume and by the same treatment schedule as the active drug."
62712992|NCT06652295|ACTIVE_COMPARATOR|Intervention/Treatment|This group was enrolled in a complex decongestive physiotherapy programme administered by a physiotherapist five days a week for three weeks.
62152355|NCT03072745|EXPERIMENTAL|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
62152356|NCT03983642|EXPERIMENTAL|Intervention group|The intervention group received a session of 40min for an 8 weeks' period. Both games requested the participants to stand on a balance board in front of the television, without shoes, while trying to control their avatars by shifting their body weights.
62524931|NCT02772952|EXPERIMENTAL|Experimental Group|Experimental group whose intervention will be a Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program.
62524932|NCT00826579|EXPERIMENTAL|Colon cancer|Colon cancer patients of all stages
62524933|NCT02487381|EXPERIMENTAL|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
62524934|NCT02487381|EXPERIMENTAL|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
62524935|NCT02487381|EXPERIMENTAL|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) a
62524936|NCT02487381|PLACEBO_COMPARATOR|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
62712993|NCT06652295|OTHER|Self-administered Group|This group was enrolled in a self-administered complex decongestive physiotherapy programme five days a week for three weeks.
62712994|NCT05682937|EXPERIMENTAL|HFOV-sigh mode|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention.
62524937|NCT01487070|EXPERIMENTAL|Macugen (Pegaptanib Sodium)|Open-label, single-center trial. Subjects will recieve intravitreous injections of Macugen 7-14 days before Vitrectomy.
62524938|NCT06395376|EXPERIMENTAL|Hot Yoga Intervention|Bikram Hot Yoga intervention: Participants perform a minimum of 60-minutes of Hot Yoga (Bikram Sequence), 3x per week in a heated room (40 degrees C) for 6-weeks
62524939|NCT06395376|OTHER|Hot Yoga Washout|"Hot Yoga Washout: Participants complete a 6-week Washout period during which the participants performed no Hot Yoga."
62524940|NCT03687658|EXPERIMENTAL|Binge Eating Group|All participants in the study will be invited to use Laddr, described in the intervention section.
62524941|NCT03687658|EXPERIMENTAL|Smoking Group|All participants in the study will be invited to use Laddr, described in the intervention section.
62524942|NCT00515931|EXPERIMENTAL|Radiotherapy|GIST patients who have progressing metastases will be treated with radiotherapy.
62712995|NCT06658366|OTHER|Comparison conventional impression vs. digital impression|"The investigators would like to investigate the accuracy of various intraoral scanning systems. For this a conventional impression is taken from all patients to generate a reference model, which is then compared to full-arch impressions from various digital intraoral scanning systems.~The examination is carried out in the same way for all participants."
62524943|NCT03564418|ACTIVE_COMPARATOR|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
62524944|NCT03564418|ACTIVE_COMPARATOR|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.
62524945|NCT04175743|EXPERIMENTAL|200 mg CT-044 HCl or Placebo|200 mg of CT-044 HCl administered every 8 hours vs placebo
62524946|NCT04175743|EXPERIMENTAL|400 mg CT-044 HCl or Placebo|400 mg of CT-044 HCl administered every 8 hours vs placebo
62524947|NCT04175743|EXPERIMENTAL|600 mg CT-044 HCl or Placebo|600 mg of CT-044 HCl administered every 8 hours vs placebo
62524948|NCT04642859|EXPERIMENTAL|Dyslexia|Students with dyslexia before and after the intervention
62524949|NCT06444932|ACTIVE_COMPARATOR|Active Comparator|
62524950|NCT06444932|EXPERIMENTAL|Experimental Group|
62524951|NCT01781520|EXPERIMENTAL|S-1 plus DC-CIK|"Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles."
62524952|NCT01781520|ACTIVE_COMPARATOR|DC-CIK alone|DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.
62712996|NCT05165706|EXPERIMENTAL|Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
62152357|NCT03983642|NO_INTERVENTION|Control group|Participants in the control group were followed-up by an assessor, who made sure that they will not get involved in any type of training program during the eight weeks' period of the trial.
62152358|NCT04012359||Bullous emphysema|Participants with known bullous emphysema will undergo lung ultrasound according to standard of care clinical practice during a regular follow-up consultation or scheduled hospitalization.
62152359|NCT04012359||Pneumothorax|Participants hospitalized in pulmonary medicine units for the treatment of a pneumothorax will undergo lung ultrasound according to standard of care clinical practice.
62152360|NCT01043614|EXPERIMENTAL|Peer group education|Small groups of female college freshmen facilitated by peer educators
62524953|NCT01781520|ACTIVE_COMPARATOR|S-1 alone|Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
62524954|NCT01781520|ACTIVE_COMPARATOR|Best supportive care|
62524955|NCT03949244|ACTIVE_COMPARATOR|Latanoprost 0.005%|Latanoprost 0.005% drops to the nailfold.
62524956|NCT03949244|EXPERIMENTAL|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% drops to the nailfold.
62524957|NCT03949244|PLACEBO_COMPARATOR|Normal saline 0.9%|Normal saline 0.9% to the nailfold.
62524958|NCT00430495|EXPERIMENTAL|Atacicept 25 mg|
62712997|NCT05165706|EXPERIMENTAL|Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
62152361|NCT00774605|EXPERIMENTAL|Varenicline free base solution|
62524959|NCT00430495|EXPERIMENTAL|Atacicept 75 mg|
62524960|NCT00430495|EXPERIMENTAL|Atacicept 150 mg|
62524961|NCT00430495|PLACEBO_COMPARATOR|Placebo|
62524962|NCT05442671|OTHER|Home exercise intervention|"* Personalized 16 week home exercise program - aerobic exercise for 20 minutes per day/4 days per week and light resistance exercise using resistance bands 3 days per week.~* Aerobic sessions will include walking, biking, or light jogging, depending on access to facilities/equipment and weather.~* Smartwatch for the length of the intervention and a heart rate monitor during exercise sessions.~* Max heart rate prescribed will be 80% of that on recent cardiopulmonary exercise test (at most 150 beats/min).~* Heart rate monitor will sync with the smartwatch.~* Activity and heart rate data will be transmitted to the study team via a data hub connected to the participant's home internet modem several times per week.~* Periodic text messaging to remind participants to wear the watch, sync the data, or adhere to heart rate goals, to ask about symptoms, or to support activity progress.~* Multiple ways to contact the study team with questions or concerns."
62524963|NCT03835221|EXPERIMENTAL|methafilcon A toric / fanfilcon A toric contact lenses|All subjects will first wear methafilcon A toric contact lenses for four (4) weeks of daily wear, then refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
62524964|NCT06006000||Older adults returning home post-ICU|Community-dwelling older adults who return home (either directly or after a stay in short-term rehab (STR)) after an ICU hospitalization.
62712998|NCT05165706|EXPERIMENTAL|Low Fat, Healthy Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
62152362|NCT00774605|EXPERIMENTAL|Varenicline transdermal delivery system|
62524965|NCT04998019|EXPERIMENTAL|PositiveLinks|Participants from clinics randomized to PL will get the patient smartphone app; clinic staff will receive the provider portal and provider smartphone app, the provider online LMS (learning management system), and the research assistant will use the administrative website to enroll participants. Patients randomized to PL will use it for 12 months or more; they can opt to use it as long as it is available during the study(access depending on enrollment date).
62152363|NCT02160496|ACTIVE_COMPARATOR|20% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 20% protein, 30% fat and 50% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
62152364|NCT02160496|ACTIVE_COMPARATOR|27% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 27% protein, 30% fat and 43% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
62524966|NCT04998019|NO_INTERVENTION|Usual Care|Participants from clinics randomized to Usual Care (UC) will receive usual clinic retention and medication adherence support services for 12M. Based on site assessments, and descriptions from the clinics, the UC condition ranges from having no ancillary support to only case management, to Ryan White funding and comprehensive services (adherence support, patient navigation, mental health, substance abuse, dental services and food banks)
62524967|NCT06095141|EXPERIMENTAL|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8.
62524968|NCT04580121|EXPERIMENTAL|Part A: Single Participant Dose Escalation|Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.
62524969|NCT04580121|EXPERIMENTAL|Part B: Multiple Participant Dose Escalation|Multiple-participant cohorts of \>= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, every-2-weeks (Q2W), or once-a-week (QW) dosing regimens, respectively to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Additionally, step-up dosing regimens with more frequent administrations of RO7283420 during cycle 1 will be evaluated.
62524970|NCT04580121|EXPERIMENTAL|Part C: Dose Expansion|Participants will receive the respective RP2D for Group I and Group II.
62524971|NCT02109510|EXPERIMENTAL|Nonintubated sedation anesthesia|nonintubated single port thoracoscopic bullectomy using local anesthesia under sedation Drug: Dexmedetomidine IV loading dose of 1ug/kg for 10 minutes and maintain dosage of 0.3-1 ug/kg/hr, ketamine IV 2-4 mg/kg/hr and intercostal nerve block with 2% lidocaine 2cc Device: facial O2 Mask
62524972|NCT02109510|ACTIVE_COMPARATOR|Intubated general anesthesia|intubated single port thoracoscopic bullectomy under general anesthesia Drug: propofol 2mg/kg IV , rocuronium 0.6mg/kg IV,1.2-2.4% sevoflurane, N20 50% 02 at fresh gas flow of 4L/min Device: double lumen endotracheal tube intubation
62152365|NCT02160496|ACTIVE_COMPARATOR|35% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 35% protein, 30% fat and 35% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
62152366|NCT00919815|EXPERIMENTAL|ciclosporin arm|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
62152367|NCT00919815|ACTIVE_COMPARATOR|prednisolone|standard course of prednisolone given in a reducing regimen over 24 weeks
62152368|NCT02009865|EXPERIMENTAL|Epanova 2 g/day|Arm 1
62152369|NCT02009865|PLACEBO_COMPARATOR|Olive Oil 2 g/day|Arm 2
62152370|NCT05747872|EXPERIMENTAL|İntervention Grup|Buerger Allen exercises programme will be applied to the type 2 diabetes mellitus patients with foot ulcer. Patients in the intervention group performed daily Buerger Allen exercises for 12 weeks. Patients in the study intervention group were taught Buerger Allen exercises and were asked to exercise twice daily for 12 weeks. Individuals will be given an exercise diary, including the pictures of the exercises, to better manage this process. Reminder phone calls were made once a week to support the exercise program and increase motivation.
62152371|NCT05747872|NO_INTERVENTION|Control Grup|The control group received standard wound care but no exercises.
62152372|NCT04128956|EXPERIMENTAL|Aspirin®|"To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy.~To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term treatment."
62152373|NCT04128956|NO_INTERVENTION|Control group|Observational study of standard of care anticoagulation (rivarobaban dosis defined in the clinical routine).
62152374|NCT01985256|EXPERIMENTAL|Single Arm|Toca 511 vector/Toca FC
62524973|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
62524974|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
62524975|NCT00907127|ACTIVE_COMPARATOR|Mediterranean Diet and Exercise|Mediterranean Diet and Exercise
62524976|NCT04156620|EXPERIMENTAL|Secukinumab|Secukinumab intravenous (i.v.) regimen
62524977|NCT04156620|PLACEBO_COMPARATOR|Placebo|Placebo intravenous (i.v.) regimen
62524978|NCT05029401|EXPERIMENTAL|Single dose IMP (DMX-1002)|"Stage 1 (single blind, placebo controlled): initial dose of placebo, followed by treatment at one of 4 ascending dose levels of IMP (3, 6, 9 or 12 mg/kg)~Stage 2 (blinded): MTD/TTD established in Stage 1 vs placebo (proof of concept)"
62152375|NCT03556852|ACTIVE_COMPARATOR|CARBETOCIN|received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
62524979|NCT05029401|PLACEBO_COMPARATOR|Matching Placebo|Placebo using capsules identical to the IMP (DMX-1002)
62524980|NCT02212912|OTHER|Improvement intervention|Improvement intervention is a multifaceted quality improvement method including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
62524981|NCT02212912|OTHER|no intervention|The control group indicated that the physicians will not be provided with the information of multifacet improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care
62524982|NCT01088321||Patients initiating abatacept|
62524983|NCT01088321||Patients initiating other biologic disease-modifying drugs|
62524984|NCT01088321||Pts initiate non-biologic disease-modify anti-rheumatic drugs|
62524985|NCT03365167|ACTIVE_COMPARATOR|LANAP|LANAP (Laser Assisted New Attachment Procedure)
62524986|NCT03365167|PLACEBO_COMPARATOR|LANAP off|laser therapy in off mode
62524987|NCT04650113|EXPERIMENTAL|group A|placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude ) 9.The pellet will be remove, and the pulp chamber filled with MTA. 10.The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement
62524988|NCT04650113|ACTIVE_COMPARATOR|group B|"1. Pre-operative radiograph showing all roots and their apices.~2. Local anesthesia will be administered and a rubber dam will take place ,that ensure good isolation of the treated teeth.~3. Removal of caries~4. Pulp chambers will access using a no.330 bur in a high-speed hand piece with water coolant.~5. Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece~6. Pulp amputation will perform using a spoon excavator.~7. Hemorrhage control will obtain within 5 minutes using sterile cotton pellets placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude )~8. The pellet will be remove, and the pulp chamber will be filled with MTA.~9. The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement.~The periapical radiographic will be taken at this baseline visit ."
62524989|NCT00999765||Bipolar Disorder - stable|
62712999|NCT04288089|EXPERIMENTAL|Palbociclib + H3B-6545 (Dose Escalation and Dose Expansion)|Participants will receive Palbociclib 75, 100, 125 milligram (mg) capsules or tablets, orally, once daily from Days 1 to 21 followed by 7 days off treatment in 28-day cycles along with H3B-6545 150, 300, 450 mg capsules or tablets, orally, once daily from Days 1 to 28 in 28-day cycles in dose escalation part. Based on MTD or RP2D determined for H3B-6545 in combination with palbociclib in dose escalation part, participants will continue to receive study treatment in dose expansion part until PD, development of unacceptable toxicity, or withdrawal of consent (up to 24 months).
62713000|NCT05592548|EXPERIMENTAL|Study|Single arm study: split face treatment
62524990|NCT00377936|ACTIVE_COMPARATOR|1|Gemcitabine
62524991|NCT00377936|EXPERIMENTAL|2|EndoTag-1 + Gemcitabine
62524992|NCT00377936|EXPERIMENTAL|3|EndoTag-1 + Gemcitabine
62524993|NCT00377936|EXPERIMENTAL|4|EndoTag-1 + Gemcitabine
62152376|NCT03556852|ACTIVE_COMPARATOR|MISOPROSTOL|received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.
62524994|NCT05089474|EXPERIMENTAL|Streamline|Streamline Surgical System
62524995|NCT01588886||with PPI|CKD with PPI use, follow up at least 5 years began PPI use
62524996|NCT01588886||with or without Pneumonia outcome|Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting.
62524997|NCT00626314|EXPERIMENTAL|1|myoblast
62524998|NCT00626314|SHAM_COMPARATOR|2|sham injection procedure
62524999|NCT01558336|EXPERIMENTAL|Praziguantel|tablet single dose
62525000|NCT02823652|EXPERIMENTAL|Arm A (Step 1: internet-based intervention)|Patients receive web-based genetic education consisting of general information about testing tumors for genetic mutations.
62525001|NCT02823652|ACTIVE_COMPARATOR|Arm B (Step 1: usual care control)|Patients receive standard genetic education consisting of conversations with the treating physicians, interaction with and information from the clinical staff, and information from usual resources about testing for genetic mutations.
62525002|NCT02823652|EXPERIMENTAL|Step 2 - genetic counseling|Patients who meet the criteria for the remote counseling substudy will receive genetic counseling over the telephone and undergo germline testing.
62525003|NCT06406946|EXPERIMENTAL|Lions Mane|Lion's mane (1.8 gram per day, consisting of 3 x 600mgcapsules)
62525004|NCT06406946|EXPERIMENTAL|Mushroom Blend|Lion's mane and reishi mushroom blend (1.8 gram per day, consisting of 3x600mg capsules)
62525005|NCT06406946|PLACEBO_COMPARATOR|Placebo|(1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules).
62525006|NCT03412786|EXPERIMENTAL|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
62525007|NCT03412786|EXPERIMENTAL|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
62525008|NCT04048343|EXPERIMENTAL|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
62525009|NCT03829137|EXPERIMENTAL|Verum laser acupuncture|Verum laser acupuncture：Low level laser therapy stimulates 7 acupuncture points on both sides of the body .
62525010|NCT03829137|SHAM_COMPARATOR|Sham laser acupuncture|sham laser acupuncture (no laser output)
62525011|NCT01660464|EXPERIMENTAL|ADHD-Team|Intervention
62525012|NCT04731870||Nurses/Doctors|Covid-19 vaccine confidence and recommendation practices of nurses/doctors
62713001|NCT04881682|EXPERIMENTAL|Immunoadsorption|3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)
62152377|NCT00069706|EXPERIMENTAL|AL-12182 0.003%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
62152378|NCT00069706|PLACEBO_COMPARATOR|AL-12182 Solution Vehicle|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
62152379|NCT00069706|ACTIVE_COMPARATOR|Latanoprost|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
62152380|NCT00069706|EXPERIMENTAL|AL-12182 0.01%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
62525013|NCT04731870||Minority populations living in rural south|Covid-19 vaccine confidence and uptake of key at-risk subgroups and tailored Covid-10 vaccine messaging for at-risk subgroups.
62525014|NCT00132249||Head Injured|The Vietnam Head Injured Subjects
62713002|NCT04881682|ACTIVE_COMPARATOR|Immunoglobulins|5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.
62713003|NCT01758029||Testosterone Undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
62525015|NCT00132249||Head Uninjured|Uninjured Vietnam Veteran Control Subjects
62713004|NCT06719076|EXPERIMENTAL|Diabetes Healthcare Program DHCP|Type-II Diabetics in the intervention group will be received for 3 months of DHCP as well as usual care. Additional for session participation reminders messages will be sent 3 days before training and the messages will be forwarded by Principal Investigator and Research Assistant. Outcome variable will be measured at two points at the baseline and after completing of 3 months of intervention.
62713005|NCT06719076|NO_INTERVENTION|No intervention arm|Type-II Diabetes in the control group will receive usual care, which includes routine consultations with physicians and pharmacological therapy as prescribed by healthcare provider. The frequency of clinic visits will be every 3 months, with monitoring of blood glucose levels, blood pressure, and lipid profiles. The usual care protocol is based on the guidelines for the management of type 2 diabetes mellitus by the American Diabetes Association (Care, 2023)
62713006|NCT06016283||MDMR|Male recipient receiving kidney graft from male donor
62713007|NCT06016283||FDMR|Male recipient receiving kidney graft from female donor
62713008|NCT06016283||MDFR|Female recipient receiving kidney graft from male donor
62713009|NCT06016283||FDFR|Female recipient receiving kidney graft from female donor
62525016|NCT02598258|EXPERIMENTAL|Sauna + Cold Water Bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
62525017|NCT05906420||ASTRAL|
62525018|NCT02251691|EXPERIMENTAL|Advagraf|Take Advagraf once daily
62525019|NCT02251691|ACTIVE_COMPARATOR|Prograf|Take tacrolimus twice daily
62525020|NCT00833742|EXPERIMENTAL|1|ISTDP therapy was provided
62525021|NCT00833742|NO_INTERVENTION|2|People referred but never seen
62525022|NCT03801382|OTHER|Digital / Paper|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
62525023|NCT03801382|OTHER|Paper / Digital|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.
62525024|NCT03801382|OTHER|Digital / Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.
62525025|NCT03801382|OTHER|Paper / Paper|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
62525026|NCT03801382|OTHER|Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A
62525027|NCT00834652|EXPERIMENTAL|1|Participants will receive sertraline and metformin.
62525028|NCT00834652|PLACEBO_COMPARATOR|2|Participants will receive sertraline and placebo.
62525029|NCT00727727||Parkinsonian patients|
62525030|NCT02139371|EXPERIMENTAL|64Cu-DOTA-AE105 PET|One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection
62525031|NCT03714360|EXPERIMENTAL|TXA tranexamic acid|a single dose of 10 mg/kg of TXA, with a maximum dose of 1g. Administered as IV injection and marked as 'project-drug' and amount (mL) in the medical record.
62525032|NCT03714360|PLACEBO_COMPARATOR|Sodium Chloride 0,9%|an equivalent volume 0.9 % Sodium Chloride.
62525033|NCT03516214|EXPERIMENTAL|EGF816 (nazartinib) and trametinib|Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
62525034|NCT05758480|EXPERIMENTAL|Patients with Long COVID|
62525035|NCT05758480|ACTIVE_COMPARATOR|COVID-19 recovered patients (Control)|
62525036|NCT04929938|EXPERIMENTAL|Inmediate UP plus Treatment As Usual|Treatment As Usual Plus Inmediate Virtual group Therapy applying the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. The treatment consists in 15 weekly sessions of 120 minutes that combines cognitive-behavioural techniques to improve emotional self-regulation skills.
62525037|NCT04929938|ACTIVE_COMPARATOR|Waiting list plus Treatment As Usual|A waiting list for treatment with delayed UP after 7 months while receiving the treatment as usual (WL + TAU).
62525038|NCT01055132|OTHER|Etafilcon A toric contact lens/Nelfilcon A toric|Etafilcon A toric contact lens first, then nelfilcon A toric second
62525039|NCT01055132|OTHER|Nelfilcon A toric/ Etafilcon A toric|Nelfilcon A toric contact lens first, then etafilcon A toric toric second
62525040|NCT04205370|ACTIVE_COMPARATOR|Deactivated device|Wear deactivated pregnancy coach device for the remainder of pregnancy.
62525041|NCT04205370|EXPERIMENTAL|Active device|Wear active device for remainder of pregnancy (including 3 day run-in period)
62525042|NCT00365937|EXPERIMENTAL|Group A|The eight HLA-A2 peptides
62525043|NCT00365937|EXPERIMENTAL|Group B|The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
62525044|NCT00365937|EXPERIMENTAL|Group C|the eight peptides HLA-A2 + IMP321
62525045|NCT00365937|EXPERIMENTAL|Group D|The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)
62525046|NCT03805100|EXPERIMENTAL|Xlucane|Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
62525047|NCT03805100|ACTIVE_COMPARATOR|Lucentis|Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
62525048|NCT04213976||Ileostomy in continuity|Paediatric patients having had an ileostomy in continuity as part of the treatment for a complex intestinal obstruction, as described by Santulli or by Bishop-Koop.
62525049|NCT04213976||Conventional ileostomy|Paediatric patients having had a loop ileostomy as part of the treatment for a complex intestinal obstruction.
62525050|NCT04250948|ACTIVE_COMPARATOR|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
62525051|NCT04250948|EXPERIMENTAL|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
62525052|NCT01568320|EXPERIMENTAL|Endovascular|Endovascular Treatment (Zenith)
62525053|NCT01881113|EXPERIMENTAL|AC-170 0.24%|
62525054|NCT01881113|PLACEBO_COMPARATOR|AC-170 0%|
62525055|NCT00782821|ACTIVE_COMPARATOR|Rabbit Antithymocyte Globulin (rATG)|Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.
62713010|NCT01911468|ACTIVE_COMPARATOR|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
62525056|NCT00782821|EXPERIMENTAL|RATG/Rituxan|Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.
62525057|NCT00782821|EXPERIMENTAL|RATG/Velcade|Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.
62525058|NCT00782821|EXPERIMENTAL|RATG/Rituxan/Velcade|"Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade.~rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1."
62525059|NCT00861198||ERCP|Patients who have a medical indication for ERCP with cholangioscopy and/or pancreatoscopy and are referred for the procedure as part of their standard medical care will be considered for the study.
62525060|NCT04604743|EXPERIMENTAL|Intervention|2 Clinics
62525061|NCT04604743|NO_INTERVENTION|Control|2 Clinics
62525062|NCT04043936|EXPERIMENTAL|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using behavioral health services. Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced. Participants in this condition will complete three separate 15-minute CBM-HS sessions."
62525063|NCT04043936|SHAM_COMPARATOR|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a CBM task with a neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
62525064|NCT04043936|ACTIVE_COMPARATOR|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
62525065|NCT04744350|ACTIVE_COMPARATOR|Surgical|Surgical treatment using a minimal invasive surgical method. At our hospital we perform a percutaneous sacroiliac osteosynthesis using cannulated, perforated and fenestrated screws. This procedure is preferably performed in our hybrid operation theatre, which allows for correct placement using an intraoperative CT-scan.
62525066|NCT04744350|ACTIVE_COMPARATOR|Conservative|Patients will receive individually tailored physiotherapy and analgesics if necessary.
62525067|NCT02075671|EXPERIMENTAL|Levulan and Blu-U Light|Entire face treated with 20% Aminolevulinic Acid (Levulan) and Blu-U light
62525068|NCT02075671|SHAM_COMPARATOR|Vehicle and Blu-U Light|Entire face treated with vehicle substance only and Blu-U light
62525069|NCT02075671|PLACEBO_COMPARATOR|Vehicle Only|Entire face treated with vehicle substance only
62525070|NCT00714129|EXPERIMENTAL|1|Weight loss diet - normal diet
62525071|NCT00714129|EXPERIMENTAL|2|Weight loss diet - low in simple sugars (specifically fructose)
62525072|NCT05810558|PLACEBO_COMPARATOR|Arm 1 Ultrasonic|Subjects will receive cleaning of the peri-implant sulcus using ultrasonic instrumentation
62525073|NCT05810558|EXPERIMENTAL|Arm 2 Glycine|Subjects will receive cleaning of the peri-implant sulcus using glycine powder air-powered debridement
62525074|NCT01328236|EXPERIMENTAL|V-DD single arm|"INDUCTION THERAPY: V-DD induction therapy for 6 cycles，28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment.~Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,（Specially for IgA type）. Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
62525075|NCT00127036|EXPERIMENTAL|XELOX + Bevacizumab|Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
62525076|NCT00127036|EXPERIMENTAL|XELIRI + Bevacizumab|Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
62525077|NCT04359576||FET|Estrogen/progesterone substituted and natural cycles
62525078|NCT01372514||suspected thromboembolic disease|Patients with thromboembolic disease according to diagnostic tests (MDTC with angiography, scintigraphy V/Q, dimer d, ecografia doppler, etc. ) required by the physician.
62525079|NCT00233506|EXPERIMENTAL|CPG 7909 IV|Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
62525080|NCT00233506|EXPERIMENTAL|CPG 7909 SQ|Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
62525081|NCT01121666|ACTIVE_COMPARATOR|Gonal-f® (Follitropin alfa)|
62525082|NCT01121666|EXPERIMENTAL|AFOLIA-150 (Follitropin alfa)|
62525083|NCT01102062|EXPERIMENTAL|Orange Juice|1 glass (=200mL) of orange juice
62525084|NCT02637375|EXPERIMENTAL|Therapy|Patients will receive ganetespib monotherapy for two weeks followed by twelve weeks of ganetespib/paclitaxel therapy followed by 4 bi-weekly doses of doxorubicin/cyclophosphamide therapy followed by surgery.
62525085|NCT01150890|PLACEBO_COMPARATOR|Placebo|Participants received placebo intravenously at baseline and week 4.
62525086|NCT01150890|EXPERIMENTAL|Brodalumab 210 mg|Participants received 210 mg brodalumab intravenously at baseline and week 4.
62525087|NCT01150890|EXPERIMENTAL|Brodalumab 350 mg|Participants received 350 mg brodalumab intravenously at baseline and week 4.
62525088|NCT01150890|EXPERIMENTAL|Brodalumab 700 mg|Participants received 700 mg brodalumab intravenously at baseline and week 4.
62525089|NCT01836406|EXPERIMENTAL|Keromin Group|
62525090|NCT01836406|PLACEBO_COMPARATOR|Placebo Group|
62525091|NCT05294939|EXPERIMENTAL|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
62525092|NCT05294939|PLACEBO_COMPARATOR|Control product|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
62525093|NCT06284577|EXPERIMENTAL|Probiotics|Participants will recieve a multi-strain probiotic daily for 6 months
62525094|NCT06284577|SHAM_COMPARATOR|Placebo|Participants will recieve maltodextrin daily for 6 months
62713011|NCT01911468|ACTIVE_COMPARATOR|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
62525095|NCT02608138||1|Urinary iodine will be measured at one point in time in school children aged 6-12. A sample of salt used at home and schools will be collected to estimate iodine levels.
62525096|NCT02122120||Before HEN|Patients with tube feeding with kitchen diet for at least twelve months
62525097|NCT02885649|EXPERIMENTAL|Treatment (enzalutamide, nephrectomy)|Patients receive enzalutamide PO daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.
62525098|NCT05007314|EXPERIMENTAL|Human Science|Arm 1 will include university graduates that hold at least a science undergraduate degree (or equivalent) in human science, including psychology, neuroscience, human biology, or medicine.
62525099|NCT05007314|ACTIVE_COMPARATOR|Natural or non-science|Arm 2 will include university graduates from non-human or non-scientific fields such as engineering, history, language studies, or law.
62525100|NCT00787020||Ventriculostomy Open|Subjects are treated with near continuous cerebrospinal fluid (CSF) diversion by positioning the stopcock in the open position and the intracranial pressure (ICP) is monitored once each hour: CSF drains into an external ventricular drainage bag.
62525101|NCT00787020||Ventriculostomy Monitored|Subjects are treated with intermittent cerebrospinal fluid (CSF) diversion. Intracranial pressure (ICP) is monitored and CSF is drained only when the ICP exceeds a threshold dictated by the attending physician.
62525102|NCT00974974|EXPERIMENTAL|IPX066|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
62525103|NCT00974974|ACTIVE_COMPARATOR|IR CD-LD|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
62525104|NCT06467773||ICVD|ischemic cerebrovascular diseases
62525105|NCT06467773||Neurological Autoimmune Diseases|Multiple Sclerosis，Neuromyelitis Optica Spectrum Disorders and Autoimmune Encephalitis
62525106|NCT06467773||other|other encephalomyelitis
62713012|NCT01911468|ACTIVE_COMPARATOR|metformin and liraglutide|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
62713013|NCT06099704||Participants with msAD|Canadian msAD participants (ages 6+) who receive Dupixent for msAD according to the Canadian-country specific prescribing information (in accordance with the Canadian Dupixent Product Monograph)
62713014|NCT04127162||alive|
62713015|NCT04127162||dead|
62525107|NCT05585476|EXPERIMENTAL|Laser + Regenerative topical treatment|"The treatments used in this arm are the following:~1. º Microfractionated laser treatment of C02, through the AcupulseDuo generator of the company Lumenis®. The treatment regimen would consist of three sessions in total with periodicity of 4 weeks, between the first and the second, and 6 weeks between the second and third. The application of laser energy will be carried out by vaginal and vulvar terminals. The dose applied will consist of monopulse shots distributed throughout the vaginal mucosa and vulvar skin of 10 mJ of energy and at a density of 10%.~2. nd Topical treatment: It consists of the application of XCM® intim of the company Mucosa Innovations. The route of administration would be vulvo-vaginal. The dose applied would be 2 ml of total product every 12 hours during 36 months."
62525108|NCT05585476|EXPERIMENTAL|Regenerative topical treatment|In this arm, only the regenerative treatment of XCM® intim of the company Mucosa Innovations will be used. The route of administration would be vulvo-vaginal. The dose applied would be 2 ml of total product every 12 hours. The total duration of treatment would be 36 months.
62525109|NCT05585476|EXPERIMENTAL|Laser treatment|"The treatments used in this arm are the following:~1. º Microfractionated laser treatment of C02, through the AcupulseDuo generator of the company Lumenis®. The treatment regimen would consist of three sessions in total with periodicity of 4 weeks, between the first and the second, and 6 weeks between the second and third. The application of laser energy will be carried out by vaginal and vulvar terminals. The dose applied will consist of monopulse shots distributed throughout the vaginal mucosa and vulvar skin of 10 mJ of energy and at a density of 10%.~2. ºPlacebo vulvo-vaginal topical gel, consisting of a watery base."
62525110|NCT05594303|EXPERIMENTAL|Bronchial basal cells|Treatment by autologous bronchial basal cells.
62525111|NCT05594303|NO_INTERVENTION|Control|No interventon.
62713016|NCT05523323|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
62713017|NCT05523323|ACTIVE_COMPARATOR|Pembrolizumab + Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib-matching placebo will be administered until progressive disease or unacceptable toxicity.
62713018|NCT05943262||mesoscale nonlinear optical microscope + whole-mount H&E & IHC staining protocol|
62525112|NCT00354250|EXPERIMENTAL|Treatment (ispinesib)|Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62713019|NCT02149459|EXPERIMENTAL|treatment arm|Partial brain re-irradiation combined with metabolic intervention (low carbohydrate diet and/or metformin treatment)
62713020|NCT04552223|EXPERIMENTAL|Nivolumab Plus Relatlimab Group|Participants in this group will receive Nivolumab and Relatlimab administered together on Day 1 of every 4 week cycle. Both drugs will be administered until disease progression or intolerable toxicity for up to 24 months.
62713021|NCT04231448|EXPERIMENTAL|CR-CHOP|
62713022|NCT04231448|PLACEBO_COMPARATOR|R-CHOP|
62713023|NCT05641935|EXPERIMENTAL|Diagnostic (CEUS with MRI/CT)|Patients receive Lumason IV and undergo CEUS imaging with MRI/CT on study. Patients' electronic medical record is reviewed every 6 months throughout study.
62525113|NCT05484453||GoCheckKids screening|GoCheckKids screening at the Child And Family Agency at the age of 12-15 months (+- 1 month) are invited to undergo a complete eye examination by an ophthalmologist for evaluation of amblyopia risk factors.
62525114|NCT05854888|EXPERIMENTAL|PeMWaC (Perineal Massage and Warm Compresses)|In the second stage of labor, the midwife performed a soft perineal massage between 3 o'clock and 9 o'clock positions (U-shaped reciprocating motion) wearing sterile gloves and lubricated their hand with sterile lubricant. The massage lasted 10 minutes and the degree of downward pressure by the thumb was determined according to mothers' response. Perineal massage was established on the II Hodge Plan, between maternal contractions and regardless of maternal position. The women could adopted the birthing position they prefer. The application of warm compresses was performed by the midwife between the III and IV Hodge plans, during pushing and regardless of the mother's position. A metal jug filled with warm water (between 45° and 59°C) was used to soak the compresses, which were squeezed out before being gently placed on the perineum during contractions.
62525115|NCT05854888|ACTIVE_COMPARATOR|Control group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum, while the non-dominant hand supported the infant's head, allowing external rotation and spontaneous birth of the shoulders. After both shoulders were removed, the midwife removed the dominant hand from the posterior perineum."
62525116|NCT04694183|EXPERIMENTAL|Conversion therapy|Camrelizumab combined with chemotherapy selected per metastasis site.
62525117|NCT00786994|EXPERIMENTAL|1|Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
62713024|NCT02379520|EXPERIMENTAL|Group A|HPV Specific T Cells
62713025|NCT02379520|EXPERIMENTAL|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
62713026|NCT06168240|EXPERIMENTAL|group A|will receive Manual lymphatic drainage plus Traditional physical therapy program that will include LASER, cold packs, manual mobilization, and exercise program. Training will applied 3 days a week, for a total of 4 weeks.
62713027|NCT06168240|ACTIVE_COMPARATOR|group B|will receive Traditional physical therapy program only that will include LASER, cold packs, manual mobilization, and exercise program. Training will applied 3 days a week, for a total of 4 weeks.
62525118|NCT00786994|EXPERIMENTAL|2|Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
62713028|NCT06716736|ACTIVE_COMPARATOR|socket preservation with dentine graft mixed with liquid platelet rich fibrin (sticky tooth)|socket preservation with dentine graft mixed with liquid platelet rich fibrin (sticky tooth) after surgical extraction of horizontally impacted lower wisdom
62713029|NCT06716736|ACTIVE_COMPARATOR|socket preservation with bone allograft|socket preservation with bone allograft after surgical extraction of horizontally impacted lower wisdom
62713030|NCT06716736|ACTIVE_COMPARATOR|socket preservation with collagen cone|socket preservation with collagen cone after surgical extraction of horizontally impacted lower wisdom
62713031|NCT05075161|EXPERIMENTAL|Pirfenidone|Patients randomized to Pirfernidone Group will receive tables of 267 mg
62713032|NCT05075161|PLACEBO_COMPARATOR|Placebo|Patients randomized to Placebo Group will receive 5 ml of Water
62525119|NCT00786994|PLACEBO_COMPARATOR|3|Placebo (petroleum jelly) for three months once a day (27 patients)
62713033|NCT06681272||Adult patients undergoing scheduled sternotomy cardiac surgery|Cohort, cardiac surgery patients who develop chronic pain Chronic post-surgical pain is defined as pain localized to the surgical site, with no other attributable cause, that persists for more than three months after surgery and has an impact on quality of life.
62713034|NCT04585308|EXPERIMENTAL|Single arm|Patients with severe native aortic valve stenosis who meet the commercially approved indications for TAVR.
62713035|NCT06214403|EXPERIMENTAL|MET-2|Participants randomized to the intervention will receive MET-2 daily for 10 days. MET-2 capsules are administered orally at 0.5 g per capsule, containing 3.1 x 10\^5-10\^11 colony forming units (CFU). An initial loading dose of 10 MET-2 capsules/day will be taken for 2 days (5 grams total). For the following 8 days, participants will take a maintenance dose of 3 MET-2 capsules/day (1.5 grams total).
62525120|NCT00786994|PLACEBO_COMPARATOR|4|Placebo (petroleum jelly) for three months twice a day (27 patients)
62713036|NCT06214403|PLACEBO_COMPARATOR|Placebo|Participants randomized to the placebo will receive microcrystalline cellulose in a capsule, identical in appearance to MET-2 but not containing live bacteria. Participants will take the placebo in the same dosing schedule as the MET-2 arm: 10 capsules daily for 2 days, followed by 3 capsules daily for 8 days.
62525121|NCT02279693|OTHER|CBCT|cone beam computed tomography (CBCT) repositioning
62713037|NCT02920320|EXPERIMENTAL|Internet-based self-help|"Internet-based self-help on the basis of the program Mindfulness-Based Compassionate Living (van den Brink \& Koster, 2015). The self-help program consists of seven text-based sessions, various exercises (z.B. breathing meditations, diaries,) and tasks. Participants have the possibility for guidance to the program on request."
62713038|NCT02920320|NO_INTERVENTION|Waiting control group|
62152381|NCT00069706|EXPERIMENTAL|AL-12182 0.03%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
62152382|NCT06285656||Group 1/|Patients with postoperative hemmorhagia
62525122|NCT02279693|OTHER|fiducial markers|kV imaging of fiducial marker repositioning
62525123|NCT04588714|EXPERIMENTAL|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|"RENEW is a 12-week program in which participants are paired with a peer mentor who serves as their health coach throughout the intervention period. The website serves as the program workbook to help promote skill practice and attainment in areas like goal setting, pacing, relaxation, etc."
62525124|NCT01718548|ACTIVE_COMPARATOR|CS and Lingzhi|CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
62525125|NCT01718548|PLACEBO_COMPARATOR|Placebo|Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
62525126|NCT04882423|EXPERIMENTAL|Test meal 1 - grilled hamburger (7 oz) with no vegetables|Randomly assigned participants are given grilled hamburger (7 oz) with no vegetables
62525127|NCT04882423|EXPERIMENTAL|Test meal 2 - grilled hamburger with steamed broccoli and Brussels sprouts|Randomly assigned participants are given grilled hamburger with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
62525128|NCT04882423|EXPERIMENTAL|Test meal 3 - grilled hamburger with steamed parsnips, fresh parsley, and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
62525129|NCT04882423|EXPERIMENTAL|Test meal 4- grilled hamburger with broccoli, Brussels sprouts, parsnips, parsley and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
62525130|NCT03477552|EXPERIMENTAL|Accuvein V400 device|In the Accuvein group, the nurse uses the Accuvein device to identify the veins before any puncture to infuse the patient and then proceeds as usual, under illumination of the device.
62152383|NCT06285656||Grup 2|Patients without postoperative hemmorhagia
62525131|NCT03477552|ACTIVE_COMPARATOR|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
62525132|NCT03738514|ACTIVE_COMPARATOR|Group 1|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
62525133|NCT03738514|SHAM_COMPARATOR|Group 2|dentifrice containing 5% potassium nitrate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
62525134|NCT03738514|PLACEBO_COMPARATOR|Group 3|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
62525135|NCT05755152|EXPERIMENTAL|Cranberry PLP|Chew the treatment chewing gum made with PLP at specific time intervals for a total of 60 minutes
62525136|NCT05755152|EXPERIMENTAL|Cranberry Extract Control|Chew the control chewing gum made with Cranberry Extract at specific time intervals for a total of 60 minutes
62525137|NCT02945605|EXPERIMENTAL|Early Vestibular Rehabilitation|Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
62525138|NCT02945605|ACTIVE_COMPARATOR|Standard of Care|Participants in this group will receive standard care as directed by their physician.
62525139|NCT01822574|ACTIVE_COMPARATOR|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
62525140|NCT01822574|ACTIVE_COMPARATOR|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
62713039|NCT06716398|EXPERIMENTAL|Test Group|
62713040|NCT06716398|PLACEBO_COMPARATOR|Comparative group|
62152384|NCT01527643|EXPERIMENTAL|Formulation A|
62152385|NCT01527643|EXPERIMENTAL|Formulation B|
62152386|NCT01205126|EXPERIMENTAL|OROS Hydromorphone hydrochloride (HCl)|OROS Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
62152387|NCT01205126|ACTIVE_COMPARATOR|Oxycodone HCl Controlled release (CR)|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
62152388|NCT05998720||normal group|There are no lesions on the hip.
62713041|NCT02953912|EXPERIMENTAL|Reciproc single-file.|The Reciproc is a single-file nickel-titanium systems used in reciprocating motion, made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue .
62713042|NCT02953912|ACTIVE_COMPARATOR|One Shape single-file .|One Shape is single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue. with electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
62713043|NCT05702645||Observational (biospecimen collection, clinical evaluation)|Patients undergo an optional saliva/buccal swab in part 1 and clinical assessment in part 2 of the study. Patients may then undergo blood sample collection in part 3 of the study.
62713044|NCT03722979|OTHER|All patients|
62713045|NCT02466724|EXPERIMENTAL|Web Group|Patients given web site (aiddly) instructions for colonoscopy
62713046|NCT02466724|NO_INTERVENTION|Paper Group|Patients given paper instructions for colonoscopy
62713047|NCT03464266|ACTIVE_COMPARATOR|DMPA and PrEP|
62713048|NCT03464266|ACTIVE_COMPARATOR|DMPA and no PrEP|
62713049|NCT03464266|ACTIVE_COMPARATOR|Condoms only and PrEP|
62713050|NCT03464266|ACTIVE_COMPARATOR|Condoms only and no PrEP|
62152389|NCT05998720||abnormal group|There are some lesions on the hip.
62152390|NCT00629447|EXPERIMENTAL|1|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
62152391|NCT05624814||Experimental group|Patients with chronic pain which failed standard therapies and with an implanted Spinal Cord Stimulator
62152392|NCT05624814||Comparison group|Patients with chronic pain following traditional therapies, i.e. pharmacological, psychological, physical and occupational therapies or surgery.
62152393|NCT05624814||Control group|Healthy volunteers matched for age and schooling to those included in the experimental group
62152394|NCT03012490|ACTIVE_COMPARATOR|Standard remote monitoring|Remote monitoring of CRT-P and CRT-D is activated. The physician will only receive the notifications related to technical events and ventricular arrhythmias. Therapy will be added or changed in response to these notifications and/or the symptoms and signs observed during ambulatory visits.
62152395|NCT03012490|EXPERIMENTAL|Comprehensive remote monitoring|Remote monitoring of CRT-P and CRT-D is activated, as well as remote assessment of symptoms and signs. In addition to notifications related to technical events and ventricular arrhythmias, the physician will receive notifications related to heart failure parameters, atrial arrhythmias, and patient's symptoms and signs. Therapy will be added or changed in response to these notifications, and/or to the symptoms and signs observed during ambulatory visits.
62152396|NCT06173167|EXPERIMENTAL|SpeedCEM Plus luted crowns|crowns delivered with a self-adhesive, self-curing resin cement (SpeedCEM Plus\\Ivoclar Vivadent AG)
62152397|NCT06173167|EXPERIMENTAL|ZirCAD Cement cemented crowns|crowns delivered with a resin modified glass ionomer cement (ZirCAD Cement\\Ivoclar Vivadent AG)
62152398|NCT04335474||Surgical drainage|Cases that have surgical management
62152399|NCT04335474||Percutaneous drainage|Cases that have the nonoperative management by percutaneous drainage
62152400|NCT04347005|EXPERIMENTAL|AR882 (Dose A)|
62152401|NCT04347005|EXPERIMENTAL|AR882 (Dose B)|
62152402|NCT04347005|EXPERIMENTAL|AR882 (Dose C)|
62152403|NCT04347005|EXPERIMENTAL|AR882 (Dose D)|
62152404|NCT04347005|EXPERIMENTAL|AR882 (Dose E)|
62152405|NCT04347005|EXPERIMENTAL|AR882 (Dose B) Solid Oral Formulation|
62152406|NCT04347005|PLACEBO_COMPARATOR|Placebo|
62152407|NCT04347005|ACTIVE_COMPARATOR|Allopurinol|
62152408|NCT04347005|ACTIVE_COMPARATOR|Febuxostat|
62152409|NCT02889900|EXPERIMENTAL|combination of cediranib and olaparib|Open label
62152410|NCT01058694|EXPERIMENTAL|Weekly SMS, brief message|Weekly SMS received on Monday at 12 noon
62152411|NCT01058694|ACTIVE_COMPARATOR|Control Group|Receives a phone, but no messages.
62152412|NCT01058694|EXPERIMENTAL|Daily SMS, Brief message|"Receive daily brief message at 12 noon: This is your reminder"
62152413|NCT01058694|EXPERIMENTAL|Daily SMS, Long Message|"Receive a daily long message at 12 noon: This is your reminder + encouragement"
62152414|NCT01058694|EXPERIMENTAL|Weekly SMS, Long Message|"Weekly message sent at 12 noon on Mondays: This is your reminder + encouragement"
62152415|NCT03619044|OTHER|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
62152416|NCT01600196|EXPERIMENTAL|Resection arm|Liver resection Plus Thrombectomy
62152417|NCT01600196|NO_INTERVENTION|Best support care arm|Best supportive care
62713051|NCT03807089|EXPERIMENTAL|Short-Turn Radius Colonoscope|Colonoscopy performed with Short-Turn Radius Colonoscope. The colonoscope will provide a forward-facing view of the colon during advancement to the cecum (standard of care). The scope will then be withdrawn all the way to the rectum and the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and be withdrawn using the retrograde view.
62713052|NCT03807089|ACTIVE_COMPARATOR|Conventional Pediatric Colonoscope|Colonoscopy will be performed with a conventional pediatric colonoscope. During withdrawal, the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and again withdrawn using the forward-facing view.
62713053|NCT06011083|ACTIVE_COMPARATOR|Group A|20 patients who were treated with Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm twice daily as a monotherapy for 3 months over a selected psoriatic plaque
62713054|NCT06011083|ACTIVE_COMPARATOR|Group B|20 patients who were treated with fractional CO2 laser sessions once per month followed by application of the same Topical Ointment twice daily for 3 months over a similar psoriatic plaque
62713055|NCT00794092|EXPERIMENTAL|Sinerem|MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
62713056|NCT01737866|EXPERIMENTAL|Group 1|End Stage Renal Diseas (ESRD) requiring hemodialysis
62713057|NCT01737866|EXPERIMENTAL|Group 2|Normal renal function (eGFR \>or = 80mL/min/1.73m\^2)
62713058|NCT01737866|EXPERIMENTAL|Group 3|Mild decrease in GFR (eGFR 60-79 mL/min/1.73m\^2)
62713059|NCT01737866|EXPERIMENTAL|Group 4|Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m\^2)
62152418|NCT03133299|ACTIVE_COMPARATOR|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
62152419|NCT03133299|EXPERIMENTAL|Vitamin D plus Glucocorticoid group|Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
62525141|NCT01822574|ACTIVE_COMPARATOR|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
62713060|NCT01737866|EXPERIMENTAL|Group 5|Severe decrease in GFR (eGFR 15-29 mL/min/1.73m\^2)
62713061|NCT01737866|EXPERIMENTAL|Group 6|Normal renal function (eGFR \>or = 80mL/min/1.73m\^2)
62152420|NCT01742585|EXPERIMENTAL|ASP1585 group|
62152421|NCT01742585|PLACEBO_COMPARATOR|placebo group|
62152422|NCT05603949||experimental group|
62152423|NCT00824057|EXPERIMENTAL|1|
62152424|NCT06604754|EXPERIMENTAL|Virtual Reality Based Training|Virtual reality (VR) based balance training utilizes immersive digital environments to enhance balance and stability through interactive and engaging exercises. Patients wear VR headsets that create realistic scenarios where they perform various balance tasks, such as navigating virtual obstacles or maintaining stability on unstable surfaces. This technology offers the advantage of providing controlled, adjustable challenges that can be tailored to the patient's specific needs and progress. VR training often incorporates real-time feedback, which helps patients improve their balance in a motivating and dynamic setting.
62152425|NCT06604754|ACTIVE_COMPARATOR|Traditional Physical Therapy Based Training:|Traditional physical therapy-based balance training focuses on improving stability and preventing falls through a variety of exercises and techniques. It typically begins with a comprehensive assessment to identify balance issues and set individualized goals. The training includes static exercises like single-leg stands, dynamic activities such as walking on uneven surfaces, and strengthening and flexibility exercises to enhance muscle control and range of motion. Coordination and functional training, including gait and daily activity simulation, are also integral. Additionally, patients receive education on fall prevention strategies and home safety. Regular monitoring ensures that the program is adjusted to the patient's progress and ongoing needs, ultimately enhancing balance and reducing fall risk.
62152426|NCT00882856|ACTIVE_COMPARATOR|Bisoprolol-washout -placebo|Bisoprolol - wash out - placebo
62525142|NCT02415569|EXPERIMENTAL|group1|Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
62152427|NCT00882856|ACTIVE_COMPARATOR|Placebo - wash out - bisoprolol|Placebo - wash out - bisoprolol
62152428|NCT01794351|EXPERIMENTAL|Placebo then resveratrol|Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
62152429|NCT01794351|EXPERIMENTAL|Resveratrol then placebo|Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
62152430|NCT01643122||Group 1|
62152431|NCT01643122||Group 2|
62152432|NCT03236480||COPD|Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled
62152433|NCT03236480||healthy control|People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study
62152434|NCT05143099|EXPERIMENTAL|1|tislelizumab combined with cetuximab and irinotecan
62152435|NCT00839085|NO_INTERVENTION|1|normal procedure of CABG
62525143|NCT02415569|EXPERIMENTAL|group2|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
62713062|NCT04322318|EXPERIMENTAL|Arm I (Regimen UH-3)|See outline in detailed description section.
62713063|NCT04322318|EXPERIMENTAL|Arm II (Regimen ICE/Cyclo/Topo)|"CYCLES 1, 2, 4, 5, 7, AND 9: Patients receive carboplatin IV over 15-60 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and ifosfamide IV over 2-4 hours on days 1-3. Treatment repeats every 21 days during cycles 1, 2, 4, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.~CYCLES 3, 6, 8, AND 10: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan IV over 30 minutes on days 1-5. Treatment repeats every 21 days during cycles 3, 6, 8, and 10 in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery and/or RT during cycles 4, 7, and 10 as clinically indicated. Patients undergo a CT scan, a PET scan, a chest x-ray, MRI, an abdominal ultrasound, and/or a bone scan throughout the trial. Patients may also undergo blood specimen collection and biopsy throughout the trial."
62152436|NCT00839085|ACTIVE_COMPARATOR|2: GSE|100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h)
62152437|NCT00839085|ACTIVE_COMPARATOR|3: Vit C|25 mg/kg through pump
62152438|NCT00025376|EXPERIMENTAL|Pre-Treatment biopsy followed by PS-341 administration|Pre-treatment tumor biopsy followed by 3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects can continue to receive another 3 cycles of the study drug if their disease has not worsened.
62152439|NCT00025376|EXPERIMENTAL|PS-341 administration followed by biopsy|3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects will have a tumor biopsy and can continue to receive another 3 cycles of the study drug if their disease has not worsened.
62152440|NCT01709630||Neonatal|Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection.
62152441|NCT01709630||Maternal|Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection
62152442|NCT03884478|EXPERIMENTAL|Alcohol + Stigma Coping PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
62525144|NCT02415569|ACTIVE_COMPARATOR|group3|Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
62525145|NCT02242565|OTHER|Control: all-sizes of ShangRing|All-sizes of ShangRings will be available.
62152443|NCT03884478|EXPERIMENTAL|Alcohol + Control PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
62152444|NCT03884478|OTHER|Control PNF|Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use \& Control) and Round 4 (Stigma-Coping \& Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.
62152445|NCT01853904|OTHER|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
62152446|NCT01853904|OTHER|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
62152447|NCT02841020|NO_INTERVENTION|Control SOC|Standard of care is followed
62152448|NCT02841020|EXPERIMENTAL|Experimental additional biopsy|Additional biopsy
62152449|NCT03740386|EXPERIMENTAL|lidocaine|lidocaine 2% 1:80000
62152450|NCT03740386|EXPERIMENTAL|articaine|articaine 4% 1:200000
62152451|NCT03740386|EXPERIMENTAL|bupivacaine|bupivacaine 0,5% 1:200000
62152452|NCT05271045|EXPERIMENTAL|fortified canola oil with vitamins A and D and γ-oryzanol|daily intake of fortified canola oil (385 IU vitamin D/ 30g \& 154 IU vitamin A/30 g \& 2130 ppm γ-oryzanol/30g)
62152453|NCT05271045|ACTIVE_COMPARATOR|fortified canola oil with vitamins A and D|daily intake of fortified canola oil (385 IU vitamin D/ 30g \& 154 IU vitamin A/30 g)
62152454|NCT05271045|PLACEBO_COMPARATOR|fortified sunflower oil with vitamins A and D|daily intake of fortified sunflower oil (385 IU vitamin D/ 30g \& 154 IU vitamin A/30 g)
62152455|NCT03507998|EXPERIMENTAL|CGX1321 Dosing|"Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned.~Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321"
62152456|NCT04105907|EXPERIMENTAL|Partial root canal treatment with the Sonendo GentleWave|
62152457|NCT05776056|OTHER|N-of-1 crossover study enrollment: start with placebo|All participants spend time receiving both active study drug (methylphenidate) and placebo (sham study drug), in randomized order, across 4 treatment blocks separated by 1 week washout periods (where no study drug is given).
62152458|NCT05776056|OTHER|N-of-1 crossover study enrollment: start with methylphenidate|All participants spend time receiving both active study drug (methylphenidate) and placebo (sham study drug), in randomized order, across 4 treatment blocks separated by 1 week washout periods (where no study drug is given).
62152459|NCT01123200|OTHER|Brain Computer Interface In-Home Use|
62525146|NCT02242565|ACTIVE_COMPARATOR|Reduced-sizes|7 adult sizes of ShangRings will be available
62152460|NCT02735005|EXPERIMENTAL|SMAF assessment|"Face to face interview for the Functional Autonomy Measurement System (SMAF) tool questionnaire For disabled patients living at home, the Social SMAF questionnaire is used in addition.~Data related to care consumption of each enrolled patients are collected too."
62525147|NCT01551641|EXPERIMENTAL|VEGF decressed|patients will receive concurrent chemoradiotherapy only
62152461|NCT02860702|EXPERIMENTAL|Exclusive Human Milk|All infants randomized to this arm will receive exclusive human milk diet with addition of human milk derived fortifier from birth to 30 days post initiation of feedings after initial palliative cardiac surgery
62152462|NCT02860702|ACTIVE_COMPARATOR|Human/Bovine Milk|All infants randomized to this arm will receive exclusive human milk diet prior to randomization and will use either human and/or bovine milk and fortifier per the institution's standard practice 30 days post initiation of feedings after initial palliative cardiac surgery
62152463|NCT03400748|EXPERIMENTAL|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
62152464|NCT01270906|EXPERIMENTAL|CHIR-258 (TKI258)|
62152465|NCT03564184|EXPERIMENTAL|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
62152466|NCT03564184|EXPERIMENTAL|MT during NICU|Consists of music therapy during NICU hospitalization, along with standard care.
62152467|NCT03564184|EXPERIMENTAL|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
62152468|NCT03564184|EXPERIMENTAL|No MT|Consists of standard care.
62152469|NCT03659942||Experimental group|New child arriving in detention CAST questionnaire will be performed
62152470|NCT01721694|EXPERIMENTAL|azithromycin 1.5%/Loteprednol 0,5% + placebo|fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops
62152471|NCT01721694|ACTIVE_COMPARATOR|azithromycin 1.5% + Loteprednol 0,5% (separately)|azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)
62152472|NCT00212459|EXPERIMENTAL|1|Patients are contacted every two weeks after initial counseling to discuss completion of bleeding records.
62152473|NCT00212459|ACTIVE_COMPARATOR|2|After the initial counseling with regards to bleeding records, there are no more contacts made with the control patients.
62152474|NCT04148885|EXPERIMENTAL|nab-paclitaxel + Carboplatin|nab-paclitaxel at 260 mg/m\^2 on days 1; Carboplatin AUG=5, d1, 21 days in one cycle, 3 cycles in total
62525148|NCT01551641|EXPERIMENTAL|thalidomide|patients will be given thalidomide concurrent chemoradiotherapy
62525149|NCT01551641|EXPERIMENTAL|without thalidomide|patients will receive concurrent chemoradiotherapy only
62525150|NCT00860366|EXPERIMENTAL|Uric Acid|Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).
62713064|NCT00027560|EXPERIMENTAL|TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES|This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
62713065|NCT02383160|ACTIVE_COMPARATOR|Active LIPUS Unit|Low-intensity pulsed ultrasound treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
62713066|NCT02383160|SHAM_COMPARATOR|Sham LIPUS Unit|Sham device treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
62525151|NCT00860366|PLACEBO_COMPARATOR|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
62713067|NCT00691392|EXPERIMENTAL|1|Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB
62713068|NCT00691392|PLACEBO_COMPARATOR|2|Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler
62713069|NCT02096211|OTHER|CERAMAX COC 36mm Acetabular Cup|The CERAMAX 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic.The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
62152475|NCT02981953|OTHER|Cardioband Tricuspid procedure|Tricuspid valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
62713070|NCT05880212|ACTIVE_COMPARATOR|Usual physiotherapy care|One physiotherapy assessment, 10 x 45-minute sessions of usual care physiotherapy (over a 10-week period), plus 1 x 45-minute followup session of usual care physiotherapy after 6 months.
62152476|NCT04693598|EXPERIMENTAL|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the lower dose (N=3 participants)
62152477|NCT04693598|EXPERIMENTAL|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the higher dose (N=3 participants)
62152478|NCT02034188|EXPERIMENTAL|Umbilical cord mesenchymal stem cells|
62152479|NCT01375725||Coumadin (warfarin)|Subjects currently receiving coumadin (warfarin) treatment.
62152480|NCT05198219|EXPERIMENTAL|Rhinolaryngoscope Ambu® aScope™ 4 Rhinolaryngo|All approved procedures performed during the study period.
62152481|NCT05198219|ACTIVE_COMPARATOR|Conventional reusable rhinolaryngoscope|All procedures performed during the study period.
62525152|NCT05813366|EXPERIMENTAL|Tryptophan rich diet + vitamin B6 supplementation|It will include 13 participants suffering from premenstrual dysphoric disorder (PMDD) who will be treated by diet rich wit tryptophan (high protein diet) for 8 weeks in addition to vitamin B6 tablets 60 mg once/day, throughout two menstrual cycles, starting from the first day of their menstrual cycle
62525153|NCT05813366|EXPERIMENTAL|Acupuncture + Vitamin B6 supplementation|It will include 13 participants suffering from premenstrual dysphoric disorder (PMDD) who will be treated by acupuncture twice a week for 8 weeks, resulting in a total of 16 visits. Each visit, including initial care, needle application and needle retention, will last about 45 min. In addition to vitamin B6 tablet 60mg once/day, throughout two menstrual cycles, starts from the first day of their menstrual cycle
62525154|NCT05813366|EXPERIMENTAL|Acupuncture + Tryptophan rich diet + vitamin B6 supplementation|It will include 13 participants suffering from premenstrual dysphoric disorder (PMDD) who will be treated by diet rich with tryptophan (high protein diet) for 8 weeks and acupuncture twice a week for 8 weeks, resulting in a total of 16 visits. Each visit, including initial care, needle application and needle retention, will last about 45 min. In addition to vitamin B6 tablet 60mg once/day, throughout two menstrual cycles, starts from the first day of their menstrual cycle
62713071|NCT05880212|EXPERIMENTAL|Individualized (STOPS) physiotherapy|One physiotherapy assessment, 10 x 45-minute sessions of individualised (STOPS) physiotherapy (weekly for 10 weeks), plus 1 x 45-minute followup session of individualised (STOPS) physiotherapy after 6 months.
62715106|NCT06157034|EXPERIMENTAL|T4|"* Mentha spicata L, commonly known as spearmint, is renowned for its aromatic properties and potential health benefits. In this clinical study, a treatment group, designated as T4, is established to explore the effects of encapsulated Mentha spicata oil.~* Intervention Details:~  * Generic Name: Mentha spicata oil~ * Dosage Form: Encapsulated~ * Concentration: 2% of Spearmint essential oil~ * Dosage: 1.5 ml per capsule~ * Frequency: Twice daily~ * Total Daily Dosage: 30 ml/day~ * Administration Timing: After breakfast and dinner~ * Duration of Treatment: 3 months~* Throughout the study duration, data will be systematically collected from participants in the T4 treatment group. This data may include subjective reports, clinical assessments, and laboratory analyses."
62152482|NCT00632905||1|Normal - BMD with T-score at or above -1.0
62152483|NCT00632905||2|Osteopenic - BMD with T-score between -1.1 and -2.4
62152484|NCT00632905||3|Osteoporotic - BMD with T-score at or below -2.5
62152485|NCT01542983|ACTIVE_COMPARATOR|Treatment-as-usual|Treatment as usual for fatigue and insomnia
62152486|NCT01542983|ACTIVE_COMPARATOR|Behavioral treatment|Brief behavioral treatment for insomnia and bright light Light and BBTI combined treatment for insomnia and fatigue
62152487|NCT01190436|EXPERIMENTAL|Bisoprolol|
62152488|NCT01653925|EXPERIMENTAL|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids.
62152489|NCT01653925|EXPERIMENTAL|Drug intervention first|Intake of 5α-Reductase Inhibitor
62152490|NCT04794439|ACTIVE_COMPARATOR|Toothpaste 1 with Stannous Fluoride|Toothpaste with Stannous Fluoride
62152491|NCT04794439|ACTIVE_COMPARATOR|Toothpaste 1 with Sodium Fluoride and sodium bicarbonate|Toothpaste with Sodium Fluoride and sodium bicarbonate
62152492|NCT04794439|ACTIVE_COMPARATOR|Toothpaste 2 with Stannous Fluoride|Toothpaste with Stannous Fluoride
62152493|NCT04794439|ACTIVE_COMPARATOR|Toothpaste 2 with sodium Fluoride and sodium bicarbonate|Toothpaste with sodium Fluoride and sodium bicarbonate
62152494|NCT04577599|OTHER|Single Arm|Mobile Low-dose Computed Tomography (LDCT) Screening
62525155|NCT06104241|EXPERIMENTAL|BGT007 Cell Injection|"This is an exploratory study of single-arm, open, modified 3+3 dose escalation. The BGT007 cell therapy group received five progressively increased dose levels (5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells) of BGT007 cells. Each subject was observed for at least 4 weeks after cell transfusion (DLT observation period). The first two dose groups (5.0×10\^7 cells and 1.0×10\^8 cells) included 1 subject each, and the other three dose groups were followed by conventional 3+3 dose increments."
62525156|NCT03706170|EXPERIMENTAL|Vegetative State|For patients in vegetative state (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
62525157|NCT03706170|EXPERIMENTAL|Minimally Conscious State|For patients in minimally conscious state (n = 15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
62525158|NCT03706170|EXPERIMENTAL|Acquired Brain damaged patients without DOC|Acquired Brain damaged patients without disorder of consciousness (patients without DOC) For patients with acquired brain damage without disorder of consciousness (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography
62525159|NCT03706170|EXPERIMENTAL|Healthy subjects|For healthy subjects (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
62525160|NCT01521039||Allogeneic SCT recipients|Patients who are receiving allogeneic stem cell transplantation at the Ohio State University are eligible and will be consented for the study.
62525161|NCT06253819||geriatrics individuals with metabolic syndrome|
62525162|NCT06253819||geriatrics individuals without metabolic syndrome|
62525163|NCT04798118|EXPERIMENTAL|group treated with toilet bronchoscope|"Toilet bronchoscopy will be done as supportive care to sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :~1. Copious secretion~2. Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
62525164|NCT04798118|ACTIVE_COMPARATOR|group treated with standered care|"sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :~1. Copious secretion~2. Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
62525165|NCT00392236|EXPERIMENTAL|A|Participants will receive treatment as usual and a 2-way pager for 6 months
62525166|NCT00392236|ACTIVE_COMPARATOR|B|Participants will receive treatment as usual
62525167|NCT00773734|EXPERIMENTAL|Apremilast 10mg|Apremilast 10 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 10 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
62525168|NCT00773734|EXPERIMENTAL|Apremilast 20mg|Apremilast 20 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 20 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
62525169|NCT00773734|EXPERIMENTAL|Apremilast 30 mg|Apremilast 30 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
62525170|NCT00773734|PLACEBO_COMPARATOR|Placebo|Oral Placebo tablets administered twice daily (BID) for 16 weeks during the placebo-controlled phase.
62525171|NCT00773734|EXPERIMENTAL|Placebo/Apremilast 20 mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 20 mg apremilast BID during the 8 week active treatment phase
62525172|NCT00773734|EXPERIMENTAL|Placebo/Apremilast 30mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 30 mg apremilast BID during the 8 week active treatment phase
62525173|NCT05355766|EXPERIMENTAL|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) to higher dose (30 mg/kg bw, bid) for 52 weeks, according to the administration plan.~The dosage form is tablets."
62525174|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
62525175|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
62152495|NCT02206906||Study Participants|All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model.
62525176|NCT02448706|ACTIVE_COMPARATOR|Hearing Aid Fitting Order A|High level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
62525177|NCT02448706|ACTIVE_COMPARATOR|Hearing Aid Fitting Order B|Low level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
62525178|NCT05056883|EXPERIMENTAL|Treatment A|K-237 0.3-0.4mg/kg (once daily)
62525179|NCT05056883|PLACEBO_COMPARATOR|Control A|Placebo (once daily)
62525180|NCT00281606|ACTIVE_COMPARATOR|LPV/r (800/200 mg) 10 ml liquid|Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
62525181|NCT00281606|ACTIVE_COMPARATOR|LPV/r (800/200 mg) 6 gel capsules|Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
62525182|NCT00220987|EXPERIMENTAL|Intensive Insulin therapy|Intensive Insulin therapy
62525183|NCT00220987|ACTIVE_COMPARATOR|Conventional Therapy|conventional insulin therapy
62525184|NCT01059539|EXPERIMENTAL|Cariprazine 3-12 mg/day for 16 weeks|Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.
62152496|NCT04008004|EXPERIMENTAL|EDP-514 HV SAD Cohorts|EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration
62525185|NCT04094376|OTHER|Day group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00)
62525186|NCT04094376|OTHER|Night group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
62525187|NCT01745705|EXPERIMENTAL|Cervical Spine Manipulation|Subjects will lie supine on a treatment table and receive a high velocity low amplitude thrust joint manipulation to their cervical spine in rotation to each side of the neck.
62152497|NCT04008004|EXPERIMENTAL|EDP-514 HV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days
62152498|NCT04008004|PLACEBO_COMPARATOR|EDP-514 HV SAD Placebo Cohort|Matching placebo, orally, once daily in one single administration
62152499|NCT04008004|PLACEBO_COMPARATOR|EDP-514 HV MAD Placebo Cohort|Matching placebo, orally, once daily for 14 days
62152500|NCT04008004|EXPERIMENTAL|EDP-514 HBV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days
62152501|NCT04008004|PLACEBO_COMPARATOR|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days
62152502|NCT03776565||Operative hysteroscopy|women with an operative hysteroscopy planned
62152503|NCT03776565||Planned caesarean section|Pregnant women with a planned caesarean section
62152504|NCT02598388|EXPERIMENTAL|Part 1 (US Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
62152505|NCT02598388|EXPERIMENTAL|Part 2 Group 1 (African Participants)|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.
62152506|NCT02598388|EXPERIMENTAL|Part 2 Group 2 (African Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
62152507|NCT04419571||Suspected or Confirmed COVID-19|All adult patients (\>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) with clinically or radiologically suspected COVID-19, or with viral PCR confirmation; diagnosis made 7-days before and 30-days after date of surgery in accordance with the COVIDsurg study criteria (3).
62152508|NCT04419571||Negative or non-suspected COVID-19|All adult patients (\>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) without clinically or radiologically suspected COVID-19, or without viral PCR (Polymerase Chain Reaction) confirmation.
62152509|NCT02684994|OTHER|Cognitive Processing Therapy|Cognitive Processing Therapy
62152510|NCT01543789|EXPERIMENTAL|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity
62152511|NCT01543789|ACTIVE_COMPARATOR|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
62152512|NCT03259126|EXPERIMENTAL|SCUT|"Use of a Small Curtain under table (SCUT) placed under the cranial part of the angiographic table"
62152513|NCT03259126|NO_INTERVENTION|Control|Control Group without the SCUT
62152514|NCT02697656|ACTIVE_COMPARATOR|Treatment as usual + self-help|Interdisciplinary treatment as usual at the outpatient pain clinic + an additional self-help binder with resources about pain management and employment advice.
62152515|NCT02697656|EXPERIMENTAL|Treatment as usual + IPS|Individual job support (IPS) as an integrated part of the interdisciplinary treatment at the outpatient pain clinic.
62152516|NCT03941977|EXPERIMENTAL|Surgery|Group evaluated with MRI and submitted to the percutaneous introduction of cannula for bone grafting
62152517|NCT00636597||1|
62152518|NCT03888807|EXPERIMENTAL|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees.
62152519|NCT03888807|SHAM_COMPARATOR|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees
62152520|NCT01593137|EXPERIMENTAL|Liraglutide + metformin|
62152521|NCT01593137|ACTIVE_COMPARATOR|glimepiride + metformin|
62152522|NCT00807079|EXPERIMENTAL|single arm|
62152523|NCT04022707|EXPERIMENTAL|High-Velocity Resistance Circuttraining (HVRCT)|The participants will perform three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three weeks from 1 to 3 circuits.
62525188|NCT01745705|SHAM_COMPARATOR|Manual Contact|Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
62525189|NCT04530240||ERA-1 Group|Before the introduction of the MELD≥30 allocation scheme August 2010 - July 2014
62525190|NCT04530240||ERA-2 Group|After the introduction of the MELD≥30 allocation scheme August 2014 - July 2018
62525191|NCT02909738||Volunteers|Healthy volunteers willing to pedal a bike for 30 minutes.
62525192|NCT02704780|ACTIVE_COMPARATOR|400 Microgram Misoprostol|Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group
62525193|NCT02704780|ACTIVE_COMPARATOR|800 Microgram Misoprostol|Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group
62525194|NCT00417404|ACTIVE_COMPARATOR|vitamin A|
62525195|NCT00417404|SHAM_COMPARATOR|sham injection|
62715107|NCT06157034|NO_INTERVENTION|Washout period|"* In this phase impact of withholding the intervention on all parameters will be studied.~* All parameters included in phase1 and 2 will be repeated after one month accordingly, to observe any change in selected parameters after discontinuation of intervention."
62713072|NCT01991379|EXPERIMENTAL|MEK162 in Combination With Imatinib Mesylate|Pts will be treated with the combination therapy of MEK162 \& imatinib. The phase Ib portion of the study, pts will receive imatinib at 400 mg once daily \& MEK162 at the standard 3+3 escalation doses. Phase Ib expansion cohort, pts will receive the RP2D: imatinib 400 mg once daily (standard of care first line imatinib dose) \& MEK162 at the RP2D twice daily. The phase II portion of the study, pts will receive imatinib at 400 mg once daily \& MEK162 at the RP2D. The MEK162 RP2D was originally determined based on the phase Ib escalation data \& it was established as 45 mg BID. After the completion of the phase Ib dose expansion \& initiation of phase II, the MEK162 RP2D was reduced to 30 mg BID30 for better long term tolerability. Patient's will now begin MEK162 at the revised RP2D of 30 mg BID. 1 cycle is 28 days. If no progression of the tumor is seen, pts will continue on therapy. Pts who have progression of disease will proceed directly to second line therapy as per standard of care.
62152524|NCT04022707|EXPERIMENTAL|Educational Control (CON)|A supervised program will be provided to the participants that includes lectures on health and fitness.
62152525|NCT06359977||Neurocritical Patients requiring weaning|The population in this study focused on neurocritical patients with endotracheal intubation. The data of quantitative EEG, beside ultrasound and sputum volume are all recorded for predicting weaning failure.
62152526|NCT01751295|ACTIVE_COMPARATOR|atorvastatin|PCI with atorvastatin pre-treatment group
62713073|NCT05064228|EXPERIMENTAL|m-ReACT app condition|Participants will download the m-ReACT app on their mobile phones and will be asked to engage with the app for a period of 12 weeks.
62713074|NCT05064228|ACTIVE_COMPARATOR|Brief Advice|Participants will be given a one time brief informational session on the importance of engaging in substance-free activity while in AUD treatment.
62713075|NCT05228275||Observational (survey, biospecimen collection)|Patients receive COVID-19 vaccine per standard of care. Patients also complete a survey at 1 month and undergo collection of blood samples at 1, 3, 6, 12, 18, and 24 months. Patients may complete an additional survey at 1 month after each vaccine boost and undergo collection of blood samples before each vaccine boost, 1 month after each vaccine boost, and at the time of COVID-19 infection.
62713076|NCT03325504|EXPERIMENTAL|hBM-MSCs-Low Dose|Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells
62713077|NCT03325504|EXPERIMENTAL|hBM-MSCs-High Dose|Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells
62152527|NCT01751295|NO_INTERVENTION|control|PCI without atorvastatin pre-treatment group
62525196|NCT04724044|PLACEBO_COMPARATOR|Placebo|These patients will be treated with 1 placebo tablet every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.
62525197|NCT04724044|ACTIVE_COMPARATOR|Clarithromycin|These patients will be treated with 1 tablet of 500 mg of clarithromycin every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.
62525198|NCT02856880|EXPERIMENTAL|Test zinc-IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 milliliter (mL) water for 60 seconds(s) followed by rinse with 10mL water
62525199|NCT02856880|EXPERIMENTAL|Test zinc non- IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
62525200|NCT02856880|ACTIVE_COMPARATOR|Positive control Toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
62152528|NCT04409392||Prothestic joint infection due to Staphylococcus lugdunensis|Patients having had a prosthetic joint infection with Staphylococcus lugdunensis
62525201|NCT02856880|ACTIVE_COMPARATOR|SLS Negative Control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
62525202|NCT02856880|ACTIVE_COMPARATOR|non-SLS negative control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
62525203|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
62525204|NCT06490237|ACTIVE_COMPARATOR|Subjects with no hearing loss|
62525205|NCT06490237|EXPERIMENTAL|subjects with hearing loss|
62713078|NCT03325504|ACTIVE_COMPARATOR|Autologous iliac crest graft|Autologous Iliac Crest Grafting
62713079|NCT02353962|EXPERIMENTAL|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
62713080|NCT02421094|ACTIVE_COMPARATOR|GR-MD-02|Active
62152529|NCT06509321|ACTIVE_COMPARATOR|subinguinal loupe-assisted varicocelectomy (LV)|we are using nitroglycerine instillation during loupe assisted varicocelectomy to enhance its efficacy by the vasodilatation effect of Nitroglycerine
62152530|NCT06509321|ACTIVE_COMPARATOR|subinguinal microscopic varicocelectomy (MV)|we are using surgical microscope to perform varicocelectomy as control group
62152531|NCT05297097|EXPERIMENTAL|Trulacta breastmilk supplement|Once daily Trulacta supplement
62152532|NCT03046394|ACTIVE_COMPARATOR|C-SACH|All the interventions will be administered to the patient in this single-subject trial, each 6 times
62713081|NCT02421094|PLACEBO_COMPARATOR|Placebo|Placebo
62525206|NCT00336076||Participants evaluated for mastocytosis|Observational study of all patients referred for suspected mast cell disease. Collection of blood or bone marrow for analysis during diagnostic procedures.
62525207|NCT04987242|EXPERIMENTAL|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration: 5 capsules thrice daily (TID) for a total of 15 capsules per day will be evaluated for 7 days
62525208|NCT04987242|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules for oral administration: 5 capsules thrice daily (TID) for a total of 15 capsules per day will be evaluated for 7 days
62525209|NCT02520752|EXPERIMENTAL|INC280|
62525210|NCT05190653|EXPERIMENTAL|Palliative and Supportive Care Intervention|Participants randomized to the intervention arm will meet (either by phone or Zoom contingent upon participant preference) with a palliative care nurse practitioner or palliative care physician. During the first meeting, pre-transplant/CAR T-cell therapy, content will focus on the provision of information and education, including: a description of palliative and supportive care, symptom management, advance care planning, prognostic and illness understanding and treatment expectations, and coping strategies. All subsequent visits will include, at minimum, these topics. All meetings will be audio-recorded using a handheld audio-recorder; the record feature of Zoom will not be utilized. Participants in the intervention arm will meet with a member of the study team (palliative care nurse practitioner or palliative care physician) one to two times weekly, or more frequently if requested by the patient and/or family caregiver, until 3 months post-transplant/CAR T-cell therapy.
62525211|NCT05190653|NO_INTERVENTION|Standard Care|Standard care will involve the usual care that patients undergoing HSCT/CAR T-cell therapy would be expected to receive, including palliative care consultation as needed or upon request. Palliative care interventions beyond what are provided in the study will be tracked in both the intervention and the standard care arms.
62525212|NCT01431859|PLACEBO_COMPARATOR|Subcutaneous injection of placebo|
62525213|NCT01431859|ACTIVE_COMPARATOR|Birch pollen immunotherapy|
62713082|NCT04287413|EXPERIMENTAL|Physiotherapist-led primary care model for back pain|The index intervention will incorporate a PT within the primary care team and make them available at the first point of contact for people with low back pain. There will be 4 key components of this intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need (e.g., no insurance coverage for PT).
62713083|NCT04287413|ACTIVE_COMPARATOR|Usual care|The physician-led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, order diagnostic imaging, prescribe medications and/or refer based on their assessment findings and patient preferences.
62713084|NCT03501368|EXPERIMENTAL|Trametinib + Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
62713085|NCT06642675|EXPERIMENTAL|experimental group: active iTBS|Patients assigned to experimental group would receive treatment of active iTBS. 50 iTBS sessions (1,800 pulses per session, 50-minute intersession interval) were delivered 10 days at 90% resting motor threshold.
62713086|NCT06642675|SHAM_COMPARATOR|control group: sham iTBS|Patients assigned to control group would receive treatment of sham iTBS. The iTBS mode in sham iTBS is as the same as the active iTBS, but would be delivered with the sham coil, which provides the sensation of TBS without enough magnetic energy to reach the cortex.
62713087|NCT03848780|EXPERIMENTAL|Desflurane Group|Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
62713088|NCT03848780|NO_INTERVENTION|Control Group|No pharmacological preconditioning was implemented
62525214|NCT03859141|EXPERIMENTAL|Experimental group-phase Ⅰ|Quadrivalent influenza vaccine
62525215|NCT03859141|EXPERIMENTAL|Experimental group-phase Ⅲ|Quadrivalent influenza vaccine
62525216|NCT03859141|ACTIVE_COMPARATOR|Control group 1-phase Ⅲ|Trivalent influenza vaccine (contains B/Victoria strain)
62525217|NCT03859141|ACTIVE_COMPARATOR|Control group 2-phase Ⅲ|Trivalent influenza vaccine (contains B/Yamagata strain)
62713089|NCT05271006|EXPERIMENTAL|Exercise group|"Weeks 1 - 12:~* For the duration of the study, participant will be completing any of the physical activities customizable within the Down Dog apps. He/she will be asked to complete a minimum of four 20-minute workouts per week.~* Every two weeks, participant will receive a survey to complete.~Week 24:~* At week 24 (12 weeks after their initial 12-week participation in the study), participant will receive a check-in email with the final survey to complete.~* Investigators will also record the use of the apps at week 24."
62525218|NCT00968292|EXPERIMENTAL|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
62525219|NCT00968292|EXPERIMENTAL|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
62525220|NCT02991027|EXPERIMENTAL|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be imaged using 2 different light sources using the DRI Triton
62525221|NCT04402775|NO_INTERVENTION|Vascular clamps|Patients randomized to the use of vascular clamps to obtain a bloodless field during arteriovenous fistula surgery (standard protocol).
62525222|NCT04402775|EXPERIMENTAL|Tourniquet|Patients randomized to the use of a tourniquet to obtain a bloodless field during arteriovenous fistula surgery.
62525223|NCT03050008|OTHER|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
62525224|NCT03050008|OTHER|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound
62525225|NCT04244201|EXPERIMENTAL|VHT treatment|Patients will be treated with VHT for 1 hour four times per week
62525226|NCT02148341|EXPERIMENTAL|Community of Practice Facilitation|Medical Centers assigned to this arm will recieive the communtiy of practice facilitation. In this process we will contact existing members of the community of practice (called the Heart Failure Network) at the facility as well as attempt to identify new providers and other staff at the facility with an interest in improving heart failure care. The facilitation includes: describing the national H2H program, providing talking points and strategies for local providers to obtain support from their local facility to initiate local projects related to H2H, providing a forum for successful sites to describe how they initiated projects to sites yet to initiate projects.
62525227|NCT02148341|EXPERIMENTAL|Usual Care|Medical centers in this arm will hear of H2H through usual routs (calls with facilty Directors and Chiefs of staff).
62525228|NCT02737332|ACTIVE_COMPARATOR|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
62525229|NCT02737332|EXPERIMENTAL|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
62525230|NCT02564419|EXPERIMENTAL|Medtronic Activa PC+S|"Objective of this pilot phase early feasibility study is to assess the safety and feasibility of Medtronic Activa PC+S implant (device) by;~1. Evaluating the ability of the Activa PC+S system to sense ECoG signals in subjects living with quadriplegia (C5 or C6 level).~2. Assessing the feasibility of activating fundamental upper extremity muscles to reproduce hand grasp.~These are important first steps towards creating and designing a device that can enhance or assist in performing activities of daily living (ADL) in the life of these subjects. Attachment 15.3"
62152533|NCT03046394|ACTIVE_COMPARATOR|B-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
62152534|NCT03046394|ACTIVE_COMPARATOR|A-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
62152535|NCT04017364|ACTIVE_COMPARATOR|PTCA of coronary de novo lesion PCB|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
62152536|NCT04017364|EXPERIMENTAL|PTCA of coronary de novo lesion SCB|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
62152537|NCT03028961|EXPERIMENTAL|Group I (Stanford Letter, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
62152538|NCT03028961|ACTIVE_COMPARATOR|Group II (traditional advance directive, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
62152539|NCT03938792|EXPERIMENTAL|PF-06741086|Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
62152540|NCT05582226|EXPERIMENTAL|ACL reconstruction utilizing stump-derived mesenchymal stem cells|This is the test group of this study. These participants will receive the augmented ACL reconstruction treatment involving extraction and injection of mesenchymal stem cells. Stem cell tissue will be harvested from each participant using the GraftNet device intraoperatively. During the intra-articular preparation phase of the reconstruction, the stem cell tissue will be applied to the ACL graft using a bovine collagen matrix.
62152541|NCT05582226|OTHER|Standard of care ACL reconstructive surgery|This is the control group of this study. These participants will receive standard ACL reconstructive surgery without any augmentations.
62152542|NCT05980078|EXPERIMENTAL|Interactive consent|They were randomized to complete an interactive consent
62152543|NCT05980078|ACTIVE_COMPARATOR|Standard written consent|They were randomized to complete a standard written consent
62152544|NCT01442766|EXPERIMENTAL|Donepezil|
62152545|NCT01442766|PLACEBO_COMPARATOR|Placebo|
62152546|NCT01452867|ACTIVE_COMPARATOR|Bag-Mask-Ventilation|Bag-Valve Mask-Ventilation in 50 patients in general anesthesia
62152547|NCT01452867|ACTIVE_COMPARATOR|Laryngeal Mask Ventilation|Laryngeal Mask Ventilation in 50 patients in general anesthesia
62152548|NCT01452867|ACTIVE_COMPARATOR|Laryngeal Tube Ventilation|Laryngeal Tube Ventilation in 50 patients in general anesthesia
62152549|NCT03917589||Patients with corticosteroids|Patients who have systematically been treated by high-dose corticosteroids after the delivery
62152550|NCT03917589||Patients without corticosteroids|Patients who haven't been systematically treated by high-dose corticosteroids after the delivery.
62152551|NCT03305705|EXPERIMENTAL|Treatment Arm 1|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
62525231|NCT06285630||Health infants|We aim to recruit parents of infants in an age range between 3 and 12 months. Healthy infants only, which were delivered in term, and that are not undergoing any antibiotic treatment.
62525232|NCT05370755|EXPERIMENTAL|Phase Ia: ICP-189 Dose Escalation|
62525233|NCT05485935|EXPERIMENTAL|Investigational device - intermittent catheter with micro-hole zone|Ready-to-use, sterile, hydrophilic coated intermittent male catheter (sizes CH12 and CH14) with a flexible tip and a micro-hole zone for urinary drainage. The investigational device is for single use.
62152552|NCT03305705|EXPERIMENTAL|Treatment Arm 2|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
62152553|NCT05308888|EXPERIMENTAL|Intervention|All patients will have to undergo an 18F-FDG PET-CT.
62152554|NCT02037568|NO_INTERVENTION|Caregiver Self-Directed|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
62152555|NCT02037568|EXPERIMENTAL|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
62525234|NCT05485935|ACTIVE_COMPARATOR|Comparator device - standard intermittent catheter|Single-use, hydrophilic coated intermittent male catheters (sizes CH12 and CH14) with sleeves: SpeediCath Flex, VaPro, VaPro Pocket, VaPro Plus and VaPor Plus Pocket.
62525235|NCT04072016|EXPERIMENTAL|Beacon Aqueous Microshunt|
62525236|NCT03850951|EXPERIMENTAL|"Lingual appliances AO®"|Patients with moderate crowding will be treated without extraction using lingual fixed appliances from American Orthodontics company.
62525237|NCT03850951|EXPERIMENTAL|"Labial appliances AO®"|Patients with moderate crowding will be treated without extraction using labial fixed appliances from American Orthodontics company.
62525238|NCT00606359|EXPERIMENTAL|Study Group 1|
62525239|NCT00606359|ACTIVE_COMPARATOR|Study Group 2|
62525240|NCT04323241|NO_INTERVENTION|control group|In group 1, plasenta is removed manually. Manual removal of the placenta will be performed by placing surgeon's dominant hand in the uterine cavity and removing the placenta by detaching it from the uterine wall as soon as possible after the delivery of the infant. The emptiness of the uterine cavity is verified manually.
62525241|NCT04323241|EXPERIMENTAL|Study Group|In group 2, plasenta is removed by controlled cord traction. Spontaneous removal will be performed by external uterine massage and traction on the umbilical cord are performed to assist spontaneous delivery of the placenta.
62525242|NCT02438852|EXPERIMENTAL|Arm I (ropivacaine hydrochloride)|Patients receive ropivacaine hydrochloride IV continuously over 72 hours after radical cystectomy.
62525243|NCT02438852|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy.
62525244|NCT03002662||BMI <18.5 underweight (Group 1)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMI \<18.5 underweight (Group 1)
62525245|NCT03002662||BMİ: 18.5 - 24.9 normal weight (Group 2)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 18.5 - 24.9 normal weight (Group 2)
62525246|NCT03002662||BMİ: 25- 29.9 overweight (Group 3)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 25- 29.9 overweight (Group 3)
62525247|NCT03002662||BMİ>30 obese (Group 4)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ\>30 obese (Group 4)
62525248|NCT05865821|ACTIVE_COMPARATOR|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt or Redivac catheter is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure.
62525249|NCT05865821|OTHER|No pressure drain|no drainage catheter in subcutaneous surgical wound
62525250|NCT03895723|EXPERIMENTAL|Minimally Invasive surgery|the intevention of Minimally Invasive procedure contains laparoscopic and robotic liver resection
62525251|NCT03895723|OTHER|Open surgery|the open surgery means traditional open surgery for liver resection
62525252|NCT04008966|ACTIVE_COMPARATOR|single trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection
62525253|NCT04008966|ACTIVE_COMPARATOR|Dual trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously
62525254|NCT02218970|EXPERIMENTAL|strength training|Strength training for leg muscles during10 weeks, 3 times a week: hack squat and plantar flexion, standing upright in a hack squat machine and lying down in a calf rise machine. Exercises will be carried out at 85% of 1-RM intensity under supervision at the institution where participants are having their SUD treatment.
62525255|NCT02218970|OTHER|control|patients treated for substance-related disorder but not participating in strength training intervention (no training control group)
62525256|NCT01412372|EXPERIMENTAL|Placebo|This arm will include those who are randomized to the placebo
62152556|NCT04985994||Tuberculosis Patients|"1. Diagnosed with pulmonary TB after detailed history collection, clinical examination, and laboratory assessment (sputum culture positive).~2. Aged 18 years or above.~3. Willing to participate in the study."
62525257|NCT01412372|EXPERIMENTAL|Mesalamine|This arm is for subjects randomized to the study drug, Mesalamine
62525258|NCT02925585||Pre/post pelvic floor surgery imaging|
62525259|NCT06019520|ACTIVE_COMPARATOR|Cisplatin group|This group of Patients will receive Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol
62525260|NCT06019520|EXPERIMENTAL|N-acetylcysteine group|Patients in the NAC arm to be given N-acetylcysteine 1200 mg/day starting 12 hrs before till 6 days after Cisplatin-based chemotherapy administration. Hydration according to standard hydration protocol will be given.
62525261|NCT02541162|EXPERIMENTAL|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
62525262|NCT02541162|NO_INTERVENTION|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
62525263|NCT04055051||Hemophilia A and B Cases|No intervention. Only patients that have undergone a liver transplant per study eligibility are in this cohort.
62525264|NCT04055051||Hemophilia A and B Controls|No intervention. Comparable patients to those in Case cohort will be put in this cohort.
62525265|NCT00554775|EXPERIMENTAL|erlotinib hydrochloride|WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
62525266|NCT00554775|PLACEBO_COMPARATOR|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm
62152557|NCT04985994||Healthy Volunteers|"1. Healthy subjects with no symptoms or history of pulmonary TB~2. Negative sputum culture~3. Matched for sex and age (±5 years) with the TB patient group."
62152558|NCT01458782|ACTIVE_COMPARATOR|ACI-C|Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
62525267|NCT04757038|EXPERIMENTAL|Hyalodisc injection|"• Group 1: One single X-ray-guided intradiscal injection (25 gauge) of 8 mg/mL of HYALODISC combined with PEP. The investigator will use one syringe for each involved disc, up to a maximum of three discs.~The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided. Both groups (Group 1 and Group 2) will be treated with PEP according to a standardized protocol."
62152559|NCT01458782|ACTIVE_COMPARATOR|AMIC|"Autologous matrix induced chondrogenesis. Microfracture of the defect and covering using the collagen membrane (ChondroGide).~Please see reference 3 for details regarding AMIC"
62152560|NCT03954106|EXPERIMENTAL|Defibrotide|"Part 1 (lead-in phase) will evaluate a 2.5 mg/kg/dose regimen before escalating to a 6.25 mg/kg/dose regimen.~After the Safety Assessment Committee establishes the recommended phase 2 dose based on dose-limiting toxicities during Part 1, Part 2 will enroll subjects at the recommended phase 2 dose."
62525268|NCT04757038|NO_INTERVENTION|Physical exercise program (PEP)|Group 2: PEP alone
62713090|NCT05271006|NO_INTERVENTION|Waitlist control group|"Weeks 1 - 12:~* For the 12 weeks of the study, participant will be asked to continue their typical, pre-study daily and weekly routine, maintaining the physical activity he/she was completing before the start of the study.~* Every two weeks, the participant will receive a survey to complete.~Week 24:~• At the end of the first 12 weeks that he/she have access to the suite of apps (i.e., 24 weeks following their randomization to the waitlist control group), participant will receive a check-in email with the final survey to complete."
62713091|NCT04240561|EXPERIMENTAL|Hearing Aid Fitting Order A|Participants wear hearing aids with a high level of signal manipulation, followed by a low level of signal manipulation
62713092|NCT04240561|EXPERIMENTAL|Hearing Aid Fitting Order B|Participants wear hearing aids with a low level of signal manipulation, followed by a high level of signal manipulation
62713093|NCT03486353|EXPERIMENTAL|Run-In Phase, Regimen 1|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 twice daily (BID) for 14 days plus azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days. One treatment cycle will be 28 days in duration.
62152561|NCT00599625|EXPERIMENTAL|1|Patients with active Crohn's Disease
62525269|NCT00929331|EXPERIMENTAL|Fluviral Adult Group|Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
62525270|NCT00929331|EXPERIMENTAL|Fluviral Elderly Group|Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
62525271|NCT04188301|ACTIVE_COMPARATOR|IVM + ALB|Single dose of oral IVM (150 µg/kg) plus ALB (400 mg)
62525272|NCT04188301|EXPERIMENTAL|IDA x 1 dose|Single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
62525273|NCT04188301|EXPERIMENTAL|IDA x 3 doses|Once daily for 3 days oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
62713094|NCT03486353|EXPERIMENTAL|Run-In Phase, Regimen 2|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 BID for 21 days plus azacitidine at a dose of 75 mg/m2 either SC or IV x 7 days every 28 days.
62713095|NCT02808780||Simponi-exposed cohort|Participants receiving Simponi at enrollment and are still receiving Simponi after participation in a therapeutic trial or participants scheduled to receive Simponi within 30 days after enrollment. Participants in this cohort may be receiving Simponi alone or in combination with thiopurines but must not be receiving other approved biologics or investigational agents at enrollment. Participants may have received other approved biologics or investigational agents prior to enrollment.
62713096|NCT02808780||Thiopurine cohort|Participants currently receiving thiopurines, having received at least 12 consecutive weeks of therapy prior to registry entry. Participants must not be receiving approved biologic agents, including Simponi, or investigational agents at enrollment. These patients may have received biologics other than Simponi or investigational agents prior to enrollment.
62713097|NCT02483429|EXPERIMENTAL|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
62152562|NCT04351243|EXPERIMENTAL|Gimsilumab|Gimsilumab 400 mg on Day 1 Gimsilumab 200 mg on Day 8
62152563|NCT04351243|PLACEBO_COMPARATOR|Placebo|Normal saline on Day 1 Normal saline on Day 8
62152564|NCT01653106|EXPERIMENTAL|Arm I (cryotherapy 120 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes.
62152565|NCT01653106|ACTIVE_COMPARATOR|Arm II (cryotherapy 360 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.
62152566|NCT00430586|EXPERIMENTAL|20 U NT 201|
62152567|NCT00430586|PLACEBO_COMPARATOR|Placebo|
62152568|NCT00430586|EXPERIMENTAL|10 U NT 201|
62152569|NCT00430586|EXPERIMENTAL|30 U NT 201|
62152570|NCT01381445|EXPERIMENTAL|GW870086 0.2% &amp; GW870086 2%|GW870086 0.2%, 2% \&amp; placebo each applied to an identified area for 42 days.
62152571|NCT01381445|EXPERIMENTAL|GW870086 2% &amp; Clobetasol Propionate|GW870086 2% \&amp; placebo applied to an identified area for 42 days, while Clobetasol Propionate is applied to an area for 21 days
62525274|NCT05065983|EXPERIMENTAL|PXVX0317 (CHIKV VLP, alum-adjuvanted) vaccine|All study participants will receive the same Investigational Product (40 µg CHIKV VLP, alum-adjuvanted according to the same single dose schedule on Day 1).
62525275|NCT05154812|EXPERIMENTAL|Yang Yin Fu Zheng Jie Du therapy|
62152572|NCT04524676|EXPERIMENTAL|Individualized Treatment Group|
62525276|NCT05154812|PLACEBO_COMPARATOR|Routine medical care|
62525277|NCT00696579|ACTIVE_COMPARATOR|A|Group A received BCG instillation 14 days after II look-TURB:6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
62525278|NCT00696579|EXPERIMENTAL|2|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
62525279|NCT02171676|EXPERIMENTAL|Docetaxel + BIBW 2992|Dose escalation
62152573|NCT02644941|EXPERIMENTAL|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
62525280|NCT01614145||Proven/probable CNS IA|Immunocompromised patients with proven/probable invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
62525281|NCT01614145||Possible/No CNS IA|Immunocompromised patients with possible/NoIA invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
62525282|NCT03365011|PLACEBO_COMPARATOR|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
62525283|NCT03365011|EXPERIMENTAL|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
62152574|NCT02644941|ACTIVE_COMPARATOR|ePTFE|The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.
62525284|NCT02849327|EXPERIMENTAL|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62525285|NCT02849327|ACTIVE_COMPARATOR|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62525286|NCT00400361|EXPERIMENTAL|1|
62525287|NCT02287207|ACTIVE_COMPARATOR|Anodal tDCS|20 minutes, 1.0 mA unilateral-anodal motor cortex (M1) tDCS stimulation
62525288|NCT02287207|SHAM_COMPARATOR|Sham tDCS|20 minutes, sham tDCS stimulation
62525289|NCT05229653|EXPERIMENTAL|Low-Dose Ketamine (LDK) Treatment Group|
62525290|NCT05229653|PLACEBO_COMPARATOR|Control Group|
62525291|NCT02688426|SHAM_COMPARATOR|0J LLLT|The sham treatment is performed in the same way as treatment with LBP, however, with the apparatus switched off
62525292|NCT02688426|EXPERIMENTAL|6J LLLT|The Laser radiation will be made with 6J by spot.
62152575|NCT03139045|ACTIVE_COMPARATOR|Venous puncture using VVV at the beginning of the procedure|
62525293|NCT03291353|EXPERIMENTAL|AML Patients|pembrolizumab 200 mg given IV once every three weeks
62152576|NCT03139045|ACTIVE_COMPARATOR|Venous puncture without VVV|
62152577|NCT00872859|EXPERIMENTAL|1|Dermamatrix with radiation
62152578|NCT00872859|EXPERIMENTAL|2|Dermamatrix without radiation
62152579|NCT00872859|EXPERIMENTAL|3|Alloderm with radiation
62152580|NCT00872859|EXPERIMENTAL|4|Alloderm without radiation
62152581|NCT03043339||Renal transplant recipient|"Participants who are scheduled for a planned renal transplant as the recipient of the kidney.~All participants will complete the following interventions:~* Stool Specimen Collection~* Anal Swab Sampling~* Short Diet Assessment (SDA)~* NHANES Dietary Screener Questionnaire (DSQ)"
62152582|NCT03043339||Renal transplant donor|"Participants who are scheduled for a planned renal transplant as the donor of the kidney.~All participants will complete the following interventions:~* Stool Specimen Collection~* Anal Swab Sampling~* Short Diet Assessment (SDA)~* NHANES Dietary Screener Questionnaire (DSQ)"
62152583|NCT03662698|EXPERIMENTAL|Guided Imagery|The GI intervention will include direct, written, and audio delivery of one of three GI vignettes (depiction).The patient will be able to choose one of the three vignettes.
62152584|NCT03662698|ACTIVE_COMPARATOR|Treatment as Usual|The control, or treatment as usual condition, will include an orientation to radiotherapy from the clinic nurse coordinator.
62152585|NCT02680314|ACTIVE_COMPARATOR|Single Dose|single dose of misoprostol
62525294|NCT04132336|EXPERIMENTAL|Naproxen sodium/caffeine - Dose 1|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/medium low dose) after extraction of third molars
62525295|NCT04132336|EXPERIMENTAL|Naproxen sodium/caffeine - Dose 2|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/low dose) after extraction of third molars
62525296|NCT04132336|EXPERIMENTAL|Naproxen sodium/caffeine - Dose 3|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ medium low dose) plus one tablet of placebo after extraction of third molars
62525297|NCT04132336|EXPERIMENTAL|Naproxen sodium/caffeine - Dose 4|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ low dose) plus one tablet of placebo after extraction of third molars
62525298|NCT04132336|ACTIVE_COMPARATOR|Naproxen sodium|Participants received a single dose of one tablet of naproxen sodium (low dose) plus one tablet of placebo after extraction of third molars
62525299|NCT04132336|ACTIVE_COMPARATOR|Caffeine|Participants received a single dose of two tablets of caffeine (medium low dose) after extraction of third molars
62525300|NCT04132336|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of two tablets of matching placebo after extraction of third molars
62525301|NCT03077035|EXPERIMENTAL|glass ionomer sealant|
62525302|NCT03077035|ACTIVE_COMPARATOR|resin-based sealant|
62525303|NCT02978820|EXPERIMENTAL|SEAS exercise group|This group received SEAS exercises in addition to brace wearing for four months
62152586|NCT02680314|ACTIVE_COMPARATOR|Multiple Dose|multiple doses of misoprostol
62152587|NCT03009123||Erectile dysfunction group|Group contains men with physician-diagnosed erectile dysfunction
62152588|NCT03009123||General population men without ED|Men 50 years and older having no ED and pre-existing prostate cancer
62152589|NCT03009123||Symptomatic BPH group without ED|Men 50 years old older with symptomatic prostatic hypertrophy but with no ED nor pre-existing prostate cancer
62525304|NCT02978820|EXPERIMENTAL|CS exercise group|This group received core stabilization exercise training (CS) in addition to brace wearing for four months
62525305|NCT01383798|PLACEBO_COMPARATOR|Placebo|Red capsule (50 mg) lactose
62525306|NCT01383798|EXPERIMENTAL|Ferrous sulfate|
62525307|NCT00986180|EXPERIMENTAL|001|NUCYNTA 50 75 or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
62525308|NCT00986180|ACTIVE_COMPARATOR|002|Oxycodone IR 5 10 or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
62525309|NCT00573157|EXPERIMENTAL|Atacicept Plus Mycophenolate mofetil Plus Corticosteroids|
62525310|NCT00573157|PLACEBO_COMPARATOR|Placebo Plus Mycophenolate mofetil Plus Corticosteroids|
62525311|NCT02930486|ACTIVE_COMPARATOR|ZipTight|ZipTight suture endobutton
62525312|NCT02930486|ACTIVE_COMPARATOR|Syndesmotic screw|Tricortical 3.5 mm syndesmotic screw
62713098|NCT02483429|NO_INTERVENTION|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
62713099|NCT02483429|NO_INTERVENTION|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
62713100|NCT03738917|ACTIVE_COMPARATOR|Dextromethorphan|Usual clinical practice + dextromethorphan (15 milligrams unit), one 15 mg-tablet t.i.d. up to a maximum of 14 days.
62713101|NCT03738917|ACTIVE_COMPARATOR|Ipratropium|Usual clinical practice + ipratropium bromide 20Micrograms Inhaler each puff), 2 puffs t.i.d. up to a maximum of 14 days.
62713102|NCT03738917|ACTIVE_COMPARATOR|Honey|Usual clinical practice + Honey 30 g (full tablespoon) t.i.d. up to a maximum of 14 days. Patients will be given two 750 milligram bottles of wildflower honey (the most frequent type of honey used in our country) and patients will be recommended to add the honey to a cup of lemon or thyme juice, milk herbal tea, yogurt, as a hot toddy, etc.
62713103|NCT03738917|PLACEBO_COMPARATOR|Usual clinical practice|Usual care.
62713104|NCT06360107|EXPERIMENTAL|Peer social-inclusion enhanced social contact brief video|Novel brief video (1-2 mins) in which an adolescent talks about feeling depressed, and the impact this has on peer relationships, getting treatment, selectively disclosing mood problems with some friends, and experiencing support from both peers and family which helped facilitate recovery from depression.
62713105|NCT06360107|ACTIVE_COMPARATOR|Generic social contact brief video|Similar to existing brief videos (1-2 mins), an adolescent talks about feeling depressed, and then asking parents for help, and receiving professional treatment. This video does not make any references to peers or social support.
62525313|NCT00270257|EXPERIMENTAL|Long term medication assisted treatment (LT-MAT)|Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
62152590|NCT03054766|EXPERIMENTAL|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Sham macular laser"
62152591|NCT03054766|EXPERIMENTAL|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
62525314|NCT00270257|EXPERIMENTAL|Short term medication assisted treatment (ST-MAT)|Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
62525315|NCT01507155|EXPERIMENTAL|Patient-Reported Measures|Patients age 18 and older with a diagnosis of Major Depressive Disorder or Generalized Anxiety disorder who received genetic testing using the Genecept Assay and completed patient scales.
62525316|NCT01507155|EXPERIMENTAL|Clinician-Reported Outcomes|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
62525317|NCT01387581||Without MelaFind|Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
62525318|NCT01387581||With MelaFind|Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion
62152592|NCT02053506|EXPERIMENTAL|Immune-enhancing nutritional beverage|This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.
62152593|NCT02053506|EXPERIMENTAL|Probiotics (BB-12)|This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).
62525319|NCT01387581||Experts Without MelaFind|PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
62525320|NCT06076850|ACTIVE_COMPARATOR|Standard Care + Active LiESWT|"Tadalafil 5mg daily - to start 5 days before surgery and continued for 12 months after surgery till end of study.~With or without Vacuum Pump~Active LiESWT"
62525321|NCT06076850|SHAM_COMPARATOR|Standard Care + Sham LiESWT|"Tadalafil 5mg daily - to start 5 days before surgery and continued for 12 months after surgery till end of study.~With or without Vacuum Pump~Sham LiESWT"
62713106|NCT06360107|OTHER|Control|Brief video (1-2 mins) provides information about symptoms of depression and how to seek help with computer-generated voice, to isolate mechanisms of information from identification and emotional engagement.
62713107|NCT04513808|ACTIVE_COMPARATOR|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.
62525322|NCT03734406|EXPERIMENTAL|Video group|"All subjects enrolled in the study group will be showed during the discharge process the video related to patient's condition (DVT vs AF), using it as a graphic support to doctor's verbal explanation of the diagnosed pathology and its possible complications.~For the purposes of the study we have selected two 3D videoclips, available on various internet sites and not covered by any copyright restrictions; these have been modified and shortened to make them suitable to use in our study setting.~The images contained show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.~The SIs will show the videos to patients on the institutional computer or, alternatively, on their personal smartphone / tablet. The videos were purposely left without audio content."
62525323|NCT03734406|NO_INTERVENTION|Control group|"Patients of the control group will receive discharge explanations without the aid of any video.~The communication strategy in these cases won't be standardized, in order to leave the treating doctors free to express themselves in the way they are used to in their clinical practice, which is based solely on doctor's verbal and non-verbal communication skills."
62525324|NCT03769883|EXPERIMENTAL|Dietary control (DCON)|The macro-nutrient distributions are in line with the current guidelines from the national Diabetes Association and Canadian guidelines, where individualization in macronutrient distribution should lie within the range of 45-60E% carbohydrate, 15-20E% protein and 20-35E% fat. The dietary plan will aim at reducing saturated fat intake \<7E% aiming at a caloric deficit of 500 kilo calories/day
62525325|NCT03769883|EXPERIMENTAL|Moderate Exercise Dose (MED)|Two aerobic training sessions per week of 45-60 min duration and one session per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
62525326|NCT03769883|EXPERIMENTAL|High Exercise Dose (HED)|Four aerobic training sessions per week of 45-60 min duration and two sessions per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
62525327|NCT03769883|NO_INTERVENTION|Control|No intervention
62525328|NCT02357329||Taste and hedonic ratings of NEFA|Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
62525329|NCT02397642|ACTIVE_COMPARATOR|Dual trigger|GnRH agonist plus 1000 IU of HCG to trigger final maturation
62152594|NCT06305910|EXPERIMENTAL|CD200AR-L|"Up to 3 dose levels (2.0, 3.75, and 5.0 micrograms/kg/dose) of CD200AR-L will be tested with a Dose Level -1 (1.0 microgram/kg/dose) in the event of toxicity at the 2.0 micrograms/kg/dose level. This will be given with fixed doses of 1mg GBM6-AD vaccine and topical imiquimod. A single dose of 300cGy re-irradiation will be given on Day 15. Patients with DMG/DIPG must have completed standard-of-care radiation before enrolling.~The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort. This study will first enroll patients ≥ 12 years of age into Dose Level 1 in order to acquire safety data prior to subsequent enrollment of study subjects aged 2-11 years."
62152595|NCT00249366|ACTIVE_COMPARATOR|Fixed-schedule treatment|Fixed-schedule administration of lorazepam for alcohol withdrawal
62152596|NCT00249366|ACTIVE_COMPARATOR|Symptom-triggered treatment|Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
62152597|NCT06139419|EXPERIMENTAL|Concurrent Tα-1 group|In this concurrent Tα-1 group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. During this treatment, thymosin alpha-1 was administered at 4.8mg each time.
62152598|NCT06139419|OTHER|Control group|In control group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation.
62152599|NCT06306222|EXPERIMENTAL|Thulium fiber laser (TFL) lithotripsy|Lithotripsy with TFL is a recently introduced procedure, that will be tested in this study.
62525330|NCT02397642|ACTIVE_COMPARATOR|Booster HCG dose|GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
62525331|NCT03039179|EXPERIMENTAL|Polyurethane foam|
62525332|NCT03039179|NO_INTERVENTION|standard care|Only application of the Walker in the immediate postoperative period.
62525333|NCT06446466|EXPERIMENTAL|Participants group|"Two interventions will be performed on the same group of subjects. Participants will be healthy volunteers with sedentary habits.~The experiments will be performed on the cycle-ergometer (H-300-R Lode, Exere Air Machine, Italy). The surface EMG activity will be recorded from the right Vastus Medialis and right Biceps Femoris caput longum at a sampling rate of 1000 Hz by a Free-EMG 1000 (BTS Bioengineering, Inc.). To stimulate the entire right thigh, 2 circular 20 cm PEMF loop-antenna devices (Torino II, Rio Grande Neurosciences, USA) will be placed at the beginning and at the end of the right leg. The PEMF waveform consists of a pulse-burst modulated 27.12 Mega-Hertz (MHz) sinusoidal carrier, with 2ms burst width repeated at 2 Hertz, with peak magnetic field at the center of the loop 5±1 microTesla."
62525334|NCT00971958|ACTIVE_COMPARATOR|Mogen Clamp|
62525335|NCT00971958|ACTIVE_COMPARATOR|Plastibell|
62525336|NCT00971958|ACTIVE_COMPARATOR|AccuCirc|AccuCirc is a device approved by the FDA for circumcision of male infants up to ten days of life.
62525337|NCT00276549|EXPERIMENTAL|Gemcitabine and Docetaxel i|
62525338|NCT05745792||Patients with Hu Abs|Patients harboring Hu Abs and a neurological syndrome
62713108|NCT04513808|ACTIVE_COMPARATOR|Sevoflurane intravenous anesthesia|Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary
62713109|NCT03066206|EXPERIMENTAL|Treatment (poziotinib)|Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62713110|NCT05247203|EXPERIMENTAL|Telitacicept Arm 1|Telitacicept 80mg, once a week for 24 weeks plus standard therapy
62152600|NCT06306222|ACTIVE_COMPARATOR|Holmium:YAG laser lithotripsy|Holmium:YAG laser lithotripsy represents the gold standard for this procedure since 30 years.
62152601|NCT01523184|PLACEBO_COMPARATOR|Placebo Capsule|Placebo Capsules
62152602|NCT01523184|ACTIVE_COMPARATOR|YKP10811 Drug Product Capsule, 10 mg|
62152603|NCT01523184|ACTIVE_COMPARATOR|YKP10811 Drug Product Capsule, 20 mg|
62152604|NCT01523184|ACTIVE_COMPARATOR|YKP10811 Drug Product Capsule, 30 mg|
62152605|NCT00091676|EXPERIMENTAL|ID-KLH + GM-CSF|
62152606|NCT00091676|ACTIVE_COMPARATOR|KLH + GM-CSF|
62152607|NCT04309578|EXPERIMENTAL|treatment arm|Single arm
62525339|NCT04725448|EXPERIMENTAL|Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin|"Drugs: Toripalimab, 240mg (6ml)/bottle, ivgtt, d1, q3w, administration until PD or death, the longest use time is two years.~Drugs: Bevacizumab, 7.5mg/kg, ivgtt, d1, q3w,the longest use time is two years.~Drugs: Nab-paclitaxel, 260mg/m2,ivgtt,d1 or 130mg/m2,ivgtt,d1,8, q3w, up to six cycles.~Drugs: Carboplatin, AUC=4～5, ivgtt, d1, q3w, up to six cycles."
62525340|NCT05224934|EXPERIMENTAL|Ultra-hypofractionated radiotherapy|Patients receive ultra-hypo-fractionated radiotherapy with 25Gy to 50Gy in five fractions, followed by surgery done at 1 to 2 months post-RT
62525341|NCT06423638|EXPERIMENTAL|Intervention|Participants will complete two 60 minute virtual Tai Chi Easy classes per week and practice on their own 10 minutes per day on 4 other days each week for six weeks.
62525342|NCT02208232||MC 6125 AS IOL|cataract surgery with implantation of intraocular lens MC 6125 AS in one eye
62525343|NCT05685901|EXPERIMENTAL|High polyphenolic olive oil|Participants were required to take 2 mL of early harvest olive oil (normal early harvest olive oil) twice a day for three months and went through a clinical questionnaire at days 15, 30, 60 and 90. Participants were sent an envelope closed with instructions and informed consent. The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity. This study was approved by the independent ethic committee of the Hospital Nuestra Señora del Prado in Talavera de la Reina, belonging to the National Health System in Spain, and conducted in accordance with Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from all patients. This questionnaire consisted in asking about having symptoms of SARS-CoV-2 infection, fever, low fever, malaise, headache, loss of smell, runny nose, sore throat.
62525344|NCT05685901|NO_INTERVENTION|No intervention|Participants were required to complete a questionnaire at days 15, 30, 60 and 90 of the study. This questionnaire consisted in asking about having symptoms of SARS-CoV-2 infection, fever, low fever, malaise, headache, loss of smell, runny nose, sore throat.
62525345|NCT05038332|ACTIVE_COMPARATOR|Moderately Hypo-fractionated Radiation Therapy|20 fractions of moderately hypofractionated radiation therapy over no more than 5-6 weeks.
62525346|NCT05038332|EXPERIMENTAL|Ultra-Hypofractionated Radiation Therapy|5 fractions of ultra-hypofractionated radiation therapy with at least one day between each treatment over the course of no more than 3-4 weeks
62525347|NCT05981820|EXPERIMENTAL|HIIT group|"This group will only participate Wingate-based HIIT training.~In the first three weeks:~* Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes~* Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set~* Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~* Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes~* Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets"
62525348|NCT05981820|EXPERIMENTAL|HIIT + creatine group|The HIIT + creatine group will participate the same Wingate-based HIIT training in addition to consume 10 g of creatine supplementation. Participants in this group will use 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation will be taken in two doses of five grams, 30 minutes before and after training.
62525349|NCT02434432|EXPERIMENTAL|condition 1|Infants in this arm will receive their mother's choice of music recorded on an Mp player and delivered via headphones.
62525350|NCT02434432|ACTIVE_COMPARATOR|condition 2|Infants in this arm wil receive a recorded Lullaby music delivered to the infant via headphones.
62525351|NCT02434432|NO_INTERVENTION|Condition 3|Infants in this arm will have the headphones applied but no music played.
62525352|NCT02754466|EXPERIMENTAL|Deep dentin lesions|Subjective vs objective criteria in selective excavation of carious lesions Group 1: selective carious dentin excavation using subjective criteria (standard protocol in Dentistry) Group 2: selective carious dentin excavation using objective criteria (polymer burs) All restorations performed using high-viscosity glass-ionomer.
62525353|NCT02754466|EXPERIMENTAL|Shallow and medium depth dentin lesion|Glass-ionomer vs Bulk fill composites in the ART approach All cavities excavated using hand-instruments only (ART approach) Group 1: restorations using high-viscosity glass-ionomer Group 2: restorations using self-etch adhesive and bulk fill composite
62525354|NCT03660293|NO_INTERVENTION|diabetic- no cardioprotectives|25 child with type 1 diabetes mellitus will not receive any cardio protective drug
62713111|NCT05247203|EXPERIMENTAL|Telitacicept Arm 2|Telitacicept 160mg, once a week for 24 weeks plus standard therapy
62713112|NCT05247203|EXPERIMENTAL|Telitacicept Arm 3|Telitacicept 160mg, once a week for 12 weeks followed by once every two weeks for another 12 weeks plus standard therapy
62713113|NCT05247203|EXPERIMENTAL|Telitacicept Arm 4|Telitacicept 240mg, once a week for 24 weeks plus standard therapy
62713114|NCT05247203|EXPERIMENTAL|Telitacicept Arm 5|Telitacicept 240mg, once every two weeks for 24 weeks plus standard therapy
62713115|NCT03064074|EXPERIMENTAL|Stage 1 Low dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~* Physical exam~* Vitals~* Blood draw for safety labs, pharmacokinetics, etc~* If the participant is female, she will have a pregnancy test~* EKG~* DXA~* Infusion of the study drug"
62525355|NCT03660293|EXPERIMENTAL|diabetic-Atorvastatin|25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
62525356|NCT03660293|EXPERIMENTAL|diabetic-Captopril|25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
62525357|NCT03660293|EXPERIMENTAL|diabetic-L-Carnitine|25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
62525358|NCT03660293|NO_INTERVENTION|Controls|50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
62713116|NCT03064074|EXPERIMENTAL|Stage 2 High dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~* Physical exam~* Vitals~* Blood draw for safety labs, pharmacokinetics, etc~* If the participant is female, she will have a pregnancy test~* EKG~* DXA~* Infusion of the study drug"
62525359|NCT01988506|EXPERIMENTAL|Interleukin 2|Interleukin 2, 1MUI.= Proleukin®, RhIL-2
62713117|NCT03064074|EXPERIMENTAL|Stage 2 Repeat dose every 6 months|"Fresolimumab will be administered every six months for a total treatment period of 12 months (Total Anticipated n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~* Physical exam~* Vitals~* Blood draw for safety labs, pharmacokinetics, etc~* If the participant is female, she will have a pregnancy test~* EKG~* DXA~* Infusion of the study drug~* Skeletal survey~* Peripheral quantitative CT (pQCT) of the forearm~* Quality of Life Surveys~* Pulmonary function test~* Walk test"
62152608|NCT04931498||GMPR sub-study|Study population will be split into five haplotypes based on a combination of rare and common variants at the GMPR locus. A total of 26 volunteers per genotypic group in a comparison between heterozygous and homozygous individuals will be tested.
62152609|NCT04931498||SWAP70 sub-study|To assess genotype-specific effects on SWAP70 protein levels as well as coronary artery disease-related immune processes, we will recruit 50 volunteers stratified by variant genotype, i.e. major and minor homozygotes only (25 participants will be recruited to each group).
62525360|NCT04426279||patient with chronic inflammatory rheumatism|
62525361|NCT01839630||Group 1|
62525362|NCT01391741|EXPERIMENTAL|Walking with visual cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
62525363|NCT01391741|ACTIVE_COMPARATOR|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
62525364|NCT01418482|EXPERIMENTAL|Mepilex Border Ag|Mepilex Border Ag, a silver dressing will be used
62525365|NCT05001711|EXPERIMENTAL|WHO Group 2|
62525366|NCT05001711|EXPERIMENTAL|WHO Group 3|
62525367|NCT03792724|EXPERIMENTAL|Cohort A|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg every 4 weeks (Q4W) from Cycle 3 and beyond
62525368|NCT03792724|EXPERIMENTAL|Cohort B|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg Q4W from Cycle 3 and beyond
62152610|NCT03810300|EXPERIMENTAL|Cash transfer|1500 taka ($18.75) per household distributed monthly
62152611|NCT03810300|EXPERIMENTAL|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
62152612|NCT03810300|EXPERIMENTAL|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
62525369|NCT03842579|EXPERIMENTAL|Exercise and Protein (EXEPROT)|Participants in EXEPROT receive: a high-protein diet combined with Resistance training. The high-protein diet is based on milk-based protein-rich products to supplement the habitual diet (corresponding to a protein intake of 1.5 g/kg/day). 4-day food records are used to estimate the needed protein. Of the shelf-products (e.g. milk, cheese) are used considering the individually preferences. Products are delivered once a week. The training intervention includes progressive explosive type heavy-resistance training two times per week. The intervention runs for 16 weeks. Adherence to the training protocol is monitored at each session. Adherence with the nutrition protocol is monitored daily plus at phone follow-ups where participants are asked about e.g. appetite, weight, habitual intake.
62525370|NCT03842579|ACTIVE_COMPARATOR|Protein-only (PROT)|"Participants in PROT-group receive the nutritional intervention: The high-protein diet.~The diet is based on daily milk-based protein-rich products to supplement the habitual diet (corresponding to a total protein intake of 1.5 g/kg/day). The needed amount of protein supplementation is estimated from 4-day food records. Of the shelf-products (e.g. milk, skyr, cheeses) are used considering the individually preferences. Products will be delivered once a week at the home of the participant. The intervention runs for 16 weeks.~Adherence with the nutrition protocol is monitored daily (registration of compliance with the dietary plan) as well as at phone follow-ups where participants are asked about e.g. changes in appetite, weight, and habitual intake."
62525371|NCT03842579|ACTIVE_COMPARATOR|Recommendations (REC)|"Participants in the REC-Group receive the comparative intervention: Recommendations.~The official national dietary recommendations for adults \>65 years, developed by the Ministry of Environment and Food of Denmark, and related materials is given to the participants and they are encouraged to follow the guidelines (recommending a protein intake of 1.0-1.3 g/kg/day). The intervention runs for 16 weeks.~During the intervention all groups will receive two seminars on specific topics related to healthy ageing (e.g. talks on physical activity, sedentary behaviour, and nutrition)."
62525372|NCT01678053|EXPERIMENTAL|PPI and BOTOX|onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
62525373|NCT01678053|OTHER|Proton pump inhibitor only|omeprazole 40mg po bid for 3 months(standard of care)
62525374|NCT02876575|OTHER|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
62525375|NCT02253030||Newly-diagnosed, untreated wet AMD|This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
62525376|NCT02253030||"Wet AMD undergoing as-needed treatment"|This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
62525377|NCT02253030||High-risk eyes|This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
62525378|NCT02253030||"Wet AMD undergoing a treat and extend strategy"|"This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals."
62152613|NCT03810300|EXPERIMENTAL|Cash transfer + nutrition BCC|1500 taka ($18.75) per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
62152614|NCT03810300|EXPERIMENTAL|Food transfer + nutrition BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
62152615|NCT03810300|EXPERIMENTAL|Control|No transfer, no behavior change communication
62152616|NCT02291549|EXPERIMENTAL|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
62152617|NCT02291549|SHAM_COMPARATOR|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
62152618|NCT00353106||Patients|Patients with chronic GVHD
62152619|NCT00353106||Content Expert Panel|Content expert panel with 5 years experience caring for patients with cGVHD.
62152620|NCT00353106||Caregivers|Caregivers of patients with cGVHD
62152621|NCT04361240||Ancillary Cohort|No Intervention: Subjects will be followed before, during and for up to 1 year after radiation with echocardiogram, blood draw, and symptoms and activity survey.
62152622|NCT06245902|EXPERIMENTAL|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
62152623|NCT06245902|EXPERIMENTAL|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
62152624|NCT06245902|ACTIVE_COMPARATOR|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
62152625|NCT06245902|ACTIVE_COMPARATOR|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
62152626|NCT06245902|PLACEBO_COMPARATOR|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
62152627|NCT03662009||Parkinson Disease|Observation of individuals with idiopathic Parkinson disease performing a multilimb dual task using the arm and the leg.
62152628|NCT03662009||Control|Observation of healthy age-matched individuals will perform a multilimb dual task using the arm and the leg.
62152629|NCT00728013|EXPERIMENTAL|A|intensive statin group
62152630|NCT00728013|EXPERIMENTAL|B|moderate statin group
62152631|NCT06031506|EXPERIMENTAL|quad zygomatic hybrid maxillary prosthesis|All patients will be rehabilitated with immediate loaded hybrid prosthesis supported by 4 zygomatic implants.
62152632|NCT04105699||Device: Blood sampling|
62152633|NCT04660110|ACTIVE_COMPARATOR|Intervention arm|A single dose/round of IPT with DP (40mg/320mg tabs, Fosun Pharmaceuticals)
62152634|NCT04660110|NO_INTERVENTION|Standard of care|Health information, no study drugs
62152635|NCT02180906||Patients with NSTI|Definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and are spreading along tissue structures.
62152636|NCT04028518|EXPERIMENTAL|The high-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
62152637|NCT04028518|EXPERIMENTAL|The low-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
62152638|NCT04028518|EXPERIMENTAL|Active Comparator: Alteplase|"Active Comparator: Alteplase Drug: Alteplase for Injection Dose:50mg;20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours of medication.Subjects were monitored according to the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018."
62152639|NCT03855514|ACTIVE_COMPARATOR|NuShield|NuShield® is a sterile, dehydrated placental allograft
62152640|NCT03855514|NO_INTERVENTION|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
62152641|NCT00651599|PLACEBO_COMPARATOR|Arm 2|
62152642|NCT00651599|EXPERIMENTAL|Arm 1|
62525379|NCT00212121|ACTIVE_COMPARATOR|1|low dose boost (16 Gy)
62525380|NCT00212121|EXPERIMENTAL|2|high boost (26 Gy)
62152643|NCT06152497|PLACEBO_COMPARATOR|1: Placebo|Lactose
62152644|NCT06152497|EXPERIMENTAL|H1 blockade: Telfast (180mg Fexofenadine)|H1: Telfast (180mg Fexofenadine)
62152645|NCT02345759||Keto-diet group|Vegetarian very low protein regimen (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
62152646|NCT02345759||Conventional LPD group|0.6 g/kg per day, including high biological value proteins
62152647|NCT02395692|EXPERIMENTAL|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62152648|NCT03159494|EXPERIMENTAL|Intervention group|10 patients with type 2 diabetes enrolled to perform 8 times of High-Intensity Training. The subjects were tested before and after the training period.
62152649|NCT03159494|EXPERIMENTAL|Pilot study|6 patients with type 2 diabetes enrolled to perform 6 times of High-Intensity Training. The subjects were tested before and after the training period
62152650|NCT00255749|EXPERIMENTAL|early intervention epoietin alfa|Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
62152651|NCT00255749|OTHER|standard intervention epoietin alfa|Patients receive epoetin alfa as in arm I once their hemoglobin level is ≤ 10.5 g/dL.
62152652|NCT06390462||Adolescents with sustained depression|PHQ-9-A ≥ 10 at least twice in a 6 months follow-up
62152653|NCT06407141|EXPERIMENTAL|Experimental Arm|
62152654|NCT06407141|SHAM_COMPARATOR|Sham Control Arm|
62525381|NCT05388240|ACTIVE_COMPARATOR|Education Group|"The Education Group will be provided with standard education by the physiotherapist at the hospital prior to surgery and will be advised to continue with their normal activities of daily living (ADL). They will have access to the standard education and resources tabs on the mobile app. Shoulder specific exercises tab on the app will be available to them upon their completion of the study (eight weeks post-intervention)."
62525382|NCT05388240|EXPERIMENTAL|Education plus Exercise Group|"The Exercise plus Education Group will be provided with standard education by the physiotherapist at the hospital prior to surgery. Participants in this group will have access to the education and resources tabs on the app."
62525383|NCT04309318||Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
62525384|NCT04309318||High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
62525385|NCT05489237|EXPERIMENTAL|Dose Escalation (Phase I)|Participants should have advanced (metastatic and/or surgically unresectable) GIST, following failure of at least prior imatinib therapy due to progression of GIST.
62525386|NCT05489237|EXPERIMENTAL|(Phase 1b) Cohort 1 - Participants with GIST progression after first-line imatinib therapy|Participants with advanced GIST who have had GIST progression after first-line imatinib only (second line therapy setting) and refused or are ineligible for other standard of care (SOC) therapies.
62525387|NCT05489237|EXPERIMENTAL|(Phase 1b): Cohort 2 - Participants with GIST progression after 2 or more lines of TKI therapy|Participants with metastatic and/or surgically unresectable GIST following progression EITHER after sequential imatinib then sunitinib (third-line therapy setting) OR after imatinib, sunitinib, and then an additional TKI agent (i.e., regorafenib or ripretinib) (fourth-line therapy setting) OR after imatinib, sunitinib, regorafenib, and ripretinib (5th line or greater therapy).
62525388|NCT05489237|EXPERIMENTAL|(Phase 1b): Cohort 3 - Participants with GIST who are treatment naïve|Participants with metastatic and/or surgically unresectable GIST who are treatment naïve (first line therapy) and refused or are ineligible for other standard of care (SOC) therapies.
62525389|NCT05489237|EXPERIMENTAL|(Phase 1b): Cohort 4|Participants with GIST progression who meet the same criteria as Cohort 2 (third line or greater TKI therapy) and have had prior treatment with investigational agents NB003 or THE-630 or a line of therapy of bezuclastinib plus sunitinib combination.
62525390|NCT00787397|EXPERIMENTAL|1. Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy-Sleep
62525391|NCT02757976|ACTIVE_COMPARATOR|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave \> 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging
62525392|NCT02757976|EXPERIMENTAL|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
62525393|NCT04146506||Male|Static Muscle stretching exercises of the knee flexors
62525394|NCT04146506||Female|Static Muscle stretching exercises of the knee flexors
62525395|NCT05496543|EXPERIMENTAL|Acupuncture group|"Participants will receive acupuncture treatment at Zhao Hai(KI 6), Da Zhong(KI 4), Tai Xi(KI 3), Tian Shu(ST 25), and Shang Ju Xu(ST 37) bilaterally.~Each treatment will last 30 minutes and participants will receive the treatment 3 times per week (every other day) for 8 weeks, 24 sessions in total. Follow-up time is week 4 and week 12 after treatment (ie, week 12 and week 20)."
62152655|NCT06133595|EXPERIMENTAL|Experimental: MiBridge|MiBridge: A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
62152656|NCT06133595|NO_INTERVENTION|No Intervention: Waitlist|Participants are on a waitlist which means they have no active intervention, only weekly measurements with the same questionnaires as in the active arm
62152657|NCT04184349|ACTIVE_COMPARATOR|Local Anesthetic (LA Group)|
62152658|NCT04184349|ACTIVE_COMPARATOR|B group|
62152659|NCT06463314|EXPERIMENTAL|participants with known and unknown HIV and/or syphilis status|All participants will undergo fingerstick blood testing with the test device administered by untrained non-professional health care providers, along with venous blood testing at a central laboratory using licensed gold standard comparator methods.
62152660|NCT03902626||Physiotherapy students|Degree course
62152661|NCT03902626||Medical students|Degree course
62152662|NCT03925909|EXPERIMENTAL|Eriomin 200 mg|The volunteers will receive one capsule containing 200 mg eriocitrin
62525396|NCT05496543|PLACEBO_COMPARATOR|Sham acupuncture group|"Participants will receive sham acupuncture treatment on bilateral sham Zhao Hai(KI 6), Da Zhong(KI 4), Tai Xi(KI 3), Tian Shu(ST 25), and Shang Ju Xu(ST 37) that match real acupuncture points.~The duration of needle retention, treatment period, and follow-up in the control group is the same as that in the intervention group."
62525397|NCT05662735|ACTIVE_COMPARATOR|Non-absorbable sutures|The hiatal hernia was corrected performing laparoscopic surgery. Primary repair of the hernia was done with non-absorbable sutures
62525398|NCT05662735|ACTIVE_COMPARATOR|Non-absorbable sutures and a TiMESH®|The hiatal hernia was corrected performing laparoscopic surgery. Primary repair of the hernia was done with non-absorbable sutures and a TiMESH® to reinforce the repair.
62525399|NCT04420221|EXPERIMENTAL|Half dose non-adj Group 1a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1.
62525400|NCT04420221|PLACEBO_COMPARATOR|Placebo Group 1b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
62525401|NCT04420221|EXPERIMENTAL|Full dose non-adj Group 2a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1
62525402|NCT04420221|PLACEBO_COMPARATOR|Placebo Group 2b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
62525403|NCT04420221|EXPERIMENTAL|Half dose adj Group 3a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1.
62525404|NCT04420221|PLACEBO_COMPARATOR|Placebo Group 3b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
62525405|NCT04420221|EXPERIMENTAL|Full dose adj Group 4a|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61)
62525406|NCT04420221|PLACEBO_COMPARATOR|Placebo Group 4b|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
62525407|NCT04420221|EXPERIMENTAL|Vaccine Group 5a|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61).
62525408|NCT04420221|PLACEBO_COMPARATOR|Placebo Group 5b|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
62525409|NCT04650152||Fenofibrate|Adult patients with triglycerides \> 2,3 mmol/l who are on statins and who are primary prescribed fenofibrate (or fenofibrate treatment break is at least 6 months) in accordance with ordinary physician practice in Russia.
62525410|NCT04781387|EXPERIMENTAL|CRS3123 200 milligram|"CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
62525411|NCT04781387|EXPERIMENTAL|CRS3123 400 milligram|"CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
62525412|NCT04781387|ACTIVE_COMPARATOR|Vancomycin 125 milligram|Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.
62525413|NCT01574482|EXPERIMENTAL|1 = Tested product|
62525414|NCT01574482|PLACEBO_COMPARATOR|2 = Control product|
62525415|NCT05223296|ACTIVE_COMPARATOR|Group I LigaSure (n=100)|100 patients subjected to LigaSure pile excision
62525416|NCT05223296|ACTIVE_COMPARATOR|Group II Conventional diathermy (n=108)|108 patients subjected to conventional diathermy for grade IV pile excision
62525417|NCT00859066||Control Group|"First year University of Michigan Radiology residents will take call as scheduled without a buddy call experience.~(Enrollment completed for the control group)"
62525418|NCT00859066||Experimental Group|2009 class of first year Radiology residents who will be assigned two 5 hour shifts working side by side with a more senior resident (who has experience taking call).
62525419|NCT00469768|EXPERIMENTAL|A|
62525420|NCT00469768|EXPERIMENTAL|B|
62525421|NCT00469768|PLACEBO_COMPARATOR|C|
62525422|NCT06044532|EXPERIMENTAL|Skin characterization|
62525423|NCT03326609|EXPERIMENTAL|Volume: 2.5 mL|Perineural injection of ropivacaine 10 mg, 2.5 mL. Concentration: Ropivacaine 4 mg/mL.
62525424|NCT03326609|EXPERIMENTAL|Volume: 5 mL|Perineural injection of ropivacaine 10 mg, 5 mL. Concentration: Ropivacaine 2 mg/mL
62525425|NCT03326609|EXPERIMENTAL|Volume: 10 mL|Perineural injection of ropivacaine 10 mg, 10 mL Concentration: Ropivacaine 1 mg/mL
62525426|NCT03326609|EXPERIMENTAL|Volume: 15 mL|Perineural injection of ropivacaine 10 mg, 15mL Concentration: Ropivacaine 0.67 mg/mL
62525427|NCT03326609|EXPERIMENTAL|Volume: 20 mL|Perineural injection of ropivacaine 10 mg, 20mL Concentration: Ropivacaine 0.5 mg/mL
62525428|NCT03166683|EXPERIMENTAL|Hemopatch|Use of hemopatch like a control of bile leakage/sealant during liver resection surgery.
62525429|NCT03166683|ACTIVE_COMPARATOR|Standard of care|Application of standards of care, may include other sealant / hemostatic devices as patches or liquid/gels, during liver resection surgery.
62525430|NCT03905564|EXPERIMENTAL|Doxylamine succinate/pyridoxine hydrochloride|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination) administered with 250 mL of water (at room temperature) under fasting conditions.
62525431|NCT03905564|ACTIVE_COMPARATOR|Diclegis (Registered Trademark)|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets) administered with 250 mL of water (at room temperature) under fasting conditions.
62525432|NCT04528030|OTHER|Treatment starting with an on ON cycle|The treatment will start ON cycle for 6 hours, followed by OFF cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
62525433|NCT04528030|OTHER|Treatment starting with an on OFF cycle|The treatment will start OFF cycle for 6 hours, followed by ON cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
62525434|NCT02969941|ACTIVE_COMPARATOR|Real Stimulation|Participants will receive active transcranial magnetic stimulation (TMS) daily for two weeks
62525435|NCT02969941|PLACEBO_COMPARATOR|Placebo Stimulation|Participants will receive sham transcranial magnetic stimulation (TMS) daily for two weeks
62525436|NCT00726154|OTHER|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
62525437|NCT00726154|OTHER|Collaborative care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
62152663|NCT03925909|EXPERIMENTAL|Eriomin 400 mg|The volunteers will receive one capsule containing 400 mg eriocitrin
62152664|NCT03925909|EXPERIMENTAL|Eriomin 800 mg|The volunteers will receive one capsule containing 800 mg eriocitrin
62525438|NCT04930757||Patients with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.|Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.
62525439|NCT04191655|EXPERIMENTAL|High Definition White Light Colonoscopy|
62525440|NCT04191655|ACTIVE_COMPARATOR|Dye Spraying Chromo-colonoscopy|
62525441|NCT01550276|EXPERIMENTAL|Suboccipital soft tissue inhibition|The SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
62525442|NCT01550276|EXPERIMENTAL|Occiput-atlas-axis global manipulation|The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
62525443|NCT01550276|EXPERIMENTAL|The combination of both treatments|
62525444|NCT01550276|PLACEBO_COMPARATOR|control group|
62525445|NCT06217484||Parkinson Disease|Participants with Parkinson Disease; Single group.
62525446|NCT04038268||Patients|Adults and children, males and females, with IgE mediated pollen, house dust mites, animal dander and moulds respiratory allergy who will initiate aeroallergen AIT, either SCIT, SLIT-drops or SLIT-tablets according to real life clinical standards of practice
62525447|NCT04038268||Prescribers|Doctors who are currently prescribing AIT as part of their regular clinical practice
62525448|NCT01533766|EXPERIMENTAL|CombiflexOmega|
62525449|NCT01533766|ACTIVE_COMPARATOR|SmofKabiven|
62525450|NCT02982031|SHAM_COMPARATOR|shamrock|shamrock: both left and right sided scan,both intertransverse and transverse process window
62525451|NCT02982031|ACTIVE_COMPARATOR|paramedian transverse scan|paramedian transverse scan (PMTS): both left and right, both intertransverse and transverse process window
62525452|NCT01567748||Hemodynamics Measured|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
62525453|NCT06429319|OTHER|"hydrous biopolymer with silver ions Argiform"|"Sixty-seven patients were screened for the study; 2 of them were screening failures, therefore, 65 patients were randomized to participate in the study, who were conventionally divided into subgroups:~* Group A included 5 patients. Patients in group A received 2 courses of therapy: both within IA/PAAG-SI/OA/2019 study and at Visit 1 (and as indicated at Visit 2) of the IA/PAAG-SI/OA/2020 study.~* Group B - 43 patients. Patients in group B also received 2 courses of therapy: both within IA/PAAG-SI/OA/2019 study and at Visit 3 (and as indicated at Visit 4) of the IA/PAAG-SI/OA/2020 study.~* Group C - 17 patients. Group C included patients who received only one course of injections in the placebo-controlled study IA/PAAG-SI/OA/2019. There were no early withdrawals from the study."
62525454|NCT01394952|EXPERIMENTAL|1.5 mg Dulaglutide|Administered once weekly, subcutaneously
62525455|NCT01394952|PLACEBO_COMPARATOR|Placebo|Administered once weekly, subcutaneously
62525456|NCT00771745|ACTIVE_COMPARATOR|rATG 4 doses|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
62525457|NCT00771745|ACTIVE_COMPARATOR|rATG 3 doses|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
62152665|NCT03925909|NO_INTERVENTION|Placebo|The volunteers will receive a capsule containing corn starch (placebo)
62152666|NCT02820506|OTHER|High risk endometrial cancer|Patients will receive sentinel node mapping, removal of PET-positive lymph nodes and finally conventional pelvic and paraaortic lymphadenectomy.
62152667|NCT02820506|OTHER|Cervical cancer tumor size 2-4 cm|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
62152668|NCT05220813|ACTIVE_COMPARATOR|local anesthetic group (control group)|44 patients will receive local infiltration anesthesia.
62152669|NCT05220813|ACTIVE_COMPARATOR|ilioinguinal iliohypogastric group|44patients will receive ilioinguinal iliohypogastric nerve blocks
62152670|NCT06168045||Term neonates|Neonates with gestational age 37+0 - 42+0 weeks
62525458|NCT03566576|EXPERIMENTAL|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~1. CTCAE Grade 4 event (ANC\<1000/ul, body temperature≥38.5°C);~2. Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
62152671|NCT06168045||Preterm neonates|Neonates with gestational age \< 37+0 weeks
62152672|NCT00022490|EXPERIMENTAL|Cytarabine/ Imatinib Mesylate|
62152673|NCT01406041||Diseases|1. Pituitary adenomas; 2. Craniopharyngioma; 3. Sellar germinoma; 4. Sellar tuberalis meningioma; 5. Hypophystis; 6. Sellar glioma; 7. Rathke's cleft cyst; 8. Hypothalamic hamartoma
62152674|NCT06374082|EXPERIMENTAL|Intervention group|WhatsApp messages based on smoking cessation counseling Knowledge-Attitude-Practice (KAP)
62152675|NCT06374082|PLACEBO_COMPARATOR|Control group|WhatsApp messages about generic mental health information
62152676|NCT01015274||Healthy control male|
62152677|NCT01948557|OTHER|Infant feeding counselling and support|All mothers provided with counselling. Subsequent support interventions depended on mothers' selection of feeding practice
62152678|NCT01626833|ACTIVE_COMPARATOR|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE\* : Norditropine® simplexx®
62152679|NCT01626833|PLACEBO_COMPARATOR|Placebo|Placebo
62152680|NCT00904085|ACTIVE_COMPARATOR|Oxymorphone|
62152681|NCT00904085|PLACEBO_COMPARATOR|Placebo|
62152682|NCT00403845|EXPERIMENTAL|Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg|In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62152683|NCT00403845|EXPERIMENTAL|Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg|In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62152684|NCT00403845|EXPERIMENTAL|Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg|In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62152685|NCT00403845|EXPERIMENTAL|Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo|In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
62152686|NCT00185692|EXPERIMENTAL|Transplantation of CD34+ cells|"Week #1: Total Lymphoid Inrradiation (TLI) 120 cGy + Anti-thymocyte Globulin (ATG) 1.5 mg/kg + Solumedrol 1.0 mg/kg Daily for 5 days.~Week #2: TLI 120 cGy (3 days a week, double on the 4th day) 5 days of CSP (oraly) one day after TLI was started. 3 days of MMF 4 days after TLI was started."
62152687|NCT02469324|ACTIVE_COMPARATOR|Cognitive-Behavioral Therapy|see intervention explanation
62152688|NCT02469324|EXPERIMENTAL|Compassionate Mind Training|
62152689|NCT00787371|EXPERIMENTAL|0.25 Dose Group|PegIntron 0.25 mcg/kg SC QW for 12 weeks
62152690|NCT00787371|EXPERIMENTAL|0.5 Dose Group|PegIntron 0.5 mcg/kg SC QW for 12 weeks
62152691|NCT00787371|EXPERIMENTAL|1.0 Dose Group|PegIntron 1.0 mcg/kg SC QW for 12 weeks
62152692|NCT00787371|NO_INTERVENTION|No-treatment Control|No treatment (no placebo)
62152693|NCT00103857|EXPERIMENTAL|1|MK0431 100 mg q.d.
62152694|NCT00103857|ACTIVE_COMPARATOR|2|Metformin 500 mg b.i.d.
62152695|NCT00103857|ACTIVE_COMPARATOR|3|Metformin 1000 mg b.i.d.
62152696|NCT00103857|EXPERIMENTAL|4|Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
62152697|NCT00103857|EXPERIMENTAL|5|Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
62152698|NCT00103857|PLACEBO_COMPARATOR|6|Placebo/Metformin 1000 mg b.i.d.
62152699|NCT00103857|EXPERIMENTAL|7|Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.
62152700|NCT00572494|EXPERIMENTAL|1|Stenting with AMS
62152701|NCT00572494|ACTIVE_COMPARATOR|2|PTA alone
62152702|NCT03120936|OTHER|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
62152703|NCT04413188|EXPERIMENTAL|A warm foot bath group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
62525459|NCT03566576|EXPERIMENTAL|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~1. CTCAE Grade 4 event (ANC\<1000/ul, body temperature≥38.5°C);~2. Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
62525460|NCT01552811||Type 1 diabetes|
62525461|NCT01552811||healthy controls|
62525462|NCT05389683|EXPERIMENTAL|Elimination Diet|Participants will be suggested an 'Elimination diet' that will be devoid of the reaction-inducing foods and it shall be followed for 4 weeks.
62525463|NCT02468492|EXPERIMENTAL|Platelet Rich Plasma|Approximately 5mL of intraarticular PRP once at baseline
62525464|NCT02468492|OTHER|Normal Saline|Approximately 5mL of intraarticular normal saline once at baseline
62525465|NCT02016261|EXPERIMENTAL|Remitted Depression Outpatients|Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission
62152704|NCT04413188|NO_INTERVENTION|Control group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
62525466|NCT03529578|EXPERIMENTAL|dHACM|Standard of Care plus Weekly Application of dHACM
62525467|NCT00755859|EXPERIMENTAL|1|Six month steroid course plus azathioprine
62152705|NCT06130605||people over the age of 18|people over the age of 18.
62152706|NCT03720028||Child w Angelman/Rett syndrome|Children with Angelman or Rett syndrome, up to 14 years of age
62152707|NCT03720028||Parent|Parents of Children with Angelman or Rett syndrome
62152708|NCT04878809|EXPERIMENTAL|Experimental group|People attending L'Horitzó School (students, teachers, administrative and service staff)
62152709|NCT04878809|OTHER|Control Group|Escola John Talabot, will provide the incidence rate of infections by SARS-CoV-2
62152710|NCT06444087||secukinumab|Patients prescribed with secukinumab
62152711|NCT00444054|EXPERIMENTAL|Dietary modification|Patients are placed on a low carbohydrate diet (\<30 grams/day) for 28 days.
62152712|NCT05689424|PLACEBO_COMPARATOR|HDV-bound Lispro 0%|Subjects will receive insulin lispro with 0% bound HDV
62152713|NCT05689424|ACTIVE_COMPARATOR|HDV-bound Lispro 1%|Subjects will receive insulin lispro with 1% bound HDV
62152714|NCT05689424|ACTIVE_COMPARATOR|HDV-bound Lispro 10%|Subjects will receive insulin lispro with 10% bound HDV
62152715|NCT05689424|ACTIVE_COMPARATOR|HDV-bound Lispro 100%|Subjects will receive insulin lispro with 100% bound HDV
62152716|NCT02383797|EXPERIMENTAL|Cartilage-hair hypoplasia (CHH)|Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.
62152717|NCT03064906|OTHER|Meal Performance and/or Exercise|"This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.~Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions."
62152718|NCT00636168|ACTIVE_COMPARATOR|A|
62152719|NCT00636168|PLACEBO_COMPARATOR|B|
62525468|NCT00755859|ACTIVE_COMPARATOR|2|six month steroid course
62525469|NCT03982472|EXPERIMENTAL|TENS right side|TENS stimulation at the right side
62152720|NCT01820702|ACTIVE_COMPARATOR|defined training programme|
62152721|NCT01820702|NO_INTERVENTION|Control|
62152722|NCT02072330|ACTIVE_COMPARATOR|TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks
62152723|NCT02072330|EXPERIMENTAL|TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.
62152724|NCT02072330|EXPERIMENTAL|TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.
62525470|NCT03982472|EXPERIMENTAL|TENS left side|TENS stimulation at the left side
62525471|NCT03982472|NO_INTERVENTION|sham stimulation|Sham stimulation
62525472|NCT01950234|EXPERIMENTAL|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
62525473|NCT01950234|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
62525474|NCT06007131|EXPERIMENTAL|Study Group|The study group will use the CPM device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI triaging team will monitor the CPM device data and call the patient as indicated by the data. The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website.
62525475|NCT06007131|NO_INTERVENTION|Control Group|The control group will not receive a device and will continue their normal standard of care.
62525476|NCT03219931|ACTIVE_COMPARATOR|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
62152725|NCT02072330|ACTIVE_COMPARATOR|Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
62152726|NCT02072330|ACTIVE_COMPARATOR|Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
62525477|NCT03219931|ACTIVE_COMPARATOR|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
62525478|NCT03219931|PLACEBO_COMPARATOR|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
62525479|NCT03219931|PLACEBO_COMPARATOR|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
62525480|NCT00545675|EXPERIMENTAL|1|Abilify(aripiprazole) + Depakote(divalproate)
62525481|NCT00545675|PLACEBO_COMPARATOR|2|Divalproate + Placebo
62525482|NCT01158573||Healthy non-asthmatic obese adults|Healthy non-asthmatic obese adults
62525483|NCT01158573||Healthy non-asthmatic non-obese adults|Healthy non-asthmatic non-obese adults
62525484|NCT01158573||Asthmatic obese adults|Asthmatic obese adults
62525485|NCT01158573||Asthmatic non-obese adults|Asthmatic non-obese adults
62525486|NCT04874675|ACTIVE_COMPARATOR|Diclofenac /Acetaminophen/Codeine|routine pain medication used in post extraction pain management
62152727|NCT06204107|EXPERIMENTAL|Group 1|"* Phase 1: CKD-379 Test drug~* Phase 2: CKD-379 Reference drug"
62152728|NCT06204107|EXPERIMENTAL|Group 2|"* Phase 1: CKD-379 Reference drug~* Phase 2: CKD-379 Test drug"
62152729|NCT03507452|EXPERIMENTAL|Dose escalation cohort a|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 mg."
62152730|NCT03507452|EXPERIMENTAL|Dose escalation cohort b|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with a total antibody dose within the range of 10 - 50 mg."
62152731|NCT03507452|EXPERIMENTAL|Dose Expansion Cohort 1|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 1 (to be determined after completion of the dose escalation)"
62152732|NCT03507452|EXPERIMENTAL|Dose Expansion Cohort 2|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 2 (to be determined after completion of the dose escalation)"
62152733|NCT03507452|EXPERIMENTAL|Dose expansion Cohort 3 (optional)|"Subjects with histologically or cytologically confirmed unresectable, metastatic or locally advanced pancreatic ductal adenocarcinoma~Dose / Regimen to be determined"
62525487|NCT04874675|ACTIVE_COMPARATOR|Ibuprofen/Acetaminophen/codeine|routine pain medication used in post extraction pain management
62525488|NCT01524614|EXPERIMENTAL|Nasal mask with no PEEP|Nasal mask with PEEP 0, then add PEEP 5, and 10
62525489|NCT01524614|EXPERIMENTAL|Nasal mask with PEEP|Nasal mask with PEEP 5, then add PEEP 10
62525490|NCT01524614|EXPERIMENTAL|Face mask with no PEEP|Face mask with PEEP 0 then add PEEP 5, 10
62525491|NCT01524614|EXPERIMENTAL|Face mask with PEEP|Face mask with PEEP 5, then add PEEP 10
62525492|NCT05435716|EXPERIMENTAL|Peripheral seismic catheterization system (IVL) + drug-coated balloon (DCB) and/or stent|
62525493|NCT05435716|OTHER|PTA + DRUG-coated balloon (DCB) and/or stent|
62152734|NCT03507452|EXPERIMENTAL|Dose escalation cohort c|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 150 mg mg."
62152735|NCT03507452|EXPERIMENTAL|Dose escalation cohort d|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 400 mg."
62152736|NCT04572165||semaglutide|New users of Ozempic® or Rybelsus®
62152737|NCT04572165||Active comparator|First-time ever users of an active comparator drug
62525494|NCT01921621|NO_INTERVENTION|Group A|Control: Group of Orthopedic Residents who receive arthroscopic surgery training at the Orthopedic Learning Center during a standard week-end Resident Arthroscopic Training Course
62525495|NCT01921621|ACTIVE_COMPARATOR|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
62525496|NCT01921621|EXPERIMENTAL|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
62525497|NCT01519986|EXPERIMENTAL|Low fat Meal|50,000 UI vitamin D3 with low fat meal
62525498|NCT01519986|EXPERIMENTAL|Medium fat meal|50,000 UI vitamin D3 with medium fat meal
62525499|NCT01519986|EXPERIMENTAL|High fat meal|50,000 UI vitamin D3 with high fat meal
62525500|NCT01832207|ACTIVE_COMPARATOR|MTS|Motor threshold of stimulation
62525501|NCT01832207|ACTIVE_COMPARATOR|STS|Sensorial threshold of stimulation
62525502|NCT01832207|SHAM_COMPARATOR|Placebo|
62525503|NCT00118131|EXPERIMENTAL|Docetaxel and Cisplatin|"A cycle is defined as an interval of 28 days.~Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).~Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).~Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15."
62525504|NCT00896155|EXPERIMENTAL|Concurrent Tamoxifen and Radiotherapy|ARM 1 will receive Tamoxifen given concurrently with radiotherapy. Tamoxifen will continue for a period of 5 years.
62525505|NCT00896155|ACTIVE_COMPARATOR|Sequential radiotherapy and tamoxifen|ARM-2 shall receive radiotherapy followed by tamoxifen sequentially. Again tamoxifen will continue for a period of 5 years.
62525506|NCT01338649|ACTIVE_COMPARATOR|Bright White|Exposure to bright white light treatment.
62525507|NCT01338649|PLACEBO_COMPARATOR|Dim red light|Exposure to dim red light treatment.
62525508|NCT01081535|EXPERIMENTAL|ketorolac|
62525509|NCT01081535|EXPERIMENTAL|fentanyl|
62525510|NCT04178161|EXPERIMENTAL|Treated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.~Treatment side receives laser treatment of the sweat glands."
62525511|NCT04178161|NO_INTERVENTION|Untreated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.~Control side is untreated."
62525512|NCT06077331|EXPERIMENTAL|HS-10374 Dose 1|
62525513|NCT06077331|EXPERIMENTAL|HS-10374 Dose 2|
62525514|NCT06077331|ACTIVE_COMPARATOR|Placebo|
62525515|NCT02175836||SCD possitive versus SCD negative group|The total Heart Failure patients subgroup experiencing Sudden Cardiac Death surrogate end-points during follow up versus the patients subgroup that is free from Sudden Cardiac Death surrogate end-points.
62525516|NCT00968760|EXPERIMENTAL|CD19-specific T cell Infusion without IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 1 - low dose of T cells without IL-2.~Group 3 - higher dose of T cells without IL-2."
62525517|NCT00968760|EXPERIMENTAL|CD19-specific T cell Infusion with IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 2 - higher dose of T cells with IL-2.~Group 4 - higher dose of T cells with IL-2."
62525518|NCT05649449|EXPERIMENTAL|Experimental|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
62525519|NCT05649449|ACTIVE_COMPARATOR|Control|Subjects receive routine mental health care from community agencies consisting of outpatient services coordinated at community behavioral health programs.
62525520|NCT04870138|EXPERIMENTAL|Mixed FA7527/FA1090|Bacterial inoculum containing a mixture of equivalent numbers of the isogenic LptA mutant and wild-type (WT) strain administered once to the anterior urethra. N= up to 25
62713118|NCT03064074|EXPERIMENTAL|Stage 2 Repeat doses every 3 months|"Fresolimumab will be administered every three months for a total treatment period of 12 months (Total anticipated n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~* Physical exam~* Vitals~* Blood draw for safety labs, pharmacokinetics, etc~* If the participant is female, she will have a pregnancy test~* EKG~* DXA~* Infusion of the study drug~* Skeletal survey~* Peripheral quantitative CT (pQCT) of the forearm~* Quality of Life Surveys~* Pulmonary function test~* Walk test"
62152738|NCT05441176|EXPERIMENTAL|Patients with suspicion of TOS|Patients coming for a visit to diagnostic TOS and submitted TULIP and MASC questionnaires
62152739|NCT00267865|EXPERIMENTAL|Rituximab, High-Dose Methotrexate & Leucovorin Treatment|Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.
62152740|NCT02056925|EXPERIMENTAL|Experimental|
62152741|NCT05245474|EXPERIMENTAL|CRT+concurrent PD-1 inhibition (Experiment Arm 1)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 8 of radiation therapy. TME surgery is scheduled in 8\~12 weeks after completion of radiation.
62525521|NCT04870138|EXPERIMENTAL|Mutant FA7527|Bacterial inoculum containing only the isogenic LptA mutant N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
62525522|NCT04870138|EXPERIMENTAL|Wild-type FA1090|Bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
62525523|NCT03606876|EXPERIMENTAL|BAT1806 injection|BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min
62525524|NCT03606876|ACTIVE_COMPARATOR|Actemra(EU-licensed)|Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min
62525525|NCT03606876|ACTIVE_COMPARATOR|Actemra(US-licensed)|Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min
62525526|NCT00729274|ACTIVE_COMPARATOR|hypertonic saline solution|Hypertonic Saline 3% solution alone.
62525527|NCT00729274|PLACEBO_COMPARATOR|nebulized normal saline solution|2 nebulisation with 30 minute interval (max 4ml)
62152742|NCT05245474|EXPERIMENTAL|CRT+sequential PD-1 inhibition (Experiment Arm 2)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 15 after completion of radiation therapy. TME surgery is scheduled in 8\~12 weeks after completion of radiation.
62525528|NCT01570283|EXPERIMENTAL|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Prophylaxis|Cohort 1 prophylaxis: Participants were administrated 5\*10\^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
62525529|NCT01570283|EXPERIMENTAL|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Treatment|Cohort 1 treatment: Participants were administrated 5\*10\^6 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
62525530|NCT01570283|EXPERIMENTAL|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Prophylaxis|Cohort 2 prophylaxis: Participants were administrated 1\*10\^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
62525531|NCT01570283|EXPERIMENTAL|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Treatment|Cohort 2 treatment: Participants were administrated 1\*10\^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
62525532|NCT01570283|EXPERIMENTAL|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Prophylaxis|Cohort 3 prophylaxis: Participants were administrated 2\*10\^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
62525533|NCT01570283|EXPERIMENTAL|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Treatment|Cohort 3 treatment: Participants were administrated 2\*10\^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
62525534|NCT04875611|EXPERIMENTAL|Experimental therapy:OPDIVO (Nivolumab)|
62525535|NCT05647226|EXPERIMENTAL|Intervention arm|Intervention participants will be given an initial 12-week low energy-diet (LED) and will have continual use of an intensive behaviour education programme delivered through an app.
62525536|NCT05647226|OTHER|Standard of care arm|All participants in the control arm will receive standard care provided by the National Health Service.
62525537|NCT03811496||GD-PD|Patients and carriers of Gaucher disease with confirmed mutations in GBA gene who have developed Parkinson's disease symptoms
62525538|NCT03811496||GD-nonPD|Patients with Gaucher disease but no known Parkinson's symptoms
62525539|NCT03811496||nonGD-nonPD|Non-Gaucher disease/healthy controls
62525540|NCT03044041|EXPERIMENTAL|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
62525541|NCT03044041|ACTIVE_COMPARATOR|High dose|Single dose of intra-articular Tranexamic acid 3 grams
62525542|NCT05124561|EXPERIMENTAL|Experimental group|6500 participants, Ad5-nCoV-IH, single dose, nebulized inhalation
62525543|NCT05124561|PLACEBO_COMPARATOR|Placebo group|6500 participants, placebo, single dose, nebulized inhalation
62525544|NCT02351544|EXPERIMENTAL|Botulinum toxin|Patients in this arm will receive botulinum toxin for migraine headaches
62525545|NCT02351544|EXPERIMENTAL|Surgery|Patients in this arm will receive surgery for migraine headaches
62152743|NCT05245474|ACTIVE_COMPARATOR|CRT without PD-1 inhibition (Control Arm)|Long-course chemoradiation plus PD-1 inhibition with no PD-1 inhibition. TME surgery is scheduled in 6\~12 weeks after completion of radiation.
62152744|NCT03615404|EXPERIMENTAL|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
62525546|NCT03737565||Coronary Artery Disease|
62525547|NCT06250049|EXPERIMENTAL|Intervention Group|This group of patients will be attended according to a diabetic foot care protocol implemented in Primary Care in Salamanca. In addition, those patients and/or caregivers will receive group education sessions on Diabetic Foot Care at the Health Centers.
62525548|NCT06250049|NO_INTERVENTION|Control Group|Usual care
62525549|NCT01915693|NO_INTERVENTION|Arm A: Self-expanding metal stents (SEMS) (Control Arm)|SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.
62525550|NCT01915693|EXPERIMENTAL|Arm B: SEMS plus external beam radiotherapy (Intervention Arm)|External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
62525551|NCT04614623|NO_INTERVENTION|Current Diabetes Management Continued|Continued Insulin Delivery Method and Current Clinic Care of Diabetes
62525552|NCT04614623|EXPERIMENTAL|Video Conferencing+Current Insulin Delivery|Patients continue current insulin delivery modality but receive enhanced clinical management support via video conferencing link by diabetes coordinator
62525553|NCT04614623|EXPERIMENTAL|AHCL pump without Video Conferencing|Patients switch to use of an Advanced Hybrid Closed Loop pump without Video Conferencing standard support
62525554|NCT04614623|EXPERIMENTAL|AHCL pump+Video Conferencing|Patients will use Advanced Hybrid Closed Loop pump with enhanced clinical support via video conferencing
62525555|NCT05028049||Sufentanil-analgesia in plain area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plain area patients.
62525556|NCT05028049||Remifentanil-analgesia in plain area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plain area patients.
62525557|NCT05028049||Sufentanil-analgesia in plateau area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
62525558|NCT05028049||Remifentanil-analgesia in plateau area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
62525559|NCT04174976||Wall hernia repair|"All patients admitted for wall hernia repair with mesh between 28/12/2017 and 28/12/2020.~."
62525560|NCT06062849|ACTIVE_COMPARATOR|totally tubeless|there is no nephrostomy tube or double J (JJ) stent
62525561|NCT06062849|ACTIVE_COMPARATOR|tubeless|only JJ stent
62525562|NCT06062849|EXPERIMENTAL|nephrostomy tube|nephrostomy tube
62525563|NCT01988961|EXPERIMENTAL|Golimumab|Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
62525564|NCT00584844|EXPERIMENTAL|F tularensis Vaccine (0.0025 mL)|Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
62525565|NCT05050890||Breast cancer|Breast cancer patients who are currently receiving neoadjuvant therapy
62525566|NCT01044654|EXPERIMENTAL|Cohort 1|3 Subjects will receive a single infusion of 0.5-1.0 x 1010 SB-728-T
62713119|NCT05180968|EXPERIMENTAL|Nabilone 0.5mg|Subjects will receive nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
62713120|NCT05180968|PLACEBO_COMPARATOR|Oral placebo|Subjects will receive placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
62152745|NCT04037072|EXPERIMENTAL|Mitomycin C|Cotton swab or strip of 2x2 cotton gauze soaked with 0.4mg/mL Mitomycin C
62525567|NCT01044654|EXPERIMENTAL|Cohort 2|3 Subjects will receive a single infusion of 2.0 x 1010 SB-728-T
62525568|NCT01044654|EXPERIMENTAL|Cohort 3|3 Subjects will receive a single infusion of 3.0 x 1010 SB-728-T
62152746|NCT04037072|PLACEBO_COMPARATOR|Control|Cotton swab or strip of 2x2 cotton gauze soaked with Normal saline
62525569|NCT01044654|EXPERIMENTAL|Cohort 4|Up to 4 HAART failure subjects will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T
62525570|NCT01044654|EXPERIMENTAL|Cohort 5|"Up to 20 subjects with heterozygote CCR5 delta-32 mutation will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T.~Cohort 5 subjects will undergo a structured treatment interruption 2 months following infusion in which their anti-retroviral therapy will be discontinued for 16 weeks. HAART will be reinstituted in subjects whose CD4+ cell counts drop to \<350 cells/mm3 and/or whose HIV-RNA increases to \>100,000 on three consecutive weekly measurements.~At the end of the STI, subjects with a sustained detectable viral load will be reinstituted on HAART. Subjects with HIV RNA levels below the limit of detection will remain off HAART. Subjects with an undetectable viral load will remain off HAART until HIV RNA levels are detectable or their CD4 count drops below 350 cell/mm3 on three consecutive weekly measurements."
62525571|NCT05035342|EXPERIMENTAL|Fecal microbiota Transplant (FMT)|Fecal microbiota Transplant (FMT) prepared from the stools of healthy donors diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min) and manufactured in capsules (n=50 capsules corresponding to approximately 50 grams of stool; 25 two days in a row).
62525572|NCT05035342|PLACEBO_COMPARATOR|Placebo of FMT|FMT vehicle (solution of saline (NaCl 0.9%)) with 80% glycerol (storage in the same conditions as preparation for FMT experimental group) administered at the same volume and same time point as the experimental group.
62525573|NCT04493320|EXPERIMENTAL|L-DOPA, Then Placebo|"Step 1 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 300 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1 week taper period.~Step 2 (3 Weeks): Participants will receive L-DOPA matching placebo tablets daily.~Participants will then enter a 1-week taper period."
62525574|NCT04493320|EXPERIMENTAL|Placebo, Then L-DOPA|"Step 1 (3 Weeks): Participants will receive 3 L-DOPA matching placebo tablets daily. Participants will then enter a 1-week taper period.~Step 2 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 300 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1-week taper period."
62152747|NCT01052714|NO_INTERVENTION|Usual Care|Control group with time-matched study visits
62152748|NCT01052714|ACTIVE_COMPARATOR|Lifestyle Balance|Weight management group education and individual counseling
62152749|NCT01052714|OTHER|Usual Care then Lifestyle Balance|Participants originally randomized to Usual Care, allowed to change over to Lifestyle Balance at month 6 per their request.
62152750|NCT03775915|EXPERIMENTAL|Real Neurofeedback|3 sessions of Real Neurofeedback over 1 week
62525575|NCT03456960|EXPERIMENTAL|Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
62525576|NCT03456960|EXPERIMENTAL|Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
62152751|NCT03775915|SHAM_COMPARATOR|Sham Neurofeedback|3 sessions of Sham Neurofeedback over 1 week
62152752|NCT04927949|SHAM_COMPARATOR|patients without HPR|standard primary PCI
62152753|NCT04927949|EXPERIMENTAL|patients with HPR randomized to cangrelor|Cangrelor perfusion started before PCI
62152754|NCT04927949|PLACEBO_COMPARATOR|patients with HPR randomized to standard of care|standard primary PCI
62152755|NCT05999448|EXPERIMENTAL|No Algorithm + Participation Enhancement Intervention|Participants are randomly assigned to support program without use of a personalized health algorithm AND receive the participation enhancement intervention.
62713121|NCT04052061|EXPERIMENTAL|CD19 t-haNK|CD19 t-haNK will be administered to patients with Diffuse Large B-Cell Lymphoma who have received 2 or more lines of therapy and are ineligible for transplant.
62713122|NCT05101070|EXPERIMENTAL|Part A-1: S-531011 Monotherapy|Participants will receive escalating doses of S-531011 by intravenous infusion for up to approximately 12 months.
62152756|NCT05999448|EXPERIMENTAL|No Algorithm + No Participation Enhancement Intervention|Participants are randomly assigned to support program without use of a personalized health algorithm AND do not receive the participation enhancement intervention.
62525577|NCT03456960|EXPERIMENTAL|Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
62713123|NCT05101070|EXPERIMENTAL|Part A-2: S-531011 + pembrolizumab|Participants will receive escalating doses of S-531011 in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
62152757|NCT05999448|EXPERIMENTAL|Algorithm 1 + Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 1 AND receive the participation enhancement intervention.
62152758|NCT05999448|EXPERIMENTAL|Algorithm 1 + No Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 1 AND do not receive the participation enhancement intervention.
62152759|NCT05999448|EXPERIMENTAL|Algorithm 2 + Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 2 AND receive the participation enhancement intervention.
62152760|NCT05999448|EXPERIMENTAL|Algorithm 2 + No Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 2 AND do not receive the participation enhancement intervention.
62152761|NCT05999448|EXPERIMENTAL|Algorithm 3 + Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 3 AND receive the participation enhancement intervention.
62152762|NCT05999448|EXPERIMENTAL|Algorithm 3 + No Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 3 AND do not receive the participation enhancement intervention.
62152763|NCT05999448|NO_INTERVENTION|Waitlist Control|Participants are enrolled in the waitlist control condition, which includes identical data collection procedures to participants enrolled in support programs. Waitlist controls are offered the opportunity to enroll in future cycles.
62525578|NCT03456960|EXPERIMENTAL|Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
62525579|NCT03456960|EXPERIMENTAL|Study 2,TAK-438ASA (Fasted + Fed condition)|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
62713124|NCT05101070|EXPERIMENTAL|Part B: S-531011 Monotherapy|Participants will receive S-531011 at the the RP2D by intravenous infusion for up to approximately 12 months.
62152764|NCT02772510|EXPERIMENTAL|Smart glove system with functional electrical stimulation|game-based virtual reality rehabilitation combined with functional electrical stimulation for upper extremity
62152765|NCT02772510|ACTIVE_COMPARATOR|Functional electrical stimulation|functional electrical stimulation on upper extremity
62152766|NCT05889832|EXPERIMENTAL|HR, HRV and BR measured with Shen.AI and reference method|
62152767|NCT02949297|OTHER|Ovation Alto Abdominal Stent Graft System|Endovascular repair of AAA using the Ovation Alto Abdominal Stent Graft System.
62152768|NCT01569399|ACTIVE_COMPARATOR|active rTMS|High frequency (10HZ) on the left DLPFC
62152769|NCT01569399|PLACEBO_COMPARATOR|sham rTMS|
62152770|NCT04936048|ACTIVE_COMPARATOR|Music therapy/Play therapy|"This sequence of interventions begins with 12 weeks of music therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of play therapy intervention.~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, and interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
62152771|NCT04936048|ACTIVE_COMPARATOR|Play therapy/Music therapy|"This sequence of interventions begins with 12 weeks of play therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of music therapy intervention.~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
62152772|NCT03249857|EXPERIMENTAL|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
62713125|NCT05101070|EXPERIMENTAL|Part C: S-531011 + pembrolizumab|Participants will receive S-531011 at the RP2D in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
62713126|NCT04009980|EXPERIMENTAL|OMK2 group|Patients receiving topical administration of OMk2 ophthalmic solution for 36 months three times/day
62713127|NCT04009980|PLACEBO_COMPARATOR|Placebo group|Patients receiving receiving only the excipients of OMk2 (placebo) for 36 months three times/day
62713128|NCT06174740|EXPERIMENTAL|Music-Cued Audiovisual Motor Training|Participants will be instructed on the task which they will perform at home online using a keyboard. The training involved auditory-cued audiovisual finger movement sequence learning task. Participants will complete an online computer-based training of 20 minutes at home 3 times per week for the duration of 8 weeks, and a total of 24 sessions, the duration and number of sessions.
62713129|NCT06174740|ACTIVE_COMPARATOR|Visually-Cued Motor Training|Participants will be instructed on the task which they will perform at home online using a keyboard. The training involved visual cues for finger-movement sequence learning task. Participants will complete an online computer-based training of 20 minutes at home 3 times per week for the duration of 8 weeks, and a total of 24 sessions, the duration and number of sessions
62152773|NCT03249857|ACTIVE_COMPARATOR|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
62152774|NCT05160909||Beach Chair|Patient positioned in beach chair position during arthroscopic shoulder stabilization
62525580|NCT03456960|EXPERIMENTAL|Study 2,TAK-438ASA (Fed + Fasted condition)|One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
62525581|NCT04840966||HOS: hospitalized COVID19 patients|Patients positive to COVID19 hospitalized
62525582|NCT04840966||HI: Home-isolated COVID19 patients|Home-isolated patients positive to COVID19
62525583|NCT04840966||CTRL: Healthy controls|Healthy COVID19 negative subjects
62713130|NCT01789190||Group S (sedentary)|Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
62713131|NCT01789190||Group A (active)|The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly
62713132|NCT05098314||EHPAD with personalized interventions|EHPAD with personalized interventions.
62152775|NCT05160909||Lateral decubitus|Patient positioned in lateral decubitus position during arthroscopic shoulder stabilization
62152776|NCT05404802|EXPERIMENTAL|Experimental Group|"Training sessions~Each training session will last for 30-45 minutes, twice a week over a 10-week period in Week 1 to Week 10. Each session will be attended by a cluster of 4 to 6 participants, and each participant will have one PARO.~Free-play sessions~Two 15-30 minutes free-play sessions in each week of the 10 weeks are conducted on days when there are no training sessions."
62152777|NCT05404802|EXPERIMENTAL|Control Group|"Training sessions~Each training session will last for 30-45 minutes, once a week over a 2-week period after all assessments are completed. Each session will be attended by a cluster of 4 to 6 participants, and each participant will have one PARO.~There is no free-play sessions for control group."
62152778|NCT02169609|EXPERIMENTAL|Dinutuximab. Immunotherapy|"Dinutuximab will be administered at 17.5 mg/m2/day for 4 days up to 5 courses. Each dose should be infused IV over approximately 10 hours.~Immunotherapy (sargramostim + isotretinoin + interleukin2) Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection daily from Day 0 through 13 (daily with the infusion of Dinutuximab and for 3 days before and 7 days afterward).~Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if \< 12kg) PO divided into 2 doses daily x 14 days.~Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion for 4 days during the first week of each course 2 and 4 given on Days 0 - 3"
62525584|NCT03858738||group A: women aged 25-49 years|"Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5.~Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device."
62525585|NCT03858738||Group B: Women aged 25-49 years or 50 ≥|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 1 or 2.Thermography examination was performed with the use of Braster device.
62525586|NCT03858738||Group C: Woman aged 50 years or over|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
62525587|NCT02289235|EXPERIMENTAL|Ginger|Ginger powder capsule 500 mg
62525588|NCT02289235|PLACEBO_COMPARATOR|Placebo|Placebo powder capsule
62525589|NCT04735952||AIM 1|No-Intervention. Participants in this group will have 1 study visit only. During that visit, breath and sputum samples will be collected.
62525590|NCT04735952||AIM 2|No-Intervention. Participants in this group will have up to 8 study visits over a 2 year period. During the study visits, breath and sputum samples will be collected.
62525591|NCT04666714|EXPERIMENTAL|Praga formulation|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Placebo pregabalin tablet, oral Night: Placebo pregabalin tablet, oral plus Praga formulation,oral"
62525592|NCT04666714|ACTIVE_COMPARATOR|Pregabalin|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Pregabalin tablet, oral Night: Pregabalin tablet plus, oral placebo Praga formulation, oral"
62525593|NCT01109563|ACTIVE_COMPARATOR|Computer Check-In Control|The Computer Check-In gives the participant contact with the research therapist, an assessment of marijuana use and the current impact of use, and a reminder about optional support sessions.
62525594|NCT01109563|EXPERIMENTAL|Marijuana Check-Ins|The MCI, a MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
62525595|NCT05486455|EXPERIMENTAL|CT scan|
62152779|NCT05873504|EXPERIMENTAL|High Oscillatory Index Device|Patients in this arm will receive a device that vibrates with high oscillatory index.
62152780|NCT05873504|ACTIVE_COMPARATOR|Low Oscillatory Index Device|Patients in this arm will receive a device that vibrates with low oscillatory index.
62713133|NCT05098314||EHPAD without personalized interventions|EHPAD without personalized interventions
62713134|NCT05024344|ACTIVE_COMPARATOR|ESP Group|One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-
62713135|NCT05024344|SHAM_COMPARATOR|Sham Group|One 30mL syringe containing 30mL of preservative free normal saline
62713136|NCT03981328|ACTIVE_COMPARATOR|self-monitored blood glucose|The control group participants will perform self-monitored blood glucose testing with a study-provided blood glucose meter, including testing supplies. They will perform capillary blood glucose monitoring as routinely used for patients with GDM i.e. at least four capillary blood glucose values daily including measurements at fasting as well as 1h after starting each meal by using a routinely available blood glucose measurement device.
62713137|NCT03981328|EXPERIMENTAL|Continuous glucose monitoring|Patients randomized to the intervention group will be equipped with a real-time CGM sensor (Dexcom G6 sensor, a small flexible device that records interstitial glucose levels every five minutes). The sensor will be inserted into the subcutaneous tissue of the anterior abdomen wall. Additionally, patients will be advised to record capillary blood glucose values if glucose alerts or readings do not match with symptoms or expectations. Participants will be educated how to exchange the sensor (has to be exchanged every ten days) and will be equipped with a real-time CGM monitor and instructed in its use. The monitor provides the user with information about current glucose levels and notifies the patient before she reaches her upper or lower glucose threshold and when glucose levels change rapidly. All patients in the intervention group will specifically trained how to use the system.
62525596|NCT04588311|ACTIVE_COMPARATOR|Erythropoietin (EPO)|Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.
62525597|NCT04588311|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.
62525598|NCT06030141|EXPERIMENTAL|nigella sativa oil application group|"Peripheral venous catheter is applied under aseptic conditions. In order to easily see whether phlebitis occurs in the catheter area, the area where the catheter is inserted is covered with a Tegaderm transparent film cover and the catheter is fixed. Determine the distal peripheral venous catheter (3.2 cm length from the entry point for catheter 20) An area of 10 cm will be determined from the distal of the catheter. Nigella sativa oil is dripped 5 drops on a 10 cm area.~The dripped oil is applied without massaging, Nigella Sativa oil will be applied to the patients in the application group before the start of amiodarone infusion and at 6-hour intervals. The patients in all groups will be evaluated with the GIFTS scale for phlebitis every hour for the first 25 hours from the time of opening the catheter, and every 6 hours for the next 48 hours."
62525599|NCT06030141|EXPERIMENTAL|Sesame oil application group|"Peripheral venous catheter is applied under aseptic conditions. In order to easily see whether phlebitis occurs in the catheter area, the area where the catheter is inserted is covered with a Tegaderm transparent film cover and the catheter is fixed. Determine the distal peripheral venous catheter (3.2 cm length from the entry point for catheter 20) An area of 10 cm will be determined from the distal of the catheter. Sesame oil is dripped 5 drops on a 10 cm area.~The dripped oil is applied without massaging, The dripped oil is applied without massaging, Sesame oil will be applied to the patients in the application group before the start of amiodarone infusion and at 6-hour intervals. The patients in all groups will be evaluated with the GIFTS scale for phlebitis every hour for the first 25 hours from the time of opening the catheter, and every 6 hours for the next 48 hours."
62525600|NCT06030141|NO_INTERVENTION|control group|Peripheral venous catheter is applied under aseptic conditions. In order to easily see whether phlebitis occurs in the catheter area, the area where the catheter is inserted is covered with a Tegaderm transparent film cover and the catheter is fixed. No oil application will be made. The patients in all groups will be evaluated with the GIFTS scale for phlebitis every hour for the first 25 hours from the time of opening the catheter, and every 6 hours for the next 48 hours.
62525601|NCT02808949|EXPERIMENTAL|Age Groups|Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.
62525602|NCT06295328|ACTIVE_COMPARATOR|NUC + Study drug|Tenofovir + Terbinafine
62713138|NCT06710288|EXPERIMENTAL|All subjects|Gemcitabine plus M-CENK plus N-803
62525603|NCT06295328|PLACEBO_COMPARATOR|NUC + Placebo|Tenofovir + Placebo
62525604|NCT06295328|ACTIVE_COMPARATOR|Study drug|Terbinafine
62525605|NCT06295328|PLACEBO_COMPARATOR|Placebo|Placebo
62525606|NCT04915014|EXPERIMENTAL|laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)|One arm benefiting from a laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)
62525607|NCT04915014|SHAM_COMPARATOR|laparoscopic Roux-en-Y gastric bypass (RYGB)|One arm benefiting from a laparoscopic Roux-en-Y gastric bypass (RYGB)
62525608|NCT05051501|EXPERIMENTAL|Probiotics C2P/Placebo|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
62525609|NCT05051501|EXPERIMENTAL|Placebo/Probiotics C2P|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
62525610|NCT04710511||Control group|Medically free children aged from 5 years to 7 years and do not practice oral habits.
62713139|NCT04722783|EXPERIMENTAL|ESDM and PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months PCIT-A for 8 months (see Study Protocol, Figure 2).
62713140|NCT04722783|EXPERIMENTAL|ESDM and active control for PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months 1h-ESDM as active control instead of 1h-PCIT-A for 8 months
62713141|NCT04722783|EXPERIMENTAL|PCIT-A and active control for ESDM|Participants receive after 4 month PCIT-A for 8 months and early special needs education as an active control for ESDM.
62525611|NCT04710511||Oral habit practicing group|Medically free children aged from 5 years to 7 years and practicing oral habits.
62525612|NCT03760250|EXPERIMENTAL|Imiquimod|5% Imiquimod cream once daily to keloid area 5-times a week for 6 weeks, starting 1-week prior to keloid excision
62525613|NCT02067429|EXPERIMENTAL|Toric Intraocular lens|Toric intraocular lens implantation during standard cataract surgery
62525614|NCT02067429|EXPERIMENTAL|Limbal Relaxing Incisions|Limbal relaxing incisions during standard cataract surgery
62525615|NCT05752682||Syncope and fall|Consecutive patients aged ≥40 years referred to the Faint \& Fall Clinics for assessment of an episode of faint or fall.
62525616|NCT00712985|EXPERIMENTAL|Zometa (Zoledronic Acid) X 1 dose|Zometa (Zoledronic Acid) 5 mg IV X 1 dose
62713142|NCT04722783|ACTIVE_COMPARATOR|Active control for ESDM and PCIT-A|Participants receive early special needs education as an active control for ESDM and PCIT-A.
62713143|NCT00361712|EXPERIMENTAL|Preemptive epidural analgesia|Parturients will receive epidural analgesia immediately upon arrival in the labor ward before onset of painful contractions (VAS\<3).
62713144|NCT00361712|ACTIVE_COMPARATOR|Standard of care|Parturients with cervical dilatation and painful labor (VAS \>5) will receive epidural analgesia as soon as possible
62713145|NCT03326245|ACTIVE_COMPARATOR|Arm A: Oral methylphenidate followed by intravenous placebo|Healthy participants receive methylphenidate 60mg orally given 30 minutes prior to bolus \[11C\]raclopride injection followed by intravenous placebo (3ml saline) given 30 minutes post bolus injection of \[11C\]raclopride. PET/phMRI scan (MRI and PET scan) was initiated at the start of the \[11C\]raclopride injection. Participants were subsequently randomized across study arms B and C in different study days with at least 48 hours between visits.
62713146|NCT03326245|ACTIVE_COMPARATOR|Arm B: Oral placebo followed by intravenous methylphenidate|Healthy participants receive oral placebo given 30 minutes prior to bolus \[11C\]raclopride injection followed by intravenous methylphenidate 0.25 mg/kg in 3ml sterile water given 30 minutes post bolus injection of \[11C\]raclopride. PET/phMRI scan (MRI and PET scan) was initiated at the start of the \[11C\]raclopride injection. Participants were subsequently randomized across study arms A and C in different study days with at least 48 hours between visits.
62713147|NCT03326245|PLACEBO_COMPARATOR|Arm C: Oral placebo followed by intravenous placebo|Healthy participants receive oral placebo given 30 minutes prior to bolus \[11C\]raclopride injection followed by intravenous placebo (3ml saline) given 30 minutes post bolus injection of \[11C\]raclopride. PET/phMRI scan (MRI and PET scan) was initiated at the start of the \[11C\]raclopride injection. Participants were subsequently randomized across study arms A and B in different study days with at least 48 hours between visits.
62713148|NCT04726241|EXPERIMENTAL|Screening (biospecimen collection)|Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).
62525617|NCT03758404|EXPERIMENTAL|Low dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single low dose AAV CNGA3
62525618|NCT03758404|EXPERIMENTAL|Intermediate dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single intermediate dose AAV CNGA3
62525619|NCT03758404|EXPERIMENTAL|High dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single high dose AAV CNGA3
62525620|NCT00706381|EXPERIMENTAL|1: Carb meal, fat meal, sincalide, placebo, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, and IV placebo + PO Ursodiol 15mg/kg day 5
62525621|NCT00706381|EXPERIMENTAL|2: Fat meal, carb meal, sincalide, placebo, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
62525622|NCT00706381|EXPERIMENTAL|3: Carb meal, fat meal, placebo, sincalide, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
62525623|NCT00706381|EXPERIMENTAL|4: Fat meal, carb meal, placebo, sincalide, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, the IV placebo + PO Ursodiol 15mg/kg day 5
62525624|NCT06024200|EXPERIMENTAL|whole-process transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
62525625|NCT06024200|SHAM_COMPARATOR|whole-process transcutaneous electrical acupoint stimulation(sham stimulation)|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
62525626|NCT04271020|EXPERIMENTAL|UroLift|
62525627|NCT05502965|ACTIVE_COMPARATOR|Exclusive Enteral Nutrition(EEN)|Subjects required exclusive enteral nutrition for one month
62525628|NCT05502965|EXPERIMENTAL|Specific Diet+ Partial Enteral Nutrition|Subjects received partial enteral nutrition with remaining energy and nutrients obtained through diet for one month
62525629|NCT02289859|ACTIVE_COMPARATOR|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
62525630|NCT02289859|ACTIVE_COMPARATOR|Wound Closure without Undermining|One side of the wound will remain un-undermined.
62152781|NCT03249805|EXPERIMENTAL|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
62152782|NCT03249805|EXPERIMENTAL|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
62525631|NCT03952234|OTHER|Dose finding safety study|In this study, the highest acceptable dose of an amino acid called citrulline will be established in people who have a mitochondrial disorder. Previous research conducted by several groups including our center at Baylor College of Medicine has determined that there is a deficiency of a compound called nitric oxide in people affected with MELAS.
62525632|NCT04316507|EXPERIMENTAL|Oncologist led genetic counselling and testing|All subjects receive Oncologist Led Genetic Counselling and Testing
62525633|NCT00885521|EXPERIMENTAL|Exercise|8 week, twice weekly exercise program with both endurance and upper and lower limb strength training
62525634|NCT00885521|NO_INTERVENTION|2|No exercise, twice weekly phone calls
62152783|NCT05558748|ACTIVE_COMPARATOR|Pediatric patients undergoing inguinal surgeries with USG-guided Caudal block.|All pediatric patients (6 months to 12 year) posted for inguinal surgery under general anesthesia with USG-guided Caudal block for analgesia
62152784|NCT05558748|ACTIVE_COMPARATOR|Pediatric patients undergoing inguinal surgeries with USG-guided Ilioinguinal/Iliohypogastric block.|All pediatric patients (6 months to 12 year) posted for inguinal surgery under general anesthesia with USG-guided Ilioinguinal/Iliohypogastric block for analgesia
62152785|NCT03741634|EXPERIMENTAL|Intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
62152786|NCT03741634|NO_INTERVENTION|No intervention|During the study, participants enrolled at one study location will non receive the Multi-sectoral agricultural intervention. At the end of the study, participants in this arm will be eligible for education in financial management and sustainable farming practices and those who pay the loan down payment will be eligible for a small loan to purchase a human-powered water pump, seeds, fertilizers and, pesticides.
62152787|NCT05935839|EXPERIMENTAL|Adult Patients with diabetes mellitus type 1|"* Laboratory-confirmed diagnosis of diabetes mellitus type 1~* Age 18-99 years~* Duration of disease at least 5, preferably 10 years with inadequate medication control (HbA1c value \> 8.5 mmol/mol)"
62525635|NCT00973401||Diabetic individuals|
62525636|NCT04973553|EXPERIMENTAL|participants with acute stroke|(a) a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation, (b) been admitted to the acute hospital for rehabilitation, (c) Upper limb hemiparesis or hemiplegia with a trace of muscle contraction:≥grade 1 at shoulder (abductors or elevators) or wrist/finger extensors measured by the MRC Scale and a score of \<61 on the Motricity Index and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS)\[24\], (d) the age of \> 18 years and (e) the ability to provide informed consent.
62525637|NCT03754465|EXPERIMENTAL|ALLO-ASC-DFU|Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
62525638|NCT03754465|PLACEBO_COMPARATOR|Hydrogel SHEET(Vehicle control)|Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
62525639|NCT00011349||Group 1|
62525640|NCT05717530|ACTIVE_COMPARATOR|wound site local anesthesic infiltration|at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site
62525641|NCT05717530|ACTIVE_COMPARATOR|Erector spinae plane block|: Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction
62525642|NCT05717530|NO_INTERVENTION|Control|There was no intervention.
62525643|NCT00569621|EXPERIMENTAL|1|
62525644|NCT00569621|PLACEBO_COMPARATOR|2|
62525645|NCT00671138|ACTIVE_COMPARATOR|I|Arm I will be inoculated with the human hookworm necator americanus at weeks 0 and 12.
62525646|NCT00671138|PLACEBO_COMPARATOR|II|Arm II participants will receive and identical sham-inoculums comprising a diluted amount of 0.2ml McIlhenny \& Co Tabasco Pepper Sauce®
62525647|NCT06070974||Single arm study|STEMI patients, who meet all the inclusion and none of the exclusion criteria, will be enrolled 3 days after PCI to study the correlation between exosome profile and severity of myocardial infarction
62525648|NCT03957330|EXPERIMENTAL|Community Mental Health Clinic|In this arm, clients will be assigned to therapists working in a community mental health clinic in Saskatchewan where the focus of the setting is primarily on face-to-face treatment and ICBT makes up a small component of the workload in the clinic.
62525649|NCT03957330|EXPERIMENTAL|Once a week therapist contact|In once a week treatment, therapists will email their clients once a week on a pre-determined day.
62525650|NCT03957330|EXPERIMENTAL|Reflection Questionnaire|"In the reflection questionnaire, patients will be asked to complete the following questions five times during the treatment period (beginning lesson 2-5 and then at the point they complete post-questionnaires):~1. How much of the lesson were you able to review?~2. How much effort were you able to put into the lesson?~3. How difficult was the lesson?~4. Please share any difficulties you had with the lesson.~5. How understandable was the lesson?~6. How helpful did you find the lesson?~7. Please describe an example of what you learned.~8. To what extent have you continued to use strategies from previous lessons~9. If applicable, please provide an example of what you are working on from previous lessons~10. Please indicate which Additional Resources you reviewed this week.~11. If applicable, please share any skills you are working on from the Additional Resources."
62525651|NCT03957330|EXPERIMENTAL|Specialized Internet Therapy Clinic|In this arm, clients will be assigned to therapists working in a specialized internet therapy clinic where the therapists only deliver ICBT.
62525652|NCT03957330|EXPERIMENTAL|Twice a week therapist contact|In twice a week treatment, therapists will email their clients twice a week on pre-determined days.
62525653|NCT03957330|EXPERIMENTAL|No Reflection Questionnaire|In this arm, no reflection questions will be asked of clients receiving ICBT.
62525654|NCT06166238||Group I|Patients who will be subjected to Millard Technique
62525655|NCT06166238||Group II|patients who will be subjected to Tension Randal
62525656|NCT01378455|EXPERIMENTAL|ICHTP group|In ICHTP (interactive computerized handwriting training program) group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software
62525657|NCT01378455|ACTIVE_COMPARATOR|THTP group|The THTP (traditional handwriting training program)group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
62525658|NCT02570113|EXPERIMENTAL|Renal Denervation by Neurolysis|Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
62525659|NCT06032962|EXPERIMENTAL|non-gynecologic surgery|Female candidates for non-gynecologic abdominal surgery
62525660|NCT01330771||hMG-HP/r-FSH|Patients with a condition
62525661|NCT00522171||Electro Surgery|Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.
62525662|NCT02583386|ACTIVE_COMPARATOR|Free From Falls training group|Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
62525663|NCT02583386|NO_INTERVENTION|Wait-list control group|Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
62525664|NCT02583386|ACTIVE_COMPARATOR|FFF training group w/ Fall Detector|"Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
62525665|NCT02583386|OTHER|Wait-list control w/ Fall Detector|"Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
62525666|NCT04050150|EXPERIMENTAL|Arm Training in Standing|Task-oriented, functional arm training completed in standing or during walking. All participants receive the same arm training intervention.
62525667|NCT02751359|ACTIVE_COMPARATOR|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
62525668|NCT02751359|PLACEBO_COMPARATOR|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
62525669|NCT03386565|ACTIVE_COMPARATOR|control group|"* Sodium chloride solution 10 mL IV just before induction of anesthesia~* IV infusion during the surgery"
62525670|NCT03386565|ACTIVE_COMPARATOR|lidocaine group|"* lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia~* IV infusion during the surgery"
62525671|NCT02229539|EXPERIMENTAL|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
62525672|NCT02229539|ACTIVE_COMPARATOR|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.~Patients will complete the Oral Symptoms booklet per the protocol."
62152788|NCT05935839|EXPERIMENTAL|Pediatric Patients with diabetes mellitus type 1|"* Laboratory-confirmed diagnosis of diabetes mellitus type 1~* Age 6-17 years~* Duration of disease at least 5, preferably 10 years with inadequate medication control (HbA1c value \> 8.5 mmol/mol)"
62525673|NCT02229539|PLACEBO_COMPARATOR|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
62525674|NCT03254602|EXPERIMENTAL|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
62713149|NCT00332696|EXPERIMENTAL|Octreotide|Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
62713150|NCT00332696|PLACEBO_COMPARATOR|Placebo|Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
62713151|NCT00534001|EXPERIMENTAL|Arm I (1-week run-in)|Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
62713152|NCT00534001|EXPERIMENTAL|Arm II (4-week run-in)|Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
62152789|NCT05935839|EXPERIMENTAL|Healthy volunteers|- Age 18-99 years
62152790|NCT01558999|EXPERIMENTAL|High concentration SI-614|
62152791|NCT01558999|EXPERIMENTAL|Low concentration SI-614|
62152792|NCT01558999|PLACEBO_COMPARATOR|Vehicle|
62152793|NCT03343041|ACTIVE_COMPARATOR|low carbohydrate nutrition|"We will use a low-carbohydrate nutrition (LCN) formulated by the MICU registered dietitian and pharmacy staff, who routinely prepare enteral and parenteral nutrition which will provide:~5% carb, 41% protein, 54% lipid."
62152794|NCT03343041|ACTIVE_COMPARATOR|standard enteral nutrition|"The standard enteral nutrition (SEN) and per cent contribution of carbohydrates used in the Yale MICU is as follows:~Jevity 1.2 56% carb, 29.5% lipid, 18.5% protein Diabetisource 33% carb, 44% lipid, 20% protein Promote 55% carb, 25% lipid, 25% protein Vital AF 37% carb, 40% lipid, 25% protein Peptamin Intense 29% carb, 34% lipid, 37% protein Osmolite 1.5 54% carb, 29.5% lipid, 16.5% protein"
62525675|NCT02884349|EXPERIMENTAL|RoM assessment|All patients recruited to the study.
62525676|NCT02833376|EXPERIMENTAL|Alcohol group|Patients allocated to this group will receive skin antisepsis with alcohol 70% prior spinal anesthesia
62525677|NCT02833376|EXPERIMENTAL|Chlorhexidine group|Patients allocated to this group will receive skin antisepsis with alcoholic solution of chlorhexidine 0.5% prior spinal anesthesia
62525678|NCT03480126|PLACEBO_COMPARATOR|Herbal Tea 1|Placebo Tea should will be ingested 3 times per day for 3 months
62525679|NCT03480126|EXPERIMENTAL|Herbal Tea 2|Experimental Herbal Tea A will be ingested 3 times per day for 3 months
62525680|NCT03480126|EXPERIMENTAL|Herbal Tea 3|Experimental Herbal Tea B will be ingested 3 times per day for 3 months
62525681|NCT03480126|EXPERIMENTAL|Herbal Tea 4|Experimental Herbal Tea C will be ingested 3 times per day for 3 months
62525682|NCT01403064|EXPERIMENTAL|Open Label ALD518|
62525683|NCT01403064|EXPERIMENTAL|ALD518 Dose 1|
62713153|NCT00557037|EXPERIMENTAL|A|Patients with chemotherapy naïve androgen independent disease
62713154|NCT00557037|EXPERIMENTAL|B|Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent
62152795|NCT03014349||primary open-angle glaucoma and/or glaucoma suspects|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
62152796|NCT05844306|EXPERIMENTAL|Device ([18F]-FDG PET-CT, X1 RMRS PET-CT)|Patients receive \[18F\]-FDG injection and undergo SOC \[18F\]-FDG PET-CT on study. Patients with at least one PET avid lesion then undergo X1 RMRS PET-CT imaging-only session on study.
62152797|NCT01635049||Women undergoing IVF treatment and CCS|•Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical need by the clinical site reproductive endocrinologist.
62152798|NCT00072670|EXPERIMENTAL|Trabectedin 0.58 milligram per square meter (mg/m^2)|Trabectedin will be administered as 3-hour intravenous infusion at dose of 0.58 mg/m\^2 weekly on Day 1, 8 and 15 in 28-day cycle and will be continued until disease progression or unacceptable toxicity.
62152799|NCT00072670|EXPERIMENTAL|Trabectedin 1.5 mg/m^2|Trabectedin will be administered at dose of 1.5 mg/m\^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
62152800|NCT00072670|EXPERIMENTAL|Trabectedin 1.2 mg/m^2|Trabectedin will be administered at dose of 1.2 mg/m\^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
62152801|NCT03980236|EXPERIMENTAL|Livongo-Insulia Study App Arm|Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration
62152802|NCT02297464|EXPERIMENTAL|Eggs - 2 per day for breakfast|Participants will consume 2 eggs per day for breakfast for 4 weeks of the study.
62152803|NCT02297464|EXPERIMENTAL|Oatmeal - 1 packet per day for breakfast|Participants will consume 1 packet of oatmeal per day for breakfast for 4 weeks of the study.
62152804|NCT06133569|EXPERIMENTAL|ReDirection|ReDirection is a self help program based on cognitive behavioral therapy methodology and consists of five modules. The program aims to help participants reduce their CSAM use by gaining a better understanding of, and skills to manage risky sexual thoughts, feelings, and behaviors.
62152805|NCT06133569|NO_INTERVENTION|Waitlist|Participants are on a waitlist which means they have no active intervention, only weekly measurements with the same questionnaires as in the active arm.
62525684|NCT01403064|EXPERIMENTAL|ALD518 Dose 2|
62525685|NCT01403064|PLACEBO_COMPARATOR|Placebo|
62713155|NCT03861338|EXPERIMENTAL|sublocade|Sublocade buprenorphine extended-release (BXR) injection, 300 mg and 100 mg
62713156|NCT01864434||Patients with a Stryker Triathlon CR TKA|Patients implanted with a Stryker Triathlon Posterior Cruciate Retaining Total Knee Arthroplasty.
62713157|NCT01864434||Patients with a Zimmer PCR TKA|Patients implanted with a Zimmer NexGen Posterior Cruciate Retaining Total Knee Arthroplasty.
62713158|NCT05697718|EXPERIMENTAL|group 1|Human umbilical cord mesenchymal stem cells（hMSCs）5.0×10\^7 cells
62713159|NCT05697718|EXPERIMENTAL|group 2|Human umbilical cord mesenchymal stem cells（hMSCs）10.0×10\^7 cells
62713160|NCT05697718|EXPERIMENTAL|group 3|Human umbilical cord mesenchymal stem cells（hMSCs）20.0×10\^7 cells
62713161|NCT01593917||Subjects previously implanted with a Trifecta™ valve in the Trifecta™ IDE Study|Subjects enrolled in this clinical study were implanted with the Trifecta™ aortic bioprosthetic valve during 2007, 2008 and 2009 as part of the Trifecta™ IDE Study conducted to obtain FDA approval.
62152806|NCT01247077|ACTIVE_COMPARATOR|placebo|Placebo and thyroxin + methimazole
62525686|NCT01644110|EXPERIMENTAL|ruxolitinib/pomalidomide|"Cohort 1 (Patient 1 - Patient 41): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.~Cohort 2 (Patient 42 - Patient 90): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be started at 0.5 mg once daily up to 2 mg once daily."
62525687|NCT05979363|EXPERIMENTAL|VRD-based Regimen Combined With BCMA CART|"VRD：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.~Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.~Participants will receive VRD-based induction, BCMA CAR-T infusion, VR consolidation, VR maintenance."
62525688|NCT01708629|EXPERIMENTAL|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
62525689|NCT01708629|EXPERIMENTAL|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
62525690|NCT01708629|ACTIVE_COMPARATOR|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
62525691|NCT01708629|PLACEBO_COMPARATOR|Placebo|Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
62525692|NCT01130636|EXPERIMENTAL|Tamiflu|Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
62525693|NCT00673387|PLACEBO_COMPARATOR|Placebo-P + Placebo-M|Placebo matched to pramlintide BID plus placebo matched to metreleptin BID
62525694|NCT00673387|EXPERIMENTAL|Pramlintide 360 mcg + Placebo-M|360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID
62525695|NCT00673387|EXPERIMENTAL|Placebo-P + Metreleptin 5.0 mg|Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID
62525696|NCT00673387|EXPERIMENTAL|Pramlintide 180 mcg + Metreleptin 2.5 mg|Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID
62525697|NCT00673387|EXPERIMENTAL|Pramlintide 180 mcg + Metreleptin 5.0 mg|Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID
62525698|NCT00673387|EXPERIMENTAL|Pramlintide 360 mcg + Metreleptin 1.25 mg|Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID
62525699|NCT00673387|EXPERIMENTAL|Pramlintide 360 mcg + Metreleptin 2.5 mg|Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID
62713162|NCT05988138|EXPERIMENTAL|Family Promoting Positive Emotions|
62713163|NCT05988138|ACTIVE_COMPARATOR|Psychoeducation|
62152807|NCT01247077|PLACEBO_COMPARATOR|selenium|selenium + methimazole + thyroxin
62152808|NCT04648904|EXPERIMENTAL|Post-Mastectomy Radiotherapy|Treatment will consist of PMRT delivered using external beam RT techniques to a dose of 26 Gy in 5 fractions of 5.2 Gy delivered on consecutive weekdays with an optional chest wall boost of 5.2 Gy for 1-2 fractions or an alternate boost schedule of 2.5 Gy for 1-4 fractions at the discretion of the treating physician.
62525700|NCT00673387|EXPERIMENTAL|Pramlintide 360 mcg + Metreleptin 5.0 mg|Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID
62525701|NCT03090997|PLACEBO_COMPARATOR|Group 1|vitamin C (500 mg/day/orally) + placebo
62525702|NCT03090997|PLACEBO_COMPARATOR|Group 2|resveratrol (500 mg/day/orally) + placebo
62525703|NCT03090997|ACTIVE_COMPARATOR|Group 3|vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)
62713164|NCT04911426|EXPERIMENTAL|Treatment plus telehealth|Individuals will receive telehealth support services, including seven brief motivational interviewing sessions, delivered by a licensed substance use counselor via live interactive video calls during the 12-week intervention.
62713165|NCT03894085|EXPERIMENTAL|GAD group|"1. General anxiety disorder(GAD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~2. MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~3. Paroxetine (20-40mg) treatment for 4 weeks"
62713166|NCT03894085|EXPERIMENTAL|PD group|"1. Panic disorder(PD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~2. MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~3. Paroxetine (20-40mg)treatment for 4 weeks"
62713167|NCT03894085|EXPERIMENTAL|SAD group|"1. Social anxiety disorder(SAD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~2. MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~3. Paroxetine (20-40mg)treatment for 4 weeks"
62713168|NCT03894085|EXPERIMENTAL|OCD group|"1. Obsessive-compulsive disorder (OCD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~2. MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~3. Paroxetine(40-80mg) treatment for 4 weeks"
62713169|NCT03894085|NO_INTERVENTION|Healthy controls|MRI scan at baseline and no drugs treatment
62713170|NCT01470105||pts bone metastases|This is a prospective, cross sectional, human use study conducted using patients with bone metastases requiring orthopaedic stabilization. Though this is an observational study, blood sampling, the SF-36 questionnaire, and ECOG performance status, and correlative studies will be performed.
62713171|NCT06254066|EXPERIMENTAL|Adebrelimab+Fluzoparib|
62713172|NCT05330975|EXPERIMENTAL|Part A: mRNA-1345 + Placebo|Single injection of mRNA-1345 and placebo, administered intramuscularly (IM), one in each arm on Day 1.
62152809|NCT05167578||Patients with multimorbidity|Patients with multimorbidity who visit the public health centres in Vantaa, Southern Finland
62152810|NCT03506802|EXPERIMENTAL|Treatment (Genetically engineered PBMC and PBSC)|Refer to outline
62713173|NCT05330975|EXPERIMENTAL|Part A: mRNA-1345 + Afluria® Quadrivalent|Single injection of mRNA-1345 and Afluria® quadrivalent, administered IM, one in each arm on Day 1.
62713174|NCT05330975|ACTIVE_COMPARATOR|Part A: Afluria® Quadrivalent + Placebo|Single injection of Afluria® quadrivalent and placebo, administered IM, one in each arm on Day 1.
62713175|NCT05330975|EXPERIMENTAL|Part B: mRNA-1345 + Placebo|Single injection of mRNA-1345 and placebo, administered IM, one in each arm on Day 1. An additional injection of mRNA-1273.214, administered on Day 29.
62713176|NCT05330975|EXPERIMENTAL|Part B: mRNA-1345 + mRNA-1273.214|Single injection of mRNA-1345 and mRNA-1273.214, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
62525704|NCT03972267|SHAM_COMPARATOR|Control Group - Free Gingival Graft|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the Control Group will not receive any kind of treatment in the palatal region.
62713177|NCT05330975|ACTIVE_COMPARATOR|Part B: mRNA-1273.214 + Placebo|Single injection of mRNA-1273.214 and placebo, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
62713178|NCT05330975|EXPERIMENTAL|Part C: mRNA-1345|Single injection of mRNA-1345 administered IM on BD Day 1.
62525705|NCT03972267|EXPERIMENTAL|Test Group - Free Gingival Graft + EMD|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. EMD will be applied immediately after the graft removal surgical procedure on the palatal donor area, leaving it in contact with the wound for 5 min. In sequence, it will be covered with an individualized acetate plate that will extend throughout the palatal area and be in position for 2 hours after the procedure
62525706|NCT02922881|EXPERIMENTAL|Ulcerative Colitis Diet|Participants will receive a structured 12-week diet with a step down phase.
62152811|NCT04728282|EXPERIMENTAL|RTSA with subscapularis repair|
62525707|NCT05107531||Parkinson's Patients with Motor Freezing|Individuals with Parkinson's Disease with motor freezing were included in this group.
62525708|NCT05107531||Parkinson's Patients Without Motor Freeze|Individuals with Parkinson's Disease without motor freeze were included in this group.
62713179|NCT00863161|EXPERIMENTAL|1|AZD3355 65 + 65 mg capsule
62713180|NCT03960840|EXPERIMENTAL|CLL/SLL|Dose escalation and expansion of rapcabtagene autoleucel in combination with ibrutinib
62713181|NCT03960840|EXPERIMENTAL|3L+ DLBCL|Dose escalation and expansion of rapcabtagene autoleucel single agent in 3L+ DLBCL
62713182|NCT03960840|EXPERIMENTAL|Adult ALL|Dose escalation and expansion of rapcabtagene autoleucel single agent in adult ALL
62713183|NCT03960840|EXPERIMENTAL|1L HR LBCL|Rapcabtagene autoleucel single agent in 1L HR LBCL
62713184|NCT04906694|EXPERIMENTAL|COVI-DROPS|10, 20, or 40 mg of COVI-DROPS administered intranasally
62713185|NCT04906694|PLACEBO_COMPARATOR|Placebo|2 mL administered intranasally
62713186|NCT05626491|EXPERIMENTAL|Active SAVIR Alpha Synch Mobile device (SASm)|Patients will receive active treatment with the device every other day over 8 weeks.
62152812|NCT04728282|ACTIVE_COMPARATOR|RTSA without subscapularis repair|
62152813|NCT01525459||Glioma patients|
62152814|NCT06251791|EXPERIMENTAL|Experimental|Experimental: Conventional Physiotherapy In the intensive care unit and who had mechanical ventilation for more than 48 hours and who were extubated. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
62713187|NCT05626491|SHAM_COMPARATOR|Sham SAVIR Alpha Synch Mobile device (SASm)|Patients will receive sham treatment (no active stimulation) with the device every other day over 8 weeks.
62713188|NCT01597739|EXPERIMENTAL|JNJ-40346527|
62713189|NCT01597739|PLACEBO_COMPARATOR|Placebo|
62713190|NCT04925141|EXPERIMENTAL|Dasatinib tablets|Dasatinib tablets 100 mg orally once daily
62713191|NCT04551300|EXPERIMENTAL|VS-505 500mg|VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
62713192|NCT04551300|EXPERIMENTAL|VS-505 750mg|VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
62152815|NCT06251791|EXPERIMENTAL|Conventional|In this group will apply only conventional physiotherapy. Conventional physiotherapy to contain breathing and,thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization. Conventional physiotherapy apply for 5 days after extubation period 1 time a day.
62525709|NCT05107531||Healthy Controls|Healthy individuals who did not have any neurological problems that would affect gait were included.
62525710|NCT04407494||COVID-19|Healthcare workers and adult outpatients attending the COVID-19 screening center of the University Hospital of Montpellier, France.
62152816|NCT06251791|NO_INTERVENTION|Healthy controls|There is no intervention in this group. Baseline measurements are to compare with experimental groups.
62152817|NCT03008785|EXPERIMENTAL|group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
62152818|NCT03008785|EXPERIMENTAL|group placebo and exercise|The placebo group received 100mg containing starch of corn.
62152819|NCT00623649|EXPERIMENTAL|Cohort 1|VCH-916 100 mg three times a day (t.i.d.)
62152820|NCT00623649|EXPERIMENTAL|Cohort 2|VCH-916 200 mg (t.i.d.)
62152821|NCT00623649|EXPERIMENTAL|Cohort 3|VCH-916 300 mg twice daily for three days
62152822|NCT00623649|EXPERIMENTAL|cohort 4|VCH-916 400 mg twice daily for three days
62152823|NCT05843370||High SVI|Participants reside in neighborhood zip code clusters that rank at the top of the social vulnerability index (most vulnerable)
62525711|NCT02833545|EXPERIMENTAL|OZONE|injection of ozone gas
62525712|NCT02833545|ACTIVE_COMPARATOR|control|injeciton of steroids intra articularly
62525713|NCT06062797|EXPERIMENTAL|Mixed Reality|Fracture visualization via Mixed Reality Viewer
62525714|NCT06062797|ACTIVE_COMPARATOR|X-ray or CT scan|Fracture visualization via X-ray or CT scan
62525715|NCT04819035||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
62525716|NCT03939325||first group|patient who exposed to frequency 60 shock wave per min
62525717|NCT03939325||second group|patient who exposed to frequency 80 shock wave per min
62525718|NCT03939325||third group|patient who exposed to frequency 100 shock wave per min
62525719|NCT05061576|ACTIVE_COMPARATOR|Standard of care|Oral advice on exercise from a physician.
62525720|NCT05061576|EXPERIMENTAL|Active intervention|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
62525721|NCT00003748|EXPERIMENTAL|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
62525722|NCT03028740|PLACEBO_COMPARATOR|Placebo|Participants received cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
62525723|NCT03028740|EXPERIMENTAL|Cenicriviroc 150 mg|Participants received cenicriviroc, 150 milligrams (mg), tablet, orally, once daily for up to approximately 40 months.
62525724|NCT02375139|EXPERIMENTAL|DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
62525725|NCT02375139|EXPERIMENTAL|E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
62713193|NCT04551300|EXPERIMENTAL|VS-505 1500mg|VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
62713194|NCT04551300|EXPERIMENTAL|VS-505 2250mg|VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
62713195|NCT04551300|ACTIVE_COMPARATOR|Sevelamer Carbonate 1600mg|Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.
62713196|NCT06451497|EXPERIMENTAL|Single arm|Dose escalation of ZM008.
62713197|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
62152824|NCT05843370||Low SVI|Participants reside in neighborhood zip code clusters that rank at the bottom of the social vulnerability index (least vulnerable)
62152825|NCT02037100||T2DM|Children 6-20 years old diagnosed with T2DM
62152826|NCT02037100||Obesity|
62152827|NCT05939830|EXPERIMENTAL|Omit ALND|"Omitting Axillary Lymph Node Dissection (ALND) in SrLNB-proven axillary complete response patients.~Finishing regional lymph node irradiation (RNI) including the axilla after surgery."
62152828|NCT01288729|EXPERIMENTAL|Group 1 - Steel Cathetar, then Teflon|Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
62152829|NCT01288729|EXPERIMENTAL|Group 2 - Teflon Cathetar, the Steel|Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
62525726|NCT03185442|EXPERIMENTAL|PRF-fMRI|
62525727|NCT02733952|ACTIVE_COMPARATOR|tranexamic acid|"bolus intravenous injection of tranexamic acid 10mg/kg (maximum1g) 15 min before incision followed by continuous infusion of 1mg/kg/h dissolved in 1L of saline for 10 h (maximum~1 g/10 h)"
62525728|NCT02733952|ACTIVE_COMPARATOR|Pericervical Tourniquet|The tourniquet method will be used where the urinary bladder will be dissected downwards from the lower uterine segment, and then a perforation will be made in the posterior leaflet of the broad ligament bilaterally at the level of uterine isthmus. A tourniquet (using 16- inch Foley catheter) will be passed through the perforation encircling the uterine arteries bilaterally. The Fallopian tubes and the ovaries will be carefully excluded from the line of the tourniquet to avoid direct compression and necrosis. The tourniquet will be released intermittently (at about 30 minutes interval) during the surgery and ﬁnally removed after the repair of the uterus
62525729|NCT05335291||Group I|
62525730|NCT02540317|EXPERIMENTAL|Active treatment, Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
62713198|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
62713199|NCT01337570|EXPERIMENTAL|Dapivirine|Vaginal ring containing 25mg of dapivirine
62713200|NCT01337570|PLACEBO_COMPARATOR|Placebo Ring|Vaginal ring containing no drug substance
62713201|NCT03679949|PLACEBO_COMPARATOR|Placebo|Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
62713202|NCT03679949|EXPERIMENTAL|Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
62713203|NCT03679949|EXPERIMENTAL|Cannabis (THC:CBD = ~1:0)|Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
62713204|NCT03679949|EXPERIMENTAL|Cannabis (THC:CBD = ~ 0:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
62713205|NCT03679949|EXPERIMENTAL|Cannabis (THC:CBD = ~ 1:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
62713206|NCT03679949|EXPERIMENTAL|Cannabis (THC:CBD = ~1:0) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
62713207|NCT03679949|EXPERIMENTAL|Cannabis (THC:CBD = ~ 0:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
62713208|NCT03679949|EXPERIMENTAL|Cannabis (THC:CBD = ~ 1:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
62713209|NCT06313203|ACTIVE_COMPARATOR|Hepatic artery infusion (HAI) chemotherapy|Liver-directed hepatic arterial chemotherapy delivered through a surgically implanted HAI-pump has been evaluated in several small series and appears to have greater efficacy than systemic therapy alone.
62713210|NCT06313203|ACTIVE_COMPARATOR|Selective Internal Radiation Therapy (SIRT)|SIRT is approved in Norway, however, usen in a limited degree. Recent research in hepatocellular carcinoma has shown the importance of personalized dosimetry to obtain high tumour radiation dose, while limiting the dose to surrounding liver tissue, yielding improved response and survival (Dosisphere study), It is likely that these findings can be applied also to cholangiocarcinoma.
62713211|NCT04796584||MS subjects who are being treated with ocrelizumab|Ocrelizumab's immunomodulating mechanisms of action is B-cell lytic. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
62713212|NCT04796584||MS subjects who are being treated with fingolimod|Fingolimod's immunomodulating mechanisms of action is to prevent mobilization of B and T cells from peripheral lymphoid organs. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
62713213|NCT04796584||MS subjects who are being treated with natalizumab|Natalizumab's immunomodulating mechanisms of action is to block transmigration of monocytes, and lymphocytes into the central nervous system. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
62525731|NCT02540317|NO_INTERVENTION|Waiting list control|The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
62713214|NCT04796584||MS subjects who are being treated with dimethyl fumarate/diroximel fumarate|Dimethyl Fumarate's immunomodulating mechanisms of action is to reduce inflammation-induced oxidative stress. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
62713215|NCT06226610|ACTIVE_COMPARATOR|ARM 1 - Dupixent|Two subcutaneous injection of 300mg Dupixent at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations. Injections may be administered in the thigh, lower abdomen or upper arm. The initial dose (two 300 mg doses) will be given in two different injection sites. There are not restriction or guidance regarding dose administration related to meals. No dose modifications will occur during study participation.
62713216|NCT06226610|PLACEBO_COMPARATOR|ARM 2 - Placebo|Two subcutaneous injection of the placebo at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations. Injections may be administered in the thigh, lower abdomen or upper arm. The initial dose (two doses) will be given in two different injection sites. There are not restriction or guidance regarding dose administration related to meals. No dose modifications will occur during study participation.
62713217|NCT06598332|EXPERIMENTAL|Treatment|Patients will receive one cycle of AZA through the vein or as a shot under the skin daily for 5 days. This will start at the same time or within 3 days of starting standard treatment for gut GVHD with steroids.
62713218|NCT04846335|EXPERIMENTAL|Active Bassado|patients with D178N/M129 mutation on prion protein will be treated with Bassad
62713219|NCT04846335|PLACEBO_COMPARATOR|Placebo|subject without the mutation will be treated with plac
62713220|NCT06437834|NO_INTERVENTION|Vaccination Offer only|all male-identifying visitors in the birthing center will receive the offer of influenza and Tdap vaccinations at the bedside only.
62713221|NCT06437834|EXPERIMENTAL|Offer of Bedside Vaccines plus Information|All male-identifying visitors in the birthing center at the birthing center will receive an information sheet about vaccinations and preventive healthcare, and will be offered influenza and Tdap vaccinations at bedside in the birthing center.
62713222|NCT06437834|EXPERIMENTAL|Offer of Bedside Vaccines plus High-touch connection|All male-identifying visitors in the birthing center will receive the information sheet, and will be offered influenza and Tdap vaccinations at bedside in the birthing center, as well as a high-touch connection to healthcare navigation supports.
62713223|NCT04466969||HF|"Patients with HF with reduced Ejection Fraction (HFrEF) is enrolled if patients meet following criteria within 6 months:~1. Ejection Fraction ratio（EF） ≤40%~2. New York Heart Association(NYHA) class II-IV"
62713224|NCT04466969||stages of CKD (stage 3b)|"CKD is diagnosed based on the following e Glomerular Filtration Rate (eGFR) categories:~Stage 3b: 30 mL/min/1.73m2 ≤ eGFR \<45 mL/min/1.73m2"
62525732|NCT02027181|EXPERIMENTAL|device FreeO2|Automatic adjustment of oxygen
62525733|NCT02027181|ACTIVE_COMPARATOR|Manual oxygenation|Manual adjustment of oxygen
62525734|NCT05882279||Pharmacists in Hospitals Prescribing NINLARO|Pharmacists included in Nikkei Research Access Panel who are active in clinical practice, with valid contact and who have instructed the dosing of NINLARO IRD therapy to patients with rrMM will self-administer a web-based survey. The questionnaires in the survey will be provided in Japanese.
62152830|NCT03996798|EXPERIMENTAL|Jessa Hospital, Herk-de-Stad|"Back to Work methodology: a revalidation trajectory with standard revalidation therapy in combination with an early focus on back to work, using a Disability Case Manager"
62152831|NCT03996798|NO_INTERVENTION|Revalidation and MS Clinic Overpelt|"Standard revalidation therapy without explicit focus on back to work"
62152832|NCT06051721|EXPERIMENTAL|Arm A: Active|Arm A participants will receive a full dose of CYB004 in 2 of 2 medicine sessions, approximately three weeks apart. All participants will receive supportive EMBARK psychotherapy throughout the study.
62525735|NCT03453671|EXPERIMENTAL|Mindfulness|Participants will use the strategy of mindfulness, i.e., present moment awareness with nonjudgment and acceptance, while exercising.
62525736|NCT03453671|EXPERIMENTAL|Distraction|Participants will use the strategy of distraction, i.e., directing their attention to something other than exercise (specifically a podcast) while exercising.
62525737|NCT03453671|ACTIVE_COMPARATOR|Self-Monitoring|Participants will monitor their internal experience while exercising, without distraction and without being taught mindfulness skills of nonjudgment and acceptance.
62525738|NCT01796158|EXPERIMENTAL|cASBI+cMET|Participants will complete the computerized alcohol screening and brief intervention (cASBI)protocol at the time of an office visit and also complete the 2-session computerized Motivational Enhancement Therapy intervention (cMET).
62525739|NCT01796158|ACTIVE_COMPARATOR|cASBI|Participants will complete the computerized screening and brief intervention protocol at the time of a primary care office visit.
62525740|NCT04206514|EXPERIMENTAL|Peer Counselor|Participants receive personalized text messages and phone calls from a peer counselor- a women who had an abortion and was trained in post abortion care and PCC
62525741|NCT04206514|EXPERIMENTAL|Nurse|Participants receive personalized text messages and phone calls from a nurse trained in post abortion care and PCC
62525742|NCT04206514|NO_INTERVENTION|control|Participants receive the standard of care for post-abortion patients in Kenya.
62525743|NCT01430793|ACTIVE_COMPARATOR|Vitamin D 600,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
62525744|NCT01430793|ACTIVE_COMPARATOR|Vitamin D 600,000 orally|Vitamin D3 600,000 units will be given orally
62525745|NCT01430793|ACTIVE_COMPARATOR|Vitamin D 200,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
62713225|NCT04466969||Stages of CKD (stage 4)|"CKD is diagnosed based on the following eGFR categories:~15 mL/min/1.73m2 ≤ eGFR \<30 mL/min/1.73m2"
62152833|NCT06051721|ACTIVE_COMPARATOR|Arm B: Control|Arm B participants will receive a low dose of CYB004 in 2 of 2 medicine sessions, approximately three weeks apart. All participants will receive supportive EMBARK psychotherapy throughout the study.
62152834|NCT02782000|EXPERIMENTAL|Long-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 6 months.
62152835|NCT02782000|ACTIVE_COMPARATOR|Short-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 3 months.
62152836|NCT03998956|ACTIVE_COMPARATOR|Circumferential PV isolation|Circumferential PV isolation only
62525746|NCT01430793|ACTIVE_COMPARATOR|Vitamin D 200,000 orally|Vitamin D 200,000 units will be given orally
62525747|NCT05709041|ACTIVE_COMPARATOR|Standard lung protective ventilator settings|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
62525748|NCT05709041|EXPERIMENTAL|Individualized lung protective ventilator settings|Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.
62525749|NCT05001932|ACTIVE_COMPARATOR|Multifocal|Patients will receive a multifocal lens bilateral (Alcon Vivity).
62152837|NCT03998956|EXPERIMENTAL|Circumferential PV and BOX isolation|Circumferential PV and BOX isolation
62152838|NCT03998956|EXPERIMENTAL|circumferential PV and BOX isolation with substrate ablation|Atrial substrate ablation apart from circumferential PV and BOX isolation
62152839|NCT06509295|PLACEBO_COMPARATOR|Calcium Hypochlorite as root canal Irrigant on Postoperative Pain and bacterial load reduction|Treatment with Calcium Hypochlorite as root canal Irrigant
62152840|NCT06509295|ACTIVE_COMPARATOR|Sodium Hypochlorite as a root Canal Irrigant|Treatment with Sodium Hypochlorite as root canal Irrigant
62152841|NCT03518450|ACTIVE_COMPARATOR|Femoral Nerve Block|Ultrasound guided femoral nerve block, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
62152842|NCT03518450|ACTIVE_COMPARATOR|Adductor Canal Block|Ultrasound guided adductor canal block, at the proximal third of the canal, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
62525750|NCT05001932|ACTIVE_COMPARATOR|Mono-vision|Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant myopia of -2.50D.
62525751|NCT05001932|ACTIVE_COMPARATOR|Minimono-vision|Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant -1.25D.
62525752|NCT05001932|ACTIVE_COMPARATOR|Monofocal|Patients will receive a monofocal lens bilateral. Target refraction will be -0.25D.
62713226|NCT04466969||stages of CKD (stage 5)|"CKD is diagnosed based on the following eGFR categories:~eGFR \<15 mL/min/1.73m2"
62713227|NCT04466969||Treated by potassium binders|Patients who have been treated by Potassium Binders
62713228|NCT01287494|EXPERIMENTAL|Depression Care Management|"DCM Intervention for Depressed Elders in Primary Care~* Treatment guidelines (TG): Eight weeks treatment with Sertraline, another 8 weeks treatment augmentation with Bupropion if patients fail to respond in the initial trial, For more complicated cases, the transfer to psychiatrists is indicated.~* Care managers: Screening, Adherence support, psychoeducation and communication.~* Psychiatric Consultation"
62713229|NCT01287494|NO_INTERVENTION|Care as Usual|
62713230|NCT01040156||LAmb|
62713231|NCT01040156||Cas|
62525753|NCT05211076|EXPERIMENTAL|Music Group|"In the selection of the music to be played,Rast,Uşşak,Kürdi,Muhayyer modes were chosen by taking expert opinion.Before starting the music application,the selected music will be sent to the mothers in this group by the researcher over the internet to the mother's phone and it will be ensured that the mother listens to the music transmitting the sound from her own phone in each session.~* Music practice will take place in mothers' rooms or in the NICU.~* The room will be quiet and your mother will be alone.~* To make the mother listen to music;The mother will be asked to sit on the bed/seat in a comfortable position.~* At the same time,the mother will be asked to close her eyes and be relaxed.~* Later, music will be turned on from the mother's phone, allowing the mother to listen to music for 30 minutes~* While the mother listening to the music,at the 16th minute of the music,researcher will manually express each breast separately for at least 15 minutes until no milk comes out"
62525754|NCT05211076|EXPERIMENTAL|Marmet Technique Group|Marmet Technique is one of the non-pharmacological methods used to increase milk production.The Marmet Technique is a combined method that includes breast massage and manual milking.The Marmet Technique will be performed in the mothers' rooms or in the Breastfeeding Room of the Neonatal Intensive Care Unit. It will be ensured that the mother is comfortable by paying attention to her privacy. Mothers will be manually milked into the hopper in their own milking set. In addition, the reservoir will be used after washing with hot water. This technique consists of two stages, these stages are emptying the milk ducts and stimulating the milk stroke reflex (massage).
62525755|NCT05211076|EXPERIMENTAL|control group|On the other hand, no application will be made to the control group, and the milking process will be carried out manually by the researcher for at least 15 minutes until the milk does not come.
62525756|NCT02848911|EXPERIMENTAL|AFM11|IV (intravenous) infusion, dose escalation
62525757|NCT05686083|ACTIVE_COMPARATOR|12.5 g of C6 ketone di-ester|Low dose of C6 ketone di-ester.
62525758|NCT05686083|ACTIVE_COMPARATOR|12.5 g of novel ketone di-ester|Low dose of novel ketone di-ester.
62525759|NCT05686083|ACTIVE_COMPARATOR|25 g of novel ketone di-ester|High dose of novel ketone di-ester.
62525760|NCT04412148|ACTIVE_COMPARATOR|Intralesional Steroids|
62525761|NCT04412148|PLACEBO_COMPARATOR|Control|
62525762|NCT05423444|EXPERIMENTAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused Cognitive Behavioral Therapy (TF-CBT) is an evidence-based psychotherapy that is considered the gold-standard treatment for trauma in youth. The TF-CBT model is flexible but it follows a specific order of phases and components, including psychoeducation, emotion regulation skills, processing the trauma narrative, and safety planning. Sessions are provided weekly for 18-weeks.
62525763|NCT05423444|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment as usual (TAU) consists of the standard-of-care psychotherapy as provided by licensed clinicians at a local clinic. The order and choice of techniques is based on the knowledge and preferences of the clinicians. Sessions are provided weekly for 18-weeks.
62525764|NCT05969379||Patients with neurological immune-related adverse events (n-irAEs)|Patients developing neurological syndromes related to administration of any immune checkpoint inhibitors, including central nervous system disorders and neuromuscular toxicties
62525765|NCT04503395|EXPERIMENTAL|ESAR|Endovascular Aneurysm Repair + Heli-FX EndoAnchors
62525766|NCT04503395|ACTIVE_COMPARATOR|FEVAR|Fenestrated EndoVascular Aneurysm Repair
62152843|NCT03518450|EXPERIMENTAL|Apex Femoral Triangle Block|Ultrasound guided femoral triangle block, at the distal third of the triangle, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
62152844|NCT03422705|SHAM_COMPARATOR|Standard of care|No intervention - no programming, no medical intervention.
62525767|NCT00172536|OTHER|Control|Received oral general education about proper diet, regular physcial activity and other medical care if necessary
62525768|NCT00172536|EXPERIMENTAL|Exercise training|Received a supervised structure treadmill training
62525769|NCT06171607|EXPERIMENTAL|Diagnostic (contrast agent, CEUS)|Patients receive a contrast tracer (Lumason or DEFINITY) IV and then undergo CEUS scan over 60-90 minutes.
62525770|NCT01941355|EXPERIMENTAL|Exercise training, psycho-educative|
62525771|NCT01941355|EXPERIMENTAL|Psycho-educative component|
62525772|NCT01941355|EXPERIMENTAL|Exercise training component|
62152845|NCT03422705|EXPERIMENTAL|Optimised programming|Optimised pacemaker programming to avoid right ventricular pacing.
62152846|NCT03422705|EXPERIMENTAL|Medical therapy|Lisinopril uptitrated to optimally tolerated dose.
62152847|NCT02367248|ACTIVE_COMPARATOR|Deferoxamine|Deferoxamine mesylate supplied in vials containing 500 mg of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water.
62525773|NCT01941355|NO_INTERVENTION|Usual care|
62525774|NCT00857584|EXPERIMENTAL|Quetiapine Extended Release|Lithium or valproate at stable doses within seric therapeutic levels
62525775|NCT00857584|ACTIVE_COMPARATOR|Sertraline|Lithium or valproate at stable doses within seric therapeutic levels
62525776|NCT01169532|EXPERIMENTAL|Treatment (ridaforolimus and vorinostat)|Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62152848|NCT02367248|ACTIVE_COMPARATOR|Xingnaojing injection|Xingnaojing injection supplied in vials containing 20 ml liquid xingnaojing.
62525777|NCT02964949|EXPERIMENTAL|Edoxaban 75 mg|Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
62152849|NCT02367248|PLACEBO_COMPARATOR|Normal Saline|0.9% sodium chloride
62152850|NCT05920538|EXPERIMENTAL|Nicardipine|Using nicardipine 0.5 mg(0.5ml) subcutaneously infiltrated by ultrasound before redial artery cannulation.
62152851|NCT05920538|PLACEBO_COMPARATOR|Normal saline|Using normal saline 0.5ml subcutaneously infiltrated by ultrasound before redial artery cannulation
62152852|NCT01350167|ACTIVE_COMPARATOR|Triphasic CT|Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
62525778|NCT02964949|ACTIVE_COMPARATOR|Edoxaban 60 mg|Edoxaban 60 mg + placebo 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
62525779|NCT02673996||Postural Tachycardia Syndrome (POTS)|Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol
62525780|NCT02673996||Healthy (control) Subjects|Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol
62525781|NCT04919863|EXPERIMENTAL|NTP42:KVA4|
62525782|NCT04919863|PLACEBO_COMPARATOR|Placebo|
62525783|NCT02963441||DME|"Center-involved macular edema based on WRC of macular Optical Coherence Tomography images~Clinically Significant macular edema based on WRC grading of widefield stereo color fundus photographs.~Sample Size: \~45 subjects with DME"
62525784|NCT00891748|EXPERIMENTAL|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
62525785|NCT02435836|EXPERIMENTAL|Aripiprazole|All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
62525786|NCT02944370|EXPERIMENTAL|PlayFit, Modified exercise games|Subjects will participate in three 60 minute game sessions each week for 12 weeks. During each game session, subjects will be divided randomly into two teams to play a modified game. Research staff will review the instructions of the game and if needed, modify the game rules during play to enhance the experience (ie. keep it fun, keep it to moderate intensity level). The length of play session between breaks increases each week.
62525787|NCT02394730|EXPERIMENTAL|vorapaxar|2.5mg of vorapaxar po qd
62525788|NCT02394730|PLACEBO_COMPARATOR|Placebo|sugar pill po qd
62525789|NCT00725751||PegIFN-2b/ribavirin with substitution therapy|Participants in this cohort received antiviral treatment and substitution therapy (opioid medicines with long-lasting effects \[methadone + buprenorphine\] or morphine)
62525790|NCT00725751||PegIFN-2b/ribavirin without substitution therapy|Participants in this cohort received antiviral treatment but did not receive substitution therapy (opioid medicines with long-lasting effects \[methadone + buprenorphine\] or morphine)
62525791|NCT01400386|EXPERIMENTAL|Soluble coffee 1|
62525792|NCT01400386|EXPERIMENTAL|Soluble coffee 2|
62525793|NCT01400386|EXPERIMENTAL|Soluble coffee 3|
62525794|NCT01400386|EXPERIMENTAL|Soluble coffee 4|
62525795|NCT04030182||Level of vitamin D|Level in blood sample of vitamin D for each patient
62525796|NCT04525638|EXPERIMENTAL|177Lu-DOTATATE + Nivolumab|Patients will receive 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion and 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
62525797|NCT01884662|EXPERIMENTAL|Virtual walking|A 3D video of legs walking from a first person perspective have been developed in consultation with persons with SCI and virtual reality experts. Participants are provided with a 3D monitor and Blue Ray player for daily viewing of the tape for two weeks.
62713232|NCT03844308|EXPERIMENTAL|Group 1|Participants will be asked to complete Isha Kriya meditation twice daily for a total of six weeks in phase 1.
62713233|NCT03844308|ACTIVE_COMPARATOR|Group 2|Participants will be asked to refrain from meditating for the first 6 weeks (phase 1) and then asked to complete Isha Kriya meditation for another 6 weeks (phase 2)
62152853|NCT01350167|ACTIVE_COMPARATOR|Ultrasound|Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
62525798|NCT01884662|ACTIVE_COMPARATOR|Wheeling tape|A 3D video was produced of legs in a wheelchair covering the identical conditions of the walking experimental video.
62525799|NCT03762941||Elderly patients acutely admitted|Elderly patients (aged ≥ 65 year) admitted to emergency departments at the Hospital of Southern Jutland or Odense University
62525800|NCT02862496||hyperemesis gravidarum|hyperemesis gravidarum group consisting of 30 pregnant women between 7-20 weeks of gestation with diagnosed hyperemesis gravidarum.
62713234|NCT04573855|EXPERIMENTAL|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
62713235|NCT04573855|NO_INTERVENTION|Control|
62713236|NCT06662279|ACTIVE_COMPARATOR|Invisalign Palatal Expander|
62152854|NCT02893618|EXPERIMENTAL|DCCR 75 mg fasted|Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
62152855|NCT02893618|EXPERIMENTAL|DCCR 150 mg fasted|Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
62525801|NCT02862496||Control group|control group consisting of 30 health pregnant women between 7-20 weeks of gestation with excluded hyperemesis gravidarum.
62525802|NCT02148679|EXPERIMENTAL|DASH/SRD|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions~Intervention: pre-prepared, home delivered DASH/SRD-compliant meals for 4 weeks after hospital discharge"
62525803|NCT02148679|PLACEBO_COMPARATOR|Attention Control|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions"
62525804|NCT02933021||All participants|Nurse visit for blood sample, questionnaire and phone call
62525805|NCT02377518|EXPERIMENTAL|oncologic patients|"Prediction of postoperative pulmonary function.~Patients with an operable lung cancer: dual energy computed tomography with Krypton will be tested to estimate the postoperative FEV1"
62525806|NCT02377518|EXPERIMENTAL|lung transplant recipients|"Detection of BOS~6 months+ lung transplant recipients will be tested using dual energy computed tomography with Krypton, with acquisition in the end-inspiratory and end-expiratory phase, in search of regional air trapping."
62713237|NCT06662279|ACTIVE_COMPARATOR|Hyrax Expander|
62713238|NCT05626634|EXPERIMENTAL|LP352, bexicaserin|Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 48-week maintenance period and a 15-day taper/down titration period.
62713239|NCT06290388|EXPERIMENTAL|Phase 1|Participants will receive escalating doses of 23ME-01473
62713240|NCT05537389|NO_INTERVENTION|Control|Patients with central venous access (central umbilical venous catheter or epicutaneous cava catheter)
62713241|NCT05537389|EXPERIMENTAL|Filter|Patients with central venous access and in-line filters (central umbilical venous catheter or epicutaneous cava catheter)
62152856|NCT02893618|EXPERIMENTAL|DCCR 300 mg fasted|Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
62152857|NCT02893618|EXPERIMENTAL|DCCR 450 mg fasted|Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
62525807|NCT03939299|EXPERIMENTAL|OCT group|Patients, whose coronary chronic total occlusion lesion was successfully implanted stent, received optical coherence tomography imaging immediately and at 9-12 months after index procedure.
62713242|NCT00784121|EXPERIMENTAL|1|Lactic Acid (Dermacyd Breeze)
62713243|NCT06362005|PLACEBO_COMPARATOR|group I (triamcinolone)|ten patients with oral lichen planus, will receive topical triamcinolone acetonide 0.1% four times per day for six weeks.
62713244|NCT06362005|PLACEBO_COMPARATOR|group II (tacrollimus)|ten patients with oral lichen planus, will receive topical tacrolimus 0.1% four times per day for six weeks.
62713245|NCT06362005|EXPERIMENTAL|group III (selenium)|ten patients with oral lichen planus, will receive topical selenium four times per day for six weeks.
62713246|NCT06362005|EXPERIMENTAL|group IV (selenium + triamcinolone )|: ten patients with oral lichen planus, will receive topical selenium combined with topical triamcinolone acetonide 0.1% three times per day for each for six weeks
62152858|NCT02893618|EXPERIMENTAL|DCCR 300 mg fed|Administered a single 300 mg dose of DCCR after a standardized meal
62152859|NCT06115070|EXPERIMENTAL|Thrombolysis group|intravenous alteplase (0.9 mg/kg; maximum dose, 90mg; 10% administered as a 1-minute bolus, the remaining infused over 1 hour;
62152860|NCT06115070|NO_INTERVENTION|Control group|according to guideline
62152861|NCT03898999||Older adult|Individuals belonging to the population group of the elderly (60 years or more)
62152862|NCT02430259|EXPERIMENTAL|Weekly Isoniazid / Rifapentine|Weekly INH / RRT given by DOT
62152863|NCT02430259|NO_INTERVENTION|No preventive treatment|Follow up without intervention
62152864|NCT05291403|EXPERIMENTAL|Experimental group (medical thoracoscopic cryotherapy)|
62152865|NCT05291403|ACTIVE_COMPARATOR|Cisplatin/erythromycin control group (sequential intrathoracic injection of cisplatin/erythromycin)|
62525808|NCT01644552||eye examinations|
62525809|NCT05162365|EXPERIMENTAL|IBI314|a cocktail of two SARS-CoV-2 S protein IgG1 antibodies, IBI314-A and IBI314-B, in a 1:1 \[w/w\] ratio
62525810|NCT05162365|PLACEBO_COMPARATOR|Placebo|
62525811|NCT02302664|ACTIVE_COMPARATOR|PRP Injection|Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
62525812|NCT02302664|SHAM_COMPARATOR|Imitation Injection|Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
62525813|NCT03868462|OTHER|Optical Coherence Tomography (OCT)|
62525814|NCT01907126|EXPERIMENTAL|Women's Prison CoOp (WPC)|Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
62525815|NCT01907126|PLACEBO_COMPARATOR|Nutrition program (NP)|Participants in this condition will receive dose-matched nutrition education.
62525816|NCT00678041|EXPERIMENTAL|Arm 1: Nitrofurantoin Group|extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
62525817|NCT00678041|PLACEBO_COMPARATOR|Arm 2: Placebo Group|identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
62525818|NCT02603302|EXPERIMENTAL|Locally advanced rectal cancer|"RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU~Surgery 8 weeks after the neoadjvuant treatment."
62525819|NCT02568566|EXPERIMENTAL|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
62525820|NCT00845806||Arabic Speakers|All subjects must be male native arabic speakers who can read and speak english.
62525821|NCT01374126|EXPERIMENTAL|Azithromycin-Artesunate|
62525822|NCT01374126|ACTIVE_COMPARATOR|Control (artesunate alone)|
62525823|NCT01461226|EXPERIMENTAL|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
62525824|NCT01461226|OTHER|Usual Care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
62525825|NCT02195466|EXPERIMENTAL|TPV + RTV + FCZ|
62525826|NCT04890951||Uterine Preservation|
62525827|NCT04890951||Hysterectomy|
62713247|NCT06362005|EXPERIMENTAL|group V ( selenium + tacrollimus)|ten patients with oral lichen planus, will receive topical selenium combined with topical tacrolimus 0.1% three times per day for each for six weeks.
62713248|NCT04326179||Age 0 to 4 at day of visit|This study is based on chart reviews of data collected as part of clinical care. Data collected as part of this study will not directly inform the care of participating patients and families.
62152866|NCT05291403|OTHER|Blank control group|Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.
62152867|NCT03323294||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and \<85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
62525828|NCT04191837|EXPERIMENTAL|Self-administered acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
62525829|NCT04191837|ACTIVE_COMPARATOR|Knee health education|A course regarding knee health will be offered to the subjects in this group.
62525830|NCT03668561|EXPERIMENTAL|Treatment (CALIGALOC)|Wearing of the Caligaloc orthosis
62525831|NCT01688076|EXPERIMENTAL|Muscle contractions|Under supervision by study personnel, subjects be asked to make active muscle contractions for one hour after Botox injections. Subjects will return for follow-up visits.
62713249|NCT05589298||PSODEEP1 Sweden|Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Sweden.
62713250|NCT05589298||PSODEEP1 Denmark|Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Denmark.
62713251|NCT05589298||PSODEEP1 Chile|Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Chile.
62713252|NCT05589298||PSODEEP1 Netherlands|Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in the Netherlands.
62713253|NCT03838744|ACTIVE_COMPARATOR|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy at the dose 1.5 or 1.3 mg/m2 (according institutional practice) given as intravenous infusion at day 1 every 3 weeks (21 days cycle)
62713254|NCT03838744|EXPERIMENTAL|Experimental arm: Trabectedin + Olaparib|Trabectedin at the dose 1.1mg/m2 given as intravenous infusion at day 1 every 3 weeks (21 days cycle) plus Olaparib per os at the dose of 150 mg twice a day
62152868|NCT03323294||Healthy Obese|Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
62525832|NCT01688076|ACTIVE_COMPARATOR|No muscle contractions|Patients will be asked to not perform muscle contractions following Botox injections.
62525833|NCT03493386|EXPERIMENTAL|Treatment Group A: Part 1|Subjects will be randomized to receive single dose of two tablets of 2 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
62525834|NCT03493386|EXPERIMENTAL|Treatment Group B: Part 1|Subjects will be randomized to receive single dose of 4 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of two tablets of 2 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
62525835|NCT03493386|EXPERIMENTAL|Treatment Group C: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
62152869|NCT03323294||Obese Insulin Resistant|Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.
62152870|NCT03323294||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance (n=20)
62152871|NCT03950726||Study Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection through the same incision
62152872|NCT03950726||Control Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection who underwent standard laparoscopic resection
62152873|NCT01354288|EXPERIMENTAL|Therapeutic education|
62152874|NCT01354288|NO_INTERVENTION|Classical management|
62152875|NCT02935673|EXPERIMENTAL|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
62152876|NCT02935673|EXPERIMENTAL|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
62152877|NCT02935673|EXPERIMENTAL|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
62152878|NCT02354417|EXPERIMENTAL|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:~For subjects \> 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to \~1 hour."
62525836|NCT03493386|EXPERIMENTAL|Treatment Group D: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fasted state during period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fed state. There will be a wash-out period of 5 days between the Periods.
62525837|NCT06004219|EXPERIMENTAL|Peer Support Group|Patients will be asked to complete a health-related quality of life (HRQOL) survey at enrollment, 3 months, and end of the study. Participants will complete the VascuQoL-6 and PROMIS in several domains of HRQOL (including global physical function, global mental function, fatigue, depression, sleep disturbance, pain behavior, and social satisfaction). Each participant will complete the PROMIS CAT tool on an iPad App and the data will be stored in the secure REDCap
62525838|NCT06004219|NO_INTERVENTION|Usual Care Group|Subjects in this group will not participate in the peer group.
62713255|NCT01769924||Live kidney donors|Nephrectomy
62713256|NCT01769924||Healthy controls|Who also meet criteria to donate a kidney
62713257|NCT06229119|OTHER|ICL|ICL implantation
62713258|NCT05061030|ACTIVE_COMPARATOR|Wharton's jelly derived mesenchymal stromal cells (Protrans)|Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects \< 50 kg and 200 million cells to subjects 50-100 kg (\>100 kg is an exclusion criterion).
62713259|NCT05061030|PLACEBO_COMPARATOR|Placebo|Placebo (saline) is given intravenously over a period of 20-40 min.
62713260|NCT05488054|EXPERIMENTAL|Healthy Individuals|Healthy control patients with no history of knee or hip surgery for comparison of baseline values
62713261|NCT05488054|EXPERIMENTAL|Surgical Patients|Patients who have undergone arthroscopic ACL surgery or arthroscopic hip surgery and are undergoing physical therapy for return to sport
62713262|NCT05318781||Patients undergoing bariatric surgery|Adult patients (≥ 30y yrs.) scheduled to undergo a first bariatric surgery recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal \[N=120\]
62525839|NCT04375683|EXPERIMENTAL|Ph-positive ALLs|Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen. Subjects younger than 60 years are received flumatinib and hyper-CVAD regimen
62713263|NCT05318781||Patients on the bariatric surgery waitlist|Age-, sex-, and BMI-matched waitlist control group \[awaiting for bariatric surgery\] recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal \[N=60\]
62713264|NCT05318781||Non-bariatric eligible individuals|"Age-and sex-matched individuals who are not eligible for bariatric surgery, as an additional non-bariatric comparison group \[N=60\]~\*The 60 age-and sex-matched non-bariatric participants will have data captured just once \[at baseline\] on a limited number of key assessments"
62713265|NCT02550145|EXPERIMENTAL|Exendin(9-39)|IV infusion of Exendin (9-39).
62713266|NCT02550145|PLACEBO_COMPARATOR|Placebo|IV infusion of normal saline
62713267|NCT05192915|OTHER|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
62525840|NCT04884867|EXPERIMENTAL|Supportive life skills coaching|CBT-based supportive like skills delivered by phone by lay coaches
62525841|NCT02423356||Echocardiography|All patients will receive 4 echocardiograms and 4 blood draws. The blood draws and echocardiograms will occur at the same visits.
62525842|NCT05215769|EXPERIMENTAL|Health services research (video)|Patients participate in a video intervention session and complete questionnaires at baseline, after participating in the video intervention, and after receiving NGS results.
62713268|NCT03701243|EXPERIMENTAL|mNT-BBAVF|These patients will receive a modified non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) at elbow for hemodialysis acess.
62713269|NCT03701243|ACTIVE_COMPARATOR|RCAVF|These patients will receive a radiocephalic arteriovenous fistula (RCAVF) at wrist for hemodialysis acess.
62713270|NCT01060943|ACTIVE_COMPARATOR|KOKEN(collagen)|atelocollagen filler
62713271|NCT01060943|EXPERIMENTAL|TheraFill|atelocollagen filler
62713272|NCT01323192|EXPERIMENTAL|JNS001|
62713273|NCT01323192|PLACEBO_COMPARATOR|Placebo|
62713274|NCT05891899||Antithrombin deficient patients|patients with proven, inherited antithrombin deficiency
62713275|NCT06026813|EXPERIMENTAL|Healthy controls|Patients without diabetes who do not have foot wounds or history of amputation
62152879|NCT02915003|EXPERIMENTAL|E-health website intervention|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
62525843|NCT01345175|EXPERIMENTAL|Pts receiving Rifaximin|This group will receive rifaximin 400mg bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
62525844|NCT01345175|PLACEBO_COMPARATOR|Pts receiving placebo|This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
62713276|NCT06026813|EXPERIMENTAL|Patients with Diabetic Neuropathy|Patients with diagnosed diabetes and neuropathy who do not have foot wounds or history of amputation.
62713277|NCT00995852|ACTIVE_COMPARATOR|bilateral|"Treatment arm B - incomplete bilateral treatment of in total two lobes (contralateral).~The study will only use Intrabronchial Valves™"
62713278|NCT00995852|ACTIVE_COMPARATOR|unilateral|Treatment arm A - unilateral treatment with complete closure of the worst lobe of the lungs
62525845|NCT05255874|EXPERIMENTAL|Aromatherapy Group|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
62525846|NCT05255874|NO_INTERVENTION|Standard of care|Routine treatment and care interventions will be applied to the patients included in the control group during the procedure. Patients in the control group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level.
62525847|NCT01520532|OTHER|Ablation|
62713279|NCT05515744|EXPERIMENTAL|Intervention Arm 1|Intervention Arm 1 Experimental Initiation of Delivery by induction or planned cesarean at 37 weeks 0-2 days.
62713280|NCT05515744|EXPERIMENTAL|Intervention Arm 2|Intervention Arm 2 Experimental Initiation of Delivery by induction or planned cesarean at 37 weeks 3-5 days.
62713281|NCT05515744|EXPERIMENTAL|Intervention Arm 3|Initiation of Delivery by induction or planned cesarean at 37 weeks 6 days to 38 weeks and 1 day.
62713282|NCT05515744|EXPERIMENTAL|Intervention Arm 4|Intervention Arm 4 Experimental Initiation of Delivery by induction or planned cesarean at 38 weeks 2-4 days.
62713283|NCT05515744|EXPERIMENTAL|Intervention Arm 5|Initiation of Delivery by induction or planned cesarean at 38 weeks 5 days to 39 weeks and 0 days.
62713284|NCT05515744|EXPERIMENTAL|Intervention Arm 6|Intervention Arm 6 Experimental Initiation of Delivery by induction or planned cesarean at 39 weeks 1-3 days.
62525848|NCT00894738||antipsychotic treated|Children with psychiatric diagnoses who are currently treated with antipsychotic medications.
62713285|NCT05515744|EXPERIMENTAL|Intervention Arm 7|Intervention Arm 7 Experimental Initiation of Delivery by induction or planned cesarean at 39 weeks 4-6 days.
62525849|NCT00894738||healthy control|Age- and gender-matched children who do not have a psychiatric diagnosis, are not taking antipsychotic medications, and are otherwise healthy.
62525850|NCT03744871|ACTIVE_COMPARATOR|Respirator|Open label use of N95 respirators (worn outdoors) (active limb, n=100)
62713286|NCT06583733|ACTIVE_COMPARATOR|control group|"The control group which will receive recommendations for self- managing urinary symptoms.~There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach."
62525851|NCT03744871|NO_INTERVENTION|No intervention|No respirators will be worn by the control group (control limb, n=100)
62713287|NCT06583733|EXPERIMENTAL|intervention group|"The intervention group, which will receive the treatment with KOKU Bladder. There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach."
62713288|NCT06295679||Repatha® with Standard of Care Exposure|Participants with clinically evident ASCVD treated with Repatha® in combination with SOC in a clinical setting. To ensure that the recruitment strategy has as little impact on routine practice as possible, the decision to treat the participant with Repatha® with SOC will be made independently of, and before, enrollment in the study.
62713289|NCT06295679||Standard of Care Exposure|Participants with clinically evident ASCVD treated with SOC alone in a clinical setting. To ensure that the recruitment strategy has as little impact on routine practice as possible, the decision to treat the participant with SOC only will be made independently of, and before, enrollment in the study.
62152880|NCT02915003|NO_INTERVENTION|Control|usual health insurance navigation, and ACA materials provided by social service agencies and clinics where individuals seek services.
62152881|NCT02875704||Stargardt disease, AMD, DR patients|Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
62525852|NCT02754908|EXPERIMENTAL|Experimental group|In addition to medical follow-up, the subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation. Qualified orchestral performers will provide the musical training. Training will start at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song). The subjects will continue on to the next level if they successfully pass the relevant test; those who do not will be encouraged to repeat test.
62525853|NCT02754908|PLACEBO_COMPARATOR|Placebo Control group|"The subjects will receive medical follow-up according to the schedule of the oncology units.~They will receive the same amount of time and attention as those in the experimental group but not in a way designed to have any specific effect on the outcome measures. They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks)."
62525854|NCT02613013|ACTIVE_COMPARATOR|single LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris \>0.1mm. and patency was determined by direct visualization of the posterior chamber.
62525855|NCT02613013|EXPERIMENTAL|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure
62525856|NCT05075720|EXPERIMENTAL|Dietary Supplement: Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
62713290|NCT00288145|ACTIVE_COMPARATOR|T|Treatment arm comprises one worksite in a matched site pair; one site assigned to treatment, the other site assigned to comparison. Treatment site worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
62713291|NCT04850599|EXPERIMENTAL|Treatment (isatuximab, carfilzomib, pomalidomide)|Patients receive isatuximab IV over 30-60 minutes on days 1, 8, 15, and 22 of cycle 1, and days 1 and 15 of subsequent cycles, carfilzomib IV over 10 to 30 minutes on days 1, 8, 15, and pomalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62152882|NCT02875704||Controls|Patients without retinal disease who will be undergoing cataract surgery
62152883|NCT02089945||transcatheter aortic valve implantation|This study recruits individuals that are undergoing transcatheter aortic valve implantation.
62152884|NCT03147222|EXPERIMENTAL|Fracture Care at Home|A trained FFC coach will visit each caregiver and fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
62152885|NCT00923078|EXPERIMENTAL|Auditory-Visual Train Order|4 weeks (20 sessions) of auditory cognitive training (Brain Fitness) followed by 4 weeks (20 sessions) of visual cognitive training (Insight)
62152886|NCT00923078|EXPERIMENTAL|Visual-Auditory Train Order|4 weeks (20 sessions) of visual cognitive training (Insight) followed by 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness)
62525857|NCT05075720|EXPERIMENTAL|Dietary Supplement: Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
62525858|NCT05075720|SHAM_COMPARATOR|Dietary Supplement: Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
62525859|NCT05705817|EXPERIMENTAL|Treatment|
62525860|NCT00910091|EXPERIMENTAL|A- BN 83495- 40mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
62525861|NCT00910091|ACTIVE_COMPARATOR|B- MA - 160mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
62525862|NCT02733315|EXPERIMENTAL|DCMP|
62525863|NCT00700609|EXPERIMENTAL|1|"Attachment Based Family Therapy (ABFT)~ABFT developed by Dr. Guy Diamond and colleagues is a brief, 12 week, manualized family-based intervention."
62525864|NCT00700609|ACTIVE_COMPARATOR|2|"Treatment as usual (TAU)~No attempt is made to standardize TAU. Regular clinical staff will provide mental health services."
62525865|NCT06056011|EXPERIMENTAL|Oral Temperature Measurement|Oral temperature measurements for subjects age Group C as 5 years or older. Both febrile and non-febrile subjects included in this arm.
62525866|NCT06056011|EXPERIMENTAL|Axillary Temperature Measurement|"Adult Axillary temperature measurement supports age Group C where C contains 18 years and older subjects.~Pediatric Axillary temperature measurement supports newborn to 5 years and less than 18 years old.~Both febrile and non-febrile subjects included in this arm."
62525867|NCT06056011|EXPERIMENTAL|Rectal Temperature Measurement|Rectal temperature measurements for all age groups (newborn to subjects older than 18 years of age) with no restrictions. Both febrile and non-febrile subjects included in this arm.
62525868|NCT01661699||Sleep apnea|Those suspected of sleep apnea and scheduled for polysomnography and treated with CPAP therapy.
62713292|NCT02503423|EXPERIMENTAL|Phase 1 - Part 1 (completed)|Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, \[7 days on/ 7 days off\] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
62713293|NCT02503423|EXPERIMENTAL|Phase 1 - Part 2 (completed)|Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
62525869|NCT01878487|OTHER|Only one arm|All patients will receive the same treatment, i.e. there is no randomization. There is therefore only one arm, all patients will by treated as per standard practice with thrombus aspiration and stenting as required, the lumen size of the vessel will be assessed with intravascular ultrasound at baseline, after thrombus aspiration and after stenting.
62525870|NCT02925819||SEVERE MITRAL VALVE DISEASE|All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
62525871|NCT02372071|OTHER|BiliCare|Two measurements with the BiliCare device
62713294|NCT02503423|EXPERIMENTAL|Phase 1 - Part 3 (optional)|The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
62713295|NCT02503423|EXPERIMENTAL|Phase 2 - Cohort 1|Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
62713296|NCT02503423|EXPERIMENTAL|Phase 2 - Cohort 2|Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
62713297|NCT02503423|EXPERIMENTAL|Phase 2 - Cohort 3|Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
62713298|NCT02503423|EXPERIMENTAL|Phase 2 - Cohort 4|Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
62525872|NCT01878162|EXPERIMENTAL|Exercise|Exercise will occur 3 times weekly for 6 months in 20-minute exercise sessions. Sessions will take place independently. Follow-up and progression of the home program will be completed in person or by video teleconferencing at regular intervals throughout the intervention phase.
62525873|NCT03460769||Pancreatic Cancer|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
62525874|NCT03460769||Chronic Pancreatitis|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
62525875|NCT03460769||Type 3c Diabetes Mellitus|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
62525876|NCT00823121|ACTIVE_COMPARATOR|frozen-embryo transfer|In this group all embryos are cryopreserved and two months later embryo transfer will perform.
62152887|NCT01005030||PostCEPT Subjects|Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
62152888|NCT01005030||Control Subjects|Non-blood relatives of PostCEPT Subjects matched for age and other demographics
62525877|NCT00823121|ACTIVE_COMPARATOR|fresh embryo transfer|In this arm fresh embryo transfers are performed on day 2 or 3.
62152889|NCT05280509|EXPERIMENTAL|Phase 1b - Dose Level 1|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
62152890|NCT05280509|EXPERIMENTAL|Phase 1b - Dose Level 2|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
62152891|NCT05280509|EXPERIMENTAL|Phase 1b - Dose Level 3|450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
62525878|NCT02016313|EXPERIMENTAL|Immediate therapy|Physiotherapy protocol
62152892|NCT05280509|EXPERIMENTAL|Phase 2 - Cohort 1 JAKi treatment-naïve MF|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose of ruxolitinib will be based on the subject's baseline platelet count."
62525879|NCT02016313|PLACEBO_COMPARATOR|waiting list|Physiotherapy protocol
62525880|NCT00512382||A|Babies and small children 1-24 months
62525881|NCT00512382||B|Children 2-18 years old
62525882|NCT03916302||Complicated outcome|"The patients meet at least one of the following criteria:~1. systolic blood pressure \< 90 mmHg for at least 15 minutes~2. need for catecholamine administration because of persistant arterial hypotension or shock~3. need for mechanical ventilation~4. need for cardiopulmonary resuscitation~5. bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
62525883|NCT03916302||Non-complicated outcome|"The patients meet none of the following criteria:~1. systolic blood pressure \< 90 mmHg for at least 15 minutes~2. need for catecholamine administration because of persistant arterial hypotension or shock~3. need for mechanical ventilation~4. need for cardiopulmonary resuscitation~5. bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
62525884|NCT04962984|EXPERIMENTAL|THAL +|patients with beta thalassemia major, requiring blood transfusion regimen. Additional blood sampling will be performed before and immediately after transfusion (21 millilters and 24 millilters respectively), on the occasion of 3 programed transfusions (consecutive or not).
62525885|NCT04962984|SHAM_COMPARATOR|THAL -|Patients with beta thalassemia trait, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
62525886|NCT04962984|SHAM_COMPARATOR|Healthy volunteers|healthy subjects, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
62525887|NCT02489019|PLACEBO_COMPARATOR|Control|Individuals assigned to this condition will receive 0.9 mcg/kg sodium chloride (NaCL)
62525888|NCT02489019|EXPERIMENTAL|Low Dose|Individuals assigned to this condition will receive 1 mcg/kg fentanyl
62525889|NCT02489019|EXPERIMENTAL|High Dose|Individuals assigned to this condition will receive 2 mcg/kg fentanyl
62525890|NCT05377593|ACTIVE_COMPARATOR|eminoplasty with patient specific Titanium onlay implant|
62525891|NCT05377593|ACTIVE_COMPARATOR|eminoplasty with patient specific zirconium dioxide onlay implant|
62525892|NCT03254030|PLACEBO_COMPARATOR|Inspection on withdrawal|Participants colonic mucosa will be examined only during withdrawal phase of the examination.
62525893|NCT03254030|ACTIVE_COMPARATOR|Inspection on insertion and withdrawal|Participants colonic mucosa will be examined during insertion and withdrawal phase of the examination
62525894|NCT01321008|EXPERIMENTAL|Radiation + Chemotherapy|Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.
62525895|NCT02212002||Control|Control group: infants born to GBS-negative mothers, who thus did not receive any antibiotic treatment before/at delivery.
62525896|NCT02212002||IAP|IAP group: infants born to GBS-positive mothers who have received adequate intrapartum antibiotic prophylaxis (IAP). According to the Institutional treatment protocol for GBS prophylaxis (derived from CDC guidelines), intravenous ampicillin is given every 4 hours until delivery (first dose 2 g, following doses 1 g each). IAP is considered adequate when the mother received at least two doses of ampicillin before delivery.
62152893|NCT05280509|EXPERIMENTAL|Phase 2 - Cohort 2 suboptimal response to Ruxolitinib|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose schedule will be the stable ruxolitinib dose schedule as the subject is currently taking prior to entry into the study."
62152894|NCT00417885|EXPERIMENTAL|A|sunitinib + exemestane
62152895|NCT00334438|OTHER|Zevalin + Velcade Single Arm Study|Zevalin (Ibritumomab Tiuxetan) and Velcade (Bortezomib)
62525897|NCT04751292||Lowlanders|People living at low (\<1500 m) altitude
62525898|NCT04751292||Highlanders|People living at high (\>2500 m) altitude
62525899|NCT02743234|EXPERIMENTAL|FMT|Fecal microbiota transplantation (FMT) following 4-10 days of vancomycin 125 mg x 4, using cryopreserved feces from a healthy anonymous donor
62525900|NCT02743234|ACTIVE_COMPARATOR|Fidaxomicin|10 days fidaxomicin 200 mg x 2 daily
62525901|NCT02743234|ACTIVE_COMPARATOR|Vancomycin|10 days vancomycin 125 x 4 daily
62525902|NCT03585465|EXPERIMENTAL|A: Cyclophosphamide Vinblastine Nivolumab|This arm was applicable to first stage, and is closed
62525903|NCT03585465|EXPERIMENTAL|B: Capecitabine Nivolumab|This arm was applicable to first stage, and is closed
62525904|NCT03585465|EXPERIMENTAL|C: Cyclophosphamide Vinblastine Capecitabine|This arm was applicable to first stage, and is closed
62525905|NCT03585465|EXPERIMENTAL|"Metronomic CT "|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine)~This arm is applicable to second stage, and 43 patients are expected"
62525906|NCT03585465|EXPERIMENTAL|"Metronomic CT + Nivolumab"|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine) + Nivolumab~This arm is applicable to second stage, and 43 patients are expected"
62525907|NCT05600504||No depression|no intervention
62525908|NCT05600504||Depression|no intervention
62525909|NCT00327288|EXPERIMENTAL|A|Docetaxel plus imexon
62525910|NCT02373748|EXPERIMENTAL|BioGaming YuGo System|
62525911|NCT05177172|PLACEBO_COMPARATOR|Control|White wheat flour bread
62525912|NCT05177172|EXPERIMENTAL|High betaglucans|White wheat flour bread included beta glucans with the highest amounts in this study
62525913|NCT05177172|EXPERIMENTAL|Low beta glucans|White wheat flour bread included beta glucans with the lowest amounts in this study
62525914|NCT05177172|EXPERIMENTAL|Low beta glucans + low polar lipids|White wheat flour bread included a combination of the lowest amounts of beta glucans and polar lipids
62525915|NCT05177172|EXPERIMENTAL|low polar lipids|White wheat flour bread included polar lipids
62525916|NCT04761458|EXPERIMENTAL|Patients scheduled for elective surgery aged 65 and +|
62525917|NCT04040153|EXPERIMENTAL|Guiding Good Choices|Enrollment in the intervention, Guiding Good Choices, a substance use initiation prevention program, will be recommended by the pediatrician to parents of those adolescents empaneled with an intervention arm pediatrician
62525918|NCT04040153|NO_INTERVENTION|Control|Parents of adolescents empaneled with a control arm pediatrician will not be offered Guiding Good Choices
62525919|NCT02005887|EXPERIMENTAL|triptorelin + letrozole|Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles
62525920|NCT02005887|EXPERIMENTAL|degarelix + letrozole|Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles
62152896|NCT02410109|EXPERIMENTAL|SCRIPT intervention|
62152897|NCT02410109|NO_INTERVENTION|Historical Control|
62152898|NCT05887609|EXPERIMENTAL|Safety Lead In|
62152899|NCT05887609|EXPERIMENTAL|Treatment|"All patients will receive MIRV at 5mg/kg AIBW administered through IV infusion on Day 1 of every 3-week cycle (Q3W).~All patients will receive Olaparib at 300mg taken orally twice daily with or without food. Dosage and administration will follow current single-agent Olaparib package insert dosage and administration guidelines.~Patients will continue to receive MIRV and Olaparib until PD, unacceptable toxicity, withdrawal of consent, or death, whichever comes first. If toxicity deems the patient to discontinue one drug, the patient may continue the other drug until PD, unacceptable toxicity, withdrawal of consent, or death, whichever comes first."
62152900|NCT06284356||Patients without complications after LSG|
62152901|NCT06284356||Patients with complications after LSG|
62152902|NCT06284356||Control Group|
62152903|NCT05602961|EXPERIMENTAL|Cohort 1 (includes GLB-COV2-043 15 μg)|12 eligible adult participants will be randomized to 15 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
62525921|NCT05367726||patients having had skin coverage of the knee|patients having had skin coverage of the knee after or at the same time than an orthopedic surgery to treat a knee prosthesis infection
62525922|NCT01912274|EXPERIMENTAL|Pracinostat with azacitadine|60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable
62525923|NCT05931666|EXPERIMENTAL|Gong Mobilization|The subject placed in a side-lying position with the affected shoulder joint facing upward. and abducted at about 90 degrees to maintain the humerus vertical position with elbow in a 90-degree position. The therapist use one hand to keep the subject's elbow joint at 90 degrees, his elbow below the subject's elbow joint, and the other hand to press the humerus head from anterior to posterior. Therapist elevate own body, pulling on the articular capsule of the shoulder joint. This gentle pulling sustained for 10- 15 seconds before relaxing for 5 seconds; the whole manoeuver last roughly 2-3 minutes.
62525924|NCT05931666|EXPERIMENTAL|Kaltenborn Mobilization|Patient lies supine on the table with the arm abducted approximately to 55⁰. The therapist stands facing the lateral side of upper arm. The scapula is fixed using a towel. The therapist's right hand holds around the patients elbow \& forearm from the ventral side. Left hand holds around the humeral head with the thumb ventrally just distal to the acromion \& the direction of movement is towards caudal assisted by therapist's body. Also anterior and posterior glides are applied with patient positioned similarly in supine lying to improve mobility at the shoulder joint.
62525925|NCT01712737|EXPERIMENTAL|Snack foods: raisins|children were given ad libitum access to raisins for 15 min
62525926|NCT01712737|EXPERIMENTAL|Snack foods: grapes|children were given ad libitum access to grapes for 15 min
62525927|NCT01712737|EXPERIMENTAL|Snack foods: a mix of almonds with raisins|children were given ad libitum access to a mix of almonds with raisins for 15 min
62152904|NCT05602961|EXPERIMENTAL|Cohort 2 (includes GLB-COV2-043 30 μg)|12 eligible adult participants will be randomized to 30 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
62152905|NCT05602961|EXPERIMENTAL|Cohort 3 (includes GLB-COV2-043 60 μg)|12 eligible adult participants will be randomized to 60 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
62152906|NCT05602961|EXPERIMENTAL|Cohort 4 (includes GLB-COV2-043 90 μg)|12 eligible adult participants will be randomized to 90 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
62152907|NCT02948309|EXPERIMENTAL|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
62152908|NCT02948309|PLACEBO_COMPARATOR|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
62525928|NCT01712737|EXPERIMENTAL|Water control|children were given ad libitum access to water
62525929|NCT01183221|EXPERIMENTAL|Syntocinon then Placebo|24IU intranasal oxytocin, minimum of 3 weeks off, then placebo
62525930|NCT01183221|PLACEBO_COMPARATOR|Placebo then Syntocinon|Placebo, minimum of 3 weeks off, then 24IU intranasal oxytocin or placebo
62525931|NCT00289757|EXPERIMENTAL|Havrix Group|"Subjects who received 2 doses of Havrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Havrix Group for data analyses during the long term follow-up."
62713299|NCT02503423|EXPERIMENTAL|Phase 2 - Cohort 5|Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
62713300|NCT02503423|EXPERIMENTAL|Phase 2 - Cohort 6|Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
62152909|NCT00237809|EXPERIMENTAL|Drug and control CRT|D-serine/control
62152910|NCT00237809|EXPERIMENTAL|Drug and CRT|D-serine/cog rehab
62152911|NCT00237809|EXPERIMENTAL|Placebo Drug and Placebo CRT|Placebo/control
62152912|NCT00237809|EXPERIMENTAL|Placebo Drug and CRT|Placebo/cog rehab
62152913|NCT03187249|EXPERIMENTAL|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
62152914|NCT03187249|EXPERIMENTAL|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
62525932|NCT04848311|EXPERIMENTAL|ICG group|Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
62525933|NCT04848311|NO_INTERVENTION|CLgroup|Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.
62525934|NCT01725776|EXPERIMENTAL|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg(as for the injectable solution)
62525935|NCT03207841|EXPERIMENTAL|LC/HP group|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake. Dietary fat sources will focus on monounsaturated and polyunsaturated fats, e.g., plant oils and nuts; dietary carbohydrate sources will emphasize whole grains, fruits, vegetables, and legumes; and dietary protein sources will include lean meats, fish, chicken, eggs, and nonfat dairy foods, e.g., fat-free milk and low-fat cheese, consistent with American Diabetes Association and Institute of Medicine guidelines. All LC-HP meals will be provided by UAB Center for Clinical and Translational Sciences (CCTS) Bionutrition Unit and delivered to participants' homes 3 times/week (a sample menu is included in Appendix J). Every delivery will include breakfast, lunch, dinner, and snacks for 2 to 3 days.
62525936|NCT03207841|NO_INTERVENTION|Control|Control group will not receive the experimental diet and will continue with their usual diets. Participants will complete three 24-hour food recalls (on 2 week days and one day in the weekend) three times (at weeks 1, 4 and 8) during the course of the study to gather dietary information including dietary intake and/or particular aspects of the diet. Participants will be asked to recall foods and beverages they consumed in the 24 hours prior to the interview. Three 24-hour food recalls appear optimal for estimating energy intake.
62525937|NCT05134246||Carotid endarterectomy (CEA)|Patients who are treated with CEA.
62525938|NCT05134246||Carotid artery stenting (CAS)|Patients who are treated with CAS.
62525939|NCT01335373||Group 1|
62152915|NCT03187249|EXPERIMENTAL|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
62525940|NCT03456895|EXPERIMENTAL|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:~1. completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)~2. completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
62525941|NCT03456895|EXPERIMENTAL|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
62525942|NCT03456895|EXPERIMENTAL|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
62525943|NCT01661179|EXPERIMENTAL|Vandetanib 300mg|300 mg/day vandetanib
62525944|NCT03317665||Standard of care|Mesh for hernia repair: Standard of care products used by the Investigator for open ventral hernia repair procedure
62525945|NCT01587586|ACTIVE_COMPARATOR|PEGASYS 180 µg Q1W + ribavirin* for 48 weeks|Pegasys 180 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses(48)
62525946|NCT01587586|EXPERIMENTAL|P1101 180 µg Q1W + ribavirin* for 48 weeks|P1101 180 µg Q1W(subcutaneous injection)with Ribavirin, multiple doses
62713301|NCT05207098||Neurocognitive Tests and Questionnaires|The performance-based measures will be administered with a total completion time estimated to be 90 minutes. The neurocognitive battery is similar in content and duration to multiple previous and ongoing studies being conducted by the Neurocognitive Research Lab.
62152916|NCT03187249|NO_INTERVENTION|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
62152917|NCT01039909|PLACEBO_COMPARATOR|Placebo|"The Placebo treatment group will be administered 8 placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive placebo approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
62152918|NCT01039909|ACTIVE_COMPARATOR|2.0g SRT2104|"The 2.0g SRT2104 treatment group will be administered 8 SRT2104 0.25g capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive SRT2104 approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
62713302|NCT05200559|EXPERIMENTAL|E7777 + Pembrolizumab|"Phase l:~E7777: Dose Level 1, 3 µg/kg; Dose Level 2, 6 µg/kg; Dose Level 3, 9 µg/kg; Dose Level 4, 12 µg/kg Day 1-3 - given up to 8 cycles (dose-limiting toxicities assessed for first two cycles, only)~Pembrolizumab: 200 mg, IV on Day 1 (21-day cycle)~Phase ll:~E7777: administered on Day 1-3 at Phase 2 Recommended Dose (P2RD); Day 1-3 up to 8 cycles~Pembrolizumab: 200 mg, IV on Day 1 (21-day cycle)"
62152919|NCT02224755|EXPERIMENTAL|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
62152920|NCT02224755|ACTIVE_COMPARATOR|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
62152921|NCT01444690|EXPERIMENTAL|Active|Dimiracetam 400 mg capsules
62152922|NCT01444690|PLACEBO_COMPARATOR|Pseudo-placebo|Dimiracetam 25 mg capsules
62525947|NCT01587586|EXPERIMENTAL|P1101 270 µg Q1W + ribavirin* for 48 weeks|P1101 270 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses
62525948|NCT01587586|EXPERIMENTAL|P1101 450 µg Q2W + ribavirin* for 48 weeks|P1101 450 µg Q2W(subcutaneous injection)+Ribavirin, multiple doses
62152923|NCT02294994|EXPERIMENTAL|half dose tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.075 µg per kilogram per minute for 24 to 36 hours.UFH heparin was administered as a bolus of 100 U/kg before PCI.
62152924|NCT02294994|ACTIVE_COMPARATOR|recommended-dose Tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours. UFH heparin was administered as a bolus of 100 U/kg before PCI.
62152925|NCT02294994|PLACEBO_COMPARATOR|none tirofiban|Tirofiban was not administered ,UFH heparin was administered as a bolus of 100 U/kg before PCI.
62152926|NCT00506025|ACTIVE_COMPARATOR|Cranberry 2xday|Cranberry juice (C) two times daily, a.m. and p.m.
62152927|NCT00506025|ACTIVE_COMPARATOR|Cranberry + Placebo|De-Activated Cranberry juice in the am, then placebo (P) in the pm
62152928|NCT00506025|PLACEBO_COMPARATOR|Placebo 2xday|Placebo in the form of juice two times daily in the a.m. and p.m.
62152929|NCT00604461|EXPERIMENTAL|Dose Escalation Followed by Maintenance Therapy|"A: Tiered Dose Escalation/Phase II Dose -~* Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m\^2.~* Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m\^2.~* Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m\^2.~B: Maintenance Therapy -~* Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first."
62152930|NCT03607851|ACTIVE_COMPARATOR|Conventional titration group|
62152931|NCT03607851|EXPERIMENTAL|Rapid titration group 1|
62152932|NCT03607851|EXPERIMENTAL|Rapid titration group 2|
62152933|NCT01156675|EXPERIMENTAL|FLEXUS™ Interspinous Spacer|
62152934|NCT01156675|ACTIVE_COMPARATOR|XSTOP® Interspinous Spacer|
62152935|NCT05436041|EXPERIMENTAL|Nutri|PCPs will receive an alert to use Nutri personalized diet goal setting software with enrolled patients
62152936|NCT05436041|NO_INTERVENTION|Control|Usual care
62525949|NCT04593966||Pediatric AVM|"1. AVM patients' age under 18-years-old who underwent intervention in investigators' institution.~2. Patients' lesions were located in eloquent and confirmed by image."
62525950|NCT04593966||Adult AVM|"1. AVM patients' age over 18-years-old who underwent intervention in investigators' institution.~2. Patients' lesions were located in eloquent and confirmed by image."
62525951|NCT02813057|ACTIVE_COMPARATOR|Stoppa repair|Stoppa inguinal hernia repair
62525952|NCT02813057|EXPERIMENTAL|TEP repair|Total extraperitoneal inguinal hernia repair
62525953|NCT03790579||Women with gestational diabetes|We randomly selected the 40 pregnant women diagnosed GDM by two-step procedure based on Carpenter-Coustan criteria at this hospital. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
62713303|NCT06441279|EXPERIMENTAL|group 1|30 patients that will have intra-articular injection of 2 ml of Platelet lysate (PL).
62152937|NCT04255251|EXPERIMENTAL|Intervention group|Subjects in this group will receive Silver Diamine Fluoride around their crown margins every six month for the next 3 years.
62152938|NCT04255251|ACTIVE_COMPARATOR|Fluoride varnish group|Subjects in this group will receive fluoride varnish around their crown margins every six month for the next 3 years.
62152939|NCT02930265|ACTIVE_COMPARATOR|Liraglutide intervention group|Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
62152940|NCT02930265|NO_INTERVENTION|Control group|Control group will accept ischemic cardiomyopathy conventional drugs and a placebo
62152941|NCT01010256||Subjects diagnosed with CMML|Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
62152942|NCT01010256||Control Group|The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
62152943|NCT03063021|EXPERIMENTAL|Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)|Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (\>0.6) and a reduced GSH/GSSG ratio (\<3.0) in the aqueous.
62713304|NCT06441279|EXPERIMENTAL|group 2|30 patients that will have intra-articular injection of Hyaluronic Acid.
62713305|NCT05075759|EXPERIMENTAL|Arm 1 (personalized clinician-led self-management telehealth)|Patients receive a personalized clinician-led self-management telehealth session at baseline and 2 months. Patients with poor response at 3 months are randomized to Arm 2 or 4, otherwise patients receive the same telehealth session at months 4 and 6. Patients may receive 2 additional telehealth sessions after 6 months.
62713306|NCT05075759|EXPERIMENTAL|Arm 2 (personalized goal setting)|Patients receive personalized goal setting for daily steps and activity (updated weekly) and 3 dietary goals (updated monthly) with social media peer support for 6 months. Patients with poor response at 3 months are randomized to Arms 1 or 4. Patients may receive personalized goal setting for daily steps and activity (updated monthly) and dietary goals (updated monthly) after 6 months.
62152944|NCT03063021|EXPERIMENTAL|Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)|Subjects with RP who don't have a high carbonyl content (\>0.6) and a reduced GSH/GSSG ratio (\<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.
62152945|NCT05907070|EXPERIMENTAL|Mandala group|Mandala drawing and coloring on paper
62152946|NCT05907070|EXPERIMENTAL|Value clarification group|Value clarification by writing on paper
62152947|NCT05907070|NO_INTERVENTION|Control group|Routine nursing care
62152948|NCT01403922|EXPERIMENTAL|1|TC-5214
62152949|NCT01403922|EXPERIMENTAL|2|TC-5214 with placebo
62152950|NCT01403922|EXPERIMENTAL|3|TC-5214 with placebo
62152951|NCT01403922|EXPERIMENTAL|4|TC-5214
62152952|NCT01928732|ACTIVE_COMPARATOR|CPT|Cognitive Processing Therapy (CPT) - a type of cognitive therapy for treating PTSD.
62152953|NCT01928732|ACTIVE_COMPARATOR|PE|Prolonged Exposure (PE) - a type of exposure therapy for treating PTSD.
62152954|NCT06594497|ACTIVE_COMPARATOR|Conventional Physiotherapy group|In line with the relevant physician's protocol, Quadriceps Isometric Exercises, Passive ROM exercises, active hip exercises while wearing a brace, ankle exercises, and ice application training are given. The patient is asked to continue as a home program for 2 weeks. After 2 weeks, electrical stimulation (15-20 minutes), current exercises, and ice application continue in the unit. (15min). A total of 30 sessions are applied. In addition, it is requested that the exercises be done at home, as in the treatment program (3x10).
62525954|NCT03790579||Healthy women|We also randomly selected 40 healthy pregnant with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
62525955|NCT02815449|EXPERIMENTAL|Low stabilizer level|Meals prepared with iron fortified cube with low stabilizer level
62525956|NCT02815449|EXPERIMENTAL|Medium stabilizer level|Meals prepared with iron fortified cube with medium stabilizer level
62713307|NCT05075759|ACTIVE_COMPARATOR|Arm 3 (waitlist)|Patients receive no intervention for 12 months. After 12 months, they may optionally receive their choice of intervention for up to 6 months.
62713308|NCT05075759|EXPERIMENTAL|Arm 4 (remote sessions with a health coach)|Patients receive remote sessions with a health coach every 1-2 weeks for 6 months. Patients may continue to receive remote sessions once a month after 6 months.
62152955|NCT06594497|EXPERIMENTAL|Conventional Physiotherapy + Kinesthetic motor imagery training group|Motor imagery training will be planned according to the PETTLEP model. A quiet environment will be provided to minimize distractions during the motor imagery session, and the patient's eyes will be closed throughout the session. At the very beginning of the session, a relaxation exercise lasting approximately 2 minutes will be performed to maximize attention during motor imagery. In relaxation exercises, patients will be asked to focus on their breathing, become aware of each body area, and relax the muscles in these areas. Care will be taken to ensure that the imagined movement is of similar duration to the real and optimal movement. Motor imagery will mostly be studied from a first-person perspective. During kinesthetic imagery, people will be asked to feel the movement of their body parts during each exercise without any body movement occurring. 3 sessions per week will last for 6 weeks in total.
62152956|NCT01474759|EXPERIMENTAL|Portion size instruction|Advice on diet, physical activity, and behavior change. Instruction in food portion size.
62152957|NCT01474759|EXPERIMENTAL|Pre-portioned foods|Advice on diet, physical activity, and behavior change. Provision of pre-portioned foods.
62525957|NCT02815449|EXPERIMENTAL|High stabilizer level|Meals prepared with iron fortified cube with high stabilizer level
62525958|NCT05181332||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
62713309|NCT05393700|EXPERIMENTAL|AOT-sleep|They will be asked to watch video-clips representing motor contents before sleeping.
62152958|NCT01474759|ACTIVE_COMPARATOR|Comparison|Advice on diet, physical activity, and behavior change. Advice on healthy eating for weight loss.
62152959|NCT01903954|ACTIVE_COMPARATOR|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
62152960|NCT01903954|EXPERIMENTAL|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
62152961|NCT04918888||Overall study population|All new oncologic patients of the outpatient-clinic of the department of radiooncology
62152962|NCT04918888||First dose received (Subpopulation 1)|Patients, who received one or two doses of SARS-CoV-2 vaccine prior to radiotherapy
62152963|NCT04918888||Vaccination during therapy (Subpopulation 2)|Patients, who will receive at least one dose of SARS-CoV-2 vaccine during or up to 6 weeks after radiotherapy
62152964|NCT00996164|EXPERIMENTAL|flibanserin 100 mg|flibanserin 100mg po qd
62152965|NCT00996164|PLACEBO_COMPARATOR|Placebo|placebo 1 tab po qd
62152966|NCT01390753|NO_INTERVENTION|Preterm formula|
62152967|NCT01390753|ACTIVE_COMPARATOR|Donor milk + preterm formula|Human milk from a donor bank
62152968|NCT01390753|NO_INTERVENTION|Breastfeeding + formula|
62152969|NCT01390753|NO_INTERVENTION|Breasfeeding|
62152970|NCT01217294|SHAM_COMPARATOR|spinal morphine, sham block|"Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as specified by the anaesthetist performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham ultrasound guided fascia iliaca plane block with saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
62525959|NCT05181332||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
62525960|NCT03952611|ACTIVE_COMPARATOR|High-Definition White-light Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
62525961|NCT03952611|ACTIVE_COMPARATOR|High-Definition White-light Colonoscopy With Reveal®|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
62152971|NCT01217294|ACTIVE_COMPARATOR|ultrasound guided fascia iliaca block|"Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
62525962|NCT03952611|ACTIVE_COMPARATOR|High-Definition White-light Colonoscopy With Endocuff Vision|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
62525963|NCT01708590|EXPERIMENTAL|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
62525964|NCT01708590|EXPERIMENTAL|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
62525965|NCT01708590|PLACEBO_COMPARATOR|placebo|Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
62525966|NCT06457399||Airway Stenosis|Patients with lower airway stenosis on waiting list for endoscopic intervention on stenosis by respiratory endoscopy unit.
62525967|NCT04414306|EXPERIMENTAL|Experimental Arm 1|Attendees at in-person events (e.g. health fairs) who meet eligibility criteria will be able to enroll and participate in-person, with some participating in online or telephone survey follow-up.
62525968|NCT04414306|EXPERIMENTAL|Experimental Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up.
62713310|NCT05393700|ACTIVE_COMPARATOR|AOT-control|They will be asked to watch video-clips representing motor contents at least 12 hours before sleeping.
62713311|NCT05393700|SHAM_COMPARATOR|Control|They will be asked to watch video-clips representing landscapes before sleeping.
62152972|NCT01233245||Group 1|
62152973|NCT05173766|EXPERIMENTAL|Ergonomic Principals|Ergonomic Principal for computer users will be used.
62152974|NCT05746026|EXPERIMENTAL|STUDY GROUP|• The study subjects who fulfilled the inclusion criteria were interviewed individually in the garden of the clubs in order to collect the necessary data (tool I, II, III, and IV). Then, the researcher interviewed the clients in group composed of 8 older adults to implement the Psycho-educational Program . Each session taken about 30-45 minutes.
62152975|NCT05746026|ACTIVE_COMPARATOR|Control group|Control group exposed to the usual routine care
62152976|NCT00602732|EXPERIMENTAL|1|Participants assigned to the ROSE program
62152977|NCT00602732|ACTIVE_COMPARATOR|2|Participants assigned to enhanced care as usual
62152978|NCT02858115||one lung ventilation lung|patients requiring one lung ventilation lung resection.
62525969|NCT04414306|EXPERIMENTAL|Experimental Arm 3|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up. This arms will serve as an experimental arm for assessing study aim 2 and as a control arm for study aim 1.
62525970|NCT04414306|EXPERIMENTAL|Experimental Arm 4|Patients identified by one or more healthcare systems to be due or overdue for colorectal cancer screening will be informed by their healthcare provider or healthcare system (e.g. via the healthcare system's patient portal) that they are due for screening and will be informed how to schedule an colorectal cancer screening related appointment (e.g. discussion with primary care provider about colorectal cancer screening options) along with the option to receive education about colorectal cancer screening. Patients who are interested in receiving education may view the education with or without participating in the research study. Patients who elect to be study participants will participate in consenting, eligibility screening, pre-test, post-test, and possible three- and six-month using a parallel structure to study arms two and three.
62525971|NCT04943978||Liver disease|Patients with either acute or chronic liver disease
62713312|NCT01501357|EXPERIMENTAL|multilevel filaments toothbrush|Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments)
62713313|NCT01501357|ACTIVE_COMPARATOR|cross toothbrushing|Children will brush with cross toothbrushing.
62713314|NCT01258673|EXPERIMENTAL|Fimasartan/HCTZ combination group|
62152979|NCT06056726||Obese Patients|Patients candidates for resective surgery for rectal cancer and also elegible for bariatric surgery
62152980|NCT00508144|EXPERIMENTAL|Alimta|Alimta 500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks.
62152981|NCT06244394||NPC patients with RTLI after IMRT|nasopharyngeal carcinoma patients with radiation-induced temporal lobe injury after intensity-modulated radiation therapy
62152982|NCT06244394||NPC patients without RTLI after IMRT|nasopharyngeal carcinoma patients without radiation-induced temporal lobe injury after intensity-modulated radiation therapy
62152983|NCT01061658|EXPERIMENTAL|Vaccine - High dosage|
62152984|NCT01061658|EXPERIMENTAL|Vaccine - Lower dosage|
62152985|NCT01061658|PLACEBO_COMPARATOR|Placebo|
62152986|NCT03490006|ACTIVE_COMPARATOR|Paravertebral Block|For this arm, the initial level will be at T3-4 and an out-of-plane technique to guide the needle tip to a point between the costotransverse ligament and the parietal pleura between the visualized transverse processes. Then, a few milliliters of 0.5% ropivacaine will be injected slowly to displace the pleura ventrally as the paravertebral space fills with local anesthetic. After negative aspiration, the rest of 0.5% ropivacaine (total 10 ml) will be injected in 5 ml increments to further fill the paravertebral space. The procedure will then be repeated in the same exact fashion at the T5-6 level. We will observe local anesthetic spread under real-time ultrasound imaging.
62152987|NCT03490006|EXPERIMENTAL|Erector Spinae Plane Block|For this arm, the needle tip will be directed under ultrasound guidance using an in-plane technique towards the T5 transverse process until the needle tip contacts os. Then, a few milliliters of ropivacaine will be injected slowly to separate the plane between the erector spinae muscle and the transverse process. After negative aspiration, the rest of the 0.5% ropivacaine will be injected (total 20ml)
62152988|NCT00407732|NO_INTERVENTION|SC|standard care
62152989|NCT00407732|EXPERIMENTAL|INT|psychosocial intervention
62525972|NCT05502523|ACTIVE_COMPARATOR|Group I (pulmonary vein first approach procedure)|Patients undergo pulmonary vein first approach surgical procedure on day of surgery.
62152990|NCT03471442|ACTIVE_COMPARATOR|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
62525973|NCT05502523|ACTIVE_COMPARATOR|Group II (pulmonary artery first surgical procedure)|Patients undergo pulmonary artery first approach surgical procedure on day of surgery.
62525974|NCT00652249||Extraventricular Drainage/Pressure|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
62525975|NCT01431911||Patients diagnosed with COPD|Patients diagnosed with COPD using ICD codes with a COPD-related exacerbation and receiving maintenance therapy
62525976|NCT03537274|EXPERIMENTAL|PEG-Intron, 0.5 mg/kg|PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
62525977|NCT03537274|EXPERIMENTAL|PEG-Intron, 1.0 mg/kg|PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
62525978|NCT03537274|EXPERIMENTAL|PEG-Intron, 1.5 mg/kg|PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
62525979|NCT03537274|ACTIVE_COMPARATOR|Interferon Alfa-2b|Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
62152991|NCT03471442|EXPERIMENTAL|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
62152992|NCT05533788|OTHER|Fed states in healthy subjects|Fed states in healthy subjects
62152993|NCT05533788|OTHER|Fasted states in healthy subjects|Fasted states in healthy subjects
62152994|NCT03846817|EXPERIMENTAL|FAIS with intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
62152995|NCT03846817|EXPERIMENTAL|FAIS without intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
62152996|NCT00749944|EXPERIMENTAL|varenicline|
62152997|NCT00749944|PLACEBO_COMPARATOR|placebo|
62152998|NCT05656456||OCD patients|Patients with obsessive-compulsive disorder
62525980|NCT01349582|ACTIVE_COMPARATOR|flow diversion|Flow diverters are low porosity braided endovascular stent devices. They can be used with or without coiling.
62525981|NCT01349582|ACTIVE_COMPARATOR|Best standard treatment|Best standard treatment can by any of the standard management options: coiling, stenting plus coiling, surgical clipping, parent vessel occlusion, observation
62525982|NCT01349582|OTHER|Registry for flow diversion|Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
62152999|NCT05656456||live-in family members|Live-in family members of OCD patients
62153000|NCT00773344|EXPERIMENTAL|A1|
62153001|NCT04624906|EXPERIMENTAL|Single arm intervention|"100 mg Acalabrutinib (ACP-196) oral capsules twice daily for 1 year~Bendamustine and rituximab will be given for 6 x 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)."
62153002|NCT02529605|ACTIVE_COMPARATOR|Product B® IsaGenesis®, Then IsaGenesis®|Participants will come into the clinic in a fasting state to receive the Product B® IsaGenesis®, which will be a one time dose of the liquid-gel formulation contained in 2 capsules, 1280 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the IsaGenesis®. This will be given for a comparison in a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule.
62153003|NCT02529605|ACTIVE_COMPARATOR|IsaGenesis®, Then Product B® IsaGenesis®|Participants will come into the clinic in a fasting state to receive the IsaGenesis®, which will be a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the Product B® IsaGenesis®. This will be given for a comparison in a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
62153004|NCT03536767|EXPERIMENTAL|Open-Label|
62153005|NCT06361212|PLACEBO_COMPARATOR|Placebo|Placebo Tablet
62153006|NCT06361212|EXPERIMENTAL|test drug|Ethoximod Tablet, 5mg and 10mg
62525983|NCT03130218|NO_INTERVENTION|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
62525984|NCT03130218|EXPERIMENTAL|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
62713315|NCT01258673|ACTIVE_COMPARATOR|Fimasartan group|
62525985|NCT04056871||Fried Frailty Phenotype|This group of patients will be assess by using 5 characteristics of Frailty which are weight loss, weakness, exhaustion, low activity and physical fitness of the patients. Patients classify as frail will have more than 3 criteria, intermediate or pre-frail will be 1 or 2 criteria present and robust will not have criteria.
62525986|NCT04056871||Groningen Frailty Index|GFI is a simple questionnaire consisting of 15 items which are classified into 8 groups, consistent of 4 domains of functioning. A score of 4 or more indicates a higher risk for frailty and possible delirium.
62153007|NCT02705456|EXPERIMENTAL|HA-Tooth Paste|"Tooth Brushing HA~Cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
62153008|NCT02705456|ACTIVE_COMPARATOR|FL-Tooth Paste|"Tooth Brushing FL~Cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
62525987|NCT02651454|EXPERIMENTAL|Daesiho-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
62525988|NCT02651454|EXPERIMENTAL|Jowiseungcheung-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
62525989|NCT02651454|PLACEBO_COMPARATOR|Placebo|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
62525990|NCT00804817|ACTIVE_COMPARATOR|Care as usual|Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
62525991|NCT00804817|EXPERIMENTAL|SCION-HSCT program|"Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
62525992|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
62525993|NCT03061682|EXPERIMENTAL|Add on lens|
62153009|NCT01428622|PLACEBO_COMPARATOR|Placebo + BI 54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
62525994|NCT06014918|EXPERIMENTAL|Patients using a new application|Patients will enter pain intensity and opioid analgesic side effects using a new application named 'Smart APS', developed for acute pain services, and later assess for adherence and satisfaction with the application use.
62153010|NCT01428622|EXPERIMENTAL|Olodaterol low dose + BI54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
62153011|NCT01428622|ACTIVE_COMPARATOR|Olodaterol medium dose + BI54903|patient to receive 2 puffs of each device
62153012|NCT01428622|EXPERIMENTAL|Olodaterol high dose + BI54903|patient to receive 2 puffs of each device
62153013|NCT01428622|EXPERIMENTAL|Olodaterol l dose + BI54903|patient to receive 2 puffs of each device
62153014|NCT01428622|EXPERIMENTAL|Olodaterol m dose + BI54903|patient to receive 2 puffs of each device
62525995|NCT01046266|EXPERIMENTAL|A|
62525996|NCT01046266|ACTIVE_COMPARATOR|B|
62713316|NCT05624268|EXPERIMENTAL|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
62525997|NCT03863483|EXPERIMENTAL|Sintilimab plus chemotherapy|Sintilimab (200 mg) plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
62525998|NCT03863483|ACTIVE_COMPARATOR|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
62713317|NCT05624268|PLACEBO_COMPARATOR|Placebo|Matched placebo
62713318|NCT02059421|EXPERIMENTAL|Johrei Therapy|"* 3 sessions per week lasting 30 minutes.~* Daily report of bedtime and wake time.~Baseline:~* Polysomnography~* Actigraphy~* Questionnaires~* Blood draw~* Urine collection~  2 weeks:~* Questionnaires~* Actigraphy download~* Sleep log reconciliation~  6 weeks:~* Polysomnography~* Actigraphy download~* sleep log reconciliation~* Questionnaires~* Blood draw~* Urine collection"
62153015|NCT01428622|EXPERIMENTAL|Olodaterol h dose + BI54903|patient to receive 2 puffs of each device
62153016|NCT03401099|ACTIVE_COMPARATOR|Radiofrequency ablation of CTI|Radiofrequency ablation of CTI (cavo-tricuspid isthmus), which is the 'conventional' treatment of atrial flutter
62153017|NCT03401099|ACTIVE_COMPARATOR|Cryoballoon PVI|Cryoballoon PVI (Pulmonary Vein Isolation), which is the 'novel treatment'
62153018|NCT01984099|ACTIVE_COMPARATOR|Chemoprohylaxis Group|Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
62713319|NCT02059421|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"* 1 session per week for a total of 6 weeks with the option of 2 additional sessions.~* Daily report of bedtime and wake time.~Baseline:~* Polysomnography~* Actigraphy~* Questionnaires~* Blood draw~* Urine collection~  2 weeks:~* Questionnaires~* Actigraphy download~* Sleep log reconciliation~  6 weeks:~* Polysomnography~* Actigraphy download~* sleep log reconciliation~* Questionnaires~* Blood draw~* Urine collection"
62713320|NCT05189262||Cardiac Sugery Patients Requiring Cardiopulmonary >1hour|Patients admitted for a complex cardiac surgery, heart valve replacement and/or CABG surgery requiring CPB \>1hour
62713321|NCT06378957|PLACEBO_COMPARATOR|Oral Placebo|Placebo (cellulose), via capsule
62153019|NCT01984099|PLACEBO_COMPARATOR|Control Group|Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
62153020|NCT01322386|EXPERIMENTAL|Oral Vancomycin|Vancocin
62525999|NCT05218382|EXPERIMENTAL|VR group|The participants will have the the virtual reality headset with immersive virtual reality.
62526000|NCT05218382|PLACEBO_COMPARATOR|Placeob group|The participants will have the virtual reality headset put on but blank screen.
62526001|NCT05495035|EXPERIMENTAL|Olverembatinib + APG-2575 combinational therapy|"* Period 1: Olverembatinib alone period (2 weeks):~* Period 2: olverembatinib in combination with APG-2575 and dexamethasone (4 weeks):"
62526002|NCT03762486|ACTIVE_COMPARATOR|TENS to around the incision|The Patient Controlled Analgesia infusion was started right after the surgery. TENS was applied to around the incision.
62526003|NCT03762486|ACTIVE_COMPARATOR|TAES to the acupuncture points|The Patient Controlled Analgesia infusion was started right after the surgery. TAES was applied to acupuncture points.
62526004|NCT03762486|NO_INTERVENTION|No stimulation|No stimulation was performed to the patients in the control group.
62526005|NCT05707312||POLEmut (POLE mutant endometrial cancer patients)|POLE mutant endometrial cancer patients
62526006|NCT05707312||MMRd (mismatch repair deficient endometrial cancer patients)|mismatch repair deficient endometrial cancer patients
62526007|NCT05707312||NSMP (no specific molecular profile endometrial cancer patients to NSMP)|no specific molecular profile endometrial cancer patients to NSMP
62526008|NCT05707312||p53abn (p53 abnormal endometrial cancer patients)|p53 abnormal endometrial cancer patients
62526009|NCT00953641|ACTIVE_COMPARATOR|Pre-Menopausal 1|Pre-Menopausal group, receiving Misoprostol
62526010|NCT00953641|PLACEBO_COMPARATOR|Pre-Menopausal 2|Patients will insert a placebo vaginal suppository 12h or more prior to the endometrial biopsy
62526011|NCT00953641|ACTIVE_COMPARATOR|Post-Menopausal 1|Post-Menopausal patients will insert a Misoprostol vaginal suppository 12h or more prior to the endometrial biopsy
62526012|NCT00953641|PLACEBO_COMPARATOR|Post-Menopausal 2|Placebo vaginal suppository prior to the endometrial biopsy
62526013|NCT01689662|EXPERIMENTAL|Tc 99m EC20|"Subjects will receive two intravenous injections 1-3 minutes apart:~1. 1 mg of folic acid~2. 1-2 mL injection of 0.1 mg of EC20 labeled with 15-25 mCi of technetium-99m"
62526014|NCT05311917|EXPERIMENTAL|home vision therapy|near glasses will be prescribed along with a complete training of the exercises and with a eye exercise form of information about how and how long to do the exercise, by optometrist No 2 (Saeid Abdi).training includes: Voluntary convergence, Bug on string, Eccentric Circles, Jumping vergence , Barrel card, chiastopic fusion, Brock string, push-up These exercises will be done 3 days a week for 20 minutes ( 10 minutes at noon and 10 minutes at night ) for 2 month. Home exercises include eight vision therapy exercises and patients will do two exercises each day at noon and two exercises at night.
62526015|NCT05311917|EXPERIMENTAL|base in prism prescription|base in prism prescription using sheards criterion near prismatic glasses will be prescribed and the amount of prism will be divided between two eyes; and random and aimless eye movements, without convergence and accommodation effects will be prescribed by optometrist No. 2 (Saeid Abdi). patients should complete their checking form for eye exercises.
62526016|NCT05311917|PLACEBO_COMPARATOR|conventional|new near glasses as a conventional treatment with the practice of random and aimless eye movements, without convergence and accommodation effects will be prescribed by optometrist No. 2 (Saeid Abdi). patients should complete the form of their eye training.
62526017|NCT01289665|EXPERIMENTAL|Lubricating Gel|
62153021|NCT04728035|EXPERIMENTAL|Dose escalation (part 1)|Patients will receive irinotecan liposome injection (CSPC) at the initial starting dose until progression or unacceptable toxicity.
62153022|NCT04728035|EXPERIMENTAL|Dose expansion (part 2)|Once the appropriate dose has been established in Part 1, patients will be enrolled into two expansion cohorts according to the sub-type of breast cancer.
62153023|NCT04214093|EXPERIMENTAL|Arm A|Dose escalation for patients with solid tumors, lymphoma and multiple myeloma with low risk of TLS. Each cohort within Arm A will test a single dose level.
62153024|NCT04214093|EXPERIMENTAL|Arm B|Dose escalation for patients with hematologic malignancies with an intermediate to high risk of TLS. Intrapatient dose ramp-ups within each cohort will be used.
62153025|NCT04471298|ACTIVE_COMPARATOR|Active dosage group 1|Qishenyiqi dripping pills, 3.12g, oral, three times a day
62153026|NCT04471298|ACTIVE_COMPARATOR|Active dosage group 2|Qishenyiqi dripping pills, 4.68g, oral, three times a day
62153027|NCT04471298|ACTIVE_COMPARATOR|Active dosage group 3|Qishenyiqi dripping pills, 6.24g, oral, three times a day
62153028|NCT04471298|PLACEBO_COMPARATOR|Control dosage group 1|Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day
62153029|NCT04471298|PLACEBO_COMPARATOR|Control dosage group 2|Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day
62153030|NCT04471298|PLACEBO_COMPARATOR|Control dosage group 3|Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day
62153031|NCT02221011|EXPERIMENTAL|shock wave (three times)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Once a week for 3 weeks
62153032|NCT02221011|SHAM_COMPARATOR|Sham shock wave|E-SWT, Elettronica Pagani, Italy Sham without energy, 1500 beats in FCU, FCR and 4000 beats diffuse in intrinsic muscle
62153033|NCT02221011|EXPERIMENTAL|Shock wave (one time)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Only one dose
62153034|NCT02222506|EXPERIMENTAL|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for diabetic foot ulcers.
62526018|NCT01289665|ACTIVE_COMPARATOR|Water|
62526019|NCT04385966|ACTIVE_COMPARATOR|Standard Volume Dose|24 patients will be included in the Standard Volume Dose arm. 20 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
62526020|NCT04385966|EXPERIMENTAL|Low Volume Dose|24 patients will be included in the Low Volume Dose arm. 10 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
62526021|NCT05066763||People with Parkinson's disease|
62526022|NCT06464432|EXPERIMENTAL|Intervention: ESTAIR Psychotherapeutic Manual|
62713322|NCT06378957|EXPERIMENTAL|Oral THC 30mg|30mg pure THC in ethanol vehicle, via capsule
62526023|NCT03230500|EXPERIMENTAL|Computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
62526024|NCT03230500|ACTIVE_COMPARATOR|Free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
62526025|NCT04405895|EXPERIMENTAL|Breakfast Diet (3Mdiet)|The Breakfast Diet (3Mdiet) will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
62526026|NCT04405895|ACTIVE_COMPARATOR|Allday Diet (6Mdiet)|The Allday Diet (6Mdiet) will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% in each of the three snacks.
62526027|NCT04717102|EXPERIMENTAL|0.75 MAC desflurane|The effects of 0.75 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
62526028|NCT04717102|ACTIVE_COMPARATOR|0.5 MAC desflurane|The effects of 0.5 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
62526029|NCT04817566|EXPERIMENTAL|stimulation group|Anodal tDCS+ intensive cognitive Training
62526030|NCT04817566|SHAM_COMPARATOR|sham group|Sham tDCS + intensive cognitive Training
62526031|NCT01721811|EXPERIMENTAL|Healthy|Healthy study participanats
62526032|NCT01721811|EXPERIMENTAL|Diabetes|Patients with diabetes
62526033|NCT03997214|NO_INTERVENTION|Control group|as usual care
62526034|NCT03997214|EXPERIMENTAL|experimental group|The intervention of inspiratory muscle strength training
62526035|NCT05094245|ACTIVE_COMPARATOR|Stellate ganglion block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
62526036|NCT05094245|NO_INTERVENTION|Conventional|Mecobalamin Tablets oral Mecobalamin Tablets tid-8
62526037|NCT06132217|EXPERIMENTAL|Dose Escalation Phase Cohort 1|
62526038|NCT06132217|EXPERIMENTAL|Dose Escalation Phase Cohort 2|
62526039|NCT06132217|EXPERIMENTAL|Dose Escalation Phase Cohort 3|
62526040|NCT06132217|EXPERIMENTAL|Dose Expansion Phase Cohort A|
62526041|NCT06132217|EXPERIMENTAL|Dose Expansion Phase Cohort B|
62526042|NCT06132217|EXPERIMENTAL|Dose Expansion Phase Cohort C|
62526043|NCT03884374|EXPERIMENTAL|African American Group|African Americans with knee osteoarthritis (OA).
62526044|NCT03884374|EXPERIMENTAL|Non-Hispanic White Group|Non-Hispanic whites with knee osteoarthritis (OA).
62526045|NCT03034655|EXPERIMENTAL|CDP exercises (10 sessions)|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
62153035|NCT04201275|EXPERIMENTAL|Cohort 1|up to HEC74647PA capsule 50 mg once daily for 3 days
62526046|NCT03034655|EXPERIMENTAL|CDP exercises (5 sessions)|Group B. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
62526047|NCT03034655|EXPERIMENTAL|Mobile posturography exercises (10 sess)|Group C. Up to six tasks with the most prominent deviations from normative control values were included in the training program. Training was performed by using the training function of Vertiguard1-RT device. This neurofeedback system contains one vibration stimulator on the front, back, left and right side, respectively. Training was performed daily under supervision of a physician over 2 weeks (10 sessions, weekend was excluded). A training session consisted of 5 repetitions of six selected training tasks. The patient received a vibrotactile feedback signal during training in those directions which showed a higher body sway than preset thresholds. Vibration was reinforced with increasing sway No vibrotactile feedback was applied if the patient's sway was below preset thresholds. The exercise difficulty was progressively increase throughout the rehabilitation sessions.
62526048|NCT03034655|EXPERIMENTAL|Mobile posturography exercises (5 sess)|Group D. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
62526049|NCT04842136||Myofascial Temporomandibular Disorder (TMD) with Sleep Bruxism (SB)|Patients with Myofascial TMD and with sleep bruxism with the diagnosis of regular or frequent teeth grinding sounds during the sleep, and one or more following clinical signs, such as jaw muscle pain or fatigue on waking up in the morning, temporal headache, hypertrophy of the masseter muscle, abnormal tooth wear, and/or jaw locking were included in the group.
62526050|NCT04842136||Myofascial Temporomandibular Disorder (TMD) without Sleep Bruxism (SB)|Patients with Myofascial TMD without sleep bruxism were included in the group.
62526051|NCT03518892||Spinal Cord Injury Group|Body Composition, Resting Metabolic Rate, and dietary assessment
62153036|NCT04201275|EXPERIMENTAL|Cohort 2|up to HEC74647PA capsule 100 mg once daily for 3 days
62526052|NCT03518892||Healthy Controls|Body Composition, Resting Metabolic Rate, and dietary assessment
62526053|NCT02803229|PLACEBO_COMPARATOR|Placebo|matched Placebo arm
62526054|NCT02803229|EXPERIMENTAL|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
62526055|NCT01250483||BPH|men aged more than 40 years who presented with BPH/LUTS and showed negative results of transrectal prostate biopsy before the period of AB medication
62713323|NCT06378957|EXPERIMENTAL|Oral THC 30mg + D-Limonene 25mg|30mg pure THC in ethanol vehicle, via capsule 25mg pure D-Limonene, via capsule
62153037|NCT04201275|EXPERIMENTAL|Cohort 3|up to HEC74647PA capsule 200 mg once daily for 3 days
62153038|NCT04201275|PLACEBO_COMPARATOR|Cohort 4|up to placebo once daily for 3 days
62713324|NCT06378957|EXPERIMENTAL|Oral THC 30mg + D-Limonene 50mg|30mg pure THC in ethanol vehicle, via capsule 50mg pure D-Limonene, via capsule
62526056|NCT01250483||prostate cancer|men aged more than 40 years who presented with BPH/LUTS and showed positive results of transrectal prostate biopsy before the period of AB medication
62526057|NCT01301586|ACTIVE_COMPARATOR|Oral antibiotic plus soy extract|
62526058|NCT01301586|ACTIVE_COMPARATOR|Oral antibiotic|
62526059|NCT02642796|NO_INTERVENTION|Group I (control)|Patient controlled analgesia (epidural fentanyl): PCA only
62526060|NCT02642796|EXPERIMENTAL|group II|PCA plus lumbar plexus \& sciatic nerve transcutaneous electric nerve stimulation (LS-TENS)
62153039|NCT02664870||Shoulder Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
62153040|NCT02664870||Hip Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy (with or without periacetabular osteotomy (PAO)) or arthroplasty
62153041|NCT02664870||Knee Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
62153042|NCT03478306|ACTIVE_COMPARATOR|Arm 1|Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
62153043|NCT03478306|PLACEBO_COMPARATOR|Arm 2|Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
62153044|NCT05722925|EXPERIMENTAL|Fluciclovine PET/CT|Participants will undergo Fluciclovine PET/CT within 30 days of a negative or equivocal PSMA PET scan. After the Fluciclovine PET/CT, the patient will follow up with their treating physician as per standard-of-care. The research team will collect clinical and imaging data at 6 months post Fluciclovine-PET/CT.
62153045|NCT04570488||Quality improvement - Display|Display of risk score/ colored flag in Epic patient list column; will be viewable to all frontline workers
62153046|NCT04570488||No Display|"No display (hidden) of risk score/ colored flag in Epic patient list column; not viewable to all frontline workers"
62153047|NCT04184765||Total laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
62153048|NCT04184765||Abdominal hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
62153049|NCT01729793|ACTIVE_COMPARATOR|Digestive Enzyme #2|A proprietary blend of dietary supplement enzymes in a capsule
62153050|NCT01729793|PLACEBO_COMPARATOR|Placebo|Capsule identical to active arm containing only microcrystalline cellulose
62153051|NCT02216994|OTHER|surgery treatment|The patients with a predicting score of more than 5 are diagnosed with HD, and are performed surgery to remove the aganglionic bowel. The patients with a score less than 5 are mostly indicative of HAD, and receive conservative treatments that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments. one stage pull through procedure to remove the dysganglionic bowel segments.
62526061|NCT02642796|EXPERIMENTAL|group III|PCA plus surgical wound transcutaneous electric nerve stimulation ( SW-TENS)
62526062|NCT06214169|OTHER|Plain Lignocaine group|Group of participants receiving only plain lignocaine for IVRA
62153052|NCT01474356|NO_INTERVENTION|BT (brachytherapy)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy only was performed.
62153053|NCT01474356|EXPERIMENTAL|BTHT (brachytherapy and hyperthermia)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy with interstitial hyperthermia was performed.
62526063|NCT06214169|OTHER|Cisatracurium group|Group of participants receiving plain lignocaine and cisatracurium combined for IVRA
62526064|NCT03792087|EXPERIMENTAL|SmofKabiven Peripheral|Continuous intravenous Infusion for SmofKabiven Peripheral via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
62526065|NCT03792087|ACTIVE_COMPARATOR|Hospital compounded emulsion|Continuous intravenous Infusion for Hospital compounded emulsion via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
62526066|NCT03531398|EXPERIMENTAL|High fat meal|Muffin containing 30g fat
62526067|NCT03531398|EXPERIMENTAL|Medium fat meal|Muffin containing 20g fat
62526068|NCT04046796||Healthy twin|
62526069|NCT04046796||Effected Twin|Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.
62526070|NCT05953753|ACTIVE_COMPARATOR|Intervention|
62526071|NCT05953753|NO_INTERVENTION|Control/No intervention|
62526072|NCT00739986|EXPERIMENTAL|1|Semapimod 60 mg IV x 1 day, placebo IV x 2 days
62526073|NCT00739986|EXPERIMENTAL|2|Semapimod 60 mg IV x 3 days
62526074|NCT00739986|PLACEBO_COMPARATOR|3|Placebo comparator IV x 3 days
62526075|NCT02240342|EXPERIMENTAL|Poor ovarian reserve women|
62526076|NCT05534308|ACTIVE_COMPARATOR|Control Group|The control group (CG) will be composed of patients undergoing the same surgical procedure, and standard treatment consisting only of compression compression by elastic stockings.
62713325|NCT06378957|EXPERIMENTAL|Oral THC 30mg + D-Limonene 100mg|30mg pure THC in ethanol vehicle, via capsule 100mg pure D-Limonene, via capsule
62713326|NCT06378957|EXPERIMENTAL|Oral THC 30mg + D-Limonene 200mg|30mg pure THC in ethanol vehicle, via capsule 200mg pure D-Limonene, via capsule
62713327|NCT00499837|EXPERIMENTAL|80 mg/kg AAT inhaled|80 mg/kg AAT inhaled
62713328|NCT00499837|PLACEBO_COMPARATOR|Placebo inhaled|Placebo inhaled
62526077|NCT05534308|EXPERIMENTAL|Intervention Group|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, in the period intraoperative associated with compression with elastic stockings.
62526078|NCT01747720|EXPERIMENTAL|Vitamin D3 (cholecalciferol) 1000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months
62153054|NCT01964547|ACTIVE_COMPARATOR|Sativex|"Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.~Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability."
62153055|NCT01964547|PLACEBO_COMPARATOR|Placebo|Oromucosal spray, containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability.
62153056|NCT03941366|OTHER|Neoadjuvant Chemotherapy and Follow-up Surgery|All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.
62153057|NCT03361202||Atrial fibrillation group|blood sampling
62153058|NCT03361202||control group|blood sampling
62153059|NCT01223014||1|Single cohort of 6 subjects
62153060|NCT02081976|ACTIVE_COMPARATOR|Standard Care Group|Dental therapist providing standard periodontal treatment
62153061|NCT02081976|EXPERIMENTAL|Integrated Care Group|a combined treatment approach of Dental Therapist, Dental Hygienist, Cardiologist along with counselor
62526079|NCT01747720|EXPERIMENTAL|Vitamin D3 (cholecalciferol) 2000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months
62526080|NCT01747720|EXPERIMENTAL|Vitamin D3 (cholecalciferol) 3000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months
62526081|NCT01747720|PLACEBO_COMPARATOR|Placebo|daily, for 12 months
62526082|NCT00163670||Motor vehicle accident|
62153062|NCT04710576|EXPERIMENTAL|Axatilimab Dose Cohort 1|Participants will be administered axatilimab 0.3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks for up to 2 years.
62153063|NCT04710576|EXPERIMENTAL|Axatilimab Dose Cohort 2|Participants will be administered axatilimab 1 mg/kg IV every 2 weeks for up to 2 years.
62153064|NCT04710576|EXPERIMENTAL|Axatilimab Dose Cohort 3|Participants will be administered axatilimab 3 mg/kg IV every 4 weeks for up to 2 years.
62526083|NCT00163670||Control|
62526084|NCT03416803|EXPERIMENTAL|Radiotherapy|Patients in the experimental group, who were at high risk for lymph node metastasis, underwent radiotherapy in the lymphatic drainage area. Radiotherapy was started in lymphatic drainage areas about 1 month after HCC surgery. The range of radiotherapy was hepatic portal area, pancreas circumference, celiac trunk and abdomen Around the aortic lymph drainage area, the dose of radiation 45Gy, conventional segmentation.
62526085|NCT03416803|NO_INTERVENTION|Blank control|Patients in the control group , who were at high risk for lymph node metastasis，were followed up.
62526086|NCT05406063|EXPERIMENTAL|SBRT with 9 Gy x 3 fractions to the treatment site.|Patients will be treated with SBRT delivering 9 Gy x 3 fractions (BED10: 51.3 Gy) to the treatment site.
62526087|NCT05406063|ACTIVE_COMPARATOR|SBRT with 7 Gy x 5 fractions to the treatment site|Patients will be treated with SBRT delivering 7 Gy x 5 fractions (BED10: 59.5 Gy) to the treatment site.
62526088|NCT02453776|EXPERIMENTAL|PRECISION dosing|Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
62526089|NCT02453776|NO_INTERVENTION|Conventional dosing of Infliximab|Infliximab 5 mg/kg every 8 or 6 weeks
62526090|NCT00838435|EXPERIMENTAL|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
62526091|NCT01833091|EXPERIMENTAL|intervention|creat light period 12 hours with cover on incubator
62526092|NCT01833091|NO_INTERVENTION|control|
62526093|NCT02548611|EXPERIMENTAL|Prasugrel|single-dose loading with 60 mg of prasugrel pre PCI
62153065|NCT02822599|ACTIVE_COMPARATOR|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
62526094|NCT02548611|ACTIVE_COMPARATOR|Clopidogrel|loading with 600 mg of clopidogrel pre PCI
62526095|NCT03201250|EXPERIMENTAL|Treatment|"Combination of cabozantinib, carfilzomib and dexamethasone~Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.~Carfilzomib: carfilzomib will be administered intravenously over 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.~Dexamethasone: dexamethasone will be administered at 40 mg orally or intravenously on days 1, 8,15 and 22 of each 28-day cycle (for patient age ≥ 75, acceptable to be given as 20 mg orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, 23)"
62713329|NCT05430061|EXPERIMENTAL|Raw corn starch|Raw corn starch is a slow digesting carbohydrate, corn starch, a commonly consumed food ingredient, considered GRAS (generally recognized as safe) CFR 182.70- 182.90 will be used as the test meal treatment. Participants will receive 21 individual containers of raw corn starch (30 g/container) and 21 cups of 4 oz unsweetened apple sauce. Participants will be asked to consume one starch container mixed in apple sauce at 10 a.m.; each day for 21 days.
62153066|NCT02822599|PLACEBO_COMPARATOR|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
62153067|NCT04325737|EXPERIMENTAL|SEP-363856|
62153068|NCT04325737|PLACEBO_COMPARATOR|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
62153069|NCT02769130|EXPERIMENTAL|Losartan|"Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins.~Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year."
62526096|NCT06123442|EXPERIMENTAL|three one-arm trials (N = 4-6/trial)|This research protocol entails three one-arm trials and a pilot RCT with 58 participants. Its primary aim is to develop the Cognitive Resilience Intervention (CRI) and assess its feasibility and acceptability. Student feedback and data on feasibility and acceptability will be collected before and after each trial to fine-tune the intervention using empirical guidance. CRI aims to help participants lead more meaningful lives, emphasizing purpose, autonomy, and the pursuit of goals while avoiding suicidal ideation. In contrast, the comparator RCT's control group will undergo General Psychoeducation (GPE), a structured program focusing on enhancing mental health awareness through psychology psycho-education sessions.
62526097|NCT05354830|EXPERIMENTAL|Foot Massage|Patients undergoing TPF surgery and foot massage
62526098|NCT05354830|NO_INTERVENTION|Control|Those who underwent TPF surgery and did not receive foot massage
62526099|NCT05023382||Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily.
62526100|NCT03347422|EXPERIMENTAL|BIVV009/BIVV009|Participants with primary CAD and without a recent history of blood transfusion during the last 6 months prior to enrollment in this study, received an intravenous (IV) infusion of BIVV009 6.5 g (for participants less than \[\<\]75 kilograms \[kg\]) or 7.5 g dose (for participants greater than or equal to \[\>=\]75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26), received placebo on Week 26 and continued to receive BIVV009 6.5 or 7.5 g in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks (for 6.5 g) or 121 weeks (for 7.5 g). All participants who completed Part A elected to continue in Part B.
62526101|NCT03347422|EXPERIMENTAL|Placebo/BIVV009|Participants with primary CAD and without a recent history of blood transfusion during the last 6 months prior to enrollment in this study, received an IV infusion of placebo matched to BIVV009 on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) received BIVV009 6.5 (if \<75 kg) or 7.5 g (if \>=75 kg) in Part B, on Week 26 and Week 27 and every 2 weeks thereafter for up to an additional 123 weeks (for 6.5 g) or 137 weeks (for 7.5 g). All participants who completed Part A elected to continue in Part B.
62526102|NCT02201238|EXPERIMENTAL|Diclofenac sodium/menthol gel (in tube)|1% diclofenac sodium plus 3% menthol gel (in 30g aluminium tube). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
62526103|NCT02201238|EXPERIMENTAL|Diclofenac sodium/menthol gel (in roll-on device)|1% diclofenac sodium plus 3% menthol gel (in roll-on applicator device supplied in 30g plastic bottles). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
62526104|NCT02201238|ACTIVE_COMPARATOR|Diclofenac sodium tablets|50mg diclofenac sodium tablets administered orally, three times daily for three consecutive days with 6h between adjacent doses on the same day
62526105|NCT02201238|ACTIVE_COMPARATOR|Voltaren gel|Voltaren gel supplied in 100g aluminium tube. Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
62526106|NCT02350244|EXPERIMENTAL|Experimental group|Subjects of the experimental group will have to follow an intervention for one month, consisting in active breaks from computer work
62526107|NCT02350244|OTHER|Control group|Control group patients had no intervention
62526108|NCT03972449|EXPERIMENTAL|Beatboxing: BEAT-Speech|
62526109|NCT03972449|EXPERIMENTAL|Traditional Articulation Approach|
62526110|NCT03570086||migraineurs without aura|
62526111|NCT03570086||health controls|
62526112|NCT01111019|EXPERIMENTAL|r-hGH (Saizen®)|
62526113|NCT01333280|EXPERIMENTAL|Double Trouble (DTR) group|Double Trouble in Recovery groups
62526114|NCT01333280|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual while on a waiting list for DTR groups
62526115|NCT05414032|EXPERIMENTAL|MRD positive Cohort - Arm A (treatment)|"Dose formulation- AZD2936 is supplied as a liquid drug product in a 20R vial containing 750 mg (nominal) of active AZD2936. The solution contains 50 mg/mL AZD2936 in 20 mM L-histidine/L- histidine-hydrochloride, 240 mM sucrose, 0.04% (w/v) poloxamer 188, at pH 6.0.~Unit dose strength(s)- 750 mg/vial (50 mg/mL) Dosage levels- 750mg administered Q3W Route of administration- IV infusion over 1 hour"
62526116|NCT05414032|NO_INTERVENTION|MRD positive Cohort - Arm B (observation)|Observation
62526117|NCT05414032|NO_INTERVENTION|MRD negative Cohort|Observation
62526118|NCT02722148|EXPERIMENTAL|Enrolled Patients|All enrolled subjects will receive a novel allergen-specific immune signature directed approach to dietary elimination therapy
62526119|NCT03926481|EXPERIMENTAL|Obesity Only|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity who are 65 years and older.
62526120|NCT03926481|EXPERIMENTAL|Sarcopenia and Obesity|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity and sarcopenia who are 65 years and older.
62526121|NCT03205930|EXPERIMENTAL|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
62526122|NCT03744702|EXPERIMENTAL|Treatment|All patients will receive ascorbic acid as this is a pilot study.
62526123|NCT05303376|EXPERIMENTAL|Active|
62526124|NCT05303376|PLACEBO_COMPARATOR|Placebo|
62526125|NCT02399735|EXPERIMENTAL|Arm A|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
62526126|NCT02399735|EXPERIMENTAL|Arm B|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
62526127|NCT02399735|EXPERIMENTAL|Arm C|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
62526128|NCT00771381|EXPERIMENTAL|1|18F-FAZA + FluGlucoScan Injection
62526129|NCT06426108|ACTIVE_COMPARATOR|Low-Intensity Laser 1J + Fluoride Varnish|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 1 Joule, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the vestibular surface (both mesial and distal aspects), as well as the center of the lesion, with an activation time of 1 Joule (equivalent to 10 seconds). In conjunction with the laser therapy, a fluoride varnish (Duraphat®, containing 22,600 ppm F, manufactured by Colgate) will be utilized as an adjuvant. Application will be facilitated using a microbrush, ensuring coverage over the entire extent of the lesion for 30 seconds. Following the interventions, patients will be advised to refrain from consuming hard foods and to postpone tooth brushing for at least four hours post-application of the varnish, adhering to the manufacturer's guidelines.
62526130|NCT06426108|PLACEBO_COMPARATOR|Low-Intensity Laser 1J + Placebo|The tooth will be subjected to low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 1 Joule, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the vestibular surface (both mesial and distal aspects), as well as the center of the lesion, with an activation time of 1 Joule (equivalent to 10 seconds). As an adjunct to the laser therapy, a placebo varnish, devoid of the active ingredient (fluoride), will be utilized. The varnish will be applied with the assistance of a microbrush, ensuring coverage over the entire length of the lesion for 30 seconds. Following the interventions, patients will be advised to abstain from consuming hard foods and to postpone tooth brushing for at least four hours post-application of the varnish.
62526131|NCT06426108|EXPERIMENTAL|Low-Intensity Laser 2J + Fluoride Varnish|The tooth will undergo low-intensity laser irradiation in continuous mode, utilizing a wavelength of 808 nm, a power output of 100 mW, a dose of 2 Joules, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicularly in contact with the tooth surface, targeting the cervical third of the vestibular surface (both mesial and distal aspects), as well as the center of the lesion, with an activation time of 2 Joules (equivalent to 20 seconds). As an adjunct to the laser therapy, a fluoride varnish (Duraphat®, containing 22,600 ppm F, manufactured by Colgate) will be utilized. The varnish application will be facilitated using a microbrush, ensuring coverage over the entire length of the lesion for 30 seconds. Following the interventions, patients will be instructed to refrain from consuming hard foods and to postpone tooth brushing for at least four hours after applying the varnish, in accordance with the manufacturer's recommendations.
62526132|NCT06426108|SHAM_COMPARATOR|Low-Intensity Laser 2J + Placebo.|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 2 Joules, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the third cervical region of the vestibular surface (both mesial and distal aspects), as well as the center of the lesion, with an activation time of 2 Joules (equivalent to 20 seconds). As an adjunct to the laser therapy, a placebo varnish, devoid of the active ingredient (fluoride), will be utilized.The varnish will be applied with the assistance of a microbrush, ensuring coverage over the entire length of the lesion for 30 seconds. Following the interventions, patients will be advised to abstain from consuming hard foods and to postpone tooth brushing for at least four hours post-application of the varnish.
62526133|NCT00846521|EXPERIMENTAL|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
62526134|NCT03989622|EXPERIMENTAL|evaluation of the visual field on the ground|evaluation of the visual field on the ground followed by 10 reeducation sessions
62526135|NCT03989622|NO_INTERVENTION|usual care|control session followed by 10 re-education sessions
62526136|NCT02302313|OTHER|painful stimuli|"No drug and no placebo will be used in this study. The study participants will only rate their pain on a numerical scale (EN) following cutaneous painful stimulation (6 for each phase) of variable intensity, delivered by a CO2 laser. ANI (Analgesia Nociception Index) will be raised simultaneously by the ANI monitor. This sequence will be performed on subjects at rest and in a state of hypnosis by the technique of remembering a pleasant memory and the ideo-sensory technique of protective glove."
62526137|NCT02000401|OTHER|Ketorolac Tromethamine|Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.
62526138|NCT04093635||Group I|Those patients that will be treated by NPWT.
62526139|NCT04093635||Group II|Those patients will be treated with standard saline moist wound care and dressing.
62153070|NCT00289952|EXPERIMENTAL|Group 1|HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.
62153071|NCT00289952|EXPERIMENTAL|Group 2|HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.
62153072|NCT04514094|EXPERIMENTAL|Silver Diamine Fluoride|"* Gross debris will be removed with cotton pellets to allow better SDF contact with denatured dentin.~* Cotton rolls will be used to protect surrounding gingival tissues and mucous membranes to avoid pigmentation or irritation.~* Affected tooth surfaces will be dried with a gentle flow of air.~* 1-2 drops only of SDF will be used for the whole visit.~* SDF will then be directly applied to affected tooth surfaces only using a micro sponge brush.~* At least one minute will be needed to allow drying of SDF.~* Excess SDF will finally be removed with cotton rolls to minimize systemic absorption.~* When possible, isolation will be continued for up to three minutes.~* After 2-4 weeks: reapplication will be done only to lesions that do not appear arrested (dark and hard)."
62153073|NCT04514094|ACTIVE_COMPARATOR|Atraumatic Restorative Treatment|"Caries removal by hand instruments with care not to expose the pulp.~* Maximum excavation from the periphery of lesions will be done, to minimize leakage at the restoration margins.~* Cotton roll isolation will then be carried out.~* Cavities will be restored by glass ionomer cement.~* Hand pressure should be applied by a gloved and petroleum jelly coated finger, then, excess material will be removed."
62153074|NCT02643368|ACTIVE_COMPARATOR|mOPV2 at 6 and 7 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
62526140|NCT06531369|ACTIVE_COMPARATOR|"Flumazenil group 1（F1 group）+Flumazenil group 2（F2 group）"|"Flumazenil group 1（F1）:Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.~Flumazenil group 2（F2）:Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later."
62526141|NCT06531369|PLACEBO_COMPARATOR|Control Group (C group)|Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
62526142|NCT05043623|EXPERIMENTAL|Arm 1 - Clinician Collected/supervised Rhinoswab first, then CTDN swab|Rhinoswab test administered and immediately followed by CTDN. Rhinoswab swab tested on respiratory panel vs CTDN swab tested on respiratory panel (standard of care).
62526143|NCT05043623|EXPERIMENTAL|Arm 2 - Clinician Collected/supervised CTDN swab first, then Rhinoswab|CTDN test administered and immediately followed by Rhinoswab. CTDN swab tested on respiratory panel (standard of care) vs Rhinoswab swab tested on respiratory panel.
62526144|NCT05043623|EXPERIMENTAL|Arm 3 - Self-collected Rhinoswab, saliva swab, CTDN|In children 5-18 years, the child/parent/guardian collects the three samples, in order of patient/parent preference. All samples will be tested on the SARS-CoV-2 laboratory panel (Allplex™ SARS-CoV-2 Assay - Seegene Inc)
62526145|NCT05043623|EXPERIMENTAL|Arm 4 - Self-collected RAT, saliva, CTDN|In children 1 month -5 years, the child/parent/guardian collects the three samples, in order of patient/parent preference. Saliva and CTDN samples will be tested on the SARS-CoV-2 laboratory panel (Allplex™ SARS-CoV-2 Assay - Seegene Inc), RAT test kit will be Abbott PanBio
62526146|NCT02899832||NIRS|Near Infra Red Spectroscopy.
62526147|NCT02932514|EXPERIMENTAL|Eversense (Senseonics) CGM System|
62526148|NCT06255301||Control group|150 patients with eye diseases other than dry eye syndrome or limbal stem cell deficiency will be included.
62526149|NCT06255301||dry eye syndrome|100 patients with dry eye syndrome will be included.
62713330|NCT05430061|SHAM_COMPARATOR|Maltodextrin DE-10|Maltodextrin dextrose equivalent 10 is a fast digesting carbohydrate, is a non-sweet nutritive polymer that consists of D-glucose units linked primarily by \[alpha\]-1-4 bonds and that has a dextrose equivalent (D.E.) of less than 20. It is regarded as Generally Recognized as Safe (GRAS) by the U.S. Food and Drug Administration for direct use as a food ingredient (GRAS, 21CFR184.1444).DE-1 Maltodextrin is commercially available. Participants will receive 21 individual containers of maltodextrin (30 g/container) and 21 cups of 4 oz unsweetened apple sauce. Participants will be asked to consume one maltodextrin container mixed in apple sauce at 10 a.m.; each day for 21 days.
62526150|NCT06255301||limbal stem cell deficiency|50 patients with limbal stem cell deficiency will be included.
62526151|NCT00409318|ACTIVE_COMPARATOR|1|Etanercept
62526152|NCT00409318|PLACEBO_COMPARATOR|2|Placebo
62526153|NCT04995692|EXPERIMENTAL|Telehealth Education for Asthma Connecting Hospital and Home (TEACHH)|New model of patient-centered asthma education
62526154|NCT04995692|ACTIVE_COMPARATOR|Standard Care (SC) Comparison Group|Standard inpatient asthma education per hospital protocol.
62526155|NCT03915730|EXPERIMENTAL|Smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
62526156|NCT03915730|EXPERIMENTAL|Non-smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Never smoked patients were included into the nonsmoker group
62526157|NCT03915730|NO_INTERVENTION|Smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of \<10% and a probing depth of ≤3 mm Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
62526158|NCT03915730|NO_INTERVENTION|Non-smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of \<10% and a probing depth of ≤3 mm Never smoked patients were included into the nonsmoker group
62526159|NCT03716245|EXPERIMENTAL|supraclavicular lymph node dissection and raidiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy
62526160|NCT03716245|ACTIVE_COMPARATOR|supraclavicular area radiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy
62526161|NCT03738852|EXPERIMENTAL|Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months|Continuous Glucose Monitor for 3 months duration
62526162|NCT03738852|EXPERIMENTAL|Aim 1: Impact of hypoglycemia on brain connectivity Type 1|Healthy controls, T1 aware, and T1 unawares
62526163|NCT03738852|EXPERIMENTAL|Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1|Healthy controls, T1 aware, and T1 unawares
62526164|NCT06271720|ACTIVE_COMPARATOR|visceral manipulation|Palpation will be applied and the pressure will directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. Once found, the collagenous barrier will be engaged for 90 to 120 seconds for each technique without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.
62713331|NCT04487444|EXPERIMENTAL|Ta1 treatment arm|Ta1 at a dose of 1.6 mg will be administered SC in 1 mL of diluent daily for a total of 1 week, in addition to standard of care.
62713332|NCT04487444|NO_INTERVENTION|Control arm|No treatment will be provided in addition to standard of care.
62713333|NCT05422261||Experimental Group|Children with Autism Spectrum Disorder and their parents
62713334|NCT05422261||Control Group|Health children and their parents
62713335|NCT02472249|EXPERIMENTAL|Norepinephrine intra-arteriel/hepatic|This is the only arm of this study. These patients will receive 24 micrograms of norepinephrine in the hepatic artery with subsequent CT perfusion imaging to evaluate liver blood flow.
62713336|NCT04975997|EXPERIMENTAL|Daratumumab in combination with Iberdomide and dexamethasone - Dose 1|Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
62526165|NCT06271720|ACTIVE_COMPARATOR|integrated neuromuscular inhibition|The practitioner first identifies TrPs to be treated within the upper trapezius muscle. The subjects will be placed in a supine position. Their arm will be positioned in slight shoulder abduction with the elbow bent and their hand resting on their stomach. Using a pincer grasp, the practitioner will move throughout the fibers of the upper trapezius and make note of any active TrPs. Once the TrPs were identified, treatment began. The first technique applied will be ischemic compression. The therapist again utilized a pincer grasp, placing the thumb and index finger over the active TrP. Slow, increasing levels of pressure will be applied until the tissue resistance barrier is identified. The pressure will be maintained until a release of the tissue barrier is felt. At that time, pressure will again be applied until a new barrier is felt. This process will be repeated until tension or tenderness is unable to be identified or 90 seconds have elapsed.
62526166|NCT04278898|EXPERIMENTAL|N-acetylcysteine then Placebo|
62526167|NCT04278898|EXPERIMENTAL|Placebo then N-acetylcysteine|
62526168|NCT02273791||HRT group|Women will be subjected to HRT using Estradiol valerate before FET
62526169|NCT02273791||MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
62526170|NCT02257294|PLACEBO_COMPARATOR|Control Arm|two placebo vials
62526171|NCT02257294|ACTIVE_COMPARATOR|Arm A|Alteplase 10mg and placebo vial
62526172|NCT02257294|ACTIVE_COMPARATOR|Arm B|Alteplase 10mg and alteplase 10mg
62526173|NCT04145583|EXPERIMENTAL|HSK3486|0.4 mg/kg
62526174|NCT04145583|EXPERIMENTAL|voriconazole , HSK3486|400 or 200 mg; 0.4 mg/kg
62526175|NCT04120584|EXPERIMENTAL|Forma Eye treatment|
62526176|NCT05210244|EXPERIMENTAL|BJ supplementation|
62526177|NCT05210244|PLACEBO_COMPARATOR|PLA supplementation|
62526178|NCT00503711|EXPERIMENTAL|100 mg Vandetanib eod|100 mg Vandetanib every other day dosing
62526179|NCT00503711|EXPERIMENTAL|100 mg Vandetanib od|100 mg Vandetanib once daily dosing
62526180|NCT00503711|EXPERIMENTAL|300 mg Vandetanib od|300 mg Vandetanib once daily dosing
62526181|NCT02893137|EXPERIMENTAL|Craniectomy and Optune|Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery. Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.
62526182|NCT02232490|EXPERIMENTAL|hepcortespenlisimut-L|Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC
62526183|NCT02232490|PLACEBO_COMPARATOR|placebo|placebo
62526184|NCT05483049||grey zone 1|HBeAg (+), HBV DNA \>20 but \< 10000000IU/mL, ALT ≤40 U/L
62713337|NCT04975997|EXPERIMENTAL|Daratumumab in combination with Iberdomide and dexamethasone - Dose 2|
62526185|NCT05483049||grey zone 2|HBeAg (-), HBV DNA \> 2000 IU/mL, ALT ≤40 U/L
62526186|NCT00395174|EXPERIMENTAL|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2005-2006 formulation containing 45μg of each hemagglutinin derived from A/New Caledonia (H1N1), A/Wisconsin (H3N2) and B/Ohio~135μg total"
62526187|NCT00395174|ACTIVE_COMPARATOR|TIV (Fluzone)|"Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and B/Malaysia~45μg total~(Fluzone, sanofi pasteur)"
62526188|NCT00112866|EXPERIMENTAL|Group I (high-dose cilengitide) 2000mg|"Preoperative Treatment: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1. (High dose 2000mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity."
62526189|NCT00112866|EXPERIMENTAL|Group II (low-dose cilengitide) 500mg|"Preoperative Treatment: Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1. (500mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity"
62526190|NCT05484843|EXPERIMENTAL|Stroke patients_intervention group|"Inclusion criteria for the study:~* Being over 18 years old~* Being of all genders, male and female~* Being able to communicate in Turkish~* Having had a hemorrhagic or ischemic stroke~* Not more than one month after the stroke event.~* Being oriented to person, place and time~* Not being aphasic~* Having a score of 21 or above on the Montreal Cognitive Assessment Scale (MOBİD)~* Not having serious vision and hearing problems~* Not having a psychiatric history~* Being open to communication and cooperation~* To be willing and voluntarily to participate in the study."
62526191|NCT05484843|EXPERIMENTAL|stroke patients_control group|"Inclusion criteria for the study:~* Being over 18 years old~* Being of all genders, male and female~* Being able to communicate in Turkish~* Having had a hemorrhagic or ischemic stroke~* Not more than one month after the stroke event.~* Being oriented to person, place and time~* Not being aphasic~* Having a score of 21 or above on the Montreal Cognitive Assessment Scale (MOBİD)~* Not having serious vision and hearing problems~* Not having a psychiatric history~* Being open to communication and cooperation~* To be willing and voluntarily to participate in the study."
62526192|NCT02418377||Obese children|"The obese subject must meet all of the following inclusion criteria to participate in this study:~1. Ideal body weight for height (WFH) of at least 140% or BMI for age above 97th percentile~2. Overweight before 10 years of age~3. Informed consent from both obese children subject and legal representative e.g. parents"
62713338|NCT04975997|EXPERIMENTAL|Daratumumab in combination with Iberdomide and dexamethasone - Dose 3|
62713339|NCT04975997|ACTIVE_COMPARATOR|Daratumumab in combination with dexamethasone and bortezomib|Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
62526193|NCT02418377||Family members of obese children|"Family member must meet all of the following inclusion criteria to participate in this study:~1. Must be parent or direct sibling of obese subject~2. Informed consent from both subject and parent is subject is below 21 years of age"
62713340|NCT02957630|EXPERIMENTAL|15 mg E4/3 mg DRSP|15 mg estetrol/3 mg drospirenone combined oral contraceptive
62713341|NCT02957630|ACTIVE_COMPARATOR|30 mcg EE/150 mcg LNG|30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive
62713342|NCT02957630|ACTIVE_COMPARATOR|20 mcg EE/3 mg DRSP|20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive
62713343|NCT06414291|PLACEBO_COMPARATOR|Water|Rehydration with low mineral content bottle water
62713344|NCT06414291|EXPERIMENTAL|Carbohydrate Electrolyte solution|Drink with 22 grams of carbohydrate, 1020 milligrams of sodium, and 760 milligrams of potassium per liter. Hydration multiplier liquid IV
62713345|NCT06414291|EXPERIMENTAL|Low Sugar electrolyte solution|10 grams of carbohydrate, 1060 milligrams of sodium, and 760 milligrams of potassium per liter. Sugar free Liquid IV
62713346|NCT05419232|ACTIVE_COMPARATOR|Short Message Service (SMS) with an associated link to a multi-media website|The participant will receive a SMS with a brief message containing the following: (1) statement encouraging them to get vaccinated and (2) a link to a multi-media page with videos and additional resources encouraging individuals to be vaccinated. The multi-media website will be housed in the Safe Return To School website and updated by a designated study team members. This page will include the following COVID-19-related resources: publicly available vaccine promotion videos, videos consisting of community members discussing vaccine topics, resources regarding local vaccine sites, and links to additional literature resources.
62713347|NCT05419232|ACTIVE_COMPARATOR|Phone Call with Peer|The participant's peer will be a study team member who has the same or similar racial demographic as the participant. All team members conducting the peer phone calls will be trained in motivational interviewing. The participant will be called by their peer via zoom or phone. Motivational interviewing techniques will be utilized with the participant to promote vaccine uptake. The team member will use a facilitator guide throughout the peer intervention.
62713348|NCT02835469||Menopur® Multidose|Treatment according to routine clinical practice.
62713349|NCT03663855|EXPERIMENTAL|Cystinuria Patients|
62713350|NCT02066649|ACTIVE_COMPARATOR|Carvedilol|Initiating patient on carvedilol after diagnosis of varices made on endoscopy
62713351|NCT02066649|ACTIVE_COMPARATOR|Variceal Band Ligation|performing variceal band ligation during endoscopy on patient after diagnosis of esophageal varices made on endoscopy
62713352|NCT02066649|ACTIVE_COMPARATOR|Combination Group (Carvedilol + Variceal band ligation)|once patient has confirmed large esophageal varices on endoscopy, he/she will be started on carvedilol (post-procedure) in addition to having variceal band ligation performed during endoscopy
62713353|NCT03800550|EXPERIMENTAL|Treatment Sequence 1: Bedaquiline and Clarithromycin|Participants will receive bedaquiline on Day 1 in Period 1, followed by clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 2. There will be washout period of at least 28 days starting on Day 1.
62713354|NCT03800550|EXPERIMENTAL|Treatment Sequence 2: Clarithromycin and Bedaquiline|Participants will receive clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 1, followed by bedaquiline on Day 1 in Period 2. There will be a washout period of at least 28 days starting after bedaquiline administration on Day 5.
62713355|NCT03440008||Control|Able-bodied, age matched subjects with no foot and ankle pathology
62153075|NCT02643368|ACTIVE_COMPARATOR|mOPV2 at 6 and 8 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
62153076|NCT02643368|ACTIVE_COMPARATOR|mOPV2 at 6 and 10 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
62526194|NCT05341297|EXPERIMENTAL|ParentKIT|Transdiagnostic parent-led Internet-delivered intervention Participants in the experimental group will have access to the ParentKIT intervention. The intervention was developed based on existing Cognitive Behavioral Therapy/ Rational Emotive Behavior Therapy protocols for parents of children with internalizing problems. It consists of nine modules delivered over three weeks.
62526195|NCT05341297|NO_INTERVENTION|Waitlist|Participants in the waitlist condition will have access to the program after 3 weeks.
62526196|NCT06190535|EXPERIMENTAL|Etamsylate +|Arm in which etamsylate (Dicynone injectable 250mg/2ml) is administrated through the nasogastric tube (NT) 2 ampules twice (X2)/day for 48 hours.
62526197|NCT06190535|NO_INTERVENTION|the standard postoperative treatment|Arm in which patients have the standard postoperative treatment
62526198|NCT01781819|EXPERIMENTAL|ARFI SVI ultrasound imaging|Acoustic Radiation Force Impulse (ARFI) Shear Wave Velocity Imaging (SVI) ultrasound imaging
62526199|NCT03535675|EXPERIMENTAL|Muscadine Plus|Each treatment cycle consists of once daily oral dosing of 4000 mg Muscadine Plus, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of study drug and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
62526200|NCT03535675|EXPERIMENTAL|Placebo|Each treatment cycle consists of once daily oral dosing of 4000 mg placebos, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of placebo and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
62526201|NCT05129436||Establishment of method|healthy volunteers who are asked to donate peripheral blood for the establishment of the method
62153077|NCT02643368|ACTIVE_COMPARATOR|mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age|Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age
62153078|NCT03090698|ACTIVE_COMPARATOR|Hylan|Intra-articular (knee) 6ml Hylan GF20 administration (single shot)
62153079|NCT03090698|ACTIVE_COMPARATOR|Hylan + Corticosteroid|Intra-articular (knee) 6ml Hylan GF20 and 1ml Triamcinolone 20mg/ml administration (single shot)
62153080|NCT03090698|ACTIVE_COMPARATOR|Corticosteroid|Intra-articular (knee) 1ml Triamcinolone administration (single shot)
62153081|NCT01887002|EXPERIMENTAL|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
62153082|NCT01887002|PLACEBO_COMPARATOR|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
62153083|NCT04459156|EXPERIMENTAL|Healthy Participants|healthy control subjects
62526202|NCT05129436||Influenza vaccination|Subjects receiving the influenza vaccine Vaxigrip Tetra 2020/2021 by Sanofi Pasteur Europe.
62526203|NCT01857765|ACTIVE_COMPARATOR|Standard of Care|
62526204|NCT01857765|EXPERIMENTAL|Rehabilitation|
62526205|NCT02713880||Patients with Transthyretin-Related Familial|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy
62526206|NCT03983174|EXPERIMENTAL|Drainage seton with flap|Drainage seton will be put around the external anal sphincter with mucosal advancement flap
62526207|NCT03983174|EXPERIMENTAL|EAS sparing seton|Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done
62713356|NCT03440008||OA|Subjects with ankle OA, with all classifications of ankle misalignment (varus, neutral, valgus)
62153084|NCT04459156|EXPERIMENTAL|Chronic Obstructive Pulmonary Disease patients|Established diagnosis of Chronic Obstructive Pulmonary Disease
62153085|NCT04459156|EXPERIMENTAL|Healthy Young Participants|healthy young subjects with age 18-30 years old
62526208|NCT04095949|EXPERIMENTAL|Artichokes|1 day of artichokes intake
62526209|NCT02369900|ACTIVE_COMPARATOR|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
62526210|NCT02369900|PLACEBO_COMPARATOR|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
62153086|NCT02400528|OTHER|Patients With Profound and Multiple Disabilities|
62153087|NCT02256826|EXPERIMENTAL|Group A|
62153088|NCT02256826|EXPERIMENTAL|Group B|
62153089|NCT02723799|EXPERIMENTAL|Hope Promotion Program (HPP)|Plus to the standard treatment protocol, all the participants in this group attend the HPP, consisting of a three individual session's carried out by the nurse in patients' homes. It includes viewing the film Hopeful Living, enrolling in a hope activity from the Hope activity book, a relaxation activity and a negotiated plan to exercise hope in a regular basis.
62153090|NCT02723799|OTHER|Standard Treatment Protocol|Participants in this group has not access to a hope intervention. Data collection for outcome variables is the same as the participants in the other arms.
62526211|NCT05042050|EXPERIMENTAL|A-iMAPS Intervention|Participants will receive six sessions of Attachment-focused iMAgery therapy for PSychosis. They will be randomised to different baseline lengths (two to five assessment sessions)
62526212|NCT05562193|EXPERIMENTAL|Physical activity intervention coupled with standard post-cancer directed treatment care group|
62526213|NCT05562193|OTHER|Standard post-cancer directed treatment care control group|
62526214|NCT03664648||Adult Pregnant Women Exposed to HEPLISAV-B|Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.
62526215|NCT04619992|OTHER|Current users of Hollister standard with tip hydrophilic intermittent catheters|Subjects in this arm are current users of Hollister standard with tip hydrophilic intermittent catheters.
62526216|NCT04619992|OTHER|New users of Hollister standard with tip hydrophilic intermittent catheters|Subjects in this arm are new users of Hollister standard with tip hydrophilic intermittent catheters.
62526217|NCT01335997|EXPERIMENTAL|ERN/LRPT/SIM → ERN/LRPT+SIM|Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.
62713357|NCT01554098|ACTIVE_COMPARATOR|Strategy : supine first|"This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.~Withdrawal in supine position followed by withdrawal with dynamic position change"
62713358|NCT01554098|ACTIVE_COMPARATOR|Strategy : dynamic first|This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
62153091|NCT02256241||The role of RING ubiquitin ligases in osteogenic progenitors|Bone marrow (BM) will be collected from healthy patients undergoing orthopedic surgery. BM will be collected from disposable tissue that is removed during the normal sequence of the surgery.
62153092|NCT02256241||The role of RING ubiquitin ligases in musculoskeletal cancer|Collection of connective tissue from patients with tumors of musculoskeletal origin - a part of the resected tumor specimens.
62153093|NCT04087239||Pregnant women from >20 weeks gestation|1,200 pregnant women (600 HIV infected mothers and 600 HIV uninfected controls) at least 20 weeks gestation were enrolled from January 2016 to June 2019. Participants are being followed as mother-baby pairs at birth, within 10 days of life 6, 10, 14 24, 48, 72 and 96 weeks of age. At each visit clinical examinations are being used to assess health and the impact of environmental factors. In addition, questionnaires are administered and bio-samples for laboratory tests. The design of the study is non-interventional cohort but participants are being offered advice regarding health and hygiene.
62153094|NCT03397147|NO_INTERVENTION|Usual Care|Usual Care
62153095|NCT03397147|EXPERIMENTAL|Sleep Coach Jr.|Parents randomized to the intervention condition will receive a binder with the treatment manual, and the intervention will be administered in person (first session) and via telephone (second session) on an individual basis. The first session will focus on parent education and developing a positive bedtime routines, and the second session will be used to address barriers specific to the individual child.
62153096|NCT04897347|EXPERIMENTAL|Robotic Trunk-Support-Trainer (TruST)|Postural-reaching control intervention with TruST
62153097|NCT04897347|ACTIVE_COMPARATOR|Static Trunk Support|Postural-reaching control intervention with Rigid Trunk Support
62153098|NCT01942525||Intrauterine growth restriction|birth weight \<10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
62153099|NCT01942525||Appropriate for gestation age|control group with birth weight \>10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
62153100|NCT00113529|EXPERIMENTAL|Sunitinib + Gefitinib|"Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib"
62526218|NCT01335997|ACTIVE_COMPARATOR|ERN/LRPT+SIM → ERN/LRPT/SIM|Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.
62526219|NCT06476366|ACTIVE_COMPARATOR|Methotrexate arm|After the enrollment of patients and taking consent, participants will be divided in two treatment groups via lottery method. Group A will be administered oral methotrexate 10mg/week after a test dose
62526220|NCT06476366|ACTIVE_COMPARATOR|Azathioprine|group B will be administered tablet azathioprine at a dose of 0.3mg/kg daily after. Both group of patients will be advised regarding strict sun protection measures (sunblock, hats, sunglasses etc.). The baseline investigations for both groups will include complete blood picture (CBC), liver function tests (LFTs), renal function tests (RFTs), electrocardiogram, chest X-ray and urine analysis while thiopurine methyltransferase (TPMT) levels will be assessed specifically for group B patients. The patients will be followed up at week 4, 12 and 24. CBC, RFTs and LFTs will be done at each follow-up and EASI score will be calculated,
62526221|NCT00554307||Indo|Infants that are treated with indomethacin
62526222|NCT00554307||Neo|Infants treated with neoprofen
62526223|NCT00554307||Control|Infants without PDA
62526224|NCT01904617|EXPERIMENTAL|D5NS at 125 mL/hr|5% dextrose in normal saline at 125 mL/hr
62526225|NCT01904617|EXPERIMENTAL|D2.5NS at 250mL/hr|2.5% dextrose in normal saline at 250 mL/hr
62526226|NCT01904617|EXPERIMENTAL|NS at 250mL/hr|Normal saline at 250mL/hr
62526227|NCT05993117|EXPERIMENTAL|G114R VNS system|
62526228|NCT02177136|EXPERIMENTAL|1.5 mg OCA titrating to 3 mg OCA|Participants randomized to 1.5 mg OCA took 1.5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 3 mg OCA daily for an additional 12 weeks.
62526229|NCT02177136|EXPERIMENTAL|5 mg OCA titrating to 10 mg OCA|Participants randomized to 5 mg OCA took 5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 10 mg OCA daily for an additional 12 weeks.
62526230|NCT02177136|EXPERIMENTAL|Placebo|Participants randomized to placebo took placebo for 24 weeks during the DB phase.
62526231|NCT02177136|EXPERIMENTAL|LTSE OCA Total|Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the LTSE phase (planned as a further 24 months) beginning at 5 or 10 mg OCA, based on the last treatment received during the DB phase. Doses up to 10 mg daily were evaluated. All participants received open-label OCA during the LTSE phase of the study.
62526232|NCT00523536|EXPERIMENTAL|1|Patient navigator-nurse disease management intervention
62713359|NCT04548973|EXPERIMENTAL|Esketamine Group|At the beginning of the operation, 0.25mg/kg ketamine was administered intravenously, and normal saline was diluted to 2mL to assist sedation and analgesia
62713360|NCT04548973|PLACEBO_COMPARATOR|Control Group|At the beginning of the operation, 2ml normal saline was given intravenously
62526233|NCT00523536|NO_INTERVENTION|2|Usual clinical care
62526234|NCT03914950|OTHER|PET/CT results with TOF/without TOF|"* Diagnostic CT of the abdomen or upper abdomen (in case of already performed diagnostic CT of the abdomen \< 2 weeks ago) with 2 phases, 1 - 4 mSv, ca. 20 sec., 1 x~* Contrast medium (Iodixanol 550 mg/ml) 1 x 1.4 ml/kg body weight i.v. for 40 sec, 1 x if creatinine, GFR, and TSH levels are within the normal range~* 1 x 500 ml water oral, 1 x~* Biopsy or FNA (fine-needle aspiration) or operation of the pancreas"
62526235|NCT04327713||fish oil supplementation|"fish oil supplementation, usually capsules with a defined content of EPA and DHA~dosage and duration of intervention differ between the included studies of our meta-analysis"
62713361|NCT02971371|EXPERIMENTAL|Virtual Reality|This group performed 40 45-min Lokomat sessions, five times a week, by using a visual feedback showing a Virtual Reality run game where the patient had to collect or avoid objects, to motivate him/her to walk actively.
62713362|NCT02971371|ACTIVE_COMPARATOR|Only RAGT|This groups performed 40 Lokomat sessions (40-45min), five times a week, between 9am and 11am, in this case was not provided an avatar, and a smile indicating the goodness of each leg movement.
62713363|NCT04427293|EXPERIMENTAL|Open Label|All participants will receive lenvatinib 12mg daily for 7 days and pembrolizumab 200 mg IV on day 1 prior to surgery
62526236|NCT04327713||placebo supplementation|"placebo supplementation, usually capsules with a defined content of non-fish oil or other components~content, dosage and duration of intervention differ between the included studies of our meta-analysis"
62713364|NCT03823989|EXPERIMENTAL|Promitil 1.25 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.25 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
62713365|NCT03823989|EXPERIMENTAL|Promitil 1.5 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.5 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
62526237|NCT01019863|EXPERIMENTAL|Oxaliplatin|oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
62526238|NCT00444093|EXPERIMENTAL|Opii normata treatment|Treamtment with opii normata in case of diarrhea
62526239|NCT00444093|EXPERIMENTAL|Loperamid Treatment|Treatment with Loperamid in case of diarrhea
62526240|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa simplex|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
62526241|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of junctional epidermolysis bullosa|"Female patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
62713366|NCT03823989|EXPERIMENTAL|Promitil 1.8 mg/kg|two treatment cycles, intravenous infusion of Promitil at a dosage of 1.8 mg/kg delivered at 21 days interval (confirmatory cohort) and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
62713367|NCT06127238|EXPERIMENTAL|ST-1898 Phase Ib|Dose Escalation:participants will be administered orally at 100mg,140mg,160mg,180mg, 220mg,QD during the study, until disease progression or intolerable toxicity.
62153101|NCT04686357|EXPERIMENTAL|Intervention group (mET)|Microbiome-driven embryo transfer of a single vitrified blastocyst in an HRT cycle according to the EMMA/ALICE test results.
62526242|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa dystrophic|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
62153102|NCT04686357|ACTIVE_COMPARATOR|Control group (FET)|Frozen embryo transfer of a single vitrified blastocyst in an HRT cycle according to the clinical standard practice.
62153103|NCT01623011|EXPERIMENTAL|Arthroscopic Sub-acromial Decompression|Arthroscopic sub-acromial decompression surgery.
62713368|NCT06127238|EXPERIMENTAL|ST-1898 Phase II|Dose Expansion: participants with advanced renal cell carcinoma will be dministered orally at recommended phase II dose from phase Ib once daily during the study, until disease progression or intolerable toxicity.
62713369|NCT05035160||Group 1|Pregnant and postpartum birthing persons with perinatal pathology.
62526243|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of Kindler syndrome|Female patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
62713370|NCT05035160||Group 2|Healthy pregnant and postpartum birthing persons.
62713371|NCT05035160||Group 3|Healthy non-pregnant persons (healthy volunteers).
62713372|NCT04870944|EXPERIMENTAL|Treatment (CBL0137)|Patients receive CBL0137 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy at baseline, ECHO prior to cycle 1, and as clinically indicated undergo collection of blood samples throughout the trial.
62713373|NCT04435691|EXPERIMENTAL|Treatment (azacitidine, venetoclax, magrolimab)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 (may be reduced to days 1-21 for subsequent cycles after principal investigator approval), and magrolimab IV over 2-3 hours on days 1, 4, 8, 11, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycle 2, and days 1 and 15 of cycle 3 and subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62713374|NCT00873275|EXPERIMENTAL|Treatment (ursodiol, combination chemotherapy, bevacizumab)|Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62713375|NCT06497309||Treadmill group|In both groups, using advanced technology-based tools (both treatments are part of the daily routine of the Institute's treatments and are used according to the instructions in the user manual), for the treadmill therapy, we use the C-Mill interactive high-tech device.
62713376|NCT06497309||Overground group|In both groups, we use an advanced technology-based device (both treatments are part of the daily routine of the Institute's treatments and are used according to the instructions in the user manual), and the Andago high-tech device for non-runner therapy.
62153104|NCT01623011|ACTIVE_COMPARATOR|Shoulder Arthroscopy|Shoulder arthroscopy only.
62526244|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa simplex|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
62526245|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of junctional epidermolysis bullosa|"Male patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
62526246|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa dystrophic|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
62526247|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of Kindler epidermolysis bullosa|Male patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
62153105|NCT01623011|OTHER|Active Monitoring with Specialist Reassessment|Active monitoring with specialist reassessment - non-operative control.
62153106|NCT05390710|EXPERIMENTAL|Triple combination|LAE005+Afuresertib+Nab-Paclitaxel
62153107|NCT05120505|EXPERIMENTAL|Metformin group|The patients will be obtain Metformin starting from 50mg everyday to 1-2g per day for 6 months.
62153108|NCT05120505|PLACEBO_COMPARATOR|Placebo group|The patients will be obtain starch tablets starting from 50mg everyday to 1-2g per day for 6 months.
62153109|NCT04552457|EXPERIMENTAL|No activity restrictions|
62153110|NCT04552457|ACTIVE_COMPARATOR|Activity restrictions|
62153111|NCT03979040|EXPERIMENTAL|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
62153112|NCT03979040|ACTIVE_COMPARATOR|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and Major Depressive Disorder (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
62153113|NCT01531413|EXPERIMENTAL|Oxygen Insufflation|At the end of the laparoscopic appendectomy we will desufflate the abdomen of CO2 then reinsufflate with oxygen to washout the CO2 leaving an oxygen rich environment
62153114|NCT06510400|EXPERIMENTAL|OMNICHROMA|single shade composite was placed to prepared tooth enamel via U veneer template technique
62713377|NCT03759496|EXPERIMENTAL|Durvalumab treated patients|Subjects will receive up to 1000mg durvalumab (MEDI4736) via weekly intravesical administration, for up to a maximum of 6 weeks or until confirmed progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
62713378|NCT01465841|EXPERIMENTAL|Embolization with the PC 400 coils|
62713379|NCT04632017||pPROM|Singleton pregnancies admitted for pPROM to the Obstetrics ward
62713380|NCT04632017||Control group|Healthy pregnant women matched for gestational age
62713381|NCT02875470|EXPERIMENTAL|Intensiv Perio Set|Root planing with diamond burs
62153115|NCT06510400|EXPERIMENTAL|Ceram. x spectra|multi shade composite was placed to prepared tooth enamel via U veneer template technique
62153116|NCT00603278|PLACEBO_COMPARATOR|Arm 1|
62153117|NCT00603278|EXPERIMENTAL|Arm 2|
62153118|NCT01482091|PLACEBO_COMPARATOR|Intranasal Saline|
62153119|NCT01482091|EXPERIMENTAL|Intranasal Fentnayl|
62153120|NCT05371002|EXPERIMENTAL|Online group nonviolent communication (NVC) interventions|"Rosenberg's Nonviolent Communication: A Language of Life: Life-changing Tools for Healthy Relationships and Raising Children Compassionately: Parenting the Nonviolent Communication Way will be used as reference guides. Six 1.5-hour weekly online group sessions (10-14 participants in each group) will be delivered by NVC professionals to the intervention group, including (1) introduction to four key principles of NVC, communication that blocks compassion, and distinguishing observations from evaluations, (2) identifying and expressing feelings, providing a list of words to express feelings and four steps to express anger, (3) taking responsibility for feelings (needs), distinguishing between an outside event and the met or unmet needs behind the feelings, (4) using positive action language to make requests, (5) review and summary, and (6) experience sharing and suggestions for further practice. Group discussion will be used to sustain the participants' engagement."
62153121|NCT05371002|ACTIVE_COMPARATOR|Waitlist control group|The participants in WL group will not be provided any materials or training content between baseline (T1) and immediate post assessment (T2). Once the participants completed the T2 assessments, they will be delivered one 1.5-hour online session about physical activity (completely different from NVC training content). In the session, the participants will be introduced the concept of Zero-time exercise and provided video demonstrations of exercise. Six 1.5-hour weekly NVC training sessions (the same as those in intervention group) will be delivered to participants as soon as they have completed the final assessment at T3 (three months after T2).
62153122|NCT04520321|PLACEBO_COMPARATOR|Vehicle (placebo)|Placebo weekly x 4
62153123|NCT04520321|EXPERIMENTAL|Low dose|TTHX1114(NM141) low-dose weekly x 4
62153124|NCT04520321|EXPERIMENTAL|Mid-dose|TTHX1114(NM141) mid-dose weekly x 4
62153125|NCT04520321|EXPERIMENTAL|High-dose|TTHX1114(NM141) high-dose weekly x 4
62526248|NCT00602277|EXPERIMENTAL|Treatment (viral therapy)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5 in course 1, followed by insertion of an IP access port. Beginning in course 2, patients receive wild-type reovirus IV over 60 minutes on days 1-5 and wild-type reovirus IP over 10 minutes on days 1 and 2\*. Treatment with IV and IP wild-type reovirus repeats every 28 days in the absence of disease progression or unacceptable toxicity. (phase II closed as of 1/7/2011). NOTE: \*Patients receive IP wild-type reovirus on days 2 and 3 in course 3.
62526249|NCT03374241|EXPERIMENTAL|Cohort 1|HM15211 or Placebo (single dose, subcutaneous injection)
62526250|NCT03374241|EXPERIMENTAL|Cohort 2|HM15211 or Placebo (single dose, subcutaneous injection)
62153126|NCT01735435|NO_INTERVENTION|Group 2 (Control group)|Group 2(Control group)-patients in this group received nutrition according to the standard hospital dietary regimen.
62153127|NCT01735435|EXPERIMENTAL|Group 1 (Indirect Calorimetry)|Group 1(Indirect Calorimetry)-The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
62153128|NCT00570622|ACTIVE_COMPARATOR|1|Patients receive 60mg of pioglitazone once a day orally for 9 days
62153129|NCT00570622|PLACEBO_COMPARATOR|2|Patients receive Placebo orally once a day for 9 days
62153130|NCT00853957|EXPERIMENTAL|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
62153131|NCT00853957|ACTIVE_COMPARATOR|Amlodipine|Amlodipine 5mg titrated to 10 mg
62153132|NCT00201656|ACTIVE_COMPARATOR|1 Retention of Cerclage|Group one = Subject whose Cerclage is retained after randomization.
62153133|NCT00201656|ACTIVE_COMPARATOR|2 - Removal of Cerclage|Group 2 = Subjects who will have cerclage removed after randomization
62153134|NCT04151030|EXPERIMENTAL|Endoscopic-PEG|"The patients who are unable to undergo an endoscopic pull PEG placement, will undergo an Endoscopic introducer style Direct-PEG procedure at the time of the index endoscopy"
62153135|NCT04151030|ACTIVE_COMPARATOR|IR-PEG|Patients who underwent PEG placement by interventional radiology (IR-PEG).
62526251|NCT03374241|EXPERIMENTAL|Cohort 3|HM15211 or Placebo (single dose, subcutaneous injection)
62526252|NCT03374241|EXPERIMENTAL|Cohort 4|HM15211 or Placebo (single dose, subcutaneous injection)
62526253|NCT03374241|EXPERIMENTAL|Cohort 5|HM15211 or Placebo (single dose, subcutaneous injection)
62526254|NCT03863093|EXPERIMENTAL|An erythritol powder|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
62526255|NCT03863093|ACTIVE_COMPARATOR|ultrasonic instrumentation|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
62526256|NCT06167590|OTHER|Anxious-depressive disorder|
62526257|NCT06167590|OTHER|Healthy controls|
62526258|NCT02159170|EXPERIMENTAL|NGF|injection of 50 µl NGF, once into the left volar forearm and injection of 50 µl NaCl (sodium chloride) once into the right volar forearm
62526259|NCT01321619|EXPERIMENTAL|Varicell|Drug A(Varicell) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
62526260|NCT01321619|EXPERIMENTAL|Placebo daflon (Drug D)|Drug D (Placebo Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
62526261|NCT00672165|EXPERIMENTAL|1|This is a phase I, dose-escalation trial. The starting dose level will be 0.5 μCi/kg of 225Ac-HuM195. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose limiting toxicity. Six patients will be treated at the maximum tolerated dose
62713382|NCT02875470|ACTIVE_COMPARATOR|Gracey curette|Root planing with Gracey curettes
62713383|NCT04155398||Study group|Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study
62713384|NCT05565586|EXPERIMENTAL|High-Fiber Diet (HFD) Intervention|Participants are expected to eat only the study meals and snacks provided
62526262|NCT03245645|EXPERIMENTAL|100% Fructose|The fructose group will help to determine whether an absolute amount of fructose will lead to IBS symptoms.
62153136|NCT01381341|EXPERIMENTAL|linifanib|
62526263|NCT03245645|PLACEBO_COMPARATOR|100% Glucose|The glucose group will serve as a control since glucose is not a FODMAP and as a result is not expected to lead to recurrent symptoms.
62713385|NCT05565586|EXPERIMENTAL|Prebiotic Food-Enriched Diet (PreFED) Intervention|Participants are expected to incorporate study snacks and meal components provided into your usual diet.
62713386|NCT04129307|EXPERIMENTAL|Motor Imagery|
62713387|NCT04129307|EXPERIMENTAL|Double time Motor imagery|
62713388|NCT04129307|ACTIVE_COMPARATOR|Action observation|
62713389|NCT05469919|EXPERIMENTAL|Ceralasertib monotherapy|This is a sequential group treatment/dose-escalation study with 2 cohorts with no masking.
62713390|NCT06258005||PocDoc testing of primary care patients|There are significant numbers of patients in primary care who should be given annual lipid checks who are not receiving them. PocDoc is a digital rapid 5-marker lipid panel that uses a smartphone as a diagnostic reader. PocDoc tests will be offered to patients overdue their annual lipid check either in surgery, in the community or in their own home.
62153137|NCT02458274||Patient without bronchiolitis obliterans syndrome|Lung transplanted patient without bronchiolitis obliterans syndrome
62153138|NCT02458274||Patient with bronchiolitis obliterans syndrome|Patient with bronchiolitis obliterans syndrome three years after lung transplantation.
62153139|NCT02346409|EXPERIMENTAL|LFP-MEG recording with tACS of the cerebellum|To explore how cerebellar stimulation (using tACS) will alter oscillations and coupling along the CTC pathway, relating these changes in brain activity to clinical improvement.
62153140|NCT02346409|ACTIVE_COMPARATOR|tACS of the cerebellum vs VIM-DBS|To evaluate the differential effects of non invasive high-frequency stimulation tACS of the cerebellum, as compared to high-frequency stimulation of the thalamus (using DBS of the VIM).
62153141|NCT03493282|ACTIVE_COMPARATOR|300 mg|High Dose CT1812
62153142|NCT03493282|ACTIVE_COMPARATOR|100 mg|Low Dose CT1812
62153143|NCT03493282|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62153144|NCT03129009|ACTIVE_COMPARATOR|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
62526264|NCT03245645|ACTIVE_COMPARATOR|Fructose and Glucose|The glucose/fructose mixture group is a cross comparison group that will determine whether the relative excess fructose concentration is an important cause of IBS symptoms.
62526265|NCT00593632|EXPERIMENTAL|High Fiber Intake|Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
62526266|NCT05690503|EXPERIMENTAL|CI-581a+CI-581b|Administration of CI-581a at 0.8mg/kg during week 1. Administration of CI-581b at 0.025mg/kg during week 3.
62526267|NCT05690503|EXPERIMENTAL|CI-581b+CI-581a|Administration of CI-581b at 0.025mg/kg during week 1. Administration of CI-581a at 0.8mg/kg during week 3.
62713391|NCT06258005||Pocdoc testing in the community|Providing lipid testing in community settings such as in pharmacy may offer a more attractive solution to consumers. This hypothesis will be tested by offering PocDoc lipid tests in a community setting.
62713392|NCT06258005||PocDoc testing in workplaces|Providing lipid testing as part of a health wellness screen in employees workplaces in may offer an attractive solution to consumers needing their lipid levels check. This hypothesis will be tested by offering PocDoc lipid tests as part of corporate wellness screens.
62713393|NCT00165828|EXPERIMENTAL|1|
62153145|NCT03129009|EXPERIMENTAL|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
62153146|NCT00973414|ACTIVE_COMPARATOR|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before CSEA
62153147|NCT00973414|ACTIVE_COMPARATOR|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after CSEA
62153148|NCT00973414|ACTIVE_COMPARATOR|Prior colloid|Colloid (6% hydroxyethyl starch) was given before CSEA
62153149|NCT00973414|ACTIVE_COMPARATOR|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after CSEA
62153150|NCT01237977|EXPERIMENTAL|Botulinum toxin type A(Meditoxin®)|
62153151|NCT01237977|ACTIVE_COMPARATOR|Botulinum toxin type A(Botox®)|
62153152|NCT00006079|EXPERIMENTAL|Arm I|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
62713394|NCT00165828|EXPERIMENTAL|2|
62713395|NCT06284759|EXPERIMENTAL|Intervention|Patients in the intervention group were monitored with a tele-nursing application based on Orem's Self-Care Theory, and training and counseling were provided for 6 weeks after discharge. Post-discharge interviews were conducted by resercher via phone call and video conference (zoom, WhatsApp, etc.). The video conference method was presented to the patient's preference and the decision was made together. The interview with each patient lasted an average of 30 minutes. Patients in the intervention group were sent infographics prepared in line with the theory, including the interview content and suggestions after each interview. The study focuses on post-discharge tele-nursing practice follow-up outcomes. Baseline data were collected at the hospital on the 2nd and 3rd postoperative day. Post-discharge data were collected on the 7th-10th day, 18th-21st day and 40th-45th day.
62713396|NCT06284759|NO_INTERVENTION|Control|Patients in the control group were discharged in accordance with the current hospital procedure. No intervention was made. The study focuses on post-discharge tele-nursing practice follow-up outcomes. Baseline data were collected at the hospital on the 2nd and 3rd postoperative day. Post-discharge data were collected on the 7th-10th day, 18th-21st day and 40th-45th day. It was collected by phone call or video conference (zoom, WhatsApp, etc.).
62713397|NCT04001842|EXPERIMENTAL|Axially vascularized constructs|Reconstructing a mandibular defect using an axially vascularized bone substitute using the arteriovenous loop (AVL)
62526268|NCT03400072|EXPERIMENTAL|Unsupervised APA program|usual care plus a 6-month unsupervised APA program
62526269|NCT03400072|EXPERIMENTAL|Supervised APA program|usual care plus a 6-month supervised APA program
62526270|NCT03400072|NO_INTERVENTION|Usual care|Usual care
62526271|NCT05301530|EXPERIMENTAL|Faceptor + Docetacel|Patients received a loading dose of Faceptor 8 mg/kg IV + docetaxel 75 mg/m\^2 IV on Cycle 1 followed by Faceptor 6 mg/kg IV + docetaxel 75 mg/m\^2 IV on the next 5 cycles (each cycle is 21 days)
62526272|NCT05301530|ACTIVE_COMPARATOR|Herceptin + Docetacel|Patients received a loading dose of Herceptin 8 mg/kg IV + docetaxel 75 mg/m\^2 IV on Cycle 1 followed by Herceptin 6 mg/kg IV + docetaxel 75 mg/m\^2 IV on the next 5 cycles (each cycle is 21 days)
62713398|NCT00776230|ACTIVE_COMPARATOR|IC51 (~12 months post filling)|6 mcg (\~12 months post filling)
62153153|NCT00006079|EXPERIMENTAL|Arm II|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
62153154|NCT00006079|PLACEBO_COMPARATOR|Arm III|Arm III: Patients receive oral placebo daily. Treatment continues for 28 days.
62153155|NCT05702892|EXPERIMENTAL|periodontitis|
62153156|NCT05702892|EXPERIMENTAL|gingivitis|
62153157|NCT05702892|EXPERIMENTAL|periodontal healthy|
62153158|NCT03647449|EXPERIMENTAL|Juice fast|"In the juice fasting arm, participants will be given vegetable/fruit pressed juices and be instructed to engage in a three-day juice fast diet totaling 800-900 kcal-per-day. The specific juices will be assigned for each day in order to maintain the calorie level."
62713399|NCT00776230|ACTIVE_COMPARATOR|IC51 (~18 months post filling)|6 mcg (\~18 months post filling)
62713400|NCT00776230|ACTIVE_COMPARATOR|IC51 (~24 months post filling)|6 mcg (\~24 months post filling)
62153159|NCT03647449|EXPERIMENTAL|Caloric restriction via Plant-based meals|"In the caloric restriction diet arm, participants will be on a whole-food plant-based diet totaling 800-900 kcal-per-day (matching the daily calories of juice fasting)."
62153160|NCT03647449|EXPERIMENTAL|Juice plus ad hoc|"In the juice plus ad hoc arm, participants will be given the same juice for three days but continue with their usual diet in addition to the juice. For this arm, there is no restriction of caloric intake or restriction to liquid only."
62713401|NCT04812925|EXPERIMENTAL|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
62713402|NCT06631144|EXPERIMENTAL|Caregiver-Enabled Care Group|"Caregiver participants will receive Ceresti's Caregiver-Enabled Care Program. (CECP) is a 6-month non-medical digital program that promotes the wellness of family caregivers, and increases their knowledge, skills and confidence (activation) in caring for a loved one with dementia. CECP delivers personalized health education, access to resources, proactive coaching, personalized support, and remote monitoring via a dedicated tablet that is shipped to the caregiver's home."
62153161|NCT00689416|EXPERIMENTAL|1|
62153162|NCT00689416|PLACEBO_COMPARATOR|2|
62713403|NCT06059300|EXPERIMENTAL|Intervention group|18200 participants who will be screened with tomosynthesis instead of digital mammography. All participants will be asked to participate in the study for 2 screening rounds. The number of participants for the second round will be less, due to drop-outs.
62713404|NCT02025790|EXPERIMENTAL|Group A - POEM|Per Oral Endoscopic Myotomy for treatment of achalasia
62713405|NCT02025790|ACTIVE_COMPARATOR|Group B - Dilatation|- Pneumatic dilatation using a balloon for treatment of achalasia.
62153163|NCT03989778|EXPERIMENTAL|Vitamin D supplement|The intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas
62153164|NCT03989778|NO_INTERVENTION|Control|control group will receive Metformin treatment during the study period.
62526273|NCT06014749||Patient under serratus intercostal plane block|patients who will undergo a modified bilateral ultrasound-guided BRILMA block (SIPB) using a high-frequency linear probe (6-15 Hz) and 80 mm needle.
62526274|NCT06014749||patient under epidural analgesia|patients who undergo Epidural Analgesia prior to General Anesthesia and fentanyl 1 mcg/kg approx according to characteristics and needs and upon arrival at the URPA is connected to the PC Levobupi 0.125% at 6 ml / h + rescue boluses of Levobupi 0.125% 4 ml if needed in the 1st hours.
62526275|NCT00368901|EXPERIMENTAL|Single arm|Every other week dosing of Aranesp SC
62526276|NCT02274844|EXPERIMENTAL|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
62153165|NCT00816205|EXPERIMENTAL|Single Arm|This is an open label, dose-finding study. After detrminig baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 3 Coated Suppositories per study.
62153166|NCT01662232|ACTIVE_COMPARATOR|Green tea beverage|200 mg EGCG as green tea beverage.
62153167|NCT01662232|ACTIVE_COMPARATOR|Green tea extract|200 mg EGCG as green tea extract and same volume water as for tea beverage.
62153168|NCT01662232|ACTIVE_COMPARATOR|Epigallocatechin-3-gallate (EGCG)|200 mg EGCG and same volume water as for tea beverage.
62153169|NCT01662232|PLACEBO_COMPARATOR|Placebo (Water)|Same volume water as for all intervention arms.
62713406|NCT04092634|EXPERIMENTAL|Dual mobility|Patients in this group will receive a dual mobility hip implant
62713407|NCT04092634|ACTIVE_COMPARATOR|Single bearing, traditional hip implant|Patients in this group will receive a traditional, single-bearing hip implant.
62153170|NCT04345588|ACTIVE_COMPARATOR|group received dexamethasone perineural|injection dexamethasone 0.05 mg/kg perineural.
62153171|NCT04345588|ACTIVE_COMPARATOR|group received dexamethasone intravenous|injection dexamethasone 0.05 mg/kg intravenously.
62153172|NCT00272415|EXPERIMENTAL|1|
62153173|NCT06075641|ACTIVE_COMPARATOR|Surgical Stripping|
62153174|NCT06075641|EXPERIMENTAL|Erbium, chromium:yttrium-scandium-gallium-garnet (Er,Cr:YSGG) Laser Techniques|
62526277|NCT02274844|NO_INTERVENTION|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
62526278|NCT01513564|EXPERIMENTAL|Conservative treatment program|"The control group were supervised isometric passive and active exercises by a physiotherapist. On the second day patients were allowed to sit in a chair being instructed to a low intensity exercise training program with regard to back pain and fear of activity. From the third or fourth day stair training, low intensity exercise, daily walks and instruction in home training were allowed.~The intervention group received the same training program but with a faster program plus a higher intensity exercise-training program."
62526279|NCT05386082||Study participants|Study participants
62526280|NCT00541970|EXPERIMENTAL|Cervarix 1/Placebo Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
62526281|NCT00541970|EXPERIMENTAL|Cervarix 1/Placebo/Cervarix 1 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
62526282|NCT00541970|EXPERIMENTAL|Cervarix 2/Placebo/Cervarix 2 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
62526283|NCT00541970|EXPERIMENTAL|Cervarix 2 Group|Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
62526284|NCT01676077||Patients with a genetically confirmed dysferlinopathy|
62526285|NCT03123861|ACTIVE_COMPARATOR|Gabapentin|Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.
62526286|NCT03123861|PLACEBO_COMPARATOR|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
62526287|NCT04713098|EXPERIMENTAL|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
62526288|NCT04713098|SHAM_COMPARATOR|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
62526289|NCT01584206|EXPERIMENTAL|Ezetimibe|Compare on and off ezetimibe
62526290|NCT05913466|EXPERIMENTAL|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
62526291|NCT05913466|PLACEBO_COMPARATOR|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
62526292|NCT01043120|EXPERIMENTAL|Barusiban|
62153175|NCT01543204|EXPERIMENTAL|Etanercept 50 mg|Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
62153176|NCT04813965|NO_INTERVENTION|Control|Participants in the control group received standard information on treatment side-effects.
62526293|NCT01043120|PLACEBO_COMPARATOR|Placebo|
62526294|NCT01208220|ACTIVE_COMPARATOR|Negative pressure wound therapy|NPWT changed TIW
62526295|NCT01208220|EXPERIMENTAL|NPWT plus Collagenase Ointment|Collagenase applied TIW with NPWT
62153177|NCT04813965|EXPERIMENTAL|Information without self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information group received standard information with additional written information about potential chemotherapy-related cognitive symptoms.
62153178|NCT04813965|EXPERIMENTAL|Information with self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information+SA group (SA=self-affirmation) received standard and additional written information about potential chemotherapy-related cognitive symptoms with a subsequent self-affirmative text.
62153179|NCT00864188|PLACEBO_COMPARATOR|1|Glucono-Delta-Lactone acidified milk containing no bacterial strains
62526296|NCT02906930|EXPERIMENTAL|3 mg oral semaglutide|
62526297|NCT02906930|EXPERIMENTAL|7 mg oral semaglutide|
62526298|NCT02906930|EXPERIMENTAL|14 mg oral semaglutide|
62526299|NCT02906930|PLACEBO_COMPARATOR|Placebo|
62526300|NCT04667260|PLACEBO_COMPARATOR|Bone substitue|Bone augmentation with bone substitute
62526301|NCT04667260|EXPERIMENTAL|Coagulum|Bone augmentation with coagulum
62526302|NCT03580174|ACTIVE_COMPARATOR|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed physiotherapy
62526303|NCT03580174|ACTIVE_COMPARATOR|Routine physiotherapy group|Ten children with CP will receive conventional, traditional physiotherapy
62526304|NCT04002336|ACTIVE_COMPARATOR|Traditional Voice Therapy|Standard of care (traditional) voice therapy.
62526305|NCT04002336|EXPERIMENTAL|App Group|Voice therapy using a smartphone app.
62713408|NCT05776524|EXPERIMENTAL|GEM-ABR [Gemcitabine - Abraxane (nab-Paclitaxel)] with TheraBionic device|Metastatic pancreatic cancer patients will be treated with amplitude-modulated radiofrequency electromagnetic fields using TheraBionic device in combination with standard chemotherapy, gemcitabine- nab-paclitaxel. amplitude-modulated radiofrequency electromagnetic fields will be delivered by the TheraBionic device.
62526306|NCT04769687|EXPERIMENTAL|Symbiotic Treatment : probiotic Vivomixx® + prebiotic Orafti®Synergy1|"The prebiotic, Orafti®Synergy1, is made from a volume-to-volume mixture of oligofructoses and Raftiline HP. Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets that can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~The probiotic, Vivomixx®, consists of 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus and L. delbrueckii subsp. Bulgaricus) from 3 strains of Bifidobacterium (B. longum, B. breve, and B. infantis) and a strain of streptococcus (S. salivarius subsp thermophilus). Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria which can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~For the study, the symbiotics will be packaged by the probiotic manufacturer in the same sachet (at the same doses as mentioned above) whether for the symbiotics or for the placebo."
62153180|NCT00864188|EXPERIMENTAL|2|Glucono-Delta-Lactone acidified milk containing one probiotic strain called Lactobacillus paracasei NCC2461.
62153181|NCT00864188|PLACEBO_COMPARATOR|3|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii subsp.bulgaricus.
62526307|NCT04769687|PLACEBO_COMPARATOR|Placebo|
62526308|NCT04415736||Delayed cerebral ischemia|Patients with subarachnoid hemorrhage that develop delayed cerebral ischemia
62526309|NCT04415736||Non delayed cerebral ischemia|Patients with subarachnoid hemorrhage that do not develop subarachnoid hemorrhage
62526310|NCT03485183|EXPERIMENTAL|Intervention Group|The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0700 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
62526311|NCT03485183|OTHER|Control Group|The PI will perform a chart review of patients who were admitted the month prior to the intervention being implemented. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid. These patients will receive the standard of care for delirium prevention.
62526312|NCT05620602||Remedial treatment within 3 months|
62526313|NCT05620602||Remedial treatment within 3 to 6 months|
62526314|NCT05620602||Remedial treatment within 6 to 12 months|
62526315|NCT05620602||Remedial treatment after 12 months|
62153182|NCT00864188|EXPERIMENTAL|4|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii and one probiotic strain called Lactobacillus paracasei NCC2461.
62713409|NCT05886036|EXPERIMENTAL|Arm I (Mosunetuzumab)|Patients receive mosunetuzumab SC on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience PD will be permitted to crossover to arm II at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT on study. Patients also undergo bone marrow biopsy and tissue biopsy at baseline, and blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and tissue biopsy at end of treatment.
62153183|NCT00864188|EXPERIMENTAL|5|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii, one probiotic strain called Lactobacillus paracasei NCC2461 and Vitamin B2,B3, C and E, Beta Carotene and an Oil.
62153184|NCT02214914|EXPERIMENTAL|BI 11634 drinking solution|single rising dose
62153185|NCT02214914|PLACEBO_COMPARATOR|Placebo|
62153186|NCT02214914|EXPERIMENTAL|BI 11634 tablet|
62153187|NCT01950689|PLACEBO_COMPARATOR|Placebo|Placebo given in parallel with radiotherapy for 6 weeks.
62153188|NCT01950689|EXPERIMENTAL|Nimorazole|Nimorazole given in parallel with radiotherapy for 6 weeks
62153189|NCT05691400|EXPERIMENTAL|CYP3A4*1/*1|"This arm will include subjects with CYP3A4\*1/\*1 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
62526316|NCT01436799|EXPERIMENTAL|Desflurane|anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane
62153190|NCT05691400|EXPERIMENTAL|CYP3A4*1/*22|"This arm will include subjects with CYP3A4\*1/\*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
62153191|NCT05691400|EXPERIMENTAL|CYP3A4*22/*22|"This arm will include subjects with CYP3A4\*22/\*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
62153192|NCT04274127|OTHER|children aged 16 to 24|estimate the positive predictive value of an early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
62526317|NCT01436799|ACTIVE_COMPARATOR|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model
62526318|NCT01155024|OTHER|Traditional Socket First, then DM Socket|Initial fitting of a traditional diagnostic prosthetic socket in first intervention period and initial fitting of a direct manufactured prosthetic socket in the second intervention period
62526319|NCT01155024|OTHER|DM Socket First, then Traditional Socket|Initial fitting of a direct manufactured prosthetic socket in first intervention period and initial fitting of a traditional diagnostic prosthetic socket in the second intervention period
62526320|NCT06204211||High myopia|HM participants characterized by AL ≥ 26.00 mm or SE ≤ -6.00 D in at least one eye at the Department of Ophthalmology of the First Affiliated Hospital of Zhengzhou University (Zhengzhou, Henan Province, China) from May 2022 to April 2023 are included as cases.
62526321|NCT06204211||Control|Demographic-matched emmetropic volunteers without consanguinity serve as controls.
62526322|NCT01021826||Hip and knee replacements recipients|Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
62526323|NCT04732481||interventional group|passive leg lift test
62153193|NCT03489811|EXPERIMENTAL|Test Essential Oil Blend|Participants in this arm receive the test essential oil inhaler to administer during the 4-week intervention.
62153194|NCT03489811|ACTIVE_COMPARATOR|Active Essential Oil Blend|Participants in this arm receive an active essential oil inhaler to administer during the 4-week intervention.
62153195|NCT03489811|PLACEBO_COMPARATOR|Control|Participants in this arm receive a control inhaler to administer during the 4-week intervention.
62153196|NCT06504719||Patients treated with trastuzumab deruxtecan or sacituzumab govitecan|Patients with TNBC, HER2-positive and/or hormone receptor positive advanced breast treated with trastuzumab deruxtecan or sacituzumab govitecan
62153197|NCT02718885|SHAM_COMPARATOR|Maltodextrin|Maltodextrin
62153198|NCT02718885|ACTIVE_COMPARATOR|Inulin|Inulin-type fructans
62526324|NCT04732481||control group|no intervention (SOC)
62526325|NCT04927026|EXPERIMENTAL|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|Solution-focused brief therapy (SFBT) involving psychoeducation and structured life review therapy, as well as mindfulness-based training
62526326|NCT04927026|NO_INTERVENTION|Control|No intervention
62526327|NCT02288182|EXPERIMENTAL|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of \> 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and \< 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
62526328|NCT02288182|ACTIVE_COMPARATOR|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
62153199|NCT05547724|EXPERIMENTAL|Virtual reality|
62153200|NCT06500104|EXPERIMENTAL|Kefir|Daily oral kefir peptide (KEFPEP®) intake, dosage: 1.2 gram per day for 12 weeks
62713410|NCT05886036|ACTIVE_COMPARATOR|Arm II (Rituximab, Rituximab and hyaluronidase human)|Patients receive rituximab IV on day 1 and rituximab and hyaluronidase human SC on days 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 2 cycles 8 weeks apart in the absence of disease progression or unacceptable toxicity. Patients may receive rituximab IV on days 8, 15, and 22 of each cycle if rituximab and hyaluronidase human is not available. Patients who experience PD will be permitted to crossover to arm I at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT on study. Patients also undergo bone marrow biopsy and tissue biopsy at baseline, and blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and tissue biopsy at end of treatment.
62153201|NCT06500104|PLACEBO_COMPARATOR|Placebo|Daily oral glucose powder intake, dosage: 805mg per day for 12 weeks
62153202|NCT01827748|EXPERIMENTAL|Intraoperative Autorefractor IAR-1|This is a auto refractor mounted on an operating microscope.
62153203|NCT01827748|ACTIVE_COMPARATOR|Hartmann-Shack Auto Refractor|The Hartmann-Shack type auto refractor used with the subject sitting upright in front of the instrument.
62526329|NCT01949961|ACTIVE_COMPARATOR|Ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
62526330|NCT01949961|PLACEBO_COMPARATOR|Sham ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
62526331|NCT02023736|ACTIVE_COMPARATOR|Treatment as Usual|Patients in the Treatment as Usual condition receive the same psychotherapy treatment as they would were they not enrolled in the study.
62526332|NCT02023736|EXPERIMENTAL|Treatment as Usual with the STIC (TAU + STIC)|Patients in the TAU + STIC condition receive the treatment that they normally would from their therapist, but with the addition of the STIC measurement and feedback system.
62526333|NCT01066091|PLACEBO_COMPARATOR|mashed potatoes|Mashed potatoes is composed of potatoes and Skim milk powder.
62526334|NCT01066091|EXPERIMENTAL|Mashed potatoes + Oleic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 75% of Oleic Acid
62526335|NCT01066091|EXPERIMENTAL|Mashed potatoes + Palmitic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 39% of saturated fat with 32% of palmitic acid.
62526336|NCT05256134|EXPERIMENTAL|Gantenerumab|Gantenerumab will be administered as subcutaneous (SC) injection with gradual uptitration.
62526337|NCT05256134|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as SC injection with gradual uptitration.
62526338|NCT01705236|EXPERIMENTAL|Fingolimod - Longitudinal Assessment|No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.
62153204|NCT06470152|EXPERIMENTAL|Patients with ASD undergoing correction surgery in reference to our novel criteria|Correcting deformity according to the PI-dependent clustering of sagittal spinal alignment.
62153205|NCT06470152|OTHER|Patients with ASD undergoing correction surgery in reference to SAAS score.|Correcting deformity according to the SAAS score.
62526339|NCT06198036|ACTIVE_COMPARATOR|Group A: Application of Hold-Relax PNF Technique|A hold-relax technique that entails stretching the muscle to its maximum length. Participant will be in supine position. The hamstring muscle will be stretched for 7 to 10 seconds while the individual reported only a slight stretch in the muscle. The participant then attempts to lower his leg towards the table while being resisted by the researcher, isometrically contracting his hamstring muscle for 3 seconds. The patient then instructed to relax for five seconds. The researcher then passively stretched the muscle until a slight sensation of stretch was experienced. The stretch will maintain for seven seconds. There were five repetitions of this sequence, each one 20 seconds apart from the previous one
62526340|NCT06198036|ACTIVE_COMPARATOR|Group B: Application of Muscle Energy Technique|Group B will receive a Muscle Energy Technique (MET) applying the reciprocal inhibition principle. Participant will be in supine lying and the affected muscle held in a mid-range position. The Reciprocal Inhibition-MET group stretched for 10 to 60 seconds after performing an isometric contraction of the muscle opposite the one that needed to be stretched for 7 to 10 seconds (30%-50% of the time) followed by 5 second rest interval. With a pause of 20 seconds in between each repetition, this sequence was performed five times(52). The readings for Active knee Extension (AKE), TUG test and WBFPS before and after treatment session determined the improvement regarding the treatment outcomes.
62526341|NCT02674061|EXPERIMENTAL|Cohort A: Pembrolizumab|Participants in Cohort A received 0-2 prior lines of treatment for recurrent ovarian cancer (ROC; 1-3 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to \~1 additional year).
62713411|NCT04949009||Patients with primary immune thrombocytopenia (ITP)|"Ever been diagnosed as ITP patients. The diagnostic criteria comply with the Chinese Guidelines for the Diagnosis and Treatment of Adult Primary Immune Thrombocytopenia (2020 Edition)"
62713412|NCT03720366|EXPERIMENTAL|Arm 1: Administration of enasidenib and Arm 1 probes|Part 1: Subjects will receive prescribed doses of Arm 1 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 1 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
62153206|NCT01184105|EXPERIMENTAL|Cohort 1 (pre)|Active treatment or placebo
62153207|NCT01184105|EXPERIMENTAL|Cohort 2 (post)|Active treatment or placebo
62526342|NCT02674061|EXPERIMENTAL|Cohort B: Pembrolizumab|Participants in Cohort B received 3-5 prior lines of treatment for ROC (4-6 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to \~1 additional year)
62526343|NCT00675064|EXPERIMENTAL|Anti-malarial experimental drug|After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules.
62526344|NCT00675064|ACTIVE_COMPARATOR|Matching placebo|After randomization subjects will receive matching placebo of GSK3697969.
62526345|NCT04470336|ACTIVE_COMPARATOR|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
62526346|NCT04470336|OTHER|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
62526347|NCT04470336|PLACEBO_COMPARATOR|Placebo|Three capsules post-breakfast Three capsules post-dinner
62153208|NCT03073902||Observed group|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
62153209|NCT02899533||FES PET/CT scan|All subjects will receive an \[18F\]FES PET/CT scan.
62153210|NCT04523909||Thoracic aortic surgery patients|
62526348|NCT01578135||Phase I|
62153211|NCT01359163|ACTIVE_COMPARATOR|Femulen commercial tablets|
62153212|NCT01359163|EXPERIMENTAL|Femulen reformulated tablets|
62153213|NCT02626117|ACTIVE_COMPARATOR|CAF+ SCTG+ laser depithelialisation|CAF + SCTG and Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium.
62153214|NCT02626117|SHAM_COMPARATOR|CAF+SCTG+ sham laser depithelialisation|CAF+ SCTG+ sham LASER deepithelialisation was applied to remove the sulcular epithelium.
62153215|NCT03466645|ACTIVE_COMPARATOR|1st group, receiving vancomycin|The 1st group receives vancomycin an hour before craniotomy
62153216|NCT03466645|ACTIVE_COMPARATOR|2nd group, receiving cefazolin|The 2nd group receives cefazolin an hour before craniotomy
62153217|NCT05823714|EXPERIMENTAL|VEN+AZA+Modified BUCY|
62153218|NCT04884191|EXPERIMENTAL|Pacritinib 100 mg QD|
62153219|NCT04884191|EXPERIMENTAL|Pacritinib 100 mg BID|
62153220|NCT04884191|EXPERIMENTAL|Pacritinib 200 mg BID|
62153221|NCT01503450|EXPERIMENTAL|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
62153222|NCT01503450|ACTIVE_COMPARATOR|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
62153223|NCT00088166|EXPERIMENTAL|I|Patients will take hCRF (XERECEPT) 2mg/day and open label-dexamethasone they are currently taking.
62526349|NCT01578135||Phase II|
62526350|NCT00017537|EXPERIMENTAL|Dose #1|dose #1 administered
62526351|NCT00017537|EXPERIMENTAL|Dose #2|dose #2 administered
62526352|NCT00017537|EXPERIMENTAL|Dose #3|Dose #3 administered
62526353|NCT00017537|EXPERIMENTAL|Dose #4|Dose #4 administered
62526354|NCT00017537|EXPERIMENTAL|Dose #5|Administered dose #5
62526355|NCT00971841|EXPERIMENTAL|Paclitaxel|One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
62526356|NCT05425693|EXPERIMENTAL|Hybrid warm-up intervention|
62526357|NCT05425693|EXPERIMENTAL|Dynamic warm-up intervention|
62713413|NCT03720366|EXPERIMENTAL|Arm 2: Administration of enasidenib and Arm 2 probes|Part 1: Subjects will receive prescribed doses of Arm 2 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 2 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
62153224|NCT00088166|PLACEBO_COMPARATOR|II|Patient will receive placebo hCRF and any open-label dexamethasone that they are currently taking
62153225|NCT04739306|EXPERIMENTAL|CT-P42|
62153226|NCT04739306|ACTIVE_COMPARATOR|Eylea|
62153227|NCT05684809|EXPERIMENTAL|Group A|in addition to Conventional treatment, PIR and cervical mobilization were given
62153228|NCT05684809|ACTIVE_COMPARATOR|Group B|in addition to Conventional treatment, PIR were given
62153229|NCT04245722|EXPERIMENTAL|FT596 Monotherapy, Lymphoma|FT596 monotherapy in adult subjects with r/r B-cell Lymphoma
62153230|NCT04245722|EXPERIMENTAL|FT596 in Combination with Rituximab, Lymphoma|FT596 in combination with Rituximab in adult subjects with r/r B-cell Lymphoma
62153231|NCT04245722|EXPERIMENTAL|FT596 in Combination with Obinutuzumab, Lymphoma|FT596 in combination with Obinutuzumab in adult subjects with r/r B-cell Lymphoma
62153232|NCT04245722|EXPERIMENTAL|FT596 Monotherapy, CLL|FT596 monotherapy in adult subjects with r/r CLL
62526358|NCT05425693|EXPERIMENTAL|Stretching warm-up intervention|
62526359|NCT05425693|NO_INTERVENTION|No warm-up intervention|
62153233|NCT04245722|EXPERIMENTAL|FT596 in Combination with Obinutuzumab, CLL|FT596 in combination with Obinutuzumab in adult subjects with r/r CLL
62153234|NCT05792176|EXPERIMENTAL|Musical Training Intervention|Participants randomized to this arm receive a 12-week intervention to teach them how to play the ukulele. The ukulele is a very manageable instrument to learn and requires less hand dexterity than other stringed instruments. Each week participants will follow the musical training intervention (MTI) protocol that provides instruction on how to tune, hold, and strum the ukulele and play basic chords. To practice the chords, they will also learn popular songs (e.g., Chain of Fools, Three Little Birds, Happy Birthday, Don't Worry Be Happy, and Stand by Me). Participants will be instructed to follow each session outlined weekly and asked to practice the instrument for at least 30 minutes, 5 days a week. They will be given a paper and digital version of the MTI protocol. A member of our research team will call the participants weekly to answer any questions about the MTI protocol.
62153235|NCT05792176|ACTIVE_COMPARATOR|Music Listening|Participants randomized to this arm will be asked to listen to their preferred music for at least 30 minutes, 5 days a week. A member of our research team will call them every week to answer any questions they have about the ML protocol. They will be asked to record their experience in a practice log.
62153236|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
62153237|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
62153238|NCT03143036|EXPERIMENTAL|Daratumumab, thalidomide and dexamethasone|
62153239|NCT05159271|EXPERIMENTAL|Azeol spray nasal group|Azéol Spray Nasal is a nasal spray. The constituents responsible for achieving the intended action are: Bifidobacterium breve LA 708, extract of cypres Cupressus sempervirens L., extract of Leguminosae Glycyrrhiza glabra L., glycerin and mannitol.
62526360|NCT02700711|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance.
62526361|NCT02700711|EXPERIMENTAL|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on placebo and methylphenidate during duloxetine maintenance.
62526362|NCT00061243|EXPERIMENTAL|1|Participants will receive different doses of the vaccine to determine the optimal dose
62526363|NCT00061243|EXPERIMENTAL|2|Participants will receive different doses of the vaccine to determine the optimal dose
62526364|NCT00061243|EXPERIMENTAL|3|Participants will receive different doses of the vaccine to determine the optimal dose
62526365|NCT00061243|EXPERIMENTAL|4|Participants will receive the vaccine through either intradermal or intramuscular administration
62526366|NCT00061243|EXPERIMENTAL|5|Participants will receive the vaccine through either intradermal or intramuscular administration
62526367|NCT02196701|EXPERIMENTAL|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
62526368|NCT01031459||Group 1|
62526369|NCT00960765||Roux-En-Y Gastric Bypass|
62526370|NCT00960765||Gastric Banding|
62526371|NCT00960765||Sucessful Response to RYGB|
62526372|NCT00960765||Failed Response to RYGB|
62526373|NCT03394911|EXPERIMENTAL|Experimental Group|250mg p.o. of healthy adult male facial skin surface lipid liquid pheromone on fresh, new, just-purchased, un-chewed Wrigley's Rain #5 sugarless chewing gum vehicle. 15 pieces or divided as tolerated.
62526374|NCT03394911|PLACEBO_COMPARATOR|Placebo Group|Placebo identical to Experimental dose with randomly assigned identification numbers on unopened, unsealed key. Placebo and Experimental doses kept together and undifferentiable without the key being opened. Key available for opening 24/7 w/pharmaceuticals tech onsite. Keep pheromone/placebo doses under a fume hood. Wear 3M Versaflo activated charcoal filter supplied air respirator or equivalent to access.
62526375|NCT06526455|EXPERIMENTAL|Treatment group|Vonorasan、tablet、20mg、qd、Days 3 to 56
62153240|NCT05159271|PLACEBO_COMPARATOR|Placebo group|The control product is a placebo with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
62153241|NCT01866527||all newborns born 1991-2006|all newborns born 1991-2006
62153242|NCT06061588|NO_INTERVENTION|The case group|Included in the case group, patients diagnosed with migraine and experiencing headache will receive standard treatment, consisting of 50 mg of dexketoprofen within 150 cc of normal saline.
62153243|NCT06061588|EXPERIMENTAL|The control group|The control group, in addition to standard treatment, will be treated with virtual reality therapy using VR goggles, which will create a virtual environment simulating moonlight by the dark seaside or a campfire ambiance with classical music (calm, slow, and soothing).
62153244|NCT04836871|EXPERIMENTAL|Double filtration plasmapheresis (DFPP) combined with chemotherapy|
62526376|NCT06526455|ACTIVE_COMPARATOR|Control group|Esomeprazole 、tablet、20mg、Days 3 to 56
62526377|NCT05007847|ACTIVE_COMPARATOR|Active|Participants randomised to the active arm will be provided with an AW Series 4 on Day 0 for the duration of the study. They shall undergo an education and training session to ensure technical competency of heart rhythm recording and familiarity with the recommended recording schedule for the duration of the study. Participants will also be given the contact details for a dedicated email mailbox for the duration of the study through which they can submit remote transmissions of ECG data.
62526378|NCT05007847|NO_INTERVENTION|Control|Participants in the control arm will be advised to continue with the standard of care and advised to contact their direct clinical team or primary care physician should they experience any symptoms of concern (palpitations, dizziness, collapse). They will be contacted by the study team at 6 and 12 months for clinical assessment (symptoms, hospitalisation data, further stroke events, mortality).
62526379|NCT04860063|PLACEBO_COMPARATOR|Placebo|Placebo three times daily for 6 months
62526380|NCT04860063|EXPERIMENTAL|Berberine|Berberine 500 mg three times daily for 6 months
62526381|NCT01856361|EXPERIMENTAL|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
62526382|NCT01856361|SHAM_COMPARATOR|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
62526383|NCT06483542||Group 1|all patients
62713414|NCT03720366|EXPERIMENTAL|Arm 3: Administration of Enasidenib and Arm 3 probes|Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
62713415|NCT03346993|EXPERIMENTAL|24C° 0,5% bupivacaine group|24C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 24C° 20 ml 0,5% bupivacaine
62713416|NCT03346993|EXPERIMENTAL|37C° 0,5% bupivacaine group|37C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 37C° 20 ml 0,5% bupivacaine
62153245|NCT02221466||diabetic patients|Diabetic patients given HBOT
62153246|NCT02221466||None diabetic patients|None diabetic patients given HBOT
62153247|NCT04947709|EXPERIMENTAL|Physical activity intervention group|The physical activity intervention will be structured to increase moderate-to-vigorous intensity aerobic physical activity, to achieve the 60-minute goal, five days per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity intervention.
62153248|NCT04947709|OTHER|Delayed-intervention control group|Participants randomized to the delayed-intervention control group will serve as the control group for 12 weeks, and will not receive physical activity intervention during this time and will not receive weekly support calls. After completion of the control group, participants will be offered physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations. This delayed-intervention control group design is used not only to boost recruitment, but to eventually confer the benefits of physical activity to all those who enter the trial.
62153249|NCT06093451|EXPERIMENTAL|Dexmedetomidine|Participants with moderate agitation will receive sublingual dexmedetomidine 120 mcg as needed. Participants with severe agitation will receive dexmedetomidine 180 mcg as needed.
62153250|NCT06093451|ACTIVE_COMPARATOR|Lorazapem|Participants with moderate agitation will receive oral lorazapam 2 mgas needed. Participants with severe agitation will receive oral lorazapam 2 mg as needed.
62153251|NCT06012214|EXPERIMENTAL|Robot-assisted minimally invasive esophagectomy|Participants will received neoadjuvant therapy followed by robot-assisted minimally invasive esophagectomy within 8 weeks.
62153252|NCT06012214|PLACEBO_COMPARATOR|Thoraco-laparoscopic minimally invasive esophagectomy|Participants will received neoadjuvant therapy followed by thoraco-laparoscopic minimally invasive esophagectomy within 8 weeks.
62153253|NCT01174472|ACTIVE_COMPARATOR|Conventional Balloon Angioplasty (COBA)|Patients with lesions treated with conventional balloon angioplasty
62526384|NCT04559971|EXPERIMENTAL|1.0mg/kg|Drug: SLN124
62526385|NCT04559971|PLACEBO_COMPARATOR|Placebo|
62526386|NCT04559971|EXPERIMENTAL|3.0mg/kg|Drug: SLN124
62526387|NCT04559971|EXPERIMENTAL|Optional Cohort|An additional dose level may be explored
62713417|NCT05071053|EXPERIMENTAL|Tusamitamab ravtansine+Ramucirumab|Participants received ramucirumab 8 milligram/kilogram (mg/kg) via intravenous (IV) infusion followed by tusamitamab ravtansine loading dose at 170 mg/meter square (m\^2) via IV infusion on Cycle 1 Day 1 (each cycle was 2 weeks); and then ramucirumab 8 mg/kg via IV infusion followed by tusamitamab ravtansine 100 mg/m\^2 via IV infusion at Cycle 2 and every 2 weeks (Q2W) in all subsequent cycles until disease progression, unacceptable adverse event (AE), death, initiation of a new anticancer therapy, or the participant's or investigator's decision to stop the treatment.
62713418|NCT05236166|OTHER|Rapid withdrawal|Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).
62713419|NCT05236166|OTHER|Slow withdrawal|Reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).
62713420|NCT06715865|EXPERIMENTAL|Thymus Transplantation Group|
62526388|NCT04304365|ACTIVE_COMPARATOR|Clinic follow-up group|All participants in this group will receive the standard of care at BMC which includes receiving a follow-up visit date and time before leaving the initial visit, when they receive the medications for abortion. Patients then return to clinic 1-2 weeks later to be seen by a provider with an ultrasound for confirmation of abortion completion. Participants who do not come for a return visit receive one phone call to reschedule their appointment.
62526389|NCT04304365|EXPERIMENTAL|Home follow-up group|Participants enrolled in the home follow-up group will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. At enrollment, they will receive instruction for timing of contact, how to use the LSPT, as well as the test itself. The participant will take the pregnancy test at home in 14 days and answer completion questions by text message for follow-up. Patients that screen positive will be asked to return to clinic for a visit with a provider.
62526390|NCT02563821|ACTIVE_COMPARATOR|PCEA-DC|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~* Injection of the rest of the loading dose (8mL).~* In this group the pump is programmed to deliver a continuous infusion at 10 mL /h consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/ mL. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~* If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is \< 3/10."
62526391|NCT02563821|ACTIVE_COMPARATOR|PCEA-BIP|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~* Injection of the rest of the loadind dose (8 mL)~* In this group the pump is programmed to deliver automated mandatory boluses of 5 mL consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/mL every 30 minutes. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~* If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is \< 3/10 (0 = no pain and 10 = insufferable pain)."
62526392|NCT05709977|EXPERIMENTAL|Acupuncture arm|Fixed set of acupuncture points
62526393|NCT05709977|ACTIVE_COMPARATOR|Control (Carelastin®) arm|Carelastin® (1 mg/ml) azelastine nasal spray, 1 spray puff (0.14 ml) per nostril twice daily (totally 0.56 ml per day)
62526394|NCT04183647|ACTIVE_COMPARATOR|Local Vibration / Whole body vibration|"Local vibration will be sequentially applied to the bilateral gastrosoleus complex with the Vibrasens © device. Application, the largest part of the muscle, each limb 5'er for a total of 10 minutes, static semi-squat position will be done.~The vibration frequency is 80 Hz and the amplitude is 1 mm."
62526395|NCT04183647|ACTIVE_COMPARATOR|Whole body vibration/local vibration|Whole body vibration application will be done with Compex® Winplate device. During this application, patients will be asked to continue static semi-squat position with 5 minutes of vibration and then 5 minutes of vibration.Vibration frequency, 30 Hz amplitude will be selected 2 mm.
62526396|NCT05559775|EXPERIMENTAL|Pemigatinib|Selective FGFR1-3 inhibitor
62526397|NCT04570540||OSA|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of \>=15 per hour or, alternatively, an apnea-hypopnea index \>=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score \>9.
62526398|NCT04570540||OSA+SH|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of \>=15 per hour or, alternatively, an apnea-hypopnea index \>=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score \>9. Furthermore, co-existing hypoventilation during sleep, defined by the presence of intermittent hypercapnia as measured by transcutaneous capnometry and arterialized capillary blood gas analysis.
62526399|NCT04570540||OHS|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of \>=15 per hour or, alternatively, an apnea-hypopnea index \>=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score \>9. Furthermore, co-existing hypoventilation during wakefulness, defined by a PCO2\>45mmHg as measured by arterialized capillary blood gas analysis.
62526400|NCT00158756|EXPERIMENTAL|Tritanrix™-HepB+Rotarix™ Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
62526401|NCT00158756|EXPERIMENTAL|Tritanrix™-HepB+Placebo Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
62526402|NCT00158756|ACTIVE_COMPARATOR|Zilbrix™+Rotarix™ Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
62526403|NCT00158756|ACTIVE_COMPARATOR|Zilbrix™+Placebo Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
62526404|NCT00158756|ACTIVE_COMPARATOR|Triple Antigen™+Engerix™-B Group|Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.
62526405|NCT06278571|EXPERIMENTAL|Intervention with mobile application and website|Group with educational site and mobile App
62526406|NCT06278571|ACTIVE_COMPARATOR|Group with educational site|Group with educational site
62526407|NCT06278571|NO_INTERVENTION|Control Group|Group with the usual care
62153254|NCT01174472|EXPERIMENTAL|Drug Eluting Balloon Angioplasty (DEB)|Patients with lesions treated with Drug Balloon Angioplasty
62153255|NCT02696109|EXPERIMENTAL|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
62153256|NCT02696109|ACTIVE_COMPARATOR|Treatment as Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
62153257|NCT03471884|EXPERIMENTAL|Nonintubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
62526408|NCT00595686|EXPERIMENTAL|Single Arm|
62153258|NCT03471884|ACTIVE_COMPARATOR|Intubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
62153259|NCT03741985|PLACEBO_COMPARATOR|The handgrip exercise|Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
62153260|NCT03741985|EXPERIMENTAL|The dumbbell exercise|Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
62153261|NCT04765046|OTHER|BIS™ System|Enrolled subjects who are undergoing a standard of care elective surgery under general anesthesia, will be equipped with the BIS system to non-invasively measure and interpret brain waive activity directly related to the effects of anesthetic agents during the surgery duration.
62153262|NCT03425175|NO_INTERVENTION|Control group|Standard care with recording of video but no audio-recording
62526409|NCT03192241|EXPERIMENTAL|Pump|Mothers provided with a manual breast pump
62526410|NCT03192241|ACTIVE_COMPARATOR|book|Mothers provided with a children's book
62153263|NCT03425175|EXPERIMENTAL|Intervention group|Standard care with the addition of simultaneous audio-recording during the operation.
62153264|NCT02399202|EXPERIMENTAL|osilodrostat ( LCI699)|Each participant will undergo a 28 day screening /baseline period (day-28 to Day -1), followed by a 4 day treatment period ( a single 30 mg dose of LCI699 (Day 1) with 4 days of PK smple collection
62153265|NCT01263522|EXPERIMENTAL|Endurance training|
62153266|NCT01263522|EXPERIMENTAL|interval training|
62153267|NCT01263522|EXPERIMENTAL|strength endurance training|
62526411|NCT03113513|ACTIVE_COMPARATOR|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
62526412|NCT03113513|ACTIVE_COMPARATOR|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
62153268|NCT01263522|PLACEBO_COMPARATOR|control|
62153269|NCT02454556|EXPERIMENTAL|FOLITIME®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
62153270|NCT02454556|ACTIVE_COMPARATOR|Gonal-F®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
62153271|NCT06220123|EXPERIMENTAL|Investigational product arm|
62153272|NCT06220123|ACTIVE_COMPARATOR|Positive control arm|
62153273|NCT06222437|EXPERIMENTAL|Protocol group|PCOS women in the age 18 to 45 years
62153274|NCT01441336|EXPERIMENTAL|Laparoscopic gastrectomy|"Laparoscopic gastrectomy procedure:~D2 lymphadenectomy \& total omentectomy in case of tumor with serosa exposure under laparoscopic exploration"
62526413|NCT04565613|NO_INTERVENTION|Standard care group|The participants will receive feeding as per standard of care (without protein or any other supplementations).
62526414|NCT04565613|EXPERIMENTAL|Study interventional group|The participants will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds.
62526415|NCT00858962|EXPERIMENTAL|Bup/Ral|Buprenorphine and Raltegravir co-administration
62526416|NCT03867461|ACTIVE_COMPARATOR|Group A|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group A: Initial Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-80 mmHg, End tidal CO2 38-40 mmHg."
62153275|NCT05097534|ACTIVE_COMPARATOR|iDSMES|"Eligible study subjects randomized to the intervention arm will receive:~A. Intensive Diabetes Self-Management, Education, and Support (iDSMES). Participants will be enrolled in groups in a virtual or in-person setting with their lifestyle coach, in this one-year educational program B. Services addressing Social Determinants of Health All study subjects will have their data collected at time points around baseline, 6 months and 12 months from consenting including glycemic control, hypertension management, dyslipidemia management, prevention or management of complications, healthcare outcomes, lifestyle change outcomes, patient-centeredness outcomes, Secondary diabetes self-management behaviors, self-efficacy in managing diabetes, diabetes distress, and Morisky Green Levine Medication Adherence Scale."
62526417|NCT03867461|ACTIVE_COMPARATOR|Group B|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group B: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg,"
62526418|NCT03867461|ACTIVE_COMPARATOR|Group C|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group C: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 24-26 mmHg, Subsequent Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg,"
62526419|NCT03867461|ACTIVE_COMPARATOR|Group D|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group D: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-100 mmHg, End tidal CO2 24-24 mmHg,"
62153276|NCT05097534|PLACEBO_COMPARATOR|Standard of Care|Eligible study subjects randomized to the intervention arm will receive standard of care offered to patients with diabetes.
62153277|NCT03031353|EXPERIMENTAL|Misoprostol|After preparing for elective caesarean section, the pessary will be given containing the misoprostol medication 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
62153278|NCT03031353|ACTIVE_COMPARATOR|Placebo|After preparing for elective caesarean section, the pessary will be given containing placebo 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
62526420|NCT00325195|EXPERIMENTAL|q2 wks|8 mg pegloticase every 2 weeks
62153279|NCT03122860|EXPERIMENTAL|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
62153280|NCT03122860|EXPERIMENTAL|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
62153281|NCT03122860|EXPERIMENTAL|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
62153282|NCT03122860|EXPERIMENTAL|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
62153283|NCT03122860|PLACEBO_COMPARATOR|Placebo|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
62153284|NCT03122860|SHAM_COMPARATOR|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
62153285|NCT05943054|EXPERIMENTAL|Patients carrying the Huntington's gene|"A long temporal perception task and a short temporal perception task"
62153286|NCT05943054|EXPERIMENTAL|Alzheimer's disease patients|"A long temporal perception task and a short temporal perception task"
62153287|NCT05943054|ACTIVE_COMPARATOR|Healthy Volunteers|"A long temporal perception task and a short temporal perception task"
62526421|NCT00325195|EXPERIMENTAL|q4 wks|8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
62153288|NCT00924833|PLACEBO_COMPARATOR|placebo|Placebo tablets. One tablet twice daily.
62153289|NCT00924833|ACTIVE_COMPARATOR|2: Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
62713421|NCT06400615|ACTIVE_COMPARATOR|Arm 1|Twenty patients who are taking GLP-1 at time of enrollment will be treated with AD109
62713422|NCT06400615|ACTIVE_COMPARATOR|Arm 2|Twenty patients who are not taking a GLP-1 will be treated with AD109 only
62153290|NCT00924833|ACTIVE_COMPARATOR|3: Nebivolol|Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
62153291|NCT05076838|EXPERIMENTAL|Valtoco In Pediatric Subjects with Epilepsy|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
62153292|NCT00096278|ACTIVE_COMPARATOR|Arm I (mFOLFOX6)|Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62153293|NCT00096278|EXPERIMENTAL|Arm II (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
62153294|NCT00546884|PLACEBO_COMPARATOR|MI|The MI condition will expose participants to the provision of an advance directive and written instructions, roughly mimicking community standards and the requirements of the federal Patient Self Determination Act.
62153295|NCT00546884|ACTIVE_COMPARATOR|GI|Subjects randomized to the GI group will be invited to meet individually with a health care professional specializing in EOL care
62153296|NCT02049177||Head and Neck Cancer Cases|Cases of Head and Neck Cancer identified in North West England in 2002/2003. Observational study - no intervention other than usual care.
62153297|NCT05099562|EXPERIMENTAL|Acupuncture group|This is a one-arm study. Breast cancer patients with peripheral neuropathy were measured using the FACT/ GOG-Ntx and EORTC QLQ-CIPN20 scales. Our clinical study included breast cancer patients diagnosed with peripheral neurotoxicity caused by taxanes-based drugs who would receive acupuncture treatment. Neurotoxicity was identified based on NCI-CTCAE 5.0 for daily or almost daily numbness in the hands and feet, tingling, and other symptoms of peripheral neuropathy over the past two to three weeks. Blood samples were collected from patients to detect SNP associated with neurotoxicity.
62153298|NCT01159314|EXPERIMENTAL|Arm A - Baerveldt 250 mm2|Patients receiving Baerveldt 250 mm2
62153299|NCT01159314|EXPERIMENTAL|Arm B - Baerveldt 350 mm2|Patients receiving Baerveldt 350 mm2
62153300|NCT06455072|EXPERIMENTAL|Nituzumab Plus Serplulimab Combined With SBRT|Nituzumab was given intravenously (400mg qw, 21 days per cycle), and Serplulimab was administered intravenously (200mg once every 3 weeks).The dose was 30-50 Gy in three to five fractions and the number of lesions was no more than four by SBRT. The treatment was continued until disease progression, death or intolerant toxicity.
62526422|NCT00325195|PLACEBO_COMPARATOR|placebo|placebo every 2 weeks
62526423|NCT05637320|EXPERIMENTAL|Intervention Arm|Treatment will be administered to participants in this arm.
62526424|NCT05637320|NO_INTERVENTION|Control Arm|No treatment will be administered to participants in this arm until post-test assessment has been completed.
62526425|NCT03519659|EXPERIMENTAL|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
62526426|NCT03519659|EXPERIMENTAL|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
62153301|NCT00648895|ACTIVE_COMPARATOR|1|Nebivolol
62153302|NCT00648895|ACTIVE_COMPARATOR|2|Metoprolol ER (TM)
62153303|NCT02625025|EXPERIMENTAL|Low pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Low Pression Pneumoperitoneum (8 mm Hg)
62526427|NCT03519659|EXPERIMENTAL|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
62526428|NCT03519659|EXPERIMENTAL|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
62526429|NCT03519659|EXPERIMENTAL|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
62526430|NCT03519659|EXPERIMENTAL|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
62526431|NCT02129296|ACTIVE_COMPARATOR|hemiosphere® BALLOON|Balloon filled with air according to the manufacturing company orders 600 or 720 ml air
62526432|NCT02129296|ACTIVE_COMPARATOR|Fluid filled balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
62526433|NCT03826498|EXPERIMENTAL|CP CB-MNC injection|CP CB-MNC injection from different donors and standard therapy.
62526434|NCT03826498|OTHER|Standard therapy|Patients with standard therapy as control group
62526435|NCT00000569|ACTIVE_COMPARATOR|Triamcinolone|1200 micrograms of triamcinolone in daily divided doses
62526436|NCT00000569|PLACEBO_COMPARATOR|Placebo|Placebo
62526437|NCT01622374|ACTIVE_COMPARATOR|Silence|the subjects received 10 minutes of silence through headphone
62526438|NCT01622374|EXPERIMENTAL|Music for the mind|
62526439|NCT01622374|EXPERIMENTAL|Mozart music|
62526440|NCT01622374|EXPERIMENTAL|Iranian traditional music|
62526441|NCT00891839|EXPERIMENTAL|Bendamustine+Rituximab|Patients receive bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2, and 375 mg/m\^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).
62526442|NCT01087632|EXPERIMENTAL|Armolipid Plus|Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg
62526443|NCT01087632|PLACEBO_COMPARATOR|Placebo|Placebo matching Armolipid plus
62526444|NCT03230799|ACTIVE_COMPARATOR|traditional cataract surgery|Central anterior continuous capsulorhexis (5-6 mm)+ irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy（ACCC+ I/A + PCCC + Anti-vit)
62153304|NCT02625025|EXPERIMENTAL|Standard pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Standard Pression Pneumoperitoneum (12 mm Hg)
62153305|NCT01036932|ACTIVE_COMPARATOR|G-CSF group|Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.
62153306|NCT01036932|PLACEBO_COMPARATOR|Placebo|After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy
62153307|NCT02452567|EXPERIMENTAL|Metabolically abnormal lean|Moderate (8-10%) diet-induced weight loss.
62526445|NCT03230799|EXPERIMENTAL|minimal invasive lens surgery|Peripheral capsulorhexis opening (1.0-1.5 mm)+irrigation/aspiration
62526446|NCT00576992||GI observation|Patients presenting for an upper endoscopy procedure with gastrointestinal symptoms or complaints.
62526447|NCT00521417|EXPERIMENTAL|short-term dynamic therapy|Group therapy 20 sessions, give insight
62526448|NCT00521417|ACTIVE_COMPARATOR|long-term dynamic therapy|Group therapy 80 sessions, give insight
62526449|NCT00842478|EXPERIMENTAL|Raspall|
62526450|NCT00842478|NO_INTERVENTION|Control|
62526451|NCT02860065|EXPERIMENTAL|CPC-201|combination of solifenacin and high doses of donepezil
62526452|NCT05504590|EXPERIMENTAL|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
62526453|NCT05504590|ACTIVE_COMPARATOR|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
62526454|NCT04636359|EXPERIMENTAL|Long term course of migraine patient without aura|Patients in this group have the history of migraine without aura more than 5 years.
62526455|NCT04636359|EXPERIMENTAL|Short term course of migraine patient without aura|Patients in this group have the history of migraine without aura equal or less than 5 years.
62526456|NCT04461366|EXPERIMENTAL|monopolar radiofrequency (MRF) group|Monopolar Radiofrequency Diathermy (LVT-250, Korea) was used at average energy160-180 W, main power 50/60 Hz, 40˚C \~ 45˚C Temperature, RF output 470 kHz, 20 mm electrode size.
62526457|NCT04461366|ACTIVE_COMPARATOR|Pulsed dye laser (PDL) group|Flash lamp pulsed dye laser; Candela SPTL-1 (Candela Corp., Wayland, Mass.) with the following parameters: (585nm wavelength, 450 msec pulse duration, 6.5 to 7.5 J/cm² energy density and 5or 7mm spot size).
62526458|NCT04700163|EXPERIMENTAL|S1 - low dose|100 mg of C144-LS and 100 mg of C135-LS, subcutaneously
62526459|NCT04700163|EXPERIMENTAL|S2 - mid dose|200 mg of C144-LS and 200 mg of C135-LS, subcutaneously
62153308|NCT01107509|EXPERIMENTAL|Neo-adjuvant everolimus|
62526460|NCT04700163|EXPERIMENTAL|V1 - low dose|1.5 mg/kg of C144-LS and 1.5 mg/kg of C135-LS, intravenously
62526461|NCT04700163|EXPERIMENTAL|V2 - mid dose|5 mg/kg of C144-LS and 5 mg/kg of C135-LS, intravenously
62526462|NCT04700163|EXPERIMENTAL|V3 - high dose|15 mg/kg of C144-LS and 15 mg/kg of C135-LS, intravenously
62526463|NCT03812705|EXPERIMENTAL|fecal microbiome transplantation|"1. Perform fecal microbiome transplantation to patient under colonoscopy or gastroscopy: injection of 200\~300 ml fecal microbiome fluid as fecal microbiome transplantation to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;~2. If patient's condition is stable or improved within 1 week, second fecal microbiome transplantation may be performed 1 week later, up to 4 times will be performed if patient response;~3. If patient's condition is not improved after the second fecal microbiome transplantation, stop fecal microbiome transplantation."
62526464|NCT01240213|ACTIVE_COMPARATOR|Vitamin D|2000 IU per day of Vitamin D
62526465|NCT01240213|PLACEBO_COMPARATOR|Placebo|
62526466|NCT06002971||Normotensive|Normotensive pregnant patients beyond the first trimester with systolic blood pressure \<140 mmHg and diastolic blood pressure \<90 mmHg
62526467|NCT06002971||Hypertensive|"Hypertensive pregnant patients beyond the first trimester:~i) without proteinuria \>300 mg in 24 h; and ii) with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg"
62526468|NCT06002971||Pre-Eclampsia|"Pre-eclampsia patients beyond the first trimester:~i) with proteinuria \>300 mg in 24 h; and ii) with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg"
62526469|NCT06219486|NO_INTERVENTION|Placebo|Usual care
62526470|NCT06219486|EXPERIMENTAL|Intervention|Use of D-dimer to guide care of the patient
62526471|NCT04822233|EXPERIMENTAL|Hall Technique (HT)|
62526472|NCT04822233|EXPERIMENTAL|Modified Hall Technique (MHT)|
62526473|NCT04822233|ACTIVE_COMPARATOR|Conventional Technique (CT)|
62526474|NCT02356003|EXPERIMENTAL|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
62526475|NCT00609466|EXPERIMENTAL|1|CG5503 IR 75mg 4 to 6 hourly for 72 hours
62526476|NCT00609466|ACTIVE_COMPARATOR|2|Morphine IR 30 mg 4 to 6 hourly for 72 hours
62526477|NCT00609466|PLACEBO_COMPARATOR|3|Matching placebo 4 to 6 hourly for 72 hours
62153309|NCT04522661|EXPERIMENTAL|Early Vitrectomy Group|Vitrectomy surgery plus intravitreal antibiotics
62526478|NCT04567914||Adolescent idiopathic scoliosis|Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness of AIS patients diagnosed by a specialist. Spirometry evaluation was performed by the investigator
62153310|NCT04522661|ACTIVE_COMPARATOR|Control Group|Intravitreal antibiotics
62153311|NCT03742882|EXPERIMENTAL|Administration of CC-90001|Single oral dose of 200 mg of CC-90001
62153312|NCT03118609|EXPERIMENTAL|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.~Up to 150 participants will complete the Understanding Needs survey"
62153313|NCT03026920|EXPERIMENTAL|clinical outcome|Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.
62153314|NCT04838509||Patients with elevated creatine kinase|
62153315|NCT01992276|EXPERIMENTAL|CR8020|Investigational monoclonal antibody against influenza A viruses
62526479|NCT04567914||Adolescent healthy individuals|Healthy adolescents aged 10-18 were selected. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness. Spirometry evaluation was performed by the investigator.
62526480|NCT00193427|EXPERIMENTAL|Intervention|Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered
62526481|NCT03421158|NO_INTERVENTION|Control|Newborns received no pain interventions during the procedure
62526482|NCT03421158|EXPERIMENTAL|Breastfeeding|Newborns were breastfed during the procedure
62526483|NCT03421158|EXPERIMENTAL|Oral Sucrose|Newborns were given oral sucrose during the procedure
62526484|NCT03421158|EXPERIMENTAL|Skin to skin contact|Newborns were placed in direct contact with their mothers during the procedure
62526485|NCT03421158|EXPERIMENTAL|Non-nutritive sucking|Newborns were given a pacifier to suck on during the procedure
62526486|NCT00306150|EXPERIMENTAL|Arm 1|
62526487|NCT00306150|PLACEBO_COMPARATOR|Arm 2|
62526488|NCT04427644||Complication positive|Patients with perioeprative complications after laparascopic sleeve gastrectomy before discharge (wound complications, thromboembolic events, staple line leakage, splenic infarction proven by imaging modalities, bleeding detected due to low hemoglobin and hematocrit values during follow-up, acute renal failure due to deterioration in biochemical parameters)
62526489|NCT04427644||Complication negative|Patients without perioeprative complications after laparascopic sleeve gastrectomy before discharge
62526490|NCT04427644||BMI 40 - 45 kg/m2|Operated patients preoperative BMI values between 40 - 45 kg/m2
62526491|NCT04427644||BMI 45 - 50 kg/m2|Operated patients preoperative BMI values between 45 - 50 kg/m2
62526492|NCT04427644||BMI over 50 kg/m2|Operated patients preoperative BMI values 45 - 50 kg/m2
62526493|NCT04427644||Clavien Dindo Major Complications|"1. Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy This grade also includes wound infections opened at the bedside~2. Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions, antibiotics and total parenteral nutrition are also included"
62153316|NCT01992276|EXPERIMENTAL|CR6261|Investigational monoclonal antibody against influenza A viruses
62153317|NCT01992276|PLACEBO_COMPARATOR|Placebo|Dextrose: 5% in water
62153318|NCT02416947|PLACEBO_COMPARATOR|0g SCF|Subjects will consume 0 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
62153319|NCT02416947|ACTIVE_COMPARATOR|10 g SCF|Subjects will consume 10 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
62153320|NCT02416947|ACTIVE_COMPARATOR|20g SCF|Subjects will consume 20 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
62153321|NCT00368602|EXPERIMENTAL|1|This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
62153322|NCT00368602|PLACEBO_COMPARATOR|2|The group will be given standard of care with placebo medication.
62526494|NCT04427644||Clavien Dindo Minor Complciations|3. Requiring surgical, endoscopic or radiological intervention 3a Intervention under regional/local anaesthesia 3b Intervention under general anaesthesia 4. Life-threatening complication requiring intensive care/intensive care unit management 4a Single-organ dysfunction 4b Multi-organ dysfunction 5. Patient demise
62526495|NCT01527084|OTHER|Group A|undergo surgery between days 10 - 15 after PCD
62526496|NCT01527084|OTHER|Group B|"continued with PCD beyond 15 days and indications for surgery in them will be,~1. Persistent sepsis or symptoms~2. Worsening of clinical condition~3. Failure to thrive~4. Complications of SAP or PCD"
62526497|NCT04629768|OTHER|Duodenal EMR + PuraStat|PuraStat will be applied to the defect after duodenal EMR of the lesion
62526498|NCT01551888|EXPERIMENTAL|Aclidinium/formoterol 400/12μg FDC|Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
62526499|NCT01551888|ACTIVE_COMPARATOR|Formoterol|Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
62526500|NCT04370951|ACTIVE_COMPARATOR|Erector Spinae Plane Block|Patients will receive a ESP block with 20mls 0.25% Levobupivicaine bilaterally, pre incision plus standardised multimodal analgesia
62526501|NCT04370951|NO_INTERVENTION|Control|no ESP block, standardised multimodal analgesia
62526502|NCT03500653|ACTIVE_COMPARATOR|Active|4 gr Curcumin daily for 1 year in addition to vedolizumab 300 mg per infusion (standard of care)
62526503|NCT03500653|PLACEBO_COMPARATOR|Sham|4 gr placebo daily for 1 year in addition to vedolizumab300 mg per infusion (standard of care)
62526504|NCT04070586||4DCBCT images|4DCBCT images are acquired and assessed offline.
62526505|NCT02483143|ACTIVE_COMPARATOR|NAC plus normal saline group|1ml/3mgr NAC+NS preCTPA 3 ml/kg for 1 h, 1 ml/kg/h for post CTPA for 6 h
62526506|NCT02483143|ACTIVE_COMPARATOR|NaHCO3 plus normal saline group|132 mEq NaHCO3+NS preCTPA 3 ml/kg for 1h, post CTPA 1ml/kg/h for 6 h
62526507|NCT02483143|PLACEBO_COMPARATOR|Normal saline alone|preCTPA 3 ml/kg NS for 1h, postCTPA 1ml/kg/h SF for 6 h
62713423|NCT06717919|ACTIVE_COMPARATOR|Conventional cold storage|Conventional cold storage at 4°C will be performed with precooled preservation solution according to local standard of care. For cold storage at the Swiss centres, IGL-1 (Institute George Lopez) is used for cold storage. Liver transplant centres in other European countries, use mainly three other storage solutions (Histidine trypophan-ketoglutarat, HTK and University of Wisconsin, UW solution, Celsior) in accordance to their national guidelines.
62713424|NCT06717919|EXPERIMENTAL|Hypothermic oxygenated perfusion|"All study centres will use either VitaSmart, Liver assist or Perlife devices for machine liver perfusion, with a pressure controlled hypothermic oxygenated liver perfusion through the portal vein (HOPE) or through the portal vein and the hepatic artery (DHOPE), targeting a flow rate between 200-250 ml/min at a pressure of 3 mmHg, and a perfusate temperature between 8-12°C. The perfusate consists of 3L re-circulating Belzer MPS® (Bridge to Life Ltd.) with an active oxygenation (70-110 kPa). The minimum perfusion duration is defined at 2 hours, while perfusion is generally continued until the recipient hepatectomy is completed. The perfusion will exclusively be performed in the recipient centre after initial cold storage and bench preparation of the liver for implantation.~The perfusion devices are routinely used in all participating centres (VitaSmart, Bridge to Life®, Liver Assist, XVIVO®, Perlife, Aferitica®)."
62713425|NCT06715683|EXPERIMENTAL|Part 1, Sequence 1|
62526508|NCT03866720|ACTIVE_COMPARATOR|Carbohydrate rich breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
62526509|NCT03866720|EXPERIMENTAL|Whey protein enriched breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
62526510|NCT03866720|NO_INTERVENTION|Extended morning fast|Participants will extend their overnight fast until the ad libitum lunch is provided.
62526511|NCT05581290|EXPERIMENTAL|Multi-Modal Sensor Patch Measurements|Subjects referred to Mayo Clinic in Arizona Cardiology Clinic who have an underlying cardiac structural condition will have a 15-minute data collection via the prototype device, AI-Flex, and standard of care electrocardiogram (ECG), temperature, and photoplethysmogram (PPG) measurements.
62526512|NCT01179698|OTHER|Stryker navigation system|
62526513|NCT01233921|EXPERIMENTAL|Arm I (palifermin)|Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.
62526514|NCT01233921|ACTIVE_COMPARATOR|Arm II (no palifermin)|Patients do not receive palifermin.
62526515|NCT03309007|EXPERIMENTAL|Metformin|Metformin started at 500 mg po twice daily (BID), and then titrated up to 1000 mg po q morning (AM) and 500 po q evening (PM) over the course of 1 month, as tolerated.
62526516|NCT03309007|PLACEBO_COMPARATOR|Placebo Oral Tablet|Near-identical CaCO3 as a Placebo Oral Tablet will be started at 648 mg po BID, and then titrated up to 1296 mg po q AM and 648 mg po q PM over the course of 1 month, as tolerated.
62526517|NCT00793494|EXPERIMENTAL|Probaclac|Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
62713426|NCT06715683|EXPERIMENTAL|Part 1, Sequence 2|
62713427|NCT06715683|EXPERIMENTAL|Part 2, Sequence 1|
62713428|NCT06715683|EXPERIMENTAL|Part 2, Sequence 2|
62713429|NCT04643015||Study Participants|Patients of any age, including males and females, who are being treated in the Department of Pediatrics and are already scheduled to undergo MRI
62526518|NCT00793494|PLACEBO_COMPARATOR|Placebo|
62713430|NCT04447755|EXPERIMENTAL|Ewing Sarcoma|Participants with Ewing sarcoma will receive lenvatinib 14 mg/m\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.
62713431|NCT04447755|EXPERIMENTAL|Rhabdomyosarcoma|Participants with rhabdomyosarcoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
62713432|NCT04447755|EXPERIMENTAL|High Grade Glioma|Participants with high grade glioma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
62153323|NCT04222088||Patients detected with Plasmodium falciparum (Artemether-lumefantrine)|Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
62526519|NCT05174676|EXPERIMENTAL|Intervention|The participant will receive 6 therapy sessions of approximately 25 minutes each WITH the application of error enhancement.
62526520|NCT05174676|SHAM_COMPARATOR|Control|The participant will receive 6 therapy sessions of approximately 25 minutes each WITHOUT the application of error enhancement.
62526521|NCT04023903|EXPERIMENTAL|RTA 402 5mg 3cap at fasting|
62526522|NCT04023903|EXPERIMENTAL|RTA 402 5mg 3cap after meal|
62526523|NCT02558231|EXPERIMENTAL|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
62526524|NCT02558231|PLACEBO_COMPARATOR|Dual oral combination treatment|Macitentan, tadalafil, and placebo
62526525|NCT04213352|NO_INTERVENTION|Control Group|The subjects will be asked to type on a computer for 5 minutes without splint or taping. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
62526526|NCT04213352|EXPERIMENTAL|Splint Group|The subjects will be asked to type on a computer for 5 minutes with a splint. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
62526527|NCT04213352|EXPERIMENTAL|Rigid Taping Group|The subjects will be asked to type on a computer for 5 minutes with rigid taping which limits the wrist flexion at the dominant side. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
62526528|NCT04566341||Feasibility of OCT TCE in identifying signs of PD|Participants that fulfill our Inclusion/Exclusion criteria will be asked to swallow our Capsule Imaging device.
62713433|NCT04447755|EXPERIMENTAL|Diffuse Midline Glioma|Participants with diffuse midline glioma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
62526529|NCT04238988|EXPERIMENTAL|Carboplatin-Paclitaxel-Pembrolizumab|"Patients will be treated with 3 cycles of neoadjuvant Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q 21)+ Pembrolizumab (200 mg flat dose every 3 weeks).~After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will undergo radical surgery.~After surgery, patients presenting with high risk factors will receive 3 cycles of adjuvant Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient consent withdrawal for up to 35 cycles."
62526530|NCT03853018|NO_INTERVENTION|Control group|The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
62526531|NCT03853018|EXPERIMENTAL|CWAT intervention group|The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
62526532|NCT03853018|EXPERIMENTAL|CWAT + motivation intervention group|Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
62526533|NCT00003138|ACTIVE_COMPARATOR|Supportive Care|Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of \>= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
62526534|NCT00003138|EXPERIMENTAL|Erythropoietin|Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.
62526535|NCT05002426||The type and orientation of Rouviere sulcus|"open type, fused type or absent type"
62526536|NCT00955136|EXPERIMENTAL|High MI impulses, myocardial infarction, echocardiography|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
62526537|NCT01234792|EXPERIMENTAL|NIC-6|6 mg Experimental nicotine gum
62713434|NCT04447755|EXPERIMENTAL|Medulloblastoma|Participants with medulloblastoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
62713435|NCT04447755|EXPERIMENTAL|Ependymoma|Participants with ependymoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
62153324|NCT04222088||Patients detected with Plasmodium vivax (Chloroquine)|Patients with mono-infection of Plasmodium falciparum with ≥ 250 per µl
62153325|NCT01811459|EXPERIMENTAL|Quetiapine|Drug: Quetiapine 50-250 mg PO BID (5 levels of treatment) + IV Placebo Rescue IV haloperidol available.
62153326|NCT01811459|EXPERIMENTAL|Haloperidol|Drug: Haloperidol 1-5 mg BID (5 levels of treatment) + PO placebo Rescue IV haloperidol available.
62526538|NCT01234792|ACTIVE_COMPARATOR|NIC-4|4 mg Nicotine Gum
62526539|NCT01234792|ACTIVE_COMPARATOR|NIC-2|2 mg Nicotine Gum
62713436|NCT04447755|EXPERIMENTAL|Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma|Participants with other solid tumors will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
62153327|NCT01811459|PLACEBO_COMPARATOR|Placebo|IV placebo + PO placebo Rescue IV haloperidol available.
62526540|NCT05341882|EXPERIMENTAL|Mindfulness|The seven weekly sessions teach veterans how to use mindfulness techniques in everyday life and when dealing with stress and negative emotions related to moral injury.
62526541|NCT05341882|ACTIVE_COMPARATOR|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
62526542|NCT00792870|EXPERIMENTAL|SURI Enhanced|
62526543|NCT00792870|ACTIVE_COMPARATOR|SURI Standard|
62526544|NCT02327117|EXPERIMENTAL|Tranexamic acid|
62526545|NCT02327117|PLACEBO_COMPARATOR|Normal Saline|
62526546|NCT02852642|EXPERIMENTAL|Exercise|Power training model based in the potentiation of the stretch-shortening cycle.
62526547|NCT02852642|NO_INTERVENTION|Control|Maintaining daily activities
62526548|NCT00390221|PLACEBO_COMPARATOR|Placebo|Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
62526549|NCT00390221|EXPERIMENTAL|150 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
62526550|NCT00390221|EXPERIMENTAL|300 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
62526551|NCT05567484|ACTIVE_COMPARATOR|group A pulse thearpy of itraconazole|Patients in pulse therapy group received oral itraconazole 100 mg, two capsules twice daily for seven days a month
62526552|NCT05567484|ACTIVE_COMPARATOR|Group B continous thearpy of itraconazole|Patients in continuous therapy group, received continuous oral 100 mg of itraconazole once daily for 12 weeks continuously.
62526553|NCT01527136|EXPERIMENTAL|Treatment (entolimod)|Patients receive entolimod IM or SC on days 1, 4, 8, and 11. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
62526554|NCT00755404|ACTIVE_COMPARATOR|A|
62526555|NCT00755404|EXPERIMENTAL|B|
62526556|NCT06142123|EXPERIMENTAL|Group A|"Group A will be treated with 3-D Ankle Mobility Exercises with combined isotonic (agonist) technique at ankle joint. Two diagonal (D2) Flexion-Extension patterns from the PNF leg patterns will be used.~Both the techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~The patients will receive Intervention consisting 14 sets (7 sets for each 3-D extension-flexion \[1 set (1 min) = exercise 30sec + rest 30 sec\]) performed for 15 minutes thrice per week for four weeks"
62526557|NCT06142123|EXPERIMENTAL|Group B|Group B will be treated with Eccentric Heel Drop Training and Conventional physiotherapy treatment All patients will be treated once daily with 10 sets of 15 repetitions with a frequency of 2sec per repetitions and an interval of 30 sec between each set of Eccentric Heel drop training, 4 days a week for four weeks
62526558|NCT05370820|EXPERIMENTAL|Cesarean Delivery|
62526559|NCT05370820|EXPERIMENTAL|Vaginal Delivery|
62713437|NCT03834896|EXPERIMENTAL|Experimental|Patients with dysphagia requiring Stage 1, 2 or 3 thickened fluids as determined by Speech and Language Therapist and who are expected to require provision of Stage 1, 2 or 3 thickened fluids for at least 2 further weeks.
62713438|NCT05611242|EXPERIMENTAL|MT+CAT|Non-stenting group constitutes best medical management (BMM)+intra-arterial treatment (IAT) with mechanical thrombectomy (for IVO) added to extra-cranial proximal carotid occlusion angioplasty or aspiration (MT+CAT)
62526560|NCT05370820|EXPERIMENTAL|Morbidly Obese|
62526561|NCT05370820|NO_INTERVENTION|No TXA|
62526562|NCT05070871|ACTIVE_COMPARATOR|Hydrolyzed Collagen type II|10 capsules daily of hydrolyzed collagen (CH) type II is taken per orally. Each capsule contains \~500 mg of CH. Once or twice daily dosing. Duration: 6 months.
62153328|NCT04266626|EXPERIMENTAL|Group A kinesiotaping therapy|"Protocols mentioned in kinesiological taping i.e. 45 minutes will be pursued as with longer sessions children may tire out easily. Taping Technique for lip muscles would be used by cutting 2 I tapes according to the structure of lip muscles.The tape will be fixed in the center of the mouth on the upper lip, will be placed on an open mouth and a 10% tension will be given to the paper. The tape will then end at the corner of the upper lip. Kinesiotape wouldn't be placed on the lips. The second tape piece will be fixed to the center of the lower lip.The edges of the tape should overlap slightly.~The other piece of tape will be placed under chin (base of tongue) on sub mandibular triangle, inside the jaw line on the base of the tongue. A strip 1-1 ½ inch long will be cut, and then will further be cut in half such that the stretch is horizontal. It will be anchored in the middle on sub mandibular triangle. Paper off the tension to both sides."
62153329|NCT04266626|ACTIVE_COMPARATOR|Group B Oral Motor Manipulation therapy|"For the oral motor manipulation technique CP chair will be required to maintain the good sitting posture of children. Trunk will be in upright position with cut out lap board of the CP chair. Hips, knees and ankles would be flexed to 90 degrees. Shoulders and arms will be rested in symmetrical manner by keeping them rested in lap board and foot rest will be used to rest the feet tightly to control movement and maintain good posture. Each child would be taken for 12 weeks of therapy with three sessions per day of 15 minutes each. Oral motor manipulation like tapping protocols would be used for 45 minutes; slow, even rhythmic pressure will be applied around lip muscle and base of tongue muscle, keeping in view the comfort level of patient.~Training to do manipulation exercises will be given to the parents of children with CP at ."
62153330|NCT04818476||HR-T1a|Patients who weretreated by radical endoscopic resection for a high-risk mucosal EAC (HR-T1a N0M0)
62526563|NCT05070871|PLACEBO_COMPARATOR|Maltodextrin|10 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once or twice daily dosing. Duration: 6 months.
62526564|NCT05070871|EXPERIMENTAL|Unhydrolyzed Collagen type II (Salmon bone meal)|10 capsules daily of salmon bone meal enriched with vitamin D3 is taken per orally. Each capsule contains 300 mg of maltodextrin, 200 mg of salmon bone meal (10 capsules = 2000 mg salmon bone meal = 340 mg elemental calcium in the form of microcrystalline hydroxyapatite), and 4 micrograms of vitamin D3 (10 capsules = 40 micrograms of vitamin D3 = 1600 IU).
62526565|NCT04607330|EXPERIMENTAL|High protein liquid|A ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.
62713439|NCT05611242|EXPERIMENTAL|MT+CAS|Acute carotid stenting (ACS) approach constitutes BMM+IAT with acute carotid stenting (ACS) of the extracranial proximal carotid artery, spanning the cervical internal carotid artery (ICA), ICA origin, and the distal common carotid artery (CCA, across the bifurcation) as in the example of left (L) carotid stenting figure below (MT+CAS). Within the stenting arm, there will be 2 different subgroups based on the antiplatelet treatment protocol per the site standard of care (oral antiplatelet or IV antiplatelet medication (e.g., Cangrelor or others).
62736715|NCT03645941|EXPERIMENTAL|Facebook+Quitline/Treatment Referral|"* Participants join a secret/private, culturally relevant Facebook group moderated by an AN tobacco research counselor for 3 months~* Once daily moderator postings for 30 days, repeated each month for 3 months; plus 3-4 daily check-ins/postings to respond to participant generated content and encourage sharing of personal stories/experiences relevant to all stages of the quitting process and treatment engagement~* Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)"
62526566|NCT03861481|EXPERIMENTAL|Rozanolixizumab|Subjects will be randomized to receive predefined subcutaneous doses of rozanolixizumab at a specified frequency
62526567|NCT03861481|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive predefined subcutaneous doses of placebo at a specified frequency
62526568|NCT01532479||Treatment Group|Subjects with ORN treated with Hyperbaric Oxygen Therapy
62526569|NCT01532479||Postive Control Group|Subjects treated with Hyperbaric Oxygen Therapy that have not had head or neck radiation therapy
62526570|NCT01532479||Negative Control Group|Subjects who have had head and neck radiation that have not had Hyperbaric Oxygen Therapy
62526571|NCT01924923||Uveal Melanoma|Scheduled for enucleation surgery
62526572|NCT00415194|EXPERIMENTAL|Pemetrexed/Cisplatin|"Pemetrexed 500 milligrams per meter square (mg/m\^2) administered intravenously (IV) plus cisplatin 75 mg/m\^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment.~Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
62526573|NCT00415194|PLACEBO_COMPARATOR|Placebo/Cisplatin|"Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m\^2 on Day 1 every 21 days.~Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose.~Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
62153331|NCT04818476||LR-T1b|Patients who were treated by radical endoscopic resection for a low-risk submucosal EAC (LR-T1b N0M0)
62526574|NCT04763018|ACTIVE_COMPARATOR|Treatment|This arm will receive a function iTEAR
62526575|NCT04763018|SHAM_COMPARATOR|Sham|This arm will receive sham treatment device
62526576|NCT02124941|EXPERIMENTAL|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans, including before and after two-weeks of placebo and NAC administration.
62526577|NCT02124941|EXPERIMENTAL|[18F]-FDG PET scan|All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
62526578|NCT02124941|EXPERIMENTAL|[11C]APP311 PET scan|All subjects will undergo \[11C\]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
62526579|NCT02124941|ACTIVE_COMPARATOR|Medication (NAC & placebo) administration|Upon completion of baseline (abstinence) 1H-MRS scanning at 7T, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
62526580|NCT02926820|EXPERIMENTAL|Cognitive training|Participants will undergo five weeks of cognitive training using the Cogmed QM program. All patients complete the same intervention.
62526581|NCT04199013|ACTIVE_COMPARATOR|Ropivacaine With Fentanyl|2.5ml of 0.75% Isobaric ropivacaine with 0.5ml (25mcg) Fentanyl
62526582|NCT04199013|ACTIVE_COMPARATOR|Ropivacaine Without Fentanyl|2.5ml of 0.75% Isobaric Ropivacaine with 0.5ml of Normal Saline
62526583|NCT01799122|ACTIVE_COMPARATOR|Precise sling vs TVT-O sling|
62526584|NCT02775708|EXPERIMENTAL|capsule endoscopy|open label arm ; up to 100 subjects indicated for capsule endoscopy (CE) procedure will undergo the CE procedure with the Pillcam endoscopy system
62526585|NCT00937482|EXPERIMENTAL|Treatment (cediranib maleate and WBRT)|Patients receive oral cediranib maleate on day 1. Patients undergo whole-brain radiotherapy 5 days a week for 3 weeks beginning on day 3. Treatment continues treatment in the absence of disease progression or unacceptable toxicity.
62526586|NCT03761680|EXPERIMENTAL|MEDPass Group|Allocation of ONS in the MEDPass mode
62526587|NCT03761680|ACTIVE_COMPARATOR|Control Group|Patients receive ONS between meals or at their request as usual
62526588|NCT01566357|NO_INTERVENTION|Fluoride-free toothpaste|
62526589|NCT01566357|ACTIVE_COMPARATOR|Fluoride toothpaste|
62526590|NCT01566357|ACTIVE_COMPARATOR|Milk|
62526591|NCT01566357|ACTIVE_COMPARATOR|Fluoridated milk|
62526592|NCT01566357|ACTIVE_COMPARATOR|CPP-ACP|
62526593|NCT01566357|ACTIVE_COMPARATOR|Fluoridated CPP-ACP|
62526594|NCT01566357|ACTIVE_COMPARATOR|Fluoride mouthrinse|
62526595|NCT01124344|ACTIVE_COMPARATOR|Placebo or BMS-866949 (3 mg)|Panel 1: Healthy Male Subjects
62526596|NCT01124344|ACTIVE_COMPARATOR|Placebo or BMS-866949 (10 mg)|Panel 2: Healthy Male Subjects
62153332|NCT04818476||HR-T1b|Patients who were treated by radical endoscopic resection for a high-risk submucosal EAC (HR-T1b N0M0)
62526597|NCT01124344|ACTIVE_COMPARATOR|Placebo or BMS-866949 (30 mg)|Panel 3: Healthy Male Subjects
62526598|NCT01124344|ACTIVE_COMPARATOR|Placebo or BMS-866949 (45 mg)|Panel 4: Healthy Male Subjects
62526599|NCT01124344|ACTIVE_COMPARATOR|Placebo or BMS-866949 (60 mg)|Panel 5: Healthy Male Subjects
62526600|NCT01124344|ACTIVE_COMPARATOR|Placebo or BMS-866949 (90 mg)|Panel 6: Healthy Male Subjects
62526601|NCT01124344|ACTIVE_COMPARATOR|Placebo or BMS-866949 (3 - 60 mg)|Panel 7: Females
62526602|NCT03258853|ACTIVE_COMPARATOR|Usual Care|Usual Care diabetes management: Patients will manage their diabetes using standard of care for diabetes as per their typical regimen including use of an insulin pump or injectable insulin. Usual care arm for 14 days. Patients will wear a continuous glucose monitor (CGM) during this arm
62526603|NCT03258853|EXPERIMENTAL|Insulin only bionic pancreas|Insulin Only Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin using a continuous glucose monitoring (CGM) device, for 14 days.
62526604|NCT02681744|NO_INTERVENTION|Control Group|These participants will be instructed to maintain their habits during 24 weeks. Before and after the aforementioned period, they will be asked to perform body composition and strength assessments, using DXA and isokinetic dynamometer, respectively.
62526605|NCT02681744|EXPERIMENTAL|Experimental group|Participants from the experimental group will assign to the resistance training program undergo physician screening at rest and under cardiopulmonary exercise test conditions before starting the program. Following a three-week familiarization process, participants undergo one repetition maximum (1-RM) testing for each of the exercises of the training program. This procedure intended to determine exercise load and will be systematically repeated in four-week intervals. Volunteers will train thrice per week during 24 weeks. The training program will involve the following exercises: chest press, lat pulldown, knee extension, hamstrings curl, leg press, hip abduction.
62526606|NCT01985074|EXPERIMENTAL|Case-management intervention|Receiving nurse-managed intervention
62526607|NCT01985074|NO_INTERVENTION|Control arm|Control group not receiving any intervention
62526608|NCT00044668|EXPERIMENTAL|AC2993|5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period
62526609|NCT03784521|EXPERIMENTAL|In-line filtration|For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used for all intravenous access during operation and postoperative period in intensive care unit (ICU).
62526610|NCT03784521|ACTIVE_COMPARATOR|Control|For patients randomized to control group, All intravenous access is managed routinely according to local standard care without filtration during operation and postoperative period in ICU.
62526611|NCT02116959|EXPERIMENTAL|Cohort 1|"Patients will receive alternating treatments beginning with systemic chemotherapy then followed by intra-arterial (IA) therapy.~Bilateral retinoblastoma patients will be in Cohort 1.~For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy."
62526612|NCT02116959|EXPERIMENTAL|Cohort 2|Patients will receive only intra-arterial (IA) therapy for more limited disease.
62526613|NCT00063635|ACTIVE_COMPARATOR|1|Metformin, 500 mg, twice daily
62526614|NCT00063635|ACTIVE_COMPARATOR|2|Vitamin E, 400 IU, twice daily
62526615|NCT00063635|PLACEBO_COMPARATOR|3|Matching placebo
62526616|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
62526617|NCT04853992|EXPERIMENTAL|Active - Placebo|Patients will receive active treatment for 7 days, followed by a washout period of 7 days and then placebo for 7 days
61975650|NCT05534750|ACTIVE_COMPARATOR|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 3 to 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
62526618|NCT04853992|EXPERIMENTAL|Placebo - Active|Patients will receive placebo for 7 days, followed by a washout period of 7 days and then active treatment for 7 days
62526619|NCT06412263||With post-operative pain (Assessed at 24 hours, 48 hours, 7 days)|Root canal treatment or retreatment performed either in single-visit or multiple-visit. Post-operative pain will then be assessed after instrumentation and obturation (completion) for multiple-visit and after obturation only for the single-visit treatment.
62526620|NCT06412263||Without post-operative pain (Assessed at 24 hours, 48 hours, 7 days)|Root canal treatment or retreatment performed either in single-visit or multiple-visit. Post-operative pain will then be assessed after instrumentation and obturation (completion) for multiple-visit and after obturation only for the single-visit treatment.
62526621|NCT06412263||Post-operative quality of life affected (Assessed at 24 hours, 48 hours, 7 days)|Quality of life after root canal treatment both after instrumentation and after treatment completed will be assessed at 24H, 48H, 7 days. Factors that will be looked at are the chewing ability, speaking ability, sleeping whether painkillers are required to sleep, ability to carry out daily functions, difficulty in social relations and the overall quality of life.
62526622|NCT06412263||Post-operative quality of life unaffected (Assessed at 24 hours, 48 hours, 7 days)|Quality of life after root canal treatment both after instrumentation and after treatment completed will be assessed at 24H, 48H, 7 days. Factors that will be looked at are the chewing ability, speaking ability, sleeping whether painkillers are required to sleep, ability to carry out daily functions, difficulty in social relations and the overall quality of life.
62526623|NCT04763694|EXPERIMENTAL|Treatment arm|Subjects wore multifocal soft contact lenses for 12 months.
62526624|NCT01983709|EXPERIMENTAL|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV."
62526625|NCT03544996||TD Insulin Pilot|Test of novel transdermal insulin (TD Insulin) formulations
62526626|NCT00197496|EXPERIMENTAL|BWSTT|Body weight supported treadmill training
61975651|NCT03867305|EXPERIMENTAL|MOBIDERM group|
62526627|NCT00197496|NO_INTERVENTION|Usual care|Usual care
62526628|NCT05476120|EXPERIMENTAL|BATHE|In each interview, the intervention group was intervened by the physician to increase compliance with the treatment using the BATHE technique, and brief information was given emphasizing the importance of drug compliance and lifestyle changes routinely applied by the Family Medicine Department in hypertension patients. The patients in the intervention group were interviewed face-to-face at the 0th and 6th months, and online at the 3rd month.
62526629|NCT05476120|NO_INTERVENTION|Control|In the control group, brief information was given at each interview, emphasizing the importance of drug compliance and lifestyle changes routinely applied by the Department of Family Medicine in hypertension patients. No intervention was made. The patients in the control group were interviewed face-to-face at 0 and 6 months, and online at 3 months.
62526630|NCT06007547|EXPERIMENTAL|Prophylactic Surfactant via Minimally Invasive Technique|Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes).
62526631|NCT06007547|ACTIVE_COMPARATOR|Rescue Surfactant via Minimally Invasive Technique|The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.
62713440|NCT06666231|ACTIVE_COMPARATOR|Anterior Quadratus Lumborum Plane Block|"After endotracheal intubation, patients in the supine position will be given a lateral tilt and the areas to be treated will be cleaned with surgical antiseptic solution. The convex USG probe will be covered in a sterile manner. Then, the sterile probe will be placed transversely on the crista iliaca. The probe will be directed cranially until the external oblique muscle, internal oblique muscle and transverse abdominis muscle are clearly visualized. The psoas major muscle and the transverse process of the vertebra will be visualized. The QL muscle will be visualized between the aponeuros of the transverse abdominis muscle and the psoas major muscle. A 20 G 100 mm block needle will be advanced from posterolateral to anteromedial using the in-plane technique. The needle will be directed between the QL muscle and the psoas major muscles. 20 ml of 0.25% bupivacaine (Buvasin®, Vem İlaç, Turkey) will be injected on each side between the fasciae of these two muscles and the LA distributio"
62713441|NCT06666231|ACTIVE_COMPARATOR|External Oblique Intercostal Plane Block|After endotracheal intubation, a 20-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
62526632|NCT01506544|EXPERIMENTAL|Arm 1 Pharmacokinetic study|This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
61975652|NCT03867305|NO_INTERVENTION|Control group|
62153333|NCT00889473|EXPERIMENTAL|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
62153334|NCT00889473|PLACEBO_COMPARATOR|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
62526633|NCT01506544|ACTIVE_COMPARATOR|Arm 2: Relative bioavailability study|This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
62713442|NCT04874948|EXPERIMENTAL|Single oral administration of 500 mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043|4 subjects to receive a single oral administration of 14C-labeled radioactive 500mg BTZ-043
62713443|NCT03279926|EXPERIMENTAL|PLAY|Preschoolers \& their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
62713444|NCT03279926|EXPERIMENTAL|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
62713445|NCT03279926|EXPERIMENTAL|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
62713446|NCT05678426|EXPERIMENTAL|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
62713447|NCT05678426|EXPERIMENTAL|Diet intervention (intermittent fasting)|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants are randomized to receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
62713448|NCT05373472|EXPERIMENTAL|Vaccine Group, low dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
62526634|NCT02243839|ACTIVE_COMPARATOR|Thrombolytic therapy|In the first arm, thrombolytic therapy (TT) is performed to the patients with obstructive prosthetic valve thrombosis. The TT regimen depends on the functional status of the patient. In patients with NYHA class III-IV dyspnea low dose, relatively faster TT regimen (25 mg tPA/6 hours) is performed. In patients with NYHA class I-II dyspnea TT with low dose and ultra-slow infusion of tPA (25 mg tPA/25 hours) is performed. During TT, patients are followed up with transesophageal echocardiography in every 24 hours.
62526635|NCT02243839|ACTIVE_COMPARATOR|Surgery|In the second arm, redo valve surgery is performed for obstructive valve thrombosis. Intraoperative and postoperative results are recorded
62526636|NCT03063879|EXPERIMENTAL|Sovodak|Sofosbuvir 400 mg and daclatasvir 60 mg
62526637|NCT02301767||women that are diagnosed with breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
62526638|NCT02301767||women at high risk of breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
62526639|NCT06095336|EXPERIMENTAL|Telereahabilitation arm|The group receiving telerehabilitation will be given a video CD containing the exercise program that will be changed every 3 weeks, and in the first week of each change program, daily sessions will be held collectively via video conferencing under the supervision of a physiotherapist. In the first 3 weeks of the 12-week exercise program, neck joint movements, neck stretching exercises and posture exercises will be given. Between weeks 4-6, in addition to the exercises in the first 3 weeks, cervical and scapular stabilization exercises will be given in the following weeks. In the following weeks, between weeks 7-9, 4-way strengthening exercises will be included in the program in addition to the exercises performed in the previous weeks. Cervical and scapular stabilization exercises and strengthening exercises will be performed in the following weeks between weeks 10-12, Exercises will be done 10 repetitions 3 times a day.
62526640|NCT06095336|EXPERIMENTAL|conventional physiotherapy arm|"Superficial heat (infrared), Transcutaneous Electrical Nerve Stimulation (TENS), therapeutic ultrasound and Hotpack application will be applied to the traditional treatment group. The patients receive 20 sessions in total, 5 days a week and 1 session daily for 4 weeks; You will receive superficial heat (infrared), TENS, therapeutic US and Hotpack treatment. . Superficial heat infrared will be applied to the tissue for 20 minutes. Conventional TENS will be applied. Therapeutic US will be applied to the cervical and thoracic region with an ultrasound device for 5 minutes at 3mHz, 1W/cm² treatment dosage, in continuous mode. Hotpack application will be done for 20 minutes. At the end of the 20 sessions, a brochure containing video-supported exercises will be given to the patients in the first group and they will be asked to do it for 12 weeks without follow-up."
62713449|NCT05373472|EXPERIMENTAL|Vaccine Group, low dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
62713450|NCT05373472|EXPERIMENTAL|Vaccine Group, high dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
62713451|NCT05373472|EXPERIMENTAL|Vaccine Group, high dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
62153335|NCT03733860|ACTIVE_COMPARATOR|Cavernous sparing group|
62713452|NCT05373472|PLACEBO_COMPARATOR|Placebo Group, low dose, 18-59 year-old|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
62153336|NCT03733860|OTHER|Conventional technique group|
62153337|NCT01501721|EXPERIMENTAL|Exercise|Home-based exercise program
62153338|NCT01501721|EXPERIMENTAL|Nutritional counseling|Nutrition counseling aiming to reduce suggar intake
62153339|NCT00994851|EXPERIMENTAL|SENNA+ CASSIA|Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days
62153340|NCT00994851|PLACEBO_COMPARATOR|Placebo|Daily administration (capsule) of placebo at bedtime, during 30 days
62153341|NCT05763732|NO_INTERVENTION|Pre RAS|"After a 10-minute washout period, participants will receive the participants' optimized stimulation.~1. The participants will undergo assessments to measure gait parameters and patterns during stimulation ON and OFF (Pre-RAS) using the 10-meter walk (during a 2-minute walk) and MDS-UPDRS-III rating scale.~2. Electrophysiological activity (e.g., local field potentials, LFPs) will be collected before assessments."
62153342|NCT05763732|EXPERIMENTAL|During RAS|"1. The participants will walk to the metronome beats for four minutes (2 minutes for the same beats as baseline cadence and 2 minutes for 10% faster than baseline cadence) (RAS), and the participants' gait parameters will be recorded.~2. Electrophysiological activity (e.g., local field potentials, LFPs) will be collected."
62153343|NCT05763732|NO_INTERVENTION|Post RAS|The same assessment as the Pre-RAS will be conducted (Post-RAS).
62153344|NCT00715598||Neuropathic Pain|Subjects in this group experience chronic neuropathic pain.
62153345|NCT00715598||Musculoskeletal Pain|Subjects in this group experience chronic musculoskeletal pain.
62153346|NCT04453488|EXPERIMENTAL|RUTI® vaccine|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
62153347|NCT04453488|PLACEBO_COMPARATOR|Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
62153348|NCT02035852||Adult Gilomas|
62153349|NCT01630668|EXPERIMENTAL|One-a-Day L. reuteri NCIMB 30242 supplement capsule|
62153350|NCT01630668|PLACEBO_COMPARATOR|One-a-Day placebo capsule|
62153351|NCT00943371|EXPERIMENTAL|1|MK6349
62153352|NCT00943371|PLACEBO_COMPARATOR|2|Placebo to MK6349
62153353|NCT03236779|EXPERIMENTAL|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
62153354|NCT03236779|ACTIVE_COMPARATOR|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
62153355|NCT01077440||Men - age 18+|
62153356|NCT03060525|EXPERIMENTAL|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
62153357|NCT03060525|EXPERIMENTAL|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
62153358|NCT03060525|OTHER|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
62153359|NCT03060525|OTHER|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
62153360|NCT01802333|EXPERIMENTAL|Arm I (standard dose cytarabine, daunorubicin hydrochloride)|"INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
62713453|NCT05373472|PLACEBO_COMPARATOR|Placebo Group, low dose, 60 year-old and above|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
62526641|NCT06095336|NO_INTERVENTION|control arm|The third group, the control group, will not receive any intervention and will be asked to continue their daily lives.
62153361|NCT01802333|EXPERIMENTAL|Arm II (high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
62153362|NCT01802333|EXPERIMENTAL|Arm III (vorinostat, high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat."
62153363|NCT02147275||hypertension disease|patients have hypertension disease, whether well-controlled or uncontrolled, more than 3 year
62526642|NCT04882631|EXPERIMENTAL|Cumulative Irritation Test|Participants will receive topical applications of three concentrations of PBI-100 Topical Cream, one application of vehicle, one application of sodium lauryl sulfate as a positive control and one application of a plain patch as a negative control daily (excluding weekends) for 21 days or 15 applications.
62526643|NCT00173875|EXPERIMENTAL|A|Iressa
62526644|NCT01620619|ACTIVE_COMPARATOR|Arthroscopic Bankart Repair & Rotator Interval Closure|
62526645|NCT01620619|ACTIVE_COMPARATOR|Arthoscopic Bankart Repair alone|
62713454|NCT05373472|PLACEBO_COMPARATOR|Placebo Group, high dose, 18-59 year-old|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
62153364|NCT02966197|EXPERIMENTAL|Balloon group|Prophylactic Internal Iliac Artery Balloon Catheterization
62153365|NCT02966197|NO_INTERVENTION|Control group|no intervention
62153366|NCT02951806|ACTIVE_COMPARATOR|(R) Rapid spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 15 seconds then 10 mg hyperbaric bupivacaine.
62153367|NCT02951806|ACTIVE_COMPARATOR|(S) Slow spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
62153368|NCT03434106|EXPERIMENTAL|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
62153369|NCT03434106|EXPERIMENTAL|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
62153370|NCT03434106|EXPERIMENTAL|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
62153371|NCT03434106|EXPERIMENTAL|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
62153372|NCT00942500|EXPERIMENTAL|Post-conditioning|
62153373|NCT00942500|NO_INTERVENTION|Conventional primary PCI|
62153374|NCT01752816|ACTIVE_COMPARATOR|endurance training|40 min bicycle or treadmill training at 60% maximal oxygen uptake
62153375|NCT01752816|EXPERIMENTAL|Strength following endurance training|20 minutes bicycle or treadmill training at 60% maximal oxygen uptake followed by 20 minutes stength training increasing from 15RM to 10RM
62713455|NCT05373472|PLACEBO_COMPARATOR|Placebo Group, high dose, 60 year-old and above|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
62153376|NCT00623714|EXPERIMENTAL|Arm 1|study medication + Pbo
62153377|NCT00623714|EXPERIMENTAL|Arm 2|Pbo + study medication
62153378|NCT03482999||Control|Standard Wound Closure with drains
62153379|NCT03482999||TissuGlu Surgical Adhesive|TissuGlu was used for approximation and adhesion of the flaps in conjunction with drains
62153380|NCT06288685|EXPERIMENTAL|group1|percutaneous A1 pulley release with Triamcinolone injection
62153381|NCT06288685|ACTIVE_COMPARATOR|group0|percutaneous A1 pulley release alone
62153382|NCT00993278|ACTIVE_COMPARATOR|Low-Carbohydrate (Modified Atkins) Diet|
62153383|NCT00993278|ACTIVE_COMPARATOR|Low-Fat (Heart Healthy) Diet|
62153384|NCT02694107|EXPERIMENTAL|Proprioceptive exercises|Proprioceptive exercises performed 3 sessions per week for 4weeks
62526646|NCT02503020|ACTIVE_COMPARATOR|Group A|Preterm infants formula A Pretarm infants were fed on formula with Arachidonic acid (0.6%) and Docosahexaenoic acid (0.3%)
62526647|NCT02503020|ACTIVE_COMPARATOR|Group B|Preterm infants formula B Pretarm infants were fed on formula with Arachidonic acid (0.3%) and Docosahexaenoic acid (0.3%)
62526648|NCT05469217||Fentanyl dependent patients|15 participants who were treated for fentanyl dependence in treatment centers in Israel
62526649|NCT05469217||Control participants|Healthy control participants from the general public
62153385|NCT02694107|NO_INTERVENTION|Control|Without any exercises
62153386|NCT03991052|ACTIVE_COMPARATOR|EV1000 monitor|MAP management will be done as usual (adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
62153387|NCT03991052|EXPERIMENTAL|EV1000 monitor + closed-loop system|Fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
62526650|NCT01754116|EXPERIMENTAL|Lead In Period GSK1265744 30 mg + midazolam 3mg|During the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
62526651|NCT01754116|EXPERIMENTAL|Lead in Period GSK1265744 30mg|On Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
62713456|NCT06123481|ACTIVE_COMPARATOR|Core decompression (CD)|Core decompression of the femoral head with sham bone marrow aspiration
62153388|NCT05187520|ACTIVE_COMPARATOR|Patient-controlled epidural analgesia (PCEA)|Patients assigned to PCEA group will receive epidural analgesia as the standard postoperative pain control strategy. After completion of cesarean section, a PCEA device will be connected to the epidural catheter to deliver mixture of local anesthetic (0.8 mg/ml) and fentanyl (2 mcg/ml) with preset continuous dose of 3-5 ml/h and a bolus dose of 3-4 ml.
62153389|NCT05187520|EXPERIMENTAL|Naldebain®|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance after completion of cesarean section.
62153390|NCT04617925|EXPERIMENTAL|belantamab mafodotin|Belantamab mafodotin will be administered as an IV infusion at a dose of 2.5 mg/kg every six weeks until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of eight doses (approximately 12 months), according to the response adapted modifications
62153391|NCT01310686||Wet AMD Non-Responders to Anti-VEGF|
62153392|NCT00734253|EXPERIMENTAL|1|Pyridorin 150 mg bid
62153393|NCT00734253|EXPERIMENTAL|2|Pyridorin 300 mg bid
62153394|NCT00734253|PLACEBO_COMPARATOR|3|Placebo bid
62153395|NCT01416285||control group|control group receiving regular education from a nurse
62153396|NCT01416285||Case management group|This is the study group. Extensive education and case management program will be performed in this group.
62153397|NCT04718116|ACTIVE_COMPARATOR|tapentadol 50 mg|tapentadol 50mg p.o 3 times daily for two days
62153398|NCT04718116|ACTIVE_COMPARATOR|tapentadol 75 mg|tapentadol 75 mg p.o 3 times daily for two days
62526652|NCT01754116|EXPERIMENTAL|Treatment A|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
62713457|NCT06123481|EXPERIMENTAL|Bone Marrow Aspirate Concentrate (BMAC)|Autologous bone marrow aspiration is concentrated and injected into the necrotic bone of the femoral head through the core decompression opening.
62153399|NCT04718116|ACTIVE_COMPARATOR|tramadol 100 mg|tramadol 100 mg p.o 3 times daily for two days
62153400|NCT05664776|EXPERIMENTAL|Arm A (control first)|The pre-existing static office chair will be used in the personal workplace for the first 6 weeks within the first half of the study. A wash-out period of a minimum of 4 weeks will be executed after the first half of the study. A dynamic office chair will be used on the personal workstation for 6 weeks within the second half of the study after the wash-out period.
62153401|NCT05664776|EXPERIMENTAL|Arm B (intervention first)|A dynamic office chair will be used in the personal workplace for the first 6 weeks within the first half of the study. A wash-out period of a minimum of 4 weeks will be executed after the first half of the study. The pre-existing static office chair will be used on the personal workstation for 6 weeks within the second half of the study after the wash-out period.
62153402|NCT03837093|EXPERIMENTAL|dose A|ILT-101
62153403|NCT03837093|EXPERIMENTAL|dose B|ILT-101
62526653|NCT01754116|EXPERIMENTAL|Treatment B|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
62526654|NCT01754116|EXPERIMENTAL|Treatment C|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
62526655|NCT01201941||Intervention group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will have access to the e-Chasqui system."
62526656|NCT01201941||Simultaneous/historical control group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will not have access to the e-Chasqui system."
62526657|NCT04832321|NO_INTERVENTION|No intervention: V1: Control|This version of the survey questionnaire depicts a young man with no symptoms of alcohol use disorder
62713458|NCT03941483|EXPERIMENTAL|ASP1128|Participants received ASP1128 solution administered by 15 minutes intravenous infusion with in 24 hours after the end of surgery and thereafter once daily for 2 days.
62713459|NCT03941483|PLACEBO_COMPARATOR|Matching placebo|Participants received placebo matched to ASP1128 solution administered by 15 minutes intravenous infusion with in 24 hours after the end of surgery and thereafter once daily for 2 days.
62736716|NCT05849675|EXPERIMENTAL|Pitolisant|Two film-coated tablets (18mg x 2 \[36mg\]) for oral administration will be encapsulated in an opaque capsule.
62153404|NCT03837093|EXPERIMENTAL|dose C|ILT-101
62153405|NCT03837093|EXPERIMENTAL|dose D|ILT-101
62153406|NCT03837093|EXPERIMENTAL|dose E|ILT-101
62153407|NCT03837093|EXPERIMENTAL|Placebo|
62153408|NCT04510493|ACTIVE_COMPARATOR|active treatment arm|Treatment with Canakinumab i.v. administered over 2 hours
62153409|NCT04510493|PLACEBO_COMPARATOR|placebo treatment arm|placebo treatment
62153410|NCT03848741|PLACEBO_COMPARATOR|Non-exercise control with placebo|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the β-hydroxy β-methylbutyrate (HMB) Plus Vitamin D (VitD) capsules.
62153411|NCT03848741|EXPERIMENTAL|Non-exercise control with HMB+VitD|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
62153412|NCT03848741|ACTIVE_COMPARATOR|Resistance exercise training with placebo|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules \~30-60 minutes before resistance exercise. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the HMB + VitD capsules.
62526658|NCT04832321|EXPERIMENTAL|Experimental: V2: Alcohol Use Disorder|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder."
62526659|NCT04832321|EXPERIMENTAL|Experimental: V3: Alcohol Use Disorder + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with complete response."
62526660|NCT04832321|EXPERIMENTAL|Experimental: V4: Alcohol Use Disorder + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with partial relapse."
62526661|NCT04832321|EXPERIMENTAL|Experimental: V5: Alcohol Use Disorder + Economic Impact|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances."
62713460|NCT03941483|NO_INTERVENTION|Observational cohort|Participant with postoperative negative NephroCheck® (NC) (AKIRisk score was ≤ 0.3 nanogram per milliliter (ng/mL)\^2/1000 at all assessments between 2 to 22 hours after time point 0 (T0) were followed up for 90 days in observational cohort. Participants did not receive any intervention.
62713461|NCT04887532|EXPERIMENTAL|HR19042 capsule|
62713462|NCT05400174|OTHER|Supine cognitive testing first|"The cognitive testing sessions will be alternated between supine and upright positions.~This group will perform cognitive testing sessions in the following order: 1) supine, 2) upright, 3) supine, 4) upright."
62153413|NCT03848741|EXPERIMENTAL|Resistance exercise training with HMB+VitD|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules \~30-60 minutes before resistance exercise. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
62153414|NCT05112302||Virtual reality|
62153415|NCT01207154||BIS guidance|Sedation guided according to a predetermined BIS level
62153416|NCT01207154||Clinical sign guided|Sedation guided by clinical signs
62153417|NCT06157099|PLACEBO_COMPARATOR|Arm I (Placebo)|Patients receive placebo PO once per day in the absence of disease progression or unacceptable toxicity for up to 5 years and undergo CT and/or MRI throughout the study.
62153418|NCT06157099|EXPERIMENTAL|Arm II (Atorvastatin)|Patients receive atorvastatin PO once per day in the absence of disease progression or unacceptable toxicity for up to 5 years and undergo CT and/or MRI throughout the study.
62153419|NCT01073722|ACTIVE_COMPARATOR|Left double lumen tube|Traditionally, single lung ventilation is obtained with a double lumen tube (DLT). In our institution a polyvinyl DLT (Broncho-cath, Mallinckrodt,) without carinal hook, is used. This type of tube exists of a tube with two lumen with two distal cuffs. One lumen (called the bronchial lumen) extends some distance further, has a slight curvature and has a small blue cuff. The other lumen (called the tracheal lumen) has a larger cuff. A DLT tube exists in four sizes and one can choose in a left or a right configuration. Almost always, we use a left sided DLT. A DLT has a much larger diameter than a standard single lumen endotracheal tube
62153420|NCT01073722|ACTIVE_COMPARATOR|EZ-blocker|The EZ-blocker (EZB) is a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. It is intended for use in combination with a standard single lumen tube. After the EZB is advanced trough the distal end of the single lumen tube, both extensions spread out and find their way in the left and right main stem bronchi. The place where the two extensions are attached to the shaft now rests on the carina. Fiber optic bronchoscopy should be used for proper positioning. After placement of the EZB, one of the cuffs can be inflated to obtain lung separation under direct visual inspection with fiber optic bronchoscopy.
62153421|NCT04922359|EXPERIMENTAL|Experimental: Lidocaine group|
62713463|NCT05400174|OTHER|Upright cognitive testing first|"The cognitive testing sessions will be alternated between supine and upright positions.~This group will perform cognitive testing sessions in the following order: 1) upright, 2) supine, 3) upright, 4) supine."
62153422|NCT04922359|PLACEBO_COMPARATOR|Placebo Comparator: comparator group|
62153423|NCT03137732|ACTIVE_COMPARATOR|Surgeon-inserted|Rectus sheath catheter will be inserted under direct vision / palpation of the space at the end of the operation.
62153424|NCT03137732|ACTIVE_COMPARATOR|Anaesthetist-inserted|Rectus sheath catheter will be inserted under ultrasound guidance by the anaethetist.
62153425|NCT02312258|PLACEBO_COMPARATOR|Placebo|Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.
62153426|NCT02312258|EXPERIMENTAL|Ixazomib|Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.
62153427|NCT06341504|EXPERIMENTAL|Prevention pop-up messages|"Same as active comparator with the addition of prevention pop-up messages delivered during the gambling session on a fixed presentation schedule.~Due to hardware limitations on the EGMs' part, the prevention messages presented only alter what is shown on the play screen (they fill it completely, hiding the game), but can't pause the game per se. The EGMs' buttons, sound, and music are still operational while the message is shown. While disrupting play flow, this still lets the participant place bets (albeit without seeing what is going on)."
62526662|NCT04832321|EXPERIMENTAL|Experimental: V6: Alcohol Use Disorder + Economic Impact + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with complete response."
62713464|NCT05919940|EXPERIMENTAL|Intervention|High protein substitution plus NMES and EM
62713465|NCT05919940|NO_INTERVENTION|Control Group|Nutrition and mobilization are carried out according to standard of care.
62713466|NCT04077177|NO_INTERVENTION|Assessment Only|
62713467|NCT04077177|EXPERIMENTAL|Intervention|
62526663|NCT04832321|EXPERIMENTAL|Experimental: V7: Alcohol Use Disorder + Economic Impact + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with partial relapse and continued negative economic impact."
62526664|NCT01066689|EXPERIMENTAL|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
62526665|NCT01066689|PLACEBO_COMPARATOR|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
62526666|NCT02254161|EXPERIMENTAL|BI 1181181 healthy young|Medium doses as tablets q.d. for 10 days
62526667|NCT02254161|EXPERIMENTAL|BI 1181181 healthy elderly|Medium doses as tablets q.d. for 10 days
62526668|NCT02254161|PLACEBO_COMPARATOR|Matching placebo in healthy young|Matching placebo for 10 days
61975653|NCT05548829||Non-hospitalised Covid-19 patients (mild infection)|COVRES1, retrospective recuitment from public advertisment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
61975654|NCT05548829||Hospitalised Covid-19 patients (severe infection)|COVRES1, retrospective recuitment from secondary care, attended wards. Obtained saliva and whole blood samples for DNA and RNA extraction.
62526669|NCT02254161|PLACEBO_COMPARATOR|Matching placebo in healthy elderly|Matching placebo for 10 days
62526670|NCT05209217||Participant Group|Participants will all have history of good to excellent clinical response to intranasal ketamine for at least two months and on a treatment schedule varying from use every other day to every fifth day. Participants will be tested one or two days beyond their customary administration date and again 2-3 hours after their administration of ketamine.
62526671|NCT06179836||good prognosis group|
62526672|NCT06179836||poor prognosis group|
62526673|NCT01515930|ACTIVE_COMPARATOR|Active Caregiver and Active Child|Parent \& Child Computer-Delivered Motivational Intervention will be delivered to participants. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered behavior change counseling intervention for children with diabetes to improve completion of daily diabetes care.
62526674|NCT01515930|EXPERIMENTAL|Active Caregiver and Child Education|Parent Computer-Delivered Motivational Intervention will be delivered to the parents only. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered informational session about diabetes related topics for their child with diabetes.
62526675|NCT01515930|ACTIVE_COMPARATOR|Education Caregiver/Education Child|Participants will receive computer-delivered information. A brief computer delivered information session about diabetes related topics for both the caregiver and the child with diabetes.
62526676|NCT05656586||Participants|"Inclusion criteria for all aims/experiments~* Receiving DBS therapy in GP for treatment of PD~* Implanted with Medtronic Percept DBS system~* At least 3 months since initial activation of the neurostimulator"
62526677|NCT03816215|EXPERIMENTAL|Adolescent Participants|Participants will be assigned to participate in community service (from a menu of options) for 30 hours.
62526678|NCT04856124||Treatment resistant depressed outpatients|Subjects had a clinically meaningful response to IV racemic ketamine and remained on other psychotropic medications during treatment with both IV ketamine and IN esketamine. Concomitant medication classes included CNS stimulants (n = 7), atypical antipsychotics (n = 6), selective serotonin reuptake inhibitors (n = 5), serotonin/norepinephrine reuptake inhibitors (n = 4), anticonvulsants (n = 3), antipsychotics (n = 3), mood stabilizers (n = 3), benzodiazepines (n = 2), norepinephrine/dopamine reuptake inhibitors (n = 2), alpha 2 antagonists (n=1), and sedative hypnotics (n = 1). Two patients (20%) previously underwent ECT with partial but transient relief from depressive symptoms, two (20%) failed TMS, and no patients reported any period of greater than 50% improvement during their current depressive episode prior to ketamine treatment.
62713468|NCT06719427|ACTIVE_COMPARATOR|Cluster Maintenance TMS|Participants will receive a cluster of treatments consisting of 5 treatments over two consecutive week days (either 2 treatments on day 1 followed by 3 treatments day 2 or vice-versa, based on scheduling)
62713469|NCT06719427|ACTIVE_COMPARATOR|Gradual Tapering TMS|Participants will receive a once daily treatment protocol delivered once weekly for 1 month, and gradually tapering the frequency of treatment to 1 treatment every 2 weeks for 2 months
62713470|NCT06702059||coronary artery bypass graft candidates|patients scheduled for CABG surgery will undergo pre-operative cardiopulmonary exercise testing and post-operative complications monitoring
61975655|NCT05548829||Non-hospitalised Covid-19 patients (mild infection) 3 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
61975656|NCT05548829||Hospitalised Covid-19 patients (severe infection) 3 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
62526679|NCT00476632||Control|Person with no history of cancer.
62153428|NCT06341504|ACTIVE_COMPARATOR|Regular gambling session control|"Gambling session on EGMs in a room replicating a bar (subdued light, music, bar paraphernalia, fake liquor on display, research assistant acting as barman and selling non-alcoholic soft drinks and chips).~Participants are invited to participate under the false pretense of giving their opinion on the realism of the bar replica and overall feeling of the gambling session in it. They are told that: (a) they are free to gamble as much and for as long as they like; (b) they are allowed to take breaks; (c) gambling is to be done with their own money; (d) the only compensation for participation are winnings that could be made while gambling; (e) net winnings across their whole session are paid up to $500, but losses are real. Lost money is given back after debriefing (see Study Detailed Description)."
62153429|NCT06092307|EXPERIMENTAL|Chronic pancreatitis|adult patients aged 18-65 years with a diagnosis of chronic pancreatitis
62153430|NCT02386085||Osteopathic manipulative treatment (OMT)|All participants will have received OMT to be eligible and will be followed for 1 week after treatment.
62153431|NCT04413175|EXPERIMENTAL|a music group|Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.
62153432|NCT04413175|NO_INTERVENTION|control group|control group
62526680|NCT04527653|EXPERIMENTAL|Tixel Treatment|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology
62526681|NCT00123955|EXPERIMENTAL|1|Spironolactone
62526682|NCT00123955|PLACEBO_COMPARATOR|2|Placebo
62526683|NCT01790035|EXPERIMENTAL|LGG|LGG (containing 10\^10 viable bacteria) taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
62153433|NCT03121417|EXPERIMENTAL|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
62153434|NCT02690792|PLACEBO_COMPARATOR|NAFLD/NASH - Placebo|"In NAFLD/NASH Group: Identically appearing Placebo capsules given as double-blinded, randomized intervention as a comparator to Vitamin E intervention.~Dosage: Placebo capsules. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
62153435|NCT02690792|ACTIVE_COMPARATOR|NAFLD/NASH - Vitamin E|"In NAFLD/NASH Group: Vitamin E capsules given as double-blinded, randomized intervention as a comparator to Placebo capsules intervention.~Dosage: Vitamin E 200 IU/capsule. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
62153436|NCT02070640|EXPERIMENTAL|NIRF-C|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
62153437|NCT00886548||Ultrasound performed|Single arm study.
62153438|NCT05504135||RMG Patients|
62153439|NCT02495402|NO_INTERVENTION|No Intervention: Control|No Intervention
62153440|NCT02495402|EXPERIMENTAL|Motivational Interviewing|A brief interview intervention for substance abuse
62153441|NCT02876653|OTHER|Severe OSA|Patients with severe OSA (AHI \> 30)
62153442|NCT02876653|OTHER|Moderate OSA|Patients with moderate OSA (5 \< AHI ≤ 30)
62153443|NCT02876653|OTHER|Healthy volunteers|Healthy volunteers (AHI ≤ 5)
62153444|NCT01577875|NO_INTERVENTION|control group|histologic prediction only with the narrow band imaging (without magnification)
62153445|NCT01577875|OTHER|test group|histologic prediction with narrow band imaging plus magnification
62153446|NCT02500433|EXPERIMENTAL|Device: Kinect-Xbox360TM|"Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.~Participants were initially exposed to the games in an hour introductory session, 2 weeks before the study began. All the sessions were supervised by physiotherapist."
62526684|NCT01790035|EXPERIMENTAL|Placebo|Placebo taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
62526685|NCT01790035|NO_INTERVENTION|No intervention|Patients who prefer not to receive LGG will not be randomized and will receive standard of care RT. These patients will serve as a non-intervention comparator cohort to the first 20 patients and will have specimens collected but will not receive the placebo.
62526686|NCT01501136|EXPERIMENTAL|sequential trial,DDGP, radiotherapy|sequential DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment followed by radiotherapy
62526687|NCT01501136|EXPERIMENTAL|sequential trial,VIPD, radiotherapy|sequential VIPD（cisplatin，Etoposide,Ifosfamide,dexamethasone，Mesna） regiment followed by radiotherapy
62526688|NCT01501136|EXPERIMENTAL|sequential trial, radiotherapy,DDGP|sequential radiotherapy followed by DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
62526689|NCT01501136|EXPERIMENTAL|sequential trial,radiotherapy, VIPD|sequential radiotherapy followed by VIPD（cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna）regiment chemotherapy
62526690|NCT01501136|EXPERIMENTAL|Radiotherapy|Suitable type intensity-modulated radiation therapy (IMRT) 50GY
62526691|NCT01547949|EXPERIMENTAL|tart cherry juice|
62526692|NCT01547949|PLACEBO_COMPARATOR|cherry flavored fruit drink|
62526693|NCT05753670|EXPERIMENTAL|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
62526694|NCT05753670|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
62526695|NCT04823962|EXPERIMENTAL|GM-CSF|rhGM-CSF (molgramostim) + hydrogel
62526696|NCT04823962|PLACEBO_COMPARATOR|Placebo|Hydrogel
62153447|NCT02500433|OTHER|Conventional therapy|"Conventional therapy was based on neurodevelopment treatment, psychomotor activities and kinesiotherapy during one month, twice per week, with 30 minutes per session.~The treatment includes: active and passive kinesitherapy, muscle and tendons stretching, training of gait and deambulation, such as coordination and handling."
62153448|NCT05661240|EXPERIMENTAL|Tumor treating fields combined with docetaxel injection|Medical device：Tumor treating fields（EFE-P100） Tumor treating fields（EFE-P100）will be used each day. Drug: docetaxel each cycle is 21 days，docetaxel will be administered intravenously，75 mg/m2 on the first day of each cycle.
62526697|NCT02963870|EXPERIMENTAL|security plan|groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with security plan and the usual treatment
62526698|NCT02963870|ACTIVE_COMPARATOR|standard treatment only.|group receiving standard treatment only.
62526699|NCT00849771||1|Operative Treatment (Open Reduction Internal Fixation)
62526700|NCT00849771||2|Non-operative/Conservative Care
62153449|NCT05661240|ACTIVE_COMPARATOR|docetaxel injection|Drug: docetaxel each cycle is 21 days，docetaxel will be administered intravenously，75 mg/m2 on the first day of each cycle.
62153450|NCT03542604|EXPERIMENTAL|CBT-I + BWL|Cognitive behavioral therapy intervention for insomnia: 6 sessions over 8-week period combining education and behavioral techniques to reduce insomnia. Sleep intervention followed by behavioral weight loss intervention.
62153451|NCT03542604|PLACEBO_COMPARATOR|EDU + BWL|Program will parallel the CBT-I intervention in number and length of sessions. Intended to disseminate basic information about sleep, including behavioral treatment information that is widely available to patients and practitioners.Will be followed by behavioral weight loss intervention.
62153452|NCT01453764|EXPERIMENTAL|Adipose SVF IV Infusion|IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
62153453|NCT04631874|EXPERIMENTAL|Sequence A(RT)|Reference drug (Champix) -\> washout -\> test drug (CDFF0318)
62153454|NCT04631874|EXPERIMENTAL|Sequence B(TR)|Test drug (CDFF0318) -\> washout -\> reference drug (Champix)
62153455|NCT03845088||Children TMJA or condyle absence with Jaw Deformity|inclusion criteria: \<12 years old; Unilateral temporomandibular joint ankylosis or condyle absence； Temporomandibular joint reconstructed with costochondral graft；
62153456|NCT05936463||Orthodontics brackets|
62153457|NCT05936463||Clear aligner appliances|
62153458|NCT02727998|EXPERIMENTAL|Single infusion of Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
62526701|NCT00418821|EXPERIMENTAL|Laronidase|Mothers treated with laronidase who intended to breastfeed their infants while receiving laronidase and their infants who were breastfeed while the mothers were receiving laronidase.
62526702|NCT03894748|EXPERIMENTAL|MT10109L(Botulinum toxin type A)|
62153459|NCT02727998|ACTIVE_COMPARATOR|Midazolam with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the midazolam infusion procedure will begin inside the MRI. A physician will oversee and administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusions at a rate 0.045 mg/kg for 40 minutes.
62526703|NCT03894748|ACTIVE_COMPARATOR|BOTOX® 50U(Botulinum toxin type A)|
62526704|NCT01911663|EXPERIMENTAL|KRG|500 mg Korea red ginseng (KRG)
62736717|NCT05849675|PLACEBO_COMPARATOR|Placebo|Two lactose film-coated tablets (2 x 65mg \[125mg\]) will be encapsulated in an opaque capsule (identical to the experimental arm drug).
62153460|NCT05272254|EXPERIMENTAL|Povidone Iodine|10% povidone iodine + fluoride varnish
62153461|NCT05272254|PLACEBO_COMPARATOR|Placebo|Placebo (iced tea) + fluoride varnish
62153462|NCT05790135|EXPERIMENTAL|Multiparametric ultrasound evaluation|Multiparametric ultrasound evaluation will be applied to all patients who will develop diarrhea above 500 ml per day.
62153463|NCT05668845|EXPERIMENTAL|PG-ANB performed at the outset of LSG|PG-ANB is performed early in the procedure as a first step before starting the sleeve gastrectomy.
62153464|NCT05668845|ACTIVE_COMPARATOR|PG-ANB performed at the end of LSG|PG-ANB is performed at the end of the sleeve gastrectomy
62153465|NCT01634802|NO_INTERVENTION|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
62153466|NCT01634802|EXPERIMENTAL|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
62153467|NCT01867879|EXPERIMENTAL|TAS-102|
62153468|NCT01867879|PLACEBO_COMPARATOR|Placebo|
62153469|NCT01595425|EXPERIMENTAL|D961H Sachet 20 mg|2 way crossover
62153470|NCT01595425|EXPERIMENTAL|D961HHPMC Capsule 20 mg|2 way crossover
62526705|NCT01911663|PLACEBO_COMPARATOR|Placebo|500 mg placebo (corn starch)
62526706|NCT02283294|EXPERIMENTAL|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
62526707|NCT02283294|ACTIVE_COMPARATOR|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
62526708|NCT04469621|EXPERIMENTAL|SAR443122|SAR443122 dose 1, twice daily for 14 days
62526709|NCT04469621|PLACEBO_COMPARATOR|Placebo|matching placebo
62526710|NCT06092385||Patients with chronic liver disease and histologically proven cirrhosis|
62526711|NCT06092385||Control subjects with no signs of cirrhosis|
62526712|NCT02091141|EXPERIMENTAL|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
62153471|NCT05553730|EXPERIMENTAL|Intervention Group|Older adults randomly sorted into intervention group will receive six months of intervention after registration.
62526713|NCT02091141|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
62153472|NCT05553730|NO_INTERVENTION|Control Group|Older adults randomly sorted into Control group will not receive six months of intervention after registration.
62526714|NCT02091141|EXPERIMENTAL|Vemurafenib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle.
62526715|NCT02091141|EXPERIMENTAL|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.
62526716|NCT02091141|EXPERIMENTAL|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.
62526717|NCT02091141|EXPERIMENTAL|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
62526718|NCT02091141|EXPERIMENTAL|Erlotinib|Participants will receive erlotinib 150 mg orally once daily in each 28-day cycle.
62713471|NCT04174196|EXPERIMENTAL|Participants with Plasmacytoma|Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas
62526719|NCT03947424|EXPERIMENTAL|Experimental 1|Long-pulse (LP) Er:YAG laser snoring treatment.
62526720|NCT03947424|EXPERIMENTAL|Experimental 2|Fotona SMOOTH mode Er:YAG laser snoring treatment.
62526721|NCT03947424|SHAM_COMPARATOR|Control|Sham laser snoring treatment with no energy applied.
62526722|NCT02059018|EXPERIMENTAL|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions over two examination days
62713472|NCT01313871||All Participants|Adults with a confirmed diagnosis of rheumatoid arthritis
62713473|NCT04995172||Observational (CT-assisted bronchoscopy, chart review)|Patients undergo RP-EBUS bronchoscopy per standard of care. If the study staff cannot reach the target lesion or is unable to determine a diagnosis, patients undergo bronchoscopy using mobile CT imaging. Patients' medical records are also reviewed for up to 6 months.
62713474|NCT01668004|EXPERIMENTAL|GLM 50 mg|GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months
62153473|NCT05351788|EXPERIMENTAL|SKB264+KL-A167|Participants received SKB264 followed by KL-A167
62153474|NCT05351788|EXPERIMENTAL|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
62153475|NCT05351788|EXPERIMENTAL|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
62153476|NCT06222086|EXPERIMENTAL|Calisthenic exercise training with telerehabilitation|The training group will be given calisthenic exercise training via video conference accompanied by a physiotherapist for 6 weeks.
62153477|NCT06222086|SHAM_COMPARATOR|Control Group|The control group will not be given any training for 6 weeks during the study period
62526723|NCT02059018|EXPERIMENTAL|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions over two examination days
62526724|NCT04516512|EXPERIMENTAL|Investigated arm|Participants included in the study who met inclusion criteria
62526725|NCT01593033|EXPERIMENTAL|Fish oil and Micronutrient Supplementation|
62526726|NCT01593033|EXPERIMENTAL|Micronutrient Supplementation|
62526727|NCT01593033|PLACEBO_COMPARATOR|Placebo|
62526728|NCT01206816|EXPERIMENTAL|two experimental arms|patients receive increasing doses of BI 6727 in combination with increasing doses of BIBW 2992
62526729|NCT03832309|ACTIVE_COMPARATOR|Group 1|Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
62526730|NCT03832309|OTHER|Control Arm|Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.
62526731|NCT05555368|OTHER|single group|The Qo0R-15 scale will be administered to 150 patients.
62713475|NCT01128569|PLACEBO_COMPARATOR|Placebo|Placebo Inhaler
62713476|NCT01128569|ACTIVE_COMPARATOR|inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)|ICS/LABA inhaler
62713477|NCT01128569|ACTIVE_COMPARATOR|ICS|ICS inhaler
62713478|NCT00148356|EXPERIMENTAL|1|ZoMaxx™ Drug-Eluting Stent System
62713479|NCT00148356|ACTIVE_COMPARATOR|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
62713480|NCT01707537|EXPERIMENTAL|Euvichol|Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
62713481|NCT02202564|EXPERIMENTAL|LT+ADV-TK|Liver transplantation and double-dose ADV-TK/ganciclovir administration The first ADV-TK dose was administered before closing the peritoneal layer; the second ADV-TK dose was administered 2 months after LT; ganciclovir was slowly administered 36 hours after LT and twice daily for 14 days.
62153478|NCT02978040|EXPERIMENTAL|Cangrelor|Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
62153479|NCT02978040|ACTIVE_COMPARATOR|Tirofiban|Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min).
62526732|NCT02505490|EXPERIMENTAL|No Television|The purpose is to determine whether a change in liking of food will occur with a lack of television.
62526733|NCT02505490|EXPERIMENTAL|Television|The purpose is to determine whether a change in liking of food will occur while watching television.
62526734|NCT03466359|EXPERIMENTAL|DEF-EI|these adolescents will follow a dietary restriction of 10% of their daily energy intake.
62713482|NCT02202564|ACTIVE_COMPARATOR|LT|Orthotopic liver transplantation
62713483|NCT04397380||ED Patients|Patients Presenting in Emergency Department
62713484|NCT03323957||Patients|all infants admitted for care
62526735|NCT03466359|EXPERIMENTAL|DEF-EX|these adolescents will increase their physical activity-induced energy expenditure by 10% per day.
62526736|NCT01914055|ACTIVE_COMPARATOR|angio-guided thrombus aspiration|thrombus aspiration guided by angiography
62526737|NCT01914055|EXPERIMENTAL|OCT-guided thrombus aspiration|thrombus aspiration guided by optical coherence tomography
62153480|NCT02978040|ACTIVE_COMPARATOR|Prasugrel|Prasugrel oral integer or chewed at an identical loading dose of 60 mg
62713485|NCT02975960|EXPERIMENTAL|Stromal vascular fraction injection|Injection of autologous stromal vascular fraction on hand.
62153481|NCT04062383|EXPERIMENTAL|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
62153482|NCT02590770|ACTIVE_COMPARATOR|gaze-contingent|attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
62153483|NCT02590770|PLACEBO_COMPARATOR|non-gaze contingent|Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns
62153484|NCT05520411|EXPERIMENTAL|HUM Flatter Me|Come to Citruslabs Office twice (1 Week Gap Between Visits) Visit 1: Take Placebo or Test Product; Eat Test Meal; Outcome Measures Visit 2: Take Placebo or Test Product; Eat Test Meal; Outcome Measures
62153485|NCT04929444|ACTIVE_COMPARATOR|Training group|The professionals of the primary care teams that are in Intervention group would receive the training at the beginning of the study
62153486|NCT04929444|NO_INTERVENTION|Common Practice|The professionals of the primary care teams that are in Control group will be offered the training after the conclusion of the study
62153487|NCT04267549|EXPERIMENTAL|treatment|"Eligible patients will be given sintilimab(200mg iv, day 1), apatinib(250mg,once daily), S-1 (60mg, twice daily, day1-14) and nab-paclitaxel(without peritoneal metastases: 260 mg/m\^2 iv for 3h; with peritoneal metastases: 200mg/m\^2 iv plus 60mg/m\^2 ip; day 1) every 3 weeks for at least 3 cycles.~The feasibility of surgery will be evaluated by a multidisciplinary team every 2-4 cycles.~Patients assessed as inoperable will be allowed to continue maintenance therapy with the original regimen until disease progression or intolerable toxicity. For patients assessed as operable, apatinib will be discontinued and one more cycle of sintilimab combined with S-1 and nab-paclitaxel will be administered; radical surgery will be performed within 2-4 weeks after the end of treatment.~Safety run-in stage will be set in the first 6 patients to determine the safety. The study will be terminated if dose-limiting toxicities (DLTs) occur in more than 2 patients."
62153488|NCT03909074|EXPERIMENTAL|Experimental group|36-71 months old children-experimental EV71 vaccine.
62153489|NCT03909074|ACTIVE_COMPARATOR|Vaccine-controlled group|36-71 months old children-control EV71 vaccine.
62153490|NCT03909074|ACTIVE_COMPARATOR|Age-controlled group|6-35 months old children-experimental EV71 vaccine.
62153491|NCT01923402||Exclusive cigarette smokers|
62153492|NCT01923402||Exclusive moist snuff consumers|
62153493|NCT01923402||Non-tobacco consumers|
62153494|NCT05226728|EXPERIMENTAL|pharmacokinetic-guided pembrolizumab cohort|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression.
62153495|NCT04364399|EXPERIMENTAL|Experimental group|Mumps vaccine, one dose
62153496|NCT04364399|ACTIVE_COMPARATOR|Control group|measles, mumps and rubella combined vaccine, live, one dose
62153497|NCT01393600|EXPERIMENTAL|NBI-98854 12.5 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.~Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
62526738|NCT02536326|EXPERIMENTAL|renal denervation|
62713486|NCT05119010|EXPERIMENTAL|A|patients will be asked to follow in a continuous way a very low-carbohydrate, high-fat diets, which strictly limit carbohydrate consumption (less than 40g / day) and allow unlimited consumption of high-fat foods, such as pork belly, butter, coconuts oils, fat meat, eggs and cheese, etc... (cf appendix A). Patients will be provided with 2 meals (lunch and dinner), every meal with 2 dishes (first course and main course) and bread for every day for 3 months (ELIOR partnership).
62153498|NCT01393600|EXPERIMENTAL|NBI-98854 50 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.~Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
62153499|NCT03406507|EXPERIMENTAL|Ravulizumab|Complement inhibitor treatment-naïve and eculizumab-experienced participants received ravulizumab.
62153500|NCT04910711|ACTIVE_COMPARATOR|DTG/LNG|Receiving dolutegravir-based antiretroviral therapy and initiating the levonorgestrel implant
62526739|NCT04736043||Patients with resected pancreatic cancer who require adjuvant chemotherapy|
62526740|NCT03901859||Patients with ADHD|drug-naive patients with ADHD, aged 7-18 year old
62526741|NCT03901859||Healthy Controls|drug-naive healthy controls, aged 7-18 year old
62526742|NCT02263235|EXPERIMENTAL|Group 1|60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
62526743|NCT02263235|EXPERIMENTAL|Group 2A|20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
62526744|NCT02263235|EXPERIMENTAL|Group 2B|30 patients (15 probable AD, 15 neurological disease without cognitive degradation)
62526745|NCT03621059|EXPERIMENTAL|Behavioral Therapy with TS|habit reversal training (HRT)
62526746|NCT03621059|NO_INTERVENTION|observational|observational and usual care Pyridoxine(50mg)
62526747|NCT03522610|EXPERIMENTAL|ADAPT|Parents participate in a 14-week in person group based version of ADAPT with web-enhanced online ADAPT materials.
62526748|NCT03522610|NO_INTERVENTION|Comparison Group|Parents receive services as usual (pamphlets, brochures, etc) on parenting typically found at a VA or Dr.'s office.
62153501|NCT04910711|OTHER|NEG/LNG|HIV negative, not receiving antiretroviral therapy and initiating the levonorgestrel implant
62153502|NCT04910711|ACTIVE_COMPARATOR|DTG/MPA|Receiving dolutegravir-based antiretroviral therapy and the depot medroxyprogesterone acetate injection
62153503|NCT04910711|OTHER|NEG/MPA|HIV negative, not receiving antiretroviral therapy and receiving the depot medroxyprogesterone acetate injection
62526749|NCT04489758|EXPERIMENTAL|Constrictive Bronchiolitis|Veterans with surgical lung biopsy-proven constrictive bronchiolitis
62526750|NCT04489758|ACTIVE_COMPARATOR|Controls|Control patients with minimal smoking history and no chronic lung disease or respiratory symptoms
62526751|NCT01916590|ACTIVE_COMPARATOR|Bupivacaine|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
62526752|NCT01916590|PLACEBO_COMPARATOR|Placebo|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.
62526753|NCT05084664|EXPERIMENTAL|group A|premodulated current
62526754|NCT05084664|EXPERIMENTAL|group B|diadynamic current
62736718|NCT06138600|ACTIVE_COMPARATOR|Cabotegravir Long Acting Injectable|Investigational Product: Cabotegravir Dosage Formulation: 600 mg suspension for injection Route of Administration: Intra-muscular injection Dosing Instructions: 1 vial (600 mg) injected monthly for the initial visit (Month 1 and 2), then every 2 months thereafter (from Month 2 onwards)
62153504|NCT05463302|ACTIVE_COMPARATOR|Active EMF blanket|participants will receive the real EMF blocker blanket
62153505|NCT05463302|PLACEBO_COMPARATOR|Sham EMF blanket|participants will receive the sham EMF blocker blanket
62153506|NCT02060175|EXPERIMENTAL|1 CILOTAX arm|Cilotax drug-eluting stents implantation
62153507|NCT02060175|ACTIVE_COMPARATOR|2 DESyne arm|DESyne drug-eluting stents implantation
62153508|NCT04439591|EXPERIMENTAL|Intervention group|Intervention group undergoes computerised brain training programme first.
62526755|NCT00874003|EXPERIMENTAL|mirtazapine, tablet, 30 mg|n=29
62526756|NCT00874003|PLACEBO_COMPARATOR|sugar pill|n=30
62526757|NCT00166036|EXPERIMENTAL|Atorvastatin 10MG|
62526758|NCT00166036|EXPERIMENTAL|Pravastatin 80mg|
62526759|NCT06303973|EXPERIMENTAL|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
62526760|NCT06303973|ACTIVE_COMPARATOR|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
62526761|NCT06429839|EXPERIMENTAL|Nimotuzumab concurrent with chemordiotherapy followed by surgery|
62153509|NCT04439591|OTHER|Control group|Waitlist control group: control group undergoes programme after intervention group has completed it in a crossover design.
62153510|NCT04202263|PLACEBO_COMPARATOR|Placebo|Placebo cream without minocycline
62153511|NCT04202263|ACTIVE_COMPARATOR|Minocycline Arm|Minocycline cream (1%,2%,3%)
62153512|NCT03486756|EXPERIMENTAL|Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform.
62153513|NCT04553809|ACTIVE_COMPARATOR|Kontrol|Patients undergoing examination for lung cancer with the use of electromagnetic navigation bronchoscopy for biopsy sampling
62153514|NCT04553809|EXPERIMENTAL|Intervention|Patients undergoing examination for lunge cancer with the use of electromagnetic navigation bronchoscopy and radial endobronchial ultrasound for biopsy sampling.
62153515|NCT04211194||Patients with upper gastrointestinal bleeding|Patients with upper gastrointestinal bleeding undergoing endoscopic procedures at AdventHealth Hospitals in Central Florida
62153516|NCT02806752|EXPERIMENTAL|Ranibizumab + Triamcinolone Acetonide|intravitreal injection: Ranibizumab 0.5mg + Triamcinolone Acetonide 2mg
62153517|NCT02806752|ACTIVE_COMPARATOR|Ranibizumab|intravitreal injection: Ranibizumab 0.5mg
62153518|NCT03654482|EXPERIMENTAL|SuperSeton arm|
62153519|NCT05894616||Post acute sequale of COVID-19 (PASC)|"Verified infection with SARS-CoV-2 during wave 1 and 2 (i.e. wild type or alfa variants), prior to 2021-02-28. Diagnosed with post-COVID.~Experience of dyspnea (mMRC\>3 within past 2 weeks) is a required inclusion criteria, with the addition of one of the following: lung obstruction (FEv1/FVC\>70 or Z-score \< -1.64), lung restriction (FEV1\<80% or FVC \< 80%, air-trapping, ground glass- or mosaic attenuation observed by HRCT."
62153520|NCT05894616||Healthy control recovered from COVID-19|Verified infection with SARS-CoV-2 during wave 1 and 2 (i.e. wild type or alfa variants), prior to 2021-02-28. Fully recovered within 12 weeks of primary infection. No other diagnoses.
62153521|NCT03867656|EXPERIMENTAL|GLP-2|Glucagon-like peptide 2
62526762|NCT00786279|PLACEBO_COMPARATOR|1|150 cc daily of flavored, calorie-free beverage without alcohol
62713487|NCT05119010|EXPERIMENTAL|B|patients will be asked to follow in a discontinuous way (15 days on, 15 days off) a very low-carbohydrate, high-fat diets, which strictly limit carbohydrate consumption (less than 40g / day) and allow unlimited consumption of high-fat foods, such as pork belly, butter, coconuts oils, fat meat, eggs and cheese...etc (cf appendix A). Patients will be provided with 2 meals (lunch and dinner), every meal with 2 dishes (first course and main course) and bread for every day for the ketogenic diet period for 3 months (ELIOR partnership).
62713488|NCT05119010|EXPERIMENTAL|C|patients will receive oral liquid ketone supplement BHB monoester, 2 tablespoons three times per day (depending on patient weight: at least 1g/kg weight body/day) 15 days-on 15 days off during 3 months. We would recommend taking it at least 30 to 60 min before meal times and they will receive standard diet (without any diet restrictions).
62526763|NCT00786279|EXPERIMENTAL|2|150 cc flavored, calorie-free beverage with 15 gm ethanol daily
62526764|NCT01630213|ACTIVE_COMPARATOR|Vitamin D3 + fish oil/placebo|Vitamin D3 2000 IU/day and fish oil (840 omega 3-fatty acids; Omacor)(or fish oil placebo)/day
62526765|NCT01630213|PLACEBO_COMPARATOR|Vitamin D3 placebo + fish oil/placebo|Vitamin D3 placebo + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo
62713489|NCT05119010|NO_INTERVENTION|D|patients will receive standard diet (without any diet restrictions) and be followed up as in arms A, B, C.
62153522|NCT03867656|EXPERIMENTAL|GIP|Glucose-dependent insulinotropic polypeptide
62153523|NCT03867656|PLACEBO_COMPARATOR|Placebo|Saline
62153524|NCT04690309|ACTIVE_COMPARATOR|Patients treated with human insulin preparations|Treatment with human regular insulin administered subcutaneously before breakfast, lunch and supper and with Neutral Protamine Hagedorn insulin (isofane insulin) administered subcutaneously before sleep.
62153525|NCT04690309|ACTIVE_COMPARATOR|Patients treated with insulin analogues|Treatment with insulin analogues lispro administered subcutaneously before breakfast, lunch and supper and with glargine administered subcutaneously before sleep.
62153526|NCT06067295||Observational|Patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.
62153527|NCT05427942||Switch from adalimumab originator|
62153528|NCT05427942||Switch from adalimumab biosimilar 40 mg/0,8 mL|
62153529|NCT04794465||Asymptomatic IBD diagnosed during the colorectal cancer screening|
62153530|NCT01521702|EXPERIMENTAL|Neoadjuvant chemotherapy|After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).
62153531|NCT01521702|ACTIVE_COMPARATOR|surgery|surgery
62153532|NCT01691404|ACTIVE_COMPARATOR|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
62153533|NCT01691404|ACTIVE_COMPARATOR|Quercetin|Subjects will be asked to consume supplements containing 160mg of quercetin-3-glucoside daily
62153534|NCT01691404|PLACEBO_COMPARATOR|Placebo|Subjects will be asked to consume capsules containing a placebo (cellulose) daily
62153535|NCT02676778|EXPERIMENTAL|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
62153536|NCT05917158|EXPERIMENTAL|RC48-ADC and JS001|
62153537|NCT04251845|ACTIVE_COMPARATOR|Trial group|Intervention : Topical Melatonin(3%) at dosage of 15 mg once daily
62153538|NCT04251845|PLACEBO_COMPARATOR|Control Group|Intervention : Placebo once daily
62713490|NCT06518915|EXPERIMENTAL|Treatment Arm|Implantation of the baroloop device
62153539|NCT01750411||Asthma|Severe Asthma Not severe Asthma
62153540|NCT04917315|EXPERIMENTAL|JLP-2002|Drug: JLP-2002
62153541|NCT04917315|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62713491|NCT04276805|ACTIVE_COMPARATOR|tVNS group|Participants will undergo cognitive training with tVNS
62526766|NCT05631834|ACTIVE_COMPARATOR|Continuous Peri operative Thoracic epidural catheters analgesia|"Epidural catheter insertion will be performed at level T9 with catheter tip at level T7 After negative test dose with Lidocaine 2%, loading dose using Ropivacaine 0.5% (see table).~Patient height (cm) Volume of LA (mL) 140-149 8 150-159 10 160-169 12 170-180 14 \>180 16 Evaluation of sensory block should be at level T4 to T10 by cold test and pinprick. If extension needed, bolus of ropivacaine 0.5% 2 mL may be added.~In post operative period▪ analgesia with intermitent automatic bolus UAB of ropivacaine 0.2% will be connected and started at 10 min after arrival in post operative care unit~▪ Pump preparation and settings: Patient 140 - 149 cm = 8 mL Patient 150 - 159 cm = 10 mL Patient 160 - 169 cm = 12 mL Patient 170 - 180 cm = 14 mL Patient \>180 cm = 16 mL IAB every 4h reduced to 3h if needed Catheter will be removed 72h after end of surgery"
62713492|NCT04276805|SHAM_COMPARATOR|Sham group|Participants will undergo cognitive training with earlobe sham
62153542|NCT03754166|EXPERIMENTAL|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
62153543|NCT03754166|NO_INTERVENTION|Usual care|Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.
62153544|NCT02124304|EXPERIMENTAL|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
62153545|NCT02124304|EXPERIMENTAL|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
62153546|NCT00268697|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD|
62153547|NCT00268697|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Ezetimibe|
62153548|NCT00268697|ACTIVE_COMPARATOR|Ezetimibe|
62153549|NCT02994498|EXPERIMENTAL|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
62526767|NCT05631834|EXPERIMENTAL|Continuous Peri operative Bilateral erector spinae catheters analgesia|"The ESP will be performed Right side level The tip of the catheter should be on t T7.~Left side level The tip of the catheter should be on T8.~Induction with ropivacaine 0.5% with loading dose as follows:~Patient height (cm) Volume of LA (mL) LEFT RIGHT 140-149 8 6 150-159 10 8 160-169 12 10 170-180 14 12 \>180 16 14~For post operative analgesia:~* Pumps with intermittent automatic bolus (IAB) of ropivacaine 0.2% started at 10 min after arrival in PACU~* Patient 140 - 149 cm = 6 mL / left side - 8 mL / right side~* Patient 150 - 159 cm = 8 mL / left side - 10 mL / right side~* Patient 160 - 169 cm = 10 mL / left side - 12 mL / right side~* Patient 170 - 179 = 12 mL / left side - 14 mL / right side~* Patient \> 180 kg = 14 mL / side - 16 mL / right side The bolus on the second catheter will be delayed by 1 hour IAB every 6h Catheter will be removed 72h after end of surgery"
62526768|NCT02446327|OTHER|Diastolic heart failure cohort|This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
62526769|NCT00667810|EXPERIMENTAL|Bapineuzumab 0.5 mg/kg|
62526770|NCT00667810|EXPERIMENTAL|Bapineuzumab 1.0 mg/kg|
62526771|NCT00667810|PLACEBO_COMPARATOR|Placebo|
62526772|NCT03625518|ACTIVE_COMPARATOR|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
62526773|NCT03625518|ACTIVE_COMPARATOR|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
62526774|NCT02831218|EXPERIMENTAL|QCA and Aspirin alone|
62526775|NCT02831218|EXPERIMENTAL|QCA and Clopidogrel alone|
62526776|NCT02831218|ACTIVE_COMPARATOR|Imaging guided and Aspirin alone|
62526777|NCT02831218|ACTIVE_COMPARATOR|Imaging guided and Clopidogrel alone|
62526778|NCT02497118|EXPERIMENTAL|Endostatin plus NP|drug:Endostatins Intravenous drip， 7.5mg/m\^2, d1-14 drug:vinorelbine Intravenous drip 25mg/m\^2,IV, d1, d8; drug:Cisplatin，75mg/m\^2 Intravenous drip,divide into d1-3 for 2 cycles
62526779|NCT02497118|ACTIVE_COMPARATOR|NP neoadjuvant chemotherapy|drug:vinorelbine Intravenous drip 25mg/m\^2,IV, d1, d8; drug:Cisplatin，75mg/m\^2 Intravenous drip,divide into d1-3 for 2 cycles
62526780|NCT06026774|EXPERIMENTAL|iNeo-Vac-R01 in combination with standard adjuvant therapy|Subjects will receive at least 4 cycles of standard adjuvant therapy according to CSCO clinical guidelines after surgery. Then subjects will receive iNeo-Vac-R01 via IH injection on Day 1 of each 21-day cycle for up to 9 cycles at an applicable dose, identified during the dose escalation phase of the study.
62526781|NCT05589961|EXPERIMENTAL|integrated treatment regimen(TRPP)|
62526782|NCT01685073|EXPERIMENTAL|Zolpidem|Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder
62526783|NCT01685073|PLACEBO_COMPARATOR|Placebo|Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder
62526784|NCT02683265|EXPERIMENTAL|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg Aptensio XR)
62526785|NCT02683265|PLACEBO_COMPARATOR|Placebo comparator|Placebo capsules
62526786|NCT03749629|ACTIVE_COMPARATOR|CANMAT + GeneSight Psychotropic Test guided tx|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the pharmacogenomic test GeneSight®. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
62526787|NCT03749629|PLACEBO_COMPARATOR|CANMAT alone|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) alone.
62526788|NCT03250494|ACTIVE_COMPARATOR|group (I) (GI) (n=25)|
62713493|NCT01507025||horizontal flap|patients were scheduled to undergo LASIK and with horizontal flaps(nasal- or temporal-hinge)
62526789|NCT03250494|ACTIVE_COMPARATOR|group (II) (GII) (n=25)|
62526790|NCT03250494|PLACEBO_COMPARATOR|group (III) (GIII) (control group) (n=25)|
62526791|NCT03071094|EXPERIMENTAL|Pexa-Vec combined with Nivolumab - Phase I|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
62526792|NCT03071094|EXPERIMENTAL|Pexa-Vec combined with Nivolumab - Phase IIa|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
62526793|NCT01678001|ACTIVE_COMPARATOR|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
62526794|NCT01678001|PLACEBO_COMPARATOR|Placebo|Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
62526795|NCT01625130|ACTIVE_COMPARATOR|broccoli sprout homogenate (BSH)|Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
62526796|NCT01625130|PLACEBO_COMPARATOR|alfalfa sprout homogenate|Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
62526797|NCT01986621||Patients undergoing elective PCI|
62526798|NCT00653965|EXPERIMENTAL|1|Rosuvastatin
62526799|NCT00653965|ACTIVE_COMPARATOR|2|Atorvastatin
62526800|NCT04060719|EXPERIMENTAL|Reference (Period 1) - BI 894416 alone|Reference (Period 1) followed by Test (Period 2)
62526801|NCT04060719|EXPERIMENTAL|Test (Period 2) - BI 894416 + Rifampicin|
62526802|NCT05154032|EXPERIMENTAL|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
62526803|NCT01855074|EXPERIMENTAL|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
62713494|NCT01507025||vertical flap|patients were scheduled to undergo LASIK and with vertical flaps(superior- hinge)
62526804|NCT01799863|EXPERIMENTAL|Ketorolac trometamol 0.45%|Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.
62526805|NCT01799863|PLACEBO_COMPARATOR|Artificial tears|Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.
62526806|NCT00026221|EXPERIMENTAL|Arm I (monoclonal antibody and biological therapy)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive low-dose interferon alfa (IFN-alpha) SC on days 1-14.
62713495|NCT04972838|EXPERIMENTAL|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
62153550|NCT02994498|EXPERIMENTAL|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
62153551|NCT02994498|EXPERIMENTAL|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
62153552|NCT01465399|EXPERIMENTAL|PRGF-Endoret|
62153553|NCT01465399|ACTIVE_COMPARATOR|Conventional treatment|
62153554|NCT05843526|ACTIVE_COMPARATOR|Titanium abutment|Titanium (Ti) grade 5 titanium abutment
62153555|NCT05843526|EXPERIMENTAL|Dental resin abutment|Dental resin (Re) Optibond ™ FL, Kerr Dental abutment
62153556|NCT05843526|EXPERIMENTAL|Polyetheretherketone abutment|Polyetheretherketone (PEEK) Polyetheretherketone abutment
62153557|NCT02713594|PLACEBO_COMPARATOR|Control|Counseling from WTQL
62153558|NCT02713594|EXPERIMENTAL|Incentive|Counseling from WTQL; Financial incentive to participate
62153559|NCT04851197|EXPERIMENTAL|control group|"The students in the control group will be filled with the Introductory and Self-Testicular Examination Characteristics Question Form, Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale, which will be prepared with Microsoft teams forms before the training. Later, the students will be given an average of 20-30 minutes of training from Powerpoint presentation and video presentation. Students' questions will be answered in the last 10 minutes. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and KKTM Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled out."
62153560|NCT04851197|EXPERIMENTAL|Intervention|"Before the training, the students in the intervention group will fill the Introductory and Characteristics Question Form on Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale. Educational materials (lecture presentation, video) will be loaded on the system in accordance with the inverted learning model, and students will be asked to come prepared for the planned lesson. Classical presentations will not be made to the students, and the education will be given in the form of question and answer discussion. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and Self Testicular Examination Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled."
62153561|NCT01848132|ACTIVE_COMPARATOR|R-CHOP|"6 cycles every 21 days.~* Rituximab: intravenous, 375 mg/m2, day 1~* Cyclophosphamide: intravenous, 750 mg/m2, day 1~* Doxorubicin: intravenous, 50 mg/m2, day 1~* Vincristine: intravenous, 1,4 mg/m2, day 1~* Prednisone: oral, 100 mg, days 1-5"
62153562|NCT01848132|EXPERIMENTAL|B-R-CAP|"6 cycles every 21 days~* Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15~* Rituximab: intravenous, 375 mg/m2, day 1~* Cyclophosphamide: intravenous, 750 mg/m2, day 1~* Doxorubicin: intravenous, 50 mg/m2, day 1~* Prednisone: oral, 100 mg, days 1-5"
62153563|NCT04379310||covid-19 pneumonia|diagnosed with covid-19 by using PCR and computed tomography scans
62153564|NCT03823690|ACTIVE_COMPARATOR|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated.~A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
62153565|NCT03823690|ACTIVE_COMPARATOR|Pyloro-duodenal stent|The uncovered DS used in this study is Wallflex (Boston, Natick, MA, USA), made of nitinol wire, with a diameter of 22mm and length of 6, 9, 12cm. This stent is a braided stent with high axial force, good flexibility and conformability.
62153566|NCT04127513|EXPERIMENTAL|12% AMMONIUM LACTATE|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 12% ammonium lactate. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
62153567|NCT04127513|ACTIVE_COMPARATOR|10% UREA|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 10% urea. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
62153568|NCT00863070||Bladder Exstrophy Patients|Patients who receive follow-up care at Connecticut CMC urology clinic for bladder exstrophy.
62526807|NCT00026221|EXPERIMENTAL|Arm II (monoclonal antibody)|Patients receive bevacizumab as in arm I.
62526808|NCT00026221|EXPERIMENTAL|Arm III (monoclonal antibody and biological therapy)|Patients receive bevacizumab as in arm I. Patients also receive high-dose IFN-alpha SC on days 1, 3, 5, 8, 10, and 12.
62526809|NCT01064141|EXPERIMENTAL|Group 1: Dengue Vaccine Group|Participants will receive CYD Dengue vaccine as Visits 1 and 2.
62526810|NCT01064141|ACTIVE_COMPARATOR|Group 2: Control Group|Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
62713496|NCT04972838|ACTIVE_COMPARATOR|Implementation as Usual (IAU)|The organizations will implement RR as usual. The research team will be available to provide support on the RR intervention as needed.
62526811|NCT01064141|EXPERIMENTAL|Group 3: Co-administration Group|Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
62526812|NCT01064141|EXPERIMENTAL|Group 4: Sequential Administration Group|Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
62526813|NCT05114837|EXPERIMENTAL|Phase I/II|Determine the maximum tolerated dose (MTD) of CAR19-tTreg. It will be administered in a single dose after high dose lymphodepleting chemotherapy to promote adoptive transfer. First dose of 1.0 x 10 6 CAR19-tTreg/kg recipient body weight (dose level 1).The subsequent doses are 3.0, 10.0 and 30.0 x 10 6 CAR19- tTreg/kg. PHASE II Expand trial on maximum tolerated dose (MTD) of CAR19-tTreg from Phase I. It will be administered in a single dose after high dose lymphodepleting chemotherapy to promote adoptive transfer.The CAR19-tTreg/kg dose is to be determined.
62526814|NCT00793780|ACTIVE_COMPARATOR|Naltrexone 25mg|
62153569|NCT03316170|EXPERIMENTAL|Social Support + NRT Sampling|"The treatment group will receive:~1. a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~2. a written directory of a range of social support resources delivered via mail,~3. a brief phone consult (10-15 minutes via phone) germane to smoking cessation,~4. a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and~5. a free, 2-week supply of nicotine patches and lozenges delivered via mail."
62526815|NCT00793780|PLACEBO_COMPARATOR|Placebo|
62526816|NCT00706095|EXPERIMENTAL|E7389 1.4 mg/m^2|
62526817|NCT00706095|EXPERIMENTAL|E7389 1.1 mg/m^2|
62526818|NCT00706095|EXPERIMENTAL|E7839 0.7 mg/m^2|
62713497|NCT03064828|ACTIVE_COMPARATOR|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kilovolts peak (kVp), 100-200mA
62153570|NCT03316170|ACTIVE_COMPARATOR|Social Support|"The control group will receive:~1. a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~2. a written directory of a range of social support resources delivered via mail,"
62153571|NCT01849523|EXPERIMENTAL|Web-based information and support|Web-based tailored information and support
62153572|NCT01849523|NO_INTERVENTION|Standard care|Standard care
62526819|NCT04136691|EXPERIMENTAL|simulation training|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed. In the research, the application of burn patient scenario was performed only with the intervention group.
62526820|NCT04136691|NO_INTERVENTION|Control|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed.
62526821|NCT04729192||Intervention|The patients will complete the ObsQoR-10T questionnaire on day 1 following delivery
62526822|NCT05237518|OTHER|36 adults|The test group should include both men and women subjects. Two equal sizes (18) sub-groups will be enrolled such that each sub-group will be monitored while lying on a different mattress type.
62526823|NCT03334617|EXPERIMENTAL|Durvalumab + olaparib|Durvalumab given in combination with olaparib .
62526824|NCT03334617|EXPERIMENTAL|Durvalumab + AZD9150|Durvalumab given in combination with AZD9150.
62526825|NCT03334617|EXPERIMENTAL|Durvalumab + AZD6738|Durvalumab given in combination with AZD6738.
62526826|NCT03334617|EXPERIMENTAL|Durvalumab + vistusertib|Durvalumab given in combination with Vistusertib (AZD2014).
62526827|NCT03334617|EXPERIMENTAL|Durvalumab + Oleclumab|Durvalumab given in combination with Oleclumab
62526828|NCT03334617|EXPERIMENTAL|durvalumab + trastuzumab deruxtecan|durvalumab given in combination with trastuzumab deruxtecan (DS-8201a)
62526829|NCT03334617|EXPERIMENTAL|durvalumab + cediranib|durvalumab given in combination with cediranib (AZD2171)
62713498|NCT03064828|EXPERIMENTAL|CT colonoscopy(low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
62526830|NCT03334617|EXPERIMENTAL|AZD6738 (ceralasertib) monotherapy|AZD6738 (ceralasertib) given as monotherapy
62526831|NCT03334617|EXPERIMENTAL|durvalumab & AZD6738 (ceralasertib)|durvalumab given in combination with AZD6738 (D15-D28)
62526832|NCT03334617|EXPERIMENTAL|durvalumab & AZD6738 (ceralasertib) (240 mg or 160 mg)|durvalumab in combination with twice daily 160 mg or 240 mg AZD6738 (D22-D28)
62526833|NCT03334617|EXPERIMENTAL|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 (ceralasertib) monotherapy on D1-7 of every 28 days
62526834|NCT00872482|EXPERIMENTAL|1|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
62526835|NCT00872482|PLACEBO_COMPARATOR|2|"A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day."
62526836|NCT02800213|EXPERIMENTAL|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
62526837|NCT02800213|ACTIVE_COMPARATOR|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
62526838|NCT04102852|EXPERIMENTAL|LGG regular dose|Patients taking LGG 1.2 × 10\^10 CFU/day, 2 capsules a day, for 1 month
62526839|NCT04102852|EXPERIMENTAL|LGG double dose|Patients taking LGG 2.4 × 10\^10 CFU/day, 4 capsules a day, for 1 month
62526840|NCT02208674|NO_INTERVENTION|Usual Care|Primary care provider-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per usual care.
62526841|NCT02208674|EXPERIMENTAL|Protocolized, pharmacist-delivered CKD Action Plan|Protocolized, pharmacist-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per KDIGO and JNC-8 recommendations.
62526842|NCT02018926|EXPERIMENTAL|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
62153573|NCT02035345|EXPERIMENTAL|Carboplatin|"Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:~* First hour - Administer 1 percent of total dose (5ml with tubing primed)~* Second hour - Administer 9 percent (45 mL)~* Third hour - Administer 90 percent (450 mL)"
62526843|NCT01829841|EXPERIMENTAL|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
62153574|NCT05193175|EXPERIMENTAL|Prolonged sitting|Uninterrupted sitting for 6 hours.
62526844|NCT01829841|ACTIVE_COMPARATOR|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
62526845|NCT01367652|ACTIVE_COMPARATOR|Letrozole|2.5 mg tablet
62526846|NCT01367652|ACTIVE_COMPARATOR|Femara|2.5 mg tablet
62153575|NCT05193175|EXPERIMENTAL|Sitting interrupted with standing|Sitting interrupted with 5 minutes of static standing every 30 minutes for 6 hours.
62526847|NCT01898325|OTHER|Naïve GD patients|"Naïve GD patients~Intervention: device - Fibroscan"
62526848|NCT01898325|OTHER|GD treated with ERT|GD treated with ERT Intervention: device - Fibroscan
62526849|NCT01898325|OTHER|Healthy control|Healthy control Intervention: device - Fibroscan
62526850|NCT01898325|OTHER|NonAlcoholic Steatohepatitis Patients|Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
62153576|NCT05193175|EXPERIMENTAL|Sitting interrupted with light stepping|Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.
62526851|NCT05285670|EXPERIMENTAL|Digital counseling plus interactive two-way SMS dialogue|Participants will receive initial counseling on a tablet followed by automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
62526852|NCT05285670|NO_INTERVENTION|Control|Control receiving standard of care.
62153577|NCT02825550|EXPERIMENTAL|Hepatoma treated using Taiwan ACE Beads|The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.
62153578|NCT03214614|EXPERIMENTAL|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
62153579|NCT03214614|PLACEBO_COMPARATOR|Placebo multiple dose|Multiple doses of Placebo oral suspension
62153580|NCT03214614|EXPERIMENTAL|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
62153581|NCT03214614|PLACEBO_COMPARATOR|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
62153582|NCT05792683|ACTIVE_COMPARATOR|Early lumbar drain|30 in this group
62153583|NCT05792683|OTHER|conservative treatment|30 in this group
62153584|NCT01517282|EXPERIMENTAL|MOR103 0.5 mg/kg|6 doses of MOR103 0.5 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
62153585|NCT01517282|EXPERIMENTAL|MOR103 1.0 mg/kg|6 doses of MOR103 1.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
62153586|NCT01517282|EXPERIMENTAL|MOR103 2.0 mg/kg|6 doses of MOR103 2.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
62153587|NCT01517282|PLACEBO_COMPARATOR|Placebo|6 doses of placebo administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
62526853|NCT00616941|EXPERIMENTAL|Cohort 1|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) once every 3 weeks for a total of 5 vaccinations.
62526854|NCT00616941|EXPERIMENTAL|Cohort 2|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 vegetable grade (VG) once every 3 weeks for a total of 5 vaccinations.
62526855|NCT00616941|EXPERIMENTAL|Cohort 3|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 VG and poly-ICLC once every 3 weeks for a total of 5 vaccinations.
62153588|NCT03645161|ACTIVE_COMPARATOR|Local rat and mouse skin test|All patients receive local skin prick test for mouse and rat. The result were recorded and compared to the imported one.
62153589|NCT03645161|ACTIVE_COMPARATOR|Imported rat and mouse skin test|All patients receive imported skin prick test for mouse and rat. The result were recorded and compared to the local one.
62526856|NCT02431182|EXPERIMENTAL|Memory training group|"Memory training:The intervention consists of twelve 90-minutes group sessions given once a week by a specialized psychologist.~The groups are formed by around 15 people. Each session has its own objectives, material and activities. The content of the intervention is based on memory training from different perspectives as cognitive and emotional aspects or social and individual skills."
62526857|NCT02431182|NO_INTERVENTION|Control group|No intervention will be administred until the delayed post-test is finished
62526858|NCT02528747||Study population|Breast cancer patients with metastatic bone disease
62526859|NCT03047837|PLACEBO_COMPARATOR|Placebo|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID) for 12 months
62526860|NCT03047837|EXPERIMENTAL|Metformin|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID), for 12 months
62526861|NCT03047837|EXPERIMENTAL|Aspirin|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID), for 12 months
62526862|NCT03047837|EXPERIMENTAL|Apirin plus Metformin|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID), for 12 months
62526863|NCT01573169|EXPERIMENTAL|low weight molecular heparin|enoxaparin 0.4 ml subcutaneous per day
62153590|NCT03603691|ACTIVE_COMPARATOR|Modified Manual Muscle Test|The MMMT will be tested in a test-retest design
62153591|NCT03603691|ACTIVE_COMPARATOR|Neurostatus BMRC|The Neurostatus BMRC measures Strength and will be used in a test-retest design
62526864|NCT01573169|PLACEBO_COMPARATOR|standard therapy|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
62526865|NCT01284296|EXPERIMENTAL|Digital block|
62153592|NCT03603691|ACTIVE_COMPARATOR|MicroFET2|The MicroFET2 is a hand held dynamometer to measure strength
62526866|NCT03771937|EXPERIMENTAL|Intervention|Intervention group received a telephone follow-up intervention, which consisted of a pre-discharge education program and three telephone follow-up sessions based on the RAM.
62526867|NCT03771937|NO_INTERVENTION|Control group|the control group received routine care.
62153593|NCT03713229||HIV-infected men who have sex with men|HIV-infected male patients who refer to conducting sexual risk practices that enable HPV transmission
62526868|NCT04354519||Confirmed Cases|"Diagnosed by health professional / Covid-19 test~Monitored through fortnightly questionnaires"
62526869|NCT04354519||Not Covid-19 cases|"Through self report no suspicion of COVID-19, tested by fortnightly questionnaire.~non Covid Cases can become COVID cases through self report."
62526870|NCT04354519||Suspected Covid-19 Cases|"Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed.~Fortnighly questionnaire"
62526871|NCT00697684|NO_INTERVENTION|Cohort 1|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
62153594|NCT03713229||HIV-infected men|HIV-infected male patients who neglect conducting sexual risk practices that enable HPV transmission
62153595|NCT03713229||HIV-infected women|HIV-infected female patients disregarding sexual risk practices
62153596|NCT03080337|NO_INTERVENTION|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
62153597|NCT03080337|EXPERIMENTAL|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
62153598|NCT03837015|ACTIVE_COMPARATOR|Estring alone|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.
62526872|NCT00697684|EXPERIMENTAL|Cohort 2|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
62526873|NCT00697684|EXPERIMENTAL|Cohort 3|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
62526874|NCT00697684|EXPERIMENTAL|Cohort 4|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
62526875|NCT01536990||Stroke|Medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction secondary to stroke.
62713499|NCT06400498|NO_INTERVENTION|No Palliative Care Consultation Prompt Group|When a patient is randomized to the No Palliative Care Consultation Prompt Group, no prompt will occur. A treating clinician can choose to place or discontinue a palliative care consultation at any time. A patient may choose to request or decline a palliative care consultation at any time.
62153599|NCT03837015|ACTIVE_COMPARATOR|Estring and vaginal RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30
62153600|NCT03837015|ACTIVE_COMPARATOR|Estring and oral RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.
62153601|NCT03837015|ACTIVE_COMPARATOR|Vaginal RepHresh Pro-B|Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.
62153602|NCT03584282|NO_INTERVENTION|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
62153603|NCT03584282|ACTIVE_COMPARATOR|Text Messaging|Participants in this group will receive the text messaging intervention.
62526876|NCT00472862|EXPERIMENTAL|2|Cognitive training
62526877|NCT00472862|ACTIVE_COMPARATOR|1|OPUS psychosocial treatment alone
62526878|NCT06174870|NO_INTERVENTION|Control|Control group
62526879|NCT06174870|EXPERIMENTAL|Intervention|IMT group
62526880|NCT02684708|ACTIVE_COMPARATOR|COPDAC-28|cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3
62526881|NCT02684708|EXPERIMENTAL|DECOPDAC-21|patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification
62153604|NCT03584282|ACTIVE_COMPARATOR|Peer Navigation|Participants in this group will receive the peer navigator intervention.
62526882|NCT03030820|EXPERIMENTAL|Dental cleaning|Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
62526883|NCT01064154|EXPERIMENTAL|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
62153605|NCT03584282|ACTIVE_COMPARATOR|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
62526884|NCT01064154|ACTIVE_COMPARATOR|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
62526885|NCT03805503|EXPERIMENTAL|chloroprocaine 1% injectable solution|"Prospective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%.~An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study.~An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study."
62526886|NCT01983917|OTHER|Use of the Diabetes Application|
62526887|NCT03098914||Beijing Haidian Hospital|
62526888|NCT03098914||Chinese PLA General Hospital|
62526889|NCT03098914||Beijing Tsinghua Chang gung Hospital|
62526890|NCT03000218|EXPERIMENTAL|UDCA 8 wks|Day 1 to 56: Ursodeoxycholic acid 300mg bid
62526891|NCT03000218|EXPERIMENTAL|UDCA for 4wks/UDCA+metformin for 4wks|Day 1 to 28: Ursodeoxycholic acid 300mg bid Day 29 to 56: Ursodeoxycholic acid 300mg and Metformin 500mg bid
62526892|NCT03000218|PLACEBO_COMPARATOR|Placebo|Day 1 to 56: Placebo bid
62526893|NCT00450619|EXPERIMENTAL|Arm A -EDTMP Alone|Patients receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg intravenous (IV) over 1 minute on day 8. Treatment repeats every 12 weeks in the absence of disease progression or unacceptable toxicity.
62153606|NCT06471153|EXPERIMENTAL|Study Group|Received the empowerment program based on the BASNEF model
62526894|NCT00450619|EXPERIMENTAL|Arm B - 153SmEDTMP with vaccine|Patients receive recombinant vaccinia-TRICOM vaccine 2 x 10\^8 PFU subcutaneously (SC) on day 1. Patients also receive recombinant fowlpox-TRICOM vaccine 1 x 10\^9 PFU SC on days 15 and 29 and sargramostim (GM-CSF)100 mcg/injection SC x 4 days. Treatment with recombinant fowlpox-TRICOM vaccine and GM-CSF\* repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg as in arm I.
62526895|NCT05060354||MS Kesimpta (ofatumumab)|MS patients treated with Kesimpta (ofatumumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
62526896|NCT05060354||MS Ocrevus (ocrelizumab)|MS patients treated with Ocrevus (ocrelizumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
62526897|NCT05060354||MS Gilenya (fingolimod) and Mayzent (siponimod)|MS patients treated with Gilenya (fingolimod) or Mayzent (siponimod) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
62526898|NCT05060354||Healthy Control|Individuals with major autoimmune disorders or current treatment with immunosuppressive or immunomodulatory drugs Received SARS-CoV2 vaccination (completed regimen) within 2-6 months of enrollment Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
62526899|NCT01021358|EXPERIMENTAL|Arm A (ABT-263 and Ketoconozole)|
62526900|NCT05012163|EXPERIMENTAL|Pennsylvania (PA) Lottery Scratch-Off Financial Incentive|"Participants in this arm will receive a message stating that they will receive a PA lottery $1 scratch-off ticket if they get a flu shot at an upcoming appointment. The message will mention that they could win $5,000 (the top prize for the scratch-off game).~Note: $1 scratch-off products vary over time; at study implementation, an active game with top prize of $5,000 (or the next-highest top prize) will be selected and will define the prize in the raffle absent upfront odds"
62526901|NCT05012163|EXPERIMENTAL|Certain Cash Payout Financial Incentive|Participants in this arm will receive a message stating that they will receive $1 in cash if they get a flu shot at an upcoming appointment.
62526902|NCT05012163|EXPERIMENTAL|Reminder / Active Control (No Financial Incentive)|Participants in this arm will receive a message stating that they can get a flu shot at an upcoming appointment. These participants will not be offered a financial incentive for getting a flu shot.
62526903|NCT05012163|NO_INTERVENTION|No Treatment Control|No additional contact beyond standard Geisinger flu shot communications
62526904|NCT04573517|EXPERIMENTAL|Early amniotomy|Subjects randomized to this arm will undergo amniotomy within 2 hours of removal of Foley balloon.
62526905|NCT04573517|ACTIVE_COMPARATOR|Delayed amniotomy|Subjects randomized to this arm will undergo amniotomy at least 4 hours after removal of Foley balloon.
62713500|NCT06400498|ACTIVE_COMPARATOR|Palliative Care Consultation Prompt Group|When a patient is randomized to the Palliative Care Consultation Prompt Group, a clinical decision support tool in the electronic health record will inform the treating clinician of the patient's serious illness and the results of the Surprise Question and prompt the treating clinician to consider a palliative care consultation. A treating clinician can choose to place or discontinue a palliative care consultation at any time, retaining full autonomy to deliver the appropriate patient care. A patient may choose to request or decline a palliative care consultation at any time.
62153607|NCT06471153|ACTIVE_COMPARATOR|Control Group|received the routine care
62526906|NCT04001101|ACTIVE_COMPARATOR|RT and Anti-PD-1|"In the pembrolizumab + RT arm, pembrolizumab will be started on study within 7 days (+/- 7 days) of start of RT.~Pembrolizumab will be given as standard of care in both arms"
62153608|NCT00801606|EXPERIMENTAL|Study drug containing zinc alone|Zinc 20 mg daily
62526907|NCT04001101|PLACEBO_COMPARATOR|Anti-PD-1|anti-PD-1 therapy alone Pembrolizumab will be given as standard of care in both arms
62526908|NCT04031781|ACTIVE_COMPARATOR|Receiving repetitive transcranial magnetic stimulation (rTMS)|This group received 5 rTMS sessions, delivered over one week over the left dorsolateral prefrontal cortex (LDLPFC ) at 5-Hz frequency and 100% motor threshold intensity.
62713501|NCT06311799|NO_INTERVENTION|Arm 1: Clinic Model|Clinical team gives WIC information only
62713502|NCT06311799|ACTIVE_COMPARATOR|Arm 2: Clinic-WIC Model|Clinical team connects patient to WIC
62713503|NCT06311799|ACTIVE_COMPARATOR|Arm 3: Clinic-RDN Model|Clinical team gives WIC information only; connects patient to registered dietitian/nutritionist (RDN)
62713504|NCT06311799|ACTIVE_COMPARATOR|Arm 4: Clinic-WIC-RDN|Clinical team connects patient to WIC and RDN
62713505|NCT06546839|ACTIVE_COMPARATOR|Group SPSIPB = SPSIPB group|SPSIPB will be performed
62713506|NCT06546839|ACTIVE_COMPARATOR|Group SAPB = SAPB group|SAPB will be performed
62153609|NCT00801606|EXPERIMENTAL|Study drug Micronutrient without zinc|micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.
62153610|NCT00801606|EXPERIMENTAL|Study drug Micronutrient with zinc|micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).
62153611|NCT00801606|PLACEBO_COMPARATOR|Placebo|Placebo only
62153612|NCT01035177||Control|Women without hip fracture, matched on age to the cases
62153613|NCT01035177||Patient|Female patients aged 60 and older with hip fracture
62153614|NCT02152384|EXPERIMENTAL|Insulin peglispro (LY2605541, with Insulin Lispro)|Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
62153615|NCT02152384|ACTIVE_COMPARATOR|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
62153616|NCT00126620|EXPERIMENTAL|OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)|Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
62153617|NCT01870336|EXPERIMENTAL|Lateral customized foot orthoses|Foot orthoses with arch support and lateral inclination set at 7° (alone)
62526909|NCT04031781|PLACEBO_COMPARATOR|Group receiving placebo rTMS|This group received Placebo rTMS was given with the same stimulation frequency at a fixed intensity of 50% of the machine output
62713507|NCT05547113||Cochlear implant patients|The group of patients will consist of 40 adult patients indicated for cochlear implantation at the Department of ENT and Head and Neck Surgery, 1st Faculty of Medicine and FN Motol. Patients who meet the indication criteria for implantation also meet the conditions for inclusion in the study, another criterias are absence of diseases of the bearing joints, absence of diseases peripheral nervous system or muscle disease and absence of disease vision that would prevent visual fixation.
62713508|NCT00642486|ACTIVE_COMPARATOR|1|laboratory-based testing
62153618|NCT01870336|EXPERIMENTAL|Knee brace|OdrA Knee brace (alone)
62713509|NCT00642486|ACTIVE_COMPARATOR|2|home-based testing
62713510|NCT06527885||Lurasidone Treatment|Adult patients suffering from schizophrenia treated for 3 months with lurasidone according to routine clinical practice.
62153619|NCT01870336|EXPERIMENTAL|Combination of the two treatments|Combination of Lateral customized foot orthoses and knee brace
62153620|NCT02089425|PLACEBO_COMPARATOR|Placebo|Placebo patch: 0% indomethacin
62153621|NCT02089425|EXPERIMENTAL|K-103-IP|K-103-IP: 0.5% indomethacin
62153622|NCT04436965|EXPERIMENTAL|Standard nutrition therapy|Dynamic nutrition assessment will be performed to patients. If malnutrion happened, patients would receive oral nutritional supplements (ONS) first, then feeded with nasal feeding tube or PEG when ONS wasn't enough. If all the these enteral nutrition methods couldn't make up for patient's nutritional deficiencies, parenteral nutrition would be considered.
62153623|NCT04436965|ACTIVE_COMPARATOR|Conventional nutrition therapy|Dynamic nutrition assessment will be performed to patients throughout whole treatment, and symptomatic treatment would be performed if needed.
62526910|NCT03449836|EXPERIMENTAL|Streptococcus salivarius 24SMBc + Strept.oralis 89a|spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
62526911|NCT03449836|ACTIVE_COMPARATOR|fluticasone + mometasone|spray with fluticasone and mometasone
62153624|NCT01566383|EXPERIMENTAL|Healthy Volunteers|Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.
62153625|NCT06196294|EXPERIMENTAL|γδT cell therapy for solid tumor|
62526912|NCT03449836|PLACEBO_COMPARATOR|placebo|spray with isotonic solution
62526913|NCT05623943||ICAS patients planning for endovascular treatment|Patients received pressure-wire-based intravascular pressure measurement and ASL measurement before and after operation.
62526914|NCT02293330|EXPERIMENTAL|C group|continuous infusion of levobupivacaine
62526915|NCT02293330|EXPERIMENTAL|B group|Intermittent bolus infusion of levobupivacaine
62526916|NCT02328235|EXPERIMENTAL|High Saturated Fat Diet|Subjects will receive a high fat diet for 5 day following a 2 week lead in diet. Measurements will be made pre-post high fat diet
62526917|NCT06109337||ADHD children|Take peripheral blood 5ml; IQ and cognitive function test; Head MRI scan
62526918|NCT06109337||typically developing controls|Take peripheral blood 5ml; IQ and cognitive function test; Head MRI scan
62526919|NCT01323049|ACTIVE_COMPARATOR|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia in this group
62526920|NCT01323049|ACTIVE_COMPARATOR|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia in this group
62526921|NCT02468622||MO patients|Patients with migraine without aura. We will take blood samples during spontaneous migraine attacks
62526922|NCT02468622||MA patients|Patients with migraine with aura. We will take blood samples during spontaneous migraine attacks
62526923|NCT04941482|EXPERIMENTAL|Multi-intervention program|A multi-intervention program will design for stroke patients including \[1\] periodic health examination for assessment of physical and mental health, recurrence risks, and harmful behaviors; \[2\] guiding the appropriate rehabilitation exercises for improving the physical status and monitoring through daily online report; \[3\] using the motivational interviewing methods to improve and prevent mental disorder; \[4\] applicating the technique of functional near-infrared spectroscopy (fNIRS) for measurement of oxy-hemoglobin on cortex prefrontal to early detect mental disorder and stroke recurrence risks.
62153626|NCT06196294|EXPERIMENTAL|CAR-γδT cell therapy for solid tumor|
62153627|NCT05005247|EXPERIMENTAL|GBS-NN/NN2|Single dose 0.5 millilitre (mL) intramuscular injection of GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
62153628|NCT04464148|EXPERIMENTAL|Pregnenolone 250 BID > Pregnenolone 400 BID|For week 0-5 participants will receive pregnenolone 250 mg twice a day (total 500 mg/day). For weeks 6-8 participants will receive 400 mg twice a day (800 mg/day), if the drug is well tolerated.
62153629|NCT05398484|EXPERIMENTAL|Participants receiving Study Drug|Advanced cancer participants will receive experimental medication, psilocybin (25mg). In addition to the pharmacologic intervention, participants will receive a manualized psychotherapy platform. The combination of interventions is referred to as psilocybin-assisted psychotherapy (PAP).
62526924|NCT04941482|ACTIVE_COMPARATOR|Standard care|Standard health check and fNIRS measure
62526925|NCT06140043|ACTIVE_COMPARATOR|2D Monitor screen|Patient consultation with 3D models of bone and skin, seen with a monitor screen
62526926|NCT06140043|EXPERIMENTAL|3D AR|Patient consultation with 3D models of bone and skin, seen in augmented reality trough AR glasses
62526927|NCT05354570|EXPERIMENTAL|Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation will be administered over approximately 6 weeks to 50.4 Gy in 28 fractions with an optional SIB to gross residual disease.
62526928|NCT04699526|EXPERIMENTAL|Intervention|Received UPC training, school policy and climate interventions, and Unplugged prevention program
62526929|NCT04699526|NO_INTERVENTION|Control|Only implemented Unplugged prevention program
62526930|NCT00870649|EXPERIMENTAL|Bilhvax vaccine (Sh28GST)|Arm 1 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of candidate vaccine at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
62526931|NCT00870649|PLACEBO_COMPARATOR|Placebo|Arm 2 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of placebo at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
62526932|NCT01024686|EXPERIMENTAL|p52-p36- GAP Vaccine|"p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.~p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
62526933|NCT01024686|NO_INTERVENTION|Infectivity Control|Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum
62526934|NCT01024686|EXPERIMENTAL|p52-p36- GAP Vaccine + Infectivity Challenge|"p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
62526935|NCT03712982|NO_INTERVENTION|Waitlist Control|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2.
62153630|NCT05398484|ACTIVE_COMPARATOR|Participants receiving Placebo|Advanced cancer participants will receive active placebo - single dose of niacin (100mg). In addition to the placebo, participants will receive the same manualized psychotherapy platform as the experimental arm.
62153631|NCT03236727|NO_INTERVENTION|Control|Data of SSEPs (amplitude and latency) before dexmedetomidine infusion.
62526936|NCT03712982|EXPERIMENTAL|Attention to Variability - Patient Only|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
62526937|NCT03712982|EXPERIMENTAL|Attention to Variability - Partner Only|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. Partners of the infertile women will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
62713511|NCT03366337|EXPERIMENTAL|Bardoxolone Methyl - ADPKD|Participants with autosomal polycystic kidney disease (ADPKD) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
62153632|NCT03236727|ACTIVE_COMPARATOR|Dexmedetomidine|Data of SSEPs (amplitude and latency) after dexmedetomidine infusion.
62153633|NCT04312425||Group C|General anesthesia was induced with classic rapid sequence induction protocol.
62153634|NCT04312425||Group M|General anesthesia was induced with modified rapid sequence induction protocol.
62526938|NCT03712982|EXPERIMENTAL|Attention to Variability - Patient & Partner|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. All participants (patients and partners) will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
62526939|NCT03712982|ACTIVE_COMPARATOR|Infertility Stories - Reading|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. They will also be instructed to do an at-home reading activity several times over a period of 2 weeks.
62526940|NCT01763814|ACTIVE_COMPARATOR|Single shot femoral nerve block|A ultrasound probe will be used to identify the nerve, and correct needle placement.
62526941|NCT01763814|ACTIVE_COMPARATOR|Femoral nerve block non stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered off.
62153635|NCT02212626|EXPERIMENTAL|Rotarex|After assessment of the lesion by angiography the occlusion is intraluminally crossed with the wire according to physician's discretion. The device is introduced and the catheter is activated while its tip is still proximal to the occlusion to allow lubrication of the spiral inside the catheter with the aspirated blood. The catheter is advanced into the occlusion with occasional retraction into the already recanalized lumen. Care must be taken to achieve sufficient cooling of the catheter tip and evacuation of the debris to get an appropriate blood flow along the catheter. In order to minimize peripheral embolization of clot the distal end of the occlusion should not be passed too fast before all loose material has been sucked back into the catheter. Several passages of the occlusion may be needed to clean out all wall-adherent thrombotic material. If residual underlying stenosis of \>30% persist further endovascular treatment can be performed according to the physician's discretion.
62526942|NCT01763814|ACTIVE_COMPARATOR|Femoral nerve block stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered on.
62526943|NCT00814918|EXPERIMENTAL|1|5-ALA Application and exposure using Blu-U light to 1/2 of face.
62153636|NCT04780685|EXPERIMENTAL|hMSCs|hMSCs will be given via IV administration.
62153637|NCT04780685|PLACEBO_COMPARATOR|Lactated Ringer's Solution|Lactated Ringer's Solution will be given via IV administration.
62526944|NCT00814918|EXPERIMENTAL|2|5-ALA Application and exposure using Candela V-beam Pulse Dye Laser to 1/2 of face.
62526945|NCT05553899|EXPERIMENTAL|Diagnostic (PET-MRI)|Patients will undergo PET-MRI
62526946|NCT01196078|EXPERIMENTAL|1|
62526947|NCT01196078|ACTIVE_COMPARATOR|2|
62526948|NCT00423683|EXPERIMENTAL|1- Arixtra Alone|Arixtra Alone
62526949|NCT00423683|ACTIVE_COMPARATOR|2 Arixtra+ filter|Arixtra + filter
62526950|NCT05020613|OTHER|Early group|Patients whose catheters are removed within the first 48 hours after surgery will form the early group.
62526951|NCT05020613|OTHER|Late group|Patients whose catheters are removed after the first 48 hours of surgery will form the early group.
62526952|NCT06305130||Primary cohort (only one in this study)|Patient data were collected from sixteen institutions across Taiwan, encompassing 6005 patients diagnosed with UTUC between 1988 and 2023. The study included all patients who underwent RNU with curative intent. After excluding those with incomplete data, a total of 2515 eligible patients were included in the final analysis.
62526953|NCT03907384|EXPERIMENTAL|Mat Pilates training|The MPT group participated in 3-one hour supervised training sessions per week for 12 weeks. All MP sessions were performed in nonconsecutive days. The MP sessions were divided into the following stages: initial warm up and stretching (10 min), general conditioning consisting of MP exercises (40 min) and stretching and cooling down (10 min). The participants performed 12 basic MP exercises (one set of 6-10 repetitions was performed per exercise). Breathing, a core principle of MP, was performed by forced but controlled inspirations and exhalations, while relaxing and contracting the abdomen, respectively. All sessions were supervised by a certified MP instructor.
62526954|NCT03907384|NO_INTERVENTION|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
62713512|NCT03366337|EXPERIMENTAL|Bardoxolone Methyl - IgAN|Participants with IgA nephropathy (IgAN) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
62713513|NCT03366337|EXPERIMENTAL|Bardoxolone Methyl - T1D|Participants with Type 1 diabetes (T1D) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
62153638|NCT01688388|EXPERIMENTAL|IORT Arm|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
62153639|NCT02516202|ACTIVE_COMPARATOR|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
62526955|NCT06444945|EXPERIMENTAL|Mulligan MWM group|Group A receiving Mulligan MWM joint mobilization
62526956|NCT06444945|EXPERIMENTAL|Kaltenborn mobilization group|Group B receiving Kaltenborn Joint mobilization
62526957|NCT05233930|EXPERIMENTAL|TKR with augmented reality-based navigation system.|This technology offers the orthopedic surgeon intraoperative assistance in positioning the implants with the help of a pair of augmented reality glasses. The cutting planes are oriented with respect to the mechanical axes calculated according to anatomical landmarks acquired with a pointer. The connected glasses calculate precisely the 3D coordinates of the instruments thanks to the analysis of their specific markers (QR-Code), filmed by the integrated camera. The navigation information is displayed in the surgeon's field of vision, who interacts with the application thanks to the glasses' accelerometers.
62526958|NCT05233930|ACTIVE_COMPARATOR|TKR with traditional mechanically aligned technique.|TKR with traditional mechanically aligned technique will be performed according to local practice and standard guidelines.
62526959|NCT02161250|EXPERIMENTAL|Resistant starch|The test beverage consumed has the resistant starch.
62526960|NCT02161250|EXPERIMENTAL|Control|The control beverage uses maltodextrin rather than the resistant starch.
62526961|NCT01806818|EXPERIMENTAL|Eperisone 50mg BID|Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days
62526962|NCT01806818|EXPERIMENTAL|Epirisone 50mg TID|
62526963|NCT01806818|PLACEBO_COMPARATOR|Placebo comparator|
62526964|NCT01247246|PLACEBO_COMPARATOR|Placebo|
62526965|NCT01247246|ACTIVE_COMPARATOR|SCV-07 0.1mg/kg|
62153640|NCT02516202|ACTIVE_COMPARATOR|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
62153641|NCT02516202|PLACEBO_COMPARATOR|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
62526966|NCT01247246|ACTIVE_COMPARATOR|SCV-07 0.3mg/kg|
62526967|NCT01247246|ACTIVE_COMPARATOR|SCV-07 1.0mg/kg|
62526968|NCT00057083|OTHER|Arm 1|
62153642|NCT05274490||copd patients with covid infection|
62153643|NCT05274490||non-copd patients with covid infection|
62153644|NCT06197100|EXPERIMENTAL|supportive care training|Training in supportive care will be given to the experimental group (Training group). The mothers will also receive a training booklet from the researchers. The training booklet covers burping newborns, massage, and nourishment for mothers. In addition, mothers will be observed nursing their children, and appropriate breastfeeding instruction will be given if the baby's holding position is a problem. Over the course of a week, the supportive care training intervention will be given in three modules to the experimental group. The interventions will be carried out by the first investigator, a pediatric nursing specialist.
62526969|NCT05818618|ACTIVE_COMPARATOR|Clobetasol propionate 0,05% gel|Patients were treated with a topic gel of clobetasol propionate 0,05%
62526970|NCT05818618|PLACEBO_COMPARATOR|Placebo|Patients were treated with a topic placebo gel control
62526971|NCT04469010|EXPERIMENTAL|Iron and Vitamin C|28mg iron bis-glycinate chelate and 240mg vitamin C
62153645|NCT06197100|ACTIVE_COMPARATOR|control groups|An educational pamphlet regarding mother-baby nutrition and how to soothe a crying infant will be distributed to mothers in the control group.
62153646|NCT01455779|OTHER|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
62153647|NCT01739972|ACTIVE_COMPARATOR|Levothyroxine|Levothyroxine in the capsule form, once daily, appropriate dosage to keep TSH at the normal range.
62153648|NCT01739972|ACTIVE_COMPARATOR|Desiccated thyroid extract|Desiccated thyroid extract in capsule form, once daily, appropriate dosage to keep TSH in the normal range.
62526972|NCT04469010|ACTIVE_COMPARATOR|Iron|28mg iron bis-glycinate chelate
62526973|NCT04469010|PLACEBO_COMPARATOR|Placebo|Matched placebo tablets
62526974|NCT02951442|EXPERIMENTAL|Renal Transplant|
62153649|NCT04526132|EXPERIMENTAL|Experimental: group1|Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml
62526975|NCT04628520|SHAM_COMPARATOR|Maintenance|Oral hygiene instruction and periodontal maintenance
62526976|NCT04628520|ACTIVE_COMPARATOR|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
62526977|NCT04628520|ACTIVE_COMPARATOR|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
62713514|NCT03366337|EXPERIMENTAL|Bardoxolone Methyl - FSGS|Participants with focal segmental glomerulosclerosis (FSGS) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
62526978|NCT00754403|EXPERIMENTAL|Pioglitazone 30 mg QD + Metformin 1000 mg QD|
62526979|NCT00754403|ACTIVE_COMPARATOR|Metformin 1000 mg QD|
62713515|NCT02724371|EXPERIMENTAL|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
62526980|NCT04701112|EXPERIMENTAL|His-bundle pacing first|"AV sequential His-bundle pacing (or VVI pacing if in atrial fibrillation) via temporary right atrial and His-bundle electrodes.~Then AV sequential Biventricular pacing via the patient's already implanted CRT device.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
62526981|NCT04701112|ACTIVE_COMPARATOR|Biventricular pacing first|"AV sequential biventricular pacing (or VVI pacing if in atrial fibrillation) via the patient's already implanted CRT device. Then AV sequential or VVI His-bundle pacing via temporary right atrial and His-bundle electrodes.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
62713516|NCT02724371|EXPERIMENTAL|Revision Breast Reconstruction|participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
62153650|NCT04526132|PLACEBO_COMPARATOR|Experimental: group2|Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml
62153651|NCT02264444|EXPERIMENTAL|Cholecystectomy visualization|All patients will undergo a standard single site cholecystectomy and will have their operation recorded and scored for visualization.
62153652|NCT05577182|EXPERIMENTAL|Part 1: Dose Escalation|INCA32459 will be administered at a protocol defined starting regimen intravenously. Subsequent dose regimens will be determined during study conduct.
62526982|NCT02935166|PLACEBO_COMPARATOR|Uncharged|Respiratory muscle training: placebo General High Intensity Training (30 minutes in cycle ergometer) and placebo respiratory muscle training: This training group performed with the valve Orygen® uncharged (placebo effect). Performing 10 consecutive inspirations (5 series) two times a day during 3 weeks.
62526983|NCT02935166|ACTIVE_COMPARATOR|Inspiratory|Respiratory muscle training: Inspiratory General Training (30 minutes in cycle ergometer) and high intensity inspiratory muscle training: The inspiratory training was conducted with the Orygen® valve. Inspiratory training load was defined as maximum and patient tolerance that would perform 10 consecutive inspirations (5 series) two times a day, during 3 weeks.
62526984|NCT02935166|ACTIVE_COMPARATOR|Inspiratory and expiratory|Respiratory muscle training: Inspiratory and expiratory General High Intensity Training (30 minutes in cycle ergometer) and inspiratory and expiratory training: The inspiratory and expiratory training was conducted with the Orygen® valve. Loading inspiratory and expiratory training was defined as maximum and patient tolerance. This was the optimal load that would allow the patient to perform 10 consecutive inspirations (5 sessions) 2 times a day,during 3 weeks.
62526985|NCT02737982||IHD Men|Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
62526986|NCT02737982||IHD Women|Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
62526987|NCT01713049|OTHER|18F-FLT|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
62153653|NCT05577182|EXPERIMENTAL|Part 2: Dose Expansion Cohort Disease Group 1|INCA32459 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for unresectable or metastatic melanoma.
62153654|NCT05577182|EXPERIMENTAL|Part 2: Dose Expansion Cohort Disease Group 2|INCA32459 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) that is PD-L1 positive.
62153655|NCT04018521|ACTIVE_COMPARATOR|Parent Connectors|trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or caregivers of all newlyenrolled youth or young adults (Y/YA) in FEP services
62526988|NCT06263062|EXPERIMENTAL|Experimental group|"routine care after a colopscopy procedure Mindfulness-Based Coping Programme in addition to routine care Prepared in accordance with the MBSR programme. Applied online with Zoom programme Teams in groups of 6 people 6 sessions in 2 weeks"
62526989|NCT06263062|NO_INTERVENTION|Control group|routine care after a colopscopy procedure Routine care will be provided by the nurse training handbook created by the researcher
62526990|NCT04677296|EXPERIMENTAL|VS002A|Amino acid based ORS/medical food (VS002A). Initial treatment dosing with VS002A will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
62526991|NCT04677296|ACTIVE_COMPARATOR|Standard WHO-ORS|Standard WHO-ORS. Initial treatment dosing with WHO-ORS will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
62526992|NCT01681602|ACTIVE_COMPARATOR|Intervention group|16 weeks of aerobic exercise
62526993|NCT01681602|NO_INTERVENTION|Control group|Usual care.
62526994|NCT00763438|EXPERIMENTAL|Sertindole|
62526995|NCT02646930|EXPERIMENTAL|Incidence of CE|To determine rates of CE in women undergoing initial IVF and outcomes
62526996|NCT01032018|ACTIVE_COMPARATOR|Referred Care|Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
62526997|NCT01032018|EXPERIMENTAL|Stepped Care|Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.
62526998|NCT00446745||Abdominal obesity|60 males were recruited according to waist circumference, from lean to obese values
62526999|NCT00943462||Glioblastoma Multiforme (GBM)|We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre-Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
62527000|NCT03726281|EXPERIMENTAL|single-arm trial of Nivolumab|Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.
62153656|NCT04018521|ACTIVE_COMPARATOR|Usual Care|Coordinated Specialty Care (CSC)
62153657|NCT02173990|EXPERIMENTAL|Aflibercept-FOLFIRI|On day 1 of each cycle patients will receive aflibercept followed by irinotecan, 5-FU and leucovorin (FOLFIRI regimen). This treatment will be repeated every 2 weeks until RECIST progression or intolerance.
62153658|NCT04480957|EXPERIMENTAL|Escalation Cohort dose 1 of ARCT-021, 21 - 55 years|Escalation Cohort dose 1 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
62153659|NCT04480957|EXPERIMENTAL|Escalation Cohort dose 2 of ARCT-021, 21 -55 years|Escalation Cohort dose 2 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
62153660|NCT04480957|EXPERIMENTAL|Escalation Cohort dose 3 of ARCT-021, 21 - 55 years|Escalation Cohort dose 3 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
62527001|NCT05402774|OTHER|point-of-care ultrasound group|
62527002|NCT05402774|NO_INTERVENTION|Control group|
62527003|NCT04995705|EXPERIMENTAL|Experimental Group Based ACT|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. This consisted of 2.5 hour sessions over 5 consecutive weeks.
62527004|NCT04995705|ACTIVE_COMPARATOR|Waitlist Control Group -|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. Participants within the waitlist control arm of the study had to wait six weeks before they were offered the same intervention as the intervention arm. They received treatment as usual.
62527005|NCT02060474|EXPERIMENTAL|AHDS patients|all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.
62527006|NCT01580813|EXPERIMENTAL|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visi
62153661|NCT04480957|EXPERIMENTAL|Escalation Cohort dose 4 of ARCT-021, 21 - 55 years|Escalation Cohort dose 4 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
62153662|NCT04480957|EXPERIMENTAL|Expansion cohort dose regimen 1, 21 - 55 years.|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
62153663|NCT04480957|EXPERIMENTAL|Expansion cohort dose regimen 2, 21 - 55 years.|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
62153664|NCT04480957|EXPERIMENTAL|Expansion cohort dose regimen 1, 56 - 80 years|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
62153665|NCT04480957|EXPERIMENTAL|Expansion cohort dose regimen 2, 56 - 80 years|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
62153666|NCT04887857|EXPERIMENTAL|CC-486 in combination with Venetoclax|
62153667|NCT04311983|ACTIVE_COMPARATOR|Tobacco Quitline only|Smokers in this study group will be offered their state Tobacco Quitline programs
62153668|NCT04311983|EXPERIMENTAL|Tobacco Quitline plus Smoke Free Homes|Smokers in this study group will be offered their state Tobacco Quitline programs, but if they decline, they will be offered a Smoke Free Homes intervention
62153669|NCT03804866|EXPERIMENTAL|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
62153670|NCT03804866|ACTIVE_COMPARATOR|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
62153671|NCT06091969|EXPERIMENTAL|Active multi-ingredient supplement (Fertility Enhancer; FE)|Volunteers will be randomized in a double-blinded fashion into the experimental treatment group, which entails daily supplementation of an active multi-ingredient supplement designed to enhance fertility (Fertility Enhancer; FE) for 3 months.
62153672|NCT06091969|PLACEBO_COMPARATOR|Inactive placebo (Placebo; PLA)|Volunteers will be randomized in a double-blinded fashion into a placebo group, which entails daily supplementation of a calorie-matched, inactive placebo (Placebo; PLA) identical in flavor to the active supplement for 3 months.
62153673|NCT05512299||PD with resting tremor|Parkinson's disease patient with pure resting tremor.
62153674|NCT05512299||PD with postural tremor|Parkinson's disease patient with postural tremor.
62153675|NCT05512299||Cerebellar degeneration with intention tremor|Cerebellar degeneration patient with intention tremor.
62153676|NCT05636306|EXPERIMENTAL|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
62527007|NCT01580813|PLACEBO_COMPARATOR|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit
62153677|NCT05636306|PLACEBO_COMPARATOR|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
62153678|NCT03883217|EXPERIMENTAL|Vibration first then no vibration|A session with PDVibe2 vibration turned on first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned off.
62527008|NCT04414761|ACTIVE_COMPARATOR|Antagonist group|Women will receive antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
62527009|NCT04414761|EXPERIMENTAL|PPOS group|Women will receive oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger.
62527010|NCT01295294|EXPERIMENTAL|tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with tranexamic acid
62527011|NCT01295294|EXPERIMENTAL|mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with mefenamic acid
62527012|NCT01295294|PLACEBO_COMPARATOR|placebo + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive placebo
62713517|NCT06217302|ACTIVE_COMPARATOR|Sotagliflozin|Oral sotagliflozin at a dose of 200 mg (one tablet) per day for three years followed by a 2-month wash-out period.
62153679|NCT03883217|EXPERIMENTAL|No vibration first then vibration|A session with PDVibe2 vibration turned off first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned on.
62153680|NCT05100511|EXPERIMENTAL|Phase I, healthy subjects|General usability of the device is tested with healthy patients. Different commercial electroretinography electrodes are tested to investigate the patient comfort, usability and signal-to-noise ratio when recording fundus image-guided focal electroretinography with the investigational device. Most suitable electrode is selected to phase II.
62153681|NCT05100511|EXPERIMENTAL|Phase II, patients with macular edema or macular degeneration|The usability of the device is tested with patients suffering either from macular edema or macular degeneration. Fundus image-guided focal electroretinography is recorded with the electrode chosen in phase I from two different retinal areas: from an area with macular edema or signs of macular degeneration and from a healthy area (area without macular edema or signs of macular degeneration).
62153682|NCT03645213|EXPERIMENTAL|Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a head-mounted VR box in the VR group.
62713518|NCT06217302|PLACEBO_COMPARATOR|Placebo|Oral tablets similar to sotagliflozin tablets but containing no active drug (one tablet per day for three years followed by a 2-month wash-out period).
62153683|NCT03645213|EXPERIMENTAL|Non- Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a computer tablet in the non-VR group. The computer tablet was the 10 centimeters far from the child.
62153684|NCT03645213|NO_INTERVENTION|Control|There was no additional intervention in the control group. Venipuncture procedures was the same other groups. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's.
62153685|NCT00476151|PLACEBO_COMPARATOR|placebo cream|vehicle cream
62153686|NCT00476151|ACTIVE_COMPARATOR|amitriptyline 4% ketamine 2% cream|active topical cream
62153687|NCT00838448|EXPERIMENTAL|Cannabis users|Cannabis users
62153688|NCT00838448|EXPERIMENTAL|Cannabis no-users|Cannabis no-users
62527013|NCT04928274|OTHER|ball retained mandibular over denture|each patient in this group received 3 implant installed in mandible and 3 ball attachments for retention of over denture
62527014|NCT04928274|OTHER|locator retained mandibular over denture|
62527015|NCT04928274|OTHER|telescopic retained mandibular over denture|
62527016|NCT05084508|EXPERIMENTAL|VNS_Low Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of low potency 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine and 1 dose of a13 valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
62713519|NCT05466032||First year TouroCOM osteopathic medical students|As required by the Touro College of Osteopathic Medicine curriculum, all first year osteopathic students are enrolled in Osteopathic Manual Manipulation (OMM). This course meets three hours per week for the duration of the school year and teaches students about different osteopathic dysfunctions, as well as techniques for how to treat them.
62713520|NCT05466032||Master of Science TouroCOM students|Students enrolled in the Master of Science in Interdisciplinary Studies in Biological and Physical Sciences at TouroCOM complete almost all of the same courses as the osteopathic medical students, but are not exposed Osteopathic Manual Manipulation (OMM). This cohort will act as the control as they undergo similar environmental stress, but will not learn about common osteopathic dysfunctions or their treatments.
62153689|NCT01362309|PLACEBO_COMPARATOR|Placebo|Inert filler in matched pill.
62153690|NCT01362309|ACTIVE_COMPARATOR|d-cycloserine 50 mg|50 mg d-cycloserine.
62153691|NCT06186063|EXPERIMENTAL|Pramlintide infusion|A stable amylin analogue.
62153692|NCT06186063|PLACEBO_COMPARATOR|Placebo infusion|Isotonic saline (0.9% NaCl).
62153693|NCT00033748|EXPERIMENTAL|Combined Monoclonal Antibody Therapy|Patients with minimal metastatic colorectal cancer are treated with 2 anti-idiotype monoclonal antibodies
62153694|NCT01668355|EXPERIMENTAL|SMI-PACT|Patient Aligned Care Team (PACT) medical home model to address the physical healthcare needs of individuals with serious mental illness
62153695|NCT01668355|NO_INTERVENTION|Usual Care|Usual Primary Care
62153696|NCT00235378||1|SLE patients
62153697|NCT00235378||2|Unaffected family members of SLE patients
62153698|NCT00235378||3|Control participants
62153699|NCT03681067|EXPERIMENTAL|GSK10708060|Humanised antibody GSK1070806
62153700|NCT03681067|PLACEBO_COMPARATOR|Placebo - sodium chloride|Placebo
62153701|NCT01528605|PLACEBO_COMPARATOR|Placebo|starch in hard shell gelatine capsules
62153702|NCT01528605|EXPERIMENTAL|Low lutein|low lutein group
62153703|NCT01528605|EXPERIMENTAL|High lutein|high lutein group
62153704|NCT01528605|EXPERIMENTAL|Low lutein zeaxanthin|lutein plus zeaxanthin group
62153705|NCT01528605|EXPERIMENTAL|High zeaxanthin|zeaxanthin group
62153706|NCT01528605|EXPERIMENTAL|high lutein zeaxanthin|Zeaxanthin plus lutein group
62153707|NCT04167852|EXPERIMENTAL|Treatment group|Subject to receive daily short message service (SMS) text message with a link to a mindfulness intervention.
62153708|NCT04167852|EXPERIMENTAL|Text group|Subject to receive daily text message but without the link to the mindfulness intervention.
62153709|NCT04167852|NO_INTERVENTION|Standard of Care group|Subject will not receive any text message reminders or the mindfulness meditation intervention.
62153710|NCT06022198|EXPERIMENTAL|Recovered From COVID-19 Pneumonia|Bronchoalveolar Lavage in Recovered From COVID-19 Pneumonia
62153711|NCT03662841|OTHER|ACE for HCC of size >10cm|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
62153712|NCT00568087|ACTIVE_COMPARATOR|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
62153713|NCT00568087|PLACEBO_COMPARATOR|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
62153714|NCT01794689|EXPERIMENTAL|Morphine US then Morphine FA|Participants randomized to receive Morphine and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
62153715|NCT01794689|PLACEBO_COMPARATOR|Placebo US then Placebo FA|Participants randomized to receive the saline placebo and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
62153716|NCT01794689|EXPERIMENTAL|Morphine FA then Morphine US|Participants randomized to receive Morphine and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
62527017|NCT05084508|EXPERIMENTAL|VNS_Med Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of medium potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
62527018|NCT05084508|EXPERIMENTAL|VNS_High Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of high potency 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose a 13-valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
62527019|NCT05084508|ACTIVE_COMPARATOR|VV_Lot1 and Lot2 Pooled Group|Healthy children aged 12 to 15 months of age receive 1 dose of a marketed varicella vaccine (VV) of Lot 1 or 1 dose of a marketed varicella vaccine (VV) of Lot 2, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and a 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
62527020|NCT04171271|EXPERIMENTAL|Activating kinesthetic motor imagery training|
62527021|NCT04171271|ACTIVE_COMPARATOR|Relaxing kinesthetic motor imagery training|
62527022|NCT04171271|NO_INTERVENTION|Control (no specific intervention)|
62527023|NCT06116318||MRD negative|c-Kit mutation tested negative
62527024|NCT06116318||MRD L1|MRD detection at low level-1：\<0.001%
62527025|NCT06116318||MRD L2|MRD detection at low level-2：0.001%≤c-Kit MRD\<0.01%
62527026|NCT06116318||MRD L3|detection at low level-3：0.01%≤c-Kit MRD\<0.1%
62527027|NCT06116318||MRD positive|MRD positive：c-Kit MRD≥0.1%
62527028|NCT03858595|EXPERIMENTAL|Intervention|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. Investigators will train our study participants (high-risk pregnant women) on how to use Salu Health Gauge to measure BP as well as how to charge them. Trained FFWs will visit the households weekly and synchronize the device with a tablet computer to collect the stored data. The FFWs will measure the weight of the participants using a digital weighing scale at enrollment and on a monthly bases thereafter. Investigators will keep monitoring up to termination of pregnancy. in any health issue arises, our health worker will ensure that an appropriate referral is made to a tertiary care facility. This intervention will be in addition to the conventional antenatal and postnatal care."
62527029|NCT03858595|NO_INTERVENTION|Control group|All those women randomized to the control arm will receive conventional antenatal and postnatal care only. Investigators will collect the outcome data from the households and/or the health centers by follow-up visits or over phone. Investigators will consell participants, women both in the control group, to make at least four antenatal visits. In addition, Investigators will provide counselling about eating healty and keeping physically active during pregnancy. Investigators will provide general nutrition education on taking balanced energy and protein diet.
62527030|NCT04784910|EXPERIMENTAL|DWP14012 20mg|orally, once daily
62527031|NCT04784910|ACTIVE_COMPARATOR|Lansoprazole 15mg|orally, once daily
62527032|NCT02459496|ACTIVE_COMPARATOR|low-carb diet, followed by conventional DGE diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
62527033|NCT02459496|ACTIVE_COMPARATOR|very-low calory diet, followed by conventional diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx. 1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
62527034|NCT03227614|NO_INTERVENTION|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
62527035|NCT03227614|EXPERIMENTAL|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
62527036|NCT04562480|EXPERIMENTAL|Treatment (hypofractionated radiation therapy, resection)|Patients undergo hypofractionated radiation therapy QD (except weekends and holidays) over 3 weeks for a total of 15 fractions. Within 3-6 weeks after completion of radiation therapy, patients undergo surgical resection.
62527037|NCT01692444||COPD|15 patients with COPD from 1 to 4 according to the GOLD 2011
62527038|NCT01692444||Non smoker Control|15 patients without COPD and no smoking history
62527039|NCT01692444||Smoker Control|15 patients without COPD but a smoking history
62527040|NCT04051463|ACTIVE_COMPARATOR|Netarsudil|A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
62527041|NCT04051463|PLACEBO_COMPARATOR|Placebo|A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.
62527042|NCT02550730|EXPERIMENTAL|Birth Sisters|Half of the women who agree to participate in the evaluation will be randomized to the Birth Sisters Best beginnings for Babies Program, which includes community doula support and consultation with Medical Legal Partnership when indicated.
62527043|NCT02550730|ACTIVE_COMPARATOR|Routine care|Half of the women who agree to participate in the evaluation will be randomized to the usual maternity care group
62527044|NCT04641065|EXPERIMENTAL|Music Intervention Group|The music intervention group will be listened to Traditional Turkish Military music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
62527045|NCT04641065|NO_INTERVENTION|No Intervention Group|The control group patients will receive standard care only
62527046|NCT00425334|EXPERIMENTAL|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
62527047|NCT00425334|ACTIVE_COMPARATOR|Control|Ringer's lactate
62527048|NCT02938403|EXPERIMENTAL|In vivo group|Those who receive in vivo counseling and Nicotine Replacement Therapy (NRT)
62527049|NCT02938403|ACTIVE_COMPARATOR|Controls|Standard smoking cessation counseling and Nicotine Replacement Therapy (NRT)
62527050|NCT04057469|EXPERIMENTAL|Tulobuterol patch|
62527051|NCT04057469|PLACEBO_COMPARATOR|Placebo|
62527052|NCT01401049|EXPERIMENTAL|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
62527053|NCT01401049|ACTIVE_COMPARATOR|Propofol/Lidocaine|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (a lipid based medication); Lusedra (a water based medication); and the drug combination of propofol with lidocaine (a local anesthetic commonly used with propofol injection).
62527054|NCT01175031|EXPERIMENTAL|REMstar Auto with A-Flex|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be measured with REMstar Auto with A-Flex.
62153717|NCT01794689|PLACEBO_COMPARATOR|Placebo FA then Placebo US|Participants randomized to receive the saline placebo and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
62153718|NCT01009645|EXPERIMENTAL|Fact Only|The educational message used will contain facts only.
62153719|NCT01009645|EXPERIMENTAL|Fact and Myth|The educational material seen by this arm will contain facts and myths only.
62153720|NCT01009645|EXPERIMENTAL|Fact, Myth, Why|The educational material seen by this arm will contain myths, facts, and refutations of the myths.
62153721|NCT01009645|PLACEBO_COMPARATOR|Control|This arm will receive fact/myth educational materials originally developed and used by the CDC.
62153722|NCT04640805|NO_INTERVENTION|Control group (standard fortification)|Pasteurized Donor Human Milk (PDHM) will be fortified as per unit protocols, at 1 packet of Human Milk Fortifier (Similac or Pre-Nan) to every 25ml PDHM at a feed volume of 80ml/kg/day
62153723|NCT04640805|EXPERIMENTAL|Intervention group (modified targeted fortification)|Pasteurized Donor Human Milk (PDHM) will be analyzed using the Miris Human Milk Analyzer, and PDHM with a fat content of 3.8g/dL or higher will be selected. Additional protein will be added using liquid protein fortifier (Similac) at 1ml to every 25ml PDHM to give an additional 0.67g/dL protein.
62153724|NCT01218048|EXPERIMENTAL|Neo-Adjuvant Cetuximab|"Neo-Adjuvant Cetuximab + Surgery + Post-Surgical Radiation + Cisplatin (or Carboplatin)~NOTE: Based the results of surgery if the treating physician feels patient is not a candidate for chemotherapy, radiation can be given alone or with cetuximab."
62527055|NCT01175031|OTHER|Manually Scored Polysomnography (PSG)|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be Manually Scored Polysomnography (PSG).
62527056|NCT00140621|EXPERIMENTAL|Agalsidase Beta|Agalsidase beta 1 milligram per kilogram (mg/kg) intravenously once every 2 weeks up to 156 weeks.
62527057|NCT03025490|NO_INTERVENTION|standard of Care|Patient undergoing sedation, treatment team does not have capnography data available.
62527058|NCT03025490|EXPERIMENTAL|Capnography|Patient undergoing sedation, treatment team does have capnography data available.
62527059|NCT01584843|NO_INTERVENTION|Non-treatment (10-20 PD)|Receive no treatment on Week 0
62153725|NCT05739409|EXPERIMENTAL|LILRB4 STAR-T cells injection|"The study was divided into two phases: dose climbing and dose extension. Dose climbing stage: adopt the 3 + 3 dose climbing design principle, and the dose group is set as follows, in which, dose group-A is the backup dose reduction dose group, and dose group A is the starting dose:~Dose Group-A: 3×105STAR+T cells / kg； Dose group A: 1×106STAR+T cells / kg； Dose group B: 3×106STAR+T cells / kg； Dose group C: 6×106STAR+T cells / kg； Dose group D: 1×107STAR+T cells / kg。"
62153726|NCT05219747|EXPERIMENTAL|A.Oleracea group|Mucoadhesive film containing Acmella oleracea extract
62153727|NCT05219747|PLACEBO_COMPARATOR|Placebo group|Mucoadhesive film without Acmella oleracea extract
62527060|NCT01584843|ACTIVE_COMPARATOR|GSK1358820 1.25 U (10-20 PD)|Receive 1.25 U of GSK1358820 on Week 0
62527061|NCT01584843|ACTIVE_COMPARATOR|GSK1358820 2.5 U (10-20 PD)|Receive 2.5 U of GSK1358820 on Week 0
62527062|NCT01584843|NO_INTERVENTION|Non-treatment (20-50 PD)|Receive no treatment on Week 0
62527063|NCT01584843|ACTIVE_COMPARATOR|GSK1358820 2.5 U (20-50 PD)|Receive 2.5 U of GSK1358820 on Week 0
62527064|NCT01584843|ACTIVE_COMPARATOR|GSK1358820 5.0 U (20-50 PD)|Receive 5.0 U of GSK1358820 on Week 0
62527065|NCT06167720||Cancer patients cohort in SEER database|A retrospective cohort of cancer patients based on the Surveillance, Epidemiology, and End Results (SEER) program database was used to assess the association of socioeconomic factors, clinical characteristics and meteorological factors with cancer patients' suicide, and to establish prediction model with multiple predictors for cancer patient
62527066|NCT06167720||Cancer patients cohort in SMCHBDP|Retrospective cohort conducted from Shandong Multi-Center Healthcare Big Data Platform (SMCHBDP) was used to verify the predictive ability and generalization ability of the prediction model.
62153728|NCT05847114|EXPERIMENTAL|Stress Ball Group|VAS-A, VAS, Spielberg Trait Anxiety Inventory was applied. Vital signs were evaluated before, during and after surgery. Stress balls were given to the patients in addition to the standard care protocol. Stress balls were used for 15 minutes during the operation, by placing the patient in both hands, counting from one to five, and tightening and loosening twice.
62153729|NCT05847114|NO_INTERVENTION|Control Group|Patients in the control group will not undergo any intervention other than the standard care protocol.
62527067|NCT05808153|EXPERIMENTAL|Symptomatic (MH) and pre-symptomatic (preMH) patients|"* Number of GAC ≥ 40~* GAP score ≥ 250~* 10 ≤ TFC ≤ 13~* TMS \>5 if TFC=13~* Diagnostic confidence level =4~* Age onset of the disease \> 20 years~* Patients in physical capacity to sign the consent"
62527068|NCT05808153|ACTIVE_COMPARATOR|Age-matched controls (healthy volunteers)|"* TFC functional UHDRS score = 13~* TMS engine UHDRS rating \< 6"
62527069|NCT00324480|EXPERIMENTAL|Treatment (chemotherapy, enzyme inhibitor)|Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib IV over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62527070|NCT04914858|EXPERIMENTAL|Education group|Education
62527071|NCT04914858|NO_INTERVENTION|Control group|No Intervention
62527072|NCT02865252|ACTIVE_COMPARATOR|MWM treatment|"Mobilization with movement (MWM) is a combination of sustained passive accessory joint mobilization with an active or functional movement.~MWM will be applied (three sets of 10 repetitions) during active knee flexion and extension range of motion (ROM). The therapist initially will apply the pain-free manual glide force on the tibia with the knee resting in a mid-range position. The glide force will be sustained while the patient performed 10 repetitions of self-active full range knee flexion and extension; overpressure was included at the end range."
62527073|NCT02865252|SHAM_COMPARATOR|MWM sham|The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).
62527074|NCT01956877||Healthy volunteers|
62527075|NCT00106340|EXPERIMENTAL|Vildagliptin|
62527076|NCT00106340|ACTIVE_COMPARATOR|Glimepiride|
62527077|NCT00973375||Endeavor group and Excel group|Endeavor group: measurements from the vessels implanted Endeavor stent(s). Excel group: measurements from the vessels implanted Excel stent(s).
62527078|NCT04192279||lactate group|Lactate early guide resuscitation
62527079|NCT04192279||control group|early guide resuscitation without lactate
62527080|NCT01622686|NO_INTERVENTION|Traditional prescription drug labels|Routine drug labels provided by the participating pharmacies
62527081|NCT01622686|EXPERIMENTAL|Reformatted medication labels|Prescription drug container labels that follow a new format and also include illustrations
62527082|NCT04467268|EXPERIMENTAL|Sleep extension intervention|"Intervention group participants met with an experienced sleep scientist to discuss and agree changes to their sleep and personal schedules. Discussions lasted 60-90 minutes, were informed by actigraphic sleep assessments from the baseline period, and aimed to increase TST by ≥1 hour/night. The structure and content of the About Sleep, Sleep Hygiene and Thoughts and Sleep components of the online Sleepful application, a self-help sleep management programme. Advice was supported by the provision of self-help booklets addressing sleep hygiene and the management of pre-sleep cognitions which had been successfully trailed in an intervention for insomnia symptoms. Finally, to capitalize on the participant's motivation at recruitment, and optimize adherence, the newly agreed sleep schedule was written into an agreement which the participant was asked to sign, simulating a 'therapeutic contract'. Schedules were reviewed by telephone at the end of the first week and revised if required."
62153730|NCT03710850|EXPERIMENTAL|Responders|Responders in terms of fecal butyrate production after acute inulin test.
62527083|NCT04467268|NO_INTERVENTION|Control group|Participants in the control group were asked to continue with their habitual sleep schedule.
62527084|NCT03899311||PSMF cohort|The cohort is instructed to follow a protein-sparing modified fast diet and is given standard health care in the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital.
62527085|NCT05885191|EXPERIMENTAL|2H intrinsically-labeled T.molitor|1 portion of bread and vegetable soup prepared with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture
62527086|NCT02833766|EXPERIMENTAL|anti-EGFR-IL-dox|Metastatic, non resectable, EGFR positive TNBC patients treated in first-line
62527087|NCT04383236|EXPERIMENTAL|ChocBalls|(L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
62527088|NCT04383236|ACTIVE_COMPARATOR|Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt)|"Each 100 g contains:~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g."
62527089|NCT05227300|EXPERIMENTAL|Buffered 2% lidocaine with 1:100,000 epinephrine|Buffered local anesthetic (addition of sodium bicarbonate to make a 10% buffered solution)
62527090|NCT05227300|ACTIVE_COMPARATOR|Unbuffered 2% lidocaine with 1:100,000 epinephrine|Standard local anesthetic
62527091|NCT04072380|EXPERIMENTAL|SUVN-G3031 2mg|Orally taken once daily for 14 days
62527092|NCT04072380|EXPERIMENTAL|SUVN-G3031 4mg|Orally taken once daily for 14 days
62527093|NCT04072380|PLACEBO_COMPARATOR|Placebo|Orally taken once daily for 14 days
62153731|NCT03710850|EXPERIMENTAL|Non-responders|Non-responders in terms of fecal butyrate production after acute inulin test.
62153732|NCT01315418|ACTIVE_COMPARATOR|1 = Tested product|
62153733|NCT01315418|SHAM_COMPARATOR|2 = Control product|
62527094|NCT00749736|ACTIVE_COMPARATOR|1|4000 IU of cholecalciferol per day
62527095|NCT00749736|ACTIVE_COMPARATOR|2|1 mcg of doxercalciferol per day.
62527096|NCT00749736|PLACEBO_COMPARATOR|3|placebo for six months
62527097|NCT06398821|PLACEBO_COMPARATOR|Placebo|Placebo for 30 days
62527098|NCT06398821|ACTIVE_COMPARATOR|G3P-01 100mg|G3P-01 100mg daily for 30 days
62527099|NCT06398821|ACTIVE_COMPARATOR|G3P-01 250mg|G3P-01 250mg daily for 30 days
62527100|NCT06398821|ACTIVE_COMPARATOR|G3P-01 1000mg|G3P-01 1000mg daily for 30 days
62527101|NCT05900557|EXPERIMENTAL|ECoG monitoring|Patients undergoing standard of care surgical evacuation of cSDH. will have subdural ECoG monitoring electrode placed crossing frontal and temporal lobes for 1-5 days of post operative monitoring. All subjects will undergo long term followup testing.
62527102|NCT00630890|EXPERIMENTAL|1|External beam radiation with Cyberknife radiosurgery boost and concurrent capecitabine
62527103|NCT01660191|ACTIVE_COMPARATOR|Pitavastatin 4mg|Pitavastatin 4mg tablet by mouth once daily for 12 weeks
62527104|NCT01660191|ACTIVE_COMPARATOR|Atorvastatin 20mg|Atorvastatin 20mg tablet by mouth once daily for 12 weeks
62527105|NCT01660191|ACTIVE_COMPARATOR|rosuvastatin 5 mg|rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
62527106|NCT05031689|PLACEBO_COMPARATOR|SPF 30 and Placebo|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
62527107|NCT05031689|ACTIVE_COMPARATOR|SPF 30 and pharmaceutical formulation with green banana peel|In Study Group, in addition to the SPF 30 sunscreen, a pharmaceutical formulation containing the extract of the green banana peel will be used.
62527108|NCT03274674|EXPERIMENTAL|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
62527109|NCT03274674|ACTIVE_COMPARATOR|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
62527110|NCT02056392|EXPERIMENTAL|Selumetinib 75mg|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
62527111|NCT02056392|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule
62527112|NCT02056392|PLACEBO_COMPARATOR|Selumetinib 75mg placebo|Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.
62527113|NCT05832528|EXPERIMENTAL|FD patient|Low-FODMAP diet in patients with FD for 6 weeks.
62527114|NCT00567866|EXPERIMENTAL|1|placebo -50 mg quetiapine- 100 mg quetiapine
62527115|NCT00567866|EXPERIMENTAL|2|50 mg quetiapine -100 mg quetiapine- placebo
62527116|NCT00567866|EXPERIMENTAL|3|50 mg quetiapine -placebo- 100 mg quetiapine
62527117|NCT00977730|ACTIVE_COMPARATOR|Protandim|
62527118|NCT00977730|PLACEBO_COMPARATOR|Sugar pill|
62527119|NCT05532059|EXPERIMENTAL|GPLET|intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8; oral lenvatinib 8 mg/day (\<60kg) or 12 mg/ d（≥60kg）from days 1 to 21; intravenous tislelizumab 200 mg on day 15
62527120|NCT05532059|ACTIVE_COMPARATOR|GP|intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8
62527121|NCT03035721|EXPERIMENTAL|Low protein formula group|Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
62527122|NCT03035721|ACTIVE_COMPARATOR|Standard protein formula group|Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
62527123|NCT03035721|NO_INTERVENTION|Breastfeeding group|Breastfed full term healthy infants
62527124|NCT02178280|NO_INTERVENTION|unresectable hilar cholangiocarcinoma|control group
62527125|NCT02178280|EXPERIMENTAL|liver transplantation|liver transplantation combined with neoadjuvant radiochemotherapy
62527126|NCT04060316|EXPERIMENTAL|GLS-1200|3 ml of GLS-1200 (1 mg/ml in 0.9% saline)
62527127|NCT04060316|PLACEBO_COMPARATOR|Sterile Saline|3 ml of 0.9% saline
62527128|NCT02468063|EXPERIMENTAL|Noradrenaline + low dose terlipressin|
62527129|NCT02468063|ACTIVE_COMPARATOR|Noradrenaline|
62527130|NCT00413686|EXPERIMENTAL|1|AZD7762 monotherapy followed by AZD7762 + gemcitabine
62527131|NCT04749472|EXPERIMENTAL|Study Group|Participants received intervention.
62527132|NCT03776838|EXPERIMENTAL|SoC+NOL analgesia guided fentanyl administration|"A bolus of 2 mcg/kg of IV Fentanyl will be given at the induction of the anesthesia. A bolus of 1 mcg/kg of IV Fentanyl will be given at the time of incision. During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administered following a pre determinate algorithm based on NOL index + heart rate + mean arterial blood pressure variations.~Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery."
62527133|NCT03776838|ACTIVE_COMPARATOR|SoC analgesia guided group|"A bolus of IV Fentanyl at the discretion of a physician will be given at the induction of the anesthesia. A bolus of IV Fentanyl at the discretion of a physician will be given at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.~Intervention will be here to use Heart rate and blood pressure to administer intraoperative intravenous fentanyl."
62527134|NCT02287909|EXPERIMENTAL|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
62527135|NCT02287909|EXPERIMENTAL|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
62527136|NCT02287909|EXPERIMENTAL|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
62153734|NCT03441464|EXPERIMENTAL|1st Tier Dose Level|3 patients administered single dose of LUM015 at 0.5 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
62527137|NCT02287909|ACTIVE_COMPARATOR|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
62527138|NCT04648332|EXPERIMENTAL|Group 1|Patients in group 1 underwent catheterization of the lumbar plexus from the posterior access on admission to the hospital and began analgesia with bupivacaine 0.125% 6-8 ml / h. Intraoperative anaesthesia was provided with a bupivacaine bolus of 0.5% 200 mg in a lumbar catheter and a sciatic nerve block with 1.5% 450 mg of lidocaine. Postoperative analgesia was provided by an elongated lumbar plexus block with bupivacaine 0.125% 6-8 ml / h.
62527139|NCT04648332|NO_INTERVENTION|Group 2|Patients in group 2 underwent intraoperative spinal anaesthesia at the level of L3-L4 with hyperbaric bupivacaine at a dose of 10-15 mg.
62153735|NCT03441464|EXPERIMENTAL|2nd Tier Dose Leel|3 patients administered single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
62153736|NCT03441464|EXPERIMENTAL|3rd Tier Dose Level|After evaluation of the fluorescence signal observed with the LUM imaging device in the three other cohorts,the subsequent 3 patients will receive a dose of 0.5-1.5 mg/kg.
62527140|NCT04648332|NO_INTERVENTION|Group 3|Group 3 patients underwent general inhalation anaesthesia with sevoflurane with a constant infusion of fentanyl for analgesia.
62153737|NCT03441464|NO_INTERVENTION|Auto-fluorescence|No LUM015 injection will be given to three (3) patients to measure baseline tissue fluorescence. The tissue will still be imaged ex-vivo using the LUM Imaging Device
62153738|NCT02223078|EXPERIMENTAL|G17DT|Three 250 µg injections over a six week period (weeks 0,2 and 6)
62527141|NCT05846867|EXPERIMENTAL|AK119 20mg/kg+ AK112 20mg/kg|Subjects will receive AK119 plus AK112 via intravenously (IV) Q2W, up to 2 years
62527142|NCT05846867|EXPERIMENTAL|AK119 40mg/kg+ AK112 20mg/kg|Subjects will receive AK119 plus AK112 via intravenously (IV) Q2W, up to 2 years
62527143|NCT05846867|EXPERIMENTAL|AK119 + AK112 20mg/kg +mFOLFOX6|Subjects will receive AK119 and AK112 plus mFOLFOX6 via intravenously (IV)Q2W, up to 12 cycles. Afterward, AK119 and AK112 will continue to be treated up to 2 years.
62527144|NCT05846867|EXPERIMENTAL|AK119 + AK112 20mg/kg +FOLFIRI|Subjects will receive AK119 and AK112 plus FOLFIRI via intravenously (IV)Q2W, up to 12 cycles. Afterward, AK119 and AK112 will continue to be treated up to 2 years.
62527145|NCT01280409|PLACEBO_COMPARATOR|Placebo|Compounded placebo
62527146|NCT01280409|EXPERIMENTAL|Metformin|Compounded metformin as the intervention
62527147|NCT03253523|NO_INTERVENTION|Continued maximal medical management|
62527148|NCT03253523|EXPERIMENTAL|Surgical occipital nerve neurolysis|
62153739|NCT02223078|PLACEBO_COMPARATOR|Placebo|Three 250 µg injections of a placebo over a six week period (weeks 0,2 and 6)
62153740|NCT03696563|ACTIVE_COMPARATOR|Control group|In this group, the - usual care based upon BLS-PCS with manual titration of oxygen. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
62153741|NCT03696563|EXPERIMENTAL|FreeO2 group|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration to reach the SpO2 target set by paramedic.
62153742|NCT01789593|OTHER|Hypoglycaemia / euglycaemia clamp|
62153743|NCT01789593|OTHER|Euglycaemia clamp / hypoglycaemia|
62153744|NCT06488027||Patients with insomnia symptoms|Patients with insomnia symptoms visiting AdSalutem sleep center
62153745|NCT03420040|EXPERIMENTAL|QS-M Needle Free Injector group|To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.
62153746|NCT03420040|ACTIVE_COMPARATOR|Glargine pen group|To observe the amount of insulin used by the Glargine pen group under good blood glucose control.
62153747|NCT05080556|ACTIVE_COMPARATOR|Arm 1 (control) - standard dosing carboplatin|Arm 1 (Standard Dosing): Carboplatin AUC5 based on nuclear medicine renal clearance.
62153748|NCT05080556|EXPERIMENTAL|Arm 2 (experimental) - adaptive therapy carboplatin according to CA125|Arm 2 (Adaptive Therapy): Carboplatin dose will be calculated according to the CA125 value.
62153749|NCT01114412||Patients|Patients with overactive bladder syndrome
62153750|NCT01114412||Healthy volunteers|Healthy volunteers
62153751|NCT01063465|EXPERIMENTAL|Early weightbearing|
62153752|NCT01063465|EXPERIMENTAL|Control group|
62153753|NCT05082688|EXPERIMENTAL|1: Young adults herpes zoster vaccination|Young adults between 18 and 35 years old will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
62153754|NCT05082688|EXPERIMENTAL|2: Older adults herpes zoster vaccination|Adults older than 60 years of age will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
62153755|NCT05082688|EXPERIMENTAL|3: Young adults influenza vaccination|Young adults between 18 and 35 years old will receive the influenza vaccine (Fluarix Tetra).
62153756|NCT05082688|EXPERIMENTAL|4: Older adults influenza vaccination|Adults older than 60 years of age will receive the influenza vaccine (Fluarix Tetra).
62527149|NCT00548171|EXPERIMENTAL|Boostrix I Group|Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.
62153757|NCT05082688|PLACEBO_COMPARATOR|5: Young adults herpes zoster vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl). 60 days later, they will receive another placebo.
62153758|NCT05082688|PLACEBO_COMPARATOR|6: Young adults influenza vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl).
62153759|NCT01780428|EXPERIMENTAL|CL-108|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg)
62153760|NCT01780428|ACTIVE_COMPARATOR|Norco|Commercial product containing hydrocodone 7.5 mg. acetaminophen 325 mg
62153761|NCT01780428|PLACEBO_COMPARATOR|Placebo|CL-108 formulation without API
62153762|NCT05190289||Compared Group|Patients without inferior clinical outcomes
62153763|NCT05190289||Case Group|Patients with inferior clinical outcomes
62527150|NCT00548171|ACTIVE_COMPARATOR|Boostrix II Group|Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.
62527151|NCT02331368|EXPERIMENTAL|Anti-PD-1 (MK-3475)|"Standard Treatment:~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.~Study Treatment:~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
62527152|NCT00319982|EXPERIMENTAL|I- Diltiazem|Diltiazem- study medication
62527153|NCT00319982|PLACEBO_COMPARATOR|II- Placebo|Placebo Comparator
62527154|NCT04269564|NO_INTERVENTION|group A|Group A patients received the standard ventilation protocol as follows: volume-controlled ventilation mode, with VT 6 ml/kg of ideal body weight, inspiratory : expiratory ratio 1 : 2, a PEEP of 4 cmH2O, and respiratory rate 10-12 breaths/min that will be adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mmHg and inspired oxygen fraction of 0.5.
62527155|NCT04269564|ACTIVE_COMPARATOR|group B|Patients in group B received the standard ventilation protocol with stepwise peep until end of surgery and extubation.
62527156|NCT06458842|EXPERIMENTAL|Ketamine|Patients in this group will receive ketamine, morphine PCA and caldolor for pain control
62527157|NCT06458842|PLACEBO_COMPARATOR|placebo|Patients in this group receive placebo, morphine PCA, and caldolor for pain control
62527158|NCT01270737|ACTIVE_COMPARATOR|Whole soy|
62153764|NCT03602573||pre-menopause|
62527159|NCT01270737|ACTIVE_COMPARATOR|daidzein|
62527160|NCT01270737|PLACEBO_COMPARATOR|milk powder|
62527161|NCT06425315||Oncogeriatric patients with undernutrition|"Our study population consists of oncogeriatric patients aged 70 and over, hospitalized in the oncogeriatric follow-up and referral unit (USSROG), with a diagnosis of moderate or severe undernutrition and undergoing cancer treatment. Patients will be recruited between January 1, 2022 and December 31, 2023.~We anticipate a sample size of between 100 and 120 patients over this period."
62527162|NCT02745886|EXPERIMENTAL|Metformin group|Metformin 0.85 twice daily for 6 months
62527163|NCT02745886|NO_INTERVENTION|Standard diet group|
62527164|NCT02745886|OTHER|CR group|Calorie restriction diet will be given to this group.
62527165|NCT03702361|EXPERIMENTAL|Rapid infusion of Vpriv|Rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive patients with type 1 Gaucher disease
62527166|NCT03850808||decline in left ventricular function|This group will be patients in whom a decline in left ventricular systolic function was found.
61975657|NCT05548829||Non-hospitalised Covid-19 patients (mild infection) 6 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
61975658|NCT05548829||Hospitalised Covid-19 patients (severe infection) 6 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
62153765|NCT03602573||post-menopause|
62153766|NCT05049174|EXPERIMENTAL|Intensive intervention|
62527167|NCT03850808||preserved left ventricular function|This group will consist of patients in whom left ventricular systolic function is preserved.
62527168|NCT06495515|EXPERIMENTAL|Treatment group|"Trial medication/treatment:~1. Dalpiciclib : 150mg orally, once a day, taken for 3 weeks, stopped for 1 week, with a cycle of 4 weeks. It is recommended to take medication at the same time every day, with warm water for delivery. It is recommended to do so on an empty stomach and fast for at least 1 hour before and after taking the medication.~2. Toremifen: 60mg orally, once a day If it is a premenopausal or perimenopausal patient, it is necessary to combine with OFS (OFS includes bilateral ovariectomy or GnRHa drugs).~The subjects will be treated according to the study protocol until disease progression, intolerable toxicity, withdrawal of informed consent, or termination of medication as determined by the researcher"
62527169|NCT06309927|EXPERIMENTAL|Operative hysteroscopy|Surgical evacuation of the uterine cavity by operative hysteroscopy (tissue removal device, Truclear Mini-Elite)
62527170|NCT06309927|ACTIVE_COMPARATOR|Suction curettage|Surgical evacuation of the uterine cavity by ultrasound guided suction curettage
62527171|NCT05214963|ACTIVE_COMPARATOR|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation
61975659|NCT04579692|EXPERIMENTAL|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain called central lateral thalamic nucleus. Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
62527172|NCT05214963|SHAM_COMPARATOR|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation
62527173|NCT00658749|EXPERIMENTAL|1|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
62527174|NCT00658749|PLACEBO_COMPARATOR|2|Physiologic saline solution
61975660|NCT06123104|EXPERIMENTAL|Automatic Tourniquet|Automatic pneumatic tourniquet
61975661|NCT06123104|ACTIVE_COMPARATOR|Combat Application Tourniquet (CAT)|Combat Application Tourniquet Generation 7
61975662|NCT02168179|EXPERIMENTAL|Supportive Care (KeraStat Skin Therapy)|Patients apply KeraStat Skin Therapy topically BID during radiation therapy.
61975663|NCT05615571||Patients with NBIA who remain without molecular diagnosis|A group of 40 patients with NBIA, who remain without molecular diagnosis
61975664|NCT05615571||Patients with NBIA with identified mutations in genes|A group of patients with 2 frequent forms of NBIA, carrying mutations in genes (already studied in the CHU molecular diagnostic laboratory)
62527175|NCT03976583|ACTIVE_COMPARATOR|Cpp-acp|MI paste Self-administration of the product by the patient once in the evening. A pea-size amount of the product should be applied per arch, using a dry finger or cotton pellet to distribute it evenly across all teeth and to work it into the interdental spaces. The product was then retained in the mouth for 1-3 min, and manipulated around the teeth using the tongue, before being expectorated and patient should not rinse it until 30 min.
62527176|NCT03976583|EXPERIMENTAL|Pearl powder|Pure pearl powder in the form of gel Self-administration of the product should be used once daily (in the evening), after a 2 min manual tooth brushing. .Participants were explicitly instructed to apply the gel by his finger allover the teeth and not to rinse their mouths after application and not to eat or drink for at least 30 min.
62527177|NCT06026020||Behcet's syndrome patients with intestinal involvement|
62527178|NCT06026020||Behcet's syndrome patients without intestinal involvement|
62527179|NCT06026020||Inflammatory bowel disease patients|
62527180|NCT06026020||Health control|
62527181|NCT03838861|ACTIVE_COMPARATOR|Control|Standard follow-up in doctors setting
62527182|NCT03838861|EXPERIMENTAL|Intervention|Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
62527183|NCT03058419|EXPERIMENTAL|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam \[2 milligram (mg)\], warfarin \[10 mg\], caffeine \[50 mg\], dextromethorphan \[30 mg\], bupropion \[150 mg\] and omeprazole \[20 mg\]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
62153767|NCT05049174|ACTIVE_COMPARATOR|Low-threshold intervention|
62527184|NCT03538119|EXPERIMENTAL|High Intensity Interval Training Program|Three sessions of exercises will be performed weekly with duration of 30 min to 45 min, divided into warm up, aerobic exercise (4x4 high-intensity intervals at 85%-95%) and recovery.
62527185|NCT03538119|EXPERIMENTAL|Moderate Intensity Continuous Training Program|Three sessions of exercises will be performed weekly with duration of 45 min to 60 min, divided into warm up, aerobic exercise (continuous intensity at 70-75%HRpeak) and recovery.
62527186|NCT03538119|NO_INTERVENTION|Control Group|Usual care. The patients will receive nutritional counseling as well as physical activity.
62527187|NCT02000661|EXPERIMENTAL|Routine use of FFR|Fractional Flow Reserve (FFR) used in most cases to guide PCI
62527188|NCT02000661|ACTIVE_COMPARATOR|Selective use of FFR|Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)
62527189|NCT06155058|EXPERIMENTAL|Robotic Mirror Therapy|Serial training with the help of exoskeletal robot therapy
62527190|NCT06155058|ACTIVE_COMPARATOR|Conventional Mirror Therapy|Serial training with the help of physical therapist
62527191|NCT03514641|OTHER|Sequence 1|Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
62527192|NCT03514641|OTHER|Sequence 2|Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
62527193|NCT03514641|OTHER|Sequence 3|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
62527194|NCT03514641|OTHER|Sequence 4|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
62153768|NCT02327806|OTHER|10 minutes of pulsed electromagnetic field therapy|10 minutes of pulsed electromagnetic field therapy
62153769|NCT02327806|OTHER|20 minutes of pulsed electromagnetic field therapy|20 minutes of pulsed electromagnetic field therapy
62153770|NCT02327806|OTHER|30 minutes of pulsed electromagnetic field therapy|30 minutes of pulsed electromagnetic field therapy
62153771|NCT05863585|EXPERIMENTAL|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage
62153772|NCT01098409|EXPERIMENTAL|sodium nitrite 24 hours before|
62153773|NCT01098409|EXPERIMENTAL|sodium nitrite during surgery|
62153774|NCT01098409|PLACEBO_COMPARATOR|0.9% sodium chloride|
62527195|NCT05759936|PLACEBO_COMPARATOR|Placebo|Placebo capsule consumed for 28 days
62527196|NCT05759936|EXPERIMENTAL|500mg seaweed|Seaweed capsule consumed for 28 days
62527197|NCT01074762|NO_INTERVENTION|Routine general practice care|In the comparison group, doctors were free to choose any treatment and change it over time. The study coordinating centre did not contact comparison practices after the end of recruitment (late 1991) until 1995.
62527198|NCT03823495|EXPERIMENTAL|Experimental group|12-week PAP (one 1-hour session per week). Each session includes 20-minute exercise, 30-minute interactive pain management education, practices on non-drug management techniques, and portfolio entry for activities of the day.
62527199|NCT03823495|NO_INTERVENTION|Control group|The control group will receive the usual care and a pain management pamphlet distributed by nursing home staff
62527200|NCT03868163||Glecaprevir plus Pibrentasvir|"Participants in this observational study will receive treatment with glecaprevir and pibrentasvir for up to 16 weeks for treatment of chronic hepatis C (CHC) genotypes 1, 2, 3, 4, 5, or 6.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice, international guidelines and/or label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
62527201|NCT06418685||VC group|Treatment with Vibrabot Capsule
62527202|NCT06418685||Other treatment group|Selecting Alternative Treatment Methods through Assessment
62527203|NCT03382314|EXPERIMENTAL|HDDO-1614|Bazedoxifene + Cholecalciferol combination drug
62527204|NCT03382314|ACTIVE_COMPARATOR|Bazedoxifene + Cholecalciferol|Co-administration of Bazedoxifene and Cholecalciferol
62527205|NCT01172821|EXPERIMENTAL|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
62527206|NCT01172821|EXPERIMENTAL|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
62527207|NCT01172821|ACTIVE_COMPARATOR|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
62527208|NCT01172821|PLACEBO_COMPARATOR|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
62527209|NCT05407025||Observational (questionnaire, biospecimen collection)|Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.
62527210|NCT01484613||Quadripolar lead|All participants receive a CRT-D system with quadripolar lead
62527211|NCT02785224||Vasopressin Steroids Epinephrine (VSE)|Patients with in-hospital cardiac arrest treated with vasopressin, methylprednisolone, and epinephrine during cardiopulmonary resuscitation, and also with stress-dose hydrocortisone for postresuscitation shock.
62527212|NCT02785224||Control|Patients with in-hospital cardiac arrest treated with normal saline placebo, normal saline placebo, and epinephrine during cardiopulmonary resuscitation, and also with normal saline placebo for postresuscitation shock.
62527213|NCT05286723|EXPERIMENTAL|Multicomponent Training|"Traditional training. 3 times a week~Warm-up:~Main work:~Aerobic training Strength training Balance and coordination training Return to calm"
62527214|NCT05050006|EXPERIMENTAL|Cohort 1|Patients who relapsed after or were refractory to at least 1 prior line of systemic therapy including a PD-1 inhibitor.
62153775|NCT06508762|EXPERIMENTAL|VX-993|Participants will be randomized to receive VX-993 in 1 of 6 treatment sequences with 3 dosing periods to assess the relative bioavailability of two VX-993 formulations and the effect of food on the pharmacokinetics of VX-993.
62153776|NCT04414865||single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
62153777|NCT01717625|EXPERIMENTAL|Montelukast|"montelukast sodium~* dosage~  * \< 1000g : 0.5 mg/D QD~ * 1000g\~1500g : 1.0 mg/D QD~ * 1500g\~2000g : 1.5 mg/D QD~ * \> 2000g : 2mg/D QD~* medication period : to discharge or GA 36wks"
62527215|NCT05050006|EXPERIMENTAL|Cohort 2|Patients who were intolerant to a PD-1 inhibitor and have persistent disease after stopping PD-1 therapy.
62527216|NCT05050006|EXPERIMENTAL|Cohort 3|Patients who had a best response of stable disease despite being treated with at least 4 doses of a PD-1 inhibitor in the previous line of therapy.
62527217|NCT01175811|EXPERIMENTAL|Premixed Insulin|Twice daily (before breakfast and lunch) insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension \[LM50\]) and once daily (before dinner) insulin lispro mix 25 (25% insulin lispro, 75% insulin lispro protamine suspension \[LM25\])
62527218|NCT01175811|ACTIVE_COMPARATOR|Basal-Bolus|Once daily (bedtime) insulin glargine and three pre-meal insulin lispro
62527219|NCT05778136|NO_INTERVENTION|Usual Care|Participants receive usual care
62527220|NCT05778136|EXPERIMENTAL|Usual Care + exercise|Participants receive usual care and one-leg resistance exercise training
62527221|NCT05348980|ACTIVE_COMPARATOR|Phenylephrine 4mg|Inj Phenylephrine HCL 04 mg as Group P4.
62527222|NCT05348980|ACTIVE_COMPARATOR|Phenylephrine 8mg|Inj Phenylephrine HCL 08 mg as Group P8.
62527223|NCT03294486|EXPERIMENTAL|Combination of TG6002 and flucytosine (5-FC, Ancotil®)|All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
62527224|NCT05863143|EXPERIMENTAL|Intervention Group|Subjects in the intervention group are required to involve in 12 sessions of nutrition education program and prescribed exercise program during the 12 weeks intervention period. Generally, respondents in the intervention group will received the developed educational materials and exercise diary as guide during this period.
62527225|NCT05863143|NO_INTERVENTION|Control Group|"Subjects required to continue with usual lifestyle (eating habits and exercise pattern) for 12 weeks. Tips on healthy eating and active living, which are suitable for them will be provided.~When the study is completed (after 12 weeks), they will receive the same intervention activities as the intervention group."
62527226|NCT05565092|EXPERIMENTAL|ALXN1820 300 mg once weekly|Participants will receive 300 milligrams (mg) once weekly (QW).
62527227|NCT05565092|EXPERIMENTAL|ALXN1820 600 mg once every 4 weeks|Participants will receive 600 mg once every 4 weeks (Q4W).
62527228|NCT05565092|EXPERIMENTAL|ALXN1820 300 mg once every 2 weeks (Optional cohort)|Participants will receive 300 mg once every 2 weeks (Q2W).
62527229|NCT06217861|EXPERIMENTAL|VGM-R02b|VGM-R02b is an adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene.
62527230|NCT04499365|EXPERIMENTAL|Experimental: 68Ga-DOTA/NOTA-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
62527231|NCT05935436|ACTIVE_COMPARATOR|CSWT Group|CSWT is performed three times a week (days 1, 3, and 5) in a session with a 3-month interval between sessions or 1-month intensive treatment.
62527232|NCT05935436|SHAM_COMPARATOR|Control Group|Patients in the control group receive sham CSWT, the energy of cardiac shock wave therapy was the lowest, and the water bladder was in contact with the skin but not close to the skin.
62527233|NCT00260169|EXPERIMENTAL|1|Participants will receive collaborative care
62527234|NCT00260169|ACTIVE_COMPARATOR|2|Participants will receive enhanced usual care
62527235|NCT03222752|ACTIVE_COMPARATOR|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
62527236|NCT03222752|SHAM_COMPARATOR|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
62527237|NCT03355014|EXPERIMENTAL|Gemigliptin+Metformin combination therapy group|"Part I (Fasted) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day~Part II (High fat diet) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day"
62527238|NCT03355014|EXPERIMENTAL|Gemigliptin and Metformin coadministration therapy group|"Part I (Fasted) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg~Part II (High fat diet) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg"
62153778|NCT01717625|NO_INTERVENTION|Control|Standard treatment of BPD and preterm infants
62153779|NCT04009109|EXPERIMENTAL|Lenalidomide|12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.
62153780|NCT04009109|EXPERIMENTAL|Lenalidomide, Ixazomib, Daratumumab, and Dexamethasone|12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 year maintenance therapy.
62527239|NCT03370874|EXPERIMENTAL|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
62527240|NCT03370874|PLACEBO_COMPARATOR|Vehicle Sheet|Hydrogel sheet without Allogenic mesenchymal stem cell
62527241|NCT04505293|EXPERIMENTAL|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ upon arrival to the casualty unit at MRRH following CT. Patients will be scanned using the InfraScanner 2000™ following each subsequent CT as allowed by patient or representative. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
62527242|NCT03535779||Group 1|Healthy volunteers receiving Tetanus (Td/IVP) vaccine were enrolled onto the study for 1 month with no additional follow up visits.
62527243|NCT03535779||Group 2|Healthy volunteers receiving the Hepatitis B (HBsAg) vaccine were enrolled onto the study for 2 months with no additional follow up visits.
62527244|NCT03168594|EXPERIMENTAL|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
62527245|NCT03168594|EXPERIMENTAL|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
62527246|NCT01531738||Control|Normal weight healthy volunteers
62527247|NCT01531738||Bariatric Surgery|obese patients due to undergo gastric bypass or gastric banding
62527248|NCT02593435||No treatment|There will be two groups, one is breast cancer patient group, another group inlude the first-degree relatives and second degree relatives of patients with BRCA1/2 mutation. All volunteers should provid tissue(s) and blood for NGS test.
62527249|NCT06049836|EXPERIMENTAL|Group A|Group A analyses 15 patient cases 3D Hologram models (first stage) and after the washout period the same 15 patients cases (anonymised, renamed and shuffled) in liver 3D models on computer monitor visualisation (PDF) (second stage)
62527250|NCT06049836|EXPERIMENTAL|Group B|Group B analyses 15 patient cases liver 3D models on computer monitor visualisation (PDF) (first stage) and after the washout period the same 15 patients cases (anonymised, renamed and shuffled) on 3D Hologram models (second stage)
62153781|NCT05563987|EXPERIMENTAL|ACT-DE|The proposed intervention was a six-week acceptance-based diabetes education programme (ACT-DE) programme comprising Acceptance and Commitment Therapy (ACT) and diabetes education (DE). it included one diabetes education session (1st session), three ACT sessions (2nd to 4th), and a booster session in the 6th week conducted by the researcher. Each session lasted about 120 minutes in groups of 6 participants. The sessions were delivered face-to-face.
62527251|NCT02908737|EXPERIMENTAL|Bass and Treble controls|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
62527252|NCT01948986|EXPERIMENTAL|Ertugliflozin 15 mg (T2DM with Normal Renal Function)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function
62527253|NCT01948986|EXPERIMENTAL|Ertugliflozin 15 mg (T2DM with Mild Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment
62527254|NCT01948986|EXPERIMENTAL|Ertugliflozin 15 mg (T2DM with Moderate Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment
62527255|NCT01948986|EXPERIMENTAL|Ertugliflozin 15 mg (T2DM with Severe Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment
62527256|NCT01948986|EXPERIMENTAL|Ertugliflozin, 15 mg (Healthy Part. with Normal Renal Funct.)|Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function
62527257|NCT01002014|EXPERIMENTAL|Nipple Sparing Mastectomy|Patients who undergo nipple sparing mastectomy with preservation of the nipple areolar complex.
62527258|NCT02074592|EXPERIMENTAL|1|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
62153782|NCT05563987|ACTIVE_COMPARATOR|DE|participants in the control group only received one session of diabetes education with the same session duration.
62153783|NCT01105559||Group 1|Participants previously received 3 doses and a booster dose of the investigational vaccine DTaP IPV Hep B PRP-T.
62153784|NCT01105559||Group 2|Participants previously received 3 doses CombAct-Hib™ + Engerix™ B + OPV and a booster dose of CombAct-Hib™ + Oral poliovirus vaccine (OPV) vaccine.
62527259|NCT02074592|ACTIVE_COMPARATOR|2|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
62527260|NCT01710553|OTHER|Metformin GSK 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 1000mg
62153785|NCT01105559||Group 3|Participants previously received 3 doses DTaP IPV Hep B PRP-T; a dose of Engerix™ B at birth, and a booster dose of DTaP IPV Hep B PRP-T vaccine.
62527261|NCT01710553|OTHER|Glucophage 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Glucophage 1000mg to asset bioequivalence
62527262|NCT04404946|ACTIVE_COMPARATOR|phenylephrine infusion|fixed-rate phenylephrine infusion
62527263|NCT04404946|ACTIVE_COMPARATOR|norepinephrine infusion|fixed-rate norepinephrine infusion
62527264|NCT04404946|PLACEBO_COMPARATOR|placebo infusion|normal saline infusion
62153786|NCT06412809|EXPERIMENTAL|Combined Land- and Water-Based Exercise|Core and lower extremity strengthening exercises done on both land and water.
62153787|NCT06412809|ACTIVE_COMPARATOR|Land-Based Exercise|Core and lower extremity strengthening exercises that are implemented solely on land.
62153788|NCT06412809|ACTIVE_COMPARATOR|Water-Based Exercise|Core and lower extremity strengthening exercises that are implemented solely in water.
62153789|NCT01441596|EXPERIMENTAL|arm A: Afatinib monotherapy|Afatinib monotherapy: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
62527265|NCT01206114||Vaccinated persons|The participants have taken one or more doses of 2009 H1N1 vaccine, either as a monovalent vaccine or as a part of a trivalent seasonal 2010-2011 influenza vaccine
62527266|NCT01206114||Not (yet) vaccinated persons|The participants do not want to take any 2009 H1N1 vaccine or have not received any yet
62527267|NCT02134743|EXPERIMENTAL|Experimental Group|At this group the patients will receive dental implants which have a modified SLA surface. These surface have wettability, which could improve and accelerate the osseointegration.Intervention: implant placement.
62527268|NCT02134743|ACTIVE_COMPARATOR|Control Group|The patient of this group will receive implant with conventional surface, SLA (Sandblasted and Acid-Etched Surface).Intervention: implant placement.
62527269|NCT05770921|EXPERIMENTAL|Non-randomized|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
62527270|NCT02235038|ACTIVE_COMPARATOR|Low carbohydrate diet|
62527271|NCT02235038|ACTIVE_COMPARATOR|Moderate carbohydrate diet|
62527272|NCT02235038|ACTIVE_COMPARATOR|High carbohydrate diet|
62153790|NCT01441596|EXPERIMENTAL|arm B: Afatinib in combination with vino|Afatinib 40 mg per day, continuous treatment, in combination with vinorelbine Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course.
62527273|NCT01414595||Group 1|CALGB 140202 outlines the standard procedures for sample procurement. Samples to be used for this project have already been obtained and are currently banked at the CALGB Pathology Coordinating Office (PCO) and the Lung Cancer Tissue Bank at Brigham and Women's Hospital.
62527274|NCT02257463|ACTIVE_COMPARATOR|Study group (group A)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training) inspiratory muscle training: (at intensity that progressively increased from 30% to 60% of patients' maximal inspiratory pressure)"
62527275|NCT02257463|ACTIVE_COMPARATOR|control positive group (group B)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training)"
62527276|NCT02257463|ACTIVE_COMPARATOR|control negative group (group C)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations"
62527277|NCT05194878|EXPERIMENTAL|Neoadjuvant chemotherapy|12 weeks of FOLFOXIRI neuoadjuvantly followed by surgery and adjuvant chemotherapy
62527278|NCT05194878|ACTIVE_COMPARATOR|Postoperative chemotherapy|surgery followed by 24 weeks of FOLFOX or CapeOX or Cape
62153791|NCT01441596|ACTIVE_COMPARATOR|arm C: investigator's choice of treatmen|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
62153792|NCT02970578|EXPERIMENTAL|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
62153793|NCT04607356|ACTIVE_COMPARATOR|Evidence-informed care|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises.
62527279|NCT02747862||Attenuated Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) who have not undergone surgical resection of the colon.
62153794|NCT04607356|EXPERIMENTAL|Evidence-informed care + Blood Flow Restriction (BFR)|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises with the addition of BFR while performing resistive exercises.
62153795|NCT02793752||Mitochondrial Activity of Cumulus Cells|One way that cumulus cells influence oocyte competence is via metabolism (Dumesic et al., 2015). Analysis of mitochondria respiration is an established methodology used for evaluation of cell metabolic homeostasis and for diagnosis of different pathologies.
62153796|NCT02793752||Competence to Blastocyst|The percentage of fertilized eggs that develop to the blastocyst stage.
62153797|NCT05107453|ACTIVE_COMPARATOR|SAPB|"The IMP is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
62153798|NCT05107453|NO_INTERVENTION|Control|
62527280|NCT02747862||Deleterious Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon.
62527281|NCT02998970|PLACEBO_COMPARATOR|Placebo|The placebo group acts as a control group. This is in order to objectively isolate empagliflozin's effect on cardiac structure and function as determined by CMR imaging.
62527282|NCT02998970|ACTIVE_COMPARATOR|Empagliflozin|The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
62153799|NCT01264874|EXPERIMENTAL|Vitamin D3|Vitamin D3 administration
62527283|NCT03865186|EXPERIMENTAL|intervention group|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
62153800|NCT01264874|PLACEBO_COMPARATOR|placebo|matched placebo
62153801|NCT05639556||Cohort 1|Forced expiratory volume in 1 second (FEV1) \<60% predicted during the 12 months prior to enrollment (\>50% of measurements, eliminating periods of exacerbation). If no stable spirometry data are available in the 12 months prior to enrollment, from the prior 24 months will be used.
62153802|NCT05639556||Cohort 2|FEV1 ≥60% predicted during the 12 months prior to enrollment (\>50% of measurements, eliminating periods of exacerbation).
62527284|NCT03865186|EXPERIMENTAL|control group|no intervention was applied to the control group
62527285|NCT05390918|EXPERIMENTAL|TAILOR|Half of the participants will be randomized into the experimental arm of this study. A study clinician will call each family approximately 4 times over 2 months. The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary. The TAILOR intervention will then be administered. TAILOR includes the assessment of existing sleep problems and sleep practices and education on Cognitive Behavioral Therapy (CBT) strategies for insomnia, with Motivational Interviewing (MI) as the communication style.
62527286|NCT05390918|OTHER|Enhanced Usual Care (EUC)|Half of the participants will be randomized into Enhanced Usual Care (EUC). A study clinician will call each family approximately 4 times over 2 months. The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
62527287|NCT05249530|EXPERIMENTAL|Force|Chiropractic spinal adjustment with force
62527288|NCT05249530|ACTIVE_COMPARATOR|Touch|non-force stimulation
62527289|NCT01689818|EXPERIMENTAL|exercise training|exercise training program which included aerobic exercise for 3 times per week.
62527290|NCT01689818|NO_INTERVENTION|control|lifestyle counseling
62527291|NCT05555563|NO_INTERVENTION|Control|Root canal instrumentation was performed using the Reciproc Blue (VDW, Munich) #50/0.5 file. During instrumentation of the root canals, irrigation was applied with 10 mL 2.5% NaOCl using side-vented needles. The final irrigation in Control group was applied with 5 ml of 17% EDTA solution and 5 ml of distilled water. The root canals were dried with sterile paper points and were filled with cold lateral condensation technique using AH Plus root canal sealer and gutta percha. Then the cavity entry was restored with composite (Solarex, GC Corparation, Tokyo, Japan) and radiography was taken. The pre-treatment and 24-month follow-up radiographs of teeth, were prepared as a Power Point presentation and the change in periapical radiolucency was assessed according to PAI scores Teeth with a PAI≤ 2 score and clinically asymptomatic were considered 'healthy' in the radiographic evaluation, while teeth with a PAI≥ 3 and/or clinically symptomatic were considered 'failure'.
62527292|NCT05555563|EXPERIMENTAL|MTAD irrigation|Root canal instrumentation was performed using the Reciproc Blue (VDW, Munich) #50/0.5 file. During instrumentation of the root canals, irrigation was applied with 10 mL 2.5% NaOCl using side-vented needles. The final irrigation in MTAD group was applied 5 ml MTAD (n=50) and 5 ml of distilled water. The root canals were dried with sterile paper points and were filled with cold lateral condensation technique using AH Plus root canal sealer and gutta percha. Then the cavity entry was restored with composite (Solarex, GC Corparation, Tokyo, Japan) and radiography was taken. The pre-treatment and 24-month follow-up radiographs of teeth, were prepared as a Power Point presentation and the change in periapical radiolucency was assessed according to PAI scores Teeth with a PAI≤ 2 score and clinically asymptomatic were considered 'healthy' in the radiographic evaluation, while teeth with a PAI≥ 3 and/or clinically symptomatic were considered 'failure'.
62153803|NCT01085253||Parkinson|"1. without gait impairment~2. with gait and/or balance impairment~3. with sleep disorders (RBD)~abnormalities of the brainstem and basal ganglia will be studied in relation with parkinsonism, gait and presence of RBD"
62153804|NCT01085253||PSP|supranuclear palsy patients study the abnormalities with the brainstem and basal ganglia and relation with the observed neurological signs (eye movements, balance, neuropsychological assessment and parkinsonism)
62527293|NCT04190069|NO_INTERVENTION|OPTIFAST only|Control group will consist of participants that have not undergone behavioral modifications with the Prescription for Wellness Program. These are participants that only go through the OPTIFAST Program.
62527294|NCT04190069|EXPERIMENTAL|UPMC PFW followed by OPTIFAST|The intervention group will consist of participants that have undergone behavioral modifications with the Prescription for Wellness Program. These are participants who undergo the Prescription for Wellness Program prior to the OPTIFAST Program.
62527295|NCT00073242|EXPERIMENTAL|leptin repletion|Repletion of leptin following weight loss induced by dietary modification.
62527296|NCT00073242|EXPERIMENTAL|T3 repletion|Repletion of T3 following weight loss induced by dietary modification.
62527297|NCT03572166|EXPERIMENTAL|Arginine Infusion|Arginine Stimulation Test
62527298|NCT03572166|ACTIVE_COMPARATOR|Hypertonic saline infusion|Hypertonic Saline Infusion Test
62527299|NCT03107143|EXPERIMENTAL|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
62527300|NCT03107143|NO_INTERVENTION|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
62527301|NCT02385253|ACTIVE_COMPARATOR|Educational training program|PCPs randomized to the intervention group will receive the educational training program at the beginning of the study, extending over a maximum of five months.
62153805|NCT01085253||controls|age matched controls
62153806|NCT01613703|EXPERIMENTAL|Experimental|
62153807|NCT01365546|EXPERIMENTAL|human VWF/FVIII concentrate|
62153808|NCT02133131|EXPERIMENTAL|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
62153809|NCT02133131|EXPERIMENTAL|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
62153810|NCT02133131|EXPERIMENTAL|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
62527302|NCT02385253|NO_INTERVENTION|Control|PCPs randomized to the control group will have the option of receiving the educational training program at the end of the study.
62527303|NCT04650503||Patients with eosinophilic asthma at baseline|Patients showing ≥3% sputum eosinophils at baseline
62527304|NCT04650503||Patients with non eosinophilic asthma at baseline|Patients showing \<3% sputum eosinophils at baseline
62527305|NCT04551430|EXPERIMENTAL|Cohort A: Cabozantinib|Patients randomized to Cohort A will take cabozantinib at a dose of 60 mg by mouth once each day of each 28-day cycle. Treatment may continue indefinitely. At time of progression, patients will continue on cabozantinib daily but will reduce their dose to 40 mg. They will cross over into Cohort B and initiate treatment.
62736719|NCT06138600|ACTIVE_COMPARATOR|Tenofovir disoproxil fumarate + Emtricitabine/Lamivudine (TDF/FTC[3TC])|Investigational Product: Tenofovir disoproxil fumarate / emtricitabine (or lamivudine) Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily
62153811|NCT02133131|EXPERIMENTAL|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
62153812|NCT02133131|EXPERIMENTAL|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
62153813|NCT02133131|EXPERIMENTAL|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
62153814|NCT02133131|EXPERIMENTAL|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
62527306|NCT04551430|EXPERIMENTAL|Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Patients randomized to Cohort B will take cabozantinib at a dose of 40 mg by mouth once each day. Nivolumab will given IV at a dose of 3 mg/kg over approximately 30 minutes every 3 weeks for 4 doses, followed by 480 mg over approximately 30 minutes every 4 weeks until treatment discontinuation. Ipilimumab will be given IV at a dose of 1 mg/kg over approximately 30 minutes every 3 weeks for 4 doses. Treatment may continue for up to 2 years.
62527307|NCT04551430|EXPERIMENTAL|Crossover from Cohort A to Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Participants who cross-over from Cohort A into Cohort B will initiate treatment with nivolumab at a dose of 3 mg/kg IV over approximately 30 minutes and ipilimumab at a dose of 1 mg/kg IV over approximately 30 minutes. Nivolumab and ipilimumab will be given every 3 weeks for 4 doses. Nivolumab will then be continued at a dose of 480 mg IV over approximately 30 minutes every 4 weeks, with cabozantinib to continue at 40 mg every day. Treatment may continue for up to 2 years.
62527308|NCT04979286|EXPERIMENTAL|Kinesiotaping Group|Y strip kinesiotaping will be applied to both the gastrocnemius muscles with approximately 20% tension.
62527309|NCT04979286|PLACEBO_COMPARATOR|Placebo Group|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
62153815|NCT00390806|EXPERIMENTAL|topotecan plus radiation|topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
62527310|NCT02603393|EXPERIMENTAL|QVA149|
62153816|NCT00390806|ACTIVE_COMPARATOR|Whole brain radiation|Whole brain radiation 3 Gy/day for 10 days
62527311|NCT02603393|ACTIVE_COMPARATOR|Tiotropium + salmeterol/fluticasone|
62153817|NCT05200286|EXPERIMENTAL|Severe renal impairment|120 mg olorofim
62153818|NCT05200286|ACTIVE_COMPARATOR|Normal renal function|120 mg olorofim
62153819|NCT00680134|EXPERIMENTAL|Group/Cohort 1|AN2690 1% Solution (30 subjects)
62153820|NCT00680134|EXPERIMENTAL|Group/Cohort 2|AN2690 5% Solution (30 subjects)
62153821|NCT04927507|NO_INTERVENTION|Control group|The control group was given routine nursing.
62153822|NCT04927507|EXPERIMENTAL|Observation group|The observation group was given the Internet plus nursing home rehabilitation mode.
62153823|NCT06296875|PLACEBO_COMPARATOR|Vegetable oil|4g/day vegetable oil for 24 weeks
62153824|NCT06296875|ACTIVE_COMPARATOR|Krill oil|4/g/day krill oil for 24 weeks
62153825|NCT00251147|ACTIVE_COMPARATOR|Open Repair|
62153826|NCT00251147|ACTIVE_COMPARATOR|Mini-open Repair|
62153827|NCT05726097|ACTIVE_COMPARATOR|Standard preparation regimen|4 L polyethylene glycol as laxative 30 + 15 mL sodium phosphate as a booster
62153828|NCT05726097|EXPERIMENTAL|Optimized preparation regimen|1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster
62153829|NCT05726097|EXPERIMENTAL|Optimized preparation regimen with prucalopride|1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster + 2 mg of prucalopride
62153830|NCT00391651|ACTIVE_COMPARATOR|1|Nitrofurantoin 100mg BID x 5 days
62153831|NCT00391651|ACTIVE_COMPARATOR|2|TMP/SMX DS BID x 3 days
62153832|NCT06416345|EXPERIMENTAL|Intervention Group|At-home use of the Cue2Walk
62153833|NCT06416345|OTHER|Control Group|Usual Care (+ Waiting List)
62153834|NCT05651802|ACTIVE_COMPARATOR|Control arm|Patients who are randomized to control arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive PCI and regular brain MRI follow-up.
62153835|NCT05651802|EXPERIMENTAL|Study arm|Patients who are randomized to study arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive regular brain MRI follow-up alone.
62153836|NCT04299022||Prospective Registry|Treatment for diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with Vivigen Cellular Bone Matrix
62153837|NCT04299022||Retrospective Data Collection|Treatment of diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with adjunct bone graft utilized in the acute, delayed, non-union and fusion settings.
62153838|NCT01594606|EXPERIMENTAL|Animal-assisted|This group receives the dog training program in which they will be teaching a dog basic obedience skills.
62527312|NCT04310618||Adults with bronchiectasis|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase
62527313|NCT04476719|EXPERIMENTAL|Atafenovir 200 mg Kapsül|Capsules containing 207.009 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride (Atabay-Turkey).
62527314|NCT04476719|ACTIVE_COMPARATOR|Arbidol 100 mg Kapsül|Capsules containing 103.504 umifenovir hydrochloride monohydrate equivalent to 100 mg umifenovir hydrochloride (OTC-Pharma Russia).
62527315|NCT00422981|ACTIVE_COMPARATOR|AL-108 5 mg|5 mg QD
62527316|NCT00422981|ACTIVE_COMPARATOR|AL-108 15 mg|15 mg BID
62527317|NCT00422981|PLACEBO_COMPARATOR|Placebo|Placebo
62153839|NCT01594606|ACTIVE_COMPARATOR|Dog Walking|This group will walk a different dog each week but will not engage in dog training.
62153840|NCT02533752||Main Group|This an observational registry - there is only one group
62153841|NCT00529529|EXPERIMENTAL|Indacaterol 300 μg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62153842|NCT00529529|EXPERIMENTAL|Indacaterol 600 μg|Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62527318|NCT05530148|EXPERIMENTAL|Martial Arts Group|Participants will be trained in the martial arts exercises using both in-person group sessions and asynchronous remote learning via video content distributed to them each week. Participants will be asked to attend as many of the 24 in-person sessions as they can. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
62527319|NCT05530148|ACTIVE_COMPARATOR|Flexing, Toning and Balance|Flexibility, Toning and Balance or FTB will be used to refer to our resistive exercise comparison. As in the experimental group, participants will be asked to attend as many of the 24 in-person intervention sessions as they can, whilst also practicing the exercises remotely via video content distributed to them. The remote portion of this intervention will be asynchronous. Heart-rate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the martial arts experimental group.
62713521|NCT06315309|EXPERIMENTAL|phase II single arm study of 2 step ATG dosing in prevention of aGVHD.|The primary outcome for the study is rate of GRFS at one-year post transplant. When accounting for competing risks, any death, relapse, Grade III-IV acute GVHD and cGVHD requiring systemic therapy are competing risks. The reported one year GRFS with the use of standard of care GVHD prevention regimen in MA HSCT (Tac/MTX) was 35%. (El-Jurdi 2023) We hypothesize that with 2 step ATG/Tac/Mini MTX regimen, we can achieve a one year GRFS of 60%.
62713522|NCT04963777|EXPERIMENTAL|Prebiotic|Oligofructose-enriched inulin
62713523|NCT04963777|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62713524|NCT05589987|EXPERIMENTAL|Power mobility|The study will take place in the child's natural environment for 12 weeks.
62713525|NCT05589987|NO_INTERVENTION|Non-power mobility|Children will perform their typical daily routine without any modification. After the study they will be invited to participate in the experimental group if positive benefits are obtained.
62153843|NCT00529529|ACTIVE_COMPARATOR|Salmeterol 50 μg|Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62153844|NCT05793489|EXPERIMENTAL|WBRT + Silibinin|Patients undergo WBRT concomitant to Silibinin
62527320|NCT02520206||Arthritis|subjects with arthritis
62527321|NCT02520206||Health control subjects|Health control
62527322|NCT02379780|ACTIVE_COMPARATOR|USG guided Subcostal TAP block|after preparing the skin, ultrasound probe was placed obliquely on the upper abdominal wall along the subcostal margin near the midline. the rectus abdominis muscles, transversus abdominis muscles and the fascial plane (TAP) between rectus abdominis and transversus abdominis muscles were identified. after identification, the block needle was introduced anteriorly in the plane of the ultrasound beam. the needle was directed the transversus abdominis plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
62527323|NCT02379780|ACTIVE_COMPARATOR|USG guided Paravertebral Block|prior to start surgery, was performed in the left lateral position. after preparing skin, ultrasound linear probe was placed, 2-3 cm lateral of the T7 / T8 level in the midline. After determining the transverse process and ribs as hyperechoic, the paravertebral space was identified as an area wedge-shaped bounded by the pleura and above the internal intercostal membrane.after identification of the paravertebral space, the block needle was introduced in plane / out of plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
62713526|NCT04773665|EXPERIMENTAL|Phase 1a, Group G1|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Day 1 and placebo at Day 28
62153845|NCT05793489|NO_INTERVENTION|WBRT|Patients undergo WBRT alone, total dose of 30 Gy in 10 fractions.
62153846|NCT00508183|ACTIVE_COMPARATOR|single row fixation|
62153847|NCT00508183|ACTIVE_COMPARATOR|double row fixation|
62153848|NCT00990132|ACTIVE_COMPARATOR|Long term oxygen therapy|LTOT will be established as per current national guidelines
62153849|NCT00990132|EXPERIMENTAL|Home mechanical ventilation|Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.
62153850|NCT05052151|ACTIVE_COMPARATOR|Low temperature|Dialysate temperature
62153851|NCT05052151|ACTIVE_COMPARATOR|High temperature|Dialysate temperature
62713527|NCT04773665|EXPERIMENTAL|Phase 1a, Group G2|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Days 1 and 28
62713528|NCT04773665|PLACEBO_COMPARATOR|Phase 1a, Group G3|20 participants age 18-54 will receive placebo at Days 1 and 28
62713529|NCT04773665|EXPERIMENTAL|Phase 1b, Group G4|27 participants age 18-54 will receive VBI-2905a at a dose of 5 μg of S protein at Day 1
62713530|NCT04773665|PLACEBO_COMPARATOR|Phase 1b, Group G5|27 participants age 18-54 will receive placebo at Day 1
62713531|NCT00593229||3|Familial atypical HUS
62713532|NCT00593229||4|Thrombotic thrombocytopenic purpura (TTP)
62713533|NCT00593229||1|Severe diarrhea-associated hemolytic uremic syndrome (D+HUS)
62713534|NCT00593229||2|Non-familial atypical HUS
62713535|NCT03399448|EXPERIMENTAL|Multiple Myeloma (MM)|
62713536|NCT03399448|EXPERIMENTAL|Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL)|
62713537|NCT03399448|EXPERIMENTAL|Melanoma|Not Recruiting at the UPenn Site
62153852|NCT05052151|ACTIVE_COMPARATOR|Low bicarbonate|Dialysate bicarbonate concentration
62153853|NCT05052151|ACTIVE_COMPARATOR|High bicarbonate|Dialysate bicarbonate concentration
62713538|NCT02189889|ACTIVE_COMPARATOR|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
62713539|NCT02189889|NO_INTERVENTION|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
62713540|NCT00516724|EXPERIMENTAL|1|Carboplatin + KU-0059436
62713541|NCT00516724|EXPERIMENTAL|2.|Paclitaxel + KU-0059436
62713542|NCT00516724|EXPERIMENTAL|3.|Paclitaxel, Carboplatin + KU-0059436
62527324|NCT04585984|PLACEBO_COMPARATOR|Control|140 men will be taking a placebo once a day during 21 days prior to the start of the IVF/ICSI cycle.
62527325|NCT04585984|EXPERIMENTAL|Experimental|140 men will be taking the probiotic compound (50% of each probiotic: Lactobacillus rhamnosus and Bifidobacterium longum at a dose of 10\^9 cfu/day) once a day for 21 days prior to the start of the IVF/ICSI cycle.
62527326|NCT05038579|EXPERIMENTAL|Musiquence|Dementia group was involved in a 14-session customized cognitive stimulation program, using Musiquence.
62527327|NCT02667171|ACTIVE_COMPARATOR|Control group|The control group will receive standardized conventional supervised COPD rehabilitation, delivered in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks.
62153854|NCT03369483||CPAP|At the end of the abdominal surgical procedure, mechanical ventilation withdrawal and extubation, patients will receive Continuous Positive Airway Pressure CPAP). CPAP will be be delivered using any commercially available CPAP equipment. CPAP will be started as soon as possible after the end of surgery. The starting airway pressure (PEEP) will be 5 cmH2O. PEEP may be changed at the discretion of the responsible physician. The maximum permissible PEEP during the trial intervention period will be 10 cmH2O. CPAP may be continued after the four-hour trial intervention period has finished, at the discretion of the responsible physician.
62527328|NCT02667171|EXPERIMENTAL|Online COPD rehabilitation|Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks.
62153855|NCT03411408|EXPERIMENTAL|HBO and RT|Hyperbaric oxygenation therapy and Accelerated Hypofractionated intensity - modulated radiotherapy
62153856|NCT03270098|EXPERIMENTAL|Aerobic Exercise|Using trainer-led video calls with traditional callisthenic body movements (e.g., jumping jacks, burpees, etc.)
62153857|NCT03270098|ACTIVE_COMPARATOR|Stretching and Toning Exercise|Using trainer-led video calls with stretching and toning exercises.
62153858|NCT02542202|EXPERIMENTAL|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
62153859|NCT01190995|EXPERIMENTAL|Sucrose|The enrolled neonates will be administered a sterile solution of 24 % sucrose orally for a period of 7 days from enrollment The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure.
62153860|NCT01190995|PLACEBO_COMPARATOR|Placebo|The enrolled neonates will be administered double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
62527329|NCT00134043|EXPERIMENTAL|Arm I|Patients receive oral suberoylanilide hydroxamic acid (SAHA) twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are then evaluated for disease response. Patients achieving a complete response receive an additional 2 courses of SAHA. Patients achieving stable disease or a partial response receive 4 additional courses of SAHA.After completion of study treatment, patients are followed within 4 weeks.
62527330|NCT05010044|EXPERIMENTAL|Participants received MBCT once a week for 8 weeks|Participants received MBCT once a week for 8 weeks. At the same time, the drug therapy for psoriasis was used .
62527331|NCT05010044|ACTIVE_COMPARATOR|Active comparator|Only the drug therapy for psoriasis was used .
62527332|NCT05492253|ACTIVE_COMPARATOR|Infant cereal|Oatmeal cereal
62527333|NCT05492253|EXPERIMENTAL|Infant fruit|Pureed prunes
62527334|NCT05492253|EXPERIMENTAL|Infant vegetable|Pureed carrots
62527335|NCT05492253|EXPERIMENTAL|Infant meat|Pureed beef
62527336|NCT04600466||Retrospective Non-Hispanics|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
62527337|NCT04600466||Retrospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
62527338|NCT04600466||Prospective Non-Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
62527339|NCT04600466||Prospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
62713543|NCT06663449|ACTIVE_COMPARATOR|GROUP USING subcostal transversus abdominis plane block|Before being taken to the surgical table preoperatively, monitoring and sedation will be performed in the operating room block unit, then subcostal tap block will be performed and postoperative PCA will be applied.Patients' perioperative pain will be monitored with a NOL (nociception level) monitor. The remifentanil dose will be adjusted to keep the NOL level between 10 and 25. After the patients are followed up for 24 hours postoperatively, their additional analgesia needs and amounts during this period will be compared.
62736720|NCT04727450|ACTIVE_COMPARATOR|1. Integrated format|Integrated or Combination of ABC of A: cognitive training. B: physical training and C: Combined Cognitive and Physical Training (CCPT).
61975665|NCT03578991|NO_INTERVENTION|Arm 1|"Control group - Treatment as usual:~Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist."
61975666|NCT03578991|EXPERIMENTAL|Arm 2|"Intervention - Smart pillbox:~Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox."
61975667|NCT03578991|EXPERIMENTAL|Arm 3|"Intervention - Smart pillbox \& Interactive digital platform:~Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform."
62713544|NCT06663449|ACTIVE_COMPARATOR|GROUP USING erector spinae plane block|Before being taken to the surgical table preoperatively, monitoring and sedation will be performed in the operating room block unit, then erector spinae plane block will be performed and postoperative PCA will be applied.Patients' perioperative pain will be monitored with a NOL (nociception level) monitor. The remifentanil dose will be adjusted to keep the NOL level between 10 and 25. After the patients are followed up for 24 hours postoperatively, their additional analgesia needs and amounts during this period will be compared.
62713545|NCT05282667|EXPERIMENTAL|Resorbable cross-linked barrier membrane|Bone graft will be covered with a resorbable barrier membrane to exclude undesired cells from the area aimed at being regenerated (peri-implantitis bone defect)
62713546|NCT05282667|EXPERIMENTAL|No barrier membrane|Bone graft will be solely packed in the peri-implantitis bone defect with no membrane to cover
62713547|NCT06229691|EXPERIMENTAL|Healthy|
62153861|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
62153862|NCT01359059|ACTIVE_COMPARATOR|IV-PCA (Patient-controlled analgesia) morphine|
62153863|NCT01359059|ACTIVE_COMPARATOR|Patient controlled epidural analgesia (PCEA) fentanyl|
62527340|NCT04583449|EXPERIMENTAL|Outcome imagery|Outcome imagery condition participants will be asked to visualize themselves successfully wearing a face covering in all required public places/situations over coming week, and to imagine how they would feel. The importance of imagining distinctive relevant visual imagery linked to having successfully routinely worn face covering will be underscored in this passage. Outcome imagery participants will then be asked to write in a free-text box how they would feel having successfully worn a face covering in required public places/situations over the week ahead.
62713548|NCT06229691|EXPERIMENTAL|Knee osteoarthritis|
62713549|NCT05250037||Screening (spirometry measurements)|Patients undergo home spirometry measurements with a portable handheld spirometer and complete questionnaires weekly, a nasal swab for viral polymerase chain reaction (PCR) surveillance every 4 weeks, and undergo blood collection and nasal swabs every 3 months for up to 2 years.
62153864|NCT06360120|ACTIVE_COMPARATOR|atorvastatin|The Atorvastatin arm consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, an open-label clopidogrel at a loading dose of 300 mg, and then 75 mg daily till the end of the 3 months
62713550|NCT06716450|EXPERIMENTAL|Participants with unknown HIV and syphilis status|All participants will self-test fingerstick blood testing with the test device, along with venous blood testing at a central laboratory using licensed gold standard comparator methods.
62713551|NCT04551729|ACTIVE_COMPARATOR|Fluid restriction|Patient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.
62153865|NCT06360120|ACTIVE_COMPARATOR|rosuvastatin|The rosuvastatin arm consisted of 300 patients who received 20 mg daily rosuvastatin for 3 months, an open-label clopidogrel at a loading dose of 300 mg, and then 75 mg daily till the end of the 3 months
62153866|NCT03790098|EXPERIMENTAL|Yoga Class Participants|Group 1 participants will meet twice per week for one hour to practice restorative-flow yoga with a certified yoga instructor. There will be a total of 24 classes. Group 1 participants will also receive an at-home supplemental booklet, a yoga video led by the class instructor, and encouragement to practice two additional days each week at home. They will be asked to fill out a form to record their at-home practice.
62153867|NCT03790098|NO_INTERVENTION|No Classes|Group 2 participants will not attend yoga classes as part of the study and will be asked not to begin yoga classes outside the study. After the 24 classes, they will be given the 'at-home' supplemental materials.
62153868|NCT00505024|EXPERIMENTAL|IVRS Only|
62153869|NCT00505024|EXPERIMENTAL|IVRS + Symptoms Report|
61975668|NCT01506479|SHAM_COMPARATOR|Control Group|Wait listed to moderate or vigorous exercise after 6 months of no exercise.
62527341|NCT04583449|EXPERIMENTAL|Process imagery|Process imagery condition participants will be asked to visualize the kinds of strategies involved in successfully wearing a face covering in all required public places/situations over the coming week. The importance of imagining distinctive relevant visual imagery linked to having effective strategies involved in successfully wearing a face covering in required public places/situations over the week ahead will be underscored in this passage. Process imagery participants will then be asked to write in a free-text box about the kinds of strategies that would be involved in successfully wearing a face covering in all required public places/situations over the coming week.
62527342|NCT04583449|EXPERIMENTAL|Combined imagery (outcome imagery and process imagery)|A third experimental condition will receive both outcome and process imagery exercises to read and complete in sequential order.
62713552|NCT04551729|EXPERIMENTAL|Liberal fluid intake|Patient will receive a lifestyle advice for liberal fluid intake for 3 months.
62713553|NCT06473051|EXPERIMENTAL|Original Set (Set O)|"Implementation strategies applied are:~* preparatory workshops~* implementation handbook~* Training and coaching of INTERCARE nurses (geriatric nurse experts)~* continuous support for participating facilities: meetings, ticket system~* benchmarking reports~Coaching of INTERCARE nurse and meetings with facilities are at INDIVIDUAL level"
62713554|NCT06473051|EXPERIMENTAL|Adapted Set (Set A)|"same as set O, except~Coaching of INTERCARE nurse and meetings with facilities are at GROUP level"
62713555|NCT06484413||rTMS Group|received rTMS
62713556|NCT04464239|EXPERIMENTAL|Part A: Cohort 1: TS-142 10 mg|Single dose of TS-142 10 mg or placebo in a fasted condition
61975669|NCT01506479|EXPERIMENTAL|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
61975670|NCT01506479|EXPERIMENTAL|Moderate Exercise|Endurance exercise at 60-65% HR max, 4x/wk for 6 months.
62153870|NCT00966745|ACTIVE_COMPARATOR|milrinone|milrinone infusion
62153871|NCT00966745|PLACEBO_COMPARATOR|placebo|
62153872|NCT04349709|EXPERIMENTAL|Brief school-based DBT-A|The students of classes randomized to experimental group receive the brief school-based DBT-A..
62153873|NCT04349709|NO_INTERVENTION|control group|The students of classes randomized to control group continue their school activity as routine.
62153874|NCT02717780|ACTIVE_COMPARATOR|SEVO-FENTA|Patients scheduled for lower limb surgery will receive a balanced anesthesia with fentanyl and sevoflurane.
62153875|NCT02717780|EXPERIMENTAL|DES-REMI|Patients scheduled for lower limb surgery will receive a balanced anesthesia with remifentanil and desflurane.
62153876|NCT02568059|EXPERIMENTAL|100 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 100 mg.
62527343|NCT04583449|NO_INTERVENTION|Public health message|A fourth condition will involve viewing a UK Government public health message (HM Government, 2020) circulated on social media as an image concerning the importance of wearing face covering while in public places.
62153877|NCT02568059|EXPERIMENTAL|200 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 200 mg.
62153878|NCT01166191|EXPERIMENTAL|SCLC|
62153879|NCT05202444|EXPERIMENTAL|Osteotomy using piezoelectrical device|
62527344|NCT01659866|OTHER|Cipro-susceptible|Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
62527345|NCT01659866|ACTIVE_COMPARATOR|Cipro-resistant|"Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~* trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~* cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~* ceftriaxone 500 mg intramuscularly 2 hours before the procedure~* gentamicin 2mg/kg intramuscularly 2 hours before the procedure~* amikacin 5 mg/kg intramuscularly 2 hours before the procedure~* aztreonam 500 mg intramuscularly 2 hours before the procedure~* imipenem 500 mg intramuscularly 2 hours before the procedure~* ceftriaxone 2000 mg intravenously 1 hour before the procedure~* gentamicin 2 mg/kg intravenously 1 hour before the procedure~* amikacin 5mg/kg intravenously 1 hour before the procedure~* aztreonam 2000 mg intravenously 1 hour before the procedure~* imipenem 1000 mg intravenously 1 hour before the procedure"
62713557|NCT04464239|EXPERIMENTAL|Part A: Cohort 2: TS-142 30 mg|Single dose of TS-142 30 mg or placebo in a fasted condition.
62713558|NCT04464239|EXPERIMENTAL|Part B: Cohort 4: TS-142 20 mg|Daily doses of 20 mg TS-142 or placebo for 7 days before bedtime.
62153880|NCT05202444|ACTIVE_COMPARATOR|Osteotomy using surgical saw|
62153881|NCT03717558|ACTIVE_COMPARATOR|Stromectol R|Stromectol R = ivermectin 3mg (tablet)
62153882|NCT03717558|EXPERIMENTAL|ivermectin T1|T1= ivermectin low grade particle Size Distribution
62153883|NCT03717558|EXPERIMENTAL|ivermectin T2|T2= ivermectin medium grade particle Size Distribution
62153884|NCT03717558|EXPERIMENTAL|ivermectin T3|T= ivermectin high grade particle Size Distribution
62153885|NCT00549666|EXPERIMENTAL|Lurasidone 40 mg|
62153886|NCT00549666|PLACEBO_COMPARATOR|Placebo|
62153887|NCT00549666|ACTIVE_COMPARATOR|Ortho Tri-Cyclen|
62153888|NCT05867992||Case group|This group enrolls patients with acute severe traumatic brain injury.
62153889|NCT05867992||Control group|This group enrolls patients with acute traumatic bone fracture but without traumatic brain injury.
62153890|NCT02151994|EXPERIMENTAL|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
62153891|NCT02151994|PLACEBO_COMPARATOR|Placebo|tablets, visually matching active medication
62153892|NCT04189172||Neuro-Patch|Patients receiving Neuro-Patch® for duraplasty
62153893|NCT00547885|ACTIVE_COMPARATOR|1|Active dihydrocodeine, long acting and Placebo dihydrocodeine short acting
62153894|NCT00547885|ACTIVE_COMPARATOR|2|Placebo dihydrocodeine, long acting and active dihydrocodeine short acting.
62153895|NCT03242863|EXPERIMENTAL|Control|Baseline proportions of high and low energy dense foods.
62153896|NCT03242863|EXPERIMENTAL|Addition|Increased portion of low energy dense foods.
62153897|NCT03242863|EXPERIMENTAL|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
62153898|NCT01285167||DACOTA|
62153899|NCT05196958|EXPERIMENTAL|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
62153900|NCT06321094|EXPERIMENTAL|patients who take vericiguat|ACS patients with ejection fraction(EF)\<45% are required to take vericiguat according to the guidelines from 2.5mg once a day to 5mg after two weeks.
62153901|NCT06321094|NO_INTERVENTION|patients who donot take vericiguat|ACS patients with EF\<45% arenot required to take vericiguat.
62153902|NCT03305185|EXPERIMENTAL|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
62153903|NCT03305185|ACTIVE_COMPARATOR|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
62153904|NCT04528602|EXPERIMENTAL|Control (Extended leg position) Group|In the control (Extended leg position) group of the study, diaper change will be performed after the legs of the babies are brought to extension.
62153905|NCT04528602|EXPERIMENTAL|Experimental (Legs are flexed toward abdomen) Group|In the experimental (Legs are flexed toward abdomen) group, the diaper change will be performed after the legs of the babies are brought closer to the abdomen while maintaining their flexion leg position.
62527346|NCT01521416||Cohort Group|
62527347|NCT04997941|EXPERIMENTAL|Tamoxifen 40mg|Tamoxifen 20mg b.i.d - Participants will be treated for 14 days.
62527348|NCT04997941|ACTIVE_COMPARATOR|Tamoxifen 20mg|Tamoxifen 10mg b.i.d - Participants will be treated for 14 days.
62527349|NCT00329472|EXPERIMENTAL|Gem/Cis|neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 \& cisplatin 70mg/m2 , 2 cycles
62527350|NCT00329472|NO_INTERVENTION|no neoadjuvant chemotherapy|
62713559|NCT05000983|ACTIVE_COMPARATOR|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
62713560|NCT05000983|EXPERIMENTAL|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
62527351|NCT01352130|ACTIVE_COMPARATOR|Ondansetron|Patients given Ondansetron
62527352|NCT01352130|ACTIVE_COMPARATOR|Granisetron|Patients given Granisetron
62153906|NCT02808676|EXPERIMENTAL|Exercises+CognitiveTraining+Vitamin D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks."
62153907|NCT02808676|EXPERIMENTAL|Exercises+CognitiveTraining+Placebo D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks."
62527353|NCT06410170||Single Cohort Group|Evaluating the anticipated utility of the Mira device for detection of the LH surge, in natural cycle frozen embryo transfer protocols
62713561|NCT05090826|EXPERIMENTAL|TECNIS Synergy IOL|Model ZFR00V
62713562|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
62713563|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
62713564|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
62153908|NCT02808676|EXPERIMENTAL|Exercises+Control CogTraining+Vitamin D3|Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks
62153909|NCT02808676|EXPERIMENTAL|Exercises+Control CogTraining+Placebo D3|Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
62153910|NCT02808676|PLACEBO_COMPARATOR|Placebo exercise+Control Cog+Placebo D3|This will be the comparator arm with control/placebo activities.
62153911|NCT00587405|ACTIVE_COMPARATOR|1|Cryotherapy
62153912|NCT00587405|ACTIVE_COMPARATOR|2|Argon Plasma Coagulation
62153913|NCT05062226|EXPERIMENTAL|GMP-based products|GMP-based nutritional protein substitutes for the dietary management of PKU and TYR
62153914|NCT03559777|ACTIVE_COMPARATOR|closed sinus lifting by Osteotome|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
62153915|NCT03559777|EXPERIMENTAL|closed sinus lifting by Densah bur|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
62153916|NCT05813522|EXPERIMENTAL|Furmonertinib|Furmonertinib 160mg po qd
62153917|NCT04550455|EXPERIMENTAL|Cladribine Tablets|All participants will receive cladribine tablets according to the current United States Federal Food and Drug Administration (FDA) package guidelines.
62153918|NCT05924373|EXPERIMENTAL|single-dose group|Human Dental Fulp Stem Cells Injection: 1X 10\^7 cells/periodontaldefect site.
62153919|NCT05924373|EXPERIMENTAL|two-dose group (low-dose)|Human Dental Pulp Stem Cells Injection: 1X 10\^6 cells/periodontaldefect site. Continuous administration twice, with an interval of 89 days between each administration.
62153920|NCT05924373|EXPERIMENTAL|two-dose group (high-dose)|Human Dental Pulp Stem Cells Injection: 1X 10\^7 cells/periodontaldefect site. Continuous administration twice, with an interval of 89 days between each administration.
62527354|NCT04218500|ACTIVE_COMPARATOR|Niacinamide 4%|Niacinamide 4%, applied twice daily for 28 days
62527355|NCT04218500|ACTIVE_COMPARATOR|Virgin coconut oil 30%|Virgin coconut oil 30%, applied twice daily for 28 days
62527356|NCT02400424|EXPERIMENTAL|SBRT|Study treatment = SBRT for peripheral primary tumor.
62527357|NCT02578264||All participants|All subjects enrolled in the study will provide tumor and normal tissue and blood samples.
62527358|NCT04403711|ACTIVE_COMPARATOR|local anesthetic and dexmedetomidine|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL dexmedetomidine
62527359|NCT04403711|PLACEBO_COMPARATOR|local anesthetic and placebo|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL normal saline
62527360|NCT04408599|EXPERIMENTAL|NC410 3mg|3mg of NC410 for IV infusion administered in 14 day dosing cycles
62527361|NCT04408599|EXPERIMENTAL|NC410 6mg|6mg of NC410 for IV infusion administered in 14 day dosing cycles
62527362|NCT04408599|EXPERIMENTAL|NC410 15mg|15mg of NC410 for IV infusion administered in 14 day dosing cycles
62713565|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
62713566|NCT03358693||Psoriasis patients receiving brodalumab|Brodalumab
62713567|NCT03358693||Psoriasis patients receiving Ixekizumab|Ixekizumab
62713568|NCT03358693||Atopic dermatitis patients receiving tralokinumab|Tralokinumab
62713569|NCT03358693||Atopic dermatitis patients receiving baricitinib|Baricitinib
62527363|NCT04408599|EXPERIMENTAL|NC410 30mg|30mg of NC410 for IV infusion administered in 14 day dosing cycles
62527364|NCT04408599|EXPERIMENTAL|NC410 60mg|60mg of NC410 for IV infusion administered in 14 day dosing cycles
62153921|NCT04392648|EXPERIMENTAL|Escalation:TAK-573 0.1-1.5mg/kg+Bortezomib+Dexamethasone|TAK-573 0.1 to 1.5 milligram per kilogram (mg/kg), infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 milligram per square meter (mg/m\^2), injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 milligram (mg) (20 mg if aged more than 75 years), tablets, orally on Days 1, 8, and 15 in each 21-days treatment cycle from Cycle 1 through Cycle 8. For participants who continue beyond Cycle 8, TAK-573 will be given as an infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle with dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally from Cycle 9 through Cycle 17.
62153922|NCT04392648|EXPERIMENTAL|Escalation:TAK-573 0.05-0.75mg/kg+Pomalidomide+Dexamethasone|TAK-573 0.05 to 0.75 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
62153923|NCT04392648|EXPERIMENTAL|Escalation:TAK-573 0.1-1.5mg/kg+Cyclophosphamide+Dexamethasone|TAK-573 0.1 to 1.5 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m\^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
62527365|NCT04408599|EXPERIMENTAL|NC410 100mg|100mg of NC410 for IV infusion administered in 14 day dosing cycles
62527366|NCT04408599|EXPERIMENTAL|NC410 200mg|200mg of NC410 for IV infusion administered in 14 day dosing cycles
62527367|NCT00660205||operation|Patients with upper gastro intestinal cancer who underwent surgery
62527368|NCT00660205||palliation|Patients with upper gastro intestinal cancer who did not underwent surgery
62527369|NCT00660205||control|Persons with no cancer who accepted to be control with blood samples and flow doppler ultrasound examination of both legs.
62527370|NCT01011244|EXPERIMENTAL|ADIPOPLUS|patients with a fistula in Crohn's disease
62527371|NCT06300671|ACTIVE_COMPARATOR|Pronation Group|Participants with a value between 6-9 according to the foot posture index-6 evaluation will be included in the pronation group.
62527372|NCT06300671|ACTIVE_COMPARATOR|Hyperpronation Group|Participants with a value between 10-12 according to the foot posture index-6 evaluation will be included in the hyperpronation group.
62527373|NCT06300671|ACTIVE_COMPARATOR|Neutral Group|Participants with a value between 0-5 according to the foot posture index-6 evaluation will be included in the neutral group.
62713570|NCT03358693||Atopic dermatitis patients receiving abrocitinib|Abrocitinib
62527374|NCT03751956|EXPERIMENTAL|HSK3486|0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection
62527375|NCT06018974|EXPERIMENTAL|Yetitablet group|Older adults in the experimental group will participate in a 12-week, 3 times per week, 30-60 minutes per session (recommendation) gaming session with Yetitablet in their home facility. Games will be played in group of 3-5 people with participants taking turns. Gaming sessions are supervised by research assistant or facility personnel.
62527376|NCT06018974|NO_INTERVENTION|Control group|Participants in control group will continue their normal daily activities in their home facility. No intervention is provided to control group (passive control group).
62527377|NCT04205019|EXPERIMENTAL|Neuro-Cell group|Patient receives treatment once at start of study and followed up for safety.
62527378|NCT03906396|EXPERIMENTAL|Intervention Group|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant for 6 weeks, 3 times per week. Games use for the activity are Sports Kinect and Sports Kinect 2. The activity can be performed in solo or in pairs with another participant. The game activity will be played only at the site chosen for this study.
62527379|NCT03906396|NO_INTERVENTION|Control Group|No standard activity is provided for the participants. The participants will continue with their normal daily life activities.
62527380|NCT03501914|EXPERIMENTAL|Mindfulness Based Intervention|Mindfulness principles based manualized intervention will be provided to the participants which is developed by colleagues in Manchester. This intervention will be adapted to be accessible for people having intellectual disability (ID) in Pakistan.Sessions will take place once-weekly for 12 weeks including an initial orientation session. It will include breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking
62527381|NCT02528123|EXPERIMENTAL|Small incision lenticule extraction|Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.
62527382|NCT05854017|ACTIVE_COMPARATOR|Active|Dietary Supplement: Theanine for stress relief formulation
62527383|NCT05854017|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62527384|NCT03293784|OTHER|COHORT 1|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
62527385|NCT03293784|OTHER|COHORT 2|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
62527386|NCT01767961|EXPERIMENTAL|Diagnostic (modified barium swallow)|Patients undergo the modified barium swallow, comprising swallowing boluses of thin liquid barium, barium honey, barium pudding, and barium crackers while undergoing fluoroscopic imaging.
62527387|NCT02642536|ACTIVE_COMPARATOR|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
62527388|NCT02642536|ACTIVE_COMPARATOR|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
62527389|NCT02475941|EXPERIMENTAL|Early Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Early weight bearing are those who are permitted in the post operative instructions to be Weight Bear as tolerated after fracture fixation.
62713571|NCT03358693||Atopic dermatitis patients receiving upadacitinib|Upadacitinib
62736721|NCT04727450|ACTIVE_COMPARATOR|2. Cognitive training + Physical Training (A+B)|Intervention of A \& B treatments.
62527390|NCT02475941|ACTIVE_COMPARATOR|Non Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Non weight bearing are those who are NOT permitted in the post operative instructions to be Weight Bear after fracture fixation.
62527391|NCT02870387|ACTIVE_COMPARATOR|Usual Inpatient Care|Usual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
62527392|NCT02870387|EXPERIMENTAL|Comprehensive Care with Inpatient Consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
62527393|NCT03724526|EXPERIMENTAL|Intervention-Text messaging|Participates will receive regular 6 text messages per week for 12 months. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week. Each message will be sent on 6 of 7 randomly selected weekdays and arrived at random times the day during working hours.
62527394|NCT03724526|NO_INTERVENTION|Control|Participates in control group will not receive text messages.
62527395|NCT05195476||Individuals diagnosed with OCD|Individuals diagnosed with OCD
62527396|NCT05195476||Healthy controls|Individuals who have not been diagnosed with any psychiatric disorders
62153924|NCT04392648|EXPERIMENTAL|Expansion: TAK-573 + Bortezomib + Dexamethasone|TAK-573, infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 mg/m\^2, injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, and 15 in each 21-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and recommended dose for expansion (RAD) determined in the previous Dose Escalation Phase.
62527397|NCT00010192|EXPERIMENTAL|Treatment (rituximab and aldesleukin)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.
62527398|NCT02760524|EXPERIMENTAL|Intervention|Subjects will receive NET intervention treatment immediately
62527399|NCT02760524|ACTIVE_COMPARATOR|Control|Subjects will receive NET intervention treatment and serve as a wait-list control
62527400|NCT05137470||Newly HD patients|Newly admitted patients with uremia who started hemodialysis treatment
62527401|NCT05137470||MHD patients|Maintenance hemodialysis patients
62527402|NCT00093600|EXPERIMENTAL|PKC412 administered sequentially|twice daily oral dosing of PKC412 administered sequentially
62713572|NCT06194578|EXPERIMENTAL|Subcutaneous Infusion of Sterile Saline|Participants will receive sterile saline subcutaneous infusion administered into abdomen and/or anterior thigh through various sizes of needles at various volume and rate of delivery at Visit 1.
62527403|NCT00093600|EXPERIMENTAL|PKC412 administered concomitantly|PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
62527404|NCT02893202|EXPERIMENTAL|Ride On Center for Kids (ROCK) facility|8-week therapeutic horseback riding
62527405|NCT02893202|EXPERIMENTAL|Triple H Equitherapy Facility|8-week therapeutic horseback riding
62527406|NCT02893202|EXPERIMENTAL|Rainer Therapeutic Riding facility|8-week therapeutic horseback riding
62527407|NCT02893202|EXPERIMENTAL|REACH Therapeutic Riding facility|8-week therapeutic horseback riding
62527408|NCT02893202|EXPERIMENTAL|Courtney Cares Riding facility|8-week therapeutic horseback riding
62527409|NCT05896930|EXPERIMENTAL|Group 1 Arm 1|Meropenem 6g IV over 6 hours plus amoxicillin/CA
62527410|NCT05896930|EXPERIMENTAL|Group 1 Arm 2|Ertapenem 1g IM plus amoxicillin/CA
62527411|NCT05896930|EXPERIMENTAL|Group 2 Arm 1|Meropenem 3g over 1 hour twice daily plus amoxicillin/CA
62527412|NCT05896930|EXPERIMENTAL|Group 2 Arm 2|Ertapenem 1g IV plus amoxicillin/CA
62527413|NCT05896930|EXPERIMENTAL|Group 2 Arm 3|Amoxicillin; CA
62527414|NCT05896930|EXPERIMENTAL|Group 2 Arm 4|Rifampicin 35mg/kg plus amoxicillin/CA
62527415|NCT05896930|EXPERIMENTAL|Group 2 Arm 5|Meropenem 6g or 4g IV over 60 minutes plus amoxicillin/CA
62527416|NCT05896930|ACTIVE_COMPARATOR|Group 1|Rifafour e-275
62527417|NCT01633411||Cohort A|Subjects in Cohort A will receive 6 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
61975671|NCT02060149|SHAM_COMPARATOR|no nebulization|Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.
62527418|NCT01633411||Cohort B|Subjects in Cohort B will receive 8 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
62527419|NCT01633411||Cohort C|Subjects in Cohort C will receive 10 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
62527420|NCT01389583|EXPERIMENTAL|AUY922|AUY922
62713573|NCT05642819||Cancer Resection|"* Patients with cancer (clinical, histological, cytological or radiological evidence) planned for surgical resection of a malignancy of the oesophagus, stomach, pancreas, colon, or rectum~* Aged 18-years and over~* Able to give written informed consent"
62713574|NCT05642819||Healthy Controls|"* Patients identified at surgical clinic as being planned for an open abdominal operation for a non-inflammatory, benign condition (e.g. donor nephrectomy)~* Aged 18-years and over~* Able to give written informed consent"
62153925|NCT04392648|EXPERIMENTAL|Expansion: TAK-573 + Pomalidomide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
62527421|NCT01411527||Cross- sectional cohort|Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children
62153926|NCT04392648|EXPERIMENTAL|Expansion: TAK-573 + Cyclophosphamide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m\^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
62153927|NCT02122042|EXPERIMENTAL|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
62153928|NCT02122042|OTHER|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
62153929|NCT04737889|EXPERIMENTAL|RL-MT|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen: Methotrexate, 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle, Temozolomide, 150mg/m2/d oral administration on day 1 to 10.~Consolidation Treatment: Autologous hematopoietic stem cell transplantation or reduced whole brain radiotherapy after high-dose chemotherapy.~Maintenance Treatment: Lenalidomide, 10mg oral administration on day 1 to 21 of each 4-week cycle for 12 months."
62153930|NCT05224388||Critically ill, prophylactic dose regimen|Prophylaxis of deep vein trombosis in critically ill patients
62153931|NCT05224388||Critically ill, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in critically ill patients
62153932|NCT05224388||Covid, prophylactic dose regimen|Prophylaxis of deep vein trombosis in Covid patients
62527422|NCT01411527||Longitudinal cohort|"209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).~116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children."
62527423|NCT06074081|EXPERIMENTAL|motor relearning program|Patients in this group will receive treatment through Motor-relearning programme. Patients will be instructed to perform multiple task like holding object, elbow extension/flexion and multiple movements of shoulder joint. This group will receive MRP for about time duration of 4 weeks,3 days per week,2 hours session per day.
62527424|NCT06074081|OTHER|mirror therapy|Patient in this group will receive treatment through mirror therapy. Patient will sit in such a way that the mirror will be placed in perpendicular direction on a table. Sound limb will place in front of mirror and affected limb will place behind the mirror. Patient will receive visual feedback from sound limb. This group will receive MT for about 4 weeks, 3 days per week, 2 hours session per day.
62527425|NCT05142566|EXPERIMENTAL|Ultrasound Closure|Open label, single arm study using ultrasound guidance during MANTA device deployment.
62527426|NCT03279211|EXPERIMENTAL|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
62527427|NCT03279211|EXPERIMENTAL|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
62527428|NCT03279211|OTHER|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
62527429|NCT00655876|EXPERIMENTAL|Chemoradiation + Cetuximab|External beam radiation therapy (RT) with concurrent weekly paclitaxel, cisplatin, and cetuximab
62527430|NCT00655876|ACTIVE_COMPARATOR|Chemoradiation|External beam radiation therapy with concurrent weekly paclitaxel, and cisplatin
62527431|NCT02991677|OTHER|control|This is an attention control group with regular contact by study staff.
62527432|NCT02991677|EXPERIMENTAL|aerobic exercise|Aerobic exercise intervention is for 12 weeks 3 times weekly with training on site.
62527433|NCT02991677|EXPERIMENTAL|resistive training|Intervention is for 12 weeks 3 times weekly with training on site.
62527434|NCT00045903|EXPERIMENTAL|Exposure and Ritual Prevention|Exposure and Ritual Prevention Therapy
62527435|NCT00045903|ACTIVE_COMPARATOR|Stress Management|Stress Management Therapy
62527436|NCT06356363||Cancer patient|Patient with cancer regardless of location or stage.
62527437|NCT01781000|EXPERIMENTAL|Auditiory verbal discrimination training|Brain Fitness \& Brain Training- Posit Science
62527438|NCT01781000|EXPERIMENTAL|Facial affect discrimination training|Behavioral: Facial Affect Training- FAT
62527439|NCT01781000|ACTIVE_COMPARATOR|Treatment as usual|standard treatment/rehabilitation protocol of schizophrenia ward
62527440|NCT01207648||Retrospective Cohort|Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
62527441|NCT05578365|EXPERIMENTAL|Pilates Group|Pilates method exercise program, performed online, 8 weeks long, twice a week + information on self-management and pain education once a week.
62527442|NCT05578365|ACTIVE_COMPARATOR|Control Group|Information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
62527443|NCT01177059|OTHER|Anti-HIV-1 Ribozyme (OZ1) transduced cells|OZ1 transduced cells Long term follow up of previously infused OZ1 transduced cells
62527444|NCT05726461|EXPERIMENTAL|AndroidAPS-rt-CGM|1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone
62713575|NCT00335829|EXPERIMENTAL|single arm, received bevacizumab and TACE|
62713576|NCT06629389|ACTIVE_COMPARATOR|Group CBD 100|The following dose regime for the 4 treatment arms will be used
62713577|NCT06629389|ACTIVE_COMPARATOR|Group CBD 300|The following dose regime for the 4 treatment arms will be used
62527445|NCT05726461|ACTIVE_COMPARATOR|sensor augmented pump(SAP)|SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
62527446|NCT00712426|ACTIVE_COMPARATOR|A|Randomized to receive creatine monohydrate (up to 40 grams daily)
62527447|NCT00712426|PLACEBO_COMPARATOR|B|Randomized to receive placebo (up to 40 grams daily)
62527448|NCT01571076|EXPERIMENTAL|Group B - Severe Male Factor|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
62527449|NCT01571076|EXPERIMENTAL|Group B - Advanced Age|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
62527450|NCT01571076|ACTIVE_COMPARATOR|Group A - Advanced Age|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
62713578|NCT06629389|ACTIVE_COMPARATOR|Group CBD 400|The following dose regime for the 4 treatment arms will be used
62713579|NCT06629389|PLACEBO_COMPARATOR|Group Placebo|The following dose regime for the 4 treatment arms will be used
62713580|NCT05926583|EXPERIMENTAL|Group 1: AAV5-hRKp.RPGR Low Dose|Participants will receive bilateral subretinal administration of AAV5-hRKp.RPGR low dose, with surgical delivery to the 2 eyes performed within 7 to 21 days apart.
62713581|NCT05926583|EXPERIMENTAL|Group 2: AAV5-hRKp.RPGR High Dose|Participants will receive bilateral subretinal administration of AAV5 hRKp.RPGR high dose, with surgical delivery to the 2 eyes performed within 7 to 21 days apart.
62713582|NCT02983240|EXPERIMENTAL|60 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
62153933|NCT05224388||Covid, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in Covid patients
62153934|NCT04430153||Low match|A group with both low observed and perceived upper limb ability.
62153935|NCT04430153||Good match|A group with both good observed and perceived upper limb ability.
62527451|NCT01571076|ACTIVE_COMPARATOR|Group A - Severe Male Factor|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.
62527452|NCT00578669|ACTIVE_COMPARATOR|1|Sequential antidepressant pharmacotherapy with (20mg) fluoxetine, begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
62527453|NCT00578669|PLACEBO_COMPARATOR|2|Sequential placebo medication (dextrose), begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
62527454|NCT03058653|EXPERIMENTAL|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
62527455|NCT02075827|ACTIVE_COMPARATOR|Problem-solving video game|Playing the video game 'Little Big Planet'
62527456|NCT02075827|EXPERIMENTAL|Competitive video game|Playing the video game 'Call of Duty'
62527457|NCT02655744||newly-diagnosed patients with primary CNS lymphoma|
62527458|NCT03050203|EXPERIMENTAL|custom pack|
62527459|NCT03050203|ACTIVE_COMPARATOR|standard care|
62527460|NCT03239886|EXPERIMENTAL|Discontinuation|All subjects will discontinue imatinib
62527461|NCT02923674|OTHER|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3)."
62527462|NCT02923674|OTHER|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass.~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
62527463|NCT02923674|OTHER|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
62527464|NCT01732874|OTHER|Expecta 200 mg|Breastfeeding mothers of pre-mature infants randomly assigned to 200 mg Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
62527465|NCT01732874|OTHER|Expecta 1 Gram|Breastfeeding mothers of pre-mature infants randomly assigned to one Gram of Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
62153936|NCT04430153||Mismatch|A group with good observed but low perceived function.
62153937|NCT02805075|EXPERIMENTAL|Supportive care (Fructooligosaccharide)|Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
62527466|NCT06194032|EXPERIMENTAL|Treatment Sequence ABCD|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (ABCD) in a crossover design with a washout period of at least 7 days between each study dose administration.
62713583|NCT02983240|EXPERIMENTAL|80 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
62736722|NCT04727450|ACTIVE_COMPARATOR|3. Physical training + CCPT (B+C)|Intervention of B \& C treatments.
62153938|NCT03571906|EXPERIMENTAL|Pre-rehab intervention|"Subjects in the prehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.~Periodic encouragements and consultations will be provided by exercise trainer, physiologist and nurse from the cardiac rehabilitation center. A physician will be available for consultations.~In addition to monitored physical activity, patients will receive nutritional and psychological counseling. This is part of a multi-professional rehabilitation program accepted by the rehabilitation center."
62153939|NCT03571906|NO_INTERVENTION|pre-operative usual care arm|"The control group will receive recommendations for a healthy and active lifestyle and physician follow-up~All subjects will undergo a stress test at baseline (post enrollment), and again prior to cardiac surgery."
62527467|NCT06194032|EXPERIMENTAL|Treatment Sequence BDAC|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (BDAC) in a crossover design with a washout period of at least 7 days between each study dose administration.
62153940|NCT04053491|EXPERIMENTAL|Axillary block group|Initial bolus will be given and then a perinervous catheter will be inserted by the axillary approach.
62713584|NCT02983240|EXPERIMENTAL|120 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
62153941|NCT04053491|EXPERIMENTAL|Infraclavicular block group|Initial bolus will be given and then a perinervous catheter will be inserted by the infraclavicular approach.
62153942|NCT04044885|EXPERIMENTAL|Nap|After each night with a 6.5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
62153943|NCT04044885|NO_INTERVENTION|No nap|After each night with a 8-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead have free time.
62527468|NCT06194032|EXPERIMENTAL|Treatment Sequence CADB|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (CADB) in a crossover design with a washout period of at least 7 days between each study dose administration.
62527469|NCT06194032|EXPERIMENTAL|Treatment Sequence DCBA|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (DCBA) in a crossover design with a washout period of at least 7 days between each study dose administration.
62527470|NCT04996563|EXPERIMENTAL|Video|A brief educational video on POP will be sent electronically to participants randomized to the video group. Participants will view the video within one week prior to their consultation visit.
62527471|NCT04996563|NO_INTERVENTION|No video|Participants assigned to this group will not be sent the educational video to view.
62527472|NCT04067336|EXPERIMENTAL|Phase 1a - Dose Escalation|
62527473|NCT04067336|EXPERIMENTAL|Phase 1b - Dose-Validation Expansion|"Cohort 1: KMT2A-r / NPM1-m patients will receive a dose previously studied in Phase 1a~Cohort 2: KMT2A-r / NPM1-m patients will receive a dose previously studied in Phase 1a"
62527474|NCT04067336|EXPERIMENTAL|Phase 2|NPM1-m patients will receive the recommended phase 2 dose determined in Phase 1
62153944|NCT05000359|OTHER|AYA Text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
62153945|NCT04645303|EXPERIMENTAL|Hyaluronic acid|1mL of hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1-pulley.
62153946|NCT04645303|ACTIVE_COMPARATOR|Triamcinolone acetonide|1 mL of Triamcinolone acetonide 10mg/ml infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1 pulley.
62153947|NCT05556200|EXPERIMENTAL|Experiment|"Eligible patients enrolled receive camrelizumab 200 mg, iv, d1, every 21 days (3 mg/kg if weight \<50 kg) in combination with apatinib 250 mg, po, qd for neoadjuvant treatment for 8 cycles.~Patients evaluated after neoadjuvant therapy with pCR receive 9 cycles of postoperative adjuvant camrelizumab (200 mg, iv, or 3 mg/kg if weight \<50 kg, d1,q3W) + apatinib (250 mg, po, qd).~Patients with non-pCR after neoadjuvant therapy receive adjuvant chemotherapy of the physician's choice (TPC)."
62153948|NCT05238337|EXPERIMENTAL|[14C]-PBI-200 Treated|\[14C\]-labeled PBI-200 will be administered as a single dose
62527475|NCT01844739|EXPERIMENTAL|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
62527476|NCT01844739|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
62527477|NCT02180126||Positive ANCA|Patients with borderline positive ANCA results.
62527478|NCT04418843|EXPERIMENTAL|Standard Endoscopic Mucosal Resection|Standard Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (\>20 mm)
62527479|NCT04418843|EXPERIMENTAL|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (\>20 mm)
62527480|NCT03727659|EXPERIMENTAL|SHADE therapy + CONNECT FaceBook support|SHADE is a 10-week, 10-session, computerized CBT/MET intervention for Cannabis Use Disorder and depression. At each visit, a study clinician meets with participants for a 'check-in' session, which includes: review of homework; plans for completing homework; suicide risk and mood assessment. The CONNECT FB intervention component will facilitate social support for between-session homework and CBT skills practice for managing depression and preventing relapse, and bolstering motivation to change. Daily posts will be delivered. Only those participating in the study will know about the existence of this group and will be able to access it. A weekly real-time, Facebook chat session will be held to provide feedback concerning homework practice or answer questions.
62527481|NCT02981303|EXPERIMENTAL|Melanoma|Imprime PGG + Pembrolizumab
62527482|NCT02981303|EXPERIMENTAL|Triple Negative Breast Cancer|Imprime PGG + Pembrolizumab
62713585|NCT04586270|EXPERIMENTAL|TAS0612 Escalation|TAS0612 administered orally
62713586|NCT04586270|EXPERIMENTAL|TAS0612 Expansion|TAS0612 administered orally
62736723|NCT04727450|ACTIVE_COMPARATOR|4. CCPT + Cognitive training (C+A)|Intervention of C \& A treatments.
62527483|NCT01321463|EXPERIMENTAL|PH-797804|
62527484|NCT01321463|PLACEBO_COMPARATOR|Placebo|
62527485|NCT02184559|EXPERIMENTAL|TAP block|
62527486|NCT02184559|ACTIVE_COMPARATOR|infiltration continues|
62153949|NCT02744105|EXPERIMENTAL|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
62527487|NCT03163004|EXPERIMENTAL|Intervention group|Implementation of standing desks in the classroom
62527488|NCT03163004|NO_INTERVENTION|Control group|
62527489|NCT04340921||1. COVID-19+ (n=120)|"COVID-19 positive without evidence of myocardial injury (n=120). Inclusion criteria: All adult (age≥18 but \<100 years of age) inpatients with confirmed COVID-19 infection.~Exclusion criteria: No biochemical evidence of acute myocardial injury (serum troponin\>99th centile within previous 48-hour period)."
62527490|NCT04340921||2. COVID-19+ Myocardial injury+ (n=20)|"COVID-19 positive with myocarditis (n=20). Inclusion criteria: All adult (age≥18 but \<100 years of age) inpatients with confirmed COVID-19 infection and clinically suspected or confirmed myocarditis including evidence of acute myocardial injury (troponin \>99th centile within the previous 48-hour period) at the time of recruitment.~Exclusion criteria: significant chronic kidney disease (eGFR ≤30 or dialysis-dependent) or septic shock at the time of initial assessment. We will also exclude patients with a diagnosis of chronic heart muscle disease and those with known significant chronic or acute obstructive coronary disease."
62527491|NCT04340921||3. COVID-19+ Complication+ (estimated 10-25%)|Inclusion criteria: Participants form Groups 1 and 2 in whom a prespecified complication ocurs will be included in a derived Group3.
62527492|NCT01783249|NO_INTERVENTION|Control|Usual care monitoring
62527493|NCT01783249|OTHER|Exercise using stationary cycling|Stationary cycling exercise program
62527494|NCT01453894|EXPERIMENTAL|Reminder and Outreach Intervention|Participants randomized to this arm will receive the Reminder and Outreach intervention.
62527495|NCT01453894|NO_INTERVENTION|Usual Care Control Group|Patients assigned to this arm will receive usual care.
62527496|NCT04341857|EXPERIMENTAL|Sintilimab combined with FLOT regimen|Oxaliplatin#80mg/m2d1#iv infusion for 2 hours# Calcium leucovate#200mg/m2d1#iv infusion# Fluorouracil#2600mg/m2,intravenous drip for 24h# Docetaxel#50mg/m2,intravenous drip for 1 h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
62527497|NCT03743792|EXPERIMENTAL|Active|Freeze-dried red raspberry powder (25 g) in active breakfast meal
62527498|NCT03743792|PLACEBO_COMPARATOR|Placebo|Placebo breakfast
62527499|NCT06185335|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will receive ANB-010 at a dose 1. ANB-010 will be administered to the first subject in group 1. Not earlier than in 28 days, the investigational product will be administered to the next two subjects in Cohort 1 (with an interval of at least 24 hours).
62527500|NCT06185335|EXPERIMENTAL|Cohort 2|Subjects in Cohort 1 will receive ANB-010 at a dose 1. Not earlier than 28 days after the ANB-010 administration to the third subject in Cohort 1, the investigational product will be administered to the first subject in Cohort 2. Not earlier than 28 days after the ANB-010 administration to the first subject in Cohort 2, the investigational product will be administered to the next two subjects in Cohort 2 (with an interval of at least 24 hours).
62527501|NCT06185335|EXPERIMENTAL|Cohort 3|Subjects in Cohort 1 will receive ANB-010 at a dose 1. Not earlier than 28 days after the ANB-010 administration to the third subject in Cohort 2, the investigational product will be administered to the first subject in Cohort 3. Not earlier than 28 days after the ANB-010 administration to the first subject in Cohort 3, the investigational product will be administered to the next two subjects in Cohort 3 (with an interval of at least 24 hours).
62527502|NCT02187510|EXPERIMENTAL|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
62527503|NCT02187510|ACTIVE_COMPARATOR|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
62527504|NCT00587600|ACTIVE_COMPARATOR|Photodynamic therapy|will have photodynamic therapy
62527505|NCT00587600|ACTIVE_COMPARATOR|radiofrequency ablation of barretts esophagus|radiofrequency ablation of barretts esophagus
62527506|NCT00026364|EXPERIMENTAL|Arm I|"Patients receive oral ZD 1839 daily. Beginning on day 15, patients receive irinotecan IV over 90 minutes, leucovorin calcium IV over 15 minutes, and fluorouracil IV weekly on weeks 1-2. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of ZD 1839 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are accrued to receive treatment at the MTD."
62153950|NCT02744105|NO_INTERVENTION|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
62153951|NCT06092905||Pregnant women with symptomatic common bile duct stones|Pregnant women with symptomatic common bile duct stones
62153952|NCT00476957|ACTIVE_COMPARATOR|1|Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
62527507|NCT04241666||normal renal function|individuals with renal clearance \>89 ml/min/1.73m²
62527508|NCT04241666||mild renal insufficiency|individuals with renal clearance 60-89 ml/min/1.73m²
62527509|NCT04241666||moderate renal insufficiency|individuals with renal clearance 30-59 ml/min/1.73m²
62527510|NCT01900483||pre bariatric surgery|
62153953|NCT00476957|ACTIVE_COMPARATOR|2|Cordis Cypher® Sirolimus-eluting Coronary Stent
62153954|NCT04733417|EXPERIMENTAL|SHR6390+famitinib|Participants will receive SHR6390 in combination with famitinib.
62527511|NCT01900483||post bariatric surgery|
62527512|NCT03285308|PLACEBO_COMPARATOR|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
62527513|NCT03285308|EXPERIMENTAL|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 μg injected subcutaneously twice daily for up to 12 weeks.
62736724|NCT04727450|NO_INTERVENTION|5. Control group|No intervention
62527514|NCT03073785|ACTIVE_COMPARATOR|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
62153955|NCT02424305|EXPERIMENTAL|face: LEO 43204 gel 0.018%|3 days treatment (once daily) on face: LEO 43204 gel 0.018%
62153956|NCT02424305|EXPERIMENTAL|arm: LEO 43204 gel 0.1%|3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
62153957|NCT02424305|EXPERIMENTAL|scalp: LEO 43204 gel 0.037%|3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%
62153958|NCT03093532|NO_INTERVENTION|Usual Care|The Usual Care group arm will received pre-printed discharge instructions and an outpatient referral. (This group represents standard of care.)
62153959|NCT03093532|ACTIVE_COMPARATOR|ED SBIRT-HTN|"The ED SBIRT-HTN (The Emergency Department Screening Brief Intervention and Referral for Treatment) arm consists of a series of risk assessment tools (surveys, video, and noninvasive bedside assessments) designed to be efficient, patient-centered and educational for participants in an emergency department setting. Through the intervention, participants will learn more about hypertension management and complications associated with uncontrolled BP. Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
62153960|NCT03093532|ACTIVE_COMPARATOR|E SBIRT-HTN + PACTH-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
62153961|NCT04543669|EXPERIMENTAL|Adacel®|All participants will receive one booster dose of commercially available Adacel® (TdaP-Tetanus, diphtheria, acellular pertussis) vaccine
62153962|NCT01334606|EXPERIMENTAL|Nano: 4mm x 32G Pen Needle|Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
62527515|NCT03073785|EXPERIMENTAL|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
62527516|NCT01736241|EXPERIMENTAL|LY3053102|A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level.
62527517|NCT01736241|PLACEBO_COMPARATOR|Placebo|A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks.
62527518|NCT05703373|EXPERIMENTAL|Multiple Micronutrient Supplement (MMS) supplied to clinic|
62527519|NCT03172663|EXPERIMENTAL|group 1|
62527520|NCT03172663|ACTIVE_COMPARATOR|group 2|
62527521|NCT03011190|EXPERIMENTAL|Iconic Therapy|The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients. Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
62527522|NCT03011190|ACTIVE_COMPARATOR|Support therapy|Support therapy consist of 10-12 weekly group sessions of 60-minute duration. Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
62527523|NCT01434186|EXPERIMENTAL|Arm 1: Saxagliptin +Metformin XR/IR|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg
62527524|NCT01434186|PLACEBO_COMPARATOR|Arm 2: Placebo +Metformin XR/IR|Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg
62153963|NCT01334606|EXPERIMENTAL|Short: 8mm x 31G Pen Needle|Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
62153964|NCT03374722||Mechanically ventilated critically ill patients|Mechanically ventilated critically ill patients who receive opioid as continuous infusion for more than 24 hours
62153965|NCT05731440||Healthy participants|"Drug: \[18F\]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: \[11C\]-Pittsburgh Compound (\[11C\]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET certified professional will prepare and administer the \[11C\]-PIB tracer. Participants will receive the PIB injection followed by 10 ml 0.9% sodium chloride (normal saline) flush."
62527525|NCT00701948||A-1|Proven nosocomial bacterial infection (NBI)
62527526|NCT00701948||A-2|Possible NBI
62527527|NCT00701948||B-1|Absence of NBI
62527528|NCT00701948||B-2|Probable absence of NBI
62527529|NCT04921020||Normal participants|
62527530|NCT04921020||Patients with blepharoptosis|
62527531|NCT04921020||Patients with blepharospasm|
62527532|NCT04921020||Patients with dry eye disease|
62527533|NCT04921020||Patients with Graves' disease|
62527534|NCT03433144|EXPERIMENTAL|Intervention TXA|patients receiving TXA10mg/kg IV pre-operatively
62153966|NCT05731440||Participants with mild cognitive impairment|"Drug: \[18F\]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: \[11C\]-Pittsburgh Compound (\[11C\]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET certified professional will prepare and administer the \[11C\]-PIB tracer. Participants will receive the PIB injection followed by 10 ml 0.9% sodium chloride (normal saline) flush."
62153967|NCT01578304|EXPERIMENTAL|Imidafenacin|
62527535|NCT03433144|PLACEBO_COMPARATOR|Placebo|patients will receive an equivalent amount of normal saline 0.9% IV pre-operatively
62527536|NCT02381951|EXPERIMENTAL|Spinal cord stimulation|
62527537|NCT01385982|OTHER|Actionable Test Results|"Creating standardized policies and procedures around actionable test results (ATR) management, and implementing them network-wide:~1. Defining the levels of severity and urgency for clinically significant test results~2. Network-wide policy for test result follow-up by the responsible providers, documentation and escalation processes to assure timely communication.~3. Standardized policies for the time frames and nature of communication of test result alerts.~4. Establish criteria for appropriate ATR management by the responsible provider.~5. Feedback performance including provider, practice and service report cards"
62527538|NCT03346486|PLACEBO_COMPARATOR|Control diet|Regular diet
62527539|NCT03346486|ACTIVE_COMPARATOR|Intervention diet|Brainfood diet
62527540|NCT01317355||cancer patients|in and out patients of 5 German university hospitals currently undergoing cancer treatment
62527541|NCT00658645|EXPERIMENTAL|Bifeprunox|
62713587|NCT00285844|EXPERIMENTAL|pioglitazone|IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention
62153968|NCT01578304|ACTIVE_COMPARATOR|Fesoterodine|
62153969|NCT00068809|EXPERIMENTAL|Short-cycle therapy (SCT)|At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
62153970|NCT02734784|EXPERIMENTAL|Photodynamic Therapy and SRP|
62153971|NCT02734784|SHAM_COMPARATOR|SRP and Sham Photodynamic Therapy|
62153972|NCT01767025|EXPERIMENTAL|Oxytocin|Oxytocin 24 IU (3 puffs) per nostril
62153973|NCT01767025|PLACEBO_COMPARATOR|Sea water|Sea water 3 puffs per nostril
62153974|NCT01779089|EXPERIMENTAL|Minocycline|Minocycline 100 mg po bid for 6 months
62153975|NCT01779089|PLACEBO_COMPARATOR|Placebo|Placebo one tablet po bid
62153976|NCT02869230|OTHER|Radioguided occult lesion localization|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
62153977|NCT02869230|EXPERIMENTAL|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
62153978|NCT00257556|EXPERIMENTAL|Menotrophin|
62153979|NCT00257556|ACTIVE_COMPARATOR|Follitropin alfa|
62527542|NCT00658645|PLACEBO_COMPARATOR|Placebo|
62527543|NCT00658645|ACTIVE_COMPARATOR|Quetiapine|
62527544|NCT01097525|ACTIVE_COMPARATOR|Wavefront guided (WFG) PRK|
62527545|NCT01097525|ACTIVE_COMPARATOR|WFG LASIK|
62713588|NCT00285844|EXPERIMENTAL|Dietary Weight Loss|IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention
62153980|NCT02813733||Thyroid surgery|All patients who underwent a thyroid procedure in 5 high volume referral centers in France were eligible for inclusion.
62153981|NCT02226237|NO_INTERVENTION|Control Group|in which patients received no specific treatment, only the usual general guidelines
62153982|NCT02226237|EXPERIMENTAL|group of pelvic floor exercises|in which patients were instructed to perform home exercises daily
62527546|NCT01097525|ACTIVE_COMPARATOR|Wavefront optimized (WFO) PRK|
62527547|NCT01097525|ACTIVE_COMPARATOR|WFO LASIK|
62527548|NCT05157867|EXPERIMENTAL|Amylase trypsin inhibitors (ATIs), then placebo|Test day 1: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline. After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of placebo (physiological saline).
62527549|NCT05157867|EXPERIMENTAL|Placebo, then Amylase trypsin inhibitors|Test day 1: intraduodenal administration of placebo (physiological saline). After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline.
62527550|NCT06219226|EXPERIMENTAL|Chlorine dioxide mouthwash|Participants will rinse once with hyper-pure ClO2 (0.003%) mouthwash.
62527551|NCT06219226|ACTIVE_COMPARATOR|Chlorhexidine mouthwash|Participants will rinse once with chlorhexidine-containing mouthwash (0.2%).
62713589|NCT06141928|OTHER|Functional Recovery|
62713590|NCT06112301||B-Cell Positive Lymphoproliferative Disorders|DNA Samples for subjects with B-Cell Positive Lymphoproliferative Disorders
62736725|NCT05073484|EXPERIMENTAL|10 mg of BAT6021|BAT6021 100mg/vial，10mg Ⅳ infusions
62153983|NCT02226237|EXPERIMENTAL|anal electrostimulation group|in which patients, and are instructed to perform the exercises mentioned in the group of pelvic floor exercises, also underwent anal electrostimulation
62153984|NCT03264222|OTHER|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
62527552|NCT00468650|ACTIVE_COMPARATOR|Open label|Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
62527553|NCT02138019|EXPERIMENTAL|Fibrin glue|In ophthalmic field, the use of organic glues has provided good results for the repair of leaking blebs and perforated corneal ulcers, conjunctival closure in strabismus surgery, surgery for retinal detachment, cataract surgery, trabeculectomy, and mucous membrane grafting to repair lesions of the conjunctival fornix. In this study, the investigators try to evaluate the effect of Fibrin Glue assisted external eye surgery.
62527554|NCT02182869|EXPERIMENTAL|Combivent® HFA|
62527555|NCT02182869|ACTIVE_COMPARATOR|Combivent® CFC|
62527556|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
62527557|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
62527558|NCT02296021|EXPERIMENTAL|berberine quadruple therapy|Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.
62153985|NCT06015659|EXPERIMENTAL|ZN-c3 + Gemcitabine|"Study procedures will be conducted as follows:~* Cycle 1 - End of Treatment~  * Days 1 - 5 of 21-day cycle: Predetermined dose of ZN-c3 1x daily.~ * Days 8 - 12 of 21-day cycle: Predetermined dose of ZN-c3 1x daily.~ * Days 15 - 19 of 21-day cycle: Predetermined dose of ZN-c3 1x daily.~ * Day 1 and 8 of 21-day cycle: Predetermined dose of Gemcitabine 1x daily.~* On-treatment tumor biopsy will be collected on either Cycle 1 Day 9 - 10 or Cycle 2 Day 9 - 10.~* Tumor assessment by Computerized Tomography (CT) or Magnetic Resonance Imaging scan every 8 weeks while on treatment.~* End of treatment visit with tumor assessment by CT or MRI and optional tumor biopsy.~* Follow up visit every 2 months after treatment has ended."
62153986|NCT05497804|EXPERIMENTAL|Treatment (combination chemotherapy)|"INDUCTION: Patients receive carfilzomib IV on days 2, 8, and 15 of cycle 1 and days 1, 8, and 15 of cycles 2-12, lenalidomide PO days 1-21 of each cycle, daratumumab SC days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, and dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive carfilzomib IV on days 1, 8, and 15, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive carfilzomib IV on day 1, lenalidomide PO days 1-21, daratumumab day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy, MRI and, CT/PET."
62527559|NCT02296021|ACTIVE_COMPARATOR|bismuth quadruple therapy|Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62527560|NCT02618408|EXPERIMENTAL|Low dose SPN-810 (18 mg)|Oral
62527561|NCT02618408|EXPERIMENTAL|High dose SPN-810 (36 mg)|Oral
62527562|NCT02618408|PLACEBO_COMPARATOR|Placebo|Oral
62527563|NCT02327416|ACTIVE_COMPARATOR|1,conventional control group|Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
62527564|NCT02327416|EXPERIMENTAL|2，combination and sequential group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
62527565|NCT02327416|EXPERIMENTAL|3, multitarget group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
62527566|NCT03752463|EXPERIMENTAL|DAOI-A group|
62527567|NCT03752463|EXPERIMENTAL|DAOI-B group|
62527568|NCT03752463|EXPERIMENTAL|DAOI-C group|
62527569|NCT03752463|PLACEBO_COMPARATOR|Placebo group|
62527570|NCT05325593|EXPERIMENTAL|romiplostim plus dexamethasone (ROM + DEX)|"Dexamethasone 40 mg daily x 4 days only in the first cycle and subcutaneous romiplostim weekly for up to 12 months~Romiplostim:~1. The starting dose should be 3 mcg/kg/week. It could be start during de 4 days of dexamethasone.~2. Patients will weekly receive dose increases of romiplostim in increments of 1 mcg/kg up to a maximum dose of 10 mcg/kg in an attempt to reach a target platelet count higher than 50x109/L.~3. Otherwise, if platelets are lower than 50x109/L treatment with romiplostim will go on until Day 365 since randomization."
62527571|NCT05325593|ACTIVE_COMPARATOR|Dexamethasone (DEX)|Dexamethasone 40 mg daily x 4 days for up to 3 cycles every 14 to 28 days
62527572|NCT05034276|EXPERIMENTAL|MORE-VR|Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.
62527573|NCT02839148|EXPERIMENTAL|Dietary supplementation|In case of dietary supplementation, we will provide milk and egg 6 days a week for 3 months to stunted children.
62527574|NCT02839148|EXPERIMENTAL|psychosocial stimulation|In case of psychosocial stimulation, we well provide PS weekly for first month, fortnightly for 2nd and 3rd months and then monthly for next 3 months. The total number of visits will be 11 over a period of 6 months.
62527575|NCT06283576||Pancreatic cancer, early|Early pancreatic cancer, T1/T2 NoM0
62527576|NCT06283576||IPMN|
62527577|NCT06283576||Pancreatic cancer, advanced|Advance pancreatic cancer T1-4, Nx, Mx
62527578|NCT06283576||Healthy controls|
62527579|NCT02632513|EXPERIMENTAL|continuous ultrasonic irrigation|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
62527580|NCT02632513|NO_INTERVENTION|Syringe irrigation|In the syringe irrigation group, irrigation was done using 27 gauge syringe.
62527581|NCT01272726||ADHD|Women with symptoms of ADHD. Women who either think they may have ADHD or have been previously diagnosed with ADHD but have not been treated for it.
62527582|NCT03996161|ACTIVE_COMPARATOR|Supine position|After the induction of anesthesia, mask ventilation is performed in the supine position.
62527583|NCT03996161|EXPERIMENTAL|Semi-sitting position|After the induction of anesthesia, mask ventilation is performed in the semi-sitting position.
62527584|NCT02709252|EXPERIMENTAL|Cohort|Only one cohort is included with comparisons of two different hemodynamic parameters
62527585|NCT05854823|EXPERIMENTAL|de-escalation radiotherapy|Postoperative radiotherapy alone
62527586|NCT04714320|EXPERIMENTAL|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered subcutaneously once-weekly for 12 weeks.
62527587|NCT04714320|PLACEBO_COMPARATOR|Placebo|IONIS-AGT-LRx-matching placebo will be administered subcutaneously once-weekly for 12 weeks.
62713591|NCT06112301||B-Cell Negative Lymphoproliferative Disorders|DNA Samples for subjects suspected of B-Cell Positive Lymphoproliferative Disorders with negative B-Cell Clonality testing
62713592|NCT06715319|EXPERIMENTAL|OCA and UDCA|"OCA 5 mg once daily for 3 months and then titrating up to 10 mg based on tolerability and response.~Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA."
62713593|NCT06715319|PLACEBO_COMPARATOR|Placebo and UDCA|Placebo once daily. Subjects receiving UDCA continued taking UDCA throughout the trial.
62153987|NCT02111499|EXPERIMENTAL|formulation 1|topical treatment, once daily for 4 weeks
62153988|NCT02111499|EXPERIMENTAL|formulation 2|topical treatment, once daily for 4 weeks
62527588|NCT02309775|ACTIVE_COMPARATOR|Auriculotherapy Group|The placement, points according to Souza (1997), will be: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. The point descriptions are: Shen Men, is located in the vertex of the angle formed by the lower root and the upper root of the antihelix; the Sympathetic is situated in the middle of the lower root below the Helix membrane (located at the lower end of the Lobe); the Kidney point is situated in cymba concha, near its junction with the lower root of the antihelix, in the same line as the Shen Men point; the Subcortex is situated on upward curve towards the apex of the antitragus, on the upper edge of the concha; the Adrenal is located at the apex of the tragus, on its projection towards the concha cava; the Cerebral point is situated above the edge of the antitragus. As sessions will held twice a week for a total of 10 sessions.
62713594|NCT03943901|EXPERIMENTAL|Split Dose R-CHOP|"Each cycle is 28 days and consists of one A treatment on Day 1 and one B treatment on Day 15 for 6 cycles~Day 1 (A part of cycle)~* Rituximab 375 mg/m2 IV (or biosimilars Ruxience or Truxima)~* Cyclophosphamide 375 mg/m2 IV~* Doxorubicin 25 mg/m2 IV~* Vincristine 1 mg IV~* Prednisone 50 mg (Days 1-5) PO~* Pegfilgrastim (supportive care) 6 mg on Day 2 (24 hours after completion of chemotherapy) or filgrastim daily as institutionally indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor.~Day 15 (B part of cycle)~* Cyclophosphamide 375 mg/m2 IV~* Doxorubicin 25 mg/m2 IV~* Vincristine 1 mg IV~* Prednisone 50 mg (Days 15-19) PO~* Pegfilgrastim (supportive care) 6 mg on Day 16 (24 hours after completion of chemotherapy) or filgrastim daily as institutionally indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor."
62153989|NCT02111499|EXPERIMENTAL|formulation 3|topical treatment, once daily for 4 weeks
62153990|NCT02111499|EXPERIMENTAL|formulation 4|topical treatment,once daily for 4 weeks
62153991|NCT02111499|PLACEBO_COMPARATOR|formulation 5|topical treatment, once daily for 4 weeks
62153992|NCT02111499|ACTIVE_COMPARATOR|formulation 6|topical treatment, once daily for 4 weeks
62153993|NCT03996577|PLACEBO_COMPARATOR|control group|the control group will be given the same volume of saline as the experimental group
62153994|NCT03996577|EXPERIMENTAL|Experimental: lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
62153995|NCT00826982||Pancreatic Cancer|
62153996|NCT00045201|EXPERIMENTAL|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62153997|NCT04086342|ACTIVE_COMPARATOR|CHI-902|Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
62153998|NCT04086342|PLACEBO_COMPARATOR|Placebo|Study subjects will enter a titration phase of 1 week with a daily oral dose of 150 mg (50 mg three times daily) of matching placebo. Then, daily dose of 300 mg of matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
62153999|NCT00689195|EXPERIMENTAL|C|Curcumin
62154000|NCT00689195|EXPERIMENTAL|A|Ashwagandha extract
62154001|NCT02804074|ACTIVE_COMPARATOR|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
62154002|NCT02804074|EXPERIMENTAL|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
62154003|NCT05749562||Adolescent Idiopathic Scoliosis with right thoracic or thoraco-lumbar curvature|Patients will be treated with a Cheneau-Toulouse-Munster (CTM) brace, with a wearing time of more than 12 hours/24h, for more than 1 month.
62154004|NCT00413283|PLACEBO_COMPARATOR|Placebo|Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
62154005|NCT00413283|EXPERIMENTAL|Romiplostim 250 μg|Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
62154006|NCT00413283|EXPERIMENTAL|Romiplostim 500 μg|Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
62154007|NCT00413283|EXPERIMENTAL|Romiplostim 750 μg|Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
62154008|NCT02134626|EXPERIMENTAL|Simvastatin|Arm 1: Simvastatin 40mg / pill, one pill once a day for three months
62154009|NCT02134626|PLACEBO_COMPARATOR|Placebo pill|Arm 2: Placebo one pill once a day for three months
62154010|NCT04180072|EXPERIMENTAL|Atezolizumab plus bevacizumab|Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Study treatment will continue until documented tumor progression or occurrence of unacceptable toxicity.
62154011|NCT00332852|EXPERIMENTAL|Letrozole|
61975672|NCT02060149|ACTIVE_COMPARATOR|nebulization with pH 7.4 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).
62154012|NCT01394406|EXPERIMENTAL|Ketamine group|
62154013|NCT01394406|PLACEBO_COMPARATOR|Saline group|
62154014|NCT03001141||Single group - observational|
62527589|NCT02309775|PLACEBO_COMPARATOR|Placebo Grup|The point stimulated will be the Trachea, which is one millimeter in the direction of the auditory meatus. This point does not cause risk to the research participant. As sessions will held twice a week for a total of 10 sessions.
62527590|NCT01660399|EXPERIMENTAL|Docetaxel/Boanmycin|Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
62527591|NCT01660399|PLACEBO_COMPARATOR|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1, 21days a cycle.
62527592|NCT01728402||Blood Draw|
62154015|NCT01336907||naive CNV subjects|Newly diagnosed CNV, before any treatment (naïve)
62154016|NCT01336907||previously diagnosed CNV subjects|Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
62154017|NCT02918045|EXPERIMENTAL|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
62154018|NCT02918045|ACTIVE_COMPARATOR|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions involves the placement of an absorbable oxidized cellulose gauze Surgicel (Ethicon, Inc, San Angelo, TX) into the extraction socket. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard local hemostatic care for oral surgery subjects.
62154019|NCT05901688||Unselected population|Routine unselected populations at 20-22 weeks and 35-37 weeks
62154020|NCT05901688||High risk population|High-risk pregnancies attending the placental disorders clinic which have been deemed to be at risk of having adverse pregnancy outcomes.
62154021|NCT06483698||Sublobar resection group|Patients in this group have received Sublobar resection.
62527593|NCT02543619|ACTIVE_COMPARATOR|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
62527594|NCT02543619|ACTIVE_COMPARATOR|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
62154022|NCT06483698||Lobectomy group|Patients in this group have received lobectomy.
62154023|NCT05713136||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing
62527595|NCT03844958|EXPERIMENTAL|Red Furu|Volunteer was randomized into group red furu
62527596|NCT03844958|EXPERIMENTAL|Fresh Tofu|Volunteer was randomized into group tofu
62527597|NCT04435821|EXPERIMENTAL|Pediatric Chronic Pain Patients|Individuals 11-18 years old, with chronic pain (lasting at least 2 months).
62154024|NCT02239991|NO_INTERVENTION|Historical control|Group of patients that had their coagulopathy secondary to the liver transplant treated based on conventional laboratory tests. Before the implementation of thromboelastometry.
62154025|NCT02239991|EXPERIMENTAL|Intervention|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
62154026|NCT05711589|PLACEBO_COMPARATOR|conventional group|cryoablation (CBA) was performed under fluoroscopic guidance
62154027|NCT05711589|EXPERIMENTAL|Zero-X group|CBA was performed under intracardiac echocardiography guidance without fluoroscopy
62154028|NCT01944774|EXPERIMENTAL|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL.
62527598|NCT03710720|EXPERIMENTAL|TF-CBT plus TIPS app|
62527599|NCT03710720|ACTIVE_COMPARATOR|TF-CBT|
62527600|NCT02590835|ACTIVE_COMPARATOR|Control group|Treated with conventional orthodontics
62527601|NCT02590835|EXPERIMENTAL|Test group|subjected to piezo-assisted orthodontics
62527602|NCT06256913||Patients with sarcomeric hypertrophic cardiomyopathy and cardiovascular events|Patients with confirmed sarcomeric hypertrophic cardiomyopathy who experienced cardiovascular events.
62527603|NCT06256913||Patients with sarcomeric hypertrophic cardiomyopathy free of cardiovascular events|Patients with confirmed sarcomeric hypertrophic cardiomyopathy free of cardiovascular events.
62527604|NCT00121316|EXPERIMENTAL|1|Pimecrolimus
62527605|NCT00121316|PLACEBO_COMPARATOR|2|Matching vehicle cream (placebo)
62527606|NCT01204450|OTHER|Single Arm Temsirolimus + Valproic Acid|"Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses~Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses"
62527607|NCT01401621|EXPERIMENTAL|Scratch-Off Test Name Condition|The name of the test the recipient needs is hidden behind a scratchoff on the reminder
61975673|NCT02060149|EXPERIMENTAL|nebulization with pH 7.8 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).
62154029|NCT01944774|EXPERIMENTAL|Nemonoxacin 650 mg|Nemonoxacin 650 mg/325mL
62527608|NCT01401621|EXPERIMENTAL|Scratch-Off Call to Action Condition|The recipient will be prompted to scratch-off the paper in order to find out how to follow the recommendation that the test be received.
62527609|NCT01401621|EXPERIMENTAL|Control Condition|A control condition with no scratch-off element.
62527610|NCT02400242|EXPERIMENTAL|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
62527611|NCT03233230|PLACEBO_COMPARATOR|Placebo|
62154030|NCT01944774|ACTIVE_COMPARATOR|Moxifloxacin 400 mg|Moxifloxacin 400mg/250mL
62154031|NCT06121778||Home|Elderly people living at home
62154032|NCT05947071|EXPERIMENTAL|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|Two doses of SD-QIV (0.5 mL; 15µg of each influenza antigen) 28-42 days apart
62154033|NCT05947071|EXPERIMENTAL|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|Two doses of HD-QIV (0.7 mL; 60µg of each influenza antigen) 28-42 days apart
62527612|NCT03233230|EXPERIMENTAL|M2951 25 mg QD|
62527613|NCT03233230|EXPERIMENTAL|M2951 75 mg QD|
62527614|NCT03233230|EXPERIMENTAL|M2951 50 mg BID|
62713595|NCT03767881|EXPERIMENTAL|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
62527615|NCT03940794|EXPERIMENTAL|Verbal instruction|"The participants will be instructed to contract the pelvic floor muscle with the following verbal instruction: (1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.Those who will not be able to contract will be taught by the ultrasound as biofeedback."
62527616|NCT05376709|EXPERIMENTAL|Short-Term Calorie Reduction(SCR)|To determine the short-term impact of calorie modification on patient outcomes by measuring and comparing the following parameters between two groups a week after starting each R-CHOP cycle: symptoms, hematologic parameters (i.e., erythrocyte-, thrombocytes-, and leucocyte counts), metabolic parameters (i.e., insulin, glucose, insulin growth factor 1), inflammatory response (C-reactive Protein, CRP), and nutrition status (i.e., weight, albumin level, and lean body mass (LBM)).
62527617|NCT05376709|NO_INTERVENTION|Control|Participated patients will be recruited and randomized to two groups: comparison group who receive standard care and experimental group who receive the SCR intervention. The standard care at NTUH includes encouraging patients to eat healthy and clean diet (e.g., avoid raw or undercooked food). There are no calorie restriction to the comparison group. The next paragraph describes the SCR intervention for experimental group.
62527618|NCT02185651|ACTIVE_COMPARATOR|Zavesca® 100 mg|"3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
62527619|NCT02185651|ACTIVE_COMPARATOR|Zavesca® 300 mg|"3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
62154034|NCT05902572||HIV treatment survey participants|HIV treatment patients eligible to be enrolled in the patient survey
62154035|NCT05902572||Provider survey participants|HIV treatment providers eligible to be enrolled in the provider survey
62527620|NCT03829696|EXPERIMENTAL|Non-pregnant women|"Participants will be provided Mifeprex® (oral mifepristone 200 mg) and misoprostol 800 mcg to be administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone) if unintended pregnancy occurs during the study period and the participant would like to end of the pregnancy. Participants who test positive for pregnancy will consult with a study clinician over the phone prior to administering mifepristone and misoprostol, and will then attend an in-person follow-up visit.~All participants will be provided with a single dose of ella® (ulipristal acetate emergency contraception 30 mg) by a clinician at the beginning of the study, as well as 6 AccuHome® midstream urine pregnancy tests."
62527621|NCT01882075|ACTIVE_COMPARATOR|Open loop|fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
62527622|NCT01882075|EXPERIMENTAL|Closed-loop|Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.
62154036|NCT05902572||Time and motion observation participants|HIV treatment providers eligible to be enrolled in the time and motion observation study
62154037|NCT05902572||HIV testing survey participants|Individuals presenting for HIV testing eligible to be enrolled in the HIV testing survey
62154038|NCT04610606|EXPERIMENTAL|Multimodal intervention (MM)|Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization (diet + mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids) and relaxation strategies.
62154039|NCT04610606|NO_INTERVENTION|Standard of care (SOC)|Education on benefits of physical activity and healthy diet, with no specific information.
62154040|NCT02198105||Femoropopliteal stenosis|"Consecutive patients with symptomatic peripheral artery disease due to femoro-popliteal stenosis/occlusion.~Intervention with Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon-PTA."
62154041|NCT01916057|EXPERIMENTAL|18F-FDG PET Scan|18F-FDG PET Scan at Day 0 and M3
62154042|NCT04412174|EXPERIMENTAL|GC022F|The patients will receive GC022F CAR-T treatment. GC022F dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg.
62154043|NCT03166215|PLACEBO_COMPARATOR|Part 1: Placebo|TAK-935 matching-placebo tablets, orally or through gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) from Days 1 to 30 in dose titration period.
62154044|NCT03166215|EXPERIMENTAL|Part 1: TAK-935|TAK-935 100 mg, tablet, orally or through G-tube/PEG tube, BID from Days 1 to 10 followed by TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 11 to 20 followed by TAK-935 100 mg tablets x3, orally or through G-tube/PEG tube, BID from Days 21 to 30 in dose titration period. The dose of TAK-935 was escalated or de-escalated during Part 1 as per investigator's discretion.
61975674|NCT00909389||Filipino Patients with Hypercholesterolemia|
62154045|NCT03166215|EXPERIMENTAL|Part 2: TAK-935|TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 31 to 40 followed by TAK-935 100 mg tablets x1, x2 or x3, orally or through G-tube/PEG tube, BID from Days 31 to Day 85 as per investigator's discretion in the maintenance period. At the end of Part 2, the dose of TAK-935 was de-escalated until discontinuation.
62154046|NCT02991456|ACTIVE_COMPARATOR|Sequence A|Daily ondansetron alone for 3 weeks, followed by the use of rolapitant (one dose on day 22) plus continued daily ondansetron for 3 weeks.
62154047|NCT02991456|ACTIVE_COMPARATOR|Sequence B|Single dose of rolapitant (one dose on day 1) plus daily ondansetron for 3 weeks, followed by daily ondansetron alone for 3 weeks.
62154048|NCT02249156||Financial incentive group|Employees of employers who have introduced the Rewards program. Currently there are two employers who have introduced the Rewards program, but there might be others that introduce it in the coming months. All intervention (and control) employers are customers of Castlight and use their price transparency product.
62527623|NCT05135208||experimental group|patients positioned with 3D camera
62527624|NCT05135208||control group|patients positioned by experienced radiology assistants
62527625|NCT01771471|EXPERIMENTAL|NuQu treatment|single administration
62527626|NCT01771471|OTHER|Saline|single administration
62154049|NCT02249156||Control population|Large employers who have not introduced the Rewards program, but work with Castlight and use their transparency product. It will be ideal if the control population looks similar to the intervention population in key characteristics - age, level of illness, industry of the employer (for example, manufacturing), pre-intervention spending, and geographic distribution. If possible, across a pool of potential control employers, we will identify control employers that look the most similar across these characteristics in the pre-intervention period. Another possible strategy we might use is to weight the individuals in the control population in our analyses by how similar they appear to those in the intervention population.
62713596|NCT04270643|EXPERIMENTAL|Vitamin D|Two oral doses of 5 mg (200,000 international units) vitamin D3 in 1 ml ethyl oleate, given at baseline and two weeks thereafter
62154050|NCT01287832|ACTIVE_COMPARATOR|High dose vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
62154051|NCT01287832|EXPERIMENTAL|High-dose daptomycin|Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
62154052|NCT06315465|EXPERIMENTAL|Modified Atkin's diet with standard of care arm|Group I will receive Modified Atkin's Diet with standard of care whereas Group II will receive standard of care alone. Children randomized into Group I, initial workup for Modified Atkin's Diet will be done in the form of Electrocardiogram, Renal Function Tests, Liver Function Tests, Complete Blood Counts, Lipid profile, Urine calcium creatinine ratio and Ultrasound Pelvis for nephrocalcinosis. If pre KD work up is normal, then Modified Atkin's Diet will be initiated in the ratio of 1:1.Urine ketones will be checked daily using ketone dipsticks. Telephonic contacts will be made in regular intervals every week to further ensure compliance at home, and to ensure proper understanding and confidence of parents. Those children who are unable to tolerate taking adequate ketogenic diet therapy requiring discontinuation of therapy, will be considered as deviates. First follow-up will be at 4 weeks of treatment initiation, followed by at 8, 12, 16, 20 and 24 weeks.
62154053|NCT06315465|OTHER|Standard of care arm|"* Standard of care intervention plan will be devised for each subject based on the principles of -~* Behavioral therapy~  1. Behavioral modification techniques~ 2. Psycho education~ 3. Cognitive behavioral therapy~ 4. Activity based interventions like eye contact exercises, attention enhancement exercises, self-help skills~ 5. Speech therapy~ 6. Parental training~* Occupational therapy~* Sensory integration therapy~* Pharmacotherapy - Anti-psychotic medications~* The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioural intervention to be provided to the child.~* Physical follow up - 4, 8, 12, 16, 20, 24 weeks~* Follow up assessments - 12 weeks (3 months) \& 24 weeks (6 months)"
62154054|NCT00860301|EXPERIMENTAL|Acupuncture group|
62154055|NCT00860301|NO_INTERVENTION|Control group|Infants come to the clinic six times, are left alone for five minutes with the acupuncture nurse who hold its hand and talks to it.
62527627|NCT00760565|EXPERIMENTAL|1|
62527628|NCT00760565|PLACEBO_COMPARATOR|10|
62527629|NCT00760565|EXPERIMENTAL|11|
62154056|NCT03326856|PLACEBO_COMPARATOR|Vehicle|Vehicle
62154057|NCT03326856|EXPERIMENTAL|Dose 1|botulinum toxin, Type A, Dose 1
62154058|NCT03326856|EXPERIMENTAL|Dose 2|botulinum toxin, Type A, Dose 2
62154059|NCT03326856|EXPERIMENTAL|Dose 3|botulinum toxin, Type A, Dose 3
62154060|NCT03326856|EXPERIMENTAL|Dose 4|botulinum toxin, Type A, Dose 4
62154061|NCT03400059|EXPERIMENTAL|Active Treatment|
62154062|NCT03400059|SHAM_COMPARATOR|Sham Treatment|
62527630|NCT00760565|PLACEBO_COMPARATOR|12|
62527631|NCT00760565|PLACEBO_COMPARATOR|2|
62527632|NCT00760565|EXPERIMENTAL|3|
62154063|NCT03364803||Participants with Cushing's Syndrome|
62154064|NCT02953756||Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery (GKRS)
62527633|NCT00760565|PLACEBO_COMPARATOR|4|
62527634|NCT00760565|EXPERIMENTAL|5|
62713597|NCT04270643|PLACEBO_COMPARATOR|Placebo|Two oral doses of 1 ml ethyl oleate
62713598|NCT04335071|EXPERIMENTAL|Actemra|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
62713599|NCT04335071|PLACEBO_COMPARATOR|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
62527635|NCT00760565|PLACEBO_COMPARATOR|6|
62527636|NCT00760565|EXPERIMENTAL|7|
62527637|NCT00760565|PLACEBO_COMPARATOR|8|
62527638|NCT00760565|EXPERIMENTAL|9|
62527639|NCT02263781|EXPERIMENTAL|Control Blood|Patients on routine postinfectious control, blood draw
62527640|NCT02263781|EXPERIMENTAL|Primary PREPL deficiency Blood|Patients with primary PREPL deficiency, blood draw
62527641|NCT02263781|EXPERIMENTAL|Prader Willi syndrome Blood|Patients with Prader-Willi syndrome, blood draw
62527642|NCT02263781|EXPERIMENTAL|Primary PREPL deficiency like Blood|Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
62527643|NCT02263781|EXPERIMENTAL|Control muscle|Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
62527644|NCT02263781|EXPERIMENTAL|Prader-Willli syndrome muscle|Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
62527645|NCT01523223|EXPERIMENTAL|Treatment (DLI)|Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.
62527646|NCT05530343|OTHER|Seattle protocol, then WATS3D brushings.|Participants in the screening or surveillance population that receive the Seattle protocol, then WATS3D brushings, during the same procedure.
62527647|NCT05530343|OTHER|WATS3D brushings, then Seattle Protocol.|Participants in the screening or surveillance population that receive the WATS3D brushings, then the Seattle protocol, during the same procedure.
62154065|NCT00915629|EXPERIMENTAL|Probiotic|Dietary supplement
62154066|NCT03029156|ACTIVE_COMPARATOR|Small volume jet nebulizer|Administration of bronchodilator through small volume jet nebulizer. The nebulized solution contains ipratropium / albuterol.
62154067|NCT03029156|EXPERIMENTAL|Aeroneb nebulizer|Administration of bronchodilator via Aeroneb nebulizer. The nebulized solution contains ipratropium / albuterol.
62154068|NCT01163214|EXPERIMENTAL|Nerve Block|Preoperative femoral block with indwelling femoral catheter and a single shot sciatic block.
62154069|NCT01163214|ACTIVE_COMPARATOR|Periarticular Injection|Injection combination prior to skin closure.
62527648|NCT03479463||Treatment with Dehydrated Human Amnion Chorion Allograft|
62527649|NCT03479463||Standard of Care|
62154070|NCT02464215|ACTIVE_COMPARATOR|open surgery|Conventional procedure,Open surgery
62527650|NCT04710966|EXPERIMENTAL|debridement group|For the debridement group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic debridement will be performed.
62527651|NCT04710966|EXPERIMENTAL|repair group|For the repair group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic repair will be performed.
62527652|NCT02860221|EXPERIMENTAL|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
62527653|NCT02860221|EXPERIMENTAL|Topical epinephrine|Topical epinephrine
62713600|NCT06716606|EXPERIMENTAL|Participants receiving Belimumab|Participants will receive belimumab.
62713601|NCT06148246|EXPERIMENTAL|Family Fit Condition (Intervention)|
62713602|NCT06148246|ACTIVE_COMPARATOR|Fitbit Only Condition|
62713603|NCT03745950|EXPERIMENTAL|Olaparib|"The Olaparib arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST (Response evaluation criteria in solid tumors) as assessed by the investigator, or unacceptable toxicity"
62713604|NCT03745950|PLACEBO_COMPARATOR|Placebo|"The placebo arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST as assessed by the investigator, or unacceptable toxicity"
62713605|NCT06488664|EXPERIMENTAL|"GNR-068 (JSC GENERIUM, Russia)"|Test drug
62713606|NCT06488664|ACTIVE_COMPARATOR|Stelara® (manufacturer Silag AG, Switzerland)|reference drug
62713607|NCT03351348|ACTIVE_COMPARATOR|Saline + usual post-operative medications|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
62154071|NCT02464215|EXPERIMENTAL|laparoscopic surgery|Minimum invasive procedure，Laparoscopic surgery
62154072|NCT03886207|EXPERIMENTAL|Warm water with ginger powder footbath|Participants who receive a warm water with added ginger powder footbath four times a week over a six-week period.
62154073|NCT03886207|ACTIVE_COMPARATOR|Warm water only footbath|Participants who receive a warm water only footbath four times a week over a six-week period.
62154074|NCT02784145|OTHER|RS|Resistant starch supplementation (5 g twice a day)
62154075|NCT02784145|OTHER|No RS|PD patients who do not receive resistant starch, but who receive recommendations concerning healthy Nutrition (based on the guidelines of the German Society for Nutrition)
62154076|NCT06005116|EXPERIMENTAL|Bladder Cancer Patients|
62154077|NCT01355692|EXPERIMENTAL|Laser therapy|
62154078|NCT05700656|EXPERIMENTAL|Galunisertib plus capecitabine|Galunisertib 150 mg BID for 14 days in a 28-day cycle plus capecitabine 1000 mg/m2 BID for 14 days in a 28-day cycle
62154079|NCT03445585||Primary Sclerosing Cholangitis|Patients with a diagnosis of primary sclerosing cholangitis (PSC).
62154080|NCT03445585||Primary Biliary Cirrhosis/Cholangitis|Patients with a diagnosis of primary biliary cirrhosis (PBC).
62154081|NCT03445585||Control group 1|Patients who do not have PBC or PSC but do have another form of chronic liver disease.
62154082|NCT03445585||Control group 2|Patients without liver disease.
62736726|NCT05073484|EXPERIMENTAL|30 mg of BAT6021|BAT6021 100mg/vial，30mg Ⅳ infusions
62154083|NCT02283632|EXPERIMENTAL|Jejunal Diversion|all subjects who receive jejunal diversion surgery
62527654|NCT02860221|ACTIVE_COMPARATOR|Control|No epinephrine
62527655|NCT05813314|ACTIVE_COMPARATOR|BMN 111 injection with vial and syringe|Study treatment will be provided in glass vials. Each glass vial will be labeled as required per country requirement. Pre-filled Diluent Transfer Syringes will be provided for reconstitution.
62154084|NCT04617847|EXPERIMENTAL|WVE-120101 (Dose A)|
62154085|NCT02265497||Hodgkin's or non-Hodgkin lymphoma|All patients with diagnoses of Hodgkin's or non-Hodgkin lymphoma with available with available clinical, histopathology and treatment data.
62154086|NCT00631202|EXPERIMENTAL|I|Treatment arm
62154087|NCT01383590|EXPERIMENTAL|Cat-PAD|
62154088|NCT04464499||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
62154089|NCT04464499||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
62154090|NCT01781923|EXPERIMENTAL|Cognitive Remediation|"12 week computer-based cognitive remediation program aimed to improve working memory, processing speed, and verbal learning/memory.~40 week small group social skills training sessions aimed to improve social skills and cognition."
62527656|NCT05813314|EXPERIMENTAL|BMN 111 injection with injector pen|Study treatment will be provided in a prefilled injector pen containing a dual chamber drug cartridge, for reconstitution and injection, after setting of the specified dose with the 2.0 mg/mL formulation.
62527657|NCT01297387||Revascularization of limb ischemia|Procedure/Surgery
62527658|NCT00631449|ACTIVE_COMPARATOR|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
62527659|NCT00631449|PLACEBO_COMPARATOR|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
62527660|NCT04102813|EXPERIMENTAL|Functional Therapy (FT)|The FT includes a variety of functional techniques such as diaphragmatic breathing, and thoracic and abdominal manipulation, designed to stimulate the neurofunctional interconnection between body, mind and immune system. The FT session will last 30 minutes.
62154091|NCT01781923|NO_INTERVENTION|Control|No intervention
62713608|NCT03351348|EXPERIMENTAL|Bupivacaine + usual post-operative medications|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
62713609|NCT06717997|OTHER|Normal placental thickness women|
62713610|NCT06717997|OTHER|High placental thickness women|
62713611|NCT03939585|EXPERIMENTAL|NK/γδ T cell-enriched cell therapy product|"This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors.~* 27 days post transplant, the participant's donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs).~* Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable.~* Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant.~* Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution."
62713612|NCT01463527|EXPERIMENTAL|Open Capnography|
62154092|NCT03937752||Anal fistula|Patients with anal fistulas, no previous fistula procedures. Ultrasound investigation done as a part of surgical treatment, such as loose seton or fistulotomy.
62154093|NCT00321555|EXPERIMENTAL|LMB-2 to Treat Hairy Cell Leukemia|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
62154094|NCT02199444|EXPERIMENTAL|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
62154095|NCT02199444|PLACEBO_COMPARATOR|Placebo|The patients received placebo three times a day
62154096|NCT04617145|ACTIVE_COMPARATOR|Aerobic exercise group|Included 30 patients who underwent aerobic training with 50 %-60% of maximum heart rate in the form of cycling by Bicycle ergometer for eight weeks, three sessions/week.
62154097|NCT04617145|ACTIVE_COMPARATOR|Resistive exercise group|Included 30 patients who underwent a resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Sessions were conducted three sessions/week for eight weeks.
62154098|NCT01798537|EXPERIMENTAL|Neomycin Colistin Nystatin Vancomycin|"All participating study arm patients will receive SDD from admission to discharge according to the following plan:~ENTERAL MEDICATION (via feeding tube) x 4 times daily:~375 mg Neomycin 100 mg Colistin Sulphate~1 million units Nystatin \* 250 mg Vancomycin \*~Nystatin will be prescribed only if there is a positive sputum or urine culture for yeast or candida Vancomycin will be prescribed only in case of a positive screen or culture for MRSA"
62154099|NCT01798537|NO_INTERVENTION|Control|No SDD given for 1 year Screening performed as in intervention arm
62154100|NCT00433706|EXPERIMENTAL|Control position by 3DOBI daily|
62154101|NCT00433706|ACTIVE_COMPARATOR|Standard imaging|
62154102|NCT05509881|EXPERIMENTAL|Continuous glucose monitoring (CGM) arm|"During the intervention period, patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices."
62154103|NCT05509881|ACTIVE_COMPARATOR|Usual care arm|During the intervention period, patients in the usual care arm will conduct self-monitored blood glucose (SMBG) at least 4 times/day. At Weeks 6 and 12 of the intervention period, usual care arm patients will also undergo 10-days of blinded CGM data collection.
62154104|NCT04288661|NO_INTERVENTION|Drain|The patients of this arm undergo perianastomotic drain placement, as per standard of care institutional practice
62527661|NCT04102813|NO_INTERVENTION|Attention Control (AC)|The AC group will listen an audiobook lasting for 30 minutes, which will be used as attention control activity
62527662|NCT03055702|EXPERIMENTAL|SMS group|receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
62154105|NCT04288661|EXPERIMENTAL|No drain|The patients of this arm do not undergo perianastomotic drain placement.
62154106|NCT01921985|ACTIVE_COMPARATOR|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
62154107|NCT01921985|PLACEBO_COMPARATOR|NaCl|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
62154108|NCT01169402|EXPERIMENTAL|Fluconazole|
62154109|NCT03966456||nivolumab|Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
62154110|NCT03966456||pembrolizumab|Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
62154111|NCT03966456||toripalimab|Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
62154112|NCT03966456||sintilimab|Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
62154113|NCT03987815|EXPERIMENTAL|Study Arm|Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles
62527663|NCT03055702|NO_INTERVENTION|Usual care group|Usual care, either telephone reminder or no reminder
62527664|NCT00520286|ACTIVE_COMPARATOR|Modafinil|Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks
62527665|NCT00520286|PLACEBO_COMPARATOR|Placebo|Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks
62527666|NCT01926717||Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy|
62527667|NCT01926717||Pancreaticoduodenectomy|
62713613|NCT01463527|PLACEBO_COMPARATOR|Capnography Blind|
62713614|NCT06664801|EXPERIMENTAL|Weight-based sotatercept dosing|Participants will receive sotatercept via subcutaneous (SC) injection every 3 weeks at an initial dose of 0.3 mg/kg and then at a maintenance dose of 0.7 mg/kg using a weight-based method during a 24-week treatment period. Participants will continue to take their background PAH therapy during the study.
62736727|NCT05073484|EXPERIMENTAL|100 mg of BAT6021|BAT6021 100mg/vial，100mg Ⅳ infusions
62736728|NCT05073484|EXPERIMENTAL|300 mg of BAT6021|BAT6021 100mg/vial，300mg Ⅳ infusions
62736729|NCT05073484|EXPERIMENTAL|600 mg of BAT6021|BAT6021 100mg/vial，600mg Ⅳ infusions
62154114|NCT00977678||Open access gastroscopy|Patients referred to open access gastroscopy
62154115|NCT00977678||Conventional outpatient gastroscopy|Gastroscopy after preceding appointment
62154116|NCT04006015||Main study group|31 people with COPD and 31 controls in the main study group.
62527668|NCT02328222|NO_INTERVENTION|CONTROL GROUP|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
62713615|NCT06664801|EXPERIMENTAL|Weight-banded sotatercept dosing|Participants will receive sotatercept via SC injection every 3 weeks at an initial dose of up to 45 mg and then at a maintenance dose of up to 90 mg using a weight-banded method during a 24-week treatment period. Participants will continue to take their background PAH therapy during the study.
62713616|NCT04209556|PLACEBO_COMPARATOR|Placebo|Placebo
62713617|NCT04209556|EXPERIMENTAL|PF-06826647 100 mg once a day (QD)|PF-06826647 100 mg once a day (QD)
62713618|NCT04209556|EXPERIMENTAL|PF-06826647 300 mg QD|PF-06826647 300 mg QD
62713619|NCT04209556|EXPERIMENTAL|PF-06826647 600 mg QD|PF-06826647 600 mg QD
62713620|NCT04209556|EXPERIMENTAL|Open Label Extension, PF-06826647 400 mg QD|PF-06826647 400 mg QD
62713621|NCT05462912|OTHER|Open|Each participant will be evaluated at baseline, when the customized foot orthoses will be made, and the corresponding tests will be conducted.
62713622|NCT03801512|EXPERIMENTAL|Steroid Injections|Inject steroid at neuritis nerve root.
62713623|NCT03801512|EXPERIMENTAL|Acupuncture|Acupuncture at acupoints BL23 to BL26.
62713624|NCT03801512|EXPERIMENTAL|Platelet Rich Plasma Injection|Inject Platelet Rich Plasma at neuritis nerve root.
62713625|NCT05124912|OTHER|Recurrent Tumor|Receives Laser Interstitial Thermal Therapy (LITT) followed by surveillance or Receives Laser Interstitial Thermal Therapy (LITT) followed by hypofractionated radiation therapy (RT).
62713626|NCT05124912|OTHER|Radiation Necrosis|Receives Laser Interstitial Thermal Therapy (LITT) and best medical management with steroids or Receives best medical management with steroids.
62154117|NCT04006015||six-minute walk substudy|We will aim to have 40 participants participating in the 6 minute walk sub-study.
62527669|NCT02328222|EXPERIMENTAL|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
62527670|NCT02875158|ACTIVE_COMPARATOR|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
62527671|NCT02875158|EXPERIMENTAL|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
62527672|NCT03306953|ACTIVE_COMPARATOR|Rectus muscle approximation|Three sutures will be done for the the purpose of rectus muscle approximation in cesarean section.
62713627|NCT01752218|EXPERIMENTAL|Arcuate Incision|Study arm will consist of patients who show cataract and corneal astigmatism.
62713628|NCT01061684||NAFLD|pediatric patients with non-alcoholic fatty liver disease (NAFLD).
62713629|NCT06145919|EXPERIMENTAL|Episodic Future Thinking (EFT)|"Mothers will receive episodic future thinking (EFT). Mothers will meet with a peer mother who will administer the EFT intervention, including generation of several specific future events reflecting positive interactions with their child. The participant will be asked to discuss their relationship with their child and to give examples of both positive and negative parenting from their personal experience. The peer mother will then ask the participant to think about their long-term parenting goals and will discuss how to create a vivid event that will be easy to remember. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, participants are asked to engage in messaging that will prompt them to think about future events."
62713630|NCT06145919|ACTIVE_COMPARATOR|Episodic Recent Thinking (ERT)|"In the episodic recent thinking (ERT) condition, the participant will be asked to discuss their relationship with their child and to give examples of both positive and negative parenting from their personal experience. The peer mother will then ask the participant to think about the present and discuss how to focus on the present. Two positive recent events and two negative recent events will be used to create ERT scenes for the parent to envision their current relationship with their child. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, participants will receive messages over the course of two weeks helping parents to focus on recent events with their child."
62713631|NCT03888560|EXPERIMENTAL|Micro-osteoperforations|Lower arch, 2 MOPs vertically at interdental area bilaterally mesial to lower 6's ; mesial to lower 1st premolar; mesial to lower 2's and between the lower 1's..The start date of lower labial segment alignment (T1) was recorded after insertion of the lower 0.014'' NiTi archwire. Participants were reviewed every 6 weeks and repeated MOPs were performed for the experimental group until the completion of lower labial segment alignment (LLS), which is when the Little's irregularity index scores one, indicating a minimum irregularity of ≤ 2 mm contact point displacement, based on the contact point displacements of the mandibular anterior segment, from canine to canine.
62713632|NCT03888560|NO_INTERVENTION|control|Conventional orthodontic treatment without any aid in tooth acceleration method / device
62736730|NCT05073484|EXPERIMENTAL|900 mg of BAT6021|BAT6021 100mg/vial，900mg Ⅳ infusions
62154118|NCT04006015||Qualitative dance substudy|We will aim for 20 participants.
62154119|NCT03366571||Anti-viral therapy group|"Subjects who have completed the 3 years research Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis"
62154120|NCT03366571||Non anti-viral therapy group|History study from literature
62154121|NCT00179478|EXPERIMENTAL|Immediate Treatment Group|Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
62527673|NCT03306953|NO_INTERVENTION|Control|No approximation for the rectus muscle will be done for the control group in cesarean section.
62527674|NCT01365117|EXPERIMENTAL|Cohort 1|
62736731|NCT05073484|EXPERIMENTAL|100mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions
62527675|NCT01365117|EXPERIMENTAL|Cohort 2|
62154122|NCT00179478|ACTIVE_COMPARATOR|Delayed Treatment Group|Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation
62154123|NCT01806402||Retina|Having clinical diagnosis of retina pathology
62154124|NCT01806402||Glaucoma|Having clinical diagnosis of glaucoma
62154125|NCT03615547|EXPERIMENTAL|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
62527676|NCT03847103|EXPERIMENTAL|Robotic-aided rehabilitation with bilateral practice|In addition to a 10-minutes sensorimotor stimulation programs, the experimental group received 40-minutes Robotic-assisted Therapy with Bilateral Practice programs.
62713633|NCT02948439|EXPERIMENTAL|Exercise Intervention|The aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
62527677|NCT03847103|ACTIVE_COMPARATOR|Unilateral task-specific training|In addition to a 10-minutes sensorimotor stimulation programs, the control subjects received 40-minute unilateral task-specific training.
62154126|NCT03615547|EXPERIMENTAL|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
62154127|NCT02216448|OTHER|simulator training|Training knee simulator in Lab
62154128|NCT02216448|OTHER|OR training|Training in the OR - 2 knee arthroscopies.
62154129|NCT06211998|ACTIVE_COMPARATOR|Group receiving inhaled treatment with compressor nebulizer|Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1
62527678|NCT05187702|EXPERIMENTAL|Functional exercise group and aerobic group|Along with functional exercises, aerobic exercises (walking) 3 per week were given.
62527679|NCT05187702|ACTIVE_COMPARATOR|Aerobic Exersize Group|aerobic exercises (walking) 3 per week were given.
62527680|NCT05187702|NO_INTERVENTION|Control Group|They continued their daily routine
62527681|NCT01914627|EXPERIMENTAL|Loion|
62527682|NCT01914627|ACTIVE_COMPARATOR|SA-Gel|
62527683|NCT00334100|OTHER|Arm 1|
62527684|NCT01516307|EXPERIMENTAL|OPT-822/OPT-821 (30 μg/100 μg) and Cyclophosphamide|Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).
62527685|NCT01516307|PLACEBO_COMPARATOR|Phosphate Buffer Saline (PBS) and Cyclophosphamide|Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).
62527686|NCT00903448|EXPERIMENTAL|A|Prilosec OTC
62527687|NCT00903448|ACTIVE_COMPARATOR|B|Prevacid
62527688|NCT05617937|EXPERIMENTAL|Connective tissue massage gruop|In addition, a total of 5 sessions of connective tissue massage were applied to the experimental group as 1 session a day on the postoperative 1st day, 2nd day, 3rd day, 4th day, 5th day. Connective tissue massage was only performed to the patients in the experimental group. A total of 5 sessions of connective tissue massage were applied to the experimental group as 1 session a day on the postoperative 1st day, 2nd day, 3rd day, 4th day, 5th day. Depending on the area of procedure, each session varied between 15 minutes and 20 minutes.
62527689|NCT05617937|NO_INTERVENTION|Conventional Physiotherapy and Rehabilitation Group|Standard medical treatment, care and pulmonary rehabilitation program were applied to bonventional Physiotherapy and Rehabilitation Group.The patients were mobilized as early as possible. Starting on the postoperative zeroth day, a postoperative rehabilitation program including pulmonary rehabilitation and early mobilization was applied to every patient in the control and experimental groups by a therapist for 1 week as in routine
62527690|NCT01324635|EXPERIMENTAL|Arm A (panobinostat, multiple fractions of SBRT)|Patients receive panobinostat PO thrice weekly for 2 weeks and undergo 10 fractions of SBRT over 2 weeks (recurrent gliomas) OR 30 fractions of SBRT over 6 weeks (high grade meningiomas).
62527691|NCT01324635|EXPERIMENTAL|Arm B (panobinostat, stereotactic radiosurgery)|Patients receive panobinostat as in Arm A and undergo a single fraction of stereotactic radiosurgery on day 1 of week 1.
62527692|NCT03267875|EXPERIMENTAL|single arm|Patients after aneurysm in the aorta, Men and women aged 18-100 (not including special populations), who are able to read understand and sign a written consent to participate in the research
62527693|NCT01592305|EXPERIMENTAL|S1 P1 TDF + DNV/r|
62527694|NCT01592305|EXPERIMENTAL|S1/S2 P2 DNV/r + ATZ|
62527695|NCT01592305|EXPERIMENTAL|S2 P1 ATZ/r|
62527696|NCT00477295|ACTIVE_COMPARATOR|Zonisamide|
62527697|NCT00477295|ACTIVE_COMPARATOR|Carbamazepine|
62527698|NCT03951896|EXPERIMENTAL|PRP|"Interventions:~A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects."
62154130|NCT06211998|ACTIVE_COMPARATOR|Group receiving inhaled treatment with mesh nebulizer|Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2
62154131|NCT02745509|EXPERIMENTAL|Extensive Intraoperative Peritoneal Lavage|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles), followed by complete aspiration of the fluid . The abdomen will be closed as per standard.
62154132|NCT02745509|NO_INTERVENTION|Standard Treatment|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal lavage will be done \< 3 cycles with 3 liters or less of warmed normal saline. The abdomen will be closed as per standard.
62154133|NCT03306329|EXPERIMENTAL|DNS-7801 (low-dose)|
62154134|NCT03306329|EXPERIMENTAL|DNS-7801 (high-dose)|
62154135|NCT03306329|PLACEBO_COMPARATOR|Placebo|
62154136|NCT01607697|EXPERIMENTAL|Mindfulness Training|Group received Mindfulness Training
62154137|NCT01607697|NO_INTERVENTION|Waitlist Control|Group received Usual Care
62527699|NCT03951896|PLACEBO_COMPARATOR|Placebo|For the control group, same amount of blood was sampled and they were given a same amount of waiting time with the other group, with the resulting injection preparate being 2 ml's of 0,9% saline instead.
62527700|NCT01974336|EXPERIMENTAL|UDCA+placebo group|15-30mg/kg/d UDCA for 2 months + placebo for 2 months
62527701|NCT01974336|EXPERIMENTAL|placebo+UDCA|placebo for 2 months+15-30mg/kg/d UDCA for 2 months
62527702|NCT03332238|PLACEBO_COMPARATOR|Placebo|Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
62527703|NCT03332238|ACTIVE_COMPARATOR|Cell Therapy|Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
62527704|NCT00698542||1|Patients in the NCU at VUH
62527705|NCT01717586|ACTIVE_COMPARATOR|Pravastatin Group|Pregnant women at high-risk for preeclampsia who are taking pravastatin during their pregnancy.
62527706|NCT01717586|PLACEBO_COMPARATOR|Control Group|Pregnant women who are at high-risk for developing preeclampsia who are taking a placebo during their pregnancy.
62527707|NCT00076804|EXPERIMENTAL|1|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
62527708|NCT00076804|NO_INTERVENTION|2|Self administration of ARVs
62527709|NCT05518084|EXPERIMENTAL|Liponovo tissue product|4,5mlLiponovo tissue product, single injection
62527710|NCT05518084|SHAM_COMPARATOR|Plasebo|4,5ml Ringer, single injection
62527711|NCT02398357|NO_INTERVENTION|Control|No anticoagulation，just routine follow-up
62527712|NCT02398357|EXPERIMENTAL|Anticoagulation|Nadroparin Calcium and Warfarin
62527713|NCT00218166|NO_INTERVENTION|A|Within subject design
62154138|NCT00670852||Total shoulder replacement with anchor peg glenoid and autologous bone grafting|Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study.
62154139|NCT01775878|NO_INTERVENTION|Usual Care|This arm received usual care from the diabetes care managers
62527714|NCT00548093|EXPERIMENTAL|1|descriptive: adenocarcinoma histology
62527715|NCT00548093|EXPERIMENTAL|2|descriptive: non-adenocarcinoma histology
62527716|NCT01776463|EXPERIMENTAL|Z-360|1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))
62527717|NCT01776463|PLACEBO_COMPARATOR|Placebo|1)Single dose study, 2)Multiple doses study
62527718|NCT04918316|ACTIVE_COMPARATOR|Corneal gas permeable lens first|"Device: corneal gas permeable contact lenses (RoseK2 corneal Blanchard Contact Lens, Inc. Manchester, NH).~Participants with an odd study ID will be fit with the corneal gas permeable lens first."
62713634|NCT02948439|NO_INTERVENTION|Control Group|These women will continue regular daily activities. Activity will be monitored periodically with questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
62154140|NCT01775878|EXPERIMENTAL|Telemonitoring Device|Patients in this arm received a telemonitoring device installed in their homes
62527719|NCT04918316|ACTIVE_COMPARATOR|Scleral lens first|"Device: scleral lenses (SynergEyes VS (Synergeyes, Inc., Carlsbad CA).~Participants with an even study ID will be fit with the scleral lens first."
62527720|NCT00666783|EXPERIMENTAL|PAL|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
62527721|NCT00666783|ACTIVE_COMPARATOR|GRA|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
62527722|NCT05633108||All Participants|Participants diagnosed with psychotic disorder at any time between 1 January 2014 and 31 December 2020 and have data available in French nationwide healthcare data system (SNDS) database during this period will be observed retrospectively.
62527723|NCT01957072|EXPERIMENTAL|Behaviour change intervention|Intensive behaviour change intervention for 3 months, followed by a maintenance phase for 3 months
62736732|NCT05073484|EXPERIMENTAL|300mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions
62736733|NCT05073484|EXPERIMENTAL|600mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions
62154141|NCT03657745||Participants who adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants adhere to the protocol if they exercise with AlzLife the minimum of 1hour/week.
62154142|NCT03657745||Participants who do not adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants do not adhere to the protocol if they exercise with AlzLife less than 1hour/week.
62154143|NCT04372732||Study group|All participants will be detected for antoantibodies and then treated with PD-1 blockade.
62527724|NCT01957072|OTHER|Wait-list Control|Usual care for 3 months, followed by intensive behaviour change intervention for 3 months
62527725|NCT02636192||Cohort 1|Cohort 1 included participants who were exposed to sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin and empagliflozin).
62527726|NCT02636192||Cohort 2|Cohort 2 included participants who were exposed to other non-SGLT2 antihyperglycemic agents (AHA).
62527727|NCT05102292|EXPERIMENTAL|HLX208|Participants receive HLX208 450mg bid po
62527728|NCT03567382|EXPERIMENTAL|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load \>10\^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
62527729|NCT03567382|EXPERIMENTAL|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load \<10\^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
62527730|NCT02390141|EXPERIMENTAL|ZP4207|Five multiple doses of ZP4207 in ascending doses
62527731|NCT02390141|PLACEBO_COMPARATOR|Placebo|Five multiple doses of corresponding placebo in ascending doses
62527732|NCT03530176|EXPERIMENTAL|single arm|18F-NaF (sodium Flouride ) is a radio-pharmaceutical used to image skeletal pathology, including primary and secondary neoplasms. Despite US Federal Drug Administration (FDA) approval and 18F-NaF being listed in the US Pharmacopeia, 18F-NaF is not currently approved by Health Canada for use as a cardiac imaging tracer. Therefore, a concurrent Health Canada Clinical Trial Application is being submitted to ensure its availability. Intervention on single arm: A dose of 18F-NaF (200 - 400 MBq) will be injected intravenously at rest. After a 60 minute, an ECG-gated PET acquisition will be performed centered over the heart for 20 minutes. A CT coronary calcium score examination will also be performed on a dedicated CT scanner and the Agatston and volume scores calculated according to standards.
62527733|NCT00639847|NO_INTERVENTION|group 1|this is the standard of care control group. The control group will be instructed to return to their regular physicians for routine follow up at a time to be specified by the physician.
62527734|NCT00639847|ACTIVE_COMPARATOR|Group 2|Group 2 will receive routine home visits from nurses provided by a home health care agency.
62154144|NCT01236898|EXPERIMENTAL|NPC-09|Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days
62154145|NCT06505382|EXPERIMENTAL|PNM group|"Participants in the experimental PNM group will receive ultrasound-guided percutaneous neuromodulation of the saphenous nerve in the painful leg.~In this study, a neurostimulation device ITO ES-160 will be used, where parameters of 2 Hz, 250 μs, and 16 minutes of continuous current will be set, with an appropriate intensity for subjects to perceive nerve stimulation along the path of the nerve (from the needle insertion point to the anterior aspect and below the knee), always ensuring it remains tolerable for them. No motor response will be observed. The black clip of channel 1 will be attached to the needle, and a TENS patch will be attached to the red clip.~The interventions will be conducted 3 times, with 1 week between the first two and a 2-week interval between the second intervention and the third. All measurements will be taken before and after the procedure."
62154146|NCT06505382|PLACEBO_COMPARATOR|NON-PNM group|"Participants in the control NON-PNM group will receive saphenous nerve puncture in the injured leg with subsequent placement of the clamps but without activating the electrostimulation function.~The needle will remain without current for 16 minutes. The interventions will be conducted 3 times, with 1 week between the first two and a 2-week interval between the second intervention and the third. All measurements will be taken before and after the procedure."
62154147|NCT04996654|EXPERIMENTAL|Exergame|Participants will perform a twelve-week training intervention in addition to their usual care as provided by the memory clinics where the patients are recruited. The training intervention will be prescribed according to a newly developed exergame-based intervention concept that consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) perceptual-motor function.
62154148|NCT04996654|ACTIVE_COMPARATOR|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
62154149|NCT04306081|EXPERIMENTAL|Treatment Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of evolocumab 420 mg via subcutaneous injections for 6 months.
62154150|NCT04306081|PLACEBO_COMPARATOR|Control Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of placebo via subcutaneous injections for 6 months.
62154151|NCT02990494|ACTIVE_COMPARATOR|STANDARD|12-week Internet-delivered behavioral weight loss program
62154152|NCT02990494|EXPERIMENTAL|PREVENT|an enhanced 12-week Internet-delivered behavioral weight loss program focused on preventing future negative consequences
62154153|NCT02990494|EXPERIMENTAL|PROMOTE|an enhanced 12-week Internet-delivered behavioral weight loss program focused on promoting future benefits
62154154|NCT01605084|EXPERIMENTAL|Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone|
62527735|NCT00639847|ACTIVE_COMPARATOR|Group 3|In-home asthma management program (AMP) provided by respiratory therapists. The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
62527736|NCT04780841|EXPERIMENTAL|RDX013 Cohort 1|RDX013 low dose oral dosage, twice daily
62527737|NCT04780841|EXPERIMENTAL|RDX013 Cohort 2|RDX013 low, mid dose oral dosage, twice daily
62527738|NCT04780841|EXPERIMENTAL|RDX013 Cohort 3|RDX013 high, mid dose oral dosage, twice daily
62527739|NCT04780841|EXPERIMENTAL|RDX013 Cohort 4|RDX013 high dose oral dosage, twice daily
62154155|NCT01605084|EXPERIMENTAL|Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone|
62154156|NCT00780078||1|Patients intubated orotracheally for over 6 days
62154157|NCT01175980|EXPERIMENTAL|Treatment (vorinostat)|Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62154158|NCT02726139||Emory University|Samples obtained at and shipped from Emory University
62154159|NCT02726139||University of Michigan|Samples obtained at and shipped from University of Michigan
62527740|NCT04780841|EXPERIMENTAL|RDX013 Part B|RDX013 dose from Part A oral dosage, twice daily
62527741|NCT04780841|PLACEBO_COMPARATOR|Placebo Part B|oral dosage, twice daily
62527742|NCT03056820|ACTIVE_COMPARATOR|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
62527743|NCT03056820|ACTIVE_COMPARATOR|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
62527744|NCT00700323|ACTIVE_COMPARATOR|1|Patients receiving active product
62527745|NCT00700323|PLACEBO_COMPARATOR|2|Patients receiving placebo
62527746|NCT00982176||1|
62527747|NCT05989113||Lower limb amputee patients with devices|
62527748|NCT03370731|EXPERIMENTAL|Adenotonsillectomy|Surgical management, i.e. adenotonsillectomy, including adenoidectomy, tonsillectomy or adenoidectomy combined tonsillectomy
62527749|NCT03370731|OTHER|Nonsurgical management|Nonsurgical management, including nasal irrigation, inhaled corticosteroids etc.
62154160|NCT03833765|EXPERIMENTAL|CAF+XCM|An envelope split-full-split thickness flap without vertical incisions will be carried out in the gingival recession area. Afterwards, a xenogenic collagen matrix (XCM) will be applied to all teeth with recession defect. The XCM will be cut into the right dimensions, measured with the probe, and its measurements recorded; then it will be placed from the CEJ to the bone crest on the recipient bed using single sutures, 7/0 PGA sutures. The matrix will be rehydrated with blood, in order to reconstitute and maintain the maximal thickness possible. The flap will be closed slightly coronal to the CEJ with a sling suture using resorbable PGA 6/0 sutures and avoiding any compression of the matrix.
62154161|NCT03833765|ACTIVE_COMPARATOR|CAF alone|An envelope split-full-split thickness flap without vertical incisions will be carried out. The root surfaces will be mechanically treated with the use of curettes. A sharp dissection into the vestibular lining mucosa will be then carried out to eliminate muscle tension. Sling sutures will be performed to accomplish a precise adaptation of the buccal flap on the exposed root surfaces and to stabilize every single surgical papilla over the de-epithelialized anatomic papillae.
62713635|NCT05317637||Adults with OI|"18 participants will be enrolled through in this pilot study. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI.~This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. All efforts will be made to complete all data collection and testing on the same day. However, procedures completed within ±12 months will be accepted. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Participants will be enrolled regardless of OI type since BWT, a finding we are attempting to validate, was observed in all types of OI. Smokers will not be excluded."
62527750|NCT03081234|EXPERIMENTAL|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
62527751|NCT03081234|ACTIVE_COMPARATOR|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
62154162|NCT00383994|EXPERIMENTAL|Immunotherapy with NK Cell, Rituximab + GM-CSF|"Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation~GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor"
62527752|NCT05451186|EXPERIMENTAL|Eye patch and headphones|Eye patch and headphones
62154163|NCT01513902|EXPERIMENTAL|Cohort 1|Ages 12 to less than 18
62154164|NCT01513902|EXPERIMENTAL|Cohort 2|Ages 6 to less than 12
62527753|NCT05451186|NO_INTERVENTION|Control group|Routine maintenance will be applied
62154165|NCT01513902|EXPERIMENTAL|Corhort 3|Ages 2 to less than 6
62154166|NCT03191097|EXPERIMENTAL|Ingavirin|
62154167|NCT03191097|PLACEBO_COMPARATOR|Placebo oral capsule|
62154168|NCT01757288|ACTIVE_COMPARATOR|PACLITAXEL (Phase II, Arm A)|PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
62154169|NCT01757288|EXPERIMENTAL|NAB-PACLITAXEL (Phase II, Arm B)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
62154170|NCT01757288|EXPERIMENTAL|NAB-PACLITAXEL (Phase I)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
62154171|NCT01588522|EXPERIMENTAL|dose-escalation of compound 31543|compound 31543 Calcitriol, Topical application, 0.25 mL to be applied to each of the four quadrants of the scalp twice daily, morning and night with 10-14 hours between applications
62527754|NCT03340142|EXPERIMENTAL|Single Arm|All patients will undergo standard of care ablation procedures. VIVO™ results will be compared to that of standard of care results, but will not be used in diagnosis or treatment.
62527755|NCT03693573|EXPERIMENTAL|Atezolizumab + Bevacizumab|Participants will receive atezolizumab in combination with bevacizumab.
62713636|NCT02755961|NO_INTERVENTION|Control group|No intervention was performed
62713637|NCT02755961|EXPERIMENTAL|Education group|Dietary education and education on phosphate binder use. Pharmacists instructed patients about how to take phosphate binders properly. Dietitians educated on dietary phosphate restriction.
62154172|NCT06226623|EXPERIMENTAL|Intervention|Participants were given 4-week healthy nutrition training. Participants' basal metabolic rates were calculated according to gender and body weight (kg) using the Schofield equation. The appropriate equation for each participant's age was used. The daily energy requirement of the participants was calculated by adding an activity factor of 1.3 to the calculated basal metabolic rate. A healthy nutrition program was prepared according to the calculated daily energy needs of the participants. While preparing this program, WHO and Turkey-Specific Healthy Nutrition Guide (TÜBER) were used. In the individual healthy nutrition program, 55% carbohydrates, 15% protein and 30% fat macronutrients were provided. Total cholesterol of the nutrition program was kept at 300 mg and below. The intervention group was asked to consume 50 g of fresh coconut daily in addition to the healthy nutrition program.
62154173|NCT06226623|NO_INTERVENTION|Control|Participants were given 4-week healthy nutrition training. Participants' basal metabolic rates were calculated according to gender and body weight (kg) using the Schofield equation. The appropriate equation for each participant's age was used. The daily energy requirement of the participants was calculated by adding an activity factor of 1.3 to the calculated basal metabolic rate. A healthy nutrition program was prepared according to the calculated daily energy needs of the participants. While preparing this program, WHO and Turkey-Specific Healthy Nutrition Guide (TÜBER) were used. In the individual healthy nutrition program, 55% carbohydrates, 15% protein and 30% fat macronutrients were provided. Total cholesterol of the nutrition program was kept at 300 mg and below. The control group was given only a healthy nutrition program.
62527756|NCT00516009|EXPERIMENTAL|1 TREATMENT GROUP|20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
62527757|NCT00516009|PLACEBO_COMPARATOR|2|20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
62527758|NCT00158600|ACTIVE_COMPARATOR|alglucosidase alfa|Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
62527759|NCT00158600|PLACEBO_COMPARATOR|Placebo|Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
62527760|NCT00719849|EXPERIMENTAL|Cyclophosphamide/Fludarabine/TBI|"Subjects with hematological malignancies with prior autologous transplant, \>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy."
62527761|NCT00719849|EXPERIMENTAL|Cyclophosphamide/Fludarabine/TBI/ATG|Subjects with hematological malignancies with prior autologous transplant \>12 mos or \<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
62154174|NCT03675282|EXPERIMENTAL|Parkinson Disease - Stage 1|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
62154175|NCT03675282|EXPERIMENTAL|Parkinson Disease - Stage 2|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
62154176|NCT03675282|EXPERIMENTAL|Parkinson Disease - Stage 3|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
62154177|NCT03675282|EXPERIMENTAL|Parkinson Disease - Stage 4|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
62154178|NCT03675282|EXPERIMENTAL|REM Sleep Behavior Disorder|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
62527762|NCT06341634||Ideation|"Patients with current suicidal ideation, recruited by staff doctors and psychologists from the child and adolescent psychiatry units of the Álvaro Cunqueiro Hospital in Vigo and the University Hospital Complex in Ourense, who have been deemed suitable for participation and have had the participation conditions explained to them and their parents, will undergo the following assessment protocol:~Paykel scale Mini International Neuropsychiatric Interview (MINI) Strengths and Difficulties Questionnaire (SDQ) Mood and Feelings Questionnaire (MFQ) European Bullying Intervention Project Questionnaire (EBIP-Q) Problematic Internet Use Scale in Adolescents (EUPI-A) Millon Adolescent Clinical Inventory (MACI)~Multimodal experimental battery:~Recording of voice features Video recording of facial microexpression Registering of autobiographical texts Collecting of saliva samples"
62154179|NCT03675282|EXPERIMENTAL|Healthy Controls|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
62154180|NCT02955225|EXPERIMENTAL|Flexible shoe with Active Insole|Subjects will be trained to change the plantar pressure using a flexible walking shoe with an activated pressure-detecting shoe insole (Moticon OpenGO insole).
62527763|NCT06341634||Clinical Population|"Psychological or psychiatric patients, devoid of suicidal ideation, recruited by staff doctors and psychologists from the child and adolescent psychiatry units of the Álvaro Cunqueiro Hospital in Vigo and the University Hospital Complex in Ourense, who have been deemed suitable for participation and have had the participation conditions explained to them and their parents, will undergo the following assessment protocol:~Paykel scale Mini International Neuropsychiatric Interview (MINI) Strengths and Difficulties Questionnaire (SDQ) Mood and Feelings Questionnaire (MFQ) European Bullying Intervention Project Questionnaire (EBIP-Q) Problematic Internet Use Scale in Adolescents (EUPI-A) Millon Adolescent Clinical Inventory (MACI)~Multimodal experimental battery:~Recording of voice features Video recording of facial microexpression Registering of autobiographical texts Collecting of saliva samples"
62527764|NCT06341634||General Population|"Students with no known psychological or psychiatric issues, and free of suicidal ideation in the past year, recruited from schools among students who voluntarily agree to participate, and who have been deemed suitable for participation and have had the participation conditions explained to them and their parents, will undergo the following assessment protocol:~Paykel scale Mini International Neuropsychiatric Interview (MINI) Strengths and Difficulties Questionnaire (SDQ) Mood and Feelings Questionnaire (MFQ) European Bullying Intervention Project Questionnaire (EBIP-Q) Problematic Internet Use Scale in Adolescents (EUPI-A) Millon Adolescent Clinical Inventory (MACI)~Multimodal experimental battery:~Recording of voice features Video recording of facial microexpression Registering of autobiographical texts Collecting of saliva samples"
62527765|NCT06449326|ACTIVE_COMPARATOR|Active iTBS|Participants in this arm will undergo 50 sessions of active accelerated (10x/day, five days) image-guided iTBS.
62713638|NCT06403449|EXPERIMENTAL|G-WET|
62713639|NCT06403449|OTHER|Waiting-List (WL) condition|
62154181|NCT02955225|ACTIVE_COMPARATOR|Flexible shoe with Passive Insole|A flexible walking shoe with a passive pressure-detecting shoe insole will be used for a comparator group.
62154182|NCT00778609|EXPERIMENTAL|Arm 1|
62154183|NCT00778609|ACTIVE_COMPARATOR|Arm 2|
62154184|NCT02008214|EXPERIMENTAL|PTX|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral PTX 400 mg each 12 h, oral
62154185|NCT02008214|PLACEBO_COMPARATOR|Placebo|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral Placebo oral daily
62154186|NCT05334225||Health Workers|Doctors, nurses, paramedics, midwifes
62154187|NCT01128439||1|
62154188|NCT02028390|EXPERIMENTAL|subjects with external wounds|Subjects with external wounds or body surface areas of interest are imaged visually and thermally with the Scout to trace the wound's perimeter visually and measure thermal variation data as described in the primary outcomes, using the ImageReview software.
62154189|NCT01748058|EXPERIMENTAL|Active video games|Exercise based on active video gaming
62154190|NCT01748058|NO_INTERVENTION|Routine care|
62154191|NCT01147757|PLACEBO_COMPARATOR|saline|Group S (n = 15): saline
62154192|NCT01147757|EXPERIMENTAL|remifentanil 0.3 mcg/kg/min|Group 0.3 (n = 15): remifentanil 0.3 mcg/kg/min
62154193|NCT01147757|EXPERIMENTAL|remifentanil 0.6 mcg/kg/min|Group 0.6 (n = 15): remifentanil 0.6 mcg/kg/min
62154194|NCT01147757|EXPERIMENTAL|remifentanil 0.9 mcg/kg/min|Group 0.9 (n = 15): remifentanil 0.9 mcg/kg/min
62154195|NCT01117285|ACTIVE_COMPARATOR|3-day post-graduate course|3-day post-graduate course on the use of the COTiD program in clinical practice
62154196|NCT01117285|EXPERIMENTAL|Combined implementation strategy|The combined implementation strategy
61975675|NCT04062331|PLACEBO_COMPARATOR|Placebo group|This group will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) without any frequency (device doesn't running; it means, device turned off) but the same duration of sessions.
62154197|NCT05401188|ACTIVE_COMPARATOR|hospitalization group|Patients in the hospitalization group, once the surgical intervention was finished, were transferred to the postoperative recovery unit and later they were discharged to the usual hospital ward. Patients received adequate intravenous fluid resuscitation based on their individual hemodynamic parameter and fluid balance, and they received analgesia according to personal requirement. In the hospital ward, the usual patient management protocols were followed until a complete recovery and consequently discharged according to the usual criteria.
62713640|NCT05859113|EXPERIMENTAL|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
62154198|NCT05401188|EXPERIMENTAL|outpatient group|Patients in the outpatient group , once operated, were transferred to the surgery unit without admission and were later discharged home if they met the ALDRETE criteria in less than 23 hours after the intervention (following the surgery criteria without admission stages). If the patient was operated during the night shift, following the advice of major outpatient surgery where overnight stays are allowed, the patient was admitted to the post-anesthetic recovery unit and discharged the next day, always in less than 23 hours. In case of being discharged after 23 hours or not meeting ALDRETE criteria, it was considered a failure of the outpatient treatment.
62154199|NCT05351411||combined progressive functional exercise|The initial implementation for the 8-week (3 days per week) combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike. The second part of the combined exercise program, the progressive resistance training program, is designed to be consistent with the resistance training section of the Canadian Physical Activity Guidelines for adults with MS. Each prescribed session consisted of 1-3 sets and 10-15 repetitions of 10 exercises targeting major muscle groups of the upper and lower extremities. The specific exercises prescribed included lunges, chair raises/squats, calf raises, knee flexion, knee extensions, shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, and abdominal curls.
62154200|NCT05351411||Placebo|Participants in the control group maintained their routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
62154201|NCT05179772|EXPERIMENTAL|Olanzapine|Everyone in the study is being given Olanzapine (open label)
62154202|NCT05320133|EXPERIMENTAL|JWC group|Jinghua Weikang Capsule containing quadruple therapy.
62154203|NCT05320133|ACTIVE_COMPARATOR|Control group|Bismuth-containing quadruple therapy.
62154204|NCT06485947|EXPERIMENTAL|Dinutuximab Beta with chemotherapy treatment called GPOH|Dinutuximab Beta will be administered at a fixed daily dose of 10 mg/m2 given as a 24-hour continuous infusion for a scheduled number of days within each treatment cycle of chemotherapy.
62154205|NCT06485947|EXPERIMENTAL|Dinutuximab Beta with chemotherapy treatment called rapid COJEC|Dinutuximab Beta will be administered at a fixed daily dose of 10 mg/m2 given as a 24-hour continuous infusion for a scheduled number of days within each treatment cycle of chemotherapy.
62527766|NCT06449326|SHAM_COMPARATOR|Sham iTBS|Participants in this arm will undergo 50 sessions of sham accelerated (10x/day, five days) image-guided iTBS.
62527767|NCT03713879|EXPERIMENTAL|indomethacin|rectal indomethacin 100 mg to be administered before or after ERCP
62527768|NCT03713879|EXPERIMENTAL|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
62527769|NCT03713879|EXPERIMENTAL|indomethacin plus pancreatic stenting|"\[rectal indomethacin 100 mg to be administered before or after ERCP\] plus \[a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire\]"
62527770|NCT01642459|EXPERIMENTAL|Same direction cannulation|The inserted direction of arterial needle is same as the direction of blood flow.
62527771|NCT01642459|ACTIVE_COMPARATOR|Opposite direction cannulation|The inserted direction of arterial needle is opposite to the direction of blood flow.
62527772|NCT02944383|EXPERIMENTAL|Gemcabene 300 mg|Participants received 300 mg Gemcabene orally, once daily for 12 weeks.
62527773|NCT02944383|EXPERIMENTAL|Gemcabene 600 mg|Participants received 600 mg Gemcabene orally, once daily for 12 weeks.
62527774|NCT02944383|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo orally, once daily for 12 weeks.
62713641|NCT05859113|ACTIVE_COMPARATOR|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
62713642|NCT05101720|EXPERIMENTAL|Ultrasound Guided Axillary Access|Direct visualization of axillary vein with ultrasound will be obtained and used as a guidance for venous puncture.
62154206|NCT01435720|EXPERIMENTAL|Cohort 1|0.0125 mg/kg
62154207|NCT01435720|EXPERIMENTAL|Cohort 2|0.05 mg/kg
62154208|NCT01435720|EXPERIMENTAL|Cohort 3|0.2 mg/kg
62154209|NCT01435720|EXPERIMENTAL|Cohort 4|0.375 mg/kg
62154210|NCT05584306|EXPERIMENTAL|610 30mg group|610 30 mg administered subcutaneously every 4 weeks
62154211|NCT05584306|EXPERIMENTAL|610 100mg group|610 100 mg administered subcutaneously every 4 weeks
62154212|NCT05584306|EXPERIMENTAL|610 300mg group|610 300mg administered subcutaneously every 4 weeks
62527775|NCT01219413|EXPERIMENTAL|aliskiren, placebo, perindopril|
62527776|NCT01219413|EXPERIMENTAL|perindopril, placebo, aliskiren|
62527777|NCT03743740|EXPERIMENTAL|Group 1|"first, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.~then, exercises will be suspended for 4 weeks. then, patients will undergo home based program 3 days per week for 6 weeks."
62527778|NCT03743740|EXPERIMENTAL|Group 2|first, patients will undergo home based program 3 days per week for 6 weeks. then, exercises will be suspended for 4 weeks. then, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
62527779|NCT02445417||EES|Epidermal Electronic System
62527780|NCT02445417||Hydrogel Electrode|Hydrogel based EEG electrode
62527781|NCT01425333|ACTIVE_COMPARATOR|Cystectomy|Patients undergoing cystectomy for ovarian endometrioma
62527782|NCT01425333|ACTIVE_COMPARATOR|Ablation|Patients undergoing ablation for ovarian endometrioma
62713643|NCT05101720|ACTIVE_COMPARATOR|Fluoroscopic Guided Axillary Access|Standard technique: using the intersection of the lateral borders of the second and third rib as a radiological landmarks.
62527783|NCT01339663|EXPERIMENTAL|Treatment (dose-escalation, T-APC boost, CTL)|"INFUSION I: Patients receive high-dose cyclophosphamide IV on day days -4 and -3 and low-dose IL-2 SC BID on days 0-14. Patients also receive CTL IV on day 0.~INFUSION II: Beginning 6-48 hours later, patients receive high-dose cyclophosphamide, low-dose IL-2, and CTL as in Infusion I. Patients also receive T-APC vaccine IV within 18-36 hours following CTL infusion and in week 4, and IL-2 SC BID on days 0-14 following second T-APC vaccination."
62527784|NCT04712617||FGIDs|Patient who were diagnosed with NERD/RH, FD, IBS and their overlaps (NERD/RH-FD, NERD/RH-IBS, FD-IBS, NERD/RH-FD-IBS)
62527785|NCT04712617||Healthy controls|Subjects who underwent GI evaluations as part of health check-up or for other problems, such as mild abdominal discomfort or pain for a relatively short period of time, but had no organic problems during GI endoscopy
62527786|NCT04804865||population|"The population includes adult patients.~* Patients died from refractory or relapsed diffuse large-cell lymphoma.~* Patients \<65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant.~* Patients \>65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles)."
62527787|NCT02546336|EXPERIMENTAL|Ultrasound-Guided Hip Denervation|This is a pilot study. 15 Hip Osteoarthritis patients with chronic pain will be recruited in this pilot arm. These will undergo Ultrasound-Guided Cooled Radiofrequency Hip Denervation as intervention.
62527788|NCT03880435|EXPERIMENTAL|Hyalobarrier® gel endo|Application of Hyalobarrier® gel endo immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second-look hysteroscopy)
62527789|NCT03880435|NO_INTERVENTION|No Hyalobarrier® gel endo|No application of Hyalobarrier® gel endo after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second- or third-look hysteroscopy)
62713644|NCT05443529||Adaptive sports group|Individuals with stroke who regularly, and on a long-term basis, participate in adaptive sports
62527790|NCT04576052||antibiotic-coating|patients who have been treated with an antibiotic-coated nail for tibia-fracture
62527791|NCT04576052||non-coated|patients who have been treated with a non-coated nail for tibia fracture
62527792|NCT00103311|EXPERIMENTAL|Arm I|Patients receive SB-715992 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62527793|NCT00103311|EXPERIMENTAL|Arm II|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62527794|NCT01294826|EXPERIMENTAL|AUY922 plus Cetuximab|
62527795|NCT03785392|ACTIVE_COMPARATOR|Group 1 Inplane|Study with the technique Inplane group
62527796|NCT03785392|ACTIVE_COMPARATOR|Group 2 out of plane|Study with the technique out of plane
62713645|NCT05443529||Non adaptive sports group|Individuals with stroke who do not engage in adaptive sports
62713646|NCT05123326||PVT|Portal Vein Thrombosis (PVT) refers to partial or complete occlusion of the portal vein lumen by a blood clot or its replacement by multiple collateral vessels with the hepato-petal flow, commonly known as 'portal cavernoma.' 240 patients to be recruited
62713647|NCT05123326||HVOTO|Occlusion of two or more hepatic veins. 100 patients
62713648|NCT03619564||No protein restriction|No protein restriction
62713649|NCT03619564||Low protein diet (LPD)|LPD: \< 0.8 g/kg bodyweight
62713650|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
62154213|NCT05584306|PLACEBO_COMPARATOR|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
62154214|NCT05584306|PLACEBO_COMPARATOR|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
62154215|NCT05584306|PLACEBO_COMPARATOR|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
62154216|NCT03999294|NO_INTERVENTION|Control Group|
62154217|NCT03999294|EXPERIMENTAL|Experimental Group|
62527797|NCT04068636|EXPERIMENTAL|Flexible endoscopy guided SNB in larynx and pharynx cancers.|Patients with larynx and pharynx cancers will undergo sentinel node biopsy via flexible endoscopy. In this procedure, a radioactive tracer will be injected at 2-4 sites edging the tumor. A SPECT scan will be performed for visualization of the sentinel node(s).
62527798|NCT00568815|EXPERIMENTAL|Chemo|
62527799|NCT01136993||All bi-directional telestroke consultations|
62527800|NCT01019928|EXPERIMENTAL|First AZD1386, then washout, then placebo|
62527801|NCT01019928|EXPERIMENTAL|First placebo, then washout, then AZD1386|
62527802|NCT03738020|EXPERIMENTAL|HA IDF|
62527803|NCT03738020|ACTIVE_COMPARATOR|Restylane|
62527804|NCT03277638|EXPERIMENTAL|Pembrolizumab injections 7 days before surgery|Patients will have intravenous pembrolizumab 7 days before surgery with Laser Interstitial Thermotherapy
62527805|NCT03277638|EXPERIMENTAL|Pembrolizumab injections 14 days after surgery|Patients will have intravenous pembrolizumab 14 days after surgery with Laser Interstitial Thermotherapy
62527806|NCT03277638|EXPERIMENTAL|Pembrolizumab injections 35 days after surgery|Patients will have intravenous pembrolizumab 35 days after surgery with Laser Interstitial Thermotherapy
62527807|NCT04852900|EXPERIMENTAL|Decompression with 30%|Decompression with 30% and mobilization
62527808|NCT04852900|EXPERIMENTAL|Decompression with 40%|Decompression with 40% and mobilization
62527809|NCT04852900|EXPERIMENTAL|Decompression with 50%|Decompression with 50% and mobilization
62527810|NCT04571125||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
62527811|NCT04571125||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
62527812|NCT00612430|EXPERIMENTAL|Bevacizumab + Etoposide|Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.
62527813|NCT00405886|EXPERIMENTAL|Neramexane 25mg/d|
62527814|NCT00405886|EXPERIMENTAL|Neramexane 50mg/d|
62527815|NCT00405886|EXPERIMENTAL|Neramexane 75mg/d|
62527816|NCT00405886|PLACEBO_COMPARATOR|Placebo|
62527817|NCT01631175|EXPERIMENTAL|(PO-Bado, FBK-R10, PHQ) Active Comparator|
62713651|NCT06088173|EXPERIMENTAL|Early Passive Mobilization Group|This group will be given Modifiye Kleinert Protocol based rehabilitation
62713652|NCT06088173|EXPERIMENTAL|Graded Motor Imagery Training Group|This group will be given Modifiye Kleinert Protocol and Graded Motor Imagery Training
62713653|NCT04778592|EXPERIMENTAL|ETX-018810|Drug: ETX-018810 BID for 4 weeks
62527818|NCT02473783|EXPERIMENTAL|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
62527819|NCT04198636|EXPERIMENTAL|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
62154218|NCT04212299|EXPERIMENTAL|Baseline ischial containment to subischial socket|
62527820|NCT04198636|ACTIVE_COMPARATOR|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
62527821|NCT00500747|EXPERIMENTAL|Group C: 100 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 100 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
62527822|NCT00500747|EXPERIMENTAL|Group B: 20 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 20 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
62527823|NCT00500747|EXPERIMENTAL|Group A: 4 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 4 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
62527824|NCT01461564|EXPERIMENTAL|Carbon dioxide|Patients insufflated with carbon dioxide during screening colonoscopy
62713654|NCT04778592|PLACEBO_COMPARATOR|Placebo|Matching Placebo BID for 4 weeks
62713655|NCT06519565|EXPERIMENTAL|PRG-1801(BCMA-targeting CAR-T Cells)|"The study was structured into two distinct phases: the dose exploration phase and the dose expansion phase. During the dose exploration phase, three dosage levels were established-35x10\^6 CAR-T, 100x10\^6 CAR-T, and 300x10\^6 CAR-T-with each dosage group comprising 3 to 6 subjects with Immune Thrombocytopenia (ITP). If dose-limiting toxicity (DLT) was observed in one out of three subjects within any dosage group, an additional three subjects were enrolled at the same dosage level. Should DLT be present in two or more out of six subjects, considerations for dose reduction or potential study discontinuation were made.~Upon determining the safe and effective fixed dose of PRG-1801 during the dose exploration phase, the study progressed to the dose expansion phase. This subsequent phase involved enrolling an additional 3 to 6 subjects at the established fixed dose. The aim was to further assess and confirm the safety and efficacy of this specific dose for treating ITP."
62713656|NCT03916809|EXPERIMENTAL|Active EMST + Standard Care|Patients randomized to the Active EMST + Standard Care arm (ACTIVE) will use the EMST150 device as packaged, i.e. following package instructions with a device that has its valve spring maintained.
62154219|NCT05197088|EXPERIMENTAL|1 week of tamsulosin|1 week of tamsulosin tablet 400mcg once a night
62154220|NCT05197088|NO_INTERVENTION|no additional medication|
62154221|NCT05963113|EXPERIMENTAL|Control, then Swallowing Exercises + Protein|"Participants randomized to 12 weeks of swallowing exercises with protein supplementation, after completing an initial 12-week period of usual activity."
62527825|NCT01461564|ACTIVE_COMPARATOR|Air|Patients insufflated with air during screening colonoscopy
62527826|NCT06131749||Pregnant women|No intervention. Followed during pregnancy at baseline and 30-34 weeks. Followed after delivery at 3-6 days.
62527827|NCT03984123|OTHER|Double cuff inflation|The first arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end-diastolic volume of left ventricle
62527828|NCT03984123|OTHER|Single cuff inflation|The second arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
62154222|NCT05963113|ACTIVE_COMPARATOR|Control, then Swallowing Exercises|"Participants randomized to 12 weeks of swallowing exercises without protein supplementation, after completing an initial 12-week period of usual activity."
62154223|NCT02834559|ACTIVE_COMPARATOR|Adjuvant therapy with 5-FU and LMWH|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
62154224|NCT02834559|PLACEBO_COMPARATOR|Standard of care|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
62154225|NCT06085859|EXPERIMENTAL|Mask oxygen supply group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter
62154226|NCT06085859|EXPERIMENTAL|Nasal oxygen supply group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
62154227|NCT01790100|EXPERIMENTAL|VX-135 low dose in combination with ribavirin|12 weeks of VX-135 in combination with ribavirin
62154228|NCT01790100|EXPERIMENTAL|VX-135 high dose in combination with ribavirin|
62154229|NCT02053714|OTHER|Self-management and education group|Self-management and education group - 8 weeks of group-based information and activities designed to improve diabetes self-management
62154230|NCT03498456|EXPERIMENTAL|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
62154231|NCT03498456|ACTIVE_COMPARATOR|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
62527829|NCT03984123|NO_INTERVENTION|Standard treatment|The third arm utilizes no cuff inflation to cause remote conditioning and serves as control group. Follow up echocardiography is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
62527830|NCT02807168|NO_INTERVENTION|Usual care|Control Group
62527831|NCT02807168|EXPERIMENTAL|Usual care plus NT-proBNP|Experimental Group
62527832|NCT05080101|ACTIVE_COMPARATOR|Conventional Physiotherapy Group|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
62154232|NCT00914056|EXPERIMENTAL|Lactulose withdrawal|Patients who were started on lactulose as a result of a precipitated HE episode underwent analysis while they were on lactulose; after this they underwent a controlled lactulose withdrawal with 3 visits post-withdrawal at 2 days, 14 days and 30 days after lactulose withdrawal
62527833|NCT05080101|EXPERIMENTAL|Basic Body Awareness Therapy Group|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
62154233|NCT00818519|EXPERIMENTAL|EE20/Drospirenone (YAZ, BAY86-5300)|In the active treatment group, participants received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP (Drospirenone) and 20µg EE (Ethinyl estradiol).
62527834|NCT05805735|EXPERIMENTAL|Face care product (Eye cream)|Comparison between assessment times. Assessments will be performed before, after 2, 4 and 8 weeks of product application.
62527835|NCT01430663||Hematological patients with proven or probable aspergillosis|
62527836|NCT01430663||Hematological patients with possible aspergillosis|
62527837|NCT00085423|EXPERIMENTAL|IL-2, CTX, fludarabine, GM-CSF|Aldesleukin (IL-2), cyclophosphamide, fludarabine phosphate, sargramostim
62527838|NCT01529918|EXPERIMENTAL|web-intervention group|Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version
62527839|NCT01529918|NO_INTERVENTION|paper-based group|Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based
62527840|NCT02054130|PLACEBO_COMPARATOR|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
62527841|NCT02054130|EXPERIMENTAL|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
62527842|NCT02054130|EXPERIMENTAL|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
62527843|NCT02054130|EXPERIMENTAL|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
62154234|NCT00818519|PLACEBO_COMPARATOR|Placebo|The participants of the placebo group received inert but identical-appearing, color-matched tablets.
62154235|NCT00911391|ACTIVE_COMPARATOR|Fluid restriction|Current best practice of intraoperative fluid restriction
62154236|NCT00911391|EXPERIMENTAL|Oesophageal Doppler|Oesophageal Doppler-guided fluid administration
62154237|NCT01531699|EXPERIMENTAL|ALT005 Ophthalmic Prep Solution|
62527844|NCT02488330|EXPERIMENTAL|Control and/or Onartuzumab treatment|Participants will receive treatment with either the control treatment (erlotinib, bevacizumab) and/or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first). All participants will continue on the same dose and schedule of control treatment as specified in their respective P-trial. The dose of onartuzumab will be calculated based on the participant's weight at the screening visit for the E-trial.
62527845|NCT01557738|EXPERIMENTAL|Acute effects of flavanol consumption|The outcome measurements will be made on all study participants before and 2 hours after consumption of the high flavanol beverage.
62527846|NCT01557738|PLACEBO_COMPARATOR|Low Flavanol Trial; acute effects|Once again, the outcome measurements will be made on all study participants before and 2 hours after consumption of the low flavanol beverage.
61975676|NCT04062331|EXPERIMENTAL|Group under TMS 1 Hertz treatment|1 Hertz group (1 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 1 Hertz.
62154238|NCT01531699|PLACEBO_COMPARATOR|saline control|
62154239|NCT01531699|EXPERIMENTAL|Comparator Product|Betadine ophthalmic prep solution
62154240|NCT03743688||Influenza Vaccine Recipients (ccIIV-4)|All participants will receive one dose of FDA-approved inactivated influenza vaccine (Flucelvax Quadrivalent) via intramuscular injection (0.5 mL) as part of their standard of care.
62154241|NCT00595764|ACTIVE_COMPARATOR|1|Physician Management
62154242|NCT00595764|EXPERIMENTAL|2|Physician Management plus Cognitive Behavioral Therapy
62154243|NCT03130946|EXPERIMENTAL|Cryo-assisted core needle biopsy|Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.
62154244|NCT03130946|ACTIVE_COMPARATOR|Fine needle aspiration alone|Patients undergo lymph node biopsy with FNA alone.
62154245|NCT01086098||All paced patients|
62154246|NCT01118156||Mental Health Clinicians|MH Clinicians at the Denver and Grand Junction VA Medical Centers
62527847|NCT01557738|EXPERIMENTAL|Long-term effects of flavanol consumption|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a high flavanol beverage.
62154247|NCT05168345|EXPERIMENTAL|IBD patients|"Arm 1: IBD patients, patients of other chronic GI disease' and healthy volunteers~Both groups will be asked to fill in the knowledge questionnaire and the self-assessment of knowledge questionnaire once, during their routine visit to the GI department. Results of the questionnaire will be compared between the groups.~IBD Patient's knowledge will also be subjectively assessed by their treating physician during their routine clinical visit, and knowledge scores will be compared (physician and questionnaire). Patients who will agree, will be asked to fill in the knowledge questionnaire a second time after two weeks for reliability testing. Patients will be recruited to represent all stages of diagnosis and all patient age groups. This will be done by recruitment of six main participant groups stratified by age (18-23 years, 24-36 years, 42-52 years, 53-70 years) and disease duration (\<1 year since diagnosis, ≥1 year since diagnosis)"
62154248|NCT03602807|EXPERIMENTAL|Active treatment|
62154249|NCT06503991|EXPERIMENTAL|COBRA and CHAMP (COACH) adapted intervention|Persons living with HIV (PLWH) and receiving routine HIV care in northern Tanzania will receive an integrated COBRA (Control of Blood Pressure and Risk Attenuation) and CHAMP (Community Health Worker-delivered Hypertension Management Pilot) multi-component hypertension intervention.
62154250|NCT03883984|EXPERIMENTAL|Cysteamine|Cysteamine Bitartrate plus standard asthma care
62154251|NCT03883984|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo plus standard asthma care
62154252|NCT02125409|EXPERIMENTAL|Group 1|Group 1, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at from 6-7 h after the last dose of ASA.
62154253|NCT02125409|EXPERIMENTAL|Group 2|Group 2, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at 24 hours after the last dose.
62154254|NCT00895076|EXPERIMENTAL|1|dexamethasone iontophoretic patch
62154255|NCT00895076|ACTIVE_COMPARATOR|2|dexamethasone intramuscular injection
62527848|NCT01557738|PLACEBO_COMPARATOR|Low Flavanol Trial; long-term effects|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a low flavanol beverage.
62527849|NCT01182558|OTHER|Activation of Hypothenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
62527850|NCT01182558|OTHER|Activation of Thenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
62527851|NCT01182558|OTHER|Activation of Extensor Digitorum Brevis|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
62527852|NCT01182558|PLACEBO_COMPARATOR|Maintain Relaxation of the Opposite Side|While the muscle of the right side is activated periodically and the compound muscle action potential is tested frequently, the muscle on the left side is maintained at rest and the compound muscle action potential is tested infrequently.
62527853|NCT01432418|EXPERIMENTAL|wheelchair training|
62527854|NCT01432418|NO_INTERVENTION|Control|Standard of care only
62527855|NCT01763684|ACTIVE_COMPARATOR|Signature Custom Guides|Oxford Partial Knee implanted using Signature Custom Guides
61975677|NCT04062331|EXPERIMENTAL|Group under TMS 5 Hertz treatment|5 Hertz group (5 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 5 Hertz .
62154256|NCT01034774|ACTIVE_COMPARATOR|ACHN-490 Injection|ACHN-490 Injection will be given either 1 or 5 consecutive days at a dose of 15mg/kg.
62154257|NCT01034774|PLACEBO_COMPARATOR|Placebo is Normal Saline|Placebo will be given either 1 or 5 consecutive days to mask when ACHN-490 Injection is given.
62154258|NCT02784366||Cancer immunotherapy patients - no GI side effect|Cancer immunotherapy patients who do not develop GI side effects.
62154259|NCT02784366||Cancer immunotherapy patients - develop GI side effects|Cancer immunotherapy patients who develop GI side effects
62527856|NCT01763684|ACTIVE_COMPARATOR|Conventional Instrumentation|Oxford Partial Knee implanted using Conventional Instrumentation
62527857|NCT01677923|NO_INTERVENTION|Control without Metformin|Conventional management of obesity including basic instructions on diet and physical activity
62527858|NCT01677923|EXPERIMENTAL|Control with Metformin|Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
62527859|NCT01677923|EXPERIMENTAL|Intervention with Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
62527860|NCT01677923|NO_INTERVENTION|Intervention without Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian
62527861|NCT03481218||Patients with type 1 diabetes|Young adults (male and female) between the ages of 18 and 35, who have type 1 diabetes for at least one year.
62527862|NCT03481218||Individuals without chronic diseases|Young adults (male and female) between the ages of 18 and 35, without chronic diseases.
62527863|NCT00749541||1normal catheter.|
62527864|NCT00749541||abnormal catheter.|
62527865|NCT02866526||group1|adolescents (14-17 years old)
62527866|NCT02866526||group 2|young adults (20-29 years old)
62527867|NCT04442490|PLACEBO_COMPARATOR|Placebo|Participants self-administered SAGE-217 matched-placebo capsules, once daily at approximately 8 PM with fat-containing food for 14 days.
62527868|NCT04442490|EXPERIMENTAL|SAGE-217 50 mg|Participants self-administered SAGE-217 50 mg capsules, once daily at approximately 8 PM with fat-containing food for 14 days. Participants who could not tolerate 50 mg received 40 mg for the remainder of the treatment period as per discretion of investigator.
62527869|NCT03678324|OTHER|Fabry|Must be 18 or older and able to have an MRI.
62154260|NCT00589628|ACTIVE_COMPARATOR|1|5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
62154261|NCT00589628|ACTIVE_COMPARATOR|2|10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.
62154262|NCT02491645|EXPERIMENTAL|Intervention group|"Children would receive both standard therapy and home based sensory interventions as described below,~* Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs .~* Home based sensory interventions - children would receive home based sensory interventions targeting visual and auditory system, tactile abnormalities, proprioceptive and vestibular abnormalities.These interventions would be carried out daily , at least 5 days a week, for a minimum duration of 1hour/day."
62154263|NCT02491645|NO_INTERVENTION|Control group|This group of children would receive only standard therapy as described below, Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs.
62154264|NCT02274116|ACTIVE_COMPARATOR|Intermittent Hypoxia (AIH)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of low oxygen.~Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes"
62154265|NCT02274116|SHAM_COMPARATOR|Intermittent Room Air (SHAM)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of room air.~Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes"
62154266|NCT01819857|ACTIVE_COMPARATOR|Droperidol 0.625 mg intravenously|
62154267|NCT01819857|ACTIVE_COMPARATOR|Droperidol 1.25 mg intravenously|
62154268|NCT01819857|ACTIVE_COMPARATOR|Ondansetron 8 mg intravenously|
62154269|NCT04243772||Lithiasic patients|Lithiasic patients of the CHU Brugmann Hospital
62154270|NCT02025712|EXPERIMENTAL|Exemestane plus Everolimus|Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
62154271|NCT01558765|EXPERIMENTAL|Intervention group|Patients receive integrated rehabilitation
62154272|NCT01558765|NO_INTERVENTION|Control group|Patients receive usual follow-up care without physical exercise
62154273|NCT06096727|EXPERIMENTAL|Energize!|Participants randomized to Energize! will start the program immediately after baseline.
62527870|NCT04373044|PLACEBO_COMPARATOR|Arm II (placebo, antiviral therapy)|Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
62527871|NCT04373044|EXPERIMENTAL|Treatment (baricitinib, antiviral therapy)|Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
62527872|NCT06111274|EXPERIMENTAL|ABSK021 with chemotherapy|There are 2 cohorts in both part A and Part B. In cohort 1, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel) , 3 weeks as one cycle, about 8 cycles in total.
62527873|NCT06111274|EXPERIMENTAL|ABSK021 in combination with chemotherapy plus the Toripalimab|There are 2 cohorts in both part A and Part B. In cohort 2, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel), with Toripalimab, 3 weeks as one cycle, about 8 cycles in total.
62527874|NCT03911518|ACTIVE_COMPARATOR|Control|Incision and drainage.
62154274|NCT06096727|OTHER|Delayed Energize!|Participants randomized to Delayed Energize! will start the program after the 3 month assessment.
62154275|NCT05730192|EXPERIMENTAL|CADDIE colonoscopy (CADDIE Arm)|CADDIE is a computer-assisted detection (CADe) device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract.
62154276|NCT05730192|ACTIVE_COMPARATOR|Standard high-definition white light colonoscopy (Control Arm)|Patients will receive a standard colonoscopy
62527875|NCT03911518|EXPERIMENTAL|Intervention|Loop drainage.
62527876|NCT04029441||the successful eradication cohort|the subjects who eradicate the Hp successfully after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
62527877|NCT04029441||the failure eradication cohort|the subjects who fail to eradicate the Hp after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
62527878|NCT02753491|ACTIVE_COMPARATOR|Intervention|In intervention group, three or four motivational short interview made with every participants.
62527879|NCT02753491|NO_INTERVENTION|Control|non intervention group,
62154277|NCT03323502|EXPERIMENTAL|ACP Specialist Program|The ACP Specialist will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients who have Alzheimer's Disease/related dementias and their family caregivers.
62154278|NCT03323502|NO_INTERVENTION|Control|There is no study interaction with control facilities. Facility will follow usual ACP procedures.
62154279|NCT03709225|EXPERIMENTAL|Music-based meditation|"The music therapy intervention consists of four in-person sessions (45 minutes) over twelve weeks. Content includes:~* Introduction to music therapy and mindfulness~* Music-based meditation~* Using personal music to shift energy, mood, and support relaxation~* Mindfulness through active music making~* Discuss bringing mindfulness to daily activities"
62154280|NCT03955406|ACTIVE_COMPARATOR|Conventional group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 6% with fresh gas flow rate 4 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 1% higher value than the EtAA concentration required to achieve 0.7 MAC. And after 10 minutes fresh gas flow rate will be reduced to 1L/min.
62527880|NCT00580216|EXPERIMENTAL|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 7 weeks followed a maintenance dosing adjusted according to the age and to the renal function for a minimum total treatment duration of 6 months.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or overdosage)."
62527881|NCT00580216|ACTIVE_COMPARATOR|Warfarin|Warfarin, INR-adjusted dose, for a minimum total treatment duration of 6 months.
62527882|NCT03050060|EXPERIMENTAL|Treatment (nelfinavir, immunotherapy, radiation therapy)|Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab, nivolumab or atezolizumab. The study will exclude irradiation of liver metastases as an added precaution.
62154281|NCT03955406|ACTIVE_COMPARATOR|Fixed Fresh Gas Flow Rate group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 18% with fresh gas flow rate 1 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 2% higher value than the EtAA concentration required to achieve 0.7 MAC.
62154282|NCT03000829|EXPERIMENTAL|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest response team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
62527883|NCT05502692||Cohort 1|ADVANCE patient cohort, who have been on the TLD state programme for more than one year
62527884|NCT05502692||Cohort 2|Existing cohorts of patients initiating TLE (and subsequently switched to TEE) more than 9 years ago and who have since transitioned to TLD within the state programme for more than one year.
62527885|NCT05042115|EXPERIMENTAL|Education in pain neurosciences and clinical hypnosis|Pain neuroscience education and clinical hypnosis
62527886|NCT05042115|ACTIVE_COMPARATOR|Education in pain neurosciences and clinical hypnosis plus Osteopathic manipulative treatment|Pain neuroscience education and clinical hypnosis, associated with osteopathic manipulative treatment
62527887|NCT04203875|EXPERIMENTAL|Orencia® (Abatacept)|Abatacept 125 mg, subcutaneous once a week for 6 months or up to one year if subject has a favorable response
62527888|NCT02039466|ACTIVE_COMPARATOR|volume controlled ventilation|volume controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
62527889|NCT02039466|ACTIVE_COMPARATOR|pressure controlled ventilation|pressure controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
62527890|NCT04761874|NO_INTERVENTION|In-Person (Conventional) Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from December 1, 2019-March 15, 2020 that were evaluated, managed, and treated by the stroke care team in person.
62527891|NCT04761874|EXPERIMENTAL|Telestroke Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from March 16, 2020-June 29, 2020 that were evaluated, managed, and treated by the stroke care team remotely via telestroke.
62527892|NCT06233084|EXPERIMENTAL|Sequence 1- Desogestrel test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Desogestrel tablets 0.075 mg test product, treatment 2= Desogestrel tablets 0.075 mg reference product.
62527893|NCT06233084|EXPERIMENTAL|Sequence 2-Desogestrel reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Desogestrel tablets 0.075 mg test product, treatment 2= Desogestrel tablets 0.075 mg reference product.
62527894|NCT01816919|EXPERIMENTAL|eNose breath samples|
62527895|NCT03137927|EXPERIMENTAL|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5\*10\*8 bacteria cells (CFU)
62527896|NCT03137927|PLACEBO_COMPARATOR|Group 1 placebo|3 individuals will get placebo
62527897|NCT03137927|EXPERIMENTAL|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10\*9 bacteria cells(CFU)
62527898|NCT03137927|PLACEBO_COMPARATOR|Group 2 placebo|3 individuals will get placebo
62713657|NCT03916809|SHAM_COMPARATOR|Sham EMST + Standard Care|Those randomized to the Sham EMST + Standard Care arm (SHAM) will use an EMST150 device that has been modified by removing the internal spring, which allows the valve to open in response to airflow through the device regardless of the amount of pressure generated.
62154283|NCT03000829|PLACEBO_COMPARATOR|Control|"Simulated observation by ICU physician by displaying a silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site participants will be told that an intensive care physician is observing the mock code."
62154284|NCT04776122|ACTIVE_COMPARATOR|Control with no device|Breathing performed with no device
62527899|NCT03137927|EXPERIMENTAL|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4\*10\*9 bacteria cells(CFU)
62154285|NCT04776122|EXPERIMENTAL|Therapy - device assisted breathing|Breathing performed with device
62527900|NCT03137927|PLACEBO_COMPARATOR|Group 3 placebo|3 individuals will get placebo
62527901|NCT03178032|EXPERIMENTAL|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
62527902|NCT05067530|EXPERIMENTAL|CDK4/6 inhibitor alone: Palbociclib (IMP)|Palbociclib alone (125 mg orally (PO) per day, days 1-14)
62527903|NCT05067530|ACTIVE_COMPARATOR|Chemotherapy alone: Paclitaxel|Paclitaxel alone (80 mg/m\^2 intravenously (IV), day 1, 8, 15 and 22)
62527904|NCT05067530|EXPERIMENTAL|CDK4/6 inhibitor + chemotherapy: Paclitaxel + Palbociclib|Paclitaxel (80 mg/m\^2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
62527905|NCT05067530|ACTIVE_COMPARATOR|Chemotherapy alone: Carboplatin|Carboplatin alone (area under the curve (AUC) 2 IV, day 1, 8, 15 and 22)
62527906|NCT05067530|EXPERIMENTAL|CDK4/6 inhibitor + chemotherapy: Carboplatin + Palbociclib|Carboplatin (AUC 2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
62713658|NCT05497375|ACTIVE_COMPARATOR|Group Hypocapnia|End-tidal carbon dioxide level will be 30±2 mmHg in the capnography, and the respiratory rate will be 14-20/minutes in the hypocapnia group.
62713659|NCT05497375|ACTIVE_COMPARATOR|Group Hypercapnia|End-tidal carbon dioxide level will be 40±2 mmHg in the capnography, and the respiratory rate will be 10-14/minutes in the hypercapnia group.
62713660|NCT05112614||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood and stool samples and have their medical records reviewed.
62154286|NCT01942772|EXPERIMENTAL|experimental test of healthy subjects|wearing experiment，motion experiment
62713661|NCT06180603|ACTIVE_COMPARATOR|Control group|Standard of care thoracentesis in the radiology department ( passively drainage using gravity)
62154287|NCT04247256|EXPERIMENTAL|Treatment arm|SCO-101 in combination with FOLFIRI
62527907|NCT04997226|ACTIVE_COMPARATOR|tDCS over the left DLPFC with adaptive memory game|"The stimulation will be carried out using a battery-powered mobile device made by Neurocon with two 5 x 5 cm electrodes The anodal electrode will be positioned above the F3 region of a standard EEG cap that is parallel to the cortical DLPFC region. The return electrode will be placed over the right eyebrow. The electrodes will remain on the subjects head for 50 minutes - the entire duration of the session. 1mA stimulation will be given for 15 minutes, then a 20-minute break and again 15 minutes of 1 mA stimulation. This protocol has been shown to improve the duration of the stimulus effect (Monte-Silva et al., 2013)."
62527908|NCT04997226|PLACEBO_COMPARATOR|Sham tDCS over the left DLPFC with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 50 minutes, similar to the active tDCS arm.
62527909|NCT04997226|ACTIVE_COMPARATOR|tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but stimulation method will be employed at 2mA intensity for 20 minutes at theta-gamma coupling using a laplacian montage (Alekseichuk et al., 2016).
62527910|NCT04997226|PLACEBO_COMPARATOR|Sham tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 20 minutes, similar to the active tACS arm.
62527911|NCT00321828|EXPERIMENTAL|Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab|Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
62527912|NCT01860911|EXPERIMENTAL|Insulin-Sensitive|One group consists of insulin sensitive volunteers.
62527913|NCT01860911|EXPERIMENTAL|Insulin-Resistant|One group consists of insulin resistant volunteers.
62527914|NCT02533375|EXPERIMENTAL|Participants receiving adalimumab|80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
62527915|NCT04275765|NO_INTERVENTION|Arm 1: Routine Care|Participants will undergo routine care but take part in assessments.
62527916|NCT04275765|ACTIVE_COMPARATOR|Arm 2:Behavioral Intervention with nudges & Facebook|Participants will receive nudges and be enrolled in social media platform.
62527917|NCT04275765|ACTIVE_COMPARATOR|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
62713662|NCT06180603|EXPERIMENTAL|Intervention group|Thoracentesis in the emergency department (manual fluid drainage using a syringe connected to a three-way stopcock)
62713663|NCT02455869|PLACEBO_COMPARATOR|Placebo group|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
61975678|NCT03886350||Patients with cystic fibrosis|Patients with CF whom follow-up is undertaken at University Hospital of Tours, France
61975679|NCT05891587|EXPERIMENTAL|Semaglutide|Participants will receive subcutaneous injections of semaglutide in escalating doses (.25mg to 1.0mg) over the course of 12 weeks.
61975680|NCT05891587|PLACEBO_COMPARATOR|Placebo|Participants will receive subcutaneous injections of a placebo saline solution over the course of 12 weeks.
61975681|NCT03615976|ACTIVE_COMPARATOR|group A|group A with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done for all patients with arthroscopic patellar denervation will be done
61975682|NCT03615976|ACTIVE_COMPARATOR|GROUP B|operative group B with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done without arthroscopic patellar denervation
61975683|NCT02496650|EXPERIMENTAL|Group D|Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
61975684|NCT02496650|NO_INTERVENTION|Group C|Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
61975685|NCT04676646|EXPERIMENTAL|Open-label run-in phase|"Cohort 1 (4 weeks duration): Patients who are hyperkalemic at study entry will begin SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily).~Cohort 2 (up to 6 weeks duration): Patients who develop hyperkalemia during the uptitration of spironolactone will receive SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
61975686|NCT04676646|EXPERIMENTAL|Randomized withdrawal phase (6 months)|"SZC arm and Placebo arm: Patients will continue on the SZC dose they were receiving at the end of the run-in phase.~The SZC / Placebo dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
61975687|NCT00679146|ACTIVE_COMPARATOR|1|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
61975688|NCT00679146|ACTIVE_COMPARATOR|2|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
61975689|NCT03403595|EXPERIMENTAL|177Lu-EB-PSMA-617 dosimetry calculation|All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.
61975690|NCT02353598|EXPERIMENTAL|Double-blind treatment window: Crenezumab dose level 1|Participants will recieve crenezumab dose level 1 once every 4 weeks.
61975691|NCT02353598|EXPERIMENTAL|Double-blind treatment window: Crenezumab dose level 2|Participants will receive crenezumab dose level 2 once every 4 weeks.
61975692|NCT02353598|EXPERIMENTAL|Double-blind treatment window: Crenezumab dose level 3|Participants will receive crenezumab dose level 3 once every 4 weeks.
61975693|NCT02353598|PLACEBO_COMPARATOR|Double-blind treatment window: Placebo|Participants will receive placebo matched to crenezumab once every 4 weeks.
62154288|NCT03730688|EXPERIMENTAL|Conventional and experimental compartment pressure measurement|Compartment pressure in the patients in this group will be measured using the conventional Intra-Compartmental Pressure Monitor System (Stryker) and using the newly-developed measuring device.
62154289|NCT04059575|EXPERIMENTAL|PERFORMANCE PLUS|performance plus better than GOLD TEX
62154290|NCT04059575|ACTIVE_COMPARATOR|GOLD TEX|GOLD TEX better than performance plus
62154291|NCT04093050|EXPERIMENTAL|TT Genotype|
62154292|NCT04093050|EXPERIMENTAL|AA/AT Genotype|
62154293|NCT01323244|EXPERIMENTAL|TMC435|TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
62527918|NCT00506129|EXPERIMENTAL|Fludarabine + Melphalan with PBPC|Fludarabine 25 mg/m\^2 intravenous (IV) daily for 5 Days prior to Allogeneic Transplant, Melphalan 70 mg/m\^2 IV daily for 2 Days prior to IV Allogeneic Transplant following Fludarabine \& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
62154294|NCT03945084|EXPERIMENTAL|Experimental Arm|Patients assigned to experimental arm will receive Niraparib 300 mg or 200 mg daily (based on weight and platelet count) plus best supportive care (BSC), in 28-day cycles, until disease progression or unacceptable toxicity or death.
62154295|NCT03945084|OTHER|Control Arm|Patients assigned to control arm will receive best supportive care alone, until disease progression or death.
62154296|NCT02370953|EXPERIMENTAL|VERION|In this group the VERION-tools (Digital Marker) are used for the alignment of the toric IOL
62154297|NCT02370953|ACTIVE_COMPARATOR|Conventional, manual ink-marking|In the group the conventional manual marking is used for the alignment of the toric IOL
62154298|NCT03237026||Cohort A|Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.
62154299|NCT03237026||Cohort B|Validation cohort will be recruited in the next 24 months of the study period .
62527919|NCT03377764||Landmark Technique|Control group
62154300|NCT05804734||Cases|Patients with hemophilia receiving an anticoagulant treatment in the period 2012-2021
62154301|NCT05804734||Controls|Patients with hemophilia cross-matched with cases on the age, the hemophilia's severity, the hemophilia's type, and the HAS-BLED score.
62154302|NCT01373723|EXPERIMENTAL|invitation letter|to participate in the screening
62527920|NCT03377764||Ultrasound guided technique|Neuroaxial block using Ultrasound guidance
62527921|NCT04768166|EXPERIMENTAL|Evaluate the safety of Miglustat administration in subjects with Spastic Paraplegia 11|100 mg of Miglustat, 3 caps per day for first 4 weeks; 100 mg of Miglustat, 6 caps per day for 8 weeks
62527922|NCT03244943|OTHER|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
62154303|NCT01373723|EXPERIMENTAL|Invitation letter, informative leaflet and phone call reminder|to participate in the screening
62154304|NCT01373723|EXPERIMENTAL|Invitation letter and informative leaflet|to participate in the screening
62154305|NCT05188248|EXPERIMENTAL|Female participants with Depression|Female participants with mild to moderate depression to determine if a single-session of tDCS can alter negative attention bias. The primary objective is to study if single-session tDCS will affect attention bias in depression and is not meant to treat depression.
62154306|NCT01652014|EXPERIMENTAL|Arm I|"Double UCB transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0."
62154307|NCT01652014|EXPERIMENTAL|Arm II|"Sub-threshold single UCB + irradiated PBMCs transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion."
62154308|NCT02632188|ACTIVE_COMPARATOR|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
62154309|NCT02632188|EXPERIMENTAL|DC-PMAT treatment|On the basis of postoperative routine treatment, patients will receive 3 cycles of dendritic cell-precision multiple antigen T (DC-PMAT) cells treatment.
62154310|NCT06542614|EXPERIMENTAL|TQH3906 capsules|TQH3906 capsules are administered orally at the same time (±2 hours) on an empty stomach every day for 12 weeks starting from Day 1.
62154311|NCT06542614|PLACEBO_COMPARATOR|Placebo of TQH3906 capsules|TQH3906 capsules placebo: TQH3906 capsules placebo administered orally once daily for 12 weeks at the same time (±2 hours) on an empty stomach starting from Day 1.
62154312|NCT01245699|NO_INTERVENTION|Before RTAVF and post-event debriefing|Before scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
62154313|NCT01245699|ACTIVE_COMPARATOR|After RTAVF and post-event debriefing|After scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
62527923|NCT01007565|EXPERIMENTAL|periarticular injection, pain level|
62527924|NCT05142098|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 4mg will be injected intramuscularly into the pterygomandibular space after achieving effective inferior dental block.
62527925|NCT05142098|EXPERIMENTAL|Etoricoxib|2 tablets 60mg each would be given orally one hour prior to the surgery.
62527926|NCT00752830|EXPERIMENTAL|1|AZD0328 administration during fasting condition
62527927|NCT00752830|EXPERIMENTAL|2|AZD0328 administration after food intake
62527928|NCT00653952|EXPERIMENTAL|001|
62527929|NCT00653952|ACTIVE_COMPARATOR|002|
62527930|NCT05276882|EXPERIMENTAL|hypnosis|
62527931|NCT05276882|ACTIVE_COMPARATOR|pre-surgery consultation|
62527932|NCT05927272|EXPERIMENTAL|Patients with active non-segmental vitiligo|
62713664|NCT02455869|ACTIVE_COMPARATOR|Atorvastatin group|SRP plus Atorvastatin SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
62527933|NCT05980741|NO_INTERVENTION|control group|Traditional nursing services are provided to the control group, based on functional nursing. The nurses in the ward are assigned to complete different tasks according to their responsibilities, technical knowledge and skills. These tasks are including carrying out health education to the patients, introducing the admission guidelines and ward conditions, informing patients of basic knowledge on diseases, treatment, and nursing, monitoring patient vital signs and so on. The basic medical inspection and care are conducted appropriately. The patients are instructed on the compliance and precautions required during the perioperative period. The wound and drainage are checked regularly after the operation.
62527934|NCT05980741|EXPERIMENTAL|study group High-quality nursing|High-quality nursing is provided to the study group based on primary nursing. Nurses in primary nursing take responsibility for the total care of a patient and are accountable for his/her care over 24 h a day from the patient's admission to discharge. In this case, nurses have more time to communicate with patients and to establish the nurse-patient relationship. In addition, high-quality nursing offers effective nursing measures to patients in terms of multiple aspects and dimensions through planning patient-centered nursing care, strengthening the perioperative nursing since admission, and fully implementing the nursing responsibility system.
62527935|NCT05980741|EXPERIMENTAL|study group Clinical Care Pathway|The clinical care pathway will be implemented immediately after admission. With the patient as the center of the nursing intervention, a flowable form is chosen to ensure that patients could receive effective nursing interventions throughout the entire hospitalization from the day of admission to the final discharge. In addition to primary care, the present program also unifies the management of nursing resources with the establishment of a highly qualified and professionally competent nursing team. The team members would cooperate with each other and give full play to their respective initiatives, with the common goal of improving the quality of care. The severity of illness, psychological status, and family and social environment in each patient differ, so individualized care plans are developed for each case.
62527936|NCT05980741|EXPERIMENTAL|study group Roy Adaptation Model|the Roy Adaptation Model (RAM) offers a comprehensive framework to guide nursing care for patients with chronic diseases. The RAM group receives standard care supplemented with interventions based on the RAM model. Negative emotions measured by the Hospital Anxiety and Depression Scale (HADS), pain intensity by the Visual Analog Scale (VAS), and HRQoL by the 36-Item Short Form Health Survey (SF-36) are measured at the preoperative visit (T0), at 30 days (T1), and at 3 months of (T2) follow-up.
62527937|NCT05100979|EXPERIMENTAL|Art of Medicine Series|Participants receiving the Art of Medicine Series will be sent text messages throughout the 4 week study intervention period. Each text message contains a link to a short, animated video teaching an evidence-based communication technique.
62154314|NCT04265872|EXPERIMENTAL|Bortezomib followed by pembro/cis|There is only one arm.
62154315|NCT06119256|EXPERIMENTAL|EBV-TCR-T cells|"Phase 1 trail:~The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.~Phase 2 trail:~According to the PK and response data, the dose escalation phase will be carried out."
62154316|NCT01280721|EXPERIMENTAL|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
62154317|NCT03405480|EXPERIMENTAL|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
62154318|NCT03405480|NO_INTERVENTION|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
62154319|NCT03469089|PLACEBO_COMPARATOR|Placebo/placebo|Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)
62154320|NCT03469089|EXPERIMENTAL|Ketamine 0.58/placebo|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil
62154321|NCT03469089|EXPERIMENTAL|Ketamine 0.58/modafinil|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)
62527938|NCT03275766|ACTIVE_COMPARATOR|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
62527939|NCT03275766|EXPERIMENTAL|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA~should inhibit overactive premotor cortices"
62527940|NCT03275766|EXPERIMENTAL|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA~should facilitate neural activity within premotor cortices"
62527941|NCT03275766|SHAM_COMPARATOR|sham TMS|"sham rTMS with a placebo coil over occipital cortex~should have no effect at all (no transcranial magnetic stimulation, only sound)"
62713665|NCT02455869|ACTIVE_COMPARATOR|Alendronate Group|Alendronate SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
62154322|NCT03469089|EXPERIMENTAL|Ketamine 0.31/placebo|Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil
62154323|NCT05928494|EXPERIMENTAL|İntervention group (n:39)|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
62154324|NCT05928494|NO_INTERVENTION|Control group (n:39)|Postpartum care practices were performed on the standard adult patient model in the basic skills laboratory of the midwifery department for the students in the control group.
62154325|NCT05009888||Adult KCL IoPPN Staff|Freely consenting Adult KCL Staff attending King's College London, IoPPN, Denmark Hill site will all have an antibody test on finger prick blood. The antibody test will give a rapid result for the presence of IgG or IgM antibodies to COVID-19
62154326|NCT05748808|EXPERIMENTAL|Tweens and teens|Kids between 10 and 16. ADHD, Asperger or ODD, with lack of aggressiveness control.
62154327|NCT05748808|NO_INTERVENTION|Control group|children who will not receive the experimental treatment.
62154328|NCT03612102|ACTIVE_COMPARATOR|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
62154329|NCT03612102|NO_INTERVENTION|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
62154330|NCT06080945|EXPERIMENTAL|Pharmacist-led care group|In addition to usual care, the patient in the intervention group received pharmacist-led multidisciplinary care. The multidisciplinary team consists of a physician, a pharmacist and a nurse. To ensure the uniformity of the material provided during counseling sessions, all professionals attended training before beginning to work with patients. Patients in the control group were given the hospital's standard of care discharge counseling on budesonide, whereas patients in the intervention group were given both the standard of care counseling and a pharmacist-driven discharge counseling on budesonide. A pharmacist first spoke with the parents to obtain comprehensive medical, familial, and social histories. After personalized pharmacogenetic testing, a pamphlet with instructions on how to take their medications was given to each parent.
62527942|NCT01984203|EXPERIMENTAL|Progressive Heavy Strength Exercises|"The Progressive Heavy Load Exercise group gradually increases the external load from 60%RM to 90%RM and correspondently decreases the number of performed repetitions pr. set for the two rotator cuff exercises. Furthermore 4 sets is performed.~A progressive exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
62527943|NCT01984203|ACTIVE_COMPARATOR|Low Load Exercises|"Active exercises comparator continuously training with 60%RM through 12 weeks.~An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
62154331|NCT06080945|NO_INTERVENTION|Usual care group|The control group will receive care as usual
62154332|NCT03880981|ACTIVE_COMPARATOR|Acetaminophen|Patients will receive 650mg PO Acetaminophen every 6 hours as needed for pain
62154333|NCT03880981|ACTIVE_COMPARATOR|Ibuprofen|Patients will receive 600mg PO Ibuprofen every 6 hours as needed for pain
62154334|NCT05410717|EXPERIMENTAL|CAR-NK cell therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell therapy group.
62154335|NCT05410717|EXPERIMENTAL|IL7/CCL19 secreting CAR-NK cell therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the IL7/CCL19 secreting CAR-NK cell therapy group.
62154336|NCT05410717|EXPERIMENTAL|PD1/PDL1/CTLA4-scfv secreting CAR-NK cell therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the PD1/PDL1/CTLA4-scfv secreting CAR-NK cell therapy group.
62154337|NCT05410717|EXPERIMENTAL|CAR-NK cell plus CBD therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell plus CBD therapy group.
62154338|NCT05410717|EXPERIMENTAL|CAR-NK cell plus NAD therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell plus NAD therapy group.
62154339|NCT04285645|EXPERIMENTAL|Experimental group|Each session will last 15 minutes, taking place 2 days a week, over a period of 4 weeks. Prior to training, the exercise protocol will be carried out. Prior to the start of the intervention, the exercises to be performed will be explained to the participants and it will be verified that they are capable of performing them correctly.
62154340|NCT04285645|NO_INTERVENTION|Control group|Athletes included in the control group will continue with their usual training routine.
62154341|NCT04507347|EXPERIMENTAL|Test product|Eligible participants will be randomized to receive test product, TRC041266 1500 mg twice daily for 48 weeks.
62154342|NCT04507347|PLACEBO_COMPARATOR|Placebo product|Eligible participants will be randomized to receive matching placebo twice daily for 48 weeks.
62154343|NCT00001806|EXPERIMENTAL|Group|Group education and counseling
62154344|NCT00001806|ACTIVE_COMPARATOR|Individual|Individual education and counseling
62527944|NCT04639713|EXPERIMENTAL|Tixel 2|Tixel 2 Treatment, 4 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject would be questioned about pain level, subjective dountime assessment and subjective response assessment. Images would be taken at baseline and in Follow-Up visits
62527945|NCT02119286|EXPERIMENTAL|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
61975694|NCT02353598|EXPERIMENTAL|Optional OLE window: Crenezumab|Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks.
62154345|NCT05285592|EXPERIMENTAL|Fecal Transplantation|"1. Donors will be supplied clean, sealable containers for collection and transport of stool. Containers will be labeled with the name, UHID and date/time of stool collection.~2. Collected stool will be immediately transferred to the laboratory facility for processing and used within 6 hours collection~3. Stool sample from Healthy donor will be processed~4. Patient preparation~5. Patient was kept NPO for 4 hours prior to stool instillation~6. Iv antibiotics were continued as per treating doctor in the event of sepsis~7. The patient was allowed to consume the prescribed diet 2 hours after the procedure instillation~8. Methods of FMT infusion.~9. Seven doses (30gm one dose) of FMT will be given via jejunal port of NJ/NG tube"
62154346|NCT05285592|ACTIVE_COMPARATOR|Standard Medical Treatment|Standard Medical Treatment
62154347|NCT00457314|EXPERIMENTAL|1|Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
62154348|NCT00457314|EXPERIMENTAL|2|Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
62154349|NCT05223725|EXPERIMENTAL|dose escalation|initial phase, increasing dose
62154350|NCT05223725|EXPERIMENTAL|low dose|second phase, fixed dose 5x10(11) vp
62154351|NCT05223725|EXPERIMENTAL|high dose|second phase, fixed dose 2x10(12) vp
62154352|NCT05223725|NO_INTERVENTION|control|second phase, blinded, randomized with no intervention delivered but with testing and monitoring.
62154353|NCT02521337||pregnant women not in active labor|
62154354|NCT02521337||pregnant women in preterm labor|
62154355|NCT02521337||pregnant women in term labor|
62154356|NCT06455605|EXPERIMENTAL|D2C7-IT + 2141-V11|"Single D2C7-IT intratumoral infusion (4613.2 ng/mL in 36 mL) over 72 hours followed by an 2141-V11 infusion over 7 hours. This is followed by injections of 2141-V11 (2mg) in the cervical perilymphatic (CPLI) subcutaneous area ipsilateral to the tumor at weeks 2, 4, 7, 10 and then every 3 weeks until week 49.~After week 49 (equivalent of 1 year of every 3 weeks CPLI of 2141-V11), patients who have completed 1 year of CPL subcutaneous injections of 2141-V11 at 2 mg every 3 weeks, who benefit from the therapy, and desire to continue on therapy, will receive CPLI of 2141-V11 at 2 mg every 4-6 weeks."
62154357|NCT04007445|ACTIVE_COMPARATOR|Formally Directed Group (Exercise Group)|A group performing a 12 - week guided exercise program at an accessible Community Health and Wellness Center
62154358|NCT04007445|PLACEBO_COMPARATOR|Self-Directed Group (Control Group)|A group receiving educational information about physical activity and exercise at home and then self-directing a 12 - week exercise program on their own.
62154359|NCT03769090|EXPERIMENTAL|BDA MDI (PT027) 160/180 μg|Budesonide/albuterol sulfate, BDA MDI, PT027 high dose
62154360|NCT03769090|EXPERIMENTAL|BDA MDI (PT027) 80/180 μg|Budesonide/albuterol sulfate, BDA MDI, PT027 low dose
62527946|NCT02119286|EXPERIMENTAL|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
62527947|NCT02119286|EXPERIMENTAL|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
62527948|NCT04787874|NO_INTERVENTION|Control|The control arm will receive no additional prehabilitation material prior to material. Rather, they will receive standard preoperative care in which they will be given standard advice on nutrition and fitness. REDcap surveys will be administered.
62527949|NCT04787874|EXPERIMENTAL|Prehab Intervention Arm|The intervention arm will receive access to the prehab program (abdominal workout videos) and surveys via RedCAP.The program will start no less than 14 days before the date of surgery.
62527950|NCT02569736||Tocilizumab|Patients with active moderate to severe RA fulfilling ACR criteria and requiring TCZ treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
62527951|NCT02569736||Methotrexate|Patients with active moderate to severe RA fulfilling ACR criteria and requiring MTX treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
62527952|NCT02569736||Healthy Controls|Healthy controls will be defined as people non-affected by an inflammatory disease (such as RA, ankylosing spondylitis, lupus...). This group will be constituted with patients affected by sciatica, osteoarthritis, osteoporosis...
62527953|NCT06304025|EXPERIMENTAL|Thawed allogeneic WJ-MSCs|Administration intravenously of 1x106 cells/kg weight of thawed allogeneic WJ-MSCs
62527954|NCT06304025|EXPERIMENTAL|Expanding allogeneic WJ-MSCs|Administration intravenously of 1x106 cells/kg weight of expanding allogeneic WJ-MSCs
62527955|NCT05561530|EXPERIMENTAL|ALG-125755|Subcutaneous injections of ALG-125755 in HV or CHB subjects, up to 6 injections over the course of up to 72 weeks
62527956|NCT05561530|PLACEBO_COMPARATOR|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 6 injections over the course of up to 72 weeks
62527957|NCT00499174|NO_INTERVENTION|Active Surveillance|Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
62527958|NCT00499174|ACTIVE_COMPARATOR|Radical Intervention|Radical prostatectomy or radiotherapy based on patient and physician preference
62527959|NCT01762930|ACTIVE_COMPARATOR|Shanchol stored at 2-8oC|Vaccines will be stored at 2-8oC before administration.
62527960|NCT01762930|EXPERIMENTAL|Shanchol stored at 25oC|Vaccines will be stored at 25oC for 14 days before administration.
62527961|NCT01762930|EXPERIMENTAL|Shanchol stored at 37oC|Vaccines will be stored at 37oC for 14 days before administration.
62527962|NCT01762930|EXPERIMENTAL|Shanchol stored at 42oC|Vaccines will be stored at 42oC for 14 days before administration.
62527963|NCT01986010|EXPERIMENTAL|HCMV seropositive (+) V160 Low Dose Intramuscular (IM)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
61975695|NCT01091493|NO_INTERVENTION|Non-Antibiotic|Patients will not receive antibiotics, although the study is double-blind.
61975696|NCT01091493|ACTIVE_COMPARATOR|Antibiotic|Patients will receive in a masked way, moxifloxacin.
61975697|NCT06164223|EXPERIMENTAL|Experimental|Group to which VR Baby Pump will be applied
61975698|NCT06164223|NO_INTERVENTION|Control|An intervention will not be applied.
61975699|NCT01725620|EXPERIMENTAL|Group 1|Enbrel, LBEC0101
61975700|NCT01725620|EXPERIMENTAL|Group 2|LBEC0101, Enbrel
61975701|NCT03835494|EXPERIMENTAL|Fallot patients|Fallot patients
61975702|NCT03835494|EXPERIMENTAL|healthy controls|healthy volunteers
61975703|NCT05217433|EXPERIMENTAL|Investigational product|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
61975704|NCT05217433|PLACEBO_COMPARATOR|Control arm|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
61975705|NCT02518828|ACTIVE_COMPARATOR|High SpO2|In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
61975706|NCT02518828|ACTIVE_COMPARATOR|Low SpO2|In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
61975707|NCT04682067|EXPERIMENTAL|Contingency Management|Participants in the contingency management (CM) treatment arm will receive the usual care (UC) treatment program offered at the Tobacco Treatment Research Program (TTRP) and will be eligible to earn gift cards at each weekly visit on their quit date up until four weeks post-quit for proof of abstinence. They will earn $20 in gift cards for quitting on the specified quit day (i.e., one week after the orientation visit), and this amount will increase by $5 with each successive weekly abstinent visit (i.e., up to $40 in gift cards at 4 weeks post-quit; up to $150 total).
62154361|NCT03769090|ACTIVE_COMPARATOR|AS MDI (PT007) 180 µg|Albuterol sulfate MDI, PT007
62154362|NCT02039102||Non-users of hormonal contraceptives|
62154363|NCT02039102||Users of hormonal contraceptives|
62527964|NCT01986010|EXPERIMENTAL|HCMV seronegative (-) V160 Low Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
62527965|NCT01986010|EXPERIMENTAL|HCMV+ V160 Medium Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
62154364|NCT03494088||Children with Autism with gastrointestinal (GI) symtpoms|
62527966|NCT01986010|EXPERIMENTAL|HCMV- V160 Medium Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
62154365|NCT03494088||Children with Autism without gastrointestinal (GI) symtpoms|
62527967|NCT01986010|EXPERIMENTAL|HCMV+ V160 High Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
62154366|NCT03494088||Healthy Children|
62154367|NCT01864590|EXPERIMENTAL|Open Abdomen - Vacuum Pack|Patients that Require open abdomen
62154368|NCT01864590|ACTIVE_COMPARATOR|Double Sylo Bag - Mesh Protocol|Open Abdomen
62527968|NCT01986010|EXPERIMENTAL|HCMV- V160 Medium Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
62527969|NCT01986010|EXPERIMENTAL|HCMV- V160 High Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
62527970|NCT01986010|EXPERIMENTAL|HCMV+ V160 High Dose plus MAPA 225 µg IM|Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
62527971|NCT01986010|EXPERIMENTAL|HCMV+ V160 Maximum Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
62527972|NCT01986010|EXPERIMENTAL|HCMV- V160 High Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
62527973|NCT01986010|EXPERIMENTAL|HCMV- V160 Maximum Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
62527974|NCT01986010|PLACEBO_COMPARATOR|HCMV+ Placebo IM|Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
62154369|NCT04992494|EXPERIMENTAL|MBCT-T (Mindfulness-Based Cognitive Therapy - Telephone)|Mindfulness-based cognitive therapy delivered by Telephone
62154370|NCT04992494|EXPERIMENTAL|MBCT-V (Mindfulness-Based Cognitive Therapy - Video)|Mindfulness-based cognitive therapy delivered by Video
62154371|NCT03075475|EXPERIMENTAL|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
62527975|NCT01986010|PLACEBO_COMPARATOR|HCMV- Placebo IM|Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
62527976|NCT01986010|EXPERIMENTAL|HCMV+ V160 Medium Dose Intradermal (ID)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
62527977|NCT01986010|EXPERIMENTAL|HCMV- V160 Medium Dose ID|Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
62154372|NCT03075475|NO_INTERVENTION|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
62154373|NCT01377545|ACTIVE_COMPARATOR|Local Anesthetic Via Catheter|30mL of Lidocaine (local Anesthetic) will be injected via a perineural catheter at hour 0.
62154374|NCT01377545|ACTIVE_COMPARATOR|Local Anesthetic Via Needle|30mL of Lidocaine (local Anesthetic) will be injected via a needle at hour 0.
62527978|NCT01986010|PLACEBO_COMPARATOR|HCMV+ Placebo ID|Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
62527979|NCT01986010|PLACEBO_COMPARATOR|HCMV- Placebo ID|Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
62527980|NCT03489161|EXPERIMENTAL|Buprenorphine|Buprenorphine administered in the emergency room after patients presenting to the emergency department (ED) due to opioid OD who have been treated with opioid antagonist (naloxone) and are stable and alert.
62527981|NCT03003949|PLACEBO_COMPARATOR|Placebo Patch and Placebo Capsule|Placebo patches worn for 16 weeks. On the 9th week of patch, oral placebo capsule taken daily for 12 days. Following the 16 weeks of patch use oral placebo capsule taken daily for 12 days.
62527982|NCT03003949|ACTIVE_COMPARATOR|Estradiol patch and progesterone capsule|Estradiol patches worn for 16 weeks. On the 9th week of patch, oral progesterone capsule taken daily for 12 days. Following the 16 weeks of estradiol patch use oral progesterone capsule taken daily for 12 days.
62527983|NCT05000086|EXPERIMENTAL|99Tc methylene diphosphonate|99Tc-MDP was applied as follows: for each course of treatment, 99Tc-MDP 22 mg (5.5mg/set, four sets) was injected intravenously once a day for 7 successive days, one course every 4 weeks until week 24.
62527984|NCT01529398|ACTIVE_COMPARATOR|sensorimotor training (SMT)|
62527985|NCT01529398|ACTIVE_COMPARATOR|Resistance training (RT)|
62527986|NCT01529398|SHAM_COMPARATOR|Control group (CG)|
62527987|NCT00801359|ACTIVE_COMPARATOR|BSSplus|
62527988|NCT00801359|EXPERIMENTAL|Ringer|
62527989|NCT04334486|EXPERIMENTAL|Video Game Trained|Subjects will participate in video gaming for 10 minutes prior to Eyesi simulator test of surgical skills.
62154375|NCT06412432|EXPERIMENTAL|Exercise training|Patients will undergo exercise training, nutritional advice, smoking cessation, lipid profile evaluation, control and management of body weight and abdominal circumference; evaluation of the drug therapy in progress; psycho-social evaluation.
62527990|NCT04334486|NO_INTERVENTION|No Video Game Training|No video gaming will occur for warm up to Eyesi simulator test of surgical skills
62527991|NCT03091270||BOLD-fMRI|Identifying the motor functional cortex in glioma patients with BOLD-fMRI.
62527992|NCT03091270||ZOOMit-fMRI|Identifying the motor functional cortex in glioma patients with ZOOMit-fMRI.
62527993|NCT03164421|EXPERIMENTAL|N-Acetylcysteine|N-Acetylcysteine used by clomiphene resistant pcos women
62527994|NCT03164421|ACTIVE_COMPARATOR|L-carnitine|L-carnitine used by clomiphene resistant pcos women
62527995|NCT04293094|EXPERIMENTAL|Dose Exploration Phase|Participants will receive AMG 650 in 1 of 3 alternative schedules. The maximum tolerated dose (MTD) of each schedule will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.
62713666|NCT06677307|EXPERIMENTAL|Arm 1: KRRO-110 (Part A and Part B)|KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD).
62713667|NCT06677307|PLACEBO_COMPARATOR|Arm 2: Placebo (Part A only)|Placebo, IV administration
62154376|NCT06412432|ACTIVE_COMPARATOR|Controls|control group who won't undergo exercise training and will be managed with optimal medical therapy
62154377|NCT01042132|ACTIVE_COMPARATOR|1) IMN and EF/IMN|"Two parts of the study are randomized;~1)initial intramedullary reaming and primary external fixation with secondary intramedullary nailing"
62154378|NCT01042132|ACTIVE_COMPARATOR|2) TR and RIA|Two parts of the study are randomized; 2)traditional reaming (TR)is compared to a new reaming device, RIA, which is a reamer connected to suction and flushing for prevention of increased intramedullary pressure
62713668|NCT03522064|EXPERIMENTAL|High dose testosterone + Carbolplatin|500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy) plus Carboplatin AUC 5
62713669|NCT05700825|ACTIVE_COMPARATOR|In-person|
62713670|NCT05700825|EXPERIMENTAL|Telehealth|
62713671|NCT05843461||Controls|10 patients without pulmonary hypertension (mean PA pressure less than 20 mmHg on RHC)
62713672|NCT05843461||PAH|10 patients with PAH
62154379|NCT03883178|EXPERIMENTAL|Neurolysis|
62527996|NCT04293094|EXPERIMENTAL|Dose Expansion Phase Group 1: TNBC|Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
62527997|NCT04293094|EXPERIMENTAL|Dose Expansion Phase Group 2: HGSOC|Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
62527998|NCT01642992||Coronary bifurcation lesion|
62527999|NCT05418166||pro-Evo|Patients regularly take Ticagrelor and Aspirin for five days.Platelet activity was test before inject Evolocumab.
62713673|NCT05843461||CTEPH|10 patients with CTEPH
62713674|NCT05631249|EXPERIMENTAL|Sotorasib treatment|Sotorasib : 120 mg, once a day, per os, until progression, unacceptable toxicity, death or lost to follow-up
62713675|NCT04672135|ACTIVE_COMPARATOR|Study Drug|Each subject receives either a single dose (SAD) or a multiple dose (MAD) of REM0046127 as oral solution with a concentration of 100 mg/mL REM0046127. The starting dose for the first cohort in the SAD is 35mg up to a maximum of 2000mg at cohort 5. The starting dose for the MAD study is 0,75 of the Maximum Tolerated Dose (MTD) from the SAD.
62154380|NCT01115153|EXPERIMENTAL|Antibiotic prophylaxis|Rate of Wound infection in patients with gangrenous appendicitis with single doses of antibiotic (before surgery)
62528000|NCT05418166||24h-Evo|Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 24h after inject.
62528001|NCT05418166||1w-Evo|Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 1 week after inject.
62713676|NCT04672135|PLACEBO_COMPARATOR|Placebo|Each subject receives either a single (SAD) or multiple (MAD) dose of REM0046127 as oral solution with a concentration of 0 mg/mL REM0046127. The dose for each cohort is corresponding the amount of solution needed in the verum group.
62713677|NCT06235502|EXPERIMENTAL|Home-based, longterm cycle-exercise|One year home-based cycle exercise on a exercise bike connected to a video app from where participants can cycle push videos forward when cycling.
62713678|NCT06235502|ACTIVE_COMPARATOR|Standard of Care|Standard of Care; exercise at fitness center, home-based exercise according to programme, self-initiated exercise
62154381|NCT01115153|ACTIVE_COMPARATOR|Antibiotic treatment, wound infection|Rate of Wound infection in patients with gangrenous appendicitis with five days antibiotic therapy (after surgery)
62154382|NCT04347889|EXPERIMENTAL|Hydroxychloroquine|Oral loading dose of 800 mg followed by once weekly oral hydroxychloroquine 400 mg for 3 months
62154383|NCT04347889|ACTIVE_COMPARATOR|Vitamin C|Oral Vitamin C 1,000 mg daily for three months
62154384|NCT01285882||Representations|
62528002|NCT05887895|EXPERIMENTAL|Treatment group sequence 1|Subjects were given HR20014, INS068, or INS062 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
62528003|NCT05887895|EXPERIMENTAL|Treatment group sequence 2|Subjects were given HR20014, INS062, or INS068 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
62713679|NCT04038073||ADHD|Attention Deficit/Hyperactivity Disorder
62713680|NCT05309954||Observational (With Bone Scan)|Individuals with a Family history of Paget's disease of bone (PDB) affecting first degree relative such as a parent or sibling that have not already diagnosed with PDB
62713681|NCT05309954||Observational (Without Bone scan)|Individuals, that are spouses, friends and/or non blood relatives of the individuals with a family history of PDB.
62736734|NCT04894838|EXPERIMENTAL|Distal gastric bypass type I|Laparoscopic distalisation of RYGB type I. The RYGB is modified by dividing the Roux limb (AL) at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long biliopancreatic limb (BPL). In cases of initial AL lengths shorter than 100 cm, the CC lengths should be adjusted to create a TALL of at least 300 cm.
62154385|NCT01427816|EXPERIMENTAL|KCT-0809 ophthalmic solution, low dose|
62154386|NCT01427816|EXPERIMENTAL|KCT-0809 ophthalmic solution, high dose|
62528004|NCT05887895|EXPERIMENTAL|Treatment group sequence 3|Subjects were given INS068, HR20014, or INS062 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
62713682|NCT05164315|EXPERIMENTAL|Tailored surgery|Arm 1 will receive tailored surgery. If there are no cancer cells or the margin is negative in the local excision/biopsy during surgery, the operation will be terminated. And if the final pathology result is T2-4, or cancer cells and margin are positive in the frozen section during surgery, or the result of digital rectal examination and visual examination using anoretractor under general anesthesia is not suitable for local excision (visible and palpable tumor nodules), a total mesorectal excision will be performed.
62713683|NCT05164315|ACTIVE_COMPARATOR|Total mesorectal excision (TME)|Arm 2 will receive TME. Surgery including high ligation of the inferior mesenteric artery and total mesorectal excision will be performed under the lithotomy position. After pelvic dissection, double-stapled anastomosis or transanal anastomosis will be performed, followed by diverting stoma. Abdominoperineal resection with permanent stoma is included.
62713684|NCT05212792||Case with COVID-19 vaccine adverse event|Patients with GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
62713685|NCT05212792||Control without COVID-19 vaccine adverse event|Participants without experiencing GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
62154387|NCT01427816|PLACEBO_COMPARATOR|Placebo|
62154388|NCT02555397|EXPERIMENTAL|Single|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.
62154389|NCT01185340|EXPERIMENTAL|LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.~For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
62713686|NCT00663611|EXPERIMENTAL|Study I and IB|Each involve six subjects and are designed to test the hypothesis that pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will yield a reasonable pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher than that in Study I. Study I and IB will be done first before proceeding to Study II
62713687|NCT00663611|EXPERIMENTAL|Study II|Is a randomized, double-blinded, placebo-controlled 12 week study involving 26 subjects divided into 2 groups: Group A and Group B. Group A will involve 13 subjects receiving pulsatile GH or placebo infusion for 4 weeks with 8 week washout after intervention. Group B will involve 13 subjects receiving conventional once a day subcutaneous infusion of GH or placebo for 4 weeks with 8 week washout after intervention.
62713688|NCT03192098|EXPERIMENTAL|Progressive|Patients will be dilated \> 3mm and can be dilated up to 6mm in diameter
62713689|NCT03192098|ACTIVE_COMPARATOR|Conservative (rule-of-3)|Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)
62154390|NCT01185340|PLACEBO_COMPARATOR|Placebo + SSRI|"Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
62713690|NCT06217081|EXPERIMENTAL|Investigational Topical Tissue Adhesive|3M Topical Tissue Adhesive
62154391|NCT02961283|EXPERIMENTAL|ASN003 Dose Escalation|Multiple ascending doses of ASN003 will be administered to determine the maximum tolerated dose (MTD).
62154392|NCT02961283|EXPERIMENTAL|ASN003 MTD - BRAFv600 melanoma|ASN003 administered at the MTD in subjects with BRAF v600 mutated metastatic melanoma
62154393|NCT02961283|EXPERIMENTAL|ASN003 MTD - BRAFv600 colon or lung cancer|ASN003 administered at the MTD in subjects with BRAFv600 mutated metastatic colorectal or non-small cell lung cancer.
62528005|NCT05887895|EXPERIMENTAL|Treatment group sequence 4|Subjects were given INS068, INS062, or HR20014 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
62528006|NCT05887895|EXPERIMENTAL|Treatment group sequence 5|Subjects were given INS062, HR20014, or INS068 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
62713691|NCT06217081|ACTIVE_COMPARATOR|Control Topical Tissue Adhesive|Histoacryl® Blue Topical Skin Adhesive
62713692|NCT05980598|EXPERIMENTAL|TransCon TLR7/8 Agonist in combination with pembrolizumab|Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist intratumoral (IT) injection in combination with pembrolizumab as a 30-minute intravenous (IV) infusion
62154394|NCT02961283|EXPERIMENTAL|ASN003 MTD - PIK3 pathway mutated cancers|ASN003 administered at the MTD in subjects who have mutations in PI3 kinase or loss of PTEN.
62154395|NCT01473459|ACTIVE_COMPARATOR|IVM Treatment|
62154396|NCT01473459|ACTIVE_COMPARATOR|Antagonist Protocol|
62154397|NCT06354725|EXPERIMENTAL|2PLYO|The 2PLYO (two-times-a-week) group performed 240 jumps over two sessions (120 jumps per session).
62154398|NCT06354725|EXPERIMENTAL|4PLYO|The 4PLYO (four-times-a-week) group performed 240 jumps over four sessions (60 jumps per session)
62154399|NCT00911716|EXPERIMENTAL|cyclophosphamide, Docetaxel, bevacizumab|
62154400|NCT01625494|EXPERIMENTAL|Irbesartan/Amlodipine 150/5 mg fixed combination|"1 tablet once daily in the morning for 4 weeks Patient will be first treated with irbesartan 150mg or amlodipine 5mg, 1 tablet /day for 4 weeks.~If OBPM is controlled on monotherapy at week 4 (SBP \<140 mmHg and DBP\<90 mmHg), patient will be withdrawn from the study"
62154401|NCT01625494|EXPERIMENTAL|Irbesartan/Amlodipine 150/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks
62154402|NCT01625494|EXPERIMENTAL|Irbesartan/Amlodipine 300/5 mg fixed combination|1 tablet once daily in the morning for 4 weeks
62154403|NCT01625494|EXPERIMENTAL|Irbesartan/Amlodipine 300/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks. If OBPM is controlled at week 12, patients will continue on the same therapy until the end of the study
62154404|NCT02464839||Hallux valgus patients|All of participants will perform a potassium hydroxide (KOH) examination and fungal culture to prove a fungal nail and feet fungal infection
62154405|NCT06448000||Group 1|Same semen samples are analyzed in group 1 and 2. Group 1 correspond to ejaculate semen samples analyzed the day of slow-freezing
62528007|NCT05887895|EXPERIMENTAL|Treatment group sequence 6|Subjects were given INS062, INS068, or HR20014 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
62528008|NCT00587015|ACTIVE_COMPARATOR|1|CAT-8015
62154406|NCT06448000||Group 2|Same semen samples are analyzed in group 1 and 2. Group 2 correspond to the same ejaculate semen samples as group 1 but analyzed after a storage time from 2 to 12 years in liquid nitrogen.
62154407|NCT02173457|EXPERIMENTAL|Arm 1|Patients administrate Chiglitazar 32mg once daily for 24 weeks
62154408|NCT02173457|EXPERIMENTAL|Arm 2|Patients administrate Chiglitazar 48mg once daily for 24 weeks
62154409|NCT02173457|ACTIVE_COMPARATOR|Arm 3|Patients administrate Sitagliptin 100mg once daily for 24 weeks
62154410|NCT01581320|EXPERIMENTAL|DP-R206|
62154411|NCT01581320|ACTIVE_COMPARATOR|Bonviva|
62154412|NCT00593528|ACTIVE_COMPARATOR|A|Naked Stents
62154413|NCT00593528|EXPERIMENTAL|B|PTFE Covered Stents
62154414|NCT03748056|EXPERIMENTAL|Targeted incentives arm|The interventions received by the experimental group include: 1) weekly emails with targeted coupons for healthier products, 2) weekly emails with targeted nutrition education, and 3) and a nominal discount on grocery purchases for using their loyalty card
62154415|NCT03748056|ACTIVE_COMPARATOR|Usual care arm|"The interventions included under usual care include 1) untargeted nutrition education, 2) occasional untargeted coupons for healthier products, and 3) a nominal discount on their grocery purchases for using their loyalty card. These interventions are only received by participants randomized to the usual care arm (rather than the entire population of shoppers), and will allow for testing whether targeting discounts and nutrition education improves the diet quality of purchases in comparison to untargeted approaches."
62154416|NCT05055804|EXPERIMENTAL|ELG Device Comparison to Whole Blood Testing|Participant will place thumb in the ELG device for scan. Scan generally takes between 1-2 minutes. ELG then displays a readout of both a glucose and A1C reading on the screen of the ELG device.
62154417|NCT01675063|OTHER|Retia Non-Invasive Sensors|Sensors will be placed on the patient and connected to an amplifier that produces a waveform for 8 hours post cardiac surgery.
62528009|NCT05188053|EXPERIMENTAL|HTX-011 Treatment Group|Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia
62528010|NCT05188053|ACTIVE_COMPARATOR|Standard Block Control Group|Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia
62528011|NCT03327636|EXPERIMENTAL|High Intensity Focused Ultrasound|Apply the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the papillary thyroid microcarcinoma.
62528012|NCT03327636|NO_INTERVENTION|Active surveillance|The participants will be monitored by the doctors actively, like more frequent in follow-up to observe their current situation.
62528013|NCT01199679|EXPERIMENTAL|Endoscopic Mucosal Resection (EMR) Group|
62528014|NCT01199679|EXPERIMENTAL|Banding Group|
62528015|NCT04690517|OTHER|Tracheal ultrasound|The patients in cardiopulmonary arrest should be performed tracheal ultrasound when tube is passed through the trachea or esophagus.
62528016|NCT04214925|EXPERIMENTAL|Group of Tai Chi intervention|Tai Chi exercise program will create by selecting the first-basic 10 forms from 24 short forms of Yang style. The forms' name: Beginning, Parting the Horse's Mane, Stork Spreading Its Wings, Brushing Your Knees and Stepping, Playing The Pipes, Fending Off the Monkey, Grasping the Sparrow's Tail Left, Grasping the Sparrow's Tail Right, Simple Whip, Moving Hands Like Clouds-Conclusion. All forms will be completed at 10 weeks. Each session will take 1 hour (15 min for warming up exercises, 30 min of Tai Chi forms, and 15 min for cooling down exercises). The 14 patients of SS in this group will be divided into two groups of 7.
62528017|NCT04214925|OTHER|Group of home exercises|The home exercise group will receive a one-hour home program, 2 days a week. The first and last 15 minutes of the exercise program will consist of warm-up and cooling- down exercises. After warm-up exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles will be performed 10 times each for 30 minutes.
62528018|NCT02175576|EXPERIMENTAL|Vanguard XP Bicruciate Knee System|153 patients receive Vanguard XP Bicruciate Knee System
62528019|NCT02175576|ACTIVE_COMPARATOR|Vanguard CR Knee System|153 patients receive Vanguard CR Knee System
62528020|NCT05174117|EXPERIMENTAL|single irradiation group|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
62528021|NCT05174117|ACTIVE_COMPARATOR|Double irradiation group|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
62528022|NCT05501366|EXPERIMENTAL|BHB Mono-ester 180mg/kg|
62528023|NCT05501366|EXPERIMENTAL|BHB mono-ester 360mg/kg|
62528024|NCT05501366|EXPERIMENTAL|C8 Ketone Di-ester 180mg/kg|
62154418|NCT02526433||Pregnancy women and new mothers|The study tracks what interventions women are already registered in and compares these with their mental wellbeing.
62154419|NCT01859689|EXPERIMENTAL|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
62154420|NCT03165825|EXPERIMENTAL|Tranforaminal|will receive cervical epidural injection via a transforaminal route with dexamethasone steroid
62154421|NCT03165825|ACTIVE_COMPARATOR|Interlaminar|will receive cervical epidural injection via an interlaminar route with betamethasone steroid
62154422|NCT05701176|EXPERIMENTAL|[18F]F-AraG PET procedures|All patients will undergo a total of 3 \[18F\]F-AraG PET scanning procedures at T=0, T=2 weeks and T=6 weeks.
62528025|NCT05501366|EXPERIMENTAL|C8 Ketone Di-ester 360mg/kg|
62154423|NCT02327975|EXPERIMENTAL|Training group|Participants in this group received twice-weekly non-consecutive sessions of physical exercise for 10 weeks. Each session lasted approximately 60-70 minutes. Exercise program consisted of strength training and aerobic exercise. Each session began with a warm low intensity (10 min), then the main part of the session (25 min) and aerobic training and recovery period (25-35 min) was performed. The equipment used during the procedure was the Thera-Band elastic band.
62154424|NCT02327975|EXPERIMENTAL|Mobile group|Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
62154425|NCT02327975|OTHER|Control group|No received intervention.
62154426|NCT03363100|EXPERIMENTAL|Intervention|
62154427|NCT03363100|NO_INTERVENTION|Control|
62154428|NCT02827110|ACTIVE_COMPARATOR|fiberoptic bronchoscope|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope
62154429|NCT02827110|EXPERIMENTAL|fiberoptic bronchoscope with pentax-AWS|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope with pentax-AWS
62154430|NCT03576118|EXPERIMENTAL|Deep neuromuscular block|Deep neuromuscular relaxation and low pressure pneumoperitoneum
62528026|NCT05501366|EXPERIMENTAL|AcAc Di-ester 180mg/kg|
62528027|NCT05501366|EXPERIMENTAL|AcAc Di-ester 360mg/kg|
62528028|NCT05501366|EXPERIMENTAL|(R)-1,3 butanediol 180mg/kg|
62528029|NCT05501366|EXPERIMENTAL|(R)-1,3 butanediol 360mg/kg|
62528030|NCT05501366|PLACEBO_COMPARATOR|Control|
62528031|NCT03814616|EXPERIMENTAL|Arm Pyramax 3 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for three days (Arm A)
62528032|NCT03814616|EXPERIMENTAL|Arm Pyramax 2 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for two days (Arm B)
62528033|NCT03814616|EXPERIMENTAL|Arm Pyramax 1 day|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for one day (Arm C)
62528034|NCT06484634|EXPERIMENTAL|LMWH Group|Women received a daily dose of 40 mg of Low Molecular Weight Heparin subcutaneously.
62528035|NCT06484634|NO_INTERVENTION|Control|Women received the placebo in the form of a multivitamin tablet.
62528036|NCT03121430|EXPERIMENTAL|Group A|subjects using the drug eluting peripheral vascular stent system
62528037|NCT03121430|ACTIVE_COMPARATOR|Group B|subjects using the Nitinol Stent System (Cordis Corporation)
62528038|NCT00969631|EXPERIMENTAL|Metformin-CC|
62528039|NCT00969631|ACTIVE_COMPARATOR|Laparoscopic ovarian diathermy (LOD)|
62528040|NCT02735850|EXPERIMENTAL|Ablative SBRT to all (max 3) sites followed by L19-IL2|Ablative cohort
62528041|NCT02735850|ACTIVE_COMPARATOR|Ablative SBRT to all (max 3) sites|Ablative cohort
62528042|NCT02735850|EXPERIMENTAL|SBRT 1 site, L19-IL2 and then standard of care|Non-ablative cohort
62528043|NCT02735850|ACTIVE_COMPARATOR|Standard of care|Non-ablative cohort
62528044|NCT00630019|EXPERIMENTAL|1|
62528045|NCT00630019|ACTIVE_COMPARATOR|2|
62528046|NCT00937378|EXPERIMENTAL|SER120|
62528047|NCT00937378|PLACEBO_COMPARATOR|Placebo|
62154431|NCT03576118|ACTIVE_COMPARATOR|Moderate neuromuscular block|Moderate neuromuscular relaxation and standard pressure pneumoperitoneum
62154432|NCT02958722|ACTIVE_COMPARATOR|carbon dioxide|Diagnostic hysteroscopy performed with the carbon dioxide (gas)
62154433|NCT02958722|ACTIVE_COMPARATOR|physiological solution|Diagnostic hysteroscopy performed with liquid solution (physiologic solution)
62154434|NCT01144533|PLACEBO_COMPARATOR|Isotonic saline|
62154435|NCT01144533|EXPERIMENTAL|Steroid|
62154436|NCT01144533|EXPERIMENTAL|Hyaluronate|
62154437|NCT01144533|EXPERIMENTAL|Steroid + Hyaluronate|
62154438|NCT03379597|EXPERIMENTAL|Probiotics Group|"Probiotics add-on treatment :（live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules, Oral）, each capsule contain more then 1.0\*10\^7 CFU.~Bifico: 840mg Bid."
62528048|NCT05494645|ACTIVE_COMPARATOR|Peripheral Nerve Block Without Exparel|Lower extremity peripheral nerve block without Exparel: 0.25-0.5% bupivacaine
62528049|NCT05494645|EXPERIMENTAL|Peripheral Nerve Block with Exparel|Liposomal bupivicaine administered for peripheral nerve block: mixed with 0.25-0.5% bupivacaine
62528050|NCT05494645|EXPERIMENTAL|Local Infiltration of Exparel|Liposomal bupivicaine administered by surgeon intra-operatively in field block, mix with 0.25% bupivacaine
62528051|NCT03954314|ACTIVE_COMPARATOR|Topical Tranexamic Acid/Placebo|Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
62528052|NCT03954314|ACTIVE_COMPARATOR|Intravenous Tranexamic Acid/Placebo|Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.
62528053|NCT06394843||<500 ml Ultrafiltration|Patients undergoing hemodialysis with less than 500 ml ultrafiltration
62528054|NCT06394843||>2000 ml Ultrafiltration|Patients undergoing hemodialysis with than 2000 ml ultrafiltration
62528055|NCT04335318|EXPERIMENTAL|Colonoscopy with AI-assistance group|Colonoscopies were performed with AI-assistance.
62528056|NCT04335318|NO_INTERVENTION|Standard Colonoscopy group|Standard clinical procedure
62713693|NCT05980598|EXPERIMENTAL|TransCon TLR7/8 Agonist in combination with TransCon IL-2 β/γ|Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist (IT injection) in combination with TransCon IL-2 β/γ as a 30-minute IV infusion
62713694|NCT05980598|ACTIVE_COMPARATOR|Pembrolizumab|Participants receive 2 cycles, once every 3 weeks of pembrolizumab alone as a 30-minute IV infusion
62736735|NCT04894838|EXPERIMENTAL|Distal gastric bypass type II|Laparoscopic distalisation of RYGB type II. The RYGB is modified by dividing the BPL at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long AL.
62528057|NCT06438536|EXPERIMENTAL|Virtual Reality-based Social Cognitive Training (VRSCT)|Patients in the experimental group will be offered 10 individual sessions of targeted, virtual reality assisted psychotherapy embedded in cognitive behavioral therapy (CBT), that aims at enhancing social cognition and daily life functioning. If the patient consents, two additional sessions will be offered in which the patient's relatives are invited to participate (one in the beginning of treatment and one at the end of treatment). The aim of the relative involvement is to enhance transfer from the therapy to the patients daily life. The treatment will be conducted by psychologists with an extensive knowledge in providing virtual reality assisted therapy. The treatment is manualized, and the therapists will receive ongoing supervision by a senior clinician having ≥ 25 years of experience in conducting assessment, treatment, and research with the autism spectrum population.
62154439|NCT03379597|NO_INTERVENTION|Control Group|No probiotics or dietary fiber group.
62154440|NCT03379597|EXPERIMENTAL|Dietary fiber Group|Prebiotics add-on treatment: dietary fibers compound powder, 30g bid
62154441|NCT03379597|EXPERIMENTAL|Dietary fiber Probiotics group|Dietary fiber and probiotics group: receiving both Bifico 840mg Bid and dietary fiber 30g bid.
62154442|NCT04613947|ACTIVE_COMPARATOR|Control|The group with standard (written and verbal) information without multiple intelligence test
62154443|NCT04613947|EXPERIMENTAL|Visual/Spatial:|The group with higher visual intelligence according to the multiple intelligence test results and watch video. Also, will given with a written informed consent document
62528058|NCT06438536|NO_INTERVENTION|Treatment as Usual (TAU)|The treatment-as-usual (TAU) group will receive the standard treatment offered to adults diagnosed with ASD in Denmark. This commonly consists of four psychoeducational sessions as well as limited supportive counseling. Some adults with ASD also receive practical help in daily life situations in community settings. The TAU will be mapped upon trial completion.
62713695|NCT03005392|EXPERIMENTAL|Evaluate physical fitness|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
62528059|NCT02319395||cases|Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
62154444|NCT04613947|EXPERIMENTAL|Verbal/Linguistic|The group with higher verbal/linguistic intelligence according to the multiple intelligence test results and verbally informed in detail about the operation. lso, will given with a written informed consent document
62154445|NCT04613947|EXPERIMENTAL|Bodily/Kinesthetic|The group with higher bodily/kinesthetic intelligence according to the multiple intelligence test results and informed with a dental model. lso, will given with a written informed consent document
62154446|NCT06506279|EXPERIMENTAL|Motor Recovery through Plasticity-Inducing Cortical Stimulation|Single arm study of post-ischemic stroke patients with an upper extremity deficit.
62528060|NCT02319395||controls|Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
62528061|NCT06064292|EXPERIMENTAL|The High Intensity Training Group (HIT)|The High Intensity Training Group (HIT) received IMT at 40% of Maximum Inspiratory Pressure (MIP), the training load was set each 2 weeks to keep 40% of MIP.
62528062|NCT06064292|EXPERIMENTAL|The Low Intensity Training Group (LIT)|The Low Intensity Training Group (LIT) received IMT at 20% of MIP, following the same rules as HIT.
62713696|NCT03005392|EXPERIMENTAL|Evaluate Cardiological changes|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
62154447|NCT00680654|EXPERIMENTAL|Arm 1|
62154448|NCT01617889|ACTIVE_COMPARATOR|Powdered milk-based formula, standard fat blend|
62528063|NCT03933436|EXPERIMENTAL|Iodine|Iodine swabs.
62528064|NCT03933436|ACTIVE_COMPARATOR|Normal Saline|Saline flush.
62528065|NCT01003093|EXPERIMENTAL|Antigen group + high adjuvans|The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.
62528066|NCT01003093|EXPERIMENTAL|Antigen group|The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.
62528067|NCT01003093|EXPERIMENTAL|Antigen + low adjuvans group|The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.
62528068|NCT04173299||Early Tips|Patients wtih early tips for Acute esophageal variceal bleeding
62713697|NCT03005392|EXPERIMENTAL|Evaluate activity physical|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
62736736|NCT05199636|EXPERIMENTAL|Dragon fruit product|A dragon fruit beverage
62154449|NCT01617889|EXPERIMENTAL|Powder milk-based formula, alternate fat blend|
62154450|NCT02885376|EXPERIMENTAL|Dentoxol|Dentoxol® is a proprietary mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. Subjects will use Dentoxol® mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
62154451|NCT02885376|PLACEBO_COMPARATOR|Placebo|The placebo rinse will be identical in color, taste and consistency as the Dentoxol rinse and will be packaged in identical bottles with the same labels. Subjects will use placebo mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
62528069|NCT04173299||stantard treatment|patients with standard treatment (medical + endoscopic) for Acute esophageal variceal bleeding
62528070|NCT03349008|PLACEBO_COMPARATOR|Control group|Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
62528071|NCT03349008|EXPERIMENTAL|Experimental group|Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
62528072|NCT03318276|EXPERIMENTAL|SID142|Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
62528073|NCT03318276|ACTIVE_COMPARATOR|Rinexin® Tab|Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks
62154452|NCT06199011|ACTIVE_COMPARATOR|Control Group: Standardized general anesthesia|The control group is standard of opioid anesthesia including reminfentanil and sufentanil. In addition to dexmedetomidine and transverse abdominal plane block, general anesthesia induction will be induced performed with sufentanil (0.5 μg kg-1), propofol (1.5 mg kg-1), and rocuronium (1 mg kg-1). General anesthesia was maintained with a continuous infusion of remifentanil (5-15 μg kg-1 h-1), cisatracurium (0.1-0.2 mg kg-1 h-1), dexmedetomidine (0.4 μg kg-1 h-1), and sevoflurane exposure guided by bispectral index. Dexmedetomidine administration and sevoflurane inhalation will be completed at 20 minutes before surgery finish. Propofol and remifentanil will be continuously infused till the end of surgery.
62528074|NCT02843594|ACTIVE_COMPARATOR|LEEP Intervention C1|Cataract surgery with micro-interventional LEEP technology lens fragmentation (non-randomized cohort 1)
62154453|NCT06199011|EXPERIMENTAL|Intervention Group: A standardized non-opioid anesthesia|Dexmedetomidine (0.5μg kg-1) and esketamine (0.25mg kg-1) was intravenously infused to provide sedation for the bilateral transverse abdominal plane block (0.33% ropivacaine and dexmedetomidine 1μg kg-1). General anesthesia was then induced with esketamine (0.25 mg kg-1 h-1), propofol (1.5 mg kg-1), and rocuronium (1 mg kg-1). Following endotracheal intubation, GA was maintained with a continuous infusion of esketamine (0.25 mg kg-1 h-1), cisatracurium (0.1-0.2 mg kg-1 h-1), dexmedetomidine (0.4 μg kg-1 h-1), and sevoflurane guided by bispectral index. The infusions of esketamine and dexmedetomidine, as well as sevoflurane inhalation will be finished at 20 minutes before surgery completion. Propofol will be continuously infused to maintain appropriate bispectral index.
62154454|NCT01984216|EXPERIMENTAL|Roux-en-Y|Roux-en-Y for the gastrojejunostomy reconstruction
62528075|NCT02843594|ACTIVE_COMPARATOR|LEEP Intervention C2|Cataract surgery with micro-interventional LEEP technology lens fragmentation (randomized cohort 2)
62528076|NCT02843594|PLACEBO_COMPARATOR|Control Phaco C2|Cataract surgery with conventional phaco-assisted lens fragmentation (randomized cohort 2)
62154455|NCT01984216|ACTIVE_COMPARATOR|Billroth II|Billroth II for the gastrojejunostomy reconstruction
62154456|NCT05686967|EXPERIMENTAL|Aerobic Exercise plus MitoQ|"Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus experimental MitoQ, 20mg/d.~Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks."
62154457|NCT05686967|PLACEBO_COMPARATOR|Aerobic Exercise plus Placebo|"Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus matching placebo capsule/d for 10 weeks.~Matched placebo capsules."
62154458|NCT05686967|EXPERIMENTAL|No Exercise plus MitoQ|No exercise plus experimental MitoQ, 20mg/d. Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks.
62154459|NCT05526937|EXPERIMENTAL|Sprouted wholemeal bread|
62154460|NCT05526937|ACTIVE_COMPARATOR|Unsprouted wholemeal bread|
62154461|NCT05526937|PLACEBO_COMPARATOR|White bread|
62154462|NCT03071172|EXPERIMENTAL|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
62154463|NCT03071172|ACTIVE_COMPARATOR|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
62154464|NCT00786344|EXPERIMENTAL|Lifestyle Redesign|
62154465|NCT00786344|NO_INTERVENTION|No Treatment Control|The no treatment control arm did not receive the intervention during the first six-month period. However the intervention, which has been proven to be beneficial, was administered to the control arm immediately following the 6 month assessment.
62154466|NCT02314000|ACTIVE_COMPARATOR|SCS starting with supra-perception|Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS
62154467|NCT02314000|EXPERIMENTAL|SCS starting with sub-perception amplitude|Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS
62154468|NCT06464666||RRI positive group|RRI value higher than 0.7 measured by renal interlobar artery US
62154469|NCT06464666||RRI negative group|RRI value lower than 0.7 measured by renal interlobar artery US
62154470|NCT06475326|EXPERIMENTAL|Adebrelimab Combined with NALIRIFOX|"Adebrelimab: 20 mg/kg, intravenous infusion, administered on day 1, every four weeks as a cycle (Q4W)~Chemotherapy:~Oxaliplatin: 60mg/m2, intravenous infusion for 2 hours, administered on day 1 Irinotecan liposome: 50mg/m2, intravenous infusion for more than 90min, administered on the first day LV: 400mg/m2, intravenous infusion for 2 hours, administered on the first day 5-FU: 2400mg/m2, continuous intravenous infusion for 46h, every two weeks as a cycle (Q2W)"
62528077|NCT01155453|EXPERIMENTAL|BKM120 + GSK1120212 DE|Dose Escalation
62528078|NCT01155453|EXPERIMENTAL|BKM120 + GSK1120212 NSCLC patients|Advanced RAS or BRAF mutant NSCLC patients
62528079|NCT01155453|EXPERIMENTAL|BKM120 + GSK1120212 ovarian cancer patients|Advanced RAS or BRAF mutant ovarian cancer patients
62528080|NCT01155453|EXPERIMENTAL|BKM120 + GSK1120212 pancreatic cancer patients|Advanced RAS or BRAF mutant pancreatic cancer patients
62528081|NCT00712205|PLACEBO_COMPARATOR|A|20 Patients with asthma in a crossover design
62528082|NCT00712205|ACTIVE_COMPARATOR|B|20 Patients with asthma in a crossover design
62528083|NCT06205017|EXPERIMENTAL|Group A (AFSM)|16 subjects (Group A: intervention group) will take AFSMs in the immediate postoperative period (Appendix A). A weaning period with AFSM nutritional protocol of 4 weeks is planned, the weaning will cover the entire observation period T0 → T1.
62528084|NCT06205017|NO_INTERVENTION|Group B (protocol in use with homogenized)|16 subjects (Group B: control group) will follow the standard weaning protocol i.e. with homogenized food (Appendix B). A weaning period with nutritional protocol, as per clinical protocol, of 4 weeks is planned, weaning will cover the entire observation period T0 → T1.
62528085|NCT00006472|OTHER|Single arm study|Taxol® (Paclitaxel), Carboplatin and 5-Fluorouracil with Simultaneous Radiotherapy Followed by Surgical Resection
62736737|NCT05199636|NO_INTERVENTION|General health advice|Based on Eatwell guide and guidelines for type 2 diabetes prevention from the National Institute for Health and Care Excellence (NICE)
62154471|NCT02837705||carriers of a mutation in the Prion gene|Carriers of a mutation in the Prion gene who are either symptomatic or pre-symptomatic and who do either know or not know their mutation status.
62154472|NCT02837705||family members of carriers of a mutation in the Prion gene|Relatives of confirmed PrP mutation carriers who carry two wild type alleles.
62154473|NCT01821599|ACTIVE_COMPARATOR|Conventional group|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
62154474|NCT01821599|EXPERIMENTAL|Accelerated group|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
62154475|NCT04243954|EXPERIMENTAL|PCA IV Hydromorphone (continuous dose = 0)|"1. Intravenous PCA with hydromorphone after successful titration of 24 hours.~2. The PCA setting:~1) Continuous dose = 0; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
62154476|NCT04243954|EXPERIMENTAL|PCA IV Hydromorphone (continuous dose ≠ 0)|"1. Intravenous PCA with hydromorphone after successful titration of 24 hours.~2. The PCA setting:~1) Continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
62154477|NCT04243954|ACTIVE_COMPARATOR|Oral Morphine|"1. Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~2. Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
62154478|NCT00409747|EXPERIMENTAL|Minocycline|
62154479|NCT01524120||Crohn's disease (CD)|Patients with CD and mucosal healing on endoscopy.
62154480|NCT01524120||Crohn's disease|Patients with CD and mucosal healing on endomicroscopy.
62154481|NCT01524120||Ulcerative colitis (UC)|Patients with UC and mucosal healing on endoscopy.
62154482|NCT01524120||Ulcerative colitis|Patients with UC and mucosal healing on endomicroscopy.
62713698|NCT03005392|NO_INTERVENTION|control grup|The control group will be recommended to maintain a level of physical activity they would routinely and habitually have during the 4 months that the study will last.
62713699|NCT01426802|EXPERIMENTAL|Vildagliptin 50 bid|
62713700|NCT05393245||COPD patients treated with tiotropium and olodaterol (Tio+Olo)|
62713701|NCT05393245||COPD patients using other Long-acting muscarinic antagonists/Long-acting β2-agonists (LAMA/LABAs)|
62154483|NCT01512355|EXPERIMENTAL|dexmedetomidine|
62154484|NCT01512355|PLACEBO_COMPARATOR|placebo|
62154485|NCT02613767||Obese|"BMI \>30 kg/m2, Protein meal,~L-\[ring 13C6\]Phenylalanine infusion"
62154486|NCT02613767||Overweight|"BMI \>25 and \< 30 kg/m2, Protein meal,~L-\[ring 13C6\]Phenylalanine infusion"
62154487|NCT02613767||Healthy-Weight|"BMI \>18 and \< 25 kg/m2, Protein meal,~L-\[ring 13C6\]Phenylalanine infusion"
62154488|NCT00946244||Term infants|Healthy term infants
62154489|NCT00946244||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth
62713702|NCT06528626|NO_INTERVENTION|Observational|
62154490|NCT00946244||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in previous study)
62154491|NCT00946244||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in previous study)
62154492|NCT03696342|EXPERIMENTAL|PRO-157|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
62154493|NCT03696342|ACTIVE_COMPARATOR|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
62154494|NCT04636515|EXPERIMENTAL|Single Arm|
62154495|NCT06092736|EXPERIMENTAL|Compound Danshen Dropping Pills|Treatment group: Compound Danshen Dropping Pills (Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day, 20 capsules each time.
62154496|NCT06092736|PLACEBO_COMPARATOR|Placebo|Placebo group: placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
62154497|NCT02056379|ACTIVE_COMPARATOR|Budesonide|2 mg of nebulized budesonide at 12/12 hours and 8 cc of intravenous normal saline.
62154498|NCT02056379|ACTIVE_COMPARATOR|Dexamethasone|This group will receive 0,15 mg/kg/dose of intravenous dexamethasone at 6/6 hours and 8 cc of nebulized normal saline at 12/12 hours.
62154499|NCT00742560|EXPERIMENTAL|Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
62154500|NCT00742560|EXPERIMENTAL|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
62713703|NCT06528626|ACTIVE_COMPARATOR|self-questionnaire SQ-R&IC|
62713704|NCT06528626|ACTIVE_COMPARATOR|rapid HIV and HCV serological tests|
62713705|NCT02805790|EXPERIMENTAL|Elamipretide, Then Placebo|Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks.
62713706|NCT02805790|PLACEBO_COMPARATOR|Placebo, Then Elamipretide|Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks.
62713707|NCT05761171|EXPERIMENTAL|Regimen A (revumenib, 3-drug re-induction, FLA)|See Detailed Description.
62736738|NCT02685566|EXPERIMENTAL|FFDM Plus DBT|Breast Images with FFDM and DBT
62736739|NCT02685566|ACTIVE_COMPARATOR|Full-Field Digital Mammography|Breast Images with FFDM alone
62736740|NCT05383781|ACTIVE_COMPARATOR|Hip and Knee exercise group|Individuals in this group will perform exercises for the Hip and knee only.
62736741|NCT05383781|EXPERIMENTAL|Hip , Knee exercise and SFE group|Individuals in this group will perform exercises for Hip , knee and also short foot exercise
62154501|NCT00742560|EXPERIMENTAL|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
62154502|NCT00742560|EXPERIMENTAL|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
62528086|NCT03576183|ACTIVE_COMPARATOR|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)~The vaccine is administered orally in 2 doses about 1 week apart."
62528087|NCT03576183|PLACEBO_COMPARATOR|Placebo|"The buffer component of VLA1701 will be used as Placebo.~The vaccine is administered orally in 2 doses about 1 week apart."
62528088|NCT01490931|EXPERIMENTAL|Ketorolac nasal spray 31.5 mg|Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
62528089|NCT00432302|EXPERIMENTAL|Sagopilone|Subjects received 28 mg ZK 219477, containing 14 kBq/7.8 µg \[14C\]-ZK 219477 in the first infusion (Treatment course 1) followed by subsequent infusions (Treatment courses 2 to n \[till disease progression\]) of 16 mg/m2 ZK 219477 without radioactive label. Interval between the treatments was at least 21 days.
62154503|NCT00742560|EXPERIMENTAL|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
62154504|NCT06119802||Atrial Fibrillation cohort|The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF. The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate \<30 ml/ (min\*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.
62154505|NCT06119802||Non-atrial Fibrillation cohort|Patients attending the Department of Cardiology to rule out atrial fibrillation.The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate \<30 ml/ (min\*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.
62154506|NCT05037123|ACTIVE_COMPARATOR|Arm 1 Continuous ketamine infusion group|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
62154507|NCT05037123|ACTIVE_COMPARATOR|Arm 2 Ketamine + Saline group|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
62736742|NCT04381416|EXPERIMENTAL|Cohort I: SEAD treatment|Following the first SEAD™ treatment, women who experience a sub-optimal treatment response (at least 3 months after the first treatment) will be eligible to receive a second SEAD™ treatment (see re-treatment criteria below), which will be performed during the first 1-3 days following the cessation of their menses immediately following decision to retreat.
62528090|NCT01779154||eosinophilic gastrointestinal disorders|Individuals with a diagnosis of EGID including: eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis
62736743|NCT04381416|EXPERIMENTAL|Cohort II: Repeted SEAD treatment 1m post op|Following the first SEAD™ treatment, women will undergo a second SEAD™ treatment during the first 1-3 days following the cessation of their next menses.
62154508|NCT05037123|PLACEBO_COMPARATOR|Arm 3 Placebo group|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
62154509|NCT05583331|ACTIVE_COMPARATOR|Cataract surgery then Vitrectomy|Patients will undergo first the cataract surgery then the vitrectomy, as a combined surgery performed on the same day.
62154510|NCT05583331|EXPERIMENTAL|Vitrectomy then cataract surgery|Patients will undergo first the vitrectomy then the cataract surgery, as a combined surgery performed on the same day.
62154511|NCT04527965|EXPERIMENTAL|Customized diet to reduce liver fat|Ad libitum diet high in plant-derived PUFA and lower in carbohydrates
62154512|NCT04527965|EXPERIMENTAL|Healthy Nordic diet|Ad libitum diet, based on Nordic foods, higher in carbohydrates (high fiber/low GI) and lower in fat but rich in monounsaturated fatty acids (MUFA) and PUFA
62154513|NCT04527965|ACTIVE_COMPARATOR|Control|Ad libitum diet in accordance with the Nordic Nutrition Recommendations
62528091|NCT02785536|ACTIVE_COMPARATOR|Standard Treatment|The standard treatment was a well-established, manual-driven, multicomponent CBT for tobacco dependence that has been delivered in multiple modalities (i.e., group, individual, and telephone), used in numerous studies, and considered intensive, comprehensive, and consistent with the Public Health Service Clinical Practice Guideline.
62528092|NCT02785536|EXPERIMENTAL|RITCh Treatment|The RITCh treatment is an adaptation of the standard treatment which proactively addresses the needs and experiences of a diverse group of lower SES smokers as well as ensures that the treatment is culturally congruent and experientially resonant for African Americans while maintaining the same amount of treatment contact (i.e., six one-hour sessions).
62528093|NCT04386174|OTHER|Group A|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
62528094|NCT04386174|OTHER|Group B|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
62528095|NCT04182048||All patients|
62528096|NCT03217396||multiple sclerosis patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
62528097|NCT03217396||neurodegenerative disease patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
62528098|NCT03217396||control subjects|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
62528099|NCT04774887|EXPERIMENTAL|HPV vaccination|Children receiving HPV vaccine will be studies for seroconversion to HPV types, and aflatoxin levels in blood will be measured and compared to seroconversion.
62528100|NCT06168565|EXPERIMENTAL|Sequence 1|Measures of end-diastolic peak velocity, systolic peak velocity, heart rate, and arterial diameter will be collected for two minutes, two minutes before, at the 8th minute after the start of the IPC administration, and two minutes after the conclusion of each IPC protocol. End-diastolic peak velocity and systolic peak velocity will be measured across different phases of the IPC cycle (all cuffs inflated, half of the cuffs inflated, and all cuffs deflated). Both the athletes and assessors will be unaware of which protocol is being carried out. All protocols will be performed with participants lying down in a supine position, on a stretcher. The moderate pressure protocol applies a pressure of 80mmHg and the high pressure protocol applies a pressure of 200mmHg.
62528101|NCT06168565|EXPERIMENTAL|Sequence 2|Measures of end-diastolic peak velocity, systolic peak velocity, heart rate, and arterial diameter will be collected for two minutes, two minutes before, at the 8th minute after the start of the IPC administration, and two minutes after the conclusion of each IPC protocol. End-diastolic peak velocity and systolic peak velocity will be measured across different phases of the IPC cycle (all cuffs inflated, half of the cuffs inflated, and all cuffs deflated). Both the athletes and assessors will be unaware of which protocol is being carried out. All protocols will be performed with participants lying down in a supine position, on a stretcher. The moderate pressure protocol applies a pressure of 80mmHg and the high pressure protocol applies a pressure of 200mmHg.
62713708|NCT05761171|EXPERIMENTAL|Regimen B (revumenib, FLA)|"COMBINATION CYCLES 1-2: Patients receive revumenib PO or via NG, ND, NJ, or G-tube every 12 hours continuously, FLA IV on days 1-5, MTX IT, hydrocortisone IT, and cytarabine IT on day 0 and optionally on days 8, 15, and 22 of each cycle. Cycles repeat every 28 days for 2 cycles.~MONOTHERAPY: Patients receive revumenib PO or via NG, ND, NJ, or G-tube every 12 hours continuously. Treatment repeats every 28 days for up to 12 cycles on study in the absence of disease progression or unacceptable toxicity. Patients may also receive MTX IT, hydrocortisone IT, and cytarabine IT on days 0, 8, 15 and 22 as clinically indicated.~All patients also undergo ECHO or MUGA, collection of blood and CSF samples, lumbar puncture, and bone marrow aspiration throughout the trial."
62713709|NCT01059747||treatment group|
62154514|NCT01437540|EXPERIMENTAL|1|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
62528102|NCT01305148|EXPERIMENTAL|Randomized - Genetic|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
62528103|NCT01305148|NO_INTERVENTION|Randomized - Clinical|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
62528104|NCT01305148|EXPERIMENTAL|Registry|Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
62528105|NCT00001586|EXPERIMENTAL|Low-Intermediate Risk B-Cell Pts|Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered. Eligible to donate cells.
62713710|NCT01282541|ACTIVE_COMPARATOR|Transconjunctival|
62154515|NCT01437540|ACTIVE_COMPARATOR|2|Inhaled formoterol fumarate 12 μg, twice per day
62154516|NCT03109210|NO_INTERVENTION|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
62528106|NCT00001586|EXPERIMENTAL|Intermediate-high Risk B-Cell Pts|Previously untreated intermediate or high risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients requiring chemotherapy. Rituximab 375 mg/m\^2 by infusion on day 1, cycle 1 followed by fludarabine on day 2-6, 25 mg/m\^2 day x 5 days administered as an intravenous push or intravenous piggyback over 10-30 minutes, repeated every 28 days.
62528107|NCT01390285|EXPERIMENTAL|TENS|
62528108|NCT01390285|SHAM_COMPARATOR|Sham TENS|
62528109|NCT03832036|EXPERIMENTAL|Patients with lumbar disc herniation|
62528110|NCT01449279|EXPERIMENTAL|Ipilimumab Treatment + Radiation Therapy|Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments. Palliative radiation therapy to 1 to 2 sites of disease will start within 5 days of the first ipilimumab dose. Subjects will have follow up visits 2 to 4 weeks after the last ipilimumab dose and then every 3 months (±2 weeks) thereafter until progression of disease.
62528111|NCT03487783|EXPERIMENTAL|Aripiprazole Oral Solution|1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
62528112|NCT03487783|PLACEBO_COMPARATOR|Placebo Oral Solution|2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
62713711|NCT01282541|ACTIVE_COMPARATOR|Transcutaneous|
62713712|NCT00800735|EXPERIMENTAL|Pegylated-interferon alfa-2a plus ribavirin|Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing \< 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
62713713|NCT01430390|EXPERIMENTAL|Biological/Genetically Modified T cells|Utilizing our initial trial experience, it was amended to include three (3) expansion cohorts. Cohort 1: patients with CD19+ relapse/refractory (R/R) B cell malignancies occurring after allogeneic/autologous HSCT or solid organ transplant (SOT) infusion occurring following conditioning chemotherapy. Cohort 2:patients with CD10+ high risk B cell malignancies eligible for autologous HSCT followed by 19-28z CRA EBV-CTLs (auto-HSCT preparative regimen serves as conditioning chemotherapy. Cohort 3: patients with CD19+ high risk B cell malignancies eligible for allogeneic HSCT followed by consolidative 19-28z CAR EBV-CTLs (allo-HSCT preparative regimen serves as conditioning chemotherapy) Each expansion cohort has a target accrual of 6 patients treated with fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose.
62713714|NCT01746524||CR FB|Subjects receiving Cruciate Retaining Fixed Bearing configuration of ATTUNE Primary Knee Implant
62713715|NCT01746524||PS FB|Subjects receiving Posterior Stabilized Fixed Bearing configuration of ATTUNE Primary Knee Implant
62713716|NCT01746524||CR RP|Subjects receiving Cruciate Retaining Rotating Platform configuration of ATTUNE Primary Knee Implant
62736744|NCT04189796|ACTIVE_COMPARATOR|Jarlsberg|Daily intake of Jarlsberg Cheese in at least 6 weeks
62154517|NCT03109210|EXPERIMENTAL|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
62154518|NCT01641848|EXPERIMENTAL|Arthritic and injured ankles|InBone TAA
62528113|NCT04099173|EXPERIMENTAL|Brief Mindfulness Based Intervention|Some participants, as a result of random selection, will be asked to participate in four, 45-minute sessions that will occur on four separate days while on the Inpatient Psychiatric Unit (IPU). These four sessions are in addition to the standard IPU treatment and are experimental. These four sessions will include mindfulness meditation practice and education, creating a Crisis Response Plan, and a brief introduction into self-compassion. As stated above, practicing mindfulness means focusing attention on what is occurring in the present moment in a non-judgmental way. The focus may be on what one is seeing or hearing or physical sensations, such as touch, as well as thoughts and emotions. Meditation is just sitting quietly and practicing mindful awareness.
62713717|NCT01746524||PS RP|Subjects receiving Posterior Stabilized Rotating Platform configuration of ATTUNE Primary Knee Implant
62713718|NCT04885101|EXPERIMENTAL|LISWT Group|Participants who will submitted to active procedure with Low Intensuty Shockwave Therapy.
62528114|NCT04099173|NO_INTERVENTION|Treatment as Usual|Participants will be asked to fill out several short paper and pencil tests to assess your response to the treatment (10 to 15 minutes) pre-intervention and immediately post-intervention while on the Inpatient Psychiatric Unit (IPU), as well as a follow-up phone call or mail one month after discharge from the IPU. All participants will receive the IPU's normal standard of care treatment (for study purposes this called treatment as usual).
62528115|NCT03891186|EXPERIMENTAL|Experimental Group|"Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the treatment as usual (TAU)."
62528116|NCT03891186|ACTIVE_COMPARATOR|Control Group|The control group will not participate in the MCT program. In both groups will be maintained the TAU.
62528117|NCT00317252|EXPERIMENTAL|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held \>= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
62528118|NCT00317252|OTHER|Continue ACE1 or ARB|Randomized to continue on prescribed ACE1 or ARB
62528119|NCT03097835|OTHER|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
62528120|NCT03097835|OTHER|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
62528121|NCT05971654|EXPERIMENTAL|Azithromycin|azithromycin.:500 mg PO once for 5 days every month
62528122|NCT05971654|NO_INTERVENTION|control|pregnant woman at risk of preterm delivery
62528123|NCT02658825|EXPERIMENTAL|Panel 1: Dose level 1|Participants will receive either treatment A (JNJ-63623872, 2400 milligram (mg) tablet orally once on Day 1) or treatment B \[(placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1\].
62528124|NCT02658825|EXPERIMENTAL|Panel 1: Dose level 2|Participants will receive either treatment C (JNJ-63623872, 3000 mg tablet orally once on Day 1) or treatment D \[placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1\].
62528125|NCT02658825|EXPERIMENTAL|Panel 2: Treatment EFG|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
62713719|NCT04885101|EXPERIMENTAL|NARFT Group|Participants who will submitted to active procedure with Non-Ablative Radiofrequency Therapy
62713720|NCT04885101|SHAM_COMPARATOR|Sham Group|Participants who submitted to sham procedure with vaccum therapy.
62713721|NCT06424223|EXPERIMENTAL|Ridge augmentation|
62713722|NCT06680921|EXPERIMENTAL|Experimental group|SIM0270 to be taken orally as a capsule in combination with Everolimus.
62713723|NCT06680921|ACTIVE_COMPARATOR|Control group|"Investigator's choice of therapy of either:~Fulvestrant alone (a solution for injection), or Everolimus in combination with exemestane, both a tablet to be taken orally."
62713724|NCT01554748|OTHER|Patient cohort|TMC total joint arthroplasty
62713725|NCT06047743|EXPERIMENTAL|Alternating unilateral Isometric Handgrip Exercise Group|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
62736745|NCT04189796|SHAM_COMPARATOR|Camembert|Daily intake of Camembert Cheese in 6 weeks
62154519|NCT00670449|EXPERIMENTAL|Fingolimod 0.5 mg|Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
62154520|NCT00670449|EXPERIMENTAL|Fingolimod 1.25 mg|Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
62154521|NCT00670449|EXPERIMENTAL|Placebo-fingolimod|Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
62154522|NCT00311545|EXPERIMENTAL|CNTO 328|CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
62154523|NCT00209053|EXPERIMENTAL|Off Pump CABG|CABG without cardiopulmonary bypass.
62154524|NCT00209053|ACTIVE_COMPARATOR|On-Pump CABG|CABG with cardiopulmonary bypass.
62154525|NCT06585163|EXPERIMENTAL|Sequence A - Hydrocodone alone followed by combined (hydrocodone + doxapram)|Subjects randomized to Sequence A will first receive a single oral administration of hydrocodone bitartrate alone on Study Day-2 and then receive a combination of hydrocodone bitartrate and doxapram hydrocholoride on study Day-4 (after a 48 hour wash-out).
62736746|NCT03130517|OTHER|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
62154526|NCT06585163|EXPERIMENTAL|Sequence B - Combined (hydrocodone + doxapram) followed by hydrocodone alone|Subjects randomized to Sequence B will first receive a single combined administration of hydrocodone bitartrate and doxapram hydrocholoride on Study Day-2 and then receive hydrocodone alone on study Day-4 (after a 48 hour wash-out).
62154527|NCT05034588||Intensiv care patients after acute kidney injury|Patients with condition after intensive care stay and acute kidney injury and subsequent convalescence (without preexisting underlying cardiac disease or other disease with potential cardiac involvement).
62154528|NCT05034588||Intensiv care patients without kidney injury|Patients with condition after intensive care stay and subsequent convalescence (without kidney injury and preexisting underlying cardiac disease or other disease with potential cardiac involvement).
62154529|NCT05780957||Firefighters who receive multi-cancer early detection (MCED) test|
62154530|NCT04499898|EXPERIMENTAL|carvedilol|Carvedilol
62154531|NCT04499898|ACTIVE_COMPARATOR|Band Ligation|Band Ligation
62154532|NCT05453435|EXPERIMENTAL|Entecavir prophylaxis|0.5mg qd
62528126|NCT02658825|EXPERIMENTAL|Panel 2: Treatment FGE|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
62528127|NCT02658825|EXPERIMENTAL|Panel 2: Treatment GEF|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
62528128|NCT02658825|EXPERIMENTAL|Panel 2: Treatment GFE|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
62713726|NCT06047743|EXPERIMENTAL|Dominant knee extension Isometric Exercise Group|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
62713727|NCT06717204||Vericiguat and conventional treatment|Vericiguat in addition to conventional treatment
62713728|NCT06717204||Conventional treatment only|Conventional treatment only
62154533|NCT05485441|EXPERIMENTAL|Students|The students
62713729|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
62154534|NCT05485441|EXPERIMENTAL|Parents|The parents
62154535|NCT06257563|EXPERIMENTAL|Isle of TEND Intervention|All participants will engage in the Isle of TEND Intervention.
62154536|NCT06387940|ACTIVE_COMPARATOR|normal carbohydrate, energy-balanced diet, (nEB)|provided participants' 100% daily energy needs, following the balanced Eatwell Guide recommendations.
62154537|NCT06387940|ACTIVE_COMPARATOR|low-carbohydrate, energy-balanced diet, (LCEB)|diet contained just 50g of carbohydrates but still met 100% of the participants' estimated daily energy needs.
62154538|NCT06387940|ACTIVE_COMPARATOR|low-carbohydrate, energy-restricted diet, (LC25)|The diet consisted of only 50g of carbohydrates and provided 25% of the estimated daily energy needs.
62154539|NCT05458544|EXPERIMENTAL|[177Lu]Ludotadipep 3.7 GBq|If investigators observed one or no DLT in 6 patients at the 3.7 GBq dose level, the study can advance to the Phase 2a part of the trial after the safety review committee (SRC) review.
62154540|NCT05423171|EXPERIMENTAL|MANUS|Children and youth living with cerebral palsy will take part in a 60-hour intensive bimanual therapy at Peps at Université Laval, during which they will play games and exercise to promote spontaneous use of the most affected hand. Participants will take part to pre-evaluation and 1-week and 6-month post-intervention.
62154541|NCT05949788||Anemia group|The very low birth weight (VLBW) infants meet the diagnostic criteria of neonatal anemia during hospitalization between January 2020 and January 2023.
62713730|NCT03181191|ACTIVE_COMPARATOR|Totally pancreatectomised patients|Oral glucose tolerance test and biopsies
62713731|NCT03181191|ACTIVE_COMPARATOR|Type 2 diabetes patients|Oral glucose tolerance test and biopsies
62154542|NCT05949788||Control group|The very low birth weight (VLBW) infants are included without anemia during hospitalization between January 2020 and January 2023.
62154543|NCT00211042||Pure Red Cell Aplasia (PRCA)|This study will examine the relationship of the presence of anti-erythropoietin antibodies to the clinical course and outcome of participants currently or previously treated with recombinant human erythropoietin and who have PRCA identified from all notified reports (spontaneous postmarketing reports or from clinical trials reports).
62154544|NCT03956771|EXPERIMENTAL|Real neurofeedback|Two sessions of neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
62154545|NCT03956771|SHAM_COMPARATOR|Sham neurofeedback|Two sessions of placebo/control neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
62154546|NCT03717233|EXPERIMENTAL|Primary Arm|Participants will be used as their own controls. Participants will be evaluated using exo-skeletons with non-motorized spring elements in parallel to the Achilles tendon. Up to 5 different levels of spring force will be evaluated to evaluate the impact upon plantar pressure and measures of fall risk.
62154547|NCT04702594|EXPERIMENTAL|UHR and SRH|All patients over the age of 60 present in the UHR and hospitalized in SRH with behavioral disorders in the context of a neurocognitive disorder
62154548|NCT02912338|EXPERIMENTAL|Resistant Training Group|sandbag 2-5lb, grip ball, twice/week, Duration:12 weeks
62713732|NCT03181191|ACTIVE_COMPARATOR|Healthy control subjects|Oral glucose tolerance test and biopsies
62736747|NCT03130517|OTHER|Control group|Control group will recieve phototherapy only
62154549|NCT02912338|ACTIVE_COMPARATOR|Control Group|not change lifestyle
62713733|NCT03848455||Parkinson's disease group|"1. Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;~2. Newly diagnosed primary PD patients, diagnosed within 3-6 months;~3. informed consent to the study;~4. age \> 18 older."
62713734|NCT03848455||Non-parkinson group|Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age \> 18 older.
62154550|NCT05963802|NO_INTERVENTION|Traditional Online tools Group|Group B will serve as the control group in this study. Participants in this group will receive instructions on how to complete the assignment using traditional online tools available on the internet, without the use of artificial intelligence. They will have a timeframe of six days to complete the assignment using these conventional tools. Similar to participants in Arm 1, they will also be required to fill out a survey on technology usability, providing feedback on their experience with the online tools.
62154551|NCT05963802|EXPERIMENTAL|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process
62713735|NCT06230965|OTHER|conventional ventilation strategy group|The conventional ventilation strategy group used a conventional ventilation strategies: tidal volume（VT）=10-12 ml/kg, respiratory rate（f）=12 beats/minute, end-expiratory positive pressure（PEEP）= 0 cm H₂O, fraction of inspired oxygen = 0.5
62713736|NCT06230965|EXPERIMENTAL|lung protective ventilation strategy group|"The lung protective ventilation strategy group used the lung protective ventilation strategies~: tidal volume（VT）=6-8 ml/kg, f=12 breaths / minute,end-expiratory positive pressure（PEEP） = 6-8 cmH₂O, and fraction of inspired oxygen = 0.5 . After mechanical ventilation every 30 minutes (continuous positive airway pressure 30 cmH₂O for 30 seconds)."
62154552|NCT06091709|EXPERIMENTAL|MEET-R Group|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
62154553|NCT06091709|OTHER|Control Group|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
62154554|NCT02003885|EXPERIMENTAL|Desflurane increment|increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery
62154555|NCT02836184|ACTIVE_COMPARATOR|control group|Group treated with calcium carbonate for 6 weeks first,then switch to nicotinic acids treatment after 2 week of wash-out.
62154556|NCT02836184|EXPERIMENTAL|nicotinic acids group|Group treated with nicotinic acids for 6 weeks first,then switch to calcium carbonate treatment after 2 week of wash-out.
62154557|NCT00603018|EXPERIMENTAL|Annorexia nervosa|Participants recovered from anorexia nervosa before and after administration of fluoxetine
62154558|NCT00629564|ACTIVE_COMPARATOR|1|20mg oral
62713737|NCT04548180||TBI BIAFAC|100 TBI subjects with BIAFAC will be enrolled. No intervention
62713738|NCT06695117|EXPERIMENTAL|Group 1: IIV-HD (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62154559|NCT00629564|ACTIVE_COMPARATOR|2|15 minute intravenous infusion
62713739|NCT06695117|EXPERIMENTAL|Group 2: rC19 (dose 1) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62154560|NCT02767037|ACTIVE_COMPARATOR|Parkinson's disease (PD) patients|40 patients will be recruited. All will meet criteria for probable PD, according to the new MDS Clinical Diagnostic criteria. All participants will be 40 or older (young-onset PD includes many genetic causes, which often have normal autonomic function).
62154561|NCT02767037|ACTIVE_COMPARATOR|parkinsonsism (non-PD) patients|20 patients will also be recruited. These will include patients with progressive supranuclear palsy, multiple system atrophy, 'vascular parkinsonism' or corticobasal syndrome. All patients will have parkinsonism according to UK brain bank criteria, with a diagnosis of one of the above conditions made according to gold-standard expert evaluation. No patient will meet MDS Criteria for probable PD.
62713740|NCT06695117|EXPERIMENTAL|Group 3: IIV-HD (in right or left deltoid) and rC19 (dose1) (in opposite deltoid)|two IM injections on D01
62713741|NCT06695117|EXPERIMENTAL|Group 4: IIV-HD + rC19 (dose 1) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62713742|NCT06695117|EXPERIMENTAL|Group 5: IIV-HD + rC19 (dose 2) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62154562|NCT02767037|ACTIVE_COMPARATOR|idiopathic REM sleep behavior disorder patient|40 patients will be recruited. All patients will have polysomnogram-confirmed RBD according to American Academy of Sleep Medicine Criteria. Patients will be free of parkinsonism and dementia according to neurological examination and will have no untreated sleep apnea, epilepsy, or other abnormalities that could cause dream enactment behavior.
62154563|NCT02767037|PLACEBO_COMPARATOR|Controls|40 controls will be age matched (within 5 years) and sex-matched (with \>90% concordance). All controls will have an examination confirming the absence of parkinsonism, and will have no symptoms of REM sleep behavior disorder, as assessed with the RBD1Q and expert interview.
62154564|NCT00637559|EXPERIMENTAL|1|40mg twice daily
62713743|NCT06695117|EXPERIMENTAL|Group 6: IIV-HD + rC19 (dose 3) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62713744|NCT06695117|EXPERIMENTAL|Group 7: IIV-HD + rC19 (dose 4) (in right or left deltoid) and placebo (in opposite deltoid)|two IM injections on D01
62713745|NCT06706622|EXPERIMENTAL|Lu AF82422 Low Dose|Participants will receive Lu AF82422 by intravenous infusion
62713746|NCT06706622|EXPERIMENTAL|Lu AF82422 High Dose|Participants will receive Lu AF82422 by intravenous infusion
62713747|NCT06706622|PLACEBO_COMPARATOR|Placebo|Participants will receive commercially available saline solution for infusion
62713748|NCT01932684|EXPERIMENTAL|Incentive spirometry|Was utilized an incentive spirometer volume in this group.
62713749|NCT01932684|NO_INTERVENTION|Control Group|
62154565|NCT00637559|EXPERIMENTAL|2|40mg three times daily
62528129|NCT02658825|EXPERIMENTAL|Panel 2: Treatment FEG|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
62528130|NCT02658825|EXPERIMENTAL|Panel 2: Treatment EGF|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
62528131|NCT04145453|EXPERIMENTAL|intervention group|Participants with PAV haplotype will receive personalised dietary recommendations regarding consumption of fruit and vegetables. The information about genotype will be given at the beginning of study.
62528132|NCT04145453|SHAM_COMPARATOR|control group 1|Participants with PAV haplotype will receive personalised dietary recommendations regarding consumption of fruit and vegetables, but the information about genotype will be given at the end of study.
62528133|NCT04145453|ACTIVE_COMPARATOR|Control group 2|Participants with AVI haplotype will receive general recommendations regarding consumption of fruit and vegetables.
62528134|NCT03569150|OTHER|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
62528135|NCT03569150|NO_INTERVENTION|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
62528136|NCT01483053|ACTIVE_COMPARATOR|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
62528137|NCT01483053|ACTIVE_COMPARATOR|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
62528138|NCT06414070|EXPERIMENTAL|Jenga Dada|Jenga Dada programming in women's economic empowerment group meetings
62528139|NCT06414070|NO_INTERVENTION|Waitlist Control|Standard women's economic empowerment group programming
62713750|NCT01932684|EXPERIMENTAL|Breath Stacking|We used a face mask silicone connected to a check valve allowing only inspiration and is connected to a spirometer showed that the volume inspired by the individual.
62713751|NCT04682665||Experimental|Patients randomized to the experimental arm of the EMT2 trial, receiving Icosapent Ethyl (EPA-EE) according to the EMT2 protocol.
62713752|NCT04682665||Placebo comparator|Patients randomized to the placebo comparator arm of the EMT2 trial, receiving placebo capsules according to the EMT2 protocol.
62713753|NCT06450106|EXPERIMENTAL|STM-416p|STM-416p
62713754|NCT05202262|EXPERIMENTAL|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
62713755|NCT05202262|EXPERIMENTAL|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
62154566|NCT00637559|EXPERIMENTAL|3|20mg three times daily
62154567|NCT02304445|ACTIVE_COMPARATOR|Transarterial Chemoembolization (TACE)|Subjects will randomized receive one TACE treatment then receive observation or up to 3 additional TACE treatments as clinically indicated.
62154568|NCT02304445|EXPERIMENTAL|TACE+Stereotactic Body Radiotherapy|Subjects will receive one TACE treatment then receive 1-5 Stereotactic Body Radiotherapy treatments.
62528140|NCT06420544|EXPERIMENTAL|Intervention group|The whole intervention has 24 sessions. Children will play with the game two times a week, each lasting 15 minutes, over a period of 12 weeks. Each session stimulates two skills (one cognitive and one non-cognitive skills) and has eight activities with increasing levels of difficulty.
62528141|NCT06420544|NO_INTERVENTION|Control group|"The control group receives standard school curricula, which is not a manualized intervention. The standard curriculum is provided by the Ministry of Education with a guideline called Curricular Bases for Kindergarten Education which includes pre-kindergarten directions to Early Year Educators regarding emotion regulation and planification to implement in class."
62528142|NCT02572934||Chemotherapy group (CT-group)|Patients treated with chemotherapy \>20 years ago
62528143|NCT02572934||Radiotherapy group (RT-group)|Patients treated with radiotherapy \>20 years ago
62528144|NCT02572934||Surgery-only group (SU-group)|Patients treated with only orchidectomy \>20 years ago
62528145|NCT02572934||Control-group|Healthy controls
62528146|NCT00228423|ACTIVE_COMPARATOR|75mg Clopidogrel|75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
62528147|NCT00228423|PLACEBO_COMPARATOR|Placebo|Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
62528148|NCT06162104||Post-poliomyelitis syndrome group|Patients suffering from post-poliomyelitis syndrome
62713756|NCT05202262|EXPERIMENTAL|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
62713757|NCT05202262|ACTIVE_COMPARATOR|Open-label Symbicort TBH 320/9 μg|Open-Label Comparator Symbicort Turbuhaler 320/9 μg
62713758|NCT06540170|OTHER|Single arm|Eligible and willing participants will be invited to participate in the program and receive three 30-minute face-to-face sessions (once every 1-2 weeks) within 3-6 weeks of enrolment.
62736748|NCT03221465|NO_INTERVENTION|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
62713759|NCT06441006|ACTIVE_COMPARATOR|Strategy 1: Control regimen for all with FQ-S MDR/RR-TB|The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 26 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest WHO guidelines and the local SOC.
62528149|NCT06162104||Healthy volunteers|Control gruoup with healthy volunteers
62528150|NCT02736877|EXPERIMENTAL|Lumera Microscope with OCT RESCAN|In the group microscope coupled to OCT, patients will undergo corneal surgery using the Lumera Microscope WITH RESCAN OCT - ZEISS. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
62528151|NCT02736877|ACTIVE_COMPARATOR|Conventional Microscope|The control group will undergo corneal transplant with conventional microscope without coupled OCT. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
62528152|NCT00658658|EXPERIMENTAL|Panitumumab|Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
62528153|NCT02358343|ACTIVE_COMPARATOR|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
62528154|NCT02358343|NO_INTERVENTION|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
62713760|NCT06441006|EXPERIMENTAL|Strategy 2: 4BPaLM for all with FQ-S MDR/RR-TB|17 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (4BPaLM). Bedaquiline 400 mg orally once daily for 2 weeks, then 200 mg once daily; pretomanid 200 mg orally once daily; linezolid 600 mg orally once daily; and moxifloxacin 400 mg orally once daily.
62154569|NCT03034863|EXPERIMENTAL|SAFER|SAFER (Safe Actions for Families to Encourage Recovery): A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving supporting partners to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and supporting partners with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or partner concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase partner support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
62154570|NCT03034863|ACTIVE_COMPARATOR|I-SPI|The comparison condition will be an assessment-only enhanced treatment-as-usual called the Individual Safety Planning Intervention (I-SPI), incorporating weekly scripted check-in phone calls to review mood symptoms and use of the safety plan, which will then be given as feedback to the Veteran's primary mental health provider.
62154571|NCT00523458|ACTIVE_COMPARATOR|1|Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
62154572|NCT00523458|EXPERIMENTAL|2|High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
62154573|NCT00523458|ACTIVE_COMPARATOR|3|Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
62528155|NCT02358343|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
62528156|NCT02358343|ACTIVE_COMPARATOR|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
62528157|NCT02358343|NO_INTERVENTION|Observational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
62736749|NCT03221465|ACTIVE_COMPARATOR|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
62154574|NCT00523458|EXPERIMENTAL|4|High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
62154575|NCT03332316|PLACEBO_COMPARATOR|DEXA0|Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
62154576|NCT03332316|EXPERIMENTAL|DEXA1|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
62154577|NCT03332316|EXPERIMENTAL|DEXA2|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
62154578|NCT03332316|EXPERIMENTAL|DEXA4|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
62528158|NCT05228821|EXPERIMENTAL|Active Drug|Generic Name: Voxelotor Dosage Form: tablet Dosage: 1500mg Frequency: QD Duration: 24 weeks
62528159|NCT02253836|EXPERIMENTAL|TAZ/RTV - TPV/RTV - TPV/RTV+TAZ|"Days 1-9: single dose TAZ/RTV~Days 16-23: morning and evening dose TPV/RTV~Days 24-32: TPV/RTV + TAZ"
62528160|NCT05549518|EXPERIMENTAL|Core stabilization + Traditional Physical Therapy|In addition to the traditional physical therapy training, core stabilization exercises will be applied in this group.
62528161|NCT05549518|ACTIVE_COMPARATOR|Traditional Physical Therapy|This group will continue the traditional physical therapy program.
62154579|NCT05343936||Active surveillance|This is a multicentric active surveillance prospective cohort study. The eligibility criteria defined are: low-risk prostate adenocarcinoma (clinical stage of cT1-T2a / Group Grade 1 (Gleason score less or equal to 6) / PSA less or equal to 10 ng/ml), transrectal prostate biopsy with at least 12 cores, estimated life expectancy over 10 years, clinical conditions for definitive treatment, multiparametric prostate MRI performed or planned.
62154580|NCT03014726|EXPERIMENTAL|DCB Treatment|Stricture patients treated by DCB
62528162|NCT05367479|ACTIVE_COMPARATOR|Cefazolin|standard of care as a pre-operative antibiotic given with 60 minutes of incision before gastric bypass surgery. given intravenous as a single dose, weight based.
62528163|NCT05367479|ACTIVE_COMPARATOR|Clindamycin|also standard of care alternative as a pre-operative antibiotic given with 60 minutes of incision before gastric bypass surgery. given intravenous as a single dose, weight based.
62528164|NCT06478264|EXPERIMENTAL|Single arm|"EP regimen:Etoposide and Cisplatin or Carboplatin~Cohort A: Stage I-IVa , EP combined with adebrelimab induction therapy for 2 cycles, sequential thoracic radiotherapy combined with EP chemotherapy for 2 cycles, and adebrelimab immunomaintenance therapy until PD or over 1 year.Thoracic radiotherapy regimen : prescription dose: PTV 50Gy/25f.~Cohort B: Stage IVb , EP regimen combined with adebrelimab injection immunotherapy for 4 cycles, PR or SD patients evaluated for 3 months, followed by chest radiotherapy, and adebrelimab immunization continued until PD or full 1 year.Chest radiotherapy : prescribed dose: PTV 30Gy/10f."
62528165|NCT01045174|ACTIVE_COMPARATOR|Breath-Actuated Nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer.
62713761|NCT06441006|EXPERIMENTAL|Strategy 3: 3BPaLM or 6BPaLM stratified medicine strategy for those with FQ-S MDR/RR-TB|"13 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (3BPaLM) for participants classified as having easier-to-treat TB and 26 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM) for participants classified as having harder-to-treat TB.~3BPaLM: 13 weeks of bedaquiline 400 mg orally once daily for 2 weeks, then 200 mg once daily; pretomanid 200 mg orally once daily, linezolid 600 mg orally once daily, and moxifloxacin 400 mg orally once daily.~6BPaLM: 26 weeks of bedaquiline 400 mg orally once daily for 2 weeks, then 200 mg once daily; pretomanid 200 mg orally once daily, linezolid 600 mg orally once daily, and moxifloxacin 400 mg orally once daily."
62713762|NCT05815914|EXPERIMENTAL|Intervention group|
62713763|NCT05815914|ACTIVE_COMPARATOR|Control group|
62713764|NCT03477604|EXPERIMENTAL|MicroStent and Standard PTA|Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
62154581|NCT05825105|EXPERIMENTAL|PRP-1|Platelet-rich plasma, short treatment (three sessions every two weeks)
62154582|NCT05825105|ACTIVE_COMPARATOR|PRP-2|Platelet-rich plasma, long treatment (three sessions every four weeks)
62528166|NCT01045174|ACTIVE_COMPARATOR|Conventional continuous-ouput nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer
62528167|NCT03272464|EXPERIMENTAL|Trametinib + Dabrafenib + INCB039110|"* Dabrafenib is administered orally every 12 hours~* Trametinib is administered orally once a day~* INCB039110 is administered orally once a day"
62528168|NCT02128217|EXPERIMENTAL|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
62528169|NCT02128217|EXPERIMENTAL|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
62154583|NCT05140499|ACTIVE_COMPARATOR|Single Shot Perineural Popliteal Nerve Block|Single shot perineural popliteal nerve block injection of 10cc 13.3% liposomal bupivacaine combined with 15cc 0.50% bupivacaine hydrochloride within one hour prior to surgery
62154584|NCT05140499|ACTIVE_COMPARATOR|Continuous perineural popliteal nerve block catheter|Placement of continuous perineural popliteal nerve block catheter with injection of 30cc 0.5% bupivacaine within one hour prior to surgery, followed by continuous infusion of 10cc 0.3% ropivacaine (current standard practice) for at least 72 hours following surgery. Saphenous single shot 20cc 0.2
62154585|NCT03136588|EXPERIMENTAL|ICT based monitoring group|Intervention: In the ICT-based centralized monitoring group, both subjects and medical staff receive feedbacks regarding a missed dose, misuse, and overuse of the medication in the form of text messages and pill box alarms.
62528170|NCT04675853||Participants with PD|
62528171|NCT04675853||Care Partners of PD participants|
62713765|NCT03477604|ACTIVE_COMPARATOR|Standard PTA|
62713766|NCT06157021|EXPERIMENTAL|Rotary pulpectomy|Rotary pulpectomy using rotary files (Fanta AF baby\* rotary files and Endo Radar\* rotary device
62713767|NCT06157021|ACTIVE_COMPARATOR|Manual pulpectomy|Manual pulpectomy using manual H files, Mani\*)
62713768|NCT02410772|ACTIVE_COMPARATOR|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, \< 55kg 1000 mg, \>= 55-75 kg 1500 mg, \>75 kg 2000 mg; ethambutol, \< 55kg 800 mg, \>= 55-75 kg 1200 mg, \>75 kg 1600 mg"
62713769|NCT02410772|EXPERIMENTAL|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, \< 55kg 1000 mg, \>= 55-75 kg 1500 mg, \>75 kg 2000 mg; ethambutol, \< 55kg 800 mg, \>= 55-75 kg 1200 mg, \>75 kg 1600 mg"
62154586|NCT03136588|NO_INTERVENTION|Control group|Use standard questionnaire to gather information for drug adherence
62528172|NCT06053918||classic follow-up (Group A)|Group A will benefit from the classic follow-up, as it has been contractualized for several years now between the UMDSP and the hematology sector. Namely a psychological follow-up in the patient's room during the hospitalization time, once a week, more if the patient is going through a difficult passage that requires closer support. This follow-up is spread over an approximate period of 6 weeks maximum, depending on the length of hospitalization
62528173|NCT06053918||Intervention group (Group B)|Group B will benefit from this same follow-up, to which will be added an interview when leaving the sector, and the extension of follow-up of the patient at home according to the same conditions: once a week, more if necessary, over a period of two months. This follow-up is spread over an approximate period of 15 weeks maximum, depending on the length of hospitalization.
62528174|NCT06047392|NO_INTERVENTION|Usual Care|
62528175|NCT06047392|ACTIVE_COMPARATOR|CT coronary angiography + usual care|
62528176|NCT05592392|EXPERIMENTAL|Therapy|SDS system implanted and Therapy On for 6 months post randomization
62528177|NCT05592392|SHAM_COMPARATOR|Control|SDS system implanted and Therapy Off for 6 months post randomization
62528178|NCT01918540|ACTIVE_COMPARATOR|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
62528179|NCT01918540|ACTIVE_COMPARATOR|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
62528180|NCT05549635||Patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP)|"The overall inclusion criteria of patients in the HP cohort are:~* Diagnosis of HP at an MDT conference according to the current international guidelines~* Age of 18 years or older~* The patients must be capable of giving informed consent"
62528181|NCT01233648|ACTIVE_COMPARATOR|AF|
62528182|NCT01233648|ACTIVE_COMPARATOR|SR|
62528183|NCT03110068||Preoperative clinical/imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo contrast-enhanced computed tomography (CECT) and contrast-enhanced ultrasound (CEUS).
62528184|NCT04666415|EXPERIMENTAL|Osteopathic treatment + as-usual treatment|"Osteopathic treatment: a protocol of 5 sessions of osteopathic treatment that have a 25 minutes duration and are spaced of around one week between two sessions.~As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers."
62528185|NCT04666415|NO_INTERVENTION|As-usual treatment|As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers.
62713770|NCT02410772|EXPERIMENTAL|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, \< 55kg 1000 mg, \>= 55-75 kg 1500 mg, \>75 kg 2000 mg; moxifloxacin, 400 mg"
62154587|NCT04382053|EXPERIMENTAL|DFV890 + SoC|DFV890 50 mg was administered orally or nasogastrically twice per day (b.i.d) approximately 12 hours apart (morning and evening) for 14 days in addition to SoC.
62528186|NCT03018808||Subjects met inclusion with at least one exclusion criteria|Subjects who meet all the inclusion criteria, but have at least one exclusion criteria or not agree to participate in the whole study will be invited to sign a special ICF in order to complete a minimal questionnaire.
62528187|NCT03018808||Subjects who satisfy all inclusion/exclusion criteria|Subjects who satisfy all inclusion/exclusion criteria and agree to sign the ICF, an interview will be conducted for information regarding medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
62528188|NCT03018808||Spirometry confirmed COPD Subjects|The spirometry confirmed COPD patients will be requested to complete the COPD Assessment Test (CAT), self-administered questionnaire related to quality of life on COPD patients.
62528189|NCT04319159|EXPERIMENTAL|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single Photodynamic therapy (PDT)."
62528190|NCT02213120||Dizziness|Patients with Dizziness
62528191|NCT03106831|EXPERIMENTAL|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
62528192|NCT03106831|EXPERIMENTAL|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
62528193|NCT02216318|PLACEBO_COMPARATOR|red light|red light during the whole day
62528194|NCT02216318|ACTIVE_COMPARATOR|Blue light|Blue light during early day
62528195|NCT02737527|EXPERIMENTAL|Ultrasound with Fluoroscope|"This group undergoes lumbar sympathetic block using ultrasound and fluoroscope.~Preparation: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Ultrasound for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
62528196|NCT02737527|ACTIVE_COMPARATOR|Fluoroscope only|"This group undergoes lumbar sympathetic block using fluoroscope only.~Device: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Fluoroscope for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
62713771|NCT04982952|EXPERIMENTAL|Contingency Management (CM)|In addition to receiving usual cessation care at the Tom Waddell Urban Health Center (TWUHC), CM intervention participants with CO-verified abstinence will obtain a CM incentive payment, via gift cards and/or cash redeemable in national retail chains.
62154588|NCT04382053|ACTIVE_COMPARATOR|Standard of Care (SoC)|SoC was used as an active comparator arm.
62154589|NCT05107232|OTHER|Participants|Patients and Healthy volunteers included will have an MRI
62154590|NCT05180175|EXPERIMENTAL|Access to protein profile|
62154591|NCT05180175|NO_INTERVENTION|No access to protein profile|
62154592|NCT04558021|EXPERIMENTAL|Intervention Arm-I|Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
62528197|NCT00856830|EXPERIMENTAL|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin.~This study has only one arm but it incorporates two phases. Phase I utilizes a combination of bendamustine and irinotecan for Regimen A followed by etoposide and carboplatin for Regimen B."
62528198|NCT04596228|EXPERIMENTAL|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device
62154593|NCT04558021|PLACEBO_COMPARATOR|Intervention Arm-II|10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
62154594|NCT00274287|EXPERIMENTAL|GM-CSF|Once patients have finished receiving the chemotherapy and no signs of disease progression they may receive GM-CSF as outlined in the protocol
62154595|NCT04070521||Observational EEG Monitoring|
62154596|NCT02871726|EXPERIMENTAL|TRUS-Robot and TRUS|TRUS and TRUS-Robot will be used during prostate biopsy
62154597|NCT02871726|ACTIVE_COMPARATOR|Routine TRUS/Fusion biopsy|Just Uronav will be used during prostate biopsy
62154598|NCT02132195|ACTIVE_COMPARATOR|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
62528199|NCT03468595|EXPERIMENTAL|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
62528200|NCT03468595|EXPERIMENTAL|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson \& Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
62528201|NCT03468595|ACTIVE_COMPARATOR|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
62528202|NCT01995266|EXPERIMENTAL|Asunaprevir + Daclatasvir|"Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and~Daclatasvir 60mg tablet by mouth once daily for 24 weeks"
62528203|NCT03750435|EXPERIMENTAL|Ablation for AF or left-sided AT|The patient will be admitted in hospital as for a standard ablation procedure and discharged the next day. The procedure will be carried out without using fluoroscopy and relying on the visualization of the electroanatomical mapping system.
62528204|NCT03986736||Patients with major trauma|Patients with major trauma will be included in the study.
62528205|NCT05005871|ACTIVE_COMPARATOR|Quadratus lumborum intramuscular block|The quadratus lumborum intramuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.
62528206|NCT05005871|ACTIVE_COMPARATOR|Quadratus lumborum transmucular block|The quadratus lumborum transmuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.
62154599|NCT02132195|NO_INTERVENTION|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study.
62154600|NCT02132195|ACTIVE_COMPARATOR|Rescue therapy|There is an option for the patient in no-treatment arm to elect to be placed in the active treatment arm of the trial (rescue therapy).
62154601|NCT05135806||Group 1|Remote evaluation first: participants will undergo a comprehensive neuropsychological assessment administered remotely via telephone calls or videoconferencing. Each participant will take part to the second evaluation (face-to-face) 8 weeks later.
62154602|NCT05135806||Group 2|Face-to-face evaluation first: participants will undergo a comprehensive neuropsychological assessment administered face-to-face. Each participant will take part to the second evaluation (remotely via telephone calls or videoconferencing) 8 weeks later.
62154603|NCT05790317|EXPERIMENTAL|Surgical Procedure with ERAS Protocol|ERAS Maintenance Protocol The basic philosophy of the ERAS Protocol is to reduce metabolic stress due to surgical trauma, and to return to normal activity as soon as possible by supporting the normalization of functions in a short time. ERAS protocols are a protocol consisting of a total of 24 items covering the perioperative period of a patient, which starts in the outpatient clinic in the preoperative period and ends at home with discharge. includes applications. Elements of this preparation and treatment method, which is different from the traditional, were applied to our patients in this group before (11), during the operation (6) and after the operation (7). In the study, the data were collected with the personal introduction form introducing the characteristics of the patients, the Rhodes Nausea-Vomiting and Regurgitation Index (WPI), the Mcgill Pain Scale and the Postoperative Evaluation Form created within the scope of the ERAS Care Protocol.
62528207|NCT02291770|ACTIVE_COMPARATOR|Mesenchymal stem cells (MSC)|"Patients with newly diagnosed cGvHD receive primary treatment plus MSC:~1. MSC+prednisone+cyclosporine;~2. MSC+prednisone+tacrolimus;~3. MSC+prednisone+mycophenolate mofetil."
62528208|NCT02291770|PLACEBO_COMPARATOR|Placebo|"Patients with newly diagnosed cGvHD receive primary treatment:~1. Placebo+prednisone+cyclosporine;~2. Placebo+prednisone+tacrolimus;~3. Placebo+prednisone+mycophenolate mofetil."
62528209|NCT06367855|ACTIVE_COMPARATOR|Dexamethasone group|
62528210|NCT06367855|PLACEBO_COMPARATOR|Normal saline group|
62528211|NCT01172483|EXPERIMENTAL|multimodal community program|multimodal community program of exercise and education
62154604|NCT05790317|NO_INTERVENTION|Surgery Procedure with the traditional method|"ItThe group that underwent surgery with the traditional method is the control group. The surgical procedure preparation procedure in the institution where the study was conducted was not exceeded.~The data in the control group were collected with the patient information form, the Postoperative Evaluation Form to evaluate the symptoms after the surgical intervention, the McGill Pain Scale Short Form, the Rhodes Nausea-Vomiting Regurgitation Index."
62154605|NCT05876286|EXPERIMENTAL|Attention Deficit Disorder With Hyperactivity|Patients with Attention Deficit Disorder With Hyperactivity. Same examinations than control group
62154606|NCT05876286|ACTIVE_COMPARATOR|Control|Healthy volunteers Same examinations than Attention Deficit Disorder With Hyperactivity group
62528212|NCT01172483|ACTIVE_COMPARATOR|active control|general practice in primary care and education of chronic disorders
62154607|NCT05466760||Patient recently diagnosed breast cancer who will undergo surgery|surgery treatment only
62528213|NCT03688282|SHAM_COMPARATOR|Sham Wearable belt|Device will be worn but not turned on for 30 minutes.
62528214|NCT03688282|EXPERIMENTAL|Wearable vibration belt (30)|Device will be worn and turned on for 30 minute treatment.
62154608|NCT05466760||Patients with recently diagnosed breast cancer who will undergo NAC.|Patients with recently diagnosed breast cancer who will undergo NAC before surgery.
62528215|NCT01749917|ACTIVE_COMPARATOR|Control group|30 people are recruited in order to the inclusion criteria for the study. The study include subjects who can complete the assessment battery of tests at the beginning and end in order to perform the control intervention.
62528216|NCT01749917|EXPERIMENTAL|Exercise program group|30 people are recruited, diagnosed with Parkinson attending to the Parkinson Association of Granada aged between 40 and 65 years. No sex differences. The study include subjects who can complete the assessment battery of tests at the beginning and end.
62528217|NCT00302081|ACTIVE_COMPARATOR|PEG2b 1.5/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks
62528218|NCT00302081|EXPERIMENTAL|PEG 2b 1.0/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks
62154609|NCT03455725|ACTIVE_COMPARATOR|CardiAMP cell therapy system|"Roll-in phase:~Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.~In the subsequent randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system."
62154610|NCT03455725|SHAM_COMPARATOR|Sham procedure control|"Randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)"
62154611|NCT01248715|EXPERIMENTAL|Oseltamirvir|These patients will receive early oseltamivir plus current, standard empiric antibacterial therapy.
62528219|NCT00302081|EXPERIMENTAL|PEG2b 1.5/R (16 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks
62154612|NCT01248715|NO_INTERVENTION|Standard of care|These patients will be treated with the current, standard care, including currently recommended antibiotics or antiviral therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP and ACIP antiviral use guidelines for hospitalized patients with confirmed of suspect influenza, per clinician discretion. In addition these patients with have a NP swab collected for influenza PCR testing and clinical information will be extracted from the medical record.
62528220|NCT02987959|EXPERIMENTAL|TAK-228 treatment|Patients with complex genomic sarcomas exhibiting PI3K pathway dysregulation will be treated with TAK-228
62528221|NCT00649818|EXPERIMENTAL|1|Lorazepam Tablets 2 mg
62528222|NCT00649818|ACTIVE_COMPARATOR|2|Ativan Tablets 2 mg
62528223|NCT05034341|EXPERIMENTAL|Multimodal Prehabilitation Arm|"The Multimodal Prehabilitation group will receive:~* An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to a home exercise program. Patients' compliance will be monitored by phone each week.~* Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar-free.~* Pain and Neuroscience Education: Per University of Florida Health Pain and Neuroscience program at Shands hospital.~* Standard Clinical Care: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with a focus on preoperative cognitive assessment."
62528224|NCT05034341|ACTIVE_COMPARATOR|Standard Clinical Care Comparison Arm|"The Standard Clinical Care Comparison group will receive:~* Education related to preoperative activity and home based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment.~* A final preoperative visit before surgery where a second set of functional assessment will be implemented"
62528225|NCT02608151|ACTIVE_COMPARATOR|Touch massage without oil|massage without oil
62528226|NCT02608151|EXPERIMENTAL|touch massage with oil|massage with an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil)
62154613|NCT03853525|EXPERIMENTAL|Women_Inguinal side BAY207543|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with BAY207543 is investigated.
62154614|NCT03853525|ACTIVE_COMPARATOR|Women_Inguinal side Vaseline|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with vaseline is investigated.
62528227|NCT00208806||congenital heart patients with congestive heart failure|20 effected patients with congestive heart failure patients total 50 patients
62528228|NCT02693093|PLACEBO_COMPARATOR|placebo|TID Day for 28 Days
62528229|NCT02693093|EXPERIMENTAL|100 mg NI-03|TID Day for 28 Days
62528230|NCT02693093|EXPERIMENTAL|200 mg NI-03|TID Day for 28 Days
62528231|NCT02693093|EXPERIMENTAL|300 mg NI-03|TID Day for 28 Days
62528232|NCT03435718|EXPERIMENTAL|OXF6|Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
62528233|NCT03435718|EXPERIMENTAL|OXF15|Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
62154615|NCT05689684|ACTIVE_COMPARATOR|Hybrid Product: Aarabinogalactan (AG)+xylan-oligosaccharides (XOS) +AXOS|Daily 2x 5g Hybrid Product, produced by Carbiotix AB. Hybrid Product is available as powder, which can be easily dissolved in water.
62154616|NCT05689684|PLACEBO_COMPARATOR|Placebo|Daily 2x 5g maltodextrin. Maltodextrin is available as powder, which can be easily dissolved in water.
62154617|NCT05576779||Ofatumumab|all eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
62154618|NCT05576779||Non-ofatumumab|patients with no evidence of ofatumumab during the index period were included in the non-ofatumumab cohort and included in subgroups based on the index medication: Siponimod, Ocrelizumab, Dimethyl fumarate, Glatiramer acetate
62154619|NCT05064566||caries diagnosis|diagnostic accuracy of clinical visual examination (ICDAS II), digital intraoral radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), by examining third molar teeth in comparison to gold standard micro-CT images.
62154620|NCT05888285|ACTIVE_COMPARATOR|ESP Block|ESP block for back pain treatment is applied
62154621|NCT05888285|ACTIVE_COMPARATOR|ESP RFT|ESP block and pulsed radiofrequency for back pain treatment is applied
62154622|NCT02301689||Heart Failure patients|
61975708|NCT04682067|PLACEBO_COMPARATOR|Usual Care|Participants in the usual care (UC) group will receive the standard smoking cessation treatment offered at the Health Promotion Research Center's Tobacco Treatment Research Program (TTRP) at the University of Oklahoma. This includes at least 4 treatment sessions of counseling and the opportunity to use nicotine replacement therapy or medications.
62154623|NCT05081778||Obese patient following a medical course|
62154624|NCT05081778||Obese patient following a surgical course|
62154625|NCT06144723|EXPERIMENTAL|HS-20105 Phase Ia (Dose escalation)|Patients with advanced solid tumors will be enrolled and receive HS-20105 of various dose strengths until the end of the study in the absence of unacceptable toxicities and disease progression.
62154626|NCT06144723|EXPERIMENTAL|HS-20105 Phase Ib (Dose expansion)|Depending on data obtained from the dose escalation, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumors. Patients enrolled will receive HS-20105 until the end of the study in the absence of unacceptable toxicities and disease progression. The recommended doses from the dose escalation will be further explored.
62154627|NCT05590026|ACTIVE_COMPARATOR|Pectointercostal and ESP block|Pectointercostal and ESP block will apply to the children after intubation. Totally bupivacain %0.25, 2.5 mg/kg will apply.
62154628|NCT05590026|PLACEBO_COMPARATOR|No Block|No block will apply to the patient
62154629|NCT01324648|EXPERIMENTAL|TG + GP TAU|
62154630|NCT01324648|EXPERIMENTAL|UG + GP TAU|
62154631|NCT01324648|ACTIVE_COMPARATOR|GP TAU|
62154632|NCT03187704|ACTIVE_COMPARATOR|filtration|Air filtration in homes
62154633|NCT03187704|SHAM_COMPARATOR|no filtration|Sham air filtration
62154634|NCT00774826|EXPERIMENTAL|1|R-CVP x 3; Restaging if\> RP then R-CVP x 5
62154635|NCT00774826|EXPERIMENTAL|2|R-CHOP x 3; Restaging if \> RP then R-CHOP x 3 plus 2 Rituximab
62154636|NCT00774826|EXPERIMENTAL|3|R-FM x 3; Restaging if \> RP then R-FM x 3 plus 2 Rituximab
62154637|NCT04191863||Children with enuresis|28 epileptic children with induced secondary nocturnal enuresis in valproate monotherapy.
62154638|NCT04191863||Children without enuresis|232 epileptic children without induced secondary nocturnal enuresis in valproate monotherapy.
62154639|NCT01439399|ACTIVE_COMPARATOR|Lidocaine|Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
62528234|NCT03435718|EXPERIMENTAL|OXF30|Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
62528235|NCT03435718|EXPERIMENTAL|OXF15x3|Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
62528236|NCT03435718|ACTIVE_COMPARATOR|ALB400|Patients receive a single 400 mg/kg dose of albendazole administered orally.
62528237|NCT04598048||EMMACE 3|Participants who were recruited to the EMMACE 3 study and have agreed to contact for further research.
62154640|NCT01439399|ACTIVE_COMPARATOR|Ketamine|Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
62154641|NCT01439399|ACTIVE_COMPARATOR|Ketamine-Lidocaine|Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.
62154642|NCT01439399|PLACEBO_COMPARATOR|Saline 0,9%|Control group
62154643|NCT04280978||Aquired Brain Injury|Suitable potential participants would be children with ABI, at least 6 months post onset, from 6 to 11 years old, without diagnosis of aphasia, dysarthria, apraxia, and/or sensorial difficulties (visual and hearing), with Italian as a first language.
62154644|NCT05431426|EXPERIMENTAL|Mild renal impaired subjects|Administration of a single dose of CH6001 800 µg in mild renal impaired subjects.
62528238|NCT05968560|EXPERIMENTAL|Group and Family-Based Cognitive Behavioral Therapy (GF-CBT-TH)|GF-CBT via telehealth is an intervention consisting of three parts: 15 group sessions for young people, 15 individual sessions for young people, and 15 group sessions for families. The group sessions for young people and families focus on teaching CBT skills. The goal is to enhance reasoning, decision-making, and positive beliefs while reducing cognitive biases, distress, and isolation. The individual sessions personalize the CBT skills learned in the group, focusing on tailoring skills to personal goals. Family members also participate in group sessions to learn the same CBT skills and how to prompt and support their young family members in using these skills. All sessions are conducted via Telehealth
62713772|NCT04982952|OTHER|Control Group|Participants who choose to attend smoking cessation in the usual care setting at TWUHC will receive a basic $5 payment for attending each study visit.
62713773|NCT06463184|EXPERIMENTAL|Xevinapant Treatment|Participants will be given a course of orally administered Xevinapant at 400 mg once daily for 4 consecutive days, prior to undergoing clinically indicated tumor resection.
62154645|NCT05431426|EXPERIMENTAL|Moderate renal impaired subjects|Administration of a single dose of CH6001 800 µg in moderate renal impaired subjects.
62154646|NCT05431426|EXPERIMENTAL|Severe renal impaired subjects|Administration of a single dose of CH6001 800 µg in severe renal impaired subjects.
62154647|NCT05431426|EXPERIMENTAL|Healthy volunteers|Administration of a single dose of CH6001 800 µg in healthy volunteers.
62154648|NCT03575507|EXPERIMENTAL|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
62154649|NCT02429973|EXPERIMENTAL|Experimental|6 cycles of gemcitabine plus rapamycin
62528239|NCT05968560|EXPERIMENTAL|Family-Based Cognitive Behavioral Therapy (F-CBT-TH)|F-CBT via telehealth consists of two parts: 15 family sessions and 15 individual sessions for young people. The family sessions focus on teaching CBT skills to a family units. The individual sessions with youth personalize the CBT skills learned in the family sessions, focusing on tailoring skills to personal goals. All sessions are conducted via Telehealth.
62528240|NCT05968560|ACTIVE_COMPARATOR|Individual Cognitive Behavioral Therapy (I-CBT-TH)|I-CBT-TH via telehealth consists of two components: 15 CBT Skill Learning sessions and 15 follow-up session that personalizes the learned skills. All sessions are conducted via Telehealth.
62528241|NCT03903926|EXPERIMENTAL|Cohort one|5000 volunteers (6-35 months)-EV71 vaccine
62528242|NCT03903926|NO_INTERVENTION|Cohort two|10000 unvaccinated volunteers (6-35 months)
62528243|NCT03903926|NO_INTERVENTION|Cohort three|500 unvaccinated volunteers (36-71 months)
62154650|NCT04948866|EXPERIMENTAL|Intervention Condition: ADRD-PC Program|"1. Dementia-specific palliative care delivered by hospital-based specialty interdisciplinary palliative care teams.~2. Standardized caregiver education will be provided by the palliative care team. Clinicians will share and discuss the booklet Advanced Dementia: A Guide for Families, which addresses common concerns and treatment decisions.~3. Transitional care will be provided by the palliative care team, including facilitation of community-based services and two post-discharge telephone calls."
62154651|NCT04948866|ACTIVE_COMPARATOR|Control Condition|Patient-family caregiver dyads randomized to the control arm will receive educational materials from the Alzheimer's Association, specifically designed for late-stage ADRD caregivers. The patient will receive usual hospital and post-acute care.
62154652|NCT05281588|EXPERIMENTAL|Micro-osteoperforations|Micro-osteoperforations- assisted upper incisors retraction
62154653|NCT05281588|NO_INTERVENTION|Control|Upper incisors retraction not associated with any clinical intervention to accelerate tooth movement
62154654|NCT01698567|ACTIVE_COMPARATOR|Antithrombin III|"Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a."
62154655|NCT01698567|PLACEBO_COMPARATOR|Placebo|placebo (normal saline)
62154656|NCT00634998|PLACEBO_COMPARATOR|2|1000mg Placebo capsules orally twice daily for 90 days
62154657|NCT00634998|EXPERIMENTAL|1|1000mg Vitamin C capsules orally twice daily for 90 days
62154658|NCT04321096|PLACEBO_COMPARATOR|Placebo|2 pills 3 times daily for 5 days
62154659|NCT04321096|EXPERIMENTAL|Camostat Mesilate|2x100 mg pills 3 times daily for 5 days
62154660|NCT01277679|OTHER|Healthy Volunteer|Healthy Volunteer cohort
62154661|NCT01277679|OTHER|Heart Failure|Heart Failure cohort
62154662|NCT03111368|ACTIVE_COMPARATOR|EUS- FNA Slow-pull|Endoscopic ultrasound-guided fine needle aspiration using a stylet slow-pull technique of solid pancreatic mass
62154663|NCT03111368|ACTIVE_COMPARATOR|EUS-FNA Negative Pressure|Endoscopic ultrasound-guided fine needle aspiration using negative pressure technique of solid pancreatic mass
62154664|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging undergoing thrombectomy|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention.
62154665|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging not undergoing thrombectomy|acute stroke patients treated with or without thrombolysis
62154666|NCT05095077|EXPERIMENTAL|Tadalafil|Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.
62154667|NCT05095077|PLACEBO_COMPARATOR|Placebo|Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.
62528244|NCT05953974||NMDAr patients|"Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti NMDAr"
62528245|NCT05953974||LGI1 patients|"Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti LGI1"
62528246|NCT05953974||CASPR2 patients|"Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti CASPR2"
62528247|NCT05953974||GABAb patients|"Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti GABAb"
62528248|NCT05953974||GAD patients|"Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti GAD"
62154668|NCT02091102|EXPERIMENTAL|755nm Alexandrite Laser|755nm Alexandrite Laser
62154669|NCT01774617||Patients with advanced liver disease|Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level \>1.5 mg/dL), severe bleeding disorder (prothrombin activity test \< 30% or platelets count \<35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.
62154670|NCT03213587|EXPERIMENTAL|apatinib|
62154671|NCT00857077|PLACEBO_COMPARATOR|1 Placebo|
62154672|NCT00857077|ACTIVE_COMPARATOR|2 Sulfadoxine-pyrimethamine (SP)|
62154673|NCT02605876|EXPERIMENTAL|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
62528249|NCT00378404|EXPERIMENTAL|1|
62713774|NCT05666830||1|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
62713775|NCT02443935|EXPERIMENTAL|MGN1703|TLR-9 agonist MGN1703 administered to HIV-1 positive patients on cART
62154674|NCT02605876|EXPERIMENTAL|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
62154675|NCT02605876|NO_INTERVENTION|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
62154676|NCT03853941|NO_INTERVENTION|Control|Patients in the control group will receive treatment as usual.
62154677|NCT03853941|EXPERIMENTAL|Experimental|The experimental group will receive clinical treatment as usual, however, the healthcare professionals treating them will have received training on how to enhance patient adherence via the use of a motivationally supportive communication style. Thus, the style/language healthcare professionals use to convey usual treatment recommendations may differ.
62154678|NCT01371227|EXPERIMENTAL|JNS002|JNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
62154679|NCT04937309|EXPERIMENTAL|intervention|standard anti emetic treatment use of non invasive vagal stimulation twice a day from the day before chemotherapy till 4 days after, with a transcutaneous auricular device. This stimulation is to be done for the three first cycles of chemotherapy.
62154680|NCT04937309|SHAM_COMPARATOR|control|"standard anti emetic treatment use of non invasive vagal stimulation twice a day from the day before chemotherapy till 4 days after, with a transcutaneous auricular sham device. This stimulation is to be done for the three first cycles of chemotherapy."
62154681|NCT04004754||Complicated CL in Gondar|Patients treated with miltefosine in Gondar will be followed up to see outcomes of treatment
62154682|NCT04004754||Complicated CL in Boru Meda|Patients treated with miltefosine in Boru Meda hospital will be followed up to see outcomes of treatment
62154683|NCT06017557|EXPERIMENTAL|Clinical Stage III-IV Ovarian Cancer|individuals who have been diagnosed or are suspected to have Clinical Stage III-IV Ovarian Cancer and CT and MRI have most commonly been used to identify sites and amounts of tumors in the abdomen and can help determine if these tumors can be safely removed by surgery. However, these imaging methods are only a prediction, and sometimes a diagnostic laparoscopy (putting a camera in the abdomen to look at all sites of disease) is performed to help this decision process.
62154684|NCT06008665|EXPERIMENTAL|Action observation therapy with Otago exercise|"* Participants' Instructions:~* Watch a video on a 22-inch screen.~* Screen positioned 1 meter away from them.~* Comfortably seated in a chair with armrests.~* No following along or movement allowed.~* Video Features: Model in the video is 70 years old or older. Model similar to the participants.~* Video Viewing: Duration: 17 minutes (1 minute per video). Supervised by the same investigator. Quiet environment during observation.~* Physical Training Session: Supervised by a therapist.~* Duration: 35 minutes (2 minutes max per session).~* Based on content from the video.~* Action Observation Training: Activities during the physical education workshops featured in the videos."
62154685|NCT06008665|ACTIVE_COMPARATOR|Otago exercise|"* Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~* Balance Training Component:~* Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~* Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~* Training Session Duration: Each session lasts for 35-40 minutes.~* Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session."
62154686|NCT01313988|ACTIVE_COMPARATOR|Dose 1|Spread that contains plant sterols and fish oil
62528250|NCT04229524|EXPERIMENTAL|angiographic intervention group|Enrolled patients will undergo thoracoscopy combined with a three-incision esophageal carcinoma radical mastectomy and two-field (chest-abdomen) lymph node dissection.Quantitative assessment of blood supply in the gastic conduit was performed using fluoroscopy before esophagogastric anastomosis.
62528251|NCT04229524|NO_INTERVENTION|control group|The same surgical method as the experimental group.The only difference is that the position of the gastic conduit anastomosis is determined based on the experience of the doctor.
62528252|NCT00757848|EXPERIMENTAL|AZD9668|
62528253|NCT00757848|PLACEBO_COMPARATOR|Placebo|
62528254|NCT04421586|EXPERIMENTAL|Pregnant women receiving VISTA counseling|Up to 30 pregnant women are screened and counseled for vaccine concerns using VISTA
62528255|NCT04421586|NO_INTERVENTION|Pregnant women receiving usual care|Up to 30 pregnant women receiving usual care
62528256|NCT04062474|EXPERIMENTAL|Epidural Intervention with Steroids|Epidural Intervention with Steroids
62528257|NCT01126411|NO_INTERVENTION|control|control group / no immunoadsorption
62528258|NCT01126411|ACTIVE_COMPARATOR|immunoadsorption|immunoadsorption
62528259|NCT00714493|OTHER|001|Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
62528260|NCT00761865|ACTIVE_COMPARATOR|Air Cast Stirrup Brace|50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
62713776|NCT05807126|EXPERIMENTAL|Treatment (magrolimab, olaparib)|Patients receive magrolimab IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Patients also receive olaparib PO BID during each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT and/or MRI throughout the trial. Patients in the dose-expansion portion of the study also undergo tumor biopsies during screening and on study.
62528261|NCT00761865|ACTIVE_COMPARATOR|High Tide Fracture Boot|50 patients will be randomly assigned to the High Tide Fracture Boot.
62528262|NCT05626439|EXPERIMENTAL|Treatment Sequence AB|Study participants randomized into this arm will receive single dose of Staccato alprazolam followed by single dose of oral alprazolam at pre-specified time points in the sequence AB.
62528263|NCT05626439|EXPERIMENTAL|Treatment Sequence BA|Study participants randomized into this arm will receive single dose of oral alprazolam followed by single dose of Staccato alprazolam at pre-specified time points in the sequence BA.
62528264|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
62713777|NCT05070858|EXPERIMENTAL|Group 1|Placebo in DBTP; Re-randomized to Combination or Cemdisiran in ETP and OLTP
62713778|NCT05070858|EXPERIMENTAL|Group 2|Combination regimen throughout the study
62713779|NCT05070858|EXPERIMENTAL|Group 3|Cemdisiran throughout the study
62713780|NCT05070858|EXPERIMENTAL|Group 4|Pozelimab monotherapy in DBTP followed by combination in ETP and OLTP
62528265|NCT04391530|EXPERIMENTAL|emotional freedom technique group|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
62528266|NCT04391530|EXPERIMENTAL|Breathin therapy group|Breathing therapy: the basic recipe After applying pre-test forms to students, the hall will be quiet and dim. In this study, breathing exercise application will be performed in three stages as (1) relax, (2) deep breath and (3) feel yourself.
62154687|NCT01313988|ACTIVE_COMPARATOR|Dose 2|Spread that contains plant sterols and fish oil
62528267|NCT04391530|NO_INTERVENTION|Control group|No intervention was made to the students in the control group.
62528268|NCT03052959|EXPERIMENTAL|Immediate Intervention|
62528269|NCT03052959|OTHER|Wait List Intervention|
62154688|NCT01313988|ACTIVE_COMPARATOR|Dose 3|Spread that contains plant sterols and fish oil
62528270|NCT02373033|ACTIVE_COMPARATOR|Intervention: Natural food folate|Food group consumed folate-rich foods (providing additional 250 μg/d folate).
62528271|NCT02373033|ACTIVE_COMPARATOR|Intervention: Folic acid|Folic acid group received a folic acid supplement (providing additional 500 μg/d folic acid).
62528272|NCT02373033|PLACEBO_COMPARATOR|Intervention: Control|Control group received apple juice containing no folate or folic acid every day.
62528273|NCT03717714|ACTIVE_COMPARATOR|Glucosamine 1500mg|Glucosamine 1500 mg per day for 12 weeks
62154689|NCT01313988|PLACEBO_COMPARATOR|Placebo|Placebo spread
62154690|NCT01313988|ACTIVE_COMPARATOR|Control|Spread that contains plant sterols
62154691|NCT04330573||Chronic Non-Specific Neck Pain|Patients with chronic non-specific neck pain. No interventions
61975709|NCT05357274||Respiratory|Patients attending primary care, non-specialist respiratory clinics and advanced nurse practitioner clinics with undiagnosed persisting respiratory symptoms that have been attributed to asthma by a physician.
62154692|NCT04330573||Control/Healthy Group|Volunteers without pain. No interventions.
62154693|NCT02845921|PLACEBO_COMPARATOR|Group C Control|Patient will be shifted to operation theatre. Electrocardiography (ECG), pulse oximeter and non-invasive blood pressure (NIBP) monitors will be attached. Baseline vitals will be noted. Intravenous access will be secured and crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs will be neither elevated or wrapped. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube.
62154694|NCT02845921|EXPERIMENTAL|Group E Leg elevation|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs are elevated and supported on a stand making an angle of 30 degree to the horizontal. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Stand will be removed and legs will be brought to horizontal position 10 minutes after intubation.
62154695|NCT02845921|EXPERIMENTAL|Group W Leg wrapping|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl. Each lower limb will be elevated alternately and wrapped from toe to mid-thigh with Esmarch bandage. Care will be taken to avoid compressing the legs to greater than arterial pressure by confirming the presence of pulse using a saturation probe. Following wrapping, the lower limbs will be brought to horizontal position. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol injected over 30 seconds. Muscle relaxation by inj. vecuronium. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Esmarch bandage will be removed 10 minutes after intubation.
62528274|NCT03717714|EXPERIMENTAL|Polycan & Glucosamine 750mg|Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks
62528275|NCT03717714|EXPERIMENTAL|Polycan & Glucosamine 1500mg|Polycan 50 mg + Glucosamine 1500 mg per day
62528276|NCT06002087|EXPERIMENTAL|Experimental group: Unified Protocol (UP)|Participants will receive 14 weekly individual sessions of 50-60 minutes each using the adapted UP treatment.
62528277|NCT06002087|NO_INTERVENTION|Control group: Waitlist Control|Participants in the control group will be placed on a waitlist and will not receive any treatment until the end of the study.
62528278|NCT01249365|EXPERIMENTAL|HPV vaccine|Healthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
62528279|NCT02030366||TBI patients|
62528280|NCT02030366||Healthy Volunteers|
62528281|NCT03275636|EXPERIMENTAL|Haploidentical donor|Peripheral blood stem cells from Haploidentical donor
62528282|NCT03275636|ACTIVE_COMPARATOR|partially matched unrelated donor|Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
62713781|NCT01282073|EXPERIMENTAL|Mycophenolate mofetil, low dose steroid|
62713782|NCT01282073|ACTIVE_COMPARATOR|Cyclosporin, low dose steroid|
62713783|NCT04542122|NO_INTERVENTION|Choices then judgements|
61975710|NCT01084174|EXPERIMENTAL|Active SLIT/Placebo OIT|These subjects will receive peanut powder given orally and placebo extract given sublingually.
61975711|NCT01084174|EXPERIMENTAL|Active OIT/Placebo SLIT|These subjects will receive peanut extract given sublingually and placebo powder given orally.
61975712|NCT05390957|EXPERIMENTAL|Single Arm|All participants in this pilot study will complete the active treatment
62713784|NCT04542122|ACTIVE_COMPARATOR|Judgements then choices|Switch in the order of clinical cases in the survey
62713785|NCT02224170|EXPERIMENTAL|Lidocaine group|
62713786|NCT02224170|ACTIVE_COMPARATOR|Dexamethasone group|
62154696|NCT05018065|ACTIVE_COMPARATOR|50 women previously diagnosed with mild - medium Covid-19 and had ambulatory care|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
62154697|NCT05018065|ACTIVE_COMPARATOR|51 women having no Covid-19 history|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
62154698|NCT02109172|EXPERIMENTAL|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
62154699|NCT02109172|PLACEBO_COMPARATOR|Placebo|Placebo inhalation solution twice daily for 7 days
62154700|NCT02109172|EXPERIMENTAL|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
62154701|NCT02365402|EXPERIMENTAL|entecavir with PEG-IFN a-2a|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow up after treatment.
62528283|NCT04990596||Age Group 50 to 59|"Inclusion criteria :~* age 50-100 years old,~* in consultation or hospitalization in one of the participating centres,~* treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~* treatment with another antithrombotic drug,~* myeloproliferative syndrome,~* platelet count \< 100 gigas/liter,~* acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~* dialysis."
62528284|NCT04990596||Age Group 60 to 69|"Inclusion criteria :~* age 50-100 years old,~* in consultation or hospitalization in one of the participating centres,~* treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~* treatment with another antithrombotic drug,~* myeloproliferative syndrome,~* platelet count \< 100 gigas/liter,~* acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~* dialysis."
62528285|NCT04990596||Age Group 70 to 79|"Inclusion criteria :~* age 50-100 years old,~* in consultation or hospitalization in one of the participating centres,~* treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~* treatment with another antithrombotic drug,~* myeloproliferative syndrome,~* platelet count \< 100 gigas/liter,~* acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~* dialysis."
62528286|NCT04990596||Age Group 80 to 89|"Inclusion criteria :~* age 50-100 years old,~* in consultation or hospitalization in one of the participating centres,~* treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~* treatment with another antithrombotic drug,~* myeloproliferative syndrome,~* platelet count \< 100 gigas/liter,~* acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~* dialysis."
62528287|NCT04990596||Age Group 90 to 100|"Inclusion criteria :~* age 50-100 years old,~* in consultation or hospitalization in one of the participating centres,~* treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~* treatment with another antithrombotic drug,~* myeloproliferative syndrome,~* platelet count \< 100 gigas/liter,~* acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~* dialysis."
62528288|NCT02777112|PLACEBO_COMPARATOR|Control|This group will receive generic information about depression and serve as control
62528289|NCT02777112|EXPERIMENTAL|e-mental health program|This group will receive the developed e-mental health program
62713787|NCT00523627||Healthy Volunteers with normal glucose regulation|Healthy volunteers with normal glucose regulation
62713788|NCT01697111|EXPERIMENTAL|Arm 1|
62713789|NCT01697111|EXPERIMENTAL|Arm 2|
62154702|NCT02365402|NO_INTERVENTION|control group|In this group, patients will be continue treated only by PEG-IFN a-2a for 48 weeks after enrolled and receive 24 weeks of follow up.
62154703|NCT03483714||Healthy Participants|Spinal manipulation
62154704|NCT03483714||Acute Low back pain participants|Spinal Manipulation
62154705|NCT03483714||Chronic low back pain participants|Spinal Manipulation
62154706|NCT04407442|EXPERIMENTAL|Treatment (azacitidine, dexamethasone, daratumumab)|"PRE-INDUCTION (CYCLE 0): Patients receive azacitidine IV on days -7 to -3 in absence of disease progression or unacceptable toxicity.~INDUCTION (CYCLES 1-2): Patients receive azacitidine IV on days 22-26, dexamethasone IV or orally (PO), and daratumumab subcutaneously (SC) over 3-5 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 3-6): Patients receive azacitidine IV on days 22-26 of cycle 3 and on days 1-5 of cycles 5-6, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity~MAINTENANCE (CYCLES 7+): Patients receive azacitidine IV on days 1-5, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity"
62154707|NCT00833599||1: NIRFLI with ICG|1) Persons affected with lymphatic or lympho-vascular disorders, 2) Family members (affected or unaffected) of persons affected with lymphatic or lympho-vascular disorders and 3) Health, normal persons (Controls) that participate at one of the clinical sites in both the lymphatic function imaging with indocyanine green and the Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) system, as well, as the genetic analysis portion of the study.
62154708|NCT00833599||2: Genetic Analysis Only|Family members of an affected subject from Group 1. Subjects in Group 2 can be either affected or unaffected and will provide a blood or saliva sample for the genetic analysis portion of the study, but will not undergo lymphatic function imaging with ICG and the NIRFLI system. Group 2 individuals are not required to travel to one of the clinical sites in order to participate in the study.
62154709|NCT04177849|ACTIVE_COMPARATOR|Anterior Cervical Decompression and Fusion (ACDF)|Patients entered into this arm are treated via an anterior approach with disk excision, root canal decompression and fusion of the affected segment with a cage and plate.
62154710|NCT04177849|EXPERIMENTAL|Posterior Foraminotomy (PF)|Patients entered into this arm are treated via a posterior approach through intermuscular planes. The root canal is decompressed by burring the medial third of the facet joint. No fusion is performed.
62154711|NCT05836402|NO_INTERVENTION|Control|-Usual diet.
62713790|NCT01697111|ACTIVE_COMPARATOR|Arm 3|
62713791|NCT06292819|ACTIVE_COMPARATOR|Bright light|
62528290|NCT02777112|EXPERIMENTAL|e-mental health program and job coaching|This group will receive the developed e-mental health program plus interactive job coaching through telephone.
62528291|NCT04967963|EXPERIMENTAL|Transplantation of HAM|HAM was used after sequestrectomy in patients with stage-2 MRONJ
62528292|NCT05829213|EXPERIMENTAL|"arch-bridge-type reconstruction arm"|"In this arm, patients will receive proximal gastrectomy and arch-bridge-type reconstruction."
62528293|NCT06081426|EXPERIMENTAL|1st phase Non-ketogenic Diet / 2nd phase Ketogenic Diet|Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study
62154712|NCT05836402|EXPERIMENTAL|Low Carbohydrate|"-Low-Carbohydrate Diet Intervention:Patients will receive a study kit. The kit will contain the following:~* Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~* A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB. (Package insert)"
62528294|NCT06081426|EXPERIMENTAL|1st phase Ketogenic Diet / 2nd phase Non-ketogenic Diet|Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study
62528295|NCT06081426|OTHER|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
62528296|NCT03450395|PLACEBO_COMPARATOR|Cereal - Cream of Rice|40 g cream of rice
62528297|NCT03450395|EXPERIMENTAL|Cereal - Oats containing beta-glucan|40 g oats
62528298|NCT05787470||Cis Man|Person assigned male at birth and whose gender identity is man.
62528299|NCT05787470||Cis Woman|Person assigned female at birth and whose gender identity is woman.
62528300|NCT05787470||Transgender Man|Person assigned female at birth and whose gender identity is man.
62154713|NCT00617708|EXPERIMENTAL|Arm I (erlotinib, gemcitabine, cixutumumab)|Patients receive erlotinib hydrochloride PO once daily on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62154714|NCT00617708|ACTIVE_COMPARATOR|Arm II (erlotinib, gemcitabine)|Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62528301|NCT05787470||Transgender Woman|Person assigned male at birth and whose gender identity is woman.
62713792|NCT06292819|ACTIVE_COMPARATOR|Near-infrared light|
62154715|NCT05912998|ACTIVE_COMPARATOR|cartilage regeneration|35 patient will have knee arthroscopy and cartilage regeneration technique and high tibial osteotomy
62154716|NCT05912998|ACTIVE_COMPARATOR|microfracture|35 patient will have knee arthroscopy and microfracture with high tibial osteotomy
62154717|NCT05912998|PLACEBO_COMPARATOR|high tibial osteotomy|35 patient will have knee arthroscopy and high tibial osteotomy
62154718|NCT02453269|EXPERIMENTAL|Transdisciplinary program|"Children in G1 were submitted to a transdisciplinary intervention once a week. Each child received a nutritional education kit including four games (Cool Diet, a board game, a memory game and a word search puzzle) and an interactive booklet containing)."
62154719|NCT02453269|NO_INTERVENTION|Control group|The children in the control group (G2) were not exposed to interventions.
62154720|NCT01279447|SHAM_COMPARATOR|Placebo|A sham infrapatellar block performed under US guidance with normal saline
62154721|NCT01279447|EXPERIMENTAL|Infrapatellar nerve block|An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
62154722|NCT04800263|EXPERIMENTAL|SHR-1905 Dose Level 1|SHR-1905 Dose level 1
62154723|NCT04800263|EXPERIMENTAL|SHR-1905 Dose Level 2|SHR-1905 Dose level 2
62154724|NCT04800263|EXPERIMENTAL|SHR-1905 Dose Level 3|SHR-1905 Dose level 3
62154725|NCT04800263|EXPERIMENTAL|SHR-1905 Dose Level 4|SHR-1905 Dose level 4
62154726|NCT04800263|EXPERIMENTAL|SHR-1905 Dose Level 5|SHR-1905 Dose level 5
62154727|NCT05986630|EXPERIMENTAL|TEOSYAL® TPVM|n=116 subjects
62154728|NCT05986630|ACTIVE_COMPARATOR|COMPARATOR|n= 39 subjects
62154729|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
62154730|NCT01912521|EXPERIMENTAL|Intervention|This arm is eligible for participation in the Mfangano Health Net Microclinic Program, a social network-based educational program.
62154731|NCT01912521|NO_INTERVENTION|Comparison|This arm is not eligible for participation in the intervention. Participants still have access to usual care at the Sena Health Center or their health facility of choice.
62154732|NCT06386354||Patients submitted to General Anesthesia with Neuromuscular Block|Patients submitted to General Anesthesia with Neuromuscular Block
62528302|NCT05787470||Transgender Man plus Testosterone|Person assigned female at birth and whose gender identity is man and are currently on testosterone replacement.
62528303|NCT05787470||Transgender Woman plus Estrogen|Person assigned male at birth and whose gender identity is woman and are currently on estrogen replacement.
62528304|NCT00397163|ACTIVE_COMPARATOR|Remote preconditioning|Simultaneous inflation (5min) and deflation (5min) of cuffs placed on upper arm and thigh - cycle repeated 2 times
62528305|NCT00397163|PLACEBO_COMPARATOR|Placebo|Deflated cuffs placed on upperarm and thigh for 20 minutes
62528306|NCT03582826|EXPERIMENTAL|MEBO/PATM cohort|"Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes.~The following subcohorts were formed for analyses of different outcomes: MEBO and PATM subcohorts, TMAU positive and negative subcohorts, Active MEBO, Active PATM, Regression and Remission; MEBO/PATM Cohort that Submitted Gut Samples, MEBO/PATM cohort that answered QoL survey, MEBO/PATM Subcohort that observed and documented both flareups and improvements."
62528307|NCT03582826|NO_INTERVENTION|non-MEBO cohort|Data volunteers that never experienced episodes of uncontrollable socially debilitating metabolic body odor (MEBO) or PATM
62528308|NCT03251963|EXPERIMENTAL|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
62528309|NCT03251963|EXPERIMENTAL|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
62528310|NCT01610453||ultrasound|primiparous women with prolonged labours will be eligible for examination
62528311|NCT06280378|EXPERIMENTAL|KL003 Cell Injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
62528312|NCT06176066|NO_INTERVENTION|Standard of Care|Standard of care glioblastoma resection with standard of care adjuvant therapy (temozolomide + radiation therapy)
62528313|NCT06176066|EXPERIMENTAL|CEST Resection|CEST MRI Based Resection of glioblastoma with standard of care adjuvant therpay (temozolomide + radiation therapy)
62528314|NCT00611481|EXPERIMENTAL|Tai Chi|
62528315|NCT00611481|ACTIVE_COMPARATOR|B. Strength training|
62528316|NCT00611481|OTHER|C. Low-Impact|
62528317|NCT04547530|ACTIVE_COMPARATOR|Vitamin D|"Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
62528318|NCT04547530|PLACEBO_COMPARATOR|Placebo|"Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
62528319|NCT03547336|EXPERIMENTAL|Theranova 400 Dialyzer|In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
62528320|NCT03547336|ACTIVE_COMPARATOR|FX800|In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
62528321|NCT05322499|EXPERIMENTAL|Combined chemotherapy group|"Camrelizumab: Subjects were infused at a dose of 200 mg/time, D1, once every 3 weeks (q3w);~Chemotherapy (considered by investigator on a patient-by-patient basis):~Irinotecan: 100-125mg/m2, d1, d8; q21d; Paclitaxel: 135-175mg/m2, d1, Q3W; Docetaxel: 60-75mg/m2, d1, Q3W Albumin paclitaxel: 100-135mg/m2, d1, d8, Q3W. Treat until disease progression or intolerable toxicity"
62528322|NCT05322499|EXPERIMENTAL|Combined anlotinib group|Camrelizumab: Subjects were infused at a dose of 200 mg/time, D1, once every 3 weeks (q3w); Anlotinib: 12mg, qd, d1-d14, q3w; Treat until disease progression or intolerable toxicity.
62528323|NCT05178433|EXPERIMENTAL|Experimental group|Use baby moisturizers in addition to basic skin care and protection during phototherapy.
62528324|NCT05178433|NO_INTERVENTION|control group|Only basic skin care and protection during phototherapy.
62528325|NCT02277678|EXPERIMENTAL|Oxycodone|Epidural oxycodone 3mg single dose as opioid administration
62528326|NCT02277678|ACTIVE_COMPARATOR|Morphine|Epidural morphine 3mg single dose as opioid administration
62528327|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
62528328|NCT03529461|OTHER|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
62528329|NCT03529461|EXPERIMENTAL|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
62528330|NCT01914068|NO_INTERVENTION|Control|No in hospital exercise training and no exercise advice.
62528331|NCT01914068|ACTIVE_COMPARATOR|Exercise Intervention|In hospital exercise training
62528332|NCT04244669|EXPERIMENTAL|SCS with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% of pain in that area.
62154733|NCT03277456|EXPERIMENTAL|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
62528333|NCT04244669|EXPERIMENTAL|SCS with SCS DTM Stimulation|IIn this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms.
62528334|NCT04671186|EXPERIMENTAL|Probiotic group|Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) throughout the study
62528335|NCT04671186|PLACEBO_COMPARATOR|Placebo Group|Placebo group is to receive placebo oral capsule daily throughout the study.
62528336|NCT02267668|EXPERIMENTAL|STEP arm|"The Baseline Evaluation Session will include formal neuropsychological evaluation, postural stability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Intervention includes exercise tolerance evaluations, 3 times per week exercise by physical therapist. Self report of symptoms and exertion."
62713793|NCT06292819|ACTIVE_COMPARATOR|Bright light+ near-infrared light|
62713794|NCT01346176|EXPERIMENTAL|Positive default|Patients in this arm will receive AD forms where specific life-extending interventions will be provided unless patients specifically opt-out from such selections
62154734|NCT00579020|EXPERIMENTAL|Moxidex|Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
62154735|NCT00579020|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
62528337|NCT02267668|ACTIVE_COMPARATOR|Control|"The Baseline Evaluation Session will include formal neuropsychological evaluation, posturalstability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Control protocol includes instructions for stretching, instructions for restricting physically demanding activity during first 3 weeks of study; instructions for light, self-guided daily exercise in last 3 weeks of study. Self report of symptoms and exertion."
62154736|NCT00579020|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
62154737|NCT01499251|EXPERIMENTAL|Macitentan|Macitentan in combination with dose-dense temozolomide
62154738|NCT03811743|EXPERIMENTAL|Adolescents Participants|Adolescents will participate in the Dyad Plus program along with their caregivers. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
62154739|NCT03811743|EXPERIMENTAL|Caregivers of adolescents participants|Adult caregivers will participate in the Dyad Plus program along with their youth participants. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
62154740|NCT04919369|EXPERIMENTAL|Treatment (tretinoin, atezolizumab)|Patients receive tretinoin PO on days 1-3 of cycles 1-3. Patients also receive atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62154741|NCT02391766|ACTIVE_COMPARATOR|empowerment group|empowerment intervention by us for us guides
62154742|NCT02391766|PLACEBO_COMPARATOR|no treatment group|dementia patients treatment as usual
62154743|NCT02771366|EXPERIMENTAL|Fermented Papaya Preparation, then granulated sugar|Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
62154744|NCT02771366|PLACEBO_COMPARATOR|Granulated Sugar, then Fermented Papaya Preparation|Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
62154745|NCT03853746|EXPERIMENTAL|Ocrelizumab|All participants will receive Ocrelizumab
62528338|NCT05364060||patients followed in psychiatry|Quantitative questionnaires
62528339|NCT06125574|EXPERIMENTAL|Treatment|
62528340|NCT06125574|NO_INTERVENTION|Control|
62528341|NCT00523224|EXPERIMENTAL|single arm|open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)
62154746|NCT04923685||MDD with elevated CM and suicidality scores|Major Depressive Disorder with elevator childhood maltreatment and suicidality scores.
62154747|NCT04923685||MDD with CM history but lower suicidality|Major Depressive disorder with childhood maltreatment history but lower suicidality scores.
62154748|NCT04923685||MDD without CM but with elevated suicidality|Major Depressive Disorder without childhood maltreatment, but with elevated suicidality scores.
62154749|NCT04923685||MDD without CM but with lower suicidality|Major Depressive Disorder without childhood maltreatment but with lower suicidality scores.
62154750|NCT04923685||Healthy controls with CM history|Healthy controls with childhood maltreatment history,
62528342|NCT01819974|NO_INTERVENTION|Control|The normal procedure at the ward
62528343|NCT01819974|ACTIVE_COMPARATOR|Stratified medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist in patients with highest medication error risk
62528344|NCT06192836||Group 1-|"Operation will be performed by Dr BL~1. Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~2. Volume of diuresis at postoperative first six hours~3. Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~4. Duration of the surgery.~5. Need for additional dose of uterotonics~6. Need for surgical methods to manage postpartum bleeding~7. Duration of hospital stay"
62528345|NCT06192836||Group 2|"Operation will be performed by Dr AC~1. Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~2. Volume of diuresis at postoperative first six hours~3. Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~4. Duration of the surgery.~5. Need for additional dose of uterotonics~6. Need for surgical methods to manage postpartum bleeding~7. Duration of hospital stay"
62154751|NCT04923685||Healthy controls without CM history|Healthy controls without childhood maltreatment history.
62154752|NCT03165032||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
62528346|NCT06192836||Group 3|"Operation will be performed by Dr SM~1. Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~2. Volume of diuresis at postoperative first six hours~3. Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~4. Duration of the surgery.~5. Need for additional dose of uterotonics~6. Need for surgical methods to manage postpartum bleeding~7. Duration of hospital stay"
62713795|NCT01346176|EXPERIMENTAL|Negative default|Patients in this arm will receive AD forms where specific life-extending interventions will not be provided unless patients specifically opt-into such selections
62154753|NCT03165032||High altitude control|Healthy highlanders living above 2500 m.
62154754|NCT03165032||Low altitude control|Healthy lowlanders living below 1000 m.
62154755|NCT05751720|EXPERIMENTAL|GLP-1/GIP Arm pre and post intervention|"The adult patients with type 2 diabetes mellitus attending Tawam Hospital Diabetes clinic, who are identified as having fatty liver disease either via ultrasound or biochemical parameter of NFS.~We will aim to include minimum 30 patients fulfilling the selection criteria as below. Informed written consent will be obtained . Intervention group will receive GLP-1 analogues (subcutaneous Tirzepatide or oral semaglutide).~The blood tests will be done at baseline, 3 months of treatment and at 6 months of treatment. Liver imaging (fibroscan and/or MRI fat measurement) will be done at baseline and at 6 months to see if there is any change.The KPa improvement in liver stiffness and total fat estimation pre and post intervention in both groups will assessed"
62528347|NCT06192836||Group 4|"Operation will be performed by Dr AS~1. Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~2. Volume of diuresis at postoperative first six hours~3. Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~4. Duration of the surgery.~5. Need for additional dose of uterotonics~6. Need for surgical methods to manage postpartum bleeding~7. Duration of hospital stay"
62528348|NCT06192836||Group 5|"Operation will be performed by Dr EDD~1. Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~2. Volume of diuresis at postoperative first six hours~3. Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~4. Duration of the surgery.~5. Need for additional dose of uterotonics~6. Need for surgical methods to manage postpartum bleeding~7. Duration of hospital stay"
62528349|NCT06192836||Group 6|"Operation will be performed by Dr SKE~1. Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~2. Volume of diuresis at postoperative first six hours~3. Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~4. Duration of the surgery.~5. Need for additional dose of uterotonics~6. Need for surgical methods to manage postpartum bleeding~7. Duration of hospital stay"
62528350|NCT03565393|PLACEBO_COMPARATOR|Fibersol-2|Receive Fibersol-2 twice daily
62528351|NCT03565393|PLACEBO_COMPARATOR|Placebo|Receive placebo twice daily
62528352|NCT00429156|ACTIVE_COMPARATOR|1|Home non-invasive ventilation
62528353|NCT00429156|SHAM_COMPARATOR|2|Home sham non-invasive ventilation with CPAP 5 cm H2O
62528354|NCT01680497|EXPERIMENTAL|JUVÉDERM VOLIFT™|All subjects receiving treatment with JUVÉDERM VOLIFT™.
62528355|NCT04319718|ACTIVE_COMPARATOR|High Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)."
62528356|NCT04319718|ACTIVE_COMPARATOR|Low Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)."
62528357|NCT01935466||Pioglitazone|Ever users of Pioglitazone
61975713|NCT02924220||Case patients|"Patients with culture-proven listeriosis. Case patients are classified in 3 groups :~* Septicemic infections: isolation of Lm in blood cultures.~* CNS infections: isolation of Lm in cerebrospinal fluid, or brain stereotaxic biopsy, or by isolation of Lm in the blood with concomitant meningitis, or radiological encephalitis, rhombencephalitis, brain abscess or meningitis.~* MF infections: defined by isolation of Lm in any maternal/fetal/neonatal bacteriological sample.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
62528358|NCT01935466||Other drugs|Never users of pioglitazone
62528359|NCT05998941|EXPERIMENTAL|TQB2868 injection + Paclitaxel injection + Cisplatin/Carboplatin injection ± Bevacizumab injection|TQB2868 injection + paclitaxel injection + cisplatin/carboplatin injection ± bevacizumab injection, 3 weeks (21 days) as a treatment cycle.
62528360|NCT01062737|EXPERIMENTAL|ASU (Avocado Soybean Unsaponifiable)|
62528361|NCT01345435|EXPERIMENTAL|Telemonitoring group|"* A Smart Care PC, blood glucose meter and body composition analyzer will be provided~* transmitting the results to the Smart Care Server via Smart Care PC~* At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management"
62528362|NCT01345435|EXPERIMENTAL|Telemonitoring & Telemedicine group|"* A Smart Care PC, blood glucose meter and body composition analyzer will be provided~* transmitting the results to the Smart Care Server via Smart Care PC~* At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management~* taking telemedicine through video telephone instead of visiting hospital"
62528363|NCT01345435|OTHER|Control group|"* Blood glucose meter and body composition analyzer will be provided~* Self-monitoring Blood Glucose (SMBG)"
61975714|NCT02924220||Control patients|"Patients without listeriosis but compatible clinical presentation. Control patients are divided in 3 groups.~* Septicemic controls: febrile patient with same co-morbidities as septicemic cases.~* CNS controls: patient with any neurological symptom leading to the empiric prescription of amoxicillin at meningeal dosage because of listeriosis presumption.~* MF controls: febrile pregnant patient without obvious focal infection.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
61975715|NCT03842098||Musculoskeletal Disorders patients|Enroll the post operative musculoskeletal disorders patients and follow up their clinic visits and treatment regimen to analyze their utility in healthcare
61975716|NCT02651298|EXPERIMENTAL|Fractional CO2-laser|3 treatments with fractional co2-laser
61975717|NCT02651298|NO_INTERVENTION|Untreated control|untreated control side of caesarean section scar
61975718|NCT05520931||Hospitalization group|Previously hospitalized Covid-19 survivors who have been admittet to the hospital with or because of SARS-CoV-2 infection. Time from infection date start is \> 6 months. The group is anticipated to encompass 2.182 privously hospitalized adult patients.
61975719|NCT05520931||PCR+ group|Non-hospitalized Covid-19 survivors that has previously testet positive in an Polymerase chain reaction test without being admittet to the hospital. Time from infection data start is \> 6 months. The group will include almost the total population of adults who have tested positive in a Polymerase Chain Reaction test. Those with secret adresses and those without access to digital mail (information channel of the questionnaire) will be excluded being approcimatelyh 7% of 650.000 possible participants. The group encompasses 593.741 participants.
62528364|NCT00757757|EXPERIMENTAL|MCS110|
62528365|NCT00784576||Cardiac surgery patients|Individuals consecutively scheduled for cardiac surgery
62528366|NCT04336514|EXPERIMENTAL|Experimental Arm|
62528367|NCT02516527|EXPERIMENTAL|Induction Phase:Ipilimumab|Ipilimumab dose as specified
62528368|NCT02516527|EXPERIMENTAL|Maintenance Phase:Ipilimumab|Ipilimumab dose as specified
62528369|NCT05500118||communication without PADs|We use traditional communication ways to discuss the conditions with patients.
62528370|NCT05500118||communication with PADs|The committee, composed of designers, doctors, nurses and patients, bases on guidelines and evidence-based medicine to make a tool. And we use this tool to discuss the conditions with patients.
62528371|NCT01874795|EXPERIMENTAL|Ganglionar Electrical Stimulation|TENS intervention consisted of continuous flow, symmetrical and rectangular TENS biphasic pulses. The frequency ofstimulation was 80 Hz and the pulse duration was 150 μs, with the intensity in adjusted to the point of muscle contraction.
62154756|NCT04795999|EXPERIMENTAL|Project With program|Project With is a 12-lesson literary-based curriculum, delivered by Youth Advocates to youth in juvenile justice facilities and group homes in Southern California either in person or virtually, under COVID-19 contingencies. Program schedule is determined by the facility. The goals of Project With are to promote optimal health and reduce teen pregnancy and sexually transmitted infections (STIs).
62154757|NCT04795999|NO_INTERVENTION|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition.
62154758|NCT06602206|ACTIVE_COMPARATOR|Conventional treatment group|Hot packs, TENS, ultrasound, and exercise
62528372|NCT01874795|SHAM_COMPARATOR|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
62528373|NCT03247517|PLACEBO_COMPARATOR|Placebo|Placebo, qd, oral capsule
62528374|NCT03247517|EXPERIMENTAL|200mg SPN-812|200mg SPN-812, qd, oral capsule
62528375|NCT03247517|EXPERIMENTAL|400mg SPN-812|400mg SPN-812, qd, oral capsule
62528376|NCT02249312|EXPERIMENTAL|BIIIL|
62528377|NCT02249312|PLACEBO_COMPARATOR|Placebo|
62528378|NCT05610592||Rectal cancer|patients underwent curative surgery
62528379|NCT03417193|ACTIVE_COMPARATOR|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
62528380|NCT03417193|ACTIVE_COMPARATOR|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
62154759|NCT06602206|EXPERIMENTAL|Conventional treatment + shoulder mobilization group|Hot packs, TENS, ultrasound, exercise, and shoulder mobilization
62154760|NCT06602206|EXPERIMENTAL|Conventional treatment + shoulder mobilization + neck mobilization group|Hot packs, TENS, ultrasound, exercise, and shoulder and neck mobilization
62528381|NCT00679926|EXPERIMENTAL|Once daily|Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.
62154761|NCT06328296|EXPERIMENTAL|Rehabilitation treatment+Myofascial Release Therapy|Study lasts 15 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
62154762|NCT06328296|ACTIVE_COMPARATOR|Rehabilitation treatment|Study lasts 15 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
62154763|NCT00807053|ACTIVE_COMPARATOR|1|Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
62154764|NCT00807053|ACTIVE_COMPARATOR|2|Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
62154765|NCT00807053|ACTIVE_COMPARATOR|3|Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
62154766|NCT00807053|PLACEBO_COMPARATOR|4|Placebo
62528382|NCT00333879|OTHER|Virtual Sound System|Efficacy of using a virtual sound system to simulate street crossing conditions.
62528383|NCT00727766|EXPERIMENTAL|Cohort 1|Clofarabine 1 mg for 14 days followed by 14 days of rest. Each cycle is 28 days long.
62528384|NCT00727766|EXPERIMENTAL|Cohort 2|Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
62528385|NCT00727766|EXPERIMENTAL|Cohort 3|Clofarabine 3 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
62528386|NCT00727766|EXPERIMENTAL|Cohort 4|Clofarabine 4 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
62528387|NCT00727766|EXPERIMENTAL|Cohort 5|Clofarabine 5 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
62528388|NCT00727766|EXPERIMENTAL|Cohort 6|Clofarabine 6 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
62528389|NCT05960240|EXPERIMENTAL|Part 1|
62528390|NCT05960240|EXPERIMENTAL|Part 2|
62528391|NCT05960240|EXPERIMENTAL|Part 3|
62528392|NCT01108406|EXPERIMENTAL|SoundBite Hearing System|"The objective of this study was to assess the long-term safety and quality of life impact of the SoundBite™ Hearing System.~Safety was measured in terms of dental, audiological and medical adverse events related to device or procedure.~Quality of Life was measured in terms of changes in Abbreviated Profile of Hearing Aid Benefit (APHAB) and as reported in a quality of life survey (SSD Questionnaire).~The duration of the study was 6 months with measures taken at Day 1, 3 months and 6 months."
62528393|NCT03698448|PLACEBO_COMPARATOR|Placebo DPI|Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID
62528394|NCT03698448|ACTIVE_COMPARATOR|Low dose OligoG DPI|17.5 mg OligoG dry powder for inhalation. 10 capsules, BID
62528395|NCT03698448|ACTIVE_COMPARATOR|medium dose OligoG DPI|27.5 mg OligoG dry powder for inhalation. 10 capsules, BID
62528396|NCT03698448|ACTIVE_COMPARATOR|High dose OligoG DPI|37.5 mg OligoG dry powder for inhalation. 10 capsules, BID
62528397|NCT03947671|EXPERIMENTAL|Body wrap|This group will receive the body wraps post surgery to maintain normothermia.
62528398|NCT03947671|ACTIVE_COMPARATOR|Tylenol|This group will receive the standard of care of monitoring temperature and administering Tylenol if a fever develops.
62528399|NCT03947671|EXPERIMENTAL|Tylenol with body wrap|This group will receive the standard of care of monitoring temperature but will be administered Tylenol and body wraps if a fever develops.
62528400|NCT02961166||IgM enriched Immunoglobulins|ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
62528401|NCT02961166||Control|ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
62528402|NCT00839592|EXPERIMENTAL|Electroacupuncture|"Acupoints will be treated at bilateral Ear Shenmen, Sishencong (EX-HN1), Anmian, and unilateral Yintang (EX-HN3) and Baihui (GV20).~Acupuncture will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) will be connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
62528403|NCT00839592|PLACEBO_COMPARATOR|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the same acupoints as stated in the electroacupuncture group. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
62528404|NCT01334983|EXPERIMENTAL|REST|Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
62528405|NCT01334983|NO_INTERVENTION|Wait list control|Participants instructed in REST after completing week 8 outcome measures
62528406|NCT03438214|ACTIVE_COMPARATOR|Vancomycin continuous infusion|Continuous infusion of vancomycin
62528407|NCT03438214|ACTIVE_COMPARATOR|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
62528408|NCT03752944|EXPERIMENTAL|prebent plate|fixation of le fort I osteotomy using prebent plate
62528409|NCT03752944|ACTIVE_COMPARATOR|Conventional four miniplates|fixation of le fort I osteotomy using conventional four miniplates
62528410|NCT05754307|ACTIVE_COMPARATOR|Control surgical technique|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
62528411|NCT05754307|EXPERIMENTAL|Test surgical technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentional excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
62528412|NCT05949671|EXPERIMENTAL|Mediterranean groups|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
62528413|NCT05949671|EXPERIMENTAL|Gluten-Free groups|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (GFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
62528414|NCT05949671|EXPERIMENTAL|Mediterranean Gluten-Free groups|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
62528415|NCT05949671|NO_INTERVENTION|control group|Patients in the control group (n=10) did not receive any special dietary intervention.
62528416|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 1|"Drug: SON-DP~1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 1 at dose level 1 once per week in 28-day cycle, for up to 6 cycles."
62528417|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 2|"Drug: SON-DP~1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 2 at dose level 2 once per week in 28-day cycle, for up to 6 cycles."
62528418|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 3|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 3 at dose level 3 once per week in 28-day cycle, for up to 6 cycles.
62528419|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 4|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 4 at dose level 4 once per week in 28-day cycle, for up to 6 cycles.
62528420|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 5|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 5 at dose level 3 twice per week in 28-day cycle, for up to 6 cycles.
62528421|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 6|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 6 at dose level 4 twice per week in 28-day cycle, for up to 6 cycles.
62528422|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 7|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 7 at dose level 5 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
62528423|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 8|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 8 at dose level 6 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
62528424|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 9|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 9 at dose level 7 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
61975720|NCT02738450|ACTIVE_COMPARATOR|ACI-24 low dose|Vaccine formulation will be administrated s.c. 7 times.
61975721|NCT02738450|ACTIVE_COMPARATOR|ACI-24 high dose|Vaccine formulation will be administrated s.c. 7 times.
61975722|NCT02738450|PLACEBO_COMPARATOR|Placebo|The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
62528425|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 10|Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D-1 dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.
62528426|NCT05989724|EXPERIMENTAL|Dose escalation, Cohort 11|Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.
62528427|NCT05989724|EXPERIMENTAL|Dose expansion, Arm 1|Drug: SON-DP Up to 18 participants with breast cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using the Final Schedule, for up to 6 cycles.
61975723|NCT04889469||Breast hypertrophy operated|Women who have had a breast reduction in the public health care system
61975724|NCT04889469||Breast hypertrophy controls|Women with symptoms of breast hypertrophy, who do not fulfill the requirements to have a breast reduction in the public health care system
61975725|NCT04889469||Augmented controls|Patients who have breast hypertrophy due to cosmetic breast augmentation
62528428|NCT05989724|EXPERIMENTAL|Dose expansion, Arm 2|Drug: SON-DP Up to 18 participants with pancreatic cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
62528429|NCT05989724|EXPERIMENTAL|Dose expansion, Arm 3|Drug: SON-DP Up to 18 participants with ovarian cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
62528430|NCT05989724|EXPERIMENTAL|Dose expansion, Arm 4|Drug: SON-DP Up to 18 participants with colorectal cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
62528431|NCT01374295|EXPERIMENTAL|video|If randomized to this arm patient watches a 3 minute video
62528432|NCT01374295|ACTIVE_COMPARATOR|standard education|If randomized to this arm patient receives standard verbal education from healthcare provider.
62528433|NCT05197218|EXPERIMENTAL|Healthy subjects|Prebiotic administration
62528434|NCT03332927|EXPERIMENTAL|Egg based breakfast foods|Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
62528435|NCT03332927|ACTIVE_COMPARATOR|Non-egg based breakfast foods|Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
62528436|NCT05870137|ACTIVE_COMPARATOR|Standard care|Standard care was delivered by the participants with access to didactic instruction and telephonic support. Participants had access to all resources through standard ward base computer systems. Access to senior support through telephone call using a bleep/on call system standard to practice within the institution.
62528437|NCT05870137|EXPERIMENTAL|Mixed reality - HoloLens2TM Supported care|HL2 supported care made all of these resources available through interaction with the HL2 device. Participants had access to all resources through the Mixed reality device (HoloLens2). Access to senior support through using the HL2 device.
62528438|NCT06258759|EXPERIMENTAL|experimental: semen|a semen of normal semen analysis
62528439|NCT06258759|EXPERIMENTAL|placebo: semen|a semen of normal semen analysis
62528440|NCT00879892|ACTIVE_COMPARATOR|Hypothermia and xenon|
62528441|NCT00879892|ACTIVE_COMPARATOR|Hypothermia|
62528442|NCT04259983||Patients with CF with normal obstruction severity|In CF children with normal obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
62528443|NCT04259983||Patients with CF with mild obstruction severity|In CF children with mild obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
61975726|NCT04889469||The general public|Random sample of the general public
61975727|NCT00661622|EXPERIMENTAL|Immunoembolization|Liver embolization treatment with injection of GM-CSF.
61975728|NCT00661622|ACTIVE_COMPARATOR|Plain embolization|Liver embolization with normal saline injected in place of GM-CSF
61975729|NCT03709160|EXPERIMENTAL|BUMETANIDE|we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.
61975730|NCT03709160|ACTIVE_COMPARATOR|INDAPAMIDE|we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.
61975731|NCT02111772|EXPERIMENTAL|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
61975732|NCT02111772|ACTIVE_COMPARATOR|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
61975733|NCT02953327|EXPERIMENTAL|Intervention arm|Intervention arm, these participants will receive BCG vaccination.
61975734|NCT02953327|PLACEBO_COMPARATOR|Placebo arm|The placebo arm will receive BCG solvent.
61975735|NCT04876443||Alcohol-related liver disease|
61975736|NCT03263494|ACTIVE_COMPARATOR|CGM|
61975737|NCT03263494|NO_INTERVENTION|BGM|
62528444|NCT04259983||Patients with CF with moderate obstruction severity|In CF children with moderate obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
62528445|NCT05925673|NO_INTERVENTION|Standard of Care|Participants will follow standard practice protocols at the Roth McFarlane Hand and Upper Limb Centre in London.
62528446|NCT05925673|EXPERIMENTAL|Mirror Therapy|Participants will engage in a home based mirror therapy intervention from 3 to 6 weeks post-fracture.
62528447|NCT05925673|EXPERIMENTAL|Neuromuscular Stimulation (NMES)|Participants will engage in a home based neuromuscular stimulation intervention from 3 to 6 weeks post-fracture.
62528448|NCT05925673|EXPERIMENTAL|Mirror Therapy + NMES|Participants will engage in a home based combined mirror therapy + neuromuscular stimulation intervention from 3 to 6 weeks post-fracture.
62528449|NCT01825889|EXPERIMENTAL|Evacetrapib (Participants With Renal Impairment)|Single oral dose of 130 milligrams (mg) evacetrapib on Day 1 to participants with severe renal impairment.
62528450|NCT01825889|EXPERIMENTAL|Evacetrapib (Healthy Participants)|Single oral dose of 130 mg evacetrapib on Day 1 to participants with normal renal function.
62528451|NCT02751970|ACTIVE_COMPARATOR|3 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of a primer and subsequently an adhesive resin.
62528452|NCT02751970|EXPERIMENTAL|2 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of an adhesive/primer step.
62528453|NCT02751970|ACTIVE_COMPARATOR|2 step SE & Dental restoration|Dental restoration with etching the dental substrates with acidic primer, followed by the application of adhesive resin.
62528454|NCT02751970|EXPERIMENTAL|1 step SE & Dental restoration|Dental restoration with etching and infiltrate the dental substrates with acidic primer/adhesive system.
62528455|NCT05174494|ACTIVE_COMPARATOR|Full mouth non surgical periodontal treatment|Each selected subject underwent to full mouth SRP.
62528456|NCT05174494|PLACEBO_COMPARATOR|Control|Each selected subject underwent full mouth traditional oral hygiene.
62528457|NCT03559621|NO_INTERVENTION|control group|Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.
62154767|NCT02708498|EXPERIMENTAL|Kronoberg Educational Intervention|The educational intervention is provided to ten nursing homes.
62528458|NCT03559621|OTHER|intervention group|A mobile-based lifestyle intervention
62528459|NCT06483139||Patients treated with plasma exchange|Treated with plasma exchange ithin 30 days of diagnosis of light chain cast nephropathy
62528460|NCT06483139||Patients not treated with plasma exchange|Patients not treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy
61975738|NCT03134989|OTHER|Cochlear implant recipients|Study group is comprised of cochlear implant patients already identified as candidates and undergoing surgery.
62528461|NCT06483139||Patients treated with daratumumab|Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
62528462|NCT06483139||Patients not treated with daratumumab|Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
62528463|NCT00843375||Higher risk, no neoplasia|"Negative study colonoscopy and one or more of the following:~* Subjects with a personal history of adenomas (confirmed by pathology) with none present on qualifying colonoscopy~* Subjects with a personal history of colorectal cancer (CRC) (longer than 3 years ago because of exclusion criteria of cancer within last 3 years) with none present at time of qualifying colonoscopy~* Any family history of CRC (1st degree relative)~* Current positive screening stool test for blood, for DNA or for both within 12 months with no follow up intervention"
61975739|NCT03019302|EXPERIMENTAL|Arrow PICC with Chloragard Technology|Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.
61975740|NCT06117150|EXPERIMENTAL|Drug-eluting Coronary Spur StEnt System|All subjects enrolled will receive the Drug-eluting Coronary Spur Stent System.
61975741|NCT06299033|EXPERIMENTAL|hNPC01 therapy|1.5×10\^7 hNPC01 cells; 3.0×10\^7 hNPC01 cells; 6.0×10\^7 hNPC01 cells
61975742|NCT05249361||Duchenne Muscular Dystrophy|Children aged 5 to 18 years with Duchenne muscular dystrophy
62528464|NCT00843375||Adenoma|"Pathologically confirmed adenomas, both non-advanced adenoma and advanced. Advanced adenoma includes any of the following:~* Sessile serrated adenoma~* Tubulovillous adenoma~* Villous adenoma~* Sessile serrated polyp/adenoma~* Traditional serrated adenoma~* Any adenoma ≥1 cm"
62528465|NCT00843375||Colorectal adenocarcinoma|Pathologically confirmed colorectal cancer either present at time of stool collection or discovered during colonoscopy
62528466|NCT00843375||Average risk, no neoplasia|"No neoplasia found at colonoscopy and:~* No prior history of adenomas or sessile serrated adenomas~* No prior history of CRC~* No first degree family history of CRC~* Negative colorectal cancer screening test (if performed) for blood, for DNA or for both within 12 months."
62713796|NCT01346176|EXPERIMENTAL|Forced Choice|Patients in this arm will receive AD forms in which they must actively choose whether to receive each intervention.
61975743|NCT02814253||Community Based Group|Patients who regularly present with exacerbations of COPD and have chronically-elevated CO2 levels. These patients are supported intensively in an out-patient setting (case-managed) and are potentially eligible for the community-based group.
61975744|NCT02814253||Acute Admissions Group|Patients who are admitted to hospital with an acute exacerbation of COPD. These patients are potentially eligible for the acute admission group.
61975745|NCT05696678|ACTIVE_COMPARATOR|Intrathecal Morphine (Control Group)|Spinal anesthesia with intrathecal morphine and postoperative continuous wound infusion with sterile saline.
61975746|NCT05696678|ACTIVE_COMPARATOR|Continuous Wound Infusion (Intervention Group)|Spinal anesthesia without intrathecal morphine and postoperative continuous wound infusion with ropivacaine.
61975747|NCT01269060|EXPERIMENTAL|Single incision sigmoidectomy|Single incision laparoscopic sigmoidectomy for sigmoid colon cancer
61975748|NCT02520401|EXPERIMENTAL|Test|Probiotic tablet
61975749|NCT02520401|PLACEBO_COMPARATOR|Control|Control tablet
61975750|NCT02454881|ACTIVE_COMPARATOR|Placebo|Oxycodone 1 mg / ml alone
61975751|NCT02454881|ACTIVE_COMPARATOR|Dexmedetomidine 2.5|Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL
62154768|NCT02708498|NO_INTERVENTION|Skåne Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
62154769|NCT02708498|EXPERIMENTAL|Skåne Educational Intervention|The educational intervention is provided to ten nursing homes.
62528467|NCT05648786|EXPERIMENTAL|Standard outpatient treatment plus Laddr®|"Laddr® is a smartphone application integrating science-based, therapeutic processes to address a wide range of behavioral problems in the context of a single mobile platform. Laddr includes tools for activating behavior change, solving problems and overcoming obstacles to effective behavior change; teaching skills and providing guidance on the execution of behavior change; and maintaining the end user's motivation to change. It enables longitudinal assessment of individuals' behavior and health status in naturalistic contexts, offers science-based self-regulation behavior change tools of relevance to an array of populations, and enables ongoing monitoring of health behavior. This study evaluates the effectiveness of new features to Laddr®. These new features are designed to be used with a support person, which could include a friend, family member, or acquaintance.~In addition to Laddr®, participants will receive standard outpatient substance use disorder treatment."
62528468|NCT05648786|ACTIVE_COMPARATOR|Standard outpatient treatment|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
62528469|NCT06314685|EXPERIMENTAL|6~11 months old|For children aged 6-11 months, they was randomly assigned in a 1:1 ratio to the experimental group and control group, and basic immunization was performed following a 0,1-month schedule. And the experimental group received one dose of booster immunization at 18 months old;
62528470|NCT06314685|EXPERIMENTAL|12~23 months old|For infants aged 12-23 months, they was randomly assigned in a 1:1:1 ratio to the two-dose experimental group, one-dose experimental group, and two-dose control group. For the 12-23 month-olds in the two-dose group, they received two doses of immunization according to a 0, 1-month schedule; while those in the one-dose group receive a single dose of immunization.
62528471|NCT06314685|EXPERIMENTAL|2~5 years old|For children aged 2-5 years, they were randomly assigned in a 1:1 ratio to the experimental group and control group and received a single dose of immunization.
62528472|NCT00291980|EXPERIMENTAL|1|HB-AS02V vaccine
62528473|NCT00291980|ACTIVE_COMPARATOR|2|HBVAXPRO vaccine
62528474|NCT01246622|EXPERIMENTAL|Treatment (biological therapy)|Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
62528475|NCT02359747||In Vitro Fertilization treatment|culture medium discarded after IVF treatment
62528476|NCT03101982|ACTIVE_COMPARATOR|test|HBO, ASIA score, blood taking
62528477|NCT03101982|NO_INTERVENTION|control|ASIA score, blood taking
62154770|NCT02708498|NO_INTERVENTION|Kronoberg Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
62528478|NCT05648461|EXPERIMENTAL|Five fraction of post operative Radiotherapy|The present study is a non -randomised phase II study that will enroll 50 patients and test feasibility of 30 Gy in 5 fractions of the primary disease and ipsilateral level I-III disease.
62713797|NCT05359237||Observational (SOC vincristine, biospecimen collection)|Patients receive vincristine IV per SOC. Patients undergo collection of blood samples at baseline (before first vincristine dose), and 2, 6-8, and 18-24 hours after a dose of vincristine. Patients may also undergo collection of blood samples with a second SOC vincristine dose at the same time points.
62713798|NCT03885700|EXPERIMENTAL|intervention group|
62154771|NCT03618888|ACTIVE_COMPARATOR|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
62154772|NCT03618888|EXPERIMENTAL|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
62154773|NCT00690313|ACTIVE_COMPARATOR|Arm 1|Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
62154774|NCT00690313|ACTIVE_COMPARATOR|Arm 2|Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
62528479|NCT06493149|EXPERIMENTAL|Tensegrity massage group|Participants in the tensegrity massage group are provided with the 5-minute massage session in the anterior compartment muscles of the forearm, tensor fasciae latae muscle, brachioradialis muscle, deltoid muscle, latissimus dorsi muscle and peroneus longus muscle.
62528480|NCT06493149|ACTIVE_COMPARATOR|Massage group|Participants in the massage group are provided with the 5-minute massage session in the anterior compartment muscles of the forearm, tensor fasciae latae muscle and brachioradialis muscle
62528481|NCT01191983|EXPERIMENTAL|Methoxy polyethylene glycol-epoetin beta|Participants will receive 1.2 mcg/kg methoxy polyethylene glycol-epoetin beta given in monthly doses at each visit. Dose will be measured on the basis of the participants Hb level during the study period. The dose administration will be the nearest possible dose using the prefilled syringes containing 50, 75 and 100 mcg/kg Q4W.
62528482|NCT01465620|EXPERIMENTAL|Coaching|active hygienic-dietetic coaching
62713799|NCT03885700|NO_INTERVENTION|control group|
62713800|NCT01820000|EXPERIMENTAL|Diffusion Weighted Imaging with MRI scans|Subjects will undergo a MRI (magnetic resonance imaging) scan where DWI (diffusion weighted imaging) will be performed. Subjects will not receive contrast during this sequence, but will receive contrast as standard MRI protocol.
62713801|NCT05522686|EXPERIMENTAL|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
61975752|NCT02454881|ACTIVE_COMPARATOR|Dexmedetomidine 5|Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL
62154775|NCT00937807|ACTIVE_COMPARATOR|sévoflurane|hypnotic use in standard general anesthesia
62154776|NCT00937807|EXPERIMENTAL|LENOXe™ (xénon 100 % v/v)|Safety of use in terms of hemodynamic stability to the LENOXe™ (xénon 100 % v/v) within the framework of the carotid surgery on the old person
62154777|NCT00925548|EXPERIMENTAL|Investigational Arm|"Investigational Arm:~* Pretreatment (Single Dose): 300 milligrams per square meter (mg/m\^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide~* tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)"
62154778|NCT00925548|ACTIVE_COMPARATOR|Control Arm|"Control Arm:~* Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion~* Placebo plus Hormonal Therapy (Standard Dose)"
62154779|NCT01274000|PLACEBO_COMPARATOR|placebo group|
62154780|NCT01274000|EXPERIMENTAL|YM060 low-dose group|
62154781|NCT01274000|EXPERIMENTAL|YM060 middle-dose group|
62154782|NCT01274000|EXPERIMENTAL|YM060 high-dose group|
62154783|NCT03816878|EXPERIMENTAL|Cohort 1: pLAIV Recipients|Participants who have received the pandemic live attenuated influenza vaccines (pLAIVs) H2N2, H6N1, or H9N2 during a previous CIR study will receive a single dose of 0.5 mL H5N1 pISV vaccine at Day 0.
62154784|NCT03816878|EXPERIMENTAL|Cohort 2: pLAIV Naive|Participants who have never previously received a pLAIV will receive one dose of 0.5 mL H5N1 pISV vaccine at Day 0.
62154785|NCT01858909|PLACEBO_COMPARATOR|Control|saline every 12 hours for 28 days
62154786|NCT01858909|EXPERIMENTAL|Melatonin|Oral 30mg/12hours melatonin 28 days
62713802|NCT05522686|EXPERIMENTAL|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
62154787|NCT04223674|EXPERIMENTAL|Serological screen and treat|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided for those with Pv seropositive regardless of their symptoms and symptomatic children with microscopic Pv/Po positive.
62154788|NCT04223674|NO_INTERVENTION|Routine care|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided only for symptomatic children with microscopic Pv/Po positive.
62154789|NCT05236218||Pilot study (n = 10)|10 participants will be recruited to complete the questionnaire (version 1). A research assistant will be present to help support them /answer any questions around the format. Readability and comprehension will be noted. Any changes (if needed) can be implemented to its format before the main data collection.
62154790|NCT05236218||Discrete Choice Experiment Questionnaire (n = 50)|Discrete Choice Experiment (DCE) Patients
62154791|NCT01697956|EXPERIMENTAL|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 42 day (6 week) Treatment Period.
62154792|NCT01697956|PLACEBO_COMPARATOR|Placebo Nasal Aerosol|Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 42 day (6 week) Treatment Period.
62154793|NCT05951335|EXPERIMENTAL|Intervention group|The group who received The m-Health supportive care transition program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, including education about physical health, TBI medical problems, and how to treat TBI patients at home.
62528483|NCT01465620|ACTIVE_COMPARATOR|control|reference hygienic-dietetic recommendations
62713803|NCT05522686|EXPERIMENTAL|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
62154794|NCT05951335|NO_INTERVENTION|Control group|The group who received the usual care from nurses for the caregiver-patient with TBI in the ward before discharge from the hospital consists of education about physical health and TBI medical problems and how to treat TBI patients at home. This includes wound care education, medication administration, and schedule control at the hospital after patients with TBI go home. After discharge, there is no program carried out by nurses.
62154795|NCT06153706|EXPERIMENTAL|L-PFR loaded with medical grade metronidazole|
62154796|NCT06153706|ACTIVE_COMPARATOR|L-PFR|
62154797|NCT04117386||Primary pterygium group|Participants who was diagnosed with primary pterygium
62154798|NCT04117386||Secondary pterygium group|Participants who was diagnosed with secondary pterygium
62154799|NCT04117386||Healthy participants as control group|Participants who have no pterygium and other inflammation disease in eyes
62154800|NCT05172648|ACTIVE_COMPARATOR|control group|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength
62154801|NCT05172648|OTHER|contrast group|Moisten the mouth with sterile distilled water with an oral cotton swab.
62154802|NCT00587756||1|Prospective cohort of consecutive patients who undergo surgery for colorectal cancer liver metastases
62154803|NCT03376763|EXPERIMENTAL|Group 1|Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena
62528484|NCT05607641|OTHER|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|
62528485|NCT05607641|ACTIVE_COMPARATOR|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|
62528486|NCT05607641|EXPERIMENTAL|Neospastil, solution for injection then Neospastil, film-coated tablets|
62539536|NCT05470205|EXPERIMENTAL|Reproducibility - Cohort 1|"Patients scheduled for hepatic venous pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE procedures using different ultrasound contrast agents (Definity and Sonazoid in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare).~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.~Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min."
62154804|NCT03376763|EXPERIMENTAL|Group 2|Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena
62154805|NCT05459584|EXPERIMENTAL|Experimental: Technological Group|Technological group (TG) patients will undergo robotic treatment for the improvement balance through the robotic platform (Hunova® Movendo Technology srl, Genova, IT), 3 times per week for 45 minutes each, in addition to the conventional treatment (total 180 minutes per day). In particular, the technological rehabilitation performed employing a footboard will be mostly aimed at improving the balance both in sitting and standing position, and will be proposed static and dynamic exercises, exercises dual-task exercises, and exercises to improve trunk control.
62528487|NCT05946954|EXPERIMENTAL|Intervention group Immediate Dentoalveolar Restoration|"* After applying anesthesia to the maxillary tuberosity, a full thickness crestal incision was made following the distal contour of the maxillary right second molar. This incision was followed by a palatal release incision to access the donor area.~* The flap was raised in the tuberosity area Then, the bone graft was harvested from the underlying bone by using a 1 cm wide flat chisel and a surgical hammer.~* The corticocancellous graft was manipulated using a rongeur to reproduce the shape of the peri-implant bone defect.~* The graft was carefully inserted to the level of the implant platform Finally, a screw-retained resin provisional crown, relined over a polyetheretherketone (PEEK) anti-rotation abutment, was placed out of occlusion, establishing the ideal emergence profile to accommodate the soft tissues and to promote a thicker and more stable gingival tissue margin"
62528488|NCT05946954|ACTIVE_COMPARATOR|Control group Ice cream cone technique|"Ice cream cone technique~1. Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone.~2. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.~The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using resorbable sutures to prevent dislodgment of the blood clot and bone grafting material"
62528489|NCT00380692|EXPERIMENTAL|Atomoxetine|atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
62528490|NCT00380692|PLACEBO_COMPARATOR|Placebo|"placebo every day (QD), by mouth (PO) for 8 weeks~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks"
62528491|NCT01624441|EXPERIMENTAL|Treatment (dinaciclib and epirubicin hydrochloride)|Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62528492|NCT00324766|ACTIVE_COMPARATOR|1|levosimendan
62528493|NCT00324766|PLACEBO_COMPARATOR|2|Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
62528494|NCT02255682|PLACEBO_COMPARATOR|Simvastatin and Q10-placebo|Simvastatin 40 mg orally administered daily and Q10-placebo for 8 weeks
62528495|NCT02255682|ACTIVE_COMPARATOR|Simvastatin and Q10|Simvastatin 40 mg orally administered daily for 8 weeks in combination with Q10 supplementation of 400 mg/daily
62528496|NCT06156345|ACTIVE_COMPARATOR|Conservative|consists of teaching the patient the relaxed jaw position and stretching exercises for masseter and pterygoid muscles with hold of 20-30 seconds and 3-5 repetitions. In addition to placebo traction.
62528497|NCT06156345|EXPERIMENTAL|Conservative with Denneroll|"Participants will be supine lining with the orthotic will be placed under participants' neck.~Treatment session time begin with 3 minutes then increase of 2-3 minutes until they reach 15 to 20 minutes in each session with the conservative management for TMD."
62528498|NCT03449927|ACTIVE_COMPARATOR|Control Arm: Regular menu|"* Calorie count initiated on day +1 of transplant and ending upon count recovery~* Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~* Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~* Interventions provided for control group: standard of care, verbal or printed handouts, standard educations created by Barnes Jewish Hospital (BJH) oncology dietitians"
62528499|NCT03449927|EXPERIMENTAL|Intervention Arm: Specialized Menu|"* Calorie count and tool provided on day +1 and ending upon count recovery~* Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~* Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~* Interventions provided for intervention group: standard of care provided by BJH oncology dietitians, tools including nausea and diarrhea menus and follow up by registered dietitian (RD) to provide additional counseling on menus as symptoms arise"
62528500|NCT03840616|EXPERIMENTAL|Oteseconazole (VT-1161) 150mg capsule|600mg oteseconazole administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14
62528501|NCT03840616|ACTIVE_COMPARATOR|Fluconazole 150mg capsule / Placebo|150mg fluconazole administered every 72 hours in 3 sequential doses starting on Day 1, followed by placebo administered once weekly starting on Day 14
61975753|NCT02454881|ACTIVE_COMPARATOR|Dexmedetomidine 10|Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL
61975754|NCT03433768||poor responders|
61975755|NCT03433768||normal responders|
62154806|NCT05459584|NO_INTERVENTION|No Intervention: Control Group|Congrol Group (CG) patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive neuromuscular facilitation, etc.).
62154807|NCT06428799||Retrospective collection of DICOM patient files for Site 1|"A total of 60 mammographic studies were retrospectively collected from Site 1 (EUC Mamocentrum Brno).~The acquisition of mammography studies from Site 1 was enabled by the contract for the transfer of mammography images for medical research purposes, signed on 14 January 2022."
61975756|NCT03966378|EXPERIMENTAL|Grape seeds extract|Every week the grape seeds extract (gel) put into the tray and apply it to the upper teeth of the participant.
61975757|NCT03966378|ACTIVE_COMPARATOR|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste apply to the teeth twice daily.
62528502|NCT00183937|EXPERIMENTAL|Bortezomib and Docetaxel|Bortezomib 1.6 mg/m2 Docetaxel 75 mg/m2
62528503|NCT01494935|EXPERIMENTAL|Normal glycemic diet|COntrol diet with fat and glycemic index similar to typical American diet.
62528504|NCT01494935|EXPERIMENTAL|High-fat, high-glycemic diet|High-fat, high-glycemic diet
62528505|NCT03595631|ACTIVE_COMPARATOR|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
62528506|NCT03595631|EXPERIMENTAL|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
62528507|NCT06206382||Upfront surgery for locally advanced pancreatic cancers|
62528508|NCT06206382||Surgery after neoadjuvant chemotherapy for locally advanced pancreatic cancers|
62528509|NCT04941118|SHAM_COMPARATOR|Control group|Only saline and local anesthetic (lidocaine)
62528510|NCT04941118|ACTIVE_COMPARATOR|Dextrose prolotherapy group|Dextrose, saline and local anesthetic (lidocaine)
62528511|NCT04280705|PLACEBO_COMPARATOR|Placebo|200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
62154808|NCT06428799||Retrospective collection of DICOM patient files for Site 2|"A total of 28 mammographic studies were retrospectively collected from Site 2 (Hospital Šumperk, a.s.).~The acquisition of mammography studies from Institution 2 was enabled by the contract for the transfer of mammography images for medical research purposes, signed on 31 January 2023."
62528512|NCT04280705|EXPERIMENTAL|Remdesivir|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.
62528513|NCT02248038|ACTIVE_COMPARATOR|open surgery|Conventional procedure
62528514|NCT02248038|EXPERIMENTAL|laparoscopic surgery|Minimum invasive procedure
62528515|NCT02527928||desoxycholate|Amphotericin B desoxicholate
62528516|NCT02527928||Anfolipidcomplex|Amphotericin B complex lipid
62528517|NCT02527928||ABLiposomal|Amphotericin B liposomal
62528518|NCT04413864|OTHER|SARS-CoV-2 (Covid-19 positive)|Patients hospitalized in intensive care unit (ICU), infected with SARS-CoV-2
62528519|NCT02401620||single-group studies|Patients with RA diagnosed
62713804|NCT05522686|OTHER|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
62528520|NCT01237925|EXPERIMENTAL|Dexchlorpheniramine 1% gel|
62528521|NCT01237925|ACTIVE_COMPARATOR|Dexchlorpheniramine 1% cream|
62528522|NCT03337165|EXPERIMENTAL|tolerogenic dendritic cells|Each dose of autologous monocyte-derived dendritic cells generated in the presence of IFN-α/GM-CSF and tolerized with Dexamethasone (1x106, 3x106, 5x106, 8x106 and 10x106 cells in 2.0 mL sodium chloride 0.9% solution) will be administered in RA patients through intra-articular injection (into the knee joint).
62528523|NCT05234372|EXPERIMENTAL|Treatment received intervention at enrollment|Participants received mobile phone delivered intervention at enrollment. The intervention had a duration of 4 weeks. Each week participants received two text messages inviting them to view a short video (Monday) and brief written content (Wed). Each week, the material consisted of a culturally tailored theme related to COVID-19 vaccination. Participants also received information on how to get vaccinated.
62528524|NCT05234372|OTHER|Control|Wait-list control. No intervention during month 1. Received the intervention at Month 2. Each week, during the first month, participants received a text with a count down of how many days were left to begin the intervention.
62528525|NCT03308266||CLP children with pain-related TMD|
62528526|NCT03308266||CLP children with no TMD|
62528527|NCT03308266||CLP children with painfree TMD|
62528528|NCT01962480|ACTIVE_COMPARATOR|sutured closure of the hernia gap|The hernia gap is sutured intracorporally
62528529|NCT01962480|NO_INTERVENTION|No closure of the hernia gap|Physiomesh is placed with at least 5 cm overlap of the gap and fixated with double crown technique
62528530|NCT05464043|EXPERIMENTAL|diabetic cohort|"Patients who receive liver or kidney transplants and immunosuppressive drugs with diabetogenic risk.~After 14 days of immunosuppressive therapy, all admitted patients will be evaluated for first-line glucose homeostasis. This patient cohort will be referred to as the diabetes risk cohort.~Subjects will then be stratified into two groups of patients: those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, the diabetic cohort, and those who have not developed glycemic dysregulation or diabetes, the control cohort. Only those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, i.e. the diabetic cohort, will be analysed in more detail with the evaluation of second-line glucose homeostasis at three different times."
62528531|NCT02896582|EXPERIMENTAL|Induction - ASCT - maintenance|Induction : 4 cycles of GA-DHAP every 21 days - Conditioning regimen and ASCT: GA-BEAM + Autologous transplantation - Maintenance : Obinutuzumab every 2 months for 3 years then every month for patients with positive MRD
62528532|NCT05897385|ACTIVE_COMPARATOR|Group L|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
62528533|NCT05897385|PLACEBO_COMPARATOR|Group P|Intraperitoneal 20ml of 0.9% normal saline
62528534|NCT01030744||Gestational Diabetes|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind Diabetes Clinic and are participants in the gestational diabetes educational program.
62528535|NCT00615654|OTHER|2|
62528536|NCT04625595|EXPERIMENTAL|350 mg BID (700 mg total daily dose) of active drug or placebo|Low dose, drug IMT-002
62528537|NCT04625595|EXPERIMENTAL|1050 mg QD (1050 mg total daily dose) of active drug or placebo|Moderate dose, drug IMT-002
62713805|NCT06053164|NO_INTERVENTION|Arm 1 - Usual Care|8 weeks of usual care with no supplemental oxygen provided
62713806|NCT06053164|EXPERIMENTAL|Arm 2 - Exertional Oxygen|8 weeks of portable oxygen use (from a concentrator) during exertion
61975758|NCT04464343||Posterior cruciate ligament injury group|According to the previous clinical diagnosis, volunteers who has never suffered the Posterior cruciate ligament injury.
62154809|NCT06428799||Retrospective collection of DICOM patient files for Site 3|"A total of 34 mammographic studies were retrospectively collected from Site 3 (Masaryk Memorial Cancer Institute).~The acquisition of mammography studies from Institution 3 was enabled by the amendment to the contract for the transfer of X-ray images for medical research purposes, signed on 21 February 2023, which follows the contract for the transfer of X-ray images for medical research purposes, signed on 3 January 2022."
62154810|NCT05141968|EXPERIMENTAL|Vitamin D supplements group|Group A: is the interventional group that supplemented with vitamin D tablets contain 2000 IU once time daily with a meal, for 3 months of intervention.
62154811|NCT05141968|NO_INTERVENTION|Control group|Group B: is the control group, that did not receive any supplements.
62154812|NCT02947880|EXPERIMENTAL|Bumetanide group|"During 3 months in the double blind, the patient will receive the experimental treatment. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
62154813|NCT02947880|PLACEBO_COMPARATOR|Placebo group|"During 3 months in the double blind, the patient will receive the placebo. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
62154814|NCT01317914|EXPERIMENTAL|Dietary instruction on Gluten Free Diet|
62154815|NCT03037827|ACTIVE_COMPARATOR|Endovenous laser ablation (EVLA) 5W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 0.7 mm/s, laser power 5 W, LEED 71 J/cm
62154816|NCT03037827|ACTIVE_COMPARATOR|Endovenous laser ablation (EVLA) 7W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1 mm/s, laser power 7 W, LEED 70 J/cm
62154817|NCT03037827|ACTIVE_COMPARATOR|Endovenous laser ablation (EVLA) 10W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1.5 mm/s, laser power 10 W, LEED 67 J/cm
62154818|NCT05537935|NO_INTERVENTION|Control|"Once a potential subject has been identified they may be contacted with information about the study in advance of their appointment in order to allow time for them to consider the study. A qualifying pain score will be confirmed with the subject prior to initiating consent. This may occur up to 30 days before the baseline, treatment visit, but inclusion/exclusion criteria will be re-confirmed prior to initiating study treatment. Patients may also be approached during a clinic visit.~Should a patient decline participation in the treatment plan, they will be invited to participate in a control group. They will be invited to complete the PROMIS questionnaire every 4 weeks, and the NPRS pain assessment every week from Baseline through week 12. These participants will receive follow up phone calls to confirm completion of these assessments weekly and will not have any in-person visits."
62154819|NCT05537935|EXPERIMENTAL|Low Dose Naloxone (LDN)|"Once a potential subject has been identified they may be contacted with information about the study in advance of their appointment in order to allow time for them to consider the study. A qualifying pain score will be confirmed with the subject prior to initiating consent. This may occur up to 30 days before the baseline, treatment visit, but inclusion/exclusion criteria will be re-confirmed prior to initiating study treatment. Patients may also be approached during a clinic visit.~Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. LDN will be given as a daytime dose."
62154820|NCT02634593|NO_INTERVENTION|Control|Control
62154821|NCT02634593|ACTIVE_COMPARATOR|Low glycemin load snacks|Low glycemic load snacks, consumed during specific times
62154822|NCT02536534||Patients with PAH and CTEPH|Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
62154823|NCT00805792|EXPERIMENTAL|Donepezil|Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.
62154824|NCT02416102|ACTIVE_COMPARATOR|Healthy non-smokers|10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
62154825|NCT02416102|EXPERIMENTAL|Smokers without COPD|10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
62154826|NCT02416102|EXPERIMENTAL|Ex-smokers with COPD|10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
62154827|NCT00749840||HIV Care Questionnaire|Patients with a new diagnosis of HIV infection.
62154828|NCT03527888|OTHER|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
62154829|NCT04471805|EXPERIMENTAL|Eumenorrheic Women|"Participants will have the anode (active electrode) placed over the brain area that controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. tDCS is administered in the early follicular phase, late follicular phase, and mid-luteal phase of their menstrual cycle.~tDCS: Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the simulation time.~Sham: Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time."
62154830|NCT05863676||Cryopreservation|Participants will have their gonadal tissue cryopreserved.
61975759|NCT04464343||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
61975760|NCT00785395|EXPERIMENTAL|A|
62154831|NCT01590056||PD patients|PD patients that are treated or are candidates for treatment with STN DBS
62528538|NCT04625595|EXPERIMENTAL|700 mg BID (1400 mg total daily dose) of active drug or placebo|Moderate to high dose, drug IMT-002
62154832|NCT01318356|EXPERIMENTAL|Cognitive behavioral therapy|
62154833|NCT01318356|EXPERIMENTAL|Doxycycline|
62154834|NCT01318356|PLACEBO_COMPARATOR|Placebo|
62154835|NCT02791308|EXPERIMENTAL|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
62154836|NCT02791308|ACTIVE_COMPARATOR|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
62154837|NCT02791308|PLACEBO_COMPARATOR|Vehicle Cream|Cream vehicle of the test product (Actavis)
62154838|NCT00451906|EXPERIMENTAL|Bevacizumab + Chemotherapy|Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.
62154839|NCT00141271|ACTIVE_COMPARATOR|20-40mg BID arm|
62154840|NCT00141271|ACTIVE_COMPARATOR|60-80mg bid arm|
62528539|NCT04625595|EXPERIMENTAL|1050 mg BID (2100 mg total daily dose) of active drug or placebo|High dose, drug IMT-002
62154841|NCT00141271|PLACEBO_COMPARATOR|Placebo|
62528540|NCT04059224|EXPERIMENTAL|Arm A: advanced BRAF V600 wild-type/NRAS-mutant melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
62154842|NCT04829188|ACTIVE_COMPARATOR|Structured Telephone Support (STS)|Post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care provider (PCP) within seven days post-discharge.
62713807|NCT06053164|EXPERIMENTAL|Arm 3 - Exertional Oxygen + Support|8 weeks of portable oxygen use (from a concentrator) during exertion, plus additional phone calls with a respiratory educator and educational material
62528541|NCT04059224|EXPERIMENTAL|Arm B: advanced BRAF V600 wild-type/NRAS wild-type melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
62528542|NCT01070459|PLACEBO_COMPARATOR|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
62154843|NCT04829188|ACTIVE_COMPARATOR|Low-intensity Remote Patient Monitoring (RPM) + Standard Response Team (RPM-Low, Standard Team)|Questions are pushed to members patients times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
62154844|NCT04829188|ACTIVE_COMPARATOR|High-intensity Remote Patient Monitoring (RPM) plus the Standard Team (RPM-High, Standard Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
62528543|NCT01070459|EXPERIMENTAL|Aerobic exercise group|The patients continues their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heart rate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week training programme 4 information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
62528544|NCT01070459|EXPERIMENTAL|Follow-up first aerobic exercise group|
62528545|NCT01070459|PLACEBO_COMPARATOR|Follow-up control group|
62528546|NCT01070459|EXPERIMENTAL|Follow-up second aerobic exercise group|
62528547|NCT00469157|OTHER|1.|
62713808|NCT05746988|EXPERIMENTAL|Carrageenan-based Mouthwash|Mouthwash with Carrageenan as an active ingredient
61975761|NCT03590145||Qatari athletes|Participants meeting general inclusion criteria.
62528548|NCT00297856||Boostrix cohort|
62528549|NCT00297856||Historical Td cohort|
62528550|NCT03823014|EXPERIMENTAL|External Erectile Prosthesis|Study participants will be recruited as couples (transgender man + sexual partner.) Couples will use an external erectile prosthesis (Elator) over the course of 1 month and keep track of their experiences. 20 men and their partners will be enrolled.
62528551|NCT04221139|EXPERIMENTAL|Healthy young adults|Healthy young adults will play four virtual reality games: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
62528552|NCT02098096|EXPERIMENTAL|Negative Work|Negative work exercise via isokinetic knee extension/flexion will be performed twice per week for 12 weeks.
62528553|NCT02098096|PLACEBO_COMPARATOR|Stretching|A home exercise program consisting of stretches for the major lower extremity muscles groups will be performed twice per week for 12 weeks.
62713809|NCT05746988|PLACEBO_COMPARATOR|Placebo Mouthwash|"Mouthwash without Carrageenan but similar in colour, taste, and mouthfeel to the experimental mouthwash"
62713810|NCT02205320|EXPERIMENTAL|Treatment Sequence I (DRL, A, B)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
62713811|NCT02205320|EXPERIMENTAL|Treatment Sequence II (DRL, B, A)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form B, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
62154845|NCT04829188|ACTIVE_COMPARATOR|Low-intensity Remote Patient Monitoring (RPM) + Enhanced Team (RPM-Low, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives).
62154846|NCT04829188|ACTIVE_COMPARATOR|High-intensity Remote Patient Monitoring (RPM) plus the Enhanced Team (RPM-High, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans.Team members (e.g., CRNP, social workers, nurses) address RPM triggers, meet with the patient three times, pharmacy review, develop care plans, and discuss advance directives).
62154847|NCT04323514|EXPERIMENTAL|Patients with COVID-19 pneumonia|Consecutive patients with COVID-19 pneumonia admitted to ARNAS Civico-Di Cristina-Benfratelli, Palermo
62528554|NCT02017548|EXPERIMENTAL|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
62528555|NCT02017548|EXPERIMENTAL|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
62528556|NCT02017548|NO_INTERVENTION|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
62154848|NCT03677986|NO_INTERVENTION|Usual Care|Participants in this group will be referred to receive office-based buprenorphine treatment
62528557|NCT00698880|ACTIVE_COMPARATOR|HVE|Hepatic vein embolization after portal vein embolization
62528558|NCT00698880|NO_INTERVENTION|PVE|Only portal vein embolization, historical control group
62528559|NCT05438498|OTHER|Evusheld (AZD7442)|Evusheld (tixagevimab+cilgavimab) 600 mg IM or IV administered one time only
62713812|NCT02205320|EXPERIMENTAL|Treatment Sequence III (A, DRL, B)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, DRL_PG, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
62713813|NCT02205320|EXPERIMENTAL|Treatment Sequence IV (A, B, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, Pegfilgrastim Form B, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
62528560|NCT02570516|ACTIVE_COMPARATOR|Indigo carmine colonoscopy|Colonoscopy using indigo carmine is performed in second place
62528561|NCT02570516|EXPERIMENTAL|NBI colonoscopy|Colonoscopy using NBI is performed in first place
62528562|NCT02307266|EXPERIMENTAL|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
62528563|NCT02307266|EXPERIMENTAL|Standard of care|Subjects will receive standard-of-care instructions only.
62528564|NCT02307266|EXPERIMENTAL|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
62528565|NCT02606214|EXPERIMENTAL|Dose Level 1: 50 mg TBA-354|50 mg TBA-354 for 14 days (two 25 mg once daily)
62713814|NCT02205320|EXPERIMENTAL|Treatment Sequence V (B, A, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, Pegfilgrastim Form A, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
62713815|NCT02205320|EXPERIMENTAL|Treatment Sequence VI (B, DRL, A)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, DRL_PG, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
62713816|NCT02750930|EXPERIMENTAL|Albiglutide arm|Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
62528566|NCT02606214|PLACEBO_COMPARATOR|Dose Level 1: Placebo|Placebo cohort for Dose Level 1
62528567|NCT02606214|EXPERIMENTAL|Dose Level 2: 100 mg TBA-354|100 mg TBA-354 for 14 days (one 100 mg tablet once daily)
62528568|NCT02606214|PLACEBO_COMPARATOR|Dose Level 2: Placebo|Placebo cohort for Dose Level 2
62528569|NCT02606214|EXPERIMENTAL|Dose Level 3: 200 mg TBA-354|200 mg TBA-354 for 14 days (two 100 mg once daily)
62528570|NCT02606214|PLACEBO_COMPARATOR|Dose Level 3: Placebo|Placebo cohort for Dose Level 3
62713817|NCT05580614|ACTIVE_COMPARATOR|Active tVNS paired with 12 sessions of ERP|
62713818|NCT05580614|SHAM_COMPARATOR|Sham tVNS paired with 12 sessions of ERP|
62713819|NCT05285891|EXPERIMENTAL|Ocrelizumab Arm|"All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6, 12, 18, and 24.~In this arm participants will continue to receive OCR infusions every 6 months through Month 48."
62528571|NCT02606214|EXPERIMENTAL|Dose Formulation Comparison Cohort|"All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort.~Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose."
62528572|NCT03966248|EXPERIMENTAL|Chinese Tuina group (CTG)|The participants in CT group will receive the traditional Chinese Tuina therapy on the basis of KOA health education and home-exercise.
62528573|NCT03966248|ACTIVE_COMPARATOR|Physical Manual group (PMG)|The participants in PM group will receive the modern physical manual therapy on the basis of KOA health education and home-exercise.
62528574|NCT02731417|EXPERIMENTAL|Urinary retention-group 1|For women with post partum urinary retention designated for experimental treatment.
62528575|NCT02731417|ACTIVE_COMPARATOR|Urinary retention-group 2|For women with post partum urinary retention designated for current departmental protocol treatment.
62528576|NCT04648566|PLACEBO_COMPARATOR|IIU control group|
62154849|NCT03677986|EXPERIMENTAL|Video DOT+|Participants in this group will be referred to receive office-based buprenorphine treatment and will receive financial incentives for taking their daily buprenorphine dose.
62154850|NCT03392844|EXPERIMENTAL|Intervention: Bed after 7 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 7 days after initiating daily diary/actigraph procedures.
62154851|NCT03392844|EXPERIMENTAL|Wait-list: Bed after 14 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 14 days after initiating daily diary/actigraph procedures.
62154852|NCT02770274|EXPERIMENTAL|Group Cilostazol|Patients receiving dual antiplatelet therapy with cilostazol 100mg twice daily and aspirin 100mg once daily for 12 months.
62528577|NCT04648566|ACTIVE_COMPARATOR|IIU PBMC group|
62528578|NCT04648566|PLACEBO_COMPARATOR|FIV control group|
62528579|NCT04648566|ACTIVE_COMPARATOR|FIV PBMC group|
62528580|NCT04648566|ACTIVE_COMPARATOR|RIF group|
62528581|NCT02086136||Suspected AD|Consecutive adult patients with suspected AD presenting to Emergency Departments will be enrolled at the time of initial medical evaluation and before the establishment of a final diagnosis.
62528582|NCT05240170|EXPERIMENTAL|RIRS group|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
62528583|NCT05240170|EXPERIMENTAL|SWL group|The medical records of all patients who underwent SWL at our institution in the past five years will be reviewed. Patients with renal rotation or position anomalies, as defined by NCCT and/or IVU, will be included for possible study participation.
62528584|NCT00167687|PLACEBO_COMPARATOR|2|
62528585|NCT05649241|EXPERIMENTAL|QuitAid, 8 weeks, Patch + Gum|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
62528586|NCT05649241|EXPERIMENTAL|QuitAid, 4 weeks, Patch + Gum|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
62528587|NCT05649241|EXPERIMENTAL|QuitAid, 8 weeks, Patch|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
62528588|NCT05649241|EXPERIMENTAL|QuitAid, 4 weeks, Patch|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
62528589|NCT05649241|EXPERIMENTAL|No QuitAid, 8 weeks, Patch + Gum|Participants received 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
62528590|NCT05649241|EXPERIMENTAL|No QuitAid, 4 weeks, Patch + Gum|Participants received 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
62528591|NCT05649241|EXPERIMENTAL|No QuitAid, 8 weeks, Patch|Participants received 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
62713820|NCT05285891|PLACEBO_COMPARATOR|Placebo Arm|"All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6, 12, 18, and 24.~In this arm, starting at Month 30, participants will receive placebo infusions every 6 months through Month 48."
62528592|NCT05649241|EXPERIMENTAL|No QuitAid, 4 weeks, Patch|Participants received 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
62528593|NCT04276844||Non diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test ≥ 16 mm for women and ≥ 18 mm for men
62528594|NCT04276844||Persistent diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test \< 16 mm for women and \< 18 mm for men
62528595|NCT04016441||Subjects|Subjects who are capable of completing an online, English survey.
62539537|NCT05470205|EXPERIMENTAL|HCC monitoring - Cohort 2|"Patients identified as having CSPH will be monitored every 6 ± 2 months to check for HCC by SHAPE with Sonazoid for the duration of this project ( for 18-24 months on average).~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min."
61975762|NCT00447642|EXPERIMENTAL|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
62154853|NCT02770274|ACTIVE_COMPARATOR|Group Aspirin|Patients receiving monotherapy with aspirin 100mg once daily for 12 months.
62154854|NCT02472808|OTHER|cTBNA without ROSE|Patients who will undergo conventional TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
62154855|NCT02472808|OTHER|cTBNA with ROSE|Patients who will undergo conventional TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
62154856|NCT02472808|OTHER|EBUS-TBNA without ROSE|Patients who will undergo EBUS-TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
62528596|NCT04131543|EXPERIMENTAL|Cabozantinib|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
62528597|NCT05331157|NO_INTERVENTION|palpation group|"In lateral decubitus position, the conventional palpation technique will be used to detect the epidural space. The midline will be identified by palpation of the spinous processes. Through the Tuffier's line, L5 spine then, the two intervertebral spaces (L3-4 and L2-3) will be detected and the middle of each intervertebral space will be marked with selection of the widest space.~After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline"
62528598|NCT05331157|EXPERIMENTAL|Ultrasonography group|In lateral decubitus position, a curved array probe will be utilized to scan the sacrum in the longitudinal paramedian plane, then the probe will be moved upwards to detect the L5-S1, L4-5, L3-4 and L2-3 intervertebral spaces then turned 90º to the transverse plane and used to scan L3-4 and L2-3 spaces inside the 2 spaces, midline will be detected by noting the site of spinous processes with selection of the space with the best sonographic image quality. Then skin surface at the middle of the long and short axis of the probe will be marked horizontally. If the 2 spaces have the same image quality, L2-3 space will be chosen for the entrance of epidural needle. After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline
62154857|NCT02472808|OTHER|EBUS-TBNA with ROSE|Patients who will undergo EBUS-TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
62528599|NCT02582866|EXPERIMENTAL|Lacosamide|"Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day.~Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks."
62154858|NCT01826994|OTHER|patients|heart type fatty acid binding protein testing
62154859|NCT05034237|EXPERIMENTAL|ND;YAG 1064 NM LASER|monthly sessions of laser hair removal
62154860|NCT04596735||Patients undergoing general endotracheal anesthesia that will be extubated following the procedure|Patients 60 years of age and older undergoing general anesthesia and non-cardiac surgery will be observed by a member of the research team independent from the team caring for the patient at the time of emergence and extubation
62154861|NCT00671853|EXPERIMENTAL|1|Quetiapine XR
62154862|NCT00671853|PLACEBO_COMPARATOR|2|Placebo for quetiapine XR
62528600|NCT02619877|EXPERIMENTAL|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
62713821|NCT04790786|EXPERIMENTAL|Lilly Bamlanivimab|The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset.
62528601|NCT02619877|ACTIVE_COMPARATOR|Standard therapy|Standard therapy for patients with diabetic foot ulcer
62528602|NCT05583136|EXPERIMENTAL|Group DD1|tACS + visuo-attentional training
62528603|NCT05583136|ACTIVE_COMPARATOR|Group DD2|Sham (placebo) tACS + visuo-attentional training
62528604|NCT05583136|ACTIVE_COMPARATOR|Group DD3|Sham (placebo) tACS + phonics training
62528605|NCT04561687|ACTIVE_COMPARATOR|Azelastine and Nasal Budesonide|Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older
62528606|NCT04561687|ACTIVE_COMPARATOR|Montelukast and Nasal budesonide|Montelukast 5mg 6-14years old and 10mg for older
62528607|NCT04561687|PLACEBO_COMPARATOR|Nasal Budesonide and Placebo|Placebo once daily
62713822|NCT04790786|EXPERIMENTAL|Regeneron Casirivimab + Imdevimab|The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset.
61975763|NCT00447642|EXPERIMENTAL|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
61975764|NCT00447642|PLACEBO_COMPARATOR|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
62154863|NCT01257724|EXPERIMENTAL|Full-serve evidence service|"The full-serve evidence service consists of:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence"
62154864|NCT01257724|ACTIVE_COMPARATOR|Self-serve evidence service|Organizations allocated to the control group will only be provided website access to a listing of systematic reviews that are organized by year of publication with links to the record on PubMed (or another publicly available source when not available on PubMed) and access to worksheets that help community-based organizations find and use research evidence.
62154865|NCT00119782|EXPERIMENTAL|1|Comprehensive worksite intervention
62154866|NCT00119782|EXPERIMENTAL|2|Delayed intervention control group
62154867|NCT03320278||SPIDS,TMH|There will be two tests in this study for evaluation. Both of them will be measured in same group.
62154868|NCT01838356||No treatment.|
62154869|NCT02301299||Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
62154870|NCT00753896|EXPERIMENTAL|1|
62154871|NCT00316121|EXPERIMENTAL|1|
62154872|NCT00316121|ACTIVE_COMPARATOR|2|
62154873|NCT06160375|OTHER|Group (P)|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
62154874|NCT06160375|OTHER|Group (E)|the patient will be in the lateral position, by using US (Esaote MyLabSeven/ Esaote S.p.A, Genoa, Italy) a linear multifrequency 12 L probe and a 20-gauge 100 mm peripheral nerve block needle (Stimupleks Ultra 360 30°-BRA-04892510-01/B. Braun Melsungen AG, Hessen, Germany), the one-sided truncal block will be performed. The transverse process was visualized by placing the probe approximately 3 cm lateral to the spinous process of the T5 vertebrae for ESPB. When the needle advances in the craniocaudal direction with an angle of 30-40° and touched the transverse process, the presence of blood and/ or air will be checked by aspiration. Hydro-dissection was performed with 2-3 mL isotonic saline and 20 mL 0.25% bupivacaine (Marcaine 0.5%, 5 mg/mL) will be injected by observing that the erector spinae muscle (ESM) separates from the transverse process.
62154875|NCT02617459|EXPERIMENTAL|Levobetaxolol eye drops|Levobetaxolol eye drops 5ml/25mg per bottle
62154876|NCT02617459|ACTIVE_COMPARATOR|Betaxolol eye drops|Betaxolol eye drops 5ml/12.5mg per bottle
62154877|NCT05305300|EXPERIMENTAL|Arm A: Primary Immunization|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 45 subjects will be enrolled in Arm A. Subjects in Group 1-3 will receive two doses of PIKA COVID-19 vaccine via IM administration on Days 0 and 7.
62154878|NCT05305300|EXPERIMENTAL|Arm B1: Booster Immunization 1|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B1 will enroll subjects who received Inactivated vaccines and will comprise of 15 subjects per dose. In arm B1, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
62154879|NCT05305300|EXPERIMENTAL|Arm B2: Booster Immunization 2|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B2 will enroll subjects who received mRNA vaccines and will comprise of 15 subjects per dose. In arm B2, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
62154880|NCT01160159||Thrombophilia|
62154881|NCT01160159||Healthy volunteers|
62154882|NCT03840993|EXPERIMENTAL|MT-2990|MT-2990, over 16 weeks
62154883|NCT03840993|PLACEBO_COMPARATOR|Placebo|Placebo, over 16 weeks
62154884|NCT01962376|ACTIVE_COMPARATOR|Bevacizumab,postoperative chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.~placebo:Physiological saline"
62528608|NCT05604248|OTHER|Lactating mother-infant pair|"8 arms of 7 lactating women for a total of 56 women following a study design integrating a model-based compartmental analysis with the Retinol Isotope Dilution (RID) technique using a Wonder women approach.~For infants, the RID test will start at day 14. After the baseline blood, they will receive 1.0 μmol 13C2-retinyl acetate and will have a second blood sample at day 28."
62154885|NCT01962376|EXPERIMENTAL|Preoperative Chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
62154886|NCT04224597||Patients with acne vulgaris|patients with acne vulgaris aged between 18-25 year
62154887|NCT04224597||Healthy controls|healthy controls aged between 18-25 year
62154888|NCT02575014|EXPERIMENTAL|Preoperative HBOT|25 out of 50 patients will receive 2 preoperative hyperbaric oxygen therapy treatments, one the day before their operation, the other within 5 hours preceding their operation. The participants will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator. Day 0 will be the first day of their HBOT treatment, Day 1 will be the day of their operation and second/final HBOT treatment.
62154889|NCT02575014|NO_INTERVENTION|No HBOT|25 out of 50 patients will not receive preoperative hyperbaric oxygen therapy. Day 1 will be the day of the operation.
62154890|NCT02569294|EXPERIMENTAL|Choice 1: Yoga intervention|See intervention description
62154891|NCT02569294|EXPERIMENTAL|Choice 2: Hypnosis intervention|See intervention description
62154892|NCT02569294|EXPERIMENTAL|Choice 3: CBT intervention|See intervention description
62154893|NCT02569294|NO_INTERVENTION|Control group|Participants who agreed not to participate in any of the interventions proposed.
62154894|NCT05985668||Suspected|Suspected Platelet Function Disorder during bleeding investigation
62528609|NCT02053480||Pyruvate Kinase Deficiency|Patients of all ages with Pyruvate Kinase Deficiency
62528610|NCT04314414|EXPERIMENTAL|Intervention group|Participants in the intervention group will receive a semi-scripted brief motivational interview from the peer recovery coach (PRC) in addition to the standard of care at Boston Medical Center (BMC) for HIV, HCV, and opioid use disorder.
62154895|NCT05985668||Confirmed|Confirmed Platelet Function Disorder by Functional or Genetic Assay, or confirmed negative by gold standard assay
62713823|NCT04790786|EXPERIMENTAL|Lilly Bamlanivimab + Etesevimab|The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset.
62154896|NCT02141152||gastric cancer|This study will recruit a total of 130 gastric cancer patients. It is expected to recruit about 250 gastric cancer patients per year. Since the incidence of each mutation is low, the different types of mutations are assumed to be mutually exclusive. So, about 30% of these patients are expected to have a mutation with a target drug. Overall response (OR) is the primary endpoint of this study. OR rate (ORR) will be compared between the group (called targeted group) of patients who have a mutation with a target drug and that (called untargeted group) of patients who have no mutation. The ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 gastric cancer patients, about 39 patients will belong to the targeted group and about 91 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 89% of power. The study on gastric cancer will take 7 months for patient accrual.
62154897|NCT02141152||colorectal cancer|This study will recruit a total of 130 colorectal cancer patients. It is expected to recruit about 300 colorectal cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The median ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 colorectal cancer patients, about 33 patients will belong to the targeted group and about 97 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on colorectal cancer will take about 6 months for accrual.
62154898|NCT02141152||biliary tract cancer/pancreatic cancer|This study will recruit a total of 78 biliary tract cancer/pancreatic cancer patients. It is expected to recruit about 100 biliary tract cancer/pancreatic cancer patients per year. About 20% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 35% for the targeted group and about 5% for the untargeted group. With N=78 biliary tract cancer/pancreatic cancer patients, about 16 patients will belong to the targeted group and about 62 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
62154899|NCT02141152||Rare cancer|Rare cancer is hepatocellular carcinoma, melanoma and neuroendocrine tumor. This study will recruit a total of 87 hepatocellular carcinoma/rare cancer patients. It is expected to recruit about 150 biliary tract cancer/pancreatic cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 30% for the targeted group and about 5% for the untargeted group. With N=87 biliary tract cancer/pancreatic cancer patients, about 22 patients will belong to the targeted group and about 65 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 86% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
62528611|NCT05808075|EXPERIMENTAL|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal Dental Composite will be selected , the tooth will be selectively etched with Phosphoric acid gel (37%) to enamel for 30 seconds .The etchant will be removed and the cavity will be rinsed with water spray for 30 seconds and air dried. A uniform thin layer of the adhesive will be applied on all the prepared surfaces then will be dispersed with a stream of air and then light cured. The restorative material will be applied using an incremental filling technique starting at the gingival wall. The restoration will be cured in 2 mm increments for 20 s. The proximal surfaces will be contoured with finishing strips following manufacturer's instructions. The occlusion will be checked with a thin articulating paper and will be adjusted by removing material with a fine diamond or stone. Finishing will be accomplished by finishing diamond stones then polished using rubber points
62528612|NCT05808075|ACTIVE_COMPARATOR|Tetric N-Ceram Nano-hybrid Dental Composite|The tooth will be selectively etched with N-Etch (IvoclarVivadent, Schaan, Liechtenstein) Phosphoric acid gel (37%) to enamel for 30 seconds. The etchant will be removed and the cavity will be rinsed with water spray for 30 seconds and dried with air syringe. A Uniform thin layer of the adhesive will be applied on all the prepared surface then dispersed with a stream of air and then light cured (Woodpecker Light Cure LED ,China).The restorative material Tetric N-Ceram Nano-hybrid will be applied using an incremental filling technique starting at the gingival wall. Each increment will be polymerized for 20 seconds., Occlusal adjustments will be made using articulating paper. Finishing will be accomplished by finishing diamond then polished using rubber points
62528613|NCT01342107|EXPERIMENTAL|FID 114675A|Contact lens soaked overnight in an investigational multi-purpose disinfecting solution randomly assigned to one eye, with contact lens removed directly from the blister pack assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
62528614|NCT01342107|ACTIVE_COMPARATOR|Blister Pack|Contact lens removed directly from the blister pack randomly assigned to one eye, with contact lens soaked overnight in an investigational multi-purpose disinfecting solution assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
62528615|NCT02551432|EXPERIMENTAL|Paclitaxel pembrolizumab|"* PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,~* Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,~* Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
62528616|NCT03174262|EXPERIMENTAL|Ergonomic Computer Workstation Training|
62528617|NCT03174262|NO_INTERVENTION|Control Group|
62154900|NCT02141152||genitourinary cancer|
62154901|NCT06100406|EXPERIMENTAL|Intervention|"Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected. The description of the intervention has been provided by Biofield Tuning Practitioners and thus describes the practitioner's experience and process while performing the intervention.~For this study, the Biofield Tuning practitioner will be using a hologram of the participant's body since the intervention will be performed remotely. A hologram is when a BT practitioner imagines the body of the participant on the table in front of them. This approach was used successfully for our last feasibility study suggesting an impact of the virtually delivered BT intervention on anxiety."
62154902|NCT06100406|NO_INTERVENTION|Waitlist control|The waitlist control group will complete the same weekly self-report questionnaires outlined in the protocol as the intervention group and weekly audio recordings. Following their one-month follow-up questionnaire, those in the waitlist group will be offered a BT session at no cost.
62528618|NCT02774135||direct occupational therapy intervention|group will be evaluated 4 times: on referral to waiting list for treatment, before and after 9-12 direct individual treatments of 45 minutes, and follow-up after 3 months.
62528619|NCT02452996|ACTIVE_COMPARATOR|6 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
62154903|NCT03349476|EXPERIMENTAL|MFAM|"The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure."
62154904|NCT02301507|EXPERIMENTAL|SMS (texting) Arm|texts received
62528620|NCT02452996|ACTIVE_COMPARATOR|18 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
62154905|NCT04518397|EXPERIMENTAL|Theatre participants|Girls in this arm will participate in the theatre intervention.
62528621|NCT02452996|ACTIVE_COMPARATOR|36 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
62528622|NCT04740814|EXPERIMENTAL|Certolizumab pegol|Subjects in this arm will receive doses of certolizumab pegol for the treatment of Rheumatoid Arthritis, in accordance with the US label.
62713824|NCT04790786|EXPERIMENTAL|Sotrovimab|The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
62154906|NCT04717687|EXPERIMENTAL|Electrodes|Electrodes
62154907|NCT03738826|EXPERIMENTAL|Intervention arm|Lupus clinic providers will use Surescripts refill information to assess adherence level and address adherence barriers. We will assess the feasibility and acceptability of the intervention.
62154908|NCT03240588|EXPERIMENTAL|Boston Scientific SCS Systems (Day 0 Enrollment)|All commercially approved Boston Scientific neurostimulation systems indicated for the treatment of chronic pain, except for Precision™ and Precision™ Plus.
62528623|NCT00446836|OTHER|Single arm|Open label use of Xyotax
62528624|NCT03065426||Roux-en-Y Gastric Bypass|Patients planning to undergo Roux-en-Y Gastric Bypass will be invited to participate in this study.
62713825|NCT04790786|EXPERIMENTAL|Bebtelovimab|The monoclonal antibody of bebtelovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
62154909|NCT03240588|EXPERIMENTAL|Boston Scientific SCS Systems (Day 0 SCS Trial Procedure)|All commercially approved Boston Scientific neurostimulation systems indicated for the treatment of chronic pain.
62528625|NCT03065426||Sleeve Gastrectomy|Patients planning to undergo Sleeve Gastrectomy will be invited to participate in this study.
62528626|NCT04241991|EXPERIMENTAL|Active laser|Each participant will receive the application of the active laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
62154910|NCT03240588|EXPERIMENTAL|Boston Scientific SCS Systems (Day 0 IPG Activation)|All commercially approved Boston Scientific neurostimulation systems indicated for the treatment of chronic pain.
62154911|NCT05497167|EXPERIMENTAL|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
62154912|NCT01151397|ACTIVE_COMPARATOR|Peg + Vitamin D + Ribavirin|Peg + Vitamin D + Ribavirin for 3 months
62154913|NCT01151397|ACTIVE_COMPARATOR|Peg + Ribavirin|Peg + Ribavirin for 6 months
62154914|NCT03070301|EXPERIMENTAL|LEE011 and everolimus|Subjects will receive LEE011 200 mg daily, in combination with everolimus 5 mg daily; in the setting of toxicity, everolimus dosing will be changed to 2.5 mg daily or 2.5 mg every other day. Subjects will continue treatment until meeting one of the criteria for removal from study.
62528627|NCT04241991|PLACEBO_COMPARATOR|Placebo laser|Each participant will receive the application of the placebo laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
62713826|NCT04998851|EXPERIMENTAL|Women with CIS or MS|Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.
62713827|NCT06137365|EXPERIMENTAL|Active|"Cannabis gummy, starting at 2.5 mg THC and increased weekly by 2.5 mg increments up to a maximum target dose of 15 mg THC, administered once daily for duration of 6-month trial participation."
62713828|NCT06137365|PLACEBO_COMPARATOR|Placebo|"Placebo cannabis gummy, containing no active THC, administered once daily for duration of 6-month trial participation."
62154915|NCT05198557|EXPERIMENTAL|MT-0551 group|Participants will receive intravenous (IV) inebilizumab on Day 1 and Day 15 of randomized controlled period (RCP). The participants who entered open label period (OLP) will receive IV inebilizumab on Day 1 and IV placebo on Day 15 of OLP and will be followed by IV inebilizumab every 26 weeks.
62528628|NCT00084032|EXPERIMENTAL|1|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.
62528629|NCT00084032|EXPERIMENTAL|2|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
62713829|NCT04803006|EXPERIMENTAL|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
62713830|NCT04803006|EXPERIMENTAL|Arm 2|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
62713831|NCT05961098|EXPERIMENTAL|RBD1016/placebo 100 mg Q4W group|Participants in the 100 mg Q4W dose group will receive corresponding doses of RBD1016 injection or placebo by subcutaneous injection on D1, D29, D57, and D85.
62713832|NCT05961098|EXPERIMENTAL|RBD1016/placebo 200 mg Q4W group|Participants in the 200 mg Q4W dose group will receive corresponding doses of RBD1016 injection or placebo by subcutaneous injection on D1, D29, D57, and D85.
62713833|NCT05961098|EXPERIMENTAL|RBD1016/placebo 200 mg Q12W group|Participants in the 200 mg Q12W dose group will receive corresponding doses of RBD1016 injection or placebo by subcutaneous injection on D1, and D85.
62528630|NCT01102374|EXPERIMENTAL|High Dose Vitamin D|100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
62713834|NCT04559893|EXPERIMENTAL|Collaborative Care|Intervention is administered to patients in this arm. Care to be delivered via collaborative care.
62154916|NCT05198557|PLACEBO_COMPARATOR|Placebo group|Participants will receive IV placebo on Day 1 and Day 15 of the RCP. The participants who entered OLP will receive IV inebilizumab on both Day 1 and Day 15 in OLP and will be followed by IV inebilizumab every 26 weeks.
62154917|NCT05396755|EXPERIMENTAL|interventional|The intervention group undergoes scheduled invasive evaluation of the biliary tract with endoscopic retrograde cholangiography (ERC) with biliary interventions (i.e. therapeutic ERC) every 8 weeks for 6 months.
62154918|NCT05396755|NO_INTERVENTION|control|The control group receives non-interventional standard of care.
62528631|NCT01102374|ACTIVE_COMPARATOR|Standard Dose Vitamin D|12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
62528632|NCT04270136|EXPERIMENTAL|breast cancer mastectomy|
62528633|NCT02613741|EXPERIMENTAL|Intervention|12 weeks of lifestyle-based physical activity intervention
62528634|NCT02613741|NO_INTERVENTION|Control|12 weeks of no intervention
62528635|NCT03728634|PLACEBO_COMPARATOR|Multiple Dose Cohort: Placebo|Participants received ION-682884 matching placebo, subcutaneously (SC) once every 4 weeks \[Q4W\] (total of 4 doses) along with daily oral supplemental doses of the recommended daily allowance (RDA) of vitamin A during the 13-week Treatment Period.
62528636|NCT03728634|EXPERIMENTAL|Multiple Dose Cohort A: ION-682884 45 mg|Participants received ION-682884, 45 milligrams (mg), SC, Q4W (total of 4 doses) along with daily oral supplemental doses of the RDA of vitamin A during the 13-week Treatment Period.
62528637|NCT03728634|EXPERIMENTAL|Multiple Dose Cohort E: ION-682884 60 mg|Participants received ION-682884, 60 mg, SC, Q4W (total of 4 doses) along with daily oral supplemental doses of the RDA of vitamin A during the 13-week Treatment Period.
62528638|NCT03728634|EXPERIMENTAL|Multiple Dose Cohort B: ION-682884 90 mg|Participants received ION-682884, 90 mg, SC, Q4W (total of 4 doses) along with daily oral supplemental doses of the RDA of vitamin A during the 13-week Treatment Period.
62528639|NCT03728634|PLACEBO_COMPARATOR|Single Dose Cohort: Placebo|Participants received single dose of ION-682884 matching placebo, SC along with daily oral supplemental doses of the RDA of vitamin A on Day 1.
62528640|NCT03728634|EXPERIMENTAL|Single Dose Cohort C: ION-682884 120 mg|Participants received single dose of ION-682884, 120 mg, SC along with daily oral supplemental doses of the RDA of vitamin A on Day 1.
62528641|NCT00356174||Children with food allergy|340 longitudinally followed children with egg and/or milk allergy without elevated peanut specific Immunoglobulin E (IgE), less than 5 kUA/L
62528642|NCT00356174||Full sibling controls for genetic studies|Approximately 250 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for genetic studies.
62528643|NCT00356174||Full sibling controls for mechanistic studies|Approximately 50 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for mechanistic studies. A subset of this cohort will be without food allergy,
62528644|NCT03889067|EXPERIMENTAL|Combination of Challenge Agents|"Wild-Type Quailes Strain Salmonella Typhi: Quailes Typhoid toxin knock out strain in a 1:1 ratio at a dose of 1-5 x 10\^4CFU~All participants will receive the same intervention in a given group for challenge (dose reduction may occur for later participants depending on the results from the first six participants)"
62528645|NCT05418530|ACTIVE_COMPARATOR|with pause- without pause|Start with an expiratory pause during aspiration and after 6hours the aspiration is performed without an expiratory pause
62528646|NCT05418530|ACTIVE_COMPARATOR|without pause - with pause|Start without an expiratory pause during aspiration and after 6hours the aspiration is performed with an expiratory pause
62528647|NCT01429116|EXPERIMENTAL|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
62713835|NCT04559893|NO_INTERVENTION|Control|Patients in this arm will receive enhanced usual care.
62528648|NCT00171301|EXPERIMENTAL|Deferasirox|Deferasirox was given orally once daily (10 to 20 mg/kg) to participants 2 years and older based on participant's body weight.
62528649|NCT02534844|EXPERIMENTAL|Parts A/B: Sham Control|Participants receive no study drug
62528650|NCT02534844|OTHER|Parts A/B: Adrabetadex|Participants receive adrabetadex
62528651|NCT05315635||Epidemiology|"Inpatients who initiate treatment for a substance use disorder (SUD) will have to complete self-questionnaires, a clinical psychiatric assessment (MINI) and a cognitive assessment (MoCA).~These participants will be assessed at admission in addiction unit and at discharge, 3 weeks after withdrawal.~Outpatients who begin treatment for an eating disorder (ED) will have to complete self-questionnaires and a clinical psychiatric assessment (MINI) at the beginning of the outpatient treatment program"
62528652|NCT04645810|EXPERIMENTAL|Experimental: High-Dose-Rate prostate brachytherapy|High-Dose-Rate brachytherapy, 2 fractions
62528653|NCT03305406||Focus Group Participants|Semi-structured focus groups
62528654|NCT03305406||Interview Participants|One-on-one interviews
62528655|NCT06248541|EXPERIMENTAL|Group 1: treatment with low-level laser therapy|Patient gets treated with a low-level laser (wavelength of 620 - 640nm) two times a day for 3 weeks.
62713836|NCT04234828||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings Sleep Device and overnight PSG
62713837|NCT06663501|EXPERIMENTAL|Stroke Intervention|In this arm, the participant will be scheduled to come to the laboratory 2-4 times per week and spend 30 minutes using the Assisted Motion with Enhanced Sensation (AMES) treatment device on the affected side of the upper limb.
62713838|NCT06663501|ACTIVE_COMPARATOR|Uninjured Control Intervention|In this arm the uninjured controls will perform the same interventions as the stroke group. The uninjured control group will perform the tests and interventions with their dominant arm/hand.
62528656|NCT06248541|PLACEBO_COMPARATOR|Group 2: treatment with conventional light diodes|Patient gets treated with conventional light diodes two times a day for 3 weeks.
62528657|NCT01968694|EXPERIMENTAL|IV Lidocaine|IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes
62154919|NCT02676726|EXPERIMENTAL|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
62154920|NCT02676726|ACTIVE_COMPARATOR|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
62154921|NCT05333835|EXPERIMENTAL|HR17031 injection|
62154922|NCT05333835|ACTIVE_COMPARATOR|INS068 injection|
62154923|NCT05333835|ACTIVE_COMPARATOR|SHR20004 injection|
62154924|NCT04314206|EXPERIMENTAL|VNRX-5024|Capsule formulation
62154925|NCT04314206|PLACEBO_COMPARATOR|Placebo|Placebo for VNRX-5024
62154926|NCT03279094|EXPERIMENTAL|Haploidentical stem cell transplantation|
62154927|NCT02751125|EXPERIMENTAL|Augmentation of new alveolar bone|Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)
62154928|NCT04122820|OTHER|Presence of HV-Labile|Presence of vertical heterophoria labile with proprioceptive Maddox
62528658|NCT01968694|PLACEBO_COMPARATOR|IV diphenhydramine|IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes
62528659|NCT03300544|EXPERIMENTAL|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 4, 6, and 8. Patients receive 5-fluorouracil IV by bolus and over 46 hours, leucovorin IV bolus, and oxaliplatin IV over 2 hours on weeks 2 and 4. Patients also receive capecitabine orally PO BID followed by radiation therapy for 28 fractions on days 1-5 of weeks 8-13. Patients undergo resection surgery on weeks 21-25.
62528660|NCT04331561|EXPERIMENTAL|Sensory Re-weighting|Adults with self-reported visually-induced dizziness will be recruited to help establish the feasibility and tolerability of the testing and training methods, as well as observe for any effects of the sensory re-weighting intervention. Tests involve assessing motion sickness, vision, somatosensation, balance, and perception of verticality. The treatment provided is designed to facilitate re-weighting of sensory feedback for orientation and balance. Participants will serve as their own controls.
61975765|NCT02842918|ACTIVE_COMPARATOR|Spinal Manual Therapy|Supine thoracic spine manipulation located between the levels of T4-T7
61975766|NCT02842918|SHAM_COMPARATOR|Spinal Range of Motion|Supine thoracic spine sham manipulation located between the levels of T4-T7; identical procedure as the active treatment intervention but without the delivery of high velocity low amplitude thrust
61975767|NCT03499223|EXPERIMENTAL|Ranibizumab + THR-317|Subjects will receive intravitreal ranibizumab in combination with THR-317
61975768|NCT03499223|ACTIVE_COMPARATOR|Sham + ranibizumab|Subjects will receive a sham injection in combination with intravitreal ranibizumab
61975769|NCT01554423|ACTIVE_COMPARATOR|Testing and Counseling|One of the four RCT arms will be comprised of couples randomly assigned to testing and counseling on HIV and associated STI co-infections based on revised procedures developed by the CDC. Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences. Randomized trial studies of behavioral interventions have incorporated testing and counseling as a comparison condition and studies in the US and SSA countries have shown that testing and counseling on its own can help to reduce HIV/STI risk behaviors.
61975770|NCT01554423|EXPERIMENTAL|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
61975771|NCT01554423|EXPERIMENTAL|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present. The six IFCBT sessions are delivered during a 2-week period with two group couples' sessions and one individual couples' session each week.
61975772|NCT01554423|EXPERIMENTAL|BMI + IFCBT|Participants assigned to this experimental arm will receive Brief Motivational Interviewing combined with Integrated Family and Cognitive Behavioral Therapy.
61975773|NCT06066645|EXPERIMENTAL|iDose TR|Travoprost Intraocular Implant in subjects who had successful iStent infinite placement
61975774|NCT06066645|SHAM_COMPARATOR|sham procedure|Sham surgical procedure in subjects who had successful iStent infinite placement
61975775|NCT02584114|EXPERIMENTAL|Memory training group|The intervention is self-administration of 4 hours of memory training over 4 days per week, for 3 weeks (12 hours total). Memory training will be done with the Peak app for memory training http://www.peak.net.
61975776|NCT02584114|ACTIVE_COMPARATOR|Non-memory training group|The intervention is self-administration of 4 hours of training of games that do not involve memory such as language and card games over 4 days per week, for 3 weeks (12 hours total).
61975777|NCT00708006|EXPERIMENTAL|1|HGS1029
61975778|NCT01306357||Zomacton® with Zomajet® needle-free device|Zomacton® 4 mg delivered by percutaneous transjection (needle-free) using the Zomajet® 2 Vision device or Zomacton® 10 mg delivered by percutaneous transjection (needle-free) using the Zomajet® Vision X needle-free device.
61975779|NCT02311010|NO_INTERVENTION|CYP 3 A 5 *3/*3 control group|CYP 3 A 5 \*3/\*3 control group will receive 0,20 mg/kg of Advagraf®
61975780|NCT02311010|ACTIVE_COMPARATOR|CYP 3 A 5 *3/*3|CYP 3 A 5 \*3/\*3 will receive 0,25 mg/kg of Advagraf®
62528661|NCT05569603|EXPERIMENTAL|Chronobiology-guided lifestyle interventions group|A multimodal program that includes (1) timed bright light therapy, (2)guidance on meal timing, and (3) sleep hygiene education.
62528662|NCT05569603|NO_INTERVENTION|wait-list control group|The participants in the wait-list group will be told that they are on a waiting list during the first 2 weeks to serve as the no-treatment control. Chronobiology-guided lifestyle interventions will be conducted after the posttest is completed.
62528663|NCT05097313|EXPERIMENTAL|consumption of 250 mg of β-glucan|Patients with oral consumption of 250 mg (one capsule) of β-glucan from Yeast Plus once a day for 84 days without interruption.
62528664|NCT05097313|EXPERIMENTAL|consumption of 500 mg of β-glucan|Patients with oral consumption of 500 mg (two capsules) of β-glucan from Yeast Plus once a day for 84 days without interruption.
62528665|NCT05097313|PLACEBO_COMPARATOR|200 mg or 400 mg placebo|Placebo patients, with oral soy protein consumption, half of the group 200 mg (one capsule) and the remaining 400 mg (two capsules) once a day for 84 days without interruption
62528666|NCT00596037|EXPERIMENTAL|LB03002 throughout|administered LB03002 for preceding 26 weeks
62154929|NCT04122820|OTHER|Absence of HV-Labile|Presence of stable vertical heterophoria or stable orthophoria with proprioceptive Maddox
62528667|NCT00596037|EXPERIMENTAL|Switched to LB03002|administered placebo for preceding 26 weeks
62528668|NCT03090607|EXPERIMENTAL|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
62528669|NCT03090607|SHAM_COMPARATOR|Saline|Endoscopic injection of saline
62528670|NCT05571735||TB cohort|"TB cohort - Bacteriologically confirmed TB patients (18 years and above)~One of the following three COVID-19 vaccines will be provided based on availability of supply from the Ministry of public health, Thailand as an intervention for the study."
62528671|NCT05571735||Healthy comparator|"Comparator- Clinically healthy individuals (54 in healthy comparator)~One of the following three COVID-19 vaccines will be provided based on availability of supply from the Ministry of public health, Thailand as an intervention for the study."
62154930|NCT01002586|EXPERIMENTAL|Wii-Fit arm|Half hour daily, five days a week, for 8 weeks
62154931|NCT01002586|ACTIVE_COMPARATOR|Walking arm|Half hour daily, five days a week, for 8 weeks
62528672|NCT05107102||patients with LVR(left ventricular remodeling)|
62528673|NCT05107102||patients without LVR(left ventricular remodeling)|
62528674|NCT02044796|EXPERIMENTAL|Treatment (filgrastim, mitoxantrone, cladribine, cytarabine)|"INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5, mitoxantrone hydrochloride IV over 60 minutes on days 1-3, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi, partial remission, or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.~CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi, patients receive G-CLA comprising filgrastim SC on days 0-5, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62528675|NCT03195153|EXPERIMENTAL|statin only|30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
62528676|NCT03195153|EXPERIMENTAL|allopurinol only|30 DAYS OF ALLOPURINOL (300 MG)
62528677|NCT03195153|EXPERIMENTAL|statin and allopurinol|30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
62528678|NCT05597956|EXPERIMENTAL|white defects|Evaluate the infiltration of the defects.
62528679|NCT05597956|EXPERIMENTAL|yellow defects|Evaluate the infiltration of the defects.
62528680|NCT05597956|EXPERIMENTAL|Brown defects|Evaluate the infiltration of the defects.
62528681|NCT04363840|NO_INTERVENTION|Observation|
62528682|NCT04363840|EXPERIMENTAL|Aspirin 81 mg|
61975781|NCT02311010|ACTIVE_COMPARATOR|CYP 3 A 5 *1/*3|CYP 3 A 5 \*1/\*3 will receive 0,30 mg/kg of Advagraf®
62154932|NCT03210025|EXPERIMENTAL|BF-Methyldopa Tablet 250mg|During the study session, healthy subjects will be administered a single dose of BF-Methyldopa Tablet 250mg after an overnight fast of approximately 10 hours
62154933|NCT03210025|ACTIVE_COMPARATOR|Metopa Tab 250mg|During the study session, healthy subjects administered a single dose of Metopa Tablet 250mg after an overnight fast of approximately 10 hours
62528683|NCT04363840|EXPERIMENTAL|Aspirin + vitamin D|Offered to COVID-19 patients who are vitamin D deficient AND randomized to aspirin
62528684|NCT04509882|EXPERIMENTAL|bear bile pill|Patients randomized to the bear bile pill arm will receive treatment with 15 pills, three times daily of bear bile pill (1350mg per day) plus on-going antidepressant therapy (SSRI/SNRI).
62528685|NCT04509882|PLACEBO_COMPARATOR|placebo|Patients randomized to the placebo arm will receive 15 pills, three times daily of placebo plus on-going antidepressant therapy (SSRI/SNRI).
62528686|NCT05318274|EXPERIMENTAL|ARM I|Radiotherapy treatment with high hypofractionation, 26 Gy in 5 fractions to the whole breast.
61975782|NCT02311010|ACTIVE_COMPARATOR|CYP 3 A 5 *1/*1|CYP 3 A 5 \*1/\*1 will receive 0,35 mg/kg of Advagraf®
61975783|NCT01589744|EXPERIMENTAL|Suction cup Hemostatic Intra-Uterin|The suction haemostatic cup will be positioned into the uterus, and the aim is to stop haemorrhage
62528687|NCT05318274|ACTIVE_COMPARATOR|ARM II|Radiotherapy treatment with standard hypofractionation, 42.5 Gy in 16 fractions with simultaneous integrated increase of 5.5 Gy to the tumor bed in high-risk patients.
62528688|NCT00070057|EXPERIMENTAL|Arm I (celecoxib)|Patients receive oral celecoxib twice daily for 1-3 weeks (according to the duration between biopsy and surgery) in the absence of unacceptable toxicity.
62528689|NCT00070057|EXPERIMENTAL|Arm II (high-dose celecoxib)|Patients receive a higher dose of oral celecoxib as in arm I.
62528690|NCT00070057|ACTIVE_COMPARATOR|Arm III (surgery)|Patients do not receive treatment. All patients undergo surgery.
62528691|NCT06387485|ACTIVE_COMPARATOR|Standard Imaging|Participants in this arm will undergo tumor excision with prior planning utilizing only Imaging (CT or MRI) without development of a 3D printed model
62528692|NCT06387485|EXPERIMENTAL|3D Printed Anatomic Model|Participants in this arm will have tumors excised with prior planning utilizing 3D printed models and Imaging (CT or MRI).
62528693|NCT03277482|EXPERIMENTAL|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab\* and radiation therapy~\*q4 weeks durvalumab for 13 cycles or until progression"
62528694|NCT03277482|EXPERIMENTAL|Phase I Radiation Dose Evaluation|"* Durvalumab~* Tremelimumab\* -- Start radiation dose from safety lead-in (level 0 or level -1) \*q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
62528695|NCT00463242|EXPERIMENTAL|Agomelatine|Dosing for each subject in this extension study began with the same dose (25 mg or 50 mg of agomelatine orally once daily) the subject was receiving at the end of Week 8, the week before this study began.
62528696|NCT00463242|ACTIVE_COMPARATOR|2|
62528697|NCT00463242|PLACEBO_COMPARATOR|3|
62528698|NCT02239341|ACTIVE_COMPARATOR|Music Intervention (M)|The M intervention will be 30 minutes (same amount of time as E group), but the participants will simply be listening to the same music in bed with no exercise component. They will be wearing the heart rate monitor as in the E group. The M group will act as a control group for the E group.
62528699|NCT02239341|EXPERIMENTAL|Muscle Conditioning Intervention (E)|E (exercise) is 30 minutes in length and will consist of 5 minutes of warm-up, 20 minutes of light strengthening exercises using a theraband, and 5 minutes of cool-down. All exercises will be completed in bed. Each participant will be listening to the same music (as the M group) during exercise. A heart rate monitor will be worn throughout each session. The first session for each participant will be used to complete baseline measurements and to assess initial muscle strength. Difficulty level will be adjusted by using different strength therabands.
62713839|NCT05990244|EXPERIMENTAL|Diagnostic (MRE, tumor grade, tumor stiffness and adhesion)|"Patients undergo a preoperative routine MRI scan and MRE the day before their scheduled surgery to assess tumor stiffness and adhesion. Additionally, molecular pathological analysis will be performed to identify genetic alterations in gliomas. During surgery, the tumor stiffness and adhesion will be assessed and recorded by the surgeon according to established evaluation criteria.~It is important to note that the surgeon does not have prior knowledge of the tumor's specific stiffness before the surgery. This information is typically obtained through intraoperative assessment and observation."
62154934|NCT03771261|PLACEBO_COMPARATOR|WL-Control|Weight loss intervention (WL-Control; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein\~0.8g/g/d.
62528700|NCT05525793|EXPERIMENTAL|Transitional care|This group is the actual intervention group.
62528701|NCT05525793|NO_INTERVENTION|Usual care|This group is the routine treatment (control) valid in the clinical practice.
62528702|NCT03059004|EXPERIMENTAL|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
62528703|NCT03059004|EXPERIMENTAL|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
62528704|NCT03059004|EXPERIMENTAL|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
62528705|NCT03059004|EXPERIMENTAL|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
62528706|NCT06085118||Patient|Infants up to and including 8 months of age (up to 8 months and 29 days), treated for a suspected or confirmed cow protein allergy.
62528707|NCT03000335||Relapse|B-ALL patients who have succumbed to relapse
62528708|NCT03000335||Remission|B-ALL patients who are in remission
62528709|NCT00714961|EXPERIMENTAL|1|
62528710|NCT00714961|PLACEBO_COMPARATOR|2|
62528711|NCT02229123|EXPERIMENTAL|Intravenous levetiracetam|1 loading dose of 30, 40 or 50 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.
62528712|NCT05738759|EXPERIMENTAL|Epidural Anesthetic Cocktail|Patients which received epidural anesthetic cocktail following endoscopic discectomy
62528713|NCT05738759|PLACEBO_COMPARATOR|Placebo|Patients which received placebo following endoscopic discectomy
62528714|NCT01080443|ACTIVE_COMPARATOR|Cellcept® 250 mg Capsule|
62528715|NCT01080443|EXPERIMENTAL|Mycophenolate Mofetil Capsule 250 mg|
62528716|NCT06514690||Patients intubated by fiberoptic bronchoscope|Fiberoptic bronchoscopy involves the introduction of a flexible tube (bronchoscope) through the nose that has a light and a video camera at its tip. It allows directing the orotracheal tube into the airway.
62154935|NCT03771261|ACTIVE_COMPARATOR|WL-Protein|High-protein weight loss intervention (WL-Protein; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of \> 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from eggs or egg protein powder that will be provided to WL-Protein participants.
62154936|NCT05843149|EXPERIMENTAL|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
62528717|NCT06514690||Patients intubated by videolaryngoscopy|The videolaryngoscopy allows tracheal intubation by introducing a laryngoscope and visualizing the glottis on an external display.
62528718|NCT02349243|EXPERIMENTAL|entacapone|An approach of 200mg entacapone at a time and 4 times a day(0.5 hour after every breakfast, lunch and supper and at 0.5 hours before bedtime) is adopted. Every participant is required to record his/her diet, exercise, and drug intake condition in a standard record card which is provided by the researchers.
62528719|NCT02349243|PLACEBO_COMPARATOR|placebo|Except for taking the placebo rather than the entacapone, any intervention in the placebo group is the same with that in the entacapone group.
62528720|NCT00923000|EXPERIMENTAL|Nubian with Long dan xie gan tang 3g|
62528721|NCT00923000|ACTIVE_COMPARATOR|Nalbuphine|
62528722|NCT00923000|ACTIVE_COMPARATOR|Morphine|
62528723|NCT00923000|EXPERIMENTAL|Morphine with Long dan xie gan tang|
62154937|NCT05843149|EXPERIMENTAL|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
62528724|NCT00923000|EXPERIMENTAL|Nubian with Long dan xie gan tang 3g tid|
62528725|NCT03106649|EXPERIMENTAL|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
62528726|NCT03106649|NO_INTERVENTION|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
62528727|NCT03178565|EXPERIMENTAL|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
62528728|NCT03178565|ACTIVE_COMPARATOR|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
62528729|NCT02095808|EXPERIMENTAL|Surgery|"The 13C-glucose solution will be given intravenously. It will be started at about the same time as the start of surgery, according to the study guidelines.~The 13C-glucose IV solution will be stopped once the surgeon has removed the tumor tissue."
62528730|NCT03822832|EXPERIMENTAL|Spesolimab|i.v.
62528731|NCT03822832|PLACEBO_COMPARATOR|Placebo|i.v.
62528732|NCT04060043|EXPERIMENTAL|Goserelin acetate Injection|Pepti 10.8mg is a generic formulation of Zoladex® 10.8mg, with the same ingredients (active and excipients), the same formulation, the same dosage, the same size and route of administration.
62528733|NCT02276014|OTHER|Supplement A|Beta-carotene 7mg formulation A
62528734|NCT02276014|OTHER|Supplement B|Beta-carotene 7mg formulation B
62528735|NCT02276014|OTHER|Supplement C|Beta-carotene 7mg formulation C
62528736|NCT05280132|EXPERIMENTAL|Personalized strategy|"Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.~A broad panel respiratory mPCR FA-PPP is performed on a respiratory tract sample collected 12 hours after inclusion.~After inclusion (D0), an algorithm of early antibiotic adaptation and discontinuation will be applied immediately and repeated every day until day 7.~This algorithm of early antibiotic adaptation and discontinuation is based on a multimodal approach, using:~* The appearance of sputum (clinical approach);~* PCT values and kinetics (biological approach);~* Results of mPCR FA-PPP (microbiological approach)."
62528737|NCT05280132|OTHER|Usual strategy|"Usual antibiotic treatment~Left at the discretion of the physician as in usual practice"
62528738|NCT02264288|EXPERIMENTAL|3 x 10^6 cells|Human Placenta Derived cells (PDA-002) administered intramuscularly (IM) on Study Days 1 and 8
62528739|NCT02264288|EXPERIMENTAL|10 x 10^6 cells|10 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
62528740|NCT02264288|EXPERIMENTAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
62528741|NCT02264288|PLACEBO_COMPARATOR|Placebo|Identically matching placebo administered IM on Study Days 1 and 8
62528742|NCT02858492|EXPERIMENTAL|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
62528743|NCT02858492|EXPERIMENTAL|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
62528744|NCT04146311|ACTIVE_COMPARATOR|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) is injected into the left infrapatellar fat pad.
62528745|NCT04146311|PLACEBO_COMPARATOR|Isotonic saline|A bolus injection (0.25 ml) of isotonic saline (0.9 %) is injected into the left infrapatellar fat pad.
62528746|NCT04146311|EXPERIMENTAL|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
62528747|NCT01939496|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
62528748|NCT01939496|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
62528749|NCT01939496|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo once daily for 6 weeks.
62528750|NCT06434077|EXPERIMENTAL|CGMAF group|GcMAF injections (100 ng)
61975784|NCT04041804|ACTIVE_COMPARATOR|Every week RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every week until getting the require expansion needed
61975785|NCT04041804|ACTIVE_COMPARATOR|Every four days RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every four days until getting the require expansion needed
62528751|NCT06434077|PLACEBO_COMPARATOR|placebo group|placebo injections (100 ng)
61975786|NCT03886376|EXPERIMENTAL|Deep Massage|The deep massage was performed three times during a training week, after a physical training and before the swimming training
61975787|NCT03886376|ACTIVE_COMPARATOR|Superficial Massage|The superficial massage was performed three times during a training week, after a physical training and before the swimming training
61975788|NCT03886376|NO_INTERVENTION|Control|The control group kept their normal routine of training. Immediately after the physical training the athletes were instructed to wait for 12 minutes (passive recovery) until the beginning of the swim training.
61975789|NCT05199298|EXPERIMENTAL|"Mandala Activity-Based Breastfeeding Program"|The group receiving Mandala Activity-Based Breastfeeding Program
61975790|NCT05199298|NO_INTERVENTION|Control group|the group that did not receive any training/initiative
61975791|NCT03487029|EXPERIMENTAL|short duration group|30sn %100 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
61975792|NCT03487029|EXPERIMENTAL|long duration group|4dk %85 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
61975793|NCT02278588||PD-R|Parkinson's disease receiving rasagiline
61975794|NCT02278588||PD-NMAO|Parkinson's disease not receiving any MAO-B inhibitors
61975795|NCT02278588||HC|Healthy Controls
61975796|NCT02237859|EXPERIMENTAL|Vancomycin|Vancomycin 125 mg PO QD vs Placebo
62528752|NCT00706511|EXPERIMENTAL|Group with OSA|Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
62528753|NCT00706511|NO_INTERVENTION|Group without OSA|Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol
62528754|NCT04505137|EXPERIMENTAL|GMA301 1500mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 1500 mg single Intravenous dose of GMA301 Injection.
62528755|NCT04505137|EXPERIMENTAL|GMA301 2000mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 2000 mg single intravenous dose of GMA301 Injection.
62154938|NCT05843149|NO_INTERVENTION|Waiting List|Study arm 3 consists of a waiting list control group, combined with the offer to participate in one of the above mentioned interventions after 6 months.
62528756|NCT03370809|EXPERIMENTAL|patients over 75 years old with cancer discovery|Elderly patients with cancer have a 18F-FDG PET whole body performed routinely in the initial assessment . A cerebral recording is added 45 minutes after the 18F-FDG injection and just before the registered whole body
62528757|NCT01697566|EXPERIMENTAL|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
62528758|NCT01697566|EXPERIMENTAL|Placebo + Lifestyle Intervention|Placebo taken by mouth twice daily for 4, 30 day cycles. Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
62528759|NCT01697566|EXPERIMENTAL|Metformin + Lifestyle Intervention|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.~Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period."
62528760|NCT01697566|PLACEBO_COMPARATOR|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
62154939|NCT00648466|EXPERIMENTAL|1|Sumatriptan Succinate Tablets 100 mg
62154940|NCT00648466|ACTIVE_COMPARATOR|2|Imitrex® Tablets 100 mg
62528761|NCT05134506|EXPERIMENTAL|Dance for PD® classes|Dance for PD® was developed by the Brooklyn Parkinson Group (BPG) in collaboration with the Mark Morris Dance Group (MMDG) in 2001. It was designed to introduce people with PD to techniques used by dancers to control movement and it integrates different dance genres while participants dance individually and in groups rather than partnered.
62528762|NCT04642937|EXPERIMENTAL|hP1A8|Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
62528763|NCT02586142|EXPERIMENTAL|Botulinum toxin type A(BTX-A) injection|To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.
62528764|NCT02586142|ACTIVE_COMPARATOR|BTX-A injection plus stretching exercise|Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.
62528765|NCT01593696|EXPERIMENTAL|Lymphodepleting regimen of Fludarabine and Cyclophosphamide|Lymphodepleting regimen of Fludarabine and Cyclophosphamide.
62528766|NCT01593696|EXPERIMENTAL|Intensive standard of care chemotherapy|Intensive standard of care chemotherapy, in lieu of the lymphodepleting chemotherapy regimen, to decrease tumor burden in preparation for the administration of the Chimeric antigen receptor (CAR) T cells.
62528767|NCT00960115|EXPERIMENTAL|Tecemotide (L-BLP25) + Cyclophosphamide|Active
62154941|NCT02953249||Study group|The study group will include 30 subjects with type 1 diabetes mellitus who require extraction of 1 or more erupted teeth
62154942|NCT02953249||Control group|The control group will include 30 healthy subjects, without diabetes mellitus, in need of tooth extraction
62154943|NCT04750902|ACTIVE_COMPARATOR|0.24% Sodium Fluoride Dentifrice|Toothpaste
62154944|NCT04750902|EXPERIMENTAL|1.5% Arginine Dentifrice|Toothpaste
62154945|NCT04750902|EXPERIMENTAL|4.0% Arginine Dentifrice|Toothpaste
62154946|NCT04750902|EXPERIMENTAL|8.0% Arginine Dentifrice|Toothpaste
62154947|NCT01344889||Cohort|
62154948|NCT01753440|OTHER|Stem cells implantation|Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF ≤40% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age \<75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF ≤40 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization.
62528768|NCT00960115|PLACEBO_COMPARATOR|Placebo + Saline|Control
62528769|NCT04549714|EXPERIMENTAL|High AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
62528770|NCT04549714|EXPERIMENTAL|Middle AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
62528771|NCT04549714|EXPERIMENTAL|Low AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
62528772|NCT01943721|EXPERIMENTAL|VISION5 Product|VISION5 Product in both eyes
62154949|NCT01692652|EXPERIMENTAL|Lotemax with warm compress group|topical loteprednol etabonate (lotemax 0.5%) qid and warm compress \& ocular massage (a minimum of four times, once or twice a daily) for 2months
62154950|NCT01692652|ACTIVE_COMPARATOR|warm compress only group|warm compress only group
62154951|NCT05496829|EXPERIMENTAL|Adherence Intervention|Multicomponent Adherence Intervention
62154952|NCT05496829|OTHER|Usual Care|Usual Care from treating providers
62154953|NCT04913194|EXPERIMENTAL|Immediate Treatment|Participants in this arm will receive the intervention within 2 weeks of completing the intake session.
62154954|NCT04913194|OTHER|Waitlist Control|Participants in this arm will not receive any intervention for two weeks. Participants will complete the treatment after 4-6 weeks of being on the waitlist after their intake session.
62154955|NCT03471637|EXPERIMENTAL|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]"
62154956|NCT01728857|EXPERIMENTAL|Fat Reduction|
62154957|NCT05860894|EXPERIMENTAL|Implantable ECG holter device|Adult patients with new onset atrial fibrillation occuring in the ICU will be implanted with an implantable ECG holter device (Biomonitor3, Biotronik) to monitor arrhythmia episodes up to 2 years after ICU discharge.
62154958|NCT06378320|EXPERIMENTAL|Maternal participants nudge group|"Participants in the app nudge group receive access to the app and questions with app cues by text weekly prior to delivery and biweekly (every 2 weeks) after delivery through 3 months postpartum."
62154959|NCT06378320|OTHER|Maternal participants no nudge group|"Participants in the app no nudge group receive access to the app and no questions with app cues through 3 months postpartum."
62154960|NCT06378320|EXPERIMENTAL|Father/partner participants nudge group|"Participants in the app nudge group receive access to the app and questions with app cues by text weekly for the first 2 months and then biweekly (every 2 weeks) for another 2 months."
62528773|NCT04365114||Single reading|Only one clinician examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
62528774|NCT04365114||Double reading|Two clinicians examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
62528775|NCT00661141|EXPERIMENTAL|Cohort 1: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
62528776|NCT00661141|EXPERIMENTAL|Cohort 2: Antizol 3.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
62528777|NCT00661141|EXPERIMENTAL|Cohort 3: Antizol 5.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
62528778|NCT00661141|EXPERIMENTAL|Cohort 4: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
62528779|NCT03253211||State|North Carolina
62528780|NCT03253211||SCD Patients|
62528781|NCT03253211||Providers|Primary care and emergency department clinicians
62528782|NCT03253211||Year|Baseline, year 2, year 3
62528783|NCT04432103|EXPERIMENTAL|Severe COVID-19 pneumonia|Hospitalized patients with SARS-CoV 2 severe infection will receive an anti SARS-CoV 2 Convalescent Plasma
62528784|NCT04432103|EXPERIMENTAL|Critical COVID- 19 pneumonia|Hospitalized patients with SARS-CoV 2 critical infection will receive an anti SARS-CoV 2 Convalescent Plasma
62154961|NCT06378320|OTHER|Father/partner participants no nudge group|"Participants in the app no nudge group receive access to the app and no questions with app cues for 4 months."
62528785|NCT02116426||The study population|"The study population includes all adult patients taken in charge by the emergency ambulance services of the participating centers for non-traumatic chest pain for suspected Acute Coronary Syndrome (ACS) without ST segment elevation.~Intervention: Blood work in the ambulance Intervention: Blood work upon arrival in the emergency room Intervention: Blood work at 3 hours post-arrival in the emergency room"
62528786|NCT03320200|EXPERIMENTAL|CNS-focused treatment|Group of subjects receiving a 10 week CNS (Central Nervous System) -focused treatment program for frozen shoulder in addition to 5 days per week home treatment program
62528787|NCT03320200|EXPERIMENTAL|Standard Care Treatment|Group of subjects receiving a 10 week standard care treatment program for frozen shoulder in addition to 5 days per week home treatment program based on conventional physiotherapy
62713840|NCT03928925|ACTIVE_COMPARATOR|BOUGIE|"For patients randomized to use of a bougie, the operator will use a bougie on the first attempt at intubation. If successful, an assistant will load an endotracheal tube over the bougie, and the operator (without removing the laryngoscope from the mouth) will guide the tube through the vocal cords to the desired depth in the trachea.~If the bougie is not successfully placed in the trachea or the endotracheal tube cannot be successfully advanced over the bougie on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
62154962|NCT00233142|EXPERIMENTAL|Expressive writing|Expressive writing
62154963|NCT00233142|SHAM_COMPARATOR|Neutral writing|Non-expressive writing
62154964|NCT05333276|EXPERIMENTAL|TQB3602 Capsule + AK105 Injection|TQB3602 capsule administered orally on day 1, 8 in 21-day cycle; every three weeks intravenous (IV) for one times of AK105 injection.
62154965|NCT02354144|EXPERIMENTAL|Carrageenan-based gel|"The intervention to be administered is:~* a commercially available gel that contains carrageenan.~* water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.~* also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
62528788|NCT05577143||Case group|All consecutive patients from participating centers with an abnormal colonoscopy (presence of mucosal lesions at endoscopy), with histological confirmation of colorectal cancer. These will be patients with one or more histologically confirmed adenocarcinomatous lesions (CRC+) located in the colonic frame or rectum, with or without synchronous liver metastases.
62528789|NCT05577143||Control group|All consecutive patients between 50 and 75 years of age for whom colonoscopy will be normal (no mucosal lesions). In this situation, histological examination is not performed.
62528790|NCT05577143||Polyp group|All consecutive patients for whom colonoscopy shows mucosal lesions that will be classified as polyps after histological examination.
62528791|NCT04161846|EXPERIMENTAL|Virtual World Program|Participants take part in a group training delivered using a virtual world approach.
62528792|NCT04161846|ACTIVE_COMPARATOR|In Person Program|Participants take part in a group training delivered using an in person approach.
62528793|NCT01777360|EXPERIMENTAL|THERMOPLASTY|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
62713841|NCT03928925|ACTIVE_COMPARATOR|Endotracheal Tube with Stylet|"For patients randomized to use of an endotracheal tube with stylet, the operator will use an endotracheal tube containing a removeable, malleable stylet, on the first attempt at intubation.~Manipulation of the shape/curve of the endotracheal tube with stylet is at the discretion of the operator, however a straight-to-cuff shape and a bend angle of 25° to 35° is encouraged. The stylet will be left in place until the tube is advanced to the trachea.~If the endotracheal tube with stylet is not successfully placed in the trachea on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
62154966|NCT02354144|PLACEBO_COMPARATOR|Control gel|"The intervention to be administered is:~* a commercially available gel that does not contain carrageenan.~* water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.~* also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
62528794|NCT02352545|EXPERIMENTAL|Experimental: Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
62154967|NCT01818999|EXPERIMENTAL|arm one|IXABEPILONE and STEREOTACTIC BODY RADIATION THERAPY (SBRT)
62154968|NCT02486107||PECD|percutaneous endoscopic cervical foraminotomy
62154969|NCT02486107||MTPF|microscopic tubular retractor assisted foraminotomy
62154970|NCT02486107||ACDF|anterior cervical discectomy and fusion
62154971|NCT04502459|ACTIVE_COMPARATOR|Cement only|The tourniquet was inﬂated just before cement application and deﬂated after its hardening
62154972|NCT04502459|ACTIVE_COMPARATOR|Skin to Cement|Inﬂation of tourniquet before skin incision and its deﬂation after hardening of cement
62154973|NCT04502459|ACTIVE_COMPARATOR|Skin to Skin|Inflate of tourniquet before incision and deflate following completion of skin closure
62154974|NCT03694145||Diabetic patients w. risk of retinopathy|The 300-500 patients to be enrolled for the study are diabetic patients normally seen by the Los Angeles County Department of Health Services (LACDHS) Teleretinal Diabetic Retinopathy Screening Program and Reading Center. In addition to receiving their recommended LACDHS annual teleretinal screening, for the study, participants will receive an additional in-person eye examination.
62154975|NCT01017159|ACTIVE_COMPARATOR|Subcutaneous immunoglobulin|
62154976|NCT01017159|PLACEBO_COMPARATOR|Saline|
62154977|NCT04620265|EXPERIMENTAL|Treadmill training 100%|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
62154978|NCT04620265|EXPERIMENTAL|Treadmill training 75%|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
62154979|NCT04620265|EXPERIMENTAL|Treadmill training 50%|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
62154980|NCT04620265|EXPERIMENTAL|Treadmill training 25%|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
62154981|NCT04620265|SHAM_COMPARATOR|Conventional program|This group received the conventional exercise program only.
62154982|NCT05150652|EXPERIMENTAL|Neoadjuvant Endocrine Therapy|Participants will begin treatment with Anastrozole. If not tolerated well, participants will discontinue and begin treatment using Letrozole. If not tolerated well, participants will discontinue and begin treatment using Exemestane. If not tolerated well, participants will discontinue and begin treatment on Tamoxifen.
62154983|NCT02721147|EXPERIMENTAL|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
62154984|NCT02721147|ACTIVE_COMPARATOR|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
62154985|NCT01654198||Psoriatic arthritis|
62154986|NCT05470465|PLACEBO_COMPARATOR|Treatment A: Placebo|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
62154987|NCT05470465|EXPERIMENTAL|Treatment B: Paroxetine|Participants will receive paroxetine on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
62528795|NCT02352545|PLACEBO_COMPARATOR|Placebo Comparator|Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
62528796|NCT01094418||IGT group|IGT diagnosed by endocrinologist
62154988|NCT05470465|EXPERIMENTAL|Treatment C: Escitalopram|Participants will receive escitalopram on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
62154989|NCT02733731|EXPERIMENTAL|Chinese Herbal Compound Ointment|This kind of CHCO composed of several chinese herbs,dong quai,angelica,resina draconis and lithospermum.The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks.
62154990|NCT02733731|ACTIVE_COMPARATOR|Estriol|The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks in two groups.
62154991|NCT06339788|EXPERIMENTAL|HD-P023|One tablet of HD-P023 by oral
62154992|NCT06339788|ACTIVE_COMPARATOR|Co-administration of Teneligliptin and Empagliflozin High|One tablet each of Teneligliptin and Empagliflozin High by oral
62154993|NCT03200509|EXPERIMENTAL|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
62154994|NCT03200509|SHAM_COMPARATOR|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
62154995|NCT03717935|EXPERIMENTAL|Essential Amino Acid (EAA) Supplement|4 weeks: Essential Amino Acid Supplement- 15g 2/day
62528797|NCT01094418||DM group|DM diagnosed by endocrinologist and whose primary NCS screening shows SNAP amplitudes of sural and superficial peroneal nerves greater than 10mA DM patients with no previous diagnosis of peripheral polyneuropathy
62528798|NCT01094418||Normal healthy participants|Normal health participants with no previous history of DM, IGT, thyroid disorder, hypercholesterolemia, or other condition associated with peripheral polyneuropathy
62528799|NCT00698893|EXPERIMENTAL|Group A|
62713842|NCT05127941||Patient group|Patients under effective anticoagulation with rivaroxaban or apixaban and treated with andexanet alfa
62528800|NCT00698893|EXPERIMENTAL|Group B|
62528801|NCT06156735|EXPERIMENTAL|Passive Music Therapy (P)|The therapist read a standardized relaxation script in the research participant's selected preferred language while improvising on the keyboard. The script was inclusive of deep breathing and imagining a positive image. The research participants were asked to close his or her eyes while relaxing and imagining. The entire intervention lasted approximately 15 minutes. The research participants were allowed to request to stop the intervention at any time
62713843|NCT04095234|EXPERIMENTAL|Acupuncture|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
62713844|NCT04095234|ACTIVE_COMPARATOR|Massage|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
62154996|NCT03717935|PLACEBO_COMPARATOR|Placebo|4 weeks: Placebo- 15g 2/day
62154997|NCT01581333|EXPERIMENTAL|Experimental Arm|Empirical antimicrobial treatment discontinuation
62154998|NCT01581333|ACTIVE_COMPARATOR|Control Arm|Standard empirical antimicrobial treatment discontinuation
62154999|NCT03810911|ACTIVE_COMPARATOR|Early start|Participants given study drug immediately at randomization
62155000|NCT03810911|NO_INTERVENTION|Delayed start|Participants given study drugs 12 weeks after randomization
62155001|NCT06298747||Selective cervical nerve root pulsed radiofrequency|A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root with a current of 1.0-1.2 V at a frequency of 2 Hz for 4 minutes at 42 °C.
62155002|NCT02635399|PLACEBO_COMPARATOR|conventional group|Conventional PPPD
62528802|NCT06156735|EXPERIMENTAL|Active Music Therapy (A)|The research participants were given a standardized assortment of percussion instruments to choose from. The therapist provided instructions of playing instruments along with the therapist. The research participant was allowed to change his or her instrument at any time and was advised to sing along with the therapist. Based on the research participant's age, the therapist selected the songs to sing and accompany on either the guitar or the keyboard. The duration of the intervention was approximately 15 minutes, which allowed about five to six songs to be sung. The research participants were allowed to request to repeat or skip any of the songs at any time.
62528803|NCT06156735|ACTIVE_COMPARATOR|Standard Care Control Condition (C)|The control condition involved mundane activities such as chatting, resting, or reading magazines, with the MT, in the treatment room.
62528804|NCT02074748||Bunion|Patients being treated for foot bunion with surgery.
62528805|NCT02074748||Controls (normal foot)|Participants in this group will not undergo surgery.
62528806|NCT06295848|EXPERIMENTAL|Cardiac Rehabilitation|The CR group will receive training for CVD and HT once a week, along with a rehabilitation program consisting of aerobic, resistance, flexibility and stretching exercises 3 days a week for 6 weeks.
62528807|NCT06295848|NO_INTERVENTION|Control|Control group will receive treatment for their RA that is considered standard of care treatment (e.g. pharmacotherapy), but will not be participated in the CR program.
62155003|NCT02635399|EXPERIMENTAL|DJ-pexy group|PPPD with additional DJ-pexy to anchor DJ to transverse colon
62155004|NCT03823794||Prevalent case of atopic dermatitis|People with atopic dermatitis meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
62528808|NCT03009916|OTHER|Healthy controls|Healthy controls found according to the protocol
62713845|NCT04445909||VA-ECMO patients|VA-ECMO support because of low cardiac output.
62713846|NCT05373485|EXPERIMENTAL|Vaccine Group, low dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
62713847|NCT05373485|EXPERIMENTAL|Vaccine Group, low dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
62713848|NCT05373485|EXPERIMENTAL|Vaccine Group, high dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
62528809|NCT03009916|OTHER|Patients with BAM|Patients with bile acid malabsorption found according to the protocol
62155005|NCT03823794||Controls|Age, gender and primary care practice-matched controls without a diagnosis of atopic dermatitis or another exclusion condition (psoriasis, photodermatitis, or ichthyosis) and registered with one of the study practices for one or more years during the study period.
62155006|NCT03543982|EXPERIMENTAL|Oral probiotic product|
62713849|NCT05373485|EXPERIMENTAL|Vaccine Group, high dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
62155007|NCT01434355||Correlative studies|Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
62528810|NCT00893737|EXPERIMENTAL|Treximet|Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.
62528811|NCT01216696|EXPERIMENTAL|Intervention|"Intervention Details:~Drug: ipilimumab~Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first."
62528812|NCT03214874|ACTIVE_COMPARATOR|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
62155008|NCT04967014|EXPERIMENTAL|Sequence A|Period I : RLD2104 Period II : HIP2104
62155009|NCT04967014|EXPERIMENTAL|Sequence B|Period I : HIP2104 Period II : RLD2104
62155010|NCT00355784|OTHER|Control|9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \</- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate \~4000 kcal/day and their plasma growth hormone concentration was allowed to decline naturally.
62155011|NCT00355784|EXPERIMENTAL|Growth Hormone Treatment|8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \</- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate \~4000 kcal/day and received exogenous growth hormone treatment administered in 4 daily injections to mimic physiological growth hormone secretion throughout the 2-week overeating period.
62155012|NCT00355784|EXPERIMENTAL|High Growth Hormone Treatment|5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \</- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate \~4000 kcal/day and received a relatively high daily dose of growth hormone.
62155013|NCT01765023|EXPERIMENTAL|Part A|single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
62528813|NCT03214874|EXPERIMENTAL|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
62528814|NCT01604590||glioblastoma patients on bevacizumab|
62528815|NCT01319773|EXPERIMENTAL|cyclosporine ophthalmic emulsion Formulation A (Formulation A)|Parallel-Group Phase (PGP): cyclosporine ophthalmic emulsion Formulation A
62528816|NCT01319773|EXPERIMENTAL|cyclosporine ophthalmic emulsion Formulation B (Formulation B)|PGP: cyclosporine ophthalmic emulsion Formulation B
62713850|NCT05373485|PLACEBO_COMPARATOR|Placebo Group, low dose, 18-59 year-old|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
62713851|NCT05373485|PLACEBO_COMPARATOR|Placebo Group, low dose, 60 year-old and above|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
62713852|NCT05373485|PLACEBO_COMPARATOR|Placebo Group, high dose, 18-59 year-old|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
62713853|NCT05373485|PLACEBO_COMPARATOR|Placebo Group, high dose, 60 year-old and above|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
62713854|NCT05270876|OTHER|Study cohort|Recipients of cochlear implant or suitable for implantation Interrupted time series: recipients received standard and novel fitting method
62713855|NCT00427193|EXPERIMENTAL|Caloric Restriction (CR)|25% caloric restriction
62713856|NCT00427193|ACTIVE_COMPARATOR|Control, Ad libitum (AL)|Ad libitum energy intake
62713857|NCT03612024||request for organ donation approved|
62713858|NCT03612024||request for organ donation rejected|
62155014|NCT01765023|EXPERIMENTAL|Part B|single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
62155015|NCT00564447|EXPERIMENTAL|Azithromycin-30 minutes Post dose|
62155016|NCT00564447|EXPERIMENTAL|Azithromycin-2 hours post dose|
62155017|NCT00564447|EXPERIMENTAL|Azithromycin-12 hours post dose|
62155018|NCT00564447|EXPERIMENTAL|Azithromycin-24 hours post dose|
62155019|NCT00564447|EXPERIMENTAL|Moxifloxacin-30 minutes post dose|
62528817|NCT01319773|OTHER|Formulation A and cyclosporine ophthalmic emulsion 0.05%|Paired-Eye Phase (PEP): cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion 0.05%
62528818|NCT01319773|OTHER|Formulation B and cyclosporine ophthalmic emulsion 0.05%|PEP: cyclosporine ophthalmic emulsion Formulation B and cyclosporine ophthalmic emulsion 0.05%
62528819|NCT01319773|EXPERIMENTAL|Formulation A and Formulation B|PEP: cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion Formulation B
62528820|NCT01753947|EXPERIMENTAL|Deliberate Practice|Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.
62713859|NCT05460182|EXPERIMENTAL|CAF+CTG|"After local anaesthesia, a split-full-split thickness flap was elevated. The papillae adjacent to the involved tooth were then de-epithelialized. A gentle root debridement was performed.~A 1-2-mm-thick CTG was harvested using a single incision approach from the palate in the area between the second pre-molar and the second molar. The wound on the donor site of the palate was then sutured. The graft was positioned on the instrumented root surface immediately apical or at the level of the CEJ and then stabilized using a compressive crossing suture, anchored to the periosteum apical to the graft and closed with a palatal knot. The flap was coronally displaced 1-2 mm above the CEJ and sutured"
62528821|NCT01753947|NO_INTERVENTION|Conventional Feedback|Residents in the control group received informal feedback as they performed the initial laparoscopic cholecystectomy in the operating room. This was left up to the discretion of the staff surgeon supervising the operation. This corresponds to the routine teaching and feedback practices that occur during conventional surgical residency training
62528822|NCT03422367|EXPERIMENTAL|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
62155020|NCT00564447|EXPERIMENTAL|Moxifloxacin-2 hours post dose|
62528823|NCT03422367|ACTIVE_COMPARATOR|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
62528824|NCT03422367|NO_INTERVENTION|Control|Participants who are unable to complete JASPER due to age or time/distance commitment can enroll for single-time point participation
62528825|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/15) - MPL (50)|Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.
62528826|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
62528827|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (50/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
62528828|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/15) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
62528829|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/50) - MPL (15)|IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, on Day 28.
62528830|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (50/50) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
62528831|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
62528832|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
62155021|NCT00564447|EXPERIMENTAL|Moxifloxacin-12 hours post dose|
62713860|NCT05460182|ACTIVE_COMPARATOR|CAF|After local anaesthesia, a split-full-split thickness flap was elevated. The papillae adjacent to the involved tooth were then de-epithelialized. A gentle root debridement was performed. The flap was coronally displaced 1-2 mm above the CEJ and sutured
62713861|NCT03889652||Cataract group|"Group 1 includes patients who are planned for cataract extraction without any other preexisting retinal or optic nerve pathology that may affect the RNFL thickness.~OCT (investigation) before and after cataract extraction"
62155022|NCT00564447|EXPERIMENTAL|Moxafloxacin-24 hours post dose|
62528833|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (50/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
62528834|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (50/150)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
62528835|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.
62528836|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/50) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
62155023|NCT05752370|EXPERIMENTAL|High flow oxygen|High flow nasal oxygen
62155024|NCT05752370|ACTIVE_COMPARATOR|Usual care|room air or normal flow oxygen
62155025|NCT03040453|OTHER|Microwave ablation|20 patients will be treated with microwave ablation
62155026|NCT03040453|OTHER|Irreversible electroporation|20 patients will be treated with irreversible electroporation
62155027|NCT00878904|EXPERIMENTAL|treatment with Panobinostat and Epirubicin|
62155028|NCT01336842|EXPERIMENTAL|Phase I dose-escalation|Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
62155029|NCT01763502|EXPERIMENTAL|FOOD|Food transfer linked to preschool enrollment
62155030|NCT01763502|EXPERIMENTAL|CASH|Cash transfer linked to preschool enrollment
62155031|NCT01763502|NO_INTERVENTION|CTRL|No transfer linked to preschool enrollment
62155032|NCT01029925|EXPERIMENTAL|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart.
62155033|NCT02699619|ACTIVE_COMPARATOR|2 Hansson pins without plate|Patients with undisplaced femoral neck fractures operated with 2 isolated Hansson pins.
62155034|NCT02699619|ACTIVE_COMPARATOR|3 Hansson pins interlocked in a plate|Patients with undisplaced femoral neck fractures operated with 3 Hansson pins interlocked in plate (Pinloc).
62528837|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (50/150) x2|Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
62528838|NCT02038907|EXPERIMENTAL|GI.1/GII.4 (15/50) - Al(OH)3 (167) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.
62528839|NCT05739552|EXPERIMENTAL|Telerehabilitation|
62528840|NCT03330080||Ecological momentary assessment (EMA)|The ecological momentary assessment (EMA) will be used for participants to complete surveys from home on two occasions each day over seven days.
62528841|NCT05277623|ACTIVE_COMPARATOR|mannitol group|
62155035|NCT02652455|EXPERIMENTAL|PD-1, CD137 and Adoptive Cell Therapy|"Combination Therapy and Immunotherapy as described in intervention descriptions.~1. Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.~2. Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment."
62528842|NCT05277623|PLACEBO_COMPARATOR|control group|
62528843|NCT06281327|EXPERIMENTAL|Treatment group: Avatrombopag|Sixty subjects will be enrolled with the indicated treatment dose of avatrombopag
62528844|NCT00784186|EXPERIMENTAL|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
62528845|NCT00784186|EXPERIMENTAL|misoprostol|800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
62528846|NCT01642914|EXPERIMENTAL|Linaclotide 290 micrograms|Linaclotide 290 micrograms
62155036|NCT01640288|OTHER|Normal Subjects|Subjects with Normal Lung Function by Pulmonary Function Tests (e.g. Spirometry) with or without smoking as a risk factor (non-smokers, ex-smokers, current smokers)
62155037|NCT01640288|OTHER|Subjects with COPD|Subjects diagnosed with COPD by GOLD criteria.
62155038|NCT03560154|EXPERIMENTAL|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (\<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
62155039|NCT03560154|NO_INTERVENTION|Home respiratory exercises|Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.
62528847|NCT01642914|EXPERIMENTAL|Linaclotide 145 Micrograms|Linaclotide 145 micrograms
62528848|NCT01642914|PLACEBO_COMPARATOR|Placebo|Matching placebo
62155040|NCT03589677||Myotonic dystrophy type 1|"Subjects of both sexes with a diagnosis of Steinert's disease (DM1), de novo or with the previous diagnosis that shows significant worsening detectable during the follow-up foreseen by the normal cure procedure with clinical presentation indicating a CNS compromise will be evaluated for:~* quality of life evaluation~* exam of neuroimaging~* study of myomiRNAs before and after rehabilitation"
62528849|NCT01053234|EXPERIMENTAL|Insulin aspart|
62713862|NCT03889652||Combined cataract and glaucoma group|Group 2 includes patients who are diagnosed with POAG controlled on medical treatment and have cataract and planned for cataract extraction only OCT is done before and after cataract extraction
62155041|NCT03462277||Control group|Control group was defined as people with negative findings in coronary angiograms.
62528850|NCT01053234|EXPERIMENTAL|NPH insulin|
62528851|NCT06404892||Group 1|Patients undergoing thoracic surgery and single-lung ventilation.
62528852|NCT02140723||preoperative short course radiation|preoperative short course radiation with 8 weeks delay of surgery
62528853|NCT01905748|EXPERIMENTAL|Patients during Migraine attacks|Patients with Migraine before, during and after Migraine attacks. Acute phase reaction profile, and activation of the coagulation system will be investigated together with thrombophilia profile.
62528854|NCT01905748|EXPERIMENTAL|Control group|Patients with acute neurologic events like convulsions not related to fever or central nervous system (CNS) infections will be studied including acute phase reaction laboratory tests, thrombophilia and activation of the coagulation system
62528855|NCT02269163|ACTIVE_COMPARATOR|Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period|Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.
62528856|NCT02269163|EXPERIMENTAL|Prometic IGIV 10% Treatment Period|Subjects will receive Prometic Immune Globulin Intravenous 10%
62528857|NCT01211080||Threatening hemangioma|The group with cosmetically threatening of functionally threatening hemangiomas warranting active treatment according to our usual criteria (location face, hands, feet with a strong growth tendency and below age of 8 months)
62528858|NCT05755503||IS modeling and validation group|Uremia patients receiving hemodialysis.This group was used to establish the IS three-compartment model and verify the accuracy and predictive value of the model
62528859|NCT04366427|EXPERIMENTAL|Low-pressure hyperbaric oxygenation (L-HBO)|Low-pressure hyperbaric oxygen administration at 1.45 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 sessions (3-4 per week).
62713863|NCT05812885|EXPERIMENTAL|Active TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
62713864|NCT05812885|PLACEBO_COMPARATOR|Placebo TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramps off.
62528860|NCT04366427|EXPERIMENTAL|Standard-pressure hyperbaric oxygenation (HBO)|Standard pressure hyperbaric oxygen administration at 2.5 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 non-consecutive sessions (3-4 per week).
62528861|NCT04366427|NO_INTERVENTION|Control|Control group of athletes, no intervention.
62528862|NCT04366427|EXPERIMENTAL|30% O2|Administration of air mixture with 30% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
62528863|NCT04366427|EXPERIMENTAL|50% O2|Administration of air mixture with 50% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
62528864|NCT02924727|EXPERIMENTAL|LCZ696 (sacubitril/valsartan)|"Following randomization, patients will receive LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Patients will be required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from ramipril matching placebo pack) twice a day for the duration of the study.~Patients randomized to LCZ who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will receive a valsartan bridge for one day. These patients will receive two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment."
62528865|NCT02924727|ACTIVE_COMPARATOR|Ramipril|"Following randomization, patients will receive the Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).~Patients will be required to take a total of two pills, (one capsule from the ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.~Patients randomized to ramipril who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will immediately start on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients will receive two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo."
62528866|NCT00536263|ACTIVE_COMPARATOR|PEG 1.0 mcg/kg weekly (QW) * 24 weeks|PegIntron 1.0 mcg/kg weekly (QW) \* 24 weeks + 24 weeks follow-up
62713865|NCT05812885|NO_INTERVENTION|No TENS|Participants will wear a TENS unit that will be turned off to blind the outcome assessor
62155042|NCT03462277||Coronary Heart Disease group|CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms.
62155043|NCT03788707|EXPERIMENTAL|Passive leg raising|Passive leg raising for 3 minutes after 20 seconds of lying flat
62155044|NCT01468597||One group|Emergency surgery
62155045|NCT06002672|PLACEBO_COMPARATOR|Control|group that consumed control lettuce
62528867|NCT00536263|EXPERIMENTAL|PEG 1.5 mcg/kg QW * 24 wks|PegIntron 1.5 mcg/kg QW \* 24 wks + 24 wks follow-up
62528868|NCT00536263|EXPERIMENTAL|PEG 1.5 mcg/kg QW * 48 wks|PegIntron 1.5 mcg/kg QW \* 48 wks + 24 wks follow-up
62528869|NCT05644470||Dental implant rehabilitation|Patients having undergone dental implant treatment, with a single implant-supported restoration in anterior jaws (premolars to premolars), will be included.
62528870|NCT01020344|ACTIVE_COMPARATOR|Lung volume reduction surgery|This group will receive lung volume reduction surgery
62528871|NCT01020344|NO_INTERVENTION|No lung volume reduction surgery|This group will not receive LVRS during the 3 months of the study
62528872|NCT06462859|EXPERIMENTAL|The experimental group|The experimental group received sensory integration therapy in addition to the NDT program.Both groups participated in NDT sessions for 45 minutes, three times a week, over a span of 8 weeks.
62528873|NCT06462859|OTHER|Control Group|The NDT program was customized for each child, incorporating a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises.Both groups participated in NDT sessions for 45 minutes, three times a week, over a span of 8 weeks.
62528874|NCT01025544|ACTIVE_COMPARATOR|Arm 1|
62528875|NCT01025544|ACTIVE_COMPARATOR|Arm 2|
62528876|NCT03310411|EXPERIMENTAL|Lasmiditan + Sumatriptan (A)|Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
62528877|NCT03310411|EXPERIMENTAL|Lasmiditan + Placebo (B)|Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
62528878|NCT03310411|ACTIVE_COMPARATOR|Sumatriptan + Placebo (C)|Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
62528879|NCT03310411|PLACEBO_COMPARATOR|Placebo + Placebo (D)|Oral doses of placebo tablets in one of four treatment periods.
62713866|NCT06112015|EXPERIMENTAL|female athletes|21 female athletes from different branches performed 4 different sessions of Bulgarian split squat exercises.
62713867|NCT00512564||1|Patients suffering from Sickle cell disease
62155046|NCT06002672|ACTIVE_COMPARATOR|Intervention|group that consumed eustress lettuce
62155047|NCT04603898|EXPERIMENTAL|Controlled Dietary Study|Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for six days. After two days of equilibration, subjects will provide a blood sample and ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on Day 3. The following day (Day 4), serial blood and urine collections will occur. On Days 5 through 7, subjects will complete a 24-hr urine collection and blood draw.
62528880|NCT04971798|EXPERIMENTAL|Cell-free Stem cell-derived Extract Formulation (CCM)|Intraarticular administration of CCM
62528881|NCT02145312|EXPERIMENTAL|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
62528882|NCT00440466|EXPERIMENTAL|001|epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
62528883|NCT00440466|EXPERIMENTAL|003|epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
62528884|NCT00440466|EXPERIMENTAL|002|epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
62528885|NCT04819399|EXPERIMENTAL|Catumaxomab|intravesical Catumaxomab instillation
62713868|NCT05796687|EXPERIMENTAL|My Future Self Intervention|My Future Self - 5 group sessions; 1 hour each over 5 weeks; content includes: health education around abstinence and contraception methods, and consideration of goals of parenthood and family planning in their adult future; future plans, discussion of healthy intimate partner relationships/
62713869|NCT05796687|NO_INTERVENTION|Control|Youth will continue to receive any services that they would normally receive around health education.
62528886|NCT03958123|EXPERIMENTAL|Treatment Group 1: Cebranopadol|"Supratherapeutic dose (1600 μg) of cebranopadol:~Participants received placebo once a day for 2 days (Days -3 and -1); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 3 days; 900 μg once a day for 3 days; 1300 μg once a day for 3 days; 1600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
62155048|NCT04453930|EXPERIMENTAL|Camrelizumab+Irinotecan+Platinum→Camrelizumab+apatinib|Participants received intravenous infusions of Camrelizumab 200 mg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) or Cisplatin 30 milligrams per square meter (mg/m\^2) followed by Irinotecan 65 mg/m\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4/5/6). On Days 8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6), Cisplatin 30 mg/m\^2 and Irinotecan 65 mg/m\^2 was administered. Thereafter, participants received maintenance (Cycle onward) Camrelizumab 200 mg on Day 1 of every 21-day cycle with Apatinib 250mg until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
62155049|NCT00777309|EXPERIMENTAL|1|Erlotinib (150 mg) once daily plus ARQ 197 (360 mg) twice daily.
62155050|NCT00777309|ACTIVE_COMPARATOR|2|Erlotinib (150 mg) once daily plus ARQ 197 placebo twice daily
62713870|NCT02914938|EXPERIMENTAL|ME-401 Alone|This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
62155051|NCT04400045|EXPERIMENTAL|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0
62155052|NCT06416540|EXPERIMENTAL|Theraband Exercises plus Conventional Physiotherapy and Rehabilitation Group (TB+CPRG)|"Upper Extremity Theraband Exercises Program Exercise training will be applied in a total of 3 sets, 30-60 min/session, 5 days/week, 8-10 repetitions/set, depending on the condition of each patient, during the patients' stay in the intensive care unit.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. These movements will be performed once a day for 10 repetitions."
62155053|NCT06416540|OTHER|Conventional Physiotherapy and Rehabilitation Group (CPRG)|"The control group will receive only conventional rehabilitation treatment. Although the duration of the session varies depending on the patient's condition, it will last approximately 30-60 minutes.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. These movements will be performed once a day for 10 repetitions."
62155054|NCT06311292|EXPERIMENTAL|Intrapulmonary Percussive Ventilation for Non-sputum Producer|Unable to produce adequate amount of lower airway bacterial sampling for culture results in last year.
62528887|NCT03958123|EXPERIMENTAL|Treatment Group 2: Cebranopadol|"Therapeutic dose (600 μg) of cebranopadol:~Participants received placebo once a day for the first 11 days (Days -3, -1 and 1-9); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
62528888|NCT03958123|EXPERIMENTAL|Treatment Group 3A: Placebo and Moxifloxacin|"Placebo / Moxifloxacin:~Participants received placebo once a day for 31 days (Days -3, -1 and 1-29) and moxifloxacin 400 mg once on the last dosing day. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
62528889|NCT03958123|EXPERIMENTAL|Treatment Group 3B: Moxifloxacin and Placebo|"Moxifloxacin / Placebo:~Participants received placebo once a day for 2 days (Days -3 and -1); moxifloxacin 400 mg once for 1 day; and placebo once a day for the following 29 days. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
62713871|NCT02914938|EXPERIMENTAL|ME-401 in Combination with Rituximab|The second arm is an open label study to evaluate the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in subjects with various B-cell malignancies. There are two planned cohorts which may enroll up to 30 subjects.
62713872|NCT02914938|EXPERIMENTAL|ME-401 in Combination with Zanubrutinib|The third arm is an open label study evaluating the safety, efficacy, MTD, DLT and pharmacokinetics of ME-401 in combination with zanubrutinib in subjects with various B-cell malignancies. This arm will include 2 stages: a safety evaluation stage (cohort of 6-12 subjects) and a disease-specific expansion cohort stage (up to 74 subjects).
62713873|NCT05140343|EXPERIMENTAL|Mobile ECG Monitoring|Standard care with clinical follow-up plus Mobile ECG Monitoring.
62528890|NCT04688931|EXPERIMENTAL|UGN-102 ± TURBT|6 weekly intravesical instillations of UGN-102 (75 mg mitomycin) starting on Day 1 + TURBT for patients with NCR due to residual LG disease at the 3-month Visit (3 months after the start of treatment with UGN-102).
62713874|NCT05140343|NO_INTERVENTION|24-hour Holter monitoring|Standard care with clinical follow-up plus repeating 24-hours Holter ECG (month 1, 6, 12)
62713875|NCT02782962||Cohort|Patients with acute vertigo/unsteadiness
62713876|NCT02847897|EXPERIMENTAL|CO2 AcuPulse Laser treatment|Subjects with vulvovaginal atrophy intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
62155055|NCT03094442|ACTIVE_COMPARATOR|Dexamethasone|"Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe.~We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug."
62713877|NCT00145626|EXPERIMENTAL|Study Participants|"Participants who meet the eligibility criteria for this study. Donor cells will be obtained using the Miltenyi Biotec CliniMACS device.~Interventions: Chemotherapy and antibodies, allogeneic stem cell transplantation."
62155056|NCT03094442|PLACEBO_COMPARATOR|Saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
62155057|NCT03391700|ACTIVE_COMPARATOR|Moderate muscle relaxation|Rocuronium is administered to maintain moderate relaxation during operation. This is conventional muscle relaxation level of this institute.
62155058|NCT03391700|EXPERIMENTAL|Deep muscle relaxation|Rocuronium is administered to maintain deep relaxation during operation.
62155059|NCT00936065|ACTIVE_COMPARATOR|Group A|
62155060|NCT00936065|EXPERIMENTAL|Group B|
62155061|NCT00936065|ACTIVE_COMPARATOR|Group C|
62155062|NCT06014671|EXPERIMENTAL|Intervention group|intervention group were took interpersonal psychotherapy
62155063|NCT06014671|EXPERIMENTAL|Control group|control group didn't took interpersonal psychotherapy
62155064|NCT03204175|EXPERIMENTAL|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
62713878|NCT00805051||Severe aortic stenosis|Patients undergoing aortic valve replacement because of severe aortic stenosis
62713879|NCT06684704|OTHER|Minimal Low-Flo Anesthesia|Group M minimal flow (n=30, fresh gas flow 0.5 L/min)
62155065|NCT03204175|ACTIVE_COMPARATOR|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
62155066|NCT05710627|NO_INTERVENTION|Control|Standard of care
62155067|NCT05710627|EXPERIMENTAL|Treatment|TENEX device will be used
62155068|NCT03928743|EXPERIMENTAL|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
62155069|NCT03928743|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
62155070|NCT06074354|EXPERIMENTAL|MY-RIDE group|
62155071|NCT06074354|ACTIVE_COMPARATOR|Attention-control group|
62155072|NCT02212275|EXPERIMENTAL|Dextromethorphan in ASD|8-12 years old: \> 30 boys will be recruited who have a known or suspected diagnosis of ASD confirmed by DSM-5 checklist and the ADOS-2 at screening. They will have the cortical metric measured 20 min prior to receiving DXM and 2 hours after receiving a single age and weight appropriate dose of DXM. The outcome reported is the difference in the cortical metric after the DXM dose and before the DXM dose.
62155073|NCT02212275|ACTIVE_COMPARATOR|Dextromethorphan in controls|30 typically developing boys 8-12 years old who have the cortical metric measured 20 min before receiving a single age and weight appropriate dose of DXM and 2 hours after the single dose of DXM. The reported value will be the difference between the cortical metric 2hrs after the single dose of DXM and the cortical metric 20 minutes prior to the single dose of DXM.
62155074|NCT03370588|EXPERIMENTAL|dexmedetomidine infusion group|
62155075|NCT03370588|ACTIVE_COMPARATOR|normal saline infusion group|
62155076|NCT02172937|EXPERIMENTAL|Decidual Stromal Cells as last line treatment|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids without any signs of improvement will be given DSCs to evaluate a possible effect. DSCs will be thawed from the freezer in plasma.
62155077|NCT02172937|ACTIVE_COMPARATOR|Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids will be given DSCs as early as possible at one or more occasions at weekly intervals dependent on clinical response. DSCs will be thawed from the freezer in plasma.
62155078|NCT04809701|EXPERIMENTAL|Configuration A first|Subjects receive the test of Configuration A first and Configuration B second.
62155079|NCT04809701|EXPERIMENTAL|Configuration B first|Subjects receive the test of Configuration B first and Configuration A second.
62155080|NCT04812977|EXPERIMENTAL|Group A|A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
62155081|NCT04812977|ACTIVE_COMPARATOR|Group B|Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
62155082|NCT01074034|EXPERIMENTAL|AV Therapy Assessment group|appropriate system performance of the atrial and ventricular tachyarrhythmia therapies in the ASSURE device
62155083|NCT03773432|OTHER|Men|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
62155084|NCT03773432|OTHER|Women|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
62155085|NCT00264576|EXPERIMENTAL|cTIV|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
62155086|NCT00264576|ACTIVE_COMPARATOR|TIV|Received one dose of egg-derived trivalent vaccine (TIV).
62155087|NCT05771272|OTHER|Elite Rowers|They are young men rowers aged between 16-18 years, rowing age of at least 2 years, and continuing to row sport actively.
62155088|NCT04967092|ACTIVE_COMPARATOR|Modified Xiao-Feng Powder|Modified Xiao-Feng Powder granules will be taken twice daily for 12 weeks
62155089|NCT04967092|PLACEBO_COMPARATOR|Placebo|Placebo granules will be taken twice daily for 12 weeks
62155090|NCT00611598||1|second primary lung cancer
62155091|NCT00611598||2|single primary lung cancer
62713880|NCT06684704|OTHER|High-Flow Anesthesia|Group Y high flow (n=30, fresh gas flow 4 L/min).
62528891|NCT04688931|ACTIVE_COMPARATOR|TURBT Alone|TURBT on Day 1 + repeat TURBT for patients with NCR due to residual LG disease at the 3-month Visit (3 months after the initial TURBT).
62155092|NCT02285322||BP control reached|Patients diagnosed with high blood pressure who lowered their blood pressure measurements during follow-up to \<140/90mmHg if aged less than 60 years old, and \<150/90mmHg for those of ≥60 years
62155093|NCT02285322||BP control not reached|Patients diagnosed with high blood pressure who did not lower their blood pressure measurement during follow-up (measurements were ≥140/90mmHg for individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years)
62528892|NCT03111914|OTHER|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
62528893|NCT04317209|EXPERIMENTAL|SHR0410 low dosage|
62528894|NCT04317209|EXPERIMENTAL|SHR0410 medium dosage|
62528895|NCT04317209|EXPERIMENTAL|SHR0410 high dosage|
62528896|NCT04317209|PLACEBO_COMPARATOR|Placebo|
62528897|NCT04821531|EXPERIMENTAL|PT Pal|Experimental Arm-PT PAL Participants randomized into this arm will receive exercise instructions via Pt_PAL. PT PAL is a mobile health technology used to facilitate communications between Care teams and patients, by allowing the team to send web-based exercise routines, surveys and educational materials. The PT Pal app captures patient activity adherence and reports
62528898|NCT04821531|ACTIVE_COMPARATOR|Exercise Manual|Control Arm- Exercise Manual Participants randomized into this arm will use the exercise manual to obtain their exercise instructions
62528899|NCT04814030|EXPERIMENTAL|AIPD-1|Trans hepatic artery infusion of PD-1 antibody, chemoembolization, FOLFOX-based infusion chemotherapy
62155094|NCT01526486|EXPERIMENTAL|Videoscopic (Minimally invasive)|Patients in this arm will have the procedure done through the three port minimally invasive approach.
62155095|NCT01526486|ACTIVE_COMPARATOR|Open (traditional approach)|Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
62155096|NCT02268253|EXPERIMENTAL|Tagraxofusp (SL-401)|
62155097|NCT03989232|EXPERIMENTAL|Semaglutide 2.0 mg|All participants will receive one injection per week during a 12-week dose escalation period, until the target dose for semaglutide 2.0 mg is reached. From week 13 to week 40, semaglutide will be given in two weekly injections of 1.0 mg each.
62155098|NCT03989232|ACTIVE_COMPARATOR|Semaglutide 1.0 mg|All participants will receive one injection per week during a 12-week dose escalation period. From week 13 to week 40, the 1.0 mg group will receive an additional injection of semaglutide placebo in order to maintain the blinding.
62528900|NCT02669758|EXPERIMENTAL|ALKS 3831|Olanzapine + samidorphan; administered as a coated bilayer tablet.
62155099|NCT05941988|EXPERIMENTAL|pre grafting partial maxillary expansion with post grafting expansion|pregrafting partial maxillary expansion then grafting left bone to consolidate for 2 months followed by post grafting expansion till full arch alignment
62155100|NCT05941988|ACTIVE_COMPARATOR|pre grafting full maxillary expansion|pre grafting full maxillary expansion till full arch alignment then grafting and let bone to consolidate
62155101|NCT01615614|EXPERIMENTAL|Treatment A|Rilpivirine 25 mg once daily will be administered for 11 days
62528901|NCT01251029|EXPERIMENTAL|sugar pil and saline|
62528902|NCT01540773|ACTIVE_COMPARATOR|amino acid supplement|supplements with the proprietary amino acid derivative blend.
62528903|NCT01540773|PLACEBO_COMPARATOR|Placebo|Non-Active
62528904|NCT02408068|ACTIVE_COMPARATOR|Chronocort : fed|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).
62528905|NCT02408068|ACTIVE_COMPARATOR|Immediate release hydrocortisone: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
62155102|NCT01615614|EXPERIMENTAL|Treatment B|Rilpivirine 50 mg once daily will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days
62155103|NCT01615614|EXPERIMENTAL|Treatment C|Rilpivirine (in a regimen to be determined based on an interim pharmacokinetic analysis of treatment A and B) will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days.
62528906|NCT02408068|ACTIVE_COMPARATOR|Chronocort: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
62528907|NCT04722822|EXPERIMENTAL|Providers recommending HPV vaccine at age 9-10 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 9-10 years of age.
62528908|NCT04722822|ACTIVE_COMPARATOR|Providers recommending HPV vaccine at age 11-12 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 11-12 years of age.
62528909|NCT02716935|EXPERIMENTAL|Fortified lipid based nutrient supplement|lipid based nutrient supplement (Nutributter) fortified with fructo-oligosaccharides and inulin
62528910|NCT02716935|ACTIVE_COMPARATOR|lipid based nutrient supplement|lipid based nutrient supplement (Nutributter)
62528911|NCT02716935|NO_INTERVENTION|non intervention group|This group will not be supplemented
62528912|NCT00895947|EXPERIMENTAL|Interferon-alpha|150 international units of interferon-alpha
62528913|NCT00895947|PLACEBO_COMPARATOR|placebo|placebo lozenges
62155104|NCT04187378|NO_INTERVENTION|Control Group|Body temperature of the patients will be measured in the pre-operative service and in the waiting room. Sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
62155105|NCT04187378|EXPERIMENTAL|Underbody Blanket Group|Patients with hypothermia (\<36C) will be warmed by air blown underbody blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
62155106|NCT04187378|EXPERIMENTAL|Surgical Access Blanket Group|Patients with hypothermia (\<36C) will be warmed by air blown surgical access blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
62155107|NCT05248217|OTHER|healthcare workers|doctors, nurses, medical secretaries, security guards, and cleaning staff
62155108|NCT00677742|EXPERIMENTAL|1|enhanced initial supply of oral contraception
62155109|NCT00677742|ACTIVE_COMPARATOR|2|conventional initial supply of oral contraception
62155110|NCT02525497|EXPERIMENTAL|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h;
62155111|NCT02525497|ACTIVE_COMPARATOR|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h;
62155112|NCT00882050|EXPERIMENTAL|Exentatide 0.27 ng/kg/min|"Exenatide to be infused by intravenous method at 0.27 ng/kg/min (0.066 pmol/kg/min) over 3-6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
62155113|NCT00882050|EXPERIMENTAL|Exentatide 0.41 ng/kg/min|"Experimental: IV Exenatide to be infused by intravenous method at 0.41 ng/kg/min (0.099 pmol/kg/min) over 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin,Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
62713881|NCT01141530||Tissue Bank Samples|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study. All samples studied will be obtained through the UAMS Tissue Bank.
62155114|NCT00882050|PLACEBO_COMPARATOR|Placebo IV NSS|"Placebo of IV normal saline solution as comparator.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
62155115|NCT02892318|EXPERIMENTAL|Cohort A1: Safety Cohort (Relapsed/refractory AML)|An initial safety evaluation of the combination will be performed in 9 participants with relapsed/refractory AML. All participants will receive atezolizumab (840 milligrams \[mg\] IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 milligrams per square meter \[mg/m\^2\] subcutaneously \[SC\] on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit (except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
62528914|NCT03427502|EXPERIMENTAL|Study Group|"Experimental: Study Group At the end of surgery before nasal packing, scrub nurse will prepare 10 ml solution 0.5% bupivacaine with 1:2,00,000 adrenaline in a syringe and pass it over to the operating surgeon. The surgeon will block anterior ethmoidal nerve.~Injection technique: External nasal nerve will be blocked through an inter-cartilaginous injection into the dorsum of the nose.~Internal nasal nerve will be blocked in septum and lateral wall of nose. Septal block is done in upper anterior part of nasal septum. Three injections will be given on lateral nasal wall. First injection will be given just antero-superior to the attachment of middle turbinate (axilla). Second injection will be given at the anterior end of middle turbinate and third injection at the medial surface of middle turbinate. Withdrawal of injection will be done prior to deposition of solution every time to ensure that the solution is not deposited directly into a blood vessel."
62713882|NCT04483778|EXPERIMENTAL|SCRI-CARB7H3(s)|Autologous CD4+ and CD8+ T-cells genetically modified to express an B7H3-specific CAR
62713883|NCT04483778|EXPERIMENTAL|SCRI-CARB7H3(s)x19|Autologous CD4+ and CD8+ T-cells genetically modified to a bispecific B7H3xCD19 CAR
62713884|NCT04483778|EXPERIMENTAL|SCRI-CARB7H3(s)x19 plus pembrolizumab|Autologous CD4+ and CD8+ T-cells genetically modified to express a bispecific B7H3xCD19 CAR given in combination with pembrolizumab
62155116|NCT02892318|EXPERIMENTAL|Cohort A2: Expansion Cohort (Relapsed/refractory AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, an expansion cohort of 11 participants with relapsed/refractory AML (Cohort A2) will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m\^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
62155117|NCT02892318|EXPERIMENTAL|Cohort A3: Safety Cohort (Previously Untreated AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m\^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
62528915|NCT03427502|PLACEBO_COMPARATOR|Control Group|"At the end of surgery before nasal packing, scrub nurse will pass 10 ml of normal saline in a syringe to the surgeron.~Injection technique remains the same as in Study group."
62528916|NCT05185401||non-Brugada population|Adult patients who underwent general anaesthesia (with propofol as induction agent) at the catheterisation laboratory of the UZ Brussel
62528917|NCT05975736|EXPERIMENTAL|Blocked Trials|There are four conditions in the experiment. Each condition will be presented in a separate block of 100 trials.
62528918|NCT05975736|EXPERIMENTAL|Mixed Trials|There are four conditions in the experiment. All condition will be presented, randomly mixed in a single block of 400 trials (with breaks every 100 trials).
62528919|NCT03416244|EXPERIMENTAL|A: Nivolumab / Ipilimumab combination treatment|Nivolumab 240 mg fixed dose IV every 2 weeks; Additionally, after 7 week safety assessment Ipilimumab 1mg/kg IV every 6 weeks
62528920|NCT03416244|EXPERIMENTAL|B. Nivolumab monotherapy|Nivolumab 240 mg fixed dose IV every 2 weeks
62528921|NCT01186601|EXPERIMENTAL|Arm 1|
62528922|NCT01484262||Liraglutide|
62528923|NCT01484262||Any insulin|
62528924|NCT05116462|EXPERIMENTAL|Sintilimab|"Neoadjuvant Treatment period: up to 3 cycles of sintilimab plus platinum-based chemotherapy prior to surgery.~adjuvant Treatment period: Subjects will receive 1 cycle of sintilimab plus platinum-based chemotherapy, and then receive sintilimab therapy after surgery until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of postoperative treatment with either sintilimab or placebo is 13 cycles."
62528925|NCT05116462|PLACEBO_COMPARATOR|Placebo|"Neoadjuvant Treatment period: up to 3 cycles of placebo plus platinum-based chemotherapy prior to surgery.~adjuvant Treatment period: Subjects will receive 1 cycle of placebo plus platinum-based chemotherapy, and then receive placebo therapy after surgery until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of postoperative treatment with either sintilimab or placebo is 13 cycles."
62528926|NCT02493413||Group A|observational time of three months in the obese group with distressed (type D) personality (high DS 14 score) with moderate aerobic exercise
62528927|NCT02493413||Group B|observational time of three months in obese group without distressed personality (low DS 14 score) with moderate aerobic exercise
62528928|NCT03198975||Preoperative imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo preoperative Gd-EOB-DTPA enhanced magnetic resonance image.
62528929|NCT04727814||Water exchange with computer-aided detection system|Computer-aided detection system overlaid videos with water exchange colonoscopy method
62713885|NCT04660734|EXPERIMENTAL|3D printing group|"Group 1 (G1) consisted of 20 patients who underwent preoperative molding of the osteosynthesis plate on a 3D printed model of the pelvis. A preoperative scan of the healthy hemi-pelvis was used to create the 3D-printed model for patients in G1 according to the following three-step methodology: 1) A scanographic acquisition of images was performed using a multi-strip scanner in thin sections. These images were recorded as digital images in the standard medical format of digital imaging and communications ; 2) A digital, 3D model of the pelvis in the stereolithography format was created to digitally treat the 2D images. The individualization of the healthy hemi-pelvis, to which a mirror effect was applied allowed for the creation of a symmetrical 3D image, as hemi-pelvises are globally symmetrical. 3) A 3D printer was used to create a physical, 3D-printed model of the affected hemi-pelvis using polylactic acid."
62528930|NCT04727814||Air insufflation with computer-aided detection system|Computer-aided detection system overlaid videos with air insufflation colonoscopy method
62528931|NCT03145636|OTHER|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
62528932|NCT03145636|OTHER|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
62528933|NCT03145636|OTHER|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
62528934|NCT03511443|OTHER|Diagnostic performance of hsRDT|Comparing diagnostic power of two diagnostics
62528935|NCT01327261|EXPERIMENTAL|Levodopa + benserazide (test formulation)|A randomized-sequence, open-label, 2-period crossover study assessing relative bioavailability of two drug products containing the association levodopa + benserazide.
62528936|NCT01327261|ACTIVE_COMPARATOR|Levodopa + benserazide (reference formulation)|
62528937|NCT04871763|EXPERIMENTAL|Geldis® gel|Patients will brush their essix retainers with a toothbrush and with Geldis® gel.
62528938|NCT04871763|ACTIVE_COMPARATOR|Tablets|Patients will leave their essix retainers in a glass with water and Polident tablets.
62528939|NCT04871763|ACTIVE_COMPARATOR|Water|Patients will brush essix retainers with a toothbrush under running water.
62528940|NCT00574912|EXPERIMENTAL|Placebo then Insulin Glargine|"Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)"
62528941|NCT02161822|EXPERIMENTAL|Simvastatin|single arm : Simvastatin
62528942|NCT01781741|EXPERIMENTAL|Treatment (TEMLA and SBRT)|Patients undergo TEMLA to remove the mediastinal lymph nodes followed by a single fraction of SBRT to the primary tumor (unless VATS procedure done) and mediastinal lymph node beds (if positive on TEMLA), with or without minimally invasive surgery.
62528943|NCT06113926|NO_INTERVENTION|"Exclusion by White Players"|"Excluded by White players in an online ball-tossing game (Cyberball)."
62528944|NCT06113926|NO_INTERVENTION|"Inclusion by White Players"|"Included by White players in an online ball-tossing game (Cyberball)."
62528945|NCT06113926|EXPERIMENTAL|"Exclusion by White Players with Bystander Acknowledgment"|"Excluded by White players in an online ball-tossing game (Cyberball) with a White bystander acknowledging the exclusion."
62528946|NCT02086630|EXPERIMENTAL|Intervention|The Heart to Heart (HTH) intervention was a flexible and individualized intervention with the following components: 3 intervention sessions with video-components; patient navigation lasting up to 24 weeks; treatment initiation support groups (up to 5); and inclusion of a Support Partner. This is a behavioral intervention. The intervention uses Motivational Interviewing.
62528947|NCT02086630|NO_INTERVENTION|Control|Treatment as usual
62528948|NCT01751035|PLACEBO_COMPARATOR|Treatment as Usual (TAU)|Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers. This could include individual and/or group therapy using a variety of treatment models.
62528949|NCT01751035|EXPERIMENTAL|RRFT|RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy. Please see intervention description for more detail about the model.
62713886|NCT04660734|EXPERIMENTAL|conventional technique group|Group 2 (G2 or control group) included 23 patients who underwent surgery using the conventional technique.The patients in the control group (G2) underwent surgery following the conventional procedure based on radiographic and CT images with 3D reconstructions.
62528950|NCT03715075||Post-caesarean section group|This single cohort observational study shall recruit women undergoing elective caesarean section within the Simpson's Centre for Reproductive Health (SCRH).
62528951|NCT03168971|EXPERIMENTAL|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a seven-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
62528952|NCT03168971|NO_INTERVENTION|Usual Care|Older adults with cancer and their primary informal caregiver will receive standard care provided by their medical team. These participants will not receive any intervention from the research team.
62528953|NCT02135653||Feasibility Phase: Eischens Yoga Group|
62528954|NCT02135653||Phase II: Eischens Yoga Group|
62528955|NCT03929783|EXPERIMENTAL|Diagnostic (CEM)|Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day.
62713887|NCT03473743|EXPERIMENTAL|Phase 1b: Dose Escalation|Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
62713888|NCT03473743|EXPERIMENTAL|Phase 2: Dose Expansion|The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
62528956|NCT04167293|EXPERIMENTAL|SBRT + PD-1 Arm|Patients assigned to this arm will receive SBRT followed by sintilimab. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
62528957|NCT04167293|OTHER|SBRT Arm|Patients assigned to this arm will receive SBRT alone. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
62528958|NCT00278889|ACTIVE_COMPARATOR|1|Bevacizumab + FOLFOX
62528959|NCT00278889|EXPERIMENTAL|2|AZD2171 + FOLFOX
62528960|NCT02032706|EXPERIMENTAL|Positional feedback|Deliver therapy when the supine position is detected
62528961|NCT04360044|EXPERIMENTAL|THC ~5%|4 puffs of cannabis flower containing THC \~5% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
62528962|NCT04360044|EXPERIMENTAL|THC ~5%/CBD ~12%|4 puffs of cannabis flower containing THC \~5% and CBD \~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
62528963|NCT04360044|EXPERIMENTAL|CBD ~12%|4 puffs of cannabis flower containing CBD \~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
62155118|NCT02892318|EXPERIMENTAL|Cohort A4: Expansion Cohort (Previously Untreated AML)|If Cohort A3 is deemed safe and tolerable, an expansion cohort (Cohort A4) of 14 participants with untreated AML, who are older and unfit for induction chemotherapy will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m\^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
62528964|NCT04360044|SHAM_COMPARATOR|Sham Cannabis|4 puffs of cannabis flower from which the THC and CBD have been extracted administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
62528965|NCT05593861||This investigation was conducted on chief surgeons at each center.|This investigation was conducted on chief surgeons at each center.
62528966|NCT00128414|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62155119|NCT01583855|ACTIVE_COMPARATOR|Manual ablation|Patients will have their ablation performed manually.
62528967|NCT00128414|EXPERIMENTAL|Colchicine|Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
62528968|NCT03407235|OTHER|Laparoscopic Novices|"Four laparoscopic task will be undertaken on a computerized laparoscopic trainer and box trainer with eye patch.~Time to completion is recorded."
62528969|NCT01884311|EXPERIMENTAL|Subgam-VF|Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.
62528970|NCT03023176|OTHER|Healthy 1-8 year-old twins|Healthy 1-8 yr old identical and fraternal twin pairs given trivalent, inactivated influenza (Fluzone® standard IIV3 0.5ml or Fluzone® standard IIV3 Pediatric Dose) per participant age and standard of care.
62528971|NCT00959361|EXPERIMENTAL|pharmaceutical care|consultation with the pharmacists
62528972|NCT00959361|NO_INTERVENTION|control|usual care without consultation with the pharmacists
62528973|NCT02519335|OTHER|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
62528974|NCT02508090||Study Population|Participants who previously received 12 weeks of miravirsen monotherapy in Study SPC3649-207 will complete up to 36 months of safety and efficacy follow-up without investigational treatment.
62528975|NCT02356926||Control|Usual care and routine management
62528976|NCT02356926||Cross checking|Systematic cross checking between emergency physicians at 11:30, 14:00 and 16:30
62528977|NCT02037035|EXPERIMENTAL|Healthy|Healthy participants will receive ketamine in the scan
62528978|NCT02037035|EXPERIMENTAL|Depressed|Depressed participants will receive ketamine in the scan
62528979|NCT01752543|ACTIVE_COMPARATOR|Conivaptan|10 patients will be randomized to conivaptan treatment
62528980|NCT01752543|PLACEBO_COMPARATOR|Dextrose|10 patients will receive placebo treatment (dextrose)
62528981|NCT03456154|EXPERIMENTAL|Botox|In this group patients will receive 3 injections of botox on each masseter (left and right), after randomization. This injection will be performed once, and the patient will be evaluated after 3 and 6 months after this day.
62528982|NCT03456154|ACTIVE_COMPARATOR|Occlusal splint|In this group patients will receive an occlusal splint, which will be manufactured after taking their full mouth impression. This appliance has to be worn everyday, for 6 months, at night.
62528983|NCT03199430|PLACEBO_COMPARATOR|Placebo|1450mg Corn flour
62528984|NCT03199430|ACTIVE_COMPARATOR|Epigallocatechin gallate|1450mg Epigallocatechin gallate
62528985|NCT00114166|ACTIVE_COMPARATOR|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle until disease progression or adverse effects prohibit further therapy
62528986|NCT00114166|ACTIVE_COMPARATOR|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle until disease progression or adverse effects prohibit further therapy
62528987|NCT02874209|EXPERIMENTAL|Patient with amyotrophic lateral sclerosis|ALS patients with, spinal and bulbar form, certain or probable diagnosis according to the revised El Escorial criteria will go through the MRI sodium
62528988|NCT02874209|PLACEBO_COMPARATOR|Healthy volunteer|Healthy Volonteer apparied for sexe and age with selected ALS patients will go through the MRI sodium
62528989|NCT04989712|EXPERIMENTAL|20 minutes MVPA|20 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 40 minutes from the start of the testing session following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
62528990|NCT04989712|EXPERIMENTAL|4 x 5 mins MVPA|4 bouts of 5 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 30 minutes from the start of the testing session and repeated at 60 mins, 90 mins and 120 mins following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
62528991|NCT04989712|EXPERIMENTAL|Uninterrupted sitting - No exercise, sitting session (control).|A sitting only exposure, glucose solution to be consumed at 0 mins.Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point
62528992|NCT06238596|EXPERIMENTAL|rehabilitation + standard of care (SOC)|All enrolled patients will start a supervised rehabilitation program for 12 weeks
62528993|NCT01454271|EXPERIMENTAL|Total Hip Arthroplasty CERAFIT® grafted|
62528994|NCT00069836|EXPERIMENTAL|Arm 1|
62713889|NCT04070209|EXPERIMENTAL|Darolutamide (BAY1841788)+ SBRT|"CRPC subjects will receive LHRH agonist in combination with the new generation of hormonal therapy Darolutamide (300mg).~Subjects who progress on LHRH + Darolutamide and develop oligometastases will receive SBRT"
62713890|NCT05551468|EXPERIMENTAL|Monitoring + Intervention modules|"Monitoring: Ecological Momentary Assessment (EMA) of affect, thoughts and social company. Optionally with a wearable to measure activity level. Six times per day for two weeks.~Timepoints: T0-T4.~Intervention modules: StayFine guided app-based personalised intervention modules. Each individual receives six of eight modules of which three are mandatory and three others are selected based on a personalization procedure.~Time point: after T0 over the course of three months."
62713891|NCT05551468|ACTIVE_COMPARATOR|Monitoring|"Monitoring:Ecological Momentary Assessment (EMA) of affect, thoughts and social company. Optionally with a wearable to measure activity level. Six times per day for two weeks.~Timepoints: T0-T4."
62713892|NCT02384421|EXPERIMENTAL|Activa PC+S Neurostimulator|"Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool~PC+S: Primary Cell+Sensing"
62528995|NCT02912845|EXPERIMENTAL|20 IU/kg KamRAB + Active Anti-Rabies Vaccine|
62528996|NCT01991418||early staged non-small cell lung cancer|patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH
62528997|NCT05549908|EXPERIMENTAL|Experimental 4 doses|Inoculate experimental vaccine according to 2-1-1 immunization procedure
62528998|NCT05549908|EXPERIMENTAL|Experimental 5 doses|Inoculate experimental vaccine according to 1-1-1-1-1 immunization procedure
62528999|NCT05549908|ACTIVE_COMPARATOR|SPEEDA® 4 doses|Inoculate SPEEDA® according to 2-1-1 immunization procedure
62529000|NCT02897986|EXPERIMENTAL|patients with refractory/relapsing solid tumors|
62529001|NCT00324402||1|Healthy pregnant women, 18-40
62529002|NCT05192694|OTHER|FAPI PET|Prospective single arm cohort
62529003|NCT05480163|EXPERIMENTAL|Measurement records in COPD patients|"1. The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session)~2. Pre-session clinical assessment by the physiotherapist~3. Installation of the Sybille waistcoat on the patient~4. First measurement phase: Recording of spirometry parameters, acoustics, movements (thoracic volumetry) for forced vital capacity (FVC) and LVC manoeuvres.~5. Second phase of measurements:~   Treatment: the physiotherapist performs the session in the classical way. Recording of acoustic parameters, movements (thoracic volumetry).~6. Third phase of measurements: Recording of spirometry, acoustics and movement parameters (thoracic volumetry) for FVC and LVC manoeuvres.~7. Removal of measurement devices~8. Post session evaluation by the physiotherapist."
62529004|NCT05480163|OTHER|Measurement records in control subject|"1. The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session)~2. Clinical assessment by the physiotherapist The subject answers the questionnaire~3. Installation of the Sybille waistcoat on the patient~4. Measurement phase: Recording of spirometry, acoustics, movements (thoracic volumetry) for FVC and LVC manoeuvres.~5. Removal of measurement devices"
62529005|NCT04263402|EXPERIMENTAL|Methylprednisolone(<40mg/d)|
62529006|NCT04263402|EXPERIMENTAL|Methylprednisolone(40~80mg/d)|
62529007|NCT04906083|EXPERIMENTAL|Intervention group|Avatrombopag+Standard medical treatment
62529008|NCT04906083|OTHER|Control group|Standard medical treatment
62529009|NCT03236415|ACTIVE_COMPARATOR|Xience Drug Eluting Stent|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery disease
62529010|NCT03236415|ACTIVE_COMPARATOR|ABSORB Bioresorbable Vascular Scaffold|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery diseasee
62529011|NCT02095925||cancer patients|Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
62529012|NCT01106664|PLACEBO_COMPARATOR|P|
62529013|NCT01106664|EXPERIMENTAL|E|
62529014|NCT05739344|EXPERIMENTAL|Experimental Group|Cognitive behavioral approach based resilience development program
62529015|NCT03945669|ACTIVE_COMPARATOR|Intramedullary Nail|Intramedullary Nailing: Alignment will be obtained by closed or limited open reduction of the fracture. A standard reamed intramedullary nail is inserted. Access above the patella, through the patella tendon or parapatellar access is used according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. Patients are administered preoperative antibiotics (Dicloxacillin) 15 minutes before surgery commences. Postoperative antibiotics is administered by discretion of the surgeon based on individual patient considerations.
62529016|NCT03945669|EXPERIMENTAL|External Ring fixator|External Ring fixation: Closed or limited open reduction of the fracture is performed. A circular frame is attached on both sides of the fracture. Connection to the bone is obtained by hydroxyapatite coated half pins and/or k-wires with olives as needed according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. After applying the ring fixator alignment is assessed radiologically and corrected both peri- and postoperatively. Patients are administered preoperative antibiotics (Dicloxacillin) preoperatively 15 minutes before surgery commences. Following surgery antibiotics are continued until wounds, pin- and wire perforations are dry.
62529017|NCT01288053|EXPERIMENTAL|Allogeneic Stem Cell Therapy|Allogeneic Stem Cell Therapy will be performed after conditioning
62529018|NCT03915366|NO_INTERVENTION|Standard of Care (SoC)|"Standard treatment for severe pneumonia and pneumonia in HIV-infected infants:~Ceftriaxone 80 mg/k/day or Ampicillin plus Gentamicin ampicillin 50 mg/kg, or benzylpenicillin 50,000 unit/kg im/iv every six hours plus Gentamicin 7.5 mg/kg/im or iv once a day Cotrimoxazole trimethoprim (TMP) 8mg/kg/dose + sulfamethoxazole (SMX) 40mg/kg/dose three times daily Prednisolone 2mg/kg during 7 days, plus 1mg/kg other 7 days, plus 0.5 mg/kg for 7 days"
62529019|NCT03915366|EXPERIMENTAL|Valganciclovir plus SoC|Treatment for cytomegalovirus (CMV) Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, and Standard or Care as described in Control Group
62713893|NCT06117059|EXPERIMENTAL|3 fractions of prostate Stereotactic Body Radiotherapy (SBRT)|3 fractions of SBRT with image guidance using the RayPilot HypoCath system given on 3 consecutive days
62155120|NCT01583855|ACTIVE_COMPARATOR|Ablation using remote catheter system|Ablation for atrial fibrillation using the Amigo remote catheter system
62155121|NCT01843049|EXPERIMENTAL|radiotherapy+chemotherapy|"Radiotherapy:~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.~Chemotherapy:~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
62155122|NCT04320472||Follow up|Follow up of all included patients up to 3 months after enrollement
62155123|NCT05817292||Probiotic|Assumption of commercially available supplements containing probiotics
62155124|NCT05817292||Control|No assumption of supplements containing probiotics
62155125|NCT04671251|EXPERIMENTAL|AEVI-007|Open-label, dose-escalation, single-arm
62529020|NCT03915366|EXPERIMENTAL|Tuberculosis Treatment plus SoC|"Treatment for tuberculosis Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
62155126|NCT01927484|EXPERIMENTAL|methotrexate|25mg oral methotrexate tablets
62155127|NCT01927484|PLACEBO_COMPARATOR|placebo|25 mg/week placebo tablets
62155128|NCT00246350|ACTIVE_COMPARATOR|1|8 light massage treatments
62155129|NCT00246350|ACTIVE_COMPARATOR|2|16 light massage treatments
62155130|NCT00246350|EXPERIMENTAL|3|8 spinal manipulation treatments
62155131|NCT00246350|EXPERIMENTAL|4|16 spinal manipulation treatments
62155132|NCT03178253||3|
62155133|NCT03105024|EXPERIMENTAL|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
62155134|NCT03105024|ACTIVE_COMPARATOR|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
62155135|NCT03105024|NO_INTERVENTION|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
62155136|NCT06165497|EXPERIMENTAL|Mindfulness, 5 minutes, male voice|Mindfulness meditation, 5 minutes duration, with a male speaker.
62155137|NCT06165497|EXPERIMENTAL|Mindfulness, 10 minutes, male voice|Mindfulness meditation, 10 minutes duration, with a male speaker.
62155138|NCT06165497|EXPERIMENTAL|Mindfulness, 5 minutes, female voice|Mindfulness meditation, 5 minutes duration, with a female speaker.
62155139|NCT06165497|EXPERIMENTAL|Mindfulness, 10 minutes, female voice|Mindfulness meditation, 10 minutes duration, with a female speaker.
62155140|NCT06165497|EXPERIMENTAL|Self-compassion, 5 minutes, male voice|Self-compassion meditation, 5 minutes duration, with a male speaker.
62155141|NCT06165497|EXPERIMENTAL|Self-compassion, 10 minutes, male voice|Self-compassion meditation, 10 minutes duration, with a male speaker.
62155142|NCT06165497|EXPERIMENTAL|Self-compassion, 5 minutes, female voice|Self-compassion meditation, 5 minutes duration, with a female speaker.
62155143|NCT06165497|EXPERIMENTAL|Self-compassion, 10 minutes, female voice|Self-compassion meditation, 10 minutes duration, with a female speaker.
62713894|NCT02638909|EXPERIMENTAL|ceritinib|Phase II, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
62713895|NCT04189445|EXPERIMENTAL|Futibatinib (Cohort A)|Advanced or metastatic solid tumors harboring FGFR1-4 rearrangements
62155144|NCT06165497|EXPERIMENTAL|Gratitude, 5 minutes, male voice|Gratitude meditation, 5 minutes duration, with a male speaker.
62155145|NCT06165497|EXPERIMENTAL|Gratitude, 10 minutes, male voice|Gratitude meditation, 10 minutes duration, with a male speaker.
62713896|NCT04189445|EXPERIMENTAL|Futibatinib (Cohort B)|Advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification
62713897|NCT04189445|EXPERIMENTAL|Futibatinib (Cohort C)|Myeloid or lymphoid neoplasm harboring FGFR1 rearrangement
62155146|NCT06165497|EXPERIMENTAL|Gratitude, 5 minutes, female voice|Gratitude meditation, 5 minutes duration, with a female speaker.
62155147|NCT06165497|EXPERIMENTAL|Gratitude, 10 minutes, female voice|Gratitude meditation, 10 minutes duration, with a female speaker.
62155148|NCT06165497|OTHER|Internet-as-usual, 5 minutes|Participants will be instructed to use the internet as they typical do for 5 minutes.
62155149|NCT06165497|OTHER|Internet-as-usual, 10 minutes|Participants will be instructed to use the internet as they typical do for 10 minutes.
62155150|NCT00321971|EXPERIMENTAL|PST-MCI/AD Caregiving|The experimental Intervention (PST-MCI/AD Caregiving) focuses on training in adaptive problem-solving attitudes and skills (Problem-Solving Therapy or PST). It was adapted from a manualized protocol for PST use in primary care. Our adaptation sought to enhance problem-solving skill levels of family caregivers as they began to face a variety of potential caregiving stressor.
62155151|NCT00321971|ACTIVE_COMPARATOR|NT-MCI/AD Caregiving|"The comparison Intervention (Caregiver Nutritional Training (NT-MCI/AD) was based on the United States Department of Health and Human Services (USDHHS) 2005 My Pyramid Dietary Guidelines for Americans over Age 50. We chose a nutrition-based comparison intervention because information about dietary practices is not likely to affect mental health outcomes. The NT intervention was matched to the PST-based intervention in terms of number and duration of sessions."
62713898|NCT02117102|EXPERIMENTAL|bladder and lumbar stimulation|Apply bladder and lumbar stimulation
62713899|NCT02117102|NO_INTERVENTION|Control group|Ordinary pediatric urine collection bag
62529021|NCT03915366|EXPERIMENTAL|Tuberculosis Treatment plus Valganciclovir plus SoC|"Treatment for CMV and for tuberculosis. Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
62713900|NCT05785208|EXPERIMENTAL|ARM A: TP53 wilde-type|Participants will receive osimertinib 80 mg once daily until disease progression or unacceptable toxicity.
62713901|NCT05785208|EXPERIMENTAL|ARM B: TP53 mutant|Participants will receive osimertinib 80 mg once daily until disease progression or unacceptable toxicity.
62155152|NCT03780634|EXPERIMENTAL|HAIC plus PD-1 antibody|Participants received PD-1 antibody intravenously and hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62155153|NCT03780634|ACTIVE_COMPARATOR|HAIC plus sorafenib|Participants received sorafenib capsules 400mg bid in continuous 21-day treatment cycles, and received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62155154|NCT01128673||Body Cooled|Infants undergoing total body cooling for HIE
62155155|NCT01128673||HIE,Selective Head Cooled|Infants undergoing head cooling for HIE
62155156|NCT03039556|EXPERIMENTAL|Change in physical activity for older adults|Older adult participants undergo alterations in daily ambulation by completing Normal Daily Steps for one week, followed by a two-week Step-Reduction and a subsequent Return to Normal Daily Steps for two weeks
62155157|NCT05307302||Adolescent basketball players|Adolescent basketball players between the ages of 13-18 playing in basketball teams
62155158|NCT03878394|EXPERIMENTAL|Group 1|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.
62155159|NCT03878394|EXPERIMENTAL|Group 2|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
62155160|NCT05693428|OTHER|Propofol|Anesthesia
62155161|NCT05693428|OTHER|Isofluran|Anesthesia
62155162|NCT05693428|OTHER|Sevofluran|Anesthesia
62155163|NCT02188745|EXPERIMENTAL|Alternating Therapy|"Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred.~17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day.~Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day.~Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day.~Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day."
62155164|NCT02418065|EXPERIMENTAL|treated group|testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle
62155165|NCT02418065|OTHER|control group|oral nutritional supplementation
62155166|NCT01494467|EXPERIMENTAL|CD5024|CD5024 1% Cream
62155167|NCT01494467|PLACEBO_COMPARATOR|CD5024 Vehicle|CD5024 Vehicle Cream
62155168|NCT03796364|ACTIVE_COMPARATOR|control group|standard SRILI treatment
62155169|NCT03796364|EXPERIMENTAL|observation group|Endostar® plus standard treatment
62529022|NCT04896411|EXPERIMENTAL|Alternative Phrase|This arm will have the code status question randomized to offer CPR vs the alternative phrase
62529023|NCT04896411|ACTIVE_COMPARATOR|Standard of care phrase|This arm will have the code status question randomized to offer CPR vs the standard of care phrase
62529024|NCT03269331||ARCC EBP Model|CTEP EBP Immersion Course
62529025|NCT03269331||Control Group|No CTEP EBP Immersion Course
62529026|NCT02500641|EXPERIMENTAL|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
62713902|NCT06206863|EXPERIMENTAL|Supportive Care (virtual exercise classes)|Participants participate in virtual exercise classes at least TIW over 20-60 minutes for 12 weeks. Participants are expected to work towards achieving the national physical activity exercise guidelines of 150 minutes of moderate intensity aerobic based physical activity and 2-3 strength training sessions each week.
62713903|NCT06719362|EXPERIMENTAL|Part 1A: DL 1|M3T01 100 mg as monotherapy.
62713904|NCT06719362|EXPERIMENTAL|Part 1A: DL 2|M3T01 200 mg as monotherapy.
62713905|NCT06719362|EXPERIMENTAL|Part 1A: DL 3|M3T01 400 mg as monotherapy.
62713906|NCT06719362|EXPERIMENTAL|Part 1A: DL 4|M3T01 600 mg as monotherapy.
62713907|NCT06719362|EXPERIMENTAL|Part 1A: DL 5|M3T01 800 mg as monotherapy.
62713908|NCT06719362|EXPERIMENTAL|Part 1B: DL 6|M3T01 400 mg in combination with pembrolizumab 200 mg.
62713909|NCT06719362|EXPERIMENTAL|Part 1B: DL 7|M3T01 600 mg in combination with pembrolizumab 200 mg.
62155170|NCT01778894||Healthy Control|Healthy controls with no history of heart disease or heart failure. Subjects will undergo a medical history review and 1 echocardiograph procedure.
62155171|NCT01778894||>Grade 2 Diastolic Dysfunction|Diastolic Heart Failure, \> Grade II (NYHA functional class) and/or \> Grade II Diastolic Dysfunction as evaluated by echocardiography
62155172|NCT04681209|EXPERIMENTAL|DRT-Condition|This is the experimental group that engaged in the DRT-based intervention activity.
62155173|NCT04681209|ACTIVE_COMPARATOR|Empathy-Condition|This is the experimental group that engaged in the empathy-based intervention activity.
62155174|NCT01555892|EXPERIMENTAL|EBV-specific T cells: A|"Group A: Patients in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiple relapsed patients in remission who are at a high risk of relapse)\*\* or any patient with primary disease or in first or subsequent remission if immunosuppressive chemotherapy is contraindicated.~Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule:~Day 0: 1 x 10\^8 cells/m2~Day 14: 2 x 10\^8 cells/m2~\*\* Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant."
62155175|NCT01555892|EXPERIMENTAL|EBV-specific T cells: B|"Group B: Patients in remission or with minimal residual disease (MRD) status after autologous or syngeneic SCT.~Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule:~Day 0: 1 x 10\^8 cells/m2~Day 14: 2 x 10\^8 cells/m2"
62155176|NCT03689452|PLACEBO_COMPARATOR|Control|15 participants will receive 3 mL of preservative free normal saline injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
62529027|NCT02500641|ACTIVE_COMPARATOR|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl.~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
62529028|NCT01584453|EXPERIMENTAL|Sodium Nitrite|
62529029|NCT01584453|PLACEBO_COMPARATOR|Placebo|
62529030|NCT03891966|ACTIVE_COMPARATOR|Splint|
62529031|NCT03891966|ACTIVE_COMPARATOR|Soft Dressing|
62529032|NCT03802955|EXPERIMENTAL|ADG106 Dose escalation|
62529033|NCT02344719|ACTIVE_COMPARATOR|6 capsules Taurin per day|After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.
62529034|NCT02344719|PLACEBO_COMPARATOR|6 capsuless placebo per day|After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.
62529035|NCT05876663|EXPERIMENTAL|Kinesio Taping along with conventional physiotherapy protocol|"All baseline measurements will be collected in the beginning. In participant of experimental group the K-tape will be first applied from the anterior aspect of the acromion process of the scapular to the spinous process of the fourth thoracic vertebra (T4). Then, the K-tape will be applied from same origin to the insertion at the spinous process of the tenth thoracic vertebra (T10). K-tape will be applied with 50% tension of its original length.~The K-tapes will be replaced with new ones every two days for six weeks. The outcome measures will be assessed after every two weeks i.e. pre-assessment, on week 2, week 4, and week 6.~Primary outcome measures include the effect of kinesio taping on pulmonary function (via Digital Spirometry) and chest expansion (via Measuring Tape).Secondary outcome measures include FSP and pectoralis minor index (via Digital Vernier Caliper)"
62529036|NCT05876663|ACTIVE_COMPARATOR|Conventional physiotherapy protocol|"Stretching exercise for Pectoralis Minor and Major muscle: Participant in supine lying try to touch the tip of shoulder with the bed surface e.g. retraction. Than in supine raise/abduct the arm at 90 and 120 degrees; try to drop down from the surface of the bed. Hold for 10 seconds 10 reps. 2 sessions per day for 6 weeks.~Strengthening of Rhomboids: Participant in sitting position instructed to depress and retract the shoulder at the same time .Hold for 20 seconds 10 reps. 2 sessions per day for 6 weeks.~Strengthening of lower and mid trapezius: In prone lying abduct arms to the side 90 degrees. Raise arms form surface of bed like an aero plane wings. Take a weight of 1 kg in hands and hold for 10 sec and 10 reps. 2 sessions per day for 6 weeks.~Deep Breathing exercise: participant instructed to take a slow and deep breath inhaling through nose and exhaling through mouth. 10 rep 3 sessions per day for 6 weeks.~Education regarding posture correction."
62529037|NCT03663634|EXPERIMENTAL|Handling Medium Supplemented with Cytochalasin B|
62529038|NCT03663634|NO_INTERVENTION|Handling Medium as it is.|
62529039|NCT03584984|EXPERIMENTAL|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|socket preservation with a mixture of autogenous bone graft acquired at the time of extraction mixed with a 50:50 ratio of Anorganic bovine bone
62529040|NCT03584984|ACTIVE_COMPARATOR|Anorganic bovine bone graft (ABB)|filling the extraction socket with ABB graft
62529041|NCT03584984|ACTIVE_COMPARATOR|Absorbable gelatin Sponge|Filling the socket with an absorbable gelatin sponge
62155177|NCT03689452|EXPERIMENTAL|Treatment|15 participants will receive 3-6 mL of platelet rich plasma injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
62155178|NCT02973035|EXPERIMENTAL|Amlodipine|Amlodipine 2.5mg added to antihypertensive therapy
62529042|NCT03123536||Point-of-care ultrasound group|High risk patients received point-of-care ultrasound assessment perioperatively, treatment was oriented by the findings of point-of-care ultrasound.
62529043|NCT03123536||Control group|High risk patients received management by the experience of the clinical team.
62529044|NCT02887300|NO_INTERVENTION|Passive control group|"After randomisation, 30 consenting, eligible study participants will be allotted a place in the passive, parallel control group. Participants will work as usual in the ED. Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
62155179|NCT02973035|EXPERIMENTAL|Valsartan|Valsartan 40mg added to antihypertensive therapy
62155180|NCT03822897|OTHER|Two Treatment Options|"Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks~Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy"
62155181|NCT00448344|EXPERIMENTAL|Arm 1|Family-supported smoking cessation
62155182|NCT00448344|OTHER|Arm 2|Standard smoking cessation
62155183|NCT06165133|EXPERIMENTAL|Non-Surgeon Physician|The intervention arm is a mesh inguinal hernia repair performed by a non-surgeon physician (NSP). These are medical officers who have finished a 2-year mandatory house job. The medical officers will be trained to perform inguinal hernia repair by a certified surgical trainer in Ghana.
62529045|NCT02887300|EXPERIMENTAL|Planned intervention - mantra meditation|"After randomisation, 30 randomly chosen, ED staff members will be taught mantra meditation by an experienced meditator. Each 4 hour session will occur once every two weeks for 8 weeks (total of 4 sessions) and consist of guided meditation as well as discussions around prescribed texts on the meaning of health care.~In addition, participants will be asked to engage in home work (20 minutes of a guided mantra meditation on a twice daily basis). Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
62529046|NCT03664518|EXPERIMENTAL|Eltrombopag|58 enrolled patients are picked up to take eltrombopag at the indicated dose.
62155184|NCT06165133|PLACEBO_COMPARATOR|Control: Surgeon|The control is a mesh inguinal hernia repair performed by a fully trained surgeon, defined as one who is accredited as fully trained with the Ghana College of Physicians and Surgeons, West African College of Surgeons, or equivalent. A trained surgeon will be assisted by an NSP who has completed the TIGER training programme. We anticipate that at least 5-10 fully trained surgeons will take part in the control arm.
62529047|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
62529048|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
62155185|NCT04222400|ACTIVE_COMPARATOR|Transplantation|Frailty assessment before, after and 6 month after surgery
62155186|NCT04222400|ACTIVE_COMPARATOR|VAD Implantation|Frailty assessment before, after and 6 month after surgery
62155187|NCT05886465|EXPERIMENTAL|HAIC plus A+T|
62155188|NCT02144285|EXPERIMENTAL|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
62155189|NCT02144285|PLACEBO_COMPARATOR|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
62529049|NCT03924206||Minimally invasive surgery with smoke evacuation system (SES)|minimally invasive surgical procedures during which a smoke evacuation device is used
62155190|NCT02144285|EXPERIMENTAL|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
62155191|NCT02144285|PLACEBO_COMPARATOR|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
62155192|NCT02144285|EXPERIMENTAL|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
62155193|NCT02144285|PLACEBO_COMPARATOR|Placebo IV (Part B)|Single dose of placebo matching LY3113593 administered IV
62155194|NCT05298709|EXPERIMENTAL|Hypercarbia/Hypocarbia/resting state during fMRI|"During real time fMRI, all subjects will completed breathing tasks though a mask that supplies gas mixtures using the RespirAct™ Gas Control System (Thornhill Medical). The RespirAct™ is a computer-controlled gas blender providing carbon dioxide (CO2), oxygen (O2) and nitrogen for a subject to inhale while breathing for the purpose of controlling the concentrations of the respective blood gases.~For hypocarbia, subjects will be instructed to pace their breathing to 16- 20 breaths-per-minute to achieve a stable target end-tidal CO2 between 30 and 40 mm Hg.~Hypercarbia will be induced by increasing CO2 concentration and flow rate of the gas mixture until a desired ETCO2 level between 40 and 50 mm Hg has been reached.~There will also be a 10 minutes rest period during which respiratory rate and heart rate will be monitored continuously."
62155195|NCT01163929|EXPERIMENTAL|paclitaxel, trastuzumab and everolimus|
62529050|NCT03924206||Minimally invasive surgery without SES|minimally invasive surgical procedures during which no smoke evacuation device is used
62155196|NCT01294644|PLACEBO_COMPARATOR|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62529051|NCT03924206||Open surgery with SES|open surgical procedures during which a smoke evacuation device is used
62529052|NCT03924206||Open surgery without SES|open surgical procedures during which no smoke evacuation device is used
62529053|NCT01909830|EXPERIMENTAL|Arm A : Gemcitabine + Pemetrexed|"Arm A : Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
62529054|NCT03517696|ACTIVE_COMPARATOR|Membrane Sweeping|Membrane sweeping
62529055|NCT03517696|NO_INTERVENTION|Control|Routine vaginal exam
62529056|NCT01145430|EXPERIMENTAL|Treatment (veliparib and liposomal doxorubicin hydrochloride)|Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62529057|NCT00396435|EXPERIMENTAL|Group A|High Hb target
62155197|NCT01294644|EXPERIMENTAL|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62155198|NCT01294644|EXPERIMENTAL|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
62155199|NCT04904354|EXPERIMENTAL|Paroxysmal atrial fibrillation|Subjects schedule for a de novo ablation of paroxysmal atrial fibrillation
62155200|NCT04904354|EXPERIMENTAL|Persistent atrial fibrillation|Subjects schedule for a de novo ablation of persistent atrial fibrillation
62529058|NCT00396435|ACTIVE_COMPARATOR|Group B|Low Hb Target
62529059|NCT02130882|ACTIVE_COMPARATOR|Drug|Benralizumab (30mg) will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background hypereosinophilic syndrome (HES) therapy will not be tapered.
62529060|NCT02130882|PLACEBO_COMPARATOR|Placebo|Placebo will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
62529061|NCT00688376|EXPERIMENTAL|1|
62529062|NCT00688376|PLACEBO_COMPARATOR|2|
62529063|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
62529064|NCT05490290|ACTIVE_COMPARATOR|Active|In the active intervention the CDSS is implemented with decision support. Physicians are made aware of the referral guidelines and appropriate exams are suggested. Their imaging requests are categorized as appropriate, under certain conditions appropriate, or inappropriate and feedback is provided. Physicians are able to change their request in response to the feedback.
62529065|NCT05490290|NO_INTERVENTION|Control|The control condition will consist of computerized order entry with structured data entry of the clinical indication and tracking of the imaging exams requested. The CDSS is implemented but without decision support and physicians are blinded to these referral guidelines. Without their knowledge their imaging requests are categorized as appropriate, under certain conditions appropriate, or inappropriate. They receive no feedback to their requests.
62529066|NCT04863222|EXPERIMENTAL|MTA, then Biodentine|The participant will receive the standard of care procedure using MTA in on a right primary molar. A left primary molar will then be treated using Biodentine.
62529067|NCT04863222|EXPERIMENTAL|Biodentine, then MTA|Investigators will prepare and treat a participants right primary molar with Biodentine. The participant will then receive the standard of care procedure using MTA in on a left primary molar.
62529068|NCT03757975||TAH|patients before and after total abdominal hysterectomy (TAH)
62529069|NCT03757975||TLH|patients before and after total laparoscopic hysterectomy (TLH)
62529070|NCT03757975||TVH|patients before and after total vaginal hysterectomy (TVH)
62529071|NCT03757975||SAH|patients before and after abdominal supracervical hysterectomy (SAH)
62529072|NCT03757975||SLH|patients before and after supracervical laparoscopic hysterectomy (SLH)
62529073|NCT05447000|EXPERIMENTAL|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
62529074|NCT05447000|EXPERIMENTAL|Deep Relaxation Exercises|Deep Relaxation Exercises therapy
62529075|NCT05447000|OTHER|Control|Control
62529076|NCT01142479|PLACEBO_COMPARATOR|herbal A|dilute of (TPE-1) decoction.
62529077|NCT01142479|EXPERIMENTAL|herbal B|TPE-1 decoction (100 ml)
62713910|NCT06719362|EXPERIMENTAL|Part 1B: DL 8|M3T01 800 mg in combination with pembrolizumab 200 mg.
62713911|NCT06719362|EXPERIMENTAL|Part 2A: Newly diagnosed glioblastoma with unmethylated MGMT promoter|Subjects will be treated with standard of care chemoradiation therapy consisting of TMZ 75 mg/m2 daily with concurrent radiation therapy (60 Gy administered over 6 weeks). Following chemoradiation therapy, subjects will have a 4-week break from TMZ before starting standard adjuvant TMZ 150-200 mg/m2 days 1-5 of 28-day cycles for 6 cycles. Subjects will be treated with M3T01 at the RP2D through an IV infusion every 3 weeks that will begin concurrently with chemoradiation therapy.
62713912|NCT06719362|EXPERIMENTAL|Part 2B: First-line tx for unresectable/metastatic HER2- esophageal, GEJ, or gastric adenocarcinoma.|Subjects with unresectable or metastatic HER2 negative esophageal, gastroesophageal (GEJ), or gastric adenocarcinoma without prior systemic therapy in the metastatic setting will be treated with M3T01 at the RPD2 in combination with standard of care pembrolizumab plus FOLFOX chemotherapy.
62713913|NCT06719362|EXPERIMENTAL|Part 2C: Second-line treatment for recurrent/metastatic HNSCC|Subjects with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have developed disease progression after first-line systemic therapy with an anti-PD-1-based regimen in the recurrent or metastatic setting will be treated with M3T01 at the RP2D in combination with pembrolizumab 200 mg IV every 3 weeks for up to 2 years.
62713914|NCT01402921|EXPERIMENTAL|Elastic Medical Compressive Therapy|"V0322BC verum medical compressive therapy is a progressive compressive sock with:~* ankle pressure: 10 mmHg~* calf pressure : 23 mmHg"
62713915|NCT01402921|PLACEBO_COMPARATOR|Placebo|"V0322BC placebo medical compressive therapy is a progressive compressive sock with:~* ankle pressure: \<5 mmHg~* calf pressure : \<7 mmHg"
62529078|NCT03728218|EXPERIMENTAL|Orthokeratology Contact lenses|
62713916|NCT02219152|EXPERIMENTAL|tranexamic acid|tranexamic acid will be administrated using the bronchoscope
62713917|NCT02219152|PLACEBO_COMPARATOR|saline|the saline will be administrated using an infusion during the biopsy.
62529079|NCT03728218|EXPERIMENTAL|Soft Multifocal Contact lenses|
62529080|NCT01633736|EXPERIMENTAL|home progressive resistance exercise|
62529081|NCT00673153|EXPERIMENTAL|Arm I|"REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .~CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.~MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses."
62155201|NCT01123005|EXPERIMENTAL|Carbogen arm|
62155202|NCT01123005|EXPERIMENTAL|DCA arm|
62529082|NCT00005614|EXPERIMENTAL|Gemcitabine Treatment|Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
62529083|NCT02158286||Esophagectomy, Emptying from gastric tube|Validate paracetamol clearance technique to scintigraphy for measuring emptying rate from the gastric tube.
62529084|NCT02631967|EXPERIMENTAL|Kono anastomosis|Patients receiving Kono anastomosis
62529085|NCT02631967|EXPERIMENTAL|Stapled side-to-side anastomosis|Patients receiving stapled side-to-side anastomosis
62529086|NCT04602065|EXPERIMENTAL|Previously received anti-PD1/PD-L1 antibodies|Patients previously received anti-PD1/PD-L1 antibodies, except for those were primarily refractory to them.
62529087|NCT04602065|EXPERIMENTAL|Patients previously never received anti-PD1/PD-L1 antibodies|Patients previously never received anti-PD1/PD-L1 antibodies.
62529088|NCT06072365||cystic fibrosis|patient with cystic fibrosis treated with With Elexacaftor/Tezacaftor/Ivacaftor,
62713918|NCT05311397|EXPERIMENTAL|The first stage（Dose-escalation）|According to the initial dose, the highest dose and the modified Fibonacci method, the dose escalation of A166 for injection is designed as: 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg (the highest dose is tentatively set at 4.8 mg/kg).
62529089|NCT04672486|EXPERIMENTAL|Intervention Arm|Participants will be offered an online problem-solving intervention that is delivered through a smartphone app (called POD Adventures) with telephone-based guidance from a lay counsellor. The app teaches problem-solving skills through interactive animated vignettes and personalized action plans, with encouraging prompts and feedback offered through an in-app guide character. In addition, methods of gamification are used to model and practice complementary coping strategies (e.g., relaxation) and enhance engagement. Participants will use the app remotely (i.e., from their home) in their own time.
62713919|NCT05311397|EXPERIMENTAL|The second stage（Dose-expansion）|The administered dose of A166 for injection is RS2D obtained in the first stage .
62155203|NCT01921166|ACTIVE_COMPARATOR|clomiphene plus gonadotropins|clomiphene plus gonadotropins
62155204|NCT01921166|ACTIVE_COMPARATOR|Leuprolide flare|Leuprolide flare
62155205|NCT00866541|EXPERIMENTAL|volunteers|artificial increased respiratory resistance
62529090|NCT04672486|NO_INTERVENTION|Usual Care|Participants randomized to the control arm will be provided with usual care. This will consist of information and contact details about local mental health service providers and two recently established government provided/affiliated helplines: (i) Manodarpan, a student mental health helpline supported by the Ministry of Human Resource Development; and (ii) a 24/7 mental health helpline (KIRAN) supported by the Social Justice and Empowerment Ministry. The same information will be provided to participants in the intervention arm.
62529091|NCT00117208|EXPERIMENTAL|1|
62529092|NCT00117208|ACTIVE_COMPARATOR|2|DNase daily for 12 weeks
62529093|NCT00117208|OTHER|3|combination
62529094|NCT05922475|EXPERIMENTAL|Post-exercise protein|Consumed 40 g of supplemental protein immediately after exercise sessions and in between breakfast and lunch on non-exercise days.
62529095|NCT05922475|EXPERIMENTAL|Pre-sleep protein|Consumed 40 g of supplemental protein 30 minutes before sleep every day.
62529096|NCT05922475|PLACEBO_COMPARATOR|Resistance exercise training only|Did not consume supplemental protein.
62155206|NCT06187402|EXPERIMENTAL|LM-24C5 Dose Escalation|
62155207|NCT06187402|EXPERIMENTAL|LM-24C5 Dose Expansion|
62155208|NCT02400749|EXPERIMENTAL|Apremilast|Patients will receive Apremilast until week 32.
62155209|NCT02400749|PLACEBO_COMPARATOR|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
62155210|NCT03209492||Leuprorelin acetate|Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
62529097|NCT02866045|ACTIVE_COMPARATOR|EUS-guided Fine Needle Biopsy|EUS-FNB is performed using a 22 or 25 G SharkCore biopsy needle with a minimum of 3 passes into the lesion.
62529098|NCT02866045|EXPERIMENTAL|Single incision needle knife biopsy|SINK biopsy is performed under direct endoscopic visualization via EGD with a minimum of 3 biopsy samples obtained.
62155211|NCT00458510|EXPERIMENTAL|Fentanyl, Open-Label treatment|All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day
62155212|NCT00898313||Sample Collection|
62529099|NCT04766736||Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
62529100|NCT04766736||Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
62529101|NCT03666559|EXPERIMENTAL|Azacitidine|Azacitidine is administered by sub-cutaneous injection at 75 mg/m2 per day for seven consecutive days every 4 weeks until progression, intolerance or end of the study.
62529102|NCT02854111|ACTIVE_COMPARATOR|oral glucose tolerance test|75-g glucose A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink a sweet liquid containing 75 g-glucose. Blood samples will be collected at timed intervals of 1 and 2 hours after you drink the glucose. This is a standard method for diagnosis of diabetes mellitus that called oral glucose tolerance test or OGTT.
62529103|NCT02854111|EXPERIMENTAL|ice cream|A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink ice cream that contained carbohydrate 73.9 g. Blood samples will be collected at timed intervals of 1 and 2 hours after you eat the ice cream.
62529104|NCT02802631|EXPERIMENTAL|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection was supplied as a sterile lyophilized powder in single-use 10-milliliter (mL) glass vials. Each vial contained 108 milligrams (mg) of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort received one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 600 mg. Within each cohort, participants received a single dose on Day 1, followed by 7 days of multiple doses (Days 4 to 10, given every 12 hours), followed by a single dose on Day 11.
62155213|NCT02338505|EXPERIMENTAL|Telelap ALF-X in obese patients with gynecological disease|
62155214|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
62155215|NCT00142532|EXPERIMENTAL|1|At the time of pre-op preparation, 18 semi-permanent intradermal acupuncture studs will be placed at acupuncture points in the back, two will be placed in the legs and two in the ear. All studs will be replaced when the epidural is removed or, for patients without epidurals, shortly before discharge. The new leg and auricular studs will then be removed at eleven days; the new back studs will be removed at the three week post-discharge consult.
62529105|NCT02802631|PLACEBO_COMPARATOR|0.9% Sodium Chloride Injection USP|Placebo was in the form of the same 100-mL bags of normal saline (0.9% Sodium Chloride Injection United States Pharmacopeia \[USP\]). Dosing was on the same schedule as participants randomized to Minocin (minocycline) for Injection.
62155216|NCT00142532|PLACEBO_COMPARATOR|2|"The treatment is the same as for the true acupuncture group, with the following exceptions. The studs in the back will be dummy studs have no needle and that have been used in previous research at MSKCC. The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
62155217|NCT00028600|EXPERIMENTAL|Autologous + Allogeneic Transplant|autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma
62155218|NCT04849091||iReadMore users|"Participants will be iReadMore users who completed a baseline reading test between XX/XX/XXXX and XX/XX/XXXX, and who performed at least 5 hours of reading training and a second (interval) reading test.~iReadMore users will self-register to participate in the study."
62155219|NCT01795989||Healthy Volunteers|Research only musculoskeletal (MSK) MRI for healthy volunteers.
62155220|NCT01795989||Clinical Efficacy|Clinically indicated musculoskeletal (MSK) MRI with sequences obtained using this pediatric elbow coil.
62155221|NCT06506500||ULIF|Unilateral Biportal Endoscopy Lumbar Interbody Fusion
62155222|NCT06506500||PLIF|Posterior Lumbar Interbody Fusion
62155223|NCT00266305|EXPERIMENTAL|Fish oil|
62155224|NCT00266305|PLACEBO_COMPARATOR|Olive oil|Control group
62155225|NCT00266305|NO_INTERVENTION|High fish|Reference group
62155226|NCT03123224|EXPERIMENTAL|Combined Aerobic and Resistance Exercise|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry. Exercises will focus on increasing the heart rate to a point at which participants will breathe more heavily and may sweat.
62529106|NCT05991648|EXPERIMENTAL|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
62529107|NCT05991648|NO_INTERVENTION|Routine care in an incubator|The newborn, dressed only in a clean diaper, is placed in a nest in the double-walled servo-controlled incubator.
62529108|NCT02757365|EXPERIMENTAL|the NSAIDs group|Patients in the this Group will received the aspirin 100mg qd until the experiment finished
62529109|NCT02757365|EXPERIMENTAL|the antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4\~8 weeks
62529110|NCT02757365|EXPERIMENTAL|the NSAIDs+antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4\~8 weeks and aspirin 100mg qd until the experiment finished
62529111|NCT02757365|NO_INTERVENTION|the control group|No treatment
62529112|NCT03984292|EXPERIMENTAL|Mass Learning|Single teaching session of 3 hours shall be provided
62529113|NCT03984292|EXPERIMENTAL|Distributed Learning|Three teaching sessions of 1 hour each shall be provided.
62529114|NCT06240520|NO_INTERVENTION|control|
62529115|NCT06240520|EXPERIMENTAL|panobinostat|
62155227|NCT03123224|ACTIVE_COMPARATOR|Balance and Flexibility|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry.
62155228|NCT06584786|PLACEBO_COMPARATOR|Placebo group (1)|Placebo group: participants with COPD AE is treated with placebo that mimic JSHT
62155229|NCT06584786|PLACEBO_COMPARATOR|Placebo group (2)|participants with stable COPD treated with placebo that mimic JSHT
62155230|NCT06584786|EXPERIMENTAL|JSHT group of stable COPD|participants with stable COPD treated with JSHT
62155231|NCT06584786|EXPERIMENTAL|JSHT group of COPDAE|participants with COPD AE is treated with JSHT
62155232|NCT00785499|EXPERIMENTAL|skim milk|skim milk
62155233|NCT00785499|EXPERIMENTAL|whey|Whey milk drink
62155234|NCT00785499|EXPERIMENTAL|casein|casein milk drink
62155235|NCT00785499|ACTIVE_COMPARATOR|water|Danish mineral water
62155236|NCT01565031||controlled asthmatics, down-titration|Adults (age between 18 and 80) with asthma under control (see definitions) during the last 3 months, treated with a combination of ICS and long-acting beta-agonist (LABA).
62529116|NCT06240520|EXPERIMENTAL|lenalidomide|
62529117|NCT06240520|EXPERIMENTAL|pyrimethamine|
62529118|NCT06240520|EXPERIMENTAL|panobinostat + lenalidomide|
62529119|NCT06240520|EXPERIMENTAL|panobinostat + pyrimethamine|
62529120|NCT06240520|EXPERIMENTAL|lenalidomide + pyrimethamine|
62529121|NCT00573781|EXPERIMENTAL|A|Diet with increased intake of rye bread, berries and fish
62155237|NCT01599078|PLACEBO_COMPARATOR|Placebo|
62155238|NCT01599078|ACTIVE_COMPARATOR|Paclitaxel|
62155239|NCT01443572|EXPERIMENTAL|desflurane group|
62155240|NCT01443572|ACTIVE_COMPARATOR|sevoflurane group|
62155241|NCT03824743||Lactate Ringer|Patients managed with Ringer Lactate
62155242|NCT03824743||Plasma-Lyte|Patients managed with Plasma-Lyte
62155243|NCT04527679|EXPERIMENTAL|GC combined Lenvatinib|"1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg)."
62529122|NCT00573781|EXPERIMENTAL|B|Increased intake of whole grain and rye bread
62529123|NCT00573781|ACTIVE_COMPARATOR|C|Control diet with decreased intake of rye bread, berries and fish
62529124|NCT01104909|ACTIVE_COMPARATOR|Clinical dry weight|Group which the dry weight will be assessed based on clinical examination.
62529125|NCT01104909|ACTIVE_COMPARATOR|Bioimpedance|Group which the dry weight will be assessed by bioimpedance data.
62155244|NCT02942771|EXPERIMENTAL|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
62529126|NCT05041621|EXPERIMENTAL|Sensor augmented MDI therapy plus mobile application with reinforcement learning algorithm|Participants with type 1 diabetes will undergo sensor-augmented MDI therapy for 4 months using a freestyle libre glucose sensor (Abbott Diabetes Care) and a mobile application integrated with the reinforcement learning algorithm.
62529127|NCT05296356|EXPERIMENTAL|OSU6162|Coated tablet, flexible dosing
62155245|NCT02942771|EXPERIMENTAL|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
62155246|NCT02942771|EXPERIMENTAL|Cohort 3- TT301/MW189|TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
62529128|NCT06358170|EXPERIMENTAL|SSE|A Circuit Training Combine with Square-Stepping Exercise, Strength training and balance training. The intervention time and frequency of this study were 12 weeks, 2 times a week, 24 times in total, 1.5 hours each time (30 minutes of main exercise).
62529129|NCT06358170|NO_INTERVENTION|Control|No intervention (daily routine)
62529130|NCT02132637|EXPERIMENTAL|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
62529131|NCT02132637|EXPERIMENTAL|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
62155247|NCT02942771|EXPERIMENTAL|Cohort 4- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
62155248|NCT02942771|PLACEBO_COMPARATOR|Placebo|No drug intervention.
62155249|NCT05111340|EXPERIMENTAL|Adult patients undergoing sedation with or without associated local anesthesia|
62155250|NCT05957822|ACTIVE_COMPARATOR|TXA empirical|Empirical Tranexamic acid (TXA) administration after the anesthesia induction
62529132|NCT04269538|EXPERIMENTAL|SAD Cohorts 1-2 Experimental Arm|Experimental Arm Active drug 150 mg and 450 mg SC dosing
62529133|NCT04269538|PLACEBO_COMPARATOR|SAD Cohorts 1-2 Placebo Arm|Placebo Arm
62529134|NCT00967044|EXPERIMENTAL|Panobinostat + Everolimus|Panobinostat (LBH589) Plus Everolimus (RAD001)
62529135|NCT05748613|EXPERIMENTAL|Computerized Anxiety Sensitivity Treatment|"CAST is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated anxiety sensitivity (AS), particularly the amplification of cognitive stress symptoms including perceived confusion and memory problems. CAST is a fully computerized, 1-hour intervention containing video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension, introduction and practice with interoceptive exposures). Procedures draw heavily on standard CBT techniques; AS, a core vulnerability for anxiety and depression is targeted using these procedures. In CAST, participants are informed that the primary purpose of the presentation is to highlight healthier, more productive, and effective ways of dealing with stress. Through participation in the intervention, people learn adaptive long-term strategies for tolerating, coping with, and effectively reducing distress and negative emotions."
62713920|NCT06447909|PLACEBO_COMPARATOR|Placebo app|Behavioral interventions are a well-established psychosocial intervention for the treatment of disruptive behavior disorders and related behavioral difficulties (e.g., ODD, ADHD). Behavioral training is based on social learning and operant conditioning principles in which parents are instructed to utilize positive reinforcement and reward systems to facilitate positive behaviors (e.g., compliance) in their child and reduce challenging behaviors (e.g., opposition). The intervention involves the use of an app to deliver a behavioral intervention using contingency reward systems. It translates established content and processes into a digital format to be delivered through a mobile app. For both conditions, there will be a parent and a child version of the app which are linked. The placebo arm will receive access to an app that does not include the contingency reward system.
62155251|NCT05957822|EXPERIMENTAL|TXA TEG6-triggered|When LY30≥3% or MA\<54 mm in CRT of TEG6, Tranexamic acid (TXA) is administered
62155252|NCT05957822|EXPERIMENTAL|TXA TEG6-non-triggered|When LY30\<3% or MA ≥ 54 mm in CRT of TEG6, Tranexamic acid (TXA) is not administered
62155253|NCT04449822|ACTIVE_COMPARATOR|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
62155254|NCT04449822|ACTIVE_COMPARATOR|Colonic stenting|The colonic stent placement
62155255|NCT05472883|EXPERIMENTAL|study arm|This arm consists of obese patients with type 2 diabetes who are scheduled for bariatric surgery.
62155256|NCT05149716|EXPERIMENTAL|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
62155257|NCT05149716|PLACEBO_COMPARATOR|Placebo supplementation|Placebo supplementation composed of capsules of starch powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
62155258|NCT06201000||Heart Failure Patients with reduced or preserved Ejection Fraction|Patients with reduced or preserved ejection fraction that have received the Guided Therapy (β-blockers, Diuretics, Angiotensin-converting enzyme (ACE) inhibitors or Angiotensin receptor blockers (ARBs) or Angiotensin Receptor-Neprilysin Inhibitor (ARNi) and Mineralocorticoid receptor antagonists (MRAs) then Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) (10 mg of dapagliflozin or empagliflozin) will be added at the study entry.
62155259|NCT01893671||LASIK|Subjects undergoing routine LASIK for the correction of myopia or hyperopia.
62155260|NCT05588297|EXPERIMENTAL|Nivolumab + Bevacizumab + CAPOX as neoadjuvant treatment for 4 cycles|"CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles;~Bevacizumab：Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles; Nivolumab：Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles;"
62155261|NCT05823766||Telephone Assessment Battery|TRACK-TBI participants may complete up to three annual telephone calls to assess outcome status and screen for PTE. These assessments will determine eligibility for the in-person study visit.
62155262|NCT05823766||Comprehensive Assessment Battery (CAB)|Participants who demonstrate decision-making capacity will be asked to complete the Comprehensive Assessment Battery (CAB). The CAB in-person is comprised of measures of cognition (i.e. attention, memory, information processing speed, executive functions), mood (i.e., depression, anxiety), social participation, subjective well-being, post-traumatic stress, interviews, global functional status measures, and a COVID-19 questionnaire.
62155263|NCT05823766||Abbreviated Assessment Battery (AAB)|Participants who do not have decision-making capacity will be asked to complete a modified assessment battery, called the Abbreviated Assessment Battery (AAB). The AAB in-person assessment will administer the Speech Intelligibility, GOAT, and CAP and/or CRS-R to study participants.
62155264|NCT05823766||TED Friend Controls|Participants enrolled in the TBI Endpoints Development (TED) cohort from 2017-2019 who did not experience a TBI prior to affiliated enrollment in TRACK-TBI will be asked to complete an assessment battery.
62155265|NCT03530735|EXPERIMENTAL|Fingerprick Autologous Blood (FAB) for Use in Dry Mouth|"All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.~Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home."
62155266|NCT01714947|EXPERIMENTAL|Alisertib|"Part A: \[\^14C\]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1.~Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles)."
62155267|NCT01027455|PLACEBO_COMPARATOR|Dry Cold|Dry (0% relative humidity) and cold (20 degrees Celsius - Room Temperature) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
62155268|NCT01027455|EXPERIMENTAL|Humidification|Humidified (98% relative humidity) and warm (37 degrees Celsius) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
62529136|NCT05748613|PLACEBO_COMPARATOR|Health Education Control|HEC is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, exercise, stress management as well as other healthy lifestyle tips. To match the interactive components in the CAST condition, behavior tracking and goal-setting are included in HEC. The HEC protocol has been used in prior studies as a control condition for CAST to account for intervention modality and time. HEC is perceived positively, with high rates of acceptability. Importantly, HEC is inert with respect to the proposed mechanism of action (AS).
62529137|NCT05355649|OTHER|PREGNOLIA TEST|Women at the time of triage will be tested with TVU CL (transvaginal ultrasound cervical length) and with the PREGNOLIA system
62529138|NCT02045992|EXPERIMENTAL|Caffeine|Caffeine 500mg
62155269|NCT03635242|ACTIVE_COMPARATOR|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
62529139|NCT02045992|PLACEBO_COMPARATOR|Placebo|Lactose 500mg
62529140|NCT04972123|EXPERIMENTAL|CPC Adminstration|Single dose of CPC will be given during tilt table test
62529141|NCT04972123|PLACEBO_COMPARATOR|Placebo Adminstration|Single dose of Placebo will be given during tilt table test
62529142|NCT05341466|EXPERIMENTAL|Repetitive Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
62529143|NCT05341466|SHAM_COMPARATOR|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
62529144|NCT01549106|EXPERIMENTAL|IPI-145|
62529145|NCT01549106|PLACEBO_COMPARATOR|Placebo|
62529146|NCT01297465|ACTIVE_COMPARATOR|Gonal-f® Plus Pergoveris®|
62529147|NCT01297465|EXPERIMENTAL|Pergoveris®|
62529148|NCT03290365|ACTIVE_COMPARATOR|Platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
62529149|NCT03290365|PLACEBO_COMPARATOR|Platelet rich plasma + normal saline|Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
62529150|NCT04178070|EXPERIMENTAL|GB224 2mg|single dose
62529151|NCT04178070|EXPERIMENTAL|GB224 5mg|single dose
62529152|NCT04178070|EXPERIMENTAL|GB224 10mg|single dose
62529153|NCT04178070|EXPERIMENTAL|GB224 15mg|single dose
62529154|NCT04178070|EXPERIMENTAL|GB224 20mg|single dose
62529155|NCT04178070|EXPERIMENTAL|GB224 30mg|single dose
62529156|NCT04178070|PLACEBO_COMPARATOR|Placebo 2mg|single dose
62529157|NCT04178070|PLACEBO_COMPARATOR|Placebo 5mg|single dose
62529158|NCT04178070|PLACEBO_COMPARATOR|Placebo 10mg|single dose
62529159|NCT04178070|PLACEBO_COMPARATOR|Placebo 15mg|single dose
62529160|NCT04178070|PLACEBO_COMPARATOR|Placebo 20mg|single dose
62529161|NCT04178070|PLACEBO_COMPARATOR|Placebo 30mg|single dose
62529162|NCT00883623|EXPERIMENTAL|Treatment Arm|Treatment Arm
62529163|NCT05638958|EXPERIMENTAL|Test group|A customized PEEK abutment mimicking the subgingival emergence of the extraction site will be screw-retained on the implant to seal the extraction site and to support healing of buccal soft tissues.
62529164|NCT05638958|ACTIVE_COMPARATOR|Control group|A commercially available healing abutment will be screwed on top of the implant and a collagen sponge will be used to protect the graft.
62155270|NCT03635242|EXPERIMENTAL|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
62155271|NCT00880724|NO_INTERVENTION|Medical management|
62529165|NCT03956810|EXPERIMENTAL|On-demand transportation|Women randomized to the intervention group will be able to contact the transportation broker via telephone, web portal, or the broker's mobile application. In addition to the current trips provided by their Medicaid managed care organization , women assigned to the intervention group will be provided with extra trips to the pharmacy and grocery store or food bank.
62529166|NCT03956810|ACTIVE_COMPARATOR|Usual transportation|Women assigned to the usual care group will receive the usual transportation services from their Medicaid managed care organization.
62155272|NCT06261515|EXPERIMENTAL|Conventional periodontal treatment|Periodontal treatment of stage III-IV periodontitis patients according to the guideline recommendation from the European Federation of Periodontology will be provided.
62529167|NCT03816514|EXPERIMENTAL|SpHb monitoring group|In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.
62529168|NCT03816514|ACTIVE_COMPARATOR|Control group|In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.
62529169|NCT04616547|EXPERIMENTAL|Tin Sn 117m DTPA|Patients receive tin Sn 117m DTPA IV over 5-10 minutes on day 1. Treatment repeats every 8 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive tin Sn 117m DTPA for an additional 2 cycles if pain recurs within 6 months after a 16-week pain observation period and no disease progression on bone scans, or evidence of clinical progression.
62529170|NCT04959318|EXPERIMENTAL|Treatment group or counseling group|The treatment group will receive a counseling intervention addressing metabolic syndrome (comprised of abdominal adiposity, high blood pressure, high cholesterol, elevated fasting glucose, and elevated triglyceride level) and low vitamin D. This group will undergo baseline body composition measurements, phlebotomy, and an introduction to the digital app for recording diet and activity.
62529171|NCT04959318|ACTIVE_COMPARATOR|Control group or comparison group|Subjects randomized to the control group will undergo baseline body composition measurements, phlebotomy, and an introduction to the app for recording diet and activity. They will receive a packet of evidence-based pamphlets addressing Service-specific approaches to healthy eating and physical activity (e.g. Performance Triad). There will be no formal recurring interaction with an RD for those randomized to this control group.
62529172|NCT01761370|ACTIVE_COMPARATOR|Treatment|AHA diet plus exercise with BIB placement
62529173|NCT01761370|SHAM_COMPARATOR|Sham control|AHA diet plus exercise with sham BIB placement
62529174|NCT03041324|EXPERIMENTAL|Cohort 1 SB-913 Starting Dose 5.00E+12 vg/kg|A single dose of each of the three components of SB-913 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
62529175|NCT03041324|EXPERIMENTAL|Cohort 2 SB-913 at Next Ascending Dose 1.00E+13 vg/kg|A single dose of each of the three components of SB-913 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
62529176|NCT03041324|EXPERIMENTAL|Cohort 3 SB-913 at Next Ascending Dose 5.00E+13 vg/kg|A single dose of each of the three components of SB-913 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
62155273|NCT06501521||Glioblastoma multiforme|Patients with GBM
62155274|NCT06501521||Low-grade glioma|Patients with low-grade gliomas.
62155275|NCT06501521||Control group|Patients without cancer or systemic inflammation
62155276|NCT01289834|ACTIVE_COMPARATOR|Hi-Fatigue Bone Cement|CPT femoral stems fixed with Hi-Fatigue Bone Cement
62529177|NCT01780987|EXPERIMENTAL|Apixaban|
62529178|NCT01780987|ACTIVE_COMPARATOR|UFH/Warfarin|
62155277|NCT01289834|ACTIVE_COMPARATOR|Palacos Bone Cement|CPT femoral stems fixed with Palacos Bone Cement
62529179|NCT01715064|NO_INTERVENTION|Control|non-exercise control consisting of movie watching.
62529180|NCT01715064|EXPERIMENTAL|Exercise|1 hour of moderate intensity exercise.
62529181|NCT00398996|ACTIVE_COMPARATOR|1 - Early integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment
62529182|NCT00398996|ACTIVE_COMPARATOR|2 - Late integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment
62529183|NCT00398996|ACTIVE_COMPARATOR|3 - Sequential-therapy group|Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment
62529184|NCT00821873|EXPERIMENTAL|CR Plug BackFill|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site
62529185|NCT02202863|EXPERIMENTAL|Red Wine Grape Pomace Flour (WGPF)|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks, except for the daily intake of 20 g of WGPF. WGPF was consumed in bread, biscuits or as flour mixed with water during lunch. Bread and biscuits with 20% WGPF were prepared especially in a bakery. WGPF intake was supervised every day at lunch. Participants were asked to consume the flour supplement with their regular meals on weekends.
62529186|NCT02202863|NO_INTERVENTION|Control|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks.
62529187|NCT02711683||DL-3-n-butylphthalide group|using DL-3-n-butylphthalide treatment in patients with mild to moderate AD already receiving donepezil
62529188|NCT02711683||donepezil group|only using donepezil treatment in patients with mild to moderate AD
62529189|NCT00673244|EXPERIMENTAL|1|
62529190|NCT05631353|ACTIVE_COMPARATOR|Group I: Patients will be treated by Carriere Motion Appliance using passive lingual arch .|Conventional mandibular anchorage During the first month, 1/4-inch heavy elastics will be used. In the following months, 3/16-inch heavy elastics will be used. The patients will be instructed to wear the elastics 24 hours per day, except during mealtimes, and to change them daily
62529191|NCT05631353|ACTIVE_COMPARATOR|Group II: Patients will be treated by Carriere Motion Appliance using direct mini-screw.|TADs mandibular anchorage. During the first month, 1/4-inch heavy elastics will be used. In the following months, 3/16-inch heavy elastics will be used. The patients will be instructed to wear the elastics 24 hours per day, except during mealtimes, and to change them daily
62529192|NCT01996943|PLACEBO_COMPARATOR|Placebo|The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.
62155278|NCT04577391|EXPERIMENTAL|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the use of involved side as maximum as possible. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating). In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook the role of the child's dominant hand.
62529193|NCT01996943|ACTIVE_COMPARATOR|Ethanol|Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.
62155279|NCT04577391|ACTIVE_COMPARATOR|Bimanual training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
62155280|NCT01745835|ACTIVE_COMPARATOR|2L Coolprep®|
62155281|NCT01745835|EXPERIMENTAL|1L Coolprep® and Bisacodyl|
62155282|NCT04168593|SHAM_COMPARATOR|A- Placebo|Sham Acupuncture and Sham Cupping
62529194|NCT03668236|EXPERIMENTAL|Fluid restriction group|"No IV fluids unless one of the extenuating circumstances occur; then, IV fluid may be given in measured amounts:~1. In case of severe hypoperfusion or severe circulatory impairment defined by either:~   * Lactate≥4 mmol/L~  * MAP\<50 mmHg (with or without vasopressor/inotrope)~  * Mottling beyond the kneecap (mottling score \>2) OR~  * Urinary output\<0.1 mL/kg bodyweight/h, but only in the first 2hrs after randomisation~   A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation~2. In case of overt fluid losses (e.g. vomiting, large aspirates,...) IV fluid may be given to correct for the loss, but not above the volume lost.~3. In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~   * Correct dehydration or electrolyte deficiencies~  * Ensure a total fluid input of 1L per 24hrs~IV fluids may be given as carrier for medication, but the volume should be reduced to the lowest possible"
62529195|NCT03668236|ACTIVE_COMPARATOR|Standard-care|"There will be no upper limit for the use of either IV or oral/enteral fluids. In particular:~1. IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~2. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~3. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
62539538|NCT05470205|EXPERIMENTAL|New β-blockers - Cohort 3|Patients newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
62155283|NCT04168593|ACTIVE_COMPARATOR|B -Cupping|Sham Acupuncture and Real Cupping
62155284|NCT04168593|ACTIVE_COMPARATOR|C - Acupuncture|Real Acupuncture and Sham Cupping
62155285|NCT04168593|ACTIVE_COMPARATOR|D - Acupuncture + Cupping|Real Acupuncture and Real Cupping
62155286|NCT05177029|EXPERIMENTAL|Part A: Lu AG06466 or Placebo|Participants will receive single dose of Lu AG06466 capsule or matching placebo orally on Day 1.
62155287|NCT05177029|EXPERIMENTAL|Part B: Lu AG06466 or Placebo|Participants will receive starting dose of Lu AG06466 capsule or matching placebo orally once daily from Day 1 to Day 4 followed by Lu AG06466 capsule or matching placebo at a titrated treatment dose orally once daily from Day 5 until Day 8. Participants will then receive LuAG06466 capsule or matching placebo at a higher assigned dose orally once daily from Day 9 to Day 15.
62155288|NCT04554615|ACTIVE_COMPARATOR|Conventional Insulin Therapy|CIT was provided as a continuous infusion of 50 IU of Actrapid HM in 50 ml of 0.9% sodium chloride using a pump, Infusion was adjusted to achieve BG level in range of 180-200 mg/dl.
62155289|NCT04554615|ACTIVE_COMPARATOR|Intensive Insulin Therapy|IIT was provided as an insulin infu-sion at rate of 1 mU/kg/min and was adjusted to achieve target BG level in range of 80-110 mg/dl.
62155290|NCT02288572|ACTIVE_COMPARATOR|Lactobacillus plantarum PCS 26|Dosage: 1.000.000.000 Colony Forming Units (CFU) per day in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
62155291|NCT02288572|PLACEBO_COMPARATOR|Placebo|Only vehicle components in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
62155292|NCT01430299|OTHER|Demineralized Bone Matrix|a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space
62155293|NCT01430299|OTHER|rh-BMP2|A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2
62155294|NCT01846078|EXPERIMENTAL|Mean absolute errors, median absolute errors|
62155295|NCT02462278|EXPERIMENTAL|TempuRing|Women will wear the continuous temperature sensor, TempuRing, for 3 menstrual cycles.
62155296|NCT03655704|EXPERIMENTAL|Apabetalone|100mg BID for 16 weeks.
62155297|NCT00785798|EXPERIMENTAL|vorinostat doxil|Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle
62155298|NCT02779127|OTHER|Intervention|"Subjects exposed to passive smoking at least 1 hour per day since 1 year, non active smokers, non exposed to passive smoking at home~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
62155299|NCT02779127|OTHER|Control|"Subjects non expose to passive smoking at home or at work, non active smokers~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
62529196|NCT01965470|EXPERIMENTAL|Combination Prevention|"* Scale-up of HTC services during 2 annual HTC campaigns, with a target of \>90% of adults having documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.~* Scale-up of universal ART for all HIV-infected adults, with a target of \>93% of HIV positive adults receiving ART.~* Scale-up of retention in care and adherence interventions, with a target of ensuring that \>95% of HIV-infected adults are virally suppressed with HIV-1 RNA \<400 copies per ML..~* Scale-up of linkage to MC services, with a target of ensuring \>60% of HIV-negative men are circumcised.~* Rapid strengthening of PMTCT services, with a target of \>90% of women initiated on indefinite ART (Option B+) during pregnancy remaining in care and on treatment at 12 months post-delivery."
62155300|NCT04424745|ACTIVE_COMPARATOR|Attention Bias Modification Training with real tDCS|
62155301|NCT04424745|PLACEBO_COMPARATOR|Attention Bias Modification Training with sham tDCS|
62155302|NCT05667909||Remission|
62155303|NCT05667909||Non-remission|
62155304|NCT05614141||Study Group|
62155305|NCT05614141||Control Group|
62155306|NCT02110914|EXPERIMENTAL|Coaching|10 coaching sessions over a period of 6 - 9 months. The intervention is life coaching based on principles of the co-active coaching model.
62155307|NCT02110914|NO_INTERVENTION|Control|Standard care
62155308|NCT02183402|EXPERIMENTAL|Digoxin with BI 1356|
62155309|NCT02183402|ACTIVE_COMPARATOR|Digoxin|
62155310|NCT02691702|EXPERIMENTAL|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
62155311|NCT02691702|EXPERIMENTAL|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
62529197|NCT01965470|ACTIVE_COMPARATOR|Enhanced Care|Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.
62529198|NCT02770885|EXPERIMENTAL|Verum first|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
62529199|NCT02770885|PLACEBO_COMPARATOR|Placebo first|Placebo: 0.5 ml normal saline (0.9% sodium chloride \[0.9% sodium chloride (NaCl)\]), injection sc via syringe once weekly for 3 weeks.
62529200|NCT05643248|EXPERIMENTAL|Cohort 1|The planned doses are 15 mg for the sentinel subject in cohort 1 and 35 mg for the remaining 2 subjects in cohort 1
62529201|NCT05643248|EXPERIMENTAL|Cohort 2|The planned dose for all 3 subjects in cohort 2 is 70 mg.
62529202|NCT05643248|EXPERIMENTAL|Cohort 3|The planned dose for all 3 subjects in the optional cohort 3 is 100 mg.
62529203|NCT06489457|EXPERIMENTAL|Semaglutide Treatment|
62529204|NCT06489457|ACTIVE_COMPARATOR|Testosterone Replacement Therapy|
62529205|NCT02502773|EXPERIMENTAL|crystalloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
62529206|NCT02502773|EXPERIMENTAL|colloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
62529207|NCT03717857||Caregiver InDepth Interviews|Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.
62529208|NCT03717857||Focus Groups|"Three focus groups with middle school students \[N = 5\], caregivers \[N =5\], and school staff \[N = 5\] will be conducted to inform the development of the intervention.~Criteria for caregiver and middle school student selection is similar to the in-depth interviews and the pilot clinical trial. Inclusion criteria specify that participants must 1) be between the ages of 11-13 , 2) be in 6th-8th grades, or have a child that meets that criteria 3) reside in one of the targeted public school districts identified by zip code, 4) attend one of the schools within these districts.In RI, caregivers will have to identify as Latino.~The school staff focus group will include school personnel from the targeted schools."
62155312|NCT02691702|EXPERIMENTAL|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
62155313|NCT02935478|EXPERIMENTAL|HCC-Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
62155314|NCT02282137|EXPERIMENTAL|68Ga-PSMA|Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.
62155315|NCT02753075|EXPERIMENTAL|Experimental Oral Rinse 1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
62155316|NCT02753075|EXPERIMENTAL|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
62155317|NCT02753075|PLACEBO_COMPARATOR|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
62155318|NCT06193915|EXPERIMENTAL|Ultrasound guided hematoma block|Patients in this group will receive ultrasound guided hematoma block before reduction of their dislocated distal radius fracture.
62155319|NCT06193915|ACTIVE_COMPARATOR|Blind hematoma block|Patients in this group will receive standard treatment; hematoma block with palpation of the fracture site (blind hematoma block)
62155320|NCT05776329|EXPERIMENTAL|Low-inflammatory and environmentally friendly dietary strategy (AIA-D)|The environmentally friendly dietary strategy (AIA-D) designed based on the planetary health diet recommendations translated to the regional context and includes nutrients related to anti-inflammatory responses
62155321|NCT05776329|ACTIVE_COMPARATOR|General healthy diet recommendations (CONV-D).|The active comparator CONV-D is based on the general healthy diet recommendations
62155322|NCT02912442||Infertile women study 1|
62155323|NCT02912442||Infertile women study 2|
62155324|NCT02912442||Repeated pregnancy loss|
62155325|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
62155326|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
62155327|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
62155328|NCT03430362|ACTIVE_COMPARATOR|Hyoscine group|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
62155329|NCT03430362|PLACEBO_COMPARATOR|Control group|Group B, will receive 2 ml of normal saline single intravenous dose
62529209|NCT06273839|EXPERIMENTAL|Test 1 tablet followed by Test 2 tablet followed by Reference capsule|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62713921|NCT06447909|EXPERIMENTAL|Treatment app|Behavioral interventions are a well-established psychosocial intervention for the treatment of disruptive behavior disorders and related behavioral difficulties (e.g., ODD, ADHD). Behavioral training is based on social learning and operant conditioning principles in which parents are instructed to utilize positive reinforcement and reward systems to facilitate positive behaviors (e.g., compliance) in their child and reduce challenging behaviors (e.g., opposition). The intervention involves the use of an app to deliver a behavioral intervention using contingency reward systems. It translates established content and processes into a digital format to be delivered through a mobile app. For both conditions, there will be a parent and a child version of the app which are linked. The treatment app involves the use of contingency reward systems to shape targeted behaviors in children. The treatment app also includes psychoeducational guides for parents to review daily.
62155330|NCT02734394|EXPERIMENTAL|Cardiovascular and strength training exercise|24 sessions (\~12 weeks) exercise
62155331|NCT03937089||Patients|Patients with persistent AF, who underwent a CA procedure in the Nancy hospital between January 2011 and April 2017, will be included in this retrospective study.
62155332|NCT03458416|EXPERIMENTAL|Cannabidiol Oral Solution: 20-40 mg/kg/day|Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.
62155333|NCT03219216|EXPERIMENTAL|Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Arm A: Hepatitis C virus (HCV) genotype (GT) 1 to GT6 participants without cirrhosis (fibrosis stage F2 to F3) received glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
62155334|NCT03219216|EXPERIMENTAL|Arm B: GLE/PIB for 12 Weeks|Arm B: HCV GT1 to GT6 participants with compensated cirrhosis (F4) received GLE/PIB 300 mg/120 mg QD for 12 weeks.
62155335|NCT06215326|EXPERIMENTAL|Moderate-intensity Continuous Training (MICT) Group|MICT plan is containing usual care protocol and additional complete a total of 12 supervised moderate-intensity continuous training sessions in 2-3 weeks.
62155336|NCT06215326|EXPERIMENTAL|High-intensity Interval Training (HIIT) Group|HIIT plan is containing usual care protocol and additional complete a total of 12 supervised high-intensity interval training training sessions in 2-3 weeks.
62155337|NCT06215326|NO_INTERVENTION|Usual care group|Usual care is including smoking cessation instruction, respiratory exercise, review by a specialist nurse, meeting with the surgeon and anesthetist, and receiving information about preparing for surgery.
62155338|NCT01490047|EXPERIMENTAL|rhTNF-α 25 µg/m² + Caelyx 40 mg/m²|Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²
62155339|NCT01490047|EXPERIMENTAL|rhTNF-α 50 µg/m² + Caelyx 40 mg/m²|Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²
62155340|NCT01490047|EXPERIMENTAL|rhTNF-α 100 µg/m² + Caelyx 40 mg/m²|Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²
62155341|NCT01490047|EXPERIMENTAL|rhTNF-α 150 µg/m² + Caelyx 40 mg/m²|Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²
62155342|NCT01490047|EXPERIMENTAL|rhTNF-α 200 µg/m² + Caelyx 40 mg/m²|Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²
62155343|NCT01490047|EXPERIMENTAL|rhTNF-α 250 µg/m² + Caelyx 40 mg/m²|Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²
62155344|NCT01490047|EXPERIMENTAL|rhTNF-α 25 µg/m² + Caelyx 30 mg/m²|Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²
62155345|NCT01219400|EXPERIMENTAL|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
62155346|NCT02010086|EXPERIMENTAL|Individual Cognitive Behavioral Therapy|
62155347|NCT02010086|ACTIVE_COMPARATOR|Standard Community Treatment|
62155348|NCT00641797|ACTIVE_COMPARATOR|Arm 1, Conventional Therapy|Patients will receive standard conventional medication therapy (i.e., meclizine, diphenhydramine, lorazepam, ondansetron).
62155349|NCT00641797|EXPERIMENTAL|Arm 2, Epley Maneuver|Patients will receive vestibular rehabilitation (the Epley Maneuver).
62155350|NCT02408978|EXPERIMENTAL|OXP005|1g naproxen
62155351|NCT02408978|ACTIVE_COMPARATOR|naproxen|1g naproxen
62155352|NCT00244426|EXPERIMENTAL|1|
62155353|NCT00244426|ACTIVE_COMPARATOR|2|
62155354|NCT02260999||healthy|\> 18 years old sufficient language knowledge
62155355|NCT02260999||chronic pain patients|
62155356|NCT02260999||patients with injury at the upper etxremity|
62529210|NCT06273839|EXPERIMENTAL|Test 1 tablet followed by Reference capsule followed by Test 2 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62529211|NCT06273839|EXPERIMENTAL|Test 2 tablet followed by Reference capsule followed by Test 1 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62155357|NCT06250374|EXPERIMENTAL|Patients with thromboendarterectomy surgery|"Anesthesia was induced with sufentanil 0.3 g/kg, etomidate 0.3-0.4 mg/kg, rocuronium 0.4 mg/kg and maintained with continuous infusion Propofol and sufentanil. A pulmonary arterial catheter was inserted in all patients. Patients were cooled by means of the oxygenator heat exchanger at a rate of one degree Celsius every three minutes. Rewarming was achieved at a rate of one degree Celsius every five to ten minutes.~The following measures were performed:~Measure 1: In normo-thermia after induction of general anesthesia Measure 2: On CPB, before circulatory arrest and in hypothermia at 18-20°C Measure 3: On bypass, after circulatory arrest and in hypothermia at 18-20°C Measure 4: At the end of the procedure, after weaning from the bypass and in normothermia.~For each measure mean arterial pressure, cardiac output, PaCO2, pH, bilateral NIRS value were also recorded."
62155358|NCT04099186|EXPERIMENTAL|hydro-mechanical pulmonary embolism fragmentation|Those patients will undergo catheter directed fragmentation followed by injection of 100 ml of heparinized saline via power injector
62529212|NCT06273839|EXPERIMENTAL|Test 2 tablet followed by Test 1 tablet followed by Reference capsule|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62155359|NCT04099186|NO_INTERVENTION|thrombolytic treated arm|patients with high risk and intermediate high risk PE who received thrombolysis as only treatment modality
62155360|NCT04650919|EXPERIMENTAL|Experimental arm|
62529213|NCT06273839|EXPERIMENTAL|Reference capsule followed by Test 1 tablet followed by Test 2 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62155361|NCT01680315|EXPERIMENTAL|Calorie information|"Low calorie yogurt~High calorie yogurt~with low calorie information sheet"
62529214|NCT06273839|EXPERIMENTAL|Reference capsule followed by Test 2 tablet followed by Test 1 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62713922|NCT04376593|EXPERIMENTAL|18F-αvβ6-BP|Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.
62155362|NCT01680315|EXPERIMENTAL|Calorie information (high)|"Low calorie yogurt~High calorie yogurt~High calorie information sheet"
62155363|NCT04995601|NO_INTERVENTION|Standard of Care|Participants will receive DVT prophylaxis using standard intermittent pneumatic compression during postoperative care after total joint replacement.
62155364|NCT04995601|EXPERIMENTAL|Recovery Force MAC|Participants will receive DVT prophylaxis using the RF Health MAC during postoperative care after total joint replacement.
62155365|NCT01790659|EXPERIMENTAL|WR 279,396|(Paromomycin and Gentamicin Topical Cream)
62529215|NCT03996642|OTHER|Patients with Active Cancer|Eligible participants will undergo an unknown number of Avatar-life review sessions depending on acceptability of the intervention to subjects and the capacity of the team to provide the intervention.
62155366|NCT01790659|EXPERIMENTAL|Paromomycin|Paromomycin alone
62155367|NCT05511389|ACTIVE_COMPARATOR|Anterolateral shock vector|"Patients with electrodes placed on the chest to obtain an anterolateral (front-to-side placement; also known as anteroapical) shock vector.~If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same."
62155368|NCT05511389|ACTIVE_COMPARATOR|Anteroposterior shock vector|"Patients with electrodes placed on the chest to obtain an anteroposterior (front-to-back placement) shock vector.~If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same."
62155369|NCT03923556|EXPERIMENTAL|Sugammadex|Sugammadex
62155370|NCT03923556|ACTIVE_COMPARATOR|Neostigmine|Neostigmine
62155371|NCT01648491|EXPERIMENTAL|Stem Cell treatment|Muscle Biopsy and Injection of autologous stem cells
62529216|NCT03306524|EXPERIMENTAL|SIPPV_VG_0_08|SIPPV VG ventilation for 15 minutes slope time = 0.08 seconds inspiratory time = 0.40 seconds
62529217|NCT03306524|EXPERIMENTAL|PSV_VG_0_08|PSV VG ventilation for 15 minutes slope time = 0.08 seconds maximum inspiratory time = 0.60 seconds
62529218|NCT03306524|EXPERIMENTAL|SIPPV_VG_0_16|SIPPV VG ventilation for 15 minutes slope time = 0.16 seconds inspiratory time = 0.40 seconds
62529219|NCT03306524|EXPERIMENTAL|PSV_VG_0_16|PSV VG ventilation for 15 minutes slope time = 0.16 seconds maximum inspiratory time = 0.60 seconds
62529220|NCT03306524|EXPERIMENTAL|SIPPV_VG_0_24|SIPPV VG ventilation for 15 minutes slope time = 0.24 seconds inspiratory time = 0.40 seconds
62529221|NCT03306524|EXPERIMENTAL|PSV_VG_0_24|PSV VG ventilation for 15 minutes slope time = 0.24 seconds maximum inspiratory time = 0.60 seconds
62529222|NCT03306524|EXPERIMENTAL|SIPPV_VG_0_32|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
62529223|NCT03306524|EXPERIMENTAL|PSV_VG_0_32|PSV VG ventilation for 15 minutes slope time = 0.32 seconds maximum inspiratory time = 0.60 seconds
62529224|NCT03306524|EXPERIMENTAL|SIPPV_VG_0_40|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
62529225|NCT03306524|EXPERIMENTAL|PSV_VG_0_40|PSV VG ventilation for 15 minutes slope time = 0.40 seconds maximum inspiratory time = 0.60 seconds
62529226|NCT04149106|ACTIVE_COMPARATOR|Standard|The Mali National Malaria Control program has initiated SMC for children less than 5 years since 2016 (countrywide) with SPAQ. This standard care will not change in this arm
62529227|NCT04149106|ACTIVE_COMPARATOR|SMC with SPAQ extended to older children|Within this arm, SMC with SPAQ will be extended to children 5-9 years old
62529228|NCT04149106|ACTIVE_COMPARATOR|SMC with DHAPQ|Children less than 10 years within this arm will received Dihydroartemisin piperaquin for SMC instead of SPAQ
62155372|NCT04614688|EXPERIMENTAL|Patient Education Group|Patients in this group will undergo the standard physician-led informed consent process and then be provided with an interactive patient education platform for hysteroscopy on a tablet available in the clinic for up to one hour of time. After the patient has explored the patient education platform, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
62155373|NCT04614688|NO_INTERVENTION|Standard Consent Group|Patients in this group will undergo the standard physician-led informed consent process only. After they have consented to the surgery, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
62155374|NCT01155674||Sepsis patients|Patients presenting sepsis
62155375|NCT01155674||SIRS patients|Patients presenting with the systemic inflammatory response syndrome
62155376|NCT01155674||Healthy subjects|Healthy blood donors
62155377|NCT03068741|ACTIVE_COMPARATOR|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
62155378|NCT03068741|PLACEBO_COMPARATOR|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
62155379|NCT03068741|EXPERIMENTAL|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
62155380|NCT03068741|ACTIVE_COMPARATOR|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure \<90mmHg, and will only continue the infusion until the systolic blood pressure is \>=100mmHg.
62529229|NCT00077545|EXPERIMENTAL|Treatment (triapine and cisplatin)|Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62529230|NCT04303286||Recovery Group|The liver function of HCC patients on the fifth day after the operation is recovered.
62155381|NCT04109651|EXPERIMENTAL|Nursing İntervention|Intervention: Other: Nursing intervention
62529231|NCT04303286||Recovery Delay Group|The liver function of HCC patients on the fifth day after the operation is delayed recovered.
62529232|NCT04303286||Control Group|The patients on benign disease of the liver
62529233|NCT01246011|EXPERIMENTAL|Heparin PF4 antibody positive -Drug (argatroban and warfarin)|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
62529234|NCT01246011|NO_INTERVENTION|Heparin PF4 antibody positive no drug|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
62529235|NCT01246011|NO_INTERVENTION|Heparin PF4 antibody negative|Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication
62529236|NCT02834650|EXPERIMENTAL|Group 1a|Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.
62713923|NCT04089514||Adalimumab Therapy|Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy
62155382|NCT04109651|OTHER|No Intervention: Control Group|Receive routine nursing care
62155383|NCT05971199|EXPERIMENTAL|treatment|Fruquintinib+sintilimab+TACE
62155384|NCT03733574|EXPERIMENTAL|LY03005 cross-over to Pristiq® (Desvenlafaxine)|Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
62155385|NCT03733574|EXPERIMENTAL|Pristiq® (Desvenlafaxine) cross-over to LY03005|Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
62155386|NCT03577054|EXPERIMENTAL|HBB Prompt|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~Providers at this hospital will have access to the most updated version of HBB Prompt (beta) after HBB training.~Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training). The recommended frequency to use the app will be once per shift."
62155387|NCT03577054|PLACEBO_COMPARATOR|Control|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~The control group will not have exposure to the HBB Prompt app post training. Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training)."
62155388|NCT01995253|EXPERIMENTAL|Controlled conditions|
62155389|NCT01995253|EXPERIMENTAL|Free-living conditions|
62155390|NCT06476496|EXPERIMENTAL|Acupuncture|Participants will receive 8 sessions of acupuncture treatment
62155391|NCT06476496|NO_INTERVENTION|Usual Care|Participants will continue to receive any current or recommended treatments from their doctors for their long COVID symptoms.
62713924|NCT00028340||1/Breast Cancer and High-Risk Patients|Pre- or postmenopausal women who have or have previously had invasive or noninvasive breast cancer of epithelial origin, or women without breast cancer but at an increased risk of breast cancer.
62713925|NCT00028340||2/Normal Volunteers|Pre- or postmenopausal women who are not at an increased risk for breast cancer.
62155392|NCT05910359|EXPERIMENTAL|Persistent Occiput Posterior Position|transabdominal and transperineal ultrasound by expert sonographers
62155393|NCT05910359|ACTIVE_COMPARATOR|Anterior Occiput Position at delivery|transabdominal and transperineal ultrasound by expert sonographers
62155394|NCT06296784|EXPERIMENTAL|e-health psychoeducation|
62155395|NCT06296784|NO_INTERVENTION|waiting list|
62155396|NCT04693013|EXPERIMENTAL|Interventional|use of virtual reality (VR)
62529237|NCT02834650|EXPERIMENTAL|Group 1b|"Group 1b comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test.~A subset of boys with DMD will have a repeat MRI with contrast at Children's Hospital of Orange County."
62529238|NCT02834650|EXPERIMENTAL|Group 2|Group 2 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a repeat MRI scan with contrast at 6 Months.
62713926|NCT06715384|EXPERIMENTAL|Polyp size measurement with Artificial intelligence (AI)|Colonoscopies will be performed according to the standard of care. Patients will have colonoscopies performed using the computer-aided measuring (CAM) system. All measured fresh polyp specimens will be immediately sized in vitro as the ground truth.
62155397|NCT04693013|NO_INTERVENTION|Control|no use of VR
62155398|NCT02144883|ACTIVE_COMPARATOR|Materials|Self-help materials mailed to subjects home.
62155399|NCT02144883|EXPERIMENTAL|Telephone Counseling and Materials|Subjects received up to 9 telephone counseling calls plus self-help quit kit and 5 additional mailings
62155400|NCT05997420|EXPERIMENTAL|Sepsis Transition and Recovery (STAR) program|Virtual sepsis navigation delivered across the peri-hospital discharge interval
62155401|NCT05997420|ACTIVE_COMPARATOR|Usual Care|Standard of care received through each facility for patients hospitalized with sepsis. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
62155402|NCT04492085||Primary hospital or clinics|
62155403|NCT04492085||Secondary hospital|
62529239|NCT02834650|EXPERIMENTAL|Group 3|Group 3 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a genetic testing.
62529240|NCT02910674|OTHER|One Arm|This is a comparative diagnostic study, no interventional actions are being taken.
62529241|NCT05145686|EXPERIMENTAL|Comparing MMP-2, -8, -9 in reversible and irreversible pulpitis|The coronal pulp samples from both reversible and irreversible groups were placed in an eppendorf tube containing TriPure Reagent transport medium. The MMP-2, -8 and -9 expression levels were determined with specific primers by real time polymerase chain reaction method (RT-PCR).
62529242|NCT05145686|ACTIVE_COMPARATOR|Comparing the clinical success of MTA and Biodientine in primary molar pulpotomy treatments|In reversible pulpitis group MTA (ProRoot MTA,white) was used in 21 teeth and Biodentine was used in the other 21 teeth for pulpotomy treatments. Final restorations were performed with stainless steel crowns in both group. At the end of 3, 6 and 9 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption.
62529243|NCT01090830|EXPERIMENTAL|Belinostat|This is a one arm, open label study of the investigational medication Belinostat.
62529244|NCT03596151|EXPERIMENTAL|Click Device|One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.
62529245|NCT03543241||MyoStrain|Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.
62529246|NCT03607526||Barriers to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying barriers to meeting the DGA recommendation for vegetable consumption.
62529247|NCT03607526||Facilitators to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying facilitators to meeting the DGA recommendation for vegetable consumption.
62529248|NCT01364181|EXPERIMENTAL|Udenafil|Udenafil 50mg qd po
62529249|NCT02649985|EXPERIMENTAL|Relapsing-Remitting Multiple Sclerosis|"Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, at least one gadolinium enhancing lesion on a MRI within 12 months of enrollment, or at least one new FLAIR bright lesion on MRI within 6 months of enrollment.~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both \[C-11\]PBR28 PET scan and \[F-18\]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of \[F-18\]PBR06 are found non-inferior to or better than \[C-11\]PBR28, the rest of the study will be completed using \[F-18\]PBR06. On the other hand, if \[F-18\]PBR06 is found to be inferior to \[C-11\]PBR28, the rest of the study will be pursued using \[C-11\]PBR28."
62529250|NCT02649985|EXPERIMENTAL|Progressive Multiple Sclerosis|Subjects meeting the definition for SPMS/PPMS (Primary Progressive Multiple Sclerosis) by International Panel Criteria and who have demonstrated deterioration in EDSS score in last 1 year.
62529251|NCT02649985|ACTIVE_COMPARATOR|Alzheimer's Disease|Subjects meeting the definition for probable AD based on NINDS-ADRDA criteria. In terms of severity of disease, the investigators will select subjects with mild AD, as defined by Mini-Mental Status Examination (MMSE) score of 20-26.
62529252|NCT02649985|OTHER|Healthy Control|This group will serve as non disease population.
62529253|NCT02649985|EXPERIMENTAL|Multiple Sclerosis Ocrelizumab|"Subjects who have been prescribed Ocrelizumab by their treating MS neurologist but have not yet started the first Ocrelizumab infusion.~Subjects will undergo two separate visits for \[F-18\]PBR06 PET scans, once before starting Ocrelizumab and the second visit 3 months after completion of the initial Ocrelizumab doses."
62529254|NCT01490983|EXPERIMENTAL|eMedonline access|patients will have access to eMedonline access for 3 months
62529255|NCT01490983|OTHER|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
62529256|NCT00121134|EXPERIMENTAL|Group A|Bevacizumab Alone
62155404|NCT04492085||Tertiary hospital|
62155405|NCT05940805|EXPERIMENTAL|Protocol Group (PG)|"The PG received the following combination of four therapeutic modalities twice a week for five weeks:~1. Low-frequency transcranial electrical stimulation;~2. Paraspinous block;~3. Dry needling of spastic upper limb muscles;~4. Muscular functional electrical stimulation (FES)."
62529257|NCT00121134|EXPERIMENTAL|Group B|Bevacizumab with cyclophosphamide and methotrexate
62529258|NCT00121134|EXPERIMENTAL|Group C|capecitabine, 14 days on/7 days off scheduling, and bevacizumab
62529259|NCT00121134|EXPERIMENTAL|Group D|capecitabine 7 days on/7 days off scheduling, and bevacizumab
62155406|NCT05940805|SHAM_COMPARATOR|Sham Group (SG)|The Sham Group also received the four modalities of the intervention, but these modalities were all inactive. For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used. The patients were blinded to their assigned treatment group.
62155407|NCT03056170|ACTIVE_COMPARATOR|Active tDCS|The anode is placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode is placed over the left temporo-parietal cortex (TPJ) In active stimulation with a Transcranial Direct Current Stimulation, the device will deliver a charge of 1 mA for 30 minutes.
62155408|NCT03056170|SHAM_COMPARATOR|Sham tDCS|In sham stimulation, with a Transcranial Direct Current Stimulation, no current will be delivered from one electrode to the other except one 30 s ramp up and down at the beginning and one at the end of the sham stimulation duration (30 min) Same electrode montage than in the active group.
62155409|NCT06495463|EXPERIMENTAL|trifluridine / tipiracil + Chemotherapy|"trifluridine / tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~combination with chemotherapy (choose one) : oxaliplatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days."
62155410|NCT02122484|PLACEBO_COMPARATOR|Control group|Patients taking placebo
62155411|NCT02122484|EXPERIMENTAL|Colchicine|Active treatment group
62155412|NCT04168450|OTHER|WiSAT Passive|This arm is composed of participants who meet their activity threshold over the 4-week period.
62155413|NCT04168450|OTHER|WiSAT Active|This arm is composed of participants who do not meet their activity threshold over the 4-week period.
62155414|NCT05634161||Cognitive Improvement software|Usability assessment of cognitive improvement software
62155415|NCT01266837|OTHER|single arm|Treatment with Everolimus
62155416|NCT04081818|ACTIVE_COMPARATOR|Intervention group (Nutritious Mushrooms)|
62155417|NCT04081818|NO_INTERVENTION|Control group|
62155418|NCT01113593|EXPERIMENTAL|1|
62155419|NCT01113593|EXPERIMENTAL|2|
62155420|NCT01113593|EXPERIMENTAL|3|
62155421|NCT01113593|EXPERIMENTAL|4|
62155422|NCT01113593|EXPERIMENTAL|5|
62155423|NCT00933634|EXPERIMENTAL|electrical cardioversion|Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
62155424|NCT00933634|ACTIVE_COMPARATOR|propafenone|Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
62155425|NCT04950010|EXPERIMENTAL|High-Intensity Interval Training (HIIT)|Breast cancer survivors randomized to HIIT will participate in a high-intensity interval training program for 8 weeks.
62155426|NCT04950010|ACTIVE_COMPARATOR|Moderate-Intensity Exercise (MOD)|Breast cancer survivors randomized to MOD will participate in a moderate-intensity aerobic exercise program for 8 weeks.
62155427|NCT04950010|NO_INTERVENTION|Usual Care (UC)|Individuals randomized to UC will be instructed to continue standard cancer care and engage in habitual lifestyle behaviors.
62155428|NCT05620199|EXPERIMENTAL|Study population|All included patients will have an upfront surgery of the primary tumor, followed by chemoradiotherapy. Resection will be done within 2-4 weeks after presentation in the multidisciplinary team meeting (MDT). After resection, restaging will take place preceding start of CRT, which should start within 4-6 weeks after resection.
62155429|NCT01962402|EXPERIMENTAL|Lorcaserin with intensive diet counseling|Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
62155430|NCT02203513|EXPERIMENTAL|Arm 1-Prexasertib|Prexasertib (LY2606368) monotherapy treatment
62155431|NCT05908136|ACTIVE_COMPARATOR|GROUP A|• Group A: 12 primary molars received stainless steel crowns (SSCs).
62529260|NCT02562339|EXPERIMENTAL|SMART-3RP for Parents or Caregivers|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
62529261|NCT02562339|EXPERIMENTAL|SMART-3RP for Adolescent Patients|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
62155432|NCT05908136|ACTIVE_COMPARATOR|group b|• Group B: 12 primary molars received resin composite strip crowns (RCSCs).
62155433|NCT05908136|ACTIVE_COMPARATOR|group c|• Group C: 12 primary molars received zirconium-filled composite strip crowns (ZFSCs).
62155434|NCT03140475||Individuals with schizophrenia|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates)~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response)~Clinical variables:~Positive and Negative Syndrome Scale / Birchwood Insight Scale / Beck Cognitive Insight Scale / Personal and Social Performance Scale / Calgary Depression Scale / Chlorpromazine equivalents~Neuropsychological variables:~National Adult Reading Test (French) / Wechsler Adult Intelligence Scale version IV (WAIS-IV) subtests (matrix reasoning, vocabulary, letter-number sequencing)"
62155435|NCT03140475||Controls|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates) /~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response) /~Clinical variables:~Calgary Depression Scale~Neuropsychological variables:~National Adult Reading Test (French) / WAIS-IV subtests (matrix reasoning, vocabulary, letter-number sequencing)"
62155436|NCT04748705|EXPERIMENTAL|IMC-1 Oral Tablet|2X IMC-1 Tablet taken orally, each morning and evening.
62155437|NCT04748705|PLACEBO_COMPARATOR|Placebo|2X Placebo Tablet taken orally, each morning and evening.
62155438|NCT05214248|EXPERIMENTAL|multimedia admission orientation|Multimedia admission orientation for the parents of infants admitted to NICU is provided to the experimental group of the parents. The multimedia orientation based on animation and graphic figures to explain the basic information about the NICU environment and precautions and the essential tests and examination taken for their infant during the initial stage of NICU admission.
62155439|NCT02174315|EXPERIMENTAL|Contingency Management|
62155440|NCT02174315|NO_INTERVENTION|Non-Contingent Control Group|
62155441|NCT03914586||Septic patients with AKI|Patients with sepsis /septic shock ( Sepsis III ) and AKI submitted to Continuous Renal Replacement Therapy with the adsorbing membrane oXiris.
62155442|NCT02869308|OTHER|Myocardial angioscintigraphy|
62155443|NCT02788708|EXPERIMENTAL|Treatment (lenvatinib, paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and lenvatinib mesylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62155444|NCT01424345|ACTIVE_COMPARATOR|control group|Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab
62155445|NCT01424345|EXPERIMENTAL|ImmuKnow Study group|The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab
62529262|NCT01471119|EXPERIMENTAL|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
62155446|NCT02980432|EXPERIMENTAL|intervention arm|all participants will be assigned to the same arm. Interventions applied include presenting a visual line or a rod with or without a moving (rotating) background while being in different whole-body roll positions. Participants will be asked to adjust the line or the rod along perceived direction of gravity.
62155447|NCT00621842|EXPERIMENTAL|Open-Label Lamotrigine Treatment|
62155448|NCT02699398|EXPERIMENTAL|VR-based therapy|3 weeks of home-based treatment for motor training using a virtual reality rehabilitation setup.
62155449|NCT02699398|ACTIVE_COMPARATOR|Control|3 weeks of home-based occupational therapy for motor training.
62529263|NCT01471119|EXPERIMENTAL|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.
62529264|NCT01471119|EXPERIMENTAL|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
62529265|NCT01471119|EXPERIMENTAL|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
62713927|NCT06715384|NO_INTERVENTION|Polyp size measurement without AI|Colonoscopies will be performed according to the standard of care without the CAM system. Patients will undergo a standard colonoscopy. Polyp size measurement will be assessed visually and non-scaled device (open biopsy forceps or snare). All measured fresh polyp specimens will be immediately sized in vitro as the ground truth.
62155450|NCT01648049|EXPERIMENTAL|CBT|Cognitive behavior therapy for both insomnia and depression featuring stimulus control and cognitive therapy.
62155451|NCT01648049|ACTIVE_COMPARATOR|Treatment as Usual|No additional treatment besides regular care.
62155452|NCT04371406|EXPERIMENTAL|Experimental Arm|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
62155453|NCT04371406|SHAM_COMPARATOR|Control Arm|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
62529266|NCT02938754|EXPERIMENTAL|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
62155454|NCT01309815||Cancer in elderly people|other
62155455|NCT04527926|EXPERIMENTAL|STEPuP Intervention|STEPuP interventions
62529267|NCT02938754|ACTIVE_COMPARATOR|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
62529268|NCT04689919|ACTIVE_COMPARATOR|Reference Group [Xarelto 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
62713928|NCT01959529|EXPERIMENTAL|Insulin degludec (IDeg)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
62155456|NCT04527926|ACTIVE_COMPARATOR|Usual Care|Standard of Care
62155457|NCT02346786|EXPERIMENTAL|Mineral Water|mineral water
62155458|NCT02346786|ACTIVE_COMPARATOR|Tap Water|usual water intake
62155459|NCT06404736|EXPERIMENTAL|QL1706|QL1706 +nab-PCb
62155460|NCT05387629|EXPERIMENTAL|Experimental|Social media increases the academic success of nursing students.
62155461|NCT05387629|NO_INTERVENTION|Control|Social media does not affect the academic success of nursing students.
62155462|NCT06560411|ACTIVE_COMPARATOR|Auto Night One, Manual Night Two|Will undergo Automatic Expiratory Positive Airway Pressure (EPAP) during Non-Invasive Ventilation in polysomnography (PSG) Night 1; Will undergo Manual EPAP during Non-Invasive Ventilation in PSG Night 2
62155463|NCT06560411|ACTIVE_COMPARATOR|Manual Night One, Auto Night Two|Will undergo Manual Expiratory Positive Airway Pressure (EPAP) during Non-Invasive Ventilation in polysomnography (PSG) Night 1; Will undergo Auto-EPAP during Non-Invasive Ventilation in PSG Night 2
62155464|NCT05917756|EXPERIMENTAL|Group A (experimental group)|MWM techniques combined with a tailored therapeutic exercise program
62155465|NCT05917756|ACTIVE_COMPARATOR|Group B (control group)|Conventional physiotherapy combined with a tailored therapeutic exercise program
62155466|NCT00484198|PLACEBO_COMPARATOR|1|
62155467|NCT00484198|EXPERIMENTAL|2|Rivoglitazone 1.0 mg
62155468|NCT00484198|EXPERIMENTAL|3|Rivoglitazone 1.5 mg
62155469|NCT00484198|ACTIVE_COMPARATOR|4|Pioglitazone 45 mg
62155470|NCT05536440|EXPERIMENTAL|Cohort 1 active|Dose A
62155471|NCT05536440|PLACEBO_COMPARATOR|Cohort 1 placebo|Dose A
62155472|NCT05536440|EXPERIMENTAL|Cohort 2 active|Dose B
62155473|NCT05536440|PLACEBO_COMPARATOR|Cohort 2 placebo|Dose B
62155474|NCT05536440|EXPERIMENTAL|Cohort 3 active|Dose C
62155475|NCT05536440|PLACEBO_COMPARATOR|Cohort 3 placebo|Dose C
62529269|NCT04689919|EXPERIMENTAL|Test Group [Xaroban 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
62529270|NCT02881138|EXPERIMENTAL|RC48-ADC|Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
62529271|NCT02585934|EXPERIMENTAL|RVT-101|RVT-101 adjunct to 5 mg or 10 mg donepezil
62529272|NCT02585934|PLACEBO_COMPARATOR|Placebo|Placebo adjunct to 5 mg or 10 mg donepezil
62529273|NCT02216513|ACTIVE_COMPARATOR|Desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days
62529274|NCT02216513|PLACEBO_COMPARATOR|placebo|normal saline IV for 4 hours for 5 consecutive days
62529275|NCT05806918|EXPERIMENTAL|Recombinant Human Interferon α-2b Gel (After the Alteration)|
62155476|NCT05536440|EXPERIMENTAL|Cohort 4 active|Dose D
62155477|NCT05536440|PLACEBO_COMPARATOR|Cohort 4 placebo|Dose D
62529276|NCT05806918|ACTIVE_COMPARATOR|Recombinant Human Interferon α-2b Gel (Before the Alteration)|
62529277|NCT01342536|EXPERIMENTAL|lifestyle counseling (OHDC)|Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression
62529278|NCT01342536|ACTIVE_COMPARATOR|lifestyle counseling (CWD)|Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention
62529279|NCT04333108|EXPERIMENTAL|Masitinib & BSC|"Experimental Arm:~Masitinib (titration to 6.0 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC).~Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control."
62529280|NCT04333108|PLACEBO_COMPARATOR|Placebo & BSC|"Placebo Comparator:~Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)"
62529281|NCT03127644|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
62529282|NCT03127644|EXPERIMENTAL|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
62529283|NCT03127644|PLACEBO_COMPARATOR|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
62529284|NCT03150849||patient group|patient with chronic lymphocytic leukemia
62529285|NCT03150849||control group|healthy control group
62529286|NCT05465239|EXPERIMENTAL|SurePace Powered Walker User|"Before any formal experiments are conducted, participants will be given an opportunity to train with the new powered walker for a pre-defined period of time to eliminate the confounding effects of being unfamiliar with using the device. (See the description of UVA's facilities and Protection of Human Subjects document for additional discussion of safety measures/protocols and Institutional Review Board procedures.) Experiments will consist of one-hour sessions (with adequate rest periods between trials and time for evaluations) in which participants will be asked to walk at a self-selected (comfortable) walking speed through a pre-defined 8 m x 4 m oval course."
62529287|NCT04007770|EXPERIMENTAL|Acupuncture|
62529288|NCT04007770|SHAM_COMPARATOR|Sham Acupuncture (SA)|
62529289|NCT04007770|OTHER|Wait-List Control|This arm is Closed to accrual.
62529290|NCT01673438|EXPERIMENTAL|Aldoxorubicin plus doxorubicin|Aldoxorubicin dosages of 175, 240, and 320 (doxorubicin equivalents of 130, 180, and 240 mg/m2) will be administered as a 30 minutes IVI on Day 1 of each cycle. In addition 35 mg/m2 of doxorubicin HCl will be administered as an IVI over \> 3 minutes no later than 3 hours, but no more than 6 hours before the start of aldoxorubicin infusion.
62529291|NCT02538848|EXPERIMENTAL|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
62529292|NCT02538848|EXPERIMENTAL|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
62529293|NCT02538848|EXPERIMENTAL|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
62713929|NCT01959529|ACTIVE_COMPARATOR|Insulin glargine (IGlar)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
62155478|NCT05536440|EXPERIMENTAL|Cohort 5 active|Dose E
62155479|NCT05536440|PLACEBO_COMPARATOR|Cohort 5 placebo|Dose E
62155480|NCT05536440|EXPERIMENTAL|Cohort 6 active|Dose F
62155481|NCT05536440|PLACEBO_COMPARATOR|Cohort 6 placebo|Dose F
62155482|NCT05536440|EXPERIMENTAL|Cohort 7 active|Dose G
62155483|NCT05536440|PLACEBO_COMPARATOR|Cohort 7 placebo|Dose G
62155484|NCT05536440|EXPERIMENTAL|Cohort 8 active|Dose H
62155485|NCT05536440|PLACEBO_COMPARATOR|Cohort 8 placebo|Dose H
62529294|NCT02538848|EXPERIMENTAL|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
62529295|NCT04407091|EXPERIMENTAL|[14C]AZD4831 Oral Solution|One 10 mg dose of \[14C\]AZD4831 Oral Solution
62529296|NCT04619719|EXPERIMENTAL|Hyperbaric Oxygen|Hyperbaric Oxygen Therapy (HBOT) + Standard of Care (SOC) as defined by current best practice treatments for COVID-19
62529297|NCT04619719|NO_INTERVENTION|Standard of Care|Standard of Care (SOC) as defined by current best practice treatments for COVID-19
62529298|NCT04567030|EXPERIMENTAL|Experimental group A (AI Group: EG-A)|Behavioral: AI intervention For the EG-A, a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
62529299|NCT04567030|EXPERIMENTAL|Experimental group B (AI with humanized Group: EG-B)|"Behavioral: AI intervention For the EG-B,a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.~The humanized counseling will also send to patients' mobile phone about each patients oral hygiene condition and advises."
62529300|NCT04567030|NO_INTERVENTION|Control group (CG)|the control group(CG) only have standard oral hygiene education
62155486|NCT05472532|EXPERIMENTAL|6 cohort|Prostate Cohorte : Castrate resistant metastatic prostate cancer patient Breast cohort : HER2+ ou RH+ metastatic breast cancer patient Lung cohort : Non-small cell lung metastatic lung cancer patient Ovarian cohort : Ovarian cancer with peritoneal carcinomatosis Colorectal cohort : Colorectal cancer with peritoneal carcinomatosis Gastric cancer : Gastric cancer with peritoneal carcinomatosis
62529301|NCT02518919|NO_INTERVENTION|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
62155487|NCT06080802|NO_INTERVENTION|control(SGLT2i/ARBs/MRA/ +/- diuretics).|Lifestyle counseling plus standard evidence-based therapy for HFpEF (SGLT2i/ARBs/MRA/ +/- diuretics).
62529302|NCT02518919|EXPERIMENTAL|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
62529303|NCT02518919|EXPERIMENTAL|Music Listening|Patients will listen to music of their choice using headphones during sedation
62155488|NCT06080802|EXPERIMENTAL|intervention|Lifestyle counseling plus standard evidence-based therapy for HFpEF (SGLT2i/ARBs/MRA/ +/- diuretics)+ metformin
62155489|NCT00079235|EXPERIMENTAL|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.
62155490|NCT04463485|EXPERIMENTAL|Delayed Clamping|The intervention group was waited 60 seconds for umbilical cord clamping in the second stage of labor.
62155491|NCT04463485|NO_INTERVENTION|Early Clamping|No interventions have been assigned.
62155492|NCT03185143|EXPERIMENTAL|Naltrexone and Acetaminophen Combination|
62155493|NCT03185143|ACTIVE_COMPARATOR|Sumatriptan 100 mg|
62155494|NCT03185143|PLACEBO_COMPARATOR|Placebo|
62155495|NCT01979211|EXPERIMENTAL|Cetuximab and Radiation|Cetuximab 400 mg/m2 IV over 120 minutes loading dose \> 4 days prior to initiation of radiation; Cetuximab 250 mg/m2 IV over 60 minutes weekly weeks 2-7 concurrent with Radiation therapy 60-66 Gy in 2 Gy daily fractions
62155496|NCT05333757||Quality of life|"Adult patients treated conservatively for idiopathic scoliosis or undergoing clinical monitoring who have completed both questionnaires at least once and simultaneously and who meet the following inclusion criteria:~* Age ≥ 18 years~* Diagnosis of idiopathic or degenerative scoliosis with curve ≥30 ° Cobb"
62155497|NCT04687345||Propeller Flap|The propeller flap is based on a perforator that serves as a pivot joint, allowing the flap to rotate up to 180°. It provides the advantages of greater freedom of movement and versatility in flap design.
62155498|NCT04687345||Rotation Flap|The rotation flap is primarily supplied by the perforator artery accompanied by the random supply from the skin base. It is also associated with a lower venous congestion risk.
62155499|NCT01249144|ACTIVE_COMPARATOR|Tecnis Z9002 Intraocular Lens (IOL)|
62713930|NCT05759780|EXPERIMENTAL|Healthy cornea|Optical imaging of the cornea in healthy subjects
62155500|NCT01249144|ACTIVE_COMPARATOR|Softec HD Intraocular Lens (IOL)|
62155501|NCT01285856|ACTIVE_COMPARATOR|buprenorphine|populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
62529304|NCT04589416|ACTIVE_COMPARATOR|Single Bond 2|Single Bond 2 is a traditional etch and rinse adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
62529305|NCT04589416|ACTIVE_COMPARATOR|Clearfil SE Bond|Clearfil SE bond is traditional two step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
62529306|NCT04589416|ACTIVE_COMPARATOR|Tri-S Bond|Tri-S bond is traditional one step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
62529307|NCT01698827||Kangaroo|"20 patients managed by Kangaroo gastrostomy tubes. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
62529308|NCT01698827||Cook|"20 patients receiving Wilson Cook gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
62529309|NCT01698827||Silmag|"20 patients managed by Silmag gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
62529310|NCT01698827||Freka|"20 patients carrying Freka gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
62529311|NCT01698827||Bard|"20 patients using the Bard gastrostomy tube. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
62529312|NCT05145582|EXPERIMENTAL|Unguided, Transdiagnostic ICBT Tailored for PSP|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD.
62529313|NCT05145582|EXPERIMENTAL|Unguided, Transdiagnostic ICBT Tailored for PSP + Online Discussion Forum|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD plus a built-in online discussion forum.
62529314|NCT01254266|EXPERIMENTAL|conservative treatment|conservative weight reduction treatment in an inpatient unit.
62529315|NCT01254266|EXPERIMENTAL|bariatric surgery|inpatient program as a pre- and post- operational 'envelope' for bariatric surgeries.
62713931|NCT05759780|EXPERIMENTAL|Healthy skin|Optical imaging of the skin in healthy subjects
62713932|NCT05759780|EXPERIMENTAL|Healthy gingiva|Optical imaging of the gingiva in healthy subjects
62713933|NCT05759780|EXPERIMENTAL|Keratoconus cornea|Optical imaging of the cornea in mild and moderate keratoconus
62155502|NCT01285856|ACTIVE_COMPARATOR|methadone|populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
62529316|NCT05803928|EXPERIMENTAL|Ablation + Lenvatinib +anti-PD-1 Antibodies|"Experimental: ablation + lenvatinib +anti-PD-1 antibodies ablation: ultrasound-guided percutaneous ablation for recurrent hepatocellular carcinoma. After local anesthesia and intravenous sedation, the unipolar needle was gradually inserted into the lesion and placed at the deepest edge of the lesion. Ablation electrodes are unipolar needles with bare ends of 2 or 3cm (depending on tumor size).~Lenvatinib: (TBILI\<2 times the upper limit of normal) about 3 to 7 days after treatment. The dosage and usage of the regimen were 8mg qd po (body weight \< 60kg) or 12mg qd po (body weight ≥60kg).~Anti-PD-1 Antibodies: About 3 to 7 days after radiofrequency ablation, (TBILI\<2 times the upper limit of normal). The dosage was used accordingt to the drug instructions., every 3 weeks for a course of treatment. The longest course of treatment is 6 months."
62529317|NCT05803928|ACTIVE_COMPARATOR|Ablation|Experimental group: ablation Ablation: ultrasound-guided percutaneous ablation for recurrent hepatocellular carcinoma. After local anesthesia and intravenous sedation, the unipolar needle was gradually inserted into the lesion and placed at the deepest edge of the lesion. Ablation electrodes are unipolar needles with bare ends of 2 or 3cm (depending on tumor size). The ablation power is 150W (range from 100 to 200W). In general, the average ablation time per lesion is about 12 minutes (ranging from 10 to 15 minutes).
62155503|NCT06598774||Smartphone addiction group|Participants with smartphone addiction
62155504|NCT06598774||Control Group|Participants without smarthone addiction
62155505|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.~An ECG is performed under controlled conditions."
62155506|NCT02558543|ACTIVE_COMPARATOR|Stromal Vascular Fraction|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo (ringer lactate) ( placebo group)
62529318|NCT04234984||Conventional radiofrequency (RF) treatment|All patients with chronic knee pain who qualify for a conventional RF treatment of the genicular nerves
62529319|NCT04335526|NO_INTERVENTION|Metformin alone|
62529320|NCT04335526|OTHER|Metformin with cholestyramine|
62529321|NCT05613296||Study group|All patients being observed during the study duration.
62529322|NCT02621918|EXPERIMENTAL|Progressive Resistance Training (PRT)|For the progressive resistance training we use 11 exercises. The exercises for upper limbs were held in the waiting room before the hemodialysis session. Resistance exercise was carried out in two sets of 15-20 repetitions, the intensity were determined by the method of maximal repetitions, where series were run until exhaustion to momentary exercises (15-20 repetitions) with specific load. The load adjustments or volume were managed when necessary, but necessarily for every 4th week of training. The effort perception should be situated between 12 and 16 on the Borg scale (Borg and Noble, 1974), as proposed by The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995).
62529323|NCT02621918|EXPERIMENTAL|Aerobic Exercise (AER)|Aerobic exercise was conducted with a mini ergometer cycling (Mini Bike E5 Acte Sports) attached to the patient chair. Patients exercised 50-60 minutes of continuous workout with increased load. The workload was adjusted when necessary, according to the perceived effort made by the patient. The scale of perceived exertion, Borg scale (Borg and Noble , 1974), was used in accordance with the proposed By The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995), which defines the values of perceived exertion between 12 and 16.
62529324|NCT02621918|PLACEBO_COMPARATOR|NEPLA|The control group performed active mobilization of members, circumduction of cervical, scapular girdle and extremities, breathing exercises with no loads, set on three to five repetitions only and no stretch exercises. The exercises were performed during the hemodialysis session, three times per week and did not exceed 5 minutes.
62529325|NCT06276036|EXPERIMENTAL|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
62529326|NCT01259115|EXPERIMENTAL|Sequence A|BTDS 10 with ketoconazole 200 mg tablets twice daily in period 1 and BTDS 10 with ketoconazole placebo tablets twice daily in period 2.
62529327|NCT01259115|EXPERIMENTAL|Sequence B|BTDS 10 with ketoconazole placebo tablets twice daily in period 1 and BTDS 10 with ketoconazole 200 mg twice daily in period 2.
62155507|NCT02558543|PLACEBO_COMPARATOR|Placebo|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo ( placebo group)
62155508|NCT02964234|EXPERIMENTAL|Empowerment|Behavior: Empowerment
62155509|NCT02964234|EXPERIMENTAL|Education|Behavior: Education
62155510|NCT00006214|EXPERIMENTAL|flutamide|"Patients receive oral flutamide once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
62155511|NCT00006214|OTHER|placebo|"Patients receive an oral placebo once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
62155512|NCT00494416|NO_INTERVENTION|ANC approach|Passive health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
62155513|NCT00494416|OTHER|advanced strategies SP|Joint with advanced strategies delivery approach (JAS). In addition to passive delivery of IPT/sulphadoxine pyrimethamine (SP) at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages, such as immunization, health promotion, and even ANC visits.
62155514|NCT00494416|OTHER|Community based|Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs). Each approach will be implemented in a zone constituted by the catchment area of a number of health centres to achieve the required sample size. The zones will be randomly assigned to a delivery approach. The main outcomes to be measured are: a) the coverage of IPT, b) compliance, c) infection prevalence, d) Hb level, e) difficulties and constraints of each approach, f) the acceptability to population and health staff and g) the performance of each approach to deliver IPT /SP. Coverage by 10%, each group should be composed of n = 3841 pregnant women.
62155515|NCT04099576|EXPERIMENTAL|Physiotherapy plus Education|The experimental group received a three-week program consisting of 15 sessions of physiotherapy and six sessions of therapeutic neuroscience education.
62155516|NCT04099576|ACTIVE_COMPARATOR|Control group|The control group received a three-week program consisting of 15 sessions of physiotherapy alone. .
62155517|NCT05029089|EXPERIMENTAL|Experimental: Entire Papilla Preservation Modified Technique (EPPMT)|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated (subperiosteal tunnel). Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. Microsurgical suturing technique with 7-0 materials was performed. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
62155518|NCT05029089|ACTIVE_COMPARATOR|Entire Papilla Preservation Modified Technique + EMD|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. 24%EDTA was applied on the exposed root surface for 2 minutes, than rinsed and EMD was applied. Vertical incision was closed with simple single sutures(7-0),whereas due to modification of the original technique additional sling suture was applied.
62529328|NCT01099527|EXPERIMENTAL|Everolimus|"Everolimus (RAD001) dose escalation of capecitabine, everolimus~Capecitabine dose escalation of capecitabine, everolimus"
62529329|NCT01305395|EXPERIMENTAL|Early Intervention Arm|Initiate sirolimus within 6 months of heart transplant
62529330|NCT01305395|EXPERIMENTAL|Late Intervention Arm: Group 2A|Initiate sirolimus after CAV is diagnosed by angiogram
62529331|NCT01305395|EXPERIMENTAL|Retrospective Arm: Angiogram group|Start sirolimus after CAV diagnosed is by angiogram
62529332|NCT01305395|EXPERIMENTAL|Late Intervention Arm: Group 2B|Start sirolimus after CAV is diagnosed by IVUS
62529333|NCT01305395|EXPERIMENTAL|Retrospective Arm: Intravascular Ultrasound|Sirolimus after CAV is diagnosed by IVUS
62529334|NCT03080753|EXPERIMENTAL|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
62529335|NCT04915482|EXPERIMENTAL|Combined use of TPO-RAs with low-dose anti-CD20 antibody|The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
62529336|NCT04915482|ACTIVE_COMPARATOR|The best available therapy other than combined use of TPO-RAs with low-dose anti-CD20 antibody|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
62529337|NCT04555850|EXPERIMENTAL|Recombinant Human Thymosin β4 0.5ug/kg|10 subjects in this group will receive NL005 for 0.5ug/kg respective.Continuous administration for 10 days.
62529338|NCT04555850|EXPERIMENTAL|Recombinant Human Thymosin β4 2.0ug/kg|10 subjects in this group will receive NL005 for 2.0ug/kg respective.Continuous administration for 10 days.
62529339|NCT04555850|EXPERIMENTAL|Recombinant Human Thymosin β4 5.0ug/kg|10 subjects in this group will receive NL005 for 5.0ug/kg respective.Continuous administration for 10 days.
62713934|NCT05069649|EXPERIMENTAL|Ergoferon|Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15-30 minutes before meals), keep the tablets in the mouth, without swallowing, until completely dissolved.
62529340|NCT04555850|OTHER|Placebo|Two subjects in each dose group (0.5/2/5ug/kg) were given placebo for 10 days.A total of six participants were given a placebo.
62529341|NCT04006223||11C-PIB or 18F-florbetapir PET/MR|Patients suspected of or diagnosed with systemic amyloidosis will be scanned by 11C-PIB or 18F-florbetapir PET/MR twice. One is before biopsy and treatment, and the other is after at least half a year of treatment.
62529342|NCT02841813||The normal mothers group|No intervention
62713935|NCT05069649|PLACEBO_COMPARATOR|Placebo|Tablet for oral use. Placebo using Ergoferon scheme.
62529343|NCT02841813||The normal full-term infants group|No intervention
62529344|NCT02841813||The preterm mothers group|No intervention
62529345|NCT02841813||The preterms group|No intervention
62155519|NCT05029089|ACTIVE_COMPARATOR|EPP Modified Technique+EMD+allograft|Procedure:The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
62529346|NCT04284995|EXPERIMENTAL|Cohort 1|Cohort 1: 0.075 mg/kg RUC-4. 8 STEMI Patients will be enrolled.
62529347|NCT04284995|EXPERIMENTAL|Cohort 2|Cohort 2: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
62529348|NCT04284995|EXPERIMENTAL|Cohort 3|Cohort 3: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
62713936|NCT06719258||MR850|20 subjects on this heating humidifier (Fisher \& Paykel MR850).
62155520|NCT05029089|ACTIVE_COMPARATOR|EPP Modified Technique+EMD+allograft+sCTG|Procedure: After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. sCTG taken form palate was sutured to the inner part of mucosa flap. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
62529349|NCT03174951|EXPERIMENTAL|Treatment group|IVIg group
62529350|NCT03174951|NO_INTERVENTION|control group|Patients who do not receive any treatment despite a history of Recurrent Pregnancy Loss problem as controls
62155521|NCT02507401||Total laryngectomy patients|Users of voice prostheses
62155522|NCT05513729||Canagliflozin treatment group|40 patients with T2DM combined with NAFLD will be assigned to receive canagliflozin on top of metformin monotherapy according to clinical guideline of type 2 diabetes as experimental group.
62155523|NCT05513729||Pioglitazone treatment group|40 patients with T2DM combined with NAFLD will be assigned to receive pioglitazone on top of metformin monotherapy according to clinical guideline of type 2 diabetes as experimental group. as placebo comparator group.
62155524|NCT04315545||Healthy women pregnant of singleton with a BMI ≥25 kg/m2|Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.
62713937|NCT06719258||FP950|20 subjects on this heating humidifier (Fisher \& Paykel FP950).
62713938|NCT04319757|EXPERIMENTAL|ACE1702 Dose Level 1|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.~Dose Level: 1 Planned number of subjects: 1 to 6"
62713939|NCT04319757|EXPERIMENTAL|ACE1702 Dose Level 2|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 2 Planned number of subjects: 1 to 6"
62155525|NCT04362618|EXPERIMENTAL|Muscle Strengthening Training (MST)-group|Subjects allocated to the MST group (n=30) will perform a muscle strengthening training program of 12 weeks.
62155526|NCT04362618|EXPERIMENTAL|Behavioral Graded Activity (BGA)-group|Subjects allocated to the BGA group (n=30) will perform a rehabilitation program according to the principles of behavioural graded activity for a period of 12 weeks.
62155527|NCT04362618|NO_INTERVENTION|Control group|Subjects allocated to the control group (n=30) have to maintain their current life-style and treatment (if any) and to refrain from other new interventions during 24 weeks.
62155528|NCT01732757|ACTIVE_COMPARATOR|Lastacaft®|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
62155529|NCT01732757|ACTIVE_COMPARATOR|Pataday™|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
62529351|NCT05874583|ACTIVE_COMPARATOR|Intravenous Group|patients receiving 2 doses of 1 g of tranexamic acid in in intra venous route 3 hours apart
62529352|NCT05874583|EXPERIMENTAL|Combined Group|receiving the first 1g of tranexamic acid Intra venously and the second topical dose was 1,5g after reduction of the fascia.
62529353|NCT01826786|EXPERIMENTAL|JNJ-42165279 (100 mg)|
62529354|NCT01826786|PLACEBO_COMPARATOR|Placebo|
62529355|NCT01632761|ACTIVE_COMPARATOR|Vitamin D + fish oil|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
62529356|NCT01632761|ACTIVE_COMPARATOR|Vitamin D + fish oil placebo|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Dietary Supplement: Fish oil placebo Fish oil placebo
62529357|NCT01632761|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil|"Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).~Dietary Supplement: Vitamin D3 placebo Vitamin D placebo"
62155530|NCT01732757|PLACEBO_COMPARATOR|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
62155531|NCT05067816|ACTIVE_COMPARATOR|Distance Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a distance scale-up format where each site implementation team will receive technical assistance individually. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
62155532|NCT05067816|EXPERIMENTAL|Quality Improvement Collaborative Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a quality improvement collaborative scale-up format where implementation teams will work collaboratively during training and implementation. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
62155533|NCT04432909||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UroCAD analysis, the result will be compared with cytology and FISH test.
62155534|NCT04432909||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD analysis.
62155535|NCT01403727||Unassisted Biopsy - CONTROL GROUP|Routine biopsy needle placement and Physician blinded to needle location
62155536|NCT01403727||Assisted Biopsy - STUDY GROUP|The physician will be shown the PercuNav screen and will correct the desired approach path.
62155537|NCT03988855|EXPERIMENTAL|Part 1|10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days.
62155538|NCT03988855|EXPERIMENTAL|Part 2|30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days
62155539|NCT04945044|EXPERIMENTAL|Computed adenoma detection system (CADe)|Tis system can detect in the screen suspicion areas of adenomatous polyps. This is an additional help for the endoscopist for the detection of lesions
62155540|NCT04945044|ACTIVE_COMPARATOR|Control group (absence of CADe)|This is the control group. As in the routine colonoscopy the endoscopist is in charge of the detection of the lesions.
62155541|NCT04014686|SHAM_COMPARATOR|Control group|No exercise intervention
62155542|NCT04014686|EXPERIMENTAL|Exercise intervention group|Exercise intervention group (resistance band exercise training for 12 weeks, 3x per week, for 60 minutes per day).
62155543|NCT03567356|NO_INTERVENTION|Treatment as Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.
62155544|NCT03567356|EXPERIMENTAL|MAT-Plus Intervention|"The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
62155545|NCT05483556|EXPERIMENTAL|Real tDCS|Five post-stroke patients will be allocated by the flip the coin method to the experimental group. Participants will receive anodal tDCS stimulation for 20 minutes
62155546|NCT05483556|SHAM_COMPARATOR|Sham tDCS|Five participants will be allocated by the flip coin method to the sham comparator group. Participants will receive the tDCS stimulation for the 30s
62155547|NCT02011789|EXPERIMENTAL|Group1|Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
62155548|NCT02011789|ACTIVE_COMPARATOR|Group 2|Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
62529358|NCT01632761|ACTIVE_COMPARATOR|Vitamin D placebo + fish oil placebo|Dietary Supplement:Vitamin D3 placebo Vitamin D placebo Dietary Supplement: Fish oil placebo Fish oil placebo
62155549|NCT06035627||Experimental group|The population of the study consisted of patients who were being treated in the general surgery clinic of the hospital, who met the sampling criteria, who were to undergo laparoscopic cholecystectomy, and who agreed to participate in the study. The sample size of the study was determined by the G\*Power 3.1.9.7 program. In the power analysis, when α =0.05, β=0.10, and 1-β =0.90, the sample size was determined as 50 people per group and a total of 100 people.
62529359|NCT00611273|EXPERIMENTAL|1|Patients who have presented to the investigator for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Note: Class 1 or Higher)7 (Appendix R) are candidates for this study.
62529360|NCT02667015|EXPERIMENTAL|Anxiety Sensitivity Intervention|Group receives the 3-week, 6-session Anxiety Sensitivity Intervention. This is a 6-session psychotherapy occurring twice weekly (60-90 minutes) for three weeks. This psychotherapeutic treatment is focused on reducing anxiety sensitivity and includes many components, but primarily consists of psychoeducation about the relationship between anxiety and substance use disorders, interoceptive exposures, in vivo exposures, and cognitive challenging.
62529361|NCT02667015|NO_INTERVENTION|Control Group|Receives only treatment as usual
62539539|NCT05470205|EXPERIMENTAL|Ccreening for varices - Cohort 4|"Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices according to the Baveno VI or the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index and FIB-4 will undergo a SHAPE examination.~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min."
62539540|NCT05200598||Mild psoriasis|
62155550|NCT06035627||Control group|The population of the study consisted of patients who were being treated in the general surgery clinic of the hospital, who met the sampling criteria, who were to undergo laparoscopic cholecystectomy, and who agreed to participate in the study. The sample size of the study was determined by the G\*Power 3.1.9.7 program. In the power analysis, when α =0.05, β=0.10, and 1-β =0.90, the sample size was determined as 50 people per group and a total of 100 people.
62155551|NCT03800563|EXPERIMENTAL|Laser assisted liposuction|Laser Assisted Liposuction with the LipoLife system. Each subject underwent laser assisted liposuction surgery w/wo facial fat grafting , using the LipoLifeTM system. Pre-surgery evaluation visit was carried out 1 week prior to the surgery. Follow up visits to evaluate safety and efficacy will take place at 1, 3 and 6 months after the surgery.
62155552|NCT05567848|EXPERIMENTAL|repetitive Transcranial Magnetic Stimulation (rTMS)|repetitive Transcranial Magnetic Stimulation (rTMS) in a iTBS pattern to the cerebellum at 100% of resting motor threshold
62155553|NCT03703947||Watchful-waiting group|The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
62529362|NCT00742924|EXPERIMENTAL|Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery .~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
62529363|NCT00742924|EXPERIMENTAL|Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
62529364|NCT00742924|EXPERIMENTAL|Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
62529365|NCT00742924|EXPERIMENTAL|Chemotherapy and 2.3 mg/m2 Zoledronic Acid after MTD|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
62539541|NCT05200598||Moderate psoriasis|
62155554|NCT03703947||EVAR group|The prospective, longitudinal part of the study will include an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months after EVAR. CT will be conducted at baseline, at 1 month after EVAR and at 12 and 24 months after EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 1 month, at 12 and 24 months of follow-up after EVAR.
62155555|NCT03703947||Cross-sectional group (after EVAR)|A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
62155556|NCT02382185|EXPERIMENTAL|Usual care|No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
62155557|NCT02382185|EXPERIMENTAL|Fluid optimisation|Application of clearsight monitor, optimisation of blood pressure and fluid optimisation. A Clearsight cardiac probe is attached and after induction of anaesthesia stroke volume is optimised using 250ml boluses of Hartmann's solution. The SV measurement prior to the final fluid bolus will be the optimal SV. Mean arterial blood pressure will be maintained within 30% of baseline values using a phenylephrine infusion.Data on haemodynamics will be recorded at baseline and then every 5 minutes, as well as before and after a fluid bolus. Haemoglobin will be maintained at\>10g/dL with blood transfusion as required.
62155558|NCT04610125|EXPERIMENTAL|Auto CAR-T|Patients will be treated with Auto CAR-T cells
62155559|NCT04791917|EXPERIMENTAL|Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
62529366|NCT01512706|EXPERIMENTAL|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
62529367|NCT01512706|EXPERIMENTAL|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
62529368|NCT01512706|EXPERIMENTAL|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
62529369|NCT01512706|EXPERIMENTAL|1280Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
62529370|NCT01512706|PLACEBO_COMPARATOR|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
62529371|NCT01512706|EXPERIMENTAL|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
62529372|NCT01512706|EXPERIMENTAL|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
62529373|NCT01512706|EXPERIMENTAL|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
62529374|NCT01512706|EXPERIMENTAL|1280Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
62529375|NCT01512706|PLACEBO_COMPARATOR|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
62713940|NCT04319757|EXPERIMENTAL|ACE1702 Dose Level 3|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 3 Planned number of subjects: 3 to 6"
62529376|NCT01512706|EXPERIMENTAL|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
62529377|NCT01512706|EXPERIMENTAL|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
62713941|NCT04319757|EXPERIMENTAL|ACE1702 Dose Level 4|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 4 Planned number of subjects: 3 to 6"
62713942|NCT04319757|EXPERIMENTAL|ACE1702 Dose Level 5|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 5 Planned number of subjects: 3 to 6"
62155560|NCT04791917|SHAM_COMPARATOR|Sham Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
62529378|NCT01512706|EXPERIMENTAL|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
62529379|NCT01512706|EXPERIMENTAL|1280Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 children aged 24 months-5 years months old on day 0, 28
62529380|NCT01512706|PLACEBO_COMPARATOR|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
62529381|NCT04132583|EXPERIMENTAL|First Deflox®, Then Cataflam DD®|Participants received single oral dose of Deflox® 50 milligrams (mg) tablet in Treatment Period 1 followed by a single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between the Treatment Periods 1 and 2.
62529382|NCT04132583|EXPERIMENTAL|First Cataflam DD®, Then Deflox®|Participants received single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 1 followed by single oral dose of Deflox® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between Treatment Periods 1 and 2.
62529383|NCT03599271|EXPERIMENTAL|Drug-Coated Device|Randomized cohort: Drug-Coated Device to dilate randomized frontal sinus ostium.
62529384|NCT03599271|ACTIVE_COMPARATOR|Control Sinus Dilation Device|Randomized cohort: Control Device to dilate randomized contralateral frontal sinus ostium.
62529385|NCT03599271|EXPERIMENTAL|PK cohort- Drug-Coated Device|PK cohort: One Drug-Coated Device to dilate both frontal sinus ostia.
62529386|NCT02335736|ACTIVE_COMPARATOR|Normal|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
62529387|NCT02335736|ACTIVE_COMPARATOR|Poor responders|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
62529388|NCT02335736|ACTIVE_COMPARATOR|Polycystic ovarian disease|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
62529389|NCT02190474|EXPERIMENTAL|Mindfulness Group|These adolescents will be invited to participate in a group mindfulness meditation program based on a protocol refined by the investigative team. The weekly group meetings will be taught by an MBSR teacher at the Yale School of Medicine, with experience teaching mindfulness interventions to adults, children, and adolescents.
62529390|NCT04881630|ACTIVE_COMPARATOR|Standard Care (SC)|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
62529391|NCT04881630|EXPERIMENTAL|Contingency Management (CM)|CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
62529392|NCT03920176|ACTIVE_COMPARATOR|Computed tomography coronary angiography|
62529393|NCT03920176|SHAM_COMPARATOR|Assign Score only|
62529394|NCT03674086||First-time hearing aid user|Using hearing aids less than or equal to three months.
62539542|NCT05200598||Severe psoriasis|
62529395|NCT03674086||Existing hearing aid user|Using hearing aids for 6 months or more.
62529396|NCT06405282||Healthy students of the Health Professions Division of NSU|Participants arrived at a predesignated room and acclimated to the ambient temperature for 15 minutes. Baseline heart rate, blood pressure, respiration rate, and oxygen saturation were taken and monitored throughout the data collection process. Participants were assessed in the HDT position (validated simulated weightlessness) for 3 hours and 45 minutes. Baseline image assessments were taken 1 minute after assuming the HDT position. Subsequent image assessments were taken every 30 minutes thereafter. Each image acquisition requires \~20 seconds and was performed by 1 of 4 trained imagers. Participants received 15 minutes of an established MLD protocol to the head, neck, and thorax before moving out of position. Immediately post-MLD, reassessment with the devices occurred. A follow-up reassessment was taken with the devices 30 minutes after MLD in the sitting position to assess potential changes and resolution of any symptoms experienced following a return to gravity environment.
62155561|NCT02822092||Patients with Psychotic Disorders taking Risp. or Arip.|Risperidone or aripiprazole will be administered. Subjects will start risperidone 1 mg qhs or 5mg qhs aripiprazole; on day 4 the daily dose will be increased to 2 mg risperidone or 10mg aripiprazole and to 3 mg risperidone or 15mg aripiprazole at day 7. The target dose is 3 mg risperidone or 15 mg aripiprazole daily but patients who remain psychotic can be increased to 4 mg risperidone or 20mg aripiprazole at week 4; 5 mg risperidone or 25 mg aripiprazole at week 6 and 6 mg risperidone or 30 mg aripiprazole at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
62155562|NCT02822092||Healthy Volunteers|Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.
62155563|NCT02731950|ACTIVE_COMPARATOR|A magnesium|"Consists of 20 patients:~Each receive bupivacaine 0.125% with 5% magnesium sulfate by infusion through a small diameter multi-hole soft catheter generally used for epidural analgesia positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 hours postoperative. A bolus of 5 ml of the study solution will be injected in the catheter after aspiration test before connection to infusion pump that delivers continuous infusion pump that delivers continuous infusion at a fixed rate of 5 ml/h.~postoperative : 25 µg fentanyl for breakthrough pain. placebo will be given in same intravenous instead of paracetamol and ketorolac of group B , to keep the investigator blinded"
62155564|NCT02731950|NO_INTERVENTION|B control|"Consists of 20 patients:~saline as placebo infusion through a small diameter multi-hole soft catheter positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 Postoperative pain control will be managed with 1gm paracetamol /6 hr, Ketorolac 30 mg every 8-12 hour .25 µg fentanyl for breakthrough pain."
62155565|NCT04760028|OTHER|sevoflurane|Adjust sevoflurane concentration as required
62155566|NCT04462159|EXPERIMENTAL|Risk Reduction Program|All participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component.
62155567|NCT05642702|EXPERIMENTAL|Test Product Code A|Peptide complexed HA Age Defying Gel with Vitamin C \& Niacinamide -
62155568|NCT05642702|EXPERIMENTAL|Test Product Code B|Peptide complexed HA Age Defying Gel with Natural Extracts
62155569|NCT05642702|EXPERIMENTAL|Test Product Code C|Peptide complexed HA Age Defying Gel with Vitamin C \& Natural Extracts
62155570|NCT05642702|ACTIVE_COMPARATOR|Positive Control|Sodium Lauryl Sulphate (SLS) analytical grade 1 % w/v
62155571|NCT05642702|ACTIVE_COMPARATOR|Negative Control|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v
62155572|NCT05992584|EXPERIMENTAL|Len-Sin-SIRT|Lenvatinib, sintilimab plus SIRT
62155573|NCT06105099|ACTIVE_COMPARATOR|Children with anterior oral cleft speech characteristics|To investigate the best speech therapy approach for children with anterior oral cleft speech characteristics, we will provide three different interventions.
62155574|NCT06105099|EXPERIMENTAL|Children with posterior oral cleft speech characteristics|To investigate the best speech therapy approach for children with potserior oral cleft speech characteristics, we will provide three different interventions.
62155575|NCT06105099|EXPERIMENTAL|Children with non-oral cleft speech characteristics|To investigate the best speech therapy approach for children with non-oral cleft speech characteristics, we will provide three different interventions.
62155576|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
62155577|NCT02820909|EXPERIMENTAL|Ultrasound guidance|46 patients in the experimental ultrasound group
62155578|NCT02820909|ACTIVE_COMPARATOR|Anatomical guidance|46 patients in the anatomical group
62155579|NCT05828654|OTHER|Single Arm|Community representatives
62529397|NCT06275191|EXPERIMENTAL|Intervention condition|"1. Academic detailing (45 to 60-minute session), plus~2. Provision of standardized patient post-extraction instructions for distribution, plus~3. Provision of blister-packaged acetaminophen and ibuprofen at recommended standard doses for distribution to to adolescent/young adult patients after tooth extraction in the course of clinical practice"
62529398|NCT06275191|ACTIVE_COMPARATOR|Control condition|Usual practice
62529399|NCT06477484||different stages of individuals with Alzheimer's disease|
62529400|NCT02261844|EXPERIMENTAL|resveratrol|Resveratrol 1 g daily for 10 days
62529401|NCT02261844|PLACEBO_COMPARATOR|Placebo|Placebo 1 pill daily for 10 days
62539543|NCT05200598||Patients without psoriasis|
62713943|NCT04319757|EXPERIMENTAL|ACE1702 Dose 6|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 6 Planned number of subjects: 3 to 6"
62713944|NCT03313973|EXPERIMENTAL|with self stretching same muscle|
62713945|NCT03313973|SHAM_COMPARATOR|with self stretching forearm muscle|
62713946|NCT04966637||Individuals with COPD|"This retrospective annual analysis will use the following validated case definition to identify a cohort of individuals with COPD: an individual aged 35 years and older having at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44) between April 1, 2016 and March 31, 2019.~This is a retrospective descriptive study with administrative data and no intervention will be administered to the cohort"
62713947|NCT06622044|EXPERIMENTAL|Vision therapy group|Accommodation facility exercises and divergence exercises
62713948|NCT06622044|ACTIVE_COMPARATOR|Prism group|wearing prism glasses
62155580|NCT02543307|EXPERIMENTAL|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients' processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients' and health care professionals' as well as institutional outcomes.
62155581|NCT02543307|NO_INTERVENTION|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
62155582|NCT03640078|EXPERIMENTAL|experimental group|Vasculitis patients The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis of serum. (acquisition imaging)
62155583|NCT00823966||Delavirdine Mesilate|Patients administered.
62155584|NCT02074709|ACTIVE_COMPARATOR|TAP block|TAP block with plain bupivacaine
62155585|NCT02074709|ACTIVE_COMPARATOR|Wound infiltration|Wound infiltration with liposomal bupivacaine
62155586|NCT02697136|EXPERIMENTAL|CER-001|CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
62155587|NCT02697136|PLACEBO_COMPARATOR|Placebo|Saline infusion; 9 weekly infusions followed by 20 biweekly infusions
62155588|NCT03861884||Cognitive assessments|Neurocognitive assessments, Birmingham Cognitive Screen
62155589|NCT03861884||MRI at 3T|Brain Imaging: MRI at 3T
62155590|NCT03861884||MRI at 7T|Brain imaging: Ultrahigh Field MRI at 7T
62529402|NCT02903992|OTHER|All patients recruited|All patients who are enrolled in study with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
62529403|NCT05912907|EXPERIMENTAL|potassium nitrate in polycarboxilate cement|
62529404|NCT05912907|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate|
62529405|NCT04614246|EXPERIMENTAL|BAY1817080 150 mg|Participants will receive 150 mg of BAY1817080 twice daily over a 12-week intervention period
62529406|NCT04614246|EXPERIMENTAL|BAY1817080 75 mg|Participants will receive 75 mg of BAY1817080 twice daily over a 12-week intervention period
62529407|NCT04614246|EXPERIMENTAL|BAY1817080 25 mg|Participants will receive 25 mg of BAY1817080 twice daily over a 12-week intervention period
62529408|NCT04614246|ACTIVE_COMPARATOR|Elagolix|Participants will receive 150 mg of Elagolix once daily over a 12-week intervention period
62529409|NCT04614246|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching BAY1817080 twice daily over a 12-week intervention period
62529410|NCT03203486|EXPERIMENTAL|Meditteranean Diet|NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
62529411|NCT03206580|EXPERIMENTAL|Concentric training|Concentric training
62155591|NCT02081820||aneurysmal subarachnoid hemorrhage|observational, no intervention
62155592|NCT04705779|EXPERIMENTAL|HARMONY|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
62155593|NCT04705779|ACTIVE_COMPARATOR|Nutrition and Exercise Education Workgroup (NEEW)|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
62155594|NCT03233997|EXPERIMENTAL|FT21018 Group|7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
62155595|NCT03233997|EXPERIMENTAL|FT21033 Group|7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
62529412|NCT03206580|EXPERIMENTAL|Concentric-eccentric training|Concentric-eccentric training
62529413|NCT02368574|NO_INTERVENTION|Class III hysterectomy Arm|Class III hysterectomy (radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. Perivesical space and perirectal space should be opened, and the ureteral tunnel is completely separated and pushed down to the junction of ureter and urinary bladder. The uterine arteries are ligated at the level of internal iliac artery, and all the supporting ligaments and connective tissues around the uterus should be separated and abscised. The uterosacral ligament is removed near the sacrum, the cardinal ligament is removed near the pelvic wall, and the vagina is removed after the excision of peivaginal connective tissues, about 3-4cm from the cervical lesion. The pelvic lymph nodes are usually dissected at the same time.
62539544|NCT04569669|EXPERIMENTAL|Patients diagnosed with Coronary Artery Disease（CAD）by CCTA|Patients admitted to hospital with the diagnosed of CAD by CCTA and who accept to participate to the study will undergo the invasive coronary angiography, fractional flow reserve (FFR) will be measured during the invasive coronary angiography.Outcome measures were comparing FFRct to FFR.
62529414|NCT02368574|EXPERIMENTAL|Class II hysterectomy Arm|Class II hysterectomy (modified radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. The scope of surgery is more extensive than Class I epifascial panhysterectomy, demanding the excision of more parametrium but reservation of the blood supply for distal ureter and urinary bladder. The ureter is separated from the ureteral tunnel, the vesicouterine ligament should be intact, and 1/2 uterosacral ligament and 1cm vagina are excised. The pelvic lymph nodes are usually dissected at the same time.
62155596|NCT03233997|EXPERIMENTAL|FT21034 Group|7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
62155597|NCT03233997|EXPERIMENTAL|FT21035 Group|7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
62155598|NCT01404702|EXPERIMENTAL|Zoledronic Acid and Interleukin-2|
62155599|NCT01863082|EXPERIMENTAL|exercise|the patients will be submitted to an exercise protocol
62155600|NCT00042939|ACTIVE_COMPARATOR|Irinotecan/Docetaxel|"Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. This constituted a cycle of treatment. Patients were evaluated after 2 cycles."
62155601|NCT00042939|EXPERIMENTAL|Irinotecan/Docetaxel/Cetuximab|"Patients received Cetuximab intravenously once a week for 6 weeks. On day 1 of cycle 1 only, an initial dose of 400 mg/m² (over 120 minutes) was administered. Thereafter, a once-a-week maintenance dose of 250 mg/m² (infused over 60 minutes), was given. The infusion rate never exceeded 5 ml/minute.~On the day of the initial dose, the administration of Cetuximab was followed by the administration of docetaxel, after a 60-minute observation period. (The observation period was 30 minutes following maintenance doses.) Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Cetuximab was administered once a week for 6 consecutive weeks. A cycle of treatment was 6 weeks."
62155602|NCT06461949|EXPERIMENTAL|Arm A:|Treatment: Dupilumab 300 mg administered subcutaneously every two weeks for 52 weeks.
62155603|NCT06461949|PLACEBO_COMPARATOR|Arm B:|Control: Placebo administered subcutaneously every two weeks for 52 weeks.
62529415|NCT03728400||Patients in neurovascular intensive care|During the patient's hospitalization in neurovascular intensive care unit, the doctor will propose to the patient to take part in this study. If the patient agree, this search will not change the patient's usual support and will not involve any further review.
62529416|NCT03492827|EXPERIMENTAL|gargle group|drugs，chlorhexidine acetate gargle dosage，15ml，twice daily， duration，3days before ESD
62529417|NCT03492827|NO_INTERVENTION|Control group|Control group will not be interventioned with gargle
62529418|NCT04412265||Covid 19 patients|The study will be conducted on all patients hospitalized affected by pneumonia COVID related.
62529419|NCT02894281||Measure of pupillary light reflex|patients without optic neuritis
62529420|NCT02894281||patients with optic neuritis|clinical database of 22 patients (measurement of pupillary light reflex already performed for the same purpose, in a former study)
62529421|NCT05335733||Postmenopausal women|
62529422|NCT05335733||Premenopausal women|
62529423|NCT03249974||Target group|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
62529424|NCT01867944|EXPERIMENTAL|Perineal Self-Acupressure|Participants in this group (intervention group) will receive education in perineal self-acupressure in addition to education in conventional treatment options for constipation.
62529425|NCT01867944|ACTIVE_COMPARATOR|Educational Control|Participants in this group (the control group) will receive education in conventional treatment options for chronic constipation.
62529426|NCT02165865|EXPERIMENTAL|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
62529427|NCT01558180|EXPERIMENTAL|Telephone Care Management|calls from a registered nurse to educate caregivers about behavioral sleep strategies
62529428|NCT01558180|PLACEBO_COMPARATOR|Usual Care|It's a placebo comparator because individuals in this group will receive an educational handout on behavioral sleep strategies. This handout approximates standard of care.
62529429|NCT03871868||study group|In Woman With Myoma Uteri
62529430|NCT03871868||control group|In Woman Without Myoma Uteri
62529431|NCT04257552|ACTIVE_COMPARATOR|Attention Control Group|If randomized to the attention control arm participants will receive discharge instruction from the postpartum nurses per usual care. Study investigators will ask them to provide us with an SMS number. This will enable collection of self-reported breast feeding duration as well as texts on general infant care. The infant care texts are educational in nature and no data will be collected. Participants will receive a total of two texts on general infant care in the first month postpartum. This increased attention to the control arm mirrors the attention received by the Healthy Beyond Pregnancy arms and seeks to isolate the effect of the intervention from a general increased level of contact with providers.
62529432|NCT04257552|ACTIVE_COMPARATOR|Pre-Scheduled Postpartum Visit:|If randomized the usual care with pre-scheduled visit arm, participants will schedule their postpartum visit with the study coordinator and receive discharge information per usual care.
62539545|NCT05342779|ACTIVE_COMPARATOR|Group A will undergo stripping of great saphenous vein. .|
62539546|NCT05342779|ACTIVE_COMPARATOR|Group B will undergo treatment by radiofrequency ablation.|
62713949|NCT06477783||Relapsed or refractory multiple myeloma patients|Patients aged 18 years or older diagnosed with relapsed or refractory multiple myeloma, who received at least 3 prior lines of treatment. They should be refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody. After confirmation of disease progression, the patients will start treatment with teclistamab per routine clinical care or will have started with teclistamab treatment ≤14 days before intended screening visit
62713950|NCT06068504|EXPERIMENTAL|Arm-cranking exercise|Patients will be perform arm-cranking exercise. The exercise will be performed in 15 sets of 2 min of exercise at a moderate intensity (13-15 in Borg scale)
62529433|NCT04257552|EXPERIMENTAL|Healthy Beyond Pregnancy|Healthy Beyond Pregnancy is a web platform with an electronic survey that assesses a participant's self-identified postpartum concerns. Participants are then presented with 3 educational videos that reflect their self-identified needs from the survey. The Healthy Beyond Pregnancy generates an individualized passport for postpartum care. This passport for care lists the women's self-identified postpartum needs as well as issues that should be prioritized based on her health history. The individualized passport for postpartum care will be printed out and given to participants. After the participant schedules her postpartum visit, she will receive a printout that includes the date and time of her appointment, a copy of the commitment statement.
62155604|NCT00821093|EXPERIMENTAL|Indacaterol 150 µg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Patients also inhaled placebo to salmeterol twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62529434|NCT05769933||Healthy participants|Healthy volunteers with no history of neurological problems or mental disorders; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
62529435|NCT05769933||Essential tremor patients|Non-hospitalized volunteers who have been diagnosed with essential tremor and are indicated for thalamic surgery. Interventions: MRI.
62155605|NCT00821093|ACTIVE_COMPARATOR|Salmeterol 50 µg|Patients inhaled salmeterol 50 μg twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]) for 12 weeks. Patients also inhaled placebo to indacaterol once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
62155606|NCT04989023|EXPERIMENTAL|Blood flow restriction (BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (80% limb occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
62529436|NCT05769933||Psychosis patients|Non-hospitalized volunteers who have been diagnosed with early psychosis, and clinically assessed; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
62529437|NCT05769933||Healthy controls|Healthy volunteers who have been clinically assessed and determined to be suitable matched controls with respect to the psychosis group; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
62529438|NCT05769933||Epilepsy patients|Non-hospitalized volunteers who have been diagnosed with epilepsy.
62529439|NCT05279365|EXPERIMENTAL|Administration of Booster Dose|study participant will receive either 30ug in 0.3 ml of Pfizer/BioNTech (BNT162b2) or 0.25 ml of Moderna vaccine administered intramuscularly.
62529440|NCT02440022|EXPERIMENTAL|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
62529441|NCT02440022|ACTIVE_COMPARATOR|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
62529442|NCT04120090|ACTIVE_COMPARATOR|Low dose|
62529443|NCT04120090|EXPERIMENTAL|High dose|
62529444|NCT04616339|ACTIVE_COMPARATOR|Formulation A (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
62529445|NCT04616339|EXPERIMENTAL|Formulation B (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation B at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
62529446|NCT04616339|EXPERIMENTAL|Formulation C (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation C at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
62529447|NCT04616339|EXPERIMENTAL|Formulation D (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation D at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
62529448|NCT04616339|ACTIVE_COMPARATOR|Formulation A (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
62529449|NCT04616339|EXPERIMENTAL|Formulation E (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation E at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
62529450|NCT04551833|EXPERIMENTAL|Group (T) : 30 patients (Tramadol group)|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 1.5 mg/kg Tramadol.
62529451|NCT04551833|EXPERIMENTAL|Group (D) : 30 patients (Dexamethasone group):|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 8mg of Dexamethasone
62529452|NCT06345989|ACTIVE_COMPARATOR|Alginate impression|Alginate impression
62155607|NCT04989023|SHAM_COMPARATOR|Sham-Blood flow restriction (sham-BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
62155608|NCT04989023|EXPERIMENTAL|Blood flow restriction (BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (60% of the limb complete occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
62529453|NCT06345989|ACTIVE_COMPARATOR|Intraoral scan|Intraoral scan using Trios 3Shape Scanner
62529454|NCT01056978||patients|Patients admitted in a palliative care unit
62529455|NCT04544501|EXPERIMENTAL|Culturally-Targeted Video|
62529456|NCT04544501|ACTIVE_COMPARATOR|FORCE Fact Sheet|
62529457|NCT00505089|EXPERIMENTAL|1|ACZ885 10mg/kg subcutaneous
62529458|NCT00505089|EXPERIMENTAL|2|ACZ885 5mg/kg intravenous
62529459|NCT00505089|EXPERIMENTAL|3|ACZ885 2mg/kg subcutaneous
62529460|NCT00505089|EXPERIMENTAL|4|ACZ885 1mg/kg intravenous
62529461|NCT06404164|OTHER|Watershed analysis|
62529462|NCT03837743|EXPERIMENTAL|DUR-928 Topical Solution|DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
62529463|NCT03837743|PLACEBO_COMPARATOR|Vehicle Topical Solution|Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
62529464|NCT06314789|EXPERIMENTAL|Lung ultrasound for newborns|In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and lUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
62529465|NCT01150318|EXPERIMENTAL|1|Patients treated by 131 iodine for thyroid cancer
62529466|NCT02636543||Group 2a-patient|75 patients who attended a genetic counselling consultation.
62529467|NCT02636543||Group 2a-public|75 persons belonging to general population.
62529468|NCT02636543||Group 2b-patient|75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).
62529469|NCT02636543||Group 2b-public|75 persons belonging to general population (those persons are different than patients from group 2a).
62529470|NCT02636543||Group 2b-professional|75 genetic professionals.
62529471|NCT06390644|EXPERIMENTAL|Periorbital Massage Therapy|Participants in this arm will receive periorbital massage therapy administered by a trained practitioner.
62529472|NCT06390644|OTHER|Control Group (Standard Care)|Participants in this arm will receive standard care for dry eye disease.
62529473|NCT04748523|ACTIVE_COMPARATOR|Intervention group|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
62529474|NCT04748523|PLACEBO_COMPARATOR|Placebo group|arm to receive 15 to 30 mg of placebo for a period of 8 weeks.
62529475|NCT03272061|EXPERIMENTAL|Aerobic-based exercise program|
62529476|NCT03272061|NO_INTERVENTION|Control program|Maintenance of habitual physical activity levels
62529477|NCT05225532|EXPERIMENTAL|LA group|Patients randomized to procedure performed in the left atrium
62529478|NCT05225532|ACTIVE_COMPARATOR|RA group|Patients randomized to procedure performed in the right atrium
62529479|NCT02889471|EXPERIMENTAL|ERCP with nasobiliary catheter|
62529480|NCT02889471|ACTIVE_COMPARATOR|ERCP only|
62529481|NCT05304286|ACTIVE_COMPARATOR|ACT Group Intervention|We will evaluate the effects of an Acceptance and Commitment Therapy (ACT) one-day group intervention (with 1-month post group zoom booster session) on the functional near-infrared spectroscopy (fNIRS) signal in groups of adolescents and adult patients diagnosed with CPSP at \>3 months post major orthopedic surgery.
62529482|NCT05304286|NO_INTERVENTION|Treatment as Usual|Treatment as Usual (TAU) for those with CPSP
62529483|NCT00662948|EXPERIMENTAL|A|Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg
62529484|NCT00662948|ACTIVE_COMPARATOR|B|Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months
62529485|NCT06160297|EXPERIMENTAL|Modified Otago Exercise Group|MOEG consists of strengthening and balance exercises. Participants were instructed to start the exercises with 5-minute flexibility exercises. The walking component of the original Otago exercises and the stair climbing exercise in the balance exercises were not included in the MOEG. The exercises included 5 strengthening exercises and 11 balance exercises.
62529486|NCT06160297|EXPERIMENTAL|Neuromuscular Exercise Group|Neuromuscular exercises basically consist of four exercise components. These; core stability / postural function, postural orientation, lower extremity muscle strength and functional exercises. Exercises also include 5-minute warm-up and cool-down periods.
62529487|NCT06160297|NO_INTERVENTION|Control Group|Traditional physiotherapy applications (Hotpack + US (Ultrasound) + TENS (Transcutaneous Electrical Stimulation) were applied to the control group initially, as in every group. After these applications, they were evaluated in terms of basic parameters. A re-evaluation was made after 12 weeks.
62529488|NCT06156189||Critically ill patients|All adult patients ventilated and intubated. These patients should also have enteral nutritional supplement initiated.
62155609|NCT04989023|SHAM_COMPARATOR|Sham-Blood flow restriction (sham-BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (max of 4/10 pain).
62155610|NCT03701022|EXPERIMENTAL|SHR1210 +Apatinib|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
62155611|NCT01768585|ACTIVE_COMPARATOR|Ivabradine|Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor
62155612|NCT01768585|PLACEBO_COMPARATOR|Placebo|Drug: Placebo bid placebo Other Name: Placebo control
62155613|NCT00470756||evertors, invertors|
62155614|NCT01543945|EXPERIMENTAL|Multimodal antiemetic management group|Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg
62155615|NCT01543945|ACTIVE_COMPARATOR|Control group|Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv
62155616|NCT03431649|EXPERIMENTAL|Beraprost Sodium|"Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~22 patients"
62155617|NCT03431649|ACTIVE_COMPARATOR|Sildenafil citrate|"Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~20 patients"
62155618|NCT05795283||Group A: Citalopram i.v. and p.o|Both intravenous and oral administration of citalopram
62155619|NCT05795283||Group B: Citalopram p.o|Oral administration of citalopram
62155620|NCT00286832||Single group study|
62155621|NCT02287948||MS subjects group|Multiple sclerosis subjects wiht mild-moderate gait disability with EDSS score not higher than 5.5
62155622|NCT02287948||Healthy subjects group|Healthy subjects age-matched with multiple sclerosis subjects.
62529489|NCT02130583|EXPERIMENTAL|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
62529490|NCT02130583|ACTIVE_COMPARATOR|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
62529491|NCT01425918|EXPERIMENTAL|Social Enhancement Intervention|"* For 5 months children will come in 4 days a week for 2-2.5 hours a session to participate in a classroom in an attempt to increase social communication and understanding.~* Parent education sessions once a week for 2 hours each session over the 5-month period."
62155623|NCT05652452|EXPERIMENTAL|Neurodynamics|
62155624|NCT05652452|ACTIVE_COMPARATOR|Static stretch|
62529492|NCT01425918|ACTIVE_COMPARATOR|Parent Education|o Parent education sessions once a week for 2 hours each session over the 5-month period.
62529493|NCT01998672|ACTIVE_COMPARATOR|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
62529494|NCT01998672|PLACEBO_COMPARATOR|Placebo|Oral drinking solution
62155625|NCT05148949|EXPERIMENTAL|Investigational vaccine group 1|100 tuberculosis patients will receive two doses of standard dosage CoronaVac plus one dose of double dosage CoronaVac at a schedule of 0, 28, 56 days.
62155626|NCT05148949|EXPERIMENTAL|Investigational vaccine group 2|100 tuberculosis patients will receive two doses of standard dosage CoronaVac plus one dose of standard dosage CoronaVac at a schedule of 0, 28, 56 days.
62155627|NCT05148949|ACTIVE_COMPARATOR|Standard regimen group|40 healthy subjects will receive two doses of standard dosage CoronaVac at a schedule of 0, 28 days.
62155628|NCT01354080|EXPERIMENTAL|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
62155629|NCT01354080|ACTIVE_COMPARATOR|classical massage|In this group of patients classical massage sessions were applied
62155630|NCT03802279||Rhabdomyolysis with myoblasts back up|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited from a diagnostically muscle biopsy and whose myoblasts are available.~Patients benefit from an effort test as part of their care."
62529495|NCT06273826||Colorectal Leakage App group|"This group comprises patients who will be monitored using the Colorectal Leakage App based on the Dutch leakage score for early detection of anastomotic insufficiency after colorectal surgeries."
62529496|NCT02493777|EXPERIMENTAL|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
62529497|NCT02493777|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
62529498|NCT02796937|EXPERIMENTAL|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
62713951|NCT06068504|ACTIVE_COMPARATOR|Heating|Patients will perform 15 sets of 2 min of immersion of their foot in a warm water (42 degrees)
62155631|NCT03802279||Rhabdomyolysis|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited or not from a diagnostically muscle biopsy but whose myoblasts are not available.~Patients benefit from an effort test as part of their care."
62529499|NCT00006243|EXPERIMENTAL|Arm I (vaccine therapy)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
62155632|NCT03802279||Witness patients : effort test|10 patient-matched healthy controls for age and sex having performed an effort test and cardiac exploration as part of their care.
62155633|NCT03802279||Witness patients : myoblasts|6 healthy controls matched by age and sex having performed a muscle biopsy as part of their care and whose myoblasts are kept.
62155634|NCT05025553|OTHER|Gut mobilization|Polyethylene Glycol (PEG) at the dose of 6.9 g/d once a day for 6 months.
62155635|NCT02985086|ACTIVE_COMPARATOR|Immediate induction with antibiotic prophylaxis|Immediate induction with antibiotic prophylaxis
62155636|NCT02985086|ACTIVE_COMPARATOR|Immediate induction without antibiotic prophylaxis|Immediate induction without antibiotic prophylaxis
62155637|NCT02985086|ACTIVE_COMPARATOR|Delayed induction with antibiotic prophylaxis|Delayed induction (\>= 12 hours after PROM) with antibiotic prophylaxis
62155638|NCT01707914|EXPERIMENTAL|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
62155639|NCT01707914|PLACEBO_COMPARATOR|Placebo|Consume 500 mL placebo/d (250 mL placebo twice daily)
62155640|NCT03723902|EXPERIMENTAL|Strength training + protein supplement|Heavy-load strength training, Protein supplementation
62155641|NCT03723902|NO_INTERVENTION|Control|No intervention
62155642|NCT01653509|EXPERIMENTAL|Test patch|Patch containing acyclovir applied to cold sore
62155643|NCT01653509|PLACEBO_COMPARATOR|Placebo patch|Patch without acyclovir applied to cold sore
62155644|NCT03434015||Left atrial appendage closure|"All patient referred to a department of interventional cardiology for percutaneous left atrial appendage closure may be included.~All centers practicing this procedure in France will participate to the present study, whatever the technique used. The patients included in the protocol will be followed as part of the care by centers that will have carried out the procedure."
62155645|NCT03656822||Routine imaging such as CT or MRI|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging,
62155646|NCT03656822||Routine imaging (CT or MRI) with a 3D printed model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D printed anatomical mode
62155647|NCT03656822||Routine imaging (CT or MRI) with a VR model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D VR anatomical model
62155648|NCT01102426|EXPERIMENTAL|Plitidepsin+Dexamethasone|plitidepsin + dexamethasone combination
62155649|NCT01102426|ACTIVE_COMPARATOR|Dexamethasone|dexamethasone single agent
62155650|NCT04113187|EXPERIMENTAL|Propranolol arm|
62155651|NCT04113187|PLACEBO_COMPARATOR|Placebo arm|
62155652|NCT06335667|EXPERIMENTAL|mpMRI + Diagnostic TURBT|
62155653|NCT06420752|EXPERIMENTAL|Functional Walking capacity|Passive stretching of the calf muscles 5 days per week for 12-weeks
62155654|NCT06420752|EXPERIMENTAL|Inflammation|Blood and muscle biopsy samples pre/post passive stretching to assess local and systemic inflammation
62155655|NCT02411188|EXPERIMENTAL|STEP Program Group|Arm: Intervention: The 12-week STEP Program intervention will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
62155656|NCT02411188|NO_INTERVENTION|Usual Care Group|The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
62155657|NCT06225063|EXPERIMENTAL|Pilates Group|In the first session participants will received the 6 basic principles of the technique. All the other sessions will last 50 minutes and consist of warm-up, main program and cool-down exercises. The degree of difficulty of the exercises of the main part will progress every 2 weeks.
62155658|NCT06225063|EXPERIMENTAL|Cognitive Functional Therapy|In this group the participants will receive personalized treatment and therefore the sessions will be done individually for each one. All interventions will include a) a cognitive component, b) specific functional training and c) lifestylwe changes
62155659|NCT05253066|EXPERIMENTAL|Chidamide group|Chidamide combined with exemestane (+/- goserelin)
62155660|NCT05253066|ACTIVE_COMPARATOR|chemotherapy group|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
62155661|NCT05090904|EXPERIMENTAL|Brensocatib 10 mg|Participants will be administered brensocatib at a dose of 10 mg once per day for 28 days. The participants will be stratified based on cystic fibrosis transmembrane conductance regulators (CFTRs) modulator treatment.
62155662|NCT05090904|EXPERIMENTAL|Brensocatib 25 mg|Participants will be administered brensocatib at a dose of 25 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
62155663|NCT05090904|EXPERIMENTAL|Brensocatib 40 mg|Participants will be administered brensocatib at a dose of 40 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
62155664|NCT05090904|EXPERIMENTAL|Brensocatib 65 mg|Following review of safety and pharmacokinetic data by the safety review committee, an additional cohort of participants may be administered brensocatib at a dose of 65 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
62155665|NCT05090904|PLACEBO_COMPARATOR|Placebo|Participants will be administered a placebo matching brensocatib once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
62155666|NCT01933776|EXPERIMENTAL|Group 1: Adults|Participants 18 through 64 years of age will receive a single booster dose of Tdap vaccine (ADACEL).
62155667|NCT01933776|EXPERIMENTAL|Group 2: Children|Participants 4 through 8 years of age will receive a single booster dose of Tdap vaccine (ADACEL)
62539547|NCT05180201|EXPERIMENTAL|LP7+FOS|Once daily oral administration of L. plantarum ATCC 202195 (10\^9 CFU/day) with 150mg fructooligosaccharide (FOS) and 100mg maltodextrin, for 7 days.
62155668|NCT01529372|EXPERIMENTAL|Percutaneous renal denervation|
62155669|NCT02705885|EXPERIMENTAL|Gingipain IgY|Participants consume lozenges containing IgY against gingipains of Porphyromonas gingivalis
62155670|NCT02705885|PLACEBO_COMPARATOR|Placebo IgY|Participants consume lozenges containing placebo IgY
62155671|NCT03331978|EXPERIMENTAL|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
62155672|NCT03331978|NO_INTERVENTION|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
62155673|NCT03122314|EXPERIMENTAL|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
62155674|NCT03122314|EXPERIMENTAL|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
62155675|NCT00795639|EXPERIMENTAL|Sitaxsentan|Monotherapy
62155676|NCT00795639|PLACEBO_COMPARATOR|Sitaxsentan Placebo|Monotherapy
62155677|NCT02269072|ACTIVE_COMPARATOR|Testosterone|Testosterone cream applied daily
62155678|NCT02269072|PLACEBO_COMPARATOR|Placebo|Identical placebo cream applied daily
62155679|NCT03563170|EXPERIMENTAL|NANT Hepatocellular Carcinoma Vaccine|Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.
62529500|NCT00006243|EXPERIMENTAL|Arm II (vaccine therapy and lower-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
62529501|NCT00006243|EXPERIMENTAL|Arm III (vaccine therapy and higher-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
62529502|NCT02563587|EXPERIMENTAL|Group LT-CT|Laughter therapy with conventional treatment
62529503|NCT02563587|PLACEBO_COMPARATOR|Group AW-CT|Accompaniment without causing the laughter of children more conventional treatment
62529504|NCT02563587|SHAM_COMPARATOR|Group CT|Conventional treatment only
62529505|NCT00968786|NO_INTERVENTION|no home monitoring|no automated measuring devices for patients use at home
62529506|NCT01560481|EXPERIMENTAL|Step A: metformin glycinate 620 mg|620mg single dose by mouth
62155680|NCT03563170|ACTIVE_COMPARATOR|Sorafenib Monotherapy|Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.
62155681|NCT01838707|ACTIVE_COMPARATOR|Bupivacaine|0.125% Bupivacaine HCL @ 4-5 ml/h
62155682|NCT01838707|ACTIVE_COMPARATOR|Bupivacaine, Morphine|0.125% Bupivacaine HCL , Morphine sulphate 3 mg @ 3-5 ml/h
62155683|NCT01838707|ACTIVE_COMPARATOR|Bupivacaine, Fentanyl|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
62155684|NCT00513123||Digital Colposcopy|Digital Colposcopy for Fluorescence (DCF)
62155685|NCT05681390|EXPERIMENTAL|Tislelizumab Combined With Anlotinib and Chemotherapy|Tislelizumab iv drip, every 3 weeks; Anlotinib, oral，once a day; chemotherapy will be choiced by investigator according guildline.
62155686|NCT03528356|PLACEBO_COMPARATOR|Regular diet|
62155687|NCT03528356|EXPERIMENTAL|White diet|
62155688|NCT00567606|EXPERIMENTAL|Strength/Weight Training|Subjects in the G1 group receive drug/supplement combination and strength/weight training exercises for upper and lower extremities and the spine.
62155689|NCT00567606|EXPERIMENTAL|Drug Supplement only|Subjects in the G2 group receive drug/supplement combination, but do not participate in strength/weight training exercises.
62155690|NCT04531007|EXPERIMENTAL|Intermediate LMS stenosis|Patients with intermediate left main stem stenosis with additional severe downstream lesion will be subject to physiology (FFR and iFR) at multiple sites along the target vessels before and after PCI of the severe lesion located in the downstream vessel. Intravascular imaging (IVUS and OCT) will be performed for additional evaluation of the left main stem stenosis.
62155691|NCT02108496|EXPERIMENTAL|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
62155692|NCT02108496|ACTIVE_COMPARATOR|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
62155693|NCT00905255|EXPERIMENTAL|Lixisenatide (Two-step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
62155694|NCT00905255|EXPERIMENTAL|Lixisenatide (One-step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to end of treatment.
62155695|NCT01351675|PLACEBO_COMPARATOR|Placebo|
62155696|NCT01351675|EXPERIMENTAL|Bardoxolone Methyl|
62529507|NCT01560481|EXPERIMENTAL|Step A: metformin glycinate 1240 mg|1240mg single dose by mouth
62529508|NCT01560481|EXPERIMENTAL|Step A: metformin glycinate 2480 mg|2480mg single dose by mouth
62529509|NCT01560481|ACTIVE_COMPARATOR|Step A: metformin hydrochloride 1000 mg|1000mg single dose by mouth
62529510|NCT01560481|EXPERIMENTAL|Step A: metformin glycinate 1240 mg, food intake|1240mg single dose by mouth after food intake
62529511|NCT01560481|EXPERIMENTAL|Step B: metformin glycinate 620 mg BID|620mg BID for 8 days
62529512|NCT01560481|ACTIVE_COMPARATOR|Step B: metformin hydrochloride 500 mg BID|500mg tablets BID for 8 days
62529513|NCT03806712||patient|patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient
62529514|NCT03806712||hematologist|medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist
62529515|NCT03806712||Nurses|nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse
62529516|NCT01536158|ACTIVE_COMPARATOR|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
62713952|NCT06068504|NO_INTERVENTION|Control|Patients will remain seated for 60 min
62155697|NCT00966706|EXPERIMENTAL|Arm I|Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62155698|NCT00966706|EXPERIMENTAL|Arm II|Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62713953|NCT05354024|EXPERIMENTAL|NDV-HXP-S 10μg (Phase II)|In the Phase III, 200 adult subjects will be assigned to receive NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety and immunogenicity.
62155699|NCT02501876||T2D-MCI|110 MCI subjects with type 2 diabetes. There is a retrospectiv observational study. No intervention will be performed.
62155700|NCT02501876||nonT2D-MCI|110 MCI subjects without diabetes. There is a retrospectiv observational study. No intervention will be performed.
62155701|NCT00438048|ACTIVE_COMPARATOR|a,b|Compare Pilocarpine and Artificial saliva
62155702|NCT04998825|EXPERIMENTAL|Proteoglycan F group|"* Taking Proteoglycan F~* Dosage of Proteoglycan F: 50mg/day~* Used time: 24 weeks"
62155703|NCT04998825|PLACEBO_COMPARATOR|Control group|"* Taking Placebo (Dextrin)~* Dosage of Placebo: 50mg/day~* Used time: 24 weeks"
62155704|NCT01074996|ACTIVE_COMPARATOR|S-1,|Subjects will receive S-1 until progression
62155705|NCT01074996|EXPERIMENTAL|S-1 plus Leucovorin|patients will receive S-1 plus Leucovorin until progression
62155706|NCT06245317|ACTIVE_COMPARATOR|Pressure control ventilation-volume guarantee (PCV-VG) group|In the PCV-VG group the tidal volume will be set to 8-10ml/kg and the respiratory rate will be adjusted according to oxygen saturation and end-tidal CO¬2.
62155707|NCT06245317|ACTIVE_COMPARATOR|Pressure control ventilation (PCV) group|In the PCV group peak inspiratory pressure will be set to 10-15 cm H2O titrated to achieve 8-10 ml/kg and the respiratory rate will be adjusted according to oxygen saturation and end-tidal Co2
62155708|NCT06245317|ACTIVE_COMPARATOR|Volume control ventilation (VCV) group|In the VCV group tidal volume will be set to 8-10 ml/kg and the respiratory rate will be adjusted according to oxygen saturation and end-tidal CO2,
62155709|NCT00857909|ACTIVE_COMPARATOR|Randomisation 1|Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
62155710|NCT00857909|ACTIVE_COMPARATOR|Randomisation 2|Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
62155711|NCT00857909|PLACEBO_COMPARATOR|Placebo|calcium tablet
62155712|NCT03647800|EXPERIMENTAL|PART 1 Dose Escalation - 10 dose cohorts|CD123 and CD3 epsilon bispecific antibody
62155713|NCT03647800|EXPERIMENTAL|PART 2 Dose expansion - 5 cohorts|90 patients, 18/cohort in 5 dose expansion cohorts, will receive the recommended dose of APVO436 determined from Part 1
62155714|NCT02161588|EXPERIMENTAL|Semaglutide|
62155715|NCT02161588|PLACEBO_COMPARATOR|Placebo|
62155716|NCT01694147||patients with sepsis related ALI/ARDS.|Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.
62155717|NCT01695044|EXPERIMENTAL|Arm 1: PSMA ADC|Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
62155718|NCT01697982|EXPERIMENTAL|Living with Hope Program|"Participants will receive the Living with Hope Program (LWHP). The LWHP involves viewing a short film and choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
62155719|NCT01697982|EXPERIMENTAL|LWH Film|Participants will viewing a short film entitled Living with Hope (LWH), which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope
62155720|NCT01697982|NO_INTERVENTION|Usual Care|Participants in the usual care group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
62155721|NCT04583293||COVID AKI|Participants who were admitted to the hospital with COVID-19 and developed AKI during their hospital stay.
62155722|NCT04583293||COVID non-AKI|Participants who were admitted to the hospital with COVID-19 and did not develop AKI during their hospital stay.
62155723|NCT02687841|EXPERIMENTAL|AST-120 and PTX|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days
62155724|NCT02687841|ACTIVE_COMPARATOR|PTX|Pentapentoxifylline 400mg QD for 10 days
62713954|NCT05354024|ACTIVE_COMPARATOR|BNT162b2 30μg (Phase II)|In the Phase III, 200 adult subjects will be assigned to receive vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety and immunogenicity.
62713955|NCT05354024|EXPERIMENTAL|NDV-HXP-S 10μg batch 1 (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the first consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
62155725|NCT03014024|EXPERIMENTAL|Low-Level Laser therapy|After inclusion in the study, patients will be treated with LLLT. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated from dorsal side of the wrist on the fracture area, and distal ulna area from the palmar side. Total 20 second on each side (3 points), with 3,6 J/cm2. the light from the laser is not visible to the eye, and will not give any perceptible stimulus. The x-ray will be used to find the fracture line.
62155726|NCT03014024|PLACEBO_COMPARATOR|Placebo Low-Level Laser therapy|After inclusion in the study, patients will be treated with placebo LLLT. This placebo laser is identical in appearance to the other super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated on the same areas, and have the same procedure and time. Since the light from the laser is invisible neither the participant nor the therapist will know whether the laser is a placebo.
62155727|NCT02907489|NO_INTERVENTION|Control: Calcium Hydroxide|Non-setting Calcium Hydroxide
62155728|NCT02907489|OTHER|Test: Triple Antibiotic Paste and Anti-Inflammatory Drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
62529517|NCT01536158|ACTIVE_COMPARATOR|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
62529518|NCT04213872|EXPERIMENTAL|Meditative Movement (MM)|The Meditative Movement (Qigong/Tai Chi Easy) program will be 8 weeks in duration with sessions once a week. Each session is approximately one hour. The PI will lead the MM sessions. The PI and the CRC will maintain contact with the MM group during the 8 weeks by telephone or in person.
62529519|NCT03559166|EXPERIMENTAL|cohort 1a - starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
62155729|NCT02033343|EXPERIMENTAL|Real-time tracking & beam adjustment|Prostate cancer radiotherapy using real-time tracking
62155730|NCT02936401|EXPERIMENTAL|MBSR|Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.
62155731|NCT02936401|EXPERIMENTAL|CONTROL|Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.
62529520|NCT03559166|PLACEBO_COMPARATOR|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
62529521|NCT03559166|PLACEBO_COMPARATOR|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
62529522|NCT03559166|PLACEBO_COMPARATOR|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
62529523|NCT03559166|PLACEBO_COMPARATOR|cohort 1e-4th SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
62529524|NCT03559166|PLACEBO_COMPARATOR|cohort 2a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
62529525|NCT03559166|PLACEBO_COMPARATOR|cohort 2b-2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
62529526|NCT03559166|PLACEBO_COMPARATOR|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
62529527|NCT03559166|PLACEBO_COMPARATOR|cohort 2d-4th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
62529528|NCT03559166|PLACEBO_COMPARATOR|cohort 2e-5th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
62529529|NCT03559166|PLACEBO_COMPARATOR|cohort 2F-6th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
62529530|NCT03911050|EXPERIMENTAL|Apple consumption|Each subject took apple blends 600 g (made from two apples with seed removal) in a single dose, and samples (urine and blood and feces) at different timepoints were collected following administration of apple blends.
62529531|NCT03911050|PLACEBO_COMPARATOR|Control group|Each subject took breakfast without any apple-related products in a single dose, and samples (urine and blood and feces) at different timepoints were collected following breakfast.
62529532|NCT01725321||Narrow band imaging|Colonoscopy with new narrow band imaging
62713956|NCT05354024|EXPERIMENTAL|NDV-HXP-S 10μg batch 2 (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the second consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
62155732|NCT05967793|EXPERIMENTAL|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
62155733|NCT05967793|ACTIVE_COMPARATOR|Routine physical therapy program|routine physical therapy exercise
62155734|NCT02450786|EXPERIMENTAL|Donepezil group|Donepezil is started in 5mg for 8 weeks followed by dose escalation to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
62529533|NCT00540293|EXPERIMENTAL|Treatment group|this patient group consists of dyslipidemia patients with various CVD risk factors
62529534|NCT03830918|EXPERIMENTAL|Arm A (temozolomide, niraparib, atezolizumab)|Patients receive temozolomide PO QD on days 1-5 and niraparib PO QD on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
62713957|NCT05354024|EXPERIMENTAL|NDV-HXP-S 10μg batch 3 (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the third consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
62529535|NCT03830918|ACTIVE_COMPARATOR|Arm B (atezolizumab)|Patients receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
62529536|NCT04361149|PLACEBO_COMPARATOR|Placebo Topical|The cream was a lipobase cream, applied topically to the participants upper back, on their left side.
62529537|NCT04361149|ACTIVE_COMPARATOR|Capsaicin Topical|Capsaicin Cream (0.075%), applied topically to the participants upper back, on their left side.
62713958|NCT05354024|ACTIVE_COMPARATOR|BNT162b2 30μg (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity only.
62155735|NCT02450786|NO_INTERVENTION|control group|No administration of any therapeutic medications for dementia including cholinesterase inhibitor or NMDA receptor blocking agents. Standard treatment protocol of Parkinson's disease with mild cognitive impairment would be fulfilled including dopaminergic or nondopaminergic medications as well as nootropic drugs.
62155736|NCT02233075|EXPERIMENTAL|REP 2139-Ca + Pegasys (TM)|REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.
62155737|NCT04054245|EXPERIMENTAL|Treatment (LOXL2 inhibitor PAT-1251)|Patients receive LOXL2 inhibitor PAT-1251 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62155738|NCT04203225|ACTIVE_COMPARATOR|Single LET|One (single) application of LET topical gel \[Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%)\] applied for 30 minutes
62529538|NCT03528083|NO_INTERVENTION|Retrospective Controls|A retrospective control group of patients with a diagnosis of bronchiolitis and meeting inclusion criteria will be used as a comparison group. These patients received usual care for bronchiolitis at our institution.
62529539|NCT03528083|EXPERIMENTAL|Quality Improvement|All patients diagnosed with bronchiolitis and meeting inclusion criteria will undergo the intervention of a bronchiolitis quality improvement process to improve bronchiolitis care quality at our institution.
62529540|NCT05340543||Patient with basal cell carcinoma|"- CBC: Presence of lobule of basal cells with palisading on the edges, stromal reaction and dilated horizontal vessels."
62529541|NCT05340543||Patient with squamous cell carcinoma|- CSC: Proliferation of keratinocytes presenting cellular atypia, crossing the JDE (invasive CSC versus in situ), glomerular vessels
62529542|NCT05340543||Patient with melanoma|Melanoma: Destructured dermal-epidermal junction (DEJ), presence of pagetoid cells, clusters of atypical melanocytes, dendritic cells
62713959|NCT06419452|OTHER|Unilateral resistance training|Unilateral resistance training uses ipsilateral limb restricted contractions, in which each limb works independently, moving or opposing a given loading task
62713960|NCT06419452|OTHER|Bilateral resistance training|Bilateral resistance training is the contraction of the same muscle in both limbs, that is, both limbs work together in a coordinated manner to cope with a given loading task
62155739|NCT04203225|EXPERIMENTAL|Triple LET|Three applications of LET topical gel, one applied every 10 minutes
62155740|NCT05360771|EXPERIMENTAL|treatment group|Percutaneously occlusion of PFO with SnowyTM PFO closure system
62155741|NCT05360771|EXPERIMENTAL|control group|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
62155742|NCT02028650||the first donor|the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
62155743|NCT02028650||the second donor|HLA-mismatched, the second donor's stem cell infusion
62155744|NCT02693665|EXPERIMENTAL|FACE-TC Intervention|Adolescent/family dyads randomized to the experimental condition receive Family Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention - 3 sessions scheduled one week apart of approximately 60 minutes duration each. Session 1 - Lyon Advance Care Planning Survey-Adolescent \& Surrogate versions. Session 2 - Respecting Choices Interview facilitated by trained/certified facilitator with adolescent and family. Focuses on patient's understanding of their illness, possible complications, goals of care and treatment preferences in 3 bad outcome situations; and the Session 3 - Five Wishes an advance directive.
62155745|NCT02693665|NO_INTERVENTION|Treatment As Usual (TAU)|Adolescent/family dyads randomized to the treatment as usual (TAU) condition receive written information on advance care planning, but no active intervention.
62155746|NCT00796575|EXPERIMENTAL|CS-8080|3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
62155747|NCT00796575|PLACEBO_COMPARATOR|placebo|placebo
62155748|NCT03588195|EXPERIMENTAL|Education Group|
62155749|NCT03588195|ACTIVE_COMPARATOR|Control Group|
62155750|NCT01438879||pleocytosis group|40 patients with clinical signs of CNS infection and having CSF pleocytosis.
62529543|NCT04350320|EXPERIMENTAL|COLCHICINE|"The colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 28 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (\<50 ml/min/1.37m2), weight \<70 kg or age \>75 years old, the dose will be adjusted to the half.~+ standard therapy for COVID-19 according to the stablished hospital protocols."
62529544|NCT04350320|PLACEBO_COMPARATOR|control group|Standard therapy for COVID-19 according to the stablished hospital protocols.
62529545|NCT00437632|EXPERIMENTAL|Subjects in Cohort-1 of Section 1|Subjects will be randomized to receive either GSK598809 10 mg or Placebo.
62529546|NCT00437632|EXPERIMENTAL|Subjects in Cohort-2 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
62529547|NCT00437632|EXPERIMENTAL|Subjects in Cohort-3 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
62529548|NCT00437632|EXPERIMENTAL|Subjects in Cohort-4 of Section 1|Subjects will be randomized to receive either GSK598809 40 mg or Placebo.
62713961|NCT06419452|OTHER|combined resistance training|Combined unilateral and bilateral forms of resistance training
62713962|NCT03705234|EXPERIMENTAL|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.
62713963|NCT03705234|PLACEBO_COMPARATOR|Placebo|Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.
62713964|NCT04490798||Lumbar back pain|Patients with lumbar back pain treated following the Acupuncture Treatment Clinic Pathway.
62155751|NCT01438879||non-pleocytosis group|20 patients not having CNS infection clinically and not having CSF pleocytosis.
62155752|NCT05809856|EXPERIMENTAL|Implantation of autologous GrOwnValve|Implantation of autologous GrOwnValve via minimal-invasive transcatheter technique into patients with high-grade pulmonary valve insufficiency and right ventricular dilatation.
62155753|NCT02736175|EXPERIMENTAL|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
62155754|NCT02736175|PLACEBO_COMPARATOR|PV|PV (placebo drug delivery vehicle)
62155755|NCT03639649|EXPERIMENTAL|STHLM3|
62155756|NCT03639649|ACTIVE_COMPARATOR|PSA|
62155757|NCT01019824|EXPERIMENTAL|Low Dose|160 mg dose
62155758|NCT01019824|EXPERIMENTAL|High Dose|320 mg dose
62155759|NCT01019824|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62155760|NCT04889326||patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination|
62713965|NCT04490798||Musculoskeletal pain|Patients with musculoskeletal pain treated following the Acupuncture Treatment Clinic Pathway.
62713966|NCT04490798||Cervicalgia|Patients with cervicalgia treated following the Acupuncture Treatment Clinic Pathway.
62713967|NCT04490798||Knee osteoarthritis|Patients with knee osteoarthritis treated following the Acupuncture Treatment Clinic Pathway.
62713968|NCT04490798||Headache|Patients with headache treated following the Acupuncture Treatment Clinic Pathway.
62713969|NCT04490798||Shoulder pain|Patients with shoulder pain treated following the Acupuncture Treatment Clinic Pathway.
62713970|NCT06010680|EXPERIMENTAL|[14C]SHR2554|
62155761|NCT04402125|EXPERIMENTAL|Intervention|Participants randomized to TEAM intervention for 6 months, then observed for 6 month follow up
62529549|NCT00437632|EXPERIMENTAL|Subjects in Cohort-5 of Section 2|Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
62155762|NCT04402125|OTHER|Waitlist|Participants randomized to waitlist for 6 months, then offered the intervention for 6 months
62529550|NCT00437632|EXPERIMENTAL|Subjects in Cohort-6 of Section 3|Subjects will receive caffeine on day -1 and after randomization subject will either receive GSK598809 or Placebo on Day 1. After washout period of 1-week subject will either receive GSK598809 or Placebo for 28 days.
62529551|NCT04006314|OTHER|Receiving PRP injections or PRP plus neural prolotherapy|PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
62713971|NCT05420948|EXPERIMENTAL|Group 1: Participants Who Receive Pembrolizumab (Alone)|Participants in this group will receive pembrolizumab 200 mg through an intravenous (IV) needle inserted into the arm. Medications will be given on day 1 of each 21-day cycle for two cycles..
62155763|NCT05640245|EXPERIMENTAL|sonelokimab dose regimen 1|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 1
62155764|NCT05640245|EXPERIMENTAL|sonelokimab dose regimen 2|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 2
62155765|NCT05640245|EXPERIMENTAL|sonelokimab dose regimen 3|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 3
62155766|NCT05640245|PLACEBO_COMPARATOR|Placebo|Subjects randomized to this arm will receive placebo
62155767|NCT05640245|ACTIVE_COMPARATOR|adalimumab|Subjects randomized to this arm will receive adalimumab
62155768|NCT02492126||Chronic Cough|Subjects with chronic cough will undergo cough reflex sensitivity testing to citric acid. The dose, starting at 0.03 mol/L citric acid will be administered as single breath inhalations using flow-limited calibrated pots and a dosimeter with 3 placebo inhalations of normal saline randomly interspersed. Following each inhalation, the number of coughs in the subsequent 15 seconds will be counted and recorded. The challenge will be terminated once the citric acid has induced 5 or more coughs.
62155769|NCT05082948|EXPERIMENTAL|Suture arm|Esophageal stent will be placed in standard of care fashion by the endoscopists using standard gastroscopes. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
62155770|NCT05082948|PLACEBO_COMPARATOR|Non-suture|Esophageal stent will be placed in standard of care fashion by the endoscopists using standard gastroscopes. No sutures will be placed to fixate the stent
62155771|NCT06432959|ACTIVE_COMPARATOR|Treatment as Usual|Participants in the TAU arm will receive either Cognitive Behavioral Therapy (CBT) or Dialectical Behavior Therapy (DBT), depending on eligibility. CBT will be twice weekly sessions for the first four weeks. From week 4 to week 8, the therapist and client will collaboratively decide whether to have once or twice weekly sessions. From week 8 to week 12, sessions will be weekly. Acute treatment will end after 12 weeks. In DBT, individual sessions will be approximately one hour per week, with optional additional or longer sessions available if deemed clinically necessary, and group sessions will be scheduled for two hours once per week.
62155772|NCT06432959|EXPERIMENTAL|TAU + Positive Affect Promoting Activities|Those assigned to the PAPA condition will also receive either CBT or DBT, as described above, and additionally will be asked to participate in positive affective promoting activities. In session positive affective promoting activities are to be provided once per week for the first four weeks of treatment and up to once per session for the remaining sessions. Clients will also be encouraged to utilize positive affect promoting activities between sessions.
62155773|NCT05709886|EXPERIMENTAL|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
62529552|NCT02957370||Diagnosed Urinary Bladder Neoplasms|Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers
62529553|NCT02957370||Non-Urinary Bladder Neoplasms|Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.
62529554|NCT03540771|ACTIVE_COMPARATOR|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
62529555|NCT03540771|ACTIVE_COMPARATOR|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
62713972|NCT05420948|EXPERIMENTAL|Group 2: Participants Who Receive Pembrolizumab + Chemotherapy with Carboplatin and Paclitaxel|Participants in this group will receive 200 mg of pembrolizumab through an intravenous (IV) needle inserted into the arm plus chemotherapy with carboplatin (AUC 6) on day 1 and paclitaxel (200 mg) on day 1 of each 21-day cycle for two cycles.
62529556|NCT03861403|EXPERIMENTAL|All Solid Tumors|"Phase 1b, Part 1 Dose Escalation: TRX518 + CTX Combination (28-Day Cycle):~Subjects receive the following treatment:~* Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~* Assigned dose of cyclophosphamide administered intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle~Phase 1b, Part 2 Dose Escalation: TRX518 + CTX + avelumab in (28-Day Cycle):~Subjects receive the following treatment:~* Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~* Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~* Fixed dose of cyclophosphamide administered at the MTD from Part 1 intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle"
62529557|NCT03861403|EXPERIMENTAL|Advanced Triple Negative Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~* Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~* Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~* Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
62529558|NCT03861403|EXPERIMENTAL|Advanced Hormone Receptor+/Endocrine Refractory Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~* Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~* Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~* Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
62155774|NCT03066986|EXPERIMENTAL|25mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison).
62155775|NCT03066986|EXPERIMENTAL|25mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison, adjuvant comparison).
62155776|NCT03066986|ACTIVE_COMPARATOR|50mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 50mcg, ie. the current standard of care.
62155777|NCT03066986|EXPERIMENTAL|50mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 50mcg (adjuvant comparison).
62155778|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
62529559|NCT03861403|EXPERIMENTAL|Advanced Metastatic Castration-Resistant Prostate Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~* Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~* Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~* Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
62155779|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
62155780|NCT03091842|EXPERIMENTAL|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
62155781|NCT03091842|EXPERIMENTAL|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
62155782|NCT03091842|ACTIVE_COMPARATOR|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
62155783|NCT04518306|EXPERIMENTAL|Triple ¼ (GMRx2)|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
62155784|NCT04518306|ACTIVE_COMPARATOR|Triple ½ (GMRx2)|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
62155785|NCT04518306|PLACEBO_COMPARATOR|Placebo|Placebo
62155786|NCT02525744|EXPERIMENTAL|LY900014 7.5 Units (U)|Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods.
62155787|NCT02525744|ACTIVE_COMPARATOR|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
62155788|NCT02525744|EXPERIMENTAL|LY900014 15 U|Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods.
62155789|NCT02525744|EXPERIMENTAL|LY900014 30 U|Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.
62155790|NCT02420509||systemic chemotherapy after CRS/HIPEC|Single-arm, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
62155791|NCT01508117|EXPERIMENTAL|Axitinib + Radiation Therapy|Axitinib 5mg twice daily for 28 days followed by concurrent axitinib plus hypofractionated radiation therapy (45 Gy in 15 fractions) followed by maintenance axitinib 5mg twice daily until progression or unacceptable toxicity
62529560|NCT03861403|EXPERIMENTAL|Advanced Platinum-Resistant Ovarian Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~* Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~* Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~* Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
62529561|NCT00324649|EXPERIMENTAL|Truvada|Truvada + NNRTI or PI.
62529562|NCT00324649|ACTIVE_COMPARATOR|Zidovudine/lamivudine|Zidovudine/lamivudine + NNRTI or PI.
62529563|NCT06314880|EXPERIMENTAL|18-50 years old|60 people per age group. The first 15 subjects in the 18-50 age group will serve as sentinels, with 10 in the experimental group and 5 in the control group.
62529564|NCT06314880|EXPERIMENTAL|6-17 years old|60 people per age group. Divided into high-dose group, low-dose group, and placebo group.
62529565|NCT06314880|EXPERIMENTAL|2-5 years old|60 people per age group. Divided into high-dose group, low-dose group, and placebo group.
62155792|NCT00130026|PLACEBO_COMPARATOR|I|Saline placebo
62155793|NCT01082159|OTHER|lumbar decompression|Percutaneous lumbar decompression with mild® Device Kit.
62155794|NCT04054856|OTHER|Patients with Morbus Parkinson|
62529566|NCT06314880|EXPERIMENTAL|6-23 months old|60 people per age group. Divided into high-dose group, low-dose group, and placebo group.
62529567|NCT06314880|EXPERIMENTAL|3-5 months old|60 people per age group. Divided into high-dose group, low-dose group, and placebo group.
62529568|NCT05213338|EXPERIMENTAL|wear-documentation|Theramon
62529569|NCT05213338|NO_INTERVENTION|controls|No microchip
62529570|NCT04792775|EXPERIMENTAL|Prolonged Exposure + Emotion Regulation Skills Training|Twelve, 90-minute sessions of Prolonged Exposure (PE) with Dialectical Behavior Therapy (DBT) Emotion Regulation Skills Training.
62529571|NCT01371266|ACTIVE_COMPARATOR|Honey|60.7 grams daily orally times 14 days
62155795|NCT04054856|OTHER|Healthy Subjects|
62529572|NCT01371266|ACTIVE_COMPARATOR|CHO|50 grams daily orally times 14 days
62529573|NCT01371266|ACTIVE_COMPARATOR|High Fructose Corn Syrup|65.7 grams daily orally times 14 days
62529574|NCT03296384|OTHER|Patients with schizophrenia|
62155796|NCT02090478|SHAM_COMPARATOR|No change in dietary sugar levels|Group met with a dietician as often as the control group to discuss diet, but the dietician gave them advice geared toward no change in dietary sugar levels
62155797|NCT02090478|EXPERIMENTAL|Low sugar group|Subjects met with a dietician who discussed diet records. After the first month (baseline, regular diet), the dietician made suggestions geared toward reducing calories from simple sugars by 40%. This will be achieved by replacing sugar calories with complex carbohydrates and fats, while maintaining energy balance (same number of calories as the baseline month).
62155798|NCT01064778|ACTIVE_COMPARATOR|Low GI|
62529575|NCT03296384|OTHER|Relatives|
62155799|NCT01064778|EXPERIMENTAL|High GI|
62155800|NCT05197504||intervention|atezolizumab + bevacizumab
62155801|NCT01527461||Lung Cancer Patients|diagnosed lung cancer patients .
62155802|NCT01527461||COPD Patients|COPD patients, not diagnosed with lung cancer.
62155803|NCT02762786|EXPERIMENTAL|Experimental|Participants in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation. The Music Children Foundation is a non-governmental organization established by a group of professional musicians with the objective of transforming children's lives and instils positive values in the entire community through music. It aims to provide free musical training to low-income children and children with chronic diseases, including those with Down's syndrome, mucopolysaccharidoses, skeletal dysplasia and visual impairment.
62155804|NCT02762786|NO_INTERVENTION|Wait-list control group|Participants in the waitlist control group will receive the same training after the experimental group had completed the intervention.
62155805|NCT03556267|OTHER|spinal needle 27 gauqge|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
62155806|NCT03556267|OTHER|spinal needle 25 gauage|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
62155807|NCT01399905|EXPERIMENTAL|High carbidopa followed by low carbidopa|450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks
62155808|NCT01399905|EXPERIMENTAL|Low carbidopa followed by high carbidopa|75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day
62155809|NCT04500665|EXPERIMENTAL|Colchicine|Colchicine 0.3 mg once daily
62155810|NCT04500665|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62529576|NCT04223531|OTHER|Saline|Each participant will receive a saline infusion of normal saline 0.9%NaCl
62529577|NCT04636060|EXPERIMENTAL|Iron-treatment group|
62529578|NCT02257541|EXPERIMENTAL|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
62529579|NCT00117325|EXPERIMENTAL|GW685698X|GW685698X
62529580|NCT02512926|EXPERIMENTAL|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide
62529581|NCT03993730|OTHER|Device Implantation|A prospective, blocked, randomised, controlled trial of primary prophylaxis ICD therapy or ILR insertion in patients with LVEF \<45% and LGE on CMR.
62529582|NCT03993730|NO_INTERVENTION|Observational Registry|A prospective observational registry of patients with LVEF \<45% and no LGE on CMR.
62529583|NCT02494609|EXPERIMENTAL|Treatment A|once daily dosing for 7 days, followed by 7-day washout
62529584|NCT02494609|EXPERIMENTAL|Treatment B|once daily dosing for 28 days
62529585|NCT02494609|EXPERIMENTAL|Treatment C|once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days
62529586|NCT01197755|EXPERIMENTAL|Dosing Regimen A|Oral Treatment
62155811|NCT05500261|EXPERIMENTAL|0.8 μg/kg intranasal dexmedetomidine|Intranasal administration of 0.8 μg/kg dexmedetomidine
62155812|NCT05500261|EXPERIMENTAL|1.5 μg/kg intranasal dexmedetomidine|Intranasal administration of 1.5 μg/kg dexmedetomidine
62155813|NCT05500261|EXPERIMENTAL|2.0 μg/kg intranasal dexmedetomidine|Intranasal administration of 2.0 μg/kg dexmedetomidine
62155814|NCT06022003|EXPERIMENTAL|Gilteritinib + Azacitidine oral (CC-486)|"Gilteritinib 120 mg/day, PO by 28 days-cycle~Azacitidine orale (CC-486) 300 mg/day, PO Day 1 to day 14, by 28 days-cycle"
62155815|NCT05881213|EXPERIMENTAL|Sequence 1|"* Period 1: D745, D150, D029 - A single oral dose of 3tablets under food intake condition~* Period 2: CKD-378 (low-dose) - A single oral dose of 1tablet under food intake condition"
62155816|NCT05881213|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-378 (low-dose) - A single oral dose of 1tablet under food intake condition~* Period 2: D745, D150, D029 - A single oral dose of 3tablets under food intake condition"
62529587|NCT01197755|EXPERIMENTAL|Dosing Regimen B|Oral Treatment
62529588|NCT01197755|PLACEBO_COMPARATOR|Dosing Regimen C|Oral Treatment
62529589|NCT03053219|EXPERIMENTAL|AC0010|each participant will be given AC0010 300mg bid
62529590|NCT05326321|EXPERIMENTAL|Virtual Reality Glasses Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure. After the AVF cannulation procedure was completed and 10 minutes later, the VAS and Hemodynamic Variables Follow-up Form were reapplied, and the 2nd and 3rd measurements were obtained. Patients' satisfaction was measured with VAS 10 minutes after the procedure. During the application of virtual reality glasses, a screen was pulled between the patients in the intervention and control groups so that there would be no interaction.
62539548|NCT05180201|EXPERIMENTAL|LP7|Once daily oral administration of L. plantarum ATCC 202195 (10\^9 CFU/day) plus 250mg maltodextrin, for 7 days.
62155817|NCT02037009|NO_INTERVENTION|Usual surveillance|surveillance performed by a qualified nurse, present in the operating room during the whole anesthesia.
62155818|NCT02037009|EXPERIMENTAL|centralised monitoring surveillance|1 anesthetic nurse is posted at a centralised monitoring station outside of the 3 operating rooms, while another one can intervene inside the 3 operating rooms whenever needed. Interphones allow communication between the monitoring station and the operating rooms.
62529591|NCT05326321|NO_INTERVENTION|Control group|Without any application to the patients in the control group, the AVF cannulation procedure before HD was performed with the constant site-area puncture technique used by the clinic (after the patient was placed in the fowler position, the arterial needle was 3 cm away from the anastomosis at an angle of 20°-45° towards the distal, and the venous needle was from the arterial needle. 3-5 cm more proximal, again at an angle of 20°-45°) was performed by the HD nurse. The 1st, 2nd and 3rd measurements were obtained as in the intervention group.
62529592|NCT02317614|EXPERIMENTAL|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
62529593|NCT02317614|NO_INTERVENTION|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
62155819|NCT02271841||Before introduction of PVI|Physicians' practices
62529594|NCT04808466|EXPERIMENTAL|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with paclitaxel): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
62529595|NCT04808466|EXPERIMENTAL|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
62529596|NCT04808466|NO_INTERVENTION|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
62529597|NCT05387538|EXPERIMENTAL|One-layer Duct-to-mucosa Pancreaticojejunostomy|pancreatic anastomosis to jejunum will be performed in one layer suturing the pancreatic duct to the mucosa of jejunum.
62529598|NCT05387538|EXPERIMENTAL|Two-layer Duct-to-mucosa Pancreaticojejunostomy|pancreatic anastomosis to jejunum will be performed in two layer. The first layer will be suturing the pancreatic capsule to the seromuscular layer of jejunum and the 2nd layer will be suturing the pancreatic duct to the mucosa of jejunum.
62529599|NCT03191110||Colorectal cancer patients|
62529600|NCT03776721|EXPERIMENTAL|Active treatment|
62529601|NCT03776721|PLACEBO_COMPARATOR|Placebo treatment|
62529602|NCT01072474|EXPERIMENTAL|Capnography|Arm with capnographic monitoring
62529603|NCT01072474|PLACEBO_COMPARATOR|Standard|Standard monitoring.
62529604|NCT02953951||Stored Blood Cells|"Blood transfusion:~Stored blood cells transfused patients"
62529605|NCT02953951||Autologous Salvaged Blood|"Blood transfusion:~Autologous salvaged blood transfused patients"
62529606|NCT02953951||Control|"Blood transfusion:~No transfusion patients"
62529607|NCT04625426|EXPERIMENTAL|3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant|"Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).~The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer."
62529608|NCT04625426|EXPERIMENTAL|Conveen EasiCleanse and Conveen Critic Barrier|Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.
62529609|NCT04625426|ACTIVE_COMPARATOR|Soap and water / Incontinence wipes and Conveen Critic Barrier|Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.
62155820|NCT02271841||After introduction of PVI|Physicians' practices
62155821|NCT03850847||Multi-Methods Study|"Step 1: Semi-structured Interviews~Step 2: National Telephone Survey"
62155822|NCT01307540|EXPERIMENTAL|Active light therapy|oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
62155823|NCT01307540|PLACEBO_COMPARATOR|Inactive light therapy|Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
62155824|NCT06049719||Patients group|Patients with low back pain (18-65 years)
62155825|NCT05248672|EXPERIMENTAL|150 mg QD|CT1812 150 mg QD
62155826|NCT05248672|EXPERIMENTAL|150 mg BID|CT1812 150 mg BID
62155827|NCT05248672|EXPERIMENTAL|300 mg QD|CT1812 300 mg QD
62155828|NCT02592902|ACTIVE_COMPARATOR|Recurrent respiratory papillomatosis|Patients with recurrent respiratory papillomatosis (RRP) - surgical collection of histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin, HPV 6 and 11, herpes simplex virus (HSV) type 2, chlamydia trachomasis, and assessment of the dysplasia.
62155829|NCT02592902|ACTIVE_COMPARATOR|Laryngeal cyst - control group|Patients with laryngeal cyst - surgical collection of a histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin and HPV 6 and 11, herpes simplex virus (HSV) type 2 and chlamydia trachomasis.
62155830|NCT01801202|EXPERIMENTAL|Hair removal|hair removal treatment using 805nm LightSheer Duet HS handpiece
62155831|NCT03100851|EXPERIMENTAL|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
62529610|NCT01090921|EXPERIMENTAL|Single-Arm|Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
62529611|NCT02426853|EXPERIMENTAL|Group 1 - UV Photography Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds. At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
62529612|NCT02426853|ACTIVE_COMPARATOR|Group 2 - Comparison Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
62529613|NCT00640679|ACTIVE_COMPARATOR|Clopidogrel Tapering|
62155832|NCT04301102|EXPERIMENTAL|Experimental|"Hemodynamic management will be based on the functional hemodynamic parameters provided by Hemosphere platform with the Acumen IQ sensor, including cardiac output, stroke volume, SVV and Acumen IQ specific parameters: maximal arterial pressure rise (dP/dtmax), dynamic arterial elastance (Eadyn) and HPI~As a pattern replacement of interstitial space, we will use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.~The protocol of action on the intravascular space will be based on the maintenance of systolic volume with colloids (hydroxyethyl starch - Voluvén®)."
62155833|NCT04301102|OTHER|Control|"Hemodynamic management will be based on the functional hemodynamic parameters provided by the HemoSphere platform® with the FloTrac® sensor, including cardiac output (CO), stroke volume (SV), and stroke volume variation (SVV)~As a pattern replacement of interstitial space, we use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.~The protocol action for the intravascular space will be based on a recently published hemodynamic optimization algorithm (Heming N, Moine P, Coscas R, Annane D. Perioperative fluid management for major elective surgery. British Journal of Surgery. 2020;107:e56-62). The fluid used will be hydroxyethyl starch (Voluven®)."
62155834|NCT06509269|ACTIVE_COMPARATOR|Desktop Scanning|Desktop scanning of Definitive Impression
62155835|NCT06509269|EXPERIMENTAL|IntraOral Scanning|Intraoral scanning of edentulous Jaw
62155836|NCT03272815|EXPERIMENTAL|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
62529614|NCT00640679|ACTIVE_COMPARATOR|Abrupt Clopidogrel Interruption|
62155837|NCT03272815|ACTIVE_COMPARATOR|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
62155838|NCT02148120|ACTIVE_COMPARATOR|CHF1535 NEXThaler 100/6, 1 puff|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg
62155839|NCT02148120|ACTIVE_COMPARATOR|CHF1535 NEXThaler 100/6 µg, 4 puffs|Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg
62529615|NCT00569530|ACTIVE_COMPARATOR|Treatment Surfactant (Infasurf) ONY, NY|Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
62529616|NCT00569530|PLACEBO_COMPARATOR|Sham (no treatment)|Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
62155840|NCT02148120|EXPERIMENTAL|CHF1535 NEXThaler 200/6 µg, 1 puff|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
62155841|NCT02148120|EXPERIMENTAL|CHF1535 NEXThaler 200/6 µg, 4 puffs|Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg
62529617|NCT04253496||Prospective|
62529618|NCT04253496||Retrospective|
62155842|NCT02148120|PLACEBO_COMPARATOR|Placebo NEXThaler|Placebo
62155843|NCT04304014|EXPERIMENTAL|L. reuteri|"Group that will receive L. reuteri one dose per day in an oral suspension~Intervention: Dietary Supplement: L. reuteri"
62155844|NCT04304014|EXPERIMENTAL|B. longum and P. Pentosaceus|"Group that will receive B. longum and P. Pentosaceus one dose per day in an oral suspension.~Intervention: Dietary Supplement: B. longum and P. Pentosaceus"
62529619|NCT04340609|EXPERIMENTAL|Intravenous Group|Dosage of intravenous route is 2 million MSCs/kg for each subject.
62529620|NCT04340609|EXPERIMENTAL|Intracoronary Group|Dosage of intracoronary route is ±50 million MSCs for each subject.
62529621|NCT04340609|NO_INTERVENTION|Control Group|Standard treatment of acute myocardia infarction
62155845|NCT00882375|EXPERIMENTAL|Nicotine|Nicotine
62155846|NCT00882375|PLACEBO_COMPARATOR|Placebo|Placebo
62529622|NCT04943484||Gastric cancer|Male and female subjects, over 18 years of age, with histological diagnosis of locally advanced gastric carcinoma (AGC), surgically resectable, without evidence of distant metastases (cT2-T4a; N0-3; M0) for which a surgical intervention with curative purposes is indicated both as a first treatment and following preoperative neoadjuvant chemotherapy
62529623|NCT00613535|ACTIVE_COMPARATOR|Lavage debridement to remove loose fragments|Articular cartilage defect left untreated by surgical tool during partial meniscectomy
62155847|NCT04095897||conventional analgesic therapy|Patient underwent mastectomy with conventional analgesic therapy
62155848|NCT04095897||Pecs II block|Patient underwent mastectomy with conventional analgesic therapy with pre induction Pecs II block
62155849|NCT00307489|EXPERIMENTAL|1|TDF
62155850|NCT00307489|EXPERIMENTAL|2|FTC/TDF
62155851|NCT01668498|EXPERIMENTAL|Erythromycin|Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
62155852|NCT01668498|ACTIVE_COMPARATOR|Doxycyline|Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
62529624|NCT00613535|ACTIVE_COMPARATOR|Mechanical Debridement|Remove large chondral flaps and loose fragments
62155853|NCT00312949|EXPERIMENTAL|1|Participants will use the interactive website
62529625|NCT00613535|ACTIVE_COMPARATOR|RF based Debridement|Debridement to remove loose fragments followed by use of Paragon T-2 RF wand to smooth the base of the shoulder of the tear
62155854|NCT00312949|ACTIVE_COMPARATOR|2|Participants will read written materials and watch a video
62155855|NCT05792475|OTHER|Define Standard of Truth (SOT) by 3 experts|Three experts A, B, and C independently define standard of truth (SOT) about 108 cases.
62155856|NCT01486745||Normal colonoscopy|
62155857|NCT01486745||Colonic polyps|
62155858|NCT01486745||Colorectal cancer patients|
62155859|NCT01486745||Breast & Prostate Cancer patients|
62529626|NCT02508753|EXPERIMENTAL|CXA-101/tazobactam therapeutic dose|
62529627|NCT02508753|EXPERIMENTAL|CXA-101/tazobactam supra-therapeutic dose|
62529628|NCT02508753|ACTIVE_COMPARATOR|Moxifloxacin|
62529629|NCT02508753|PLACEBO_COMPARATOR|Placebo|
62155860|NCT04361617|ACTIVE_COMPARATOR|Epigenetic age knowledge arm|Half of the intervention participants will be randomly selected to be informed of epigenetic age before the intervention.
62155861|NCT04361617|ACTIVE_COMPARATOR|No epigenetic age knowledge arm|The other half of intervention participants will not be informed of epigenetic age before the intervention.
62155862|NCT03327025|EXPERIMENTAL|Intervention|
62155863|NCT01171950|OTHER|All Patients|All patients meeting the patient selection criteria will be treated with the CentriMag device.
62155864|NCT02363153|EXPERIMENTAL|Diet and Exercise|Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.
62155865|NCT03785756|EXPERIMENTAL|Prolonged Release Group|"2 × 300 mg ibuprofen PR tablets at Hours 0 and 12~2 × placebo of PR tablets at Hours 8 and 16~2 × placebo of IR tablets at Hours 0, 8, 12, and 16"
62155866|NCT03785756|ACTIVE_COMPARATOR|Immediate Release Group|"2 × 200 mg ibuprofen IR tablets at Hours 0, 8, and 16~2 × placebo of IR tablets at Hour 12~2 × placebo of PR tablets at Hours 0, 8, 12, and 16"
62155867|NCT03785756|PLACEBO_COMPARATOR|Placebo Group|"2 × placebo of PR tablets at Hours 0, 8, 12, and 16~2 × placebo of IR tablets at Hours 0, 8, 12, and 16"
62529630|NCT04896814|EXPERIMENTAL|Transcutaneous tibial nerve stimulation|The participant will receive an intervention session per week that will be held for a period of 12 weeks. The total application time will be 30 minutes. A symmetrical biphasic current will be applied, with a frequency of 20 Hz in continuous mode and a pulsed frequency of 200 µs.
62529631|NCT04896814|PLACEBO_COMPARATOR|Placebo|The participant will receive one intervention session per week will be performed during a 12 weeks period time. The total application time will be 30 minutes. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied in other localization.
62529632|NCT06432049|EXPERIMENTAL|PMC|endodontically treated molar restored with Stainless steel crown
62155868|NCT01351896|EXPERIMENTAL|Arm A (Concurrent PCV13 and lenalidomide)|"Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on day 1 of courses 3 and 5.~Patients may undergo bone marrow biopsy and aspirate and CT during screening and blood sample collection throughout the study. (Blood sample collection discontinued with approval of protocol version 24 dated 3/15/2024)"
62155869|NCT01351896|EXPERIMENTAL|Arm B (Sequential PCV13 and lenalidomide)|Patients receive PCV13 IM on days 1 and 78 (cycles 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 1 of course 4. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo bone marrow biopsy and aspirate and CT during screening and blood sample collection throughout the study. (Blood sample collection discontinued with approval of protocol version 24 dated 3/15/2024)
62155870|NCT03779776|EXPERIMENTAL|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d, containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
62529633|NCT06432049|EXPERIMENTAL|EMX|endodontically treated molar restored with endocrown fabricated from CAD-CAM lithium disillicate
62529634|NCT06432049|EXPERIMENTAL|COP|endodontically treated molar restored with endocrown fabricated from CAD-CAM composite
62529635|NCT01716624|ACTIVE_COMPARATOR|Oxybutynin|
62529636|NCT01716624|EXPERIMENTAL|Botulinum Toxin A injection|
62529637|NCT04917653||Atrial fibrillation|"Patients with recent-onset atrial fibrillation treated by cardioversion intervention.~Intervention:~Device: Heart rhythm monitoring with portable device. Biomarkers: Biomarker kinetics based on blood samples."
62529638|NCT01104792|EXPERIMENTAL|Cariprazine|Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.
62529639|NCT00160641|EXPERIMENTAL|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
62713973|NCT06656637|EXPERIMENTAL|Memory Drilling BRAIN ITP (EXP)|"In the BRAIN ITP, the standard PM training for both the experimental (EXP) and control group (CON1), takes place during the patient's individual cognitive training sessions with the cognitive trainer. In total, there are seven sessions. At each of these sessions the cognitive trainer will review a new compensatory strategy for PM and assign a naturalistic PM practice task as homework to practice the strategy. The experimental group will receive the additional computerized memory drills training."
62529640|NCT03816566|EXPERIMENTAL|Wearable Device and PSG|The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.
62529641|NCT04343326|ACTIVE_COMPARATOR|accelerated corneal cross linking+ delivery of systemic oxygen|corneal cross linking is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
62529642|NCT04343326|ACTIVE_COMPARATOR|accelerated corneal collagen cross-linking|corneal cross linking with the same accelerated protocol without additional oxygen therapy.
62529643|NCT04343326|ACTIVE_COMPARATOR|conventional corneal collagen cross-linking|Conventional corneal cross linking using 30 mW/CM2 UV-A ablation for 30 minutes
62529644|NCT02987101|EXPERIMENTAL|Autologous SVF + Standard of care|"local injection around and under wound with autologous stromal vascular fraction.~Standard wound care is given independent of this study."
62155871|NCT03779776|PLACEBO_COMPARATOR|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d,VD 80 IU/kg/d ) within daily on parenteral nutrition until fed 120ml/kg.
62155872|NCT00166075||Female ED patients|All eligible African American female patients were approached in the ED waiting room during study periods. Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
62529645|NCT02987101|OTHER|Standard of care|Standard wound care is given independent of this study.
62529646|NCT03720379|ACTIVE_COMPARATOR|Fluoride Varnish - Fluor PROTECTOR S|"Fluor Protector S - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor, 1.5% ammonium fluoride (7700 ppm fluoride), additional ingredients~APPLICATION OF Fluor Protector S will be performed AT BASELINE, after 3,6 months (control 1) and after 9 and 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
62529647|NCT03720379|PLACEBO_COMPARATOR|PLACEBO|"- Placebo - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor.~APPLICATION OF PLACEBO will be performed AT BASELINE, after 3,6 months (control 1) and after 9 AND 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
62529648|NCT01647672|EXPERIMENTAL|Abraxane|Abraxane for neoadjuvant chemotherapy
62529649|NCT03443388|ACTIVE_COMPARATOR|Part 2: Helmet|"After a screening period, 10 patients with drug resistant epilepsy will first be assigned to wear one Hövding inflatable helmet in their daily lives. Subjects will fill out questionnaires about their seizures, injuries, and the circumstances of inflation when it occurs. After experiencing a seizure resulting in a fall or any helmet deployment, patients will crossover to the no helmet group. If no seizure resulting in fall occurs in 3 months, participation will end."
62155873|NCT01074528|EXPERIMENTAL|mindfulness based stress reduction|8-week mindfulness based stress reduction program
62155874|NCT01074528|NO_INTERVENTION|control group|patients who have to wait before entering the MBSR program or who do not want to follow this program
62529650|NCT03443388|NO_INTERVENTION|Part 2: No Helmet|"After a screening period, 10 subjects with drug resistant epilepsy will first be assigned to not wear an inflatable helmet. Subjects will fill out questionnaires about their seizures and injuries. After approximately 3 months, patients will crossover to the helmet group."
62529651|NCT04557306|EXPERIMENTAL|CBT101 q2w|CBT101 cells, every 2 weeks
62529652|NCT04557306|EXPERIMENTAL|CBT101 q4w|CBT101 cells, every 4 weeks
62529653|NCT05351554|EXPERIMENTAL|Treatment Arm 1|Namilumab with prednisone, or equivalent
62155875|NCT02565225||RheumaLive App use|RheumaLive App use and evaluation of feasibility
62155876|NCT02565225||RheumaLive App use & threshold values|RheumaLive App use and evaluation of feasibility
62155877|NCT03760809|EXPERIMENTAL|group A|Dexmedetomidine(0.5 μg／kg)/hydromophine-based general anesthesia
62155878|NCT03760809|EXPERIMENTAL|group B|Dexmedetomidine(1μg／kg)/hydromophine-based general anesthesia
62155879|NCT05118867|EXPERIMENTAL|IPREPARED Hospital Recovery Club|Participants and their recovery partners (informal caregivers) will use the iPREPARED mobile health technology. They will watch a short video to prepare them for their hospital stay and asked to use the provided resources and tools to maintain their brain health during their hospital stay.
62529654|NCT05351554|PLACEBO_COMPARATOR|Treatment Arm 2|Placebo with prednisone, or equivalent
62529655|NCT05351554|EXPERIMENTAL|Treatment Arm 3|Namilumab with current dose of prednisone, or equivalent
62529656|NCT00415766|ACTIVE_COMPARATOR|rHCG 250 ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
62529657|NCT00415766|ACTIVE_COMPARATOR|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
62529658|NCT00415766|ACTIVE_COMPARATOR|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
62155880|NCT05118867|NO_INTERVENTION|Standard Hospital Care Group|Participants will receive standard protocolized care procedures.
62155881|NCT05542004|NO_INTERVENTION|Control|No letter
62155882|NCT05542004|EXPERIMENTAL|Standard Letter|This group will receive a standard letter on the benefits of influenza vaccination without behavioral economic enhancement
62155883|NCT05542004|EXPERIMENTAL|Priming & Hot State Activation - 1 reminder|The standard letter sent out two times instead of once
62155884|NCT05542004|EXPERIMENTAL|Depersonalized Letter|The standard letter without the recipient's name
62155885|NCT05542004|EXPERIMENTAL|Gain-Framing/Context|Text added to the standard letter employing the specified behavioral economic principle
62155886|NCT05542004|EXPERIMENTAL|Loss-Framing/Context|Text added to the standard letter employing the specified behavioral economic principle
62155887|NCT05542004|EXPERIMENTAL|Collective Goal|Text added to the standard letter employing the specified behavioral economic principle
62155888|NCT05542004|EXPERIMENTAL|Active Choice/Implementation Intention Prompt|Text added to the standard letter employing the specified behavioral economic principle
62155889|NCT05542004|EXPERIMENTAL|Cardiovascular Gain Frame|Text added to the standard letter employing the specified behavioral economic principle
62155890|NCT05542004|EXPERIMENTAL|Expert Authority|Text added to the standard letter employing the specified behavioral economic principle
62155891|NCT02612285|EXPERIMENTAL|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
62155892|NCT05702190|ACTIVE_COMPARATOR|Opium tincture|Administration of opium tincture (Dropizol)
62529659|NCT06057441|NO_INTERVENTION|No noise stimulation|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed without noise.
62529660|NCT06057441|ACTIVE_COMPARATOR|Auditory white noise stimulation|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in auditory white noise.
62529661|NCT06057441|ACTIVE_COMPARATOR|Visual white pixel noise, 25%|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in visual white pixel noise at 25%.
62155893|NCT05702190|PLACEBO_COMPARATOR|Placebo|Administration of placebo (identical to opium tincture in taste and appearance)
62155894|NCT05159037|EXPERIMENTAL|Active GC-MRT Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will have been trained with prior to a stressful speech task.
62529662|NCT06057441|ACTIVE_COMPARATOR|Visual white pixel noise, 50%|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in visual white pixel noise at 50%.
62529663|NCT00003521|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62529664|NCT01120041|EXPERIMENTAL|Prenatal MI - Postpartum MI|Motivational interviewing counseling given during the prenatal and postpartum phases
62529665|NCT01120041|EXPERIMENTAL|Prenatal MI - Postpartum Health Ed|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
62529666|NCT01120041|EXPERIMENTAL|Prenatal Health Ed - Postpartum MI|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
62529667|NCT01120041|PLACEBO_COMPARATOR|Prenatal Health Ed/Postpartum Health Ed|Traditional health education given during the prenatal phase and the postpartum phase
62529668|NCT01663935|OTHER|Levodopa/carbidopa 4mg/kg/day|Treatment drug taken orally three times daily
62529669|NCT04047524|OTHER|Prehabilitation|These participants will receive a home based prehabilitation programme for a period of 2-6 weeks prior to surgery and will be provided with a Fitbit Charge 2.
62155895|NCT05159037|PLACEBO_COMPARATOR|Control Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will not have been trained with but ranked as highly liked prior to a stressful speech task.
62529670|NCT04047524|OTHER|Control|These participants will receive a Fitbit Flex and told to continue with their every day activity levels for a period of 2-6 weeks prior to surgery
62529671|NCT00354341|EXPERIMENTAL|Group 1 (Early Epoetin Beta)|Along with their standard treatment participants will receive epoetin beta at a starting dose of 2000 International Units (IU) subcutaneously (SC) once weekly to reach and maintain target hemoglobin (Hb) between 13 and 15 grams per deciliter (g/dL), for 15 months. Epoetin beta doses will be adjusted according to individual participant's Hb level. Standard treatment will be as per investigator discretion.
62529672|NCT00354341|ACTIVE_COMPARATOR|Group 2 (No/Late Epoetin Beta)|Participants will receive their standard treatment for 15 months but no treatment for anemia correction unless Hb level will be less than (\<) 10.5 g/dL on 2 consecutive visits of 2 weeks interval or the Hb level will be \<10 g/dL on a single determination. In such cases participants could receive epoetin beta at a starting dose of 2000 IU SC once weekly to reach and maintain a target Hb level of 10.5 to 11.5 g/dL. Standard treatment will be as per investigator discretion.
62529673|NCT04408430|EXPERIMENTAL|Transseptal ViMAC|110 MAC patients treated with transseptal Valve-in-MAC.
62529674|NCT04408430|NO_INTERVENTION|Registry of untreated patients|100 MAC patients not eligible for transseptal ViMAC, treated with conservative management including medications.
62529675|NCT02731027||Healthy Controls|
62529676|NCT02731027||Participants with Spinal Cord Injury|
62529677|NCT00485420|ACTIVE_COMPARATOR|Usual Care|Member with recurrent or chronic depression receives usual specialty mental health care
62529678|NCT00485420|EXPERIMENTAL|Internet-based disease managment program|Usual care is augmented with internet based education, self monitoring and clinical monitoring
62529679|NCT03158974|EXPERIMENTAL|VIR007|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
62529680|NCT03246126|EXPERIMENTAL|Primary Arm: Treatment with Valiant Thoracoabdominal Stent Graft System|The implantation of the Valiant Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance.
62155896|NCT00038376|EXPERIMENTAL|1|Alpha-interferon + Isotretinoin
62155897|NCT05700279|ACTIVE_COMPARATOR|Stellate Ganglion Block Treatment|Participants randomly assigned to the Stellate Ganglion Block (SGB) condition will receive 2 SGB treatments separated by 2 weeks.
62155898|NCT05700279|ACTIVE_COMPARATOR|Cognitive Processing Therapy|Participants randomly assigned to the Cognitive Processing Therapy (CPT) condition will receive 1-week massed CPT treatment consisting of 10 CPT sessions given within a single 5-day period via telehealth.
62155899|NCT05700279|NO_INTERVENTION|Usual Care|Participants randomly assigned to the Usual Care condition will not receive any active intervention.
62155900|NCT04314102||1|"Individuals will be evaluated before knee arthroplasty surgery. They will come for control in the 1st and 3rd months after surgery.~No intervention will be made."
62155901|NCT04292795|EXPERIMENTAL|Group A|Intervention: Shortwave Diathermy Frequency: 27.12 MHz Time Duration: 10min Duration of Treatment: 4 weeks. Sessions per Week: 2 sessions per week
62155902|NCT04292795|EXPERIMENTAL|Group B|Intervention: Therapeutic Ultrasound Frequency: 1-3MHz Intensity: 0.2-1W/cm2 Time Duration: 10mins Duration of Treatment: 4 weeks Sessions per Week: 2 sessions per week
62155903|NCT04168437|EXPERIMENTAL|Health-Related Quality of Life Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report.
62529681|NCT03246126|EXPERIMENTAL|Expanded Use Arm: Treatment with Valiant Thoracoabdominal Stent Graft System|The implantation of the Valiant Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance.
62529682|NCT05583838|EXPERIMENTAL|Optimized rhTPO treatment|The study in a 2:1 randomization ratio (117 subjects to rhTPO group).
62529683|NCT05583838|ACTIVE_COMPARATOR|Eltrombopag treatment|The study in a 2:1 randomization ratio (58 subjects to Eltrombopag group).
62529684|NCT02093130|EXPERIMENTAL|Pomegranate Juice|Eight ounces of 100% Pomegranate Juice daily
62529685|NCT02093130|PLACEBO_COMPARATOR|Placebo|Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.
62529686|NCT02671227|ACTIVE_COMPARATOR|intrathecal bupivacaine + Mg sulfate|intrathecal bupivacaine 15 mg + intrathecal Mg sulfate 50 mg. in gynecologic laparoscopic surgeries.
62529687|NCT02671227|ACTIVE_COMPARATOR|intrathecal bupivacaine|intrathecal bupivacaine 15 mg in gynecologic laparoscopic surgeries.
62529688|NCT03548649|EXPERIMENTAL|exoskeleton robot training group|subjects will receive exoskeleton robot training for 20 sessions (1 hr/session).
62529689|NCT05596721|EXPERIMENTAL|Azithromycin + ICS/LABA|Azithromycin: 500mg, po, 3 times per week for 12w ICS/LABA: Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w
62529690|NCT05596721|PLACEBO_COMPARATOR|ICS/LABA|ICS/LABA: Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w
62529691|NCT02070874|EXPERIMENTAL|telehealth enhanced pain management|video-case conferences for providers PainTracker for patients
62529692|NCT02070874|NO_INTERVENTION|usual care|usual care
62529693|NCT04302558|EXPERIMENTAL|Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while the blood flow to the leg is reduced by a blood flow restriction cuff.
62529694|NCT04302558|SHAM_COMPARATOR|SHAM Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while a blood flow restriction cuff is applied but inflation pressure will be limited
62529695|NCT04101500|PLACEBO_COMPARATOR|AECOPD(P+C1)|Placebo Tablets(P) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
62529696|NCT04101500|EXPERIMENTAL|AECOPD(C1+C2)|Compound Sodium Chlolate and Aminophylline Tablets(C2) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
62529697|NCT05301153||Myasthenia Gravis cases|"1. Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by ficoll density gradient centrifugation according to the manufacturer's protocol.~2. Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39.~3. Autoantibodies detection:~Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA according to the manufacturer's protocol."
62529698|NCT05301153||Healthy Control|"1. Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by ficoll density gradient centrifugation according to the manufacturer's protocol.~2. Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39."
62529699|NCT00852969|ACTIVE_COMPARATOR|Niacin|
62529700|NCT00852969|PLACEBO_COMPARATOR|Placebo|
62529701|NCT05178381|EXPERIMENTAL|Target: frontal pole; Order: frontal pole first|In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the frontal pole stimulation in the first TMS session and vertex stimulation in the second TMS session.
62529702|NCT05178381|EXPERIMENTAL|Target: frontal pole; Order: vertex first|In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the vertex stimulation in the first TMS session and frontal pole stimulation in the second TMS session.
62529703|NCT05178381|EXPERIMENTAL|Target: IFG; Order: IFG first|In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive IFG stimulation in the first TMS session and vertex stimulation in the second TMS session.
62529704|NCT05178381|EXPERIMENTAL|Target: IFG; Order: vertex first|In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive vertex stimulation in the first TMS session and IFG stimulation in the second TMS session.
62529705|NCT04031638||Radioactive Iodine treatment for thyroid cancer|
62155904|NCT04168437|NO_INTERVENTION|Wait List to Receive the Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report following completion of the study.
62155905|NCT03633318||IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
62155906|NCT03633318||Control Group|Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
62529706|NCT02955914||Optimism|Based on quality of life assessment
62529707|NCT02955914||Pessimism|Based on quality of life assessment
62529708|NCT05711836||patients|
62529709|NCT05711836||controls|
62529710|NCT00751907|EXPERIMENTAL|Atorvastatin|40mg Atorvastatin nightly for 4 months
62529711|NCT00751907|PLACEBO_COMPARATOR|Placebo|matching placebo nightly for 4 months
62529712|NCT03621358|PLACEBO_COMPARATOR|Control Gummy|Control gummy with free flavour (without encapsulating)
62529713|NCT03621358|EXPERIMENTAL|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
62529714|NCT03621358|EXPERIMENTAL|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
62529715|NCT03614897|EXPERIMENTAL|Education|Providers participating in education related to guidelines for treating patients at risk of falling
62155907|NCT03824340|ACTIVE_COMPARATOR|Doxycycline before ICSI|extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
62529716|NCT01076686||Bupivacaine and low dose SKY0402|
62529717|NCT01076686||Bupivacaine and high dose SKY0402|
62529718|NCT01076686||Bupivacaine|
62529719|NCT01076686||High dose SKY0402|
62529720|NCT03601364||Group 1|1.Mechanical ventilator closed group (Mechanical ventilator off)
62529721|NCT03601364||Group 2|"1. Tidal Voltage 3-4ml / kg (TV),~2. FIO2 50%, Flow: 2L / min,~3. Frequency; 10-12 applied group."
62529722|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,~1. Tidal Voltage 3-4ml / kg (TV),~2. FIO2 50%, Flow: 2L / min,~3. Frequency; 10-12 applied group."
62529723|NCT01752686|EXPERIMENTAL|carboplatin chemotherapy|At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.
62529724|NCT01752686|NO_INTERVENTION|Observation arm|In this observation arm, patients should be follow up with regular interval without treatment.
62529725|NCT03142906|EXPERIMENTAL|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
62529726|NCT03142906|NO_INTERVENTION|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
62529727|NCT01190943||Ancillary-Correlative (biomarker sampling and analysis)|Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
62529728|NCT02682095||Patients: achieved BP control|Patients who have achieved blood pressure control (≤140/90 mmHg)
62529729|NCT02682095||Patients: not achieved BP control|Patients who have not achieved blood pressure control (\>140/90 mmHg)
62529730|NCT02682095||Individual interviews|Hypertensive patients who have considered changing lifestyle regarding one or more of the areas of tobacco, alcohol, diet, physical activity or stress.
62529731|NCT02682095||Focus-group interviews|Hypertensive patients
62529732|NCT03376230||Control patients|
62713974|NCT06656637|ACTIVE_COMPARATOR|Standard of Care BRAIN ITP (CON1)|In the BRAIN ITP, the standard PM training for both the experimental (EXP) and control group (CON1), takes place during the patient's individual cognitive training sessions with the cognitive trainer. In total, there are seven sessions. At each of these sessions the cognitive trainer will review a new compensatory strategy for PM and assign a naturalistic PM practice task as homework to practice the strategy. The CON1 group will not receive the additional memory drilling.
62713975|NCT06656637|ACTIVE_COMPARATOR|Standard of Care PTSD ITP (CON2)|The PTSD ITP group (CON2) will receive the traditional standard of care (cognitive training and cognitive processing therapy). There is no spaced training or practice.
62529733|NCT03376230||Crohn's disease patients|
62529734|NCT03376230||Ulcerative colitis patients|
62529735|NCT00992524|ACTIVE_COMPARATOR|Oral Titrated Misoprostol Solution|
62529736|NCT00992524|ACTIVE_COMPARATOR|Vaginal Misoprostol|
62529737|NCT00758680|EXPERIMENTAL|MK-1006 20 mg Once Daily (Panel A)|After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU).
62529738|NCT00758680|EXPERIMENTAL|MK-1006 40 mg Once Daily (Panel B)|After a 2-week run-in/wash-off period, participants received single daily doses of 40 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
62529739|NCT00758680|EXPERIMENTAL|MK-1006 80 mg Once Daily (Panel C)|After a 2-week run-in/wash-off period, participants received single daily doses of 80 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
62713976|NCT04224701|EXPERIMENTAL|Investigational Product, 30 µg/ Placebo|30 µg IM, months 0, 2 and 6
62713977|NCT04224701|EXPERIMENTAL|Investigational Product, 300 µg/ Placebo|300 µg IM, months 0, 2 and 6
62529740|NCT00758680|EXPERIMENTAL|MK-1006 120 mg Once Daily (Panel D)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
62529741|NCT00758680|EXPERIMENTAL|MK-1006 20 mg Twice Daily (Panel E)|After a 2-week run-in/wash-off period, participants received twice-daily doses (b.i.d.) of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
62713978|NCT05207813||Basivertebral nerve ablation treatment|Patient-reported outcomes at three (3) follow-up visits for previously treated participants from the CLBP Single-Arm study.
62155908|NCT03824340|NO_INTERVENTION|control group|control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
62155909|NCT04468659|EXPERIMENTAL|A45 Trial: Lecanemab 5 mg/kg + 10 mg/kg (Core Study)|Participants will receive lecanemab 5 milligram per kilogram (mg/kg), administered as intravenous (IV) infusion, every two weeks from Week 0 to 6, then 10 mg/kg, administered as IV infusion, every two weeks from Week 8 to 94, and 10 mg/kg, administered as IV infusion, every four weeks from Week 96 to 216 in core study.
62529742|NCT00758680|EXPERIMENTAL|MK-1006 30 mg Twice Daily (Panel F)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 30 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
62529743|NCT00758680|EXPERIMENTAL|MK-1006 50 mg Twice Daily (Panel G)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
62529744|NCT00758680|EXPERIMENTAL|MK-1006 120 mg Once Daily Outpatient (Panel H)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
62529745|NCT00758680|EXPERIMENTAL|MK-1006 50 mg Twice Daily Outpatient (Panel I)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
62155910|NCT04468659|PLACEBO_COMPARATOR|A45 Trial: Placebo (Core Study)|Participants will receive placebo (0.9 percent \[%\] sodium chloride solution), administered as IV infusion, every two weeks from Week 0 to 94, then every four weeks from Week 96 to 216.
62155911|NCT04468659|EXPERIMENTAL|A3 Trial: Lecanemab 5 mg/kg + 10 mg/kg (Core Study)|Participants will receive lecanemab 5 mg/kg, administered as IV infusion, every four weeks from Week 0 to 4, then 10 mg/kg, administered as IV infusion, every four weeks from Week 8 to 216 in core study.
62155912|NCT04468659|PLACEBO_COMPARATOR|A3 Trial: Placebo (Core Study)|Participants will receive placebo (0.9% sodium chloride solution), administered as IV infusion, every four weeks from Week 0 to 216.
62155913|NCT04468659|EXPERIMENTAL|A45 Trial: Lecanemab 10 mg/kg (Extension Phase)|Participants progressing to early Alzheimer's disease (EAD) during the core study (progressors) will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks after transition to the extension phase through to at least Week 216 from randomization in the core study. Participants completing the core study (completers) will enter extension phase and will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks for up to Week 312. Eligible participants receiving placebo in core study will continue to extension phase.
62155914|NCT04468659|EXPERIMENTAL|A3 Trial: Lecanemab 10 mg/kg (Extension Phase)|Participants progressing to EAD during the core study (progressors) will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks after transition to the extension phase through to at least Week 216 from randomization in the core study. Participants completing the core study (completers) will enter extension phase and will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks for up to Week 312. Eligible participants receiving placebo in core study will continue to extension phase.
62155915|NCT02716272|EXPERIMENTAL|MONOTHERAPY ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
62529746|NCT00758680|PLACEBO_COMPARATOR|Placebo|After a 2-week run-in/wash-off period, participants received dose-matched placebo to MK-1006 over a multiple-dosing period while remaining domiciled in the CRU.
62529747|NCT04390542|EXPERIMENTAL|Psychoeducation intervention|Psychoeducatoinal intervention
62529748|NCT04390542|NO_INTERVENTION|Usual care|Information from healthcare providers
62529749|NCT04086836||Patient suffering a late stroke after TAVR|All patients suffering a stroke after TAVR will be studied
62155916|NCT02716272|EXPERIMENTAL|COMBINATION ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
62529750|NCT00675753||Preterm group|Preterm (36 6/7 weeks gestation or earlier) mothers and their newborns.
62529751|NCT00675753||Term group|Term (\> 37 weeks gestation) mothers and their newborns.
62529752|NCT04265339|NO_INTERVENTION|None smokers|50 participants who are non-smokers
62529753|NCT04265339|EXPERIMENTAL|Smoking Cessation|50 smokers who quit smoking
62529754|NCT04265339|NO_INTERVENTION|Active smokers|50 smokers who continue smoking
62529755|NCT06227013|EXPERIMENTAL|interventional group|Whistleblowing intervention
62529756|NCT06227013|NO_INTERVENTION|control group|no intervention
62529757|NCT03213730|EXPERIMENTAL|Experimental group|Standard care + 3D-MOT protocol.
62529758|NCT03213730|ACTIVE_COMPARATOR|Active control group|Standard care + visual attention task (2048 online game)
62529759|NCT03213730|NO_INTERVENTION|Control group|Standard care alone
62713979|NCT03060902|EXPERIMENTAL|Dialectical Behavior Therapy Skills|Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
62155917|NCT03455751|NO_INTERVENTION|Control|The control arm will receive no intervention and will follow standard of care for post-operative pain management.
62155918|NCT03455751|EXPERIMENTAL|PGx-guided|The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
62529760|NCT02752763|EXPERIMENTAL|preservative free artificial tear drop|preservative free artificial tears drop is a drop group declaring different kind of active agent like hydroxypropyl methylcellulose, carboxymethyl cellulose etc commonly used in dry eye treatment. Preservative free artificial tear( carboxymethyl cellulose, hydroxypropyl methylcellulose) was used as four times one drop daily. In our study, we prescribed to patients preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.
62529761|NCT02752763|EXPERIMENTAL|%40 Autologous serum(AS)|peripheral venous blood (14-20 ml) that drawn from antecubital vein of patients to prepare Autologous Serum. Blood sample was left at room temperature over 2 hours for clotting. Serum was obtained after centrifugation at 4000 revolutions per minute (rpm) for 10 minutes at 4 °C using a Nuve NF1200R. Next, in a laminar flow cabinet under sterile conditions, approximately 10 mL of supernatant was collected and diluted to 40 % with isotonic saline solution. It is recommended for dry eye diseases, too. %40 diluted Autologous Serum used as four times one drop daily.
62529762|NCT03709823|EXPERIMENTAL|1.5 mg Cytisine, Commercial Schedule|1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
62529763|NCT03709823|EXPERIMENTAL|3.0 mg Cytisine, Commercial Schedule|3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
62529764|NCT03709823|PLACEBO_COMPARATOR|Placebo, Commercial Schedule|Placebo tablets using the commercial 25-day titration schedule + behavioral support
62529765|NCT03709823|EXPERIMENTAL|1.5 mg Cytisine, TID Schedule|1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
62529766|NCT03709823|EXPERIMENTAL|3.0 mg Cytisine, TID Schedule|3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
62713980|NCT03060902|NO_INTERVENTION|Family Services as Usual|Mothers will continue with services they are receiving in the community
62529767|NCT03709823|PLACEBO_COMPARATOR|Placebo, TID Schedule|Placebo tablets for 25 days using a simplified TID schedule + behavioral support
62529768|NCT04227236|EXPERIMENTAL|E-based virtual training|Participants in the e-based virtual training (up to 8 participants per session) will be placed at one of eight computers (with headphones), which we estimate will take less time (about 40 minutes), due to the individualized learning and 1:1 nature of the training instead of 1:15. Participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
62713981|NCT06348095|EXPERIMENTAL|Probiotics group|2B CFU/ strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure.
62713982|NCT06348095|PLACEBO_COMPARATOR|Placebo group|Maltodextrin, one strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure.
62155919|NCT05242874|EXPERIMENTAL|Triple group|A three-drug antiemetic regimen with fosaprepitant, tropisetron, and olanzapine (triple group)
62155920|NCT05242874|ACTIVE_COMPARATOR|Quadruple group|A four-drug regimen including fosaprepitant, tropisetron, olanzapine, and dexamethasone (quadruple group)
62155921|NCT00731692|EXPERIMENTAL|FTY720D 0.5 mg|Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment
62155922|NCT00731692|PLACEBO_COMPARATOR|Placebo|Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization
62155923|NCT00731692|EXPERIMENTAL|FTY720D 1.25 mg switch to 0.5 mg|Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009
62155924|NCT05031052|EXPERIMENTAL|Normothermic machine perfusion (NMP)|End-ischemic NMP will be performed immediately after arrival of the allocated and static cold stored ECD kidney graft. The study protocol aims a duration of 4 hours. Machine perfusion will be performed with a combination of patient's blood group matched packed red blood cells (RBC) and a special manufactured solution with the currently only certified device in Europe (XVIVO - KidneyAssist®). After 4 hours of perfusion and viability assessment, the kidney allograft will be disconnected from the device immediately prior to transplantation and flushed with three litres of Custodiol HTK solution via the renal artery. Then transplantation will be performed in typical method.
62155925|NCT05031052|ACTIVE_COMPARATOR|Statical cold storage (SCS)|Conventional method kidney transplantation of statical cold stored and transported ECD kidney allograft. The allocated kidney allograft will be flushed with Custodiol HTK solution during back table preparation with the aim of immediate implantation into recipient.
62155926|NCT03417115||Advanced breast cancer - Her2 positive|Patients with HER2-positive advanced breast cancer
62155927|NCT03417115||Advanced breast cancer - triple negative|Patients with triple negative advanced breast cancer
62155928|NCT03417115||Advanced breast cancer - HR positive, Her2 negative|Patients with HR positive, Her2 negative advanced breast cancer
62155929|NCT03417115||Early breast cancer - HER2 positive|Patients with HER2 positive early breast cancer
62155930|NCT03417115||Early breast cancer - triple negative|Patients with triple negative early breast cancer
62155931|NCT03417115||Early breast cancer - HR positive, HER2 negative|Patients with HR positive, HER2 negative early breast cancer
62529769|NCT04227236|ACTIVE_COMPARATOR|In-person training|Participants in-person training will participate in a class with 15-20 participants like the usual MPC training environment. The training will last 1 hour. Like the e-based virtual training, participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
62529770|NCT03590392|EXPERIMENTAL|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10\^9 vp through intramuscular route.
62529771|NCT03590392|EXPERIMENTAL|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10\^10 vp through intramuscular route.
62529772|NCT03590392|EXPERIMENTAL|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10\^10 vp through intramuscular route.
62529773|NCT03796039|EXPERIMENTAL|Standing and Social Intervention|Participants be exposed to an additional 100 minutes of standing per week. Participants will do this by standing for 20 minutes Monday through Friday.
62529774|NCT03796039|NO_INTERVENTION|Control Group|Control group will receive social visits, but no exposure to standing
62529775|NCT03961048|EXPERIMENTAL|Bilateral catheters|patients receiving bilateral catheters (such as for patients undergoing sternotomies/midline incisions or with planned bilateral thoracotomy incisions)
62529776|NCT03961048|EXPERIMENTAL|Single catheter|patients who only have one catheter in place (such as in patients who have unilateral thoracotomies and not midline sternotomies)
62713983|NCT04804527|EXPERIMENTAL|Intensified physiotherapy|In addition to usual care physiotherapy patients in the intensified physiotherapy group will receive an extra physiotherapy session of up to 30 minutes on every weekday starting on the first postoperative day. The session will include progressive functional training of basic mobility and walking in the ward delivered by an experienced physiotherapist affiliated with the trial. The aim of this additional session is to improve the functional advances achieved during the earlier physiotherapy session.
62155932|NCT06473194|EXPERIMENTAL|age , gender|group according to age and according to gender
62529777|NCT03014180|EXPERIMENTAL|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
62529778|NCT02227147|EXPERIMENTAL|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, formulation containing anti-oxidant
62529779|NCT02227147|PLACEBO_COMPARATOR|Placebo|Vehicle: formulation containing anti-oxidant
62529780|NCT03734783||Patients|HBsAg positive more than 6 months
62529781|NCT03734783||health control|
62529782|NCT04810403|EXPERIMENTAL|SOMEBODY Eating Disorder Prevention Program|All participants will be recruited to participate in the SOcial MEdia (SOME) adaptation of activities from the BODY Project (SOMEBODY).
62529783|NCT04168190|EXPERIMENTAL|Phase 1: V116 0.5 mL|Participants will receive a single intramuscular (IM) 0.5 mL vaccination on Day 1 of Phase 1
62529784|NCT04168190|EXPERIMENTAL|Phase 1: V116 1.0 mL|Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 1
62529785|NCT04168190|ACTIVE_COMPARATOR|Phase 1: Pneumovax™23|Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 1
62713984|NCT04804527|ACTIVE_COMPARATOR|Usual care physiotherapy|Patients will receive approximately 30 minutes physiotherapy once daily in the ward delivered by the ward's usual physiotherapists i.e. starting on the first postoperative day and thereafter primarily on weekdays until discharge (a mean of 8.82 days after admission). Usual care physiotherapy is individualized taking the patients ability and previous level of functioning into account and includes 1) progressive functional training of basic mobility e.g. in-out of bed, sit-to-stand and walking including progression in walking aid, stair training if possible, and advices toward better physical functional level, 2) basic bed exercises with progression to standing exercises according to a hand-out training program and recommendations on doing exercises daily and being as physical active as possible during the day.
62529786|NCT04168190|EXPERIMENTAL|Phase 2: V116|Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 2
62529787|NCT04168190|ACTIVE_COMPARATOR|Phase 2: Pneumovax™23|Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 2
62529788|NCT01379001|EXPERIMENTAL|Young|Young healthy controls, aged 21-35
62529789|NCT01379001|EXPERIMENTAL|Older|Older healthy controls, aged 65-80
62155933|NCT03829566|EXPERIMENTAL|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
62529790|NCT01340105|EXPERIMENTAL|Microwave|Hepatocellular carcinoma treated with microwave ablation
62529791|NCT01340105|ACTIVE_COMPARATOR|Radiofrequency|Hepatocellular carcinoma treated with radiofrequency ablation
62529792|NCT06069778|EXPERIMENTAL|Phase 1 - BNT321 Dose Level 1 + mFOLFIRINOX|BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)
62529793|NCT06069778|EXPERIMENTAL|Phase 1 - BNT321 Dose Level 2 + mFOLFIRINOX|BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)
62529794|NCT06069778|EXPERIMENTAL|Phase 2 - BNT321 RP2D + mFOLFIRINOX|BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)
62529795|NCT06069778|ACTIVE_COMPARATOR|Phase 2 - mFOLFIRINOX|mFOLFIRINOX chemotherapy (24 weeks) as monotherapy
62529796|NCT03123510|EXPERIMENTAL|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
62529797|NCT03123510|PLACEBO_COMPARATOR|placebo|sugar pills
62529798|NCT04406597|EXPERIMENTAL|the New Tissue Containment System group|Using the New Tissue Containment System during Laparoscopic Ovarian Cystectomy
62529799|NCT04406597|NO_INTERVENTION|Open group|Without any protection system during Laparoscopic Ovarian Cystectomy
62529800|NCT01846013|EXPERIMENTAL|Stand|
62529801|NCT01846013|EXPERIMENTAL|Move|
62529802|NCT01846013|EXPERIMENTAL|Stand and Move|
62529803|NCT01846013|NO_INTERVENTION|General Wellness|
62529804|NCT00788294|ACTIVE_COMPARATOR|10 mg IV|
62529805|NCT00788294|ACTIVE_COMPARATOR|5 mg SC|
62529806|NCT00788294|ACTIVE_COMPARATOR|10 mg SC|
62529807|NCT00788294|ACTIVE_COMPARATOR|19 mg SC|
62529808|NCT01268332|EXPERIMENTAL|Intravaginal Ring|Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
62529809|NCT01268332|NO_INTERVENTION|No Intravaginal Ring|Intravaginal ring will not be inserted into participants.
62529810|NCT03694366||Five facilities in Bassar District|Estimated population of 34,676 served by five public sector facilities in Bassar District.
62529811|NCT03694366||Seven facilities in Binah District|Estimated population of 31,027 served by seven public sector facilities in Binah District.
62529812|NCT03694366||Four facilities in Dankpen District|Estimated total population of 40,165 served by four public sector facilities in Dankpen District.
62529813|NCT03694366||Five facilities in Kéran District|Estimated total population of 31,866 served by five public sector facilities in Kéran District.
62529814|NCT01700036|EXPERIMENTAL|Treatment arm|Alpha-1-Antitrypsin (AAT) for the treatment of Steroid Refractory Acute Graft vs Host Disease.
62529815|NCT04557202|ACTIVE_COMPARATOR|Group A|Group A had 58 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha1-blockers for one week preoperatively and another two weeks postoperatively
62529816|NCT04557202|PLACEBO_COMPARATOR|Group B|62 patients who underwent non-stented ureteroscopy and laser and received placebo.
62529817|NCT04392583||Device: ENTACT Septal Staple|Septoplasty
62529818|NCT05117983|ACTIVE_COMPARATOR|MDD patient with HRSD score of at least 18|MDD patients who meet the DSM-5 diagnostic criteria of MDD and their current episode show a Hamilton Rating Scale for Depression (HRSD) score of at least 18
62529819|NCT05117983|ACTIVE_COMPARATOR|BD patient with HRSD score of at least 18|BD patients who meet the DSM-5 diagnostic criteria of BD and their current depression episode show a Hamilton Rating Scale for Depression (HRSD) score of at least 18
62529820|NCT02351960|EXPERIMENTAL|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
62529821|NCT02351960|EXPERIMENTAL|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
62529822|NCT03778658|EXPERIMENTAL|Outpatient Physical Activity Program|The intervention will investigate a multi modal outpatient physical activity program incorporating both strength training utilizing resistance bands, as well as an aerobic activity based on hip-hop dancing.
62529823|NCT04181749|NO_INTERVENTION|No treatment|Patients will not be prescribed aspirin and statin
62529824|NCT04181749|ACTIVE_COMPARATOR|Aspirin and Atorvastatin|Patients prescribed aspirin and atorvastatin
62529825|NCT00511095|EXPERIMENTAL|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL
62529826|NCT03166423|EXPERIMENTAL|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
62529827|NCT03166423|EXPERIMENTAL|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
62529828|NCT03008876|EXPERIMENTAL|acetaminophen|Group of patients randomized to receive acetaminophen to treat their PDA
62529829|NCT03008876|ACTIVE_COMPARATOR|ibuprofen|Group of patients randomized to receive ibuprofen to treat their PDA
62529830|NCT05211661||Invasively ventilated patients (n=15)|"First measurement (comprehensive protocol) within 48 hours from initiation of MV.~Serial measurements every third day including 2 measurements after extubation."
62155934|NCT01956396|EXPERIMENTAL|Experimental: PrePex™ device|Adult male circumcision by the PrePex™ device
62155935|NCT01628263|EXPERIMENTAL|Follow up Clinic|Participants will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse.
62529831|NCT01832935|ACTIVE_COMPARATOR|insulin glargine|patients receiving variable doses of Insulin glargine.start with 0.2 to 0.6unit per kg
62529832|NCT01832935|ACTIVE_COMPARATOR|Insulin NPH|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
62155936|NCT01628263|NO_INTERVENTION|Control|Participants will not receive an offer of a follow up clinic
62529833|NCT02796118|EXPERIMENTAL|ASP2151 Low dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
62155937|NCT05310292|EXPERIMENTAL|Subjects diagnosed with IKH|10 patients, diagnosed with IKH
62155938|NCT05310292|EXPERIMENTAL|Healthy control subjects|10 subjects, healthy, matched for gender, BMI, age
62529834|NCT02796118|EXPERIMENTAL|ASP2151 High dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
62529835|NCT02796118|EXPERIMENTAL|ASP2151 Low dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
62529836|NCT02796118|EXPERIMENTAL|ASP2151 High dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
62529837|NCT02796118|PLACEBO_COMPARATOR|Placebo in non-elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
62529838|NCT02796118|PLACEBO_COMPARATOR|Placebo in elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
62529839|NCT01376817|EXPERIMENTAL|Omega 3|
62529840|NCT01376817|ACTIVE_COMPARATOR|MCT / LCT|
62529841|NCT02890030||Case-Control|Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy
62529842|NCT02694471|EXPERIMENTAL|Old group|16 old participants (55-65 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
62529843|NCT02694471|ACTIVE_COMPARATOR|Young group|7 young participants (18-30 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
62529844|NCT05153421|EXPERIMENTAL|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
62155939|NCT02771561|OTHER|Patent Foramen Ovale Closure|All eligible participants undergo a patent foramen ovale closure procedure
62155940|NCT01199302|EXPERIMENTAL|Brodalumab 350 mg|Participants received brodalumab 350 mg intravenously (IV) on day 1, week 4 and every 4 weeks thereafter for up to 132 weeks.
62155941|NCT02793557|PLACEBO_COMPARATOR|Placebo|Intradermal injection of 50 μl solution. One application in SAD part for each dosing occasion. 2 or 3 times weekly for 3 month in MD part.
62155942|NCT02793557|EXPERIMENTAL|FOL-005: Solution 1|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
62155943|NCT02793557|EXPERIMENTAL|FOL-005: Solution 2|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
62155944|NCT02793557|EXPERIMENTAL|FOL-005: Solution 3|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
62155945|NCT02793557|EXPERIMENTAL|FOL-005: Solution 4|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
62529845|NCT02537366|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.07 ml/kg/h Adaptation to sedation status by changing infusion speed of 0.02 ml/kg/h every 30 minutes up to 0.14 ml/kg/h Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
62529846|NCT02537366|EXPERIMENTAL|DEX|Dexmedetomidine diluted to 10 µg/ml in Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.7 µg/kg/h (= 0.07 ml/kg/h) Adaptation to sedation status by changing infusion speed of 0.2 µg/kg/h (= 0.02 ml/kg/h) every 30 minutes up to 1.4 µg/kg/h (= 0.14 ml/kg/h) Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
62529847|NCT03908177|EXPERIMENTAL|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
62529848|NCT03908177|ACTIVE_COMPARATOR|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
62529849|NCT03108092|EXPERIMENTAL|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
62529850|NCT03108092|SHAM_COMPARATOR|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
62529851|NCT04940949|EXPERIMENTAL|Single Intravenous (IV) Dose of Lu AF90103|Participants will receive a single IV dose of Lu AF90103.
62529852|NCT04940949|PLACEBO_COMPARATOR|Single IV Dose of Placebo|Participants will receive a single IV dose of placebo matching to Lu AF90103.
62155946|NCT05353062|ACTIVE_COMPARATOR|Standard therapy|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
62155947|NCT05353062|EXPERIMENTAL|Bipolar hemostatic forceps|Endoscopic therapy with bipolar hemostatic forceps
62529853|NCT04940949|EXPERIMENTAL|2 Single IV Doses of Lu AF90103|Participants will receive 2 single IV doses of Lu AF90103 separated by at least 5 days.
62713985|NCT05187234|EXPERIMENTAL|Education|Experimental: intervention group The patients were interviewed 3 times, initially at the 1st month and at the 3rd month. All forms were initially administered to patients in the intervention group. Patients were randomly assigned to the intervention group and participated in a one-on-one Roy Adaptation Model-based training program consisting of an initial 30-45 minute session. Hemodialysis Patient Education Manual prepared by the researchers was applied to the patients in the intervention group during the training. All forms were re-administered to the patients in the intervention group in the 1st and 3rd months.
62155948|NCT03436537||Gingival recession (GR) group|GR group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
62155949|NCT03436537||Gingival enlargement (GE) group|GE group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
62155950|NCT03436537||periodontal healthy (H) group|H group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
62155951|NCT01846156|EXPERIMENTAL|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
62155952|NCT01846156|EXPERIMENTAL|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
62155953|NCT01846156|ACTIVE_COMPARATOR|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
62155954|NCT01072071|NO_INTERVENTION|Control group|Patients will be receiving standard of care ICU treatment of their underlying disease according to internationally accepted guidelines and recommendations.
62155955|NCT01072071|EXPERIMENTAL|Furosemide group|patients will be receiving standard of care ICU treatment of their underlying condition according to international guidelines and recommendations. In addition, furosemide will be administered in continuous infusion as per protocol in order to achieve a preset target diuresis that is adjusted according to haemodynamic tolerance.
62155956|NCT05434507|EXPERIMENTAL|K-clipTM transcatheter annuloplasty system|
62155957|NCT06032156|PLACEBO_COMPARATOR|Placebo|Single dose of a taste-matched calorie-free placebo
62155958|NCT06032156|EXPERIMENTAL|High Dose β-OHB|Single dose of a ketone monoester (\[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate; 0.6 g β-OHB/kg body weight)
62155959|NCT06032156|EXPERIMENTAL|Low Dose β-OHB|Single dose of a ketone monoester (\[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate; 0.3 g β-OHB/kg body weight)
62155960|NCT06421376|EXPERIMENTAL|Inductive chemoimmunotherapy+chemoradiotherapy±surgery|In this group, the patients were given 2 cycles of inductive therapy of cardonilizumab combined with chemotherapy, followed by concurrent chemoradiotherapy with two cycles of nab-paclitaxel and cisplatin plus radiotherapy of 50-50.4 Gy. After clinical evaluation, surgery was feasible for a part of patients.
62155961|NCT00623844|EXPERIMENTAL|Intervention|Physical activity intervention: structured daily 30-min activity classes at preschool, activity homeworks, parent and teacher education
62155962|NCT00623844|NO_INTERVENTION|Control|Keep usual activities in kindergarten
62155963|NCT01207453|OTHER|Milnacipran then placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
62155964|NCT01207453|OTHER|Placebo then milnacipran|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to milnacipran for 6 weeks."
62155965|NCT01248663|ACTIVE_COMPARATOR|antecolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing an antecolic duodeno-jejunostomy
62155966|NCT01248663|EXPERIMENTAL|retrocolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing a retrocolic duodeno-jejunostomy
62155967|NCT04819204|EXPERIMENTAL|GnRH antagonist alone|Intervention: Cetrorelix acetate (Cetrotide)
62155968|NCT04819204|EXPERIMENTAL|GnRH antagonist + Testosterone add-back|Intervention: Cetrorelix acetate (Cetrotide) + Testosterone gel (Androgel)
62529854|NCT00142233|EXPERIMENTAL|ANTOX (vers.)1.2|"Adults and children aged 10+ will take two ANTOX (vers)1.2 tablets three times per day. (Antioxidant treatment: daily: 300 μg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine) plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one ANTOX (vers)1.2 tablet three times daily (Antioxidant treatment: daily: 150 μg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine) plus one placebo Magnesiocard (2.5 mmol) tablet three times a day."
62713986|NCT05187234|NO_INTERVENTION|Control|Education and training manual based on the Roy adaptation model was not given to the patients.
62155969|NCT03403153|OTHER|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
62529855|NCT00142233|EXPERIMENTAL|Magnesium|"Adults and children aged 10+ will take two Magnesiocard (2.5 mmol) tablets three times per day (total dose: 15 mmol = 365 mg per day) plus two placebo ANTOX (vers)1.2 tablets three times a day.~Children aged five to nine years of age will take one Magnesiocard (2.5 mmol) tablet three times a day (total dose: 7.5 mmol = 182 mg per day) plus one placebo ANTOX (vers)1.2 tablet three times a day."
62713987|NCT04715126|ACTIVE_COMPARATOR|Oxyjun (Extract of Terminilia Arjuna).|
62713988|NCT04715126|PLACEBO_COMPARATOR|Placebo (Microcrystalline cellulose)|
62713989|NCT01497756|EXPERIMENTAL|CAPP application|Patients in whom device is used
62713990|NCT00657267|EXPERIMENTAL|Single-Arm Study|
62529856|NCT00142233|PLACEBO_COMPARATOR|Placebo|"Adults and children aged 10+ will take two placebo ANTOX (vers)1.2 tablets three times a day, plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one placebo ANTOX (vers)1.2 tablet three times a day, plus one placebo Magnesiocard (2.5 mmol) tablet three times per day."
62529857|NCT05436717|EXPERIMENTAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies, such as the promotion of wellbeing through the practice of mindfulness, compassion, acceptance, and spirituality and the estimated time for completing the whole program is 8 weeks
62529858|NCT02699684|OTHER|AOHG, then AOA|Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
62155970|NCT05848102|EXPERIMENTAL|Dapagliflozin arm|In the Dapagliflozin arm, participants with functional mitral regurgitation of more than moderate and left ventricular ejection fraction of more than 40% will add oral drug of Forxiga (Dapagliflozin, specification: 10mg) of 10 mg per day on the basis of regular guideline directed medical therapy for functional mitral regurgitation for 6 months.
62155971|NCT05848102|NO_INTERVENTION|GDMT arm|In the guideline directed medical therapy (GDMT) arm, participants with functional mitral regurgitation of more than moderate and left ventricular ejection fraction of more than 40% will continue to maintain the original treatment of GDMT for 6 month.
62155972|NCT05568277|EXPERIMENTAL|Education|A minimum of 12-week training program and follow-up based on Pender's Health Promotion Model is planned until the 24th gestational week.
62155973|NCT05568277|NO_INTERVENTION|Control|No intervention will be made by the researcher and they will receive routine antenatal care. After the post-test data are collected, the education booklet prepared by the researcher will be given to the pregnant women and sent to their e-mail addresses.
62155974|NCT05049265|EXPERIMENTAL|JS007|
62529859|NCT02699684|OTHER|AOA, then AOHG|Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
62529860|NCT04629417|EXPERIMENTAL|Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
62529861|NCT04629417|ACTIVE_COMPARATOR|OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
62155975|NCT01868555|EXPERIMENTAL|IDegAsp 30|
62155976|NCT01868555|EXPERIMENTAL|IDegAsp 45|
62529862|NCT05191303|EXPERIMENTAL|Intervention group|In addition to standard usual care of breastfeeding counseling, the intervention group will have an opportunity to access the mobile application breastfeeding counseling from weeks 18 of pregnancy, continuing for up to 6 months after childbirth.
62529863|NCT05191303|NO_INTERVENTION|Control group|"The control group receives the standard usual care of breastfeeding counseling in maternity care and in hospital from weeks 18 of pregnancy, continuing for up to 6 months after childbirth.~The standard usual care of breastfeeding follows the 10 steps of the Baby Friendly Hospital Initiative programme and Finnish Institute for Health and Welfare recommendation."
62529864|NCT01007942|EXPERIMENTAL|Everolimus + vinorelbine + trastuzumab|Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
62155977|NCT01868555|EXPERIMENTAL|insulin degludec (B)|
62155978|NCT01868555|EXPERIMENTAL|insulin degludec (E)|
62155979|NCT04894136||ICSI-TESE cycles for obstructive azoospermia|Couples who underwent ICSI-TESE cycles for obstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
62529865|NCT01007942|PLACEBO_COMPARATOR|placebo + vinorelbine + trastuzumab|Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only
62155980|NCT04894136||ICSI-TESE cycles for nonobstructive azoospermia|Couples who underwent ICSI-TESE cycles for nonobstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
62155981|NCT01255267||Acute coronary syndrome patients|
62155982|NCT01255267||Chronic coronary artery disease patients|
62155983|NCT01255267||Healthy control|
62529866|NCT02321735|OTHER|Long-Term Ovarian Cancer survivors|Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
62155984|NCT05415722|EXPERIMENTAL|Arm 1: TERN-501 1 mg|Orally administered.
62155985|NCT05415722|EXPERIMENTAL|Arm 2: TERN-501 3 mg|Orally administered.
62155986|NCT05415722|EXPERIMENTAL|Arm 3: TERN-501 6 mg|Orally administered.
62155987|NCT05415722|EXPERIMENTAL|Arm 4: TERN-501 3 mg + TERN-101 10 mg|Orally administered.
62155988|NCT05415722|EXPERIMENTAL|Arm 5: TERN-501 6 mg + TERN-101 10 mg|Orally administered.
62713991|NCT05714202|EXPERIMENTAL|Treatment Group A: TAR-200 + Cetrelimab|Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.
62155989|NCT05415722|EXPERIMENTAL|Arm 6:TERN-101 10 mg|Orally administered.
62155990|NCT05415722|PLACEBO_COMPARATOR|Arm 7: Matching placebo|Orally administered.
62155991|NCT03307356|EXPERIMENTAL|Uterine Transplantation|Women will undergo extensive medical and psychological screening. Five women that meet all inclusion and exclusion criteria will undergo ovarian stimulation, oocyte retrieval and will create embryos that will be stored for future use. Women will then undergo uterine transplantation from a donor. Following transplant women will be closely monitored for complications (including infection and rejection). If no complications arise, or complications that do arise can be treated, attempts at pregnancy will begin approximately 6 months after transplant. Pregnancy in the setting of uterine transplant requires directly placing embryos directly into the uterus.
62155992|NCT01714479|PLACEBO_COMPARATOR|Load Carriage - Control|Load Carriage - with a calorie-free placebo
62155993|NCT01714479|EXPERIMENTAL|Load Carriage - leucine-enriched nutrition supplement|Load Carriage with leucine-enriched amino acid supplementation
62529867|NCT05043844|NO_INTERVENTION|Control|In the control group, an investigator performed only a pulmonary recruitment maneuver on the Trendelenburg position before the emergence of anesthesia.
62529868|NCT05043844|EXPERIMENTAL|Abdominal binder|In the abdominal binder group, a pulmonary recruitment maneuver was performed on the Trendelenburg position and the abdominal binder which had a standard height of 22 cm was placed on the abdomen of the patient before the emergence of anesthesia.
62529869|NCT05590832|EXPERIMENTAL|İnitiative group|"All pregnant women participating in the study were divided into intervention and control groups by applying randomization. Pre-test data of both groups will be collected before 18th gestational week, and post-test data will be collected after 37th gestational week.~Pregnant women assigned to the initiative group were added to a group established via Whatsapp. Information messages will be sent via Whatsapp on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks. When necessary, individual messages will be sent to the pregnant women and special directions will be given according to their weight gain rates."
62529870|NCT05590832|NO_INTERVENTION|Control group|In the same way, a Whatsapp group will be set up to the control group and messages will be sent once a month about the subjects included in antenatal care up to 37 weeks. Topics included in routine maintenance will be included.
62155994|NCT01714479|PLACEBO_COMPARATOR|Conventional Exercise - Control|Conventional Exercise with a calorie-free placebo
62155995|NCT01714479|ACTIVE_COMPARATOR|Conventional Exercise - Leucine-enriched Nutrition Supplement|Conventional Exercise with leucine-enriched Amino Acid supplementation
62529871|NCT02835781||Acellular dermal matrix arm|The females undergoing breast reconstruction surgery after breast removal because of breast cancer. The breast reconstruction will be performed using acellular dermal matrix implantation.
62529872|NCT05898321|EXPERIMENTAL|GnRHa group|Patients with fibroid remained will be enrolled and one third of them will be administrated with Zoladex (3.60mg/28 days) for three to six months,.
62155996|NCT04387773|EXPERIMENTAL|GOCOVRI Treatment|All participants will have gait, balance, dyskinesia assessed before and after receiving GOCOVRI (274 mg/day).
62155997|NCT03410680|NO_INTERVENTION|Control arm|Patients will receive the standard of care at the clinic. Questionnaires will be applied 4 times in a period of 10 months
62155998|NCT03410680|EXPERIMENTAL|Intervention arm|"Each participant will receive FUERTES for a period of 4 months. It consists of receiving a habit-formation kit, which include an information and habit-formation tool that can be accessed through a web platform, a mobile app and a booklet; b) pill cases; c) a fidget cube; and f) a notebook. Patients will have the option of contacting a MD though WhatsApp regarding questions related to their treatment.~After completing baseline a questionnaire, patients with a score of 2 for barriers that might affect their ART adherence will be assigned a coach. The coach will have 7 one-on-one sessions with the patient in a period of 4 months in order to catalyze ART adherence. MSM living with HIV who have been taking ART for \>3 years will provide a one-time one-on-one peer support session"
62155999|NCT05705245||recruitment|Patients who received alveolar recruitment manouever during bariatric surgery
62156000|NCT05705245||non recruitment|patients who did not receive alveolar recruitment manoeuver during bariatric surgery
62156001|NCT00630409|EXPERIMENTAL|Treatment|Patients will receive 3 cycles of therapy as an outpatient. Each 21-day cycle of therapy will comprise: Gemcitabine: IV on days 1 and 8. Doxil: on day 1. Patients with either responding or stable disease will continue to receive additional 3 cycles of therapy with gemcitabine and Doxil until there is radiological evidence of disease progression or they are unable or unwilling to continue treatment.
62156002|NCT03448302||Patients with colorectal adenocarcinoma|The patients will undergo computed tomography perfusion
62156003|NCT04409132|EXPERIMENTAL|Triferic AVNU infusion pre-dialyzer|Patients will receive one (1) 6.75 mg Fe dose of Triferic AVNU by continuous infusion over 3 hours into the predialyzer blood line.
62156004|NCT04409132|EXPERIMENTAL|Triferic AVNU for injection at T=0 and T= 3 hours|Patients will receive two (2) doses of Triferic AVNU 3.4 mg IV (2.25 mL) at T=0 and T=3 hours of hemodialysis into the venous drip chamber.
62156005|NCT04409132|EXPERIMENTAL|Triferic AVNU for injection at T=0|Patients will receive one (1) dose of Triferic AVNU 0.08 mg/kg IV, up to 6.75 mg Fe, at T=0 of hemodialysis into the venous drip chamber.
62529873|NCT05898321|EXPERIMENTAL|mifepristone group|Patients with fibroid remained will be enrolled and one third of them will be administrated with mifepristone(10.0mg/d) for three to six months.
62529874|NCT05898321|NO_INTERVENTION|control group|Patients with fibroid remained will be enrolled and the third group was serviced as controls and no drugs will be used.
62529875|NCT04719520|NO_INTERVENTION|traditional method|radio and telephone to notify the patient's family to the operating room
62529876|NCT04719520|EXPERIMENTAL|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
62529877|NCT01599065||Magnet|group treated by disabling ICD during procedure
62529878|NCT01599065||Off-On|Group having ICD turned off during the procedure
62529879|NCT04258475|EXPERIMENTAL|Raltegravir-Calcium PK measure|"Period 1: Raltegravir 1200 mg alone; Period 2: Calcium carbonate antacid 500 mg and 1200 mg of raltegravir given concomitantly; Period 3: two tablets of calcium carbonate antacid 500 mg and 1200 mg of raltegravir given concomitantly.~Patients will have a total of 8 visits during the study. Day 1 visit: Raltegravir 1200 mg oral daily until day 7. Day 7 visit: Timed serial phlebotomy before dosing t(0) and 0.5, 1, 1.5, 2, 3, 4, 6 hours after observed dosing.~Day 8 visit: 24 h PK sampling followed by Raltegravir 1200 mg + Calcium carbonate 500 mg oral daily until day 14.~Day 14 visit: Timed serial phlebotomy before dosing t(0) and 0.5, 1, 1.5, 2, 3, 4, 6 hours after observed dosing.~Day 15 visit: 24 h PK Sampling followed by Raltegravir 1200 mg + Calcium carbonate 1000 mg oral daily until day 21.~Day 21 visit: Timed serial phlebotomy before dosing t(0) and 0.5, 1, 1.5, 2, 3, 4, 6 hours after observed dosing.~Day 22 visit: 24 h PK Sampling. Day 51 visit: Final safety visit."
62529880|NCT05916261|EXPERIMENTAL|Personalized neoantigen vaccine or neoantigen tumor vaccine + Pembrolizumab|In dose escalation phase, subject will only receive personalized neoantigen tumor vaccine. In dose expansion phase, subject will receive personalized neoantigen tumor vaccine combination with Pembrolizumab .
62529881|NCT04193306|EXPERIMENTAL|Alirocumab|alirocumab 150 mg s.c. every 2 weeks, for 48 weeks
62529882|NCT04193306|PLACEBO_COMPARATOR|Placebo|placebo s.c. every 2 weeks, for 48 weeks
62156006|NCT04409132|EXPERIMENTAL|Triferic AVNU for injection at T=0, T=1.5 and T= 3 hours|Patients will receive three (3) doses of Triferic AVNU 2.25 mg Fe (1.5 mL) at T=0, T=1.5 and T=3.0 hours of hemodialysis into the venous drip chamber.
62156007|NCT01794234||Cohort|
62529883|NCT02984618|EXPERIMENTAL|Treatment group|Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
62529884|NCT02984618|ACTIVE_COMPARATOR|Control group|Patients will receive classic epidural blood patch with 20ml of autologous blood
62156008|NCT02443532|EXPERIMENTAL|Structured Group education|Six weekly interactive group sessions of 4 hours each, providing information and developing skills for diabetes self-management, including eating habits, food composition, calculation of bolus insulin, information on physical exercise, blood glucose self-monitoring, management of hypoglycemia.
62156009|NCT02443532|OTHER|Individual education|Usual care (individual consultations as routinely performed)
62156010|NCT05567029|EXPERIMENTAL|Risankizumab Dose A|Participants will receive subcutaneous dose of risankizumab dose A.
62156011|NCT05567029|EXPERIMENTAL|Risankizumab Dose B|Participants will receive subcutaneous dose of risankizumab dose B.
62529885|NCT04215848|EXPERIMENTAL|As-needed Budesonide/Formoterol|As-needed Budesonide/Formoterol (160/4.5 ug)
62529886|NCT04215848|ACTIVE_COMPARATOR|Budesonide|Budesonide (200 ug) twice daily
62529887|NCT02447796|ACTIVE_COMPARATOR|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
62156012|NCT05396573|EXPERIMENTAL|RQ3013|
62156013|NCT05396573|ACTIVE_COMPARATOR|Comirnaty|
62156014|NCT04917601|EXPERIMENTAL|Evira Care treatment|"The intervention arm will receive Evira Care in combination with Standard Lifestyle Care. If the standard treatment, after the first month of treatment, contains more frequent visits than every third month, the number of standard visits shall be reduced to a maximum of one visit every third month. During the first 2-4 weeks, participants will receive information about the system and how to utilize the daily weighings and communication system. The families will be informed about possible lifestyle changes that may be effective and that they are supposed to do lifestyle changes primarily regarding energy intake that they do consider feasible in their specific living situations.~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
62529888|NCT02447796|ACTIVE_COMPARATOR|Dexmedetomidine (DEX)|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
62529889|NCT04016961|EXPERIMENTAL|Animal Assisted Therapy - Dog Session|Therapy dog added to PT and OT session
62529890|NCT04016961|ACTIVE_COMPARATOR|Treatment as usual - No Dog session|No dog added to PT and OT session - PT and OT session as usual standard of care
62529891|NCT05213143|EXPERIMENTAL|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening.
62529892|NCT02390349|EXPERIMENTAL|CuraMed (BCM-95)|67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks
62529893|NCT02390349|EXPERIMENTAL|Curamin|67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks
62529894|NCT02390349|PLACEBO_COMPARATOR|Placebo|67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks
62529895|NCT01753466|EXPERIMENTAL|Hydration|Participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 L water per day, depending on sex and weight, in addition to usual consumed beverages, for 6 weeks
62529896|NCT01753466|NO_INTERVENTION|Control|
62529897|NCT04352387|EXPERIMENTAL|Montessori Method for Dementia|The design of the Montessori Method for Dementia program covered five aspects, namely cognitive stimulation, life skills, motor movements and fitness, sensory stimulation, and socialization. Each 1-hour session included two to three activities tailored to the local cultural context.
62529898|NCT04352387|ACTIVE_COMPARATOR|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
62529899|NCT02982798|EXPERIMENTAL|Group I|Period I: administration of Metformin + Rosuvastatin Period II: JLP-1310
62529900|NCT02982798|EXPERIMENTAL|Group II|Period I: JLP-1301 Period II: administration of Metformin + Rosuvastatin
62529901|NCT03449550|ACTIVE_COMPARATOR|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
62529902|NCT03449550|ACTIVE_COMPARATOR|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
62529903|NCT01738828||Subjects with CAD|
62529904|NCT01738828||Subjects without CAD|
62529905|NCT01921530|ACTIVE_COMPARATOR|Interbody Fusion|
62529906|NCT01921530|ACTIVE_COMPARATOR|Posterolateral Fusion|
62529907|NCT02357563|EXPERIMENTAL|Ulipristal acetate|Women will be treated with an oral dose of ulipristal acetate 5 mg/day for 2 courses of 3 months each
62529908|NCT02357563|ACTIVE_COMPARATOR|Leuprolile acetate|Women will be treated with an injection IM on leuprolide acetate 11,25 in the luteal phase repeated 3 months later
62529909|NCT05495828||Orelabrutinib|Patients with relapsed or refractory B-cell lymphoma (including r/rCLL/SLL, r/rMCL) intolerant to ibrutinib/zanubrutinib or other BTK inhibitors who have decided to receive Orelabrutinib therapy
62529910|NCT02721693|EXPERIMENTAL|Treadmill exercise test|Patients are subjected to an incremental Cardiopulmonary Exercise Test to exhaustion
62529911|NCT06367491||Patients with bone metastasis|All patients with bone metastasis
62529912|NCT04104854|EXPERIMENTAL|drug coated balloon|A total of 110 patients are assigned to drug coated balloon treated group after randomization schedule.
62529913|NCT04104854|NO_INTERVENTION|drug eluted stent implantation|A total of 110 patients are assigned to drug eluted stent treated group after randomization schedule.
62529914|NCT00954330|EXPERIMENTAL|surgery|All twenty-five patients underwent ligament repair, where the ruptured ends of the FTA (in 11 cases) or FTA and FC (in 14 cases) ligaments were rejoined by using absorbable sutures. A supine position and a tourniquet were used. A curvilinear skin incision of 5-10 cm was made; the retinacular structures were incised and the hematoma was removed.
62529915|NCT00954330|ACTIVE_COMPARATOR|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle
62156015|NCT04917601|ACTIVE_COMPARATOR|Standard Lifestyle Care|"The control group will receive the standard care of treatment for childhood obesity, which addresses lifestyles without any restriction in visits or clinical support.~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
62156016|NCT01410721|EXPERIMENTAL|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
62529916|NCT00686530||1|
62529917|NCT06436040||MPR(major pathological response)|defned as having no more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy
62156017|NCT01410721|ACTIVE_COMPARATOR|Cognitive Rehabilitation Control Arm|Baseline training and follow-up at two months and four months.
62156018|NCT01868607||Adult lung function|
62529918|NCT06436040||non-MPR|defned as having more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy
62156019|NCT02784834|EXPERIMENTAL|Dimethyl fumarate (DMF)|"Cohort 1: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 2 x 28 day cycles.~Cohort 2: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 1 week, then escalating to the assigned dose of (240mg PO BID for the remainder of 2 x 28 day cycles.~Cohort 3: dimethyl fumarate 120 mg PO BID for 1 week, then escalate to the dose of 360mg PO BID for the remainder of 2 x 28 day cycles."
62156020|NCT05541185|EXPERIMENTAL|Nigella sativa oil group|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
62529919|NCT06417736|EXPERIMENTAL|membrane-inhibiting formula combined with oral progestins|Megestrol acetate(160mg/day) and membrane-inhibiting formula, 24weeks
62529920|NCT05420974|EXPERIMENTAL|NIR fluorescence|The included patients will be subdivided in four equal subgroups in order to evaluate alteration of NIR fluorescence signal during arthroscopy in combination with a (temporary) tourniquet and irrigation pump system.
62529921|NCT04134806||Young Adults|Neurologically healthy young adults between ages 18 and 40
62529922|NCT04134806||Older Adults|Neurologically healthy older adults between ages 60 and 85
62529923|NCT04134806||Mild Cognitive Impairment/Mild Dementia|Older adults between ages 60 and 85 with Mild Cognitive Impairment or Mild Dementia
62529924|NCT03429517||Patients|ACS Lipogram
62529925|NCT03429517||Controls|Normal LDL-C level Lipogram
62529926|NCT01595386|PLACEBO_COMPARATOR|Normal Saline|The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
62529927|NCT01595386|EXPERIMENTAL|Hydrocortisone|Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
62529928|NCT00548951|ACTIVE_COMPARATOR|1|Subject receives Snoezelen sessions once per week.
62529929|NCT00548951|ACTIVE_COMPARATOR|2|Subject receives Snoezelen sessions three times per week.
62529930|NCT00548951|OTHER|3|Subject receives no sessions per week.
62529931|NCT03397771|EXPERIMENTAL|Litoxetine oral capsules|oral experimental study medication litoxetine
62156021|NCT05541185|EXPERIMENTAL|Naproxen and lidocaine gel group|1 ml of naproxen and lidocaine gel was applied to both knee areas of the naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
62156022|NCT05541185|PLACEBO_COMPARATOR|Massage group|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
62156023|NCT05689177|EXPERIMENTAL|Booster dose administration to younger participants|Participants 18-25 y.o. take a booster dose of vaccine against COVID-19 (Soberana Plus (FINLAY-FR-1A), Republic of Cuba)
62156024|NCT05689177|EXPERIMENTAL|Booster dose administration to older participants|Participants 26-80 y.o. take a booster dose of vaccine against COVID-19 (Soberana Plus (FINLAY-FR-1A) Republic of Cuba)
62156025|NCT06453759|EXPERIMENTAL|Thalamic SEEG|The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes.
62156026|NCT05174871|ACTIVE_COMPARATOR|Active control|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months
62529932|NCT03397771|PLACEBO_COMPARATOR|Placebo oral capsules|oral comparator
62529933|NCT01853930|OTHER|Laboratory training|Patients will be trained in the laboratory with feedback by a rehabilitation therapist
62529934|NCT01853930|OTHER|Home-based training|Patients will self instruct using the computer-based training with remote intervention by a therapist
62529935|NCT00703573|EXPERIMENTAL|Group A|S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
62529936|NCT00703573|EXPERIMENTAL|Group B|S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)
62529937|NCT00703573|PLACEBO_COMPARATOR|Group C|Placebo BID (four tablets of placebo BID)
62529938|NCT05641974|EXPERIMENTAL|Helpers Stay Quit Training|Research participants randomized to the experimental arm will receive the on-line Helpers Stay Quit training which provides training on how to help others quit smoking.
62529939|NCT05641974|NO_INTERVENTION|Usual Care|Research participants randomized to the arm without intervention will receive Quitline usual care. They will be contacted for assessment of abstinence at 7 months after enrollment in services. If the participant has relapsed, the Quitline will attempt to re-engage the participant in cessation services (telephone and/or web-based).
62529940|NCT03525925|EXPERIMENTAL|Treatment (ibrutinib, nivolumab)|Participants receive ibrutinib PO daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab IV over 60 minutes on days 1 and 15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.
62156027|NCT05174871|EXPERIMENTAL|Time-Restricted Feeding|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months. During this time, participants will have their feeding time restricted to 8 hours per day.
62156028|NCT03493906|EXPERIMENTAL|Intervention|Patient Ambassador Support
62529941|NCT02716727|ACTIVE_COMPARATOR|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
62156029|NCT01709045||Patients scheduled for CEA|All patients who are scheduled for carotid endarterectomy (CEA)
62529942|NCT02716727|ACTIVE_COMPARATOR|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
62529943|NCT03791710|PLACEBO_COMPARATOR|control group|this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
62529944|NCT03791710|ACTIVE_COMPARATOR|fat grafting group|this group of patients will have the autologous fat grafting for their burn wounds
62529945|NCT01945073|NO_INTERVENTION|Control (RC)|Routine clinical care with no intervention
62529946|NCT01945073|EXPERIMENTAL|Educational Booklet (BK)|Routine clinical care and educational booklet (BK) given
62529947|NCT01945073|EXPERIMENTAL|Educational Booklet and Counselling (CB)|Routine clinical care, aided by formal counselling and active discussions from the educational booklet (CB)
62529948|NCT00589329|EXPERIMENTAL|A|"roup A will be assigned to receive antibiotics:~* Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~* Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days."
62529949|NCT00589329|PLACEBO_COMPARATOR|B|Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
62529950|NCT06084962|EXPERIMENTAL|Administration of DeepTag-GPRC5D Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62529951|NCT00915928|ACTIVE_COMPARATOR|ACE inhibitor|patients randomized to this arm will be treated with ACE inhibitors after surgery
62529952|NCT00915928|PLACEBO_COMPARATOR|Placebo|patients randomized to this arm will be treated with placebo after surgery
62529953|NCT05068089||Nissen fundoplication surgery and Enteral nutrition|The cohort population retrospectively enrolled in the study is represented by pediatric patients with severe motor and intellectual disabilities (with progressive e non- progressive neurological disease) followed-up at Nutrition Unit of Ospedale Pediatrico Bambino Gesù between January 2009 to January 2020.
62529954|NCT01026181||LSG|Laparoscopic Sleeve Gastrectomy
62156030|NCT04397185|EXPERIMENTAL|Breast Cancer Locator (BCL)|Subject randomized to BCL surgical guidance to perform partial mastectomy
62156031|NCT04397185|ACTIVE_COMPARATOR|Wire Localization (WL)|Subject randomized to WL surgical guidance to perform partial mastectomy
62156032|NCT04930263|EXPERIMENTAL|Aerobic exercise|"Behavioral: walking exercise~1. The intervention was 24 weeks walking intervention program with moderate-intensity, 5 sessions a week for 30 minutes per section~2. individualized education~3. telephone and social media counselling~4. booklet guidance"
62156033|NCT04930263|ACTIVE_COMPARATOR|control group|Given routine care and life health manual for the participants.
62156034|NCT01411605|EXPERIMENTAL|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
62529955|NCT01026181||LRYGB|Laparoscopic Roux-en-Y Gastric Bypass
62529956|NCT01026181||LAGB|Laparoscopic Adjustable Gastric Banding
62529957|NCT06289153|EXPERIMENTAL|Internal Brace|Patients will undergo ACL Reconstruction (ACLR) with an internal brace. At 6 months post-operation patients will fill out clinical outcome surveys. At the routine 1 year postoperative visit, all patients will fill out clinical outcome surveys and undergo MRI evaluation of the knee.
62529958|NCT06289153|ACTIVE_COMPARATOR|Standard ACLR|Patients will undergo ACLR without an internal brace. At 6 months post-operation patients will fill out clinical outcome surveys. At the routine 1 year postoperative visit, all patients will fill out clinical outcome surveys and undergo MRI evaluation of the knee.
62529959|NCT03810755|OTHER|Control group|Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
62529960|NCT03810755|OTHER|Supervision group|Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
62529961|NCT04022928|EXPERIMENTAL|PRP injection|Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
62529962|NCT01672112|OTHER|Codeine|Oral Codeine 60mg 6hrly/prn
62529963|NCT01672112|ACTIVE_COMPARATOR|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
62529964|NCT04585165||Risk of HIV acquisition|Individuals reporting behavioral risk of HIV acquisition.
62529965|NCT06030219|EXPERIMENTAL|Omadacycline|Subjects will receive 3 tablets on day 1 and day 2 (450 mg) followed by 2 tablets (300 mg) for days 3 through 10.
62156035|NCT03687554|EXPERIMENTAL|Venglustat|Single dose of Venglustat is given, orally under fasting conditions
62156036|NCT02400645|ACTIVE_COMPARATOR|Group A: pre-incisional bupivacaine|Intervention: Pre-incisional wound infiltration with bupivacaine plain 0.25%. Ketorolac 30mg IV will be given following surgical procedure.
62156037|NCT02400645|ACTIVE_COMPARATOR|Group B: laparoscope to place TAP block|Intervention: laparoscope to place TAP block with liposomal bupivacaine and bupivacaine plain 0.25%. Ketorolac 30 mg IV will be given following surgical procedure.
62529966|NCT06030219|ACTIVE_COMPARATOR|Vancomycin (oral)|Vancomycin 125 mg capsules will be taken four times daily for a total of 10 days.
62529967|NCT06030219|ACTIVE_COMPARATOR|Moxifloxacin|Moxifloxacin 400 mg tablets will be taken once per day for a total of 10 days.
62539549|NCT05180201|EXPERIMENTAL|LP1+FOS|Once daily oral administration of L. plantarum ATCC 202195 (10\^9 CFU/day) with 150mg FOS and 100mg maltodextrin, for one day, followed by 6 days of placebo (250mg maltodextrin).
62529968|NCT03484117|NO_INTERVENTION|Treatment as Usual|Participants in this arm will receive bilingual written materials on healthy living with HIV at the baseline visit. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants.
62529969|NCT03484117|EXPERIMENTAL|Community Health Worker|Participants in the intervention arm will receive 5 one-on-one sessions over 24 weeks with a Spanish-speaking CHW. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants
62156038|NCT04135183|EXPERIMENTAL|Comprehensive evaluation group|The effectiveness of initial treatment and the next treatment plan were determined based on the CAP guidelines of Chinese Thoracic Society (CTS) or Infectious Diseases Society of America/American Thoracic Society(IDSA/ATS). The evaluation process was independently evaluated and documented by at least two clinicians. In case of disagreement, the final determination shall vote on the majority of votes.
62156039|NCT04135183|EXPERIMENTAL|PSI evaluation group|The changes of PSI scores and serum CRP were used to evaluate the therapeutic effects. If both PSI scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of PSI scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both PSI scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
62156040|NCT04135183|EXPERIMENTAL|Expand-CURB evaluation group|The changes of Expand-CURB scores and serum CRP were used to evaluate the therapeutic effects. If both Expand-CURB scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of Expand-CURB scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both Expand-CURB scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
62156041|NCT04135183|NO_INTERVENTION|Prospective observational group|Patients' Expand-CURB scores, PSI scores and serum CRP before and after 3-5 days of initial treatment will be recorded. And the initial treatment, whether the initial treatment was changed 3-5 days of initial treatment and the final outcomes (ICU admission, 30-day mortality, average length of stay) will be recorded.
62156042|NCT04722471||400 mg|Treatments where 400 mg tablet presentation of micronized vaginal progesterone was used, the protocol being one vaginal tablet twice a day.
62156043|NCT04722471||200 mg|Treatments where 200 mg tablet presentation of micronized vaginal progesterone was used, the protocol being two vaginal tablets twice a day.
62156044|NCT01330745|OTHER|aortic valve replacement|
62529970|NCT02838654||cervical epidural injection group|cervical epidural injection group
62529971|NCT01020136|EXPERIMENTAL|Sequence 1 (BABA)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -\> A -\> B -\> A
62529972|NCT01020136|EXPERIMENTAL|Sequence 2 (ABAB)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -\> B-\> A -\> B
62529973|NCT02831647|EXPERIMENTAL|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PRAGUE for a period of 9 days.
62529974|NCT05404607|EXPERIMENTAL|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive the fascial distortion method followed by the neuromuscular inhibition technique for trigger points. After this, neural mobilization will be given as stander treatment.
62529975|NCT05404607|ACTIVE_COMPARATOR|Fascial distortion method|Fascial distortion will be applied to 27 participants where the tip of the thumb worms its way through the peripheral tissue until it rests on the distortion. Force is focused directly on the most painful spot until the provider feels like a button-slipping-into-a-buttonhole. After this, neural mobilization will be given as a stander treatment.
62529976|NCT01325181|ACTIVE_COMPARATOR|Low-fluence PDT with Verteporfin|Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
62529977|NCT01325181|ACTIVE_COMPARATOR|Ranibizumab|Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered
62529978|NCT01159197|EXPERIMENTAL|cognitive behaviorial therapy|
62529979|NCT05808218|EXPERIMENTAL|CLTS|This arm will receive a standard community-led total sanitation) intervention).
62529980|NCT05808218|EXPERIMENTAL|CLTS Plus|Includes all activities in the CLTS arm with the addition of village-level Care Groups for sanitation and hygiene promotion.
62529981|NCT05808218|NO_INTERVENTION|Control|
62529982|NCT02302547|ACTIVE_COMPARATOR|triple therapy|Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).
62529983|NCT02302547|EXPERIMENTAL|dual therapy|"Truvada®245mg:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)"
62529984|NCT04236726||Non-invasive ventilation|Users of non-invasive ventilation
62529985|NCT04236726||Long term tracheostomy ventilation|Long term tracheostomy ventilated patients
62529986|NCT00459121|EXPERIMENTAL|Zactima, Paclitaxel, Carboplatin|"Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.~Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
62529987|NCT02034058|OTHER|Wingspan Stent System|Placement of the Wingspan Stent
62529988|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule A: 0.2 mg BI 894999|Once daily continuous oral intake in 3-week cycles.
62529989|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule A: 0.5 mg BI 894999|Once daily continuous oral intake in 3-week cycles.
62156045|NCT03095261|EXPERIMENTAL|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
62529990|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule A: 1 mg BI 894999|Once daily continuous oral intake in 3-week cycles.
62156046|NCT03095261|ACTIVE_COMPARATOR|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
62156047|NCT03067870|EXPERIMENTAL|Stem Cells|Autologous bone marrow-derived stem cell transplantation.
62156048|NCT03263117|ACTIVE_COMPARATOR|Sedation|The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.
62156049|NCT03263117|ACTIVE_COMPARATOR|General Anesthesia|The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.
62156050|NCT01992497|PLACEBO_COMPARATOR|Formula + placebo|
62156051|NCT01992497|EXPERIMENTAL|Formula + probiotic|Formula + probiotic
62156052|NCT01992497|EXPERIMENTAL|Breastfed + probiotic|Breastfed + probiotic
62156053|NCT01992497|PLACEBO_COMPARATOR|Breastfed + placebo|
62156054|NCT02255006|EXPERIMENTAL|active acupuncture|The participants in this group receive real acupuncture treatment at first. Afterwards crossover study is scheduled to be performed.
62156055|NCT02255006|SHAM_COMPARATOR|Sham acupuncture|The participants in this group receive sham acupuncture treatment at first. afterwards crossover study is scheduled to be performed
62156056|NCT02255006|EXPERIMENTAL|Euglycon|Glibenclamide (Euglucon, Roche Pharma) is administered 3 hours before FMD measurement.
62156057|NCT02255006|EXPERIMENTAL|Celebrex|Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.
62156058|NCT05976672|NO_INTERVENTION|Treatment as usual|Participants will receive standard of care treatment as usual and will receive no contact from a peer recover support specialist (PRSS intervention) when data anomalies are detected by machine learning algorithms.
62529991|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule A: 1.5 mg BI 894999|Once daily continuous oral intake in 3-week cycles.
62529992|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule A: 2 mg BI 894999|Once daily continuous oral intake in 3-week cycles.
62529993|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule A: 5 mg BI 894999|Once daily continuous oral intake in 3-week cycles.
62529994|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule B: 1.5 mg BI 894999|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62529995|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule B: 2 mg BI 894999|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62529996|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule B: 2.5 mg BI 894999|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62529997|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule C: 5/2.5 mg BI 894999|Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.
62156059|NCT05976672|EXPERIMENTAL|PRSS intervention|Participants receiving PRSS intervention will be contacted by the PRSS who will be blinded (not knowing whether an alert was caused by data anomaly or a random generation), and will contact the participant by phone and assess the need for assistance. PRSS will follow-up with the participant to assist participant if needed (once after the initial alert and then a second follow-up).
62156060|NCT03060356|ACTIVE_COMPARATOR|Melanoma|Intravenous infusion 1x10\^8 total T cells modified with RNA anti-cMET CAR
62156061|NCT03060356|ACTIVE_COMPARATOR|Breast|Intravenous infusion 1x10\^8 total T cells modified with RNA anti-cMET CAR
62156062|NCT00674609|PLACEBO_COMPARATOR|Placebo|Placebo control
62156063|NCT00674609|EXPERIMENTAL|Sativex|Active treatment
62156064|NCT00674609|EXPERIMENTAL|THC Alone|Active treatment
62156065|NCT05771402|EXPERIMENTAL|Group 1|NAs combined with anti-PD-1 antibody and Peg-IFNα
62156066|NCT05771402|ACTIVE_COMPARATOR|Group 2|NAs combined with Peg-IFNα
62156067|NCT01101633|ACTIVE_COMPARATOR|1|500 ml beverage containing alginate (3%)
62156068|NCT01101633|ACTIVE_COMPARATOR|2|330 ml beverage containing alginate (3%)
62156069|NCT01101633|PLACEBO_COMPARATOR|3|500 ml beverage without alginate (placebo)
62156070|NCT01101633|PLACEBO_COMPARATOR|4|330 ml beverage without alginate (placebo)
62529998|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule C: 6/3 mg BI 894999|Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.
62529999|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule C: 7/3.5 mg BI 894999|Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.
62530000|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule B: 1.5 mg BI 894999 (DLBCL patients)|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62530001|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule B: 2 mg BI 894999 (DLBCL patients)|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62530002|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule B: 2.5 mg BI 894999 (DLBCL patients)|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62530003|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule C: 4/2 mg BI 894999 (DLBCL patients)|Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.
62156071|NCT01164319|ACTIVE_COMPARATOR|Group 1 (no early recurrence)|Patients without atrial fibrillation recurrences through the implantable cardiac monitors during the 3 months post-ablation period.
62530004|NCT02516553|EXPERIMENTAL|Phase Ia - Schedule C: BI 894999 5/2.5 mg (DLBCL patients)|Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.
62530005|NCT02516553|EXPERIMENTAL|Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (SCLC patients)|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62530006|NCT02516553|EXPERIMENTAL|Phase Ib - Schedule B: 2.5 mg BI 894999 (CRC patients)|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62530007|NCT02516553|EXPERIMENTAL|Phase Ib - Schedule B: 2 or 2.5 mg BI 894999 (mCRPC patients)|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62530008|NCT02516553|EXPERIMENTAL|Phase Ib - Schedule B: 2.5 mg BI 894999 (NC patients)|Once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles.
62530009|NCT02516553|EXPERIMENTAL|Phase Ib - Schedule C: 6/3 or 7/3.5 mg BI 894999 (NC patients)|Once daily loading dose on Day 1 followed by six days daily intake of maintenance dose, followed by one week off, repeated every two weeks in cycles of 28 days.
62530010|NCT04842565|EXPERIMENTAL|TACE+Sintilimab|
62156072|NCT01164319|ACTIVE_COMPARATOR|Group 2 (early AF recurrence)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period.
62156073|NCT01164319|ACTIVE_COMPARATOR|Group 3 (early recurrence-no reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 would not receive reablation.
62156074|NCT01164319|ACTIVE_COMPARATOR|Group 4 (early recurrence-early reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 will receive early reablation based on data stored by implanted monitor.
62156075|NCT05353725||COVID-19 ARDS|Patients with COVID-19 ARDS on veno-venous ECMO (vvECMO)
62156076|NCT05353725||Influenza ARDS|Patients with Influenza ARDS on vvECMO
62156077|NCT05353725||ARDS of Other Ethiologies|Patients with ARDS of Other Ethiologies on vvECMO
62156078|NCT02213094|EXPERIMENTAL|Nicotinamide 500 mg|Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
62530011|NCT02641197|EXPERIMENTAL|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after brachial artery occlusion by a standard upper arm pneumatic blood pressure cuff. The procedure is non-invasive and does not employ ultrasound.
62530012|NCT02898753|EXPERIMENTAL|VAL-1221 3 mg/kg|"Part 1: Participants will receive VAL-1221 3 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 3 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 3 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 10 mg/kg and further to 30 mg/kg (after at least 12 weeks of dosing at 10 mg/kg), depending upon the pharmacodynamics, efficacy, and safety data."
62713992|NCT05714202|ACTIVE_COMPARATOR|Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture|Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance).
62156079|NCT02213094|EXPERIMENTAL|Nicotinamide 1000 mg|Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
62530013|NCT02898753|EXPERIMENTAL|VAL-1221 10 mg/kg|"Part 1: Participants will receive VAL-1221 10 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 10 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 10 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 30 mg/kg IV infusion, depending upon the pharmacodynamics, efficacy, and safety data."
62156080|NCT03057197|NO_INTERVENTION|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
62530014|NCT02898753|EXPERIMENTAL|VAL-1221 30 mg/kg|"Part 1: Participants will receive VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 30 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 30 mg/kg IV inufsion every other week."
62530015|NCT02898753|ACTIVE_COMPARATOR|rhGAA|"Part 1: Participants will be maintained on their current dose and regimen of Myozyme or Lumizyme.~Part 2: Participants from Part 1 of the study who were randomized to rhGAA can enter Part 2 of the study and receive VAL-1221 either 3 mg/kg, 10 mg/kg, or 30 mg/kg (based on the dose of VAL-1221 in respective cohorts to which they were randomized in Part 1) IV infusion every other week."
62530016|NCT03663439|EXPERIMENTAL|modified shell technique|block of bone from the mandibular ramus divided into two shells ,grafting one shell in the anterior maxilla to increase width
62713993|NCT05714202|EXPERIMENTAL|Treatment Group C: TAR-200 Alone|Participants will receive intravesical TAR-200 alone once Q3W.
62713994|NCT03401320|EXPERIMENTAL|Cohort 1: Letrozole ISM 50 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 50 mg Letrozole ISM
62156081|NCT03057197|EXPERIMENTAL|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
62156082|NCT04118998|EXPERIMENTAL|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
62156083|NCT04118998|ACTIVE_COMPARATOR|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
62156084|NCT02547974|EXPERIMENTAL|GSK3277513A F1 Group|Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
62530017|NCT03663439|ACTIVE_COMPARATOR|onlay bone graft|grafting block of bone from the mandibular ramus in the atrophic anterior maxilla
62530018|NCT05966675|EXPERIMENTAL|Conduction System Pacing|Patients who receive Conduction System Pacing in form of Left Bundle Branch Area Pacing or His Bundle Pacing.
62530019|NCT05966675|ACTIVE_COMPARATOR|Standard Pacing Method|Patients who receive currently standard pacing method with exact type of ventricular pacing depending upon left ventricular ejection fraction (LVEF): right ventricular pacing in case of LVEF \>= 40% or biventricular pacing if LVEF is determined to be less than 40%, as per current ESC guidelines.
62530020|NCT02160275|ACTIVE_COMPARATOR|Open Loop|4 days patient-managed insulin pump therapy with blinded continuous glucose monitoring
62530021|NCT02160275|EXPERIMENTAL|Closed Loop|4 days of automated blood glucose control with the Artificial Pancreas (Inreda Diabetic BV)
62530022|NCT01229735|EXPERIMENTAL|Levetiracetam|250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
62530023|NCT01229735|ACTIVE_COMPARATOR|Topiramate|25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks
62530024|NCT03589586|EXPERIMENTAL|DermACELL AWM + Conventional Care|DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.
62530025|NCT03589586|NO_INTERVENTION|Conventional Care|Conventional wound care will include advanced wound dressings and multilayer compression.
62530026|NCT01163630|EXPERIMENTAL|1|esomeprazole 20mg/ASA 81 mg FDC after a 10-hour fast
62530027|NCT01163630|EXPERIMENTAL|2|esomeprazole 20mg/ASA 81 mg FDC 30 minutes after start of a high-fat, high-calorie breakfast
62530028|NCT01262742|ACTIVE_COMPARATOR|Carbetocin 80mcg|
62530029|NCT01262742|ACTIVE_COMPARATOR|Carbetocin 90mcg|
62530030|NCT01262742|ACTIVE_COMPARATOR|Carbetocin 100mcg|
62530031|NCT01262742|ACTIVE_COMPARATOR|Carbetocin 110mcg|
62530032|NCT01262742|ACTIVE_COMPARATOR|Carbetocin 120mcg|
62530033|NCT01049711||erythropoietin|
62530034|NCT03659526||Control|Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
62530035|NCT03659526||Deformation imaging|Significant coronary disease (diameter stenosis \>50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
62530036|NCT03659526||High p(CAD)|Intermediate-to-high probability of significant epicardial coronary disease (\>50%).
62530037|NCT03659526||All comers|Probability of severe disease ranging from 15 to 85%.
62530038|NCT00436904|EXPERIMENTAL|Alemtuzumab + Rituximab|Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
62530039|NCT04525235|ACTIVE_COMPARATOR|Rifampicin standard dose|rifampicin standard dose + phenotyping cocktail
62530040|NCT04525235|EXPERIMENTAL|Rifampicin high dose|rifampicin high dose + phenotyping cocktail
62530041|NCT04751539|EXPERIMENTAL|AND017 single dose escalation|Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.
62530042|NCT04751539|PLACEBO_COMPARATOR|AND017 repeated dose escalation|Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.
62530043|NCT04751539|PLACEBO_COMPARATOR|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
62530044|NCT03446911|ACTIVE_COMPARATOR|SABR|Patients receive prior to surgery (lobectomy) SABR.
62530045|NCT03446911|ACTIVE_COMPARATOR|SABR + pembrolizumab|Patients receive prior to surgery (lobectomy) SABR + 2 rounds of pembrolizumab
62530046|NCT02637921|ACTIVE_COMPARATOR|Hypoxic ambulatory|Participants ambulatory in normobaric hypoxia with standardised nutritional intake
62530047|NCT02637921|EXPERIMENTAL|Hypoxic Bed rest|Participants are on bed rest in normobaric hypoxia with standardised nutritional intake
62530048|NCT02637921|ACTIVE_COMPARATOR|Normoxic bed rest|Participants are on bed rest in normobaric normoxia with standardised nutritional intake
62713995|NCT03401320|EXPERIMENTAL|Cohort 2: Letrozole ISM 100 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 100 mg Letrozole ISM
62713996|NCT03401320|EXPERIMENTAL|Cohort 3: Letrozole ISM 200 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 200 mg Letrozole ISM
62530049|NCT01517659|EXPERIMENTAL|Fat Reduction|The Zeltiq CoolSculpting System will be used to treat subcutaneous fat on each inner thigh.
62530050|NCT01608386|EXPERIMENTAL|anterior approach+IVC clamping|Use anterior approach combined with infrahepatic Inferior Vena Cava clamping in right hepatectomy for HCC patients.
62530051|NCT01608386|NO_INTERVENTION|anterior approach|Only use anterior approach in right hepatectomy for HCC patients.
62530052|NCT04175535|OTHER|The experimental group|PPECD was performed in the experimental group
62530053|NCT04175535|OTHER|control group|ACDF was performed in the control group
62530054|NCT02620150|EXPERIMENTAL|Experimental|CCBT plus Escitalopram, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
62530055|NCT02620150|PLACEBO_COMPARATOR|Placebo|CCBT plus Placebo, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
62530056|NCT02188511|EXPERIMENTAL|Group A|Electronic cigarette (nicotine/placebo) - Day 8 Intervention: Electronic cigarette exposure will be limited to one day.
62530057|NCT02188511|EXPERIMENTAL|Group B|Electronic cigarette (nicotine/placebo) - Days 7 through 8 Electronic cigarette exposure will be limited to two days
62530058|NCT02188511|EXPERIMENTAL|Group C|Electronic cigarette (nicotine/placebo) - Days 6 through 8 Electronic cigarette exposure will be limited to 3 days
62530059|NCT02188511|EXPERIMENTAL|Group D|Electronic cigarette (nicotine/placebo) - Days 5 through 8 Electronic cigarette exposure will be limited to 4 days
62530060|NCT02188511|EXPERIMENTAL|Group E|Electronic cigarette (nicotine/placebo) - Days 4 through 8 Electronic cigarette exposure will be limited to 5 days.
62530061|NCT04023643|EXPERIMENTAL|CPAP + PS|Weaning from mechanical ventilation using CPAP + PS
62713997|NCT03401320|EXPERIMENTAL|Cohort 4: Letrozole ISM 400 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 400 mg Letrozole ISM
62530062|NCT04023643|ACTIVE_COMPARATOR|SIMV + PS|Weaning from mechanical ventilation using SIMV+PS
62530063|NCT06137690||Group A|the elderly group , the age ≥ 60 years
62530064|NCT06137690||Group B|the non-elderly group , the age \< 60 years
62530065|NCT03601650|EXPERIMENTAL|Mindful eating|Participants will be encouraged to focus on the sensory properties of their food every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to focus on the sensory properties of their food every time they eat.
62530066|NCT03601650|ACTIVE_COMPARATOR|Eating without distractions|Participants will be encouraged to eat their food without distractions every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to eat their food without distractions every time they eat.
62530067|NCT03601650|NO_INTERVENTION|No strategy control|Participants will simply complete the measures
62156085|NCT02547974|EXPERIMENTAL|GSK3277513A F2 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
62530068|NCT04573764|ACTIVE_COMPARATOR|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|
62530069|NCT04573764|PLACEBO_COMPARATOR|Placebo|
62156086|NCT02547974|EXPERIMENTAL|GSK3277513A F3 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
62530070|NCT03744663|ACTIVE_COMPARATOR|Suboxone® SL|Patients assigned to this group will continue with their already established dose of Suboxone ® SL films for 24 weeks along with weekly therapy.
62156087|NCT02547974|PLACEBO_COMPARATOR|Placebo Group|Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
62530071|NCT03744663|EXPERIMENTAL|Sublocade®|Patients assigned to the Sublocade® group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy.
62530072|NCT03627520|OTHER|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
62530073|NCT06445634|OTHER|Gatt combined with goinosynechiolysis in secondary synechial angle closure|Outcome of Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
62530074|NCT01058720|EXPERIMENTAL|Vitamin D3|Patients would receive 2000 IU of vitamin D3 daily for 12 weeks
62530075|NCT04164914|EXPERIMENTAL|Healthy subjects|Prebiotic administration
62530076|NCT03954509||semi-structured interview|"Screening and inclusion of patients hospitalized or seen in day hospital to conduct semi-structured interviews according to the interview grid. This interview schedule was established after review of the literature and identification of primary and secondary objectives.~* Identification of key ideas through content analysis of the interviews conducted and based of the anchored theory.~* This step is performed until the results are saturated (approximately 15 patients). The principle of saturation is based on the fact that from a threshold, the diversity of the elements collected decreases. Much more than an end signal, this principle is a methodological guarantee since it allows the possibility of comparing divergent or contradictory data and thus validating the data."
62530077|NCT03954509||questionnaires|"* From the previous results: elaboration of a written questionnaire built according to the results obtained thanks to the previous interviews. In order to apply the simple correspondence factor analysis method, this questionnaire will be constructed on a Likert scale. The objective is twofold:~  1. to reduce the observer's bias by considering both the literature reviews but also the points of view of patients to develop the questionnaire;~ 2. reach a larger patient population (more than 100 patients) compared to the previous qualitative analysis (15 patients planned), in order to generalize the results. This methodology combines both qualitative and quantitative study to minimize bias induced by both types of study.~* Dissemination of the questionnaire and filling by the patient independently. The health professional who submitted the questionnaire will remain available to answer any questions the patient may have."
62530078|NCT01264731|ACTIVE_COMPARATOR|peptide vaccine plus imiquimod|Peptide Vaccine: Days 1, 8, 15, 36, 57, 78 Imiquimod: Applied daily on days 1-85.
62530079|NCT01264731|ACTIVE_COMPARATOR|Imiquimod|Imiquimod: Applied daily on days 1-85.
62530080|NCT00184353||brain metastases|6 patients
62156088|NCT04429672|EXPERIMENTAL|Experimental Group (EG)|"The participants of the Experimental Group receive as treatment the intervention called The Right to your Sexual Health, which is socio-educational and is composed of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Conduct and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of the opening, development and closing phase established in a manual for the facilitator, it should be noted that the intervention is applied by a multidisciplinary team in which the areas of medicine, nursing and psychology participate. In addition, Information and Communication Technologies (ICTs) are used through a Moodle platform that has available to participants digital support material as digital presentations on each of the thematic axes, as well as audiovisual material through the Podcast format of conversations concerning each of the axes."
62530081|NCT00184353||healthy|13 volunteers
62713998|NCT03261830|ACTIVE_COMPARATOR|Pre-operative Antibiotics|Patients randomized to preoperative antibiotics will receive 25mg/kg cefazolin IV up to 1g or clindamycin 10mg/kg up to 600mg IV in cases of documented allergy to cefazolin.
62530082|NCT02935205|EXPERIMENTAL|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62530083|NCT04310813||Endoscopic urologic patients|Patients with bladder cancer or benign prostate hyperplasia undergoing urologic endoscopic procedures.
62530084|NCT06303037|EXPERIMENTAL|Group L|Low-dose esketamine
62530085|NCT06303037|EXPERIMENTAL|Group M|Medium dose esketamine
62530086|NCT00000408|EXPERIMENTAL|email discussion group|
62530087|NCT00000408|NO_INTERVENTION|rancomized control group|usual care
62530088|NCT05217706|EXPERIMENTAL|Treatment|This group will be given ketamine 0.2mg/kg
62530089|NCT05217706|PLACEBO_COMPARATOR|Placebo|This group will be given normal saline in matched syringe
62530090|NCT04461561|EXPERIMENTAL|ELNEC-PPC WBT pluss usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
62530091|NCT04461561|NO_INTERVENTION|Usual care only|Participants nurses deliver usual care as his/her role appropriate to neonates, infants, toddlers, preschoolers, school age, also to adolescents in selected unit of perinatal, neonatal, and settings which can be pediatric.
62530092|NCT00039026|EXPERIMENTAL|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
62530093|NCT00039026|EXPERIMENTAL|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
62530094|NCT00039026|PLACEBO_COMPARATOR|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
62530095|NCT00039026|PLACEBO_COMPARATOR|Placebo 0.04 mL|Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL
62530096|NCT03822065|EXPERIMENTAL|Sequence 1: LY03005 Fed Crossover to Fasted|Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.
62530097|NCT03822065|EXPERIMENTAL|Sequence 2: LY03005 Fasted Crossover to Fed|Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.
62530098|NCT02926430|EXPERIMENTAL|Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1|Participants will receive 5\*10\^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
62530099|NCT02926430|EXPERIMENTAL|Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2|Participants will receive 5\*10\^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
62530100|NCT02926430|EXPERIMENTAL|Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3|Participants will receive 1\*10\^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
62530101|NCT02926430|EXPERIMENTAL|Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4|Participants will receive 1\*10\^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
62530102|NCT02926430|EXPERIMENTAL|Placebo (Day 1 and Day 365): Group 5|Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
62530103|NCT01211418|EXPERIMENTAL|Integrative Meditation|
62530104|NCT01211418|ACTIVE_COMPARATOR|Nondirective Therapy|
62713999|NCT03261830|PLACEBO_COMPARATOR|Saline Placebo|Patients randomized to the no-antibiotic group will receive a saline placebo. This placebo will consist of a 10 mL pre-filled syringe of normal saline.
62156089|NCT04429672|ACTIVE_COMPARATOR|Control Group (CG)|The participants of the Control Group receive the usual sexual health intervention applied by Secretary of Health consisting of six sessions (one a week) lasting 50 minutes each using illustrative material through rotating official secretary of health folios on reproductive health, sexually transmitted diseases and sexual violence.
62530105|NCT00030992|EXPERIMENTAL|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
62530106|NCT03255655|EXPERIMENTAL|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
62530107|NCT03255655|PLACEBO_COMPARATOR|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
62530108|NCT05919121|ACTIVE_COMPARATOR|Therapeutic exercise group|Therapeutic exercise group, group A.
62530109|NCT05919121|EXPERIMENTAL|hydrocortisone phonophoresis group|This group (B) will receive the same exercise program in addition to hydrocortisone phonophoresis. Patients will receive topical medium phonophoresis of 10% hydrocortisone gel.
62530110|NCT05919121|EXPERIMENTAL|hydrocortisone iontophoresis group|This group (C) will receive the same exercise program in addition to hydrocortisone iontophoresis.
62530111|NCT03712839||Acquired Brain Injury group with anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. To determine the presence of anosognosia, patients must present an overestimation value of their capacities greater than 5 (\>5) in the discrepancy index on the Patient Competency Rating Scale (PCRS) (Prigatano et al., 1998).
62530112|NCT03712839||Acquired Brain Injury group without anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. These patients must present a score of \< 5 on the PCRS Scale.
62530113|NCT03712839||Control group|Healthy participants matched in age, gender and educational level with the others two groups.
62530114|NCT03340363|EXPERIMENTAL|environmental change|Shoppers were exposed to modifications to the supermarket environment to encourage selection of low-cost, kid-friendly meals
62714000|NCT03836443|ACTIVE_COMPARATOR|NAFL patients (group 1)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
62530115|NCT03340363|EXPERIMENTAL|environmental change and messaging|Shoppers were exposed to modifications to the supermarket environment and weekly messages via text or email to encourage selection of low-cost, kid-friendly meals
62530116|NCT05899751||Patients Treated With High-dose Methotrexate|Patients with a diagnosis of any cancer receiving high-dose methotrexate chemotherapy.
62156090|NCT05164926|EXPERIMENTAL|Experimental group, whose perineum was massaged with St. John's Wort oil during labor|St. John's Wort oil will be applied to this group during perineal massage during labor.
62530117|NCT06262230|EXPERIMENTAL|paired ASD and ordinary children|In this prevent study, ordinary children will be paired with children with ASD based on ages, hobbies, and other aspects.
62530118|NCT05715983|ACTIVE_COMPARATOR|Bascom II procedure|Pilonidal sinus is excised, subcutaneous fat and skin are closed in the lateralization with interrupted suture.
62530119|NCT05715983|ACTIVE_COMPARATOR|Sinus Laser Closer (SiLaC)|Pilonidal sinus is locally excised by dermopunch or scalpel, curettage of the sinus tract with laser destruction
62156091|NCT04657718|OTHER|All subjects|The KODEX-EPD system will be used in combination with leads to image during all procedures.
62156092|NCT06467240||intervention group|will receive a hybrid rapid maxillary expander assisted by Micro-osteo perforation (MOPs) in mid palatine suture
62156093|NCT06467240||control group|will receive a hybrid rapid maxillary expander without any thing
62156094|NCT05077046|EXPERIMENTAL|Intervention first arm|"Due to the counter-balanced design of this study all participants will experience both an interventional and a control period. Within the intervention first arm participants will be asked to execute the assessment trial / test battery with the intervention pen first. After a wash-out period, the participants will execute the same assessment trial / test battery with the control pen."
62530120|NCT05556759|PLACEBO_COMPARATOR|control group|patients will be operated on under general anesthesia
62156095|NCT05077046|EXPERIMENTAL|Control first arm|"Due to the counter-balanced design of this study all participants will experience both an interventional and a control period. Within the control first arm participants will be asked to execute the assessment trial / test battery with the control pen first. After a wash-out period, the participants will execute the same assessment trial / test battery with the intervention pen."
62530121|NCT05556759|ACTIVE_COMPARATOR|IPS group|patients will receive an ultrasound-guided anterior iliopsoas muscle space (IPS) block
62156096|NCT06173622|EXPERIMENTAL|Fetal positioning group|The neonates in the experimental group were put into fetal positioning at least 10 minutes before the procedure, and then venipuncture was performed. The fetal positioning was maintained throughout the procedure and the patient was kept in the fetal position for at least five more minutes after needle removal.
62156097|NCT06173622|NO_INTERVENTION|Control group|No intervention was performed by the researchers on the neonates included in the control group, and venipuncture was performed in accordance with the standard procedure of the neonatal intensive care unit.
62530122|NCT05556759|ACTIVE_COMPARATOR|Supra-iliac QL group|patients will receive an ultrasound-guided supra-iliac anterior quadratus lumborum (QL) block
62156098|NCT05125614||Developement set|Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at Seoul St.Mary's Hospital
62156099|NCT05125614||Validation set|Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at St.Vincent''s Hospital
62156100|NCT00901459|ACTIVE_COMPARATOR|rTMS 90% MT - Low frequency rTMS|Intervention type: device. Intervention description: low frequency rTMS was administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues using 90% MT (Motor Threshold) 1 Hz rTMS Dose on Superior Frontal Gyrus
62156101|NCT00901459|ACTIVE_COMPARATOR|Location Control|rTMS Dosing: 90% MT (Motor Threshold) 1 Hz rTNS Location: Motor Cortex
62156102|NCT00901459|ACTIVE_COMPARATOR|Frequency Control|rTMS Dosing: 90% MT (Motor Threshold) 10 Hz rTNS Location: Superior Frontal Gyrus
62156103|NCT00674765|EXPERIMENTAL|1|Seroquel
62530123|NCT01011179|EXPERIMENTAL|Internet-based JIA Self-Management Program|
62156104|NCT00674765|PLACEBO_COMPARATOR|2|Placebo
62156105|NCT06415825|EXPERIMENTAL|With pre-contr.|The patients will receive standard advice and an additional one - preliminary contraction of the muscles in the corresponding kinesiology segment.
62156106|NCT06415825|ACTIVE_COMPARATOR|Without pre-contr.|The patients will receive standard advice.
62156107|NCT00134056|ACTIVE_COMPARATOR|Arm I: placebo|Patients receive docetaxel and prednisone as in arm I. Patients also receive oral placebo once daily on days 1-21. Treatment repeat every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral placebo treatment for up to 52 weeks.
62156108|NCT00134056|EXPERIMENTAL|Arm II: atrasentan hydrochloride|Patients receive docetaxel IV over 1 hour on day 1. Patients also receive oral atrasentan and oral prednisone once daily on days 1-21. Treatment repeats every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral atrasentan treatment for up to 52 weeks.
62156109|NCT05019014||Neurodegenerative disease|Participants with a diagnosis of Probable Alzheimer's Disease, prodromal Alzheimer's Disease, Frontotemporal Dementia, Mild Cognitive Impairment, Dementia with Lewy Bodies, mild and moderate/severe TBI, and familial or sporadic ALS per El Escorial Criteria or individuals with known gene mutations associated with ALS.
62530124|NCT01011179|ACTIVE_COMPARATOR|Attention Control Group|
62530125|NCT04346420|EXPERIMENTAL|O2 DTM+|The standard nasal cannula interface is accompanied with the DTM
62530126|NCT04346420|ACTIVE_COMPARATOR|O2 DTM-|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient, without the DTM
62530127|NCT03512860|EXPERIMENTAL|E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B)|Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration.
62530128|NCT03512860|EXPERIMENTAL|E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A)|Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).
62530129|NCT05177874|EXPERIMENTAL|Traumacel FAM Trium|Randomized application haemostatic agent Traumacel FAM Trium in the bleeding site.
62530130|NCT05177874|ACTIVE_COMPARATOR|Surgicel Fibrillar|Randomized application of haemostatic agent Surgicel Fibrillar in the bleeding site.
62530131|NCT01359917||autologous fat transfer|patients received fat transfer for HIV lipodystrophy
62156110|NCT05019014||Age-matched controls|Healthy participants with no diagnosis.
62156111|NCT05667740|EXPERIMENTAL|Gamma-PN3|"Inactivated whole-cell pneumococcal vaccine at 50, 250 or 1000 mcg of protein content.~One dose on Day 1 and second dose Day 29"
62530132|NCT01359917||polylactic acid|treatment with polylactic acid (PLA) for HIV lipodystrophy
62156112|NCT05667740|PLACEBO_COMPARATOR|Placebo|Saline on Day 1 and second dose Day 29
62530133|NCT01359917||bio-alcamid|bio-alcamid injections
62530134|NCT04864470|EXPERIMENTAL|Intervention|"Stroke Odysseys is a performing arts intervention for people who have had strokes which provides an opportunity for communication of experiences of stroke to an audience through acquired skills in movement, music, song and the spoken word.~Stroke Odysseys comprises three distinct stages:~1. weekly workshops over 12 weeks for stroke participants facilitated by an integrated team of expert artists and ambassadors from the charity Rosetta Life~2. a smaller group of ambassadors recruited from the workshops will be trained to become co-facilitators (stroke ambassadors)~3. a performance tour including education and taster workshops for audiences."
62530135|NCT06299124|EXPERIMENTAL|RGT-419B monotherapy|Dose escalation and dose expansion of RGT-419B monotherapy
62530136|NCT02077439|EXPERIMENTAL|Hand Robotic Training|Hand Robotic Training
62530137|NCT02077439|EXPERIMENTAL|Hand and Arm Robotic Training|Hand and Arm Robotic Training
62530138|NCT02077439|ACTIVE_COMPARATOR|Conventional therapy|Conventional therapy
62530139|NCT06406270|EXPERIMENTAL|Fava-based diet|At the end of the morning of each intervention visit, participants were provided with meals, which they consumed for seven consecutive days (in a 4-day rotation menu). Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat and fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers regardless of their energy requirements.
62530140|NCT06406270|EXPERIMENTAL|Buckwheat-based diet|At the end of the morning of each intervention visit, participants were provided with meals, which they consumed for seven consecutive days (in a 4-day rotation menu). Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat and fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers regardless of their energy requirements.
62530141|NCT03670264|EXPERIMENTAL|Quitline Incentive|The incentive structure emphasizes engaging with the Quitline Delivered Treatment, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the Quitline, for maintaining involvement in the Quitline program (per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the Way to Health (WTH) platform.
62530142|NCT03670264|EXPERIMENTAL|Tobacco Cessation Incentive|The incentive structure emphasizes quitting regardless of engagement with the Quitline Delivered Treatment (though the Quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, compensation for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the WTH platform.
62530143|NCT03670264|PLACEBO_COMPARATOR|No Financial Incentive|No financial incentive to engage in Quitline Delivered Treatment or report abstinence. Study procedures and reminders are managed through the WTH platform.
62530144|NCT02565173|EXPERIMENTAL|trabodenoson 4.5% BID|trabodenoson 4.5% Ophthalmic Formulation
62530145|NCT02565173|EXPERIMENTAL|trabodenoson 6.0% QD|trabodenoson 6.0% Ophthalmic Formulation
62530146|NCT02565173|EXPERIMENTAL|trabodenoson 3.0% QD|trabodenoson 3.0% Ophthalmic Formulation
62530147|NCT02565173|ACTIVE_COMPARATOR|timolol 0.5% BID|timolol 0.5% Ophthalmic Formulation
62530148|NCT02565173|PLACEBO_COMPARATOR|placebo BID|placebo Ophthalmic Formulation
62530149|NCT02114476|PLACEBO_COMPARATOR|nonhormonal contraception|nonhormonal intrauterine device tubal sterilization
62530150|NCT02114476|EXPERIMENTAL|progestin implant|Jadelle
62530151|NCT05182255||Esophageal Stent Systems|Freedom from endoscopic re-intervention due to recurrence of dysphagia
62156113|NCT05667740|ACTIVE_COMPARATOR|Prevenar-13|Licensed pneumococcal vaccine on Day 1 and saline on Day 29
62156114|NCT05667740|ACTIVE_COMPARATOR|Pneumovax-23|Licensed pneumococcal vaccine on Day 1 and saline on Day 29
62156115|NCT01739738||no Ureteral Stent - control group|non-stented volunteers to receive ultrasound for peristalsis changes detection
62156116|NCT01739738||Ureteral stent|patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
62530152|NCT03551496|EXPERIMENTAL|DES BTK|Treatment with DES BTK
62714001|NCT03836443|ACTIVE_COMPARATOR|NASH patients (group 2)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
62714002|NCT03814135|EXPERIMENTAL|HIPNOS 3|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 3 and 1 placebo tablet, oral, once a day."
62156117|NCT02627586|ACTIVE_COMPARATOR|Moderate intensity continuous exercise|Moderate intensity continuous exercise (MICE) is performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group will perform MICE training three times per week. Cycling resistance will be adjusted weekly according to heart rate and Borg scale.
62530153|NCT03551496|ACTIVE_COMPARATOR|Conventional PTA|Treatment with standard PTA
62530154|NCT02452541|OTHER|Prognostic evaluation|Prognostic tests/exams performed according to a determined schedule during the acute phase of care following admission in the intensive care unit.
62530155|NCT04112173|EXPERIMENTAL|Perturbation-Based Balance Training|perturbation-based balance training
62530156|NCT00845819|ACTIVE_COMPARATOR|EGF|rhEGF + povidone iodine, chlorhexidine, \& nystatin
62530157|NCT00845819|PLACEBO_COMPARATOR|Placebo|Placebo + povidone iodine, chlorhexidine, \& nystatin
62714003|NCT03814135|EXPERIMENTAL|HIPNOS 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 5 and 1 placebo tablet, oral, once a day."
62714004|NCT03814135|PLACEBO_COMPARATOR|HIPNOS Placebo|The study is double-dummy. Thus, the patient will take 2 tablet of placebo, oral, once a day.
62714005|NCT06392308||Smoker group|who smoke more than one cigarette per day continuously or cumulatively for six months; more than four times a week but averaging less than one cigarette per day
62530158|NCT02245022|EXPERIMENTAL|Dolutegravir 50mg od|30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
62530159|NCT02245022|ACTIVE_COMPARATOR|Standard of Care|Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)
62714006|NCT06392308||Non-smoker group|never smoke
62530160|NCT03107026|EXPERIMENTAL|dasotraline 4mg|dasotraline 4mg once daily
62530161|NCT03107026|EXPERIMENTAL|dasotraline 6mg|dasotraline 6mg once daily
62530162|NCT03107026|PLACEBO_COMPARATOR|Placebo|Placebo, once daily
62530163|NCT02774096|NO_INTERVENTION|Control group（Ascending aorta）|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
62530164|NCT02774096|EXPERIMENTAL|Xenon Post-conditioning|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
62530165|NCT01108211|EXPERIMENTAL|Treatment Group|This group will receive Vibration Therapy.
62530166|NCT01108211|NO_INTERVENTION|Observation Group|This group does not receive Vibration Therapy
62530167|NCT04790838||Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
62530168|NCT04790838||Reference Product|ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK
62530169|NCT02715544|EXPERIMENTAL|Intervention group|The group will receive healthy lifestyle intervention
62530170|NCT02715544|ACTIVE_COMPARATOR|control group|Other: physical activity and dietary guidelines
62530171|NCT03898518|NO_INTERVENTION|Control Group|The control group was in the facility for all jump rope exercise sessions but did not participate in the exercise intervention.
62530172|NCT03898518|EXPERIMENTAL|Experimental Group|The experimental group performed the jump rope exercise intervention.
62530173|NCT02384330||Dysport® (abobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
62530174|NCT02384330||Botox® (onabotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
62530175|NCT02384330||Xeomin® (incobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
62530176|NCT02433054||CE-certified dedicated venous stents|Patients receiving self-expanding venous nitinol stents.
62530177|NCT06207214|EXPERIMENTAL|Self-help book for University Students|The Unbreakable Student: 6 Rules for Staying Sane at University by Dr Nic Hooper.
62530178|NCT00725205||Chronic hepatitis C participants|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection pen) and Ribavirin combination therapy as their usual medical treatment according to the approved dosage/regimen were selected for this study.
62530179|NCT00759135|EXPERIMENTAL|1|Single therapeutic dose of 2.5 mg NX-1207
62530180|NCT00759135|EXPERIMENTAL|2|Single low dose of 0.125 mg NX-1207 for dose-response evaluation
62530181|NCT00759135|ACTIVE_COMPARATOR|3|5.0 mg finasteride q.d.
62530182|NCT03830827|EXPERIMENTAL|MBRP+vortioxetine intervention|"Participants who allocate to the experimental group will receive 8-week 10-20mg/day vortioxetine combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~10-20mg/day vortioxetine will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
62714007|NCT06101173|EXPERIMENTAL|Experimental vaccine group A, Low dose, Intramuscular injection (IM)|1 dose of Low-adjuvant dose VLP-Polio vaccine on Visit 1
62714008|NCT06101173|ACTIVE_COMPARATOR|Control vaccine group A, IM|1 dose of IPOL vaccine on Visit 1
62714009|NCT06101173|EXPERIMENTAL|Experimental vaccine group B, Medium dose, Intramuscular injection (IM)|1 dose of Medium dose VLP-Polio vaccine on Visit 1
62530183|NCT03830827|EXPERIMENTAL|MBRP intervention|"Participants who allocate to the control group will receive 8-week 1-2#/day placebo combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~1-2#/day placebo will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
62530184|NCT00920517|ACTIVE_COMPARATOR|1|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 180
62530185|NCT00920517|ACTIVE_COMPARATOR|2|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 120
62714010|NCT06101173|ACTIVE_COMPARATOR|Control vaccine group B, IM|1 dose of IPOL vaccine on Visit 1
62714011|NCT06101173|EXPERIMENTAL|Experimental vaccine group C, High dose, Intramuscular injection (IM)|1 dose of High dose VLP-Polio vaccine on Visit 1
62714012|NCT06101173|ACTIVE_COMPARATOR|Control vaccine group C, IM|1 dose of IPOL vaccine on Visit 1
62714013|NCT00660218|EXPERIMENTAL|Radiation therapy, cetuximab, paclitaxel poliglumex|Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
62530186|NCT02008786|EXPERIMENTAL|Rosuvastatin, placebo|rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
62530187|NCT02008786|EXPERIMENTAL|Ramipril, placebo|ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo
62530188|NCT03688438|NO_INTERVENTION|Standard of Care|Standard of care wound closure and dressing No active interventions
62530189|NCT03688438|EXPERIMENTAL|WoundVAC (CINPT)|Closed-Incision Negative-Pressure Therapy
62530190|NCT03476369|EXPERIMENTAL|Fentanyl and Crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
62156118|NCT02627586|EXPERIMENTAL|High-intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. Moderate intensity continuous exercise (MICE) is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group performs two HIIT sessions and one MICE session per week.~In both training forms cycling resistance will be adjusted weekly according to heart rate and Borg scale."
62156119|NCT01839032|EXPERIMENTAL|Vinorelbine cisplatin radiotherapy|Induction period + radio chemotherapy
62156120|NCT02788435|NO_INTERVENTION|Control|Patients in the control arm will undergo a graduated prescription of voice use immediately following surgery.
62156121|NCT02788435|EXPERIMENTAL|Absolute Voice Rest|Patients in the experimental arm will undergo 7 days of absolute voice rest following surgery.
62156122|NCT03639545|ACTIVE_COMPARATOR|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
61975797|NCT05859789|ACTIVE_COMPARATOR|control group: Kegel exercise group|"will receive Kegel exercise (3 sessions /week for 12 weeks)- Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
62530191|NCT03476369|ACTIVE_COMPARATOR|Fentanyl and Non-crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
62530192|NCT04677881|PLACEBO_COMPARATOR|Wholegrain bread with yeast|The control group will be given min. 5 slices of bread baked with yeast per day.
62530193|NCT04677881|EXPERIMENTAL|Wholegrain bread with sourdough|The experimental group will be given min. 5 slices of bread baked with sourdough per day.
62530194|NCT03276065|EXPERIMENTAL|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
62530195|NCT03276065|ACTIVE_COMPARATOR|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
62530196|NCT04902625|ACTIVE_COMPARATOR|Naltrexone-Bupropion combination|The patients in this arm will receive 2 tablets of naltrexone-bupropion 8/90mg 2 times daily in combination with the Back On Track module.
62530197|NCT04902625|NO_INTERVENTION|Control|The patients is this arm will only participate in the Back On Track module and will not receive any investigational or placebo product.
62530198|NCT02477163|EXPERIMENTAL|single group|Patients of chronic renal failure
62530199|NCT05889468|ACTIVE_COMPARATOR|Treatment Group|The treatment group will be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission. Patients will be scheduled for a 4-6 week postpartum clinic appointment, which is standard for these patients outside of this proposal.
62530200|NCT05889468|PLACEBO_COMPARATOR|Placebo Group|The control group will receive a 6-week supply of placebo medication from the Investigational Pharmacy prior to discharge. The placebo will be identically appearing to the 81 mg aspirin. Patients will be scheduled for a 4-6 week postpartum clinic appointment, which is standard for these patients outside of this proposal.
62530201|NCT01475058|EXPERIMENTAL|Treatment (T cell therapy)|Patients undergo one IV infusion of donor-derived CD8+ central memory-derived CMV/CD19 or EBV/CD19 bi-specific T cells, at least 30 days after HCT.
62530202|NCT06300814|EXPERIMENTAL|Progressive relaxation exercise group|15 children aged 9-16 years who met the inclusion and exclusion criteria.
62530203|NCT06300814|EXPERIMENTAL|Music recital group|15 children aged 9-16 years who met the inclusion and exclusion criteria.
62156123|NCT03639545|ACTIVE_COMPARATOR|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
62156124|NCT03639545|ACTIVE_COMPARATOR|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
62530204|NCT06300814|NO_INTERVENTION|Control group|15 children aged 9-16 years who met the inclusion and exclusion criteria.
62530205|NCT01409161|EXPERIMENTAL|Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)|"INDUCTION: Patients receive tretinoin PO BID, arsenic trioxide IV over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at weeks 1-4.~CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks 1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
62530206|NCT03542955|ACTIVE_COMPARATOR|ActiPatch Group|Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.
62530207|NCT03542955|PLACEBO_COMPARATOR|Control Group|Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.
62156125|NCT03639545|PLACEBO_COMPARATOR|*placebo*|placebo for 12 weeks, once daily with water, by mouth
62530208|NCT06050473|ACTIVE_COMPARATOR|Supraclavicular nerve-sacrificing procedure|Surgeon will not attempt to identify the supraclavicular nerve branches.
62530209|NCT06050473|ACTIVE_COMPARATOR|Supraclavicular nerve-preserving procedure|Surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
62156126|NCT00540800|ACTIVE_COMPARATOR|A|Three-weekly chemotherapy
62530210|NCT01653561|EXPERIMENTAL|Apatinib|Apatinib 500mg/d
62530211|NCT05367518|ACTIVE_COMPARATOR|Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g|Probiotic Streptococcus salivarius K12 Fast Melt Powder (Dose 1: 1 Billion colony forming units /g)
62530212|NCT05367518|ACTIVE_COMPARATOR|Streptococcus salivarius K12 Fast Melt Powder 100 million colony forming units /g|Group B: Dose 2 Streptococcus salivarius K12 Fast Melt Powder (Dose 2: 100 Million colony forming unit/gram)
62530213|NCT00682682|EXPERIMENTAL|1|all study participants will have 4 visits: VR alone, VR + opioid, opioid alone, and no VR/opioid
62156127|NCT00540800|EXPERIMENTAL|B|Weekly chemotherapy
62530214|NCT04243434|EXPERIMENTAL|Cohort A|Marqibo formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1, and VSLI-RTU formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
62156128|NCT02344706||Mini-EEG, NCSE|Unconscious patients due to seizures, of whom EEG is registered
62530215|NCT04243434|EXPERIMENTAL|Cohort B|VSLI-RTU formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1 and Marqibo formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
62156129|NCT06432023||Patients|patients with white matter hyperintensities, patients with enlarged perivascular spaces, Focus will be on patients with a clinical diagnosis of muscular dystrophy or autism spectrum disorder or traumatic brain injury.
62156130|NCT06432023||Controls|Patients who need a diagnostic scan but do not carry a diagnosis of psychomotor or cognitive impairment or without a history of TBI and tumors. No white matter hyperintensities.
62530216|NCT02440113||Nellix|Patients with endovascular Nellix repair
62530217|NCT03686449|EXPERIMENTAL|study group 1|Non-cultured Autologous Keratinocyte Suspension
62530218|NCT03686449|EXPERIMENTAL|study group 2|Adipose-Derived Stem cell-Keratinocyte Suspension
62530219|NCT03686449|ACTIVE_COMPARATOR|Control group|Split skin graft
62530220|NCT05918224|EXPERIMENTAL|Experimental group|S. salivarius K12 group: The S. salivarius K12 lozenges (NOW Foods, USA) contained not less than 1×109 CFU viable cells of S. salivarius K12 as the active ingredient. The S. salivarius K12 lozenges were dissolved in the mouth and then swallowed through the first day of RT to the end of treatment (1 lozenge 3 times a day).
62530221|NCT05918224|PLACEBO_COMPARATOR|Placebo group|Placebo group: Placebo lozenges contained sugar and starch used as excipients in the active formulation. The placebo lozenge were dissolved in the mouth and then swallowed through the first day of RT to the end of treatment (1 lozenge 3 times a day).
62530222|NCT05344248|EXPERIMENTAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Ib：60mg、150mg、300mg、600mg；Each patient can only receive multiple doses at one dose level.Each patient received weekly dosing (QW) at weeks 0, 1, 2, 3, and 4, and quad-weekly dosing (Q4W) beginning at week 5 through week 12。 II：Multiple subcutaneous injections of the study drug and placebo in two doses of 300mg and 150mg were performed.Each patient can only receive multiple doses at one dose level.Weekly dosing (QW) was given at 0, 1, 2, 3, and 4 weeks, and quad-weekly dosing (Q4W) was given from 5 weeks to 12 weeks.
62530223|NCT05344248|PLACEBO_COMPARATOR|Placebo|Ib：60mg、150mg、300mg、600mg；Each patient can only receive multiple doses at one dose level.Each patient received weekly dosing (QW) at weeks 0, 1, 2, 3, and 4, and quad-weekly dosing (Q4W) beginning at week 5 through week 12。 II：Multiple subcutaneous injections of the study drug and placebo in two doses of 300mg and 150mg were performed.Each patient can only receive multiple doses at one dose level.Weekly dosing (QW) was given at 0, 1, 2, 3, and 4 weeks, and quad-weekly dosing (Q4W) was given from 5 weeks to 12 weeks.
62530224|NCT01331226|EXPERIMENTAL|3 session telephone counseling|
62530225|NCT01331226|EXPERIMENTAL|1 session telephone counseling|
62156131|NCT06498323|EXPERIMENTAL|tenecteplase|Intravenous tenecteplase (0.25mg/kg) will be given in acute ischemic stroke patients on mobile stroke units within 4.5 hours according to the eligibility criteria after randomization allocation.
62156132|NCT06498323|ACTIVE_COMPARATOR|alteplase|Intravenous alteplase (0.9mg/kg) will be given in acute ischemic stroke patients on mobile stroke units within 4.5 hours according to the eligibility criteria after randomization allocation.
62156133|NCT05555199|EXPERIMENTAL|Intervention|One interventional arm that will undergo all interventional procedures (when applicable).
62156134|NCT01864980||Hb group:15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
62156135|NCT01864980||SpHb group: 15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
62156136|NCT03858556||Patients with lumbar disc herniation|"3times(baseline, 1weeks, 2weeks) of Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion in inpatients with lumbar intervertebral disc herniation hospitalized at Korean medicine hospital.~-Integrative Korean medicine treatment Procedure/Surgery: Chuna manipulation Drug: Herbal medicine Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s) Other: Other intervention(s)"
62156137|NCT03858556||Normal|"baseline Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion.~-No treatment"
62156138|NCT04206618||premenopausal normal|premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
62156139|NCT04206618||postmenopausal normal|postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
62156140|NCT04206618||postmenopausal osteopenia|postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage
62530226|NCT01331226|ACTIVE_COMPARATOR|written materials|
62530227|NCT05873010|EXPERIMENTAL|Manual Compression and Stretching|
62530228|NCT00826449|EXPERIMENTAL|Phase I|Dasatinib + Erlotinib
62530229|NCT03276221|ACTIVE_COMPARATOR|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
62156141|NCT04206618||postmenopausal osteoporosis|postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage
62156142|NCT04206618||hip fracture|postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis
62156143|NCT04206618||controls (knee osteoarthitis)|postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls
62156144|NCT04206618||teriparatide group|postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months
62530230|NCT03276221|NO_INTERVENTION|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
62530231|NCT03276221|NO_INTERVENTION|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
62530232|NCT01775852|ACTIVE_COMPARATOR|ACT-IM|The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine.
62530233|NCT01775852|NO_INTERVENTION|Waitlist/Treatment as Usual|The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.
62530234|NCT04498403|EXPERIMENTAL|Crisaborole 2%|Crisaborole 2% ointment applied twice daily (BID)
62156145|NCT04206618||denosumab group|postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months
62530235|NCT04141475|ACTIVE_COMPARATOR|Alpha-Lipoic Acid group|
62156146|NCT04644692||Case group: patients with heart failure with preserved ejection fraction|
62530236|NCT04141475|PLACEBO_COMPARATOR|placebo group|
62530237|NCT02637635|EXPERIMENTAL|Breast reconstruction with implant|The patients will undergo breast reconstruction with an expander prosthesis.
62156147|NCT04644692||Control Group:Never diagnosed with either preserved or altered ejection fraction heart failure.|Non dyspnoeic patients with no history of Heart failure.
62530238|NCT02637635|EXPERIMENTAL|Autologous fat transplantation|The patients will undergo lipofilling as a pre-treatment before they will undergo breast reconstruction with an expander prosthesis.
62530239|NCT02591732||Patient treated with Apixaban|
62530240|NCT02591732||Patient treated with Rivaroxaban|
62530241|NCT02591732||Patient treated with Dabigatran|
62530242|NCT02591732||Patient treated with vitamin K antagonists|
62530243|NCT00131378|EXPERIMENTAL|Male on GH|"Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
62530244|NCT00131378|PLACEBO_COMPARATOR|Male on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
62530245|NCT00131378|EXPERIMENTAL|Female on GH|"Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
62156148|NCT06443736|EXPERIMENTAL|Standardized perineal massage|
62156149|NCT06443736|ACTIVE_COMPARATOR|Standard prevention|
62156150|NCT01049815|EXPERIMENTAL|Sevelamer hydrochloride|
62530246|NCT00131378|PLACEBO_COMPARATOR|Female on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
62530247|NCT01792219|EXPERIMENTAL|interprofessioal education module|an interprofessional education module will be given to learn to collaborate interprofessionally.
62156151|NCT01049815|ACTIVE_COMPARATOR|Calcium carbonate|
62156152|NCT01862224|EXPERIMENTAL|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
62156153|NCT01862224|PLACEBO_COMPARATOR|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
62156154|NCT03612388||cardioplegia with MPS® (Myocardial protection system)|cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
62156155|NCT03612388||cardioplegia with Cardioplexol ®|cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)
62156156|NCT02875444||"group abdominal aortic aneurysm"|Patients with non-operated abdominal aortic aneurysm with angio-CT realized between 01/01 2010 au 04/15/2012
62156157|NCT06031493|EXPERIMENTAL|Multimodal Intervention Group|Multimodal Intervention on sexual dysfunction and quality-of-life after treatment for cervical cancer: application of topical vaginal estrogens, systematic evaluation of the need of systemic hormone replacement therapy (and treatment if needed), application of hormone-free vaginal-vulvar moisturizing cream containing hyaluronic acid, use of a vaginal vibrator twice a week for 5 to 10 minutes each time with the help of intimate lubricant, access to online informational content about sexuality, access to online informational content about nutrition, access to online informational content about sports, access to online informational content about lifestyle habits
62156158|NCT06031493|NO_INTERVENTION|Standard Care Group|Standard follow-up in Gynecological Oncology Units of participating centers after treatment for cervical cancer
62530248|NCT00476554|EXPERIMENTAL|Arm A: High dose|High-dose (Arm A): 200 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
62530249|NCT00476554|EXPERIMENTAL|Arm B: High dose|Low-dose (Arm B): 100 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
62530250|NCT05935241|EXPERIMENTAL|mPATH|mPATH is a personalized physical activity intervention that includes personalized physical activity plans and training sessions, exercise at home by following personalized exercise videos, and biweekly phone coaching over 24 weeks, supported by wearable devices-enabled mHealth strategies. mHealth strategies and exercise videos will be used to support participant's physical activity during 6-12months
62530251|NCT05935241|ACTIVE_COMPARATOR|Education and Social control|This attention control group is designed to match the intervention for mPATH's staff-subject interaction duration through monthly home visits in the first 6 months
62530252|NCT05842421|EXPERIMENTAL|Intervention group|After clinical examination, each lesion that is suspicious for non-melanoma skin cancer and/or its precursor, is examined with dermoscopy, optical coherence tomography, in vivo reflectance confocal microscopy and each patient gets 3D total body photography. Afterwards, decision for management of each lesion is made (excision, biopsy, local treatment or no treatment). Surgeons are blinded to the groups but get the planning of surgery of the investigator. Pathologists are blinded to the groups.
62530253|NCT05842421|NO_INTERVENTION|Control group|After clinical examination, each lesion that is suspicious for non-melanoma skin cancer and/or its precursor, is examined with dermoscopy as is the standard of care. Afterwards, decision for management of each lesion is made (excision, biopsy, local treatment or no treatment). Surgeons are blinded to the groups but get the planning of surgery of the investigator. Pathologists are blinded to the groups.
62530254|NCT01476735|ACTIVE_COMPARATOR|split-dose polyethylene glycol solution|first dose (1,5 l) of polyethylene glycol solution taken at 6-7.00 in the evening before colonoscopy, second dose (1,5 l) taken at 5.30-6.00 in the morning of a day of colonoscopy; additional bisacodyl taken at 12.00 at the day before colonoscopy
62530255|NCT01476735|ACTIVE_COMPARATOR|Individual preparation for colonoscopy|
62530256|NCT05932992|ACTIVE_COMPARATOR|Mother screening|In this arm, mothers / children dyads will be enrolled. Mothers will be trained to measure mid-upper arm circumference (MUAC) on their children weekly for 6 months. All other standard care will be provided.
62530257|NCT05932992|NO_INTERVENTION|standard of care|In this arm, mothers / children dyads will be enrolled. No study intervention will be performed. all other standard of care will be provided.
62530258|NCT04483635|PLACEBO_COMPARATOR|Placebo|"10 placebo tablets taken orally at baseline, followed by 1 placebo tablet once a week for 16 weeks~Note that the study may be prolonged according to the overall infection rate monitored monthly."
62530259|NCT04483635|EXPERIMENTAL|Vitamin D3|"10 tablets containing 10,000 IU (total : 100,000 IU) of Vitamin D3 taken orally at baseline, followed by 10,000 IU once a week for 16 weeks.~Note that the study may be prolonged according to the overall infection rate monitored monthly."
62530260|NCT03587389|EXPERIMENTAL|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
62530261|NCT05154630|EXPERIMENTAL|TQB2858 injection|Participants will receive 3 mg/60 mg/600 mg/1200 mg/1800 mg single dose of TQB2858 injection on Day 1, iv (injection of vein), once every three weeks.
62714014|NCT05030467|EXPERIMENTAL|Intervention Arm|Providers within the clinics randomized to the intervention arm will receive a variety of EHR-based tools for eligible patients with uncontrolled hypertension.
62156159|NCT03943771|EXPERIMENTAL|Virtual modelization group|Patients having their kidney modelized in three dimensions on a software
62156160|NCT03943771|EXPERIMENTAL|Printed modelization group|Patients having their kidney modelized and printed in three dimensions
62156161|NCT03943771|SHAM_COMPARATOR|Control group|No kidney model
62530262|NCT04713553|EXPERIMENTAL|Arm 1|30-microgram dose of US manufactured drug substance (Lot 1)
62530263|NCT04713553|EXPERIMENTAL|Arm 2|30-microgram dose of US manufactured drug substance (Lot 2)
62530264|NCT04713553|EXPERIMENTAL|Arm 3|30-microgram dose of US manufactured drug substance (Lot 3)
62530265|NCT04713553|EXPERIMENTAL|Arm 4|30-microgram dose of EU manufactured drug substance (Lot 4)
62530266|NCT04713553|EXPERIMENTAL|Arm 5|20-microgram dose of US manufactured drug substance (corresponding to Arm 1, 2 or 3 lot)
62530267|NCT04713553|EXPERIMENTAL|Booster 1: BNT162b2|30-microgram dose
62530268|NCT04713553|EXPERIMENTAL|Booster 2: BNT162b2.B.1.351|30-microgram dose
62530269|NCT01752647|EXPERIMENTAL|Low dose computed tomography|Patients will have one baseline LDCT scan.
62530270|NCT05778552||Home-based pelvic muscle training devices group|Patients underwent pelvic muscle training by home-based device and at home.
62530271|NCT05778552||Traditional pelvic muscle training devices group|Patients underwent traditional pelvic muscle training at hospital
62539550|NCT05180201|EXPERIMENTAL|LP1|Once daily oral administration of L. plantarum ATCC 202195 (10\^9 CFU/day) plus 250mg maltodextrin for one day, followed by 6 days of placebo (250 mg maltodextrin).
62539551|NCT05180201|PLACEBO_COMPARATOR|Placebo|Once daily oral administration of placebo (250 mg maltodextrin), for 7 days.
62714015|NCT05030467|NO_INTERVENTION|Control Arm|Providers within the clinics randomized to usual care will receive no EHR tools, except those currently available in clinical practice.
62714016|NCT03292237|NO_INTERVENTION|Standard Nutrition Arm|"In ICU:~1. After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~2. PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops.~3. Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm.~After ICU:~1. Nutrition management will be as per usual site management at that hospital.~2. Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools."
62156162|NCT04420351|EXPERIMENTAL|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
62156163|NCT04420351|OTHER|Antiplatelet treatment|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018
62156164|NCT03964272|EXPERIMENTAL|ExAblate 4000 System|Exablate bilateral treatment for Parkinson's Disease Motor Features
62530272|NCT04043130|EXPERIMENTAL|Pulse Treatment App|The treatment app is a web-based mobile health app designed for Black \& Latinx women ages 18-20. Through culturally and age-appropriate content, Pulse provides information on birth control, healthy relationships, sexual health, pregnancy, \& utilization of clinical services to encourage users to choose effective birth control, seek reproductive health services, and prevent unplanned pregnancies. Users access Pulse autonomously and on their own terms. The app does not require users to follow a specific sequence of content viewed. Participants randomized to the intervention condition are given access to Pulse and receive Multimedia Messaging Service (MMS) messages related to sexual health several times a week for 6 weeks. Participants receive a baseline survey, 6-week follow-up survey, and 6-month follow-up survey via an electronic survey platform (6-month survey only administered to participants recruited between November 2018-March 2019).
62530273|NCT04043130|ACTIVE_COMPARATOR|Pulse Control App|The control app, also called Pulse, is a web-based mobile health app designed by the study team for young women ages 18-20. Although Pulse control and Pulse treatment apps look and feel similar aesthetically, they contain different content. Pulse control app provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Users access Pulse autonomously, on their own terms, and in their own time and place. The app does not require the user to follow a specific sequence of content viewed; however, all users receive a monetary incentive after completing a baseline survey and registering with the app. Control participants also receive MMS messages related to general health for six weeks. Participants receive a baseline survey and a six-week follow-up which are conducted online via an electronic survey platform.
62530274|NCT02908282|OTHER|PUFA (polyunsaturated fatty acids)-group|REMOGEN OMEGA: Usage according to instructions for use.
62530275|NCT02908282|OTHER|C (control)-group|Povidone: Usage according to instructions for use.
62714017|NCT03292237|EXPERIMENTAL|Intensive Arm|"Intervention~In ICU:~1. Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation~2. The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge~3. If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management."
62156165|NCT03539237|EXPERIMENTAL|"Video-group"|"Video group: Individuals in this group receive the intervention Video demonstration of physical activity intensity levels. They watch a 3-minute-video explaining and visualizing light-, moderate-, and vigorous-intensity levels of physical activity before completing a tablet PC-supported physical activity assessment at the DZHK-examination center.The video can not be skipped."
62156166|NCT03539237|NO_INTERVENTION|"No video-group"|"No video group: Individuals in this group do not receive the intervention Video demonstration of physical activity intensity levels. They complete a tablet PC-supported physical activity assessment at the DZHK-examination center without receiving a 3-minute-video explaining and visualizing the different intensity levels of physical activity."
62530276|NCT00497952|EXPERIMENTAL|Multiple Sclerosis Patients|Recipients treated with a hematopoetic stem cell infusion from a living donor
62156167|NCT01858649|ACTIVE_COMPARATOR|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
62156168|NCT01858649|ACTIVE_COMPARATOR|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
62156169|NCT05082545|EXPERIMENTAL|Dose escalation:SHR-2002+SHR-1316|SHR-2002 +SHR-1316 C1D1 SHR-2002,C1D22 SHR-2002+SHR-1316, C2 SHR-2002+SHR-1316
62530277|NCT00505375|EXPERIMENTAL|1|Intravenous infusions of CTLA-4 Ig
62156170|NCT05082545|EXPERIMENTAL|Dose expansion stage: SHR-2002+SHR-1316|Dose expansion of SHR-2002 will be decided after finishing few cohorts in Dose escalation part.
62156171|NCT05082545|EXPERIMENTAL|Indication expansion stage：SHR-2002+SHR-1316|Indication expansion of SHR-2002 will be decided after finishing few cohorts in Dose expansion part.
62530278|NCT00505375|PLACEBO_COMPARATOR|2|Intravenous infusions of placebo
62714018|NCT06716359||Cesarean section surgery|Observational study
62156172|NCT05981209|EXPERIMENTAL|Treatment (elotuzumab, CC-92480, dexamethasone)|Patients receive elotuzumab IV on days 1, 8, 15, and 22 of cycles 1 and 2 and then on day 1 of each subsequent cycle. Patients also receive CC-92480 PO on days 1-21 of each cycle and dexamethasone IV or PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo an ECHO during screening and undergo MRI, CT, or x-ray imaging during screening and on study as clinically indicated. Patients also undergo blood sample collection as well as bone marrow biopsy and aspiration during screening and on study.
62156173|NCT00990184|EXPERIMENTAL|Colesevelam Hydrochloride|
62156174|NCT02082639|EXPERIMENTAL|HPV Group|Subjects will receive two doses of HPV vaccine intramuscularly
62156175|NCT02082639|EXPERIMENTAL|HAV Group|Subjects will receive two doses of HAV vaccine intramuscularly
62156176|NCT02082639|EXPERIMENTAL|HPV+HAV Group|Subjects will receive two doses of both HPV and HAV vaccines intramuscularly
62156177|NCT04097314|EXPERIMENTAL|Zibotentan|
62156178|NCT04097314|PLACEBO_COMPARATOR|Placebo|
62156179|NCT01485809|EXPERIMENTAL|Gefitinib|
62530279|NCT05344430|OTHER|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|Cone beam Computed Tomography (CBCT) with Navigational software guidance for percutaneous transthoracic needle biopsy
62530280|NCT05344430|OTHER|multidetector computed tomography (MDCT) for percutaneous transthoracic needle biopsy|Multidetector Computer Tomography for percutaneous transthoracic needle biopsy
62530281|NCT03476863|EXPERIMENTAL|Alveolar Recruitment Maneuver|
62530282|NCT03476863|ACTIVE_COMPARATOR|Conventional mechanical ventilation|
62530283|NCT05680935|EXPERIMENTAL|atherosclerosis of the brachiocephalic arteries|The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries.
62530284|NCT05680935|EXPERIMENTAL|No brachiocephalic atherosclerosis|The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Up to 30 people - the control group without brachiocephalic atherosclerosis.
62530285|NCT02955017|ACTIVE_COMPARATOR|Traditional follow-up|
62530286|NCT02955017|EXPERIMENTAL|"Distance follow-up new technologies"|
62530287|NCT03972202|EXPERIMENTAL|Patients with cerebellar ataxia (CA)|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
62530288|NCT03972202|ACTIVE_COMPARATOR|Matched controls|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
62530289|NCT03972202|EXPERIMENTAL|Additional healthy volunteers|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI) Transcranial magnetic stimulation (TMS)
62530290|NCT06291350||MMPg and periodontitis|15 adult patients with MMPg and periodontitis
62530291|NCT06291350||no MMPg and periodontitis|15 adult patients not suffering from MMPg with periodontitis
62530292|NCT06291350||no MMPg with healthy periodontal conditions|15 adult patients not suffering from MMPg with healthy periodontal conditions
62530293|NCT01088802|EXPERIMENTAL|Dose de-escalating radiation therapy with chemotherapy|This protocol combines selective radiation therapy dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks) in patients with HPV-associated cancers of the oropharynx
62714019|NCT05961371|EXPERIMENTAL|Exercise|In-person, supervised resistance training program
62714020|NCT05961371|NO_INTERVENTION|Control|Waitlist control group. Will be offered the exercise program following a 9-month wait.
62530294|NCT01936623|EXPERIMENTAL|Computerized Brief Intervention|Computerized Brief Intervention is delivered using a talking, animated cartoon-like parrot that provides patient feedback, empathic reflection, and personalization regarding their drug use.
62530295|NCT01936623|OTHER|Delayed Computerized Brief Intervention|Participants receive only a substance abuse assessment at baseline. At three-month follow-up, they then receive the computerized brief intervention.
62530296|NCT01597466|EXPERIMENTAL|Epidrum|Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
62530297|NCT01597466|ACTIVE_COMPARATOR|Loss of resistance technique|
62530298|NCT00045669|EXPERIMENTAL|Imatinib Mesylate|Adult patients with unresectable or metastatic adenoid cystic carcinoma measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks
62530299|NCT03596892|EXPERIMENTAL|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
62530300|NCT03596892|ACTIVE_COMPARATOR|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
62530301|NCT05861336|EXPERIMENTAL|Chemotherapy+Losartan+Stereotactic Radiation|"Chemotherapy will be administered for six cycles as per clinical practice (nab-paclitaxel and gemcitabine: nab-paclitaxel 125 mg/m2 on days 1, 8, and 15, Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days) Losartan will be administered per os every day during induction chemotherapy and maintained until starting SBRT.~SBRT will be administered in 7 consecutive fractions for a total dose of 35-42 Gy if no progression will be observed after induction therapy."
62530302|NCT02131597|EXPERIMENTAL|Treatment (guadecitabine)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 4-8 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 3 courses are taken off therapy after 6 courses. Patients may continue to receive treatment after 24 courses if the investigator determines it is in the patient's best interest.
62530303|NCT06319937|EXPERIMENTAL|OA Group|Knee OA were included in the study. All patients exhibited evident radiographic changes in either unilateral or bilateral knees, consistent with a diagnosis of osteoarthritis, and were classified as Kellgren Lawrence (K-L) grade 2.
62530304|NCT00562575|EXPERIMENTAL|1|SLx-4090
62530305|NCT00562575|PLACEBO_COMPARATOR|2|Matching Placebo Dose
62530306|NCT01930955|ACTIVE_COMPARATOR|Amoxicillin|Amoxicillin were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
62530307|NCT01930955|NO_INTERVENTION|control|Non-antibiotics were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
62530308|NCT03202979|EXPERIMENTAL|Group 1|Trazodone 20 mg
62530309|NCT03202979|EXPERIMENTAL|Group 2|Trazodone 10 mg
62530310|NCT03202979|PLACEBO_COMPARATOR|Group 3|Placebo
62530311|NCT01196676|EXPERIMENTAL|1|AZD4451
62530312|NCT01196676|PLACEBO_COMPARATOR|2|Placebo
62530313|NCT02636426|EXPERIMENTAL|sorafenib|In this phase I study patients are treated with high-dose, pulsatile sorafenib in escalating AUC0-12h cohorts.
62530314|NCT00510289|EXPERIMENTAL|all patients|sorafenib
62530315|NCT05739214|EXPERIMENTAL|laser sequential mode|All patients received 2 sessions of laser therapy / week with different wavelengths in sequential mode in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care
62530316|NCT05739214|EXPERIMENTAL|laser seperate mode|All patients received 2 sessions of laser therapy / week with different wavelengths in seperate mode in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care
62714021|NCT04576494|EXPERIMENTAL|5q-SMA type 2 and type 3 adults|5q-SMA type 2 and type 3 adults
62714022|NCT06717815|EXPERIMENTAL|Cohort 1 (20 mg, Bid)|9\~12 subjects will be orally administered with IPD11406 20 mg twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.
62530317|NCT05739214|ACTIVE_COMPARATOR|traditional wound care|"Traditional wound care inform of~1. Wound care treatment~   * Debridement to remove necrotic tissue~  * Irrigation of the wound by normal saline~  * Change dressing daily to protect wound from infection~2. Foot care~   * Wash feet daily, dry carefully especially between toe~  * Avoid extreme temperatures~  * Inspection daily of foot blisters~3. Foot wear~   * Avoid walking bare foot~  * Properly fitted shoes~  * Avoid wearing open-toed shoes"
62714023|NCT06717815|EXPERIMENTAL|Cohort 2 (40 mg, Bid)|After cohort 1 complete 28 days of dosing and evaluation, the Safety Monitoring Committee (SMC) will assess the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available pharmacokinetic (PK) data. Based on SMC approval, 9\~12 subjects will be orally administered 40 mg with IPD11406 twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.
62714024|NCT06717815|EXPERIMENTAL|Cohort 3 (80 mg, Bid)|After cohort 2 complete 28 days of dosing and evaluation, the Safety Monitoring Committee (SMC) will assess the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available pharmacokinetic (PK) data. Based on SMC approval, 9\~12 subjects will be orally administered 80 mg with IPD11406 twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.
62156180|NCT03643445|EXPERIMENTAL|Motivational Interviewing (MI) Treatment|Motivational interviewing is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices. Patients assigned to these MI-trained therapists will be in the motivation-oriented condition. All individual meetings patients have with their therapist while they are in the program will entail sessions that are guided by MI principles. That is, revisiting patients' motivation to recover and overcoming obstacles to ambivalence or low motivation.
62714025|NCT05876923|EXPERIMENTAL|Aim 1 (vitals, spirometry, CPET, blood samples, DEXA)|Participants undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study.
62156181|NCT03643445|ACTIVE_COMPARATOR|Psychoeducation-Oriented Treatment|"The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. Two staff members in the eating disorders program will deliver the psychoeducation-infused interventions, which are intended to be equivalent to treatment-as-usual in many eating disorder programs, but in a structured and standardized way, and with the use of the self-help manual. Psychoeducation is a very common intervention, often used as part of cognitive-behavioural treatment for eating disorders. The idea is that information about eating disorders and their health risks facilitates recovery and allows patients to buy in to treatment."
62156182|NCT05448794|EXPERIMENTAL|evaluation prolotherapy for frozen shoulder|This pilot study highlighted that prospective studies are required to prove its clinical application for FS and other conditions.
62530318|NCT03692390|EXPERIMENTAL|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app while undergoing procedural sedation
62156183|NCT06180109|EXPERIMENTAL|Empagliflozin film coated tablets|Empagliflozin 25 mg film coated tablets
62156184|NCT06180109|ACTIVE_COMPARATOR|Jardiance film-coated tablets|Jardiance (Empagliflozin) 25 mg film-coated tablets
62156185|NCT00663923|EXPERIMENTAL|cross-cylinder|In this technique the laser is programmed with the axis and amount of cylinder,so that the steepest meridian is flattened with central cylindrical ablation and the flattest meridian steepens with paracentral ablation
62156186|NCT00663923|ACTIVE_COMPARATOR|single|In this technique ,cylinder is treated only on one meridian by performing an elliptical ablation to to flatten the steeper meridian to match the flatter meridian.
62156187|NCT03563989|EXPERIMENTAL|Stentys Xposition S Self-Apposing stent|STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System
62530319|NCT03692390|NO_INTERVENTION|Standard-of-Care|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
62530320|NCT06412718||Patients|
62530321|NCT06412718||Control group|
62530322|NCT02387983|EXPERIMENTAL|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
62530323|NCT04325035|EXPERIMENTAL|Istaroxime - Part A|Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min
62530324|NCT04325035|PLACEBO_COMPARATOR|Placebo - Part A|Placebo (lactose lyophilized powder) IV infusion for 24 hours
62530325|NCT04325035|EXPERIMENTAL|Istaroxime - Part B|Istaroxime IV infusion at 1.0 µg/kg/min for 6 hours, 0.5 µg/kg/min for 42 hours, 0.25 µg/kg/min for 12 hours.
62530326|NCT04325035|EXPERIMENTAL|Istaroxime and Placebo - Part B|Istaroxime IV infusion at 0.5 µg/kg/min for 48 hours, followed by placebo IV infusion for 12 hours.
62530327|NCT04325035|PLACEBO_COMPARATOR|Placebo - Part B|Placebo (lactose lyophilized powder) IV infusion for 60 hours.
62530328|NCT01521182|ACTIVE_COMPARATOR|1 = Tested product|
62530329|NCT01521182|PLACEBO_COMPARATOR|2 = Control product|
62530330|NCT01454908|OTHER|Partial Knee Arthroplasty|Oxford Mobile Bearing Unicompartmental Knee Arthroplasties
62530331|NCT02633488|PLACEBO_COMPARATOR|Placebo|12 weeks of Placebo tablet 3 x daily
62530332|NCT02633488|EXPERIMENTAL|Metformin|12 weeks of Metformin tablet 850 mg 3 x daily
62530333|NCT00242619|EXPERIMENTAL|Rosiglitzone|This group includes all 12 subjects who received rosiglitazone. Rosiglitazone was administered in addition to current antidepressant and/or mood-stabilizing medication at a dose of 4 mg/day for the first 4 weeks, with subsequent increase in dose to 9 mg/day for the remaining 8 weeks of the 12-week trial.
62530334|NCT04752046|ACTIVE_COMPARATOR|obturator group|patients with resected maxillary defects were managed with surgical obturator
62530335|NCT04752046|ACTIVE_COMPARATOR|scapular flap group|
62714026|NCT05876923|EXPERIMENTAL|Aim 2 (aerobic based training program, Aim 1 activities)|CLL patients complete aerobic based training program on study. Patients then complete all Aim 1 activities again after completion of aerobic based training program.
62530336|NCT05030558|EXPERIMENTAL|Interventional group|The web-supported interactive nursing program intervention will last 4 weeks. In the first week of the training, the identity and causes of the disease, which is one of the sub-dimensions of the perception of illness, will be emphasized, and the themes of misperception determined in this field through qualitative study will be emphasized. In the second week, they will be asked to look at training sessions that discuss perceptions of the illness's timeline and consequences. In the last two weeks of the training, they will be asked to attend the trainings for the control of Fibromyalgia symptoms. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times). Data collection forms will be applied to the intervention group 3 times before starting the web-based interactive nurse program, at the end of the program (in the 1st month) and then at the end of the 2nd month.
62530337|NCT05030558|ACTIVE_COMPARATOR|Control Group|"The Fibromyalgia patient booklet of the Turkish Physical Medicine and Rehabilitation Association will be available in pdf format on the website of the participants assigned to the control group. Participants in this group will be able to access other trainings after the end of the study, if they wish.~Data collection forms will be applied to the control group 3 times in total, before the start of the study, in the 1st month and the 2nd month of the study."
62530338|NCT04162132||DynamiCare group|Patients at Morgan Street location of BrightView who were given the DynamiCare smartphone app.
62530339|NCT04162132||Non-DynamiCare group|Patients at Colerain location of BrightView who were not given the DynamiCare smartphone app.
62530340|NCT02053935|OTHER|Dopamine|All patients will receive the same intervention.
62530341|NCT02393443|EXPERIMENTAL|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
62530342|NCT02393443|PLACEBO_COMPARATOR|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
62530343|NCT04202809|EXPERIMENTAL|Chemo- and Radiochemotherapy + Durvalumab|
62530344|NCT04202809|NO_INTERVENTION|Chemo- and Radiochemotherapy|
62530345|NCT02552056|EXPERIMENTAL|CAMH training|"Intervention clinics will receive a CAMH integration package comprising of:~* Training PHC workers (midwives, nurses and/or clinical officers) on how to screen and refer for CAMH, based on WHO mhGAP implementation guide.~* Support supervision in the clinics to reinforce training and provide on-job support to PHC staff.~* Provision of job aids and training materials"
62530346|NCT02552056|NO_INTERVENTION|No CAMH training|Clinics will continue to provide the standard of care.
62530347|NCT03321162||double scan protocol|In C1(double scan technique) , after CT scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance.
62530348|NCT03321162||triple scan protocol|In C2 (triple scan technique) , after CT scan for patient wearing scan appliance , CT scan for scan appliance alone .
62530349|NCT05325073|OTHER|EPO Arm|
62530350|NCT03482349|EXPERIMENTAL|Total Knee Robotically-Assisted|The intervention is then performed with a new device and surgical procedure. At first the femur and the tibia are fixed to the operating table with a special clamp and the knee bones are exposed with the standard technique; then the surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
62530351|NCT03482349|NO_INTERVENTION|Total Knee Manual-Executed by Surgeon|Your orthopaedic surgeon will remove the damaged cartilage and bone, and then position the new metal and plastic implants to restore the alignment and function of your knee.
62530352|NCT00250796|ACTIVE_COMPARATOR|Arm 1|Thalidomide+alpha interferon
62530353|NCT00250796|EXPERIMENTAL|Arm 2|Thalidomide+interferon+Octreotide
62530354|NCT02731326|EXPERIMENTAL|iHEART|Participants will transmit daily ECGs using AliveCor for 6 months following cardioversion or ablation procedure to treat AF/AFL. Participants will also receive read-only behavioral altering messaging three times per week focusing on AF, cardiovascular risk factors, and healthy living.
62530355|NCT02731326|NO_INTERVENTION|Usual Care|Participants will continue with usual care with their physician.
62530356|NCT02275130|EXPERIMENTAL|Calcium Hydroxyapatite|30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique
62530357|NCT00080938|EXPERIMENTAL|Temozolomide and Radiation|Temozolomide:administered orally. Radiation: whole brain radiation therapy
62530358|NCT05203718|EXPERIMENTAL|Patients with Obesity|NYU Langone Health patients ≥18 to 80 years of age with a BMI ≥30.0 kg/m2
62530359|NCT05154435|ACTIVE_COMPARATOR|Grup HYT|The group (GRUP HYT) to be treated with targeted fluid therapy will be monitored with a Mostcaretm (Vygon, VytechHealth, Padova, Italy) pulse contour hemodynamic monitor after arterial cannulation. Cardiacindex (CI), stroke volume variance (SVV), pulse pressure variance (PPV), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), oxygen delivery (Do2), arterial elastance (Ea) measurements and mean arterial pressure Every 5 minutes to be followed, fluid therapy will be planned in accordance with our algorithm.
62530360|NCT05154435|NO_INTERVENTION|Grup KON|Fluid deficit due to fasting time will be calculated in accordance with the 4-2-1 rule for patients in Group KON. half of the calculated fluid volume in the first hour; the remaining half will be given at the 2nd and 3rd Hours. (4ml/kg/hr for the first 10 kilograms, 2ml/kg/hr for the second 10 kg, 1ml/kg/hr for each subsequent kilogram). Maintenance fluid will be considered as a medium-sized surgical trauma and will be given at 4 ml/kg/hr. Hemorrhages will be replaced with 3 times the blood loss with balanced crystalloid or 1 times HES.
62530361|NCT04684004||TTC patients with hyperglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by higher blood glucose values at admission, and so defined as hyperglycemics.
62530362|NCT04684004||TTC patients with normoglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by normal blood glucose values at admission, and so defined as normoglycemics.
62530363|NCT01483469|ACTIVE_COMPARATOR|Concept Proof|
62530364|NCT01483469|EXPERIMENTAL|Receptor Occupancy|
62156188|NCT03563989|ACTIVE_COMPARATOR|Conventional Balloon-expandable stent|Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.
62530365|NCT03533738|EXPERIMENTAL|Food selection 1|To consume vegetables followed by meat \& rice together
62156189|NCT00925327|EXPERIMENTAL|Corneal collagen cross-linking with riboflavin and UVA light|
62156190|NCT00694902|EXPERIMENTAL|Sequence 1 of Cohort-I|Subjects in Sequence 1 will receive Placebo during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
62156191|NCT00694902|EXPERIMENTAL|Sequence 2 of Cohort-I|Subjects in Sequence 2 will receive 10 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
62156192|NCT00694902|EXPERIMENTAL|Sequence 3 of Cohort-I|Subjects in Sequence 3 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
62156193|NCT00694902|EXPERIMENTAL|Sequence 4 of Cohort-I|Subjects in Sequence 4 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
62156194|NCT00694902|EXPERIMENTAL|Sequence 5 of Cohort-II|Subjects in Sequence 5 will receive Placebo during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
62156195|NCT00694902|EXPERIMENTAL|Sequence 6 of Cohort-II|Subjects in Sequence 6 will receive 30 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
62156196|NCT00694902|EXPERIMENTAL|Sequence 7 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
62530366|NCT03533738|EXPERIMENTAL|Food selection 2|To consume meat followed by vegetables \& rice together
62530367|NCT03533738|EXPERIMENTAL|Food selection 3|To consume as follows: vegetables, meat, rice
62530368|NCT03533738|EXPERIMENTAL|Food selection 4|To consume vegetables followed by meat and rice together
62530369|NCT03533738|EXPERIMENTAL|Food selection 5|To consume rice followed by vegetables \& meat together
62530370|NCT02433262|PLACEBO_COMPARATOR|WHO (World Health Organisation)|"Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria:~Fasting glucose \>6 2 hour glucose \>7.7"
62530371|NCT02433262|ACTIVE_COMPARATOR|IADPSG|Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria: (International Association of Diabetes \& Pregnancy Study Group) Fasting glucose \>5 2 hour glucose \>8.4
62530372|NCT00643136|EXPERIMENTAL|Pregabalin|
62530373|NCT00643136|PLACEBO_COMPARATOR|Placebo|
62156197|NCT00694902|EXPERIMENTAL|Sequence 8 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
62156198|NCT00694902|EXPERIMENTAL|Cohort III|Subjects in Cohort III after randomization will either receive 1000 microgram GSK610677 or placebo.
62530374|NCT00090610|EXPERIMENTAL|Arm 1 - Combination Therapy|Docetaxel 30mg/m2 mg IV on Days 1 and 8, in combination with carboplatin AUC 6 IV on Day 1, repeated every 21 days X 6 cycles or until disease progression
62530375|NCT00090610|EXPERIMENTAL|Arm 2 - Sequential Therapy|Docetaxel 30mg/m2 IV on Days 1 and 8, repeated every 21 days for 6 cycles until disease progression. Once subjects have completed 6 cycles of docetaxel, they receive carboplatin AUC 6 IV every 21 days for 6 cycles or until disease progression.
62530376|NCT06180265|OTHER|septic shock patients|Septic shock patients undergoing major abdominal surgery treated with polymyxin-B
62530377|NCT04293328|EXPERIMENTAL|Monthly replacement lenses without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
62530378|NCT04293328|ACTIVE_COMPARATOR|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
62530379|NCT06348706|ACTIVE_COMPARATOR|Dipeptidyl peptidase-4 inhibitors supplementation|Intervention group receiving Dipeptidyl peptidase-4 inhibitors supplementation
62530380|NCT06348706|NO_INTERVENTION|Control group|Control group not receiving Dipeptidyl peptidase-4 inhibitors supplementation
62530381|NCT02414438|NO_INTERVENTION|Current Practice Arm|Physicians follow current care procedures
62530382|NCT02414438|EXPERIMENTAL|FirstStep and NextStep Information|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are able to order test results in Round 2
62156199|NCT01851694|EXPERIMENTAL|GLP-1|The incretin, Glucagon-Like-peptide-1 (GLP-1) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins. (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
62530383|NCT02414438|EXPERIMENTAL|FirstStep and NextStep Results|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are specifically prompted to order test results in Round 2
62530384|NCT02524730|OTHER|Scorpio NRG CR Total Knee System|Primary total knee replacement
62530385|NCT03183492|EXPERIMENTAL|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
62530386|NCT03627507|EXPERIMENTAL|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
62530387|NCT03627507|ACTIVE_COMPARATOR|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
62530388|NCT03514849|EXPERIMENTAL|PCI group|
62530389|NCT03514849|PLACEBO_COMPARATOR|Control group|
62530390|NCT05352165|EXPERIMENTAL|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
62156200|NCT01851694|EXPERIMENTAL|GIP|The incretin, Glucose-dependent Insulinotropic Polypeptide (GIP) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
62156201|NCT02646878|OTHER|Harmony 1 Sensor Group A|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 90 minutes after sensor insertion.
62530391|NCT05352165|ACTIVE_COMPARATOR|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
62530392|NCT05352165|ACTIVE_COMPARATOR|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
62156202|NCT02646878|OTHER|Harmony 1 Sensor Group B|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 12 hours after sensor insertion.
62156203|NCT05786911||vaginal delivery under epidural|60 patients, having had a vaginal delivery under an epidural, will be recruited at the maternity ward
62156204|NCT04803253|EXPERIMENTAL|Participants using the ORTHOPUS set of prosthetic solution|
62156205|NCT00739388|EXPERIMENTAL|Arm: 5-azacytidine|5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.
62156206|NCT05281809|EXPERIMENTAL|Treatment Arm|CAR -T-cell collection, infusion
62156207|NCT05201625|ACTIVE_COMPARATOR|control group|Healthy control group
62156208|NCT05201625|ACTIVE_COMPARATOR|ICU COVID 19 patients|ICU COVID 19 patients
62156209|NCT05201625|ACTIVE_COMPARATOR|non-ICU covid 19 patients|non-ICU covid 19 patients
62156210|NCT01201278|EXPERIMENTAL|Nasal insulin 8 IU|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
62156211|NCT01201278|EXPERIMENTAL|Nasal insulin 16 IU|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
62530393|NCT05352165|ACTIVE_COMPARATOR|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
62156212|NCT01201278|ACTIVE_COMPARATOR|Subcutaneous insulin lispro 8 U|Subcutaneous insulin lispro (Humalog®) 8 U
62156213|NCT00997152|EXPERIMENTAL|Dose 1 JTT-654|
62156214|NCT00997152|EXPERIMENTAL|Dose 2 JTT-654|
62156215|NCT00997152|PLACEBO_COMPARATOR|Placebo|
62156216|NCT02506322|EXPERIMENTAL|SEKT Cognitive-Behavioral-Emotional|Specific psychotherapy (SEKT - 4 modules) for typical problems of Bipolar patients to maintain remission and to prevent relapse. Including classical elements of self observation, psychoeducation, cognitive and behavioral interventions, social rhythm but also emotion regulation and meta-cognitive techniques. Delivered in a group setting in 4 one day treatment workshops, each one month apart. Homework assignment and electronical monitoring during time between sessions.
62156217|NCT02506322|ACTIVE_COMPARATOR|FEST Clinical Supportive Educational|This supportive, active control psychotherapy (FEST) is using general principals and non-specific interventions such as positive attitude, optimism, support, empathy, focus on emotion, self-help, strengthening and eliciting own resources, time and room for discussion of personal experiences. Psychoeducation about illness and drug treatment (mood stabilizer) to facilitate compliance.
62156218|NCT00976053|ACTIVE_COMPARATOR|SPECT myocardial perfusion imaging|
62156219|NCT00976053|ACTIVE_COMPARATOR|PET myocardial perfusion imaging|
62156220|NCT01637194|EXPERIMENTAL|Treatment (enzyme inhibitor, monoclonal antibody therapy)|Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62156221|NCT04126993|EXPERIMENTAL|Camrelizumab+ Apatinib test group|Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
62156222|NCT04126993|ACTIVE_COMPARATOR|Apatinib single drug control group|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
62156223|NCT01574105||Heparin Resistant|Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
62156224|NCT01574105||Heparin Sensitive|Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.
62156225|NCT03924362|ACTIVE_COMPARATOR|Simultaneous Bilateral PCNL|Patients undergo simultaneous bilateral PCNL.
62530394|NCT05352165|ACTIVE_COMPARATOR|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
62156226|NCT03924362|ACTIVE_COMPARATOR|Unilateral PCNL|Patients undergoing unilateral staged PCNL.
62156227|NCT02033915|EXPERIMENTAL|Interactive Discussion Group|The interactive discussion groups were held for six times (8-10 persons for each group). During the 50-60 minutes' discussion, the facilitators guided the participants to discuss a case vignette, focusing on the key issues of hospital suicide prevention, and to enhance their abilities of suicide risk identification and evaluation. Two research team members who served as facilitators led the group in a standardized manner.
62530395|NCT05352165|ACTIVE_COMPARATOR|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
62530396|NCT06013410|EXPERIMENTAL|IBS group|patients diagnosed with IBS according to clinical presentations
62530397|NCT06013410|NO_INTERVENTION|Healthy control group|healthy control group
62530398|NCT05430984|ACTIVE_COMPARATOR|Laparoscopic TAPP inguinal hernia repair with mesh fixation|the mesh will be fixed to the abdominal wall using suture, spiral tacks.
62530399|NCT05430984|ACTIVE_COMPARATOR|Laparoscopic TAPP inguinal hernia repair without mesh fixation|the mesh will be left as it is and the operation will be concluded
62530400|NCT02068664||Observational|prism adaptation treatment
62530401|NCT04681066|ACTIVE_COMPARATOR|2.0 mg/kg (1.25 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
62530402|NCT04681066|ACTIVE_COMPARATOR|1.0 mg/kg (0.625 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
62156228|NCT01092325|EXPERIMENTAL|Cohort 1 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
62156229|NCT01092325|PLACEBO_COMPARATOR|Cohort 1 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
62156230|NCT01092325|EXPERIMENTAL|Cohort 2 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
62156231|NCT01092325|PLACEBO_COMPARATOR|Cohort 2 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
62156232|NCT01092325|ACTIVE_COMPARATOR|Echo Cohort A CXL-1020|A 4 hour infusion of a fixed dose of CXL-1020 which was studied in Cohort 1 or Cohort 2 which is expected to be well tolerated and have hemodynamic effect
62530403|NCT04681066|ACTIVE_COMPARATOR|0.5 mg/kg (0.3125 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
62714027|NCT05876923|ACTIVE_COMPARATOR|Aims 3-4 arm I (indolent NHL usual care)|Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients receive usual care on study.
62156233|NCT01092325|ACTIVE_COMPARATOR|Echo Cohort B CXL-1020|CXL-1020 administered at a fixed rate for the initial 2 hours and at a higher fixed rate for the last 2 hours of a 4 hour infusion at doses which were studied in Cohort 1 or Cohort 2 and expected to be well tolerated and have hemodynamic effects
62530404|NCT04681066|PLACEBO_COMPARATOR|Placebo (1.25, 0.625, or 0.3125 mL/kg)|patients randomized to placebo will receive one of three following volumes (1.25 mL/kg, 0.625 mL/kg, and 0.3125 mL/kg. although three volumes - all patients randomized to placebo will be analyzed together as one arm. administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
62530405|NCT00914914|EXPERIMENTAL|p28 Phase I Safety|A total of 15 patients were administered p28 i.v. as a short infusion three times per week for 4 weeks followed by a 2-week rest under an accelerated titration 3þ3 dose escalation design.
62530406|NCT04492826||Infected patients|patients with bone flap surgeries
62530407|NCT00088621|EXPERIMENTAL|Lurasidone 80 mg tablet|Lurasidone 80mg oral tablet taken once a day
62530408|NCT01305174|ACTIVE_COMPARATOR|Balloon expandable stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted"
62530409|NCT01305174|ACTIVE_COMPARATOR|Selfexpanding stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter."
62530410|NCT00144911|EXPERIMENTAL|Arm 1|
62530411|NCT04889144|EXPERIMENTAL|Arm I (PLAN intervention)|Patients participate in PLAN intervention, consisting of 3 coaching sessions over 45-60 minutes each with a health coach.
62530412|NCT04889144|ACTIVE_COMPARATOR|Arm II (Best practice)|Patients receive usual care.
62530413|NCT02528513|EXPERIMENTAL|midazolam|"1. Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~2. After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation."
62530414|NCT02528513|EXPERIMENTAL|midazolam/propofol|"1. Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~2. After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation."
62530415|NCT02528513|EXPERIMENTAL|midazolam/dexmedetomidine|"1. Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~2. After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation."
62530416|NCT01449097|EXPERIMENTAL|Adductor-Canal-Blockade|
62530417|NCT01449097|ACTIVE_COMPARATOR|The femoral nerve block|
62530418|NCT01449097|PLACEBO_COMPARATOR|Placebo|
62530419|NCT05589532|EXPERIMENTAL|Prosthetic single-tooth prosthesis using PEEK|An implant-supported single tooth prosthesis using a PEEK polymer in its composition
62530420|NCT04166448||Group 1: High risk IUGR patients|EPF\<10th perc or PA\<10th perc and Doppler ombilical IP\> 95th percentile, EPF or PA\<3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),
62530421|NCT04166448||Group 2: Low risk IUGR patients|EPF et PA\>20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)
62530422|NCT03801889|EXPERIMENTAL|Cohort 1|SP-420 initially at 28 mg/kg
62530423|NCT03801889|EXPERIMENTAL|Cohort 2|SP -20 initially at 56 mg/kg
62530424|NCT03801889|EXPERIMENTAL|Cohort 3|SP-420 initially at 84 mg/kg
62530425|NCT02901964|EXPERIMENTAL|Group Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
62530426|NCT02901964|ACTIVE_COMPARATOR|Group Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
62530427|NCT03277235|EXPERIMENTAL|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
62156234|NCT03968276|EXPERIMENTAL|use of digital tablet|"if the patient is included in the study, an educational tablet (digital tablet) is given to the patient.~The first connection to the tablet and then to the My medication protects my vessels application is made by the investigator in the presence of the patient. The application is configured by the investigator with the choice of the vascular pathology(s) corresponding to the patient included and the prescribed anti-thrombotic treatments. Thus, for each patient, the content of the tablet is adapted and personalized according to his vascular profile.~After discharge from hospital, the patient has the educational tablet at his disposal for 1 month at home. The application offers patients various information supports (tools, questionnaires and pill box). Throughout its use, it may contact the investigating physician via a telephone number available within the application if it encounters a problem related to the study."
62530428|NCT03277235|NO_INTERVENTION|Control|Usual care
62530429|NCT00539227||NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC). Questionnaires taking about 20-30 minutes to complete.
62530430|NCT03554213||Phase 1: TCV in 2018|Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.
62530431|NCT03554213||Phase 2: TCV in 2019|Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.
62530432|NCT04791475|EXPERIMENTAL|Dexmedetomidine with 0.5% bupivacaine|1mcg/kg dexmedetomidine as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
62530433|NCT04791475|ACTIVE_COMPARATOR|Dexamethasone with 0.5% bupivacaine|4mg dexamethasone as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
62530434|NCT00813631|EXPERIMENTAL|silver-releasing dressings|Silver, in its common ionic (active) form (Ag+), is particularly attractive as an antibacterial agent because it can be readily incorporated into dressing materials. Silver-dressing are wound products designed to control infection and provide a wound environment conducive to management exudates, pain, and malodour.
62530435|NCT01965392|EXPERIMENTAL|healtn education|one group received an educational program
62156235|NCT03276286|EXPERIMENTAL|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
62156236|NCT06411054|EXPERIMENTAL|Au-TENS group|Women will receive acu-TENS from 15 minutes before USG-MVA to 15 minutes after USG-MVA.
62714028|NCT05876923|ACTIVE_COMPARATOR|Aims 3-4 arm II (indolent NHL aerobic based training program)|Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients complete aerobic based training program on study. Patients then complete all baseline activities again after completion of aerobic based training program.
62714029|NCT05876923|EXPERIMENTAL|Aim 5 (repeat baseline activities)|All patients from Aims 3-4 will be invited to repeat Aims 3-4 baseline activities.
62156237|NCT06411054|SHAM_COMPARATOR|Sham acu-TENS group|Women will receive sham acu-TENS from 15 minutes before USG-MVA to 15 minutes after USG-MVA. In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current.
62156238|NCT01472796|ACTIVE_COMPARATOR|Tekturna (Aliskirin) with vit. D supplementation|Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.
62156239|NCT01472796|PLACEBO_COMPARATOR|Tekturna (Aliskiren) with placebo|Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)
62530436|NCT04229459|EXPERIMENTAL|Neoadjuvant Treatment|All subjects will receive induction chemotherapy and chemoradiation combined with cetuximab followed by nivolumab and cetuximab as neoadjuvant treatment
62530437|NCT04175210|EXPERIMENTAL|ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
62530438|NCT04175210|EXPERIMENTAL|ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
62714030|NCT04770493|EXPERIMENTAL|Lamotrigine|Lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks
62714031|NCT04770493|PLACEBO_COMPARATOR|Placebo|Identical matching placebo capsules
62530439|NCT05934240|ACTIVE_COMPARATOR|Experimental group|Diaphragmatic mobilization, toracic mobilization and manipulation
62530440|NCT05934240|PLACEBO_COMPARATOR|Control group|Placebo mobilization and manipulation
62530441|NCT04539886|EXPERIMENTAL|CellFX System|The CellFX System consists of a electrical pulse console combined with a handpiece coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm). Based on the size of the SH lesion and treatment tip used, a predetermined treatment energy setting is selected to deliver a sequence of electrical pulses to the SH lesion area directly beneath the treatment tip.
62156240|NCT04618653||Early AA Attenders with Alcohol Use Disorder|observational study that includes three fixed assessments (Baseline, 3, and 6-month). Subset of participants will also provide daily EMA data.
62714032|NCT06410521|EXPERIMENTAL|Supervised multicomponent exercise|Experimental arm will perform the supervised exercise programme three times a week, with each session taking approximately 60-80 minutes for a period of 12 weeks.
62714033|NCT06410521|ACTIVE_COMPARATOR|Usual care|Active comparator arm will be advised to lifestyle modification and to perform regular walking for a period of 12 weeks.
62714034|NCT06410521|EXPERIMENTAL|Home-based exercise|After 12 weeks, both groups (Supervised multicomponent exercise and Usual care) will transit for the home-based exercise experimental arm. Experimental arm will perform regular walking at least three times week, with each walking taking approximately 30-40 minutes for a period of 12 weeks.
62714035|NCT06150157|EXPERIMENTAL|Dose Escalation (Part 1) and Dose Expansion (Part 2)|In dose escalation (Part 1), participants will receive JNJ-88549968. The dose will be escalated sequentially to determine the recommended phase 2 dose (RP2D) and optimal dosing schedule(s) based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens. In dose expansion (Part 2), participants will receive JNJ-88549968 at the RP2D regimen(s) determined in dose escalation (Part 1).
62156241|NCT00763919|EXPERIMENTAL|Customized Adherence Enhancement (CAE)|"Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles.~Treatment Modules:~Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module"
62156242|NCT05728372|EXPERIMENTAL|Treatment (64CDP PET)|Patients receive standard of care pembrolizumab IV at baseline. Patients then receive 64CDP IV days 1 and 29 on study. Patients undergo PET scan on days 2 and 30 on study. Patients also undergo standard of care SBRT days 8-18.
62156243|NCT06388824|PLACEBO_COMPARATOR|Placebo Group of patients undergoing surgical abortion with normal saline|Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
62156244|NCT06388824|ACTIVE_COMPARATOR|Group of patients undergoing surgical abortion with esketamine|Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery
62156245|NCT00410150|EXPERIMENTAL|Group 1 (Heliox-powered albuterol)|Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
62156246|NCT00410150|ACTIVE_COMPARATOR|Group 2 (Oxygen-powered albuterol)|Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.
62156247|NCT03921775|EXPERIMENTAL|Treatment group A|IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance
62530442|NCT04539886|ACTIVE_COMPARATOR|Intralesional Electrodesiccation|Intralesional Electrodesiccation involves using a Hyfrecator electrosurgical unit and a non-insulated epilation needle electrode to apply a high-frequency electric current within the lesion.
62530443|NCT03516396|EXPERIMENTAL|Training Plus|"Intervention: Community Development~Training plus enhanced community development activities"
62714036|NCT03864068|PLACEBO_COMPARATOR|Placebo Treatment bid|Women with PCOS (N = 30) will receive the daily placebo (maltodextrin and inulin) in an identical fashion as the active study group and will be monitored the same.
62714037|NCT03864068|EXPERIMENTAL|Active Treatment with Inositol 1gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 1000 mg of myo-inositol and 25 mg of d-chiro-inositol) over the initial 3 mos RCT period.
62156248|NCT03921775|ACTIVE_COMPARATOR|Treatment B|IV pumping of propofol at 120\~150mg/kg/h for anesthesia induction and 3\~12mg/kg/h for anesthesia maintenance
62156249|NCT02092909|EXPERIMENTAL|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
62156250|NCT03243838|EXPERIMENTAL|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
62156251|NCT00589745|OTHER|Subjects being evaluated for CF|Subjects will be referred from physicians who are clinically concerned about the possibility of Cystic Fibrosis. Nasal potential difference measurement will be obtained to potentially help aid in diagnosis.
62156252|NCT05990868|ACTIVE_COMPARATOR|Rectal tylenol group: Group 1|Randomization to the study group (Group 1): will receive standard anesthesia and 650 mg rectal Tylenol at the time of egg retrieval.
62714038|NCT03864068|EXPERIMENTAL|Active Treatment with Inositol 2 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 2000 mg of myo-inositol and 50 mg of d-chiro-inositol) over the initial 3 mos RCT period.
62714039|NCT03864068|EXPERIMENTAL|Active Treatment with Inositol 3 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 3000 mg of myo-inositol and 75 mg of d-chiro-inositol) over the initial 3 mos RCT period.
62714040|NCT00624845|EXPERIMENTAL|Drug|
62714041|NCT00624845|PLACEBO_COMPARATOR|Vehicle|
62156253|NCT05990868|PLACEBO_COMPARATOR|Placebo group: Group 2|Randomization to the standard of care group (Group 2): will receive standard anesthesia and rectal placebo at the time of oocyte retrieval. Placebo is a substance that has no therapeutic effect and used as a control in testing new drugs.
62530444|NCT03516396|ACTIVE_COMPARATOR|Control|No inputs
62530445|NCT03516396|EXPERIMENTAL|Training Only|"Intervention: Training~Training Only (livestock management and child nutrition)"
62156254|NCT06063915|ACTIVE_COMPARATOR|Gold Rehab + Strength Training|Gold standard rehabilitation plus traditional strength training with overloads
62156255|NCT06063915|EXPERIMENTAL|Gold Rehab + Isoinertial|Gold standard rehabilitation with the inclusion of isoinertial training
62156256|NCT03936725||Chronic and non specific low back pain patients|Chronic and non specific low back pain patients
62156257|NCT05088122||one group|
62156258|NCT04535440||Rectal varices with bleed|
62156259|NCT04535440||Rectal varices without bleed|
62156260|NCT05059145|EXPERIMENTAL|Chlorhexidine gluconate, 1% vaginal cream|8 ml vaginal cream every night for a week and then prophylactic treatment with 8 ml/week for another 11 weeks
62530446|NCT01008852|EXPERIMENTAL|Treatment Group 1|
62530447|NCT01008852|EXPERIMENTAL|Treatment Group 2|
62530448|NCT01008852|EXPERIMENTAL|Treatment Group 3|
62530449|NCT01008852|EXPERIMENTAL|Treatment Group 4|
62530450|NCT01008852|PLACEBO_COMPARATOR|Treatment Group 5|
62530451|NCT04190810|EXPERIMENTAL|Inhibition group|The inhibition group gets the instructions to respond to pictures that are not related to smoking by swiping/pulling them towards themselves, whereas pictures with tobacco-related content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
62530452|NCT04190810|EXPERIMENTAL|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon non-smoking related images by swiping/pulling towards themselves the picture. Pictures containing tobacco-related content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
62530453|NCT04190810|SHAM_COMPARATOR|Control group|This type of active control group receives the instructions to swipe tobacco-related pictures to the left and non-tobacco related pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
62530454|NCT01992523|EXPERIMENTAL|Ticagrelor mashed pills|Ticagrelor loading dose (LD) 180 mg as mashed pills
62156261|NCT05059145|ACTIVE_COMPARATOR|Fluconazole, 150 mg oral capsule|Fluconazole150 mg (oral capsule) every 3 days for the first 3 doses, then prophylactic treatment with 150 mg/week for another 11 weeks
62530455|NCT01992523|ACTIVE_COMPARATOR|Ticagrelor integral pills|Ticagrelor loading dose (LD) 180 mg as integral pills
62530456|NCT02836496|EXPERIMENTAL|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
62156262|NCT05109832|EXPERIMENTAL|14C-IMP4297|In this study, one 100 mg dose of 14C IMP4297 Oral Suspension, 100 mg (100 μCi).
62156263|NCT02710669|EXPERIMENTAL|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
62156264|NCT02710669|ACTIVE_COMPARATOR|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
62530457|NCT02836496|PLACEBO_COMPARATOR|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
62530458|NCT01167322|EXPERIMENTAL|NPC-07|Single administration of NPC-07 at a dose of 20mg/kg body weight
62156265|NCT02710669|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) is infused over 10 minutes
62156266|NCT03933241|EXPERIMENTAL|experiment group|nasal irrigation after transsphenoidal surgery for pituitary tumor
62714042|NCT00859833|EXPERIMENTAL|myocardial perfusion reserve|Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequentially (30 minutes apart) in the same sequence in every patient. The shorter acting drug (adenosine) is given first so it has time to wear off before giving the second drug. It is ideal to measure MPR with each drug during the same imaging session so that there are no other clinical variables that change between the administration of the 2 agents. See below.
62156267|NCT03933241|NO_INTERVENTION|matched group|without nasal irrigation after transsphenoidal surgery for pituitary tumor
62156268|NCT02802176|EXPERIMENTAL|Intra-vaginal culture - INVOcell device|3 day intra-vaginal incubation using the INVOcell device
62156269|NCT02802176|ACTIVE_COMPARATOR|Traditional IVF culture|3 day traditional IVF incubation
62530459|NCT01400919|EXPERIMENTAL|Protégé™ EverFlex™ and GPS™ Self-Expanding Stent Systems|The objective of the study is to confirm the safety and effectiveness of the Protégé EverFlex and Protégé GPS Self-Expanding Stent Systems in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
62530460|NCT04351048|EXPERIMENTAL|SW|stepwise excavation
62530461|NCT04351048|EXPERIMENTAL|OneS|one step excavation
62530462|NCT02488421||Patient treated with Apixaban|
62530463|NCT02488421||Patient treated with Rivaroxaban|
62156270|NCT04664179|EXPERIMENTAL|Arm A: Treatment without lymphodepletion chemotherapy|"C7R-EBVSTs~Group B will be activated if only limited expansion and clinical efficacy is observed in Group A"
62156271|NCT04664179|EXPERIMENTAL|Arm B: Treatment with lymphodepletion chemotherapy|C7R-EBVSTs with lymphodepletion chemotherapy
62156272|NCT06275256|EXPERIMENTAL|Rezum|This arm will receive the Rezum procedure.
62156273|NCT06275256|EXPERIMENTAL|iTind|This arm will receive the iTind Procedure
62156274|NCT02173756|EXPERIMENTAL|oral morphine gel|1 mg / ml of Morphine hydrochloride, presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
62156275|NCT02173756|PLACEBO_COMPARATOR|placebo gel|1 mg / ml of Placebo gel that is presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
62156276|NCT00986661|EXPERIMENTAL|PV-10 Injection (Intralesional)|Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.
62156277|NCT05773599|EXPERIMENTAL|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. 4 sessions of laughter yoga will be applied to the experimental group with a low sleep quality score, one day apart. Afterwards, sleep quality and life satisfaction will be evaluated with the posttest.
62156278|NCT05773599|NO_INTERVENTION|kontrol|A pre-test will be applied to evaluate sleep quality and life satisfaction. The control group with a low sleep quality score will not receive any intervention. In parallel with the experimental group, sleep quality and life satisfaction will be evaluated again with the posttest.
62156279|NCT04443556|ACTIVE_COMPARATOR|Group Rhomboid Intercostal and Subserratus Plane Block|Standart postoperative analgesia + Continue Rhomboid Intercostal and Subserratus Plane Block
62530464|NCT02488421||Patient treated with Dabigatran|
62530465|NCT02488421||Patient treated with vitamin K antagonists|
62530466|NCT01688570|ACTIVE_COMPARATOR|Duloxetine|Neuromuscular fatigue testing with duloxetine dose
62530467|NCT01688570|ACTIVE_COMPARATOR|Cyproheptadine|Neuromuscular fatigue testing with cyproheptadine dose
62530468|NCT01688570|PLACEBO_COMPARATOR|Placebo|Neuromuscular fatigue testing with placebo dose
62156280|NCT04443556|OTHER|Control Group|Standart postoperative analgesia
62530469|NCT05211414|EXPERIMENTAL|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
62714043|NCT06024291|EXPERIMENTAL|HIIT group|The exercise intervention will consist of a supervised HIIT (two walking- and one indoor cycling-based session weekly), starting with a habituation week at an intensity of 75% of the maximal heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and for a total duration of 45 min per session: warm-up for 10 min at 60%-70% HRmax followed by a high-intensity interval consisting of 4×4 min at 80%-95% HRmax with 3 min of active recovery at 60%-70% HRmax and a 10 min cool-down at 60%-70% HRmax. Heart rate will be monitored during training by Garmin HRM-Dual heart rate sensors combined with Garmin Forerunner 45S watches. Exercise scientists motivate the participants during the intervals and will control each participant's heart rate during and after every training session.
62156281|NCT03019809|EXPERIMENTAL|Plerixafor/G-CSF for HSCT conditioning|Myeloablative conditioning regimen with Plerixafor and G-CSF as addition agents before stem cell transplantation in WAS patients.
62156282|NCT06437158|EXPERIMENTAL|Low-dose Concentrations (1mg/ml) of Bleomycin|In this arm, patients with lymphatic malformations were treated by intracapsular injection with low-dose concentrations (1mg/ml) of Bleomycin.
62156283|NCT06437158|EXPERIMENTAL|High-dose Concentrations (2mg/ml) of Bleomycin|In this arm, patients with lymphatic malformations were treated by intracapsular injection with high-dose concentrations (2mg/ml) of Bleomycin.
62156284|NCT02674867|EXPERIMENTAL|Early treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART before 6 months-of-age (early treatment group) with an initial virologic success (HIV-1 RNA \<400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
62156285|NCT02674867|OTHER|Late treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART after 24 months-of-age (late treatment group) with an initial virologic success (HIV-1 RNA \<400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
62156286|NCT02967822||Patients with MRKH syndrome|"Biological samples for patients.~Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study."
62156287|NCT02967822||Healthy relatives|"Biological samples for healthy relatives.~Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)"
62156288|NCT02611193|EXPERIMENTAL|Manipulative treatment|Manipulative Treatment
62156289|NCT02611193|SHAM_COMPARATOR|Simulated manipulative treatment|Simulated manipulative treatment
62156290|NCT04155372|EXPERIMENTAL|30min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 30 min.
62156291|NCT04155372|EXPERIMENTAL|60min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 60 min.
62156292|NCT04155372|EXPERIMENTAL|90min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 90 min.
62156293|NCT01134497|ACTIVE_COMPARATOR|Arm A (control): carboplatin + placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle.
62156294|NCT01134497|EXPERIMENTAL|Arm B: carboplatin + ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
62530470|NCT05211414|NO_INTERVENTION|Usual Care|
62530471|NCT05320601|EXPERIMENTAL|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation 1 session
62156295|NCT01742832|ACTIVE_COMPARATOR|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
62156296|NCT01742832|PLACEBO_COMPARATOR|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
62156297|NCT03468348|PLACEBO_COMPARATOR|placebo group|
62156298|NCT03468348|ACTIVE_COMPARATOR|duloxetine 30|
62156299|NCT03468348|ACTIVE_COMPARATOR|duloxetine 60|
62156300|NCT03468348|ACTIVE_COMPARATOR|duloxetine 90|
62156301|NCT00558441|EXPERIMENTAL|1|
62156302|NCT03420729|EXPERIMENTAL|magnetic assisted capsule endoscopy|All participants will undergo magnetic assisted capsule endoscopy at the sloan medical centre
62156303|NCT03420729|ACTIVE_COMPARATOR|gastroscopy|All participants will undergo gastroscopy as standard of care at sheffield teaching hospitals
62156304|NCT05852197||Use a combination of anticoagulant or antiplatelet drugs ， group 1|
62156305|NCT05852197||Use a combination of anticoagulant or antiplatelet drugs， group 2|
62156306|NCT04503629|EXPERIMENTAL|Anaprazole Sodium 20mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
62156307|NCT04503629|EXPERIMENTAL|Anaprazole Sodium 40mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
62530472|NCT05320601|EXPERIMENTAL|Dry Needling|Dry Needling 1 session
62530473|NCT02573090|EXPERIMENTAL|Non-invasive resin based fissure sealing|Application of resin based fissure sealing after acid etching of carious occlusal surface
62530474|NCT02573090|ACTIVE_COMPARATOR|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
62530475|NCT05433727||Mycosis fungoides group|Patients who routinely have punch skin biopsy for diagnostic purposes and who were both clinically and histopathologically diagnosed with mycosis fungoides will be included. Patients who only have mycosis fungoides patch lesion on their body, over the age of 18, and who have not received topical treatment for the last 2 weeks or systemic therapy for 4 weeks will be included. Demographic, clinical, videodermoscopy, capillaroscopy (lesional) and histopathological data will be recorded.
62530476|NCT05433727||Parapsoriasis group|Patients who routinely have punch skin biopsy for diagnostic purposes and who were both clinically and histopathologically diagnosed with parapsoriasis will be included. Patients who only have parapsoriasis patch lesion on their body, over the age of 18, and who have not received topical treatment for the last 2 weeks or systemic therapy for 4 weeks will be included. Demographic, clinical, videodermoscopy,capillaroscopy (lesional) and histopathological data will be recorded.
62530477|NCT05009680|EXPERIMENTAL|Part 1 GB1211, Single Dose (Child Pugh B)|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
62530478|NCT05009680|EXPERIMENTAL|Part 1 GB1211 Healthy Matched Participants, Single Dose|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
62714044|NCT06024291|ACTIVE_COMPARATOR|Physical activity recommendation group|Asking physically inactive participants to maintain their inactive habits may not reflect realistic conditions and is no longer considered the best option in a randomised controlled exercise intervention. Indeed, most participants will be aware of the positive effects of PA - or will become aware of them during an exercise intervention study. Further, denying an exercise intervention to participants who would have benefited from it (for instance, participants at risk of cardiometabolic diseases) might be ethically questionable. In accordance with current practices, control group participants will be informed about the World Health Organization physical activity guidelines at the beginning of the study.
62714045|NCT05658575|EXPERIMENTAL|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
62714046|NCT05658575|PLACEBO_COMPARATOR|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
62714047|NCT01127620|EXPERIMENTAL|Bilastine|20 mg encapsulated tablets
62156308|NCT04503629|ACTIVE_COMPARATOR|Rabeprazole sodium 10mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
62156309|NCT04034732|EXPERIMENTAL|Mindfulness-based Relapses Prevention (MBRP)|The MBRP program will be delivered by an instructor with training in MBSR/MBCT who has more than two years of teaching experience in MBSR/MBCT. The MBRP programme will consist of 2.5 hour weekly sessions for 8 weeks. The mindfulness curriculum will include training in mindfulness through (1) a body scan, (2) sitting meditation and (3) mindful stretching exercises.
62156310|NCT04034732|ACTIVE_COMPARATOR|Usual Care Control Group (UCCG)|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
62156311|NCT04251325||Basic Life Support Course Participants|The study population includes all Danish citizens who attended a BLS training course certificate from 2016-2018 above the age of 15.
62156312|NCT04251325||Background population|The entire danish population above 15 years whom have not attended a BLS training course certificate from 2016-2018.
62156313|NCT03627156|EXPERIMENTAL|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
62530479|NCT05009680|EXPERIMENTAL|Part 2 GB1211 Multiple Dose, Twice a day (Child Pugh B)|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
62530480|NCT05009680|PLACEBO_COMPARATOR|Part 2 Placebo, Twice a day (Child Pugh B)|Placebo is administered twice daily
62530481|NCT05009680|EXPERIMENTAL|Part 1 GB1211, Single Dose (Child Pugh C)|Part 1 GB1211 Healthy Matched Participants, Single Dose
62530482|NCT05009680|EXPERIMENTAL|Part 3 GB1211 Healthy Matched Participants, Single Dose|Part 1 GB1211 Healthy Matched Participants, Single Dose
62714048|NCT01127620|ACTIVE_COMPARATOR|Cetirizine|10 mg encapsulated tablets
62714049|NCT01127620|PLACEBO_COMPARATOR|Placebo|Encapsulated tablets
62714050|NCT04240054|EXPERIMENTAL|Safety Lead-in Cohort A|"Six transplant-eligible multiple myeloma patients with renal impairment will be enrolled.~Bortezomib (1.5 mg/m\^2) subcutaneous on days 1,8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
62156314|NCT03627156|NO_INTERVENTION|Control|Control Arm is an arm to which the intervention will not be implemented.
62156315|NCT00835328|EXPERIMENTAL|Exendin (9-39) 0.02 mg/kg/hr|Cohort 1: Participants will be administered 0.02 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is \< 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
62156316|NCT00835328|EXPERIMENTAL|Exendin (9-39) 0.04 mg/kg/hr|Cohort 2: Participants will be administered 0.04 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is \< 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
62530483|NCT03550105|EXPERIMENTAL|GJ-Only|Study Subjects with Baseline Glucose of \> 150mg/dl, will have Gentle Jogger Only for 7 days
62530484|NCT03550105|EXPERIMENTAL|GJ-OGTT|Study Subjects with Baseline Glucose of \< 150mg/dl, will have Oral Glucose Tolerance Test (OGTT) at baseline and after 7 days of Gentle Jogger
62530485|NCT05644015|EXPERIMENTAL|experimental group (play group)|The experimental group played the escape room game. The experimental group played the game once in total.
62530486|NCT05644015|NO_INTERVENTION|control group|No intervention was made in the control group.
62530487|NCT02802774|ACTIVE_COMPARATOR|Plaster Splint|
62530488|NCT02802774|ACTIVE_COMPARATOR|Velcro Brace|
62530489|NCT02802774|ACTIVE_COMPARATOR|Soft Dressing|
62530490|NCT01662349|EXPERIMENTAL|Plasma|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
62530491|NCT05913778|EXPERIMENTAL|Enhanced external counterpulsation 35 hours per year|Subjects with Heart failure with Enhanced external counterpulsation therapy (inflation pressure 220-280 mm Hg; 35 procedures) was given as a 1-hour session, once daily, for a total of 35 sessions, 1 course per 12 months
62530492|NCT05913778|EXPERIMENTAL|Enhanced external counterpulsation 70 hours per year|Subjects with Heart failure with Enhanced external counterpulsation therapy (inflation pressure 220-280 mm Hg; 35 procedures) was given as a 1-hour session, once daily, for a total of 35 sessions, 1 course per 6 months
62530493|NCT05913778|SHAM_COMPARATOR|SHAM external counterpulsation|Subjects with Heart failure with SHAM external counterpulsation (inflation pressure 80 mm Hg; 35 procedures) was given as a 1-hour session, once daily, for a total of 35 sessions, 1 course per 12 months
62530494|NCT01323465|EXPERIMENTAL|Sequence 1A|Sativex and rifampicin
62530495|NCT01323465|EXPERIMENTAL|Sequence 1B|Sativex and rifampicin
62530496|NCT01323465|EXPERIMENTAL|Sequence 2C|Sativex and ketoconazole
62530497|NCT01323465|EXPERIMENTAL|Sequence 2D|Sativex and ketoconazole
62530498|NCT01323465|EXPERIMENTAL|Sequence 3E|Sativex and omeprazole
62530499|NCT01323465|EXPERIMENTAL|Sequence 3F|Sativex and omeprazole
62530500|NCT04811586|EXPERIMENTAL|one-step Hybrid Coronary Revascularization (HCR)|One-step HCR is defined as off-pump MIDCAB LIMA-LAD revascularization immediately followed by PCI for at-least one non-LAD lesion(or LAD-diagonal lesion) with DES implantation in a hybrid operating room.
62530501|NCT04811586|ACTIVE_COMPARATOR|Percutaneous Coronary Intervention (PCI)|PCI will be performed using standard technique at the discretion of interventional cardiologist with DES implantation in a routine catheter lab.
62530502|NCT04425538|EXPERIMENTAL|Infliximab|All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.
62714051|NCT04240054|EXPERIMENTAL|Expansion Cohort A|"15 transplant-eligible multiple myeloma patients with renal impairment will be enrolled.~Bortezomib (1.5 mg/m\^2)subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
62156317|NCT00835328|EXPERIMENTAL|Exendin (9-39) 0.10 mg/kg/hr|Cohort 3: Participants will be administered 0.10 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 6 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is \< 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
62530503|NCT01141244|EXPERIMENTAL|Treatment (temsirolimus, irinotecan, temozolomide)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and temozolomide PO and irinotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
62530504|NCT01432379||botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
62530505|NCT03296436|EXPERIMENTAL|Treatment Group|Group that will be receiving the investigational product
62530506|NCT02398773|EXPERIMENTAL|Diagnostic (FES PET/CT)|Between 0 to 30 days before start of endocrine therapy, patients receive F-18 16 alpha-fluoroestradiol IV over 2 minutes and undergo PET/CT. Patients may undergo a second FES-PET/CT study at least 24 hours after the first study and no later than 10 days after the initial study.
62530507|NCT00796263|OTHER|HAART|"The proposed HAART regimen consists of:~* 2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications~* Dolutegravir(DTG) 50 mg orally once daily"
61975798|NCT05859789|EXPERIMENTAL|study group: Kegel exercise combined with Mediterranean diet regimen for 12 weeks.|kegel and Mediterranean diet regimen :kegel ex same as controlled group in addition toMediterranean diet. The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will
61975799|NCT03894579|EXPERIMENTAL|SNK01|SNK01 infused weekly for 4 consecutive weeks
62530508|NCT01910974|EXPERIMENTAL|endoscopic sub-mucosal dissection|
62530509|NCT01199471||Chinese Patients Requiring Surgery with Anesthesia|Chinese patients 18 to 70 years of age, meeting the American Society of Anesthesiologists (ASA) Physical Status Class 1 (normal healthy), Class 2 (mild systemic disease), or Class 3 (severe systemic disease), who underwent surgery requiring general anesthesia (sevoflurane) administered per local Prescribing Information and endotracheal intubation or laryngeal mask airway (LMA).
62530510|NCT00570895|ACTIVE_COMPARATOR|A|Subjects in Arm A will receive the juice without ascorbic acid in addition to the muffin with ferrous fumarate.
62530511|NCT00570895|ACTIVE_COMPARATOR|B|Subjects in Arm A will receive the juice with 25mg ascorbic acid in addition to the muffin with ferrous fumarate
62530512|NCT03231644||FD/MAS Patients|Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.
62530513|NCT02118090|EXPERIMENTAL|Chloroquine|Patients treat with chloroquine sulfate (NIVAQUINE) 10 mg/kg/day - 3 days
62530514|NCT02118090|ACTIVE_COMPARATOR|DHA-PP|Patient treat with DHA 40 mg and PP 320 mg, (Duo-Cotecxin®) The approximate total adult dose is 2-4 mg/kg for DHA and 20mg/kg for PP
62530515|NCT02931006|PLACEBO_COMPARATOR|control|
62530516|NCT02931006|ACTIVE_COMPARATOR|experimental|
62530517|NCT01164345|EXPERIMENTAL|MOZOBIL|treatment with mozobil for autologous stem cell collection
62530518|NCT03287336|EXPERIMENTAL|Cohort 1|Dose of Tranexamic acid 5mg/kg will be administered.
62530519|NCT03287336|EXPERIMENTAL|Cohort 2|Dose of Tranexamic acid 10 mg/kg will be administered.
62156318|NCT00835328|EXPERIMENTAL|Exendin (9-39) 0.20 mg/kg/hr|Cohort 4: Participants will be administered 0.20 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is \< 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
62156319|NCT01872104|NO_INTERVENTION|Chemotherapy alone|Group that be scheduled to undergo chemothrapy only using FOLFOX4 protocol.
62156320|NCT01872104|EXPERIMENTAL|PDT and Chemotherapy|Group that not only be scheduled to undergo chemothrapy using FOLFOX4 protocol,but also receive colonscopy-assisted PDT.
62156321|NCT02364856||Children with cerebral palsy|
62156322|NCT04721483|ACTIVE_COMPARATOR|T3-T4 sympathicotomy|In this group, patients underwent a classical T3 and T4 sympathicotomy to treat primary palmar hyperhidrosis
62530520|NCT03287336|EXPERIMENTAL|Cohort 3|Dose of Tranexamic acid 15 mg/kg will be administered.
62530521|NCT04141358||Study group|Patients with end-stage renal disease who will undergo arteriovenous fistula (AVF) surgery will be recruited and follow-up them up to 6 weeks or until the AVF become suitable for hemodialysis.
62530522|NCT06633237|EXPERIMENTAL|Core training program|This group will participate in the core training intervention integrated into the warm-up during basketball training sessions. The core training program will be applied twice a week for 8 weeks. The intervention focuses on improving core and trunk stability to reduce jump-landing errors and enhance jumping performance.
62530523|NCT06633237|NO_INTERVENTION|Standard warm-up|This group will participate in the core training intervention integrated into the warm-up during basketball training sessions. The core training program will be applied twice a week for 8 weeks. The intervention focuses on improving core and trunk stability to reduce jump-landing errors and enhance jumping performance.
62530524|NCT02788786|EXPERIMENTAL|chlorhexidine|0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks
62530525|NCT02788786|EXPERIMENTAL|cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride oral rinse; 15ml, twice-daily, for 12 weeks
62530526|NCT02788786|ACTIVE_COMPARATOR|Salt and Water|Salt and water based oral rinse; 15ml, twice-daily, for 12 weeks
62156323|NCT04721483|EXPERIMENTAL|T3-T4 ramicotomy|In this group, patients underwent a selective T3 and T4 gray ramicotomy
62530527|NCT02788786|NO_INTERVENTION|No oral rinse|No rinse provided in this group
61975800|NCT06261320|EXPERIMENTAL|Experimental group|
62156324|NCT04655300||Group 1|
62156325|NCT04655300||Group 2|
62530528|NCT05872893|EXPERIMENTAL|ondansetron + dexamethasone, continuous infusion|Patients will receive a continuous infusion of age-adjusted doses of first-generation 5-HT3 receptor antagonist ondansetron in combination with dexamethasone
62530529|NCT05872893|ACTIVE_COMPARATOR|ondansetron + dexamethasone, push injection|Patients will receive standard i/v push injections of first-generation 5-HT3 receptor antagonist ondansetron and dexamethasone
62530530|NCT05476913|EXPERIMENTAL|geko™ T-3 interventional|The geko™ device will be applied bilaterally as soon as possible after randomisation and each geko™ device will be used to deliver one 24-hour dose. Devices will be worn continuously and changed every 24 hours. Treatment will be continued for a maximum of 30 days or until patient recovers mobility and is discharged, whichever comes earlier.
62530531|NCT05476913|NO_INTERVENTION|Intermittent Pneumatic Compression (IPC)|Control treatment will be IPC using NHS approved devices as used for standard clinical care. They will be applied to both legs as soon as possible after randomisation. They will not be changed unless damaged or soiled. Treatment will be continued for a maximum of 30 days or until patient recovers mobility and is discharged, whichever comes earlier.
62156326|NCT04655300||Group 3|
62530532|NCT03938714|ACTIVE_COMPARATOR|CH( Conventional Hemorrhoidectomy)|Closed Conventional Hemorrhoidectomy
62530533|NCT03938714|EXPERIMENTAL|HS( Harmonic Scalpel)|Harmonic Scalpel Hemorrhoidectomy
61975801|NCT00075140||1|All Participants hav a family member with Huntington Disease
61975802|NCT02176876|EXPERIMENTAL|GS-5745|Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.
61975803|NCT02176876|PLACEBO_COMPARATOR|Placebo to match GS-5745|Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.
62156327|NCT04655300||Group 4|
62156328|NCT04655300||Group 5|
62156329|NCT04655300||Group 6|
62156330|NCT00576485|EXPERIMENTAL|1|Cataract surgery and implantation of a spherical intraocular lens
62156331|NCT00576485|EXPERIMENTAL|2|Cataract surgery and implantation of a spherical intraocular lens
62156332|NCT05852509|EXPERIMENTAL|TPA4You group|Participants in the TPA4You group will be given an overview of the TPA4You program and PA exercise safety instructions. HF-FCPs will receive 28 PA sessions delivered by the coach over 12 weeks. The coached sessions will taper from 3 days/week (weeks 1-4) to 2 days/week (weeks 5-12) but exercise on 3 days/week will be recommended throughout. Participants will receive tailored motivational text messages every other day to encourage daily exercise and wearing the Fitbit.
62156333|NCT05852509|OTHER|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
62156334|NCT04748926|EXPERIMENTAL|Group 1|Participants will receive caplets after fast (treatment A) on Day 1 and caplets after meal (treatment B) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.
62156335|NCT04748926|EXPERIMENTAL|Group 2|Participants will receive caplets after meal (treatment B) on Day 1 and caplets after fast (treatment A) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.
62530534|NCT00635063|EXPERIMENTAL|AD 923|
62530535|NCT00635063|ACTIVE_COMPARATOR|MSIR|
62530536|NCT03876418|NO_INTERVENTION|Usual Care|Patients undergo twice daily measurement of intra-abdominal pressure. Clinicians manage patients according to usual care.
62530537|NCT03876418|ACTIVE_COMPARATOR|Aggressive|Patients undergo aggressive surveillance (q6h) if intra-abdominal pressure is elevated as well as prevention and treatment according to protocol driven guidelines adapted from the World Society of the Abdominal Compartment. This may include nasogastric decompression, limiting fluid administration, drainage of ascites, paralysis and/or abdominal decompression.
62530538|NCT01751763||Group 1|
62530539|NCT05416697|EXPERIMENTAL|cannabinoid|Cannabinoid in form of cannabis 2.7 mg THC 2.5 mg twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study
62530540|NCT05416697|PLACEBO_COMPARATOR|placeba|Placebo 1 droplet twice daily for 1 week then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study
62530541|NCT06152406|ACTIVE_COMPARATOR|Right Ventricular Only Pacing|All study participants will have an RV lead inserted, but this arm will have an RV lead only.
62530542|NCT06152406|OTHER|HIS Bundle Pacing|Participants in this group will have HIS bundle pacing, but in addition will have an RV lead inserted that will serve as a backup alternative in the event HIS bundle pacing is not effective.
62530543|NCT02717858|EXPERIMENTAL|Liraglutide|
62156336|NCT04103333|EXPERIMENTAL|Angelman Syndrome: Group 1|Participants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62530544|NCT02717858|PLACEBO_COMPARATOR|Placebo|
62156337|NCT04103333|EXPERIMENTAL|Angelman Syndrome: Group 2|Participants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62156338|NCT04103333|EXPERIMENTAL|Angelman Syndrome: Group 3|Participants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62156339|NCT04103333|EXPERIMENTAL|Angelman Syndrome: Group 4|Participants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62156340|NCT04103333|EXPERIMENTAL|Dup15q Syndrome: Group 1|Participants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62530545|NCT03870867||Seniors who have fallen|Emergency department patients over the age of 65 who present to the emergency department after a fall.
62530546|NCT01157806|EXPERIMENTAL|radiochemotherapy instead of surgery|
62156341|NCT04103333|EXPERIMENTAL|Dup15q Syndrome: Group 2|Participants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62156342|NCT04103333|EXPERIMENTAL|Dup15q Syndrome: Group 3|Participants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62156343|NCT04103333|EXPERIMENTAL|Dup15q Syndrome: Group 4|Participants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
62156344|NCT00753337|EXPERIMENTAL|Assurant Cobalt Iliac Stent|Assurant® Cobalt Iliac Stent System
62156345|NCT06393855|EXPERIMENTAL|contact lens with 8.4-mm base curve in right eye|A contact lens placed on the cornea after the single-step Trans-PRK，with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye
62156346|NCT06393855|EXPERIMENTAL|contact lens with 8.8-mm base curve in right eye|A contact lens placed on the cornea after the single-step Trans-PRK，with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye
62156347|NCT03684499|OTHER|study group (1)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
62530547|NCT03239912|EXPERIMENTAL|Twin-block group|Functional treatment will be applied using the Twin-block appliance.
62530548|NCT03239912|EXPERIMENTAL|Twin-block combined with low level laser|Functional treatment will be applied using the Twin-block appliance combined with low level laser.
62530549|NCT01699035||stroke survivors|stroke survivors who have either returned to work, have thought about returning to work, or have tried to return to work
61975804|NCT03921554|EXPERIMENTAL|Aicardi Goutières Syndrome patients receiving Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
62530550|NCT04561375|ACTIVE_COMPARATOR|Intervention Group|30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
62530551|NCT04561375|PLACEBO_COMPARATOR|Control Group|placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia
62530552|NCT04952636|EXPERIMENTAL|Arthroscopic Cuistow|Patients who receive arthroscopic Cuistow procedure
62530553|NCT04952636|EXPERIMENTAL|Open Cuistow|Patients who receive open Cuistow procedure
61975805|NCT06228560|EXPERIMENTAL|LP-003 group 1|Participants received LP-003 subcutaneously during the 24-week treatment period
61975806|NCT06228560|EXPERIMENTAL|LP-003 group 2|Participants received LP-003 subcutaneously during the 24-week treatment period
62156348|NCT03684499|NO_INTERVENTION|control group( 2)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
62530554|NCT04452253|EXPERIMENTAL|PS128|"The PS128, which belongs to Lactobacillus plantarum subsp. plantarum, 2 caps daily use and used in both sub-project 1 and 2.~Sub-project 2 (Open label) for IT specialists only take PS128."
62530555|NCT04452253|EXPERIMENTAL|PS23 live|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use, only used in sub-project 1.
62530556|NCT04452253|EXPERIMENTAL|PS23 heat-treated|PS23 heat-treated, 2 caps daily use, only used in sub-project 1.
62530557|NCT04452253|PLACEBO_COMPARATOR|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use, only used in sub-project 1.
62156349|NCT05121376|EXPERIMENTAL|BMN 331|AAV Gene Therapy Infusion
62156350|NCT02704637|EXPERIMENTAL|HS-1000 recording|Each non-invasive recording session with the HS-1000 device will be done for 10 consecutive uninterrupted minutes. Patients will be recorded once daily for the duration of their time in ICU or for up to 14 days total. In the case the PI or a member of the study team positively confirms vasospasm based on clinical assessment or follow-up care during the monitoring period, the patient will be recorded twice daily for up to 14 consecutive days or for their duration in the ICU.
62156351|NCT01916447|EXPERIMENTAL|TAS-102 and CPT-11 with or without Bevacizumab|
62156352|NCT02049684||Surgery|
62156353|NCT02049684||Physiotherapy|
62156354|NCT00197444|EXPERIMENTAL|1|Chemoradiotherapy
62156355|NCT00657709|EXPERIMENTAL|rMenB Lot1|Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
62156356|NCT00657709|EXPERIMENTAL|rMenB Lot2|Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
62156357|NCT00657709|EXPERIMENTAL|rMenB Lot3|Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
62156358|NCT00657709|ACTIVE_COMPARATOR|Routine|Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
62156359|NCT00657709|ACTIVE_COMPARATOR|MenC + Routine|Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.
62530558|NCT03265288|EXPERIMENTAL|LAU-7b|Active drug fenretinide (as LAU-7b capsules)
62530559|NCT03265288|PLACEBO_COMPARATOR|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
62530560|NCT03321838|EXPERIMENTAL|Accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
62530561|NCT04682730|EXPERIMENTAL|Deliberative Loop|28-page Context-Setting Document; 2-page addendum to Context-Setting Document; 90 minute Deliberative session; 8-page post-session survey
62530562|NCT04838548|EXPERIMENTAL|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
62530563|NCT05136300|EXPERIMENTAL|Intervention|An integrated multidisciplinary rehabilitation program on general quality of life (short form 36, SF-36, subdomain general health) in the 12 months postoperative period in patients undergoing elective minimal invasive surgery in lung cancer
62530564|NCT05136300|NO_INTERVENTION|Control|Standard of care
62156360|NCT00380809|ACTIVE_COMPARATOR|Rotational Atherectomy + PES|Elective lesion preparation with rotational atherectomy priot to stent implantation
62156361|NCT00380809|ACTIVE_COMPARATOR|Standard Treatment (PES without Rotational Atherectomy)|Stenting without prior rotational atherectomy, usually preceeded with balloon dilatation
62156362|NCT06430606||Patients undergoing robotic-assisted laparoscopic surgery|The patients consist of ASA I-II or III group undergoing robotic-assisted laparoscopic surgery.
62156363|NCT03312972|EXPERIMENTAL|HDR Brachytherapy|HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion in one to two fractions.
62156364|NCT03382535|ACTIVE_COMPARATOR|Voice therapy|An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
62530565|NCT02203214||Ligamys|All patients treated with Ligamys can be included in the study. Patients must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled.
62530566|NCT00690976|EXPERIMENTAL|1.Group Intervention|A group-based intervention consisting of 4 sessions lasting approximately 90 minutes each. Using a variety of pedagogical and interactive approaches, facilitators will introduce new concepts and skills.
62530567|NCT00690976|ACTIVE_COMPARATOR|2. HCT|Offer of HIV counseling and testing
62530568|NCT03311100||Lung cancer|
62530569|NCT03311100||Central Nervous System Cancers|
62530570|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
62530571|NCT03311100||Skin cancers|
62530572|NCT03311100||Sarcomas|
61975807|NCT06228560|EXPERIMENTAL|LP-003 group 3|Participants received LP-003 subcutaneously during the 24-week treatment period
62530573|NCT03311100||Urothelial cancer|
62530574|NCT03311100||Hepatocarcinoma|
62530575|NCT03452332|EXPERIMENTAL|Treatment (tremelimumab, durvalumab, SABR)|Participants receive tremelimumab IV over 1 hour followed by durvalumab IV over 1 hour on day 1 of each cycle. Participants also undergo SABR over 30-45 minutes on days 8, 10, and 12 of cycle 1. Treatment with tremelimumab repeats every 4 weeks for up to 4 cycles, and treatment with durvalumab repeats every 4 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
62530576|NCT04298060|EXPERIMENTAL|DAS181 SD group Cohort 1, Stage 1|DAS181 SD group 4.5mg/day for 7 or 10 days
62530577|NCT04298060|EXPERIMENTAL|DAS181 HD group Cohort 1, Stage 1|DAS181 HD group 9mg/day for 7 or 10 days.
62530578|NCT04298060|PLACEBO_COMPARATOR|Placebo, Cohort 1, Stage 1|Placebo 0mg/day for 7 or 10 days
62156365|NCT03382535|EXPERIMENTAL|Voice therapy with carryover strategies|A voice therapy as described above and an enhanced carryover program. By carryover we mean the process of extending new vocal skills outside the clinic. It includes supplementary tasks and reminders that will be tailored individually out of those direct and indirect methods that the subjects have adopted during therapy sessions. Additionally, the teachers will be doing vocal warm-up and relaxation exercises together with their pupils int the beginning and in the middle of a school day. The intervention will take eight weeks.
62156366|NCT03382535|OTHER|Control group|No intervention during eight weeks since this group will act as a temporary control group. After eight weeks, half of the participants in this group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
62156367|NCT02670161|ACTIVE_COMPARATOR|Treatment A (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
62530579|NCT04298060|EXPERIMENTAL|DAS181 group, Cohort 1, Stage 2|DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.
62530580|NCT04298060|PLACEBO_COMPARATOR|Placebo, Cohort 1, Stage 2|Placebo 0mg/day for 7 or 10 days
62530581|NCT04298060|EXPERIMENTAL|DAS181 group, Cohort 2, Stage1 and 2|DAS181 4.5mg/day or 9mg/day for 7 or 10 days
62530582|NCT01239875|EXPERIMENTAL|Arm A|Patients receive pneumococcal polyvalent vaccine intramuscularly in weeks -4, 2, and 10. Patients undergo cryoablation followed by dendritic cell vaccine (CA-DC) intratumorally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
62530583|NCT01239875|EXPERIMENTAL|Arm B|Patients receive pneumococcal polyvalent vaccine as in arm A. Patients also receive autologous dendritic cell-tumor fusion vaccine (TL-DC) intradermally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
62530584|NCT01879865|OTHER|Non-stimulation|No auditory stimulation during dexmedetomidine infusion and recovery.
62530585|NCT01879865|OTHER|Stimulation|Auditory stimulation during dexmedetomidine infusion and recovery.
62530586|NCT01476618||Denver VA OIF/OEF and mental health providers|Denver VA OIF/OEF and mental health providers
62530587|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.~No interventions will be administered."
62530588|NCT05695677|OTHER|Tecar treatment sucess|
62530589|NCT01072955|EXPERIMENTAL|heparin of bovine origin|5.000UI/mL bottle with 5mL
62530590|NCT01072955|ACTIVE_COMPARATOR|heparin of porcine origin|5000 USP Heparin Units / mL vial with 10 mL vial
62530591|NCT00003875|EXPERIMENTAL|Treatment (chemo, stem cell rescue, interleukin therapy)|"PREPARATIVE REGIMEN: Patients receive busulfan IV over 2 hours or PO every 6 hours on days -7 to -4 and etoposide IV on day -3.~STEM CELL INFUSION: Patients undergo autologous or syngeneic PBSC rescue on day 0.~POST-TRANSPLANT ALDESLEUKIN THERAPY: Beginning 30-100 days after transplant, patients receive low-dose aldesleukin SC daily for 12 weeks."
62530592|NCT03296761||ESM-1<5ng/ml|
62530593|NCT03296761||ESM-1≥5ng/ml|
62530594|NCT04714983|EXPERIMENTAL|Dose-level 1|The dose-level 1 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
62530595|NCT04714983|EXPERIMENTAL|Dose-level 2|The dose-level 2 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
62530596|NCT04714983|EXPERIMENTAL|Dose-level 3|The dose-level 3 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
62530597|NCT06182176|EXPERIMENTAL|SMC plus anthelminthics group|Anthelminthic drugs (albendazole and praziquantel) will be administered 24 hours (on Day 0) before administration of the following SMC drugs: Sulphadoxine-pyrimethamine (SP) on Day 1 and Amodiaquine (AQ) daily on Days 1, 2 and 3.
62530598|NCT06182176|ACTIVE_COMPARATOR|SMC group|Participants randomized into the control communities will receive Vitamin A and Zinc supplements as control drugs on Day 0. On Day 1, these participants will receive the SMC drug (Sulphadoxine-pyrimethamine) (SP) and Amodiaquine (AQ) daily on Days 1,2 and 3.
62530599|NCT05284461|PLACEBO_COMPARATOR|Mechanized parallel abutments|Implants were immediately covered with this type of abutments after insertion. This is the most common procedure. It would be the gold standard
62530600|NCT05284461|EXPERIMENTAL|Anodized parallel abutments|Implants were immediately covered with this kind of abutments after insertion. Only the surface treatment varies to the gold standard
62530601|NCT05284461|EXPERIMENTAL|Mechanized convergent abutments|Implants were immediately covered with this kind of abutments after insertion. Only the geometry of the emergence profile varies with regards to the gold standard
62530602|NCT05284461|EXPERIMENTAL|Anodized convergent abutments|Implants were immediately covered with this kind of abutments after insertion. Both the surface treatment and the geometry vary with regards to the gold standard
62530603|NCT01906567||severe preeclamptic women|"Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:~• SBP of 160 mm Hg or higher or DBP of 110 mm Hg or higher on 2 occasions at least 6 hours apart~• Proteinuria of more than 5 g in a 24-hour collection or more than 3+ on 2 random urine samples collected at least 4 hours apart~• Pulmonary edema or cyanosis~• Oliguria (\< 400 mL in 24 h)~• Persistent headaches~• Epigastric pain and/or impaired liver function~• Thrombocytopenia~• Oligohydramnios, decreased fetal growth, or placental abruption"
62156368|NCT02670161|ACTIVE_COMPARATOR|Treatment B (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
62156369|NCT02670161|ACTIVE_COMPARATOR|Treatment C (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
62156370|NCT05873634||HFpEF|Participants with HFpEF
62156371|NCT05873634||Non-HFpEF|Participants without HFpEF
62156372|NCT06541795|EXPERIMENTAL|AcrySof IQ Vivity Extended Vision IOL and AcrySof IQ Vivity Toric Extended Vision IOL|AcrySof IQ Vivity Extended Vision IOL implanted in both eyes during cataract surgery
62156373|NCT02384122|ACTIVE_COMPARATOR|Octreotide|Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
62156374|NCT02384122|NO_INTERVENTION|Standard of care|Patients receive standard of care without a placebo.
62156375|NCT01736488|EXPERIMENTAL|Fimasartan 60mg|60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
62530604|NCT01906567||mild preeclamptic women|Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage in the patient.
62530605|NCT01906567||Healthy Pregnant Women|healthy pregnant women at term who not developed any complication of pregnancy
62530606|NCT00097903|EXPERIMENTAL|1|Karenitecin IV/ Karenitecin tablet
62530607|NCT05206292|OTHER|Patient cohort|There is only one patient arm. It corresponds to the cohort of included patients, all of whom had psychotic disorders with no known organic etiology.
62530608|NCT04465552||Hospitalized COVID-19 Patients|
62530609|NCT02885597|EXPERIMENTAL|Juanbi group|participants should administrate both Juanbi pill and Methotrexate
62530610|NCT02885597|PLACEBO_COMPARATOR|placebo group|participants should administrate both Juanbi pill placebo and Methotrexate
62530611|NCT02547155|EXPERIMENTAL|Spinal anesthesia|Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
62530612|NCT02547155|ACTIVE_COMPARATOR|General anesthesia|Subjects randomized to general anesthesia will receive propofol induction, in combination with a muscle relaxant and inhalational gas per anesthesia standard of care at our institution
62530613|NCT05962580|EXPERIMENTAL|Isolated anterior cruciate ligament recnostruction with lateral extra articular tenodesis|Arthroscopic anatomical single bundle anterior cruciate ligament reconstruction with modified Lemiere technique for extra-articular tenodesis
62156376|NCT01736488|ACTIVE_COMPARATOR|Atenolol 50mg|50mg/day of Atenolol will be oral administered for the study period (8 weeks)
62156377|NCT03975361|OTHER|Bliss-Believe|Patients included in the BLISS-BELIEVE study (NCT03312907).
61975808|NCT06228560|ACTIVE_COMPARATOR|Omalizumab|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24-week treatment period
62530614|NCT05962580|ACTIVE_COMPARATOR|Isolated anterior cruciate ligament recnostruction without lateral extra articular tenodesis|Arthroscopic anatomical single bundle anterior cruciate ligament reconstruction only
62530615|NCT02951468||Nonunion group|All patients who were treated for clavicular non- or malunion with a locking compression plate and an iliac crest bone graft between January 2010 and December 2014 were included in this retrospective study.
61975809|NCT06228560|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24-week treatment period
61975810|NCT05373329|EXPERIMENTAL|self-guided app use|Participants receive the self-guided app intervention immediately. All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
62156378|NCT05487209||postmenopausal group|
62156379|NCT05487209||non-menopausal group|
62156380|NCT03398902|EXPERIMENTAL|Sleep extension|Participants in the sleep extension group will keep daily sleep diaries. Sleep diaries will be reviewed with the participant and an instructor trained in Cognitive Behavioral Therapy for Insomnia (CBTI) on a weekly basis. These weekly sessions will take place by telephone or videoconferencing.
62156381|NCT03398902|ACTIVE_COMPARATOR|Habitual sleep|Participants in the habitual sleep group will be instructed to keep their habitual bedtimes and wake times. Participants will keep daily sleep diaries that will we reviewed by a study team member each week. These weekly sessions will take place by telephone or videoconferencing.
62156382|NCT01033123|EXPERIMENTAL|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
62156383|NCT03610984||Intensive structured education group|Regular outpatient visit in every 3 months to these patients. The glucose control and diabetes complication screening will be evaluated in visit. Patients will also be evaluated by specialized psychologists, dietitians and therapists. Diabetes self-management education will be regularly exposed to patients
62156384|NCT03610984||Conventional education group|Outpatients visit to endocrinologists when necessary in a conventional way.
62156385|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
62156386|NCT01212809|ACTIVE_COMPARATOR|Juvéderm Ultra|Juvéderm Ultra injection
62156387|NCT01212809|ACTIVE_COMPARATOR|Cosmoderm 1|Cosmoderm 1 injection
62156388|NCT04184271|EXPERIMENTAL|38% silver diamine fluoride|38% silver diamine fluoride, topical, 1 drop, single application
62156389|NCT03031782|EXPERIMENTAL|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
62156390|NCT03031782|PLACEBO_COMPARATOR|Treatment Period 2 - placebo|placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
62156391|NCT02663297|EXPERIMENTAL|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10\^7 cells/m\^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10\^8/m\^2) given in the same trial.~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
62156392|NCT00798837|OTHER|IMAX|"There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions.~* A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
61975811|NCT05373329|NO_INTERVENTION|waitlist control|Participants receive the self-guided intervention after an 8-week waiting period (waitlist control group). All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
62530616|NCT00470067|EXPERIMENTAL|Doxorubicin and carboplatin|Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1
62530617|NCT01483859|OTHER|right hepatectomy with preoperative LSM|patients undergoing right hepatectomy with preoperative LSM between August 2007 and July 2011
62530618|NCT03275818|EXPERIMENTAL|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:~* Age ≥ 21: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days~* Age ≥ 6 months and ≤ 20 years: 240 mg/m2 (for patients weighing \> 10 kg) and 11.5 mg/kg (for patients weighing ≤ 10 kg) on days 1, 8 and 15 in cycles of 28 days"
62530619|NCT05472662|EXPERIMENTAL|Test|"Placebo HFA-152a propellant via pressurised metered-dose inhaler (pMDI):~Administration: Single-dose administration."
62530620|NCT05472662|PLACEBO_COMPARATOR|Reference|"Placebo HFA-134a propellant via pressurised metered-dose inhaler (pMDI):~Administration: Single-dose administration."
62530621|NCT05591586|ACTIVE_COMPARATOR|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 5 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
62539552|NCT03536533|EXPERIMENTAL|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
62156393|NCT01866904||Stable CAD patients aged 50 years or older|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 additional risk factor
62156394|NCT01414192||Ezetimibe monotherapy without prior treatment|Enrolled participants who had no prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
62156395|NCT01414192||Ezetimibe monotherpay with prior treatment|Enrolled participants with prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
62156396|NCT01414192||Ezetimibe plus statin|Enrolled participants who were being coadministered ezetimide (Ezetrol®) and another prescription statin.
62156397|NCT01414192||Ezetimibe/simvastatin|Enrolled participants who were receiving ezetimibe and simavastatin fixed dose combination tablet (Inegy®).
62156398|NCT02169089|EXPERIMENTAL|Spironolactone|Spironolactone
62156399|NCT02169089|PLACEBO_COMPARATOR|Placebo|Placebo
62156400|NCT05185089|EXPERIMENTAL|Orvepitant 30mg|Orvepitant 30mg tablet once daily for 4 weeks
62156401|NCT05185089|EXPERIMENTAL|Orvepitant 10mg|Orvepitant 10mg tablet once daily for 4 weeks
62156402|NCT05185089|PLACEBO_COMPARATOR|Placebo|Placebo tablet once daily for 4 weeks
62156403|NCT02707302|EXPERIMENTAL|Iodophor-impregnated adhesive drapes|"In the iodophor-impregnated adhesive drapes group, routine disinfection will be carried out and bacteria samples will be harvested 1 cm from the wound site using sterilized swabs prior to use of the surgical adhesive drapes, and again at the end of surgery before skin suturing, for preoperative bacterial culture. The packaging of the 3M™ iodophor-impregnated adhesive drapes will be opened and the aseptic adhesive drapes unfolded until the stop instruction. The adhesive drapes will then be pasted to the surgical wound and smoothed using an aseptic cloth, taking care to avoid air bubbles."
62156404|NCT02707302|EXPERIMENTAL|Iodophor-free adhesive drapes|Patients in the iodophor-free adhesive drapes group will undergo the same procedures, but with iodophor-free drapes.
62156405|NCT06585137|ACTIVE_COMPARATOR|Intervention Group|Participants in the intervention group will participate in a web-based mind-body awareness program.
62156406|NCT06585137|NO_INTERVENTION|Control Group|No intervention will be applied to the control group.
62156407|NCT05428215|ACTIVE_COMPARATOR|PO then SL|Subjects will administer 17-beta-estradiol orally (PO) for Study Day 1-14, followed by administration of 17-beta-estradiol sublingually (SL) for Study Day 15-28.
62156408|NCT05428215|ACTIVE_COMPARATOR|SL then PO|Subjects will administer 17-beta-estradiol sublingually (SL) for Study Day 1-14, followed by administration of 17-beta-estradiol orally (PO) for Study Day 15-28.
62156409|NCT03555656|EXPERIMENTAL|Repeated educational intervention|Repetition every 6 months of a group educational session
62530622|NCT05591586|EXPERIMENTAL|Mobile video interpreting access (mVI)|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
62156410|NCT03555656|ACTIVE_COMPARATOR|Control group|Initial single group educational session, with no repetition
62530623|NCT00998478|EXPERIMENTAL|Activity prescription|
62156411|NCT00939211|EXPERIMENTAL|AZD9164 100 mcg First, then Placebo for Spririva|1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
62156412|NCT00939211|EXPERIMENTAL|AZD9164 400 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
62156413|NCT00939211|EXPERIMENTAL|AZD9164 1200 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
62156414|NCT00939211|ACTIVE_COMPARATOR|Spiriva 18 mcg First, then Placebo for AZD9164|1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
62530624|NCT00998478|NO_INTERVENTION|Normal Curriculum|Followed normal curriculum including physical education
62156415|NCT00939211|PLACEBO_COMPARATOR|Placebo for Spiriva First, then Placebo for AZD9164|1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)
62156416|NCT02147652|EXPERIMENTAL|Personalized music|
62156417|NCT03850678|EXPERIMENTAL|Hearing Aid|Group of participants with hearing loss. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels, while manipulating different hearing aid parameters and also without the provision of amplification, will be assessed.
62530625|NCT05244395|EXPERIMENTAL|Duchenne Muscular Dystrophy Gait Assessment Scale|The DMD-GAS was developed using the two-round Delphi method. After a detailed literature review, the items of scale were compiled. The DMD-GAS was designed to consist of 10 items and each item scored as 0,1,2. The DMD-GAS was presented to the expert group (10 physical therapists), who had experience in the management of patients with DMD. According to the scale items, it is classified as 2: no compensation, 1: minimal compensation, and 0: excessive compensation for the relevant body part.
62530626|NCT05062902|ACTIVE_COMPARATOR|Template Injection|For the standard template injection, 200 units of BoNT diluted in 6mL of preservative saline will be prepared. 1/4 of the prepared BoNT solution will be administered to each of the pubococcygeus and puborectalis muscle at 5 and 7 o'clock position, respectively. The index finger will be used for palpation as the 20-gauge spinal needle with a trumpet guide (i.e. paracervical block kit) piercing through the vaginal mucosa to the intended muscle groups. The syringe will be withdrawn before each injection to avoid intravascular injection.
62539553|NCT04355065|EXPERIMENTAL|Cognitive Training with Virtual Reality Videogame|"The Secret trail of mon is a therapeutic video game that has been created for the cognitive training of patients with ADHD.~Five mechanisms have been designed to work on five cognitive functions that are deficient in ADHD: attention, memory, reasoning, planning and visuospatial ability.~Patients have to go to the hospital once a week for training sessions of approximately forty minutes duration during 12 weeks."
62530627|NCT05062902|EXPERIMENTAL|Guided Injection|For the guided injection, pelvic floor injections (total of 4) will be made to the pubococcygeus and puborectalis muscles each, at NMJ locations (1.5 ml per site), at patient-specific locations and depths identified from vaginal HD-sEMG recordings. NMJ mappings will be generated for each participant. The channel locations will provide angle measurements for each NMJ. The device will calculate these parameters based on acquired HD-sEMG. The index finger will be used for palpation and guidance of injection needle through the vaginal mucosa to the defined injection sites. The BoNT dosage with respect to the total 200 units administered to each site will be patient specific, determined as the ratio of the resting average resting root-mean square (RMS) value of a specific region divided by the total average resting RMS.
62530628|NCT06258603|EXPERIMENTAL|Patients who received oral care bundle|"A oral care bundle protocol created by the researchers and it was applied by a researcher to experimental group."
62530629|NCT06258603|OTHER|Patients receiving routine clinical oral care|Routine oral care protocol used in intensive care unit was applied to control group by the patient's primary nurse.
62530630|NCT04300140|EXPERIMENTAL|Phase 1b: Batiraxcept + cabozantinib|Two dose levels of batiraxcept administered Q2W (once every two weeks) in combination with QD (once a day) cabozantinib will be evaluated.
62530631|NCT04300140|EXPERIMENTAL|Phase 2 Part A: batiraxcept + cabozantinib|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib will be evaluated.
62530632|NCT04300140|EXPERIMENTAL|Phase 2 Part B: batiraxcept + cabozantinib + nivolumab|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib and nivolumab.
62530633|NCT04300140|EXPERIMENTAL|Phase 2 Part C: batiraxcept alone|One dose level of batiraxcept administered Q2W will be evaluated.
62530634|NCT01440036||Carotid endarterectomy|Patients that have the common indication for the treatment of carotid artery stenosis by surgery - CEA (carotid endarterectomy), symptomatic and asymptomatic patients.
62156418|NCT03850678|NO_INTERVENTION|Normal Hearing|Group of participants with normal hearing that serve as a reference group. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels will be assessed.
62156419|NCT02379975|EXPERIMENTAL|rheumatoid arthristis|individuals with rheumatoid arthritis
62530635|NCT03591393|EXPERIMENTAL|Pregnant women|"* questionnaire at 1st and 3rd trimester, 10-12 weeks postpartum and 12 months postpartum~* pelvic floor ultrasound at 1st trimester and at 3rd trimester"
62530636|NCT04342260|EXPERIMENTAL|Active Monitoring|Clinicians will receive symptom alerts if the survey suggests increased or worsening symptoms.
62714052|NCT04240054|EXPERIMENTAL|Expansion Cohort B|"20 transplant-eligible non-renal impairment multiple myeloma patients will be enrolled.~Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
62714053|NCT03593148|OTHER|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
62714054|NCT05952050|EXPERIMENTAL|Intranasal dexmedetomidine|
62156420|NCT02379975|ACTIVE_COMPARATOR|health|healthy individuals
62156421|NCT03202056|EXPERIMENTAL|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
62530637|NCT04342260|ACTIVE_COMPARATOR|Passive Monitoring|Clinicians will not receive any symptom alerts.
62156422|NCT03202056|SHAM_COMPARATOR|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
62156423|NCT03202056|NO_INTERVENTION|Control|Control group. No intervention.
62156424|NCT05885334|PLACEBO_COMPARATOR|Naturalistic Intervention|Natural intervention (actual provision of information and answering of questions). This arm will evaluate the natural learning during the action.
62156425|NCT05885334|EXPERIMENTAL|Virtual Reality|Virtual Reality intervention specifically designed for this study. Using VR to learn procedures will encourage caregivers to learn in a fully immersive and participatory environment where they will have to interact with the virtual content, enhancing their learning experience.
62530638|NCT02422771|NO_INTERVENTION|Control group|Athletes in this group will continue with their usual warm-up for the duration of the indoor soccer season.
62530639|NCT02422771|EXPERIMENTAL|Intervention group|FIFA 11+ warm-up
62530640|NCT04948164|EXPERIMENTAL|Test group|
62530641|NCT04948164|PLACEBO_COMPARATOR|Control group|
62530642|NCT03131674|EXPERIMENTAL|Direct treatment|
62530643|NCT03131674|EXPERIMENTAL|Delayed treatment|
62530644|NCT06007066|EXPERIMENTAL|Preoperative administration of HSK16149 40mg|HSK16149 40mg will be administered the night before and 2h before surgery
62530645|NCT06007066|EXPERIMENTAL|Preoperative administration of HSK16149 60mg|HSK16149 60mg will be administered the night before and 2h before surgery
62530646|NCT06007066|EXPERIMENTAL|Preoperative and postoperative administration of HSK16149 40mg|HSK16149 40mg will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery
62530647|NCT06007066|EXPERIMENTAL|Preoperative and postoperative administration of HSK16149 60mg|HSK16149 60mg will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery
62530648|NCT06007066|PLACEBO_COMPARATOR|placebo|The placebo will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery
62714055|NCT05952050|ACTIVE_COMPARATOR|Intravenous dexmedetomidine|
62714056|NCT03582579|EXPERIMENTAL|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
62714057|NCT03582579|EXPERIMENTAL|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
62714058|NCT03582579|EXPERIMENTAL|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
62714059|NCT03582579|EXPERIMENTAL|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
62714060|NCT02182518|EXPERIMENTAL|Epinastine + Pseudoephedrine|
62714061|NCT02182518|EXPERIMENTAL|Epinastine|
62530649|NCT05578196|EXPERIMENTAL|The experimental group with FMT|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group
62530650|NCT05578196|OTHER|The control group with physiological saline|The gastrointestinal tube access was established, and the standard preparation of physiological saline solution 20ml
62530651|NCT03524924||non-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: \< 0.3151361243 Male: \< 1.211878526
62530652|NCT03524924||pre-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 0.3151361243 to \< 2.1301121973 Male: 1.211878526 to \< 3.0052612772
62530653|NCT03524924||frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 2.1301121973 to \< 6 Male: 3.0052612772 to \< 7
62530654|NCT05914935|EXPERIMENTAL|Recombinant L-IFN adenovirus injection and Ommaya reservoir|Recombinant L-IFN adenovirus injection was locally injected through the Ommaya reservoir.A single injection dose of 5.0×10\^10 VP (total dose per injection) was administered during the treatment period.
62156426|NCT05885334|EXPERIMENTAL|Augmented Reality|Augmented Reality Intervention specifically designed for this study. This intervention will increase participants' skills through active learning as they interact with real-world care situations while receiving simultaneous support from AR devices.
62156427|NCT05885334|ACTIVE_COMPARATOR|Videos with 360 degrees|Intervention using immersion 360 degrees specifically designed for this study. Participants enrolled in this arm, by completing it, is assumed that will experience a form of learning more participatory and immersive than conventional videos, as they can interact with the content by changing the camera angle.
62156428|NCT00391794|EXPERIMENTAL|ESSG|eight weekly 90-minute sessions
62156429|NCT00391794|ACTIVE_COMPARATOR|ES|one 4-hour educational program
62530655|NCT02424643|NO_INTERVENTION|No Incentive|Participants in this arm will receive no compensation for taking the online survey.
62530656|NCT02424643|EXPERIMENTAL|Monetary Incentive|Participants in this arm will receive a $20 Amazon.com incentive for participating in the online survey.
62530657|NCT02424643|EXPERIMENTAL|Altruistic Incentive|Participants in this arm will receive altruistic messages throughout the length of the survey in hopes of improving survey completion.
62156430|NCT03933098|EXPERIMENTAL|Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
62156431|NCT03933098|EXPERIMENTAL|Test group B: Lot 2 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 2 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
62156432|NCT03933098|EXPERIMENTAL|Test group C: Lot 3 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 3 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
62156433|NCT03933098|ACTIVE_COMPARATOR|Test group D: Typbar TCV|"One dose of Typbar TCV will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
62530658|NCT02424643|EXPERIMENTAL|Dashboard Incentive|Participants in this arm will receive a dashboard at the end of the survey that will compare their data entered into the survey to other participants who have taken the survey. A preview of this dashboard will be shown at the beginning of the survey as a teaser in the hopes to improve survey completion.
62530659|NCT01513382|EXPERIMENTAL|Methylene Blue|The effect of methylene blue dye in detection and total excision of pilonidal sinus will be studied histopathologically.
62156434|NCT01491100||Group 1|
62156435|NCT04014452|EXPERIMENTAL|Microwave ablation group|Microwave ablation is used for the treatment of Complicated Monochorionic Pregnancies
62530660|NCT05841927|EXPERIMENTAL|ASD active|Dietary Supplement: Docosahexaenoic acid 200mg DHA once, twice a day
62530661|NCT05841927|PLACEBO_COMPARATOR|ASD placebo|Dietary Supplement: Placebo dietary intervention Vitamin D 400IU once, once a day
62530662|NCT01041066|ACTIVE_COMPARATOR|group L|0.4 mg/kg labetalol
62530663|NCT01041066|ACTIVE_COMPARATOR|group N|20 ㎍/kg nicardipine
62530664|NCT02669940||Participants With Chronic Hepatitis C Genotype 1|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.
62530665|NCT00515541|ACTIVE_COMPARATOR|A|Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
62530666|NCT00515541|ACTIVE_COMPARATOR|B|Patient is on regular dose of Aspirin ( \< or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
62530667|NCT00515541|ACTIVE_COMPARATOR|C|Patient is taking regularly 75mg of clopidogrel daily and Aspirin (\< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
62530668|NCT00515541|ACTIVE_COMPARATOR|D|Patient is regularly taking Warfarin daily and Aspirin (\< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza
62530669|NCT00993486|EXPERIMENTAL|L1 (dose 1.0x10E4 T-cells/kg)|
62530670|NCT00993486|EXPERIMENTAL|L2 (dose 5.0x10E4 T-cells/kg)|
62530671|NCT00993486|EXPERIMENTAL|L3 (dose 1.3x10E5 T-cells/kg)|
62530672|NCT00993486|EXPERIMENTAL|L4 (dose 3.2x10E5 T-cells/kg)|
62530673|NCT00993486|EXPERIMENTAL|L5 (dose 7.9x10E5 T-cells/kg)|
62530674|NCT00993486|EXPERIMENTAL|L6 (dose 2.0x10E6 T-cells/kg)|
62530675|NCT00993486|EXPERIMENTAL|L7 (dose 5.0x10E6 T-cells/kg)|
62530676|NCT01267994|EXPERIMENTAL|Single Arm-Open Label|Single Arm-Open Label use of Anakinra
62530677|NCT02747550|EXPERIMENTAL|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
62530678|NCT02747550|ACTIVE_COMPARATOR|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy.
62530679|NCT04015323|EXPERIMENTAL|IFC Therapy 2 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 2 kHz
62530680|NCT04015323|EXPERIMENTAL|IFC Therapy 4 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 4 kHz
62530681|NCT04015323|EXPERIMENTAL|IFC Therapy 8 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 8 kHz
62530682|NCT01682863|EXPERIMENTAL|QVA149 dose 1|QVA149 27.5/12.5 μg capsules
62530683|NCT01682863|EXPERIMENTAL|QVA149 dose 2|QVA149 27.5/25 μg capsules
62530684|NCT01682863|ACTIVE_COMPARATOR|QAB149|QAB149 75 μg capsules
62530685|NCT03254381|EXPERIMENTAL|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
62530686|NCT03254381|EXPERIMENTAL|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
62530687|NCT03462849|OTHER|Patients with EFL at PEP 5|Patients with EFL at PEP 5 at the time of inclusion either in supine or semi-recumbent position
62530688|NCT03462849|OTHER|Patients with no EFL at PEP 5|Patients with no EFL at PEP 5 at the time of inclusion in both supine and semi-recumbent positions
62530689|NCT05477498|EXPERIMENTAL|Iron substitution|Iron deficiency status will be assessed at the baseline visit (Day 0) as well as after 6 weeks of iron substitution (Week 6). The study drug will be given as FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection. Infusions of 10 or 20 mL (which is the amount of FCM that is equivalent to 500 or 1000 mg of iron, respectively) will be administered in ≥6 minutes diluted in ≈100 mL of sterile 0.9% sodium chloride solution (NaCl) for 10 mL, or in ≥15 minutes diluted in ≈200 mL for 20 mL. Dosing will be based on screening Hb level and weight, rather than on ferritin and TSAT results. On Day 0 (baseline visit), patients with Hb ≤14 g/dL, both \<70 kg and \>70 kg will receive 1000 mg FCM (20 mL), whereas patients with Hb \>14g/dL will receive 500 mg FCM (10 mL).
62530690|NCT05477498|PLACEBO_COMPARATOR|Placebo|Patients in the control group will receive a placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
62530691|NCT04771663|EXPERIMENTAL|Hypoxic|In this phase, participants inhale the hypoxic mixture for five minutes.
62530692|NCT04771663|EXPERIMENTAL|Hypoxic and Hypercapnic|In this phase, participants inhale the hypoxic and hypercapnic mixture for five minutes.
62530693|NCT05384639|EXPERIMENTAL|Dual-task Group|
62530694|NCT05384639|ACTIVE_COMPARATOR|Cycling Group|
62530695|NCT05384639|ACTIVE_COMPARATOR|Cognitive Group|
62530696|NCT04644874||Older cancer patients|All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,
62530697|NCT03252912|EXPERIMENTAL|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
62530698|NCT06073210|EXPERIMENTAL|Therapeutic exercise plus motor imagery|This group will perform a therapeutic exercise programme (aerobic and strength training) to which motor imagery training will be added.
62530699|NCT06073210|EXPERIMENTAL|Therapeutic exercise plus action observation|This group will perform a therapeutic exercise programme (aerobic and strength training) to which action observation training will be added.
62156436|NCT04014452|ACTIVE_COMPARATOR|Radiofrequency ablation group|Radiofrequency ablation is used for the treatment of Complicated Monochorionic Pregnancies
62156437|NCT03213379|NO_INTERVENTION|Referent group|"The patient of the referent group will have 2 measures of actimetry:~A first one at baseline before the apomorphim set-up:the report will be provided to the investigator and a second one before the 6 months follow-up visit but this report will not be provided to the investigator."
62156438|NCT03213379|EXPERIMENTAL|Actimetry group|"The patient of the Actimetry group will have at least 4 measures of actimetry and the reports will be all provided to the investigator:~One at baseline before the apomorphim set-up/ the second one 8 days after the hospitalisation/ the third one 28 days after the hospitalisation and the last one before the 6 months follow-up visit One optional measure can be performed 84 days after the hospitalisation."
62156439|NCT00554814|EXPERIMENTAL|3|Blédilait Biofer® milk (1,1mg/100kcal)
62530700|NCT06073210|ACTIVE_COMPARATOR|Therapeutic exercise|This group will perform a therapeutic exercise programme (aerobic and strength training) to which sham action observation training will be added.
62530701|NCT00848107|EXPERIMENTAL|Treprostinil|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
62530702|NCT03720327|ACTIVE_COMPARATOR|Get FIT|The Get FIT intervention
62530703|NCT03720327|EXPERIMENTAL|Get FIT+|The Get FIT+ intervention, which includes push-only personalized text messages from a health coach.
62530704|NCT02018783|EXPERIMENTAL|Sensodyne|Digital application for 60 seconds.
62530705|NCT02018783|EXPERIMENTAL|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
62530706|NCT02018783|EXPERIMENTAL|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
62530707|NCT02018783|PLACEBO_COMPARATOR|Cocorico|Digital application for 60 seconds
62530708|NCT06354010||Patients with adulthood-onset bilateral sensorineural hearing loss (SNHL)|
62156440|NCT00554814|EXPERIMENTAL|1|Blédilait Biofer® milk (2mg/100kcal)
62530709|NCT06354010||Patients that carry mutations in the gene GJB2 from patients with adulthood-onset bilateral SNHL|
62530710|NCT03929341|EXPERIMENTAL|CCTA first approach with Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test and have Cardiac Link pathway activated for expedited cardiology referral.
62530711|NCT03929341|EXPERIMENTAL|CCTA first approach without Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test, but Cardiac Link pathway will not be activated.
62530712|NCT03929341|ACTIVE_COMPARATOR|Usual Care with Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, and have Cardiac Link pathway activated for expedited cardiology referral.
62530713|NCT03929341|ACTIVE_COMPARATOR|Usual Care without Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, but Cardiac Link pathway will not be activated.
62530714|NCT00281671|PLACEBO_COMPARATOR|Placebo|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
62530715|NCT00281671|EXPERIMENTAL|Nesiritide|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
62530716|NCT02584400|EXPERIMENTAL|[18F]HX4 PET imaging|Injection with the hypoxia tracer \[18F\]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases
62530717|NCT00997568||TEE Procedure|Patients who have been scheduled for a TEE procedure by their physician
62530718|NCT04353765||cabozantinib arm|
62530719|NCT04353765||non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm|
62530720|NCT03344861|EXPERIMENTAL|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
62530721|NCT03652558|EXPERIMENTAL|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
62530722|NCT03652558|NO_INTERVENTION|non-ozone group|Only active periodontal therapy was performed
62530723|NCT00259272|EXPERIMENTAL|A|
62530724|NCT02011113|EXPERIMENTAL|Pomalidomide plus dexamethasone|
62530725|NCT02342106||Poor responders|In order to define the poor response in IVF, at least two of the following three features must be present: (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test . Two episodes of poor ovarian response after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test. By definition, the term poor ovarian response refers to the ovarian response, and therefore, one stimulated cycle is considered essential for the diagnosis .
62530726|NCT02342106||Good responders|"Total number of antral follicles : 22-35 Normal (good) antral count, should have an excellent response to ovarian stimulation.Likely to respond well to low doses of FSH drugs.~Very low risk for IVF cycle cancellation. Some risk for ovarian overstimulation if a Lupron trigger is not used for final egg maturation injection.~Excellent pregnancy success rates."
62530727|NCT00902720|EXPERIMENTAL|Cryopreservation|The ovarian tissue is frozen and banked at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
62530728|NCT01866059|EXPERIMENTAL|Calcium silicate cement|Biodentine
62530729|NCT01866059|ACTIVE_COMPARATOR|Glass Ionomer Cement|Fuji IX
62530730|NCT01866059|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer Cement|Fuji II LC
62530731|NCT02603718|EXPERIMENTAL|Standard physical therapy treatment with feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured, and provided to both therapist and patient on-line during one of the two treatments.
62530732|NCT02603718|EXPERIMENTAL|Standard physical therapy treatment without feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured but feedback is not provided.
62530733|NCT00996775|ACTIVE_COMPARATOR|standard care only|standard care only - harmful effects of alcohol use and NIAAA limits
62530734|NCT00996775|EXPERIMENTAL|Brief alcohol intervention|Group receiving brief alcohol intervention
62530735|NCT01168206|PLACEBO_COMPARATOR|Placebo|
62530736|NCT01168206|EXPERIMENTAL|TK3|1 capsule, 3 times per day.
62530737|NCT05676281|OTHER|Healthy Together (includes Streetwyze) (Control/Standardized Care)|Control - standardized Healthy Together program: The Healthy Together Program is not standard of care at Family Health Centers (FHC). Instead, it was originally developed by FHC clinicians interested in addressing childhood obesity and has been implemented by a limited number of clinicians at FHC. UCSD has been working in partnership with FHC to create standardized protocols and to incorporate additional research-oriented tools into this standardized protocol, which will be used as our experimental control.
62530738|NCT05676281|ACTIVE_COMPARATOR|Healthy Together + Promotora support|In addition to the basic program described above, those randomized to this intervention will receive Promotora support. Families assigned to a promotora will receive 30-60 minutes of phone-based support weekly, with more frequent interactions that will taper starting at month 3 of the intervention. Promotoras may also provide home-visit support up to 4 times during the 6 months, based on family interest and needs. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families. For families in this condition, they will be asked to engage in at least 30 minutes of additional sessions per week with the promotora beyond the 1- hour allotted time working with FHC professionals.
62530739|NCT05676281|ACTIVE_COMPARATOR|Healthy Together + Parenting training|In addition to the basic program described above, those randomized to this intervention will attend Parenting Training sessions with the mental health provider at FHC. Families assigned to parenting training will receive 10-12 sessions. Sessions will focus on topics like strategies to support the child's physical, social, and emotional growth. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.
62530740|NCT05676281|ACTIVE_COMPARATOR|Healthy Togethers + Parenting Training + Promotora support|Those randomized to this intervention will receive all components described above including the Healthy Together Program, Parenting Training and Promotora support. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.. Families in this group will also be asked to engage in at least 30-60 minutes of additional sessions per week including up to 4 home visits.
62156441|NCT00554814|ACTIVE_COMPARATOR|2|Milk supplemented with ferrous sulphate (2mg/100kcal)
62156442|NCT05796271|EXPERIMENTAL|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
62530741|NCT02928718||High risk patients|Patients who are at high risk of post-ERCP pancreatitis, who have at least one of the following factors: clinically suspected sphincter of Oddi dysfunction, history of post-ERCP pancreatitis, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation, balloon dilatation of intact sphincter, endoscopic ampullectomy, and 2≥minor criteria(an age of less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas, excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush).
62530742|NCT04492020|EXPERIMENTAL|Treatment Sequence A|Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event
62530743|NCT04492020|EXPERIMENTAL|Treatment Sequence B|Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event
62530744|NCT01439750|EXPERIMENTAL|Phase I|The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
62530745|NCT01439750|EXPERIMENTAL|Phase II|The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms. Rituximab 375 mg/m2 on day 5,12,19,26 for 1st cycles, then day 5 montly for next 5 cycles, then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days for 6 cycles (dose determined from phase I). Bortezomib 1.6 mg/m2 weekly on day 12,19,26 for 3 cycles then every 2 weeks as maintenance dose until toxicity or progression.
62530746|NCT03860662|ACTIVE_COMPARATOR|Spastic hemiplegia , Botox|Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
62530747|NCT03860662|OTHER|Spastic hemiplegia, Baclofen|Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.
62530748|NCT04267107|EXPERIMENTAL|Managing Fatigue:The Individual Program|"Participants in the experimental group will receive the 6-week MFIP. Individuals in experimental group :~* will participate in six one-to-one sessions (each takes 60 to 90 minutes)~* will complete the Feasibility Questionnaire #1, after each session (10 questions) (Appendix 6)~* will complete Feasibility Questionnaire #2 after completing all six-sessions (12 questions) (Appendix 7)~* will complete the post-test measurement after completion of the program (approximately 60 minutes to complete)~* will complete the follow-up measurement, three months after the completion of the program (approximately 60 minutes to complete)~* will be advised to continue with their current healthcare services.~* may participate in one focus group (one-hour session)"
62530749|NCT04267107|NO_INTERVENTION|Control Group|"Participants in the control group will not receive the IMFP and they will be advised to continue with their current healthcare services.~Participants in the control group:~* will complete post-test measurements after 6 weeks (approximately 60 minutes),~* will complete the follow-up measurements three months later after completing the program (approximately 60 minutes).~* will be advised to continue with their current healthcare services.~Following the study, participants in the control group will be offered the manual of the program and a three-hour training workshop after (three months after the baseline testing). In this workshop, they will learn about the about the program, including the pre-session activities, in-session activities, and homework. This workshop will be conducted by occupational therapists."
62530750|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
62530751|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
62530752|NCT02821052||insulin degludec/insulin aspart|
62156443|NCT04814719||Pentosan Polysulfate Sodium|Pentosan Polysulfate Sodium (PPS) at Dose and frequency selected in Stage 1 of Parent Study for 6 weeks
62156444|NCT04814719||Placebo|Placebo for 6 weeks
62156445|NCT02718456|NO_INTERVENTION|Standard of care|Standard HIV counseling and referral to care
62714062|NCT04174352|EXPERIMENTAL|Tamoxifen Dose Levels|"Three participants will be enrolled to each dose level of oral tamoxifen (n = 12)~Dose Level 1 = 20 mg daily Dose Level 2 = 80 mg daily Dose Level 3 = 160 mg daily Dose Level 4 = 200 mg daily~Tamoxifen should be started within 14 days of the FES-PET/CT scan, at least 24 hours after FES injection. Participants will continue tamoxifen therapy until there is radiologic or clinical evidence of progressive disease or drug intolerance."
62530753|NCT01908816|EXPERIMENTAL|ranibizumab|0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.
62530754|NCT02556983||Suspected appendicitis|Patients who are suspected as having acute appendicitis
62530755|NCT02832180|EXPERIMENTAL|Daily single dose of OC containing EE and NET|Daily single dose of OC Containing EE and NET alone.
62156446|NCT02718456|EXPERIMENTAL|CD4 testing|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week.
62156447|NCT02718456|EXPERIMENTAL|CD4 testing plus peer counseling|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week. Additionally, a trained peer counselor provides supplemental counseling at the time of diagnosis and at the 1 week telephone follow-up.
62156448|NCT04213768|EXPERIMENTAL|Plication|
62714063|NCT01344343|EXPERIMENTAL|Accelerated hip fracture surgery|Arrival in the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair
62156449|NCT04213768|ACTIVE_COMPARATOR|Resection|
62714064|NCT01344343|NO_INTERVENTION|Standard care|Surgical hip fracture repair according to the standard timing
62714065|NCT04882098|EXPERIMENTAL|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.
62714066|NCT04882098|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
51310272|NCT06674993|EXPERIMENTAL|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
62156450|NCT00582855|EXPERIMENTAL|1|
62156451|NCT00582855|PLACEBO_COMPARATOR|2|
62156452|NCT01245998|ACTIVE_COMPARATOR|dalteparin 5000 I.U./24 h s.c.|
62156453|NCT01245998|ACTIVE_COMPARATOR|dalteparin 15000 I.U./24 h s.c.|
62530756|NCT02832180|EXPERIMENTAL|Daily single dose of OC in combination with BMS-986142|Daily single dose of OC containing EE and NET in combination with BMS-986142.
62530757|NCT04638335||travelers over the age of 60|blood sample taken to test the presence of Anti-HAV antibodies
62530758|NCT04638335||travelers having lived in a tropical country for more than 5 years|blood sample taken to test the presence of Anti-HAV antibodies
62530759|NCT03964064|EXPERIMENTAL|I125 Seed Implantation|3D-printing Template-assisted CT-guided I125 Seed Implantation Prescription dose: gtv140-160gy ctv100-140gy Particle activity: 0.4-0.5mCi
62530760|NCT03964064|EXPERIMENTAL|Stereotactic Radiotherapy|According to the tumor volume, location, organ function and other factors, the dosage of stereotactic directional radiotherapy was determined. The range of BED value of radiotherapy was 80-100 for tumors above 5 mm from gastrointestinal tract and 60-80 for tumors below 5 mm from gastrointestinal tract.
62530761|NCT00894426||1|Morning Symptoms (+)
62530762|NCT00894426||2|Morning Symptoms (-)
62530763|NCT04173624|EXPERIMENTAL|Endosonography|Endosonography is endoscopic method to diagnose pancreatic and biliary disorders. Participants randomized to this arm will undergo diagnostic endosonography under propofol sedation in supervision of trained anesthesiologists. If choledocholithiasis is diagnosed on endosonography, patient will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
62530764|NCT04173624|EXPERIMENTAL|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for diagnosis of pancreatic and biliary disorders. Participants randomized to this arm will undergo MRCP. If choledocholithiasis is diagnosed on MRCP, participants will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
62530765|NCT02988024|EXPERIMENTAL|LY03005|LY03005 80 mg
62156454|NCT01745445|EXPERIMENTAL|radiotherapy alone arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; All patients will be radiated by external beam radiation, using 3-D conformal radiation technique.
62530766|NCT02988024|ACTIVE_COMPARATOR|Pristiq|Pristiq 50 mg
62530767|NCT06388759|EXPERIMENTAL|TQ05105 Tablets|TQ05105 Tablets，28 days as a treatment cycle.
62530768|NCT05199519|OTHER|IBI345|Single arm
62530769|NCT01386151|ACTIVE_COMPARATOR|Study drug|Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
62530770|NCT01386151|PLACEBO_COMPARATOR|Placebo|Saline will be used as a placebo comparator
62530771|NCT02141035|EXPERIMENTAL|Acetyl-l-carnitine|Acetyl-l-carnitine will be administered for 2 months duration at a dosage of 3000 mg/d starting at the time of decompression surgery.
62714067|NCT04882098|EXPERIMENTAL|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
62530772|NCT02141035|PLACEBO_COMPARATOR|Placebo|Placebo will be given for 2 months starting at the time of decompression surgery
62530773|NCT02868918|EXPERIMENTAL|biodentine|bioactive dentin substitute used to act like natural dentin in insulating the pulp against external stimuli intervention
62530774|NCT02868918|ACTIVE_COMPARATOR|glass ionomer cement|high viscosity glass ionomer used as a base material comparator other name : - fuji ix
62530775|NCT04832893|ACTIVE_COMPARATOR|Use of FFP2 respirator|Using of FFP2 respirator during the 30 minutes test
62530776|NCT04832893|ACTIVE_COMPARATOR|Use of surgical mask|Using of surgical mask during the 30 minutes test
62530777|NCT04832893|SHAM_COMPARATOR|no mask|The 30 minutes test will be carried out without mask
62530778|NCT02109419||All participants|All participants, including control, mild cognitive impairment, and dementia.
62530779|NCT03052868|OTHER|Data Collection|The study visit will be scheduled for three to six months after completing adjuvant chemotherapy treatment. At the study visit, informed consent will be obtained and neurocognitive attention testing will be performed. The assessments chosen were carefully selected based on breadth, psychometric properties, standardized broad clinical use, good external validity and time efficiency. The testing time for the battery of neuropsychological tests is approximately 45-60 minutes. Participants will also be asked to complete a packet of several questionnaires including several self-rated measures of mood and quality of life, in addition to a brief questionnaire to obtain information about exercise, sleep, and education and employment backgrounds. It is estimated that questionnaire completion will require no more than 30 minutes. Participants will be seen on only one occasion, and may receive, upon request, written feedback about the results of the evaluation.
62530780|NCT02571192|EXPERIMENTAL|Experimental Drug|single oral dose radiolabelled 50mg of SHP626
62530781|NCT03170427|SHAM_COMPARATOR|8 mg (2 mL) levobupivacaine|8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
61975812|NCT03773705|ACTIVE_COMPARATOR|Electrocautery group|Electrocautery used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
62530782|NCT03170427|ACTIVE_COMPARATOR|6 mg (1.6 mL) levobupivacaine|6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
62530783|NCT06008366|EXPERIMENTAL|Dose escalation and dose expansion|All subjects enrolled in the part of dose escalation and dose expansion will receive 7MW3711 by introvenous infusion
62530784|NCT06008366|EXPERIMENTAL|Cohort expansion|All subjects enrolled in the part of cohort expansion will be treated by 7MW3711 will receive 7MW3711 by introvenous infusion
62530785|NCT00237913|ACTIVE_COMPARATOR|A1|
62530786|NCT00237913|ACTIVE_COMPARATOR|B1|
62530787|NCT04062656|EXPERIMENTAL|B - Nivolumab|"Responders~* 6 preoperative cycles nivolumab (i.v., 240mg, q2w)~* 4 postoperative cycles nivolumab (i.v., 240mg, q2w)~* followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~* 2 preoperative cycles nivolumab (i.v., 240mg, q2w)~* 4 additional cycles nivolumab (i.v., 240mg, q2w)+FLOT (i.v., 240mg, q2w) pre- and postoperative~* followed by nivolumab monotherapy for up to one year (i.v., 480 mg, q4w)"
62530788|NCT04062656|EXPERIMENTAL|D - Nivolumab + relatlimab|"Responders~* 6 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~* 4 postoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~* followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~* 2 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~* 4 additional cycles nivolumab (i.v.,240 mg, q2w)+FLOT (i.v.,q2w) pre- and postoperative~* followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
62530789|NCT00102518|EXPERIMENTAL|NCT00102063 and NCT00110461 Subjects|All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).
62530790|NCT03011736|EXPERIMENTAL|Supportive Care (parathyroidectomy)|Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.
62530791|NCT04081766|ACTIVE_COMPARATOR|SUGAR Handshake|"Participants assigned to the intervention group will receive an individualised, pharmacist-led patient counselling session (SUGAR Handshake package) at the inclusion visit.~Participants will also receive a pictogram with the main instructions for easy recall of the counselling contents.~They will also receive a glucometer and test strips with a demonstration on proper use, to measure their fasting blood glucose levels on a daily basis for 12 weeks.~At week 6, participants will receive a phone call to reinforce the intervention and to remind them of the study protocol. For the qualitative evaluation of the intervention, a number of participants are interviewed and asked questions through the sixth week-phone call.~Additionally, participants in this group will be provided with the usual care that is normally provided in the outpatient clinics at King Abdullah University Hospital."
62530792|NCT04081766|NO_INTERVENTION|Control|"Participants within this group will receive the usual care provided by the health care professionals in the outpatient clinics at King Abdullah University Hospital.~They will also be provided with instructions on hypoglycemia diagnosis, and treatment and a demonstration on glucometer use at the inclusion visit. They will be asked to measure their fasting blood glucose level daily for 12 weeks.~Participants will receive a phone call at week 6 of the inclusion visit to remind them of measuring blood glucose levels and documenting hypoglycemic episodes on the diaries., plus a counselling session about hypoglycaemia recognition and treatment at the inclusion visit.~For the qualitative evaluation of the study, a number of participants will be interviewed and asked questions through the sixth week-phone call."
62530793|NCT04605003|ACTIVE_COMPARATOR|Conventional Autoclave|The conventional autoclave is the gold standard of sterilising all medical equipments.
62530794|NCT04605003|ACTIVE_COMPARATOR|Novel rig-S|A novel devise used with the high level disinfectant
61975813|NCT03773705|ACTIVE_COMPARATOR|Scalpel group|Scalpel used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
61975814|NCT02315170|EXPERIMENTAL|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
61975815|NCT02315170|ACTIVE_COMPARATOR|standard lid speculum|Standard wire eyelid speculum
62530795|NCT03065218|EXPERIMENTAL|99mTc sestamilbi|25 mCi 99mTc sestamibi intravenous injection, once. Then imaged for 45 minutes. More imaging might be required and this will be determined by a nuclear medicine physician onsite
62530796|NCT03400943|EXPERIMENTAL|Vilaprisan (A1)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
62530797|NCT03400943|EXPERIMENTAL|Vilaprisan (A2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks without a break.
62530798|NCT03400943|EXPERIMENTAL|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan (2 mg) in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
62530799|NCT03400943|EXPERIMENTAL|Vilaprisan+Placebo (B2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
62530800|NCT02589483|EXPERIMENTAL|Prospective pilot|Patient included prospectivly will be all treated according to study protocol.The rectal anastomosis will be reinforced with HemoPatch.
62530801|NCT05656521|EXPERIMENTAL|'005 Treatment Arm|'005 IV 20 mg + Standard of care
62530802|NCT05656521|ACTIVE_COMPARATOR|Dexamethasone Treatment Arm|Dexamethasone 6 mg + Standard of care
62530803|NCT02027675|EXPERIMENTAL|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
62530804|NCT02027675|EXPERIMENTAL|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.~Each arm corresponds to a different intervention order."
62530805|NCT05763108||Recurrent patellar dislocation group|50 patients with recurrent patellar dislocation and without any genetic disorders.
62530806|NCT05763108||Patients without joint hipermobility|200 patients without recurrent patellar dislocation and genetic disorders.
62530807|NCT00482651|EXPERIMENTAL|UAP, SAP|
62530808|NCT02763371|EXPERIMENTAL|Dietary: high GI lunch|High GI-rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
62530809|NCT02763371|EXPERIMENTAL|Dietary: low GI lunch|Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
62530810|NCT02936180|ACTIVE_COMPARATOR|Standard dose influenza vaccine|Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
62530811|NCT02936180|ACTIVE_COMPARATOR|High dose influenza vaccine|Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
62530812|NCT00918138|EXPERIMENTAL|Saxagliptin + Metformin XR + matching Metformin XR placebo|(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
62530813|NCT00918138|ACTIVE_COMPARATOR|Metformin XR + Metformin XR + matching Saxagliptin placebo|(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
62530814|NCT01118286||Group 1|
62714068|NCT01045369|EXPERIMENTAL|Kaletra And Intelence|This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
62530815|NCT00798421||Heathcare worker|health care worker exposed to patient with influenza
62530816|NCT06408883||normal transit constipation group|Patients with confirmed normal transit constipation.
62530817|NCT06408883||dyssynergic defecation group|Patients with confirmed dyssynergic defecation.(abnormal balloon expulsion test and/or high anal sphincter pressure and/or failure of the anorectal angle to open)
62530818|NCT06408883||slow-transit constipation group|Patients with confirmed slow-transit constipation.(diagnosed by colon transit scintigraphy)
62530819|NCT06408883||slow-transit constipation + dyssynergic defecation|Patients with confirmed slow-transit constipation and dyssynergic defecation.
62530820|NCT02610036||neuropathic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
62530821|NCT02610036||neuroischemic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
62530822|NCT03092063|EXPERIMENTAL|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
62530823|NCT03092063|EXPERIMENTAL|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
62530824|NCT03092063|EXPERIMENTAL|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
62530825|NCT03092063|EXPERIMENTAL|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
62530826|NCT03092063|EXPERIMENTAL|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
62714069|NCT01957865|EXPERIMENTAL|Fixed SMS, real-time monitoring|SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
62714070|NCT01957865|EXPERIMENTAL|Triggered SMS, real-time monitoring|Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
62714071|NCT01957865|NO_INTERVENTION|control|Real-time adherence monitoring only (no SMS)
62530827|NCT03092063|EXPERIMENTAL|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
62530828|NCT04905030|EXPERIMENTAL|Immigrant mother stratum|The receiver is an immigrant mother born in Eritrea, Somalia, Syria, Afghanistan, Iran or Iraq.
62530829|NCT04905030|EXPERIMENTAL|Educ 1 stratum|The receiver is a mother born in Sweden whose education does not exceed 3 years of high school.
62530830|NCT04905030|EXPERIMENTAL|Educ 2 stratum|The receiver is a mother born in Sweden whose education is at least 3 years of high school but no more than high school diploma.
62530831|NCT04905030|EXPERIMENTAL|Educ 3 stratum|The receiver is a mother born in Sweden whose education is at least some college (undergrad) but does not exceed an undergraduate degree
62530832|NCT04905030|EXPERIMENTAL|Educ 4 stratum|The receiver is a mother born in Sweden whose education is an undergraduate degree plus at least some graduate education
62530833|NCT05737316|EXPERIMENTAL|Combat PD|Combat PD is an aerobic exercise programme hosted on a mobile application.
62530834|NCT05737316|ACTIVE_COMPARATOR|Usual Care|Home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises
62530835|NCT02439931|EXPERIMENTAL|Remote psychosocial intervention|10 sessions of remotely delivered psychoeducation and support
62530836|NCT03107312||Known vaccination history|Single blood sample collection from subjects with verified records of vaccination or recent booster immunization against measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection
62714072|NCT05941286|EXPERIMENTAL|CGM system with both glucose predictive alerts and threshold alerts on|Patients will wear a real-time CGM (The Guardian Connect CGM System with Guardian sensor 3, Medtronic), which provide glucose readings every 5 minutes for up to 7 days. High/low predictive/threshold alerts will be enabled in this group, with low glucose alert set at 3.9 mmol/L and high glucose alert set at 16.7 mmol/L. Notably, predictive threshold alerts are triggered when a high/low glucose value is predicted within the next 15 min. In addition, patients will undergo POC testing at least 4 times per day (usually before meals and bedtime).
62714073|NCT05941286|EXPERIMENTAL|CGM system with only glucose threshold alerts on|Patients will wear a real-time CGM (The Guardian Connect CGM System with Guardian sensor 3, Medtronic), which provide glucose readings every 5 minutes for up to 7 days. Only high/low threshold alerts will be enabled in this group, with the same high/low glucose alert set, which is 3.9 mmol/L and 16.7 mmol/L respectively. In addition, patients will undergo POC testing at least 4 times per day (usually before meals and bedtime).
62714074|NCT05941286|ACTIVE_COMPARATOR|CGM system with glucose alerts off|Patients will wear a real-time CGM (The Guardian Connect CGM System with Guardian sensor 3, Medtronic), which provide glucose readings every 5 minutes for up to 7 days. High/low predictive/threshold alerts will be off in this group. In addition, patients will undergo POC testing at least 4 times per day (usually before meals and bedtime).
62714075|NCT02327767|EXPERIMENTAL|Resonating Arm Exerciser|The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
62530837|NCT03107312||Migrants|Single blood sample collection from recent migrants to Germany without verified vaccination records
62530838|NCT01656538|EXPERIMENTAL|Paclitaxel plus Reolysin|Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16.
62530839|NCT01656538|ACTIVE_COMPARATOR|Paclitaxel|Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks.
62530840|NCT00415441|EXPERIMENTAL|Active physiotherapy|Manual therapy and home exercise program
62530841|NCT00415441|PLACEBO_COMPARATOR|Placebo physiotherapy|Manual therapy and home exercise program
62530842|NCT04809935|ACTIVE_COMPARATOR|EUS-CPB|Chemical ablation of the coeliac plexus
62530843|NCT04809935|ACTIVE_COMPARATOR|EUS-CPA|Radiofrequency ablation of the coeliac plexus
62530844|NCT03487952||LDCT screening group|People receive questionnaire administration at baseline, then subsequent yearly chest LDCT scan and follow up.
62530845|NCT02197013||Introcan Safety 3|Closed IV Catheter
62530846|NCT02197013||Introcan Safety|IV catheter
62530847|NCT04271553|NO_INTERVENTION|Control|Patient will undergo standard workflow for elective surgical admissions.
62530848|NCT04271553|EXPERIMENTAL|Video|In addition to standard workflow, will also receive the intervention bundle which consists of a cartoon video and sets of activity sheets
62530849|NCT05973266|EXPERIMENTAL|Experimental Group|Patients using mobile application as well as verbal and written information in bowel preparation training in patients who will undergo colonoscopy will constitute the experimental group.
62530850|NCT05973266|NO_INTERVENTION|Control Group|Patients who will be given oral and written information in bowel preparation training in patients who will undergo colonoscopy will form the control group.
62530851|NCT03942705||Kenyan Women|Women living in western Kenya will be asked to complete a self collected vaginal sample for HPV DNA screening and asked to undergo a second screening by VIA. As per Kenyan standard of care, vaccination against HPV will be offered to children/grandchildren (boys and girls) of women, and to the women themselves if age 26 or younger. The second vaccine dose (for children ages 9 through 14) and third doses (for children and adult women ages 15 through 26) will be administered at subsequent visits. There will be no requirement for HPV vaccination (of children or mothers up to 26 years of age) for participation in the study. Results of the screening will be returned to participants and they will be referred to receive standard care as applicable.
62530852|NCT05537194||Patients with hypoxia|
62530853|NCT05537194||Patients without hypoxia|
62530854|NCT06187493|OTHER|Efficacy of ACEi|Patients receive an ACEi medication, such as lisinopril, enalapril, or ramipril. These drugs work by blocking the production of angiotensin II, a hormone that can constrict blood vessels and raise blood pressure.
62156455|NCT06224244|ACTIVE_COMPARATOR|Simultaneous integrated boost to 40 Gy (SIB 40)|"Patients with the following clinico-pathological characteristics~* pTis G3,~* pT1 pN0/pN1mic, G1-G3 luminal biology or Her-2 positive"
62156456|NCT06224244|ACTIVE_COMPARATOR|Simultaneous integrated boost to 43 Gy (SIB 43)|"Patients with the following clinico-pathological characteristics:~* Triple negative disease,~* pT2 pN0/pN1mic,~* ≤ 50 years not Luminal A"
62530855|NCT06187493|OTHER|Efficacy of SGLT2i|Patients receive an SGLT2i medication, such as dapagliflozin, empagliflozin, or canagliflozin. These drugs work by preventing the kidneys from reabsorbing glucose from the urine, leading to lower blood sugar levels and potentially reducing the risk of kidney damage.
62156457|NCT03596697|EXPERIMENTAL|CRV431|Either single or multiple doses of varying dose levels
62156458|NCT03596697|PLACEBO_COMPARATOR|Placebo|
62156459|NCT03596697|EXPERIMENTAL|TDF|300 mg TDF
62530856|NCT01675661|ACTIVE_COMPARATOR|NAC plus CM|N-acetylcysteine (NAC) plus Contingency Management (CM)
62530857|NCT01675661|PLACEBO_COMPARATOR|Placebo plus CM|Placebo plus Contingency Management (CM)
62530858|NCT00423475|ACTIVE_COMPARATOR|I|Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
62156460|NCT03161665|EXPERIMENTAL|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
62530859|NCT00423475|EXPERIMENTAL|II|Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
62530860|NCT06008743|EXPERIMENTAL|All subjects|All subjects (healthy and stroke survivors) participating in the study
62530861|NCT05483725||First booster dose group|
62530862|NCT01041183|ACTIVE_COMPARATOR|group I|0.3 mg IV ramosetron
62530863|NCT01041183|ACTIVE_COMPARATOR|group II|0.1 mg oral ramosetron
62714076|NCT02327767|NO_INTERVENTION|Physical Therapy|The control group will continue with existing physical therapy treatment of passive range of motion (PROM) and therapeutic exercise to their involved upper extremity by the physical therapist.
62714077|NCT05175014|EXPERIMENTAL|Single full dose of PCV 10|27 clusters randomized to receive a vaccination campaign with the full dose.
62714078|NCT05175014|EXPERIMENTAL|Single fractional dose of PCV10 (1/5)|27 clusters randomized to receive a vaccination campaign with the fractional dose (1/5).
62714079|NCT05175014|NO_INTERVENTION|Control Group|9 clusters randomized to the control arm.
62714080|NCT01071460|OTHER|SFA Stenting|
62156461|NCT05214521|EXPERIMENTAL|"digital interactive technology Smart glove SensoRehab"|"The operation of the digital interactive complex Smart glove SensoRehab is based on the visual and kinesthetic (proprioceptive) biofeedback principle by using a set of cognitive interactive computer games controlled by finger and hand movements. The technique involves neurosensory training and retraining to improve the fine use of the hand and arm, and the patient's cognitive and emotional state."
62156462|NCT05569018|EXPERIMENTAL|Blended group transversal protocol (BLGr-TP)|Treatment protocol based on the transdiagnostic perspective administered in blended (face-to-face + online) and group format. It consists of the following components: Psychoeducation about emotional disorders and emotion regulation; Motivation for change; Psychoeducation about emotions; Awareness of emotional experiences; Promotion of cognitive flexibility; Psychoeducation and awareness of avoidance strategies that maintain emotional problems; Interoceptive exposure: exposure to physical sensations; Situational and emotional exposure; Learning to move on; Learning to enjoy; Learning to live; Living and learning; Relapse prevention.
62156463|NCT05569018|ACTIVE_COMPARATOR|Face-to-face group transversal protocol (FFGr-TP)|Treatment protocol based on the transdiagnostic perspective administered in traditional (face-to-face) group format. It consists of the following components: Psychoeducation about emotional disorders and emotion regulation; Motivation for change; Psychoeducation about emotions; Awareness of emotional experiences; Promotion of cognitive flexibility; Psychoeducation and awareness of avoidance strategies that maintain emotional problems; Interoceptive exposure: exposure to physical sensations; Situational and emotional exposure; Learning to move on; Learning to enjoy; Learning to live; Living and learning; Relapse prevention.
62156464|NCT04148794|EXPERIMENTAL|Intervention group|Participants who join the class of eALS
62530864|NCT01041183|ACTIVE_COMPARATOR|group III|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
62530865|NCT05937828||Immune thrombocytopenia (ITP)|Immune thrombocytopenia (ITP) : defined according to the international working group criteria (Rodeghiero et al., Blood 2009).
62530866|NCT05937828||Autoimmune Hemolytic anemia (AIHA)|Autoimmune haemolytic anaemia (AIHA) : Hb \< 110 g/L with a positive direct antiglobulin test (DAT) and at least one of the following haemolysis criteria: reticulocyte count \> 120 G/L, free bilirubin \> 17 mmol/L, or haptoglobin \< 10 mg/dL.
62530867|NCT05937828||Evans syndrome (all bi or tri cytopenias)|Evans syndrome (ES) : simultaneous (less than 1 month) or sequential association of at least two autoimmune cytopenia among ITP, AIHA and autoimmune neutropenia (AIN).
62530868|NCT06311162|EXPERIMENTAL|Treatment group (Life-style app)|Parents receive a smartphone app during the main intervention period of 20 weeks. The app (life-style app) aims to promote healthy behaviour through cognitive-behavioural impact factors.
62530869|NCT06311162|SHAM_COMPARATOR|Control group|The parents get an information sheet with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
62714081|NCT03811470||1|Patients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
62714082|NCT05757869|EXPERIMENTAL|Milvexian|Participants will receive milvexian 100 milligrams (mg) orally, twice daily and placebo that matches apixaban beginning on Day 1 through end of treatment (EOT). Participants after the EOT visit may have an option to receive open-label apixaban at the appropriate dose (5 mg or 2.5 mg, twice daily), for which the sponsor provides a 30-day supply.
62714083|NCT05757869|ACTIVE_COMPARATOR|Apixaban|Participants will receive a placebo that matches milvexian and a capsule containing apixaban 5 mg or 2.5 mg orally, twice daily. Participants after the EOT visit may have an option to receive open-label apixaban (5 mg or 2.5 mg, twice daily) at the appropriate dose, for which the sponsor provides a 30-day supply.
62530870|NCT04847349|EXPERIMENTAL|Live microbial (Probiotic) consortium OL-1, standard dose|Combination of a standard dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
62530871|NCT04847349|EXPERIMENTAL|Live microbial (Probiotic) consortium OL-1, high dose|Combination of a high dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
62530872|NCT04847349|PLACEBO_COMPARATOR|Placebo for live microbial (probiotic) consortium|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics, taken once per day with breakfast for 21 days.
62530873|NCT04856150|EXPERIMENTAL|Q-1802|Q-1802 dose exploration and Q-1802 dose extension
62714084|NCT04750161||Psoriasis Vulgaris|
62530874|NCT02902536||Myasthenia Positive Antibodies|Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia
62530875|NCT02902536||Myasthenia Double Negative|Patients without AChR or MuSK antibodies
62530876|NCT02902536||Normal Controls|Patients without myasthenia
62530877|NCT00022542|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 2 additional courses.
62530878|NCT00775905|EXPERIMENTAL|1|amlodipine 10 mg tablets of Ranbaxy
62530879|NCT00775905|ACTIVE_COMPARATOR|2|Norvasc® 10 mg tablets
62530880|NCT01069991|EXPERIMENTAL|Patient education group|Patient education program delivered to high school students with persistent asthma.
62530881|NCT01069991|EXPERIMENTAL|Wait list control group|Control students received no intervention until the one year follow up period was completed.
62530882|NCT05860205|NO_INTERVENTION|No treatment condition|Group 1 (no treatment condition) will only receive educational materials through email and a weekly phone call from Coordinator to reduce dropouts for 12 weeks.
62530883|NCT05860205|ACTIVE_COMPARATOR|Multiple component mobile-aid pain reduction intervention + sham osteopathic manipulation treatment|Group 2 will receive the new intervention and sham osteopathic manipulative treatment for 12 weeks.
62530884|NCT05860205|ACTIVE_COMPARATOR|Multiple component mobile-aid pain reduction intervention + osteopathic manipulation treatment|Group 3 will receive both the multiple component mobile-aid pain reduction intervention and actual osteopathic manipulation treatment for 12 weeks.
62530885|NCT00295295|EXPERIMENTAL|Vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
62530886|NCT00295295|ACTIVE_COMPARATOR|Standing|Standing 10 min/day
62530887|NCT06506162|ACTIVE_COMPARATOR|Low Nicotine Gum|Participants in this arm will only use Lucy brand 2mg nicotine gum
62530888|NCT06506162|ACTIVE_COMPARATOR|High Nicotine Gum|Participants in this arm will only use Lucy brand 6mg nicotine gum
62530889|NCT06506162|ACTIVE_COMPARATOR|Low Nicotine Pouch|Participants in this arm will only use ON! brand 2mg nicotine pouches
62530890|NCT06506162|ACTIVE_COMPARATOR|High Nicotine Pouch|Participants in this arm will only use ON! brand 6mg nicotine pouches
62530891|NCT00658021|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection, twice a day
62530892|NCT00658021|EXPERIMENTAL|Exenatide 5 µg|Subcutaneous injection, twice a day
62530893|NCT00658021|EXPERIMENTAL|Exenatide 10 µg|Subcutaneous injection, twice a day
62530894|NCT04713150||COVID-19 Positive During Pregnancy|Sixty mother-child dyads, who have or had a confirmed positive COVID-19 test during pregnancy, will be recruited and enrolled in this study. All women enrolled must be 18 years of age or older. Her child will go on to participate at 2-5 days of age, and again at 3-, 6-, 9-, 12- and 24-months of age.
62530895|NCT04713150||COVID-19 Negative During Pregnancy|Twenty-five mother-child dyads, who have a confirmed negative COVID-19 test during pregnancy will be recruited and enrolled in the study. Women without any SARS-CoV-2 positive test during pregnancy or any suspected COVID illness, even if not tested, will be enrolled. All women enrolled must be 18 years of age or older. Her child will go on to participate at 3-, 6-, 9-, 12- and 24-months of age.
62530896|NCT02468752|SHAM_COMPARATOR|Air|Normobaric air breathing
62530897|NCT02468752|EXPERIMENTAL|Oxygen|Normobaric oxygen breathing
62530898|NCT02782793||Patient's with complex colon polyps|
62530899|NCT06394349|EXPERIMENTAL|PRP+308nm|The observation group received PRP intradermal injections (0.5cm apart, 0.02ml injected) once a month and 308 nm excimer phototherapy twice a week for 6 consecutive months.
62530900|NCT06394349|PLACEBO_COMPARATOR|NS+308nm|The control group received the same frequency of saline injections (0.5cm apart, 0.02ml injected) and phototherapy for 6 consecutive months.
62530901|NCT00664131||1|
62530902|NCT03669939||Communication strategy|Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers
62530903|NCT03669939||Standard of Care|Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines
62530904|NCT03577483|OTHER|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to criteria
62530905|NCT03577483|OTHER|Multiple system atrophy|Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
62530906|NCT03577483|OTHER|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
62530907|NCT00188292||High-grade disease|Those who had histologic anal high-grade disease.
62530908|NCT00188292||Control|Those who had less than highgrade histologic anal disease
62530909|NCT04105426|ACTIVE_COMPARATOR|Antioxidants|This arm of patients received one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
62530910|NCT04105426|PLACEBO_COMPARATOR|Placebo|This arm of patients received placebo for 3 months.
62714085|NCT04750161||Atopic Dermatitis|
62714086|NCT04750161||Ichthyosis Vulgaris|
62714087|NCT04750161||Healthy Controls|
62714088|NCT04999735||Patients with FSHD|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
62530911|NCT00804713|EXPERIMENTAL|All study participants|Subjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
62530912|NCT03886987|EXPERIMENTAL|Device and Control|"Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml~Negative control: Blank patch Dose: Not applicable"
62530913|NCT01097941|ACTIVE_COMPARATOR|LAIV/LAIV|
62530914|NCT01097941|ACTIVE_COMPARATOR|IIV/IIV|
62530915|NCT01097941|ACTIVE_COMPARATOR|IIV/LAIV|
62530916|NCT04689555|EXPERIMENTAL|Novel method without manual compression|
62530917|NCT04689555|ACTIVE_COMPARATOR|Standard method with manual compression|
62530918|NCT00807677|EXPERIMENTAL|1|TAK-901
62530919|NCT02593682|EXPERIMENTAL|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
62530920|NCT02593682|PLACEBO_COMPARATOR|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
62530921|NCT01023191|ACTIVE_COMPARATOR|Percutaneous insertion|To undergo insertion of catheter using percutaneous technique under local anaesthetic
62530922|NCT01023191|ACTIVE_COMPARATOR|Open insertion|To undergo insertion of catheter using open technique under general anaesthetic
62530923|NCT01050608||Sprixx Device Group|Treatment group utilizing multimodal hand hygiene device
62530924|NCT01050608||Standard Hand Hygiene Group|Utilizing wall mounted dispensers and CDC based guidelines.
62530925|NCT02569112|ACTIVE_COMPARATOR|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
62530926|NCT02569112|EXPERIMENTAL|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
62530927|NCT03122067|EXPERIMENTAL|oxytocin group|male participants with oxytocin treatment
62530928|NCT03122067|PLACEBO_COMPARATOR|placebo group|male participants with placebo treatment
62530929|NCT06490445|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo, inhaled TID via the Fixed-dose Syqe Inhaler.
62530930|NCT06490445|EXPERIMENTAL|0.25 mg THC|Participants will inhale medical cannabis aerosol containing 0.25 mg THC via the Fixed-dose Syqe Inhaler three times a day.
62530931|NCT06490445|EXPERIMENTAL|0.5 mg THC|Participants will inhale medical cannabis aerosol containing 0.5 mg THC via the Fixed-dose Syqe Inhaler three times a day.
62530932|NCT06490445|EXPERIMENTAL|1.0 mg THC|Participants will inhale medical cannabis aerosol containing 1.0 mg THC via the Fixed-dose Syqe Inhaler three times a day.
62530933|NCT04793048|ACTIVE_COMPARATOR|Active group received an active device and a scaling and root planing (SRP) at baseline|
62530934|NCT04793048|SHAM_COMPARATOR|Sham group received a sham device and a scaling and root planing (SRP) at baseline|
62530935|NCT01612026||Ultrasound|
62530936|NCT01612026||Fluoroscopy|
62530937|NCT05672823|EXPERIMENTAL|Minimally invasive, upper extremity|Radial artery for pigtail catheter and pacing over the Left Ventricular (LV) stiff wire OR radial artery for pigtail catheter and brachial vein for temporary pacemaker when not pacing over the LV stiff wire.
62530938|NCT05672823|ACTIVE_COMPARATOR|Lower extremity|Femoral artery for pigtail catheter and pacing over the LV stiff wire OR femoral artery for pigtail catheter and femoral vein for temporary pacemaker when not pacing over the LV stiff wire.
62530939|NCT01674127|EXPERIMENTAL|Methyldopa|In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
62530940|NCT01674127|PLACEBO_COMPARATOR|placebo|
62530941|NCT03312595|OTHER|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
62530942|NCT05282186|EXPERIMENTAL|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
62530943|NCT05282186|ACTIVE_COMPARATOR|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health.
62530944|NCT00975403|EXPERIMENTAL|Dead space breathing|
62530945|NCT00975403|SHAM_COMPARATOR|Room air breathing|
62530946|NCT03757351|EXPERIMENTAL|DNL747 First, Placebo Second|
62530947|NCT03757351|EXPERIMENTAL|Placebo First, DNL747 Second|
62530948|NCT03757351|EXPERIMENTAL|Open-Label Extension|Conducted in the Netherlands only.
62530949|NCT04849065|EXPERIMENTAL|MNC (Mononuclear cells)|"MNC (Mononuclear cells) (patients in which stem cells will be injected into the two muscles on one side and placebo -vehicle- in the two contralateral muscles).~This group would consist of 74 patients."
62530950|NCT04849065|PLACEBO_COMPARATOR|Saline|(patients in which placebo -vehicle- will be injected into both muscles on both sides). This group would consist of 26 patients.
62530951|NCT02107820|ACTIVE_COMPARATOR|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
62530952|NCT02107820|EXPERIMENTAL|'Bladder Training (BT) and PTNS|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
62530953|NCT02514850|EXPERIMENTAL|Biochaperone Combo|single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
62530954|NCT02514850|ACTIVE_COMPARATOR|Humalog Mix25|single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
62530955|NCT02514850|ACTIVE_COMPARATOR|Humalog and Lantus|simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
62530956|NCT01193127|EXPERIMENTAL|OMS302 Solution|OMS302 Solution
62530957|NCT01193127|EXPERIMENTAL|OMS302 Mydriatic Solution|OMS302 Mydriatic Solution
62530958|NCT01193127|EXPERIMENTAL|OMS302 Anti-inflammatory Solution|OMS302 Anti-inflammatory Solution
62530959|NCT01193127|PLACEBO_COMPARATOR|Balanced Salt Solution (BSS) Solution|Balanced Salt Solution (BSS) Solution
62530960|NCT00778024|EXPERIMENTAL|1|fluoxetine HCL 40 mg capsules of ranbaxy
62530961|NCT00778024|ACTIVE_COMPARATOR|2|PROZAC® 40 mg capsules
62530962|NCT03979781|EXPERIMENTAL|Treatment Group|Intervention group
62714089|NCT04999735||Healthy controls|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
62714090|NCT00953706|PLACEBO_COMPARATOR|Placebo|Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
62156465|NCT01874470|PLACEBO_COMPARATOR|standard medication|Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic
62156466|NCT01874470|EXPERIMENTAL|renal denervation|Allegro Renal Denervation System (AngioCare)
62714091|NCT00953706|EXPERIMENTAL|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
62156467|NCT05486988||2 cycles chemotherapy combined with PD-1/PD-L1 inhibitors|Participants receive 2 cycles chemotherapy combined with PD-1/PD-L1 inhibitors, after achieving CR/PR/SD according to RECIST v1.1, then will continue immune monotherapy maintenance therapy.
62530963|NCT03979781|ACTIVE_COMPARATOR|Control Group|Standard of Care group
62530964|NCT00831766|EXPERIMENTAL|Phase I: Dose Escalation|"Induction: A dose escalation plan for induction therapy using a standard 3x3 design with dose escalation of Lenalidomide only, to determine maximum tolerated dose (MTD). Idarubicin and cytarabine doses will be fixed.~Idarubicin: 12 mg/m\^2.~Cytarabine: 200 mg/m\^2.~Lenalidomide: According to dose escalation levels. Level 1: 5 mg/d; Level 2: 10 mg/d; Level 3: 15 mg/d; Level 4: 20 mg/d; Level 5: 25 mg/d."
62530965|NCT00831766|EXPERIMENTAL|Phase II: Treatment at MTD|"Idarubicin: 12 mg/m\^2.~Cytarabine: 200 mg/m\^2.~Lenalidomide: Maximum Tolerated Dose (MTD)."
62530966|NCT05850988|ACTIVE_COMPARATOR|Group Eighty|Patients in Group E will receive %80 oxygen for 3 minutes during preoxygenation
62530967|NCT05850988|ACTIVE_COMPARATOR|Group Hundred|Patients in Group H will receive %100 oxygen for 3 minutes during preoxygenation
62530968|NCT03258073|EXPERIMENTAL|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
62530969|NCT03824496||Suspected acute stroke|"Any patient with suspected acute stroke triggering a stroke code and had a brain imaging angiogram"
62714092|NCT02398812|ACTIVE_COMPARATOR|Active comparator|In addition to usual care, participants allocated to intervention group will receive medication assessment and treatment plan based on it
62714093|NCT02398812|NO_INTERVENTION|Usual care|Usual care (reference group).
62714094|NCT01523938|EXPERIMENTAL|Hypnotherapy|
62530970|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
62530971|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
62530972|NCT04126213|EXPERIMENTAL|RSV MAT 60 Group-Mother|Maternal subjects randomized to RSV MAT 60 Group received a single dose of RSV MAT (60 µg) vaccine at Day 1, and were followed up until the study end.
62530973|NCT04126213|EXPERIMENTAL|RSV MAT 120 Group-Mother|Maternal subjects randomized to RSV MAT 120 group received a single dose of RSV MAT (120 µg) vaccine at Day 1, and were followed up until the study end.
62530974|NCT04126213|PLACEBO_COMPARATOR|Control Group-Mother|Maternal subjects randomized to the Control Group received a single dose of Placebo at Day 1, and were followed up until the study end.
62530975|NCT04126213|NO_INTERVENTION|RSV MAT 60 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 60 Group-Mother) who received a single dose of RSV MAT (60 µg) vaccine during pregnancy.
62530976|NCT04126213|NO_INTERVENTION|RSV MAT 120 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 120 Group-Mother) who received a single dose of RSV MAT (120 µg) vaccine during pregnancy.
62530977|NCT04126213|NO_INTERVENTION|Control Group-Infant|This group consisted of infants born to mothers (from Control Group-Mother) who received a single dose of placebo during pregnancy.
62714095|NCT01523938|NO_INTERVENTION|No Hypnotherapy|
62156468|NCT05486988||4-6 cycles chemotherapy combined with PD-1/PD-L1 inhibitors|Participants receive 4\~6 cycles chemotherapy combined with PD-1/PD-L1 inhibitors, after achieving CR/PR/SD according to RECIST v1.1, then will continue immune monotherapy maintenance therapy.
62530978|NCT00599378|EXPERIMENTAL|1|Implementation Intentions-based telephone counseling. Partnership intervention between rural Primary Care Physicians, their patients, and CRC Information Specialists using an implementation intentions based approach.
62530979|NCT00599378|NO_INTERVENTION|2|Healthy Living information on Physical Activity and Nutrition
62530980|NCT01830491|EXPERIMENTAL|Clopidogrel napadisilate|aspirin 100mg
62530981|NCT01830491|ACTIVE_COMPARATOR|clopidogrel bisulfate|aspirin 100mg
62156469|NCT06012786||Group 1 (Patients with Stage 0 lymphedema)|It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent). The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55)
62530982|NCT05919316|EXPERIMENTAL|Rhinophototherapy|Intranasal Rhinophototherapy is an electronic allergic rhinitis treatment device (brand Bionette) also a medical device that producing low level narrow band red light at a wavelength of 630nm. It is a Class B medical device (registration of Malaysia number GB67793908818). It is powered by two alkaline button batteries with a dimension of 52mm x 40mm and weighing less than 20g . Light is produced via nasal prongs which are to be inserted into both nostrils. Plastic nasal cannula are available and can be replaced to ensure sterility and prevent transmission of infection.
62530983|NCT05919316|ACTIVE_COMPARATOR|Intranasal Corticosteroids|Mometasone furoate will be available in the form of Nasonex Nasal Spray. It has a dose of 50 mcg/dose mometasone furoate per spray, registration no: MAL20001010AZ, distributed by: Merck Sharp \& Dohme (Malaysia) Sdn. Bhd.
62530984|NCT05080426|EXPERIMENTAL|Intervention Group - Managers|"Mangers in the intervention group will be asked to:~1. Complete an online survey;~2. Take the Family Supportive Supervisor Training online (FSST);~3. Take the Supervisor Support for Leave Use module;~4. Track their behaviors for two weeks;~5. Participate in a webinar and have the opportunity to ask questions and give comments;~6. Complete a post-training survey;~7. 8-10 managers may also participate in the focus group."
62530985|NCT05080426|NO_INTERVENTION|Control Group - Managers|"Managers in the control group will be asked to:~1. Complete an online survey three times over the course of 5 months."
62530986|NCT05080426|EXPERIMENTAL|Intervention Group - Employees|"Employees in the intervention group will be asked to:~1. Complete an online survey three times over the course of 6 months."
62156470|NCT06012786||Group 2 (Patients with Stage 1,2 or 3 lymphedema)|Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55)
62156471|NCT04425252|OTHER|Standard of Care|Subjects are hospitalized for COVID-19 and will receive all supportive/interventional care per institutional guidelines.
62156472|NCT04425252|EXPERIMENTAL|Brequinar|Subjects will receive standard of care plus brequinar 100 mg daily (Study Days 1-5).
62156473|NCT04072809||All participants|All participants in the study will experience the same procedures.
62156474|NCT01779492|EXPERIMENTAL|GL2907|Oxycodone HCl 20mg
62530987|NCT05080426|NO_INTERVENTION|Control Group - Employees|"Employees in the control group will be asked to:~1. Complete an online survey three times over the course of 5 months."
62530988|NCT01616108|EXPERIMENTAL|Bupivacaine Injection|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
62530989|NCT00049582|EXPERIMENTAL|Treatment (decitabine)|"Patients receive decitabine IV over 3 hours twice daily OR IV over 1 hour once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
62530990|NCT04176406|ACTIVE_COMPARATOR|rTMS over a node within the fronto-parietal network|excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.
62530991|NCT04176406|SHAM_COMPARATOR|Sham rTMS over a node within the fronto-parietal network|electrical sham coil applied over a node within the fronto-parietal network.
62530992|NCT04176406|ACTIVE_COMPARATOR|rTMS over the DLPFC|excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.
62156475|NCT01779492|ACTIVE_COMPARATOR|Oxycontine CR 10mg|Oxycodone HCl 10mg
62156476|NCT01092715|EXPERIMENTAL|Mobilization|Spinal mobilization and exercises
62156477|NCT01092715|ACTIVE_COMPARATOR|Massage|Neck massage and exercises
62156478|NCT02482324|OTHER|Treatment A-B|12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
62156479|NCT02482324|OTHER|Treatment B-A|12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
62156480|NCT04893759|EXPERIMENTAL|APG-1252|
62156481|NCT04738370||Pregnancy of unknown location|Patients will be approached for recruitment following PUL classification. Sample collection at time of classification +/- 48 hours later, timed for when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
62530993|NCT04176406|SHAM_COMPARATOR|Sham rTMS over the DLPFC|electrical sham coil applied over the DLPFC.
62530994|NCT03467880||Healthy subjects|Healthy subjects.
62530995|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
62530996|NCT03467880||Asthma|Patience with asthma.
62530997|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
62530998|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
62530999|NCT03677076||Ancillary/Correlative|Patients will complete questionnaires and have research blood drawn.
62156482|NCT04738370||Ectopic Pregnancy|Patients will be approached for recruitment following Ectopic Pregnancy diagnosis. Ectopic pregnancies that are recruited as PUL do not need to be re-approached as they are already part of the study. Sample collection at time of diagnosis when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
62531000|NCT03086837|EXPERIMENTAL|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
62714096|NCT06703944||Neuroblastoma With Bone Marrow Metastasis Group|For the diagnosis of neuroblastoma with bone marrow metastasis, the medical practices including as follows: bone marrow biopsy, bone marrow cytology of aspiration smear, flow cytometry and positron emission tomography-computed tomography(PET-CT). Bone marrow biopsy or smear analysis may reveal characteristic NB cells. Flow cytometry may detect NB cells with phenotype of cluster of differentiation antigen 45(CD45)-/cluster of differentiation antigen 56(CD56)+/cluster of differentiation antigen 81(CD81)+/GD2 ganglioside (GD2)+. PET/CT imaging reveal the metastatic NB cells in term of metabolic activity and spatial distribution of metastatic involvement. A positive result from any of these methods is sufficient for diagnosed as NB with bone marrow metastasis.
62531001|NCT03086837|NO_INTERVENTION|Control|No information
62156483|NCT00608959|EXPERIMENTAL|omiganan 1% gel|Omiganan has a rapid bactericidal and fungicidal effect which is under development for the prevention of infections arising from short-term central venous catheters, as well as for the prevention of surgical wound infections in contaminated wounds.
62531002|NCT02853370|EXPERIMENTAL|Bendamustine and Rituximab|"Induction Phase (Cycle 1 to Cycle 3 ):~Bendamustine 90 mg/sqm i.v. d1 \& d2\* Rituximab 375 mg/m2 i.v. d1\*\*~Extended Phase (Cycle 4 to Cycle 6):~Bendamustine 90 mg/sqm i.v. d1 \& d2\* Rituximab 375 mg/m2 i.v. d1~From Cycle 4 to Cycle 6, every 4 weeks, depending on the response after the first 3 Cycles~\*Or days 2-3 according to institutional/patient/physician preference~\*\*Administration of Rituximab during cycle 1 and cycle 2 can be postponed to day 8 or 14 in case of risk of tumor lysis syndrome (TLS)"
62156484|NCT00608959|ACTIVE_COMPARATOR|chlorhexidine 2%|
62156485|NCT05507372|EXPERIMENTAL|Dopamine Receptor Modulator|Pimozide 1mg Oral
62156486|NCT05507372|PLACEBO_COMPARATOR|Placebo|Placebo Oral
62531003|NCT00440544|EXPERIMENTAL|1|100 ug H1 antigen alone in BCG naive subjects
62531004|NCT00440544|EXPERIMENTAL|2|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
62156487|NCT01502241|ACTIVE_COMPARATOR|Radiotherapy|6 weeks standard partial brain treatment.
62156488|NCT01502241|EXPERIMENTAL|Temozolomide|Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007
62156489|NCT01929616|EXPERIMENTAL|Regorafenib|A treatment cycle is defined as a 4 weeks period. Regorafenib will be administered once a day orally at a dose of 160 mg (4 tablets of 40 mg), for 3 weeks.
62156490|NCT02935894|EXPERIMENTAL|Single group|"All subjects will participate in 4 study day visits in the same order.~1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).~2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).~3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).~4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
62156491|NCT00442559|EXPERIMENTAL|Montelukast|Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
62156492|NCT00442559|ACTIVE_COMPARATOR|Inhaled Corticosteroids (ICS)|Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
62531005|NCT00440544|EXPERIMENTAL|3|50 ug H1 antigen in BCG immunized subjects
62531006|NCT00440544|EXPERIMENTAL|4|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
62531007|NCT00440544|EXPERIMENTAL|5|100 ug H1 antigen in BCG immunized subjects
62531008|NCT00440544|EXPERIMENTAL|6|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
62531009|NCT03080415|EXPERIMENTAL|Combined Therapy SOF and DCV|
62531010|NCT05508464|ACTIVE_COMPARATOR|Standard of Care|Standard or care palliative radiotherapy (includes the option for no treatment)
62531011|NCT05508464|ACTIVE_COMPARATOR|SABR|SABR to all tumors 6Gy x 5 over 3 weeks
62531012|NCT03599830|OTHER|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
62531013|NCT00601809|EXPERIMENTAL|GG|
62531014|NCT00601809|OTHER|TT|
62531015|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
62531016|NCT05795738|NO_INTERVENTION|Control group|regular kindergarten education
62531017|NCT05795738|EXPERIMENTAL|Chinese characters-based visual-motor program|visual perceptual motor activities using Chinese characters as activity materials.
62531018|NCT05795738|EXPERIMENTAL|traditional visual-motor training program|visual perceptual motor activities using commercial or self-designed toys and pencil-paper sheets as activity materials.
62531019|NCT02737748|EXPERIMENTAL|TWB-103 Group|Subjects will receive TWB-103 2 to 3 times till 100% re-epithelialization or up to 10 days (around once every 3 days).
62531020|NCT02737748|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive placebo 2 to 3 times till 100% re-epithelialization or up to 10 days (around once every 3 days).
62531021|NCT02933268|ACTIVE_COMPARATOR|Ad libitum water intake|Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality \> 300 mOsmo/kg
62531022|NCT02933268|ACTIVE_COMPARATOR|High water intake|Personalised daily water intake prescription to achieve target urine osmolality \< 270 mOsm/kg.
62156493|NCT01571440|PLACEBO_COMPARATOR|No Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times daily.
62156494|NCT01571440|ACTIVE_COMPARATOR|12 g Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times daily
62156495|NCT01299324|EXPERIMENTAL|BMAC Infusion|Infusion of autologous bone marrow aspirate concentrated nucleated sells into the coronary sinus
62156496|NCT01299324|NO_INTERVENTION|Control|Standard of care only. No infusion
62156497|NCT06483594||Patients with liver abscess formation after TACE for HCC|
62531023|NCT06584890||Decision from Experts|Decisions maded by Intensive Care doctors
62531024|NCT06584890||Decision from AI|Decisions maded by Artificial intelegence models
62156498|NCT06483594||Patients without liver abscess after TACE with HCC|
62531025|NCT02218125|EXPERIMENTAL|Group 1- MVA Mosaic|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
62531026|NCT02218125|PLACEBO_COMPARATOR|Group 2 - Placebo|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
62156499|NCT05206916|OTHER|evaluation of cryotherapy as treatment for obstructive sleep apnea patients|
62531027|NCT02218125|EXPERIMENTAL|Group 3 - MVA Mosaic|Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
62531028|NCT02218125|PLACEBO_COMPARATOR|Group 4- Placebo|Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
62531029|NCT05576766|ACTIVE_COMPARATOR|Routine care group|Perioperative management according to routine care.
62531030|NCT05576766|EXPERIMENTAL|ERAS group|Perioperative management according to the Enhanced Recovery after Surgery (ERAS) pathway.
62531031|NCT02902783||Consented deceased organ donors|Data will be collected on deceased donors, declared by neurological determination of death (DND) and by circulatory determination of death (DCD).
62531032|NCT03568279|ACTIVE_COMPARATOR|Control|The attending anesthesiologist provided intubation without two-handed jaw thrust.
62531033|NCT03568279|EXPERIMENTAL|Two-hand|The attending anesthesiologist provided intubation with two-handed jaw thrust.
62531034|NCT04190719|EXPERIMENTAL|Paprika group|Patients coming for elective major surgery will participate to Paprika program
62531035|NCT04190719|NO_INTERVENTION|Historical group|Patients previously operated with same characteristics
62531036|NCT00663767|PLACEBO_COMPARATOR|Placebo|
62714097|NCT06703944||Neuroblastoma Without Bone Marrow Metastasis Group|For the diagnosis of bone marrow metastasis in the enrolled participants, if there is no positive result from any of these tests as follows: bone marrow biopsy, bone marrow cytology of smear, flow cytometry or PET/CT, the participant is classified into the Neuroblastoma Without Bone Marrow Metastasis Group.
62156500|NCT03581318||Assessing Gadolinium deposition within the brain in healthy and patient subjects|Both healthy subjects and patient subjects who have previously undergone MRI and received gadolinium.
62156501|NCT03581318||Child Patient or Healthy Child|Healthy children will be used as controls for children with cardiac disease. Child patient will undergo MRI scans.
62156502|NCT03581318||Healthy Volunteers|Subjects will be used as controls for adults with cardiac disease.
62156503|NCT03581318||Research Patients Cardiac and Non Cardiac|Adults with cardiac disease that will undergo MRI scans.
62156504|NCT05452408|EXPERIMENTAL|Antitumor B KAC|ATB will be administered on an outpatient basis.
62156505|NCT05665348|ACTIVE_COMPARATOR|DOULET ATEZOLIZUMAB-BEVACIZUMAB|Standard treatment of HCC by the combination atezolizumab-bevacizumab, 1 cure each 3 weeks during 24 months
62156506|NCT05665348|EXPERIMENTAL|TRIPLET ATEZOLIZUMAB BEVACIZUMAB IPILIMUMAB|Standard treatment of HCC by the combination atezolizumab-bevacizumab with addition of ipilimumab for the 4 firsts cures of treatment each 3 weeks, then only treatment by the doublet atezolizumab-bevacizumab each 3 weeks. The total duration of treatment is 24 months.
62156507|NCT02954809|EXPERIMENTAL|Experimental|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
62531037|NCT00663767|EXPERIMENTAL|Placebo, ARRY-371797|
62531038|NCT00663767|EXPERIMENTAL|ARRY-371797, Placebo|
62531039|NCT00663767|EXPERIMENTAL|ARRY-371797|
62531040|NCT00663767|ACTIVE_COMPARATOR|Celecoxib, Placebo|
62531041|NCT00663767|EXPERIMENTAL|Celecoxib, ARRY-371797|
62531042|NCT05498402|ACTIVE_COMPARATOR|Bag-valve-mask ventilation|Providers will perform a cardiopulmonary resuscitation, and deliver ventilations using a bag-valve-mask
62531043|NCT05498402|EXPERIMENTAL|Supraglottic airway device ventilation|Providers will perform a cardiopulmonary resuscitation, and deliver ventilations using an i-gel® supraglottic airway device
62531044|NCT00336245|EXPERIMENTAL|Copper T Intrauterine Contraceptive Device|
62531045|NCT00336245|ACTIVE_COMPARATOR|Hormonal Contraception|
62531046|NCT06170437|EXPERIMENTAL|Intervention|The study's investigators will train bilingual study staff to deliver the intervention to residents using a script that matches the content in the smoke-free home intervention pamphlet. The in-person delivery of the intervention and pamphlet will be the primary modes of intervention delivery to residents. The pamphlet will include: (1) the harms of tobacco, e-cigarette use, cannabis use and exposure (secondhand and thirdhand), (2) an exercise to calculate personal cost of tobacco use, (3) benefits of a smoke-free home, (4) skill-building on how to adopt a smoke-free home, and (5) motivational language on smoke-free home adoption. The study staff will qualitatively assess participants' knowledge by prompting questions on the topics covered and will refer participants to lay-health workers (LHWs) for one-on-one coaching. Participants will receive a pledge to designate their homes smoke-free.
62531047|NCT06170437|NO_INTERVENTION|Waitlist Control Group|The current standard of care does not include any interventions for smoke-free home adoption or referrals to tobacco treatment resources. At the end of the primary endpoint (6 months), control participants will be offered the intervention.
62156508|NCT02954809|ACTIVE_COMPARATOR|Attention Control|Exposure to dim light delivered with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
62156509|NCT02868086|EXPERIMENTAL|Tested patients|Patients treated with anti-angiogenics for ARMD : monitoring using optical coherence tomography angiography
62156510|NCT02868086|ACTIVE_COMPARATOR|Control patients|Patients treated with anti-angiogenics for ARMD : monitoring during common practice via optical coherence tomography B scans
62531048|NCT02470390|ACTIVE_COMPARATOR|Nasal fentanyl|"nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.~Will be administered on either study day 1 or 3 per protocol and randomization."
62531049|NCT02470390|ACTIVE_COMPARATOR|Sub-Lingual fentanyl|"sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.~Will be administered on either study day 1 or 3 per protocol and randomization."
62531050|NCT02470390|ACTIVE_COMPARATOR|IV fentanyl|"IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.~Will be administered on study day 5 per protocol."
62531051|NCT05506410||Arms|Experimental:Rituximab、Bendamustine、Cytarabine、Prednisone （R-BAP） combined with BTK inhibitors To observe the efficacy and safety of R-BAP combined with BTK inhibitors in the treatment of newly-treated patients with mantle cell lymphoma (MCL)
62531052|NCT03216070|EXPERIMENTAL|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
62531053|NCT05960318||Adolescents and adults|Adolescents from 12 years old and adults with common cold, nasal mucosa inflammation and/or rhinitis, who have bought the product.
62531054|NCT05960318||Children|Children from 2 to 12 years old with common cold, nasal mucosa inflammation and/or rhinitis, whose parents/caregivers have bought the product.
62531055|NCT03564444|EXPERIMENTAL|Bivalent influenza vaccine|A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1
62531056|NCT03564444|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
62531057|NCT03956121||Exposed group|Exposed group( with magnesium sulfate): fetuses aged 24 + 0AW to 32 + 0AW and benefiting from MgSO4 for neuroprotective purposes, with decision of extraction or spontaneous or induced labour
62531058|NCT03956121||Control group|Control group (without magnesium sulfate) : fetuses aged 32 + 1SA to 35 + 0SA without MgSO4, with extraction decision or spontaneous or induced labour
62531059|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac \& neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
62714098|NCT04859192|EXPERIMENTAL|study group|For 6 weeks, students in study group will receive their routine flipped classroom in addition to gamified activities that they are required to complete before class session.
62714099|NCT04859192|NO_INTERVENTION|control group|The control group will not receive any intervention only their routine flipped classroom education
62714100|NCT01816984|EXPERIMENTAL|Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)|"Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and after dose escalation, 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.~All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62156511|NCT02267200||reversible PAH group|reversible PAH was defined as sPAP decreasing to 40 mmHg after follow-up more than 6 months through echocardiography.
62156512|NCT02267200||irreversible PAH group|irreversible PAH was defined as 6 months after surgery through echocardiography ，the sPAP remaining 40 mmHg or up
62156513|NCT04478552|EXPERIMENTAL|Intervention group|
62531060|NCT05135052|EXPERIMENTAL|Treatment arm|Treatment with Rhenium-SCT, Single treatment.
62156514|NCT04478552|PLACEBO_COMPARATOR|Control group|
62156515|NCT06277245|EXPERIMENTAL|LNK01001 12 mg|o Period 1: Participants receive LNK01001 12 mg twice daily for 16 weeks. Period 2: Participants will continue on LNK01001 12 mg twice daily from Week 16 to Week 52.
62156516|NCT06277245|EXPERIMENTAL|LNK01001 24 mg|o Period 1: Participants receive LNK01001 24 mg twice daily for 16 weeks. Period 2: Participants will continue on LNK01001 24 mg twice daily from Week 16 to Week 52.
62156517|NCT06277245|PLACEBO_COMPARATOR|Placebo / LNK01001 12 mg|o Period 1: Participants receive a placebo twice daily for 16 weeks. Period 2: Participants will switch to receive LNK01001 12 mg twice daily from Week 16 to Week 52.
62531061|NCT01406392|ACTIVE_COMPARATOR|Sublingual Misoprostol 12,5mcg|Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
62531062|NCT01406392|ACTIVE_COMPARATOR|Vaginal Misoprostol 25 mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.
62156518|NCT06277245|PLACEBO_COMPARATOR|Placebo / LNK01001 24mg|o Period 1: Participants receive a placebo twice daily for 16 weeks. Period 2: Participants will switch to receive LNK01001 24 mg twice daily from Week 16 to Week 52.
62531063|NCT03441724||STEMI before PCI|ST-segment elevation, recording acquired before coronary intervention
62531064|NCT03441724||STEMI after PCI|ST-segment elevation, recording acquired from the same patients after coronary intervention
62531065|NCT05323331|EXPERIMENTAL|Circuit Training|"This group preformed interval training alternating between aerobic and resistance training, varying between moderate to high intensity. Each set started with 3 minutes of aerobic training on cycle or treadmill followed by resistance training and a rest interval. Eight circuits were formed; horizontal rowing, chest press, leg press, shoulder press, leg extension, lateral pull down, leg flexion and partial squat. Weight was calculated through 1 RM calculation.~This training is to be carried out for 12 weeks, in three phases, the intensity progressing from light to moderate (30% of RM to 50%). Sessions will be carried out thrice a week."
62156519|NCT01308099||POTS & Controls|"Participants will have a physical prior to the study day and collect urine for 24 hours.~On the study day the following procedures take place:~After blood samples taken (about 2 tbsp), the subject will lie down. A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The arm blood pressure cuff will be inflated 60 points above the highest number on your normal blood pressure for five minutes. The blood pressure and forearm blood flow will be recorded. At the end of 5 minutes, the cuff will be released and the measurements of blood pressure and calf blood flow will be repeated. The brachial artery diameter and flow will be measured at baseline, during cuff inflation and for 3 minutes after deflation.~The study lasts about 2 hours."
62156520|NCT00884806|EXPERIMENTAL|FID 114675A|FID 114675A used for 7 days, per protocol-specified instructions. Silicone hydrogel or hydrogel contact lenses worn bilaterally on a daily wear basis, one brand only.
62156521|NCT03368105|EXPERIMENTAL|LP299v group|Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.
62156522|NCT03368105|PLACEBO_COMPARATOR|Placebo group|Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.
62156523|NCT02349802|EXPERIMENTAL|Arm 1|exenatide suspension - 9 mg / 0.85 mL
62156524|NCT02349802|EXPERIMENTAL|Arm 2|exenatide suspension - 9 mg / 0.85 mL
62156525|NCT02349802|EXPERIMENTAL|Arm 3|exenatide suspension - 4.5 mg /1.1 mL
62531066|NCT05323331|ACTIVE_COMPARATOR|Aerobic Training|The control group consists of aerobic exercise training, with 20 minutes on the cycle, 15 minutes of treadmill and 10 minutes of walking
62531067|NCT01176708|EXPERIMENTAL|Liver transplanted|10 Liver transplanted patients
62531068|NCT01176708|EXPERIMENTAL|Kidney transplanted|10 kidney transplanted individuals
62531069|NCT01176708|EXPERIMENTAL|Healthy controls|10 healthy controls
62531070|NCT05791513|EXPERIMENTAL|Using the MAP-Knee Tool|The treating clinician will use the MAP-Knee Tool together with the adolescent. The tool includes four separate components: 1) a tool for diagnosing the most common types of non-traumatic knee pain (SMILE), 2) credible explanations of the aetiology and pathogenesis specific to the diagnosis based on multiple methods with an iterative design, 3) a presentation of prognostic factors based on an individual participant data meta-analysis(19), and 4) an option grid that presents the users of the tool with pros and cons of commonly used management options based on a systematic literature search of systematic and narrative reviews within non-traumatic adolescent knee pain. An overarching focus of all components was to support shared decision-making and base decisions on all three pillars of evidence-based medicine: patient values, clinical expertise, and relevant research. Therefore, the tool should not provide the users with definitive answers simply based on available evidence.
62531071|NCT05791513|ACTIVE_COMPARATOR|Not using the MAP-Knee Tool|The treating clinician will not use the MAP-Knee Tool in the consultation and will conduct the consultation as per usual practice.
62531072|NCT03849287|EXPERIMENTAL|Group 1|"* Period 1: CKD-333, formula I~* Period 2: CKD-333, formula II~* Period 3: CKD-330, D090"
62531073|NCT03849287|EXPERIMENTAL|Group 2|"* Period 1: CKD-333, formula I~* Period 2: CKD-330, D090~* Period 3: CKD-333, formula II"
62531074|NCT03849287|EXPERIMENTAL|Group 3|"* Period 1: CKD-333, formula II~* Period 2: CKD-330, D090~* Period 3: CKD-333, formula I"
62156526|NCT02349802|EXPERIMENTAL|Arm 4|exenatide suspension - 9 mg / 1.1 mL
62156527|NCT02349802|EXPERIMENTAL|Arm 5|exenatide suspension - 9 mg / 1.5 mL
62156528|NCT03230981|EXPERIMENTAL|Healthy subjects|Optical imaging of the cornea in healthy subjects
62156529|NCT04371445|EXPERIMENTAL|Intracanalicular dexamethasone insert group|This arm will receive the DEXTENZA® insert within minutes after the completion of the surgery.
62156530|NCT04371445|ACTIVE_COMPARATOR|Topical steroid drop group|This arm will receive the prescription for daily prednisolone acetate 1% eye drops 4 times a day for the first week following the procedure, starting on the day of surgery.
62531075|NCT03849287|EXPERIMENTAL|Group 4|"* Period 1: CKD-333, formula II~* Period 2: CKD-333, formula I~* Period 3: CKD-330, D090"
62531076|NCT03849287|EXPERIMENTAL|Group 5|"* Period 1: CKD-330, D090~* Period 2: CKD-333, formula I~* Period 3: CKD-333, formula II"
62531077|NCT03849287|EXPERIMENTAL|Group 6|"* Period 1: CKD-330, D090~* Period 2: CKD-333, formula II~* Period 3: CKD-333, formula I"
62156531|NCT05811000|ACTIVE_COMPARATOR|Aricept 5 mg|Aricept 5 mg + Placebo of PM012 eight tablets, daily during 12 weeks (oral)
62531078|NCT05783518|EXPERIMENTAL|propofol group|
62531079|NCT05783518|EXPERIMENTAL|propofol and desflurane group|
62531080|NCT05783518|EXPERIMENTAL|desflurane group|
62531081|NCT01555008|EXPERIMENTAL|Treatment A|
62531082|NCT01555008|PLACEBO_COMPARATOR|LX4211 Placebo|
62531083|NCT04068844|EXPERIMENTAL|Central HFpEF whole body exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to whole body cycle training.
62531084|NCT04068844|EXPERIMENTAL|Central HFpEF isolated single leg exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to isolated single leg training.
62531085|NCT04068844|EXPERIMENTAL|Peripheral HFpEF whole body exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to whole body cycle training.
62531086|NCT04068844|EXPERIMENTAL|Peripheral HFpEF isolated single leg exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to isolated single leg training.
62156532|NCT05811000|EXPERIMENTAL|PM012 2,600 mg|PM012 2,600 mg + Placebo of PM012 four tablets +Placebo of Aricept one tablet, daily during 12 weeks (oral)
62156533|NCT05811000|EXPERIMENTAL|PM012 3,900 mg|PM012 3,900 mg + Placebo of PM012 two tablets +Placebo of Aricept one tablet, daily during 12 weeks (oral)
62156534|NCT05811000|EXPERIMENTAL|PM012 5,200 mg|PM012 5,200 mg + Placebo of Aricept one tablet, daily during 12 weeks (oral)
62156535|NCT00728325|ACTIVE_COMPARATOR|1|Standard Vocational Rehabilitation (VRP)
62156536|NCT00728325|EXPERIMENTAL|2|Supported Employment (SE)
62531087|NCT04100785|EXPERIMENTAL|Internet-delivered Cognitive Behavioural Therapy (iCBT)|The iCBT programme comprised of 6 online modules, delivered over 4 weeks, with 3 face-to-face sessions provided by a clinician.The face-to-face sessions were conducted at week 1, 3 and 4. The objectives of the face-to-face sessions was for participants to discuss with the clinician about the application of the content of the modules and the active therapeutic interventions were all found in the online modules.
62531088|NCT04100785|NO_INTERVENTION|Delayed Wait-list control|The delayed wait-list control did not receive any therapy interventions for 4 weeks from the pre-treatment assessment and from the fifth week onwards, they received the same intervention as the iCBT experimental group.
62156537|NCT02449902|ACTIVE_COMPARATOR|Treatment 1|Estradiol 10 μg vaginal softgel capsule
62156538|NCT02449902|PLACEBO_COMPARATOR|Treatment 2|Placebo vaginal softgel capsule
62156539|NCT04565873||P1|Primigravida in group 1
62156540|NCT04565873||M1|Multipara in group 1
62531089|NCT00266396|EXPERIMENTAL|weight-bearing recommendation|Weight-bearing recommendation after THA and TKA
62531090|NCT00561561|EXPERIMENTAL|1|Subjects with schizophrenia
62156541|NCT04565873||P2|Primigravida in group 2
62156542|NCT04565873||M2|Multipara in group 2
62156543|NCT01923870|EXPERIMENTAL|Moderate Hepatic Impairment|Males age 18-70 with a BMI between 25-42 kg/m\^2 with moderate hepatic impairment (Child-Pugh Class B)
62156544|NCT01923870|EXPERIMENTAL|Healthy Volunteers|Males age 18-70 with a BMI between 25-42 kg/m\^2
62156545|NCT02207777|EXPERIMENTAL|Roux-en-Y gastric bypass (RYGB)|Subjects in this group are scheduled to undergo roux-en-Y gastric bypass surgery to obtain approximately 16-18% (with a range of 16-25%) weight loss.
62156546|NCT02207777|ACTIVE_COMPARATOR|Low-calorie diet|Subjects in this group will participate in a low-calorie diet intervention to obtain approximately 16-18% (with a range of 16-25%) weight loss.
62156547|NCT02545426|ACTIVE_COMPARATOR|Calcium dialysate 2.5mEq/L|Dialysis with low calcium concentration
62156548|NCT02545426|ACTIVE_COMPARATOR|Calcium dialysate 3.5mEq/L|Dialysis with high calcium concentration
62156549|NCT05760417||Patients wiht Hyperthyroidism|Patients diagnosed with hyperthyroidism.
62156550|NCT04564222|EXPERIMENTAL|Micronutrient Enriched Crackers (MECs)|"Micronutrient Enriched Crackers (MECs) are a deep-fried snack product rich in iron, zinc, calcium, and vitamin A made from chicken liver and chicken eggshell powder.~Consume daily, 75 gram/day, during pregnancy (from 8-14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
62531091|NCT00561561|ACTIVE_COMPARATOR|2|Health controls
62531092|NCT00561561|ACTIVE_COMPARATOR|3|Family members of subjects with schizophrenia
62531093|NCT00561561|ACTIVE_COMPARATOR|4|Family members of healthy controls
62531094|NCT05941689|EXPERIMENTAL|AI-assisted group|Subjects in this group undergo AI-assisted colonoscopy. The AI-assisted system not only has the function of automatic polyp detection, but also has the function of colonoscopy quality control.
62531095|NCT05941689|NO_INTERVENTION|control group|Subjects in this group undergo routine colonoscopy.
62531096|NCT00426712|EXPERIMENTAL|1|Low dose
62531097|NCT00426712|EXPERIMENTAL|2|Middle dose
62531098|NCT00426712|EXPERIMENTAL|3|High dose
62156551|NCT04564222|PLACEBO_COMPARATOR|Placebo|"Placebo Crackers are a deep-fried snack product made from the basic cracker ingredients (mainly wheat flour) with the addition of Pangium edule seeds to provide a color similar to the intervention product (MECs).~Consume daily, 75 gram/day, during pregnancy (from 8-14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
62156552|NCT03145909|EXPERIMENTAL|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
62156553|NCT03145909|EXPERIMENTAL|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
62156554|NCT05329142||Stage 1: Usual Care clinical data:|The patient will firstly be identified as having attended the ED due to acute illicit drug toxicity and must fit the inclusion and exclusion criteria. The research team will complete the electronic Case Report Form (eCRF), which will include defined data.
62156555|NCT05329142||Stage 2: Surplus sampling Mass Spectrometry|"The research team will select patients with acute moderate / severe toxicity, which will be defined as those requiring at least one of:~* Patient admitted to hospital due to acute illicit drug toxicity~* Pre-hospital cardio/pulmonary resuscitation~* Any part of patient's ED care was in the Resuscitation area of the ED~* Patient died in the ED or within 72 hours~A surplus sample of the standard of care SST sample from this group will be analysed by way of Mass Spectrometry."
62156556|NCT05557838|EXPERIMENTAL|cohort 1|durvalumab in combination with tremelimumab
62156557|NCT05557838|EXPERIMENTAL|cohort 2|durvalumab in combination with tremelimumab
62531099|NCT00426712|ACTIVE_COMPARATOR|4|
62531100|NCT02444793|EXPERIMENTAL|PF-05082566 + KW-0761|During Parts 1 \& 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
62531101|NCT05903456|EXPERIMENTAL|TACE +lenvatinib+Icaritin soft capsules|Trial drug Lenvatinib, 8mg (2 tablets for patients weighing less than 60kg), or 12mg (3 tablets for patients weighing more than 60kg), once daily. Icariin Soft Capsules 1200 mg/d (6 tablets in two doses) should be swallowed with warm water within 30 minutes after meal. Take lenvatinib and Icaritin soft capsules 3 to 5 days after TACE. Until the disease progresses or the patient becomes intolerant.
62531102|NCT03271450||Continuer at 90 Days: Dabigatran|
62531103|NCT03271450||Continuer at 180 Days: Dabigatran|
61975816|NCT03106220|ACTIVE_COMPARATOR|home exercise|participate in home exercise program
62531104|NCT03271450||Continuer at 270 Days: Dabigatran|
62531105|NCT03271450||Continuer at 90 Days: Apixaban|
62531106|NCT03271450||Continuer at 180 Days: Apixaban|
62531107|NCT03271450||Continuer at 270 Days: Apixaban|
62531108|NCT03271450||Continuer at 90 Days: Rivaroxaban|
62531109|NCT03271450||Continuer at 180 Days: Rivaroxaban|
62531110|NCT03271450||Continuer at 270 Days: Rivaroxaban|
62531111|NCT03271450||Continuer at 90 Days: Edoxaban|
62531112|NCT03271450||Continuer at 180 Days: Edoxaban|
62156558|NCT05123118|EXPERIMENTAL|Integrated intervention|Integrated intervention of smoking cessation and breastfeeding
62156559|NCT05123118|ACTIVE_COMPARATOR|Attention placebo control group|Instructions on general pregnancy and infant care
62156560|NCT03857594||Individuals at risk of hereditary cancer syndrome|All individuals at risk of a hereditary cancer syndrome with or without a known germline mutation from clinical genetic testing.
62156561|NCT06280599|EXPERIMENTAL|Transitional care model|In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
62156562|NCT06280599|NO_INTERVENTION|Post-stroke usual care|Treatment as usual after discharged home
62156563|NCT01809444|ACTIVE_COMPARATOR|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.
62156564|NCT01809444|EXPERIMENTAL|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
62156565|NCT05506319|EXPERIMENTAL|norepinephrine group|Initial suspension of norepinephrine.
62156566|NCT05506319|EXPERIMENTAL|vasopressin group|Initial suspension of vasopressin.
62156567|NCT04964037||Treatment success group|No intervention
62156568|NCT04964037||Treatment failure group|No intervention
62156569|NCT05236868|EXPERIMENTAL|Seltorexant|Participants will receive a single oral dose of seltorexant. At 2 hours after oral dosing, participants will receive 14C-seltorexant as an intravenous (IV) infusion over 15 minutes.
62156570|NCT05053035|EXPERIMENTAL|AL001|AL001 every 4 weeks
62531113|NCT03271450||Continuer at 270 Days: Edoxaban|
62156571|NCT05053035|PLACEBO_COMPARATOR|Placebo|Placebo every 4 weeks
62156572|NCT01069744||Control Group|Control group When neonates are considered ready for oral feedings these feedings will be started with the standard oral feeding protocol for the NICU but without the NTrainer stimulation regimen described previously.
62156573|NCT01069744||NTrainer System|NTrainer Experimental Group When neonates are considered ready for oral feedings these feedings will be started simultaneously with the NTrainer therapy. Control and experimental interventions will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to quiet alert (NIDCAP state 3 or 4). Preterm infants in the experimental group will receive alternating 3-minute epochs of patterned oral somatosensory stimulation and null conditions using the NTrainer© during the tube (gavage) feeding session up to 4 times per day.
62531114|NCT03271450||Continuer at 90 Days: Warfarin|
62531115|NCT03271450||Continuer at 180 Days: Warfarin|
62531116|NCT03271450||Continuer at 270 Days: Warfarin|
62531117|NCT03271450||Discontinuer at 90 Days: Dabigatran|
62531118|NCT03271450||Discontinuer at 180 Days: Dabigatran|
62156574|NCT01741207|NO_INTERVENTION|control|control This group is without N-acetylcystein : just receives standard treatment
62156575|NCT01741207|ACTIVE_COMPARATOR|N-acetylcystein|receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
62156576|NCT00456235|EXPERIMENTAL|adjument MMF|adjusting the dose according to the MMF AUC of mycophenolic acid
62156577|NCT00456235|ACTIVE_COMPARATOR|continued treatment|Continued treatment empirically usual
62156578|NCT06095778|EXPERIMENTAL|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
62531119|NCT03271450||Discontinuer at 270 Days: Dabigatran|
62531120|NCT03271450||Discontinuer at 90 Days: Apixaban|
62156579|NCT01821222|EXPERIMENTAL|Wired mothers intervention|The wired mothers' intervention consisted of two components: an automated short messaging service (SMS) system providing wired mothers with unidirectional text messaging and a mobile phone voucher system providing the possibility of direct two-way communication between wired mothers and their primary health care providers. While only women with registered phone numbers received text messages, all women in the intervention group were given mobile phone vouchers to contact their local primary health care provider.
62156580|NCT01821222|NO_INTERVENTION|Control|The control group received standard care
62156581|NCT03826056|ACTIVE_COMPARATOR|Current standard education group|A study team member will use the current hospital standard educational material to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
62156582|NCT03826056|EXPERIMENTAL|New personalized education group|A study team member will use the new personalized educational materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
62156583|NCT02349815||Group 1|Women prescribed JAYDESS in Sweden
62531121|NCT03271450||Discontinuer at 180 Days: Apixaban|
62531122|NCT03271450||Discontinuer at 270 Days: Apixaban|
62531123|NCT03271450||Discontinuer at 90 Days: Rivaroxaban|
62531124|NCT03271450||Discontinuer at 180 Days: Rivaroxaban|
62531125|NCT03271450||Discontinuer at 270 Days: Rivaroxaban|
62531126|NCT03271450||Discontinuer at 90 Days: Edoxaban|
62531127|NCT03271450||Discontinuer at 180 Days: Edoxaban|
62531128|NCT03271450||Discontinuer at 270 Days: Edoxaban|
62531129|NCT03271450||Discontinuer at 90 Days: Warfarin|
62531130|NCT03271450||Discontinuer at 180 Days: Warfarin|
62531131|NCT03271450||Discontinuer at 270 Days: Warfarin|
62531132|NCT05982717||Participants With DS or LGS|Participants with a medical record of diagnosis with either DS or LGS that are treated in the participating hospitals and reside in the reference area of these hospitals will be included and data will be retrospectively collected for the period between 01 January 2021 to 31 December 2022.
62531133|NCT03682224|ACTIVE_COMPARATOR|Exparel|
62531134|NCT03682224|ACTIVE_COMPARATOR|Marcaine|
62531135|NCT04180163|EXPERIMENTAL|Lanadelumab 300 mg q2w or q4w|Lanadelumab 300 mg solution, subcutaneously (SC), once every 2 weeks (q2w) for 26 weeks in Treatment Period A. This was followed by Treatment Period B (additional 26 weeks, total of 52 weeks including Treatment Period A) during which participants remained on Treatment Period A regimen or received 300 mg lanadelumab solution once every 4 weeks (q4w) for 26 weeks if well-controlled (attack-free) for 26 consecutive weeks with lanadelumab treatment. The dose frequency change was based on the Investigator's discretion and approval by the Sponsor's Medical Monitor.
62531136|NCT04460859||Intubated mechanically ventilated ARDS patients|Intubated mechanically ventilated patients with moderate to severe ARDS according to the Berlin definition
62531137|NCT04275206|EXPERIMENTAL|Medicinal water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in tap water.)
62531138|NCT04275206|PLACEBO_COMPARATOR|Tap water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in medicinal water.)
62531139|NCT03641391|EXPERIMENTAL|Direct electrical stimulation|Intraoperative direct cortical electrical stimulation or intraoperative direct subcortical electrical stimulation on language or language-associate areas, and the participants' after-discharge activity would be monitored. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
62531140|NCT05779423|EXPERIMENTAL|Ipilimumab + Nivolumab + Cryoablation|"Study will be conducted in two stages:~Stage 1: Will enroll 15 participants, and if 6 or more have clinical benefit, the study will proceed to Stage 2.~* Baseline CT scan.~* Cycle 1-4: Pre-determined doses of ipilimumab and nivolumab. Medications administered under direction of treating oncologist.~* Day 2 - 14: Core Needle Biopsy followed by cryoablation between Cycle 1 - 2~* Surveillance CT scan at weeks 8 - 12, weeks 16 - 24.~* Follow up for 6 months to assess safety after cryoablation. Participants followed for duration of response.~Stage 2: Will enroll 22 participants~* Baseline CT scan.~* Cycle 1-4: Pre-determined doses of ipilimumab and nivolumab. Medications administered under direction of treating oncologist.~* Day 2- 14: Core Needle Biopsy followed by cryoablation between Cycle 1 - 2.~* Surveillance CT scan at weeks 8 - 12, weeks 16 - 24~* Follow up period to assess safety 6 months after cryoablation. Patients followed for duration of response."
62531141|NCT02517437|ACTIVE_COMPARATOR|Suprascapular & axillary blocks|Suprascapular and axillary blocks.
62531142|NCT02517437|ACTIVE_COMPARATOR|Interscalene block|Interscalene block.
62531143|NCT03994497|OTHER|Patient in need of a kidney transplant|
62531144|NCT02915965|EXPERIMENTAL|DCX and surgery|docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy
62531145|NCT00658827||Group 1a: Remicade Cohort|Female patients who were exposed to Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
62531146|NCT00658827||Group 1b: Remicade Cohort|Infants born to Group 1a patients.
62531147|NCT00658827||Group 2a: Other Anti-TNF agents Cohort|Female patients who were exposed to anti-TNFs other than Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
62531148|NCT00658827||Group 2b: Other Anti-TNF agents Cohort|Infants born to Group 2a patients.
62531149|NCT00658827||Group 3a: Non-biologic Systemic Therapy Control Cohort|Female patients who were exposed to systemic therapy other than biologic agents at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
61975817|NCT03106220|PLACEBO_COMPARATOR|standard care|encouraged to join physical therapy and walking goals
61975818|NCT03249298|ACTIVE_COMPARATOR|Crystalloids|"Bolus of crystalloids~Bolus of 250 ml crystaloids will be infused regarding the measures"
61975819|NCT03249298|ACTIVE_COMPARATOR|Colloids|"Bolus of colloids~Bolus of 250 ml colloids will be infused regarding the measures"
61975820|NCT02033122|ACTIVE_COMPARATOR|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
61975821|NCT02033122|SHAM_COMPARATOR|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
61975822|NCT05653687|EXPERIMENTAL|Fluoroscopy|
61975823|NCT05653687|NO_INTERVENTION|Freehand|
61975824|NCT01938599|EXPERIMENTAL|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
61975825|NCT01938599|PLACEBO_COMPARATOR|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
61975826|NCT06261554|EXPERIMENTAL|Sesame immunotherapy|Children with sesame allergy receiving OIT.
61975827|NCT06261554|NO_INTERVENTION|Sesame avoidance|Children with sesame allergy not undergoing OIT.
61975828|NCT03357159|EXPERIMENTAL|cyclophosphamide and ATLG|The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.
61975829|NCT03838640|EXPERIMENTAL|Study group|Consecutive eligible patients requiring endoscopic surgery for sinonasal pathology Transnasal localization of internal carotid artery with TEE ECHO device will be performed
61975830|NCT04217473|EXPERIMENTAL|TILT-123|"Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
62531150|NCT00658827||Group 3b: Non-biologic Systemic Therapy Control Cohort|Infants born to Group 3a patients.
62531151|NCT00658827||Group 4a: Population Control Cohort|Female patients with no record of the diseases of interest and no exposure to biologic or non-biologic systemic therapy at any time during pregnancy (and up to 3 months prior to LMP, if the information is available).
62531152|NCT00658827||Group 4b: Population Control Cohort|Infants born to Group 4a patients.
62531153|NCT00687089||Subutex group|People who used opiates and willing to start with subutex treatment
62531154|NCT03573505|EXPERIMENTAL|BG00011|Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
62531155|NCT03573505|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo once weekly by (SC) injection for 52 weeks.
62531156|NCT03579966|EXPERIMENTAL|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day. Initially, the daily amifampridine doses were to be the doses that were determined at the end of the Run-in Period from the MSK-002 study. The usual range was from 30 to 80 mg total daily dose, given in three (3) or four (4) doses, with no single dose \> 20 mg
62531157|NCT05532124|EXPERIMENTAL|Part A: LAENNEC 4ml|Dosing twice a week for 2 weeks
62531158|NCT05532124|EXPERIMENTAL|Part A: LAENNEC 6ml|Dosing twice a week for 2 weeks
62531159|NCT05532124|EXPERIMENTAL|Part A: LAENNEC 10ml|Dosing twice a week for 2 weeks
62156584|NCT06351800|EXPERIMENTAL|Predictplusprevent intervention|The intervention will provide information about the likelihood of experiencing depression and anxiety. Additionally, it will offer a personalized depression prevention plan (PPP) based on various interventions such as physical exercise, sleep, expanding relationships, problem-solving, improving communication, assertiveness, decision-making, and managing thoughts.
62531160|NCT05532124|ACTIVE_COMPARATOR|Part A: Normal Saline|Dosing twice a week for 2 weeks
62531161|NCT05532124|EXPERIMENTAL|Part B: LAENNEC 1|It is administered twice a week or placebo, and administered until it is normalized for up to 6 weeks or ALT.
62531162|NCT05532124|EXPERIMENTAL|Part B: LAENNEC 2|It is administered twice a week or placebo, and administered until it is normalized for up to 6 weeks or ALT.
62531163|NCT05532124|ACTIVE_COMPARATOR|Part B: Normal Saline|It is administered twice a week or placebo, and administered until it is normalized for up to 6 weeks or ALT.
62531164|NCT02571166|EXPERIMENTAL|HSV529|
62531165|NCT05393843|ACTIVE_COMPARATOR|intervention|"patients receiving~* diet~* Omega-3 fatty acids (EnerZona Omega3Rx®, Enervit, Italia), at a daily dosage of 2.4 gr at breakfast.~* Anthocyanins (EnerZona Maqui Response Buste®, Enervit, Italia) at a total daily dosage of 108 mg divided into three equal intakes at breakfast, lunch and dinner.~* Alpha-cyclodextrins (EnerZona Maqui Response Buste®, Enervit, Italia) at a total daily dosage of 15 gr divided into three equal intakes at breakfast, lunch and din-ner"
62531166|NCT05393843|PLACEBO_COMPARATOR|placebo|"patients receiving~* diet~* placebo (sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins)"
62531167|NCT02562105||Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
62531168|NCT02365870|ACTIVE_COMPARATOR|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
62531169|NCT02365870|PLACEBO_COMPARATOR|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
62531170|NCT00144664|EXPERIMENTAL|1|MRA(Tocilizumab)
62531171|NCT05808673|EXPERIMENTAL|Post-change CMAB807X|120 mg Subcutaneous injection around belly button
62531172|NCT05808673|OTHER|Pre-change CMAB807X|120 mg Subcutaneous injection around belly button
62531173|NCT05808673|ACTIVE_COMPARATOR|Xgeva®|120 mg Subcutaneous injection around belly button
62531174|NCT00722982||1|
62531175|NCT00722982||2|
62531176|NCT05291039|ACTIVE_COMPARATOR|Infliximab.|group 1 (n=20): patients will receive IFX,
62531177|NCT05291039|ACTIVE_COMPARATOR|Adalimumab.|group 2 (n=20): patients will receive ADA
62531178|NCT01287039|PLACEBO_COMPARATOR|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
62531179|NCT01287039|EXPERIMENTAL|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
62531180|NCT04646941||T2DM with OSA|Type 2 diabetes patients with obstructive sleep apnea
62531181|NCT04646941||T2DM without OSA|Type 2 diabetes patients without obstructive sleep apnea
62531182|NCT04325763|EXPERIMENTAL|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62531183|NCT04325763|EXPERIMENTAL|TQB2450+Anlotinib(blank)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62531184|NCT04325763|PLACEBO_COMPARATOR|TQB2450(blank)+Anlotinib(blank)|TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62531185|NCT00186758|SHAM_COMPARATOR|1, Phase l, True or Sham|this treatment will be True or Sham (placebo) on one side of the head, phase I
62531186|NCT00186758|ACTIVE_COMPARATOR|2, phase ll, Sham or True|This treatment will be Sham(placebo)or True on the other side of the head phase II.
62531187|NCT05967052|EXPERIMENTAL|Pregabalin|
62531188|NCT05967052|EXPERIMENTAL|Pregabalin + Rehabilitation|
62531189|NCT05967052|EXPERIMENTAL|Rehabilitation + Placebo|
62531190|NCT05967052|PLACEBO_COMPARATOR|Placebo|
62531191|NCT02314091|EXPERIMENTAL|Onlay|Onlay mesh repair group
62531192|NCT02314091|EXPERIMENTAL|sublay|Sublay mesh repair group
62531193|NCT05262998|ACTIVE_COMPARATOR|CONTROL|Plate fixation
62531194|NCT05262998|EXPERIMENTAL|INTERVENTION|Intramedullary Screw
62531195|NCT01884818|EXPERIMENTAL|Manipulation|Subjects will receive 6 manipulation treatments within 3 weeks period. The manipulated segments are determined individually in baseline assessment.
62531196|NCT01884818|SHAM_COMPARATOR|TNS for thoracic spine|6 TNS treatments at home for 20min in limited power of devices in three weeks period.
62156585|NCT06351800|ACTIVE_COMPARATOR|Active control group|The intervention in the active control group will involve assessing the risk level of experiencing depression and/or anxiety in the next 12 months every 3 months. Additionally, participants assigned to this intervention will have free access to the 24 self-help booklets for preventing depression and anxiety included in the 'predictplusprevent' web platform. However, this group will not receive personalized prevention plans, decision support systems, or monitoring and feedback. They will also not have access to the 8 self-guided and interactive modules used in the intervention group.
62531197|NCT00798876|PLACEBO_COMPARATOR|Standard Western Diet|Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
62714101|NCT03522402|EXPERIMENTAL|30 degree rotated lateral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
62714102|NCT03522402|ACTIVE_COMPARATOR|neutral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in the neutral position.The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
62156586|NCT04907344|EXPERIMENTAL|Part 1: Camrelizumab + Chemotherapy|
62531198|NCT00798876|EXPERIMENTAL|Low-Fat Diet|Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
62531199|NCT00416702|EXPERIMENTAL|1|QAB149
62531200|NCT04669847|EXPERIMENTAL|Study Group|Patients who performed Trunk-oriented exercise program and conventional exercise program
62531201|NCT04669847|EXPERIMENTAL|Control Group|Patients who performed a conventional exercise program
62531202|NCT01271751|EXPERIMENTAL|GFT505 80mg|
62531203|NCT01271751|PLACEBO_COMPARATOR|Matching placebo|
62531204|NCT06320808|EXPERIMENTAL|FDA-template PMI|Patient medication information designed according to FDA template
62531205|NCT06320808|EXPERIMENTAL|Decision Critical PMI|Patient medication information designed according to FDA template and modified, according to decision science principles, to include benefit information
62531206|NCT06320808|EXPERIMENTAL|Standard Information|Standard of care patient medication information
62531207|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
62714103|NCT04098263|ACTIVE_COMPARATOR|Part B: Cohort 1|300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days
62156587|NCT04907344|EXPERIMENTAL|Part 2: Camrelizumab + Chemotherapy|
62156588|NCT04907344|ACTIVE_COMPARATOR|Part 2: Chemotherapy|
62156589|NCT01223053|ACTIVE_COMPARATOR|Active|Topical ketoprofen 10% Cream
62156590|NCT01223053|PLACEBO_COMPARATOR|Placebo Cream|Placebo Cream
62531208|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
62531209|NCT02908035|ACTIVE_COMPARATOR|Active Comparator: Temsirolimus Delivery High Dose|High-Dose Group: 0.4 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
62531210|NCT02908035|ACTIVE_COMPARATOR|Active Comparator: Temsirolimus Delivery Low Dose|Low-Dose Group: 0.1 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
62531211|NCT02908035|PLACEBO_COMPARATOR|Placebo Comparator: Saline Delivery|Control Group: Saline/contrast (80% normal saline for injection:20% non-ionic contrast) The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
62531212|NCT01221012||men wearing Semipermeable garment|
62531213|NCT01221012||air permeable garment type BP2|
62531214|NCT01221012||air permeable garment type BP3|
62531215|NCT01221012||air permeable garment type MO|
62531216|NCT01221012||air permeable garment type BP1|
62531217|NCT05561543|PLACEBO_COMPARATOR|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
62531218|NCT05561543|EXPERIMENTAL|Peppermint oil|50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
62531219|NCT06160505||Patients that underwent mastoidectomy alone|This is the control group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy for CSOM without mastoid obliteration
62531220|NCT06160505||Patients that underwent mastoidectomy + mastoid obliteration|This is the intervention group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy for CSOM followed by obliteration of the mastoid cavity using S53P4 bioactive glass
62531221|NCT05033093|ACTIVE_COMPARATOR|Ah Plus|All samples will be filled with Ah Plus root canal sealer and gutta percha
62156591|NCT05607147|OTHER|SARS-CoV-2 testing|There is only one arm in this study- the study is a non-randomized pilot. All the subjects will be tested for SARS CoV 2 viral Antigen and antibody to the virus as described.
62156592|NCT03528447|EXPERIMENTAL|Pulmonary Rehabilitation|Lung transplantation candidates who refered from Lung Transplantation surgery team will undergo the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Patient will evaluate at the beginning and end of the program.Cognitive functions and exercise capacities of the patients before and after the program will be evaluated.
62156593|NCT00443820|EXPERIMENTAL|1|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
62156594|NCT00443820|PLACEBO_COMPARATOR|2|Vehicle (placebo) for 48 weeks
62531222|NCT05033093|ACTIVE_COMPARATOR|I Root SP|All samples will be filled with I Root SP root canal sealer and gutta percha
62531223|NCT05033093|ACTIVE_COMPARATOR|GuttaFlow Bioseal|All samples will be filled with GuttaFlow Bioseal canal sealer and gutta percha
62156595|NCT00443820|EXPERIMENTAL|3|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
62156596|NCT00443820|PLACEBO_COMPARATOR|4|Vehicle (placebo) for 24 weeks
62156597|NCT03500809|EXPERIMENTAL|Aqueous release (Burping) of the wound|"Following uneventful cataract surgery, wound burping will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma).~After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up."
62531224|NCT02117700|EXPERIMENTAL|N-acetyl cysteine-1|N-acetyl cysteine 600 mg once/day + Placebo once/day for 16 weeks
62531225|NCT02117700|EXPERIMENTAL|N-acetyl cysteine-2|N-acetyl cysteine 600 mg twice/day for 16 weeks
62531226|NCT02117700|PLACEBO_COMPARATOR|Placebo|Placebo twice/day for 16 weeks
62531227|NCT04067427|ACTIVE_COMPARATOR|Mental training|AF ablation followed by 3 months of a daily app-based mental training for 10 to 15 minutes per session. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
62531228|NCT04067427|NO_INTERVENTION|Control|AF ablation without subsequent mental training. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
62531229|NCT02454660|EXPERIMENTAL|SMS (Text messaging)|This group will receive text messages during their entire enrollment period in the study.
62531230|NCT02454660|NO_INTERVENTION|No SMS (No text messages)|This group will not receive text messages during their entire enrollment period in the study.
62531231|NCT05874739||Control Cohort|Control participants who are age- and gender-matched to the PD cohort
62531232|NCT05874739||PD Cohort|PD Patients who have completed their participation in the Mobilise-D Clinical Validation Study
62714104|NCT04098263|ACTIVE_COMPARATOR|Part B: Cohort 2|1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days
62531233|NCT02650479|OTHER|IV exenatide - pilot study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
62531234|NCT02650479|EXPERIMENTAL|Treatment Group A - core study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
62531235|NCT02650479|EXPERIMENTAL|Treatment Group B - core study|IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
62714105|NCT04098263|ACTIVE_COMPARATOR|Part B: Cohort 3|3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days
62531236|NCT02650479|EXPERIMENTAL|Treatment Group C - core study|IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
62531237|NCT02365558|EXPERIMENTAL|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
62714106|NCT04098263|OTHER|Part A|3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally
62714107|NCT01172028|EXPERIMENTAL|Alimta and Taxotere|Alimta and Taxotere given in combination with dose modifications.
62531238|NCT02365558|EXPERIMENTAL|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.~Evacetrapib will be co-administered once, orally on Day 14."
62531239|NCT00543608|EXPERIMENTAL|1|Dose 1 iclaprim
62531240|NCT00543608|EXPERIMENTAL|2|Dose 2 iclaprim
62714108|NCT05754866|EXPERIMENTAL|Transbronchial lung cryobiopsy|
62714109|NCT05754866|ACTIVE_COMPARATOR|Transbronchial lung biopsy|
62531241|NCT00543608|ACTIVE_COMPARATOR|3|vancomycin
62531242|NCT02994940|EXPERIMENTAL|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
62531243|NCT02994940|EXPERIMENTAL|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
62531244|NCT02125162|EXPERIMENTAL|Treatment A|BCX4161 400 mg formulated as hard gelatin capsules given orally under fasting conditions x1
62531245|NCT02125162|EXPERIMENTAL|Treatment B|BCX4161 400 mg formulated as soft gelatin capsules given orally under fasting conditions x1
62714110|NCT01786590|EXPERIMENTAL|EBUS-TBNA|
62714111|NCT04972825|EXPERIMENTAL|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
62531246|NCT02125162|EXPERIMENTAL|Treatment C|BCX4161 400 mg formulated as soft gelatin capsules given orally after a high-fat breakfast x1
62156598|NCT02385539|ACTIVE_COMPARATOR|Levobupivacaine (LB) 6 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 6 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB6F25 (LB 6 mg, Fentanyl 25 mcg), LB6F35 (LB 6 mg, Fentanyl 35 mcg), LB6S5 (LB 6 mg, Sufentanil 5 mcg), LB6S7 (LB 6 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
62714112|NCT04972825|ACTIVE_COMPARATOR|Implementation as Usual (IAU)|The organizations will implement Mind the Gap as usual. The research team will be available to provide support on the Mind the Gap intervention as needed.
62714113|NCT01215851|EXPERIMENTAL|TMC207|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide placebo administered once daily
62156599|NCT02385539|ACTIVE_COMPARATOR|Levobupivacaine (LB) 8 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 8 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB8F25 (LB 8 mg, Fentanyl 25 mcg), LB8F35 (LB 8 mg, Fentanyl 35 mcg), LB8S5 (LB 8 mg, Sufentanil 5 mcg), LB8S7 (LB 8 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
62531247|NCT02860338||GROUP 1- CNS Protocol|"Patients in a specialized dementia practice. Evaluated and treated for hypoxia, elevated BNP, hyperhomocysteinemia, B 12 deficiency as measured by elevated methymalonic acid, Vitamin D 25-OH deficiency, elevated CRP, and decreased IGF-1, and other metabolic abnormalities.~Treated with maximal doses of acetylcholinesterase inhibitors, memantine, methylfolate/methylB12/N-acetylcysteine, dextromethorphan/quinidine, and SSRI's; dose and duration based on protocol."
62531248|NCT02860338||GROUP 2- Community Care|Patients referred to a neuropsychology practice for cognitive evaluation and treated for MCI or dementia by their primary care clinician or non-dementia specialist according to specific provider's usual practice pattern.
62531249|NCT02305953||Frozen serum|The cohort consists of original subjects from the Inno-6025 Trial who previously consented to measuring protein in the blood involved in skin inflammation.
62531250|NCT05145881|ACTIVE_COMPARATOR|Low dose probiotics|
62531251|NCT05145881|EXPERIMENTAL|Normal dose probiotics|
62531252|NCT02925507||Healthy Controls|Healthy patients with no neurologic impairments or disease
62531253|NCT02925507||Stroke Subjects|Patients with new onset stroke for ischemic, hemorrhagic or TIA
62531254|NCT06258798||One group of patients (double gate)|"Study design:~* Direction of data collection: retrospective~* Number of gates (sets of eligibility criteria): double gate (AI, human)~* Participant sampling method: Consecutive~* Method of allocating participants to index tests: Each participant received all index tests~* Number of reference standards: Single test standard~* Limited verification: Full verification (not limited)"
62531255|NCT02819050|EXPERIMENTAL|Sprinting|Take off NCPAP twice daily for 3hours (day 1), Take off NCPAP twice daily for 6hours (day 2), Take off NCPAP twice daily for 9hours (day 3), Placed back on NCPAP for 24hours (day 4), Switch to nasal cannula at a flow rate of 1.5-2 L/min (day 5)
62531256|NCT02819050|ACTIVE_COMPARATOR|Non-Sprinting|"* If the infant was on NCPAP 6, Infant was weaned down to CPAP 5 for 96 hours. If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC.~* If the infant was on NCPAP 5, the infant was continued on CPAP 5 for 96 hours If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC."
62531257|NCT00654758|EXPERIMENTAL|1|Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel.
62531258|NCT01782235|EXPERIMENTAL|Tocilizumab arm|Tocilizumab arm will receive tocilizumab.
62531259|NCT01782235|PLACEBO_COMPARATOR|Placebo arm|Placebo arm will receive placebo.
62531260|NCT04568473|EXPERIMENTAL|PRG Barrier Coat (SHOFU Inc., Japan)|"BioSmart Light Cured Protective Shield with bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology.~S-PRG filler possesses a three-layer structure with a stabilized glass-ionomer-like structure surrounding multifunctional glass fillers, and is subsequently protected by a surface modified layer."
62531261|NCT04568473|EXPERIMENTAL|EMBRACE™ Varnish (Pulpdent Corporation, USA)|"Resin-based 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release.~The incorporation of CXP™ (xylitol-coated calcium and phosphate) in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish"
62531262|NCT04568473|ACTIVE_COMPARATOR|Duraphat® (Colgate Palmolive Company, New York, NY)|It is attributed to the reactivity of the fluoride by adsorbing to the surface and attracting calcium ions forming loosely-bound calcium fluoride (CaF2)- like reservoir which is also considered responsible for the anticaries mechanism and protection against cariogenic acid attack.
62531263|NCT02312518|EXPERIMENTAL|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
62531264|NCT02312518|OTHER|Usual and Customary Practice|usual and customary practice
62531265|NCT03234725||LCI out group|The whitdrawal of the colonoscop happen in LCI mode.
62531266|NCT03234725||WL (white light) out group|The whitdrawal of the colonoscop happen in WL mode.
62531267|NCT03881956|OTHER|Women with gestational diabetes|88 women with gestational diabetes (46 for the intervention group and 42 for the control group) were in the arm.
62156600|NCT02385539|PLACEBO_COMPARATOR|Levobupivacaine (LB) 12 mg|"Patients will be stratified into three groups by 80 patients: those who will receive 6, 8 or 12 mg of Levobupivacaine intrathecally (Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients will receive 12 mg of Levobupivacaine alone intrathecally.~Hemodynamic side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered"
62156601|NCT03308500|EXPERIMENTAL|High-intensity intermittent games HIIG|High-intensity intermittent games (HIIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 75% ≤ - RPE 6-8.
62531268|NCT06048965||Expert group|
62531269|NCT00562237|PLACEBO_COMPARATOR|1|
62531270|NCT00562237|EXPERIMENTAL|2|
62156602|NCT03308500|ACTIVE_COMPARATOR|Moderate-intensity games (MIG)|Moderate intensity games (MIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 60-74% ≤ - RPE 4-5.
62531271|NCT00562237|EXPERIMENTAL|3|
62531272|NCT00562237|EXPERIMENTAL|4|
62531273|NCT00562237|EXPERIMENTAL|5|
62531274|NCT00562237|EXPERIMENTAL|6|
62531275|NCT00562237|EXPERIMENTAL|7|
62531276|NCT05437926||Light skin|Light skin Fitzpatrick 1-2 approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
62531277|NCT05437926||Dark skin|Dark skin Fitzpatrick 5-6 approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
62531278|NCT01788618|OTHER|Experimental group|Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
62531279|NCT01788618|OTHER|The control group 1 (Homework)|Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
62531280|NCT01788618|OTHER|Control group 2 ( telephone follow)|Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
62531281|NCT01837524|EXPERIMENTAL|Grocery-Store-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted during grocery shopping trips at a local supermarket. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will be similar in content to that delivered in an in-office visit, including how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
62531282|NCT01837524|ACTIVE_COMPARATOR|Office-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted in an office at one of our medical office buildings. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will include how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
62531283|NCT01671332|ACTIVE_COMPARATOR|Docetaxel|
62531284|NCT01671332|EXPERIMENTAL|Docetaxel plus Suramin|
62531285|NCT05765630|ACTIVE_COMPARATOR|Healthy patients|
62531286|NCT05765630|EXPERIMENTAL|CKD patients not receiving antiplatelet agents|
62714114|NCT01215851|EXPERIMENTAL|TMC207 and pyrazinamide|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: \< or = 55kg received 2 tablets/day; \>55kg to 75kg received 3 tablets/day; \>75kg received 4 tablets/day
62714115|NCT01215851|EXPERIMENTAL|PA-824 and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: \< or = 55kg received 2 tablets/day; \>55kg to 75kg received 3 tablets/day; \>75kg received 4 tablets/day and moxifloxacin placebo (matched to moxifloxacin tablets) administered once daily
62714116|NCT01215851|EXPERIMENTAL|PA-824 and moxifloxacin and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: \< or = 55kg received 2 tablets/day; \>55kg to 75kg received 3 tablets/day; \>75kg received 4 tablets/day and moxifloxacin administered once daily as 400mg tablets
62714117|NCT01215851|ACTIVE_COMPARATOR|Rifafour e-275 mg|Rifafour e-275 administered once daily with each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol and dose by weight as follows: 30kg-37kg received 2 tablets/day; 38kg-54kg received 3 tablets/days; 55kg-70kg received 4 tablets/day; \> or = 71kg received 5 tablets/day
62714118|NCT01215851|EXPERIMENTAL|TMC207 and PA-824|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus PA-824 administered once daily as 200mg tablets
62531287|NCT05765630|EXPERIMENTAL|CKD patients receiving antiplatelet agents|
62531288|NCT05765630|EXPERIMENTAL|Patients with constitutional thrombopathy with RAP1B activation defect|
62531289|NCT05765630|EXPERIMENTAL|Patients with ACS in the previous month treated with antiplatelet agents|
62531290|NCT03735069|EXPERIMENTAL|IPT (Indirect pulp treatment) group|In this group, complete caries excavation from the dentin-enamel junction will be done. Caries near the pulp will be removed with caution until the remaining dentin shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material will be placed (Vitrebond; St.Paul, MN), followed by resin-modified glass ionomer (RMGI) build-up material (Vitremer; St. Paul, MN), and the final restoration of choice for MIH involved teeth; a preformed Stainless Steel Crown (SSC).
62531291|NCT03735069|EXPERIMENTAL|Cvek/partial pulpotomy group|"In this group, partial pulpotomy will be attempted first, inflamed pulp tissue will be removed until healthy pulp tissue is reached (2-4mm depth), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated twice if required; otherwise, cervical pulpotomy will be done.~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be placed in the pulp chamber (2-3mm thickness), a moist cotton pellet will be placed and Intermediate Restorative Material (IRM) to ensure setting. Patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
62531292|NCT03735069|EXPERIMENTAL|Cervical pulpotomy group|"In this group, a cervical pulpotomy procedure will be done where all pulp chamber tissue shall be removed until healthy pulp tissue is reached, as indicated by bleeding from all canals and arrest of hemorrhage upon pressure (for maximum 6 minutes).~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be mixed according to manufacturer instructions and will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with Intermediate Restorative Material (IRM), the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
62531293|NCT05944601|NO_INTERVENTION|Healthy controls|Elderly people without cognitive impairment or subjective cognitive decline.
62531294|NCT05944601|NO_INTERVENTION|Subjective cognitive decline|Individuals presenting cognitive complains that are not confirmed by neuropsychological testing.
62531295|NCT05944601|EXPERIMENTAL|patients with MCI due to AD|Patients with Mild Cognitive Impairment with abnormal spinal fluid test for amyloid beta protein.
62531296|NCT02502279|NO_INTERVENTION|Control|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters with 0 PEEP/CPAP.
62531297|NCT02502279|ACTIVE_COMPARATOR|Lung Recruitment- PEEP group|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
62531298|NCT02502279|ACTIVE_COMPARATOR|Lung Recruitment- PEEP and CPAP group|"Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus~1. lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.~2. Postoperative CPAP mask immediately after extubation"
62531299|NCT04390295|EXPERIMENTAL|SHR3824+Metformin, Placebo+Metformin|once daily for SHR3824 and placebo, three times daily for metformin, 24 weeks
62531300|NCT04390295|EXPERIMENTAL|SHR3824 5 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
62531301|NCT04390295|EXPERIMENTAL|SHR3824 10 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
62156603|NCT04372706|EXPERIMENTAL|Part 1: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors
62156604|NCT04372706|EXPERIMENTAL|Part 2: RTX-240 Solid Tumor Expansion|Phase 2: RTX-240 monotherapy dose expansion in Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and anal cancers
62531302|NCT03696030|EXPERIMENTAL|Treatment (HER2-CAR T cells)|Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.
62531303|NCT04635826|EXPERIMENTAL|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
62531304|NCT04635826|EXPERIMENTAL|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo
62531305|NCT04635826|PLACEBO_COMPARATOR|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
62531306|NCT04635826|EXPERIMENTAL|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall
62531307|NCT05933980|EXPERIMENTAL|regorafenib,Toripalima and celecoxib|"Regorafenib:in dose ramping stage,the initial dose is 80mg per dose, taken orally once a day. After 3 weeks of treatment, the medication is stopped for 1 week (i.e. from day 1 to day 21 and not from day 22 to day 28), with a treatment cycle of 4 weeks.The optimal recommended dose of regofinib (80mg, 120mg, or 160mg) obtained from the phase Ib dose ramping was included in the phase II study dose extension queue.~Toripalimab:240mg, intravenous drip, administered every three weeks. celecoxib:200mg each time, taken orally twice a day."
62531308|NCT00938249|EXPERIMENTAL|Monascus Garlic Fermented Extract|
62531309|NCT00938249|PLACEBO_COMPARATOR|Placebo|
62531310|NCT05236283||Bern ICU|
62714119|NCT05390788|EXPERIMENTAL|Experimental Group|Joint Position Sense is measured in 6 different moments. 1st Moment: Measurement with no intervention; 2nd Moment: 5 days later, imediately before intervention (kinesiotaping/neuromuscular bands); 3rd Moment: Imediately after intervention; 4th Moment: 5 days after the previous measurement, with kinesiotape still applied; 5th Moment: Measurement imediately after removing kinesiotape; 6th Moment: 5 days after the previous measurement, with no intervention (follow-up)
62714120|NCT05390788|NO_INTERVENTION|Control Group|4 Measurements with no intervention, with a 5 day interval between
62531311|NCT05236283||Lausanne ICU|
62531312|NCT05974436|EXPERIMENTAL|Hemodiafiltration with high-flux dialyzer|Patients are dialysed at midweek using hemodiafiltration (autoflow) with an FX800 Cordiax high-flux dialyzer, with dialysate flow of 700mL/min
62531313|NCT05974436|EXPERIMENTAL|Hemodialysis with medium cut-off dialyzer and high dialysate flow|Patients are dialysed at midweek using hemodialysis with a Theranova 400 medium cut-off dialyzer with dialysate flow of 700mL/min
62156605|NCT04372706|EXPERIMENTAL|Part 3: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in AML
62156606|NCT04372706|EXPERIMENTAL|Part 4: RTX-240 Plus Pembrolizumab Dose Escalation|Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors
62531314|NCT05974436|EXPERIMENTAL|Hemodialysis with medium cut-off dialyzer and low dialysate flow|Patients are dialysed at midweek using hemodialysis with a Theranova 400 medium cut-off dialyzer with dialysate flow of 300mL/min
62531315|NCT00587990|EXPERIMENTAL|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10\^7 cells
62531316|NCT00587990|EXPERIMENTAL|Higher dose MSC injection|Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10\^8 cells
62531317|NCT00587990|PLACEBO_COMPARATOR|(3) Placebo|Participants will receive placebo injections
62531318|NCT04735757||Healthy volunteers|Healthy volunteers, matched by age and gender to patient groups.
62531319|NCT04735757||COVID-19 patients|Patients discharged from the ICU after invasive ventilation for COVID-19.
62531320|NCT04735757||ICU patients|Patients discharged from the ICU after invasive ventilation for ARDS.
62531321|NCT03537716|EXPERIMENTAL|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic system
62531322|NCT01795274|EXPERIMENTAL|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
62531323|NCT05199168|NO_INTERVENTION|Thoracoscopic esophagectomy without IONM|
62531324|NCT05199168|EXPERIMENTAL|Thoracoscopic esophagectomy with IONM|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
62531325|NCT05869461|EXPERIMENTAL|Intervention|This group will receive access to the wellness sessions that have specific content geared towards our key populations and they will also receive peer navigation for 6 months.
62531326|NCT05869461|NO_INTERVENTION|Control|Control arm participants will receive standard HIV care through the Mumbai Districts AIDS Control Society (MDACS)-run ART clinics. In addition, participants will have access to an abbreviated version of the wellness groups to help them remain engaged with the study team and to control for attention.
62531327|NCT04134507||Extended Depth of Focus IOL|Post-LASIK patients with implantation of a presbyopia-correcting IOL
62531328|NCT04134507||Monofocal IOL|Post-LASIK patients with implantation of a monofocal IOL
62531329|NCT02014207|EXPERIMENTAL|golden crinkle|
62531330|NCT02014207|EXPERIMENTAL|high blanch|
62531331|NCT02014207|EXPERIMENTAL|low blanche|
62531332|NCT02014207|EXPERIMENTAL|high chill|
62531333|NCT02014207|EXPERIMENTAL|low chill|
62531334|NCT04428112|EXPERIMENTAL|Building Better Caregivers Workshop Group|Building Better Caregivers Workshop is a 6-week online self-management and skills building workshop. Participants receive the online workshop as soon as possible after randomization.
62531335|NCT04428112|ACTIVE_COMPARATOR|Attention Control Group|Participants will be offered the online workshop after the 12 month trial is completed if they so desire.
62531336|NCT04941521|EXPERIMENTAL|Exenatide and Drug Counseling|Participants will receive once weekly exenatide injections and drug counseling sessions.
62531337|NCT05036356|EXPERIMENTAL|Controlled App Group|"Subjects will receive access to the Headspace app and will receive weekly reminders to complete activities from the Inspiration, Ideation, Implementation block model of human-centered design in the app."
62531338|NCT05036356|EXPERIMENTAL|Ad lib App Group|Subjects will receive access to the Headspace app and be encouraged to use it ad lib.
62531339|NCT05913089|EXPERIMENTAL|TQB2450 injection + Chemotherapy|TQB2450 injection combined with chemotherapy, 21 days as a treatment cycle.
62531340|NCT05913089|EXPERIMENTAL|TQB2450 injection + Anlotinib Hydrochloride Capsule|TQB2450 injection combined with anlotinib hydrochloride capsule, 21 days as a treatment cycle.
62531341|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
62531342|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
62531343|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
62531344|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
62531345|NCT05841303|EXPERIMENTAL|Vit. C injection|"Derma pen device model M8 with 24 -micro needle will be adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min with intermittent motion used on the sextant gingival area for 30-40 seconds/tooth.~vitamin C will be injected with microneedle at two points for each site in the attached gingiva of one site of the jaw either the left or the right side at 3 mm apical to the free gingival margin in the facial side of the tooth until the blanching of the gingiva will be seen and apical to the mucogingival junction.~- Vitamin C will again be injected at the same site after 1 week and after 2 weeks from the baseline final injection which will be given."
62531346|NCT05841303|ACTIVE_COMPARATOR|Injectable-platelet Rich Fibrin (i-PRF)|"The derma pen will be used same as vitamin C group. I-PRF will be immediately aspirated using micro needle. I-PRF will be injected on the site with thin gingival phenotype (split mouth technique) with micro needling with derma pen at two points for each site in the attached gingiva at 3 mm apical to the free gingival margin in the facial side of the tooth until the blanching of the gingiva was seen and apical to the mucogingival junction.~4. I-PRF will again be injected at the same site after 1 week and after 2 weeks from the baseline final injection which will be given."
62531347|NCT03123432|EXPERIMENTAL|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
62714121|NCT05721950||Brigatinib 90 mg/180mg|Participants with ALK positive locally advanced or metastatic NSCLC will be observed ambispectively (retrospective plus prospective) after receiving recommended dose of brigatinib, 90 mg orally once daily for first 7 days followed by 180 mg once daily for up to 36 months as their first line of treatment as part of routine medical care up to approximately 16 months. Data will be collected every 3 months after their first dose until the 36 month or participant death, loss to follow-up, or withdrawal from the study for any reason in the real-world setting from September 1, 2022 and December 31, 2026.
62531348|NCT03123432|ACTIVE_COMPARATOR|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
62531349|NCT05347381|EXPERIMENTAL|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
62531350|NCT03506984|EXPERIMENTAL|Group A|the participant will do a program of inspiratory muscle training for 10-15 minutes once daily using Threshold Inspiration Muscle Training Device
62531351|NCT03506984|EXPERIMENTAL|Group B|the participant will start cycling slowly for five minutes without resistance at the beginning of the exercise as warming up, then the active phase will last 20-30 minutes, then decrease the speed with no resistance at the end of the exercise as cooling down using Electronic Bicycle Ergometer
62156607|NCT05897307|PLACEBO_COMPARATOR|Group (C)|will not receive any regional anesthesia and only will receive fentanyl 1μg/kg/hr.
62156608|NCT05897307|ACTIVE_COMPARATOR|Group (R)|will receive 30 ml of 0.25% of plain ropivacaine for each side.
62531352|NCT06169501|EXPERIMENTAL|Intervention|All study participants will receive the app-based mindfulness intervention.
62531353|NCT02926456||Cohort 1|HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram \[mg\] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than \[\<\]50 copies/milliliters) since at least six months.
62531354|NCT04877886|EXPERIMENTAL|Ultrasound with IV contrast|use ultrasound with IV contrast to perform in acute flank pain patient
62531355|NCT04877886|ACTIVE_COMPARATOR|CT with IV contrast|to compare with ultrasound with IV contrast in acute flank pain patient
62531356|NCT04877886|ACTIVE_COMPARATOR|Ultrasound without IV contrast|baseline for the Ultrasound with IV contrast
62531357|NCT04877886|ACTIVE_COMPARATOR|CT without IV contrast|baseline for the CT with IV contrast
62531358|NCT00062543|EXPERIMENTAL|Hepatic Artery Infusion|Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 \* 106 CD34+ cells/kg. Next 3 patients receive 2.5 \* 106 CD34+cells/kg. Next 3 patients receive 5 \* 106 CD34+ cells/kg. Less than 1 \* 105 T cells/kg administered.
62531359|NCT05041881|ACTIVE_COMPARATOR|Trifocal IOL group|Patients implanted during cataract or refractive surgery with trifocal lens, which allowed to see for far, intermediate and near distance, but due to optic design having unwanted effect like optical phenomena and lower contrast sensitivity
62531360|NCT05041881|ACTIVE_COMPARATOR|Accommodating IOL group|Patients implanted during cataract or refractive surgery with accommodating lens, which allowed to see for far and should improve intermediate distance better than monofocal lens do.
62531361|NCT05041881|ACTIVE_COMPARATOR|Monofocal IOL group|Patients implanted during cataract or refractive surgery with standard monofocal lens, which allowed to see for far but patients do not experiences optical phenomena or low contrast sensitivity.
62714122|NCT04996329|EXPERIMENTAL|comprehensive smoking cessation intervention group|Early health warning intervention combined with brief smoking cessation intervention Early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD
62531362|NCT02078336|EXPERIMENTAL|Midazolam|Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment
62714123|NCT04996329|ACTIVE_COMPARATOR|brief smoking cessation intervention group|brief smoking cessation intervention only
62714124|NCT04019002|EXPERIMENTAL|Cohort 1: Newly Diagnosed- Standard Treatment|"This arm is for patients with histologically proven newly diagnosed glioblastoma who will undergo standard treatment with radiation therapy (RT) and temozolomide (TMZ).~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at two time points: before receiving standard treatment with RT/TMZ and at the first post-radiation follow-up scan (8 weeks later)."
62156609|NCT05897307|ACTIVE_COMPARATOR|Group (DR)|will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
62156610|NCT01857245|EXPERIMENTAL|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
62531363|NCT02078336|ACTIVE_COMPARATOR|Lorazepam / Valium+Akineton+Dehydrobenzperidol+Atropine sulfat|"Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment~OR~Valium 10 mg/2 ml solution for injection 10mg Intramuscular use Single dose 45 minutes before dental treatment~+ Akineton 5 mg/ml solution for injection 5mg Intramuscular use Single dose 45 minutes before dental treatment~+ Dehydrobenzperidol 5 mg/2 ml solution for injection 0,000125 ml/cm2 Intramuscular use Single dose 45 minutes before dental treatment~+ Atropine sulfate Sterop 0,25mg/1ml solution for injection 0,25mg Intramuscular use Single dose 45 minutes before dental treatment"
62156611|NCT01857245|EXPERIMENTAL|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
62156612|NCT01857245|ACTIVE_COMPARATOR|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
62156613|NCT01432223|EXPERIMENTAL|Nab-paclitaxel|Nab-paclitaxel q3w 260mg/m2
62156614|NCT00361088|EXPERIMENTAL|Phase I|
62156615|NCT00361088|EXPERIMENTAL|Phase II|
62156616|NCT00788541|EXPERIMENTAL|3 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 6 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
62156617|NCT00788541|EXPERIMENTAL|3 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 3.75 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
62156618|NCT00788541|EXPERIMENTAL|48 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 96 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
62156619|NCT00788541|EXPERIMENTAL|48 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
62156620|NCT00788541|PLACEBO_COMPARATOR|Anecortave Acetate Vehicle, low volume|Anecortave Acetate Vehicle, one injection of 0.5 mL in the study eye monthly for 6 months.
62156621|NCT00788541|PLACEBO_COMPARATOR|Anecortave Acetate Vehicle, high volume|Anecortave Acetate Vehicle, one injection of 0.8 mL in the study eye monthly for 6 months.
62156622|NCT05151016|EXPERIMENTAL|mifepristone|mifepristone tablets，10mg，One tablet daily, oral treatment
62156623|NCT05151016|ACTIVE_COMPARATOR|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
62531364|NCT05673330|ACTIVE_COMPARATOR|Spinal Mobilizations|"1. Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~2. Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
62531365|NCT05673330|ACTIVE_COMPARATOR|Myofascial Release technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
62531366|NCT04340349|EXPERIMENTAL|Experimental: Hydroxychloroquine plus Bromhexine|200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
62531367|NCT04340349|PLACEBO_COMPARATOR|Hydroxychloroquine plus Bromhexine|200 mg of Hydroxycholoroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
62156624|NCT06440200|EXPERIMENTAL|group gamed-based activites|The group game-based activity will be twice a week lasting 12 weeks. There will be many motion sensing games in the group game-based activities. The games designed for activities can provide somatosensory control and visual and auditory feedback.
62156625|NCT06440200|NO_INTERVENTION|control group|The activities will be the psychiatric day wards and half-way house offered as usual.
62156626|NCT05926557|EXPERIMENTAL|Spermidine Group|Mechanical therapy (NSMD) will be performed by means of an ultrasonic scaler with a plastic tip. Finally, the spermidine-based gel will be applied in the peri-implant sulcus using a blunt-tipped needle.
62714125|NCT04019002|EXPERIMENTAL|Cohort 2: Recurrent- Standard Surgical Resection|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will receive surgical resection for the recurrence.~Patients will receive one injection of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at one time point: before surgery."
62156627|NCT05926557|ACTIVE_COMPARATOR|NSMD Group|Control group will be treated only through a non-surgical mechanical therapy with curettes or scaler peek tips.
62156628|NCT03183856|EXPERIMENTAL|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
62156629|NCT03183856|ACTIVE_COMPARATOR|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
62531368|NCT05357092|EXPERIMENTAL|Intervention group|"Patients treated with clear aligners to bring cleft segments closer previous to primary lip surgery.~An average of 15 aligners will be needed although it depends on the cleft."
62531369|NCT05357092|NO_INTERVENTION|Gold Standard|The reference therapeutic action (no pre-surgical orthopedic intervention previous to primary lip surgery)
62156630|NCT03252210|EXPERIMENTAL|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.~Post Hoc Multiple Comparisons"
62156631|NCT00930319||1|Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC
62156632|NCT01727076|EXPERIMENTAL|Treatment (recombinant interleukin-15)|Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62156633|NCT01964586|ACTIVE_COMPARATOR|Lidocaine plus Adrenaline|Lidocaine and adrenaline diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes from the surgery.
62156634|NCT01964586|ACTIVE_COMPARATOR|Dexmedetomidine|2 mcg/kg dexmedetomidine diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes the surgery.
62156635|NCT05726994||cystic fibrosis and Kaftrio®|20 children with cystic fibrosis aged 6 to 12 who initiate Kaftrio®
62156636|NCT01454297||Newly diagnosed Multiple Myeloma|This is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease.
62156637|NCT03596775|EXPERIMENTAL|Dexmedetomidine group|the children received 0.5 μg/kg of intravenous dexmedetomidine over 10 minutes after induction of anesthesia
62156638|NCT03596775|PLACEBO_COMPARATOR|Control Comparator group|the children received 10ml saline over 10 minutes after induction of anesthesia
62156639|NCT02144116|EXPERIMENTAL|Experimental group|Patients with fibromyalgia included in a dance-movement therapy programme
62156640|NCT02144116|ACTIVE_COMPARATOR|Control group|Patients with fibromyalgia who receive a standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
62156641|NCT05941156|EXPERIMENTAL|CAR-T Cell Infusion|Pretreatment was initiated at -5 days prior to CAR T cell reinfusion, and CAR T cell therapy was performed 2 days after completion of chemotherapy. All patients were pretreated with FC regimen, fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day. Anti CD56-CAR T cells were transfused back 2 days after chemotherapy. The freeze-thawed cell product solution is injected back into the body as soon as the patient can accept it. The patient's vital signs should be closely monitored throughout the infusion, and oxygen saturation should be measured at 15-minute intervals before, at the end of, and after infusion, and continue until the patient is stable. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
62531370|NCT05979649|EXPERIMENTAL|experimental group|"1. Throughout the intervention period, we will deliver weekly customized feeds to youths at a consistent time, covering stressful events, coping strategies, social support, and emotional intelligence, totaling eight deliveries.~2. After peer interveners (peer mentors) receive counseling credentials, every fifth participant will be randomly paired with a peer intervener. Over the next eight weeks, they will engage in individualized conversations via online video conferences biweekly.The intervention will last eight weeks, with four conversations in total.~3. After each personalized conversation, the interveners will collaboratively develop behavioral corrective tasks for the following two weeks from the To Do List, including at least one task from each category: social support, coping strategies, and emotional intelligence. During the next conversation, the interveners will inquire about the participants' completion status and personal experiences."
62531371|NCT05979649|PLACEBO_COMPARATOR|control group|Throughout the eight weeks of intervention, articles without professional psychological knowledge will be delivered to the control group participants once a week at a consistent time, totaling eight deliveries in total.
62156642|NCT03385447|EXPERIMENTAL|Physical Activity|Participants were subjected to a 12-week exercise program targeting the federal physical activity guidelines.
62156643|NCT05652114|EXPERIMENTAL|Child play of Mightier|Ad lib child biofeedback video game play in home
62156644|NCT03031223|EXPERIMENTAL|low-level laser therapy|"The treatment group will receive LLLT following the protocol outlined below:~LLLT protocol - radiance will be administered to the injury site transcutaneously at a wavelength of 808 nm using a Twin Flex Evolution diode laser (MMO Equipamento Opto-Eletronicos, Brazil). Twelve sessions will be held (three per week over four weeks). The dose administered to the surface of the skin will be 983 J/cm2 per session, with a treatment area of 4.72 W/cm² and total radiant energy of 25 J. According to the literature, this dose is capable of enhancing functional recovery following an injury."
62714126|NCT04019002|EXPERIMENTAL|Cohort 3: Recurrent- Standard Treatment|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will undergo standard treatment for the recurrence.~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at three time points: prior to treatment (baseline), approximately 7-14 days after the initiation of treatment, and 6-8 weeks after the initiation of treatment."
62531372|NCT05979649|OTHER|Peer intervener group|"Peer interveners will participate in a one-day course conducted by several instructors with backgrounds in psychology and medicine. They will be required to pass a standardized patient test after the course to obtain the qualification for intervention."
62714127|NCT06507306|EXPERIMENTAL|Monotherapy Dose Escalation|
62714128|NCT06507306|EXPERIMENTAL|Combo Therapy Dose Escalation|
62531373|NCT04436887|NO_INTERVENTION|Primary closure|Primary closure of midline laparotomy
62531374|NCT04436887|EXPERIMENTAL|Mesh closure|Sub-lay permanent mesh supported the closure
62531375|NCT04268316|EXPERIMENTAL|Virtual Reality Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in virtual reality. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable activities to enjoy in virtual reality.
62714129|NCT06507306|EXPERIMENTAL|Combo Therapy Dose Expansion - RP2D|
62714130|NCT06507306|EXPERIMENTAL|Combo Therapy Dose Expansion - RP2D-1|
62156645|NCT03031223|PLACEBO_COMPARATOR|placebo|laser therapy is applied at low intensity without emitting radiation.
62156646|NCT02060071|OTHER|Aortic setnsosi|blood test
62156647|NCT02060071|OTHER|controls|blood test
62156648|NCT03122444|EXPERIMENTAL|Imipramine|Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.
62156649|NCT01919489|EXPERIMENTAL|Liraglutide + OADs|Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
62156650|NCT01919489|ACTIVE_COMPARATOR|Glargine + OADs|Glargine once daily in combination to oral anti-diabetic agents (OADs)
62156651|NCT00576550|EXPERIMENTAL|1:1|Part 1 of the study (maintenance part)
62156652|NCT00576550|NO_INTERVENTION|1:2|Part 1 of the study (maintenance part)
62156653|NCT00576550|EXPERIMENTAL|2:1|Part 2 of the study (eczema part)
62714131|NCT06507306|EXPERIMENTAL|Combo Therapy Dose Expansion OBD|
62714132|NCT05688969|ACTIVE_COMPARATOR|Early Biopsy|"The investigators will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks (early) or 6-8 months (late) after starting therapy. This is not a clinical trial: the investigators will not be assigning volunteers to a specific osteoporosis therapy, though the investigators will randomize volunteers to either the early or late second biopsy."
62156654|NCT00576550|ACTIVE_COMPARATOR|2:2|Part 2 of the study (eczema part)
62531376|NCT04268316|ACTIVE_COMPARATOR|Behavioral Activation in real-life|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life.
62531377|NCT04268316|NO_INTERVENTION|Waitlist Control|Participants randomized to this arm will not receive any type of intervention and will be asked to complete the PHQ-9 once a week for three weeks (4 sessions) to track symptoms. Participants will be offered to engage in behavioral activation in real life or with virtual reality when the four weeks are complete. Their data will only be used from the time they were on the waitlist.
62531378|NCT06138236|EXPERIMENTAL|Infiltration|1. Infiltration of collagen hydrolyzed peptides
62531379|NCT06138236|EXPERIMENTAL|ESWT(Extracorporeal Shockwave Therapy)|ESWT (Extracorporeal Shockwave Therapy)
62531380|NCT06138236|EXPERIMENTAL|Combination|Combination of both treatments
62531381|NCT00375830|EXPERIMENTAL|Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Preliminary pilot assessment to confirm feasibility \& improved diagnostic accuracy of the combined 18F-NaF CT \& 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
62531382|NCT00375830|EXPERIMENTAL|Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Assessment to define the accuracy of the combined 18F-NaF CT \& 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
62531383|NCT00375830|EXPERIMENTAL|Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan|Assessment to define the utility of 18F-NaF \& 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.
62531384|NCT05731791|ACTIVE_COMPARATOR|ARM 1 - CT-based breast radiation treatment|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment.
62531385|NCT05731791|ACTIVE_COMPARATOR|ARM 2 - MRI-based breast radiation treatment|Patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment.
62531386|NCT05944380|EXPERIMENTAL|PENG with 20mL 0,5% Ropivacaine|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL of 0.5% ropivacaine. Using appropriate sterile precautions and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz) or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in the plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence in 5 mL increments with a periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site is wiped clean.
62531387|NCT05944380|EXPERIMENTAL|PENG block with 20mL 0,9% normal saline|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL of 0.9% normal saline. Using appropriate sterile precautions and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz) or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in the plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.9% normal saline is injected beneath the psoas tendon and above the iliopubic eminence in 5 mL increments with a periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site is wiped clean.
62531388|NCT04175444||Normal Subjects|This is a study of normal subjects to establish a normative database.
62531389|NCT05094492|EXPERIMENTAL|Self assembling peptide P11-4 with fluoride|P11-4 forms a 3D matrix within subsurface of incipient carious lesions , allowing formation of new hydroxyapatite crystal facilitating guided regeneration of enamel lesions. Combination with fluoride will have a synergistic effect on remineralization potential
62531390|NCT05094492|ACTIVE_COMPARATOR|Fluoride varnish|Gold standard agent for remineralization of incipient carious lesions.
62531391|NCT05466006|ACTIVE_COMPARATOR|Subepithelial Connective Tissue Graft (SCTG)|Soft tissue augmentation at peri-implant small buccal dehiscence with subepithelial connective tissue graft harvested from the patient's palate
62531392|NCT05466006|EXPERIMENTAL|Volume Stable Collagen Matrix (VCMX)|Soft tissue augmentation at peri-implant small buccal dehiscence with xenogenic volume stable collagen matrix
62531393|NCT02062294||Cohort|
62531394|NCT01480843|EXPERIMENTAL|Glargine|We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
62531395|NCT04798612|EXPERIMENTAL|Intervention arm|Two 45 mikrogram doses of interferon-alfa2a (Pegasys). Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
62531396|NCT04798612|PLACEBO_COMPARATOR|Placebo|Two 1 ml doses of saline liquid. Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
62531397|NCT01777620|ACTIVE_COMPARATOR|BOTOX®|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
62531398|NCT01777620|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
62156655|NCT01686724|OTHER|Business as Usual (BAU)|This group receives services as usual in their schools. They will receive the intervention after follow-up measures are gathered.
62156656|NCT01686724|EXPERIMENTAL|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
62156657|NCT04716517|EXPERIMENTAL|Cention N|Intervention Alkasite Restoration will be used to restore cervical carious in adult patients.
62156658|NCT04716517|ACTIVE_COMPARATOR|Resin Modified Glass Ionomer|Comparator Resin-modified glass ionomer material will be used to restore cervical carious in adult patients.
62531399|NCT01123837|ACTIVE_COMPARATOR|D5LR|In the treatment group, a 250cc bolus over 2 hrs of D5LR will be initiated prior to the end of surgery and continued in PACU.Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning
62531400|NCT01123837|ACTIVE_COMPARATOR|lactated ringers|In the control group, a 250cc bolus over 2 hrs of LR will be initiated prior to the end of surgery and continued in PACU. Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning.
62531401|NCT04121754|EXPERIMENTAL|Investigational Device|Will walk for 30 minutes at a time, 3 times a week, for 5 weeks using the investigational device.
62531402|NCT04121754|ACTIVE_COMPARATOR|Active Walking Control|Will walk for 30 minutes at a time, 3 times a week, for 5 weeks using only foot sensors.
62531403|NCT02588950|EXPERIMENTAL|Part A: U-500R Single Injection|Bolus of U-500R administered via single subcutaneous (SC) injection.
62531404|NCT02588950|EXPERIMENTAL|Part A: U-500R CSII|Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII).
62531405|NCT02588950|EXPERIMENTAL|Part B: U-500R TID|U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
62531406|NCT02588950|EXPERIMENTAL|Part B: U-500R BID|U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days
62531407|NCT01413516|PLACEBO_COMPARATOR|Placebo Control|Smoking cessation counseling with placebo comparator
62156659|NCT03046888|EXPERIMENTAL|PCNL|Percutant nephrolithotomy is a standard procedure for stones treatment over 2 cm.The puncture will be performed with an 18-G nephrostomy needle. The access thus gained guaranteed the transpapillary route of the percutaneous tract, a basic condition for the prevention of bleeding. Subsequently, following withdrawal of the puncture needle and urine drainage, a flexible guidewire will be inserted and advanced to the upper calyx or ureter.
62156660|NCT03046888|EXPERIMENTAL|Robot assisted pyelolithotomy|Robot assisted pyelolithotomy, is a new technique to remove stones of more than 2 cm. A 12-mm camera port is placed at the level of the umbilicus and lateral. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
62531408|NCT01413516|ACTIVE_COMPARATOR|Experimental: Varenicline|Smoking cessation counseling with varenicline
62531409|NCT03320421|EXPERIMENTAL|SIB group|"Radiation therapy:~daily 5 days per week for 3 weeks. 43.5 Gy in 15 fractions to the whole breast 49.5 Gy in 15 fractions to the tumor bed boost"
62531410|NCT03321435||placenta previa group|
62531411|NCT03321435||Normal control group|
62531412|NCT06273930|NO_INTERVENTION|Control|"Superiority parallel 3-arm randomized control trial. The intention behind a superiority trial is that CSPS \& Arginine are superior to commercially available desensitizing agents.~Double blinded study (Participants and Outcome Assessor)~Allocation ratio 1:1:1~Patients are chosen based on inclusion criteria. Patients undergo non-surgical periodontal therapy as part of their treatment. DH is assessed using the Schiff scale evaluation and tactile test Visual analogue Score (VAS) after treatment.~2 groups of patients receiving desensitizing agents applied for two consecutive 3-second applications, while others are placed in a control group.~DH is evaluated again immediately using the Schiff scale and tactile test VAS after the application of desensitizing agents Patients are instructed to maintain their oral hygiene by brushing their teeth twice daily with a specific dentifrice provided to them along with a soft toothbrush."
62531413|NCT06273930|ACTIVE_COMPARATOR|5% CSPS group|"Superiority parallel 3-arm randomized control trial. The intention behind a superiority trial is that CSPS \& Arginine are superior to commercially available desensitizing agents.~Double blinded study (Participants and Outcome Assessor)~Allocation ratio 1:1:1~Patients are chosen based on inclusion criteria. Patients undergo non-surgical periodontal therapy as part of their treatment. DH is assessed using the Schiff scale evaluation and tactile test Visual analogue Score (VAS) after treatment.~2 groups of patients receiving desensitizing agents applied for two consecutive 3-second applications, while others are placed in a control group.~DH is evaluated again immediately using the Schiff scale and tactile test VAS after the application of desensitizing agents Patients are instructed to maintain their oral hygiene by brushing their teeth twice daily with a specific dentifrice provided to them along with a soft toothbrush."
62531414|NCT06273930|ACTIVE_COMPARATOR|8% arginine group|"Superiority parallel 3-arm randomized control trial. The intention behind a superiority trial is that CSPS \& Arginine are superior to commercially available desensitizing agents.~Double blinded study (Participants and Outcome Assessor)~Allocation ratio 1:1:1~Patients are chosen based on inclusion criteria. Patients undergo non-surgical periodontal therapy as part of their treatment. DH is assessed using the Schiff scale evaluation and tactile test Visual analogue Score (VAS) after treatment.~2 groups of patients receiving desensitizing agents applied for two consecutive 3-second applications, while others are placed in a control group.~DH is evaluated again immediately using the Schiff scale and tactile test VAS after the application of desensitizing agents Patients are instructed to maintain their oral hygiene by brushing their teeth twice daily with a specific dentifrice provided to them along with a soft toothbrush."
62531415|NCT01906892|EXPERIMENTAL|1a|6 weeks of group drumming workshops
62531416|NCT01906892|EXPERIMENTAL|1b|6 weeks of group drumming workshops
62531417|NCT01906892|EXPERIMENTAL|2a|2 weeks of active group drumming followed by 2 weeks of control activity involving a literary-based activity
62531418|NCT01906892|ACTIVE_COMPARATOR|2b|2 weeks of the literary-based comparative activity followed by 2 weeks of watching live group drumming
62531419|NCT01906892|ACTIVE_COMPARATOR|2c|2 weeks of listening to live group drumming followed by 2 weeks of listening to recordings of group drumming
62531420|NCT01906892|ACTIVE_COMPARATOR|2d|2 weeks of listening to recorded group drumming followed by 2 weeks of participation in group drumming
62156661|NCT02107235|EXPERIMENTAL|Rigosertib + Cisplatin + Radiation|"Oral rigosertib will be started 7 days before initiation of concurrent treatment with cisplatin and radiation therapy and will be administered on a continuous basis for a fixed duration of 8 weeks. Three oral rigosertib escalating doses will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID.~Cisplatin will be administered intravenously at a dose of 40 mg/m\^2 on Days 1, 8, 15, 22, 29, 36, and 43 of the 7-week concurrent treatment course.~The prescribed radiotherapy dose will be 70 Gray (Gy) in 2 Gy once-daily fraction size (total of 35 fractions) over the 7-week concurrent treatment course. The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, 5 fractions per week."
62156662|NCT03665714|EXPERIMENTAL|Impact Oral|"Preoperatively:~1 bottle each time (250ml/bottle), 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~1. Patient should receive:~   * 1 bottle (250 ml each) per day of test product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~  * 2 bottles (250 ml each) per day of test product on D 3 and D 4 post surgery, corresponding to 707Kcal.~  * 3 bottles (250 ml each) per day of test product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~2. At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
62156663|NCT03665714|ACTIVE_COMPARATOR|Enteral nutrition Emulsion(TPF-T)|"Preoperatively:~272ml each time, 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~1. Patient should receive:~   * 272ml of control product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~  * 544ml of control product on D 3 and D 4 post surgery, corresponding to 707Kcal.~  * 816ml of control product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~2. At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
62156664|NCT03726502|ACTIVE_COMPARATOR|ureteroscopy with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
62531421|NCT01906892|EXPERIMENTAL|3a|10 weeks of participatory group drumming workshops
62156665|NCT03726502|PLACEBO_COMPARATOR|ureteroscopy alone|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
62531422|NCT01906892|ACTIVE_COMPARATOR|3b|10 weeks of engagement with other non-musical social activities
62531423|NCT03694600||men or women between 21-84|Multi-analyte blood test alone versus ultrasound in subjects diagnosed with liver cirrhosis
62531424|NCT03967496||No Delirium|No Delirium: CAM-ICU score of less than 3 throughout Post-Anesthesia Care Unit stay
62531425|NCT03967496||Initial Delirium|Initial Delirium: CAM-ICU score of 3 or more at 15 minutes following end of anesthesia and/or at 30 minutes following end of anesthesia
62531426|NCT03967496||Delirium|Delirium: CAM-ICU score of 3 or more immediately prior to discharge from Post-Anesthesia Care Unit
62531427|NCT05940155||mild cases|
62156666|NCT03726502|ACTIVE_COMPARATOR|with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
62156667|NCT03726502|PLACEBO_COMPARATOR|without safety guide-wire|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
62156668|NCT04085614|EXPERIMENTAL|Dynamic Coronary Roadmap group|Patients will be treated via standard of care for Percutaneous Coronary Intervention (PCI) with navigation support of Dynamic Coronary Roadmap.
62156669|NCT04085614|ACTIVE_COMPARATOR|Control group|Patients will be treated via standard of care for Percutaneous Coronary Intervention (PCI) without navigation support of Dynamic Coronary Roadmap.
62156670|NCT01760876|EXPERIMENTAL|Biofreedom stent|Coronary intervention
62156671|NCT05745259|ACTIVE_COMPARATOR|Alteplase|Patients will receive intravenous Alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
62156672|NCT05745259|EXPERIMENTAL|Tenecteplase|Patients will receive intravenous Tenecteplase, 0.25mg/kg, maximum 25mg, administered as a bolus over 5\~10 seconds
62156673|NCT01597999|OTHER|No treatment|Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
62156674|NCT05177835|EXPERIMENTAL|ABX464 -25mg|All subjects will receive ABX464 given at 25 mg QD.
62531428|NCT05940155||moderate cases|
62531429|NCT05940155||severe cases|
62531430|NCT05748249|ACTIVE_COMPARATOR|First arm Vertistop® L.|"BPPV patients will be assigned to the first arm have a sufficient serum concentration of Vitamin D between 31 and 100 ng/mL (76 and 250 nmol/L), which will be treated with Vertistop® L."
62531431|NCT05748249|NO_INTERVENTION|Second arm No Therapy|"BPPV patients will be assigned to the second arm having serum concentrations of Vitamin D Sufficient between 31 and 100 ng/mL that will not be treated"
62531432|NCT05748249|EXPERIMENTAL|Third arm Vertistop® D|"In the third arm, patients with serum values of Vitamin D insufficient i.e. between 20 and 30 ng/mL (50- 75 nmol/L) or deficient i.e. less than 20 ng/mL (50 nmol/L) which they will instead be treated with Vertistop® D."
62531433|NCT04360096|EXPERIMENTAL|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
62531434|NCT04360096|EXPERIMENTAL|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
62531435|NCT03041649|ACTIVE_COMPARATOR|GT button change - Mic-Key|Subjects randomized to the Mic-Key arm will have the Mic-Key button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mini One button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
62531436|NCT03041649|ACTIVE_COMPARATOR|GT button change - Mini One|Subjects randomized to the Mini One arm will have the Mini One button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mic-Key button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
62156675|NCT01405508|EXPERIMENTAL|Placebo tablets / Brivaracetam bolus|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
62531437|NCT05835739||Cohort A (Retrospective)|all consecutive women with a germline deleterious mutation in BRCA1-2 admitted to the participant Center since 1st of January 2010 until site activation will be enrolled
62156676|NCT01405508|EXPERIMENTAL|Brivaracetam (BRV) tablets / BRV bolus|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"
62531438|NCT05835739||Cohort B (Prospective):|all consecutive women with a germline deleterious mutation in BRCA1-2 admitted to the participant Center since site activation until September 2025 will be enrolled
62156677|NCT01405508|EXPERIMENTAL|Placebo tablets / Brivaracetam infusion|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
62156678|NCT01405508|EXPERIMENTAL|Brivaracetam (BRV) tablets / BRV infusion|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
62156679|NCT01379677|OTHER|Single arm|This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.
62531439|NCT05295238|EXPERIMENTAL|Compass Course|Four groups of up to 12 participants (48 total) will receive the study intervention during Spring and Fall 2022. All participants will complete study questionnaires before and after the sessions.
62156680|NCT02938286|EXPERIMENTAL|Fractional CO2 laser at 5% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 5% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied to this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
62531440|NCT00912483|EXPERIMENTAL|Test|Heparin Sodium 5.000UI/0.25mL
62531441|NCT00912483|ACTIVE_COMPARATOR|Ative comparator|Heparin Sodium 5.000USP/mL
62531442|NCT06230718|EXPERIMENTAL|Intervention group|"The intervention group will receive 3 experimental procedures~1. Placebo control~2. Motor Imagery- Active Comparator~3. Action Observation (OA) Active comparator muscle activation control by surface electromyography will be recorded in these three situations"
62531443|NCT01561430|EXPERIMENTAL|15 mg LY2886721|LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks.
62531444|NCT01561430|EXPERIMENTAL|35 mg LY2886721|LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.
62531445|NCT01561430|EXPERIMENTAL|70 mg LY2886721|LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.
62531446|NCT01561430|PLACEBO_COMPARATOR|Placebo|Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.
62531447|NCT02330315|EXPERIMENTAL|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
62531448|NCT02330315|SHAM_COMPARATOR|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
62531449|NCT02497651|EXPERIMENTAL|Healthy, heavy smoking men|Twelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
62531450|NCT02497651|EXPERIMENTAL|Healthy, non-smoking men|Twelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
62531451|NCT01831765|EXPERIMENTAL|Meal time FIAsp and insulin detemir|
62531452|NCT01831765|ACTIVE_COMPARATOR|Meal time insulin aspart and insulin detemir|
62531453|NCT01831765|EXPERIMENTAL|Post meal FIAsp and insulin detemir|
62531454|NCT02044406|EXPERIMENTAL|1 BI 1181181 single rising dose part|single rising doses of BI 1181181
62531455|NCT02044406|EXPERIMENTAL|2 BI 1181181 bioavailability part|bioavailability, food effect part of BI 11881181
62531456|NCT00599521|EXPERIMENTAL|Adapalene lotion 0.1%|
62531457|NCT00599521|PLACEBO_COMPARATOR|Adapalene Lotion vehicle|
62531458|NCT00923273|EXPERIMENTAL|Treatment level 1 - 3mg load|Sirolimus 3mg load/1mg/day; Pemetrexed 375mg/m\^2
62531459|NCT00923273|EXPERIMENTAL|Treatment level 2 - 6 mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m\^2
62531460|NCT00923273|EXPERIMENTAL|Treatment level 3 - 6mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m\^2
62531461|NCT00923273|EXPERIMENTAL|Treatment level 4 - 10 mg load|Sirolimus 10mg load/3mg/day; Pemetrexed 500mg/m\^2
62531462|NCT00923273|EXPERIMENTAL|Treatment level 5 - 15 mg load|Sirolimus 15mg load/5mg/day; Pemetrexed 500mg/m\^2
62156681|NCT02938286|EXPERIMENTAL|Fractional CO2 laser at 15% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
62156682|NCT02938286|EXPERIMENTAL|Fractional Er:YAG laser at 5% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 5% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 5% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
62156683|NCT02938286|EXPERIMENTAL|Fractional Er:YAG laser at 15% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 15% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 15% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
62531463|NCT02119819|EXPERIMENTAL|10 mg LY2944876|"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
62156684|NCT06307054|EXPERIMENTAL|Anti CLL-1 CAR NK cells|
62531464|NCT02119819|EXPERIMENTAL|15 mg LY2944876|15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
62531465|NCT02119819|EXPERIMENTAL|30 mg LY2944876|30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
62156685|NCT04859062|PLACEBO_COMPARATOR|control|no lidocaine gel 2% is applied
62156686|NCT04859062|EXPERIMENTAL|lidocaine group|the lidocaine gel 2% is applied to the operative eye preoperatively
62156687|NCT02263859|EXPERIMENTAL|Treatment|The Treatment Group will be implanted with the aura6000 System and have therapy turned ON at the Month 1 follow-up visit.
62531466|NCT02119819|EXPERIMENTAL|50 mg LY2944876|50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
62531467|NCT02119819|EXPERIMENTAL|Exenatide extended-release|2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
62531468|NCT02119819|PLACEBO_COMPARATOR|Placebo|"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
62531469|NCT05073952|ACTIVE_COMPARATOR|Connective tissue graft|patient in this group will be treated with a flap and a connective tissue graft at the moment of implant placement.
62156688|NCT02263859|OTHER|Control|The Control Group will be implanted with the aura6000 System and receive treatment as-usual, (i.e. any non-PAP, non-surgical OSA treatment including oral appliances and positional devices being used prior to enrollment in the study) until 14 days (washout period) prior to the Month 4 visit. At the Month 4 + 1 day follow-up visit, subjects in the Control Group will have therapy turned ON for the duration of the study.
62156689|NCT02883985|EXPERIMENTAL|Radiation Therapy: 6 Gy/ fraction|All patients will be treated with 6 Gy /fraction delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
62156690|NCT03196518|EXPERIMENTAL|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
62156691|NCT04914520|EXPERIMENTAL|Step 1: VN-0200 low dose|Healthy adults subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
62531470|NCT05073952|ACTIVE_COMPARATOR|Flapess|patient in this group will be treated with a flapless approach at the moment of implant placement.
62531471|NCT05340348|OTHER|Patient library|All the patients are included in one arm. They will undergo various type of samples.
62531472|NCT04880824||PG cohort|800 randomized surgical study patients with a frailty syndrome (Pre-frail and frail) of the intervention study PRÄP-GO (PG cohort). 400 study patients receive the intervention and 400 study patients receive standard of care.
62531473|NCT04880824||NFC cohort|400 non-frail surgical control group (NFC cohort)
62531474|NCT04880824||NO cohort|300 non-operative control group (NO cohort)
62531475|NCT04880824||GB cohort|Skill-Change-Management: a maximum of 30 coworkers and analysis of guiding principle: to a maximum of 35 patients, 30 relatives and 45 coworkers
62531476|NCT05417035|EXPERIMENTAL|Nebido|i.m 250 mg/3months 2 injectionjs
62531477|NCT05417035|ACTIVE_COMPARATOR|Testoviron Depot|i.m75mg/month 6 injections
62531478|NCT05727371|EXPERIMENTAL|RegenMatrix-PRP-XLHA|Patients randomized in this group will receive a single injection of a combination of platelet-rich plasma plus cross-linked hyaluronic acid, prepared with the medical device RegenMatrix.
62531479|NCT05727371|ACTIVE_COMPARATOR|Hylan G-F 20|Patients randomized in this group will receive a single injection of cross-linked hyaluronic acid Hylan G-F 20 (Synvisc-One®).
62531480|NCT05727371|PLACEBO_COMPARATOR|Placebo|Patients randomized in this group will receive a single injection of saline solution (0.9% NaCl)
62156692|NCT04914520|EXPERIMENTAL|Step 1: VN-0200 medium dose|Healthy adults subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
62156693|NCT04914520|EXPERIMENTAL|Step 1: VN-0200 high dose|Healthy adults subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
62156694|NCT04914520|PLACEBO_COMPARATOR|Step 1: Placebo|Healthy adults and elderly subjects will be randomized to receive intramuscular injection of placebo.
62156695|NCT04914520|EXPERIMENTAL|Step 2: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
62156696|NCT04914520|EXPERIMENTAL|Step 2: VN-0200 dose medium dose|Healthy elderly subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
62156697|NCT04914520|EXPERIMENTAL|Step 2: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
62156698|NCT04914520|PLACEBO_COMPARATOR|Step 2: Placebo|Healthy adults and elderly subjects will be randomized to receive intramuscular injection of placebo.
62156699|NCT03119051|EXPERIMENTAL|online cognitive training|Patients will receive 3-4 times of 20-30 minutes' training game every week
62156700|NCT03119051|NO_INTERVENTION|no training|Patients will not undergo preoperative cognitive training.
62156701|NCT03119051|EXPERIMENTAL|Cognitive training and physical exercise|Patients will receive 3-4 times of 20-30 minutes' training game every week and 2 times of 60 minutes' Tai Chi Training
62531481|NCT05671016||Patient aged 65 or older receiving radiotherapy treatment for a newly diagnosed GBM|Patients aged 65 or older who have been newly diagnosed with a Glioblastoma (either through histological confirmation or confirmed by a consultant radiologist in a multidisciplinary team meeting setting) who are planned to be treated with radiotherapy. There is only 1 arm in this study, there is no randomisation. All participants will undertake questionnaires (as described in detail elsewhere in the form) and if the required MRI sequences are not available on their diagnostic imaging then they will undertake a trail specific MRI scan.
62156702|NCT05602571|EXPERIMENTAL|ESWT+Exercise|Home exercise program including stretching and eccentric strengthening exercises twice a day for 3 months + 3 sessions of ESWT once a week for 3 weeks.
62156703|NCT05602571|ACTIVE_COMPARATOR|PRP+ESWT+Exercise|Home exercise program including stretching and eccentric strengthening exercises twice a day for 3 months + 3 sessions of ESWT once a week for 3 weeks + PRP injection
62156704|NCT05602571|SHAM_COMPARATOR|Sham PRP+ESWT+Exercise|Home exercise program including stretching and eccentric strengthening exercises twice a day for 3 months + 3 sessions of ESWT once a week for 3 weeks + Sham PRP injection
62156705|NCT05456061|NO_INTERVENTION|Group 1|No intervention
62156706|NCT05456061|ACTIVE_COMPARATOR|Group 2|3% diquafosol eye drops 6 times / day
62531482|NCT04312295|EXPERIMENTAL|ACP-SCT program|The ACP simulation-based communication training (ACP-SCT)program was designed 12 hours (4hours/week) workshop for nephrology nurses.
62156707|NCT05456061|ACTIVE_COMPARATOR|Group 3|Punctal plug insertion, lower eyelid
62156708|NCT05456061|ACTIVE_COMPARATOR|Group 4|3% diquafosol eye drops 6 times / day + Punctal plug insertion, lower eyelid
62156709|NCT02181179|ACTIVE_COMPARATOR|Yoga|This will involve participating in at least two 60-minute Vinyasa yoga sessions each week for eight weeks (weeks 1-8). This will begin the week following a baseline laboratory appointment. These sessions will be conducted at a local Austin studio that has numerous locations in the area.
62156710|NCT02181179|NO_INTERVENTION|Waitlist|If randomized to this group, participants will complete weekly assessments only and not yoga during their time in the study. Following full completion of the study (i.e., after week 10), participants will be compensated with a voucher for 2 free months of yoga.
62156711|NCT05051709|ACTIVE_COMPARATOR|Foot with no fusion|
62156712|NCT05051709|ACTIVE_COMPARATOR|Foot with fusion|
62156713|NCT04604899|EXPERIMENTAL|Retreated subjects|Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
62156714|NCT00950235|OTHER|Usual Care|This arm will receive one additional nutrition counseling session that typically received in the health system. This arm will be compared to our intervention group
62156715|NCT00950235|EXPERIMENTAL|Weight Management Counseling|In-person and group session counseling
62156716|NCT03395197|EXPERIMENTAL|Combination arm|Talazoparib plus enzalutamide
62156717|NCT03395197|ACTIVE_COMPARATOR|Monotherapy arm|Ezalutamide plus placebo
62156718|NCT05974631|EXPERIMENTAL|DBT + DBT PE|This condition combines one year of standard Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure (DBT PE) protocol for PTSD.
62156719|NCT05974631|ACTIVE_COMPARATOR|PE + SRM|This condition provides up to 18 sessions of Prolonged Exposure therapy (PE) for PTSD augmented with suicide risk management (SRM).
62156720|NCT01330472|ACTIVE_COMPARATOR|Xanax XR tablets 3 mg (sourced from Caugus)|Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE)
62156721|NCT01330472|EXPERIMENTAL|Xanax XR tablets 3 mg (sourced from Barceloneta),|Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST)
62156722|NCT04391439||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
62156723|NCT01017055||Voice and Swallowing Evaluations|
62156724|NCT00689637|EXPERIMENTAL|1|AZD3480 + warfarin
62156725|NCT00689637|EXPERIMENTAL|2|Placebo+ warfarin
62156726|NCT03975309||Previous DHS Participants|Observational
62156727|NCT06502067|ACTIVE_COMPARATOR|will receive serratus posterior superior block using bupivacaine|between the SPSM and the 3rd rib after using a test dose of 1- 2 mL saline and Following hydro-dissection,30ml 0.25%bupivacaine will be injected.
62156728|NCT06502067|OTHER|Arm B: (control group) patients will only receive general anesthesia without block.|Narcotic postoperative
62531483|NCT04312295|NO_INTERVENTION|Without ACP-SCT program|The control group only gives the ACP simulation-based communication training program handbook.
62531484|NCT04260867|EXPERIMENTAL|Aromatherapy|
62531485|NCT04260867|SHAM_COMPARATOR|Sham|
62531486|NCT00925080||A|
62531487|NCT02804711|EXPERIMENTAL|Four doses of low dose vaccine|four doses of 15µg/0.6ml per dose
62531488|NCT02804711|EXPERIMENTAL|Four doses of middle dose vaccine|four doses of 30µg/0.6ml per dose
62531489|NCT02804711|EXPERIMENTAL|Four doses of high dose vaccine|four doses of 60µg/0.6ml per dose
62531490|NCT02804711|EXPERIMENTAL|Three doses of low dose vaccine and one dose of placebo|three doses of 15µg/0.6ml per dose and one dose of placebo
62531491|NCT02804711|EXPERIMENTAL|Three doses of middle dose vaccine and one dose of placebo|three doses of 30µg/0.6ml per dose and one dose of placebo
62531492|NCT02804711|EXPERIMENTAL|Three doses of high dose vaccine and one dose of placebo|three doses of 60µg/0.6ml per dose and one dose of placebo
62531493|NCT02804711|PLACEBO_COMPARATOR|Four doses of placebo|four doses of placebo
62531494|NCT01928706|EXPERIMENTAL|Denture liner Mucopren Soft; Group 1|The existing mandibular dentures were relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22).
62531495|NCT01928706|ACTIVE_COMPARATOR|Denture liner Kooliner; Group 2|The existing mandibular dentures were relined with a a hard acrylic resin based denture liner (Kooliner; Group 2 n=22).
62531496|NCT00355810|EXPERIMENTAL|placebo followed by probiotic|placebo, then washout period, then Lactobacillus plantarum MF1298
62531497|NCT00355810|EXPERIMENTAL|probiotic followed by placebo|Lactobacillus plantarum MF1298, then washout period, then placebo
62531498|NCT05452135||Healty Adults|aged between 20 - 30 years right dominant being a volunteer to participate in the study
62531499|NCT01212354|EXPERIMENTAL|A - experimental|7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
62531500|NCT01212354|ACTIVE_COMPARATOR|B - control|7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
62531501|NCT06148168|ACTIVE_COMPARATOR|Group A|24 patients will receive OSCTAP block with 25 ml volume on each side (5 ml normal saline plus 20 ml of 0.25 % bupivacaine)
62531502|NCT06148168|ACTIVE_COMPARATOR|Group B|24 patients will receive OSCTAP block with 25 ml volume on each side (5 ml normal saline containing 500 mg MgSO4 plus 20 ml of 0.25% bupivacaine)
62531503|NCT06148168|ACTIVE_COMPARATOR|Group C|24 patients will receive OSCTAP block with 25 ml volume on each side (5 ml normal saline containing 250 mg MgSO4 plus 20 ml of 0.25% bupivacain)
62531504|NCT04579016|ACTIVE_COMPARATOR|Standard care|Standard care
62531505|NCT04579016|EXPERIMENTAL|PAIGE2 intervention|One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.
62531506|NCT04063436|EXPERIMENTAL|Experimental|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
62531507|NCT04249544|EXPERIMENTAL|Impulsive group, placebo then pramipexole|half of the impulsive group will first get the placebo on the first day and pramipexole on the second day
62531508|NCT04249544|EXPERIMENTAL|Impulsive group, pramipexole then placebo|half of the impulsive group will first get the pramipexole on the first day and the placebo on the second day
62531509|NCT04249544|EXPERIMENTAL|Non-impulsive group, placebo then pramipexole|half of the non-impulsive group will first get the placebo on the first day and the pramipexole on the second day
62531510|NCT04249544|EXPERIMENTAL|Non-impulsive, pramipexole then placebo|half of the non-impulsive group will first get the pramipexole on the first day and the placebo on the second day
62531511|NCT03216018|EXPERIMENTAL|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
62531512|NCT03216018|NO_INTERVENTION|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
62531513|NCT05219461|EXPERIMENTAL|Group A rhEGF 10mcg/mL|"single dose of rhEGF 10mcg/mL eye drop or single dose of placebo~\*single dose means daily dose (administration twice daily)"
62531514|NCT05219461|EXPERIMENTAL|Group B rhEGF 50mcg/mL|"single dose of rhEGF 50mcg/mL eye drop or single dose of placebo~\*single dose means daily dose (administration twice daily)"
62531515|NCT05219461|EXPERIMENTAL|Group C rhEGF 100mcg/mL|"single dose of rhEGF 100mcg/mL eye drop or single dose of placebo~\*single dose means daily dose (administration twice daily)"
62531516|NCT05219461|EXPERIMENTAL|Group D rhEGF 10mcg/mL|multiple dose of rhEGF 10mcg/mL eye drop or multiple dose of placebo
62531517|NCT05219461|EXPERIMENTAL|Group E rhEGF 50mcg/mL|multiple dose of rhEGF 50mcg/mL eye drop or multiple dose of placebo
62531518|NCT05219461|EXPERIMENTAL|Group F rhEGF 100mcg/mL|multiple dose of rhEGF 100mcg/mL eye drop or multiple dose of placebo
62531519|NCT04321954|EXPERIMENTAL|LENVATINIB|"Study procedures include screening for eligibility and study treatment, evaluations, and follow up visits~* Lenvatinib will be administered orally daily at a predetermined dose for 2, 4, or 6 cycles, dependent on response. 1 cycle is 28 days.~* Surgery per standard of care will follow lenvatinib treatment."
62531520|NCT03595085|EXPERIMENTAL|catheter directed interventions|Those patients will undergo catheter directed fragmentation followed by local thrombolysis using streptokinase
62531521|NCT03595085|ACTIVE_COMPARATOR|systemic thrombolysis|Those patients will receive systemic streptokinase
62531522|NCT01889212|EXPERIMENTAL|NSCLC, erlotinib treatment, 11C-erlotinib PET/CT|
62531523|NCT03865368|EXPERIMENTAL|Active Whole Body Vibration Training|Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
62531524|NCT03865368|ACTIVE_COMPARATOR|Control Group|The same exercises as the aWBVT group were performed on the vibration platform, with the vibration application turned off
62156729|NCT03918187|EXPERIMENTAL|bupivacaine|12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
62156730|NCT03918187|ACTIVE_COMPARATOR|nalbuphine|12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
62531525|NCT05439876|EXPERIMENTAL|Melatonin|Melatonin
62531526|NCT05439876|PLACEBO_COMPARATOR|Placebo|Placebo
62531527|NCT05107388|EXPERIMENTAL|Continuous interstitial glucose measurements|Variations of interstitial glucose are measured during 14 days with FreeStyle Libre Pro
62531528|NCT03728855|NO_INTERVENTION|Standard care|Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
62156731|NCT03918187|ACTIVE_COMPARATOR|midazolam|12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .
62531529|NCT03728855|EXPERIMENTAL|Self-administration of medication (SAM)|During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.
62156732|NCT00187356|EXPERIMENTAL|Surgical Conduit|The surgical arm will be composed of the experimental arm (the use of the radial artery) versus an active comparator (the use of the saphenous vein graft).
62156733|NCT04804371|OTHER|18F-FDG PETCT scan|18F-FDG tracer (5 MBq/kg body weight of FDG; up to 550 MBq) will be injected into the intravenous
62714133|NCT05688969|ACTIVE_COMPARATOR|Late Biopsy|"The investigators will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks (early) or 6-8 months (late) after starting therapy. This is not a clinical trial: the investigators will not be assigning volunteers to a specific osteoporosis therapy, though the investigators will randomize volunteers to either the early or late second biopsy."
62714134|NCT06138171||Fibromyalgia - FM|"Cohort of women diagnosed with FM recruited consecutively in the clinical department following the criteria:~* age range 18-65 years~* education \> 5 years~* diagnosis of FM according to Wolfe, 2016~Exclusion criteria~* severe psychiatric disorders and/or cognitive impairment~* difficulties in comprehension/expression in Italian~* history of other chronic pain disorder(s)~* history of other neurological disorders besides migraine"
62714135|NCT06138171||Chronic migraine - CM|"Cohort of women diagnosed with CM recruited consecutively in the clinical department following the criteria:~* age range 18-65 years~* education \> 5 years~* diagnosis of CM according to Olesen, 2017~Exclusion criteria~* severe psychiatric disorders and/or cognitive impairment~* difficulties in comprehension/expression in Italian~* history of other chronic pain disorder(s)~* history of other neurological disorders besides migraine"
62156734|NCT03665675|EXPERIMENTAL|Treatment (CMV-specific CTLs)|Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days.
62156735|NCT03665675|EXPERIMENTAL|Treatment (AdV-specific CTLs)|Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days.
62156736|NCT00584909|EXPERIMENTAL|Open Label|
62156737|NCT06037577|EXPERIMENTAL|Anti-human CCL24 monoclonal antibody (CM-101)|Single 5 mg/kg of CM-101, Subcutaneous administration
62156738|NCT06037577|PLACEBO_COMPARATOR|Placebo|Placebo : Subcutaneous administration
62156739|NCT00006229|EXPERIMENTAL|BMS-275291|
62156740|NCT00006229|PLACEBO_COMPARATOR|Placebo|
62156741|NCT03044756|EXPERIMENTAL|-ve arm|The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
62156742|NCT03044756|NO_INTERVENTION|+ve arm|The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
62156743|NCT04943614|EXPERIMENTAL|BIODEX training group|These individuals will receive conventional along with postural stability training with biodex balance system which stimulates specific movement patterns or strategies by placing markers on a specific location on-screen grid subject attempted to touch targets nine times using an onscreen cursor manoeuvred by the subject leg on the device platform
62156744|NCT04943614|ACTIVE_COMPARATOR|Conventional therapy group|These individuals will perform balance exercises including proprioception exercises, balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program (advices).
62156745|NCT00720161|ACTIVE_COMPARATOR|A: Metformin during 12 months and then 6 months Placebo|Metformin during 12 months and then 6 months Placebo
62156746|NCT00720161|PLACEBO_COMPARATOR|B: Placebo during 6 months, afterwards 12 months metformin|Placebo during 6 months, afterwards 12 months metformin
62156747|NCT01952002||IMT - Inspiratory Muscle Training|21 (16 males/5 femalesen) with a mean age of 73 ± 7.4 years were studied. Among the 21 study participants, the most prevalent clinical condition was coronary artery disease (11 cases); four individuals showing a diagnosis of chronic obstructive pulmonary disease and/or asthma, two presented congestive heart failure and the last four had other diseases
62531530|NCT04514536|EXPERIMENTAL|Health monitoring|Subjects have to monitor their health autonomously using the monitoring platform (connected health devices and app on the touchpad).
62531531|NCT06337253|EXPERIMENTAL|Intervention|"The intervention in this study is the administration of one cycle of SPAQ medicines. SPAQ medicines procured by Malaria Consortium are from Tridem Pharma, one of the three manufacturers with WHO prequalification, with whom Malaria Consortium has framework agreements.~Each monthly SMC cycle consists of one dispersible tablet of SP and three daily dispersible tablets of AQ. There are two doses of SPAQ: a lower dose for children aged 3-12 months, and a higher dose for children aged 12 to 59 months. For children aged 12 to 59 months, the dosage comprises a single dose of a full tablet of SP 500/25mg and three daily doses of a full tablet of AQ 153mg. Those aged 3-12 months are administered half the dose given to those aged 12 to 59 months, given as full dispersible tablets."
62531532|NCT03259438|EXPERIMENTAL|Qigong|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include guided instruction in the theory and background of qigong and healing. Practice will include gentle stretching and guided qigong movement as well as seated and lying down meditations. Participants will be asked to complete about 30 minutes a day of home assignments.
62531533|NCT03259438|ACTIVE_COMPARATOR|Healthy Living (CHIP + Pre-Train)|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) as well as core-stretching, strengthening, and light aerobic movements through a Pre-Train exercise program. Participants will be asked to complete about 30 minutes a day of home assignments.
62531534|NCT05693207|EXPERIMENTAL|People with iPD with freezing of gait|
62531535|NCT05693207|OTHER|People with iPD without freezing of gait|control group
62531536|NCT06278740||SCI with Manual Wheelchair Usage|Patients with spinal cord injuries who use manual wheelchairs
62531537|NCT06278740||SCI without Manual Wheelchair Usage|Patients with spinal cord injuries who do not use manual wheelchairs
62531538|NCT02280668|ACTIVE_COMPARATOR|Control Group|Will perform the eccentric muscle damage exercise and will not perform any icing interventions post damage. These participants will be the control group.
62156748|NCT05316649||HPB group|Adult patients undergoing for elective liver or pancreas surgery at Department of Surgery, University Hospital Hradec Kralove, Czech Republic.
62156749|NCT05944666|EXPERIMENTAL|Medical rehabilitation (MR) in acute period of IS-inpatient stage|"Devices Patients in acute period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
62531539|NCT02280668|EXPERIMENTAL|Icing Protocol 1|Will perform the eccentric muscle damage exercise and will begin the icing intervention immediately after the muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
62531540|NCT02280668|EXPERIMENTAL|Icing Protocol 2|Will perform the eccentric muscle damage exercise and will begin the icing intervention 6 hours post muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
62531541|NCT04030065|EXPERIMENTAL|Experimental Arm - omega 3 fatty acid|
62531542|NCT04030065|NO_INTERVENTION|Control Arm - No intervention|
62531543|NCT02563106|EXPERIMENTAL|SYN-004|SYN-004 150 mg
62531544|NCT02563106|PLACEBO_COMPARATOR|Placebo|Matching placebo
61975831|NCT05780567|EXPERIMENTAL|TQB3616 capsules combined with endocrine|"The dose of TQB3616 capsules is 180mg, taken orally when fasting, once a day for 28 consecutive days as one treatment cycle.~The dose of Letrozole is 2.5mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Anastrozole is 1mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Tamoxifen is 10mg, taken orally, twice a day for 28 consecutive days as one treatment cycle."
61975832|NCT05780567|PLACEBO_COMPARATOR|placebo combined with endocrine|"The dose of placebo is 180mg, taken orally when fasting, once a day for 28 consecutive days as one treatment cycle.~The dose of Letrozole is 2.5mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Anastrozole is 1mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Tamoxifen is 10mg, taken orally, twice a day for 28 consecutive days as one treatment cycle."
62531545|NCT02770677|NO_INTERVENTION|Control group|Control group will be asked to continue their normal daily life without Yoga training
62531546|NCT02770677|EXPERIMENTAL|Yoga group|Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks
62531547|NCT04320121|EXPERIMENTAL|Nelutri™ group|This group takes Nelutri™ for 12 weeks
62531548|NCT04320121|PLACEBO_COMPARATOR|Placebo group|This group takes placebo for 12 weeks
62531549|NCT03963024|EXPERIMENTAL|Single Arm Treatment|"Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;"
62531550|NCT04185051|EXPERIMENTAL|Cohort 1: JNJ-67953964 or Placebo|Participants will receive JNJ-67953964 or matching placebo oral capsules once daily (QD) over 4 weeks (28 days).
62531551|NCT04185051|EXPERIMENTAL|Cohort 2: JNJ-67953964 or Placebo|Participants in this cohort will receive JNJ-67953964 only or will be randomly assigned to receive JNJ-67953964 or matching placebo.
62531552|NCT00807248|PLACEBO_COMPARATOR|Escitalopram placebo and gaboxadol placebo|
62531553|NCT00807248|ACTIVE_COMPARATOR|Escitalopram 20 mg and gaboxadol placebo|
62531554|NCT00807248|EXPERIMENTAL|Escitalopram 20 mg and gaboxadol 5 mg|
62531555|NCT00807248|EXPERIMENTAL|Escitalopram 20 mg and gaboxadol 10 mg|
62531556|NCT01948466|EXPERIMENTAL|Commercials|Schools Administered Commercials
62531557|NCT01948466|NO_INTERVENTION|Control|Schools not Administered Commercials
62531558|NCT06090773||Acute kidney injury|Patients with acute injuries in ICU patients.
62531559|NCT06090773||Patients with non-acute kidney injury|ICU patients without acute injury patients.
62531560|NCT00995280|ACTIVE_COMPARATOR|1|Single lumen needle use in oocyte retrieval
62531561|NCT00995280|ACTIVE_COMPARATOR|2|Double lumen needle with follicle flushing during oocyte retrieval
62531562|NCT00351975|EXPERIMENTAL|Arm I (chemotherapy)|Patients receive azacitidine SC on days 1-5.
62531563|NCT00351975|EXPERIMENTAL|Arm II (chemotherapy, enzyme inhibitor therapy)|Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.
62531564|NCT03768726|EXPERIMENTAL|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
62531565|NCT04981496||Simulated Arrhythmias|Simulate ventricular and/or atrial tachycardia via VVI or AAI pacing an ICD with an implantable loop recorder implant (or a surface bipolar electrogram) and haemodynamics.
62531566|NCT04981496||Clinical Arrhythmias|Genuine clinical VT (acute presentation), RV lead fracture/noise or sinus tachycardia on exercise whilst recording haemodynamics and a surface bipolar electrogram.
62531567|NCT05362734||First fresh embryo transfer (group A)|The two groups analysed were defined according to the modality of first embryo transfer: cycles in which a fresh ET was performed at first, after a dual triggering or a rescue protocol (Group A) and cycles where a frozen-thawed ET was performed at first, after being chosen a freeze-all strategy (Group B).
62531568|NCT05362734||First cryopreserved embryo transfer (group B)|The two groups analysed were defined according to the modality of first embryo transfer: cycles in which a fresh ET was performed at first, after a dual triggering or a rescue protocol (Group A) and cycles where a frozen-thawed ET was performed at first, after being chosen a freeze-all strategy (Group B).
62531569|NCT04942158|EXPERIMENTAL|CTZ group|Non-instrumentation endodontic treatment and use of a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste)
62531570|NCT04942158|ACTIVE_COMPARATOR|ZOE group|Endodontic treatment with instrumentation and filling with Zinc Oxide and Eugenol paste (ZOE paste)
62531571|NCT00796679|EXPERIMENTAL|1|paricalcitol
62531572|NCT00796679|PLACEBO_COMPARATOR|2|placebo
62531573|NCT02003521||Intervension|Lung Flute
62531574|NCT03453801|EXPERIMENTAL|MZ twins 2-5 yo|Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.
62156750|NCT05944666|EXPERIMENTAL|MR in early recovery period of IS- inpatient stage|"Devices Patients in the early recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
62714136|NCT06138171||Vulvodynia - VU|"Cohort of women diagnosed with VU recruited consecutively in the clinical department following the criteria:~* age range 18-65 years~* education \> 5 years~* diagnosis of VU according to Bornstein et al., 2016~Exclusion criteria~* severe psychiatric disorders and/or cognitive impairment~* difficulties in comprehension/expression in Italian~* history of other chronic pain disorder(s)~* history of other neurological disorders besides migraine"
62531575|NCT03453801|EXPERIMENTAL|Non-twins 6 mo-10 yo|Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.
62714137|NCT06138171||Control group (no chronic pain condition)|"Cohort of women recruited consecutively from the general population with the following criteria:~* age range 18-65 years~* education \> 5 years~* no previous diagnosis of chronic pain conditions~Exclusion criteria~* severe psychiatric disorders and/or cognitive impairment~* difficulties in comprehension/expression in Italian~* history of other chronic pain disorder(s)~* history of other neurological disorders"
62156751|NCT05944666|EXPERIMENTAL|MR in late recovery period of IS-inpatient stage|"Devices Patients in the late recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
62531576|NCT03453801|EXPERIMENTAL|Non-twins 6-12 mo Flu/MMRV Naïve|Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
62156752|NCT05944666|EXPERIMENTAL|MR in early recovery period of IS - outpatient stage|"Devices Patients in the early recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
62156753|NCT05944666|EXPERIMENTAL|MR in late recovery period of IS - outpatient stage|"Devices Patients in the late recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
62156754|NCT04063449|EXPERIMENTAL|Experimental:group A|endostar,210 mg,CIV 72h,d1-d3; sintilimab,200mg,IV,d1; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar plus sintilimab for maintenance therapy until PD or intolerable toxicity ;
62156755|NCT04063449|ACTIVE_COMPARATOR|control:group B|endostar,210 mg,CIV 72h,d1-d3; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar for maintenance therapy until PD or intolerable toxicity ;
62531577|NCT06360783||Ghana|Aggregated testing and treatment data from centers in Ghana.
62531578|NCT06360783||Malawi|Aggregated testing and treatment data from centers in Malawi.
62531579|NCT06360783||Rwanda|Aggregated testing and treatment data from centers in Rwanda.
62531580|NCT06360783||Zambia|Aggregated testing and treatment data from centers in Zambia.
62531581|NCT06360783||Zimbabwe|Aggregated testing and treatment data from centers in Zimbabwe.
62531582|NCT04465773|EXPERIMENTAL|pupillometry|General anesthesia for scheduled gynecological surgery Propofol target concentration adjusted to maintain bispectral index between 45 and 55 for 10 minutes Remifentanil target concentration 1 ng/ml for 10 minutes Tetanic stimulations of 10-20-30-40-50-60 milliamps (5 seconds per stimulation, 2 minutes between stimulations) Continuous pupillometry VideoAlgesiGraph
62156756|NCT06053983|EXPERIMENTAL|rosuvastatin 20 mg|
62156757|NCT06053983|EXPERIMENTAL|atorvastatin 40 mg|
62531583|NCT01020955|ACTIVE_COMPARATOR|NutropinAq and Increlex|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and Increlex (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
62531584|NCT01020955|PLACEBO_COMPARATOR|NutropinAq and placebo|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and placebo for 6 months.
62531585|NCT04575766|EXPERIMENTAL|Dose escalation study of FT-7051|
62531586|NCT01324674|PLACEBO_COMPARATOR|Placebo group|Is the group of subjects that will take placebo
62531587|NCT01324674|EXPERIMENTAL|experimental group|Is the group of subjects that will take Bach´s Flower remedies
62531588|NCT00950963|EXPERIMENTAL|Phone Counseling|The telephone outreach intervention was considered an adjunct to usual care. The study nurse focused on optimizing lipids utilizing published guidelines through phone contact.
62531589|NCT00950963|ACTIVE_COMPARATOR|Standard Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
62531590|NCT04487938||Tobacco use and/or alcohol consumption|
62531591|NCT04487938||No tobacco use and/or alcohol consumption|
62531592|NCT05827835|EXPERIMENTAL|Treatment Group|R/R CD7+Malignant Hematologic Diseases
62531593|NCT01772758|EXPERIMENTAL|Protocol 1: AOC|measurements at baseline and 2 hours following the antioxidant cocktail that is comprised of over the counter vitamins (vitamin C 1000mg, vitamin E 600 IU, and alpha lipoic acid 600 mg) that will be given in two doses, 30 minutes apart.
62531594|NCT01772758|EXPERIMENTAL|Protocol 2: BH4 (5mg)|measurements at baseline and 3 hours following the single dose of 5mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
62531595|NCT01772758|EXPERIMENTAL|Protocol 2: BH4 (20mg)|measurements at baseline and 3 hours following the single dose of 20mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
62531596|NCT01772758|NO_INTERVENTION|Healthy Controls|baseline measurements were done with no intervention
62531597|NCT04155307|EXPERIMENTAL|Detection of anismus in patients with distal constipation|
62531598|NCT05528835||Group A|Women with history of previous one Caesarean section
62531599|NCT05528835||Group B|Women with history of previous normal vaginal delivery.
62531600|NCT02728570|EXPERIMENTAL|Low Flavonoids then High Flavonoids|Participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks.
62156758|NCT00407485|EXPERIMENTAL|Treatment (ziv-aflibercept)|Patients receive 4 mg/kg VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
62156759|NCT05386706|EXPERIMENTAL|Digital Intervention|A mini program-based digital intervention.
62156760|NCT05386706|ACTIVE_COMPARATOR|Metformin|Traditional metformin monotherapy.
62156761|NCT01791335||COPD patients receiving NIV|
62156762|NCT04421456|EXPERIMENTAL|GWP42003-P 300 mg|GWP42003-P 300 milligrams (mg) per day
62531601|NCT02728570|EXPERIMENTAL|High Flavonoids then Low Flavonoids|Participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks.
62531602|NCT00815256|EXPERIMENTAL|Cross linking (CXL)|Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
62156763|NCT04421456|PLACEBO_COMPARATOR|Placebo|Matching placebo
62531603|NCT01523457|EXPERIMENTAL|MPC modified FOLFIRINOX|Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
62531604|NCT01523457|EXPERIMENTAL|LAPC modified FOLFIRINOX|Patients with locally advanced pancreatic cancer (LAPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
62156764|NCT04421456|EXPERIMENTAL|GWP42003-P 1000 mg|GWP42003-P 1000 mg per day
62156765|NCT03315195|EXPERIMENTAL|Preoperative oral nutritional supplement|Oral nutritional supplement 500 kcal/day for 14 days and dietary advice
62156766|NCT03315195|NO_INTERVENTION|Conventional treatment|Dietary advice
62156767|NCT03262389|EXPERIMENTAL|Multiple Myeloma Patients|Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
62156768|NCT02043652|EXPERIMENTAL|Chloroquine and primaquine|Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
62156769|NCT05546021|ACTIVE_COMPARATOR|NOL monitor|Patients will receive opioids as per the guidance of a nociception level monitor (NOL)
62156770|NCT05546021|NO_INTERVENTION|Standard care|Patients will be treated as per the department´s standard protocol.
62156771|NCT06584734|OTHER|Patients in hemodiafiltration|Patients having hemodiafiltration sessions 3 times a week, they used to do intradyalitic exercise but this exercise was neither measured, quantified, or supervised, so they were withdrawn from this exercise for three months and after this time, structured, measured and supervised intradialytic exercise was introduced.
62156772|NCT00715156||A|Subjects with mild (S1) reaction to peach fruit
62156773|NCT00715156||B|Subjects with severe reaction to peach fruit
62531605|NCT02513511|EXPERIMENTAL|Hypnosis|the investigators will put the patient into a hypnotic state and analyze laryngoscopy under hypnosis, followed by intubation.
62531606|NCT03457467|EXPERIMENTAL|SBRT+apatinib group|Apatinib mesylate tablets: 500mg / day, 28 days / cycle, follow-up to the progress of the disease, toxicity intolerable or patients require withdrawal; SBRT: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment.
62156774|NCT04229940|EXPERIMENTAL|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
62714138|NCT06563479|EXPERIMENTAL|Personalized Chemoradiation Therapy|Patient without evidence of hypoxia will receive 30Gy in 2Gy per fraction. Concurrent chemotherapy will be given as per guidelines. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks) posttreatment standard FDG PET/CT scan will be performed and if there is persistent disease, standard neck dissection will be performed. Further standard of care will be given pending pathologic findings.1. Hypoxia negative: The entire target volume which includes GTV and CTV will receive 30Gy in 2 Gy per fraction over 15 days (PTV30). 2. Hypoxia positive (same as the standard of care): The CTV will receive 50Gy in 2Gy per fraction over 25 days. This is name PTV50 and will receive 50Gy in 2Gy per fraction over 25 days. The GTV will receive an additional boost of 20Gy in 2 Gy per fraction so that the total PTV70 dose is 70Gy.
62156775|NCT04229940|ACTIVE_COMPARATOR|No bridging|The hernia defect is left without closure prior to application of the mesh.
62156776|NCT04293718||Acute erosive gingivitis|Patients presenting acute erosive gingivitis, isolated or predominant compared to other oral lesions, which required at least one papillary gingival biopsy for diagnostic purposes. Patients were included in the study regardless of age and general health.
62156777|NCT01662804|EXPERIMENTAL|hu3F8 and rIL-2|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8 (day 1 and day 8) in the presence of 6 × 10\^6 U rIL-2/m\^2/d x 5 days sc (day 8 through day 12). These 2 doses of hu3F8 and 5 doses of rIL-2 constitute a treatment cycle.
62156778|NCT04123119|EXPERIMENTAL|Rotarix Arm|
62156779|NCT02913898|EXPERIMENTAL|IBLT (information bias learning task)|Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.
62156780|NCT02913898|PLACEBO_COMPARATOR|IBLT control|Computerised task in which information is provided by both positive and negative outcomes. Completed 10 mins per day every day for 2 weeks
62156781|NCT05024266|EXPERIMENTAL|Tislelizumab + Albumin Paclitaxel + Carboplatin|Tislelizumab 200mg d1, Albumin Paclitaxel 260mg/m2 d1, Carboplatin AUC5 d1, Q3W
62531607|NCT05637346|EXPERIMENTAL|Patients scheduled for laparotomy|This is a single-center observational feasibility study to develop an automatic segmentation and registration algorithm based on ultrasound imaging of the pelvic arteries. The duration of this study will be approximately 1 year. Patients scheduled for a laparotomy at the NKI are eligible for inclusion. Patients are informed about the study before the planned surgery and, after being provided with the necessary information regarding participation in the study, will be asked for informed consent. The ultrasound acquisitions for this study will be performed intra-operatively with CE marked equipment for intra-operative ultrasound. There is no impact on the standard surgical procedure or decision making of the surgery. After surgery, no further participation or cooperation of the patient is required.
62531608|NCT01209130|EXPERIMENTAL|A|
62531609|NCT01209130|EXPERIMENTAL|B|
62531610|NCT02316665|EXPERIMENTAL|continuous positive airway pressure|Patients will receive continuous positive airway pressure during three months
62531611|NCT02316665|SHAM_COMPARATOR|Sham-continuous positive airway pressure|Patients will receive sham-continuous positive airway pressure during 3 months
62156782|NCT05306483|ACTIVE_COMPARATOR|Ventricular septal defect closure surgery|Surgical closure would be done under general anesthesia, hypothermic cardiopulmonary bypass and cardioplegic arrest. Chest would be opened through standard median sternotomy Surgical techniques would be determined according to the nature of every defect and includes direct closure, patch closure which involves the use of autologous pericardium; however, polyethylene terephthalate (Dacron; C.R Bard, Haverhill, MA) and expanded polytetrafluoroethylene (Gore-Tex; W.L. Gore \& Associates, Inc.,AZ) may be occasionally used. These patches are held with continuous or interrupted sutures. Direct closure (without a patch may be done for the very small defects.Most VSDs would be repaired through right atriotomy to avoid the the undesirable effects of the trans ventricular approach.
62531612|NCT06152952||Group 1 : The rhomboid flap Approach|The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers (gluteal fascia with 2/0 Vicryl, subcutaneous fat with 3/0 Vicryl, and the skin with 4/0 Prolene). As all sides will be equal in length, the flap fits in place without tension. A suction drain will be left behind and the wound will be dressed as usual. Pressure wound dressing will be applied and removed on the third postoperative day.
62531613|NCT06152952||Group 2 : The deep suturing approach|A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. Tension will be released by a limited sharp dissection above the fascia. After haemostasis is ensured using electrocautery, a suction drain will be inserted through a separate incision, then the deep fascia will be approximated and the wound will be closed in layers using polyglactin 0 sutures. Finally, the skin will be closed with 2/0 polypropylene interrupted mattress sutures.
62531614|NCT05332028|EXPERIMENTAL|Group 1: Patients undergoing paravertebral block|After cleaning the area with antiseptic solution, the sterilized linear USG probe (Esaote MyLab30®, CA631 high-frequency probe, United Kingdom) was covered. The flat probe was placed between two transverse processes on the paramedian plane; transverse processes, superior costotransverse ligament and pleura were consecutively visualized. The linear ultrasound probe was fixed to the T3-T4 vertebra level. The skin and subcutaneous tissue were anaesthetized with 2% lidocaine, then 22 gauge 100 mm needle (Stimuplex ®; B Braun, Melsungen, Germany) was led in a cranial-cephalic direction to the paravertebral gap. Trapezius, rhomboid, erector spinae muscles were crossed by seeing the tip of the needle. Transverse processes were reached and the intercostal muscles were passed. When the needle reached the paravertebral level, a 20 mL of 0.25% bupivacaine was applied as a single administration.
62531615|NCT05332028|ACTIVE_COMPARATOR|Group 2: Patients undergoing Mid-Point Transverse Process Pleura (MTP) block|After cleaning the area with antiseptic solution, the sterilized linear USG probe (Esaote MyLab30®, CA631 high-frequency probe, United Kingdom) was covered. The flat probe was placed between two transverse processes on the paramedian plane; transverse processes, superior costotransverse ligament and pleura were consecutively visualized. The linear ultrasound probe was fixed to the T3-T4 vertebra level. The skin and subcutaneous tissue were anaesthetized with 2% lidocaine, then 22 gauge 100 mm needle (Stimuplex ®; B Braun, Melsungen, Germany) was led in a cranial-cephalic direction to the paravertebral gap. Trapezius, rhomboid, erector spinae muscles were crossed by seeing the tip of the needle. Transverse processes were reached and the intercostal muscles were passed. When the needle reached the midpoint level between the transverse process and pleura, a 20 mL of 0.25% bupivacaine was applied as a single administration.
62531616|NCT04886258|ACTIVE_COMPARATOR|DFV890|DFV890
62531617|NCT04886258|PLACEBO_COMPARATOR|Placebo|Placebo
62531618|NCT03609723||MPS® in patients with CABG|Patients undergoing coronary artery bypass grafting with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC)
62531619|NCT03609723||OPCABG in patients with CABG|Patients undergoing coronary artery bypass grafting without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
62156783|NCT05306483|ACTIVE_COMPARATOR|catheter closure of ventricular septal defect|"Under general anesthesia, patients will be fully heparinized (100IU/Kg) with follow up by activated clotting time. IntraoperativeTEE will be done for more detailed assessment of the defect size, relation to the surrounding structures especially the distance from the tricuspid and the aortic valve to guide the procedure and for proper assessment after device positioning yet before its release.~Left ventricular angiogram will be done in LAO 60, cranial 30 projection to define location and size of the defect. Accordingly, proper selection of the device siz."
62531620|NCT00128830|EXPERIMENTAL|Etravirine + 2 antiretrovirals|
62531621|NCT02452983|EXPERIMENTAL|Sertraline|Sertraline tablets 100mg daily for 4 (28-day) cycles
62156784|NCT01549171||Iloprost|This is the study group with 1 uM Iloprost.
62531622|NCT03888950|EXPERIMENTAL|early research PET-CT|The patient will undergo an early research PET-CT after 2 cycles of anti-PD1 (PET1) between the baseline PET-CT and the PET-CT at 3 months of initiation of treatment
61975833|NCT04226378||Omnipod cohort|Adults with T1D who switch from MDI therapy to insulin pump therapy with Omnipod.
62156785|NCT01549171||Control|This is the control group with vehicle (normal saline) only.
62156786|NCT03946631||Blood Glucose Test - 2hour GTT|Only one arm: intervention group. The intervention is fasting 2 hour glucose tolerance test in the immediate postpartum period. The screening test consists of fingerstick blood glucose testing after a glucose drink. First, a fasting blood glucose finger stick will be performed. Second, the glucose drink is orally ingested containing 75g glucose. The drink is to be orally ingested over 60 seconds. Lastly, fingerstick blood glucose testing is completed at 1 hour post drink and 2 hours post drink.
62156787|NCT02512315|ACTIVE_COMPARATOR|CCRT group (Group A)|Patients who are allocated into in this group will be treated with concurrent chemoradiation (CCRT).
62156788|NCT02512315|EXPERIMENTAL|NACT-CCRT group (Group B)|Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CCRT.
62156789|NCT02074033||antibiotics for pneumonia|We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed )
62156790|NCT01900015|ACTIVE_COMPARATOR|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
62531623|NCT05055440||Mechanically ventilated patients with COVID-19 in the ICU|Mechanically ventilated patients with COVID-19 admitted to the intensive care unit using sedation and neuromuscular blocker
62156791|NCT01900015|ACTIVE_COMPARATOR|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
62156792|NCT03517332||Cohort 1|"Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma~Subjects of cohort 1 must not:~• Have been treated for above diagnosed malignancy"
62156793|NCT03517332||Cohort 2|"Negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2).~Subjects of cohort 2 must:~• Meet the listed matching criteria~Subjects of cohort 2 must not:~• Have been diagnosed/treated for a malignancy previously"
62156794|NCT02451553|EXPERIMENTAL|Treatment (afatinib dimaleate, capecitabine)|Patients receive afatinib dimaleate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62156795|NCT03889951||group 1|group of ALL patients with IKZF1 deletion mutation.
62156796|NCT03889951||group 2|group of ALL patients with no detected mutation
62156797|NCT00545922|EXPERIMENTAL|A|7 weekly sessions of group cognitive behavioral therapy
62156798|NCT00545922|ACTIVE_COMPARATOR|B|Minimal Telephone Contact
62156799|NCT04945616|EXPERIMENTAL|group A： Aspirin + Clopidogrel + placebo or SHR2285 (dose 1)|
62531624|NCT04969510|EXPERIMENTAL|PRAX-114 (10 mg)|10 mg PRAX-114 once daily
62531625|NCT04969510|EXPERIMENTAL|PRAX-114 (20 mg)|20 mg PRAX-114 once daily
62531626|NCT04969510|EXPERIMENTAL|PRAX-114 (40 mg)|40 mg PRAX-114 once daily
62531627|NCT04969510|EXPERIMENTAL|PRAX-114 (60 mg)|60 mg PRAX-114 once daily
62531628|NCT04969510|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62531629|NCT05303337||Patients switching towards a long-aging injectable treatment|
62531630|NCT05303337||Patients maintaining oral ART 2-drug regimens|
62531631|NCT05303337||Patients maintaining oral ART 3 drug regimens|
62531632|NCT00839735||COPD|Chronic obstructive pulmonary disease
62531633|NCT00839735||Asthma|
62531634|NCT00839735||Healthy controls|
62531635|NCT01751932|EXPERIMENTAL|CGM Monitoring|Fitting of Dexcom G4 Platinum CGM monitor and Medtronic Enlite CGM monitor
62156800|NCT04945616|EXPERIMENTAL|group B ：Aspirin + Clopidogrel + placebo or SHR2285 (dose 2)|
62156801|NCT04945616|EXPERIMENTAL|group C： Aspirin + Ticagrelor + placebo or SHR2285|
62156802|NCT04756986|EXPERIMENTAL|malic acid group|patients will receive a topical spray containing 1% malic acid
62531636|NCT02808156|EXPERIMENTAL|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
62531637|NCT02808156|EXPERIMENTAL|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
62531638|NCT01915706|NO_INTERVENTION|Observation|Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
62531639|NCT01915706|EXPERIMENTAL|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3.
62531640|NCT03203564|ACTIVE_COMPARATOR|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
62531641|NCT03203564|PLACEBO_COMPARATOR|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
62531642|NCT05084703|EXPERIMENTAL|Patients operated for previous shoulder instability|Different functionnal test to be done
62531643|NCT05084703|ACTIVE_COMPARATOR|Healthy volunteer|Different functionnal test to be done
62531644|NCT04930419|OTHER|Videolaryngoscopy group|
62531645|NCT04930419|OTHER|Direct laryngoscopy group|
62531646|NCT01850186|EXPERIMENTAL|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
62531647|NCT01850186|PLACEBO_COMPARATOR|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
62531648|NCT04252898|EXPERIMENTAL|Intervention arm|In this arm (site n°1), participants will purchase their products in the restaurant first in a control phase and then in an interventional phase with the Nutri-Score affixed on food products.
62531649|NCT04252898|NO_INTERVENTION|Control arm|In this arm (site n°2), participants will purchase their products in the restaurant during the whole study without any label affixed on food products.
62156803|NCT04756986|NO_INTERVENTION|placebo group|patients will receive a topical placebo spray
62156804|NCT01090739|EXPERIMENTAL|TOPAS|TOPAS Treatment for Fecal Incontinence
62156805|NCT05192902|EXPERIMENTAL|Student-administered|
62156806|NCT05192902|PLACEBO_COMPARATOR|Dentist-administered|
62156807|NCT06454578|EXPERIMENTAL|Adebrelimab + Apatinib|
62156808|NCT00490113|EXPERIMENTAL|1|
62156809|NCT03636958|ACTIVE_COMPARATOR|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
62156810|NCT03636958|EXPERIMENTAL|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
62156811|NCT04880135|EXPERIMENTAL|Supervised stretching and strengthening exercise|Stretching and strengthening exercises will be performed under the supervision of Physical therapist for a period of one month
62531650|NCT05500196||Myotomy length|Extended myotomy \>2.5cm
62531651|NCT05500196||MYOTOMY LENGTH|Extended myotomy\>3
62531652|NCT04682769||Patients with medically stable coronary heart disease and Depressive Disorder|
62531653|NCT05969613|EXPERIMENTAL|Regional Block|Bupivacaine 0.25%
62531654|NCT05969613|ACTIVE_COMPARATOR|Wound infilteration|Bupivacaine 0.25%
62531655|NCT05969613|ACTIVE_COMPARATOR|caudal block|Bupivacaine 0.25%
62531656|NCT00627315||Surgery|Obese adult men and women who are undergoing bariatric surgery (gastric bypass or gastric banding).
62531657|NCT04796753||Youth basketball players who belonged to basketball developmental teams (U12, U14,U16,U17).|All participants completed the same ten-minute neuromuscular warm-up consisting of the following exercises: joint mobility exercises, dynamic stretching exercises, jumps, multidirectional displacements and changes of direction. Following, subjects were allowed three practice trials for each test. Consistent feedback was provided throughout to ensure proper technique. The performance of each test was recorded using two cameras (Iphone XS, Apple). To allow visible tracking of the different joints, participants were required to wear shorts with the hem at approximately mid-thigh. When scoring performance, each test was viewed in both planes (sagittal and frontal views).
62531658|NCT04457336|EXPERIMENTAL|Tildacerfont Group 1|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1
62531659|NCT04457336|EXPERIMENTAL|Tildacerfont Group 2|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2
62531660|NCT04457336|EXPERIMENTAL|Tildacerfont Group 3|Tildacerfont administered daily via oral tablet for 70 weeks at dose level 3
62156812|NCT04880135|EXPERIMENTAL|Home-based stretching and strengthening exercises|Stretching and strengthening exercises will be performed at home by individuals having musculoskeletal pain due to quarantine for a period of one month.
62156813|NCT01918943||PLIF and Aspen device patients|All patients will receive PLIF and Aspen device
62156814|NCT00913445|ACTIVE_COMPARATOR|surgery, absorbable stitches|wound healing after absorbable and nonabsorbable stitches are compared
62156815|NCT00913445|ACTIVE_COMPARATOR|surgery, nonabsorbable stitches|
62156816|NCT01883297|EXPERIMENTAL|Re-Stimulated Tumor-Infiltrating Lymphocytes and interleukin-2|Cyclophosphamide will be given prior to Re-Stimulated Tumor-Infiltrating Lymphocytes, and interleukin-2.
62156817|NCT02802332|ACTIVE_COMPARATOR|Footlength Card|Pregnant women will receive a card that enables them to measure the length of their baby's foot. The card contains a phone number to pre-recorded message that provides basic information/advice regarding care of preterm and/or low birth weight babies
62531661|NCT04457336|PLACEBO_COMPARATOR|Placebo|Placebo administered daily via oral tablet for 12 weeks.
62531662|NCT02916043||Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery with cardiopulmonary bypass
62156818|NCT02802332|NO_INTERVENTION|No Footlength Card|Women in this group do receive any footlength card.
62156819|NCT03277391|ACTIVE_COMPARATOR|Serratus anterior plane block|Deep serratus anterior plane block
62156820|NCT03277391|ACTIVE_COMPARATOR|patient-controlled analgesia|patient-controlled analgesia: pump containing morphine (1mg/ml) and dehydrobenzperidol (50 mcg/ml).
62156821|NCT04707885|EXPERIMENTAL|ECochG monitoring|For those randomized to the experimental group, the CI surgery will proceed in a standard fashion. However, the surgeon will utilize ECochG-guided monitoring by placing the external device coil and processor over the receiver/stimulator of the implanted components. Also, a sound applicator (i.e. speaker) will be placed in the external auditory canal by the surgeon. During electrode insertion the surgeon will utilize the ECochG feedback to adjust insertion if needed. That is, once the electrode has been inserted at least 75% (75% of the electrode contacts inside the cochlea), the surgeon may proceed to full insertion if indicated during ECochG feedback or may modify and/or cease electrode insertion if indicated by the ECochG feedback in attempts to preserve RH.
62531663|NCT01303757|EXPERIMENTAL|Low glycemic load diet|Low glycemic load diet
62531664|NCT01303757|ACTIVE_COMPARATOR|Low fat diet|Low fat diet
62531665|NCT00856219|ACTIVE_COMPARATOR|Enteral Continuous|Continuous tube feeding for 72 hours.
62531666|NCT00856219|ACTIVE_COMPARATOR|Enteral Intermittent|Intermittent tube feedings for 72 hours
62531667|NCT00856219|ACTIVE_COMPARATOR|Parenteral|Parenteral continuously for 72 hours
62531668|NCT04438226|EXPERIMENTAL|Posterolateral|Patients treated with a hemiarthroplasty using the posterolateral approach
62531669|NCT04438226|EXPERIMENTAL|Direct lateral|Patients treated with a hemiarthroplasty using the direct lateral approach
62531670|NCT06168786|EXPERIMENTAL|Cadonilimab plus Fruquintinib and SBRT|
62531671|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.~Blood bag (volume of blood: from 450 to 500 mL)."
62531672|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
62531673|NCT02472171|EXPERIMENTAL|Group 1|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
62531674|NCT02472171|EXPERIMENTAL|Group 2|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil"
62531675|NCT02472171|EXPERIMENTAL|Group 3|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
62531676|NCT02472171|EXPERIMENTAL|Group 4|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil"
62531677|NCT02472171|EXPERIMENTAL|Group 5|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil"
62531678|NCT02472171|EXPERIMENTAL|Group 6|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil"
62531679|NCT05656001|EXPERIMENTAL|real-time functional magnetic resonance imaging neurofeedback and real-time biofeedback|Three sessions of real-time functional magnetic resonance imaging neurofeedback (rt-fMRI-NF) or real-time biofeedback training where participants will receive direct visual feedback from the blood oxygenation level dependent (BOLD) imaging signaling from the salience network in rt-fMRI-NF or visual feeback from a physiological signal in the real-time biofeedback (active condition)
62531680|NCT05656001|SHAM_COMPARATOR|Sham feedback|Three session where participants will be given a yoked sham feedback as control condition.
62531681|NCT01339481||Subjects with RA initiating abatacept treatment regimen|Subjects naïve to both abatacept and belatacept
62531682|NCT04600778|PLACEBO_COMPARATOR|placebo|twice daily
62531683|NCT04600778|EXPERIMENTAL|Cavosonstat 5 mg|twice daily
62531684|NCT04600778|EXPERIMENTAL|Cavosonstat 10 mg|twice daily
62531685|NCT04600778|EXPERIMENTAL|Cavosonstat 25 mg|twice daily
62531686|NCT01622036||Cancer patients undergoing first medical oncology visit.|
62531687|NCT01220297|EXPERIMENTAL|Carmustine Etoposide Cyclophosphamide|Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
62531688|NCT01220297|EXPERIMENTAL|FTBI + Cyclophosphamide|FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
62531689|NCT01600690|NO_INTERVENTION|Continue statin regimen|Patients randomized to this arm will continue their usual statin regimen and dose, without any intervention.
62531690|NCT01600690|EXPERIMENTAL|Statin withdrawal|Patients randomized to this arm will stop statin treatment for 5 days.
62531691|NCT03282630|EXPERIMENTAL|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
62531692|NCT03282630|SHAM_COMPARATOR|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
62531693|NCT04384744||GH-POR|Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
62531694|NCT04384744||NGH-POR|Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
62531695|NCT04384744||NGH-NOR|Participants with normal ovarian reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
62531696|NCT01551225|ACTIVE_COMPARATOR|Escitalopram|17 or 18 Patients with IBS and panic disorder treated with Escitalopram.
62531697|NCT01551225|PLACEBO_COMPARATOR|Placebo tablets to Escitalopram|17 or 18 Patients with IBS and panic disorder treated with placebo.
62531698|NCT02317718||Normal vitamin D levels group|MORE THAN 20 NG/ML VITAMIN D LEVELS
62531699|NCT02317718||Deficient Vitamin D GROUP|LESS THAN 20 NG/ML LEVELS
62531700|NCT05646420|EXPERIMENTAL|ADPKD patients|"The study will include 90 patients with diagnosis of ADPKD based on renal ultrasonography findings or genetic test.~Specifically, five groups of patients will be identified according to KDIGO classification:~* 18 subjects with normal or high renal function: eGFR ≥90 ml/min/1.73m2 - CKD G1 stage~* 18 subjects with mildly decreased renal function: eGFR 89-60 ml/min/1.73m2 - CKD G2 stage~* 18 subjects with mildly to moderately decreased renal function: eGFR 59 to 45 ml/min/1.73m2 - CKD G3a stage~* 18 subjects with moderately to severely decreased renal function: eGFR 44 to 30 ml/min/1.73m2 - CKD G3b stage~* 18 subjects with severely decreased renal function: eGFR 29 to 15 ml/min/1.73m2 - CKD G4 stage."
62531701|NCT02430779|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
62531702|NCT02430779|NO_INTERVENTION|Control|The patients without treatment
62531703|NCT04974866|EXPERIMENTAL|study drug|EGFR TKIs
62531704|NCT00521027|OTHER|Treatment|Debridement with Versajet Hydrosurgery system
62531705|NCT00521027|OTHER|Control|Conventional surgical debridement techniques
62531706|NCT04000763|EXPERIMENTAL|Transcutaneous Nerve Stimulator(TENS)|Adult females who have difficulty emptying their bladder due to non-obstructive urinary retention or because of an under-active bladder will be given transcutaneous nerve stimulation (TENS) therapy.
62531707|NCT03525158|OTHER|Baseline phase ('A') and Intervention phase ('B')|"Baseline phase ('A'): Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Intervention phase ('B'): A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma)."
62531708|NCT03637725||Coronary Artery Disease|Suspected or known coronary artery disease
62531709|NCT02286596||heparin-induced extracorporeal LDL precipitation|Lipid apheresis treatment for 3 hours
62531710|NCT02286596||dextran sulfate adsorption|Lipid apheresis treatment for 3 hours
62156822|NCT04707885|NO_INTERVENTION|Control Group|For those randomized to the control group, they will receive their CI per the standard of care. That is, all procedures that take place during a routine CI surgery will be the same for those in the control group. As such, no ECochG monitoring will be performed. However, all study surgeons will be asked to adhere to soft surgical principles (non-traumatic cochlear opening, slow electrode insertions) to enhance HP outcomes even in the absence of intraoperative ECochG monitoring. Further, the standard of care for cochlear implantation is to perform full electrode insertions with all electrode contacts inside of the cochlea. Thus, for subjects in the control group, surgeons will be asked to perform full electrode insertions.
62531711|NCT02163486|ACTIVE_COMPARATOR|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
62531712|NCT02163486|EXPERIMENTAL|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For \> 90 kg no.5. I-GEL
62531713|NCT02575911|EXPERIMENTAL|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
62156823|NCT06506578||Irradiated patients|Patients irradiated for benign brain tumor, without chemotherapy
62531714|NCT04069871|ACTIVE_COMPARATOR|TENS|
62531715|NCT04069871|SHAM_COMPARATOR|Control|
62531716|NCT00968799|EXPERIMENTAL|HIPEC treatment|"Cytoreduction~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).~Perfusion is performed with the open or Coliseum technique for 90 min."
62156824|NCT03575494||female infertility|Women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months
62156825|NCT03575494||healthy|healthy patients who had minimum two normal pregnancies
62156826|NCT04255823|EXPERIMENTAL|Multi-faceted intervention|"A patient education material on PPI deprescribing will be send to patients with long-term treatment with PPI (\>300DDD/patient/year).~Their general practitioner (GP) will receive a dear doctor letter with an algorithm related to PPI deprescribing."
62156827|NCT04255823|EXPERIMENTAL|"Dear doctor letter of the GP"|"Only the GP will receive the dear doctor letter with the algorithm.~Their patients will not receive any patient education material."
62156828|NCT04255823|NO_INTERVENTION|Control|Neither the patients nor their GP will receive information.
62156829|NCT03451903||Mechanical thrombectomy group|Patients with acute stroke treated by mechanical thrombectomy.
62531717|NCT05385159|EXPERIMENTAL|ADSVF group|Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery
62531718|NCT05385159|PLACEBO_COMPARATOR|Placebo group|Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery
62531719|NCT01546376||HIV-cancer patients who recived RT|
62156830|NCT03451903||Combined procedure group|Patients with acute stroke treated by intravenous thrombolysis (with actilyse) and mechanical thrombectomy.
62156831|NCT00959634|EXPERIMENTAL|1|Dose 1 BID
62156832|NCT00959634|EXPERIMENTAL|2|Dose 2 BID
62156833|NCT00959634|PLACEBO_COMPARATOR|3|Placebo BID
62156834|NCT03338491|EXPERIMENTAL|Induction of Implemental Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer \& Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
62531720|NCT01980966|EXPERIMENTAL|MHAA4549A|
62531721|NCT01980966|PLACEBO_COMPARATOR|Placebo|
62531722|NCT01980966|ACTIVE_COMPARATOR|Tamiflu|
62531723|NCT03884452|EXPERIMENTAL|Atorvastatin 80 mg|80 mg atorvastatin taken orally, once daily for 12 weeks
62156835|NCT03338491|EXPERIMENTAL|Induction of Deliberative Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer \& Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
62531724|NCT03884452|EXPERIMENTAL|Ezetimibe + Atorvastatin 40 mg|10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
62156836|NCT03338491|NO_INTERVENTION|Control|Participants will revive no induction of any mindset.
62156837|NCT04669119|EXPERIMENTAL|Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins
62156838|NCT04669119|EXPERIMENTAL|Bromelain/Boswellia Serrata Casperome and placebo|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and placebo
62156839|NCT04669119|PLACEBO_COMPARATOR|Placebo|Patients treated post-operatively for 30 days with placebo
62531725|NCT03884452|EXPERIMENTAL|Ezetimibe + Atorvastatin 80 mg|10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
62531726|NCT03884452|EXPERIMENTAL|Simvastatin 80 mg|80 mg simvastatin taken orally, once daily for 12 weeks
62531727|NCT03884452|EXPERIMENTAL|Ezetimibe + Simvastatin 40 mg|10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
62531728|NCT03884452|EXPERIMENTAL|Ezetimibe + Simvastatin 80 mg|10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks
62531729|NCT02767895|EXPERIMENTAL|Prehabilitation|Participants will be referred to the Michigan Surgical \& Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health
62531730|NCT02767895|NO_INTERVENTION|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
62531731|NCT03134118|EXPERIMENTAL|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
61975834|NCT04226378||MDI cohort|Adults with T1D who continue MDI therapy.
62156840|NCT05931224|EXPERIMENTAL|Experimental Group|
62156841|NCT05931224|EXPERIMENTAL|Comparator Group|
62531732|NCT05515692|EXPERIMENTAL|Treatment (electron beam radiotherapy)|Patients undergo radiotherapy simulation on day -14 using either a clinical setup or CT simulation at the discretion of the treating radiation oncologist. Patients then undergo electron beam radiotherapy on day 0. Patients also undergo skin biopsies at baseline, day 28, and day 168 after radiotherapy, and high frequency ultrasound (HFUS) scans on days 28, 56, 84, 112, 140, and 168 after radiotherapy.
62156842|NCT02290353|EXPERIMENTAL|Adult (Stroke) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
62156843|NCT02290353|EXPERIMENTAL|Teenagers (Cerebral Palsy) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
62156844|NCT05866289||Includes 681 patients who were placed in prone position|
62156845|NCT05866289||Includes 388 patients who were placed in supine position|
62156846|NCT02995707|EXPERIMENTAL|thalidomide thalassemia|thalidomide:50mg/d p.o
62156847|NCT05894551||healthy participants|Volunteers aged 18-25 years, healthy individuals without any spinal or neurologic injury and any injury leading to ligament, muscle or bone defect in their lower extremities
62156848|NCT01557439|EXPERIMENTAL|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
62714139|NCT06563479|ACTIVE_COMPARATOR|Standard Chemoradiation Therapy|Patient will receive 70Gy in 2Gy per fraction regardless of hypoxia status. Concurrent chemotherapy will be given as per guidelines. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks) posttreatment standard FDG PET/CT scan will be performed and if there is persistent disease, standard neck dissection will be performed. Further standard of care will be given pending pathologic findings.
62156849|NCT01557439|ACTIVE_COMPARATOR|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
62156850|NCT04996186||Patients enrolled|Patients with Multiple sclerosis, with an age older than 18 years old and symptoms of fecal incontinence or chronic constipation
62156851|NCT05658900|EXPERIMENTAL|Enucleation with albumin PRF|
62156852|NCT05658900|ACTIVE_COMPARATOR|Enucleation without albumin PRF|
62531733|NCT04502823|NO_INTERVENTION|Control Group|"Clinical practice: Management by Doppler and CTG findings.~In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification:~* Fetuses with an EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with an EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks."
62531734|NCT04502823|EXPERIMENTAL|Intervention Group|Management based on sFlt-1/PlGF values
62531735|NCT03155386||Standard Angiomammography (SenoBright®)|
62531736|NCT03155386||Optimized angiomammography|
62531737|NCT05204836|EXPERIMENTAL|Zoledronic Acid Injection|Participants will receive 1 dose of 5 mg/100 mL intravenous zoledronic acid
62531738|NCT05204836|PLACEBO_COMPARATOR|Placebo|Participants will receive 1 dose 100 ml Saline.
62531739|NCT05172466|EXPERIMENTAL|BeCare application|individuals with relapsing-remitting MS (RRMS) on Natalizumab therapy
62531740|NCT01478165|PLACEBO_COMPARATOR|Tiva group (Group T)|
62531741|NCT01478165|ACTIVE_COMPARATOR|TIVA plus palonosetron group (Group T+P)|
62531742|NCT05912439|NO_INTERVENTION|Control|Measures for participants in control group are obtained at baseline and 42 days later. The control group receives no further contact, access to the mHealth application or information until study-end questionnaire measures are provided.
62531743|NCT05912439|ACTIVE_COMPARATOR|Treatment-As-Usual|For participants in Treatment-As-Usual (TAU) group measures are obtained at baseline and 42 days later. Participants receive an approximately 10 minutes long introduction regarding study specifications and the mHealth application. Active participation in TAU group is defined as downloading the Sidekick app and completing at least 3 health exercises within it. Time of exercise is defined as the timestamp on completion of exercise within any of the three types of exercise categories (physical activity, nutrition and mental health) of the app. Exercise frequency refers to how often a given exercise was completed by a participant in TAU group. Time of attrition is defined as the time stamp of last completing health exercise within the Sidekick throughout intervention period. Participants in TAU group use the application individually throughout trial period without any motivational support.
62714140|NCT04273945|ACTIVE_COMPARATOR|Macitentan 10 milligrams (mg) + Placebo|Run-in period:Participants who are either endothelin receptor antagonist (ERA)-naïve or who are receiving daily dose of macitentan or ambrisentan less (\<) 10 milligrams (mg), or daily dose of bosentan \<250 mg, will enter 4-week open-label run-in period with macitentan 10 mg prior to randomization. ERA-pre-treated participants will bypass run-in period and will be randomized to either macitentan 75 mg or macitentan 10 mg directly.Double-blind Treatment (DBT) Period:Participants will receive macitentan 10 mg orally up to End of DBT.To maintain blind, participants will receive macitentan 37.5 mg-matching placebo for 4 weeks and macitentan 75 mg-matching placebo thereafter up to DBT.Treatment Extension Period:After EDBT, participants will receive macitentan 37.5 mg once a day (qd) orally for 4 weeks, prior to receiving open-label macitentan 75 mg qd orally for 2 years. To maintain blind, participants will receive macitentan 75 mg-matching placebo during 4-week uptitration.
62156853|NCT06087159|EXPERIMENTAL|mWEL Intervention|Teachers or parents of children in participating schools who are randomly assigned to receive the mWEL intervention.
62156854|NCT06087159|NO_INTERVENTION|Control|Teachers or parents of children in participating schools who are randomly assigned to the control arm.
62156855|NCT05383586|EXPERIMENTAL|Creative Music Therapy|20 minutes of infant-directed singing in lullaby-style accompanied with the monochord for preterm infant and parent during kangaroo-care
62156856|NCT03556059|ACTIVE_COMPARATOR|RNYGB|The role of EOSS for the surgical intervention: Roux-en-Y gastric bypass for severe obesity
62156857|NCT03556059|ACTIVE_COMPARATOR|Sleeve|The role of EOSS for the surgical intervention: Sleeve Gastrectomy for severe obesity
62156858|NCT03556059|ACTIVE_COMPARATOR|MGB/OAGB|The role of EOSS for the surgical intervention: Mini/One anastomosis gastric bypass for severe obesity
62156859|NCT05270096||Relapsed leukemia|"T-ALL:~First relapse with high MRD after re-induction Newly diagnosed with high MRD after consolidation~B-ALL:~1st relapse high risk group, Second or higher relapse, post CAR-T or post HSCT~AML:~Second or higher relapse"
62156860|NCT03677271|OTHER|Physical Activity|
62531744|NCT05912439|EXPERIMENTAL|Intervention|For participants in intervention group measures are obtained at baseline and 42 days later. Participants receive an approximately 10 minutes long introduction regarding study specifications and the mHealth application. Active participation in intervention group is defined as downloading the Sidekick app and completing at least 3 health exercises within it. Time of exercise is defined as the timestamp on completion of exercise within any of the three types of exercise categories (physical activity, nutrition and mental health) of the app. Exercise frequency refers to how often a given exercise was completed by a participant in TAU group. Time of attrition is defined as the time stamp of last completing health exercise within the Sidekick throughout intervention period. Participants in intervention group receive weekly motivational support in form of individual and group feedback on usage, participation in friendly health task competitions and weekly altruistic rewards for usage.
62531745|NCT02845765||Patients with erectile dysfunction|Patients with erectile dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline and 6 months after therapy with Phosphodiesterase type 5 Inhibitor (PDE5I).
62531746|NCT02845765||Subject healthy volunteers|Patients without erectile dysfunction or ocular disease. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline
62156861|NCT04775537||OssiMend™ Bioactive Moldable|Patients undergoing Lumber Spine Fusion
62531747|NCT01203020|EXPERIMENTAL|Allogeneic hematopoietic progenitor cell transplant|Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
62531748|NCT05238818|EXPERIMENTAL|GT202 in Metastatic or Recurrent Gynecological Tumor patients|Autologous Tumor Infiltrating Lymphocyte Injection (GT202) will be infused at 1.0×10\^8 cells, 5.0×10\^8 cells and 2.0×10\^9 cells in metastatic or recurrent gynecological tumor patients.
62531749|NCT02878941|OTHER|Elbow Fracture|Patients with an intraarticular elbow fracture and/or dislocation. Synovial fluid from the injured elbow will be obtained during the subject's emergency department encounter by one of the Chief Residents or Attending surgeon as part of standard of care procedures for pain control-related injection and aspiration. Patients with an intraarticular elbow fracture and/or dislocation receive an intraarticular elbow injection with anesthetic (i.e. lidocaine or marcaine) to provide analgesia for elbow range of motion testing and orthopaedic reduction maneveuers as the current standard of care. The patients would be asked to consent for 2 elbow joint aspirations: 1.Aspiration of the injured elbow at time of surgical fracture fixation; 2.Aspiration of the uninjured elbow at time of surgical fracture fixation.
62531750|NCT04227353|EXPERIMENTAL|HEAL ABC|Participants allocated to the intervention will be encouraged to follow the HEAL ABC resources in order to make a healthy eating and active lifestyle change. This will be achieved by setting specific goal(s) and by making concrete plan(s) to implement changes in their everyday life. Interventions will be delivered in the form of written resources that will guide participants. Supportive phone calls using motivational interviewing techniques will be provided to participants every two weeks to encourage lifestyle changes.
62531751|NCT04227353|NO_INTERVENTION|HEALTH|Participants allocated to the control group will be referred to publicly available resources on healthy lifestyle recommendations but will not receive any additional support.
62531752|NCT01770392|ACTIVE_COMPARATOR|Test|multiple doses of Rifampicin + single dose of Nintedanib
62531753|NCT01770392|EXPERIMENTAL|Reference|single dose of Nintedanib
62531754|NCT01096030|EXPERIMENTAL|Regorafenib|
62531755|NCT00328068||Back pain / peripheral arthritis|Patients with chronic back pain of unknown origin and onset of back pain \<45 years of age or patients with peripheral arthritis / enthesitis / dactylitis of unknown origin and onset \<45 years of age
62531756|NCT00993837|EXPERIMENTAL|conversion|
62531757|NCT01857141|EXPERIMENTAL|dexmedetomidine|
62531758|NCT01857141|PLACEBO_COMPARATOR|normal saline|
62531759|NCT04401865|EXPERIMENTAL|Pulsed, Accelerated|5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
62531760|NCT04401865|ACTIVE_COMPARATOR|Conventional|4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
62531761|NCT05298319|EXPERIMENTAL|Group 1|10 L/min of oxygen flow
62531762|NCT05298319|EXPERIMENTAL|Group 2|20 L/min of oxygen flow
62531763|NCT05298319|EXPERIMENTAL|Group 3|30 L/min of oxygen flow
62531764|NCT05298319|EXPERIMENTAL|Group 4|40 L/min of oxygen flow
62156862|NCT04750772|EXPERIMENTAL|68Ga-DOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
62156863|NCT04750772|EXPERIMENTAL|18F-DOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
62156864|NCT02287571|ACTIVE_COMPARATOR|Skin traction|Prior to hip fracture surgery, affected limb was wrapped with a special elastic bandage and pulled from the sole of the foot with a weight of 5-10% of total body weight of the patient (min 2.3 kg, max 4.5 kg).
62531765|NCT05298319|EXPERIMENTAL|Group 5|50 L/min of oxygen flow
62531766|NCT05298319|EXPERIMENTAL|Group 6|60 L/min of oxygen flow
62531767|NCT04647721|EXPERIMENTAL|Left side Radiesse® / Right side Restylane®|
62531768|NCT04647721|EXPERIMENTAL|Left side Restylane® / Right side Radiesse®|
62531769|NCT05737342|EXPERIMENTAL|ANKASCIN 568-P Red yeast rice capsules|ANKASCIN 568-P is a fermented product from the red yeast rice fungus \<Monascus purpureus NTU 568\>. It does not contain Monacolin K, an ingredient that may harm the human body, and is rich in new active ingredients. Take 2 red yeast rice capsules (each containing 440mg ANKASCIN 568-P) every day, and the control group takes 2 placebo capsules (containing equal weight maltodextrin) every day, respectively, at the 0th, 4th , , 12, 24, Collect blood samples for biochemical analysis and record the general body position measurement, blood pressure, blood lipid, blood sugar and other related changes of the subjects, and monitor the liver, kidney, and thyroid functions.
62531770|NCT05737342|PLACEBO_COMPARATOR|Placebo Capsules|Maltodextrin was used as a placebo.
62531771|NCT01335386|EXPERIMENTAL|KLYX|
62531772|NCT01335386|ACTIVE_COMPARATOR|Glycerine|
62156865|NCT02287571|EXPERIMENTAL|Position splint|Prior to hip fracture surgery, position splint was applied to the affected limb in order to keep the extremity in the proper positon without any weight lifting.
62156866|NCT01451840|ACTIVE_COMPARATOR|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of intravenous remifentanil before emergence of a desflurane-based anesthesia
62156867|NCT01451840|EXPERIMENTAL|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
62156868|NCT02660086|EXPERIMENTAL|Personalized feedback|Emails and letters providing personalized nutrition feedback about food choices and health, social norms, and financial incentives for healthy food choices
62156869|NCT02660086|NO_INTERVENTION|Control|Monthly letters with general nutrition information
62156870|NCT03686176|EXPERIMENTAL|Virtual Reality Group (Study Group)|In this arm, patients will receive support from child life specialists plus may use virtual reality simulation goggles during a qualifying medical procedure.
62156871|NCT03686176|NO_INTERVENTION|Active Control Group|In this arm, patients will receive standard of care with child life specialists plus distraction of the child's choosing, during a qualifying medical procedure.
62156872|NCT03686176|NO_INTERVENTION|External Control (Reference Group)|No virtual reality and no child life specialists; no standardized or formal form of support.
62156873|NCT00955097|EXPERIMENTAL|Definity Contrast Dye|During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors
62156874|NCT05060874||single group|gripwise or jamar will be randomly assessed first
62156875|NCT04324606|EXPERIMENTAL|Group 1a|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19
62531773|NCT00643565|EXPERIMENTAL|Bevacizumab + Chemotherapy|Participants received continuous IV infusion of bevacizumab (7.5 mg/kg every 3 weeks) on Day 1 of 3-week cycles followed by induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy) as per institutional practice for a total of 9 cycles during induction treatment phase. As per the investigator decision, local therapy (radiotherapy and /or surgery) was expected to start after 4 weeks of the last bevacizumab administration in the induction phase and resumed to bevacizumab in the maintenance phase at least 4 weeks after the last dose of local therapy. During maintenance treatment phase, participants received IV infusion of bevacizumab (5 mg/kg every 2 weeks) followed by vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Days 1 and 15 of 4-week cycles for a total of 12 cycles.
62531774|NCT00643565|ACTIVE_COMPARATOR|Chemotherapy|Participants received 9 cycles of induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy administered every 3 weeks as per institutional practice. As per the investigator evaluation, participants had option to undergo local therapy (radiotherapy and /or surgery) during last 3 cycles of IVA (i.e. from Cycle 6 to Cycle 9). During maintenance treatment phase, participants received vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Day 1 and 15 of 4-week cycles for a total of 12 cycles.
62156876|NCT04324606|ACTIVE_COMPARATOR|Group 1b|Volunteers will receive a standard single dose of MenACWY vaccine
62156877|NCT04324606|EXPERIMENTAL|Group 1c|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 5x10\^10vp ChAdOx1 nCoV-19 9 months later
62156878|NCT04324606|EXPERIMENTAL|Group 1d|Volunteers will receive a standard single dose of MenACWY vaccine. 9 moths later they will receive two doses of 5x10\^10vp ChAdOx1 nCoV-19 4-12 weeks apart
62156879|NCT04324606|EXPERIMENTAL|Group 2a|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19
62156880|NCT04324606|ACTIVE_COMPARATOR|Group 2b|Volunteers will receive a standard single dose of MenACWY vaccine
62156881|NCT04324606|EXPERIMENTAL|Group 2c|Volunteers will receive two doses of 5x10\^10vp ChAdOx1 nCoV-19 at week 0 and week 8
62156882|NCT04324606|EXPERIMENTAL|Group 2d|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 2.5x10\^10vp ChAdOx1 nCoV-19 at week 8
62156883|NCT04324606|ACTIVE_COMPARATOR|Group 2e|Volunteers will receive two standard single doses of MenACWY vaccine at week 0 and week 8
62156884|NCT04324606|EXPERIMENTAL|Group 2f|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
62156885|NCT04324606|ACTIVE_COMPARATOR|Group 2g|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
62156886|NCT04324606|EXPERIMENTAL|Group 3a|Volunteers will receive one dose of 5x10\^10vp ChAdOx1 nCoV-19 at week 0 and one dose of 5x10\^10vp ChAdOx1 nCoV-19 at week 4
62156887|NCT04324606|EXPERIMENTAL|Group 3b|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 at week 0, a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
62156888|NCT04324606|EXPERIMENTAL|Group 4a|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19
62156889|NCT04324606|ACTIVE_COMPARATOR|Group 4b|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 delivered intramuscularly
62531775|NCT02894437||patients|SCI recruited Physical Medicine and Nantes University Hospital Rehabilitation. Recruitment will try to balance the number of people in four sub-groups followed and complicated (= history of pelvic pressure sores), not followed and uncomplicated, monitored and uncomplicated, not followed and complicated
62531776|NCT02894437||health professionals|those involved in the chain of care Spinal Cord concerning various professions (including medical, paramedical and administrative) decision and variable influence on the organization of the die care of spinal injuries.
62531777|NCT02402114|EXPERIMENTAL|Intervention|Subject randomized to this group receives 1 oral dose of Hydrocortisone 120 mg
62531778|NCT02402114|PLACEBO_COMPARATOR|Placebo|Subject randomized to this group will receive an oral sugar/placebo pill that looks similar to the Hydrocortisone pill.
62531779|NCT04809883||observational study of gastric and pyloric motor function measured with Endoflip|observational study of gastric and pyloric motor function measured with Endoflip during fasting and postprandial periods There is NO intervention
61975835|NCT01761110|NO_INTERVENTION|Pre-intervention|Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
62156890|NCT04324606|EXPERIMENTAL|Group 4c|Volunteers will receive a single dose of 5x10\^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
62156891|NCT04324606|ACTIVE_COMPARATOR|Group 4d|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
62156892|NCT04324606|EXPERIMENTAL|Group 5a|Volunteers will receive two doses of 5x10\^10vp ChAdOx1 nCoV-19 ≤ 16 weeks apart, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
62156893|NCT04324606|EXPERIMENTAL|Group 5b|Volunteers will receive two standard single doses of MenACWY vaccine ≤ 16 weeks apart, a dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months then a second dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) 4-12 weeks later
62156894|NCT05316324|EXPERIMENTAL|Prepectoral Breast Reconstruction with ADM|
62156895|NCT05316324|EXPERIMENTAL|Prepectoral Breast Reconstruction without ADM|
62156896|NCT01702103|EXPERIMENTAL|Mometasone|Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
62156897|NCT01702103|ACTIVE_COMPARATOR|Nasonex®|Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
62156898|NCT01870895|EXPERIMENTAL|YM060 group|
62156899|NCT01870895|PLACEBO_COMPARATOR|Placebo group|
62156900|NCT05174026|EXPERIMENTAL|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minute, and then undergo PET-MRI over 1 hour, 30 days before radiation therapy, and 3 and 6 months after radiation therapy.
62156901|NCT03788278||PTSD patients|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
62156902|NCT03788278||Non PTSD participants|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
62156903|NCT00700557|ACTIVE_COMPARATOR|Probiotics - Lactobacillus casei and Bifidobacterium breve|"Yakult LB®~1 sachet (1g) of Lactobacillus casei and Bifidobacterium breve - 6 x 108 UFC/g on a juice three times a day"
62156904|NCT00700557|PLACEBO_COMPARATOR|maize starch|725mg on juice three times a day
62531780|NCT04859621|EXPERIMENTAL|Vitamin D3 4000 IU|4000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
62531781|NCT04859621|EXPERIMENTAL|Vitamin D3 2000 IU|2000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
62531782|NCT04859621|PLACEBO_COMPARATOR|Placebo|Placebo Oral Tablet plus standard antibiotic therapy
62531783|NCT01133886|EXPERIMENTAL|Decitabine|
62531784|NCT01517230|ACTIVE_COMPARATOR|intervention|seven clusters where radio media campaign will be broadcast.
62531785|NCT01517230|NO_INTERVENTION|control|Seven clusters where radio media campaign won't be broadcast.
62531786|NCT02490267||1|children with primary or secondary glaucoma
62531787|NCT02490267||2|children w/ cataract or previously treated for cataract
62156905|NCT04552184|ACTIVE_COMPARATOR|GPOEM|
62156906|NCT04552184|SHAM_COMPARATOR|SHAM|
62156907|NCT01150305||1|Patient presenting familial dominant non syndromic hearing loss starting between 4 and 40 years old, over 2 generations
62156908|NCT01150305||2|Healthy volunteer from the same families
62156909|NCT04421534|EXPERIMENTAL|Standard of care in addition to 400 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 400 mg oral lactoferrin daily \[two sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals\]
62156910|NCT04421534|EXPERIMENTAL|Standard of care in addition to 600 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 600 mg oral lactoferrin daily \[three sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals\]
62531788|NCT02490267||3|children w/ microphthalmia, anophthalmia or coloboma
62531789|NCT02490267||control group|age matched children without eye and vision problems.
62531790|NCT01682616|EXPERIMENTAL|Arm 1|Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
62531791|NCT04054960|EXPERIMENTAL|Real tPCS|Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.
62531792|NCT04054960|SHAM_COMPARATOR|Sham tPCS|Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
62531793|NCT04054960|ACTIVE_COMPARATOR|Levodopa|Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).
62531794|NCT02177656|NO_INTERVENTION|Usual care|Patients in the usual care group received six patient educational materials in the hospital, a baseline and follow-up phone call by blinded research assistants.
62156911|NCT04421534|ACTIVE_COMPARATOR|Standard of care only|Standard of care treatment; as per MOHP protocol
62156912|NCT06207747|EXPERIMENTAL|This study will prospectively collect data from metastatic or stage III.D unresectable melanoma pts|"Timing of PET/CT scans:~* Baseline PET/CT less than 4 weeks before first ICI infusion~* Follow-up: 4 weeks (+/- 5 days) after first infusion, 16 weeks (+/- 7 days) after first infusion, then after every 16 weeks (+/- 7 days) or before in case of PD suspicion"
62156913|NCT02635698|EXPERIMENTAL|Intervention group, Optifast|OPTIFAST, medically supervised weight-management program
62156914|NCT02635698|ACTIVE_COMPARATOR|Control group, Low-energy, low-fat|Food-based program, current standard of care for weight management
62531795|NCT02177656|EXPERIMENTAL|MI tailored intervention|The MI intervention was provided by a heart failure specialist nurse. The nurse conducted a home-based motivational interviewing intervention followed up by three phone calls over the course of 90 days. The intervention began with a conversation about the participant's self-identified goals. In the home intervention, the nurse focused on self-care areas that the participant identified as high priority. During the home-based intervention, the participant also set specific goals, which the nurse followed up with and reinforced over the follow-up phone calls.
62156915|NCT00406276|EXPERIMENTAL|RAD001+Docetaxel|RAD001 in combination with Docetaxel.
62531796|NCT01831453|PLACEBO_COMPARATOR|isopropylmyristate oil|placebo Soft gelatinous capsules filled with isopropylmyristate oil
62531797|NCT01831453|ACTIVE_COMPARATOR|experimental|omega-3 1 gram three times daily for 6 months
62531798|NCT05328336|EXPERIMENTAL|Experimental: Tislelizumab and Nab Paclitaxel|Experimental: Tislelizumab and Nab Paclitaxel Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
62531799|NCT00818688||1|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
62531800|NCT00818688||2|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
62531801|NCT03806374|ACTIVE_COMPARATOR|Fentanyl|Administered propofol and fentanyl for induction.
62531802|NCT03806374|ACTIVE_COMPARATOR|Ketamine and lidocaine|Administered propofol, ketamine and lidocaine for induction.
62531803|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
62531804|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
62531805|NCT03358745|EXPERIMENTAL|Standard meal, bread/butter as starter|"Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal and consists of bread and butter, soup, salad and cheese. The participants eat the bread and butter portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).~Blood samples are taken before the lunch and every 30 min postprandial for 4 h."
62531806|NCT03358745|EXPERIMENTAL|Standard meal with soup as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the soup portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
62531807|NCT03358745|EXPERIMENTAL|Standard meal with cheese as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the cheese portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
62531808|NCT03358745|EXPERIMENTAL|Standard meal with salad as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the salad portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
61975836|NCT01761110|EXPERIMENTAL|Post-intervention|Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
62156916|NCT05256836|EXPERIMENTAL|tablet group|A total of 36 sessions per week for 12 weeks of cognitive training program using a tablet computer are performed.
62156917|NCT05256836|NO_INTERVENTION|control group|Subjects assigned to the control group did not receive any separate cognitive training for 12 weeks.
62156918|NCT03657641|EXPERIMENTAL|Treatment (pembrolizumab, regorafenib)|Participants receive pembrolizumab IV over 30 minutes on day 1 and regorafenib PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62156919|NCT06606769|EXPERIMENTAL|exercise|supervised exercise training; twice a week for 12 months
62156920|NCT02313077|EXPERIMENTAL|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
62531809|NCT01428050|EXPERIMENTAL|3% saline|Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration
62531810|NCT01428050|ACTIVE_COMPARATOR|Lactated Ringers|15cc/kg/hr of lactated ringers solution intraoperatively
62531811|NCT02509299|EXPERIMENTAL|Experimental group 1|patients will be involved in the Physiotherapy program 1. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises added to standard treatment.
62531812|NCT02509299|EXPERIMENTAL|Experimental group 2|patients will be involved in the physiotherapy program 2. The program was a combined intervention including the Control Group treatment plus neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises.
62531813|NCT02509299|OTHER|Control group|patients will receive standard medical treatment without physiotherapy intervention.
62531814|NCT01340768|EXPERIMENTAL|Sitagliptin|Sitagliptin 100mg taken orally once daily with or without metformin
62531815|NCT01340768|ACTIVE_COMPARATOR|Sulfonylurea Therapy|Usual sulfonylurea therapy with or without metformin
62531816|NCT01316302|EXPERIMENTAL|Pristiq|Flexible dose, 50-100mg QD
62531817|NCT01316302|PLACEBO_COMPARATOR|Placebo|Matching placebo
62531818|NCT02217787|OTHER|fasted condition|
62531819|NCT02217787|OTHER|fed condition|
62531820|NCT01541813||iron overloads except C282Y homozygosity|Patients with an iron overloads except C282Y homozygosity
62156921|NCT02313077|EXPERIMENTAL|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
62156922|NCT02313077|EXPERIMENTAL|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
62531821|NCT04097249||Healthy subjects|Participants free from any pain specific to the upper limb, chronic pain or other disease.
62531822|NCT04099550|ACTIVE_COMPARATOR|SMBG with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The control group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
62531823|NCT04099550|EXPERIMENTAL|RT-CGM with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.
62531824|NCT06188013||proliferative diabetic retinopathy|Age ≥18 years old；patients diagnosed with PDR by FFA
62531825|NCT06188013||non-proliferative diabetic retinopathy|Age ≥18 years old；patients diagnosed with NPDR by FFA
62531826|NCT06188013||diabetes mellitus without retinopathy|Age ≥18 years old；patients diagnosed with Diabetes Mellitus；patients weren't diagnosed with diabetic retinopathy
62531827|NCT06188013||health control|Age ≥18 years old；patients weren't diagnosed with Diabetes Mellitus
62531828|NCT05912283|EXPERIMENTAL|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
62531829|NCT05912283|EXPERIMENTAL|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
62531830|NCT05912283|ACTIVE_COMPARATOR|Control Latex Condom|Commercial natural rubber latex condom
62531831|NCT05521139||CRKP-PLA|Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-resistant Klebsiella pneumoniae.
62531832|NCT05521139||CSKP-PLA|Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-sensitive Klebsiella pneumoniae.
62156923|NCT02313077|EXPERIMENTAL|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
62156924|NCT02313077|EXPERIMENTAL|Group 5|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 15).
62531833|NCT04096508|EXPERIMENTAL|Group A|Patients sit comfortably in a chair for 20 min listening classic music before the procedure.
62156925|NCT05756101|EXPERIMENTAL|Control group|Sponge restraint belt, restraint method: adjust the fixed wrist strap according to the diameter of the patient's hand (foot) wrist, and then circle the fixed strap around the wrist strap, one end is pierced through the strap hole without knots, and the two ends of the fixed strap are fixed on both sides of the bed as needed.
62156926|NCT05756101|EXPERIMENTAL|Experimental group|A new type of restraint device, which is an adjustable protective restraint device (patent number ZL202020155913.1), including upper fixation bracket I, upper fixation bracket II, lower fixation bracket I, lower fixation bracket II and gloves; The plurality of fixed brackets are provided with breathable holes and breathable cotton is placed to increase air permeability and comfort. Place the patient's elbow joint on top of the lower fixation bracket I and II, and then install and connect the upper fixation bracket I and the upper fixation bracket 2 through the upper and lower tightening belts, and adjust their tightness; The upper and lower fixed bracket connections are adjustment module 1 and adjustment module 2, forming a detachable and rotating connection within a certain angle range to adjust the angle of elbow joint movement of the patient; The patient's hand is made by wearing gloves with a grip ball on the palm surface.
62531834|NCT04096508|EXPERIMENTAL|Group B|Patients sit comfortably in a chair for 20 min listening popular music before the procedure.
62531835|NCT04096508|NO_INTERVENTION|Control group|Patients sit comfortably in a chair for 20 min without music listening before the procedure.
62531836|NCT04197427|EXPERIMENTAL|Experimental Oral Rinse|"In this arm the test article,oral rinse, a proprietary formulation of agents including xylitol, Caffeine, Essential oils, Monk fruit extract, which can reduce the plaque formation Subjects rinse twice a day with 10 mL of the oral rinse for 2 minutes for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
62156927|NCT00538499|OTHER|Fentanyl citrate|
62156928|NCT00538499|EXPERIMENTAL|bupivcaine hydrochloride|
62156929|NCT00538499|OTHER|videothoracoscopy|
62156930|NCT00741923|EXPERIMENTAL|Bean group|A group consuming 5 cups/week of navy beans for a month
62156931|NCT06501508||Stratafix|All patients in which Stratafix symmetric was used for the primary closure of the abdominal wall incision
62156932|NCT06501508||Control|All patients in which other, conventional suture types were used for primary closure of the abdominal wall incision
62531837|NCT04197427|PLACEBO_COMPARATOR|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
62531838|NCT01551108|ACTIVE_COMPARATOR|Mobile phone intervention: minimal|Intervention: limited behavioral strategies
62531839|NCT01551108|EXPERIMENTAL|Mobile phone intervention: intensive|Intervention: advanced behavioral strategies
62531840|NCT05975138||trans-gingival short implants|trans-gingival implant insertion in the posterior atrophic maxilla
62531841|NCT05975138||subcrestal short implants|subcrestal implant insertion in the posterior atrophic maxilla
62531842|NCT01248689|ACTIVE_COMPARATOR|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
62531843|NCT01248689|ACTIVE_COMPARATOR|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
62531844|NCT01248689|ACTIVE_COMPARATOR|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
62531845|NCT01195103|EXPERIMENTAL|10 mg/kg Lusedra|10 mg/kg Lusedra initial bolus.
62531846|NCT01195103|ACTIVE_COMPARATOR|6.5 mg/kg Lusedra|6.5 mg/kg Lusedra initial bolus.
62531847|NCT01195103|ACTIVE_COMPARATOR|Placebo + Midazolam|Placebo initial bolus with dose of midazolam based on patient's weight
62531848|NCT04481321||Patient with benign gynaecologic disease|Patients consulting for endometriosis, pelvic pain, abnormal uterine bleeding and/or infertility, or for a pelvic mass,
62531849|NCT02903719|OTHER|Group A|"1. st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml~2. nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml"
62531850|NCT02903719|OTHER|Group B|"1. st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml~2. nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml"
62531851|NCT00988065|EXPERIMENTAL|Sugammadex 4 mg/kg|Participants were to receive one dose of sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
62531852|NCT00988065|EXPERIMENTAL|Sugammadex 16 mg/kg|Participants were to receive one dose of sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
62156933|NCT00731913||1|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
62156934|NCT00731913||2|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
62156935|NCT02558803|NO_INTERVENTION|Usual Care|The clinical team will be left to identify the need for a follow-up HPV vaccine through existing mechanisms
62736750|NCT03221465|EXPERIMENTAL|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
62156936|NCT02558803|EXPERIMENTAL|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
62156937|NCT05809466|EXPERIMENTAL|Vegan group|
62156938|NCT05809466|EXPERIMENTAL|Vegan group with resistance exercise|
62156939|NCT05809466|ACTIVE_COMPARATOR|Omnivorous group|
62531853|NCT00988065|PLACEBO_COMPARATOR|Placebo|Participants were to receive one dose of placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
62531854|NCT02255825|ACTIVE_COMPARATOR|Control Group|Amniocentesis will be performed, Whole Genome Sequencing will not be performed, and psychosocial assessment will be performed.
62531855|NCT02255825|EXPERIMENTAL|Intervention Group|Amniocentesis will be performed, Whole Genome Sequencing will be performed if the karyotype is normal, and psychosocial assessment will be performed.
62531856|NCT04414462|EXPERIMENTAL|Group I|Group I will receive following exergaming training: heading, tightrope tension,snowboard slalom and table tilt game
62531857|NCT04414462|ACTIVE_COMPARATOR|Group II|Group II will receive Habituation,wobble board exercises,double leg,single leg and tandem stance training.
62156940|NCT02316171|EXPERIMENTAL|CVA21|CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
62156941|NCT02316171|EXPERIMENTAL|CVA21/Mitomycin C|Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
62156942|NCT04188457||Stroke - usual follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with regular follow-up
62531858|NCT03050710|OTHER|Princess® VOLUME Lidocaine|
62531859|NCT02844400||Adjuvant and Curative Chemotherapy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with adjuvant or curative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
62531860|NCT02844400||Palliative Chemoteraphy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with palliative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
62531861|NCT02733926|NO_INTERVENTION|City kindergarten|Children living in a normal city kindergarten that hardly has vegetation in backyards
62531862|NCT02733926|EXPERIMENTAL|adding of vegetation into the backyards.|"Children living in a normal city kindergarten that has plenty of vegetation in backyards.~Intervention: adding of vegetation into the backyards."
62156943|NCT04188457||Stroke - intensive follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with intensive follow-up
62156944|NCT04188457||myocardial infarction - usual follow-up|Patient who has had a first or recurrent myocardial infarction with usual follow-up
62156945|NCT04188457||myocardial infarction -intensive follow-up|Patient who has had a first or recurrent myocardial infarction with intensive follow-up
62156946|NCT04021277|EXPERIMENTAL|Part 1a: ACT with chemotherapy in metastatic solid tumours|20 uL/kg or 40 uL/kg PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and ultrasound insonation over the targeted liver metastasis in patients with solid tumours
62156947|NCT04021277|EXPERIMENTAL|Part 1b ACT with chemotherapy in metastatic CRC|20 uL/kg or 40 uL/kg PS101 administered together with standard of care chemotherapy (FOLFIRI) and ultrasound insonation over the targeted liver metastasis in patients with metastatic colorectal cancer
62156948|NCT00692757|EXPERIMENTAL|A|Hypochlorous acid
62156949|NCT00692757|ACTIVE_COMPARATOR|B|Iodopovidone
61975837|NCT01521455|EXPERIMENTAL|HCP0910|Fluticasone /salmeterol 250/50 combination capsule
62156950|NCT01699178|EXPERIMENTAL|Oral testosterone undecanoate|Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
62156951|NCT01699178|ACTIVE_COMPARATOR|Transdermal testosterone gel (AndroGel)|Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
62156952|NCT04532814|OTHER|Lean|Control
62531863|NCT02733926|NO_INTERVENTION|Nature kindergarten|Children living in a city kindergarten where children go regularly into a natural forest
62531864|NCT06162130|EXPERIMENTAL|Other|female athletes
62531865|NCT01727466|EXPERIMENTAL|Facing Your Fears|FYF is a group CBT approach to managing anxiety symptoms in children with high-functioning autism spectrum disorders and anxiety.
62531866|NCT04781192|EXPERIMENTAL|Dose Finding Regorafenib|We will use a 3 + 3 design with two dose levels of 80 mg and 120 mg to discover the Maximum Tolerated Dose (MTD) for regorafenib
62531867|NCT01691924|PLACEBO_COMPARATOR|Placebo|Placebo capsules: solid microcrystalline cellulose c.s.p
62531868|NCT01691924|EXPERIMENTAL|PBF-509|The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
62531869|NCT02041156|EXPERIMENTAL|aerobic with resistance training|Regular aerobic activity combined with 3 sessions/week of resistance training totalling 150 minutes per week of physical activity
62156953|NCT04532814|EXPERIMENTAL|Obese|
62531870|NCT02041156|ACTIVE_COMPARATOR|aerobic with balance training|Regular aerobic activity combined with 3 sessions/week of balance training totalling 150 minutes per week of physical activity
62531871|NCT01103466|ACTIVE_COMPARATOR|New ostomy appliance (Atlas)|Atlas= new base plate. Due to company confidentiality the product is just called Atlas and this is not short for any other names
62531872|NCT01103466|ACTIVE_COMPARATOR|SenSura|Commercially available ostomy appliance
62156954|NCT01940913|ACTIVE_COMPARATOR|Probiotics|
62156955|NCT01940913|PLACEBO_COMPARATOR|Placebo|
62531873|NCT01103466|ACTIVE_COMPARATOR|Conform 2|Commercially available ostomy appliance
62156956|NCT00992849|EXPERIMENTAL|Bevacizumab|Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.
62156957|NCT06452914|EXPERIMENTAL|Semiconductor Embedded Therapeutic Socks|Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
62156958|NCT06452914|PLACEBO_COMPARATOR|Placebo Socks|Treatment of Distal Symmetric Polyneuropathy Using Placebo Socks as a Comparator to Semiconductor Embedded Therapeutic Socks
62531874|NCT00686075|EXPERIMENTAL|MEDI-534, Cohort 1|Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
62531875|NCT00686075|PLACEBO_COMPARATOR|Placebo, Cohort 1|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
62531876|NCT00686075|EXPERIMENTAL|MEDI-534, Cohort 2|Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
62531877|NCT00686075|PLACEBO_COMPARATOR|Placebo, Cohort 2|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
62531878|NCT00686075|EXPERIMENTAL|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
62531879|NCT00686075|PLACEBO_COMPARATOR|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
62531880|NCT00686075|EXPERIMENTAL|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
62531881|NCT00686075|PLACEBO_COMPARATOR|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
62531882|NCT00686075|EXPERIMENTAL|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
62531883|NCT00686075|PLACEBO_COMPARATOR|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
62531884|NCT02539862|EXPERIMENTAL|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
62531885|NCT02539862|OTHER|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
62531886|NCT03775720|EXPERIMENTAL|Low genetic risk group|Dietary advice to maintain salt intake to 6g/day
62531887|NCT03775720|EXPERIMENTAL|High genetic risk group|Dietary advice to reduce salt intake to 4g/day
62531888|NCT04317183|EXPERIMENTAL|Chamomile topical gel|"Topical oral chamomile gel three times daily for three weeks.~Topical oral chamomile gel is prepared with the aid of Pharmacognosy and pharmaceutics departments, faculty of pharmacy, Alexandria University and mucoadhesive hydrogels (Carbopol® 970)."
62531889|NCT04317183|ACTIVE_COMPARATOR|conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel BBC oral spray Oracure gel~Dose: Three times a day for three weeks"
62531890|NCT04317183|EXPERIMENTAL|combination therapy|"Topical oral chamomile gel three times daily for three weeks in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel BBC oral spray Oracure gel~Symptomatic treatment dose: Three times a day for three weeks"
62531891|NCT03809988|EXPERIMENTAL|Interventional Arm (Arm A)|Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
62531892|NCT03809988|ACTIVE_COMPARATOR|Control Arm (Arm B)|Patients will receive endocrine therapy (letrozole or fulvestrant).
62736751|NCT01385618||high responder|females with \>15 follicles or E2\>3000 after treatment with gonadotropins
62531893|NCT02936011|OTHER|CTO PCI with Absorb BVS|Single arm observational after successful CTO PCI with Absorb BVS after antegrade or retrograde dissection and re-entry
62531894|NCT06486961|EXPERIMENTAL|BeatMove Experimental Group|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
62156959|NCT05329402|EXPERIMENTAL|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Disposable Powered Articulating Endoscopic Linear Cutter Stapler
62156960|NCT05329402|ACTIVE_COMPARATOR|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|ECHELON Flex Powered Articulating Endoscopic Linear Cutters
62156961|NCT02301871|ACTIVE_COMPARATOR|Conventional group|The treatment was given for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
62531895|NCT06486961|ACTIVE_COMPARATOR|Control Group with Music at Random Tempo|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
62531896|NCT06486961|ACTIVE_COMPARATOR|Control Group without Music|The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
62156962|NCT02301871|EXPERIMENTAL|DNF Group|"DNF training along with conventional treatment. In this programme, emphasis was placed on first attaining the correct craniocervical flexion action, with minimal activity of the superficial cervical flexor muscles. The craniocervical flexion action involves a specific craniocervical movement (nodding - yes movement) of head such that it remains in contact with the supporting surface. Once the correct action had been achieved, participants were instructed in the use of the sphygmomanometer to guide the training of the CCF muscle contraction at the various incremental levels of pressure (22 to 30 mmHg, progressively inner range positions)."
62156963|NCT02301871|EXPERIMENTAL|MET Group|MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
62156964|NCT02181881|ACTIVE_COMPARATOR|DuoPACT|A 6-session HIV medication adherence support program for couples.
62531897|NCT05433363||normal control|normal, cognitive test normal, PET(-)
62531898|NCT05433363||cognitive disorder due to AD|PET Aβ（+），MCI-AD and AD dementia
62156965|NCT02181881|ACTIVE_COMPARATOR|Life Steps|A 3-session HIV medication adherence support program for individuals.
62156966|NCT02181881|NO_INTERVENTION|Treatment as usual (TAU)|HIV positive individuals will continue to follow their current HIV treatment plan.
62156967|NCT06452888|SHAM_COMPARATOR|No intervention|The control group indicated that the physicians will not be provided with the information of multifaceted improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care.
62531899|NCT05433363||cognitive disorder NOT due to AD|PET Aβ（-），MCI or dementia not due to AD
62531900|NCT05291065|EXPERIMENTAL|Fasted exercise|Fasted prior to exercise
62531901|NCT05291065|EXPERIMENTAL|High protein breakfast exercise|High protein breakfast consumption prior to exercise
62714141|NCT04273945|EXPERIMENTAL|Macitentan 75 mg + Placebo|Run-in period:Participants who are either ERA-naive or who are receiving a daily dose of macitentan or ambrisentan \<10 mg, or a daily dose of bosentan \<250 mg, will enter 4-week open-label run-in period with macitentan 10 mg prior to randomization. ERA-pre-treated patients will bypass the run-in period and will be randomized to either macitentan 75 mg or macitentan 10 mg directly.DBT Period: participants will receive macitentan 37.5 mg orally for 4 weeks and macitentan 75 mg thereafter up to End of DBT. To maintain the blind, participants will receive macitentan 10 mg-matching placebo up to End of DBT.Treatment Extension Period: After EDBT, participants will continue to receive macitentan 75 mg orally for 2 years. To maintain the blind, participants will receive macitentan 37.5 mg-matching placebo during the 4-week up-titration period.
62156968|NCT06452888|EXPERIMENTAL|Intervention Group|Patients in the intervention group will receive the organizational management based clinical decision support system, including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
62156969|NCT02167191|EXPERIMENTAL|HIT|High intensity interval training sessions on an cycle ergometer
62156970|NCT03650972|NO_INTERVENTION|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
62531902|NCT05291065|EXPERIMENTAL|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
62714142|NCT06268470|ACTIVE_COMPARATOR|Desloratadine|Oral desloratadine 20 mg/day (antihistamine) for 4 weeks
61975838|NCT01521455|ACTIVE_COMPARATOR|Seretide Diskus|Seretide 250 Diskus
61975839|NCT05838885|EXPERIMENTAL|YPEG-GH low dose group|
62531903|NCT05453773|EXPERIMENTAL|Tobacco flavor preparation; High Sweetness, High Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
62531904|NCT05453773|EXPERIMENTAL|Tobacco flavor preparation; High Sweetness, Medium Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
62156971|NCT03650972|ACTIVE_COMPARATOR|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
62156972|NCT04769219|EXPERIMENTAL|secondary prevention training|Secondary prevention training will be given to 43 randomly selected patients between the fourth and sixth hours after AMI (in accordance with the patient's request). Secondary protection training will be carried out in two parts. First of all, the anatomical structure and functions of the heart, the definition of AMI, its causes, symptoms and risk factors will be explained, and then the issues to be considered after AMI will be explained. The content of the training will also be given to the participants in a written booklet.
62156973|NCT04769219|NO_INTERVENTION|nursing care|43 randomly selected patients will form the control group and this group will be provided with routine care and follow-up in the clinic. No intervention will be made.
62156974|NCT05058547|EXPERIMENTAL|SWEPPE|Participants will receive the smartphone application SWEPPE.
62156975|NCT05058547|NO_INTERVENTION|Control|Participants randomized to the control group will not receive any active intervention for return to work after completing an Interdisciplinary Pain Rehabilitation Program .
62156976|NCT03204318|EXPERIMENTAL|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
62156977|NCT03204318|EXPERIMENTAL|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
62156978|NCT03204318|PLACEBO_COMPARATOR|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
62156979|NCT02423707|ACTIVE_COMPARATOR|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections with dose 1000 SQ-U and dose interval 4 weeks.
62531905|NCT05453773|EXPERIMENTAL|Tobacco flavor preparation; Medium Sweetness, High Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
62714143|NCT06268470|EXPERIMENTAL|Desloratadine plus cilostazol and dipyridamole|Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks
62714144|NCT02144467||Large-sample healthy participants|MRI scanning.
62714145|NCT02915497|NO_INTERVENTION|Treatment As Usual + Resilience-Based Supportive Therapy|Routine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
61975840|NCT05838885|EXPERIMENTAL|YPEG-GH high dose group|
61975841|NCT05838885|ACTIVE_COMPARATOR|rhGH low dose group|
62156980|NCT02423707|PLACEBO_COMPARATOR|ALK diluent|3 intralymphatic injections with dose interval 4 weeks.
62156981|NCT06493448||Cohort A|Type I liver metastases, resectable type, with the option of direct surgical resection or preoperative systemic therapy
62156982|NCT06493448||Cohort B|Type II liver metastases, potentially resectable type, preoperative systemic therapy is applied to gain the chance of surgery
62156983|NCT06493448||Cohort C|Type III liver metastases, systemic treatment according to recommended guidelines and patient characteristics
62156984|NCT05742646|ACTIVE_COMPARATOR|MATADORS app basic information|
62156985|NCT05742646|EXPERIMENTAL|MATADORS app to include basic information and expanded educational features|
62156986|NCT01255709|EXPERIMENTAL|Arm T1 Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
62156987|NCT01255709|ACTIVE_COMPARATOR|Arm C Primatene Mist|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
62156988|NCT01255709|EXPERIMENTAL|Arm T2 Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
62156989|NCT00828139|EXPERIMENTAL|Arm I (ziv-aflibercept, topotecan hydrochloride)|Patients receive ziv-aflibercept IV over 1 hour on day 1 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive ziv-aflibercept IV on day 1 and topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62531906|NCT05453773|EXPERIMENTAL|Tobacco flavor preparation; Medium Sweetness, Medium Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
62531907|NCT04312529|EXPERIMENTAL|Overhead athletes|
62531908|NCT02460367|EXPERIMENTAL|Phase 1: Dose Escalation|Up to 18 participants will be enrolled and treated at escalating doses of Indoximod with a fixed dose of tergenpumatucel-L and docetaxel. Treatment may continue until definitive disease progression or significant toxicology.
62531909|NCT02348723|EXPERIMENTAL|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
62714146|NCT02915497|EXPERIMENTAL|Abbreviated Early Prolonged Exposure Therapy|AEPET, including Manualized Resilience-Based supportive Therapy.
62714147|NCT01092884|ACTIVE_COMPARATOR|Polypodium leucotomos|Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract
62714148|NCT01092884|PLACEBO_COMPARATOR|Sugar pill|Subjects randomized to this arm will receive oral supplementation with placebo
62714149|NCT01847443|EXPERIMENTAL|Test nicotine gum (2 mg)|A single dose of Nicotine Mint Gum (2 mg) to be chewed.
62714150|NCT01847443|EXPERIMENTAL|Test nicotine gum (4 mg)|A single dose of Nicotine Mint Gum (4 mg) to be chewed.
62714151|NCT01847443|ACTIVE_COMPARATOR|Reference nicotine gum (2 mg)|A single dose of reference nicotine gum (2 mg) to be chewed.
62714152|NCT01847443|ACTIVE_COMPARATOR|Reference nicotine gum (4 mg)|A single dose of reference nicotine gum (4 mg) to be chewed.
62714153|NCT03276182|EXPERIMENTAL|cataract patients|cataract patients undergoing phacoemulsification
62156990|NCT00828139|ACTIVE_COMPARATOR|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62156991|NCT03622580|EXPERIMENTAL|A: Faricimab 6 mg Q8W|Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
62156992|NCT03622580|EXPERIMENTAL|B: Faricimab 6 mg PTI|Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.
62156993|NCT03622580|ACTIVE_COMPARATOR|C: Aflibercept 2 mg Q8W|Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
62156994|NCT05890781|OTHER|Immune organoids from pediatric patient tissues using iPSC|To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
62156995|NCT03900598|EXPERIMENTAL|Part 1 (Dose Escalation): JNJ-67856633|Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.
62156996|NCT03900598|EXPERIMENTAL|Part 2 (Cohort Expansion): JNJ-67856633|Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
62156997|NCT02442102|EXPERIMENTAL|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
62156998|NCT05130099|EXPERIMENTAL|Interdisciplinary complex intervention|
62156999|NCT05130099|NO_INTERVENTION|Usual care|Six months after the intervention period (T3), the participants randomized to usual care will be offered a modified version of the intervention in line with their personally expressed needs.
62157000|NCT02463292||patient group|The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.
62157001|NCT02463292||peer control group|The control group will be recruited as good friends (same gender, approx. same age of the patients, in command of the German language). The patients will be given a study information for controls to hand this to their good friend and ask the friend to contact the study nurse for participation in the study. No intervention.
62157002|NCT04102605|EXPERIMENTAL|Nunap Vision|Nunap Vision , 5 days a week for 12 weeks
62157003|NCT04102605|SHAM_COMPARATOR|Nunap Vision-C|Nunap Vision-C, 5 days a week for 12 weeks
62157004|NCT01815294|EXPERIMENTAL|Treatment A: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1
62157005|NCT01815294|EXPERIMENTAL|Treatment B: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1
62157006|NCT00329771||Episodic migraineurs|Eligible subjects with episodic migraine (with or without aura)
62157007|NCT02105688|EXPERIMENTAL|Immediate Treatment Arm: Grazoprevir/Elbasvir|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
62157008|NCT02105688|PLACEBO_COMPARATOR|Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir|In Part A, participants receive placebo to MK-5172A once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants received 12 weeks of open-label treatment with the MK-5172A FDC and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
62157009|NCT01969188||SpA in RA|Patients with SpA with psoriatic arthritis (PsA), ankylosing spondylitis (AS), no biologic therapy for 3 months, over 18 yrs old.
62531910|NCT02348723|ACTIVE_COMPARATOR|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
62531911|NCT00289536|EXPERIMENTAL|Low Dose|
62157010|NCT05714774|EXPERIMENTAL|Patients with localized prostate cancer|Patients with localized prostate cancer for which focal treatment, hemi-ablation or total ablation of the prostate is indicated will be treated by HIFU applied by FocalOne device.
62714154|NCT04651530|ACTIVE_COMPARATOR|Phaco|Cataract surgery only
62157011|NCT02531997|ACTIVE_COMPARATOR|Hypnotic Relaxation Therapy|Hypnotic relaxation will be performed in three sessions, two weeks apart, over 6 weeks. The hypnosis sessions will build on each other in terms of content.
62531912|NCT00289536|EXPERIMENTAL|Medium Dose|
62531913|NCT00289536|EXPERIMENTAL|High Dose|
62714155|NCT04651530|EXPERIMENTAL|Phaco+ECP|Cataract surgery combined with endoscopic cyclophotocoagulation
62714156|NCT05922930|EXPERIMENTAL|TROP2-CAR-NK|"Participants will receive 1 dose of TROP2-CAR-NK and will visit the study clinic up to 16 times to have tests and procedures (such as blood draws, biopsies, and CT scans).~Participants will receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) for 3 days in a row. Participants will receive cyclophosphamide and fludarabine by vein over about 3 hours total."
62714157|NCT01650454|EXPERIMENTAL|Patients from Memento cohort.|"Patients with mild cognitive impairment included in MEMENTO cohort.~These patients will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12."
62714158|NCT01650454|EXPERIMENTAL|Patients with memory disorders|Patients with mild cognitive impairment not included in MEMENTO cohort. For these patients a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
62157012|NCT02531997|OTHER|Progressive Muscle Relaxation (PMR)|The PMR will consist of progressive tensing and relaxing of the muscles from head to toe to a soothing sound of the participant's choosing.
62157013|NCT01803958|EXPERIMENTAL|partial breast irradiation|38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days
62157014|NCT01803958|ACTIVE_COMPARATOR|whole breast irradiation|50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week, or other biologically equivalent schedule
62157015|NCT03819647|EXPERIMENTAL|stiripentol (Diacomit)|
62531914|NCT01381250|EXPERIMENTAL|Treatment|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
62531915|NCT04310969|EXPERIMENTAL|treatment group|Patients are treated every two weeks for a total of three times. Forceful expression of the meibomian glands is followed after each therapy.
62531916|NCT04310969|SHAM_COMPARATOR|control group|Forceful expression of the meibomian glands only for patients.
62531917|NCT04310969|ACTIVE_COMPARATOR|active control group|LipiFlow® treatment is used as an active comparator.
62531918|NCT06306586|EXPERIMENTAL|Digital Treatment for Adolescents With Eating Disorders|The digital treatment is guided by a therapist and comprises 8 modules, running over a span of 10 weeks.
62531919|NCT00872885|EXPERIMENTAL|A|Dose 1
62531920|NCT00872885|EXPERIMENTAL|B|Dose 2
62531921|NCT00872885|EXPERIMENTAL|C|Dose 3
62531922|NCT00872885|ACTIVE_COMPARATOR|D|Morphine
62531923|NCT00872885|PLACEBO_COMPARATOR|E|Placebo
62531924|NCT05526326||Post-Approval Transplant Recipient cohort|Adult liver transplant recipients who are transplanted with an OrganOx metra® perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria
62531925|NCT03370016|EXPERIMENTAL|Reduction in pressure|This group receives 8mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
62531926|NCT03370016|ACTIVE_COMPARATOR|Stand Amount of Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
62157016|NCT03274934|EXPERIMENTAL|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
62531927|NCT04259463||Concious sedation|Patients undergoing third molars extraction under concious sedation. The patient is fully familiarized with the sedation procedure. The anesthesiologist suppresses the patient's consciousness with the help of intravenous medication;
62531928|NCT04259463||Full anesthesia|Patients undergoing third molars extraction under full anesthesia. . The patient is fully acquainted with the procedure of general anesthesia. It is a controlled state of unconsciousness when protective reflexes disappear, the patient cannot breathe and does not respond to verbal commands. A special intubation tube is introduced into the airways.
62531929|NCT03862066||Received Nivolumab|
62531930|NCT03862066||Nivolumab Naive|
62531931|NCT00769093|ACTIVE_COMPARATOR|Group 1|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The first study group (n=6) will receive bevacizumab, the antiangiogenic agent for three weeks, then dexamethasone for three weeks.
62531932|NCT00769093|ACTIVE_COMPARATOR|Group 2|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
62531933|NCT04186923|EXPERIMENTAL|Intervention group (IG)|Families receive permanent contact persons to support in the organisation of everyday life, financial applications, during emotional coping with illness and open communication within the family.
62531934|NCT04186923|NO_INTERVENTION|Control Group|In the control group the families are treated according to the standard of care.
62531935|NCT03341819|ACTIVE_COMPARATOR|Retained Urinary Catheter|
62531936|NCT03341819|EXPERIMENTAL|Non-retained Urinary Catheter|
62531937|NCT03804502|EXPERIMENTAL|TearCare|Subjects will receive one TearCare treatment at the baseline visit
62531938|NCT00941148|ACTIVE_COMPARATOR|Insulin glargine|Insulin glargine, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)
62714159|NCT01650454|ACTIVE_COMPARATOR|Healthy volunteers|Healthy volunteers matched in age, sex and educational level with patients. For these volunteers a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
62714160|NCT01650454|ACTIVE_COMPARATOR|control group|this group is composed with Healthy volunteers these volunteers will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12.
62531939|NCT00941148|ACTIVE_COMPARATOR|NPH Insulin|NPH Insulin, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)
62531940|NCT00941148|ACTIVE_COMPARATOR|Insulin detemir|Insulin detemir, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)
62531941|NCT04873765|EXPERIMENTAL|Pegfilgrastim Megalabs|Pegfilgrastim injectable 6 mg in a single subcutaneous application.
62531942|NCT04873765|ACTIVE_COMPARATOR|Pegfilgastrim Neulastim|Neulastim injectable 6 mg in a single subcutaneous application.
62157017|NCT03274934|EXPERIMENTAL|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
62157018|NCT03274934|EXPERIMENTAL|Control group|Behavioral: No intervention, school counseling as usual
62157019|NCT05851521|EXPERIMENTAL|Temporary prostatic stent (Exime®)|Post-operative placement of temporary prostatic stent (EXIME)
62531943|NCT03889366|EXPERIMENTAL|NXP001 Oral Capsule|
62531944|NCT03889366|EXPERIMENTAL|NXP001 Oral Suspension|
62531945|NCT03889366|ACTIVE_COMPARATOR|Emend®|
62714161|NCT06492759|EXPERIMENTAL|Treatment (radiation, pembrolizumab, chemotherapy)|Patients undergo radiation therapy once every other day for 3 doses. Beginning within 48 hours of their first dose of radiation therapy, patients receive standard of care pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive 1 of 3 standard of care chemotherapy options: nab-paclitaxel IV on days 1, 8, and 15 of each cycle, or paclitaxel IV on days 1, 8, and 15 of each cycle, or carboplatin IV and gemcitabine IV on days 1 and 8 of each cycle. Cycles of nab-paclitaxel and paclitaxel repeat every 28 days and cycles of carboplatin and gemcitabine repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo a biopsy at baseline and 2 weeks after radiation therapy and also undergo CT scans, bone scans and blood sample collections throughout the trial.
62531946|NCT02013479|EXPERIMENTAL|SelenoPRECISE|SelenoPRECISE
62531947|NCT02013479|PLACEBO_COMPARATOR|Placebo|Placebo
62531948|NCT06431165|ACTIVE_COMPARATOR|Group A|Group A: Bolus 10 ml Syringe with Lidocaine 0.5% (2.5 ml lidocaine 2% + 7.5 ml N.S), and infusion 50 ml Syringe with Lidocaine 0.5% (12.5 ml Lidocaine 2% + 37.5 ml N.S).
62531949|NCT06431165|ACTIVE_COMPARATOR|Group B|Group B: Bolus 10 ml Syringe with Lidocaine 1% (5 ml lidocaine 2% + 5 ml N.S), and infusion 50 ml Syringe with Lidocaine 1% (25 ml Lidocaine 2% + 25 ml N.S).
62531950|NCT06431165|ACTIVE_COMPARATOR|Group C|Group C: Bolus 10 ml Syringe with plain Lidocaine 2%, and infusion 50 ml Syringe with plain Lidocaine 2%.
62531951|NCT04964518|EXPERIMENTAL|APG2575 + Azacitidine|200 mg APG2575 dose ramp up +AZA
62531952|NCT02953470|EXPERIMENTAL|Individual tailored functional exercise|Receives general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. The intervention group, which is based on a behavioural medicine approach in physiotherapy, also receive individual tailored functional exercise with the goal to enhance the ability to perform everyday activities by reduce pain-related disability and pain-related beliefs and increase physical function. The participants receive 9 visits from a physiotherapist during the 12 weeks period. The participants will also fill in a activity diary to check the compliance to the intervention and to enhance their self-efficacy in relation to perform everyday activities, exercise and physical activity.
62531953|NCT02953470|ACTIVE_COMPARATOR|Standard care|The participants in the comparison Group will receive standard care which means that they receives one visit from physiotherapist where the participant receive general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. During intervention week 1-8 and 10 the participants receive telephone calls once a week where they will be reminded to follow the advice about physical activity.
62531954|NCT05201196|ACTIVE_COMPARATOR|Conventional physical therapy|Conventional physical therapy Muscle strengthening and Muscle Stretching, TENS.
61975842|NCT05838885|ACTIVE_COMPARATOR|rhGH high dose group|
62157020|NCT05851521|ACTIVE_COMPARATOR|Indwelling catheter|Post-operative placement of indwelling catheter
62531955|NCT05201196|EXPERIMENTAL|Task Oriented Training|Experimental group was given Task Oriented protocol including different task specific functional activities
62531956|NCT01455311||Cystic Pancreatic Tumor Specimens|Specimen collection via EUS Guided Fine Needle Aspiration EchoBrush Sampling
62157021|NCT05809635||Best Vitelliform Macular Dystrophy (VMD) Participants|Participants with a clinical picture of Retinitis pigmentosa with dominant and recessive variants in the BEST1 gene
62157022|NCT04964206||Neuraxial analgesia exposure|For mothers who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided according to routine practice of each study center.
62531957|NCT03368456|EXPERIMENTAL|S4E App Intervention|Participants in the S4E condition will first receive the intervention in the waiting area via iPads provided for them. Content includes the theoretically driven components of Storytelling for Empowerment: (a) Storytelling scenarios, (b) drug use and HIV/STI knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual risk and drug use behaviors, and increase HIV/STI testing, (e) clinician-youth communication, and (f) highlighting prevention principles
62531958|NCT03368456|PLACEBO_COMPARATOR|Usual Care Condition|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
62531959|NCT03890146||intensive care patients|patient hospitalised in intensive care unit veinous and capillary ponction
62531960|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.~This group will also complete a 3-hour nutrition module prior to study completion."
62531961|NCT01282723||Pregnant, In Labor|
62157023|NCT04964206||No neuraxial analgesia exposure|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
62157024|NCT03536637|EXPERIMENTAL|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
62157025|NCT03536637|EXPERIMENTAL|Study Treatment 2|DMT310 Powder mixed with Placebo Diluent
62531962|NCT02496936|EXPERIMENTAL|Saturated Fat (SFA)|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
62714162|NCT03547440||type 1 diabetes mellitus|Children with type 1 diabetes mellitus, usually not obese, with diabetic ketoacidosis. They could be with or without stationary metabolic profile. They are recruited at the onset of the T1DM into the Torino and Novara Pediatric Hospitals and then they are divided in relation to the ethnicity.
62157026|NCT03536637|EXPERIMENTAL|Study Treatment 3|Placebo powder mixed with Hydrogen Peroxide
62157027|NCT03536637|PLACEBO_COMPARATOR|Control|Placebo powder mixed with Placebo Diluent
62157028|NCT05278117|EXPERIMENTAL|complete burst abdomen repair|complete burst abdomen repair
62157029|NCT03473665|ACTIVE_COMPARATOR|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
62157030|NCT03473665|ACTIVE_COMPARATOR|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
62714163|NCT03547440||Control healthy|Healthy children without relevant metabolic or systemic co-morbility. They are recruited from orthopedy department of the Torino and Novara Pediatric hospitals and then they are divided in relation to the ethnicity
62714164|NCT06677957|EXPERIMENTAL|Treatment A|Participants will receive a single oral dose of Digoxin and Rosuvastatin drug cocktail.
62157031|NCT03473665|ACTIVE_COMPARATOR|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
62157032|NCT03473665|ACTIVE_COMPARATOR|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
62157033|NCT02531061|EXPERIMENTAL|active erosion|"HR-pQCT for measure bone parameters in active erosion group. The active erosion group will be defined by grades 2 and 3, ie by the presence of Doppler signals confluence in less than 50% of the synovial surface (grade 2) and in over 50% of the surface synovial for grade 3"
62157034|NCT02531061|EXPERIMENTAL|inactive erosion|"HR-pQCT for measure bone parameters in active erosion group. The inactive erosion group will be defined by grades 0 and 1, ie the absence of Doppler signal for grade 0 and the presence of some non confluence Doppler signals for the grade 1"
62157035|NCT04135872||hypoalbuminemia|hypoalbuminemia was classified as serum albumin level (SAL) \<35g/L
62157036|NCT04135872||normal albumin level|patients with serum albumin level (SAL) of 35g/L or higher
62157037|NCT03957759||COPD patients|
62157038|NCT06285578|PLACEBO_COMPARATOR|Placebo control (C)|The subjects do not perform HIIT training, but consume one placebo packet every day on a fasting status for 8 weeks.
62531963|NCT02496936|EXPERIMENTAL|Monounsaturated Fat (MUFA)|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
62157039|NCT06285578|EXPERIMENTAL|Probiotics supplementation (P)|Each participant consume one probiotic packet every day on a fasting status for 8 weeks.
62157040|NCT06285578|EXPERIMENTAL|HIIT intervention (H)|HIIT training for 3 sessions per week and consume one placebo packet every day on a fasting status for 8 weeks.
62157041|NCT06285578|EXPERIMENTAL|HIIT with probiotics intervention (HP)|Conduct HIIT training 3 sessions per week for 8 weeks and consume one probiotic packet every day on a fasting status for 8 weeks.
62157042|NCT00825513|EXPERIMENTAL|Akreos Toric|Akreos Toric Intraocular Lens
62157043|NCT00825513|ACTIVE_COMPARATOR|Akreos Advanced|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
62157044|NCT01062776|PLACEBO_COMPARATOR|5 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
62157045|NCT01062776|PLACEBO_COMPARATOR|10 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
62157046|NCT01062776|EXPERIMENTAL|5 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
62157047|NCT01062776|EXPERIMENTAL|10 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
62157048|NCT00338325|EXPERIMENTAL|Treatment|50% randomized to receive treatment: reading pre-operatively
62714165|NCT06677957|EXPERIMENTAL|Treatment B|Participants will receive a single dose of Digoxin and Rosuvastatin drug cocktail administered 2 hours after the Divarasib dose on Day 5.
62714166|NCT04239248|EXPERIMENTAL|ACTIVE-RCT-I Tasty&Healthy intervention group|Patients with mild-moderately symptomatic disease, will follow the Tasty\&Healthy dietary approach.
62714167|NCT04239248|ACTIVE_COMPARATOR|ACTIVE-RCT-I Control group|Patients with mild-moderately symptomatic disease, will receive EEN with Modulen formula only.
62714168|NCT04239248|EXPERIMENTAL|MH-RCT-II Tasty&Healthy intervention group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will follow the Tasty\&Healthy dietary approach.
62714169|NCT04239248|NO_INTERVENTION|MH-RCT-II Control group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will continue their habitual diet.
62714170|NCT02921789|ACTIVE_COMPARATOR|Standard of Care (SOC) Regimen|Participants received SOC regimen (basiliximab induction, MMF, Tacrolimus, Methylprednisone, Prednisolone). Basiliximab 20 milligrams (mg) administered by intravenous injection prior to transplantation or intra- operatively before revascularisation as induction therapy and 20mg on day 3 or 4 or 5 post-transplant. MMF 1 gram (g) administered orally or intravenously twice daily until 12 months post transplant. Tacrolimus 0.1 milligram per kilogram per day (mg/kg/day) (two equally divided doses at 0.05 mg/kg/day every 12 hours with a target trough level of 4 - 11 nanogram per milliliter (ng/mL) administered orally within 48 hours post-transplant until 12 months post transplant. Methylprednisone 500, 250, 125 and 60mg administered orally or intravenously on days 0, 1, 2 and 3 respectively and continue through 12 months post transplant. Prednisolone administered orally by tapered doses of 20-30 mg on days 4-14, 10-20mg on days 15-28, 5-10mg on days 29 through 12 months post transplant.
62531964|NCT02496936|EXPERIMENTAL|Polyunsaturated Fat Linoleic (PUFA-LA)|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
62531965|NCT02496936|EXPERIMENTAL|Polyunsaturated Fat Alpha-Linolenic (ALA)|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
62157049|NCT00338325|NO_INTERVENTION|Control|50% randomized to receive no intervention pre-operatively: no reading
62157050|NCT03576625|PLACEBO_COMPARATOR|High oleic sunflower oil (HOSO)|30 ml HOSO emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
62157051|NCT03576625|EXPERIMENTAL|Buglossoides oil emulsion|30 ml Buglossoides oil emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
62157052|NCT03199456|EXPERIMENTAL|Zip Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
62157053|NCT03199456|ACTIVE_COMPARATOR|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
62531966|NCT02496936|EXPERIMENTAL|Polyunsaturated Fat Long Chain Omega-3 (LCn3)|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
62531967|NCT03321630|OTHER|Lenvatinib & Pembrolizumab|
62531968|NCT01267747||Atrial fibrillation or flutter patients|Patients with 'lone' paroxysmal, persistent, or permanent atrial fibrillation
62531969|NCT05496335|EXPERIMENTAL|AGN-151586, BOTOX|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Eligible participants will receive BOTOX injections and will be followed for up to 4 months.
62157054|NCT02994329|ACTIVE_COMPARATOR|Oral HIV self test|In this arm, community health workers conducting door-to-door HIV testing will offer oral HIV self testing (OraQuick® HIV Self-Test (Orasure Technologies, Thailand)) as an alternative to standard of care finger-prick HIV testing for individuals who are present at the time of the visit. In addition they will provide demonstration to an adult who is present at the time of the visit and leave up to 2 oral HIV self test kits to allow testing with the partner
62157055|NCT02994329|NO_INTERVENTION|Standard of Care|In this arm community health workers will conduct door-to-door HIV testing using the current Zambian national HIV testing algorithm of finger-prick rapid HIV tests
62157056|NCT03562702|ACTIVE_COMPARATOR|Standard IV Rehydration Therapy|Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
62531970|NCT05496335|EXPERIMENTAL|Placebo, BOTOX|Participants will receive 5 intramuscular injections of placebo in the glabellar complex on Day 1. Eligible participants will receive BOTOX injections and will be followed for up to 4 months.
62531971|NCT05541653|EXPERIMENTAL|Intervention|"At the individual level, participants in the intervention arm receive place-based and financial well-being interventions.~These include, at the individual level:~* Tax preparation~* Access to public benefits~* Financial counseling and microgrants~At the neighborhood level:~* Abandoned house remediation~* Trash cleanup~* Vacant lot greening~* Tree planting"
62157057|NCT03562702|EXPERIMENTAL|Oral Rehydration Therapy (ORT)|Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.
62157058|NCT00409006|EXPERIMENTAL|Pemetrexed/Cisplatin/Gefitinib|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
62157059|NCT00409006|EXPERIMENTAL|Pemetrexed/Cisplatin|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
62531972|NCT05541653|NO_INTERVENTION|Control|Participants in the control arm will not receive any of the listed interventions.
62531973|NCT01170013|EXPERIMENTAL|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
62531974|NCT01170013|ACTIVE_COMPARATOR|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
62531975|NCT05473962||exposed to Alex storm|"Child and/or young adult aged under 18 at the time of exposure having been assessed by the CUMPS teams during the ALEX Storm interventions of October 2020"
62157060|NCT00949234|OTHER|Open-Label|This was an open-label demonstration project. Therefore, medications were not blinded and participants were made aware of the regimen they received for PEP.
62531976|NCT03900065|NO_INTERVENTION|Control group|No preconditioning of the flap.
62157061|NCT00297089|ACTIVE_COMPARATOR|A|Pemetrexed + ABT-751
62157062|NCT00297089|PLACEBO_COMPARATOR|B|Pemetrexed + placebo
62157063|NCT04095338|ACTIVE_COMPARATOR|control group|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks
62531977|NCT03900065|EXPERIMENTAL|Preconditioned group|Preconditioning of the flap prior to surgery.
62531978|NCT04594707|EXPERIMENTAL|Zinpentraxin Alfa|"Corhort A: Participants entering, following participation in study PRM-151-202.~Cohort B: Participants entering, following participation in study WA42293."
62531979|NCT06048432|EXPERIMENTAL|Intervention|Conventional phyisiotherapy + telecare
62531980|NCT06048432|ACTIVE_COMPARATOR|Control|Conventional physiotherapy
62157064|NCT04095338|EXPERIMENTAL|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks.
62157065|NCT04095338|EXPERIMENTAL|robotic treadmill arm|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks.
62157066|NCT01658176|EXPERIMENTAL|PF-04691502 + Exemestane|PF-04691502 in combination with Exemestane
62157067|NCT01658176|ACTIVE_COMPARATOR|Exemestane|Exemestane alone
62736752|NCT01385618||low responder|patients with \<3 follicles or no response to treatment with gonadotropins
62736753|NCT01385618||control|females with an indication for treatment because of male subfertility
62531981|NCT00369317|EXPERIMENTAL|Treatment (combination chemotherapy)|"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity."
62531982|NCT03790150||Mechanically Ventilated Patients|All patients admitted to the critical care unit and require mechanical ventilation
62157068|NCT05845866|EXPERIMENTAL|Modified Body Project|Participants will receive this four week intervention followed by 6 months of behavioral weight management
62157069|NCT05845866|ACTIVE_COMPARATOR|Facts about obesity, myths about weight loss|Participants will receive this four week intervention followed by 6 months of behavioral weight management
62157070|NCT02854982||Prostate Cancer|Group drawn of the case group of the case control study, entitled EPICAP
62157071|NCT02854982||No Prostate Cancer|Group drawn of the control group of the case control study, entitled EPICAP
62157072|NCT05725447||Patients group|Individuals with premenstrual syndrome
62531983|NCT01789827|EXPERIMENTAL|Cohort I (scintigraphy prior to immunotherapy and 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.
62157073|NCT05670600|EXPERIMENTAL|intervention group|The intervention group received training by sending foot and ankle exercise videos to their mobile phones via WhatsApp.
62157074|NCT00551954|EXPERIMENTAL|1|20 weeks of treatment with acarbose (100 mg t.i.d.)
62531984|NCT01789827|EXPERIMENTAL|Cohort II (scintograpy prior to immunotherapy, 3-4, 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.
62531985|NCT03633734|EXPERIMENTAL|Sequential treatment|"One cycle of sequential treatment lasts for 56 days.~1. Stage 1(28 days): AG regimen. Nab-paclitaxel (Abraxane) 125mg/m\^2 + gemcitabine 1000mg/m\^2 (days 1, 8, 15, 28)~2. Stage 2(28 days)：mFolfirinox regimen. Fluorouracil 2400 mg/m\^2 continuous intravenous drip 46h + calcium folinate 400 mg/m\^2 + irinotecan 135 mg/m\^2 + oxaliplatin 68 mg/m\^2 (day 1, 15, a total of 28 days).~Repeat the cycle above until progression or intolerance of toxicity."
62157075|NCT00551954|PLACEBO_COMPARATOR|2|20 weeks of treatment with placebo (one tablet t.i.d.)
62157076|NCT02838888||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
62157077|NCT02952170|EXPERIMENTAL|MRI for steatosis assessment|Abdominal MRI for assessment of hepatic steatosis
62157078|NCT04327349|OTHER|COVID-19 Patients|
62157079|NCT00547716|EXPERIMENTAL|1.|Omega-3 Fatty Acids 4 grams/day
62531986|NCT01333891|ACTIVE_COMPARATOR|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
62157080|NCT00547716|PLACEBO_COMPARATOR|2.|Placebo comparator along with interferon.
62157081|NCT04394585|EXPERIMENTAL|Smart phone app group|Patients used smart phone app based human coaching program for 3 months postoperatively.
62157082|NCT04394585|ACTIVE_COMPARATOR|Nutritional consultation group|Patients have two consulting with clinical nutritionist at 1 month and 3 months postoperatively.
62157083|NCT04580732|ACTIVE_COMPARATOR|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
62157084|NCT04580732|PLACEBO_COMPARATOR|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
62157085|NCT03639194|EXPERIMENTAL|Part A: ABBV-011 Dose Escalation|ABBV-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared.
62157086|NCT03639194|EXPERIMENTAL|Part B: ABBV-011 Dose Expansion|ABBV-011 via intravenous administration at dose regimen(s) that will not exceed the maximum tolerated dose determined in Part A.
62157087|NCT03639194|EXPERIMENTAL|Part C: ABBV-011 + Budigalimab Escalation and Expansion|ABBV-011 via intravenous administration at various doses and dosing regimens starting at least 1 dose level below the recommended single-agent dose of ABBV-011 for Part B plus Budigalimab via intravenous administration at fixed doses and various dosing regimens.
62157088|NCT03639194|EXPERIMENTAL|Part D: ABBV-011 Dose Evaluation for Japan|ABBV-011 via intravenous administration will be administered every 3 weeks (Q3wk), on Day 1 of each 21-day cycle or alternate dosing regimens.
62157089|NCT02581826|ACTIVE_COMPARATOR|Silodosin|"1. Silodosin capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~2. This arm received Silodosin in the first intervention period and Placebo in the second period (after washout period of 14-21 days).~3. The patients received 4 mg of Silodosin 1 times a day, total dosage 12 mg for 14-21 days."
62157090|NCT02581826|PLACEBO_COMPARATOR|Placebo|"1. Placebo capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~2. This arm received Placebo in the first period and Silodosin in the second period (after washout period of 14-21 days).~3. The patients received 4 mg of Placebo 1 times a day, total dosage 12 mg for 14-21 days."
62531987|NCT01333891|ACTIVE_COMPARATOR|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
62531988|NCT01333891|ACTIVE_COMPARATOR|Suction Cup|suction force of 25, 50, 75, and 100 mmHg
62531989|NCT05392335|ACTIVE_COMPARATOR|myofascial stretch group|Patients will be given myofascial stretch
62531990|NCT05392335|EXPERIMENTAL|Functional massage along with myofascial stretch group|patients will be given functional massage along with myofascial stretching
62531991|NCT03237949|ACTIVE_COMPARATOR|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
62157091|NCT02951949||Postmenopausal women|Postmenopausal women attending the outpatient service of a third level hospital for health control.
62157092|NCT06549270||Responders|Patients with high frequency episodic migraine (HFEM) or chronic migraine (CM) undergoing treatment with monoclonal antibodies directed against calcitonin gene related peptide pathway (mAbs) who obtained a reduction in monthly migraine days equal or higher than 50% after three months of treatment compared to pre-treatment values.
62157093|NCT06549270||Non-Responders|Patients with HFEM or CM undergoing mAbs treatment who obtained a reduction in monthly migraine days \< 50% after three months of treatment compared to pre-treatment values.
62157094|NCT02822963||A|Non anticoagulant and/or antiplatelet users.
62531992|NCT03237949|EXPERIMENTAL|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
62157095|NCT02822963||B|Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.
62531993|NCT03047798|EXPERIMENTAL|aqueous single-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in aqueous single-phase form.
62157096|NCT02822963||C|Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.
62157097|NCT05450159|EXPERIMENTAL|Intervention group|Participants in the intervention group will watch their respective training video individually approximately four to six weeks after their baseline visit. Each training video will be 20-25 minutes in length where they will receive voice-over feedback on their driving from a member of the study team alongside video clips taken from the device of their behind-the-wheel performance. They will also receive a written summary of their feedback to keep at the end of their feedback session.
62157098|NCT05450159|ACTIVE_COMPARATOR|Control group|Four to six weeks after their first baseline visit, control group participants individually will watch a 30-minute (generic) video that describes the benefits and challenges of aging-in-place that discusses the importance of community mobility in later life. At the end of their session, participants will be given a government brochure on this topic.
62157099|NCT02759406|EXPERIMENTAL|Mach-5 Grooved|grooved
62157100|NCT02759406|EXPERIMENTAL|Mach 5 Bare Metal|bare metal
62157101|NCT05989386|EXPERIMENTAL|Group A|Intra-operative wound irrigation of 0.9% solution saline solution
62157102|NCT05989386|ACTIVE_COMPARATOR|Group B|No intra-operative wound lavage done
62157103|NCT01099878|ACTIVE_COMPARATOR|Cycling Exercise with Functional Electrical Stimulation|Cycling Exercise with Functional Electrical Stimulation
62157104|NCT01099878|PLACEBO_COMPARATOR|Cycling Exercise|Cycling Exercise
62157105|NCT06292247|EXPERIMENTAL|Cognitive behavioral therapy group|CBT is based on the principle that, the way we think profoundly impacts the way we feel and behave. Therefore, learning to think differently can enable the child to feel and act differently. It is a multi-component therapy that companies cognitive (cognitive restructuring) and behavioral (relaxation and distraction) interventions to change these maladaptive cognitions, which change the emotional distress and problematic behaviors. The following techniques were used in our research in a row, unrelated play, animated video modeling, stress-ball relaxation technique, audio music therapy, and positive reinforcement. These have been used effectively to manage children's anxiety during the dental appointment.
62157106|NCT06292247|EXPERIMENTAL|Auricular Plaster Therapy group|APT intervention involves the application of plaster with seeds on specific points of the outer ear, known as auricular points (acupoints). According to Traditional Chinese Medicine, these points correspond to various regions of the body. Applying pressure to these points (acupressure) will stimulate and regulate energy flow throughout the body. This process is believed to restore balance and harmony within the body's system and achieve a therapeutic effect e.g. (anxiety reduction)
62157107|NCT06292247|EXPERIMENTAL|Control group (Tell show do)|TSD is considered the cornerstone of behavior management techniques. It aims to introduce the child to the dental setting before commencing any procedure. With the TSD technique, the child should be informed about the process with a demonstration of the dental procedure using a simulator.
62157108|NCT06584877||Research participant with tumour or congenital condition|The participant identified to have a tumour or congenital condition (a condition from birth) that is likely to be due to errors of the genetic code (DNA).
62157109|NCT06584877||Relatives|parents, siblings or close relatives of the participant with the tumour or congenital condition.
62157110|NCT03680781|EXPERIMENTAL|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
62157111|NCT00514670|EXPERIMENTAL|1|Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes.
62157112|NCT00514670|NO_INTERVENTION|2|No hand sanitizer or disinfecting wipes were used.
62157113|NCT02222649|EXPERIMENTAL|Vitamin D3|Group supplemented with high single dose of 200,000 IU of vitamin D3 (cholecalciferol)
62157114|NCT02222649|PLACEBO_COMPARATOR|placebo group|Placebo capsules with starch
62157115|NCT02158845|ACTIVE_COMPARATOR|LNG-IUS|LNG-IUS: levonorgestrel intrauterine system
62157116|NCT02158845|ACTIVE_COMPARATOR|GnRHa|GnRHa: leuprolide
62157117|NCT06102278||Training cohort|All cases were randomly grouped according to 7:3, with 70% defined as the training group
62157118|NCT06102278||Validation cohort|All cases were randomly grouped according to 7:3, with 30% defined as the validation group
62157119|NCT02912104|EXPERIMENTAL|hAECs transplantation|To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of POF patients
62157120|NCT01346722|OTHER|Group A|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with conventional rice-based diet (Diet- CR)
62531994|NCT03047798|EXPERIMENTAL|oil-water two-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in oil-water two-phase form.
62531995|NCT03047798|PLACEBO_COMPARATOR|Control|The control mouthrinse only contained sodium fluoride
62531996|NCT01674153|EXPERIMENTAL|HD-Exercise-HDF|Prescribe intra-dialytic exercise of three bouts in 4 hours dialysis session.
62531997|NCT04791878|EXPERIMENTAL|Mesenchymal stem cells|allogeneic bone marrow derived mesenchymal stem cells
62157121|NCT01346722|OTHER|Group B|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with a rice-based diet plus zinc fortificant (Diet-CR+Z)
62157122|NCT00783185|EXPERIMENTAL|ACT|Anti-Cannabis-Consumption-Training
62157123|NCT00783185|ACTIVE_COMPARATOR|CG|Control group
62531998|NCT06276049|EXPERIMENTAL|Intervention group|Engage in 12 weeks of SDL task-based training with LearnGuide\&#39;s support.
62531999|NCT06276049|NO_INTERVENTION|control group|the control group engaged in SDL task-based training without the support of LearnGuide or any similar artificial intelligence (AI) assistance.
62532000|NCT04617054|EXPERIMENTAL|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106|
62532001|NCT00813566|EXPERIMENTAL|All Participants|All participants will receive multi-tracer PET scans at up to 3 time points: baseline, at the conclusion of standard of care chemoradiation, and at the time of documented recurrence within two years.
62532002|NCT01709838|OTHER|Deferasirox|All patients were treated with 10mg/kg/day deferasirox with dose adjustments after 4 weeks of treatment according to baseline Liver Iron Concentration (LIC).
62532003|NCT04781101|EXPERIMENTAL|conventional therapy|conventional therapy
62532004|NCT04781101|EXPERIMENTAL|RoboGait®|Group 1 (n = 13) received conventional therapy (65 min, 2 days/week ×8) and group 2 (n = 13) received 25 minutes of robot-assisted gait training (RoboGait®) in addition to conventional therapy (40 min, 2 days/week ×8).
62532005|NCT01169428|ACTIVE_COMPARATOR|Standard Behavioral Weight-Loss Maintenence|"Attention/Education/Support Control~Group designed to control for educational content as well as multiple nonspecific treatment factors (e.g., support, time invested, leader attention, positive expectancy)"
62532006|NCT01169428|ACTIVE_COMPARATOR|Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss.
62532007|NCT05710939|ACTIVE_COMPARATOR|scapular stabilization exercises|scapular stabilization exercises applied to 1st group for 5 days/week for 6 weeks
62157124|NCT04113226|ACTIVE_COMPARATOR|classical rituximab-based chemotherapy|Rituximab-based physician's choice chemotherapy
62157125|NCT04113226|EXPERIMENTAL|rituximab plus lenalidomide|Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression.
62532008|NCT05710939|ACTIVE_COMPARATOR|classic shoulder exercises|classic shoulder exercises applied to 1st group for 5 days/week for 6 weeks
62532009|NCT01524679|EXPERIMENTAL|Treatment group|pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
62532010|NCT01524679|NO_INTERVENTION|Control group|ongoing nucleos(t)ide based treatment alone
62532011|NCT00015340|EXPERIMENTAL|Buprenorphine/Naloxone|
62532012|NCT01898650|EXPERIMENTAL|craniofacial abnormalities|Subjects with craniosynostosis or other craniofacial abnormalities associated with ICP who will undergo an MR scan.
62532013|NCT03173638|EXPERIMENTAL|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
62532014|NCT04846036|EXPERIMENTAL|Sonlicromanol|Paediatric-equivalent dose (as determined by Physiologically Based Pharmacokinetics (PBPK) modelling and the results of the Adaptive PK study) of sonlicromanol twice daily administered as an oral liquid for 26 weeks
62532015|NCT04846036|PLACEBO_COMPARATOR|Placebo|Matching placebo twice daily orally for 26 weeks
62532016|NCT03322930||Retinitis Pigmentosa|patients with a diagnosis of retinitis pigmentosa and reduced rod function on baseline testing
62532017|NCT03322930||Age-related Macular Degeneration|patients with a diagnosis of intermediate AMD and reduced rod function on baseline testing
62532018|NCT01372774|ACTIVE_COMPARATOR|Arm I - WBRT|Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
62532019|NCT01372774|EXPERIMENTAL|Arm II - SRS|Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
62736423|NCT05662540|EXPERIMENTAL|PET/MR|This is a prospective, single-arm clinical study. Subjects who meet the inclusion criteria will receive PET/MR examination within 28 days before treatment after signing the informed consent form for pre-treatment evaluation. Stage I/II patients received PET/MR again 21-35 days after 2 and 4 courses of standard treatment for mid-term and final efficacy evaluation. Stage III/IV patients received PET/MR again 21-35 days after 3 and 6 courses of standard treatment for mid-term and final efficacy evaluation. Follow-up assessments are then continued, every 12 weeks for the first year, and every 24 weeks thereafter (clinical symptoms, physical examination, enhanced CT of the cervix, abdomen, and pelvis, and enhanced MR of the nasopharynx) until disease progression (PD), death, withdrawal of informed consent, or study finish. For subjects with suspected PD, histopathological results should be obtained whenever possible to confirm or exclude PD status.
62157126|NCT01526850|EXPERIMENTAL|allogenic mesenchymal stem cells (MSCs)|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
62157127|NCT01526850|ACTIVE_COMPARATOR|Control group|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
62157128|NCT06600490|NO_INTERVENTION|Usual Care|No letter
62157129|NCT06600490|EXPERIMENTAL|Standard Letter|This group will receive a standard letter on the benefits of influenza vaccination without behavioral economic enhancement
62157130|NCT06600490|EXPERIMENTAL|Repeated Letter|The standard letter sent out two times instead of once
62157131|NCT06600490|EXPERIMENTAL|Cardiovascular Gain-Framing Letter|Text added to the standard letter highlighting potential cardiovascular benefits of influenza vaccination
62157132|NCT06600490|EXPERIMENTAL|Repeated Cardiovascular Gain-Framing Letter|The cardiovascular gain-framing letter sent out two times instead of once
62532020|NCT03547700|EXPERIMENTAL|Romidepsin plus Ixazomib|The phase I study includes three dose levels (DL) for romidepsin: DL4: 10 mg/m2 on Days 1, 8, 15; DL5: 14 mg/m2 Days 1, 8; DL6: 14 mg/m2 Days 1, 8, 15. Ixazomib is 4 mg PO Days 1, 8, 15. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study. Each cycle is 28 days and patients will receive treatment until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met.
62532021|NCT01806506|EXPERIMENTAL|Laparoscopic sleeve gastrectomy|The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
62532022|NCT01806506|EXPERIMENTAL|Roux-en-Y Gastric Bypass|The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
62532023|NCT05988632|EXPERIMENTAL|Insulin, Then Placebo|There will be one single administration of intranasal human insulin (80IU) before alcohol self-administration. After a one week washout period, there will be one single intranasal administration of placebo (saline, 0.9% solution) before alcohol self administration.
62532024|NCT05988632|EXPERIMENTAL|Placebo, Then Insulin|There will be one single intranasal administration of placebo (saline, 0.9% solution) before alcohol self administration. After a one week washout period, there will be one single administration of intranasal human insulin (80IU) before alcohol self-administration.
62532025|NCT00927693|EXPERIMENTAL|Scan group|"Scan group undergoes complete cardiac risk assessment and CAC scanning at baseline."
62532026|NCT00927693|NO_INTERVENTION|No scan group|"No scan group undergoes only complete cardiac risk assessment (without CAC scan) at baseline."
62532027|NCT03683368|EXPERIMENTAL|Soft cannula first|Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.
62532028|NCT03683368|EXPERIMENTAL|Steel cannula first|Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.
62532029|NCT04333238|ACTIVE_COMPARATOR|Standard template|Usual outpatient progress note with standard Subjective Objective Assessment Plan (SOAP) format
62532030|NCT04333238|EXPERIMENTAL|New template|The assessment and plan section is placed in the beginning, subjective data grouped into the assessment section, and elements not related to the current presentation were deemphasized
62532031|NCT04620135|EXPERIMENTAL|Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle|1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.
62532032|NCT04620135|ACTIVE_COMPARATOR|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|1 drop ripasudil twice daily in the morning and evening in each eye.
62532033|NCT02352779|EXPERIMENTAL|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
62157133|NCT06600490|EXPERIMENTAL|Respiratory Gain-Framing Letter|Text added to the standard letter highlighting potential respiratory disease-related benefits of influenza vaccination
62157134|NCT06600490|EXPERIMENTAL|Implementation Intention Prompt Letter|Implementation intention prompt added to the standard letter
62157135|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
62532034|NCT02352779|EXPERIMENTAL|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
62532035|NCT02352779|PLACEBO_COMPARATOR|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
62532036|NCT00943267|EXPERIMENTAL|Activated protein C|
62532037|NCT00943267|PLACEBO_COMPARATOR|Saline|
62532038|NCT04236570|OTHER|Pain tests with the standardized protocol|This arm will consisted of pain tests using the standardized protocol (thermode(hot plate) and cold water bath)). The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the standardized protocol, the TS will consisted of a noxius heat stimulus generated by a thermode (hot plate), applied for two minutes on the non-dominant anterior forearm. The CS will consisted of a cold pressor test (CT), wherein participants immersed their dominant forearm in a cold water bath for two minutes.
62532039|NCT04236570|OTHER|Pain tests with the TENS protocol|This arm will consisted of pain tests using the TENS protocol. The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the TENS protocol, the TS will consisted of a noxius electrical stimulus generated by TENS, applied for 5 seconds on the non-dominant knee at a frequency of 1 Hz and 5 Hz. The CS will consisted of a noxius electrical stimulus generated by TENS' applied for 120 seconds on the non dominant knee and ankle at a frequency of 2 Hz
62157136|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
62157137|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
62157138|NCT06081972|PLACEBO_COMPARATOR|Placebo|Participants who will be randomized in the placebo group will receive maltodextrin (500mg/day).
62157139|NCT06081972|EXPERIMENTAL|Chicory RG-I|Participants who will be randomized in the placebo group will receive Chicory RG-I (500mg/day).
62157140|NCT06081972|EXPERIMENTAL|Carrot RG-I|Participants who will be randomized in the placebo group will receive Carrot RG-I (500mg/day).
62532040|NCT01593514|ACTIVE_COMPARATOR|Group 1 Conjugate-conjugate|Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
62532041|NCT01593514|EXPERIMENTAL|Group 2 Polysaccharide-conjugate|"Group II will receive one full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.5 mL of MenACWY-PS vaccine will be administered subcutaneously and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
62157141|NCT01026441|OTHER|Treatment for cellulite and circumference reduction|All subjects will be treated with the device
62157142|NCT02079402|ACTIVE_COMPARATOR|Liberal (target-guided) fluid resuscitation|"Noradrenaline to MAP \>= 65 mmHg.~Fluid boluses may be given as long as hemodynamic variables improve (dynamic or static variable(s) of choice). A fluid bolus is to be followed by evaluation of effect 30 minutes after the intervention at the latest.~'Variable(s) of choice' refers to the variable(s) used to assess hemodynamic improvement.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
62157143|NCT02079402|EXPERIMENTAL|Conservative (trigger-guided) fluid resuscitation|"Noradrenaline to MAP \>= 65 mmHg.~A fluid bolus of 250-500 ml may be given followed by evaluation of effect 30 minutes after the intervention at the latest if one of the following occurs:~* Plasma lactate concentration ≥ 4 mmol/l at point-of-care testing.~* Severe hypotension (MAP \< 50mmHg).~* Mottling beyond edge of kneecap.~* Severe oliguria (only in the first 2 hours after randomisation). Severe oliguria defined as urine output ≤ 0.1 ml/kg/hour IBW last hour.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
62157144|NCT00842959|OTHER|ZO|XL Stabi ZO or Invent ZO
62157145|NCT05935306|ACTIVE_COMPARATOR|G1- Control group|Conventional treatment + FBM simulation (n = 17 patients): All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group. The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off. Thus for the participant does not identify the group to which he belongs, the device activation sound (beep) will be recorded and it will turn on at the time of application.
62157146|NCT05935306|EXPERIMENTAL|G2- Intervention group|"Conventional treatment with placebo ibuprofen + FBM (n = 17) All participants will undergo the same surgical procedure. Patients will receive FBM (Table 1) and will be treated identically to the G2 group.~The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away. A dot will be irradiated in the middle of the square (Figure 1). Placebo ibuprofen will be manipulated."
62157147|NCT01769729|EXPERIMENTAL|PEPP + care management|"This 4-month collaborative psychotherapy, entitled Program for Emotional and Physical Pain (PEPP), will include 1 joint meetings with the behavioral health specialist (BHS), primary care provider (PCP), and patient, 10 psychotherapy sessions, and continued collaboration between the BHS and the PCP to assure a shared treatment plan.~Care management will include monthly calls with a depression care manager."
62157148|NCT01769729|ACTIVE_COMPARATOR|Care management alone|Care management will include monthly calls with a depression care manager.
62157149|NCT02765204|EXPERIMENTAL|DS-D-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
62157150|NCT02765204|EXPERIMENTAL|DS-DG-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
62157151|NCT02765204|EXPERIMENTAL|D-DG-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
62157152|NCT02765204|EXPERIMENTAL|D-DS-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
62157153|NCT02765204|EXPERIMENTAL|DG-D-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
62157154|NCT02765204|EXPERIMENTAL|DG-DS-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
62157155|NCT05209256|EXPERIMENTAL|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
62157156|NCT05209256|SHAM_COMPARATOR|chemotherapy|arboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
62157157|NCT02465632|EXPERIMENTAL|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
62157158|NCT02465632|ACTIVE_COMPARATOR|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
62157159|NCT02465632|PLACEBO_COMPARATOR|Placebo topical gel|apply a thin layer of the gel to the face
62157160|NCT00595725|EXPERIMENTAL|1|
62157161|NCT02131792|EXPERIMENTAL|Lateral Rectus Muscle Slanted Recession|Slanted recession of the lateral rectus muscle for the intermittent exotropia with convergence weakness
62157162|NCT06192537|EXPERIMENTAL|Intervention|
62532042|NCT01593514|EXPERIMENTAL|Group 3 Polysaccharide (subcutaneously)-conjugate|Group III will receive a full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine subcutaneously, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
62532043|NCT01593514|EXPERIMENTAL|Group 4: 1/5th dose Polysaccharide:conjugate|"Group IV will receive one fifth dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.1 mL of MenACWY-PS vaccine will be administered IM and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
62532044|NCT06334965|EXPERIMENTAL|PET-MRI|PET-MRI added in care pathway
62532045|NCT06126068|ACTIVE_COMPARATOR|first arm - Loading dose of magnesium sulfate|This arm received Loading dose of magnesium sulfate only. those that developed complication in each arm were managed according to departmental protocol.
62532046|NCT06126068|ACTIVE_COMPARATOR|2. Pritchard regimen|This arm received the full dose of magnesium sulfate regimen by Pritchard. those that developed complication in each arm were managed according to departmental protocol also.
62532047|NCT00042458|PLACEBO_COMPARATOR|Placebo|Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
62157163|NCT06200909|EXPERIMENTAL|Mindfulness Meditation (MM)|8-week mindfulness meditation program is based on Kabat-Zinn's MBSR program and will be led by MBSR-trained facilitators. The program has been modified to make it more accessible to caregivers. Weekly sessions will be 120-minutes long (instead of original 150-180-minute sessions). Formal meditation practices described in the original MBSR program (i.e., body scan, sitting meditation, mindful movement, mindful eating and walking) will be taught, in addition to loving kindness meditation (LKM). Participants will be given guided meditation recordings and compliance with home practice will be monitored with a practice log. The prescribed home practice has been modified to accommodate the needs of the caregiver: each practice is offered in 5- to 10-minute intervals (5 min, 10 min, and 20 min practice) to accommodate the caregiver's schedule.
62532048|NCT00042458|ACTIVE_COMPARATOR|Pramlintide Acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
62736424|NCT06351163||Intussusception|Pediatric patients exhibiting clinical signs and symptoms of intussusception between January 2016 and December 2020 that fit in with the inclusion criteria of the study.
62736425|NCT05648617|ACTIVE_COMPARATOR|Protein Supplement group|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein supplement. The participants will be asked to add it to their soft food or their beverages to reach the goal of consuming 30g daily for 12 weeks (3months).
62157164|NCT06200909|ACTIVE_COMPARATOR|Psychoeducation|"Psychoeducation (PSY) condition will be similar to MM with respect to number and duration of weekly sessions and daily homework. PSY is a lecture-based program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. Each session focuses on a specific topic related to wellness (e.g., nutrition, physical activity, medical screening) and caregiver-specific topics (e.g., understanding dementia and neurodegenerative disease, legal and financial issues)."
62157165|NCT06200909|ACTIVE_COMPARATOR|Respite control|Participant allocated to RC will not be exposed to a program, but will be offered 120-minutes of weekly respite care. Caregivers will be asked to record how they spend respite hours each week.
62157166|NCT00801151|EXPERIMENTAL|Vorinostat, vinorelbine|Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
62157167|NCT00891709|EXPERIMENTAL|1|LEO 29102 2.5 mg/g cream
62157168|NCT00891709|PLACEBO_COMPARATOR|2|LEO 29102 cream vehicle
62157169|NCT05893693|EXPERIMENTAL|CT0594CP CAR-T Cells [BCMA-UCAR-T (CT0594)andCD94-UCAR-T(CT7590) ]|CT0594CP
62157170|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
62157171|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
62157172|NCT01800994||asthma, COPD|patients with asthma and COPD treated with inhalation devices
62157173|NCT01844063|EXPERIMENTAL|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
62157174|NCT01844063|EXPERIMENTAL|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
62157175|NCT01844063|EXPERIMENTAL|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
62157176|NCT00957918|EXPERIMENTAL|Nicotine|Active drug is nicotine dihydrate bitartrate, provided as an oral capsule at escalating doses, 1 mg to 6 mg, once every 6 hours
62157177|NCT00957918|PLACEBO_COMPARATOR|placebo|Subjects in this arm receive placebo capsules orally
62157178|NCT05512598|EXPERIMENTAL|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
62157179|NCT00847977|ACTIVE_COMPARATOR|1|Heafusine - Physiologic serum
62157180|NCT00847977|EXPERIMENTAL|2|Isofundine - Tetraspan
62157181|NCT03800602|EXPERIMENTAL|Treatment (nivolumab, metformin)|Patients receive metformin PO BID starting on day 1. After 14 days of metformin only period patients also receive nivolumab IV every 4 weeks starting on day 15. Courses repeat every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity or consent withdrawal.
62157182|NCT04403815||right radial access|"diagnostic coronary angiography and/or PCI performed through right wrist and distal (snuffbox) radial access"
62157183|NCT04403815||left distal radial access|"diagnostic coronary angiography and/or PCI performed through left distal (snuffbox) radial access"
62157184|NCT05007600|EXPERIMENTAL|trial group|Participants in the experimental group received an 8-week intensive (Monday to Friday) online interactive course.
62157185|NCT05007600|NO_INTERVENTION|Control group|Participants in the control group consumed 8 weeks of unidirectional online video and audio programs (such as from YouTube).
62157186|NCT02754375|EXPERIMENTAL|Patient|Patient with resistant depression treated with rTMS
62157187|NCT00744705||1|Normal subjects who received routine health check-up in a comprehensive medical testing center
62157188|NCT00711022|EXPERIMENTAL|OsseoSpeed|
62157189|NCT06266676|EXPERIMENTAL|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
62157190|NCT06266676|ACTIVE_COMPARATOR|slide presentation|The control group, on the other hand, employs a unidirectional teaching method by the instructor, offering self-directed learning through online asynchronous courses, primarily using researcher-created online presentations.
62532049|NCT05665114|EXPERIMENTAL|QN-030a|QN-030a in Adult subjects with r/r AML
62532050|NCT00110526|EXPERIMENTAL|Ad.hIL-12|
62736426|NCT05648617|NO_INTERVENTION|control group|Receive no intervention- usual care, will receive the standard care of the clinic without supplemented with PS.
62736427|NCT00584532|PLACEBO_COMPARATOR|A|A=Placebo ARM of Study
62157191|NCT04037592|EXPERIMENTAL|Active standardized iTBS-DMPFC|This active group will receive standardized dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
62157192|NCT04037592|EXPERIMENTAL|Active high-dosage iTBS-DMPFC|This active group will receive high dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
62157193|NCT04037592|SHAM_COMPARATOR|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Patients in the sham group will receive the same standardized or high-dosage iTBS performing by a sham coil
62157194|NCT04258306|ACTIVE_COMPARATOR|Resveratrol|180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.
62532051|NCT01307839|ACTIVE_COMPARATOR|5% lidocaine patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
62532052|NCT01307839|PLACEBO_COMPARATOR|placebo patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
62157195|NCT04258306|EXPERIMENTAL|REVIFAST|180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold \& Zucc. Root supported on Magnesium hydroxide).
62157196|NCT02054000|ACTIVE_COMPARATOR|Tirofiban group|If thrombolysis in myocardial infarction flow \<3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
62532053|NCT06053775|ACTIVE_COMPARATOR|Online Cognitive Training|15 sessions of 20 minutes each one.Training will focus on the stimulation of several cognitive functions (attention, memory and learning, language, executive functions,processing speed, etc) through different exercises. The sessions will be adjusted to the individual performance level. The participant will perform these exercises from their computer or tablet, through the NeuronUp2GO platform, and the researcher will have access to all the session data.
62157197|NCT02054000|PLACEBO_COMPARATOR|Placebo group|If thrombolysis in myocardial infarction flow \<3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery
62532054|NCT06053775|EXPERIMENTAL|Transcranial Direct Current Stimulation|"tDCS: 15 daily sessions targeting left DLPFC (anode: F3, cathode: Fp2) Current intensity will be set at 2mA and will be applied for 20 minutes, with 15-second ramps up and down at the beginning and end of the stimulation period.~During the session, the participant will be performing the OCT."
62532055|NCT06053775|EXPERIMENTAL|Transcranial Alternating Current Stimulation|"tACS: 15 daily sessions targeting left DLPFC (anodes: F3, F4; frequency: 4Hz -theta-tACS-). Current intensity will be set at 2mA and will be applied for 20 minutes, with 15-second ramps up and down at the beginning and end of the stimulation period.~Participant will be performing the OCT during stimulation."
62157198|NCT05612113|ACTIVE_COMPARATOR|Baseline - Session Goal Formulation|"In the baseline phase, the therapist will formulate two session goals, see under descriptions of primary outcome measure.~In this SCED-study, the baseline phase will be of randomized length (5-9 sessions) for each therapist.~The reason for defining this as an active comparator is that we the behavior of formulating two session goals before each session should be considered an intervention, stimulating the therapist to reflect on the upcoming session goals, on defining concrete behaviors to reach the session goal, and to reflect upon his/her session behaviors afterwards. Thus, regarding the baselinephase as a no intervention would be misleading."
62157199|NCT05612113|EXPERIMENTAL|Live Supervision with Bug-in-the-Ear (BITEar) as method|"LS with the Bug-in-the-Ear (BITEar) is a video based supervision format where the supervisor watches the therapy session live through a webcam in the therapy room. During the therapy session, the supervisor provide verbal feedback and guidance to the therapist who wears wireless in-ear headphones.~In this SCED-study, the intervention phase consist of 5 to 9 BITEar supervision sessions (number of supervision sessions is randomized between therapists)~The BITEar supervision will consist of three phases:~Pre-supervision (15 minutes): Discussion of the therapists session goals, how the therapist wants the supervisor's help and agreement on prompts and cues from supervisor~Live supervision during the therapy session (≈ 45-60 minutes): Supervisor gives real time feedback and guidance focusing on helping the therapist achieve session goals~Post-supervision (15 minutes): Reflection about the session, session goals and the supervision."
62532056|NCT06053775|SHAM_COMPARATOR|tES sham|"15 sessions of sham stimulation for 20 minutes, acting as a placebo control group. The electrode montage will be the same as that used in the active neuromodulation conditions: tDCS for half of the participants and tACS for the other half. In this sham stimulation condition, the current will only be delivered for a 15 seconds, at the ramp-up and ramp-down times at the beginning and end of the session.~The OCT will also be the same as those performed by participants in the other groups"
62532057|NCT03880916|EXPERIMENTAL|Duloxetine group|"1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
62532058|NCT03880916|PLACEBO_COMPARATOR|Placebo group|"1. Phase I (preemptive): 2weeks before operation (Placebo for 2weeks)~2. Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
62532059|NCT03180463|EXPERIMENTAL|Group 1|Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).
62532060|NCT03180463|PLACEBO_COMPARATOR|Group 2|Core decompression surgery.
62532061|NCT03550573|EXPERIMENTAL|hypertrophic cardiomyopathy without sudden death history|
62532062|NCT03550573|EXPERIMENTAL|hypertrophic cardiomyopathy with sudden death history|
62532063|NCT02686645|EXPERIMENTAL|Fecal Microbiota Therapy|Vancomycin 125 mg po qid for 7 days or metronidazole 500 mg po tid for 7 days pre-treatment. Loperamide 4 mg po after morning prep and 2 mg post treatment. The route of administration fecal microbiota will be by retention enema via a rectal tube.
62736428|NCT00584532|ACTIVE_COMPARATOR|B|B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.
62157200|NCT05235815|EXPERIMENTAL|Sonoanatomy and retro SCTL compartment block|"During phase 1, ten healthy human volunteers will be involved. A bilateral ultrasound scan will be performed in the paravertebral region to describe the sonoanatomy of the retro SCTL compartment.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block."
62532064|NCT02861079|EXPERIMENTAL|Propess with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
62532065|NCT02861079|ACTIVE_COMPARATOR|Propess vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
62532066|NCT01327144|EXPERIMENTAL|Famciclovir 500mg|1 tablet each 8 hours for 7 days
62532067|NCT01327144|ACTIVE_COMPARATOR|Aciclovir 400mg|2 tablets of Aciclovir 400 mg each 4 hours for 7 days
62532068|NCT02833701|EXPERIMENTAL|Treatment (bevacizumab and ascorbic acid)|Patients receive ascorbic acid IV over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62532069|NCT03544489|EXPERIMENTAL|E-ICD Intervention|E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Borg scale, and exercise logs), and 3) telephone coaching by cardiac rehabilitation (CR) staff. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months.
62532070|NCT03544489|NO_INTERVENTION|Usual Care|"Usual Care will receive treatment as usual from their health care clinicians with outcomes measured at baseline, 3, 6, and 12 months. Participants will not be discouraged from physical activity, but will be asked not to change their current level of activity for 6 months while in the study. Usual care involves ICD interrogation and follow-up every 3 months, measured either in-person or with home telephonic transmissions. Because participants in usual care may choose to participate in another exercise program, we will monitor those who participate in exercise programs and use the StepWatch monitor to quantify the amount and timing of physical activity. To control for group differences in attention, investigators will telephone usual care participants requesting information about health care utilization twice during the study at 3, 6, and 12 months."
62532071|NCT01167257|EXPERIMENTAL|Experimental arm|"Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation~Liposome encapsulated botulinum toxin A'"
62532072|NCT01167257|PLACEBO_COMPARATOR|Control arm|"Normal saline 50 mL in single intravesical instillation~Normal saline instillation'"
62532073|NCT04104048||patients who were diagnosed as Anterior STEMI|"1. Patients who were diagnosed as Anterior STEMI according to criteria developed by the European Society of Cardiology.~2. Onset of maximal intensity of chest pain within 12 hours before procedure"
62532074|NCT02948153||asthma with bronchial hypersecretion|In a clinical study, participants are often divided into groups. Group one: they were defined as those who expectorated daily for at least three months for a minimum period of two consecutive years, without attribution to any other cause or disease.
62532075|NCT02948153||asthma without hypersecretion|In a clinical study, participants are often divided into groups. Group two: We defined asthma as a history of variable respiratory symptoms and evidence of variable expiratory airflow limitation.
62532076|NCT02972918||Levosimendan|At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
62532077|NCT04810130|SHAM_COMPARATOR|Kicking|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer kicking intervention).
62532078|NCT04810130|EXPERIMENTAL|Soccer Heading (Frontal)|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer heading intervention).
62532079|NCT04810130|EXPERIMENTAL|Soccer Heading (Oblique)|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer heading intervention).
62532080|NCT02871271|EXPERIMENTAL|IQP-AS-121|To be taken once daily dosing of 1 tablet in the morning.
62157201|NCT00956527|EXPERIMENTAL|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
62157202|NCT04834167|EXPERIMENTAL|Treatment|Eligible patients will receive ten picopulse treatments for bi-monthly.
62157203|NCT00961389||delirious patients|minimal any positive CAM-ICU score during ICU admission
62157204|NCT00961389||non-delirious patients|without any positive CAM-ICU score during ICU admission
62532081|NCT06151496|ACTIVE_COMPARATOR|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62532082|NCT06151496|EXPERIMENTAL|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62532083|NCT05133791|ACTIVE_COMPARATOR|0.5 mg|Annexin A5-CW800, 0.5 mg, 1 dose
62532084|NCT05133791|ACTIVE_COMPARATOR|1.0 mg|Annexin A5-CW800, 1.0 mg, 1 dose
62532085|NCT05133791|ACTIVE_COMPARATOR|2.0 mg|Annexin A5-CW800, 2.0 mg, 1 dose
62532086|NCT02838810|EXPERIMENTAL|Experimental|CHB patients with low level HBsAg.Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg \<1000 IU/mL and Hepatitis B virus DNA \<100 IU/mL, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL, peginterferon treatment will be stopped and patients will receive 24 weeks follow up.
62532087|NCT02838810|OTHER|Control|Patients do not need to change their NAs treatment.
62157205|NCT00575081||Stereotactic Brain Procedures|Patients who have consented to undergo or have undergone a stereotactic brain procedure for any reason including those who need Deep Brain Stimulation, SEEG or other brain neurmodulation device implant.
62157206|NCT01305837|EXPERIMENTAL|methylprednisolone|all patients will be treated with the active drug methylprednisolone 500 mg in 3 days every month for 60 weeks.
62157207|NCT01177644|EXPERIMENTAL|Active|
62157208|NCT02799693||Recurrent VT failing RF ablation|Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
62157209|NCT06337799|EXPERIMENTAL|Research Pharmacist Monitoring|The research pharmacist will help the mother find a primary care physician if she doesn't have one and discuss strategies to lower blood pressure, if needed. The pharmacist interactions will occur 7 days after enrollment and then approximately every 2 weeks to 2 months during 12 months of follow up, depending on blood pressure control. They may recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed.
62157210|NCT02669056|EXPERIMENTAL|preterm babies|preterm babies (less than 28 weeks)
62157211|NCT02669056|OTHER|term babies|term babies with blood test prescription
62157212|NCT01092689|EXPERIMENTAL|PhIP|Prior to surgery, consented subjects will ingest a capsule containing \[14C\]PhIP. This amount of \[14C\]PhIP (84 micrograms PhIP; 15.6 micro-curies) is equivalent to that in 2 very well done grilled/barbecued chicken breasts (Sinha 1995); the amount of radioactivity is equivalent to the dose received in a commercial airline flying at 30,000 ft. for 5 h (HPS 2007) or to the amount received during a typical chest x-ray.
62157213|NCT05063175|ACTIVE_COMPARATOR|Control Group|Children in the control group received the conventional physical therapy protocol which was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking.
62157214|NCT05063175|EXPERIMENTAL|Experimental Group|The children in the experimental group received the conventional protocol applied to the control group. Further, they wore TheraTog orthotic undergarment with its strapping system for 8 hours daily for 12 successive weeks.
62157215|NCT04680559|EXPERIMENTAL|MCBI Group|Training in mindfulness and compassion (MCBI) is facilitated in eight weekly sessions of 2 hours. With a didactic format, through theory, class discussions, and guided meditation practices.
62157216|NCT04680559|ACTIVE_COMPARATOR|Active-Wait List Group|Completion of a record during these 8 weeks. Active work of introspection about one's own sensations, thoughts, distractions, judgments, etc. in therapy sessions. Registered after each session.
62157217|NCT02529176|EXPERIMENTAL|Best-practice alert|Receive the best-practice alert (BPA) during the course of their clinical work in the electronic medical record.
62157218|NCT02529176|NO_INTERVENTION|No alert|Physicians will receive no best-practice alert from the electronic medical record.
62157219|NCT04428619|ACTIVE_COMPARATOR|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|The PENFS device has a battery activated generator and wire harness. Four leads are attached to the generator, each with a sterile 2 mm, titanium needle. The patient's ear is trans-illuminated to identify neurovascular bundles that are avoided during needle placement. The generator is attached with adhesive to the skin behind the patient's ear. Needles are inserted into the dorsal and ventral aspects of the ear, within 1-1.5 mm of the vascular branches to create a field effect. The device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The device is worn for 5 days/week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will be asked to wear a SmartWatch during the study to monitor heart rate.
62157220|NCT04428619|SHAM_COMPARATOR|Sham Device|The sham devices will be identical to the active devices but will not administer electrical charges. Per manufacturer design and patient anecdotal experience from previous studies, both active stimulation and sham are below detectable sensation threshold. Per report from previous studies, some patients may experience a sensation around the ear after percutaneous needle placement; however, this sensation can occur with equal likelihood in the active or sham device. The device is worn for 5 days a week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will also be asked to wear a SmartWatch as above.
62157221|NCT02865083|ACTIVE_COMPARATOR|Treatment|Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
62157222|NCT02865083|NO_INTERVENTION|Standard|Patients will receive use of the standard of care option which is the montgomery straps
62157223|NCT01469442|EXPERIMENTAL|external biliary duct stent|'External Biliary duct stent in the bile duct by cystic way'
62157224|NCT01469442|NO_INTERVENTION|without external biliary duct stent|
62157225|NCT03039322||HCC|
62157226|NCT03039322||liver cirrhosis No HCC|
62532088|NCT02554136|EXPERIMENTAL|Sequence 1|HGP0918 -\> HGP0816 -\> HGP0918 + HGP0816
62714171|NCT02921789|EXPERIMENTAL|Bleselumab Regimen|Participants received bleselumab regimen (basiliximab induction, bleselumab, Tacrolimus, Methylprednisone, Prednisolone). Basiliximab 20mg administered by intravenous injection prior to transplantation or intra - operatively before revascularisation as induction therapy and 20mg on day 3 or 4 or 5 post-transplant. Bleselumab 200mg administered by intravenous infusion on day 0, 7, 14, 28, 42, 56, 70, 90 and once per month until month 12. Tacrolimus 0.1 mg/kg/day (two equally divided doses at 0.05 mg/kg/day every 12 hours with a target trough level of 4 - 11 ng/mL) administered orally within 48 hours post transplant until 12 months post transplant. Methylprednisone 500, 250, 125 and 60mg administered orally or intravenously on days 0, 1, 2 and 3 respectively and continue through 12 months post transplant. Prednisolone administered orally by tapered doses of 20-30 mg on days 4-14, 10-20mg on days 15-28, 5-10mg on days 29 through 12 months post transplant.
62532089|NCT02554136|EXPERIMENTAL|Sequence 2|HGP0816 -\> HGP0918 + HGP0816 -\> HGP0918
62532090|NCT02554136|EXPERIMENTAL|Sequence 3|HGP0918 + HGP0816 -\> HGP0918 -\> HGP0816
62532091|NCT02554136|EXPERIMENTAL|Sequence 4|HGP0918 -\> HGP0918 + HGP0816 -\> HGP0816
62532092|NCT02554136|EXPERIMENTAL|Sequence 5|HGP0816 -\> HGP0918 -\> HGP0918 + HGP0816
62532093|NCT02554136|EXPERIMENTAL|Sequence 6|HGP0918 + HGP0816 -\> HGP0816 -\> HGP0918
62714172|NCT02167711|EXPERIMENTAL|SIRT|
62532094|NCT03465826|EXPERIMENTAL|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
62532095|NCT03465826|ACTIVE_COMPARATOR|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
62532096|NCT06456983|NO_INTERVENTION|treatment as usual (TAU)|Patients randomized to TAU only will continue on a stable drug regime for the next 28 weeks, but will not receive maintenance electroconvulsive therapy (mECT)
62532097|NCT06456983|ACTIVE_COMPARATOR|maintenance electroconvulsive therapy (mECT) plus TAU|All subjects will enter PHASE 1 and will receive a full course of routine ECT (maximum of 6 weeks and 3 treatments per week) while being on stable antipsychotic medication. All ECT-responders (patients with improvement of 30% or more on Brief Psychiatric Rating Scale (BPRS) will enter PHASE 2 and will be randomly assigned to the active comparator (mECT plus treatment-as-usual, TAU) or the control intervention (TAU) which both last 28 weeks. Non-responders (patients without improvement of at least 30 % on BPRS scale) will not enter PHASE 2.
62532098|NCT06058286|EXPERIMENTAL|Continuous quality improvement of antenatal HIV, syphilis and hepatitis B testing|Intervention facilities will receive targeted and enhanced support in line with the continuous quality improvement (CQI) approach, over a period of approximately 12 months, to promote implementation of the national guidelines and sustained provision of routine testing for HIV, syphilis and hepatitis B at least once during pregnancy. District-level CQI coaches will provide training in CQI methods to two facility representatives from each of the 20 intervention arm facilities. The CQI coaches will then work with these facility-level 'CQI advocates' to implement a process of quality improvement to identify and address barriers to antenatal testing.
62532099|NCT06058286|NO_INTERVENTION|Routine antenatal care and testing|"In the control clusters, pregnant women will receive the existing standard of antenatal care, including antenatal testing for HIV, syphilis and hepatitis B (usual care).~Current Indonesian guidelines recommend antenatal screening and treatment for HIV/syphilis/hepatitis B according to clinical protocols (for syphilis this is a single rapid test with no further confirmation of positive tests before commencing treatment using one injection of penicillin at an ANC clinic; for HIV there are three sequential rapid tests with confirmed cases initiating HIV antiretroviral therapy from the closest Care Support and Treatment clinic within the pregnancy period, and for hepatitis B, pregnant women with a reactive hepatitis B serum antigen test will be referred to a hospital for management based on clinical features)"
62532100|NCT02395952|ACTIVE_COMPARATOR|Lubrication|
62532101|NCT02395952|ACTIVE_COMPARATOR|Bandage Contact Lens|Acuvue Oasys Contact Lens
62532102|NCT02395952|ACTIVE_COMPARATOR|Prokera|Wet amniotic membrane mounted on plastic retaining ring
62532103|NCT02395952|ACTIVE_COMPARATOR|Ambiodisk|Freeze dried amniotic membrane
62532104|NCT02767830|EXPERIMENTAL|Excercise and Nutrition Program|Children and their care givers will receive 5 lectures on nutrition and exercise and will be given a weekly running program. At the end of the study children will be encouraged to participate in an annual 0.25-0.5 mile race.
62532105|NCT01501864|EXPERIMENTAL|School Support Group|School Support Intervention
62532106|NCT01501864|NO_INTERVENTION|Control|No school support
62532107|NCT02700126||undergoing propofol based TIVA for clip|This study is an observational study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm. We will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
62532108|NCT05948514||adult patients followed up in the nutrition and access device was inserted for parenteral nutrition|no intervention, observational study patients are enrolled, and followed up until a catheter related complication occurs
62532109|NCT04430257|EXPERIMENTAL|PrEP for health|Participants in the PrEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.
62157227|NCT06309745||RPLND cohort|Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or \<3cm IIB will be assessed for rRPLND. Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC. Patients who are not deemed eligible for or decline rRPLND, will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study.
62157228|NCT06309745||Carboplatin AUC10 cohort|Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study.
62157229|NCT01783379||ICU patient on micafungin|ICU patients with an invasive fungal infection on micafungin treatment
62532110|NCT04430257|ACTIVE_COMPARATOR|Standard of care|Participants in the standard of care arm will receive PrEP information and referrals.
62532111|NCT02212288||PKU patients|Adult PKU patients;Blood samples;Urine sample only at inclusion
62532112|NCT02212288||Healthy controls|Adult Healthy controls;Blood samples;Urine samples only at inclusion
62532113|NCT02950818|EXPERIMENTAL|Take Heart self-management program|Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
62532114|NCT02950818|NO_INTERVENTION|Waitlist control|Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
62532115|NCT01026155|EXPERIMENTAL|Respiratory muscle traininig|Low caloric diet and physical activities + Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
62532116|NCT01026155|ACTIVE_COMPARATOR|Control|Low caloric diet and physical activities
62157230|NCT05721898||Fracture Cases|Fragility Fracture Cases: Post-menopausal females between 50-80 years who have experienced a fragility fracture of the arms (including wrist fractures) or legs (including hip, pelvis, or ankle fractures) after the age of 50 years. Fractures of the spine, digits, toes or face will not be considered. A fragility fracture is operationally define based on self-report of an arm or leg fracture caused by falls from a height \<6 inches. A fragility fracture will not count if it is associated with 1) running, bicycling or other similar fast-moving activity such as sports subjects, 2) being struck by a falling or otherwise quickly moving heavy object, or 3) a motor vehicle accident. Insufficiency/stress fractures will not be included. Body mass index between 18.5 and 35 kg/m2.
62157231|NCT05721898||Non-Fracture Controls|Controls: Post-menopausal females between 50-80 years who have not experienced a fracture at any site after the age of 40 years (does not include fractures of the digits, toes or face). Does not self-report losing more than 1.5 inches in stature (height) in the previous 15 years. Body mass index between 18.5 and 35 kg/m2.
62157232|NCT03131271|EXPERIMENTAL|Experimental Group|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter. Immediately after its removal, the responsible nurse removed the catheter. A neutral instruction set was used on each patient prior to application of the ice pack. Patients in the experimental group were told that they may or may not experience pain during the catheter removal. The patients were also told that the aim of the study was to measure the effect of ice bag application upon pain during catheter removal, and that ice pack application may or may not be effective in terms of their own pain.
62157233|NCT03131271|NO_INTERVENTION|Control Group|The control group received the standard clinic procedure in that the catheter was removed by the assigned nurse without any cold application to the femoral region. Each control patient was informed that some patients may experience pain during catheter removal, and that they may or may not experience pain. Patients were also told that their pain levels would be measured during catheter removal.
62157234|NCT03935152|ACTIVE_COMPARATOR|Dydrogesterone|dydrogesterone 10 mg by mouth every 8 hours until delivery
62157235|NCT03935152|PLACEBO_COMPARATOR|Placebo|placebo by mouth every 8 hours until delivery
62157236|NCT00649402|EXPERIMENTAL|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
62157237|NCT00649402|ACTIVE_COMPARATOR|2|Lotrel® Capsules 10 mg/20 mg
62157238|NCT01176409|EXPERIMENTAL|High dose valacyclovir|Valacyclovir 1g po BID
62157239|NCT01176409|ACTIVE_COMPARATOR|Low dose valacyclovir|Valacyclovir 500mg po BID
62157240|NCT01176409|PLACEBO_COMPARATOR|Placebo|Inert placebo
62157241|NCT03386344|PLACEBO_COMPARATOR|Placebo|Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
62157242|NCT03386344|EXPERIMENTAL|Sotagliflozin 200 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
62714173|NCT05495581|EXPERIMENTAL|Mild renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
62532117|NCT04758975|EXPERIMENTAL|Venetoclax + Rituximab +/- Ibrutinib|"VENETOCLAX: Cycle 1 Day 1-Cycle 1 Day 28 Ramp-up with weekly dose escalation; Cycles 2-12: 400 mg QD RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2~At the end of Cycle 12 the MRD status is checked:~3 consecutive uMRD in PB + 1 uMRD in BM at last assessment treatment discontinuation and follow-up At least 1 MRD+ sample in the last 3 assessments venetoclax 400 mg QD until uMRD or up to 24 months or unacceptable toxicity (whichever occurs first) in combination with IBRUTINIB 420 mg QD until uMRD or PD or unacceptable toxicity"
62714174|NCT05495581|EXPERIMENTAL|Moderate renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
62157243|NCT03386344|EXPERIMENTAL|Sotagliflozin 400 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
62157244|NCT05627622|EXPERIMENTAL|Experimental group,|Receiving stone-prevention information on a monthly basis, using WhatsApp Messenger® application.
62157245|NCT05627622|NO_INTERVENTION|control group|will not receive stone-prevention information
62532118|NCT01673243||Cancer|Parents of children with cancer will complete a questionnaire.
62532119|NCT01673243||Sickle cell disease|Parents of children with sickle cell disease will complete a questionnaire.
62532120|NCT01673243||Survivors|Parents of survivors of childhood cancer will complete a questionnaire.
62532121|NCT02507544|EXPERIMENTAL|TRX-818|
62532122|NCT05533827|EXPERIMENTAL|Kaleidoscope|Kaleidoscope
62532123|NCT05533827|EXPERIMENTAL|Music|Music listening
62532124|NCT05533827|EXPERIMENTAL|Virtual reality glasses|Virtual reality glasses
62532125|NCT05533827|NO_INTERVENTION|Control|Control
62532126|NCT02067273|EXPERIMENTAL|TMS Intervention for 5 days|Application of Transcranial Magnetic Stimulation (TMS) for up to 5 days
62532127|NCT02067273|EXPERIMENTAL|TMS Intervention for 1 day|Application of Transcranial Magnetic Stimulation (TMS) for 1 day
62532128|NCT00805753|ACTIVE_COMPARATOR|Arm 1 ACTH 40 units|Receive ACTH at the dose of 40 units sub-cutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days.
62714175|NCT05495581|EXPERIMENTAL|Severe renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
62714176|NCT05495581|EXPERIMENTAL|Normal renal function|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
62157246|NCT05143320||Covid+|
62157247|NCT05143320||Covid-|
62157248|NCT04043663|EXPERIMENTAL|Virtual reality program group|Virtual reality program based on a virtual reality guided tour registered in the investigator's pediatric OR setting before surgery.
62157249|NCT04043663|ACTIVE_COMPARATOR|control group|standard perioperative care without virtual reality program
62157250|NCT01802398||No treatment|Observational cohort study of older (age≥60 years) adults who present to an emergency department with syncope (otherwise known as fainting)
62157251|NCT04150900|EXPERIMENTAL|Pembrolizumab + Bavituximab|Pembro and Bavituximab for progressive recurrent/metastatic squamous cell carcinoma of head and neck
62157252|NCT04455542||LMND-ALS|The main clinical manifestations were muscle weakness with atrophy and bundle fibrillation, the pyramidal tract sign was relatively mild, and extensive neurogenic damage with CMAP amplitude decreased could be seen in patients with electromyography.
62157253|NCT04455542||UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
62157254|NCT04455542||FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy
62157255|NCT04062279||case group|patients diagnosed with idiopathic paaarkinson's disease according to the clinical criteria.
62157256|NCT04117659|EXPERIMENTAL|Phosphodiesterase-5 inhibitor withdrawal|In this single arm pretreatment with an oral phosphodiesterase-5 inhibitor will be discontinued
62157257|NCT04277273|OTHER|Patients treated in the MaxilloFacial Prosthesis consultation|Patients treated in the MaxilloFacial Prosthesis consultation (Dental Department, Pitié-Salpêtrière Hospital Group)
62157258|NCT00883272||Normal Controls|25 women with CADP-CT \> 66 seconds were treated with Femarelle
62157259|NCT00883272||Thrombophilic|Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT \< 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
62157260|NCT02619825|OTHER|"Group 1 healthy volunteers"|Echography and Elastography To determine physiological standards across age classes of myocardial stiffness estimated by Elastography in ultrafast (estimated right ventricular stiffness \[VD\] and left ventricular \[LV\]). This will be done in groups of children without heart condition, age group (10 children per group, four age groups \[0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years\]).
62532129|NCT00805753|ACTIVE_COMPARATOR|Arm 2 ACTH 80 units|Receive ACTH at the dose of 80 units sub-cutaneously for up to 12 weeks.
62714177|NCT03940716|EXPERIMENTAL|IntERact|"Participants randomized to this condition will receive behavioral therapy comprised of motivational interviewing, cognitive behavioral skills therapy, and care management. Youth will receive a total of six sessions, one delivered in the emergency department at the time of recruitment and five delivered over the five subsequent weeks after the ED visit (i.e., baseline). Participants will also receive a smartphone APP that will deliver intervention content between therapy sessions, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
62532130|NCT04532801|EXPERIMENTAL|kisspeptin-10|kisspeptin infusion
62532131|NCT04532801|PLACEBO_COMPARATOR|placebo|placebo
62157261|NCT02619825|OTHER|Group 2 Patients CMH primitive|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Hypertrophic Cardiomyopathy (HCM) non obstructive primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
62157262|NCT02619825|OTHER|Group 3 Patients primitive CMD:|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Dilated Cardiomyopathy primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
62157263|NCT03522844|EXPERIMENTAL|Mindfulness-Based Stress Reduction (MBSR)|
62532132|NCT05322551||Obese only|"Definition of Obese:~Body Mass Index ≥ 30kg/m\^2 (WHO classification)~Definition of Non Diabetes: Fasting Plasma Glucose (FPG) \< FPG 100 mg/dL (5.6 mmol/L)"
62532133|NCT05322551||Obese with prediabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m\^2 (WHO classification)~Definition of Prediabetes: FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG) OR A1C 5.7-6.4% (39-47 mmol/mol)"
62157264|NCT03522844|ACTIVE_COMPARATOR|Escitalopram|
62532134|NCT05322551||Obese with diabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m\^2 (WHO classification)~Definition of Diabetes: (American Diabetes Association, 2020) FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.\* OR A1C ≥6.5% (48 mmol/mol)."
62532135|NCT01888666||rapid palatal expansion (RPE) using the Haas appliance|
62532136|NCT01888666||slow palatal expansion (SPE)|
62157265|NCT06092684|EXPERIMENTAL|BT-KTM-I|Patients received 0.5mg/kg BT-KTM-I during anesthesia induction period. Patients received 0.5mg/kg/h BT-KTM-I during anesthesia maintenance period.
62157266|NCT06092684|ACTIVE_COMPARATOR|Ketanest®S|Patients received 0.5mg/kg Ketanest®S during anesthesia induction period. Patients received 0.5mg/kg/h Ketanest®S during anesthesia maintenance period.
62157267|NCT02493556|EXPERIMENTAL|LLLT before muscle damage|Low Level Laser Therapy (LLLT) will be applied before the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
62532137|NCT03785366|EXPERIMENTAL|VeraCept|VeraCept subjects will be inserted with VeraCept on Day 1. At Day 57 subjects will be informed that they received VeraCept and may continue in the study for up to 5 years
62532138|NCT03785366|ACTIVE_COMPARATOR|ParaGard|ParaGard subjects will be inserted with ParaGard on Day 1. At Day 57 subjects will be informed that they received ParaGard and may choose to have the ParaGard removed or continue use per standard of clinical care.
62532139|NCT05509816|EXPERIMENTAL|Midazolam + Imlunestrant|Midazolam administered orally alone on day 1 followed by imlunestrant administered orally alone on days 3 to 8. On day 9, midazolam is administered orally in combination with imlunestrant orally.
62157268|NCT02493556|PLACEBO_COMPARATOR|Placebo LLLT before muscle damage|Placebo LLLT will be applied before the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
62157269|NCT02493556|ACTIVE_COMPARATOR|LLLT after muscle damage|Low Level Laser Therapy (LLLT) will be applied after the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
62157270|NCT02493556|PLACEBO_COMPARATOR|Placebo LLLT after muscle damage|Placebo LLLT will be applied after the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
62157271|NCT02948686|ACTIVE_COMPARATOR|SET (Self-Etching)|55 teeth will receive restorations using Self-Etching Application Strategy
62157272|NCT02948686|EXPERIMENTAL|SEE (Selective Enamel Etching)|55 teeth will receive restorations using Enamel Etching Application Strategy
62157273|NCT02948686|EXPERIMENTAL|SETT (Self-Etching, more time)|55 teeth will receive restorations using Self Etching with Extended time Application Strategy
62157274|NCT02948686|EXPERIMENTAL|SETL (Self-Etching, more layers)|55 teeth will receive restorations using Self Etching with Extended layers number Strategy
62157275|NCT00080119|EXPERIMENTAL|HIVneg/INH|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
62157276|NCT00080119|PLACEBO_COMPARATOR|HIVneg/PL|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
62157277|NCT00080119|EXPERIMENTAL|HIVpos/INH|HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
62157278|NCT00080119|PLACEBO_COMPARATOR|HIVpos/PL|HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
62157279|NCT01655199|EXPERIMENTAL|COPD group|Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
62157280|NCT02501616|ACTIVE_COMPARATOR|Metformin first|"Metformin first 8 wks --\> Dapagliflozin 8wks.~Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day."
62532140|NCT01162746|EXPERIMENTAL|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
62714178|NCT03940716|NO_INTERVENTION|Enhanced Usual Care Condition|Participants randomized to this condition will receive a pamphlet with violence, mental health, and substance use resources.
62532141|NCT01162746|ACTIVE_COMPARATOR|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
62532142|NCT00667030|EXPERIMENTAL|Lifestyle Modification|Combined hypocaloric diet and aerobic exercise training
62532143|NCT06084650||waldenstrom macroglobulinemia patients|
62532144|NCT06084650||healthy patients matched age and sex without waldenstrom macroglobulinemia and ocular disease|
62714179|NCT05886478||Brentuximab Vedotin|Participants with CTCL who were retreated with BV after relapse will be observed retrospectively and the outcomes will be observed from June 2023 to September 2023.
62714180|NCT05820503|EXPERIMENTAL|R group :Ultrasound-guided lower abdominis rectus sheath block group|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally.
62714181|NCT05820503|NO_INTERVENTION|Control group|Do nothing with it
62157281|NCT02501616|ACTIVE_COMPARATOR|Dapagliflozin first|"Dapagliflozin first 8 wks --\> Metformin 8wks.~Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed."
62157282|NCT04733573|ACTIVE_COMPARATOR|Occlusal appliance by Okeson with canone guidance|Occlusal appliance will be used while sleeping for 30 days.
62157283|NCT04733573|ACTIVE_COMPARATOR|Bimaxillary splint without canine guidance|Bimaxillary splint will be used while sleeping for 30 days.
62157284|NCT02896556|EXPERIMENTAL|Resin infiltrate|This is a single-arm study. Resin infiltration technique will be performed to all patients.
62157285|NCT06340191|EXPERIMENTAL|Intervention group|Pilates in addition to cueing
62157286|NCT06340191|ACTIVE_COMPARATOR|Control group|Pilates without cueing
62157287|NCT01566552|OTHER|SINGLE DOSE AMBISOME|
62157288|NCT04927806|EXPERIMENTAL|SilverKnight group|Silver Knight is an anti-microbial additive that uses silver ions to disrupt the normal enzymatic activities of bacteria
62157289|NCT04927806|NO_INTERVENTION|Control group|The control group uses standard ventilator circuits.
62532145|NCT05736627|EXPERIMENTAL|Online setting|Research course delivered digitally (Zoom or Teams meeting rooms) at a distance.
62157290|NCT00279409|ACTIVE_COMPARATOR|aripiprazole|"This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripiprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial."
62157291|NCT00279409|PLACEBO_COMPARATOR|Sugar pill|"This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis."
62157292|NCT01400945|EXPERIMENTAL|S-Pantoprazole|Experimental drug: AGSPT201 Tab. (contain S-Patoprazole) Active comparator: Pantoloc Tab. (contain pantoprazole)
62157293|NCT04320433|EXPERIMENTAL|Experimental|Participants will undergo two trials visit (with a week of separation). During the visits they will ingest an oral glucose load solution (oral glucose tolerance test) and gas exchange will be measured over the following 3-hours. The glucose levels will be monitored through a Glucose meter in different time frames.
62157294|NCT05967377|ACTIVE_COMPARATOR|Sorafenib - Period 1|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 200 mg Sorafenib (Nexavar®) in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157295|NCT05967377|EXPERIMENTAL|XS005 Sorafenib Capsule A - Period 1|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg (2 x 50 mg) XS005 Sorafenib Capsule A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157296|NCT05967377|EXPERIMENTAL|XS005 Sorafenib Tablet A - Period 1|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg XS005 Sorafenib Tablet A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157297|NCT05967377|EXPERIMENTAL|XS005 Sorafenib Capsule A - Period 2|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg (2 x 50 mg) XS005 Sorafenib Capsule A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157298|NCT05967377|EXPERIMENTAL|XS005 Sorafenib Tablet A - Period 2|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg XS005 Sorafenib Tablet A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157299|NCT05967377|ACTIVE_COMPARATOR|Sorafenib - Period 2|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 200 mg Sorafenib (Nexavar®) in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157300|NCT05967377|EXPERIMENTAL|XS005 Sorafenib Tablet A - Period 3|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg XS005 Sorafenib Tablet A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62532146|NCT05736627|NO_INTERVENTION|Onsite setting|Research course delivered physically in educational facilities.
62532147|NCT05837572|OTHER|Group 1|Each participant will attend the laboratory twice to perform two identical trials in order to asses validity (first trial) and reproducibility (second trial)
62532148|NCT03046407|EXPERIMENTAL|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
62532149|NCT00918840||DermaVir + HAART|"* Dosage: 0.4 mg DNA~* Dosage form: 3.2 mL DNA/PEIm nanomedicine~* Administration with 4 DermaPrep patches~* Frequency: every 4 weeks~* Duration: 8 weeks (3 DermaVir treatments)"
62532150|NCT00918840||Placebo + HAART|"* Dosage form: 3.2 mL Placebo~* Administration with 4 DermaPrep patches~* Frequency: every four weeks~* Duration: 8 weeks (3 Placebo treatments)"
62532151|NCT04075162||Low charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)
62532152|NCT04075162||No charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at no charge
62532153|NCT04832516|EXPERIMENTAL|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
62714182|NCT05820503|EXPERIMENTAL|Local anesthesia infiltration Group|Local anesthesia drugs were injected into the peri-umbilicus cord
62532154|NCT04832516|ACTIVE_COMPARATOR|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
62532155|NCT03378050|EXPERIMENTAL|Intervention group|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages."
62714183|NCT05794607|EXPERIMENTAL|Study group|
62714184|NCT05794607|NO_INTERVENTION|Control group|
62157301|NCT05967377|ACTIVE_COMPARATOR|Sorafenib - Period 3|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 200 mg Sorafenib (Nexavar®) in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157302|NCT05967377|EXPERIMENTAL|XS005 Sorafenib Capsule A - Period 3|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg (2 x 50 mg) XS005 Sorafenib Capsule A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
62157303|NCT04932083|PLACEBO_COMPARATOR|Bupivacaine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml sterile water.
62157304|NCT04932083|EXPERIMENTAL|Fentanyl|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml fentanyl (25µg).
62157305|NCT04932083|EXPERIMENTAL|Nalbuphine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water.
62157306|NCT04932083|EXPERIMENTAL|Midazolam|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 2mg of midazolam in 0.5 ml sterile water.
62157307|NCT06505252|EXPERIMENTAL|HA group or group A|"* All patients underwent operations under general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* The incision will be closed with vicryl 4/0 sutures.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle or sickle knife.~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization. The previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally. HA was used in liquid form, using a 2 mL vial (® Hyalgan) containing 20 mg of sodium hyaluronate that is synthesized by fermentation. The vial will be prepared for direct injection."
62157308|NCT06505252|EXPERIMENTAL|PRP group or group B|"* All patients underwent operations under general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* The incision will be closed with vicryl 4/0 sutures.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle or sickle knife.~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization The previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally PRPG was inserted into the external auditory canal (EAC) on the outer face of the TM remnant and fat graft. Special attention will be given to obtaining close contact among the PRPG, TM, and fat graft. The"
62157309|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
62532156|NCT03378050|ACTIVE_COMPARATOR|Control group|"Participants is the control group will be placed on a waiting list for 12 weeks. They will receive the intervention, after they complete the 12-week follow-up assessment. Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
62532157|NCT04008654|ACTIVE_COMPARATOR|ERAS group|This groups will receive ERAS protocol
62532158|NCT04008654|PLACEBO_COMPARATOR|Conventional care|This group will not receive the ERAS protocol.
62532159|NCT00906386|EXPERIMENTAL|1|
62532160|NCT00906386|PLACEBO_COMPARATOR|placebo|
62532161|NCT01545661|EXPERIMENTAL|Sputum induction|Enrolled patients receive sputum induction (using ultrasonic nebulisation with hypertonic saline)
62532162|NCT01545661|ACTIVE_COMPARATOR|No sputum induction|Enrolled patients randomised to this study arm will receive an observed expectorated sputum collection attempt. Research nurses train study patients on the method of producing sputum spontaneously.
62532163|NCT01038440|PLACEBO_COMPARATOR|Control|
62714185|NCT00976456|ACTIVE_COMPARATOR|Bevacizumab + Pemetrexed|Bevacizumab + Pemetrexed
61975843|NCT05467436|EXPERIMENTAL|Experimental group|"Subject will receive standard prescription for local anesthetics, IV sedation drugs and analgesics at the time of first surgery.~Subject will receive individually tailored-prescription for local anesthetics, IV sedation drugs and analgesics, based upon pharmacogenomic assessment at the time of second surgery."
62532164|NCT01038440|ACTIVE_COMPARATOR|EPA 0.5 g/d|
62532165|NCT01038440|ACTIVE_COMPARATOR|EPA 1.5 g/d|
62532166|NCT01038440|ACTIVE_COMPARATOR|EPA 3.0 g/d|
62157310|NCT03073122||Control|Brain MRI, Neurocognitive and psychological testing
62157311|NCT02407288|ACTIVE_COMPARATOR|active tDCS|patients will received 2 sessions per day for 5 consecutive days. Each session will last 20 minutes. The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
62157312|NCT02407288|PLACEBO_COMPARATOR|SHAM tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the 10 first seconds.
62532167|NCT01038440|EXPERIMENTAL|SDA 0.5 g/d|
62532168|NCT01038440|EXPERIMENTAL|SDA 1.5 g/d|
62532169|NCT01038440|EXPERIMENTAL|SDA 3.0 g/d|
62532170|NCT01038440|EXPERIMENTAL|SDA 6.0 g/d|
62714186|NCT00976456|ACTIVE_COMPARATOR|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab + Pemetrexed + Carboplatin
61975844|NCT03460483|EXPERIMENTAL|Comprehensive LS genetic testing|Testing for inherited forms of cancer and tumor sequencing
61975845|NCT04123054|ACTIVE_COMPARATOR|Sensor-Augmented MDI + Mobile App (control)|Participants will continue their usual multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data.
62714187|NCT01931917|EXPERIMENTAL|IY Parents and Babies Program|In the Incredible Years Parents and Babies Program, parents learn how to help their babies feel loved, safe, and secure. They learn how to encourage their babies' physical and language development. The parenting group format fosters peer support networks and shared learning. Trained Incredible Years facilitators use video clips of real-life situational vignettes to support the training and stimulate parenting group discussions and practice exercises with their babies. The program is group based with 6-8 mothers and partners attending 8 2 hour sessions with their babies.
62157313|NCT05959226|EXPERIMENTAL|Exercise and Enteral Nutrition Intervention|A comprehensive postoperative management combined physical exercise intervention with oral nutritional support
62157314|NCT05959226|ACTIVE_COMPARATOR|Enteral Nutrition Intervention|The control group will not receive exercise intervention, but will receive postoperative nutritional support treatment with the same standards as the experimental group.
62714188|NCT01931917|ACTIVE_COMPARATOR|Usual Care|Usual care consists of the elements that are being offered to all mothers in the participating municipalities which is 5 home visits by health visitors, a mothers group, a health nurse station and extra visits if needed.
62157315|NCT04278690|NO_INTERVENTION|Usual Care|Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.
62157316|NCT04278690|EXPERIMENTAL|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.
62157317|NCT04278690|EXPERIMENTAL|HELPix+Tech|After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app
62157318|NCT04449445|OTHER|Standard enteral tube feeds|Patients will be instructed to continue a normal diet before surgery. Post-operatively, patients will receive standard of care isocaloric and iso-nitrogenous standard enteral tube feeds
62157319|NCT04449445|EXPERIMENTAL|Nestle IMPACT AR|Patients will be encouraged to continue their regular diet until their surgery day. In addition, beginning 5 days before surgery, subjects will be instructed to drink three, 6 ounce cartons of Nestle IMPACT AR each day until their surgery. Post operatively patients who are able to eat orally, will be given three, 6 ounce cartons of Nestle IMPACT AR to drink each day for 5 days. Patients who are not able to tolerate an oral diet will be given Nestle IMPACT via a continuous tube feeding for 5 days through a temporary nasogastric feeding tube placed per standard post-operative care. Dosing of the tube feeding will be based on weight at a rate of approximately 70-75 cc/hour.
62157320|NCT02084576|EXPERIMENTAL|Nepafenac|One drop in the study eye 3 times daily for 30 days
62157321|NCT02084576|ACTIVE_COMPARATOR|Ketorolac|One drop in the study eye 4 times daily for 30 days
62157322|NCT00984334|PLACEBO_COMPARATOR|Capsules with no active drug|Placebo capsules once daily for three weeks then twice daily for three weeks.
62714189|NCT02801786|PLACEBO_COMPARATOR|Placebo|Five capsules containing placebo
62714190|NCT02801786|EXPERIMENTAL|Tamoxifen|Five capsules containing 20mg of tamoxifen.
62157323|NCT00984334|ACTIVE_COMPARATOR|Naloxone SR 2.5 mg capsules|Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
62157324|NCT00984334|EXPERIMENTAL|Naloxone SR 10mg capsules|Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
62157325|NCT00984334|EXPERIMENTAL|Naloxone SR 20 mg capsules|Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
62157326|NCT00984334|EXPERIMENTAL|Naloxone SR 5mg capsules|Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
62157327|NCT04127747|ACTIVE_COMPARATOR|Standard dose group|
62157328|NCT04127747|EXPERIMENTAL|Individualized dose group|
62714191|NCT02801786|EXPERIMENTAL|Lidocaine|One sachet containing lidocaine gel at 4%
62157329|NCT05860218|OTHER|advices|• Group I (control) will receive advices only.
62157330|NCT05860218|EXPERIMENTAL|exercises plus advices|• Group II (experimental) will receive a suggested functional exercise program plus advises
62157331|NCT02607176|EXPERIMENTAL|Heweizhixie capsule|Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
62157332|NCT00988845|EXPERIMENTAL|Indole-3-carbinol|
62157333|NCT03573375|EXPERIMENTAL|Cancer Patients in Supportive Care Clinic (SCC)|
62157334|NCT03627299|EXPERIMENTAL|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks
62532171|NCT04602910|EXPERIMENTAL|the phases of planning and acting|Each part of the website page was assessed for comprehensibility and usability by patients. Health care providers were asked to assess the acceptability of the website. A 5-point Likert scale was used for patient and health care provider ratings for each item. If the score were less than 3, then we would modify the website content based on the user feedback from patients and health care providers
62714192|NCT06493734|EXPERIMENTAL|Stereotactic body radiation therapy|Single-arm study
62532172|NCT03858543|EXPERIMENTAL|Fractional laser treatment & Poly-L Lactic Acid (Sculptra)|One Fractional laser treatment on half of the body with Sciton Laser and Scluptra
62532173|NCT03858543|ACTIVE_COMPARATOR|Fractional laser treatment|One Fractional laser treatment on half of the body with Sciton Laser
62714193|NCT04273269|EXPERIMENTAL|8x10^12 vg/Kg LYS-GM101|Subjects will receive a single infusion: 8x10\^12 vg/Kg LYS-GM101
62714194|NCT05015504|EXPERIMENTAL|Time restricted feeding|The study will consist of three phases. In phase I all study subjects will be in the ad libitum feeding phase for one week followed by Phase II. In Phase II the subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week. For phase III (final week), patients will be returned to an ad libitum feeding. The first and third phases will serve as control phases, and the second phase will be the experimental phase
62714195|NCT01298323|ACTIVE_COMPARATOR|Vandetanib Control|Control - treatment 300mg vandetanib opel label
62157335|NCT04755907||Group A|colorectal cancer patients at resectable stage II/III who will receive adjuvant chemotherapy after surgery
62157336|NCT04755907||Group B|colorectal cancer patients at locally advanced stage who will receive neoadjuvant chemotherapy before surgery and adjuvant chemotherapy after surgery
62157337|NCT04755907||Group C|colorectal cancer patients with liver metastases
62157338|NCT06233422||Major Depressive Disorder (MDD) Group|MDD group will consist of 70 participants with MDD, aged between 18-65, with a Patient Health Questionnaire-9 (PHQ-9) score of at least 10; who are also experiencing at least 1 sleep or circadian problem in the past 3 months.
62157339|NCT06233422||Healthy Control Group|Healthy control group will consist of 70 healthy control participants, aged between 18-65, with a Patient Health Questionnaire-9 (PHQ-9) score of below 5, indicating minimal or no depressive symptoms.
62157340|NCT02398539|ACTIVE_COMPARATOR|Group 1|Silver nitrate treatment will include weekly applications in the pediatric surgery office by a clinician.
62157341|NCT02398539|ACTIVE_COMPARATOR|Group 2|Triamcinolone cream, 0.5% applied three times per day by the patient's caregiver.
62157342|NCT05851144|EXPERIMENTAL|Intervention|Intervention arm involves participants to the Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula with multi-prong interventions.
62157343|NCT05851144|NO_INTERVENTION|Control|Participants in the control group follow regular routine with physical activities, food service, and parental engagment.
62157344|NCT03022747|ACTIVE_COMPARATOR|Standard maintenance therapy|Standard maintenance therapy with 6 mercaptopurine and methotrexate
62157345|NCT03022747|EXPERIMENTAL|Allopurinol treatment|The second 12 week phase during which allopurinol is added to oral 6-mercaptopurine and methotrexate therapy
62157346|NCT03503188|EXPERIMENTAL|All participants|
62157347|NCT02577315|EXPERIMENTAL|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
62157348|NCT02577315|EXPERIMENTAL|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
62157349|NCT01259219|EXPERIMENTAL|Rifabutin (Mycobutin)|Rifabutin is a red-violet powder souble in chloroform and methanol, sparingly souluble in ethanol, and very slightly soluble in water. Mycobutin capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. Mycobutin capsules for oral administered contain 150mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose magenesium stearate, red iron oxide3, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.
62157350|NCT03153566|EXPERIMENTAL|study group|include (15) patients will be injected with Tuberculin vaccine 0.3 ml every 2 weeks, vaccine will be injected in the largest wart, 4 sessions will be done then patients will be followed for 2 months
62157351|NCT03153566|ACTIVE_COMPARATOR|control group|include (15) patients will be treated with cryotherapy every 2 weeks ,4 sessions will be done then patients will be followed for 2 months
62157352|NCT03153566|EXPERIMENTAL|combined group|include (15) patients will be treated with combined cryotherapy and Tuberculin vaccine , one week cryotherapy and the other week Tuberculin vaccine , then patients will be followed for 2 weeks
62157353|NCT01540019|EXPERIMENTAL|Paullinea cupana|50mg of Paullinia cupana as capsule, twice daily
62157354|NCT04634994|EXPERIMENTAL|[F-18]SDM-8 tracer|Subjects will be administered standardized questionnaires for cognitive testing/other co-morbidities. They will undergo PET Scan and 3T Brain MRI. For PET Scan, an intra-arterial catheter will be inserted into the radial artery for \[F-18\]SDM-8 metabolite blood sampling by a trained anesthesiologist. Allen's test will be performed prior to insertion of the intra-arterial catheter. If arterial line can't be established to obtain metabolite samples, a venous line will be placed. In addition, an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer. Radiopharmaceutical will be injected as a bolus (approximately 5mCi for \[F-18\]SDM-8 followed by 5 mL of saline). The PET session will last up to 120 min. A head support apparatus will be used to minimize head motion. Brain PET data acquisition will begin at the moment of radiotracer injection. For MRI, several pulse sequences will be performed, no IV contrast will be used.
62157355|NCT00110422|EXPERIMENTAL|A1|
62157356|NCT00110422|ACTIVE_COMPARATOR|B1|
62157357|NCT05031065||Women undergoing radiation treatment after lumpectomy for breast cancer.|There is no specific study intervention being used. Samples will be collected from participants undergoing standard of care radiotherapy at pre-specified timepoints.
62157358|NCT01377844|EXPERIMENTAL|EGT0001442|EGT0001442 capsule, 20 mg, daily, 96 weeks
62157359|NCT01377844|PLACEBO_COMPARATOR|Placebo|Placebo
62157360|NCT05549713||Blepharoplasty group|As a single arm study, all examinees will undergo upper blepharoplasty. Data regarding corneal topography, tear film quality and contrast sensitivity will be obtained before the surgery, seven days and one month postoperatively
62157361|NCT03242239|EXPERIMENTAL|ALT02|
62157362|NCT03242239|ACTIVE_COMPARATOR|EU-licensed Herceptin|
62157363|NCT03242239|ACTIVE_COMPARATOR|US-licensed Herceptin|
62157364|NCT03743909||patients with aberrant CD markers|by flowcytometry from hospital information system
62157365|NCT03743909||patients without aberrant CD markers|by flowcytometry from hospital information system
62157366|NCT01406899|NO_INTERVENTION|Treatment as Usual|Standard treatment as usual (TAU) in the VA Connecticut Healthcare System substance abuse clinic consisting of individual and group therapy sessions and regular urine monitoring.
62157367|NCT01406899|EXPERIMENTAL|Computer-based treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
62157368|NCT02162927|EXPERIMENTAL|Potassium Nitrate (N)|This involves 1 serving (2 pills) of potassium nitrate KNO3- (N) (8 mmols NO3-). The supplementation period is six days. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
62157369|NCT02162927|PLACEBO_COMPARATOR|Potassium Chloride|This involves 1 serving (2 pills) of the nitrate-free placebo (PL) potassium chloride (8 mmol KCl) for a six-day supplementation period. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
62532174|NCT04581174|EXPERIMENTAL|1st degree of hypertrophy according to Camacho|Patients with 1st degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
62714196|NCT01298323|EXPERIMENTAL|Experimental|Experimental - treatment 300mg vandetanib opel label
62157370|NCT02416349|ACTIVE_COMPARATOR|Respiratory Muscles Stretching|Respiratory Muscles Stretching Neck stretching, upper chest stretching, pectoralis major stretching and lateral chest stretching.
62157371|NCT02416349|PLACEBO_COMPARATOR|Control Group|All volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
62157372|NCT01331278|ACTIVE_COMPARATOR|Custom Cutting Blocks|
62157373|NCT01331278|ACTIVE_COMPARATOR|Computer Assisted Surgery|
62157374|NCT02732470|EXPERIMENTAL|Qi Gong|The effect of Qi Gong training on quality of life in patients with systemic lupus erythematosus
62157375|NCT03214471|NO_INTERVENTION|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
62157376|NCT03214471|EXPERIMENTAL|Intervention|usual care + BARI-LIFESTYLE intervention
62157377|NCT02374294|EXPERIMENTAL|Epiflo|After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
62157378|NCT02374294|NO_INTERVENTION|Standard of Care|After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed. Intermittent dressing changes will take place as needed.
62157379|NCT02069379|NO_INTERVENTION|Controls|metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.
62157380|NCT02069379|EXPERIMENTAL|Metformin|16 weeks treatment with metformin (insulin sensitizing treatment)
62157381|NCT02069379|PLACEBO_COMPARATOR|Placebo|Placebo comparator to metformin treatment
62532175|NCT04581174|EXPERIMENTAL|2nd degree of hypertrophy according to Camacho|Patients with 2nd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
62532176|NCT04581174|EXPERIMENTAL|3rd degree of hypertrophy according to Camacho|Patients with 3rd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
62532177|NCT04581174|EXPERIMENTAL|4th degree of hypertrophy according to Camacho|Patients with 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
62532178|NCT01118897|EXPERIMENTAL|Neoadjuvant chemoradiation|All patients will receive concurrent chemoradiation. Chemotherapy will consist of Inj. Gemcitabine 300mg/mt2 weekly throughout the course of Radiotherapy. Radiotherapy will be delivered using Tomotherapy to a dose of 57Gy/25# over 5 weeks
62532179|NCT04993014|ACTIVE_COMPARATOR|Cohort 1, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 positive CTCs at baseline
62157382|NCT03267797|EXPERIMENTAL|Treatment group|Peripheral blood mononuclear cells (PBMCs) were administered into the uterine cavity of RIF patients in this group.
62157383|NCT03267797|PLACEBO_COMPARATOR|Control group|Phosphate buffer saline (PBS) as placebo was injected into the uterine cavity of RIF patients in this group.
62157384|NCT04255004|ACTIVE_COMPARATOR|A-PBMNC therapy|Patients in A-PBMNC therapy are treated with wound bed multiple perilesional and intramuscular injections of PBMNC cells suspension (0.2-0.3cc in boluses). This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
62157385|NCT04255004|NO_INTERVENTION|No A-PBMNC therapy|Patients in No A-PBMNC therapy receive only supportive treatment including wound care and pain killer drug.
62157386|NCT05293093|EXPERIMENTAL|Wheelchair Skills Training Program intervention study|A one-group pretest-posttest design study will be conducted, consisting of three phases (3- or 5-week baseline phase, 4-week training phase, 4-week retention phase)
62157387|NCT02574234|EXPERIMENTAL|Patients with orthopedic surgery|"Patients will be included in the consultation of anesthesia. The usual laboratory tests will be carried out and a determination of apelin and inflammatory cytokines. Assessment of cognitive functions using the Informant Questionnaire on Cognitive Decline in the Elderly (ICQODE), Mini Mental State examination (MMS) and the scale of Instrumental activities of daily living (IADL).~Day of surgery: liquid sampling cerebrospinal. Day 1 to day 7 postoperatively: determination of inflammatory cytokines and apelin, postoperative delirium research (Confusion Assessment Method (CAM)), residual cognitive dysfunction research (MMS, IADL, IQCODE).~3 months after operation: evaluation of cognitive performance (IQCODE, IADL)"
62157388|NCT05494346|OTHER|Arm A: Patients with peak nasal flow performed|This arm is made up of major patients. Nasal flow point measurements will be performed at D0 and D3.
62157389|NCT05494346|NO_INTERVENTION|Arm B: No peak nasal flow|This arm is made up of minor patients. Unlike arm A, nasal flow measurements will not be performed at D0 and D3.
62157390|NCT05615506|EXPERIMENTAL|patients|suction diathermy adenoidectomy
62157391|NCT05803122||Patients with Mild Cognitive Impairment (MCI)|Patients with diagnosis of MCI based on diagnostic research criteria , after a protocol of clinical, neuropsychological, structural brain imaging evaluation and biomarkers positivity assessment (amyloid-Positron Emission Tomography (PET) and/or Cerebral Spinal Fluid -CSF).
62157392|NCT05803122||Patients with Alzheimer's Disease (AD)|Patients with diagnosis of AD based on diagnostic research criteria , after a protocol of clinical, neuropsychological, structural brain imaging evaluation and biomarkers positivity assessment (amyloid-PET and/or CSF).
62157393|NCT02803866||Parents of preterm newborns (25-32 weeks of gestation)|Parents (mother or mother+father) of preterm newborns admitted at the Gregorio Marañón Hospital from birth, recruited during the first 10 days of preterm newborn hospitalization and receiving the training program CAP-PREM
62157394|NCT00440037|EXPERIMENTAL|AMG 531|
62532180|NCT04993014|EXPERIMENTAL|Cohort 1, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 positive CTCs at baseline
62157395|NCT05770206|EXPERIMENTAL|experimental Group|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
62157396|NCT05770206|ACTIVE_COMPARATOR|Control Group|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
62157397|NCT02489799|ACTIVE_COMPARATOR|Intervention|Advance care planning video
62157398|NCT02489799|PLACEBO_COMPARATOR|Control|Control video - no advance care planning content
62157399|NCT01478256|ACTIVE_COMPARATOR|Besifloxocin|Use of topical besifloxocin to treat acute blepharitis
62157400|NCT01478256|ACTIVE_COMPARATOR|Erythromycin|Topical Erythromycin ointment for treatment of acute blepharitis
62157401|NCT00021099|EXPERIMENTAL|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62157402|NCT01351597|EXPERIMENTAL|docetaxel/ oxaliplatin|All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
62157403|NCT01267188|EXPERIMENTAL|NBI-98854|Open-label, dose titration of active drug
62157404|NCT06383507|EXPERIMENTAL|Anti-CD70 UCAR-T Cell Injection|"In the discovery phase, accelerated titration combined with the 3+3 dose escalation principle was adopted, starting from the initial dose of 3×106/kg. If a grade ≥3 AE occurs during DLT observation, the accelerated titration mode will switch to 3+3 dose escalation, at least 12 eligible patients will be enrolled and receive 4 doses of CD70 UCAR-T cell therapy (3 × 10\^6 cells/kg, 6 × 10\^6 cells/kg, 8× 10\^6 cells/kg, 1 × 10\^7 cells/kg).~In the dose expansion phase, each group will choose one or two dose groups to verify the safety and efficacy, and plan to recruit about 6 subjects in each dose group."
62157405|NCT02835196||Optical Elastography Assessment of Skin Thickness|
62532181|NCT04993014|ACTIVE_COMPARATOR|Cohort 2, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 negative/absent CTCs at baseline
62532182|NCT04993014|EXPERIMENTAL|Cohort 2, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 negative/absent CTCs at baseline
62532183|NCT03401125||Sickle cell disease patients (SS genotype)|Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.
62532184|NCT01715792||Group 1|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant rejection reported during the overall study period (01 September to 31 October 2010).
62532185|NCT06399848|OTHER|Peritoneal Dialysis Daily|Each patient will compare their regular daily treatment with the effect of skipping a single day of treatment. There will be no other intervention.
62532186|NCT06075459||Implanted patients with Intensity IOLs, 12-24 months previously|Men and women who had implantation on both eyes using Hanita Lenses SeeLens SL IOL, for 12 to 24 months post operation.
62532187|NCT00724048|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), placebo capsule will be taken twice daily (BID) as 2 separate doses.
62157406|NCT02835196||Visual Assessment of Skin Thickness|
62157407|NCT05619991|EXPERIMENTAL|Group watching video|For the Educational Video, a scenario appropriate for the age group, about the preparation for the surgery, the operating room environment and the post-operative process will be created by the researchers. Expert opinion will be taken for the suitability of the scenario.
62157408|NCT05619991|OTHER|Scheduled training group|For the Planned Education, a power point presentation will be prepared by the researchers, appropriate for the age group, about the preparation for the surgery, the operating room environment and the post-operative process, and the patients will be trained before the surgery.
62157409|NCT05619991|NO_INTERVENTION|Control group|Before the operation, the fear and vital signs of the children in the sample will be evaluated. In the postoperative period, the pain, fear and vital signs of the children in the control group will be recorded and a questionnaire examining the satisfaction status will be applied.
62157410|NCT01647802|EXPERIMENTAL|Turner-Vertic'Easy-Tina|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Vertic'Easy; (3) Tina.
62532188|NCT00724048|EXPERIMENTAL|ACR16 10 mg BID|Participants will receive ACR16 10 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 10 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 20 mg).
62157411|NCT01647802|EXPERIMENTAL|Turner-Tina-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Tina; (3) Vertic'Easy.
62157412|NCT01647802|EXPERIMENTAL|Vertic'Easy-Turner-Tina|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Turner; (3) Tina.
62157413|NCT01647802|EXPERIMENTAL|Vertic'Easy-Tina-Turner|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Tina; (3) Turner.
62157414|NCT01647802|EXPERIMENTAL|Tina-Turner-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Turner; (3) Vertic'Easy.
62157415|NCT01647802|EXPERIMENTAL|Tina-Vertic'Easy-Turner|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Vertic'Easy; (3) Turner.
62157416|NCT05444374|EXPERIMENTAL|Serplulimab plus Bevacizumab Combined With Chemotherapy|"Each cycle being 21 days, Cisplatin plus Paclitaxel up to 4-6 cycles, the maximum duration of treatment with Serplulimab is 2 years (up to 35 cycles).~* Serplulimab, 300 mg IV, Day1 of each cycle~* Bevacizumab, 7.5 mg/kg, IV, Day1 of each cycle~* Cisplatin: 50 mg/m2, IV, Day1 of each cycle~* Paclitaxel: 175 mg/m2, IV, Day1 of each cycle"
62532189|NCT00724048|EXPERIMENTAL|ACR16 22.5 mg BID|Participants will receive ACR16 22.5 mg capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 22.5 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 45 mg).
62532190|NCT00724048|EXPERIMENTAL|ACR16 45 mg BID|Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 45 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 90 mg).
62157417|NCT01304225|ACTIVE_COMPARATOR|100ms single-shot|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
62157418|NCT01304225|EXPERIMENTAL|20ms multiple-shot|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
62157419|NCT01304225|EXPERIMENTAL|20ms multiple-shot, barely visible|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
62157420|NCT05986851|EXPERIMENTAL|Daily oral azeliragon|Azeliragon to be administered once daily for several days before, during, and after radiation therapy.
62157421|NCT06381388|EXPERIMENTAL|Active cTBS|cTBS delivered with an active TMS coil
62157422|NCT05610878|EXPERIMENTAL|Cultured ASCs enrichment fat grafting|Fat graft will be supplemented with naïve ASCs
62157423|NCT05610878|EXPERIMENTAL|Curcumin-preconditioned ASCs enrichment fat grafting|Fat graft will be augmented with curcumin preconditioned ASCs
62157424|NCT05610878|ACTIVE_COMPARATOR|conventional fat grafting|Fat graft will not be supplemented with ex-vivo expanded ASCs
62157425|NCT06079047|EXPERIMENTAL|group Dexamethasone|"adductor canal block with 10 ml of 0.5% bupivacaine + 10 ml of 0.9% saline solution + 2 ml of dexamethasone (8 mg)"
62157426|NCT06079047|ACTIVE_COMPARATOR|group Controle|"adductor canal block with 10 ml of 0.5% bupivacaine + 10 ml of 0.9% saline solution + 2 ml of 0.9% saline solution"
62157427|NCT01803945|PLACEBO_COMPARATOR|Placebo Group|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
62157428|NCT01803945|ACTIVE_COMPARATOR|AVE8112|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
62532191|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
62532192|NCT02838121|EXPERIMENTAL|Aclasta|Aclasta IV once annual for 2 years
62157429|NCT00383500|EXPERIMENTAL|Flexitouch device|Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)
62157430|NCT00383500|EXPERIMENTAL|Manual Lymphatic Drainage (MLD)|Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment
62157431|NCT00383500|NO_INTERVENTION|Observational Control (no intervention)|Control group, no intervention. No Flexitouch or manual massage therapy
62157432|NCT03955341|NO_INTERVENTION|conventional selective caries removal without disinfection|After collecting the first sample of dentin, the cavity will be restored
62157433|NCT03955341|OTHER|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
62157434|NCT03955341|OTHER|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
62157435|NCT01237600|EXPERIMENTAL|Cultivated limbal transplantation|
62157436|NCT01016275||Iliac lesions TASC A or B|All lesion types belonging to the iliac TASC A or B.
62157437|NCT06470945|EXPERIMENTAL|intervention- Glass ceramic sectional veneer|participants receive Glass ceramic sectional veneer covering only the area of defect
62157438|NCT06470945|ACTIVE_COMPARATOR|control- Glass ceramic laminate veneer|participants receive laminate veneers made of glass ceramics as a gold standard
62157439|NCT03150004|EXPERIMENTAL|CLAG-M regimen|Subject's treatment cycle is 30 days.
62157440|NCT03150004|EXPERIMENTAL|CLLDAC regimen|Subject's treatment cycle is 30 days. Subject may be treated on an outpatient basis (CLLDAC arm only). In addition, subjects who fail to achieve a CR/CRi after the first 30-day cycle may receive a second cycle of CLLDAC, per the discretion of the treating physician. Subjects who receive this second cycle should begin cycle 2 no later than 49 days after cycle 1.
62157441|NCT04706442|EXPERIMENTAL|Standard hospital care with follow up + Supportive Parenting App|Receive standard hospital care and follow up, and access to the Supportive Parenting App from pregnancy to 6 months postpartum
62157442|NCT04706442|NO_INTERVENTION|Standard hospital care with follow up|Receive standard hospital care with follow up
62157443|NCT03256305|EXPERIMENTAL|"personalized rTMS+drug treatment"|"Received personalized rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks"
62532193|NCT02838121|PLACEBO_COMPARATOR|Placebo|Placebo group
62532194|NCT03317886|ACTIVE_COMPARATOR|mesenteric approach|mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
62532195|NCT03317886|ACTIVE_COMPARATOR|conventional approach|Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
62532196|NCT04271735|PLACEBO_COMPARATOR|Participants with mild to moderate Psoriasis receiving Placebo|Participants with mild to moderate Psoriasis receiving placebo (2 capsules) twice daily by mouth for 28 days.
62532197|NCT04271735|EXPERIMENTAL|Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside|Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside Chloride 500mg (2 capsules) twice daily by mouth for 28 days.
62532198|NCT00889369|EXPERIMENTAL|A|Use of duloxetine, flexible dose (60-120mg/day) for 8 weeks, following a 2-week placebo lead-in phase
62532199|NCT02740387|EXPERIMENTAL|OTO-104|12 mg dexamethasone
62532200|NCT01476592|EXPERIMENTAL|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
62532201|NCT03915353||Experiment|No interventions
62532202|NCT03915353||Control|No interventions
62532203|NCT04738474|EXPERIMENTAL|PRISM Intervention|Subjects in this group will receive the PRISM intervention
62157444|NCT03256305|ACTIVE_COMPARATOR|Traditional rTMS +drug treatment|Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
62157445|NCT00614354|EXPERIMENTAL|1|
62157446|NCT03928821|EXPERIMENTAL|Group 1: PGT121 + VRC07-523LS|Participants will receive PGT121 and VRC07-523LS administered sequentially in this order at Day 0.
62157447|NCT03928821|EXPERIMENTAL|Group 2: PGDM1400 + VRC07-523LS|Participants will receive PGDM1400 and VRC07-523LS administered sequentially in this order at Day 0.
62157448|NCT03928821|EXPERIMENTAL|Group 3: 10-1074 + VRC07-523LS|Participants will receive 10-1074 and VRC07-523LS administered sequentially in this order at Day 0.
62157449|NCT03928821|EXPERIMENTAL|Group 4: PGDM1400 + PGT121 + VRC07-523LS|Participants will receive PGDM1400, PGT121, and VRC07-523LS administered sequentially in this order at Day 0 and Month 4.
62157450|NCT01384916|EXPERIMENTAL|Yoga|
62157451|NCT01384916|ACTIVE_COMPARATOR|Health education|
62157452|NCT04434222|ACTIVE_COMPARATOR|Compressive stockings group|Group receives postoperatively compressive stockings for a period of 6 weeks.
62157453|NCT04434222|NO_INTERVENTION|Control group|The control group is treated without compressive stockings.
62157454|NCT06021002|OTHER|Single nasal challenge R848 allergic rhinitis|
62157455|NCT06021002|OTHER|Single nasal challenge R848 healthy|
62157456|NCT06021002|OTHER|Single nasal challenge saline|Single nasal challenge saline allergic rhinitis and healthy
62157457|NCT06021002|OTHER|Repeat nasal challenge R848 allergic rhinitis|
62157458|NCT06021002|OTHER|Repeat nasal challenge R848 healthy|
62157459|NCT06021002|OTHER|Repeat nasal challenge saline|Repeat nasal challenge saline allergic rhinitis and healthy
62532204|NCT04738474|PLACEBO_COMPARATOR|Usual Care|Subjects in this arm will receive usual care
62532205|NCT01219374||egg donors|anonymous egg donors
62532206|NCT02712333|EXPERIMENTAL|Air purifiers|Participants in this group received an intervention of true air purifiers placed in the center of the room.
62532207|NCT02712333|SHAM_COMPARATOR|Control|Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.
62532208|NCT00006083|EXPERIMENTAL|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
62532209|NCT00006083|PLACEBO_COMPARATOR|placebo|placebo injected subcutaneously daily
62532210|NCT00987753|EXPERIMENTAL|infusion of L-377202|
62157460|NCT06021002|NO_INTERVENTION|Sample collection only|Sample collection only (no nasal challenge) to optimise laboratory protocols
62157461|NCT03778307||Trauma exposed without PTSD|Individuals with a history of trauma exposure who do not have current PTSD
62157462|NCT03778307||Trauma exposed with PTSD|Individuals with a history of trauma exposure and a current diagnosis of PTSD
62157463|NCT05128799||3WP|Patients who had 3WP as part of their end-of-life care
62157464|NCT05128799||Usual Care|Patients who did not have 3WP as part of their end-of-life care
62157465|NCT05161247|EXPERIMENTAL|Zona pellucida sperm selection|"Semen processing: liquefaction followed by centrifugation and swim-up.~Zona pellucida sperm selection: Spermatozoa are selected according to their ability to adhere to zona pellucida proteins obtained from their partners native zona pellucida.~Intracytoplasmic sperm injection (ICSI): Each oocyte is injected with a single morphologically normal spermatozoa. The injection procedure is carried out in a sterilized dish using holding pipette and injection needle."
62157466|NCT05161247|ACTIVE_COMPARATOR|Conventional sperm selection|"Semen processing: liquefaction followed by centrifugation and swim-up. Samples are incubated until time of injection.~Conventional sperm selection: Spermatozoa are selected according to their morphology.~Intracytoplasmic sperm injection (ICSI): Each oocyte is injected with a single morphologically normal spermatozoa. The injection procedure is carried out in a sterilized dish using holding pipette and injection needle."
62157467|NCT05793580|OTHER|VSB arm|longitudinal follow-up of VSB users preoperatively and at 1, 3, 6, 12 and 60 months post-implantation.
62157468|NCT06412029||Part 1|Part 1: Participants attend training, complete clinic assessments and observations and may complete an interview on study.
62157469|NCT06412029||Part 2|Part 2: Identified clinic staff will be interviewed to discuss factors that influence health related social needs (HRSN) screening at their clinic and help develop generalized guidance.
62157470|NCT06412029||Part 3|Part 3: Participants attend a co-design workshop and complete surveys on study feasibility.
62157471|NCT01492127|NO_INTERVENTION|Blood test|Blood test :carcinoma in cirrhotic patients
62157472|NCT02376062|EXPERIMENTAL|Bundled Intervention|"* On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~* Weekly case conferences~* Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
62532211|NCT00326963|EXPERIMENTAL|Enfuvirtide+PI+ARV's|"Eligible participants received Fuzeon® (enfuvirtide) 90 milligram (mg) subcutaneously (SC) two times a day (bid) for 24 weeks plus new protease inhibitor (PI) (darunavir/ritonavir) plus other investigator-choice antiretrovirals (ARVs). Participants selected their preferred injection device among the following three options: 27 gauge (G) ½ needle/syringe, 31G 8 millimeter (mm) needle/syringe or Biojector 2000 (B2000) needle-free injection device (NFID)."
62532212|NCT04902092|ACTIVE_COMPARATOR|High Intensity Physical Training|12-week, 36 session, cardiorespiratory-focussed physical exercise program delivered by an accredited exercise physiologist
62532213|NCT04902092|ACTIVE_COMPARATOR|Low Intensity Physical Training|12- week, 36 session, strength-focussed physical exercise program delivered by an accredited exercise physiologist
62532214|NCT05716386|EXPERIMENTAL|Intervention|The low sodium diet will be provided low salt diet 1.5 gm/day in three main meals for three months.The food will be provided by the nutritionists and delivered directly to their home
62532215|NCT05716386|PLACEBO_COMPARATOR|Control|The control group will continue with their usual diet and record the food recall
62532216|NCT01267721||Study Group|A single group of 100 consecutive patients will undergo additional blood sampling at different time points
62532217|NCT04770467|EXPERIMENTAL|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
62532218|NCT04770467|PLACEBO_COMPARATOR|Placebo in adult subjects with severe COVID-19|
62157473|NCT04187456|EXPERIMENTAL|Midazolam + Savolitinib|"* Treatment Period 1: Single administration of midazolam (1 mg) will occur on Study Day 1, after a high fat, high calorie breakfast, followed by PK sampling for 24 hours.~* Treatment Period 2: Single administration of midazolam 1 mg in combination with a single administration of savolitinib (600 mg), after a high fat, high calorie breakfast will occur on Study Day 5 and PK sampling will occur for 24 hours."
62157474|NCT04178876|EXPERIMENTAL|Aspiration and Sclerotherapy of endometriomas|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
62157475|NCT04178876|ACTIVE_COMPARATOR|laparoscopic stripping technique|cystectomy of endometriomas during laparoscopy
62157476|NCT00629993|EXPERIMENTAL|Multi-component Academic Detailing|"Multi-component, academic detailing regarding ACS guidelines on cervical cancer screening approaches.~Includes an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients."
62157477|NCT01768572|EXPERIMENTAL|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
62157478|NCT01768572|EXPERIMENTAL|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
62157479|NCT01768572|ACTIVE_COMPARATOR|Tocilizumab q4w|Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
62157480|NCT05143580|EXPERIMENTAL|Cognitive Therapy Group|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education.~* Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~* Use gamification to evaluate: pain relief skills, lung expansion skills."
62157481|NCT05143580|PLACEBO_COMPARATOR|Routine Care Group|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education."
62157482|NCT04683900|EXPERIMENTAL|Standard of Care + Mediterranean Diet|Participants will be given standard of care for constipation (handout) plus individualized diet education on the Mediterranean diet and instructed to follow the diet during the 8-week intervention period. Diet education will be administered by a study dietitian and followed with weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
62157483|NCT04683900|ACTIVE_COMPARATOR|Standard of Care|Participants will be given standard of care for constipation (handout) to utilize during the 8-week intervention period. A study dietitian will follow up with weekly phone calls to support adherence and monitor for adverse events.
62157484|NCT02097056|EXPERIMENTAL|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
62157485|NCT01131325|EXPERIMENTAL|Nilotinib|
62157486|NCT02481934|EXPERIMENTAL|NKAE cells infusion + chemotherapy|Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
62532219|NCT04770467|EXPERIMENTAL|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
62532220|NCT04770467|EXPERIMENTAL|Placebo in adult subjects with mild-moderate COVID-19|
62714197|NCT03543865|EXPERIMENTAL|New Hope (NH)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation.~Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
62157487|NCT04727099|EXPERIMENTAL|Benign Pigmented Lesions|Up to six (6) treatments with PicoWay laser for treatment of benign pigmented lesions
62532221|NCT02768714|EXPERIMENTAL|Eurofarma's pegfilgrastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Eurofarma's pegfilgrastim (subcutaneous injection)
62532222|NCT02768714|ACTIVE_COMPARATOR|Neulastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Neulastim (subcutaneous injection)
62532223|NCT02181426|PLACEBO_COMPARATOR|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
62157488|NCT04727099|EXPERIMENTAL|Wrinkles|Up to six (6) treatments with PicoWay laser for treatment of wrinkles
62157489|NCT01328223||radiotherapy efficacy|"1. Concurrent stage with RT: sorafenib 400mg twice daily~2. Maintenance stage after RT: sorafenib 400mg twice daily Treatment can be continued until the occurrence of clinical or radiologic progression, the occurrence of either unacceptable adverse events, death, or any criteria met for removal from the protocol treatment. Basically, minimum maintenance duration of 6 months is recommended, not mandatory."
62157490|NCT01498354|EXPERIMENTAL|2-D high definition TEO (transanal endoscopic operation)|
62532224|NCT02181426|ACTIVE_COMPARATOR|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
62532225|NCT02181426|ACTIVE_COMPARATOR|15 mg Ketorolac|participant receives 15 mg of Ketorolac
62532226|NCT02181426|ACTIVE_COMPARATOR|30 mg Ketorolac|participant receives 30mg of Ketorolac
62532227|NCT01989962|EXPERIMENTAL|E4E Intervention Group|E4E Intervention Group is a group of family physicians who will participate in the first wave of E4E intervention.
62157491|NCT01498354|ACTIVE_COMPARATOR|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge
62157492|NCT04374175||Adenocarcinoma group|Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
62157493|NCT04374175||Control group|Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.
62157494|NCT01946256|ACTIVE_COMPARATOR|Amoxicillin|Amoxicillin 500mg three times in a day for 1 week
62157495|NCT01946256|PLACEBO_COMPARATOR|Erythromycin|Erythromycin 500mg four times in a day for 1 week
62532228|NCT01989962|SHAM_COMPARATOR|E4E Late Intervention Control Group|E4E Late Intervention Control Group is a group of family physicians who will participate in the second wave of E4E intervention 12 month later after the completion of the first wave of E4E intervention.
62157496|NCT01429168|EXPERIMENTAL|Part 1: All Enrolled Participants|All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
62157497|NCT01429168|EXPERIMENTAL|Part 2: Etoricoxib|
62157498|NCT01429168|PLACEBO_COMPARATOR|Part 2: Placebo|
62157499|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
62157500|NCT01308879|EXPERIMENTAL|Weekly feedback|After clinical questionnaires are entered into the system (CFStm), an automated online report is available weekly to clinicians in the experimental group that shows current mental health status of youths, alerts, and trends over time based on youth, caregiver, and clinician responses. Reports also show some clinical data on caregivers.
62157501|NCT01308879|OTHER|No feedback|Clinicians in the control group do not have access to weekly feedback. Instead, they receive reports every 90 days after the youth is enrolled in CFStm. Because the average duration of CFS enrollment was 3.8 months, many youths would have been discharged before the first 90-day report became available three months after treatment start. Thus, we considered the 90-day feedback group to be essentially a no-feedback group.
62157502|NCT04553627|EXPERIMENTAL|Interventional cohort|Zeltiq system is a thermoelectric device that applies controlled cooling ot skin. The CoolAdvantage applicators use gentle vacuum pressure to draw tissue into the cup shaped applicator. A gelpad is applied to skin to improve thermal coupling between participant and the applicator cooling surface.
62157503|NCT03338829|NO_INTERVENTION|Control|The control arm will received compensation at time of enrollment for agreeing to participate.
62736429|NCT01958580|EXPERIMENTAL|Treatment (gemcitabine, docetaxel, brachytherapy/IMRT, EBRT)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks."
62157504|NCT03338829|EXPERIMENTAL|Positive Incentive|The positive incentive arm will receive compensation per prescribed test, payable every month based on testing adherence.
62157505|NCT03338829|EXPERIMENTAL|Loss Aversion|"The loss aversion arm will have compensation deposited into a University of Iowa Women's Health account. The participant will then lose compensation depending on actual adherence to recommended testing"
62157506|NCT01070199|EXPERIMENTAL|liquid to liquid,|
62157507|NCT01070199|EXPERIMENTAL|liquid to solid,|
62157508|NCT01070199|EXPERIMENTAL|solid to liquid|
62157509|NCT01070199|EXPERIMENTAL|solid to solid|
62157510|NCT05434559||Study cohort|People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 in the two participating sensors
62157511|NCT03917342|ACTIVE_COMPARATOR|Control Group|EEG measure in 15 healthy women undergoing elective hysteroscopy under single shot spinal anesthesia. Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
62157512|NCT03917342|ACTIVE_COMPARATOR|Healthy parturients|EEG measure in 15 healthy parturients undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
62157513|NCT03917342|ACTIVE_COMPARATOR|Preeclamptic parturients|EEG measure in 15 parturients with preeclampsia undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
62157514|NCT01430416|EXPERIMENTAL|AEB071|
62157515|NCT05822791||ECG-Detected AF|Patients with atrial fibrillation detected on 12-lead ECGs done post-stroke
62157516|NCT05822791||Device-Detected AF|Patients with atrial fibrillation detected on prolonged Holter monitoring lasting at least 7 days.
62157517|NCT02896673|EXPERIMENTAL|ventilatory conditions and measures with scanner and EIT|"The patient is installed on the scanner bed, EIT electrodes are connected to the acquisition device of the EIT signal.~Esophageal pressure signals, pressure and flow in the airways will be acquired continuously"
62157518|NCT05390515|EXPERIMENTAL|Tildrakizumab treatment|Biological/vaccine: tildrakizumab
62157519|NCT00801905|ACTIVE_COMPARATOR|1: Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
62157520|NCT00801905|PLACEBO_COMPARATOR|2: placebo|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
62157521|NCT06023771||Acute pancreatitis requiring invasive intervention|Single-center cohort of acute pancreatitis patients requiring invasive intervention for the treatment of local complications during the whole course of disease.
62157522|NCT03015753|EXPERIMENTAL|Tai Chi training|The participants in this arm will receive 12-week Tai Chi training (1 hour per day, 5 days per week).
62532229|NCT03783273|EXPERIMENTAL|Whey protein complex-bound D3 + juice|200 microgram vitamin D3 in a whey protein-complex added to 500 mL of juice.
62532230|NCT03783273|ACTIVE_COMPARATOR|D3 + juice|200 microgram vitamin D3 added to 500 mL of juice.
62532231|NCT03783273|ACTIVE_COMPARATOR|D3 + milk|200 microgram vitamin D3 added to 500 mL of skimmed-milk.
62532232|NCT03783273|ACTIVE_COMPARATOR|D3 droplets|200 microgram vitamin D3 as droplets + 500 mL of water.
62532233|NCT03783273|PLACEBO_COMPARATOR|No vitamin D|500 mL of Water.
62532234|NCT00327860||Cohort 1|"Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2"
62532235|NCT00327860||Cohort 2|"Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease."
62532236|NCT00327860||Cohort 3|Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
62532237|NCT01495156|EXPERIMENTAL|Lithium/Adjunctive SGA|
62532238|NCT01495156|PLACEBO_COMPARATOR|Placebo/Adjunctive SGA|
62532239|NCT01167959||obesity diabetes, surgical and dietary|
62532240|NCT02043587|EXPERIMENTAL|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age \>50); PEG-asp 2000 IU/m2 IV d16, age \>50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age \< 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX \<0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age \>50 1000 IU/m2, cap 3750 IU/m2~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4~1A-C repeat x1(2A-C) then 3rd Course B (3B)~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age \>50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age \>50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, \& Maint."
62532241|NCT04948060|EXPERIMENTAL|Control 1-1|Patients and clinicians in control practices will receive usual Electronic Health Record (EHR) reminders for lung cancer screening (LCS).
62532242|NCT04948060|EXPERIMENTAL|Intervention 1-1|In addition to control group improvements, patients and clinicians in the intervention group will also receive an LCS Care Coordinator.
62532243|NCT04948060|EXPERIMENTAL|Control 1-2|Patients and Clinicians in control practices will have access to existing LCS services, smoking cessation, and lung cancer treatment services, but no additional system improvements will be introduced.
62532244|NCT04948060|EXPERIMENTAL|Intervention 1-2|In addition to control group improvements, patients and clinicians in the intervention group will also receive quality of care benchmarking and feedback academic detailing.
62532245|NCT04948060|EXPERIMENTAL|Intervention 1-3|In addition to control group improvements, patients and clinicians in the intervention group will also receive practice facilitation.
62532246|NCT04948060|EXPERIMENTAL|Intervention 1-4|In addition to control group improvements, patients and clinicians in the intervention group will also receive the opportunity to participate in a learning collaborative.
62532247|NCT04948060|EXPERIMENTAL|Intervention 1-5|In addition to control group improvements, patients and clinicians in the intervention group will also receive information technology support.
62532248|NCT03208361|EXPERIMENTAL|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
62532249|NCT03208361|ACTIVE_COMPARATOR|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
62532250|NCT02890654||Teenagers with scoliosis|"Patients will be evaluated at three times during the study :~* First time measure : 1 month before the scoliosis surgery~* Second time measure : 3 months after the scoliosis surgery~* Third time measure : 1 year after the scoliosis surgery"
62532251|NCT04097236|ACTIVE_COMPARATOR|45° semirecumbent position|
62532252|NCT04097236|ACTIVE_COMPARATOR|No elevation of the upper section of the bed|
62157523|NCT03015753|OTHER|Waiting list control group|Participants in this arm will be asked to maintain their usual lifestyles and exercises for 12 weeks. At the end of the trial , the participants will be offered Tai Chi training similar as Tai Chi group.
62532253|NCT02203422|EXPERIMENTAL|combination treatment group|60 enrolled patients are randomly picked up to take cyclosporin A in combination with rhTPO at the indicated dose.
62532254|NCT02203422|ACTIVE_COMPARATOR|single treatment group|60 enrolled patients are randomly picked up to take cyclosporin A at the indicated dose.
62532255|NCT04711616|EXPERIMENTAL|physical therapy intervention|
62532256|NCT00891917|PLACEBO_COMPARATOR|Syrup|identical placebo formulation to be administered twice a day.
62532257|NCT00891917|ACTIVE_COMPARATOR|Ubiquinol-10 Syrup|CoQ (LiQ-NOL®) 10.0 mg/kg/d to be administered twice a day
62532258|NCT02098239|ACTIVE_COMPARATOR|Group A|Jaundiced patients with bilirubin value \>80 μmol/L. Received G17DT immediately prior to biliary stenting.
62532259|NCT02098239|ACTIVE_COMPARATOR|Group B|Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was \<40 μmol/L.
62532260|NCT03512132||control|
62532261|NCT03512132||T1D with normal albumin levels|
62532262|NCT03512132||T1D with macroalbuminuria|
62532263|NCT03512132||T1D with microalbuminuria|
62532264|NCT03512132||T1D with microalbuminuria and statins|
62532265|NCT06345365|EXPERIMENTAL|mitoxantrone liposome, Ara-Cytarabine and azacitidine|Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
62532266|NCT06345365|ACTIVE_COMPARATOR|Daunorubicin, Ara-Cytarabine and azacitidine|Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3 Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
62532267|NCT05939635|ACTIVE_COMPARATOR|Group M-TAPA|A bilateral M-TAPA (60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
62532268|NCT05939635|ACTIVE_COMPARATOR|Group EOIB|A bilateral EOIB (60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
62532269|NCT03084367||iFR post angiographically successful PCI|
62532270|NCT00384644||1|sepsis, septic shock ptients
62714198|NCT03543865|EXPERIMENTAL|Elders' Resiliency (ER)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation.~All youth will complete another study assessment after 30 days. The 30-day time frame will allow ample time to complete the NH intervention with participants and assess any changes in youth's mental health status for all study arms. Following another 30-day period, all participants will be re-assessed and re-randomized, using the same blocking and 1:1 ratio to either the Elders' Resilience (ER) intervention plus CM, or CM alone. To track long term outcomes, all youth will complete a final assessment 3 month later (6 months post-enrollment)."
62714199|NCT03543865|OTHER|Control Condition|"The control condition will only receive Case Management (CM) (n=76).~The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
62714200|NCT03543865|EXPERIMENTAL|New Hope (NH), Elders' Resiliency (ER), Case Management (CM)|The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type. All youth will complete another study assessment after 30 days.After another 30-days, all participants will be re-assessed/re-randomized, using the same blocking and 1:1 ratio to either the ER intervention plus CM, or CM alone.
62736430|NCT06215820|EXPERIMENTAL|MR-107A-02|15 mg Twice daily (BID) during in patient phase (0-48 hours following randomization) 15 mg BID dosing morning and evening, during out patient phase (5 days) .
62157524|NCT02648659|EXPERIMENTAL|triple with clarithromycin|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin bid for 2 weeks
62157525|NCT02648659|EXPERIMENTAL|triple with metronidazole|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Metronidazole 500mg tid for 2 weeks
62157526|NCT02648659|EXPERIMENTAL|quadruple|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin 500mg bid, Metronidazole 500mg tid for 2 weeks
62157527|NCT04543032|EXPERIMENTAL|study group|the patients in this group will receive sensorimotor training for 6 weeks in addition to medical care.
62157528|NCT04543032|NO_INTERVENTION|control group|the patients in this group will receive medical care only.
62157529|NCT03029585|EXPERIMENTAL|NanoPac® 100 mg/m2|Intraperitoneal NanoPac® 100 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
62157530|NCT03029585|EXPERIMENTAL|NanoPac® 200 mg/m2|Intraperitoneal NanoPac® 200 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
62532271|NCT00384644||2|cardiogenic shock patients
62157531|NCT03029585|EXPERIMENTAL|NanoPac® 300 mg/m2|Intraperitoneal NanoPac® 300 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
62157532|NCT03029585|EXPERIMENTAL|NanoPac® 400 mg/m2|Intraperitoneal NanoPac® 400 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
62157533|NCT03029585|ACTIVE_COMPARATOR|Standard of Care Intravenous Chemotherapy|Standard of care intravenous chemotherapy (with platinum and taxane agents) administered per institutional standards.
62532272|NCT04068649|EXPERIMENTAL|Arm I (palliative RT)|Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
62532273|NCT04068649|EXPERIMENTAL|Arm II (SBRT)|Patients undergo single fraction SBRT.
62532274|NCT04663295|EXPERIMENTAL|Subjects with Type 1 diabetes wearing HCL pump system|Subjects 14-75 years of age who have been diagnosed with Type 1 diabetes.
62532275|NCT00555386|ACTIVE_COMPARATOR|1|6g of chocolate (supplemented with selenium and isoflavones) per day for the duration of one menstrual cycle (25-35 days)
62532276|NCT00555386|PLACEBO_COMPARATOR|2|6g of chocolate (control) per day for the duration of one menstrual cycle (25-35 days)
62532277|NCT03598868|EXPERIMENTAL|Vortioxetine|Vortioxetine 5-20 mg
62157534|NCT00441168|ACTIVE_COMPARATOR|VAD Treatment|vincristine in combination with adriamycin and dexamethasone
62157535|NCT00441168|EXPERIMENTAL|PAD Treatment|bortezomib in combination with adriamycin and dexamethasone
62157536|NCT02249429|EXPERIMENTAL|bimiralisib (PQR309)|
62157537|NCT01840124|EXPERIMENTAL|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
62157538|NCT02618876|ACTIVE_COMPARATOR|Nalbuphine group|30 children will be given Caudal Bupivacaine plus Nalbuphine.
62157539|NCT02618876|OTHER|Control group|30 children will be given Caudal Bupivacaine.
62157540|NCT05286242||Healthy control|Healthy controls Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
62532278|NCT03598868|PLACEBO_COMPARATOR|Placebo|Placebo augmentation
62532279|NCT05545358||Amputees with phantom pain|Adult patients who have been amputated for more than 2 years and have chronic phantom pain
62532280|NCT05545358||Amputees without phantom pain|Adult patients who have been amputated for more than 2 years and do not have chronic phantom pain
62532281|NCT05545358||Healthy participants|Healthy adult participants with no neurological history
62157541|NCT05286242||Disease control|"Disease controls (individuals with a qualifying autoimmune condition, but not treated with any immunomodulator).~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
62157542|NCT05286242||B-cell depleted|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with B-cell depleting anti-CD20 monoclonal antibodies.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
62157543|NCT05286242||Other immunomodulator|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with a non-CD20 monoclonal antibody immunomodulator to treat their disease.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
62157544|NCT05581108|EXPERIMENTAL|Juice PLUS+® OMEGA|The Juice Plus+®Omega Blend capsules contain the following ingredients: DHA and EPAenriched oil of the micro algae Schizochytrium sp., pomegranate seed oil, coating agent: pullulan; raspberry seed oil, sea buckthorn oil 9, release agent: silicon dioxide; high oleic safflower seed oil, tomato seed oil, orange oil, vanilla oil, antioxidant: rosemary extract.
62157545|NCT05581108|PLACEBO_COMPARATOR|Matched placebo|Placebo capsules consist of medium chain triglycerides oil+ excipients like silicon dioxide aerosil, lecithin, vanilla flavor, orange oil, water and hypromellose(shell).
62157546|NCT01282918|OTHER|Study group|Patients without DF (Defibrillation) testing during ICD implantation
62157547|NCT01282918|OTHER|Control group|Patients with DF testing during ICD implantation (according to standardized procedure)
62157548|NCT04392856|EXPERIMENTAL|Unified Protocol Transdiagnostic Treatment Emotional Disorders|"An adaptation of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to women in a homeless situation will be implemented in public shelters setting in Madrid, Spain.~The UP adaptation is an intervention based protocol for emotional disorders, consisted of 12 treatment sessions of one and a half hours of duration each, at a rate of one per week."
62157549|NCT04392856|OTHER|Waitlist Control condition|The participants assigned to the waitlist control condition will not immediately receive the intervention. They will wait for 3 months, which is the duration of the intervention in the experimental group. After that time, they will be offered the same psychological treatment as those assigned to the UP (experimental condition).
62157550|NCT06565416|NO_INTERVENTION|Pre-Intervention|Baseline prior to any involvement with the project
62157551|NCT06565416|NO_INTERVENTION|Intervention|A workgroup for each clinic meets for approximately 6 months to select the specific goals for the clinic to be targeted during the implementation phase.
62157552|NCT06565416|ACTIVE_COMPARATOR|Implementation|Evidence-based implementation strategies are put into practice for approximately 6 months.
62157553|NCT06565416|NO_INTERVENTION|Sustainment|Measuring the degree to which the clinic maintains the implementation phase goals.
62157554|NCT02195180|EXPERIMENTAL|standard of care combined with ERY001|standard of care = Gemcitabine or folfox
62157555|NCT02195180|SHAM_COMPARATOR|standard of care alone|standard of care = Gemcitabine or folfox
62157556|NCT06128356|EXPERIMENTAL|Sublingual dexmedetomidine|Participants will be administered two 60 micrograms sublingual films of IGLMI following start of an autonomic crises. The maximum amount for the study is four oral films of 60 micrograms in 24 hours, two at the beginning of the crises and if needed, two additional within two hours.
62157557|NCT06287671||Study cohort|Patients undergoing elective colorectal resection or stoma closure
62532282|NCT02605993|EXPERIMENTAL|Cohort 1|"During the Treatment Period, participants were administered ravulizumab 1400 milligram (mg) on Day 1, ravulizumab 1000 mg on Day 15 and Day 29, and then ravulizumab 1000 mg every 4 weeks for 7 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kilograms (kg), 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
62532283|NCT02605993|EXPERIMENTAL|Cohort 2|"During the Treatment Period, participants were administered ravulizumab 2000 mg on Day 1, ravulizumab 1600 mg on Day 22 and Day 43, and then ravulizumab 1600 mg every 6 weeks for 4 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
62532284|NCT02605993|EXPERIMENTAL|Cohort 3|"During the Treatment Period, participants were administered ravulizumab 1600 mg on Day 1 and Day 15, ravulizumab 2400 mg on Day 29, and then ravulizumab 2400 mg every 8 weeks for 3 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
62532285|NCT02605993|EXPERIMENTAL|Cohort 4|"During the Treatment Period, participants were administered ravulizumab 3000 mg on Day 1, ravulizumab 5400 mg on Day 29, and then ravulizumab 5400 mg every 12 weeks for 2 doses.~During the Extension Period, participants were administered ravulizumab 5400 mg every 12 weeks for up to 5 years."
62157558|NCT01469884|EXPERIMENTAL|Certican®|Arm1(conversion):Certican®+mycophenolate+prednisone
62157559|NCT01469884|ACTIVE_COMPARATOR|Tacrolimus or Cyclosporine|Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
62157560|NCT01156194|ACTIVE_COMPARATOR|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
62157561|NCT01156194|ACTIVE_COMPARATOR|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
62157562|NCT01156194|PLACEBO_COMPARATOR|Placebo|globules identical to true comparators
62157563|NCT00668746|EXPERIMENTAL|Minocycline HCl microspheres|Minocycline HCl microspheres
62157564|NCT00668746|NO_INTERVENTION|No drug intervention|No drug intervention
62157565|NCT05848219||Dabrafenib + trametinib (dab/tram)|Patients with a first diagnosis of metastatic melanoma, who received dab/tram in the United States
62157566|NCT05848219||Encorafenib + binimetinib (enco/bini)|Patients with a first diagnosis of metastatic melanoma, who received enco/bini in the United States
62157567|NCT01966094||HIV+ subjects with HAND|Human immunodeficiency virus (HIV) positive subjects with HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
62157568|NCT01966094||HIV+ subjects without HAND|Human immunodeficiency virus (HIV) positive subjects without HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
62157569|NCT06281639||study group|Caregivers who have a child with a scheduled Pediatric congenital ultrasound (PCU) the day of recruitment
62157570|NCT01077284|EXPERIMENTAL|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
62157571|NCT01077284|ACTIVE_COMPARATOR|Allopurinol|Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
62157572|NCT01077284|PLACEBO_COMPARATOR|Placebo|Placebo-matching capsules, orally, once daily for up to 6 months.
62157573|NCT03503500|EXPERIMENTAL|Laid-back breastfeeding|Women will breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves, without following particular procedure to breastfed.
62157574|NCT03503500|ACTIVE_COMPARATOR|Standard care|Staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast,
62157575|NCT02450747|EXPERIMENTAL|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
62157576|NCT01237509||group1|Patients with T1D
62157577|NCT01389791|NO_INTERVENTION|Roc|Patients in this group receive neither MgSO4 nor priming dose of rocuronium.
62157578|NCT01389791|ACTIVE_COMPARATOR|priming|patients in this group receive 0.06mg/kg of rocuronium before 0.54mg/kg of rocuronium.
62157579|NCT01389791|EXPERIMENTAL|Mg&priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
62157580|NCT01389791|ACTIVE_COMPARATOR|MgSO4|Patients in this group receive intravenous MgSO4 before administration of rocuronium.
62157581|NCT04976517||non-diabetes group|patients who underwent heart tranplantation without diabetes
62157582|NCT04976517||pre-transplant diabetes group|patients who underwent heart tranplantation with diabetes before the transplantation
62157583|NCT04976517||post transplant daibetes group|patients who underwent heart tranplantation without diabetes until after the transplantation
62157584|NCT01759459|EXPERIMENTAL|Lidocaine|1% Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
62157585|NCT01759459|EXPERIMENTAL|Buffered Lidocaine|"1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm~Buffered lidocaine is compounded by the following process:~2.3 mLs of 8.4% sodium bicarbonate is added to a vial of 1% lidocaine"
62157586|NCT01759459|EXPERIMENTAL|Bacteriostatic Normal Saline|Bacteriostatic Normal Saline for injection, 0.50 mL administered one time intradermally in peripheral forearm
62157587|NCT06490497||Caregiver of a glioblastoma patient undergoing glioblastoma treated in oncology|
62532286|NCT01630967|EXPERIMENTAL|Degarelix|Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
62532287|NCT04211727||Cohort 1|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
62532288|NCT04211727||Cohort 2|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
62532289|NCT05940753||Cohort: medical oncology patients in the out-patient clinic or treatment unit on 13 or 14 march 2023|No interventions.
62532290|NCT06633536||Ravulizumab group|Open-label
62532291|NCT05069194||COPD|Patients with chronic obstructive pulmonary disease
62157588|NCT04387149||CSA-AKI|Patients that developed cardiac surgery-associated Acute Kidney Injury
62157589|NCT04387149||non CSA-AKI|Patients that did not developed cardiac surgery-associated Acute Kidney Injury
62157590|NCT03384342|EXPERIMENTAL|Experimental group|"* For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.~* At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment."
62157591|NCT03384342|NO_INTERVENTION|Control group|"* Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~* If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
62157592|NCT05766371|EXPERIMENTAL|Pembrolizumab, 177Lu-PSMA-617|Participants will receive an infusion of 7.4 gigabequerel (GBq) (+/- 10%) of 177Lu-PSMA-617 on Cycle 1 Day 1 (of a 28 day cycle), and again on Cycle 2 Day 15 dose (6 weeks after first dose and at every at rise in PSA for up to a maximum of 6 doses. Beginning Cycle 2 Day 1 (Day 29), participants will receive 400 mg of Pembrolizumab every 6 weeks.
62157593|NCT04611893||Ischemic stroke patient|Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic
62157594|NCT04572425|ACTIVE_COMPARATOR|Guided imagery|10 minutes of guided imagery (using Apple iPad and headphones, subject watches 10 minute video of a guided-imagery session depicting a peaceful walk through a forest with instrumental background music and 2-dimensional imagery)
62157595|NCT04572425|EXPERIMENTAL|Virtual reality|10 minutes of virtual reality (using study-administered Facebook Oculus Go VR headset with headphones, subject engages with VR application Forest of Serenity (Holosphere VR®, Birmingham, UK) that features a forest environment with voice narration that can be played in a seated or fixed position.
62157596|NCT04651426|PLACEBO_COMPARATOR|Placebo|The Placebo is a Patch identical to the F3 and F4 patches in aesthetics but without any biomineral, therefore with no reflectance ability.
62157597|NCT04651426|ACTIVE_COMPARATOR|F3 Patch|The F3 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum 2 m x kg
62157598|NCT04651426|ACTIVE_COMPARATOR|F4 Patch|The F4 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum of 4 m x kg
62532292|NCT05069194||High Risk|People who do not suffer from COPD, but have high risk factor for COPD.
62157599|NCT05064059|EXPERIMENTAL|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
62157600|NCT05064059|ACTIVE_COMPARATOR|Standard of Care (Regorafenib or TAS-102)|At the Investigator's choice, participants will receive 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle or 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
62157601|NCT04518111||Unicompartmental Knee Arthroplasty (UKA)|Patients who underwent primary UKA with Oxford Partial Knee with the Microplasty® instrumentation for AMOA.
62157602|NCT04518111||High Tibial Osteotomy (HTO)|Patients who underwent Open Wedge HTO for AMOA.
62532293|NCT05069194||Health|People who do not suffer from COPD and do not have a high risk factor for COPD either.
62157603|NCT02632630|ACTIVE_COMPARATOR|Amino Acids w/Electrolytes in Dextrose|Peripheral parenteral nutrition (PPN)
62157604|NCT02632630|ACTIVE_COMPARATOR|Ensure product|Calorie and protein dense oral nutritional supplement for patients with elevated nutritional needs.
62157605|NCT02632630|ACTIVE_COMPARATOR|Crystalloid solutions|Standard care intravenous maintenance fluids.
62157606|NCT02632630|ACTIVE_COMPARATOR|Oral nutritional supplementation|Nutrient-enhanced drink products that provide macronutrients and micronutrients with the aim of increasing oral nutritional intake.
62157607|NCT03747575|EXPERIMENTAL|Treatment|Participants will receive MSTT1041A
62157608|NCT03747575|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to MSTT1041A
62157609|NCT05971615|OTHER|Peripheral Venous Blood Gases|
62157610|NCT05817513|EXPERIMENTAL|Control group|(Control group): will consist of 26 young females . They will receive traditional exercises for scoliosis.
62157611|NCT05817513|EXPERIMENTAL|(Study group)|(Study group): will consist of 26 young females. They will receive the same traditional scoliosis exercises in addition to myofascial release ( MFR ) .
62157612|NCT06449599|ACTIVE_COMPARATOR|block group|local anesthesia will be applied to surgical field as a part of the routine procedure and additionally rhomboid intercostal plane block will be applied
62157613|NCT06449599|SHAM_COMPARATOR|control group|only local anesthesia will be applied to surgical field as a part of the routine procedure.
62532294|NCT06394700|EXPERIMENTAL|Written Exposure Therapy (WET)|
62532295|NCT06394700|EXPERIMENTAL|Written Exposure Therapy plus mindfulness-based App (WET+MBA)|
62532296|NCT06394700|PLACEBO_COMPARATOR|Minimal Contact Control (MCC)|
62157614|NCT06348160|EXPERIMENTAL|iHERO Resource Group|Toolkit consisting of micro-videos and supplemental online resources.
62157615|NCT06348160|NO_INTERVENTION|Control|
62157616|NCT05983939|EXPERIMENTAL|PIPE-791|
62157617|NCT05983939|PLACEBO_COMPARATOR|Placebo|
62157618|NCT06181019|ACTIVE_COMPARATOR|Be treated with mirabegron.|Patients were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
62157619|NCT06181019|EXPERIMENTAL|Be treated with acupuncture combined with mirabegron.|Patients were treated with acupuncture combined with mirabegron.
62157620|NCT02862158|EXPERIMENTAL|Experimental|FDT visual field will be compared to standard HVF in detecting glaucomatous visual field loss
62157621|NCT02634528|EXPERIMENTAL|Julphar Insulin N|Julphar Insulin N, human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
62532297|NCT04695145|EXPERIMENTAL|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer with special training in medical issues. The exercise will be monitored with continuous heart rate registration.~The group training session will begin with a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied."
62532298|NCT04695145|ACTIVE_COMPARATOR|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
62157622|NCT02634528|ACTIVE_COMPARATOR|Huminsulin® Basal|Huminsulin® Basal, neutral protamine hagedorn (NPH), human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
62157623|NCT03868202|NO_INTERVENTION|Premenopausal women|Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.
62157624|NCT03868202|ACTIVE_COMPARATOR|Postmenopausal women|Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
62157625|NCT00234299|ACTIVE_COMPARATOR|Group A|Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
62157626|NCT00234299|PLACEBO_COMPARATOR|Group B|Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
62157627|NCT05233904|ACTIVE_COMPARATOR|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice.
62157628|NCT05233904|EXPERIMENTAL|Experimental Treatment Workflow|Patients do not require a CT simulation appointment. A radiation treatment appointment will be scheduled on an optical surface guidance-equipped treatment unit as soon as available, but a minimum of 24 hours is required between EBAF processing and fraction 1.
62157629|NCT01688271||Anesthesiologists|
62157630|NCT04151147|EXPERIMENTAL|CGF application in the extraction socket|Partially impacted third molar was extracted with the help of straight elevator and third molar forceps. After extraction, any remains of the dental follicle were removed and the extraction sockets were irrigated with 60 mL of sterile saline. CGF fibrin gel was then randomly placed into one socket and wound closure was completed with silk suture.
62157631|NCT04151147|EXPERIMENTAL|non-CGF application in the extraction socket|Opposite side of the patient was considered as the control. After extraction of the third molar, dental follicle were removed and to prevent the flap laceration, bone contouring was also performed under sterile saline irrigation. Finally, wound closure was completed with silk suture.
62157632|NCT00547300|EXPERIMENTAL|Nebivolol|Nebivolol 5 mg, 10 mg or 20 mg
62157633|NCT00547300|ACTIVE_COMPARATOR|Metoprolol ER|Metoprolol ER 50 mg, 100 mg or 200 mg
62157634|NCT01271361|EXPERIMENTAL|primary PCI with thrombectomy|thrombectomy before implantation of drug eluting stent
62157635|NCT01271361|ACTIVE_COMPARATOR|primary PCI without thrombectomy|implantation of a drug eluting stent without thrombectomy
62157636|NCT04889820|ACTIVE_COMPARATOR|The Control group|- The patients who are assigned into control group take a curative surgery within 2 weeks after successful SEMS placement. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during 6 months (total 12 cycles).
62157637|NCT04889820|EXPERIMENTAL|The Experimental group|- The patients who are assigned into the experimental group take a neoadjuvant FOLFOX chemotherapy within 2 weeks after successful SEMS placement. After three cycles of FOLFOX, they will take a curative surgery. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during about 4 months (total 9 cycles). The perioperative FOLFOX chemotherapy in the experimetal group will be totally 12 cycles during 6months.
62157638|NCT05670678||a2 growing up stage 3 formula puls lactoferrin supplement|"per 100g serving~* Lactoferrin 30 mg~* Galactooligosaccharides (GOS) at 3 g~* DHA 0.37~* Lactoferrin supplement plus: 2.68 ml per serving, 20 mg per 2 ml, 600 mg per bottle"
62532299|NCT02013011|ACTIVE_COMPARATOR|recruitment maneuver and PEEP|apply recruitment maneuver and positive end expiratory pressure (PEEP) 5 centimeter of water (cmH2O) after induction of anesthesia
62157639|NCT05670678||Enfinitas growing up stage 3 formula|"per 100g serving~* Lactoferrin 330 mg~* Galactooligosaccharides (GOS) at 1.58 mg~* β-Glucan 22 mg~* DHA 0.4"
62157640|NCT05851170|EXPERIMENTAL|Use of warm compresses and almond oil use during the second stage|Warm compresses will be attached to the perineum between pushing During active pushing - almond oil will be used on the perineum (our routine care).
62157641|NCT05851170|ACTIVE_COMPARATOR|Use of almond oil use (routine care) during the second stage|During active pushing - almond oil will be applied on the perineum
62157642|NCT05839743|EXPERIMENTAL|Aerobic Exercise Group|
62157643|NCT05839743|EXPERIMENTAL|Balance Exercise Group|
62157644|NCT05839743|EXPERIMENTAL|Combined Exercise Group|
62157645|NCT02462447||Prostate Cancer|Subjects will receive two PET/CT examinations, one with 11C-sarcosine and one with 11C-choline. These scans will take 30-45 minutes each.
62157646|NCT02462447||Healthy Volunteer|Subjects will receive one PET/CT examination, with 11C-sarcosine. This scan will take approximately 90 minutes.
62157647|NCT04512456|EXPERIMENTAL|Active HIV-infected patients|Exercise training
62157648|NCT04512456|NO_INTERVENTION|Inactive HIV-infected patients|No intervention.
62157649|NCT04512456|NO_INTERVENTION|Healthy subjects|No intervention.
62157650|NCT03561870|EXPERIMENTAL|Olaparib|
62157651|NCT05114811|EXPERIMENTAL|Physiotherapist massage|Perineal massage was applied by a physiotherapist expert in urogynecology and obstetrics during a total of 6 to 10 sessions (from 34th gestation week until delivery) of 30 minutes each on a weekly basis.
62157652|NCT05114811|EXPERIMENTAL|Self-massage intervention|Self-massage group received permanent instructions on perineal massage during pregnancy: it should be applied at least twice a week (on alternate days) during 10 minutes using a water-based lubricant from the 34th gestation week until delivery.
62157653|NCT05114811|NO_INTERVENTION|Control|Group receiving standard obstetric care (consultation and check-ups with the gynaecologist and midwife). No contact with the research physiotherapists.
62157654|NCT04173000|EXPERIMENTAL|Intervention|All adolescent/parent dyads enrolled at each practice will have access to the meHealth for ADHD software without medication continuity tools prior to being given access to the medication continuity tools.
62532300|NCT02013011|ACTIVE_COMPARATOR|PEEP|apply positive end expiratory pressure (PEEP) 5 cmH2O after induction of anesthesia
62532301|NCT02450955|ACTIVE_COMPARATOR|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading.
62157655|NCT03754088||Cystic fibrosis|Three cystic fibrosis patients who are homozygous for the p.Phe508del mutation.
62532302|NCT02450955|EXPERIMENTAL|Occiput-Atlas-Axis Technique|The technique is applied in two stages: in the first stage, a light core decompression is performed and then small circumductions are made with the aim of increasing viscoelasticity of tissues. Subsequently the appropriate joint barrier is sought by selective tension and high-velocity rotation manipulation is performed in a cranial helical motion without raising the subjects head.
62157656|NCT03754088||Healthy subjects|Three healthy subjects.
62157657|NCT03927963|PLACEBO_COMPARATOR|propofol|
62157658|NCT03927963|ACTIVE_COMPARATOR|dexmedetomidine|
62532303|NCT01206049|EXPERIMENTAL|Combination chemotherapy + panitumumab|
62532304|NCT01206049|EXPERIMENTAL|Combination chemotherapy + bevacizumab|
62532305|NCT04013321|EXPERIMENTAL|Test intervention group|Chronic insomniacs will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device.
62157659|NCT00003996|EXPERIMENTAL|chemotherapy + carmustine + etoposide + cisplatin + radiation|Patients receive pre-irradiation chemotherapy consisting of carmustine IV over 1 hour on days 1-3 and oral etoposide on days 1-21 and 29-49 immediately followed by cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 2 courses. Patients receive concurrent cranial radiotherapy daily over 8 weeks during course 2. Patients then receive carmustine IV over 1-2 hours every 8 weeks for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before the study, prior to each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 4 months for 1 year, every 6 months for 4 years, annually for 5 years, and then for survival.
62157660|NCT00848198||Normal|Subjects with no objective signs of Dry Eye Disease
62532306|NCT04013321|ACTIVE_COMPARATOR|Active control|Chronic insomniacs in the active control group will be tracking their sleep with the device, without feedback or coaching. But they will also undergo online cognitive behavioral therapy for insomnia (CBTi).
62532307|NCT04013321|NO_INTERVENTION|Passive control|Chronic insomniacs in the passive control group will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
62157661|NCT00848198||Dry Eye Disease|Subjects with objective signs of Dry Eye Disease
62157662|NCT01941706|EXPERIMENTAL|Project UPLIFT (Treatment)|Participants randomly assigned to the Treatment group receive the UPLIFT Intervention immediately after completing the Baseline Assessment. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
62157663|NCT01941706|EXPERIMENTAL|Project UPLIFT (TAU Waitlist Control)|Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
62157664|NCT06019715|EXPERIMENTAL|Intervention Arm|This arm will receive the full intervention, including 4 months of health coaching support, 8 virtual health coaching visits, a Fitbit device, and an at home blood pressure monitor.
62157665|NCT06153589|EXPERIMENTAL|Musicotherapy + debridement and usual analgesic protocol|Patients in the experimental arm will receive classic debridement care and usual use of analgesic treatment, accompanied by a musicotherapy session respecting the standardized method of the U-shaped sequence.
62157666|NCT06153589|NO_INTERVENTION|Debridement and usual analgesic protocol|Patients in the experimental arm will receive classic debridement care and usual use of analgesic treatment.
62157667|NCT00257309|ACTIVE_COMPARATOR|Thrombolysis|Weight adjusted tenecteplase bolus + Unfrationated heparin
62157668|NCT00257309|ACTIVE_COMPARATOR|Primary angioplasty|Primary angioplasty
62157669|NCT00135200|EXPERIMENTAL|Bexxar therapeutic|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from the subject's body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated based on the scans performed following the dosimetric dose."
62157670|NCT01599221||Subjects with EBA2|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
62157671|NCT06068803|EXPERIMENTAL|Ketone drink|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 4-week supplementation period. Physical activity and blood glucose will be monitored using wearable devices.
62157672|NCT06068803|PLACEBO_COMPARATOR|Placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 4-week supplementation period. Physical activity and blood glucose will be monitored using wearable devices.
62157673|NCT02066454|EXPERIMENTAL|Apixaban|oral direct anti-Xa anticoagulant
62157674|NCT02703519|NO_INTERVENTION|1 cesarean section|control group
62157675|NCT02703519|NO_INTERVENTION|2 cesarean sections|control group
62157676|NCT02703519|EXPERIMENTAL|resection of uterine scar tissue|2 cesarean sections with resection of uterine scar tissue from first cesarean section
62157677|NCT00202228|EXPERIMENTAL|1|Individuals living with HIV who are naive to antiretroviral treatment, or who have been on a treatment interruption for at least six months
62532308|NCT04013321|NO_INTERVENTION|Healthy control|Healthy sleepers will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
62532309|NCT03188666|EXPERIMENTAL|REGN2477|
62157678|NCT00202228|EXPERIMENTAL|2|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT
62157679|NCT00202228|EXPERIMENTAL|3|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT and have liver disease.
62157680|NCT00202228|EXPERIMENTAL|4|HIV negative control group
62532310|NCT03188666|EXPERIMENTAL|Placebo|
62532311|NCT04354116|EXPERIMENTAL|MARPE|Maxillary expander anchored in mini-implants (MARPE)
62532312|NCT04354116|ACTIVE_COMPARATOR|Hyrax|Tooth-born anchored maxillary expanders, without mini-implants
62532313|NCT00883909||observational|A follow-up study in adult male subjects who have received investigational
62532314|NCT04565925|EXPERIMENTAL|Sildenafil 20mg TID then Placebo TID|Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.
62532315|NCT04565925|EXPERIMENTAL|Placebo TID then Sildenafil 20mg TID|Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
62532316|NCT03140852|ACTIVE_COMPARATOR|Treatment|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the spring 2017.
62532317|NCT03140852|OTHER|Control|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the fall 2017.
62532318|NCT05250466|EXPERIMENTAL|Radiofrequency group|AI Temperature-controlled Radiofrequency Technology
62157681|NCT02217891||participants from existing MSK protocol 12-245|"Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings.~Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling."
62157682|NCT04231175|EXPERIMENTAL|experimental arm A|patients will undergo dedicated MRI imaging of the pelvis, abdomen, and thorax. Based on the findings of the MRI scan patients will be allocated to one of the diagnostic/treatment options
62532319|NCT05250466|ACTIVE_COMPARATOR|Electrical stimulation group|Electrical Stimulation
62532320|NCT05000879|EXPERIMENTAL|MMB for Moms|Subjects will receive digital delivery of Mindful Mood Balance for Moms for 12 weeks. Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
62157683|NCT04231175|NO_INTERVENTION|arm B|patients will undergo the current standard diagnostic work-up of DLS at indication (MDT decision) and otherwise continue to CRS-HIPEC.
62157684|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
62157685|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
62157686|NCT04132999|ACTIVE_COMPARATOR|Family-informed intervention (INT)|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team.
62157687|NCT04132999|ACTIVE_COMPARATOR|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
62157688|NCT03846635||Patients with Suspected Cellulitis|"Patients who undergo an infectious diseases consultation for suspected cellulitis of the upper or lower limbs are eligible to be enrolled. Patients who consent to participation will have chart data extracted and undergo a skin surface temperature measurement of the affected area and surrounding skin using a commercially available infrared thermometer. The dimensions of suspected cellulitis are also measured.~Patients with cellulitis admitted to hospital undergo daily measurements of temperature and dimensions. These patients are also asked standardized questions about their symptoms based on the patient global impression of improvement scale."
62157689|NCT03249272|ACTIVE_COMPARATOR|Hypertrophic cardiomyopathy|
62157690|NCT03249272|ACTIVE_COMPARATOR|Non-ischemic dilated cardiomyopathy|
62157691|NCT03249272|ACTIVE_COMPARATOR|Control|
62157692|NCT03398889||Unexplained Atherosclerosis phenotype|Residual score in linear regression \>2
62157693|NCT03398889||Explained Atherosclerosis phenotype|Residual score in linear regression \<-2, \<2
62157694|NCT03398889||Protected Atherosclerosis phenotype|Residual score \<-2
62157695|NCT05301842|EXPERIMENTAL|Arm A|Tremelimumab, Durvalumab and Lenvatinib in combination with Transarterial Chemoembolization (TACE)
62157696|NCT05301842|EXPERIMENTAL|Arm B|Tremelimumab and Durvalumab in combination with Transarterial Chemoemobolization (TACE)
62157697|NCT05301842|ACTIVE_COMPARATOR|Arm C|Transarterial Chemoembolization (TACE)
62157698|NCT04787692|EXPERIMENTAL|Opioid and Benzodiazepine Naive-patients|Opioid and Benzodiazepine Naive-patients, defined as no medications 30 days prior to surgery
62157699|NCT04787692|EXPERIMENTAL|Opioid and Benzodiazepine Tolerant-patients|Opioid and Benzodiazepine Tolerant-patients, defined as use of medications on most days for 1 or more months (\>30 days) prior to surgery
62157700|NCT05825456||endoprosthetic reconstruction|This is the group of patients with metastatic pathologic fractures treated with endoprosthesis. For example, proximal femur prosthesis for femoral neck fractures.
62157701|NCT05825456||intramedullary nail|This is the group of patients with metastatic pathologic fractures treated with intramedullary nail, and additional bone cement if needed. For example, proximal femur nail for trochanteric fractures, or long femoral nail for femoral shaft fractures.
62157702|NCT05825456||open reduction internal fixation with plate and screws|This is the group of patients with metastatic pathologic fractures treated with open reduction internal fixation; with plates and screws. For example, reconstruction plates for pelvic fractures or 3.5 locking compression plates for humeral or femur shaft fractures.
62532321|NCT05000879|NO_INTERVENTION|Waitlist Control|Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
62157703|NCT03684772|EXPERIMENTAL|ICVT|Digoxin and Furosemide (0.125%)
62157704|NCT03684772|EXPERIMENTAL|Furosemide|Furosemide (0.125%)
62157705|NCT03684772|EXPERIMENTAL|Digoxin|Digoxin (0.125%)
62532322|NCT00430820||1|30 patients
62532323|NCT00430820||2|30 patients
62532324|NCT00430820||3|30 patients
62532325|NCT02080013|SHAM_COMPARATOR|ClosureFast group|Radiofrequency Ablation for the Treatment of Great Saphenous Vein Reflux
62157706|NCT03684772|PLACEBO_COMPARATOR|Placebo|Vehicle Gel
62157707|NCT01973296|EXPERIMENTAL|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
62157708|NCT01973296|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
62157709|NCT02256553|EXPERIMENTAL|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
62532326|NCT02080013|SHAM_COMPARATOR|group 1|EVL group Endovenous Laser Ablation for the Treatment of Great Saphenous Vein Reflux
62532327|NCT00106067|EXPERIMENTAL|Arm 1|In the intervention arm, Patients and their family caregivers have access to a coping and communication support practitioner (CCSP) (see intervention description) in addition to receiving the usual care in the site.
62532328|NCT00106067|NO_INTERVENTION|Arm 2|In the control arm, Patients are receiving the usual care in the site.
62157710|NCT03663049|NO_INTERVENTION|Usual care|These patients will continue as statins as usual.
62157711|NCT03663049|EXPERIMENTAL|Discontinue statin|Patients randomized to this group will stop using the statins they are currently prescribed and will not use their statin medication for 12 weeks.
62157712|NCT05656937|EXPERIMENTAL|Oblique orientation|cannulation will be oblique approach
62157713|NCT05656937|ACTIVE_COMPARATOR|transverse approach|cannulation will be transverse approach
62157714|NCT06384859|EXPERIMENTAL|ESWT + PRP|Receive ESWT once a week for 4 weeks and PRP injection at a week later
62157715|NCT06384859|ACTIVE_COMPARATOR|ESWT|Receive ESWT once a week for 4 weeks
62157716|NCT04491370|EXPERIMENTAL|Polatuzumab vedotin|"Evaluable patients for safety Patients receiving 1 dose of Polatuzumab Vedotin will be evaluable for safety.~Evaluable patients for response Only in patients who are in PR or SD prior to PV and received a minimum of 3 doses will be evaluable.~Evaluable patients for EFS, PFS, OS All patients who have completed conditioning and autoSCT will be evaluable for EFS, PFS, and OS."
62157717|NCT00472082|EXPERIMENTAL|1|The study drug Efalizumab will be given as part of a triple drug regimen including mycophenolate mofetil and prednisone. A test dose of Efalizumab 0.7mg/kg will be given at the enrollment visit. Beginning with study visit 2, Efalizumab 1mg/kg will be administered subcutaneously by injection on a weekly basis for 1 year. Mycophenolate mofetil will be given at a dose of 2gm/day which is the same as the standard of care dose. If patient experiences drug toxicity with mycophenolate mofetil they may be reduced and resume a minimum of at least 1gram daily to continue in the study. Patients will be maintained at 10mg of prednisone daily, same as standard of care.
62157718|NCT05377372|EXPERIMENTAL|Breastfeeding Intervention Group|Ten mother-infant dyads will be recruited to a six-month, community-based intervention aimed to promote sustained breastfeeding for at least six months among mothers of infants with sickle cell disease. The intervention will include an online, social media-based support group, online educational modules, monthly in-person educational sessions, access to free breast pump rentals, and monthly peer-led home visits by certified Vanderbilt-affiliated Maternal Infant Health Outreach Specialists. We obtain whole blood specimens for analysis of oxidative stress and inflammation at 3, 6, 12 and 24 months.
62157719|NCT05377372|OTHER|Observation Group|A 24 month observation of 10 mother-infant dyads affected by sickle cell disease that initiate breastfeeding. These dyads will observed for breastfeeding exclusivity/dosage and duration. We obtain whole blood specimens for analysis of oxidative stress and inflammation at 3, 6, 12 and 24 months.
62157720|NCT00001876||Combo|Patients with rheumatoid arthritis and biopsy-proven pulmonary fibrosis.
62157721|NCT00001876||pulmonary fibrosis|Patients with biobsy-proven idiopathic pulmonary fibrosis only.
62157722|NCT00001876||rheumatoid arthritis|Patients with rheumatoid arthritis only.
62532329|NCT01853631|EXPERIMENTAL|Dose Escalation: CD19 CAR T Cells for B-cell ALL|Each patient will receive a dose of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
62157723|NCT05458271|EXPERIMENTAL|VCMX|"All patients will be treated by scaling/root planing to obtain infection control if needed. In addition, patients will receive oral hygiene instructions.~The test group will be treated with add of VCMX. Following the local anesthesia, a split thickness flap will be raised-up to uncover the implant screw. Care will be taken to preserve pre-existing KT amount. A mesio-distal and apical partial thickness dissection will be performed to release residual muscle tension and allow the passive apical displacement of the flap. The randomisation envelope will be then opened. In test group the VCMX will be gently shaped and secured under the flap with suture. Care will be applied to completely cover the xenograft."
62157724|NCT05458271|ACTIVE_COMPARATOR|CTG|The control group patients will be treated by flap surgery with add of CTG. In the control group (APF) a CTG harvested from palate will be secured under the flap with suture.
62157725|NCT04521088||visitors of the outpatient clinic for COVID-19|visitors of the outpatient clinic for COVID-19
62532330|NCT01853631|EXPERIMENTAL|Dose Expansion: CD19 CAR T Cells for B-cell ALL|Each patient will receive the maximum tolerated dose (MTD) of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
62532331|NCT01853631|EXPERIMENTAL|Dose Escalation: CD19 CAR T Cells for B-cell NHL/CLL|Each patient will receive a dose of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
62532332|NCT01853631|EXPERIMENTAL|Dose Expansion: CD19 CAR T Cells for B-cell NHL/CLL|Each patient will receive the maximum tolerated dose (MTD) of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
62532333|NCT00073619|EXPERIMENTAL|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
62532334|NCT00073619|NO_INTERVENTION|Non-intervention Comparison|Provide no active intervention to the comparison group, although assess the children at the same assessment points as the experimental group. Participants in the control arm were told they were FRIENDS Program participants.They received rewards for participating in the assessments.
62532335|NCT03343652|EXPERIMENTAL|NB|Nivolumab 3 mg/kg IV infusion on day 1,14 + Bendamustine hydrochloride 90 mg/kg IV infusion on day 1,2 up to 3 cycles. Duration of cycle 28 days
62157726|NCT00911014||Vesicovaginal fistula repair|Women undergoing repair of vesicovaginal fistula
62157727|NCT04493125|EXPERIMENTAL|Mosapride group|Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.
62157728|NCT04493125|PLACEBO_COMPARATOR|Placebo group|Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery
62157729|NCT03930173|EXPERIMENTAL|18F-fluciclovine PET/CT of the brain|"Arm includes participants with a known diagnosis of brain metastases who have undergone prior intracranial SRS and whose MRI brain scan is equivocal for radiation necrosis versus tumor progression.~Participants will undergo 18F-fluciclovine PET/CT of the brain. Qualitative and quantitative metrics will be documented at the time of image acquisition. Qualitative image assessment will be performed independently by 3 separate physicians."
62157730|NCT02026583|EXPERIMENTAL|Simvastatin|
62157731|NCT01732406||Acomegaly with Pegvisomant|Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
62157732|NCT01732406||Acromegaly with somatostatin analog|Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly
62157733|NCT01732406||Active Acromegaly|Patients not on drugs for treatment of acromegaly
62157734|NCT00002723|EXPERIMENTAL|Low dose suramin|Low dose suramin
62157735|NCT00002723|EXPERIMENTAL|Intermediate dose suramin|Intermediate dose suramin
62157736|NCT00002723|EXPERIMENTAL|High dose suramin|High dose suramin
62157737|NCT03958305||LAPAROTOMY|Radical hysterectomy by laparotomy
62157738|NCT03958305||MINIMALLY INVASIVE SURGERY|Radical hysterectomy by minimally invasive surgery (Laparoscopy or Robotics)
62157739|NCT01803828|ACTIVE_COMPARATOR|Drug Group (Tadalafil)|Tadalafil 20 mg
62157740|NCT01803828|PLACEBO_COMPARATOR|Placebo Group (PLC)|Placebo 20 mg
62157741|NCT04175938|ACTIVE_COMPARATOR|Subjects with Fuch's Endothelial Dystrophy|Persons with a diagnosis of Fuch's Endothelial Dystrophy will wear a contact lens in an affected eye for three hours.
62157742|NCT04175938|OTHER|Subjects with healthy eyes|Persons with healthy eyes will wear a contact lens in one eye for three hours.
62157743|NCT03444298|PLACEBO_COMPARATOR|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Neutral Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
62157744|NCT03444298|ACTIVE_COMPARATOR|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
62157745|NCT00535626|OTHER|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell used in revision total hip replacement
62157746|NCT00005713||Continuing, preventative care for asthma|Low-income children with asthma will receive continuing, preventive care for asthma with trained staff in New York City Bureau of Child Health clinics
62157747|NCT06585644|EXPERIMENTAL|Treatment group|Furmonertinib in combination with anlotinib and chemotherapy as a neoadjuvant treatment regimen. The enrolled patients will take furmonertinib, with a dose of 80mg/d, from day 1 to day 21, q3w/cycle; and anrotinib, with a dose of 12mg/d, from day 1 to day 14, q3w/cycle. They will receive furmonertinib and anrotinib treatment for 3 cycles, and combined platinum-based chemotherapy for 4 cycles. CT assessment (RECIST1.1) will be conducted within 3 weeks after the completion of treatment. All patients will undergo radical lung lobectomy and systemic lymph node dissection 3 weeks after the end of treatment. Patients who undergo surgery (CR+PR+SD) will take furmonertinib at a dose of 80mg/d for 1 year. PD patients will be transferred to the oncology or radiation department for comprehensive treatment.
62157748|NCT02480283||Control|Subjects aged 18 to 55 who have never used cannabis by self report (validated via urine drug screen), who have never used tobacco/cigarettes and have the capacity to give informed consent.
62157749|NCT02480283||Cannabis Smokers|The exposed cohort will have daily or near daily cannabis smoking histories equivalent to a minimum of 20 joint years (number of joints smoked per day multiplied by years of cannabis smoking), will not have a significant tobacco/cigarette smoking history and will be able to provide informed consent.
62157750|NCT03838159|EXPERIMENTAL|Experimental: Neo-Adjuvant Immunotherapy|"* Neoadjuvant treatment (200 mg/m3 Paclitaxel+ AUC5 Carboplatin+ 360 mg Nivolumab) will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~* Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) .~* Adjuvant treatment:Nivolumab: 480 mg Q4W (+/- 3 days) for 6 months (6 cycles). Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+ 7 days) from surgery and for 6 months."
62157751|NCT03838159|ACTIVE_COMPARATOR|Control: Neo-Adjuvant Chemotherapy|"* Neoadjuvant treatment (200mg/m3 Paclitaxel+ AUC5 Carboplatin). It will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~* Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)"
62157752|NCT04326400||Hospital de la Princesa employees|
62157753|NCT05576233|ACTIVE_COMPARATOR|1.The culture taken after disinfection with providing/iodine|1.Blood cultures routinely performed with alcohol/povidine-iodine
62157754|NCT05576233|ACTIVE_COMPARATOR|2.The culture taken after disinfection with chlorhexidine/alcohol|2. Blood cultures routinely performed with chlorhexidine/alcohol
62157755|NCT04521647|EXPERIMENTAL|menthol flavor|Participants will receive 5% nicotine in an e-cigarette
62157756|NCT04521647|EXPERIMENTAL|tobacco flavor|Participants will receive 5% nicotine in an e-cigarette
62532336|NCT02954263|EXPERIMENTAL|TD-1439|Capsule formulation
62157757|NCT03623776|EXPERIMENTAL|JS001 alone|Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
62532337|NCT02954263|PLACEBO_COMPARATOR|Placebo|Capsule formulation
62157758|NCT03623776|EXPERIMENTAL|JS001+chemotherapy|Subjects receive JS001 240 mg, pemetrexed of 500 mg/m\^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
62157759|NCT03697018|EXPERIMENTAL|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material, enriched with zirconia (10% by weight), the material offers natural esthetics with successful outcome.
62157760|NCT03697018|ACTIVE_COMPARATOR|monolithic zirconia|Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
62532338|NCT03222583|EXPERIMENTAL|Glecaprevir/Pibrentasvir|"Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 or 16 weeks during the double-blind (DB) treatment period.~Participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
62157761|NCT04405089|EXPERIMENTAL|Active tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over right frontal cortex, cathode over left frontal cortex; 2 mAmps for 26 minutes).
62157762|NCT04405089|SHAM_COMPARATOR|Sham tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
62157763|NCT00515879|EXPERIMENTAL|CBT plus d-cycloserine|Participants will receive cognitive behavioral therapy plus D-cycloserine
62157764|NCT00515879|PLACEBO_COMPARATOR|CBT plus placebo|Participants will receive cognitive behavioral therapy plus pill placebo
62157765|NCT02167334|EXPERIMENTAL|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
62157766|NCT02167334|ACTIVE_COMPARATOR|Oxygenation with simple breathing mask|spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
62157767|NCT01074229|PLACEBO_COMPARATOR|Placebo|sterile normal saline as placebo
62157768|NCT01074229|ACTIVE_COMPARATOR|Drug .5% Ropivacaine|Instillation of 20 cc of 0.5% ropivacaine
62157769|NCT01074229|ACTIVE_COMPARATOR|20 cc of 0.25% ropivacaine|Instillation of 20 cc of 0.25% ropivacaine
62157770|NCT06171126|PLACEBO_COMPARATOR|Placebo|Own faeces instilled to the small intestine during gastroscopy
62157771|NCT06171126|EXPERIMENTAL|Arm A|90g of faeces from Donor A is instilled to the small intestine during gastroscopy
62157772|NCT06171126|EXPERIMENTAL|Arm B|90g of faeces from Donor B is instilled to the small intestine during gastroscopy
62157773|NCT06171126|EXPERIMENTAL|Arm C|90g of faeces from Donor C is instilled to the small intestine during gastroscopy
62157774|NCT05935072|EXPERIMENTAL|rest with fixed meal|
62532339|NCT03222583|EXPERIMENTAL|Placebo / Glecaprevir/Pibrentasvir|"Participants received placebo to glecaprevir/pibrentasvir for 8 or 16 weeks during the DB treatment period followed by glecaprevir/pibrentasvir (300 mg/120 mg) once daily for 8 or 16 weeks during the open-label (OL) treatment period.~In each period participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
62736431|NCT06215820|ACTIVE_COMPARATOR|Tramadol|"50 mg, administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization).~Placebo will be administered during out patient phase."
62157775|NCT05935072|EXPERIMENTAL|rest with ad libitum meal|
62157776|NCT05935072|EXPERIMENTAL|Exercise with fixed meal|
62157777|NCT05935072|EXPERIMENTAL|Exercise with ad libitum meal|
62157778|NCT05612009||1. Signal Expert Protection|After scoring clinically and with dental plaque imaging methods, Signal Expert Protection toothpaste was given to 10 volunteers.
62157779|NCT05612009||2. Colgate Hemp Seed Oil|After scoring clinically and with dental plaque imaging methods, Colgate Hemp Seed Oil toothpaste was given to 10 volunteers.
62157780|NCT05612009||3. Gumgumix|After scoring clinically and with dental plaque imaging methods, Gumgumix toothpaste was given to 10 volunteers.
62532340|NCT05477511||Mother|Chinese mother in Hong Kong who had been assessed in HAPO follow-up study when their children was at either 7 or 11-14 years of age
62532341|NCT05477511||18 years old child of the enrolled mother|Children who had been assessed in HAPO follow-up study at either 7 or 11-14 years of age
62157781|NCT01291524|EXPERIMENTAL|Pregabalin controlled release, 330 mg, 400-500 calorie|
62157782|NCT01291524|EXPERIMENTAL|Pregabalin controlled release, 330 mg, 600- 750 calorie|
62157783|NCT01291524|EXPERIMENTAL|Pregabalin controlled release, 330 mg, bedtime|
62157784|NCT01291524|OTHER|Pregabalin immediate release, 300 mg|Reference Treatment
62157785|NCT02259959|EXPERIMENTAL|BI 1744 CL in combination with Tiotropium|
62157786|NCT02259959|PLACEBO_COMPARATOR|Placebo|
62157787|NCT05516511||cases|systemic lupus erythematosus patients
62157788|NCT05516511||control|healthy individuals
62157789|NCT05771285|ACTIVE_COMPARATOR|Group with two-minute pre-injection application of cold|Before applying the subcutaneous injection, cold application pack was applied on the injection site for two minutes. Then, the low molecular weight heparin injection was applied to this cold-applied area in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
62157790|NCT05771285|ACTIVE_COMPARATOR|Group with five-minute pre-injection application of cold|Before applying the subcutaneous injection, cold application pack was applied on the injection site for five minutes. Then, the low molecular weight heparin injection was applied to this cold-applied area in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
62532342|NCT04248218|NO_INTERVENTION|Normal/Control|Control Group/Standard Care
62532343|NCT04248218|ACTIVE_COMPARATOR|Active Rehabilitation Group/Case|Active Rehabilitation Cohort/Intervention
62532344|NCT02515149|NO_INTERVENTION|Standard of care|Referral laboratory based CD4 measurement after home-based HIV testing
62532345|NCT02515149|EXPERIMENTAL|Point of care|POC CD4 testing after home-based HIV testing
62532346|NCT00663520||1|"Women with chest pain and Clean heart vessels"
62532347|NCT00663520||2|Healthy volunteers
62532348|NCT03021109|EXPERIMENTAL|Inferior vena cava diameteres|Measurement of inferior vena cava diameters with ultrasound
62532349|NCT05122936||XOWI Group|Obesity Cohort undergoing XRXPY-based Obesity Wellness Intervention
62736432|NCT06215820|PLACEBO_COMPARATOR|Placebo|Placebo is administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization) and twice daily during the out patient phase.
62157791|NCT05771285|NO_INTERVENTION|Control group|Without applying any tools or processes, the low molecular weight heparin injection was applied in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
62157792|NCT02602002|EXPERIMENTAL|Active|Remifentanil 0.1 ug/kg/min to 0.10 ug/kg/min
62157793|NCT02602002|PLACEBO_COMPARATOR|Placebo|Saline (0.9%)
62157794|NCT01195402|NO_INTERVENTION|Control|Subjects do not receive any kind of active intervention.
62157795|NCT01195402|ACTIVE_COMPARATOR|pulmonary outpatient rehabilitation|Subjects participate in an outpatient pulmonary rehabilitation program
62532350|NCT05275803|EXPERIMENTAL|Probiotics|The participants would use probiotics for 30 days
62532351|NCT05275803|EXPERIMENTAL|Control|The participants would use not probiotics
62532352|NCT03052218|EXPERIMENTAL|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
62532353|NCT04091659|ACTIVE_COMPARATOR|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
62532354|NCT04091659|EXPERIMENTAL|Virtual Reality|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
62532355|NCT02498106|ACTIVE_COMPARATOR|nutritional supplement|2 Orthica Soft Multi Mini capsules and 1 Orthica Fish EPA Mini capsule per day; duration: 6 months
62714201|NCT01624753|EXPERIMENTAL|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
62157796|NCT03419754|EXPERIMENTAL|Glucose and Fidgetting|75 g of glucose will be given at the beginning of the study day (days one with glucose+fidgeting )
62532356|NCT02498106|PLACEBO_COMPARATOR|placebo|During 6 months one group receives 3 placebo supplements daily with identical look and feel to Orthica Soft Multi Mini and Orthica Fish EPA Mini
62714202|NCT06719180|EXPERIMENTAL|Vaginal Cuff Anesthesia|
62714203|NCT06719180|PLACEBO_COMPARATOR|Vaginal Cuff Saline|
62157797|NCT03419754|PLACEBO_COMPARATOR|Fidgetting|Subjects will fidget their legs in an up and down motion for 2.5 min on and then 2.5 min off for the duration of the study.
62157798|NCT00318591|EXPERIMENTAL|SpeediCath|hydrophilic-coated intermittent catheter
62157799|NCT00318591|EXPERIMENTAL|Conveen Uncoated|uncoated urinary intermittent catheter
62157800|NCT01293201|EXPERIMENTAL|STAHIST Investigational Medical Product|STAHIST Tablet, dosed one tablet BID
62157801|NCT01293201|PLACEBO_COMPARATOR|Placebo|Placebo tablet, identical appearance to IMP, dosed one tablet BID
62157802|NCT02776917|EXPERIMENTAL|Cirmtuzumab + Paclitaxel|"Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Paclitaxel 80 mg/m\^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle."
62157803|NCT05134233|EXPERIMENTAL|Parameter Trials|Approximately 36 parameter combinations will be tested per study session, expected 6 sessions of trials. Response recorded using TMS and EMG.
62157804|NCT00814554|NO_INTERVENTION|control|no intervention was carried out in high school
62157805|NCT00814554|EXPERIMENTAL|Educational strategy|Educational strategy was carried out in high school.
62157806|NCT00814554|EXPERIMENTAL|Screening strategy|Screening strategy was carried out in high school.
62157807|NCT00814554|EXPERIMENTAL|Environmental strategy|Environmental strategy was carried out in high school.
62157808|NCT00814554|EXPERIMENTAL|Educational and Screening strategies|Educational strategy and Screening strategy were carried out in high school
62157809|NCT00814554|EXPERIMENTAL|Screening and Environmental strategies|Screening strategy and Environmental strategy were carried out in high school
62157810|NCT00814554|EXPERIMENTAL|Educational and Environmental strategies|Educational strategy and Environmental strategy were carried out in high school
62157811|NCT00814554|EXPERIMENTAL|the three strategies|Educational strategy, Screening strategy and Environmental strategy were carried out in high school.
62157812|NCT00782873||obese subjects|BMI \> 35
62157813|NCT01911819|EXPERIMENTAL|Sinus augmentation using Bio-oss|Sinus augmentation using Bio-oss
62157814|NCT01911819|EXPERIMENTAL|Sinus augmentation using Equimatrix|Sinus augmentation using Equimatrix
62157815|NCT01911819|EXPERIMENTAL|Sinus augmentation using OSSIF-i sem|Sinus augmentation using OSSIF-i sem
62157816|NCT05888272|EXPERIMENTAL|Experimental - Stress Managment|A locally adapted self-help guidebook originally developed by the World Health Organization (WHO), 'Doing what matters in times of stress' for managing disruptive emotions and psychological distress, will be delivered to women entrepreneurs at their residences, followed by 7 phone calls from a trained mental health helper to reinforce the materials over a 10-week period. The intervention is intended to help people manage their psychological distress associated with a range of adversities but is not intended for participants with severe mental health problems such as psychosis or imminent risk of suicide
62157817|NCT05888272|NO_INTERVENTION|Waitlist Control|This group will receive the DWMTS handbook if the study documents a positive impact on the outcomes of interest.
62714204|NCT05992129|OTHER|structural foot types and their influence on core in collegiate athletes|Athletes do 12 weeks of exercises and then evaluate how they influenced core stability
62714205|NCT05992129|OTHER|structural foot types and their influence on performance in collgiate athletes|Athletes do 12 weeks of exercises and then evaluate how they influenced on sport performance
62157818|NCT02467673|ACTIVE_COMPARATOR|NANOPARTICULATE estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal nanostructured estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
62157819|NCT02467673|ACTIVE_COMPARATOR|MICRONIZED estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal micronized estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
62157820|NCT03733756|EXPERIMENTAL|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
62157821|NCT03733756|ACTIVE_COMPARATOR|POEM involving longitudinal muscle|participants are operated POEM involving the whole layer of muscle, both circular and longitudinal muscle
62157822|NCT00370747|EXPERIMENTAL|Ecabet|Ophthalmic solution in the Study eye four times daily for 90 days.
62157823|NCT00370747|PLACEBO_COMPARATOR|Placebo|Ophthalmic solution in the Study eye four times daily for 90 days.
62157824|NCT04785794|EXPERIMENTAL|M2SR dose, 50-64 years of age|Intranasal M2SR vaccine followed by standard, licensed IIV
62157825|NCT04785794|PLACEBO_COMPARATOR|Placebo dose, 50-64 years of age|Intranasal physiological saline followed by standard, licensed IIV
62157826|NCT04785794|EXPERIMENTAL|M2SR dose, 65-85 years of age|Intranasal M2SR vaccine followed by licensed IIV recommended for people 65 years and older
62157827|NCT04785794|PLACEBO_COMPARATOR|Placebo dose, 65-85 years of age|Intranasal physiological saline followed by licensed IIV recommended for people 65 years and older
62157828|NCT00903981|EXPERIMENTAL|Avanafil 100mg|
62157829|NCT00903981|EXPERIMENTAL|Avanafil 200mg|
62157830|NCT00903981|PLACEBO_COMPARATOR|Placebo|
62157831|NCT03385109||Senhance Treated|All patients enrolled who go on to have a surgery in which the Senhance system is used
62157832|NCT00074932|OTHER|1|
62157833|NCT03988309|ACTIVE_COMPARATOR|"Test, subjects categorised as low risk or Not low risk"|"A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either low risk or not low risk categories. Low risk subjects satisfy all conditions and not low risk satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as not low risk will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects."
62157834|NCT03988309|NO_INTERVENTION|Control|Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.
62157835|NCT04078373||Without urinary disorders|Subacute stroke patients without urinary disorders
62157836|NCT04078373||With urinary disorders|Subacute stroke patients with urinary disorders
62157837|NCT06222671|EXPERIMENTAL|608 Dose A|608 Dose A subcutaneous (SC) injection.
62157838|NCT06222671|EXPERIMENTAL|608 Dose B|608 Dose B subcutaneous (SC) injection.
62157839|NCT06222671|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous (SC) injection.
62157840|NCT04955886|EXPERIMENTAL|Recurrent or Metastatic Nasopharyngeal Carcinoma.|Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma were given Surufatinib Combined With Toripalimab.
62157841|NCT03778788|ACTIVE_COMPARATOR|App group|Participants will receive the MetS mobile application (MetS app) instalment and briefing by a research assistant (RA2) after the educational talk. They will be able view the booklet content in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting for their exercise plan and exercise record.
62157842|NCT03778788|ACTIVE_COMPARATOR|Booklet group|The participants will additionally receive a Hong Kong version Lifestyle Intervention Programme (LIP) booklet to take home and use for 20 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
62157843|NCT03778788|ACTIVE_COMPARATOR|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
62157844|NCT04783389|EXPERIMENTAL|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
62157845|NCT04783389|EXPERIMENTAL|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
62157846|NCT04783389|PLACEBO_COMPARATOR|Placebo|Placebo subcutaneous (SC) injection.
62157847|NCT03209336|EXPERIMENTAL|A group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated by surgical resection and the radiotherapy is given during the operation after the removal of the tumour.
62714206|NCT04516603|EXPERIMENTAL|Fampridine SR|"Single oral administration of a tablet fampridine (10 mg) formulated for oral administration taken once in the morning without food. Tablets must be administered whole.~The single intake is followed by a washout period of at least 7 days equalling over 40 half-lives of the active substance fampridine (t½ = 3.61 h) between experimental and control intervention."
62736433|NCT01454609|PLACEBO_COMPARATOR|Saline|0.9% normal saline
62157848|NCT03209336|NO_INTERVENTION|B group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated only by surgical resection and no radiotherapy afer the removal of the tumour.
62157849|NCT01484015|EXPERIMENTAL|Arm I (standard infusion)|Patients receive cefepime hydrochloride IV over 30 minutes.
62157850|NCT01484015|EXPERIMENTAL|Arm II (prolonged infusion)|Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
62157851|NCT02344602|EXPERIMENTAL|Febuxostat (trade name Uloric®)|Oral tablet, 80mg, OD, 8 weeks
62157852|NCT03851809|EXPERIMENTAL|neurologic intensive care in acute brain injury|With the guidance of Taiwan Neurosurgical Society and Taiwan Neurological Society, patients in the control group were given the consistent treatment. (http://www.neurosurgery.org.tw/nsr/tbi/main.htm and http://www.stroke.org.tw/guideline/guideline_1.asp). The intensive treatments were established according to the traumatic brain injury treatment guidelines and spontaneously intracerebral hemorrhage general treatment principles from these two society in Taiwan.
62157853|NCT05717725|ACTIVE_COMPARATOR|Pulsed-field ablation arm|Patients will undergo catheter ablation using for atrial fibrillation using pulsed-field energy
62157854|NCT05717725|SHAM_COMPARATOR|Sham procedure arm|Patients will receive sham procedure (no ablation)
62157855|NCT01736722|EXPERIMENTAL|MRI-guided laser induced thermal therapy|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
62157856|NCT06593275|EXPERIMENTAL|Control group|This group is defined by the use of a collagen hemostatic sponge and photocured fluid resin for the protection of the palatal donor area by means of an adhesive protocol to the palatal surfaces of the neighboring teeth and fixed with X-suture to improve its stability in the area. A visual analog scale examination will be performed to assess the postoperative pain generated in the palate from day 1 to 14 and ending with the removal of this protection.
62157857|NCT06593275|EXPERIMENTAL|Experimental group|This group is defined by the use of a collagen hemostatic sponge and a self-adhesive dressing for the protection of the palatal donor area and fixed with an X-shaped suture to improve its stability in the area. A visual analog scale examination will be performed to evaluate the postoperative pain generated in the palate from day 1 to 14 and ending with the removal of this protection.
62157858|NCT04554199|EXPERIMENTAL|EEG and MMSE measurements before receiving RPD|EEG and MMSE were measured for all participant before wearing the removable partial dentures.
62157859|NCT04554199|EXPERIMENTAL|EEG and MMSE measurements after receiving RPD|EEG and MMSE were measured for all participant after wearing the removable partial dentures
62157860|NCT02518802|EXPERIMENTAL|Synchronous therapy|'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen. Gefitinb, 250mg per day,take orally for 2 years. Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
62157861|NCT02518802|ACTIVE_COMPARATOR|Chemotherapy|Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
62157862|NCT03699761|EXPERIMENTAL|Pelvic Peritonization|
62532357|NCT06353711|EXPERIMENTAL|CA-LINC Intervention|"CA-LINC is a 90-day culturally adapted LINC intervention developed with and for Black youth. The CA-LINC intervention integrates engagement and follow-up strategies to assess/monitor suicide risk, facilitate service use referrals/linkages, develop/reﬁne safety plans, and create villages of care. The CA-LINC intervention incorporates African-centered principles and empowerment and motivational strategies to support, enhance strengths, promote hope, improve family relationships, and reinforce caring messages. This consumer-, community-, and theory-driven care coordination intervention is designed to reduce suicide ideation and behavior (SIB) by improving service engagement and delivery standards. CA-LINC is implemented by Peer Support Specialists and Community Health Workers assigned to mental health hubs in Black Faith Based Organizations (FBOs) to facilitate standardization and access to care."
62714207|NCT04516603|PLACEBO_COMPARATOR|Placebo|Identically looking placebo tablets consisting of the identical additives formulated for oral administration.
62157863|NCT03699761|NO_INTERVENTION|Without Pelvic Peritonization|
62157864|NCT04017598|ACTIVE_COMPARATOR|Ferrous Sulfate|Iron will be given orally in the form of tablets. A supplement of 60 mg will be taken daily for 12 weeks. World Health Organization standard dose and commonly used form of iron.
62157865|NCT04017598|EXPERIMENTAL|Ferrous Bisglycinate|Iron will be given orally in the form of tablets. A supplement of 18 mg will be taken daily for 12 weeks. Ferrous bisglycinate has a bioavailability 2-4x greater than ferrous sulfate.
62157866|NCT04017598|PLACEBO_COMPARATOR|Placebo|Placebo will be given orally in the form of tablets as a control made of microcrystalline cellulose.
62157867|NCT02900937|EXPERIMENTAL|Coronary Scaffold Implantation|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
62157868|NCT05560061|EXPERIMENTAL|Uneven terrain walking training|Participants will complete walking practice on an uneven terrain surface.
62157869|NCT05560061|ACTIVE_COMPARATOR|Flat terrain walking|Participants will complete walking practice on a level surface.
62157870|NCT02992496|ACTIVE_COMPARATOR|Ketamine treatment group|Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
62157871|NCT02992496|ACTIVE_COMPARATOR|Control group|Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks
62157872|NCT01733199|EXPERIMENTAL|BA-|Patient with no secondary behavioural addiction
62157873|NCT01733199|EXPERIMENTAL|BA+/DDS-|Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
62157874|NCT01733199|EXPERIMENTAL|BA+/DDS+|Patients with secondary behavioural addiction and dopamine dysregulation syndrome
62157875|NCT05188404||Cannabis Users|Older adults (60 and up) who report pain, sleep problems, and/or negative mood (anxiety and/or depression) and who desire to use cannabis for these issues (n=300)
62157876|NCT05188404||Cannabis Non-users|Older adults (60 and up) who report pain, sleep problems, and/or negative mood (anxiety and/or depression) and do NOT desire to use cannabis for these issues (n=50)
62157877|NCT04619823|OTHER|Patient infected by arboviruses|
62157878|NCT05256758|EXPERIMENTAL|OxFAST Fibrate group|49 patients randomised to receive fenofibrate 200mg capsules.
62157879|NCT05256758|PLACEBO_COMPARATOR|OxFAST placebo group|13 patients randomised to receive placebo will act as controls.
62157880|NCT03906240|NO_INTERVENTION|No intervention|Veterans will access the online portal and complete session measures, but will not be presented with any intervention content (i.e., videos, journaling exercise, and goal setting exercise)
62157881|NCT03906240|EXPERIMENTAL|Moral Elevation Intervention|Moral Elevation Intervention (described in intervention section).
62157882|NCT04508829|EXPERIMENTAL|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or TPF regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3+5-FU 750mg/m2, CIV, 120h, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
62532358|NCT06353711|ACTIVE_COMPARATOR|Treatment as Usual|The treatment as usual arm includes care coordination services provided by Peer Support Specialists and Community Health Workers in the FBO mental health hubs. This condition includes screening to determine youth suicide risk (high vs. low). Youth presenting with high risk are typically referred to an inpatient treatment facility. Youth presenting with low risk may be referred to a local outpatient provider. MH hub staff may attempt to follow up with families (typically not more than a one-time check-in) to ensure they are connected to the referral source. Following initial referrals, mental health hubs typically continue to provide crisis response and referral services to youth and caregivers as needed.
62532359|NCT00085930|EXPERIMENTAL|EBV specific CTLs w/out lymphodepletion|Escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells administered to patients with Neuroblastoma.
62532360|NCT04658017|EXPERIMENTAL|GARNET device|All enrolled subjects will receive treatment with the GARNET device.
62157883|NCT00282009|ACTIVE_COMPARATOR|Basic Internet|Basic Internet
62157884|NCT00282009|EXPERIMENTAL|Enhanced Internet|Enhanced Internet
62157885|NCT00282009|EXPERIMENTAL|Enhanced Internet plus Phone|Enhanced Internet + proactive telephone counseling
62157886|NCT06720896|ACTIVE_COMPARATOR|Active|APT-001 topical ophthalmic ointment, administered once daily for approximately 43 days
62157887|NCT06720896|PLACEBO_COMPARATOR|Control|Vehicle control of APT-001 topical ophthalmic ointment, administered once daily for approximately 43 days
62157888|NCT00293085|ACTIVE_COMPARATOR|Docetaxel|"Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
62157889|NCT00293085|NO_INTERVENTION|Comparative arm|No chemotherapy will be administered. No specific salvage therapy after progression is defined.
62157890|NCT03543540|EXPERIMENTAL|Nexvax2 (Arm A)|
62157891|NCT03543540|EXPERIMENTAL|Nexvax2 (Arm B)|
62157892|NCT03543540|PLACEBO_COMPARATOR|Nexvax2 Placebo (Arm C)|
62157893|NCT03543540|PLACEBO_COMPARATOR|Nexvax2 Placebo (Arm D)|
62157894|NCT03063983|EXPERIMENTAL|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
62157895|NCT03063983|NO_INTERVENTION|Control|31 weeks of MAP
62157896|NCT02209376|EXPERIMENTAL|Arm 1|
62532361|NCT01278719||Antrochaonal polyp; non recurrent type|
62532362|NCT01278719||Antrochoanal polyp; recurrent type|
62532363|NCT01278719||Ethmoidal polyp - non recurrent type|
62532364|NCT01278719||Ethmoidal polyp - recurrent type|
62532365|NCT02766374|EXPERIMENTAL|Heart Rate Variability Biofeedback|"During the first training session, we will measure heart rate variability (HRV) amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal heart rate variability biofeedback (HRV-BF), and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
62714208|NCT06248151|EXPERIMENTAL|Exercise|In the exercise session, participants will perform aerobic, free active and flexibility exercises and will last approximately 45 minutes.
62714209|NCT06248151|OTHER|Control|In the control session, participants will remain seated for 60 minutes.
62157897|NCT04845542|EXPERIMENTAL|ReStoreD|8-week intervention that is remotely delivered, consisting of psychoeducation and positive psychology activities. Participants complete two activities individually and two together each week.
62157898|NCT04845542|NO_INTERVENTION|Waitlist-control|Participants will be waitlisted for 8 weeks.
62157899|NCT00721045|ACTIVE_COMPARATOR|A1|15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.
62157900|NCT00721045|SHAM_COMPARATOR|A2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
62157901|NCT00721045|ACTIVE_COMPARATOR|B1|15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.
62157902|NCT00721045|SHAM_COMPARATOR|B2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
62157903|NCT00721045|ACTIVE_COMPARATOR|C1|15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.
62157904|NCT00721045|SHAM_COMPARATOR|C2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
62157905|NCT04694859||Symptomatic Severe Aortic Valve Stenosis|Patients \>18 years old with symptomatic severe aortic valve stenosis.
62157906|NCT05360134|EXPERIMENTAL|Carica Papaya Arm|1100mg of Carica Papaya Leaf extract administered three times daily for upto one week preoperatively and from post-operative day 3 to day 7.
62157907|NCT05360134|PLACEBO_COMPARATOR|Placebo Arm|Placebo administered 3 time daily for upto one week preoperatively and from post-operative day 3 to day 7.
62157908|NCT03439800|EXPERIMENTAL|Mental and Physical Practice|"Action observation: is defined as the observation of the motor action, in this study, through a video.~Mental Practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical Practice: is the execution of the motor action."
62157909|NCT03439800|ACTIVE_COMPARATOR|Physical Practice|Physical Practice: is the execution of the motor action.
62157910|NCT01167816|EXPERIMENTAL|azacitabine|
62157911|NCT01352026|EXPERIMENTAL|Metformin|
62157912|NCT01180400|EXPERIMENTAL|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
62157913|NCT01180400|PLACEBO_COMPARATOR|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
62157914|NCT03473652|OTHER|Adapted walking platform|
62157915|NCT03529006|ACTIVE_COMPARATOR|Sequent Please Drug Coated Balloon Group|For Sequent Please Group, PCI (percutaneous coronary intervention) PCI procedure with Sequent Please inflation will be performed - drug eluting balloon will be used in the narrowed part of the artery. This method of treatment is one of the standard ones, which is typically used for treatment patients with diagnosis of in stent restenosis, the exact intervention and anesthesia procedures will be performed according to physician's usual practice. For bailout situation Xience stent implantation is possible.
62157916|NCT03529006|ACTIVE_COMPARATOR|Absorb Stent Group|Absorb scaffold group will be treated by PCI procedure with Absorb BVS implantation - implantation of bioresorbable vascular scaffold (Absorb). Coronary stent implantation for treatment in stent restenosis is one of the standard method of treatment this disease, but Absorb system has not been investigated in this indication yet.
62157917|NCT03840278|EXPERIMENTAL|Bihormonal iLet first, then Insulin-Only iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the bihormonal iLet bionic pancreas for 1 week. They then used the insulin-only iLet bionic pancreas for 1 week."
62157918|NCT03840278|EXPERIMENTAL|Insulin-Only iLet first, then Bihormonal iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the insulin-only iLet bionic pancreas for 1 week. They then used the bihormonal iLet bionic pancreas for 1 week."
62157919|NCT06564077|EXPERIMENTAL|Eldoa technique with conventional therapy|"It is myofascial stretching technique of the cervical spine. Patients were asked to adopt desired position to target intervertebral segments. Breathing is also important factor in ELDOA stretch. Patients were instructed to not to hold or strain breathing through promoting diaphragmatic breathing.~* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
62157920|NCT06564077|ACTIVE_COMPARATOR|conventional therapy|"* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
62157921|NCT02571959|EXPERIMENTAL|amoxicillin and clavulanic acid|All volunteers receive a dose of amoxicillin and clavulanic acid
62157922|NCT01721109|EXPERIMENTAL|EVG/COBI/FTC/TDF|Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
62157923|NCT02135445|EXPERIMENTAL|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
62157924|NCT02135445|ACTIVE_COMPARATOR|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
62157925|NCT00336375|EXPERIMENTAL|1|All treatment doses accompanied with intake of fatty food
62157926|NCT00336375|ACTIVE_COMPARATOR|2|All treatment doses not-accompanied with intake of fatty food.
62157927|NCT03763409|EXPERIMENTAL|losartan|50 mg single-dose oral losartan
62157928|NCT03763409|PLACEBO_COMPARATOR|placebo|microcellulose placebo in identical capsule
62714210|NCT04451161|OTHER|BASIS with TF-CBT|"Implementation intervention: experimental arm (Beliefs and Attitudes for Successful Implementation in Schools)~Clinical Intervention: experimental arm (Trauma-Focused CBT)"
62157929|NCT04276649||Caltrate+Mesalazine|Patients in this group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months.
62157930|NCT04276649||Mesalazine|Patients in this group were received with Mesalazine 4g/d orally at least 12 months.
62157931|NCT01387984||Type 2 diabetes mellitus|
62157932|NCT00865033|EXPERIMENTAL|1|Metformin HCL Tablets, 1000 mg
62157933|NCT00865033|ACTIVE_COMPARATOR|2|Glucophage 1000 mg Tablets
62714211|NCT04451161|OTHER|AC with TF-CBT|"Implementation intervention: control arm~Clinical Intervention: experimental arm (Trauma-Focused CBT)"
62714212|NCT04451161|OTHER|Enhanced Treatment as Usual|"Implementation intervention: non-applicable~Clinical Intervention: control arm (Enhanced TAU)"
62157934|NCT04271813|EXPERIMENTAL|Anlotinib and Sintilimab|the combination of Anlotinib with Sintilimab as first-line treatment
62157935|NCT01005563|EXPERIMENTAL|Arm 1: Beef/Pork|Participants consuming diet with beef/pork as predominate sources of protein
62714213|NCT05574556||myoelectric activity of the quadriceps muscle|electromyography myoelectric activity of the quadriceps muscle
62714214|NCT03769688|EXPERIMENTAL|Cervicovaginal secretions|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of cervicovaginal secretions (10 mg in 1 ml total volume, 0.9 ml normal saline).
62714215|NCT03769688|PLACEBO_COMPARATOR|Saline placebo|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of sterile saline placebo (1 ml total volume).
62157936|NCT01005563|EXPERIMENTAL|Arm 2: Soy/Legumes|Participants consuming diet with soy/legumes as predominate sources of protein
62157937|NCT04167150|ACTIVE_COMPARATOR|Dose 1|Participants consume 8 fl oz of tart cherry juice per day.
62157938|NCT04167150|EXPERIMENTAL|Dose 2|Participants consume 2 x 8 fl oz of tart cherry juice per day.
62157939|NCT06367244|EXPERIMENTAL|Kidney transplant arm|Kidney transplant patients will be assigned to the kidney transplant arm and receive the standard 12-week exercise intervention in the TWP. Specific to the kidney arm will be certain patient reported outcomes (PROs). The Kidney Disease Quality of Life-36 (KDQOL-36) is a short form survey widely used to measure patient-reported QOL in patients on dialysis and is a validated tool in kidney transplant patients. Participants in the kidney arm will also receive disease-specific exercise and wellness materials to support their behaviour change.
62157940|NCT06367244|EXPERIMENTAL|Liver transplant arm|Liver transplant patients will be assigned to the liver transplant arm and receive the standard 12-week exercise intervention in the TWP. Specific to the liver arm will be certain PROs and functional fitness measures. The Chronic Liver Disease Questionnaire (CLQD) measures health-related QOL in patients with advanced liver disease and has been previously used in patients awaiting transplant. Liver arm participants will also complete the Liver frailty index, which requires a timed 5 sit-to-stands in addition to the other measures collected for the Fried Frailty Index. Participants in this arm will receive liver-specific exercise and wellness materials to support their behaviour change.
62157941|NCT01718223|EXPERIMENTAL|Treatment (interstitial photodynamic therapy using temoporfin)|Patients receive temoporfin IV over at least 6 minutes on day 1 and undergo interstitial photodynamic therapy on day 3. Within 4-6 weeks, patients undergo surgical resection.
62157942|NCT04623996|EXPERIMENTAL|Single Arm TP-0184|TP-0184 is administered orally once a day
62157943|NCT05601167|EXPERIMENTAL|JTBC00201 (nirmatrelvir/ritonavir, Skayvira)|Group 1 (n=132) received the study drug nirmatrelvir/ritonavir, tablets 300/100 mg, 2 times a day with 12 ±2 hours interval for 5 days in the setting of pathogenetic and symptomatic therapy provided by Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 validated of the time of the study
62157944|NCT05601167|ACTIVE_COMPARATOR|Standard of care|Group 2 (n=132) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 validated of the time of the study
62157945|NCT04585048|NO_INTERVENTION|waiting list|waiting list
62157946|NCT04585048|EXPERIMENTAL|treatment|treatment with the Integrated Behavioral Therapy fo Selective Mutism
62157947|NCT02817685||1|Chronic Hepatitis B patient
62157948|NCT02817685||2|Chronic Hepatitis B patient
62157949|NCT02817685||3|cirrhotic patient
62157950|NCT02817685||4|cirrhotic patient
62157951|NCT02817685||5|ultrasound-difficult patient
62157952|NCT02817685||6|ultrasound-difficult patient
62157953|NCT05779254||Oral Antibiotic Prophylaxis +|At the Uzsoki Hospital and the Department of Surgery at the University of Debrecen, patients receive preoperative neomycin- metronidazole oral antibiotic prophylaxis in addition to mechanical bowel preparation.
62157954|NCT05779254||Oral Antibiotic Prophylaxis -|Patients admitted to the Csolnoky Ferenc Hospital in Veszprém will receive preoperative mechanical bowel preparation and no oral antibiotic prophylaxis.
62157955|NCT02821572||patient|
62157956|NCT02821572||control|
62157957|NCT03720717|EXPERIMENTAL|Opioid Tolerant - baclofen|Patients identified as opioid tolerant if they reported using daily opioids greater than one month. Randomized into baclofen (10 mg p.o.) group. Drug was given within 30 minutes of OR entry. Although pseudo-randomization was planned to be initiated near the end of the trial in order to assure balance group numbers, the early termination of the study did not require this and so all randomized to either baclofen or placebo, independent of opioid status.
62157958|NCT03720717|PLACEBO_COMPARATOR|Opioid Tolerant - placebo|Patients identified as opioid tolerant if they reported using daily opioids greater than one month. Randomized into placebo group with dummy pill administration. Pill was given within 30 minutes of OR entry.Although pseudo-randomization was planned to be initiated near the end of the trial in order to assure balance group numbers, the early termination of the study did not require this and so all randomized to either baclofen or placebo, independent of opioid status.
62157959|NCT03720717|EXPERIMENTAL|Opioid Naive - baclofen|Patients identified as opioid naive if they reported minimal preoperative use of opioids with a criteria of non-daily use and/or use less than one month. Randomized into baclofen (10 mg p.o.) group. Drug was given within 30 minutes of OR entry.Although pseudo-randomization was planned to be initiated near the end of the trial in order to assure balance group numbers, the early termination of the study did not require this and so all randomized to either baclofen or placebo, independent of opioid status.
62157960|NCT03720717|PLACEBO_COMPARATOR|Opioid Naive - placebo|Patients identified as opioid naive if they reported minimal preoperative use of opioids with a criteria of non-daily use and/or use less than one month. Randomized into placebo group with dummy pill administration. Pill was given within 30 minutes of OR entry.Although pseudo-randomization was planned to be initiated near the end of the trial in order to assure balance group numbers, the early termination of the study did not require this and so all randomized to either baclofen or placebo, independent of opioid status.
62157961|NCT01368549||Metanx®|Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.
62714216|NCT05916040||TNTRect MRI-guided radiotherapy group with simultaneous integrated boost|Interventions include having received MRI-guided therapy with simultaneous integrated boost on the gross tumor volume in patients with rectum cancer.
62714217|NCT00731484||Volunteer Patients/Subjects|These subjects should present the general population.
62157962|NCT05114499||Donepezil monotherapy group|Donepezil 5mg qd
62157963|NCT05114499||GV-971 monotherapy group|GV-971 450mg bid
62157964|NCT05114499||Donepezil combined with GV-971 group|Donepezil 5mg qd+GV-971 450mg bid
62157965|NCT00992693|EXPERIMENTAL|Treatment with IV Ribavirin|In this open label treatment study, the investigators intend to treat all subjects who present with a tentative diagnosis of VHF and meet entry criteria with a 10 day course of IV Ribavirin.
62157966|NCT04762446||SSI group|Participants who developed surgical site infection (SSI) based on the definition of Centre for Disease Control and Prevention.
62157967|NCT04762446||Non-SSI group|Participants who did not develop SSI.
62736434|NCT01454609|EXPERIMENTAL|Bupivacaine|0.25% bupivacaine
62157968|NCT04967677||Czech healthy occupational therapy students|Czech healthy occupational therapy students will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test. Video of their performance will be obtained.
62157969|NCT03736889|EXPERIMENTAL|Tislelizumab (BGB-A317) Injection|
62157970|NCT01426217|NO_INTERVENTION|Control|Control arm using standard of care operating room procedures and equipment
62157971|NCT01426217|EXPERIMENTAL|Problem Solving Innovations (PSI) Experimental|Implementation of the passive bundle including HubScrub and DocIt
62157972|NCT01217645|EXPERIMENTAL|150 mg [14C] AZD6765|
62157973|NCT01932645||Prostatitis patients|We will enroll patients from the outpatient clinic who are suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation). Patients with these symptoms and identified as having prostatitis will be approached to enroll.
62157974|NCT01932645||Controls|Male patients seen in the outpatient clinic who do not have prostatitis (not suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), and do not have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation)) will be approached to enrol as controls.
62157975|NCT04774198||Occurrence of persistent postoperative hypotension|Patients with need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)\>65 mmHg, after pancreaticoduodenectomy.
62157976|NCT04774198||No occurrence of persistent postoperative hypotension|Patients without need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)\>65 mmHg, after pancreaticoduodenectomy.
62157977|NCT04114279|EXPERIMENTAL|Laparoscopic Duodenal Atresia Repair|All participants will attempt a laparoscopic duodenal atresia repair on the synthetic high fidelity simulator.
62157978|NCT00942188|EXPERIMENTAL|0.6 milligrams (mg) LY2189102|
62157979|NCT00942188|EXPERIMENTAL|18 mg LY2189102|
62157980|NCT00942188|EXPERIMENTAL|180 mg LY2189102|
62157981|NCT00942188|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride
62532366|NCT02766374|PLACEBO_COMPARATOR|Placebo Biofeedback|"A credible Placebo Biofeedback (PBO-BF) consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
62532367|NCT03524989|ACTIVE_COMPARATOR|Treatment|Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
62532368|NCT03524989|SHAM_COMPARATOR|Control/Crossover|SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
62532369|NCT00426361|EXPERIMENTAL|Cervarix Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.
62532370|NCT00426361|EXPERIMENTAL|Boostrix Polio → Cervarix Group|Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.
62532371|NCT00426361|EXPERIMENTAL|Cervarix + Boostrix Polio Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.
62532372|NCT02870179||Healthy volunteer|Smoker or non-smoker
62532373|NCT01299259|EXPERIMENTAL|Text Message Reminders|Subjects randomized to the the intervention group will receive a total of 4 text messages on days 2 through 5 to remind them to schedule and attend a PCP follow-up appointment
62532374|NCT01299259|NO_INTERVENTION|Control Group|The control group will not receive any additional reminders to follow-up with PCP.
62532375|NCT04260438|EXPERIMENTAL|Group 1|"1. Period 1: Treatment A~2. Period 2: Treatment B~3. Period 3: Treatment C"
62532376|NCT04260438|EXPERIMENTAL|Group 2|"1. Period 1: Treatment A~2. Period 2: Treatment C~3. Period 3: Treatment B"
62736435|NCT01454609|EXPERIMENTAL|Bupivacaine with clonidine|0.25% bupivacaine with 1 microgram/kg of clonidine
62157982|NCT01786915|EXPERIMENTAL|Bendavia 10mg|Bendavia capsule, 10mg, once daily for 7 days
62157983|NCT01786915|PLACEBO_COMPARATOR|Placebo|Placebo (matching), once daily for 7 days
62157984|NCT01786915|EXPERIMENTAL|Bendavia 50mg|Bendavia capsule, 50mg, once daily for 7 days
62157985|NCT02400398||Tube feeding with peptide-base formula|The peptide-based formula (Peptamen) will be administered through a gastrojejunal or jejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered for three 28-day cycles.
62157986|NCT04475874|ACTIVE_COMPARATOR|supervised stretching exercises :group A|The intervention group A practiced a 30 to 45-minute supervised active stretching program three times a week for four weeks
62157987|NCT04475874|ACTIVE_COMPARATOR|non-supervised active stretching home program: group B|practiced non-supervised active stretching home program
62157988|NCT04475874|NO_INTERVENTION|Standard of care: group c|control group
62157989|NCT01624532|EXPERIMENTAL|GC1109|"Step1: GC1109 0.3 mL or 0.5 mL or 0.1mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
62157990|NCT01624532|PLACEBO_COMPARATOR|Placebo of GC1109|"Step1: Placebo of GC1109 0.5mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: Placebo of GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
62157991|NCT02286245|EXPERIMENTAL|1: focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board. Patients are invited to recall in case of worsening or onset of new symptoms and to get an appointment with their general practitioner during working hours.
62157992|NCT02286245|ACTIVE_COMPARATOR|2: Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
62532377|NCT04260438|EXPERIMENTAL|Group 3|"1. Period 1: Treatment B~2. Period 2: Treatment A~3. Period 3: Treatment C"
62157993|NCT04990037|EXPERIMENTAL|CAN04 and FOLFIRINOX|Subjects will receive bi-weekly doses of CAN04 in combination with FOLFIRINOX given as standard regimen.
62157994|NCT00634348|ACTIVE_COMPARATOR|Aripiprazole|
62157995|NCT00634348|ACTIVE_COMPARATOR|Ziprasidone|
62157996|NCT05857163|EXPERIMENTAL|Test Group|Rifasutenizol capsules, 400 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin placebo tablets, BID, taken orally within half an hour after breakfast and dinner Bismuth potassium citrate placebo capsules, BID, taken orally within half an hour before breakfast and dinner
62157997|NCT05857163|ACTIVE_COMPARATOR|Control Group|Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin tablets, 500 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Bismuth potassium citrate capsules, 240 mg, BID, taken orally within half an hour before breakfast and dinner Rifasutenizol placebo capsules, BID, taken orally within half an hour after breakfast and dinner
62157998|NCT01280656||Conventional Interferon Plus Ribavirin|Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
62157999|NCT01280656||Peginterferon Alfa-2a Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
62158000|NCT01280656||Peginterferon Alfa-2b Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
62532378|NCT04260438|EXPERIMENTAL|Group 4|"1. Period 1: Treatment B~2. Period 2: Treatment C~3. Period 3: Treatment A"
62532379|NCT04260438|EXPERIMENTAL|Group 5|"1. Period 1: Treatment C~2. Period 2: Treatment A~3. Period 3: Treatment B"
62158001|NCT03873922|EXPERIMENTAL|Ketogenic diet intervention|Ketogenic meals will be offered for the participants during the trial.
62158002|NCT03873922|NO_INTERVENTION|Control group|Conventional hospital meals as usual will be offered during the trial.
62158003|NCT06721689|EXPERIMENTAL|PEEL-224|Phase 1A will test the safety, tolerability and PK profile of PEEL-224 as a single agent in pediatric patients with refractory, progressive and relapsed solid tumors.
62158004|NCT06721689|EXPERIMENTAL|PEEL-224, Vincristine, and Temozolomide|Phase 1B will test the safety, tolerability and pharmacokinetic profile of PEEL-224 in combination with vincristine and temozolomide in pediatric subjects with refractory, progressive and relapsed solid tumors. Phase 2 will preliminary evaluate the activity profile of PEEL-224 in combination with vincristine and temozolomide in pediatric patients with refractory, progressive and relapsed NBL and RMS.
62158005|NCT01755598|EXPERIMENTAL|M72AS01 Group|Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
62158006|NCT01755598|PLACEBO_COMPARATOR|Control group|Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
62158007|NCT01201109||Diabetics|Diabetic patients operated for carpal tunnel syndrome
62158008|NCT01201109||Non-diabetics|Non-diabetic patients operated for carpal tunnel syndrome
62158009|NCT01720407|EXPERIMENTAL|Imiquimod|
62158010|NCT01720407|PLACEBO_COMPARATOR|Placebo|
62158011|NCT02161432|EXPERIMENTAL|Treatment A|single dose of BI 187004 in fasted state
62158012|NCT02161432|EXPERIMENTAL|Treatment B|single dose of BI 187004
62158013|NCT02161432|EXPERIMENTAL|Treatment C|single dose of BI 187004 in fed state
62158014|NCT04362683||High Power Atrial Fibrillation Ablation|"In our center, routine medical care for atrial fibrillation ablation includes:~* Multidirectional high-density mapping~* High power - short duration settings~* Contact force sensing ablation catheter"
62158015|NCT02889172|EXPERIMENTAL|Problem Solving Therapy|Will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City. The aim is evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
62158016|NCT02889172|NO_INTERVENTION|Control|This group will receive the usual treatment , without intervention with Brief Intervention ( PST )
62158017|NCT01936376||head & neck cancer patients, cisplatin treatment|
62532380|NCT04260438|EXPERIMENTAL|Group 6|"1. Period 1: Treatment C~2. Period 2: Treatment B~3. Period 3: Treatment A"
62532381|NCT04328857|EXPERIMENTAL|Treatment|Upper limb rehabilitation with pseudoelastic orthosis
62532382|NCT04328857|NO_INTERVENTION|Control|Upper limb rehabilitation without pseudoelastic orthosis
62158018|NCT01936376||cancer patients, no cisplatin, no nephrotoxic agent|
62158019|NCT05546177|EXPERIMENTAL|instrumented assisted soft tissue mobilization|the patients will receive instrumented assisted soft tissue mobilization three times a week for eight weeks
62158020|NCT05546177|ACTIVE_COMPARATOR|traditional therapy|the patients will receive traditional therapy three times a week for eight weeks
62158021|NCT02464072|EXPERIMENTAL|Subtotal Parathyroidectomy|Patients will be submitted to subtotal parathyroidectomy. The intention is to leave a parathyroid remanent equivalent to two normal parathyroid glands in situ. The type of the operation is the intervention. No drugs or devices are tested.
62532383|NCT00914953|EXPERIMENTAL|oxytocin|
62532384|NCT02362555||ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
62532385|NCT02362555||Non ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
62532386|NCT00593736|EXPERIMENTAL|Ramelteon 1 mg QD|
62532387|NCT00593736|EXPERIMENTAL|Ramelteon 4 mg QD|
62532388|NCT00593736|EXPERIMENTAL|Ramelteon 8 mg QD|
62532389|NCT00593736|PLACEBO_COMPARATOR|Placebo QD|
62158022|NCT02464072|ACTIVE_COMPARATOR|Total Parathyroidectomy + 45 autografts|Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
62714218|NCT04591574|OTHER|Intervention Group|All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital.
62158023|NCT02464072|EXPERIMENTAL|Total Parathyroidectomy + 90 autografts|Patients will be submitted to a total parathyroidectomy and 90 fragments of parathyroid tissue are grafted in the forearm. The type of operation is the intervention. No new device or drug is involved. .
62158024|NCT02185586|EXPERIMENTAL|LALC|lower abdominal laparoscopic cholecystectomy
62158025|NCT02185586|EXPERIMENTAL|SLC|single laparoscopic cholecystectomy
62158026|NCT02185586|PLACEBO_COMPARATOR|UALC|upper abdominal laparoscopic cholecystectomy
62158027|NCT01989845|EXPERIMENTAL|oral rivaroxaban in cancer-associated VTE|
62158028|NCT00782353|EXPERIMENTAL|Cohort 1|Subjects randomized 8:2 (active:placebo) to receive ANA598 200 mg bid
62158029|NCT00782353|EXPERIMENTAL|Cohort 2|Subjects randomized 8:2 (active:placebo) to receive ANA598 400 mg bid
62158030|NCT00782353|EXPERIMENTAL|Cohort 3|Subjects randomized 8:2 (active:placebo) to receive ANA598 800 mg bid
62158031|NCT04944836|PLACEBO_COMPARATOR|Control|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the control group, these will be placebo. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
62158032|NCT04944836|EXPERIMENTAL|Clomiphene|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
62158033|NCT03114592|NO_INTERVENTION|Standard Care|"* Complete a survey asking about kidney function and participant demographics.~* Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
62158034|NCT03114592|EXPERIMENTAL|mHealth Tool|"* Complete a survey asking about kidney function and participant demographics.~* Review a 15-20 minute educational tool on a tablet about kidney health~* Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
62158035|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
62158036|NCT00051740|ACTIVE_COMPARATOR|Cognitive Adaptation Therapy|Subjects receive Cognitive adaptation therapy as part of treatment for schizophrenia
62158037|NCT00051740|ACTIVE_COMPARATOR|Minimal Environmental Support|Subjects receive minimal environmental support in schizophrenia treatment
62158038|NCT02852499||Mothers|Pregnant women.
62158039|NCT02852499||Fathers|Futur fathers.
62158040|NCT02852499||Children|Children after childbirth.
62158041|NCT03037736|PLACEBO_COMPARATOR|Placebo|Patients will receive 0.1mL of normal saline injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
62158042|NCT03037736|ACTIVE_COMPARATOR|5-Fluorouracil|Patients will receive 0.1mL of 5-Fluorouracil, 5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
62158043|NCT03037736|ACTIVE_COMPARATOR|Bevacizumab|Patients will receive 0.1mL of bevacizumab, 2.5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
62714219|NCT04591574|ACTIVE_COMPARATOR|Usual care group|Current usual care transfusion practice, namely single RBC transfusions when Hb 70g/L or less (or modified according to clinician decision) to achieve target Hb 70-90g/L. HB measured at least weekly in hospital
62158044|NCT03622372|EXPERIMENTAL|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
62158045|NCT03622372|ACTIVE_COMPARATOR|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
62158046|NCT05959837|EXPERIMENTAL|Single Group Intervention Arm|Exercise intervention with adaptive rower
62158047|NCT04447586|ACTIVE_COMPARATOR|Patients following Command A and B|This group of patients followed the Commands A and B with this specific order, and performed 3 exhalation attempts for each command.
62158048|NCT04447586|ACTIVE_COMPARATOR|Patients following Command B and A|This group of patients followed the Commands B and A with this specific order, and performed 3 exhalation attempts for each command.
62158049|NCT04447586|ACTIVE_COMPARATOR|intervention group|"Intervention group was requested to exhale as indicated by the right command, performing 3 sets of 10 repetitions."
62158050|NCT04447586|NO_INTERVENTION|control group|"Did not perform exhalation attempts by the right command."
62158051|NCT05982847||Boys|
62158052|NCT05982847||Girls|
62158053|NCT03370094||patients with suspected stroke|patients with suspected stroke due to paramedic's initial evaluation of face, arm, and speech function will be diagnosed with audio-video-streaming of suspected stroke symptoms and signs
62158054|NCT01681394|ACTIVE_COMPARATOR|Product 1|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
62532390|NCT05906108|EXPERIMENTAL|Intervention group|WeChat-based self-initiated learning, personalized and interactive behavioural support
62158055|NCT01681394|PLACEBO_COMPARATOR|Control product|250 g of chocolate cream
62158056|NCT04156685|EXPERIMENTAL|PartA, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
62532391|NCT05906108|ACTIVE_COMPARATOR|Control group|General health information
62532392|NCT05888623||Computer Assisted Detection|Colonoscopies performed at a VA facility with computer assisted detection (CADe) artificial intelligence available.
62532393|NCT05888623||Conventional Colonoscopy|Colonoscopies performed at a VA facility without CADe artificial intelligence available
62532394|NCT02929186|EXPERIMENTAL|Opt-In|Opt-In Outreach
62158057|NCT04156685|EXPERIMENTAL|PartA, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
62158058|NCT04156685|EXPERIMENTAL|PartB, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
62158059|NCT04156685|EXPERIMENTAL|PartB, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
62158060|NCT02848898|EXPERIMENTAL|Equistasi Group|arm treated with application of devices
62158061|NCT02848898|PLACEBO_COMPARATOR|Placebo Group|arm treated with application of inactivated devices
62158062|NCT06518811|EXPERIMENTAL|Exercise group|The asynchronous video-based telerehabilitation programme had a duration of eight weeks. The exercise group participants were instructed to perform the exercises on a regular basis, three days a week, with a time interval of 24 hours between each session. The exercises were to be performed using the instructional videos and recorded in the exercise diaries provided.
62158063|NCT06518811|NO_INTERVENTION|Control group|Control group participants were informed about the benefits of ergonomic training for activities of daily living. Also handbooks containing the same information were distributed.
62158064|NCT01551121||intervention group|"Patient in the intervention group will have camera installed in their room. These cameras can either work in visible or infrared range. They are physically linked to a server that will store and analyze images in real-time. The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy"
62158065|NCT01551121||non-equipped group|"Patient in the non-equipped group will have usual care"
62158066|NCT01709071|EXPERIMENTAL|Low dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
62158067|NCT01709071|EXPERIMENTAL|Low dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
62158068|NCT01709071|EXPERIMENTAL|Middle dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
62158069|NCT01709071|EXPERIMENTAL|Middle dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
62158070|NCT01709071|EXPERIMENTAL|High dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
62158071|NCT01709071|EXPERIMENTAL|High dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
62158072|NCT01709071|ACTIVE_COMPARATOR|Conventional IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.~Infants receive three injections with an interval of 8 weeks between doses."
62158073|NCT01342718|EXPERIMENTAL|GJS/Duolac7S|GJS: Real herbal extract granule/Duolac7S: Real probiotics
62158074|NCT01342718|PLACEBO_COMPARATOR|GJS-P/Duolac7S|GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
62532395|NCT02929186|EXPERIMENTAL|Opt-Out|Opt-Out Outreach
62532396|NCT00912925|PLACEBO_COMPARATOR|Placebo|Patients in the placebo-control group were administered a solution of 100 millimolar (mM) sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
62532397|NCT00912925|ACTIVE_COMPARATOR|Aldurazyme treatment|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 Units/kg (approximately 0.58 mg/kg = labeled dose) administered intravenously over approximately 4 hours once weekly for 26 weeks.
62714220|NCT05427695|ACTIVE_COMPARATOR|Saline Nasal Irrigation (Control)|Patients will perform nasal irrigation with an isotonic saline solution, using a 240ml NeilMed sinus rinse bottle, 2 times/day for 14 days. A blinded packet supplied by IDS containing a premeasured amount of saline to be mixed with 240ml of distilled water will be provided to patients for each irrigation.
62532398|NCT03653117|EXPERIMENTAL|TPLA|TPLA procedure
62532399|NCT00258050|EXPERIMENTAL|Subjects with cancer|"In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.~In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study."
62532400|NCT02789397|ACTIVE_COMPARATOR|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12. Azathioprine: Starting dose of azathioprine will be 50 mg and increased in 25 mg increments to a maximum dose of 150 mg or 2 mg/k/day (whichever is lowest) as tolerated. Azathioprine will be administered by mouth daily for 18 months.
62532401|NCT02789397|PLACEBO_COMPARATOR|Placebo|IV placebo will be administered on the same schedule as Rituximab. Oral placebo will be administered by mouth daily for 18 months.
62532402|NCT05321511|ACTIVE_COMPARATOR|a-GnRH|Administration of triptorelin acetate 0.2 mg for final oocyte maturation.
62532403|NCT05321511|ACTIVE_COMPARATOR|hCG|Administration of coriogonadotropine alfa 250 mcg for final oocyte maturation.
62736436|NCT06417385|EXPERIMENTAL|taVNS treatment group|All 10 infants will receive active taVNS during breastfeeding sessions. There is no randomization or blinding involved.
62736437|NCT03617536|EXPERIMENTAL|CR845 0.25 mg Oral Tablet|Oral CR845 0.25 mg to be taken orally once daily for 12 weeks
62158075|NCT01342718|PLACEBO_COMPARATOR|GJS/Duolac7S-P|GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
62158076|NCT01342718|PLACEBO_COMPARATOR|GJS-P/Duolac7S-P|GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
62158077|NCT04254965|EXPERIMENTAL|Group 1|Participants of integrated music therapy (integration of active and passive music therapy) includes instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process. The four stages of activities are warm-up, main activities, secondary activities, and the ending section.
62532404|NCT05321511|EXPERIMENTAL|a-GnRH + hCG|Administration of triptorelin acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation.
62158078|NCT04254965|ACTIVE_COMPARATOR|Group 2|Participants of the music listening group will receive background music listening, music selection based on the musical preference and background of subjects, for relax or boost the spirit of the subjects.
62158079|NCT04254965|SHAM_COMPARATOR|Group 3|Participants in the control group receive their regular occupational therapy during the experimental period.
62158080|NCT05978089|EXPERIMENTAL|Treatment group|Yangxinshi tablets
62158081|NCT05978089|PLACEBO_COMPARATOR|Control group|Yangxinshi tablet simulants
62158082|NCT01996514|EXPERIMENTAL|Sweetener, non-food advertisements|non-caloric sweetener with water followed by TV program with non-food advertisements while feeding at 30 min
62158083|NCT01996514|EXPERIMENTAL|Glucose, non-food advertisements|Glucose with water followed by TV program with non-food advertisements while feeding at 30 min
62158084|NCT01996514|EXPERIMENTAL|Sweetener, food advertisements|non-caloric sweetener with water followed by TV program with food advertisements while feeding at 30 min
62158085|NCT01996514|EXPERIMENTAL|Glucose, food advertisements|Glucose with water followed by TV program with food advertisements while feeding at 30 min
62158086|NCT02985476|ACTIVE_COMPARATOR|Interventional|Care as usual plus 8 weekly ELIJAH health reports shared with the participant and General Practitioner for 6 months i.e.: My history, My plan, My Update delivered via post or by email (dependant on participant preference) in addition to care as usual.
62158087|NCT02985476|NO_INTERVENTION|Observational|Care as usual dictated by disease pathway of diagnosed inflammatory bowel disease i.e.; access to out-patient and in-patient hospital based care and community health resources via General Practitioner.
62158088|NCT00472368|EXPERIMENTAL|LBH589|
62158089|NCT01894620|PLACEBO_COMPARATOR|rTMS with sham coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
62158090|NCT01894620|ACTIVE_COMPARATOR|rTMS with real coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
62158091|NCT06185699|OTHER|N95/FFP2 masks during the whole working hours, and only took off it for less than 1 hour|Individuals (ı) who wore N95/FFP2 masks during the whole working hours, and only took off it for less than 1 hour. In order to detect the presence of Demodex mites, standard superficial skin biopsy (SSSB) was applied
62158092|NCT06185699|OTHER|3-ply surgical mask during all working hours, only took it off for less than 1 hour|Individuals who wore a 3-ply surgical mask during all working hours, only took it off for less than 1 hour.In order to detect the presence of Demodex mites, standard superficial skin biopsy (SSSB) was applied
62158093|NCT06185699|OTHER|control (who rarely used masks under pandemic conditions)|people who wore a 3-ply surgical mask for less than 3 days a week, less than 2 hours a day and spending time mostly at home during the day or plus those who worked alone all day in their rooms and who wear a 3-ply surgical mask for less than 1 hour during the day as required. In order to detect the presence of Demodex mites, standard superficial skin biopsy (SSSB) was applied
62158094|NCT06719791|EXPERIMENTAL|Open label single arm, drug sirolomus|All subjects will receive the experimental drug
62158095|NCT00755794|EXPERIMENTAL|1|Montelukast
62158096|NCT04265417||RARC group|Participants in this group underwent robotic assisted rectal cancer resection
62532405|NCT05231538|EXPERIMENTAL|Neurodevelopmental Therapy|The treatment group received neurodevelopment treatment lasting for 3 months (3sessions per week). Additionally, for this study, the NDT programme included passive stretching of the lower limb muscles (e.g. hamstrings, gastrocsoleus), followed by techniques of reducing spasticity and facilitating more normal patterns of movement while working on motor functions. In each session, exercises included patients sustaining themselves on their forearms and hands, sitting, crawling, semi-kneeling, and in standing positions supported by the Physical therapist until tone reduction achieved. Balance and corrective reactions were developed by using a CP ball and tilt board.
62532406|NCT05231538|ACTIVE_COMPARATOR|Routine Physical Therapy|The control group underwent the exercises (stretching, passive range of motion, and active range of motion).
62532407|NCT02011386||Treatment|Treatment: Injection Golimumab 50 mg every month on the same date
62532408|NCT02029586|EXPERIMENTAL|MB12066|
62532409|NCT02029586|PLACEBO_COMPARATOR|Placebo|
62158097|NCT04265417||NOSE group|Participants in this group underwent robotic rectal cancer resection assisted rectal with natural orifice extraction
62158098|NCT00794274|EXPERIMENTAL|Open label drug|"Drug: CC-100004~After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis"
62158099|NCT03852771|EXPERIMENTAL|Treatment|All participants will receive the intervention
62158100|NCT02755909|OTHER|Subjects|Pra-anesthetic education given to the subjects includes the anatomy of a normal heart, normal blood circulation, anatomy and pathophysiology of the disease in the respected subject, surgery procedures needed, anesthetic procedures needed for the surgery, and cardiopulmonary bypass procedures. Education and discussion were given repeatedly until subjects could repeat the materials given correctly.
62158101|NCT00578929|EXPERIMENTAL|Olopatadine 0.6% 1 Spray|Olopatadine HCl 0.6% 1 spray per nostril twice daily
62158102|NCT00578929|PLACEBO_COMPARATOR|Vehicle 1 spray|Vehicle 1 spray per nostril twice daily
62158103|NCT00578929|EXPERIMENTAL|Olopatadine 0.6% 2 sprays|Olopatadine HCl 0.6% 2 sprays per nostril twice daily
62158104|NCT00578929|PLACEBO_COMPARATOR|Vehicle 2 sprays|Vehicle 2 sprays per nostril twice daily
62158105|NCT06076317|NO_INTERVENTION|Standard arm|Patients will have the usual care
62158106|NCT06076317|EXPERIMENTAL|Interventional arm|Patients will have telemedicine session
62158107|NCT04785261|ACTIVE_COMPARATOR|conventional treatment|Patients in this group will be given conventional treatment including Artelac® Eye Drops (1-2 drips each time, every 4 hours) and Vidisic® Gel (1 drip each time, at bedtime) for 12 weeks.
62158108|NCT04785261|EXPERIMENTAL|conventional treatment + TCM|Patients in this group will be given conventional treatment and traditional Chinese medicine (6.0g twice daily) for 12 weeks.
62158109|NCT01037699|ACTIVE_COMPARATOR|FSH YOUNGER|
62158110|NCT01037699|ACTIVE_COMPARATOR|FSH OLDER|
62158111|NCT01037699|EXPERIMENTAL|FSH LH YOUNGER (Recombinant Luteotrophin alfa)|
62158112|NCT01037699|EXPERIMENTAL|FSH LH OLDER|
62158113|NCT03671499|EXPERIMENTAL|Social Cognitive Theory based text messages|The study only contains 1 arm. All participants will receive the same experimental protocol. Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
62158114|NCT06201949|EXPERIMENTAL|Test group|
62158115|NCT06201949|ACTIVE_COMPARATOR|Control group|
62158116|NCT01567176|OTHER|Single Arm|
62158117|NCT04249115|EXPERIMENTAL|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of targeted lesion.
62532410|NCT05410132|EXPERIMENTAL|Internet-based mindfulness-based training group (iMBT)|"Participants in the iMBT group will be expected to complete an Internet-based mindfulness-based training delivered over a 6-week period via an internet e-learning mental health platform. They will be assessed at four different time points:~(1) before intervention (T0), (2) 2,4 weeks since the commencement of group (T1,2), (3) 6 weeks after (i.e., when the intervention ends) (T3), (4) at 3-month follow-up(T4)."
62532411|NCT05410132|NO_INTERVENTION|Treatment-as-usual control group (TAU)|The TAU group will be advised to seek assistance from their usual healthcare provider when needed. They will be offered access to the Internet-based mindfulness-based course content after the study has ended.
62532412|NCT02029573|EXPERIMENTAL|Atorvastatin in Combination With Radiotherapy and Temozolomide|
62532413|NCT05016193|EXPERIMENTAL|Intervention Group|"* Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~* Participants will be asked to wear the Axem Home prototype headband when doing their daily upper-extremity rehabilitation exercises at home.~* Participants will perform a short motor assessment while wearing the Axem Home prototype headband once per week."
62158118|NCT04184609|EXPERIMENTAL|Exercise test|"All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design:~1. Control~2. Albuterol"
62532414|NCT05016193|ACTIVE_COMPARATOR|Control Group|"* Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~* Participants will be asked to keep track of how many minutes of rehabilitation they have completed as per standard care.~* Participants will perform a short motor assessment while wearing the Axem Home prototype headband once at the beginning of the study and again at the end of the study during the clinical assessment sessions."
62532415|NCT01030653|EXPERIMENTAL|Voriconazole low dose first then high dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
62532416|NCT01030653|EXPERIMENTAL|Voriconazole high dose first then low dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
62532417|NCT01022944|OTHER|Group 2 :|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
62532418|NCT01022944|OTHER|Group 1|Children with chronic middle ear effusion having adenoidectomy.
62736438|NCT03617536|EXPERIMENTAL|CR845 0.5 mg Oral Tablet|Oral CR845 0.5 mg to be taken orally once daily for 12 weeks
62158119|NCT02954276|EXPERIMENTAL|75 mg Omexa sumatriptan sublingual tablet|
62158120|NCT02954276|ACTIVE_COMPARATOR|100 mg Imitrex oral tablet|
62158121|NCT01942551|EXPERIMENTAL|tadalafil, dutasteride|
62158122|NCT01942551|EXPERIMENTAL|dutasteride, tadalafil|
62158123|NCT01301183|EXPERIMENTAL|Rh IGF-1 + Transdermal estradiol|RhIGF-1 with transdermal 17-beta estradiol
62158124|NCT01301183|PLACEBO_COMPARATOR|Placebo + Transdermal estradiol|Placebo and transdermal 17-beta estradiol
62158125|NCT01572896|EXPERIMENTAL|Taking Charge Experimental Group|
62158126|NCT01572896|ACTIVE_COMPARATOR|Control Group|
62158127|NCT02299011|EXPERIMENTAL|Orsiro drug eluting stent|Orsiro drug eluting stent
62158128|NCT02299011|ACTIVE_COMPARATOR|Biomatrix drug eluting stent|Biomatrix drug eluting stent
62158129|NCT02499991|EXPERIMENTAL|Treatment|"Treatment group will keep diary of social events according to training instructions.~Memory intervention will be used."
62158130|NCT02499991|NO_INTERVENTION|Control|Control group will use own memory of social events without training instructions.
62158131|NCT01261793|PLACEBO_COMPARATOR|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
62158132|NCT01261793|EXPERIMENTAL|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles
62158133|NCT01261793|EXPERIMENTAL|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
62158134|NCT05928520|EXPERIMENTAL|Tramadol group|Swabs soaked with tramadol 5% 2 mg/kg diluted with saline 0.9%
62158135|NCT05928520|ACTIVE_COMPARATOR|Lidocaine group|Swabs soaked with lidocaine 2% 2mg /kg diluted with saline 0.9%
62532419|NCT04475783|EXPERIMENTAL|Sirolomus DCB group|Intervention with Sirolimus-coated balloon catheter
62532420|NCT04475783|ACTIVE_COMPARATOR|Paclitaxel DCB group|Intervention with Paclitaxel-coated balloon catheter
62714221|NCT05427695|EXPERIMENTAL|Lactobacillus sakei nasal irrigation|Patients will perform nasal irrigation with Lactobacillus sakei, using a 240ml NeilMed sinus rinse bottle, 2 times/day for 14 days. A blinded packet provided by IDS containing a premeasured amount of Lactobacillus sakei to be mixed with 240ml of distilled water will be provided to patients for each irrigation.
62714222|NCT00863876||1|non-operated healthy eyes
62158136|NCT05850286|EXPERIMENTAL|VRD-based Regimen Combined With CART-ASCT-CART2|"Autologous BCMA-directed CAR-T cells, Double infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg respectively.~Participants will receive VRD-based regimen induction, first CAR-T infusion, consolidation, ASCT and second CAR-T infusion. Maintenance therapy was initiated on day 100 and entered the follow-up period."
62158137|NCT00215943|ACTIVE_COMPARATOR|VAD Treatment|"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one cycle of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle."
62158138|NCT00215943|ACTIVE_COMPARATOR|Thalidomide and Dexamethasone Treatment|Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.
62532421|NCT02912169|EXPERIMENTAL|Autologous Adipose-derived Stromal Vascular Fraction infusion|Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
62532422|NCT05342701|EXPERIMENTAL|CHAMP-ASP|"CHAMP, is a mastery climate motor skills intervention, that provides children the opportunity to establish behaviors that reinforce decision-making while participating in a motor activity tasks. Children will participate in CHAMP for 35 minutes/day 3-4 days per week for 19 weeks.~Each 35-min session consists of three parts:~1. 3-5 min of motor skill introductory activity that includes a group motor activity, the teaching of the lesson that includes a demonstration and understanding of developmentally appropriate learning clues;~2. 25 min of motor skill instruction and practice (i.e., 'active motor engagement'), participants will be encouraged to move through 3-4 motor activity stations that align with the TARGET structure; and~3. 3 -5 min motor skill closure activity that involves a review of the lesson and critical elements."
62714223|NCT00863876||2|eyes 1 months following LASIK
62714224|NCT00863876||3|eyes 3-6 months following LASIK
62714225|NCT00863876||4|eyes with spherical monofocal IOLs more than 3 months postop
62714226|NCT00863876||5|eyes with aspherical monofocal IOLs more than 3 months postop
62714227|NCT00863876||6|eyes with toric monofocal IOLs more than 3 months postop
62158139|NCT04366895|EXPERIMENTAL|control|Participants in control group (Group-A) received conventional manufactured implant overdenture
62158140|NCT04366895|EXPERIMENTAL|intervention|participants in intervention group (Group-B) received CAD-CAM manufactured implant overdenture.
62158141|NCT02474745|EXPERIMENTAL|INTERVENTION GROUP|"Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
62158142|NCT02474745|OTHER|CONTROL GROUP|"Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
62158143|NCT02320045|EXPERIMENTAL|Group 1: Normal|Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2
62158144|NCT02320045|EXPERIMENTAL|Group 2: Mild Renal Dysfunction|Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2
62158145|NCT02320045|EXPERIMENTAL|Goup 3: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2
62158146|NCT02320045|EXPERIMENTAL|Group 4: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) \>30-44 mL/min/1.73 m2
62158147|NCT04179799||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
62158148|NCT01234025|EXPERIMENTAL|Part 1 Cohort 1|
62532423|NCT05342701|NO_INTERVENTION|Control - Standard of Practice|The Control (standard of practice) condition will be the school typical ASP and will be implemented according to the existing procedures.
62714228|NCT00863876||7|eyes with diffractive multifocal IOLs more than 3 months postop
62714229|NCT00863876||8|eyes with phakic IOLs more than 3 months postop
62714230|NCT00863876||9|eyes with keratoconus
62714231|NCT04326452|EXPERIMENTAL|Enrolled Subjects|The purpose of this study is to compare the use of our bidirectional oxygenation mouthpiece with conventional oxygen support versus conventional oxygen support of any Person Under Investigation for infection by the COVID-19 virus.
62158149|NCT01234025|EXPERIMENTAL|Part 1 Cohort 2|
62158150|NCT01234025|EXPERIMENTAL|Part 2 Arm A|
62158151|NCT01234025|EXPERIMENTAL|Part 2 Arm B|
62532424|NCT03169712|ACTIVE_COMPARATOR|CBT for PTSD|15 sessions of trauma-focused CBT
62532425|NCT03169712|EXPERIMENTAL|Imagery Rehearsal Therapy + CBT for PTSD|5 sessions of IRT + 15 sessions of trauma-focused CBT
62532426|NCT04326465|EXPERIMENTAL|Fractional CO2 Laser Therapy at 10-15% Laser Density Coverage|Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 10-15% laser density. The patient will receive three laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
62736439|NCT03617536|EXPERIMENTAL|CR845 1 mg Oral Tablet|Oral CR845 1 mg to be taken orally once daily for 12 weeks
62158152|NCT02558816|EXPERIMENTAL|Ibrutinib - GA101 - GDC_0199|STEP A:C1:Ibrutinib 560mg D2-28;GA101 1000mg day 1/2,8,15;C2-6:Ibrutinib 560mg D 1-28;GA101 1000mg D1 / C7 (Maintenance phase)-C24:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2cycles (from C8) STEP B:C1:Ibrutinib 560mg D2-28;GA101 1000mg D1/2,8,15 / C1bis : Ibrutinib 560mg day 1-28 ; GA101 1000mg D 1 ; GDC-0199 20mg/d at W1, 50mg/d at W2, 100mg at W3, 200 mg/d at W4 / C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC-0199:400mg/d W1 and 400, 600 or 800mg/d W2-3-4 + 400, 600 or 800 mg/d C3-C6 (patients 1-12).Patients 13-24:GDC-199 400mg/d / C7(Maintenance phase)-C23:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2 cycles (from C8);GDC:400, 600 or 800 mg D1-28 (patient 1-12).Patients 13-24 : 400mg/d STEP C:C1-C1bis=Step B; C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC:400mg/d C7 (Maintenance phase)-C23 : Ibrutinib 560mg D1-28 (--\>progression);GA101 1000mg D1/2 cycles (from C8);GDC-0199 400mg/d
62532427|NCT04146116|EXPERIMENTAL|Nasal povidone-iodine|Intranasal povidone-iodine (PDI PROFEND) will be applied to the patients' noses before orthopedic trauma surgery and after surgery. This intranasal povidone-iodine was developed under the Tentative Final Monograph for Health-Care Antiseptic Drug Products 21 CFR Parts 333 and 369 (Docket # 75N-183H), Federal Register Volume 59, Number 116, Friday, June 17, 1994, Proposed Rules. However, the product need not be controlled like a pharmaceutical drug. The product may be stored and controlled similarly to an iodine or alcohol skin preparation product.
62532428|NCT04709835|PLACEBO_COMPARATOR|Placebo|Participants will receive AT-527-matched placebo twice a day (BID) on Days 1-5.
62532429|NCT04709835|EXPERIMENTAL|AT-527 550 mg (1x550 mg)|Participants will receive 550 mg AT-527 (1x550 mg) twice a day (BID) on Days 1-5.
62532430|NCT04709835|EXPERIMENTAL|AT-527 1100 mg (4x275 mg)|Participants will receive 1100 mg AT-527 (4x275 mg) twice a day (BID) on Days 1-5.
62532431|NCT05284487|ACTIVE_COMPARATOR|Group 1: Jalosome® Soothing gel|"Jalosome® soothing gel ((L-Acetyl Carnitine chloridrate, Allantoin, Hydrogenated phosphatidylcholine, Sodium Hyaluronate) will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
62158153|NCT04471415|EXPERIMENTAL|Part 1a & Part 1b|"Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 of 3.3 mg/m2 via intravenous injection~Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 at 10 mg via subcutaneous injection"
62158154|NCT04471415|EXPERIMENTAL|Part 2|"Cohort 1: Phase 1 single-agent safety expansion of DRP-104 administered subQ (the RP2R) in patients with advanced solid tumors (excluding primary CNS tumors and HCC). DRP-104 will be administered twice weekly subQ in this safety expansion at the twice weekly subQ MTD/MAD/RP2D of DRP-104 determined in Part 1-Cohort 1b. A minimum of 14 and up to 20 patients will be enrolled.~Cohort 2: Phase 2a expansion at the MTD/MAD/RP2D/RP2R and schedule of administration (subQ twice or thrice weekly) of DRP-104 in patients with locally advanced or metastatic NSCLC whose tumors contain a known mutation in kelchlike ECH-associated protein 1 (KEAP1), nuclear factor erythroid 2-related factor 2 (NFE2L2) and/or serine/threonine kinase 11 (STK11), (N=55). If the thrice weekly schedule is selected as the RP2S, a safety review will be conducted after 8 patients have enrolled and are followed for at least one cycle of treatment before additional patients are enrolled into Part 2-Cohort 2."
62158155|NCT04471415|EXPERIMENTAL|Part 3|Phase 1 combination dose escalation of DRP-104 and atezolizumab in patients with advanced solid tumors (excluding primary CNS tumors and HCC) previously treated with an agent targeting checkpoint pathway inhibition (such as anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibody), starting one dose level below the MTD/MAD/RP2D (MTD-1) of the recommended phase 2 route and schedule of administration of singleagent DRP-104 and in combination with 1200 mg atezolizumab administered via intravenous infusion on day 1 and repeated every 3 weeks (up to approximately 12 patients);
62158156|NCT04471415|EXPERIMENTAL|Part 4|Phase 1 combination safety expansion at the MTD/MAD/RP2D, route, and schedule of administration of DRP-104 with atezolizumab in a similar patient population as the dose-escalation (N=14 patients).
62158157|NCT04999722|ACTIVE_COMPARATOR|APP group|Participants with diabetes who had access to a mobile APP
62158158|NCT04999722|PLACEBO_COMPARATOR|Control Group|Diabetes participants who accepted the traditional management model
62158159|NCT04301947|ACTIVE_COMPARATOR|Standard warm-up protocol|The standard warm-up protocol consists of 5 (five) minutes of stationary cycling, followed by calf, hamstring and quadriceps stretching. For all stretching positions 30 (thirty) seconds will be set. For calf stretching, the participant places his hands on the waist and projects his dominant limb behind of the center of mass line, the contralateral limb will be placed forward until the stretch sensation on the dominant limb start. For hamstring stretching, the participant will be instructed to bend over the hip, reaching the foot of the dominant limb in dorsiflexion. Emphasis will be placed on maintaining the heel of the dominant limb on the floor and maintaining posture. Finally, for quadriceps stretching, the participant will perform a knee flexion and will hold the dominant lower limb foot close to the gluteus with the ipsilateral upper limb hand. Emphasis will be placed on maintaining trunk posture.
62158160|NCT04301947|EXPERIMENTAL|Gluteal activation warm-up|"The gluteal activation warm-up protocol consists of performing a standard warm-up protocol with additional shell exercise. The shell exercise will be performed with the participant side-lying with hip and knee flexed, an elastic band (PREFORM BETTER Inc. Rhode Island, USA) will be placed around the distal thigh to promote resistance and the participants will be instructed to perform hip abduction movements. The exercise will be performed in multiple sets (3 sets) of 12 repetitions, with 30 seconds interval between exercises in order to minimize the fatigue effect. Medium and heavy elastic bands tensions will be used and adjusted according to the effort perception parameter from the OMNI scale for effort perception for resistance training."
62158161|NCT06299345|SHAM_COMPARATOR|control group (CG)|Physically performed the task once per session. No MI. The physical task is a mirror tracing game that requires participants to trace a star shape viewed through a mirror, going as fast as possible while staying within the lines.
62532432|NCT05284487|PLACEBO_COMPARATOR|Group 2: Placebo|"Placebo will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
62158162|NCT06299345|EXPERIMENTAL|low-dose group (LD)|In addition to physically performing the motor task once in session 1, then they performed MI for 6 minutes (2 min x 3 sets) per session. MI for this study took the form of non-guided first-person mental practice. First-person imagery was explained to each participant where they imagined performing the target skill through their own eyes rather than if they were a bystander watching someone else do the task (third person).
62158163|NCT06299345|EXPERIMENTAL|high-dose group (HD)|In addition to physically performing the motor task once in session 1, then MI for 12 minutes (2 min x 6 sets) per session. The MI technique was the same as the LD group.
62158164|NCT05146479||Fluoride varnish (FA group)|Application of 5% NaF varnish onto first permanent molars
62158165|NCT05146479||Fluoride varnish + dental sealant (FA+S group)|Application of 5% NaF varnish plus pit and fissure sealant onto first permanent molars
62158166|NCT01219751|EXPERIMENTAL|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
62158167|NCT05530239||Healthy subjects|Subjects with no documented hematological pathology (neither constitutional nor acquired). From the recruitment of living kidney donors, transplantation unit of Grenoble Alpes University Hospital
62158168|NCT05530239||SCD patients|Patients with SCD
62158169|NCT05530239||Control patients|With a constitutional non-sickle cell disease of the red blood cell, or an acquired red blood cell disease.
62158170|NCT01613456|PLACEBO_COMPARATOR|Placebo|Dicalcium phosphate, Maltodextrin and Magnesium stearate.
62158171|NCT01613456|EXPERIMENTAL|Saccharomyces cerevisiae CNCM I-3856|
62158172|NCT01537263||Ultrasound Perfusion Imaging|Patient with subarachnoid hemorrhage.
62158173|NCT00111865|EXPERIMENTAL|Exercise|Aerobic Exercise Training
62158174|NCT00111865|NO_INTERVENTION|Usual Care|
62158175|NCT00118937|PLACEBO_COMPARATOR|1|Single-blind placebo run-in period. Duration one month.
62158176|NCT00118937|ACTIVE_COMPARATOR|2|Metformin 2000 mg, double-masked randomized during 12 months.
62158177|NCT00118937|PLACEBO_COMPARATOR|3|Placebo, double-masked randomized during 12 months.
62532433|NCT00866736|EXPERIMENTAL|dasatinib|
62532434|NCT04242914|EXPERIMENTAL|Research: Ketamine + Midazolam|Research group will receive ketamine and midazolam.
62158178|NCT04870905|EXPERIMENTAL|ICRT arm|
62158179|NCT04743999|EXPERIMENTAL|Quality of life evaluation|This prospective arm will consist of evaluating quality of life outcomes in women in women with advanced endometrial cancer undergoing adjuvant concurrent chemotherapy with carbo/Taxol and radiation therapy. Assessments will occur following surgery (baseline), 3, 6, 12, and 24 months.
62158180|NCT05587907|EXPERIMENTAL|Group 1|18 soccer players follow a 6-month exercise program with visual stimuli, 5 times a week and lasting 15 minutes each time, which precedes their regular soccer training program.
62158181|NCT05587907|NO_INTERVENTION|Group 2|20 soccer players follow a regular soccer training program.
62158182|NCT06426511|EXPERIMENTAL|Observation for undetectable ctDNA after adjuvant therapy|Observation follow-up for patients with undetectable ctDNA after 4 cycles of adjuvant chemotherapy plus toripalimab.
62158183|NCT06426511|ACTIVE_COMPARATOR|Consolidation toripalimab for detectable ctDNA after adjuvant therapy|Consolidation toripalimab therapy for up to 13 cycles for patients with detectable ctDNA after 4 cycles of adjuvant chemotherapy plus toripalimab.
62532435|NCT04242914|EXPERIMENTAL|Control: Midazolam|Control group will receive midazolam.
62532436|NCT00418301|EXPERIMENTAL|Precision Spinal Cord Stimulation and PET Scan|Positron emission tomography (PET) scan imaging procedures to assess Spinal Cord Stimulation.
62532437|NCT04477772|EXPERIMENTAL|1mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects
62532438|NCT04477772|EXPERIMENTAL|3mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 9 subjects
62736440|NCT03617536|PLACEBO_COMPARATOR|Placebo Oral Tablet|Oral Placebo to be taken orally once daily
62158184|NCT01296477||Asthma IQ Primary Care Tool|
62158185|NCT01296477||Usual Asthma Care in Primary Care|
62158186|NCT06719947|EXPERIMENTAL|Active HD-tDCS Group|Patients randomly included in this group will receive 10 sessions of anodal HD-tDCS stimulation. The intervention will take place at the participant's home, with electrodes positioned in a circular arrangement-one central electrode and four peripheral electrodes-over the cortical representation zone of the left primary diaphragmatic motor cortex, with a continuous current applied
62158187|NCT06719947|PLACEBO_COMPARATOR|HD-tDCS sham group|Patients randomly included in this group will receive 10 sessions of sham HD-tDCS stimulation. The intervention will take place at the participant's home, with electrodes positioned in a circular arrangement-one central electrode and four peripheral electrodes-over the cortical representation zone of the left primary diaphragmatic motor cortex. Only an initial 30-second ramp stimulus will be applied, followed by a non-effective current
62158188|NCT00135226|ACTIVE_COMPARATOR|Aspirin + Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.
62158189|NCT00135226|ACTIVE_COMPARATOR|Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.
62158190|NCT00135226|ACTIVE_COMPARATOR|Placebo Aspirin + Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.
62158191|NCT00135226|ACTIVE_COMPARATOR|Placebo Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.
62158192|NCT05976828|EXPERIMENTAL|First Dose Level|Dose Cohort 1: IBRX -042 1e11 virus particles per dose
62532439|NCT04477772|EXPERIMENTAL|10mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects
62532440|NCT04477772|EXPERIMENTAL|200mg, Q3W until to 2 years|Dose expansion, enrolled 9 subjects and indication expansion if RP2D is 200mg
62532441|NCT04477772|EXPERIMENTAL|240mg JS004+100mg JS001, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 6-9 subjects and indication expansion if RP2D is confirmed this arm
62532442|NCT04477772|EXPERIMENTAL|240mg JS004+200mg JS001, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 6-9 subjects and indication expansion if RP2D is confirmed this arm
62736441|NCT04749043|ACTIVE_COMPARATOR|Virtual Reality then Nitrous Oxide|30 minute exposure to virtual reality, 5 minute washout period, then 30 minute exposure to nitrous oxide
62532443|NCT06253026||Air mission personnel|Military crew that goes to air search and rescue missions in groups of five
62532444|NCT06253026||Control|Ground military personnel
62736442|NCT04749043|ACTIVE_COMPARATOR|Nitrous Oxide then Virtual Reality|30 minute exposure to nitrous oxide, 5 minute washout period, then 30 minute exposure to virtual reality
62736443|NCT06149221|EXPERIMENTAL|NTAP treatment|Treatment arm subjects receive the trial intervention
62158193|NCT05976828|EXPERIMENTAL|Second Dose Level|Dose Cohort 2: IBRX-042 5e11 virus particles per dose
62158194|NCT05976828|EXPERIMENTAL|De-escalation Dose Level|Dose Cohort -1: IBRX-042 5e10 virus particles per dose
62158195|NCT00850954|EXPERIMENTAL|Group I (smoking cessation)|Participants receive smoking cessation intervention materials based on TTM.
62158196|NCT00850954|EXPERIMENTAL|Group II (informational)|Participants receive fotonovelas and other materials on secondhand smoking and how to assist the smoker in quitting.
62158197|NCT04823156|EXPERIMENTAL|Calcium Supplementation|1000 mg of calcium carbonate one hour before exercise
62158198|NCT04823156|NO_INTERVENTION|No Calcium Supplementation|No calcium supplementation
62158199|NCT01861509|EXPERIMENTAL|BP-C1 IM Injections|BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days.
62158200|NCT04344886|EXPERIMENTAL|Conventional (dual-phase) SPECT/CT|Adult patients with primary hyperparathyroidism undergoing conventional (dual-phase) SPECT/CT (after 10 and 150 minutes) and conventional minimally-invasive radio-guided parathyroidectomy in a time span 2-3 hours from radionuclide administration.
62158201|NCT04344886|EXPERIMENTAL|Multi-phase SPECT/CT|Adult patients with primary hyperparathyroidism undergoing multi-phase SPECT/CT (after 10, 90, 150, 210 minutes) and individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
62158202|NCT02637999|EXPERIMENTAL|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
62158203|NCT02637999|EXPERIMENTAL|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
62158204|NCT02637999|ACTIVE_COMPARATOR|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
62158205|NCT03366727|EXPERIMENTAL|DCB group|this group treated with drug coated balloon catheter, Orchid
62158206|NCT03366727|EXPERIMENTAL|PTA group|this group treated with plain balloon catheter, Admiral Xtreme
62158207|NCT04459949|ACTIVE_COMPARATOR|Sharkskin Arm|
62532445|NCT05533762|ACTIVE_COMPARATOR|arch insole|"Half of the subjects are randomly assigned to assess balance capacity with arch insole first.~Three day wash out, the subjects are assess balance capacity with sham insole."
62532446|NCT05533762|SHAM_COMPARATOR|sham insole|"Half of the subjects are randomly assigned to assess balance capacity with sham insole first.~Three day wash out, the subjects are assess balance capacity with arch insole."
62158208|NCT04459949|PLACEBO_COMPARATOR|Grieshaber Arm|
62158209|NCT02465866|EXPERIMENTAL|Treatment A: CL-108 (Fasted)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
62158210|NCT02465866|EXPERIMENTAL|Treatment B: CL-108 (Fed)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
62158211|NCT02465866|ACTIVE_COMPARATOR|Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
62158212|NCT02465866|ACTIVE_COMPARATOR|Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
62158213|NCT01525888|NO_INTERVENTION|control|continue with treatment with angiotensin converting enzyme inhibitor or angiotensin blocker during all study period
62158214|NCT01525888|EXPERIMENTAL|drug stop|temporary stop of angiotensin converting enzyme inhibitor and angiotensin blocker treatment at least 72 hours before coronary angiography and renew of treatment 72 hours after angiography
62532447|NCT01300910|ACTIVE_COMPARATOR|1|One group of men will undergo a circumcision using the Shang Ring and men are to return for regular follow-up visits to evaluate pain and wound healing. . The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 60 days.
62532448|NCT01300910|ACTIVE_COMPARATOR|2|One group of men will undergo a conventional circumcision using a WHO recommended surgical technique, either the forceps-guided method or the dorsal slit method. Men are to return for regular follow-up visits to evaluate pain and wound healing, with the last scheduled follow-up visit at 60 days.
62158215|NCT01555879||All patients|All patients in T3 who have used Abatacept for at least 3 months between 2009-03-17 and 2011-11-30.
62158216|NCT01529853|EXPERIMENTAL|SAR156597 dose 1|SAR156597 dose 1, subcutaneous injection once every week
62158217|NCT01529853|EXPERIMENTAL|SAR156597 dose 2|SAR156597 dose 2, subcutaneous injection once every week
62158218|NCT01529853|EXPERIMENTAL|SAR156597 dose 3|SAR156597 dose 3, subcutaneous injection once every week
62158219|NCT01529853|PLACEBO_COMPARATOR|Placebo|Placebo (for SAR156597), subcutaneous injection once every week
62158220|NCT05956093|EXPERIMENTAL|high-grade epithelial ovarian cancers.|individuals who have been diagnosed or are suspected to have high-grade serous ovarian cancers (HGSOC). They must have had a CT scan of their abdomen and pelvis within 6 weeks before enrolling in the study and be at clinical stage III or IV.
62158221|NCT03425500|EXPERIMENTAL|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
62158222|NCT03425500|ACTIVE_COMPARATOR|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
62158223|NCT00313963|EXPERIMENTAL|1|
62158224|NCT00313963|PLACEBO_COMPARATOR|2|
62158225|NCT04153994|EXPERIMENTAL|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique.
62532449|NCT02141425|EXPERIMENTAL|ASP015K low dose|
62532450|NCT02141425|EXPERIMENTAL|ASP015K medium dose|
62532451|NCT02141425|EXPERIMENTAL|ASP015K high dose|Optional, depending on safety review and regulatory authority input
62532452|NCT02141425|PLACEBO_COMPARATOR|Placebo|
62158226|NCT04153994|NO_INTERVENTION|Erector Spinae Plane Blockade Control - Standard of Care|Patients will receive the standard of care for pediatric scoliosis surgery including multi-modal opioid pain management. If the patient declines to consent to enrollment into the randomized study, patients may still participate by allowing prospective data and samples collection/analysis with respect to perioperative choice.
62158227|NCT04453137|ACTIVE_COMPARATOR|Humira 40 mg/mL (Adalimumab Originator)|During the LeadIn Period, patients will receive Humira (initial dose of 80 mg \[2 × 40 mg\] administered subcutaneously \[SC\], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index \[PASI\] ≥ 75 \[PASI75\]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.
62158228|NCT04453137|ACTIVE_COMPARATOR|IC - Humira 40 mg/mL (Adalimumab Originator)|patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections)
62158229|NCT04453137|EXPERIMENTAL|IC - Humira/AVT02 40 mg/mL (Adalimimab Biosimilar)|"patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26:~* Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections),~* Sw2-Humira (40 mg every other week) for 4 weeks (2 injections),~* Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections)."
62158230|NCT04453137|EXPERIMENTAL|AVT02 40 mg/mL (Adalimimab Biosimilar)|At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 \[PASI50\]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.
62158231|NCT04745910|EXPERIMENTAL|Treatment (pegloticase)|Patients receive pegloticase IV over 120 minutes. Patients whose serum uric acid does not drop below 6 mg/dL within 24 hours receive a second dose of pegloticase IV over 120 minutes on day 2. Patients whose serum uric acid does not drop below 6 mg/dL after two doses of pegloticase receive standard of care rasburicase IV QD for 5 days.
62158232|NCT05228964|EXPERIMENTAL|Open-label focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min once a day, five days a week for 3 weeks.
62158233|NCT06076525|EXPERIMENTAL|Older Adult Fallers (participate in Aim 1 only)|This group is exposed to the perturbations during treadmill walking in Aim 1 to collect data on their balance control mechanisms.
62158234|NCT06076525|ACTIVE_COMPARATOR|Older Adult Non-Fallers - Control Group (participate in Aims 1 and 2)|This group acts as a comparison for the Older Adult Non-Fallers - Experimental Group within the same demographic.
62158235|NCT06076525|EXPERIMENTAL|Older Adult Non-Fallers - Experimental Group (participate in Aims 1 and 2)|This group is exposed to the interventions in both Aims 1 and 2, the latter of which involves targeted training designed to improve their balance control flexibility.
62158236|NCT06076525|ACTIVE_COMPARATOR|Younger Adult Non-Fallers - Control Group (participate in Aims 1 and 2)|This group serves as the control for the Younger Adult Non-Fallers - Experimental Group.
62158237|NCT06076525|EXPERIMENTAL|Younger Adult Non-Fallers - Experimental Group (participate in Aims 1 and 2)|This group is exposed to the interventions in both Aims 1 and 2, the latter of which involves targeted training designed to improve their balance control flexibility.
62158238|NCT06561412|NO_INTERVENTION|Control|Participants will not receive the produce prescription vouchers but will still receive compensation for completing different study related tasks and will receive their usual medical care.
62158239|NCT06561412|EXPERIMENTAL|Produce Prescription|Participants will receive either $40 (families of 2 members or less) or $60 (families of more than 2 members) produce vouchers every 2 weeks for 6 months, for a total of $480 or $720. They will also receive compensation for completing different study related tasks and will receive their usual medical care.
62158240|NCT03292744|EXPERIMENTAL|Alfacalcidol|Alfacalcidol 0,5 mcg once daily for 90 days
62158241|NCT03292744|PLACEBO_COMPARATOR|Placebo|Amylum same capsule form, weight and colour with treatment arm
62158242|NCT02951702|NO_INTERVENTION|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
62158243|NCT02951702|EXPERIMENTAL|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
62158244|NCT02210949|OTHER|Erythropoietin Iron|"Erythropoietin and iron:~Administration of Erythropoietin (600 IU/kg (14.4 g/L)) twice weekly for three weeks .~Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once."
62158245|NCT00819078|ACTIVE_COMPARATOR|Bupropion Sr|40 adolescent patients
62158246|NCT00819078|PLACEBO_COMPARATOR|Placebo (sugar pill)|40 adolescent patients will receive placebo
62158247|NCT03324048|OTHER|Patients anxious|Patients anxious will be perform relaxation session.
62158248|NCT06157294|ACTIVE_COMPARATOR|Intra-articular pulsed radiofrequency group|This arm consists of patients who received intra-articular pulse radiofrequency treatment.
62158249|NCT06157294|ACTIVE_COMPARATOR|Median branch pulsed radiofrequency group|This arm consists of patients who received median branch pulse radiofrequency treatment.
62158250|NCT04780906|SHAM_COMPARATOR|Sham first (group 1)|Performs the first round of test with the sham comparator than with the experimental wrist taping
62158251|NCT04780906|EXPERIMENTAL|Wrist taping first (group 2)|Performs the first round of test with the experimental wrist taping than with the sham comparator
62158252|NCT00547326|EXPERIMENTAL|1|Treatement with osteopatic cranial techniques
62158253|NCT00547326|PLACEBO_COMPARATOR|2|Treatment with placebo
62532453|NCT06494345|EXPERIMENTAL|Genolair, solution for subcutaneous administration|Omalizumab biosimilar
62532454|NCT06494345|ACTIVE_COMPARATOR|Genolair, lyophilisate for the preparation of solution for subcutaneous administration|Omalizumab biosimilar
62532455|NCT06494345|ACTIVE_COMPARATOR|Xolair®, solution for subcutaneous administration|Omalizumab
62532456|NCT04779515|EXPERIMENTAL|Low-pressure|Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg
62532457|NCT04779515|ACTIVE_COMPARATOR|Standard-pressure|Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg
62532458|NCT05358470|EXPERIMENTAL|Exercise therapy and adapted physical activity-based intervention|The intervention in the experimental group (EG) consists of a exercise therapy and adapted physical activity program based on racket sports. The immediate EG will receive sixteen, twice a week, one-hour sessions of group-based, racket sports specific fundamental movement skills training. All sessions will be guided and supervised by a physiotherapist and delivered in groups of 5 participants to promote exchange and conviviality and to optimize the rates of participation and compliance.
62532459|NCT05358470|NO_INTERVENTION|Usual care|Participants in the CG receive conventional management with general physical activity recommendation.
62532460|NCT02504190||lymphoma patients eligible for TEAM conditioning|Lymphoma Patients who are eligible will be included. Patients will undergo TEAM conditioning regimen followed by autologous haematopoietic stem cells transplantation according to standard practice of the centre and drugs label in France.
62532461|NCT05484037|EXPERIMENTAL|Intervention group|Intervention group/telehealth Arm: will be provided access to their electronic asthma action plan (eAAP) via a web Uniform Resource Locator (URL), receive weekly short message service (SMS) check-ins for one year, and be able to communicate with the site's research coordinator (RC) and Certified Respiratory Educator (CRE) via an integrated and interactive (two-way) SMS feature to manage their asthma
62532462|NCT05484037|ACTIVE_COMPARATOR|Control group|Control group/standard care Arm: will receive their written Asthma Action Plan (wAAP) and information on how to use it by the site's Certified Respiratory Educator to manage their asthma
62532463|NCT03801265|ACTIVE_COMPARATOR|Lumbar Plexus block|0.5% ropivacaine 100 mg (20 ml) will be injected
62532464|NCT03801265|EXPERIMENTAL|Quadratus Lumborum type 3 block|0.5% ropivacaine 100 mg (20 ml) will be injected
62532465|NCT02448264|EXPERIMENTAL|BCX7353|BCX7353 capsules administered orally
62532466|NCT02448264|PLACEBO_COMPARATOR|Placebo|Placebo to Match BCX7353 capsules, administered orally
62532467|NCT04866732|EXPERIMENTAL|Needs assessment and feasibility group|Based on our target population's needs/preferences, an existing Physical Activity (PA) program will be modified and tailored to the needs of the target population. We anticipate that this PA program will include the following components: a) PA component - ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to CVD risk factors prevention; c) daily diary to record if they are facing any barriers in completing various components of the intervention; d) problem-solving sessions
62532468|NCT01865240|EXPERIMENTAL|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
62532469|NCT01865240|NO_INTERVENTION|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
62532470|NCT05025514||Patients treated for cancer, vaccinated or eligible for anti-COVID vaccination.|"Patients undergoing treatment with anti-PD immunotherapy, anti-PDL1 or anti-CTLA4 immunotherapy for any tumour (solid, liquid) treated in the medical oncology departments of the Occitanie area.~who have been vaccinated or who are eligible for inoculation with one of the available anti-COVID19 vaccines."
62532471|NCT02322463||Arab children (case subjects)|Arab patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
62532472|NCT02322463||Jewish children (controls)|Jewish patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
62532473|NCT01879748|EXPERIMENTAL|Rasagiline|Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
62532474|NCT01879748|PLACEBO_COMPARATOR|Placebo|Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
62532475|NCT04842773|EXPERIMENTAL|US measurement of sarcopenia|
62532476|NCT01058460|NO_INTERVENTION|cytology|Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
62532477|NCT01058460|EXPERIMENTAL|HPV-cytology|Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
62532478|NCT00986063|ACTIVE_COMPARATOR|Standard of care|AIDS patients taking care with standard of care
62532479|NCT00986063|EXPERIMENTAL|Genetic test|AIDS patients who required highly active antiretroviral therapy(HAART) whom genotype status will be determined before initiation of HAART
62532480|NCT02836938||Severe|Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
62532481|NCT02836938||Mild|Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
62532482|NCT02836938||Control|Bronchiolitis obliterans syndrome (BOS), stage 0
62532483|NCT05101837|EXPERIMENTAL|MIND-GROUP|Daily mindfulness sessions on android
62532484|NCT05892939|EXPERIMENTAL|Oxytoxin group|Drug: intranasal Oxytocin(24IU)
62532485|NCT05892939|PLACEBO_COMPARATOR|Placebo group|Drug: intranasal Placebo
62532486|NCT05578456|EXPERIMENTAL|prednisone and aspirin|
62532487|NCT05578456|PLACEBO_COMPARATOR|placebo|
62158254|NCT02848586|ACTIVE_COMPARATOR|ECIGS|Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
62158255|NCT02848586|ACTIVE_COMPARATOR|Usual brand|Subjects will receive their usual brand of combustible cigarettes for a total of 4 weeks. A mobile contingency management mCM procedure will be used. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks later (Visit 4) and again 2 weeks later (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
62158256|NCT04607889||Part 1 - Attribute development|An elicitation phase to develop the list of attributes and levels based on literature review and telephone interviews with patients.
62158257|NCT04607889||Part 2 - Pilot study|A pilot phase consisting of a self-administered, online survey, to be completed by patients and physicians, followed by telephone interviews with a subsample of participants.
62532488|NCT03884543|EXPERIMENTAL|Individualized high PEEP strategy|Recruitment maneuver (performed after induction of anesthesia, after any disconnection from the mechanical ventilator, and before extubation) followed by the decremental PEEP trial to determine the highest level of PEEP resulting in the lowest driving pressure. This is again followed by a recruitment maneuver, after which PEEP is set at the level indicated by the decremental PEEP trial.
62532489|NCT03884543|NO_INTERVENTION|Standard low PEEP strategy|PEEP at maximum 5cm H2O. No recruitment maneuvers. Patients are randomized and intraoperatively ventilated with conventional strategy. (PEEP at maximum 5cm H2O without recruitment maneuvers)
62532490|NCT01264926||rotator cuff tear, pain|
62532491|NCT00788749|PLACEBO_COMPARATOR|Placebo|Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
62532492|NCT00788749|EXPERIMENTAL|Prednisolone|25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months
62532493|NCT00525447|EXPERIMENTAL|1|
62532494|NCT04729309|EXPERIMENTAL|Mass Balance (MB) Cohort|Participants will receive oral \[14C\] RO7049389 under fasted conditions, followed by intravenous IV \[13C\] after a two-hour period.
62532495|NCT04729309|EXPERIMENTAL|Absolute Bioavailability (BA) Cohort|In Periods 1 and 2, participants will receive oral \[12C\] RO7049389 under fasted conditions, followed by IV \[13C\] RO7049389. There is a minimum 7-day washout between periods.
62532496|NCT06361979|EXPERIMENTAL|ARM1|
62532497|NCT00148642|EXPERIMENTAL|1|silver salts coated endotracheal tube
62532498|NCT00148642|PLACEBO_COMPARATOR|2|uncoated endotracheal tube
62532499|NCT03756467|NO_INTERVENTION|Arm 1|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff
62532500|NCT03756467|EXPERIMENTAL|Arm 2|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up
62532501|NCT03756467|ACTIVE_COMPARATOR|Arm 3|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up.
62532502|NCT04669691|EXPERIMENTAL|Lowest dose, less adjuvant aH5N1 vaccine|Two consecutive intramuscular (IM) administrations (Day 1 and Day 22)
62532503|NCT04669691|EXPERIMENTAL|Low dose, less adjuvant aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
62532504|NCT04669691|EXPERIMENTAL|Mid dose, less adjuvant aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
62532505|NCT04669691|EXPERIMENTAL|Lowest dose, adjuvanted aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
62532506|NCT04669691|EXPERIMENTAL|Low dose, adjuvanted aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
62532507|NCT04669691|EXPERIMENTAL|Mid dose, adjuvanted aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
62532508|NCT05200546||"group before"|1st period of 6 months during which only the current detection technique will be used.
62532509|NCT05200546||"group after"|- 2nd period of 6 months after implementation of the PCR solution (CPO and VRE) of the BD company in parallel with the usual screening technique
62532510|NCT03360591|EXPERIMENTAL|Physiologically-guided strategy|"Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.~* Lesions showing positive FFR measurements (\<0.80) must be treated with PCI, before or after TAVI.~* Lesions showing clearly negative values (FFR \>0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.~* Lesions showing borderline FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.~* In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values."
62532511|NCT03360591|OTHER|Angiographically-guided strategy|Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
62158258|NCT04607889||Part 3 - Main study|The main study, with a self-administered, online survey, to be completed by cancer patients and physicians.
62158259|NCT02326194|PLACEBO_COMPARATOR|Placebo group (one shot)|one dose
62532512|NCT03623386|EXPERIMENTAL|Patients with PD neurofeedback training|Patients will receive neurofeedback training.
62532513|NCT03623386|ACTIVE_COMPARATOR|Patients with PD control|Patients will not receive neurofeedback training.
62532514|NCT03623386|NO_INTERVENTION|Patients with PD|Patients perform mental imagery (motor and visual aspects combined) in the MRI scanner without neurofeedback training.
62532515|NCT05632211|EXPERIMENTAL|AVT05 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
62532516|NCT05632211|ACTIVE_COMPARATOR|EU Simponi 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
62532517|NCT05632211|ACTIVE_COMPARATOR|US Simponi 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
62532518|NCT06324318|EXPERIMENTAL|Parenting in 2 Worlds (treatment)|A 10-week parenting intervention focused on improving overall family functioning and strengthen parenting skills to communicate with adolescents to avoid risk behaviors.
62532519|NCT06324318|ACTIVE_COMPARATOR|Healthy Families in 2 Worlds|A 10-week parenting intervention curriculum focused on improving parental knowledge of family health topics.
62532520|NCT00963781|EXPERIMENTAL|Six months DAPT|All patients will be assigned to 6 months of DAPT
62532521|NCT05644600|EXPERIMENTAL|Treatment A|The subjects will receive Nintedanib soft capsules, fasted state.
62532522|NCT05644600|EXPERIMENTAL|Treatment B|The subjects will receive dose B of the oral suspension of AZD5055 immediately followed by nintedanib in the fasted state.
62532523|NCT05644600|EXPERIMENTAL|Treatment C|The subjects will receive dose C of the oral suspension of AZD5055 immediately followed by nintedanib in the fasted state.
62532524|NCT05644600|EXPERIMENTAL|Treatment D|"The subjects will receive dose C of the oral suspension of AZD5055 4 hours after nintedanib in the fasted state.~Participants would remain in the fasted state until 1.5 hours after AZD5055 administration."
62532525|NCT00895414|EXPERIMENTAL|Doxorubicin alone first, then Doxorubicin with Enalapril|Patients receive doxorubicin hydrochloride IV over 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2.
62532526|NCT00895414|EXPERIMENTAL|Doxorubicin with Enalapril first, then Doxorubicin alone|Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
62532527|NCT03009630|EXPERIMENTAL|RFA group|Patients with early-stage peripheral lung cancer will be performed RFA with the guidance of ENB. Post treatment response and follow up will be evaluated and carried out according to the standard procedure.
62532528|NCT05234593|OTHER|Lightning Stick|Feasibility and acceptability
62532529|NCT06167356||Patients with non-muscle invasive bladder cancer|Patients with non-muscle invasive bladder cancer who underwent one of the following endoscopic resection surgeries : TURBK, MAPPING, TURBK SECOND LOOK, BLADDER BIOPSIES
62532530|NCT04285593|EXPERIMENTAL|Experimental group|"Each session will last 10 minutes, taking place two days a week, over a period of four weeks. The intervention will take place at the beginning of the training session.~The players included in the experimental group will perform an exercise protocol with Bulgarian squats."
62532531|NCT04285593|NO_INTERVENTION|Control group|The players included in the control group will continue with their usual warm-up routine.
62532532|NCT05371860|EXPERIMENTAL|Omit breast radiation|
62532533|NCT03730818|EXPERIMENTAL|Water-based Exercise Group|"The Water-based Exercise Group will compromise participants attending a 2 weekly exercise intervention each session lasting 1 hour for 12 weeks.~Each session will consist of:~* 10 minutes of warm-up: general mobilisation, walking, active stretching~* 40 minutes of global training: 20 minutes of endurance exercise and 20 minutes of resistance exercises targeting large main muscle groups involved in daily life activities (squats, lateral hip abduction, row, etc.) using body weight and elastic bands~* 10 minutes of cooling down: stretching, breathing exercises and relaxation Intensity will be monitored with the modified Borg Scale to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
62532534|NCT03730818|ACTIVE_COMPARATOR|Land-based Exercise Group|"The land-based exercise group will attend as well 2 weekly sessions lasting 1 hour each for 12 weeks.~Each session will consist of the same structure as the Water-based Exercise Group including:~* 10 minutes warm up~* 40 minutes of global training (20 minutes of endurance exercise and 20 minutes of resistance training)~* 10 minutes cool down. The exercises will be adapted from the water-based exercise group to match the requirements on the water-based exercise group. Intensity will be monitored with the Perceived Rate of Exertion Scale (modified Borg Scale, Borg 1982) to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
62158260|NCT02326194|PLACEBO_COMPARATOR|Placebo group (two shots)|two doses, with one dose to each arm at a same time.
62158261|NCT02326194|EXPERIMENTAL|Low dose vaccine group|one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
62158262|NCT02326194|EXPERIMENTAL|High dose vaccine group|two doses, high dose, with one dose to each arm at a same time
62158263|NCT04779047|ACTIVE_COMPARATOR|group 1|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days plus tocilizumab 800 mg once
62532535|NCT00727870|OTHER|1|After the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem dressing.
62532536|NCT00727870|OTHER|2|Arm 2: after the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem Silver dressing.
62158264|NCT04779047|ACTIVE_COMPARATOR|group 2|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days and Ivermectin 36 mg at day 1,3 and 6 plus tocilizumab 800 mg once.
62532537|NCT00727870|OTHER|3|Arm 3: after the two biopsies, one site will be covered with Shapes by PolyMem dressing and the other site will be covered the Shapes by PolyMem Silver dressing.
62532538|NCT01045213|EXPERIMENTAL|Proactive Integrated Care|COPD education, self-management education, remote monitoring (Health Buddy, pulse oximeter, pedometer, spirometer) and enhance communication with cell phone contact with a coordinator.
62532539|NCT06117878|EXPERIMENTAL|Group A(low-dose group)|NK510 1×10\^9 NK cells/dose.
62532540|NCT06117878|EXPERIMENTAL|Group B(medium-dose group)|NK510 3×10\^9 NK cells/dose.
62532541|NCT06117878|EXPERIMENTAL|Group C(high-dose group)|NK510 9×10\^9 NK cells/dose.
62532542|NCT06117878|EXPERIMENTAL|Group D(high-dose group，postoperative adjuvant treatmen)|NK510 9×10\^9 NK cells/dose.
62532543|NCT00718913|EXPERIMENTAL|1|TCX -\>RT -\> TCX
62532544|NCT02195089|EXPERIMENTAL|BLS_ILB_E710c 500mg|"* Drug: BLS_ILB_E710c 500mg~* Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 \& 8)"
62532545|NCT02195089|EXPERIMENTAL|BLS_ILS_E710c 1000mg|"* Drug: BLS_ILS_E710c 1000mg~* Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 \& 8)"
62532546|NCT02195089|EXPERIMENTAL|BLS_ILS_E710c 1500mg|"* Drug: BLS_ILS_E710c 1500mg~* Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 \& 8)"
62532547|NCT04471337|EXPERIMENTAL|Arm A: Moderately impaired renal function|Participants with moderately impaired renal function will receive multiple doses of BAY1817080.
62532548|NCT04471337|EXPERIMENTAL|Arm B: Normal renal function matched to Arm A|Participants with normal renal function matched to Arm A will receive multiple doses of BAY1817080.
62532549|NCT04471337|EXPERIMENTAL|Arm C: End stage renal disease on dialysis|Participants with ESRD requiring dialysis will receive single dose of BAY1817080.
62532550|NCT04471337|EXPERIMENTAL|Arm D: Normal renal function matched to Arm C|Participants with normal renal function matched to Arm C will receive single dose of BAY1817080.
62532551|NCT04625725|EXPERIMENTAL|AZD7442|"Approximately 5150 participants will be randomized in a 2:1 ratio~• Arm 1 (n=approximately 3433) will receive a single dose (× 2IM injections) of 300 mg of AZD7442"
62532552|NCT04625725|PLACEBO_COMPARATOR|Placebo|"Approximately 5150 participants will be randomized in a 2:1 ratio~• Arm 2 (n=approximately 1717) will receive saline placebo"
62532553|NCT04625725|EXPERIMENTAL|Sub-study AZD7442 Arm 1|"Approximately 500 participants will receive AZD7442 in the repeat dose sub-study.~-Sub-study Arm 1 (\~ 12 month repeat dose interval): Participants who received AZD7442 300 mg IM on Day 1 of the parent study will receive a second dose of AZD7442 300mg IM on sub-study Day 1."
62532554|NCT04625725|EXPERIMENTAL|Sub-study AZD7442 Arm 2|"Approximately 500 participants will receive AZD7442 in the repeat dose sub-study.~-Sub-study Arm 2(\~ 6 month repeat dose interval): Participants who received placebo on Day 1 of the parent study will receive their first dose of AZD7442 300mg IM on sub-study Day1 followed by a second dose on sub-study Day 183."
62532555|NCT04625725|EXPERIMENTAL|Sub-study AZD7442 Arm 3|A subset of Arm 1 and Arm 2 participants who will receive additional doses of AZD7442, 600mg, at Day 183 and Day 366 of the sub-study.
62532556|NCT03324932|OTHER|AI+denosumab VS only AI|We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.
62532557|NCT04784754|PLACEBO_COMPARATOR|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
62532558|NCT04784754|EXPERIMENTAL|Melatonin 3 mg|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
62532559|NCT04784754|EXPERIMENTAL|Melatonin 30 mg|Melatonin capsules will be prepared using hypromellose capsules containing 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
62532560|NCT03924089|EXPERIMENTAL|Oral nutritional supplement with probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics.~Physical activity recommendations."
62532561|NCT03924089|EXPERIMENTAL|Oral nutritional supplement without probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics.~Physical activity recommendations."
62532562|NCT03924089|ACTIVE_COMPARATOR|Individualized dietary recommendations|Individualized dietary recommendations. Physical activity recommendations.
62532563|NCT04619095|EXPERIMENTAL|Psyllium|For participants aged 8-11 and weighing \> 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing \> 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
62532564|NCT04619095|PLACEBO_COMPARATOR|Placebo|For participants aged 8-11 and weighing \> 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing \> 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
62532565|NCT05994001|EXPERIMENTAL|Group 1|6 mg/kg cardonilizumab, 14 days for 1 course.
62532566|NCT05994001|EXPERIMENTAL|Group 2|1.8mg /mg LM-302 was treated for 1 course for 14 days.
62532567|NCT05994001|EXPERIMENTAL|Group 3|6 mg/kg cardonilizumab for 14 days was a course of treatment; RP2D LM-302 is 1 course of treatment for 14 days
62532568|NCT06015243|EXPERIMENTAL|Experimental: GR1802|GR1802 injection 300mg every two weeks for 16-week treatment
62532569|NCT00373698|EXPERIMENTAL|Three Component Model|Three Component Model of Collaborative Care: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
62532570|NCT00373698|NO_INTERVENTION|Usual Care|"Patients randomized to Usual Care will receive care as usual by VA clinicians."
62532571|NCT03011138||V 1|Gait velocity will be set at 1.0km/h.
62532572|NCT03011138||V 2|Gait velocity will be set at 1.5km/h.
62532573|NCT03011138||V 3|Gait velocity will be set at 2.0km/h.
62532574|NCT03011138||V 4|Gait velocity will be set at 2.5km/h.
62532575|NCT03011138||V 5|Gait velocity will be set at 3.0km/h.
62532576|NCT03011138||V 6|Gait velocity will be set at 3.5km/h.
62532577|NCT03011138||V 7|Gait velocity will be set at 4.0km/h.
62532578|NCT02001831|EXPERIMENTAL|Supplement|"Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):~Carbohydrate 28.5 g~Protein 8 g as Whey Protein Isolate~ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg~Vitamin D3 10 μg~Resveratrol 150 mg"
62532579|NCT02001831|PLACEBO_COMPARATOR|Control|"Placebo control~Liquid nutrient support~Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the supplement (whey protein, omega 3, vitamin D and resveratrol)."
62532580|NCT03074123|EXPERIMENTAL|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
62532581|NCT06490614|EXPERIMENTAL|Dexmedetomidine group|Patients will be subjected to SCPB consisting of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline.
62532582|NCT06490614|EXPERIMENTAL|Nalbuphine group|Patients will be subjected to SCPB consisting of bupivacaine 0.25% and 10 mg of Nalbuphine (nalufin 20mg/ml) and adrenaline 1:200,000 in a total volume of 10ml normal saline.
62532583|NCT01214915|EXPERIMENTAL|Anagrelide Hydrochloride|
62532584|NCT02521935|ACTIVE_COMPARATOR|Complete traditional dentures|Complete maxillary/mandible dentures made in the traditional manner.
62532585|NCT02521935|ACTIVE_COMPARATOR|Complete CADCAM dentures|Complete maxillary/mandible dentures made with CADCAM (computer-aided design/computer-aided manufacturing) technology
62532586|NCT00566566||1|ALL survivors 5 years after completion of treatment, during routine medical follow up
62532587|NCT04526886|EXPERIMENTAL|Study Arm|All patients in this single-arm study will be exposed to the experimental chemotherapy dose-adjustment algorithm.
62532588|NCT00271154|PLACEBO_COMPARATOR|CRT OFF|Cardiac Resynchronization Therapy (CRT) turned OFF in conjunction with optimal medical therapy
62532589|NCT00271154|ACTIVE_COMPARATOR|CRT ON|Cardiac Resynchronization Therapy (CRT) turned ON in conjunction with optimal medical therapy
62532590|NCT05157906|EXPERIMENTAL|Experimental Group|Subjects will have access to the Grow Happy program materials, including the Grow Happy Book, 99+ Ways to Grow Happy Tips and Engagement Videos, which are provided digitally during the trial duration of 12 weeks.
62532591|NCT05157906|ACTIVE_COMPARATOR|Control Group|No additional education materials will be proactively provided during trial duration. Subjects will only be provided with the Indonesian standard of care only.
62714232|NCT05130840|EXPERIMENTAL|Stage IV HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
62158265|NCT05028322|ACTIVE_COMPARATOR|Intra-muscular vaccination (Group 1)|This group corresponds to the use of the vaccine as used in the current recommendations.
62532592|NCT02834676||Chemonucleolysis by Gelified Ethanol|Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy and ozone-oxygen therapy. Written informed consent was obtained from all participants.
62532593|NCT06404658|NO_INTERVENTION|Control group|did not receive any block just spinal anathesia.
62532594|NCT06404658|ACTIVE_COMPARATOR|Genicular nerve block|patients who receive Genicular nerve block with spinal anathesia .
62532595|NCT06404658|ACTIVE_COMPARATOR|IPACK block|patients who receive IPACK block with spinal anathesia.
62532596|NCT04674748|EXPERIMENTAL|Dose Escalation of INCB086550|In this study 3 dose levels will be evaluated to determine the MTD or RP2D (Decided by SMC according to the safety and PK data)
62532597|NCT05623072|ACTIVE_COMPARATOR|Experimental group|Participants will take active tDCS stimulation
62714233|NCT05130840|EXPERIMENTAL|Stage II-III HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
62158266|NCT05028322|ACTIVE_COMPARATOR|Intra-dermal vaccination group without application of IMIQUIMOD cream (Group 2)|Administration mode change for Intra-dermal vaccination. ( Instead of Intra-musculaire ) , to have a comparative with the experimental group.
62158267|NCT05028322|EXPERIMENTAL|Intra-dermal vaccination group with application of IMIQUIMOD cream (Group 3)|"Intra-dermal vaccin administration, with an immunity booster few minutes before by IMIQUIMOD application cream.~Experimental group."
62532598|NCT05623072|SHAM_COMPARATOR|Control group|Participants will take sham tDCS stimulation
62532599|NCT05302830|EXPERIMENTAL|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
62532600|NCT05302830|PLACEBO_COMPARATOR|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
62532601|NCT04040608||experimental group|differences in responses to visual analog scales depending on screen sizes
62532602|NCT00628537|EXPERIMENTAL|1|BION™ Experimental Group
62532603|NCT00628537|ACTIVE_COMPARATOR|2|Surface Stimulation Group
62532604|NCT00628537|ACTIVE_COMPARATOR|3|Control Group with conservative therapy (Range of motion exercises)
62532605|NCT04721444||Arm A - Cohort A1|Training set: Pneumonitis in the context of IO therapy and negative for infectious pneumonia (including COVID-19)
62532606|NCT04721444||Arms A and B - Cohort B1|Training set B1: IO and RT naive and pneumonia (without COVID-19)
62532607|NCT04721444||Arms A and B - Cohort B2|Training set B2: IO and RT naive and confirmed COVID-19 positive with pneumonia
62532608|NCT04721444||Arm B - Cohort A2|Training set: Pneumonitis in the context of thoracic RT and negative for infectious pneumonia (including COVID-19)
62532609|NCT04721444||Arm A - Test Cohort (Cohort C1)|Test set C1: Patients on IO and with possible toxicity versus COVID-19 or other infective pneumonitis
62532610|NCT04721444||Arm B - Test Cohort (Cohort C2)|Test set C2: Patients with pneumonitis in context of thoracic RT with possible toxicity versus COVID-19 or other infective pneumonitis.
62158268|NCT01880359|PLACEBO_COMPARATOR|Radiotherapy+ Cisplatin+ Placebo|Accelerated radiotherapy (Therapeutic Planning Target Volume (PTV): 70 Gray (Gy), 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) Patients will receive placebo (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only).
62158269|NCT01880359|EXPERIMENTAL|Radiotherapy+ Cisplatin+ Nimorazole|"Accelerated radiotherapy (Therapeutic PTV: 70 Gy, 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) .~Patients will receive nimorazole (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only)."
62158270|NCT01075672|EXPERIMENTAL|Cognitive Behavioral Therapy|
62158271|NCT01075672|EXPERIMENTAL|Behavioral Medicine with Cognitive Behavioral Therapy|Participants enrolled in this arm of this study will be treated by the behavioral medicine interns with cognitive behavioral therapy focused on both their general health concerns and mental health concerns.
62158272|NCT00022399|EXPERIMENTAL|Celecoxib|Participants receive celecoxib 400mg by mouth twice daily for 4 to 6 weeks prior to standard-of-care prostatectomy.
62158273|NCT00022399|PLACEBO_COMPARATOR|Placebo-control|Participants receive placebo for 4 to 6 weeks prior to standard-of-care prostatectomy.
62532611|NCT04721444||Arm C|Patients with radiotherapy planning CT scans and post-treatment surveillance CT scans at 3, 6 and 12-months post treatment
62532612|NCT00714896|OTHER|1|Assessment only + referral list to State quitline and smoking cessation education classes at Kaiser
62532613|NCT00714896|EXPERIMENTAL|2|Participants will receive self-help information handouts, expert system intervention that includes a stage-based manual and individualized written feedback reports plus in-person brief stage-appropriate counseling at baseline and 3-month assessment. Current smokers who indicate desire to quit smoking or former smokers who indicate high cravings for cigarettes will be offered nicotine replacement medications. Participants will receive three telephone counseling sessions delivered between baseline and 3 month at weeks 2, 4 and 8. As-needed telephone check-calls will be provided to participants on and 2 days after quit date, or to participants who have quit smoking and anticipate high risk situations.
62532614|NCT02279134|NO_INTERVENTION|Surgery alone|No adjuvant treatment after radical resection is developed in this arm
62532615|NCT02279134|EXPERIMENTAL|Adjuvant Chemoradiation|Adjuvant chemoradiation after radical resection is developed in this arm
62532616|NCT02279134|ACTIVE_COMPARATOR|Adjuvant Radiation|Adjuvant radiation after radical resection is developed in this arm
62532617|NCT03735316|EXPERIMENTAL|B12a|Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
62532618|NCT03735316|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo
62532619|NCT03986138|EXPERIMENTAL|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
62532620|NCT03986138|EXPERIMENTAL|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI
62532621|NCT06080100|ACTIVE_COMPARATOR|Main group|patients with high anxiety and stress instability who underwent xenon analgosedation before refractive laser vision correction
62532622|NCT06080100|OTHER|Control group|patients with high anxiety and stress instability who underwent local anesthesia using standard premedication with hydroxyzine (hydroxyzine) 25 mg.
62532623|NCT06218875||GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device)|Patients treated with the EXCC Device
62532624|NCT06218875||GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device)|Patients treated with the IBE Device
62532625|NCT02808689|ACTIVE_COMPARATOR|Asthma Center|"Use of Currently Accepted Asthma Care Guidelines:~1. Assessment and monitoring: the use of objective measures of lung function to assess severity of asthma and to monitor the course of therapy,~2. Control of factors contributing to symptom exacerbation: environmental control measures to avoid or eliminate factors that precipitate asthma symptoms or exacerbations,~3. Pharmacotherapy: comprehensive pharmacologic therapy for long-term management, and~4. Education for partnership in care: patient education that fosters a partnership among the patient, his/her family, and clinicians."
62714234|NCT02723734||African-American Men (AAM)|AAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
62714235|NCT02723734||Non-African American Men (NAAM)|NAAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
62714236|NCT01997164|EXPERIMENTAL|Cohorts 1 through 4|Participants in cohorts 1 through 4 will receive IVT REGN910-3 and IAI
62714237|NCT01997164|EXPERIMENTAL|Cohort 5|Participants in cohort 5 will receive IVT REGN910 and IAI
62714238|NCT05921344|EXPERIMENTAL|Preclinical Research of mμSORS for Noninvasive Blood Glucose Detection|Enrolled subjects will perform oral glucose tolerance test. A measurement session of blood glucose consists of plasma sample and a measurement by mμSORS will be conducted synchronously.
62532626|NCT02808689|ACTIVE_COMPARATOR|Asthma Center plus Functional Medicine|"All the factors in the Asthma Center Arm plus:~Address lifestyle factors such as nutrition and exercise that influence long-term health and chronic diseases. The intention is to reduce ongoing biologic imbalances from deficiencies in dietary oxidants/antioxidants via vitamin supplementation, hormonal imbalances through evaluation and management, and the need for medications with unwarranted side effects that compound the chronic medical conditions and adverse effects (e.g. excess use of antibiotics), and to systematically evaluate intolerances to certain foods and additives."
62532627|NCT01224730|EXPERIMENTAL|Perifosine 100 mg|Perifosine 100 mg orally daily under Fed and Fasted conditions
62532628|NCT04271579|ACTIVE_COMPARATOR|Unilateral lymphnode dissection|Salvage lymphnode dissection is performed on the PSMA PET positive side, according to template (obturator, iliac external, iliac internal, iliac commun) and possibly including other anatomical pelvic regions
62532629|NCT04271579|ACTIVE_COMPARATOR|bilateral Lymphnode dissection|In addition, a salvage lymphnode dissection is performed on the opposite side with resection of the corresponding fields, which were taken on the PSMA-PET positive side
62532630|NCT04008628|ACTIVE_COMPARATOR|Nitrous oxide|Inhalation of a 50%/50% mixture of nitrous oxide and oxygen. Reassurance of the child during procedure
62532631|NCT04008628|NO_INTERVENTION|Standard care|Infants will be reassured as currently performed in routine clinical practice
62532632|NCT01989988|ACTIVE_COMPARATOR|LRYGB|20 subjects Randomized will undergo LRYGB surgery
62532633|NCT01989988|ACTIVE_COMPARATOR|SADJB|20 subjects will undergo SADJB surgery
62532634|NCT01989988|ACTIVE_COMPARATOR|LMGB|20 subjects will undergo LMGB surgery
62532635|NCT02912585|EXPERIMENTAL|Own mother's colostrum|Oropharyngeal administration of own mother's colostrum.
62532636|NCT02912585|PLACEBO_COMPARATOR|Placebo|Oropharyngeal administration of sterile water.
62532637|NCT02912585|ACTIVE_COMPARATOR|Donor human milk|Oropharyngeal administration of donor human milk.
62532638|NCT04644822|EXPERIMENTAL|[18F]PSMA-1007 Injection|A single dose of 3 - 4 MBq/kg Body Weight (up to a maximum of 400 MBq) of \[18F\]PSMA-1007 Injection will be administered followed by PET/CT imaging. (Patients on ADT treatment will receive the second dose approximately 6 months after the first dose)
62532639|NCT00107510|EXPERIMENTAL|docetaxel + carboplatin + pegfilgrastim + surgery|"Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.~After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years."
62532640|NCT04053686|EXPERIMENTAL|Intervention|The intervention group will aim to regularly break up participants' prolonged sitting time with three-minute incidental movement breaks every half hour at work. Support for behaviour change will include a lecture/workshop, electronic prompts, break logging, team competition, health champions, and email support.
62532641|NCT06483347|EXPERIMENTAL|IT injection of double ICI|Arm 1: intra-tumor injection of double ICIs only.
62532642|NCT06483347|EXPERIMENTAL|IT injection of double ICI and chemodrug|Arm 2: intra-tumor injection of double ICIs and a chemodrug.
62532643|NCT06483347|EXPERIMENTAL|IT injection of double ICI and chemodrug plus bevacizumab|Arm 3: intra-tumor injection of double ICIs, a chemodrug, and bevacizumab.
62532644|NCT03948139|OTHER|Functional Bracing Group|In a presented abstract, the functional brace group has been to shown equivalent outcomes to the hip spica cast. Subject will be administered the functional brace without going to the operating room to be put under full anesthesia. Most cases will not require any sedation in this group (in some cases, light sedation may be needed). Brace will be used for up to 8 weeks post-administration, until adequate callous formation is confirmed.
62532645|NCT03948139|OTHER|Spica Cast Group|If subject is randomized into the hip spica cast group, subject will proceed to the operating room and be given general anesthesia to administer the spica cast. Cast will be used for up to 8 weeks, until adequate callous formation is confirmed.
62532646|NCT02148289|ACTIVE_COMPARATOR|Nitrate rich beverage|Nitrate rich beverage will contain 140ml nitrate rich beetroot juice + 200ml blackcurrant juice containing 12.7mmol nitrate
62532647|NCT02148289|PLACEBO_COMPARATOR|Nitrate free beverage|Nitrate free beverage will 140ml water + 200ml blackcurrant juice containing \<0.5mmol nitrate
62158274|NCT00101296|EXPERIMENTAL|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
62532648|NCT05882994|EXPERIMENTAL|rom exercise|In this study, ROM exercises will be applied by the researcher 2 days a week for 12 weeks to the intervention group separated by simple randomization method.In this study, considering the existing literature, it was planned to apply the exercise to the patients twice a week, for 12 weeks, with 5 minutes of warm-up, 15 minutes of rom exercises , and 5 minutes of cooling down . Range of motion exercises include wrist rotation (clockwise and counterclockwise), wrist flexion and extension. elbow joint full flexion and extension; rotating ankles (clockwise and counterclockwise); and full flexion and extension of the ankles will be performed. Each movement will be made 20 rounds per minute. The researcher will have the patients perform rom exercises and supervise them during the exercise .
62532649|NCT05882994|NO_INTERVENTION|control group|Patients in the control group will receive routine care during hemodialysis.At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks.
62532650|NCT00822796|EXPERIMENTAL|A|Burn patients with \>20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
62532651|NCT00822796|ACTIVE_COMPARATOR|B|Burn patients with \>20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management
62532652|NCT01581866|EXPERIMENTAL|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
62532653|NCT01581866|EXPERIMENTAL|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
62532654|NCT06190418|ACTIVE_COMPARATOR|Loaded sit to stand strengthening exercise group|This group will be provided with loaded sit to stand strengthening exercises in spastic diplegic children.1 repetition maximum of the load will be provided. Exercise will be conducted 3 times a week for 6 weeks, pre and post session functional strength of lower limb will be measured by performing functional strength tests and physiological cost index will be measured to calculate energy expenditure.
62532655|NCT06190418|ACTIVE_COMPARATOR|Unloaded sit to stand strengthening exercise group|This Group will be provided with unloaded sit to stand exercises in diplegic spastic CP, 3 times a week for 6 weeks. Pre and post session functional strength of lower limb muscles will be measured by performing functional strength tests and physiological cost index will be measured to determine energy expenditure.
62532656|NCT04631952|EXPERIMENTAL|Online exercise|SMS messages on encouraging active lifestyle plus an online exercise video
62532657|NCT04631952|ACTIVE_COMPARATOR|SMS message|SMS messages on encouraging active lifestyle
62532658|NCT06453135|EXPERIMENTAL|Eculizumab|A single dose of eculizumab was given on the Day 0 before the transplant surgery.
62532659|NCT03716414||Experimental SLN arm|"Experimental SLN arm~1. Intra-operative sentinel lymph node (SLN) mapping with indocyanine green injected into the stroma of the cervix.~2. Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceed to a total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy including complete pelvic lymphadenectomy and aortic lymph node dissection.~If only unilateral SLN or non SLN are detected, surgeons will proceed to complete pelvic lymphadenectomy and aortic lymph node dissection."
62532660|NCT02866006|EXPERIMENTAL|BVAC-C mono(High dose)|BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)
62532661|NCT02866006|EXPERIMENTAL|BVAC-C mono(Intermediate dose)|BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)
62532662|NCT02866006|EXPERIMENTAL|BVAC-C + Topo Combi|BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks
62532663|NCT01423656|EXPERIMENTAL|LEO 29102|
62532664|NCT01423656|PLACEBO_COMPARATOR|LEO 29102 vehicle|
62532665|NCT01654614||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
62532666|NCT01654614||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
62532667|NCT02629354|EXPERIMENTAL|Ibuprofen and Caffeine|
62532668|NCT02629354|ACTIVE_COMPARATOR|Ibuprofen|
62532669|NCT01113944|ACTIVE_COMPARATOR|Program 1|Program 1
62532670|NCT01113944|ACTIVE_COMPARATOR|Program 2|Program 2
62532671|NCT03880786|EXPERIMENTAL|PNE test lead|
62532672|NCT00399880|EXPERIMENTAL|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
62532673|NCT00399880|NO_INTERVENTION|Usual care|
62158275|NCT01215253|ACTIVE_COMPARATOR|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl \<60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if \<30ml/min. For patients with CrCl \<60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if \<30ml/min.
62532674|NCT03293407||BAYQ6256_Ventavis|Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician
62532675|NCT02338193|EXPERIMENTAL|DAPA/MET Extended Release (XR)|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
62532676|NCT02338193|ACTIVE_COMPARATOR|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
62532677|NCT02338193|ACTIVE_COMPARATOR|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
62532678|NCT02304627|EXPERIMENTAL|Eating meal immediately after dosing|
62532679|NCT02304627|EXPERIMENTAL|Eating meal 30 min after dosing|
62532680|NCT02304627|EXPERIMENTAL|Eating meal 1 hour after dosing|
62532681|NCT02304627|EXPERIMENTAL|Eating meal 6 hour after dosing|
62532682|NCT06633211|ACTIVE_COMPARATOR|DBBM + collagen matrix|An alveolar ridge preservation will be performed using particulate xenograft DBBM (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland), and the alveolus will be sealed with a collagen matrix (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland).
62532683|NCT06633211|EXPERIMENTAL|DBBM + Regenfast + collagen matrix|An alveolar preservation will be performed by means of a particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland).
62532684|NCT03269318|EXPERIMENTAL|Personalised Medicine|Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
62532685|NCT03269318|NO_INTERVENTION|Standard Care|Standard of care (Standard Care will be prescribed controller medication based on guidelines)
62532686|NCT03204708|ACTIVE_COMPARATOR|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
62532687|NCT03204708|ACTIVE_COMPARATOR|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
62532688|NCT01366950|EXPERIMENTAL|Excercise group|
62532689|NCT01366950|NO_INTERVENTION|Reference|
62532690|NCT01315132|EXPERIMENTAL|Allogeneic Transplantation|Matched Sibling Allogeneic Transplantation
62532691|NCT01857843|EXPERIMENTAL|ZES group|
62532692|NCT01857843|ACTIVE_COMPARATOR|EES group|
62532693|NCT01857843|EXPERIMENTAL|Vytorin group|
62532694|NCT01857843|ACTIVE_COMPARATOR|Mevalotin group|
62532695|NCT04413331||Vasculitis|Those with systemic vasculitis
62532696|NCT04413331||EGPA vasculitis|
62532697|NCT02286310|EXPERIMENTAL|Group A|Kinetic Chain Exercises
62532698|NCT02286310|ACTIVE_COMPARATOR|Group B|Traditional Exercises
62532699|NCT04645966|EXPERIMENTAL|MenABCWY with PLP - 6 months of age|Group 1 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.
62532700|NCT04645966|EXPERIMENTAL|MenABCWY - 6 months of age|Group 2 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule
62532701|NCT04645966|EXPERIMENTAL|Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age|Group 3 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP or Scheduled Liquid Pracetamol (SLP) during primary vaccinations.
62532702|NCT04645966|EXPERIMENTAL|Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age|Group 4 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule
62532703|NCT04645966|EXPERIMENTAL|Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age|Group 5 - Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.
62532704|NCT04645966|EXPERIMENTAL|MenABCWY with SLP - 2 months of age|Group 7 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given SLP during primary vaccinations.
62532705|NCT04645966|EXPERIMENTAL|Bexsero and Nimenrix with PLP - 2 months of age|Group 8 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations
62532706|NCT04645966|EXPERIMENTAL|Bexsero and Nimenrix - 2 months of age|Group 10 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule
62532707|NCT04645966|EXPERIMENTAL|MenABCWY with TLP - 2 months of age|Group 11 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with Therapeutic Liquid Paracetamol (TLP) during primary vaccinations.
62532708|NCT04645966|EXPERIMENTAL|Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age|Group 13 - Participants 2 months of age vaccinated with MenABCWY and placebo on a 2+1 schedule, with a determined ratio of participants given SLP or TLP during primary vaccinations.
62532709|NCT04645966|EXPERIMENTAL|Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age|Group 14 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule with a determined ratio of participants given PLP or TLP during primary vaccinations.
62532710|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
61975846|NCT04123054|EXPERIMENTAL|Sensor-Augmented MDI + Mobile App + Basal-Bolus Optimization Algorithm|Participants will undergo multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data. Every week, participants' insulin doses will be updated by the optimization algorithm's recommendations.
62532711|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
62532712|NCT01342900|NO_INTERVENTION|standard care|The data from the InSPectra Monitor in the Control group will be inaccessible for the Investigator since this is not a part of their daily medical practice
62532713|NCT01342900|ACTIVE_COMPARATOR|Treatment group,|The data given by the monitor will be available for the Investigator and used to apply the optimization protocol
62532714|NCT04661683|EXPERIMENTAL|Exposure to Combustible Hookah Smoke|Participants will be exposed to combustible hookah smoke. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
62532715|NCT04661683|EXPERIMENTAL|Exposure to Electronic Hookah Aerosol|Participants will be exposed to electronic hookah aerosol. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
62532716|NCT04661683|EXPERIMENTAL|Exposure to Clean Air|Participants will be exposed to Clean Room Air. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
62532717|NCT00151112|EXPERIMENTAL|1|combination of lateral position and 20° Trendelenburg Position
62532718|NCT00151112|ACTIVE_COMPARATOR|2|standard positioning
62532719|NCT00525551|ACTIVE_COMPARATOR|1|
62532720|NCT00525551|PLACEBO_COMPARATOR|2|
62532721|NCT05869903|EXPERIMENTAL|Orforglipron Dose 1|Participant will receive orforglipron administered orally.
62532722|NCT05869903|EXPERIMENTAL|Orforglipron Dose 2|Participant will receive orforglipron administered orally.
61975847|NCT02326376||CAPS patients|CAPS patients treated with anakinra, using the Kineret graduated syringe
62532723|NCT05869903|EXPERIMENTAL|Orforglipron Dose 3|Participant will receive orforglipron administered orally.
62532724|NCT05869903|PLACEBO_COMPARATOR|Placebo|Participants will be given placebo.
62532725|NCT01714232|EXPERIMENTAL|Study Staff Test BGMSs|All testing and lancing were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems (BGMS): Contour® PLUS BGMS; OneTouch® SelectSimple™ BGMS; Accu-Chek® Performa BGMS; Accu-Chek® Active BGMS; Freestyle Freedom® BGMS.
62532726|NCT03361475|EXPERIMENTAL|Intervention school|One school workshop and a small talk were conducted first at the beginning of the programme, which was to promote SME and introduce the function of SME App for students, followed by downloading and using immediately to connect family members, then let them continue to use for one month with system reminder.
62532727|NCT03361475|NO_INTERVENTION|Waitlist control schools|The intervention won't be provided during evaluation period and will be provided after the evaluation period
62532728|NCT00989820|NO_INTERVENTION|Surgery|This is the standard arm. Surgery without hyperbaric oxygen treatment
62532729|NCT00989820|EXPERIMENTAL|Hyperbaric oxygen therapy with surgery|Intervention arm. Hyperbaric oxygen therapy with surgery.
62532730|NCT04536532|EXPERIMENTAL|HEC121120 tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
62532731|NCT04536532|PLACEBO_COMPARATOR|HEC121120 placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
62532732|NCT04536532|ACTIVE_COMPARATOR|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
62532733|NCT04536532|PLACEBO_COMPARATOR|entecavir placebo tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
62532734|NCT02958982|EXPERIMENTAL|RP3128|RP3128, A CRAC channel modulator
62532735|NCT02958982|PLACEBO_COMPARATOR|Placebo|Placebo
62532736|NCT02578030|EXPERIMENTAL|SHP465 12.5 mg|A single dose of SHP465 12.5 mg for Subjects aged 6-12 years
62532737|NCT02578030|EXPERIMENTAL|SHP465 25 mg|A single dose of SHP465 25 mg for Subjects aged 13-17 years
62532738|NCT00252239|ACTIVE_COMPARATOR|1|tenecteplase
62532739|NCT00252239|ACTIVE_COMPARATOR|2|tissue plasminogen activator, tPA
62532740|NCT00573404|EXPERIMENTAL|Therapeutic Intervention|
62532741|NCT05527574|EXPERIMENTAL|Exercise Intervention Frail|Resistance Exercise Intervention (home video education: resistance training and diet education) for Frail participants
62532742|NCT05527574|NO_INTERVENTION|Standard of Care or Control Frail|Standard of Care (standard diet and physical activity education) for Frail Participants
62532743|NCT05527574|EXPERIMENTAL|Exercise Intervention Pre-Frail|Resistance Exercise Intervention (home video education: resistance training and diet education) for Pre-Frail participants
62532744|NCT05527574|NO_INTERVENTION|Standard of Care or Control Pre-Frail|Standard of Care (standard diet and physical activity education) for Pre-Frail Participants
62532745|NCT05816057|EXPERIMENTAL|semaglutide injection|Semaglutide 0.25 mg、0.5 mg、1.0mg
62532746|NCT05816057|ACTIVE_COMPARATOR|ozempic®|Ozempic® 0.25 mg、0.5 mg、1.0mg
62532747|NCT01996332|EXPERIMENTAL|Tarceva Arm|
62532748|NCT00619112|EXPERIMENTAL|Temozolomide|single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14
62532749|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
62532750|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
62532751|NCT04968665||healthy volunteers|gait testing and MRI at baseline for healthy volunteers
62532752|NCT04968665||ACL-deficient patients|gait testing and MRI at pre-operation, 6 months post-operation, 1 year post-operation, 2 years post-operation
62532753|NCT03918694|ACTIVE_COMPARATOR|Experimental|Participants will receive Vit C tablets
62532754|NCT03918694|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo tablets
61975848|NCT01435954||Patients with Benign Prostatic Hyperplasia (BPH)|Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
62532755|NCT01627353|ACTIVE_COMPARATOR|Standard of Care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
62532756|NCT01627353|EXPERIMENTAL|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.25% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
62532757|NCT06002737|EXPERIMENTAL|Arm 1|Using Experimental harmonic scalpel to dissect the vessel
62532758|NCT06002737|ACTIVE_COMPARATOR|Arm 2|Using Harmonic Ace+7(Ethicon Endo-Surgery, LL), 5mm Diameter Shears with Advanced Hemostasis to dissect the vessel
61975849|NCT01533233|EXPERIMENTAL|nonintubated anesthesia|Thoracoscopic lobectomy using nonintubated anesthesia
61975850|NCT01533233|ACTIVE_COMPARATOR|intubated general anesthesia|Thoracoscopic lobectomy using intubated general anesthesia
61975851|NCT05885789||Paediatric patients|
61975852|NCT06360666||General Anesthesia|Patients undergoing elective laparoscopic major surgery in general anesthesia
62714239|NCT03961308|ACTIVE_COMPARATOR|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
62532759|NCT01830205|EXPERIMENTAL|Group A (Normal renal function): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
62532760|NCT01830205|EXPERIMENTAL|Group B (End Stage Renal Disease): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
62532761|NCT01830205|EXPERIMENTAL|Group C (Moderate renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
62532762|NCT01830205|EXPERIMENTAL|Group D (Severe renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
62532763|NCT03039660|EXPERIMENTAL|RefreshMD|An online course for sleep improvement in medical students
62532764|NCT03039660|PLACEBO_COMPARATOR|Bond Between Us|An online course covering communication skills and the physician-patient relationship
62532765|NCT02748967|EXPERIMENTAL|Group 1|Participants with age (greater than or equal to \[\>=\] 20 to less than \[\<\] 50 years) will receive single dose of 0.5 milliliter (mL) of ExPEC4V (4:4:4:4) or placebo on Day 1.
62532766|NCT02748967|EXPERIMENTAL|Group 2|Participants with age \>= 20 to \< 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
62532767|NCT02748967|EXPERIMENTAL|Group 3|Participants with age \>= 20 to \< 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
62532768|NCT02748967|EXPERIMENTAL|Group 4|Participants with age greater than or equal to \[\>=\] 50 will receive single dose of 0.5 mL of ExPEC4V (4:4:4:4) or placebo on Day 1.
62532769|NCT02748967|EXPERIMENTAL|Group 5|Participants with age \>= 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
62532770|NCT02748967|EXPERIMENTAL|Group 6|Participants with age \>= 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
62532771|NCT05567120|OTHER|PATH-Care|Problem Adaptation THerapy (PATH) adapted for caregivers along with tablet based exercises to enhance and reinforce the therapy sessions.
62532772|NCT05385965|EXPERIMENTAL|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery, activity pacing) for managing pain.
62532773|NCT05385965|NO_INTERVENTION|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
62532774|NCT01268501|EXPERIMENTAL|Lotrafilcon B multifocal|Lotrafilcon B multifocal contact lenses worn bilaterally for 3 weeks on a daily wear basis
62532775|NCT02135835|EXPERIMENTAL|Shenfu Zhusheye|80 ml Shenfu Zhusheye + 70 ml 5% glucose injection, ivdrip, once a day for 7 days.
62532776|NCT02135835|PLACEBO_COMPARATOR|5% glucose injection|150 ml 5% glucose injection, ivdrip, once a day for 7 days.
62532777|NCT04467801|EXPERIMENTAL|Treatment|"Ipatasertib, 400 mg once daily, Oral, Days 1-14 of each 21 day cycle (2 weeks on and 1 week off).~Docetaxel, 75 mg/m2, Intra-venous, Day 1 of each 21 day cycle."
62532778|NCT05934955|EXPERIMENTAL|BI 1839100 low dose|
62532779|NCT05934955|EXPERIMENTAL|BI 1839100 medium dose|
62532780|NCT05934955|EXPERIMENTAL|BI 1839100 high dose|
62532781|NCT05934955|PLACEBO_COMPARATOR|Placebo|
62714240|NCT03961308|EXPERIMENTAL|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
62714241|NCT06049914|EXPERIMENTAL|Experimental group|"1. Exercise interventions~   * Visiting the primary clinic twice a week and exercising at home once a week for a total of 6 weeks during the introductory and expanding period, and then visiting the primary clinic once a week and exercising at home twice a week for 6 weeks during the maintenance period~  * For exercise intervention, the researcher visits the primary clinic and conducts it face-to-face~  * Flexibility and strength Exercises: Up to 4 group exercises under the guidance of researchers, up to 40 minutes scheduled~2. Nutritional interventions~   * Evaluate nutritional status through Mini Nutritional Assessment(MNA) survey at the time of Visit 1~  * Supplementary protein products are provided only for the malnourished group and at risk group with a MNA score of 23.5 or lower~  * Supplementary protein products: 'Mediwell', healthy five-grain flavor, liquid 150 ml, 150 kcal, 20g carbohydrates, 2g sugars, 8g protein, 5g fat"
62158276|NCT01215253|PLACEBO_COMPARATOR|Placebo|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl \<60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if \<30ml/min. For patients with CrCl \<60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if \<30ml/min.
62158277|NCT06266390|ACTIVE_COMPARATOR|Positive Correlation Target|TMS treatment will be administered using a TMS target positively correlated with the sgACC.
62158278|NCT06266390|ACTIVE_COMPARATOR|Anticorrelation Target|TMS treatment will be administered using a TMS target anticorrelated with the sgACC.
62158279|NCT01835847|EXPERIMENTAL|A single-arm study|
62158280|NCT00975078|EXPERIMENTAL|adrenal insufficiency|
62158281|NCT02936258|OTHER|MRI|Men in Arm A will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI. The unbiopsied men will have a repeat MRI at 2 years.
62158282|NCT02936258|ACTIVE_COMPARATOR|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
62158283|NCT04408495|EXPERIMENTAL|Intervention group_MRA|Recruitment maneuvers and high PEEP
62158284|NCT04408495|ACTIVE_COMPARATOR|Control group|No recruitment maneuvers and low PEEP
62158285|NCT01133678|EXPERIMENTAL|Everolimus|Everolimus 5 mg PO Daily for 2 21-day cycles
62158286|NCT01133678|EXPERIMENTAL|Placebo|Placebo 5 mg PO Daily for 2 21-day cycles
62532782|NCT02724930|NO_INTERVENTION|Standard Implementation|Standard COPES implementation consists of provider education including brief in-person presentations and written material.
62532783|NCT02724930|EXPERIMENTAL|Implementation Facilitation|"Enhanced facilitation of COPES implementation.~All clusters start in the standard implementation group and cross-over from the control group to the intervention group in a randomized stepped-wedge fashion at 7 time points over the course of the 33 week implementation."
62532784|NCT06552065|EXPERIMENTAL|10 will receive cross -linked collagen with silk fibroin membrane around immediate implant.|Local anesthesia is given. Atraumatic extraction is done. Osteotomy is done. Immediate implant is placed along with crosslinked collagen with silk fibroin membrane. Suture is done.
62532785|NCT06552065|ACTIVE_COMPARATOR|10 will receive cross linked collagen membrane around immediate implant|Local anesthesia is given. Atraumatic extraction is done. Osteotomy is done. Immediate implant is placed along with crosslinked collagen membrane. Suture is done.
62532786|NCT02384135|OTHER|interventional|Patients with D-dimer levels between the usual cutoff and the age-adjusted cutoff will be left untreated and followed-up for three months
62532787|NCT04399044|NO_INTERVENTION|Group 1: No flap|Participants will undergo the scheduled vascular surgery procedure without involvement of the plastic surgery team and use of muscle flaps for graft coverage.
62532788|NCT04399044|EXPERIMENTAL|Group 2: Prophylactic muscle flap|Participants will undergo the scheduled vascular surgery procedure and then a muscle flap will be used to cover the vascular graft by a plastic surgeon in the same setting.
62532789|NCT03301623|EXPERIMENTAL|Clinical Decision Support|Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
62532790|NCT03301623|EXPERIMENTAL|Patient Education and Activation Tools|Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. They will receive these materials every time they have an office visit with their PCP.
62532791|NCT01612299|ACTIVE_COMPARATOR|Standard Immunosuppression|Tacrolimus + Myfortic®/Cellcept + Corticosteroids
62532792|NCT01612299|EXPERIMENTAL|Zortress®|Tacrolimus + Zortress® + Corticosteroids
62532793|NCT04326114|EXPERIMENTAL|Inspiratory training|
62532794|NCT04326114|EXPERIMENTAL|Expiratory training|
62532795|NCT04326114|NO_INTERVENTION|Control|
62532796|NCT05310162|EXPERIMENTAL|Food, fun and family|This intervention aims to change eating and screen time habits in children to decrease the amount of added sugar consumed and the time spent using recreational screens, this with guides and precise instructions given to the parents to have a healthier lifestyle.
62532797|NCT05310162|ACTIVE_COMPARATOR|Counseling|The parents will receive simple verbal instructions to reduce the consumption of added sugar and recreational screen time, giving advice on which foods to avoid and the amount of time permitted for the use of screens.
62532798|NCT01080664|EXPERIMENTAL|Regimen 1|Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
62532799|NCT01080664|EXPERIMENTAL|Regimen 2|Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle
62532800|NCT02361970||severe sepsis and septic shock|patients were diagnosed severe sepsis or septic shock
62532801|NCT02361970||patient control|Patients after elective surgeries presented with SIRS but without sepsis
62532802|NCT02361970||volunteer|Health persons
62532803|NCT06425497||Kidney transplant patients|The study population will be composed by patients who underwent a kidney transplant, single or double, from a deceased or living donor, from 01/01/2010 to 07/31/2023 at the U.O.C. of the Hepatobiliary Surgery and Transplants of the Tor Vergata Polyclinic, with at least one year of post-transplant follow-up.
62532804|NCT03024658|NO_INTERVENTION|Zero PEEP|This group of patients did not receive any PEEP at the time of induction of general anesthesia (n= 30)
62532805|NCT03024658|EXPERIMENTAL|PEEP- 10 cm of H2O|This group comprised of patients who received a PEEP of 10 cm H2O at the time of induction of general anesthesia (n= 30)
62532806|NCT02532725||Lean|Men aged 35-55 years, having \<20% body fat
62532807|NCT02532725||Obese|Men aged 35-55 years, having \>29% body fat
62532808|NCT03279497|EXPERIMENTAL|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
62532809|NCT03279497|SHAM_COMPARATOR|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
62532810|NCT02885181|EXPERIMENTAL|GS-9876 - 30 mg|GS-9876 30 mg + filgotinib placebo for 12 weeks
62532811|NCT02885181|EXPERIMENTAL|GS-9876 - 10 mg|GS-9876 10 mg + filgotinib placebo for 12 weeks
62532812|NCT02885181|EXPERIMENTAL|Filgotinib|Filgotinib + GS-9876 placebo for 12 weeks
62532813|NCT02885181|PLACEBO_COMPARATOR|Placebo|GS-9876 placebo + filgotinib placebo for 12 weeks
62532814|NCT01356264|EXPERIMENTAL|multimodal prehabilitation begun preop|The prehabilitation program will begin several weeks preop and continue in the postoperative period
62532815|NCT01356264|ACTIVE_COMPARATOR|Multimodal prehabilitation begun postop|The prehabilitation program will begin after the surgery.
62532816|NCT01004094|EXPERIMENTAL|simple goal setting|This group will only set a goal.
62532817|NCT01004094|EXPERIMENTAL|goal setting plus action intentions|This group will set goals and form action intentions (plans) to facilitate goal attainment.
62532818|NCT01004094|EXPERIMENTAL|goal setting plus coping intentions|This group will set goals and form coping intentions (plans) to facilitate goal attainment.
62532819|NCT01004094|EXPERIMENTAL|goal setting plus action intentions plus coping intentions|This group will set goals, form action intentions (plans), and form coping intentions (plans) to facilitate goal attainment.
62532820|NCT02564211|EXPERIMENTAL|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
62532821|NCT04433338|EXPERIMENTAL|Intervention group|"Participants in the intervention group will follow a low-calorie diet during 14 days before undergoing surgery. The diet will consist of both meal replacements and regular foods.~For women, the diet provides ± 900 kcal, 50 grams of carbohydrates, 85 grams of protein, 30 grams of fat and 25 grams of fibres.~For men, the diet provides ± 1000 kcal, 55 grams of carbohydrates, 100 grams of protein, 30 grams of fat and 30 grams of fibres."
62532822|NCT04433338|NO_INTERVENTION|Control group|Participants in the control group can eat according to the standard nutritional advices provided by their dietitian. These advices are intended to educate participants on the recommended eating pattern after surgery.
62532823|NCT05937984|ACTIVE_COMPARATOR|Active cTMS|Controlled Transcranial Magnetic Stimulation (cTMS) will be delivered at 10 Hz, 1500 pulses targeting the hand representation of the left primary motor cortex. cTMS delivery will require \~9 min to complete. This intervention will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
62532824|NCT05937984|SHAM_COMPARATOR|Sham cTMS|Sham cTMS will be delivered at as a placebo control. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active cTMS. This will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
62532825|NCT02828306||Patients with skull defects|Patients with skull defects after craniotomy for example tumor resection, head trauma, stroke which need a Patient Specific Implant.
62532826|NCT03654599|EXPERIMENTAL|Baseline and Digital Stories (DS) for patients|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
62532827|NCT03654599|ACTIVE_COMPARATOR|Baseline and Information Control (IC) for patients|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
62532828|NCT03654599|EXPERIMENTAL|Baseline and Digital Stories (DS) for caregivers|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
62532829|NCT03654599|ACTIVE_COMPARATOR|Baseline and Information Control (IC) for caregivers|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
62532830|NCT00756483||M, 1|Male patients that have undergone total knee replacement
62714242|NCT06049914|NO_INTERVENTION|Control group|"* Control group: Providing only video and educational materials without intervention (12 weeks)~* Videos and educational materials are provided to both the experimental group and the control group for home exercise.~* Subjects write flexibility exercises, strength exercises, aerobic exercises, and meal diaries at home."
62158287|NCT00513292|ACTIVE_COMPARATOR|FEC-75 then Paclitaxel/trastuzumab|Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
62532831|NCT00756483||F, 1|Female patients that have undergone total knee replacement
62532832|NCT00756483||M, 2|Male patients that have undergone total hip replacement
62532833|NCT00756483||F, 2|Female patients that have undergone total hip replacement
62532834|NCT02468895||Idiopathic Inflammatory Myopathy|PM, DM, sIBM, necrotizing myopathy, anti-synthetase syndrome, suspected myopathy
62532835|NCT05552170||day case group|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
62532836|NCT02166814|EXPERIMENTAL|Fimasartan and Rosuvastatin|Combination of Fimasartan and Rosuvastatin
62532837|NCT02166814|ACTIVE_COMPARATOR|Fimasartan|Fimasartan monotherapy
62532838|NCT02166814|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin monotherapy
62532839|NCT02323516|EXPERIMENTAL|Acetylsalicylic acid + loperamide|Acetylsalicylic acid + loperamide
62532840|NCT02323516|ACTIVE_COMPARATOR|diosmectite + loperamide|Acetylsalicylic acid + loperamide
62532841|NCT04158700|EXPERIMENTAL|LY3200882 and Pembrolizumab (Dose Level 1)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered intravenously (IV).
62532842|NCT04158700|EXPERIMENTAL|LY3200882 and Pembrolizumab (Dose Level 2)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered IV.
62532843|NCT04158700|EXPERIMENTAL|LY3200882 and Pembrolizumab Expansion|Participants with urothelial carcinoma, non-small cell lung cancer, or hepatocellular carcinoma: LY3200882 administered orally twice in combination with pembrolizumab administered IV.
62532844|NCT02129452||CDR (Clinical dementia rating) 0|10 participants complaining subjective memory problem and acquiring CDR 0
62532845|NCT02129452||CDR 0.5|10 participants complaining subjective memory problem and acquiring CDR 0.5
62532846|NCT02129452||CDR 1|10 participants with mild cognitive impairment and acquiring CDR 1
62532847|NCT02129452||CDR 2|10 participants with moderate to severe cognitive impairment and acquiring CDR 2
62532848|NCT05027243|EXPERIMENTAL|bilateral temporomandibular joint arthroscopy|
62532849|NCT02783248||Mitral Stenosis|"No specific protocol intervention occurs. All the cares are made as done usually.~Patients who may be included are all consecutive patients who agreed to participate in the study and having a PMC in a French medical-surgical centers that perform more than 5 year PMC.~All patients undergoing echocardiography with the realization of the score Wilkins and Cormier.~Will then be included to validate the result of late score that patients who had a good immediate result of the PMC defined by: mitral valve area ≥ 1.5 cm² and IM ≤ 2/4. Patients with a poor immediate result of the PMC will not be monitored as part of the study but their data will be collected for the description of the population and analysis of immediate results.~Patients in the study will receive an annual monitoring as recommended, independently of the study."
62532850|NCT03469336|OTHER|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
62532851|NCT04569396||Non-Alcoholic Fatty Liver Disease|A total of 72 severely or morbidly obese patients with non-alcoholic fatty liver disease and associated co-morbidities like diabetes and hypertension were enrolled into the study.
62532852|NCT04844762|ACTIVE_COMPARATOR|usual brand menthol cigarette (UBMC)|Study participant's usual brand menthol cigarette
62532853|NCT04844762|ACTIVE_COMPARATOR|menthol roll-your-own cigarette (mRYO)|Mentholated pipe tobacco in a roll-your-own cigarette tube
62532854|NCT04844762|ACTIVE_COMPARATOR|menthol filtered little cigar (mFLC)|The menthol filtered cigar will be Cheyenne (Cheyennecigars.com) Seneca (senecacigars.com)
62532855|NCT04844762|ACTIVE_COMPARATOR|non-menthol cigarette (nmC)|The non-menthol cigarette will be Newport non-menthol cigarettes.
62532856|NCT03249337|ACTIVE_COMPARATOR|Glanatec(R) 3 times a day|
62532857|NCT03249337|ACTIVE_COMPARATOR|Glanatec (R) 6 times a day|
62532858|NCT04428333|EXPERIMENTAL|Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy|
62532859|NCT04428333|PLACEBO_COMPARATOR|Placebo + Pembrolizumab + 5-FU-platinum chemotherapy|
62532860|NCT02241421|PLACEBO_COMPARATOR|Placebo|No intervention: Placebo 3x2 capsules per day during 7 consecutive days.
62532861|NCT02241421|EXPERIMENTAL|Treatment Antibiotics: Amoxicillin|Experimental: Amoxicillin (broad spectrum antibiotics) 1500 mg/day (3x2 capsules of 250 mg) during 7 consecutive days.
62532862|NCT02241421|EXPERIMENTAL|Treatment Antibiotics: Vancomycin|Experimental: Vancomycin (small spectrum antibiotics) 1500mg/day (3x2 capsules of 250 mg) during 7 consecutive days
62532863|NCT02969681|EXPERIMENTAL|Ascorbic Acid with chemotherapy group|"Ascorbic Acid with mFOLFOX6 with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks~mFOLFOX6:~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
62532864|NCT02969681|ACTIVE_COMPARATOR|Chemotherapy group|"mFOLFOX6:~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
62532865|NCT03256331|EXPERIMENTAL|BEL-X-HG|3+3 dose escalation
62532866|NCT00746018|EXPERIMENTAL|1|The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
62532867|NCT03712215|EXPERIMENTAL|Experimental Group 1|synchronized FES mode, according to the parameters based on the Gueddes et al., (1991): current frequency (F) 30 Hz; pulse width (T) 0,4 ms; upload time (Rise) 1s; time of muscle contraction (On time) 1 s; down time (Decay) 2s e muscle relaxation time (Off time) 1 s.
62532868|NCT03712215|EXPERIMENTAL|Experimental Group 2|the same apparatus will be used, differing in the parameters that will be based on the studies of Cancelliero et al., (2012) for the EDET procedure, being used in synchronized FES mode, with frequency of 30 Hz; pulse width (T) 0,4 ms, climb (ramp) of 0,7 s (maximum value). The support was of 0.4 s, already standardized and fixed in the apparatus
62714243|NCT06555770|EXPERIMENTAL|Stres topu grubu|Pain levels will be tested with VAS 10 minutes before the surgery, and anxiety levels with the VAS-A and Spielberg Continuous Anxiety Scale. The stress balls will be given to both hands of the patient, counting to five and pressing twice. The patient will be shown to use the stress balls for 15 minutes during the surgery. The patient will be told to use the stress balls for 15 minutes during the surgery. After 15 minutes, the researcher will inform the patient and make sure the patient drops the balls.
62736754|NCT02922816|PLACEBO_COMPARATOR|Control arm|The control arm will participate in the bowel preparation and stool or perirectal swab sampling but will not receive Fecal Microbiota Transplant (FMT) nor will they be fasting during their first study cycle (Cycle 0). Participants testing positive for a multi-drug resistant organism at the of Cycle 0 will be eligible to receive microbiota restoration transplant (MRT) for up to two cycles, as necessary (Cycles 1 and 2).
61975853|NCT06360666||Loco Regional Anesthesia - Awareness|Patients undergoing elective laparoscopic major surgery using a combined subarachnoid and thoracic epidural anesthesia approach, keeping the patient spontaneously breathing
62532869|NCT03712215|NO_INTERVENTION|Control Group|The control group (CG) with the same characteristics of the experimental groups will perform conventional physiotherapy
62532870|NCT01062867|EXPERIMENTAL|ORG25435|Infusion of intravenous anaesthetic agent to induce anaesthesia
62532871|NCT04376762|EXPERIMENTAL|Fibrinogen Concentrate|Fibrinogen Concentrate (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
62532872|NCT04376762|ACTIVE_COMPARATOR|Cryoprecipitate|. Cryoprecipitate (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
62532873|NCT01552265||single-group MCI patients|
62532874|NCT03964649||Truven Health MarketScan Research Database|To compare RA-related costs among patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs (individually, as well as to TNFi and to non-TNFi each combined as groups).
62532875|NCT02540759|PLACEBO_COMPARATOR|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
62532876|NCT02540759|EXPERIMENTAL|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
62532877|NCT02540759|EXPERIMENTAL|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
62532878|NCT02540759|EXPERIMENTAL|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
62532879|NCT03467139|EXPERIMENTAL|Study Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. Then, abdominal breathing exercise training was given 3 times a week as 30 sets of 3 sets a week and the patients were treated for 8 weeks
62532880|NCT03467139|NO_INTERVENTION|Control Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion.
62532881|NCT01687478|EXPERIMENTAL|Olanzapine + Fluoxetine|"Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
62532882|NCT01687478|PLACEBO_COMPARATOR|Placebo + Fluoxetine|"Placebo matches the Olanzapine tablet for blinding.~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
62532883|NCT03603548|ACTIVE_COMPARATOR|Advagraf|
62532884|NCT03603548|EXPERIMENTAL|Envarsus|
62532885|NCT04540354|EXPERIMENTAL|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will not receive an ICD device
62532886|NCT04540354|ACTIVE_COMPARATOR|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive an ICD device
62532887|NCT04495283|EXPERIMENTAL|PGB and APAP (Group A)|Group A receives PGB plus APAP prior to surgery and placebo 1 post-surgery.
62532888|NCT04495283|EXPERIMENTAL|APAP (Group B)|Group B receives placebo 2 prior to surgery and APAP post-surgery.
62532889|NCT04495283|EXPERIMENTAL|Placebo (Group C).|Group C receives placebo 1 prior to surgery and placebo 2 post-surgery.
62532890|NCT02939833|EXPERIMENTAL|ropivacaine|patients in this group will receive scalp nerve blocks with 0.5% ropivacaine after anesthesia induction and before skull-pin insertion
62532891|NCT02939833|PLACEBO_COMPARATOR|saline|patients in this group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion
62532892|NCT01957176|EXPERIMENTAL|Cohort A (Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML) adult subjects)|All subjects in this cohort received eltrombopag (ELT) at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 50 to 300 mg once daily (OD) for subjects of non-East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e., Japanese, Chinese, Taiwanese, Thai and Korean) were 25 to 150 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
62532893|NCT01957176|EXPERIMENTAL|Cohort B (Idiopathic thrombocytopenic purpura (ITP) adult subjects)|All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
62532894|NCT01957176|EXPERIMENTAL|Cohort C (Idiopathic thrombocytopenic purpura (ITP) pediatric subjects)|All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
62532895|NCT05189886||Prospective|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
62532896|NCT05189886||Retrospective|The retrospective phase will collect data from previous TAVR procedures completed between February 2019 and October 1, 2021. Data from up to 200 patient charts will be collected using the Society of Thoracic Surgeons/American College of Cardiology that is maintained by the CMH Cardiology Department. The population will be de-identified as the purpose is to obtain descriptive information from the medical records to utilize for propensity match scoring.
62532897|NCT04428515||Radiotherapy Response Monitoring|Those undergoing radiation therapy treatment to their lymph nodes upon diagnosis of head and neck cancer
62532898|NCT04361903||Patients treated with ruxolutinib|SARS-CoV-2 COVID-19 patients with rapid worsening of respiratory parameters in the last 12 hours treated with ruxolutinib, dosage of at least 20 mg x 2 / day in the first 48 hours.
62532899|NCT02143635|EXPERIMENTAL|Arm A|
62532900|NCT02143635|EXPERIMENTAL|Arm B|
62532901|NCT02143635|EXPERIMENTAL|Arm C|
62532902|NCT02143635|EXPERIMENTAL|Arm D|
62532903|NCT05157958|EXPERIMENTAL|ALLO-ASC-SHEET|"Allogeneic mesenchymal stem cells~Dressing for Dystrophic Epidermolysis Bullosa wound"
62532904|NCT05157958|ACTIVE_COMPARATOR|Conventional Therapy|"Hydrogel Sheet~Matching control"
62532905|NCT05691686|EXPERIMENTAL|Finely milled whole wheat-legume bread|Treatment with finely milled whole wheat-legume bread.
62532906|NCT05691686|EXPERIMENTAL|Less processed whole wheat-legume bread|Treatment with less processed whole wheat-legume bread.
62532907|NCT05691686|EXPERIMENTAL|Less processed whole wheat bread|Treatment with of less processed whole wheat bread.
62532908|NCT05691686|ACTIVE_COMPARATOR|Reference Food (white wheat bread)|Treatment with reference food.
62532909|NCT00309049|ACTIVE_COMPARATOR|A1|
62532910|NCT00309049|ACTIVE_COMPARATOR|A2|
62532911|NCT00309049|ACTIVE_COMPARATOR|A3|
62532912|NCT00590811||adolescents|3rd year high school girls (14-16 years old)
62532913|NCT00590811||young adults|1st year university young females (18 - 20 years old)
62532914|NCT03934320|OTHER|FAMCAT|
62532915|NCT06427837|EXPERIMENTAL|Same 2nd course|The same snack food will be served in the second course
62532916|NCT06427837|EXPERIMENTAL|Different 2nd course|A different snack food will be served in the second course
62532917|NCT02480868|EXPERIMENTAL|ARTEBONE|Bone Void Filler
62532918|NCT05918731|NO_INTERVENTION|Usual Care Group|Patients who were assigned to receive usual care were instructed to continue up with their regular medical appointments and their usual check-ups/reviews and if they had any questions, to call the health coach.
62736755|NCT02922816|EXPERIMENTAL|Fecal Microbiota Transplant (FMT)|The experimental arm will participate in the bowel preparation, stool or perirectal swab sampling, and will receive Fecal Microbiota Transplant (FMT) using Allogeneic Human Stool in Glycerol 10% (AHSG) on Day 1 of each cycle (Cycles 1 and 2).
62736756|NCT00814580|EXPERIMENTAL|001|Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
62532919|NCT05918731|ACTIVE_COMPARATOR|Self-management Intervention Group|In the intervention group, a self-management program was implemented.
62532920|NCT00391235||BPD|Children with bipolar disorder
62532921|NCT00391235||HC|Healthy comparison children
62532922|NCT02788682||Patients|WT+ Diplotype
62532923|NCT02788682||Controls|WT- Diplotype
62532924|NCT02517086|ACTIVE_COMPARATOR|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
62532925|NCT02517086|ACTIVE_COMPARATOR|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
62532926|NCT02517086|ACTIVE_COMPARATOR|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
62532927|NCT02931903|EXPERIMENTAL|Hybrid superstructure|Vita Enamic is a hybrid ceramic, consisting of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
62532928|NCT02931903|ACTIVE_COMPARATOR|Ceramic superstructure|IPS Emax, is the mostly used ceramic superstructures in implant supported restorations.
62532929|NCT06455007|EXPERIMENTAL|Propolis group|. Propolis 3x10 drops (7 days) were used in the propolis group.
62532930|NCT06455007|NO_INTERVENTION|Control group|
62532931|NCT01510548|ACTIVE_COMPARATOR|Adalimumab 20 mg per week|Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections
62532932|NCT01510548|ACTIVE_COMPARATOR|Adalimumab 40 mg per week|Patient will get at double blind situation adalimumab 40 mg per week injections
62532933|NCT01510548|PLACEBO_COMPARATOR|placebo arm|Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms
62532934|NCT02451332|EXPERIMENTAL|vaccinated|These women will have received the seasonal influenza vaccine.
62532935|NCT04016220|EXPERIMENTAL|Budesonide group|The experimental group received a first nebulization of 5 mg of terbutaline(solution of 5mg/ 2 ml ) in association with 0.5 mg of ipratropium bromide (solution of 0.5 mg/ 2 ml) and 0.5 mg of budesonide (solution of 0.5 mg/2 ml) followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min. All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
62532936|NCT04016220|PLACEBO_COMPARATOR|normal saline|The control group received a nebulization of 2 ml normal saline at baseline, 20, 40, 60 and 120 min as placebo comparator in association with nebulized terbutaline . All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
62532937|NCT04730882||Healthy Control|Healthy subjects 18-35 years of age
62532938|NCT04730882||Type 1 Diabetes|People with type 1 diabetes (18-35 yrs) who have type 1 diabetes based on WHO diagnostic criteria for \> 1 year
62532939|NCT06086418|PLACEBO_COMPARATOR|placebo|0.2% ropivacaine for popliteal nerve block
62532940|NCT06086418|ACTIVE_COMPARATOR|0.1mg/kg Dexamethasone|0.1mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
62532941|NCT06086418|ACTIVE_COMPARATOR|0,05mg/kg dexamethasone|0.05mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
62532942|NCT00004180|EXPERIMENTAL|Well-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
62532943|NCT00004180|EXPERIMENTAL|De-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
62532944|NCT00004180|EXPERIMENTAL|Myxoid/ round-cell liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
62532945|NCT00004180|EXPERIMENTAL|Pleomorphic liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
62532946|NCT03908762|EXPERIMENTAL|iSage|The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose \<70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.
62532947|NCT03908762|ACTIVE_COMPARATOR|Conventional Management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet. In the case of glargine or detemir (Basaglar, Lantus, Levemir) adjustments of 1 unit of insulin/day are made until the fasting blood sugars (2 of 3 consecutive values) are 80-130 mg/dl. In the instance of Toujeo or Tresiba, adjustments of 2 units are made every 5 days. Volunteers will have meters downloaded (or interviewed where necessary) to obtain data on fasting blood sugar and episodes of hypoglycemia (perceived or measured \<70 mg/dl). The PCP is free to request glucose logs and set return appointments as needed to manage the patient.
62532948|NCT01018589|EXPERIMENTAL|A|Cicatrix cream
62736757|NCT00814580|ACTIVE_COMPARATOR|002|Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
62736758|NCT01723046|EXPERIMENTAL|Training with the device|Training with new upper limb robot assisted therapy device
62532949|NCT04710316|EXPERIMENTAL|Patients|- Hospitalized patients in one of the four centers in Bamako, with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures
62532950|NCT04710316|EXPERIMENTAL|Caregivers|"Caregivers of one of the four centers in Bamako.~* Serological screening: all.~* Molecular screening: with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have seroconverted to SARS-CoV-2 or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures"
62532951|NCT02325518|EXPERIMENTAL|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
62532952|NCT02325518|ACTIVE_COMPARATOR|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
62532953|NCT04775186|EXPERIMENTAL|Laparoscopic Burch colposuspension|
62532954|NCT04775186|EXPERIMENTAL|midurethral sling|
62532955|NCT01283594|EXPERIMENTAL|Tozadenant (SYN115) 60 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
62158288|NCT00513292|EXPERIMENTAL|Paclitaxel/trastuzumab then trastuzumab/FEC-75|Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.
62158289|NCT02413645|OTHER|100 μg TriMix mRNA (TriMix_100)|"Cohort 1 (control group) 3 patients will receive 100 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a dose limiting toxicity (DLT), DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
62532956|NCT01283594|EXPERIMENTAL|Tozadenant (SYN115) 120 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
62532957|NCT01283594|EXPERIMENTAL|Tozadenant (SYN115) 180 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
62532958|NCT01283594|EXPERIMENTAL|Tozadenant (SYN115) 240 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
62532959|NCT01283594|PLACEBO_COMPARATOR|Sugar Pill|White-coated, modified-oval placebo tablets.
62532960|NCT04938323|EXPERIMENTAL|BCG Vaccine|Participants randomized to the BCG Vaccine Arm will receive the vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
62532961|NCT04938323|PLACEBO_COMPARATOR|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines': upper arm.
62532962|NCT03465124|ACTIVE_COMPARATOR|Femtosecond Laser assisted Cataract Surgery|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order.
62532963|NCT03465124|ACTIVE_COMPARATOR|Manual Cataract Surgery|Manual Cataract Surgery will be performed in contralateral (to LCS) eye of patient with bilateral age-related cataract.
62532964|NCT06270212|ACTIVE_COMPARATOR|STAIRWAY|Unpaired evaluation of STAIRWAY during induction of steady-state sedation in volunteer study participants (PART A), and during induction and maintenance of PS according to SOC in study patients (PART B).
62532965|NCT06270212|OTHER|NO DEVICE|Unpaired evaluation of NO DEVICE during induction of steady-state sedation in volunteer study participants (PART A), and during induction and maintenance of PS according to SOC in study patients (PART B).
62532966|NCT06344663||control group|"Mothers who will be included in the control group will be interviewed twice in total. Pretest data will be obtained by applying the Personal Information Form, Insufficient Milk Perception Scale and Breastfeeding Motivation Scale during the first interview. A sample of the mothers' saliva will be taken to measure cortisol values. Four weeks after the pre-test data are obtained, post-test data will be obtained by applying the Insufficient Milk Perception Scale and Breastfeeding Motivation Scale. Finally, a saliva sample will be taken to check the cortisol value again."
62532967|NCT06344663||intervention group|"Before starting the motivational interviews, pre-test data will be obtained by applying the Personal Information Form, Insufficient Milk Perception Scale and Breastfeeding Motivation Scale to the mothers in the intervention group. Afterwards, a sample of the mothers' saliva will be taken to measure their cortisol levels. A total of 4 sessions of motivational interviews will be held for infertile women, 1 session per week for four weeks. At the end of four weeks, post-test data will be obtained by applying the Insufficient Milk Perception Scale and Breastfeeding Motivation Scale. A sample of the mothers' saliva will be taken to measure cortisol levels again."
62532968|NCT00296634|EXPERIMENTAL|1|45 microgram dose Hemagglutinin (HA), 120 subjects receiving Aluminum hydroxide and 120 not receiving Aluminum hydroxide.
62532969|NCT00296634|EXPERIMENTAL|2|15 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
62532970|NCT00296634|EXPERIMENTAL|4|3.75 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
61975854|NCT05871827||Traditional Overlay|Subjects who underwent THA without use of computer navigation
62532971|NCT00296634|EXPERIMENTAL|3|7.5 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
62532972|NCT04527445|EXPERIMENTAL|Reduced Radiation Fluoroscopy|Reduced radiation fluoroscopy technique is performed by the C-arm set at 1 pulses-per-second and reduction of current.
62532973|NCT04527445|ACTIVE_COMPARATOR|Conventional Fluoroscopy|The standard of care is the conventional fluoroscopy, the C-arm is set at 30 pulses-per-second and the current set as the default.
62532974|NCT03063840|EXPERIMENTAL|Microwave ablation (MWA)|Microwave ablation (MWA)
62532975|NCT06442306|EXPERIMENTAL|Pain Neuroscience Education group|The PNE group received the a-PNE education curriculum which was created with patient-friendly verbiage and used to educate subjects about the inner workings of the nervous system. The a-PNE curriculum, a PowerPoint presentation was divided into four, 15-minute, one-on-one sessions with the PI in a private treatment room to facilitate discussion and minimize distractions. The educational information was related directly to the patients' CMP/OpD experience to personalize the intervention and presented at a pace that was appropriate for each patient. At the conclusion of each session, the PNE group was provided handouts containing information that was reviewed during that session. At the end of the a-PNE intervention, the patients completed the three questionnaires.
62532976|NCT06442306|ACTIVE_COMPARATOR|General Health Education group|The GHE group was provided practical education for healthy living over four monthly sessions, 15-minutes per session. The GHE intervention was comprised of topics promoting healthy living in a one-on-one session with the PI in a private treatment room to facilitate discussion. At the conclusion of each session, the GHE group was provided handouts containing information that was reviewed during the session. At the end of the GHE intervention, the patients completed the three questionnaires.
62532977|NCT03052127|EXPERIMENTAL|Single Low Dose Light-activated AU-011|Low dose Light-activated AU-011 followed by a single laser light application
62532978|NCT03052127|EXPERIMENTAL|Single Medium Dose Light-activated AU-011|Medium dose Light-activated AU-011 followed by a single laser light application
62532979|NCT03052127|EXPERIMENTAL|Single High Dose Light-activated AU-011|High dose Light-activated AU-011 followed by a single laser light application
62532980|NCT03052127|EXPERIMENTAL|2 Repeat Medium Dose Light-activated AU-011|2 repeat medium doses of Light-activated AU-011 each followed by a single laser light application
62532981|NCT03052127|EXPERIMENTAL|3 Repeat Medium Dose Light-activated AU-011|3 repeat medium doses of Light-activated AU-011 followed by a single laser light application
62532982|NCT03052127|EXPERIMENTAL|Single High Dose Light-activated AU-011 x 2 lasers|High dose Light-activated AU-011 followed by two laser light applications
62532983|NCT03052127|EXPERIMENTAL|3 Repeat High Dose Light-activated AU-011|3 repeat high doses of Light-activated AU-011 each followed by a single laser light application
62532984|NCT03052127|EXPERIMENTAL|3 Repeat High Dose Light-activated AU-011 x 2 lasers|3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
61975855|NCT05871827||Computer Navigation|Subjects who underwent THA with use of computer navigation
62158290|NCT02413645|OTHER|300 μg TriMix mRNA (TriMix_300)|"Cohort 2 (control group) 3 patients will receive 300 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
62158291|NCT02413645|EXPERIMENTAL|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 3 (experimental group) 3 patients will receive 600 μg of mRNA (300 μg HIV mRNA + 300 μg TriMix mRNA). If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
62532985|NCT03052127|EXPERIMENTAL|Expansion 3 Repeat High Dose Light-activated AU-011 x 2 lasers|Expansion of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications (up to 12 additional subjects)
62532986|NCT03052127|EXPERIMENTAL|Observation until Documented Growth of Tumor|Observation until documented growth of tumor and then treatment with 2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
62532987|NCT03052127|EXPERIMENTAL|2 Cycles of 3 Repeat High Dose Light-activated AU-011x2 lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
62532988|NCT03052127|EXPERIMENTAL|Exp: 2 Cycles 3 Repeat High Dose Light-activatedAU-011x2lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications in subjects with evidence of documented tumor growth prior to study entry
62532989|NCT03177174|ACTIVE_COMPARATOR|Docetaxel|
62532990|NCT03177174|ACTIVE_COMPARATOR|Cisplatin|
62532991|NCT03177174|ACTIVE_COMPARATOR|DocetaxelCisplatin|Cisplatin combined with Docetaxel
62532992|NCT02485171|EXPERIMENTAL|Experimental|Introduction of a walking aid device SAFEWALKER for elderly patients during rehabilitation after a post-fall syndrome.
62532993|NCT02485171|NO_INTERVENTION|No intervention|No introduction of a walking aid device for elderly patients during rehabilitation after a post-fall syndrome.
62532994|NCT02712060||EDS patients|Patients with the diagnosis of Ehlers-Danlos syndrome
62532995|NCT02712060||controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
62532996|NCT03775759|EXPERIMENTAL|Study arm|Tricuspid valve ring annuloplasty or replacement at the time of LVAD implantation plus medical therapy
62532997|NCT03775759|ACTIVE_COMPARATOR|Control arm|LVAD implantation plus medical therapy
62532998|NCT03205891|EXPERIMENTAL|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.~Each cycle is 21 days.~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
62532999|NCT05960812|ACTIVE_COMPARATOR|group 1 (patient treated by skillful neglect with biceps tenotomy)|neglect of upper border subscapularis tear and doing biceps tenotomy
62533000|NCT05960812|ACTIVE_COMPARATOR|group 2 (patient treated by arthroscopic repair with biceps tenotomy)|repair of upper border subscapularis tear and doing biceps tenotomy
62533001|NCT03043859|EXPERIMENTAL|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
62533002|NCT03043859|NO_INTERVENTION|Wait Listed Control|Participants in the control arm will not receive any intervention.
62533003|NCT00899990||Observational (biomarker sampling)|Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.
62533004|NCT02447744|EXPERIMENTAL|Mindfulness group|This arm receives an 8-week mindfulness based behavioral intervention program.
62533005|NCT02447744|OTHER|Waitlist control group|This arm waits while the mindfulness group receives their intervention, and then receives the mindfulness based intervention after their waiting period.
62533006|NCT02623348|EXPERIMENTAL|pedometer|Patients will be given pedometers and instructions to increase physical activity based on pedometer output
62533007|NCT02623348|NO_INTERVENTION|usual care|No intervention
61975856|NCT01344161|PLACEBO_COMPARATOR|Lactose|
61975857|NCT01344161|EXPERIMENTAL|Vitamin D|
62533008|NCT03802253|EXPERIMENTAL|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
62533009|NCT03802253|ACTIVE_COMPARATOR|RCD|Participants in this group will focus on standard care with daily reduced calorie diet (RCD)
62533010|NCT03123458|EXPERIMENTAL|Single arm, cfMSC to treat immune disorders|cfMSCs treatment
62533011|NCT04571151|ACTIVE_COMPARATOR|Lexette + Sorilux|"Halobetasol Propionate Topical Foam (Lexette Foam) + Calcipotriol Foam (Sorilux Foam) for 2 weeks~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g."
62736759|NCT01723046|NO_INTERVENTION|Control group|The control group is treated with conventional therapy.
62533012|NCT04571151|PLACEBO_COMPARATOR|Lexette + Vehicle|"Halobetasol Propionate Topical Foam (Lexette Foam) + Vehicle Foam for 2 weeks~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.~Vehicle Foam would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application."
62533013|NCT04571151|ACTIVE_COMPARATOR|Sorilux|"Calcipotriol Foam (Sorilux Foam) for 6 weeks~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 6 weeks. SORILUX Foam contains calcipotriene 50 mcg/g."
62533014|NCT04571151|PLACEBO_COMPARATOR|Vehicle|"Vehicle Foam for 6 weeks.~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.~Vehicle Foam would be applied over the affected area twice daily for 6 weeks."
62533015|NCT04131777||Roll-in|Initial patients enrolled until optimal RF algorithm is determined
62533016|NCT04131777||Optimized|Patients treated using optimal RF algorithm
62533017|NCT01226771|EXPERIMENTAL|"Group A (Loading)"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
62533018|NCT01226771|EXPERIMENTAL|"Group B (Priming)"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
62533019|NCT01226771|ACTIVE_COMPARATOR|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
62533020|NCT04439695|EXPERIMENTAL|Low Dose KBP-V001|Subjects in this group will receive the low dose of KBP-V001.
62533021|NCT04439695|EXPERIMENTAL|Intermediate KBP-V001|Subjects in this group will receive the intermediate dose of KBP-V001.
62533022|NCT04439695|EXPERIMENTAL|High Dose KBP-V001|Subjects in this group will receive the high dose of KBP-V001.
62533023|NCT04439695|PLACEBO_COMPARATOR|Placebo|Subjects in this group will receive placebo
62533024|NCT02465294|PLACEBO_COMPARATOR|Potato starch and magnesium stearate|This arm will be used as a control to asses the efficacy of the other probiotic arms. The placebo will contain encapsulated potato starch and magnesium stearate which is used the matrix in the probiotic supplements. The placebo refers only to the intervention supplement, not the behavioral lifestyle intervention. All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
62533025|NCT02465294|EXPERIMENTAL|Lactobacillus|Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
62533026|NCT02465294|EXPERIMENTAL|Mix of Bifidobacterium and Lactobacillus|A blend of Bifidobacterium and Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
62533027|NCT06303479|EXPERIMENTAL|Instrumental breathing exercise group|Instrumental breathing exercise group consisting of 13 healthy adults between the ages of 18-30
62533028|NCT06303479|EXPERIMENTAL|Non-Instrumental breathing exercise group|Non-Instrumental breathing exercise group consisting of 13 healthy adults between the ages of 18-30
62533029|NCT03713775|EXPERIMENTAL|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Weight Loss Programme with behavioural support. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counsellors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients. The programme conventionally includes the 3 phases (meal replacement phase, transition phase, and weight maintenance phase) but the Consultant will have full discretion to modify and tailor this programme to suit each individual participant.
62533030|NCT03713775|ACTIVE_COMPARATOR|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min at the John Radcliffe Hospital, Oxford) together with supporting written information (i.e. a copy of the booklet 'Facts not fads - Your simple guide to healthy weight loss.')
62533031|NCT05396261|EXPERIMENTAL|Treatment arm|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
62533032|NCT04405167|EXPERIMENTAL|A1: Tasquinimod single agent dose escalation|There are up to 5 planned dose levels, with 3 de-escalation dose levels available in case dose level 1 is determined to exceed the MTD. This arm will enroll 15-30 subjects if all dose levels are explored.
62533033|NCT04405167|EXPERIMENTAL|A2: Tasquinimod single agent expansion|Additional subjects will enroll in arm A2 at the MTD and optimal schedule, so that 12 subjects total who are evaluable for response will have received the MTD/optimal schedule of single agent tasquinimod. Enrollment in arm A2 will not begin until enrollment in arm A1 has been completed and a single agent MTD/optimal schedule has been established.
62533034|NCT04405167|EXPERIMENTAL|B1: Tasquinimod+IRd dose escalation|Dose levels will be defined according to the same tasquinimod doses as in the single agent (Arm A1) dose escalation. Enrollment in arm B1 will not begin until enrollment in arm A1 has been completed and an MTD/optimal schedule has been established for single agent tasquinimod. Initial subjects in arm B1 will be enrolled at the lower of dose level 1 or one dose level below the single agent MTD . If this initial dose level is determined to exceed the combination MTD, further subjects will be enrolled at one dose level lower. Enrollment is not planned in arm B1 at doses higher than the single agent MTD. There are 9-12 planned subjects if all dose levels are explored.
62533035|NCT04405167|EXPERIMENTAL|B2: Tasquinimod+IRd expansion|Additional subjects will enroll in arm B2 at the MTD and optimal schedule, so that 12 subjects total who are both evaluable for response and previously refractory to their most recent Imid/PI combination will have received the MTD/optimal schedule of tasquinimod in combination with ixazomib, lenalidomide, and dexamethasone. To facilitate rapid enrollment and gain more experience with the combination therapy, up to 12 additional subjects with triple-class refractory myeloma (who are not previously refractory to their most recent Imid/PI combination) may be enrolled in cohort B2. Enrollment in arm B2 will not begin until enrollment in arm B1 has been completed and a combination MTD/optimal schedule has been established.
62533036|NCT01375153|PLACEBO_COMPARATOR|Placebo|0,9% NaCl administered as a continuous intravenous infusion during four hours.
62533037|NCT01375153|ACTIVE_COMPARATOR|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours.
62533038|NCT01857271|EXPERIMENTAL|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
62533039|NCT02936453|EXPERIMENTAL|All patients|"Patients will participate during 8-12 months, during which there will be :~* Pre-implant evaluations (6-8 weeks)~* Device implantation and stimulation optimization (6-8 weeks)~* Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system.~An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system."
62533040|NCT01470911|EXPERIMENTAL|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
62533041|NCT01470911|PLACEBO_COMPARATOR|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
62533042|NCT05177718|OTHER|Treatment Single Arm|SINGLE ARM: 30 patients with multiple sclerosis treated with Natlizumab infusion given monthly at the dose of 300 mg IV
62533043|NCT06088134||Non-recurrence group|
62533044|NCT06088134||Recurrence group|
62533045|NCT00095316|PLACEBO_COMPARATOR|Placebo|Subjects receive placebo intravenously daily for 28 days
62533046|NCT00095316|EXPERIMENTAL|Caspofungin|Subjects receive 50mg/day caspofungin intravenously (IV) for 28 days
62533047|NCT02519738|ACTIVE_COMPARATOR|Silver Nitrate|Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
62533048|NCT02519738|ACTIVE_COMPARATOR|Kenalog (Triamcinolone)|Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
62736760|NCT05453071|ACTIVE_COMPARATOR|BETY Group|Since 2004, group exercise sessions have been organized as a routine form of treatment for individuals diagnosed with rheumatism in the Department of Physiotherapy and Rehabilitation of Hacettepe University. The first evaluation will be made if the individuals who come to the routine doctor's examination agree to participate in the study. According to being included in one of the two groups as those who decided to attend the BETY sessions that have been going on for 18 years and those who did not agree to attend the sessions; The individuals included in the BETY group (Group 1) will be evaluated on the day of the last exercise session after their participation in the 12-week exercise group.
62158292|NCT02413645|EXPERIMENTAL|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 4 (experimental group) 3 patients will receive 900 μg of mRNA (i.e. 600 μg HIV mRNA and 300 μg TriMix mRNA). If two or more of the three first patients have a DLT, then additional three patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients have a DLT, additional three patients will be enrolled at 900 μg dose level. If two or more of the six patients receiving 900 μg of mRNA have a DLT, then additional 3 patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients of the six patients have a DLT, six patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
62158293|NCT02413645|EXPERIMENTAL|1200μg mRNA(900 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 5 (experimental group) 6 patients will receive 1200 μg of mRNA (i.e. 900 μg HIV mRNA + 300 μg TriMix mRNA) in case one or no patients of the six patients at the previous dose level have a DLT.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
62158294|NCT06090253|EXPERIMENTAL|Active|Gerotechnology enhanced multi-component exercise or Football training sessions.
62158295|NCT06090253|EXPERIMENTAL|General community-dwelling aged cohort|Gerotechnology enhanced multi-component exercise.
62158296|NCT06090253|EXPERIMENTAL|Geriatric symptoms|Walking exercise and slow sports and exercise.
62158297|NCT06090253|EXPERIMENTAL|Chronic disease burden|Walking exercise and slow sports and exercise.
62158298|NCT06090253|EXPERIMENTAL|Frail|Elderly home gym training service.
62158299|NCT06090253|NO_INTERVENTION|Control|No training session will be provided.
62158300|NCT02297854|EXPERIMENTAL|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
62158301|NCT02297854|ACTIVE_COMPARATOR|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco
62158302|NCT06247267||Primary/Secondary Untreated Hypogonadism|Subjects in group 1 will take clinically indicated testosterone replacement therapy (Fortesta-injection, gel and transdermal) for 12 months with titration for a serum total T level between 300-600 ng/dL.
62158303|NCT06247267||Male-to-Female (MTF)|Subjects in group 2 will take clinically indicated estrogen therapy (Estradiol-orally and transdermal and/or spironolactone-orally) for 12 months for hormonal transition period.
62533049|NCT02519738|ACTIVE_COMPARATOR|Washcloth Abrasion|Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.
62533050|NCT00093873|EXPERIMENTAL|AMG 706|AMG 706 QD
62533051|NCT03617757|EXPERIMENTAL|All recruited patients|Blood taking procedure, oral glucose tolerance test and questionnaire will be included.
62158304|NCT06247267||Female-to-Male (FTM)|Subjects in group 3 will take clinically indicated testoserone replacement therapy (Fortesta-injection, gel and transdermal) for 12 months for hormonal transition period.
62158305|NCT02217098|ACTIVE_COMPARATOR|GIC Restorations|Restorations using Glass Ionomer Cement
62533052|NCT04058249|EXPERIMENTAL|Right DLPFC aiTBS stimulation|
62533053|NCT02410980|EXPERIMENTAL|Tretinoin cream 0.1%|Assessment of the skin change
62533054|NCT03382730|OTHER|Oral Chlorhexidine Mouth Rinse|Application of chlorhexidine gluconate mouth rinse per unit protocol.
62533055|NCT03382730|EXPERIMENTAL|De-Adoption of Oral Chlorhexidine Mouth Rinse|No application of chlorhexidine gluconate mouth rinse. Oral care bundle.
62533056|NCT04243083|EXPERIMENTAL|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
62533057|NCT04243083|EXPERIMENTAL|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
62533058|NCT04243083|EXPERIMENTAL|Food Effect Panel|Twelve subjects will receive a single dose of TLL018 in 2 treatment periods, one after a high fat, high calorie breakfast (fed) and the second treatment period under fasted conditions to determine the effect of food on the PK of TLL018.
62533059|NCT04237337||serious cancer ICSRs (cases)|
62533060|NCT04237337||other serious reactions ICSRs (non-cases)|
62158306|NCT02217098|EXPERIMENTAL|Compomer Restorations|Restorations using Compomer
62158307|NCT02217098|EXPERIMENTAL|Carbomer Restorations|Restorations using Glass Carbomer
62158308|NCT06527833|EXPERIMENTAL|Non Packing group|• In Group (A \[Non-Packing group\]), The surgery will be performed by making a cruciate incision over the abscess and incision widened using forceps to allow complete drainage of the cavity containing, without any catheter drainage and packing avoided. The lesion will be left open to heal by secondary intension. The patient was advised to have a sitz bath and apply dressing over the cavity.
62533061|NCT04047914|EXPERIMENTAL|experimental aPDT group|Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 10 minute pre-irradiation time. The irradiations were carried out with a red light-emitting diode (LED) (λ = 660 nm), for 300 seconds, irradiance of 400 mW / cm2, radiant exposure 124 J / cm2, with uniform application in each anterior nostril.
62533062|NCT04047914|ACTIVE_COMPARATOR|control mupirocin group|A standard treatment will be performed conventionally with topical mupirocin. Will be performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
62533063|NCT03715361||Patients|Patients (500 patients ≤ ) who undergo out- or inpatient treatment and who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
62533064|NCT03715361||Control Group|Fifty volunteers who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
62533065|NCT00742066|EXPERIMENTAL|I|Irbesartan
62533066|NCT00742066|ACTIVE_COMPARATOR|II|Felodipine
62533067|NCT00742066|PLACEBO_COMPARATOR|III|Placebo
62533068|NCT00315237|EXPERIMENTAL|1|
62533069|NCT00315237|NO_INTERVENTION|2|best supportive care for 18 week duration
62533070|NCT04013984|EXPERIMENTAL|Accupuncture|"Acupuncture twice a week during the preceding cycle and the ovarian stimulation by GnRH agonist stopped protocol."
62533071|NCT04013984|NO_INTERVENTION|Non-accupuncture|"Ovarian stimulation by GnRH agonist stopped protocol without intervention."
62533072|NCT02337296|OTHER|Phase 1 - Intervention|Five patients will be enrolled consecutively for the ADHERE intervention and be followed in order to refine the intervention as needed. This permits the investigation of the process of change at baseline, after the intervention, and across the phases.
62533073|NCT02337296|NO_INTERVENTION|Phase 2 - Control Group|Following completion of Phase 1 and prior to initiation of enrollment in the intervention group, patients will be enrolled in the control group and will receive usual care.
62533074|NCT02337296|EXPERIMENTAL|Phase 2 - Intervention Group|Following enrollment of all control group patients, the intervention group will be recruited and enrolled and the ADHERE intervention will be conducted by the trained APRN interventionist at cancer center.
62533075|NCT01851200|EXPERIMENTAL|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
62533076|NCT03630250|EXPERIMENTAL|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 \& 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
62533077|NCT03630250|NO_INTERVENTION|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
62533078|NCT03630250|EXPERIMENTAL|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 \& 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
62533079|NCT00420459|EXPERIMENTAL|Aripiprazole|
62736761|NCT05453071|NO_INTERVENTION|Control Group|Individuals (Group 2), who do not agree to participate in BETY sessions but agree to participate in evaluations with 12-week intervals, will be evaluated when they come for their routine check-ups at 12-week intervals, and recommendations given routinely.
61975858|NCT02560584|EXPERIMENTAL|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
61975859|NCT01455337|ACTIVE_COMPARATOR|prednisolone|
61975860|NCT01455337|EXPERIMENTAL|pentoxifylline|
62158309|NCT06527833|OTHER|Packing group|In group (B \[Packing group\]), an elliptical incision will be made, and the abscess will be fully drained then packing the cavity will be done with sterile gauze with a change of dressing every 24 hours until it is completely healed.
62158310|NCT06149559|EXPERIMENTAL|rozanolixizumab|Study participants will receive pre-defined doses of rozanolixizumab for 6 weeks.
62158311|NCT05313477|ACTIVE_COMPARATOR|Supplement group|"Vitamin D2 supplement based on initial vitamin D level~* ≥ 20ng/mL -\> vitamin D2 20,000unit/week~* 10-19.9ng/mL -\> vitamin D2 40,000unit/week~* \<10ng/mL -\> vitamin D2 60,000unit/week Calcium carbonate 1000mg/day"
62158312|NCT05313477|NO_INTERVENTION|No supplement group|no medication supplement
62158313|NCT05230056|EXPERIMENTAL|PG|
62158314|NCT05230056|ACTIVE_COMPARATOR|CTRL|
62533080|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
62533081|NCT02293889|EXPERIMENTAL|Vitamin D|Vitamin D3 2000IU/daily 3 months
62533082|NCT02293889|EXPERIMENTAL|Physical Activity|PA intervention People with Osteoarthritis Walking Programme
62533083|NCT02293889|EXPERIMENTAL|Vitamin D and Physical Activity|Vitamin D3 2000IU/daily 3 months PA intervention People with Osteoarthritis Walking Programme
62533084|NCT02293889|PLACEBO_COMPARATOR|Placebo|Placebo capsule: edible oil
62533085|NCT03970928|ACTIVE_COMPARATOR|goal-directed fluid management (GDFM)|A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light. The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor. 0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
62533086|NCT03970928|NO_INTERVENTION|Conventional fluid management group (CFMG)|This group will receive conventional fluid management described as follows: 0.9 % NaCl at a rate of 4- 8 mL/kg/h will be infused in CFGM group, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.
62533087|NCT04885465|EXPERIMENTAL|Intervention group|Study participants will receive a web-based support program
62533088|NCT04885465|NO_INTERVENTION|Control group waiting list|Study participants in the control group waiting list will receive standard support from health care and municipalities. After study termination they will receive access to the same web-based program as the experimental group
62533089|NCT02590250||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
62533090|NCT03659097|EXPERIMENTAL|Periodontally accelerated osteogenic orthodontics|Patients in this group will undergo orthodontic treatment plus periodontally accelerated osteogenic orthodontics in order to induce tooth movement.
62533091|NCT03659097|NO_INTERVENTION|Traditional orthodontics|Patients in this group will undergo traditional orthodontics without any surgical interventions
62533092|NCT03038594|EXPERIMENTAL|Growth Hormone|Daily subcutaneous injections of 0.05 mg/kg/day of Growth Hormone \[somatropin, Genotropin, Pfizer, New York, NY\] will be administered, from one week prior to discharge until 9 months post-burn.
62533093|NCT03038594|PLACEBO_COMPARATOR|0.09% saline solution|Daily subcutaneous injections of 0.09% of saline solution will be administered, from one week prior to discharge until 9 months post-burn.
62533094|NCT01557361|ACTIVE_COMPARATOR|Standard RRT initiation|RRT is initiated \>12 hours after eligibility determination. Once a decision is made to start RRT, a dialysis catheter will be placed and RRT initiated as soon as possible.
62533095|NCT01557361|EXPERIMENTAL|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility.
62533096|NCT02459548|EXPERIMENTAL|Primary Care Group|This group will be follow up in Primary Care at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
62533097|NCT02459548|OTHER|Sleep Unit Group|This group will be follow up in Sleep unit at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
62736762|NCT04087941|PLACEBO_COMPARATOR|Placebo|
62736763|NCT04087941|EXPERIMENTAL|VM-202|
62158315|NCT00732498|EXPERIMENTAL|ESHAP followed by Zevalin and Rituximab|Etoposide, Methylprednisolone, Cytarabine, Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.
62533098|NCT04125849|ACTIVE_COMPARATOR|Thoraco-laparoscopic esophagectomy|Treated by thoraco-laparoscopic esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
62533099|NCT04125849|ACTIVE_COMPARATOR|Mediastinoscopy-assisted transhiatal esophagectomy|Treated by mediastinoscopy-assisted transhiatal esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
62533100|NCT06414720||Endometriosis patients|Patients diagnosed with endometriosis attending the Obstetrics and Gynecology Clinic at the Santa Maria della Misericordia Hospital in Udine, who have not yet started medical therapy.
62158316|NCT04513925|EXPERIMENTAL|Atezolizumab + Tiragolumab|Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
62158317|NCT04513925|ACTIVE_COMPARATOR|Durvalumab|Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.
62533101|NCT04600102||GROUP 1|Healthy able-bodied individuals with no history of lower extremity trauma.
62533102|NCT04600102||GROUP 2|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
62533103|NCT06199063|EXPERIMENTAL|Self-Stretching Exercises Group (SSEG)|Self-stretching (SS) is defined as stretching applied by the individual to himself/herself. For this application, firstly the painful area was determined, and stretching was applied to the muscle with pain. Firstly, the participant stood with his/her arm free on the side to be stretched and lateral flexed his/her head. With his/her other hand, he/she applied 10 seconds of stretching in the direction of lateral flexion, a 10-second rest period was given between each stretching, and this method was performed with a total of 10 repetitions.
62533104|NCT06199063|EXPERIMENTAL|Post-Isometric Relaxation Exercises Group (PIREG)|Post-isometric relaxation (PIR) was performed by a physiotherapist in a supine position. The physiotherapist sat on the head side of the patient. The painful side was determined, and the physiotherapist fixed the head with his/her hand and performed 50% voluntary isometric contraction of the painful muscle for 10 seconds. Then, the physiotherapist asked the patient to relax and stretch for 10 seconds to lateral flexion. This method was 10 repetitions with 10 seconds of rest between each repetition.
62533105|NCT06199063|EXPERIMENTAL|Reciprocal-Inhibition Exercises Group (RIEG)|Reciprocal inhibition (RI) was applied by a physiotherapist in a supine position. The physiotherapist sat on the head side of the patient. The painful side was determined, and the physiotherapist fixed the head with his/her hand and performed 50% voluntary isometric contraction of the antagonist of the painful muscle for 10 seconds. Then physiotherapist asked the patient to relax and stretch for 10 seconds in the lateral flexion direction. This method was 10 repetitions and there were 10 seconds of rest between each repetition.
62533106|NCT01323751|EXPERIMENTAL|Treat Regimen|ACY-1215 Bortezomib Dexamethasone
62533107|NCT05379231|EXPERIMENTAL|Speech Intelligibility with CROS device|"The focus of this study is on Speech Intelligibility (SI), evaluated by the US Matrix Test, which measures a speech recognition threshold (SRT) in dB SNR (signal to noise ratio).~Therefore each participant will perform the tests with the experimental rechargeable CROS transmitter (CROS) in different interventions, like comparison to monaural fitting and unaided condition.~All participants will perform the same tests. The order of the intervention in the speech test is randomized, but will be performed in the same visit by each participant."
62533108|NCT03509805|EXPERIMENTAL|OSA in obese patient during pregnancy|OSA in polysomnography
62533109|NCT03509805|EXPERIMENTAL|no OSA in obese patient during pregnancy|no OSA in polysomnography
62533110|NCT02518516||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (rosuvastatin, high doses of atorvastatin, and high doses of simvastatin between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
62533111|NCT02518516||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
62533112|NCT02743910||Stage II-III breast cancer|Up to 229 newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. ptDNA blood samples as well as a representative tumor tissue sample from both the diagnostic and surgical procedure (if available) will be collected.
62533113|NCT03093389|EXPERIMENTAL|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
62533114|NCT03093389|EXPERIMENTAL|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
62158318|NCT04692441|OTHER|Intervention|All participants undergo the same intervention: Drinking heavy cream and undergoing MRI.
62158319|NCT06232005|ACTIVE_COMPARATOR|25 Patients with recurrent urethral stricture undergoing visual internal urethrotomy only.|Standard procedure of visual internal urethrotomy only for urethral stricture
62158320|NCT06232005|EXPERIMENTAL|25 Patients with recurrent urethral stricture undergoing visual internal urethrotomy with intralesio|intralesional injection of mitomycin-c following the standard visual internal urethrotomy
62533115|NCT03093389|EXPERIMENTAL|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
62533116|NCT03093389|EXPERIMENTAL|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
62533117|NCT06460207|EXPERIMENTAL|Positive stimuli neurofeedback|Participants will encounter only positive stimuli during the fMRI task but will be tested on both positive and negative valence stimuli during the behavioral memory tests.
62533118|NCT06460207|EXPERIMENTAL|Negative stimuli neurofeedback|Participants will encounter only negative stimuli during the fMRI task but will be tested on both positive and negative valence stimuli during the behavioral memory tests.
62533119|NCT01119716||All Enrolled Participants|Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
62533120|NCT01242995||pancreatobiliary disorders/thin scope|All patients will be evaluated with cholangioscopy and/or pancreatoscopy using the thin scope.
62533121|NCT04158388|EXPERIMENTAL|EXPERIMENTAL DIET GROUP|
62533122|NCT04158388|OTHER|CONTROL GROUP|
62533123|NCT04158388|EXPERIMENTAL|EXPERIMENTAL MASSAGE GROUP|That group received moderate pressure digital manual therapy.
62533124|NCT04158388|EXPERIMENTAL|EXPERIMENTAL PLACEBO GROUP|That group was treated with a US (in off mode) without conductive gel. Placebo group.
62533125|NCT01235195|ACTIVE_COMPARATOR|Sertraline 50 mg capsules|
62533126|NCT01235195|ACTIVE_COMPARATOR|Sertraline 50 mg tablet|
62533127|NCT02718508|NO_INTERVENTION|Standard Care|All enrolled adolescents will continue to receive standard trauma center care, a brief intervention during their hospitalization by a trauma center social worker which is required by institutional policy.
62533128|NCT02718508|EXPERIMENTAL|Standard Care plus e-Parenting Group|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
62533129|NCT02140411|EXPERIMENTAL|Ranibizumab|Ranibizumab treatment
62533130|NCT05151666|EXPERIMENTAL|Hemodialysis Patients|
62533131|NCT01489631|ACTIVE_COMPARATOR|epidural analgesia|The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.
62533132|NCT01489631|ACTIVE_COMPARATOR|local infiltration|The second group will receive local infiltration with ropivacaine of the knee during surgery.
62533133|NCT01489631|ACTIVE_COMPARATOR|local infiltration and gabapentin|The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.
62533134|NCT03821870||Standard treatment|Standard first line treatment
62533135|NCT06402617|PLACEBO_COMPARATOR|Pulmonary vein isolation with diagnostic RETRO-Mapping only|"All patients will undergo standard pulmonary vein isolation (PVI) procedures with 3D electroanatomic mapping using the CARTO™ system (Biosense Webster, USA), or the EnSite X™ system (Abbott, USA). A decapolar catheter will be inserted into the coronary sinus. A 3D electroanatomic map of the left atrium will be created and all pulmonary veins will be identified. Radio-frequency ablation will be performed to achieve PVI.~After the PVI procedure, patients in the control arm will have the same mapping for identification and categorisation of focal sources, but no adjunctive ablation. RETRO-Mapping will be performed using custom-built hardware called Tau20 that has been validated for reproducibility against existing commercial technologies."
62533136|NCT06402617|EXPERIMENTAL|Pulmonary vein isolation with adjunctive ablation guided by RETRO-Mapping|In addition to and after the PVI procedure, patients the intervention arm will then have RETRO-Mapping performed of the remaining atria and atrial fibrillation cycle length measured in coronary sinus and left atrial appendage. Each segment will be mapped for 30 seconds and the activation pattern categories; if focal activation is identified, it will then be ablated. A further 30 seconds will be mapped at the same segments post-ablation to determine effect. The coronary sinus and left atrial appendage cycle length will be documented at the start of RETRO-Mapping and after each lesion set.
62533137|NCT01851239||medical ICU inpatients|
62533138|NCT01851239||surgical ICU inpatients|
62533139|NCT04644835|EXPERIMENTAL|LESW group|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
62533140|NCT04644835|SHAM_COMPARATOR|Control group|This group of patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
62533141|NCT00955526|EXPERIMENTAL|Istradefylline 20mg|
62533142|NCT00955526|EXPERIMENTAL|Istradefylline 40mg|
62533143|NCT00955526|PLACEBO_COMPARATOR|Placebo|
62533144|NCT04301908||antiviral therapy group|Patients with chronic hepatitis B and cirrhosis were treated with antiviral drugs
62533145|NCT02861742|OTHER|Study procedure|Delivery of questionnaires, Questionnaire T1 to fill, Questionnaire T2 to fill, Questionnaire T3 to fill, Questionnaire T4 to fill, Questionnaire T5 to fill
62533146|NCT00699374|EXPERIMENTAL|Arm A|sunitinib arm
62533147|NCT00699374|ACTIVE_COMPARATOR|Arm B|sorafenib arm
62533148|NCT01323712|PLACEBO_COMPARATOR|Placebo|
62533149|NCT04013230|ACTIVE_COMPARATOR|Usual care|Usual care according to regular treatment routines at the clinic.
62533150|NCT04013230|ACTIVE_COMPARATOR|Web-COP|Usual care plus group sessions and a web-based treatment program
62533151|NCT00313339|NO_INTERVENTION|Control Group|A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
62533152|NCT00313339|EXPERIMENTAL|Treatment Group|Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.
62533153|NCT06483568|EXPERIMENTAL|Positive Psychology Intervention Activities|Four week intervention with four weekly activities including gratitude journal, random acts of kindness, self-compassionate letter, and capitalizing on positive events activities.
62533154|NCT06483568|SHAM_COMPARATOR|Personal Organization Activities|Control participants will complete procedure-matched activities related to personal organization, including writing in a completed tasks journal, completing a weekly task burst, productivity letter, and talking to others about tasks activities.
62533155|NCT02390609|EXPERIMENTAL|Group 1: Sequence 1 (ABC)|Participants will receive Treatment A (Ibrutinib 560 milligram \[mg\] capsules \[reference\] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus \[+\] / minus \[-\] 2) days will be maintained between each treatment period.
62736764|NCT05780008|EXPERIMENTAL|Eat My ABCs|"The experimental arm will receive the 14-week program including three main components: (1) Eat My ABCs child curriculum, (2) child fruit/vegetable letters to parents, and (3) program cookbook."
62533156|NCT02390609|EXPERIMENTAL|Group 1: Sequence 2 (BCA)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533157|NCT02390609|EXPERIMENTAL|Group 1: Sequence 3 (CAB)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533158|NCT02390609|EXPERIMENTAL|Group 1: Sequence 4 (ACB)|Participants will receive Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533159|NCT02390609|EXPERIMENTAL|Group 1: Sequence 5 (BAC)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533160|NCT02390609|EXPERIMENTAL|Group 1: Sequence 6 (CBA)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533161|NCT02390609|EXPERIMENTAL|Group 2: Sequence 1 (AFDE)|Participants will receive Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533162|NCT02390609|EXPERIMENTAL|Group 2: Sequence 2 (DAEF)|Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533163|NCT02390609|EXPERIMENTAL|Group 2: Sequence 3 (EDFA)|Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533164|NCT02390609|EXPERIMENTAL|Group 2: Sequence 4 (FEAD)|Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules \[reference\] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
62533165|NCT02119923|EXPERIMENTAL|Working memory training|
62533166|NCT02119923|PLACEBO_COMPARATOR|Placebo training|
62533167|NCT04791514|EXPERIMENTAL|Treprostinil Palmitil Inhalation Powder|Participant received a single dose of TPIP 112.5 micrograms (μg) via oral inhalation on Day 1. The participant then entered into a 16-week Extended Use Treatment (EUT) Period during which TPIP, administered via oral inhalation, was titrated up to a mean daily dose of 320 μg.
62533168|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
62533169|NCT00704574||A|
62533170|NCT01016886|EXPERIMENTAL|1|
62533171|NCT02472223|ACTIVE_COMPARATOR|Betadine 5%|One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
62533172|NCT02472223|PLACEBO_COMPARATOR|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
62533173|NCT03986827|EXPERIMENTAL|Cool Kids Anxiety Program - Social Enhanced (CK-E)|CK-E is a G-CBT treatment developed specifically for treatment of youth SAD. The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session.
62533174|NCT03986827|ACTIVE_COMPARATOR|Cool Kids Anxiety Program (CK)|"The standard Cool Kids Anxiety Program is a treatment program based on generic CBT techniques such as cognitive restructuring and gradual exposure.~The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session."
62533175|NCT04305587|EXPERIMENTAL|Active Obesity|Part B
62533176|NCT04305587|PLACEBO_COMPARATOR|Placebo Obesity|Part B
62533177|NCT04305587|EXPERIMENTAL|Active T2DM|Parts A and C
62533178|NCT04305587|PLACEBO_COMPARATOR|Placebo T2DM|Parts A and C
62533179|NCT02879734|NO_INTERVENTION|Without Omentopexy|Patients that did not undergo prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter
62533180|NCT02879734|EXPERIMENTAL|With Omentopexy|Patients that underwent prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter. Intervention = Prophylactic laparoscopic omentopexy
62533181|NCT02069483|ACTIVE_COMPARATOR|Motivational Interviewing|Subjects will engage in motivational interviewing and come up with messages to motivate quitting during the activity.
62533182|NCT02069483|ACTIVE_COMPARATOR|Tailored Feedback|Subjects will use reasons for quitting that they provided during the phone baseline for the text messages and audio recordings.
62533183|NCT03812744|EXPERIMENTAL|WCCE|
62533184|NCT03812744|PLACEBO_COMPARATOR|Placebo|
62533185|NCT03565458|EXPERIMENTAL|gemigliptin|gemigliptin single dose
62533186|NCT03565458|EXPERIMENTAL|dapagliflozin|dapagliflozin single dose
62533187|NCT03565458|EXPERIMENTAL|gemigliptin and dapagliflozin|co-administration of gemigliptin and dapagliflozin
62533188|NCT03565458|EXPERIMENTAL|empagliflozin|empagliflozin single dose
62533189|NCT03565458|EXPERIMENTAL|gemigliptin and empagliflozin|co-administration of gemigliptin and empagliflozin
62533190|NCT05703269|ACTIVE_COMPARATOR|SSRS = single fraction stereotactic radiosurgery|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions. SSRS has recently become a standard-of-care treatment for patients with 1-4 brain metastases and is also commonly used for patients with up to 15 metastases, due to improved neurocognitive outcomes compared to whole brain radiotherapy.
62533191|NCT05703269|EXPERIMENTAL|FSRS = fractionated stereotactic radiosurgery|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
62533192|NCT01447420|EXPERIMENTAL|Peginterferon Alfa-2a Plus Ribavirin|
62533193|NCT02387515|EXPERIMENTAL|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology.
62533194|NCT02760992|ACTIVE_COMPARATOR|Oral Baclofen|Subject will start baclofen at a 5 mg oral dose every 8 hours. Oral baclofen will be increased incrementally and self-administered over 13 days to a maximum dose of 20 mg every 8 hours. Following IV administration, subjects will be changed back to oral baclofen at a 15 mg dose self-administered every 8 hours and tapered off of baclofen over 15 days.
62533195|NCT02760992|EXPERIMENTAL|IV Baclofen|Subjects will be crossed over to 16 mg intravenous baclofen infused over 120 or 150 minutes every 8 hours for 11 doses.
62533196|NCT02266134|EXPERIMENTAL|Standardized Implementation, Patients|Sites in standardized condition arm will receive the standard implementation of measurement-based care intervention (PHQ-9).
62533197|NCT02266134|EXPERIMENTAL|Tailored Implementation, Patients|Sites in the tailored condition arm will receive the tailored implementation of measurement-based care intervention (PHQ-9).
62533198|NCT02266134|EXPERIMENTAL|Standardized Implementation, Therapists|Sites randomized to the standardized condition will be expected to use the measurement-based care intervention (PHQ-9) prior to each session with a depressed client and they will work as a team to maximize fidelity.
62533199|NCT02266134|EXPERIMENTAL|Tailored Implementation, Therapists|Sites randomized to the tailored condition will develop a site-specific protocol for use of the measurement-based care intervention (PHQ-9), and they will work as a team to maximize the fit of measurement-based care to this clinic.
62533200|NCT01796613|ACTIVE_COMPARATOR|Vaginal Ring - intermittent regimen|3 weeks ring use followed by one week of no ring use to allow menstruation
62533201|NCT01796613|ACTIVE_COMPARATOR|Vaginal Ring - continuous regimen|3 weeks of ring use with no off period. The next ring is immediately inserted after the previous one
62533202|NCT06351475|EXPERIMENTAL|20% Albumin + Ringer Lactate group|Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
62533203|NCT06351475|ACTIVE_COMPARATOR|Control group|Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.
62533204|NCT06432270||diabetic group|Patients with a diagnosis of diabetes mellitus who are about to undergo general anesthesia who are expected to undergo laparoscopic surgery
62533205|NCT06432270||Non-diabetic group|Nondiabetic patients anticipating laparoscopic surgery who are about to undergo general anesthesia
62533206|NCT01433549|OTHER|Lotrafilcon B / Senofilcon A|Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
62533207|NCT01433549|OTHER|Senofilcon A / Lotrafilcon B|Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
62533208|NCT05427201|EXPERIMENTAL|DLPFC-rTMS + ACT|Active DLPFC-rTMS with ACT treatment
62533209|NCT05427201|ACTIVE_COMPARATOR|Sham-rTMS + ACT|Sham delivered rTMS with ACT treatment
62533210|NCT04128020|EXPERIMENTAL|Nivolumab|Nivolumab: 0.3, 0.5, or 1.0 mg/kg IV, days 1 \& 15
62533211|NCT04128020|EXPERIMENTAL|Nivolumab + Azacitidine|Azacitidine 8,16, 24 mg/m\^2, days 1-5 Nivolumab @MTD (1.0 mg/kg or lower), days 8 \& 15
62533212|NCT04407208|EXPERIMENTAL|Convalescent plasma recipient|Recipients receive 3 times of each 100 ml convalescent plasma on day 0, 3, and 6
62533213|NCT04635293|ACTIVE_COMPARATOR|patients who were administered levosimendan at a dose of 0.1µg/Kg/min for 24 hours prior to surgery|
62533214|NCT04635293|PLACEBO_COMPARATOR|patients who were not administered levosimendan prior to surgery|
62533215|NCT03468335|OTHER|Single Arm|"Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
62533216|NCT04023162|EXPERIMENTAL|Biomedical (Physiotherapy) group|Therapy Exercise and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
62533217|NCT04023162|EXPERIMENTAL|Biopsychosocial (Graded Activity) group|Operant Conditioning implement in Physiotherapy, Therapy Exercises and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
62533218|NCT04023162|NO_INTERVENTION|Usual care|Usual care and written instructions on Therapy Exercise and Back School for self-care.
62533219|NCT01741051|EXPERIMENTAL|HEPA Filter|HEPA filter(s) placed in the participant's home from approximately 10 weeks gestation until birth.
62533220|NCT01741051|NO_INTERVENTION|Control|
62533221|NCT03916510|EXPERIMENTAL|Dosing schedules 1 to 4|"Dosing Group 1:~- Loading dose pre chemoradiation (CRT) - 1x10\^12 viral particles (vp)~Dosing Group 2:~* Loading dose pre CRT - 1x10\^12 vp~* Maintenance dose post CRT - 1x10\^12vp~Dosing Group 3:~* Loading doses pre CRT - 3x10\^12vp~* Maintenance dose post CRT - 3x10\^12vp~Dosing Group 4:~* Loading dose pre CRT - 3x10\^12vp~* Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 3x10\^12vp~* Maintenance post CRT - 3x10\^12vp"
62533222|NCT01470768|OTHER|Arm 1 - AA Formula with DHA and ARA|Marketed AA formula with Docosahexanoic Acid (DHA) and Arachidonic Acid (ARA)
62533223|NCT01470768|OTHER|Arm 2 - AA Formula with alternative levels of DHA and ARA|
62533224|NCT02589314||root planning|
62533225|NCT02767882|ACTIVE_COMPARATOR|Group D1|Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
62533226|NCT02767882|EXPERIMENTAL|Group D2|4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
62533227|NCT02767882|PLACEBO_COMPARATOR|Group C|4ml bolus injection of 0.9% saline will be given intravenously prior to incision
62533228|NCT00732550|EXPERIMENTAL|Single trocar|Patients will undergo cholecystectomy by the single trocar approach
62533229|NCT00732550|ACTIVE_COMPARATOR|Standard lap cholecystectomy|Standard lap choly
62533230|NCT00553306|EXPERIMENTAL|Arm I|Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
62533231|NCT00527865|EXPERIMENTAL|1|6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo
62533232|NCT00527865|EXPERIMENTAL|2|6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo
62533233|NCT00527865|EXPERIMENTAL|3|6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo
62533234|NCT00527865|EXPERIMENTAL|4|6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo
62533235|NCT00948727|EXPERIMENTAL|Dose adjustment according CN activity|
62533236|NCT02906566|OTHER|Older Group Ages 55-75|Active and Placebo. Participants received retinol lotion on one arm and placebo to match on the other arm.
62533237|NCT02906566|NO_INTERVENTION|Young Group Ages 18-25|Participants in the group will give tissue sample only for comparison.
62533238|NCT02256527||Promus Premier|observational data
62533239|NCT04007991|EXPERIMENTAL|Ecopipam HCI 2 mg/kg/day|Ecopipam HCl 12.5-, 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings
62533240|NCT04007991|PLACEBO_COMPARATOR|Placebo|Matching Placebo tablets taken orally in the evening
62533241|NCT03420664|EXPERIMENTAL|Cast immobilisation|A below knee cast is applied in order to achieve ankle immobilisation for one hour
62533242|NCT03420664|EXPERIMENTAL|Orthosis (VACOped) immobilisation|A below knee orthosis which allows for ankle movement is applied for one hour.
62533243|NCT00388076|EXPERIMENTAL|Part 1|pazopanib and paclitaxel
62533244|NCT00388076|EXPERIMENTAL|Part 2|pazopanib, paclitaxel, and carboplatin
62533245|NCT00388076|EXPERIMENTAL|Part 3|pazopanib, paclitaxel, and lapatinib
61975861|NCT05817188||Dementia patients|This register-based project will include all patients diagnosed with dementia and registered in the Swedish Registry for Cognitive/Dementia Diseases. Identification of cases and control and data collation are carried out by Swedish authorities.
62533246|NCT02655666||Medtronic MiniMed Paradigm® REAL-Time System|Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor
62533247|NCT05495958|PLACEBO_COMPARATOR|Prescribe topical placebo eye drop|
62533248|NCT05495958|ACTIVE_COMPARATOR|Prescribe topical Vitamin D eye drop|
61975862|NCT01148758|EXPERIMENTAL|Single Arm|
62533249|NCT05189782||Subjects of the GNC-038 clinical trial (1)|Patients enrolled in the GNC-038 Phase Ib/II clinical trial in Shanghai Ruijin Hospital.
62533250|NCT05189782||Non-malignant controls (2)|Patients who have tonsillectomy due to obstructive sleep apnea and hyponea syndrome.
62533251|NCT02183207|EXPERIMENTAL|PEG insertion arm via EG Scan|Percutaneous endoscopic insertion of gastrostomy via visualization through E.G. ScanTM
62533252|NCT04276363|EXPERIMENTAL|Thrive Professional Learning plus ParentCorps|1) Professional Development, Program Training and Coaching; 2) Program for Parents of Pre-K Students; and 3) Program for Pre-K Students. The three intervention components are expected to strengthen relationships and communication between parents and teachers and promote safe, nurturing and predictable environments, which contribute to child mental health and achievement.
62533253|NCT04276363|EXPERIMENTAL|Thrive Professional Learning only|Best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders.
62533254|NCT04276363|EXPERIMENTAL|Inspire Professional Learning|Led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
62533255|NCT05182320||OrthoPath|
62533256|NCT05182320||Control|
62533257|NCT06288503|EXPERIMENTAL|Intervention|Hydrolysed rice protein formula
62533258|NCT06288503|ACTIVE_COMPARATOR|Control|Cow's milk based extensively hydrolysed formula
62533259|NCT06415877|PLACEBO_COMPARATOR|placebo|beef tongue stitched
62533260|NCT06415877|SHAM_COMPARATOR|sham comparator|episio model
62533261|NCT06415877|EXPERIMENTAL|experimental group|modified tripe coated veal
62533262|NCT05190809|EXPERIMENTAL|Study group|Group of female patients who will undergo Goldilocks mastectomy in which they will receive an autologous fat grafting in the remaining breast flaps
62533263|NCT03244501|EXPERIMENTAL|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
62533264|NCT03244501|EXPERIMENTAL|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
62533265|NCT03244501|SHAM_COMPARATOR|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
62533266|NCT03151408|EXPERIMENTAL|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
62533267|NCT03151408|PLACEBO_COMPARATOR|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
62533268|NCT00654966|EXPERIMENTAL|1|Heart failure patients
62533269|NCT00654966|ACTIVE_COMPARATOR|2|Healthy subjects
62533270|NCT00369655|EXPERIMENTAL|Treatment (ziv-afibercept)|Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62533271|NCT04864405|ACTIVE_COMPARATOR|Morning administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient wake up time
62533272|NCT04864405|ACTIVE_COMPARATOR|Evening administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient bed time
62533273|NCT06160570|ACTIVE_COMPARATOR|IMRT|Intensive Modulated Radiation Therapy
62533274|NCT06160570|ACTIVE_COMPARATOR|3DCRT|3-Dimension Conformal Radiation Therapy
62533275|NCT00870597|EXPERIMENTAL|1|Multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
62533276|NCT00870597|EXPERIMENTAL|2|Multifocal IOL implantation without transconjunctival vitrectomy
62533277|NCT01250197|EXPERIMENTAL|Formulation A|AR-12286 Ophthalmic Solution Formulation A
62533278|NCT01250197|EXPERIMENTAL|Formulation B|AR-12286 Ophthalmic Solution Formulation B
62533279|NCT04576299||Healthcare workers.|"Survey developed specifically for the objective of this study: Healthcare worker perception of patient safety in times of pandemic.~The application will be done through a digital questionnaire in the surveymonkey platform (Link of the instrument: https://es.surveymonkey.com/r/COVIDSP)"
62533280|NCT05965453||Participants received thoracic endovascular aortic repair with Castor single branch stent graft|Participants who have an inadequate proximal landing zone received thoracic endovascular aortic repair by meant of the Castor single branch stent graft
62533281|NCT01563276||Progressive Supranuclear Palsy|Patients with a diagnosis of probable or possible PSP as defined by the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria.
62533282|NCT01563276||Parkinson's Disease|"Idiopathic PD according to the UK Parkinsons Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)"
62533283|NCT01563276||Healthy Control|
62533284|NCT06405217|EXPERIMENTAL|Recombinant human thyroid stimulating hormone group|Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
62533285|NCT06405217|NO_INTERVENTION|Withdraw group|Thyroid hormone withdraw for 4-6 weeks
62533286|NCT03035344||ALL paediatric patients|Metabolome study in children diagnosed with ALL after bone marrow biopsy
62533287|NCT03035344||Healthy matched controls|Metabolome study in healthy children matched for gender and age with the patients group
62533288|NCT02205983|EXPERIMENTAL|2 mg hydromophone|Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
62533289|NCT02205983|EXPERIMENTAL|4 mg hydromphone|Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
62533290|NCT02205983|EXPERIMENTAL|1000 mg acetaminophen|Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
62533291|NCT02205983|PLACEBO_COMPARATOR|Dextrose|Healthy adult volunteers will recieve Dextrose (placebo).
62533292|NCT01064050|EXPERIMENTAL|trachea-bronchial stent (Novatech)|
62533293|NCT01064050|NO_INTERVENTION|control|
62533294|NCT02928367||Pneumonia patients|rectal swab (4x) divided over two time points (day 0 and day 28) nasopharyngeal swab (2x) divided over two time points (day 0 and day 28) blood draw (90ml) divided over two time points (day 0 and day 28)
62533295|NCT02928367||Healthy subjects|rectal swab (2x) nasopharyngeal swab (2x) blood draw (70ml)
62533296|NCT06355999|EXPERIMENTAL|Color Feedback|Observers are told if the color but not if the shape was correctly identified
62533297|NCT06355999|EXPERIMENTAL|Shape Feedback|Observers are told if the shape but not if the color was correctly identified
62533298|NCT02761005|EXPERIMENTAL|23S rRNA wt|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains without mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.
62533299|NCT02761005|EXPERIMENTAL|23S rRNA mutation|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains with mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week for the eradication of H. pylori,
62533300|NCT01706237|EXPERIMENTAL|Shield|A shield (similar to a contact lens) is placed on the eye after myopic LASIK procedure.
62533301|NCT02739945|OTHER|Open cubital tunnel release|In situ decompression (MacKinnon and Novak 2005) is made through a 6-10 cm longitudinal incision along the course of the ulnar nerve midway between the medial epicondyle and the olecranon.
62533302|NCT02739945|OTHER|Endoscopic cubital tunnel release|Endoscopic release follows Hoffmann's technique (Hoffmann 2006) that demonstrated the safety and efficacy of this technique in a cadaveric model and in a clinical study.
62533303|NCT04917289|EXPERIMENTAL|Treatment Arm|Patients in this arm will receive treatment or change current adjuvant therapy immediately after detecting CTC.
62533304|NCT04917289|NO_INTERVENTION|Control Arm|Patients in this arm will keep follow-up after detecting CTC until radiology evidence of recurrence appear.
62533305|NCT02958423|EXPERIMENTAL|Transcranial DCS Healthy Volunteers|5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)
62533306|NCT02958423|EXPERIMENTAL|Transspinal DCS Healthy Volunteers|5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)
62533307|NCT02958423|EXPERIMENTAL|Transcranial DCS CPP patients|5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
62533308|NCT02958423|EXPERIMENTAL|Transspinal DCS CPP patients|5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
62533309|NCT06330181|ACTIVE_COMPARATOR|Virtual reality (VR) game 1|Participants will be asked to play a virtual reality game twice a day for 10 days.
62533310|NCT06330181|ACTIVE_COMPARATOR|Virtual reality (VR) game 2|Participants will be asked to play a virtual reality game twice a day for 10 days.
62533311|NCT02336035|NO_INTERVENTION|Cast immobilization|"Cast immobilization for 5 weeks from primary injury/reduction. Thereafter active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
62533312|NCT02336035|EXPERIMENTAL|Operation|"Operation with a volar plate. Cast immobilization for 2 weeks after operation, thereafter active motion without weight for 4 weeks. 6 weeks after operation the patients are allowed active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
62533313|NCT06179927|EXPERIMENTAL|QT robot treatment|Twenty children from the experimental group will undergo the treatment using QT Robot and the tablet.
62533314|NCT06179927|EXPERIMENTAL|Traditional treatment|Twenty children belonging to the control group will be subjected to the same training but in a traditional way, that is, by presenting image stimuli in a paper format.
62533315|NCT00605761|EXPERIMENTAL|Cohort 1|50 mg treatment
62736765|NCT04835220|NO_INTERVENTION|Control Group|Electronic pill bottle cap (MEMs bottle cap) with no Telehealth calls
62533316|NCT00605761|EXPERIMENTAL|Cohort 2|150 mg treatment
62533317|NCT04048044|ACTIVE_COMPARATOR|Telomere length, GigaHz exposure|Measurement of white blood cell telomeres before and yearly for 5 years
62533318|NCT02932306|EXPERIMENTAL|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent \[%\]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
62533319|NCT02932306|PLACEBO_COMPARATOR|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
62533320|NCT04164225|EXPERIMENTAL|Qigong|Qigong exercises, focused on a mind-body connection
62533321|NCT04164225|ACTIVE_COMPARATOR|P.Volve|P.Volve exercises, focused on just physical movement
62533322|NCT04320654|EXPERIMENTAL|advice of staying active|The patients will be advised to stay as physically active as possible and continue their everyday activities as normally as possible.
62533323|NCT04320654|EXPERIMENTAL|walking program|Patients will be encouraged to go about their normal daily activities. At week one, patients will be asked to familiarize themselves with wearing the pedometer and recording their daily steps in a walking diary for the subsequent 7 days. The patients will return to see the physiotherapist at the end of week one to discuss any issues with the program, pedometer or recording of desired information. A step target for week two will be agreed between the physiotherapist and the patient by referring to the mean daily step count recorded at baseline, and the average step count calculated from the walking diary
62533324|NCT04320654|EXPERIMENTAL|Backward walking|All patients will be instructed to walk at their desired pace 3 days per week with a steady rhythm. The duration of each training session will initially be 15 minutes and will gradually increase, and finally reach 25 minutes, for every session (Hao Chen, 2011). There will be no constraint or indication about head and trunk position during backward training
62533325|NCT04320654|EXPERIMENTAL|Targeted home-based hip exercise|Patients who will be assigned in this group will perform a hip exercise program for six weeks, three times / week to ensure an adequate recovery between exercise sessions (appendix V). The strengthening exercises will focus on strengthening the gluteus maximus (GMax), gluteus medius (GMed), gluteus minimus (GMin) and short hip external rotator muscles (Distefano et al., 2009).
62533326|NCT04320654|NO_INTERVENTION|control group|The patients will not be given any intervention and will be asked to come after 6 weeks for re-assessment
62533327|NCT02823418||No neuraxial labor analgesia|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
62533328|NCT02823418||Neuraxial labor analgesia|For patients who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
62533329|NCT03857750||Elderly (>80 years)|Patients planned for elective surgery above 80 years
62533330|NCT03857750||Younger (18-40 years)|Patients planned for elective surgery between 18-40 years
62533331|NCT02730351|EXPERIMENTAL|FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®|Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.
62736766|NCT04835220|OTHER|Telehealth intervention group|Electronic pill bottle cap (MEMs bottle cap) with regular telehealth visits to the veterans at the VAMCs on the stewardship program. These visits will involve contacting the veterans by telephone, administering a questionnaire to review their medication-taking behavior for oral chemotherapy, and potentially contacting the treating oncologist in the event that the veterans are at risk of non-adherence (based on their responses).
62533332|NCT02730351|EXPERIMENTAL|FP 250 mcg + Placebo ELLIPTA®|Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.
62533333|NCT01690741|EXPERIMENTAL|Nerofe|Nerofe administered intravenously 3x/week
62533334|NCT04425135|EXPERIMENTAL|Camrelizumab +apatinib mesylate+Pemetrixed + Carboplatin|Camrelizumab combined with apatinib mesylate,Pemetrixed and Carboplatin in the treatment（4-6 cycle）of effective (CR, PR, SD) patients continued to be treated with Camrelizumab combined with apadine mesylate until PD, toxicity intolerance, and other reasons that the researcher thinks need to stop the research treatment.
62533335|NCT03544710|EXPERIMENTAL|Bathing|Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
62533336|NCT03544710|NO_INTERVENTION|No bathing|"No intervention done for participants in this arm. They go through the routine ward procedure as below.~Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
62533337|NCT01841476|EXPERIMENTAL|POL6326|2-hour single intravenous infusion doses of POL6326
62533338|NCT00620555|EXPERIMENTAL|gabapentin|
62533339|NCT01208623||2D|2D digital venography images alone
62533340|NCT01208623||3D|3D rotational venography
62533341|NCT01208623||Combine|combined MDCT angiography/venography
62533342|NCT00475150|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62533343|NCT02546401|EXPERIMENTAL|Group 1|"Patients will perform their bolus for 2 weeks before meals (BE) and for 2 weeks after meals (AF).~Intervention: drug (insulin Aspart)"
62533344|NCT02546401|EXPERIMENTAL|Group 2|"Patients will perform their bolus for 2 weeks after meals (AF) and for 2 weeks before meals (BE).~Intervention: drug (insulin Aspart)"
62533345|NCT01987973|ACTIVE_COMPARATOR|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
62533346|NCT01987973|EXPERIMENTAL|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
62533347|NCT04471974|EXPERIMENTAL|Safety Cohort|Patients receive 96mg pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62533348|NCT04471974|EXPERIMENTAL|Cohort A: Transdifferentiated mCRPC|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62533349|NCT04471974|EXPERIMENTAL|Cohort B: mCRPC without evidence of transdifferentiation|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62533350|NCT06149715|EXPERIMENTAL|Bottle Filter Arm|Receive a filter which attaches to a bottle. If the household does not have an eligible tap, they are randomly assigned to either this arm or the Bucket Filter Arm.
62533351|NCT06149715|EXPERIMENTAL|Bucket Filter Arm|Receive a filter which attaches to a bucket. If the household does not have an eligible tap, they are randomly assigned to either this arm or the Bottle Filter Arm.
62533352|NCT06149715|EXPERIMENTAL|Tap Filter Arm|All households with an eligible tap (compatible with filter and runs) will receive a tap filter.
62533353|NCT03472417|ACTIVE_COMPARATOR|Active partial rebreathing device|
62533354|NCT03472417|SHAM_COMPARATOR|Dummy partial rebreathing device|
62533355|NCT01913925|ACTIVE_COMPARATOR|Tyrosine-Containing Food Bar|150 mg/kg dose of tyrosine per administration, administered twice
62158321|NCT06341998|EXPERIMENTAL|sirolimus combined with chemotherapy treat recurrent/refractory yolk sac tumor in children|This study employed an open single-group clinical laboratory design method (Simon Phase II study) to investigate the efficacy and safety of combining sirolimus with TIC chemotherapy (albumin-paclitaxel + isocyclophosphamide + carboplatin) in the treatment of children with recurrent/refractory vitellocystoma. AFP levels were assessed after each course of treatment, while imaging evaluations were conducted every two courses. The remission rate following chemotherapy in this single-group clinical trial was compared to that reported in the literature for treating recurrent/refractory yolk sac tumor, evaluating overall remission rate (ORR) and event-free survival rate (EFS), as well as monitoring and recording chemotherapy-related side effects.
62533356|NCT01913925|PLACEBO_COMPARATOR|Placebo bar|0 mg/kg dose of tyrosine per administration, administered twice
62533357|NCT04296058||SOX4 high|Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group
62533358|NCT04296058||SOX4 low|Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group
62736767|NCT04036201|EXPERIMENTAL|Group 1(22-24 mm)|Group 1 (patients with axial length between 22 and 24 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyalurindase 150 IU (1 ml) to a total volume of 7 ml.
62533359|NCT02129244|ACTIVE_COMPARATOR|NCM Plus Intervention|The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.
62533360|NCT02129244|NO_INTERVENTION|Standard/Usual Care|Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.
62533361|NCT01877226|EXPERIMENTAL|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
62533362|NCT01054235|EXPERIMENTAL|experimental|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
62533363|NCT00123474|EXPERIMENTAL|1|
62533364|NCT00123474|EXPERIMENTAL|2|
62533365|NCT00123474|EXPERIMENTAL|3|
62533366|NCT00123474|EXPERIMENTAL|4|
62533367|NCT06483321|EXPERIMENTAL|Creatine Supplementation|Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate
62533368|NCT06483321|PLACEBO_COMPARATOR|Placebo|Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
62533369|NCT01948713|EXPERIMENTAL|Group 1|Strengthening of pelvic floor muscles.
62533370|NCT01948713|EXPERIMENTAL|Group 2|Strengthening of pelvic floor muscles associated with strengthening of hip muscles.
62533371|NCT00851318|EXPERIMENTAL|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
62533372|NCT00851318|EXPERIMENTAL|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
62533373|NCT02730117|EXPERIMENTAL|Early renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, starting within 12 hours after randomization~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
62533374|NCT02730117|PLACEBO_COMPARATOR|Conventional renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, after the patients reached at least one of the following criteria;~1. pH \< 7.15 or serum HCO3 \< 15 mEq/L~2. serum K \>= 6 mEq/L~3. Signs of volume overload or P/F ratio \< 200~4. BUN \> 60 mg/dL~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
62533375|NCT01445210|ACTIVE_COMPARATOR|0,2% Ropivacaine|"Patients randomized to the experimental group receive a continuous infusion of 0,2 % Ropivacaine by elastomeric infusion pump at 5 ml/h in the saphenous catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
62533376|NCT01445210|PLACEBO_COMPARATOR|Control|"Patients randomized to the control group receive a continuous infusion of isoton saline by elastomeric infusion pump at 5 ml/h in their catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
62533377|NCT00671918|EXPERIMENTAL|Lymphoseek, Lymphatic mapping, Injection|
62533378|NCT02064114|ACTIVE_COMPARATOR|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
62736768|NCT04036201|EXPERIMENTAL|Group 2(24.1-26 mm)|Group 2 (patients with axial length between 24.1 and 26 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyaluronidase 150 IU (1 ml) to a total volume of 7 m
62158322|NCT00376935|PLACEBO_COMPARATOR|1|Participants will receive palifermin placebo injection on Days 1, 2, and 3
62158323|NCT00376935|EXPERIMENTAL|2|Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
62158324|NCT00376935|EXPERIMENTAL|3|Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
62158325|NCT00376935|EXPERIMENTAL|4|Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
62158326|NCT00965471|EXPERIMENTAL|managed group|
62533379|NCT02064114|ACTIVE_COMPARATOR|control group|conventional treatment, followed for a period of 3,6 and 12 months after the procedure.
62533380|NCT02102516|EXPERIMENTAL|SPRIX(intranasal ketorolac tromethamine)|Based on subject weight
62533381|NCT02677714|EXPERIMENTAL|Patients with breast cancer receiving chemotherapy|After reconstitution and radiolabeling, 99mTc-rhAnnexin V-128 was administered as a single intravenous bolus of 350 MBq +/- 10% at baseline, after the 2nd cycle, after the 4th cycle and 12 weeks after AC chemotherapy.
62736769|NCT04900246|EXPERIMENTAL|Visual Inspection + BWX Radiographic Assessment + Assessment of the iTero Element 5D scan|In this group, the evaluations will follow this order. First the visual inspection, then the bitewing X-ray assessment and, lastly, the iTero assessment.
62533382|NCT03512418|EXPERIMENTAL|PrEPsteps|Participants receive the digital pills with Truvada, plus the PrEPsteps intervention that is programmed at the randomization study visit (Study Visit 2). Participants will use PrEPsteps and the digital pill to measure Truvada adherence for months 1-3.
62533383|NCT03512418|ACTIVE_COMPARATOR|Control|Participants receive digital pills with Truvada alone. Participants will use digital pills with Truvada for months 1-3.
62714244|NCT06555770|EXPERIMENTAL|Müzik grubu|"Pain levels will be tested with VAS 10 minutes before the surgery, and anxiety levels with the VAS-A and Spielberg Continuous Anxiety Scale. According to the randomization, the patient in the music intervention group will first be asked by the researcher to select his favorite music from the playlist. The playlist will be created using the Spotify app. The playlist will include a total of 50 songs from each group (pop, Turkish art music, local Turkish and religious music), including ten songs. Options will be shown to the patient on the phone (Apple/MU783TU/A) and the music he wants will be added to the playlist.~The patient will be told that the selected music will be listened to for 15 minutes during cataract surgery."
62714245|NCT06555770|NO_INTERVENTION|Kontrol grubu|Pain levels will be tested with VAS 10 minutes before the surgery, and anxiety levels with the VAS-A and Spielberg Continuous Anxiety Scale. The patient in the control group will not be given any intervention.
62714246|NCT06705140|EXPERIMENTAL|Cohort 1: Group 1- (SD RSVt vaccine)|Participants will receive 2 intranasal administrations of SD RSVt vaccine
62714247|NCT06705140|PLACEBO_COMPARATOR|Cohort 1: Group 2-Control|Participants will receive 2 intranasal administrations of placebo
62533384|NCT00229983|EXPERIMENTAL|Motivational Enhancement Therapy|Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
62533385|NCT00229983|NO_INTERVENTION|Enhanced Standard Care|Adolescents who are randomized to Enhanced Standard Care will receive the usual care at the outpatient adolescent substance abuse program. This will include an evaluation by pediatric and mental health staff and could include treatment in a group therapy program, urine drug testing, buprenorphine replacement therapy (for those dependent on opioids), and psychopharmacology evaluation and management.
62533386|NCT05004584|EXPERIMENTAL|Wheat home-based|
62533387|NCT05004584|EXPERIMENTAL|Rye home-based|
62533388|NCT05004584|EXPERIMENTAL|Rye clinic-based|
62533389|NCT05004584|EXPERIMENTAL|Wheat clinic-based|
62533390|NCT05004584|EXPERIMENTAL|Wheat/Rye clinic-based with blood sampling|
62533391|NCT01383135|OTHER|Healty Volunteers|Normal volunteers to receive 5 to 14 mCi F18-FPPRGD2 by intravenous (IV) injection.
62533392|NCT01383135|EXPERIMENTAL|Breast Cancer|Breast cancer patients to receive 4 to 11 mCi F18-FPPRGD2 by IV injection.
62533393|NCT01383135|EXPERIMENTAL|Glioblastoma Multiform (brain)|Glioblastoma multiform patients to receive 5 to14 mCi F18-FPPRGD2 by IV injection.
62533394|NCT01383135|EXPERIMENTAL|Lung Cancer|Lung cancer patients to receive X to XX mCi F18-FPPRGD2 by IV injection.
62533395|NCT01589965|EXPERIMENTAL|Treatment group: T5|Small Lottery reward
62533396|NCT01589965|NO_INTERVENTION|Control group|
62533397|NCT01589965|EXPERIMENTAL|Treatment group T1|High Lottery reward
62533398|NCT04153383||TMAD|Tissue motion annular displacement (TMAD) of tricuspid valve annulus transesophageal echocardiography
62533399|NCT04622215|OTHER|ICIQ questionnaire|
62533400|NCT06223243|EXPERIMENTAL|stingless bee honey|stingless bee honey mouthrinse was prescribed to participants assigned to this group.
62533401|NCT06223243|ACTIVE_COMPARATOR|chlorhexidine|chlorhexidine mouthrinse was prescribed to participants assigned to this group.
62533402|NCT06223243|PLACEBO_COMPARATOR|normal saline|Normal saline mouthrinse was prescribed to participants assigned to this group.
62533403|NCT00527306|EXPERIMENTAL|I - Multivitamin|The multivitamin will contain 100% of the US reference daily intakes (recommended daily amounts) of vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, and E. It also contains several inactive ingredients including sodium bisulfite and gelatin.
62533404|NCT00527306|PLACEBO_COMPARATOR|II - Inactive Medication|The placebo will be a gelatin capsule filled with lactose.
62533405|NCT04040023|OTHER|I Group: PBMi|Non-drug intervention First part of PBM program (PBMi) Training part for medical care staff to improve transfusion practices
62533406|NCT04040023|EXPERIMENTAL|C Group: PBMc|"Patient Blood Management: full program~PBMi intervention and Drug intervention (systematic correction of pre- and postoperative iron and vitamin deficiencies, and erythropoietin preoperative treatment for anemic patient)"
62533407|NCT06178432|EXPERIMENTAL|Arm of CRG003 injection|The dose of CRG003 injection will be calculated according to the participant's weight with single intravenous infusion.
62533408|NCT02015559|EXPERIMENTAL|Arm I (mucoadhesive oral wound rinse)|Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
62533409|NCT02015559|NO_INTERVENTION|Arm II (no intervention)|Patients receive no intervention.
62533410|NCT05900128|ACTIVE_COMPARATOR|Intervention|asthmatic patients who receive the educative intervention
62533411|NCT05900128|PLACEBO_COMPARATOR|no intervention|asthmatic patients who don't receive the educative intervention
62533412|NCT03102801|ACTIVE_COMPARATOR|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
62533413|NCT03102801|ACTIVE_COMPARATOR|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
62533414|NCT00987389|EXPERIMENTAL|Plasma Exchange with Standard Glucocorticoids|Participants in this arm undergo plasma exchange and take a standard glucocorticoid dose.
62533415|NCT00987389|ACTIVE_COMPARATOR|No Plasma Exchange with Standard Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a standard glucocorticoid dose.
62533416|NCT00987389|EXPERIMENTAL|Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm undergo plasma exchange and take a reduced glucocorticoid dose.
62533417|NCT00987389|ACTIVE_COMPARATOR|No Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a reduced glucocorticoid dose.
62533418|NCT01459562|EXPERIMENTAL|NI-0501|
62533419|NCT01459562|PLACEBO_COMPARATOR|Placebo|
62533420|NCT01330459|ACTIVE_COMPARATOR|Hydrocodone/acetaminophen|"Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
62533421|NCT01330459|PLACEBO_COMPARATOR|Placebo|"Subject will receive placebo 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
62533422|NCT02427035|EXPERIMENTAL|Low|A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
62533423|NCT02427035|EXPERIMENTAL|High|A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
62533424|NCT05571865|OTHER|Control subjects (non-diabetic).|"Control subjects (non-diabetic):~10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)"
62533425|NCT05571865|OTHER|Diabetic Subjects|"Diabetic subjects:~10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)"
62533426|NCT05451992|PLACEBO_COMPARATOR|Placebo|Control group that will consume a placebo product
62533427|NCT05451992|EXPERIMENTAL|SuperFood|The superfood group will have to consume the superfood product (vegetable smoothie)
62533428|NCT05040438|EXPERIMENTAL|Autologous NK cell infusion combined with HAIC|HAIC of 5-FU (500 mg/m2, Q4W) and cisplatin (15 mg/m2, Q4W) will be administered for up to 4 cycles to patients with locally advanced HCC. Subjects who achieved sustained SD or better based on the mRECIST criteria after 2nd cycle of HAIC will be enrolled to receive 1x10\^9 cells VAX-NK/HCC infusion.
62533429|NCT01120509|EXPERIMENTAL|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
62533430|NCT02397408|EXPERIMENTAL|Diagnostic 11C- and 18F-choline PET/MR imaging|Patients are given 370 megabecquerel (MBq) 11C-Choline (11C) intravenously and 3 MBq/kg 18F-Choline (18F) intravenously prior to a whole-body PET/MR imaging
62533431|NCT00801580|EXPERIMENTAL|1|The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C \[cytarabine\]).
62533432|NCT05713968||patients with EAT-10 higher than 3 or frailty questionnaire higher than 2|patients may have high risk of aspiration
62533433|NCT05713968||patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients may have low risk of aspiration
62533434|NCT01404715|EXPERIMENTAL|Metformin and Imatinib Co-Adminisdered|Subjects will be dosed with Metformin (1850 mg) in conjunction with imatinib (600mg).
62533435|NCT01404715|EXPERIMENTAL|Metformin Alone|Subjects will be dosed with Metformin alone (1850mg)
62533436|NCT02299024|NO_INTERVENTION|Control|Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
62533437|NCT02299024|EXPERIMENTAL|Dual Modality Educational Intervention|"Patients in this arm are discharged from the ED with an additional information sheet about their prescribed opioid pain medication, via the intervention titled Additional Opioid Information. The sheet is read aloud to them by a research assistant. They are called 4-7 days later for a follow up survey."
62533438|NCT05789693|EXPERIMENTAL|Intervention|"Physical activity changes expected~Description:~* Develop four sessions in the Tutorial Action Plan of the school~* Connect several subjects aligned with the messages from the tutory~* Physical education teachers provide some insights about healty behaviours"
62533439|NCT05789693|NO_INTERVENTION|No intervention|"No Physical activity changes expected~Descrption:~- No intervention"
62533440|NCT06017076|PLACEBO_COMPARATOR|warming matress group|From the end of anesthesia, warming matriss at 40 ℃ was used for insulation until the end of surgery.
62533441|NCT06017076|EXPERIMENTAL|oral functional drinks group|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
62533442|NCT04311788|EXPERIMENTAL|Intervention group|Prophylactic self gripping mesh (Program, Medtronic) will be placed in rectorectus space to prevent incisional hernia.
62533443|NCT04311788|ACTIVE_COMPARATOR|Control group|Abdomen of the patients in the control group will be closed by using small stitch closure with suture to wound length of 4:1 and slowly absorbable monofilament suture.
62533444|NCT04059458|EXPERIMENTAL|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
62533445|NCT04059458|ACTIVE_COMPARATOR|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
62714248|NCT06705140|EXPERIMENTAL|Cohort 1: Group 3- (HD RSVt vaccine)|Participants will receive 2 intranasal administrations of HD RSVt vaccine
62714249|NCT06705140|PLACEBO_COMPARATOR|Cohort 1: Group 4-Control|Participants will receive 2 intranasal administrations of placebo
62714250|NCT06705140|EXPERIMENTAL|Cohort 2: Group 1- (LD RSVt vaccine)|Participants will receive 2 intranasal administrations of LD RSVt vaccine
62158327|NCT00965471|PLACEBO_COMPARATOR|control group|
62533446|NCT04769063|EXPERIMENTAL|Hip|
62533447|NCT04769063|EXPERIMENTAL|Knee|
62533448|NCT04769063|NO_INTERVENTION|Control|
62533449|NCT05201352|EXPERIMENTAL|Experimental arm|trifluridine/tipiracil + XB2001
62533450|NCT05201352|PLACEBO_COMPARATOR|Control arm|trifluridine/tipiracil + placebo
62714251|NCT06705140|EXPERIMENTAL|Cohort 2: Group 2- (SD RSVt vaccine)|Participants will receive 2 intranasal administrations of SD RSVt vaccine
62714252|NCT06705140|EXPERIMENTAL|Cohort 2: Group 3- (HD RSVt vaccine|Participants will receive 2 intranasal administrations of HD RSVt vaccine
62714253|NCT06705140|PLACEBO_COMPARATOR|Cohort 2: Group 4-Control|Participants will receive 2 intranasal administrations of placebo
62714254|NCT04406987||decompression|patients treated with decompression for lumbar spinal stenosis
62158328|NCT06197035|EXPERIMENTAL|COPCA (Coping With and Caring for Infants With Special Needs) Intervention|"The intervention will be delivered by COPCA coaches who follow the programme's theoretical and practical principles. Caregivers learnt how to stimulate their infant's development by challenging their motor behaviour with trial and error experiences.~This aim to empower the caregivers' competencies to stimulate the infant's daily development, by increasing their motor repertoire.~and enhancing their capacity to adapt movements to situations."
62158329|NCT06197035|ACTIVE_COMPARATOR|Standard physiotherapy|Standard care will be based on what paediatric physiotherapists generally assume to be useful to promote the development of infants with special needs. Standard care is heterogeneous and eclectic, uses parent training and often includes components of neurodevelopmental treatment with hands-on techniques.
62158330|NCT04161976|EXPERIMENTAL|LY900027|LY900027 administered to participants with type 1 diabetes mellitus (T1DM) using continuous subcutaneous insulin infusion (CSII) in one of two dosing periods.
62533451|NCT03056157|EXPERIMENTAL|Adaptive Disclosure for Moral Injury and Loss|AD-MIL is a manualized, 12-session individual psychotherapy designed to improve functioning and to reduce PTSD symptoms by facilitating Veterans doing corrective things in their life to heal and repair traumatic loss and moral injuries. The change agents are: (1) emotional-processing of traumatic loss and moral injuries and motivating a healing and action plan by writing therapeutic letters (e.g., to a lost unit member, to victims of personal transgressions, to people who transgressed); (2) skills training and behavioral contracting to improve functioning and targeting moral injury- and traumatic loss-related psychological and behavioral obstacles to positive and potentially habilitative engagements in occupational, relationship, and family roles; and (3) teaching self- and other-compassion and mindfulness. The goal is to redress the functional impact of moral emotions (anger, shame).
62533452|NCT03056157|ACTIVE_COMPARATOR|Present Centered Therapy|PCT is a manualized evidenced-based PTSD treatment used in several large-scale PTSD trials that focuses on improving day-to-day functioning. It incorporates the essential therapeutic elements common to different types of psychotherapies, including supportive empathic listening and unconditional positive regard. The therapist plays an active role but does not impart any systematic training. The focus is to create an understanding of how the symptoms of PTSD are related to day-to-day difficulties and to help patients develop new, more adaptive functional responses to these stressors with a problem-focused and problem-solving approach. In prior trials, PCT showed equivalent change to active therapies at the last follow-up. The VA offers PCT as an evidence-based therapy for PTSD.
62533453|NCT03096743|EXPERIMENTAL|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
62533454|NCT03096743|EXPERIMENTAL|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
62533455|NCT04896749|EXPERIMENTAL|Group A/ Nerve mobilization group|In this group, patients will receive nerve mobilization exercises along with routine physical therapy. Patients will also be given home plan for cervical isometric exercises.
62533456|NCT04896749|ACTIVE_COMPARATOR|Group B/ Conventional physical therapy group|In this group, patients will receive routine physical therapy and also given home plan for cervical isometric exercises
62533457|NCT04763564|EXPERIMENTAL|Liraglutide then Placebo|Participants will be randomly assigned to 6-week Liraglutide treatment. Then after a 5-day washout, treatment will continue with 6 weeks of placebo.
62533458|NCT04763564|EXPERIMENTAL|Placebo then Liraglutide|Participants will be randomly assigned to 6-week placebo treatment. Then after a 5-day washout, treatment will continue with 6 weeks of Liraglutide.
62533459|NCT03858192|EXPERIMENTAL|Elective colorectal surgery|Patients who are expected to undergo a major colorectal surgery procedure will be recruited to this study preoperatively and followed-up until three months postoperatively.
62533460|NCT03858192|EXPERIMENTAL|Emergency abdominal surgery|Patients who are admitted as an emergency and undergo abdominal surgery will be recruited from general surgery wards either preoperatively or within 48 hours of surgery. They will be followed-up until three month postoperatively.
61975863|NCT02969512|EXPERIMENTAL|HIPPER|The HIPPER group will receive 12 interactive online modules (\~20 minutes each). HIPPER participants will receive email or phone contact (participant preference) to provide them with website portal access consisting of the web address, and simple instructions to access the website using personalized encrypted login information to the site.
62158331|NCT04161976|ACTIVE_COMPARATOR|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII in one of two dosing periods.
62158332|NCT00296686|EXPERIMENTAL|tranylcypromine|sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3
62158333|NCT01878955||->6 4-9 mm follicles in bilateral ovaries|Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
62158334|NCT03782545|EXPERIMENTAL|Treatment with the truSculpt RF device|Subjects will be treated with the truSculpt RF device
62158335|NCT06244888|EXPERIMENTAL|System Identification|All participants who lose at least 3% of their initial body weight will be asked to participate in a system identification experiment every day for 52 weeks.
62158336|NCT03843333|EXPERIMENTAL|CHW Intervention|CHWs will deliver three intervention components (Tai Ji Quan: Moving for Better Balance, Behavioral Activation, and Resource Navigation) to all participants at intervention sites over a 6-month period.
62533461|NCT03858192|EXPERIMENTAL|Medical patients|Patients admitted under general medicine with an infection will be recruited from general medicine wards within 48 hours of admission. They will be followed-up until three month post-admission
62533462|NCT06634251||male group|This group consists of 250 healthy male adults whose pelvic CT scans were analyzed to define the optimal antegrade entry point and anatomical parameters for anterior column fixation. The fluoroscopic visualization technique and screw placement were simulated to assess anatomical variations and feasibility specific to the male cohort.
62158337|NCT03843333|ACTIVE_COMPARATOR|Enhanced Usual Care|Comparison participants will receive a guide on community resources for older adults, and assistance from the research team in making initial connections to resources if desired.
62158338|NCT01804140||Cohort|
62158339|NCT02206607|EXPERIMENTAL|PF-04937319 IR MST|Reference formulation
62158340|NCT02206607|EXPERIMENTAL|PF-04937319 MR 1|Test MR #1
62158341|NCT02206607|EXPERIMENTAL|PF-04937319 MR 2|Test MR #2
62158342|NCT02206607|EXPERIMENTAL|PF-04937319 MR 3|Test MR #3
62158343|NCT05438745||Experimental Group|Ambulance Service Staff participating in pet therapy sessions.
62158344|NCT06441214||Retrospective cohort|All patients with Waldenström's macroglobulinemia enrolled in Pre-Reimbursement Access Program (PRAP) of Zanubrutinib, as per Compassionate Use Program (CUP) of Zanubrutinib, and patients treated with commercial drug (Brukinsa®) from PRAP closure to the study start.
62158345|NCT06441214||Prospective cohort|Patients with Waldenström's macroglobulinemia treated with Zanubrutinibin clinical practice enrolled from the study start up to 12 months.
62158346|NCT06585735|EXPERIMENTAL|Group A|Group I receive 15 gms of Protein supplements (proteolytic enzyme with 70000 Hb unit tyrosine \[HUT\] fortified with 15 gms of whey protein), given daily for 6 weeks.
62714255|NCT04406987||fusion|patients treated with decompression with fusion for lumbar spinal stenosis
61975864|NCT02969512|ACTIVE_COMPARATOR|OASIS Online Educational Webinars|To provide a comparable level of education, participants in the Online Education group will receive 2 hours of OASIS online educational webinars as per current practice.
61975865|NCT03258489|ACTIVE_COMPARATOR|Transcutaneous nervous electric stimulation (TENS)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after TENS. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
61975866|NCT03258489|ACTIVE_COMPARATOR|Interferential electrical stimulation (IES)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after Interferential electrical stimulation (IES). The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
61975867|NCT03258489|PLACEBO_COMPARATOR|TENS and IES Placebo|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after of the TENS and IES placebo. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
61975868|NCT00933309|EXPERIMENTAL|Group 1|Exemestane alone
61975869|NCT00933309|EXPERIMENTAL|Group 2|Exemestane plus Avandamet
61975870|NCT00536601|EXPERIMENTAL|Regimen CBV (patients with HL or NHL)|Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.
61975871|NCT00536601|EXPERIMENTAL|Regimen M200/M120 (patients with MM or amyloidosis)|Patients receive 200 or 120 mg/m\^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.
61975872|NCT00536601|EXPERIMENTAL|Regimen BuC2iv (patients with ALL, AML, HL, or NHL)|Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.
61975873|NCT00536601|EXPERIMENTAL|Regimen CT6 (patients with ALL)|Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.
61975874|NCT00536601|EXPERIMENTAL|Regimen CTtCp (patients with other solid tumors)|Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
61975875|NCT00536601|EXPERIMENTAL|Regimen VCp (patients with testicular cancer)|Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.
61975876|NCT00536601|EXPERIMENTAL|Regimen TtC1500/ECpM (patients with NBL or SRBCT)|Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.
61975877|NCT04837157|EXPERIMENTAL|Intervention Group|9 treatment sessions will be performed with the ATLAS2030 exoskeleton. The rehabilitation sessions last approximately 90 minutes. Two sessions are scheduled per week, for two weeks.
61975878|NCT06456060|ACTIVE_COMPARATOR|Control (Alvogyl) Group|In Control Group, after flushing the socket with normal saline a gauze soaked with Alvogyl will be used to cover the socket..
61975879|NCT06456060|EXPERIMENTAL|Study (Honey) Group|In the Study (Honey) Group, after flushing the socket with normal saline, 2 ml of Honey soaked in a sterile gauze will be applied to cover the socket.
61975880|NCT04337749|ACTIVE_COMPARATOR|Chorhexidine scrub|Chorhexidine scrub was given to participants for 2 weeks
61975881|NCT04337749|ACTIVE_COMPARATOR|ZnO-NPs socks|ZnO-NPs socks were given to participants for 2 weeks
61975882|NCT04337749|ACTIVE_COMPARATOR|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks were given to participants for 2 weeks
61975883|NCT04337749|PLACEBO_COMPARATOR|Placebo|Placebo socks were given to participants for 2 weeks
61975884|NCT04212104|EXPERIMENTAL|watch mukbang|participants are assigned to watch a dim sum mukbang by a famous host, Peggie Neo (https://youtu.be/2dRf535eAPK, accessed: 2018-9-12)
61975885|NCT04212104|PLACEBO_COMPARATOR|watch non-food content video|participants are assigned to watch the Big Bang Theory, The Euclid Alternative ( https://youtu.be/V8kUL9owk6Q, accessed: 2018-9-12).
61975886|NCT01199523|PLACEBO_COMPARATOR|Placebo|
61975887|NCT01199523|EXPERIMENTAL|mirabegron high dose|
61975888|NCT01199523|EXPERIMENTAL|mirabegron medium dose|
61975889|NCT01199523|EXPERIMENTAL|mirabegron low dose|
61975890|NCT01199523|ACTIVE_COMPARATOR|moxifloxacin|
61975891|NCT03352206||2-Drug Treated Communities|"Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
62158347|NCT06585735|ACTIVE_COMPARATOR|Group B|Group II will receive equivalent dose of plain protein supplement without proteolytic enzyme, given daily for 6 weeks.
62158348|NCT05327270|EXPERIMENTAL|Nivolumab|Nivolumab will be given as an injection directly into an oral lesion.
62158349|NCT02797899|ACTIVE_COMPARATOR|Palatal donor site received PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and received platelet rich fibrin and periodontal pack as assigned randomly by a flip of coin during the screening visits.
62158350|NCT02797899|ACTIVE_COMPARATOR|Palatal donor site NOT receiving PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and sutured followed by periodontal pack application.
62158351|NCT03535545|EXPERIMENTAL|Healthy Individuals|Healthy volunteers will receive \[68Ga\]CBP8 and undergo PET imaging.
62158352|NCT03535545|EXPERIMENTAL|Lung Cancer Subjects|Lung cancer patients will receive \[68Ga\]CBP8 and undergo PET imaging.
62158353|NCT03535545|EXPERIMENTAL|Pulmonary Fibrosis Subjects|Idiopathic pulmonary fibrosis patients or patients with other types of interstitial lung disease with a fibrotic component will receive \[68Ga\]CBP8 and undergo PET imaging.
62158354|NCT05365230|ACTIVE_COMPARATOR|On-demand personalized follow-up care|On-demand personalized follow-up care (on-demand access to a Wellness Beyond Cancer Program (WBCP) nurse and an annual follow-up by telephone with WBCP nurse following the patient's annual mammogram). Both groups of participants will have yearly mammograms (current standard of care) organized by their healthcare provider.
62533463|NCT06634251||female group|This group consists of 250 healthy female adults whose pelvic CT scans were analyzed to define the optimal antegrade entry point and anatomical parameters for anterior column fixation. The fluoroscopic visualization technique and screw placement were simulated to assess anatomical variations and feasibility specific to the female cohort.
62533464|NCT00471952|EXPERIMENTAL|1|Maxalt 10mg with Caffeine 75mg
62533465|NCT00471952|ACTIVE_COMPARATOR|2|Maxalt 10mg plus Placebo
61975892|NCT03352206||3-Drug Treated Communities|"Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
62158355|NCT05365230|ACTIVE_COMPARATOR|Guideline-based follow-up care|Guideline-based follow-up care (i.e. current standard of care). Both groups will have yearly mammograms (current standard of care) organized by their healthcare provider.
62158356|NCT05591937|ACTIVE_COMPARATOR|Symptom Severity Decision-Making|Using current symptom severity level to guide triaging and adapting level of care.
62158357|NCT05591937|EXPERIMENTAL|Data-Driven Decision-Making|Using data-driven algorithm that considers social determinants of mental health, early life adversity/stress, predisposing, enabling and need influences upon health services use, and comprehensive mental health status to guide triaging and adapting level of care.
62158358|NCT06090760|EXPERIMENTAL|Mindfulness Intervention Group|Mindfulness training will be provided to the participant after randomization for dealing with social media use.
62158359|NCT06090760|NO_INTERVENTION|Waitlist Control Group|No mindfulness training will be provided to the participants.
62533466|NCT00471952|PLACEBO_COMPARATOR|3|Double placebo
62533467|NCT02443259||late preterms from pre eclamptic mothers|late preterms born to pre eclamptic mothers
62533468|NCT02443259||late preterms|late preterm neonates
62533469|NCT06370130|EXPERIMENTAL|K1|a group administered 0.2 mg/kg of esketamine
62533470|NCT06370130|ACTIVE_COMPARATOR|K2|a group administered esketamine of 0.3 mg/kg (K2)
62533471|NCT04029311|EXPERIMENTAL|Combination Therapy with Preferred Mask|Preferred Mask refers to a type of existing medical mask used for PAP therapy.
61975893|NCT04904887|OTHER|Assessment of intermediate vision, defocus curve|"Standardized logarithm of the minimum angle of resolution (logMAR) charts were used for visual acuity measurement at 4 m, 80 cm, and 40 cm.~he binocular defocus curve: The binocular defocus curve was done to evaluate the functional range of vision. The curve was obtained while the patient wearing his distance correction to provide the best distance visual acuity in both eyes. The test was performed under photopic conditions (85 candelas/m2) using ETDRS charts at a distance of 4m with the introduction of defocusing lenses from +1.00 D to -4.00 D in 0.50 D steps."
61975894|NCT04700618|EXPERIMENTAL|Study group|The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.
61975895|NCT04700618|PLACEBO_COMPARATOR|Control group|The control group had never been vaccinated with any pneumococcal vaccine.
61975896|NCT04519151|EXPERIMENTAL|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
61975897|NCT00656474|EXPERIMENTAL|1|GLYC-101 Active Retro-auricular Site (1 per participant)
61975898|NCT00656474|PLACEBO_COMPARATOR|2 Comparator|"Placebo Retro-auricular Site (1 per participant)~This arm undergoes laser ablation with subsequent Placebo gel administration"
61975899|NCT02324374|EXPERIMENTAL|Endocytoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
61975900|NCT02396433|EXPERIMENTAL|Carboplatin, eribulin, and E7449|This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
61975901|NCT01454947|EXPERIMENTAL|SA, AJ, PC|Participants are given all 3 interventions.
61975902|NCT01454947|EXPERIMENTAL|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
62158360|NCT03694210|EXPERIMENTAL|EndoRotor Therapy|Physicians will perform direct endoscopic necrosectomy using the EndoRotor in patients with walled off necrosis.
62158361|NCT01672255|ACTIVE_COMPARATOR|Trial 1-SSRI|90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac). Repeat 90 minute exercise after 6 week treatment.
62158362|NCT01672255|PLACEBO_COMPARATOR|Trial 2-Placebo|90 minute exercise at baseline with 6 weeks treatment with placebo. Repeat 90 minute exercise after 6 weeks treatment of placebo.
62158363|NCT04745338|PLACEBO_COMPARATOR|low caloric diet|low caloric diet (1200cal/day)
62158364|NCT04745338|ACTIVE_COMPARATOR|cryolipolysis|cryolipolysis 3 sessions one session every 6 weeks by 3max cool shaping device
62158365|NCT01874210||Hemodialysis|Hemodialysis patients
62158366|NCT01874210||Control|"1. Household contacts on the same diet~2. Healthy unrelated controls"
62158367|NCT04440956|EXPERIMENTAL|Intervention|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection."
62158368|NCT06035601|EXPERIMENTAL|Electronic health record (EHR)-integrated texting platform|Patients will be enrolled into a texting platform for the management of recurrent UTI.
62158369|NCT06035601|ACTIVE_COMPARATOR|Usual care|Patients will receive usual care through their providers.
62158370|NCT05832489|EXPERIMENTAL|Group A|Adult patients with ADHD (ADHD-P) receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)
62158371|NCT05832489|EXPERIMENTAL|Group B|Adult patients with attention deficit due to/emphasized by mood disorders (ADHD-HD) receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)
62158372|NCT05832489|EXPERIMENTAL|Group C|Adult Healthy controls receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)
62158373|NCT04876261|ACTIVE_COMPARATOR|Group A|Group A will receive Oliphenolia® bitter on intervention visit 1 followed by Oliphenolia® on intervention visit 2 and followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on the third and final intervention visit
62158374|NCT04876261|ACTIVE_COMPARATOR|Group B|Group B will receive Oliphenolia® on intervention visit 1 followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 2 and followed by Oliphenolia® bitter on the third and final intervention visit
62158375|NCT04876261|ACTIVE_COMPARATOR|Group C|Group C will receive La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 1 followed by Oliphenolia® bitter on intervention visit 2 and followed by Oliphenolia® on the third and final intervention visit
62158376|NCT03161509|EXPERIMENTAL|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
62158377|NCT03161509|EXPERIMENTAL|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
62158378|NCT01630239|EXPERIMENTAL|Visualise Thermal Therapy System|
62158379|NCT05301725||PPI group|PPI regimen
62158380|NCT05301725||P-CAB group|P-CAB regimen
62158381|NCT01906073|EXPERIMENTAL|intranasal fentanyl spray|Fentanyl for nasal administration (NF), is supplied as sprays containing a phosphate buffered solution of fentanyl citrate. NF is available in three strengths: 0.5 mg/ml, 1 mg/ml and 2 mg/ml in multiple-dose sprays. The corresponding doses are 50, 100 and 200 µg/puff. NF is applied as one puff in one nostril. One puff defines and equals one dose. Applying a puff to each nostril the upper dose can be increased to 400 µg. The doses used in this study are 50, 100, 200 ad 400µg. Fentanyl may be administered for up to 6 pain episodes/ 24 hours. For each pain episode, a dose of NF is self-administrated in one nostril. If pain relief is not achieved, another dose of NF could be administered in the opposite nostril after 15 minutes.
62158382|NCT01906073|ACTIVE_COMPARATOR|slow release morphine|The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
62533472|NCT04029311|EXPERIMENTAL|Combination Therapy with Custom Mask|Custom Mask refers to a mask which is supported by an interface which attaches directly to the patient's oral appliance.
62158383|NCT02168153|ACTIVE_COMPARATOR|Chiropractic Manipulative Therapy|Participants will complete questionnaires and biomechanical assessments, and additionally receive CMT treatment.
62158384|NCT02168153|PLACEBO_COMPARATOR|Wait-List Control Group|Participants will complete questionnaires and biomechanical assessments
62158385|NCT02001467|ACTIVE_COMPARATOR|Simulation-based training|Simulation-based training to an expert criterion followed by clinical training until proficiency and certification.
62158386|NCT02001467|NO_INTERVENTION|Control|No training is provided the control group participants.
62158387|NCT01659697||Intensive Lifestyle counseling|
62158388|NCT01659697||usual lifestyle counseling|
62158389|NCT04007822||Physiotherapists|Physiotherapists will be recruited using the following inclusion criteria: (1) two years of experience in treating patients with chronic pain, (2) currently working in an MSK outpatient clinic and (3) able to read and speak English to a level allowing satisfactory completion of the study procedures. There are no exclusion criterium. Potential participants will be recruited through the relevant gatekeeper. The gatekeeper will be responsible of forwarding the participant information sheet and consent form to the physiotherapists. Physiotherapists will be asked to demonstrate their interest by replying to the email. Any questions will be answered by the research team via email or phone.
62158390|NCT00782743||1|patients with required new anticoagulation with phenprocoumon 1/2 of them with a GFR\< 60 ml/min and \>15 ml/min
62158391|NCT00782743||2|patients with required therapy with ASS, 1/2 of them with a GFR \<60 ml/min and \>15 ml/min
62158392|NCT00234832|EXPERIMENTAL|Sibutramine|Subjects were randomized to receive sibutramine 10 mg once daily (QD) during the Treatment Period after a 6-week Lead-in Period
62533473|NCT02066103|EXPERIMENTAL|Treatment|
62533474|NCT00040768|EXPERIMENTAL|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who received prior bortezomib and achieved at least a partial response of at least 6 months duration may also receive therapy as above.
62158393|NCT00234832|PLACEBO_COMPARATOR|Placebo|Subjects were randomized to receive placebo QD during the Treatment Period after a 6-week Lead-in Period
62158394|NCT00234832|EXPERIMENTAL|Lead-in sibutramine|All subjects received 10 mg sibutramine QD during a 6-week Lead-in Period
62158395|NCT04182451|EXPERIMENTAL|Meso Wound Matrix and Standard of Care|This is a single arm study
62533475|NCT03866902|EXPERIMENTAL|Nutrition and Physical Activity Intervention|"Classes for the intervention mothers will be run by a bilingual interventionist and will last 105 minutes weekly for 12 weeks and then monthly for 6 months.~Classes for intervention group children will be 105 minutes weekly for 12 weeks and then monthly for 6 months."
62533476|NCT03866902|ACTIVE_COMPARATOR|English for Second Language Intervention|"Mothers in the control group will receive English as a Second Language (ESL) classes taught by professional ESL teachers; they will receive the same number of contacts and time as the intervention group mothers for 105 minutes weekly for 12 weeks and 105 minutes monthly for 6 months.~Children in the control group will be read to and color with crayons 105 minutes weekly for 12 weeks and then 105 minutes monthly for 6 months."
62533477|NCT04590066|NO_INTERVENTION|Holdout control|Participants will only receive the standard pharmacy messaging.
62533478|NCT04590066|EXPERIMENTAL|Unpacking Risks Treatment|Participants will be asked to think about the risks of catching the flu this flu season and to respond with the location they are most likely to catch the flu out of a list of given options (e.g. at work, at home).
62533479|NCT04590066|EXPERIMENTAL|Unpacking Risks Control|Participants will be asked to think about the risks of catching the flu this flu season and to respond to confirm that they have received the message.
62533480|NCT04590066|EXPERIMENTAL|Active Commitment Treatment|"Participants receive a gain framed notification that they are eligible for a flu shot. In addition, participants are told Many people find it helpful to make a plan to get their shot and are asked to commit by texting back I will get a flu shot. Depending on their response, participants receive a general reminder or a commitment reminder 3 days later."
62533481|NCT04590066|EXPERIMENTAL|Active Commitment Control|Participants receive a gain framed notification that they are eligible for a flu shot. Participants receive a general reminder 3 days later.
62533482|NCT04590066|EXPERIMENTAL|Self-Generated Social Norms Treatment|Participants will first receive a message enjoining them to consider 2 peers who would want them to vaccinate. Then they will be asked to do those peers a favor by getting a vaccine at their next opportunity. They will receive a reminder 3 days later.
62533483|NCT04590066|EXPERIMENTAL|Self-Generated Social Norms Control|articipants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
62533484|NCT04590066|EXPERIMENTAL|Foot-in-the-Door Treatment|Participants will first receive a message enjoining them to encourage someone else to receive a flu vaccine this year. They will then be given a message that they might copy-paste to forward to friends, thereby lowering the effort costs of messaging others. They will receive a reminder 3 days later.
62533485|NCT04590066|EXPERIMENTAL|Foot-in-the-Door Control|Participants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
62533486|NCT04590066|EXPERIMENTAL|Prosocial Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (i.e., protecting loved ones; preserving scarce resources).
62533487|NCT04590066|EXPERIMENTAL|Self-Oriented Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot.
62714256|NCT00770393|EXPERIMENTAL|1|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging.
62714257|NCT00770393|ACTIVE_COMPARATOR|2|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
62714258|NCT02131766|EXPERIMENTAL|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM.~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
62158396|NCT04031534|EXPERIMENTAL|Measure of hypoxia by F-Miso PET scan and RMI|Patient will undergo F-Miso PET scan and MRI to detect hypoxia. Imaging will be correlated with immunohistochemistry on tumour biopsy
62158397|NCT00889863|EXPERIMENTAL|Canakinumab|In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a \>0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
62158398|NCT00889863|PLACEBO_COMPARATOR|Placebo|Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a \>0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
62158399|NCT02267122|EXPERIMENTAL|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound.
62158400|NCT02267122|EXPERIMENTAL|Mupirocin ointment application|After placing the staples, a Mupirocin ointment application was placed covering the wound.
62158401|NCT02267122|NO_INTERVENTION|Conventional dressing|After placing the staples, a conventional dressing, without application of any special gauze or ointment, was placed covering the wound
62158402|NCT00455104||National Registry|To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
62158403|NCT06360445|EXPERIMENTAL|Olaparib Tablet test formulation 100mg|Treatment A: During the study session, healthy subjects were administered a single dose of Olaparib Tablet test formulation100mg under Fasting conditions(test)
62158404|NCT06360445|ACTIVE_COMPARATOR|Olaparib Tablet reference formulation 100mg|Treatment B: During the study session, healthy subjects were administered a single dose of Olaparib Tablet reference formulation 100mg under Fasting conditions(reference for Treatment A)
62158405|NCT06360445|EXPERIMENTAL|Olaparib Tablet test formulation 150mg(fast)|Treatment C: During the study session, healthy subjects were administered a single dose of Olaparib Tablet test formulation 150mg under Fasting conditions(test)
62158406|NCT06360445|ACTIVE_COMPARATOR|Olaparib Tablet reference formulation 150mg(fast)|Treatment D: During the study session, healthy subjects were administered a single dose of Olaparib Tablet reference formulation 150mg under Fasting conditions(reference for Treatment C)
62158407|NCT06360445|EXPERIMENTAL|Olaparib Tablet test formulation 150mg(fed)|Treatment E: During the study session, healthy subjects were administered a single dose of Olaparib Tablet test formulation 150mg under Fed conditions(test)
62158408|NCT06360445|ACTIVE_COMPARATOR|Olaparib Tablet reference formulation 150mg(fed)|Treatment F: During the study session, healthy subjects were administered a single dose of Olaparib Tablet reference formulation 150mg under Fed conditions(reference for Treatment E)
62158409|NCT04186819|EXPERIMENTAL|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
62158410|NCT02637466|EXPERIMENTAL|Vortioxetine|In cycle I of the study, participants will be randomized on to flexible-dose VTX (10-20 mg) versus. Vortioxetine starting dose will be 10 mg daily. Vortioxetine starting dose will be 10 mg daily with a dose escalation up to 20 mg daily at week #4. Study cycle II is an 8-week, open label treatment design for non-responders completing the Cycle I RCT. One treatment arm will continue VTX non-responders to 8 week VTX (10-20 mg/day) augmentation with cognitive behavioral therapy (10 sessions). The 2nd treatment arm will continue placebo non-responders who complete the RCT to VTX (10 to 20 mg/day). The third treatment arm will continue VTX responders/remitters who complete the RCT to open-label VTX for another 8-weeks to assess maintenance efficacy for up to 16 weeks.
62158411|NCT02637466|PLACEBO_COMPARATOR|Placebo|"In cycle I of the study, 80 eligible depressed women with breast cancer will be randomized into an 8-week, double-blind, placebo-controlled, flexible-dose vortioxetine (10-20 mg) treatment arm versus placebo arm.~Responders to placebo treatment will complete their study participation at the end of Cycle I, and will not proceed to Cycle II."
62158412|NCT01628822|EXPERIMENTAL|Active relaxation|
62158413|NCT01628822|PLACEBO_COMPARATOR|Placebo relaxation|
62158414|NCT00312546|EXPERIMENTAL|2A|Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
62158415|NCT00312546|EXPERIMENTAL|2B|Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
62533488|NCT04590066|EXPERIMENTAL|Prosocial + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (e.g., protecting loved ones; preserving scarce resources). The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
62533489|NCT04590066|EXPERIMENTAL|Self-Oriented + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
62158416|NCT00312546|EXPERIMENTAL|3A|VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
62533490|NCT04590066|EXPERIMENTAL|Dynamic + Static Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before and how many Americans got their flu shot last year.
62533491|NCT04590066|EXPERIMENTAL|Dynamic Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before.
62533492|NCT04590066|EXPERIMENTAL|Dynamic Norms Control|Participants will only receive a text message encouraging them to get a flu shot. They will not receive any norm information.
62533493|NCT04590066|EXPERIMENTAL|Sharing Humor|Participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
62736770|NCT04900246|EXPERIMENTAL|Visual Inspection + Assessment of the iTero Element 5D scan + BWX Radiographic Evaluation|In this group, the evaluations will follow this order. First the visual inspection, then the iTero assessment and, lastly, the bitewing X-ray assessment.
62158417|NCT00312546|EXPERIMENTAL|3B|Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
62158418|NCT00157209|EXPERIMENTAL|Tecemotide (L-BLP25) plus Best Supportive Care (BSC)|
62158419|NCT00157209|ACTIVE_COMPARATOR|Best Supportive Care (BSC) Alone|
62158420|NCT03603275||Patient/caregiver of Kovaltry or Jivi|Patients who are switching factor replacement products to Kovaltry or Jivi and patients who have switched factor replacement products to Kovaltry or Jivi previously
62158421|NCT03603275||Physician Group|Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network
62158422|NCT05357599|EXPERIMENTAL|Beta Blocker at EUS|
62158423|NCT04127695|EXPERIMENTAL|ABBV-0805 Dose 1 or Placebo|Participants will receive ABBV-0805 Dose 1 or Placebo.
62158424|NCT04127695|EXPERIMENTAL|ABBV-0805 Dose 2 or Placebo|Participants will receive ABBV-0805 Dose 2 or Placebo.
62736771|NCT04922372|EXPERIMENTAL|intervention arm copping veneered with composite resin|
62158425|NCT04127695|EXPERIMENTAL|ABBV-0805 Dose 3 or Placebo|Participants will receive ABBV-0805 Dose 3 or Placebo.
62158426|NCT04127695|EXPERIMENTAL|ABBV-0805 Dose 4 or Placebo|Participants will receive ABBV-0805 Dose 4 or Placebo. Note: This dosing group may be added after a review of data from dosing groups 1-3.
62158427|NCT04688554||Refractory Obsessive Compulsive Disorder|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical capsulotomy
62158428|NCT04688554||Refractory Pain|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
62158429|NCT04688554||Refractory Tremor|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical thalamotomy
62158430|NCT04688554||Refractory Depression|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
62158431|NCT06719570|EXPERIMENTAL|MK-8591A Sequence 1A|Participants will receive Doravine/Islatravir (DOR/ISL) fixed-dose combination (FDC) tablet under fasting conditions followed by a DOR/ISL FDC tablet under fed conditions followed by a single dose Doravine tablet and a single dose Islatravir capsule under fasting conditions.
62158432|NCT06719570|EXPERIMENTAL|MK-8591A Sequence 2A|Participants will receive DOR/ISL FDC tablet under fasting conditions followed by a single dose DOR tablet and a single dose ISL capsule under fasting conditions followed by DOR/ISL FDC tablet under fed conditions.
62158433|NCT06719570|EXPERIMENTAL|MK-8591A Sequence 1B|Participants will receive DOR/ISL FDC tablet under fed conditions followed by a DOR/ISL FDC tablet under fasting conditions followed by a single dose DOR tablet and a single dose ISL capsule under fasting conditions.
62158434|NCT06719570|EXPERIMENTAL|MK-8591A Sequence 2B|Participants will receive DOR/ISL FDC tablet under fed conditions followed by a single dose DOR tablet and a single dose ISL capsule under fasting condition followed by a DOR/ISL FDC tablet under fasting conditions.
62158435|NCT06719570|EXPERIMENTAL|MK-8591A Sequence 1C|Participants will receive a single dose DOR tablet and a single dose ISL capsule under fasting conditions followed by DOR/ISL FDC tablet under fasting conditions followed by followed by a DOR/ISL FDC tablet under fed conditions.
62158436|NCT06719570|EXPERIMENTAL|MK-8591A Sequence 2C|Participants will receive a single dose DOR tablet and a single dose ISL capsule under fasting conditions followed by DOR/ISL FDC tablet under fed conditions followed by followed by a DOR/ISL FDC tablet under fasting conditions.
62158437|NCT04362059|EXPERIMENTAL|Treatment Arm|Patients will be administered surfactant via COVSurf Drug Delivery System
62158438|NCT04362059|ACTIVE_COMPARATOR|Control Arm|Patients shall receive regular Standard of Care treatment
62158439|NCT02319304|OTHER|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:~FOLFOX: combination of drugs administered in a specific sequence as prescribed below.~* Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours~* Leucovorin: 200 mg/m2 IV bolus over 2 hours~* 5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours~Part II:~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
62158440|NCT01773707|EXPERIMENTAL|abatacept IV infusion|CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)
62533494|NCT04590066|EXPERIMENTAL|Humor Placebo|Participants will receive a text message encouraging them to get the flu shot. This message will include the same joke but participants will not be encouraged to share it.
62158441|NCT01773707|PLACEBO_COMPARATOR|Placebo|The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.
62158442|NCT01533896|NO_INTERVENTION|Control|Parents and children in the control group received routine primary care during the well child visit.
62158443|NCT01533896|EXPERIMENTAL|Grow Nicely|Grow Nicely multimedia program.
62158444|NCT03557307|EXPERIMENTAL|Benralizumab|Benralizumab subcutaneous injection
62158445|NCT03152409|ACTIVE_COMPARATOR|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
62158446|NCT03152409|PLACEBO_COMPARATOR|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
62158447|NCT01079117|ACTIVE_COMPARATOR|Sevre-Long™|slow release oral morphine
62158448|NCT01079117|ACTIVE_COMPARATOR|Methadone|Methodone
62158449|NCT06255132|EXPERIMENTAL|Patients undergoing open heart surgery|
62158450|NCT05543759||Cases|Children aged 6-59 months of both sexes from households established permanently in the catchment area of the selected health posts or health centers, meeting the SAM or MAM acute malnutrition case definitions described below with no medical complications and disability, and whose caregiver has granted consent to participate.
62158451|NCT03873038|EXPERIMENTAL|Part 1: Panel A- MK-2060 (8 mg)|Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.
62158452|NCT03873038|EXPERIMENTAL|Part 1: Panel B- MK-2060 (20 mg)|Participants will receive a single 20-mg dose of MK-2060 via IV infusion.
62158453|NCT03873038|EXPERIMENTAL|Part 1: Panel C- MK-2060 (40 mg)|Participants will receive a single 40-mg dose of MK-2060 via IV infusion.
62714259|NCT02131766|PLACEBO_COMPARATOR|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week.
62714260|NCT04524988|ACTIVE_COMPARATOR|Fundamentals of Laparoscopic Surgery (FLS)|This group will undergo 2.5h of training on the current standard laparoscopic simulation trainer (FLS), including the following tasks: peg transfer, intracorporeal knot tying and ligating loop.
62158454|NCT03873038|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive a single dose of placebo via IV infusion.
62158455|NCT03873038|EXPERIMENTAL|Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance|Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 3 weeks (Weeks 2-4)
62158456|NCT03873038|PLACEBO_COMPARATOR|Part 2: Placebo|Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via IV infusion weekly for 3 weeks (Weeks 2-4)
62158457|NCT06034444||interRAI LTCF|Nursing homes in Quebec where interRAI evaluations and care plans will be introduced.
62533495|NCT04590066|EXPERIMENTAL|No Humor Condition|Participants will receive a text message encouraging them to get the flu shot.
62158458|NCT03664271|EXPERIMENTAL|in-clinic video intervention|Intervention: Caregivers will watch an educational video in clinic, and also be given information about how to access the video from home (ideal condition). The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
62158459|NCT03664271|ACTIVE_COMPARATOR|at home video intervention|Intervention: Caregivers will be given information about how to watch the video at home, but will not watch it in clinic (real-world condition).The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
62158460|NCT03664271|NO_INTERVENTION|usual care|Control: Caregivers will not watch the educational video, but will be given access to it at the conclusion of the study.
62158461|NCT05749315|ACTIVE_COMPARATOR|Group A|Group A Speech Language Delayed Children
62158462|NCT05749315|ACTIVE_COMPARATOR|Group B|Group B Speech Language Delayed Children
62158463|NCT01448993|PLACEBO_COMPARATOR|Placebo|Taking placebo 3 times per week for four weeks
62158464|NCT01448993|ACTIVE_COMPARATOR|AZI|
62533496|NCT04590066|EXPERIMENTAL|Connecting the Past Self to the Future Self Treatment|"Participants will receive a text message prompt to recall the negative experience of getting sick. When asked, Do you wish you could have avoided getting sick by getting a simple shot?, participants will have the chance to respond Y for yes or N for no. Regardless of their response, they will be prompted with a second text message to connect their past experience with present-day opportunities for preventative care (getting a flu shot) to protect the future self from the flu."
62533497|NCT04590066|EXPERIMENTAL|Connecting the Past Self to the Future Self Control|In the first text message, participants will receive a simple text message encouragement to receive a flu shot. In the second text message, they will receive a reminder of the appointment time and provider name.
62158465|NCT01291745||Patients with MYELODYSPLASTIC SYNDROMES|Patients diagnosed with MDS according to FAB, WHO and IPSS classifications. Patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine).
62158466|NCT04999800|EXPERIMENTAL|Pembrolizumab combined with Anlotinib|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week, combined with Pembrolizumab 200 mg iv on day 1, and every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated
62158467|NCT01479842|EXPERIMENTAL|Treatment (enzyme inhibitor, chemo, monoclonal antibody)|Patients receive BTK inhibitor PCI-32765 PO QD on days 1-28. Patients also receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue receiving BTK inhibitor PCI-32765 PO in the absence of disease progression or unacceptable toxicity.
62158468|NCT03157414|ACTIVE_COMPARATOR|Empagliflozin|10 mg once daily for 24 weeks
62158469|NCT03157414|PLACEBO_COMPARATOR|Placebo|1 capsule once daily for 24 weeks
62158470|NCT06000202|EXPERIMENTAL|Laser Arm|Non-ablative thermal-only Er:YAG laser (Fotona Dynamis) treatment using R11 and PS03 handpieces
62158471|NCT06000202|SHAM_COMPARATOR|Sham Arm|The same procedure is applied but with a sham handpiece.
62158472|NCT06719739|EXPERIMENTAL|Functional IOL|Experimental group
62158473|NCT06719739|OTHER|Monofocal IOL|Control Group
62158474|NCT00424476|PLACEBO_COMPARATOR|Placebo|Placebo
62158475|NCT00424476|EXPERIMENTAL|Belimumab 1 mg/kg|Belimumab 1 mg/kg
62736772|NCT04922372|ACTIVE_COMPARATOR|control arm copping veneered with manual layering|
62158476|NCT00424476|EXPERIMENTAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg
62158477|NCT02782273|ACTIVE_COMPARATOR|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
62158478|NCT02782273|ACTIVE_COMPARATOR|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
62158479|NCT05007002|EXPERIMENTAL|Robot-based therapy|Chronic stroke patients receiving robot-based therapy
62158480|NCT00007709||1|
62158481|NCT05473468|EXPERIMENTAL|Treatment group|
62158482|NCT04789616|EXPERIMENTAL|Maraviroc (Celsentri)|Maraviroc (Celsentri) will be administered to this group. Participants will be administered a dose of 300mg to be taken twice per day for the duration of the exercise intervention (8 weeks).
62158483|NCT04789616|PLACEBO_COMPARATOR|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. Participants will be administered the placebo identical to the 300mg maraviroc tablet for the duration of the exercise intervention (8 weeks)."
62158484|NCT00958971|EXPERIMENTAL|TKI258 - Positive|These are the participants who had a positive T(4;14) status
62158485|NCT00958971|EXPERIMENTAL|TKI258 - Negative|These are the participants who had a negative T(4;14) status
62158486|NCT00958971|EXPERIMENTAL|TKI258 Non-interpretable|These are the participants who had a non-interpretable T(4;14) status
62158487|NCT01621087|EXPERIMENTAL|Safflower oil|
62158488|NCT01621087|NO_INTERVENTION|Control group (no diet instruction)|
62158489|NCT02152111|EXPERIMENTAL|Dietary Supplement: Coconut flour|Diet hipoernergetic plus 26g/day coconut flour during three months (12weeks).
62158490|NCT02152111|ACTIVE_COMPARATOR|Nutritional Treatment|All patients received an individualized diet plan and balanced. The diet was calculated to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of total energy value
62533498|NCT04590066|EXPERIMENTAL|Reverse Inference Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are healthier, wealthier, and more educated.
62158491|NCT04626128|EXPERIMENTAL|Cohort 1 (Low Dose)|Subjects will receive a low dose of 0.03 mg CLS-AX
62158492|NCT04626128|EXPERIMENTAL|Cohort 2 (Low-mid Dose)|Subjects will receive a low-mid dose of 0.10 mg CLS-AX
62158493|NCT04626128|EXPERIMENTAL|Cohort 3 (High-mid Dose)|Subjects will receive a high-mid dose of 0.50 mg CLS-AX
62533499|NCT04590066|EXPERIMENTAL|Reverse Inference Control Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are less likely to get the flu.
62533500|NCT04140435||TTNB group|Patients with PCLs suitable for biopsy.
62533501|NCT03402750|EXPERIMENTAL|Meds to Beds|Patients receive medication in-hand at discharge from the hospital
62533502|NCT03402750|ACTIVE_COMPARATOR|Standard Care|Electronic prescription with patient pickup at the pharmacy
62158494|NCT04626128|EXPERIMENTAL|Cohort 4 (High Dose)|Subjects will receive a high-mid dose of 1.0 mg CLS-AX
62158495|NCT04854096|EXPERIMENTAL|NS-018|Self-administered NS-018 300 mg orally, twice daily, preferably at the same time each day in consecutive 4-week (28-day) cycles
62158496|NCT04854096|ACTIVE_COMPARATOR|Best Available Therapy (BAT)|Single agent per Investigator discretion or no therapy
62158497|NCT05322447|OTHER|Control Group|maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
62158498|NCT05322447|EXPERIMENTAL|experimental group|high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level.
62158499|NCT01123356|EXPERIMENTAL|Oratumumab and Lenalidomide|"Single arm, non randomized study~Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.~* Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.~* Treatment to be administered for up to 6 cycles"
62158500|NCT05147207|EXPERIMENTAL|Superpath|This is a minimally invasive surgical approach.
62158501|NCT05147207|NO_INTERVENTION|Posterior Approach|This is the traditional THA surgical approach used.
62158502|NCT03602053|EXPERIMENTAL|ROTAVAC 5D|Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P\[11\] monovalent vaccine at a dose of 0.5mL containing NLT log 10\^5.0 focus forming units (FFU) per dose. 5D is in liquid form.
62533503|NCT05437367|OTHER|posture correction exercises group 1|Group A (Control group 1): Participants using smartphones more than 4 hours per day will receive posture correction exercises only.
62533504|NCT05437367|EXPERIMENTAL|scapular stabilization and postural correction exercises group 1|Group B (Experimental group 1): Participants using smartphones more than 4 hours per day will receive scapular stabilization and postural correction exercises.
62533505|NCT05437367|OTHER|posture correction exercises group 2|Group C (Control group 2): Participants using smartphones less than 4 hours per day will receive posture correction exercises only.
62714261|NCT04524988|EXPERIMENTAL|Essentials in Minimally Invasive Gynecology (EMIG)|This group will undergo 2.5h of training on a new gynecology-specific laparoscopic simulation trainer (EMIG), including the following tasks: peg transfer, intracorporeal knot tying and running suture.
61975903|NCT01454947|EXPERIMENTAL|SA, PC|Participants receive the Suggested Alternative and Peer Comparison interventions, but not the Accountable Justification intervention.
61975904|NCT01454947|EXPERIMENTAL|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternative intervention.
62158503|NCT03602053|EXPERIMENTAL|ROTAVAC®|Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P\[11\] monovalent vaccine at a dose of 0.5mL containing NLT log 10\^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
62158504|NCT03602053|ACTIVE_COMPARATOR|Rotarix®|GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P\[8\] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
62158505|NCT06204237|EXPERIMENTAL|[89Zr]Zr-DFO-APAC|
62158506|NCT06479499|EXPERIMENTAL|Pilates exercises|Group A will receive Pilates exercise with duration of 10-15 minutes and gradually progressing to 20-30 minutes. The session will hold 3 times per week over period of 8 weeks. It begins with warm-up and cool-down of about 5-10 minutes with rest interval of 1-2 minutes.
62158507|NCT06479499|EXPERIMENTAL|Aerobic exercise|Group B will receive aerobic exercise it begins with a warm-up of 5-10 minutes. The duration of session will be 5-10 minutes in short interval of 1-2 minutes and then gradually reducing it to 30 seconds. The cool-down will be 5-10 minutes. The session will hold 3 times per week over period of 8 weeks.
62158508|NCT06188949|ACTIVE_COMPARATOR|Dolichos biflorus (Horsegram) seed extract|1 capsule twice a day (Before breakfast \& dinner)
62158509|NCT06188949|ACTIVE_COMPARATOR|Carica papaya leaves extract|1 capsule twice a day (Before breakfast \& dinner)
62158510|NCT06188949|PLACEBO_COMPARATOR|Placebo (MCC)|1 capsule twice a day (Before breakfast \& dinner)
62158511|NCT05836753|ACTIVE_COMPARATOR|Sarecycline treatment group|The first dose should be given immediately after randomization (within 30 minutes); Take one tablet once a day for 7 days continuously (the patient with dysphagia will be administrated through a nasal feeding tube).
62158512|NCT05836753|PLACEBO_COMPARATOR|Sarecycline placebo control group|The control group received Sarecycline placebo tablets (each containing Sarecycline 0 mg) in the same way as the experimental group.
62158513|NCT02447861||3q29 deletion|"Individuals with 3q29 deletion syndrome (sometimes called 3q29 micro deletion)"
62158514|NCT02447861||3q29 duplication|"Individuals with 3q29 duplication syndrome (sometimes called 3q29 micro duplication)"
62158515|NCT02447861||Parents|parents of individuals with the 3q29 deletion or 3q29 duplication
62158516|NCT02447861||Healthy Controls|Unrelated age-matched controls without 3q29 deletion or duplication
62158517|NCT01961934|EXPERIMENTAL|Sodium Acetate C11 PET/CT Imaging|
62158518|NCT04363645|EXPERIMENTAL|Multicontext approach (Intervention) Arm|Participants received 30-minute sessions of strategy and self-monitoring practice within the context of everyday activities. These sessions were delivered either daily or twice a day. The total number of sessions varied depending on the participant's length of stay in acute rehabilitation.
61975905|NCT01454947|EXPERIMENTAL|Peer Comparison (PC)|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
62158519|NCT06201754||ICU patients|We will include all ICU inpatients who undergo bedside air quality monitoring
62158520|NCT04288440|ACTIVE_COMPARATOR|Silicone filled eyes|Eyes filled with silicone oil
62158521|NCT04288440|ACTIVE_COMPARATOR|Idiopathic ERM|Eyes not filled with silicone oil
62158522|NCT03044834||Pleuropulmonary Blastoma|"* Patients born between 01/01/2000 and 01/01/2016 ;~* Followed up for PPB~* Treated in a French department of paediatric oncology or paediatric surgery~* Study agreement"
62533506|NCT05437367|EXPERIMENTAL|scapular stabilization and postural correction exercises group 2|Group D (Experimental group 2): Participants using smartphones less than 4 hours per day will receive scapular stabilization and postural correction exercises.
62533507|NCT01340326|ACTIVE_COMPARATOR|Valsartan,high dose|high dose group (valsartan up to 320 mg/day)
62533508|NCT01340326|OTHER|Valsartan, usual dose|usual dose group (valsartan 80 mg/day)
62533509|NCT05579275|EXPERIMENTAL|cohort-experimental|Patients will receive treatment for up to 1 year. Actual follow-up will be decided according to the patient 's condition and benefit, and each test requirement and data collection will be completed at specified time during the follow-up cycle.
62533510|NCT03282474|EXPERIMENTAL|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
62158523|NCT00379210|EXPERIMENTAL|1|"Meditation training group-- received Mindfulness Based Stress Management from the Penn Program for Stress Management.~The meditation practice initially emphasized attention to a single focus. For most concentrative exercises, this focus was the breath. The sensations of breathing were to be examined closely, and when attention wandered it was to be redirected back to the breath. In other exercises, the focus of attention was to be directed to sensations within specific body parts (body scan exercise) and sensations of walking (walking meditation). During the 5th week of classes, the mindfulness training was expanded to include some explicit training in receptive attention."
62158524|NCT00379210|ACTIVE_COMPARATOR|2|"Nutrition education group~An active comparison condition involving nutrition education was offered. This course matched the mindfulness course in all dimensions including course duration, homework, psychosocial support, and teacher expertise. The course was taught by a nurse who had expertise in nutrition and offered a program described in the book, Nutrition for Life by Lisa Hark."
62158525|NCT04213235|EXPERIMENTAL|Physical exercise|
62158526|NCT02832830|EXPERIMENTAL|A|intensity modulated radiotherapy (IMRT) 10 x 3 Gy
62158527|NCT02832830|ACTIVE_COMPARATOR|B|fractionated conventional external beam RT 10×3 Gy
62158528|NCT02291861|PLACEBO_COMPARATOR|Placebo|Placebo tablets taken twice daily for 12 weeks.
62158529|NCT02291861|EXPERIMENTAL|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
62158530|NCT02291861|EXPERIMENTAL|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
62158531|NCT02291861|EXPERIMENTAL|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
62158532|NCT05995275|EXPERIMENTAL|mRNA-1769 Dose A|Participants will receive intramuscular (IM) injection of mRNA-1769 at Dose A on Day 1 and Day 29.
62158533|NCT05995275|EXPERIMENTAL|mRNA-1769 Dose B|Participants will receive IM injection of mRNA-1769 at Dose B on Day 1 and Day 29.
62158534|NCT05995275|EXPERIMENTAL|mRNA-1769 Dose C|Participants will receive IM injection of mRNA-1769 at Dose C on Day 1 and Day 29.
62158535|NCT05995275|PLACEBO_COMPARATOR|Placebo|Participants will receive IM injection of placebo matched to mRNA-1769 on Day 1 and Day 29.
62158536|NCT04520620|EXPERIMENTAL|enoxaparin treatment|"Patients infected by SARS-CoV-2 in intensive care unit with enoxaparin treatment will be included.~They will have enoxaparin pharmacokinetic and ultrasound of the lower limbs at 7, 14 and 21 days after inclusion."
62158537|NCT04778605||Patients with septic shock stabilized between H6 and H24 of treatment under noradrenaline.|
62533511|NCT00942435|EXPERIMENTAL|YM150 group|
62533512|NCT00942435|ACTIVE_COMPARATOR|mechanical prophylaxis group|
62533513|NCT05840237|EXPERIMENTAL|Oxaloacetate Arm|1,000 mg of Anhydrous Enol-Oxaloacetate taken BID with Breakfast and Lunch
62533514|NCT05840237|PLACEBO_COMPARATOR|Placebo Arm|1,000 mg of white Rice Flour taken BID with Breakfast and Lunch
62158538|NCT01256814|EXPERIMENTAL|Behaviorial Intervention|SystemCHANGE-HIV is a 10-week, small-group intervention that will promote behavior changes to improve the following: physical activity, sleep behaviors and mental wellness. S
62158539|NCT01256814|ACTIVE_COMPARATOR|Control|"The control group will receive the manual Symptom Management Manual: Strategies for People Living with HIV/AIDS."
62533515|NCT00283023|EXPERIMENTAL|A|Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
62158540|NCT02077114|EXPERIMENTAL|Ipilimumab|Patient who according to standard criteria are candidates to treatment with Ipilimumab
62158541|NCT02077114|EXPERIMENTAL|Vemurafenib|Patients who according to standard criteria are candidates to treatment with Vemurafenib
62158542|NCT05159726|EXPERIMENTAL|Written Discharge Education + Video Education|These patients will view a 12-minute educational video on SMM warning signs, in addition to the written discharge instructions provided by nursing staff. At the completion of the video, they will complete a post-video questionnaire to assess their knowledge on the covered topics.
62158543|NCT05159726|NO_INTERVENTION|Written Discharge Education|They will receive the written discharge instructions provided by nursing staff and complete the post-discharge instruction questionnaire.
61975906|NCT01454947|EXPERIMENTAL|Suggested Alternatives (SA)|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
62158544|NCT03778606|EXPERIMENTAL|Potato starch supplementation|Twelve patients found to be colonized with C. difficile will undergo twice a day potato starch supplementation.
62158545|NCT05644067|EXPERIMENTAL|SumayaVac-1(SUM-101)|Candidate malaria Vaccine (Investigational Medicinal Product (IMP)). 20 participants will be randomised to receive three monthly inoculations of the IMP
62158546|NCT05644067|PLACEBO_COMPARATOR|Verorab|Comparator used as a control. 20 participants will be randomised to receive three monthly inoculations of the comparator.
62158547|NCT03042572|EXPERIMENTAL|Allogeneic Mesenchymal Stromal Cell|Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection
62533516|NCT01462773|EXPERIMENTAL|Treatment (enzyme inhibitor, interferon therapy)|Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22 and recombinant interferon alfa-2b SC on days 1, 3, and 5 (days 1 and 3 only in week 4 course 1) of weeks 1-4. Treatment repeats every 5 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
62158548|NCT03042572|PLACEBO_COMPARATOR|Placebo|Intramuscular placebo injection
62158549|NCT03235297||Healthy subjects|Healthy subjects
62158550|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
62158551|NCT03362853|EXPERIMENTAL|Nemonoxacin 500Mg Capsule|
62158552|NCT03362853|EXPERIMENTAL|Nemonoxacin 750Mg Capsule|
62158553|NCT03362853|PLACEBO_COMPARATOR|Placebo oral capsule|
62158554|NCT03362853|ACTIVE_COMPARATOR|Moxifloxacin 400Mg Tablet|
62714262|NCT05506254||Patients who have previously received hLB-001|
62158555|NCT05690178|EXPERIMENTAL|DTM group|This group of participants (N=20) received Deep Tissue Massage therapy.
62158556|NCT05690178|NO_INTERVENTION|Control group|This group of participants (N=20) did not receive any intervention.
62158557|NCT02741921|EXPERIMENTAL|Normal airway|intubation with normal airway Cormack-Lehane classivication I
62158558|NCT02741921|EXPERIMENTAL|difficult airway|intubation with difficult airway Cormack-Lehane classivication III
62158559|NCT06416605|EXPERIMENTAL|group A|Horizontal bone augmentation will be done by bone shell technique
62158560|NCT06416605|EXPERIMENTAL|group B|Horizontal bone augmentation will be done by autogenous tooth shell technique
62158561|NCT02757456|OTHER|Aerobic Exercise program|Intervention of aerobic exercise
62158562|NCT02757456|OTHER|Control|no aerobic exercise program
62158563|NCT06505499||EXPERIMENTAL GROUP|Children and teenagers with CP with an instrumented gait analysis performed since 2019.
62158564|NCT02568202||Survey|
62158565|NCT00593983|EXPERIMENTAL|1|
62714263|NCT06633757|EXPERIMENTAL|PCD Participants|RCT1100 mRNA therapy supplied to eligible participants with Primary Ciliary Dyskinesia caused by disease-causing mutations in the DNAI1 gene
62714264|NCT03920891|EXPERIMENTAL|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
62714265|NCT03920891|ACTIVE_COMPARATOR|Radiofrequency Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
62714266|NCT02700438|ACTIVE_COMPARATOR|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
62158566|NCT00593983|PLACEBO_COMPARATOR|2|Control
62158567|NCT04389086|EXPERIMENTAL|Induction chemotherapy + chemoradiotherapy + surgery|Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
62158568|NCT04389086|ACTIVE_COMPARATOR|Neoadjuvant chemotherapy + surgery|Neoadjuvant chemoradiotherapy followed by surgery
62158569|NCT05265247|EXPERIMENTAL|Test Product/Reference Product|Participants will be randomly assigned to receive Esomeprazole 20 mg delayed-release one capsule once daily as oral administration on day 1 of period 1 and will receive Esomeprazole 20 mg delayed-release one capsule (Nexium 24HR) once daily as oral administration on day 1 of period 2. Participants are instructed to consume the entire amount of ambient temperature water (240 milliliter \[mL\]) along their investigational product. There will be washout period of 7 days between two treatment periods.
62533517|NCT03791723|EXPERIMENTAL|Sacubitril/valsartan|After catheter ablation, during a single blind, run-in period, participants received placebo. Then started with 50 mg sacubitril/valsarta for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
62736773|NCT03545087|EXPERIMENTAL|Lanabecestat Control|Lanabecestat administered orally to participants with normal renal function
62736774|NCT03545087|EXPERIMENTAL|Lanabecestat Severe Renal Impairment|Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
62158570|NCT05265247|EXPERIMENTAL|Reference Product/Test Products|Participants will be randomly assigned to receive Esomeprazole 20 mg delayed-release one capsule (Nexium 24HR) once daily as oral administration on day 1 of period 1 and will receive Esomeprazole 20 mg delayed-release one capsule once daily as oral administration on day 1 of period 2. Participants are instructed to consume the entire amount of ambient temperature water (240 milliliter \[mL\]) along their investigational product. There will be washout period of 7 days between two treatment periods.
62158571|NCT00993434|ACTIVE_COMPARATOR|Kid STRIDE Booklet|
62158572|NCT00993434|PLACEBO_COMPARATOR|Safety Booklet|
62533518|NCT03791723|ACTIVE_COMPARATOR|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40mg Valsartan twice daily qd for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
62533519|NCT00978263|EXPERIMENTAL|Glargine|Initial basal Insulin therapy was according to the dose administrated at bedtime in the last day hospitalization. basal Insulin doses were titrated every 3 days to achieve target FPG values between 80 and 130 mg/dl.
62533520|NCT00978263|EXPERIMENTAL|metformin-based Oral Antidiabetic Drugs|Subject in metformin-based OAD group was visited every two weeks in the first month and the every four weeks for another five months. The subjects will start with Metformin 425mg bid, The dosage was titrated (up to 850mg bid) based on the fasting blood glucose every two weeks. If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.
62533521|NCT00801099|EXPERIMENTAL|Abx|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
61975907|NCT01454947|EXPERIMENTAL|Accountable Justification (AJ)|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
61975908|NCT01454947|NO_INTERVENTION|Education Control|Participants do not receive any of the 3 interventions.
62158573|NCT04995497|EXPERIMENTAL|Erector Spinae Plane Block-Administration of Lidocaine|Bilateral ultrasound guided erector spinae plane catheter placement for the administration of lidocaine. Dose will be 2 mg/kg ideal body weight. Bolus will be divided equally between the two ESP catheters. This is followed by lidocaine infusion via ESP catheter at 2 mg/kg/hr for 48 hours after catheter placement.
62158574|NCT04995497|ACTIVE_COMPARATOR|Intravenous-Administration of Lidocaine|Sham block procedure (catheter will be taped to subjects skin). Subject will receive a bolus of lidocaine at 2 mg/kg ideal body weight. This is followed by lidocaine infusion via intravenous route at 2 mg/kg/hr for 48 hours after sham catheter placement.
62158575|NCT02226029|EXPERIMENTAL|Lipid emulsion 1|Rapeseed oil 20%, sucrose FAE P-1670 0.7%, water 79.3%
62158576|NCT02226029|EXPERIMENTAL|Lipid emulsion 2|Rapeseed oil 20%, sodium stearoyl lactylate P45 veg 1.5%, water 78.5%
62158577|NCT04864353|EXPERIMENTAL|Experimental: Intervention|Participants will after baseline receive a guided intervention with weekly therapist support.
62158578|NCT04864353|NO_INTERVENTION|Control: Waitlist|Participants will not receive intervention until 7 weeks after baseline.
62158579|NCT04590625|EXPERIMENTAL|Group1|"1. Neoadjuvant therapy:~   Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~   Neoadjuvant therapy is 3-4 cycles.After Neoadjuvant therapy will received interval cytoreductive surgery.~2. Adjuvant therapy:~   After interval cytoreductive surgery,patients will received adjuvant therapy same as neoadjuvant therapy.~   Adjuvant therapy is 3 cycles~3. maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
62158580|NCT04590625|EXPERIMENTAL|Group2|"1.Adjuvant therapy:~After primary cytoreductive surgery,patients will received adjuvant therapy:~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~Adjuvant therapy is 3 cycles 3.maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
62533522|NCT02734654|NO_INTERVENTION|Control group|patients do not receive remote preconditioning prior to lung lobectomy
61975909|NCT05058443|EXPERIMENTAL|Denosumab|Denosumab 60 mg were injected subcutaneously every 6 months (Q6M)
62158581|NCT03249961|EXPERIMENTAL|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
62158582|NCT03249961|EXPERIMENTAL|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
62158583|NCT01241448|PLACEBO_COMPARATOR|Placebo|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
62158584|NCT01241448|EXPERIMENTAL|2.5 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
62158585|NCT01241448|EXPERIMENTAL|10 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
62158586|NCT01241448|EXPERIMENTAL|20 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
62158587|NCT02391259|EXPERIMENTAL|AMG 557|AMG 557 administered as subcutaneous and intravenous doses.
62158588|NCT02391259|PLACEBO_COMPARATOR|Placebo|No active drug
62158589|NCT01589211|ACTIVE_COMPARATOR|Brief advice|A brief advice to stop smoking of about 10 min accompanied with self-help material
62533523|NCT02734654|EXPERIMENTAL|RIPC group|patients receive remote preconditioning prior to lung lobectomy
62533524|NCT02857751||Surf therapy cohort 1|The first cohort of participants to enroll in the study (i.e., participants in the first 6-week program)
62533525|NCT02857751||Surf therapy cohort 2|The second cohort of participants to enroll in the study (i.e., participants in the second 6-week program)
62533526|NCT02857751||Surf therapy cohort 3|The third cohort of participants to enroll in the study (i.e., participants in the third 6-week program)
62533527|NCT02857751||Surf therapy cohort 4|The fourth cohort of participants to enroll in the study (i.e., participants in the fourth 6-week program)
62533528|NCT02857751||Surf therapy cohort 5|The fifth cohort of participants to enroll in the study (i.e., participants in the fifth 6-week program)
62533529|NCT02318186||0 months - 1 year|
62533530|NCT02318186||11-16 years|
62158590|NCT01589211|EXPERIMENTAL|Compact cessation course|Cessation intervention of 2 x 120 min in a group setting
62158591|NCT01589211|ACTIVE_COMPARATOR|Standard cessation course|Cessation course in a group setting over 6 dates
62158592|NCT04843956|EXPERIMENTAL|Patients with solid pancreatic lesions|Patients who will undergo endoscopic ultrasound biopsy. Samples of at least 3 passes will be obtained, each pass obtained with a different technique (capillary with suction, capillary without suction and wet suction)
62158593|NCT02781233|EXPERIMENTAL|Training group|Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.
62158594|NCT02781233|PLACEBO_COMPARATOR|Control group|Usual daily activities
62158595|NCT03345199|EXPERIMENTAL|Inspiratory Muscle Trainer (IMT)|Inspiratory Muscle Trainer (IMT) provides resistance as a person inhales, thereby strengthening respiratory muscles.
62158596|NCT02830893|EXPERIMENTAL|The LARA Therapy|The LARA arm of this study will use the LARA system while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. LARA is a system that facilitates patients to perform high amounts of arm movement with the affected upper extremity. Study participants are able to actively propel themselves in the unit.
62533531|NCT02318186||7-11 years|
62533532|NCT02318186||4-6 years|
62533533|NCT02318186||1-3 years|
62533534|NCT03418090|ACTIVE_COMPARATOR|Arm 1|Subjects will first undergo hyperpolarized 129Xe MRI followed by 133Xe scintigraphy
62533535|NCT03418090|ACTIVE_COMPARATOR|Arm 2|Subjects will first undergo 133Xe scintigraphy followed by hyperpolarized 129Xe MRI
62533536|NCT02548130||Patients before MELD score|Recipients before the MELD score
62533537|NCT02548130||Patients after the MELD score|Recipients after the MELD score
62533538|NCT03292536|EXPERIMENTAL|Merestinib, all patients|
62533539|NCT03311035|EXPERIMENTAL|Group A|patients undergoing ligation of intersphincteric fistula tract (LIFT technique)
62533540|NCT03311035|EXPERIMENTAL|Group B|patients undergoing Seton method
62533541|NCT00934297||Pilot group|Real-time US imaging with simultaneous display of dynamically corresponding MR images (from a previous MRI screening) will be used to re-locate the lesion previously reported as occult under a second-look ultrasound screening.
62533542|NCT02619435|EXPERIMENTAL|regorafenib|
62533543|NCT03069950|EXPERIMENTAL|HAI FUDR/Dex in addition to Pmab plus FOLFIRI|Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
62533544|NCT03069950|EXPERIMENTAL|Pmab plus FOLFIRI alone|The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
62533545|NCT02176408|EXPERIMENTAL|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
62533546|NCT02176408|ACTIVE_COMPARATOR|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
62533547|NCT03788304|ACTIVE_COMPARATOR|Non invasive ventilation|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~* Positive End Expiratory Pressure (PEEP): 5 cmH2O.~* Pressure support (PS): 12-20 cmH2O.~* FiO2 will be adjusted to achieve a SpO2 at least 95%"
62533548|NCT03788304|EXPERIMENTAL|High flow nasal cannula|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~* Temperature at 37°C or 34°C~* Flow rate 30: 50 L/min.~* FiO2 will be adjusted to achieve a SpO2 at least 95%"
62533549|NCT04009512|EXPERIMENTAL|Primary Study Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
62533550|NCT04009512|EXPERIMENTAL|Expanded Use Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments. The expanded use arm provides broaden inclusion criteria to include select patients excluded from the primary study arm.
62533551|NCT06148142|EXPERIMENTAL|Assigned Interventions|The intervention to experimental/intervention group will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; and third, end-line survey at 12 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance. Patients will be able to view the educational material in the pharmacy via a tablet, since audio-visual presentations make learning easier. The intervention group will receive phone call intervention at 3 months and 6 months.
62533552|NCT06148142|ACTIVE_COMPARATOR|Control group|In the control group, routine pharmacy services and counselling will be provided without interference during all-pharmacy visits, as per each country's pharmacy practice guidelines, and they will serve as a comparator group to determine the impact of the intervention implementation. Assessments will be completed at the same time points as those in the intervention group.
62533553|NCT02320760|EXPERIMENTAL|Physical activity on prescription|
62533554|NCT02320760|NO_INTERVENTION|Ordinary care|
62533555|NCT04183075|EXPERIMENTAL|FontActiv Superprotein/Hypercaloric Fiber|Full Nutritional Supplement
62533556|NCT04183075|ACTIVE_COMPARATOR|Carbohydrates and C Vitamin|Nutritional Supplement
62533557|NCT02802449|PLACEBO_COMPARATOR|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
62533558|NCT02802449|ACTIVE_COMPARATOR|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] to take under direct observation at the baseline and week 2 visit.
62533559|NCT02472028|EXPERIMENTAL|blood pressure lowering algorithm|enhanced strategy aiming to reduce systolic blood pressure to \<135 mmHg
62158597|NCT02830893|ACTIVE_COMPARATOR|The Standard Therapy|The control arm of this study will use a standard wheelchair while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. Study participants will have no exposure to LARA and they will use a standard wheelchair. They will use their unaffected upper and lower extremities to propel themselves in the unit.
62533560|NCT02472028|ACTIVE_COMPARATOR|usual strategy|usual strategy based on the usual care of routine care
62533561|NCT02852720|EXPERIMENTAL|Pharmacokinetics|A bilateral TAP block will be performed with 20 ml levobupivacaine 0,25% and epinephrine (5ug/ml). After the blockade, venous blood samples will be taken on predefined times.
61975910|NCT05058443|PLACEBO_COMPARATOR|Placebo|Equal volume of saline (0.9%) as placebo were injected subcutaneously every 6 months (Q6M)
61975911|NCT01716598|EXPERIMENTAL|Treatment|Targeted Lung Denervation Therapy (TLD Therapy)
62158598|NCT00708799|EXPERIMENTAL|Arm 1|Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
62158599|NCT00708799|NO_INTERVENTION|Arm 2|Standard antibiotic therapy
62158600|NCT05293691|EXPERIMENTAL|Body, Breath & Mind|"The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
62158601|NCT05293691|ACTIVE_COMPARATOR|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored.The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
62158602|NCT05293691|OTHER|Waitlist control group|Participants in the waitlist control group are given access to the Body, Breath \& Mind program after eight weeks, provided they have participated in the previous surveys in the form of a diagnostic pre-, peri-, and post-module.
62158603|NCT03481725|EXPERIMENTAL|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
62158604|NCT03481725|SHAM_COMPARATOR|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
62158605|NCT01373359|EXPERIMENTAL|Sublingual misoprostol|400 µg powdered misoprostol administered sublingually; IM placebo
62158606|NCT01373359|ACTIVE_COMPARATOR|Oxytocin|10 IU IM oxytocin; placebo powder
62158607|NCT05072795|EXPERIMENTAL|Stress Induction|Participants completed the Trier Social Stress Test (TSST)
62158608|NCT05072795|NO_INTERVENTION|No intervention|Participants did not complete the Trier Social Stress Test (TSST).
62158609|NCT06158620|EXPERIMENTAL|Sprix|"Phase I will consist of a single-arm open label pilot study. Prior to the initiation of a large-scale randomized trial, we propose a single-arm open label pilot study to evaluate the feasibility, practicality, and qualitative outcomes of utilizing intra-nasal ketorolac in patients with indwelling ureteral stents. We seek to enroll 20 patients for the initial pilot.~Phase II will consist of a randomized trial comparing intranasal ketorolac to Diclofenac, a commonly used oral NSAID. , Diclofenac potassium. Following ureteroscopy and stent placement, patients will receive standard of care medications to mitigate post operative pain and stent discomfort, and will be randomized to receive either as needed intra-nasal ketorolac or oral diclofenac. We seek to enroll and randomize 60 patients in a 1:1 fashion. Analysis will be intention to treat."
62158610|NCT06158620|ACTIVE_COMPARATOR|Diclofenac|Phase II will consist of a randomized trial comparing intranasal ketorolac to Diclofenac, a commonly used oral NSAID. , Diclofenac potassium. Following ureteroscopy and stent placement, patients will receive standard of care medications to mitigate post operative pain and stent discomfort, and will be randomized to receive either as needed intra-nasal ketorolac or oral diclofenac. We seek to enroll and randomize 60 patients in a 1:1 fashion. Analysis will be intention to treat.
62158611|NCT04975386|ACTIVE_COMPARATOR|spinal anesthesia|
62158612|NCT04975386|ACTIVE_COMPARATOR|lumbar plexus+sacral plexus block|
62158613|NCT00267774|EXPERIMENTAL|FFR guided PCI|
62158614|NCT00267774|ACTIVE_COMPARATOR|Angio-guided PCI|
62158615|NCT04497818||Netizens|Netizens of Al Qassim province of Saudi Arabia were the target population for this cross sectional study. Sample size is (n=385) estimated based on the population size in Al Qassim province (Confidence Interval 95%, Design effect 1 \& hypothesized % frequency of outcome factor of 50%). Assessment of Fear of COVID-19 was estimated using FEAR OF COVID-19, a 5 item Likert Scale. Assessment of Dental Anxiety was estimated using Modified Dental Anxiety 5 item Likert Scale. An online Survey form (Arabic 7 English) was developed using Google form application. The Google form link was shared to the netizens of Al Qassim province, across all relevant Social media platforms. Statistical analysis is done using SPSS 22.00 software program.
62158616|NCT06046976|ACTIVE_COMPARATOR|Healthy|
62533562|NCT06424015|ACTIVE_COMPARATOR|Intralipid and heparin|Between 0600 (-180 min) and 1300 (240 min) Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance.
62533563|NCT06424015|PLACEBO_COMPARATOR|Saline|Between 0600 (-180 min) and 1300 (240 min) saline will be infused
62533564|NCT01406483|OTHER|CABG|
62533565|NCT03764761|EXPERIMENTAL|AAC Intervention|Participants will use AAC technology of different designs delivered on iMacs or Surface tablets
62158617|NCT06046976|EXPERIMENTAL|Diabetes mellitus type 2|
62158618|NCT06010303|EXPERIMENTAL|LBL-007|LBL-007 in combination with tislelizumab plus chemotherapy doublet.
62158619|NCT06010303|ACTIVE_COMPARATOR|Tislelizumab and Chemotherapy|Tislelizumab plus chemotherapy doublet.
62158620|NCT04618211|OTHER|Low dose/placebo|Single low dose of deucrictibant or placebo
62158621|NCT04618211|OTHER|Medium dose/placebo|Single medium dose of deucrictibant or placebo
62533566|NCT01064752||Minocycline|HIV-1 infected, not on anti-retroviral medication
62533567|NCT04601610|EXPERIMENTAL|Cohort 1|Subjects who have not received first-line system treatment previously;
62533568|NCT04601610|EXPERIMENTAL|Cohort 2|Subjects who have received at least first-line system treatment
62158622|NCT04618211|OTHER|High dose/placebo|Single high dose of deucrictibant or placebo
62158623|NCT01596894|EXPERIMENTAL|Azithromycin + Metronidazole|Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
62158624|NCT01596894|ACTIVE_COMPARATOR|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
62533569|NCT03250559|ACTIVE_COMPARATOR|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.~Intervention: percutaneous nephrolithotomy."
62533570|NCT03250559|ACTIVE_COMPARATOR|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.~Intervention: percutaneous nephrolithotomy."
62158625|NCT06660004|EXPERIMENTAL|Creatine hcl|One capsule per day of creatine hcl during breakfast
62158626|NCT06660004|EXPERIMENTAL|Creatine hcl 2|One capsule during breakfast and one during dinner of creatine hcl
62158627|NCT06660004|EXPERIMENTAL|Creatine ethyl ester|One capsule during breakfast and one during dinner of creatine ethyl ester
62158628|NCT06660004|PLACEBO_COMPARATOR|Placebo|One capsule per day of inulin during breakfast
62158629|NCT06315322|EXPERIMENTAL|Brivaracetam arm|Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
62158630|NCT01236144|EXPERIMENTAL|AC220 Intervention|
62158631|NCT01236144|EXPERIMENTAL|Plerixafor Intervention|
62158632|NCT01236144|EXPERIMENTAL|Ganetespib|
62158633|NCT05060406|EXPERIMENTAL|LY06006 60mg|"injection~Interventions:~Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
62158634|NCT05060406|PLACEBO_COMPARATOR|Placebo|"injection~Interventions:~Drug: Placebo； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
62158635|NCT03196622|EXPERIMENTAL|Older people|A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.
62158636|NCT03941756|EXPERIMENTAL|Group I (LVB)|Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.
62158637|NCT03941756|NO_INTERVENTION|Group II (no intervention)|Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.
62158638|NCT04271254|EXPERIMENTAL|PET/MR|Each patient will undergo one combined PET/MR scan prior to surgery. The PET/MR scans are for research purposes and not part of the patient's standard of care.
62158639|NCT04884282|EXPERIMENTAL|Arm A - tedopi + docetaxel|Tedopi every 3 weeks plus docetaxel every 3 weeks only for 6 cycles, then maintenance with Tedopi alone every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal.
62158640|NCT04884282|EXPERIMENTAL|Arm B - tedopi + nivolumab|Tedopi every 3 weeks plus nivolumab 360 mg every 3 weeks for 6 cycles, then maintenance nivolumab 360 mg every 3 weeks plus Tedopi every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal
62158641|NCT04884282|OTHER|Arm C - docetaxel|Docetaxel every 3 weeks until disease progression, unacceptable toxicity, patient refusal, or for a maximum of 6 cycles (whichever comes first).
62158642|NCT05022953|EXPERIMENTAL|Digital Story Group|"Digital Story Group: One of the researchers gave the experimental group participants a 15-minute briefing on how to perform digital storytelling. She also told them not to talk to the control group participants about the content of the briefing. She created a Pixton account (https://edu.pixton.com/educators/) and a class named Isolation. She sent the link (https://join.pixton.com/x5xb6) to the experimental group participants. She asked them to click on the link and make stories out of their knowledge of isolation in four weeks."
62158643|NCT05022953|NO_INTERVENTION|Control Group|Control group participants did not go through any training in isolation.
62158644|NCT02303509|EXPERIMENTAL|UCB5857 Part 1|Part 1: Subjects assigned to UCB5857 or placebo single dose.
62158645|NCT02303509|EXPERIMENTAL|UCB5857 Part 2|Part 2: Subjects assigned to UCB5857 or placebo multiple doses.
62533571|NCT05331196||Patients with colorectal cancer|Patients with colorectal cancer who underwent elective surgery.
62533572|NCT03322618|EXPERIMENTAL|SpA HLA-B27 +,|
62533573|NCT03322618|EXPERIMENTAL|SpA HLA-B27-|
62533574|NCT03322618|ACTIVE_COMPARATOR|healthy subject|
62533575|NCT01877746|EXPERIMENTAL|R1 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the first dosing regimen
62533576|NCT01877746|EXPERIMENTAL|R2 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the second dosing regimen
62533577|NCT01877746|OTHER|S - standard therapy|only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy
62533578|NCT03473626|EXPERIMENTAL|Alicaforsen tablets|Regimen A - Alicaforsen tablets with food
62533579|NCT03473626|EXPERIMENTAL|alicaforsen tablets|Regimen B - Alicaforsen tablets without food
62533580|NCT02968836|ACTIVE_COMPARATOR|Active group|Blend of amino acids
62533581|NCT02968836|PLACEBO_COMPARATOR|Placebo group|maltodextrin only
62533582|NCT04122066||respiratory symptoms reported in studied patients|If Sofosbuvir\\Daclatasvir regimen has respiratory side effects or not and the factors increase incidence of respiratory complications
62533583|NCT04966273|EXPERIMENTAL|Biosensors Microcatheter (BM)|Use of Biosensors Microcatheter
62158646|NCT00585910|EXPERIMENTAL|1|Total treatment period is 7 weeks. Atomoxetine treatment will be initiated and maintained for 4 weeks. If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
62158647|NCT06585592||TAO|
62158648|NCT04125342|EXPERIMENTAL|Conditioned NIV in High Risk Patients|
62158649|NCT04125342|ACTIVE_COMPARATOR|HFOT in High Risk Patients|
62533584|NCT04899388|ACTIVE_COMPARATOR|PENG|the patients lied in the supine position. The probe was originally placed in a transverse plane above the anterior superior iliac spine in the ipsilateral surgical site and then counterclockwise rotated about 45 degrees to line up with the pubic ramus. The iliopubic eminence, iliopsoas muscle and tendon, femoral artery, and pectineus muscle were all visible in this view. By an in-plane technique, from lateral to medial, a 22-gauge, 80-mm needle was placed in the musculofascial plane between both the psoas tendon anteriorly and the pubic ramus posteriorly .The local anesthetic medication was delivered after negative aspiration while looking out for proper fluid distribution for a total volume of 20 mL of Bupivacaine 0.25%
62736775|NCT01547351||ARMS Questionnaire Group|Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire. These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
62736776|NCT01532921||Subjects with Tricuspid Valve Repair|All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
62158650|NCT04125342|EXPERIMENTAL|Conditioned NIV in Obese Intermediate Risk Patients|
62158651|NCT04125342|ACTIVE_COMPARATOR|HFOT in Obese Intermediate Risk Patient|
62158652|NCT03490188|EXPERIMENTAL|Treatment Arm|Patients assigned to treatment arm will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center. In addition, they will be matched with a mentor who will conduct 5 meetings with the patients (which includes one video chat meeting, 4 30-minute phone calls) and discuss the following topics related to post-discharge: Medications, Lab Work, Fluid Intake and Adherence to doctor's appointment
62158653|NCT03490188|NO_INTERVENTION|Control Arm|Control arm recipient will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center
62158654|NCT03622242|EXPERIMENTAL|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
62158655|NCT03622242|ACTIVE_COMPARATOR|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
62158656|NCT03855384|EXPERIMENTAL|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
62158657|NCT03855384|PLACEBO_COMPARATOR|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
62158658|NCT06719895|EXPERIMENTAL|web based education|
62158659|NCT06719895|NO_INTERVENTION|control|
62158660|NCT03795792|EXPERIMENTAL|Curcumin|Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
62158661|NCT03795792|PLACEBO_COMPARATOR|Hydrollased collagen|Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
62158662|NCT01894750|EXPERIMENTAL|skill bulding Intevention|group-based skill building self-care program
62158663|NCT01894750|NO_INTERVENTION|usual care|
62158664|NCT04454125|ACTIVE_COMPARATOR|Routine Care|
62158665|NCT04454125|EXPERIMENTAL|AQI Intervention|
62158666|NCT03522909||Study|We will be reviewing records of parturients seen at Johns Hopkins Hospital in the Center for Peripartum Optimization (CPO) clinic between January 2017 to January 2018
62158667|NCT03522909||Control|A matched controlled group patients not seen at the CPO clinic
62158668|NCT02265471||university hospital|university hospital
62158669|NCT02265471||large or small public hospitals|large or small public hospitals
62158670|NCT02265471||private HCFs|private HCFs
62158671|NCT02265471||referral centers for cancer|referral centers for cancer
62158672|NCT02265471||chirurgical facilities, clinic|chirurgical facilities, clinic
62158673|NCT02265471||mixed group|local hospitals, long term care and post-op and rehabilitation facilities, and nursing homes
62158674|NCT00460434|EXPERIMENTAL|1|Tension-free Vaginal Tape (TVT) surgery
62158675|NCT00460434|SHAM_COMPARATOR|2|Sham Tension-free Vaginal Tape (TVT) surgery
62158676|NCT05531149|EXPERIMENTAL|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
62158677|NCT05531149|PLACEBO_COMPARATOR|Placebo|Human albumin 1%
62158678|NCT05501340|EXPERIMENTAL|PRaG combined PD-1 inhibitor intraperitoneal injection|PRaG(PD-1 inhibitor,Radiotherapy and GM-CSF) combined with PD-1 inhibitor intraperitoneal injection
62158679|NCT01305551|EXPERIMENTAL|Treatment A-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fasted state.
62158680|NCT01305551|EXPERIMENTAL|Treatment B-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fasted state.
62158681|NCT01305551|EXPERIMENTAL|Treatment C-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fed state.
62158682|NCT01305551|EXPERIMENTAL|Treatment D-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fed state.
62158683|NCT00108407|EXPERIMENTAL|1|Integrated Cognitive Behavioral Therapy
62158684|NCT00108407|EXPERIMENTAL|2|Twelve Step Facilitation Therapy
62158685|NCT04887597|EXPERIMENTAL|Secukinumab Treatment|all patients receive Secukinumab as well as a biopsy before and after treatment
62158686|NCT06414213|EXPERIMENTAL|MI/Active tDCS|The participants received active tDCS current and participated in the Motor Imagery intervention.
62158687|NCT06414213|SHAM_COMPARATOR|MI/Sham tDCS|The participants received sham tDCS current and participated in the Motor Imagery intervention.
62158688|NCT06414213|NO_INTERVENTION|Control|The control group watched an unrelated (non stimulating) video for a duration equal to the MI groups' intervention tasks.
62158689|NCT04366648|EXPERIMENTAL|50mg/m2|Starting dose, administered once only
62158690|NCT04366648|EXPERIMENTAL|75mg/m2|Second dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
62158691|NCT04366648|EXPERIMENTAL|100mg/m2|Third dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
62158692|NCT04366648|EXPERIMENTAL|125mg/m2|Forth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
62158693|NCT04366648|EXPERIMENTAL|150mg/m2|Fifth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
62158694|NCT04366648|EXPERIMENTAL|180mg/m2|Sixth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
62158695|NCT04366648|ACTIVE_COMPARATOR|175mg/m2|CPT-11, given every 14 days, first 2 cycles of drug delivery will accompanied with PK test,
62158696|NCT01706055||Group 1|
62158697|NCT02473549|EXPERIMENTAL|Brain Stimulation|Patients will receive, Sham TDCS, Anodal TDCS, Cathodal TDCS, and Magnetic Resonance Imaging (MRI).
62158698|NCT01341106|EXPERIMENTAL|Treatment Arm|Patients will be treated with entecavir
62158699|NCT03834909|ACTIVE_COMPARATOR|Standard Dose Truvada®|Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day
62158700|NCT03834909|EXPERIMENTAL|Pregnancy-Adjusted Truvada®|Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day
62158701|NCT03761979|ACTIVE_COMPARATOR|Strontium dose of 170 mg|The Sponsor provided each 170 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
62158702|NCT03761979|ACTIVE_COMPARATOR|strontium dose of 340 mg|The Sponsor provided each 340 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
62158703|NCT03761979|ACTIVE_COMPARATOR|Strontium dose of 680 mg|The Sponsor provided each 680 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
62158704|NCT04566276|EXPERIMENTAL|Adult Cohort 1: 10 µg|12 healthy adults aged 18-55 years will receive 10 µg of the vaccine IM
62158705|NCT04566276|EXPERIMENTAL|Adult Cohort 2: 25 µg|12 healthy adults aged 18-55 years will receive 25 µg of the vaccine IM
62158706|NCT04566276|EXPERIMENTAL|Adult Cohort 3: 50 µg|12 healthy adults aged 18-55 years will receive 50 µg of the vaccine IM
62158707|NCT04566276|EXPERIMENTAL|Elderly Cohort 1 :10 µg|12 elderlies aged 56-75 years will receive 10 µg of the vaccine IM
62158708|NCT04566276|EXPERIMENTAL|Elderly Cohort 2: 25 µg|12 elderlies aged 56-75 years will receive 25 µg of the vaccine IM
62158709|NCT04566276|EXPERIMENTAL|Elderly Cohort 3: 50 µg|12 elderlies aged 56-75 years will receive 50 µg of the vaccine IM
62158710|NCT04566276|EXPERIMENTAL|Phase 2: ChulaCov19 vaccine Dose 50 ug|adults between 18 and 59 years of age will receive 2 IM ChulaCov19 vaccine Dose 50 ug vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
62158711|NCT04566276|OTHER|Phase 2: Placebo|adults between 18 and 59 years of age will receive 2 IM saline vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
62158712|NCT04536779|EXPERIMENTAL|Individuals with low mobility (Disabled and Elder)|minimum 8-10 training sessions in at least three months.
62158713|NCT04677985|EXPERIMENTAL|Menthol based topical analgesic|Menthol based topical analgesic was applied to a variety of upper and lower body muscles and tendons.
62158714|NCT04677985|PLACEBO_COMPARATOR|Placebo|Placebo (cream that smelled like menthol) was applied to a variety of upper and lower body muscles and tendons.
62158715|NCT02855892|PLACEBO_COMPARATOR|Control Group|- Placebo, two-week interval, intradermal administration
62158716|NCT02855892|EXPERIMENTAL|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
62158717|NCT02855892|EXPERIMENTAL|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
62158718|NCT02855892|EXPERIMENTAL|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
62158719|NCT02292056|EXPERIMENTAL|Counseling Group|Participation in the study will be completed in a single session and will involve a pre-counseling questionnaire, followed by a pre-counseling quiz, individualized counseling session, post-counseling quiz and post-counseling questionnaire.
62158720|NCT02190942||Vasculitis Contact Registry Patients|Consent will be obtained from at least 20 randomly selected patients with each of the following self-identified diagnoses in the VCRC Patient Contact Registry: Behçet's disease, EGPA, GCA, GPA, MPA, PAN and TAK that have already completed the VCRC Diagnostic Questionnaires. Permission will be obtained to contact subjects' primary vasculitis care providers to request that the providers complete an online version of this questionnaire (or print copy, if they prefer), and request specific chart items from their office to further verify the data.
62533585|NCT04899388|ACTIVE_COMPARATOR|ESPB|"TThe patient was positioned at the lateral decubitus posture in the ipsilateral surgical site. The convex USG transducer was moved from the midline to the side of the operation and positioned 4-6 cm lateral to the L3 spinous process in a longitudinal parasagittal plane. The needle was advanced using the in-plane superior-to-inferior approach. The needle was advanced with the tip introduced up to the plane anterior to the erector spinae muscle and the posterior surface of the L3 transverse process. 0.5-1 ml of normal saline was administered for hydrodissection and to ensure proper placement .If there was any resistance during administering local anesthesia, the needle was modified by drawing it back a few millimeters. the prepared local anesthetic solution 20 ml bupivacaine 0.25 % was delivered through the point between both the transverse process and the erector spinae muscle"
62533586|NCT04899388|PLACEBO_COMPARATOR|control|patients received spinal anesthesia without any block
62533587|NCT01676415|ACTIVE_COMPARATOR|Prednisone|Oral steroid medication
62158721|NCT00751088|ACTIVE_COMPARATOR|1|Patients treated with Ajust positioning
62158722|NCT00751088|ACTIVE_COMPARATOR|2|Patients treated with MiniArc positioning
62158723|NCT00751088|ACTIVE_COMPARATOR|3|Patients treated with TVT secur system
62533588|NCT01676415|ACTIVE_COMPARATOR|Topical Mometasone|Topical steroid medication
62158724|NCT00751088|ACTIVE_COMPARATOR|4|Patients treated with tension free vaginal tape
62158725|NCT02548585|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (matched to either 100 micrograms \[mcg\], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
62158726|NCT02548585|EXPERIMENTAL|Cohort 1: MEDI0382 100 mcg|Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
62158727|NCT02548585|EXPERIMENTAL|Cohort 2: MEDI0382 150 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
62158728|NCT02548585|EXPERIMENTAL|Cohort 3: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
62158729|NCT02548585|EXPERIMENTAL|Cohort 4: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
62158730|NCT02548585|EXPERIMENTAL|Cohort 5: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
62533589|NCT03667209|EXPERIMENTAL|Traditional exercise and pain neuroscience education|Will include exercises of the neck and scapular regions using traditional methods and pain neuroscience education
62533590|NCT03667209|ACTIVE_COMPARATOR|Suspension exercise and pain neuroscience education|Will include suspension exercises of the neck and scapular regions using traditional methods and pain education.
62533591|NCT05597137|EXPERIMENTAL|Experimental Group|During the study period, all subjects were required to avoid a diet high in zinc in order to avoid interference with dietary zinc intake and reduce bias in the weeks 1-2. In the weeks 3-4, all subjects were started to receive zinc supplementation at the normal adult dose (zinc tablets: 1 tablet (10mg Zinc) once daily after meals), while maintaining the avoidance of high-zinc foods.
62533592|NCT03257514|ACTIVE_COMPARATOR|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
62533593|NCT03257514|PLACEBO_COMPARATOR|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
62158731|NCT02548585|EXPERIMENTAL|Cohort 6: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).
62158732|NCT04977089||Ischemic heart disease patients .|Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.
62158733|NCT02713776|EXPERIMENTAL|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
62158734|NCT02713776|PLACEBO_COMPARATOR|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
62158735|NCT03805698|EXPERIMENTAL|Platelet-rich Plasma (PRP) group|"Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will be treated intraoperatively with platelet-rich plasma (PRP) (24 subjects).~Intervention: use of Cascade device; Autologous Fibrin \& Platelet System; once processed, the platelet-rich plasma (PRP)is injected into the debrided wrist"
62158736|NCT03805698|ACTIVE_COMPARATOR|Standard Treatment group|"Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will undergo treatment, as is standard of care, followed by no treatment with platelet-rich plasma (PRP)(24 subjects).~Intervention: No platelet-rich plasma (PRP) injection into debrided wrist"
62533594|NCT06403124|EXPERIMENTAL|Patients with posterior wall of acetabulum fracture|
62533595|NCT03782909|EXPERIMENTAL|Behaviour change intervention|Intensive behaviour change for 6 weeks, followed by a maintenance phase for 6 weeks
62533596|NCT05535153||Experime|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
62533597|NCT02658838|EXPERIMENTAL|full amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with full amount low molecular weight heparin until they leave hospital.
62533598|NCT02658838|EXPERIMENTAL|half amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with half amount low molecular weight heparin until they leave hospital.
62533599|NCT02658838|EXPERIMENTAL|No low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with no low molecular weight heparin.
62533600|NCT04006483||Stannous Fluoride Dentifrice|Twice daily brushing
62533601|NCT04006483||Positive control dentifrice|Twice daily brushing
62533602|NCT04006483||Negative control dentifrice|Twice daily brushing
62158737|NCT06673524|ACTIVE_COMPARATOR|Group T (Transversus Abmoninis Plane Block)|TAP Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position, the ultrasound (USG) probe is placed in an oblique position lateral to the xiphoid process at the lower border of the rib cage. The rectus abdominis muscle and its posterior sheath are visualized above the transversus abdominis muscle. At this level, only the aponeurosis of the internal oblique muscle can be seen between the transversus and external oblique muscles. By applying some pressure and tilt to the probe, the image of the myofascial planes is better optimized. Using a 22-25G, 50-100 mm block needle, an in-plane technique is applied, advancing either medially to laterally or vice versa. In the fascial plane between the rectus abdominis and transversus abdominis or between the internal oblique and transversus abdominis muscles, 20 ml of 0.25% bupivacaine is injected. The same procedure is then applied to the opposite side.
62158738|NCT06673524|ACTIVE_COMPARATOR|Group R (Rectus-Intercostal Fascial Plane Block)|Rectus-Intercostal Fascial Plane Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position and under ultrasound (USG) guidance, a linear probe is placed 2-3 cm lateral and caudal to the xiphoid process to visualize the rectus abdominis muscle and the 6th-7th costal cartilages. Using an in-plane technique, the needle is advanced from caudal to cephalad. After confirming the target by hydrodissecting between the ribs and the rectus abdominis muscle, 20 ml of 0.25% bupivacaine is injected into the interfascial plane between the 6th-7th ribs and the rectus abdominis muscle using a 22-G, 80 mm block needle. The same procedure is then applied to the opposite side.
62158739|NCT05749939|EXPERIMENTAL|Treatment|Receives access to the online ACT course immediately after enrollment
62158740|NCT05749939|NO_INTERVENTION|Waitlist|Receives access to the online ACT course 30 days after enrollment
62158741|NCT02153697|EXPERIMENTAL|Pigmanorm Cream, Q-switched Ruby laser,solar lentigines|Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28.
62158742|NCT01589406||group A group B|A:Patients for surgical intervention B:Patients for radiotherapy
62158743|NCT04083950|EXPERIMENTAL|Single group|All participants will receive the vaccine and aspirin.
62158744|NCT00916318|EXPERIMENTAL|A: experimental|"(A) internet based information and communication tool Sundabarn.se("
62158745|NCT00916318|EXPERIMENTAL|(B): experimental|(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A
62158746|NCT00916318|EXPERIMENTAL|(c): experimental|(C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A
62158747|NCT00916318|ACTIVE_COMPARATOR|(D): control group|
62158748|NCT00882323|EXPERIMENTAL|Fludarabine|
62158749|NCT00887471||Children who underwent PITA|Children who underwent partial intracapsular tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
62158750|NCT00887471||Children who underwent T&A|Children who underwent total tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
62158751|NCT06721195||Remimazolam Sedation Group|"his cohort includes patients undergoing painless gastrointestinal endoscopy (gastroscopy, colonoscopy, or both) who receive sedation with remimazolam. The study aims to evaluate the incidence of euphoria induced by remimazolam and explore related factors. All patients receive sedation according to standard clinical guidelines, including pre-procedural sufentanil and lidocaine gel for oral preparation, followed by remimazolam for induction and maintenance.~Data collected include demographic characteristics, pre- and post-procedure euphoria scores assessed using the ARCI-MBG scale, perioperative safety indicators, and patient satisfaction."
62158752|NCT06309641||Ferric derisomaltose|Adult patients with anemia scheduled for administration of ferric derisomaltose as prescribed in routine care.
62158753|NCT06309641||Ferric carboxymaltose|Adult patients with anemia scheduled for administration of ferric carboxymaltose as prescribed in routine care.
62158754|NCT06309641||Case reports|Patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
62158755|NCT00084825|EXPERIMENTAL|Docetaxel + Imatinib Mesylate|Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.
62533603|NCT05227911||Abdominal Surgery Group|Participant undergoing abdominal surgery for any indication
62158756|NCT05847634||Acute Respiratory Distress Syndrome|Adults admitted to ICU with ARDS confirmed according to Berlin Definition
62158757|NCT03781934|EXPERIMENTAL|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|Phase 2a expansion cohort HCC
62158758|NCT03781934|EXPERIMENTAL|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|Phase 2a expansion cohort HCC
62158759|NCT03236818|OTHER|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
62158760|NCT04223141|EXPERIMENTAL|Study group|Robot-assisted laparoscopic resection of sigmoid colon with colorectal anastomosis constructed by the double purse-string technique
62158761|NCT01918852|ACTIVE_COMPARATOR|Capecitabine|Capecitabine 1250 mg/m2 for patients \< 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
62533604|NCT01987037||tests evaluation|children with autism spectrum disorder subjected to the NP-MOT tests
62533605|NCT01123135|ACTIVE_COMPARATOR|Vaginal ERT|Vaginal ERT cream 1 gm at bed time 3 times a week
62533606|NCT01123135|PLACEBO_COMPARATOR|Placebo|1gm of placebo at bed time 3 times a week
62533607|NCT04673682|EXPERIMENTAL|Group 1|"1. Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)~2. Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)"
62533608|NCT04673682|EXPERIMENTAL|Group 2|"1. Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)~2. Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)"
62158762|NCT01918852|EXPERIMENTAL|S1|S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
62158763|NCT01922102|EXPERIMENTAL|Group I|0.5 mg ranibizumab driven by visual acuity stability criteria
62158764|NCT01922102|EXPERIMENTAL|Group II|0.5 mg ranibizumab driven by disease activity criteria
62158765|NCT01922102|ACTIVE_COMPARATOR|Group III|verteporfin PDT
62158766|NCT06656663|EXPERIMENTAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and Link Workers (LWs), based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have a good knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
62158767|NCT06656663|ACTIVE_COMPARATOR|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
62158768|NCT04527341||cardiac surgery patients in ICU|
62158769|NCT05852379|EXPERIMENTAL|Active transcutaneous auricular vagus nerve stimulation|PtaVNS, twice daily, 30 minutes each time over 6 months. Followed by 6 months home excercice program, physiotherapy twice a week, and continuous low frequency antidromic pelvic neuromodulation (CAPN).
62158770|NCT05852379|SHAM_COMPARATOR|Sham transcutaneous auricular vagus nerve stimulation|Sham PtaVNS (fictive stimulation), twice daily, 30 minutes each time over 6 months. Followed by 6 months home excercice program, physiotherapy twice a week, and continuous low frequency antidromic pelvic neuromodulation (CAPN).
62158771|NCT02275806|OTHER|All enrolled patients|"Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8~Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71."
62158772|NCT00761332||Teriparatide|Patients treated with teriparatide
62158773|NCT00761332||Antiresorptive|Patients treated with antiresorptive therapy
62158774|NCT04257500|EXPERIMENTAL|Contraceptive Ring|Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing), which releases 120 mcg of etonogestrel and 15 mcg of ethinyl estradiol daily.
62158775|NCT05142553|EXPERIMENTAL|COVID-19 Vaccine HIPRA|40 ug/0.5 ml
62533609|NCT04020757|OTHER|Bicarb Variation|Variation in dialysis bicarbonate, lowered to 30 mEq/L for week 2 of 3
62533610|NCT05061186|EXPERIMENTAL|Resistive Expiratory muscle Training Group|Mild Resistive Expiratory muscle Training Group
62533611|NCT05061186|ACTIVE_COMPARATOR|Conventional Breathing Exercise Group|Breathing Ex: Pursed lip Breathing, Diaphragmatic breathing ex, incentive spirometer
62533612|NCT05379816|NO_INTERVENTION|conservative treatment|analgesics are used for PTPS
62158776|NCT05142553|ACTIVE_COMPARATOR|Cominarty (Pfizer-BioNtech)|30 micrograms/dose concentrate for dispersion for injection
62533613|NCT05379816|ACTIVE_COMPARATOR|Interventional treatment|perineural injection
62533614|NCT06406218|EXPERIMENTAL|Phase I Cardiac Rehabilitation Exercise Training|
62533615|NCT06406218|NO_INTERVENTION|Guideline control|During hospitalization, patients assigned to the guideline control only receive routine medication treatment according to the guidelines, without any exercise intervention or education.
62533616|NCT00634881|EXPERIMENTAL|Cohort A: Alemtuzumab i.v.|Intravenous administration of alemtuzumab according to the 3 + 3 dose escalation design.
62533617|NCT00634881|EXPERIMENTAL|Cohort B: Alemtuzumab s.c.|After i.v. MTD (maximum tolerable dosage) has been determined, subcutaneous dose escalation is performed according to the same escalation rules as for cohort A, starting with the recommended dose level of i.v. application.
62533618|NCT00186888|OTHER|Stratum A|Patients with early bilateral or unilateral, or patients with bilateral that have already had the advanced eye enucleated. Treatment included vincristine and carboplatin for 8 courses, given at 3-4 week intervals. Focal therapies any time after second course can include cryotherapy, laser photocoagulation, thermotherapy, and plaque radiotherapy
62533619|NCT00186888|OTHER|Stratum B|"Patients with bilateral disease (at least one advanced stage eye), candidate for conservative management.~Treatment included window treatment with vincristine and topotecan, Followed by 3 more courses of vincristine-topotecan if they had a response to the window+ 6 courses of vincristine and carboplatin. If they do not respond to the window, they receive 6 courses of vincristine, carboplatin, and etoposide. Periocular carboplatin is also given three times, depending on whether they respond to window. External Beam Radiation 44-46 Gy administered using standard practices."
62533620|NCT00186888|OTHER|Stratum C|"Patients with advanced unilateral advanced intraocular disease. First intervention is enucleation.~If enucleated eye does not have disease outside the retina (low risk), no additional treatment is given.~For patients whose enucleated eye shows tumor outside the retina (intermediate risk), they will receive 4 courses of vincristine, cyclophosphamide, and doxorubicin followed by G-CSF.~For patients with high risk disease (involvement of the sclera, optic nerve at the level of the cut-end), treatment after enucleation is 6 courses of alternating chemotherapy with vincristine, carboplatin, etoposide (VCE) to alternate with vincristine, cyclophosphamide, and doxorubicin (VCD). High risk patients also receive external-beam radiation therapy."
62533621|NCT00345943||Adolescents with Bulimia Nervosa or subclinical BN|Adolescents with Bulimia Nervosa or subclinical Bulimia Nervosa
62533622|NCT00345943||Healthy control adolescents|Healthy control adolescents
62533623|NCT04244123||growth hormone deficiency|growth hormone deficiency, requiring growth hormone treatment
62533624|NCT04244123||small for gestational age|small for gestational age and failure of post natal catch up height gain, requiring growth hormone treatment
62533625|NCT04244123||Turner syndrome|short stature due to Turner syndrome, on growth hormone treatment
62533626|NCT04244123||chronic renal failure|short stature due to chronic renal failure, treated with growth hormone treatment
62158777|NCT06472778||Participants with Smoldering Multiple Myeloma (SMM)|Participants diagnosed with SMM between 01 January 2016 and 31 December 2021 will be enrolled in this study. Only data available outside of clinical studies from participant medical records will be collected. The data collected per participant in this study is defined as data in medical charts from date of SMM diagnosis until 31 December 2023, death or lost to follow-up, whichever comes first.
62158778|NCT05734885|EXPERIMENTAL|Midwife Massage Experimental Group (1)|"Back and sacral massage will be applied to pregnant women in labor in the application group. Massage will be applied by the research midwife. Midwife massage will be performed when cervical dilation is 5-6 cm and 8-9 cm.~Massage application time will last 20 minutes."
62533627|NCT04244123||Prader Willi syndrome|short stature due to Prader Willi syndrome, treated with growth hormone treatment
62158779|NCT05734885|EXPERIMENTAL|Spouse Massage Experimental Group (2)|"Back and sacral massage will be applied to pregnant women in labor in the application group. Massage will be applied by the spouse of the pregnant woman. Massage will be performed when cervical dilation is 5-6 cm and 8-9 cm.~Massage application time will last 20 minutes."
62158780|NCT05734885|NO_INTERVENTION|Control Group|It will be perform routine practice who the women in the control group.
62158781|NCT06359574|EXPERIMENTAL|Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training group 1|Receives CCM-C training two weeks after baseline assessment.
62158782|NCT06359574|EXPERIMENTAL|Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training group 2|Receives CCM-C training two weeks after follow-up 1 assessment.
62158783|NCT04882956|ACTIVE_COMPARATOR|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
62158784|NCT04882956|ACTIVE_COMPARATOR|Eylea|Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months
62158785|NCT05165524|ACTIVE_COMPARATOR|Laser|
62158786|NCT05165524|ACTIVE_COMPARATOR|Cream|
62158787|NCT05165524|NO_INTERVENTION|Control|
62158788|NCT00859677||1|HIV-positive and MRSA negative
62158789|NCT00859677||2|HIV-positive and MRSA infected (skin/soft tissue)
62158790|NCT00859677||3|HIV-positive and MRSA colonized
62158791|NCT00859677||4|HIV-negative and MRSA negative
62158792|NCT00859677||5|HIV-negative and MRSA infected (skin/soft tissue)
62533628|NCT02281292|EXPERIMENTAL|LKA651 (Part 1)|LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye
62158793|NCT00859677||6|HIV-negative and MRSA colonized
62158794|NCT01129375|EXPERIMENTAL|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~* Day 1: clopidogrel 300 mg loading dose~* Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
62158795|NCT01129375|PLACEBO_COMPARATOR|Group placebo - placebo + omeprazole|"Period 1:~* Day 1: placebo loading dose~* Day 2 to Day 5: placebo, once daily~Period 2:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: placebo loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
62158796|NCT01129375|EXPERIMENTAL|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~* Day 1: clopidogrel 300 mg loading dose~* Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions"
62158797|NCT01129375|PLACEBO_COMPARATOR|Group placebo + omeprazole placebo|"Period 1:~* Day -5 to Day -1: omeprazole 80 mg, once daily~* Day 1: placebo loading dose + omeprazole 80 mg concomitantly~* Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~* Day 1: placebo loading dose~* Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
62533629|NCT02281292|PLACEBO_COMPARATOR|Sham injection (Part 1)|Sham injection in the study eye
62158798|NCT06601686|EXPERIMENTAL|Stimulation|Participants will undergo sham, TES or TES-TI stimulation while completing cognitive assessments.
62158799|NCT03562117|EXPERIMENTAL|Normal Hepatic function, Part 1 (Group D)|The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
62158800|NCT03562117|EXPERIMENTAL|Moderate hepatic impairment, Part 1 (Group B)|The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
62158801|NCT03562117|EXPERIMENTAL|Mild hepatic impairment, Part 2 (Group A)|The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
62158802|NCT03562117|EXPERIMENTAL|Severe hepatic impairment, Part 2 (Group C)|The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
62158803|NCT03562117|EXPERIMENTAL|Normal Hepatic function, Part 2 (Group E)|The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
62158804|NCT02502188|EXPERIMENTAL|Part 1 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
62158805|NCT02502188|EXPERIMENTAL|Part 2 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
62158806|NCT03966599|ACTIVE_COMPARATOR|Lateral position|The patient position was changed to lateral during surgery
62158807|NCT03966599|ACTIVE_COMPARATOR|prone position|The patient position was changed to prone during surgery
62533630|NCT02281292|EXPERIMENTAL|LKA651 and Lucentis (Part 2)|LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
62533631|NCT02281292|PLACEBO_COMPARATOR|Sham injection and Lucentis (Part 2)|Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
62533632|NCT02599038|EXPERIMENTAL|Serine supplementation|Serine oral administration 20mg/kg/day
62158808|NCT05308342|EXPERIMENTAL|UC-MSCs+hormone replacement group|Group A was the hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells group(test group).
62158809|NCT05308342|ACTIVE_COMPARATOR|hormone replacement group|Group B was the hormone replacement group (control group).
62158810|NCT06382155|EXPERIMENTAL|Vosoritide Dose 1 - Low Dose|Vosoritide Dose 1 daily injection
62158811|NCT06382155|EXPERIMENTAL|Vosoritide Dose 2 - Medium Dose|Vosoritide Dose 2 daily injection
62158812|NCT06382155|EXPERIMENTAL|Vosoritide Dose 3 - High Dose|Vosoritide Dose 3 daily injection
62158813|NCT06382155|PLACEBO_COMPARATOR|Placebo|Placebo daily injection
62158814|NCT06382155|ACTIVE_COMPARATOR|Human Growth Hormone|hGH daily injection
62158815|NCT04910399|EXPERIMENTAL|Blue fish hydrolysate|The test product is a food supplement named BrainBooster in our project. It is presented as a capsule containing a blue fish hydrolysate, containing peptides and n-3 polyunsaturated fatty acids.
62158816|NCT04910399|PLACEBO_COMPARATOR|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
62158817|NCT03829371|EXPERIMENTAL|ARM A (enrollment closed)|"Velcade (V):~* 1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;~* 1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 from cycle 5.~Melphalan (M):~- 9 mg/m2 orally on days 1, 2 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is a 42-day cycle. Duration: Maximum 9 cycles can be performed."
62158818|NCT03829371|EXPERIMENTAL|ARM B (enrollment closed)|"Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle. Duration: until PD or intolerance."
62158819|NCT03829371|EXPERIMENTAL|ARM A2|"Velcade (V):~- 1.3 mg/m2 subcutaneously twice weekly on weeks 1, 2, 4, and 5 of cycle 1 (days 1,4,8,11,22,25,29,32) and once weekly on weeks 1, 2, 4, and 5 of cycles 2 through 9 (days 1,8,22,29).~Melphalan (M):~- 9 mg/m2 orally on days 1, 2, 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle.~Daratumumab:~-16 mg per kilogram of body weight or 1800 mg Daratumumab subcutaneous (SC) (according to local clinical practice) with oral or intravenous dexamethasone (to manage infusion reactions) at a dose of 20 mg once weekly in cycle 1 (days 1,8,15,22,29,36), every 3 weeks in cycles 2 through 9 (days 1,22), and every 4 weeks thereafter until disease progression or unacceptable toxic effects. Dexamethasone at a dose of 20 mg was substituted for prednisone on day 1 of each cycle."
62158820|NCT03829371|EXPERIMENTAL|ARM B2|"Lenalidomide (R):~- 25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.~Daratumumab:~-intravenous at a dose of 16 mg per kilogram of body weight or 1800 mg Daratumumab subcutaneous (SC) (according to local clinical practice) once weekly during cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks thereafter; preinfusion medications were administered approximately 1 hour before each daratumumab dose."
62158821|NCT06093893|EXPERIMENTAL|Dexmedetomidine group|Participants randomized into this group will be given Dexmedetomidine to lower their blood pressure during jaw surgery.
62158822|NCT06093893|EXPERIMENTAL|Nicardipine group|Participants randomized into this group will be given Nicardipine to lower their blood pressure during jaw surgery.
62158823|NCT06093893|EXPERIMENTAL|Labetalol group|Participants randomized into this group will be given Labetalol to lower their blood pressure during jaw surgery.
62158824|NCT04516980||Participants with ankle sprain.|Participants with ankle sprain
62158825|NCT04516980||Participants without ankle sprain|Participants without ankle sprain
62158826|NCT06451705|ACTIVE_COMPARATOR|PECS|PECS II block before surgery using isobaric bupivacaine 0.25% 20 mL (50 mg)
62158827|NCT06451705|ACTIVE_COMPARATOR|LIA|Local infiltration anesthesia after completion of surgery using isobaric bupivacaine 0.25% 20 mL (50 mg)
62158828|NCT02391714|PLACEBO_COMPARATOR|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
62158829|NCT02391714|EXPERIMENTAL|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
62158830|NCT04896229|EXPERIMENTAL|Experimental: Intervention|Parent/student/dyads in the treatment condition will be sent program materials via mail and text or email, including smart-speaker hardware, wireless network bridges for wireless network connectivity, and web links to Talk STEM Familia, including set-up video tutorials, and graphic instructions. Intervention activities will take place in participants' homes over the 24-week intervention period and will include using the dual-language Talk STEM Familia technology to receive instruction, practice, and feedback on academic vocabulary.
62158831|NCT04896229|NO_INTERVENTION|Treatment as usual|Parent/student dyads in this arm will receive treatment-as-usual (the vocabulary instruction regularly provided in their schools). They will receive the TSF technology after post-test data has been collected.
62158832|NCT05438043|EXPERIMENTAL|Daratumumab|Participants will receive a single dose of daratumumab 16 milligrams per kilograms (mg/kg) intravenous (IV) or 1800 mg subcutaneous (SC) infusion on Cycle 1 Day 1 (28-day cycle), as monotherapy or in combination with standards of care treatment (that is, pomalidomide and dexamethasone, lenalidomide and dexamethasone, carfilzomib and dexamethasone) or standards of care treatment alone, depending on the treatment received in the parent study. Participants who received daratumumab IV during the parent study, will have an option to switch to daratumumab SC on Day 1 of any cycle during this long-term extension study.
62158833|NCT04851288|EXPERIMENTAL|MitoQ, 20 mg/day|Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
62158834|NCT04851288|PLACEBO_COMPARATOR|Placebo|Matched placebo capsules.
62158835|NCT05182242|EXPERIMENTAL|Patients|Pregnant women with sonographic signs
62158836|NCT05182242|OTHER|Health professionals|biologists, geneticists, obstetricians, midwives of the Pluridisciplinary Centers of Prenatal Diagnosis and genetic services
61975912|NCT04462003|ACTIVE_COMPARATOR|Apixaban|50 patients with DVT with malignancy were randomized to apixaban 10 mg twice daily dose for 7 days followed by apixaban 5 mg twice daily
62158837|NCT05172843|ACTIVE_COMPARATOR|Knee Arthroplasty|Surgical knee replacement using either total knee replacement (TKA) or unicompartmental knee replacement (UKA)
62158838|NCT05172843|EXPERIMENTAL|Supervised weight loss program|The supervised intensive dietary weight loss program with meal replacements
62158839|NCT04264156|EXPERIMENTAL|Lucinactant (160 mg/kg) + nCPAP|Lucinactant for inhalation, 160 mg total phospholipids (TPL)/kg Delivered as an aerosol once, with up to 3 repeats of 80 mg/kg allowed within 36 hours of birth
62158840|NCT04264156|SHAM_COMPARATOR|nCPAP Only|nCPAP Only as sham comparator. Bubble nCPAP is standard of care. Treatment time behind barrier to match active treatment delivery time
62158841|NCT04004806|NO_INTERVENTION|Pre-Intervention|Phase 1 (Observational phase): All residents and staff physicians rotating through the inpatient medicine services during the first three (3) months, who agreed to be a part of the study, will be provided with Hill Rom tracking devices to quantify the time spent at the patient's bedside by each member as part of the daily practice.
62158842|NCT04004806|EXPERIMENTAL|Intervention|Phase 2 (Intervention phase): The interventional phase will be six (6) months duration. During this period, the recorded time spent by the individual study participants at the patient's bedside will be compared to their respective peers, and percentile scores will be generated. Based on these percentile scores, the study participants will receive emails notifying them of the results. Participants whose scores fall in the lower 50th percentile will be encouraged to increase patient interaction times. Participants with scores in the top 50th percentile will receive congratulatory emails to encourage them to keep up the performance.
62158843|NCT04004806|NO_INTERVENTION|Post-Intervention|Phase 3: (Post Intervention observation phase): The final phase of the study will be again three (3) months. The intervention of feedback emails and text pages will be discontinued and the study participants will only be monitored to see if the past intervention made an impact on their daily clinical practice in terms of time spent with the patients.
62158844|NCT00230009|NO_INTERVENTION|Assessment only|
62158845|NCT00230009|EXPERIMENTAL|Brief intervention session|
62158846|NCT04526171|EXPERIMENTAL|Vaparshun|In intervention clusters, two full day events, with a gap of 4 weeks between the two events, were organized at cluster level. Eligible households with a government or contract tor built toilet were invited to enroll for a toilet makeover. Intervention activities, delivered at cluster level, included films on toilet improvement, comfort and convenience of toile use, addressing pit filling anxiety and celebrating proud toilet owners by providing certificates and acknowledging them during the events.
62158847|NCT04526171|NO_INTERVENTION|Control Arm|No intervention was delivered to clusters in the control arm.
62158848|NCT00203788|EXPERIMENTAL|1|Individual Placement and Support Plus Workplace Fundamentals Module
62158849|NCT00203788|ACTIVE_COMPARATOR|2|Brokered Vocational Rehabilitation
62158850|NCT04513041|EXPERIMENTAL|Pinhole/Tunnel|Participants will receive Pinhole surgical technique for treatment of soft tissue recession at one side of the mouth and Tunnel technique for treatment of soft tissue recession at the other side of the mouth
62158851|NCT03461120|EXPERIMENTAL|Treatment|Bupivacaine 0.3% \[or ropivacaine 0.5%\] infusion for 7 days via femoral and sciatic perineural catheters
62158852|NCT03461120|OTHER|Control|Bupivacaine 0.1% \[or ropivacaine 0.2%\] infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
62158853|NCT01107717|EXPERIMENTAL|Triple Therapy|initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
62158854|NCT01107717|ACTIVE_COMPARATOR|conventional therapy|sequential addition of metformin, glyburide and basal insulin
62158855|NCT06172777||suspected asthma|enrollment 200 subjects
62158856|NCT06172777||Suspected COPD|enrollment 200 subjects
62158857|NCT06172777||confirmed asthma|enrollment 200 subjects
62158858|NCT06172777||confirmed COPD|enrollment 200 subjects.
62158859|NCT01415180||Children: previously healthy|Previously healthy children, without chronic disease prior to the sepsis episode, expected to comprise about 50-60% of the total study population.
62158860|NCT01415180||Children: chronic, complex conditions|Children with chronic, complex conditions prior to the sepsis episode, expected to comprise about 40-50% of the study population.
62158861|NCT05108428|EXPERIMENTAL|MRI-guided adaptive radiation|Patients will receive capecitabine-based chemoradiotherapy (chemotherapy with capecitabine + radiation). Dosing will be modified based on tumor changes measured daily and weekly by MR-guided radiotherapy (MRgRT) utilizing MR-linac (MRL) systems. Chemoradiotherapy will be followed by standard of care consolidated chemotherapy. (FOLFOX)
62158862|NCT06721975|EXPERIMENTAL|p-Tm:YAG laser system|This is a new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG)
62158863|NCT06721975|ACTIVE_COMPARATOR|TFL laser system|The thulium fiber laser (TFL) has demonstrated effectiveness in this procedure.
62158864|NCT05876221||aTTP-Patients|Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
62158865|NCT03623308|EXPERIMENTAL|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
62158866|NCT03623308|EXPERIMENTAL|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
62158867|NCT03474978|EXPERIMENTAL|Upper Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in upper extremity
62158868|NCT03474978|EXPERIMENTAL|Lower Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in lower extremity
62158869|NCT06721364|EXPERIMENTAL|Single arm|This is single arm pretest post-test, behavioural Suicide prevention intervention, so all the participants will be given the intervention
62158870|NCT06566079|EXPERIMENTAL|Part 1 Dose Escalation|Patients will receive ISM6331 once daily in sequential cohorts of increasing doses.
61975913|NCT04462003|ACTIVE_COMPARATOR|Enoxaparin|50 patients with DVT with malignancy were randomized to enoxaparin (1mg/Kg/SC every 12 h)
62158871|NCT06566079|EXPERIMENTAL|Part 2 Dose Selection Optimization|Participants will receive ISM6331 once daily at each dose level from the two dose levels recommended by Study Review Committee.
62533633|NCT06055530||School aged children in Ethiopia|A number of school aged children in Ethiopia from 5-7 different schools in the Jimma region.
62158872|NCT04200898|EXPERIMENTAL|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
62533634|NCT06055530||School aged children in Uganda|A number of school aged children from Uganda. Children from 5-7 different schools will be in the group.
62158873|NCT05888103|EXPERIMENTAL|Inclisiran|Inclisiran s.c
62158874|NCT05888103|PLACEBO_COMPARATOR|Placebo|Placebo s.c.
62158875|NCT06721286|EXPERIMENTAL|Preoperative neoadjuvant therapy group|
62158876|NCT06721286|EXPERIMENTAL|Control group|
62158877|NCT05185102|EXPERIMENTAL|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
62158878|NCT03537534|EXPERIMENTAL|Experiment|Lidocaine jelly (2%) 5mL x 1 dose only
62158879|NCT03537534|PLACEBO_COMPARATOR|Placebo|Surgilube 5mL x 1 dose only
62533635|NCT02884401|OTHER|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
62533636|NCT04171206|EXPERIMENTAL|Free From Abuse|This is a brief internet-delivered intervention designed to boost participants' ability to recognise abusive behaviour, reduce acceptance of myths related to domestic violence and IPV, as well as decrease abuse perpetration and victimisation.
62533637|NCT04171206|PLACEBO_COMPARATOR|Technology and crime|This is a brief internet-delivered placebo intervention designed to inform participants about how the development of technology could affect crime.
61975914|NCT05585697||Type 2 diabetes or control|Individuals with type 2 diabetes. Expect to include 26. Individuals without type 2 diabetes. Expect to include 26.
61975915|NCT05460117|EXPERIMENTAL|Radiofrequency stimulus on the dominant PLANTAR FASCIOPATHY|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Plantar fasciopathy
61975916|NCT05589233||Patients COVID-19 positive admitted to the hospital|COVID-19-positive patients admitted eighter to the standard ward or intensive care unit who were vaccinated against SARS-Cov-2
61975917|NCT04730245|EXPERIMENTAL|Microbiota modification|
61975918|NCT01072812|EXPERIMENTAL|Posiphen® tartrate capsules|
61975919|NCT02805621||Subject|Patients with know or suspected coronary artery disease, who underwent both CT angiography and invasive coronary angiography including invasive FFR measurements.
61975920|NCT03958721|EXPERIMENTAL|Concurrent Adjuvant Capecitabine and Radiotherapy|
61975921|NCT05278247|EXPERIMENTAL|single arm for all subjects|all subjects receive the same diagnostic measurement
61975922|NCT02826031|EXPERIMENTAL|Sodium Hyaluronate Injection + DICL-SR|"Each syringe (2.5mL) contains 25mg of sodium hyaluronate, and one Artz® will be administered via intra-articular injection into the target knee at the baseline and Weeks 1, 2, 3 and 4 respectively for the combination group.~From the run-in period to the end of study, both groups will receive DICL-SR 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID） daily"
61975923|NCT02826031|ACTIVE_COMPARATOR|DICL-SR|From the run-in period to the end of study, both groups will receive Diclofenac Sodium Sustained-release Tablets(DICL-SR) 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID daily）. A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.
61975924|NCT04977908|EXPERIMENTAL|Fully closed-loop system with ultra-rapid Lispro insulin|"The fully closed-loop system (CamAPS HX) will consist of:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm~* Cloud upload system to review CGM/insulin data.~Participants will use ultra-rapid Lispro insulin in the closed-loop system"
61975925|NCT04977908|ACTIVE_COMPARATOR|Standard insulin pump therapy with CGM|"Participants will use their own insulin pump and usual insulin throughout this study period.~The CGM will be the Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)"
61975926|NCT03249233|EXPERIMENTAL|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
61975927|NCT03249233|EXPERIMENTAL|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
61975928|NCT03249233|ACTIVE_COMPARATOR|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
61975929|NCT03249233|ACTIVE_COMPARATOR|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
61975930|NCT00848367|EXPERIMENTAL|High attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
61975931|NCT00848367|EXPERIMENTAL|Low attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
61975932|NCT00751244|ACTIVE_COMPARATOR|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
61975933|NCT00751244|ACTIVE_COMPARATOR|2|12 weekly sessions of one-to-one PCT (psychotherapy)
61975934|NCT00751244|OTHER|3|90-day wait-list group
62158880|NCT05488314|EXPERIMENTAL|Phase 1 (Combination Dose Selection)|Participants will receive capmatinib 400 milligrams (mg) orally twice daily from Cycle 1 Day 1, in combination with amivantamab 700 mg intravenous (IV) infusion (for body weight less than 80 kilograms \[kg\]) or 1050 mg IV infusion (for body weight greater than or equal to 80 kg) once weekly from Cycle 1 Day 1 for 4 weeks and then every 2 weeks from Week 5 (Cycle 2; each cycle of 28 days). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET).
62158881|NCT05488314|EXPERIMENTAL|Phase 2 (Dose Expansion)|Participants with mesenchymal-epithelial transition (MET) exon 14 skipping mutation who are treatment naïve (Cohort 1A), who have received prior therapy (Cohort 1B), or participants with MET amplification who have received prior therapy (Cohort 1C) will receive capmatinib in combination with amivantamab at the RP2CD determined by the SET in Phase 1.
62158882|NCT04344236|NO_INTERVENTION|Control|
62158883|NCT04344236|EXPERIMENTAL|Saline oral/nasal rinse|
62158884|NCT04344236|EXPERIMENTAL|0.5% Povidone/Iodine oral/nasal rinse|
62533638|NCT03422939||Less experienced dietitians|There was no intervention, but we conducted separate analyses to identify differences according to the level of experience of the dietician. We used the median number of years of professional experience (median=8) to split the sample and create two subgroups: 1) less experienced dieticians (less than 9 years of experience; n= 225)
62533639|NCT03422939||More experienced dietitians|and 2) more experienced dieticians (9 years of experience or more; n=215).
62533640|NCT05819216|EXPERIMENTAL|partial body weight support treadmill training group|A set of 24 sessions of partial body weight support treadmill training involve administration of a motorized treadmill with an attached overhead unweighting system of 30% of each participant's body weight will be decreased. The treatment session lasts for 45 min (3 sessions/ week, for 8 weeks).
62533641|NCT05819216|EXPERIMENTAL|loaded treadmill training group|A set of 24 sessions of loaded treadmill training includes a motorized treadmill with an additional load (sand bags) attached to the child's lower extremities. A 60% mass lower limb weight will be added.
62158885|NCT04344236|EXPERIMENTAL|0.12% Chlorhexidine oral/nasal rinse|
62158886|NCT04422210|EXPERIMENTAL|Dose Escalation (Arm A1) (Maintenance only)|Cohort A1: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
62158887|NCT04422210|EXPERIMENTAL|Dose Escalation (Arm A2) (Maintenance only)|Cohort A2: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
62533642|NCT05637619||Dentate Patients|Patients with natural dentition - maxilla and mandible
62533643|NCT05637619||Zirconia|Patients that have a full-mouth (maxilla or mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial
62533644|NCT05637619||Hybrid Acrylic|Patients that have a full-mouth (maxilla or mandible) dental implant supported rehabilitation restored with acrylic material (hybrid acrylic)
62533645|NCT03893435|EXPERIMENTAL|Sacubitril/Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
62533646|NCT03893435|ACTIVE_COMPARATOR|Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Valsartan with an initial dose of 40 mg PO BID, with subsequent titrations to target maintenance dose of 160 mg BID as tolerated.
62158888|NCT04422210|EXPERIMENTAL|Dose Escalation (Arm A3) (Maintenance only)|Cohort A3: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.
62158889|NCT04422210|EXPERIMENTAL|Dose Escalation (Arm B1) (Induction + Maintenance)|Cohort B1: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
62533647|NCT00201409|EXPERIMENTAL|1|Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).
62533648|NCT00201409|PLACEBO_COMPARATOR|2|Participants will be randomized to receive placebo.
62533649|NCT03856112|EXPERIMENTAL|Arm I (ixazomib, venetoclax, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, venetoclax PO QD on days 1-28 and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62533650|NCT03856112|ACTIVE_COMPARATOR|Arm II (ixazomib, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62533651|NCT03856112|EXPERIMENTAL|Arm III (ixazomib, venetoclax, dexamethasone)|PI-refractory patients receive ixazomib citrate, venetoclax and dexamethasone as Arm I.
62533652|NCT01264536|EXPERIMENTAL|Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
62533653|NCT01264536|PLACEBO_COMPARATOR|maltodextrin|Maltodextrin is an inert sugar.
62533654|NCT06021535||Calcified Aortic Stenosis|Patients with calcified aortic valve or aortic stenosis will be enrolled Stool, blood samples and aortic valve of operated patients will be retrieved to evaluate the composition of the gut microbiota and its metabolites A follow up is planned for patients with no intervention on the aortic valve to assess the evolution of the aortic stenosis and the change in the gut microbiota.
62158890|NCT04422210|EXPERIMENTAL|Dose Escalation (Arm B2) (Induction + Maintenance)|Cohort B2: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
62158891|NCT04422210|EXPERIMENTAL|Dose Escalation (Arm B3) (Induction + Maintenance)|Cohort B3: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
62158892|NCT04422210|EXPERIMENTAL|Dose Escalation (Arm B4) (Induction + Maintenance)|Cohort B4: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
62533655|NCT06021535||Control|Patients without calcified aortic valve will be enrolled Stool and blood samples will be retrieved to evaluate the composition of the gut microbiota and its metabolites No follow up is scheduled.
62533656|NCT04299906|EXPERIMENTAL|Solaris Vascular Stent Graft|Implant of Solaris Vascular Stent Graft in aorto-iliac lesions
62533657|NCT05476419|EXPERIMENTAL|Direct intra-oral scanning technique for the post space.|intervention will be the direct scanning of the prepared post space inside the patient mouth by using an intraoral scanner.
62533658|NCT05476419|ACTIVE_COMPARATOR|In-direct scanning of the conventional post space silicone impression.|The comparator will be extraoral scanning of the conventional sillicon impression of the prepared post space by using an extraoral scanner.
62533659|NCT05428410||IL-4R responders|IL-4R was injected subcutaneously. Base line and treatment end point nasal polyp score were compared and NPS \>1.
62533660|NCT05428410||IL-4R nonresponders|IL-4R was injected subcutaneously. Base line and treatment end point nasal polyp score were compared and NPS ≤1.
62533661|NCT05428410||Controls|Placebo was injected subcutaneously.
62714267|NCT02700438|EXPERIMENTAL|Urgent PC Neuromodulation System®|The Urgent PC Neuromodulation System® (Uroplasty, Minnetonka, MN, USA) was used for percutaneous posterior tibial nerve stimulation. Subjects underwent one 30-min session 2 days per week for 8 consecutive weeks in an outpatient clinic. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion. PPTNS was undertaken at the highest amplification (0-20 mA) at a frequency of 20 Hz, causing neither a motor response nor pain.
62714268|NCT00011583|EXPERIMENTAL|1|1 hour/day of mechanically-assisted upper limb therapy
61975935|NCT04337606|EXPERIMENTAL|chidamide in combination with decitabine|chidamide 10mg/day, days 1-5, 20mg/day, day 8, 11,15, 18; decitabine 10 mg/day, days 1-5, every 3 weeks
61975936|NCT04337606|EXPERIMENTAL|decitabine in combination with Camrelizumab|decitabine 10 mg/day, days 1-5, every 3 weeks; camrelizumab 200mg d6
61975937|NCT01291992||Continuous EEG Monitoring|Immediately after surgery, while still sedated and in the cardiac surgery recovery unit, 9 sticker electrodes applied to the skin just below the hairline, which record brain activity onto a computer. The EEG will be recorded for 24 hours. This brain activity (EEG) will later be interpreted by a neurologist who will be looking for evidence of seizure activity in the brain waves. Other relevant information: age, sex, the nature of other health problems, drugs used, complications and whether or not seizures are found will be stored on our computer for further evaluation.
61975938|NCT03649698|EXPERIMENTAL|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
61975939|NCT03649698|EXPERIMENTAL|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
61975940|NCT03649698|EXPERIMENTAL|2 Anabolic interventions|Home-based training program and high quality protein supplement
61975941|NCT03649698|EXPERIMENTAL|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
61975942|NCT03649698|PLACEBO_COMPARATOR|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
61975943|NCT03421821|EXPERIMENTAL|Subfascial Injection Group|30 ml of 0.33% ropivacaine was injected to subfascial.
61975944|NCT03421821|ACTIVE_COMPARATOR|Extrafascial Injection Group|30 ml of 0.33% ropivacaine was injected to extrafascial.
61975945|NCT05242848|EXPERIMENTAL|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
61975946|NCT05242848|NO_INTERVENTION|Standard|Participants randomised to standard treatment will receive regular OAT clinic follow-up without added supplementation.
62158893|NCT04422210|EXPERIMENTAL|Dose Expansion|If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort would continue to test venetoclax in both induction and maintenance. Participants would be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction precluded identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax would only be investigated in dose-expansion in the maintenance setting. Participants would be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
62158894|NCT01732419|EXPERIMENTAL|Home-based training|"After the first three supervised training sessions in the hospitals, patients in the home-based training group are instructed to wear a heart rate monitor during exercise training at home. Prescribed exercise exists of two or three exercise sessions per week, of one hour at 70 - 85% of their maximum heart rate.~Once a week the heart rate data is uploaded and evaluated by an exercise specialist together with the patient by telephone."
62158895|NCT01732419|ACTIVE_COMPARATOR|Centre-based training|Patients in the centre-based training group will perform all trainings sessions under direct supervision of a physical therapist specialized in CR. Training sessions will be performed on an cycle ergometer, starting with a warm up phase of 5 min, followed by 50 min of cycling at 70-85% of the maximal HR and a cooling down period of 5 min. During the training period, physical therapists will record attendance, training duration and actual training intensity. After the 12-week training period patients receive individual advice from their physical therapist on physical activities.
62158896|NCT04662320|EXPERIMENTAL|Brief Electrical Stimulation|Single, 10 minute dose of electrical stimulation delivered to the ulnar nerve during surgical intervention for cubital tunnel decompression.
62158897|NCT04662320|NO_INTERVENTION|Standard of Care|Surgical intervention for cubital tunnel decompression.
62158898|NCT02574910|EXPERIMENTAL|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
62158899|NCT02574910|EXPERIMENTAL|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
62158900|NCT02574910|EXPERIMENTAL|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
62158901|NCT05203003||Adult patients who are included in the CONFIRM phase III trial|
62158902|NCT02004834|ACTIVE_COMPARATOR|0,5% levobupivacaine with 2% lidocaine|7,0 ml.of mixture 0,5% levobupivacaine with 2% lidocaine are given per level Th2,Th3,Th4 for ultrasound guided paravertebral blocks in breast surgery
62158903|NCT02004834|ACTIVE_COMPARATOR|0,5% levobupivacine|7,0 ml. 0,5% levobupivacaine are given per level Th2,Th3,Th4, given for ultrasound guided paravertebral blocks in breast surgery
62158904|NCT06107335|ACTIVE_COMPARATOR|Fluid restriction using crystalloid|Fluid restriction will be achieved with the crystalloid lactated ringer's injection administered at at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr).
62158905|NCT06107335|EXPERIMENTAL|Fluid replacement using colloid as guided by stroke volume variation (SVV)|Fluid replacement will be achieved with the colloid 5% albumin infusion. Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device.
62158906|NCT04599855|EXPERIMENTAL|Esketamine 56 Milligram (mg)|Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale \[MADRS\] assessment).
62158907|NCT04599855|EXPERIMENTAL|Esketamine 84 mg|Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
62158908|NCT04599855|EXPERIMENTAL|Placebo|Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
62158909|NCT06668077|EXPERIMENTAL|Combined intervention|Experimental: Active iTBS of the DLPFC combined with inhibitory control training. An experimental group will receive: i) an informative session; ii) 4 pre treatment sessions (one assessment session with questionnaires, one with fMRI and one with biological samples. Also, a counselling session on diet and on physical exercise); iii) participate in 2 weekly individual intervention sessions that consist of iTBS of the left DLPFC (10 min) followed immediately by inhibitory control training for 10 minutes; iv) 3 sessions of post treatment assessment (one with questionnaires, one with fMRI and one with biological samples); v) 2 follow-up assessment sessions (3 months after completing the intervention) to repeat questionnaires and biological samples
62533662|NCT04814212|EXPERIMENTAL|Drug-coated balloon (DCB)|The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.
62533663|NCT04814212|ACTIVE_COMPARATOR|Drug-eluting stent (DES)|The coronary lesions fulfilling the inclusion criteria and randomized to the DES group.
62533664|NCT02125253|EXPERIMENTAL|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
62533665|NCT02125253|ACTIVE_COMPARATOR|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
62533666|NCT02125253|PLACEBO_COMPARATOR|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
62158910|NCT06668077|ACTIVE_COMPARATOR|Active iTBS|Experimental: Active iTBS of the DLPFC only. An experimental group will receive: i) an informative session; ii) 4 pre treatment sessions (one assessment session with questionnaires, one with fMRI and one with biological samples. Also, a counselling session on diet and on physical exercise); iii) participate in 2 weekly individual intervention sessions that consist of iTBS of the left DLPFC that will last about 10 minutes each; iv) 3 sessions of post treatment assessment (one with questionnaires, one with fMRI and one with biological samples); v) 2 follow-up assessment sessions (3 months after completing the intervention) to repeat questionnaires and biological samples
62158911|NCT06668077|SHAM_COMPARATOR|Sham iTBS|Control: iTBS of the vertex (sham). The control group will receive: i) an informative session; ii) 4 pre treatment sessions (one assessment session with questionnaires, one with fMRI and one with biological samples. Also, a counselling session on diet and on physical exercise); iii) participate in 2 weekly individual intervention sessions that consist of iTBS of the vertex that will last about 10 minutes each; iv) 3 sessions of post treatment assessment (one with questionnaires, one with fMRI and one with biological samples); v) 2 follow-up assessment sessions (3 months after completing the intervention) to repeat questionnaires and biological samples
62158912|NCT05061823|EXPERIMENTAL|Bintrafusp alfa|
62158913|NCT01991678|EXPERIMENTAL|normal hepatic function|12 Patients will receive a 90-minute IV infusion
62158914|NCT01991678|EXPERIMENTAL|mild hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
62158915|NCT01991678|EXPERIMENTAL|severe hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
62158916|NCT03770156||Subjects who contacted CUMP by phone|Subjects who contacted CUMP (Medical Psychological Emergency Cell) by phone from Paris November 13th, 2015, London 11th,2017 ; Barcelone 17-18th, 2017 ; Strasbourg 11th, 2018.
62158917|NCT03527758|NO_INTERVENTION|Standard Invasive intraoperative monitoring|
62158918|NCT03527758|EXPERIMENTAL|Flo TracIQ with HPI software|
62158919|NCT05121649||Before|Injured patients included in the study from health trusts where video streaming not yet has been implemented in the EMCC
62158920|NCT05121649||After|Injured patients included in the study from health trusts where video streaming has been implemented in the EMCC
62158921|NCT04907877|EXPERIMENTAL|Probiotic|NordBiotic ImmunoVir, a mixute of bidido- and lactobacteria administered in a dose of 5 billion once a day for 28 days
62158922|NCT04907877|PLACEBO_COMPARATOR|Placebo|Maltodextrine administered once a day for 28 days
62158923|NCT06095115|EXPERIMENTAL|JNJ-77242113|Adolescent and adult participants will receive JNJ-77242113 from Week 0 through Week 156. At Week 24, adult participants who are psoriasis area and severity index (PASI) 75 or investigator global assessment (IGA) score of 0 or 1 responders (that is, those who achieve an IGA score of 0 or 1 and have \>=2-grade improvement from baseline) will be re-randomized either to continue JNJ-77242113 or to placebo (and will be retreated with JNJ-77242113 upon loss of \>=50% of their Week 24 PASI improvement). Adult participants identified as both PASI 75 and IGA 0 or 1 score non-responders will continue to receive JNJ-77242113 through Week 52. From Week 52 to Week 156, all adult participants will receive JNJ-77242113. Adolescents will not participate in re-randomization regardless of their PASI score or IGA score at Week 24. Adolescents will continue to receive JNJ-77242113 from Week 0 through Week 156.
62158924|NCT06095115|EXPERIMENTAL|Placebo|Adolescent and adult participants will receive JNJ-77242113 matching placebo from Week 0 to Week 16. Participants will cross-over to receive JNJ-77242113 from Week 16 through Week 156.
62158925|NCT00716209||1|Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)
62533667|NCT06049459|ACTIVE_COMPARATOR|Optical Correction alone|Optical correction alone (16 weeks) (Each participant will complete both study conditions.)
62533668|NCT06049459|EXPERIMENTAL|Therapeutic (Dichoptic) Virtual Reality Games plus Continued Optical Correction|Therapeutic (Dichoptic) Virtual Reality Games plus continued optical correction (16 weeks) (Each participant will complete both study conditions.)
62533669|NCT05068453|EXPERIMENTAL|OH2+HX-008+RT|Patients will get OH2 （once every two weeks）and HX-008 (once every three weeks)and radiotherapy (totally 3 times).
62533670|NCT05797818|EXPERIMENTAL|Methylene Blue|"All subjects will have an initial baseline culture done of their nasal microbiome followed by an administration of 0.01% methylene blue solution. Next, subjects will undergo two minute of non-thermal red light exposure. A second round of solution administration and light exposure will be repeated resulting in 4 minutes of red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
62533671|NCT05797818|EXPERIMENTAL|Chlorhexidine gluconate|"All subjects will have an initial baseline culture done of their nasal microbiome followed by an administration of 0.25% chlorhexidine solution. Next, subjects will undergo two minute of non-thermal red light exposure. A second round of solution administration and light exposure will be repeated resulting in 4 minutes of red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
62158926|NCT03726528|EXPERIMENTAL|Experimental intervention|
62158927|NCT02786277|EXPERIMENTAL|Recommended|Those whose uplift score represents a probability of benefit greater than 0.5 will generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will not generate an alert.
62158928|NCT02786277|EXPERIMENTAL|Anti-recommended|Those whose uplift score represents a probability of benefit greater than 0.5 will not generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will generate an alert.
62158929|NCT05819177||Cohort undergoing rehabilitation|This group of patients underwent standard rehabilitation programs set by national guidelines.
62158930|NCT05609864||Injectable drugs|Patient's data and data relating to prepared/administrated/discarded injectable drugs will be collected during 24 hours in the operating rooms by anesthesia department
62158931|NCT06212596|EXPERIMENTAL|Selinexor cylophosphamide prednisone|Participants will receive treatment with Selinexor, Cyclophosphamide and Prednisone.
62158932|NCT06212596|ACTIVE_COMPARATOR|Cyclophosphamide predinisone|Participants will receive treatment with Cyclophosphamide and Prednisone. Participants who experience disease progression on the CP arm, may receive SCP.
62158933|NCT05250362|EXPERIMENTAL|Treatment|
62158934|NCT03321175|EXPERIMENTAL|Subcutaneous irrigaton|Patients will receive 200 cc subcutaneous saline irrigation before skin incision closure.
62158935|NCT03321175|NO_INTERVENTION|Subcutaneous no irrigation|Patients will not receive subcutaneous saline irrigation before skin incision closure.
62158936|NCT03074968|PLACEBO_COMPARATOR|control|normal saline
62158937|NCT03074968|ACTIVE_COMPARATOR|benzydamine hydrochloride|Benzydamine Hydrochloride
62158938|NCT02240810||PLATINUM Diversity (Overall)|PLATINUM Diversity (Overall) population. Test device is Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (CSS)
62714269|NCT00011583|ACTIVE_COMPARATOR|2|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
62158939|NCT01145326|SHAM_COMPARATOR|Control|Sham-Functional microneedles (no actual microneedles) application, prior to 4% lidocaine gel (LG4) placement.
62158940|NCT01145326|EXPERIMENTAL|Microneedle|Functional microarray (FMA) (microneedles) application, prior to 4% lidocaine gel (LG4) placement.
62158941|NCT02033668|ACTIVE_COMPARATOR|Arm A|Participants in this arm will receive single 200 milligram (mg) dose of GSK933776 administered by IV infusion
62158942|NCT02033668|EXPERIMENTAL|Arm B|Participants in this arm will receive single 200 mg dose of GSK933776 administered SQ
62158943|NCT02033668|EXPERIMENTAL|Arm C|Participants in this arm will receive 50 mg dose of GSK933776 administered SQ once weekly for 4 weeks (total dose = 200 mg).
62158944|NCT02033668|EXPERIMENTAL|Arm D|Participants in this arm will receive single 200 mg dose of GSK933776 administered IM
62158945|NCT04871932||Recently unvaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, human papillomavirus \[HPV\] vaccine, and severe acute respiratory syndrome \[SARS\]-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Female)．
62158946|NCT04871932||Recently unvaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Male)．
62158947|NCT04871932||Recently vaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Female)．
62158948|NCT04871932||Recently vaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Male)．
62158949|NCT03867123|EXPERIMENTAL|Arm 1 (chemoradiation phase)|"Radiotherapy (RT) + temozolomide (TMZ) + LAM561 (during Concurrent phase - duration 6 weeks)\*:~LAM561 will be initiated at the start of the concurrent phase and will be administered on a continuous daily basis together with TMZ and RT for 6 weeks at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~RT will be administered only during the concurrent phase, consisting of fractionated focal irradiation administered using 1.8- 2 Gy/fraction, daily for 5 days/week for 6 weeks, for a total dose of up to 60 Gy.~TMZ will be administered during the concurrent phase at a starting dose of 75 mg/m2/day given daily for 6 weeks.~\* One extra week may be allowed."
62533672|NCT05797818|EXPERIMENTAL|Methylene blue and Chlorhexidine gluconate|"All subjects will have an initial baseline culture done of their nasal microbiome followed by an administration of 0.01% methylene blue and 0.25% chlorhexidine gluconate solution. Next, subjects will undergo two minute of non-thermal red light exposure. A second round of solution administration and light exposure will be repeated resulting in 4 minutes of red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
62533673|NCT05797818|EXPERIMENTAL|Light Only|"All subjects will have an initial baseline culture done of their nasal microbiome followed by 4 minutes of non-thermal red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
62533674|NCT02878486|EXPERIMENTAL|Group 1|Subjects will have clinic visits, home visits, and telephone visits. Subjects will be asked to wear a wrist monitor (Jawbone Up) for duration of the study, will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
62533675|NCT02878486|ACTIVE_COMPARATOR|Group 2|Subjects will make clinic visits. At home visits, subjects will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
62533676|NCT04674865|ACTIVE_COMPARATOR|Conventional treatment protocol group|Standardized treatment protocol including chest physical therapy as well as limb physical therapy and functional mobility was addressed.
62533677|NCT04674865|EXPERIMENTAL|ANB group|2 sessions per day was added to the standardized treatment protocol
62533678|NCT02175316|EXPERIMENTAL|Experimental: EECP for DOMS|All enrolled subjects will receive EECP treatment Delayed Onset Muscle Soreness.
62714270|NCT02789852|EXPERIMENTAL|Orthosis Group|Will use the night orthosis for interphalangeal in the treatment of OA hand.
62158950|NCT03867123|EXPERIMENTAL|Arm 2 (maintenance phase)|"TMZ + LAM561 (during Maintenance phase with TMZ 200 mg/m2/day at Cycle 2 - duration 8 weeks):~LAM561 will be initiated on day 2 of Cycle 2 of the maintenance phase, when TMZ 200 mg/m2/day is given and administered on a continuous basis for two 28-day cycles. LAM561 will be administered at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~TMZ will be administered at 200 mg/m2/day given daily the first 5 days for two 28-day cycles (if no toxicity is seen). In case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery.~Both arms will be followed by a 4-week safety follow-up"
62158951|NCT05651035|EXPERIMENTAL|Breastfeeding group|Preterm infants in this group are breastfed by their mothers during their first oral feeding. Before, during and after feeding, the preterm infant's oxygen saturation level and peak heart rate are measured for 30 minutes. In addition, the test test weighing is determined by weighing the baby before and after feeding.
62158952|NCT05651035|NO_INTERVENTION|Bottle-feeding group|Preterm infants in this group are fed with their mother's milk in the bottle during their first oral feeding.
62158953|NCT02125799|EXPERIMENTAL|Accelerated HF-rTMS|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
62158954|NCT06523803|EXPERIMENTAL|ZW171|
62158955|NCT02397902|EXPERIMENTAL|Dairy|Add 4 daily servings of high fat dairy to diet for a period of 4 weeks
62158956|NCT02397902|ACTIVE_COMPARATOR|Plant-based|Add 4 daily servings of fruit to diet and/or plant-based milk, remove all dairy from diet for a period of 4 weeks
62158957|NCT06720376||main cohort|
62158958|NCT02496663|EXPERIMENTAL|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA and CT scan, MRI and blood sample collection throughout the study.
62158959|NCT04973007|ACTIVE_COMPARATOR|Gadoxetate disodium exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
62158960|NCT04973007|ACTIVE_COMPARATOR|Gadobenate Dimeglumine exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
62158961|NCT02183961|EXPERIMENTAL|Laryngopharyngeal reflux|EER was detected using three methods: oropharyngeal pH was monitored for 24 hours using the Restech system; detection of pepsin in middle ear fluid obtained during myringotomy was done using Peptest, and detection of pepsin in adenoid specimen was done immunohistochemically using antibody P3635Rb-h.
62158962|NCT05771545||Pre-Innovation (Usual Care)|Patients evaluated in the psychiatric emergency department for possible involuntary admission during the year prior to the innovation in care. During this period, the attending psychiatrist was required to physically come to the hospital to examine the patient.
62158963|NCT05771545||Innovation (Tele-Psychiatry)|Patients evaluated in the psychiatric emergency department for possible involuntary admission during the innovation period. Instead of physically coming to the hospital, the attending physician will evaluate the patient via video-link, which will be facilitated by the on-site psychiatric resident.
62158964|NCT02197494|EXPERIMENTAL|Test|Valsartan Tablets USP 320 mg DIVIS
62158965|NCT02197494|ACTIVE_COMPARATOR|Reference|Diovan® (Valsartan) 320 Tablets
62158966|NCT01277302|EXPERIMENTAL|Ranibizumab 0.5 mg monthly - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
62533679|NCT04791423|EXPERIMENTAL|Single dose of GRAd-COV2|1 single IM dose of GRAd-COV2 2 x 10\^11 vp plus 1 dose of saline placebo after 21 days
62533680|NCT04791423|EXPERIMENTAL|Double dose of GRAd-COV2|2 repeated (21 days apart) IM dose of GRAd-COV2 1 x 10\^11
62533681|NCT04791423|PLACEBO_COMPARATOR|Placebo|Two doses of saline placebo on day 1 and day 22
62714271|NCT02789852|NO_INTERVENTION|Control Group|wait for treatment
61975947|NCT04162015|EXPERIMENTAL|nivolumab with pemetrexed and cisplatin or carboplatin|Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.
61975948|NCT03595033|EXPERIMENTAL|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
61975949|NCT02031926|EXPERIMENTAL|Positive expiratory pressure|
61975950|NCT02702505|EXPERIMENTAL|NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time. The new formulation has received the Food and Drug Administrations 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).19
61975951|NCT02702505|OTHER|ProRoot MTA|Control group. This group will receive the old formulation of MTA in the pulpotomy and the tooth will receive a full coverage stainless steel crown restoration.
61975952|NCT05802667||STEMI|A total of 300 STEMI patients admitted to the Department of Cardiology, Peking University Third Hospital from April 1, 2023 to March 31, 2024 were enrolled.
61975953|NCT03701347|ACTIVE_COMPARATOR|Reeve's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Reeve's simulators
61975954|NCT03701347|ACTIVE_COMPARATOR|Hefler's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Hefler's simulators
61975955|NCT03701347|EXPERIMENTAL|Ida's Model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Ida's simulators
62158967|NCT01277302|EXPERIMENTAL|Ranibizumab 0.5 mg PRN - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
62158968|NCT01277302|EXPERIMENTAL|Ranibizumab 0.5 mg monthly - non-randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
62158969|NCT04024436|EXPERIMENTAL|Futibatinib|"Group/Cohort 1 Description HR+ HER2- Measurable Disease w/ FGFR2 Amplification~Group/Cohort 2 Description TNBC Measurable Disease w/ FGFR2 Amplification~Group/Cohort 3 Description HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification"
62158970|NCT04024436|EXPERIMENTAL|Futibatinib plus Fulvestrant|Group/Cohort 4 Description HR+ HER2- Measurable Disease w/ FGFR1 Amplification
62158971|NCT05809271|EXPERIMENTAL|MDMA with booster|MDMA followed by MDMA
62158972|NCT05809271|EXPERIMENTAL|MDMA without booster|MDMA followed by placebo
62158973|NCT05809271|PLACEBO_COMPARATOR|Placebo|Placebo followed by placebo
62158974|NCT05306158|EXPERIMENTAL|CC+ECIG Condition|Combustible Cigarette (CC) and Electronic Cigarette (ECIG) users will be trained to avoid CC and ECIG-related images and approach positive images.
62158975|NCT05306158|ACTIVE_COMPARATOR|CC Only Condition|Participants in this arm will be trained to avoid only combustible cigarette images, not electronic cigarettes images.
62158976|NCT05306158|SHAM_COMPARATOR|Sham Condition|Participants will pull and push all pictures of CC and ECIG images equally with no preference towards one or the other.
62158977|NCT05816928||COVID19-associated ARDS (CARDS)|This group included COVID19 patients with acute respiratory distress syndrome. Patients were put under prone position while their pulmonary function was measured using EIT before and after proning.
62158978|NCT05816928||Non-COVID19-associated ARDS (non-CARDS)|This group included patients with acute respiratory distress syndrome from other etiologies. Patients were put under prone position while their pulmonary function was measured using EIT before and after proning.
62158979|NCT01363206|EXPERIMENTAL|Single arm open label|GM-CSF and Ipilimumab
62158980|NCT02054442|EXPERIMENTAL|Arm A: MTX in combination with cetuximab|"The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.~Premedication: H1-receptor antagonist and dexamethasone.~The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
62533682|NCT02015429|ACTIVE_COMPARATOR|Control|Pasta meal with added fractions or control with no fractions Pasta meal with no pea fractions
62533683|NCT02015429|EXPERIMENTAL|10 g protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein added to pasta meal
62533684|NCT02015429|EXPERIMENTAL|7 g yellow pea fibre|Pasta meal with added fractions or control with no fractions 7 g net yellow pea fibre added to pasta meal
62533685|NCT02015429|EXPERIMENTAL|Yellow pea fibre & protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein plus 7 g net yellow pea fibre added to pasta meal
62533686|NCT02881840|EXPERIMENTAL|14C-APD421|
62533687|NCT01539135|ACTIVE_COMPARATOR|Hi-Lo endotracheal tube|Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
62533688|NCT01539135|EXPERIMENTAL|TaperGuard endotracheal tube|TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
62533689|NCT00119067|ACTIVE_COMPARATOR|Anthrax Vaccine Adsorbed 8-SQ|receive 8 injections of AVA injected SQ at the same points as the original licensure: 0m, 2weeks, 1m, 6m, 12m, 18m, and 2 boosters - 30m and 42m.
62714272|NCT03139058|OTHER|prevalence of cirrhosis|Study the prevalence of cirrhosis in patients with VADS cancer
61975956|NCT02998840|ACTIVE_COMPARATOR|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
61975957|NCT02998840|ACTIVE_COMPARATOR|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
61975958|NCT02998840|SHAM_COMPARATOR|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
61975959|NCT02998840|SHAM_COMPARATOR|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
61975960|NCT05000125||Slides from the German Co-Screening program|From 32506 LBC slides (ThinPrep, Hologic Inc., USA) from the German Co-screening program measured in 2020 with the TIS all abnormal findings according to Munich III groups (II-p - V) and 3% of normal slides (Munich III groups (I+II-a)) will be selected for the additional measurement with the Genius Digital cytology system.
61975961|NCT03796429|EXPERIMENTAL|GS+Toripalimab|
61975962|NCT05649254||study group|in which TENS application will be applied
61975963|NCT05649254||Control group|placebo treatment
61975964|NCT01079091|EXPERIMENTAL|ADVOS (Hepa Wash)|"Treatment with the liver support system Hepa Wash"
61975965|NCT04360954||Acute COVID infection|Active infection with positive RT-PCR
61975966|NCT04360954||Convalescent COVID|Recent documented infection. Now asymptomatic and RT-PCR negative.
61975967|NCT04360954||US Controls|Human samples pre-COVID.
61975968|NCT04360954||LMIC Controls|Samples from LMIC pre-COVID.
61975969|NCT01509833|EXPERIMENTAL|rFSH|Administration of recombinant FSH for ovarian stimulation.
61975970|NCT01509833|EXPERIMENTAL|hCG(100IU)|Administration of late follicular low dose hCG(100U) for ovarian stimulation.
61975971|NCT01509833|EXPERIMENTAL|hCG(200IU)|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
62158981|NCT02054442|ACTIVE_COMPARATOR|Arm B: MTX|"The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
62158982|NCT05759143|EXPERIMENTAL|Nest Refinement Phase|"20 participants and clinicians will complete study procedures as outlined:~* Nest portal orientation and access.~* Semi-structured, 30-minute interviews. Solicited feedback on content and processes will refine the intervention for a pilot phase."
62158983|NCT05759143|EXPERIMENTAL|Nest Pilot Phase|"10 Participants and 10 clinicians will complete study procedures as outlined:~* Baseline survey (participant).~* Standard clinic visit.~* Nest portal orientation and access (participant and clinician).~* Post-visit survey (participant and clinician).~* Brief, 30-minute, semi-structured interview (participant and clinician)."
62714273|NCT04624178|EXPERIMENTAL|Rucaparib in combination with Nivolumab|"One treatment cycle will consist of 28 days. Patients will receive rucaparib at 600 mg, orally, twice daily, continuously for 28 days. They will receive 480mg of nivolumab intravenously on day 1 of every four-week cycle. This is the recommended phase II dose of the combination therapy. Re-staging scans will be performed every 8 weeks.~Treatment will be repeated until the patient develops progressive disease or unacceptable toxicity or for a maximum duration of 26 cycles as long as patients are receiving benefit from treatment, have not had disease progression, met any criteria for study withdrawal and are tolerating therapy."
62714274|NCT05066412|EXPERIMENTAL|Arm 1|Prophylactic CD45RA-depleted DLI
62714275|NCT04945460|PLACEBO_COMPARATOR|Placebo|Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period.
62158984|NCT06067958|ACTIVE_COMPARATOR|Dexmedetomidine|Intranasal Dexmedetomidine 2 microgram/kilogram, 30 minutes before eye examination
62714276|NCT04945460|EXPERIMENTAL|Sotatercept 0.3 mg/kg|Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period.
62158985|NCT06067958|PLACEBO_COMPARATOR|Placebo|Saline 0.9%, volume will change to match that of dexmedetomidine based on participants' weight. 30 minutes before eye examination
62158986|NCT05064475||Recurrent breast cancer patients with elevated tumor markers|PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer cells by using 18F-FDG. Its ability to identify tumor recurrence before detection of morphologic changes in conventional imaging reflecting its importance in detecting BC recurrence in asymptomatic patients with high tumor markers and negative results of radiological imaging. 18F-FDG PET/CT is frequently used for BC evaluation. However, data on its value in evaluating BC recurrence in patients with elevated tumor markers are limited and unclear
62158987|NCT02823886|EXPERIMENTAL|STEMI patients|
62158988|NCT04769947||Cohort 1|Cohort 1 retrospective/prospective study: 293 patients enrolled and reported in Fava et al 2019 (1) with at least 1 year of follow up at the end of the study (February 2017) and 107 patients enrolled but not reported in Fava et al 2019 since their follow-up was shorter than 1 year. The data for these patients will be collected since the end of previous study.
62158989|NCT04769947||Cohort 2|Cohort 2 retrospective/prospective study: patient not enrolled in the previous study (Fava et al 2019). The data for these patients will be collected since patient diagnosis to the end of the study.
62158990|NCT04769947||Cohort 3|Cohort 3 prospective study: patients who have discontinued TKI therapy after the study approval in each center. These patients will also participate in the validation process of Phase 2 of a questionnaire developed by an expert panel of eight CML patients with the purpose of capturing the experiences of people along all phases of the TFR.
62158991|NCT03574649|EXPERIMENTAL|NANT NSCLC Combination Immunotherapy regimen|
62158992|NCT03574649|ACTIVE_COMPARATOR|Standard of Care|
62533690|NCT00119067|EXPERIMENTAL|Anthrax Vaccine Adsorbed 8-IM|receive 8 injections of AVA IM administered at 0m, 2weeks, 1m, 6m, 12m, 18m, and 2 boosters - 30m and 42m.
62533691|NCT00119067|EXPERIMENTAL|Anthrax Vaccine Adsorbed 7-IM|receive 7 injections of AVA IM administered at 0m, 1m, 6m, 12m, 18m, and 2 boosters - 30m and 42m.
62533692|NCT00119067|EXPERIMENTAL|Anthrax Vaccine Adsorbed 5-IM|receive 5 injections of AVA IM administered at 0m, 1m, 6m, and 2 boosters - 30m and 42m.
62533693|NCT00119067|EXPERIMENTAL|Anthrax Vaccine Adsorbed 4-IM|receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42
62714277|NCT04945460|EXPERIMENTAL|Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg|Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week treatment Period.
62714278|NCT03914625|ACTIVE_COMPARATOR|Arm A (SR-Avg control)|Arm A: See detailed description.
62714279|NCT03914625|EXPERIMENTAL|Arm B (SR-Avg experimental)|Arm B: See detailed description.
62533694|NCT00119067|PLACEBO_COMPARATOR|Saline placebo IM or SQ|Saline injections to be administered either IM or SQ at 0m, 2weeks, 1m, 6m, 12m, 18m, and 2 boosters - 30m and 42m.
62533695|NCT00684892|EXPERIMENTAL|1|
62533696|NCT03944174||Single Trans-sacral Screw|
62533697|NCT03944174||Two Iliosacral Screws|
62533698|NCT04364425|EXPERIMENTAL|low dose steroid|patient received ultrasound-guided 40mg triamcinolone + 4cc xylocaine + 12cc NS
62533699|NCT04364425|ACTIVE_COMPARATOR|high dose steroid|patient received ultrasound-guided 10mg triamcinolone + 4cc xylocaine + 15cc NS
62533700|NCT02149108|EXPERIMENTAL|Nintedanib (BIBF 1120) + BSC|
62533701|NCT02149108|PLACEBO_COMPARATOR|Placebo + BSC|
62533702|NCT03557424|EXPERIMENTAL|Polyglucosamine Glucomannan normal dose|Patients received the single dose Polyglucosamine und Glucomannan (0,5 g resp. 1 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
62533703|NCT03557424|EXPERIMENTAL|Polyglucosamine Glucomannan high dose|Patients received the higher dose of Polyglucosamine und Glucomannan (1 g resp. 1,34 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
62533704|NCT03557424|PLACEBO_COMPARATOR|Placebo|Patients received Placebo three times per day over 65 days. The Placebo is administered according to the respective Intervention (Drug: Placebo Comparator: Placebo) as a powder which is dissolved in water. The solution is taken orally.
62533705|NCT05107141|ACTIVE_COMPARATOR|xenograft and a collagen membrane|
62533706|NCT05107141|ACTIVE_COMPARATOR|allograft and a collagen membrane|
62158993|NCT03430609|ACTIVE_COMPARATOR|Bipolar tweezers Astus Medical©|Laparoscopic treatment for endometrioma Astus© will use Bipolar coagulation (bipolar tweezers, Astus Medical ©, Copyright 2015, Tampa FL, USA) with 30 W power and a Valleylab generator (Medronic ©, Copyright 2017, Medtronic Parkway, Minneapolis, USA); the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
62533707|NCT04473911|EXPERIMENTAL|Regimen 1: Fludarabine, Cyclophosphamide, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician~* Pre- stem cell transplant:~  * Fludarabine predetermined dose, intravenously, 4 times per cycle~ * Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~ * Total body irradiation (TBI) once during treatment cycle~* Post stem cell transplant:~  * Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~ * Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral.~ * Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle~ * RGI-2001: IV, predetermined dose, weekly to 6 total doses"
62533708|NCT04473911|EXPERIMENTAL|Regimen 2: Fludarabine, Melphalan, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician~* Pre- stem cell transplant:~  * Fludarabine predetermined dose, intravenously 3 times per cycle~ * Melphalan, infusion, determined dosage, once per cycle~ * Total body irradiation (TBI) once per cycle.~* Post stem cell transplant~  * Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~ * Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral:~ * Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle~ * RGI-2001: IV, predetermined dose, weekly to 6 total doses"
62533709|NCT00716287||1|Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.
62158994|NCT03430609|ACTIVE_COMPARATOR|2-0 Vicryl® Suture|Laparoscopic treatment for endometrioma Vicryl® will use suturing with simple suture (2-0/Vicryl polyglactin absorbable synthetic suture; Ethicon Inc., New Jersey, USA); the number of sutures will be recorded. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
62158995|NCT03430609|ACTIVE_COMPARATOR|Surgicel®|Laparoscopic treatment for endometrioma Surgicel® will use Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA). Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
62158996|NCT05810285||VITAMIN E|Patients who received cemented total knee arthroplasty with vitamin E blended polyethylene mobile bearing
62158997|NCT05810285||POLYETHYLENE|Patients who received cemented total knee arthroplasty with conventional polyethylene mobile bearing
62158998|NCT06359483|EXPERIMENTAL|Three Meals/Day Phase|Participants in this arm consumed three meals daily, each providing a standardized amount of calories and macronutrients. Meals were served at specific times throughout the day, and blood samples were collected at baseline, after the last day of Phase 1, and after the last day of Phase 2. This arm aimed to investigate the impact of consuming three meals daily on bone remodeling and P1NP levels.
62158999|NCT06359483|EXPERIMENTAL|Eight Meals/Day Phase|Participants in this arm consumed eight meals per day, with smaller portions served more frequently throughout the day than the three-meals-per-day arm. Each meal provided a standardized amount of calories and macronutrients. Blood samples were collected at the same time points as in the three-meals-per-day arm. This arm aimed to compare the effects of consuming eight meals per day versus three meals per day on bone remodeling and P1NP levels.
62159000|NCT00237718|ACTIVE_COMPARATOR|ALA and Vitamin E|600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months
62159001|NCT00237718|PLACEBO_COMPARATOR|Placebo|placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months
62159002|NCT01072058|OTHER|TNF blockers|
62159003|NCT06636708|ACTIVE_COMPARATOR|Standard Eye Drops|Eyes randomized to this arm will receive a standard drop of 0.5% proparacaine HCl
62159004|NCT06636708|EXPERIMENTAL|Nanodropper|Eyes randomized to this arm will receive a Nanodropper-mediated microdrop of 0.5% proparacaine HCl
62533710|NCT02361294||Patient|Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.
62533711|NCT02361294||Control|Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.
62533712|NCT00902031|EXPERIMENTAL|Docusate + Sennoside|
62159005|NCT04246905|ACTIVE_COMPARATOR|sulforaphane|sulforaphane treatment arm
62159006|NCT04246905|PLACEBO_COMPARATOR|placebo|placebo arm
62159007|NCT00681135|EXPERIMENTAL|1|
62159008|NCT00681135|EXPERIMENTAL|2|
62533713|NCT00902031|PLACEBO_COMPARATOR|Sennoside + Placebo|
62533714|NCT03163524|EXPERIMENTAL|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
62714280|NCT03914625|ACTIVE_COMPARATOR|Arm C (SR-High Control)|Arm C: See detailed description.
62714281|NCT03914625|EXPERIMENTAL|Arm D (SR-High experimental)|Arm D See detailed description.
62714282|NCT03914625|EXPERIMENTAL|B-LLy|See detailed description.
62159009|NCT00681135|EXPERIMENTAL|3|
62159010|NCT00681135|ACTIVE_COMPARATOR|4|
62714283|NCT03914625|EXPERIMENTAL|DS B-ALL|See detailed description.
62714284|NCT03914625|EXPERIMENTAL|NCI SR or HR DS B-ALL|See detailed description.
62159011|NCT01184755|EXPERIMENTAL|Resperate device used for 8 weeks|Participants to use Resperate device to guide breathing for 8 weeks. After the primary 8-week trial, this group is divided into two subgroups to examine 16-week data: one subgroup that stops using the device after 8 weeks, and one asked to continue to use the device for the full 16 weeks.
62159012|NCT01184755|ACTIVE_COMPARATOR|Relaxation control device|Participants use modified device to pace breathing in the 13/minute range for daily practice for 8 weeks and no device thereafter
62159013|NCT01184755|NO_INTERVENTION|Usual Care|Participants continue their usual medication and other management for their hypertension. All participants (including UC) are given a home BP monitor and asked to take their BP in morning and evening 3 days/week.
62159014|NCT06476483|OTHER|DIALOG|This is the comparison group, they will complete the DIALOG measure biweekly for 5 months. DIALOG scores pre and post-intervention will be used in the analyses.
62159015|NCT06476483|ACTIVE_COMPARATOR|DIALOG+|This is the treatment group. The participants in this group have agreed to participate in DIALOG+ and will receive the intervention biweekly for 10 sessions (5 months). Pre and post-intervention DIALOG scores will be used in the analysis.
62159016|NCT02005484|EXPERIMENTAL|Trastuzumab Monotherapy|Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
62159017|NCT02422355||Femoral Neck Fractures AO/OTA 31-B1:3|Fixation using the implant FNS.
62159018|NCT03839355|ACTIVE_COMPARATOR|Eliquis|
62159019|NCT03839355|ACTIVE_COMPARATOR|Warfarin|
62159020|NCT01461434|EXPERIMENTAL|loop recorder|patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
62159021|NCT01461434|NO_INTERVENTION|regular follow-up|patients will receive regular follow-ups with standard ECG
62159022|NCT02594267|EXPERIMENTAL|Part 1: Dose Finding, Cohort 1|"Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1."
62159023|NCT04906759|EXPERIMENTAL|Meals plus exercise|
62159024|NCT04906759|EXPERIMENTAL|Meals only|
62159025|NCT06605157|EXPERIMENTAL|Music Therapy|"Live delivery of a music therapy protocol that is designed to be led by a board-certified music therapist (MT-BC). Activity blocks are identical to the reading arm:~* T0 Baseline measures~* Weeks 1-4: music therapy intervention~* T1 measures (end of week 4)~* Weeks 5-8: music therapy intervention~* T2 measures (end of week 8)~* Weeks 5-8: music therapy intervention~* T3 measures (end of week 12)~* T4 measures 4-week-follow-up (week 16)"
62159026|NCT06605157|ACTIVE_COMPARATOR|Reading Aloud|"Live reading aloud of an age-appropriate book by a group leader to control for social attention and isolate the effects of music.~Activity blocks are identical to the music therapy arm:~* T0 Baseline measures~* Weeks 1-4: music therapy intervention~* T1 measures (end of week 4)~* Weeks 5-8: music therapy intervention~* T2 measures (end of week 8)~* Weeks 5-8: music therapy intervention~* T3 measures (end of week 12)~* T4 measures 4-week-follow-up (week 16)"
62159027|NCT06003686|EXPERIMENTAL|Paralyzed Veterans of America (PVA) Cardio-Metabolic Disease (CMD) Consumer Guide Group|Hard paper copy of as well as an electronic copy of the guide will be provided to subjects and study staff will provide a general review of the contents of the guide with subjects during their education sessions. Participants will be in this group for 6 months.
62159028|NCT06003686|ACTIVE_COMPARATOR|WebMD Group|Subjects will be introduced to WebMD and its contents. A brief document will be provided that includes site summary and website. Study staff will provide a very brief overview of the site. Participants will be in this group for 6 months.
62159029|NCT01540474|EXPERIMENTAL|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion. This is a first-in-human study of FMP012. 30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine. Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
62159030|NCT01540474|EXPERIMENTAL|Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
62159031|NCT01540474|EXPERIMENTAL|Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
62714285|NCT06277115|OTHER|Single arm (therapy initiation followed by therapy withdrawal)|Continuous positive airway pressure (CPAP)
62159032|NCT01540474|OTHER|Control group-Challenged Only|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
62159033|NCT05718492|EXPERIMENTAL|HAIC|Treated by HAIC alone.
62714286|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
62159034|NCT02649478|EXPERIMENTAL|Fluticasone / Salmeterol|"fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler (LOMI) inhaler device twice a day by inhalation throughout the study"
62714287|NCT03158064|EXPERIMENTAL|Duravalumab + Tremelimumab|"Duravalumab/Tremelimumab: Durvalumab and Tremelimumab will be administered by IV every 4 weeks for up to 4 doses/cycles, then Durvalumab by IV every 4 weeks starting at Week 16 for 9 doses (total treatment duration of 12 months).~Participants enrolled now will receive tremelimumab \*300mg with durvalumab 1500mg for 1 cycle followed by 12 cycles of durvalumab 1500mg every 4 weeks or until lack of clinical benefit or unacceptable toxicity."
61975972|NCT00298220|ACTIVE_COMPARATOR|training|tailored multi-component implementation program
61975973|NCT00298220|NO_INTERVENTION|control|
62159035|NCT02649478|ACTIVE_COMPARATOR|Advair Diskus 100/50|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
62159036|NCT02649478|PLACEBO_COMPARATOR|placebo inhaler|placebo inhaled powder twice a day by inhalation throughout the study
62159037|NCT06337045|EXPERIMENTAL|Complex prevention and rehabilitation intervention (single arm)|It was a single-arm study.
62159038|NCT05921487|EXPERIMENTAL|Time Restricted Eating|This is a single-arm study in a convenience sample of Veterans with paraplegia and obesity. The intervention will test adherence of participants to a TRE window with a self-selected start time. The duration of the eating window will be 10 hours, maintained through study's end (end of week 6).
62159039|NCT03029689|EXPERIMENTAL|Current ART + Raltegravir|Current ART + Raltegravir
62159040|NCT03029689|PLACEBO_COMPARATOR|Current ART + placebo|Current ART + placebo
62159041|NCT02395406|ACTIVE_COMPARATOR|Totaltrack|OTI with Totaltrack
62159042|NCT02395406|ACTIVE_COMPARATOR|Airtraq|OTI with Airtraq
62159043|NCT06721897|EXPERIMENTAL|Intervention Group|The intervention group (IG) will undergo a 6-week prehabilitation program for total hip/knee replacement surgery. Once the surgery is complete, they will follow the same rehabilitation program proposed for the control group.
62159044|NCT06721897|EXPERIMENTAL|Control Group|The control group (CG) will carry out a post-operative physiotherapy program in addition to a home exercise program that will be shown by the physiotherapist before hospital discharge.
62159045|NCT05942183||CAM-ICU positive|delirium positive
62159046|NCT05942183||CAM-ICU negative|delirium negative
62159047|NCT04225871|EXPERIMENTAL|0.3 mg/kg zilucoplan (RA101495)|
62159048|NCT06154837|EXPERIMENTAL|Part A: Single ascending dose (SAD) of GSK3862995B|Healthy participants will receive GSK3862995B.
62159049|NCT06154837|EXPERIMENTAL|Part B: Repeat doses GSK3862995B|Participants with COPD will receive repeat doses of GSK3862995B.
62159050|NCT06154837|EXPERIMENTAL|Part B: Placebo|Participants with COPD will receive repeat doses of Placebo.
62159051|NCT04910204|EXPERIMENTAL|Early FEST + TST|Participants will receive FEST+TST at 3 to 6 months from SCI onset.
62159052|NCT04910204|EXPERIMENTAL|Delayed FEST + TST|Participants will receive FEST+TST at 6 to 9 months from SCI onset.
62159053|NCT06721208|EXPERIMENTAL|intervention|"- patients who will use the Move for Knee APP (intervention arm);"
62159054|NCT06721208|NO_INTERVENTION|control|patients who will be advised to engage in free physical activity (control arm).
62533715|NCT03163524|SHAM_COMPARATOR|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
62714288|NCT05186740|ACTIVE_COMPARATOR|Device: The ProVee Urethral Expander System|The ProVee Urethral Expander System consists of two components: a nitinol Expander implant and a 19Fr Delivery System designed to allow the Expander to be deployed under direct vision for the treatment arm.
62714289|NCT05186740|SHAM_COMPARATOR|Sham: Ureteroscope and urethral access sheath|An ureteroscope housed within the inner lumen of an urethral access sheath will be used under direct vision for the Sham procedure.
62159055|NCT05719155|EXPERIMENTAL|Sequence 1|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379)
62533716|NCT05280730||Boys with DMD|Boys ages 3 and above will be enrolled.
62533717|NCT05280730||Healthy boys|Healthy boys as a control group for brain imaging.
62533718|NCT00491140||Observation|Colorectal cancer patients
62714290|NCT05186740|OTHER|Crossover ProVee Urethral Expander System|"All subjects shall be unblinded following the 3 month follow-up visit. Those subjects randomized to the Sham Arm will be given the opportunity to crossover to the ProVee Urethral Expander System."
62714291|NCT03436342|EXPERIMENTAL|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
62714292|NCT06626230|EXPERIMENTAL|Dose Level 1|Participants will receive a supply of curcumin gelatin capsules to insert 500 mg intra-anally every day for a 14-day treatment period
62159056|NCT05719155|EXPERIMENTAL|Sequence 2|Period 1: Test drug(CKD-379) Period 2: Reference drug(D759+D745+D150)
62159057|NCT04976322|EXPERIMENTAL|Dapirolizumab pegol|Subjects will receive dapriolizumab pegol throughout the Treatment Period.
62159058|NCT00014235|EXPERIMENTAL|Arm I (indolent disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27."
62159059|NCT00014235|EXPERIMENTAL|Arm II (aggressive disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I."
62159060|NCT04150419|EXPERIMENTAL|G1|
62159061|NCT04150419|EXPERIMENTAL|G2|
62159062|NCT04150419|ACTIVE_COMPARATOR|G3|
62159063|NCT04552444||the death group|Through the corresponding treatment, the patients who died within 28 days
62159064|NCT04552444||the survival group|Through the corresponding treatment, the patients who survived within 28 days
62159065|NCT05841030||MDD Participants With Anhedonia|Data will be collected, for major depressive disorder (MDD) participants with anhedonia who have had an inadequate response to a standard of care (SOC) antidepressant treatment, from participant's source medical records from routine clinical practice over a period of 12 months.
62533719|NCT03983083|EXPERIMENTAL|Intervention|Aspects of the HEALED intervention are based on various components of successful interventions for breast cancer survivors and older adults, NCI funding priorities, CPS-3 survivor preferences discussed in prior focus groups and survivorship research from other cohorts. As such, HEALED participants will receive monthly motivational e-mails, based on prior studies of the most effective delivery time intervals for interventions involving cancer survivors, with links to a web-based platform which will provide: physical activity information (largely consisting of publicly available evidence-based resources), at-home exercise demonstrations/videos for survivors of all fitness levels, personal survivor stories, physical activity/sitting recommendations (based on National Guidelines and ACS guidelines for survivors), positive messaging, a space for SMART goal setting, a platform for physical activity tracking, a discussion board, etc.
62159066|NCT00816816|OTHER|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
62159067|NCT00282854||Group I: Cases|Children with rolandic epilepsy
62159068|NCT00282854||Group II: Controls|Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
62159069|NCT05104684|EXPERIMENTAL|group A:Chest Physical Therapy|Patients in group A will receive CPT program daily for three weeks before HSCT (hospital stay for allogeneic-HCT). The program consists of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment. The total duration of each CPT session ranged from 45-60 minutes according to patient tolerance. The choice of airway clearance method that will be applied depends on two factors; patient preference and the individual response of the patient to treatment.
62159070|NCT05104684|ACTIVE_COMPARATOR|Control group (B):Routine medical treatment|patients in group B will receive routine medical treatment
62159071|NCT02440256|OTHER|Cluster 1|Cluster 1 is the first OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the sixth month of the trial. Cluster 1 will be a 'no intervention' arm in the first 6 months of the study, and will cross-over to an experimental arm for months 6-24.
62159072|NCT02440256|OTHER|Cluster 2|Cluster 2 is the second OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the twelfth month of the trial. Cluster 2 will be a 'no intervention' arm in the first 12 months of the study, and will cross-over to a experimental arm for month 12-24.
62159073|NCT02440256|OTHER|Cluster 3|Cluster 3 is the final OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the 18th month of the trial. As such, Cluster 3 will be a 'no intervention' arm in the first 18 months of the study, and will cross-over to an experimental arm for months 18-24.
62159074|NCT02677688|EXPERIMENTAL|Autologous EBV specific CTL infusion|
62159075|NCT02862288|EXPERIMENTAL|Renal tumor|Microwave ablation of renal tumor
62159076|NCT02862288|EXPERIMENTAL|Lung tumor|Microwave ablation of lung tumor
62159077|NCT02862288|EXPERIMENTAL|Bone tumor|Microwave ablation of bone tumor
62159078|NCT01249794|NO_INTERVENTION|Best available treatment|
62159079|NCT01249794|EXPERIMENTAL|non invasive ventilation|
62714293|NCT06626230|EXPERIMENTAL|Dose Level 2|Participants will receive a supply of curcumin gelatin capsules to insert 1000 mg intra-anally every day for a 14-day treatment period
62714294|NCT06626230|EXPERIMENTAL|Dose Level 3|Participants will receive a supply of curcumin gelatin capsules to insert 1500 mg intra-anally every day for a 14-day treatment period
62159080|NCT05967273|EXPERIMENTAL|CirrhosisRx|Providers in this arm will have access to the CirrhosisRx CDS system, which aggregates and organizes clinical data, presents them in clinically relevant/intuitive fashion for cirrhosis care, and linked to order sets consistent with national guidelines.
62159081|NCT05967273|NO_INTERVENTION|Usual Care|Providers in this arm will not have access to the CirrhosisRx CDS system.
62159082|NCT04993976|EXPERIMENTAL|Prehabilitation group|Strength training along with warm-up and cool down for 8 weeks
62159083|NCT04993976|ACTIVE_COMPARATOR|Control group|Supervised Standard care plan for 8 weeks
62533720|NCT03983083|NO_INTERVENTION|Wait-list control|"Wait-listed control group will be instructed to continue behavior as-usual. They will receive access to the HEALED website at the end of the 12-week intervention period."
62533721|NCT00000259|PLACEBO_COMPARATOR|Placebo|Subject inhales no drug (100% oxygen)
62159084|NCT04232410||OSA Pcrit-DISE|Patients diagnosed with OSA and eligible for non-CPAP treatments
62533722|NCT00000259|ACTIVE_COMPARATOR|0.3% sevoflurane|
62714295|NCT06626230|EXPERIMENTAL|Dose Level 4|Participants will receive a supply of curcumin gelatin capsules to insert 2000 mg intra-anally every day for a 14-day treatment period
62714296|NCT06626230|EXPERIMENTAL|Dose Level 5|Participants will receive a supply of curcumin gelatin capsules to insert 2500 mg intra-anally every day for a 14-day treatment period
61975974|NCT02426892|EXPERIMENTAL|ISA101 + Nivolumab|"HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.~Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose.~There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond."
62533723|NCT00000259|ACTIVE_COMPARATOR|0.6% sevoflurane|
62533724|NCT00000259|ACTIVE_COMPARATOR|15% Nitrous oxide|
62533725|NCT00000259|ACTIVE_COMPARATOR|30% Nitrous oxide|
62533726|NCT04300010|ACTIVE_COMPARATOR|Blue Light Therapy|FDA cleared blue light product, Omniluxblue (Globalmed Technologies, Glen Elen, CA), which emits a 415 nm blue light irradiance of 40mW/cm2. Following the application of blue light protective eyewear, the blue light therapy device will be centered over the deltopectoral interval according to device standardized use instructions and a 23-minute treatment will be administered to dry skin. As was done in the topical BPO group, following treatment, a skin swab culture of the treatment shoulder will be taken, then both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder. Participants and research personnel conducting the blue light treatments will be wearing medical grade blue light protective glasses for safety.
62714297|NCT06626230|EXPERIMENTAL|Dose Level 6|Participants will receive a supply of curcumin gelatin capsules to insert 3000 mg intra-anally every day for a 14-day treatment period
62714298|NCT06626230|EXPERIMENTAL|Dose Level 7|Participants will receive a supply of curcumin gelatin capsules to insert 3500 mg intra-anally every day for a 14-day treatment period
62714299|NCT06626230|EXPERIMENTAL|Dose Level 8|Participants will receive a supply of curcumin gelatin capsules to insert 4000 mg intra-anally every day for a 14-day treatment period
62714300|NCT02847403|EXPERIMENTAL|exenatide|long-acting exenatide 2 mg subcutaneously once-weekly
62714301|NCT02847403|PLACEBO_COMPARATOR|placebo|no drug assigned
62714302|NCT03307382|EXPERIMENTAL|SpyGlass DS Cholangioscopy|ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
62159085|NCT04058847|EXPERIMENTAL|Intervention|Use of Your Heart Forecast and an e-mail follow up-program.
62159086|NCT04058847|NO_INTERVENTION|Control|The control group uses standard regime (business as usual).
62159087|NCT01086514|EXPERIMENTAL|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|In this study we will perform Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) on patients with newly diagnosed breast cancer using a dedicated research system, derived from a standard digital mammography unit and review workstation (Senographe DS and SenoAdvantage) modified to deliver the required dual energy paired exposures and visualization of combined images.
62159088|NCT02976363||Quadrantectomy Group|The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
62159089|NCT02976363||Control Group|While for the control group women with no breast cancer history were invited. Data from Maximal Respiratory Pressures (MIP/MEP) were collected at one phase in the sample of control group.
62159090|NCT06327997|EXPERIMENTAL|Fast CAR T cells|Pretreatment was given 5 days before CAR T infusion for 3 consecutive days, and CAR T cell infusion was performed on the 0th day
62159091|NCT06492226|EXPERIMENTAL|NKF-INS(A)|Single subcutaneous dose administration over three treatment periods
62159092|NCT06492226|ACTIVE_COMPARATOR|EU-NovoRapid®|Single subcutaneous dose administration over three treatment periods
62159093|NCT06492226|ACTIVE_COMPARATOR|US-NovoLog®|Single subcutaneous dose administration over three treatment periods
62159094|NCT06496867|EXPERIMENTAL|Early Internal Fixation|Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s).
62159095|NCT06496867|ACTIVE_COMPARATOR|Nonoperative Care with Early Rehabilitation|Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization
62159096|NCT01292005|EXPERIMENTAL|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
62159097|NCT01292005|PLACEBO_COMPARATOR|Placebo|Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
62159098|NCT04505215|EXPERIMENTAL|Mulligan Technique|In addition to the exercises applied to the participants in the control group, the participants in this group used Mobilization with movement, which was performed with the principle of painless movement 3 times a week for a total of 12 times a week for 4 weeks. Mobilization with movement has been performed by a certified physiotherapist who has been practicing this technique for 10 years.
62159099|NCT04505215|EXPERIMENTAL|Muscle Energy Technique|In addition to the exercises applied to the participants in the control group, the Janda method (Post Isometric Relaxation Technique) from Muscle Energy Technique (3 times a week) was used 3 times a week for 4 weeks.
62159100|NCT04505215|ACTIVE_COMPARATOR|Only Exercise (Control)|Stretching and strengthening exercises for the forearm extensors were shown to the participants in the control group for 4 weeks every day of the week.
62159101|NCT05586165|NO_INTERVENTION|Holdout|
62159102|NCT05586165|EXPERIMENTAL|Simple Reminder|
62159103|NCT05586165|EXPERIMENTAL|Flu Tag Along|
62159104|NCT05586165|EXPERIMENTAL|Covid-19 Booster + Flu Bundle|
62159105|NCT04650763|NO_INTERVENTION|Control Group|Dental implant was placed in these patients following full protocol of immediate implant placement.
62159106|NCT04650763|EXPERIMENTAL|PRP Group|In this group Platelet Rich Plasma (PRP) was injected in soft tissue over surgical site.
62533727|NCT04300010|ACTIVE_COMPARATOR|5% Topical Benzoyl Peroxide Gel|A pea-sized amount, \~0.5 grams, will be applied to a 10cm strip over the deltopectoral interval beginning the morning 48 hours prior to schedule research visit to obtain cultures. The benzoyl peroxide will be applied on dry skin after a shower. The gel will be applied once in the morning and once in the evening for two consecutive days as well as the morning of the scheduled research visit. Following treatment, a skin swab culture of the treatment shoulder will be taken, both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder.
62714303|NCT04279743|EXPERIMENTAL|ApoE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
62159107|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
62159108|NCT06181513|EXPERIMENTAL|Probiotics|Participants received 1 capsule daily of probiotics, administered orally for 16 weeks.
62159109|NCT06181513|PLACEBO_COMPARATOR|Placebo|Participants received 1 capsule daily of placebo, administered orally for 16 weeks.
62159110|NCT03347084|ACTIVE_COMPARATOR|Excitation|Excitation Paradigm: LIFUP excites the activity of hippocampal neurons.
62159111|NCT03347084|ACTIVE_COMPARATOR|Inhibition|Inhibition Paradigm: LIFUP inhibits the activity of hippocampal neurons.
62159112|NCT06361056|EXPERIMENTAL|mHealth app|"Women enrolled in the mHealth app study will receive access to the mHealth app, a list of available clinical trials within a 50-mile radius of their zip code, and the existing standard of care packet of cancer center resources."
62159113|NCT05942664|SHAM_COMPARATOR|Normal sleep|Participants will be asked to sleep during their normal sleep times prior to this visit
62159114|NCT05942664|ACTIVE_COMPARATOR|Sleep deprivation|Participants will be asked to go to bed normally but wake up earlier, such that normal sleep duration is restricted by 60%. For example, if someone normally sleeps for 8 hours by falling asleep at 11 pm and waking up at 7 am, they will be asked to fall asleep normally (11 pm) and sleep for 3.2 hours, which results in a wake-up time of 2:12 am.
62159115|NCT06566612||Anorexia Nervosa|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa.
62159116|NCT06566612||Bulimia Nervosa|Participants that meet DSM-V criteria for Bulimia Nervosa.
62159117|NCT06566612||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
62159118|NCT01912599|ACTIVE_COMPARATOR|Non-Glaucomatous|Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
62159119|NCT01912599|ACTIVE_COMPARATOR|Glaucoma|Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
62159120|NCT05660811|OTHER|30 days DAPT and long-term treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
62159121|NCT05660811|OTHER|6 months DAPT and long-term treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
62159122|NCT05660811|OTHER|30 days DAPT and 6 months treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
62159123|NCT05660811|OTHER|6 months DAPT and 6 months treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
62159124|NCT03424187|EXPERIMENTAL|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
62159125|NCT03424187|EXPERIMENTAL|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
62714304|NCT04279743|EXPERIMENTAL|ApoE4 non carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
62714305|NCT04261777|EXPERIMENTAL|SPL-01-001|
62159126|NCT03424187|EXPERIMENTAL|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
62159127|NCT06721468|EXPERIMENTAL|Objective 1: Sensory Evaluation|three different strains of trout (fish-meal diet, CX line, CLX line)
62533728|NCT04300010|ACTIVE_COMPARATOR|Light and Gel|Prior to treatment, a skin swab culture will be taken, 5% topical benzoyl peroxide treatment will be performed on dry skin immediately after a shower as described in the above paragraph. Again, five total treatments will be performed prior to research visit. On the day of the research visit, the blue light therapy protocol described above will be performed exactly the same followed by culture obtainment.
62533729|NCT00678197|EXPERIMENTAL|A|
62533730|NCT00678197|EXPERIMENTAL|B|
62533731|NCT00678197|NO_INTERVENTION|C|
62533732|NCT01383213|EXPERIMENTAL|CPAP (group A)|group A will be treated with CPAP using a helmet, initial PEEP of 10 cmH20 and an FiO2 set in order to maintain SpO2 ≥92%
62533733|NCT01383213|ACTIVE_COMPARATOR|oxygen therapy (group B)|group B (standard treatment) will be treated with oxygen therapy by Venturi mask with an FiO2 set in order to maintain SpO2 ≥92%.
62533734|NCT06438809|EXPERIMENTAL|Open label single arm study|All patients will receive a single injection of umbilical cord-derived mesenchymal stem cells (120 million cells), and their therapeutic response will be monitored over a period of 24 months.
62533735|NCT01350583|EXPERIMENTAL|Sodium Bicarbonate Therapy|Dose Escalation
62533736|NCT02188914||Inhalant use disorder group|Subjects must have a diagnosis of inhalant use disorder, according to the DSM-5, who are under a treatment program for addictive disorders.
62533737|NCT02188914||Normal control group|Normal control without a history of drug abuse or dependency.
62533738|NCT00867997|ACTIVE_COMPARATOR|Dentifrice|Chemoactive (remineralizing, neuroactive) dentifrice treatment
62714306|NCT06320990|EXPERIMENTAL|Tamoxifen|Tamoxifen 20mg by mouth daily for up to 6 months
62714307|NCT01224886|EXPERIMENTAL|Sedentary obese|
62159128|NCT06721468|EXPERIMENTAL|Objective 2: Repeated Exposure|2 oz of trout each week for 10 weeks
62159129|NCT06721468|EXPERIMENTAL|Objective 2: Repeated Exposure Plus Child-Centered Nutrition Phrases|2 oz of trout each week plus exposure to positive nutrition message about trout each week for 10 weeks
62159130|NCT06721468|PLACEBO_COMPARATOR|Objective 2: Puzzle Game|Exposure to a puzzle game each week for 10 weeks
62159131|NCT06721468|NO_INTERVENTION|Objective 3: Eat Smart Idaho|Only receive Eat Smart Idaho's standard 6-lesson in-person series of classes
62159132|NCT06721468|EXPERIMENTAL|Objective 3: Child-Centered Nutrition Phrases|"Receive Eat Smart Idaho's standard 6-lesson in-person series of classes AND asked to view an online trout-specific nutrition education and recipe preparation video series, About Trout! Pond to Plate."
62159133|NCT06721468|EXPERIMENTAL|Objective 3: Repeated Exposure|Receive Eat Smart Idaho's standard 6-lesson in-person series of classes AND receive 2 servings of trout per week for 12 weeks, to prepare at home and consume (2 oz. serving for child and 4 oz. serving for adult).
62159134|NCT06721468|EXPERIMENTAL|Objective 3: Repeated Exposure Plus Child Centered Nutrition Phrases|"Receive Eat Smart Idaho's standard 6-lesson in-person series of classes, AND receive 2 servings of trout per week for 12 weeks, to prepare at home and consume (2 oz. serving for child and 4 oz. serving for adult), AND asked to view an online trout-specific nutrition education and recipe preparation video series, About Trout! Pond to Plate."
62533739|NCT00867997|ACTIVE_COMPARATOR|Sealant|DBA/sealant application
62533740|NCT00867997|ACTIVE_COMPARATOR|Resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
62533741|NCT01631071|EXPERIMENTAL|Elderly subjects aged over 60 years|
62533742|NCT01631071|EXPERIMENTAL|Adults from 18 to 60 years old inclusive|
62533743|NCT00894101|EXPERIMENTAL|[F-18] FLT and FDG|
62533744|NCT01566903||arteriovenous malformations|
62159135|NCT00817739|ACTIVE_COMPARATOR|Continuous Therapy|Continuous complete androgen suppression therapy with leuprorelin 3.75 mg sustained release (SR), injection, subcutaneously once every 28 days and flutamide, 250 mg, tablet, orally thrice daily until there are signs of disease progression.
62159136|NCT00817739|EXPERIMENTAL|Intermittent therapy|Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach \>=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are \<normal (that is, \<4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
62159137|NCT02816645|EXPERIMENTAL|<5 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~* \< 5 years~* Between 5 and 10 years~* Between 10 and 15 years~* \> 15 years"
62159138|NCT02816645|EXPERIMENTAL|Between 5 and 10 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~* \< 5 years~* Between 5 and 10 years~* Between 10 and 15 years~* \> 15 years"
62159139|NCT02816645|EXPERIMENTAL|Between 10 and 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~* \< 5 years~* Between 5 and 10 years~* Between 10 and 15 years~* \> 15 years"
62159140|NCT02816645|EXPERIMENTAL|> 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~* \< 5 years~* Between 5 and 10 years~* Between 10 and 15 years~* \> 15 years"
62159141|NCT04165213|NO_INTERVENTION|Instructor-trained COPE clinicians|"Clinicians from PACE sites randomized to this study arm (control) will receive instructor-led training in the evidence-based dementia care program called COPE. After clinician consent and enrollment, outcome measures will be collected prior to training (pre-training baseline), after training (post-training baseline), and after delivering COPE to dyads (4 months post-implementation).~Dyads (caregivers and PLWDs) receiving COPE from Instructor-trained COPE clinicians are represented in the study arms Caregivers receiving COPE from instructor-trained COPE clinicians and PLWDs COPE from instructor-trained COPE clinicians.~These participants are receiving the usual instructor-led training - not the experimental training."
62533745|NCT01566903||Arterial stenosis|
62533746|NCT01566903||Post-treatment follow-up|Patient with an arteriovenous malformation for which treatment by embolization or radiosurgery is indicated
62159142|NCT04165213|EXPERIMENTAL|COPE module-trained clinicians|"Clinicians from PACE sites randomized to this study arm (intervention) will receive self-paced online module training in the evidence-based dementia care program called COPE. After clinician consent and enrollment, outcome measures will be collected prior to training (pre-training baseline), after training (post-training baseline), and after delivering COPE to dyads (4 months post-implementation).~Dyads (caregivers and PLWDs) receiving COPE from module-trained COPE clinicians are represented in the study arms Caregivers receiving COPE from module-trained COPE clinicians and PLWDs COPE from module-trained COPE clinicians."
62159143|NCT04165213|NO_INTERVENTION|Caregivers receiving COPE from instructor-trained COPE clinicians|"Caregivers of eligible PLWDS enrolled at PACE sites randomized to the control arm will be recruited by instructor-trained COPE clinicians. After initial recruitment, the study team will carry out consent and screening procedures with caregivers and collect caregiver outcome data at baseline (before meeting with COPE clinicians) and follow-up (4 months post-implementation). Caregivers must complete a minimal dose of 4 sessions out of 10 to be included in follow-up measures. Outcomes will be reviewed for change from baseline to follow-up and compared to caregivers receiving COPE from module-trained COPE clinicians for non-inferiority.~These participants are receiving COPE from clinicians trained in the instructor-led COPE training."
62159144|NCT04165213|EXPERIMENTAL|Caregivers receiving COPE from module-trained COPE clinicians|"Primary caregivers of eligible PLWDS enrolled at PACE sites randomized to the intervention arm will be recruited by module-trained COPE clinicians. After initial recruitment, the study team will carry out consent and screening procedures with caregivers and collect caregiver outcome data at baseline (before meeting with COPE clinicians) and follow-up (4 months post-implementation). Caregivers must complete a minimal dose of 4 sessions out of 10 to be included in follow-up measures. Outcomes will be reviewed for change from baseline to follow-up and compared to caregivers receiving COPE from instructor-trained COPE clinicians for non-inferiority."
62533747|NCT04295135|EXPERIMENTAL|OneSheet access|PCPs who receive access to, and training in the Chronic Pain OneSheet, and use it while caring for patients with chronic pain.
62533748|NCT04295135|NO_INTERVENTION|Normal practice|PCPs who do not receive access to, or training in the Chronic Pain OneSheet, and care for patients with chronic pain as they would normally.
62533749|NCT02771886|ACTIVE_COMPARATOR|2-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 2nd week in the study. The duration of the study will be 6 weeks."
62533750|NCT02771886|ACTIVE_COMPARATOR|4-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 4th week in the study. The duration of the study will be 6 weeks."
62533751|NCT05375526|EXPERIMENTAL|Primary staging laparotomy for suspicion of early stage EOC|In case of a primary staging laparotomy the diagnosis of malignancy is based on a frozen section of the resected adnexa, followed by the sentinel node technique during the same procedure.
62533752|NCT05375526|EXPERIMENTAL|Secondary staging laparotomy for EOC|On the other hand, in some cases early stage EOC is only diagnosed after the primary surgery, when the surgeon resects the ovary with the suspicion of benign disease. If the adnexa are already removed before the diagnosis of malignancy, a secondary staging laparotomy is required and, in this case, a single step approach for SLN is not feasible.
62533753|NCT01874067||Arthritis glove|Early inflammatory, rheumatoid or hand osteoarthritis with hand/wrist swelling and pain
62533754|NCT02674321|EXPERIMENTAL|SD-809|• SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.
62714308|NCT01224886|EXPERIMENTAL|Sedentary normal weight|
62714309|NCT01224886|NO_INTERVENTION|Athletes|
62714310|NCT01528579|ACTIVE_COMPARATOR|Neck Specific exercises|Neck Specific exercises from a structured frame of exercises
62714311|NCT01528579|ACTIVE_COMPARATOR|Behavioral approach|Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
62159145|NCT04165213|NO_INTERVENTION|PLWDs receiving COPE from instructor-trained COPE clinicians|"Eligible PLWDS enrolled at PACE sites randomized to the control arm will be screened for eligibility and initial interest by instructor-trained COPE clinicians before caregiver recruitment. PLWDs will only be enrolled if caregivers consent to participate. PLWD outcome data will be collected at baseline (before meeting with COPE clinicians) and follow-up (4 months post-implementation). A minimal dose of 4 sessions out of 10 sessions must be completed for PLWD to be included in follow-up measures. Outcomes will be reviewed for change from baseline to follow-up and compared to PLWDS receiving COPE from module-trained COPE clinicians for non-inferiority.~These participants are receiving COPE from clinicians trained in the usual instructor-led COPE training."
62159146|NCT04165213|EXPERIMENTAL|PLWDs receiving COPE from module-trained COPE clinicians|"Eligible PLWDS enrolled at PACE sites randomized to the intervention arm will be screened for eligibility and initial interest by module-trained COPE clinicians before caregiver recruitment. PLWDs will only be enrolled if caregivers consent to participate. PLWD outcome data will be collected at baseline (before meeting with COPE clinicians) and follow-up (4 months post-implementation). A minimal dose of 4 sessions out of 10 sessions must be completed for PLWD to be included in follow-up measures. Outcomes will be reviewed for change from baseline to follow-up and compared to PLWDS receiving COPE from instructor-trained COPE clinicians for non-inferiority."
62159147|NCT01622023|EXPERIMENTAL|Study group|intrauterine insemination after 24 hours
62159148|NCT01622023|ACTIVE_COMPARATOR|Control group|intrauterine insemination after 48 hours
62159149|NCT06193382|EXPERIMENTAL|PCIT Group|Participants in this group will receive the PCIT intervention for up to 5 weeks.
62159150|NCT04080778|EXPERIMENTAL|magnetic seizure therapy (MST)|
62533755|NCT05405972|EXPERIMENTAL|Group Receiving Intervention|"The intervention group receives a link each week connecting them to the videos for both parents and children as well as a communicating/connecting activity. The intervention is self-paced over a 4 week period.~The intervention was titled the Connected Family Series - For Foster Families (CFS-FF) (further referred to as the intervention) and was created/adapted in partnership from the Connected Family Series (CFS) by psychologists at the Karyn Purvis Institute of Childhood Development (KPICD). A letter of support from the KPICD is available in Appendix D. Adaptation was needed as the original intervention was geared toward adoptive families and excluded foster families. This process was done with the original creator (Dr. Jana Hunsley) with members of the research team and fostering community."
62159151|NCT04080778|ACTIVE_COMPARATOR|electroconvulsive therapy (ECT)|
62159152|NCT04133636|EXPERIMENTAL|JNJ-68284528|Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A(Progressive disease post 1-3 prior lines of therapy), Cohort B(Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma \[NDMM\], standard risk \[International Staging System Stage I/II\] and post initial therapy); Cohort E(NDMM,transplant not planned,high risk disease) will first receive quadruplet induction regimen of daratumumab,bortezomib,lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Part B:Cohort G(NDMM,transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel; Cohort H(NDMM,transplant-eligible) will receive D-VRd followed by cilta-cel.
62159153|NCT05071105|EXPERIMENTAL|40Gy/5fx|The starting dose level will be 8Gy x 5 fractions, i.e., 40 Gy/5 nonconsecutive once-daily fractions.
62159154|NCT05071105|EXPERIMENTAL|42.5Gy/5fx|The intermediate dose level will be 8.5Gy x 5 fractions, i.e. 42.5Gy/5 nonconsecutive once-daily fractions.
62159155|NCT05071105|EXPERIMENTAL|45Gy/5fx|The higher dose level will be 9Gy x 5 fractions, i.e. 45Gy/5 nonconsecutive once-daily fractions
62159156|NCT06290453||Multiple sclerosis patients (MS)|"included 40 patients with newly discovered MS (duration of the disease is 3 years or less) and diagnosed according to the revised McDonald criteria. The patients will be recruited from the neurology department of Assiut University Hospital.~MS patients will be further subdivided into two subgroups: 20 patients with RRMS and 20 patients with Progressive MS group."
62159157|NCT06290453||Control (C)|Group II: included 20 healthy individuals who will be age- and sex-matched as a control group, with no history of any neurological or autoimmune disease.
62159158|NCT05746585|EXPERIMENTAL|The TALK intervention for Black male adolescents and young adults (AYA)|The TALK, a parent-centered, adolescent-involved health promotion intervention for Black male adolescents and young adults (AYA). Through the use of entertainment videos and educational modules, investigators will provide parents with resources and tools for communicating with their adolescents about sexual health and experiences of racial discrimination, and how these experiences impact sexual health.
62159159|NCT03529942|EXPERIMENTAL|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
62159160|NCT06470373|ACTIVE_COMPARATOR|RBS-001 treatment group|All eligible subjects according to the inclusion/exclusion criteria will be randomized into the RBS-001 treatment group or Eylea® treatment group in a ratio of 1:1 with the BCVA score
62159161|NCT06470373|ACTIVE_COMPARATOR|Eylea® treatment group|All eligible subjects according to the inclusion/exclusion criteria will be randomized into the RBS-001 treatment group or Eylea® treatment group in a ratio of 1:1 with the BCVA score
62159162|NCT02933645|ACTIVE_COMPARATOR|Insulin nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration \[18F\]-FDG PET-CT scan lasting 100 min is started."
62159163|NCT02933645|PLACEBO_COMPARATOR|Placebo nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration \[18F\]-FDG PET-CT scan lasting 100 min is started."
62159164|NCT04879823|EXPERIMENTAL|Dexamethasone|"IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup.~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
62159165|NCT04879823|PLACEBO_COMPARATOR|Placebo|"An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
62159166|NCT05881161|EXPERIMENTAL|Adherence self-efficacy-enhancing exercise followed by internet intervention (Med-Stress Student)|
62159167|NCT05881161|ACTIVE_COMPARATOR|Internet intervention (Med-Stress Student)|
62159168|NCT06442462|ACTIVE_COMPARATOR|Active SPG302 to be administered to participants with Schizophrenia|Participants with schizophrenia will be randomized to receive SPG302 300 mg or placebo (two capsules of 150 mg) once daily for six weeks.
62159169|NCT06442462|PLACEBO_COMPARATOR|Placebo comparator to be administered to participants with Schizophrenia|Participants with schizophrenia will be randomized to receive SPG302 300 mg or placebo (two capsules of 150 mg) once daily for six weeks.
62159170|NCT06291935|EXPERIMENTAL|VG901|Participants will receive a single dose of intravitreal injection of VG901 in most affected eye at Day 0.
62159171|NCT06716970|EXPERIMENTAL|QR12000 75mg|Participants will be treated with one tablet of QR12000 75mg, one tablet of QR12000 150mg placebo and one tablet of Sacubitril/valsartan 200 mg placebo once daily for up to 8 weeks. Participants continue with one tablet of QR12000 150mg once daily for 44 weeks during TOP observation period.
62533756|NCT05405972|NO_INTERVENTION|Control Group|Families in the control group receive no video links during the 4 week period. Families assigned to the control do have the opportunity to participate in the intervention post-data collection and analysis and outside of the research protocol.
62533757|NCT03853148|ACTIVE_COMPARATOR|Otago|The Otago exercise program consists of the following: 1) A series of warm-up exercises, 2) Select exercises from the 17 Otago exercises which challenge the participant's strength and balance for up to 30 minutes, three times a week, 3) A walking program for up to 30 minutes, three times a week. Each Otago will be tailored for each participant's ability level.
62714312|NCT01528579|ACTIVE_COMPARATOR|Prescribed physical activity|Prescribed physical activity from a physiotherapist without neck specific exercises
62714313|NCT05857748||Single arm of DED patients|"1. Age ≥18 years at index date.~2. Confirmed diagnosis of DED.~3. Newly started on lifitegrast ophthalmic solution within the recruitment period and not receiving lifitegrast ophthalmic solution within 6 months prior to recruitment.~4. Received continuous medical care at the healthcare site defined as at least one clinical visit within 6 months."
62159172|NCT06716970|EXPERIMENTAL|QR12000 150mg|Participants will be treated with one tablet of QR12000 150mg, one tablet of QR12000 75mg placebo and one tablet of Sacubitril/valsartan 200 mg placebo once daily for up to 8 weeks. Participants continue with one tablet of QR12000 150mg once daily for 44 weeks during TOP observation period.
62159173|NCT06716970|ACTIVE_COMPARATOR|Sacubitril/valsartan 200 mg|Participants will be treated with one tablet of Sacubitril/valsartan 200 mg, one tablet of QR12000 75mg placebo and one tablet of QR12000 150mg placebo once daily for up to 8 weeks. Participants continue with one tablet of QR12000 150mg once daily for 44 weeks during TOP observation period.
62159174|NCT00360035|EXPERIMENTAL|GX15-070MS|Obatoclax mesylate 60mg
62533758|NCT03853148|ACTIVE_COMPARATOR|Otago + Gentle yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the Otago+GYYB group each exercise and their perceived benefits.
62714314|NCT04287972|EXPERIMENTAL|LSG-DPC|Laparoscopic Sleeve Gastrectomy and Diaphragmatic Pillar Closure.
62714315|NCT04287972|ACTIVE_COMPARATOR|LSG|Laparoscopic Sleeve Gastrectomy
62714316|NCT03186339||TAVI patients|patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
62714317|NCT03186339||SAVR patients|patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
62714318|NCT03186339||MM patients|patients in whom the aortic stenosis is medically managed
62159175|NCT06618001|EXPERIMENTAL|JNJ-89853413|Participants will receive JNJ-89853413 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-89853413 at the RP2D determined in Part 1.
62159176|NCT06315621|ACTIVE_COMPARATOR|Physical impression|
62159177|NCT06315621|EXPERIMENTAL|Scanning using intraoral scanner without markers|
62159178|NCT06315621|EXPERIMENTAL|Scanning using Intraoral scanner with markers|
62159179|NCT05498428|EXPERIMENTAL|Cohort 1(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q2W) + Lazertinib|Participants with treatment-naive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) exon 19 deletion (exon19del) or exon 21 leucine 858 to arginine substitution (exon 21 L858R) mutation, will receive amivantamab SC-CF injection, 1600 milligrams (mg) or 2240 mg if body weight is greater than or equal to (\>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily.
62159180|NCT05498428|EXPERIMENTAL|Cohort 2(Exon20 NSCLC,1L, Previously Untreated): Amivantamab (Q3W) + Chemotherapy|Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR exon20ins mutation will receive Amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is \>=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is \>=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle, starting with Cycle 2 along with pemetrexed 500 milligrams per meter square (mg/m\^2) as intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and IV infusion carboplatin area under the concentration-time curve 5 milligrams per milliliters (mg/mL) per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles.
62159181|NCT05498428|EXPERIMENTAL|Cohort 3(Exon19del/Exon21 L858R NSCLC,2L,Post Osimertinib):Amivantamab(Q3W)+Lazertinib+Chemotherapy|Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is \>=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is \>=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m\^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Lazertinib 240 mg orally once daily starting Cycle 5 Day 1 when carboplatin is complete or sooner if carboplatin discontinued earlier than Cycle 4.
62159182|NCT05498428|EXPERIMENTAL|Cohort 3b(Exon19del/Exon21 L858R NSCLC, 2L, Post Osimertinib): Amivantamab (Q3W)+Chemotherapy|Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is \>=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is \>=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m\^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression.
62159183|NCT05498428|EXPERIMENTAL|Cohort 4(Previously Treated with Amivantamab IV): Switch from Amivantamab IV to SC-CF (Q2W)|Participants who were previously on amivantamab IV once every 2 weeks (Q2W) regimen as part of standard of care, for at least 8 weeks, either as monotherapy or combination with lazertinib, will receive amivantamab SC-CF injection 1600 mg and 2240 mg if body weight is greater than or equal to 80 kg.
62159184|NCT05498428|EXPERIMENTAL|Cohort 5(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q4W) + Lazertinib|Participants with treatment-naïve locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation will receive amivantamab SC-CF induction with 1,600 mg (or 2,240 mg if BW \>=80 kg) on Cycle 1 Days 1, 8, 15, and 22, starting with Cycle 2 on Day 1 of each next 28-day cycle, amivantamab SC-CF (160 mg/mL co-formulated with rHuPH20) by manual injection at 3,520 mg (or 4,640 mg if BW \>=80 kg); along with lazertinib 240 mg by mouth once daily from Cycle 1 Day 1.
62533759|NCT03853148|ACTIVE_COMPARATOR|Otago + GYYB + Behavioral activation|This condition will incorporate Otago and GYYB as above and will also include behavioral activation to address motivation and affect. Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities. Each participant outlines general values and specific behaviors that 'demonstrate' each value, compiling a list of the latter. This list is then used to generate 10 to 20 highly defined values-based, reinforcing activities. Next, this list is combined with the activities outlines in Otago and GYYB and this master list is used to schedule these values-based activities for the next two days.
62533760|NCT03853148|EXPERIMENTAL|Caregiver Gentle yoga & yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the GYYB group each exercise and their perceived benefits.
62533761|NCT04326205|EXPERIMENTAL|Dual-aided|active tDCS to the ipsilesional primary motor cortex (M1lesioned) followed by FES to the paretic hand during MT
62533762|NCT04326205|ACTIVE_COMPARATOR|FES-alone|sham tDCS to the M1lesioned followed by FES to the paretic hand during MT
62736777|NCT03529838|PLACEBO_COMPARATOR|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
62159185|NCT05498428|EXPERIMENTAL|Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Anticoagulant|Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation treated will receive will receive amivantamab SC-CF injection, 1600 milligrams (mg) and 2240 mg if body weight is greater than or equal to (\>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily from Cycle 1 Day 1. Participants will additionally take prophylactic anticoagulation with a direct oral anticoagulant (DOAC) or a low molecular weight heparin (LMWH) for the first four months of study treatment (from Day 1 through Day 120) with the combination of amivantamab and lazertinib.
62159186|NCT05498428|EXPERIMENTAL|Cohort 7(Exon19del/Exon21 L858R NSCLC,2L,Post Amivantamab+Lazertinib):Amivantamab(Q3W)+Chemotherapy|Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after the combination of amivantamab and lazertinib will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is \>=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is \>=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m\^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression.
62159187|NCT06721533|EXPERIMENTAL|Arm 1|1. Real 10 Hz cerebellar rTMS (250 pulses) to the right cerebellar hemisphere immediately followed by 1 Hz cerebellar rTMS (600 pulses) to the same area. Pharyngeal motor evoked potential (PMEP) amplitude measured
62159188|NCT06721533|EXPERIMENTAL|Arm 2|2. Sham 10 Hz cerebellar rTMS (250 pulses) to the right cerebellar hemisphere immediately followed by 1 Hz cerebellar rTMS (600 pulses) to the same area. PMEP amplitude measured
62159189|NCT06721533|EXPERIMENTAL|Arm 3|3. Real 10 Hz cerebellar rTMS (250 pulses) to the right cerebellar hemisphere followed after 45 minutes by 1 Hz cerebellar rTMS (600 pulses) to the same area. PMEP amplitude measured
62159190|NCT06721533|EXPERIMENTAL|Arm 4|4. Real 10 Hz cerebellar rTMS (250 pulses) to the right cerebellar hemisphere followed after 90 minutes by 1 Hz cerebellar rTMS (600 pulses) to the same area. PMEP amplitude measured
62159191|NCT06721533|EXPERIMENTAL|Arm 5|5. Real 1 Hz cerebellar rTMS (600 pulses) to the right cerebellar hemisphere immediately followed by 10 Hz cerebellar rTMS (250 pulses) to the same area. PMEP amplitude measured
62159192|NCT06721533|EXPERIMENTAL|Arm 6|6. Sham 1 Hz cerebellar rTMS (600 pulses) to the right cerebellar hemisphere immediately followed by 10 Hz cerebellar rTMS (250 pulses) to the same area. PMEP amplitude measured
62159193|NCT06721533|EXPERIMENTAL|Arm 7|7. Real 1 Hz cerebellar rTMS (600 pulses) to the right cerebellar hemisphere followed after 30 minutes by 10 Hz cerebellar rTMS (250 pulses) to the same area. PMEP amplitude measured
62159194|NCT06721533|EXPERIMENTAL|Arm 8|8. Real 1 Hz cerebellar rTMS (600 pulses) to the right cerebellar hemisphere followed after 60 minutes by 10 Hz cerebellar rTMS (250 pulses) to the same area. PMEP amplitude measured
62159195|NCT06721533|EXPERIMENTAL|Arm 9|Most excitatory metaplastic protocol (comparing effects of arms 1-8 against one another) to right cerebellar hemisphere. Swallowing accuracy measurements.
62159196|NCT06721533|EXPERIMENTAL|Arm 10|Single dose cerebellar rTMS to right hemisphere. Swallowing accuracy measurements.
62159197|NCT05262660||SAAE group|Patients who were diagnosed with primary aldosteronism choice SAAE at our institution
62159198|NCT05262660||MRA group|Patients who were diagnosed with primary aldosteronism choice medical treatment(mineralocorticoid receptor antagonists, MRA)) at our institution
62159199|NCT04203368|ACTIVE_COMPARATOR|adenosine group|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil
62159200|NCT04203368|SHAM_COMPARATOR|verapamil group|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
62159201|NCT05324748|PLACEBO_COMPARATOR|Placebo Arm|
62159202|NCT05324748|EXPERIMENTAL|Intervention Arm|
62159203|NCT00947804||1. Patients with symptoms of ACS|Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG).
62159204|NCT00947804||2. Patients without symptoms of ACS|Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization.
62159205|NCT03933735|EXPERIMENTAL|Arm A: Dose Escalation|Up to 15 cohorts of participants receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
62714319|NCT05380687|EXPERIMENTAL|Training A - PEEP 10-5-5-5|"The respiratory muscles of all participants will be trained in 4 consecutive blocks of 30 minutes during ventilation in neural pressure support mode (NPS) with a pressure support of 7 cmH2O.~During training A, the 4 blocks are~A1. PEEP 10 cmH2O \| A2. PEEP 5 cmH2O \| A3. PEEP \*5\* cmH2O \| A4. PEEP 5 cmH2O~During the training, ventilator data will be recorded and respiratory muscles will be imaged using ultrasound.~Before and after each training block, an inspiratory and an expiratory hold (both ≤ 30 seconds) will be performed to assess fatigue."
62159206|NCT03933735|EXPERIMENTAL|Arm B: Dose Expansion Dose A|An expansion cohort will be enrolled at the recommended phase 2 Dose A.
62533763|NCT04326205|ACTIVE_COMPARATOR|tDCS-alone|active tDCS to the M1lesioned followed by sham FES to the paretic hand during MT
62533764|NCT04326205|PLACEBO_COMPARATOR|Dual-sham|sham tDCS to the M1lesioned followed by sham FES to the paretic hand during M
62533765|NCT04935424||Experimental：Leukoderma|Device: ApolloVue® S100 image system
62533766|NCT02912650|EXPERIMENTAL|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
62159207|NCT03933735|EXPERIMENTAL|Arm B: Dose Expansion Dose B|An expansion cohort will be enrolled at the recommended phase 2 Dose B.
62159208|NCT03933735|EXPERIMENTAL|Arm E: Monotherapy Once Every 4 Weeks (Q4W)|An expansion cohort will be enrolled at the recommended phase 2 Dose A.
62159209|NCT03933735|EXPERIMENTAL|Arm F: Monotherapy Dose C|An expansion cohort will be enrolled at the recommended phase 2 Dose C.
62159210|NCT01972373|EXPERIMENTAL|NIR endoscopy with Bevacizumab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, bevacizumab-IRDye800CW will be administered to a total of 30 patients with proven locally advanced rectal cancer.
62159211|NCT00606723|EXPERIMENTAL|1|"Group I: Relapsed AML-patients with blast cell reduction to \<20% before the second course of induction therapy. These patients will receive conventional SCT.~Group II: Patients with non response to frontline treatment of AML, patients with blast cells \<20% before the second course of induction therapy who do not achieve a second remission and relapsed AML-patients with blast cells \>=20% before the second course of induction therapy. If these patients have a matched donor (MSD/MD) they will receive SCT with FLAMSA.~Group III: Patients who are eligible for Group II but have no matched donor. These patients will receive SCT from a haploidentical donor."
62159212|NCT05820451||Left sided device|All patients implanted with a left sided support Impella device - this includes but is not limited to Impella 2.5, Impella CP, Impella 5.0, Impella 5.5.
62159213|NCT05820451||Right sided device|All patients implanted with a right sided support Impella device -this includes the Impella RP
62159214|NCT01636700|ACTIVE_COMPARATOR|tramadol infiltration|infiltration of tramadol 2mg/kg
62159215|NCT01636700|PLACEBO_COMPARATOR|Saline solution|Infiltration of saline
62159216|NCT01497678|OTHER|Extracellular Matrix|Implantation of Extracellular Matrix
62159217|NCT04004923|ACTIVE_COMPARATOR|Monopolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
62159218|NCT04004923|ACTIVE_COMPARATOR|Bipolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
62159219|NCT00856453|EXPERIMENTAL|Yoga classes plus home yoga practic|
62159220|NCT00856453|EXPERIMENTAL|home yoga practice alone|
62159221|NCT03240471|EXPERIMENTAL|One week of plaster cast|One week of plaster cast after a non-reduced distal radius fracture.
62159222|NCT03240471|OTHER|Control; four-five weeks of plaster cast|Four-five weeks of plaster cast after a non-reduced distal radius fracture, usual care.
62159223|NCT05722821|EXPERIMENTAL|Experimental group|An experimental group (GE): that after an initial evaluation will be subjected to a hypopressive abdominal gymnastics program, for 12 weeks with 2 weekly sessions (Tuesday and Thursday, controlling adherence to the sessions through attendance), with a duration of 45 min per session. Once the intervention is finished, you will be subjected to a final evaluation to see if there is a difference or not with the results obtained at the beginning.
62159224|NCT05722821|NO_INTERVENTION|Control group|A control group (CG): that will not be subjected to treatment, which will be evaluated in the pre and post phase of the study, and a follow-up by telephone contact of adherence to physical activity. The participants assigned to this group will receive general advice on the positive effects of the regular practice of physical activity aimed at preventing urinary incontinence, and they will be given the guide of recommendations for the promotion of physical activity.
61975975|NCT02296268||Pre-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC prior to the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
62159225|NCT05374967|OTHER|Control group|The control group will receive the current standard of care: an informational brochure on how to cope with fatigue.
62159226|NCT05374967|EXPERIMENTAL|Lifestyle intervention|Participants will undergo a multimodal lifestyle intervention, which focuses on nutrition, sleep, stress, and exercise. The lifestyle intervention includes digital lessons/webinars and online counseling by a nutritionist and a lifestyle coach.
62533767|NCT02912650|ACTIVE_COMPARATOR|Ibuprofen 250 mg|2 caplets of IBU 125 mg
62159227|NCT01393964|EXPERIMENTAL|Arm 1: Lenalidomide + Dexamethasone +Elotuzumab|Severe Renal Impairment
62159228|NCT01393964|EXPERIMENTAL|Arm 2: Lenalidomide + Dexamethasone +Elotuzumab|End-stage renal disease
62159229|NCT01393964|EXPERIMENTAL|Arm 3: Lenalidomide + Dexamethasone +Elotuzumab|Normal renal function
62159230|NCT06587360|EXPERIMENTAL|fertiShare intervention|sharing bad news eLearning course
62533768|NCT02912650|ACTIVE_COMPARATOR|Acetaminophen 650 mg|2 tablets of APAP 325 mg
62533769|NCT02912650|ACTIVE_COMPARATOR|Placebo|2 caplets of Placebo
62533770|NCT03400085|NO_INTERVENTION|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
62533771|NCT03400085|EXPERIMENTAL|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
62159231|NCT06587360|ACTIVE_COMPARATOR|fertiShare control|basic communication training skills eLearning course
62159232|NCT02700009|EXPERIMENTAL|Computer-assisted CBT (CCBT)|12 weeks of CCBT for depression
62159233|NCT02700009|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Treatment as usual by primary care physicians
62159234|NCT03974308|EXPERIMENTAL|Study group 1|Patients with spine osteoarthritis who will be treated in polish spas in Subcarpathian Region. Comprehensive physiotherapy including balneotherapy will be applied.
62159235|NCT03974308|ACTIVE_COMPARATOR|Study group 2|Patients with spine osteoarthritis who will be treated in outpatient treatment. Comprehensive physiotherapy without balneotherapy will be applied.
62533772|NCT00737750|EXPERIMENTAL|KH|Kneehab is a garment integrated NMES device with multipath technology.
62159236|NCT03974308|OTHER|Control group|Patients with spine osteoarthritis who will not have applied physiotherapy nor balneotherapy.
62159237|NCT04050722|EXPERIMENTAL|Test Product|Participants with no visible plaque will be instructed to apply full ribbon of the test product (containing 0.454 percent \[%\] of stannous fluoride\] on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
62159238|NCT04050722|OTHER|Negative Control Dentifrice|Participants with no visible plaque will be instructed to apply full ribbon of the negative control dentifrice (containing sodium fluoride) on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
62159239|NCT02857686|ACTIVE_COMPARATOR|arm intravenous regional anesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
62159240|NCT02857686|EXPERIMENTAL|forearm intravenous regional anesthesia|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
62159241|NCT06574724|EXPERIMENTAL|Green space intervention|Participants that visit a green space
62159242|NCT06720220|PLACEBO_COMPARATOR|Group C (Sedation / Control group)|The patients will receive only dexmedetomidine as a sedative for AFOI with placebo airway topicalization by nebulization, atomization and spray as you go using normal saline 0.9%.
62159243|NCT06720220|ACTIVE_COMPARATOR|Group N (Nebulization group)|"The patients will receive dexmedetomidine as a sedative in addition to lidocaine 2% nebulization for airway topicalization and placebo airway topicalization by atomization and spray as you go using normal saline 0.9%."
62159244|NCT06720220|ACTIVE_COMPARATOR|Group A (Atomization group)|"The patients will receive dexmedetomidine as a sedative in addition to lidocaine 2% by atomization modified McKenzie technique and placebo airway topicalization by nebulization and spray as you go using normal saline 0.9%."
62159245|NCT06720220|ACTIVE_COMPARATOR|Group S (SAYGo group)|"The patients will receive dexmedetomidine as a sedative in addition to lidocaine 2% by Spray as You Go technique and placebo airway topicalization by atomization and nebulization using normal saline 0.9%."
62159246|NCT02085824|EXPERIMENTAL|enoxaparin|enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
62159247|NCT02085824|EXPERIMENTAL|rivaroxaban|rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
62159248|NCT02085824|EXPERIMENTAL|dabigatran|dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
62159249|NCT02861716|EXPERIMENTAL|fentanyl and dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl and dexmedetomidine in 2ml volume will be injected slowly over 20 seconds.
62159250|NCT02861716|ACTIVE_COMPARATOR|dexmedetomidine and placebo for fentanyl|intrathecal bupivacaine (0.5%) 0.4mg/kg plus dexmedetomidine 0.2 μg/kg in 2ml volume and placebo (for fentanyl 0.2 μg/kg) it will be injected slowly over 20 seconds.
62159251|NCT02861716|ACTIVE_COMPARATOR|fentanyl and placebo for dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl 0.2 μg/kg in 2ml volume and placebo (for dexmedetomidine 0.2 μg/kg) it will be injected slowly over 20 seconds.
62159252|NCT04088305|EXPERIMENTAL|Study group|Patients of study group will accept vancomycin strategies decided by a serum trough concentration model.
62159253|NCT04088305|NO_INTERVENTION|Control group|Patients of control group will accept vancomycin dosages decided by attending physician.
62159254|NCT06506630|PLACEBO_COMPARATOR|CoQ10 1R|take orally 600 mg placebo per day
62159255|NCT06506630|EXPERIMENTAL|CoQ10 2R|take orally 600 mg drug per day (contains 100mg coenzyme Q10)
62533773|NCT00737750|ACTIVE_COMPARATOR|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
62714320|NCT05380687|EXPERIMENTAL|Training B - PEEP 10-5-0-5|"The respiratory muscles of all participants will be trained in 4 consecutive blocks of 30 minutes during ventilation in neural pressure support mode (NPS) with a pressure support of 7 cmH2O.~During training B, the 4 blocks are~B1. PEEP 10 cmH2O \| B2. PEEP 5 cmH2O \| B3. PEEP \*0\* cmH2O \| B4. PEEP 5 cmH2O~During the training, ventilator data will be recorded and respiratory muscles will be imaged using ultrasound.~Before and after each training block, an inspiratory and an expiratory hold (both ≤ 30 seconds) will be performed to assess fatigue."
62533774|NCT00737750|ACTIVE_COMPARATOR|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
62159256|NCT06506630|EXPERIMENTAL|CoQ10 3R|take orally 600 mg drug per day (contains 200mg coenzyme Q10)
62159257|NCT01852851|ACTIVE_COMPARATOR|Intervention Group|The intervention group will participate in the on-line eLearning program, an ergonomic assessment by an Occupational Therapist and job retention vocational counselling by a Vocational Rehabilitation Counsellor
62159258|NCT01852851|NO_INTERVENTION|Control Group|"The control group will receive usual care and receive printed educational materials about work and arthritis."
62159259|NCT00748098|OTHER|GSK1838262:placebo|GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
62159260|NCT00748098|OTHER|Placebo:GSK1838262|Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2
62159261|NCT05364073|EXPERIMENTAL|Stage 1 Dose Escalation and Backfill|Experimental: Previously treated patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations
62159262|NCT05364073|EXPERIMENTAL|Stage 2 Expansion Cohort 1|Previously Treated NSCLC Patients with EGFR Exon 20 Insertion Mutations
62159263|NCT05364073|EXPERIMENTAL|Stage 2 Expansion Cohort 2|Previously treated NSCLC Patients with HER2 Exon 20 Insertion Mutations
62159264|NCT05364073|EXPERIMENTAL|Stage 2 Expansion Cohort 3|Previously treated NSCLC Patients with EGFR Activating Mutations, who are not eligible for Cohorts 1 and 4
62159265|NCT05364073|EXPERIMENTAL|Stage 2 Expansion Cohort 4|Untreated or Previously treated EGFR TKI Naïve NSCLC Patients with EGFR Uncommon Mutations, excluding EGFR exon 20 insertion mutations
62159266|NCT06211751|EXPERIMENTAL|TQB3909 tablets+ TQB3702 tablets|TQB3909 tablets combined with TQB3702 tablets, administered orally, 28 days as a treatment cycle.
62533775|NCT04091711|EXPERIMENTAL|ReX-C intervention|Subjects use ReX-C to receive oral oncolytic medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
62714321|NCT03377517|EXPERIMENTAL|ResearchTreatment Plan|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
62159267|NCT05542589|EXPERIMENTAL|Phenytoin phonophoresis group|The topical phenytoin will be applied on the head of ultrasound and is usually given for 5-10 minute sessions, three times per week and six weeks as a total treatment duration.
62159268|NCT05542589|SHAM_COMPARATOR|sham phenytoin phonophoresis group|The topical phenytoin will be applied on the head of ultrasound (sham ultrasound) and is usually given for 5-10 minute sessions, three times per week and six weeks as total treatment duration.
62159269|NCT02192645|EXPERIMENTAL|Sanfujiu|"Formula for Sanfujiu: Huangjiezi; Xixin; Yanhusuo; and so on Acupoint for Sanfujiu: Different ten acupoints determined according to Chinese medicine theory for each time.~Timepoint: Five times of 3 years at Sanfu Point application: The patients will be treated with herbal cake-separated moxibustion on acupoints and lasted 60 minutes each time."
62159270|NCT02192645|PLACEBO_COMPARATOR|placebo|"Formula for placebo: Fuxiaomai; and so on. the appearance is similar as drugs of Sanfujiu Acupoint for placebo: Ten acupoints determined according to Chinese medicine theory are the same as Sanfujiu group of each timepoint .~Timepoint: Five times per year for 3 years. Point application: The patients will be treated with placebo on acupoints and lasted 60 minutes each time."
62159271|NCT02192645|NO_INTERVENTION|waiting list|No intervention in the first year. Accept Sanfujiu in the second and the third years.
62159272|NCT04800978|EXPERIMENTAL|BVAC-C+Durvalumab|"• Part A: The primary objective of the part A is to assess the maximum tolerable dose of BVAC-C combined with durvalumab 1500 mg as defined by dose-limiting toxicities (DLTs), and to find the maximum tolerated dose (MTD) that can be safely used for Part B (single arm phase II).~• Part B: The primary objective of the part B is to evaluate the safety and clinical efficacy, as measured by 6-month PFS rate, of the combination therapy of durvalumab and BVAC-C in patients with HPV 16 or 18 positive cervical cancer recurrent after or refractory to first-line platinum-based chemotherapy +/-bevacizumab."
62159273|NCT03284840||Adults (18-65 years)|
62159274|NCT03284840||Elderly (65-74 years)|
62159275|NCT02364674|EXPERIMENTAL|HRCT scans|HRCT scan will be taken
62159276|NCT05884671|ACTIVE_COMPARATOR|Sulpiride|All study participants receive both placebo and the active medication (sulpiride 400mg), in a within-subjects , double-blind, randomized design.
62159277|NCT05884671|PLACEBO_COMPARATOR|Placebo|All study participants receive both placebo and the active medication (sulpiride 400mg), in a within-subjects , double-blind, randomized design.
62159278|NCT05524935|EXPERIMENTAL|Pembrolizumab and Olaparib|Participants will be given 200 mg Pembrolizumab IV every 21 days + will take 300 mg Olaparib by mouth twice daily days 1-21 of each 21 day cycle. Treatment will continue until progression, unacceptable toxicity, or for a maximum of 35 treatment cycles
62159279|NCT06452095|EXPERIMENTAL|Hyperbaric oxygen therapy|HBOT GROUP will have HBOT with 100% oxygen for 90 min, once daily, five times a week for 8 consecutive weeks. This will be given at a slightly higher pressure than normal air pressure (2 times regular air pressure)
62159280|NCT06452095|SHAM_COMPARATOR|Hyperbaric oxygen sham|CONTROL GROUP will have sham treatment, which will look and feel like HBOT, but will not have high enough oxygen concentration for any therapeutic or health benefit. Sham treatment with 21% oxygen (the amount of oxygen normally present in the air) for 90 min, once daily, five times a week for 8 consecutive weeks. This will be given at standard atmospheric pressure (1.03 ATA). The air pressure will vary slightly to mimic the feeling of HBOT.
62159281|NCT05457647|EXPERIMENTAL|Riboflavin/UV-A corneal cross-linking monitored by theranostic software module|One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, Epi-OFF, or transepithelial, Epi-ON, treatment protocol. Only one eye of each participant is designated as the study eye.
62159282|NCT02700386|EXPERIMENTAL|Adjuvant Hypofractionated Radiation|"Adjuvant Hypofractionated Radiation (4005 cGy) will last 3-4 weeks with 15 treatments, +/- 4 additional fractions as a boost. Radiation should commence within 180 days of the date of primary surgery. Four additional fractions (a boost or conedown) to areas deemed to be at particularly high risk of recurrence may be added at the end of the radiation course. Fraction size for the boost treatment will continue at 267 cGy for an additional 1068 cGy in four fractions."
62159283|NCT05570344|ACTIVE_COMPARATOR|Enrolment in rTMS sessions alone|All study participants will be scheduled to receive 30 sessions of rTMS treatment for 6 weeks as pre-established by the Alberta Health Services Strategic Clinical Network for Addiction and Mental Health and Nova Scotia Health.
62159284|NCT05570344|EXPERIMENTAL|Enrolment in rTMS sessions plus Text4Support|Participants in the rTMS plus Text4Support group of the study would be assisted by a study team member assigned that purpose to register onto the Text4Support program. The process would require all participants to input their phone numbers into the Text4Support platform that will be used to deliver the daily messages. Starting a day after enrollment, participants will receive daily supportive text messages designed by mental health therapists, clinical psychologists, psychiatrists, and mental health service users. These messages are based on cognitive behavior therapy principles crafted to enhance positively the mood of its users with depressive symptoms and other related mental health problems of concern. The messages will be pre-programmed into a software program that will deliver the messages to participants automatically to the participants' mobile phones at 10 AM (Mountain Time) and 12 PM (Atlantic Time), and each participant will receive these messages continuously for 6 weeks.
62159285|NCT03473275||1: control|"Healthy normotensive participants. Cold pressor test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.~PinPrick test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
62159286|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
62159287|NCT03473275||3. resistant hypertensive|"Patients with proven resistant hypertension and not renal denervated or for whom a renal denervation is planned according to the criteria of the CHUV.~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
62714322|NCT03899350||Spontaneous Supratentorial Intracerebral Haemorrhage|Participants with spontaneous supratentorial intracerebral haemorrhage.
62714323|NCT03899350||Spontaneous Intracerebellar Hemorrhage|Participants with spontaneous intracerebellar hemorrhage.
62159288|NCT03473275||4. renal denervation|Patients with a renal denervation. Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
62159289|NCT05982756|EXPERIMENTAL|Test group: Induction treatment plan A|Bortezomib+DAG pre-excitation regimen
62159290|NCT05982756|ACTIVE_COMPARATOR|Control group: induction regimen B|DAG pre-excitation plan alone
62159291|NCT05206552||Parturients above the age of 18|Study participants will include women after labour whom gave birth to a healthy neonate at 37 weeks with the ability to comply with study requirments
62159292|NCT04304378|ACTIVE_COMPARATOR|Stabilization Techniques (ST)|"Participants randomized into ST will receive 6 weekly 1-hour sessions of Stabilization Techniques from a Khmer-speaking mental health professional. Sessions provide an opportunity to improve emotion regulation and provide coping skills for managing symptoms of PTSD.~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
62159293|NCT04304378|EXPERIMENTAL|Stabilization Techniques with Behavioral Activation (ST+BA)|"Participants randomized into ST+BA will receive 3 weekly 1-hour sessions of ST and 3 weekly 1-hour sessions of BA from a Khmer-speaking mental health professional. Sessions include stabilization techniques and behavioral skills that aim to establish and maintain routines, reduce avoidance, and manage negative emotions.~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
62159294|NCT06332391|EXPERIMENTAL|Exercise-similar cardiac pacing|Atrial pacing to replicate exercise heart rate envelope once daily, 3 days per week, over 6 weeks while symptoms and vital signs are monitored and outcome measures assessed.
62159295|NCT06332391|SHAM_COMPARATOR|Sham cardiac pacing|Sham pacing to replicate exercise heart rate envelope once daily, 3 days per week, over 6 weeks while symptoms and vital signs are monitored and outcome measures assessed.
62159296|NCT02301117|EXPERIMENTAL|Mild Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
62159297|NCT02301117|EXPERIMENTAL|Moderate Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
62159298|NCT02301117|EXPERIMENTAL|Severe Renal Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort will be determined based on the Interim Assessment of mild and moderate cohorts"
62159299|NCT02301117|EXPERIMENTAL|Normal Renal Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
62159300|NCT02799745|ACTIVE_COMPARATOR|Enzalutamide|Participants received 160-milligrams (mg) enzalutamide administered as four 40-mg capsules, orally once daily for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow-up period, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
62533776|NCT02378350|ACTIVE_COMPARATOR|ESRD patients receiving HD treatment|no investigational drug involved. Only observe therapy treatment
62533777|NCT02378350|EXPERIMENTAL|ESRD patients receiving PD treatment|no investigational drug involved. Only observe therapy treatment
62533778|NCT06499857|ACTIVE_COMPARATOR|Semaglutide|Participants will have a 2 in 3 chance of receiving semaglutide (2.4 mg).
62533779|NCT06499857|PLACEBO_COMPARATOR|Placebo|Participants will have a 1 in 3 chance of receiving placebo.
62533780|NCT02045082|EXPERIMENTAL|Flocked swab (Copan 519CS01)|Sampling of the cornea by the flocked swab
62533781|NCT02045082|EXPERIMENTAL|Traditionnal fiber swab (Copan 164KS01)|Sampling of the cornea by the traditional finer swab
62714324|NCT06392906|EXPERIMENTAL|1 week external beam radiation therapy|10 Gy in 5 fractions of external beam radiation therapy
62714325|NCT06392906|ACTIVE_COMPARATOR|2 week external beam radiation therapy|20 Gy in 10 fractions of standard fraction external beam radiation therapy
62714326|NCT04897945|EXPERIMENTAL|Shared decision-making with pharmacists|Participants randomized to the intervention arm will have an in-person visit to complete the baseline survey, record the participant's weight and receive a pharmacist-coordinated shared decision making intervention. Intervention participants will have follow-up research assessments visits at 6, 12 and 24 months.
62714327|NCT04897945|NO_INTERVENTION|Usual Care|Participants randomized to the usual care control arm will have an in-person visit with the research study team to complete the baseline survey and record the participant's weight. These participants will then return to usual care with research assessments at 6, 12 and 24 months follow-up.
62714328|NCT06657365|EXPERIMENTAL|VOLNEWMER|A non-invasive skin tightening treatment using the Volnewmer device.
62714329|NCT06657365|ACTIVE_COMPARATOR|Thermage CPT|A non-invasive skin tightening treatment using the Thermage CPT device.
62714330|NCT03467516|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10\^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
62159301|NCT02799745|OTHER|Active Surveillance (AS)|Participants did not receive any study treatment in this arm but were on continued active surveillance (AS) for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow up, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
62159302|NCT00907933|EXPERIMENTAL|Part 1 - Arm 1|HVTs
62159303|NCT00907933|PLACEBO_COMPARATOR|Part 2 - Arm 3|HVTs
62159304|NCT00907933|EXPERIMENTAL|Part 1 - Arm 2|HVTs
62159305|NCT00907933|EXPERIMENTAL|Part 1 - Arm 3|HVTs
62714331|NCT03816176|EXPERIMENTAL|Isavuconazonium sulfate|Participants received 10 milligrams/killograms (mg/kg) dose of isavuconazonium sulfate every 8 hours (± 2 hours) on days 1 and 2 for a total of 6 doses (via intravenous or oral administration at the investigator's discretion) followed by once-daily maintenance dose of 10 mg/kg for up to 84 days IA or 180 days IM or until the participant had a successful outcome as judged by the investigator, whichever occured first. The route of administration could have been changed per the investigator's discretion.
62714332|NCT02065219|EXPERIMENTAL|Bupivacaine|injection, 25 mg, once, 5 min
62159306|NCT00907933|EXPERIMENTAL|Part 1 - Arm 4|HVTs
62159307|NCT00907933|EXPERIMENTAL|Part 1 - Arm 5|HVTs
62159308|NCT00907933|PLACEBO_COMPARATOR|Part 1 - Arm 6|HVTs
62159309|NCT00907933|EXPERIMENTAL|Part 2 - Arm 1|HVTs
62159310|NCT00907933|EXPERIMENTAL|Part 2 - Arm 2|HVTs
62159311|NCT00555620|EXPERIMENTAL|A|
62159312|NCT00555620|EXPERIMENTAL|B|
62159313|NCT03394508|PLACEBO_COMPARATOR|Placebo|ALK diluent 0,3% human albumin'
62159314|NCT03394508|EXPERIMENTAL|Active treatment|Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension
62159315|NCT04109209|ACTIVE_COMPARATOR|Usual Care Group|"* 60 Participants will be randomized to receive usual care for caregivers of patients with malignant brain tumors~* Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~* Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
62159316|NCT04109209|EXPERIMENTAL|Psychosocial Intervention Group|"* 60 Participants of caregivers of patients with malignant brain tumors will be randomized into the psychosocial intervention arm~* Caregivers assigned to the intervention arm will receive usual care and the psychosocial intervention. The intervention entails six one-on-one sessions with an interventionist (psychologist or social worker)~* Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
62159317|NCT03460132|EXPERIMENTAL|Extraction cases|patients receive Tomas orthodontic miniscrew implant as a mean of anchorage augmentation
62159318|NCT05564221|EXPERIMENTAL|YH35324|There will be 5 dose groups of YH35324, escalating from low to high doses in a stepwise manner: Cohort 1(A mg/kg) → Cohort 2(B mg/kg) → Cohorts 3(C mg/kg) and 4(C mg/kg) → Cohort 5(C mg/kg) YH35324 and placebo will be administered in a double-blinded manner.
62159319|NCT05564221|PLACEBO_COMPARATOR|Placebo|There will be 5 dose groups of YH35324, escalating from low to high doses in a stepwise manner: Cohort 1(A mg/kg) → Cohort 2(B mg/kg) → Cohorts 3(C mg/kg) and 4(C mg/kg) → Cohort 5(C mg/kg) YH35324 and placebo will be administered in a double-blinded manner.
62159320|NCT05564221|ACTIVE_COMPARATOR|Omalizumab|For Cohort 3, omalizumab 300 mg will be administered in an open-label manner.
62159321|NCT06143293|EXPERIMENTAL|Order 1 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F1=1Hz, F2=10Hz, F3=30Hz, period 1,2 and 3 respectively"
62159322|NCT06143293|EXPERIMENTAL|Order 2 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F2=10Hz, F3=30Hz, F1=1Hz, period 1,2 and 3 respectively"
62159323|NCT06143293|EXPERIMENTAL|Order 3 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F3=30Hz, F1=1Hz, F2=10Hz, period 1,2 and 3 respectively"
62159324|NCT06143293|EXPERIMENTAL|Order 4 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F1=1Hz, F3=30Hz, F2=10Hz, period 1,2 and 3 respectively"
62159325|NCT06143293|EXPERIMENTAL|Order 5 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F2=10Hz, F1=1Hz, F3=30Hz, period 1,2 and 3 respectively"
62159326|NCT06143293|EXPERIMENTAL|Order 6 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F3=30Hz, F2=10Hz, F1=1Hz, period 1,2 and 3 respectively"
62159327|NCT02722278|EXPERIMENTAL|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
62159328|NCT02722278|ACTIVE_COMPARATOR|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
62159329|NCT03020914|EXPERIMENTAL|Audiovisual Distraction|Patients get audiovisual distraction during surgery and in the recovery room using video goggles and headphones; patients can choose a movie from a preexisting library; with an initial dose of midazolam in preparation for the administration of the neuraxial anesthesia, additional sedation with midazolam in 1 mg increments if requested by the patient or deemed necessary by the anesthesia provider.
62714333|NCT02065219|PLACEBO_COMPARATOR|Placebo|injection, 10 ml 0.9% sodium chloride, once, 5 min
62714334|NCT06372795|ACTIVE_COMPARATOR|Control group|
62714335|NCT06372795|EXPERIMENTAL|Test group|
62714336|NCT02234349|EXPERIMENTAL|pancreas kidney transplant|Patients with pancreas kidney transplantation
62159330|NCT03020914|NO_INTERVENTION|Standard of care sedation|Standard of care sedation with with a initial dose of midazolam in preparation for the administration of the neuraxial anesthesia; propofol infusion titrated to effect.
62159331|NCT01018992|PLACEBO_COMPARATOR|Placebo|Adult women with DSM-IV defined PTSD will receive matching placebo for 6 weeks
62159332|NCT01018992|EXPERIMENTAL|GSK561679|Adult women with DSM-IV-defined PTSD will receive GSK561679 at a fixed dose of 350 mg/day for 6-weeks
62159333|NCT05213585|EXPERIMENTAL|Treated eyes|All participants will have one eye randomly selected for treatment.
62159334|NCT05213585|NO_INTERVENTION|Untreated eyes|No treatment will be given to the control eye.
62159335|NCT04019301|EXPERIMENTAL|Community-based Qigong Group|Participants randomized into this group follow one, 75 minutes class per week supplemented by home practice for 20 minutes on 3 additional days.
62159336|NCT04019301|EXPERIMENTAL|Internet-based Qigong Group|Participants randomized into this group follow two online sessions for 40 minutes each, also supplemented by home practice for 20 minutes on 3 additional days.
62159337|NCT04019301|NO_INTERVENTION|Self-Care Control Group|The Self-care control group, will be requested not to practice any Qigong during the study. Participants will be provided with an educational book on caregiving that includes self-guided activities related to caregiving and caregiver health (The Caregiver Helpbook: Powerful Tools for Caregiving). The book's evidence-based program is designed to provide caregivers the tools to increase their self-care and their confidence to handle difficult situations, emotions, and decisions. In addition, study staff will call participants in the self-care control group once a month.
62159338|NCT02556606|EXPERIMENTAL|Ketamine 0.10 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
62533782|NCT06088056|EXPERIMENTAL|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
62714337|NCT02234349|EXPERIMENTAL|kidney transplant subjects|Patients with kidney transplantation
62159339|NCT02556606|EXPERIMENTAL|Ketamine 0.25 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
62159340|NCT02556606|EXPERIMENTAL|Ketamine 0.50 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
62159341|NCT02556606|ACTIVE_COMPARATOR|Midazolam 0.03 mg/kg|randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg
62159342|NCT03928665||Control group|
62159343|NCT03928665||Sleep apnea using CEPAP|
62159344|NCT03928665||Sleep apnea not using CEPAP|
62159345|NCT03928665||Glaucoma control group|
62159346|NCT03373188|ACTIVE_COMPARATOR|Arm I (surgery)|Patients undergo surgery.
62159347|NCT03373188|EXPERIMENTAL|Arm II (VX15/2503, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
62159348|NCT03373188|EXPERIMENTAL|Arm III (VX15/2503, ipilimumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
62159349|NCT03373188|EXPERIMENTAL|Arm IV (VX15/2503, nivolumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
62159350|NCT01989156|EXPERIMENTAL|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
62159351|NCT01989156|ACTIVE_COMPARATOR|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
62159352|NCT01989156|SHAM_COMPARATOR|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
62159353|NCT06114537|EXPERIMENTAL|Treatment group|Patients in the treatment group receives twice daily a 250mg tablet acetazolamide for 16 weeks. At week 16, depending on the results, the treated group will stop the treatment or continue with a lower dose twice daily a 125mg tablet acetazolamide for 4 weeks. At week 20, depending on the results, the initial treated group will continue with twice daily a 125mg tablet or go back to twice daily a 250mg tablet acetazolamide till week 32.
62159354|NCT06114537|NO_INTERVENTION|Control Group|
62159355|NCT06570993|EXPERIMENTAL|Intervention|Households will receive sunlight reflecting 'cool roof' coating on their roofs.
62159356|NCT06570993|NO_INTERVENTION|Control|No cool roof application. Households will keep their original roofing for the duration of the trial.
62159357|NCT05196256|EXPERIMENTAL|Dural Puncture Epidural group (DPE)|Dural puncture with a 25 Gauge needle, then placement of the epidural catheter (Tuohy 18 Gauge). The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractionated bolus of 20 mL will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
62159358|NCT05196256|ACTIVE_COMPARATOR|Epidural group (EP)|Placement of an epidural catheter through a 18 Gauge Tuohy needle. The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent boluses mode (PIB) and patient controlled epidural analgesia (PCEA); An initial fraction bolus of 20ml will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
62714338|NCT02234349|NO_INTERVENTION|Control|
62714339|NCT06236516|EXPERIMENTAL|One Fraction SBRT|Consenting and eligible patients will receive a prescription dose of 25-34 Gy in one fraction with adaptation based on daily anatomic changes as per clinical standard of care.
62159359|NCT05196256|ACTIVE_COMPARATOR|Combined Spinal-Epidural group (CSE)|Spinal injection through a 25 Gauge needle of Levobupivacaine 2.5mg and Sufentanyl 2.5 mcg in a total volume of 2 mL, placing an epidural catheter through a Tuohy 18 Gauge needle. The epidural medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL. The epidural medication is administered on a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractioned bolus of 20 mL will be administered epidurally 30 min after the intrathecal injection, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20min, all along the dilatation and expulsion period.
62159360|NCT06130904|EXPERIMENTAL|Academic detailing intervention|
62159361|NCT06130904|NO_INTERVENTION|Control group|Control dentists will receive no intervention at all. Only dentist's prescribing data will be analyzed.
62159362|NCT01892982|EXPERIMENTAL|Problem Solving Education tailored to NICU|NICU-PSE integrates motivational interviewing and problem solving, with ongoing monitoring and linkage to mental health services for mothers with worsening depressive symptoms over time. The intervention is provided over six sessions, including three tailored, post-discharge sessions, which address issues common to families of preterm infants: caregiver burden, complexity of medical follow-up, and social reintegration following hospitalization.
62159363|NCT01892982|NO_INTERVENTION|Control|Both study groups receive standard NICU medical, social work, and nursing services. At each study site, attending neonatologists and pediatrics residents constitute the medical team, and all families are assigned a social worker.
62159364|NCT06062147|EXPERIMENTAL|teacher training|Teacher training and support for teachers in setting up specific arrangements.
62159365|NCT06062147|NO_INTERVENTION|control class|Teacher will proceed in the usual way, referring to the procedures put in place by the national education system for identifying and referring children at risk
62159366|NCT01123044|EXPERIMENTAL|corneal stem cell transplant|
62159367|NCT01123044|NO_INTERVENTION|conservative medical therapy|
62159368|NCT01998334|EXPERIMENTAL|CVVH 6h|CVVH 6h for first three days
62159369|NCT01998334|EXPERIMENTAL|CVVH 10h|CVVH 10h for first three days
62159370|NCT01998334|EXPERIMENTAL|CVVHDF|CVVHDF 6h for first three days
62159371|NCT01241032|EXPERIMENTAL|Udenafil|Udenafil 200mg
62159372|NCT01241032|ACTIVE_COMPARATOR|Udenafil + Alcohol|Udenafil 200mg + Alcohol
62159373|NCT02721849|EXPERIMENTAL|adolescent yoga / parent control|The adolescent will receive an 12 week yoga course, while one parent will only answer the questionnaires.
62159374|NCT02721849|EXPERIMENTAL|adolescent waitlist / parent yoga|One parent will participate in an 12 week yoga course, while the adolescent will receive the intervention after the follow-up period.
62159375|NCT02721849|EXPERIMENTAL|adolescent yoga / parent yoga|Both adolescent and parent will participate in an 12 week yoga course at the same time.
62159376|NCT02721849|NO_INTERVENTION|adolescent waitlist / parent control|The adolescent will receive the intervention after the follow-up period, while one parent will only answer the questionnaires.
62159377|NCT05888493|EXPERIMENTAL|Tisagenlecleucel|Participants randomized to the tisagenlecleucel treatment strategy will receive a single infusion of 0.6 to 6 x 10\^8 CAR-positive viable T-cells
62159378|NCT05888493|ACTIVE_COMPARATOR|R2 or R-CHOP|Participants randomized to Standard of Care treatment will receive either R2 or R-CHOP based on investigator choice of therapies, and this has to be determined prior to randomization.
62159379|NCT01923935|EXPERIMENTAL|BUSULFEX®, Alkeran®|"BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)~Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)"
62159380|NCT02189785||Healthy Controls|Healthy men and women ages 18-25 years
62159381|NCT05033158|OTHER|Cancer patients|Level of antibodies against SARS-CoV-2 will be measured in these patients
62159382|NCT03463122|OTHER|Training first|This group completed 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy followed by four weeks of conventional therapy
62159383|NCT03463122|OTHER|Waiting first|This group completed four weeks of conventional therapy followed by 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy.
62159384|NCT01458288|EXPERIMENTAL|TG-0054 (3.14 mg/kg)|TG-0054 (3.14 mg/kg)
62159385|NCT02167230|EXPERIMENTAL|Jailed-balloon technique|Apply jailed-balloon technique to protect the side branch during coronary bifurcation PCI
62159386|NCT02167230|ACTIVE_COMPARATOR|Jailed-wire technique|Apply jailed-wire technique to protect the side branch during coronary bifurcation PCI
62159387|NCT03586739|EXPERIMENTAL|"Covered stents strategy"|
62159388|NCT03586739|ACTIVE_COMPARATOR|"Bare metal stents strategy"|
62159389|NCT03369119|ACTIVE_COMPARATOR|Montelukast|Children received 4 mg oral montelukast granule daily until discharge.
62159390|NCT03369119|PLACEBO_COMPARATOR|Placebo|Children receive 4 mg oral placebo montelukast granule daily until discharge
62159391|NCT03472118|EXPERIMENTAL|High Flow Apneic Oxygenation|Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
62159392|NCT06060847|EXPERIMENTAL|Patients affected by HCC induced by metabolic syndrome as unique risk factor|Patients aged 18 years old and older, affected by HCC with MS (metabolic syndrome) as unique risk factor who comply with the criteria for bariatric surgery, will undergo liver resection and sleeve gastrectomy with minimally-invasive technique in the same surgical procedure
62159393|NCT06060847|ACTIVE_COMPARATOR|Patients with HCC related to metabolic syndrome as unique risk factor|Patients aged 18 years old and older, affected by HCC (hepatocellular carcinoma) with MS (metabolic syndrome) as unique risk factor who will undergo liver resection only
62159394|NCT05835856|EXPERIMENTAL|NAO robot group|
62159395|NCT05835856|EXPERIMENTAL|Google Nest Hub (2e generation) group|
62159396|NCT05835856|EXPERIMENTAL|Gatebox group|
62159397|NCT05835856|EXPERIMENTAL|CelesTE robot group|
62159398|NCT05835856|OTHER|Control group|
62714340|NCT06382844||Cutaneous T-cell lymphoma|Patients with cutaneous T-cell lymphoma
62159399|NCT06374407|ACTIVE_COMPARATOR|Control group|The control group comprises participants who do not receive the specific Mind diet intervention but undergo the same procedures as the intervention group, including weighing at the beginning and end of the study, completing identical questionnaires, and providing fecal samples at recruitment and follow-up. They will also use the same meal-planning app as the intervention group.
62159400|NCT06374407|EXPERIMENTAL|Intervention group|The intervention group consists of participants who receive the Mind diet intervention. Like the control group, they will be weighed at the start and end of the study, answer the same questionnaires, and provide fecal samples at recruitment and follow-up. Additionally, they will use the same meal-planning app as the control group, but their dietary pattern will be based on the Mind diet.
62159401|NCT03555617|EXPERIMENTAL|TD-1473 formulation bridging & food effect|Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.
62159402|NCT03555617|EXPERIMENTAL|TD-1473 with Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.
62159403|NCT03555617|EXPERIMENTAL|TD-1473 without Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.
62159404|NCT06719882||Vivity/Vivity toric|
62159405|NCT05567185|EXPERIMENTAL|Dose Escalation: Erdafinitib Intravesical Delivery System|Participants with bladder cancer and fibroblast growth factor receptor (FGFR) mutations or fusions will receive erdafitinib intravesical delivery system and study will evaluate 2 dose levels of erdafitinib. Participants with a complete response (CR) may continue to receive treatment up to a duration of 1 year as long as there is no disease recurrence or progression, intolerable toxicity or withdrawal of consent.
62159406|NCT00224198||Lung Disease|All study individuals will be males or females that are 18 years or older and are able to provide informed consent and have been diagnosed with lung disease.
62159407|NCT05179109|EXPERIMENTAL|Robot-assisted laparoscopy|Surgery for deep endometriosis using robot-assisted laparoscopy.
62159408|NCT05179109|ACTIVE_COMPARATOR|Conventional laparoscopy|Surgery for deep endometriosis using conventional laparoscopy.
62159409|NCT03034772|ACTIVE_COMPARATOR|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
62159410|NCT03034772|PLACEBO_COMPARATOR|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
62159411|NCT03059056|EXPERIMENTAL|pharmacokinetic evaluation|Empagliflozin 25 mg
62159412|NCT04853394|EXPERIMENTAL|MASLIHAT peer education|A peer educator prevention intervention program consisting of five weekly 2-hour small group sessions.
62159413|NCT04853394|SHAM_COMPARATOR|TANSIHAT health education|A health education program consisting of five weekly 2-hour sessions small group sessions.
62159414|NCT05722756||group A|treated with Vojta therapy
62159415|NCT05722756||group B|treated with Vojta therapy combined with craniosacral therapy
62159416|NCT00719056|EXPERIMENTAL|1|Surgical chemoprophylaxis of one dose of teicoplanin upon introduction of anesthesia for total hip or knee arthroplasty.
62533783|NCT06457165||Difficult Intubation|"Abdominal circumference, waist circumference, arm circumference, distance between incisions,TMD and SMD measurements, Mallampati test, Wilson score, and suprasternal subcutaneous adipose tissue thickness were measured and recorded. ECG, SBP and DBP, and SpO2 monitoring were performed. Pre-oxygenation was performed using a 100% oxygen face mask for 3 min before the induction of anesthesia. Induction of anesthesia was achieved with IV 1 mg/kg lidocaine, 0.125 mcgr/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium bromide. After 2 min of adequate muscle relaxation, the patient was intubated with an endotracheal tube of appropriate diameter. Cormack-Lehane score was evaluated during laryngoscopy. Patients with more than 3 intubation attempts by an experienced anesthesiologist were considered difficult to intubate. In maintenance, 0.1 mcg/kg/h remifentanil was administered in sevoflurane O2-air mixture.~Age, sex, body weight,BMI, and ASA scores were recorded."
62714341|NCT06382844||Control group 1|patients with benign/reactive erythroderma
62159417|NCT00719056|ACTIVE_COMPARATOR|2|Surgical chemoprophylaxis with multiple dose of other antimicrobials for up to six consecutive days for total hip or knee arthroplasty.
62159418|NCT05272631||Retrograde Femoral Nail Advanced (RFNA) Cohort|Participants with a distal femur or femoral shaft fracture or who require revision due to a malunion or nonunion will undergo surgery with RFNA based on surgeon's decision and the site's standard of care (SOC). Participants with impending pathologic fracture are also included.
62159419|NCT05272631||Tibial Nail Advanced (TNA) Cohort|Participants with open or closed, proximal, distal or shaft fractures of the tibia, or who require revision due to a malunion or nonunion will undergo surgery with TNA based on surgeon's decision and the site's SOC.
62159420|NCT02962076|EXPERIMENTAL|Single Arm - PET/CT Imaging With [C-11] MHED|Single Arm - positron emission tomography/computed tomography imaging with \[C-11\] meta-Hydroxyephedrine tracer
62159421|NCT04528368|EXPERIMENTAL|Convalescent Plasma + Standard treatment|Participants will receive the standard treatment and convalescent plasma
62159422|NCT04528368|NO_INTERVENTION|Standard treatment|Participants will receive the standard treatment
62159423|NCT03554200|EXPERIMENTAL|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
62159424|NCT03554200|PLACEBO_COMPARATOR|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
62714342|NCT06382844||Control group 2|patients with systemic inflammatory processes regardless of whether they have cutaneous involvement
62714343|NCT06382844||Control group 3|healthy adult subjects, age- and sex-matched with patients
62159425|NCT06584851||Children with spastic cerebral palsy|Children between 2 and 9 years old.
62159426|NCT06584851||Typical developing children|Children between 2 and 9 years old.
62714344|NCT00188214|OTHER|CT perfusion scan|
62159427|NCT06584851||Adolescents and adults with HSP|Adolescents between 12 and 18 years of age and adults.
62159428|NCT06584851||Typically developing adolescents and adults|Age- and gender- matched with the recruited HSP patients
62159429|NCT04876092|EXPERIMENTAL|JNJ-67856633 and Ibrutinib|Participants will receive JNJ-67856633 together with Ibrutinib orally on a 21-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET).
62159430|NCT05308901|EXPERIMENTAL|Pembrolizumab + Lenvatinib|Lenvatinib 20 mg daily plus pembrolizumab 200 mg IV every 3 weeks.
62159431|NCT03994185|EXPERIMENTAL|Group Treated with stent graft|This is a single arm study. All subjects will be treated with the WRAPSODY stent graft.
62159432|NCT03553056|EXPERIMENTAL|Intervention|NZ Step Away app
62159433|NCT03553056|ACTIVE_COMPARATOR|Control|Modified NZ Step Away app
62159434|NCT01864200|EXPERIMENTAL|CroFab|crotalidae polyvalent immune fab (ovine) per approved labeling
62159435|NCT01864200|PLACEBO_COMPARATOR|Saline placebo|Saline placebo
62159436|NCT03638700|ACTIVE_COMPARATOR|guidewire type 1: VisiGlide™ angled tip|Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
62159437|NCT03638700|ACTIVE_COMPARATOR|guidewire type 2: VisiGlide2™ angled tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
62159438|NCT03638700|ACTIVE_COMPARATOR|guidewire type 1: VisiGlide™ straight tip|Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
62159439|NCT03638700|ACTIVE_COMPARATOR|guidewire type 2: VisiGlide2™ straight tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
62159440|NCT05219708|EXPERIMENTAL|Calorie and protein nutritional supplementation|Study participants randomized to the intervention will receive 30 days worth of the nutritional supplement (i.e. Ensure Original) to be consumed twice per day in between meals in addition to standard of care for heart failure.
62159441|NCT05219708|ACTIVE_COMPARATOR|Control|The control group will receive standard of care for heart failure.
62159442|NCT00554905|EXPERIMENTAL|1|TACE first, then RFA within 2 weeks
62159443|NCT00554905|ACTIVE_COMPARATOR|2|RFA alone
62159444|NCT03317522||Belfast HAPO|"All pregnant women who attended the Royal Victoria Maternity Hospital, Belfast were eligible to participate unless they met one or more exclusion criteria.~All eligible women from the Belfast centre were invited to take part in a prospective observational study involving an additional fasting serum sample for lipids at 28 weeks gestation and long term follow up of their HAPO offspring. Only those women who had remained blinded to oral glucose tolerance test (OGTT) results during pregnancy were included (fasting plasma glucose ≤5·8 mmol/L and 2-hour glucose ≤11·1 mmol/L). Offspring from these pregnancies had anthropometric measurements performed within 72 hours of birth and at age 5-7 years."
62159445|NCT01701089|EXPERIMENTAL|RO4602522 Group 1|
62159446|NCT01701089|EXPERIMENTAL|RO4602522 Group 2|
62159447|NCT05234476|EXPERIMENTAL|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
62159448|NCT05234476|ACTIVE_COMPARATOR|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
62159449|NCT01024023|ACTIVE_COMPARATOR|PPAM Aid|Suitable participants randomised to the treatment arm will receive the non articulated pneumatic early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
62533784|NCT06457165||Not Difficult Intubation|"Abdominal circumference, waist circumference, arm circumference, distance between incisions,TMD and SMD measurements, Mallampati test, Wilson score, and suprasternal subcutaneous adipose tissue thickness were measured and recorded. ECG, SBP and DBP, and SpO2 monitoring were performed. Pre-oxygenation was performed using a 100% oxygen face mask for 3 min before the induction of anesthesia. Induction of anesthesia was achieved with IV 1 mg/kg lidocaine, 0.125 mcgr/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium bromide. After 2 min of adequate muscle relaxation, the patient was intubated with an endotracheal tube of appropriate diameter. Cormack-Lehane score was evaluated during laryngoscopy. Patients with more than 3 intubation attempts by an experienced anesthesiologist were considered difficult to intubate. In maintenance, 0.1 mcg/kg/h remifentanil was administered in sevoflurane O2-air mixture.~Age, sex, body weight,BMI, and ASA scores were recorded."
62533785|NCT06031987|ACTIVE_COMPARATOR|SMBG arm|Self Monitoring of Blood Glucose group
62533786|NCT06031987|EXPERIMENTAL|CGMS arm|Continuous glucose monitoring system, CGM
62533787|NCT01123967|EXPERIMENTAL|PRO+NRT+TC|Proactive outreach (mailed invitation letter followed by telephone outreach) combined with free nicotine replacement therapy (NRT) and telephone counseling (PRO+NRT+TC)to usual care (UC)
62533788|NCT01123967|ACTIVE_COMPARATOR|Usual Care (UC)|Usual (standard) care - Smoking cessation products: patch, gum, lozenge, inhaler and nasal spray
62533789|NCT05808192||tolerant|patients who withdraw IS drugs after LT
62533790|NCT05808192||non tolerant|patients who couldn't wean IS drugs
62714345|NCT01564342|OTHER|wounds irrigated with sterile normal saline|Patients in this arm had their wounds irrigated with sterile normal saline
62159450|NCT01024023|ACTIVE_COMPARATOR|AMA Aid|Suitable participants randomised to the treatment arm will receive the articulated early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
62159451|NCT06413472||ARDS patients-PCV|Intubated patients with a diagnosis of ARDS in the intensive care unit, ventilated using Pressure-Controlled Ventilation (PCV).
62159452|NCT06413472||ARDS patients-VCV|Intubated patients with a diagnosis of ARDS in the intensive care unit, ventilated using Volume-Controlled Ventilation (VCV).
62159453|NCT03307993|EXPERIMENTAL|Idalopirdine|"Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose)~If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2."
62159454|NCT06185101|EXPERIMENTAL|STEP-UP intervention group|Participants will engage in a behavioral intervention for pain self-management that incorporates educational podcasts and sessions with a community health worker.
62159455|NCT06185101|NO_INTERVENTION|Control group|Members of the control group will not initially receive the STEP-UP intervention. After completing the 8-week follow-up telephone survey, individuals in the control group will be invited to take part in the STEP-UP intervention.
62159456|NCT05145634|EXPERIMENTAL|Educational group|The interventions administered to the experimental group were one-on-one instruction and Health Brief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards.
62159457|NCT05145634|NO_INTERVENTION|Control group|Patients in the control group only received brochure and medication cards.
62159458|NCT02416297|EXPERIMENTAL|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice.
62159459|NCT02416297|NO_INTERVENTION|Control|Anterior retraction after premolars extraction will be done conventionally (slide mechanics)
62159460|NCT06190249|EXPERIMENTAL|LN-144 Therapy|"All patients will receive LN-144 therapy, consisting of these steps:~1. Harvest (surgical resection of tumor tissue) to provide the autologous tissue that serves as the source of LN-144.~2. Production of LN-144 investigational product (IP) at a central Good Manufacturing Practice (GMP) facility~3. A 5-day nonmyeloablative lymphodepletion (NMA-LD) preparative regimen~4. Infusion of the LN-144 product (Day 0)~5. Administration of IV interleukin-2 (IL-2) for ≤ 6 doses.~6. Infusion of pembrolizumab 200 mg (Week 12) every 3 weeks for up to 1 year (17 cycles)"
62533791|NCT05490485|EXPERIMENTAL|Camrelizumab|Camrelizumab (PD-1 MAB) combined with cisplatin for advanced cutaneous squamous cell carcinoma
62533792|NCT02755077|EXPERIMENTAL|Mask ventilation in rotated head position|Patient's head will be axially rotated 45 degrees to the right
62159461|NCT06452043|EXPERIMENTAL|Nature-based intervention|Nature-based group intervention of once a week for 8 weeks
62159462|NCT06721065||Phase I: Remote Simultaneous Medical Interpreting/RSMI (Arm 1)|This phase will enroll Spanish- and Mandarin-speaking patients with LEP (Stages II and III disease) and English- speaking providers
62159463|NCT06721065||Phase I: Remote Consecutive Medical Interpreting/RCMI (Arm 2)|This phase will enroll Spanish- and Mandarin-speaking patients with LEP (Stages II and III disease) and English- speaking providers
62159464|NCT06721065||Phase I: Remote Consecutive Video Medical Interpreting/RCVI (Arm 3)|This phase will enroll Spanish- and Mandarin-speaking patients with LEP (Stages II and III disease) and English- speaking providers
62159465|NCT06721065||Phase II: CFIR mixed-methods explanatory, multi- stakeholder process evaluation|Will examine RSMI utilization (Arm 1 participants only and clinic staff), intervention barriers and facilitators, and implementation potential
62159466|NCT05664425|EXPERIMENTAL|Mechanical treatment arm + oral hygiene reinforcement|Subjects receive oral hygiene reinforcement, and additionally submucosal instrumentation with ultrasonics with a plastic tip.
62159467|NCT05664425|NO_INTERVENTION|Oral hygiene reinforcement alone|Subjects receive oral hygiene reinforcement, but do not receive submucosal instrumentation.
62159468|NCT05085678|NO_INTERVENTION|Control group|"Standard of care:~* a short overview of the physician on adjuvant endocrine therapy~* a brochure on adjuvant endocrine therapy~* a voluntary group session on adjuvant endocrine therapy~and a monthly questionnaire on the patient reported outcomes"
62533793|NCT02755077|NO_INTERVENTION|Mask ventilation in neutral head position|
62533794|NCT00469911|EXPERIMENTAL|Magnetic Resonance Spectroscopy|Patients will have Magnetic Resonance Spectroscopy to measure in vivo accumulation of triglycerides in myocardial tissue
62533795|NCT00469911|EXPERIMENTAL|Ex vivo heart biopsy|Patients will have their normal routine clinical heart biopsy of myocardial heart tissue.
62533796|NCT03917017|EXPERIMENTAL|Radiomics and Watson artificial intelligence|
62533797|NCT06408948|EXPERIMENTAL|[14C]SHR7280|
62159469|NCT05085678|EXPERIMENTAL|Intervention group|"Standard care with the access of to the online tool Co'moon and a monthly questionnaire on patient reported outcomes.~The outcome of the questionnaires are summarized for the physician to discuss during the follow-up consultation."
62533798|NCT01907568||Patients with schizophrenia|With and without hallucinations
62533799|NCT01907568||Patients with borderline personality disorder|With and without hallucinations
62533800|NCT01907568||Patients with hearing impairment|With and without hallucinations
62533801|NCT01907568||Patients with visual loss|With and without hallucinations
62533802|NCT01907568||Patients with Parkinson's Disease|With and without hallucinations
62533803|NCT01907568||Patients with Alzheimer's Disease|With and without hallucinations
62533804|NCT01907568||Patients with dementia with Lewy Bodies|With and without hallucinations
62533805|NCT01907568||Patients with Posttraumatic Stress Disorder|With and without hallucinations
62533806|NCT01907568||Patients with delirium|With and without hallucinations
62533807|NCT01907568||Healthy participants|With and without hallucinations
62533808|NCT01907568||Patients with mood disorder|With and without hallucinations
62533809|NCT04245956|EXPERIMENTAL|Transcatheter Mitral Valve Repair arm|Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system
62159470|NCT06161012|EXPERIMENTAL|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear two different study lenses, one at a time, over two wear periods (test then control). Each wear period will be approximately 2 weeks in duration, with a washout period of approximately 1 week between wear periods. Subjects will be advised to wear the study lenses for a minimum of 8 hours per day on at least 5 days per week of each wear period.
62159471|NCT06161012|EXPERIMENTAL|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear two different study lenses, one at a time, over two wear periods (control then test). Each wear period will be approximately 2 weeks in duration, with a washout period of approximately 1 week between wear periods. Subjects will be advised to wear the study lenses for a minimum of 8 hours per day on at least 5 days per week of each wear period.
62159472|NCT03932253|EXPERIMENTAL|1a：0.2 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 6 mg，8mg, 12mg, 15mg.1b(NRAS),1b(NF1)|1a dose-escalation phase: 9 dose groups during the dose-escalation phase, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 6 mg,8mg, 12mg and 15mg orally, continuous once a day for 28 days a cycle. 1b dose-extension phase: 12mg orally,continuous once a day for 28 days a cycle.
62159473|NCT05583474|EXPERIMENTAL|subject receive OPC-1085EL solution|OPC-1085EL group ，one drop for each eye, once per day for 8 weeks
62159474|NCT05583474|ACTIVE_COMPARATOR|subject receive 0.005% latanoprost ophthalmic solution|0.005% latanoprost ophthalmic solution group ，one drop for each eye, once per day for 8 weeks
62159475|NCT03095378|ACTIVE_COMPARATOR|Control|Root treatment with scaling and root planing.
62159476|NCT03095378|EXPERIMENTAL|Citric acid plus tetracycline|Root treatment with 50% citric acid plus 10% tetracycline, pH1, passive application for 90s.
62159477|NCT03095378|EXPERIMENTAL|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy with toluidine blue O (100ug/ml - 60s pre-irradiation - pH4) and red laser (660nm, 30 milliwatts, 45 joules per square centimeter, sweeping mode, 90s)
62159478|NCT00835445||1|Asthmatics with polyps
62159479|NCT00835445||2|Non-asthmatics with polyps
62159480|NCT00718744|EXPERIMENTAL|A|In each individual patient, 10 mg/ml histamine dihydrochloride solution and a phenolated saline solution will be applied as positive and negative control respectively.
62159481|NCT02199171|EXPERIMENTAL|HIPEC carboplatin|"Patients receive hyperthermic carboplatin intraperitoneally over 60 minutes during the planned surgical cytoreductive procedure.~Doses as appropriate for assigned dose level in 500 cubic centimeters (cc)"
62159482|NCT06584955|EXPERIMENTAL|Patients more than 200 pounds|Participants will be screened for insomnia using the ESAS tool.
62159483|NCT06584955|EXPERIMENTAL|Patients between 150-200 pounds|
62159484|NCT04782570|EXPERIMENTAL|Verum TMS|ITBS (intermittent Theta Burst Stimulation) over left frontal cortex
62159485|NCT04782570|SHAM_COMPARATOR|Sham TMS|Sham TMS over left frontal cortex
62159486|NCT03245996|EXPERIMENTAL|Subjects|Subjects with a cardiac pacemaker
62714346|NCT01564342|OTHER|wound irrigation with tap water|Patients in the arm had their wounds irrigated with tap water
62714347|NCT05166668|ACTIVE_COMPARATOR|standard GnRH antagonist protocol|Gonadotropins (300-450 IU) IM start on cycle day 2 then the dose modulated according to response
62714348|NCT05166668|ACTIVE_COMPARATOR|Aromatase inhibitor/flexible antagonist protocol|letrozole orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
62714349|NCT05340413|EXPERIMENTAL|Cohort 1|"HER2-negative ABC with documented germline or somatic mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Patients with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations that are considered to be non-detrimental (e.g., Variants of uncertain clinical significance or Variant of unknown significance or Variant, favor polymorphism or benign polymorphism, etc.) will not be eligible for this cohort."
62714350|NCT05340413|ACTIVE_COMPARATOR|Cohort 2|HER2-negative ABC with RAD51-foci low score in the most recent locally recurrence or biopsy from the metastatic context and without known or with negative germline or somatic mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Mutation status will be assessed in, at least, olaparib responding patients in this subgroup.
62159487|NCT03241121|EXPERIMENTAL|Time restricted feeding|For those in the intervention phase (Part 2)
62159488|NCT03241121|ACTIVE_COMPARATOR|Regular dietary advices|For those in the intervention phase (Part 2)
62159489|NCT01928888|EXPERIMENTAL|Arm HFP|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo
62159490|NCT01928888|EXPERIMENTAL|Arm HPF|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine
62159491|NCT01928888|EXPERIMENTAL|Arm FHP|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo
62159492|NCT01928888|EXPERIMENTAL|Arm FPH|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid
62159493|NCT01928888|EXPERIMENTAL|Arm PHF|1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine
62159494|NCT01928888|EXPERIMENTAL|Arm PFH|1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid
62159495|NCT01000415|EXPERIMENTAL|Cisplatin plus gemcitabine|Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
62159496|NCT06720467|EXPERIMENTAL|patients with eyelid warts will receive treatment in the form of intralesional injection of Candida|Intralesional injection of 0.2 ml of 1/1000 solution of Candida albicans antigen using an insulin syringe directly into the warts; Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.). The same injection was repeated every 2 weeks until complete clearance for a maximum of six treatment sessions.
62159497|NCT02642640|OTHER|melatonin-placebo|subjects will receive melatonin first and placebo second
62159498|NCT02642640|OTHER|placebo-melatonin|subjects will receive placebo first and melatonin second
62533810|NCT03545035||Study group|All patients being observed during the study duration.
62159499|NCT04282018|EXPERIMENTAL|Part A: BGB-10188 Monotherapy Dose Escalation|BGB-10188 capsules administered orally once daily (QD) in 5 cohorts of escalating doses
62159500|NCT04282018|EXPERIMENTAL|Part B: BGB-10188 + Zanubrutinib Dose Escalation|BGB-10188 capsules administered orally QD at the latest cleared dose of BGB-10188 monotherapy (Part A) in combination with zanubrutinib 160mg (2\*80mg capsules) administered orally twice daily (BID)
62159501|NCT04282018|EXPERIMENTAL|Part C: BGB-10188 + Zanubrutinib Dose Expansion|This Part was originally planned but was cancelled by the sponsor and will not be initiated.
62159502|NCT04282018|EXPERIMENTAL|Part D: BGB-10188 + Tislelizumab Infusion Dose Escalation|BGB-10188 capsules administered orally QD in up to 6 cohorts of escalating doses in combination with tislelizumab 200mg IV infusion administered every 3 weeks (Q3W)
62159503|NCT04282018|EXPERIMENTAL|Part E: BGB-10188 + Tislelizumab Infusion Dose Expansion|BGB-10188 capsules administered orally QD at two doses in combination with tislelizumab 200mg IV infusion administered Q3W
62159504|NCT06565195|EXPERIMENTAL|LY3962681 (SAD)|Single ascending dose of LY3962681 or placebo administered intrathecally (IT) to healthy volunteers.
62159505|NCT06565195|EXPERIMENTAL|LY3962681 (MAD)|Multiple ascending doses of LY3962681 or placebo administered IT to participants with Parkinson's disease.
62159506|NCT05363839|EXPERIMENTAL|SAD Cohorts 1 to 3 - Participants Receiving ACH-000029|Each SAD cohort participant will be randomized to receive 10mg for cohort 1; up to 30mg and up to 60mg for cohorts 2 and 3 respectively dependent on dose review committee.
62159507|NCT05363839|PLACEBO_COMPARATOR|SAD Cohorts 1 to 3 - Participants Receiving Placebo|Each SAD cohort participant will be randomized to receive placebo on a ratio of 3:1 (active: placebo).
62159508|NCT05652985|EXPERIMENTAL|interventional group|Inter-professional Collaboration Training
62159509|NCT05652985|NO_INTERVENTION|control group|Regarding the control group, the participants will receive no training
62159510|NCT06480227|ACTIVE_COMPARATOR|Solyx Single-incision Sling|Solyx Single-incision Sling
62159511|NCT06480227|ACTIVE_COMPARATOR|Bulkamid Transurethral Bulking Agent|Bulkamid Transurethral Bulking Agent
62159512|NCT05145491|ACTIVE_COMPARATOR|Immediate Vitrectomy|
62159513|NCT05145491|OTHER|Deferred Vitrectomy|
62159514|NCT01250717|EXPERIMENTAL|Docetaxel Followed by Radical Prostatectomy|Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy
62159515|NCT06607185|EXPERIMENTAL|LY4066434 Monotherapy Dose Escalation|Escalating doses of LY4066434 administered orally.
62159516|NCT06607185|EXPERIMENTAL|LY4066434 Dose Optimization|LY4066434 administered orally either alone or with another investigational agent.
62159517|NCT06585761||pre-SGLT2I group|patients with heart failure newly introduced to one of SGLT2I members
62159518|NCT06585761||Post-SGLT2I group|patients with heart failure on one of SGLT2I members for at least 2 months
62159519|NCT01469819|EXPERIMENTAL|Lubiprostone|Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.
62159520|NCT06721923|ACTIVE_COMPARATOR|Continuous protein|Continuous protein arm will have dietary protein supplement mixed into the enteral formula product to be provided around the clock without break.
62159521|NCT06721923|EXPERIMENTAL|Bolus protein|Bolus protein arm will provide protein powder mixed with water every 4h through syringe. This will be in addition to continuous enteral formula feeding which remains standard of care.
62159522|NCT02831088|EXPERIMENTAL|Neu2000KWL High-dose group|
62159523|NCT02831088|EXPERIMENTAL|Neu2000KWL Low-dose group|
62159524|NCT02831088|PLACEBO_COMPARATOR|Placebo|
62533811|NCT06316648|ACTIVE_COMPARATOR|control group|At 00:00 the night before the surgery, the researcher told the patients in the control group that they could have fruit juice/water if they wanted and waited for 10 minutes. The researcher then initiated the restriction process by informing the patients that they could no longer have food/water. Fasting, thirst, blood glucose and nausea-vomiting evaluations applied to the patients in the intervention group were also performed on the patients in the control group at the same hours. IV fluid therapy was not administered to both groups before surgical intervention.
62159525|NCT06005311|EXPERIMENTAL|microfluidic chip method|"Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).~In the microfluidic chip method for sperm sorting, a small amount of semen sample is loaded onto the chip, which contains channels and chambers that allow for the separation of sperm based on their motility and morphology. The chip is designed to mimic the natural environment of the female reproductive tract, where sperm undergo a series of selection processes before reaching the egg."
62159526|NCT06005311|ACTIVE_COMPARATOR|density-gradient centrifugation method|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
62714351|NCT06218979|PLACEBO_COMPARATOR|Control phase|Study drug dose (1 mg risperidone) and 250 ml of water at 8:00 a.m., and 250 ml of water at 8:30 a.m.
62159527|NCT06155123||HFEM or CM treated with mAbs|Patients with high frequency episodic or chronic migraine undergoing treatment with monoclonal antibodies directed against calcitonin gene related peptide pathway
62159528|NCT06155123||Healthy Controls|Group of healthy controls comparable for demographic features
62159529|NCT01002209|SHAM_COMPARATOR|Sham Hyperbaric Oxygen Treatment|
62159530|NCT01002209|EXPERIMENTAL|Hyperbaric oxygen treatment (HBO)|
62533812|NCT06316648|EXPERIMENTAL|whey intake|Since whey powder contains 73.45 grams of carbohydrate per 100 grams, whey was given to the patients in this study, unlike OCS (Oral Carbohydrate Solution), as it met the requirement in the ERAS protocol that at least 45 g of oral carbohydrate solution can be given two hours before surgery. It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink. Before the surgery, the patients' hunger, thirst, blood glucose and nausea and vomiting levels were evaluated.
62714352|NCT06218979|ACTIVE_COMPARATOR|Tea phase|Study drug dose (1 mg risperidone) and 250 ml of tea at 8:00 a.m., and 250 ml of tea at 8:30 a.m.
62159531|NCT02854657|EXPERIMENTAL|skin self-examination|"Participants from the treatment arms of the original RCT. It is anticipated that 228 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study. These subjects received Skin Self- examination structured training.~The subject are being followed for an additional period of time after receiving an educational intervention."
62159532|NCT02854657|EXPERIMENTAL|Skin Self- examination:Distance (remote) learning|Participants receive the Skin Self- examination structured training with partner assistance educational intervention via mailed workbook while under the customary care of their own dermatologists. It is anticipated that 50 new participant dyads will be recruited and randomized to this group.
62159533|NCT02854657|ACTIVE_COMPARATOR|Active control|"Participants from the control arm of the original RCT. It is anticipated that 100 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the Skin Self- examination structured training with partner assistance."
62159534|NCT02854657|PLACEBO_COMPARATOR|Assessment-only control|"Participants who receive customary care from their own dermatologists. It is anticipated that 150 new participant dyads will be recruited and randomized to this group.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the structured training in skin self-examination with partner assistance."
62159535|NCT02854657|NO_INTERVENTION|Observational study 1|"Feasibility of wearing 2 sensors No intervention. At the conclusion of the study, participants receive a report of their UV exposure and physical activity over the 7 days of the study.~N= 10"
62159536|NCT02854657|NO_INTERVENTION|Observational study 2|"Feasibility of completing online daily survey. The research team will strive to integrate event level data in real -time No intervention. At the conclusion of the study, participants receive an event level reports of their daily UV exposure and physical activity over the 7 days of the study.~N= 30"
62159537|NCT02854657|NO_INTERVENTION|Relationship Factors Study Observational Study|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.~No intervention- Control group. n=144 Results pending\*"
62159538|NCT02854657|ACTIVE_COMPARATOR|Relationship Factors Study- Skin Self Examination|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.~Intervention= Skin self-examination training n=197 Results Pending\*"
62159539|NCT02854657|ACTIVE_COMPARATOR|Comparison of distance (remote) learning vs in-person learning|Controls re-enrolled from the original study (n=38) and newly enrolled in the distance (remote) learning (n=106) are compared with participants receiving the workbook in-person in the original study and re-enrolled (n=134) and participants newly enrolled in distance (remote) learning, who had the workbook mailed to them (n=63). Online surveys assessed SSE knowledge, confidence, anxiety and performance. Electronic health record review identified biopsies of concerning moles and the number of melanomas identified.
62159540|NCT05164094|EXPERIMENTAL|Part A: mRNA-1189 Dose Level 2|Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
62159541|NCT05164094|EXPERIMENTAL|Part A: mRNA-1189 Dose Level 3|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
62159542|NCT05164094|EXPERIMENTAL|Part A: mRNA-1189 Dose Level 4|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
62159543|NCT05164094|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
62159544|NCT05164094|EXPERIMENTAL|Part B: mRNA-1189 Dose Level 1|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
62159545|NCT05164094|EXPERIMENTAL|Part B: mRNA-1189 Dose Level 2|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
62159546|NCT05164094|EXPERIMENTAL|Part B: mRNA-1189 Dose Level 3|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
62533813|NCT03996096||Group with the TKI withdrawal syndrome|There is no intervention. Patients will stop their tyrosine kinase inhibitor yielding to 2 subsets: patients with or without the TKI withdrawal syndrome.
62533814|NCT03996096||Group without the TKI withdrawal syndrome|As abovementioned.
62159547|NCT05164094|EXPERIMENTAL|Part B: mRNA-1189 Dose Level 4|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
62533815|NCT03599492||Cirrhosis Patients|10 Patients with body mass index (BMI) etiology of cirrhosis
62533816|NCT01147263||Patients diagnosed with Fibromyalgia|
62533817|NCT04771403|EXPERIMENTAL|FMPD AP system|Participants will use the FMPD AP system for automated insulin delivery for a 76 hour study visit.
62533818|NCT04771403|EXPERIMENTAL|MPC AP System|Participants will use the MPC AP system for automated insulin delivery for a 76 hour study visit.
62533819|NCT04771403|EXPERIMENTAL|Dexcom G6 Training Arm|Participants will use the Dexcom G6 CGM system within the MPC AP system to generate sensor glucose data during a 7 day period.
62533820|NCT02714517|EXPERIMENTAL|hydrotherapy|patients receive daily conventional physiotherapy and three 30- minutes sessions of in- water exercises per week, for four weeks
62533821|NCT02714517|ACTIVE_COMPARATOR|controls|patients receive daily conventional physiotherapy and three 30- minutes sessions of on- land exercises per week, for four weeks
62533822|NCT03559400|EXPERIMENTAL|gentamicin injection at fracture site|Subjects with an open tibia fracture who receive gentamicin in saline solution administered after closure at the time of initial debridement.
62533823|NCT03559400|PLACEBO_COMPARATOR|placebo saline injection at fracture site|Subjects with an open tibia fracture who receive placebo saline solution administered after closure at the time of initial debridement.
62533824|NCT01666197|EXPERIMENTAL|diclofenac potassium 25 mg tablet|
62159548|NCT05164094|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
62159549|NCT05164094|EXPERIMENTAL|Part C: mRNA-1189 Dose Level 1|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
62159550|NCT05164094|EXPERIMENTAL|Part C: mRNA-1189 Dose Level 2|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
62159551|NCT05164094|EXPERIMENTAL|Part C: mRNA-1189 Dose Level 3|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
62159552|NCT05164094|PLACEBO_COMPARATOR|Part C: Placebo|Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
62159553|NCT06719557|EXPERIMENTAL|Part 1: MK-1084 + Itraconazole|Part 1: In Period 1 participants receive a single dose of MK-1084 on Day 1 under fasting conditions. In Period 2 participants receive itraconazole once daily (QD) for 7 consecutive days (Day 1 - Day 7), plus a single dose of MK-1084 administered approximately 2 hours after itraconazole dosing on Day 5. There will be a washout of at least 7 days between dosing in Period 1 and the first dose in Period 2.
62159554|NCT06719557|EXPERIMENTAL|Part 2: MK-1084 + Phenytoin|Part 2: In Period 1 participants receive a single dose of MK-1084 on Day 1 under fasting conditions. In Period 2 participants receive phenytoin three times daily (TID) for 14 consecutive days (Day 1 - Day 14), plus a single dose of MK-1084 co-administered on the morning of Day 13. There will be a washout of at least 7 days between dosing in Period 1 and the first dose in Period 2.
62159555|NCT03462771|EXPERIMENTAL|Group exercise fish oil|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive omega-3 fatty acid supplements to be ingested 2g in the main meals, totaling 4g daily.
62159556|NCT03462771|PLACEBO_COMPARATOR|Group exercise placebo|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive sunflower oil to be ingested 2g in the main meals, totaling 4g daily.
62159557|NCT06207383|OTHER|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation using technique at the investigator's discretion but including pulmonary vein isolation as an endpoint.
62159558|NCT06207383|ACTIVE_COMPARATOR|Conduction system pacing + atrioventricular nodal ablation|Conduction system pacing (either His bundle pacing or left bundle branch area pacing) with catheter ablation of the atrioventricular node.
62159559|NCT01727193|ACTIVE_COMPARATOR|Azathioprine|cholinesterase inhibitors+Glucocorticoid +Azathioprine
62159560|NCT01727193|ACTIVE_COMPARATOR|Leflunomide|cholinesterase inhibitors+glucocorticoid+Leflunomide
62159561|NCT05208021|EXPERIMENTAL|Intervention group|"Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program was applied to the intervention group"
62159562|NCT05208021|NO_INTERVENTION|Control Group|Only data collection was carried out. No attempt was made by the researcher during the study
62159563|NCT05899868|OTHER|Time to intubation using FASTER device|Time from fiberoptic placement into airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
62159564|NCT04474691|EXPERIMENTAL|Visual-acoustic biofeedback|
62159565|NCT04474691|ACTIVE_COMPARATOR|Traditional articulation treatment|
62159566|NCT06720519||Positive Samples|Positive samples for viruses or bacteria typical of meningitis/encephalitis
62159567|NCT06702774|EXPERIMENTAL|Intervention|A single active case finding campaign for Tuberculosis will occur in Year 1 alongside the usual care.
62533825|NCT01666197|PLACEBO_COMPARATOR|placebo|
62533826|NCT02416414||Solid Organ Transplant Recipients|Subjects who have received a Solid Organ Transplant.
62533827|NCT02416414||Healthy Controls|Healthy individuals.
62159568|NCT06702774|NO_INTERVENTION|Control|Usual care will be provided and no active case finding activities will be implemented.
62159569|NCT06716281|EXPERIMENTAL|MSC group|IxCell hUC-MSC-O;2.5×10\^7 cells/1 mL, 1 mL/vial; 2ml
62159570|NCT06716281|PLACEBO_COMPARATOR|placebo group|Sodium Chloride Injection；1 mL/vial；2ml
62159571|NCT03849300|NO_INTERVENTION|Control Group|No exercise intervention
62159572|NCT03849300|EXPERIMENTAL|Aquatic walking exercise group 1|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
62159573|NCT03849300|EXPERIMENTAL|Aquatic walking exercise group 2|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
62533828|NCT00567047|EXPERIMENTAL|1|Vildagliptin
62533829|NCT00586352|ACTIVE_COMPARATOR|Normal|Subjects who have normal endoscopic findings
62533830|NCT00586352|ACTIVE_COMPARATOR|Newly diagnosed Crohn's disease|Subjects who are newly diagnosed with Crohn's disease after endoscopy.
62533831|NCT00586352|ACTIVE_COMPARATOR|Newly diagnosed Ulcerative Colitis|Subjects diagnosed with Ulcerative Colitis after endoscopy
62533832|NCT00829803|EXPERIMENTAL|SNAP Monitor EEG signals|
62533833|NCT00829803|ACTIVE_COMPARATOR|BIS Monitor EEG signals (VISTA)|
62533834|NCT04934449|EXPERIMENTAL|Hard splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, hard occlusal splints for 2 months during sleep
62533835|NCT04934449|EXPERIMENTAL|Hard splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, hard occlusal splints for 2 months during sleep
62533836|NCT04934449|EXPERIMENTAL|Soft splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, soft occlusal splints for 2 months during sleep
62159574|NCT03849300|ACTIVE_COMPARATOR|Land-based walking exercise group|"The land-based walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of low-intensity forward, backward, and lateral side-stepping movements on flat group. The remaining 30 minutes included treadmill walking exercise.~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
62159575|NCT00123500|ACTIVE_COMPARATOR|1|Worksite Intervention
62159576|NCT00123500|PLACEBO_COMPARATOR|2|Control Group
62159577|NCT03527329||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
62159578|NCT03527329||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
62159579|NCT02747459|EXPERIMENTAL|SSS Intervention|Sensory Supported Swimming-eight, 30 minute lessons
62159580|NCT05401799|ACTIVE_COMPARATOR|Conventional Upper Extremity Neuroeducation|74 patients will receive the standard occupational therapy sessions that they would normally receive during their IRF stay. UE neuroeducation sessions are typically focused on improving strength and mobility of the upper arm. Clinicians will not be given instructions on how to run their sessions, however they will not be allowed to use BURT. Other devices that would normally be used during neuro-educational sessions (including X-cite, electrical stimulation and RT-300) will be allowed for use in this group. The therapists will track the activity, level of assistance and time provided in a tracking sheet, as well as document any adverse events that may occur
62159581|NCT05401799|EXPERIMENTAL|BURT Upper Extremity|As part of routine therapy, 74 patients will receive up to 5 sessions per week of BURT UE therapy in place of conventional neuro re-education. Patients in this arm of the study will receive any conventional therapy during the remainder of their treatment sessions. When using BURT, therapists will track the activity, level of assistance and time provided in a tracking sheet, as well as document any adverse events that may occur.
62159582|NCT01039506||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 based regimens
62159583|NCT04937049|EXPERIMENTAL|EMAeHealth digital tool|This team has designed a digital tool called EMAeHealth involving healthcare professionals. It is organized into 4 areas: 1) an Information area, 2) a Communication area, 3) a Health Self-management area, 4) a Clinical data area, The tool is conceived as a complement that can reinforce maternal health education with resources that facilitate its accessibility, and rapid remote response, which will also improve its results. It will be incorporated into the Osakidetza-Basque Health Service corporate Website.
62159584|NCT04937049|NO_INTERVENTION|No EMAeHealth digital tool|Usual care. This group, like experimental group, receives the usual care, which includes traditional maternal education, but does not receive the EMAeHealth intervention
62159585|NCT01705444|OTHER|Foley catheter and The Spanner Insertion|Quality of life questionnaire after using the Foley catheter and the Spanner
62159586|NCT04593004|EXPERIMENTAL|Teledermatology|
62159587|NCT04593004|ACTIVE_COMPARATOR|Face-to-face consultation|
62159588|NCT05424952|NO_INTERVENTION|Control|Eligible adults with unvaccinated senior parents/grandparents or children.
62159589|NCT05424952|EXPERIMENTAL|Intervention|Eligible adults with unvaccinated senior parents/grandparents or children.
62533837|NCT04934449|EXPERIMENTAL|Soft splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, soft occlusal splints for 2 months during sleep
62533838|NCT02318238|ACTIVE_COMPARATOR|6 minute walking test|walking during 6 minutes
62533839|NCT02318238|EXPERIMENTAL|6 minute step test|stepping during 6 minutes
62159590|NCT01913444|EXPERIMENTAL|Recombinant Antithrombin Infusion|The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO. Loading dose(IU)=(100-baseline AT activity)/2.3 x Wt(kg). Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2 x Wt(kg). The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO. This will be followed by the maintenance continuous infusion. AT levels will be checked 2hours after the initiation of treatment. For AT levels that are \<80% or \>100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment. If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made. Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
62159591|NCT03522688|PLACEBO_COMPARATOR|control group|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
62159592|NCT03522688|ACTIVE_COMPARATOR|treatment group|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
62533840|NCT02318238|EXPERIMENTAL|4 meter gait speed|walking as fast as possible on 4 meters
62533841|NCT02351271|EXPERIMENTAL|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
62533842|NCT02351271|ACTIVE_COMPARATOR|Manual capsulorhexis&lens fragmentation|The Conventional group acts as a control group with conventional capsulorhexis and ultrasound phacoemulsification
62714353|NCT06218979|ACTIVE_COMPARATOR|Cola beverage phase|Study drug dose (1 mg risperidone) and 250 ml cola drink at 8:00 a.m., and 250 ml cola beverage at 8:30 a.m.
62714354|NCT03291522||Men with azoospermia|Ultrasound-guided rete testis flushing and aspiration
62714355|NCT03549780|OTHER|Stomal Occlusion|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
62159593|NCT02769754|PLACEBO_COMPARATOR|Control|In the control group (group A) no additional treatment will be applied after performing the usual surgical hemostasis.
62159594|NCT02769754|EXPERIMENTAL|Hemopatch|Hemopatch will be apply in the treatment group (group B), once the standard surgical hemostasis is achieved
62159595|NCT03344458|EXPERIMENTAL|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
62159596|NCT04678297|EXPERIMENTAL|Physical activity + emotion regulation group|Participants randomized to the experimental group attend two group-based class sessions per week, each 1.25hours long, that are led by certified instructors who guide participants through various exercises. Participants are encouraged to practice the activities at home for 20 minutes each day.
62159597|NCT04678297|ACTIVE_COMPARATOR|Physical activity control group|Participants randomized to the control group attend two group-based class sessions per week, each 1.25hours long, that are led by trained therapists who guide participants through a series of stretching exercises. Participants are encouraged to practice the activities at home for 20 minutes each day.
62159598|NCT05791552|OTHER|Group A|Patient WITH cognitive impairment and no nasal pathologies. CSF analysis is planned or results are already available
62159599|NCT05791552|OTHER|Group B|Patient WITHOUT cognitive impairment and without nasal pathologies
62159600|NCT06027216|EXPERIMENTAL|Field Expansion|Field of view on the nasal side (same side as the blind eye) with and without multiplexing prism
62159601|NCT05103033|EXPERIMENTAL|Systems Analysis and Improvement Approach (SAIA) for mental health|Those receiving SAIA-MH will attend a 1-week in-person training for facility learning collaboratives. Following the 1-week in-person training, SAIA-MH standard operating procedures will be implemented, including: (1) structured internal/external facilitation following tablet-based guides used in pilot study (1x per week first month; 2x per week for next two months; 1x per month for remainder); (2) facilitation in the 5-step SAIA-MH improvement process.
62159602|NCT05103033|OTHER|Attentional Placebo Control|"Control facilities will mimic activities of the intervention group in time and contacts, but without the active ingredient of the SAIA-MH implementation strategy"
62159603|NCT01767376|EXPERIMENTAL|Nimenrix+ Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.
62159604|NCT01767376|EXPERIMENTAL|Nimenrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
62159605|NCT01767376|EXPERIMENTAL|Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
62159606|NCT06478589|EXPERIMENTAL|Adapted Patient Priorities Care (PPC) approach plus Usual Care|
62159607|NCT06478589|ACTIVE_COMPARATOR|Usual Care|
62159608|NCT03676400|EXPERIMENTAL|NGF-574H|"NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss.~NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks."
62159609|NCT03676400|PLACEBO_COMPARATOR|placebo|Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
62159610|NCT02205476|EXPERIMENTAL|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
62714356|NCT06289465||Seasonal Workers (Experimental group)|"Criteria:~* Volunteering to participate in the study.~* To be between the ages of 18-34.~* Having worked as a seasonal worker in Giresun for at least 1 month during the hazelnut harvest period."
62159611|NCT02205476|EXPERIMENTAL|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
62159612|NCT06095492|EXPERIMENTAL|Empa group|
62714357|NCT06289465||Controls (Control group)|"Criteria:~* Volunteering to participate in the study.~* To be between the ages of 18-34.~* Not having worked in any agricultural work during the summer period.~* Living in the same socioeconomic environment as the group working as seasonal workers"
62159613|NCT06095492|ACTIVE_COMPARATOR|Lina group|
62159614|NCT05725928|NO_INTERVENTION|Usual Care|No intervention
62159615|NCT05725928|EXPERIMENTAL|Mobility Technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session
62159616|NCT03417375|EXPERIMENTAL|Osteocel Plus|Experimental product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
62159617|NCT03417375|ACTIVE_COMPARATOR|alloOss|The control product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
62159618|NCT00324363|EXPERIMENTAL|Exenatide|Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
62159619|NCT00324363|PLACEBO_COMPARATOR|Placebo|Placebo in volume equal to exenatide
62159620|NCT05321576|ACTIVE_COMPARATOR|erector spinae plane block group|Before this process, it will be produced from the bupivacaine plan, which will be made by entering unilaterally 3 cm lateral in the ultrasound to be made from a work section that will be made before the shipment and by lidocaine.
62159621|NCT05321576|ACTIVE_COMPARATOR|control group|give opiod in this group of patients
62159622|NCT06496750|EXPERIMENTAL|Ketamine|Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks.
62159623|NCT06496750|ACTIVE_COMPARATOR|Midazolam|Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks.
62159624|NCT04362865||COVID-19 infection|Patients with confirmed or suspected COVID-19 infections
62533843|NCT05567263|ACTIVE_COMPARATOR|Bulk- Fill|Restorative procedure of the teeth will be performed using Filtek-Bulk Fill Posterior Restorative, Bulk-fill resin composite, (3M, ESPE) following application of an etch-and-rinse single bottle adhesive (3M, ESPE).
62533844|NCT05567263|EXPERIMENTAL|Surefill One|Restorative procedure of the teeth will be performed using Surefil one™ Self-Adhesive Composite Hybrid (Dentsply, Sirona),
62533845|NCT05269602||L5 Radiculopathy|Patients who have Lumbar 5 root compression with the Magnetic Resonance İmaging
62714358|NCT06566014|EXPERIMENTAL|AI feedback|The participant will receive AI feedback upon completing the task of analyzing 20 images. The AI feedback will include a prediction (Normal/Spina Bifida) along with a confidence score ranging from 0.0 to 1.0, where 0.0 indicates the lowest confidence and 1.0 indicates the highest confidence.
62159625|NCT04362865||No COVID-19 infection|Patients without confirmed or suspected COVID-19 infections (i.e., normal donors)
62159626|NCT05185739|ACTIVE_COMPARATOR|Pembrolizumab|
62714359|NCT06566014|PLACEBO_COMPARATOR|No AI feedback|The participants will complete the task of analyzing 20 images without any AI feedback.
62159627|NCT05185739|ACTIVE_COMPARATOR|Lenvatinib.|
62159628|NCT05185739|EXPERIMENTAL|Pembrolizumab and Lenvatinib.|
62159629|NCT06547775|EXPERIMENTAL|Group 1: KN069 Dose 1|Participants will receive a single SC KN069 12mg.
62159630|NCT06547775|EXPERIMENTAL|Group 2: KN069 Dose 2|Participants will receive a single SC KN069 30mg.
62159631|NCT06547775|EXPERIMENTAL|Group 3: KN069 Dose 3|Participants will receive a single SC KN069 60mg.
62159632|NCT06547775|EXPERIMENTAL|Group 4: KN069 Dose 4|Participants will receive a single SC KN069 120mg.
62159633|NCT06547775|EXPERIMENTAL|Group 5: KN069 Dose 5|Participants will receive a single SC KN069 240mg.
62159634|NCT06029595|EXPERIMENTAL|CHF6001 - CHF6001 total daily dose 3200 μg;|
62159635|NCT06029595|PLACEBO_COMPARATOR|Placebo|
62159636|NCT06721598||Hem101 Arm|Subjects received Hem101 in Study Hem101-01-01 will be followed for 11 month
62159637|NCT01167972||1|
62159638|NCT06577025|EXPERIMENTAL|Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel|Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release, and completion of induction, participants will begin consolidation with 4 cycles of Tal-D (each cycle is of 28 days), followed by a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days); cilta-cel will be administered 5 to 7 days after the start of the conditioning regimen.
62159639|NCT06577025|EXPERIMENTAL|Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation|Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release and completion of induction, participants will begin consolidation with a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days) with infusion of cilta-cel 5 to 7 days after the start of the conditioning regimen. Following cilta-cel infusion, alternating cycles of Tal-D (Cycle 1, 3, 5, and 7) and Tec-D (Cycle 2, 4, 6, and 8) will be started, no earlier than Day 84 and no later than Day 168 post cilta-cel infusion. Each cycle of Tal-D and Tec-D is 84 days which includes an extended treatment-free interval.
62159640|NCT04978584|EXPERIMENTAL|Treatment (uLTRA, CHOP)|"COHORT I (SMART STOP): Patients receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progr"
62159641|NCT05832320|EXPERIMENTAL|Oral etoposide with dual induction of ATRA and RIF|RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
62533846|NCT05269602||S1 Radiculopathy|Patients who have Sacral 1 root compression with the Magnetic Resonance İmaging
62533847|NCT02337959|EXPERIMENTAL|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
62533848|NCT02337959|EXPERIMENTAL|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
62533849|NCT02337959|EXPERIMENTAL|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
62533850|NCT01473524|EXPERIMENTAL|DB OCA 5-10 mg|OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.
62533851|NCT01473524|EXPERIMENTAL|DB OCA 10 mg|OCA 10 mg for 12 months during the DB phase.
62533852|NCT01473524|PLACEBO_COMPARATOR|DB Placebo|Matching placebo for 12 months during the DB phase.
62533853|NCT01473524|EXPERIMENTAL|LTSE OCA|After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg. Participants who were previously titrated above 10 mg OCA daily were down-titrated to ≤10 mg OCA daily.
62533854|NCT04319185|EXPERIMENTAL|Intervention|All patients who qualify for the study will receive the intervention
62714360|NCT02771405|EXPERIMENTAL|Sofosbuvir +Ribavirin|Sofosbuvir 400 mg/day +ribavirin for 24 weeks
62159642|NCT05832320|ACTIVE_COMPARATOR|Daunorubicin with dual induction of ATRA and RIF|RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
62159643|NCT06075433||complex coronary artery disease|"\<Clinical factors\>~Age 75 or older History of diabetes (those who have had diabetes in the past or are taking diabetes medication) History of chronic kidney disease (GFR \<60ml/min/1.73m2) or dialysis History of stroke History of coronary artery bypass surgery Left ventricular dysfunction (LVEF \<40%) Severe valve disease Troponin positive acute coronary syndrome \<Lesion/procedure factors\>~Left main lesion Chronic total occlusion Bifurcation lesion with branches larger than 2 mm Calcified lesion (moderate to severe calcified lesion) Restenosis (in-stent restenosis) Multivessel PCI Three or more stents implanted (≥3 stents implanted) When the stent length of one lesion is more than 50 mm (total stent length \>50 mm in a lesion)"
62159644|NCT06291298|EXPERIMENTAL|COGMUSE-AUT|Participants will complete the computerized cognitive training intervention for 60 minutes per day, 3 times per week for 6 weeks at home totaling to 18 hours.
62159645|NCT06721819|EXPERIMENTAL|Sleep Hygiene, brain games, and IV Acetaminophen bundle intervention|"Preoperative Intervention: Two weeks of following a sleep hygiene protocol and 10 hours minimum of playing brain games.~Cognitive Exercise: Patients will be given an iPad, which will be pre-installed with access to Lumosity, a cognitive exercise software application. Participants will be instructed to try and complete 1 hour of Lumosity exercise daily prior to surgery, with a pre-operative cognitive exercise goal of 10 hours.~Sleep Hygiene: Preoperatively, investigators will deliver the digital CBT-I, (Cognitive Behavioral Therapy- Insomnia) over 2 weeks before surgery and in parallel to cognitive exercise.~Postoperative Intervention: Eight doses of IV acetaminophen at 1000g each dose delivered every 6 hours for the first 48 hours within 1 hour of admission to CVICU. Acetaminophen administration in any form other than the blinded study medication during this time will not be allowed."
62159646|NCT06721819|ACTIVE_COMPARATOR|ERAS Protocol with three doses IV Acetaminophen|No preoperative intervention and three doses of IV acetaminophen (as following ERAS protocol) at 1000mg per dose within 48 hours post operatively. Control patients will be on intravenous acetaminophen for the first 24 hours (three doses at 8 hourly intervals).
62159647|NCT02975609|ACTIVE_COMPARATOR|Conventional Fractionated Radiotherapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
62159648|NCT02975609|EXPERIMENTAL|Stereotactic Body Radiation Therapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
62159649|NCT05528510|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive guselkumab (Dose 1) subcutaneous (SC) injection followed by guselkumab (Dose 2) SC injection.
62159650|NCT05528510|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab (Dose 1) SC injection followed by guselkumab (Dose 3) SC injection.
62159651|NCT05528510|PLACEBO_COMPARATOR|Group 3: Placebo|Participants will receive matching placebo SC injection.
62159652|NCT04184622|EXPERIMENTAL|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
62159653|NCT04184622|EXPERIMENTAL|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
62159654|NCT04184622|EXPERIMENTAL|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
62159655|NCT04184622|PLACEBO_COMPARATOR|Placebo|Placebo administered SC once a week.
62159656|NCT03001830|EXPERIMENTAL|Treatment Arm|Treatment with AAV2/8-HLP-FVIII-V3
62159657|NCT04312672||Follow up cohort|no intervention follow up study
62159658|NCT00559871|PLACEBO_COMPARATOR|1|One placebo tablet administered tid from Day 1 to 28
62159659|NCT00559871|ACTIVE_COMPARATOR|2|One 30-mg tablet of Fipamezole tid from Day 1 to 28
62159660|NCT00559871|ACTIVE_COMPARATOR|3|One 30-mg tablet of Fipamezole tid from Day 1 to 7; and one 60-mg tablet of Fipamezole tid from Day 8 to 28
62159661|NCT00559871|ACTIVE_COMPARATOR|4|One 30-mg tablet of Fipamezole tid from Day 1 to 7; one 60-mg tablet of Fipamezole tid from Day 8 to 14; and one 90-mg tablet of Fipamezole tid from Day 15 to 28
62159662|NCT06660563|EXPERIMENTAL|JNJ-80948543|Participants will receive JNJ-80948543 in combination with JNJ-75348780 to determine the recommended phase 2 regimen (RP2R) in Part 1 (Dose escalation). JNJ-80948543 will be dosed in an escalation manner in combination with fixed doses of JNJ-75348780. In Part 2 (Dose expansion) participants will receive RP2R of JNJ-80948543 as determined in Part 1 in combination with JNJ-75348780.
62159663|NCT05299606|EXPERIMENTAL|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
62159664|NCT05753358|EXPERIMENTAL|Needs Assessment and Total Worker Health Program|The initial phase was a needs assessment for wildland firefighters across segments and geographic locations to identify and prioritize program components. During the first phase, we recruited firefighters and collected baseline data in order to assess their needs using surveys for quantitative data and interviews and focus groups for qualitative data. The total worker health program includes 14, 30-minute modules on health topics highlighted during the needs assessment phase. Participants completed the program either individually or as part of a group.
62159665|NCT01391234|EXPERIMENTAL|STAT RT planning and delivery workflow|single arm
62159666|NCT02374476|EXPERIMENTAL|Bipolar Ablation|All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.
62159667|NCT02374476|ACTIVE_COMPARATOR|Registry|Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful
62159668|NCT04456296|ACTIVE_COMPARATOR|AVEED (Testosterone Undecanoate Injection)|Fixed dosage level of 750 milligrams (mg)/3 milliliters (mL) administered by intramuscular injections.
62159669|NCT04456296|ACTIVE_COMPARATOR|FORTESTA (Testosterone Gel)|40 mg once daily topical gel administration.
62159670|NCT04456296|ACTIVE_COMPARATOR|TESTIM (Testosterone Gel)|50 mg once daily topical gel administration.
62533855|NCT04865393|EXPERIMENTAL|SPR206|SPR206 100mg single-dose IV infused over 1 hour
62159671|NCT06575751|ACTIVE_COMPARATOR|Broad Spectrum Cannabidiol (bsCBD) 400 mg|bsCBD in a 400 mg dose will be used as described in the study arms.
62159672|NCT06575751|ACTIVE_COMPARATOR|Broad Spectrum Cannabidiol (bsCBD) 200 mg|bsCBD in a 200 mg dose will be used as described in the study arms.
62159673|NCT06575751|PLACEBO_COMPARATOR|Placebo|A medically inert placebo medication will be used as described in the study arms.
62159674|NCT06721481||Pregnant women|Pregnant women who attend their first prenatal consultation at the maternity ward of the University hospital of Besançon
62159675|NCT00062478|EXPERIMENTAL|1|Karenitecin for intravenous use
62159676|NCT04362111|EXPERIMENTAL|Anakinra Group|The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to 100 mg twice daily for the remaining 5 days.
62159677|NCT04362111|PLACEBO_COMPARATOR|Control Group|The control group will receive normal saline placebo subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to twice daily for the remaining 5 days.
62159678|NCT02691884||Patients before/after Pressure Exertion|100 pregnant patients at term in low risk pregnancies, undergoing a routine cardiotocography, will experience different amounts of manual pressure on their abdomen. The amount of pressure applied will be recorded and the fetal heart rate will be compared before and at the time of maternal abdominal pressure.
62159679|NCT01515202|EXPERIMENTAL|Panel 1: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
62159680|NCT01515202|EXPERIMENTAL|Panel 2: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
62159681|NCT01515202|EXPERIMENTAL|Panel 3: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
62159682|NCT01515202|EXPERIMENTAL|Panel 4: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
62159683|NCT01515202|EXPERIMENTAL|Panel 5: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
62159684|NCT06641908|EXPERIMENTAL|Dose Escalation: M3554 Monotherapy|
62159685|NCT04015050|EXPERIMENTAL|Test product|Cow's milk based infant formula containing prebiotics and postbiotics
62159686|NCT04015050|ACTIVE_COMPARATOR|Control product|Cow's milk based infant formula without prebiotics and postbiotics
62159687|NCT05795309|EXPERIMENTAL|Hybrid Automated Insulin Delivery|The intervention is the Medtronic 780G Hybrid Automated Insulin Delivery system
62159688|NCT05795309|NO_INTERVENTION|Standard care|The control is Standard Care with real-time CGM
62159689|NCT02791685|EXPERIMENTAL|Cardiac Rehabilitation - Movn Program|Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
62533856|NCT01283529||Children 0 - 15 years|Children undergoing neurosurgery in general anesthesia
62533857|NCT00311402|OTHER|Aggrenox Capsule|
62714361|NCT02771405|EXPERIMENTAL|Sofosbuvir+Simeprevir±Ribavirin|Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks
62159690|NCT02791685|EXPERIMENTAL|Pulmonary Rehabilitation - Movn Program|Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
62159691|NCT02791685|ACTIVE_COMPARATOR|Traditional Cardiac Rehabilitation|Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
62159692|NCT00860509|PLACEBO_COMPARATOR|Low Phytosterol Diet|Diet with 100 mg of daily phytosterols
62159693|NCT00860509|ACTIVE_COMPARATOR|High Phytosterol Diet|Diet with 600 mg of daily phytosterols
62159694|NCT06721429|EXPERIMENTAL|dual task exercise group|Patients in the dual-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training. In addition, cognitive exercise training will be incorporated into each session, performed concurrently with the conventional physiotherapy. The cognitive exercises provided in this study are structured to target areas such as memory, verbal fluency, executive functions, calculation, and attention.
62159695|NCT06721429|ACTIVE_COMPARATOR|single task exercise group|Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
62159696|NCT06721429|NO_INTERVENTION|control group|The control group will be instructed to continue with their daily activities and refrain from participating in any exercise training program for eight weeks after the initial assessment. After the exercise training period, the control group will also be invited to join the exercise training program of their choice.
62159697|NCT00472199|EXPERIMENTAL|Pramipexole|4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
62159698|NCT00472199|PLACEBO_COMPARATOR|Placebo|4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
62159699|NCT02201992|EXPERIMENTAL|Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62159700|NCT02201992|ACTIVE_COMPARATOR|Arm B (observation)|Patients undergo observation.
62159701|NCT05107921|EXPERIMENTAL|Bromfenac sodium hydrate eye drops|The patients will receive bromfenac sodium hydrate eye drops twice daily for 14 days.
62533858|NCT00311402|OTHER|Acetylsalicylic Acid (ASA) 81 mg Tablet|
62533859|NCT01648660|ACTIVE_COMPARATOR|D2x - D1x|"Cross Over from double dosage to single dosage:~daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA"
62533860|NCT01648660|ACTIVE_COMPARATOR|D1x - D2x|"Cross Over from double dosage to single dosage:~daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA"
62533861|NCT01648660|ACTIVE_COMPARATOR|D1x - D1x|single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)
62714362|NCT02771405|EXPERIMENTAL|Sofosbuvir+Daclatasvir±Ribavirin|Sofosbuvir 400 mg/day +Daclatasvir 60 mg/day ± ribavirin for 12 weeks
62159702|NCT03406299|EXPERIMENTAL|SLOG regimen|Arm 1 interventions : SLOG regimen: treatment for every 14 days as one cycle Tegafur (S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day) Leucovorin 30 mg/b.i.d., day 1-7; Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1; Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (FDR, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin
62159703|NCT03406299|ACTIVE_COMPARATOR|GC regimen|Arm 2 interventions : GC regimen: treatment for every 21 days as one cycle Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
62159704|NCT04596917|EXPERIMENTAL|Preferred music listening|Patients will be randomized to listen to music with iPod that has preferred music selections that patients can choose.
62159705|NCT04596917|EXPERIMENTAL|Hypnotic music with relaxation breathing|Patients will be randomized to listen to hypnotic music with relaxation breathing narrative.
62159706|NCT06088082|NO_INTERVENTION|CONTROL GROUP|) will receive standard routine postoperative analgesia at our institute.
62159707|NCT06088082|EXPERIMENTAL|TREATMENT GROUP|The patients will be divided into two groups; group-1 (n= 50) will receive pre-procedure right US-guided TAP and bilateral PRS blocks with bupivacaine 0.25% 20 ml for TAP block and 10 ml for PRS block .
62159708|NCT06721520|EXPERIMENTAL|Botox|Patients will be randomized to the intrapyloric Botox injection intervention arm intraoperatively just after the pylorus is identified and just prior to the time at which pyloric drainage would occur routinely, at which point it is feasible for the surgeon to perform either intervention.
62159709|NCT06721520|ACTIVE_COMPARATOR|Pyloromyotomy|Patients will be randomized to the pyloromyotomy intervention arm intraoperatively just after the pylorus is identified and just prior to the time at which pyloric drainage would occur routinely, at which point it is feasible for the surgeon to perform either intervention.
62159710|NCT03796585|EXPERIMENTAL|Intervention|Pharmacists assigned to this group will receive an immunization registry training program and informational flyer.
62159711|NCT03796585|ACTIVE_COMPARATOR|Control|Pharmacists assigned to this group will receive an informational flyer. They will not receive training.
62159712|NCT05449145|PLACEBO_COMPARATOR|Placebo|MCT oil (first 4-week) plus Omega-3 FA (second 4-week)
62159713|NCT05449145|EXPERIMENTAL|Vitamin D|Vit D (first 4-week) plus Omega-3 FA (second 4-week)
62159714|NCT04025762|EXPERIMENTAL|Day and night hybrid closed loop control|"The day and night hybrid closed-loop system (CamAPS FX) will consist of:~* Dana RS insulin pump (Sooil)~* G6 real-time CGM sensor (Dexcom)~* An unlocked android smartphone hosting the CamAPS FX app with Cambridge control algorithm"
62159715|NCT04025762|ACTIVE_COMPARATOR|Sensor augmented pump therapy|The comparator will consist of Dana RS insulin pump (Sooil) and G6 real-time CGM sensor (Dexcom)
62159716|NCT06721936|ACTIVE_COMPARATOR|Laser CO2 Therapy group|Participants in this group will undergo three treatment sessions using the Monalisa Touch CO2 fractional laser, administered by a senior gynaecologist (MD3) on an outpatient basis, once a month for three consecutive months. Each session will last approximately 15 minutes and will be performed without anaesthesia
62159717|NCT06721936|EXPERIMENTAL|Multimodal pelviperineal physioterapy group|Participants in this group will attend eight personalized sessions of multimodal PPT, each lasting 50-60 minutes, administered once a week the six first sessions, and the last 2 sessions, one session every two weeks. The multimodal PPT protocol includes: 1) Pelvic Floor Muscle Training (PFMT); 2) Non-Ablative Radiofrequency Therapy (Model: RNG, INDIBA); 3) Therapeutic Pelvic Health Education.
62159718|NCT06460103|EXPERIMENTAL|"Straumann® Bone Level Tapered SLActive® mini-implant (hydrophilic surface)"|"Tooth extraction + Straumann® Bone Level Tapered, SLActive® mini-implant placement + bone augmentation (bone graft maxgraft® cortico-cancellous granules 0.5-2.0mm and dental membrane collprotect®membrane)"
62159719|NCT06460103|ACTIVE_COMPARATOR|"Straumann® Bone Level Tapered implants SLA® mini-implant (hydrophobic surface)"|"Tooth extraction + Straumann® Bone Level Tapered , SLA® mini-implant placement + bone augmentation (bone graft maxgraft® cortico-cancellous granules 0.5-2.0mm and dental membrane collprotect®membrane)"
62533862|NCT03155321||Polish General Surgeons|The group is formed by active polish general surgeons, both specialists and in training
62159720|NCT00067808|ACTIVE_COMPARATOR|Decitabine 10 mg/m^2 IV|10 mg/m\^2 intravenous (IV) over 1 hour daily for 10 days
62159721|NCT00067808|ACTIVE_COMPARATOR|Decitabine 20 mg/m2 IV|20 mg/m2 IV over 1 hour daily for 5 days
62159722|NCT00067808|ACTIVE_COMPARATOR|Decitabine 20 mg/m2 SQ|20 mg/m2 subcutaneous (SQ) daily for 5 days
62533863|NCT04447339||Open|Prophylactic NSM cases by Open approach
62533864|NCT01760525|EXPERIMENTAL|CGM097 - Dose escalation|
62533865|NCT01760525|EXPERIMENTAL|CGM097 - Dose Expansion at MTD or RP2D|
62533866|NCT00265395|ACTIVE_COMPARATOR|Standard therapy|Slow responders (defined as being polymerase chain reaction \[PCR\] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.
62533867|NCT00265395|EXPERIMENTAL|Extended therapy|Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.
62159723|NCT01420328|PLACEBO_COMPARATOR|Placebo Arm|Obese subjects treated with placebo for 6 weeks
62159724|NCT01420328|ACTIVE_COMPARATOR|Vytorin Arm|Obese subjects treated with Vytorin for 6 weeks
62159725|NCT02412345|EXPERIMENTAL|Extracorporeal Shockwave therapy|Extracorporeal shockwave therapy at the penis. 6 sessions.
62159726|NCT02412345|SHAM_COMPARATOR|Sham treatment|Extracorporal shockwave therapy with a placebo probe. 6 sessions
62159727|NCT04348799||BPD group|premature infants diagnosed with BPD after postnatal day 28
62159728|NCT04348799||control group|premature infants without BPD after postnatal day 28
62159729|NCT01071720|OTHER|CKD-501 1mg (fed-fasted group)|CKD-501 1mg should be administered following a high-fat, high-caloric diet(fed condition) in one period and on an empty stomach(fasting condition) in the other period.
62533868|NCT03393806|EXPERIMENTAL|Participants receiving GSK3772847|Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks
62159730|NCT01071720|OTHER|CKD-501 1mg (fasted-fed group)|CKD-501 1mg should be administered on an empty stomach(fasting condition) in one period and following a high-fat, high-caloric diet(fed condition) in the other period.
62159731|NCT05813145|PLACEBO_COMPARATOR|Placebo Group|n=25: will receive Placebo plus four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week.
62159732|NCT05813145|ACTIVE_COMPARATOR|fenofibrate group|"n=25: will receive fenofibrate 160mg once daily for 3 month plus four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week.~."
62159733|NCT05669989|EXPERIMENTAL|Isatuximab|Participants will receive isatuximab as monotherapy or in a combination regimen, according to the treatment the participant received on the parental protocol
62159734|NCT06423430|SHAM_COMPARATOR|Sham-stimulation group|Group will be implanted with DBS system but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.
62159735|NCT06423430|ACTIVE_COMPARATOR|Active-stimulation group|Group will have DBS system activated 2 weeks post-implant.
62159736|NCT05319756|EXPERIMENTAL|gabapentin 600 mg single dose|
62159737|NCT05319756|EXPERIMENTAL|gabapentin 1200 mg single dose|
62159738|NCT05319756|EXPERIMENTAL|gabapentin 600 mg and oxycodone HCl 20 mg|
62159739|NCT05319756|EXPERIMENTAL|gabapentin 1200 mg and oxycodone HCl 20 mg|
62159740|NCT05319756|ACTIVE_COMPARATOR|oxycodone HCl 20 mg single dose|
62159741|NCT05319756|PLACEBO_COMPARATOR|placebo single dose|
62159742|NCT05044286||40 Transgender and Gender Diverse for World Café Conversation|We will host two world cafe conversations. The first (n = 20) will be specifically or black transgender and gender diverse adults (18+), who are HIV-negative, and have indications for PrEP. The second (n = 20) will be open to transgender and gender diverse adults, who are HIV-negative, and have indication for PrEP.
62159743|NCT05044286||20 Other Key stakeholders for World Café Conversation|We will interview 20 other key stakeholders including medical providers, HIV prevention specialists, outreach workers, PrEP navigators/educators.
62159744|NCT05044286||500 Transgender and Gender Diverse for Survey|We will survey 500 TGD adults (18+), who are HIV negative, and have indications for PrEP.
62159745|NCT04223323|EXPERIMENTAL|Intervention|The intervention arm consists of daily consumption of the investigator's intervention snack over the course of 12 weeks.
62159746|NCT04223323|PLACEBO_COMPARATOR|Isocaloric Control|The control arm consists of daily consumption of an isocaloric snack over the course of 12 weeks.
62159747|NCT01810328|ACTIVE_COMPARATOR|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
62159748|NCT01810328|ACTIVE_COMPARATOR|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
62159749|NCT01295619|EXPERIMENTAL|I-020805|This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.
62159750|NCT04958265|EXPERIMENTAL|Crovalimab|Participants will be enrolled in three cohorts: \[1\] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; \[2\] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and \[3\] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.
62159751|NCT05625438|EXPERIMENTAL|Bedside Telerehabilitation|"Participants will be assigned 45-minute therapy training exercises each day for 5 days per week.~Participants will use the HandyMotion device to interact with the telerehabilitation program displayed on the TV set in the patient room."
62159752|NCT05591456|EXPERIMENTAL|group 1|The first group 50 patient (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week,
62159753|NCT05591456|ACTIVE_COMPARATOR|group 2|the second group 50 patient (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
62159754|NCT03219788|PLACEBO_COMPARATOR|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
62533869|NCT03393806|PLACEBO_COMPARATOR|Participants receiving placebo|Participants will be randomized to receive matching placebo as IV infusion
62533870|NCT02829294|EXPERIMENTAL|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
62533871|NCT03584724|EXPERIMENTAL|Norflo Oro|The study subject will take the entire content of one packet of Norflo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
62533872|NCT03584724|PLACEBO_COMPARATOR|Placebo for Norflo Oro|The study subject will take the entire content of one packet of Placebo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
62533873|NCT00405444|EXPERIMENTAL|1|
62533874|NCT00405444|PLACEBO_COMPARATOR|2|
62533875|NCT01776697|ACTIVE_COMPARATOR|pelubiprofen (30mg) tablet IR TID, fasting|
62533876|NCT01776697|ACTIVE_COMPARATOR|pelubiprofen (30mg) tablet IR TID, fed|
62533877|NCT01776697|EXPERIMENTAL|pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD|
62159755|NCT03219788|ACTIVE_COMPARATOR|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
62159756|NCT03219788|ACTIVE_COMPARATOR|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
62533878|NCT05712421|EXPERIMENTAL|North Star|
62533879|NCT05712421|ACTIVE_COMPARATOR|Levothyroxine|
62533880|NCT06385561|ACTIVE_COMPARATOR|Active treatment|Tramadol
62533881|NCT06385561|PLACEBO_COMPARATOR|Placebo treatment|Placebo
62533882|NCT04070235|EXPERIMENTAL|SH229/DCV 400mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg once daily and DCV tablets 60 mg once daily QD (n=40) for 12weeks
62159757|NCT04861259|EXPERIMENTAL|Crovalimab|Participants will be enrolled in three cohorts: \[1\] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; \[2\] Switch Cohort - participants who switch to crovalimab from another Complement Component 5 (C5) inhibitor and \[3\] C5 Single Nucleotide Polymorphism (C5 inhibitor) Cohort - participants with documented C5 polymorphism.
62159758|NCT02272608||control|patients WHO do not have sleep apnea
62714363|NCT02771405|EXPERIMENTAL|Sofosbuvir+Ledipasvir±Ribavirin|Sofosbuvir 400 mg/day +Ledipasvir 90 mg/day ±ribavirin for 12 weeks
62159759|NCT02272608||mild OSAS|mild apnea patients (AHI: 5-15)
62159760|NCT02272608||moderate OSAS|moderate apnea patients (AHI: 16-30)
62159761|NCT02272608||severe OSAS|severe OSAS patients (AHI: more than 30)
62159762|NCT06720558|EXPERIMENTAL|Deceptive Placebo|
62159763|NCT06720558|OTHER|Control - Open-Label PLacebo|The Control Arm will not be exposed to any intervention for the first three weeks. After this time and for the following three weeks, participants will receive placebo probiotic pills in an open-label fashion: they will be honestly informed that the pills are inert placebos.
62159764|NCT02020200|EXPERIMENTAL|MPH or Placebo|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
62159765|NCT02270411||Healthy Subjects|Healthy subjects.
62159766|NCT02270411||Atopic Dermatitis|Patient has a history of atopic dermatitis for at least 6 months. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
62159767|NCT02270411||Acne Rosacea|Patient has a history of acne rosacea for at least 6 months.
62159768|NCT02270411||Acne Vulgaris|Patient has a history of acne vulgaris for at least 6 months.
62159769|NCT02270411||Psoriasis|Patient has a history of psoriasis for at least 6 months.
62159770|NCT02270411||Hidradenitis Suppurativa (HS)|Patient has a history of HS for at least 6 months.
62159771|NCT02406859|EXPERIMENTAL|Anorectal Manometry|Part 1 \[Anorectal Manometry\]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
62159772|NCT02406859|EXPERIMENTAL|Bowel Biofeedback Training|Part 2 \[Bowel Biofeedback\]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
62714364|NCT04276441||Non- Atrial Fibrillation (AF) Cohort|Participants without a history of AF will be randomly assigned into the study to either an Apple Watch/iPhone group or an iPhone group only.
62714365|NCT04276441||Atrial Fibrillation (AF) Cohort|Participants with a diagnosis of AF taking a direct oral anti-coagulant (DOAC) for at least 30 days will be randomly assigned to Apple Watch/iPhone group or iPhone group only.
62714366|NCT06551220||Trastuzumab Deruxtecan|
61975976|NCT02296268||Post-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC after the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Each patient will undergo an assessment in the Aerobics Clinic and will receive a prescription for aerobic training based on the assessment findings. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
61975977|NCT02296268||Stroke Rehabilitation Physiotherapists|Physiotherapists whose current practice involves working full-time or part-time on in- or out-patient stroke service at the NSRC. Their self-efficacy regarding the clinical utilization of aerobic exercise post-stroke will be conducted prior to, and after, implementation of the Aerobics Clinic.
61975978|NCT01806948|PLACEBO_COMPARATOR|Control|Single dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, placebo will be intravenously injected at 4 hours after surgery.
61975979|NCT01806948|EXPERIMENTAL|Experimental|Double dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, Ramosetron 0.3 mg will be intravenously injected at 4 hours after surgery.
61975980|NCT00323115|EXPERIMENTAL|Vaccine|
61975981|NCT02564042|EXPERIMENTAL|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram \[mg/g\]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
61975982|NCT02564042|EXPERIMENTAL|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
62159773|NCT04909099||Knee Ostearthritis/ Low Bakc Pain|Patients referred for physical therapy rehabilitation
62159774|NCT06275919|EXPERIMENTAL|Arm A (interventional arm)|REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
62159775|NCT06275919|ACTIVE_COMPARATOR|Arm B (control arm)|Local Standard of Care until disease progression or unacceptable toxicity
62159776|NCT02958826||No Smoke Evacuation|No Smoke Evacuation Group, anonymous questionnaire administered
62159777|NCT02958826||Smoke Evacuation|Smoke Evacuation Group, anonymous questionnaire administered
62159778|NCT06270199|ACTIVE_COMPARATOR|Control|Standard cell therapy (control group)
62159779|NCT06270199|EXPERIMENTAL|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|Treatment: three infusions of MSC 5x10\^6/Kg
62714367|NCT01444820|EXPERIMENTAL|Hypofractionation|One phase technique (IMRT or 3D-CRT): radiotherapy to the prostate + pelvic lymphnodes
62714368|NCT01444820|OTHER|Conventional|two-phase technique (IMRT or 3D-CRT): 1) whole pelvis including the prostate and regional lymph nodes; 2) boost to the prostate
62714369|NCT02965963|EXPERIMENTAL|Dopamine|Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max
62533883|NCT04070235|EXPERIMENTAL|SH229/DCV 600mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 600 mg once daily and DCV tablets 60 mg once daily (n=40).
62159780|NCT06270199|EXPERIMENTAL|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|Treatment: six infusions of MSC 5x10\^6/Kg
62159781|NCT05393570|EXPERIMENTAL|Treatment|
62159782|NCT01241994|NO_INTERVENTION|basal hemodialysis|
62159783|NCT01241994|ACTIVE_COMPARATOR|AASD|
62159784|NCT06452355|EXPERIMENTAL|Intervention|The KOKO device will be administered to participants who are diagnosed with abnormal postpartum uterine bleeding or hemorrhage.
62159785|NCT05225324||Equfina 50 mg|Participants who will be prescribed with Equfina 50 mg tablets, orally within the scope of the approved label for Korea under the medical judgment of the investigator will be observed prospectively for 24 weeks.
62159786|NCT02724423|EXPERIMENTAL|NRL-1 Ictal|During the ictal or peri-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
62159787|NCT02724423|EXPERIMENTAL|NRL-1 Inter-Ictal|During the inter-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
62159788|NCT06720324|EXPERIMENTAL|Fludarabine + Cyclophosphamide +CD7-specific CAR-T Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on day -5, -4, and -3, followed by the infusion of CD7-specific CAR-T Cells with the dose of 1-3×10\^6/kg.
62159789|NCT01117532|EXPERIMENTAL|EFT|Four 90 minute group EFT classes
62159790|NCT01117532|NO_INTERVENTION|No Treatment|
62159791|NCT05859529|EXPERIMENTAL|Experimental：JS002 AI|The drug was administered by a single subcutaneous injection via AI
62159792|NCT05859529|ACTIVE_COMPARATOR|Experimental：JS002 PFS|The drug was administered by a single subcutaneous injection via PFS
62533884|NCT04070235|EXPERIMENTAL|SH229/DCV 800mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 800 mg once daily and DCV tablets 60 mg once daily (n=40).
62533885|NCT04070235|EXPERIMENTAL|SH229/DCV|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg,600 mg or 800 mg once daily and DCV tablets 60 mg once daily
62159793|NCT03889327|EXPERIMENTAL|Cognitive Feedback and Psychoeducation (CFP)|Participants assigned to the cognitive feedback and psychoeducation (CFP) treatment group will watch a brief video integrating both neuropsychological test feedback and psychoeducation. The computerized intervention will cover MS disease-related information, define objective cognition, explain neuropsychological assessment, and inform patients of their cognitive test performance outcomes. The CFP intervention will also define and explain perceived cognition and subjective measures of cognition, and compare objective performance on neuropsychological tests to a subjective measure of perceived cognition. The intervention will also discuss emotion, attention, and misattribution related to PCI. The proposed intervention will incorporate expert testimony on MS disease course and related symptomology and interpretations of neuropsychological test performance.
62159794|NCT03889327|ACTIVE_COMPARATOR|Healthy Eating Habits (HEH)|The control group, healthy eating habits (HEH) group, will watch a brief psychoeducational video of same length in time as the treatment group. The control intervention will include information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The proposed control intervention will include expert testimony from a nutritionist and expert dietician.
62159795|NCT05569265|EXPERIMENTAL|Hemodynamic prediction index based goal directed hemodynamic therapy|Hemodynamic handling will be based hemodynamic prediction index (HPI)
62533886|NCT05888194|EXPERIMENTAL|Mucogyne group|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
61975983|NCT02564042|EXPERIMENTAL|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
62533887|NCT05888194|NO_INTERVENTION|Control group|Standard of care e.i no treatment
62533888|NCT04832126||Patient|patients with channelopathies
62533889|NCT04832126||Family|relatives of patients with channelopathies
62533890|NCT02040168||28 days - 18 yo|Children requiring mechanical ventilation for at least 24h from 28 days to 18 yo
62533891|NCT02040168||18 months - 18 yo|Post traumatic stress disorder evaluation in children requiring mechanical ventilation for at least 24h from 18 month to 18 Years old
61975984|NCT02564042|EXPERIMENTAL|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
61975985|NCT02564042|PLACEBO_COMPARATOR|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
61975986|NCT02564042|PLACEBO_COMPARATOR|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
61975987|NCT03584022|EXPERIMENTAL|Biopsy + Nerve Repair|Subjects will undergo standard sural nerve biopsy plus repair of the 6 cm nerve defect using a synthetic polymer (PCLF) nerve tube.
61975988|NCT03584022|SHAM_COMPARATOR|Biopsy Only|Subjects will undergo the same standard sural nerve biopsy procedure as the Experimental Group, but will not include the nerve repair.
61975989|NCT04913025|ACTIVE_COMPARATOR|Standard interval|Standard of care regimen Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 4 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 6 weeks
61975990|NCT04913025|EXPERIMENTAL|Extended interval|Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 8 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 12 weeks
61975991|NCT03838133|EXPERIMENTAL|TLC590 dose 1 (152 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
62159796|NCT05569265|NO_INTERVENTION|No HPI|Patients in the control group will be treated according to standard practice.
62159797|NCT05955885|EXPERIMENTAL|Flurbiprofen Oral Lozenge|30 participants will be asked to suck one (1) flurbiprofen 8.75 mg honey and lemon lozenge (tradename: Strepfen) until dissolved.
62159798|NCT05955885|PLACEBO_COMPARATOR|Placebo lozenge|30 participants will be asked to suck one (1) non-medicated Difflam Soothing Drops + Immune Support Honey \& Lemon flavour lozenge until dissolved.
62159799|NCT05955885|EXPERIMENTAL|Flurbiprofen 8.75 MG|30 participants will be asked to perform three (3) oral actuations (2.91 mg per actuation) of flurbiprofen 8.75mg spray.
62159800|NCT05955885|OTHER|Low dose flurbiprofen spray|30 participants will be asked to perform one (1) oral actuation of flurbiprofen 8.75 mg spray, equivalent to a 2.91mg dosage. This will serve a a low dose control as there is no placebo spray available.
62159801|NCT01356121|ACTIVE_COMPARATOR|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
62159802|NCT01356121|ACTIVE_COMPARATOR|Propofol|Propofol will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
62159803|NCT01356121|NO_INTERVENTION|No Sedation|No sedation given in this group
62159804|NCT06720532||mCRPC Patients with 177Lutetium-PSMA RLT|Patients diagnosed with metastatic castration-resistant prostate carcinoma (mCRPC) undergoing initial treatment with 177Lutetium-PSMA radioligand therapy at the Klinikum rechts der Isar.
62159805|NCT02604199|PLACEBO_COMPARATOR|PBO Low Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
62159806|NCT02604199|PLACEBO_COMPARATOR|PBO High Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
62159807|NCT02604199|EXPERIMENTAL|ARC-520 Injection 1 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
62159808|NCT02604199|EXPERIMENTAL|ARC-520 Injection 2 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
62159809|NCT05412927||Patients who have had prior ACS events.|Patients who have had prior ACS events and who remain at high risk for recurrent ACS events will be implanted with PMA P150009 AngelMed Guardian® System and enrolled in the PAS, for the purpose of accruing 314 adjudicated True Positive (TP) or False Positive (FP) ACS events.
62159810|NCT03571100|ACTIVE_COMPARATOR|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
62159811|NCT03571100|ACTIVE_COMPARATOR|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
62159812|NCT03050931||Epilepsy with intracranial electrodes|Electrical Impedance Tomography with depth electrodes or intracranial electrode mats
62159813|NCT03050931||Epilepsy with scalp electrodes|Electrical Impedance Tomography with scalp electrodes
62159814|NCT03751761|EXPERIMENTAL|durvalumab, tremelimumab, paclitaxel|
62159815|NCT01488240|ACTIVE_COMPARATOR|Proximal|part of scar proximal to heart
62159816|NCT01488240|ACTIVE_COMPARATOR|Distal|part of scar distal to heart
62159817|NCT06694766|OTHER|women vaccinated during pregnancy|Participants who received a yellow fever vaccination during pregnancy
62159818|NCT06694766|OTHER|women vaccinated outside pregnancy|Participants who received a yellow fever vaccination outside pregnancy
62159819|NCT06468618|EXPERIMENTAL|DREAMS Program|"Enrolled participants and parent(s) will complete:~* Baseline visit with survey~* Standard of care stem cell infusion~* In-clinic visit with introduction to DREAMS program, Sleep and Circadian Care Kit, Actigraph, and Fitbit.~* Follow up survey"
62159820|NCT03807934|EXPERIMENTAL|Active High-Definition Stimulation|Active high-definition stimulation of targeted brain regions involved in perception and cognition.
62159821|NCT03807934|SHAM_COMPARATOR|Sham High-Definition Stimulation|Sham high-definition stimulation of targeted brain regions involved in perception and cognition.
62159822|NCT03658018|EXPERIMENTAL|Intracept System Ablation|
62159823|NCT02114502|EXPERIMENTAL|Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT|Busulfan test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5. Palifermin 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2. SAHA 1,000 mg by mouth on Days -8 to -3. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3. Carfilzomib 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1. SAHA 1,000 mg by mouth on Days -7 to -3. Melphalan 60 mg/m2 by vein on Days -3 and -2. Stem cell transplant on Day 0. Dexamethasone 8 mg by vein twice a day from Day -9 PM to Day -2 PM. Caphosol oral rinses 30 mL four times a day from Day -9 until discharge. Oral glutamine 15 g four times a day, swished, gargled and spit on Day -9 until discharge. Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
62159824|NCT06386744|EXPERIMENTAL|SGX945|This is an open-label study and all participants will receive SGX945.
62159825|NCT05431543|EXPERIMENTAL|Combination ophthalmic solution (LNZ101) dosed bilaterally|LNZ 101: Aceclidine/Brimonidine combination ophthalmic solution
62159826|NCT05431543|EXPERIMENTAL|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LNZ 100: Aceclidine ophthalmic solution
62159827|NCT05431543|EXPERIMENTAL|Vehicle Ophthalmic Solution dosed bilaterally|Proprietary vehicle ophthalmic solution
62159828|NCT06290557|EXPERIMENTAL|Verum|Low Dose single application Low Dose multiple application High Dose single application high dose multiple application
62159829|NCT06290557|PLACEBO_COMPARATOR|Placebo|placebo
62533892|NCT04078126|EXPERIMENTAL|Budesonide and formoterol fumarate (MDI BFF)|Subject treated with MDI BFF followed by washout period
62533893|NCT04078126|ACTIVE_COMPARATOR|Symbicort Turbuhaler|Subject treated with Symbicort followed by washout period
62533894|NCT01196325||Laser Group|Patients who are clinically indicated for the laser treatment
62533895|NCT01196325||Anti-VEGF Group (Bevacizumab)|Patients who are clinically indicated for the intravitreal injection of Bevacizumab
62159830|NCT03148353|EXPERIMENTAL|Modified subacromial injection|"1. Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~   * Device for guidance: high-resolution ultrasound~  * Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~2. Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon~   * Device for guidance: high-resolution ultrasound~  * Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
62159831|NCT03148353|PLACEBO_COMPARATOR|Standardized subacromial injection|"1. Intervention procedure: corticoseroid injection into the subacromial bursa only~   * Device for guidance: high-resolution ultrasound~  * Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~2. Intervention procedure: lidocaine injection into the subacromial bursa only~   * Device for guidance: high-resolution ultrasound~  * Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
62159832|NCT06535607|EXPERIMENTAL|Volrustomig|This single-arm study consists of multiple sub-studies, divided by indication.
62159833|NCT01598454|EXPERIMENTAL|Racotumomab|
62159834|NCT06720779|EXPERIMENTAL|TRAK treatment group|Combined treatment of conventional rehabilitation plus virtual telerehabilitation treatment with the TRAK Platform.
62159835|NCT06720779|ACTIVE_COMPARATOR|Knee control group|Conventional face-to-face rehabilitation treatment.
62159836|NCT03426709|EXPERIMENTAL|Low intensity Internet-delivered psychotherapy|improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies).
62159837|NCT03426709|NO_INTERVENTION|Improved Treatment-as-usual (TAU)|In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
62159838|NCT06608485||Pediatric; Adult Surgical Procedures (HARMONIC 700 Shears)|This prospective study will involve collection of clinical data in a post-market setting from pediatric surgical procedures (general) and adult surgical procedures (general, gynecological, urological, and thoracic surgical procedures). Investigators will perform each procedure using the device in compliance with their standard surgical approach and the HARMONIC 700 Shears instruction for use (IFU). All subjects enrolled will be followed post-operatively through discharge and again at approximately 28 days post-surgery.
62159839|NCT01880008||Treatment|All patients included in this study were treated with temozolomide and radiotherapy after subtotal resection of a WHO grade III or IV glioma.
62159840|NCT02851394|ACTIVE_COMPARATOR|Levobupivacaine group|
62159841|NCT02851394|EXPERIMENTAL|Levobupivacaine + tramadol group|
62159842|NCT06602128|EXPERIMENTAL|Breathing Exercise Application Group|Patients in the breathing exercise practice group will have breathing exercise practice for 15-20 minutes half an hour before the angiography procedure. The breathing exercise application will be applied to the patients face to face by the researcher.
62159843|NCT06602128|NO_INTERVENTION|Control group|There will be no intervention for individuals in this group.
62159844|NCT02617186|ACTIVE_COMPARATOR|Thoracoscopic Lobectomy|
62159845|NCT02617186|ACTIVE_COMPARATOR|Robotic Lobectomy|
62533896|NCT01196325||Anti-VEGF Group (Ranibizumab)|Patients who are clinically indicated for intravitreal injection of Ranibizumab
62159846|NCT00267956|EXPERIMENTAL|CNTO1275 (ustekinumab)|Group 1: Patients will receive CNTO 1275 63 mg at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive placebo to maintain the blind.
62159847|NCT00267956|PLACEBO_COMPARATOR|Placebo|Group 2: Patients will receive placebo at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive CNTO 1275 63 mg.
62159848|NCT01309802|NO_INTERVENTION|placebo|no intervention
62159849|NCT01309802|ACTIVE_COMPARATOR|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
62159850|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
62533897|NCT01196325||Age-matched controls|Group of non-diabetic participants who will be age and gender matched
62533898|NCT06399809|EXPERIMENTAL|Fisetin|Sharp Clinical Services will provide fisetin (100 mg capsules). Randomized participants will receive fisetin 20 mgs/kg once daily for two days, followed by 12 days without therapy. Fisetin will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.
62159851|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
62159852|NCT01026571||Bicuspid aortic valve|Collection of patients who are known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
62159853|NCT01026571||Relative|Collection of patients who are a relative to a patient known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
62159854|NCT03190941|EXPERIMENTAL|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
62714370|NCT02965963|EXPERIMENTAL|Metoclopramide|Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max
62714371|NCT02965963|EXPERIMENTAL|Placebos|Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max
62159855|NCT03190941|EXPERIMENTAL|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
62159856|NCT06544226||Group of eating disorder patients aged above 10|This is a cohort study in which all participants are diagnosed with eating disorders and undertake the same set of assessments and tasks, although the frequency of these assessments and tasks is subject to their current care plan.
62159857|NCT06721832|ACTIVE_COMPARATOR|Group E|patients will receive bilateral in-plane ultrasound guided erector spinea plane block with 30 ml of bupivacaine 0. 25% (15 ml in each side) after induction of general anesthesia
62159858|NCT06721832|PLACEBO_COMPARATOR|Group C|patients will receive a sham block with saline at the corresponding puncture site and same volumes as in group E (sham block) after induction of general anesthesia
62159859|NCT01796834|EXPERIMENTAL|Mindfulness-Based Stress Reduction|Subjects attend a community based Mindfulness-Based Stress Reduction course.
62159860|NCT04528680|EXPERIMENTAL|SC9/ABX (phase 1); SC9/ABX/Carboplatin (phase 2)|Infusion of albumin-bound paclitaxel immediately followed by sonication using the SC9 device and microbubbles in order to open the blood-brain barrier in phase 1. In phase 2, patients will receive carboplatin immediately prior to sonication using the SC9 device and microbubbles in order to open the blood-brain barrier, then will receive albumin-bound paclitaxel upon completion of sonication.
62159861|NCT05703477|EXPERIMENTAL|FMT Responder|
62159862|NCT05703477|EXPERIMENTAL|FMT non-Responder|
62159863|NCT01075815|EXPERIMENTAL|rFSH + rhLH|Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.
62159864|NCT01075815|ACTIVE_COMPARATOR|rFSH|rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.
62159865|NCT06666387|OTHER|PET-MR examination|
62159866|NCT02104375|EXPERIMENTAL|L-citrulline|L-citrulline (6 g/day for 2 weeks)
62159867|NCT02104375|PLACEBO_COMPARATOR|Maltodextrin|6g/day of placebo (maltodextrin)
62159868|NCT02389894|ACTIVE_COMPARATOR|Embol-X Embolic Protection Device|The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
62159869|NCT02389894|ACTIVE_COMPARATOR|CardioGard Cannula|The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
62159870|NCT02389894|NO_INTERVENTION|Standard Cannula|Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
62159871|NCT03456778||Shear Wave Elastography for Asymptomatic Volunteers|Patients with extremity pain but without tendon involvement will have tendon imagining using shear wave elastography.
62159872|NCT03456778||Shear Wave Elastography Symptomatic Volunteers|Patients diagnosed with tendinopathy will have tendon imagining using shear wave elastography. Participants may have the option to have repeated imaging to examine tendon healing for up to a year after receiving standard of care treatment.
62159873|NCT06126315|EXPERIMENTAL|alcar 1.5 g|2 pockets of ALCAR will be administered t.i.d for 48 weeks. Total daily dosage: 1.5 g
62159874|NCT06126315|EXPERIMENTAL|alcar 3 g|2 pockets of ALCAR will be administered t.i.d for 48 weeks. Total daily dosage: 3 g
62159875|NCT06126315|PLACEBO_COMPARATOR|placebo|2 pockets of placebo will be administered t.i.d for 48 weeks.
62159876|NCT03011801|EXPERIMENTAL|Behavioral: Interpersonal Therapy|Individual psychotherapy that includes an initial engagement session and a total of 8 sessions. IPT focuses on psychoeducation and interpersonal skill building to decrease interpersonal conflict and increase interpersonal support and competence.
62159877|NCT03011801|PLACEBO_COMPARATOR|Enhanced Usual Care|Maternity support services (MSS) is the usual standard of care for pregnant women. A multi-disciplinary team of obstetric care providers routinely screen women for possible depression diagnosis. If a woman screens positive, she is seen by a behavioral health specialist (BHS) for further assessment and to initiate treatment, if necessary. The goals of MSS include offering services to promote healthy pregnancies and positive birth and parenting outcomes, including integrating mental health and prenatal care. Women with elevated depressive symptoms are seen by BHS throughout the pregnancy and postpartum period and then bridged to mental health treatment. BHS provides eclectic-based care but does not provide IPT.
62159878|NCT01562275|EXPERIMENTAL|Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
62533899|NCT06399809|PLACEBO_COMPARATOR|Placebo|Sharp Clinical Services will provide placebo (100 mg capsules). Randomized participants will receive placebo 20 mgs/kg once daily for two days, followed by 12 days without therapy. Placebo will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.
62159879|NCT01562275|EXPERIMENTAL|Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
62159880|NCT01562275|EXPERIMENTAL|Stage 2 (Indication specific dose expansion cohort)|Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
62159881|NCT06721806|ACTIVE_COMPARATOR|PRP and bone regeneration after enucleation of odontogenic jaw cysts|effect of PRP on regeneration
62159882|NCT06721806|PLACEBO_COMPARATOR|bone regeneration power without PRP|bone healing without use of PRP
62159883|NCT03708744|EXPERIMENTAL|Treatment A|Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
62159884|NCT03708744|EXPERIMENTAL|Treatment B|Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
62159885|NCT03708744|EXPERIMENTAL|Treatment C|Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
62159886|NCT03708744|ACTIVE_COMPARATOR|Treatment D|Treatment D: Intranasal zolmitriptan 2.5 mg
62159887|NCT05248425|NO_INTERVENTION|Usual Care|All participants will answer questionnaires at specified time points. This arm will receive usual care and their questionnaire responses will not be reviewed.
62159888|NCT05248425|EXPERIMENTAL|Monitored|All participants will answer questionnaires at specified time points. The monitored arm will have their responses reviewed for new or worsening symptoms which will be assessed and managed by a study nurse in addition to usual care.
62159889|NCT06580990|EXPERIMENTAL|Specific neck exercises with the Spinetrack|Exercise the deep neck muscles using the Spinetrak twice a week for 6 weeks.
62159890|NCT06580990|ACTIVE_COMPARATOR|Standard specific neck exercises|Exercise programme for the deep neck musculature twice a week for 6 weeks.
62159891|NCT06580990|NO_INTERVENTION|Usual care group|This group will receive instructions from the doctor based on their assessment, taking into account education and analgesics
62159892|NCT05555121|ACTIVE_COMPARATOR|Endometrin 100 mg three times per day (TID)|Women with progesterone levels ≥ 8.8 ng/ml during frozen embryo transfer cycle will take Endometrin 100 mg TID until 10th week of pregnancy
62159893|NCT05555121|ACTIVE_COMPARATOR|Endometrin 200 mg three times per day (TID)|Women with progesterone levels \< 8.8 ng/ml during frozen embryo transfer cycle will take Endometrin 200 mg TID until 10th week of pregnancy
62159894|NCT01328483|NO_INTERVENTION|No Intrapartum Oropharyngeal (IP-OP) Suction|Neonates randomized to No IP-OP group received supportive treatment as per standard unit protocols. They were also assessed as vigorous or non-vigorous and received care according to NRP 2005.
62159895|NCT01328483|EXPERIMENTAL|Intrapartum Oropharyngeal (IP-OP) suction|The neonates randomized to IP-OP group were provided oropharyngeal suctioning at the delivery of head before the delivery of shoulder, using suction machine at a negative pressure of 100mm of Hg or Dee Lee's suction trap in the event of electricity failure or non availability of suction machine.Subsequently, all the neonates born through MSAF were assessed by pediatrician as vigorous or non vigorous and provided care as per NRP guidelines 2005.
62159896|NCT00583349|EXPERIMENTAL|Abraxane administration|Patients will restrict their fluid intakes the morning of treatments and will have emptied their bladders at each of their visits and have up to 100ml of Abraxane solution administered to their bladder via urinary catheter once weekly for six weeks.
62159897|NCT03595306|EXPERIMENTAL|Prebiotic A|
62533900|NCT01864850|ACTIVE_COMPARATOR|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
62533901|NCT01864850|EXPERIMENTAL|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
62533902|NCT05396378||Gestational diabetes|Any parturient who after information agrees to participate in the study. The treatment of the gestational diabetes may be by diet, metformin or insulin according to the hospital's normal protocol.
62159898|NCT03595306|EXPERIMENTAL|Prebiotic B|
62159899|NCT03595306|EXPERIMENTAL|Prebiotic C|
62159900|NCT02241980||Medicare Part D patients|Survey
62159901|NCT02241980||Physician Providers|Survey
62159902|NCT04194671|EXPERIMENTAL|Mesenchymal stem cells cohort|
62159903|NCT04194671|PLACEBO_COMPARATOR|Saline cohort|
62159904|NCT05417685||Musculoskeletal disorder|
62159905|NCT00543049|OTHER|1 non-continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 50.0 mg once daily. After 28 days, treatment will be paused for 14 days and cycle one is completed, followed by resumption of therapy as cycle one for up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
62533903|NCT05396378||Type II diabetes|Any parturient who after information agrees to participate in the study. The treatment of the diabetes may be by diet, metformin or insulin according to the hospital's normal protocol.
62533904|NCT03433898|EXPERIMENTAL|Part 1|
62533905|NCT03433898|EXPERIMENTAL|Part 2|
62533906|NCT03433898|EXPERIMENTAL|Part 3|
62533907|NCT04053361|ACTIVE_COMPARATOR|Group A: Clinical ablation|"* Cinical arrhythmia is fairly documented AF, pulmonary vein isolation will be performed. If AF persists after this step, electrical cardioversion will be performed.~* If clinical arrhythmia is fairly documented type 1 AFL, cavo-tricuspid isthmus ablation will be performed.~* If clinical arrhythmia is AT, it will be induced (if not persistent), identified by means of activation and/or entrainment mapping, and ablated.~* If clinical arrhythmia is AT that is non-inducible during EP study, no ablation will be done.~* If other incidental (or induced) AT is observed that can be qualified as non-clinical it will not be targeted unless considered important to ablate at discretion of operator.~* No induction protocols for other, on top of already ablated, arrhythmias will be attempted."
62159906|NCT00543049|OTHER|2 continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 37.5 mg once daily continuously. Treatment period up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
62159907|NCT04123938|EXPERIMENTAL|Pea Protein|Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
62159908|NCT04123938|ACTIVE_COMPARATOR|Whey Protein|Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
62159909|NCT04123938|PLACEBO_COMPARATOR|Maltodextrin|Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
62714372|NCT04843488|ACTIVE_COMPARATOR|Ridge Augmentation with a perforate PTFE mesh|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
62159910|NCT03602547|EXPERIMENTAL|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
62159911|NCT02609776|EXPERIMENTAL|Part 1:Amivantamab Monotherapy+Combination Dose Escalations|The first cohort of participants will receive intravenous (IV) infusions of Amivantamab 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of Amivantamab once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and Amivantamab on Cycle 1 Day 1 (C1D1) prior to initiation of Amivantamab (C1D1) at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter, on 28-day Amivantamab treatment cycle. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with standard of care carboplatin and pemetrexed.
62159912|NCT02609776|EXPERIMENTAL|Part 2:Amivantamab Monotherapy+Combination Dose Expansion|Participants will receive IV infusion of Amivantamab as monotherapy at Phase 2 dose (RP2D) regimen or in combination lazertinib at the recommended Phase 2 combination dose (RP2CD) regimen as determined in Part 1. The purpose of dose expansion is to further evaluate safety, tolerability, pharmacokinetic, and to assess preliminary efficacy in monotherapy and combination therapy cohorts.
62159913|NCT03722602|EXPERIMENTAL|Rehabilitation group|Patients with stroke receiving standard inpatient rehabilitation for five weeks
62159914|NCT02674971|ACTIVE_COMPARATOR|INCREASE|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) per day.
62159915|NCT02674971|ACTIVE_COMPARATOR|COMBINATION|This condition will be identical to the INCREASE condition, except it will also have a goal regarding the number of high-ED foods to consume and substituting low-ED foods for high-ED foods. Thus, this condition will have ED goals to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day. Foods with an ED \>1.0 kcal/g but \< 3.0 kcal/g will be unlimited; however, lower ED foods will be strongly encouraged. Furthermore, additions to beverages (i.e., sugar, cream) will count toward the \> 3.0 kcal/g goal if the additions meet that ED criteria.
62159916|NCT03867396|ACTIVE_COMPARATOR|Cochlear Implant and Hearing Aid|Subject wears a hearing aid on the contralateral side of the cochlear implant. Subject will use a clinic-loaned Naida hearing aid for listening tests.
62159917|NCT03867396|ACTIVE_COMPARATOR|Cochlear Implant alone|Subject only uses the cochlear implant; hearing on the contralateral side is unaided.
62159918|NCT03867396|EXPERIMENTAL|Cochlear Implant and CROS|Subject wears the CROS device on the contralateral side of the cochlear implant. Subject will use a clinic-loaned CROS device.
62159919|NCT04944589|EXPERIMENTAL|single visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in single visit including access cavity, chemo-mechanical preparation and obturation, all were done in one visit
62159920|NCT04944589|EXPERIMENTAL|Multiple visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in multiple visit including access cavity, chemo-mechanical preparation and obturation, all were done in two or three visits
62159921|NCT05459974|ACTIVE_COMPARATOR|Colchicine arm|
62159922|NCT05459974|PLACEBO_COMPARATOR|Placebo arm|
62159923|NCT05972109|NO_INTERVENTION|Control: No workplace SSB sales ban, no brief intervention|Participants receive no workplace SSB sales ban (environmental intervention) and no brief counseling intervention.
62159924|NCT05972109|EXPERIMENTAL|Workplace SSB sales ban only|Participants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options.
62159925|NCT05972109|EXPERIMENTAL|Brief intervention only|Participants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls.
62159926|NCT05972109|EXPERIMENTAL|Multilevel Intervention (workplace SSB sales ban + brief intervention)|"Sales ban: Participants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options.~Brief Intervention: Participants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls."
62159927|NCT04047303|EXPERIMENTAL|Administration of CC-90010|During the preoperative period, all subjects will be given a course of orally administrated CC-90010 at 30 mg once daily for 4 consecutive days on Cycle 1 Day 1 to Day 4. The last CC-90010 dose (Day 4) will be administrated 6-24 hours prior to brain tumor resection. Following recovery from surgery and a minimum of 4 weeks from the first CC-90010 dose (Cycle 1 Day 1), subjects who are fit to continue study treatment my restart CC-90010 on Day 1 of Cycle 2 at 45 mg given orally once daily for 4 consecutive days followed by 24 consecutive days off (4 days on/24 days off), in each 28 day cycle.
62159928|NCT05799040||Self-developed pulmonary lobar ventilation detector|
62159929|NCT05799040||imported Chartis detection system|
62159930|NCT01693393|OTHER|Cyclosporine A|All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
62159931|NCT05786768|ACTIVE_COMPARATOR|Rituximab 375 mg/m2|single infusion of Rituximab (375 mg/m2)
62159932|NCT05786768|EXPERIMENTAL|Obinutuzumab 300 mg/1.73 m2|single infusion of Obinutuzumab 300 mg/1.73 m2
62159933|NCT03185858|EXPERIMENTAL|SINEMA intervention group|The intervention arm will implement the SINEMA model for one year, which consists of a provider-facing intervention aiming to strengthen the capacity of village doctors in delivering stroke secondary prevention, and a stroke survivor-facing intervention aiming to promote medication adherence and physical activity.
62159934|NCT03185858|NO_INTERVENTION|Control group|Villages in the control arm continue their usual practice without the introduction of any of the SINEMA activities described above. People who have hypertension or who are at high-risk of hypertension may receive follow-up visits four times per year as part of the basic public health services required by the government.
62159935|NCT02306005||Type 1 diabetic patients|Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology. Measurement of lipid profile and lipoproteins before and after administration of insulin. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
62159936|NCT04676763|EXPERIMENTAL|Substance P challenge in Part 1|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 1 will include a single challenge visit.
62159937|NCT04676763|EXPERIMENTAL|Substance P challenge in Part 2|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 2 will include two challenge visits.
62159938|NCT04566120|EXPERIMENTAL|Cinnamon extract mouthwash|Participants will be exposed to cinnamon extract mouthwash and will be instructed to use 10 ml of cinnamon extract mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
62159939|NCT04566120|ACTIVE_COMPARATOR|Chlorohexidine based mouthwash|Participants will be exposed to chlorohexidine based mouthwash. and will be instructed to use 10 ml of 0.12% chlorhexidine based mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
62159940|NCT05491837|EXPERIMENTAL|Interventional group|"Interventional group will be provided a brief sequence of acute hypoxia consisting of 9% oxygen via device HYP 123 for one minute followed by normoxia 21% of oxygen for a total of 15 repetition.~This protocols will be provided 3 times/week for a period of 4 weeks."
62159941|NCT05491837|SHAM_COMPARATOR|Control group|"SHAM group' participants will be provided 21% of O2 (normoxia), comprised of 15 repetitions of 1-minute then switching to another 1-minute of 21% O2.~This protocols will be provided 3 times/week for a period of 4 weeks."
62159942|NCT06343662|NO_INTERVENTION|No Intervention: Control Group|Patients who receive the treatment program, will previously constitute their own control group (waiting list control group).
62159943|NCT06343662|EXPERIMENTAL|Experimental group|Patients admitted to the brain injury unit will participate in a music therapy protocol starting one week after admission. Prior to the group session, three evaluations will be conducted over six days. Post-treatment assessments will also be conducted to enable longitudinal evaluation of the patient over the course of a week.
62159944|NCT05500313|EXPERIMENTAL|Hypno-breastfeeding Education|An announcement was made on social media platforms for hypno-breastfeeding education programme, and they were invited to the education. Pre-applicant women were informed about the education and research process and their informed consent was signed via e-mail. An average of 4-5 women were included in each group. this group, the training consisted of 4 sessions and a total of 12 hours. It included information about breastfeeding, hypnosis approaches and different techniques. In line with the demands of the group, the session days and hours were decided with together. The Hypno-Breastfeeding Education Programme was offered to each group in a maximum of 2 weeks.
62533908|NCT04053361|EXPERIMENTAL|Group B: Clinical plus substrate-based ablation|"- The initial ablation steps will be identical to those in patients from Group A.~Supplemental ablation will consist of:~* Empirical lesion set within right atrium: superior vena cava isolation, posteroseptal bicaval line, and cavo-tricuspid isthmus ablation (if not already ablated)~AND~* Homogenization of low-voltage zones (if any) in left / right atrium defined by bipolar voltage \<0.5 mV in sinus rhythm or \<0.2 mV in AF / AT. The threshold can be adapted in severely diseased atria to delineate reasonably smaller zones (\<20% of atrial surface) achievable to ablate.~* Arrhythmia induction protocol by10-second burst atrial pacing with cycle length of 300 ms decremented by 10 ms up to atrial refractoriness or cycle length of 200 ms.~* Inducible ATs will be mapped and ablated if feasible. In case of inducible persistent (\>5 min) AF, pulmonary vein isolation will be performed if not previously done as per protocol."
62159945|NCT05500313|EXPERIMENTAL|Standart Breastfeeding Education|An announcement was made on social media platforms for standart breatfeeding education programme, and they were invited to the education. Pre-applicant women were informed about the education and research process and their informed consent was signed via e-mail.This education was done in one go. In this group, the training consisted of 1 sessions and a total of 3 hours. It included only information about breastfeeding.
62159946|NCT02458794|ACTIVE_COMPARATOR|LMA SupremeTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
62533909|NCT01944176|EXPERIMENTAL|Simvastatin|simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
62533910|NCT01944176|PLACEBO_COMPARATOR|B1-6-12|B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks
62533911|NCT01359969|EXPERIMENTAL|Recombinant Human C1 Inhibitor|Patients presented to the clinic within 5 hours of onset received rhC1INH 50 U/kg body weight up to a maximum of 4200 U.
62533912|NCT05719688|EXPERIMENTAL|Mechanical thrombectomy:Thrombectomy system|Subjects will be treated with Thrombectomy system,Thrombectomy system is an intraarterial thrombectomy removal device that can be re-inserted into the sheath to restore blood flow by removing blood clots in occluded vessels.
62533913|NCT05719688|ACTIVE_COMPARATOR|Intracranial thrombectomy stent :Solitaire FR Revascularization Device|Subjects will be treated with Solitaire FR Revascularization Device ,the Device made by Micro Therapeutics Inc. DBA ev3 Neurovascular
62533914|NCT05149677|NO_INTERVENTION|Standard of Care for labor pain|Standard of Care of Care for labor pain
62159947|NCT02458794|ACTIVE_COMPARATOR|Ambu-Aura GainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
62533915|NCT05149677|EXPERIMENTAL|Music therapy intervention + Standard of Care for labor pain|Music therapy intervention + Standard of Care for labor pain
62533916|NCT04664790|ACTIVE_COMPARATOR|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week.
62533917|NCT04664790|ACTIVE_COMPARATOR|Cognitive training|Neuropsychologist guided cognitive training.
62159948|NCT06436612|EXPERIMENTAL|Arm I|MRI or CT-guided SBRT will be delivered in the pre-operative setting. Patients will receive 5.0-6.0 Gy x 5 fractions delivered daily.
62159949|NCT06510205||Mentor Group|Who recieves Mentor breast implants per request
62159950|NCT03636295|EXPERIMENTAL|Reduced INR Target|Warfarin therapy will be titrated to a target INR in the range of 1.5 to 2.5.
62159951|NCT03636295|ACTIVE_COMPARATOR|Standard INR Target|"Warfarin therapy will be titrated to a standard of care target INR range."
62159952|NCT00587171|ACTIVE_COMPARATOR|Active|2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
62159953|NCT00587171|SHAM_COMPARATOR|Control|2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
62159954|NCT02122822|EXPERIMENTAL|gp96 group|autologous gp96 vaccination + basal treatment
62159955|NCT02289885|EXPERIMENTAL|normal model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
62159956|NCT02289885|EXPERIMENTAL|ascites positive model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
62159957|NCT03542721|PLACEBO_COMPARATOR|Placebo of DA-5515 Capsule|Placebo of DA-5515 (three times a day)
62714373|NCT04843488|EXPERIMENTAL|Ridge Augmentation with a perforate PTFE mesh covered with a collagen membrane|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The mesh will be covered with a native collagen membrane. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
62714374|NCT05431595|EXPERIMENTAL|Group 1|Participants will receive haloperidol by vein every 12 hours (or more often, as needed).
62714375|NCT05431595|EXPERIMENTAL|Group 2|Participants will receive chlorpromazine by vein every 12 hours (or more often, as needed).
62159958|NCT03542721|EXPERIMENTAL|DA-5515 Capsule|Garlic oil, Gingko biloba ex.,Crataegus berry ex.,Melissa officinalis ex., (three times a day)
62159959|NCT05589129|EXPERIMENTAL|Whey Protein Supplement|Whey protein will come in powder form and will consist of 20g of protein, and 25.3g of product. We will use Optimum Nutrition Double Chocolate Whey Protein Isolate.
62159960|NCT05589129|PLACEBO_COMPARATOR|Carbohydrate Control|Carbohydrate control will come in powder form and will consist of 20g of carbohydrate and 21.6g of product. We will use Nesquik Chocolate Powder mix.
62159961|NCT04362722|EXPERIMENTAL|Single arm|"40 patients will be enrolled and treated with a mixture of 6.5 Mio IU (\~1.08 mg) L19IL2 and 200 µg L19TNF once weekly for 4 consecutive weeks. The dose will be distributed among the lesions via multiple intralesional injections.~New lesions occurring during the treatment phase will also be treated as described but the treatment period for new lesions will not be extended beyond the previously defined 4 weeks treatment period with clock-start at the time of the first intralesional L19IL2/L19TNF injection.~After the Tumor Assessment/Safety visit, patients may receive surgery in a curative intention within 6 weeks, in order to assess the pathological response with estimation of percent of residual viable tumor cells."
62159962|NCT04704986|ACTIVE_COMPARATOR|PVI using the Arctic Front Cryoballoon (Medtronic)|Pulmonary vein isolation using the Arctic Front Cryoballoon (Medtronic)
62159963|NCT04704986|ACTIVE_COMPARATOR|PVI using the PolarX Cryoballoon (Boston Scientific)|Pulmonary vein isolation using the PolarX Cryoballoon (Boston Scientific)
62159964|NCT01848483|EXPERIMENTAL|AIDS EPC Package plus MI|AIDS EPC Package plus MI: AIDS Early Palliative Care (EPC) Package and Motivational Interviewing (MI) At least one early Palliative Care visit plus four weekly MI sessions within a 3 month period of time.
62714376|NCT05431595|EXPERIMENTAL|Group 3|Participants will receive valproate by vein every 12 hours.
62714377|NCT05431595|EXPERIMENTAL|Group 4|Participants will receive placebo every by vein every 12 hours.
62714378|NCT03279107|NO_INTERVENTION|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
62714379|NCT03279107|EXPERIMENTAL|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
62159965|NCT01848483|OTHER|Standard of Care (SOC)|Standard of Care (SOC): Routine Infectious Disease Program HIV-care clinic appointment
62159966|NCT05033054||Group 1|Group 1: take prescribed SGLT2i after baseline visit.
62159967|NCT00874393|ACTIVE_COMPARATOR|Dopamine and hydrocortisone|Dopamine AND hydrocortisone
62159968|NCT00874393|ACTIVE_COMPARATOR|Dopamine and placebo|Dopamine AND normal saline placebo
62159969|NCT00874393|ACTIVE_COMPARATOR|Placebo and hydrocortisone|Dextrose (D5W) placebo AND hydrocortisone
62159970|NCT00874393|PLACEBO_COMPARATOR|Placebo and Placebo|Dextrose (D5W) placebo AND normal saline placebo
62159971|NCT03362294|EXPERIMENTAL|GA Depot 40mg once monthly|Monthly IM injection
62159972|NCT03362294|EXPERIMENTAL|GA Depot 25mg once monthly|Monthly IM injection
62159973|NCT03457168|ACTIVE_COMPARATOR|Intensive asleep SBP control|To reduce the asleep SBP mean up to a target \<110 mmHg. Treatment of elevated asleep SBP mean
62159974|NCT03457168|ACTIVE_COMPARATOR|Conventional asleep SBP control|To reduce the asleep SBP mean up to a target \<120 mmHg. Treatment of elevated asleep SBP mean
62714380|NCT03279107|EXPERIMENTAL|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
62714381|NCT03279107|EXPERIMENTAL|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
62714382|NCT03279107|EXPERIMENTAL|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
62714383|NCT06235580||Patients|
62714384|NCT06235580||Controls|
62714385|NCT06235580||Unaffected related subjects|
62714386|NCT01527630|EXPERIMENTAL|Formulation A|
62714387|NCT01527630|EXPERIMENTAL|Formulation B|
62714388|NCT04991220|EXPERIMENTAL|preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
62159975|NCT03529435|ACTIVE_COMPARATOR|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
62159976|NCT03529435|EXPERIMENTAL|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
62159977|NCT06121739|EXPERIMENTAL|Child Mental health Literacy Program|Teachers from four schools will attend a nine-session workshop on mental health literacy. They will participate in face-to-face sessions and use an online platform.
62159978|NCT06121739|NO_INTERVENTION|Control|Teachers from four schools will not receive any additional mental health training
62159979|NCT04317872|EXPERIMENTAL|Current protocol|"Current protocol: patients will receive a single shot of 25mg of aacidexam iv (5cc) at induction. After 12 hours these patients will another shot of 10mg of aacidexam iv (2cc) on the ward."
62159980|NCT04317872|ACTIVE_COMPARATOR|Old protocol|"Old protocol: patients will receive a single shot of 5mg of aacidexam iv at induction (5cc). After arrival 12 hours these patients will receive a placebo, i.e. a shot of 2 cc of NaCl 0.9% iv (Mini-Plasco van B. Braun)."
62159981|NCT02123758|EXPERIMENTAL|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
62159982|NCT02123758|EXPERIMENTAL|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
62159983|NCT04673357|EXPERIMENTAL|Open- Label Ustekinumab Intravenous (IV): Induction Period|All participants will receive a single IV administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square \[mg/m\^2\]) or weight-tiered induction dose (milligram per kilogram \[mg/kg\]).
62159984|NCT04673357|EXPERIMENTAL|Ustekinumab Subcutaneous (SC) Every 8 Weeks (q8w): Maintenance Period|Participants will receive SC administration of ustekinumab q8w based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at maintenance weeks (Weeks M)-0, M-8, M-16, M-24, M 32, and M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
62159985|NCT04673357|EXPERIMENTAL|Ustekinumab SC Every 12 Weeks (q12w): Maintenance Period|Participants will receive SC administration of ustekinumab q12w based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
62159986|NCT06721299|EXPERIMENTAL|Clenbuterol Cohort 1|20 mcg taken orally twice daily
62159987|NCT06721299|EXPERIMENTAL|Clenbuterol Cohort 2|40 mcg taken orally twice daily
62159988|NCT06721299|EXPERIMENTAL|Clenbuterol Cohort 3|60 mcg taken orally twice daily
62159989|NCT06720064|NO_INTERVENTION|Control|"Standard care bundle approach; The following materials will be used by nurses while performing their care in accordance with the relevant care bundle and checklist;~* Transparent catheter cover (3M™ IV-Tegaderm™) (Control group)~* Needle-free interventional apparatus (BD Qsyte split septum™),~* Prefilled flush syringe (BD PosiFlush™)~* Alcohol swab (alcohol cloth),~* Solupred Swab (3M™), (will be used to clean the dressing area)"
62159990|NCT06720064|EXPERIMENTAL|Care bundle approach with Chlorhexidine Dressing|"Care bundle approach with Chlorhexidine Dressing The following materials will be used by nurses while performing their care in accordance with the relevant care bundle and checklist;~* Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™) (Study group)~* Needle-free interventional apparatus (BD Qsyte split septum™),~* Prefilled flush syringe (BD PosiFlush™)~* Alcohol swab (alcohol cloth),~* Solupred Swab (3M™), (will be used to clean the dressing area)"
62159991|NCT04047355|EXPERIMENTAL|Group A: Propranolol first|"Participants randomly assigned to this group will receive Propranolol first. After the washout period, they will receive Placebo.~Propranolol will be given in liquid or pill form."
62533918|NCT06059443|EXPERIMENTAL|mLab App Plus|Participants randomized to intervention will receive standard of care counseling, complete online surveys, be provided with the mLab App Plus, and a box of condoms. The intervention arm will also complete two HIV/Syphilis Ab Combo Rapid Tests (DPP® HIV-Syphilis Test) at their baseline (first test) and 3-month follow- up (second test) appointments.
62533919|NCT06059443|NO_INTERVENTION|Standard of Care|Participants randomized to standard care will receive standard of care counseling, complete online surveys and be sent an email with links to mobile-optimized online prevention information, including Pre-Exposure Prophylaxis(PrEP) and HIV/STI testing information found on the Centers for Disease Control (CDC) website, and a box of condoms.
62533920|NCT06633718|EXPERIMENTAL|Meropenem and Pralurbactam|Meropenem and Pralurbactam (120min infusion)
62533921|NCT06633718|ACTIVE_COMPARATOR|Ceftazidime-avibactam|Ceftazidime-avibactam (120min infusion) 、 Metronidazole(60min infusion)
62533922|NCT05375877|OTHER|Digital eHealth platform with connected mobile 1-lead ECGs + Standard of Care|"Patients will be fitted with a 1-channel ECG monitor after inclusion in the study and discharged to post ablation care. Here, ECGs are recorded regularly until the occurrence of an arrhythmic event. After the occurrence of an event, a discussion with the investigator will be performed. Interim medical contacts will be limited to the agreed-upon follow-up appointments for the long-term ECGs and other appointments routinely scheduled in the patient's care according to the Standard of Care.~long-term ECGs at defined time points"
62736778|NCT03529838|ACTIVE_COMPARATOR|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
62159992|NCT04047355|PLACEBO_COMPARATOR|Group B: Placebo first|"Participants randomly assigned to this group will receive Placebo first. After the washout period, they will receive Propranolol.~Placebo will look identical to the study drug Propranolol."
62159993|NCT02990845|EXPERIMENTAL|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
62159994|NCT02531516|EXPERIMENTAL|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
62159995|NCT02531516|ACTIVE_COMPARATOR|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
62159996|NCT04947319|EXPERIMENTAL|Tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A)|Patients with relapsed or refractory PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib monotherapy.
62533923|NCT02759601|OTHER|Tefinostat|"This is an open label, dose escalating, phase I/II study of Tefinostat administered orally, once or twice daily in 28 day cycles of treatment in patients with advanced hepatocellular carcinoma.~Up to 5 cohorts of 3-6 patients (number is dependent on DLT occurrence) will be treated for 28 days once or twice daily (360, 480mg once daily, then 240, 360, 480mg twice daily) to determine safety and tolerability of Tefinostat and to identify the recommended dose for Phase II."
62159997|NCT04947319|EXPERIMENTAL|Tirabrutinib + MTR in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 1)|Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + methotrexate/temozolomide/rituximab (MTR)
62159998|NCT04947319|EXPERIMENTAL|Tirabrutinib + R-MPV in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 2)|Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + rituximab/methotrexate/procarbazine/vincristine (R-MPV)
62159999|NCT00801528|ACTIVE_COMPARATOR|Ropivacaine|Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr
62160000|NCT00801528|ACTIVE_COMPARATOR|Diclofenac|Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr
62160001|NCT00801528|PLACEBO_COMPARATOR|Water for injection|Continuous wound instillation of water for injection at a rate set of 10 mL/hr
62160002|NCT06719960||Propofol|aged 65 years and older who received propofol
62160003|NCT06719960||Dexmedetomidine|aged 65 years and older who received propofol + dexmedetomidine
62160004|NCT06721377|ACTIVE_COMPARATOR|control|Equator attachment
62533924|NCT04542616|ACTIVE_COMPARATOR|Baerveldt 350|The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
62533925|NCT04542616|ACTIVE_COMPARATOR|Ahmed ClearPath 250|The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
62533926|NCT02028494|EXPERIMENTAL|Arm A: Capecitabine 2,000 mg (flat dose)|Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).
62533927|NCT02028494|ACTIVE_COMPARATOR|Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day|Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
62533928|NCT06040775|EXPERIMENTAL|Theta burst transcranial magnetic stimulation arm|Theta burst transcranial magnetic stimulation with Applied Behaviour Analysis
62533929|NCT06040775|SHAM_COMPARATOR|Sham arm|Sham transcranial magnetic stimulation with Applied Behaviour Analysis
62533930|NCT05950230||Cases|45 Patients with history and results of recovered COVID-19 infection.
62533931|NCT05950230||Control|45 Patients with negative history of COVID-19 infection.
62533932|NCT05535985|EXPERIMENTAL|acupuncture group|In the acupuncture group, acupoints of Baihui, Shenting, Sishencong will be selected for acupuncture stimulation be anesthesia. The needle will be kept for 30 minutes, during which the needle will be performed once every 10 minutes for 10 seconds each time, 4 times in total. The therapist will give the subject verbal cues before and during the needle manipulation.
62714389|NCT04972851|EXPERIMENTAL|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
62714390|NCT04972851|ACTIVE_COMPARATOR|Implementation as Usual (IAU)|The organizations will implement SDLMI as usual. The research team will be available to provide support on the SDLMI intervention as needed.
62160005|NCT06721377|EXPERIMENTAL|study|Novaloc attachment
62160006|NCT06673069|EXPERIMENTAL|Cohort 1|Participants will receive a single dose of ION269.
62160007|NCT06673069|EXPERIMENTAL|Cohort 2|Participants will receive a single dose of ION269.
62160008|NCT06673069|EXPERIMENTAL|Cohort 3|Participants will receive a single dose of ION269.
62160009|NCT03479502|ACTIVE_COMPARATOR|Methylprednisolone|Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.
62160010|NCT03479502|ACTIVE_COMPARATOR|Doxycycline|Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.
62160011|NCT00422162|EXPERIMENTAL|Duloxetine Hydrochloride (60 mg)|"Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo"
62160012|NCT00422162|EXPERIMENTAL|Duloxetine Hydrochloride (120 mg)|"Up to Week 4: 60 mg every morning and 60 mg every evening, PO.~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose"
62160013|NCT01322347|ACTIVE_COMPARATOR|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
62160014|NCT01322347|PLACEBO_COMPARATOR|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
62160015|NCT01707277|EXPERIMENTAL|Inspiratory muscle training|Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)
62160016|NCT01707277|ACTIVE_COMPARATOR|Usual care|Pharmacological treatment
62160017|NCT04057300|EXPERIMENTAL|Ticagrelor 90mg|Ticagrelor: 180 mg loading dose followed by 90 mg BID. Aspirin: 325 loading dose followed by 81 mg daily.
62160018|NCT04057300|ACTIVE_COMPARATOR|Clopidogrel 75mg|Clopidogrel: 300 mg loading dose followed by 75 mg daily. Aspirin: 325 loading dose followed by 81 mg daily.
62160019|NCT02031445|PLACEBO_COMPARATOR|Placebo|BID
62160020|NCT02031445|EXPERIMENTAL|MRX-6|BID
62160021|NCT00231166|EXPERIMENTAL|HCD122|
62160022|NCT06498388||Normal Mammographic Breast Density (NMBD)|Women with Normal Mammographic Breast Density (NMBD): Each participant will take part in one imaging session, using the BRAVE system.
62160023|NCT06498388||Elevated Mammographic Breast Density (EMBD)|Women with Elevated Mammographic Breast Density (EMBD): Each participant will take part in one imaging session, using the BRAVE system.
62160024|NCT06721416|EXPERIMENTAL|Virtual Reality Beased|VR based aerobic exercise
62160025|NCT06721416|EXPERIMENTAL|Traditional|Cycling ergometer based aerobic exercise
62160026|NCT06721416|EXPERIMENTAL|Conventional|Conventional physical therapy approaches
62160027|NCT06557330|EXPERIMENTAL|Single Arm|This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of Measurable Residual Disease (MRD) adapted duration of BR for untreated or R/R iNHL (indolent non-hodgkin lymphoma). All patients will receive Bendamustine 90 mg/m2 IV on Days 1-2 and Rituximab 375 mg/m2 IV(BR) on Day 1 of each cycle. Each cycle will last 28 days. On day 1 of each cycle, patients will receive Rituximab before Bendamustine, and CBC (complete blood count), CMP (comprehensive metabolic panel) will be obtained to capture any hematologic toxicities as well as clonoSEQ testing to determine MRD status. After completing Cycle 3, imaging results (with confirmatory biopsy if applicable) and the clonoSEQ MRD testing results obtained from ctDNA (blood collection) will determine whether patients will receive Cycles 5 and 6 of Bendamustine and Rituximab (BR).
62160028|NCT06508801|EXPERIMENTAL|BFR plus IRT Group|Blood Flow Restriction plus Instability Resistance Training group. Participants will receive 2 sessions per week over 6 weeks.
62160029|NCT06508801|OTHER|IRT Only Control Group|Instability Resistance Training only group. Participants will receive 2 sessions per week over 6 weeks.
62160030|NCT05963854||SC|Food Waste Tracking Survey and Curbside over 2 consecutive weeks
62160031|NCT00640354|EXPERIMENTAL|1|Pediatric residents randomized to having an automated external defibrillator
62160032|NCT00640354|ACTIVE_COMPARATOR|2|Pediatric residents randomized to having a manual defibrillator
62160033|NCT02755948|EXPERIMENTAL|RSV A Memphis 37|Participants will be inoculated with RSV Memphis 37 virus.
62160034|NCT02755948|EXPERIMENTAL|Influenza A/California/04/2009-like (H1N1)|Participants will be inoculated with Influenza A/California/04/2009-like (H1N1).
62160035|NCT02755948|EXPERIMENTAL|Influenza A/Belgium/4217/2015 (H3N2)|Participants will be inoculated with Influenza A/Belgium/4217/2015 (H3N2).
62160036|NCT01895868|ACTIVE_COMPARATOR|Simulation-based training|Participants in the intervention group receive simulation training using two types of ultrasound simulators: The Scantrainer (Medaphor) and the BluePhantom (CAE). All participants are training to pre-established proficiency-criteria.
62160037|NCT01895868|NO_INTERVENTION|Control|Clinical training alone.
62160038|NCT03578744|EXPERIMENTAL|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
62160039|NCT03578744|EXPERIMENTAL|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
62160040|NCT01596517|EXPERIMENTAL|Korean CHC|Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
62160041|NCT03399799|EXPERIMENTAL|Part 1: Dose Escalation (Talquetamab) - Intravenous (IV)|Participants will receive IV infusion of Talquetamab at minimum anticipated biologic effect level (MABEL)-based starting dose until the completion of the end of treatment visit. Subsequent dose levels will be selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data. All participants (ongoing and those who are in follow-up) will transition to open-label extension (OLE) phase and will continue to receive the study treatment.
62160042|NCT03399799|EXPERIMENTAL|Part 1: Dose Escalation (Talquetamab) - Subcutaneous (SC)|Participants will receive Talquetamab SC. The dose levels will be selected to identify safe and tolerable putative RP2D(s). All participants (ongoing and those who are in follow-up) will transition to OLE phase and will continue to receive the study treatment.
62160043|NCT03399799|EXPERIMENTAL|Part 2: Dose Expansion (Talquetamab)|Participants will receive IV infusion or SC injection of Talquetamab at each putative recommended Phase 2 dose(s) (RP2D\[s\]) as determined in Part 1. All participants (ongoing and those who are in follow-up) will transition to OLE phase and will continue to receive the study treatment.
62160044|NCT05618509|ACTIVE_COMPARATOR|Patient with STENDO|
62160045|NCT05618509|PLACEBO_COMPARATOR|Patient with placebo|
62160046|NCT00765791|ACTIVE_COMPARATOR|Group 1 (Not 2B)|Selective neck dissection is performed on the dominant arm. Level 2B is not dissected.
62160047|NCT00765791|ACTIVE_COMPARATOR|Group 2 (2B)|Selective neck dissection is performed on the dominant arm. Level 2B is dissected.
62160048|NCT06388889|EXPERIMENTAL|150 mg BID|Dexpramipexole 150 mg oral tablet taken twice a day.
62160049|NCT04807452|ACTIVE_COMPARATOR|Strength and balance training|Exercises like ROMS, stretching, static balance and dynamic balance
62160050|NCT04807452|EXPERIMENTAL|Aerobics training|Control Group received aerobic training.
62533933|NCT05535985|PLACEBO_COMPARATOR|placebo acupuncture group|The patients will be treated with consolation needle. Choose treatment of points that near but without going through the acupoints(upper arm deltoid muscle). Use the Park needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time and number of needles will be the same as those in the acupuncture group. The therapist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.
62533934|NCT05535985|NO_INTERVENTION|control group|The patients will undergoing routine anesthesia without acupuncture treatment.
62160051|NCT03809169|EXPERIMENTAL|ROSE with guide sheath|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique and presence of ROSE
62160052|NCT03809169|EXPERIMENTAL|ROSE without guide sheath|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no guide sheath and the presence of ROSE.
62160053|NCT03809169|EXPERIMENTAL|Guide sheath without ROSE|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique but without ROSE.
62160054|NCT03809169|EXPERIMENTAL|No guide sheath without ROSE|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no the guide sheath an without the presence of ROSE.
62160055|NCT01862679|EXPERIMENTAL|8 weeks HF haemodialysis / 8 weeks HD-filtration|8 weeks high-flux haemodialysis followed by 8 weeks haemodiafiltration
62160056|NCT01862679|EXPERIMENTAL|8 weeks HD-filtration /8 weeks HF haemodialysis|8 weeks haemodiafiltration followed by 8 weeks high-flux haemodialysis
62160057|NCT05975593|OTHER|Cervical Cancer|"* Patients will have blood and tumor collected at various time points throughout participation in the study.~* Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI."
62160058|NCT05975593|OTHER|Pancreatic Cancer|"* Patients will have blood and tumor collected at various time points throughout participation in the study.~* Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI."
62160059|NCT02845557||Control subjects without diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
62160060|NCT02845557||Subjects with type 2 diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
62533935|NCT01181960||001|Risperidone long acting injectable - New Starts Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
62533936|NCT01181960||002|Risperidone long acting injectable - Continuous Users Patients who have been on Risperidone long acting injectable for at least 6 months before baseline with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
62533937|NCT01181960||003|Paliperidone Palmitate -New and Continuous Users Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
62533938|NCT01181960||004|Other Antipsychotics - New Starts Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
62533939|NCT03560648|OTHER|Reference group|To define the normal muscle aging from HD-sEMG and accelerometer signals correlated to muscular parameters obtained from Dual Energy X-ray Absorptiometry (DEXA), handgrip strength and muscular echography. Data will be collected in healthy volunteers, aged 25 to 75 years old, physically active on IPAQ questionnaire.
62160061|NCT06721793|PLACEBO_COMPARATOR|Water|Water masked with non-caloric and no-sodium
62160062|NCT06721793|EXPERIMENTAL|Carbohydrate electrolyte solution|2% carbohydrate solution with 1,020 mg/L of Sodium
62160063|NCT06721793|EXPERIMENTAL|no-sugar electrolyte solution|1% carbohydrate solution with 1,060 mg/L of Sodium
62160064|NCT06721793|EXPERIMENTAL|Caffeinated carbohydrate electrolyte solution|1% carbohydrate solution with 1,000 mg/L of Sodium, and 200mg/L Caffeine
62160065|NCT04002856|EXPERIMENTAL|Profhilo®|"The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated after 1 month (T1).~2 mL of Profhilo® was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 vertical-lines (3-4-3 ). The amount of product injected was 0.2 ml for each injection point."
62160066|NCT06721494|PLACEBO_COMPARATOR|Placebo|Participants receive methamphetamine HCl (30 mg) followed by placebo (saline).
62160067|NCT06721494|ACTIVE_COMPARATOR|Active|Participants receive methamphetamine HCl (30 mg) followed by one of four doses of CS-1103
62160068|NCT00101387|EXPERIMENTAL|Lumbar PENS + exercise|Lumbar PENS twice a week for six weeks combined with general conditioning and aerobic exercise
62160069|NCT00101387|ACTIVE_COMPARATOR|Lumbar PENS|Lumbar PENS twice a week for 6 weeks
62160070|NCT00101387|PLACEBO_COMPARATOR|Control PENS|Control lumbar PENS twice a week for 6 weeks
62160071|NCT00101387|ACTIVE_COMPARATOR|Control PENS + exercise|Control PENS twice a week for 6 weeks along with general conditioning and aerobic exercise
62160072|NCT03293147|EXPERIMENTAL|Arm A|Intervention group: Non-adherent hypertensive patients randomised in Arm A will receive standard clinical care plus HPLC-MS/MS-guided intervention.
62160073|NCT03293147|ACTIVE_COMPARATOR|Arm B|Control group: Non-adherent hypertensive patients randomised in Arm B will receive clinical standard care.
62160074|NCT03293147|ACTIVE_COMPARATOR|Arm C|Control group: Adherent hypertensive patients randomised in Arm C will receive clinical standard care.
62160075|NCT03443245||Stroke patients|Patient will have thrombolysis treatment as part of their standard care.
62160076|NCT03443245||Healthy Volunteers|Healthy volunteers to act as control group for stroke patients.
62160077|NCT01776749|NO_INTERVENTION|no SubQ|No subcutaneous leads due to adequate low back stimulation by only SCS. Patient not randomised
62160078|NCT01776749|ACTIVE_COMPARATOR|SubQ ON|Subcutaneous stimulation on
62160079|NCT01776749|SHAM_COMPARATOR|SubQ OFF|subcutaneous leads implanted, but no stimulation
62160080|NCT01320683|EXPERIMENTAL|Treatment (combination chemotherapy and radioimmunotherapy)|FOLFOX\* + BEVACIZUMAB CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 12 courses in the absence of disease progression or unacceptable toxicity. RIT: Within 4-12 weeks after completion of post-hepatic resection therapy chemotherapy, patients receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes. Treatment repeats every 6-10 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. NOTE:\*Patients previously failing oxaliplatin regimen receive FOLIFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, leucovorin calcium over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62160081|NCT03740919|ACTIVE_COMPARATOR|Insulin Lispro (Humalog)|Participants received 100 units per milliliter (U/mL) insulin lispro (Humalog) administered subcutaneously (SC), 0 to 2 minutes before each meal with once or twice daily basal insulin. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
62160082|NCT03740919|EXPERIMENTAL|LY900014|Participants received 100 U/mL LY900014 administered SC, 0 to 2 minutes before start of the meal.
62160083|NCT03740919|EXPERIMENTAL|LY900014 Postmeal|Participants received 100 U/mL LY900014 administered SC, up to 20 minutes after the start of the meal.
62160084|NCT02765984||normal placental site|women with normal implantation site at early trimester with normal placental site
62160085|NCT02765984||Low placental site|women with low implantation site at early trimester with low placental site
62160086|NCT04759378|EXPERIMENTAL|IBS patients who have upper GIT symptoms|
62160087|NCT02143713|EXPERIMENTAL|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
62160088|NCT02143713|EXPERIMENTAL|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
62160089|NCT02962622|EXPERIMENTAL|Hispanic women living with HIV|High intensity interval training (HIIT) on normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neuro-cognitive impairment (HAND) on antiretroviral therapy (CART) receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
62160090|NCT02962622|EXPERIMENTAL|Hispanic women living without HIV|High intensity interval training (HIIT) on a comparison group of 15 Hispanic women without HIV receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
62160091|NCT03803488|EXPERIMENTAL|simulation of injection|The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.
62160092|NCT06720025|EXPERIMENTAL|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
62160093|NCT06720025|ACTIVE_COMPARATOR|rHuEPO injection|Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
62160094|NCT04974021||Participants|HFrEF patients undergoing iron therapy with intravenous carboxymaltose (FCM). FCM administered dosage as per clinical routine. FCM administration is repeated no sooner than 3 months than last therapy, based on repeat ferritin and transferrin saturation levels.
62160095|NCT04195334|EXPERIMENTAL|IMN and union|putting an intramedullary nail in femoral shaft fractures and finding a relation between the nail diameter to femoral canal diameter and how this will affect healing or predict union
62160096|NCT01028976|PLACEBO_COMPARATOR|Placebo|Two tablets, daily, for 8 weeks
62160097|NCT01028976|EXPERIMENTAL|Vitamin C|Two tablets, daily, for 8 weeks
62160098|NCT03621683|EXPERIMENTAL|ovarian bio-stimulation|"Intervention:~ovarian bio-stimulation: blood rich plasma platelets"
62160099|NCT03621683|ACTIVE_COMPARATOR|Antioxidant therapy|"Intervention:~antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3"
62160100|NCT05945979|EXPERIMENTAL|A power supplement with biotin|40 participants using the product for 90 days. Aims to evaluate the clinical, subjective and instrumental usage
62160101|NCT02903602|EXPERIMENTAL|CHW training method-Sharing Histories|"Experimental clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing the experimental teaching methodology, Sharing Histories.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
62160102|NCT02903602|ACTIVE_COMPARATOR|CHW training method-Standard|"Control clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing a standard CHW teaching methodology.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
62160103|NCT03442309|EXPERIMENTAL|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
62160104|NCT03442309|ACTIVE_COMPARATOR|Complex prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
62160105|NCT06242184|EXPERIMENTAL|Group A (Nano-fortified Adhesive)|Titanium dioxide nanoparticles incorporated in dentin adhesive
62160106|NCT06242184|EXPERIMENTAL|Group B (Adhesive without Nanoparticles)|Adhesive without nanoparticles
62160107|NCT05672862||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
62160108|NCT00426218|EXPERIMENTAL|1|ACZ885
62160109|NCT00993590|EXPERIMENTAL|M CHESS group|The intervention group will receive access for 12 months to M-CHESS via a smartphone to: (1) contact their case managers and primary provider; (2) communicate with the managed care organization case managers; (3) communicate with peers; (4) share information about changes in health status; (5) receive reminders to take medications and complete medical follow-up; (6) receive feedback on use of their asthma action plan; (7) receive tailored inquiries and insights regarding attendance or use of asthma resources; and (8) access audio and video versions of asthma educational materials and lower reading level versions of text materials; (9) provide monthly study outcome data monthly for 12 months.
62160110|NCT00993590|ACTIVE_COMPARATOR|Control group|The control group will receive standard care plus a smartphone for 12 months; they will provide study outcome data monthly for the next 12 months.
62160111|NCT06375317|EXPERIMENTAL|HAIC Combined with PD-L1 Plus Regorafenib|
62160112|NCT03734172||Paediatric diagnostic group|Paediatric diagnostic group
62160113|NCT00722514|EXPERIMENTAL|IG|Patient education
62160114|NCT00722514|OTHER|CG|without patient education
62160115|NCT05328297|EXPERIMENTAL|JNJ-55308942|Participants will receive a JNJ-55308942 capsule once daily for 6 weeks.
62160116|NCT05328297|PLACEBO_COMPARATOR|Placebo|Participants will receive a matching placebo capsule once daily for 6 weeks.
62160117|NCT00992030|EXPERIMENTAL|ARM A|Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
62160118|NCT00992030|ACTIVE_COMPARATOR|ARM B|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation
62160119|NCT04374435|EXPERIMENTAL|MKTP with Surgical Blade|The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.
62160120|NCT04374435|EXPERIMENTAL|MKTP with Negative Pressure Instrument|Blister grafting technique with dissociation of the cells was performed in the second arm of the study.
62160121|NCT04374435|EXPERIMENTAL|Suction blister grafting without cell dissociation|In this arm, transplanting the blisters without dissociation of the cells will be conducted.
62160122|NCT04540952|EXPERIMENTAL|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
62160123|NCT04540952|ACTIVE_COMPARATOR|Control|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
62160124|NCT05057819|EXPERIMENTAL|Empagliflozin first, Placebo second|Oral empagliflozin 25 mg daily in the morning for 20 days, followed by oral placebo (daily in the morning) for 20 days after a wash-out period of 2-6 weeks
62160125|NCT05057819|PLACEBO_COMPARATOR|Placebo first, Empagliflozin second|Oral placebo (daily in the morning) for 20 days, followed by oral empagliflozin 25 mg daily in the morning for 20 days after a wash-out period of 2-6 weeks
62160126|NCT06495177||Hospital Arm|Patients presenting with coronary heart disease
62160127|NCT06495177||Primary Care Arm|People at high risk of cardiovascular disease
62160128|NCT04065685|ACTIVE_COMPARATOR|CG|control group receiving the usual care, the standardized information on anticipated directives
62160129|NCT04065685|ACTIVE_COMPARATOR|IG p+r|intervention group with patients and her/his relative
62160130|NCT04065685|ACTIVE_COMPARATOR|IG p|intervention group with patients without relative
62533940|NCT03560648|OTHER|Test group|"To evaluate the capacity of MFA to detect early muscle aging in  tests  individuals, sedentary volunteers within the same age group (45-55 years old)."
62533941|NCT03612557|EXPERIMENTAL|active treatment arm|penicillin G benzathine treatment
62533942|NCT04140305|EXPERIMENTAL|Administration of RPC-1063|Patients with relapsing MS will receive RPC-1063 orally:
62533943|NCT04830059|EXPERIMENTAL|High intensity intermittent training|HIIT exercise program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes.
62533944|NCT04830059|EXPERIMENTAL|HIIT with pollution reduction|HIIT program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
62160131|NCT04685434||pediatric patients diagnosed with rheumatic diseases.|The Shriners Hospital for Children Upper Extremity Evaluation, the Jebsen-Taylor Hand Function Test, and the Childhood Health Assessment Questionnaire will be administered in children with rheumatic diseases. The Shriners Hospital for Children Upper Extremity Evaluation will be administered two weeks after the first examination and the results will be compared.
62160132|NCT03852485||Normal|no glaucoma or retinal pathology or corneal conditions
62160133|NCT03852485||Glaucoma|diagnosis of glaucoma
62160134|NCT03852485||Retina|diagnosis of AMD, DR or other retinal pathology
62160135|NCT03852485||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
62160136|NCT02254200|EXPERIMENTAL|Fatmax group|Group who performed a continuous training program at the intensity eliciting the maximal fat oxidation
62160137|NCT02254200|EXPERIMENTAL|HIIT group|Group who performed a continuous training program with high intensity interval
62160138|NCT00700999|OTHER|Arm 1|Intervention-Paroxetine
62160139|NCT00700999|NO_INTERVENTION|Arm 2|No Intervention
62160140|NCT05943509|EXPERIMENTAL|Alternative Rehabilitation Strategies|Patients who screened positive for hearing loss and were randomized into the counselling on alternative rehabilitation strategies intervention arm.
62160141|NCT05943509|ACTIVE_COMPARATOR|Usual Care|Patients who screened positive for hearing loss and were randomized into the usual care audiology pathway control arm alone.
62160142|NCT00795392||1|Patients assessed with ASA physical status scale
62533945|NCT04830059|EXPERIMENTAL|Moderate intensity continuous training|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise.
62533946|NCT04830059|EXPERIMENTAL|MICT with pollution reduction|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
62533947|NCT04830059|EXPERIMENTAL|Stretch control group|Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.
62533948|NCT04830059|EXPERIMENTAL|Control with pollution reduction|"Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.~Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10."
62533949|NCT00886223|EXPERIMENTAL|1|
62533950|NCT04226326|OTHER|Subjects with Chronic Total Occlusion (CTO)|All subjects in this study have been scheduled for a clinically-indicated cardiac catheterization.
62533951|NCT01194518|EXPERIMENTAL|Lifestyle Intervention Program|
62533952|NCT01344278|EXPERIMENTAL|Lifestyle Counseling|
62533953|NCT01344278|NO_INTERVENTION|Control|
62533954|NCT04536935|ACTIVE_COMPARATOR|Phase 2: Mobile Mental Health App - 1|Participants randomized to a free mobile mental health application that focuses on meditation.
62533955|NCT04536935|ACTIVE_COMPARATOR|Phase 2: Mobile Mental Health App - 2|Participants randomized to a free mobile mental health application that assists with coping with COVID-19.
62160143|NCT00795392||2|Patients assessed with full-scale psychological factors
62160144|NCT04954833|EXPERIMENTAL|TEST/CONTROL|Eligible subjects will randomly be assigned to one of two unique sequences of the two lens types, Test/Control.
62160145|NCT04954833|EXPERIMENTAL|CONTROL/TEST|Eligible subjects will randomly be assigned to one of two unique sequences of the two lens types, Control/Test.
62160146|NCT00763087|ACTIVE_COMPARATOR|nonweightbearing exercise|
62160147|NCT00763087|PLACEBO_COMPARATOR|nonexercising control|
62160148|NCT00763087|EXPERIMENTAL|weightbearing exercise|
62160149|NCT00841425||Swimmers|
62160150|NCT01025921|PLACEBO_COMPARATOR|Inhaled colistin|They will receive inhaled colistin three times daily for 10 days.
62160151|NCT01025921|PLACEBO_COMPARATOR|Inhaled normal saline|Inhaled normal saline three times daily for 10 days
62160152|NCT01535261|EXPERIMENTAL|Ranibizumab arm|Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
62160153|NCT05185674||COVID-19 survivors subjects|"All patients discharged from the National University Hospital of Colombia (Bogotá, Colombia) who required admission to the Intensive Care Unit of the same institution with a confirmed diagnosis of SARS-CoV-2 disease (COVID-19 disease) between April 1, 2020 and March 31, 2021~* Severe Acute Respiratory Syndrome (SARS)~* Coronavirus (CoV)"
62160154|NCT00560209|PLACEBO_COMPARATOR|P|
62533956|NCT04536935|ACTIVE_COMPARATOR|Phase 2: Mobile Mental Health App - 3|Participants randomized to a free mobile mental health application that focuses on positive psychology.
62533957|NCT04536935|ACTIVE_COMPARATOR|Phase 2: Mobile Mental Health App - 4|Participants randomized to a free mobile application that addresses mental health issues through mood tracking.
62533958|NCT05318430|EXPERIMENTAL|Experimental group|the closed-suction drainage device will be placed subcutaneously when closing the incision
62533959|NCT05318430|NO_INTERVENTION|Control group|the closed-suction drainage device will not be placed subcutaneously when closing the incision
62533960|NCT05254600|EXPERIMENTAL|Intervention group|Intervention group will attend the RISE for Nurse Leaders program, which consists of nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC)
62533961|NCT05254600|ACTIVE_COMPARATOR|Wait-list control group|Control group will attend the RISE for Nurse Leaders program after the 3-month wait-list period
62533962|NCT00979914|EXPERIMENTAL|Patient education programme|Patients with osteoarthritis who were referred to the patient education programme.The patients followed the patient education programme.
62533963|NCT00979914|NO_INTERVENTION|Control|Patients randomized to control group
62533964|NCT02146963||alcohol withdrawal|
62533965|NCT05126355|EXPERIMENTAL|On the Move|On the Move group exercise program to improve walking. Delivered twice per week for 12 weeks.
62160155|NCT00560209|EXPERIMENTAL|E2|
62160156|NCT00560209|EXPERIMENTAL|E1|
62160157|NCT06177938|EXPERIMENTAL|Lactose solution|Single ingestion of a lactose solution (25 g lactose dissolved in 150 mL water).
62160158|NCT06177938|PLACEBO_COMPARATOR|Glucose solution|Single ingestion of a glucose solution (13 g glucose dissolved in 150 mL water).
62160159|NCT05551273|EXPERIMENTAL|Arm A|Selgantolimod 3 mg once weekly for 24 weeks
62160160|NCT05551273|PLACEBO_COMPARATOR|Arm B|Matching Placebo for Selgantolimod once weekly for 24 weeks
62160161|NCT06720142||Bone void following bone tumor resection|Patients are being targeted because they have already agreed to receive OSTEOCRETE as part of standard clinical care. They will complete surveys, blood draws to test for magnesium levels, and low-dose CT scans at various post-operative timepoints.
62160162|NCT06720142||Bone defect caused by aseptic loosening of orthopaedic implants|Patients are being targeted because they have already agreed to receive OSTEOCRETE as part of standard clinical care. They will complete surveys, blood draws to test for magnesium levels, and low-dose CT scans at various post-operative timepoints.
62160163|NCT06720142||Bone defect caused by trauma-related condition|Patients are being targeted because they have already agreed to receive OSTEOCRETE as part of standard clinical care. They will complete surveys, blood draws to test for magnesium levels, and low-dose CT scans at various post-operative timepoints.
62160164|NCT02426424|EXPERIMENTAL|Investigatory 1|The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.
62160165|NCT02426424|EXPERIMENTAL|Investigatory 2|The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.
62160166|NCT04555694|ACTIVE_COMPARATOR|Restasis and Lotemax|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes and Lotemax ophthalmic solution twice a day in both eyes.
62160167|NCT04555694|ACTIVE_COMPARATOR|Restasis and Dextenza|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes, as well as receiving Dextenza insertion in both lower lids.
62160168|NCT04555694|ACTIVE_COMPARATOR|Restasis|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes
62160169|NCT02659059|EXPERIMENTAL|Nivolumab+Ipilimumab|"Part 1~Specified Dose on Specified Days"
62160170|NCT02659059|EXPERIMENTAL|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2~Specified Dose on Specified Days"
62160171|NCT05585827|EXPERIMENTAL|Immediate eCBT with concurrent TAU|Those randomized into the this group will get immediate e-CBT with TAU.
62160172|NCT05585827|NO_INTERVENTION|Delayed eCBT with concurrent TAU|Those randomized to the delayed arm of the study, will receive TAU and wait 14 weeks before receiving the intervention. TAU will include ongoing review by the patient's primary care physician, neurologist and PD nurse. TAU does not preclude clinically indicated adjustments to medication or specialist referrals but physicians are asked to keep medication constant if possible. For patients with PD ordinary treatment includes a multitude of interventions, including pharmacological treatment, speech therapy and physical therapy. Pharmacological interventions include the use of dopaminergic treatments, including levodopa and dopamine agonist use, with adjunct use of monoamine oxidase B-inhibitors.
62160173|NCT05673772|EXPERIMENTAL|Study group|Short-course radiotherapy and 4 cycles of mFOLFOX6 followed by TME. Adjuvant chemotherapy will be given according to the pathological stage (CR\~pStageI: 6 cycles of capecitabine or 4 cycles of 5-FU with leucovorin, pStageII-III: 8 cycles of mFOLFOX6)
62160174|NCT05673772|ACTIVE_COMPARATOR|Control group|Conventional chemoradiotherapy followed by TME. Adjuvant chemotherapy will be given according to the pathological stage (CR\~pStageI: 6 cycles of capecitabine or 4 cycles of 5-FU with leucovorin, pStageII-III: 8 cycles of mFOLFOX6)
62160175|NCT01182506|EXPERIMENTAL|Breast cancer survivors|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
62160176|NCT01182506|EXPERIMENTAL|Collateral source|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
62160177|NCT02311335||1|Dyslipidemia patients
62160178|NCT00538629||schizophrenic|patients with schizophrenia
62160179|NCT00538629||bipolar disorder|patients with bipolar disorder
62160180|NCT00396409|EXPERIMENTAL|Depigold+Omalizumab|Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
62160181|NCT00396409|EXPERIMENTAL|Depigoid+Placebo|Depigoid® (grass/rye pollen 50/50) + Placebo
62160182|NCT05163678||patient group|"All adolescents or young adults presenting for a consultation in the FSEF Relais systems.~They will be assessed upon entry into the device (T0), at the end of the follow-up (T1) and 6 months after the end of the follow-up (T6)."
62160183|NCT04783272|EXPERIMENTAL|Treatment|Photoacoustic Computed Tomography (PACT) Imaging
62160184|NCT01587703|EXPERIMENTAL|Single and Repeat Dose finding cohort|All subjects will follow a 3+3 dose escalation design for GSK525762 and the dose will be escalated based on all available data, including PK data and the safety profile of prior cohorts, as well as the recommended dose from the Neuenschwander- Continuous Reassessment Method (N-CRM) design.
62160185|NCT01587703|EXPERIMENTAL|Expansion Cohort|Up to 150 additional subjects with NMC and other solid tumors may be enrolled in expansion cohorts. The recommended Phase 2 (Part 2) dose (RP2D) of GSK525762 will be determined based on the MTD or biologically active dose (example: clinical response), the safety profile and available pharmacodynamic data generated from all subjects in Parts 1
62533966|NCT05126355|OTHER|On the Move - Delayed|Individuals in this arm will be placed on a wait-list for 12 weeks and will receive no intervention during this time. At the end of the 12 weeks they will receive the On the Move group exercise program. This is a wait-list control group.
62533967|NCT03726853|EXPERIMENTAL|CKD-497 200mg|CKD-497 200mg
62160186|NCT01587703|EXPERIMENTAL|Besylate Sub study|Tablet and amorphous tablet in one of the two sequences (ABCD or BACD). Where Treatment A: RP2D/MTD as amorphous free-base tablet + low dose stable isotope in solution, fasted Treatment B: RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment C: half to one-third of RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment D: RP2D/MTD as besylate tablet, fed
62160187|NCT02182245|EXPERIMENTAL|Combination Therapy|
62160188|NCT02182245|EXPERIMENTAL|Monotherapy|
62160189|NCT06505785|EXPERIMENTAL|The cretive drama group|"10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development."
62160190|NCT06505785|NO_INTERVENTION|the control group|This group will consist of students who choose another elective course other than the creative drama course, and no interference will be made.
62160191|NCT02595788||Supine position|Examination in the supine position
62160192|NCT02595788||Prone position|Change from supine to prone position
62160193|NCT05333133|EXPERIMENTAL|High calorie formula on IGF-1, TNF-alpha and total lymphocyte counts|Interventional study with pre-, post design after the subjects are diagnosed with TB and UTI, they will receive 400 ml (equal with 400 kcal) of high calorie formula per day, prescribed by the researcher (a pediatrician) for 90 days consumption. Body weight and body height will be monitored by the researcher group every 30 days to record the tolerance, acceptance and complaints (and the side effects) the blood will be withdraw at day 0 (before intervention) and day 90 (after intervention) to investigate the IGF-1, TNF-alpha and total lymphocyte counts
62160194|NCT00702871|ACTIVE_COMPARATOR|1|Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
62160195|NCT00702871|ACTIVE_COMPARATOR|2|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
62160196|NCT04597047|OTHER|All Patients:|Capillary and Venous Blood Collections
62160197|NCT05993247|ACTIVE_COMPARATOR|Probiotics arm|Probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) per oral, three times a day, for 8 weeks
62160198|NCT05993247|PLACEBO_COMPARATOR|Placebo arm|Placebo capsule in the same form as probiotics, per oral, three times a day, for 8 weeks
62160199|NCT06129422|EXPERIMENTAL|NMK89|Patients will receive a single infusion of NMK89
62160200|NCT01602900|EXPERIMENTAL|GSK356278|Investigational drug
62160201|NCT04162977|EXPERIMENTAL|High-risk youth|The 23-item Substance Use Risk Profile Scale (SURPS) will be used to identify high-risk adolescents who enter the intervention trial. Adolescents who score high on one of SURPS subscales (i.e., high-risk youth) will be invited to participate in two group-based intervention sessions which target their dominant personality profile. The criterion for high scores on SURPS personality traits are determined based on norms from high-risk adolescents in the same age range who participated in previous trials on personality-targeted interventions.
62160202|NCT04064840|ACTIVE_COMPARATOR|IVF: dual trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
62160203|NCT04064840|PLACEBO_COMPARATOR|IVF: hCG trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
62160204|NCT04064840|ACTIVE_COMPARATOR|FET: agonist|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
62160205|NCT04064840|PLACEBO_COMPARATOR|FET: control|On the day of FET, normal saline will be injected subcutaneously.
62160206|NCT05316311|EXPERIMENTAL|CERENOVUS ENTERPRISE 2 Intracranial Stent|Participants with severe symptomatic intracranial artery stenosis will be treated with CERENOVUS ENTERPRISE 2 Intracranial Stent.
62160207|NCT06126887|EXPERIMENTAL|Incrediwear Daytime|Incrediwear back brace worn 7AM-7PM (against skin)
62160208|NCT06126887|SHAM_COMPARATOR|Incrediwear Sham Daytime|Incrediwear sham back brace worn 7AM-7PM (against skin)
62160209|NCT06126887|PLACEBO_COMPARATOR|Control Daytime|Standard-issue brace (e.g. Horizon Lumbar Brace (Aspen Medical Products, LLC)) worn 7AM-7PM
62160210|NCT06126887|ACTIVE_COMPARATOR|Incrediwear 24 hour|Incrediwear back brace worn 7AM-7PM (against skin). Incrediwear waist sleeve worn 7PM-7AM (against skin)
62160211|NCT02998658|EXPERIMENTAL|Vaginal cuff closure using barbed sutures|Vaginal cuff is closed with barbed sutures
62160212|NCT02998658|ACTIVE_COMPARATOR|Vaginal cuff closure using conventional sutures|Vaginal cuff is closed with conventional sutures
62533968|NCT03726853|EXPERIMENTAL|CKD-497 300mg|CKD-497 300mg
62160213|NCT01107171|PLACEBO_COMPARATOR|placebo|Tang-min Lin pills analogue
62533969|NCT03726853|ACTIVE_COMPARATOR|Active Comparator|compartor
62533970|NCT03726853|PLACEBO_COMPARATOR|Placebo|CKD-497 placebo and comparator placebo
62160214|NCT01107171|EXPERIMENTAL|Tang-min-ling pills high dosage|Tang-min-ling pills, high dosage, 12g, tid po
62160215|NCT01107171|EXPERIMENTAL|Tang-min-ling pills low dosage|low dosage group:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
62160216|NCT05517122|EXPERIMENTAL|Nicotinamide (NAM)|
62160217|NCT05517122|EXPERIMENTAL|Nicotinamide Riboside (NR)|
62160218|NCT05517122|EXPERIMENTAL|Nicotinamide Mono Nucleotide (NMN)|
62160219|NCT05517122|PLACEBO_COMPARATOR|Microcrystalline cellulose|
62160220|NCT03771300|EXPERIMENTAL|Mindfulness condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
62160221|NCT03771300|EXPERIMENTAL|Mindfulness condition complemented by VR|This condition is equivalent to the mindfulness condition (group sessions, held once a week over a space of 6 weeks and offered as an extra-curricular activity), unlike the time of each session, which is reduced from 90 to 75 minutes of duration.
62533971|NCT04431583||2008-2012 Participants|Participants who underwent bariatric surgery between 2008 and 2012 (inclusive).
62533972|NCT04431583||2013-2016 Participants|Participants who underwent bariatric surgery between 2013 and 2016 (inclusive).
62533973|NCT04431583||2017- 2018 Participants|Participants who underwent bariatric surgery between 2017 and 2018 (inclusive).
62533974|NCT01875458||CASES|Adults with current or past history of bisphosphonate treatment (exposed) with Bisphosphonate related Osteonecrosis of the Jaws (BRONJ), or, Adults with current or past history of bisphosphonate treatment (exposed) with atypical fracture
62160222|NCT03771300|ACTIVE_COMPARATOR|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extra-curricular activity.
62160223|NCT05594537||ZXR00+ZXR00 emmetropia group|The bilateral implantation of ZXR00 IOLs，and emmetropia was considered as the target refraction for both eyes.
62160224|NCT05594537||ZXR00+ZXR00 micromonovision group|The bilateral implantation of ZXR00 IOLs，and the ZXR00 IOLs power calculations were performed using a micro-monovision approach aiming for minimal residual myopia (≈ -0.50 D) in the nondominant eye and emmetropia in the dominant eye.
62160225|NCT05594537||ZXR00ZMB00 group|The blended implantation of bifocal IOLs (ZMB00) and ZXR IOLs.
62160226|NCT01141985|OTHER|Treated|This is a single arm study.
62160227|NCT06162611|ACTIVE_COMPARATOR|Etonogestrel contraceptive implant with oral levonorgestrel|Patients will be randomized 1:1 to each arm and will receive the contraceptive implant with a same-day encapsulated pill with either oral levonorgestrel 1.5mg
62160228|NCT06162611|PLACEBO_COMPARATOR|Etonogestrel contraceptive implant with placebo|Patients will be randomized 1:1 to each arm and will receive the contraceptive implant with a same-day encapsulated pill with placebo X 1 dose
62160229|NCT01873963||Pediatric cardiomyopathy|Diagnosis of primary or idiopathic dilated, hypertrophic or restrictive cardiomyopathy. Diagnosis must have been made before the age of 18 and must be confirmed by established echocardiographic criteria or cardiac MRI (cMRI) at the time of diagnosis.
62160230|NCT04647409|OTHER|participants|
62160231|NCT03276806|EXPERIMENTAL|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
62160232|NCT03276806|ACTIVE_COMPARATOR|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
62160233|NCT02512107|ACTIVE_COMPARATOR|Juice Plus+|Subject will be taking supplement.
62160234|NCT02512107|PLACEBO_COMPARATOR|Placebo|Subjects will be taking the placebo.
62160235|NCT02088645|EXPERIMENTAL|Phase 0: One arm; Phase I: One arm|"Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)~Phase I: expected 12 - 18 patients, intravenous application of max. 6 x 7-8 GBq 177Lu-PP-F11N (increasing number of applications by one in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study."
62533975|NCT01875458||COUNTER MATCHED CONTROLS|Adults with current or past history of bisphosphonate treatment (exposed) without bisphosphonate related osteonecrosis of the jaws (BRONJ, or, Adults with current or past history of bisphosphonate treatment (exposed) with typical fracture or joint replacement or osteoporosis
62533976|NCT01875458||MATCHED CONTROLS|Adults without current bisphosphonate treatment (unexposed) with Typical fracture (healthy fracture patients) Adults without current bisphosphonate treatment (unexposed) without BRONJ (healthy oral surgery subjects or adults with radionecrosis of the jaws)
62736444|NCT05618210||erector spinae plane block group|In the ESPB group, after the patients are placed in the prone position, the linear ultrasound probe will be placed in the midline in the transverse plane to visualize the spinous processes, and the transverse process, trapezius, latissimus dorsi and erector spina muscles will be visualized on the side where VATS is planned at the T5 vertebra level. With an 'in-plane' approach, using a 22 gauge 5-8 cm block needle with extension line (Braun, Melsungen, Germany), which can be seen on ultrasound, the skin, subcutaneous and trapezius, latissimus dorsi and erector spina muscles are passed in the cranio-caudal direction and 0.5- After confirming the needle site with 1 ml of saline, the ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.
62160236|NCT05104242|NO_INTERVENTION|Standard diet - Control group|The standard diet will include energy intake of 30-35 kcal/kg of ideal body weight (IBW)/day and protein intake of 0.75 g/kg of IBW/day for females and 0.84 g/kg of IBW/day for males
62160237|NCT05104242|EXPERIMENTAL|Low AGE diet - Intervention group|"The low AGE diet will be the same as the standard diet in terms of calories (i.e. 30-35 kcal/kg/day) and protein (0.75-0.84 g/kg/day). However, it will reduce the dietary AGE content by changing cooking methods in food preparation to avoid exposure to dry heat such as frying, broiling, grilling and roasting, and to favour cooking with lower temperatures and high-water content as in stewing, steaming, boiling and poaching. In addition, the low-AGE group will be instructed to choose foods with low content of AGEs based on a food choice list that will contain examples of foods commonly available in the UK to be chosen as allowed, moderate intake, or occasional. The goal will be to reduce dietary AGE intake to less than 8000 kU/day."
62160238|NCT02917434|ACTIVE_COMPARATOR|Patients with PsA and obesity|Very Low Energy Diet (VLED)
62160239|NCT02917434|OTHER|Patients with obesity|Very Low Energy Diet (VLED)
62160240|NCT01795313|EXPERIMENTAL|HLA-A2 restricted tumor antigen vaccine|This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod
62160241|NCT04318366||COVID-19 patients|
62160242|NCT05408156|EXPERIMENTAL|Customized insoles group|The participant allocated in the CIG will receive a semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate. -ethylene vinyl (EVA) and manufactured by researcher C. The insole will be used on both feet to maintain symmetry between the limbs and generate greater comfort, since this will not be a corrective intervention.
62160243|NCT05408156|SHAM_COMPARATOR|Sham Insoles Group|The SIG will receive the same unmolded insole with a semi-flexible base and 2.5mm coverage with Shore A 28, but without the bars used in the intervention group.
62160244|NCT04107766||Population|Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.
62533977|NCT01875458||Healthy Adult Volunteers|Healthy volunteers with or without current bisphosphonate treatment without jaw or extremity pathologies or injuries to contribute blood and saliva samples only.
62533978|NCT03850925|EXPERIMENTAL|Picosecond laser|Intervention: four consecutive sessions of 1,064-nm picosecond laser at 3-week intervals
62533979|NCT03850925|ACTIVE_COMPARATOR|Fractional laser|Intervention: four consecutive sessions of nonablative fractional laser at 3-week intervals
62160245|NCT03427177|EXPERIMENTAL|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool.
62160246|NCT03427177|NO_INTERVENTION|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
62160247|NCT06683820||Triple Recipient Strategy|The simultaneous use of split liver transplantation (SLT), domino liver transplantation (DLT) and auxiliary liver transplantation (ALT)
62160248|NCT02885610|PLACEBO_COMPARATOR|Placebo Comparator|Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses
62160249|NCT02885610|EXPERIMENTAL|RC18 80 mg plus standard therapy|RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses
62160250|NCT02885610|EXPERIMENTAL|RC18 160 mg plus standard therapy|RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses
62160251|NCT02885610|EXPERIMENTAL|RC18 240 mg plus standard therapy|RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses
62160252|NCT06183580|EXPERIMENTAL|dACC Arm|Participants assigned to the Neurofeedback from the dorsal anterior cingulate cortex
62160253|NCT06183580|EXPERIMENTAL|rAMY Arm|Participants assigned to the Neurofeedback from the amygdala
62160254|NCT05746468|EXPERIMENTAL|Intervention group|The intervention group will receive a combination of (1) a time-based system-triggered EMI, which will collect participants' sources and status of depression, anxiety and depression in daily life and provide instructions (audios and videos) on mindfulness practice, and (2) a longitudinal survey in parents of children with ASD. The participants will first complete a baseline questionnaire, and then participate in EMI via a smartphone application (App) for 8 consecutive weeks and receive the exercise prompts daily. The EMI will include questions of the self-reported feelings of depression, anxiety and depression. After the 8-week EMI, the participants will be invited to complete a post-experimental survey with similar questions in the baseline questionnaire. Two months after completing the EMI, participants will be contacted to complete a telephone follow-up survey with similar questions in the baseline questionnaire.
62160255|NCT05746468|ACTIVE_COMPARATOR|Control group|The control group will receive the longitudinal survey exactly the same as the intervention group and 8-week mindfulness-based short-messages sent by the research team on a daily basis. The messages will contain instructions of mindfulness-based practice which will be the same as the intervention group.
62160256|NCT02619578|OTHER|TEAS Group|TEAS consisted of 30 min of stimulation (12-15 mA, 2/100 Hz) at the Hegu (L14) and Neiguan (PC6) before anesthesia. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
62160257|NCT02619578|OTHER|Con Group|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
62160258|NCT05671055||Main arm|Use of icompanion through will all assessments are performed
62160259|NCT02293278|EXPERIMENTAL|Physical Activity Intervention|"The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
62160260|NCT02293278|NO_INTERVENTION|Control Group|"Day cares randomly assigned to the control group will continue with their existing programming. Day care providers will receive the PA intervention upon completion of their involvement in the 6 month trial, including: 2 three hour educational workshops, Healthy Opportunities for Preschoolers manual and program outlining the ideal implementation of activities from the manual.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
62160261|NCT05647304|OTHER|5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
62160262|NCT05647304|OTHER|10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
62160263|NCT06458296|ACTIVE_COMPARATOR|Control Group|
62160264|NCT06458296|EXPERIMENTAL|AI-Guided Group|
62160265|NCT02391389|EXPERIMENTAL|CPAP or PPV during DCC|Infant will receive CPAP or PPV from 30 to 90 seconds after birth while attached to the placenta, and then the umbilical cord will be cut at 90 seconds
62160266|NCT01560962|OTHER|PI vs no intervention|In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention.
62160267|NCT01560962|OTHER|PI vs hygiene|In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash.
62160268|NCT01560962|OTHER|PI vs azasite|In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days.
62160269|NCT01560962|OTHER|PI vs tobradex|In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin.
62160270|NCT01807234|EXPERIMENTAL|Ketorolac/Placebo|Ketorolac 31.5 mg single dose nasal spray and Placebo
62160271|NCT01807234|EXPERIMENTAL|Sumatriptan/Placebo|Sumatriptan 20 mg single dose nasal spray and placebo
62160272|NCT01807234|PLACEBO_COMPARATOR|Ketorolac Placebo/Sumatriptan placebo|single dose Ketorolac placebo, single dose Sumatriptan placebo
62160273|NCT06351917|EXPERIMENTAL|PlexoZome® Levagen®|PlexoZome® Levagen® topical spray solution applied as 3 full pumps on the affected knee area providing 5.6mg of active per 3 pumps.
62160274|NCT06351917|PLACEBO_COMPARATOR|Placebo Comparator|Placebo topical spray solution applied as 3 full pumps on the affected knee area providing 0mg of active per 3 pumps.
62160275|NCT02255526||Healthy Volunteers|Healthy volunteers between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
62160276|NCT02255526||Heart Failure|Heart failure patients between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
62160277|NCT02842645||Control|Children born at term and not exposed to drugs during pregnancy
62160278|NCT02842645||Case|Case = Children exposed to drugs during pregnancy
62160279|NCT06200818|ACTIVE_COMPARATOR|Formocresol|
62160280|NCT06200818|EXPERIMENTAL|Diode laser|
62160281|NCT06200818|EXPERIMENTAL|Er:CrYSGG|
62160282|NCT04733950|EXPERIMENTAL|Patients with cochlear implant|Patients with cochlear implant for 6 months and more
62160283|NCT04733950|ACTIVE_COMPARATOR|Healthy volunteers (normal hearing)|Healthy volunteers with a normal tonal audiometry for age
62533980|NCT06421883|EXPERIMENTAL|Experimental probiotic group|Experimental probiotic group patients will receive probiotic 5 billion unit per day with their standard therapy collect blood sample and measure TMAO at baseline and after 3 months
62714740|NCT06719063|EXPERIMENTAL|Experimental|"The evaluation sessions aim to measure the impact of hemineglect on autonomy. This measurement will be conducted using the Catherine Bergego Scale, which will be completed by both the patient and the occupational therapist. Evaluation sessions will last approximately 45 minutes and will take place once a week for 10 to 12 weeks.~After 3 to 5 weeks of evaluations (Phase A: baseline), the patient will participate in three weekly rehabilitation sessions, each lasting 45 minutes, over a 5-week period (Phase B: therapy). These sessions will be individual and conducted by an occupational therapist. Each session will follow a similar structure: review of the previous session, explanation of the current session, a 15-minute multisensory experience using virtual reality, and a final review focusing particularly on tolerance.~A multisensory experience has been specifically designed for the rehabilitation protocol. The experience consists of two 360° nature-themed films. Throughout the experie"
62160284|NCT04891497|EXPERIMENTAL|Intraarterial Treatment plus Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
62160285|NCT04891497|PLACEBO_COMPARATOR|Intraarterial Treatment plus placebo|Placebo 240mg orally twice daily for 3 consecutive days
62160286|NCT02774876|ACTIVE_COMPARATOR|Carbohydrate meal|
62160287|NCT02774876|ACTIVE_COMPARATOR|Carbohydrate + fat meal|
62160288|NCT02774876|ACTIVE_COMPARATOR|Carbohydrate + protein meal|
62160289|NCT02774876|ACTIVE_COMPARATOR|Carbohydrate + fat + protein meal|
62160290|NCT03576378|EXPERIMENTAL|Experimental: Brentuximab vedotin plus EPEM|Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)
62160291|NCT04859465|EXPERIMENTAL|Abraxane combined with liposomal doxorubicin|Abraxane combined with liposomal doxorubicin in the treatment of advanced or unresectable angiosarcoma
62160292|NCT06322589|PLACEBO_COMPARATOR|placebo drink|
62160293|NCT06322589|EXPERIMENTAL|SOD like Super Drink|
62160294|NCT06018233||People involved with creating and operating regimes which address key societal challenges.|Qualitative semi-structured interviews to explore approaches taken to regimes, including one case study group regarding the Public Benefit and Privacy Panel in Scotland. No use of drugs and no personal health related interventions. Same approaches taken to 3 other case study groups which do not involve health.
62160295|NCT02275351|EXPERIMENTAL|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
62160296|NCT02275351|EXPERIMENTAL|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
62160297|NCT02275351|PLACEBO_COMPARATOR|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
62160298|NCT00842179||Manual Closure|Patients who received vascular closure with manual compression after percutaneous coronary intervention (PCI)
62160299|NCT00842179||Perclose Device|Patients who received vascular closure with the Perclose VCD after percutaneous coronary intervention (PCI)
62160300|NCT01276080|EXPERIMENTAL|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
62160301|NCT01276080|ACTIVE_COMPARATOR|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
62160302|NCT03302494|EXPERIMENTAL|WaveCrest|WaveCrest left atrial appendage occluder
62533981|NCT06421883|NO_INTERVENTION|control group|No Intervention: control group patients will receive their standard therapy only collect blood sample and measure TMAO at baseline and after 3 months
62533982|NCT00095797|EXPERIMENTAL|Treatment (XK469R)|Patients receive XK469R IV over 30-60 minutes on days 1, 3, and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62533983|NCT02100943||OSA in Pregnancy|Pregnant women between 32 0/7 prior to 35 6/7 weeks gestation
62533984|NCT05400408|EXPERIMENTAL|Colorectal Cancer|Subjects who were diagnosed as Colorectal Cancer patients by colonoscopy.
62533985|NCT05400408|EXPERIMENTAL|Pancreatic Cancer|Subjects who were diagnosed as Pancreatic Cancer patients by Endoscopic Retrograde Cholangio Pancreatography.
62160303|NCT03302494|ACTIVE_COMPARATOR|Watchman (control)|Watchman left atrial appendage closure device
62160304|NCT03218488||Participants 6-18 years of Age With Moderate to Severe Plaque Psoriasis|All Participants diagnosed with moderate to severe plaque psoriasis who will either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study as per routine clinical practice, will be monitored for the long-term safety of ustekinumab and long-term effects of ustekinumab on growth and development. The primary data source for the study will be the medical records of participants and standardized questionnaires (completed by the physician and by the participant/parent).
62160305|NCT06649019|EXPERIMENTAL|AO1DfA/DT1fA|Eligible subjects will be randomized into the AO1DfA/DT1fA wear sequence, to wear the test lens followed by the control lens, bilaterally, with a 1-to-10 day(s) washout period between wear periods.
62160306|NCT06649019|EXPERIMENTAL|DT1Fa/AO1DfA|Eligible subjects will be randomized into the DT1Fa/AO1DfA wear sequence, to wear the control lens followed by the test lens, bilaterally, with a 1-to-10 day(s) washout period between wear periods.
62533986|NCT05400408|OTHER|Healthy volunteers|Subjects who were found with no Colorectal or Pancreatic malignancies, by either colonoscopy or by Endoscopic Retrograde Cholangio Pancreatography.
62714391|NCT06120140|EXPERIMENTAL|Arm A and Subcutaneous (SC) Expansion Cohort: Enhanced Dermatologic Management|Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule (100 milligrams \[mg\] twice daily for 12 weeks), clindamycin 1 percent (%) topical lotion, chlorhexidine 4% topical solution, and noncomedogenic skin moisturizer (once daily) during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab (1050 mg for body weight \[BW\] less than 80 kilograms \[kg\] and 1400 mg for BW greater than or equal to \[\>=\] 80 kg as IV infusion \[Arm A\], once weekly for the first 4 weeks, then once every 2 weeks) and subcutaneously (expansion cohort) (cycle 1: 1600 mg or 2240 mg once weekly based on BW; cycles 2 onwards: 3520 mg or 4640 mg based on BW on Day 1 of each 28-day cycle) with lazertinib (240 mg, tablet, once daily) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1).
62160307|NCT06213363|EXPERIMENTAL|TCR1672 tablet|TCR1672 tablet
62160308|NCT06213363|PLACEBO_COMPARATOR|TCR1672 placebo|TCR1672 placebo
62160309|NCT05666193|EXPERIMENTAL|HyperSight Imaging Arm|Subjects imaged with the new HyperSight CBCT imaging system.
62160310|NCT00678821|EXPERIMENTAL|1|Patients with PH will be randomized to either aerobic exercise training plus education (AET) or education only (Ed-only) treatments
62160311|NCT00678821|ACTIVE_COMPARATOR|2|A comparison group of patients with ILD who do not have secondary PH (ILD-only) will also undergo the AET arm
62160312|NCT06415071||Patients diagnosed with hypertension|
62160313|NCT03025698|EXPERIMENTAL|Cohort A (Option 1)|Regimen 1: hATG (ATGAM®), CsA and eltrombopag begin on Day 1.
62160314|NCT03025698|EXPERIMENTAL|Cohort A (option 2)|CsA and eltrombopag begin on Day 1.
62160315|NCT03025698|EXPERIMENTAL|Cohort B|previously untreated SAA, hATG (ATGAM®), CsA and eltrombopag begin on Day 1 and all patients will be treated with the same regimen
62160316|NCT04210219|EXPERIMENTAL|JNJ-64264681: Dose Escalation and Expansion|Participants will receive oral administration of JNJ-64264681 capsule at a dose assigned by the sponsor Study Evaluation Team (SET), based on the available safety, pharmacokinetics, and pharmacodynamics data in dose escalation treatment group (Part 1); and recommended Phase 2 dose (RP2D) determined in Part 1 in cohort expansion treatment group (Part 2).
62160317|NCT06049758|ACTIVE_COMPARATOR|Laparoscopic hemicolectomy with Complete Mesocolic Excision|Patients will have laparoscopic hemicolectomy with Complete Mesocolic Excision, D3 lymph node dissection.
62160318|NCT06049758|ACTIVE_COMPARATOR|Conventional laparoscopic right hemicolectomy|Patients will have conventional laparoscopic right hemicolectomy with D2 lymph node dissection.
62160319|NCT05663541||Patient with multiple sclerosis|Patient with multiple sclerosis
62160320|NCT04464434|EXPERIMENTAL|Upfront autologous HSCT|
62160321|NCT04464434|ACTIVE_COMPARATOR|Immunosuppressive therapy|"12 monthly i.v. pulses CYC 750 mg/m2 (= 9 g/m2 cumulative) followed by at least 12 months of oral MMF daily (3 grams as maximum daily dosage) or mycophenolic acid (up to 2.160 grams daily).~Hyperhydration, alkalinisation of the urine and mesna is recommended, and will be given according to local protocols in order to prevent haemorrhagic cystitis."
62160322|NCT06721780|NO_INTERVENTION|Standard care|This is standard care (what they would normally receive if they were not enrolled into this study)
62160323|NCT06721780|ACTIVE_COMPARATOR|Participants randomised to wear AR headset|"AR headset: MagicLeap 2 - running Divertini's Watering Plants world."
62160324|NCT06721780|ACTIVE_COMPARATOR|Participants randomised to wear VR headset|VR Headset: Oculus Quest 2 - Running SyncVR's Relaxation and Pain control simulations
62533987|NCT02391818||Breast Cancer Patients receiving ACT|Adraimycin/Cytoxan/Taxol
62533988|NCT02391818||Breast Cancer patients receiving RT only|radiation therapy
62533989|NCT00421395|EXPERIMENTAL|multi|escalating in increments of 2.5 mCi/m2
62533990|NCT03256279|EXPERIMENTAL|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
62714392|NCT06120140|ACTIVE_COMPARATOR|Arm B: Standard-of-Care Dermatologic Management|Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as intravenous (IV) infusion plus lazertinib, dose and dosing schedule as same as experimental arm.
62160325|NCT00987155|EXPERIMENTAL|high intensity interval training|8 weeks of high intensity 4 times 4 interval training at 85-90% of peak heart rate during hybrid cycling
62160326|NCT04937179|SHAM_COMPARATOR|Ischemic Conditioning Low|Blood flow restriction with low compression
62160327|NCT04937179|ACTIVE_COMPARATOR|Ischemic Conditioning High|Blood flow restriction with high compression
62160328|NCT03258034|EXPERIMENTAL|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
62160329|NCT05687110|EXPERIMENTAL|Treatment (novobiocin sodium)|Patients receive novobiocin sodium PO QD for 5 days in a row followed by 2 days off each week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline, on day 15 of cycle 1, and at time of progression. Patients undergo medical imaging scans at baseline and every 8 weeks. Patients also undergo blood sample collection on study.
62160330|NCT03686917||CHAT-P|Survey
62160331|NCT01678755|EXPERIMENTAL|ABT-126 Low Dose|ABT-126 Low Dose
62160332|NCT01678755|EXPERIMENTAL|ABT-126 High Dose|ABT-126 High Dose
62160333|NCT01678755|PLACEBO_COMPARATOR|Placebo|Placebo
62160334|NCT02435498|EXPERIMENTAL|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
62160335|NCT02435498|ACTIVE_COMPARATOR|Video|The online video will contain the same information within the website.
62160336|NCT02435498|ACTIVE_COMPARATOR|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
62160337|NCT00832650|EXPERIMENTAL|Fesoterodine|Tablets
62160338|NCT00832650|PLACEBO_COMPARATOR|Placebo|Tablets
62160339|NCT00832650|ACTIVE_COMPARATOR|Solifenacin|Tablets
62160340|NCT02558322||Primary medical care in rural areas|People living in districts, where less than 50% of the population live in cities with more than 20,000 residents and the population density outside of the cities is below 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
62160341|NCT02558322||Primary medical care in region environs|People living in districts, where 50% or more of the population live in cities with more than 20,000 residents and/or population density outside of the cities is above 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
62160342|NCT02558322||Primary medical care in in urban areas|People living in cities with a population of at least 100,000 residents.
62160343|NCT03438968|EXPERIMENTAL|High-Intensity aerobic training|Individuals will exercise using a high-intensity interval exercise training protocol
62160344|NCT03438968|ACTIVE_COMPARATOR|Standard Moderate continuous training|Individuals will exercise using a standard moderate intensity continuous exercise training protocol
62160345|NCT05621096|EXPERIMENTAL|Single arm|Subjects will receive 4 gray (Gy) radiation in 2 fractions in the bridging period following lymphocyte pheresis, prior to lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T-cell infusion. Post CAR T-cell infusion radiation therapy will be allowed as determined by study investigator but prespecified at time of radiation oncology consultation.
62160346|NCT04909593|EXPERIMENTAL|Spinal Cord Stimulation|SCS trial systems including external trial stimulators, lead(s)/extensions(s), and operating room (OR) cable(s)/extender(s) and optional sensor.
62160347|NCT05693272|EXPERIMENTAL|COVAC-01 10µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
62160348|NCT05693272|EXPERIMENTAL|COVAC-01 25µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
62160349|NCT05693272|EXPERIMENTAL|COVAC-01 50µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
62160350|NCT05693272|PLACEBO_COMPARATOR|Placebo Control|12 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
62160351|NCT04217798|EXPERIMENTAL|Niparib combined with oral etoposide|Subjects will received niraparib 200mg or 100mg alternate once daily and oral etoposide 50mg on day 1-20 of a 30-day cycle. Oral etoposide was administered for a maximum of 6-8 cycles. Treatment was continued until disease progression, patient withdrawal or unacceptable toxic effects.
62160352|NCT04657224|EXPERIMENTAL|Part A: Dose escalation: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 will be administered together until disease progression, intolerable toxicity, withdrawal of consent, or the investigator.
62160353|NCT04657224|EXPERIMENTAL|Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
62160354|NCT05413954|PLACEBO_COMPARATOR|Control|Control snack
62160355|NCT05413954|EXPERIMENTAL|Test|Test snack
62160356|NCT01411683|EXPERIMENTAL|4 mini dental implants|Retention of an overdenture by means of 4 mini implants.
62160357|NCT01411683|EXPERIMENTAL|2 mini dental implants|Retention of an overdenture by means of 2 mini implants.
62160358|NCT01411683|ACTIVE_COMPARATOR|2 conventional dental implants|Retention of an overdenture by means of 2 conventional implants associated to ball attachments.
62160359|NCT03627572||Active cohort (N=1000)|Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
62160360|NCT03627572||Passive cohort (N=9000)|Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
62160361|NCT06634199||Observational Study Group|Real world non-small cell lung cancer (NSCLC) stage IIIA/B and IIIC; PD-L1\>1%; non-resectable patients in treatment with IO after concurrent chemo-radiotherapy without progression.
62160362|NCT06399718|EXPERIMENTAL|Double-Blind Period: BOTOX|Participants will receive BOTOX injections across both the right and left masseter muscle on Day 1.
62160363|NCT06399718|PLACEBO_COMPARATOR|Double-Blind Period: Placebo|Participants will receive placebo injections across both the right and left masseter muscle on Day 1.
62160364|NCT06399718|EXPERIMENTAL|Open-Label Period: BOTOX|Participants who are eligible for re-treatment will receive BOTOX injections on either the Day 180, 210, 240, or 270 visit and will be followed for up to 6 months.
62160365|NCT04937920|ACTIVE_COMPARATOR|DBI-002 probiotic gel|Topical application of DBI-002 probiotic gel on skin affected with tinea versicolor
62160366|NCT04937920|PLACEBO_COMPARATOR|Aqueous gel|Topical application of aqueous gel on skin affected with tinea versicolor
62160367|NCT01855672|ACTIVE_COMPARATOR|Perceivable Stimulation|Stimulation of the occipital nerves.
62160368|NCT01855672|ACTIVE_COMPARATOR|Non-Perceivable|Stimulation of the occipital nerves.
62714393|NCT06547918|EXPERIMENTAL|Experimental: Participants with Type 1 and Type 2 diabetes|
62160369|NCT04920578|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD) Cohorts (Double-blind)|Healthy male participants will receive JNJ-69095897 or matching placebo orally in Cohorts 1-8.
62160370|NCT04920578|EXPERIMENTAL|Part 2: Single Dose Cohort (Open-label)|Healthy male participants will receive JNJ-69095897 orally in Cohort 9.
62160371|NCT04920578|EXPERIMENTAL|Part 3: Single or Divided Dose Cohort (Double-blind)|Healthy male participants and women of non-childbearing potential (WONCBP) will receive JNJ-69095897 or matching placebo orally in Cohort 10.
62160372|NCT00104845|EXPERIMENTAL|human gp100 DNA vaccine|Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.
62160373|NCT00104845|EXPERIMENTAL|mouse gp100 DNA vaccine|Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16
62160374|NCT03180788|ACTIVE_COMPARATOR|Traditional ESD|The patients in this Group will undergo traditional ESD.
62160375|NCT03180788|EXPERIMENTAL|Traction assisted ESD|The patients in this Group will undergo traction assisted ESD
62160376|NCT05345041|EXPERIMENTAL|Keep it Movin'|
62160377|NCT05345041|ACTIVE_COMPARATOR|Go 4 Life Self Guided Education|
62160378|NCT01816165|EXPERIMENTAL|Acipimox|Drug: acipimox
62160379|NCT01816165|PLACEBO_COMPARATOR|Placebo|Drug: Placebo
62160380|NCT04970966|EXPERIMENTAL|PuraSinus|Placement of PuraSinus in ethmoid cavity following ESS
62533991|NCT03256279|ACTIVE_COMPARATOR|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
62533992|NCT05930548|ACTIVE_COMPARATOR|Resin modified glass ionomer|RMGI is recommended to restore carious cervical lesions; especially with its ability to inhibit secondary caries due to its fluoride releasing ability. The main advantage of RMGI is its capability to chemically bond to tooth structure, even in the presence of moist dentin. RMGI reaction can be achieved by both acid-base reaction (induced by glass ionomer component) and polymerization reaction (induced by resin component). Thus, RMGI has better mechanical properties, wear resistance, and improved esthetics compared with conventional glass ionomer (AlQranei MS et al, 2021). In addition, the coefficient of thermal expansion of glass ionomer which is similar to that of tooth structure, allows for proper marginal adaptation without marginal leakage (Bollu IP et al, 2016).
62533993|NCT05930548|EXPERIMENTAL|Low shrinkage giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
62533994|NCT00191113|NO_INTERVENTION|Control|Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
62533995|NCT00191113|EXPERIMENTAL|Humatrope|Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
62533996|NCT03828916|OTHER|NuShield|
62533997|NCT00721630|EXPERIMENTAL|1|The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.
62533998|NCT00442039|EXPERIMENTAL|Lithium dosing 1|The starting dose of lithium was 300 mg for patients weighing \< 20 kg \[no patients were enrolled that weighed less than 20 kg\] and 600 mg for patients weighing ≥ 20 kg.
62533999|NCT00442039|EXPERIMENTAL|Lithium dosing 2|"The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability."
62534000|NCT00442039|EXPERIMENTAL|Lithium dosing 3|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
62714394|NCT04186585|EXPERIMENTAL|First design level|All the 8 patients receives a daily oral dose of BP-C2 in ml equals the body weight divided by 5 for 4 weeks. This represents 15 ml for a patient of 75 kg
62714395|NCT04186585|EXPERIMENTAL|Second design level|Based on the results from the first design level, the daily BP-C2 dose will individually be increased by a factor of 1.4 or 1.2 in case of none or mild toxicity increase. If moderate or severe increase in toxicity is observed, the individual dose will be reduced by 0.8 or 0.6, respectively. Duration of the treatment is 4 weeks
62714396|NCT04186585|EXPERIMENTAL|Third design level|Based on the results from the second design level, the daily BP-C2 dose will individually be increased in case of none or mild toxicity increase and reduced if moderate or severe increase in toxicity is observed. Duration of the treatment is 4 weeks
62714397|NCT01455480|EXPERIMENTAL|RPh201|
62160381|NCT04970966|ACTIVE_COMPARATOR|Bioresorbable Nasal Dressing|Placement of bioresorbable nasal dressing (PosiSep X) in ethmoid cavity following ESS
62160382|NCT06720415|EXPERIMENTAL|Oral methadone, immediately prior to transport|
62160383|NCT06720415|ACTIVE_COMPARATOR|Intravenous methadone|
62160384|NCT06450405|ACTIVE_COMPARATOR|TGM initiating TRT|Transgender men/non-binary/non-gender-conforming initiating testosterone replacement therapy
62160385|NCT06450405|NO_INTERVENTION|CGF control group|Cisgender females serving as a control group
62160386|NCT06700395|EXPERIMENTAL|TQB2029 injection|TQB2029 injection, 28 days as a treatment cycle.
62160387|NCT05867615|EXPERIMENTAL|[177Lu]Lu-PSMA I&T|\[177Lu\]Lu-PSMA I\&T, intravenous, dosage of 5.5 - 7.4 GBq every 8 weeks
62160388|NCT05594225|EXPERIMENTAL|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
62534001|NCT00442039|PLACEBO_COMPARATOR|Placebo|
62714398|NCT04567524|ACTIVE_COMPARATOR|Arm 1|"LYN-005: capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone.~AND~IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient."
62714399|NCT04567524|PLACEBO_COMPARATOR|Arm 2|"LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate.~AND~IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets."
62160389|NCT05594225|NO_INTERVENTION|Standard-of-care|Participants will be provided routine instructions related to physical activity and rehabilitation exercises
62160390|NCT04044820|ACTIVE_COMPARATOR|Standardized Discharge Prescription|Based on a previous study examining mean number of opioid pills used by patients undergoing elective, unilateral hand and forearm surgery
62160391|NCT04044820|NO_INTERVENTION|Usual Discharge Prescription|Routine standard of care involves prescription for opioids at the discretion of the surgical team
62160392|NCT05793983||Patients with acute or chronic liver disease|"1. Presence of chronic liver disease, or cirrhosis due to any aetiology (latter based upon a histopathological diagnosis or compatible laboratory data and radiological findings)~2. Acute alcoholic hepatitis~3. Acute liver failure due to any aetiology~4. Acute-on-chronic liver failure"
62534002|NCT02065700|EXPERIMENTAL|Filgotinib Darwin 1|"Participants in Study GLPG0634-CL-203 (NCT01888874) were rolled-over to receive an oral dose of filgotinib at a daily dose of 200 milligrams (mg) in this extension study, with the exception of male participants in the United States (US) who were limited to a daily dose of 100 mg due to a Food and Drug Administration (FDA) requirement based on a non-clinical finding. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval.~In case of intolerance or for safety reasons, and as per investigator's discretion, a daily dose of filgotinib 200 mg could be decreased to 100 mg per day, and later returned to 200 mg per day after the reasons for decreasing the dose were resolved."
62534003|NCT02065700|EXPERIMENTAL|Filgotinib Darwin 2|"Participants from Study GLPG0634-CL-204 (NCT01894516) were rolled-over to receive oral dose of filgotinib tablet at 200 mg once daily (q.d) in this extension study. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval.~Participants started the study with the same dose level (filgotinib 200 mg per day) and in case of intolerance or safety reasons and as per investigator's discretion, the daily dose of filgotinib was decreased to 100 mg q.d and was returned to 200 mg per day after the reasons for decreasing the dose had resolved and at the investigator's discretion."
62534004|NCT05055830||Children (<21 years of age) who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care and are admitted to the pediatric cardiac intensive care unit
62534005|NCT04395495||Neurofibromatosis 1 (NF1)|Individuals with a confirmed or suspected diagnosis of Neurofibromatosis Type 1 (NF1). Diagnosis may be made clinically and/or confirmed through genetic testing. Clinical (non-genetic) diagnosis requires that individuals meet the National Institute of Health's (NIH) clinical diagnostic criteria for NF1.
62534006|NCT04395495||Noonan Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
62534007|NCT04395495||Noonan Syndrome with Multiple Lentigines|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome with Multiple Lentigines. Diagnosis may be made clinically and/or confirmed through genetic testing.
62534008|NCT04395495||Noonan Neurofibromatosis Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Neurofibromatosis Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
62534009|NCT04395495||Cardiofaciocutaneous Syndrome|Individuals with a confirmed or suspected diagnosis of Cardiofaciocutaneous Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
62534010|NCT04395495||Costello Syndrome|Individuals with a confirmed or suspected diagnosis of Costello Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
62534011|NCT04395495||Legius Syndrome|Individuals with a confirmed or suspected diagnosis of Legius Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
62534012|NCT04395495||Smith-Kingsmore Syndrome|Individuals with a confirmed or suspected diagnosis of Smith-Kingsmore Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
62534013|NCT04395495||GATOR-1 Mutation|Individuals with a suspected or known mutation of GATOR-1.
62534014|NCT04395495||SYNGAP1-Related Intellectual Disability|Individuals with a suspected or known mutation of SYNGAP1.
62534015|NCT04395495||DLG4 Mutation|Individuals with a suspected or known mutation of DLG4.
62534016|NCT04395495||MAPK1 Gene Mutation|Individuals with a suspected or known mutation of MAPK1.
62534017|NCT04395495||MTOR Gene Mutation|"1. Individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~2. Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway."
62534018|NCT04395495||RAS Mutation|"1. Individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~2. Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway."
62714400|NCT04170920|EXPERIMENTAL|Mobile Health Application Intervention|"LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
62714401|NCT06145594|EXPERIMENTAL|EMA+Maintenance TMS|Weekly EMA monitoring and a cluster of 5 maintenance sessions scheduled if/when PHQ9 scores reach threshold, per algorithm. Participants continue other concurrent treatment as usual (TAU) with medications, psychotherapy, etc per outpatient clinicians.
62714402|NCT06145594|ACTIVE_COMPARATOR|EMA only|Weekly EMA monitoring without scheduled maintenance TMS. Participants in this arm may get TMS retreatment according to current standard of care (i.e., through their insurance coverage). Participants continue other concurrent treatment as usual (TAU) with medications, psychotherapy, etc per outpatient clinicians.
62714403|NCT06245434|EXPERIMENTAL|Main group with acute brain injury and initial Disorders of consciousness|50 patients in the initial phase of acute brain injury with disturbed consciousness, hospitalized in the Neurological Intensive Care Unit and at risk of delayed awakening
62714404|NCT06245434|ACTIVE_COMPARATOR|Comparative group with acute brain injury without Disorders of consciousness|20 patients in the initial phase of brain damage WITHOUT disturbance of consciousness, hospitalized in the Neurological Intensive Care Unit and presenting similar causes of brain damage.
62714405|NCT06245434|ACTIVE_COMPARATOR|Comparative group with post-acute Disorders of consciousness|20 patients in the sub-acute or chronic phase of a consciousness disorder and admitted to the Post-Resuscitation Rehabilitation Service.
62534019|NCT04077918|ACTIVE_COMPARATOR|Plant protein diet|18 g of plant protein diet added every day for 3 months , and after washout for 1 month, 18 g of animal protein diet added every day for 3 months
62534020|NCT04077918|ACTIVE_COMPARATOR|Animal protein diet|18 g of animal protein diet added every day for 3 months, and after washout for 1 month, 18 g of plant protein diet added every day for 3 months
62534021|NCT01058772|EXPERIMENTAL|INDUCTION of LABOUR|"At enrollment patients assigned to the induction group will be admitted to the obstetric ward and will undergo induction of labour as described in the intervention section.~Once patient's Bishop score exceeds 7 or regular contractions are diagnosed, patients will be transferred to the delivery ward for artificial rupture of membranes (ARM) or Oxytocin augmentation as indicated."
62534022|NCT01058772|NO_INTERVENTION|EXPECTANT MANAGEMENT|"Patients enrolled in the conservative management arm will be followed up twice weekly for foetal wellbeing by Non-stress test and Biophysical profile. Patients will be followed up to 41+0 weeks.~Patients, who will not deliver by this gestational age, will be admitted for labour induction (see the above protocol). Induction of labour will be offered when non-reassuring foetal status is suspected. All patients in the conservative arm will undergo foetal weight ultrasound estimation prior to induction. Patients with estimated foetal weight over 4000 gr will be offered a C-section."
62534023|NCT03859765|EXPERIMENTAL|HCT Symptoms and Steps|HCT Symptoms and Steps participants will complete in-person (3) and video-conferencing (4) coping skills training and activity coaching sessions teaching cognitive behavioral coping skills to manage pain, fatigue, and distress and increase activity. Participants will be given a wireless activity tracker and a smartphone for accessing the study mobile app.
62534024|NCT03859765|NO_INTERVENTION|HCT Education|HCT Education participants will receive 1 brief in clinic session prior to discharge home providing education related to symptom management and physical activity, and a wireless activity tracker. HCT Education participants will also receive 6 brief phone calls upon return home.
62534025|NCT00045188|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.
62534026|NCT01754337|ACTIVE_COMPARATOR|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels.
62534027|NCT01754337|ACTIVE_COMPARATOR|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels.
62534028|NCT01754337|ACTIVE_COMPARATOR|Insulin pump therapy|Patient's conventional treatment will be implemented.
62534029|NCT01844466|EXPERIMENTAL|stroke patients|
62534030|NCT05173675|EXPERIMENTAL|Program arm|"Usual Care+~Phase 1 (6 months, months 1-6), Program. Includes empathetic communications (phone \& letter), health-promoting incentives, educational materials.~Phase 2 (6 months, months 7-12) No Program. During this follow-up period they will receive monthly SMS texts with customized messages encouraging health promoting behaviors."
62534031|NCT05173675|OTHER|Control arm|"Usual Care+~Phase 1 (6 months, months 1-6), No Program.~Phase 2 (6 months, months 7-12) Material components of program including health-promoting incentives and educational materials."
62534032|NCT05569551|EXPERIMENTAL|Adhesive pouch|Experimental group will be applied with Wondaleaf adhesive pouch to cover up the umbilical stump
62534033|NCT05569551|NO_INTERVENTION|Conventional care|Control group will not be applied with Wondaleaf adhesive pouch, but the umbilical stump is managed with conventional care, by cleaning with antiseptic.
62714406|NCT00605059|EXPERIMENTAL|Assess [123I] AV94 and SPECT imaging|
62714407|NCT04554303||S-amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
62160393|NCT05793983||Patients undergoing diagnostic or therapeutic abdominal paracentesis|Patients with acute or chronic liver disease of any aetiology undergoing clinically-indicated paracentesis for ascites
62160394|NCT05793983||Patients undergoing broncho-alveolar lavage|"1. Intubated patients with liver disease in intensive care~2. Undergoing a bronchoscopy or a non-directed broncho-alveolar lavage as part of their routine clinical care"
62160395|NCT05793983||Patients with acute or chronic liver disease undergoing liver biopsy|
62160396|NCT05793983||Patients with undergoing transjugular intrahepatic shunt (TIPSS) placement|
62160397|NCT05793983||Patients with acute or chronic liver disease undergoing orthoptic liver transplantation|
62160398|NCT05793983||Patients undergoing surgical liver resection or hepatectomy for liver-related diseases|
62160399|NCT05793983||Patients with ascites without chronic liver disease|"1. Absence of cirrhosis based on clinical, radiological or histopathological features, including patients with non-cirrhotic portal hypertension, cardiac ascites (ascites due to heart failure) or patients with chronic kidney disease undergoing continuous ambulatory peritoneal dialysis (CAPD)~2. Presence of clinically significant ascites~3. Undergoing diagnostic or therapeutic paracentesis"
62160400|NCT05793983||Patients with sepsis without acute or chronic liver disease|
62534034|NCT03012984|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
62534035|NCT03012984|PLACEBO_COMPARATOR|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
62534036|NCT00317707|EXPERIMENTAL|N-3 PUFA|
62534037|NCT00317707|PLACEBO_COMPARATOR|Olive oil|
62534038|NCT00837473|OTHER|Plexur-P Bone Void Filler|Single arm. Open Label.
62534039|NCT04051112|EXPERIMENTAL|SCB-313|
62534040|NCT01156142|EXPERIMENTAL|Arm I|Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
62160401|NCT05793983||Patients with haemochromatosis who undergo regular venesection|
62160402|NCT05793983||Healthy subjects|
62160403|NCT03969251|EXPERIMENTAL|Transcranial Magnetic Stimulation (rTMS)|repetitive transcranial magnetic stimulation
62160404|NCT03969251|SHAM_COMPARATOR|Sham (SS)|repetitive sham rTMS
62534041|NCT01156142|PLACEBO_COMPARATOR|Arm II|Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.
62534042|NCT03141814||asthma|20 patients with ongoing ashma
62534043|NCT03141814||complete asthma remission|20 subjects with complete asthma remission
62534044|NCT03141814||clinical asthma remission|20 subjects with clinical asthma remission
62534045|NCT03141814||non-asthmatic healthy controls|20 subjects without respiratory symptoms and normal lung function and no bronchial hyperresponsiveness to methacholine and/or AMP
62534046|NCT06288230|EXPERIMENTAL|vesemnogene lantuparvovec|One-time Intravenous administration of vesemnogene lantuparvovec.
62534047|NCT06370286|EXPERIMENTAL|concurrent exercise (CE)|Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
62534048|NCT06370286|EXPERIMENTAL|aerobic exercise (AE)|Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve \[HRR\]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
62534049|NCT06370286|NO_INTERVENTION|control (CON)|Participants in the control group read books for 35 minutes.
62534050|NCT04923789||ASCT Without CART|Patients who undergone ASCT successfully and did not receive CART cell infusion.
62534051|NCT04923789||ASCT Bridging CART|Patients who undergone ASCT and received CART cell infusion sequently within 1 month. Patients with disease recurrence or progression prior to the infusion of CART cells will be excluded.
62534052|NCT05328934|EXPERIMENTAL|Initial Assignment: SoftHand Pro|This arm of the crossover design will begin the trial using the SoftHand Pro.
62534053|NCT05328934|ACTIVE_COMPARATOR|Initial Assignment: Ossur i-Limb|This arm of the crossover design will begin the trial using the i-Limb.
62534054|NCT05316883|OTHER|clozapine treatment|Open label clozapine will be given to all participants in clinical doses adjusted to sideeffects and clinical effect
62534055|NCT02936414|EXPERIMENTAL|Berberine group|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
62534056|NCT02936414|PLACEBO_COMPARATOR|Placebo group|Accept placebo(300 mg/tid)+SGAs monotherapy.
62534057|NCT05312320|ACTIVE_COMPARATOR|Information film|Randomized to receive a short information film online.
62534058|NCT05312320|NO_INTERVENTION|Standard care|No film, only questionnaire.
62534059|NCT04851938|ACTIVE_COMPARATOR|Active TENS 1 Group|
62534060|NCT04851938|ACTIVE_COMPARATOR|Active TENS 2 Group|
62534061|NCT04851938|PLACEBO_COMPARATOR|Placebo Group|
62534062|NCT04851938|SHAM_COMPARATOR|Control Group|
62534063|NCT01750489|NO_INTERVENTION|COPD|
62534064|NCT01750489|EXPERIMENTAL|COPD with non-invasive ventilation (NIV)|Starting non-invasive ventilation with the patient's own device during registration of MSNA.
62534065|NCT01750489|NO_INTERVENTION|Healthy control subjects|
62714408|NCT04554303||Amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
62160405|NCT02430597|EXPERIMENTAL|IRE Group|irreversible electroporation for Unresectable Hilus Pulmonis Neoplasms
62160406|NCT02430597|NO_INTERVENTION|Control|The patients without treatment
62160407|NCT03423992|EXPERIMENTAL|Biological: Chimeric antigen receptor T cells|
62714409|NCT06716788||68Ga-HSA PET/CT in participants with hypoproteinemia|Participants who are with hypoproteinemia will be injected with 2.22 MBq/kg body weight of 68Ga-HSA in one dose intravenously and then undergo PET/CT scan within 1 h.
62534066|NCT00810576|EXPERIMENTAL|Vorinostat + Bortezomib|Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\^2 intravenous (IV) on Days 1, 4, 8, 11.
62534067|NCT05410782|EXPERIMENTAL|Power Prenatal for Sperm|This is a single arm study. Participants will take supplements for 3 months. The supplements is Power Prenatal for Sperm (active ingredients - https://birdandbe.com/the-power-prenatal-for-sperm)
62534068|NCT05498675||Sacubitril/valsartan group|Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
62534069|NCT05498675||ACEI/ARB group|"Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
62534070|NCT01568060||Infanrix-IPV group|Infants and children who received at least one dose of Infanrix-IPV as a part of routine practice at a private clinic or hospital in korea
62534071|NCT03365752|EXPERIMENTAL|Chloroprocaine|
62534072|NCT03365752|ACTIVE_COMPARATOR|Mepivacaine|
62534073|NCT03365752|ACTIVE_COMPARATOR|General Anesthesia|
62534074|NCT00077857|EXPERIMENTAL|1250 mg/m^2 capecitabine + docetaxel|1250 mg/m\^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m\^2 intravenous on day 1 of each 3 week cycle.
62534075|NCT00077857|EXPERIMENTAL|825 mg/m^2 capecitabine + docetaxel|825 mg/m\^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m\^2 intravenous on day 1 of each 3 week cycle.
62534076|NCT06419595|OTHER|Recruitment by Research Coordinator (RC)|Study participants will be randomized for recruitment follow up by research team RC.
62534077|NCT06419595|OTHER|Recruitment by EYE|Study participants will be randomized for recruitment follow up by the EYE peer group (community youth research group)
62714410|NCT02685397|ACTIVE_COMPARATOR|LHRH agonist + Enzalutamide|Subjects will receive LHRH agonist in combination with the new generation of hormonal therapy (enzalutamide, 40mg)
62714411|NCT02685397|EXPERIMENTAL|LHRH agonist + Enzalutamide + SBRT|Subjects will receive LHRH agonist in combination with the new generation of hormone therapy (enzalutamide, 40mg) plus the additional SBRT treatment
62714412|NCT06541808|EXPERIMENTAL|mechanical Vagus Nerve Stimulation (Low Intensity)|4 minutes of mechanical vagal stimulation (2 minutes on each side) administered only once along the entire experiment
62160408|NCT06378281|NO_INTERVENTION|Standard informed consent|According to ethical requirements of Swiss Human Research Act, the interviewer will explain the nature of the study, its purposes, duration, the potential risks and benefits it entails, and study procedures. He will inform that study participation is voluntary and that participants may withdraw at any time. He will also explain that the study is independent from the prison authorities. Participants will then be given time to read the informed consent, or, if they are not able to read, it will be read to them by the interviewer. The interviewer will answer all questions.
62160409|NCT06378281|EXPERIMENTAL|Modified teach-to-goal informed consent|The standard process will first be used. After that, the interviewer will ask participants to summarize the content of the informed consent. The interviewer will correct not-well understood components and ask questions about forgotten components. In case of misconceptions, the participant will be asked to summarize again the corresponding components. A list of key components to be addressed will be developed by study team members, including experts in prison research and ethics, based on components listed in Art. 16 of the Swiss Human Research Act. The material of the informed consent of the parent-randomized controlled trial will be used.
62160410|NCT03310372|EXPERIMENTAL|ultrafractionated brain irradiation - temozolomide|
62160411|NCT04172688|PLACEBO_COMPARATOR|Placebo|Two 3.3g doses/day (12 kcal/dose) of maltodextrin
62160412|NCT04172688|EXPERIMENTAL|Prebiotic|Two 8g doses/day (12 kcal/dose) of oligofructose-enriched inulin
62160413|NCT06585436|EXPERIMENTAL|selective removal (chitosan loaded nano hydroxyapatite )|selective removal then apply chitosan loaded nano hydroxyapatite
62160414|NCT06585436|EXPERIMENTAL|selective removal (nano bioactive glass/GIC)|selective removal then apply (nano bioactive glass/GIC)
62160415|NCT06585436|EXPERIMENTAL|selective removal (nanosilver)|selective removal then apply (nanosilver)
62160416|NCT06585436|EXPERIMENTAL|stepwise removal (chitosan loaded nano hydroxyapatite )|stepwise removal then apply (chitosan loaded nano hydroxyapatite )
62160417|NCT06585436|EXPERIMENTAL|stepwise removal (nano bioactive glass/GIC)|selective removal (nano bioactive glass/GIC)
62160418|NCT06585436|EXPERIMENTAL|stepwise removal (nanosilver)|selective removal then apply (nanosilver)
62160419|NCT04944784|EXPERIMENTAL|Reldesemtiv Group, Double-Blind Period|Participants in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Day 1 until Week 24.
62160420|NCT04944784|PLACEBO_COMPARATOR|Placebo Group, Double-Blind Period|Participants in this arm take 2 placebo oral tablets twice a day from Day 1 until Week 24.
62160421|NCT04944784|EXPERIMENTAL|Delayed Start Group, Active Drug Period|Participants in this arm were those who received placebo in the double-blind period and reldesemtiv in the active drug period. Participants take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Week 24 until Week 48. Patients who were down-titrated for any reason during the 24 weeks of blinded dosing take 1 reldesemtiv 150 mg oral tablet twice a day for a 300 mg total daily dose from Week 24 until Week 48.
62160422|NCT04944784|EXPERIMENTAL|Early Start Group, Active Drug Period|Participants in this arm were those who received reldesemtiv in the double-blind and active drug periods. Participants take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Week 24 until Week 48. Patients who were down-titrated for any reason during the 24 weeks of blinded dosing take 1 reldesemtiv 150 mg oral tablet twice a day for a 300 mg total daily dose from Week 24 until Week 48.
62160423|NCT05937581|EXPERIMENTAL|Part A [Single ascending dose (SAD)]: CSL040 (minimum dose)|Single Intravenous (IV) Administration
62160424|NCT05937581|EXPERIMENTAL|Part A (SAD): CSL040 (lower dose)|Single IV Administration
62160425|NCT05937581|EXPERIMENTAL|Part A (SAD): CSL040 (low dose)|Single IV Administration
62160426|NCT05937581|EXPERIMENTAL|Part A (SAD): CSL040 (medium dose)|Single IV Administration
62160427|NCT05937581|EXPERIMENTAL|Part A (SAD): CSL040 (medium-high dose)|Single IV Administration
62160428|NCT05937581|EXPERIMENTAL|Part A (SAD): CSL040 (maximum dose)|Single IV Administration
62160429|NCT05937581|PLACEBO_COMPARATOR|Part A (SAD): Placebo|Single IV Administration
62160430|NCT05937581|EXPERIMENTAL|Part B [Multiple ascending dose (MAD)]: CSL040 (minimum dose)|IV Administration not to exceed 5 doses over 14 days
62160431|NCT05937581|EXPERIMENTAL|Part B (MAD): CSL040 (medium dose)|IV Administration not to exceed 5 doses over 14 days
62160432|NCT05937581|EXPERIMENTAL|Part B (MAD): CSL040 (high dose)|IV Administration not to exceed 5 doses over 14 days
62160433|NCT05937581|PLACEBO_COMPARATOR|Part B (MAD): Placebo|IV Administration not to exceed 5 doses over 14 days
62160434|NCT00996905|NO_INTERVENTION|Beginner Conventional (BC)|Beginner level (residents) doing epidural insertions the conventional way (ie. no ultrasound scanning)
62160435|NCT00996905|EXPERIMENTAL|Beginner Ultrasound (BU)|Beginner level (residents) doing epidural insertions with the help of ultrasound scanning.
62160436|NCT00996905|NO_INTERVENTION|Experienced Conventional|Experienced level (fellows) doing epidural insertions the conventional way.
62160437|NCT00996905|EXPERIMENTAL|Experienced Ultrasound|Experienced level (fellows) doing epidural insertions with the help of ultrasound scanning.
62160438|NCT04873544|EXPERIMENTAL|Common protocols for TKA|Common protocols for TKA
62160439|NCT05815771|ACTIVE_COMPARATOR|Micro fragmented adipose tissue|Micro fragmented adipose tissue mixed with Bone marrow stem cells injection on healing of TMJ internal disc derangement without reduction
62160440|NCT05815771|ACTIVE_COMPARATOR|Bone marrow stem cells aspiration|Bone marrow stem cells injection on healing of TMJ internal disc derangement without reduction
62160441|NCT05815771|PLACEBO_COMPARATOR|hyaluronic acid gel injection|Intra and periarticular injection of 2 mm of hyaluronic acid gel on healing of TMJ internal disc derangement without reduction
62160442|NCT03063346|EXPERIMENTAL|Protein hydrolysate high dose|
62160443|NCT03063346|EXPERIMENTAL|Protein hydrolysate low dose|
62160444|NCT03063346|PLACEBO_COMPARATOR|Placebo|
62160445|NCT05492721|ACTIVE_COMPARATOR|Dermabond|Dermabond over incisions
62160446|NCT05492721|ACTIVE_COMPARATOR|Swiftset|Swiftset over incisions
62160447|NCT05195034|ACTIVE_COMPARATOR|DEX group|The DEX group patients will be received dexmedetomidine intraoperatively.
62160448|NCT05195034|PLACEBO_COMPARATOR|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively.
62160449|NCT00964756|EXPERIMENTAL|Gene therapy|
62160450|NCT00871494|EXPERIMENTAL|Azithromycin switch therapy (switch from intravenous to oral).|
62534078|NCT01329900|EXPERIMENTAL|Ofatumumab + Stem Cell Collection|Ofatumumab 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8. Ifosfamide 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously. Etoposide 150 mg/m2 by vein over 2 hours every 12 hours for 6 doses. Mesna 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts). Mesna 2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide). After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose. G-CSF 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis. Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
62534079|NCT00670163|EXPERIMENTAL|1|Participating community will provide Comunidades Positivas plus enhanced partner therapy.
62534080|NCT00670163|EXPERIMENTAL|2|Participating community will provide enhanced partner therapy alone.
62534081|NCT00670163|EXPERIMENTAL|3|Participating community will provide Comunidades Positivas alone.
62534082|NCT00670163|ACTIVE_COMPARATOR|4|Participating community will provide standard of care.
62534083|NCT02827838|EXPERIMENTAL|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
62534084|NCT06172244|EXPERIMENTAL|Whole body vibration|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
62534085|NCT02943928|EXPERIMENTAL|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis.
62534086|NCT02943928|EXPERIMENTAL|Traditional method by experience|Operator inserted the double lumen tube by experience
62534087|NCT05540028|EXPERIMENTAL|Adult Cohort Group 1|Participants will receive a single 0.5mL dose of IVT PCV-25 administered by intramuscular injection on Day 1
62534088|NCT05540028|ACTIVE_COMPARATOR|Adult Cohort Group 2|Participants will receive a single 0.5mL dose of PCV 20 administered by intramuscular injection on Day 1
62534089|NCT06380868|EXPERIMENTAL|Intravascular imaging-guided PCI group|For patients in this group, intravascular imaging will be encouraged to performed prior-to and post-coronary intervention using new generation drug-eluting stents
62534090|NCT06380868|ACTIVE_COMPARATOR|Angiography-guided PCI group|For patients in this group, implantation of a new generation drug-eluting stent will be guided by angiography only. Unless coronary artery lesion is complex or ambiguous, intravascular imaging is not allowed to be used. If intravascular imaging is used because of the reason mentioned above, post-stenting assessment is absolutely not allowed.
62534091|NCT00149812|EXPERIMENTAL|Intervention|"Intervention: Keeping Families Strong Cognitive Behavioral and Communication intervention with mothers recovering from depression and their children, 9 years and older."
62534092|NCT04332887|EXPERIMENTAL|Multidimensional Exercise Program|Patients in the intervention group received a 12-week multidimensional exercise programme that consisted of individual nursing consultation, an exercise program that included moderate intensity walking for 30-45 minutes per day, three days per week and combined resistance exercise, nutrition assessment and instructions, and support.
62534093|NCT04332887|NO_INTERVENTION|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
62534094|NCT05394311|EXPERIMENTAL|Intervention arm - sport based mental health promotion program|The experimental arm will receive an intervention for around 10 months' period after baseline data collection.
62714413|NCT06541808|EXPERIMENTAL|mechanical Vagus Nerve Stimulation (Intermediate Intensity)|12 minutes of mechanical vagal stimulation(3 sessions of 2 minutes of stimulation, with 2 minutes of rest for each side) administered only once along the entire experiment
62714414|NCT06541808|EXPERIMENTAL|mechanical Vagus Nerve Stimulation (High Intensity)|16 minutes of mechanical vagal stimulation (8 minutes on each side) administered only once along the entire experiment
62714415|NCT06541808|SHAM_COMPARATOR|Sham Vagus Nerve Stimulation|Participants will be treated with a fake vagus stimulation not able to stretch the vagus nerve
62714416|NCT05377060|EXPERIMENTAL|Plasma p-tau Disclosure|To receive risk estimate based on plasma p-tau results in addition to age, sex, and cognitive screening score.
62160451|NCT03317509|ACTIVE_COMPARATOR|Real rTMS|Each patient received high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days
62160452|NCT03317509|SHAM_COMPARATOR|Sham rTMS|Each patient received rTMS with the same pulse as the first group but with the coil placed perpendicular to the scalp.
62160453|NCT03685578||Mechanical Thrombectomy|EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter, CEREGLIDE 71 Intermediate Catheter
62534095|NCT05394311|NO_INTERVENTION|Control group - treatment as usual|This group receive the intervention available in the existing health care and education system in the study area.
62534096|NCT03874286||Liver Transplant|Participants will obtain a liver biopsy at 4 months post transplant and 12 months post transplant.
62534097|NCT02297698|EXPERIMENTAL|Trastuzumab + NeuVax|Patients randomized to this arm will receive vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) (NeuVax vaccine) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumbab to overlap with the PVS. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
62714417|NCT05377060|ACTIVE_COMPARATOR|Standard Disclosure|To receive risk estimate based on age, sex, and cognitive screening score.
62160454|NCT02350426|EXPERIMENTAL|Arm 1|As per randomization schedule, subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-FDG followed by PET/CT2 scan with 18F-GE-180 in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
62160455|NCT02350426|EXPERIMENTAL|Arm 2|As per randomization schedule, , subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-GE-180 followed by PET/CT2 scan with 18F-FDG in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
62160456|NCT06721169||Phenol|Patients with uncomplicated pilonidal sinus disease who receive phenol therapy will be included in this group.
61975992|NCT03838133|EXPERIMENTAL|TLC590 dose 2 (190 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
61975993|NCT03838133|EXPERIMENTAL|TLC590 dose 3 (228 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
62160457|NCT06721169||Lazer ablation|Patients with uncomplicated pilonidal sinus disease who underwent laser ablation will be included in this group.
62160458|NCT03368300|OTHER|Patients|Parkinson's patient
62160459|NCT03368300|OTHER|witnesses: without parkinson's disease|Subjects without parkinson's disease
62160460|NCT05785975|EXPERIMENTAL|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
62160461|NCT05785975|NO_INTERVENTION|Routine Care for colorectal cancer screening|The comparators will be individuals with an average risk of colorectal cancer of both genders attending the selected health centres / or recruited through a community outreach approach.
62160462|NCT03059147|EXPERIMENTAL|SF1126 + Nivolumab|SF1126 900-1100 mg/m2 IV twice weekly + Nivolumab 240 mg IV every 2 weeks
62534098|NCT02297698|ACTIVE_COMPARATOR|Trastuzumab + GM-CSF|Patients randomized to this arm will receive inoculations of GM-CSF (250 μg) administered in an identical manner to those receiving nelipepimut-S/GM-CSF (NeuVax). Patients will be blinded as to whether they are receiving nelipepimut-S/GM-CSF or GM-CSF alone. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
62534099|NCT04419792||Narcolepsy|
62534100|NCT02651259|EXPERIMENTAL|Cohort 1 (pregnant women enrolled in the second trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
62534101|NCT02651259|EXPERIMENTAL|Cohort 2 (pregnant women enrolled in the third trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
62534102|NCT06372327|EXPERIMENTAL|1 x 1 minute Exercise Snack / Day|Participants will be assigned a daily goal of 1, 1-minute exercise snack to break up prolonged sitting.
62534103|NCT06372327|EXPERIMENTAL|1 x 4 Exercise Snack / Day|Participants will be assigned a daily goal of 1, 4-minute exercise snack to break up prolonged sitting.
62714418|NCT02083224||Cancer patients|
62714419|NCT06314178||Pregnant women between 24-42 weeks of gestation|No interventions
62714420|NCT06718179|EXPERIMENTAL|Short duration of DAPT|
62534104|NCT06372327|EXPERIMENTAL|4x1 Exercise Snacks / Day|Participants will be assigned a daily goal of 4, 1-minute exercise snack to break up prolonged sitting.
62534105|NCT06372327|EXPERIMENTAL|4x4 Exercise Snacks/Day|Participants will be assigned a daily goal of 4, 4-minute exercise snack to break up prolonged sitting.
62534106|NCT05160233|ACTIVE_COMPARATOR|Standard Implementation|All primary care clinics will implement reSET and reSET-O using standard implementation approach.
62534107|NCT05160233|EXPERIMENTAL|Standard Implementation Plus Health Coaching|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
62534108|NCT05160233|EXPERIMENTAL|Standard Implementation Plus Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and a practice facilitator will provide the clinic with support for implementation.
62714421|NCT06718179|ACTIVE_COMPARATOR|Conventional duration of DAPT|
62714422|NCT03753048|ACTIVE_COMPARATOR|Y-Graft|The group includes patients who underwent CABG in Y-Graft Configuration.
62714423|NCT03753048|ACTIVE_COMPARATOR|In-Situ|The group includes patients who underwent CABG in In-Situ Configuration.
61975994|NCT03838133|ACTIVE_COMPARATOR|Naropin®|Naronpin injection contains ropivacaine HCl 50 mg (0.5%, 10 mL)
61975995|NCT03838133|PLACEBO_COMPARATOR|Placebo|Normal Saline (0.9% sodium chloride, 10 mL)
61975996|NCT03838133|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine HCl 50 mg (0.5%, 10 mL)
61975997|NCT06140303|EXPERIMENTAL|SkinTE|SkinTE plus standard care
61975998|NCT06140303|OTHER|Control|Standard care alone
61975999|NCT04766125|OTHER|Standard adverse event information|
61976000|NCT04766125|OTHER|Elaborated adverse event information|
61976001|NCT02685020|EXPERIMENTAL|Group 1A|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
61976002|NCT02685020|PLACEBO_COMPARATOR|Group 1B|Participants will receive placebo at weeks 0, 12, 24 and 48.
61976003|NCT02685020|EXPERIMENTAL|Group 2A|Participants will receive Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 0, 12 and 24.
62160463|NCT04099797|EXPERIMENTAL|C7R-GD2.CAR T cells (Cohort 1)|"The dose level for autologous cell C7R-GD2.CAR T cells administered via intravenous (IV) infusion was determined in the initial phase of the protocol. The standard IV dose is 10 million cells/m2 with lymphodepletion chemotherapy.~In this subsequent phase of the study, the safe dosing levels for autologous cell C7R-GD2.CAR T cell immunotherapy administered intracerebroventricularly (ICV) via ommaya reservoir or programmable VP shunt in combination with subsequent IV doses will be determined."
62160464|NCT04099797|EXPERIMENTAL|C7R-GD2.CAR T cells (Cohort 2)|The dose level for autologous cell C7R-GD2.CAR T cell immunotherapy administered via intravenous (IV) infusion was determined in the initial phase of the protocol. The standard IV dosing is 10 million cells/m2 with lymphodepletion chemotherapy.
62160465|NCT06721338|EXPERIMENTAL|Stroke patients with LVO|"Eligible patients for the study will be stroke patients with large vessel occlusion who meet inclusion criteria.~* Age \> 18-year-old~* Last known well less than 24 hours~* Large vessel occlusion of intra-cranial ICA or MCA M1 segment~* ASPECTS of 4 or above~* Baseline modified Rankin scale of 3 or less.~* More than 20 ml penumbra on CTP~* Less than 100 ml infarct core on CTP~Before the mechanical thrombectomy is completed, a surgical cut will be made to the other groin that has not been operated on. A catheter and wire are used to access the newly punctured femoral vein. A device called an aspiration filter will connect a catheter from your femoral vein to an aspiration catheter at the target site. Once this connection is complete, full removal of the blockage by the stent retriever will occur while blood flow is reversed."
62160466|NCT06442969|OTHER|All participants|All participants will receive the intervention
62160467|NCT04644770|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
62160468|NCT04644770|EXPERIMENTAL|Part 2: Dose Expansion|Participants in one or more cohorts will receive intravenous (IV) injection of JNJ-69086420 at the RP2D(s) determined in Part 1.
62160469|NCT05120284|ACTIVE_COMPARATOR|Pre-Surgical Dichloroacetate (DCA)|Study medication begins in subjects randomized to preoperative DCA. All subjects will be given the 12.5 mg/kg/12 hour DCA for pre-surgical dosing. Post-surgery the GSTZ1 haplotype will be utilized to dose all patients.
62160470|NCT05120284|ACTIVE_COMPARATOR|No Pre-Surgical Dichloroacetate (DCA)|Subject randomized to start DCA after surgery will do so 12-24 hours postoperatively, depending on their ability to safely receive medication.
62160471|NCT00183209|EXPERIMENTAL|14 session behavioral intervention|7 sessions addressing problem alcohol and drug use and 7 session addressing parenting challenges (monitoring, negotiation, etc) based on based on Social Action Theory (Ewart, 1991) and Motivational Interviewing
62160472|NCT00183209|ACTIVE_COMPARATOR|Brief Video Intervention|Single session brief video intervention to build motivation to reduce or eliminate problem drinking/drug use
62160473|NCT06176131||cardio-share|"Patients with successful cardio-share model fulfill at least one of the following:~1. A plan for follow-up after discharge established, based on communication with Primary Care (home-care and/or General Practice) before discharge~2. The patient has accessed MinSP-Ass. and received information on heart failure~3. The patient has sent vital measurements and symptoms through MinSP-Ass. to the hospital cardiologist"
62160474|NCT06176131||Others|"All others who fulfill the inclusion criteria but none of the three elements have been successful are the comparative group Others"
62160475|NCT04847908|EXPERIMENTAL|High-intensity interval exercise intervention|Change according to definition.
62160476|NCT06698276|EXPERIMENTAL|2 months reopen group|a biomaterial will be used to alveolar ridge preservation, and after 2 months participants of this group will receive a dental implant
62160477|NCT06698276|EXPERIMENTAL|3 months reopen group|a biomaterial will be used to alveolar ridge preservation, and after 3 months participants of this group will receive a dental implant
62160478|NCT04540796|EXPERIMENTAL|Part A: Dose Escalation|Participants will receive JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
62160479|NCT04540796|EXPERIMENTAL|Part B: Cohort Expansion|Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
62160480|NCT00768911|EXPERIMENTAL|1|
62160481|NCT05807542|EXPERIMENTAL|Tislelizumab combined with chemotherapy|
62534109|NCT05160233|EXPERIMENTAL|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
62534110|NCT01943110|EXPERIMENTAL|Saline injection with ID adapters|"Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:~* Upper deltoid with the side-load ID adapter~* Upper deltoid with the AD ID adapter~* Suprascapular (behind the shoulder) with the side-load ID adapter~* Suprascapular with the AD ID adapter~* Forearm with the side-load ID adapter~* Forearm with the AD ID adapter"
62534111|NCT02329938|ACTIVE_COMPARATOR|Lichtenstein tension free reair|mesh repair of inguinal hernia
62534112|NCT02329938|ACTIVE_COMPARATOR|Desarda's repair|non-mesh repair of inguinal hernia
62534113|NCT01089244||Group A|"Patients with a suspected WHO II low grade glioma, disease progression within~1 year"
62714741|NCT01740687||Essure+NovaSure|The group of women relying on Essure micro-inserts for permanent birth control when NovaSure is performed following a successful Essure Confirmation Test
62160482|NCT06374186|EXPERIMENTAL|Behavioral Intervention with financial rewards and coaching|Individuals in the treatment group will receive financial rewards (contingency management) and diabetes coaching (motivational interviewing) in addition to wearing a continuous glucose monitor while receiving their usual diabetes treatment.
62160483|NCT06374186|ACTIVE_COMPARATOR|Control|Individuals in the control group will not receive any interventions and will only wear a continuous glucose monitor while receiving their usual diabetes treatment.
62160484|NCT02699437||Pregnant women with preeclampsia|Testing for antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) will be performed in pregnant women with preeclampsia.
62534114|NCT01089244||Group B|Patients with a suspected WHO II low grade glioma, progression free within 1 year
62160485|NCT03736265|EXPERIMENTAL|Carvedilol+ Nucleos(t)ide Analogues|Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
62714424|NCT04936191|EXPERIMENTAL|DynamX Bioadaptor|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor and DESyne DES groups.
62160486|NCT03736265|NO_INTERVENTION|Nucleos(t)ide Analogues|Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
62714425|NCT04936191|ACTIVE_COMPARATOR|DESyne Drug-eluting Stent|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor and DESyne DES groups.
62714426|NCT02154022||1|Participants who are currently enrolled in IRB approved NIH Intramural Research Program clinical trial
62160487|NCT06721156|EXPERIMENTAL|MK-1167 3 mg|Participants receive 3 mg of MK-1167 once daily (QD) for up to approximately 24 weeks.
62160488|NCT06721156|EXPERIMENTAL|MK-1167 1 mg|Participants receive 1 mg of MK-1167 QD for up to approximately 24 weeks.
62160489|NCT06721156|EXPERIMENTAL|MK-1167 0.3 mg|Participants take 0.3 mg of MK-1167 QD for up to approximately 24 weeks.
62160490|NCT06721156|PLACEBO_COMPARATOR|Placebo|Participants take placebo QD for up to approximately 24 weeks.
62160491|NCT06557876|ACTIVE_COMPARATOR|Pulmonary vein isolation by pulse field ablation|
62160492|NCT06557876|ACTIVE_COMPARATOR|Pulmonary vein isolation by cryoablation|
62160493|NCT02325752|NO_INTERVENTION|Control|Patients in the control group received usual care by the hospital. There was no contact between the patients in the control group and the study team throughout the 3 months interval. A scheduled telephone call was made at the end of 3 months when they were invited to participate in a telephone survey.
62160494|NCT02325752|ACTIVE_COMPARATOR|Intervention|Intervention
62160495|NCT05440422|ACTIVE_COMPARATOR|Patient|anifrolumab
62160496|NCT05440422|PLACEBO_COMPARATOR|Patient placebo|placebo
62714427|NCT06373666|EXPERIMENTAL|Spatz4 Balloon|Subject will be implanted with the Spatz4 gastric balloon for a period of up to 12 months. At 16 weeks an up adjustment will performed to evaluate the adjustment function.
62714742|NCT02987257|PLACEBO_COMPARATOR|Harmonized supportive care|Harmonized supportive care with etanercept placebo days 1 and 4
62160497|NCT06564142|EXPERIMENTAL|Povetacicept|Participants will be randomized to receive Povetacicept.
62160498|NCT06564142|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive placebo matched to Povetacicept.
62160499|NCT04908488|OTHER|P1fA, then AMfA|Verofilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62160500|NCT04908488|OTHER|AMfA, then P1fA|Etafilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
62160501|NCT00705172||A|
62160502|NCT01153997|EXPERIMENTAL|A|
62160503|NCT01153997|EXPERIMENTAL|B|
62160504|NCT01153997|PLACEBO_COMPARATOR|C|
62160505|NCT01153997|PLACEBO_COMPARATOR|D|
62160506|NCT01755130|EXPERIMENTAL|Diagnostic (LOUISA 3D)|Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.
62160507|NCT05650437|ACTIVE_COMPARATOR|Ultraviolet therapy group|35 women will undergo three weekly sessions of UV therapy in addition to routine aerobic activity and vitamin D supplements (800 IU) daily for three months
62160508|NCT05650437|ACTIVE_COMPARATOR|Non Ultraviolet therapy group|35 women will undergo three weekly sessions of routine aerobic activity and vitamin D supplements (800 IU) daily for three months
62160509|NCT06096506|EXPERIMENTAL|Intervention clinics|Participants will be recruited from those receiving care at University of Texas (UT) Physician Clinics serving the Acres Homes neighborhood in Houston
62160510|NCT06096506|NO_INTERVENTION|Control Clinics|Participants will be recruited from UT Physicians clinics outside of the Acres Homes service area
62160511|NCT03335722|ACTIVE_COMPARATOR|Active TDCS and Fluency Intervention|Participants will receive 1-milliamp (mA) tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
62160512|NCT03335722|SHAM_COMPARATOR|Sham TDCS and Fluency Intervention|Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
62160513|NCT06695988|EXPERIMENTAL|Time Restricted Eating Group|The TRE group will consume calorie-containing food and drinks only over an 8-hour window between 6 a.m. to 8 p.m. for 8 weeks. During the fasting period, they can take only calorie-free fluids.
62160514|NCT06695988|NO_INTERVENTION|Control|They will follow their usual eating patterns and consume food over a period of 12 hours or more.
62714743|NCT02987257|ACTIVE_COMPARATOR|Etanercept 50mg sc day 1 and day 4|Harmonized supportive care with placebo days 1 and 4
62714744|NCT04155476|EXPERIMENTAL|Nitroglycerin exposure|
62714745|NCT04155476|PLACEBO_COMPARATOR|Non-Nitroglycerin exposure|
62160515|NCT05563961|ACTIVE_COMPARATOR|Panadol|• Cohort 1- 6 Subjects to receive oral Panadol® 4,000 mg (2 tablets Q6H, 4 dosages, 8 tablets or 4,000 mg)
62534115|NCT01273935||Responder|Responder versus Non-Responder as a result of platelet function test
62534116|NCT01273935||Non-Responder|According to the result of platelet function test
62534117|NCT01085734|ACTIVE_COMPARATOR|Group 1|Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema
62534118|NCT01085734|ACTIVE_COMPARATOR|Group 2|Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema
62714428|NCT06546462|EXPERIMENTAL|Osteopathic Manipulation arm|"* All subjects receive osteopathic structural exam and screening for somatic dysfunction of the cranium, spine, sacrum, and ribs.~* The OMT arm will have the following techniques performed for the stated time to total 14 minutes.~  1. Thoracic inlet release: 45 seconds maximum~ 2. Suboccipital release: 1 minute maximum~ 3. Occipito-mastoid suture release: 1 minute maximum~ 4. Venous sinus drainage: 1 minute maximum~ 5. Balanced membranous tension: 1 minute maximum~ 6. Compression of the 4th Ventricle (CV4): 1 minute maximum~ 7. Cervical soft tissue: 1 minute maximum~ 8. Trapezius inhibition: 45 seconds maximum~ 9. Bilateral rib raising: 2 minutes max (1 min per side)~ 10. Sacroiliac gapping: 1 minute maximum~ 11. Sacral rock: 1 minute maximum~ 12. Seated bilateral thoracic and lumbar paraspinal articulation: 2 minutes maximum"
62714429|NCT06546462|SHAM_COMPARATOR|Sham Light touch arm|"* All subjects receive osteopathic structural exam and screening for somatic dysfunction of the cranium, spine, sacrum, and ribs..~* The sham group will follow an established protocol of light systematic touch for the same duration as the OMT group. It consists of contacting a sequence of anatomical areas for 2 minutes each: right ankle, left knee, right hip, diaphragm, right shoulder, neck, and cranium. Total procedure time is 14 minutes."
61976004|NCT02685020|PLACEBO_COMPARATOR|Group 2B|Participants will receive placebo at weeks 0, 12 and 24.
61976005|NCT02685020|EXPERIMENTAL|Group 3A|Participants will receive Ad26.Mos.HIV vaccine at Week 0; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 8 and 24.
61976006|NCT02685020|PLACEBO_COMPARATOR|Group 3B|Participants will receive placebo at weeks 0, 8 and 24.
61976007|NCT02129725|EXPERIMENTAL|sildenafil citrate|In the parent study, subjects are randomized to sildenafil 25 mg tid.
61976008|NCT02129725|PLACEBO_COMPARATOR|placebo oral capsule|In the parent study, subjects are randomized to matching placebo
61976009|NCT01122706|EXPERIMENTAL|Taiji|35 healthy participants will regularly during 12 weeks attend Taiji training classes twice a week for one hour. (Sept. 6th till Nov. 25th 2010).
61976010|NCT01122706|NO_INTERVENTION|waiting list control group|35 healthy participants are not allowed to attend any Taiji training during the intervention period (Sept. 6th till Nov. 25th 2010).
61976011|NCT01863212|EXPERIMENTAL|Risk allele carriers|Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
61976012|NCT01863212|EXPERIMENTAL|Non risk allele carriers|Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
61976013|NCT04646707|EXPERIMENTAL|Study group|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
61976014|NCT04646707|PLACEBO_COMPARATOR|Placebo Group|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
61976015|NCT03395886||remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
61976016|NCT03395886||dexmedetomidine group|Eligible patients will receive a continuous infusion of dexmiditomidine starting with 0.5 μg/kg/h. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 1 μg/kg/h.
61976017|NCT03259854|ACTIVE_COMPARATOR|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
61976018|NCT03259854|EXPERIMENTAL|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
61976019|NCT00543348|ACTIVE_COMPARATOR|1|CUTTING BALLOON ANGIOPLASTY
61976020|NCT00543348|PLACEBO_COMPARATOR|2|Balloon angioplasty with a high pressure balloon
61976021|NCT04405986|EXPERIMENTAL|Electrophysiological procedure|Brainstem reflexes and neural conduction will be explored using Auditory Evoked Potentials (AEP) and blink and Masseter Inhibitory Reflex (MIR) in hospitalised patients with COVID infection
61976022|NCT01866501|EXPERIMENTAL|Blended Technique|Using the blended technique device operators will establish proximal humerus intraosseous vascular access.
61976023|NCT01548482|EXPERIMENTAL|Treatment (trebananib, temsirolimus)|Patients receive trebananib IV over 60 minutes and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61976024|NCT01913912|ACTIVE_COMPARATOR|Lisdexamfetamine dimesylate (LDX)|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the optimal dose of LDX will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking LDX at the DRUG unit.
61976025|NCT01913912|PLACEBO_COMPARATOR|Sugar pill|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the placebo will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking placebo at the DRUG unit.
61976026|NCT04635215||Participants|There are not multiple groups in this study
61976027|NCT01220947|EXPERIMENTAL|Group A|Danoprevir 200 mg twice a day (BID) + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
62534119|NCT02828241|EXPERIMENTAL|DFD-04 Ointment|DFD-04 (Itraconazole) Ointment
62534120|NCT02828241|PLACEBO_COMPARATOR|Placebo Ointment|Placebo Ointment
62534121|NCT02065856|EXPERIMENTAL|AVANZ Salsola kali|Subcutaneous immunotherapy
62534122|NCT02875964|EXPERIMENTAL|registration of intracerebral activity|epileptic patient receiving implantation of intracranial electrodes
62534123|NCT06182761|EXPERIMENTAL|sunvozertinib in combination with Anlotinib|
62534124|NCT02913092|EXPERIMENTAL|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed and responded to (e.g. outreach worker contacts the participant for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide asthma education over the phone
62534125|NCT02913092|NO_INTERVENTION|Usual Care|Usual care group will receive the electronic tracker but the sensor-generated alerts will not be delivered. If the usual care group rescue inhaler data reveals frequent use of rescue medication (daily use for \>3 days) investigators will reach out (via app or phone call) to advise the participant to see their physician
62534126|NCT00935610|ACTIVE_COMPARATOR|Immunocal|20g of Immunocal
62534127|NCT00935610|PLACEBO_COMPARATOR|Casein|20g of Casein
62534128|NCT05146297|ACTIVE_COMPARATOR|Patient Participants|Patients with invasive breast, prostate or liver cancer, who face a treatment decision
62534129|NCT05146297|ACTIVE_COMPARATOR|Physician Participants|Oncologists, and advanced practitioners caring for patients with breast, prostate, liver cancer including medical, surgical, radiation oncologists, interventional radiologists, urologists \& hepatologists
62534130|NCT01507363|ACTIVE_COMPARATOR|"Gabapentin high"|Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
62534131|NCT01507363|ACTIVE_COMPARATOR|"Gabapentin intermediate"|Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
62534132|NCT01507363|PLACEBO_COMPARATOR|Placebo|Placebo tablets for 7 days, starting on the day of surgery
62534133|NCT03963986|ACTIVE_COMPARATOR|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
62534134|NCT03963986|NO_INTERVENTION|STANDARD group|The STANDARD group participants dont receive an access to an online digital platform but they receive an adapted advice sheet.
62714430|NCT00956891||group A|autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)
62160516|NCT05563961|EXPERIMENTAL|SafeTynadol®|"* Cohort 2- 6 Subjects to receive oral SafeTynadol® 4,000 mg (2 tablets Q6H, 4 dosages, 8 tablets or 4,000 mg)~* Cohort 3- 6 Subjects to receive oral SafeTynadol® 4,500 mg (3 tablets at first dosage and 2 tablets at second to forth dosage Q6H, 4 dosages, 9 tablets or 4,500 mg)~* Cohort 4- 6 Subjects to receive oral SafeTynadol® 5,000 mg (3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H, 4 dosages, 10 tablets or 5,000 mg)~* Cohort 5- 6 Subjects to receive oral SafeTynadol® 6,000 mg (3 tablets Q6H, 4 dosages, 12 tablets or 6,000 mg)~* Cohort 6- 6 Subjects to receive oral SafeTynadol® 8,000 mg (4 tablets Q6H, 4 dosages, 16 tablets or 8,000 mg)~* Cohort 7- 6 Subjects to receive oral SafeTynadol® 10,000 mg (5 tablets Q6H, 4 dosages, 20 tablets or 10,000 mg)~* Cohort 8- 6 Subjects to receive oral SafeTynadol® 12,000 mg (6 tablets Q6H, 4 dosages, 24 tablets or 12,000 mg)"
62160517|NCT04445246|EXPERIMENTAL|Inhaled Iloprost therapy|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization
62160518|NCT02181192|EXPERIMENTAL|delayed radiotherapy|PET/CT and Radiotherapy after achievement of PSA marginal value Additive imaging
62160519|NCT02181192|ACTIVE_COMPARATOR|instant radiotherapy|Instant Radiotherapy according to guidelines
62160520|NCT04764695|EXPERIMENTAL|Patients diagnosed with HM|As it is a pre-test / post-test design, the child himself will be the control at the end of the study. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.
62160521|NCT00635752|EXPERIMENTAL|1|Participants will receive trauma-focused cognitive behavioral therapy (TF-CBT)
62160522|NCT00635752|ACTIVE_COMPARATOR|2|Participants will receive sessions of treatment as usual (TAU)
62534135|NCT00372411|EXPERIMENTAL|Arm 1|Robot-Assisted Therapy - MIT-MANUS System
62160523|NCT04831398|PLACEBO_COMPARATOR|Placebo|Placebo (PLA) is 10 sublingual sprays of a diluted (1 microliter/29ml filtered water) mint extract.
62160524|NCT04831398|EXPERIMENTAL|Melatonin|5mg commercially available melatonin (MEL) spray will be given sublingually.
62160525|NCT02368288|EXPERIMENTAL|entecavir with PEG-IFN a-2a|after enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks.
62534136|NCT00372411|ACTIVE_COMPARATOR|Arm 2|Intensive Comparison Therapy
62534137|NCT00372411|OTHER|Arm 3|Usual Care
62534138|NCT03516110||Prostate cancer subjects 60-<70 years|
62534139|NCT03516110||Prostate cancer subjects 70-<75 years|
62534140|NCT03516110||Prostate cancer subjects ≥ 75 years|
62534141|NCT02549027|EXPERIMENTAL|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
62714431|NCT00956891||group B|only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation.
62714432|NCT06716216|EXPERIMENTAL|Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.|Drug: BGM0504 Administered SC
62160526|NCT02368288|NO_INTERVENTION|peginterferon alpha 2a|in this group, patients will be continue treated only with PEG-IFN a-2a for 48 weeks after enrolled.
62160527|NCT03094143|EXPERIMENTAL|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
62160528|NCT03094143|NO_INTERVENTION|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
62160529|NCT03094143|NO_INTERVENTION|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
62160530|NCT03094143|NO_INTERVENTION|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
62160531|NCT02076802||lifestyle counseling|physical exercises
62160532|NCT04417907|PLACEBO_COMPARATOR|Placebo|Participants will take 2mg placebo PO QD for six weeks.
62160533|NCT04417907|EXPERIMENTAL|PER 1 Week Titration|Participants will take 2mg perampanel PO QD for one week, followed by 4mg perampanel PO QD for five weeks.
62160534|NCT04417907|EXPERIMENTAL|PER 2 Week Titration|Participants will take 2mg perampanel PO QD for two weeks, followed by 4mg perampanel PO QD for four weeks.
62160535|NCT04417907|EXPERIMENTAL|PER 4 mg|Participants will take 4mg perampanel PO QD for six weeks
62160536|NCT06719583||Participants with Parkinson's Disease|Data collected from these participants include demographic information and family health history. Participants may also complete a physical exam. Participants also complete a smell test and contribute a blood or saliva sample for genetic analyses.
62160537|NCT06719583||Control Participants|Data collected from these participants include demographic information and family health history. Participants also complete a smell test and contribute a blood or saliva sample for genetic analyses.
62160538|NCT01524887|EXPERIMENTAL|IGIV, 10% at high dose (0.4 g/kg)|
62160539|NCT01524887|EXPERIMENTAL|IGIV, 10% at low dose (0.2 g/kg)|
62160540|NCT01524887|PLACEBO_COMPARATOR|Placebo control|
62160541|NCT05217758|EXPERIMENTAL|Mifepristone|Glucocorticoid Receptor (GR) blockade using the generic drug mifepristone
62160542|NCT05217758|PLACEBO_COMPARATOR|Placebo|
62160543|NCT01786551|EXPERIMENTAL|Eplerenone|Eplerenone 50 mg daily for 14 days
62160544|NCT03807947|EXPERIMENTAL|Radial access|
62160545|NCT03807947|ACTIVE_COMPARATOR|Transfemoral Access|
62160546|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
62160547|NCT05540951|EXPERIMENTAL|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
62160548|NCT05540951|ACTIVE_COMPARATOR|BEV|Bevacizumab Plus Chemotherapy
62160549|NCT06721455||Children having heart surgery|Children under 18 years of age having heart surgery with cardio-pulmonary bypass at Boston Children's Hospital
62160550|NCT05026177|PLACEBO_COMPARATOR|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks
62160551|NCT05026177|EXPERIMENTAL|Simufilam 50 mg|Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
62160552|NCT05026177|EXPERIMENTAL|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
62160553|NCT05957276||Participants With Inherited Retinal Diseases (IRDs)|Adult and pediatric (greater than or equal to \[\>=\] 3 years) participants with a documented genetic diagnosis of X-linked retinitis pigmentosa (XLRP) or Achromatopsia (ACHM) and any signs or symptoms of IRD or documented retinal changes detected by imaging or electrophysiology.
62160554|NCT04904302|EXPERIMENTAL|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62160555|NCT02769390|NO_INTERVENTION|Bupivacaine 0,166%|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% for hypospadia surgery
62160556|NCT02769390|ACTIVE_COMPARATOR|Clonidine 1 mcg/Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 1 mcg/ Kg of clonidine for hypospadia surgery
62160557|NCT02769390|ACTIVE_COMPARATOR|Clonidine 2 mcg/ Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 2 mcg/ Kg of clonidine for hypospadia surgery
62160558|NCT02769390|ACTIVE_COMPARATOR|Clonidine 3 mcg/Kg|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 3 mcg/ Kg of clonidine for hypospadia surgery
62160559|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
62160560|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
62160561|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
62160562|NCT03188978|EXPERIMENTAL|Treatment|Atorvastatin 40mg once daily orally for 8 weeks starting 2 weeks before AVF creation
62160563|NCT03188978|PLACEBO_COMPARATOR|Placebo|1 tablet once daily orally for 8 weeks starting 2 weeks before AVF creation
62160564|NCT06270004|ACTIVE_COMPARATOR|nonsmoker periodontitis patients|
62160565|NCT06270004|ACTIVE_COMPARATOR|smoker periodontitis patients|cigarette smoker more the three years ago
62714433|NCT06716216|EXPERIMENTAL|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.|Drug: BGM0504 Administered SC
62160566|NCT06389071|ACTIVE_COMPARATOR|Treatment + PRP Arm|
62160567|NCT06389071|ACTIVE_COMPARATOR|Treatment only Arm|
62160568|NCT02854709|NO_INTERVENTION|Control|Continue with habitual sleep duration
62160569|NCT02854709|EXPERIMENTAL|Intervention|Sleep extension
62714434|NCT06716216|ACTIVE_COMPARATOR|Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week|Drug: Semaglutide Administered SC
62534142|NCT02549027|EXPERIMENTAL|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
62534143|NCT02549027|EXPERIMENTAL|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
62534144|NCT02549027|EXPERIMENTAL|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
62534145|NCT03482700|OTHER|Intervention|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
62534146|NCT03482700|OTHER|Control|Usual standard of care
62534147|NCT00307437|PLACEBO_COMPARATOR|Group I: Placebo|
62534148|NCT00307437|EXPERIMENTAL|Group II: Ustekinumab 45 mg|
62534149|NCT00307437|EXPERIMENTAL|Group III: Ustekinumab 90 mg|
62534150|NCT06112392|EXPERIMENTAL|Parkinson's disease group|"Diagnostic criteria: Patients with Parkinson's disease who met the diagnostic criteria for MDS as probable PD or confirmed PD in 2016~Inclusion criteria:~1. Age 40-85;~2. Patients with Parkinson's disease who met the diagnostic criteria of MDS as probable PD or confirmed PD in 2016;~3. The patient or his/her legal guardian agrees to participate in the study and signs the informed consent;~4. Hoehn-yahr (H\&Y) 3 \~ 5;"
62534151|NCT06112392|EXPERIMENTAL|Non-parkinson's disease group|"Exclusion criteria:~1. Allergic to local anesthetic drugs;~2. Unable to cooperate with motor or non-motor function monitoring;~3. Patients with Parkinson's superposition syndrome, such as cortical basal ganglia degeneration, lewy body dementia, multisystem atrophy and progressive supranuclear palsy, were excluded; Patients with secondary Parkinson's disease, such as vascular Parkinson's disease, drug toxicity or traumatic Parkinson's disease;~4. Refuse to sign the consent form."
62534152|NCT06187558||Pelvic Organ Suspension Patients|This group comprises patients who have undergone multiport or single-port access laparoscopic surgery (SPAL) at the Tertiary referral University Hospital of Cagliari, Italy. These patients suffer from benign (like endometriosis, pelvic prolapse) or malignant (like endometrial cancer) gynecological diseases. During their surgery, they have experienced at least one instance of the described pelvic organ suspension technique using an adjustable tension suture tied to a Foley catheter fragment for organ suspension.
62160570|NCT00914732|EXPERIMENTAL|Group B, liquid, subcutaneous|Group B: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) liquid formulation by the subcutaneous route on Day 0 and 28.
62160571|NCT00914732|EXPERIMENTAL|Group C, liquid, intradermal|Group C: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (2x10\^7 TCID50/0.1mL per dose) liquid formulation by the intradermal route on Day 0 and 28.
62160572|NCT00914732|EXPERIMENTAL|Group A, lyophilized, subcutaneous|Group A: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) lyophilized formulation by the subcutaneous route on Day 0 and 28.
62714435|NCT05907811|SHAM_COMPARATOR|Group general anesthesia (GA)|Anesthesia induction was applied to all patients with 1mg/kg lidocaine, 1μcg/kg fentanyl, 2mg/kg propofol, 0.6mg/kg rocuronium. When the TOF value was 0, the patients were intubated with an endotracheal tube. In the maintenance, desflurane at 8% concentration was used in a mixture of 50% O2 + 50% air. The time to reach 25% of the TOF value was noted in both groups. 0.1mg/kg rocuronium will be added to patients who reach 0.25.It was planned to administer 0.05mg/kg morphine 30 minutes before the end of the operation to the GA group.
62714746|NCT04234568|EXPERIMENTAL|Treatment (lutetium Lu 177 dotatate, triapine)|Patients receive lutetium Lu 177 dotatate IV for 30 to 40 minutes on day 1 of each cycle and triapine PO on days 1 throughout 14 of each cycle. Cycles repeat every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI scan throughout the trial. Patients undergo blood specimen collection on study.
62714747|NCT01143220||ICD / CRT-D patient|Patients implanted with a single or dual chamber ICD or CRT-D device approved in Japan capable of using the IBP feature.
62714748|NCT00736983|ACTIVE_COMPARATOR|1|Adalimumab
61976028|NCT01220947|EXPERIMENTAL|Group B|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
62160573|NCT02400372|EXPERIMENTAL|research group|Medihoney Dressing
62160574|NCT02400372|NO_INTERVENTION|control group|Paraffin gauze with saline Dressing
62160575|NCT02400372|NO_INTERVENTION|3. Comparison group|Polymem dressing
62160576|NCT01461967|EXPERIMENTAL|Part 1a|
62160577|NCT01461967|PLACEBO_COMPARATOR|Part 1b|
62160578|NCT01461967|EXPERIMENTAL|Part 2|
62534153|NCT01759732|EXPERIMENTAL|HAPLO|
62160579|NCT02659176|ACTIVE_COMPARATOR|Transperineal repair with PIS|transperineal repair of anterior rectocele with limited internal sphincterotomy
62160580|NCT02659176|ACTIVE_COMPARATOR|Transperineal repair without PIS|transperineal repair of anterior rectocele only
62160581|NCT04471428|EXPERIMENTAL|Atezolizumab + Cabozantinib|Participants received atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on Days 1-21 of each cycle.
62160582|NCT04471428|ACTIVE_COMPARATOR|Docetaxel|Participants received docetaxel on Day 1 of each 21-day cycle.
62160583|NCT00402298|EXPERIMENTAL|Full dose (125 mg) MDMA-assisted therapy|Participants will receive an initial dose of 125 mg MDMA followed 2.5 hours later by a supplemental dose of 62.5 mg MDMA during the course of two day-long therapy sessions.
62160584|NCT00402298|ACTIVE_COMPARATOR|Active Comparator (25 mg) MDMA-assisted therapy|Participants will receive an initial dose of 25 mg MDMA followed 2.5 hours later by a supplemental dose of 12.5 mg MDMA during the course of two day-long therapy sessions.
62160585|NCT05433129|OTHER|Block Testing|Perturbations to the system will be investigated through a series of testing (block design separated by baseline rest): A. transient hyperemic response testing via carotid compression methods, B. orthostatic challenge responses (lying-to-sit, sit-to-stand),8 C. vascular chemo-reactivity via fast and slow breathing exercises and D. impact of neurovascular coupling through cognitive/Stroop testing. Work here will establish areas for improvement in real time.
62160586|NCT06611423|EXPERIMENTAL|IV Saline placebo followed by SC AZD3427|Participants will receive IV administration of saline only placebo prior to a PET examination. This is followed by a single SC dose of AZD3427 on Day 1 (V2).
62160587|NCT06611423|PLACEBO_COMPARATOR|IV Saline placebo followed by SC AZD3427 placebo|Participants will receive IV administration of saline only placebo prior to a PET examination. This is followed by a single SC dose of AZD3427 Placebo on Day 1 (V2).
62160588|NCT06611423|EXPERIMENTAL|IV Dopamine diluted in saline followed by SC AZD3427|Participants will receive IV administration of dopamine diluted in saline prior to a PET examination. This is followed by a single SC dose of AZD3427 on Day 1 (V2)
62160589|NCT06611423|PLACEBO_COMPARATOR|IV Dopamine diluted in saline followed by SC AZD3427 placebo|Participants will receive IV administration of dopamine diluted in saline prior to a PET examination. This is followed by a single SC dose of AZD3427 Placebo on Day 1 (V2).
62160590|NCT05572515|EXPERIMENTAL|Teclistamab|Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2.
62160591|NCT05572515|EXPERIMENTAL|Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)|Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study.
62160592|NCT01345253|EXPERIMENTAL|Belimumab|10mg/kg
62160593|NCT01345253|PLACEBO_COMPARATOR|Placebo|placebo
62160594|NCT03809871|EXPERIMENTAL|Biomarker group|These participants will receive information about cardiometabolic biomarkers pre and post weight management course
62160595|NCT03809871|NO_INTERVENTION|Control group|They will receive the same weight management programme as the experimental group, but they will not have biomarker information.
62160596|NCT06036485|EXPERIMENTAL|Kerecis Omega 3|
62160597|NCT06036485|ACTIVE_COMPARATOR|Surgical debridement|
62160598|NCT05338775|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive either talquetamab (treatment regimen A) or teclistamab (treatment regimen B) with a PD-1 inhibitor biweekly.
62534154|NCT04359511|EXPERIMENTAL|corticosteroid + Optimized Standard of Care|"* prednisone 0.7 mg/kg/day for 10 days, administered orally, once a day, or~* hydrocortisone hemisuccinate 3.5 mg/kg/day by continuous infusion for 10 days, administered by IV route if the patient cannot take drugs by oral route,~  * standard of care"
62534155|NCT04359511|NO_INTERVENTION|Optimized Standard of Care|standard of care
62534156|NCT05910476|ACTIVE_COMPARATOR|rosuvastatin/ezetimibe 20/10mg|rosuzet 10/20mg
62534157|NCT05910476|ACTIVE_COMPARATOR|atorvastatin/ezetimibe 40/10mg|NB zet 10/40mg
62534158|NCT03828513|ACTIVE_COMPARATOR|High flow nasal cannula oxygen applied|High flow nasal cannula oxygen is start at a flow rate of 80 L/min with 100% oxygen in the preoperative period.
62534159|NCT03828513|ACTIVE_COMPARATOR|High flow nasal cannula oxygen is not applied|Preoxygenation will be applied with an oxygen supplement of 5 l/min to an endtidal O2\> 90%.
62534160|NCT05512637||neurodevelopmental disorders|"Step 1 - Screening: the targeted sample is the siblings of the autistic children, these siblings being at risk of neurodevelopmental disorders.~Step 2 - Clinical interview: All the children with a positive screening."
62534161|NCT02258854|EXPERIMENTAL|Dose 2 gevokizumab|
62534162|NCT00936897|ACTIVE_COMPARATOR|Ibandronate|Ibandronate 150mg PO QM (tablet)
62714749|NCT00736983|PLACEBO_COMPARATOR|2|ciprofloxacin
62534163|NCT00936897|EXPERIMENTAL|Denosumab|denosumab 60mg Subcutaneous Q6M (pre-filled syringe)
61976029|NCT01220947|EXPERIMENTAL|Group C|Danoprevir 50 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
62160599|NCT05338775|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive either treatment regimen A or treatment regimen B with a PD-1 inhibitor at the dose levels identified in Part 1.
62160600|NCT01195987||Hepatitis C with Arthritis|
62160601|NCT01195987||Hepatitis C without Arthritis|
62160602|NCT02720783|EXPERIMENTAL|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg|One vaginal pessary (2.7 g) of Econazole nitrate 150 mg plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
62160603|NCT02720783|ACTIVE_COMPARATOR|Placebo plus Econazole nitrate 150 mg|One vaginal pessary (2,7 g) of Placebo plus Econazole nitrate 150 mg, once daily, for 3 consecutive days
62160604|NCT02720783|ACTIVE_COMPARATOR|Placebo plus Benzydamine HCl 6 mg|One vaginal pessary (2,7 g) of Placebo plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
62160605|NCT02720783|PLACEBO_COMPARATOR|Placebo|One vaginal pessary (2.7 g) of Placebo, once daily, for 3 consecutive days
62160606|NCT06584760||Endometriosis group|Patients undergoing endometriosis surgery in the gynecology department of the Fourth Affiliated Hospital of Zhejiang University School of Medicine
62160607|NCT03152474|ACTIVE_COMPARATOR|Solumedrol 20mg|Solumedrol injection will be given in the vein every 8 hrs. for 7 days.
62160608|NCT03152474|ACTIVE_COMPARATOR|Vitamin A 100,000 IU|Vitamin A injection will be given in the arm muscle for 7 days.
62160609|NCT03152474|PLACEBO_COMPARATOR|Placebo|Placebo will be given in the vein every 8 hrs. for 7 days or given in the arm muscle for 7 days.
62534164|NCT03507023|PLACEBO_COMPARATOR|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 6 weeks.
62534165|NCT03507023|EXPERIMENTAL|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 6 weeks.
62714750|NCT05772325|ACTIVE_COMPARATOR|Brief standardized dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists.
62160610|NCT06720883||Patients affected by pCCA requiring curative intent robotic surgery with biliary reconstruction|All patients affected by pCCA candidate for curative intent robotic liver resection with biliary reconstruction will be enrolled in the study after the work up for surgery. Preoperative, intraoperative and postoperative data will be collected. The DaVinci® robotic platform available at the Padova University hospital will be utilised primarily. We will include patients with age≥18 years, with histologically proven pCCA or highly presumed bile duct malignancy with difficulties to obtain histological evidence with negative Immunoglobulin G4 (IgG4 sample). We will not include patients with distant metastases, previous radiotherapy, vascular encasement, ASA score\>4, synchronous malignancy in other organs or indication for palliative surgery
62160611|NCT06533111|EXPERIMENTAL|Epic Health Record semi-structured handoff cognitive aid|
62160612|NCT06533111|ACTIVE_COMPARATOR|Usual care|
62160613|NCT05549102||Treatment Group|Participants undergoing a course of Cognitive Behavioural Therapy (CBT)
62160614|NCT05549102||Waiting List Group|Participants on the Waiting List for CBT
62160615|NCT06528314|EXPERIMENTAL|EFX 50 mg|
62160616|NCT06528314|PLACEBO_COMPARATOR|Placebo|
62160617|NCT06095089|EXPERIMENTAL|Part 1 (Dose Escalation) and Part 2 (Dose Expansion)|Participants will receive JNJ-78278343+JNJ-87189401 escalated sequentially in Part 1 to select a recommended Phase 2 regimen (RP2R). Participants will receive the combination treatment at the RP2R in Part 2 (dose expansion).
62160618|NCT02122354|EXPERIMENTAL|Survey + videogame|"Hide and Seek videogame"
62160619|NCT03842189|EXPERIMENTAL|M281|
62160620|NCT05021185|EXPERIMENTAL|Interactive Mobile Doctor (iMD) Intervention|Participants will receive up to a total of 3 iMD sessions prior to their completion of radiation therapy; each session will take about 10-15 minutes and includes: 1) computerized assessments that will be delivered on the screen via text with accompanying audio and participants will respond directly on the tablet 2) tailored videos that deliver messages specific to patient's responses to selected assessment questions and 3) a summary printout
62160621|NCT05021185|NO_INTERVENTION|Control Group|Participants will complete questionnaires and receive a handout containing tobacco cessation resources.
62160622|NCT06721130||Treatment naive patients presenting with Cavernous Sinus Syndrome with cavernous sinus lesion on MRI|
62160623|NCT06166901|EXPERIMENTAL|AcrySof IQ PanOptix IOL - Non Toric|Implantation with AcrySof IQ PanOptix non toric IOL in both eyes 3-5 years prior to enrollment
62160624|NCT06166901|EXPERIMENTAL|AcrySof IQ PanOptix IOL - Toric|Implantation with AcrySof IQ PanOptix IOL in both eyes 3-5 years prior to enrollment, with at least one of the eyes implanted with a toric AcrySof IQ PanOptix IOL
62160625|NCT05554991|EXPERIMENTAL|Liquid oral supplement comprising HMO|2 ampules/day for 21 days
62160626|NCT05554991|PLACEBO_COMPARATOR|Placebo|2 ampules/day for 21 days
62160627|NCT06720636|EXPERIMENTAL|Study group|Subjects will receive the EndoSign test prior to their scheduled clinically indicated upper endoscopy by an expert endoscopist, per routine standard of care. Additional biopsies will be taken and 10cc of blood will be collected from the cannula used for sedation. Subjects will also receive three questionnaires regarding baseline characteristics, gastrointestinal symptoms and acceptability.
62160628|NCT05534854||Patient with heritable kidney cancer syndrome|Patients with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
62160629|NCT05534854||Family members of heritable kidney cancer syndrome|Family members (related by blood) of patients who have or are suspected of having heritable kidney cancer syndromes, including VHL and HLRCC Disease.
62714751|NCT05772325|EXPERIMENTAL|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian.
62714752|NCT01750125||Healthy subjects|In these health subjects we will measure ascending aortic blood flow with pulse wave Doppler and also record the raw audio of the Doppler signal
62714753|NCT03875638|EXPERIMENTAL|Early Alzheimer's Disease Group Low Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of low-dose levetiracetam (125 mg twice daily)
62160630|NCT05534854||Not proven genetic etiology|Patients and biologic family members with a heritable kidney cancer syndrome of suspected, but not proven genetic etiology.
62160631|NCT05144243|EXPERIMENTAL|Venetoclax in Combination with Azacitidine|Participants will receive oral tablet venetoclax dose ramp-up only in Cycle 1 Days 1-3 until target dose is reached. Particpants will then receive oral tablet venetoclax at the target dose every day (QD) on Cycle Days 1 - 28 plus Azacitidine through subcutaneous injection (SC) QD on Cycle Days 1 - 7 (28-day cycle).
62160632|NCT06022406|EXPERIMENTAL|FMT capsules|"10 participants taking FMT. The study product consists of fecal microbiota capsules prepared by Dr. Silverman's team in London, Ontario, Canada. Dr. Silverman has received approval from Health Canada to evaluate FMT in patients with metastatic malignant melanoma or with fatty liver within a clinical trial setting (CTA control nos. 235387and 195078 respectively).~Approximately 30 to 40 capsules will be prepared from 80-100g of healthy human feces from a single healthy donor and administered as a single dose. Capsules will be prepared by a modified method as described by Kao et al, 201747,48 (see Investigator brochure)."
62160633|NCT06022406|PLACEBO_COMPARATOR|Placebo capsules|10 participants taking Placebo. Placebo capsules contain microcrystalline cellulose, for equivalence in weight and color that will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
62160634|NCT05518149|EXPERIMENTAL|Aticaprant 10 mg|Participants will enter this study directly or after completing double-blind phase of studies 67953964MDD3001 or 67953964MDD3002 and will receive Aticaprant 10 milligrams (mg), once daily, orally in addition to the current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy on Day 1 up to 52 weeks.
62160635|NCT04898634|EXPERIMENTAL|JNJ-78278343|Participants will receive JNJ-78278343. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 at recommended phase 2 dose (RP2D) as determined in Part 1.
62160636|NCT02112799|EXPERIMENTAL|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
62160637|NCT02112799|PLACEBO_COMPARATOR|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
62160638|NCT02112799|EXPERIMENTAL|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
62160639|NCT02112799|ACTIVE_COMPARATOR|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
62160640|NCT06720155|EXPERIMENTAL|Sleeper Stretch|
62160641|NCT06720155|ACTIVE_COMPARATOR|Control Group|
62160642|NCT04726319|EXPERIMENTAL|Intervention|In addition to usual care, patients will be asked to answer questions about any family history through the use of a questionnaire.
62160643|NCT04726319|NO_INTERVENTION|Usual Care|Patients receive usual care, which consists of health care providers inquiring about and dealing with family history as they would in usual practice.
62160644|NCT06187155|EXPERIMENTAL|INR-self management|"The participants will be responsible to monitor their INR regularly and adjust the warfarin dose by themselves accordingly, without seeking medical advice from medical personnel for 6 months.~All participants will receive full education class of minimum one-hour time and training about how to interpret INR levels and adjust their medication dose according to a pre-determined dose-INR schedule."
62160645|NCT06187155|NO_INTERVENTION|Standard of care|Regular INR monitoring and seeking medical advice at Aswan Heart Centre
62160646|NCT06377059|EXPERIMENTAL|WARD equipment alarms|alarms will notify the health personel that there is an abnormal vital sign, and the personel will act accordingly.
62160647|NCT02877680|EXPERIMENTAL|Intervention|Smartphone app for parents to track adolescents' strength behaviors related to living with and managing type 1 diabetes, including regular feedback to parents and training about how to recognize and reinforce positive behaviors in teens.
62160648|NCT02877680|NO_INTERVENTION|Usual Care|Usual diabetes care and study-related data collection, without use of app during the study period. They will be offered an opportunity to try the app and share their feedback with the study team after completing follow-up data collection.
62160649|NCT06372756||Standard dose group|Raw data from 400 patients with conventional dose head and neck CTA, coronary CTA, and abdominal CTA were included. Filtered back-projection, iteration, and deep learning reconstruction were performed. To evaluate the impact of deep learning reconstruction on image quality and diagnostic performance in patients with conventional dose CTA.
62160650|NCT06372756||Double low dose group|Raw data from 800 patients with low tube voltage and contrast medium head and neck CTA, coronary CTA, and abdominal CTA were included. Filtered back-projection, iteration, and deep learning reconstruction were performed. To evaluate the impact of deep learning reconstruction on image quality and diagnostic performance in patients with double-low-dose CTA.
62160651|NCT04882878|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids \[GCs\]).
62534166|NCT04290975|EXPERIMENTAL|Task-shifted arm|In the task-shifted arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a CHW, with a physician consult available to the CHW as needed.
62534167|NCT04290975|ACTIVE_COMPARATOR|Enhanced usual care arm|In the enhanced usual care arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a physician, with a CHW collecting standardized data to mirror that of the intervention arm.
62534168|NCT02826772|EXPERIMENTAL|Phase 1 GT0918 level 1|generic name: not applicable dosage form: tablet dosage: oral dosage to be determined dosage frequency: daily dosage duration: 6 months
62534169|NCT00683631||TheraSphere|TheraSphere
62714436|NCT05907811|EXPERIMENTAL|Group General anesthesia and Thoracal epidural (GAE)|Electrodes were placed for TOF monitoring after thoracic epidural catheterization in the GAE group. Anesthesia induction was applied to all patients with 1mg/kg lidocaine, 1μcg/kg fentanyl, 2mg/kg propofol, 0.6mg/kg rocuronium. When the TOF value was 0, the patients were intubated with an endotracheal tube. In the maintenance, desflurane at 8% concentration was used in a mixture of 50% O2 + 50% air. The time to reach 25% of the TOF value was noted in both groups. 0.1mg/kg rocuronium will be added to patients who reach 0.25.The number of additional muscle relaxant requirements made will be recorded. In the GAE group, 5 ml of epidural medication will be given per hour. When the TOF value reached 70%, inhaler anesthetics were discontinued and the patients with a TOF value of 90% were extubated.
62714437|NCT05833217|NO_INTERVENTION|Chart Review (not actively recruiting)|Chart review of previously consented participants from the entire NIH RECOVER cohort, comprised of 15,000 infected and 2,600 noninfected patients across the country.
62160652|NCT04882878|EXPERIMENTAL|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
62160653|NCT04882878|EXPERIMENTAL|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
62160654|NCT03386357|EXPERIMENTAL|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases.
62160655|NCT03386357|ACTIVE_COMPARATOR|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w) without radiotherapy
62160656|NCT04397276|EXPERIMENTAL|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
62160657|NCT04397276|EXPERIMENTAL|Part 2: Dose Expansion|Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.
62534170|NCT02934659|EXPERIMENTAL|Investigational|Intervention - Atlas Knee System device for medial knee osteoarthritis
62534171|NCT01840865|EXPERIMENTAL|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
62534172|NCT01840865|EXPERIMENTAL|0,75 Hz stimulation|slow transcranial oscillating stimulation (\~0,75Hz) during periods of Slow Wave Sleep
62534173|NCT05104190|EXPERIMENTAL|plastic wafers group|"In one arm/ group 1 (plastic wafers group), debonding was done by open mouth technique. All brackets were removed using same plier i.e. angled direct bracket remover. Figure pressure in the apical direction was applied concomitantly applied to stabilize each tooth. Loose cotton was used between thumb and tooth during debonding. Arch wires and ligatures were not removed during debonding.~Patient pain score during procedure was measured using visual analogue scale ranging from zero to one hundred (0-100) In"
62160658|NCT06602362|EXPERIMENTAL|Path 1 (choking involved sex prior to non-choking involved sex)|Path 1 will involve 3 data collection time points including baseline data collection, post choking involved sex data collection time point, and post non-choking involved sex time point, in that order. After enrollment, subjects will be sent a brief Qualtrics survey link once a day to determine when they are eligible for data collection based on their sexual activity within the last 24 hours. Subjects placed in the group following Path 1 will first come in for a baseline data collection which will occur after a 48 hour washout period of not engaging in partnered sex. Next, subjects will be asked to come in for an experimental data collection visit within the 24 hours post engaging in choking involved sex. Last, subjects will be asked to come in for an experimental data collection visit within 24 hours of engaging in sex that did not involve any choking.
62160659|NCT06602362|EXPERIMENTAL|Path 2 (non-choking involved sex prior to choking involved sex)|Path 2 will involve 3 data collection time points including baseline data collection, post non-choking involved sex time point, and post choking involved sex time point, in that order. After enrollment, subjects will be sent a brief Qualtrics survey link once a day to determine when they are eligible for data collection based on their sexual activity within the last 24 hours. Subjects placed in the group following Path 2 will first come in for a baseline data collection which will occur after a 48 hour washout period of not engaging in partnered sex. Next, subjects will be asked to come in for an experimental data collection visit within the 24 hours after engaging in sex that did not involve any choking. Last, subjects will be asked to come in for an experimental data collection visit within 24 hours of engaging in choking involved sex.
62160660|NCT06720103||lumbar spondylosis patients|one hundred thirty-two subjects (who have chronic lumbar spondylosis); from both genders will participate in this group.
62160661|NCT03976102|EXPERIMENTAL|Arm A: DRL_RI|DRL_RI (rituximab-Dr. Reddy's Lab) for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36
62160662|NCT03976102|ACTIVE_COMPARATOR|Arm B: MabThera®|MabThera® for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Week 12, 20, 28 and 36.
62160663|NCT00508547||Guselkumab|Participants will receive guselkumab as prescribed by a physician according to standard of care for psoriasis.
62160664|NCT00508547||Infliximab|Participants will receive infliximab as prescribed by a physician according to standard of care for psoriasis.
62160665|NCT00508547||Ustekinumab|Participants will receive ustekinumab as prescribed by a physician according to standard of care for psoriasis.
62534174|NCT05104190|EXPERIMENTAL|finger pressure group|In another arm/ group 2( finger pressure group) brackets were removed in the same way with the same debonding plier as in group 1 but soft acrylic sheets folded 4 times were placed between upper and lower dentition with the patient biting on this wafer. Wires and ligatures were left tied to brackets during debonding. After the procedure, patient was asked about pain using visual analogue scale.
62534175|NCT03388489|EXPERIMENTAL|Mind-Body Walking|breathing, walking and meditation
62534176|NCT03388489|NO_INTERVENTION|Usual care|maintain their daily activity
62534177|NCT04216667|ACTIVE_COMPARATOR|PVI|Pulmonary vein isolation alone will be performed using radiofrequency energy
62534178|NCT04216667|EXPERIMENTAL|PVI + PWI|Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
62534179|NCT04216667|EXPERIMENTAL|PVI + PWI + LAAEI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
62534180|NCT04216667|EXPERIMENTAL|PVI + PWI + LAAEI + CSI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy
62534181|NCT03220061|EXPERIMENTAL|experimental|music therapy was used in the study for 30 minutes
62714438|NCT05833217|EXPERIMENTAL|COVID infected and healthy controls|Participants will perform a needle fat biopsy for tissue harvesting in the subacute phase (15-30d) of Covid-19 infection or as a healthy control. Our goal is 20 COVID-19 infected participants and 10 healthy controls.
61976030|NCT01220947|EXPERIMENTAL|Group D|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 μg sc qw + Copegus 1000 mg or 1200 mg po daily for 12 weeks or 24 weeks
61976031|NCT01220947|ACTIVE_COMPARATOR|Group E|Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 48 weeks
61976032|NCT00536406|EXPERIMENTAL|A|Participants will receive the BE-ACTIV treatment
61976033|NCT00536406|ACTIVE_COMPARATOR|B|Participants will receive treatment as usual
61976034|NCT01857388|EXPERIMENTAL|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
61976035|NCT01857388|NO_INTERVENTION|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
61976036|NCT06248892|EXPERIMENTAL|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the relevant guidelines."
61976037|NCT06248892|ACTIVE_COMPARATOR|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the control group was given enteral nutritional support with nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation."
61976038|NCT04774107|EXPERIMENTAL|P1101 + Ribavirin|P1101 400 µg SC Ribavirin 800-1400 mg PO
61976039|NCT03966001||Planned Cesarean Group|Pregnant women undergoing a planned cesarean section at 38-42 gestational week.
61976040|NCT03966001||Emergency Cesarean Group|Pregnant women who are planning to give normal birth between 38-42 weeks of gestation but have to been performed an urgent cesarean section due to an emergency such as acute fetal distress, cephalo-pelvic disproportion or another obstetrical condition.
61976041|NCT01906151|OTHER|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
61976042|NCT02867787|EXPERIMENTAL|Botox arm|intramuscular injection of botulinum toxin
62160666|NCT00508547||Biological Therapies|Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
62160667|NCT00508547||Conventional Systemic Agents|Participants will receive conventional systemic agents as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
62534182|NCT03220061|NO_INTERVENTION|control|usual care was given to participant in control group
62534183|NCT01679639|EXPERIMENTAL|Aleglitazar|
62534184|NCT03634475|EXPERIMENTAL|PP-001|Single intravitreal injection of 3 up to 4 doses of PP-001
62534185|NCT05200000|EXPERIMENTAL|SygeLIX-Coll-T|Extract of umbilical cord lining constituted of Wharton's jelly put in suspension in microvials. Instillation by the patient in the sick eye of 1 drop 5 times a days (morning, noon, afternoon, evening and bedtime) for 40 days.
62534186|NCT01194986|EXPERIMENTAL|Pilot panel|\[11C\]AZ12807110 distribution and kinetics
62714439|NCT05833217|EXPERIMENTAL|Healthy Controls Only|"We are looking for 20 healthy controls for 2 in-person visits on separate days.~1. An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if the participant is insulin-sensitive or insulin resistant.~2. A Needle Fat Biopsy: After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Patients will have a local anesthetic prior to the procedure."
62714440|NCT06698003|EXPERIMENTAL|Cohort 1|Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses
62160668|NCT00508547||IL-17 Inhibitor|Participants will receive an IL-17 inhibitor as prescribed by a physician according to standard of care for psoriasis.
62160669|NCT03255785|EXPERIMENTAL|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
62160670|NCT06108050|EXPERIMENTAL|Part A1 Dose Exploration: JZP898 monotherapy|
62160671|NCT06108050|EXPERIMENTAL|Part A2 Dose Exploration: JZP898 in combination with pembrolizumab|
62160672|NCT06108050|EXPERIMENTAL|Part B Combination Expansion: JZP898 in combination with pembrolizumab|
62160673|NCT03458494|EXPERIMENTAL|Mediterranean Diet|during one week participants will receive food products common in the diet of Mediterranean populations
62160674|NCT03458494|EXPERIMENTAL|Low-fat diet|during one week participants will receive food products low in fat content
62160675|NCT05985525||Observational|All patients
62160676|NCT03188887|ACTIVE_COMPARATOR|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade or SGLT2i.
62160677|NCT03188887|EXPERIMENTAL|EXPERIMENTAL|Corticotherapy + RAS blockade or SGLT2i treatment. Drug injection (intravenous) + tablets
62160678|NCT06387576|NO_INTERVENTION|Arm 1: Status-quo post-discharge appointment scheduling process|Eligible, assigned participants will receive the current status-quo scheduling process for their post-discharge appointment (post-discharge via phone).
62160679|NCT06387576|EXPERIMENTAL|Arm 2: Pre-discharge iPad video scheduling for post-discharge appointment|Eligible, assigned participants will schedule their post-discharge appointment via a video scheduling process prior to discharge.
62160680|NCT06719921|EXPERIMENTAL|Non-Fluoroscopic Lab Group|Ablation procedures will utilize ICE and 3D mapping systems for non-fluoroscopic guidance. ICE is mandatory for real-time anatomical visualization.
62160681|NCT06719921|ACTIVE_COMPARATOR|Fluoroscopic Lab Group|Ablation procedures will be conducted in a fluoroscopic lab. The use of ICE, 3D EP mapping systems, and other tools will follow the same recommendations as in the non-fluoroscopic lab group. Radiation exposure will be closely monitored and minimized in accordance with the ALARA (As Low As Reasonably Achievable) principles when necessary.
62534187|NCT01194986|EXPERIMENTAL|Main panel|Histamine receptor occupancy reached by AZD5213
62534188|NCT06159777|EXPERIMENTAL|Pre-operative|Participants will be instructed to take 17 grams of powder Polyethylene glycol 3350 (PEG) every day starting 3 days prior to scheduled surgery date and continue to take 17 grams of PEG every day for 7 days following the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used.
62534189|NCT06159777|ACTIVE_COMPARATOR|Post-operative|Participants will be instructed to take 17 grams of powder PEG\* every day for 7 days starting the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used.
62534190|NCT00811356|EXPERIMENTAL|Single Dose, Repeat Dose, Drug-Drug Interaction|"GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121."
62534191|NCT02252991|OTHER|Arm A with physical activity during the treatment|In the arm A, patients will realise physical activity during the treatment. Blood samples will be realised. Questionnaries will be given to the patients.
62534192|NCT02252991|OTHER|Arm B with physical activity after the treatment|In the arm B, the physical activity will be realised after treatment. Blood samples will be realised. Questionnaries will be given to the patients.
62534193|NCT06429579|EXPERIMENTAL|Potts-shunt combined with conventional drug therapy group|The comprehensive therapy included Potts-shunt procedure and conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
62534194|NCT06429579|ACTIVE_COMPARATOR|Only conventional drug therapy group|Only admitted with conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
62534195|NCT01140503|EXPERIMENTAL|apremilast|apremilast 20mg bid
62714441|NCT06698003|EXPERIMENTAL|Cohort 2|Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
62714754|NCT03875638|EXPERIMENTAL|Early Alzheimer's Disease Group High Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of high-dose levetiracetam (500mg twice daily).
62160682|NCT05053555|EXPERIMENTAL|Group A (Prospective cohort )|20 patients, will undergo initial diagnostic workup, staging and treatment per institutional standard of care. Intervention: High dose rate brachytherapy (HDRBT)
62160683|NCT05053555|EXPERIMENTAL|Group B( Retrospective chart review )|40 patients who meet same eligibility criteria, but did not receive HDRBT between 1/1/2000 and 1/1/2021.
62160684|NCT04344899||Historical|Retrospective Review
62160685|NCT04344899||ERAS Patients|Prospective Review
62160686|NCT04276740|ACTIVE_COMPARATOR|MitoQ|Participants will take oral MitoQ 40 mg daily
62160687|NCT04276740|PLACEBO_COMPARATOR|Placebo|Participants will take an oral matched placebo daily
62160688|NCT05476770|EXPERIMENTAL|Part 1|"Tagraxofusp~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT)~* Day 1~* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
62160689|NCT05476770|EXPERIMENTAL|Part 2 - Cohort A|"Tagraxofsup~-Days 4-8~Fludarabine -Days 1-5~Cytarabine~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy~* Day 1~* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator~CNS2/3 IT Therapy~* Days 1, 8, 15, and 22~* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
62160690|NCT05476770|EXPERIMENTAL|Part 2 - Cohort B|"Tagraxofsup~-Days 8-12~Dexamethasone -Days 1-5~Vincristine~-Days 1, 8, 15, and 22~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy~* Day 1~* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator~CNS2/3 IT Therapy~* Days 1, 8, 15, and 22~* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
62160691|NCT05476770|EXPERIMENTAL|Part 2 - Cohort C|"Tagraxofsup -Days 1-5~Azacitidine~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy~* Day 1~* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator~CNS2/3 IT Therapy~* Days 1, 8, 15, and 22~* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
62160692|NCT06184295|EXPERIMENTAL|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
62160693|NCT06184295|NO_INTERVENTION|TBI - Non Intervention Group|Participants will receive no intervention
62160694|NCT06184295|NO_INTERVENTION|Participants without disability group|Participants will receive no intervention
62160695|NCT01476137|EXPERIMENTAL|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 1|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
62160696|NCT01476137|EXPERIMENTAL|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 2|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
62160697|NCT01476137|EXPERIMENTAL|Part 1: Cohort 1|GSK1120212 1.5mg + GSK2110183 50mg
62160698|NCT01476137|EXPERIMENTAL|Part 1: Cohort 2|GSK1120212 1.5mg + GSK2110183 100mg
62160699|NCT01476137|EXPERIMENTAL|Part 1: Cohort 3a|GSK1120212 2mg + GSK2110183 100mg
62160700|NCT01476137|EXPERIMENTAL|Part 1: Cohort 3b|GSK1120212 1.5mg + GSK2110183 125mg
62160701|NCT01476137|EXPERIMENTAL|Part 1: Cohort 4a|GSK1120212 2mg + GSK2110183 125mg
62160702|NCT01476137|EXPERIMENTAL|Part 2A: GSK1120212 2mg|Maximum tolerated dose of GSK1120212 as determined in prior single-agent trials
62160703|NCT01476137|EXPERIMENTAL|Part 2A; GSK2110183 125mg|GSK2110183 125mg
62160704|NCT01476137|EXPERIMENTAL|Part 2A: GSK2110183 MTD|Maximum tolerated dose (MTD) as determined in ongoing single agent trial PKB115340
62534196|NCT03665441|EXPERIMENTAL|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed every 2 weeks in combination with~Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle as follows:~* Abraxane (125 mg/m2) IV~* Gemcitabine (1000 mg/m2) IV~Or~Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle as follows:~* Onivyde 70 mg/m2 (irinotecan freebase) IV (recommended dose in patients homozygous for UGT1A1\*28 is 50 mg/m2)~* Leucovorin 400 mg/m2 IV~* 5 FU 2400 mg/m2~Or~* FOLFIRI: Irinotecan 180 mg/m2 IV~* Leucovorin 400 mg/m² IV~* 5 FU 400 mg/m² IV bolus~* 5 FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5 FU"
62534197|NCT03665441|OTHER|Chemotherapy alone|Standard treatment: Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle Or Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle
62534198|NCT05912361|EXPERIMENTAL|Students using AI-platform for assessing the risk of pulp exposure receiving a training session|"Students will go through a one-hour hands-on training session before taking the test at the online platform. The session includes a theoretical session related to basic aspects of AI in radiology, CNN (Convolutional Neural Network) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which participants check 11 cases of teeth with deep caries and will find the closest line between caries and pulp.~Then, they will receive access to log in to the website on which pretreatment x-rays of cases undergoing caries excavation therapy is uploaded. The performance of students on will be assessed."
62160705|NCT06090487|OTHER|Group sacubitril: (study group)|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation.
62160706|NCT06090487|OTHER|Group dapagliflozin: (control group):|This group includes (15) patients who will have a 10 mg single oral dose (4) 1 month before the operation.
62160707|NCT04639960|EXPERIMENTAL|Risperidone|
62160708|NCT04639960|PLACEBO_COMPARATOR|Placebo|
62160709|NCT06720337|EXPERIMENTAL|group A|Patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) plus 0.5 µg/kg of dexmedetomidine (Precedex® 100 µg/ml) diluted in 2 ml of normal saline at each side
62160710|NCT06720337|EXPERIMENTAL|group b|patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) plus 1.5 mL (150 mg) MgSO4 and 0.5 mL normal saline at each side
62160711|NCT02451982|EXPERIMENTAL|Arm A: CY/GVAX alone|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
62160712|NCT02451982|EXPERIMENTAL|Arm B: CY/GVAX with nivolumab|Patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide, nivolumab, and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive nivolumab every 4 weeks for another 6 treatments as well as cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
62160713|NCT02451982|EXPERIMENTAL|Arm C: CY/GVAX with nivolumab and urelumab|Patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and GVAX pancreatic cancer vaccine on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and the vaccine on day 1. Beginning approximately 28 days after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and GVAX on day 1. Treatment with cyclophosphamide, nivolumab, urelumab, and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive nivolumab and urelumab every 4 weeks for another 6 treatments as well as cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
62160714|NCT02451982|EXPERIMENTAL|Arm D: BMS-986253 and Nivolumab|Patients receive BMS-986253 and nivolumab on day 0 (Cycle 1), 15 days prior to surgery. 6-10 weeks after surgery, patients receive Cycle 2, with nivolumab on day 0 and BMS-986253 on days 0 and 14. Patients then receive standard adjuvant chemoradiotherapy. Approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive 4 additional 28-day cycles of immunotherapy, with Nivolumab on Day 0 and BMS-986253 on Days 0 and 14. Patients will then enter the extended treatment phase where they will receive nivolumab alone every 4 weeks for another 6 treatments.
62160715|NCT02691689|OTHER|Patients with ASD or VSD and PAH|
62160716|NCT01263223|EXPERIMENTAL|LY2216684, placebo, LY or placebo|"Period 1: 18 milligrams (mg) LY2216684 administered orally once daily on Days 1-4~Period 2: placebo administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
62160717|NCT01263223|EXPERIMENTAL|Placebo, LY2216684, placebo or LY|"Period 1: placebo administered orally once daily on Days 1-4~Period 2: 18 mg LY2216684 administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
62160718|NCT05713253|EXPERIMENTAL|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
62160719|NCT03670277|EXPERIMENTAL|TEST arm|For subjects enrolled in the Test arm, the Test Soft Contact Lens will be bilaterally fitted to the subject's eyes. Endpoint measures will be collected over one eye only - Test Arm: OD only.
62160720|NCT03670277|EXPERIMENTAL|CONTROL arm|Subjects enrolled in the Control Arm will be established orthokeratology lens wearers. Endpoint measures will be collected over one eye only - Control Arm: Better OK fitted eyes based on investigator's judgement.
62160721|NCT06616415|EXPERIMENTAL|Belumosudil|Participants will receive belumosudil 200 mg tablets orally QD in 28-day cycles until clinically significant progression of cGVHD
62160722|NCT04639752|EXPERIMENTAL|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
62160723|NCT04639752|ACTIVE_COMPARATOR|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
62534199|NCT05912361|NO_INTERVENTION|Students using AI-platform for assessing the risk of pulp exposure without any training session|Students will not receive any training before starting the experiment. Only a 5-minute video will be played as the guide for answering the questions in the website. Then, they will receive access to log in to the website on which pretreatment x-rays of cases undergoing caries excavation therapy is uploaded. The performance of students on will be assessed.
62534200|NCT01682395|ACTIVE_COMPARATOR|G-SV Resection and colostomy|Gangrenous sigmoid volvulus patients randomized to undergo resection with colostomy and delayed anastomosis
62534201|NCT01682395|EXPERIMENTAL|G-SV Resection and anastomosis|Gangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
62534202|NCT01682395|ACTIVE_COMPARATOR|NG-SV resection and anastomosis|Nongangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
62534203|NCT01682395|EXPERIMENTAL|NG-SV mesosigmoidopexy|Nongangrenous sigmoid volvulus subjects randomized to undergo mesosigmoidopexy
62534204|NCT01600430|ACTIVE_COMPARATOR|Oral Vitamin D--200 IU/day|Cholecalciferol 200 IU given orally once per day
62534205|NCT01600430|PLACEBO_COMPARATOR|Placebo|Identical-appearing treatment that does not contain the test drug given orally four times per day.
62534206|NCT01600430|ACTIVE_COMPARATOR|Oral Vitamin D--800 IU/day|Cholecalciferol 800 IU given orally once per day
62534207|NCT03574948|EXPERIMENTAL|5-HTP|8 weeks active substance 5-HTP (2 x 100 mg per day)
62534208|NCT03574948|PLACEBO_COMPARATOR|placebo oral capsule|8 weeks placebo (2 x 1 capsule per day)
62714755|NCT03875638|PLACEBO_COMPARATOR|Early Alzheimer's Disease Group Placebo|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of placebo twice daily.
62160724|NCT05287178|EXPERIMENTAL|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
62160725|NCT05798520|EXPERIMENTAL|Part 1: BIIB091 High Dose + Matching Placebo for DRF|Participants will receive BIIB091 high dose and matching placebo for DRF, orally, for up to 48 weeks.
62160726|NCT05798520|EXPERIMENTAL|Part 1: BIIB091 Low Dose + Matching Placebo for DRF|Participants will receive BIIB091 low dose and matching placebo for DRF, orally, for up to 48 weeks.
62160727|NCT05798520|ACTIVE_COMPARATOR|Part 1: DRF + Matching Placebo for BIIB091|Participants will receive DRF standard dose and matching placebo for BIIB091, orally, for up to 48 weeks.
62160728|NCT05798520|EXPERIMENTAL|Part 2: BIIB091 + DRF Standard Dose|Participants will receive selected dose of BIIB091 (based on Part 1 data) and DRF standard dose, orally, for up to 48 weeks.
62160729|NCT05798520|EXPERIMENTAL|Part 2: BIIB091 + DRF Low Dose|Participants will receive selected dose of BIIB091 (based on Part 1 data) and DRF low dose, orally, for up to 48 weeks.
62160730|NCT05798520|ACTIVE_COMPARATOR|Part 2: DRF + Matching Placebo for BIIB091|Participants will receive DRF standard dose and matching placebo for BIIB091, orally, for up to 48 weeks.
62160731|NCT06686888|EXPERIMENTAL|Small intestinal delivery capsules|SCFA
62160732|NCT06686888|EXPERIMENTAL|Colon-delivery capsules|SCFA
62160733|NCT06686888|PLACEBO_COMPARATOR|placebo capsules|Microcristalline cellulose
62160734|NCT05522777|EXPERIMENTAL|Test product consumption group|Drink one bottle of Yakult a day
62160735|NCT03771573|EXPERIMENTAL|Home based intervention|will be submitted to a total of 24 sessions of an unsupervised Cardiovascular Physical Therapy protocol, composed of the following steps: warm up, proper training (aerobic training + muscle training for upper and lower limbs with theraband in 5 series with 10 repetitions) often three times a week for eight weeks.
62160736|NCT03771573|PLACEBO_COMPARATOR|Control group|Will not be submitted to the Cardiovascular Physiotherapy Rehabilitation protocol for unsupervised domiciliary, only monitorization of cardiovascular variables.
62160737|NCT03771573|ACTIVE_COMPARATOR|Professional seupervision based|eight weeks of supervised activities by professional. Each day and for 20 days (20 sessions), volunteers will undergo exercises on cycle ergometer during 30 minutes for upper and lower limbs
62160738|NCT05241197|EXPERIMENTAL|Low load training with blood flow restriction (LL-BFR) group.|All participants in this arm will use a BFR tourniquet system during the execution of two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 20% 1 repetition maximum (RM), being progressively increased by 5% every four weeks. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. For each exercise, each participant will perform four sets with 30 repetitions the first set and 15 repetitions in the subsequent three sets, counting a total of 75 repetitions. All exercises will be performed in full range of motion (full plantar flexion to full dorsal flexion), with an interset rest period of 1 minute. Three minutes rest was provided between exercises.
62160739|NCT05241197|ACTIVE_COMPARATOR|High load training (HLT) group.|The HLT group will performed the same exercises than the BFR group, however with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. All exercises will be performed in full range of motion, with an interset rest period of 1 minute and a rest period between exercises of 3 minutes.
62160740|NCT05037968|EXPERIMENTAL|MagnetOs Flex Matrix|MagnetOs Flex Matrix use in instrumented posterolateral fusion, 5cc-10cc mixed with local autograft bone in a 1:1 ratio per spine level at the randomized assigned side
62160741|NCT05037968|ACTIVE_COMPARATOR|Trinity Elite|Trinity Elite is a cryopreserved, viable cellular allograft containing cancellous bone and demineralized cortical bone designed for surgical use, applied per spine level at the contralateral side. Trinity Elite will be used as a bone graft extender (mixed with local autograft)
62160742|NCT04530721||stroke group|
62160743|NCT04530721||normal group|
62160744|NCT06644235|EXPERIMENTAL|Cold Application Group|Measurements were taken from the participants in the intervention group in DFU care before (sociodemographic data, the Site, Ischemia, Neuropathy, Bacterial Infection, and Depth (SINBAD) score, score, HbA1c level, pain and comfort levels), during (pain) and after (pain and comfort) cold application.
62160745|NCT06644235|NO_INTERVENTION|Control Group|The solution was used at room temperature (+18°C to +24°C) as used in routine care without any intervention in DFU care.
62160746|NCT01748851|EXPERIMENTAL|XELOX|Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks
62160747|NCT01748851|ACTIVE_COMPARATOR|FOLFOX|Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks
62160748|NCT06171919|EXPERIMENTAL|CTI-MLP approach|To finalize protocols and a medical-legal partnership training manual for health and social service providers at Hope and Help Inc.
62160749|NCT06171919|EXPERIMENTAL|CTI-MLP assessment|To assess the feasibility and acceptability of a comprehensive critical-time intervention medical legal partnership (CTI-MLP) approach to improve HIV care continuum outcomes among formerly incarcerated individuals and determine the most efficient mechanisms for CTI-MLP delivery
62714756|NCT03875638|NO_INTERVENTION|Healthy Control Group|A group of demographically similar subjects without Alzheimer's Disease will undergo baseline testing only, without any intervention
62160750|NCT05708976|EXPERIMENTAL|Active Whole-body Hyperthermia (Active Treatment)|Participants receive 8 cognitive behavioral therapy (CBT) sessions and 4 bi-weekly whole-body hyperthermia (WBH) sessions that raise core body temperature to 38.5 C. Each active WBH session (including preparation and post-session activities) is up to approximately 3.5 hours, and each CBT session is approximately 50 minutes.
62160751|NCT05708976|PLACEBO_COMPARATOR|Sham Whole-body Hyperthermia (Sham Treatment)|Participants receive 8 cognitive behavioral therapy (CBT) sessions and 4 bi-weekly sham whole-body hyperthermia (WBH) sessions, which minimally raise body temperature. Each sham WBH session (including preparation and post-session activities) is up to approximately 3.5 hours, and each CBT session is approximately 50 minutes.
62160752|NCT01608919|NO_INTERVENTION|diagnostic blood tests|We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
62160753|NCT06423352|EXPERIMENTAL|Zilebesiran|Participants will be administered a single dose of zilebesiran.
62160754|NCT06423352|PLACEBO_COMPARATOR|Placebo|Participants will be administered a single dose of placebo.
62160755|NCT03703492|EXPERIMENTAL|Research Arm|Directed breast PET/MRI with 18F-FES; 18F-FES uptake of the known malignancy to be measured on the PET/MRI examination
62160756|NCT06286592|EXPERIMENTAL|Conditions 1, 2 & 3|"Condition 1 = Brief Mindfulness Video Condition 2 = Forgiveness Video Condition 3 = ACT Video~\*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
62160757|NCT06286592|EXPERIMENTAL|Conditions 1 & 2|"Condition 1 = Brief Mindfulness Video Condition 2 = Forgiveness Video~\*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
62160758|NCT06286592|EXPERIMENTAL|Condition 1|"Condition 1 = Brief Mindfulness Video~\*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
62160759|NCT06286592|EXPERIMENTAL|Conditions 1 & 3|"Condition 1 = Brief Mindfulness Video Condition 3 = ACT Video~\*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
62160760|NCT06286592|EXPERIMENTAL|Conditions 2 & 3|"Condition 2 = Forgiveness Video Condition 3 = ACT Video~\*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
62534209|NCT02303041|EXPERIMENTAL|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
62160761|NCT06286592|EXPERIMENTAL|Condition 2|"Condition 2 = Forgiveness Video~\*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
62534210|NCT02303041|EXPERIMENTAL|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
62534211|NCT05941455|EXPERIMENTAL|Venus-Neo group|Procedure: surgical aortic valve replacement
62160762|NCT06286592|EXPERIMENTAL|Condition 3|"Condition 3 = ACT Video~\*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
62160763|NCT06286592|NO_INTERVENTION|No Intervention|Treatment as usual.
62160764|NCT04469517||HHT|patients with HHT
62160765|NCT04469517||control|persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives
62160766|NCT04878861|EXPERIMENTAL|Training in blind field|All participants undergo this intervention. Internal control is comparing sighted and non-sighted parts of the field.
62160767|NCT06720987|EXPERIMENTAL|Monotherapy Dose Escalation|"Drug: KQB365~- Intravenous KQB365"
62160768|NCT06720987|EXPERIMENTAL|Combo Therapy Dose Escalation|"Drug: KQB365 - Intravenous KQB365~Drug:~- Intravenous cetuximab"
62534212|NCT03424018|EXPERIMENTAL|BMN 111|
62714442|NCT03093116|EXPERIMENTAL|Repotrectinib (TPX-0005)|"Phase 1~Oral repotrectinib (TPX-0005):~Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.~Phase 2~Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts~* EXP-1: ROS1 TKI-naïve ROS1+ NSCLC~* EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC~* EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)~* EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)~* EXP-5: TRK TKI-naïve NTRK+ solid tumors~* EXP-6: TRK TKI-pretreated NTRK+ solid tumors"
62160769|NCT06720987|EXPERIMENTAL|Monotherapy Dose Expansion - RP2D|"Drug: KQB365~- Intravenous KQB365"
62160770|NCT06720987|EXPERIMENTAL|Monotherapy Dose Expansion - RP2D-1|"Drug: KQB365~- Intravenous KQB365"
62160771|NCT06720987|EXPERIMENTAL|Combo Therapy Dose Expansion - RP2D|"Drug: KQB365 - Intravenous KQB365~Drug:~- Intravenous cetuximab"
62160772|NCT06720987|EXPERIMENTAL|Combo Therapy Dose Expansion - RP2D-1|"Drug: KQB365 - Intravenous KQB365~Drug:~- Intravenous cetuximab"
62160773|NCT05903820|ACTIVE_COMPARATOR|Continuous estradiol 50 mcg/day|The continuous standard-dose 17-β-estradiol group will receive the standard therapy for prevention of osteoporosis. A transdermal patch that releases 50ug/24 hrs of 17-β-estradiol will be administered continuously during the 16 weeks of treatment.
62160774|NCT05903820|ACTIVE_COMPARATOR|Continuous estradiol 25 mcg/day|The continuous low-dose 17-β-estradiol group will receive a transdermal patch that releases 25ug/24 hrs of 17-β-estradiol administered continuously during the 16 weeks of treatment.
62160775|NCT05903820|EXPERIMENTAL|Rhythmic estradiol 25-50 mcg/day|The rhythmic 17-β-estradiol group will receive a transdermal patch for two weeks that releases 25ug/24hrs of 17-β-estradiol, and a patch of 50ug/24hrs for 2 weeks in each 4-week cycle.
62160776|NCT05557253|EXPERIMENTAL|remimazolam group|General anesthesia is induced and maintained with remimazolam.
62160777|NCT05557253|ACTIVE_COMPARATOR|balanced group|General anesthesia is induced with propofol and maintained with desflurane.
62160778|NCT04045587||Severe Asthma Participants|Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.
62160779|NCT04702191|EXPERIMENTAL|Triple P (Positive Parenting Program)|Triple P - level 4 group: All 600 participants will undergo screening and a baseline assessment before randomization. Once randomized, the Triple P group (n=200) will be provided with 8-week group/individual sessions.
62160780|NCT04702191|EXPERIMENTAL|Circle of Security Parenting|Circle of Security - Parenting (COS-P): Once randomized to the COSP group (n=200), caregivers will be provided with an 8-week group session.
62160781|NCT04702191|NO_INTERVENTION|Treatment As Usual|Treatment as usual: Caregivers randomized to this arm (n=200) will receive either a different program, or brief services depending on the organization.
62160782|NCT05699603|EXPERIMENTAL|Prevention (calcipotriene, fluorouracil)|Participants receive calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study. Participants also undergo skin biopsies throughout the study. Patients who continue to experience AKs at week 8 may receive a second course of calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study.
62160783|NCT06169878|EXPERIMENTAL|experimental group|After total hip hip replacement surgery, the abduction apparatus, which provides abduction in the lower extremities and can be adjusted according to the height and weight of the patients, was used while lying and walking.
62160784|NCT06169878|NO_INTERVENTION|control group|Pillows routinely used in the field were used to ensure abduction after total hip replacement surgery.
62160785|NCT06608511||Skin cancer|Participants with melanoma or non-melanoma skin cancer
62160786|NCT04035733|EXPERIMENTAL|Open-label single arm study|
62160787|NCT06564246|ACTIVE_COMPARATOR|Vonoprazan 20mg (Vonseca)|• Group 1 (control group): 22 patients who will receive Vonoprazan 20mg (Vonseca) and placebo of pantoprazole (pantoloc) daily for 8 weeks
62160788|NCT06564246|ACTIVE_COMPARATOR|Pantoprazole 40 mg (Pantoloc)|• Group 2: 22 patients who will receive Pantoprazole 40 mg (Pantoloc) and placebo of vonoprazan (vonseca) daily for 8 weeks.
62160789|NCT01998971|EXPERIMENTAL|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
62160790|NCT01998971|EXPERIMENTAL|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
62160791|NCT01998971|EXPERIMENTAL|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
62160792|NCT01998971|EXPERIMENTAL|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
62160793|NCT01998971|EXPERIMENTAL|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
62534213|NCT04975009|EXPERIMENTAL|PTSD group|Participants will be screened and diagnosed using typical screening procedures and diagnostic criteria (e.g., the clinically administered PTSD scale). Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
62534214|NCT04975009|EXPERIMENTAL|Healthy control group|Participants will be healthy adults without a history of psychiatric illness. Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
62534215|NCT00901992|EXPERIMENTAL|MEDIAS 2 ICT|MEDIAS 2 ICT - education program for the initiation of intensive conventional insulin treatment (ICT) in type 2 diabetic patients
62160794|NCT01998971|EXPERIMENTAL|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
62160795|NCT05457296|EXPERIMENTAL|capsule hydrocortisone intake in patients with corticotrope deficiency|Hydrocortisone taken in capsule form (15mg), one intake/ one day test.
62160796|NCT05457296|ACTIVE_COMPARATOR|tablet hydrocortisone intake in patients with corticotrope deficiency|Hydrocortisone taken in tablet form (15mg), one intake/ one day test.
62534216|NCT00901992|ACTIVE_COMPARATOR|Current ICT program (ACC)|This education program consists of 10 lessons combining an insulin education program with an hypertension program
62534217|NCT04961463|EXPERIMENTAL|İnterventions group|İnterventions group:The 7-session psychoeducation program prepared on the basis of the Roy Adaptation Model was applied to the intervention group once a week for 90-120 minutes
62534218|NCT04961463|NO_INTERVENTION|Control group|Except for the routine hospital controls, no intervention was made to the control group
62534219|NCT03322735|EXPERIMENTAL|anti-tumor response of BCMA CAR-T|"Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.~Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy."
62534220|NCT05119348|EXPERIMENTAL|Stop coronavirus (STOPCOV)|A fieldworker will deliver the STOPCOV pack and personal protective equipment at baseline. The fieldworker will communicate with intervention households daily, delivering STOPCOV hygiene information.
62534221|NCT05119348|NO_INTERVENTION|Control|Participants received no additional messaging about managing COVID19 in the household.
62534222|NCT03878771|EXPERIMENTAL|autologous Platelet rich fibrin in Orabase (PRF)|applied to oral ulcer and/or mucositis 3 times per day
62534223|NCT03878771|ACTIVE_COMPARATOR|Clobetasol propionate 0.05%(Dermovate cream) in orabase|applied to oral ulcer and/or mucositis 3 times per day
62160797|NCT05457296|NO_INTERVENTION|healthy controls|healthy non treated controls, one day test.
62160798|NCT06645691|EXPERIMENTAL|Hyperpolarized Pyruvate [13C] Injection|Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner.
62160799|NCT01871597|EXPERIMENTAL|Intervention Group|Intervention - Pulmonary Artery Energy Seal
62160800|NCT01684345|PLACEBO_COMPARATOR|Placebo|
62160801|NCT01684345|EXPERIMENTAL|Dose 1 gevokizumab|
62160802|NCT01684345|EXPERIMENTAL|Dose 2 gevokizumab|
62160803|NCT04810351||Younger 1|young patients ( 18-69 years old) with oral or rectal fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during more than one week but less than three weeks of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
62160804|NCT04810351||Older 1|old patients ( \> 70 years old) with oral or rectal fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during more than one week but less than three weeks out of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
62160805|NCT04810351||Young 2|young patients (18-69 years old) with oral or rectal fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during more than 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever.
62160806|NCT04810351||Older 2|old patients ( \> 70 years old) with oral or rectal fever fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever13 .
62160807|NCT06720805|EXPERIMENTAL|Pentabiocel|"Children with IBS who received probiotics once a day for 12 weeks.~Every sachet contains:~* Lactobacillus casei LMG 101/37P-17504 (5Å109 CFU/sachet)~* Lactobacillus plantarum CECT 4528 (5Å109 CFU/sachet)~* Bifidobacterium animalis subsp. lactis Bi1 LMG P- 17502 (10Å109 CFU/sachet)~* Bifidobacterium breve Bbr8 LMG P-17501 (10Å109 CFU/sachet)~* Bifidobacterium breve Bl10 LMG P-17500 (10Å\~109 CFU/sachet)"
62160808|NCT06720805|PLACEBO_COMPARATOR|Placebo|Children with irritative bowel sindrome who received placebo once a day for 12 weeks
62160809|NCT06080438|EXPERIMENTAL|Botulinum toxin group|The left eye of each participant will receive botulinum toxin eye drops and will remain in this group for up to 40 minutes.
62160810|NCT03821285|EXPERIMENTAL|pulmonary rehabilitation|Pulmonary rehabilitation program
62160811|NCT02142478||Adapted scheme|Participants referred by their GP practices to Centre A will take part in the Adapted Exercise for Health (EFH) scheme.
62160812|NCT02142478||Standard scheme|Participants referred by their GP practices to Centre B will take part in the Standard Exercise for Health (EFH) scheme.
62160813|NCT05955768|EXPERIMENTAL|Trial group|Disposable cervical dilator stick combined with lidocaine hydrochloride injection.
62160814|NCT05955768|PLACEBO_COMPARATOR|Control group|Disposable cervical dilator stick combined with normal saline injection.
62160815|NCT00841321|ACTIVE_COMPARATOR|Arm 1|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to take the intervention or placebo.
62160816|NCT00841321|PLACEBO_COMPARATOR|Arm 2|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to receive the placebo.
62160817|NCT03841227|ACTIVE_COMPARATOR|Active-tDCS|10 patients will receive Active-tDCS intervention (2mA, 20 min) at home.
62160818|NCT03841227|SHAM_COMPARATOR|Sham-tDCS|10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home.
62160819|NCT04430894|EXPERIMENTAL|Induction|"All participants will receive 4 cycles of induction therapy. Based on the recommendation of investigators, participants may or may not proceed to an autologous stem cell transplant (SCT) after cycles 1-4. Each cycle is 28 days in length (see dosing details below.)~For patient undergoing upfront stem cell transplant (SCT): 4 cycles followed by stem cell collection, high-dose chemotherapy, and autologous SCT followed by 2 cycles (called consolidation).~For patients deferring SCT following collection: 4 cycles followed by stem cell collection followed by 4 additional cycles.~Carfilzomib: 56 mg/m2 IV on days 1, 8,15 Lenalidomide 25 mg orally (PO) on Days 1-21 Isatuximab: 10 mg/kg IV weekly for cycles 1-2 (days 1, 8, 15, 22), then every 2 weeks for cycles 3-6 (days 1 and 15), and monthly (day 1) thereafter Dexamethasone: 20 mg orally (PO) administered day of and day after carfilzomib and isatuximab (days 1, 2, 8, 9, 15, and 16; days 22 and 23 during cycles 1-2 only)."
62160820|NCT04430894|EXPERIMENTAL|Maintenance-High Risk|"Only patients that have achieved a partial response (PR) or better after induction therapy with or without stem cell transplant will continue on to maintenance therapy. The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk.~High Risk: subjects with high risk cytogenetics (deletion (del 17, translocation (t)(4:14), t(14;16), t(14;20), 1q duplications) will receive the following study treatment for up to two years (24 28-day cycles) until progressive disease (PD) or unacceptable toxicity:~Lenalidomide 10 mg orally (PO) Day 1-21 Carfilzomib 56 mg/m2 or last tolerated dose IV Days 1, 15 Isatuximab 10 mg/kg IV Day 1"
62160821|NCT04430894|EXPERIMENTAL|Maintenance- Standard Risk|"Only patients that have achieved a partial response (PR) or better after induction therapy with or without stem cell transplant will continue on to maintenance therapy. The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk.~Standard Risk: subjects without high risk cytogenetics (deletion (del 17, translocation (t)(4:14), t(14;16), t(14;20), 1q duplications) will receive the following study treatment for up to two years (24 28-day cycles) until progressive disease (PD) or unacceptable toxicity:~- Lenalidomide 10 mg orally (PO) Day 1-21"
62160822|NCT00585364||CF (non-ABPA)|cystic fibrosis and culture positive for A. fumigatus in airway cultures.
62160823|NCT00585364||CF and ABPA|cystic fibrosis and diagnosis of ABPA
62160824|NCT00585364||healthy control|healthy non-CF
62160825|NCT05243602|EXPERIMENTAL|Switch to B/F/TAF|Participants in this arm will switch from their current ARV regimen to the study drug B/F/TAF. This is an oral drug administered once daily for the duration of the study.
62160826|NCT05243602|ACTIVE_COMPARATOR|Continue current regimen|Participants in this arm will be maintained on their pre-enrollment ARV regimen for the duration of the study.
62160827|NCT00165035|EXPERIMENTAL|1|CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
62160828|NCT00165035|ACTIVE_COMPARATOR|2|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
62160829|NCT04765020|EXPERIMENTAL|Intervention group|12 weeks moderate to high-intensity exercise program
62160830|NCT04765020|NO_INTERVENTION|Control group|exercise recommendations
62534224|NCT04264702||Prospective arm|Patients who have undergone surgery for stage I to IV colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
62160831|NCT06720974|EXPERIMENTAL|AquaReBal - water-based RBT|AquaReBal (water-based RBT) will be conducted at a warm therapy pool. Participants will not wear a safety harness in water as there is minimal risk of injury due to the water properties. The level of the water will be between umbilicus and xiphoid process to allow the participant to freely move in the standing position and ensure safety during perturbations. In addition, in the tasks that involve moving, the turbulence of the water will create additional perturbations.
62160832|NCT06720974|ACTIVE_COMPARATOR|Land-based RBT|Land-based RBT will serve as a dose-matched control group. The training will be conducted using a safety harness that does not support weight but prevents a fall to the ground. Inclusion of a control group in a pilot feasibility study allows for a more realistic examination of recruitment, randomization, implementation of interventions, blinded assessment procedures, and retention.
62160833|NCT06632483||Vericiguat|New users who have been initiated on Vericiguat between 01 Sep 2022 and 31 Aug 2023 in 15 Sites in India
62160834|NCT06608498|ACTIVE_COMPARATOR|Intervention (SPARK Coping)|Participants will be given a link to SPARK Coping immediately following their baseline assessments are complete.
62160835|NCT06608498|NO_INTERVENTION|Waitlist Control|Participants will wait until their follow-up assessment to be given access to the SPARK Coping intervention.
62160836|NCT03234049|NO_INTERVENTION|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
62160837|NCT03234049|EXPERIMENTAL|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
62160838|NCT03476954|EXPERIMENTAL|Respiratory impedance monitoring session|
62160839|NCT06721247|ACTIVE_COMPARATOR|intervention group|oral magnesium intake is given to bronchial asthma patients together with the usual asthma medication according to GINA guidelines 2024
62160840|NCT06721247|PLACEBO_COMPARATOR|control group|asthmatic patients who take the usual asthma treatment according to GINA guideline 2024
62160841|NCT04190550|EXPERIMENTAL|Treatment (navtemadlin, cytarabine, idarubicin)|Patients receive navtemadlin PO QD on days 1-7, cytarabine IV BID over 3 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease may receive cytarabine IV BID over 3 hours for 5 days and idarubicin IV over 10-15 minutes for 2 days starting between days 14-21 of cycle 1 or the second cycle of navtemadlin, cytarabine, and idarubicin. Patients who achieve a CR or a CRi in either cycle 1 or 2 may receive cytarabine IV BID over 3 hours on days 1, 3, and 5 for 3-4 additional 28 to 35-day cycles in the absence of disease progression or unacceptable toxicity.
62160842|NCT04474522|ACTIVE_COMPARATOR|intervention group using morphology and NIPGT-A|Both morphology and NIPGT-A result will be used to prioritize the sequence of embryo transfer in the intervention group.
62160843|NCT04474522|NO_INTERVENTION|control group based on morphology alone|Morphology only will be used to prioritize the sequence of embryo transfer in the intervention arm.
62160844|NCT05022849|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by JNJ-75229414 IV infusion escalated sequentially with a targeted dose consistent with the dose required by the cohort being enrolled to determine recommended Phase 2 dose (RP2D) regimen(s). Additional, intermediate dose levels may be implemented based on the review of all available data including, but not limited to, safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) by the study evaluation team (SET). Participants may receive bridging therapy (anti-androgen receptor agents \[example, abiraterone, enzalutamide\] and radiotherapy, or chemotherapy \[example, docetaxel\]) if clinically indicated to maintain disease stability.
62160845|NCT05022849|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive JNJ-75229414 for each RP2D regimen determined in Part 1.
62534225|NCT04264702||Control Arm|The control arm will consist of matched Stage I to Stage IV CRC cases using the following criteria: sex, age of diagnosis and ECOG performance prior to ACT, and a minimum of 3 evaluations per year. The patient cases would have a minimum of 2 years follow-up data and received treatment no more than 3 years prior to study start date.
62160846|NCT04843046|ACTIVE_COMPARATOR|CBT + pioglitazone|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a pioglitazone (45 mg) capsule every day during weeks 1-12.
62534226|NCT02195453|EXPERIMENTAL|Yangzhengxiaoji Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Yangzhengxiaoji Capsule four granules t.i.d po"
62534227|NCT02195453|PLACEBO_COMPARATOR|Placebo Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Placebo Capsule four granules t.i.d po"
62534228|NCT06308614|EXPERIMENTAL|Estetrol|20 mg estetrol monohydrate
62534229|NCT06308614|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62160847|NCT04843046|PLACEBO_COMPARATOR|CBT + placebo|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a placebo capsule every day during weeks 1-12.
62160848|NCT05684120|EXPERIMENTAL|Treatment Group|Individuals in this arm will take part in the Mood Lifters program immediately after recruitment.
62160849|NCT05684120|NO_INTERVENTION|Waitlist Control Group|Individuals in this arm will be invited to take part in the Mood Lifters program after they complete post-treatment surveys as part of the control group.
62534230|NCT01087489|EXPERIMENTAL|4% lidocaine|Eyes were anesthetized with 0.5% proparacaine and then with three cotton swabs soaked in 4% liquid lidocaine applied with moderate pressure to the site of the injection inferotemporally to the limbus. Each participant was assigned to have this prep during one of the consecutive study visits if unilateral or in one eye if patient requires bilateral injections given the same day
62160850|NCT00376259|EXPERIMENTAL|Combination therapy|Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
62160851|NCT00376259|ACTIVE_COMPARATOR|Adefovir monotherapy|Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
62160852|NCT05480280|EXPERIMENTAL|mFOLFOX6 + dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days. mFOLFOX6 will be administered every 2 weeks.
62160853|NCT06641271|EXPERIMENTAL|Experimental - Active Stimulation|Participants in this arm will receive active stimulation during the paired motor task.
62160854|NCT06641271|SHAM_COMPARATOR|Control - Sham Stimulation|Participants in this arm will receive sham stimulation during the paired motor task to create a control to the experimental group.
62160855|NCT04747496||NVAF patients|NVAF adult patients with one or more risk factors treated with edoxaban.
62160856|NCT04430673|EXPERIMENTAL|Home-School based VR trial|The VR system will be provided to each participant for a 2-week home- or school- based trial. No additional interventions.
62160857|NCT01072149|EXPERIMENTAL|50mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62160858|NCT01072149|EXPERIMENTAL|100mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62160859|NCT01072149|EXPERIMENTAL|200mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
62160860|NCT01072149|PLACEBO_COMPARATOR|placebo|placebo
62160861|NCT04026555|ACTIVE_COMPARATOR|MEWS++ Monitoring|This consists of all the patients that will be receiving MEWS++ escalation monitoring and provider alerting.
62160862|NCT04026555|PLACEBO_COMPARATOR|Standard of Care Monitoring|Patients in the control arm will have a score calculated but no alert will be sent.
62160863|NCT04300478|OTHER|Sedentary Control/REx|Subjects will complete the Sedentary control testing sessions, have a 7-14 day washout period, and then complete the REx
62160864|NCT04300478|OTHER|REx/Sedentary Control|Subjects will complete the REx testing sessions, have a 7-14 day washout period, and then complete the Sedentary control
62160865|NCT01850888|EXPERIMENTAL|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
62160866|NCT05203822|EXPERIMENTAL|Tepotinib then Itraconazole|Participants received a single oral dose of Tepotinib 500 milligrams (mg) on Day and Day 12 under fed condition followed by single oral dose of itraconazole 200 mg on Days 8 to 11 and Days 13 to 18. On Day 12, participants received a single dose of 200 mg itraconazole simultaneously with a single dose of 500 mg Tepotinib.
62160867|NCT02475707|EXPERIMENTAL|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.
62160868|NCT02475707|EXPERIMENTAL|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
62160869|NCT06721143|ACTIVE_COMPARATOR|Group I|AION-301
62160870|NCT06721143|PLACEBO_COMPARATOR|Group II|Placebo
62160871|NCT06720675||SCS - Static Clod Storage|HCC patients transplanted between January 2016 and December 2020, who received liver grafts preserved with SCS and a minimum follow-up of 12 months.
62160872|NCT06720675||HOPE - Hypothermic Oxynated Perfusion|HCC patients transplanted between January 2016 and December 2020, who received liver grafts preserved with HOPE and a minimum follow-up of 12 months.
62160873|NCT05065099|EXPERIMENTAL|OnTRACK Intervention|"In the intervention condition, HCPs will be trained in the usage of the OnTRACK system.~They will be oriented to the educational videos, the symptom tracking, and the interpretation of the data that is provided by the patients and families, and the associated management strategies based on that data. Additionally, patients and parents will be trained to use the OnTRACK smartphone app on their phone from diagnosis to recovery (or 12 weeks if not recovered), including daily exertional monitoring symptom ratings and use of the educational videos. School personnel will be introduced to the OnTRACK app and the data summary features in the school dashboard and the associated supports that can be provided to the student based on that data."
62160874|NCT05065099|NO_INTERVENTION|Treatment as Usual|"In the control condition, the HCP provides usual/standard care to the patients and parents as is the practice within the specific clinic. The OnTRACK app and the educational modules are not provided."
62160875|NCT02267746|ACTIVE_COMPARATOR|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
62160876|NCT02267746|EXPERIMENTAL|Tazarotene|Tazarotene 0/1% foam (Actavis)
62160877|NCT02267746|PLACEBO_COMPARATOR|Vehicle foam|Foam vehicle of the test product (Actavis)
62160878|NCT06086132||Breast cancer|"Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs.~(Non-interventional prospective patient registry)"
62160879|NCT06086132||Female and Male|"Diagnosis of cancer scheduled for treatment according to the treating physician's discretion.~(Non-interventional patient registry)"
62160880|NCT06191419|EXPERIMENTAL|Participants that Smoke|Each smoker is asked to smell up to 20 samples per session. Samples include controls (clean air, irrelevant odor), blocking odors, cigarette smoke, and cigarette smoke mixed with blocking odors or irrelevant odors.
62160881|NCT04242498|EXPERIMENTAL|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
62160882|NCT04242498|EXPERIMENTAL|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
62160883|NCT04242498|EXPERIMENTAL|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
62160884|NCT04242498|PLACEBO_COMPARATOR|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
62160885|NCT06119386|EXPERIMENTAL|Group 1 - Treated Eye|Patients with treatment
62160886|NCT04794101|EXPERIMENTAL|Deferred Treatment From MGT-RPGR-021 of Intermediate Dose|Deferred treatment
62160887|NCT04794101|EXPERIMENTAL|Already Treated in MGT-RPGR-021|Already treated
62160888|NCT04794101|EXPERIMENTAL|Deferred Treatment From MGT-RPGR-021 Low Dose|Deferred treatment
62160889|NCT06334952|OTHER|tDCS - Sham|Patient will be randomized to firstly receive tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
62160890|NCT06334952|OTHER|Sham - tDCS|Patient will be randomized to firstly receive Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
62160891|NCT01731444|EXPERIMENTAL|Phenylephrine|20 ug/cc
62160892|NCT01731444|ACTIVE_COMPARATOR|Epinephrine|1:1000000
62160893|NCT06720922|EXPERIMENTAL|Minimally Invasive Surgery|
62160894|NCT06720922|ACTIVE_COMPARATOR|Open Surgery|
62160895|NCT02465606|EXPERIMENTAL|Group 1: Lebrikizumab Dose Level 1 Monotherapy|During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
62160896|NCT02465606|ACTIVE_COMPARATOR|Group 2: Topical Corticosteroid Creams Only|During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
62160897|NCT06719726|EXPERIMENTAL|PECS I Block Intervention Arm|This arm involves the application of a preoperative PECS I block with 10 mL of 0.5% bupivacaine under ultrasound guidance. The intervention targets the right breast, aiming to evaluate its effectiveness in managing postoperative pain compared to local anesthetic infiltration.
62160898|NCT06719726|EXPERIMENTAL|Local Anesthetic Infiltration Intervention Arm|This arm involves the administration of intraoperative local anesthetic infiltration using 10 mL of 0.5% bupivacaine under direct visualization. The intervention targets the left breast, aiming to compare its effectiveness in managing postoperative pain against the PECS I block.
62160899|NCT04295499|EXPERIMENTAL|Test Device: Qualis Silicone Hydrogel Soft Contact Lens|Test lenses will be worn on a daily wear basis for up to one month with removal for cleaning, disinfection, and storage prior to sleeping. Subjects will be instructed to wear the test lenses at least 6 hours a day, a minimum of 5 days per week. The Test Device is investigational and not cleared/approved by the US FDA.
62160900|NCT04295499|ACTIVE_COMPARATOR|Control Device: Acuvue Vita Monthly Contact Lens|Test lenses will be worn on a daily wear basis for up to one month with removal for cleaning, disinfection, and storage prior to sleeping. Subjects will be instructed to wear the test lenses at least 6 hours a day, a minimum of 5 days per week. The Control Device is cleared by the US FDA.
62160901|NCT06720506|EXPERIMENTAL|group F|patients will received intrathecal with dose 10-20ug
62160902|NCT06720506|EXPERIMENTAL|group N|Nalbuphine will given IV as shot in. Dose 1mg /kg
62160903|NCT05347095|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.
62160904|NCT05347095|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. At Week 24, guselkumab Dose 3 SC non-responders will switch to receive guselkumab dose 2 SC. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
62160905|NCT05347095|EXPERIMENTAL|Group 3: Placebo|Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
62534231|NCT01087489|EXPERIMENTAL|3.5% ophthalmic lidocaine gel|Eye was anesthetized with 0.5% proparacaine and then with 3.5% ophthalmic lidocaine gel applied to the surface of the eye. Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day.
62534232|NCT05003934|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62160906|NCT05744505|EXPERIMENTAL|Laser group|Every 3 weeks, a fixed 1 / 2 of the alopecia area was treated with a 1565-nm non-ablative fractional laser.
62160907|NCT05744505|PLACEBO_COMPARATOR|control group|There was no treatment for the other half of the alopecia area in the patients.
62534233|NCT06387602|EXPERIMENTAL|ART Group|Week 1 CRYOTHERAPY STRENGTHENING OF ADDUCTORS Adductor Isometrics Side-lying adductor strengthening Adductor resistance with stepper ACTIVE RELEASE TECHNIQUE Week 2 STRENGTHENING OF ADDUCTORS Adductor Isometrics Side-lying adductor strengthening Adductor resistance with stepper ACTIVE RELEASE TECHNIQUE
62534234|NCT06387602|EXPERIMENTAL|PIR Group|Week 1 CRYOTHERAPY STRENGTHENING OF ADDUCTORS Adductor Isometrics Side-lying adductor strengthening Adductor resistance with stepper POST ISOMETRIC RELAXATION Week 2 STRENGTHENING OF ADDUCTORS Adductor Isometrics Side-lying adductor strengthening Adductor resistance with stepper POST ISOMETRIC RELAXATION
62160908|NCT06410547|NO_INTERVENTION|No Intervention|This arm will be treated as usual. No intervention will be performed.
62160909|NCT06410547|ACTIVE_COMPARATOR|LLM Recommendation|On admission, an LLM is asked to indicate the guideline-concordant therapy that the patient should receive. The information is sent to the treating physician.
62160910|NCT03724695|NO_INTERVENTION|Control|Usual Care
62160911|NCT03724695|EXPERIMENTAL|AHCAH Nudge|"The investigators have developed methods for sending nudges to clinicians via secure text messages to primary teams to alert them that their patient was identified as high-risk for 6-month mortality and that an AHCAH liaison would visit their patient to discuss the AHCAH program and to facilitate enrollment if the patient was amenable. The investigators propose that these secure text messages would be sent to the teams of patients randomized to the intervention by the AHCAH liaison within 72 hours of eligibility identification (to allow for the liaison not being available over the weekend). The investigator team will track all aspects of messaging and timing. Clinicians can choose to opt out a patient from the liaison visit and AHCAH enrollment within a two-hour timeframe."
62534235|NCT03275064|EXPERIMENTAL|LNA043 40 mg Part B|LNA043 40 mg Part B
62534236|NCT03275064|EXPERIMENTAL|LNA043 20 mg Part B|LNA043 20 mg Part B
62534237|NCT03275064|EXPERIMENTAL|LNA043 20 mg Part A|LNA043 20 mg Part A
62534238|NCT03275064|PLACEBO_COMPARATOR|Placebo Part A|Placebo Part A
62160912|NCT04352894|EXPERIMENTAL|fluorescence guided peritoneal exploration|Indocyanine green (ICG) intravenous injection and peritoneal exploration with technology able to detect fluorescence generated by ICG
62160913|NCT03981120|NO_INTERVENTION|Standard Care Group|Patients in the control arm will not undergo laser and acupuncture treatment. The treatment and control group will be compared to the baseline pregnancy rate of women meeting the same inclusion and exclusion criteria from the clinic through a chart review over the two years prior to initiation of the study.
62160914|NCT03981120|EXPERIMENTAL|Laser and Acupuncture Group|"The patients in the treatment arm will have 7 treatments before transfer (2-4 sessions a week), for the 3 weeks from starting estrace leading to the day before embryo transfer, then one (before and after transfer) on the day of transfer (total 8 sessions). Each treatment leading up to transfer day treatment consists of:~1. Traditional Acupuncture at points Sp9 to SP6 EA2Hz Milliamp (Pantheon device), ST-36 B, LI4 unilateral, LV3 unilateral and/or LU7 unilateral, K6 unilateral.~2. Bioflex Array (Photobiomodulation) - simultaneously array placements with each treatment over the sacrum (points BL-31, BL 32, BL 33 BL 34, DU2, DU3) and lower Abdomen above uterus (Ren 2 to Ren 6)~3. Laser acupuncture over ST-9, ST10, SJ 17, ST-11. Ren 3 and Ren 4. 6.75 J per point at ST 9, ST10 (over carotid) and SJ17 (vertebral artery).~On the day of FET on site at IVF clinic there will be a before and after traditional and laser acupuncture treatment."
62160915|NCT03876678|EXPERIMENTAL|Light therapy and oral L. salivarius AP-32|Light therapy and taking 1 L. salivarius AP-32 probiotic capsule two times everyday for 7 days.
62160916|NCT03876678|EXPERIMENTAL|Light therapy and oral B. animalis subsp. lactis CP-9|Light therapy and taking 1 B. animalis subsp. lactis CP-9 probiotic capsule two times everyday for 7 days.
62160917|NCT03876678|PLACEBO_COMPARATOR|Light therapy and oral placebo|Light therapy and taking 1 placebo capsule two times everyday for 7 days.
62160918|NCT05513222|EXPERIMENTAL|flipped autograft|
62160919|NCT02154516|ACTIVE_COMPARATOR|Control Total Hip Replacement Device|"Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:~* R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~* OXINIUM heads on polyethylene liners or~* Ceramic heads on ceramic liners (all uncemented components)"
62160920|NCT02154516|EXPERIMENTAL|Investigational Hard-on-Hard Total Hip Replacement Device|"Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:~* R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~* R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)~* R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)~* Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)"
62160921|NCT04707287||Breast Cancer Patients|All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment
62160922|NCT06585358||Pulmonary tuberculosis|
62160923|NCT04994418|EXPERIMENTAL|Arm 1. Recommended sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300mg) from whole food while consuming placebo from pills
62160924|NCT04994418|EXPERIMENTAL|Arm 2. High sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300 mg) from whole food while consuming high sodium from pills (3400 mg)
62160925|NCT04994418|EXPERIMENTAL|Arm 3. High sodium and high fructose diet|7 day consumption of high fructose drink (200g) and recommended sodium (2300 mg)from whole food while consuming high sodium pills from pills (3400 mg)
62160926|NCT05676541|EXPERIMENTAL|Intervention|
62160927|NCT05676541|NO_INTERVENTION|Control|
62160928|NCT05082493|EXPERIMENTAL|Berubicin HCL - MTD phase|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
62534239|NCT03275064|PLACEBO_COMPARATOR|Placebo Part B|Placebo Part B
62534240|NCT02875015|EXPERIMENTAL|Liposomal Bupivacaine|20mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
62534241|NCT02875015|ACTIVE_COMPARATOR|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
62160929|NCT05340283||Observational group|Patients with Parkinson's disease who were referred to a Home Rehabilitation Service in Gijón, Asturias region, Spain, during the years 2015 to 2021.
62160930|NCT05008211|EXPERIMENTAL|Intervention|"There will be a respiratory team, same as the usual care, responsible for patients requiring domiciliary NIV in the intervention group.~The IMB model-based intervention of this study is a six-week program consisted of a one-hour face-to-face home visit in the first week, two 20-minute telephone follow-ups in the second and fourth weeks, and a half-hour face-to-face follow-up at hospital in the sixth week, and a telephone consultation hotline during office hours.~There are three major components including information, motivation and behavioral skill interventions as proposed by the IMB model and will be deliberately arranged in the different sessions."
62534242|NCT04278950|ACTIVE_COMPARATOR|Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with 0.10% PVP-I (0.01% available iodine). Patients will be instructed to dilute 2.5mL of the betadine (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
62534243|NCT04278950|PLACEBO_COMPARATOR|Placebo Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with a placebo PVP-I solution. Patients will be instructed to dilute 2.5mL of the placebo PVP-I (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
62534244|NCT04311372|EXPERIMENTAL|Educational session+Material+Videos (Group 1)|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
62534245|NCT04311372|ACTIVE_COMPARATOR|Educational session+Material ONLY (Group 2)|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
62160931|NCT05008211|PLACEBO_COMPARATOR|Control - usual care|There is a respiratory team of health care professionals responsible for patients requiring domiciliary NIV. The team is led by a Medical Consultant and with respiratory nurse(s) as team members who are responsible for assisting patients or their family to initiate domiciliary NIV and teaching the relevant technical skills. The nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems such as leakage and pressure sore in hospital before discharge. Commercial leaflet or booklet according to the choice of ventilator with information of the ventilator, interface, accessories and the ventilator company will be provided to the patient.
62160932|NCT04237987|EXPERIMENTAL|Interleukin-2 and ciclosporin and corticosteroid|One million units of Recombinant Human Interleukin-2 (IL-2) will be administered subcutaneously every other day for 3 months. Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 3 months after withdraw of IL-2.
62160933|NCT04237987|ACTIVE_COMPARATOR|ciclosporin and corticosteroid|Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 6 months.
62160934|NCT06055972|EXPERIMENTAL|Letter Recipients with Coronary Calcium Score/Educational Materials|Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination.
62160935|NCT06055972|NO_INTERVENTION|Non-Letter Recipients (Control)|Patients in the control group will not receive any letter in the mail with their coronary calcium score and educational materials.
62160936|NCT04798898|EXPERIMENTAL|Intervention (+RFA) arm|Preoperative partial RFA necrosis in the liver metastasis followed by liver resection
62160937|NCT04798898|NO_INTERVENTION|Control (-RFA) arm|Liver resection
62160938|NCT03227458|ACTIVE_COMPARATOR|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
62160939|NCT03227458|ACTIVE_COMPARATOR|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
62160940|NCT03227458|ACTIVE_COMPARATOR|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
62160941|NCT06647121|EXPERIMENTAL|ACT Workshop Plus ACTaide Mobile App|In this condition, participants will attend a 1-hour virtual ACT psychoeducational workshop where they will learn about ACT, practice the dropping anchor exercise (with a guided image sequence), and learn how to use the ACTaide mobile app, which they will be asked to use to practice the dropping anchor exercise daily for two weeks. The main feature of the ACTaide app is the annotated image sequence to guide users through the steps of the exercise. The app also features customizable reminders notifications. Participants will receive three reminders per day encouraging them to practice the exercise.
62160942|NCT06647121|ACTIVE_COMPARATOR|ACT Workshop Plus Reminders-only Mobile App|In this condition, participants will attend a 1-hour virtual ACT psychoeducational workshop where they will learn about ACT, practice the dropping anchor exercise (without a guided image sequence), and learn how to use the reminders-only mobile app, which they will be asked to use to practice the dropping anchor exercise daily for two weeks. This app will not include the annotated image sequence from ACTaide and instead will only include customizable reminders notifications. Participants will receive three reminders per day encouraging them to practice the exercise.
62160943|NCT04400214|EXPERIMENTAL|Food Allergy Superheroes Training (FAST) Program|Participants enrolled in this arm of the study will receive 5, 20 minutes skills training sessions designed to promote adherence to food allergy safety guidelines. These sessions will occur over the period of \<2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
62160944|NCT04400214|ACTIVE_COMPARATOR|Food Allergy Knowledge (FAK) Intervention|Participants enrolled in this arm of the study will receive 5, 20 minutes educational training sessions designed to increase knowledge pertaining to food allergies. These sessions will occur over the period of \<2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
62534246|NCT05608980|ACTIVE_COMPARATOR|Treatment arm|0.01%hypochlorous acid group
62160945|NCT06720402|ACTIVE_COMPARATOR|Pediatricians|The group which consist of pediatricians.
62160946|NCT06720402|ACTIVE_COMPARATOR|Family physicians|The group which consist of family physicians.
62160947|NCT04916340|EXPERIMENTAL|Muscular Strength|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular strength
62160948|NCT04916340|EXPERIMENTAL|Muscular fitness|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular fitness
62160949|NCT06202105|EXPERIMENTAL|Laparoscopic total gastrectomy|"5 trocars were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.~The right gastroepiploic vein was divided and right gastroepiploic and inferior pyloric artery were transected at their origin from the gastroduodenal artery to dissect group 6.~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.~The left gastric vein was divided and then the left gastric artery was vascularized to remove group 7.~The dissection was continued upward along the splenic artery and its branches to remove group 11p,d and/or along the splenic hilum to remove group 10.~The dissection was then conducted the right and left of the esophago-gastric junction to remove group 1,2.~As a general rule, Roux en Y method was used for esophagoo-jejunal reconstruction for all cases"
62160950|NCT06202105|ACTIVE_COMPARATOR|Open total gastrectomy|An incision of 15\~20 cm length is made in the abdominal midline . Standard total gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, along splenic artery, proper hepatic artery, and/or the splenic hilum) . Roux-en Y esophagojejunal anastomosis is performed for reconstruction.
62534247|NCT05608980|PLACEBO_COMPARATOR|Placebo|eyelid wipes
62534248|NCT05935111|ACTIVE_COMPARATOR|Physical Activity Self-efficacy (PAS) group|Participants assigned to the PAS group will proceed through the weight management program provided by the center and will be given 4 weeks of 24-hour access to the PAS intervention during data collection for this study. The login credential for PAS participants will provide access to both the PAS intervention and to a secure website to complete data collection at W1, W2, and W3.
62160951|NCT04288414||fNIRS applied|All of the participants' brain activity was evaluated with fNIRS.
62160952|NCT03402399|OTHER|Primary Myelofibrosis|Blood test
62160953|NCT03402399|OTHER|Secondary Myelofibrosis|Blood test
62160954|NCT05316155|EXPERIMENTAL|Part 1: Dose Escalation|Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D\[s\]) for Part 2.
62160955|NCT05316155|EXPERIMENTAL|Part 2: Dose Expansion|Participants in each of 5 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1.
62160956|NCT05316155|EXPERIMENTAL|Part 3: RP2D Dose Expansion|Participants in 2 of the disease-specific NMIBC cohorts (cohorts 1 and 3) may be enrolled at RP2D to determine the safety, evaluate PK and preliminary clinical activity.
62160957|NCT04462302|EXPERIMENTAL|Internet-based program + Pain Education|If you are in this group, in additional to your usual care, you will be provided access to the 8-session Internet-based pain program plus pain education. You will need to complete your sessions within 10 weeks of being provided your log-in code. You will be allowed to revisit sessions that you have completed during this 10 weeks. After completion of the study, you will still be provided access to the 8-session Internet-based pain program.
62160958|NCT04462302|NO_INTERVENTION|Pain Education Only|If you are in this group, in addition to your usual care, you will be provided pain education at your initial clinic visit. After you have completed the 6-month follow up assessment, you will be provided a secure log-in code and invited to complete the 8 sessions of this Internet-based pain program on your own.
62160959|NCT04205045||Non-Habitual Milk Consumers (NHMC)|"Healthy subjects who are non-habitual milk consumers because of gastrointestinal discomforts upon milk consumption.~Lactose breath test; Gut permeability test; Milk test."
62160960|NCT04205045||Habitual Milk Consumers (HMC)|"Healthy subjects with regular milk consumption.~Intervention to be performed:~Lactose breath test; Gut permeability test; Milk test."
62160961|NCT05527691|EXPERIMENTAL|SupportGroove|"8-week intervention that is remotely delivered through a mobile app, consisting of daily quests (positive psychology-based activities) completed individually and as a couple."
62160962|NCT05527691|NO_INTERVENTION|Waitlist control|Participants will be waitlisted for 8 weeks.
62160963|NCT01483131|EXPERIMENTAL|Low intensity resistance training|
62160964|NCT01483131|EXPERIMENTAL|High intensity resistance training|
62160965|NCT01483131|EXPERIMENTAL|Low intensity resistance training with vascular occlusion|
62160966|NCT06293053|EXPERIMENTAL|Dupilumab|Administered subcutaneously (SC) based on weight and age
62160967|NCT04451720|EXPERIMENTAL|Risankizumab|In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.
62160968|NCT04451720|EXPERIMENTAL|Placebo|In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.
62160969|NCT05485415|ACTIVE_COMPARATOR|Intervention|Personalised intervention
62160970|NCT05485415|PLACEBO_COMPARATOR|Control|General sleep advice
62160971|NCT06450288|EXPERIMENTAL|GO group|Participants who reside in the Concordia Tsat Sing Kong Transitional Housing Estate (still under construction) will be invited to join the GO wellness program.
62160972|NCT06721390|EXPERIMENTAL|Piano Improvisation|This intervention will involve group piano improvisation training sessions once a week for 12 weeks, in addition to daily in-home practice for 4-5 days.
62534249|NCT05935111|NO_INTERVENTION|Usual Care (UC) group|Participants assigned to the UC group will proceed through the weight management program provided by the center. The login credential for UC participants will provide access to a secure website to complete data collection (i.e., a survey battery, physical activity monitoring) at W1, W2, and W3.
62160973|NCT06721390|ACTIVE_COMPARATOR|Music Listening|The music listening condition will involve group music listening sessions (led by a trained instructor) once a week for 12 weeks and daily in-home music listening practice.
62160974|NCT03389399||Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days|This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
62160975|NCT04634552|EXPERIMENTAL|Part 3: Cohort A (Talquetamab)|Cohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (\>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. All participants (ongoing and those who are in follow-up) will transition to open-label extension (OLE) phase and will continue to receive the study treatment.
62534250|NCT05134753|EXPERIMENTAL|Study arm|Patients will undergo sinus augmentation with advanced PRF
62534251|NCT05134753|PLACEBO_COMPARATOR|Controlled arm|Patients will undergo sinus augmentation with PRF
62534252|NCT02815358|EXPERIMENTAL|Segmental Stabilization Group|Patients receiving segmental stabilization exercises.
62534253|NCT02815358|ACTIVE_COMPARATOR|Control Group|Patients receiving home exercises.
62534254|NCT00813527|EXPERIMENTAL|Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD|
62714757|NCT06717724|EXPERIMENTAL|Experimental|Participants in the experimental arm received daily periarticular injections of procaine complex solution (5 ml containing 100 mg procaine hydrochloride) over a 10-day period. All injections were administered using sterile technique. Prior to treatment, sensitivity to procaine hydrochloride was assessed with a subcutaneous test dose (0.5 ml)
62534255|NCT00813527|ACTIVE_COMPARATOR|Fenofibrate 145 mg QD|
62534256|NCT01001988|EXPERIMENTAL|Study group|Participants received a single dose of JE-CV administered in Study JEC02. In Study JEC05 there were yearly visits with blood samples taken for immunogenicity assessment.
62714758|NCT06717724|ACTIVE_COMPARATOR|Control|Participants received only physical therapy without procaine injections.
62160976|NCT04634552|EXPERIMENTAL|Part 3: Cohort B (Talquetamab)|Cohort B will enroll participants with multiple myeloma who have previously received \>= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. All participants (ongoing and those who are in follow-up) will transition to OLE phase and will continue to receive the study treatment.
62160977|NCT04634552|EXPERIMENTAL|Part 3: Cohort C (Talquetamab)|Cohort C will enroll participants with multiple myeloma who have previously received \>= 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. All participants (ongoing and those who are in follow-up) will transition to OLE phase and will continue to receive the study treatment.
62160978|NCT04634552|EXPERIMENTAL|Part 3: Cohort D (Talquetamab)|Cohort D will enroll participants with multiple myeloma who have previously received \>= 3 prior lines of therapy. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. Participants in this cohort will receive tocilizumab prophylaxis for cytokine release syndrome (CRS) including all outpatient dosing. Participants will transition to OLE phase upon communication by the sponsor.
62534257|NCT00853463|NO_INTERVENTION|No Alert|The responsible physician of a patient randomized to the control arm will not be contacted regarding the increased VTE risk of the patient.
62534258|NCT00853463|OTHER|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
62534259|NCT02413216|EXPERIMENTAL|TicHelper|In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
62160979|NCT05135741|EXPERIMENTAL|pressure bio feedback|Experimental
62160980|NCT05135741|EXPERIMENTAL|deep cervical exercises|comparative
62160981|NCT01541176|EXPERIMENTAL|Absence of corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
62160982|NCT01541176|ACTIVE_COMPARATOR|Corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
62160983|NCT04189224|EXPERIMENTAL|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Test/Control.
62160984|NCT04189224|EXPERIMENTAL|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Control/Test.
62160985|NCT02965352|EXPERIMENTAL|Hand strength|Volunteers without motor abnormalities. The tests were performed in a single session lasting 30 minutes, when volunteers used the door handle device, the linear switch device, and the door key device, in order to quantify the hand strength.
62160986|NCT05815693|NO_INTERVENTION|Group 1|usual care for anxiety, depression, chronic pain and insomnia
62160987|NCT05815693|EXPERIMENTAL|Group 2|mindfulness-based stress reduction (MBSR) for anxiety, depression, chronic pain and insomnia
62160988|NCT02650661|EXPERIMENTAL|Online program & Health coaching|"This group is provided with Online health management program, Health coaching and Workshop."
62160989|NCT02650661|EXPERIMENTAL|Online program|"This group is provided with Online health management program."
62160990|NCT02650661|ACTIVE_COMPARATOR|Enhanced Usual Care|"This group is provided with Standard health educational booklet."
62160991|NCT04276857|OTHER|Single arm study|All eligible patients will receive combination chemotherapy and if there i s a positive response they will undergo IRE.
62160992|NCT06721104||Autism Spectrum Disorder|
62160993|NCT06721104||Healthy Children|
62160994|NCT04015180|EXPERIMENTAL|Aflibercept arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
62160995|NCT04015180|ACTIVE_COMPARATOR|Laser photocoagulation arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
62160996|NCT02962609|EXPERIMENTAL|Semielevated Side-Lying Position-ESL|Preterm infants feed in the ESL position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
62160997|NCT02962609|EXPERIMENTAL|Semielevated Supine Position-ESU|Before feeding: In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
62160998|NCT04028063|EXPERIMENTAL|Part 1: Stage 1, Safety Lead-In|The safety lead-in will enroll 6 participants. Balstilimab 300mg flat q3 weeks up to 2 years; Zalifrelimab 1mg/kg q6 weeks x 4; Doxorubicin 75mg/m2 q3 weeks x 2, starts at C2 The participants will complete a dose-limiting toxiciy (DLT) observation period of 9 weeks.
62160999|NCT04028063|EXPERIMENTAL|Part 1: Stage 2, Expansion|Balstilimab 300mg flat q3 weeks up to 2 years; Zalifrelimab 1mg/kg q6 weeks up to 2 years; Doxorubicin 75mg/m2 q3 weeks x 6
62161000|NCT04028063|EXPERIMENTAL|Part 2: Stage 2, Dose 1|Doxorubicin 60mg/m2 q3 weeks x 6 doses Botensilimab 75mg q6 weeks up to two years
62161001|NCT04028063|EXPERIMENTAL|Stage 2, Dose 2|Doxorubicin 75mg/m2 q3 weeks x 6 doses Botensilimab 75mg q6 weeks up to two years
62161002|NCT04028063|EXPERIMENTAL|Stage 2, Dose 3 Combination of Doxorubicin with Botensilimab and Balstilimab|Doxorubicin 75mg/m2 q3 weeks x 6 doses Botensilimab 75mg flat q6 weeks up to 2 years Balstilimab 450mg q3 weeks up to 2 years
62161003|NCT06134804|EXPERIMENTAL|Group 1: Coadministration (CoAd) Group|Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30.
62161004|NCT06134804|EXPERIMENTAL|Group 2: Control Group|Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30.
62161005|NCT03414515||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
62161006|NCT06720207||Research group|It is expected to include 30 newly diagnosed NHL or MM patients, and the tracer radiation used in the study is extremely small and will not have any physiological effects on the subjects.
62161007|NCT04546178|EXPERIMENTAL|PE+ intervention group|This group will participate in 15 sessions of PE+ therapy and participate in frequent symptom assessments; this is the same group of participants as the pre-intervention scores group, but they have crossed over from pre-intervention phase into intervention (active) phase.
62161008|NCT04546178|ACTIVE_COMPARATOR|Pre-intervention scores group (TAU)|This group will participate in symptom assessments but will not receive the PE+ intervention until the begin the active part of the trial. Participants in this group have been diagnosed with a psychotic disorder, have also experienced adversity, and use substances. This group will receive medication for psychosis as well as access to standard education programs and clinical care; thus treatment as usual (TAU).
62161009|NCT02570815|EXPERIMENTAL|indocyanine green|Non-toxic, fluorescent dye
62161010|NCT01504178|EXPERIMENTAL|duloxetine|The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.
62161011|NCT01504178|PLACEBO_COMPARATOR|positive control (L-Dopa)|The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.
62161012|NCT01504178|PLACEBO_COMPARATOR|negative control|The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.
62161013|NCT05270889|EXPERIMENTAL|Tislelizumab+Zanidatamab|
62161014|NCT06720090|EXPERIMENTAL|Higher dose|Participants will be given wearable light therapy devices that emit a higher light intensity.
62161015|NCT06720090|SHAM_COMPARATOR|Lower dose|Participants will be given wearable light therapy devices that emit a lower light intensity.
62161016|NCT05028283|EXPERIMENTAL|participants|patients with atrophic acne scars on the cheeks who will reviewing the dermatological clinics at the Dermatology and Venereology Hospital at least 69 patients they will be undergo fat grafting for one session and will be follow up for 6 months after the procedure
62161017|NCT06167330|EXPERIMENTAL|Progressive rehabilitation program|The progressive rehabilitation program is a multicomponent intervention, including pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy.
62161018|NCT06167330|EXPERIMENTAL|Stimulation devices|The treatment program includes Transcutaneous Electrical Nerve Stimulation and Cranial Electrical Stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol.
62534260|NCT02413216|ACTIVE_COMPARATOR|Internet-Based Resources Condition|Participants who are assigned to the Internet-Based Resources (IBR) condition will receive a collection of materials with inks to the best available online resources about tic disorders and their treatment. The sites that are provided use a variety of online print, video, and animation materials to teach patients about various aspects of chronic tic disorders and their management. Participants will will be asked to explore and use the website information over the course of 8 weeks in any manner they find helpful. Participants will be asked to spend 30-60 minutes per day reviewing and discussing the information provided.
62534261|NCT00555360|EXPERIMENTAL|Arm 1|Veterans with heart failure that can identify an out-of-home informal caregiver
62534262|NCT00555360|ACTIVE_COMPARATOR|Arm 2|Veterans with heart failure that can identify an out-of-home informal caregiver
62161019|NCT04176549||Ectopic Pregnancy|Patients diagnosed with ectopic pregnancy Samples collected: Plasma, Serum, Urine, Oral swab, Vaginal Swab If surgery required for tubal ectopic: Fallopian tube, peritoneal washing, trophoblast
62161020|NCT04176549||Surgical termination of pregnancy|Patients undergoing elective surgical termination of pregnancy Samples collected: Plasma, Serum, Urine, Oral swab Vaginal swab, Trophoblast
62161021|NCT04176549||Elective hysterectomy and salpingo-oophorectomy|Patients undergoing elective hysterectomy and salpingo-oophorectomy Samples collected: Fallopian tube, peritoneal washing
62161022|NCT05721053||Older Adults in Radiation Therapy|Older Adults who are receiving Radiation Therapy.
62161023|NCT05689502|EXPERIMENTAL|Treatment|
62161024|NCT06272981|EXPERIMENTAL|Pulsed Field (PF)/Radiofrequency (RF) Ablation System|Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.
62534263|NCT02052050|EXPERIMENTAL|core stability|Stabilized muscle program will consist of two months of individual physical training that it will be conducted 3 times/week for 90 min each. A correct progression to improve stabilization of deep abdominal muscles will be made.
62534264|NCT02052050|NO_INTERVENTION|control group|usual care
62534265|NCT05806619||Patients with suspected glioma|Patients at diagnosis of both sexes with suspected glioma
62161025|NCT06638892|EXPERIMENTAL|Using PrEP, Doing it for Ourselves (UPDOs) intervention|"This group will receive the UPDOs intervention that includes edutainment, e.g., videos, blogs, vlogs, and Q Care Plus."
62161026|NCT06638892|OTHER|Standard of Care|This group will receive CDC standard of care, e.g., CDC videos and website.
62161027|NCT06665464|ACTIVE_COMPARATOR|Fish oil supplement 1|
62161028|NCT06665464|EXPERIMENTAL|Fish oil supplement 2|
62161029|NCT05513560|EXPERIMENTAL|IBUDILAST|Participants will receive 20 mg dose (2 pills) twice per day taken by mouth.
62161030|NCT05513560|EXPERIMENTAL|PENTOXIFYLLINE|Participants will receive a 400mg dose (1 pill) 3 times per day taken by mouth.
62161031|NCT05513560|PLACEBO_COMPARATOR|PLACEBO|Participants will receive 2 placebo pills twice per day taken by mouth OR 1 placebo pill 3 times a day taken by mouth.
62161032|NCT05761873|ACTIVE_COMPARATOR|Paper audit and feedback only|Provision of A\&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
62161033|NCT05761873|EXPERIMENTAL|Paper and email audit and feedback|Provision of A\&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
62161034|NCT00690534|ACTIVE_COMPARATOR|CMAY|Insulin in young
62161035|NCT00690534|EXPERIMENTAL|IMAY|L-NMMA + insulin in young
62161036|NCT00690534|EXPERIMENTAL|SNPY|SNP in young
62161037|NCT00690534|ACTIVE_COMPARATOR|CSNP|Insulin in elderly
62161038|NCT00690534|EXPERIMENTAL|ISNP|SNP in elderly
62161039|NCT00690534|EXPERIMENTAL|SNPE|SNP in elderly
62161040|NCT00690534|ACTIVE_COMPARATOR|CMealO|Meal in elderly
62161041|NCT00690534|EXPERIMENTAL|SMealO|SNP+meal in elderly
62161042|NCT00690534|ACTIVE_COMPARATOR|MealY|meal in young
62161043|NCT00690534|EXPERIMENTAL|ExIns|insulin+exercise in elderly
62161044|NCT00690534|EXPERIMENTAL|ExMeal|meal+exercise in elderly
62161045|NCT06648707|OTHER|Assigned intervention|The intervention group will start 6 week dual-task invention immediately after baseline.
62161046|NCT06648707|OTHER|Assigned waitlist control|The control group will start 6 week dual-task invention after the follow-up assessment 6 weeks after baseline.
62161047|NCT06650410|EXPERIMENTAL|Immediate receipt group|Participants in this group will receive the VIVA intervention in the first 8 weeks of the study. After the 8-week period, participants will be asked to practice behaviour change techniques for the next 10 weeks.
62161048|NCT06650410|OTHER|Wait-list control and delayed receipt group|Participants in this group will continue with their usual care for the first 10 weeks of the study. At week 10, they will receive the same VIVA intervention.
62161049|NCT06037109||Apparently Healthy Adults|Apparently healthy adults (age ≥ 21 years); who have provided written informed consent for sample use in this study
62161050|NCT06037109||Adults with Chronic, Stable Morbidities|Adults (age ≥ 21 years);with one or more of the following chronic, stable morbid conditions.
62161051|NCT00004578|ACTIVE_COMPARATOR|1|Group 1, n=32 initiated with ABT-378 \& ritonavir; after 3 wks stavudine and lamivudine was added.
62161052|NCT00004578|ACTIVE_COMPARATOR|2|Group II patients (n=68) to be randomized after all Group I patients are enrolled and safety analysis is completed.
62161053|NCT04279054|ACTIVE_COMPARATOR|Group A: 150 mcg morphine|Patients in this group will receive 150mcg of morphine in their neuraxial block
62161054|NCT04279054|EXPERIMENTAL|Group B: 50 mcg morphine|Patients in this group will receive 50mcg of morphine in their neuraxial block
62161055|NCT00703365|EXPERIMENTAL|1|Sorafenib
62534266|NCT05806619||Patients at relapse/progression|Patients at relapse/progression with neurosurgical reoperation indication
62534267|NCT05483595|OTHER|ZFXN group|Subjects actually testing ZFXN
62161056|NCT06585332||Persons with HD|One group - adult patients with genetically confirmed Huntington disease.
62161057|NCT06559306|EXPERIMENTAL|Part 1: Seltorexant|Participants will receive seltorexant orally once daily for 6 weeks during the double-blind (DB) treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant throughout the study.
62161058|NCT06559306|PLACEBO_COMPARATOR|Part 1: Placebo|Participants will receive matching placebo orally once daily for 6 weeks during the DB treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline SSRI/SNRI antidepressant throughout the study.
62161059|NCT06559306|EXPERIMENTAL|Part 2: Open Label (OL) Seltorexant|All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. In Part 2 open-label phases (induction and stabilization) all participants (newly enrolled direct entry participants and Part 1 roll-over participants) will receive seltorexant orally in addition to their background SSRI/SNRI treatment.
62534268|NCT05483595|OTHER|Placebo group|Subjects actually testing placebo
62534269|NCT04620928|EXPERIMENTAL|Concept Retrieval|Patients will be given behavioral intervention, and their brain activity recorded.
62534270|NCT04558268|EXPERIMENTAL|treatment group|
62534271|NCT04558268|PLACEBO_COMPARATOR|placebo group|
62534272|NCT01498731|EXPERIMENTAL|Copeptin|"Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions.~To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software Praxis-connect i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.~Patients who test positive for Copeptin will be treated as by standard practise."
62161060|NCT06559306|EXPERIMENTAL|Part 2: DB Seltorexant|All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phase will receive treatment with seltorexant orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study.
62161061|NCT06559306|PLACEBO_COMPARATOR|Part 2: DB Placebo|All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phases will receive treatment with matching placebo orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study.
62161062|NCT01671371|OTHER|Immediate Ultrasound|A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
62161063|NCT01671371|OTHER|Delayed Ultrasound|A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization
62161064|NCT06450834||Ostene|Patients who received Ostene during their thoracolumbar spine surgery
62161065|NCT06450834||No Ostene|Propensity score matched cohort from previous study that did not receive Ostene during their spine surgery
62161066|NCT06098508|EXPERIMENTAL|Osteopathic Manual Treatment|
62161067|NCT06098508|SHAM_COMPARATOR|Sham Treatment Arm|
62161068|NCT05472194|EXPERIMENTAL|Experimental Condition|Participants allocated to the Experimental condition will be following a cognitive training program using a set of game-based activities specifically developed to train executive functions.
62161069|NCT05472194|ACTIVE_COMPARATOR|Control Condition|Participants allocated to the Control condition will be following the same sessions of the training program (similar to the Experimental group) while playing with a set of commonly used games within the school context (e.g. puzzles).
62161070|NCT06130566|EXPERIMENTAL|Amlitelimab dose 1|Subcutaneous injection as per protocol
62161071|NCT06130566|EXPERIMENTAL|Amlitelimab dose 2|Subcutaneous injection as per protocol
62161072|NCT06130566|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection as per protocol
62161073|NCT03180086|EXPERIMENTAL|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
62161074|NCT00398749||Epoetin alfa|Epoetin alfa 40 000 IU once weekly variable treatment length
62161075|NCT03890692|EXPERIMENTAL|patients will undergo flexible nasoendoscopy|Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\\ septum\\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
62161076|NCT01304940||PTSD group|Individuals in this group meet criteria for PTSD as defined by DSM-IV
62161077|NCT01304940||trauma control group|individuals in this group do not meet criteria for any Axis I diagnosis as defined by DSM-IV
62161078|NCT06336642|EXPERIMENTAL|Group 1: SPOT-ON|Participants will work with the healthcare team to find the best ways to reduce your shortness of breath by finding what combination of treatments work for participant. Participants will receive education about shortness of breath by the research staff in addition to information about standard treatments or medications for your shortness of breath that would be offered by your medical team.
62161079|NCT06336642|EXPERIMENTAL|Group 2: SPOT-ON Waitlist|Participants will work with the healthcare team to find the best ways to reduce your shortness of breath by finding what combination of treatments work for participant. Participants will receive education about shortness of breath by the research staff in addition to information about standard treatments or medications for your shortness of breath that would be offered by your medical team.
62161080|NCT00525200|ACTIVE_COMPARATOR|A|
62161081|NCT00525200|EXPERIMENTAL|B|
62161082|NCT03363009|EXPERIMENTAL|Connected device with close following|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be analyzed every day and used for coaching
62161083|NCT03363009|OTHER|Connected device with standard coaching|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be saved but not used for coaching
62161084|NCT06280391|EXPERIMENTAL|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
62161085|NCT06280391|EXPERIMENTAL|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) with alternating placebo administration at the 2week interval between active IMP as SC injection for up to 52 weeks
62161086|NCT06280391|PLACEBO_COMPARATOR|Placebo|SC administration of matching placebo Q2W for up to 52 weeks
62161087|NCT03684434|EXPERIMENTAL|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
62161088|NCT03684434|ACTIVE_COMPARATOR|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
62161089|NCT01668992|EXPERIMENTAL|Family intervention|Families receive 12-week program on parenting skills, discipline methods and family communication.
62161090|NCT01668992|NO_INTERVENTION|Waitlist control|Families are on a waitlist and receive the intervention only after the trial is complete.
62161091|NCT00706602||1|Swiss COPD cohort
62161092|NCT00706602||2|Dutch COPD cohort
62161093|NCT04912726|EXPERIMENTAL|Intervention|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
62161094|NCT04912726|NO_INTERVENTION|Placebo|The control group will receive placebo at the same loading dose and infusion with 0.9% saline solution plus standard management under the unit protocol immediately after the echocardiographic diagnosis.
62161095|NCT04107844||Athletes without concussion|We follow the athletes in terms of injuries and make a baseline test each season.
62161096|NCT04107844||Athletes suffering a concussion|We follow the athletes in terms of injuries and make a baseline test each season and when they suffer a concussion, then we follow them with the same test as at baseline every 14th day for 3 months, after that they will get enrolled in another study.
62161097|NCT06645106|EXPERIMENTAL|Rapid Point of Care (POC) Syphilis testing|
62161098|NCT01072734|EXPERIMENTAL|Vaccine group|single group: all included patients will receive the vaccine
62161099|NCT04972318|ACTIVE_COMPARATOR|ARDSNet strategy|"Patients will receive a mechanical ventilation strategy based on fixed values of positive end-expiratory pressure according to inspired fraction of oxygen.~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before.~This arm is similar to the ARMA (Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome) trial."
62161100|NCT04972318|EXPERIMENTAL|STAMINA strategy|"Patients will receive a mechanical ventilation strategy based on positive end-expiratory pressure tailored to achieve the optimal respiratory system compliance and to have driving pressure limited to 14 cmH2O.~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before."
62161101|NCT06719934|EXPERIMENTAL|Dienogest group|will take 2 mg oral Dienogest
62161102|NCT06719934|EXPERIMENTAL|Uterine artery embolization|will undergoes uterine artery embolization by local anasthesia
62161103|NCT05407844|NO_INTERVENTION|Standard care|Standard cancer care
62161104|NCT05407844|EXPERIMENTAL|Standard care + DeCIDE PC intervention|Community health worker support and standard cancer care
62161105|NCT05652335|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive JNJ-79635322. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
62161106|NCT05652335|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive JNJ-79635322 at the RP2D regimen(s) determined in Part 1.
62161107|NCT06330363|EXPERIMENTAL|LLLT|The LLLT will be performed using a Cube plus30 (Eltech K-Laser s.r.l., Italy). Settings will be based on manufacturer's guidelines for skin and deep tissue stimulation. The LLLT will take 25 min, with 3x5 min of treatment separated by 5 min of rest. In total 16800 J in form of light energy will be applied (3 x 5600 J). All 4 available wavelength will be used (660, 800, 905 and 970 nm). The randomization procedure to allocate the treated leg will occur via a random-number generator stratified for sex (www.randomization.com) performed by an independent researcher of the research group. During the laser treatment protective goggles (K-Laser Protective Goggles, Eltech K-Laser s.r.l.) need to be worn and will therefore be provided. LLLT will only be applied by trained personal.
62161108|NCT06330363|SHAM_COMPARATOR|Sham|Sham laser based on the same laser device which emitts only light.
62161109|NCT05531292|EXPERIMENTAL|Study Lens|investigational IOL Model C0002
62161110|NCT05531292|ACTIVE_COMPARATOR|Control Lens|control IOL Model ZCB00/DCB00
62534273|NCT01498731|NO_INTERVENTION|Standard|Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
61976043|NCT05967611||Healthy Adults|At least 30 healthy adult participants aged 18-45 years performing the Trendelenburg hip abduction test
62161111|NCT05344352|ACTIVE_COMPARATOR|Mutistrain probiotic|
62161112|NCT05344352|PLACEBO_COMPARATOR|Placebo|
62161113|NCT05130359|PLACEBO_COMPARATOR|Placebo|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
62161114|NCT05130359|EXPERIMENTAL|Banana peel extract|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
62161115|NCT06721273|EXPERIMENTAL|Iodine supplement|In intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.
62161116|NCT06721273|PLACEBO_COMPARATOR|Placebo|Women will take a placebo tablet daily (containing white wheat flour, which is similar to iodine table in terms of size, shape, and color, Tavan Institute, Tehran, Iran) 2 months before starting the new IVF cycle.
62161117|NCT04950816|EXPERIMENTAL|tailored MBI (.b)|
62161118|NCT04950816|ACTIVE_COMPARATOR|attention control condition|
62161119|NCT02397226|ACTIVE_COMPARATOR|Radiofrequency ablation|Treatment with radiofrequency ablation using radiofrequency ablation catheter. This intervention implies tumescent anesthesia.
62161120|NCT02397226|ACTIVE_COMPARATOR|High ligation/stripping|Treatment with high ligation/stripping using a vein stripping catheter. This intervention implies general anesthesia.
62534274|NCT00715936|ACTIVE_COMPARATOR|Control|Routine services for infants and young children delivered by the Lady Health Workers of the National Programme for Family Planning and Primary Healthcare (Basic Health and Nutrition Education and Services)
62534275|NCT00715936|EXPERIMENTAL|ECD Group|Stimulation and care for development (plus basic health and nutrition education and services)
62534276|NCT00715936|EXPERIMENTAL|Enhanced Nutrition|Care for Nutrition: Enhanced education messages and Sprinkles for children aged 6-24 months (plus basic health and nutrition education and services)
62534277|NCT00715936|EXPERIMENTAL|ECD and Enhanced Nutrition|Stimulation and care for development and care for nutrition (plus basic health and nutrition education and services)
62534278|NCT01377376|EXPERIMENTAL|ARQ 197|ARQ 197 and Erlotinib
61976044|NCT01909050||refractory celiac disease|
61976045|NCT01909050||well-controlled celiac disease|
61976046|NCT01909050||uncontrolled celiac disease|either newly diagnosed with celiac disease or not on a gluten-free diet
61976047|NCT01909050||gluten-sensitivity|
61976048|NCT01909050||disorders other than celiac disease.|
61976049|NCT00931814|OTHER|exercise|
61976050|NCT02889484||Disc hernia patients treated in Sweden|Individuals undergoing lumbar disc hernia surgery and included in the Swespine register
62161121|NCT04245423|ACTIVE_COMPARATOR|Augmented Usual Care (AUC)|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. Almost all practices have hired mental health clinicians, equivalent to the care managers in the investigators' collaborative care model, to treat mild and moderate depression and anxiety. These clinicians typically are licensed clinical social workers; a few are nurses or psychologists. No care managers have received systematic training in treating patients with OUD. The clinicians will retain their role and continue to treat and monitor patients with mental health conditions in these practices. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD. Patients are informed that the primary care practice provides both OUD and mental health treatment and are referred back to their provider for referral or to schedule care. A list of available community resources are available to the patient.
62161122|NCT04245423|EXPERIMENTAL|Collaborative Care (CC)|"CC condition includes the following elements:~1. Personnel trained to assist with scheduling, reminders and referrals;~2. PCP trained and waivered to provide evidence-based pharmacotherapy for OUD;~3. Addictions psychiatrist with collaborative care expertise to provide treatment consultation and supervision in both OUD and mental health issues;~4. A care manager trained in evidence-based interventions for individuals with OUD and psychiatric disorders, who provides care in the primary care practice as part of the collaborative care team;~5. Measurement-guided care and treat-to-target practices, using validated measures of substance use, depression, anxiety as well as measures of adherence and side effects;~6. Electronic and in-person systematic communication regarding patient care among team members, facilitated by the electronic health record; and~7. Shared patient-provider decision making."
62161123|NCT04245423|EXPERIMENTAL|Collaborative Care + Certified Recovery Specialist (CC+)|In addition to the collaborative care model described above, patients in the CC+ condition will have access to a Certified Recovery Specialist (CRS) to assist with treatment engagement and retention. A CRS is a person in the community who is in recovery and may share similar experiences and barriers that participants have faced. They will work with participants as a peer to help them coordinate information and needs with their providers. The CRS will take participants to their PCP appointments and any other appointments that they may have to help them engage and stay in care to remain healthy. They will also provide education and help participants work on their recovery goals. They will identify and support linkages to community resources and help participants identify barriers to full participation in their recovery and develop strategies to overcome those barriers.
62161124|NCT05961228|OTHER|scoliosis|adolescent age 10-15 with idiopathic scoliosis
62161125|NCT03512041|EXPERIMENTAL|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
62161126|NCT03512041|EXPERIMENTAL|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
62161127|NCT03512041|EXPERIMENTAL|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
62534279|NCT01377376|PLACEBO_COMPARATOR|Placebo|Placebo and Erlotinib
62534280|NCT04842838|EXPERIMENTAL|DCB strategy|
62161128|NCT03512041|SHAM_COMPARATOR|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
62161129|NCT06286319|EXPERIMENTAL|Explanted Lungs|"After the lungs are explanted from the recipient donor, they will be connected to the Angel Cooler via a tracheostomy tube or special adaptor to assess the function of this device in providing cooling oxygen and positive pressure to keep the lungs inflated while on the back table. The lungs will be hooked up to the cooling machine for 15-20 minutes. During this time, investigators will monitor the airway temperature, pressure and oxygen concentration continuously during the entire preservation time. Once these measures are obtained and synced to a corresponding computer, investigators will then disconnect the lungs from the device and continue the standard procedure of sending them to pathology where they will be discarded per usual in lung transplantation."
62161130|NCT04606381|EXPERIMENTAL|Part 1: Ami-LC-MD and Ami-LC|Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.
62161131|NCT04606381|EXPERIMENTAL|Part 2: Ami-HC and Ami-HC-CF|Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).
62161132|NCT04606381|EXPERIMENTAL|Part 3: Ami-HC-CF + Lazertinib and Ami-HC+ Lazertinib|Participants will receive SC infusion of either Ami-HC-CF or Ami-HC in combination with lazertinib tablet.
62161133|NCT01452204|EXPERIMENTAL|Pulsed Electromagnetical Field|
62161134|NCT01452204|PLACEBO_COMPARATOR|Placebo|
62534281|NCT04842838|ACTIVE_COMPARATOR|DES strategy|
62534282|NCT06414317|EXPERIMENTAL|Supportive Care (ENST)|Patients and caregivers receive access to the bladder cancer ENST and patients undergo psychological distress and nutrition screenings and may attend social work, psychology, and/or nutrition consultations as appropriate throughout the study. Patients, caregivers, and providers also attend virtual support group meetings periodically on study.
62534283|NCT03056586|EXPERIMENTAL|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.~Follow-up will be after 3, 6, and 12 month period."
62534284|NCT03056586|NO_INTERVENTION|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
62714759|NCT01678521||Hypercholesterolemic patients|Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment
62161135|NCT04396236|EXPERIMENTAL|Lasmiditan High Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
62161136|NCT04396236|EXPERIMENTAL|Lasmiditan Mid Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
62161137|NCT04396236|EXPERIMENTAL|Lasmiditan Low Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
62161138|NCT04396236|PLACEBO_COMPARATOR|Placebo|Placebo administered orally.
62161139|NCT03144076|EXPERIMENTAL|Group A|\[Other: RSBY Health Insurance\] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
62161140|NCT03144076|EXPERIMENTAL|Group B|\[Other: RSBY Health Insurance\] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
62161141|NCT03144076|EXPERIMENTAL|Group C|\[Other: RSBY Health Insurance\] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
62161142|NCT03144076|NO_INTERVENTION|Group D|\[No intervention\] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
62161143|NCT01361789|ACTIVE_COMPARATOR|COXIB|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
62161144|NCT01361789|ACTIVE_COMPARATOR|Dexamethasone|dexamethasone 8 mg iv
62161145|NCT01361789|ACTIVE_COMPARATOR|COXIB and dexamethasone|combination of coxib AND dexamethasone
62161146|NCT06173063|EXPERIMENTAL|Mobility+ Arm|Adult patients using Mobility+ novel enteral feeding system for nutritional intake.
62161147|NCT02804815|ACTIVE_COMPARATOR|Aspirin 100mg|Aspirin 100mg
62161148|NCT02804815|PLACEBO_COMPARATOR|Placebo 100mg|100mg Placebo
62161149|NCT02804815|ACTIVE_COMPARATOR|Aspirin 300mg|Aspirin 300mg
62161150|NCT02804815|PLACEBO_COMPARATOR|Placebo 300mg|300mg Placebo
62161151|NCT05038319|ACTIVE_COMPARATOR|Cyanoacrylate injection and EUS guided coil and glue injection|The procedure would be performed under conscious sedation.The endoscope would be used to reach the site of Varices. In Conventional technique treatment with cyanoacrylate the injection was performed using a 23-G sclerotherapy needle catheter . One vial of N-butyl-2-cyanoacrylate (0.5 mL) was mixed with Lipiodol) in a 1:1 ratio, and injected intravesically as a 1 mL bolus. The injection was repeated until total hardening of the varix. In treatment with coil and cyanoacrylate once the gastric varix was identified, the total diameter of the vascular pseudotumor was measured and the puncture was made at the site of the widest varix. The puncture was performed using a 19 G needle . the size of the coil after release should not be greater than the caliber of the vessel. Following coil deployment, 2 mL of distilled water was injected, followed by one vial (0.5 mL) of N-butyl-2-cyanoacrylate mixed with Lipiodol in 1:1 ratio.
62161152|NCT05038319|PLACEBO_COMPARATOR|COIL and GLUE|"Cyanoacrylate injection, first published by Soehendra in 1986, remains the conventional treatment method.~Since coils were first used to treat ectopic varices by Levy in 2008(6), this technique has been increasingly implemented into clinical practice. However, its higher cost has been a limiting factor in more widespread use.~Depending on the ectasia of the varix the following coil was deployed: 8 mm x 20 cm, 10 mm x 20 cm, or 10 mm x 30 cm (Interlock-18 Fibered IDC Occlusion System,Cook)."
62161153|NCT00001154||Patients|Subjects with new and undefined dyslipidemia
62161154|NCT05526248|EXPERIMENTAL|Lead-in phase: Darolutamide treatment|Darolutamide treatment arm is single cohort in lead-in phase.
62161155|NCT05526248|EXPERIMENTAL|Randomized phase: Darolutamide treatment|The conduct of the randomized phase is dependent on the results of the lead-in phase.
62161156|NCT05526248|ACTIVE_COMPARATOR|Randomized phase: Enzalutamide treatment|The conduct of the randomized phase is dependent on the results of the lead-in phase.
62161157|NCT04485013|EXPERIMENTAL|Phase 1a, Monotherapy Dose Escalation|
62161158|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)|Arm 1 will enroll subjects with advanced/metastatic, prior checkpoint inhibitor treated Head and Neck Squamous Cell Carcinoma (HNSCC)
62161159|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)|Arm 2 will enroll subjects with advanced/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
62161160|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)|Arm 3 will enroll subjects with advanced/metastatic colorectal cancer (CRC)
62161161|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), prior anti-EGFR therapy|Arm 4 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild-type colorectal cancer (CRC) who have progressed on a prior anti-EGFR therapy
62714760|NCT04192591|EXPERIMENTAL|Superion™ IDS device|Superion™ Indirect Decompression System (IDS)
62161162|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), no prior anti-EGFR therapy|Arm 5 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild type colorectal cancer (CRC) who have not received a prior anti-EGFR therapy
62161163|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)|Arm 6 will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
62161164|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)|Arm 7 will enroll subjects with advanced/metastatic prior checkpoint inhibitor treated non-small cell lung cancer (NSCLC)
62534285|NCT04776837||Main Cohort|"* Patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival)~* Prior to starting anti-cancer therapy and at subsequent designated visits (every one month)~* Collections include:~  * Blood sample~ * Questionnaires quality of life, mood, and symptoms~ * Tissue may be obtained for next-generation sequencing."
62161165|NCT04485013|EXPERIMENTAL|Phase 1b, Dose Expansion: TTX-080 as monotherapy OR in combination with pembrolizumab|"Arm 8: TTX-080 monotherapy:~* Advanced/metastatic, prior checkpoint inhibitor treated renal cell carcinoma with predominance of clear cell component~* Advanced/metastatic acral melanoma~Arm 8: TTX-080 in combination with pembrolizumab:~• Advanced/metastatic triple-negative breast cancer (estrogen and progesterone receptor negative and HER2 negative) who has received a prior checkpoint inhibitor"
62161166|NCT04485013|EXPERIMENTAL|TTX-080 in combination with FOLFIRI plus cetuximab|Arm 9: TTX-080 in combination with FOLFIRI plus cetuximab Randomized Arms in subjects with metastatic RAS, BRAF and HER2 wild type colorectal cancer (CRC) who have been received oxaliplatin and 5-FU based chemotherapy in the first line or adjuvant (relapse within 6 months) setting. Prior bevacizumab allowed. No prior EGFR inhibitor or irinotecan containing regimen
62161167|NCT04485013|EXPERIMENTAL|FOLFIRI plus cetuximab|Arm 10: FOLFIRI plus cetuximab Randomized Arms in subjects with metastatic RAS, BRAF and HER2 wild type colorectal cancer (CRC) who have been received oxaliplatin and 5-FU based chemotherapy in the first line or adjuvant (relapse within 6 months) setting. Prior bevacizumab allowed. No prior EGFR inhibitor or irinotecan containing regimen
62161168|NCT04395196|ACTIVE_COMPARATOR|High-dose choline supplementation|2 g choline cation
62161169|NCT04395196|PLACEBO_COMPARATOR|Placebo|Placebo identical to active treatment in appearance, taste, and smell.
62161170|NCT01445379|EXPERIMENTAL|1|Ipilumumab (DSE) given on day 1 of 21 day cycle for 4 cycles, from cycle 5+ ipilumumab will be given \~every 12wks
62161171|NCT00538616|ACTIVE_COMPARATOR|Precedex-Propofol|Patients received an infusion of precedex for six hours and then a washout and then a propofol infusion for six hours.
62161172|NCT00538616|ACTIVE_COMPARATOR|Propofol- Precedex|Patients received an infusion of propofol for six hours and then a washout and then a precedex infusion for six hours.
62161173|NCT06448546||Control|Patients who are not diagnosed with HD
62161174|NCT06448546||Experimental Group 1|Underweight HD patients
62161175|NCT06448546||Experimental Group 2|Overweight HD patients
62161176|NCT02959866|EXPERIMENTAL|Online income tool|Patients who complete the online income tool with their health provider during the study period.
62161177|NCT04653987||Puncture angle : ≤30 (group I) >30 (group II)|The patients will be divided into two groups based on the puncture angle: ≤30° group and \>30° group. The two groups will be retrospectively analyzed for technical success, fluoroscopy time and complications.
62161178|NCT04653987||Technical Parameters of all Interventions|Peripheral bile duct diameter, central bile duct diameter, number of punctures, type of drainage and total fluoroscopy time will be noted.
62161179|NCT04077463|EXPERIMENTAL|Phase 1 (monotherapy dose escalation): Lazertinib|Participants will receive Lazertinib monotherapy orally once daily (QD) in 21-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. The subsequent doses of Lazertinib will be assigned by the Study Evaluation Team (SET) according to the dose escalation strategy by Bayesian logistic regression model (BLRM).
62161180|NCT04077463|EXPERIMENTAL|Phase 1b (combination): Lazertinib and Amivantamab|Participants will receive Lazertinib and Amivantamab, after the safety of RP2D of Lazertinib is confirmed in the Phase 1, in 28-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. This phase will start enrolling participants after the safety of Amivantamab is confirmed in Japanese participants in Study 61186372EDI1001 (NCT02609776).
62161181|NCT04077463|EXPERIMENTAL|Phase 1b (combination): Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP)|Participants will receive Lazertinib starting dose administered orally once daily (QD) in combination with Amivantamab, and doses of platinum-based chemotherapy (carboplatin and pemetrexed) per standard of care according to local guidance in a 21-day cycle for 4 cycles followed by maintenance with Lazertinib, Amivantamab and pemetrexed until disease progression or unacceptable toxicities.
62161182|NCT04077463|EXPERIMENTAL|Phase 1b (expansion) Cohort A: Lazertinib and Amivantamab|"This cohort A will further characterize the safety, tolerability, and preliminary antitumor activity of Lazertinib and Amivantamab based combinations within specific NSCLC population who have progressed after osimertinib and subsequent platinum-based chemotherapy, and platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR TKI is allowed if administered prior to osimertinib. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter."
62161183|NCT04077463|EXPERIMENTAL|Phase 1b (expansion) Cohort B: Lazertinib and Amivantamab|This Cohort B will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants previously treated with advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
62161184|NCT04077463|EXPERIMENTAL|Phase 1b (expansion) Cohort C: Lazertinib and Amivantamab|This Cohort C will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants with uncommon EGFR mutations. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
62534286|NCT00471289|EXPERIMENTAL|1|PTA with primary placement of Drug (paclitaxel) Eluting Stent
62534287|NCT00471289|ACTIVE_COMPARATOR|2|PTA
62534288|NCT04683744||Healthcare system leadership, providers, and staff|Leadership, providers, and staff at the study team's affiliated health systems.
62534289|NCT04683744||Patients receiving primary care at the study team's affiliated health systems|Patients who had a least one primary care visit during the past 24 months at the study team's affiliated health care systems.
62534290|NCT02398630|OTHER|Open Label|"This is a single arm open label study.~Its procedures involve:~* Transvaginal Echography~* Conventional Virtual Histerosalpingography~* Virtual Histerosalpingography by MRI~* Blood draw for Antimullerian Hormone Dosing"
62534291|NCT03870282|EXPERIMENTAL|9h 15m Goal|
62161185|NCT04077463|EXPERIMENTAL|Phase 1b (expansion) Cohort D: Lazertinib and Amivantamab|Cohort D will seek to validate one or both potential biomarker strategies (next generation sequencing \[NGS\] and Immunohistochemical \[IHC\]), previously identified in Cohort E of Study 61186372EDI1001, in participants with osimertinib-relapsed, but chemotherapy-naive, EGFR Exon19del or L858R mutated NSCLC. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
62161186|NCT04077463|EXPERIMENTAL|Phase 1b (expansion) Cohort E: Lazertinib and Amivantamab|Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter. Cohort E will seek to validate the immunohistochemical (IHC)-based biomarker strategy, by characterizing the activity of Amivantamab and Lazertinib combination in biomarker-positive participants with osimertinib-relapsed, but chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC. In addition, Cohort E will seek to collect prospective data to confirm that prophylactic anticoagulation safely and effectively decreases the incidence of VTE events for patients treated with the combination of Amivantamab and Lazertinib, using Cohort F as reference.
62161187|NCT04077463|EXPERIMENTAL|Phase 1b (expansion) Cohort F: Amivantamab Monotherapy|Participants will receive Amivantamab monotherapy once weekly (QW) for 4 weeks, then every 2 weeks thereafter. Cohort F will seek to validate the IHC-based biomarker strategy, previously identified in Cohort D, by characterizing the activity of JNJ-61186372 monotherapy (Cohort F) in biomarker-positive participants with osimertinib-relapsed, but chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC.
62161188|NCT02988232|EXPERIMENTAL|Treatment(SGHH)|Admission to Sogyeonghwalhyeol-tang granule
62161189|NCT02988232|PLACEBO_COMPARATOR|Placebo|admission to placebo
62161190|NCT05267379||PEP patients|Patients who develop PEP
62161191|NCT05267379||Control cohort|Patients who do not develop PEP
62161192|NCT05871489||Lesotho Cohort|200 patients receiving an all-oral shorter regimen in Lesotho under routine program conditions.
62161193|NCT05871489||Peru Cohort|50 patients receiving an all-oral shorter regimen in Peru under routine program conditions.
62161194|NCT05871489||Kazakhstan Cohort|550 patients receiving an all-oral shorter regimen in Kazakhstan under routine program conditions.
62161195|NCT04005248|OTHER|Testing for HCV|HCV IgG test and questionnaire; both at visit to the sexual health clinic
62161196|NCT03594045|EXPERIMENTAL|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
62161197|NCT03594045|EXPERIMENTAL|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
62161198|NCT06611241|EXPERIMENTAL|Hazard Anticipation Program for Parents of Teen Drivers|Parents and teens randomly assigned to this arm of the trial will engage in a web-based training that provides parents with guidance on how to train their teen to identify potential hazards on the roadway. Parents are also given an opportunity to practice these new skills with teens when watching videos unfold together. The program will take 4 hours to complete and can be done over a two-week period at the parent's convenience.
62161199|NCT06611241|NO_INTERVENTION|Control|The parents and teens in this arm of the study will not receive an intervention of any kind.
62161200|NCT03017716|NO_INTERVENTION|IBP patients on standard therapy|IBP patients on standard therapy.
62161201|NCT03017716|ACTIVE_COMPARATOR|IBP patients on standard therapy and GFD|IBP patients on standard therapy and GFD
62161202|NCT00804765|EXPERIMENTAL|1|Therapeutic education
62534292|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Texts B"|
62534293|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Texts A"|
62534294|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Texts A&B"|
62161203|NCT00804765|PLACEBO_COMPARATOR|2|
62161204|NCT04114903||Study A|Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users.
62161205|NCT04114903||Study B|Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity.
62161206|NCT00405899||Immunotherapy|Patients starting immunotherapy
62161207|NCT00405899||Non-immunotherapy|Patients being treated using methods other than immunotherapy
62161208|NCT06719830||Right group|Septal accessory pathway more to right
62161209|NCT06719830||Left group|Septal accessory pathway more to left
62161210|NCT05149976||Normal group|"* A person judged normal among VFSS (video fluoroscopic swallowing study) examiners~* Normal subjects without symptoms of dysphagia"
62161211|NCT05149976||Residue Group|- As a result of VFSS (video fluoroscopic swallowing study), the subjects who have residues left around the pharynx or airway
62161212|NCT05149976||Aspiration Group|- VFSS (video fluoroscopic swallowing study) test result, the subjects who have aspiration in the airway
62161213|NCT06714929|NO_INTERVENTION|Control|Assessment only
62534295|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive B"|
62534296|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive B | Texts B"|
62534297|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive B | Texts A"|
62534298|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive B | Texts A&B"|
62534299|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive A"|
62534300|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive A | Texts B"|
62534301|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive A | Texts A"|
62534302|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive A | Texts A&B"|
62534303|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive A&B"|
62534304|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive A&B | Texts B"|
62534305|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentive A&B | Texts A"|
62534306|NCT03870282|EXPERIMENTAL|"9h 15m Goal | Incentives A&B | Texts A&B"|
62161214|NCT06714929|EXPERIMENTAL|Hydration Intervention|4-month community participatory school-based hydration intervention that includes provision of refillable water bottles in schools with hydration stations in addition to: 1) social marketing, 2) behavioral reinforcement, and 3) education and outreach.
62161215|NCT06719986|EXPERIMENTAL|Nalmefene Hydrochloride (HCl) injection|Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
62161216|NCT06719986|ACTIVE_COMPARATOR|Narcan intranasal|Naloxone 4 mg for intranasal (IN) administration
62161217|NCT06089915|EXPERIMENTAL|Occupational therapy + robot-assisted exercise|Standard occupational therapy five times per week for 90 minutes (tailored to the patient's needs and abilities) + five 30' sessions (2-3 per week) of robot-assisted exercise for fingers and hand using Amadeo device + five 30' sessions (2-3 per week) of robot-assisted exercise using Armeo Spring exoskeleton for facilitating gross movements of upper limbs
62161218|NCT06089915|ACTIVE_COMPARATOR|Occupational therapy only|Standard occupational therapy five times per week for 90 minutes (tailored to the patient's needs and abilities)
62161219|NCT05450822||Healthy Controls|Healthy volunteers with no pre-existing or current psychiatric, neurological or server somatic illness.
62161220|NCT05450822||Cohort I|Patients who have a history of only one epileptic seizure.
62161221|NCT05450822||Cohort II|Patients who are newly diagnosed with epilepsy.
62161222|NCT05450822||Cohort III|Patients who are newly diagnosed with epilepsy and have an epileptogenic lesion on MRI concordant with seizure semiology and/or EEG.
62161223|NCT05667012|EXPERIMENTAL|High intensity|Women who practice sports professionally.
62161224|NCT05667012|ACTIVE_COMPARATOR|Low intensity|Women who practice sport in a non-professional way.
62161225|NCT05569525|EXPERIMENTAL|Test|Patients receiving non-surgical periodontal treatment within 1 week from enrollment.
62161226|NCT05569525|ACTIVE_COMPARATOR|Control|Patients receiving non-surgical periodontal treatment 6 months after the enrollment.
62161227|NCT04512352|EXPERIMENTAL|Treatment group|Online curriculum has been delivered to this group of participants on an Internet-based platform
62161228|NCT04512352|NO_INTERVENTION|Wait-list control group|Participants in wait-list control group would not have access to the online curriculum until the intervention process for treatment group is finished.
62161229|NCT03523442|EXPERIMENTAL|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days. After final analysis (FA), participants who are receiving apalutamide in the open-label treatment phase may continue receiving single oral dose apalutamide 240 mg once daily in a long-term extension (LTE) phase if they continue to derive benefit from treatment (based on investigator assessment).
62534307|NCT03870282|EXPERIMENTAL|Personal Goal|
62534308|NCT03870282|EXPERIMENTAL|"Personal Goal | Texts B"|
62534309|NCT03870282|EXPERIMENTAL|"Personal Goal | Texts A"|
62534310|NCT03870282|EXPERIMENTAL|"Personal Goal | Texts A&B"|
62534311|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive B"|
62534312|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive B | Texts B"|
62534313|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive B | Text A"|
62534314|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive B | Texts A&B"|
62161230|NCT06295692|EXPERIMENTAL|JNJ-77242113- Participants With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP)|Participants with GPP or EP will receive JNJ-77242113 tablet orally.
62161231|NCT01595724||Group 1|
62161232|NCT06313944||Patients with Clinical Alzheimer's syndrome treated with TPS|Patients with clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months that have planned treatment with TPS
62161233|NCT02077556|EXPERIMENTAL|Everolimus|Everolimus/Tacrolimus/Methylprednisolone \& Prednisolone
62161234|NCT02077556|ACTIVE_COMPARATOR|Mycophenolate mofetil|Mycophenolate mofetil/Tacrolimus/ Methylprednisolone \& Prednisolone
62161235|NCT00330135|EXPERIMENTAL|1|Sodium hyaluronate 2.5 ml - 1 injection
62161236|NCT00330135|PLACEBO_COMPARATOR|2|Placebo injection - 1 injection
62534315|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive A"|
62534316|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive A | Texts B"|
62534317|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive A | Texts A"|
62534318|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive A | Texts A&B"|
62534319|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive A&B"|
62534320|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive A&B | Texts B"|
62534321|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentive A&B | Texts A"|
62534322|NCT03870282|EXPERIMENTAL|"Personal Goal | Incentives A&B | Texts A&B"|
62534323|NCT02208986|ACTIVE_COMPARATOR|0.2mg Triptorelin|Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.
62534324|NCT02208986|ACTIVE_COMPARATOR|0.3mg Triptorelin|Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.
62534325|NCT02208986|ACTIVE_COMPARATOR|Active Comparator: 0.4mg Triptorelin|Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.
62534326|NCT03283319|EXPERIMENTAL|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
62534327|NCT03283319|EXPERIMENTAL|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
62534328|NCT03283319|EXPERIMENTAL|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
62534329|NCT03283319|EXPERIMENTAL|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
62534330|NCT03283319|EXPERIMENTAL|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
62534331|NCT03283319|EXPERIMENTAL|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
62534332|NCT00699062|PLACEBO_COMPARATOR|Placebo pill|The patients allocated into this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator plus placebo for 6 months.
62161237|NCT02312245|EXPERIMENTAL|Arm A (Avatar-directed paclitaxel)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
62161238|NCT02312245|EXPERIMENTAL|Arm B (Avatar-directed gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62161239|NCT02312245|EXPERIMENTAL|Arm C (Avatar-directed liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62534333|NCT00699062|EXPERIMENTAL|Singular pill|The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months
62161240|NCT02312245|EXPERIMENTAL|Arm D (Avatar-directed topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 every 21 days or days 1, 8, and 15 every 28 days. Patients may also receive bevacizumab IV over 90 minutes on day 1 every 21 days or days 1 and 15 every 28 days. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
62161241|NCT03582917|EXPERIMENTAL|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
62161242|NCT03582917|NO_INTERVENTION|No treatment|
62161243|NCT01670942||Traumatic Pneumothorax1|hypobaric chamber
62534334|NCT05607979|ACTIVE_COMPARATOR|TRIAL INTERVENTION|Trial intervention is wound treatment with Lavior Diabetic Wound Gel.
62534335|NCT05607979|ACTIVE_COMPARATOR|CONTROL THERAPY|Control therapy is defined as Smith \& Nephew Solosite Gel Hydrogel Wound Dressing, according to actual guidelines or local clinical standards. Standard therapy is defined as the currently accepted and widely used treatment for the respective wound type, based on the results of past research. Therapy options for standard wound care are treatments that experts agree to be appropriate, accepted, and widely used.
62534336|NCT06206200|EXPERIMENTAL|Dual task training|Patients will recieve 12 sessions (2x/week) of standard of care exercise-based physiotherapy with implementation of cognitive dual task training. This implies that the patients will perform cognitive tasks simultaneously during at least 50% of their physical rehabilitative exercises.
62161244|NCT05594888||PART 1- Group A|"Male and female volunteers (age 18-64 years) working at University Hospital Balgrist. Assessment of validity and intrasubject reliability of maximum isometric grip strength assessed with:~* JAMAR© Smart Dynamometer \[kg\]~* JAMAR© Hydraulic Dynamometer \[kg\]~* Martin Vigorimeter \[kPa\]"
62161245|NCT05594888||PART 1 - Group B|"Male and female volunteers (age 18-64 years) working at University Hospital Balgrist. Assessment of validity and intrasubject reliability and assessment of intersession reliability of maximum isometric grip strength assessed with:~* JAMAR© Smart Dynamometer \[kg\]~* JAMAR© Hydraulic Dynamometer \[kg\]~* Martin Vigorimeter \[kPa\]"
62161246|NCT05594888||PART 2|"Male and female volunteers (age ≥ 10 years).~Maximum isometric grip strength is assessed (no intervention):~* JAMAR© Smart Dynamometer \[kg\]~* JAMAR© Hydraulic Dynamometer \[kg\]~* Martin Vigorimeter \[KPa\]"
62161247|NCT05937659||Biometric Data Collection|Adult subjects with cancer and prescribed concurrent systemic therapy and radiation therapy and enrolled in the study.
62534337|NCT06206200|ACTIVE_COMPARATOR|Standard of care physiotherapy|Patients will recieve 12 sessions (2x/week) of standard of care exercise-based physiotherapy without implementation of cognitive dual task training.
62534338|NCT05363514|EXPERIMENTAL|Low Dose Naltrexone|Low Dose Naltrexone 4.5mg OD PO. Capsules are masked and provided in blister packs.
62534339|NCT05363514|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose 4.5mg OD PO. Capsules are masked and provided in blister packs.
62161248|NCT00596960|EXPERIMENTAL|Motivational Enhancement Therapy|Motivational enhancement therapy
62161249|NCT00596960|ACTIVE_COMPARATOR|Health Education|health education intervention
62534340|NCT05395455|NO_INTERVENTION|Periodontally Healthy|Systemically and periodontally healthy
62534341|NCT05395455|ACTIVE_COMPARATOR|Stage III Grade B Periodontitis|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62534342|NCT05395455|ACTIVE_COMPARATOR|Stage III Grade C Periodontitis|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
62161250|NCT03799965|ACTIVE_COMPARATOR|ERAS protocol are evaluated|"* It is to compare the durations of stay in the intensive care unit and in hospital~* It is to compare the incidences of complications of the groups"
62161251|NCT03799965|ACTIVE_COMPARATOR|ERAS protocol are not evaluated|"* It is to compare the durations of stay in the intensive care unit and in hospital~* It is to compare the incidences of complications of the groups"
62161252|NCT05544708|EXPERIMENTAL|Intervention|Wellness Ambassadors will undergo training to recruit and deliver a lifestyle intervention to members of their social networks. HCL in the intervention group will deliver the intervention immediately following baseline visits and randomization.
62161253|NCT05544708|NO_INTERVENTION|Delayed Intervention|Wellness Ambassadors will undergo training to recruit and deliver a lifestyle intervention to members of their social networks. HCL in the delayed intervention group will deliver the intervention after 24 week data collection visits are complete.
62161254|NCT01196741|ACTIVE_COMPARATOR|Saracatinib plus weekly paclitaxel|
62534343|NCT01774552||Port-wine stain|Photo Acoustic Microscopy and Optical Coherence tomography
62161255|NCT01196741|PLACEBO_COMPARATOR|Placebo plus weekly paclitaxel|
62161256|NCT03767244|EXPERIMENTAL|Apalutamide + ADT|Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy (RP) with pelvic lymph node dissection (pLND), followed by an additional six cycles of treatment.
62161257|NCT03767244|EXPERIMENTAL|Placebo + ADT|Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by RP with pLND, followed by an additional six cycles of placebo treatment.
62161258|NCT03514667|ACTIVE_COMPARATOR|intervention group|80 mg nanomicielle curcumin capsules once a day for 12 weeks
62161259|NCT03514667|PLACEBO_COMPARATOR|control group|placebo capsules once a day for 12 weeks
62161260|NCT05980325|EXPERIMENTAL|Nordic Walking|Patients in this arm will be assigned to a 12-week exercise intervention twice weekly based on Nordic Walking (NW). The intervention will be structured as follows: i) 10 min warm-up, ii) 40 min NW with muscle strengthening exercises interspersed in between and iii) 10 min cool-down. Intensity will be monitored with a heart rate monitor (when available) and/or Borg Scale to reach a moderate intensity for the first 6 weeks (4 - 6 or 55-65% HR reserve) to a moderate-to-high intensity the following weeks (7 - 8 or 65-75% HR reserve).
62161261|NCT05980325|EXPERIMENTAL|Aquatic Exercise|Patients in this group will be assigned to a 12-week, twice weekly water-based exercise programme to be conducted at a chest-high swimming pool kept around 30 to 32 degrees Celsius. Each session will be structured as previous: i) 10 min warm up; ii) 40 min of combined endurance and strength exercise training and iii) 10 min cool down. Intensity will be monitored using the Borg Scale to be moderate during the first 6 weeks (4 - 6) and moderate-to-high the following 6 weeks (7-8).
62161262|NCT05980325|ACTIVE_COMPARATOR|Functional Exercise Training|In this group, patients will participate in a traditional, circuit-based exercise training at a fitness facility twice daily during 12 weeks. Each session will consist of: i) 10 min warm up; ii) 40 min of combined resistance and endurance training using a circuit-based structure and iii) 10 min cool-down. Intensity will be monitored with a HR monitor (when available) and/or Borg Scale to reach a moderate intensity for the first 6 weeks (4 - 6 or 55-65% HR reserve) and will progress to moderate-to-high over the following weeks (7-8 or 65-75% HR reserve).
62161263|NCT02884999||severe trauma patients|Severe trauma patients admitted to the site in the first 24 hours
62161264|NCT06375460|EXPERIMENTAL|Physical Activity Focused App Prompt|The app prompts will ask participants what went well, or did not go well with their physical activity in the previous 24 hours in relation to their blood glucose numbers.
62161265|NCT06375460|EXPERIMENTAL|Diet Focused App Prompt|The app prompts will ask participants what went well, or did not go well with their diet in the previous 24 hours in relation to their blood glucose numbers.
62161266|NCT06375460|EXPERIMENTAL|No App Prompt|No app prompt will be sent to the participant
62161267|NCT06719752|ACTIVE_COMPARATOR|Assessing the acute effects of mobilization|Participants will undergo an active intervention consisting of passive mobilization of rhythmic gliding.
62161268|NCT06415695|EXPERIMENTAL|A single-group, pre-post design to evaluate a three-month weight loss intervention in adult.|Ten 40-minute education sessions appropriate to Saudi people will be developed and will cover essential topics for enhancing diet, lifestyle, and health. Each session comprises four modules, including activities and homework reviewed by a dietitian. Based on the EMPOWER weight loss program developed by the Nakamura lab for the US population, adjustments will be made to align with Saudi preferences, including food choices and cooking methods. Participants will access these materials online.
62161269|NCT02219529|EXPERIMENTAL|MCE|patients were assigned to swallow MCE first, followed by the gastroscopy
62161270|NCT02219529|ACTIVE_COMPARATOR|Standard gastroscopy|patients were assigned to swallow MCE first, followed by the gastroscopy
62161271|NCT04273854|EXPERIMENTAL|Intervention|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice.
62161272|NCT04273854|NO_INTERVENTION|Control|The control arm will be managed as per usual NHS led care with assessment by their own health care professionals and adjustment of their medications as is needed. The BP of this group will be monitored and recorded at the same time-points and in the same manner as the intervention arm as will all other secondary outcome measures.
62161273|NCT05731492|EXPERIMENTAL|Open-label Core Treatment Period: Macitentan|Participants will receive macitentan as a monotherapy or add-on to an existing therapy daily for 24 weeks during core treatment period. Optional treatment extension period of up to 1 year for those participants who completed the core treatment period.
62161274|NCT05977699|ACTIVE_COMPARATOR|salbutamol delivered via pressurized metered dose inhaler|200mcg of salbutamol will be delivered using a pressurized metered dose inhaler plus spacer
62161275|NCT05977699|PLACEBO_COMPARATOR|placebo|normal saline will be administered with a vibrating mesh nebulizer and 200mcg of placebo will be administered using a pressurized metered dose inhaler plus spacer
62161276|NCT05977699|EXPERIMENTAL|salbutamol delivered with vibrating mesh nebulizer|200microliters of salbutamol will be administered using a vibrating mesh nebulizer
62161277|NCT04471051||COVID19 Convalescent Plasma Treatment|Hospitalized COVID19 patients who receive COVID19 Convalescent Plasma under Expanded Access protocol NCT04372368.
62161278|NCT04823078|ACTIVE_COMPARATOR|Activity base therapy|
62161279|NCT04823078|OTHER|Strength training|
62161280|NCT06253195|EXPERIMENTAL|Phase 1a: Dose Escalation|Sequential cohorts of increasing dose levels of BGB-43395 will be evaluated as monotherapy and in combination with either fulvestrant or letrozole.
62161281|NCT06253195|EXPERIMENTAL|Phase 1b: Dose Expansion|The recommended dose for expansion (RDFE) for BGB-43395 in combination with fulvestrant from Phase 1a will be evaluated in HR+ breast cancer and selected tumor cohorts.
61976051|NCT02889484||Disc hernia patients treated in Norway|Individuals undergoing lumbar disc hernia surgery and included in the NORspine register
62161282|NCT01040299|EXPERIMENTAL|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
62161283|NCT01040299|SHAM_COMPARATOR|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
62161284|NCT01040299|ACTIVE_COMPARATOR|control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
62161285|NCT06277011|EXPERIMENTAL|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
62161286|NCT05939050|EXPERIMENTAL|Partisipants|
62161287|NCT04110392|EXPERIMENTAL|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
62161288|NCT06005441|EXPERIMENTAL|CBL-514 Injection|Participant will receive CBL-514 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
62161289|NCT06005441|EXPERIMENTAL|CBL-A1 Injection|Participant will receive CBL-A1 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
62534344|NCT05951855|EXPERIMENTAL|Selinexor combined with chidamide|R/R AML who are ineligible for intensive chemotherapy will receive selinexor in combination with chidamide, 28 days per cycle, Selinexor will be used as 40 or 60mg BIW for two weeks, and chidamide will be used as 10mg/d from day 1 to 28. Depending on the level of recovery, patients will either be forced to come off study or have the option to continue the medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant.
62534345|NCT00227110|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone 30 mg/d will be given for 8 weeks and titrated to 45 mg/d until the end of the 6-month study in a randomized, double-blind, study design.
62534346|NCT00227110|PLACEBO_COMPARATOR|Placebo|Placebo once daily is given following a randomized, double-blind, placebo-controlled study design.
62534347|NCT01284621|EXPERIMENTAL|BI 10773|1 tablet per days for 5 days, oral administration with 240 mL water for each treatment
62534348|NCT01284621|OTHER|Ramipril|1 tablet on day 1 and 2 tablets per day on day 2-5, oral administration with 240 mL water for each treatment
62534349|NCT01284621|OTHER|BI 10773 + Ramipril|1 tablet BI 10773 and 1 tablet on day 1 and 2 tablets ramipril per day on day 2-5, oral administration with 240 mL water for each treatment
62534350|NCT03074773|ACTIVE_COMPARATOR|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
62161290|NCT06005441|EXPERIMENTAL|CBL-A2 Injection|Participant will receive CBL-A2 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
62534351|NCT03074773|ACTIVE_COMPARATOR|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
62534352|NCT06634342|EXPERIMENTAL|Participants of a syringe services program|Participants of the syringe services program who will be offered point-of-care hepatitis C RNA testing will be adults 22 or older who do not already know they have HCV infection.
62534353|NCT02955381|EXPERIMENTAL|Restylane Silk, 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
62161291|NCT06005441|PLACEBO_COMPARATOR|0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
62161292|NCT04810104|EXPERIMENTAL|Active drug: AZD0328|Participants will receive AZD0328 capsules for oral administration.AZD0328 is a selective α7 nicotinic receptor agonist, The total daily dosage of AZD0328 is 1mg per day; administered as 0.5mg twice daily / BID. The study treatment period is 12-weeks.
62161293|NCT04810104|PLACEBO_COMPARATOR|Placebo|Participants will receive identical-appearing placebo capsules for oral administration.Participants will be instructed to take 2 capsules in the morning and 2 capsules in the evening for a 12-week period.
62161294|NCT05655689||Bacterial keratitis|Microbial keratitis patients diagnosed with bacterial keratitis and treated with the empiric topical antibiotics eye drops at the usual doses for the management of bacterial keratitis, as part of routine medical care.
62534354|NCT02955381|PLACEBO_COMPARATOR|Placebo (Saline), 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
62534355|NCT02334592|EXPERIMENTAL|Low Pressure 100W sunbed|
62534356|NCT02334592|EXPERIMENTAL|Low Pressure 160W sunbed|
62534357|NCT02334592|EXPERIMENTAL|High Pressure sunbed|
62534358|NCT02334592|NO_INTERVENTION|Control group|
61976052|NCT02889484||Disc hernia patients treated in Denmark|Individuals undergoing lumbar disc hernia surgery and included in the Danespine register
61976053|NCT01918761|EXPERIMENTAL|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 (i.v) q21d Dacomitinib 45mg/ orally (continuous)
61976054|NCT04620720|NO_INTERVENTION|control group|routuine analgesics wil be given
62534359|NCT00044967||Group 1|"Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline.~The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance.~Patients may be referred for genetic counseling."
62534360|NCT03335449|EXPERIMENTAL|Protective ventilation group|Protective ventilation (PV group) (Vt 6 ml/Kg of ideal body weight, PEEP 8-10 cmH 2 O and repeated recruitment maneuvers.
62534361|NCT03335449|NO_INTERVENTION|Standard ventilation group|Standard ventilation (SV group) (Tidal Volume, Vt 10 ml/Kg of ideal body weight, Positive End Expiratory Pressure, PEEP 5 cmH 2 O, no recruitment maneuvers)
62161295|NCT05655689||Fungal keratitis|Microbial keratitis patients diagnosed with fungal keratitis and treated with the empiric topical antifungals eye drops at the usual doses for the management of fungal keratitis, as part of routine medical care.
62161296|NCT05655689||Mixed bacterial and fungal keratitis|Microbial keratitis patients diagnosed with mixed bacterial and fungal keratitis and treated with the empiric topical antibiotics and antifungals eye drops at the usual doses for the management of mixed bacterial and fungal keratitis, as part of routine medical care.
62161297|NCT06721754|NO_INTERVENTION|Standard Wound Treatment|
62161298|NCT06721754|ACTIVE_COMPARATOR|Negative Pressure Wound Treatment|
62161299|NCT05346484|EXPERIMENTAL|CF33-hNIS IT Administration Monotherapy|
62161300|NCT05346484|EXPERIMENTAL|CF33-hNIS IV Administration Monotherapy|
62161301|NCT05346484|EXPERIMENTAL|CF33-hNIS IT Administration in Combination with Pembrolizumab|
62161302|NCT05346484|EXPERIMENTAL|CF33-hNIS IV Administration in Combination with Pembrolizumab|
62161303|NCT03030599|PLACEBO_COMPARATOR|Placebo|Placebo
62161304|NCT03030599|EXPERIMENTAL|JZP-258|JZP-258
62161305|NCT05071664|EXPERIMENTAL|Group 1: Guselkumab and Golimumab|Participants will receive subcutaneous (SC) guselkumab and golimumab.
62161306|NCT05071664|ACTIVE_COMPARATOR|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab and placebo.
62161307|NCT06590961|EXPERIMENTAL|UBX-303061|UBX-303061
62161308|NCT03891433|ACTIVE_COMPARATOR|Carbapenems group|Meropenem (1g intravenously every 8 hours or adjusted to renal function) or Ertapenem (1g intravenously every 24 hours or adjusted to renal function) by 10 days.
62161309|NCT03891433|ACTIVE_COMPARATOR|Piperacillin/tazobactam.|Piperacillin / Tazobactam (4.5gr intravenously every 6 hours or adjusted to renal function) by 10 days.
62161310|NCT01762345|EXPERIMENTAL|pessary device|pessary (disposable intra-vaginal device)
62161311|NCT06032273|EXPERIMENTAL|Access to investigator-designed lung transplant education website|Access to an investigator-designed web-based educational resource with information about lung transplant for three months.
62161312|NCT06032273|NO_INTERVENTION|No access to lung transplant education website|No access to the investigator-designed lung transplant educational resource.
62161313|NCT04228068|EXPERIMENTAL|Intervention|The exercise program will be for the first 12 weeks after returning home. The intervention will be provided after patients return home. Each patient will receive 7 home visits in total over the intervention period by a physiotherapist (PT) and/or a physiotherapy assistant (PTA). Participants in the intervention group will receive a copy of the Toolkit before discharge from the hospital, and the study coordinator will walk them through it and explain what should be expected during the intervention period.
62161314|NCT04228068|ACTIVE_COMPARATOR|Conventional care|Usual care
62534362|NCT01525264|EXPERIMENTAL|Culturally Relavent Education|Education about improving diet using a DVD with Korean role models and native Korean language.
62714761|NCT03929913|EXPERIMENTAL|Transcatheter Mitral Valve Cerclage Annuloplasty|"To evaluate the feasibility and safety of Transcatheter Mitral Cerclage Annuloplasty (TMCA) to treat symptomatic heart failure accompanied by mitral valve regurgitation despite optimal medical therapy.~The TMCA implant is attached to a guidewire and pulled through the internal jugular sheath, along the coronary sinus, through the basal septum, through the tricuspid valve, and back out of the internal jugular sheath. The position of the TMCA implant is adjusted so that the coronary protection element lies directly over any underlying branch of the left coronary artery."
62161315|NCT05588843|EXPERIMENTAL|SAR443122 level 1|Dose level 1
62161316|NCT05588843|EXPERIMENTAL|SAR443122 level 2|Dose level 2
62161317|NCT05588843|EXPERIMENTAL|SAR443122 level 3|Dose level 3
62161318|NCT05588843|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62161319|NCT04975646|EXPERIMENTAL|Test group|Prescribed exercise program
62161320|NCT04975646|NO_INTERVENTION|Control group|Exercising at patient's own discretion
62161321|NCT02747056|EXPERIMENTAL|Autism spectrum disorder studyA part1|The subjects will perform clinical, psychological and neuropsychological assessment. the subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
62161322|NCT02747056|EXPERIMENTAL|Autism spectrum disorder studyA part2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
62161323|NCT02747056|OTHER|Control adults Study A, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
62161324|NCT02747056|OTHER|Control adults Study A, part 2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
62534363|NCT01525264|ACTIVE_COMPARATOR|Healthy Wife Intervention|Intervention group of couples who received education about importance of a Healthy Diet. It was an attention control group
62161325|NCT02747056|EXPERIMENTAL|Autism spectrum disorder Study B, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
62161326|NCT02747056|EXPERIMENTAL|Autism spectrum disorder Study B, part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements.
62534364|NCT05109806|EXPERIMENTAL|Experimental group|Problem prevention therapy will be given as per intervention. a group of parents will be included for a group session for narration of their problems in relevance to health related quality of life .After the assessment the next session the solution to these problems would be given to them.
62534365|NCT05109806|OTHER|control group|for this group only a general education regarding disease will be conducted and no further interventions will be provide to them .
62534366|NCT01478386|OTHER|Viscosupplementation injections|Control group will receive a series of three viscosupplementation injections into the affected knee
62534367|NCT01478386|EXPERIMENTAL|Off-loading knee brace|
62534368|NCT01478386|EXPERIMENTAL|Viscosupplementation and knee brace|
62534369|NCT03835676|EXPERIMENTAL|Pulmonary hypertension treated with Treprostinil|Thirty patients who will be treated with Treprostinil.
62534370|NCT03275714|ACTIVE_COMPARATOR|People With a Bipolar Affective Disorder|
62534371|NCT03275714|ACTIVE_COMPARATOR|Control subjects without a psychiatric disorder|
62534372|NCT05241028|EXPERIMENTAL|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
62534373|NCT02878122||Patients with epithelial ovarian cancer|Cancer treatment
62534374|NCT03759119|EXPERIMENTAL|Tummy Time and Parent Education|This group will receive tummy time and parent education and be encouraged to perform tummy time on their own. They will utilize the PT Pal application to record their tummy time adherence. The primary investigator performs the intervention to the participants two times a day for 10 minutes for 4 weeks.
62534375|NCT03759119|NO_INTERVENTION|Parent education|This group will receive parent education only and utilize the PT Pal application to record their adherence. The primary caregiver will be encouraged to perform the same dosage of tummy time (2x/day, 10 minutes each, 4 weeks) and record their adherence on the PT Pal application.
62534376|NCT06165250|EXPERIMENTAL|BR1018A-1 + BR1018B + BR1018C|
62534377|NCT06165250|ACTIVE_COMPARATOR|BR1018A + BR1018B-1 + BR1018C|
62534378|NCT06165250|ACTIVE_COMPARATOR|BR1018A-1 + BR1018B + BR1018C-1|
62534379|NCT05121792|EXPERIMENTAL|Therapist online training in Prolonged Grief Disorder Therapy|Participants will be given access to an online 10-module interactive tutorial about Prolonged Grief Disorder Therapy.
62534380|NCT01037296|OTHER|manual ablation|
62534381|NCT01037296|EXPERIMENTAL|robotic ablation|
62534382|NCT05990153|EXPERIMENTAL|Myofascial Release (MR) + Therapeutic exercise (TE)|Patients in the MR+TE group will undergo 12 sessions (3 d/week) of sub-occipital inhibition treatment as a combined muscle and soft tissue inhibition technique. The physiotherapist will apply deep pressure which will be maintained for a total of 10 minutes until the sub-occipital tissues are released. In addition to this technique, the method of pumping and manual treatment (acupressure) of the trigger points on the sub-occipital muscles, on the upper bundles of the trapezius bilaterally, on the sternocleidomastoid bilaterally and on the scalene muscles bilaterally will be applied for a further 10 minutes for a total treatment with myofascial release equal to 20 minutes. At the end of the MR session, the 20-minute TE session will be performed in the same way as described in the TE intervention group.
62161327|NCT02747056|OTHER|Control adults, Study B part 1|The subjects will perform clinical, psychological and neuropsychological assessment.The subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
62534383|NCT05990153|EXPERIMENTAL|Manual therapy (MT) + Therapeutic exercise (TE)|The MT+TE intervention group will carry out rehabilitation treatment with a structured protocol based on mobilizations according to the Mulligan method. Treatment according to Mulligan will be carried out at the discretion of the therapist on the basis of daily evaluations of cervical dysfunction and the eventual manifestation of headache. 5 different techniques will be performed on the patient in 12 sessions (3 v/week, for 4 weeks) as described in Satpute, K., Bedekar, N. \& Hall, T. Effectiveness of Mulligan manual therapy over exercise on headache frequency, intensity and disability for patients with migraine, tension-type headache and cervicogenic headache - a protocol of a pragmatic randomized controlled trial. BMC Musculoskelet Disord 22, (2021)..
62534384|NCT05990153|EXPERIMENTAL|Therapeutic exercise (TE)|Patients in the TE intervention group will be asked to perform 12 sessions (3 day/week) of TE supervised by a physiotherapist. Each session will have a total duration of 40 min divided into 20 min of aerobic exercise and 20 min of TE. Aerobic exercise consists of a total of 20 min of activity on a stationary bike using parameters to increase performance (intensity over 20 min) progressively based on fatigue (Borg scale).The TE consists of warm-up and cool-down exercises for the cervical ROM, associated with stretching exercises of the cervical and scapulothoracic muscles. After the warm-up, muscle strengthening exercises will be performed (isometric, concentric and eccentric contractions of the cervical muscles).
62534385|NCT05990153|ACTIVE_COMPARATOR|Control|Patients assigned to the control group will follow the pharmacological treatment according to medical doctor indications (clinical practice).
62534386|NCT00330226||Psychopharmacotherapy|patients under antipsychotic or mood stabilizer treatment
62534387|NCT03186781|EXPERIMENTAL|Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs|HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
62534388|NCT03186781|EXPERIMENTAL|Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
62534389|NCT03186781|EXPERIMENTAL|Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
62161328|NCT02747056|OTHER|Control adults, Study B part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements
62161329|NCT04999020|EXPERIMENTAL|Ravulizumab|Participants will receive ravulizumab in both Parts A and B.
62534390|NCT03186781|EXPERIMENTAL|Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
62534391|NCT03186781|EXPERIMENTAL|Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
62534392|NCT03186781|EXPERIMENTAL|Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)
62534393|NCT04034537|EXPERIMENTAL|cPSTA GROUP|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo cardiac Phase Space Tomography Analysis (cPSTA) signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
62534394|NCT05263622|EXPERIMENTAL|Group A|Half of patients will be included in this group according to the split-mouth design.
62534395|NCT05263622|EXPERIMENTAL|Group B|Half of patients will be included in this group according to the split-mouth design.
62534396|NCT00537420|PLACEBO_COMPARATOR|1|Nasal Placebo
62534397|NCT00537420|PLACEBO_COMPARATOR|2|Capsule Placebo
62534398|NCT00537420|EXPERIMENTAL|3|Nasal PYY3-36 200 ug
62534399|NCT00537420|EXPERIMENTAL|4|Nasal PYY3-36 400 ug
62534400|NCT00537420|EXPERIMENTAL|5|Nasal PYY3-36 600 ug
62534401|NCT00537420|ACTIVE_COMPARATOR|6|Sibutramine 10 mg
62534402|NCT01286935|EXPERIMENTAL|Low Dose (50mg/day)|
62534403|NCT01286935|EXPERIMENTAL|High Dose (100mg/day)|
62534404|NCT01286935|PLACEBO_COMPARATOR|Placebo|
62534405|NCT06118606|EXPERIMENTAL|Interventional arm|Intervention arm
62534406|NCT00827632|ACTIVE_COMPARATOR|Normal Weight group|Participants with a BMI of 19-24.9 kg/m\^2
62534407|NCT00827632|ACTIVE_COMPARATOR|Obese group|Participants with a BMI of 30-39.9 kg/m\^2
62534408|NCT04021849|EXPERIMENTAL|Intervention|Participants will be gathered in a classroom with computers to receive an asynchronous virtual class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
62534409|NCT04021849|SHAM_COMPARATOR|Control|Participants will be gathered in a classroom with computers to receive a face-to-face class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
61976055|NCT04620720|EXPERIMENTAL|intervention group|patient will receive cap gabapentin 1200 mg 2 hours before surgery
61976056|NCT04236011|EXPERIMENTAL|GC012F treatment|BCMA+ R/R multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)\*10E5/kg cells will be administered at Day 0.
61976057|NCT02600949|EXPERIMENTAL|Cohort A (personalized vaccine, imiquimod)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients then receive imiquimod cream topically in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
62161330|NCT04999020|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo in both Parts A and B.
62161331|NCT06179719|EXPERIMENTAL|Healthy controls|
62161332|NCT03015428|EXPERIMENTAL|Psychoeducation|"Interventions:~Give information Teach and train strategies"
62534410|NCT00866801||Healthy|Healthy subjects scheduled for general anesthesia
62534411|NCT00866801||Healthy with thoracic epidural anelgesia|Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
62534412|NCT00866801||Diabetes|Subjects with diabetes scheduled for general anesthesia
62534413|NCT00866801||Diabetes with autonomic neuropathy|Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia
62534414|NCT05214703|EXPERIMENTAL|cold therapy|Pain scores were measured with a visual analog scale (VAS) before the port catheter was removed from the patients in the experimental group. Before the port catheters were removed, cold application with an ice pack was applied to the patients whose first visual analog scale measurement was made by the researchers. The cold application was terminated an average of 15 minutes after the body temperature decreased by 1 °C.
62534415|NCT05214703|NO_INTERVENTION|no intervention|The patients in the control group did not receive any intervention before and after port catheter removal.
62534416|NCT00888056|EXPERIMENTAL|ARM A|Bilateral chronic electrical stimulation of the hypothalamus/fornix
62714762|NCT05139316|EXPERIMENTAL|DTX401, Then Placebo|Participants receive single peripheral intravenous (IV) infusion of DTX401 in solution. At week 48 participants receive single peripheral IV infusion of Placebo.
62714763|NCT05139316|PLACEBO_COMPARATOR|Placebo, Then DTX401|Participants receive single peripheral IV infusion of Placebo. At week 48 eligible participants receive single peripheral IV infusion of DTX401 solution.
62161333|NCT04741646|EXPERIMENTAL|Treatment Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Ferric Citrate (FC). The full medication dose will be 3g/day for participants weighing \<31 kg, 5g/day for those weighing \>31 - \<51 kg, and 6g/day for participants \>51 kg. These doses will be divided into three doses to be taken with meals.
62161334|NCT04741646|PLACEBO_COMPARATOR|Control Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Placebo. The full medication dose will be 3g/day for participants weighing \<31 kg, 5g/day for those weighing \>31 - \<51 kg, and 6g/day for participants \>51 kg. These doses will be divided into three doses to be taken with meals.
62161335|NCT01996098|EXPERIMENTAL|6-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
62161336|NCT01996098|EXPERIMENTAL|12-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
62161337|NCT01996098|NO_INTERVENTION|Chemotherapy alone|No intervention
62161338|NCT04933188||control|Lean health controls with a BMI\<25kg/m2
62161339|NCT04933188||overweight|patients with a BMI of 25-30kg/m2
62161340|NCT04933188||obesity|patients with a BMI of over 30kg/m2
62161341|NCT03530345|EXPERIMENTAL|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
62161342|NCT03530345|PLACEBO_COMPARATOR|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
62161343|NCT04232202|EXPERIMENTAL|Laser|After extraction, Er:YAG and Nd:YAG lasers used for degranulation, disinfection, deepithelialization, clot stabilization and photobiomodulation.
62161344|NCT04232202|ACTIVE_COMPARATOR|Control|Standard extraction procedure.
62161345|NCT06455098|EXPERIMENTAL|Pulsed Field (PF) Ablation System|Participants with PAF will undergo pulsed field ablation procedure with the OMNYPULSE™ catheter in combination with TRUPULSE™ generator for PVI and to deliver pulsed field (PF) energy for treatment of atrial fibrillation. Study participants will be followed for 12 months after the study index procedure.
62161346|NCT06633588|EXPERIMENTAL|Polyhexanide|
62161347|NCT06633588|ACTIVE_COMPARATOR|Mupirocin and Chlorhexidine|
62161348|NCT06555796|EXPERIMENTAL|Xaluritamig|Xaluritamig will be administered as a short-term intravenous (IV) infusion for a total of 6 cycles. One treatment cycle consists of 28 days.
62161349|NCT01317771||Proximal Biceps Tendon Tenodesis|
62161350|NCT01596777|PLACEBO_COMPARATOR|Treatment A|Administration of LOP placebo (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under placebo condition.
62161351|NCT01596777|PLACEBO_COMPARATOR|Treatment B|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under loperamide-induced obstipation condition.
62161352|NCT01596777|ACTIVE_COMPARATOR|Treatment C|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX 12 mg sc. (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after subcutaneous administration.
62161353|NCT01596777|ACTIVE_COMPARATOR|Treatment D|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX IR (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of immediate release capsule.
62161354|NCT01596777|ACTIVE_COMPARATOR|Treatment E|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX ER (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of extended release capsule.
62161355|NCT06720181||Group 1|Patients with chronic pelvic pain and deep infiltrating endometriosis
62161356|NCT06720181||Group 2|Patients with cystic endometriosis (ovarian endometriomas) without chronic pelvic pain
62161357|NCT06720181||Group 3|Women with no gynecological pathology, under routine outpatient follow-up, matched for age and body mass index
62161358|NCT06361914|ACTIVE_COMPARATOR|Digital Sleep hygiene education|Sleep hygiene education is the commonly delivered treatment for insomnia in patients with chronic pain. The digital sleep hygiene education treatment in the Hvil® app includes the sleep hygiene education element that entails specific information relating to lifestyle (diet, exercise, substance use) and environmental factors (light, noise, temperature) that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake. Parallel to engaging with this element, participants are asked to fill in a sleep diary during the intervention's entire course.
62161359|NCT06361914|EXPERIMENTAL|Digital CBT-I|"The digital CBT-I intervention in the Hvil® app is designed to be completed over a period of nine weeks (5 weeks with the components described below and 4 weeks with maintenance of new habits), and is based on the current consensus concerning non-pharmacological treatment of insomnia including five treatment components (sleep restriction, stimulus control, deactivation/relaxation training, cognitive therapy, sleep hygiene education). Each treatment component consists of an information module (i.e., content and purpose of the specific component), assessment module (i.e., assessment of the severity of the problem addressed by the component), application module (i.e., specific information on different types of exercises the participant should engage in), and evaluation module (i.e., assessment of the treatment gain). Participants are encouraged to complete the information and assessment module in one streak, estimated to last 30-60 minutes."
62161360|NCT00331799|ACTIVE_COMPARATOR|1|Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
62161361|NCT04617197|EXPERIMENTAL|Variable-frequency combination 1|Non disclosure
62161362|NCT04617197|ACTIVE_COMPARATOR|Variable-frequency combination 2|Non disclosure
62714764|NCT05139316|EXPERIMENTAL|DTX401 (Japan Only)|Participants receive single peripheral intravenous (IV)infusion of DTX401 in solution.
62161363|NCT04617197|PLACEBO_COMPARATOR|Control (Placebo)|Non-disclosure
62161364|NCT06023745||case|30 patients diagnosed as a clinical disease of CHB according to the diagnostic criteria of CHB based on, HBsAg, HBeAg serostatus ,HBV DNA level, biochemical liver function, and ultrasonography
62161365|NCT06023745||control|healthy volunteers with negativity for HBsAg, anti- HCV and anti-HIV and with no abnormalities based on physical examination
62161366|NCT05395754|EXPERIMENTAL|PCheck|"Participants allocated to the intervention arm will receive the intervention (use of the PCheck app) for 12 months of follow-up. Participants will be encouraged to use the app as much as they wish throughout the study and will be informed that there will be no set expectation for how frequently they must use the app, although they will be encouraged to use it regularly to thoroughly test it. The app will send notification reminders to check in (in other words, use the daily check-in feature to track their mood, stress, and behaviors related to STI-prevention over time). The notification settings can be adjusted in phone settings by the participant. To encourage peer support and a sense of community, users can interact with community members anonymously through a message board, monitored by research staff. Participants in the intervention will continue routine PrEP care and STI testing through the clinic."
62161367|NCT05395754|NO_INTERVENTION|Routine Care|Participants in the routine care arm will continue routine PrEP care and STI testing through the clinic.
62161368|NCT02006914||Chromium Picolinate|Subjects who are HIV+ and insulin resistant
62161369|NCT02006914||Placebo|HIV+ and insulin resistant
62161370|NCT01982266|EXPERIMENTAL|GRADION™ Hip Total Cartilage Replacement (TCR)™|
62161371|NCT05823220|EXPERIMENTAL|Homeless diversion (HD) group|
62161372|NCT05823220|ACTIVE_COMPARATOR|Treatment-as-usual (TAU) group|
62161373|NCT06385080|EXPERIMENTAL|Cohort 1: Amivantamab Monotherapy (Dose Expansion)|Participants will receive subcutaneous injection of amivantamab monotherapy 1600 milligrams (mg) (2240 mg, if body weight \>=80 kilograms \[kg\]) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight \>=80 kg) once every week (q1w) for the remainder of Cycle 1 (Days 8 and 15), and every 3 weeks (q3w) from Cycle 2 onwards.
62161374|NCT06385080|EXPERIMENTAL|Cohort 2: Amivantamab + Pembrolizumab (Dose Expansion Including Safety Run-in)|Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight \>=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight \>=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous injection of pembrolizumab 200 mg q3w (on Day 1 of each 21-day cycle).
62161375|NCT06385080|EXPERIMENTAL|Cohort 3A (Dose Confirmation): Amivantamab + Paclitaxel|Participants will receive subcutaneous injection of amivantamab 1600 mg (2240 mg, if body weight \>=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight \>=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards, along with intravenous injection of paclitaxel 175 mg/m\^2 q3w (on Day 1 of each 21-day cycle) in dose confirmation Cohort 3A. The recommended Phase 2 combination dose (RP2CD) of amivantamab will be determined in conjunction with study evaluation team (SET) in this dose confirmation Cohort 3A.
62161376|NCT06385080|EXPERIMENTAL|Cohort 3B (Dose Expansion): Amivantamab + Paclitaxel|Participants will receive subcutaneous injection of amivantamab at the determined RP2CD in addition to intravenous injection of paclitaxel 175 mg/m\^2 q3w (on Day 1 of each 21-day cycle) as confirmed by SET in Cohort 3A.
62161377|NCT06385080|EXPERIMENTAL|Cohort 4: Amivantamab Monotherapy|Participants will receive subcutaneous injection of amivantamab monotherapy 1600 mg (2240 mg, if body weight \>=80 kg) on Cycle 1 Day 1 and 2400 mg (3360 mg, if body weight \>=80 kg) q1w for the remainder of Cycle 1 (Days 8 and 15), and q3w from Cycle 2 onwards.
62161378|NCT05483478|EXPERIMENTAL|mobile health combined Multi-course Program|The experimental group received the combination of mobile health and multi-course intervention. In the pre-test, the experimental group joined the LINE group by scanning the QR code. The LINE messages were nutrition and exercise content, as well as exercise videos. One message each for nutrition and exercise was sent every Monday, Wednesday, and Friday, for a total of 12 weeks. The multi-course includes exercise and nutrition, 1 time per week, 2 hours each time, a total of 12 times, and each unit is 50 minutes long. The three measurement time points of the tracking effect were: before intervention, after 4-times interventions, and after 12-times interventions. The following data were collected in the two groups: frailty assessment, grip strength, lower limb muscle strength, health literacy scale and nutrition knowledge scale.
62161379|NCT05483478|ACTIVE_COMPARATOR|Multi-course Program|The control group received multi-course includes exercise and nutrition, 1 time per week, 2 hours each time, a total of 12 times, and each unit is 50 minutes long. The three measurement time points of the tracking effect were: before intervention, after 4-times interventions, and after 12-times interventions. The following data were collected in the two groups: frailty assessment, grip strength, lower limb muscle strength, health literacy scale and nutrition knowledge scale.
62161380|NCT05339256|EXPERIMENTAL|Telehealth buprenorphine induction and maintenance|Sublingual (SL) Buprenorphine and a medical management protocol adapted to the unique needs of home-based telehealth for MOUD using SL buprenorphine
62161381|NCT05339256|ACTIVE_COMPARATOR|Standard in-person SL buprenorphine induction and maintenance|In-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
62161382|NCT02276937|PLACEBO_COMPARATOR|Placebo (0 ciu/limb)|Placebo control
62534417|NCT00707382|OTHER|Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1) the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment in accordance with the current guidelines from Sct. Hans hospital. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described in the clinical guidelines."
62161383|NCT02276937|ACTIVE_COMPARATOR|DVC1-0101 low dose (1x10^9 ciu/limb)|Low dose cohort
62161384|NCT02276937|ACTIVE_COMPARATOR|DVC1-0101 high dose (5x10^9 ciu/limb)|High dose cohort
62714765|NCT00956384|EXPERIMENTAL|One-stage dermal matrix/implant|One-stage breast reconstruction with dermal matrix and implant
62161385|NCT05064709|EXPERIMENTAL|CCM Group (CCM ON)|CCM therapy will be turned on in 2/3 of the subjects for the entire duration of the study.
62161386|NCT05064709|SHAM_COMPARATOR|Sham Group (CCM OFF)|CCM therapy will be turned off in 1/3 of the subjects for the first 18 months of the study. After 18 months, CCM therapy will be turned on for the rest of the study duration.
62161387|NCT05350709|ACTIVE_COMPARATOR|mirror therapy|An exercise program has been prepared for patients for use in mirror therapy. In this exercise program, firstly, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages) is shown. The patient will repeat the movement for 3 minutes. The patient will hold the affected extremity behind the mirror with the healthy extremity, the patient will look towards the affected side from the mirror and try to do the movements with the affected extremity. . The treatment period will be 20 sessions, 5 days a week, for 4 weeks.The exercises will take 1 hour, including half an hour of mirror therapy and half an hour of conventional exercises.
62161388|NCT05350709|ACTIVE_COMPARATOR|action observational therapy|An exercise video has been prepared for the patients to watch for the action observation therapy. In this video, first of all, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist, etc.) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages, etc.). is shown. The patient will first watch the video of each movement, and then repeat the movement for 3 minutes. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks.The exercises will take 1 hour, including half an hour of action observational therapy and half an hour of conventional exercises.
62534418|NCT00707382|OTHER|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
62534419|NCT00707382|NO_INTERVENTION|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
62534420|NCT05545371|EXPERIMENTAL|4 doses|Inoculate rabies vaccine according to 1-1-1-1 immunization procedure
62161389|NCT05350709|ACTIVE_COMPARATOR|conventional therapy|Conventional therapy includes range of motion exercises, walking and balance exercises. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks. The exercises will last for half an hour daily.
62161390|NCT04890093|EXPERIMENTAL|1/Dose Escalation|Dose escalation of PEN-866 along with fixed doses of vincristine and temozolomide
62161391|NCT04890093|EXPERIMENTAL|2/MTD/RP2D|PEN-866 at the MTD or RP2D from phase 1 plus vincristine and temozolomide
62161392|NCT06718374||non diabetic|
62161393|NCT06718374||diabetic|
62161394|NCT05280522||Repeated Measures Experiment|Participants are positioned in an isokinetic dynamometer (Biodex System 4 Isokinetic Dynamometer , Biodex Medical Systems, Inc., Shirley, NY) with the knee flexed to approximately 90 degrees. After 3-4 submaximal warm up contractions, participants generate maximum knee extension force while vigorous verbal encouragement is provided. Two trials are collected with 30 seconds between trials. The maximum forces from the 2 trials is used to determine the target force of 20% MVIC used for the volitional and NMES contractions and to normalize the force of the muscle contractions.
62161395|NCT02853188|EXPERIMENTAL|cancer of lung|
62161396|NCT05701657|OTHER|Module 1|"Module 1 is approximately 10 days (minimum of 8 days) and includes two study visits and remote data collection. Visit 1 will include application of an accelerometer and continuous glucose monitoring device for remote data collection over the next 8 to 10 days. A stool sample collection kit and instructions for stool collection and completion of dietary assessments during the observation period will be provided.~At Visit 2, anthropometry (height, weight and body circumferences), body composition by bioelectrical impedance (BIA), vital signs (temperature, respiratory rate and blood pressure), and grip strength will be measured. Medications will be recorded. A liquid MMTT with timed biospecimen collection (blood, urine, saliva, hair, and nails) and visual analogue assessments will be completed.~Participants in Module 1 will be asked to adhere to their usual routine (e.g., diet, exercise, sleep, supplements, medication use, etc.) throughout the study."
62161397|NCT05701657|OTHER|Module 2|"Module 2 is a minimum of 10 weeks long. It includes a total of six (6) study visits that occur before and after each of the three (3), 14-day dietary intervention periods (i.e., Diets A, B, and C), separated by washout periods of at least 14 days. Participants will be asked to consume only the foods provided and to adhere to their other usual routines throughout the study.~At the beginning of each diet period, anthropometry (weight and circumferences), vital signs (temperature, respiratory rate and blood pressure) and body composition by BIA will be measured. Biospecimens (blood, urine and saliva) will be collected. An accelerometer and a continuous glucose monitoring device will be applied for remote data collection. A stool sample collection kit will be provided together with instructions for stool collection and dietary assessments. At the end of each diet, a diet-specific meal test with timed biospecimen blood collection and visual analogue assessments will be completed."
62534421|NCT05545371|EXPERIMENTAL|5 doses|Inoculate rabies vaccine according to 1-1-1-1-1 immunization procedure
62534422|NCT05491876|EXPERIMENTAL|Chest physiotherapy with breathing exercises and ACBT|Group A will recieve chest physiotherapy with breathing exercises and ACBT.
62534423|NCT05491876|EXPERIMENTAL|Chest physiotherapy with breathing exercises|Group B will receive chest physiotherapy with breathing exercises.
62534424|NCT00642681||1: TI Inhalation Powder|Technosphere® Insulin (TI) Inhalation Powder
62534425|NCT04098289||Hysteroscopic septum resection without in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with natural conception (without the use of in vitro fertilization techniques).
62534426|NCT04098289||Hysteroscopic septum resection with in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
62534427|NCT04098289||Natural conception, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with natural conception (without in vitro fertilization techniques).
62534428|NCT04098289||In vitro fertilization, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
62534429|NCT01025271|OTHER|open label|patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin
62534430|NCT05600790|EXPERIMENTAL|the MIED+TAU group|Intervention description: provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
62534431|NCT05600790|NO_INTERVENTION|the TAU-only group|TAU consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therap
62534432|NCT01008982|EXPERIMENTAL|single arm|
62161398|NCT05701657|OTHER|Module 3|"Module 3 is a minimum of 10 weeks long. It includes three (3), 14-day dietary interventions (i.e. Diets A, B, and C) completed while participants are domiciled under the supervision of study staff. At the end of each dietary intervention period, participants return to their usual residence and routine for a minimum of 2 weeks.~At the beginning of each diet period, anthropometry (weight and circumferences), vital signs (temperature, respiratory rate and blood pressure) and body composition by BIA and DXA, and physical measures will be measured. Biospecimens (blood, urine and saliva) will be collected. An accelerometer and a continuous glucose monitoring device will be applied. Excluding pregnant females, participants will receive a dose of doubly labeled water. Weight and vital signs will be measured daily and questionnaires administered.~A diet-specific MMTT and a separate liquid MMTT with timed blood biospecimen collection and visual analogue assessments will be completed."
62161399|NCT06721871|ACTIVE_COMPARATOR|Active Comparator: Dose Level 1/Treatment Period 1: 1mg/kg/dose 3x/day|Participants may be randomized to crofelemer powder for oral solution during Treatment Period 1 (1 month duration)
62161400|NCT06721871|PLACEBO_COMPARATOR|Placebo Comparator: Dose Level 1/Treatment Period 1: Placebo 3x/day|Participants may be randomized to the placebo comparator during Treatment Period 1 (1 month duration)
62161401|NCT06721871|ACTIVE_COMPARATOR|Active Comparator: Dose Level 1/Treatment Period 2: 1mg/kg/dose 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator
62161402|NCT06721871|PLACEBO_COMPARATOR|Placebo Comparator: Dose Level 1/Treatment Period 2: Placebo 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator
62161403|NCT06721871|ACTIVE_COMPARATOR|Active Comparator: Dose Level 2/Treatment Period 1: 3mg/kg/dose 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator or continue on crofelemer powder for oral solution or the placebo comparator that they were previously on during Dose Level 1 (1 month duration)
62161404|NCT06721871|PLACEBO_COMPARATOR|Placebo Comparator: Dose Level 2/Treatment Period 1: Placebo 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator or continue on crofelemer powder for oral solution or the placebo comparator that they were previously on during Dose Level 1 (1 month duration)
62161405|NCT06721871|ACTIVE_COMPARATOR|Active Comparator: Dose Level 2/Treatment Period 2: 3mg/kg/dose 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator
62161406|NCT06721871|PLACEBO_COMPARATOR|Placebo Comparator: Dose Level 2/Treatment Period 2: Placebo 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator
62161407|NCT06721871|ACTIVE_COMPARATOR|Active Comparator: Dose Level 3/Treatment Period 1: 10mg/kg/dose 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator or continue on crofelemer powder for oral solution or the placebo comparator that they were previously on during Dose Level 2 (1 month duration)
62161408|NCT06721871|PLACEBO_COMPARATOR|Placebo Comparator: Dose Level 3/Treatment Period 1: Placebo 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator or continue on crofelemer powder for oral solutionor the placebo comparator that they were previously on during Dose Level 2 (1 month duration)
62161409|NCT06721871|ACTIVE_COMPARATOR|Active Comparator: Dose Level 3/Treatment Period 2: 10mg/kg/dose 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator
62161410|NCT06721871|PLACEBO_COMPARATOR|Placebo Comparator: Dose Level 3/Treatment Period 2: Placebo 3x/day|Participants will crossover to either crofelemer powder for oral solution or placebo comparator
62161411|NCT03904693|EXPERIMENTAL|FDC therapy + Placebo macitentan + Placebo tadalafil|Subjects to receive FDC macitentan/tadalafil (macitentan 10 mg and tadalafil 40 mg) plus matching placebos for the two other study treatments.
62534433|NCT00616798|EXPERIMENTAL|3|
62534434|NCT00616798|PLACEBO_COMPARATOR|4|
62534435|NCT00616798|EXPERIMENTAL|1|
62534436|NCT00616798|EXPERIMENTAL|2|
62534437|NCT00128050|ACTIVE_COMPARATOR|1|Patients treated with recombinant FVIIa
62534438|NCT00128050|PLACEBO_COMPARATOR|2|Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo
62534439|NCT02511821|EXPERIMENTAL|Supportive Care (Vivofit watch, online surveys)|Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
62534440|NCT03936426|EXPERIMENTAL|SARTATE|All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.
62534441|NCT05743205|EXPERIMENTAL|Educational Intervention|Educational intervention
62534442|NCT06050889|EXPERIMENTAL|High Intensity Exercise|Participants will complete an upper body resistance exercise until they report a high fatigue level.
62534443|NCT06050889|EXPERIMENTAL|Low Intensity Exercise|Participants will complete an upper body resistance exercise until they report a low fatigue level.
62534444|NCT06049979||AGI group|critical ill patient with AGIUS score\>2
62161412|NCT03904693|ACTIVE_COMPARATOR|Macitentan mono-therapy + Placebo tadalafil + Placebo FDC|Subjects to receive macitentan 10 mg plus matching placebos for the two other study treatments.
62161413|NCT03904693|ACTIVE_COMPARATOR|Tadalafil mono-therapy + Placebo macitentan + Placebo FDC|Subjects to receive tadalafil 40 mg (2 x 20 mg) plus matching placebos for the two other study treatments.
62161414|NCT06373328||Children|"This is a non-interventional study with data collection online, chart review, and biospecimen collection (nasopharyngeal swab). The swab will then be used for biomarker discovery.~Findings will be compared and analyzed between the children and adult groups."
62534445|NCT06049979||non-AGI group|critical ill patient with AGIUS score 0\~2
62534446|NCT03937336|NO_INTERVENTION|Control Group|
62534447|NCT03937336|EXPERIMENTAL|Bike Intervention Group|A 1-month bike-based program (1 session/week)
62534448|NCT01276301|EXPERIMENTAL|Reference|single dose BI 10773
62534449|NCT01276301|ACTIVE_COMPARATOR|Test|single dose BI 10773 + single dose verapamil
62534450|NCT03303183|ACTIVE_COMPARATOR|Direct Ear Scanner|Digitale impression via direct ear scanner
62534451|NCT03303183|ACTIVE_COMPARATOR|Silicone Ear impression|Impression via silicone
62534452|NCT01672216|EXPERIMENTAL|Triple Target Treatment|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
62534453|NCT01672216|ACTIVE_COMPARATOR|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
62534454|NCT02870218|ACTIVE_COMPARATOR|0.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
62534455|NCT02870218|ACTIVE_COMPARATOR|1.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
62534456|NCT02870218|ACTIVE_COMPARATOR|2.50mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
62534457|NCT02870218|ACTIVE_COMPARATOR|5.60mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
62534458|NCT02870218|ACTIVE_COMPARATOR|16.9mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
62161415|NCT06373328||Adults|"This is a non-interventional study with data collection online, chart review, and biospecimen collection (nasopharyngeal swab). The swab will then be used for biomarker discovery.~Findings will be compared and analyzed between the children and adult groups."
62161416|NCT04954898|EXPERIMENTAL|Study Lens|TECNIS Multifocal Toric 1-piece lens, Model ZMT
62534459|NCT02870218|EXPERIMENTAL|Halo G6 & Tribeca e-liquid|"Difference detection assessments.~Nicotine discrimination thresholds"
62534460|NCT02870218|EXPERIMENTAL|Spectrum Research Cigarette|"Difference detection assessments.~Nicotine discrimination thresholds"
62534461|NCT00935688|EXPERIMENTAL|Rapid diagnostic tests|malaria diagnosis by rapid diagnostic test
62534462|NCT00935688|NO_INTERVENTION|Clinic Microscopy|malaria diagnosed with field light-microscopy
62534463|NCT00935688|NO_INTERVENTION|Clinical Diagnosis|Malaria diagnosed on the basis of clinical symptoms alone (i.e. not laboratory diagnosis)
62534464|NCT03913819||substance abuse group|Patients with voiding dysfunction secondary to substance abuse in a special clinic
62534465|NCT04300283|EXPERIMENTAL|Pre-operative hypnosis|
62534466|NCT04144478|EXPERIMENTAL|experimental|Web based education intervention
62534467|NCT04144478|NO_INTERVENTION|No intervention|Normal polyclinics application
62534468|NCT03246646|EXPERIMENTAL|Coaching + VA CRAFT|Telephone coaching along with web-based CRAFT course
62161417|NCT06195553|EXPERIMENTAL|STEPPS for patients plus Family Connections for their families|Intervention group that receives STEPPS program for patients to carry out the intervention about BPD symptoms and in parallel another group that receives Family Connectios program for their families to carry out the intervention about associated symptoms.
62161418|NCT06195553|ACTIVE_COMPARATOR|STEPPS for patients only|Intervention group that receives STEPPS program for patients only to carry out the intervention about BPD symptoms.
62534469|NCT03246646|OTHER|Treatment as usual|Treatment as usual matched comparison
62534470|NCT01135186|OTHER|Sapropterin|open label study of sapropterin dihydrochloride
62161419|NCT03054194|EXPERIMENTAL|Cohort 1: Dose 1 E2730|Participants will receive Dose 1 of oral E2730 on Day 1.
62161420|NCT03054194|PLACEBO_COMPARATOR|Cohort 1: Matching placebo|Participants will receive matching oral placebo on Day 1.
62161421|NCT03054194|EXPERIMENTAL|Cohort 2: Dose 2 E2730|Participants will receive Dose 2 of oral E2730 on Day 1.
62161422|NCT03054194|PLACEBO_COMPARATOR|Cohort 2: Matching placebo|Participants will receive oral matching placebo on Day 1.
62161423|NCT03054194|EXPERIMENTAL|Cohort 3: Dose 3 E2730|Participants will receive Dose 3 of oral E2730 on Day 1.
62161424|NCT03054194|PLACEBO_COMPARATOR|Cohort 3: Matching placebo|Participants will receive oral matching placebo on Day 1.
62161425|NCT06455527|EXPERIMENTAL|Active tDCS|Participants randomized to the Active tDCS arm will complete 10 sessions of 30-minute active remotely supervised (RS)-tDCS with chest strap and impedance-based HRV data collection over the course of approximately 2-4 weeks.
62161426|NCT06455527|SHAM_COMPARATOR|Sham tDCS|Participants randomized to the Active tDCS arm will complete 10 sessions of 30-minute sham RS-tDCS with chest strap and impedance-based HRV data collection over the course of approximately 2-4 weeks.
62161427|NCT05995353|EXPERIMENTAL|PK Cohort 1: SS1|Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
62161428|NCT05995353|EXPERIMENTAL|PK Cohort 1: SS2 Dose A|Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
62161429|NCT05995353|EXPERIMENTAL|PK Cohort 1: SS2 Dose B|Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
62161430|NCT05995353|EXPERIMENTAL|PK Cohort 1: SS3 Dose A|Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
62161431|NCT05995353|EXPERIMENTAL|PK Cohort 1: SS3 Dose B|Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
62161432|NCT05995353|EXPERIMENTAL|PK Cohort 2: SS1|Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
62161433|NCT05995353|EXPERIMENTAL|PK Cohort 2: SS2 Dose A|Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
62161434|NCT05995353|EXPERIMENTAL|PK Cohort 2: SS2 Dose B|Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
62161435|NCT05995353|EXPERIMENTAL|PK Cohort 2: SS3 Dose A|Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
62161436|NCT05995353|EXPERIMENTAL|PK Cohort 2: SS3 Dose B|Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
62161437|NCT05995353|EXPERIMENTAL|Expansion Cohort 3: SS1|Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
62161438|NCT05995353|EXPERIMENTAL|Expansion Cohort 3: SS2 Dose A|Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
62161439|NCT05995353|EXPERIMENTAL|Expansion Cohort 3: SS2 Dose B|Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
62161440|NCT05995353|EXPERIMENTAL|Expansion Cohort 3: SS3 Dose A|Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
62161441|NCT05995353|EXPERIMENTAL|Expansion Cohort 3: SS3 Dose B|Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
62161442|NCT06557889|EXPERIMENTAL|Patient with PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck|
62161443|NCT04004520|EXPERIMENTAL|Virtual Reality with Meditation|Participants will receive a virtual reality and audio guided mindfulness meditation program available at (https://guidedmeditationvr.com/)
62161444|NCT04004520|OTHER|Virtual Reality Control|Participants will receive a virtual reality of historic photographs and written narratives program (https://lookingglassvr.com/)
62161445|NCT04004520|OTHER|Audio Control|Participants will receive an online audio-only guided mindfulness meditation available at (https://www.uclahealth.org/marc/mindful-meditations).
62161446|NCT06600581|PLACEBO_COMPARATOR|Group 1|Placebo - 2 mL USP injectable saline, twice a week
62714766|NCT00956384|ACTIVE_COMPARATOR|Two-stage tissue expander/implant|Two-stage breast reconstruction with tissue expander and implant
62161447|NCT06600581|EXPERIMENTAL|Group 2|0.5 mg total protein in 2 mL final volume, twice a week
62161448|NCT06600581|EXPERIMENTAL|Group 3|1 mg total protein in 2 mL final volume, once a week, alternating with placebo (saline)
62161449|NCT06600581|EXPERIMENTAL|Group 4|1 mg total protein in 2 mL final volume twice a week
62161450|NCT06600581|EXPERIMENTAL|Group 5|2 mg total protein in 2 mL final volume, once a week, alternating with placebo (saline)
62161451|NCT03167437|EXPERIMENTAL|1|participants will receive Vorinostat 100mg PO BID for 12 weeks
62161452|NCT03167437|EXPERIMENTAL|2|participants will receive Vorinostat 100mg PO BID for 6months
62161453|NCT03167437|ACTIVE_COMPARATOR|3|participants will receive ustekinumab (weight base induction dose followed by 90mg SC every 8 weeks for 24 months)
62161454|NCT06297200|EXPERIMENTAL|Pain, Craving, and Anxiety measures|Multi visit - LIFU/Sham. Participants will complete pain, craving, and anxiety measures pre and post intervention.
62161455|NCT05893017|EXPERIMENTAL|Virtual Reality Exercises|Virtual Reality Exercises will be applied
62161456|NCT05893017|EXPERIMENTAL|Virtual Reality Exercises and Kinesiotaping|Virtual Reality Exercises and Kinesio taping for quadriceps and hamstring muscles will be applied
62161457|NCT05893017|EXPERIMENTAL|Virtual Reality Exercises and Valgus Orthoses|Virtual Reality Exercises and Valgus Orthoses will be applied.
62534471|NCT03958253|EXPERIMENTAL|Lung Cancer Screening Toolbox|"* WU Staff will train local screening staff using a train-the-trainer model three months prior to the intervention and will provide technical assistance on an ongoing basis.~* During the 3 hour train-the-trainer session, the selected staff from the referral sites will learn about the program, receive an orientation to the toolbox elements, and discuss how to adapt the elements of the toolbox to their referral sites."
62534472|NCT05920512|EXPERIMENTAL|Patients with severe haemophilia|confirmed as hemophilia and FVIII/FIX activity \<1%
62534473|NCT04220931|EXPERIMENTAL|botulinum toxin injection|"Injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.~The endoscopic procedure will be performed under unconscious sedation with intravenous injection of propofol by an anesthesiologist."
62534474|NCT04220931|NO_INTERVENTION|standard care|standard care (no endoscopy)
62534475|NCT05684783||Group 1 interviews|Care professionals with experience of being or working with Dementia Champions, and people affected by dementia who have received care from services with Dementia Champions.
62161458|NCT05379400|EXPERIMENTAL|Portable Air Cleaner (PAC) group|"This study will utilize a portable air cleaner as an intervention for the potential reduction of air pollution-associated inflammation. This commercially available device has no significant risks. The researchers plan to use a commercially available PAC with a true HEPA filter for the true arm."
62534476|NCT05684783||Group 2 interviews|Homecare professionals working in services where there are no Dementia Champions, and people affected by dementia who have received care from services with no Dementia Champions.
62161459|NCT05379400|SHAM_COMPARATOR|Sham Portable Air Cleaner (PAC) group|For the sham arm, the same model will be used with HEPA filter removed, and has identical appearance and sound. The researchers will use a PAC designed to filter air in rooms up to approximately 350 ft2, with minimal noise on the lowest setting.
62161460|NCT03630432|ACTIVE_COMPARATOR|Group A|Immediate 8 week course of pulmonary rehabilitation
62161461|NCT03630432|PLACEBO_COMPARATOR|Group B|Initial 8 weeks of usual care
62161462|NCT04828668|EXPERIMENTAL|Formula C|30 participants will be randomized to masked active study product (Formula C) for 28-days; they will continue to the open label extension phase (with commercially available product for an additional 28-days when they will receive commercially available product.
62161463|NCT04828668|PLACEBO_COMPARATOR|Placebo|30 participants will be randomized to placebo for 28-days; they will roll-over to the open label extension phase of study product (Formula C) for an additional 28-days when they will receive commercially available product.
62161464|NCT02097420|OTHER|Single device arm|Mitral valve replacement
62161465|NCT06095102|EXPERIMENTAL|JNJ-77242113|Participants will receive JNJ-77242113 from Week 0 through Week 156.
62161466|NCT06095102|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo from Week 0 through Week 16 and thereafter will receive JNJ-77242113 from Week 16 through Week 156.
62161467|NCT05230823|EXPERIMENTAL|Intervention|The intervention consists of a traditional 12-week outpatient CR program with added weekly behavioural weight loss classes.
62161468|NCT03610802||Biological relatives|Biological relative (mother, father, siblings, children, grandparents, aunts, uncles, or first cousins) of patient, with no clinical evidence of having a PID.
62161469|NCT03610802||Patients|Patients with PID, which may be defined by laboratory and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity.
62534477|NCT04100720|EXPERIMENTAL|Cardiovalve Transfemoral Tricuspid Valve|Replacement (Implant) delivered through a transfemoral access
62534478|NCT05900258|EXPERIMENTAL|Treatment|
62534479|NCT04173832|EXPERIMENTAL|Tianqi Pingchan Granule Combined With Amantadine|
62534480|NCT04173832|PLACEBO_COMPARATOR|placebo Combined With Amantadine|
62534481|NCT01730066|EXPERIMENTAL|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria preoperatively and given the same study product enterally postoperatively
62534482|NCT01730066|NO_INTERVENTION|Control|No intervention.What has been the standard procedure so far
62534483|NCT02185053|EXPERIMENTAL|CPC-201|
62534484|NCT00476983|EXPERIMENTAL|1|SQV/r 1500/100 mg OD + Truvada OD
62534485|NCT04632160|EXPERIMENTAL|Treatment|Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
62714443|NCT02708680|ACTIVE_COMPARATOR|Entinostat plus Atezolizumab|"Participants in this arm will receive entinostat in combination with atezolizumab.~Phase 1b Dose Determination: The initial 3 to 6 participants will receive entinostat at a starting dose of 5 milligrams (mg) (Dose Group 1) on Days 1, 8, and 15 along with atezolizumab 1200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle. If the 5 mg dose exceeds the maximum tolerated dose (MTD), then a 3 mg dose of entinostat (Dose Group -1) will be evaluated in the same manner. If the -1 dose level exceeds the MTD, then a 2 mg dose of entinostat (Dose Group -2) will be evaluated.~Phase 2 Dose Expansion: Participants will receive the RP2D identified in the Dose Determination Phase."
62714444|NCT02708680|PLACEBO_COMPARATOR|Placebo plus Atezolizumab|Participants in this arm will receive placebo in combination with atezolizumab 1200 mg.
62161470|NCT04642495||Human subjects aged 4 and above|Human volunteers aged 4 and above.
62161471|NCT04822246|OTHER|Control: Hand instrumentation for caries excavation|Hand instrumentation for caries excavation
62161472|NCT04822246|EXPERIMENTAL|Intervention 1: EMS Airflow device for caries excavation|Powder/water jet prophylaxis device (EMS Airflow) for caries excavation
62161473|NCT04822246|EXPERIMENTAL|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|Hand excavation and Powder/ jet prophylaxis device (EMS Airflow) for caries excavation
62161474|NCT04497844|EXPERIMENTAL|Niraparib with Abiraterone Acetate plus Prednisone (AAP)|Participants will receive the following in each 28-day treatment cycle: niraparib 200 milligrams (mg), abiraterone acetate (AA) 1000 mg plus prednisone 5 mg once daily.
62161475|NCT04497844|ACTIVE_COMPARATOR|AA plus Prednisone (AAP)|Participants will receive the following in each 28-day treatment cycle: matching placebo for Niraparib along with AA 1000 mg plus prednisone 5 mg once daily.
62161476|NCT04256421|ACTIVE_COMPARATOR|Placebo + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
62534486|NCT04478630|ACTIVE_COMPARATOR|Peppermint Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of peppermint essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4).The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening).The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
62534487|NCT04478630|ACTIVE_COMPARATOR|Ginger Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of ginger essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy.The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
62161477|NCT04256421|EXPERIMENTAL|Tiragolumab + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
62161478|NCT01493388||A|
62161479|NCT04728347|EXPERIMENTAL|ARCT-021|Participants will receive a single dose of ARCT-021 on Day 1
62161480|NCT04728347|NO_INTERVENTION|Long-term follow up from ARCT-021-01|Participants will not receive intervention but will be followed for safety.
62161481|NCT04285671|EXPERIMENTAL|Treatment (necitumumab, trastuzumab, osimertinib)|Patients receive necitumumab IV over 60 minutes and trastuzumab IV over 30-90 minutes on days 1 and 15. Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62161482|NCT06536465|EXPERIMENTAL|REC-3964 High-dose|Participants will receive 500 mg REC-3964 q12h REC-3964 250 mg capsules
62161483|NCT06536465|EXPERIMENTAL|REC-3964 Low-dose|"Participants will receive 250 mg REC-3964 q12h REC-3964 250 mg capsules"
62161484|NCT06536465|NO_INTERVENTION|Observation|Participants will undergo watchful waiting
62161485|NCT05415072|EXPERIMENTAL|Phase I: Dose Escalation|Patients with metastatic uveal melanoma or other GNAQ/11 mutant melanomas
62161486|NCT05415072|EXPERIMENTAL|Phase II: Tebe naive group|Patients with metastatic uveal melanoma that has not received prior treatment with tebentafusp
62161487|NCT05415072|EXPERIMENTAL|Phase II: Tebe pre-treated|Patients with metastatic uveal melanoma that have been previously treated with tebentafusp
62534488|NCT04478630|PLACEBO_COMPARATOR|Pure Vanilla Extract (placebo-control)|Usual care plus a personal pocket diffuser prepared with 14 drops of pure vanilla extract (placebo). Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
62161488|NCT05415072|EXPERIMENTAL|Phase II: Non-uveal melanoma|Optional Arm: To explore patients with non-uveal melanoma that harbor GNAQ or 11 mutations, based on emerging data from dose escalation
62161489|NCT02516371|OTHER|lymphocytes|To evaluate the subpopulation of lymphocytes in cancer patients
62161490|NCT04276142|EXPERIMENTAL|Migraine - ceprica|online program: ceprica in addition to treatment as usual
62161491|NCT04276142|OTHER|Migraine - active control intervention|active control intervention: psychoeducation in addition to treatment as usual
62161492|NCT05056207|OTHER|Cohort I (patients receiving annual lymphedema screening)|We will retrospectively retrieve information on patients who previously underwent preoperative perometer lymphedema screening during the past year who were treated definitively for their breast cancer with an ALND, and for whom no follow-up postoperative lymphedema screening was done.
62161493|NCT05056207|OTHER|Cohort II (patients followed intensively for lymphedema)|We will prospectively follow a cohort of 279 patients who have recently undergone ALND in this upcoming year with intensive lymphedema screening.
62161494|NCT01818453|ACTIVE_COMPARATOR|Computerized self-help program for depression|Participants will have access to a computerized self-help program for depression, called deprexis, for 8 weeks.
62161495|NCT01818453|NO_INTERVENTION|Wait List Control|"Participants randomly assigned to a wait list control condition will wait 8 weeks after assignment before they can access the deprexis program."
62161496|NCT02031055|EXPERIMENTAL|TAS-102 with light tracer dose of [14C]FTD|
62161497|NCT02031055|EXPERIMENTAL|TAS-102 with light tracer dose of [14C]TPI|
62161498|NCT01133600|ACTIVE_COMPARATOR|daptomycin|Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is \<30ml/min.
62161499|NCT01133600|ACTIVE_COMPARATOR|vancomycin|Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
62161500|NCT06470438|EXPERIMENTAL|Part A: Dose Escalation|Participants will receive JNJ-88998377 at a selected starting dose. Subsequent dose levels and schedules will be selected based on the review of all available data to establish recommended Phase 2 dose (RP2D).
62161501|NCT06470438|EXPERIMENTAL|Part B: Dose Expansion|Participants will receive JNJ-88998377 at RP2D determined in Part A. Additional expansion cohort(s) may be added with a lower RP2D(s), or different dose schedule(s) based on all available data.
62534489|NCT01687244|EXPERIMENTAL|rAd-IFN Dose 1x10^11vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
62534490|NCT01687244|EXPERIMENTAL|rAd-IFN dose 3x10^11 vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
62534491|NCT04934410||Patients undergoing Implantation of left ventricular assist device (Etomidate)|High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is etomidate.
62534492|NCT04934410||Patients undergoing Implantation of left ventricular assist device (Midazolam)|High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is midazolam.
62534493|NCT04934410||Patients undergoing Implantation of left ventricular assist device (Sevoflurane)|High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is sevoflurane.
62534494|NCT03895671|EXPERIMENTAL|AP-CML|Patient with Philadelphia chromosome positive CML in accelerated phase is defined by the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), ≥ 20% basophils in PB or BM, ≥ 30% blasts plus promyelocytes (with blasts \<30%) in PB or BM, \<100 x109/L platelets unrelated to therapy, or by clonal cytogenetics evolution (i.e., the presence of cytogenetic abnormalities other than the Philadelphia chromosome);
62534495|NCT03895671|EXPERIMENTAL|MBC-CML|Patient with Philadelphia chromosome positive CML in myeloid blast crisis is defined by the presence of ≥ 30% blasts in the bone marrow and/or peripheral blood or the presence of extramedullary disease.
62534496|NCT06504420|EXPERIMENTAL|Sirolimus|Sirolimus 1.5mg po. QD
62534497|NCT06504420|PLACEBO_COMPARATOR|placeobo|Sirolimus placebo 1.5mg po. QD
62534498|NCT00928161|NO_INTERVENTION|Group 1|Patients with no acid reflux.
62534499|NCT00928161|ACTIVE_COMPARATOR|Group 2|Patients with acid reflux.
62534500|NCT05420870|EXPERIMENTAL|Exercise group|
62534501|NCT05420870|NO_INTERVENTION|Usual care group|
62534502|NCT03670290||Group 1|Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
62534503|NCT03670290||Group 2|Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
62534504|NCT03670290||Group 3|Group III will receive 10 ml of Bupivacaine 0.25% solution through the epidural catheter.
62534505|NCT05131243|EXPERIMENTAL|ctDNA positive patients|Postoperative ctDNA-positive patients will receive chemotherapy for 6 months.The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
62534506|NCT05131243|ACTIVE_COMPARATOR|ctDNA negative patients|Postoperative ctDNA-negative patients will receive chemotherapy for 3 months. The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
62534507|NCT01348412|EXPERIMENTAL|ARM A|Hepatic artery infusion through an implanted arterial catheter of the combination of raltitrexed (3 mg/m ²) and oxaliplatin (100 mg/m ²) every 21 days.
62534508|NCT01348412|ACTIVE_COMPARATOR|ARM B|Intravenous standard chemotherapy.
62534509|NCT01166165|ACTIVE_COMPARATOR|Cholecalciferol|
62534510|NCT01166165|PLACEBO_COMPARATOR|Placebo|
62534511|NCT02444923|EXPERIMENTAL|Scleral rigid gas permeable contact lenses|The experimental intervention is the Scleral Rigid Gas Permeable contact lens (SRGPcl), Zenlens™. These lenses are designed to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with corneal contact.
62534512|NCT02444923|PLACEBO_COMPARATOR|Corneal rigid gas permeable contact lenses|The control intervention is the RoseK2™ Corneal Rigid Gas Permeable contact lens (CRGPcl). Corneal lenses are considered the gold standard in the management of the visual disability due to keratoconus and other related irregular cornea disorders.
62714445|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
62534513|NCT03771248|ACTIVE_COMPARATOR|Co-cr telescopic partial denture|A removable partial denture, that gains retention from a telescopic crown made of cobalt chromium
62534514|NCT03771248|EXPERIMENTAL|PEEK telescopic partial denture|A removable partial denture, its attachment is a telescopic crown made of PEEK
62534515|NCT02078427||rAHF-PFM|Participants treated with rAHF-PFM alone
62534516|NCT02078427||rAHF-PEG|Participants treated with rAHF-PEG alone
62534517|NCT02078427||rAHF-PFM then rAHF-PEG|Participants treated with rAHF-PFM and subsequently switched to rAHF-PEG
62534518|NCT02249130|EXPERIMENTAL|Treatment of HIV- infected patients|14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)
62534519|NCT05267743|EXPERIMENTAL|Tegoprazan 50mg QD|Tegoprazan 50mg tablet, once daily, oral administration
62534520|NCT05267743|ACTIVE_COMPARATOR|Lansoprazole 30mg QD|Lansoprazole 30mg capsule, once dauly, oral administration
62534521|NCT02192320|EXPERIMENTAL|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone: 0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
62534522|NCT02192320|ACTIVE_COMPARATOR|Atorvastatin|Atorvastatin: 20 mg (every evening orally) for 5 weeks
62534523|NCT00604123|EXPERIMENTAL|JNJ-17166864|
62534524|NCT00604123|PLACEBO_COMPARATOR|Placebo|
62534525|NCT05076695|EXPERIMENTAL|TPPF group|Patients will be treated with Trastuzumab, Pyrotinib, Palbociclib plus Fulvestrant(TPPF).
62534526|NCT03638778|ACTIVE_COMPARATOR|Oral semaglutide (reference)|Participants will receive oral semaglutide (reference) for 10 days.
62534527|NCT03638778|EXPERIMENTAL|Oral semaglutide formulation B|Participants will receive oral semaglutide formulation B for 10 days.
62534528|NCT03638778|EXPERIMENTAL|Oral semaglutide formulation C|Participants will receive oral semaglutide formulation C for 10 days.
62714767|NCT05409066|EXPERIMENTAL|Epcoritamab Dose A in Combination With R2|Participants will receive epcoritamab Dose A in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).
62534529|NCT03638778|EXPERIMENTAL|Oral semaglutide formulation D|Participants will receive oral semaglutide formulation D for 10 days.
62534530|NCT02067468|EXPERIMENTAL|HPV test|Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy
62161502|NCT04985266|ACTIVE_COMPARATOR|Standard endocrine therapy|"Standard endocrine therapy will continue for up to 24 months on trial.~Standard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane)."
62161503|NCT04985266|EXPERIMENTAL|Palbociclib and fulvestrant|"Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.~Palbociclib will be given orally once a day on days 1-21 of each 28 day cycle.~Fulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit."
62714446|NCT04939597|EXPERIMENTAL|Arm I (memantine hydrochloride)|Patients receive memantine hydrochloride orally PO QD for week 1 and then BID for weeks 2-24 in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 24, and 48 months. Patients undergo MRI and may optionally undergo blood sample collection throughout the trial.
62161504|NCT02885714|PLACEBO_COMPARATOR|Group I|Placebo surgery + supervised specific exercises
62534531|NCT02067468|ACTIVE_COMPARATOR|COLPOSCOPY|Women with ASC-US cytology are immediately refer to colposcopy
62534532|NCT02067468|ACTIVE_COMPARATOR|CYTOLOGY|Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher
62534533|NCT04405843|EXPERIMENTAL|Ivermectin|Ivermectin, 300 micrograms / kg, once daily for 5 days
62534534|NCT04405843|PLACEBO_COMPARATOR|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
62534535|NCT03333590|EXPERIMENTAL|Cohort 1 (Minimal Efficacious Dose) rAAVrh74.MCK.GALGT2|N = 3 \[2.5 x E13 vg/kg per leg, delivered bilaterally (total 5.0 x E13 vg/kg)\]
62534536|NCT03333590|EXPERIMENTAL|Cohort 2 (Dose Escalation) rAAVrh74.MCK.GALGT2|N=3 \[5 x E13 vg/kg per leg, delivered bilaterally (total 1.0 x E14 vg/kg)\]
62534537|NCT02854592||rtPA|Intravenous rt-PA thrombolysis shall be administered within 4.5 h after symptom onset, at a dose of 0.9 mg/kg body weight (maximum, 90 mg), with 10% of the dose given as a bolus over 1 min and the remaining 90% infused over 60 min.
62534538|NCT02854592||urokinase|1,000,000-1,500,000 units of urokinase intravenous infused over 30 minutes within 4.5 h of stroke onset .
62534539|NCT06396767||DIA measured via Ultrasonography|"Ultrasonographic measurements will be done preoperatively a day before surgery (T0) and on Postoperative day 1(T1) in Cardiac Surgery Recovery Unit (CSRU). Measurements will be done on both right and left sides during Quiet (Q) and Deep (D) breathing in semi- recumbent posture (30-450 recline of the bed).~Three measurements will be taken during both quiet and deep breathing and an average value will be derived (Qavg and Davg). this will be done for both right and left hemidiaphragms (both pre-surgery and post-surgery). So, for each patient a total of 8 diaphragmatic measurements will be obtained (4 in the pre-surgery period and another 4 in post-surgery period). Measurement technique and definition of Diaphragmatic Inspiratory Amplitude:~All examinations will be performed by Sonosite SII ultrasound machine (FUJIFILM Sonosite Inc, Bothell, WA, USA) using a 3.5- to5 MHz phased array probe or a 3-12 MHz linear probe."
62534540|NCT03479567|OTHER|HC|Healthy controls, i.e. older adults without cognitive impairment
62534541|NCT03479567|OTHER|MiD|older adults with mild dementia
62534542|NCT03479567|OTHER|MoD|older adults with moderate dementia
62534543|NCT06130098|ACTIVE_COMPARATOR|control group|"Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and Oxford Knee Score Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients."
62534544|NCT06130098|ACTIVE_COMPARATOR|experimental group|"Active Comparator: experimental group Providing education to patients by preparing a pre-discharge education brochure. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of the patient information form, EQ-5D-5L Quality of Life and Oxford Knee Score Scale. Evaluation of the wound site in terms of complications at the end of the first and fourth weeks. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, a call is made at the end of the first week after discharge.~Providing training on the subjects included in the training brochure during the first phone call~In the fourth meeting, tele-nursing service was provided through the Telephone Counseling Protocol~Refilling of the EQ-5D-5L quality of life and Oxford Knee Score scale by patients at routine check-up at the end of the fourth and sixth weeks after discharge"
62534545|NCT01975727|PLACEBO_COMPARATOR|Injection of Placebo|Intravenous Saline 0.9% 10 ml
62534546|NCT01975727|ACTIVE_COMPARATOR|Dexamethasone 3 mg|Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
62534547|NCT01975727|ACTIVE_COMPARATOR|Dexamethasone 6 mg|Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
62534548|NCT01975727|ACTIVE_COMPARATOR|Dexamethasone 12 mg|Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml
62534549|NCT06189547||Without prior cancer|
62534550|NCT06189547||With prior colorectal cancer history|
62534551|NCT06189547||With prior prostate cancer history|
62534552|NCT06189547||With prior breast cancer history|
62534553|NCT06189547||With prior uterine cancer history|
62534554|NCT06189547||With prior bladder cancer history|
62534555|NCT06189547||With prior skin cancer history|
62534556|NCT06189547||With prior lung cancer history|
62534557|NCT06189547||With prior kidney cancer history|
62534558|NCT06189547||With prior thyroid cancer history|
62534559|NCT06189547||With prior stomach cancer history|
62534560|NCT06125132|ACTIVE_COMPARATOR|OMNICHROMA one shade composite|a one-shade composite resin as experimental group
62161505|NCT02885714|ACTIVE_COMPARATOR|Group II|Rotator cuff repair + supervised specific exercises
62161506|NCT06721702|EXPERIMENTAL|Intervention group: Motivational Interviewing|The motivational interview, consisting of six sessions, including the preparation session, was applied to the intervention group.Each session lasted an average of 40 minutes. Motivational interviewing sessions were conducted with nine different groups consisting of five people in the intervention group.
62534561|NCT06125132|ACTIVE_COMPARATOR|Zen Chroma one shade composite|a one-shade composite resin as experimental group
62161507|NCT06721702|NO_INTERVENTION|Control Group|Control group did not receive any intervention other than the daily routine practices.
62161508|NCT05910879|ACTIVE_COMPARATOR|Promotores Health Education only condition|"The Promotores de Salud Health Education intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation.~When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines."
62161509|NCT05910879|EXPERIMENTAL|Self-Affirmation Implementation Intentions (SAII) intervention (plus Promotores Health Education)|"The SAII is designed to reduce stigma and enhance uptake of health messaging. SAII couples; (a) self-affirming interventions that focus on restoring self-integrity in the face of identity threats, with (b) implementation intention interventions focus on whether realization of goal intentions for health behaviors is facilitated by forming an implementation intention that spells out when, where, and how of goal striving in advance."
62161510|NCT06596473|EXPERIMENTAL|Phase 1a: BG-C477 Monotherapy Dose Escalation|Sequential cohorts of increasing dose levels of BG-C477 will be evaluated as monotherapy.
62161511|NCT06596473|EXPERIMENTAL|Phase 1a: BG-C477 Monotherapy Safety Expansion|Selected dose levels that have been determined to be safe in Phase 1a dose escalation will be further evaluated in monotherapy.
62161512|NCT06596473|EXPERIMENTAL|Phase 1b Part A: BG-C477 Monotherapy Dose Optimization|Participants with selected advanced solid tumors will be evaluated at different dose levels of RDFEs identified in Phase 1a.
62161513|NCT06596473|EXPERIMENTAL|Phase 1b Part B: Combination Therapy Expansion|Sequential cohorts of increasing dose levels of BG-C477 will be evaluated in combination with capecitabine with or without bevacizumab.
62161514|NCT02221778|EXPERIMENTAL|SBRT|SBRT according to the intervention description
62161515|NCT06569836|OTHER|Assigned intervention|The intervention group will start the 12-week intervention immediately
62161516|NCT06569836|OTHER|Assigned waitlist control|"The waitlist control group will have weekly educational and virtual workshops for 12 weeks.~After 12 weeks assessment, the control group will receive the same intervention as the intervention group for 12 weeks."
62161517|NCT05476601|EXPERIMENTAL|CMAP Plus|CMAP Plus is comprised of an existing culturally adapted manually assisted problem-solving intervention (CMAP) integrated with CBT based Motivational Interviewing (MICBT) called (CMAP Plus). The TAU of intervention group participants will be continued along with study intervention.
62161518|NCT05476601|NO_INTERVENTION|TAU alone|This will be comprised of standard care they will be receiving from participating centres at recruitment sites. The standard care for individuals with SUD in Pakistan usually includes a 2-3-week detoxification programme, followed by 2 months of weekly 1:1 session along with some family sessions, followed by a period of support groups programmes.
62161519|NCT00561678|EXPERIMENTAL|Precedex|Precedex (Dexmedetomidine)
62534562|NCT06125132|ACTIVE_COMPARATOR|Filtek Z250 multi shade composite|a multi-shade composite resin as control group
62161520|NCT00561678|PLACEBO_COMPARATOR|Placebo|Placebo - normal saline
62161521|NCT05105100||Participants with Melanoma|Participants will undergo a pre-treatment tumor core biopsy and Peripheral blood mononuclear cell (PBMC) collection. Then, patients will be started on pembrolizumab per standard of care and PBMCs will be collected every 3 weeks (1 cycle)
62161522|NCT05307653|EXPERIMENTAL|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
62534563|NCT06186180|EXPERIMENTAL|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device.
62534564|NCT06186180|NO_INTERVENTION|control|no intervention
62534565|NCT02080169|EXPERIMENTAL|midazolam|Initiative dosage of midazolam is 0.05 mg/kg given intravenously, the maintenance dosage is 0.01-0.05 mg/kg/h, drug dosage is adjusted by target sedation level.
62534566|NCT02080169|EXPERIMENTAL|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min, the maintenance dosage is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level.
62534567|NCT02080169|EXPERIMENTAL|midazolam & dexmedetomidine|"Initiative dosage of midazolam is 0.05 mg/kg given intravenously, The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min(given or not according to patients' condition),.~The maintenance dosage of midazolam is 0.01-0.05 mg/kg/h, the maintenance dosage of dexmedetomidine is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level."
62534568|NCT02405884|OTHER|measurement of intraocular pressure|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
62534569|NCT04485039|OTHER|TPOXX: oral antiviral|Single oral dose of TPOXX 600 mg
62161523|NCT05307653|EXPERIMENTAL|Erector spinea plain block group|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
62161524|NCT05307653|EXPERIMENTAL|Caudal group|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
62534570|NCT04485039|OTHER|TPOXX: oral antiviral and sevelamer carbonate|Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate
62534571|NCT04485039|OTHER|TPOXX: oral antiviral and sucroferric oxyhydroxide|Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet
62534572|NCT04485039|OTHER|TPOXX: oral antiviral and calcium acetate|Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate
62534573|NCT04485039|OTHER|TPOXX: oral antiviral and lanthanum carbonate|Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet
62161525|NCT02327702|EXPERIMENTAL|Chinese naive pregnant chronice hepatitis B|Chinese naive pregnant chronice hepatitis B were enrolled to take emtricitabine (200 mg one time per day) till 48 weeks after delivery.
62161526|NCT04394078||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
62714447|NCT04939597|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for week 1 and then BID for weeks 2-24 in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 24, and 48 months. Patients undergo MRI and may optionally undergo blood sample collection throughout the trial.
62161527|NCT05095506|EXPERIMENTAL|eHeatlh Intervention Arm|The intervention platform is an interactive, web-based self-management program comprised of computer-adaptive tests (CATs) to assess depression, anxiety, and resilience and multimedia-assisted components. Participants will access the system once a week for 6 weeks, complete the symptom monitoring CATs, receive score reports, and watch a system-assigned self-management strategy video (which is selected by the system based on the participant's current level of depression/anxiety symptoms).
62161528|NCT05095506|ACTIVE_COMPARATOR|Active Control Arm|The active control condition is a static web-based program which also includes computer-adaptive tests (CATs) to assess depression, anxiety, and resilience, but does not provide score reports and plays a predetermined educational video (related to health promotion after SCI) each week. Participants will access the system once a week for 6 weeks, complete the symptom monitoring CATs and watch the educational video.
62534574|NCT06063265|EXPERIMENTAL|IATP|
62714448|NCT05251649|EXPERIMENTAL|tACS combined with 40 Hz sound stimulation group|15 daily (Monday-Friday) 20min sessions of tACS combined with 40 Hz sound stimulation
62714449|NCT05251649|EXPERIMENTAL|tACS group|15 daily (Monday-Friday) 20min sessions of tACS stimulation
62161529|NCT01348763|EXPERIMENTAL|Truvada, Darunavir/r and Maraviroc|Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
62161530|NCT00754533|OTHER|1|Continuous training
62161531|NCT00754533|OTHER|2|Interval training
62161532|NCT06721507|EXPERIMENTAL|Standard of Care plus Drug|Participant receives drug for 3 months prior to surgery
62714450|NCT05251649|EXPERIMENTAL|40 Hz sound stimulation group|15 daily (Monday-Friday) 20min sessions of 40 Hz sound stimulation
62161533|NCT06721507|ACTIVE_COMPARATOR|Standard of Care Alone|
62161534|NCT01154842||Hemodialysis|Adult hemodialysis patients (age\>18 years)
62161535|NCT06552897|OTHER|Arm 1: Adductor Canal Block (ACB) Group, Arm 2: Combined Adductor Canal Block and Selective Tibial N|Arm 1: Adductor Canal Block (ACB) Group Arm Type: Active Comparator Description: This group receives the standard intervention of an Adductor Canal Block (ACB), which serves as the control or comparator arm in the study.
62161536|NCT06552897|OTHER|Arm 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Group|Arm 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Group Arm Type: Experimental Description: This group receives the experimental intervention combining Adductor Canal Block (ACB) with Selective Tibial Nerve Block (STNB) to evaluate its efficacy in enhancing postoperative analgesia.
62534575|NCT06063265|NO_INTERVENTION|Control|
62534576|NCT01043653||Maryland Assessment of Recovery in Serious Mental Illness|Individuals with serious mental illness treated in mental health outpatient programs
62714451|NCT06264609|EXPERIMENTAL|Group 1 Low Turnover - crossover|Alendronate
62714452|NCT06264609|EXPERIMENTAL|Group 2 Low Turnover - crossover|Teriparatide
62714453|NCT06264609|EXPERIMENTAL|Group 2 Low Turnover - continuation|Alendronate
62534577|NCT01441713||Pharmaceutical group|Patients in pharmaceutical castration treatment for advanced prostate cancer
62534578|NCT01441713||Surgical group|Patients having undergone surgical castration treatment for advanced prostate cancer
62534579|NCT02337023||healthy subjects|
62534580|NCT02337023||patients with Kleine-Levin Syndrome|
62534581|NCT06453629|EXPERIMENTAL|Floreo VR|Floreo VR is a 12 week program
62534582|NCT06453629|ACTIVE_COMPARATOR|VR Control|VR Control is a 12 week program that matches the Floreo VR interactions
62534583|NCT06453629|OTHER|VR Control Crossover|For participants who opt in, they will run the 12 week Floreo VR program
62534584|NCT02831608|EXPERIMENTAL|Drug: influenza vaccine|Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.
62534585|NCT02831608|PLACEBO_COMPARATOR|Drug: placebo|Saline administered as a deep subcutaneous injection at one occasion per subject.
62534586|NCT01119183|NO_INTERVENTION|1|
62534587|NCT01119183|ACTIVE_COMPARATOR|2|
62534588|NCT01119183|EXPERIMENTAL|3|
62161537|NCT03997552|EXPERIMENTAL|Non-incised papillae surgical approach (NIPSA)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
62534589|NCT03441932|ACTIVE_COMPARATOR|Dysphagia screening failed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
62534590|NCT03441932|ACTIVE_COMPARATOR|Dysphagia screening passed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
62534591|NCT01794026|EXPERIMENTAL|diffusion MRI|histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
62534592|NCT06627491|NO_INTERVENTION|Control|Participants will rest quietly with eyes closed during the control condition.
62534593|NCT06627491|EXPERIMENTAL|Fast|Participants will imagine 2 blocks of 25 fast muscle contractions separated by 30 sec
62534594|NCT06627491|EXPERIMENTAL|Slow|Participants will imagine 2 blocks of 25 slow muscle contractions separated by 30 sec
62534595|NCT05640336|ACTIVE_COMPARATOR|Single DAIR Surgery Arm|Subjects will undergo a single Debridement Antibiotics and Implant Retention (DAIR) surgical procedure, along with IV antibiotics and followed by oral suppressive antibiotics. This method is currently used and considered to be standard of care.
62534596|NCT05640336|ACTIVE_COMPARATOR|Double DAIR Surgery Arm|Subjects will undergo planned double Debridement Antibiotics and Implant Retention (DAIR) surgical procedure, along with IV antibiotics and followed by oral suppressive antibiotics. This method is currently used and considered to be standard of care.
62534597|NCT04435535|OTHER|Positive expiratory pressure (PEP)|PEP 10 cmH2O 15 min
62534598|NCT04470687|EXPERIMENTAL|Carotid plaque or stenosis ultrasound enhanced UF assesment|symptomatic or asymptomatic patients with atheromatous carotid stenosis scheduled for carotid endarterectomy
62534599|NCT02938559|EXPERIMENTAL|Cognitive Therapy plus Memory Support|
62534600|NCT02938559|ACTIVE_COMPARATOR|Cognitive Therapy-as-usual|
62534601|NCT05962203|EXPERIMENTAL|Multi-factorial geriatric assessment, monitoring & management systems|All participants in the observational/interventional study (MV-FIT) will receive guideline-based, multi-factorial geriatric assessment, monitoring \& managements (multi-component healthcare). Other: GFR Measuremments, Blood sampling, Urine sampling
62714454|NCT01578161|EXPERIMENTAL|Dexmedetomidine0.25|dexmedetomidine 0.25 microg.kg(-1),(Group D0.25) ivs. for 10min.
62161538|NCT03997552|ACTIVE_COMPARATOR|marginal approach by palatal incision|A small incision in the palatal aspect and a limited papila elevation to the buccal aspect will be made for treating isolated periodontal defect. Enamel matrix derivates will be applied on the debrided root surfaces.
62534602|NCT01768013|EXPERIMENTAL|LEO 90105 Ointment|
62534603|NCT02149329|EXPERIMENTAL|Short treatment|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
62534604|NCT02149329|NO_INTERVENTION|Extended treatment|Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature \<38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC \> 0,5 x10\^9/L), whichever comes first.
62534605|NCT02470273||Dermatology patients|Patients with a suspicious skin lesion indicated for biopsy
62534606|NCT04885153|EXPERIMENTAL|Intervention Group|Subjects who were given simvastatin 10 mg and fenofibrate 200 mg.
62534607|NCT04885153|PLACEBO_COMPARATOR|Control Group|Subjects who were given simvastatin 10 mg and placebo (lactic acid) 200 mg.
62534608|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
62534609|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
62534610|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
62534611|NCT05921357||Peri-implantitis|Implants with a pocket depth of more than 5 mm and bleeding on probing
62714455|NCT01578161|EXPERIMENTAL|Dexmedetomidine0.5|dexmedetomidine 0.5 microg.kg(-1),(group D0.5) ivs. for 10min.
62534612|NCT05921357||Peri-implant mucositis|Implants with no bone loss but bleeding on probing
62714456|NCT01578161|EXPERIMENTAL|Dexmedetomidine1.0|dexmedetomidine 1 microg.kg(-1) ivs. for 10min.
62714457|NCT01578161|PLACEBO_COMPARATOR|NormalSaline|Normal saline 10ml ivs. for 10min.
62714458|NCT02568553|EXPERIMENTAL|Treatment (blinatumomab, lenalidomide)|"INDUCTION: Patients receive blinatumomab IV continuously on days 1-56 and lenalidomide PO on days 29-49 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving response including stable disease receive blinatumomab IV continuously on days 1-7 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receiving response including stable disease after completion of Consolidation receive lenalidomide PO on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
62714459|NCT01905540|EXPERIMENTAL|SSP-004184AQ (single dose)|40 mg/kg (oral capsule form) given once on Day 1
62714460|NCT01905540|EXPERIMENTAL|SSP-004184SS (single dose)|21.8 mg/kg (oral capsule form) given once on Day 1
62534613|NCT05921357||Peri-implant health|Implants with no bone loss but no bleeding on probing
62534614|NCT02331290||All patients|20 newly diagnosed patients with small-cell lung cancer and adenocarcinoma of the lung stage III or IV
62714461|NCT01905540|EXPERIMENTAL|SSP-004184AQ (2 doses)|40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
62534615|NCT03043976|ACTIVE_COMPARATOR|feedback and goal-setting group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
62534616|NCT03043976|ACTIVE_COMPARATOR|Control group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'WT and will undertake a blood sample (BNP). After a run-in period (1 week) with an Actigraph GT9X Link device disabled from showing the number of steps, patients will wear an Actigraph GT9X Link device which still only displays time and battery level and will upload data via the Study Admin Mobile application for smartphones/tablets without receiving any feedback. After 8 weeks, patients will be assessed (SF36, 6'WT, BNP) and will start to wear a new device enabled to display the daily step count. Patients will be asked to aim for an average specified number of steps/day, receiving a weekly summary of the previous week with targets to achieve week by week. After 8 weeks, patients will be assessed (6'WT, SF36, BNP) and will carry on wearing the device and receiving feedbacks and targets for a further 8 week period, after that patients will be finally assessed (SF36, 6'WT, BNP)
62534617|NCT03043976|PLACEBO_COMPARATOR|newly diagnosed patients|"In the week leading up to their inpatient admission for diagnostic investigations, patients who are treatment-naïve will be given the Actigraph GT9X Link device which will only display the time and the charge level of the battery. Patients will be asked, as well, to fill a questionnaire about their quality of life, to perform a 6MWT and a blood sample (BNP). As soon as patients start the drug therapy, patients will wear a second Actigraph GT9X Link device still disabled from showing real time data about the number of daily steps. Participants will not receive any feedback during the whole period and will be asked, as well, to upload the data collected through the remote mobile system. At their first clinical assessment (after about 4 or 5 weeks), 6'WT, BNP and questionnaire about quality of life will be reassessed.~If patients are not being started on drug therapy then they will be withdrawn from the study"
62534618|NCT01982812|EXPERIMENTAL|Oral Levetiracetam|Oral Levetiracetam administered by NG tube.
62161539|NCT03997552|ACTIVE_COMPARATOR|Minimally invasive surgical technique (MIST)|The incision of the defect-associated papilla will be performed according to the principles of the papilla preservation techniques. Enamel matrix derivates will be applied on the debrided root surfaces. Stable primary closure of the flaps will be obtained with internal modified mattress sutures.
62161540|NCT04119050|EXPERIMENTAL|M281 administered every 4 weeks (double-blind period)|Participants will receive M281 administered every 4 weeks alternating with placebo every 4 weeks during the 24 weeks double-blind period.
62161541|NCT04119050|EXPERIMENTAL|M281 administered every 2 weeks (double-blind period)|Participants will receive M281 administered every 2 weeks during the 24 weeks double-blind period.
62161542|NCT04119050|EXPERIMENTAL|Placebo administered every 2 weeks (double-blind period)|Participants will receive M281 matching placebo administered every 2 weeks during the 24 weeks double-blind period.
62714462|NCT01905540|EXPERIMENTAL|SSP-004184SS (2 doses)|21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
62714463|NCT06247787|EXPERIMENTAL|Treatment (Imetelstat, fludarabine, cytarabine)|Patients receive imeletstat IV over 2 hours on days 1 and 8, fludarabine IV over 1 hour on days 2-6, and cytarabine IV over 1-3 hours on days 2-6 of each cycle. Patients also receive cytarabine IT or methotrexate IT, and hydrocortisone IT at the provider's discretion. Patients then receive leucovorin calcium IV or PO 24 and 30 hours after each IT triples dose. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, bone marrow biopsy and/or aspirate, blood sample collection, and lumbar puncture for CSF sample collection during screening and on the trial.
62714464|NCT02146924|EXPERIMENTAL|Arm I (cellular immunotherapy closed to accrual January 2019)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
62714768|NCT05409066|EXPERIMENTAL|Epcoritamab Dose B in Combination With R2|Participants will receive epcoritamab Dose B in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days). Enrollment is closed for this arm.
62161543|NCT04119050|EXPERIMENTAL|M281 administered every 4 weeks (open-label extension period)|Participants will receive M281 administered every 4 weeks during the 144 weeks open-label extension period.
62161544|NCT04119050|EXPERIMENTAL|M281 administered every 2 weeks (open-label extension period)|Participants will receive M281 administered every 2 weeks during the 144 weeks open-label extension period.
62161545|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
62161546|NCT05653050|EXPERIMENTAL|Fully closed-loop system with age-approved ultra-rapid insulin|"The fully closed-loop system (CamAPS HX) will consist of:~* Mylife YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland).~* Freestyle Libre 3 real-time CGM sensor (Abbott, Diabetes Care, CA, USA)~* Android smartphone hosting CamAPS HX App with the Cambridge model predictive control algorithm.~* Cloud upload system to review CGM/insulin data.~Participants will use ultra-rapid insulin aspart in the closed-loop system."
62161547|NCT05653050|ACTIVE_COMPARATOR|Standard insulin pump therapy with CGM|"Participants will use their own insulin pump and usual insulin throughout this study period.~The CGM will be the Freestyle Libre 3 real-time CGM sensor (Abbott, Diabetes Care, CA, USA)."
62161548|NCT03799757|ACTIVE_COMPARATOR|Bupivacaine|The wound was installed by 40ml of 0.25% bupivacaine through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes.
62534619|NCT01982812|ACTIVE_COMPARATOR|Standard AED|Standard AED regimen
62534620|NCT06317090|EXPERIMENTAL|Test|LPRF block as a grafting material
62534621|NCT06317090|EXPERIMENTAL|Control|50% autogenous bone, 50% DBBM as a grafting material
62534622|NCT01418963|EXPERIMENTAL|Active|
62161549|NCT03799757|PLACEBO_COMPARATOR|Placebo|The wound was installed by 40ml of 0.9% normal saline through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes. (placebo group)
62161550|NCT00291928|PLACEBO_COMPARATOR|Dose ranging|A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
62161551|NCT00291928|PLACEBO_COMPARATOR|Parallel Arm RCT|a parallel group part with randomization into one of 4 treatment arms (Part B).
62534623|NCT01418963|PLACEBO_COMPARATOR|Placebo|
62534624|NCT01363024|EXPERIMENTAL|A|
62534625|NCT00638027|EXPERIMENTAL|1|Memantine 10 mg bid
62534626|NCT00638027|PLACEBO_COMPARATOR|2|Placebo
62534627|NCT04626453|EXPERIMENTAL|sedentary older adults with Type 2 Diabetes|Sedentary older adults with Type 2 Diabetes as the intervention group will do a 2-month home exercise.
62534628|NCT04626453|NO_INTERVENTION|Active older adults with Type 2 Diabetes|Active older adults with Type 2 Diabetes will not do exercise.
62534629|NCT04626453|NO_INTERVENTION|Healthy older adults|Healthy older adults will not do exercise.
62534630|NCT00110136|EXPERIMENTAL|St. John's Wort|Patient given one 300mg St. John's Wort tablet three times per day
62534631|NCT06293378|EXPERIMENTAL|Cohort A：Patients with PBC were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
62534632|NCT06293378|EXPERIMENTAL|Cohort B：Patients with HBV were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
62534633|NCT06293378|EXPERIMENTAL|Cohort C：Patients with HCV were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
62534634|NCT06293378|EXPERIMENTAL|Cohort D：Patients with alcoholic liver fibrosis/cirrhosis were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
62534635|NCT03474497|EXPERIMENTAL|Pembrolizumab/IL-2/Radiotherapy|All patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.
62714465|NCT02146924|ACTIVE_COMPARATOR|Arm II (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells after 28 days.
62161552|NCT06349941|EXPERIMENTAL|Movn cardiac rehabilitaion|Cardiac rehabilitation delivered through Movn app
62534636|NCT06309654|EXPERIMENTAL|home-based circuit training (HBCT) protocol|Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks.
62714769|NCT05409066|ACTIVE_COMPARATOR|Lenalidomide and Rituximab (R2)|Participants will receive lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).
62161553|NCT01911988||Colon&Rectal Stage II /Stage III|
62161554|NCT06337903|EXPERIMENTAL|Self-compassion intervention|8-week manualized online Mindful Self-Compassion course
62161555|NCT03358485|EXPERIMENTAL|Aolanti Weikang tablets|3，6 or 8 Aolanti Weikang tablets each time,tid
62161556|NCT03358485|PLACEBO_COMPARATOR|Placebo|3,6 or 8 tablets each time,tid
62534637|NCT06309654|SHAM_COMPARATOR|Standard of care (CONT)|"Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise)."
62534638|NCT04305951|NO_INTERVENTION|Routine care group|Subjects assigned to this group will continue their routine care without receiving any acupuncture and acupressure treatment during the study period. The routine care may include physiotherapy and intellectual activities. Post-trial treatment of either CAT, CAE, or CAT+CAE will be offered to serve as a compensation for their participation.
62534639|NCT04305951|EXPERIMENTAL|CAT group|Subjects assigned to comprehensive acupuncture therapy (CAT) group will receive CAT treatment in addition to routine care.
62534640|NCT04305951|EXPERIMENTAL|CAE group|Subjects assigned to 'Comfy Acupressure for the Elderly (CAE)' group will receive CAE in addition to routine care.
62534641|NCT04305951|EXPERIMENTAL|CAT + CAE group|Subjects assigned to CAT+CAE group will receive CAT+CAE in addition to routine care.
62534642|NCT04557020|EXPERIMENTAL|Arm A|IC with anti-PD1 mab+CCRT+anti-PD1 mab
62534643|NCT04557020|ACTIVE_COMPARATOR|Arm B|IC+CCRT
62534644|NCT02077673||open surgery|25 patients undergoing open gastroesophageal resection
62534645|NCT02077673||robotic-assissted surgery|25 patients under-going robotic-assisted gastroesophageal surgery
62534646|NCT01421173|EXPERIMENTAL|Vorinostat + GemBuMel|Vorinostat 200 mg by mouth on Days -8 to -2. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion. Remaining dose is 10 mg/m2/min on Day -8 and -3. Busulfan pharmacokinetics (PK) will be performed with the first dose of 105 mg/m2 by vein on Day -8. The doses of days -6 and -5 will be subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting were not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5. Melphalan 60 mg/m2 by vein on Days -2 and -3. Stem cells by vein over about 30-60 minutes on Day 0. Rituximab 375 mg/m2 on days +1 and +8 for cluster of differentiation antigen 20 (CD20+) tumors. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented. Palifermin 60 mcg/kg by vein daily for 6 doses starting on Day 0. Dexamethasone 8 mg by vein twice a day from day -8 AM to day -2 PM.
62534647|NCT06049810|EXPERIMENTAL|Group 3|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
62534648|NCT06049810|EXPERIMENTAL|Group 4|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
62534649|NCT06049810|EXPERIMENTAL|Group 6|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
62534650|NCT06049810|PLACEBO_COMPARATOR|Group 5|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
62534651|NCT06049810|EXPERIMENTAL|Group 1|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44
62534652|NCT06049810|PLACEBO_COMPARATOR|Group 2|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44
62534653|NCT00951496|EXPERIMENTAL|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
62534654|NCT00951496|EXPERIMENTAL|Arm II (paclitaxel, bevacizumab, carboplatin IP)|Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
62534655|NCT00951496|EXPERIMENTAL|Arm III (paclitaxel IP, bevacizumab, cisplatin IP)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
62534656|NCT04709770|EXPERIMENTAL|Low-volume preparation|"Low-volume preparation of 2-liters polyethylene glycol with citrate and simethicone. This formulation includes 4 large (A) and 4 small (B) sachets; the components of 2 sachets A and 2 sachets B are mixed in 1 liter of water.~Each sachet A contains:~* polyethylene glycol (4000) 52.50 g;~* simethicone 0.08 g;~* sodium sulphate anhydrous 3.75 g.~Each sachet B contains:~* sodium citrate 1.863 g;~* anhydrous citric acid 0.813 g;~* sodium chloride 0.73 g;~* potassium chloride: 0.37 g;~* acesulfame potassium 0.13 g. Participants will drink the first liter of preparation at 19.00 p.m. on the day before the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids. The second liter of preparation will be administered at 7.00 a.m. on the day of the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids."
62534657|NCT04709770|ACTIVE_COMPARATOR|High-volume preparation|"High-volume preparation with 4-liters polyethyleneglycol with simethicone. This formulation includes 4 sachets, each dissolved in 1 liter of water.~Each sachet contains:~* polyethylene glycol (4000) 58.30 g;~* simethicone 0.08 g;~* sodium sulphate anhydrous 5.68 g;~* sodium bicarbonate 1.68 g;~* sodium chloride 1.46 g;~* potassium chloride 0.74 g. Participants will drink the first 2 liters of preparation at 19.00 p.m. on the day before colonoscopy, at a rate of 250 ml every 15 minutes. The remaining 2 liters of preparation will be administered at 6.00 a.m. on the day of the endoscopic procedure, at a rate of 250 ml every 15 minutes."
62534658|NCT03511326|EXPERIMENTAL|Luxerm®|
62534659|NCT02345629|EXPERIMENTAL|Cordotomy Group|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours. Quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call. Participants undergo quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Sensory testing to include sharpness and heat detection.
62534660|NCT02345629|ACTIVE_COMPARATOR|Comprehensive Medical Management Group|Participants receive best supportive care for 1 week. Depending on pain level after the first week, they may have a cordotomy at that time. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call.
62534661|NCT01151228|PLACEBO_COMPARATOR|Zero volume|Patients will not ingest any apple juice prior to the second ultrasound.
62534662|NCT01151228|EXPERIMENTAL|50 mL|Patients will ingest 50 mL apple juice prior to the second ultrasound.
62534663|NCT01151228|EXPERIMENTAL|100 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
62534664|NCT01151228|EXPERIMENTAL|200 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
62534665|NCT01151228|EXPERIMENTAL|300 mL|Patients will ingest 300 mL apple juice prior to the second ultrasound.
62534666|NCT01151228|EXPERIMENTAL|400 mL|Patients will ingest 400 mL apple juice prior to the second ultrasound.
62534667|NCT00858143||1|
62161557|NCT00042510|EXPERIMENTAL|Treatment Group|500µg G17DT administered on Weeks 1, 5 and 9 and an additional treatment at Week 25. Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m\^2. 5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m\^2/d.
62534668|NCT04137016|EXPERIMENTAL|HIV-subjects with APP|HIV-infected patients using the App + standard clinical management (SCM)
62534669|NCT04137016|NO_INTERVENTION|Control group|HIV-infected patients, who only receive Standard Clinical Management (without the App)
62534670|NCT00863395|EXPERIMENTAL|Skin Biopsy|
62534671|NCT02816099|EXPERIMENTAL|Type-1 diabetes patients|
62534672|NCT02816099|OTHER|Controls|
62534673|NCT03260985|EXPERIMENTAL|Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
62714770|NCT05889286||Arm A: Symptomatic patient cohort|Arm A will consist of 20 patients who have suspected prosthetic infection and who are scheduled to undergo surgery debridement/removal.
62714771|NCT05889286||Arm B: Asymptomatic patient cohort|Arm B will consist of 10 asymptomatic normal control patients who have remotely placed total knee prosthesis without clinical or laboratory evidence of infection per inclusion criteria.
62736445|NCT05618210||Rhomboid block|In the rhomboid intercostal block group, after the patients are placed in the prone position, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and a 50-80 mm needle will be injected into the plan between them at the T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection.
62161558|NCT06538870|EXPERIMENTAL|Patients taking TNF-alpha inhibitors|Adult patients (18 years of age or older) taking a TNF-alpha inhibitor as defined by the NIH and missing teeth will be recruited to receive dental implant placement according to standard of care for ideal dental restoration. Patients must have been taking a stable dose of the drug for at least 6 months and have no contra-indications to implant placement (regular tobacco use in the last year, periodontal disease, pathology in the jaw bone(s), history of head and neck radiation, history of antiresorptive or antiangiogenic agents, uncontrolled diabetes, pregnancy, other medical conditions that preclude safe delivery of outpatient medical care) to be eligible for enrollment in the study.
62161559|NCT06538870|EXPERIMENTAL|Patients not taking TNF-alpha inhibitors|Patients over age 18 not taking TNF alpha inhibitors will be recruited and matched via age and sex to the patients taking TNF-alpha inhibitors. The general exclusion criteria (regular tobacco use in the last year, periodontal disease, pathology in the jaw bone(s), history of head and neck radiation, history of antiresorptive or antiangiogenic agents, uncontrolled diabetes, pregnancy, other medical conditions that preclude safe delivery of outpatient medical care) will apply to both arms equally.
62534674|NCT03260985|NO_INTERVENTION|Delayed Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
62534675|NCT03995186|EXPERIMENTAL|Behavioural activation group|
62534676|NCT03995186|ACTIVE_COMPARATOR|Activity monitoring group|
62534677|NCT03995186|NO_INTERVENTION|Waiting list control group|
62534678|NCT06020287||AP-RARP|the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach
62534679|NCT06020287||RS-RARP|the robot-assisted laparoscopic radical prostatectomy with the Retzius-sparing approach
62534680|NCT06020287||anterior-RARP|he robot-assisted laparoscopic radical prostatectomy with anterior approach
62534681|NCT05486793|EXPERIMENTAL|Written Exposure Therapy (WET)|Participants randomized into this arm will receive the WET intervention administered by mental health clinicians.
62534682|NCT05486793|EXPERIMENTAL|Community Health Workers- Written Exposure Therapy (CHW-WET)|Participants randomized into this arm will receive the WET intervention administered by community health workers.
62534683|NCT05486793|ACTIVE_COMPARATOR|Emotion Focused Supportive Therapy (EFST)|Participants randomized into this arm will receive the EFST intervention.
62534684|NCT05193643|EXPERIMENTAL|Sonovein Treatment|
62534685|NCT00719030|EXPERIMENTAL|1|Pomegranate pill
62534686|NCT00719030|PLACEBO_COMPARATOR|2|
62534687|NCT03251235|EXPERIMENTAL|Treatment Group|Group receives four weekly sessions of CBT prior to experimental testing/ fMRI
62534688|NCT03251235|NO_INTERVENTION|Waiting Group|Group receives four weekly sessions of CBT after experimental testing/ fMRI
62534689|NCT04959591|EXPERIMENTAL|Experimental (Pre): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg after anesthetic induction/before surgical incision and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given at the end of surgery before skin closure.
62534690|NCT04959591|EXPERIMENTAL|Experimental(post): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg at the end of surgery before skin closure and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given after anesthetic induction/before surgical incision.
62534691|NCT04959591|PLACEBO_COMPARATOR|Placebo comparator : placebo|Participants will receive 1.5ml/kg placebo (0.9% saline) before and after surgery and the same dose will be given postoperatively at 8hour intervals for 24hours.
62534692|NCT05824416|EXPERIMENTAL|ALBA|25 minutes of therapy with ALBA and 20 minutes with conventional therapy per session for 5 days a week during 4 weeks.
62534693|NCT05824416|ACTIVE_COMPARATOR|Conventional Therapy|45 minutes conventional therapy per session for 5 days a week during 4 weeks.
62736446|NCT01701362|ACTIVE_COMPARATOR|pregabalin|
62534694|NCT02312908|EXPERIMENTAL|Clonazepam|Clonazepam 0.5 mg 1 Tablet by mouth, 1/day before sleeping for 4 weeks
62534695|NCT02312908|PLACEBO_COMPARATOR|Placebo|Placebo 1 Tablet by mouth, 1/day before sleeping for 4 weeks
62534696|NCT00565617|EXPERIMENTAL|Synergy, Epidural cortical stimulation|Epidural cortical stimulation (medial prefrontal cortex) for treatment resistant depression. The primary aim of this pilot study was to assess the feasibility and safety of EpCS in patients with treatment-resistant depression. Ultimately, for EpCS to be found effective, a much larger double blind placebo controlled study would be needed.
62534697|NCT03002571|EXPERIMENTAL|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
62534698|NCT03002571|ACTIVE_COMPARATOR|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
62534699|NCT01337258||Men at increased risk for Prostate Cancer (PCA)|
62534700|NCT02555748|ACTIVE_COMPARATOR|Pazopanib|"The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).~During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
62534701|NCT02555748|ACTIVE_COMPARATOR|Sunitinib|"Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).~During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
62534702|NCT06084897|EXPERIMENTAL|Consolidation radiotherapy|This treatment group will be receive radiotherapy on the basis of standard first-line treatment, after all planned cycles of chemotherapy combined with PD-1 inhibitor completed.
62534703|NCT06084897|EXPERIMENTAL|Salvage radiotherapy|This treatment group will be receive salvage radiotherapy on the basis of standard first-line treatment, when disease progressed and salvage radiotherapy is recommended by multidisciplinary team.
62534704|NCT03261986|OTHER|Trident II acetabular cup|Subjects receive the Trident II acetabular cup and RSA beads and undergo a series of post-operative RSA exams.
62161560|NCT00963105|EXPERIMENTAL|Lenalidomide 5 mg|"Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
62161561|NCT00963105|EXPERIMENTAL|Lenalidomide 10 mg|"Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
62161562|NCT00963105|EXPERIMENTAL|Lenalidomide 15 mg|"Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
62161563|NCT06628180|SHAM_COMPARATOR|Sham LIFU|Sham application of LIFU - all follow up (MRI, questionnaires) will be identical.
62161564|NCT06628180|EXPERIMENTAL|Verum LIFU|Active LIFU application with 3 week follow-up (MRI, questionnaires)
62161565|NCT02834624|ACTIVE_COMPARATOR|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
62534705|NCT04358289|NO_INTERVENTION|Arm 1: Control group|For commune health center and community
62534706|NCT04358289|OTHER|Arm 2: Basic antimicrobial stewardship education|For commune health center and community
62534707|NCT04358289|OTHER|Arm 3: 3. Basic AS education + community education|For commune health center and community
62534708|NCT04358289|OTHER|Arm 4: Education + participatory action research|For commune health center and community
62534709|NCT04358289|OTHER|Hospital intervention|For hospital: The hospital interventions will use quality improvement using a participatory action research approach to improve antibiotic stewardship. These activities will be evaluated through a before and after knowledge, attitudes and practice (KAP) survey, to assess whether or not the engagement activities had a measurable impact on knowledge and behaviour. There are not sufficient hospitals in the area to conduct a cluster randomized evaluation, so we will conduct a before and after survey, patient record review, and overall antibiotic use data from the Pharmacy Department
62534710|NCT02392351|EXPERIMENTAL|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
62534711|NCT02392351|SHAM_COMPARATOR|Masked Procedure|Percutaneous renal angiography
62534712|NCT04992650|EXPERIMENTAL|Breast reconstruction with fat grafting|fat grafting
62534713|NCT04992650|NO_INTERVENTION|breast reconstruction without fat grafting|No Fat grafting
62534714|NCT03898089|OTHER|Core Exercise Group|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks.
62534715|NCT03898089|EXPERIMENTAL|Core Exercise plus Myofascial Relaxation Group|In addition to the core stabilization exercises myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks.
62534716|NCT04084600|EXPERIMENTAL|Intervention Group|Once a week for 6 consecutive weeks, this group will receive a manual therapy protocol with an approach based on Taylor et al., 1990; Schleip et al., 2012; Bienfait, 1999 and Myers, 2016, lasting 20 minutes, focused on the upper quadrant homolateral to the surgery. Shortly thereafter, this group will participate in a kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
62161566|NCT02834624|ACTIVE_COMPARATOR|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
62161567|NCT05564052|EXPERIMENTAL|Phase 2: Treatment Arm A1 (Rituximab plus Ibrutinib)|Participants will receive rituximab 375 milligrams per meter square (mg/m\^2) intravenously (IV) on Day 1 of Cycles 1 to 6 with ibrutinib 560 milligrams (mg) orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
62161568|NCT05564052|EXPERIMENTAL|Phase 2: Treatment Arm A2 (Rituximab plus Ibrutinib)|Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 420 mg orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
62161569|NCT05564052|EXPERIMENTAL|Phase 2: Treatment Arm A3 (Rituximab plus Ibrutinib)|Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 140 mg orally, twice daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
62736447|NCT01701362|PLACEBO_COMPARATOR|placebo|
62736448|NCT01692496|EXPERIMENTAL|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
62534717|NCT04084600|SHAM_COMPARATOR|Sham Group|Once a week for 6 consecutive weeks, this group will receive a soft and shallow traditional massage, lasting 20 minutes. Shortly thereafter, this group will participate to the same kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
62534718|NCT05321173||Extubation ≤ 8 hour|Patients who mechanically ventilated less than 8 hours postoperatively
62534719|NCT05321173||Extubation > 8 hour|Patients who mechanically ventilated more than 8 hours postoperatively
62534720|NCT04141124|SHAM_COMPARATOR|Control|5 minutes of reading fictitious biological medical results that are almost normal and unrelated to the upcoming scenario. This condition reflects a likely activity in relation to other patients in charge, pending an announced critical situation.
62534721|NCT04141124|ACTIVE_COMPARATOR|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
62534722|NCT04141124|EXPERIMENTAL|Breathing exercise combined with HRV|5 minutes of relaxing breathing, guided by a computer helping to follow inspiration and expiration and coupled with direct biological feedback on HRV.
62534723|NCT00988442|EXPERIMENTAL|Enhanced nursing telephone support with standard care|Participants received enhanced nursing telephone support plus care as usual.
62534724|NCT00988442|ACTIVE_COMPARATOR|Standard care|Participants received care as usual.
62534725|NCT01171118|EXPERIMENTAL|Sedation & Physostigmine & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
62534726|NCT01171118|PLACEBO_COMPARATOR|Sedation & Placebo & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
62534727|NCT01171118|EXPERIMENTAL|Sedation & Physostigmine & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
62534728|NCT01171118|PLACEBO_COMPARATOR|Sedation & Placebo & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
62534729|NCT02340130|EXPERIMENTAL|DP/MG/14-1|DP/MG/14-1: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised B. tropicalis 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
62534730|NCT02340130|EXPERIMENTAL|DP/MG/14-2|DP/MG/14-2: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised L.destructor 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
62534731|NCT03373773|ACTIVE_COMPARATOR|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of \>5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter at home."
62534732|NCT03373773|ACTIVE_COMPARATOR|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of \>5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter in a medical office."
62534733|NCT05623306|EXPERIMENTAL|SEEG Guided DBS ON-OFF (Stimulation-Sham)|Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period.
62534734|NCT05623306|SHAM_COMPARATOR|SEEG Guided DBS OFF-ON (Sham-Stimulation)|Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.
62534735|NCT05251519|EXPERIMENTAL|Kinesio Taping Group (KTG)|Conventional rehabilitation application will be performed in addition to Kinesio Tex tape derotation taping.
62534736|NCT05251519|ACTIVE_COMPARATOR|Conventional Rehabilitation Group (CRG)|A conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
62534737|NCT00715221||1|Normal Weight
62534738|NCT00715221||2|Obese without diabetes
62534739|NCT00715221||3|Obese with diabetes
62534740|NCT02373189|EXPERIMENTAL|Bright light|Participants received morning bright light.
62534741|NCT05749250|EXPERIMENTAL|Cavitation therapy|Subjects treated with cavitation energy
62534742|NCT05749250|NO_INTERVENTION|Control|Control subjects not treated with cavitation energy
62534743|NCT05886010|EXPERIMENTAL|Condition 1 :prototypes 1 everyday|Application on the brown spots of the face and the hands for the prototypes 1 at D0,D1,D2,D3,D4 and D5
62534744|NCT05886010|EXPERIMENTAL|Condition 2 : prototypes 1 every week|Application on the brown spots of the face and the hands for the prototypes 1 at D0,D7,D14,D21,D28, D35, D42, D49, D56, D63, D70 and D77.
62534745|NCT05886010|EXPERIMENTAL|Condition 3 : prototypes 1 every two weeks|Application on the brown spots of the face and the hands for the prototypes 1 at D0,D14,D28, D42, D56 and D70
62534746|NCT05886010|EXPERIMENTAL|Condition 4 : prototypes 2 every two weeks|Application on the brown spots of the face and the hands for the prototypes 2 at D0,D14,D28, D42, D56 and D70
62534747|NCT05886010|EXPERIMENTAL|Condition 5 : prototypes 3 every two weeks|Application on the brown spots of the face and the hands for the prototypes 3 at D0,D14,D28, D42, D56 and D70
62534748|NCT05854810|ACTIVE_COMPARATOR|PCOS Patient|
62534749|NCT05854810|ACTIVE_COMPARATOR|Male factor infertility|
62534750|NCT02879357|EXPERIMENTAL|Trained Clinicians|Training in Serious Illness Communication Guide
62161570|NCT05564052|EXPERIMENTAL|Phase 2: Treatment Arm B (Rituximab plus Lenalidomide or Bortezomib)|Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 (each cycle length is 21 or 28 days) with physician's choice of either lenalidomide 20 mg orally, once daily from Day 1 through Day 21 of 28-day cycle or bortezomib 1.3 mg/m\^2 IV or subcutaneously (SC) on Days 1, 4, 8 and 11 of a 21-day cycle until disease progression or unacceptable toxicity.
62534751|NCT02879357|NO_INTERVENTION|Untrained Clinicians|No training in Serious Illness Communication Guide
62534752|NCT04445363|EXPERIMENTAL|Cohort 1,0.5% Bid|Jaktinib hydrochloride cream 0.5% concentration, twice daily
62161571|NCT06092827|EXPERIMENTAL|Physical activity|Adults 18 to 75 with an active diabetic foot ulcer
62161572|NCT06719687|EXPERIMENTAL|Patients with peripheral pulmonary lesions|30 patients with peripheral pulmonary lesions who meet the inclusion and exclusion criteria will be prospectively enrolled. Self-driving robotic-assisted bronchoscopy will be performed to diagnose the lesions.
62161573|NCT03761849|EXPERIMENTAL|RO7234292 Q8W|RO4234292 is administered intrathecally every 8 weeks.
62161574|NCT03761849|EXPERIMENTAL|RO7234292 Q16W|RO7234292 is administered intrathecally every 16 weeks. Participants in this arm will also receive placebo at alternate weeks to keep the blind.
62161575|NCT03761849|PLACEBO_COMPARATOR|Placebo|Placebo will be administered every 8 weeks by IT injection.
62534753|NCT04445363|EXPERIMENTAL|Cohort 1,1.5% Bid|Jaktinib hydrochloride cream 1.5% concentration, twice daily
62534754|NCT04445363|EXPERIMENTAL|Cohort 1,2.5% Qd|Jaktinib hydrochloride cream 2.5% concentration, once daily
62534755|NCT04445363|EXPERIMENTAL|Cohort 1,2.5% Bid|Jaktinib hydrochloride cream 2.5% concentration, twice daily
62534756|NCT04445363|PLACEBO_COMPARATOR|Dose extension: Placebo|Placebo, twice daily
62534757|NCT04445363|EXPERIMENTAL|Dose extension: 1.5% Bid|Jaktinib hydrochloride cream 1.5% concentration, twice daily
62714466|NCT06225466|ACTIVE_COMPARATOR|Neuromuscular blockade|"Rocuronium 0.6 mg/kg IV (max 50 mg) intraop with repeated doses of 0.2 mg/kg (max 15 mg) as indicated. Sugammadex 2-4 mg/kg IV at the end of surgery.~SOC drugs:~1. Midazolam 0.5 mg/kg (max 15 mg) and acetaminophen 15 mg/kg (max 800 mg) PO 20-30 minutes before surgery.~2. Sevoflurane induction and maintenance of anesthesia~3. Dexamethasone 0.5 mg/kg IV (max 8 mg) intraop~4. Dexmedetomidine 0.3 mcg/kg IV (max 12 mcg) intraop~5. Fentanyl at the discretion of the anesthesiologist. In the post-anesthesia care unit (PACU), fentanyl 0.5 mcg/kg IV (max 25 mcg) for pain score 4 or greater (max 3 doses).~6. Ondansetron 0.1 mg/kg (max 4 mg) IV intraop~7. Ibuprofen 10 mg/kg (max 500 mg) PO every 6 hours beginning after surgery and alternating with acetaminophen 15 mg/kg (max 800 mg) every 6 hours.~Device monitoring:~1. Bispectral index system intraop~2. TetraGraph neuromuscular transmission monitor intraop~3. ExSpiron respiratory volume monitor intraop and in PACU"
62736449|NCT05263180|EXPERIMENTAL|Experimental: EMB-09|Participants enrolled at different time will receive EMB-09 once a week (IV) at different ascending dose levels.
62736450|NCT00241410|EXPERIMENTAL|1|4 consecutive groups, dose escalation
62534758|NCT04445363|EXPERIMENTAL|Dose extension: 2.5% Bid|Jaktinib hydrochloride cream 2.5% concentration, twice daily
62534759|NCT05353010|EXPERIMENTAL|Period 1: A; Period 2: B and C|A: Oral Administration of Tacrolimus 5mg once / B: Oral Administration of IN-A001(Tegoprazan) 50mg QD for 7 days / C: Oral Administration of IN-A001(Tegoprazan) 50mg + Tacrolimus 5mg once
62736451|NCT00241410|PLACEBO_COMPARATOR|2|4 consecutive groups
62736452|NCT03969290|EXPERIMENTAL|Sequence 1|Verofilcon A contact lens in the right eye (OD), with etafilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
62736453|NCT03969290|ACTIVE_COMPARATOR|Sequence 2|Etafilcon A contact lens in the right eye (OD), with verofilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
62161576|NCT01477177|EXPERIMENTAL|Polar Wand Treatment|Cryotherapy device utilizing carbon dioxide (room temperature gas) for treatment of GI neoplasia
62161577|NCT06721949|EXPERIMENTAL|Taurine|Participants randomized to the Taurine arm will receive two 675 mg taurine capsules twice daily for 12 weeks.
62161578|NCT06721949|PLACEBO_COMPARATOR|Placebo|Participants randomized to the Placebo arm will receive two placebo capsules twice daily for 12 weeks. The placebo capsules will be visually identical to the taurine capsules.
62161579|NCT06484660|EXPERIMENTAL|Minimally Invasive Approach In The Mucosal Advancement Flap Technique|
62534760|NCT03838510|EXPERIMENTAL|Brief Counseling Intervention|
62534761|NCT03838510|NO_INTERVENTION|Control Group|
62534762|NCT04849962|ACTIVE_COMPARATOR|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
62534763|NCT04849962|EXPERIMENTAL|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
62534764|NCT05220189||Hematuria patients aged ≥40|Device: EarlyTect Bladder Cancer test, PENK methylation assay by LTE (Linear Target Enrichment)-qMSP (quantitative methylation-specific real time PCR)
62534765|NCT01740635|EXPERIMENTAL|EPIC WheelS Training Program|The EPIC WheelS program includes a comprehensive, structured library of educational material and training activities, organized in a hierarchy from simple to complex. Experimental group subjects will attend 2 training sessions with an expert Trainer. The Trainer will individualize a structured home training program, delivered via a computer tablet, and subjects will train at home for 1 month.
62534766|NCT01740635|NO_INTERVENTION|Cognitive games|To provide a comparable level of investigator attention, control group subjects will receive two 1-hour social visits. To control for Trainer bias, the experimental and control groups will have separate Trainers. During social visits, the Trainer will discuss subjects' current community activities and their experience using the wheelchair, and provide verbal information related to barriers encountered. Subjects will receive a computer tablet with cognitive stimulation games to account for activity and tablet device exposure. Participants in the extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week (total 75 minutes/week) and document these on a simple calendar-style form provided. To minimize attrition, control subjects will receive a DVD with a condensed MWC skills education program after the post-intervention data collection is complete.
62534767|NCT00752011|EXPERIMENTAL|Carboplatin + TAS-106|Carboplatin starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle. TAS-106 starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
62534768|NCT04575064|OTHER|Standard of Care (SoC)|This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
62534769|NCT04575064|EXPERIMENTAL|Remdesivir + SoC|Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
62534770|NCT00132028|EXPERIMENTAL|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
62534771|NCT00977379|ACTIVE_COMPARATOR|WBRT Followed by Standard of Care|Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system \[CNS\] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
62534772|NCT00977379|EXPERIMENTAL|WBRT+Capecitabine Followed by Capecitabine Maintenance|Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m\^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).
62534773|NCT04468516|EXPERIMENTAL|Treatment|Intervention is applied to the C1 of the spine.
62161580|NCT05178069|PLACEBO_COMPARATOR|Placebo Comparator: Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
62534774|NCT04468516|PLACEBO_COMPARATOR|Placebo|Intervention is applied in reduced intensity to the trapezius muscle.
62534775|NCT04468516|NO_INTERVENTION|Waitlist period|Participants will have a 1 month waitlist period where no intervention takes place.
62534776|NCT05973292|EXPERIMENTAL|Group ZA|Participants received Zirconia anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ MDP-containing resin cement.
62534777|NCT05973292|EXPERIMENTAL|Ggroup ZB|Participants received Zirconia anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ Non-MDP-containing resin cement.
62534778|NCT05973292|EXPERIMENTAL|Group EA|Participants received E-max anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ MDP-containing resin cement.
62534779|NCT05973292|EXPERIMENTAL|Group EB|Participants received E-max anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ Non-MDP-containing resin cement.
62534780|NCT04111055|EXPERIMENTAL|Closed-loop group|The MAP of the patient will be managed by the CLV system to avoid hypotension. The MAP target selected in the closed-loop system will be the patient's MAP target ( same target as patient's MAP value preoperatively). Then the closed-loop system will have to adjust norepinephrine infusion rate to keep that MAP value within 10% of patient's target.
62534781|NCT03670693|EXPERIMENTAL|Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index \<4 and CRP\<5mg/dl and faecal calprotectin \<50ug/g) suffering from fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 \>14, and a score of \>4 in the Fatigue questionnaire.)
62534782|NCT03670693|EXPERIMENTAL|Non-Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index \<4 and CRP\<5mg/dl and faecal calprotectin \<50ug/g) without fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 \<14, and a score of \<4 in the Fatigue questionnaire.)
62534783|NCT03670693|EXPERIMENTAL|Healthy Volunteers|Age,gender,muscle mass, and physical activity-matched healthy controls.
62534784|NCT03413293||Nosocomial infected cirrhotic patients|
62534785|NCT02049450|EXPERIMENTAL|INC424 (ruxolitinib) - Study Treatment|Regularly transfused adult patients with thalassemia and spleen enlargement.
62534786|NCT02455050|OTHER|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
62534787|NCT02455050|OTHER|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
62534788|NCT02455050|OTHER|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
62534789|NCT02455050|OTHER|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
62161581|NCT05178069|ACTIVE_COMPARATOR|Active Comparator: Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
62736454|NCT04704687|EXPERIMENTAL|tDCS|
62534790|NCT01788592||Drug eluting stent|Patients who receiving drug eluting stents
62534791|NCT01195792|EXPERIMENTAL|2 mg GSK1521498|Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
62534792|NCT01195792|EXPERIMENTAL|5 mg GSK1521498|Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
62534793|NCT01195792|PLACEBO_COMPARATOR|Placebo|Approximately 20 subjects will be randomised to receive matching placebo.
62534794|NCT00777036|EXPERIMENTAL|Cohort 1: Imatinib-resistant/intolerant CP-CML|"Dasatinib 60 mg/m² tablet every day (QD) \[with a maximum dose of 100 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² powder for oral suspension (PFOS) QD \[with a maximum dose of 120 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit"
62534795|NCT00777036|EXPERIMENTAL|Cohort 2: Ph+ALL or AP- or BP-CML|"Dasatinib 80 mg/m² tablet QD \[with a maximum dose of 140 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 96 mg/m² PFOS QD \[with a maximum dose of 170 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit"
62534796|NCT00777036|EXPERIMENTAL|Cohort 3: Newly diagnosed, treatment naïve CP-CML|"Dasatinib 60 mg/m² tablet QD \[with a maximum dose of 100 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² PFOS QD \[with a maximum dose of 120 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit"
62534797|NCT03534843||Surgical treatment|Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
62534798|NCT03534843||Non-surgical treatment|Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
62534799|NCT03494335||Volunteer participants|Volunteer participants will participate in surveys assessing their perception of various imaging aspects.
62534800|NCT04981730|EXPERIMENTAL|Web-based intervention|Participants in the intervention will receive both the standardized usual care and guided web-based, individually-tailored childbirth and parenting intervention program, consisting of training sessions plus weekly email, message, or video-conference contact from their assigned nurse specialist.
62534801|NCT04981730|NO_INTERVENTION|Control|Participants in the control group will receive attention from the research nurse and the standardized usual care.
62534802|NCT00012649||Group 1|
62534803|NCT03483246|EXPERIMENTAL|Group B - fecal microbiota transplantation|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation
62534804|NCT03483246|PLACEBO_COMPARATOR|Group A- Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation
62161582|NCT06181123||healthy group|Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
62161583|NCT06181123||Patient group|Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
62534805|NCT03456583||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
62534806|NCT01437943|ACTIVE_COMPARATOR|Aliskiren|Aliskiren 150 mg daily for 180 days
62534807|NCT01437943|PLACEBO_COMPARATOR|Placebo|Placebo identical to Aliskiren drug daily for 180 days
62534808|NCT00521534||A|CRT programmed to VDD pacing mode
62534809|NCT00521534||B|CRT programmed to DDD with overdrive pacing based on first night average sinus rate.
62534810|NCT01205386||CROSSER|
62534811|NCT03463408|EXPERIMENTAL|Immunotherapy arm|"Cohort A will comprise adult soft tissue sarcoma patents who consent to and receive ipilimumab + nivolumab concurrently with standard of care radiation. Ipilimumab will be given at a dose of 1 mg/kg every 6 weeks (total two doses) and nivolumab given as a flat dose of 240 mg every 2 weeks (total four doses).~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
62161584|NCT04853238||Cohort 1: Participants with stable disease|
62161585|NCT04853238||Cohort 2: Participants with moderate acute exacerbation not requiring hospitalization|
62161586|NCT04853238||Cohort 3: Participants requiring hospitalization for an acute exacerbation|
62161587|NCT06720129|OTHER|The control group|The control group received standard care plus a hydrocolloid dressing for protection
62534812|NCT03463408|NO_INTERVENTION|no immunotherapy arm|"Cohort B will comprise patients eligible for the trial who do not wish to receive immunotherapy but consent to the same blood draws, surveys, and specimen analysis as Cohort A. Cohort B will serve as a non-randomized but pragmatic and clinically relevant control group.~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
62161588|NCT06720129|OTHER|The observation group|The observation group employed the modified pressure-reducing fixation protective nasal strip
62534813|NCT01234922|EXPERIMENTAL|Arm I|Patients receive oral benazepril hydrochloride once daily on days 1-7.
62534814|NCT01234922|EXPERIMENTAL|Arm II|Patients receive oral lisinopril once daily on days 1-7.
62534815|NCT01234922|EXPERIMENTAL|Arm III|Patients receive oral ramipril twice daily on days 1-7.
62534816|NCT01234922|EXPERIMENTAL|Arm IV|Patients receive oral losartan potassium once daily on days 1-7.
62534817|NCT06169189|ACTIVE_COMPARATOR|Experimental intervention group|The experimental group will be given 8-week global warming-climate change based training
62534818|NCT06169189|NO_INTERVENTION|Control Group|The initiative will not be implemented.
62534819|NCT05729685|EXPERIMENTAL|Interval training|The interval group trained using the interval trainining method.
62534820|NCT05729685|EXPERIMENTAL|Continuous training|The continuous group trained using the continuous training method.
62534821|NCT01844856|EXPERIMENTAL|Eravacycline, 1.0 mg/kg q12h|Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
62534822|NCT01844856|ACTIVE_COMPARATOR|Ertapenem, 1.0 g q24h|Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
62534823|NCT03167723|EXPERIMENTAL|28 French chest tube for hemothorax|28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
62534824|NCT03167723|EXPERIMENTAL|14 French chest tube for hemothorax|14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
62534825|NCT06634108|EXPERIMENTAL|Genistein Treatment and Washout|The Investigators plan to recruit 40 heart failure participants, including 20 participants with heart failure with reduced ejection fraction (LVEF\<40%) and 20 participants with transthyretin amyloid (ATTR) cardiomyopathy. After an initial telephone call to screen participants, the Investigators will invite qualified people for informed consent and a baseline fasting blood draw. Participants will receive escalating doses of genistein after their baseline fasting blood and stool sample collections. At baseline and again at 3 months, the Investigators will also perform transthoracic echocardiography and a 6-minute walk test.
62534826|NCT00003224|EXPERIMENTAL|Group 1: peptide 946 plus QS-21|100 mcg peptide gp100 \[280-288\] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
62534827|NCT00003224|EXPERIMENTAL|Group 2. p946 plus IFA|100 mcg peptide gp100 \[280-288\] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
62534828|NCT00003224|EXPERIMENTAL|Group 3: p946 plus Tet-p plus QS-21|100 mcg peptide gp100 \[280-288\],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
62534829|NCT00003224|EXPERIMENTAL|Group 4. p946, Tet-p plus IFA|100 mcg peptide gp100 \[280-288\], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
62534830|NCT00003224|EXPERIMENTAL|Group 5: p946/Tet-p plus QS-21|282 mcg gp100 \[280-288\]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
62534831|NCT00003224|EXPERIMENTAL|Group 6. p946/Tet-p plus IFA|282 mcg gp100 \[280-288\]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
62534832|NCT03783039|EXPERIMENTAL|SURGICEL Powder|SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
62534833|NCT03783039|ACTIVE_COMPARATOR|SURGICEL Original|SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form
62534834|NCT02189980|PLACEBO_COMPARATOR|Saline & nasal clip|Saline and nasal clip inhaled post-operatively
62534835|NCT02189980|EXPERIMENTAL|Aromatherapy blend & nasal clip|Aromatherapy blend and nasal clip inhaled post-operatively
62534836|NCT06633354|EXPERIMENTAL|Administration of CD5+ T-ALL Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
62534837|NCT03803930|OTHER|Arm 22G+SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
62534838|NCT03803930|OTHER|Arm 22G+MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
62534839|NCT03803930|OTHER|Arm 20G+SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
62534840|NCT03803930|OTHER|Arm 20G+MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
62534841|NCT02728843|EXPERIMENTAL|Deferiprone 300 mg|One-half of a 600 mg tablet of deferiprone twice a day, for a total daily dosage of 600 mg
62161589|NCT06719648|EXPERIMENTAL|Novomatrix and LPRF|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
62534842|NCT02728843|EXPERIMENTAL|Deferiprone 600 mg|One 600 mg tablet of deferiprone twice a day, for a total daily dosage of 1200 mg
62534843|NCT02728843|EXPERIMENTAL|Deferiprone 900 mg|One and a half 600 mg tablets of deferiprone twice a day, for a total daily dosage of 1800 mg
62534844|NCT02728843|EXPERIMENTAL|Deferiprone 1200 mg|Two 600 mg tablets of deferiprone twice a day, for a total daily dosage of 2400 mg
62534845|NCT02728843|PLACEBO_COMPARATOR|Placebo|Depending on dosage cohort, either one half-tablet, one tablet, one and a half tablets, or two tablets of placebo, twice a day
62534846|NCT05475886|EXPERIMENTAL|Hydroxyethyl starch (130/0.4) coload group|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia.
62534847|NCT04709211|ACTIVE_COMPARATOR|Group I: Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca Block using bupivacaine 0.25%
62534848|NCT04709211|ACTIVE_COMPARATOR|Group Q: Anterior Quadratus lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using bupivacaine 0.25%
62534849|NCT04120038|EXPERIMENTAL|SMART & Peer Support|
62534850|NCT04047186|EXPERIMENTAL|neoadjuvant PD-1 group|receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor
62534851|NCT03881020|EXPERIMENTAL|SMART|Silver modified atraumatic restorative treatment group in which advantage Arrest Silver diamine Fluoride 38% (Elevate oral Care, USA ) will be applied to carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
62534852|NCT03881020|ACTIVE_COMPARATOR|Conventional ART|Conventional atraumatic restorative treatment group in which a sharp excavator will be used to remove caries from carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
62534853|NCT05006768|EXPERIMENTAL|T test|Test drug (Barcimiant) 1 tablet contains 4 mg Baricitinib
62534854|NCT05006768|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
62534855|NCT05006768|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
62534856|NCT03286010|EXPERIMENTAL|Intervention|Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).
62534857|NCT03286010|NO_INTERVENTION|Control|Participants in the control group will be eligible to participate in the study, but cannot participate because there are no groups within their geographical region. They will be offered the W@H program after their 26-week follow up.
62534858|NCT00190190|EXPERIMENTAL|1|With Peeling of Limiting the Intern of the Retina
62534859|NCT00190190|ACTIVE_COMPARATOR|2|Traditional Procedure Without Peeling of Limiting
62534860|NCT00840515||Emulsion|
62534861|NCT01650701|EXPERIMENTAL|Lenalidomide + Rituximab|"* Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles~* Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
62534862|NCT01650701|ACTIVE_COMPARATOR|Control|• ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
62534863|NCT04364659|EXPERIMENTAL|Food-specific ICT + TAU|Participants in the Food-specific ICT + TAU group will be encouraged to complete the FoodT phone app (a food-specific go/no-go task) and a food diary daily for four weeks. After four weeks, they will be asked to complete a post-intervention questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
62534864|NCT04364659|NO_INTERVENTION|TAU|Participants in the TAU group will not receive the Food-specific ICT. After four weeks, they will be asked to complete a 'post-intervention' questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
62534865|NCT02494180|PLACEBO_COMPARATOR|A: intravenous fentanyl, midazolam|group A will be given intravenous 0.1mg fentanyl and 5mg midazolam prior oocyte retrieval
62534866|NCT02494180|PLACEBO_COMPARATOR|B: intravenous pethidine, diazepam|group B will be given intravenous 25mg pethidine, 5mg diazepam prior oocyte retrieval
62534867|NCT05621408|EXPERIMENTAL|Attention Training Techniqe|The treatment manual will consist of up to six weekly group sessions with 45-90 minutes duration.
62534868|NCT05621408|NO_INTERVENTION|Wait-list control|The wait-list control condition will not receive any psychological intervention during the six weeks waiting period. Subsequently, this group will also receive the intervention if the study entry criteria is still fulfilled
62534869|NCT03017703|EXPERIMENTAL|Type 2 Diabetes|8 weeks of treatment with Aldosterone blocker Eplerenone
62534870|NCT03017703|EXPERIMENTAL|Healthy|8 weeks of treatment with Aldosterone blocker Eplerenone
62534871|NCT00152178|EXPERIMENTAL|1|UFT (uracil, tegafur) and tamoxifen
62534872|NCT00152178|ACTIVE_COMPARATOR|2|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
62534873|NCT03141866|EXPERIMENTAL|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
62534874|NCT03141866|EXPERIMENTAL|Exercise Intervention 2: Machine-based resistance training|Specialised, chair-based resistance training equipment for older adults.
62534875|NCT00730587||1|Full-term healthy infants ages 5 months to 3 years.
62534876|NCT05735340|ACTIVE_COMPARATOR|Diabetes Education|Participants in this arm will receive traditional diabetes education following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow-up will be conducted at 3-months and 6-months.
62534877|NCT05735340|EXPERIMENTAL|T1DES|Participants in this arm will receive a emotion regulation intervention called T1DES following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow-up will be conducted at 3-months and 6-months.
62534878|NCT00732576|ACTIVE_COMPARATOR|1|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA)
62534879|NCT00732576|ACTIVE_COMPARATOR|2|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
62534880|NCT00732576|ACTIVE_COMPARATOR|3|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
62534881|NCT00732576|ACTIVE_COMPARATOR|4|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
62534882|NCT00732576|ACTIVE_COMPARATOR|5|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA)
62534883|NCT00732576|ACTIVE_COMPARATOR|6|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
62534884|NCT00732576|ACTIVE_COMPARATOR|7|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
62534885|NCT00732576|ACTIVE_COMPARATOR|8|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
62534886|NCT00537303|EXPERIMENTAL|Advanced|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
62736455|NCT04704687|ACTIVE_COMPARATOR|Sham|
62534887|NCT00537303|ACTIVE_COMPARATOR|Basic|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
62534888|NCT06244849|OTHER|Patient with Crohn disease (n=150)|CD patients requiring to undergo an ileo-colonoscopy for routine investigations (assessment of disease activity or complications as stricture or screening of colorectal cancer for CD)
62534889|NCT06244849|OTHER|Patient without Crohn disease (n=20)|Non-IBD patients (control) requiring to undergo an ileo-colonoscopy for routine investigations (screening for colorectal cancer or diagnosis of irritable bowel syndrome for controls).
62534890|NCT02628743|EXPERIMENTAL|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
62534891|NCT05782959|EXPERIMENTAL|Cohort 1|BCD-245 (anti-GD-2 monoclonal antibody), dose 1
62534892|NCT05782959|EXPERIMENTAL|Cohort 2|BCD-245 (anti-GD-2 monoclonal antibody), dose 2
62534893|NCT05782959|EXPERIMENTAL|Cohort 3|BCD-245 (anti-GD-2 monoclonal antibody), dose 3
62534894|NCT05782959|EXPERIMENTAL|Cohort 4|BCD-245 (anti-GD-2 monoclonal antibody), dose 4
62534895|NCT01119794|EXPERIMENTAL|ofatumumab and bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
62534896|NCT03261960|EXPERIMENTAL|Experimental Arm|BLI4700 Bowel Preparation
62534897|NCT03261960|ACTIVE_COMPARATOR|Control Arm|FDA Approved Bowel Preparation
62714467|NCT06225466|OTHER|No neuromuscular blockade|"Anesthesia will be administered in a standard fashion. Rocuronium and sugammadex will not be administered.~SOC drugs:~1. Midazolam 0.5 mg/kg (max 15 mg) and acetaminophen 15 mg/kg (max 800 mg) PO 20-30 minutes before surgery.~2. Sevoflurane induction and maintenance of anesthesia~3. Dexamethasone 0.5 mg/kg IV (max 8 mg) intraop~4. Dexmedetomidine 0.3 mcg/kg IV (max 12 mcg) intraop~5. Fentanyl at the discretion of the anesthesiologist. In the post-anesthesia care unit (PACU), fentanyl 0.5 mcg/kg IV (max 25 mcg) for pain score 4 or greater (max 3 doses).~6. Ondansetron 0.1 mg/kg (max 4 mg) IV intraop~7. Ibuprofen 10 mg/kg (max 500 mg) PO every 6 hours beginning after surgery and alternating with acetaminophen 15 mg/kg (max 800 mg) every 6 hours.~Device monitoring:~1. Bispectral index system intraop~2. ExSpiron respiratory volume monitor intraop and in PACU"
62714468|NCT04733534|ACTIVE_COMPARATOR|Dasatinib plus Quercetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16\^INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 will assess the permanence of change after completion of the trial."
62736456|NCT02243319|EXPERIMENTAL|Group 1|"A → B → C~A: HGP1201 for 9 days B: HGP0904 for 9 days C: HGP1201+ HGP0904 for 9 days"
62736457|NCT02243319|EXPERIMENTAL|Group 2|C → A → B
62736458|NCT02243319|EXPERIMENTAL|Group 3|B → C → A
62161590|NCT06719648|ACTIVE_COMPARATOR|Connective tissue graft and LPRF|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
62534898|NCT00782574|EXPERIMENTAL|1|"Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator.~Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid).~The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions."
62534899|NCT03131544|EXPERIMENTAL|FLA for BPH Active Treatment|
62534900|NCT04041349|NO_INTERVENTION|The standard treatment group|The standard treatment group is treated with conventional drugs and cholinesterase inhibitors
62534901|NCT04041349|EXPERIMENTAL|mouse nerve growth factor (mNGF)group|Conventional drugs and cholinesterase inhibitors + mouse nerve growth factor (mNGF) of 20 μg (9000 U)/day for 14 consecutive days by intramuscular injection.
62534902|NCT05532371|EXPERIMENTAL|Aerobic exercise training combined with lower limb strengthening group (AG)|Aerobic exercise training combined with lower limb strengthening.
62534903|NCT05532371|EXPERIMENTAL|Dual-task training combined with lower limb strengthening group (DG)|Dual-task training combined with lower limb strengthening.
62534904|NCT05532371|EXPERIMENTAL|Aerobic exercise training combined with dual-task training and lower limb strengthening group (ADG)|Aerobic exercise training combined with dual-task training and lower limb strengthening.
62534905|NCT05532371|ACTIVE_COMPARATOR|Only lower limb strengthening group (CG)|Only lower limb strengthening.
62534906|NCT03994601|EXPERIMENTAL|Arm A: BMS-986288 Monotherapy|
62534907|NCT03994601|EXPERIMENTAL|Arm B: BMS-986288 in combination with Nivolumab|
62534908|NCT03994601|EXPERIMENTAL|Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib|
62534909|NCT02553083|ACTIVE_COMPARATOR|Group 1|Nexium 40 mg and amoxicillin 1.5 gr twice daily for 14 days
62534910|NCT02553083|ACTIVE_COMPARATOR|Group 2|Nexium 40 mg and doxycycline 200 mg twice daily for 14 days
62534911|NCT02553083|ACTIVE_COMPARATOR|Group 3|Nexium 20 mg, clarythromicin 500 mg, and amoxicillin 1 gr twice daily for 14 days
62534912|NCT06389643|ACTIVE_COMPARATOR|Four-point scleral fixation group|Four-point scleral fixation group
62736459|NCT02243319|EXPERIMENTAL|Group 4|C → B → A
62534913|NCT06389643|ACTIVE_COMPARATOR|Yamane technique group|Yamane technique group
62534914|NCT05653310|EXPERIMENTAL|Tradipitant|Oral Capsule
62534915|NCT05653310|PLACEBO_COMPARATOR|Placebo|Oral Capsule
62534916|NCT02191631|EXPERIMENTAL|Internet-delivered CBT|Participants will receive 12 weeks of internet-delivered cognitive behavior therapy with psychologist support.
62534917|NCT02191631|NO_INTERVENTION|Wait list|Participants will receive no treatment for 12 weeks. After that period participants will receive Internet-delivered Cognitive Behavior Therapy.
62534918|NCT01799525|EXPERIMENTAL|Hypercapnia|Intervention: SAH patients are subjected to gradual hypercapnia by reduction of respiratory volume in one trial session every day. PaCO2 is raised from normocapnia to 50 mmHg for 10 - 15 minutes and 60 mmHg for 10 - 15 minutes.
62161591|NCT02880293|EXPERIMENTAL|Patients will undergo donor/recipient bone marrow|All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
62161592|NCT04824209||AP group|Healthy patients between 25-55 years with Apical Periodontitis
62161593|NCT04824209||Control Group|Healthy patients between 25-55 years without Apical Periodontitis
62534919|NCT03173430|EXPERIMENTAL|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
62534920|NCT01190553|EXPERIMENTAL|Treatment|IV amantadine treatment
62534921|NCT01069276||Patients with clinical signs of stroke|Patients with clinical signs of stroke
62714469|NCT04733534|ACTIVE_COMPARATOR|Fisetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 to will assess the permanence of change after completion of the trial."
62161594|NCT01804686|EXPERIMENTAL|Ibrutinib|
62736460|NCT02243319|EXPERIMENTAL|Group 5|B → A → C
62161595|NCT05374174||Measurement Group|All participants will have their arm spasticity to be measured using standard clinical scales
62161596|NCT04730271|ACTIVE_COMPARATOR|Manual Arm|Subjects enrolled into this arm of the study will receive an ATTUNE primary total knee replacement that has been implanted using manual instrumentation which is the current standard of care at the participating sites.
62161597|NCT04730271|EXPERIMENTAL|Robotic-Assisted Arm|Subjects enrolled into this arm will receive an ATTUNE primary total knee replacement that has been implanted with the use of the VELYS Robotic-Assisted Solution device.
62161598|NCT03121261|EXPERIMENTAL|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
62161599|NCT03121261|ACTIVE_COMPARATOR|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
62534922|NCT06633731|EXPERIMENTAL|Topical Treatment|Subjects received a topical facial treatment applied by a license esthetician in a series of 3 sessions at 1 month intervals. The treatment included a topical treatment, biocellulose mask, and serum. Additionally, subjects followed a 12 weeks skincare regimen including a gentle cleanser, bland moisturizer, and bland sunscreen.
62534923|NCT02335983|EXPERIMENTAL|RRMM Dose-evaluation: Carfilzomib 56 mg/m²|"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
62534924|NCT02335983|EXPERIMENTAL|RRMM Dose-evaluation: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
62534925|NCT02335983|EXPERIMENTAL|RRMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
62534926|NCT02335983|EXPERIMENTAL|NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²|"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
62736461|NCT02243319|EXPERIMENTAL|Group 6|A → C → B
62161600|NCT03669965|EXPERIMENTAL|Part A Arm 1|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
62161601|NCT03669965|EXPERIMENTAL|Part A Arm 2|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
62161602|NCT03669965|EXPERIMENTAL|Part A Arm 3|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
62161603|NCT03669965|EXPERIMENTAL|Part B KRT-232 Arm|Recommended KRT-232 dose and schedule from Part A
62161604|NCT03669965|ACTIVE_COMPARATOR|Part B Ruxolitinib Arm|Ruxolitinib per approved prescribing label
62161605|NCT03669965|EXPERIMENTAL|Part A Arm 4b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
62534927|NCT02335983|EXPERIMENTAL|NDMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
62534928|NCT02335983|EXPERIMENTAL|NDMM Dose-expansion: Carfilzomib 56 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
62534929|NCT05984979||People without diabetes|
62534930|NCT05984979||People with type 1 diabetes|
62534931|NCT05984979||People with type 2 diabetes|
62534932|NCT04592835|EXPERIMENTAL|Cohort 1 (288mg)|72 mg/0.3 mL x 4 injection sites
62534933|NCT04592835|EXPERIMENTAL|Cohort 2 (576 mg)|144 mg/0.6 mL x 4 injection sites
62534934|NCT04592835|EXPERIMENTAL|Cohort 3 (960 mg)|216 mg/1.0 mL x 4 injection sites
62534935|NCT05477095|EXPERIMENTAL|UB-313 Cohort 1|UB-313 100mcg administered by intramuscular (IM) injection at Week 0, Week 4 and Week 12
62534936|NCT05477095|EXPERIMENTAL|UB-313 Cohort 2|UB-313 300mcg administered by IM injection at Week 0 and 100mcg at Week 4 and Week 12
62534937|NCT05477095|EXPERIMENTAL|UB-313 Cohort 3|UB-313 300mcg administered by IM injection at Week 0, Week 4 and Week 12
62534938|NCT05477095|EXPERIMENTAL|UB-313 Cohort 4|UB-313 600mcg administered by IM injection at Week 0 and 100mcg at Week 4 and Week 12
62534939|NCT05477095|PLACEBO_COMPARATOR|Placebo Comparator|Placebo (normal saline), administered by IM injection at Week 0, Week 4 and Week 12
62534940|NCT06633224||Cancer Patients|Participants will have blood and stool samples collected within 5 days of any pre or post treatment timepoint prior to, during, at completion of therapy and up to 34 weeks following non-investigational, standard of care, CCRT. Participants will also be given quality of life questionnaires to complete throughout the course of the study.
62714470|NCT01071954|EXPERIMENTAL|Romiplostim|Participants received romiplostim administered by subcutaneous injection once a week. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of between 50 x 10\^9/L and 200 x 10\^9/L.
62714471|NCT03824158|ACTIVE_COMPARATOR|Facilitated advance care planning (in-person or telephonic)|Patients randomized to this arm will participate in in-person or telephonic facilitated advance care planning (ACP) discussions using the Respecting Choices model.
62534941|NCT03885479||IBD patients|"1. Full history taking and examination~2. Colonoscopy, biopsy and histopathology to determine the extent of the lesion~3. An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)~4. Patients will be categorized into 3 groups (UC patients, Crohn disease patients and controls)~5. All of the following factors will be taken into consideration; type and duration of the treatment, age of diagnosis, BMI, smoking status and activity of the disease at the time of the study"
62534942|NCT03885479||Controls|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
62534943|NCT01206101|EXPERIMENTAL|Liraglutide|
62534944|NCT01206101|PLACEBO_COMPARATOR|Liraglutide placebo|
62534945|NCT01260519|EXPERIMENTAL|active arm: heparin|
62534946|NCT03659292|EXPERIMENTAL|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
62534947|NCT03659292|OTHER|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
62534948|NCT05584592|EXPERIMENTAL|Intergrate early palliatuve care + Conventional chemotherapy|
62534949|NCT05584592|ACTIVE_COMPARATOR|Conventional chemotherapy|
62534950|NCT00460538|PLACEBO_COMPARATOR|2|
62534951|NCT00460538|ACTIVE_COMPARATOR|1|
62534952|NCT06080256|EXPERIMENTAL|Alirocumab added to statin therapy|Alirocumab (75 mg every 2 weeks for 6 months) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management.
62534953|NCT06080256|ACTIVE_COMPARATOR|Statin therapy|Atorvastatin 20-40mg. Anti-platelet aggregation and risk factor management in both arms.
62714472|NCT03824158|ACTIVE_COMPARATOR|Web-based advance care planning|Patients randomized to this arm will participate in web-based ACP via the PREPARE website.
62161606|NCT03669965|EXPERIMENTAL|Part A Arm 2b|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
62161607|NCT00139659|EXPERIMENTAL|Inhaled Insulin|
62534954|NCT03156335|EXPERIMENTAL|Focused Ultrasound|
62534955|NCT05755776||ETV group|Participants in this group will continue ETV daily until the end of the study.
62534956|NCT05755776||TMF group|Participants in this group will switch to TMF 25 mg, daily until the end of the study.
62534957|NCT01996618|EXPERIMENTAL|Ranolazine|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
62161608|NCT00139659|ACTIVE_COMPARATOR|Subcutaneous Insulin|
62534958|NCT01996618|PLACEBO_COMPARATOR|Placebo|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double-blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24-hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
62534959|NCT01934335|EXPERIMENTAL|Vandetanib|Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery
62534960|NCT01934335|PLACEBO_COMPARATOR|Placebo|Placebo, PO, q day for 7-14 days prior to surgery.
62534961|NCT03680066|EXPERIMENTAL|Foods with traces|Oral food challenge with foods with traces
62534962|NCT04001127|EXPERIMENTAL|High Intensity Functional Training|Intervention group assigned to 16 weeks of group-based high intensity functional training supervised by physiotherapists.
62534963|NCT02016703|EXPERIMENTAL|5 g group|5g erythritol dissolved in 250 ml (2% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
62534964|NCT02016703|EXPERIMENTAL|15 g group|15g erythritol dissolved in 250 ml (6% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
62534965|NCT02016703|EXPERIMENTAL|25 g group|25g erythritol dissolved in 250 ml (10% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
62534966|NCT02016703|EXPERIMENTAL|20 g group|20g erythritol dissolved in 250 ml (8% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
62534967|NCT00090363|PLACEBO_COMPARATOR|Placebo|Matching placebo oral tablet once daily, with best supportive care
62534968|NCT00090363|EXPERIMENTAL|ZD4054 10 mg|ZD4054 10 mg oral tablet once daily, with best supportive care
62534969|NCT00090363|EXPERIMENTAL|ZD4054 15 mg|ZD4054 15 mg oral tablet once daily, with best supportive care
62534970|NCT03533023|EXPERIMENTAL|TRE + SOC|Time Restricted Eating + Standard of Care
62534971|NCT03533023|OTHER|SOC|Standard of Care
62534972|NCT05876988|EXPERIMENTAL|experimental group|"Electroacupuncture intervention will take about 45 minutes every time. For experimental group, acupuncture points are mainly in the head, limbs and abdomen, and a total of six pairs of electric acupuncture for head. The Montreal Cognitive Assessment (MoCA) serves as the primary outcome. Digit span test will be the secondary outcome for attentional function and working memory. In addition, EORTCQLQ-C30 will be used to examine the quality of life of elderly cancer patients. Functional changes and side eﬀects associated with therapies will be measured using the Functional Assessment of Cancer Therapy (FACT). Most items of these functional assessments are 5-point Likert scale questions. Functional items which would be rated as 3 (quite a bit) or higher and incidences would be signiﬁcantly diﬀerent between the two groups in any assessment point will be extracted for statistical analysis."
62534973|NCT05876988|PLACEBO_COMPARATOR|control group|Electroacupuncture intervention will take about 45 minutes every time. For the control group, acupuncture points are mainly on the head and limbs, only a pair of electric needles for head. The Montreal Cognitive Assessment (MoCA) serves as the primary outcome. Digit span test will be the secondary outcome for attentional function and working memory. The quality of life and multiple functional assessments will also be evaluated.
62534974|NCT01934725||Patients w/ cryptogenic ischemic stroke|Patients aged 15 to 49 years with unexplained first-ever ischemic stroke
62534975|NCT01934725||Stroke-free control subjects|Stroke-free subjects age- and gender-matched to patients
62534976|NCT00416884|EXPERIMENTAL|TBI, Campath, Fludarabine T-cell Deplete|(Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m\^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
62534977|NCT03148561|OTHER|Misoprostol group|The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
62534978|NCT03148561|NO_INTERVENTION|Expectant group|Women did not receive any medication.
62534979|NCT04973930|ACTIVE_COMPARATOR|Tele-Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy is a time-limited, affect-focused treatment of repeatedly demonstrated efficacy for major depression in the general population. It was also helpful to patients with comorbid depression and breast cancer in our prior randomized controlled trial. IPT focuses on the connection between upsetting life circumstances (e.g., diagnosis of breast cancer) and their effect on mood, and vice versa. We have considerable experience, enhanced by the Covid-19 lockdown, in delivering IPT as a HIPAA-secure tele-therapy.
62161609|NCT04175392|ACTIVE_COMPARATOR|Treatment Group: Probiotic|Probiotic 1 billion units Supplement Once Daily
62161610|NCT04175392|PLACEBO_COMPARATOR|Control Group: Placebo|Placebo Capsule Once Daily
62161611|NCT00612521|OTHER|1|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
62534980|NCT04973930|ACTIVE_COMPARATOR|Tele-Serotonin Reuptake Inhibitor|Both venlafaxine and escitalopram are FDA-approved treatments with demonstrated efficacy in treating major depression in the general population. Although little formal research has been done in treating patients with depression and breast cancer, these two are the favored treatments among serotonin reuptake inhibitors due to minimal interference with oncotherapy. The choice between prescribing these two study medications will depend upon prior treatment history. Venlafaxine XR will be serially titrated under expert psychopharmacologist tele-guidance from 75 mg to 300 mg daily, depending on clinical response and tolerance. Escitalopram will similarly be dosed between 5 mg and 30 mg daily.
62534981|NCT00849758||1|chemotherapy: elderly patients receiving 4x adjuvant taxotere cyclophosphamide adjuvant for breast cancer
62534982|NCT00849758||2|adjuvant hormone therapy: 40 patients receiving adjuvant aromatase inhibitor without chemotherapy
62161612|NCT00612521|OTHER|2|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
62161613|NCT03352570|EXPERIMENTAL|COLOVAC device|colorectal surgery performed per standard of care with deployment of the Colovac device to protect the anastomosis site
62534983|NCT01527812|EXPERIMENTAL|Above the femoral nerve|In Group I we will inject the local anaesthetic below the fascia iliaca and above the femoral nerve.
62534984|NCT01527812|EXPERIMENTAL|Below the femoral nerve|In Group II we will inject the local anaesthetic below the femoral nerve and above the fascia of the iliopsoas muscle.
62161614|NCT03580629|EXPERIMENTAL|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
62534985|NCT01527812|EXPERIMENTAL|Circumferential|In Group III a circumferential spread will be achieved with multiple injections.
62534986|NCT04559737|NO_INTERVENTION|Usual Care|Patients will receive Auto-Monitoring text messages. The Auto-Monitoring tool that will be used is a function within Somnoware (Somnoware, Inc.) patient management platform, which is the national KP benchmarked platform for sleep management software. Fixed scheduled follow-up visits will be scheduled at 1-month (telephone encounter), 3-months (in-person or video encounter), and 1-year (in-person or video encounter). This sequence of follow-up visits reflects current real-world practice. Patients are eligible for additional visits when self-initiated. Sleep questionnaires will be delivered at 1, 3, and 6 months and at 1 year.
62534987|NCT04559737|ACTIVE_COMPARATOR|Case Management|Patients will undergo the same follow-up process as described in the Usual Care Pathway. A population CM dashboard (Somnoware, Inc.) will be used to automatically identify PAP strugglers (defined as \<70% nights with ≥4 hours use during the preceding month) for 1 year. Video encounters will be triggered for these select patients for troubleshooting. Additionally, throughout this 1-year period, Q1 window of \<70% nights \>4 hours will trigger a phone call and at the discretion of the case manager convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year.
62534988|NCT03516253|EXPERIMENTAL|Intervention group|Dietary Supplement: Fish oil + EPO. Fish oil (2 gel capsules, each 1g fish oil with 500 mg EPA+DHA) and EPO (Evening primrose oil 3 gel capsules with 117 mg GLA), 3 months with lunch.
62534989|NCT03516253|NO_INTERVENTION|Control group|Dietary Supplement: Mineral oil (5 gel capsules, each 1g mineral oil), 3 months with lunch.
62534990|NCT05243953|EXPERIMENTAL|Levcromakalim|A time- and volume-controlled infusion pump is used to administer levcromakalim by intravenous infusion over 20 minutes.
62534991|NCT05243953|PLACEBO_COMPARATOR|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
62534992|NCT01103726|EXPERIMENTAL|Stage 1|
62534993|NCT01103726|EXPERIMENTAL|Stage 2|
62534994|NCT03283462|ACTIVE_COMPARATOR|Mitopure|
62534995|NCT03283462|PLACEBO_COMPARATOR|Placebo|
62534996|NCT05103566|EXPERIMENTAL|Treatment group|The gammaCore device supplies non-invasive stimulation to the cervical branch of the vagus nerve.
62534997|NCT04949711|EXPERIMENTAL|Intervention|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive ridesharing vouchers.
62714473|NCT05448950|EXPERIMENTAL|VIG Continued Access|"Patients referred for AVG implant should be screened for study eligibility. A member of the Research Team will evaluate the patient for eligibility. If all initial inclusion criteria are met and no exclusion criteria are present, a member of the Research Team should inform the patient about the study's purpose and should obtain written informed consent.~Final enrollment eligibility is determined at the time of surgery, after the physician has confirmed the final inclusion criterion is met. Enrolled subjects will be assigned a unique study subject identification number."
62534998|NCT04949711|SHAM_COMPARATOR|Control|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive online shopping voucher.
62534999|NCT02376543|ACTIVE_COMPARATOR|19 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
62535000|NCT02376543|ACTIVE_COMPARATOR|22 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
62535001|NCT01296282||Heart failure patients|
62535002|NCT03792763|EXPERIMENTAL|Arm A, denosumab|"Denosumab 120 MG/1.7 ML Subcutaneous Solution \[XGEVA\]~Every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
62535003|NCT03792763|PLACEBO_COMPARATOR|Arm B, placebo|"Placebo 1.7 ml Subcutaneous Solution~SC every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
62535004|NCT03839030|EXPERIMENTAL|MBHP-Educa|Experimental: Intervention Group A novel Mindfulness-based Health Promotion program for Educators for active teachers will be employed. The intervention will be held once a week for 8-weeks, two-hour meetings (16.0-h total). Participants will be encouraged to meditate for 10-30 min/day via audio recording.
62535005|NCT03839030|NO_INTERVENTION|Control Group|Control Group Teacher education as usual. These participants will participate in teacher training (Neuroscience for Education - Neuro Educa). The Neuro-Educa will be held once a week for 8-weeks, two-hour meetings (16.0-h total).
62535006|NCT04955028||intraoperative massive hemorrhage|blood loss of ≥200 mL with or without artery embolization (UAE) or local CSP resection by laparoscopy or laparotomy as additional interventions.
62535007|NCT04955028||the non-massive hemorrhage group|blood loss of \<200 mL
62535008|NCT05039138|EXPERIMENTAL|Group I (control)|: it includes 17 patients who will receive traditional strength training program.
62535009|NCT05039138|EXPERIMENTAL|Group II (experimental):|it includes 17 patients who will receive upper extremity neuromuscular training exercises
62535010|NCT05894967|EXPERIMENTAL|C1 - Standard Perceptual Learning (SPL)|Participants will complete SPL training during the first phase of training. In the cross-over they will then complete either SPL, LT, SS, MD, NT, TWF, or NCC.
62535011|NCT05894967|EXPERIMENTAL|C2 - Long Training (LT)|Participants will complete LT training during the first phase of training. In the cross-over they will then complete either LT, SPL, or NCC.
62535012|NCT05894967|EXPERIMENTAL|C3 - Short Staircases (SS)|Participants will complete SS training during the first phase of training. In the cross-over they will then complete either SS, SPL, or NCC.
62535013|NCT05894967|EXPERIMENTAL|C4 - Mixed Difficulty (MD)|Participants will complete MD training during the first phase of training. In the cross-over they will then complete either MD, SPL, or NCC.
62535014|NCT05894967|EXPERIMENTAL|C5 - Noise Training (NT)|Participants will complete NT training during the first phase of training. In the cross-over they will then complete either NT, SPL, or NCC.
62535015|NCT05894967|EXPERIMENTAL|C6 - Training with Flankers (TWF|Participants will complete TWF training during the first phase of training. In the cross-over they will then complete eitherTWF, SPL, or NCC.
62535016|NCT05894967|EXPERIMENTAL|C7 - Parafoveal Training (PT)|Participants will complete PT training during the first phase of training. In the cross-over they will then complete either PT, SV, CF, ExAT, EnAT, MF, or NCC.
62535017|NCT05894967|EXPERIMENTAL|C8 - Stimulus Variety (SV)|Participants will complete SV training during the first phase of training. In the cross-over they will then complete either SV, PT, or NCC.
62535018|NCT05894967|EXPERIMENTAL|C8a - Complex Features (CF)|Participants will complete CF training during the first phase of training. In the cross-over they will then complete either CF, PT, NCC.
62535019|NCT05894967|EXPERIMENTAL|C9 - Exogenous Attention Training (ExAT)|Participants will complete ExAT training during the first phase of training. In the cross-over they will then complete either ExAT, PT, NCC.
62535020|NCT05894967|EXPERIMENTAL|C10 - Endogenous Attention Training (EnAT)|Participants will complete EnAT training during the first phase of training. In the cross-over they will then complete either EnAT, PT, NCC.
62535021|NCT05894967|EXPERIMENTAL|C11 - Multisensory Facilitation (MF)|Participants will complete MF training during the first phase of training. In the cross-over they will then complete either MF, PT, NCC.
62161615|NCT02812706|EXPERIMENTAL|Phase 1, Cohort 1: Isatuximab 10 mg/kg|Participants received Isatuximab 10 milligram per kilogram (mg/kg) intravenous (IV) infusion once every week (QW) for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then every 2 weeks (Q2W) (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable adverse events, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 112 weeks).
62535022|NCT05894967|OTHER|No Contact Control|Participants will complete NCC training during the first phase of training. In the cross-over they will then complete either SPL, LT, SS, MD, NT, TWF, PT, SV, CF, ExAT, EnAT, MF, NCC.
62535023|NCT02627248|EXPERIMENTAL|Docetaxel, Epirubicin and Cyclophosphamide (TEC)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
62535024|NCT02627248|EXPERIMENTAL|Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
62535025|NCT02627248|EXPERIMENTAL|Epirubicin and Docetaxel (ET)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
62535026|NCT02627248|EXPERIMENTAL|Epirubicin and Docetaxel+Huaier (ET+HE)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
62535027|NCT04443348|EXPERIMENTAL|Group A (No RT Boost)|No RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy.There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
62535028|NCT04443348|EXPERIMENTAL|Group B (Low Dose RT Boost)|Low-dose RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
62535029|NCT04443348|EXPERIMENTAL|Group C (High Dose RT Boost)|High-dose RT boost plus pembrolizumab followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
62535030|NCT05445674|EXPERIMENTAL|Plasma Exchange|6 sessions of PE with human serum 5% albumin. Plasma exchange sessions will occur on days 1, 3, 8, 10, 15 and 17
62535031|NCT05445674|SHAM_COMPARATOR|Sham Plasma Exchange|6 sessions of sham plasma exchange (one infusion of sterile saline solution 0.9%) on days 1, 3, 8, 10, 15 and 17.
62535032|NCT04570462|EXPERIMENTAL|Experimental Arm- Induction of Mild Hypothermia Protocol|Determination of metabolic rate by the metabolic cart (noninvasive connection of the device to the ventilator for 20 minutes). Initiate hypothermia (established Northwell hypothermia status post cardiac arrest protocol) using the Arctic Sun. The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.
62535033|NCT00879957|ACTIVE_COMPARATOR|Heparin group|The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
62535034|NCT00879957|EXPERIMENTAL|No heparin group|This group will only receive the prescribed fluids to infuse through their PICCs. No heparin will be added to the intravenous infusions.
62535035|NCT04731753||Group treated with study product|Subjects will undergo one mechanical debridement procedure with Cutimed DebriClean
62535036|NCT00708773|EXPERIMENTAL|Single Arm|
62535037|NCT03903809|EXPERIMENTAL|HS-20039 Pegol-Sihematide|Pegol-Sihematide's starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 13 doses
62535038|NCT03903809|ACTIVE_COMPARATOR|ReHuman Erythropoietin Injection|ESPO(Recombinant Human Erythropoietin Injection) ESPO's starting dose was 6000 IU per week
62535039|NCT02354209||HIV-1 patients receiving bPI ARV|"Non interventional study. Interventions will be clinically directed rather than by protocol.~The following procedures will be carried out:~1. Questionnaire on compliance and adherence~2. Clinic Visit~3. 20ml blood sample to be taken for Virological Resistance Testing and Next Generation Sequencing (only if plasma viral load is detectable)"
62535040|NCT03590912|NO_INTERVENTION|Wait and watch (Group D)|Wait and watch for 1 month
62535041|NCT03590912|EXPERIMENTAL|Mometasone spray (Group B)|Standard dose of mometasone furoate nasal spray (one spray in each nostril once daily) for one month will be given
62535042|NCT03590912|EXPERIMENTAL|antibiotic + histaminic + oxymetazoline drops (Group A)|This group will receive oral cefpodoxime (10 mg/kg/day in two divided dose for a week) plus oral histaminics and oxymetazoline drops. Standard dose of oral histaminics (levocetirizine, 1.25 mg for age below six years, 2.5 mg for older age) for a month plus oxymetazoline nasal drops (Nasivion 0.025%) for two weeks will be given
62535043|NCT03590912|EXPERIMENTAL|Oral steroid (Group C)|Patients in this group will receive one mg/kg/day of oral prednisolone (Oral steroid) in two divided dose for a week followed by half mg/kg/day in two divided dose for next one week
62535044|NCT02930967|EXPERIMENTAL|CSR T cells|"A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors.~CSR T dosage ranging from: 5×10\^4 /kg to 1×10\^7 /kg will be tested."
62535045|NCT05843019||Cross sectional|"The patients in the cross sectional study will have done a synactenstest to investigate how their own product of kortisol os after longterm use of systemic steroids.~The group consists of patients referred to the Respiratory Clinic, ENT, RH, for evaluation of CRS/CRSwNP/CRSnNP and with or without asthma for biological treatment. They are classified according to the type of inflammation they have (type-2 or non-type-2), whether they have CRSwNP or CRSsNP, their adherence, comorbidity with asthma, and finally the severity of the disease. All patients are given standard questionnaires to assess CRS/CRSwNP/CRSnNP and asthma (STARR-15, SNOT22, ACQ, ACT, MARS-5-L/N, Fosterscore - routine questionnaires for all patients in the Respiratory Clinic)."
62535046|NCT01531829|EXPERIMENTAL|Low dose (50mg/2h) rt-PA plus LMWH|Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
62535047|NCT01531829|ACTIVE_COMPARATOR|LMWH|Low molecular weight heparin
62535048|NCT05519319|ACTIVE_COMPARATOR|Photodynamic therapy(PDT)|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visual-radiography. The dilation catheter was then withdrawn to leave the PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
62535049|NCT05519319|ACTIVE_COMPARATOR|Radiofrequency ablation(RFA)|An RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
62535050|NCT05519319|ACTIVE_COMPARATOR|RFA+PDT|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visual-radiography. The dilation catheter was then withdrawn to leave the PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s. After that An RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
62535051|NCT03415061|EXPERIMENTAL|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to postoperative day 7
62535052|NCT03415061|PLACEBO_COMPARATOR|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to postoperative day 7
62535053|NCT05792696|EXPERIMENTAL|PPI guided strategies|The decision making for prevention and treatment of hypotension was PPI guided to maintain the PPI between 1 and 3.
62535054|NCT05792696|OTHER|conventional strategies|The decision making for prevention and treatment of hypotension dependent on the experience of anesthesiologist.
62535055|NCT00370812|ACTIVE_COMPARATOR|A|AMT with conventional medical therapy
62535056|NCT00370812|ACTIVE_COMPARATOR|B|Medical treatment alone
62535057|NCT04049110|EXPERIMENTAL|Dapagliflozin first, placebo second|Dapagliflozin followed by placebo
62535058|NCT04049110|EXPERIMENTAL|Placebo first, Dapagliflozin second|Placebo followed by dapagliflozin
62535059|NCT04136457|EXPERIMENTAL|Endurance|Endurance training
62535060|NCT04136457|EXPERIMENTAL|Resistance|Resistance training
62535061|NCT04136457|EXPERIMENTAL|Sprint|Sprint training
62161616|NCT02812706|EXPERIMENTAL|Phase 1, Cohort 2: Isatuximab 20 mg/kg|Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable adverse events, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 137 weeks).
62535062|NCT06287749||Pancreatic Ductal Adenocarcinoma patients|Resectable PDAC patients
62535063|NCT01712750||VOT on bypass|
62535064|NCT00723723||Patients with coronary heart disease|Patients being treated with a statin for secondary prevention of coronary heart disease
62535065|NCT01912027|EXPERIMENTAL|Arthroscopic Latarjet technique|Arthroscopic Latarjet technique
62535066|NCT01912027|ACTIVE_COMPARATOR|Open Latarjet technique|Open Latarjet technique
62535067|NCT01463215|EXPERIMENTAL|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
62714474|NCT03218917|EXPERIMENTAL|Brensocatib 10 mg|Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.
62535068|NCT04380766||Pre-COVID|All patients with pancreatic cancer diagnosis before COVID-19 pandemic
62535069|NCT04380766||COVID|All patients with pancreatic cancer diagnosis during COVID-19 pandemic
62535070|NCT00556400|ACTIVE_COMPARATOR|Lo-ovral|1 tablet of lo-ovral is administered twice a day
62714475|NCT03218917|EXPERIMENTAL|Brensocatib 25 mg|Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.
62535071|NCT00556400|PLACEBO_COMPARATOR|sugar pill|Sugar pill was provided as a placebo
62535072|NCT02393248|EXPERIMENTAL|Part 1: Intermittent pemigatinib 1/2/4 mg QD|Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
62535073|NCT02393248|EXPERIMENTAL|Part 1: Intermittent pemigatinib 6 mg QD|Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
62535074|NCT02393248|EXPERIMENTAL|Part 1: Intermittent pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
62535075|NCT02393248|EXPERIMENTAL|Part 1: Intermittent pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
62535076|NCT02393248|EXPERIMENTAL|Part 1: Intermittent pemigatinib 20 mg QD|Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
62535077|NCT02393248|EXPERIMENTAL|Part 1: Continuous pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
62535078|NCT02393248|EXPERIMENTAL|Part 1: Continuous pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
62535079|NCT02393248|EXPERIMENTAL|Part 1: Continuous pemigatinib 20 mg QD|Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
62535080|NCT02393248|EXPERIMENTAL|Part 1: Continuous pemigatinib 7.5 mg BID|Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle.
62535081|NCT02393248|EXPERIMENTAL|Part 1: Continuous pemigatinib 10 mg BID|Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle.
62535082|NCT02393248|EXPERIMENTAL|Part 2: Intermittent pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
62535083|NCT02393248|EXPERIMENTAL|Part 2: Intermittent pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
62535084|NCT02393248|EXPERIMENTAL|Part 2: Continuous pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
62535085|NCT02393248|EXPERIMENTAL|Part 2: Continuous pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
62535086|NCT02393248|EXPERIMENTAL|Part 2: Continuous pemigatinib 20 mg QD|Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
62535087|NCT02393248|EXPERIMENTAL|Part 3: Gem/Cis/intermittent pemigatinib 9 mg|Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m\^2) (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.
62535088|NCT02393248|EXPERIMENTAL|Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg|Participants received gemcitabine intravenously starting at 1000 mg/m\^2 (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.
62714476|NCT03218917|PLACEBO_COMPARATOR|Placebo|Participants received the matching placebo QD before breakfast, for 24 weeks.
62714477|NCT06427395|EXPERIMENTAL|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 months).
62714478|NCT06591780|EXPERIMENTAL|Real-Time Biofeedback Walking Trials|"Real-time biofeedback of propulsion and plantar pressure to measure the immediate effects of biofeedback on walking function and gait mechanics.~Permuted block randomization (blocks of 4) will be used to allocate the order of the biofeedback stimulus (plantar pressure-intervention A or propulsion-intervention B).~Participants will receive both interventions in session 3, but the order will be randomized."
62736462|NCT02653443|EXPERIMENTAL|Day 6|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
62736463|NCT02653443|EXPERIMENTAL|Day 7|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
62161617|NCT02812706|EXPERIMENTAL|Phase 2: Isatuximab 20 mg/kg|Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable adverse events, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 248 weeks).
62535089|NCT02393248|EXPERIMENTAL|Part 3: Tras/intermittent pemigatinib 13.5 mg|Trastuzumab (Tras) was administered as an open-label, commercial product at an initial dose of 8 mg/kilograms (kg) over a 90-minute intravenous infusion, followed by 6 mg/kg over a 30- to 90-minute intravenous infusion once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.
62535090|NCT02393248|EXPERIMENTAL|Part 3: Doc/intermittent pemigatinib 13.5 mg|Participants received docetaxel (Doc) intravenously starting at 75 mg/m\^2 (1 hour) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.
62535091|NCT02393248|EXPERIMENTAL|Part 3: Pem/intermittent pemigatinib 9 mg|Participants received pembrolizumab (Pem) intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
62535092|NCT02393248|EXPERIMENTAL|Part 3: Pem/intermittent pemigatinib 13.5 mg|Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
62535093|NCT02393248|EXPERIMENTAL|Part 3: Pem/continuous pemigatinib 13.5 mg|Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
62535094|NCT02393248|EXPERIMENTAL|Part 3: Ref/continuous pemigatinib 9 mg|Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
62535095|NCT02393248|EXPERIMENTAL|Part 3: Ref/continuous pemigatinib 13.5 mg|Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
62535096|NCT02393248|EXPERIMENTAL|Part 3: Ref/continuous pemigatinib 20 mg|Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
62535097|NCT03499886|EXPERIMENTAL|Ketamine Hydrochloride 50Mg/1mL|"In the intervention group, Ketamine Hydrochloride 50Mg/1mL was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention."
62535098|NCT03499886|EXPERIMENTAL|Ketamine Hydrochloride 50Mg/mL|in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
62161618|NCT05816122|EXPERIMENTAL|MSCopilot® Detect|Performance of digital tests and standard test in clinic at D0, M6, M12, M18 and M24 (if applicable) Use of MSCopilot® Detect at-home in between visits during 18 or 24 months (if applicable)
62535099|NCT04066595|EXPERIMENTAL|Experimental (cohorts 1 and 2)|Cohort 1 will consist of patients who have been pre-treated with checkpoint inhibitors only (2nd line setting for cabozantinib). Cohort 2 will consist of patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (3rd line setting for cabozantinib). Both cohorts receive the same treatment.
62535100|NCT02087995|EXPERIMENTAL|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
62736464|NCT01890044||Moderate to highest risk for VTE|Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.
62736465|NCT05002985|EXPERIMENTAL|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
62161619|NCT02240836|EXPERIMENTAL|Intervention. Exercise|The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
62161620|NCT02240836|NO_INTERVENTION|Control group|Control group, standard treatment regimen
62535101|NCT01081834|EXPERIMENTAL|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
62535102|NCT01081834|EXPERIMENTAL|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
62535103|NCT01081834|EXPERIMENTAL|Placebo/Sitagliptin|In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
62535104|NCT00437840|EXPERIMENTAL|Treatment Arm A|In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
62535105|NCT00437840|EXPERIMENTAL|Treatment Arm B|In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
62535106|NCT00437840|EXPERIMENTAL|Treatment Arm C|In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
62535107|NCT00437840|EXPERIMENTAL|Treatment Arm D|In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
62535108|NCT04597632|EXPERIMENTAL|brolucizumab 6 mg|Participants received brolucizumab 6 mg/0.05 mL solution by intravitreal injection in a Treat-to-Control regimen with injection intervals from 4 up to 20 weeks. Intervals could have changed in steps of 4 weeks at a time per investigators' decisions determined by the disease activity.
62535109|NCT04105127|ACTIVE_COMPARATOR|Anterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the palatal surfaces of central upper incisors
62535110|NCT04105127|ACTIVE_COMPARATOR|Posterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the occlusal surfaces of first or second upper/lower molars
62535111|NCT01709253|EXPERIMENTAL|Arm 1|27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
62535112|NCT01709253|EXPERIMENTAL|Arm 2|27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
62535113|NCT01709253|EXPERIMENTAL|Arm 3|27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
62535114|NCT01709253|EXPERIMENTAL|Arm 4|27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
62535115|NCT01212588|EXPERIMENTAL|Mifepristone|Mifepristone 600mg once daily x 7 days
62535116|NCT01212588|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets one daily
62535117|NCT02435095|ACTIVE_COMPARATOR|Maintenance treatment (Control)|287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
62535118|NCT02435095|EXPERIMENTAL|Intermittent Treatment (Experimental)|"287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental)."
62714479|NCT06604429|EXPERIMENTAL|Virtual Reality Exercise|The group included 50 girls who received diet advice, aerobic and virtual reality exercises 3 times per week for 8 weeks. they received diet advice and aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Then This was followed by the main part, which consisted of 25 min of exercise when girl immersed in the game and did physical activities for the upper and lower extremities according to the game's requirements, and finally a 5 min cool-down part to lower the heart rate and end the session with static flexibility routines, the total session that would be applied about 50 min (including 30 mins of Virtual reality exercises)
62535119|NCT03055650|EXPERIMENTAL|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
62535120|NCT06082895|EXPERIMENTAL|intervention group|This group will consist of 45 pregnant women. The training program based on the motivational interviewing method will continue once a week for a total of 4 weeks.
62736466|NCT01876303||Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)|Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
62535121|NCT06082895|NO_INTERVENTION|control group|This group will consist of 45 pregnant women. This group will not be given any training program and routine pregnancy follow-ups will continue.
62535122|NCT02877459|EXPERIMENTAL|AeriSeal System|Subjects will be treated with AeriSeal Foam.
62535123|NCT00695812||1|Siblings of children with Autism
62535124|NCT00695812||2|Siblings of children with typical development
62535125|NCT04283201|EXPERIMENTAL|Diet|
62535126|NCT04283201|EXPERIMENTAL|Physical activity|
62535127|NCT03816852|EXPERIMENTAL|High dose group|Intravenous infusion with hucMSCs, 9\*10\^7 cells, 30ml
62535128|NCT03816852|EXPERIMENTAL|Medium dose group|Intravenous infusion with hucMSCs, 6\*10\^7 cells, 30ml
62535129|NCT03816852|EXPERIMENTAL|Low dose group|Intravenous infusion with hucMSCs, 3\*10\^7 cells, 30ml
62535130|NCT03151811|EXPERIMENTAL|Arm A: Melflufen+Dexamethasone|Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.
62535131|NCT03151811|ACTIVE_COMPARATOR|Arm B: Pomalidomide+Dexamethasone|Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.
62535132|NCT03751618|EXPERIMENTAL|Capsular suture|Capsular suture at the end of hip arthroscopy
62535133|NCT03751618|ACTIVE_COMPARATOR|No capsular suture|No capsular suture at the end of hip arthroscopy
62535134|NCT04500418|ACTIVE_COMPARATOR|Cenicriviroc (CVC)|Approximately 122 patients. Day 1: CVC 450 mg (300 mg AM; 150 mg PM; if patients receive their first dose on Day 1 past 2 PM, then their evening dose will be 300 mg and their next dose will be the following AM.) Days 2-28: CVC BID 150 mg (AM/PM). Every dose should be taken with food (within 30 min).
62535135|NCT04500418|PLACEBO_COMPARATOR|Placebo|Approximately 61 patients. A matching placebo will be given to the patients in the Placebo group at an equal volume and at the same schedule.
62535136|NCT03454178||Hypertensive patients|150 Chinese patients with a diagnosis of essential hypertension from a primary care clinic
62535137|NCT06116084|ACTIVE_COMPARATOR|Ericksonian hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
62535138|NCT06116084|EXPERIMENTAL|Experimental hypnosis|Hypnosis session with headphones and microphones
62535139|NCT02967796||Supplemented group|6 capsule of Proteochoc during 4 day, from day 0 (day of delivery) to day 4
62535140|NCT02967796||Control group|no supplementation, just the same follow-up as supplemented group
62535141|NCT04732026||Cases|150 infants with invasive serotype III GBS disease (isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
62535142|NCT04732026||Controls|450 infants exposed to serotype III GBS at birth - but who do not develop invasive GBS disease in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
62535143|NCT00554606|EXPERIMENTAL|Canakinumab|Participants received one single dose of 600 mg canakinumab via intravenous infusion on Day 1 and thereafter every 6 weeks until completion of the 54-week treatment period.
62535144|NCT01333371|ACTIVE_COMPARATOR|closed reduction with percutaneous k-wire fixation and casted|
62535145|NCT01333371|ACTIVE_COMPARATOR|open reduction internal fixation with a volar locked plate|
62535146|NCT06071169|EXPERIMENTAL|Intervention|progressive relaxation exercise group The nurses will perform the relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
62535147|NCT06071169|NO_INTERVENTION|Control|Control group No application has been made.
62535148|NCT05194137|ACTIVE_COMPARATOR|a proprioception protocol associated with vaginal palpation and feedback (CG)|"The participants of CG will be placed in the supine position with flexion of the hip and knee and feet supported on the stretcher. Vaginal palpation will be used as a proprioceptive resource to facilitate PFM voluntary contraction. The physiotherapist responsible for conducting the treatment, wearing gloves, will perform a one or two-finger vaginal palpation, depending on participant's vaginal canal.~Positive reinforcements will be verbalized after each PFM contraction. The training protocol will be tailored, and the evolution will be the same for CG and BPFMT."
62535149|NCT05194137|EXPERIMENTAL|a proprioception protocol associated with biofeedback (BG)|The participants of BG will receive the same protocol of CG but associated with biofeedback with an electromyographic sensor through the Miotol equipment (Miotec, Brazil). The participants of the BG will also be positioned in the same position described to CG. The electromyographic sensor will be covered with neutral gel and inserted into the participant's vaginal canal. Participants will see the visual response of the contraction on the computer screen. The software has five different interfaces for visualize PFM contraction and each participant will be able to choose the one that she prefers at each session. The training protocol will be tailored, and the evolution will be the same for CG and BG. During the first session, it will be explained what is biofeedback and what means everything that appears on the software interface.
62535150|NCT06013839|EXPERIMENTAL|TXA127 SC 0.5mg/kg/day|TXA127 (talfirastide) 0.5mg/kg/day given via subcutaneous injection for 6 months
62535151|NCT04142957||Focus Groups|"The investigators will invite 13-15 participants to attend the focus groups, of which it is expected that 10-12 to attend. Participants will be asked to bring a smart phone. An Informed Consent Form will be signed by the participant and a delegated researcher before the focus groups begin.~The current generation of COPD Pal will be downloaded onto the participants' own smart phones (see Appendix 1 for current screenshots of app), participants will then be explained the purpose of the app, and asked to interact with it for 15-60 minutes, as required.~A semi-structured focus group will then be conducted with the participants to facilitate conversation and discussion regarding COPD Pal. Once introductions have been completed, questions will be asked relating to the usability and acceptability of COPD Pal (see the Interview Schedule, Appendix 2). The focus group will last 30-60 minutes, as required."
62535152|NCT00859586|EXPERIMENTAL|Miltenyi Magnetic cell sorter for CD3|"Miltenyi Magnetic cell sorter device will be used for CD3 selection of granulocyte colony stimulating factor mobilized allogeneic PBSCT. In stage 1, subjects will receive 1 x 10 to the eight power CD3 cells/kg. In stage II, the dose of CD3+ cells will be increased to 2 x 10 to the eight power cells/kg.~This phase II clinical trial is designed to evaluate a novel non-myeloablative but highly immunosuppressive disease specific conditioning regimen and infusion of unmanipulated lymphocytes from a haplo-identical familial donor in subjects with relapsed disease following matched sibling stem cell transplantation who are not candidates for alternative treatment options. The clinical trial will evaluate recipient survival at six months post-relapse of disease."
62535153|NCT03223792|ACTIVE_COMPARATOR|Control|
62535154|NCT03223792|EXPERIMENTAL|Investigational|
62736467|NCT04820114|ACTIVE_COMPARATOR|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life.
62535155|NCT01868893|EXPERIMENTAL|Obinutuzumab + Chlorambucil|Obinutuzumab was administered intravenously for 6 cycles (28-day cycles) as: 100 mg on Day 1, 900 mg on Day 2, and 1000 mg on Days 8 and 15 for Cycle 1; and 1000 mg on Day 1 of Cycles 2 to 6. Chlorambucil was administered orally at a dose of 0.5 mg/kg body weight on Days 1 and 15 for Cycles 1 through 6 (28-day cycles).
62535156|NCT05727072|EXPERIMENTAL|LY3848575 IV|Single ascending doses of LY3848575 administered intravenously (IV).
62535157|NCT05727072|PLACEBO_COMPARATOR|Placebo IV|Placebo administered IV.
62535158|NCT05727072|EXPERIMENTAL|LY3848575 SC|Multiple doses of LY3848575 administered subcutaneously (SC).
62535159|NCT05727072|PLACEBO_COMPARATOR|Placebo SC|Placebo administered SC.
62535160|NCT03570671|EXPERIMENTAL|Spasm positive|Ergonovine-induced coronary spasm provocation test positive: defined as transient, total, or sub-total occlusion (\>90% stenosis) of a coronary artery with symptoms of myocardial ischemia (angina pain and ischemic ECG change).
62535161|NCT03570671|PLACEBO_COMPARATOR|Spasm negative|Suspected vasospastic angina subjects with negative ergonovine provocation test are considered as reference modality.
62535162|NCT03967535||Control|Individuals between 45-85 years old with no diagnosis of dementia. No intervention used
62535163|NCT03967535||Dementia|Individuals between 45-85 years old with a diagnosis of dementia. No intervention used
62535164|NCT04473755||ADHD|This group will include participants who meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
62535165|NCT04473755||Non-ADHD|This group will include participants who do not meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
62535166|NCT00005727|EXPERIMENTAL|Intervention|Specially-designed nutrition education curriculum designed to lower dietary fat intake in people with low literacy skills.
62535167|NCT00005727|ACTIVE_COMPARATOR|Control|General nutrition education curriculum.
62535168|NCT03506906|ACTIVE_COMPARATOR|Conventional-approach|The non-invasive ventilation therapy will be optimized according to routine tests (blood gas analysis, lung function, ventilator's built-in software analysis)
62535169|NCT03506906|EXPERIMENTAL|Sleep studies-based approach|Additionally to the routine tests, the results of a nocturnal polysomnography and transcutaneous capnometry under the non-invasive ventilation therapy will be considered for the therapy optimization.
62535170|NCT03778398|EXPERIMENTAL|Neurologic music therapy|Patients will receive 2 days of 40 minutes per week, total 3 months of customized piano training. Each session will be started with finger warming exercises, then with the right hand, left handed and with both hands, a simple pentatonic array will be played. In the following lessons, notes will be marked with colors and simple songs will be taught.
62535171|NCT05436262|OTHER|Real time neurofeedback with task|Participants will undergo a real-time fMRI scan during which two distinct tasks will be performed.
62535172|NCT05436262|OTHER|Overt tapping and/or motor imagery practice|Participants will undergo an overt tapping task at baseline. Participants are assigned to a group where the participants will then perform respective motor and/or imagery tasks at home for 3 weeks.
62535173|NCT00593047|PLACEBO_COMPARATOR|1|Statin + placebo
62535174|NCT00593047|EXPERIMENTAL|2|Statin + KB2115 dose 1
62535175|NCT00593047|EXPERIMENTAL|3|Statin + KB2115 dose 2
62535176|NCT00593047|EXPERIMENTAL|4|Statin + KB2115 dose 3
62535177|NCT04697836|EXPERIMENTAL|ST (superficial cervical plexus block combined with Translareyngeal block)|Superficial cervical plexus block combined with Translareyngeal block Group.
62535178|NCT04697836|ACTIVE_COMPARATOR|S (superficial cervical plexus block)|Superficial cervical plexus block Group
62714480|NCT06604429|ACTIVE_COMPARATOR|Control group (aerobic exercise)|This group serves as the control group, it included 50 girls who received diet advice and aerobic exercises in form of cycle ergometer training for 3 times per week for 8 weeks. Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes. Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.
62714481|NCT01126957|EXPERIMENTAL|Ketamine|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
62714482|NCT01126957|PLACEBO_COMPARATOR|Placebo|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
62714483|NCT06168396|ACTIVE_COMPARATOR|Baseline (Without Somatosensation Device)|Participants will perform all outcome measures without wearing the somatosensation device.
62535179|NCT01584557|ACTIVE_COMPARATOR|Tolvaptan, Samsca|Tolvaptan, Samsca, uncoated tablet, 30 mg, once per day, up to 7 days.
62535180|NCT01584557|PLACEBO_COMPARATOR|sugar pill|placebo, sugar pill
62535181|NCT00390559|EXPERIMENTAL|ActiveP/ActiveC|21 mg patch/Nicotine-containing cigarette
62535182|NCT00390559|EXPERIMENTAL|PlaceboP/ActiveC|0 mg patch/nicotine-containing cigarette
62535183|NCT00390559|EXPERIMENTAL|Active P/PlaceboC|21 mg patch/no nicotine cigarette
62535184|NCT00390559|EXPERIMENTAL|PlaceboP/PlaceboC|0 mg patch/no nicotine cigarette
62535185|NCT02744118|EXPERIMENTAL|Marijuana Screening and Brief Counseling|The marijuana screening and brief counseling intervention will be developed based on a tested adolescent tobacco cessation intervention and the Public Health Service 5As model. The proposed intervention will be adapted using current literature, input from content experts, and qualitative data gathered using focus groups.
62535186|NCT02744118|ACTIVE_COMPARATOR|Healthy Internet Use Model|The media screening and brief counseling intervention is based on a media use screening and brief counseling intervention tested as the active comparator for a 5As tobacco cessation randomized control trial (NCT01312480) and the 2010 American Academy of Pediatrics policy statement on children and media.
62535187|NCT04732624|EXPERIMENTAL|Enteral-based Protocolized Resuscitation|Administration of Enteral-based Resuscitation using Oral Rehydration Solution (ORS) either by mouth of via naso-enteric access for moderate sized burn injuries (20-40% TBSA) per resuscitation protocol for burn-injured patients. Resuscitation will be administered in the acute resuscitation phase of burn injury (24-72 hours post injury). Patients will receive supplemental Intravenous Fluid (IV Fluid) resuscitation using Lactated Ringer's solution as needed per protocol.
62535188|NCT04732624|ACTIVE_COMPARATOR|Intravenous Fluid Protocolized Resuscitation|Administration of Intravenous Fluid using Lactated Ringer's solution per standard of care resuscitation protocol for patients with moderate sized burn injuries (20-40% TBSA).
62535189|NCT06396065|EXPERIMENTAL|AK112 in combination with Pemetrexed and Carboplatin|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
62535190|NCT06396065|ACTIVE_COMPARATOR|Placebo in combination with Pemetrexed and Carboplatin|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
62535191|NCT05250648|ACTIVE_COMPARATOR|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|
62535192|NCT05250648|EXPERIMENTAL|complete cytoreductive surgery without HIPEC|
62535193|NCT04810286|EXPERIMENTAL|Experimental Group|3D-print myofunctional appliance
62535194|NCT04810286|ACTIVE_COMPARATOR|Control Group|Prefabricated myfunctional appliance
62535195|NCT03777423|EXPERIMENTAL|PEEK framework partial dentures|High performance ketone polymers introduced lately.These polymer-based frameworks provide better esthetics, higher elasticity, lighter in weight, have low water sorption and solubility, and are easily repaired and reproduced.
62535196|NCT03777423|ACTIVE_COMPARATOR|Cobalt-chromium framework partial dentures|it is considered the gold standard framework. These frameworks are less bulky with high strength, conduct heat and electricity well, and have good durability. some disadvantages include hypersensitivity, adverse tissue reactions and bad aesthetics.
62535197|NCT03045991|EXPERIMENTAL|sequential training group (SEQ)|"The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
62535198|NCT03045991|ACTIVE_COMPARATOR|control intervention group (CI)|"The control intervention group (CI) will receive a control training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
62535199|NCT00946686|EXPERIMENTAL|1|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
62535200|NCT00946686|ACTIVE_COMPARATOR|2|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
62714484|NCT06168396|EXPERIMENTAL|With Somatosensation Device|Participants will perform all outcome measures while wearing the somatosensation device.
62714485|NCT06568419|EXPERIMENTAL|Digital transdiagnostic work-focused CBT treatment program|digital transdiagnostic work-focused CBT treatment program for patients with common mental health disorders on sick leave or work assessment allowance
62714486|NCT01913327|EXPERIMENTAL|aripiprazole|aripiprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
62714487|NCT01913327|ACTIVE_COMPARATOR|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
62714488|NCT06711627|ACTIVE_COMPARATOR|Standard of Care (SoC)|The SoC arm includes implementing the standard clinical protocol for nutritional and gestational weight gain counseling recommended for all pregnant women. Additionally, participants in the SoC arm will receive $500 after delivery to be used for baby items.
62714489|NCT06711627|EXPERIMENTAL|Food Provision|The Food Provision arm includes the same nutritional and gestational weight gain counseling provided as standard of care. In addition, participants in the Food Provision arm will be provided with a total of $1000 during their pregnancy to be used specifically for the purchase of healthy foods.
62161621|NCT06532032|EXPERIMENTAL|Phase 1 (Combination Dose Selection)|Participants will receive amivantamab intravenous (IV) infusion administered based on body weight from Cycle 1 Day 1, Day 2, and subsequent doses on Days 8 and 15, and then on Day 1 of each 21-day treatment cycle. Docetaxel will be administered on Day 2 of Cycle 1 (before Day 2 amivantamab infusion) and then on Day 1 of each 21-day treatment cycle, thereafter. Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined. Participants will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for discontinuation of study treatment is met.
62714490|NCT00506142|EXPERIMENTAL|Cohort 1|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
62714491|NCT00506142|EXPERIMENTAL|Cohort 2|Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
61976058|NCT02600949|EXPERIMENTAL|Cohort B (personalized vaccine, imiquimod, pembrolizumab)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
62535201|NCT02906761|EXPERIMENTAL|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
62535202|NCT02906761|PLACEBO_COMPARATOR|Placebo|Placebo (2 tablets) twice daily for 6 months
62535203|NCT01902368|OTHER|screen detected, early diagnosis cohort|Subjects will be informed they have celiac disease and will be started on the gluten free diet.
62535204|NCT01902368|NO_INTERVENTION|screen detected, delayed diagnosis cohort|Subjects will not be told they have celiac disease and will not start the gluten free diet.
62535205|NCT00973609|ACTIVE_COMPARATOR|Fluoropyrimidine + Bevacizumab|Standard therapy
62535206|NCT00973609|EXPERIMENTAL|Bevacizumab monotherapy|
62535207|NCT00973609|EXPERIMENTAL|No maintenance treatment|
62535208|NCT03957252||Training Cohort|Up to 1400 men from Alberta in addition to up to 2,500 men from external institutions, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with Total PSA greater than or equal to than 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test.
62535209|NCT03957252||Validation Cohort|Up to 1400 men from Alberta in addition to up to 2,500 men from external institutions, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with Tota PSA greater than or equal to 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test.
62535210|NCT05795556||Home-dwelling geriatric outpatients|"Home-dwelling geriatric outpatients from the Falls Clinic at Gentofte Hospital .~Clinical assesment: Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles, screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)"
62535211|NCT04441710||Caregivers|Staff of university hospitals
62535212|NCT04441710||Primary care caregivers|Population of professional caregivers such as general practitioner or freelance nurse.
62535213|NCT04441710||Patients|
62535214|NCT06633250|EXPERIMENTAL|Test Formula|Hydrolyzed rice protein formula
62535215|NCT06633250|ACTIVE_COMPARATOR|Control Formula|Commercially available extensively hydrolyzed cow's milk formula
62535216|NCT03521180||Subjects with Celiac Disease|"Group 1 will start the gluten challenge with 4 slices of white bread once daily for 3 days. Blood will be taken at pre-specified time points for up to 9 days following the start of gluten challenge for biomarker analyses.~Based on data from the first 5 subjects, the 2nd group of 5 subjects may: 1) not be needed if the objectives are met; 2) receive gluten at increased quantity (not to exceed 6 slices of bread once daily for 3 days) or have biomarker samples collected at adjusted time points; 3) same as the first 5 subjects; 4) reducing the duration of gluten free diet for a minimum of 3 months instead of 6 month for the Inclusion Criteria # 5;5) subjects may be re-enrolled once.~The same applies to the 3rd group of subjects. A notification will be provided to the clinical study site for detailed changes."
62535217|NCT02564146|ACTIVE_COMPARATOR|nab-paclitaxel and gemcitabine (A)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: Continuing application of nab-paclitaxel and gemcitabine treatment cycles"
62535218|NCT02564146|EXPERIMENTAL|gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles"
62736468|NCT04820114|EXPERIMENTAL|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
61976059|NCT02600949|EXPERIMENTAL|Cohort C and D (vaccine, imiquimod, pembrolizumab, APX005M)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 9, 12, 15, 18, 21, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Beginning about 1 hour after each vaccine, patients also receive sotigalimab IV over 60 minutes on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and weeks 6,12, and 24, then every 3 months, and at week 39.
62535219|NCT05915975|EXPERIMENTAL|Behavioral Care Coordinated with Medical Care|Participants in this group will work with a study team member for four months to improve your skills to manage diabetes, to strengthen the child-caregiver relationship, and/or to address emotional challenges that your child might be experiencing.
62535220|NCT05915975|ACTIVE_COMPARATOR|Behavioral Care Not Coordinated with Medical Care|Participants will receive the standard of care treatment for four months plus a list of clinics that accept their insurance.
62535221|NCT00328016|EXPERIMENTAL|Device Guided Breathing|Individual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
62535222|NCT00328016|PLACEBO_COMPARATOR|Control Group|Control group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
62535223|NCT04227847|EXPERIMENTAL|Part A|SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
62535224|NCT04227847|EXPERIMENTAL|Part B|SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
62535225|NCT04227847|EXPERIMENTAL|Part C|SEA-CD70 expansion cohort in relapsed/refractory AML
62535226|NCT04227847|EXPERIMENTAL|Part D|SEA-CD70 + azacitidine dose-finding/dose optimization cohorts in relapsed/refractory MDS or MDS/AML, and previously untreated higher-risk MDS or MDS/AML
62535227|NCT04227847|EXPERIMENTAL|Part E|SEA-CD70 + azacitidine expansion cohort in previously untreated higher-risk MDS or MDS/AML
62535228|NCT04227847|EXPERIMENTAL|Part F|SEA-CD70 + azacitidine expansion cohort in relapsed/refractory MDS or MDS/AML
62535229|NCT01962584||SAM|patients with suspected acute myocarditis
62535230|NCT01962584||HC|Healthy controls
62535231|NCT04362748|EXPERIMENTAL|Dose Escalation Phase|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
62535232|NCT04362748|EXPERIMENTAL|Dose Expansion Phase: Group 1|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
62535233|NCT04362748|EXPERIMENTAL|Dose Expansion Phase: Group 2|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
62535234|NCT06158256|EXPERIMENTAL|Static apnea at low Lung Volume|Participants will remain at rest in the supine position for 6 minutes. Participants in the experimental group will perform intermittent apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
62535235|NCT06158256|NO_INTERVENTION|Static at normal breathing|Participants will remain at rest in the supine position for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
62535236|NCT04859543|OTHER|Diagnostic group|Tumor and blood samples will be collected from each patient and broad molecular profiling will be performed. The results of the evaluation of the tumor specimens will determine if the patient's tumor has an actionable mutation for which treatment is available.
62736469|NCT01058681|OTHER|isocaloric|impacts of isocaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
62736470|NCT01058681|OTHER|hypercaloric|impacts of hypercaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
62736471|NCT01058681|OTHER|per os and IV glucose during the clamp|impacts of per os glucose on LH pulsatility in euglycemic and hyperinsulinemic clamps
62535237|NCT06382480|EXPERIMENTAL|HP/HC - HC/HP|Isocaloric 4-week HP/HC intervention followed by a 4-week HC/HP intervention.
62535238|NCT06382480|EXPERIMENTAL|HC/HP - HP/HC|Isocaloric 4-week HC/HP intervention followed by a 4-week HP/HC intervention.
62535239|NCT03624608|EXPERIMENTAL|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
62535240|NCT05652738|ACTIVE_COMPARATOR|Group I: (passive cooling group)|
62535241|NCT05652738|PLACEBO_COMPARATOR|Group II: (Blanket roll III cooling group)|
62535242|NCT00969540|ACTIVE_COMPARATOR|Active Mattress Cover|Subjects in this arm will be given the placebo mattress cover followed active mattress cover .
62535243|NCT00969540|PLACEBO_COMPARATOR|Placebo Mattress Cover|Subjects in this arm will be given the active mattress cover followed by the placebo mattress cover.
62535244|NCT06447311|EXPERIMENTAL|Test group|In Test group, the prepared Hyaluronic acid gel will be injected using a syringe into the defect site.
62535245|NCT06447311|PLACEBO_COMPARATOR|Control group|In Control group, saline placebo gel will be injected into the defect site using a syringe.
62535246|NCT04735861|EXPERIMENTAL|Combination Arm|Sintilimab 200mg iv., q3w, up to 2 years; Bevacizumab 15mg/kg iv., q3w, up to 22 cycles. Treatment is given until confirmed progression, death, unacceptable toxicity, or any other protocol-specified criterion for withdrawal, whichever occurs first.
62535247|NCT05083130|NO_INTERVENTION|standard care|Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites
62535248|NCT05083130|EXPERIMENTAL|prone position|prone position group will have a special intervention team who visits patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day
62535249|NCT05268835|ACTIVE_COMPARATOR|Clindamycin 150mg|Patients receiving 150mg of clindamycin (Dalacin C, Pfizer) after surgery every 8 hours
62535250|NCT05268835|ACTIVE_COMPARATOR|Clindamycin 300mg|Patients receiving 300mg of clindamycin after surgery every 8 hours
62535251|NCT05268835|ACTIVE_COMPARATOR|Clindamycin 600mg|Patients receiving 600mg of clindamycin after surgery every 12 hours
62535252|NCT03915028|EXPERIMENTAL|Treated group by thermal cure|Treated group will benefit, within 6 weeks of the inclusion, from the thermal cure in one of the thermal establishments.
62535253|NCT03915028|NO_INTERVENTION|Control group|Control group will receive a thermal cure after the end of the study
62535254|NCT02235090|SHAM_COMPARATOR|Zero-strength of direct current stimulation|Sham transdermal direct current stimulation of cervical spinal cord
62535255|NCT02235090|EXPERIMENTAL|100 microamperes direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
62535256|NCT02235090|EXPERIMENTAL|1 milliampere direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
62161622|NCT06532032|EXPERIMENTAL|Phase 2 (Dose Expansion)|Participants will receive amivantamab in combination with docetaxel in 2 cohorts (Cohort A \[adenocarcinoma\] and Cohort B \[squamous\]) at the RP2CD determined in Phase 1. Participants will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for discontinuation of study treatment is met.
62535257|NCT03981419|EXPERIMENTAL|GRF6021|Participants received 4 doses of GRF6021, 250 milliliters (mL), intravenous (IV) infusion. The first dose was administered on day before surgery, the next two doses on the day of surgery i.e., within 4 hours before start of surgery (first incision), and then upon arrival in the postoperative care unit (within 5 hours after the first incision) and the last dose was administered on the day after the surgery.
62736472|NCT04505319|EXPERIMENTAL|DEFINISSE CORE FILLER|"Cross linked sodium hyaluronate 25 mg/ml with 0,3% lidocaine hydrochloride will be inject during the first visit and a touch up after one month if indicated by the physician.~The filler will inject in the face."
61976060|NCT02821182|EXPERIMENTAL|Anti-PD1 treatment in combination with SBRT|Patients receiving anti-PD1 treatment will be treated with high-dose radiotherapy to one lesion in 3 fractions prior to the second cycle of systemic therapy.
62161623|NCT06719531|EXPERIMENTAL|Subjects with diabetes wearing DS5|Subjects wearing DS5 over 7-14 days and participating in FSTs
62161624|NCT03441152|EXPERIMENTAL|tDCS+CT|application of tDCS in combination with CT
62161625|NCT03441152|SHAM_COMPARATOR|Sham tDCS|application of sham tDCS in combination with CT
62161626|NCT03441152|ACTIVE_COMPARATOR|CT|application of CT
62535258|NCT03981419|PLACEBO_COMPARATOR|Placebo|Participants received 4 doses of GRF6021 matching placebo, 250 mL, IV infusion. The first dose was administered on day before surgery, the next two doses on the day of surgery i.e., within 4 hours before start of surgery (first incision), and then upon arrival in the postoperative care unit (within 5 hours after the first incision) and the last dose was administered on the day after the surgery.
62535259|NCT01051219|ACTIVE_COMPARATOR|Losartan, daily medication|50 milligrams Losartan to be taken orally daily
62535260|NCT01051219|PLACEBO_COMPARATOR|Placebo|A matched placebo will be given for patients to take once daily
62535261|NCT05947110|EXPERIMENTAL|Plyo-HKT group|Participants in this group received the Plyo-HKT program
62535262|NCT05947110|ACTIVE_COMPARATOR|Control group|Participants in this group received the standard exercise program.
62535263|NCT02164474|EXPERIMENTAL|High-Intensity Interval Training (HIIT)|Participants will perform a series of high-intensity intervals with an interval length of 60-seconds at 90% of peak aerobic capacity workload, and a rest length of 60-seconds.
62535264|NCT02164474|ACTIVE_COMPARATOR|Moderate-Intensity Continuous Exercise|Participants will engage in exercise at 45% of peak aerobic capacity workload.
62535265|NCT04289597||Obese patients|Obese patients with BMI\>30
62535266|NCT05832710||Sedentary|It will be obtained by open call for both students and administrative staff at the CES University (Medellín) and Universidad Santo Tomás (Bogotá).
62535267|NCT05832710||Physically active|A sample of physical education majors and personal trainers who reside and work in Medellín and Bogotá will be invited to participate (Universidad Santo Tomás and Smart Fit).
62736473|NCT06051019|EXPERIMENTAL|Aerobic training (FIRST), then balance training (SECOND)|Crossover trial: aerobic training (first treatment), then balance training (second treatment).
62736474|NCT06051019|EXPERIMENTAL|Balance training (FIRST), then aerobic training (SECOND)|Crossover trial: balance training (first treatment), then aerobic training (second treatment).
62535268|NCT05832710||Professional Athletes|A sample of elite and sub-elite athletes with \>2 years at the competitive level will be invited to participate (ARTHROS Physiotherapy and Exercise Center, INDEPORTES Antioquia, and Universidad Santo Tomás).
62535269|NCT00668161|EXPERIMENTAL|1|Exercise
62535270|NCT00668161|NO_INTERVENTION|2|Control
62535271|NCT04636164|EXPERIMENTAL|DNN group|using deep neural networks for skin lesion diagnosis
62535272|NCT04636164|NO_INTERVENTION|Control group|conventional diagnosis
62535273|NCT03705130||Group 1|All subjects will wear the 3 contact lenses: Single Vision, Multifocal 1 and Multifocal 2.
62535274|NCT05141331|EXPERIMENTAL|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges
62535275|NCT05141331|ACTIVE_COMPARATOR|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
62535276|NCT00665938|ACTIVE_COMPARATOR|1|
62535277|NCT00665938|EXPERIMENTAL|2|
62535278|NCT00665938|EXPERIMENTAL|3|
62535279|NCT02767154|ACTIVE_COMPARATOR|PrimECC|1250 ml of a priming solution based on the colloid Dextran 40 to use for extracorporeal circulation.
62535280|NCT02767154|ACTIVE_COMPARATOR|Ringer-Acetate/Mannitol|1250 ml of a priming solution based on the crystalloid Ringer-Acetate (1000ml) and Mannitol (250ml).
62535281|NCT03681236|NO_INTERVENTION|No alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O
62535282|NCT03681236|ACTIVE_COMPARATOR|Alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O. In addition to this, performing alveolar recruitment maneuver at 2 moments: before surgical incision, end of pneumoperitoneum
62161627|NCT04641234||Cohort 1|Adult Belgian patients diagnosed with neovascular age-related macular degeneration (nAMD) with treatment-naïve study eye.
62161628|NCT04590404|EXPERIMENTAL|MIST (Metabolism-Informed Smoking Treatment)|At hospital discharge, participants randomized to the MIST precision care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescriptions will be informed by nicotine metabolism (i.e., NMR result) such that faster metabolizers are prescribed varenicline and slower metabolizers are prescribed NRT.
62535283|NCT01570803|EXPERIMENTAL|Complete SE Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
62535284|NCT01570803|ACTIVE_COMPARATOR|SMART CONTROL Stent|same to Complete SE
62535285|NCT01036139|EXPERIMENTAL|BF2.649 (pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
62535286|NCT01036139|PLACEBO_COMPARATOR|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
62535287|NCT06050161|EXPERIMENTAL|Artisential laparoscopic instrument|Artisential laparoscopic instrument use for suturing during minimally invasive gynecologic surgery
62535288|NCT06050161|ACTIVE_COMPARATOR|Conventional laparoscopic instrument|"Conventional (straight stick) laparoscopic instrument use for suturing during minimally invasive gynecologic surgery"
62535289|NCT06050161|ACTIVE_COMPARATOR|Robotic instrument|Robotic instrument use for suturing during minimally invasive gynecologic surgery
62535290|NCT03648853|EXPERIMENTAL|intervention|all participants receive the same intervention
62535291|NCT00586235||1|patients with indeterminate kidney or liver lesions
62535292|NCT01550627|ACTIVE_COMPARATOR|extra-fluid|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day).
62161629|NCT04590404|ACTIVE_COMPARATOR|Usual Care|At hospital discharge, participants randomized to the Usual Care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescription will not be informed by nicotine metabolism.
62161630|NCT02246556|ACTIVE_COMPARATOR|Patching therapy|Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
62535293|NCT01550627|PLACEBO_COMPARATOR|non extra fluid (control group)|The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
62535294|NCT02092896|PLACEBO_COMPARATOR|Placebo + Insulin + Study 2|Study 2: Cognitive performance test
62535295|NCT02092896|EXPERIMENTAL|Liraglutide + Insulin + Study 2|Study 2: Cognitive performance test
62535296|NCT02092896|EXPERIMENTAL|Liraglutide + Insulin + Study 1|Study 1: Gastric emptying test
62535297|NCT02092896|PLACEBO_COMPARATOR|Placebo + Insulin + Study 1|Study 1: Gastric emptying test
62535298|NCT04002908||In-facility Observations|Mothers and their LBW babies will be observed starting within 6 hours of birth until the baby is discharged from the health facility.
62535299|NCT04002908||Prospective cohort study - Quantitative|Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
62714772|NCT06095960|EXPERIMENTAL|Telehealth MOM|Telehealth MOM. Each patient will receive ESoC which includes: education on the symptoms to watch for and when to call their healthcare provider, an in-person comprehensive postpartum visit around 6 weeks postpartum, and any additional care deemed necessary by their health care providers. Patients in the Telehealth MOM arm will be also provided with a remote monitoring blood pressure cuff and thermometer and will be instructed to take their blood pressure and temperature twice a day for 14 days after discharge from the hospital. A Registered Nurse will monitor blood pressure and temperature readings over the 14-day period and will contact the patient if the readings are out of range to discuss symptoms and the recommend a course of action. A Registered Nurse will conduct an early postpartum telehealth visit between 10-14 days postpartum.
62535300|NCT04002908||Prospective cohort study - Qualitative|"Research specialists at each site will be speaking to key informants (includes doctors, nurses, midwives, community health workers (CHWs), Ministry of Health (MOH) officials, supply chain \& milk bank experts) who are knowledgeable about breastfeeding policy, supply chain, or milk banks. Clinicians in study health facilities who work on labor and delivery, postnatal, newborn and neonatal ICU wards. They participate in In-depth interviews. Mothers, family members and health care workers of LBW babies, as well as community leaders (including religious leaders) who are knowledgeable about infant feeding in their communities will participate in focus group discussions. Focus group discussion will take up to 2 hours. In-depth interviews will take up to 1 hour.~Mothers (6-month extension): Mothers chosen and consented for IDIs will include those currently enrolled in the prospective cohort. Additionally, their infants need to be between 9 and 12 months of age."
62535301|NCT04002908||Retrospective Chart review|The retrospective chart review is a review of secondary data of mothers and their LBW babies who were born in the study health facilities prior to the start of the study.
62535302|NCT04002908||Donor Human Milk Readiness Assessment|"Key stakeholders in the area of newborn health who determine policy and procedures or who are directly involved with the provision of care. This includes clinicians, nurses, lactation/nutrition specialists, hospital leadership and/or Ministry of Health officials present in the study health facilities.~This is a one-time data collection exercise in the form of either: (1) a largely qualitative facility readiness assessment tool with some qualitative questions for facility staff or (2) a facility tool observing the flow of milk along with key informant interviews in the study facilities. This could take anywhere from 1hr to a day depending on the tool administered, key informants involved and size of the study facility."
62535303|NCT03994718|EXPERIMENTAL|Music|The musician will either offer music that can either be played for the participant or an instrument so they can experience playing themselves. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. The outpatient music intervention will consist of providing a recording of similar music for the participant to listen to for at least 30 minutes per week, along a with telephone call session with the music therapist.
62535304|NCT03994718|EXPERIMENTAL|Visual art|The creative visual artist will assess interest in spending time using the materials provided. Participants will be offered watercolor painting, drawing, or adult coloring. There will be a guided activity based on their art making preference. A standardized prompt will be utilized for both writing and visual art sessions. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For remote follow-up sessions, participants will be supplied with a small art kit to use at home.
62535305|NCT03994718|EXPERIMENTAL|Creative writing|The writer will ask the participant about their interests and experiences in writing or storytelling. The following options are offered; introduction to journaling, storytelling or writing exercises with prompts to get started, interactive writing or storytelling activities. For participants who are unable to write or prefer not to, the writer can scribe their words on a laptop and print them out. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For follow-up sessions, participants will be supplied with a journal.
62535306|NCT02701270|EXPERIMENTAL|Experimental Dietary Fibre 1|
62535307|NCT02701270|EXPERIMENTAL|Experimental Dietary Fibre 2|
62535308|NCT02701270|ACTIVE_COMPARATOR|Polydextrose|
62535309|NCT02701270|ACTIVE_COMPARATOR|Dextrose control|
62535310|NCT03778827|EXPERIMENTAL|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of one weekly 60-minute individual parent training session and 12 weekly hours ( 3 hours per day for 4 days per week) with the child in center-based therapy environment for a total of 13 weekly treatment hours.
62714492|NCT03531736|EXPERIMENTAL|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m\^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m\^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10\^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
62714493|NCT06715033||1|Group A (Experimental): 34 affected ankles of both genders diagnosed with functional ankle instability (FAI) who met the inclusion criteria. Their ages ranged from 18 to 25 years, and the patients had a history of initial injury, ongoing bouts of instability, and ratings of patient-perceived function and disability.
62714494|NCT06715033||2|Group B (Control): This group consisted of 34 matched non-affected ankles in the study.
62714495|NCT05076045|EXPERIMENTAL|Personal sound amplification products|Speech perception will be evaluated using personal sound amplification products.
62714496|NCT05076045|NO_INTERVENTION|Control|Speech perception will be evaluated without using hearing devices.
62714497|NCT05456256|EXPERIMENTAL|LP-300 in Combination with Pemetrexed and Carboplatin|"LP-300 (investigational drug) + Pemetrexed and Carboplatin (standard of care chemotherapies)~Dosing occurs on Day 1 of a 21-day cycle."
62161631|NCT02246556|ACTIVE_COMPARATOR|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
62161632|NCT02246556|EXPERIMENTAL|Dichoptic therapy|Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
62161633|NCT00610194|EXPERIMENTAL|Arm 1|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
62161634|NCT05362279|EXPERIMENTAL|Test after post-test training|Pre-test will be applied to the nurses in the experimental group before the training. The post-test will be applied to the experimental group, to which the pre-test was applied, one month after the training was given.
62535311|NCT03778827|NO_INTERVENTION|Delayed Treatment Group (DTG)|Delayed Treatment Group will consist of treatment as usual. At the end of controlled phase, participants in the DTG will be offered PRT-C in a preschool setting in an open-label fashion with a design similar to the double-blind phase.
62535312|NCT00880737||Stable PE patients|Hemodynamically stable patients with acute symptomatic pulmonary embolism
62535313|NCT04422782|OTHER|Single Arm|Single Arm
62535314|NCT01561508|EXPERIMENTAL|GABA|2/3 of participants will be randomized to the GABA treatment group. Dosage will be based on body weight and will be adjusted at each study visit.
62535315|NCT01561508|PLACEBO_COMPARATOR|Placebo|1/3 of participants will receive placebo.
62535316|NCT00563576|EXPERIMENTAL|Depo-Provera/Femring|Subjects will receive an estrogen vaginal ring (100 mcg) during the first 90 days of Depo-Provera use.
62535317|NCT00563576|OTHER|Depo-Provera Injection Alone|Subjects will receive Depo-Provera intramuscular injection.
62535318|NCT04632511|OTHER|Obese group|Metabolome measurements on feces and urine.
62535319|NCT04632511|OTHER|Children with overweight, not yet obese|Metabolome measurements on feces and urine.
62535320|NCT04632511|OTHER|Normal-weight control group|Metabolome measurements on feces and urine.
62535321|NCT02637661||Initial AMI|To study the sensitivity, specificity, positive predictive value, and negative predictive value of different earlobe crease as risk factors of AMI
62535322|NCT02637661||No coronary heart disease|To study the characteristics of earlobe crease
62535323|NCT02752906|EXPERIMENTAL|MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine-primed adolescents (greater than or equal to \[\>=\] 15 to less than \[\< \]18 years) or adults (\>= 18 years) received a single dose of a MenACYW Conjugate vaccine on Day 0.
62535324|NCT02752906|ACTIVE_COMPARATOR|Menactra®|Healthy, meningococcal- vaccine-primed adolescents (\>= 15 to \< 18 years) or adults (\>= 18 years) received a single dose of Menactra ® vaccine on Day 0.
62535325|NCT03934411|EXPERIMENTAL|Tramadol treatment|
62535326|NCT03934411|PLACEBO_COMPARATOR|Placebo treatment|
62714498|NCT05456256|ACTIVE_COMPARATOR|Pemetrexed and Carboplatin (Standard of Care)|"Pemetrexed and Carboplatin Only (standard of care chemotherapies)~Dosing occurs on Day 1 of a 21-day cycle."
62535327|NCT03852173|EXPERIMENTAL|"Intervention group Wasserschulen"|Schools receive refillable drinking bottles for all school children and drying racks for each classroom. Schools receive special project educational material and informational material and one training session for teachers. The intervention will be implemented during one school year (2018/2019), but schools can use the material and bottles also after ending of the intervention period.
62535328|NCT03852173|NO_INTERVENTION|Control group|No intervention (usual education). Schools do not receive any project material. Schools got the information that they are part of a study on drinking and eating habits of third grade elementary school children.
62535329|NCT01687426|ACTIVE_COMPARATOR|Brimonidine Tartrate 0.025%|
62535330|NCT01687426|PLACEBO_COMPARATOR|Vehicle|
62535331|NCT02264470||Patients with clinical stroke|All patients with stroke, 18 years or older, are asked for participation.
62714499|NCT01901536|EXPERIMENTAL|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
62535332|NCT05070000||US|Ultrasound
62535333|NCT05070000||CT|Computed tomography
62535334|NCT05070000||US after CT|Ultrasound after Computed tomography
62535335|NCT00478426|EXPERIMENTAL|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
62535336|NCT01034254|EXPERIMENTAL|influenza vaccine|Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
62714500|NCT01901536|NO_INTERVENTION|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
62535337|NCT01034254|PLACEBO_COMPARATOR|saline placebo|Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
62535338|NCT03318731|PLACEBO_COMPARATOR|Sugar Pill|Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
62535339|NCT03318731|EXPERIMENTAL|Fenugreek Extract, Low Dose|300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
62535340|NCT03318731|EXPERIMENTAL|Fenugreek Extract, High Dose|500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
62535341|NCT06632522|EXPERIMENTAL|radiotherapy combined with Camrelizumab and Apatinib|radiotherapy combined with Camrelizumab and Apatinib in the treatment of liver cancer patients with VP4
62535342|NCT05837013|EXPERIMENTAL|General anesthesia (GA) and TEP Group|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
62535343|NCT05837013|ACTIVE_COMPARATOR|Spinal anesthesia (with nerve block) (SA) and TEP Group|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
62736475|NCT01681186|EXPERIMENTAL|LY2940680 (Part A)|Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
62535344|NCT05837013|EXPERIMENTAL|General anesthesia (GA) and open surgical procedure (Lichtenstein)|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
62535345|NCT05837013|ACTIVE_COMPARATOR|Spinal anesthesia (with nerve block) (SA) open surgical procedure (Lichtenstein)|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
62535346|NCT02854852||Patients undergoing general anesthesia|Patients ASA 1-3, undergoing different types of general anesthesia, in supine position, with standard or advanced hemodynamic monitoring.
62535347|NCT04106167||Treatment with Fate Therapeutics' FT500 Cellular Immunotherapy|Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.
62535348|NCT00865787||Olive Oil A|
62535349|NCT00865787||Olive Oil B|
62535350|NCT05980195|EXPERIMENTAL|Hyperbaric oxygen therapy plus standard medical treatment|Patients will receive hyperbaric oxygen therapy plus standard medical treatment after stenting
62535351|NCT05980195|ACTIVE_COMPARATOR|Standard medical treatment|Patients will receive standard medical treatment after stenting
62535352|NCT00566007|ACTIVE_COMPARATOR|1|Discectomy/micro discectomy
62535353|NCT00566007|ACTIVE_COMPARATOR|2|Intradiscal ozone infiltration
62535354|NCT00566007|ACTIVE_COMPARATOR|3|Intradiscal oxygen infiltration (control arm)
62535355|NCT05009914|EXPERIMENTAL|cardiac denervation group|In this group, patients undergoing CABG will receive the procedure of our new way of cardiac denervation, excision of Marshall ligament and Waterstone fat pad.
62535356|NCT05009914|NO_INTERVENTION|controlled group|In this group ,patients undergoing CABG will not receive the procedure of cardiac denervation.
62535357|NCT04819048|EXPERIMENTAL|Low-Level Laser Therapy+acupuncture|"The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.~After LLLT irradiation,the following acupuncture points will be selected: Jiache,Xiaguan,Quanliao,Baihui,Fengchi, Hegu.The needles will be inserted and rotated manually with a frequency of about 100 turns per minute clockwise and counterclockwise ,as above vertically into a depth of 25-30 mm to achieve the proper feel called Deqi in every point on the affected side, and then the needles will be retained for 30 minutes."
62161635|NCT05362279|NO_INTERVENTION|Test without training|The nurses in the control group are the group to be administered the post-test without any intervention after the pre-test. The post-test will be administered one month after the pre-test.
62535358|NCT04819048|ACTIVE_COMPARATOR|Low-Level Laser Therapy|The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.
62161636|NCT06293456|EXPERIMENTAL|Dignity Therapy|The DT intervention is a 45-75-minute virtual interview, which is recorded and transcribed within 72-96 hours of the interview.
62714501|NCT03009461|EXPERIMENTAL|Sor-HAIC group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
62714502|NCT03009461|ACTIVE_COMPARATOR|Sor group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
62736476|NCT01681186|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo given once orally in up to 1 of 2 study periods
62161637|NCT03508830|EXPERIMENTAL|Liposomal Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation: 266mg (20cc) Liposomal Bupivacaine admixed with 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) and varied 0.9% normal saline volume for total volume of 60cc."
62161638|NCT03508830|ACTIVE_COMPARATOR|Standard Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation - 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) admixed with varied 0.9% normal saline volume for total volume of 60cc."
62161639|NCT05596318|EXPERIMENTAL|Digital cognitive behavior therapy for insomnia (CBT-I)|
62161640|NCT05596318|ACTIVE_COMPARATOR|Digital sleep hygiene education (SHE)|
62161641|NCT03872661|EXPERIMENTAL|Drug and surgery|Neoadjuvant therapy followed by surgery. Neoadjuvant therapy included four drugs. IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles; bevacizumab was administered at a dose of 15 mg/kg; pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles; carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles. Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
62535359|NCT03510780|ACTIVE_COMPARATOR|EMD treated patients|"Periodontal surgery with Enamel Matrix Derivative is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers EMD will be applied to the entire root surfaces ; then, ABG will be applied alternatively with EMD into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositionated and sutures completed by interrupted sutures."
62535360|NCT03510780|EXPERIMENTAL|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
62535361|NCT03193073|ACTIVE_COMPARATOR|CKD patients with different stages|"1. Full clinical history and through clinical examination.~2. Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.~3. Iron study at time of diagnosis and 3 months after treatment .~4. Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
62535362|NCT03193073|ACTIVE_COMPARATOR|Newly renal transplanted patients .|"1. Full clinical history and through clinical examination.~2. Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.~3. Pre-transplant full blood count serial measures every / 3 months for 2 years.~4. Pre transplant serum Iron study and annually for 2 years.~5. 24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~6. Post-transplant serum FGF-23 (as independent risk factor) at 6months.~7. Different immunosuppressive protocols.~8. Pre-transplant panel reactive antibody,donor-specific antibody"
62535363|NCT04653272||Experimental|"* Patients aged 16 to 40 years with ACL anterior cruciate ligament rupture, meniscal injury, patella instability or dislocation (Young Adult group),~* Patients over 55 years of age with gonarthrosis (Senior adults group)."
62535364|NCT04653272||Control|"* a group of young (16 to 40 years old)~* senior (over 55 years old) adult controls~* Everybody free of knee pathology."
62535365|NCT06344936|EXPERIMENTAL|Group A|
62535366|NCT04034563|OTHER|Risk of advanced neoplasia at 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy at 3-years
62535367|NCT04034563|OTHER|Risk of advanced neoplasia beyond 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy beyond 3-years
62535368|NCT02086903|EXPERIMENTAL|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
62535369|NCT02086903|EXPERIMENTAL|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
62535370|NCT05658458|EXPERIMENTAL|Vericiguat therapy|Adult participants with chronic HFrEF who are naïve to vericiguat and will be prescribed vericiguat as per local label by their treating physician (cardiologists).
62535371|NCT01152151|ACTIVE_COMPARATOR|Postal reminders|Postal reminders
62535372|NCT01152151|ACTIVE_COMPARATOR|Electronic reminders|Electronic reminders
62535373|NCT05325307|EXPERIMENTAL|Acupressure Group (experimental)|The experimental group will be given acupressure.
62535374|NCT05325307|PLACEBO_COMPARATOR|Placebo Acupressure Group (control)|The placebo group will be given placebo acupressure
62161642|NCT04517604|EXPERIMENTAL|iTBS+yoga|Participants will receive 6 sessions of intermittent theta burst stimulation (iTBS) and the LoveYourBrain Yoga program. The LoveYourBrain Yoga program was specifically designed for people with TBI.
62161643|NCT01381185|NO_INTERVENTION|Standard therapy|standard dose of 100mg aspirin qd and 1x75mg Clopidogrel will be given
62161644|NCT01381185|ACTIVE_COMPARATOR|ASA/CLP increase|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd
62535375|NCT02992418|EXPERIMENTAL|Concomitant Administration Group|Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.
62535376|NCT02992418|EXPERIMENTAL|Sequential Administration Group|Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.
62535377|NCT05217719|EXPERIMENTAL|the TPO group|Patients in TPO group will be treated with rhTPO at a dose of 15000u/d, subcutaneous injection, for 7 consecutive days.
62535378|NCT05217719|PLACEBO_COMPARATOR|the control group|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously, for 7 consecutive days.
62714503|NCT04889924|EXPERIMENTAL|Axillary radiotherapy without lymphadenectomy|Axillary radiotherapy (level I and II) + level III and supraclavicular +/- internal mammary chain without lymphadenectomy
62535379|NCT03577418|EXPERIMENTAL|Clinician-facilitated educational intervention|
62535380|NCT03577418|ACTIVE_COMPARATOR|Enhanced usual care|
62535381|NCT01203410||Cohort 1|Term infants \>2500g birthweight.
62535382|NCT03690661|EXPERIMENTAL|Intervention Video Game|Participants will play the Intervention Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
62535383|NCT03690661|PLACEBO_COMPARATOR|Control Video Game|Participants will play the Control Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
62535384|NCT02105974|EXPERIMENTAL|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
62714504|NCT04889924|ACTIVE_COMPARATOR|Axillary lymph node dissection|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
62161645|NCT03985020|NO_INTERVENTION|Standard of Care|The control group will receive standard of care dietary advice for their solid food and beverage intake.
62535385|NCT02105974|EXPERIMENTAL|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
62535386|NCT03220347|EXPERIMENTAL|CC-90010 in patients with solid tumors and NHL|Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.
62535387|NCT03544918||Patients with long QT syndrome.|Patents with Long QT syndrome hospitilized. To be followed over time with no intervention. Observational study.
62535388|NCT03544918||Patients in Telemark with normal QT time|Patients in Telemark with normal QT time. To be followed over time with no intervention. Observational study.
62535389|NCT00529282|EXPERIMENTAL|001|Ceftobiprole Medocaril 500 mg every 8 hours 120-minute infusion \[250 mL\]
62535390|NCT00529282|ACTIVE_COMPARATOR|002|Cefepime with or without vancomycin 2 g every 8 hrs-30 min infusion vancomycin 1 000mg every 12 hrs-60 min infusion
62535391|NCT05479916|EXPERIMENTAL|Low glycated milk protein|40 grams of low glycated milk protein, blocked lysine level \~5%
62535392|NCT05479916|EXPERIMENTAL|High glycated milk protein|40 grams of high glycated milk protein, blocked lysine level \~50%
62535393|NCT02048930||Initiation cohort|Receive their first prescription for ICS therapy as one of the study drugs
62535394|NCT02048930||Step-up cohort|Receive a prescription for one of the study drugs at a dose ≥50% that of their prescribed ICS dose during baseline.
62535395|NCT02048930||Switch cohort|switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose
62535396|NCT05999058|ACTIVE_COMPARATOR|group A|group A higher nasolacrimal duct obstruction
62535397|NCT05999058|EXPERIMENTAL|group B|group B: lower nasolacrimal duct obstruction
62535398|NCT05999058|EXPERIMENTAL|group C|group C: nasolacrimal duct stenosis
62535399|NCT02026115|ACTIVE_COMPARATOR|usual hospice care|The usual care group will receive the typical hospice care and interact with PAINReportIt to provide data necessary for the analysis of study aims. They will use the tablet computer at baseline and at the study end and daily between. They also will have access to what looks like PAINUCope, but is really computer games so that they have similar attention with the computer as the experimental group. For ethical purposes, we will provide a PAINReportIt Summary to their hospice nurses to have access to their pain assessment information, something we did not do in previous studies focused on efficacy of the interventions.
62535400|NCT02026115|EXPERIMENTAL|PAINRelieveIt (experimental group)|We will use Nursing Consult LLC's PAINRelieveIt software that includes: (1) PAINReportIt that has screens to collect pain, medications, and misconception data; (2) the intervention for the nurse clinicians, PAINConsultN; and (3) the intervention for the patients and lay caregiver, PAINUCope. This innovative, new program is the first computerized, multi-dimensional, self-report measure of pain with clinician decision support for analgesic prescriptions and multimedia patient education tailored to the patient's misconceptions and pain. Prototype versions of PAINConsultN and PAINUCope were tested in recently completed studies among outpatients with cancer and patients with sickle cell disease in outpatient, emergency and hospital settings.
62535401|NCT04657926|EXPERIMENTAL|APPA|"APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA) administered to 75 participants as 2 x 400mg capsules b.d. for 28 days~."
62535402|NCT04657926|PLACEBO_COMPARATOR|Placebo|2 capsules b.d. for 28 days
62535403|NCT00094861|PLACEBO_COMPARATOR|Placebo|"Participants received a single intravenous (IV) dose of placebo administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy was given as follows:~* standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~* paclitaxel 50 mg/m\^2 intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~* carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m\^2 and carboplatin dosed at AUC 6.0."
62535404|NCT00094861|EXPERIMENTAL|Palifermin|"Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy (administered for 6 to 7 weeks) was given as follows:~* standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~* paclitaxel 50 mg/m\^2 IV infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~* carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m\^2 and carboplatin dosed at AUC 6.0."
62535405|NCT04205305|ACTIVE_COMPARATOR|Conventional blood pressure control group|systolic blood pressure \<180 mmHg
62535406|NCT04205305|EXPERIMENTAL|Intensive blood pressure control group|systolic blood pressure \<140 mmHg
62535407|NCT01685411|EXPERIMENTAL|Allogeneic Hematopoietic Stem Cell Transplant|Patients treated with Allopurinol, Keppra, Busulfan, Cyclophosphamide, Filgrastim, antithymocyte globulin, Tacrolimus, Mycophenolate mofetil and allogeneic hematopoietic stem cell transplant infusion.
62535408|NCT02226757|EXPERIMENTAL|Paclitaxel-trastuzumab|Paclitaxel-trastuzumab weekly
62535409|NCT05362838|ACTIVE_COMPARATOR|robotic-assisted laparoscopy|The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port will be placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two to three ports (5/8 mm) for the robotic arms.
62535410|NCT05362838|ACTIVE_COMPARATOR|conventional laparoscopy|Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery.
62535411|NCT01835054||Patients with mitral regurgitation|"At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.~At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.)."
62535412|NCT04053920|EXPERIMENTAL|Low load|Training at 30-40% one-repetition maximum (1RM)
62535413|NCT04053920|EXPERIMENTAL|High load|Training at 65-75% one-repetition maximum (1RM)
62714505|NCT06718218|ACTIVE_COMPARATOR|Mindfulness Pain Management|
62714506|NCT06718218|EXPERIMENTAL|Mindfulness Recording With Sustained Tone|
62714507|NCT06718218|EXPERIMENTAL|Mindfulness Recording with Binaural Beats|
62714508|NCT06718218|EXPERIMENTAL|Mindfulness Recording with Binaural Beats and Theta Music|
62714509|NCT04779099|EXPERIMENTAL|4-session intervention|
62535414|NCT06017479|EXPERIMENTAL|Pre-urodynamic Fosfomycin|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
62535415|NCT06017479|EXPERIMENTAL|Pre-urodynamic Levofloxacin|Levofloxacin 500 miligrams single dosage 1 hour before the urodynamic examination
62535416|NCT03848637|EXPERIMENTAL|Group 1|"* Period 1: D387 (reference drug)~* Period 2: CKD-387 (test drug)"
62535417|NCT03848637|EXPERIMENTAL|Group 2|"* Period 1: CKD-387 (test drug)~* Period 2: D387 (reference drug)"
62535418|NCT04325204|EXPERIMENTAL|Caregivers|Caregivers of a person living with dementia will participate in the Faith-HAT intervention for 6 weeks.
62535419|NCT04325204|EXPERIMENTAL|Persons living with dementia|Persons living with dementia will participate in the Faith-HAT intervention for 6 weeks.
62535420|NCT03562559||TKA Patients|
62535421|NCT03518801|EXPERIMENTAL|Prolonged Exposure + Cannabidiol|Psychotherapy plus active medication
62535422|NCT03518801|ACTIVE_COMPARATOR|Prolonged Exposure + Placebo|Psychotherapy plus placebo medication
62535423|NCT00824616|PLACEBO_COMPARATOR|Placebo|Participants receiving placebo tablets three times daily plus insulin injection once daily
62535424|NCT00824616|EXPERIMENTAL|MK-0941|Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
62535425|NCT01752309||Rheumatoid Arthritis, ultrasound, persistence disease activity|Patients diagnosed with early Rheumatoid Arthritis will be assessed three times in one year with ultrasound to evaluate the predictive value of ultrasound.
62535426|NCT00140426|PLACEBO_COMPARATOR|placebo|double blind study of risperidone for anorexia nervosa. this is the subject group that receives placebo.
62535427|NCT00140426|ACTIVE_COMPARATOR|risperidone|Study is double blind, placebo controlled. This is the subject group on active medication
62535428|NCT00719771|OTHER|Global® AP™ Shoulder|Global® AP™ Shoulder
62535429|NCT06299917|EXPERIMENTAL|WORK-ON|"The 6-months WORK-ON VR includes three parts in addition to usual care:~1: A coordinating occupational therapist (OT) (10 hours): An initial assessment and goal setting process. Support to navigate offers in the municipalities and to involve the employer.~Provides individual support in relation to the goals agreed upon. After six months, goals, the patients' progress during the intervention and future need for support are evaluated.~Follow-up consultation 12 months after baseline. Group sessions to meet with others in the same situation and exchange experiences.~1. Legislative offers (social worker and coordinating OT)~2. Acceptance of the disease in relation to work (nurse and the coordinating OT).~3. Coping strategies (physiotherapist and coordinating OT).~4. Follow-up (nurse and the coordinating OT). Up to 8 individual consultations are offered with a physiotherapist, nurse and or social worker to achieve the goals."
62535430|NCT06299917|NO_INTERVENTION|Usual care|Both the intervention and the control group will receive usual care in the outpatient department. Usual care consists of planned outpatient consultations every 3-12 months depending on the patient's needs, alternating between a rheumatologist and rheumatology nurses. In addition, they have access to support from a telephone help-line to the rheumatology nurses. The planned consultations include review of blood tests, joint examinations, review of completed questionnaires in DANBIO, which is a national rheumatology quality database, adherence to the pharmacological treatment and evaluation of whether pharmacological adjustment is necessary. The nurses can provide limited occasional patient education tailored to the specific patient on management of their disease, medications and symptoms. The participants in the control group will be offered pamphlets for their employer and colleagues (Dear Employer and Dear colleague)
62535431|NCT03552835|EXPERIMENTAL|no caries removal|mandibular occlusal caries were treated with placement of stainless steel crown with no caries removal
62535432|NCT03552835|EXPERIMENTAL|partial caries removal upto soft dentin|mandibular occlusal caries were treated by partial caries removal upto soft dentin
62535433|NCT03552835|EXPERIMENTAL|partial caries removal upto firm dentin|mandibular occlusal caries were treated by partial caries removal upto firm dentin
62535434|NCT01783548|EXPERIMENTAL|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
62535435|NCT01783548|PLACEBO_COMPARATOR|Placebo Nasal Aerosol|Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.
62535436|NCT02272634|EXPERIMENTAL|Treatment A|Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
62535437|NCT02272634|EXPERIMENTAL|Treatment B|Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
62535438|NCT02272634|PLACEBO_COMPARATOR|Treatment C|Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days.
62535439|NCT06483841|EXPERIMENTAL|Testing the Parents as Partners program|Couples (n=51) randomly assigned to this arm will go through 8 weekly group sessions of the Parents as Partners program, facilitated by two trained psychologists. Baseline, post-test and follow-up assessments will entail filling questionnaires collecting data on (co)parental, dyadic and work-family dimensions. At post-test, 6-10 couples will participate in an interview to collect information of their perceived usefulness of the intervention.
62535440|NCT06483841|NO_INTERVENTION|Wait-list control group|Couples (n=51) randomly assigned to this arm will not have access to the intervention during the 8 weeks period in which the intervention group is participating in the program. and until their participation in the study is finished, i.e., they have completed all assessments. Baseline, post-test and follow-up assessments will entail filling questionnaires collecting data on (co)parental, dyadic and work-family dimensions. After follow-up, this group will be offered to participate in the intervention if they wish to and if positive outcomes are found.
62714510|NCT04779099|ACTIVE_COMPARATOR|Treatment as usual|
62714511|NCT02531087||Individuals with OI|Individuals with OI with confirmed specific genetic mutations
62535441|NCT01673971||Natural History|
62535442|NCT01673971||Treatment|
62535443|NCT01293539|OTHER|Intraocular Retinoblastoma Patients|Single group assignment of patients with intraocular retinoblastoma, unilateral or bilateral.
62535444|NCT00789737|EXPERIMENTAL|Welchol|Welchol 625mg tablets
62535445|NCT00789737|PLACEBO_COMPARATOR|placebo|placebo
62535446|NCT01920607|ACTIVE_COMPARATOR|NMS|Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)
62535447|NCT01920607|EXPERIMENTAL|SAM|Implantation under general anesthesia of magnetic anal sphincter (Fenix)
62535448|NCT05632328|EXPERIMENTAL|COHORT 1: AGEN1423 Plus Botensilimab|Treatment is AGEN1423 plus Botensilimab for 4 cycles (8 weeks) followed by Botensilimab alone for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Botensilimab will be administered every 2 weeks.
62535449|NCT05632328|EXPERIMENTAL|COHORT 2: AGEN1423 Plus Botensilimab and Chemotherapy|Treatment is AGEN1423 plus Botensilimab in combination with gemcitabine and nab-paclitaxel for 2 cycles (8 weeks) followed by Botensilimab in combination with gemcitabine and nab-paclitaxel for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Botensilimab will be administered once every 2 weeks.
62535450|NCT02315196|EXPERIMENTAL|Treatment (doxil, carboplatin, surgery, paclitaxel)|"NEOADJUVANT: Patients receive pegylated liposomal doxorubicin hydrochloride\* IV over 90 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients undergo definitive surgery at the discretion of the treating physician. Patients then receive paclitaxel IV over 60 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.~\*NOTE: If there is a shortage of pegylated liposomal doxorubicin hydrochloride, patients receive epirubicin hydrochloride IV over 15-20 minutes on day 1."
62535451|NCT02653430|EXPERIMENTAL|Bariatric Surgery|Sleeve Gastrectomy
62535452|NCT02520063|EXPERIMENTAL|Phase I Cohort 1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
62535453|NCT02520063|EXPERIMENTAL|Phase I Cohort 2|Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
62535454|NCT02520063|EXPERIMENTAL|Phase I Cohort -1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
62535455|NCT02520063|EXPERIMENTAL|Phase II|Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
62535456|NCT06299020|NO_INTERVENTION|Non fasting|Non fasting arm: usual diet and behavior
62535457|NCT06299020|EXPERIMENTAL|Fasting|Intermittent fasting
62535458|NCT02092467|EXPERIMENTAL|Treatment Arm 1|
62535459|NCT02092467|EXPERIMENTAL|Treatment Arm 2|
62535460|NCT02092467|ACTIVE_COMPARATOR|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
62535461|NCT05819723|ACTIVE_COMPARATOR|spinal anesthesia only|The spinal anaesthesia will be done under a complete aseptic technique induced using 3ml bupivacaine 0.5% with 25μg fentanyl
62535462|NCT05819723|ACTIVE_COMPARATOR|spinal anesthesia with erector spinae block|The spinal anaesthesia will be done under a complete aseptic technique induced using 3ml bupivacaine 0.5% with 25μg fentanyl, then erector spinae block will be given The transverse process of the 4th lumbar vertebra will be identified 4-6 cm laterally to the midline. An echogenic needle will be inserted using the out-of-plane technique until it touches the transverse process. Following negative aspira¬tion, 20 ml of 0.25% bupivacaine will be injected
62535463|NCT02472535|EXPERIMENTAL|placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules|
62714512|NCT02531087||Controls/Unaffected|Individuals who do not have OI and who are not related to an individual with OI
62714513|NCT04700423|EXPERIMENTAL|A: moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
62161646|NCT03985020|ACTIVE_COMPARATOR|Water Intervention|We will order and deliver bottled water to the homes of subjects in the treatment group. We will provide each participant with a weekly supply of about 36 16.9 fl oz single-serving containers. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously.
62535464|NCT00986518|EXPERIMENTAL|adaptive cell immunotherapy|
62535465|NCT02781870|OTHER|No-fixation|These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible without fixation.
62535466|NCT02781870|EXPERIMENTAL|LiquiBand Fix glue fixation|"These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.~Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation."
62535467|NCT03463473|EXPERIMENTAL|3 mg/kg (Q3W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 3 mg/kg.
62535468|NCT03463473|EXPERIMENTAL|10 mg/kg (Q3W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 10 mg/kg.
62535469|NCT03463473|EXPERIMENTAL|20 mg/kg (Q3W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 20 mg/kg.
62535470|NCT03463473|EXPERIMENTAL|10 mg/kg (Q2W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 2weeks (Q2W) starting at 10 mg/kg.
62535471|NCT00581126|EXPERIMENTAL|1|Patients will receive Benefix IV according to blood amount
62535472|NCT02740699|OTHER|Moderate to High Statin Treatment in Participants with Coronary Artery Plaque|Participants with coronary artery plaque will receive moderate to high statin treatment at either 20-40 mg once daily Rosuvastatin or 40-80 mg once daily of Atorvastatin.
62535473|NCT04914221|EXPERIMENTAL|Group I|Period I- comparator / Period II- comparator / Period III-JLP-2002
62535474|NCT04914221|EXPERIMENTAL|Group II|Period I- comparator / Period II- -JLP-2002 / Period III- comparator
62535475|NCT04914221|EXPERIMENTAL|Group III|Period I- JLP-2002/ Period II- comparator / Period III- comparator
62535476|NCT05407324|EXPERIMENTAL|CORT113176 (Dazucorilant) 300 mg|300 mg of dazucorilant will be administered once daily.
62714514|NCT04700423|ACTIVE_COMPARATOR|B: ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using 3 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
62714515|NCT04700423|ACTIVE_COMPARATOR|C: albendazole (400 mg)|Monotherapy of albendazole (400 mg) administered orally at day 0 Other names: Zentel®
62535477|NCT05407324|EXPERIMENTAL|CORT113176 (Dazucorilant) 150 mg|150 mg of dazucorilant will be administered once daily.
62161647|NCT03985020|EXPERIMENTAL|Stevia Intervention|We will order and deliver a commercially-available stevia-sweetened soft drink Zevia (Los Angeles, CA) to each participant in the treatment group. We will provide each participant with a weekly supply of 24 12 fl oz single-serving containers. Zevia will be provided in an assortment of flavors for the first week, then catered to the preference of the participant for the remainder of the study. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously. Participants will also be asked to keep track of how many containers they consume using a sticker chart, and we will also phone parents weekly to verify the sticker charts
62161648|NCT03145181|EXPERIMENTAL|Part 1: Dose Escalation (IV)|Participants will receive Teclistamab intravenously (IV).
62535478|NCT05407324|PLACEBO_COMPARATOR|Placebo (matched to study drug)|Placebo will be administered once daily.
62535479|NCT01735955|EXPERIMENTAL|Nilotinib|Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
62535480|NCT03862755|EXPERIMENTAL|Thromboprophylaxis|All surgical patients classified into low risk and moderate/high risk groups based on Caprini score and received different thromboprophylaxis strategies Briefly, early ambulation alone was used in patients at low risk, early ambulation plus chemoprophylaxis with Low Molecular Weight Heparin was used in patients at moderate/high risk.
62535481|NCT05341349|EXPERIMENTAL|Arm I (SRS, pembrolizumab, TTFields)|Patients receive standard of care pembrolizumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
62535482|NCT05341349|EXPERIMENTAL|Arm II (nivolumab, ipilimumab, SRS, TTFields)|Patients receive standard of care nivolumab and ipilimumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
62535483|NCT00985712|EXPERIMENTAL|HumaPen Luxura|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks
62535484|NCT00985712|EXPERIMENTAL|HumaPen Memoir|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks
62535485|NCT02651779|ACTIVE_COMPARATOR|Closed reduction and plasterimmobilisation|The control group will be treated with closed reduction and cast immobilization. This will take place under local anaesthesia by means of a haematoma block with 20 cc Lidocaine 1%. Closed reduction will be preferably performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilizing wrist and hand in the reduced position. Additional radiographs will be performed to verify the success of the reduction. After this has been confirmed, the wrist will be immobilized initially in a split plaster and later changed into a circular cast for five to six weeks immobilization in total.
62535486|NCT02651779|OTHER|Open reduction and internal plate fixation|The surgery will be performed by a certified trauma surgeon. According to the current standard treatment protocol, antibiotic prophylaxis will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis muscle and the radial artery. After the fracture site is exposed, the fracture will be reduced and provisionally fixed under fluoroscopy with K-Wires/reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Fracture reduction and screw placement will be confirmed by radiographic images. Additionally, fixation can be supported by a dorsal plate or radial column plate. This will be at discretion of the surgeon and depends on the fracture configuration and the position of the fragments. Wound closure will be performed at the discretion of the surgeon using standard techniques.
62535487|NCT01043835|EXPERIMENTAL|Laparoscopy-assisted gastrectomy|
62535488|NCT01043835|ACTIVE_COMPARATOR|Open gastrectomy|
62535489|NCT03183336|EXPERIMENTAL|Interpositional block graft|ridge split interpositional block graft
62161649|NCT03145181|EXPERIMENTAL|Part 2: Dose Expansion (IV)|Participants will receive Teclistamab IV.
62535490|NCT03183336|ACTIVE_COMPARATOR|Onlay block graft|decortication onlay block graft
62714516|NCT04700423|ACTIVE_COMPARATOR|D: ivermectin (200 µg/kg)|Monotherapy of ivermectin ( 200 µg/kg using 3 mg tablets) administered orally at day 0 Other names: Stromectol®
62161650|NCT03145181|EXPERIMENTAL|Part 1: Dose Escalation (SC)|Participants will receive Teclistamab subcutaneously (SC).
62161651|NCT03145181|EXPERIMENTAL|Part 2: Dose Expansion (SC)|Participants will receive Teclistamab SC.
62535491|NCT01021059|EXPERIMENTAL|1|rh IL-15 daily for 12 days of 42 days cycle.
62535492|NCT05572671|EXPERIMENTAL|fMRI smoking lapse task|
62535493|NCT04795830|ACTIVE_COMPARATOR|Control group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of GC Corporation's EQUIA Forte High Translucency glass ionomer restorative (GC EQUIA Forte HT Fil Capsule) will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
62714517|NCT04700423|ACTIVE_COMPARATOR|E: moxidectin (8 mg)|Monotherapy of moxidectin (8 mg using 2 mg tablets) administered orally at day 0
62714518|NCT06431711||Individuals with CSVD|This does not entail the application of interventions.
62736477|NCT01681186|EXPERIMENTAL|LY2940680 Capsule Fasted (Part B)|100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
62161652|NCT05739019||COVID-19 infection group|Infertile women attending for frozen embryo transfer with a recent past COVID-19 infection
62535494|NCT04795830|ACTIVE_COMPARATOR|Control group with Restoration|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
62535495|NCT04795830|EXPERIMENTAL|Study group with Restoration|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
62535496|NCT04795830|EXPERIMENTAL|Study group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
62535497|NCT02674906|ACTIVE_COMPARATOR|citrate|A quantity of 20 ml ACD-A per 100 ml of collected blood is used to prevent coagulation in the cell savage process. Pre-prepared ACD-A solutions is available (composition of ACD-A solution used: 22.0 g sodium citrate dehydrate, 24.5 g glucose monohydrate, 8.0 g citric acid monohydrate per 1000 ml of water
62535498|NCT02674906|ACTIVE_COMPARATOR|heparin|A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.
62535499|NCT03379389|EXPERIMENTAL|Methenamine + Methylthioninium|Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
62535500|NCT03379389|ACTIVE_COMPARATOR|Methenamine+Methylthioninium+Acriflavine+Atropa belladona|Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
62535501|NCT03202524|ACTIVE_COMPARATOR|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
62535502|NCT03202524|EXPERIMENTAL|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
62161653|NCT05739019||Control group|Infertile women attending for frozen embryo transfer without a recent past COVID-19 infection
62161654|NCT06721910|PLACEBO_COMPARATOR|Placebo|Infusion of 100 ml normal saline
62161655|NCT06721910|ACTIVE_COMPARATOR|IL-6R ab|Infusion of tocilizumab, 8mg/kg body weight or max. 800mg in 100 ml normal saline
62161656|NCT04389554||Control Group|Healthy pregnant women
62161657|NCT04389554||Study Group|Pregnant women with COVID-19
62161658|NCT05700851|OTHER|Immuno-nutrition|"Participants will be advised to take daily one sachet (74 g) of the immuno-nutrition supplement (Oral Impact®, Nestle) dissolved in 125 ml of water and will be followed-up for 6 weeks.~Participants will receive individualised (to patient needs and food preferences) dietetic advice formulated and delivered by an experienced renal dietitian under an honorary NHS research contract, who is a member of the research team and will be supervised by an NHS renal dietitian, aiming to achieve estimated nutritional requirements for people on haemodialysis (i.e., energy: 30-35 kcal/kg/day, and protein intake: 1.0-1.2 g/kg/day). Each dietetic advice provided to participants will also be reviewed by the NHS clinical renal dietitians who are members of the participants' usual clinical care team."
62161659|NCT04371029|EXPERIMENTAL|Experimental|A Polysomnography (PSG) will be performed in all patient the night before extubation, the day prior discharge and 3 month after. Recording will consist in EEG, EOG et EMG of the chin. We will record NIM EMG. We will also performed an actimetry during hospitalization in the post ICU ward. A quality of sleep questionnaire (Pittsburgh questionnaire) will be completed by the patients during the visit at 3 month.
62161660|NCT03658395|ACTIVE_COMPARATOR|LSCP Only|A Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, is used utilizing robot-assisted Laparoscopic Sacrocolopopexy.
62161661|NCT03658395|ACTIVE_COMPARATOR|LSCP + PR|"The Laparoscopic Sacrocolopopexy involves a Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, utilizing robot-assisted Laparoscopic Sacrocolopopexy.~In addition, patients will receive posterior repair. Posterior repair is performed by midline fascial plication. Plication of superficial perineal muscles (perineorrhaphy) is performed in conjunction with posterior repair. All repairs are performed using polydioxanone 2/0 for fascial repair and 4/0 polyglactin suture for skin closure."
62535503|NCT01006226|EXPERIMENTAL|64Cu-ATSM PET|
62535504|NCT04322110|EXPERIMENTAL|VLCK diet group|Subjects undergoing treatment with weight loss program PronoKal Method
62535505|NCT04322110|ACTIVE_COMPARATOR|Control group|Subjects undergoing treatment with low calorie diet
62535506|NCT02283983|ACTIVE_COMPARATOR|Standard cryoprotection|Proposal helmet without mittens and booties
62535507|NCT02283983|EXPERIMENTAL|Cryoprotection with mittens and booties|Standard cryoprotection with mittens and booties
62535508|NCT00528411|ACTIVE_COMPARATOR|1|Aspirin + Placebo
62535509|NCT00528411|ACTIVE_COMPARATOR|2|Aspirin + clopidogrel
62535510|NCT00528411|EXPERIMENTAL|3|Aspirin + Ticagrelor
62714519|NCT01871441|EXPERIMENTAL|Treatment (haploidentical allogeneic HSCT)|"Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28."
62161662|NCT04754594|EXPERIMENTAL|BNT162b2|2 doses
62161663|NCT04754594|PLACEBO_COMPARATOR|Placebo|2 doses
62535511|NCT04330716|ACTIVE_COMPARATOR|Group A: Standard genetic counseling|Will receive standard genetic counseling prior to genetic testing.
62535512|NCT04330716|EXPERIMENTAL|Group B: Educational video|Will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing.
62535513|NCT02261350|EXPERIMENTAL|Food Fortification|Food Fortification
62535514|NCT02261350|EXPERIMENTAL|Oral Nutritional Supplements|Oral Nutritional Supplements - Fortisip Compact
62535515|NCT02261350|NO_INTERVENTION|Usual Care|
62535516|NCT06423443|EXPERIMENTAL|Digital Cognitive Behavioral Therapy|
62535517|NCT06423443|ACTIVE_COMPARATOR|Health Education|
62535518|NCT02976324|EXPERIMENTAL|external diaphragmatic pacemaker group|use the external diaphragmatic pacemakerI 9 counts per minute, with stimulate frequency 40 Hz
62535519|NCT02976324|NO_INTERVENTION|control group|No inervention, just receive conventional therapy
62535520|NCT05522985|EXPERIMENTAL|Treprizumab combined with TP|"treprizumab injection: 240mg once, intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.~paclitaxel for injection (albumin binding type) 260 mg / m2, intravenous drip, D1, every 3 weeks as a cycle, a total of 3 cycles; cisplatin: 75mg / m2, intravenous drip, D1, once every 3 weeks, a total of 3 cycles; Treprizumab was infused before and at least 60 minutes apart from chemotherapy; The intravenous infusion time of treprizumab shall be at least 60 minutes. Intravenous bolus or single rapid intravenous injection is not allowed."
62535521|NCT05522985|ACTIVE_COMPARATOR|TP（paclitaxel +cisplatin）|paclitaxel for injection (albumin binding type) 260 mg / m2, intravenous drip, D1, every 3 weeks as a cycle, a total of 3 cycles; cisplatin: 75mg / m2, intravenous drip, D1, once every 3 weeks, a total of 3 cycles;
62535522|NCT03033082||Erectile dysfunction patients|Questionnaire sheets.
62535523|NCT03033082||Normal males|Questionnaire sheets.
62535524|NCT00769990|EXPERIMENTAL|Genistein|Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
62535525|NCT04755933|EXPERIMENTAL|Intervention|An online learning tool, designed to helps parents develop a calm, consistent behaviour management style, whilst learning skills to discourage children's avoidance.
62535526|NCT04755933|NO_INTERVENTION|Control|The participants in the control arm will not receive access to the online course, but will complete the same sets of questionnaires at each of the timepoints.
62535527|NCT01625962||mTBI|"Service members who have sustained impact-induced mTBI or blast-induced mTBI (n = 74 completers)"
62161664|NCT00515060||Cancer Therapy-Induced Pain|Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
62535528|NCT01625962||ECI|Service members who have sustained an extracranial injury (ECI) with no evidence of TBI (n = 32 completers)
62535529|NCT04290273|EXPERIMENTAL|Morning exposure in week 1|Participants will have their first week of testing starting in the morning
62535530|NCT04290273|EXPERIMENTAL|Afternoon exposure in week 1|Participants will have their first week of testing starting in the afternoon
62535531|NCT00681850||1|Control group
62535532|NCT00681850||2|Benchmarking group
62714520|NCT05026723|EXPERIMENTAL|Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI)|The Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
62714521|NCT05026723|ACTIVE_COMPARATOR|Standard MTM|The Standard Medically Tailored Meal (MTM) intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian.
62714522|NCT02791464|NO_INTERVENTION|wait list control|Waitlist control subjects interested in learning the TM program will be asked to wait for 4 months before learning if they were randomly assigned to this comparison group. Controls will receive usual medical care during 4 month intervention period.
62736478|NCT01681186|EXPERIMENTAL|LY2940680 Tablet Fasted (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
62161665|NCT05147545|EXPERIMENTAL|Subjects free of malignancy|Moderate intensity physical effort and meal (once)
62161666|NCT05147545|EXPERIMENTAL|Patients with colon cancer|Low intensity physical effort and meal (visit 1, day of cycle 1 chemotherapy) and low intensity physical effort (visit 2, day of cycle 2 chemotherapy)
62161667|NCT06721572|EXPERIMENTAL|Active TEA first followed by sham TEA|Subjects will undergo active TEA for 4 weeks (week 1-4) followed by a 2-week washout period and then sham TEA for 4 weeks (week 7-10). Subjects will have two instruction visits, one before starting active TEA and one before starting sham TEA.
62161668|NCT06721572|EXPERIMENTAL|Sham TEA first followed by active TEA|Subjects will undergo sham TEA for 4 weeks (week 1-4) followed by a 2-week washout period and then active TEA for 4 weeks (week 7-10). Subjects will have two instruction visits, one before starting active TEA and one before starting sham TEA.
62535533|NCT01877044|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62535534|NCT01877044|EXPERIMENTAL|NAXUS 7.5 grams|Arabinoxylan
62535535|NCT01877044|EXPERIMENTAL|NAXUS 15.0 grams|Arabinoxylan
62535536|NCT00416650|EXPERIMENTAL|Therapeutic Intervention|Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.
62535537|NCT01172119|EXPERIMENTAL|BioFreedom Standard Dose|
62535538|NCT01172119|EXPERIMENTAL|BioFreedom Low Dose|
62535539|NCT01172119|ACTIVE_COMPARATOR|Taxus Liberte drug eluting stents|
62535540|NCT05200897|EXPERIMENTAL|Amyloid positive mild cognitive impairment+ BDNF met carrier|Transdermal trigeminal electrical modulation for 3 months
62535541|NCT05200897|EXPERIMENTAL|Amyloid positive mild cognitive impairment+ BDNF Val/Val|Transdermal trigeminal electrical modulation for 3 months
62535542|NCT05200897|EXPERIMENTAL|Amyloid negative mild cognitive impairment+ BDNF met carrier|Transdermal trigeminal electrical modulation for 3 months
62535543|NCT05200897|EXPERIMENTAL|Amyloid negative mild cognitive impairment+ BDNF Val/Val|Transdermal trigeminal electrical modulation for 3 months
62535544|NCT05819203|EXPERIMENTAL|Healsea Babykids|Healsea® Babykids, nasal spray indistinguishable from the comparator. Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).
62535545|NCT05819203|PLACEBO_COMPARATOR|Placebo|"The comparator is a saline isotonic nasal spray considered as inert Placebo i.e., neutral for the nasal mucosa.~Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes )."
62535546|NCT06240247||Gingival healthy|People who do not have clinical attachment loss in their gums, pocket or bone loss, and whose bleeding percentage in their gums is 10% or less
62535547|NCT06240247||Gingivitis|People who do not have clinical attachment loss in their gums, pocket or bone loss, and whose bleeding percentage in their gums is 10% or more
62535548|NCT01607307|ACTIVE_COMPARATOR|Oral/enteral TJ-100 solution|Oral/enteral TJ-100 solution
62535549|NCT01607307|PLACEBO_COMPARATOR|Oral/enteral placebo solution|Oral/enteral placebo solution
62535550|NCT04044911|ACTIVE_COMPARATOR|Tea making followed by stepping|Five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (CogWatch) is followed after a 3-week break by a control condition in which participants receive five 1-hour weekly stepping training sessions.
62535551|NCT04044911|ACTIVE_COMPARATOR|Stepping followed by tea making|A control condition comprising five 1-hour weekly stepping training sessions is followed after a 3-week break by five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (COgWatch)
62535552|NCT05783830|EXPERIMENTAL|ACD856|
62535553|NCT06220747||women aged 12-45 years old|
62535554|NCT04423029|EXPERIMENTAL|Monotherapy Dose Escalation|
62535555|NCT04423029|EXPERIMENTAL|Monotherapy Dose Expansion (Melanoma)|
62535556|NCT04423029|EXPERIMENTAL|Monotherapy Dose Expansion (NSCLC)|
62535557|NCT04423029|EXPERIMENTAL|Combination Dose Escalation|
62535558|NCT04423029|EXPERIMENTAL|Combination Dose Expansion (Melanoma)|
62535559|NCT04423029|EXPERIMENTAL|Combination Dose Expansion (NSCLC)|
62535560|NCT02242916||Patients with recurrent HN tumors|Patients with recurrent Head and Neck tumors
62535561|NCT03525652|ACTIVE_COMPARATOR|Therapeutic vaccine|Therapeutic vaccine will be prepared ex vivo using the peripheral mononuclear cells from the patients and the vaccine (as maturated dendritic cells) will be infused back to the patients in 3 times with a 2-week interval.
62535562|NCT03525652|EXPERIMENTAL|Therapeutic vaccine plus PD-1 knockout|Therapeutic vaccine and PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the vaccine (as maturated dendritic cells) and maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
62535563|NCT03525652|ACTIVE_COMPARATOR|PD-1 knockout T cells|PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
62535564|NCT02564081|EXPERIMENTAL|Static Stretching lower limb|Three 30 s bouts of static stretching for the gastrocnemius and the hamstrings respectively
62535565|NCT02564081|ACTIVE_COMPARATOR|Static stretching Cervical|Six 30 s bouts of static stretching of the cervical spine in the sagittal plane (flexion only)
62535566|NCT02564081|NO_INTERVENTION|Ctrl|No intervention
62535567|NCT04731337|ACTIVE_COMPARATOR|Patient's normal canine occlusal relationship|The distance between the gingival zenith from the upper to the lower deciduous canines was determined by the digital calliper in millimetres (Shenzhen Jiabaili Electronic Commerce Co., Ltd) (fig1,2,3) at the right and left sides and a digital camera photographed the reading (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
62161669|NCT04806347|EXPERIMENTAL|Treatment arm|Participants will undergo a conditioning regimen, specific for the original disease, After that peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCRαβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems will be administered intravenously on Day 0 to all participants.
62161670|NCT03353649|EXPERIMENTAL|Binge Eating Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (images of highly palatable foods for obese individuals), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets. Specifically, participants in this sample will be exposed to images of food and control non-food images. In different trials, subjects will be given a now cue instructing them to engage with the immediate hedonic properties of the stimulus or a later cue instructing them to imagine the long-term consequences of using the stimulus.~This arm includes fMRI and the now vs. later cue intervention"
62161671|NCT03353649|EXPERIMENTAL|Smoking Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (tobacco-related images or smokers), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets.~A similar approach to the Binge Eating sample will be used for the smoking sample using two stimulus sets. Instead of foods and non-food control images, smokers will see smoking-related images and the same control non-food non-smoking images as the Binge Eating sample.~This Arm includes fMRI and the now vs. later cue intervention"
62161672|NCT04556227|EXPERIMENTAL|Simultaneous Cycle/Cognitive Training|After discharge from the hospital the group will engage in recumbent cycling with simultaneous cognitive training on a tablet.
62535568|NCT04731337|SHAM_COMPARATOR|Canine occlusal relationship after full mouth rehabilitation|The distance between the gingival zenith from the upper to the lower deciduous canines was determined by the digital calliper in millimetres (Shenzhen Jiabaili Electronic Commerce Co., Ltd) (fig1,2,3) at the right and left sides and a digital camera photographed the reading (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
62535569|NCT01778686|EXPERIMENTAL|Citalopram and Pindolol|"Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.~Pindolol peroral administration starting 3 days before scanning:~Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon."
62535570|NCT01778686|PLACEBO_COMPARATOR|Placebo|"Placebo for pindolol: sugar tablets that resembles pindolol~Placebo for ATD: amino acid drink balanced formula (containing tryptophan)~Placebo for Seropram: NaCl infusion"
62535571|NCT01778686|EXPERIMENTAL|Acute tryptophan depletion|Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.
62535572|NCT04730349|EXPERIMENTAL|A1W Dosing schema|
62535573|NCT04730349|EXPERIMENTAL|A1F Dosing schema|
62535574|NCT04730349|EXPERIMENTAL|A2W Dosing schema|
62736479|NCT01681186|EXPERIMENTAL|LY2940680 Tablet Fed (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods
62535575|NCT04730349|EXPERIMENTAL|A2F Dosing schema|
62535576|NCT04730349|EXPERIMENTAL|Part B: Cohort B1 Neuroblastoma|
62535577|NCT04730349|EXPERIMENTAL|Part B: Cohort B2 Ewing sarcoma|
62535578|NCT04730349|EXPERIMENTAL|Part B: Cohort B3 Rhabdomyosarcoma|
62535579|NCT04730349|EXPERIMENTAL|Part B: Cohort B4 Miscellaneous solid tumors|
62535580|NCT04730349|EXPERIMENTAL|Part B: Cohort B5 NHL/leukemia|
62535581|NCT04730349|EXPERIMENTAL|Part B: Cohort B6 High-grade glioma|
62535582|NCT04730349|EXPERIMENTAL|Part B: Cohort B7 Medulloblastoma and Embryonal Tumors|
62535583|NCT04730349|EXPERIMENTAL|Part B: Cohort B8 Ependymoma|
62535584|NCT04730349|EXPERIMENTAL|Part B: Cohort B9 Miscellaneous brain tumors|
62535585|NCT03868150|ACTIVE_COMPARATOR|Inducible Atrial Fibrillation|Treatment with Amiodarone
62535586|NCT03868150|OTHER|Inducible Atrial Fibrillation - Standard Care|No initial Amiodarone Treatment unless POAF seen on post operative care unit.
62535587|NCT03868150|OTHER|Non-Inducible Atrial Fibrillation|Amiodarone treatment if POAF seen on post-operative care unit
62535588|NCT06422312|ACTIVE_COMPARATOR|Control|Participants in this arm will receive cystoscopy using the clinic's standard of care flexible reusable cystoscope of the urologist's choice.
62535589|NCT06422312|EXPERIMENTAL|Intervention|Participants in this arm will receive cystoscopy using the Redpine® Rflex endoTMHD Cysto scope.
62535590|NCT06063616|EXPERIMENTAL|Reiki group|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
62161673|NCT04556227|NO_INTERVENTION|Usual Care|After discharge from the hospital the group will complete baseline activies.
62161674|NCT04630028|EXPERIMENTAL|Induction Period (I): Ustekinumab|All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square \[mg/m\^2\]) or weight-tiered induction dose (milligram per kilogram \[mg/kg\]).
62535591|NCT06063616|SHAM_COMPARATOR|Sham Reiki group|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
62535592|NCT06407986||Normal lung function|After using a bronchodilator, FEV1/FVC ≥70%, FEV1 and FVC ≥80% of reference values.
62535593|NCT06407986||Preserved ratio impaired spirometry|After using a bronchodilator, FEV1/FVC≥70%, FEV1 and/or FVC\<80% of reference values.
62535594|NCT05924854|EXPERIMENTAL|Electroacupuncture group (E group)|When the patient's vital signs are stable, the blind researcher (acupuncturist) checks the electroacupuncture device, (SDZ-Ⅱ, Suzhou Medical Supplies Factory),after the check is been done, acupuncturist uses Huatuo brand copper milli-needle needles to pierce Baihui point（DU20）, Shenting point (DU24), bilateral Zulinqi (GB41) and bilateral Taichong (LR3) , and fixed and connection them to SDZ-Ⅱ..At first, sets the device output to zero ,then .the acupuncturist turns on the power of the treatment instrument with the output frequency from 50 to 100hz on a weak to strong wave mode continuously , 20 min after the intervention, stops the machine, the acupuncturist turns off the device and pulls out the needles.
62535595|NCT05924854|NO_INTERVENTION|sevoflurane general anesthesia group（S group）|Anesthesia induction, anesthesia maintenance and anesthesia monitoring will carry out exactly the same in both groups,only difference is that S group has no electroacupuncture intervention.
62535596|NCT05631223|EXPERIMENTAL|Interventional Telemedicine Arm|Single Arm Intervention
62535597|NCT02208635|EXPERIMENTAL|Biofortified Maize|Participants in this arm were fed zinc biofortified maize (\~30 µg Zn/g).
62535598|NCT02208635|EXPERIMENTAL|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).
62535599|NCT02208635|ACTIVE_COMPARATOR|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
62535600|NCT04596514|EXPERIMENTAL|Intervention group - REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
62535601|NCT04596514|ACTIVE_COMPARATOR|Control group - ACLS|Advanced cardiovascular life support as described in the guidelines
62535602|NCT04422353|EXPERIMENTAL|video Dance classes|"The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm.~Classes will be divided into four stages: Joint warm-up and stretching on the chairs; strengthening, balance, and rhythm exercises with the support of the chair; exercises inspired by the samba and forró (Brazilian ballroom dance) basic steps; and Final cool down. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.~The video Dance classes will happen in the period of self-isolation and social distance during the Covid-19 pandemic."
62535603|NCT04422353|ACTIVE_COMPARATOR|Unsupervised physical activities|The unsupervised physical activity programs will happen in the period of self-isolation and social distance during the Covid-19 pandemic. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
62535604|NCT04422353|NO_INTERVENTION|control group|The control group will be people with PD, engaged, before the Covid-19 pandemic, in the Dance, the Nordic Walk and the Aquatic Jogging extension projects at Federal University of Rio Grande do Sul but did not do any type of physical activity during the Covid-19 pandemic.
62714523|NCT02791464|EXPERIMENTAL|Transcendental Meditation|The TM technique is a simple, effortless, mental technique to reducing stress which allows the mind to experience finer levels of the thinking process to achieve a state of restful alertness. The Transcendental Meditation program will be taught as a standard seven-step program over five consecutive days.
62736480|NCT01681186|EXPERIMENTAL|LY2940680 Tablet Fasted + PPI (Part B)|30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
62535605|NCT01367665|EXPERIMENTAL|Vismodegib - Locally Advanced|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
62161675|NCT04630028|EXPERIMENTAL|Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)|Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
62161676|NCT04630028|EXPERIMENTAL|Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)|Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
62161677|NCT05256355|OTHER|MSUS novices|Measurement of competence
62161678|NCT05256355|OTHER|MSUS intermediates|Measurement of competence
62161679|NCT05256355|OTHER|MSUS experts|Measurement of competence
62161680|NCT06282575|EXPERIMENTAL|Zanidatamab with Standard-of-care Therapy Arm|Zanidatamab plus standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations.
62161681|NCT06282575|ACTIVE_COMPARATOR|Standard-of-care Therapy Arm|Standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations.
62161682|NCT05327114|EXPERIMENTAL|Nipocalimab|Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.
62161683|NCT05327114|PLACEBO_COMPARATOR|Placebo|Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.
62161684|NCT03662737||Group 1 -Chronic cannabis use|Individuals between 18 and 50 years old who have been using at least 2 joints per day for at least 3 years. They should have used cannabis during the last 24h but not during the 3h prior to participation to the study and they should test positive for cannabis in their urine. Individuals with another substance use or severe mental disorder will be excluded (except tobacco use)
62161685|NCT03662737||Group 2 - Alcohol dependence|Individuals between 18 and 50 years old diagnosed with alcohol use disorder according to DSM-V criteria and have been consuming alcohol for at least 3 years. Individuals who are diagnosed with another substance use or severe mental disorder will be excluded (except tobacco use).
62161686|NCT03662737||Control Group|Individuals matched in gender and age with the experimental groups and with no diagnosis of substance use or severe mental disorder (except tobacco use)
62161687|NCT03617549||All Participants|Mothers of singleton moderate preterm appropriate for Gestational Age (AGA) infants (29-32+6 weeks gestation in the neonatal intensive care unit at the Golisano Children's Hospital
62161688|NCT03729999|EXPERIMENTAL|Ultrasonography|Patients requiring single lung ventilation for a surgical procedure will have a bedside ultrasound to evaluate lung isolation.
62535606|NCT01367665|EXPERIMENTAL|Vismodegib - Metastatic|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
62161689|NCT03728803|SHAM_COMPARATOR|Sham inspiratory muscle training|"Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance.~The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks."
62161690|NCT03728803|ACTIVE_COMPARATOR|Active inspiratory muscle training|Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.
62161691|NCT06439524|ACTIVE_COMPARATOR|Rel-CT|40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate, one tablet daily for 6 months
62161692|NCT06439524|NO_INTERVENTION|no study drug|no study drug
62161693|NCT06203756|ACTIVE_COMPARATOR|Femur First, Non Sensor-assisted|Standard robotic surgery cohort with a femur first workflow. Sensor used only to measure final balance achieved with surgeon blinded to measurements.
62161694|NCT06203756|ACTIVE_COMPARATOR|Femur First, Sensor-assisted|Sensor-assisted robotic surgery cohort with a femur first workflow
62161695|NCT06203756|ACTIVE_COMPARATOR|Tibia First, Non Sensor-assisted|Standard robotic surgery cohort with a tibia first workflow. Sensor used only to measure final balance achieved with surgeon blinded to measurements.
62161696|NCT06203756|ACTIVE_COMPARATOR|Tibia First, Sensor-assisted|Sensor-assisted robotic surgery cohort with a tibia first workflow
62161697|NCT06203756|OTHER|Revision Total Knee Arthroplasty|Sensor-assisted robotic surgery cohort with a tibia first workflow. Revision Total Knee Arthroplasty components.
62161698|NCT01109394||1/Cohort 1|Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit.
62161699|NCT01109394||2/Cohort 2|Human samples, specimens and data collected on IRB approved protocols that are now closed
62535607|NCT01325727|EXPERIMENTAL|Brief computerized feedback|Brief computerized feedback
62535608|NCT01325727|ACTIVE_COMPARATOR|Resources only|
62161700|NCT01109394||3/Cohort 3|Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer.
62161701|NCT06720649|EXPERIMENTAL|patient underwent ACL reconstruction|
62161702|NCT03709264|EXPERIMENTAL|Amino Acids infusion|
62161703|NCT03709264|PLACEBO_COMPARATOR|Placebo|
62161704|NCT04869046|EXPERIMENTAL|Levobupivacaine group|Instillation of 0,1 ml/kg (0,5 mg/kg) levobupivacaine 0,5% in surgical wound before fascia closure
62161705|NCT04869046|PLACEBO_COMPARATOR|Control Group|Instillation of 0,1 ml/kg 0,9% Sodium Chloride in surgical wound before fascia closure
62161706|NCT06642376|EXPERIMENTAL|Breathing Exercise Application Group|Nurses in the intervention group will be made to practice breathing exercises. The breathing exercise will first be explained to the nurses face-to-face and they will be made to do it. Then, face-to-face practice will be done three days a week, and on the other days, the audio recording of the breathing exercise will be sent by the researcher to the nurses via WhatsApp and they will be practiced daily. The breathing exercise will continue for 30 days.
62161707|NCT06642376|NO_INTERVENTION|Control group|There will be no intervention for individuals in this group.
62161708|NCT04198272|EXPERIMENTAL|Facilitated|Schools that are randomized to this arm will be exposed to all of the components in the self-service version in addition to peer facilitation of the CyberRwanda platform at CyberRwanda clubs.
62161709|NCT04198272|ACTIVE_COMPARATOR|Self-service|"Schools that are randomized to this arm will be exposed to the following components of the intervention:~* Self-guided access to the online CyberRwanda platform; and~* Promotion of the CyberRwanda program through school launch events."
62161710|NCT04198272|NO_INTERVENTION|Control|Schools in this arm will not receive any intervention.
62161711|NCT06386289|EXPERIMENTAL|Single Arm|Mechanical Thrombectomy
62161712|NCT05884398|EXPERIMENTAL|Arm A (Intermittent ADT Group)|Participants with PSA level \<0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and treated with apalutamide with intermittent ADT per protocol or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) or have discontinued the study, whichever occurs first.
62161713|NCT05884398|EXPERIMENTAL|Arm B (Continuous ADT Group)|Participants with PSA level \<0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and continue to receive apalutamide plus ADT or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) or have discontinued the study, whichever occurs first.
62161714|NCT00557518|ACTIVE_COMPARATOR|1|
62535609|NCT01910389|ACTIVE_COMPARATOR|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
62161715|NCT00557518|PLACEBO_COMPARATOR|2|
62161716|NCT06721546|OTHER|intervention|"The intervention group was provided with group education on healthy nutrition and functional foods based on the health promotion model, the provision of booklets, sending reminder messages and nursing interventions aimed at increasing motivation by providing telephone counseling. The intervention group was given an appointment for Tuesday-Thursday of the week for training at KEAH via telephone. After the training given to the intervention group, 2 reminder messages were given at two-week intervals and 3 telephone consultations were given, including the post-test application. 12 weeks after the training developed and applied according to the health promotion model given to the intervention group, post-test data were collected in both groups. In the post-test, the Eating Habits and Functional Foods Information Form, Functional Food Consumption Form, Self-Efficacy Scale for Diabetes Management and Healthy Lifestyle Behaviors II were applied as measurement tools."
62161717|NCT06721546|NO_INTERVENTION|control|In this group, type 2 diabetics were given pre-tests and post-tests (Functional Food Consumption Form, Diabetes Self-Efficacy Scale, Healthy Lifestyle Behaviors II Scale) during the pre-randomization phase during the familiarization phase between October 1 and October 30, 2024 during weekday daytime hours. No intervention was made to the control group. After the study was completed, the participants in the control group were given the right to be informed from an ethical perspective and a day was set for them to come to the hospital for 'healthy nutrition and functional food education' and education was started. The education is also provided in the booklet after the training.
62161718|NCT06526442||Plan to include patients with resectable pancreatic cancer 150|Investigators anticipate that 150 resectable pancreatic cancer participants are enrolled in this group and all participants undego magnetic resonance imaging.
62161719|NCT06526442||Plan to include patients with unresectable pancreatic cancer 50|Investigators anticipate that 50 unresectable pancreatic cancer participants are enrolled in this group and all participants undego magnetic resonance imaging.
62535610|NCT01910389|PLACEBO_COMPARATOR|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
62535611|NCT00630929|ACTIVE_COMPARATOR|A|
62161720|NCT05398042|PLACEBO_COMPARATOR|Placebo|Ketone placebo will be provided
62161721|NCT05398042|EXPERIMENTAL|Ketone|Ketone esters will be provided
62535612|NCT00630929|PLACEBO_COMPARATOR|C|
62535613|NCT00630929|EXPERIMENTAL|B|
62535614|NCT01695863|EXPERIMENTAL|miralax|miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
62535615|NCT01695863|EXPERIMENTAL|moviprep split dose|Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen
62535616|NCT02171494|EXPERIMENTAL|IVAX warfarin|Treatment A: IVAX warfarin
62535617|NCT02171494|ACTIVE_COMPARATOR|BMS coumadin|Treatment B: BMS coumadin tablets
62535618|NCT02212327||PD subjects|
62535619|NCT02212327||Controls|
62535620|NCT04715932|ACTIVE_COMPARATOR|Hesperidin 1000mg|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
62535621|NCT04715932|PLACEBO_COMPARATOR|Placebo 1000mg|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
62161722|NCT03598790|EXPERIMENTAL|Bimekizumab dose regimen 1|"Subjects are randomized to receive either dose regimen 1 (BKZ 1) or dose regimen 2 (BKZ 2) during the 144-week Treatment Period (open-label), those on BKZ 1 will switch to BKZ 2 at Week 24 or later (at the next scheduled clinic visit after Week 48)~Eligible subjects who completed the Treatment Period (open-label), and have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks.~Intervention Name: Bimekizumab"
62161723|NCT03598790|EXPERIMENTAL|Bimekizumab dose regimen 2|"Subjects are randomized to receive BKZ 2 during the 144-week Treatment Period (open-label).~Eligible subjects who completed the Treatment Period (open-label), would continue OLE2 on BKZ 2.~Intervention Name: Bimekizumab"
62161724|NCT02114372||CogState Brief Battery|Enrolled participants will be randomized in a balanced manner to CogState brief battery in both the Main Study and the SubStudy. CogState consists of four tasks that respectively measure the functions of attention, processing speed, visual learning, and working memory. The CogState Brief Battery is an approximately 15 minute computerized battery with demonstrated reliability, validity, and short term stability, that was developed expressly for maximal sensitivity to detect change. CogState can be administered via the internet or on a stand-alone computer and is available in over 50 languages.
62161725|NCT02114372||Cognitive Drug Research Assessment System (CDR-AS)|Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
62161726|NCT02114372||Delis Kaplan Executive Function System (DKEFS)|Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions that has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
62161727|NCT02114372||COGNITO|Enrolled participants will be randomized in a balanced manner to COGNITO at the other site of the SubStudy. COGNITO is an approximately 45 to 60 minute computerized neuropsychometric examination based on well-known cognitive tests designed for both cognition research and clinical assessment. COGNITO assesses reaction time, primary and working memory, visuospatial and verbal secondary memory, implicit learning, language skills, functional and semantic categorization of visual data, focused and divided attention, and crystallized intelligence. Responses are made via a tactile screen which permits the recording of response latency (deducting reaction time provides an estimation of information processing time).
62161728|NCT02623101|ACTIVE_COMPARATOR|Standard of care procedure|"Clinical suspected basal cell carcinomas, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most clinical suspicious part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. Hematoxylin/eosin stained sections of the punch biopsies will be evaluated by an experienced pathologist. Subjects will receive surgical excision according to subtype.~When there is any doubt by reflectance confocal microscopic diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma."
62161729|NCT02623101|EXPERIMENTAL|Reflectance confocal microscopy (RCM)|The Vivascope 1500 and Vivascope 3000 (handheld divice) will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed on clinical suspected basal cell carcinomas, of all subtypes. When there are signs of a basal cell carcinoma imaged by RCM, subjects will receive surgical excision according to subtype. When there is any doubt by RCM diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma.
62161730|NCT05727878|EXPERIMENTAL|Cohort 1, Arm 1|KPI-012 High Dose KPI-012 Ophthalmic Solution 3 U/mL 1 drop 4 times/day for 56 days
62161731|NCT05727878|EXPERIMENTAL|Cohort 2, Arm 1|KPI-012 Low Dose KPI-012 Ophthalmic Solution 1 U/mL 1 drop 4 times/day for 56 days
62161732|NCT05727878|EXPERIMENTAL|Cohort 2, Arm 2|KPI-012 High Dose KPI-012 Ophthalmic Solution 3 U/mL 1 drop 4 times/day for 56 days
62161733|NCT05727878|PLACEBO_COMPARATOR|Cohort 2, Arm 3|KPI-012 Vehicle KPI-012 Ophthalmic Solution 0 U/mL 1 drop 4 times/day for 56 days
62161734|NCT05555615|EXPERIMENTAL|Pimavanserin|"Pimavanserin once daily. All patients will receive the pimavanserin low dose (patients aged 5 to 12 years: 10 mg/day pimavanserin; patients aged 13 to 17 years: 20 mg/day) the first 2 weeks of the study. Thereafter, the dose may be increased to the high dose (5 to 12 years: 20 mg/day; 13 to 17 years: 34 mg/day) based on the Investigator's assessment of clinical response.~After Week 2 and up to Week 20, dose adjustments are allowed at any clinic visit based on the Investigator's assessment of clinical response and tolerability. No further dose adjustments are allowed after Week 20."
62161735|NCT05509777|EXPERIMENTAL|Mirikizumab Dose 1|Mirikizumab administered intravenously (IV) or subcutaneously (SC) in participants that weigh greater than (\>) 40 kilograms (kg).
62535622|NCT05443581|EXPERIMENTAL|Intervention group|"Participations in this group are required to follow a healthy vegetarian diet （avoid meat, poultry, fish, dairy） during the 24-weeks trail.~Daily energy intake = BMR(basal metabolic rate) × 1.25-500kcal；BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%."
62535623|NCT05443581|ACTIVE_COMPARATOR|Control group|"Participations in this group are required to follow a healthy omnivorous diet (No restriction on food sources) during the 24-weeks trail.~Daily energy intake = BMR × 1.25-500kcal；BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%."
62535624|NCT01626443|ACTIVE_COMPARATOR|Folic acid|
62535625|NCT01626443|EXPERIMENTAL|Inofolic Combi|
61976061|NCT03251768|EXPERIMENTAL|Test group|"intervention: rHSA-GCSF 2.4 mg Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（2.4mg）will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle.After injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
62161736|NCT05509777|EXPERIMENTAL|Mirikizumab Dose 2|"Mirikizumab administered IV or SC in participants that weigh \>20 kg to less than or equal to (≤) 40 kg.~Dosing is based on assessments of the participant's weight and appropriate weight class."
62161737|NCT05509777|EXPERIMENTAL|Mirikizumab Dose 3|"Mirikizumab administered IV or SC in participants that weigh greater than or equal to (≥)10 kg to less than or equal to ≤20 kg.~Dosing is based on assessments of the participant's weight and appropriate weight class."
62161738|NCT04707924|EXPERIMENTAL|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
62161739|NCT04707924|NO_INTERVENTION|Control area|No treatment performed on control areas.
62161740|NCT03770338|NO_INTERVENTION|Control|Recruitment for fusion surgery as usual
62161741|NCT03770338|EXPERIMENTAL|Teriparatide|Preoperative 1 month use of teriparatide, before lumbar fusion surgery
62161742|NCT05670106|EXPERIMENTAL|[177Lu]Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)|Patients will receive the investigational product 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) may be used
62161743|NCT01014013|EXPERIMENTAL|ertapenem sodium (MK0826)|ertapenem sodium
62161744|NCT01014013|ACTIVE_COMPARATOR|ceftriaxone sodium|ceftriaxone sodium
62161745|NCT03153449|OTHER|ATTUNE Revision knee system|The ATTUNE Revision knees system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in complex primary knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
62161746|NCT06721182|EXPERIMENTAL|Intervention group (cesarean section + REBOA)|
62161747|NCT04136249|NO_INTERVENTION|Control chimiotherapeutic arm|Standard care as comparaison procedure that includes chemotherapy
62161748|NCT04136249|EXPERIMENTAL|Physical over-activity|The procedure under study which includes a re-training mixing EMS and EXC with a nutrition adapted to the needs related to the physical over-activity following the chemotherapy
62161749|NCT05619445|EXPERIMENTAL|Whole Liquid Egg|Whole Liquid Eggs
62161750|NCT05619445|EXPERIMENTAL|Plant-Based Egg Substitute|Plant-Based Egg Substitute
62161751|NCT03896971|EXPERIMENTAL|Thrombopoietin mimetic plus immunosuppressive therapy|The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months. Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
62161752|NCT03896971|NO_INTERVENTION|Immunosuppressive therapy|A comparative group will be collected retrospectively and treated with cyclosporin A alone as standard.
62161753|NCT05499507|ACTIVE_COMPARATOR|Change of Heart (COH)|Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
62161754|NCT05499507|EXPERIMENTAL|Change of Heart Plus (COH+)|Includes all components of COH plus the addition of interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).
62161755|NCT03879252|EXPERIMENTAL|Tooth brushing|
62161756|NCT03879252|ACTIVE_COMPARATOR|Mouthwash|
62161757|NCT01534052|EXPERIMENTAL|Enzalutamide|Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
62535626|NCT02374489|EXPERIMENTAL|single-arm studies|"LDK378 in suitable patients:~Collect tumor tissue for immunohistochemistry staining to confirm the status of ROS1 or ALK expression. If the patient fits all criteria, LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle"
62161758|NCT03991325||difficult laryngoscopy|group of patients with Cormack and Lehane grade III or IV
62161759|NCT03991325||easy laryngoscopy|group of patients with Cormack and Lehane grade I or II
62161760|NCT06514742|EXPERIMENTAL|Aticaprant|
62161761|NCT06514742|PLACEBO_COMPARATOR|Placebo|
62161762|NCT05083182|EXPERIMENTAL|Cohort 1: Ustekinumab|Participants will receive a weight-based dose of ustekinumab subcutaneously (SC) at Week 0, Week 4 and then every 12 weeks up to Week 52.
62535627|NCT06632431||Endometrial cancer group|Patients diagnosed with endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy)
62161763|NCT05083182|EXPERIMENTAL|Cohort 2: Guselkumab|The dose of guselkumab will be based on the participant's weight. Participants will receive guselkumab SC at Weeks 0 and 4 followed by either every 4 weeks (Q4W) (with historical radiographic evidence of joint damage) or every 8 weeks (Q8W) (without historical evidence of joint damage) dosing with the last dose at Week 52. Participants at high risk of joint damage can also be considered for Q4W dosing per investigator.
62161764|NCT02163499|EXPERIMENTAL|Sodium Zirconium Cyclosilicate|
62161765|NCT06721858|PLACEBO_COMPARATOR|Control group, where no intervention will be made and only research questionnaires will be applied|The determined scale forms will be applied to the people in the control group who will be included in the study as a pre-test at the beginning of the study, as a post-test 10 days after the pre-test, and finally as a follow-up test one month after the pre-test.
62161766|NCT06721858|EXPERIMENTAL|intervention group to which emotion-focused therapy will be applied|Participants in the intervention group will first be given face-to-face individual interviews to establish the therapeutic environment and relationship (Individual interviews are designed as orientation, diagnosis and planning stages, 30-minute interviews). Then, three intervention stages (40-minute, group therapy) will be applied and the last session will be both intervention (post-test application) and termination stage (completion of emotion-focused therapy application). After the individual interviews, individuals will be included in 3 intervention sessions as group training. It is planned that each group will have at least 4 and at most 6 people. If the specified number cannot be reached, the study will continue until the specified number is reached.
62161767|NCT05910619|ACTIVE_COMPARATOR|Active brain stimulation|These participants will receive focused TPS (pulsed stimulation) of the specified default mode network regions as specified in the detailed study description.
62161768|NCT05910619|SHAM_COMPARATOR|Sham brain stimulation|"These participants will also receive focused TPS (pulsed stimulation) of the specified default mode network regions as specified in the detailed study description, though the device will be set to Sham in a blinded fashion by the biostatistician by placing an air pouch in the device hand piece."
62535628|NCT01341782|EXPERIMENTAL|Paricalcitol|Participants received paricalcitol at an initial dose of 2 µg, and maxacalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 1 µg based on protocol-specified criteria up to a maximum of 7 µg.
62535629|NCT01341782|ACTIVE_COMPARATOR|Maxacalcitol|Participants received maxacalcitol at an initial dose of 5 µg (iPTH \< 500 pg/mL at Screening) or 10 µg (iPTH ≥ 500 pg/mL at Screening), and paricalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 2.5 µg based on protocol-specified criteria up to a maximum of 20 µg.
62714524|NCT05958589|EXPERIMENTAL|General anesthesia + caudal block|General anesthesia with intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg), in combination with a single shot caudal block with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
62161769|NCT00170950|EXPERIMENTAL|Benazepril/amlodipine|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of \< 140/\< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
62161770|NCT00170950|ACTIVE_COMPARATOR|Benazepril/hydrochlorothiazide|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of \< 140/\< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
62161771|NCT04557150|EXPERIMENTAL|Part I: Dose Escalation|Participants will receive forimtamig as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.
62161772|NCT04557150|EXPERIMENTAL|Part II: Dose Expansion|Dose Expansion cohorts with IV and/or SC administration, respectively, will be initiated at the Recommended Phase 2 Doses (RP2Ds) determined in Part I: Dose Escalation phase.
62161773|NCT01242345|NO_INTERVENTION|No Intervention|Standard monitoring.
62161774|NCT01242345|EXPERIMENTAL|Capnography|Arm with capnographic monitoring
62161775|NCT04609826|EXPERIMENTAL|Arm A: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until a recommended Phase 2 dose (RP2D) has been identified.
62161776|NCT04609826|EXPERIMENTAL|Arm B: JNJ-74856665 + Azacitidine (AZA)|Participants will receive JNJ-74856665 orally in combination with AZA administered intravenously (IV) or subcutaneously (SC) in a 28-day cycle.
62161777|NCT04609826|EXPERIMENTAL|Arm C: JNJ-74856665 + Venetoclax (VEN)|Participants will receive JNJ-74856665 orally in combination with VEN in a 28-day cycle.
62161778|NCT04609826|EXPERIMENTAL|Arm D: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. Participants with transfusion dependent relapsed/refractory Myelodysplastic Syndrome (MDS) will be included.
62161779|NCT04604626||Population 1|Adults and children with severe obesity ie (BMI\> 35 kg / m² for adults and Z BMI score\> 3DS for age and sex for children) and / or eating disorders with genetic diagnosis as part of care.
62161780|NCT04604626||Population 2|Adults and children with obesity and / or eating disorders hypothalamic lesion (craniopharyngioma example).
62161781|NCT05481996|EXPERIMENTAL|App-Based Pain Education and Exercise|Patients allocated to the experimental group will receive a login and password for individual access to the smartphone app designed for the study. The app's content for this group will include three components: 1) a physical exercise program of 8 weeks; 2) weekly messages; and 3) an online booklet. The exercise component will include 8 weeks of training, with two sessions per week of core strengthening exercises. The app will provide illustrations, with animated images (GIFs), descriptions and audios of how to perform each exercise. The message component will provide eight messages (one per week), which will have their contents taken from the online booklet. Messages will include information about the benefits of exercise, motivation, and positive messages about coping with pain. The online booklet will contain general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises.
62161782|NCT05481996|ACTIVE_COMPARATOR|Online Booklet|Patients allocated to the control group will receive a login and password for individual access to the smartphone app designed for the study. The app's content for this group will include two components: 1) an online booklet; and 2) weekly messages. The online booklet will contain general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. The message component will provide eight messages (one per week), which will have their contents taken from the online booklet. Messages will include information about the benefits of exercise, motivation, and positive messages about coping with pain.
62535630|NCT05892692|NO_INTERVENTION|EMA-only Condition|To examine situational precipitants of sexual assault, risky sexual behavior, and substance-use among freshman women (N=100) using EMA for 6 weeks. To examine within- and between-persons factors that may influence the relationships among these situational precipitants and adverse consequences.
62535631|NCT05892692|OTHER|Focus Group|To gather preliminary research about the feasibility of an EMI sexual assault intervention prior to an experimental condition. A small group of freshman women (N=20) will participate in an EMI protocol for six weeks, followed by providing feedback about their experience, including issues with phrasing, technical issues, and convenience.
62714525|NCT05958589|ACTIVE_COMPARATOR|General anesthesia|General anesthesia with intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg)
62161783|NCT04736602|EXPERIMENTAL|Triptorelin Pamoate 15mg for injection|"Triptorelin was injected at day 1 and month 3.~If participants were willing to enter the extension phase, two additional Triptorelin injections were given at month 6 and month 9."
62161784|NCT05452005|EXPERIMENTAL|Experimental [18F]-αvβ6-BP|Patients receive \[18F\]-αvβ6-BP BP IV and then undergo a PET/CT scan over 30 minutes 60 minutes post-injection.
62161785|NCT05542836||Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
62161786|NCT05542836||Standard postoperative activity restrictions|Standard conservative postoperative activity and return to work recommendations
62161787|NCT06720792|ACTIVE_COMPARATOR|Game play|Participants receive an email with the link to book a slot to play the Escape Game. The date when students can play the Escape Game is defined when 4 students are available at the same slot. Students receive a further email with all the instructions to play the game.
62161788|NCT06720792|PLACEBO_COMPARATOR|email on mental health-related information|Students receive an email detailing mental health services and describing the most common mental health problems. Participants are randomized so that the two groups are similar in terms of sex, age and field of study (stratified balanced randomization).
62161789|NCT06237465|EXPERIMENTAL|Experimental|During their treatment visit, subjects will receive Botulinum Toxin-A in one axillae and normal saline in the other, in a double-blinded fashion.
62161790|NCT06237465|PLACEBO_COMPARATOR|Placebo Comparator|At three months, Group 1 subjects will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
62161791|NCT06669533|EXPERIMENTAL|Non-pregnant women|Non-pregnant women will either receive 600 mcg misoprostol (3 tablets) or identical placebo 3 (tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
62161792|NCT05986279|EXPERIMENTAL|Rehab|6 weeks of vestibular physical therapy guided by the use of the MINDGAPS decision support system
62161793|NCT05986279|NO_INTERVENTION|Observational|Normative data development of performance on vestibular measures following mTBI
62161794|NCT05656651|EXPERIMENTAL|Cancer patients|Single exercise intervention following a HIIT protocol, duration \~20 mins
62535632|NCT05892692|EXPERIMENTAL|EMA/EMI Condition|To examine whether an EMA/EMI condition, relative to an EMA-only and a minimal assessment-only condition, decreases incidents of sexual assault, risky sexual behavior, and alcohol use among freshman women (N=288). It is hypothesized that the 6-week EMA/EMI condition, relative to the other conditions, will be associated with lower rates of assault, risky sexual sex, and substance use from baseline to a 6-month followup.
62161795|NCT05656651|ACTIVE_COMPARATOR|Healthy adults|Single exercise intervention following a HIIT protocol, duration \~20 mins
62161796|NCT04354623||High Risk Subjects (n=50)|All subjects will be recruited from falls and geriatrics clinics at Vancouver General Hospital. These clinics see about 2500 patients per year and are currently used for research recruitment. Each clinic patient has gait speed measured, which will allow to recruit both high and low risk fallers. This test will allow us to recruit 50 subjects at marked risk for falls, providing us with prospectively gathered dataset of greater than 100 events, five times higher than any other sensor study.
62161797|NCT04354623||Low Risk Subjects (n=50)|We will use newspaper advertisements to recruit and then screen low risk subjects. All subjects will have a gait speed \> 0.8 m/s and have had no falls in the last year.
62161798|NCT04332991|ACTIVE_COMPARATOR|Hydroxychlorquine|Participants assigned to the hydroxychloroquine arm will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
62161799|NCT04332991|PLACEBO_COMPARATOR|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
62161800|NCT05159076|EXPERIMENTAL|Behavioral Intervention|Participants will undergo an eight-week behavioral intervention protocol (once a week) aimed at increasing the level of physical activity, consisting of a brief educational program: brief education for asthma and benefits of physical activity and behavioral intervention based on Social Cognitive Theory and the Theory of Stages of Behavior Change.
62161801|NCT05802498|NO_INTERVENTION|control GROUP|This group will perform 8 continuous weeks of treatment, 5 days a week, for a total of 180 minutes, including muscle stretching, joint range increase with passive and active assisted mobilization sessions of the scapulohumeral and pelvic girdles. Motor coordination exercises. Postural exercises with exercises for trunk control in sitting and standing positions with feedback and feed-forward techniques. gait training; gait training; proprioceptive exercises and exercises to maintain static and dynamic balance in monopodalica; strengthening of trunk muscles; postural exercises, muscle relaxation/stretching, release of the tracks; re-education in postural passages and transfers with fall prevention strategies.
62535633|NCT04645264|EXPERIMENTAL|Indwelling Foley|Indwelling Foley placed during surgery
62535634|NCT04645264|ACTIVE_COMPARATOR|Straight Catheter|straight catheterization (in-and-out straight catheterization) will take place at the end of the surgery
62535635|NCT04645264|NO_INTERVENTION|No Catheter|Patient is not catheterized
62535636|NCT04056286|EXPERIMENTAL|Healthy + Whey|Healthy (overnight fast)
62535637|NCT04056286|EXPERIMENTAL|Catabolic + Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
62535638|NCT04056286|EXPERIMENTAL|Catabolic + 3-OHB / Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
62535639|NCT03214796||Albumin infusion|Patients with decompensated cirrhosis and an indication for routine human albumin infusion
62535640|NCT05485701||Perinatal women|Women will be recruited in their first trimester of pregnancy and followed-up until 6 months post-partum. This is the 'exposed' group.
62535641|NCT05485701||Non-perinatal women|Non-perinatal women will be recruited as the 'non-exposed' group and followed-up over the same duration as the perinatal group.
62714526|NCT01164007|EXPERIMENTAL|Dacarbazine + Bevacizumab|Participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease will receive dacarbazine and bevacizumab until disease progression, unacceptable toxicity, participant withdrawal, or physician decision to discontinue.
62714527|NCT06694233||Obstetric population candidate for aspirin prescription|Moderate- and high-risk obstetric population
62161802|NCT05802498|EXPERIMENTAL|irma group|This group will perform 8 continuous weeks of treatment, 5 days a week, for a total of 180 minutes, including muscle stretching, increasing joint range with assisted passive and active mobilisation sessions of the scapulohumeral and pelvic girdles. Motor coordination exercises. Postural exercises with exercises for trunk control in sitting and standing with feedback and feed-forward technique. Gait training; gait training; proprioceptive exercises and static and dynamic balance maintenance in monopodalics; trunk muscle strengthening; postural exercises, muscle relaxation/relaxation, caterpillar release; re-education in postural transitions and transfers with fall prevention strategies. Prior to neuromotor rehabilitation treatment, the subjects will undergo rehabilitation training using the NIRVANA augmentative reality system.
62161803|NCT01489163|EXPERIMENTAL|Lifestyle Counseling|
62161804|NCT01489163|NO_INTERVENTION|Control|
62161805|NCT05088733|EXPERIMENTAL|Yang Yin Fu Zheng Jie Du therapy|
62161806|NCT05088733|PLACEBO_COMPARATOR|Routine medical care|
62161807|NCT06473571|ACTIVE_COMPARATOR|Intervention Protocol (The 3GT)|"Participants will be asked to identify three things that went well that day and their role for this occurring \[What went well today, and what was your role in making it happen? as adapted from (Sexton \& Adair, 2019)\]. They will be asked to engage in this exercise for 15 days during the evening."
62161808|NCT06473571|ACTIVE_COMPARATOR|Control Group|Participants will be asked to reflect on early memories of their life, with no specific prompts provided, for 15 days during the evening. This activity is consistent with prior efficacy studies of 3GT (Seligman et al., 2005).
62161809|NCT01879488|ACTIVE_COMPARATOR|Nebulization during pressure support ventilation|Patients ventilated in pressure support mode during nebulization
62161810|NCT01879488|ACTIVE_COMPARATOR|Nebulization during volume assist control mode|Patients ventilated in volume assist control mode during nebulization
62161811|NCT01964118|OTHER|Control group|The participants randomized to the crossover group begin study participation as a control group (no changes in food intake) for the first 6 months and switch to IF for the remaining 6 months of the study.
62161812|NCT01964118|EXPERIMENTAL|Intermittent Fasting group|Participant with a BMI between 28 and 35 kg/m2 will fast 3 non-consecutive days per week, whereas participant with a BMI between 24 and 27.9 kg/m2 will fast 2 non-consecutive days per week. Individuals following intermittent fasting (IF) will work with the study dietitian to design their weekly meal plans and menus for the non-fasting days. The subjects following IF will be asked to skip breakfast, lunch, dinner, snacks, and calorie-containing beverages on the fast days, but we will give them the option to consume at dinner a big salad (i.e. non-starchy raw and/or cooked vegetables dressed with 2 tablespoons of salad dressing prepared with vegetable oil, vinegar and seasonings).
62161813|NCT04415580|EXPERIMENTAL|Vestibular Rehabilitation Group|
62161814|NCT04415580|ACTIVE_COMPARATOR|Conventional rehabilitation Group|
62161815|NCT01581476|ACTIVE_COMPARATOR|Statin|Participants receive active statin and placebo ACE Inhibitor
62161816|NCT01581476|ACTIVE_COMPARATOR|Angiotensin-converting enzyme inhibitor|Participants receive active ACE Inhibitor and placebo statin
62161817|NCT01581476|PLACEBO_COMPARATOR|Placebo|Participants receive placebo ACE Inhibitor and placebo statin
62161818|NCT01581476|OTHER|Combination therapy|Participants receive both active ACE Inhibitor and active Statin
62161819|NCT02920645||AVM-related ICH patients|patients that suffered intracerebral hemorrhage (ICH) due to a ruptured artery-venous malformation (AVM)
62535642|NCT04332965|EXPERIMENTAL|Patients with chronic periodontitis|Patients with CP (n=30) had teeth with 30% periodontal bone loss and ≥ 2 non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and bleeding on probing.
62161820|NCT06423183|EXPERIMENTAL|Mindfulness-Based Team Resilience Training|
62161821|NCT02920216|EXPERIMENTAL|eligible patient for a salvage surgery|
62161822|NCT05465187||Patients|Adults patients aged for more than 18 years old, admitted in an intensive care unit in Grand-Est region in France, for whom a decision of withholding or withdrawing of life-sustaining therapy is taken during the month of study.
62161823|NCT04067115|EXPERIMENTAL|Trabectedin and Irinotecan|Trabectedin will be delivered by infusion on day 1 followed by 2 doses on irinotecan delivered by infusion for one hour on day 2 and day 4 of 21 day cycles. Some patients will receive an 18F-FLT Imaging scan prior to the first administration of trabectedin and once after administration of trabectedin.
62535643|NCT04332965|EXPERIMENTAL|Patients with gingivitis|Participants with G (n=30) had gingival index ≥ 2 and other inflammation signs.
62161824|NCT02287428|EXPERIMENTAL|Coh 1 (Original Cohort): Standard RT Followed by NeoVax|"After the screening procedures confirm participant eligible to participate in the research study (must be registered to within 6 weeks of resection):~* \~ 6 weeks of standard radiation therapy (RT) followed by an RT-recovery period.~* During that time, participant NeoAntigen Vaccine-Preparation is created (process takes \~ 12 weeks)~After participant recovers from RT and vaccine is created, participant will re-screen to confirm participant is eligible to receive study vaccinations. Once registered, participant will proceed to receive study vaccinations:~- NeoAntigen Vaccine: NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases (\~ 7 months total: 5 priming followed by 2 boost vaccine administrations)"
62535644|NCT04332965|NO_INTERVENTION|Participants with periodontal healthy|The H group (n=30) consisted of individuals with no attachment loss, no history of periodontal disease, PD ≤3 mm, and whole-mouth bleeding scores \<10%.
62535645|NCT03636412|EXPERIMENTAL|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
62535646|NCT03636412|NO_INTERVENTION|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
62535647|NCT01136967|EXPERIMENTAL|Cohort 1 (V600E BRAF negative)|Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.
62161825|NCT02287428|EXPERIMENTAL|Coh 1a: Pembrolizumab w Std RT Followed by NeoVax + Pembro|"* RT: Standard RT (60Gy) over 6 weeks~* Pembrolizumab: Starts within 2 weeks of start of RT, and continues every 3 weeks for up to 2 years~* NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 \[priming doses\], 78 and 134 \[booster doses\] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
62161826|NCT02287428|EXPERIMENTAL|Coh 1b: Std RT Followed by NeoVax + Pembrolizumab|"* RT: Standard RT (60Gy) over 6 weeks~* Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~* NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 \[priming doses\], 78 and 134 \[booster doses\] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
62161827|NCT02287428|EXPERIMENTAL|Coh 1c: Std RT (+ 1 dose Pembro) Followed by NeoVax & Pembo|"* RT: Standard RT (60Gy) over 6 weeks~* Pembrolizumab: Single dose of pembrolizumab administered within 2 weeks of start of RT; re-starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years.~* NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 \[priming doses\], 78 and 134 \[booster doses\] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
62161828|NCT02287428|EXPERIMENTAL|Coh 1d: Std RT+TMZ Followed by 6 Cyc TMZ + NeoVax + Pembro|"• RT: Standard RT (60Gy) + concurrent daily temozolomide (TMZ) over 6 weeks. Concurrent TMZ @ 75 mg/m2/day for 6 weeks.~Followed by:~* 6 cycles of Adjuvant temozolomide (TMZ): Starts 4-6 weeks after completion of RT. TMZ (150-200 mg/m2/day) on days 1-5 of each 28-day cycle for 6 cycles.~* Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~* NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 \[priming doses\], 78 and 134 \[booster doses\] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
62161829|NCT04890249|EXPERIMENTAL|Investigational Lens Device #1|Investigational IOL Model C1V000
62161830|NCT04890249|EXPERIMENTAL|Investigational Lens Device #2|Investigational IOL Model C2V000
62161831|NCT04890249|ACTIVE_COMPARATOR|Control Lens|Control IOL Model ICB00
62161832|NCT02119611|OTHER|Single-arm|Therapy
62161833|NCT01289899|EXPERIMENTAL|Arm A|BR-A-657 120mg or placebo
62161834|NCT01289899|EXPERIMENTAL|Arm B|BR-A-657 360mg or placebo
62161835|NCT06720740|ACTIVE_COMPARATOR|Standard of Care Ureteral Stent|
62161836|NCT06720740|EXPERIMENTAL|RELIEF Ureteral Stent|
62161837|NCT04836559|EXPERIMENTAL|JNJ-40411813|Participants will receive JNJ-40411813 twice a day (bid) up to 12 weeks in double blind period. Up to 3 different doses (low, medium, high) of JNJ-40411813 will be administered in this study. Participants will also receive concomitant anti-epileptic drugs (AEDs) one of which must include levetiracetam or brivaracetam. Immediately after the last study drug intake by the participants in the double-blind period, participants will enter into a 2-year open label extension (OLE) period and continue receiving JNJ-40411813 as well as the AEDs during OLE period.
62161838|NCT04836559|PLACEBO_COMPARATOR|Placebo|Participants will receive JNJ-40411813 matching placebo (bid) up to 12 weeks. Participants will also receive concomitant AEDs one of which must include levetiracetam or brivaracetam during double blind period. Participants who had been receiving placebo in double blind period will start with the JNJ-40411813 dose in the OLE period.
62161839|NCT06027424||Non-OSA|AHI \< 5 events/h (AHI, apnea-hypopnea index, the number of apneas and hypopneas per hour of total sleep time)
62161840|NCT06027424||Mild OSA|5 events/h ≤ AHI \< 15 events/h
62161841|NCT06027424||Moderate OSA|15 events/h ≤ AHI \< 30 events/h
62161842|NCT06027424||Severe OSA|AHI ≥ 30 events/h
62161843|NCT05489770|ACTIVE_COMPARATOR|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|"Constituents: 29.4 % (w/w) Black Elderberry (Sambucus nigra) fruit juice, 70% (w/w) of glucose syrup.~The main ingredient is black elderberry juice and it meets the requirements of the European Parliaments Directive (2012/12/EU) relating to fruit juices. The product also contains two food additives: citric acid (E330) as acidity regulator and potassium sorbate (E202) as preservative. Primary packaging: Plastic Polyethylene terephthalate (PET) amber bottles 120ml. Caps are white tamper-proof caps with security seal. Secondary Packaging: None. Outer Carton: Cardboard 376mm x 191mm x 116mm. 32 bottles per case."
62161844|NCT05489770|PLACEBO_COMPARATOR|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|"Constituents: 70% (w/w) of glucose syrup, Flavouring agent: Elderberry Blossom. Colourants:~Carmoisine (311804) (E-122) and Brilliant Black (419358) E-151. The product also contains two food additives: citric acid (E330) as acidity regulator and potassium sorbate (E202) as preservative. Primary packaging: Plastic PET amber bottles 120ml. Caps are white tamper-proof caps with security seal. Secondary Packaging: None. Outer Carton: Cardboard 376mm x 191mm x 116mm. 32 bottles per case."
62161845|NCT04557098|EXPERIMENTAL|Part 3: Teclistamab|Participants will receive teclistamab subcutaneously (SC) at recommended Phase 2 dose (RP2D) in Cohort A and Cohort C.
62535648|NCT01136967|EXPERIMENTAL|Cohort 2 (V600E BRAF positive)|Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.
62161846|NCT04696809|EXPERIMENTAL|Japanese Participants with Relapsed or Refractory Multiple Myeloma (MM)|Japanese participants will receive Teclistamab subcutaneously (SC) at four dose levels. Cohort 1 will receive Teclistamab at Dose 1 and 2 (step-up doses) prior to first treatment dose on Day 1 followed by Dose 3 weekly (that is, on Days 1,8, and 15 of a 21-day cycle). Cohort 2 will receive Teclistamab at Dose 1 and 4 (step up doses) prior to first treatment dose on Day 1 followed by Dose 5 weekly. Cohort 3 will receive Teclistamab at Dose 1, 4, and 5 (step up doses) prior to first treatment dose on Day 1 followed by Dose 6 weekly. Cohort 4 will receive Teclistamab at Dose 1, 4, and 5 (step up doses) prior to first treatment dose on Day 1 followed by Dose 7 weekly for (2 cycles), then biweekly (cycle 3 to 6) on Days 1 and 15 and monthly (cycle 7) on Day 1 of 1 28-day cycle. In Phase 2 , participants will receive Teclistamab SC at Dose 1 and 4 (step up doses) up to 8 days prior to first treatment dose on Day 1 followed by Dose 5 on Days 1,8,15, and 22 of a 28-day cycle.
62535649|NCT06389539|EXPERIMENTAL|SBD111 medical food|This group will receive SBD111 medical food capsules to be consumed over 18 months.
62535650|NCT06389539|PLACEBO_COMPARATOR|Placebo|This group will receive placebo capsules to be consumed over 18 months.
62535651|NCT04638530|OTHER|Residents|All residents will participate in the activity
62161847|NCT06260722|EXPERIMENTAL|Retatrutide Dose Level 1|Participants will receive retatrutide administered subcutaneously (SC).
62161848|NCT06260722|EXPERIMENTAL|Retatrutide Dose Level 2|Participants will receive retatrutide administered SC.
62161849|NCT06260722|ACTIVE_COMPARATOR|Semaglutide|Participants will receive semaglutide administered SC.
62161850|NCT05384808|EXPERIMENTAL|No dog present|Conventional psychotherapy with no dog being present.
62161851|NCT05384808|EXPERIMENTAL|Dog present and active part of therapeutic narrative.|The dog is actively integrated into the therapeutic narrative.
62161852|NCT05384808|EXPERIMENTAL|Dog present but not active part of therapeutic narrative.|The dog is present but not actively integrated into the therapeutic narrative.
62161853|NCT00908193|EXPERIMENTAL|1|robot-assisted coelioscopy
62161854|NCT00908193|ACTIVE_COMPARATOR|2|conventional coelioscopy
62161855|NCT05570578|ACTIVE_COMPARATOR|HD-tDCS|high-density transcranial direct current stimulation (HD-tDCS) over Broca's area
62161856|NCT05570578|SHAM_COMPARATOR|sham-tDCS|sham transcranial direct current stimulation. The same setup will be used as in the HD-tDCS arm, except that the current will be ramped up for 30 seconds and then switched off. This does not lead to neural effects, but the patients have a similar sensation.
62161857|NCT00877500|EXPERIMENTAL|Group I (ixabepilone)|Participants receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62161858|NCT00877500|ACTIVE_COMPARATOR|Group II (standard of care)|Participants receive standard of care for 18 weeks.
62161859|NCT05913609|EXPERIMENTAL|Yaari Extractor group|Prospective experimental arm
62161860|NCT05913609|NO_INTERVENTION|Control group|Historical control arm - retrospective review of medical records at the same study sites
62161861|NCT04291560|EXPERIMENTAL|Prenatal Heart Smart Intervention|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, the group will complete a sequential static stretching exercise 5 days per week for 10 weeks. The stretching exercise consists of 20 seconds of stretching, for 3 repetitions per muscle group.
62161862|NCT04291560|NO_INTERVENTION|Usual Care (Control)|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, this group will complete moderate-intensity walking 5 days per week for 10 weeks in accordance to usual care.
62161863|NCT06462768||Adult with SSc|Adult with SSc
62161864|NCT06462768||Other connective tissue disease|Adult with other connective tissue disease
62161865|NCT06462768||Control|Healthy adult volunteer
62161866|NCT00447499|EXPERIMENTAL|Somatuline Autogel (lanreotide acetate)|Somatuline Autogel (lanreotide acetate) Injection
62535652|NCT02640053|EXPERIMENTAL|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
62535653|NCT02640053|ACTIVE_COMPARATOR|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
62535654|NCT02185716|ACTIVE_COMPARATOR|local infiltration|Group L (n=25) will be given total 30 ml 0.25 % levobupivacaine infiltration around trocar-site with injector in sterilized conditions without administering TAP block at the end of the operation
62161867|NCT05831995|EXPERIMENTAL|Experimental Monotherapy Dose Escalation|"A classic 3+3 design will be used to explore the maximum tolerated dose (MTD) and to determine the recommended phase II dose (RP2D). Three to four patients will be enrolled to ensure at least 3 evaluable patients for DLT (Dose Limiting Toxicity). ABM-168 monotherapy will be conducted in seven provisional dose levels starting at 0.5mg oral administration per day and up to and including 12mg oral administration. Each treatment cycle is 28-days. DLT will be evaluated in the first 28-day cycle. Patients will receive daily doses of ABM-168 until disease progression; intolerable toxicity; withdrawal consent; or other clinical observation is met."
62161868|NCT05831995|EXPERIMENTAL|Experimental Monotherapy Dose Expansion-1|Expansion will be conducted in the adult patients with advanced solid tumors that carry either RAS, RAF or NF-1 mutations. Cohort EX1 will enroll the patients with preferred indications (i.e., melanoma, colon cancer, lung cancer, and pancreatic carcinoma) who had confirmed RAS, RAF or NF-1 mutations and measurable target lesion(s) at baseline. Patients with measurable brain metastases lesion(s) at baseline are highly preferred. Up to 15 evaluable patients will be enrolled for each into each preferred indication. Other indication(s) that show confirmed response, complete response (CR) or partial response (PR) in at least one subject in the dose escalation study will facilitate the preferred indication(s) for Cohort EX1 enrollment as well.
62161869|NCT05831995|EXPERIMENTAL|Experimental Monotherapy Dose Expansion-2|Expansion will be conducted in the adult patients with advanced solid tumors that carry either RAS, RAF or NF-1 mutations. Cohort EX2 will enroll the patients who had primary CNS tumors with confirmed RAS, RAF or NF-1 mutations at baseline. Up to 30 evaluable patients will be enrolled.
62161870|NCT00729261|EXPERIMENTAL|armA I|Patients remain intubated until the patients Glasgow coma score improves to greater than 8.
62161871|NCT00729261|EXPERIMENTAL|arm 2|Patients that meet standard airway and ventilatory criteria for extubation but have a Glasgow coma score of less than or equal to 8 are immediately extubated.
62161872|NCT05199935|EXPERIMENTAL|Intervention|Are shown the intervention video after filling out baseline questionnaire
62161873|NCT05199935|OTHER|Control|Are shown a control at Time 0, baseline and the intervention video after main outcome data is collected at Time 1
62535655|NCT02185716|NO_INTERVENTION|Control|Only routine general anesthesia will be applied
62535656|NCT02185716|EXPERIMENTAL|TAP|Group T (n=25) will be given bilateral total 30 ml 0.25 % levobupivacaine administering TAP block under the guidance of ultrasound at the preoperative period.
62535657|NCT05873829|EXPERIMENTAL|Intervention Group|Hand-foot exercises were applied to the intervention group.
62535658|NCT05873829|NO_INTERVENTION|Control Group|No intervention other than standard care was applied to the control group.
62714528|NCT05343988|EXPERIMENTAL|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|The peripheral neurostimulator, PENFS device, will be placed over the external ear of enrolled patients. The device will continuously stay in place for 120 hours.
62161874|NCT05683639|NO_INTERVENTION|Standard protocol|The standard protocol comprises no heating of the aspiration needle.
62161875|NCT05683639|EXPERIMENTAL|Warming protocol|The aspiration needle will be warm-up overnight the day before the oocyte pick-up procedure
62161876|NCT01740284|ACTIVE_COMPARATOR|Grazax + Aerius|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (desloratidine) 2.5 mg
62161877|NCT01740284|PLACEBO_COMPARATOR|Grazax + Placebo|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (Placebo)
62161878|NCT01811329|ACTIVE_COMPARATOR|Palm fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
62535659|NCT05384080||Participants With IBD|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab IV induction treatment in accordance with the current Summary of Product Characteristics (SmPC) and National Drug Program (NDP) at baseline or receiving vedolizumab ongoing or maintenance IV treatment with the option to switch to vedolizumab SC treatment, will be observed prospectively for 24 months.
62535660|NCT03875859|EXPERIMENTAL|Remetinostat|Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.
62535661|NCT02174380|NO_INTERVENTION|Passive Household Contact Evaluation|Passive case finding refers to the current National TB program of voluntary self-reporting of symptomatic patients to the health system for diagnosis of TB and initiation of effective chemotherapy
62535662|NCT02174380|EXPERIMENTAL|Active Household Contact Evaluation|The intervention program includes households visits of all newly diagnosed TB cases enrolled in TB treatment within a DISA NTP clinic in SJL district. During the home visit health staff will evaluate all household contacts for symptoms of active TB. Any person reporting cough for \>14 days will be asked to provide a spot sputum for microscopy and referred to the clinic for chest x-ray and clinical evaluation. All household contacts ≤19 years will be referred to the clinic for chest x-ray, pediatric clinical evaluation and initiation of treatment for active or latent TB as required. Counseling including TB infection control practices and importance of diagnosis and treatment completion for TB cases will be provided to household members.
62535663|NCT03330821|EXPERIMENTAL|Treatment (idarubicin, cytarabine, pevonedistat)|"INDUCTION: Patients receive idarubicin IV over 10-15 minutes on days 1-3, cytarabine IV over 1-3 hours on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Patients with gross residual disease on day 14 bone marrow may receive a second course of induction chemotherapy.~CONSOLIDATION: Patients who achieve CR and will not undergo bone marrow transplant receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28-35 days for 4 courses in the absence of disease progression or unaccepted toxicity."
62535664|NCT00802594|EXPERIMENTAL|DB289|
62535665|NCT05191017|EXPERIMENTAL|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with enzalutamide until the recommended Phase 2 combination dose (RP2cD) is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
62535666|NCT05191017|EXPERIMENTAL|Phase 2|"NUV-422 will be administered orally at the RP2cD in combination with enzalutamide.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
62535667|NCT03753763|EXPERIMENTAL|Active|Safinamide methanesulfonate film-coated tablets once daily
62535668|NCT03753763|PLACEBO_COMPARATOR|Placebo|Safinamide Methanesulfonate matching placebo film-coated tablets once daily
62535669|NCT02169700|EXPERIMENTAL|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling.
62535670|NCT02169700|SHAM_COMPARATOR|Sham Ischemic compression. Dry Needling|Sham Ischemic compression was carried out after dry needling.
62161879|NCT01811329|EXPERIMENTAL|Palm fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
62161880|NCT01811329|ACTIVE_COMPARATOR|Dairy fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.
62535671|NCT02169700|NO_INTERVENTION|Control group|No intervention. Control group
62535672|NCT05367050|ACTIVE_COMPARATOR|Treatment|"Patients participate in the Lucid Lane therapy program including working with a mental health pain coach for up to 4 weeks before surgery and 4 weeks after surgery.~All patients receive therapy provided by Lucid Lane, for 4 weeks after surgery"
62535673|NCT05367050|ACTIVE_COMPARATOR|Control|"Patients will participate in a a surgery preparedness course provided by the VA before surgery (Standard of Care) and Lucid Lane therapy after surgery~All patients receive therapy provided by Lucid Lane, for 4 weeks after surgery"
62535674|NCT03603379|EXPERIMENTAL|C225-ILs-dox i.v.|C225-ILs-dox administered intravenously
62535675|NCT02005263|EXPERIMENTAL|Salpingography|Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
62535676|NCT01466010||osteoid osteoma|patients with osteoid osteoma at any location
62535677|NCT00182468|EXPERIMENTAL|1|Women are screened for intimate partner violence prior to seeing a health care provider.
62535678|NCT00182468|NO_INTERVENTION|2|Women see their health care provider without being asked about intimate partner violence.
62535679|NCT04675619|EXPERIMENTAL|Oral pirfenidone|Pirfenidone will be administered orally in 267 mg capsules taken with food. The dose will be titrated over 2 weeks from one capsule three times a day during Week 1 to two capsules three times a day during Week 2 then maintenance dose (three capsules three times a day Week 3.
62535680|NCT04675619|EXPERIMENTAL|Standard care|Standard care
62535681|NCT02789618|ACTIVE_COMPARATOR|A01|Toothpaste containing calcium silicate and Sodium Monofluorophosphate (1450ppm F) and a gel containing sodium fluoride (1450ppm F)
62161881|NCT01811329|EXPERIMENTAL|Dairy fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
62161882|NCT06438549|EXPERIMENTAL|Integrated HCP-CHW Intervention Arm|CHW visit with brief tobacco cessation intervention.
62161883|NCT06438549|OTHER|Control arm|Standard of Care
62161884|NCT06511076|EXPERIMENTAL|Treatment Sequence AB|Study participants randomized to this arm will receive a single subcutaneous (sc) injection of zilucoplan using pre-filled syringe (ZLP-PFS; Treatment A) as reference and a single sc injection of zilucoplan using an autoinjector (ZLP-AI; Treatment B) as test in the treatment sequence A-B on Day 1 of each Treatment Period.
62161885|NCT06511076|EXPERIMENTAL|Treatment Sequence BA|Study participants randomized to this arm will receive a single sc injection of zilucoplan using pre-filled syringe (ZLP-PFS; Treatment A) as reference and a single sc injection of zilucoplan using an autoinjector (ZLP-AI; Treatment B) as test in the treatment sequence B-A on Day 1 of each Treatment Period.
62161886|NCT04951609|EXPERIMENTAL|Seltorexant|Participants will receive weight based dose of Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6). Participants will continue baseline selective serotonin reuptake inhibitor (SSRI) antidepressant (Fluoxetine or escitalopram) orally once daily.
62161887|NCT04951609|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo tablets to seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
62161888|NCT02846142|ACTIVE_COMPARATOR|SAD PTI-428|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
62161889|NCT02846142|PLACEBO_COMPARATOR|SAD placebo|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
62161890|NCT02846142|ACTIVE_COMPARATOR|MAD PTI-428|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
62161891|NCT02846142|PLACEBO_COMPARATOR|MAD placebo|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
62161892|NCT02846142|EXPERIMENTAL|OC (ethinyl estradiol and levonorgestrel) DDI Period A|Treatment period A will consist of once daily oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).
62161893|NCT02846142|ACTIVE_COMPARATOR|OC (ethinyl estradiol and levonorgestrel) DDI Period B|Treatment period B will randomize subjects to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
62161894|NCT02846142|PLACEBO_COMPARATOR|OC (ethinyl estradiol and levonorgestrel) DDI|Treatment period B will randomize subjects 4:1 to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
62161895|NCT05966896|EXPERIMENTAL|Epidural stimulation with Physical Therapy|"Stimulation parameters will be optimized for each lower extremity and joint movement. During physical therapy sessions, electrode configurations may be adjusted as needed to optimize stimulation frequencies, and voltage intensity ranges to best enable voluntary control of lower extremity (ankle, knee, and hip) flexion and extension, as well as standing.~Intensive physical therapy will consist of 3 visits per week over the course of 6 months directed by a licensed physical therapist with over a decade of experience working with individuals with spinal cord injury, and the epidural stimulator will be ON continuously during these sessions. Physical therapy will involve neurorehabilitation to facilitate voluntary lower extremity movement in the presence of stimulation, with the research participants in the supine, seated, and standing positions."
62161896|NCT04734236|ACTIVE_COMPARATOR|New technique group|
62161897|NCT04734236|SHAM_COMPARATOR|Xpert group|
62161898|NCT05850858||Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
62161899|NCT05850858||patient liver cirrhosis (child B,C)|
62161900|NCT05850858||normal individuals|
62161901|NCT05449756||Children who participated in randomised clinical trail, called TEMPO, in their first year of life|Children who participated in randomised clinical trail, called TEMPO, in their first year of life
62161902|NCT06715163|EXPERIMENTAL|Dose 1 (42mg) of DAO|Lowest dose of DAO administered in this study
62161903|NCT06715163|PLACEBO_COMPARATOR|Placebo tablets|placebo tablets
62161904|NCT06715163|EXPERIMENTAL|Dose 2 (84mg) of DAO|Medium dose of DAO administered in this study
62161905|NCT06715163|EXPERIMENTAL|Dose 3 (210mg) of DAO|Highest dose of DAO administered in this study
62161906|NCT05556512|EXPERIMENTAL|Tirzepatide|Participants will receive escalated doses of tirzepatide subcutaneously (SC) up to a maximum tolerated dose.
62161907|NCT05556512|PLACEBO_COMPARATOR|Placebo|Participants will receive tirzepatide matched placebo.
62535682|NCT02789618|ACTIVE_COMPARATOR|B99|Toothpaste containing Stannous Fluoride and a dentinal bonding agent
62535683|NCT02789618|PLACEBO_COMPARATOR|M89|Toothpaste containing sodium fluoride (1450ppm F)
62535684|NCT03449680|EXPERIMENTAL|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
62535685|NCT03449680|PLACEBO_COMPARATOR|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
62535686|NCT03409393|EXPERIMENTAL|Intervention Group|The COPUS intervention plus usual care (OPUS treatment).
62535687|NCT03409393|OTHER|Control Group|Usual care (OPUS treatment).
62161908|NCT04181827|EXPERIMENTAL|Arm A: PVd or DPd (Standard Therapy)|Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m\^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
62161909|NCT04181827|EXPERIMENTAL|Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])|Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 (cilta-cel) along with conditioning regimen (cyclophosphamide 300 milligram \[mg\]/m\^2 intravenous \[IV\] and fludarabine 30 mg/m\^2 IV daily, for 3 days), and JNJ-68284528 (cilta-cel) infusion 0.75 \* 10\^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
62161910|NCT05741866|ACTIVE_COMPARATOR|Control|Bordered Polyurethane Dressing
62161911|NCT05741866|EXPERIMENTAL|Intervention|CHG Bordered Polyurethane Dressing
62161912|NCT06049199|EXPERIMENTAL|Hearing impaired group|The hearing impaired group will compare the reference condition (SpeechEnhancer on) with the intervention condition (SpeechEnhancer off).
62161913|NCT06206616||Celiac Disease Children|Pediatric patients affected by newly diagnosed CD according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will be evaluated before the start of gluten-free diet and after 6 months of gluten-free diet.
62161914|NCT06721741|ACTIVE_COMPARATOR|Stainless steel crown|Control group
62161915|NCT06721741|EXPERIMENTAL|Bioflex crown|Intervention group
62161916|NCT00557154|EXPERIMENTAL|1|Ultrasound used to visualize peripheral venous anatomy. This guides subsequent attempts at venipuncture.
62161917|NCT00557154|ACTIVE_COMPARATOR|2|Routine venipuncture using standard methods.
62161918|NCT03607578|OTHER|Control Group - Minimal Intervention|Minimal intervention
62161919|NCT03607578|EXPERIMENTAL|Protection Routine 1|
62161920|NCT03607578|EXPERIMENTAL|Protection Routine 2|
62161921|NCT03607578|EXPERIMENTAL|Protection Routine 1+2|
62161922|NCT06701149|EXPERIMENTAL|Rademikibart injection|Received subcutaneous injection administration on the morning of the first day .
62161923|NCT06701149|ACTIVE_COMPARATOR|CBP-201 injection|Received subcutaneous injection administration on the morning of the first day.
62161924|NCT06571019|EXPERIMENTAL|Intervention|Households will receive sunlight reflecting 'cool roof' coating on their roofs.
62161925|NCT06571019|NO_INTERVENTION|Control|No cool roof application. Households will keep their original roofing for the duration of the trial.
62161926|NCT06236815|EXPERIMENTAL|delta-9-THC|
62161927|NCT06236815|EXPERIMENTAL|delta-8-THC|
62161928|NCT06236815|PLACEBO_COMPARATOR|Placebo|
62161929|NCT05129592|ACTIVE_COMPARATOR|Nicotine corrective control|A factual message about nicotine that does not contain a causal explanation for what actually causes tobacco-caused disease or an explanation for why the misperception that nicotine causes cancer may have come to be believed.
62161930|NCT05129592|EXPERIMENTAL|Nicotine corrective with causal explanation|A factual message about nicotine that contain a causal explanation for what actually causes tobacco-caused disease: tar and chemicals created in tobacco smoke when tobacco is lit on fire.
62161931|NCT05129592|EXPERIMENTAL|Nicotine corrective with reason for misperception|A factual message about nicotine that contains an explanation for why the misperception may have come to be believed: that health messaging often discuses nicotine and tobacco-caused disease at the same time and people incorrectly make the connection that nicotine causes cancer.
62161932|NCT05129592|EXPERIMENTAL|Nicotine corrective with both components of coherence|A factual message about nicotine that contains both a causal explanation for what actually causes tobacco-caused disease and an explanation for why the misperception may have come to be believed.
62161933|NCT06212622||STANDARD CARE WITH ORAL OXYCODONE|"These patients will receive oral oxycodone prior to their post operative day 1 and 2 physiotherapy sessions~The dose is age dependent (and also on frailty status):~\< 65 years old: Oxycodone 5mg immediate release~65 - 85 years old: Oxycodone 4mg immediate release~\> 85 years old: Oxycodone 3mg immediate release~\<50kg or particularly frail: Oxycodone 2mg immediate release"
62161934|NCT06212622||INTERVENTION GROUP WITH SUBCUTANEOUS ALFENTANIL|"These patients will receive subcutaneous alfentanil prior to their post operative day 1 and 2 physiotherapy sessions~This is 100 micrograms as a subcutaneous injection"
62535688|NCT03560986|EXPERIMENTAL|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
62535689|NCT03560986|PLACEBO_COMPARATOR|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
62161935|NCT06559072|EXPERIMENTAL|Atorvastatin group|On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
62161936|NCT06559072|NO_INTERVENTION|Conventional treatment group|Conventional treatment for aneurysmal subarachnoid hemorrhage typically includes measures such as blood pressure control, hemostasis, reduction of intracranial pressure, prevention of complications, and, when deemed necessary based on the patient's condition, surgical intervention. No specific interventions are applied unless warranted.
62161937|NCT05601362|ACTIVE_COMPARATOR|Gamified Attention Bias Modification|Digital therapeutic intervention based on Attention Bias Modification Training (ABMT) designed to decrease negative attention bias.
62161938|NCT05601362|SHAM_COMPARATOR|Gamified Placebo Training|Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias
62161939|NCT02766764|ACTIVE_COMPARATOR|Study group|Women will receive oral DHEA 25 mg t.d.s daily for 12 weeks before ICSI in addition to daily GH injections from day 6 of hMG administration until the day of hCG administration.
62161940|NCT02766764|PLACEBO_COMPARATOR|Placebo group|Women will receive an oral placebo similar to DHEA t.d.s daily for 12 weeks before ICSI in addition to daily placebo injections similar to GH from day 6 of hMG administration until the day of hCG administration.
62535690|NCT04530708|NO_INTERVENTION|A: Standard of care|Normal standard of care and follow-up.
62535691|NCT04530708|EXPERIMENTAL|B: Thoracic radiotherapy|Addition of thoracic radiotherapy to 36 Gy after medical treatment.
62535692|NCT00296231|EXPERIMENTAL|Nasal High Frequency Ventilation|Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.
62161941|NCT04908800|EXPERIMENTAL|Part A single ascending dose (SAD) and Part B multiple ascending dose (MAD): KRP-A218|Administration Route: Oral
62161942|NCT04908800|PLACEBO_COMPARATOR|Part A (SAD) and Part B (MAD): Placebo|Administration Route: Oral
62535693|NCT06632561|EXPERIMENTAL|Empagliflozin arm|37 patients received Empagliflozin 10 mg/day in addition to their guideline-directed medical therapy for HF
62535694|NCT06632561|PLACEBO_COMPARATOR|Placebo arm|37 patients received placebo in addition to their guideline-directed medical therapy for HF
62535695|NCT00654290|EXPERIMENTAL|P|Propranolol from 7 days pre-operation to 5 days post CABG
62535696|NCT00654290|ACTIVE_COMPARATOR|A|Amiodarone treated 7 days pre-operation to 5 days post CABG
62535697|NCT00654290|ACTIVE_COMPARATOR|AP|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
62535698|NCT04428216|ACTIVE_COMPARATOR|Group RIB = Rhomboid intercostal block group|In group RIB, RIB block will be performed with patients in the lateral decubitus position. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injected into the fascial plane.
62535699|NCT04428216|NO_INTERVENTION|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
62535700|NCT05016895|EXPERIMENTAL|Bi-annual single dose azithromycin|Mass, community-based distribution of single dose azithromycin solution (200 mg/5ml) dosed at 20 mg/kg weight to all eligible infants ages 1 to 11 months twice yearly (approximately 6 months apart)
62535701|NCT04892225|EXPERIMENTAL|Intervention group|Individuals in this group will be randomly assigned to text message in Urdu language on dietary sodium and fluid restriction daily for 8 weeks.
62161943|NCT04908800|EXPERIMENTAL|Part C drug-drug interaction (DDI): KRP-A218 and itraconazole|Administration Route: Oral
62161944|NCT01539902|EXPERIMENTAL|Human Umbilical Cord derived MSCs|
62161945|NCT01539902|PLACEBO_COMPARATOR|Cyclophosphamide|
62161946|NCT04396717|EXPERIMENTAL|Pritumumab|"Dose Escalation phase (3+3 patients):~Pritumumab administered sequentially as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at: 1.6 mg/kg, 4.8 mg/kg, 8.0 mg/kg, 12.0 mg/kg, and 16.2 mg/kg, for a maximum of 6 cycles or progression or unacceptable toxicity.~Expansion phase (6-12 patients): Pritumumab administered as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at or below MTD for a maximum of 6 cycles or progression or unacceptable toxicity."
62535702|NCT04892225|NO_INTERVENTION|Control group|Randomly assigned Control group will not receive any text message.
62535703|NCT03048188|EXPERIMENTAL|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
62535704|NCT04744883|EXPERIMENTAL|SMT plus placebo/naloxone|Participants are randomly assigned to an 8 week SMT treatment group conducted by certified physical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
62535705|NCT04744883|EXPERIMENTAL|MT plus placebo/naloxone|Participants are randomly assigned to an 8 week MT treatment group conducted by certified clinical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
62535706|NCT05226546|OTHER|control group|Patient underwent simple olfactive training for one month.
62535707|NCT05226546|EXPERIMENTAL|PRP injected group|Patient had one injection in each olfactory cleft.
62535708|NCT03885752|ACTIVE_COMPARATOR|the control group|
62535709|NCT03885752|PLACEBO_COMPARATOR|the gum group|
62161947|NCT03761706|EXPERIMENTAL|Intervention Cohort|This is a one-arm intervention study that includes assessments and questionnaires at several time points as early stage breast cancer patients undergo chemotherapy and at 6 months post-chemotherapy. Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits to evaluate engagement in physical activity. Study participants will complete questionnaires, an exercise log, and submit blood samples as multiple time points.
62161948|NCT05576012|EXPERIMENTAL|SOL-116 single dose (Parts 1 and 2); multiple dose (Part 3) (SC administration)|
62161949|NCT05576012|PLACEBO_COMPARATOR|Placebo single dose (Parts 1 and 2); multiple dose (Part 3) (SC administration)|
62161950|NCT06721650|OTHER|study group|
62161951|NCT06721650|OTHER|control group|
62161952|NCT05951556|EXPERIMENTAL|All Participants|All Participants will receive trial device and will be trained (via Telehealth) in its use.
62161953|NCT02572986|EXPERIMENTAL|Permethrin cream 5%|Manufactured by Dr. Reddy's Laboratories, Ltd
62161954|NCT02572986|ACTIVE_COMPARATOR|Elimite™ Cream (permethrin) 5%|Manufactured by Prestium Pharma, Inc
62535710|NCT04172116||long pouch RYGB|Patients with the variation of a long and narrow pouch (hypothesis: slower transit of food)
62535711|NCT04172116||short pouch RYGB|Patients with the variation of a short and wide pouch (hypothesis: faster pouch emptying as compared with long and narrow pouch)
62535712|NCT04863599|OTHER|OMS procedure under general anesthesia or sedation|Questionnaire
62161955|NCT04818918||STEMI group|"Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery.~Absolute coronary flow and microvascular resistance will be measured in the LAD."
62161956|NCT04818918||Control group|"Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions \<90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value \>0.8).~Absolute coronary flow and microvascular resistance will be measured in the LAD."
62161957|NCT06390124|EXPERIMENTAL|Experimental group|Platelet derived growth factor (PDGF) is to be used to soak the implant surface and in combination with the bone grafting material
62161958|NCT02511106|EXPERIMENTAL|AZD9291|AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
62161959|NCT02511106|PLACEBO_COMPARATOR|Placebo AZD9291|Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
62161960|NCT00874172|ACTIVE_COMPARATOR|2|Combination of acetaminophen, morphine
62161961|NCT00874172|EXPERIMENTAL|1|Combination of acetaminophen, nitrous oxide, nefopam, morphine
62161962|NCT03677856|EXPERIMENTAL|Paravertebral Blockade|Anaesthesia to single side of the patient's chest
62161963|NCT03677856|ACTIVE_COMPARATOR|Thoracic epidural block|Anaesthesia to both sides of the patient's chest
62161964|NCT01249378|ACTIVE_COMPARATOR|10 g non emulsified of milk fat|They are compared using the repeated measurements taken within subjects
62161965|NCT01249378|ACTIVE_COMPARATOR|40 g non emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
62161966|NCT01249378|ACTIVE_COMPARATOR|40 g finely emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
62161967|NCT05431608|EXPERIMENTAL|Dose Level -1B|MCARH125 dose 50 million total CAR+ cells MCARH109 dose 50 million total CAR+ cells
62161968|NCT05431608|EXPERIMENTAL|Dose Level -1A|MCARH125 dose 50 million CAR+ cells MCARH109 dose 0 total CAR+ cells
62161969|NCT05431608|EXPERIMENTAL|Dose Level 0|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 0 total CAR+ cells
62535713|NCT01604135|ACTIVE_COMPARATOR|Corneal Collagen Crosslinking|The keratokonic eye which progresses most is included and randomized. Significant progression is defined in the eligibility criteria section. If randomized to the treatment arm the cornea is treated with collagen crosslinking as described below.
62535714|NCT01604135|NO_INTERVENTION|Control group|The keratokonic eye which progresses most is included and randomized to either the treatment group (CXL) or the control group.
62535715|NCT01288014||Edlerly Recipients of Zoster Vaccine|Blood samples are collected before and after vaccination in people age 60 or more, who are getting the zoster vaccine as part of their routine health care.
62535716|NCT03779737|ACTIVE_COMPARATOR|Habitual training|The control group will be monitored passively for the detection of adverse or secondary events.
62535717|NCT03779737|EXPERIMENTAL|Muscular resistance training|This phase includes the execution of the study with three arms, one group will be assigned to strength training and the other to aerobic capacity training, taking into account the plan of sessions per week.
62535718|NCT03779737|EXPERIMENTAL|Cardiorespiratory training|In stage, a combined program of strength and aerobic capacity will be implemented, which will last six months more than will be compared with the previously defined control group.
62535719|NCT02620644|OTHER|G1 Diabetics with no retinpathy|Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
62161970|NCT05431608|EXPERIMENTAL|Dose Level 1|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 50 million total CAR+ cells
62161971|NCT05431608|EXPERIMENTAL|Dose Level 2|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 150 million total CAR+ cells
62535720|NCT02620644|OTHER|G2 Non diabetics|Group consists of non-diabetic subjects, free from any ocular pathology(21 eyes).OCT retinal GCC measurements.
62535721|NCT03476733||patient with drug related problem|patient with drug related problem
62535722|NCT03476733||patient without drug related problem|patient without drug related problem
62535723|NCT03077555|ACTIVE_COMPARATOR|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
62714529|NCT05357040|ACTIVE_COMPARATOR|Treatment; Nitrous Oxide 50% or 25%, group|Four-weekly, 60-minute inhalation sessions of 25% or 50% nitrous oxide, randomly assigned.
62161972|NCT04119778|EXPERIMENTAL|Aerobic Exercise|The exercise intervention will last 16 weeks, comprised of home-based exercise with weekly telephone counselling to encourage participants to continue to exercise, supplemented with 8 supervised exercise sessions (2 sessions per month). Each session will last for an hour. The supervised exercise sessions will be provided by professional exercise specialists twice in the first week in each month throughout the intervention period, an hour each time. Exercise trainers will lead the classes. Each class will include both aerobic exercise and resistance exercise. They are encouraged to do aerobic exercise for at least 150 min weekly at a moderate intensity level, as well as perform resistance exercises alternate day. Participants are also provided an exercise diary, containing details of their weekly prescribed exercises and the scales they have to refer to.
62535724|NCT03077555|EXPERIMENTAL|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
62535725|NCT03694327|EXPERIMENTAL|Treatment A Mobile Application|Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.
62535726|NCT03694327|ACTIVE_COMPARATOR|Treatment B Mobile Application|Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.
62535727|NCT02935153|EXPERIMENTAL|B Cell Malignancies|Experimental: B Cell Malignancies The trial will be conducted in a manner of simon two-stage design with Anti-CD22-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
62535728|NCT03673527|EXPERIMENTAL|topical formulation of tacrolimus|
62535729|NCT04888598||Type 1 diabetic patients|Recently diagnosed type 1 diabetes patients
62714530|NCT05357040|PLACEBO_COMPARATOR|Control; Oxygen-air mixture, group|Four-weekly, 60-minute inhalation sessions of an oxygen and air mixture.
62161973|NCT04119778|EXPERIMENTAL|Tai chi|Our tai-chi classes will be based on a 16-form tai-chi exercise set. The classes will run twice a week for 16 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 16 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
62161974|NCT04119778|NO_INTERVENTION|Self Management Group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 16 weeks and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
62161975|NCT06079190|EXPERIMENTAL|GSK4527226 Dose 1|Participants will receive GSK4527226 Dose 1
62161976|NCT06079190|EXPERIMENTAL|GSK4527226 Dose 2|Participants will receive GSK4527226 Dose 2
62161977|NCT06079190|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62161978|NCT02326493|EXPERIMENTAL|CRT implantation|Patients who have a class I indication for cardiac resynchronization therapy according to current international guidelines
62161979|NCT05012462|EXPERIMENTAL|Apheresis Platelet Donation: CM-1500|The subjects will be connected to the CM-1500 during apheresis platelet donation
62161980|NCT05012462|EXPERIMENTAL|Apheresis Platelet Donation: CM-1600|The subjects will be connected to the CM-1600 during apheresis platelet donation
62161981|NCT02038803||Adults- Cystic Fibrosis|Adults with cystic fibrosis who have respiratory colonization with Pseudomonas Aeruginosa. The actual study will involve instructing adult patients with CF on the use of a new form of Tobramycin for inhalation (powder) and then assessing this new form of TOBI podhaler vs the old TOBI solution related to patient preference on use, time involved in taking the new medication vs the old, and impact on their pulmonary function and subsequent exacerbation rate plus quality of life.
62161982|NCT02332525|EXPERIMENTAL|Intervention|20 elders (10 mild cognitive impairment, 10 cognitive normal elders) those who received oral vibrational stimulation
62161983|NCT01217723|EXPERIMENTAL|Thymoglobulin|Thymoglobulin will be administered on Days -2, -1 prior to the transplant and on the day of transplant.
62161984|NCT01217723|OTHER|No Thymoglobulin|Patients will receive a standard preparative regimen. (i.e. one that does not normally contain Thymoglobulin.)
62161985|NCT05099068|EXPERIMENTAL|IMMUNOTHERAPY COHORTS|This cohort include following cancers treated with immunotherapy : metastatic Small cell lung cancer (SLCC); recurrent/Metastatic Head and Neck squamous cell carcinoma (HNSCC); MSI-High, any tumor types and HPV-related cancers,any tumor types
62161986|NCT05099068|EXPERIMENTAL|TARGETED THERAPIES COHORTS|This cohort include following cancers treated with targeted therapies : Metastatic GIST; BRAF-mutated tumors (CRC (BRAF V600E), lung (V600 only) and thyroid (all BRAF mutation with known sensitivity to Dabrafenib) cancer); All solid tumor types with RET fusion / mutation and Chronic Lymphocytic Leukemia (CLL) in the relapsed setting.
62161987|NCT05099068|EXPERIMENTAL|CHEMOTHERAPY COHORTS|This cohort include following cancers treated with chemotherapies : metastatic Small cell lung cancer (SLCC); recurrent/Metastatic Head and Neck squamous cell carcinoma (HNSCC); Metastatic Triple negative breast cancer (TNBC); Glioblastoma; Advanced high grade epithelial ovarian cancer
62161988|NCT06720597|ACTIVE_COMPARATOR|PDE5 Inhibitor Therapy in Men with Vasculogenic Erectile Dysfunction (ED)|Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: Daily low-dose PDE5 inhibitor therapy. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
62161989|NCT06720597|ACTIVE_COMPARATOR|Testosterone Therapy in Hypogonadal Men|Population: 40 hypogonadal men aged 18 or above Intervention: Testosterone therapy as per clinical guidelines. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
62161990|NCT06720597|NO_INTERVENTION|Vasculogenic ED confirmed by penile Doppler ultrasound|Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: None Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.
62161991|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
62161992|NCT02104921||Healthy volunteers|
62161993|NCT03255174|EXPERIMENTAL|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
62161994|NCT06471127|EXPERIMENTAL|Experimental word-learning task for aphasia|The word learning task includes 210 trials across 7 learning blocks (30 trials/block). Each trial features two novel objects (target and foil) on the screen, with an audio recording naming one object. Subjects must quickly and accurately identify the named object. Correct responses are rewarded with a happy face, and incorrect ones with a sad face. The target object's position is counter-balanced, and trial order is randomized for each subject. Short pauses occur every 60 trials to reduce fatigue. After 7 learning blocks, feedback is discontinued, and an immediate test block assesses word-referent recognition. A week later, a second test block, with the same instructions, measures retained learning. Each test block consists of 30 randomized trials without feedback.
62161995|NCT06640426|NO_INTERVENTION|Usual Care|This is a group will serve as usual care and have no intervention during the study period
62161996|NCT06640426|EXPERIMENTAL|Two Messages|This group will receive two messages as part of the study -- one email and one text message.
62161997|NCT06640426|EXPERIMENTAL|Up To Five Messages|This group will receive up to five messages as part o the study -- two emails and three text messages.
62161998|NCT06519955|NO_INTERVENTION|Control|No medication administration. Standard of care medications will be offered.
62161999|NCT06519955|ACTIVE_COMPARATOR|Post Closure|Once the fascia has been closed, the PLIA will be administered using a pediatric catheter.
62162000|NCT06519955|ACTIVE_COMPARATOR|Throughout Procedure|The injection will be performed throughout the surgical procedure.
62162001|NCT05635526||1|8-12 years old
62162002|NCT05635526||2|13-16 years old
62162003|NCT05635526||3|over 16 years old
62162004|NCT04407247|ACTIVE_COMPARATOR|Arm I (infliximab)|Patients receive infliximab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
62162005|NCT04407247|EXPERIMENTAL|Arm II (vedolizumab)|Patients receive vedolizumab IV over 1 hour at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
62535730|NCT03967171|EXPERIMENTAL|before uterine incision oxytocin group|IV infusion of 20 IU of oxytocin started before uterine incision
62535731|NCT03967171|ACTIVE_COMPARATOR|after clamping the umbilical cord oxytocin group|IV infusion of 20 IU of oxytocin started immediately after clamping the umbilical cord
62535732|NCT02085135|EXPERIMENTAL|Titration Schedule 1|
62535733|NCT02085135|EXPERIMENTAL|Titration Schedule 2|
62535734|NCT04728503|EXPERIMENTAL|5-Minute Mindful Movement Video|5 minute mindful movement video watched in the exam room on an iPad
62535735|NCT04728503|PLACEBO_COMPARATOR|Written Educative Materials|1 page printed written educative material about mindfulness benefits read for 5 minutes in the exam room
62535736|NCT00527553|EXPERIMENTAL|A|daily consumption of a regular egg
62535737|NCT00527553|EXPERIMENTAL|B|daily consumption of a lutein-enriched egg, eggs laid by chickens on a lutein-enriched feed.
62535738|NCT00527553|EXPERIMENTAL|C|daily consumtion of a zeaxanthin-enriched egg, eggs laid by chickens on a zeaxantin-enriched feed.
62535739|NCT00527553|EXPERIMENTAL|D|daily egg product from enriched eggs
62535740|NCT00527553|NO_INTERVENTION|E|control subjects were not blinded as they did not receive any aditional supplementation. Only markers measured during the trial period as a control.
62535741|NCT01467414|EXPERIMENTAL|NN1250|
62535742|NCT01910779|ACTIVE_COMPARATOR|100 joule arm|100 joule as first biphasic shock energy
62535743|NCT01910779|ACTIVE_COMPARATOR|120 joule arm|120 joule as first biphasic shock energy
62535744|NCT02001220|ACTIVE_COMPARATOR|Once daily screening|Patients will undergo assessments to determine readiness to undergo an SBT once daily.
62162006|NCT06719908|ACTIVE_COMPARATOR|AFA-281 with Ethanol|AFA-281 (40 mg) will be administered as a single dose (oral) in combination with Alcohol (0.6 g/kg in females or 0.7g/kg in males).
62162007|NCT06719908|PLACEBO_COMPARATOR|AFA-281 with Ethanol Placebo|AFA-281 (40 mg) will be administered as a single dose (oral) in combination with the Alcohol placebo (0.6 g/kg in females or 0.7g/kg in males).
62162008|NCT06719908|PLACEBO_COMPARATOR|AFA-281 placebo with Ethanol|AFA-281 placebo (40 mg) will be administered as a single dose (oral) in combination with the Alcohol (0.6 g/kg in females or 0.7g/kg in males).
62162009|NCT06719908|SHAM_COMPARATOR|AFA-281 placebo with Ethanol placebo|AFA-281 placebo (40 mg) will be administered as a single dose (oral) in combination with the Alcohol placebo (0.6 g/kg in females or 0.7g/kg in males).
62162010|NCT03656718|EXPERIMENTAL|Part A, Group 1: nivolumab (dose 1) + rHuPH20|
62162011|NCT03656718|EXPERIMENTAL|Part B, Group 3: nivolumab (dose 2) + rHuPH20|
62162012|NCT03656718|EXPERIMENTAL|Part B, Group 2: nivolumab (dose 1)|
62162013|NCT03656718|EXPERIMENTAL|Part B, Group 4: nivolumab (dose 2)|
62162014|NCT03656718|EXPERIMENTAL|Part C: nivolumab (dose 3) + rHuPH20|
62162015|NCT03656718|EXPERIMENTAL|Part D, Group 5: nivolumab (dose 3) + rHuPH20|
62162016|NCT03656718|EXPERIMENTAL|Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20|
62162017|NCT01190488|EXPERIMENTAL|Intervention - Decision Aid|In addition to usual care, patients assigned to the intervention group will also be asked to view and/or read the EOL-PtDA during their hospitalization. The EOL-PtDA can be utilized anytime in the course of their hospitalization (all hospital rooms at UCH have a DVD player). This could be before, during, or after the palliative care team consultation.
62162018|NCT01190488|ACTIVE_COMPARATOR|Active comparison|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
62162019|NCT00110279|EXPERIMENTAL|1|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops.
62535745|NCT02001220|EXPERIMENTAL|At least twice daily screening|Patients will undergo assessments to determine readiness to undergo an SBT at least twice daily.
62535746|NCT01740726|EXPERIMENTAL|Behavioral Activation|
62535747|NCT01740726|ACTIVE_COMPARATOR|Fluoxetine|
62535748|NCT01366430|ACTIVE_COMPARATOR|Gefoni manenuver|Gefoni manenuver for Geotropic HC-BPPV
62535749|NCT01366430|ACTIVE_COMPARATOR|sham maneuver|sham maneuver for geotropic HC-BPPV
62535750|NCT01366430|ACTIVE_COMPARATOR|barbecue maneuver|barbecue maneuver for geotropic HC-BPPV
62535751|NCT01345916|EXPERIMENTAL|CHF 1535 100/6 NEXT Dry Powder Inhaler®|CHF1535 100/6 NEXT DPI® 1 inhalation bis in day (b.i.d) (daily dose BDP 200/FF 12 µg)
62535752|NCT01345916|ACTIVE_COMPARATOR|CHF1535 100/6 pMDI|CHF1535 100/6 pressurisedMeterDoseInhaler 1 inhalation b.i.d (total daily dose BDP 200/FF 12 µg)
62535753|NCT01345916|ACTIVE_COMPARATOR|beclomethasone dipropionate DPI|beclomethasone dipropionate 100 µg DPI, 1 inhalation b.i.d (total daily dose BDP 200 µg)
62535754|NCT01235832|ACTIVE_COMPARATOR|Lower-Fat Diet|The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
62162020|NCT00110279|EXPERIMENTAL|2|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
62162021|NCT04795518||Cross sectional study by questionnaire among group of pediatric dentistry|"An interviewed questionnaire is divided into two parts. The first part of the questionnaire will investigate the socio-demographic characteristics of the respondents. The second part of the questionnaire is divided into five sections to cover the following items:~1. Use of antibiotics pattern~2. Knowledge about antibiotics~3. Sources of information"
62162022|NCT00111384||Group A|Affected participants, must have a correct clinical diagnosis of NF1.
62162023|NCT00111384||Group B|Unaffected individuals greater than 2 years of age who are relatives of participants.
62162024|NCT00725127|ACTIVE_COMPARATOR|1|100 mg/day ASA upon awakening.
62162025|NCT00725127|ACTIVE_COMPARATOR|2|100 mg/day ASA at bedtime
62162026|NCT04698499|ACTIVE_COMPARATOR|Pen and Paper|Participants will complete swallowing exercises using printed materials and diary for tracking.
62162027|NCT04698499|EXPERIMENTAL|Mobile health system|Participants will complete swallowing exercises using a mobile health system with surface electromyography (sEMG) biofeedback.
62162028|NCT05379634|EXPERIMENTAL|Nipocalimab|Participants will receive Nipocalimab at Week 0 (Baseline) and then every 2 weeks (Q2W) up to Week 50 during double-blind period. Participants on glucocorticoids (GC) at baseline will receive a stable dose of oral GC (prednisone or equivalent) from 4 weeks prior to the first administration of study intervention to Week 0. No changes in GC doses are allowed between Week 0 and Week 24. From Week 24 to Week 44, GC doses will be tapered. No changes to GC doses will be allowed from Week 44 to Week 52. Eligible participants will enter long-term extension (LTE) period and continue receiving Nipocalimab starting from Week 52 up to Week 98 and will be followed up to Week 106.
62162029|NCT05379634|PLACEBO_COMPARATOR|Placebo|Participants will receive Nipocalimab matching placebo at Week 0 (Baseline) and then Q2W up to Week 50 during double-blind period. Participants on GC at baseline will receive a stable dose of oral GC (prednisone or equivalent) from 4 weeks prior to the first administration of study intervention to Week 0. No changes in GC doses are allowed between Week 0 and Week 24. From Week 24 to Week 44, GC doses will be tapered. No changes to GC doses will be allowed from Week 44 to Week 52. Eligible participants will enter LTE period and continue receiving Nipocalimab matching placebo Q2W starting from Week 52 up to Week 98 and will be followed up to Week 106.
62162030|NCT06720727|EXPERIMENTAL|Single arm|Craniospinal irradiation involves delivery of radiation therapy to the whole brain, spinal cord, nerve roots, the covering meninges(leptomeninges) and subarachnoid space and provides a viable means of mitigating leptomeningeal spread and possibly improving survival.
62162031|NCT05092269|EXPERIMENTAL|Ustekinumab|Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004, CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Participants enrolling from the Exposure Optimization Substudy may be eligible to remain on the every 4 weeks (q4w) dosing regimen.
62162032|NCT01140152||No rejection|Intestinal transplant recipients with no evidence of biopsy proven rejection
62162033|NCT01140152||Rejection|Intestinal transplant recipients who had evidence of biopsy proven rejection
62162034|NCT06720272|EXPERIMENTAL|School nurse program|The experimental intervention consists in a school nurse program providing integrated health care through diagnosis, intervention, and follow-up of group A beta-hemolytic streptococcal pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with rheumatic heart disease.
62162035|NCT06720272|NO_INTERVENTION|Standard of care|No school nurse prorgam.
62162036|NCT06721676|EXPERIMENTAL|A single arm study|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.the transporter has A2 flex function to improve coaxiality and commissural aligment to reduce coronary occlusion
62162037|NCT01176747|EXPERIMENTAL|BDP/formoterol NEXT DPI|Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
62162038|NCT02522299|EXPERIMENTAL|GSK2269557 1000 microgram (mcg)|Subjects will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device.
62162039|NCT02522299|PLACEBO_COMPARATOR|Placebo via DISKUS|Subjects will receive 2 inhalations of placebo once daily for 84 days via DISKUS device.
62162040|NCT02522299|EXPERIMENTAL|GSK2269557 700 mcg|Subjects will receive 2 inhalations of GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
62162041|NCT02522299|PLACEBO_COMPARATOR|Placebo via ELLIPTA|Subjects will receive Placebo once daily for 84 consecutive days via ELLIPTA.
62162042|NCT06142799|EXPERIMENTAL|immediate overlay placement|Immediately after root canal treatment an overlay is cemented, and the patient is asked to record the pain after 6, 12, 24, 48 and 72 hours after treatment
62535755|NCT01235832|ACTIVE_COMPARATOR|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
62535756|NCT01235832|EXPERIMENTAL|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
62162043|NCT06142799|ACTIVE_COMPARATOR|delayed overlay placement|After root canal treatment the tooth is left in infraoclussion and the patient is asked to record the pain after 6, 12, 24, 48 and 72 hours
62535757|NCT03466437|EXPERIMENTAL|Glass-fiber post + composite resin restoration|
62535758|NCT03466437|EXPERIMENTAL|Glass-fiber post + metalceramic crown|
62535759|NCT03466437|ACTIVE_COMPARATOR|Cast-metal post + metalceramic crown|
62535760|NCT05984875||A|Newly diagnosed high grade serous or endometroid OC undergoing primary debulking surgery
62162044|NCT06636773|EXPERIMENTAL|Behavioral Weight Loss Plus Aerobic Physical Activity|The intervention is a 12-month behavioral intervention focused on modifying eating behaviors and physical activity. Participants will be provided weekly group-based behavioral session for months 1-6, with these sessions being offered twice per month during months 7-12. Participants will be instructed to self-monitor their weight, eating behaviors, and physical activity. A reduced energy diet ranging from 1200-2100 kilocalories per day will be recommended for participants. Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress from an initial amount of 100 minutes per week to 300 minutes per week across the initial 6 months of the intervention, with this level of physical activity continuing to be recommended between months 7-12.
62162045|NCT06636773|EXPERIMENTAL|Behavioral Weight Loss Plus Aerobic Physical Activity and Yoga|The intervention is a 12-month behavioral intervention focused on modifying eating behaviors and physical activity. Participants will be provided weekly group-based behavioral session for months 1-6, with these sessions being offered twice per month during months 7-12. Participants will be instructed to self-monitor their weight, eating behaviors, and physical activity. A reduced energy diet ranging from 1200-2100 kilocalories per day will be recommended for participants. Physical activity will be recommended in the form of aerobic types of activity such as brisk walking combined with yoga. Aerobic activity will progress from an initial amount of 60 minutes per week to 180 minutes per week across the initial 6 months of the intervention, with this level continuing to be recommended between months 7-12. Yoga will progress from 40 minutes per week to 120 minutes per week across the initial 6 months of the intervention, with this level continuing to be recommended between months 7-12.
62535761|NCT05984875||B|Newly diagnosed high grade serous or endometroid OC undergoing NACT followed by interval debulking surgery. This cohort also includes patients that will not be deemed suitable for interval debulking surgery following NACT
62535762|NCT05984875||C|Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing primary debulking surgery
62162046|NCT06721845||Group I: Septic patients with positive microbial cultures.|
62162047|NCT06721845||Group II: septic patients with negative microbial culture|
62162048|NCT06719999|NO_INTERVENTION|Lean, ongoing diet (n=40)|
62162049|NCT06719999|EXPERIMENTAL|Lean, B4HT (n= 40)|B4HT Mediterranean Lunch box
62162050|NCT06719999|NO_INTERVENTION|OW/OB without prediabetes/T2DM ongoing diet (n=40)|
62162051|NCT06719999|EXPERIMENTAL|OW/OB without prediabetes/T2DM, B4HT (n= 40)|B4HT Mediterranean Lunch box
62162052|NCT06719999|NO_INTERVENTION|OW/OB, with prediabetes/T2DM, ongoing diet (n=40)|
62535763|NCT05984875||D|Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing NACT followed by interval debulking surgery. This cohort also includes patients with the selected histological subtypes that will not be deemed suitable to interval debulking surgery following NACT
62535764|NCT05984875||E|Women undergoing adnexectomy for benign pathology
62162053|NCT06719999|EXPERIMENTAL|OW/OB with prediabetes/T2DM, B4HT (n= 40)|B4HT Mediterranean Lunch box
62162054|NCT01125956|NO_INTERVENTION|Control|This group will receive usual diabetes care through their primary care clinicians.
62162055|NCT01125956|EXPERIMENTAL|Peer counseling|A peer counselor will be assigned to each participant who currently has good diabetes control but had poor control in the past 3 years.
62162056|NCT01125956|EXPERIMENTAL|Financial incentives|Patient participants in the financial incentive arm will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
62162057|NCT06705842|ACTIVE_COMPARATOR|PVI|
62162058|NCT06705842|ACTIVE_COMPARATOR|Usual Care|
62162059|NCT06202898|EXPERIMENTAL|ENTRUST|The proposed intervention 'ENTRUST' will address structural disparities transgender women encounter by providing skills to aid with economic navigation while simultaneously strengthening and improving social cohesion to increase the odds of them linking to care that is available to them.
62162060|NCT06202898|ACTIVE_COMPARATOR|Control|Comparison control group.
62162061|NCT06106308|EXPERIMENTAL|Onvansertib 20mg + Standard of Care|Participants will receive 20 mg of onvansertib on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFIRI/BEV on Day 1 and Day 15 of each 28-day treatment cycle.
62162062|NCT06106308|EXPERIMENTAL|Onvansertib 30 mg + Standard of Care (SOC)|Participants will receive 30 mg of onvansertib + on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFIRI on Day 1 and Day 15 of each 28-day treatment cycle.
62162063|NCT06106308|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants will receive FOLFIRI/Bev on Day 1 and Day 15 of each 28-day treatment cycle.
62162064|NCT06106308|EXPERIMENTAL|Onvansertib 20 mg + Standard of Care|Participants will receive 20 mg of onvansertib on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFOX on Day 1 and Day 15 of each 28-day treatment cycle.
62162065|NCT06106308|EXPERIMENTAL|Onvansertib 30 mg + Standard of Care|Participants will receive 30 mg onvansertib on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFOX on Day 1 and Day 15 of each 28-day treatment cycle.
62535765|NCT05523154|ACTIVE_COMPARATOR|Arm I (biospecimen collection, routine testing)|Patients undergo the collection of bile samples during standard of care surgery. Samples undergo routine laboratory testing.
62535766|NCT05523154|EXPERIMENTAL|Arm II (biospecimen, nanopore sequencing, routine testing)|Patients undergo the collection of bile samples during standard of care surgery. Samples undergo nanopore sequencing and routine laboratory testing.
62535767|NCT03275116|ACTIVE_COMPARATOR|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
62535768|NCT03275116|ACTIVE_COMPARATOR|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
62535769|NCT03384082|EXPERIMENTAL|Hysteroscopic treatment|Hysteroscopic surgery
62535770|NCT03384082|NO_INTERVENTION|Control group|No treatment
62535771|NCT01822275|OTHER|Low Dose WBRT|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
62535772|NCT04383223|NO_INTERVENTION|YLH Historical Control Group|"Participants in this group will have the following phases:~* Screening~* Single visit assessment"
62535773|NCT04383223|EXPERIMENTAL|YLH iTransition Intervention Group|"Participants in this group will have the following phases:~* Screening~* Baseline Visit~* Follow-Up visits at 6, 12 and 18 month~* Interview visits for selected YLH around 3 and 9 month"
62162066|NCT06106308|ACTIVE_COMPARATOR|Standard of Care|Participants will receive FOLFOX/Bev on Day 1 and Day 15 of each 28-day treatment cycle.
62714531|NCT02987608|NO_INTERVENTION|Control Phase (No Power Up)|60 young people will receive CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires will be administered three months later.
62714532|NCT02987608|EXPERIMENTAL|Intervention Phase (Power Up)|60 young people use Power Up alongside CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires and a Power Up feedback form will be administered three months later.
62714533|NCT05039021|EXPERIMENTAL|Pediatric; adult (HPB, lower gastrointestinal, gastric, gynecological, urological, thoracic)|Any pediatric or adult (hepato-pancreato-biliary, lower gastrointestinal, gastric, gynecological, urological, thoracic) procedures where the HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
62714534|NCT02393859|ACTIVE_COMPARATOR|High Risk Consolidation 3 (HC3) Chemotherapy|One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m\^2/day intravenous \[IV\] on Days 1-6), vincrisitne (1.5 mg/m\^2/day IV on Days 1 and 6), daunorubicin (30 mg/m\^2 IV over 24 hours on Day 5), methotrexate (1 g/m\^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m\^2 IV for 1 hour on Days 2-4), and pegylated \[PEG\]-asparaginase (1000 U/m\^2 IV for 2 hours or intramuscularly \[IM\] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m\^2 IV or IM every 48 hours for a total of 6 doses).
62714535|NCT02393859|EXPERIMENTAL|Blinatumomab|15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
62714536|NCT06421740||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
62714537|NCT03991585|EXPERIMENTAL|Three times a week MCRF|Participants in this arm will participate in the MCRF intervention sessions three times a week for 12 consecutive weeks.
62714538|NCT03991585|EXPERIMENTAL|One time a week MCRF|Participants in this arm will participate in the MCRF intervention sessions one time a week for 12 consecutive weeks.
62714539|NCT05018364||cases|measure serum erythropoietin level
62535774|NCT04383223|EXPERIMENTAL|Provider Group|"Participants in this group will have the following phases:~* Screening~* Baseline Visit~* Follow-Up visits at 6, 12 and 18 month~* Interview visits for selected YLH around 3, 9 and 15 month"
62535775|NCT04383223|EXPERIMENTAL|Transition Champion Group|"Participants in this group will have the following phases:~* Screening~* Baseline Visit and Follow-Up visits at 6, 12 and 18 month~* Interview visits for selected YLH around 3, 9 and 15 month"
62535776|NCT03411096|EXPERIMENTAL|Quadratus lumborum block|Quadratus lumborum block with 0.75% ropivacaine
62535777|NCT03411096|PLACEBO_COMPARATOR|Placebo|Quadratus lumborum block with normal saline
62535778|NCT04270318|ACTIVE_COMPARATOR|CH pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the CH pulpotomy.Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
62535779|NCT04270318|EXPERIMENTAL|CH pulpotomy-NaOCl|After hemorrhage control,pulp chamber was cleansed with 5% NaOCl for 30 s prior the CH pulpotomy. Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
62535780|NCT04270318|ACTIVE_COMPARATOR|MTA pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs.
62535781|NCT04270318|EXPERIMENTAL|MTA pulpotomy-NaOCl|"After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. MTA NaOCl (n = 31 teeth): Pulp chamber was cleansed with 5% NaOCl for 30 s prior the MTA pulpotomy.~Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs."
62535782|NCT00927797|EXPERIMENTAL|Immunochemotherapy, Maintencance|
62535783|NCT03548701||Emergency Department|Patients enrolled in the Emergency Department undergoing evaluation for threatened abortion abnormalities.
62535784|NCT03548701||Obstetric Clinic|Patients with normal pregnancies being treated at first obstetric visit in clinic.
62535785|NCT03527381|EXPERIMENTAL|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
62714540|NCT05018364||controls|measure serum erythropoietin level
62714541|NCT04856462|EXPERIMENTAL|Education Support Group|Caregivers receiving structured education and support
62714542|NCT04856462|ACTIVE_COMPARATOR|Control Group|Caregivers participating in weekly support calls
62714543|NCT06158022|EXPERIMENTAL|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62162067|NCT06721962|EXPERIMENTAL|Cohort 1|Dose level 1
62162068|NCT06721962|EXPERIMENTAL|Cohort 2|Dose level 2
62162069|NCT06721962|EXPERIMENTAL|Cohort 2A|Dose level 2 with conditioning
62162070|NCT06721962|EXPERIMENTAL|Cohort 3|Dose level 3
62162071|NCT06721962|EXPERIMENTAL|Cohort 3A|Dose level 3 with conditioning
62162072|NCT03331276|EXPERIMENTAL|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with high Sn-2 Palmitate, Alpha Lactalbumin and Osteopontin to better mimic human milk.
62162073|NCT03331276|ACTIVE_COMPARATOR|Brand|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
62162074|NCT01118429|EXPERIMENTAL|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
62162075|NCT01118429|PLACEBO_COMPARATOR|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
62162076|NCT01815255||tenofovir (TDF)|HIV-infected children who are currently on TDF-based regimen or are changing to TDF based on their clinical indication
62162077|NCT03337204|EXPERIMENTAL|Engaged4Life|"Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later); and 2) a one-time, 3hr workshop and peer mentoring (via phone 2X/week for 3 weeks). The workshop includes psychoeducation on the relationship between active engagement and health and well-being and a goal setting activity focused on carefully assessing and then make improvements upon existing activity portfolios. Peer mentors provide support as participants implement their goals."
62162078|NCT03337204|ACTIVE_COMPARATOR|Technology-assisted self-monitoring only|Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later). While it is expected that wearing the Fitbit and raising consciousness of activity engagement may initially result in behavior change, it is not expected to have a sustained impact on outcomes over time.
62162079|NCT03015415|EXPERIMENTAL|surgical|Patients undergoing surgical elbow arthrolysis. Elbow Open Arthrolyses
62162080|NCT03015415|EXPERIMENTAL|non-surgical|Patients submitted to a non-surgical rehabilitation protocol using splints Non-surgical intervention
62162081|NCT06600100|EXPERIMENTAL|Inhibitory control training|Inhibitory control training using the active version of the FoodT App. An experimental group will receive: i) an informative session; ii) 3 pre-treatment sessions (one assessment with questionnaires and two counselling sessions: one on diet and one on physical exercise); iii) A psychology session in which the investigator will explain the task to participants and the procedure for the next two weeks. A daily reminder will be sent by WhatsApp to the participants' phone to train for 10 minutes a day from Monday to Friday for two weeks; iv) a session of post treatment assessment (questionnaires); v) one follow-up session three months after completing the intervention to repeat the evaluation
62162082|NCT06600100|PLACEBO_COMPARATOR|Placebo inhibitory control training|Placebo inhibitory control training using the placebo version of the FoodT App. The placebo group will receive: i) an informative session; ii) 3 pre-treatment sessions (one assessment with questionnaires and two counselling sessions: one on diet and one on physical exercise); iii) A psychology session in which the investigator will explain the task to participants and the procedure for the next two weeks. It won't be necessary to meet every day; A daily reminder will be sent by WhatsApp to the participants' phone to train for 10 minutes a day from Monday to Friday for two weeks; iv) a session of post treatment assessment (questionnaires); v) one follow-up session three months after completing the intervention to repeat the evaluation
62162083|NCT05369832|EXPERIMENTAL|Cohort 1 - Advanced therapy-naive|
62162084|NCT05369832|EXPERIMENTAL|Cohort 2 - Advanced therapy-exposed|
62162085|NCT06523686|EXPERIMENTAL|Allogeneic-xenogeneic combination|A mix of 2/3 allogeneic bone with 1/3 xenogeneic bone
62162086|NCT06523686|EXPERIMENTAL|Autogenous-xenogeneic combination|A mix of 2/3 autogenous bone and 1/3 xenogeneic bone
62162087|NCT01078571||RA patients in treatment with adalimumab (Humira)|RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks
62162088|NCT01648699|EXPERIMENTAL|Osmotic Release Oral System (OROS) Hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
62162089|NCT00965393|PLACEBO_COMPARATOR|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of placebo (saline).
62162090|NCT00965393|ACTIVE_COMPARATOR|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of bradykinin receptor antagonist (HOE-140).
62162091|NCT05262244|EXPERIMENTAL|AMD with bevacizumab-800CW|Patients with AMD receive bevacizumab-800CW followed by angiography
62535786|NCT03527381|PLACEBO_COMPARATOR|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
62162092|NCT06519981|EXPERIMENTAL|HRS-9231 or matching placebo Dose level 1|Dose level 1
62162093|NCT06519981|EXPERIMENTAL|HRS-9231 or matching placebo Dose level 2|
62162094|NCT01623180|EXPERIMENTAL|BioFreedom™ Drug Coated Stent (DCS)|BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.
62162095|NCT01623180|ACTIVE_COMPARATOR|Gazelle™ Bare Metal Coronary Stent (BMS)|GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.
62162096|NCT05424822|EXPERIMENTAL|Part A: Dose Escalation|Participants will receive JNJ-80948543 either by subcutaneous (SC) or intravenous (IV) administration to determine the putative recommended Phase 2 dose (RP2D) dosing schedule(s) and route(s) of administration based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens.
62162097|NCT05424822|EXPERIMENTAL|Part B: Cohort Expansion|Participants will receive JNJ-80948543 by SC or IV administration.
62162098|NCT00969995||migraine1|50 subjects with migraine without aura
62162099|NCT00969995||migraine 2|50 subjects with migraine with aura
62162100|NCT00969995||tension|50 subjects with tension headache
62162101|NCT00969995||cluster|50 subjects with cluster headache
62162102|NCT00969995||Healthy|50 healthy subjects
62162103|NCT06555744|EXPERIMENTAL|ZW191|
62162104|NCT03422328|EXPERIMENTAL|Open-label macitentan 10 mg|10 mg macitentan film coated tablet, administered orally once daily
62162105|NCT05512988|EXPERIMENTAL|Experimental|MSCs Participants will receive HUC-MSCs
62162106|NCT05512988|PLACEBO_COMPARATOR|Comparator|Comparator participants will receive saline solution
62714544|NCT06158022|EXPERIMENTAL|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62162107|NCT06524739|EXPERIMENTAL|IgPro20|
62162108|NCT06524739|PLACEBO_COMPARATOR|Placebo|
62162109|NCT04387201|EXPERIMENTAL|Cyanocobalamin, then Dulaglutide|Participants first received Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks. After a washout period of 3 weeks, they then received Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
62162110|NCT04387201|EXPERIMENTAL|Dulaglutide, then Cyanocobalamin|Participants first received Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks. After a washout period of of 3 weeks, they then Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
62162111|NCT05519215||ECHELON 3000 Stapler|This prospective study will include the participants who plan to have a laparoscopic sleeve gastrectomy (LSG) or lung resection surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the ECHELON 3000 Stapler and reloads instructions for use (IFU).
62162112|NCT05487300|OTHER|Testing on-levodopa first, then off-levodopa|Participants underwent autonomic testing one hour after taking their regular morning dose of levodopa (ON state). On a separate day, they then underwent autonomic testing after at least 12 hours from the last dose of levodopa (OFF state).
62162113|NCT05487300|OTHER|Testing off-levodopa, then on-levodopa|Participants underwent autonomic testing after at least 12 hours from the last dose of levodopa (OFF state). On a separate day, they then underwent autonomic testing one hour after taking their regular morning dose of levodopa (ON state).
62162114|NCT05472142|ACTIVE_COMPARATOR|Control Cluster|Clinics in the control group will only be provided with health information technology; they will not participate in the 12-month intervention which incorporates health information technology and practice facilitation.
62162115|NCT05472142|EXPERIMENTAL|Intervention Cluster|Clinics in the intervention group will participate in the 12-month intervention which incorporates health information technology and practice facilitation.
62162116|NCT01417923|EXPERIMENTAL|vitamin D|We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks
62535787|NCT04334694|OTHER|Atrial flow regulator|In this arm, patients who have elevated left ventricle filling pressures get (Occlutech® AFR device) and optimal therapy for Heart failure (HF).
62162117|NCT03770884||Rheumatoid arthritis|EULAR-ACR criteria Whatever the treatment and the disease activity
62162118|NCT03770884||Axial spondyloarthritis|ASAS criteria for axial disease Whatever the treatment and the disease activity
62162119|NCT03770884||digital osteoarthritis|According to ACR criteria Whatever the treatment and the disease activity
62535788|NCT05710692|EXPERIMENTAL|PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks|PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks (available only in the optional extension part)
62535789|NCT06189729|OTHER|Cluster 1|Participants will receive text reminders at Month 0 only. They will receive an HIV self-test at Months 3, 6, 9 and 12, upon submission of the self-test result.
62535790|NCT06189729|OTHER|Cluster 2|Participants will receive text reminders at Months 0 and 3. They will receive an HIV self-test at Months 6, 9 and 12, upon submission of the self-test result.
62535791|NCT06189729|OTHER|Cluster 3|Participants will receive text reminders at Months 0, 3 and 6. They will receive an HIV self-test at Months 9 and 12, upon submission of the self-test result.
62535792|NCT02504671|EXPERIMENTAL|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid \>=5 mg/week.
62162120|NCT06719622|EXPERIMENTAL|Budesonide|
62162121|NCT06719622|ACTIVE_COMPARATOR|Omeprazole|
62162122|NCT02976961|EXPERIMENTAL|Intervention|Implantable cardioverter defibrillator implant + usual care + supportive care given via an e-health platform. The supportive care consists of information, dialogue with a nurse or psychologist, CBT-based psychological intervention online, quizzes to increase knowledge
62162123|NCT02976961|NO_INTERVENTION|Usual care|Implantable cardioverter defibrillator implant + usual care
62714545|NCT05969275|EXPERIMENTAL|Umbilical Cord Mesenchymal Stromal Cells (UC-MSCs)|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
62714546|NCT05969275|PLACEBO_COMPARATOR|Placebo|Intravenous infusion of placebo, with excipients
62736481|NCT03030352|EXPERIMENTAL|How-to Parenting Program|The How-to Parenting Program consists of seven 2 ½-hour weekly sessions. It is a manual-based program in which participants have their own exercise booklet containing parenting skills and exercises. Groups are led by 2 group leaders and formed of 6 to 10 parents.
62162124|NCT02661581|EXPERIMENTAL|Peer Support|Peer support intervention group: During the first 3 months of DSME, participants in the DSMS intervention group will be invited to attend 6 lifestyle change sessions delivered a 2-person peer leader team and conducted bi-weekly. Immediately following the 3 months of DSME, participants are invited to attend 9 months of weekly DSMS sessions (60-minutes per session) delivered by a Peer Leader. These sessions are designed to sustain the self-management gains achieved in the 3 months of DSME.
62162125|NCT02661581|NO_INTERVENTION|Control|Immediately following the 6 bi-weekly DSME sessions, participants randomized to the control group will have completed their participation in the study.
62162126|NCT03587272|EXPERIMENTAL|SUN regimen|"Alemtuzumab, low dose total body irradiation, Sirolimus~HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, SUN) can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD)."
62162127|NCT06475690|EXPERIMENTAL|AC group|AC group (active communication group): Prior to oocyte retrieval 24h, anesthesiologist and patient sign an informed consent form for anesthesia, then anxiety and depressive symptoms are assessed by scales including APAIS, GAD-7, PHQ-9 and HAD. This is the first score for all questionnaire. Subsequently, active communication will be performed, including addressing surgical procedures, anesthesia processes, and potential complications. No matter whether the patient asks the anesthesiologist about surgery and anesthesia or not, the active communication will be provided. One hour before surgery, patients' anxiety will be reassessed using APAIS. This is the second score for APAIS. Anxiety and depressive symptoms will be evaluated by GAD-7, PHQ-9 and HAD between 24 to 48 hours after oocyte retrieval operation. This is the second score for GAD-7, PHQ-9 and HAD.
62162128|NCT06475690|NO_INTERVENTION|CON group|CON group (control group): Prior to oocyte retrieval 24h, anesthesiologist and patient sign an informed consent form for anesthesia, then anxiety and depressive symptoms are assessed by scales including APAIS, GAD-7, PHQ-9 and HAD. This is the first score for all questionnaire. If a patient doesn't ask any question about surgery or anesthesia, no interpretation will be provided. That is to say, the anesthesiologist will not actively communicate with the patient about surgical and anesthesia issues. One hour before surgery, patients' anxiety will be reassessed using APAIS. This is the second score for APAIS. Anxiety and depressive symptoms will be evaluated by GAD-7, PHQ-9 and HAD between 24 to 48 hours after oocyte retrieval operation. This is the second score for GAD-7, PHQ-9 and HAD.
62162129|NCT06449612|EXPERIMENTAL|'TeleRehaStroke' Intervention Group|"The 'TeleRehaStroke' programme is an application-based training programme for patients after a stroke, comprising three main modules: (1) training, (2) coaching, and (3) monitoring:~Training: Six-week training programmes have been created that focus on the lower extremity and balance. Via the application, patients are provided with a personalised training plan adapted to their individual impairments including exercise videos.~Coaching: Participants will be accompanied by a coaching therapist via messenger, which is included in the application.~Monitoring: Blood pressure measurements can be entered and saved in the application. Questionnaires can be sent to be filled in by the participants."
62162130|NCT06450639|EXPERIMENTAL|Satralizumab|Participants will receive Satralizumab subcutaneous (SC) injection at a dose of 60 mg or 120 mg on Day 1 and Weeks 2 and 4 and then every 4 weeks (Q4W) from Weeks 8 to 104 (maintenance doses) until the study completion visit.
62162131|NCT03229083|EXPERIMENTAL|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
62162132|NCT00483171|PLACEBO_COMPARATOR|Placebo|
62162133|NCT00483171|OTHER|Non-pharmacological weight loss program (NPP)|
62162134|NCT00483171|OTHER|Low Calorie Diet|
62162135|NCT06473272||Symptomatic group|The symptomatic group consisted of patients who were diagnosed with their first ipsilateral ischemic lesions in the carotid territory (anterior circulation) based on head computed tomography (CT) or magnetic resonance imaging (MRI) conducted within the previous 8 weeks.
62162136|NCT06473272||Asymptomatic group|The asymptomatic group included patients who showed no intracranial ischemic lesions on head CT/MRI images and exhibited no neurological symptoms.
62162137|NCT06719973|EXPERIMENTAL|Module 1 (Dose Finding): M9466 + Carboplatin|
62162138|NCT06719973|EXPERIMENTAL|Module 2 Part A (Dose Reassessment): M9466 + Carboplatin + Etoposide + Atezolizumab|
62162139|NCT06719973|EXPERIMENTAL|Module 2 Part B (Dose Expansion): M9466 + Carboplatin + Etoposide + Atezolizumab|
62162140|NCT03704363|EXPERIMENTAL|Infliximab|Intravenous infusion(biosimilar infliximab). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
62162141|NCT03704363|PLACEBO_COMPARATOR|Placebo|Intravenous infusion (NaCl intravenous infusion). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98.
62162142|NCT03749538|EXPERIMENTAL|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: three times, once per day.
62162143|NCT03749538|PLACEBO_COMPARATOR|Placebo|This group will not receive a transcranial direct current stimulation session.
62162144|NCT02068079|OTHER|Vemurafenib and Trientine|
62714547|NCT05283889|EXPERIMENTAL|Group 1 (GRFA)|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
62714548|NCT05283889|ACTIVE_COMPARATOR|Group 2 (Sham)|The same procedure will be employed as per Group 1 - However, the sham procedure will involve no electrical signal applied to the participant.
62162145|NCT06361576||Participants enrolled and treated with nivolumab in the metastatic setting|
62162146|NCT00966641|EXPERIMENTAL|PL 3100|Active experimental drug
62162147|NCT00966641|ACTIVE_COMPARATOR|Naproxen|Active comparator
62162148|NCT01525875|ACTIVE_COMPARATOR|Magnesium oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
62162149|NCT01525875|PLACEBO_COMPARATOR|Placebo|Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
62162150|NCT06457256|EXPERIMENTAL|CLS-A-FUERTE|Receiving the CLS-A-FUERTE program immediately
62162151|NCT06457256|NO_INTERVENTION|School Services as Usual (SA)|Receiving School Services as Usual while waiting to receive the CLS-A-FUERTE program in the subsequent schoolyear
62162152|NCT05844982|ACTIVE_COMPARATOR|Intravitreal faricimab|Study eyes assigned to receive faricimab will receive a dose of 6.0 mg of faricimab. Faricimab is supplied in a single use vial.
62162153|NCT05844982|ACTIVE_COMPARATOR|Fluocinolone Acetonide Intravitreal Implants|Study eyes assigned to receive fluocinolone acetonide intravitreal implant will receive a dose of 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien). The implant is supplied in a sterile single use applicator with a 25-gauge needle
62162154|NCT05844982|NO_INTERVENTION|Observation|
62162155|NCT05468697|EXPERIMENTAL|Part 1 - Beltuzifan 120 mg + Palbociclib 75 mg|Participants receive beltuzifan 120 mg orally once per day (QD) and palbociclib 75 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.
62162156|NCT05468697|EXPERIMENTAL|Part 1 - Beltuzifan 120 mg + Palbociclib 100 mg|Participants receive beltuzifan 120 mg orally QD and palbociclib 100 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.
62162157|NCT05468697|EXPERIMENTAL|Part 1 - Beltuzifan 120 mg + Palbociclib 125 mg|Participants receive beltuzifan 120 mg orally QD and palbociclib 125 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.
62162158|NCT05468697|EXPERIMENTAL|Part 2 - Beltuzifan 120 mg + Palbociclib|Participants receive beltuzifan 120 mg orally QD and palbociclib orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation. Palbociclib will be administered at a dosage level determined in Part 1.
62162159|NCT05468697|EXPERIMENTAL|Part 2 - Beltuzifan 120 mg|Participants receive beltuzifan 120 mg orally QD until progressive disease or discontinuation.
62162160|NCT06614582|EXPERIMENTAL|Self-Supporting Nasopharyngeal Airway (ssNPA)|Participants will use the device up to 24 months.
62162161|NCT05908539|EXPERIMENTAL|Equipment box (general)|A box of exercise equipment is distributed to community dwelling older adults.
62162162|NCT05908539|EXPERIMENTAL|Equipment box with briefing (general)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment is provided to community dwelling older adults.
62162163|NCT05908539|EXPERIMENTAL|Group-based exercise (general)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment and an 8-week group exercise training program is provided to community dwelling older adults.
62162164|NCT05908539|EXPERIMENTAL|Group-based exercise with behavioral modification (general)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment and an 8-week group exercise training program is provided to community dwelling older adults, following by a 6-week behavioral modification.
62162165|NCT05908539|EXPERIMENTAL|Equipment box (home-bound)|A box of exercise equipment is distributed to home-bound community dwelling older adults.
62714549|NCT03361215||Atopic dermatitis|Patients with dermatologist-diagnosed atopic dermatitis, psoriasis or autoimmune skin disease.
62162166|NCT05908539|EXPERIMENTAL|Equipment box with briefing (home-bound)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment is provided to home-bound community dwelling older adults.
62162167|NCT05908539|EXPERIMENTAL|Home-based exercise with behavioral modification (home-bound)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment and an 8-week group exercise training program is provided to home-bound community dwelling older adults, following by a 6-week behavioral modification.
62162168|NCT05451641|EXPERIMENTAL|Wide-rigid cuff|The wide-rigid cuff will be randomly assigned to one of the subject's arms.
62162169|NCT05451641|EXPERIMENTAL|Narrow-elastic band|The narrow-elastic band will be randomly assigned to another arm of the subject.
62162170|NCT04577833|EXPERIMENTAL|Treatment Sequence ABD|Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
62162171|NCT04577833|EXPERIMENTAL|Treatment Sequence ADB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
62162172|NCT04577833|EXPERIMENTAL|Treatment Sequence CBD|Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
62162173|NCT04577833|EXPERIMENTAL|Treatment Sequence CDB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
62162174|NCT02693548||Familial hypercholesterolaemia patients|Index cases with genetic diagnosis of FH and their relatives over 15 years old with a genetic diagnosis of FH.
62162175|NCT02693548||Unaffected relatives|Relatives of FH patients without FH (genetically defined)
62162176|NCT00473031|EXPERIMENTAL|1|High Protein
62162177|NCT00473031|ACTIVE_COMPARATOR|2|Normal Protein
62162178|NCT05121012||Group 1|Patients with MSA-P
62162179|NCT06721728|EXPERIMENTAL|Type 1 diabetes mellitus children|children diagnosed with type 1 diabetes mellitus will receive an educational program with oral hygiene measures and diet advice related to their condition.
62162180|NCT04915625||Death group|Retrospective observational studies
62535793|NCT02504671|EXPERIMENTAL|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid \>=5 mg/week.
62162181|NCT04915625||Survival group|Retrospective observational studies
62162182|NCT05264506|EXPERIMENTAL|Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A)|The NOMAC-E2 COC active tablets contain 2.5 mg NOMAC and 1.5 mg E2 and will be used in a 24/4 regimen, i.e., 28-day cycles with 24 days of active tablet intake followed by 4 days of placebo tablet intake.
62162183|NCT00087516|ACTIVE_COMPARATOR|Sitagliptin 100 mg/100 mg|Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
62162184|NCT00087516|ACTIVE_COMPARATOR|Sitagliptin 200 mg/200 mg|Phase A and B: Oral tablets of sitagliptin 200 mg q.d
62162185|NCT00087516|PLACEBO_COMPARATOR|Placebo/Sitagliptin 100 mg|Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
62162186|NCT00087516|PLACEBO_COMPARATOR|Placebo/Sitagliptin 200 mg|Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.
62162187|NCT03586284|ACTIVE_COMPARATOR|Oral Valganciclovir|Oral Valganciclovir 900mg PO BID Topical placebo solution, 1 drop applied 6 times daily
62162188|NCT03586284|ACTIVE_COMPARATOR|Topical Ganciclovir 2%|Topical Ganciclovir 2% solution, 1 drop applied 6 times daily Placebo pills PO BID
62162189|NCT03586284|PLACEBO_COMPARATOR|Placebo|Topical placebo solution, 1 drop applied 6 times daily Placebo pills PO BID
62162190|NCT02814461|EXPERIMENTAL|Axitinib|Combined axitinib and radiotherapy (fixed strength)
62162191|NCT02896153||Adult population going to a pharmacy|Adult population going to a pharmacy will be asked to complete a questionnaire.
62162192|NCT04560049|EXPERIMENTAL|Phenolisation|Surgical pit excision and phenolisation of sinus tract
62162193|NCT04560049|ACTIVE_COMPARATOR|Silver Nitrate Irrigation|Surgical pit excision and silver nitrate irrigation of sinus tract
62162194|NCT06720038|EXPERIMENTAL|VAX-31 Low|Participants will receive 4 doses of VAX-31 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
62162195|NCT06720038|EXPERIMENTAL|VAX-31 Mid|Participants will receive 4 doses of VAX-31 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
62162196|NCT06720038|EXPERIMENTAL|VAX-31 High|Participants will receive 4 doses of VAX-31 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
62162197|NCT06720038|ACTIVE_COMPARATOR|PCV20|Participants will receive 4 doses of PCV20 administered as an intramuscular injection of the standard dose at 2, 4, 6, and 12-15 months of age.
62162198|NCT03774082|EXPERIMENTAL|INC424 (ruxolitinib)|Subjects who will be administered 5mg ruxolitinib tablet or ruxolitinib oral pediatric formulation twice a day.
62162199|NCT02588027|ACTIVE_COMPARATOR|Control|Ibuprofen 400mg by mouth three times daily. Patients will also receive the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
62535794|NCT02504671|EXPERIMENTAL|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid \>=5 mg/week.
62162200|NCT02588027|PLACEBO_COMPARATOR|Placebo|Placebo tablet by mouth three times daily. Patients will also received the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
62162201|NCT00628706|EXPERIMENTAL|A|Inhalation of THC, using a Volcano vaporizer
62162202|NCT00628706|PLACEBO_COMPARATOR|B|Inhalation of vehicle, using a Volcano vaporizer
62162203|NCT05486819|ACTIVE_COMPARATOR|Group (L)|receive 3 ml (60 mg) of lignocaine 2% added to propofol during injection
62162204|NCT05486819|ACTIVE_COMPARATOR|Group (B)|receive 3 ml of sodium bicarbonate 8.5% added to propofol during injection
62162205|NCT05486819|PLACEBO_COMPARATOR|Group (S)|receive 3 ml of normal saline added to propofol during injection
62162206|NCT05838300|EXPERIMENTAL|Warm humidified CO2|
62162207|NCT05838300|ACTIVE_COMPARATOR|Dry CO2|
62162208|NCT04953793|EXPERIMENTAL|TAY SUCCESS intervention|This intervention group received the TAY SUCCESS intervention over the course of 1 school year approximately 30 sessions.
62162209|NCT04953793|ACTIVE_COMPARATOR|Usual Care|This usual care group received typical High school or transition program curriculum over the course of 1 school year.
62162210|NCT00755248||1|Pts undergoing CABG or OPCAB
62162211|NCT06211764|EXPERIMENTAL|Group A: TAR-200|Participants will receive intravesical TAR-200 every 3 weeks during an induction phase and every 12 weeks during a maintenance phase.
62162212|NCT06211764|ACTIVE_COMPARATOR|Group B: Mitomycin C (MMC) or Gemcitabine|Participants will receive either single agent intravesical MMC or gemcitabine every week during an induction phase and every 4 weeks during a maintenance phase.
62162213|NCT06415552|OTHER|Mindfulness-Based Stress Reduction|8-week Mindfulness-Based Stress Reduction course
62535795|NCT02504671|EXPERIMENTAL|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid \>=5 mg/week.
62535796|NCT02504671|EXPERIMENTAL|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid \>=5 mg/week.
62535797|NCT02504671|PLACEBO_COMPARATOR|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid \>=5 mg/week.
62535798|NCT05102214|EXPERIMENTAL|Phase 1a dose-escalation stage|Phase 1a uses the Bayesian optimal interval (BOIN) design, to investigate the safety and determine the MTD of HLX301. Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 15 mg/kg are planned for dose finding. Intra-patient dose escalation is not permitted. Enrollment will continue until a maximum of 30 patients are enrolled.
62162214|NCT06347211|ACTIVE_COMPARATOR|HPI + GDHT treatment|HPI + GDHT using Acumen IQ and Hemosphere monitor with HPI algorithm incorporated following our protocol for hemodynamic treatment (fluids,vasopressors and inotropes).
62162215|NCT06347211|NO_INTERVENTION|Control|Conventional treatment with invasive blood pressure monitoring. Administration of fluids and/or vasopressors are guided by standard hemodynamic parameters at the discretion of the attending physician.
62162216|NCT01202344|OTHER|Restenosis|Patients who have restinosis immediately following angioplasty.
62162217|NCT01202344|OTHER|No Restenosis|Patients who do not have restinosis immediately following angioplasty.
62162218|NCT03901963|EXPERIMENTAL|Daratumumab + Lenalidomide|Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
62162219|NCT03901963|ACTIVE_COMPARATOR|Lenalidomide|Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
62162220|NCT04636463|EXPERIMENTAL|Hand Surgery with Music|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) while listing to music
62162221|NCT04636463|NO_INTERVENTION|Hand Surgery without Music (Control Group)|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) without listening to music
62162222|NCT00872404|EXPERIMENTAL|1|CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion
62162223|NCT06721117||Dentists|"The participants of the study will consist of dentists working at Sakarya Oral and Dental Health Hospital. The aim is to include 50 dentists in the study. The individuals to be included in the study will be selected by random lottery.~Inclusion criteria; To have graduated from the Faculty of Dentistry To have 1 year or more professional experience~Exclusion criteria; To have received physical therapy from any region in the last 6 months or to be currently receiving physical therapy, To have a congenital musculoskeletal deformity, To have a neurological or rheumatic disease, To have undergone surgery due to a musculoskeletal disorder."
62162224|NCT05259592|EXPERIMENTAL|Modular Patient Centred CBT (MPC) for CPTSD|MPC (Folke, Friis, Thomsen \& Roitmann, 2020) is a treatment programme consisting of up to 32 therapy sessions broken down by five treatment modules (each consisting of six sessions). Prior to the treatment modules, the client completes an intro module (two sessions) focusing on psyhoeducation on CPTSD, individual case formulation and introduction to the further treatment programme. After the intro module (and after each treatment module), the client and therapist jointly decide which treatment module to proceed with based on 'co-decision'. The treatment modules directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares. Each treatment module is structured in such a way that it can be offered alone and independently of the other modules.
62162225|NCT05259592|ACTIVE_COMPARATOR|Modular CBT for CPTSD without co-decision|Because the study investigates a potentially beneficial effect of including the client directly in treatment decisions (by having the client determine the order of treatment modules together with the therapist), the patient-centred version of the treatment is compared with a control treatment, where the five treatment modules are delivered in a predefined order. The control treatment thus consists of the same treatment components as described above. It is only the aspect of co-decision that has been taken out. Instead, the therapist will just inform the client about the order of treatment modules in the programme. The order of treatment modules in the control treatment will be: 1) Affect dysregulation (6 sessions), 2) Disturbed relationships (6 sessions), 3) Negative self-concept (6 sessions), 4) PTSD symptoms (6 sessions) and 5) Insomnia and trauma-related nightmares (6 sessions).
62162226|NCT06516562||Heart failure with reduced or mildly reduced ejection fraction|
62162227|NCT00719719||Drug Anaphylaxis|Drug Anaphylaxis
62162228|NCT00719719||Food Anaphylaxis|Food Anaphylaxis
62162229|NCT00719719||Idiopathic Anaphylaxis|Idiopathic Anaphylaxis
62162230|NCT00719719||Venom Anaphylaxis|Venom Anaphylaxis
62162231|NCT06494033||Prophylaxis guided by Cytomegalovirus-specific T cell Immunity|The immunological response of participants in this group will be followed for 1 year.
62162232|NCT05791786||AFE|"participants of the AFE registry and biorepository include affected individuals diagnosed with AFE~All subjects or their next of kin must be able to provide a signed and dated informed consent form.~In the case of lethal AFE, the surviving family member or next of kin must be able to provide a signed and dated informed consent form with an accompanying death certificate and proof of legal kinship"
62535799|NCT05102214|EXPERIMENTAL|Phase 1b dose-expansion stage|Patients with NSCLC will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX301. Phase 1b dose expansion will include 20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
62535800|NCT05102214|EXPERIMENTAL|Phase 2 clinical expansion stage: Cohort A|20 per-protocol treated patients with non-small cell lung cancer (NSCLC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
62714550|NCT03361215||Controls|Healthy volunteers with no history of atopic, autoimmune or chronic inflammatory disease.
62535801|NCT05102214|EXPERIMENTAL|Phase 2 clinical expansion stage: Cohort B|20 per-protocol treated patients with gastric/esophagogastric junction adenocarcinoma (GC/EGJ), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
62714551|NCT03170518|EXPERIMENTAL|Single-blind run-in Period: Placebo|Participants will receive 1 placebo tablet matching canagliflozin 100 milligram (mg) once-daily during the 2-week single-blind placebo run-in period.
62714552|NCT03170518|EXPERIMENTAL|Double-blind Treatment Phase: Canagliflozin or Placebo|Canagliflozin 100 mg/matching placebo once-daily during first 12 weeks. At Week 13, participants who have glycated hemoglobin (HbA1c) of greater than or equal to (\>=)7.0 percent (%), estimated glomerular filtration rate (eGFR) \>=60 milliliter/minute/1.73 meter square (mL/min/1.73 m\^2) will be re-randomized to either remain on canagliflozin 100 mg/matching placebo or up-titrate to canagliflozin 300 mg/matching placebo till Week 52.
62162233|NCT05201781|EXPERIMENTAL|Cilta-cel|Participants who had previously received treatment with cilta-cel in a Company-sponsored clinical study (example, NCT04923893, NCT03758417, NCT04181827, NCT05347485, NCT04133636, and NCT03548207) in the global development program will be enrolled into this study once the individual's participation in the particular interventional study has ended or a study has been terminated. Participants will not receive any treatment in this study and will be followed-up at least once per year on delayed adverse events for up to 15 years after receiving the last dose of cilta-cel.
62162234|NCT06406361|EXPERIMENTAL|Experimental group|Stress management training is planned to be applied once a week as a total of 6 sessions of 40 minutes to nurses.
62162235|NCT06406361|NO_INTERVENTION|control group|not intervention
62162236|NCT06082687||de-identified human tissue|This Project will receive de-identified human tissue from cooperating institutions for unknown/undisclosed donors.
62162237|NCT02420847|EXPERIMENTAL|Treatment (ixazomib, gemcitabine, doxorubicin)|Patients receive ixazomib citrate PO, gemcitabine hydrochloride IV over 90 minutes, and doxorubicin hydrochloride IV over 15-30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
62162238|NCT01093976|EXPERIMENTAL|Dronabinol|Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks
62162239|NCT02338310|NO_INTERVENTION|No Aromatase Inhibitor|No aromatase inhibitor given around the time of surgery
62162240|NCT02338310|EXPERIMENTAL|Aromatase Inhibitor|Aromatase Inhibitor given perioperatively for 4 weeks (two weeks before and two weeks after surgery) Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day)
62162241|NCT06381921|EXPERIMENTAL|IBS-PPSM intervention group|After the baseline visit, the IBS-PPSM group will receive 10 video modules focused on IBS knowledge and self-management skills plus one-on-one consultation with a nurse for personalized advice about self-monitoring, diet, sleep, and goal setting. The IBS-PPSM group will be taught to use the abdominal belt/smart watch system for daily recording of bio-signals and voluntary report of episodes of visceral pain. We will follow up with all participants 4 weeks after enrollment, in a final lab visit, and measure primary outcomes to compare to the baseline data.
62162242|NCT06381921|NO_INTERVENTION|IBS-control group|The IBS-control group will not receive pain self-management intervention. Participants will be taught to use the abdominal belt/smart watch system for daily recording of bio-signals and voluntary report of episodes of visceral pain. We will follow up with all participants 4 weeks after enrollment, in a final lab visit, and measure primary outcomes to compare to the baseline data.
62162243|NCT02011568|OTHER|Moderate hypothermia|Therapeutic hypothermia at 31 degrees celsius
62162244|NCT02011568|ACTIVE_COMPARATOR|Mild Hypothermia|Therapeutic Hypothermia at 34 degrees Celsius
62162245|NCT05584397||Tenofovir-containing ART|Cohort 1: Tenofovir-containing ART (tenofovir disoproxil fumarate \[TDF\] OR tenofovir alafenamide \[TAF\] PLUS any other ART drugs) prescribed for daily use by participants' primary care providers.
62162246|NCT05584397||NRTI-sparing ART|Cohort 2: NRTI-sparing ART (specifically: rilpivirine PLUS dolutegravir OR rilpivirine PLUS cabotegravir) prescribed for daily use by participants' primary care providers.
62162247|NCT05083169|EXPERIMENTAL|Arm A: Teclistamab-daratumumab (Tec-Dara)|Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose.
62162248|NCT05083169|EXPERIMENTAL|Arm B: DPd or DVd|Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously.
62162249|NCT05250973|EXPERIMENTAL|Cohort1 (Arm A): Daratumumab + Immediate Cyclophosphamide, Bortezomib and Dexamethasone (VCd)|Participants with newly diagnosed systemic amyloid light chain (AL) amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive daratumumab 1800 milligrams (mg) subcutaneously (SC) starting on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] either orally or intravenously \[IV\], bortezomib 1.3 mg/m\^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
62535802|NCT05102214|EXPERIMENTAL|Phase 2 clinical expansion stage: Cohort C|20 per-protocol treated patients with head and neck squamous cell carcinoma (HNSCC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
62535803|NCT05102214|EXPERIMENTAL|Phase 2 clinical expansion stage: Cohort D|20 per-protocol treated patients with urothelial carcinoma (UC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
62535804|NCT06086392|ACTIVE_COMPARATOR|Placebo|0.2% ropivacaine for supraclavicular brachial plexus block
62535805|NCT06086392|ACTIVE_COMPARATOR|0.1mg/kg Dexamethasone|0,1mg/kg dexamethasone added to 0.2% ropivacaine for supraclavicular brachial plexus block
62535806|NCT06086392|ACTIVE_COMPARATOR|0,05mg/kg dexamethasone|0,05mg/kg dexamethasone added to 0.2% ropivacaine for supraclavicular brachial plexus block
62535807|NCT01782300|EXPERIMENTAL|TV003 Vaccine|Participants will receive an injection of the TV003 vaccine at study entry and Day 360.
62535808|NCT01782300|PLACEBO_COMPARATOR|Placebo Vaccine|Participants will receive an injection of the placebo vaccine at study entry and Day 360.
62535809|NCT03579927|EXPERIMENTAL|Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)|Participants receive rituximab IV over 3 hours on days -14 and -8, carmustine IV over 2 hours on day -13, etoposide IV over 3 hours BID on days -12 to -9, cytarabine IV over 1 hour BID on days -12 to -9, melphalan IV over 30 minutes on day -8, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5. Participants undergo ASCT on day 0. Beginning day 0, participants receive filgrastim SC QD until evidence of an ANC of 0.5 x 10\^9/L per 3 consecutive days.
62736482|NCT03030352|NO_INTERVENTION|Wait-list Control Group|Parents assigned to the wait-list control group will receive no intervention for the duration of the trial. The How-to Parenting Program will be delivered to them the following year. This delayed participation is ethically sound, as the program does not target at-risk families.
62162250|NCT05250973|EXPERIMENTAL|Cohort1 (Arm B): Daratumumab + Deferred VCd|Participants with newly diagnosed systemic AL amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive SC daratumumab 1800mg on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (Cyclophosphamide 300 mg/m\^2 either orally or IV, Bortezomib 1.3 mg/m\^2 SC or IV, Dexamethasone 40 mg weekly either orally or IV) starting at Cycle 4 Day 1, weekly (Days 1, 8, 15, 22) in every 28-day cycle for a maximum of 6 cycles (Cycle 9 Day 22).
62162251|NCT05250973|EXPERIMENTAL|Cohort 2: Daratumumab + VCd|Participants with racial and ethnic minorities, including Black or African American participants, with newly diagnosed AL amyloidosis will receive SC injection of daratumumab 1800 mg SC on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] either orally or intravenously \[IV\], bortezomib 1.3 mg/m\^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
62162252|NCT05441410|EXPERIMENTAL|PfSPZ-CVac/Pyramax|200.000 PfSPZ of PfSPZ Challenge NF54 will be administered by DVI along with one weight-adjusted oral dose of Pyramax each on day 1, day 6, and day 29
62162253|NCT05441410|EXPERIMENTAL|MVA ME-TRAP/ChAd63 ME-TRAP|MVA ME-TRAP 1.5 x 10\^8 pfu will be administered intramuscularly on day 1 for priming. ChAd63 ME-TRAP 5 x 10\^10 vp will subsequently administered by DVI on day 29.
62162254|NCT05441410|PLACEBO_COMPARATOR|Saline/placebo pill|"As placebo comparator to PfSPZ-CVac/Pyramax, saline will be administered intravenously along with an oral placebo pill on day 1, day 6, and day 29.~As placebo comparator to MVA ME-TRAP/ChAd63 ME-TRAP, saline will be administered intramuscularly on day 1 and intravenously on day 29. No placebo pill will be used to compare to the arm MVA ME-TRAP/ChAd63 ME-TRAP."
62162255|NCT04993313|EXPERIMENTAL|Arm I (counseling, photo guide)|Patients undergo verbal counseling and view a photo guide. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
62162256|NCT04993313|ACTIVE_COMPARATOR|Arm II (counseling)|Patients undergo verbal counseling. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
62162257|NCT04397263|EXPERIMENTAL|Guselkumab|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.
62162258|NCT06670755|EXPERIMENTAL|Group A: 2 doses of ID93/GLA-SE with 1 x 10^7 cfu BCG (historically BCG-vaccinated group)|12 historically BCG-vaccinated volunteers will be vaccinated with 2 doses of ID93/GLA-SE and after 112 days receive 1 x 10\^7 cfu aerosol inhaled BCG as a challenge. All Group A volunteers will have a bronchoscopy 14 days post challenge.
62162259|NCT06670755|EXPERIMENTAL|Group B: 1 x 10^7 cfu BCG (historically BCG-vaccinated group)|12 historically BCG-vaccinated volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG. All Group B volunteers will have a bronchoscopy 14 days post challenge.
62162260|NCT06670755|EXPERIMENTAL|Group C: 2 doses of ID93/GLA-SE with 1 x 10^7 cfu BCG (BCG-naïve group)|12 BCG-naïve volunteers will be vaccinated with 2 doses of ID93/GLA-SE and after 112 days receive 1 x 10\^7 cfu aerosol inhaled BCG as a challenge. All Group C volunteers will have a bronchoscopy 14 days post challenge.
62162261|NCT06670755|EXPERIMENTAL|Group D: 1 x 10^7 cfu BCG (BCG-naïve group)|12 BCG-naïve volunteers will receive 1 x 10\^7 cfu aerosol inhaled BCG. All Group D volunteers will have a bronchoscopy 14 days post challenge.
62162262|NCT05000593|EXPERIMENTAL|stem cell treating group|Intra-articular injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 1 week for a total of 3 times.
62162263|NCT06720428|EXPERIMENTAL|Dry eye acupoint therapy instrument treatment group One|Dry eye acupoint therapy instrument treatment group One was treated with instrument twice a week, at least two day apart, each time lasting 30 minutes. Treatment points include Jingming, Cunzhu, Si Zhukong , Sun , Sibai and Chengqi.
62535810|NCT05408234|EXPERIMENTAL|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
62535811|NCT04308226|NO_INTERVENTION|Usual care without patient navigation|Participants assigned to this arm will be given basic educational materials on general lung health and referred back to their primary care provider (PCP) for management as per usual practice.
62535812|NCT04308226|EXPERIMENTAL|Usual care with patient navigation|Participants assigned to this arm will be informed about lung cancer screening (LCS), provided educational materials on LCS and patient navigation, and offered access to an LCS navigator who will partner with participants and primary care providers (PCPs) to facilitate low-dose computed tomography (LDCT) completion and follow-up.
62162264|NCT06720428|EXPERIMENTAL|Dry eye acupoint therapy instrument treatment group Two|Dry eye acupoint therapy instrument treatment group Two had the same treatment method with different treatment parameters.
62162265|NCT06720428|ACTIVE_COMPARATOR|Artificial tear treatment group|The artificial tear treatment group was treated with artificial tear (Ali eye drops) four times a day.
62162266|NCT05172063||Persistent SARS-CoV-2 Infection Group|Pediatric Cancer patients with persistent SARS-CoV-2 infection
62162267|NCT05172063||SARS-CoV-2 Clearance Group|Pediatric Cancer patients who tested negative for SARS-CoV-2 within 14 days of diagnosis.
62535813|NCT01120704|EXPERIMENTAL|1, 26Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62736483|NCT03593486|EXPERIMENTAL|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
62162268|NCT06658704|EXPERIMENTAL|Exercise intervention|Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks. Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16. Follow-up tests is also included after 6-, 12- and 24 months.
62162269|NCT06658704|ACTIVE_COMPARATOR|Control|Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks. Follow-up tests is also included after 6-, 12- and 24 months.
62162270|NCT05526001|EXPERIMENTAL|ELIXCYTE|Subjects will be intra-articular (IA) injected with 4 mL of ELIXCYTE (containing 32×10\^6 ADSCs) at the target knee once
62162271|NCT05526001|PLACEBO_COMPARATOR|Placebo control (Saline)|Subjects will be intra-articular (IA) injected with 4 mL of saline at the target knee once
62162272|NCT04902040|EXPERIMENTAL|Arm A (radiation therapy, plinabulin, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients receive plinabulin IV over 30-60 minutes on days 1 and 4 of cycle 1, days 1 and 4 of cycle 2 (if receiving radiation therapy in cycle 2), and day 1 and or 15 (any day receiving immunotherapy) of subsequent cycles. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
62162273|NCT04902040|ACTIVE_COMPARATOR|Arm B (radiation therapy, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
62162274|NCT05125510||Hospitalized ICU Cohort|COVID-19+ patients over age 16 who are critically ill and admitted to an ICU and/or required mechanical ventilation (MV) in participating hospitals will be invited to participate. Patients who were hospitalized prior to study start up will be invited to participate in CANCOV.
62162275|NCT05125510||Hospitalized non-ICU Cohort|COVID-19+ patients over age 16 admitted to acute care hospitals, GIM/other wards of participating hospitals will be invited to participate. Patients who were hospitalized prior to this study start up (from January 25, 2020 to study start up) will be invited to participate in this study.
62162276|NCT05125510||Non-Hospitalized Cohort|Individuals who are community dwelling, over the age of 16, are COVID-19+ and never hospitalized for their COVID-19 infection are included. These individuals may be diagnosed by participating hospital emergency rooms / in-person assessment centres / virtual clinics. In addition, we will include individuals who were diagnosed from January 25, 2020 within 6 months of study start up.
62162277|NCT05125510||Caregiver Cohort|Up to 500 family caregivers of patients admitted to the GIM wards and ICUs of participating hospitals will be invited to participate.
62162278|NCT05125510||Antibody Negative/Presumed COVID-19 comparator cohort|Approximately 500 individuals who do not have a positive COVID-19 test (nasal swab, serological antibody assay, etc.) but who have experienced COVID-19 symptoms and have strong epidemiologic links suggesting probable COVID-19 infection (such as household or occupational contacts and close timing of their symptoms to an index case) will be invited to participate.
62162279|NCT06721325|EXPERIMENTAL|EXPERIMENTAL|Psychotherapy, legal advice and physiotherapy intervention
62162280|NCT06721325|ACTIVE_COMPARATOR|CONTROL|Psychotherapy and legal advice
62162281|NCT05698199|EXPERIMENTAL|Participants with Newly Diagnosed Glioblastoma (GBM)|Ten participants with histopathological diagnosis of WHO grade IV glioma (Glioblastoma; GBM) and have undergone a gross/near gross total surgical resection of tumor by analysis of residual enhancing tumor remnant on the immediate post-operative MRI
62535814|NCT01120704|EXPERIMENTAL|2, 26Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62162282|NCT01518517|EXPERIMENTAL|GRASPA|"Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).~GRASPA® administration takes place as below:~* for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)~* for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)"
62162283|NCT01518517|ACTIVE_COMPARATOR|reference L-asparaginase|"For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).~•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).~NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)~•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles)."
62535815|NCT01120704|EXPERIMENTAL|3, 26Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62736484|NCT03593486|SHAM_COMPARATOR|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
62162284|NCT01823458|EXPERIMENTAL|Lottery Insurance|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
62535816|NCT01120704|EXPERIMENTAL|4, 26Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535817|NCT01120704|EXPERIMENTAL|5, 26Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62162285|NCT01823458|EXPERIMENTAL|Standard Lottery|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Subjects in the 'Standard Lottery' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They also receive the expected value of the insurance ($2) for attending a second exercise class during the week on either Wednesday or Thursday. They have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
62162286|NCT06517706|SHAM_COMPARATOR|Control Condition|Combination of cognitive training with sham tDCS
62162287|NCT06517706|EXPERIMENTAL|Experimental Condition|Combination of cognitive training with active tDCS
62162288|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
62162289|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
62162290|NCT04360928|EXPERIMENTAL|Graymont X ERIS Knee Splint Degree Splinting Group|These patients will be randomized to receive the Graymont X ERIS Knee Splint. Patients will follow the same standardized postoperative rehabilitation protocol.
62162291|NCT04360928|SHAM_COMPARATOR|Standard Hinged Knee Brace|These patients will be randomized to receive a standard hinged knee brace. Patients will follow the same standardized postoperative rehabilitation protocol.
62162292|NCT04750447||Open Angle Glaucoma|Patients aged 30-90 Primary open angle glaucoma on maximum tolerated medical therapy Going to receive XEN63 ab interno gelatin stent with or without MMC in study eye ± cataract surgery
62162293|NCT05655260|EXPERIMENTAL|p53 abn subtype and nonendometrioid carcinomas|p53 abn stage I-II MI (myometrial invasion) \>0%; MMR-D/NSMP nonendometrioid stage I-II MI \>0%
62162294|NCT05655260|EXPERIMENTAL|MMR-D molecular subgroup|MMR-D stage IA-B grade 1-2, substantial LVSI; MMR-D stage IA grade 3, substantial LVSI; MMR-D stage IB grade 3; MMR-D stage II grade 1-3;
62162295|NCT05655260|EXPERIMENTAL|NSMP molecular subgroup|NSMP stage IA-B grade 1-2, substantial LVSI; NSMP stage IA grade 3, substantial LVSI; NSMP stage IB grade 3; NSMP stage II grade 1-3;
62162296|NCT02342275|ACTIVE_COMPARATOR|Propranolol|Propranolol
62162297|NCT02342275|ACTIVE_COMPARATOR|Atenolol|Atenolol
62162298|NCT06394193|EXPERIMENTAL|Community-based Participatory Research|Coaching a six-month soccer program with the Va Meh Du intervention
62162299|NCT06394193|NO_INTERVENTION|Standard Soccer Coaching|Standard six month soccer program without the Va Meh Du Intervention.
62162300|NCT06318169|EXPERIMENTAL|Pegozafermin Regimen 1|
62535818|NCT01120704|EXPERIMENTAL|6, 26Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62162301|NCT06318169|EXPERIMENTAL|Pegozafermin Regimen 2|
62162302|NCT06318169|PLACEBO_COMPARATOR|Placebo|Matched Placebo will be administered in Regimens 1 and 2.
62736485|NCT02398136|EXPERIMENTAL|Ketamine|Intranasal ketamine up to 75 mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
62162303|NCT06715787|EXPERIMENTAL|FEAST Perinatal Support Program|Active behavioral intervention
62162304|NCT06715787|NO_INTERVENTION|Control with standard care|This arm is a waitlist control with receipt of written materials on improving diet.
62162305|NCT03590847|EXPERIMENTAL|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
62162306|NCT04429087|EXPERIMENTAL|Arm 1: BI 764532|
62162307|NCT04429087|EXPERIMENTAL|Arm 2: BI 764532|
62162308|NCT06116786|EXPERIMENTAL|Part 1: JNJ-86974680+Cetrelimab|Participants will receive JNJ-86974680 alone (dose 1, dose 2, dose 3, and dose 4) daily in 4 cohorts and then along with a set dose of cetrelimab.
62162309|NCT06116786|EXPERIMENTAL|Part 2: JNJ-86974680+Cetrelimab+Radiation Therapy (RT)|Participants will receive treatment with the identified safe dose of JNJ-86974680 in combination with cetrelimab from part 1, in conjunction with radiation.
62162310|NCT06288347|EXPERIMENTAL|Experimental group|The experimental group used the GGON module for 15 days after the first assessment.
62162311|NCT06288347|ACTIVE_COMPARATOR|Control group|The control group used the GGON module for 15 days after the second assessment.
62162312|NCT05710614|ACTIVE_COMPARATOR|animal protein|Whey protein will be used as the active comparator for animal protein arm
62162313|NCT05710614|EXPERIMENTAL|plant protein|A combination of pea and soy protein will be used as the experimental arm
62162314|NCT00635323|EXPERIMENTAL|A|
62162315|NCT06431360|EXPERIMENTAL|Experimental group|Sr-90 brachytherapy followed by hyperthermia.
62162316|NCT06431360|NO_INTERVENTION|Control group|Sr-90 brachytherapy alone.
62162317|NCT06028438|ACTIVE_COMPARATOR|Certolizumab + Placebo|Participants will receive placebo intravenously (IV) and certolizumab dose 1 subcutaneously at Week 0, 2, and 4 followed by placebo IV and certolizumab dose 2 subcutaneously at Weeks 6 to 22.
62162318|NCT06028438|EXPERIMENTAL|Certolizumab + Nipocalimab|Participants will receive nipocalimab IV and certolizumab dose 1 subcutaneously at Week 0, 2, and 4 followed by nipocalimab IV and certolizumab dose 2 subcutaneously at Weeks 6 to 22.
62162319|NCT06466798|EXPERIMENTAL|Nivolumab plus Methotrexate|"Enrolled patients with medulloblastoma and other CNS malignancies will receive:~1. Intraventricular Methotrexate infusions 2 mg daily for 4 consecutive days per week every other week on weeks 1, 3, 5, 7, 9, and 11.~2. Intraventricular Nivolumab infusions. Nivolumab will be administered once every other week on weeks 2, 4, 6, 8, 10, and 12. Dosing will be based upon patient body weight."
62162320|NCT06466798|EXPERIMENTAL|Nivolumab plus 5-Azacytidine|"Enrolled patients with ependymoma will receive:~1. Intraventricular 5-Azacytidine infusions 10 mg once weekly for twelve consecutive weeks.~2. Intraventricular Nivolumab infusions once every other week on weeks 1, 3, 5, 7, 9, and 11. Dosing will be based upon patient body weight."
62162321|NCT03672188|EXPERIMENTAL|Part A: SAD VIR-2218 50 mg|Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
62162322|NCT03672188|EXPERIMENTAL|Part A: SAD VIR-2218 100 mg|Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
62162323|NCT03672188|EXPERIMENTAL|Part A: SAD VIR-2218 200 mg|Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
62162324|NCT03672188|EXPERIMENTAL|Part A: SAD VIR-2218 400 mg|Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
62162325|NCT03672188|EXPERIMENTAL|Part A: SAD VIR-2218 600 mg|Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
62162326|NCT03672188|EXPERIMENTAL|Part A: SAD VIR-2218 900 mg|Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
62162327|NCT03672188|PLACEBO_COMPARATOR|Part A: SAD Placebo|Healthy subjects received a single dose of placebo administered SC
62162328|NCT03672188|EXPERIMENTAL|Part B: MAD VIR-2218 20 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
62162329|NCT03672188|EXPERIMENTAL|Part B: MAD VIR-2218 50 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
62162330|NCT03672188|EXPERIMENTAL|Part B: MAD VIR-2218 100 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
62162331|NCT03672188|EXPERIMENTAL|Part B: MAD VIR-2218 200 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
62162332|NCT03672188|EXPERIMENTAL|Part C: MAD VIR-2218 50 mg|Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
62162333|NCT03672188|EXPERIMENTAL|Part C: MAD VIR-2218 200 mg|Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
62162334|NCT03672188|PLACEBO_COMPARATOR|Part B: MAD Placebo|Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
62162335|NCT03672188|PLACEBO_COMPARATOR|Part C: MAD Placebo|Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
62162336|NCT06721039|ACTIVE_COMPARATOR|Group 1|Bilateral QL block: sonovisible block needle will be inserted under ultra-sonographic monitoring between the iliac wing and rib at the midaxillary line for the TQL block in the lateral decubitus positioning of the patient. The space between the quadratus lumborum and psoas major muscles will be visualized with Ultrasound Guided and 0.25% bupivacaine will be injected after visualization of the tip of the needle reaching the plane, 2ml of anaesthetic solution will be instilled to view the hydro dissection, confirming the correct placement. Following this, the total volume of 40 ml of 0.25% bupivacaine will be instilled, creating a meniscus between the planes
62162337|NCT06721039|ACTIVE_COMPARATOR|Group 2|Intraperitoneal and port sites infiltration with 40 ml of 0.25% bupivacaine will be injected under the direct vision into the hepato-diaphragmatic space, near and above the hepato-duodenal ligament and above the gall bladder also injected at the port sites at the end of operation before removal of the probes
62162338|NCT06574503|EXPERIMENTAL|GP681 tablet 40mg|atients in the GP681 tablet 40mg group will receive a single oral dose of GP681 tablet 40mg with water.
62162339|NCT06574503|PLACEBO_COMPARATOR|Placebo group|Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg with water.
62162340|NCT03772119||Surgical treatment of hemivertebra|cohort of children with a vertebral malformation treated by surgical resection
62162341|NCT05968326|EXPERIMENTAL|Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX|Participants will receive autogene cevumeran, atezolizumab and mFOLFIRINOX.
62162342|NCT05968326|ACTIVE_COMPARATOR|Arm 2: mFOLFIRINOX|Participants will receive mFOLFIRINOX.
62162343|NCT05686343||Treated|
62162344|NCT05686343||Untreated|
62162345|NCT06635135|EXPERIMENTAL|Aticaprant|
62162346|NCT06635135|PLACEBO_COMPARATOR|Placebo|
62162347|NCT05935982|EXPERIMENTAL|Virtual reality exercise program in special physical education|During normal special physical education hours, participants will be provided with a virtual reality headset and exercise games and be prescribed to exercise at a moderate intensity.
62162348|NCT05444777|EXPERIMENTAL|Ketamine group (Group K)|Group K was given ketamine @ 0.5mg/kg (prepared by dilution in 0.9% normal saline in 10 ml syringe) at the time of wound closure.
62162349|NCT05444777|OTHER|Saline group (Group S)|Group S was given saline in 10 ml syringe
62162350|NCT05390697|EXPERIMENTAL|Intervention group|The educational videos included five modules distributed over five weeks.
62162351|NCT05390697|NO_INTERVENTION|Control group|Participants in the control group were given exposure to the digital version of the MCH handbook, 2020 edition, consisting of animated pictures and simple instructions.
62162352|NCT03907046|ACTIVE_COMPARATOR|Apixaban|Apixaban dosing will be 5 mg tablet in morning and 5 mg tablet in evening. A reduced dose of 2.5 mg tablet in morning and 2.5 mg tablet in evening will be used if: (1) ≥2 of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine 1.5-2.4 mg/dL, or (2) Patient is taking a strong CYP3A4/pGP inhibitor (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin).
62162353|NCT03907046|PLACEBO_COMPARATOR|Aspirin|Aspirin dose will be 81 mg tablet once daily.
62736486|NCT02398136|ACTIVE_COMPARATOR|Midazolam|Intranasal midazolam 3.75mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
62162354|NCT06209411|ACTIVE_COMPARATOR|Referral Arm|CHW will contact participants with GDM from communities in the referral arm beginning at 6 weeks postpartum to arrange a convenient time for a home visit within the first postpartum year. During the home visit, CHW will provide 1) T2DM education and 2) referral to the postnatal clinic at a government hospital for T2DM screening.
62736487|NCT02304341||intermediate units|Children admitted to the paediatric inpatient unit in 7 regional hospitals French
62162355|NCT06209411|EXPERIMENTAL|Home Testing Arm|CHW will contact participants with GDM from communities in the home-based testing arm beginning at 6 weeks postpartum to arrange a convenient time for a home visit within the first postpartum year. During the home visit, CHW will provide 1) T2DM education, and 2) offer home-based OGTT.
62162356|NCT04874493||Observational (questionnaire)|Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.
62162357|NCT05490680|PLACEBO_COMPARATOR|Placebo|Placebo oral film, on-demand use once per day, at maximum 60 films during a 12-week period
62162358|NCT05490680|EXPERIMENTAL|Sildenafil|Sildenafil 25 mg, 50 mg, 75 mg or 100 mg oral film (flexible-dose), on-demand use once per day, at maximum 60 films during a 12-week period
62162359|NCT00518596|EXPERIMENTAL|Probiotic Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, given L. plantarum preparations orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
62162360|NCT00518596|PLACEBO_COMPARATOR|Control Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, receiving placebo preparations (a control solution of sterile 2.0 cc 5% dextrose-saline)orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
62162361|NCT04567745|OTHER|Cognitive diagnosis|
62162362|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
62535819|NCT01120704|EXPERIMENTAL|7, 26Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62535820|NCT01120704|EXPERIMENTAL|8, 26Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535821|NCT01120704|EXPERIMENTAL|9, 26Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62714553|NCT03375099|EXPERIMENTAL|Lethal Means Counseling|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners.
62736488|NCT05962151|EXPERIMENTAL|NAL ER|NAL ER, tablets, 27 mg QD to BID, 54 mg BID, 108 mg BID
62736489|NCT05962151|PLACEBO_COMPARATOR|Placebo|Placebo, tablets, 0 mg QD to BID, 0 mg BID, 0 mg BID
62162363|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
62162364|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
62162365|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, \>4 hours).
62162366|NCT05596409|EXPERIMENTAL|Elacestrant|Subjects will take a starting dose of 400 mg of elacestrant dihydrochloride in tablet form once daily for up to 6 months.
62162367|NCT04004663|EXPERIMENTAL|Treatment Sequence 1|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D).
62162368|NCT04004663|EXPERIMENTAL|Treatment Sequence 2|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment D); Period 3 (Treatment A); Period 4 (Treatment C).
62162369|NCT04004663|EXPERIMENTAL|Treatment Sequence 3|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment C); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment B).
62162370|NCT04004663|EXPERIMENTAL|Treatment Sequence 4|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment D); Period 2 (Treatment C); Period 3 (Treatment B); Period 4 (Treatment A).
62162371|NCT02086071|OTHER|Re biopsies feasibility|the Interest of the study is to evaluate the feasibility of the re biopsy; the re biopsy is done if the patient agrees to perform it.
62162372|NCT04196517|EXPERIMENTAL|Arm 1 - PALS|The Patient Activated Learning System (Palsforhealth.com)
62162373|NCT04196517|EXPERIMENTAL|Arm 2 - WebMD|WebMD.com
62162374|NCT06071871|EXPERIMENTAL|Part 1|"Patients whose large B-cell lymphoma has progressed/not responded to previous treatment and are due to start standard CAR-T therapy.~All patients receive 2 cycles of glofitamab and polatuzumab vedotin (Glofit-Pola). Obinutuzumab pre-treatment is given on cycle 1 day 1.~Patients have a PET-CT scan to check the response after cycle 2. If the scan shows a response and patients are still suitable for CAR-T cell therapy, patients will proceed to receive planned CAR-T therapy and will not receive further Glofit-Pola in Part 1. If not, patients can receive 4 more cycles of glofitamab and polatuzumab vedotin, and then 6 cycles of glofitamab."
62162375|NCT06071871|EXPERIMENTAL|Part 2|"Patients whose large B-cell lymphoma has progressed/not responded after standard CAR-T cell therapy.~All patients receive 6 cycles of glofitamab and polatuzumab vedotin (Glofit-Pola), and then 6 cycles of glofitamab alone. Obinutuzumab pre-treatment is given on cycle 1 day 1."
62162376|NCT00730925|EXPERIMENTAL|BIBW 2992|patient to receive tablets of BIBW 2992 once a day, starting at high dose until progression of the disease
62162377|NCT00730925|EXPERIMENTAL|BIBW 2992 + paclitaxel|patient whose disease progressed on treatment with BIBW 2992 monotherapy to receive tablet of BIBW 2992 once a day in combination with i.v. paclitaxel 3 weekly
62162378|NCT02008539|EXPERIMENTAL|treatment arm|
62162379|NCT03536520|ACTIVE_COMPARATOR|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62162380|NCT03536520|PLACEBO_COMPARATOR|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
62162381|NCT05822102||People with Cystic Fibrosis who are taking ETI that has reached a steady state dosing level.|Blood samples will be collected from people with CF who are taking ETI at a continuous dosing regimen for a minimum of 14 days.
62162382|NCT01138098|EXPERIMENTAL|Infanrix-hexa/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-hexa vaccine in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
62162383|NCT01138098|ACTIVE_COMPARATOR|Infanrix-IPV+Hib/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
62162384|NCT06454799|EXPERIMENTAL|Acupressure group|"On the day of the Applied Oral Exam, which will be administered at the end of the semester within the scope of the Principles of Nursing course, each student in the Acupressure group will be taken to the appropriate classroom 15 minutes before taking the exam and will first fill out the Personal Information Form, State Exam Anxiety Scale and Vital Signs Tracking Chart. Then, acupressure will be applied to the student. After the application, the State Test Anxiety Scale and Vital Signs Follow-up Chart will be filled in again and then the student will be sent for the exam.~The application will be carried out on 3 body points. These; Pericardium 6, Yintang and Shen men points. Acupressure will be applied to each of these acupressure points for 1 minute."
62162385|NCT06454799|NO_INTERVENTION|control group|"On the day of the Applied Oral Exam, which will be administered at the end of the semester within the scope of the Principles of Nursing course, each student in the control group will be taken to the appropriate classroom 15 minutes before taking the exam and will first fill out the Personal Information Form, State Exam Anxiety Scale and Vital Signs Tracking Chart. After waiting 15 minutes without any practice, the State Test Anxiety Scale and Vital Signs Tracking Chart will be filled in again and then the student will be sent for the exam."
62162386|NCT01630161|ACTIVE_COMPARATOR|Usual Care|Participants randomized to the Usual Care condition will receive standard care following recruitment.
62162387|NCT01630161|ACTIVE_COMPARATOR|Relapse-Prevention Intervention|Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
62162388|NCT01016730|EXPERIMENTAL|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
62162389|NCT01412398||Group 1|Drug (incl. Placebo)
62162390|NCT04449549|EXPERIMENTAL|1|Nilotinib will be administered at 300 mg orally BID; Paclitaxel will be administered IV at 80 mg/m2 on Days 1, 8, and 15 in 28-day cycles.
62162391|NCT05413811|EXPERIMENTAL|5 Fluorouracil Cream|The participants will receive 8 doses of intravaginal 5 Fluorouracil Cream.
62162392|NCT05413811|PLACEBO_COMPARATOR|Placebo Cream|The participants will receive 8 doses of intravaginal placebo cream.
62162393|NCT05119166||Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study|The CHILD Cohort Study is a prospective longitudinal birth cohort study. It is an observational study of healthy term infants in Canada (Vancouver, Edmonton, Manitoba, Toronto). The birth years were between 2009-2012, and is currently at the 8 year postnatal follow up phase. IMiC will receive 400 breast milk samples from 400 dyads (100/site) that were taken between 3-4 months postnatal.
62162394|NCT05119166||The Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Study|(NCT03268902). ELICIT is a randomized controlled trial (RCT) evaluating the efficacy of antimicrobials and nicotinamide in increasing growth in the setting of Rural Tanzania. It is factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis to infants. IMiC will receive 400 breast milk samples from 200 dyads, 2 samples per dyad taken at 1 \& 5 months postnatal.
62162395|NCT05119166||VITAL Pakistan|Two Randomized Controlled Trials: Mumta (Nutritional support for lactating women with or without azithromycin)PW - NCT04012177 and MumtaLW - NCT03564652 VITAL is a community-based, randomized control, assessor blinded trial in peri-urban settings of Karachi, Pakistan to study the impact of Lipid-based Nutritional Supplement for Pregnant and Lactating women which is balanced energy-protein (BEP) dietary supplement, a locally produced ready-to-use nutritional product for lactating women (LW) and single prophylaxis dose of Azithromycin for infants, on growth of infants over the period of six months since birth compared to current standard of care. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 \& 2-3 months.
62162396|NCT05119166||Micronutriments pour la Santé de la Mère et de l'Enfant (MISAME)-3 study (NCT03533712)|MISAME-3 is a randomized controlled clinical trial in the setting of Rural Burkina Faso. A BEP supplement provides less than 25% of protein of the total energy content, and includes different vitamins and minerals. The first part of an exploratory study will determine which type of BEP supplement (bar, drink, biscuit, soup or paste) is most accepted by pregnant women. Subsequently, two products will be tested for longer-term acceptability and at-home use (phase 1). The effect of the most suitable supplement will be tested in a controlled clinical trial (phase 2). The intervention group will receive the dietary supplement during pregnancy and/or lactation, while the control group complies with the standard iron and folic acid tablets following the national guidelines. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 \& 3-4 months.
62162397|NCT05417568|EXPERIMENTAL|Healthy Participants|"Healthy participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day washout period on a self-selected diet, and finally the opposite diet from the first for the last four days."
62162398|NCT05417568|EXPERIMENTAL|Calcium Oxalate Kidney Stone|"Calcium oxalate kidney stone participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day washout period on a self-selected diet, and finally the opposite diet from the first for the last four days."
62162399|NCT03992599||Laparoscopic modified central mesocolic excision|Patients receiving laparoscopic colectomy with the concept of modified complete mesocolic excision for right-sided colon cancer
62162400|NCT02164578|EXPERIMENTAL|Rivaroxaban|5mg b.i.d. for 20 weeks (primary phase) + additional 32 weeks (extension phase)
62162401|NCT02164578|ACTIVE_COMPARATOR|Aspirin|100mg once daily for 20 weeks (primary phase) + additional 32 weeks (extension phase)
62162402|NCT00105339||Illustration Style Preference Group|Ten participants at each site will be invited to attend a focus group to determine their comfort with and preference for one of four styles of illustration. The same two concepts will be presented in each of the four styles and ratings will be obtained from all participants. Detailed information on why participants rated each of the styles the way they did will also be obtained by reviewing comments on the rating sheets and audiotapes of the groups. Groups will be run by the study coordinator at the Florida and New York sites, and by Dannie Hoffman, protocol coordinator, in Los Angeles, using a focus group script developed by Dr. Murphy.
62162403|NCT00105339||Review of Draft Focus Group|Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
62162404|NCT00105339||Comprehension/Recall Assessment|The assessment will be read to the participants to preclude reading problems. Responses will be recorded by the interviewer on the assessment instrument.
62162405|NCT05776745|EXPERIMENTAL|Epileptic|Epileptic with stereoelectroencephalography
62162406|NCT06170931|ACTIVE_COMPARATOR|A knee of a patient with osteoarthritis of both knees|Posterior cruciate ligament protective approach in patients with knee osteoarthritis
62162407|NCT06170931|ACTIVE_COMPARATOR|The other knee of a patient with osteoarthritis in both knees|Posterior cruciate ligament transection approach in patients with knee osteoarthritis
62162408|NCT03894280|EXPERIMENTAL|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
62162409|NCT03894280|ACTIVE_COMPARATOR|Reference Product|SERETIDE DISKUS 250/50
62162410|NCT04130061|EXPERIMENTAL|Randomized|
62162411|NCT04130061|NO_INTERVENTION|Control|
62162412|NCT05513261|OTHER|Control arm: High definition colonoscopy|Diagnostic test: Standard colonoscopy
62162413|NCT05513261|EXPERIMENTAL|PolyDeep assisted high definition colonoscopy|Diagnostic test: PolyDeep
62162414|NCT03960437|OTHER|Study Participant|Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.
62162415|NCT05955222|EXPERIMENTAL|PEEK splint group|Patients received splints produced from PEEK blocks
62162416|NCT05955222|EXPERIMENTAL|PMMA splint group|Patients received splints produced from PMMA blocks
62162417|NCT05955222|ACTIVE_COMPARATOR|Traditional splint group|Patients received splints produced fabricated traditional methods (vacuum forming )
62162418|NCT01280396||SGAs|patients receiving SGAs
62162419|NCT00113334|EXPERIMENTAL|ABT-510 (Thrombospondin)|Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.
62162420|NCT04116671|EXPERIMENTAL|Neuromechanical Gait Assist|All participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance.
62162421|NCT03387592|ACTIVE_COMPARATOR|FOLFIRI regimen|CPT-11 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by Calcio levofolinate 200 mg/m2, given as a 2h i.v. infusion on days 1 every 2 weeks followed by 5-Fluorouracil 400 mg/m2 given as bolus, and then 5-Fluorouracil 2400 mg/m2 given as a 48 h continuous infusion on day 1, every 2 weeks, until progression or for a maximum of 12 cycles
62535822|NCT01120704|EXPERIMENTAL|10, 26Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
61976062|NCT03251768|ACTIVE_COMPARATOR|Positive control group|"intervention: GCSF Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. (The minimum of usage was continuous 7 days ,The maximum of usage was continuous 14 days)"
62162422|NCT03387592|EXPERIMENTAL|CAPTEM regimen|Capecitabine 750 mg/m2 twice a day on days 1-14 in combination with Temozolomide 200 mg/m2 daily on days 10-14, every 4 weeks, until progression or for a maximum of 6 cycles
62162423|NCT06505122|EXPERIMENTAL|Dyadic Life Review|The Dyadic Life Review Arm (DLR) consists of 8 sessions delivered by a trained licensed clinician. Each session facilitates a recall of each phase of life. The patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life. Interventionists are able to use clinical judgment to prompt further or ask follow-up questions or reflections. Additionally, the patient and caregiver will be asked to respond to the other dyad member's memory or reflection. Each session will have flexibility for clinical judgement.
62162424|NCT06505122|NO_INTERVENTION|Case-As-Usual|The Care-As-Usual (CAU) arm will follow current practices for responding to patient distress. The CAU for patients involves a supportive follow-up phone call from the social work team to further assess the patient's experience of distress. In some instances, the social worker will use their clinical judgement to further refer the patient to community resources to support distress. The number of phone calls and any subsequent community referrals or appointments related to distress that occur will be tracked.
62535823|NCT01120704|EXPERIMENTAL|11, 26Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
61976063|NCT02642614|EXPERIMENTAL|BI 1026706 low dose|
62162425|NCT02659488|OTHER|Lisdexamfetamine|During the Treatment Phase, subjects will be evaluated after 1, 2, 3, 4, 6, 8, 10, and 12 weeks (see Figure 2). The morning after completing the first fMRI scan, LDX will be started at 30 mg q AM (Baseline). After 1 week, LDX will then be increased to 50 mg q AM (Visit 1); after another week, LDX will be increased to 70 mg q AM (Visit 2). A single downward dose titration to 50 mg is allowed during week 3 if 70 mg/d is not tolerated. LDX dose at week 4 (50 or 70 mg/d) will be maintained for the next 8 weeks. Patients who do not tolerate 50 or 70 mg/day will be terminated. For patients who complete the 12-week treatment phase, LDX will be stopped at week 12 visit.
62162426|NCT04933110||Multiple Sclerosis|Individuals with early-stage multiple sclerosis
62162427|NCT04933110||Healthy Volunteers|Healthy volunteers of similar age and sex as individuals with multiple sclerosis
62162428|NCT03771209|EXPERIMENTAL|ultrasound assessment|The aim of this study is the creation of a five-step ultrasound examination to evaluate and monitor HF patients during hospitalization and short follow-up.
62162429|NCT01272388|ACTIVE_COMPARATOR|Tadalafil|
62162430|NCT01272388|PLACEBO_COMPARATOR|Placebo|
62162431|NCT04433247|EXPERIMENTAL|Peer Led Group Intervention|In the virtual peer-led group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
62162432|NCT04433247|NO_INTERVENTION|Wait-List Control|Participants will be placed on a wait list for four weeks, an equal span of time of participants in the peer led group intervention. At four weeks, participants will complete their post-test assessment, then receive the intervention.
62162433|NCT02820298|EXPERIMENTAL|Group 1 - Bexagliflozin dosed in fed state, then in fasted state|Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.
62162434|NCT02820298|EXPERIMENTAL|Group 2 - Bexagliflozin in fasted state, then in fed state|Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.
62162435|NCT01021683||Itraconazole|Participants who have been receiving itraconazole will be observed prospectively. Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
62162436|NCT01844362|EXPERIMENTAL|Uterine transplantation|Patients undergo transplantation of the uterus from live donor.
62162437|NCT05611476|EXPERIMENTAL|Single group|This group will receive Cognitive Muscular Therapy for low back pain
62162438|NCT05293379||Patients sensitized in the VACCIPREV program|Patients from 3 vaccination centers who agreed to participate to the VACCIPREV program by using the teleconsultation booth and completing the questionnaires of tobacco dependance and assessment of sleep quality.
62162439|NCT02843698|EXPERIMENTAL|Dexmedetomidine group|Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour
62162440|NCT02843698|PLACEBO_COMPARATOR|Control group|Patients will receive normal saline
62162441|NCT03785418|EXPERIMENTAL|Experimental Arm|Multicomponent Risk Factor Modification Intervention focused on healthy eating, regular exercise and behavioural therapy
62162442|NCT03785418|NO_INTERVENTION|Control Arm|Standard Clinical Practice
62162443|NCT00491439||Corneal wounds after Epi-LASIK|Corneal wounds after Epi-LASIK
62162444|NCT00491439||penetrating keratoplasty|Corneal wound after penetrating keratoplasty
62162445|NCT00491439||corneal epithelial debridement|Corneal wound after pars plana vitrectioy with corneal epithelial debridement for diabetic retinopathy
62162446|NCT05416970||non-alcoholic fatty liver disease affected patients|Patients affected by NAFLD based on clinical, biochemical, imaging and histology, in accordance to CPG diagnostic criteria, continuously followed by the Hepato-gastroenterology Division of the University of Campania Luigi Vanvitelli, between January 2018 and January 2022 were enrolled, after signing an informed consent, in the present study.
62162447|NCT01326624||NYHA class III or IV|"Patients with NYHA class III or IV during the past month and one or more of the following:~* Hospitalization for cardiac decongestion and stabilization.~* Advanced heart failure receiving intravenous diuretics/inotropics in an outpatient clinic.~* Awaiting cardiac transplantation"
62162448|NCT01326624||left ventricular ejection fraction ≤ 35%|"Patients with left ventricular ejection fraction ≤ 35% and either one of the following:~* Coronary revascularization within 3 calendar months prior to enrollment.~* Heart failure of non-ischemic origin diagnosed within 3 calendar months prior to enrollment."
62535824|NCT01120704|EXPERIMENTAL|12, 26Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62162449|NCT01326624||Awaiting ICD re-implantation|
62162450|NCT01326624||Acute myocardial infarction|Patients hospitalized with acute myocardial infarction and Killip Class III/IV.
62162451|NCT00050167|EXPERIMENTAL|Weekly Paclitaxel (WP)|Weekly Paclitaxel (WP) for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles
62162452|NCT00050167|EXPERIMENTAL|Docetaxel and Capecitabine (DX)|Docetaxel + Capecitabine (DX) days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.
62162453|NCT04182542|EXPERIMENTAL|RF|The right side will be treated with radiofrequency
62535825|NCT01120704|EXPERIMENTAL|13, 26Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62162454|NCT04182542|NO_INTERVENTION|NI|The left side will not receive treatment.
62162455|NCT02282917|EXPERIMENTAL|AR-42 Administration|AR-42 will be administered three times per week beginning 3 weeks prior to surgery.
62162456|NCT04232488|EXPERIMENTAL|Angiography performed using distal radial artery|Patients undergoing coronary angiography with or without intervention using distal radial artery ('snuff box') as a vascular access
62535826|NCT01120704|EXPERIMENTAL|14, 26Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535827|NCT01120704|EXPERIMENTAL|15, 26Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62714554|NCT03375099|ACTIVE_COMPARATOR|Lethal Means Counseling plus Gun Locks|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners. Individuals in this condition will also receive a free gun (cable) lock for each of their personal firearms.
61976064|NCT02642614|EXPERIMENTAL|BI 1026706 medium|
61976065|NCT02642614|EXPERIMENTAL|BI 1026706 high dose|
61976066|NCT02642614|PLACEBO_COMPARATOR|Placebo|
61976067|NCT04341454|EXPERIMENTAL|DWP14012 X mg QD|"* Morning: 1 tablet of DWP14012 X mg + 1 tablet of DWP14012 Y mg placebo~* Evening: 1 tablet of DWP14012 Y mg placebo"
61976068|NCT04341454|EXPERIMENTAL|DWP14012 Y mg BID|"* Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg~* Evening: 1 tablet of DWP14012 Y mg"
61976069|NCT04341454|PLACEBO_COMPARATOR|placebo|"* Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg placebo~* Evening: 1 tablet of DWP14012 Y mg placebo"
61976070|NCT05575011|EXPERIMENTAL|Part A: Cohort 1: BIIB115 Dose 1|Participants will receive a single dose of BIIB115, Dose 1, via IT bolus injection, on Day 1.
61976071|NCT05575011|EXPERIMENTAL|Part A: Cohort 2: BIIB115 Dose 2|Participants will receive a single dose of BIIB115, Dose 2, via IT bolus injection, on Day 1.
61976072|NCT05575011|EXPERIMENTAL|Part A: Cohort 3: BIIB115 Dose 3|Participants will receive a single dose of BIIB115, Dose 3, via IT bolus injection, on Day 1.
61976073|NCT05575011|EXPERIMENTAL|Part A: Cohort 4: BIIB115 Dose 4|Participants will receive a single dose of BIIB115, Dose 4, via IT bolus injection, on Day 1.
61976074|NCT05575011|PLACEBO_COMPARATOR|Part A: Cohorts 1-4: BIIB115-Matching Placebo|Participants will receive a single dose of BIIB115-matching placebo, via IT bolus injection, on Day 1.
61976075|NCT05575011|EXPERIMENTAL|Part B: Cohort 5: BIIB115 Dose 3|Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 3, via IT bolus injection at two separate time points.
61976076|NCT05575011|EXPERIMENTAL|Part B: Cohort 6: BIIB115 Dose 4|Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 4, via IT bolus injectionat two separate time points.
61976077|NCT06147310|EXPERIMENTAL|Study Group|Alveolar ridge preservation with Alb-PRF + A-PRF after extraction
61976078|NCT06147310|PLACEBO_COMPARATOR|Control Group|Spontaneous healing after extraction
61976079|NCT02260050|EXPERIMENTAL|WAL 801 CL new formulation|
61976080|NCT02260050|ACTIVE_COMPARATOR|WAL 801 CL conventional formulation|
61976081|NCT00632411|EXPERIMENTAL|Proactive group|Research study staff will contact participant to initiate the program. Half of participants will be randomized to the proactive condition and the other half to the reactive conditions.
61976082|NCT00632411|EXPERIMENTAL|Reactive group|Participant will contact the research study staff to initiate the program.
61976083|NCT04334408|ACTIVE_COMPARATOR|Subjects with CADASIL treatment intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with Fremanezumab injections.
61976084|NCT04334408|PLACEBO_COMPARATOR|Subjects with CADASIL placebo intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with placebo injections.
61976085|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
61976086|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
61976087|NCT04013724|EXPERIMENTAL|Intervention group|"The behavioral group intervention consisted of 6 sessions over 12 weeks and were led by 2 trained facilitators, followed by monthly group meetings from weeks 14 to 26. This program was adapted from the Royal Australian College of General Practitioners' Supporting Smoking Cessation Guide for Health Professionals17 and the World Health Organization's Strengthening Health Systems for Treating Tobacco Dependence in Primary Care training package.18~The topics that were explored during the group sessions include:~1. Introduction to the Program and Reasons to Quit~2. Benefits of Quitting and Understanding Why We Smoke and Ways of Quitting~3. Withdrawal Symptoms and Social Support~4. Dealing with Stress and Anxiety and Coping with Depression~5. Assertiveness Training and Anger Management~6. Tobacco-Free Lifestyle and Dealing with High Risk Situations"
61976088|NCT04013724|NO_INTERVENTION|Control|The control group was provided questionnaires to fill at the end of Weeks 4, 12, and 26. During the rest of the study, they continued receiving usual care, including clinical care at CSAT.
61976089|NCT00296894|EXPERIMENTAL|1|Drug - adalimimab sc
61976090|NCT00296894|PLACEBO_COMPARATOR|2|Placebo
61976091|NCT02701504||Sleep apnea group|The patients who are found to have sleep apnea based on the results of the portable sleep study
61976092|NCT02701504||Non sleep apnea group|The patients who are found to have no sleep apnea based on the results of the portable sleep study
62162457|NCT04232488|ACTIVE_COMPARATOR|Angiography performed using proximal radial artery|Patients undergoing coronary angiography with or without intervention using proximal radial artery as a vascular access
62162458|NCT02586857|EXPERIMENTAL|Cohort 1|ACP-196 200 mg administered orally (PO) twice per day (BID)
62162459|NCT02586857|EXPERIMENTAL|Cohort 2|ACP-196 400mg administered orally (PO) once per day (QD).
62162460|NCT06648889|EXPERIMENTAL|GMALL-Isatuximab|"Cohort 1: In this Cohort, Isatuximab shall be implemented as part of a combination therapy for patients with R/R T-ALL, defined as bone marrow infiltration of ≥5% (R/R T-ALL).~Cohort 2: In this Cohort, Isatuximab shall be implemented as single drug treatment for patients with molecular failure/relapse. Cohort 2 will include patients with hematologic remission (bone marrow blast count \<5%) of T-cell ALL, but with molecular failure or molecular relapse (MRD+ T-ALL)."
62162461|NCT01746628|PLACEBO_COMPARATOR|Hysterectomy without FloSeal|Endometrial curettage Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
62162462|NCT01746628|ACTIVE_COMPARATOR|Hysterectomy with FloSeal|Endometrial curettage FloSeal placement into uterine cavity Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
62162463|NCT00966888|EXPERIMENTAL|Arm I|Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
62162464|NCT00966888|ACTIVE_COMPARATOR|Arm II|Patients receive standard of care and observation only.
62162465|NCT03900286|EXPERIMENTAL|Single Arm Study|Total Diet Replacement for 12 weeks, food reintroduction 6 weeks
62162466|NCT03479671|NO_INTERVENTION|Saline|Insulin sensitivity (rate of glucose disposal)
62162467|NCT03479671|EXPERIMENTAL|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
62162468|NCT03479671|EXPERIMENTAL|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
62162469|NCT06585345|EXPERIMENTAL|Experimental group|CD7 positive relapsed or refractory acute leukemia
62162470|NCT02579941|EXPERIMENTAL|Pregnant women at term, vaginal childbirth|
62162471|NCT02579941|EXPERIMENTAL|Pregnant women at term, cesarean delivery|
62535828|NCT01120704|EXPERIMENTAL|16, 26Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62714555|NCT03375099|ACTIVE_COMPARATOR|Health and Stress Reduction|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework.
62714556|NCT03375099|ACTIVE_COMPARATOR|Health + Stress Reduction plus Gun Locks|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework. Individuals randomized to this condition will also receive a free gun (cable) lock for each of their personal firearms. This will control for whether the effect of the provision of gun locks is accounted for by the simultaneous use of lethal means counseling.
62714557|NCT06016075|OTHER|Hyperpolarised MRI|Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
62162472|NCT02579941|EXPERIMENTAL|Female volunteers, age 18 to 40|
62162473|NCT06048471|EXPERIMENTAL|HiTop|
62535829|NCT01120704|EXPERIMENTAL|17, 8Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62162474|NCT06048471|SHAM_COMPARATOR|Sham stimulation|
62162475|NCT00475436|EXPERIMENTAL|Arm 1|
62162476|NCT04662749||concave group|the group whose level of sinus floor is lower than both of the adjacent teeth
62162477|NCT04662749||angle group|the group whose level of sinus floor is lower than one of the adjacent teeth and higher than the other one of the adjacent teeth
62162478|NCT04662749||flat group|the group whose level of sinus floor is similar to both of the adjacent teeth
62714558|NCT06016075|OTHER|Sodium MRI|MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.
62162479|NCT06057701|EXPERIMENTAL|control group|This group consists of 20 postmenopausal women suffering from thoracic hyper kyphosis. They receive daily session of 30minutes even by therapist or at home for 12 weeks. the corrective exercises for the thoracic spine consist of strengthening exercises for back muscles and stretching exercises for pectoral muscles
62162480|NCT06057701|EXPERIMENTAL|interventional group|This group consists of 20 postmenopausal women suffering from thoracic hyper kyphosis, who receive the corrective exercises prescribed above in addition to resisted diaphragmatic breathing exercise. They receive daily session of 30minutes even by therapist or at home for 12 weeks.
62162481|NCT05965726|EXPERIMENTAL|Paxlovid 25 day dosing|Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days
62162482|NCT05965726|EXPERIMENTAL|Paxlovid 15 day dosing|Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 15 days then ritonavir 100mg plus nirmatrelvir-matching placebo x 10 days
62162483|NCT05965726|PLACEBO_COMPARATOR|Control|ritonavir 100mg plus nirmatrelvir-matching placebo bid x 25 days
62162484|NCT01737645||obese patients|BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
62162485|NCT01737645||Thin patients|BMI less than or equal to 30 kg/m2
62162486|NCT00487253|ACTIVE_COMPARATOR|Group 1|"Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.~presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)"
62162487|NCT00487253|ACTIVE_COMPARATOR|Group 2|Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.
62162488|NCT01795183|EXPERIMENTAL|Amisulpride|Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week
62162489|NCT05837650|EXPERIMENTAL|Emotional Awareness and Expression Therapy (EAET)|In this experimental arm, participants are required to attend 8 online sessions and fill out questionnaires before treatment, and immediately after treatment.
62162490|NCT05837650|NO_INTERVENTION|Wait list control|In this control arm, participants are required to wait 8 weeks until the treatment arm is completed and fill out questionnaires before and after the treatment date.
62162491|NCT04269811|EXPERIMENTAL|Flu-Bu-Mel|Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2
62162492|NCT01743807|EXPERIMENTAL|Dose Level 1|GNKG168 0.25 mg/kg/day on days 1 through 5
62162493|NCT01743807|EXPERIMENTAL|Dose Level 2|GNKG168 0.75 mg/kg/day on days 1 through 5
62162494|NCT01743807|EXPERIMENTAL|Dose Level 3|GNKG168 1.5 mg/kg/day on days 1 through 5
62162495|NCT01743807|EXPERIMENTAL|Dose Level 0|If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
62162496|NCT02297945|EXPERIMENTAL|Metyrapone|Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.
62162497|NCT05224596||Cancer arm|Baseline blood samples will be collected from new diagnosis cancer participants.
62162498|NCT05224596||Benign disease arm|Baseline blood samples will be collected from new diagnosis benign gastric disease participants.
62162499|NCT03379428|EXPERIMENTAL|Trastuzumab plus Ibrutinib 560 mg|In Phase I, starting dose of Ibrutinib will be 560 mg orally per day. 3 patients will be enrolled first. If none of these have DLTs, 3 new patients will be enrolled at the next higher Ibrutinib dose level (840 mg orally per day). If 1 of these 3 patients have a DLT, expand this arm to 6 patients. If 2 or more of these 6 patients have a DLT, enroll 3 patients in lower dose lever (420 mg).
62162500|NCT03379428|EXPERIMENTAL|Trastuzumab plus Ibrutinib 840 mg|If no patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this higher dose is tolerated.
62162501|NCT03379428|EXPERIMENTAL|Trastuzumab plus Ibrutinib 420 mg|If 2 or more patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this lower dose is tolerated.
62162502|NCT03379428|EXPERIMENTAL|Phase II- Trastuzumab plus Maximum Tolerated Dose|Maximum tolerated dose from Phase I will be used here in Phase II.
62162503|NCT06107205|ACTIVE_COMPARATOR|TTYP01|Healthy subjects were administered 1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
62162504|NCT06107205|ACTIVE_COMPARATOR|Radicava|Healthy subjects were administered 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
62162505|NCT06107205|ACTIVE_COMPARATOR|Radicava ORS|Healthy subjects were administered 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
62162506|NCT01562821|EXPERIMENTAL|Low dose|
62162507|NCT01562821|EXPERIMENTAL|High dose|
62162508|NCT01562821|PLACEBO_COMPARATOR|Placebo|
62162509|NCT01224509|EXPERIMENTAL|Mifepristone|
62714559|NCT06016075|OTHER|Deuterium metabolic imaging (DMI) MRI|Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
62714560|NCT04691388|EXPERIMENTAL|sintilimab +anlotinib|
62714561|NCT04083417|ACTIVE_COMPARATOR|Phenoxymethylpenicillin group|Patients randomized to oral phenoxymethylpenicillin 1000 mg three times daily for ten days
62162510|NCT01224509|ACTIVE_COMPARATOR|Non-treatment|
62162511|NCT04998032|EXPERIMENTAL|supaglutide RP3D dose+metformin|Supaglutide Subcutaneous injection once a week for 52weeks,combined with metformin
62162512|NCT04998032|PLACEBO_COMPARATOR|placebo+metformin|Placebo Subcutaneous injection once a week for 52weeks,,combined with metformin
62162513|NCT02368977|EXPERIMENTAL|All subjects|All subjects will undergo examination with a Third Eye Panoramic device in conjunction with a standard colonoscope to evaluate the feasibility of using the study device to provide video imaging of areas of the colon that are difficult to evaluate with the colonoscope alone.
62162514|NCT03932032|EXPERIMENTAL|Attention Bias Modification Treatment|Attention Bias Modification Treatment is a computer-based attention training program.
62162515|NCT03932032|SHAM_COMPARATOR|Neutral Control Task|Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.
62162516|NCT06049017|EXPERIMENTAL|Group 1: JNJ-77242113 Dose-1|Participants will receive JNJ-77242113 Dose-1 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week long term extension (LTE) period and receive the same treatment up to Week 76.
62162517|NCT06049017|EXPERIMENTAL|Group 2: JNJ-77242113 Dose-2|Participants will receive JNJ-77242113 Dose-2 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.
62162518|NCT06049017|EXPERIMENTAL|Group 3: JNJ-77242113 Dose-3|Participants will receive JNJ-77242113 Dose-3 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.
62714562|NCT04083417|EXPERIMENTAL|No antibiotic treatment group|Patients randomized to no antibiotic treatment
62714563|NCT04714593|EXPERIMENTAL|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10\^6 CAR+T cells/kg.
62714564|NCT04714593|EXPERIMENTAL|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2×10\^6 CAR+T cells/kg.
62162519|NCT06049017|EXPERIMENTAL|Group 4: Placebo|Participants will receive placebo tablets orally from Week 0 through Week 28. Placebo-treated participants who meet the criteria of inadequate response at Week 16, will receive JNJ-77242113 Dose-3 tablet orally through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention, will continue in the 48-week LTE period and receive the same treatment up to Week 76.
62162520|NCT02883361|EXPERIMENTAL|Treatment|Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.
62162521|NCT02883361|PLACEBO_COMPARATOR|Control|Attend 4 in-person sessions to complete questionnaires and receive educational handouts.
62162522|NCT03301220|NO_INTERVENTION|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
62162523|NCT03301220|EXPERIMENTAL|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.
62162524|NCT03572998|OTHER|Breast cancer patients|study subject
62162525|NCT01943370|EXPERIMENTAL|Early saline irrigation|Initiation of early saline irrigation
62162526|NCT01943370|ACTIVE_COMPARATOR|Late or Routine Saline Irrigation|Routine initiation of saline irrigation
62162527|NCT06162221|EXPERIMENTAL|Subprotocol A: KRAS G12C-Mutated Solid Tumors|RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W-Q4W)
62162528|NCT06162221|EXPERIMENTAL|Subprotocol B: RAS-mutated NSCLC|RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W-Q4W)
62162529|NCT04478799|EXPERIMENTAL|Group A (Transcutanous Posterior Tibial Nerve Stimulation)|Patients belonging to the group A received Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
61976093|NCT05156320|EXPERIMENTAL|Main Efficacy Population (Apitegromab 10 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 10 mg/kg for up to 52 weeks.
62162530|NCT04478799|SHAM_COMPARATOR|Group B (Sham Control)|Patients belonging to the group B received Sham Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
62162531|NCT05734235|EXPERIMENTAL|Vitamin C & Vitamin E|After subjects undergo UVB treatment then they will be instructed to take two Vitamin C and one Vitamin E tablets daily for 8 days.
62162532|NCT06632418|NO_INTERVENTION|Routine care|Participants receive routine care for their fistula.
62162533|NCT06632418|EXPERIMENTAL|rhPDGF-BB-enhanced collagen plug|Participants receive collagen plug saturated with rhPDGF-BB.
62162534|NCT03440580|ACTIVE_COMPARATOR|Intervention|The intervention school will receive the BOOSTH intervention: Boosth activity tracker, Boosth sync app, Boosht game app
62535830|NCT01120704|EXPERIMENTAL|18, 8Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62714565|NCT04714593|EXPERIMENTAL|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5×10\^6 CAR+T cells/kg.
62162535|NCT03440580|NO_INTERVENTION|control group|The control school will receive the standard curriculum. After the study is finished the children of the control school will receive the Boosth product
62162536|NCT02121808|EXPERIMENTAL|Supine|NIPPV and Tidal volume
62162537|NCT02121808|EXPERIMENTAL|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
62162538|NCT02121808|EXPERIMENTAL|Proclive (Global 25 deg)|NIPPV and Tidal volume
62162539|NCT04873362|ACTIVE_COMPARATOR|Arm A: Placebo + Trastuzumab Emtansine|Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
62162540|NCT04873362|EXPERIMENTAL|Arm B: Atezolizumab + Trastuzumab Emtansine|Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
61976094|NCT05156320|EXPERIMENTAL|Main Efficacy Population (Apitegromab 20 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
61976095|NCT05156320|PLACEBO_COMPARATOR|Main Efficacy Population (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
62162541|NCT04562714|EXPERIMENTAL|Intervention (FGM + DSME)|Study participants randomized to the intervention arm will be provided with a FreeStyle Libre flash glucose monitor (FGM) system to use for 16 weeks in Phase 1. Study participants will receive one training session on proper use of the FGM and encouraged to test at least 4 times per day: fasting and post-meals. Participants will also receive six diabetes self-management education (DSME) sessions, consisting of four individual in-clinic sessions and two telephone sessions.
62162542|NCT04562714|OTHER|Control (DSME alone)|Study participants in the control arm will receive six diabetes self-management education sessions matched to time and location of the intervention group. The sessions will consist of four individual in-clinic sessions and two telephone sessions over 16 weeks. Control participants will be encouraged to self-monitor blood glucose four times daily (fasting and post-meals) as per existing diabetes self-care guidelines
62162543|NCT04542551|ACTIVE_COMPARATOR|Without stricture - dilation with 60-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 60-Fr dilator
62162544|NCT04542551|SHAM_COMPARATOR|Without stricture - dilation with 15-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 15-Fr dilator (sham)
62162545|NCT04542551|ACTIVE_COMPARATOR|Non severe stricture - dilation with 60-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 60-Fr dilator
62162546|NCT04542551|ACTIVE_COMPARATOR|Non severe stricture - dilation with 46-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 46-Fr dilator
62162547|NCT04542551|ACTIVE_COMPARATOR|Severe stricture - dilation with 51-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 51-Fr dilator
62162548|NCT04542551|ACTIVE_COMPARATOR|Severe stricture - dilation with 42-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 42-Fr dilator
62162549|NCT05850234|EXPERIMENTAL|GC012F (AZD0120)|GC012F (AZD0120) will be administrated in one infusion
62162550|NCT02152995|EXPERIMENTAL|Cohort A (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients with RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.
62162551|NCT02152995|EXPERIMENTAL|Cohort B (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients without BRAF/RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.
62162552|NCT02152995|EXPERIMENTAL|Cohort C (trametinib)|Patients may continue trametinib at the doctor's discretion and do not receive iodine I-131.
62162553|NCT03759405|EXPERIMENTAL|Chronic heart failure treatment group|One case of CHF caused by coronary heart disease, one case of CHF caused by dilated heart disease and one case of CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation.
62162554|NCT05240729|ACTIVE_COMPARATOR|Retroclavicular|Retroclavicular approach to the infraclavicular region, the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will then be inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip will be constantly seen, until it will be positioned posterior to the axillary artery.
62162555|NCT05240729|ACTIVE_COMPARATOR|Costoclavicular|A new approach to the infraclavicular block The ultrasound transducer will be placed parallel and inferior to the clavicle and angled cephalad to optimize the ultrasound view. The block needle will be inserted in-plane from a lateral to medial direction into the costoclavicular space and the entire drug will be deposited in this location
62162556|NCT05240729|ACTIVE_COMPARATOR|Classic|Infraclavicular brachial plexus block (ICPB) ultrasound probe will be placed near the lower edge of the clavicle, and a transverse view of the subclavian artery and vein will be visualized. Using a needle guide, the needle will be advanced under real-time ultrasound guidance, and local anaesthetic will be injected near the subclavian artery, 15 mm medially and 15 mm laterally to the artery. The extent of sensory and motor block will be evaluated at 30 minutes after the injection
62162557|NCT05118308|EXPERIMENTAL|Transjugular approach|Transjugular hepatic venous pressure gradient measurement with liver biopsy (HVPG-LB).
62162558|NCT05118308|EXPERIMENTAL|Endoscopic ultrasound approach|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy (EUS-PPG-LB)
62162559|NCT01094600|EXPERIMENTAL|Secretin|Single arm (open label).
62162560|NCT05387785|EXPERIMENTAL|500 mg QD|500 mg QD of ANG-3070 will be taken once a day for 10 days.
62162561|NCT05387785|EXPERIMENTAL|300 mg BID|300 mg BID of ANG-3070 will be taken twice a day for 10 days.
62162562|NCT05387785|PLACEBO_COMPARATOR|Placebo-to-match 500 mg QD|Placebo-to-match 500 mg QD of ANG-3070 will be taken once a day for 10 days.
62162563|NCT05387785|PLACEBO_COMPARATOR|Placebo-to-match 300 mg BID|Placebo-to-match 300 mg BID of ANG-3070 will be taken twice a day for 10 days.
62162564|NCT06585579|EXPERIMENTAL|Mucogyne group|"For each eligible patient, the study will consist of:~* A Screening/Inclusion visit~* A treatment period (application of the medical device Mucogyne® ovule) for 21 days~* An End Of Study visit (Day 21 (+10) after surgery)"
62162565|NCT06585579|NO_INTERVENTION|Control group|standard of care e.i no treatment
62162566|NCT04150250|EXPERIMENTAL|iOWH032|On Day 1, participants were challenged with 10\^6 colony-forming units (CFU) of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral iOWH032 500 mg tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
62535831|NCT01120704|EXPERIMENTAL|19, 8Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62162567|NCT04150250|PLACEBO_COMPARATOR|Placebo|On Day 1, participants were challenged with 10\^6 CFU of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral matching iOWH032 placebo tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
62162568|NCT06276946|ACTIVE_COMPARATOR|Mean Parotid|Standard radiotherapy planning aims to restrict the mean parotid radiation dose to less than or equal to 14 Gy.
62535832|NCT01120704|EXPERIMENTAL|20, 8Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535833|NCT01120704|EXPERIMENTAL|21, 8Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62162569|NCT06276946|EXPERIMENTAL|Parotid Duct|Magnetic resonance images will be used to localize the parotid ducts and limit the radiation dose to these structures to less than or equal to 14 Gy.
62535834|NCT01120704|EXPERIMENTAL|22, 8Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535835|NCT01120704|EXPERIMENTAL|23, 8Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62162570|NCT06460961|EXPERIMENTAL|Arm 1: MK-6837 Monotherapy|Participants receive escalating doses of MK-6837 via intravenous (IV) infusion once every 3 weeks (Q3W) (Day 1 of every 21-day cycle) until progressive disease or discontinuation.
62162571|NCT06460961|EXPERIMENTAL|Arm 2: MK-6837 + Pembrolizumab Combination Therapy|Participants receive escalating doses of MK-6837 via IV infusion Q3W (Day 1 of every 21-day cycle) until progressive disease or discontinuation PLUS 200mg of pembrolizumab via IV infusion Q3W (Day 1 of every 21-day cycle) for up to 35 administrations (up to \~2 years).
62162572|NCT05001802|ACTIVE_COMPARATOR|transverse quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
62162573|NCT05001802|EXPERIMENTAL|longitudinal quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
62162574|NCT05609682|PLACEBO_COMPARATOR|Placebo Arm|Standard ERAS protocol post-operative care with placebo
62162575|NCT05609682|ACTIVE_COMPARATOR|Gabapentin Arm|Standard ERAS protocol with scheduled postoperative gabapentin
62162576|NCT04342715||Patients|Patients who have a diagnosis of visceral leishmaniasis and will be treated with SSG/PM
62162577|NCT04342715||Control|Healthy volunteers
62162578|NCT06581224|EXPERIMENTAL|PHP Team|PHP Team
62162579|NCT06581224|NO_INTERVENTION|Usual Care|Usual Care hospital medicine team
62162580|NCT02825849|EXPERIMENTAL|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
62162581|NCT02825849|NO_INTERVENTION|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
62535836|NCT01120704|EXPERIMENTAL|24, 8Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535837|NCT01120704|EXPERIMENTAL|25, 8Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62162582|NCT02423447|ACTIVE_COMPARATOR|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
62162583|NCT02423447|ACTIVE_COMPARATOR|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
62162584|NCT03284957|EXPERIMENTAL|Amcenestrant Monotherapy: Arm #1 Part A Dose Escalation, Part B Dose Expansion|"Part A: Amcenestrant will be administered orally once daily (QD). Treatment will begin with an identified starting dose. Administration of higher doses to subsequent participants is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug will be administered in a 28-day cycle.~Part B: When the dose escalation phase ends, the recommended dose will be administered for the expansion cohort. Drug will be administered in a 28-day cycle."
62535838|NCT01120704|EXPERIMENTAL|26, 8Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535839|NCT01120704|EXPERIMENTAL|27, 8Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62535840|NCT01120704|EXPERIMENTAL|28, 8Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62714566|NCT04714593|EXPERIMENTAL|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10\^6 CAR+Tcells/kg.
62162585|NCT03284957|EXPERIMENTAL|Amcenestrant/Palbociclib: Arm #2 Part C Dose Escalation, Part D Dose Expansion|"Part C: Amcenestrant will be administered in combination with palbociclib: amcenestrant starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of amcenestrant (with standard palbociclib dose) to subsequent participants will be based on occurrence of DLTs at initial and subsequent doses, until MAD of amcenestrant is reached. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle).~Part D: Based on the results in Part C, participants will be administered either: 1) a determined amcenestrant dose (RD) with standard dose of palbociclib in combination therapy, or 2) one of two randomized dose levels of amcenestrant with standard dose of palbociclib in combination therapy. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle)."
62162586|NCT03284957|EXPERIMENTAL|Amcenestrant/Alpelisib: Arm #3 Part F Safety Run-In, Part G Dose Expansion|"Part F: Amcenestrant will be administered in combination with alpelisib at a fixed standard dose. Additional dose levels of amcenestrant with alpelisib could be explored if needed based on the safety and PK results. Lower dose of alpelisib could be explored based on the PK results and safety profile from the initial combination administration. Both amcenestrant and alpelisib will be administered in a 28-day cycle.~Part G: Based on the conclusion in Part F, participants will be administered the determined RD of amcenestrant and alpelisib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
62162587|NCT03284957|EXPERIMENTAL|Amcenestrant/Everolimus: Arm #4 Part H Dose Escalation, Part I Dose Expansion|"Part H: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of everolimus. Additional dose levels of amcenestrant with everolimus could be explored if needed based on the safety and PK results. Both amcenestrant and everolimus will be administered in a 28-day cycle.~Part I: Based on the conclusion in Part H, participants will be administered the determined RD of amcenestrant and RD of everolimus given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
62162588|NCT03284957|EXPERIMENTAL|Amcenestrant/Abemaciclib: Arm #5 Part J Dose Escalation, Part K Dose Expansion|"Part J: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of abemaciclib. Additional dose levels of amcenestrant with abemaciclib could be explored if needed based on the safety and PK results. Both amcenestrant and abemaciclib will be administered in a 28-day cycle.~Part K: Based on the conclusion in Part J, participants will be administered the determined RD of amcenestrant and RD of abemaciclib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
62162589|NCT06485830|EXPERIMENTAL|Neural mobilization of the lower limb|Several neural mobilization techniques will be performed for the lower limb, with a special focus on the sciatic nerve. First, three different passive techniques will be used. These will consist of two sets of ten repetitions each with one minute rest between sets. This will last approximately 5 minutes. Then, three dynamic neural mobilization techniques will be performed, with each exercise lasting for 5 minutes per set, including two different sets (one minute rest between them), with a total of 10 minutes of mobilization and one minute of rest per exercise. Therefore the complete approach will last for 30 minutes approximately. Following this set of dynamic neural mobilization exercises, static neural mobilizations of the sciatic nerve will be performed again following the same order and duration than in the beginning.
62162590|NCT06485830|ACTIVE_COMPARATOR|Conventional physiotherapy treatment|A conventional treatment will be performed, consisting of passive and active mobilizations, active stretching, and techniques aimed at improving daily life activities
62162591|NCT04060641||RDN Patients|Patients who have received renal denervation with the Medtronic SymplicitySpyral device will have DNA collected in using a buccal swab.
62162592|NCT04389983|ACTIVE_COMPARATOR|Healthy, under 65 years|Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter (All MCT doses administered as a single dose at time 0)
62535841|NCT01120704|EXPERIMENTAL|29, 8Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62535842|NCT01120704|EXPERIMENTAL|30, 8Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535843|NCT01120704|EXPERIMENTAL|31, 8Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
62535844|NCT01120704|EXPERIMENTAL|32, 8Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
62535845|NCT01278901||Cohort of consecutive patients undergoing EGD treated with PPI|Patients positive for helicobacter pylori undergoing EGD, started on PPI therapy for a month, repeated diagnostic tests for Helicobacter pylori after a month of therapy (urease test, histology and breath test)
62535846|NCT06437574|EXPERIMENTAL|Intensive Lipid Lowering|Single arm with dual agents (ezetimibe and simvastatin) or single agent (ezetimibe). These agents target the two primary sources of cholesterol, absorption in the gut (ezetimibe) and synthesis in the liver (simvastatin). The dual agents are available in a single pill that is FDA approved and sold under the trade name, Vytorin.
62535847|NCT03849183|EXPERIMENTAL|Nitroglycerin|Nitroglycerin 5mcg/kg (0.5cc) is subcutaneously injected before radial artery cannulation.
62535848|NCT03849183|ACTIVE_COMPARATOR|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation.
62162593|NCT04389983|ACTIVE_COMPARATOR|Healthy, over 65 years|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
62535849|NCT02476240|ACTIVE_COMPARATOR|Internally Focused PD-SAFEx|While performing the exercises in PD-SAFEx™, participants will be instructed to focus their attention on sensory feedback. This will include focusing participants' attention on the stretch in their limbs while walking, on the straightness of their backs while sitting, on limb and body orientation in space while coordinating their movements, and on chest movements during breathing exercises. Throughout each exercise session, the instructor and volunteers will constantly provide attention-directing instructions.
62535850|NCT02476240|EXPERIMENTAL|Externally Focused PD-SAFEx|While performing the exercises from the PD-SAFEx™ program, participants will be instructed to focus their attention externally on the movement of coloured labels attached to their feet, knees, elbows and hands. Participants will be reminded and encouraged by the exercise instructor and volunteers to perform all exercises while focusing attention on the labels.
62535851|NCT02476240|NO_INTERVENTION|Control Group|This group will be asked to refrain from changing activities of their daily lives throughout the 20-week duration of the experiment (from pre-assessment to washout).
62535852|NCT06009627|EXPERIMENTAL|Dalcelli+Goserelin+Exemestane|SD patients undergoing 2 cycles of preoperative treatment were randomly assigned to Group A and received darcelli, Exemestane, and Goserelin
62535853|NCT06009627|ACTIVE_COMPARATOR|Docetaxel, epirubicin hydrochloride, Cyclophosphamide|SD patients undergoing 2 cycles of preoperative treatment were randomly assigned to Group B and received TAC chemotherapy
62535854|NCT01274676|ACTIVE_COMPARATOR|carotid stenting with MOMA|
62535855|NCT01274676|ACTIVE_COMPARATOR|Carotid stenting with filter wire EZ|
62535856|NCT05599061|EXPERIMENTAL|Optimal Medical Treatment (OMT) + PCI|
61976096|NCT05156320|EXPERIMENTAL|Exploratory Subpopulation (Apitegromab)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
61976097|NCT05156320|PLACEBO_COMPARATOR|Exploratory Subpopulation (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
61976098|NCT03582072|EXPERIMENTAL|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by \> 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
61976099|NCT03582072|NO_INTERVENTION|control|practice outside of the top 20% of prescribers whose prescribing increase by \>4%, GPs were not sent a letter
61976100|NCT01073982|PLACEBO_COMPARATOR|cherry flavored fruit drink|
61976101|NCT01073982|EXPERIMENTAL|tart cherry juice|
61976102|NCT01259323|EXPERIMENTAL|Cohort 1|
61976103|NCT01259323|EXPERIMENTAL|Cohort 2|
61976104|NCT01259323|EXPERIMENTAL|Cohort 3|
61976105|NCT01325389|EXPERIMENTAL|Myo+Mel|Patients are treated with 2g of myo + 3mg of melatonin daily
61976106|NCT01325389|PLACEBO_COMPARATOR|Placebo|
61976107|NCT01785732|ACTIVE_COMPARATOR|Renal denervation|Patients are randomized to renal denervation
61976108|NCT01785732|NO_INTERVENTION|Optimization of medical therapy|Antihypertensive treatment is optimized
61976109|NCT01726153|NO_INTERVENTION|Web sites|Individuals assigned to this arm are given a list of websites where they can view additional information relating to condom use.
61976110|NCT01726153|EXPERIMENTAL|Condom-HIM|Individuals assigned to this arm must follow an on-line one session tailored intervention.
61976111|NCT04719507|EXPERIMENTAL|erector spinae arm|ultrasound guided erector spinae block
61976112|NCT04719507|EXPERIMENTAL|thoracic paravertebral arm|ultrasound guided thoracic paravertebral block.
61976113|NCT04719507|ACTIVE_COMPARATOR|drug arm|pethidine (1 mg/kg ) once
61976114|NCT03912116|EXPERIMENTAL|Amniotic Umbilical Cord Particulate Injection|100mg Amniotic Umbilical Cord Particulate in 8cc saline
61976115|NCT03912116|PLACEBO_COMPARATOR|Saline Injection|8cc saline
61976116|NCT00548925|EXPERIMENTAL|1|
61976117|NCT00548925|PLACEBO_COMPARATOR|2|
61976118|NCT04492618|EXPERIMENTAL|Necrobiosis Lipoidica|Adults with cutaneous Necrobiosis Lipoidica (NL) up to 10% of the body surface area (BSA) treated with Ruxolitinib cream
61976119|NCT03902067|EXPERIMENTAL|UC-MSC|UC-MSC transplantation
61976120|NCT03902067|PLACEBO_COMPARATOR|Control Group|Routine treatment
61976121|NCT00818662|EXPERIMENTAL|IGIV, 10% 400mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
61976122|NCT00818662|EXPERIMENTAL|IGIV, 10% 200mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
61976123|NCT00818662|PLACEBO_COMPARATOR|Human Albumin 0.25% Solution - 4 mL/kg|0.25% human albumin solution infused at 4 mL/kg/2weeks
61976124|NCT00818662|PLACEBO_COMPARATOR|Human Albumin 0.25% Solution - 2 mL/kg|0.25% human albumin solution infused at 2 mL/kg/2weeks
61976125|NCT06392503||retrospective cohort group|patients before the study started
61976126|NCT06392503||prospective cohort group|spatients after the study started
61976127|NCT04909320|EXPERIMENTAL|Intervention group|
61976128|NCT04909320|ACTIVE_COMPARATOR|Control group|
61976129|NCT05402592|PLACEBO_COMPARATOR|Control Group|Patients will be given 800 ml of water by the blind caregiver until 24:00 at night before the surgery, and 400 ml of water 2-3 hours before the surgery in the morning.Blood samples for plasma glucose, plasma cortisol, and serum insulin levels will be drawn just before the morning dose, 40 minutes and 90 minutes after ingestion of the beverage, and during anesthesia induction. Gastric volume and pH will be evaluated within the first 10 minutes intraoperatively. Vital signs will be evaluated before, during and after surgery. To evaluate the biochemical parameters, blood samples will be taken again preoperatively and at the 6th and 24th hours postoperatively. Postoperative subjective well-being findings of the patients will be evaluated. The SF-36 quality of life scale will be applied to evaluate the quality of life of the patients on the 30th day after surgery.
62162594|NCT04389983|ACTIVE_COMPARATOR|Alzheimer's Disease subjects|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
62162595|NCT06293794|EXPERIMENTAL|Traditional Clinical Decision Support (CDS)|
62162596|NCT06293794|EXPERIMENTAL|Personalized Clinical Decision Support (CDS)|
62162597|NCT04673032||Boston Scientific Radiofrequency Ablation Systems|Subjects with pain treated with a commercially approved Boston Scientific RF system
62162598|NCT05461092|ACTIVE_COMPARATOR|Standard of Care Anesthesia without Thoracolumbar Interfascial Plane (TLIP) Block of bupivicaine.|Subjects will receive standard of care anesthesia without TLIP Block of bupivicaine.
62162599|NCT05461092|EXPERIMENTAL|Standard of Care Anesthesia with Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivacaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
62162600|NCT04291716|OTHER|Single Arm|This is a single-arm study. All subjects enrolled in the study will wear the device during stay in the EMU.
62162601|NCT02739841|EXPERIMENTAL|Ventilator hyperinflation|For the ventilator hyperinflation techniques (VHI), the study consists of three consecutive periods 1) baseline period: 10 minutes rest in side lying by effected lung uppermost with head-up 30 degree 2) Intervention period: Patients were positioned as same as baseline period and 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial 3) recovery period: 10 minutes rest in the same position but reduce VT to initial.
62162602|NCT02739841|EXPERIMENTAL|Chest physical therapy|For the conventional chest physical therapy (CPT), the study will be performed in the similar procedure except the intervention period, the patient will be received vibration and passive of the both upper extremity.
62162603|NCT06577493|EXPERIMENTAL|Experimental Arm|Patient to take two 99.5mg phenazopyridine hydrochloride (AZO) for a total of 199 mg by mouth once immediately prior to the start of urodynamic testing.
62162604|NCT06577493|NO_INTERVENTION|Control Arm|Patient to not receive any medication prior to the start of urodynamic testing.
62162605|NCT02453971|EXPERIMENTAL|eCHUG-D|The eCHUG group is requested to conduct the German Version of eCHECKUP TO GO and to fill in their code on the last page of the program.
62535857|NCT05599061|ACTIVE_COMPARATOR|Optimal Medical Treatment (OMT)|
62535858|NCT05384288||Pediatric Influenza Vaccine Recipients|Pediatric patients eligible to receive seasonal influenza vaccine.
62535859|NCT04717765|EXPERIMENTAL|Preventive in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the first day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
62535860|NCT04717765|ACTIVE_COMPARATOR|Preventive in oral mucositis caused by chemo or radiotherapy - Vit E|"Topical Vit. E spray, from the first day to the last day, every day that the chemo or radiotherapy treatment is administered.~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
62535861|NCT04717765|NO_INTERVENTION|Preventive in oral mucositis caused by chemo or radiotherapy - mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the first to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
62535862|NCT04717765|EXPERIMENTAL|Curative in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the tenth day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
62162606|NCT02453971|NO_INTERVENTION|control|It is an assessment only condition.
62162607|NCT00070707|EXPERIMENTAL|Mometasone|Mometasone nasal spray 200 mcg, administered once daily (QD) for 4 weeks
62162608|NCT00070707|PLACEBO_COMPARATOR|Placebo|Matching placebo nasal spray, administered QD for 4 weeks
62162609|NCT03984734|ACTIVE_COMPARATOR|Control group|Patients undergoing pancreatoduodenectomy with antrectomy
62714567|NCT06142864||"-Case patients"|"-Case patients will be patients reporting at least one fall in the last 6 months."
62162610|NCT03984734|EXPERIMENTAL|Study group|Patients undergoing pancreatoduodenectomy with pylorus-preserving pancreatoduodenectomy
62162611|NCT03287947|EXPERIMENTAL|A|Nintedanib
62162612|NCT04973176|ACTIVE_COMPARATOR|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Standard Bougie|Patients randomised to standard bougie will be intubated using standard bougie (Frova® airway intubation catheter )
62162613|NCT04973176|ACTIVE_COMPARATOR|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Flexi-tip Bougie|Patients randomised to Flexi-tio bougie will be intubated using Flexi-tip bougie (P3 medical Ltd, Bristol, UK)
62162614|NCT02518659|OTHER|Inulin|Intervention by inulin, max 20gr per day
62162615|NCT02518659|NO_INTERVENTION|No Inulin|Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
62535863|NCT04717765|ACTIVE_COMPARATOR|Curative in oral mucositis caused by chemo or radiotherapy - mucositis Vit E|"Topical Vit. E spray, application from the tenth day, and until the last day, every day that the chemo or radiotherapy treatment is administered.~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
62714568|NCT06142864||"-Control patients"|"-Control patients will be patients reporting no fall in the last 6 months."
62162616|NCT02639234|EXPERIMENTAL|Vigil™ + Nivolumab|Patients meeting study eligibility criteria will receive doublet therapy comprising of (i) Vigil™ 1 x 10\^7 cells by intradermal injection every 2 weeks (for a minimum of 4 and a maximum of 12 doses) and (ii) nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks.
62162617|NCT03970304|EXPERIMENTAL|Vaccination, Colonoscopy|Individuals receive immunization with Vivotif typhoid vaccine prior to routine colonoscopy examination. During colonoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings will also be obtained.
62162618|NCT03970304|EXPERIMENTAL|Colonoscopy, Vacciniation, Colonoscopy|Individuals receive immunization with Vivotif typhoid vaccine after initial colonoscopy exam and specimen collection and prior to a routine follow up colonoscopy examination during which additional specimens will be collected.
62162619|NCT03970304|NO_INTERVENTION|Colonoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during colonoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum).
62162620|NCT04749771|EXPERIMENTAL|Filming Interactions to Nurture Development (FIND)|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly sessions lasting 30-45 minutes. The process begins with an initial session in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
62162621|NCT04749771|ACTIVE_COMPARATOR|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 sessions each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
62162622|NCT02108054|EXPERIMENTAL|1|People with alcohol use disorder
62162623|NCT02108054|EXPERIMENTAL|2|People without alcohol use disorder
62162624|NCT02825888||Non-obese|Body Mass index less than 30 kg/m2
62162625|NCT02825888||Obese|Body Mass index more than 30 kg/m2
62714569|NCT05311514|EXPERIMENTAL|Allogeneic Platelet Lysate eye drops 50%|Patients with ocular chronic severe graft versus host disease receive 50% allogeneic Platelet Lysate in the form of eye drops 6-8 times a day
62162626|NCT01596699|EXPERIMENTAL|Patients with Myeloid Malignancies|
62162627|NCT01596699|EXPERIMENTAL|Patients with Non-Malignancies|
62162628|NCT04296409||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Deglutition Handicap Index, and Turkish version of the Eating Assessment Tool.
62162629|NCT02714998|ACTIVE_COMPARATOR|Methotrexate only|Single dose of systemic Methotrexate administered to 55 patients.
62162630|NCT02714998|ACTIVE_COMPARATOR|Salpingectomy only group|Laparoscopic unilateral salpingectomy performed to 61 patients.
62162631|NCT02714998|ACTIVE_COMPARATOR|Salpingectomy following Methotrexate|15 patients underwent laparoscopic unilateral salpingectomy following unsuccessful single dose of methotrexate administration.
62162632|NCT06101134|EXPERIMENTAL|Cohort 1: Metastatic Melanoma|
62162633|NCT06101134|EXPERIMENTAL|Cohort 2: Resected Melanoma|
62162634|NCT02884622|OTHER|CF patients|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added and blood sampling will be collected for this study
62162635|NCT01445509|EXPERIMENTAL|Arm 1|Group 1 will receive dasatinib and bevacizumab together at the start of study in a dose escalation fashion
62714570|NCT05311514|ACTIVE_COMPARATOR|Allogeneic Platelet Lysate eye drops 20%|Patients with ocular chronic severe graft versus host disease receive 20% allogeneic Platelet Lysate in the form of eye drops 6-8 times a day
62714571|NCT05775900|EXPERIMENTAL|Cetuximab in Combination With Capecitabine|"Patients were given cetuximab (a '3+3' design was adopted in the experimental arm, with four dose levels of 400mg/m2, 500mg/m2, 600mg/m2 and 700mg/m2 for dose exploration) every 3 weeks (Q3W).~Capecitabine, 1000mg/m2, twice a day (BID, once in the morning and once in the evening), 14 days of continuous oral administration followed by 7 days of rest.~The two-drug combination therapy was continued every 3 weeks in a cycle until patients developed disease progression or met other criteria for termination of study treatment specified in the protocol."
62162636|NCT01445509|EXPERIMENTAL|Arm 2|Group 2 will be randomized as to which agent they receive for cycle one. Cycles 2 and beyond are treated using both agents.
62162637|NCT06570798|EXPERIMENTAL|Subprotocol A: Inebilizumab 3 Doses|Participants will receive 3 doses of inebilizumab administered via an intravenous (IV) infusion.
62162638|NCT06570798|EXPERIMENTAL|Subprotocol A: Inebilizumab 4 Doses|Participants will receive 4 doses of inebilizumab administered via an IV infusion.
62162639|NCT06570798|EXPERIMENTAL|Subprotocol B: Blinatumomab Low-dose|Participants will receive blinatumomab low-dose administered via SC injection.
62162640|NCT06570798|EXPERIMENTAL|Subprotocol B: Blinatumomab Medium-dose|Participants will receive blinatumomab medium-dose administered via SC injection.
62162641|NCT06570798|EXPERIMENTAL|Subprotocol B: Blinatumomab High-dose|Participants will receive blinatumomab high-dose administered via SC injection.
62162642|NCT06563154||Patient Group|
62162643|NCT06355271|ACTIVE_COMPARATOR|Control|Spinal anesthesia with no fentanyl
62162644|NCT06355271|EXPERIMENTAL|Experimental 1|Spinal anesthesia with 10 mcg of fentanyl
62162645|NCT06355271|EXPERIMENTAL|Experimental 2|Spinal anesthesia with 20 mcg of fentanyl
62162646|NCT03110640|EXPERIMENTAL|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
62162647|NCT04936308|EXPERIMENTAL|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
62162648|NCT04936308|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab SC.
62162649|NCT04936308|EXPERIMENTAL|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive guselkumab SC.
62162650|NCT05931367|EXPERIMENTAL|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
62162651|NCT05931367|EXPERIMENTAL|Retatrutide Dose 2|Participants will receive retatrutide SC.
62162652|NCT05931367|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo.
62162653|NCT02468037|EXPERIMENTAL|Phlebotomy|All subjects receive counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of 500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals, serum ferritin and complete blood counts are determined. When serum ferritin reaches the lowest quartile of normal (\<50 ng/mL for females and \<70 ng/mL for males, but no sooner than 3 months or later than 6 months after beginning phlebotomy, subjects will be retested for glucose tolerance as described
62162654|NCT02468037|NO_INTERVENTION|Control|Subjects receive counseling to follow a healthy diet and regular exercise.
62162655|NCT04255485||Short time anesthesia group|Unilateral cochlear implantation,which time of anesthesia is less than 3 hours
62162656|NCT04255485||Long time anesthesia group|Bilateral cochlear implantation, which time of anesthesia is more than 3 hours
62162657|NCT05817864||Observational group|All participants included will be in one observational cohort.
62162658|NCT01233193|EXPERIMENTAL|Intervention|The intervention group receive an pharmacist intervention (health education, Home Blood Pressure Monitoring and Referral to physician as needed) This group will be followed for 6 months
62162659|NCT01233193|NO_INTERVENTION|Control|The control group receive usual care in the community pharmacy
62162660|NCT06719674|EXPERIMENTAL|Professional Mechanical Plaque Removal + Laser|The patients will be treated in accordance with treatment guidelines for Stage III periodontitis issued by the European Federation of Periodontology. At baseline, oral hygiene instructions were given together with supra- and subgingival professional mechanical plaque removal (PMPR) using a combination of the ultrasonic scaler and hand instruments plus diode laser, according to the clinical situation. After completing treatment, patients will be asked to return at 1 month for review and again at 3 months to repeat the measurement of clinical parameters and collection of the saliva samples.
62162661|NCT06719674|ACTIVE_COMPARATOR|Professional Mechanical Plaque Removal|The patients will be treated in accordance with treatment guidelines for Stage III periodontitis issued by the European Federation of Periodontology (13). At baseline, oral hygiene instructions were given together with supra- and subgingival professional mechanical plaque removal (PMPR) using a combination of the ultrasonic scaler and hand instruments, according to the clinical situation. After completing treatment, patients will be asked to return at 1 month for review and again at 3 months to repeat the measurement of clinical parameters and collection of the saliva samples.
62535864|NCT04717765|NO_INTERVENTION|Curative in oral mucositis caused by chemo or radiotherapy- mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the tenth to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
62714572|NCT06378437|EXPERIMENTAL|Dose Escalation of GLB-001 in Study Participants with PV and ET-Phase 1a|Phase 1a (Dose Escalation) will evaluate the safety and tolerability of GLB-001 in PV and ET study participants. A standard 3+3 dose-escalation design will be applied to evaluate a set of dose levels to determine and the maximum tolerated dose (MTD) and/or recommended expansion doses (RED) in PV and ET study participants who are eligible for dose limiting toxicity (DLT) evaluation.
62162662|NCT02161393|EXPERIMENTAL|Physical Activity Intervention|12 week home-based walking programme consisting of weekly physical activity consultations and a pedometer-driven walking programme
62162663|NCT02161393|ACTIVE_COMPARATOR|Pulmonary Rehabilitation Programme|6-week supervised outpatient programme consisting of twice-weekly exercise sessions and once-weekly education sessions.
62162664|NCT02606617|ACTIVE_COMPARATOR|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
62162665|NCT02606617|PLACEBO_COMPARATOR|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
62162666|NCT03941587|ACTIVE_COMPARATOR|Aflibercept + RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection + RF-PDT ( 6mg/m2 intravenous infusion of Verteporfin followed by laser light at a dose rate of 25 Joules/cm2) at baseline.~Aflibercept- 1st treatment (baseline) followed by minimum retreatment interval of 4 weeks (from Baseline to week 8) and then retreatment at intervals of 4 weeks pro re nata (PRN) retreatment( week 12-48). Primary endpoint at week 52.~RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.~At each visit, subjects will be assessed based on BCVA, ophthalmic examination and Optical Coherence Tomography (OCT)"
62162667|NCT03941587|ACTIVE_COMPARATOR|Aflibercept + sham RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection, at baseline. A minimum of 1 injection(baseline) followed by minimum pro re nata (PRN) retreatment interval of 4 weeks ( from baseline to week 8) and then a minimum of 4 weeks retreatment thereafter (week 12-48). Primary endpoint at week 52.~Sham RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.~At each visit, subjects will be assessed based on Best Corrected Visual Acuity (BCVA), ophthalmic examination and Optical Coherence Tomography (OCT)"
62162668|NCT06004245|EXPERIMENTAL|RO7589831 Dose Escalation|
62162669|NCT06004245|EXPERIMENTAL|RO7589831 Monotherapy Expansion|
62162670|NCT06004245|EXPERIMENTAL|RO7589831 + Pembrolizumab Expansion|
62162671|NCT04214808|EXPERIMENTAL|Avodart Soft Capsule 0.5mg to AD-208|Period 1: Avodart Soft Capsule 0.5mg, 1 Capsule Period 2: AD-208, 1 tab
62162672|NCT04214808|EXPERIMENTAL|AD-208 to Avodart Soft Capsule 0.5mg|Period 1: AD-208, 1 tab Period 2: Avodart Soft Capsule 0.5mg, 1 Capsule
62162673|NCT04595500||GERD|
62162674|NCT04595500||Control|
62162675|NCT05662852|EXPERIMENTAL|Tdap for Plasma Donors|Dose: 0.5 mL; Route: Intramuscular (IM) in the deltoid muscle; Frequency: Every 90 days; Duration: 5 doses over 1 year.
62162676|NCT00466856|EXPERIMENTAL|Sir-Spheres|
62162677|NCT00310050|EXPERIMENTAL|Pemetrexed in combination with concomitant radiotherapy|Patients will receive Pemetrexed plus Radiotherapy.
62162678|NCT06243666||Vaccine group for long-term effectiveness evaluation|No intervention was implemented in this study. Participants who have participated in the immunobridging clinical trial of the bivalent HPV vaccine (Unique Protocol ID:HPV-PRO-006,Identifiers: NCT02562508) and were aged 9-17 years at the time of enrollment, and have received at least one dose of the vaccine were recruited as the vaccine group for long-term effectiveness evaluation.
62162679|NCT06243666||Control group for long-term effectiveness evaluation|No intervention was implemented in this study. Participants with no previous HPV vaccination history were recruited as the control group for long-term effectiveness evaluation.
62162680|NCT06243666||Vaccine group for immuno-persistence evaluation|No intervention was implemented in this study. Participants who have participated in the immunobridging clinical trial of the bivalent HPV vaccine (Unique Protocol ID:HPV-PRO-006,Identifiers: NCT02562508) and were aged 9-26 years at the time of enrollment, and have received at least one dose of the vaccine were recruited as the vaccine group for immuno-persistence evaluation.
62535865|NCT04717765|EXPERIMENTAL|Preventive osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + extraction|"For patients who need dental extraction for the adequacy of the oral cavity. Application of LLL phototherapy on the day the dental extraction is performed and every 72hr, totaling 5 applications. It must be done at least 3 months before the beginning of the chemo or radiotherapy treatment.~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of the root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
62535866|NCT04717765|ACTIVE_COMPARATOR|Preventive osteonecrosis resulting from chemo or radiotherapy - LPRF+ extraction|"For patients who need dental extraction for the adequacy of the oral cavity. LPRF placement on the day the tooth extraction is performed. The procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.~After the LPRF has been placed, the suture should be done in a way that facilitates healing for primary intention."
62162681|NCT02829099|EXPERIMENTAL|JNJ-64457107|In Part 1, the first cohort will receive JNJ-64457107 at a starting dose of 75 microgram per kilogram (mcg/kg). The proposed treatment schedule is intravenous (IV) dosing every 14 days. JNJ-64457107 doses will be escalated following a modified Continual Reassessment Method (mCRM); the JNJ-64457107 dose will be increased by not more than half-logarithmical (3.2-fold) dose increments. Dose escalation will continue until the maximum tolerated dose (MTD) and/or RP2D of JNJ-64457107 are defined or the maximum-administered dose (MAD) has been reached. In Part 2, subjects will receive JNJ-64457107 at the RP2D and regimen determined in Part 1.
62162682|NCT00814359|EXPERIMENTAL|Magic Mouthwash Plus Sucralfate|
62162683|NCT00814359|ACTIVE_COMPARATOR|Benzydamine HCl|
62162684|NCT05533814|EXPERIMENTAL|Perampanel|Participants will be administered oral perampanel at a starting dose of 2 milligram (mg) per day. Doses of perampanel will then be up titrated in increments of 2 mg every 2 weeks up to maximum of 8 mg per day at the discretion of the investigator, and the dose may be administered up to maximum tolerated dose (MTD) according to the clinical response and tolerance of individual participants.
62162685|NCT05075135|EXPERIMENTAL|3D-splint group|Patients wear the Swibrace 3D splint for 6 weeks of immobilization of the wrist for distal radius fractures, including the basis of the thumb for scaphoid fractures. X-rays after week 1, 3 and 6 are planned to document bone healing, together with weekly visits at the hand therapy unit to measure patient satisfaction and hand function. This results in 2-3 surgeon and 6 hand therapy visits at the Inselspital Bern, where regular check-ups on the patient's comfort in the splint are made.
62162686|NCT05075135|ACTIVE_COMPARATOR|Plaster cast group|"The control intervention is the same as the study intervention, but the participants wear the gold-standard plaster cast instead of the newly designed Swibrace 3D-splint."
62162687|NCT06721078|OTHER|Peer navigation effectiveness|To determine the effectiveness of peer navigation on viral suppression and retention in care among adolescents living with HIV in South Africa.
62535867|NCT04717765|NO_INTERVENTION|Preventive osteonecrosis resulting from chemo or radiotherapy - extraction only|"For patients who need dental extraction for the adequacy of the oral cavity, the procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.~The suture should be done in a way that facilitates healing for primary intention."
62714573|NCT06378437|EXPERIMENTAL|Dose Exploration of GLB-001 in Study Participants with MF, LR-MDS, AML and HR-MDS-Phase 1b|Phase Ib 1b (Dose Exploration) will utilize a standard 3+3 dose-escalation design to evaluate the safety and tolerability of GLB-001 in MF, LR-MDS, HR-MDS and AML study participants. The starting dose will be selected within the range of tolerated dose levels determined in Phase 1a (Dose escalation).
62714574|NCT06378437|EXPERIMENTAL|Dose Expansion of GLB-001 in Study Participants with PV, ET, MF, LR-MDS, AML and HR-MDS-Phase 1c|Phase 1c (Dose Expansion) will be conducted to further determine the tolerability, efficacy and the recommended phase 2 dose (RP2D) of GLB-001 in study participants with relapsed or refractory or intolerant myeloid malignancies including PV, ET, MF, LR-MDS, HR-MDS and AML.
62162688|NCT05652036|ACTIVE_COMPARATOR|5 mL Group|100 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder in 5 separate injections of 1 mL. One injection will be at the trigone.
62162689|NCT05652036|ACTIVE_COMPARATOR|10 mL Group|100 units BTX-A reconstituted in 10 mL normal saline, injected into the bladder in 10 separate injections of 1 mL. One injection will be at the trigone
62162690|NCT04826744||Adults with palpebral involvement of atopic dermatitis|
62162691|NCT02351388|ACTIVE_COMPARATOR|Active stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
62162692|NCT02351388|SHAM_COMPARATOR|Sham stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
62162693|NCT00401791|EXPERIMENTAL|1|
62162694|NCT00401791|NO_INTERVENTION|2|
62162695|NCT05776875|EXPERIMENTAL|Atezolizumab and Bevacizumab in combination with TACE|"THIS IS A SINGLE ARM PILOT/FEASABILITY STUDY. THE STUDY CONSISTS OF A SCREENING PERIOD (DAY -28 TO DAY -1), A TREATMENT PERIOD, AND A TREATMENT DISCONTINUATION VISIT.~The atezolizumab and bevacizumab combination will be given every 21 days, atezolizumab 1200 mg and bevacizumab 15 mg/kg will be administered intravenously on a Q3 week schedule.~Subjects will start the combination of bevacizumab and atezolizumab followed by TACE treatment 4 weeks ±1 week or up to 5 weeks after study drugs. Full recovery from the procedure is required prior to systemic treatment."
62162696|NCT05250492|EXPERIMENTAL|Patients with PENG block|
62162697|NCT05250492|ACTIVE_COMPARATOR|Patients with intra-articular infiltration|
62162698|NCT05134142||Observational (Physical tests, questionnaires, record review)|Patients undergo physical performance assessments and complete quality of life assessments and questionnaires pre-hemipelvectomy, at 6 weeks post-hemipelvectomy, and then every 3 months up to 12 months and yearly thereafter for 10 years. Patients who are 1 year out from surgery complete pain-related questionnaires once. Patients who have already undergone hemipelvectomy prior to enrollment undergo medical record review.
62162699|NCT00365183|EXPERIMENTAL|Xcytrin® (motexafin gadolinium)|
62162700|NCT02335242|PLACEBO_COMPARATOR|Placebo tablets (resembling Revatio)|Placebo Drug: Placebo tablets (resembling Revatio)
62162701|NCT02335242|EXPERIMENTAL|Sildenafil 20 mg tablets (Revatio)|Active Drug: Sildenafil tablets (Revatio)
62162702|NCT04596358||Healtcare workers|Women who work as nurses or doctors in public hospitals of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
62162703|NCT04596358||Non-Healthcare workers|Women who perform technical and managerial professions in a public administration body of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
62162704|NCT06720935||Patients undergoing to percutaneous coronary intervention with coils|The study involves patients undergoing coils embolization for treating coronary artery perforation or coronary fistulas/aneurysm during percutaneous coronary intervention
62162705|NCT04160871|EXPERIMENTAL|Family Connections|Experimental group
62162706|NCT04160871|ACTIVE_COMPARATOR|Treatment As Usual|Control group
62162707|NCT05755698|EXPERIMENTAL|Emotional Awareness and Expression Therapy (EAET)|In this experimental arm, participants are required to attend 8 online sessions, and fill out questionnaires before treatment, immediately after treatment, and at a 3-month follow-up.
62162708|NCT06166095|EXPERIMENTAL|high-dose moderate to vigorous physical activity (MVPA)|"Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of moderate to vigorous physical activity (MVPA) per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max.~Participants will be asked to track their activity using Fitbit."
62162709|NCT06166095|EXPERIMENTAL|moderate-dose moderate to vigorous physical activity (MVPA)|"Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of moderate to vigorous physical activity (MVPA) per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max.~Participants will be asked to track their activity using Fitbit."
62162710|NCT06166095|EXPERIMENTAL|walking attention control|"Participants will be provided sleep education material and will be asked to perform 15 minutes of leisure walking three times per week. This exercise intensity does not meet the recommended volume of exercise necessary for health benefits.~Instructing participants to walk will reduce the likelihood that participants will undertake a more vigorous exercise routine.~Participants will be asked to track their sleep each night using Fitbit."
62162711|NCT01879735|EXPERIMENTAL|ICG's effect on 11C-CSar transport|"Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments."
62162712|NCT01879735|EXPERIMENTAL|Infusion method|Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.
62162713|NCT01763645|EXPERIMENTAL|BCD-021 (CISC BIOCAD)|BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
62162714|NCT01763645|ACTIVE_COMPARATOR|Avastin (F. Hoffmann-La Roche Ltd)|In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
62162715|NCT03889912|EXPERIMENTAL|Cemiplimab|"Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion. After completion of the above, three additional cohorts (A, B and C) of patients will be evaluated. Cohorts D, H and I may open after completion of Cohort B.~Note: Cohort E through G will not be opened for participation."
62162716|NCT05054361||recent onset patients|patients with recently diagnosed type 1 diabetes
62162717|NCT05054361||at risk patients|patients with a high genetic risk type 1 diabetes
62162718|NCT05054361||control subjects|control patients (no risk of type 1 diabetes and no diagnosed type 1 diabetes)
62162719|NCT05054361||control subjects for endoscopy|patients without type 1 diabetes requiring UGI endoscopy for any medical reason
62162720|NCT03733899|EXPERIMENTAL|Upper lid margin/Lower lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences of an ocular surface region. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
62162721|NCT03733899|EXPERIMENTAL|Lower lid margin/Cornea/ Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
62162722|NCT03733899|EXPERIMENTAL|Cornea/Upper lid margin/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
62162723|NCT03733899|EXPERIMENTAL|Cornea/Lower lid margin/Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
62162724|NCT03733899|EXPERIMENTAL|Upper lid margin/Cornea/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
62162725|NCT03733899|EXPERIMENTAL|Lower lid margin/Upper lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
62162726|NCT03697837|EXPERIMENTAL|Parent Management Training|Parents will receive a web-based parenting intervention for tantrums and disruptive behavior in young children
62162727|NCT02195219|EXPERIMENTAL|open reduction internal fixation|open reduction internal fixation
62162728|NCT02195219|ACTIVE_COMPARATOR|non operative treatment|'sling rest and early functional recovery
62162729|NCT03749616|ACTIVE_COMPARATOR|Acetaminophen|"Acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.~Oxycodone 5mg 1-2 tablets q4-6 hours will be available as needed for breakthrough pain."
62162730|NCT03749616|EXPERIMENTAL|NSAID|"NSAID administered ibuprofen 400-800 mg, up to three times a day and acetaminophen with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day as needed for pain control.~Oxycodone 5mg 1-2 tablets q4-6 hours will be available for breakthrough pain."
62535868|NCT04717765|EXPERIMENTAL|Curative osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and application of LLL phototherapy on the day of surgery and every 72hr, totaling 5 applications. The suture should be done in a way to facilitate healing for primary intention.~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of what would be the dental root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
62535869|NCT04717765|ACTIVE_COMPARATOR|Curative osteonecrosis resulting from chemo or radiotherapy - LPRF + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and placement of the LPRF on the day of surgery will be performed.~After the LPRF is placed, the suture should be done in a way that facilitates healing for primary intention."
62162731|NCT06597435|EXPERIMENTAL|Nicotine pouch containing high nicotine (6-8mg)|Participants will self-administer a nicotine pouch containing 6-8mg nicotine.
62162732|NCT06597435|PLACEBO_COMPARATOR|Nicotine pouch containing low nicotine (3-4mg)|Participants will self-administer a nicotine pouch containing 3-4mg nicotine.
62535870|NCT04717765|NO_INTERVENTION|Curative osteonecrosis resulting from chemo or radiotherapy - sequestrectomy only|"Patients who were diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy and removal of necrotic tissue will be performed.~The suture should be done in a way that facilitates healing for primary intention."
62535871|NCT04719260|EXPERIMENTAL|Nutrition Thinking®|Nutrition Thinking® approach to promote weight loss and healthy diet pattern.
62535872|NCT04719260|ACTIVE_COMPARATOR|Standard Nutritional Approach|The traditional nutritional prescriptive approach.
62535873|NCT02895152|EXPERIMENTAL|Feedback|Those randomised to the feedback arm will receive weekly feedback on their activity levels and tailored advice on how to improve activity levels.
62535874|NCT02895152|NO_INTERVENTION|Control|Control arm will wear the activity monitor as specified in the protocol but will not receive feedback on activity levels
62535875|NCT03760003|EXPERIMENTAL|ABX464|ABX464 will be administrated orally (Capsules) and daily for 16 weeks
62535876|NCT03760003|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo will be adminstrated orally (Capsules) and daily for 16 weeks
62162733|NCT06597435|EXPERIMENTAL|Nicotine pouch with low pH (less than 8.5)|Participants will self-administer a nicotine pouch with low pH (less than 8.5).
62162734|NCT06597435|PLACEBO_COMPARATOR|Nicotine pouch with high pH (8.5 or greater)|Participants will self-administer a nicotine pouch with high pH (8.5 or greater).
62162735|NCT01517139||Feasibility Cohort|100 pairs of children and their mothers recruited from 2 provinces.
62162736|NCT06034002|EXPERIMENTAL|Part 1a Dose Escalation Cohort Disease Group A - with MF|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myelofibrosis (MF) will enroll in this group.
62535877|NCT04953572|EXPERIMENTAL|test group|Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy
62535878|NCT04953572|ACTIVE_COMPARATOR|control group 1|Patients in the control group 1 received microfracture surgical treatment
62535879|NCT04953572|ACTIVE_COMPARATOR|control group 2|Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane
62162737|NCT06034002|EXPERIMENTAL|Part 1a Dose Escalation Cohort Disease Group A - with ET|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with essential thrombocythemia (ET) will enroll in this group.
62162738|NCT06034002|EXPERIMENTAL|Part 1b: Dose Expansion - with MF|INCA033989 will be administered at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group.
62162739|NCT06034002|EXPERIMENTAL|Part 1b: Dose Expansion - with ET|INCA033989 will be administered at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group.
62162740|NCT04248881|ACTIVE_COMPARATOR|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
62162741|NCT04248881|NO_INTERVENTION|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2020 (first timers) and have not yet received health education information."
62162742|NCT03803423|EXPERIMENTAL|The Donor App|Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.
62162743|NCT02361983||DLT versus bronchial blockers|double lumen tube versus bronchial blockers
62162744|NCT05807555||Infant with sepsis (Case)|Patient hospitalized in the pediatric intensive care unit (ICU) for severe sepsis
62162745|NCT05807555||Healthy child of the same sex and age (Control)|Healthy children will be matched to cases by age and gender
62162746|NCT04246892||group before alarm withdrawal|
62162747|NCT04246892||groupe after alarm withdrawal|
62535880|NCT04953572|ACTIVE_COMPARATOR|control group 3|Patients in the control group 3 received autologous osteochondral transplantation
62535881|NCT05655221|PLACEBO_COMPARATOR|Cohort 1|B1344/Placebo:2mg.
62535882|NCT05655221|PLACEBO_COMPARATOR|Cohort 2|B1344/Placebo:5mg.
62535883|NCT05655221|PLACEBO_COMPARATOR|Cohort 3|B1344/Placebo:15mg.
62535884|NCT05655221|PLACEBO_COMPARATOR|Cohort 4|B1344/Placebo:30mg.
62535885|NCT05655221|PLACEBO_COMPARATOR|Cohort 5|B1344/Placebo:45mg.
62535886|NCT05655221|PLACEBO_COMPARATOR|Cohort 6|B1344/Placebo:60mg.
62535887|NCT05655221|PLACEBO_COMPARATOR|Cohort 7|B1344/Placebo:80mg.
62535888|NCT05296538|EXPERIMENTAL|Broad-Minded Affective Coping Intervention + Risk assessment and signposting|Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. They will then be offered six sessions of the Broad-Minded Affective Coping (BMAC) Intervention. Sessions will take place weekly where possible and the intervention window will be eight weeks. A booster session will be offered in the 8 weeks following the end of therapy.
62535889|NCT05296538|OTHER|Risk assessment and signposting + Treatment As Usual|Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. In addition they will be able to access usual care from their University counselling service or other health services.
62535890|NCT02829151|EXPERIMENTAL|Triple antiplatelet therapy group|Patient group with triple antiplatelet therapy using aspirin, clopidogrel, and cilostazol
62162748|NCT01844908|EXPERIMENTAL|Electroacupuncture|
62162749|NCT02010021|NO_INTERVENTION|No drug treatment|Post-menopausal women with stage I-III breast cancer will have surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.
62162750|NCT02010021|ACTIVE_COMPARATOR|Letrozole-presurgical|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
62162751|NCT04563026|EXPERIMENTAL|DUR-928 (larsucosterol, 30 mg)|
62535891|NCT02829151|ACTIVE_COMPARATOR|DAP (Dual antiplatelet therapy) A|Patient group with dual antiplatelet therapy using aspirin and clopidogrel
62535892|NCT02829151|ACTIVE_COMPARATOR|DAP (Dual antiplatelet therapy) B|Patient group with angioplasty using aspirin and cilostazol
62162752|NCT04563026|EXPERIMENTAL|DUR-928 (larsucosterol, 90 mg)|
62535893|NCT06568055||Refractory CMV group|Participants who had a kidney transplantation (including re-transplantation) with refractory CMV infection will be identified from five solid organ transplantation centres in England and followed retrospectively for at least 6 months and up to 7 years until the end of 2024 or exit date from the cohort for any reasons, including death or end of participation in the registry (follow up period).
62535894|NCT06568055||Reference cohort of non-refractory CMV group|Participants with non-refractory CMV infection who have responded to initial anti-CMV therapy post-transplant with no CMV refractory to treatment will be followed retrospectively for at least 6 months and up to 7 years until the end of 2024 or exit date from the cohort for any reasons, including death or end of participation in the registry (follow up period).
62714575|NCT04177355|EXPERIMENTAL|Part A, Group 1 (T1): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 1 mcg of 3M-052-AF and 500 mcg of Aluminum Hydroxide Suspension (Alum), as one intramuscular (IM) injection at Months 0 and 2.
62714576|NCT04177355|PLACEBO_COMPARATOR|Part A, Group 1 (P1): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
62162753|NCT04563026|PLACEBO_COMPARATOR|(Placebo) Sterile Water for Injection|
62162754|NCT06720909|EXPERIMENTAL|MBSR-Only|This experimental arm receives the 8-week MBSR program only.
62162755|NCT06720909|EXPERIMENTAL|OLP-Only|This experimental arm receives the OLP treatment only.
62162756|NCT06720909|EXPERIMENTAL|MBSR+OLP|This experimental arm receives the 8-week MBSR program AND the 8-week OLP treatment.
62535895|NCT02984085|EXPERIMENTAL|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene 7) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
62535896|NCT01129843|EXPERIMENTAL|Directly observed home based daily iron therapy|Village volunteers will provide directly observed home based daily iron supplementation( ferrous sulphate) to enrolled anemic women in the experimental arm
62535897|NCT01129843|ACTIVE_COMPARATOR|Clinic driven unsupervised daily iron therapy|In the control group of villages, clinic driven unsupervised iron ( ferrous sulphate) supplementation will be offered on monthly basis to anemic women for 3 months
62535898|NCT01846910|ACTIVE_COMPARATOR|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
62535899|NCT01846910|EXPERIMENTAL|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
62535900|NCT01284946|EXPERIMENTAL|Exjade|Safety and efficacy
62535901|NCT06633471|EXPERIMENTAL|30 subjects assigned to receive Rain|Rain is one of the test formulations being evaluated for safety and efficacy in treating DED.
62162757|NCT05167825|EXPERIMENTAL|Macitentan|Participants will receive oral dose of macitentan based on age and weight through Week 52.
62162758|NCT05656404|EXPERIMENTAL|Donor lungs assessed using TorEx Lung Perfusion System|
62162759|NCT03322579|EXPERIMENTAL|Patients with Eustachian tube dysfunction|
62162760|NCT00926978|OTHER|Radiopharmacokinetics|"1-2 mCi I-124 orally, once per day, twice total 0.9mg rhTSH intravenous injection, once per day, four total~After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
62162761|NCT05888402|EXPERIMENTAL|Induction Toripalimab and chemotherapy followed by concurrent chemoradiotherapy|Participants will receive 2 cycles of induction therapy of platinum-based chemotherapy combined with Toripalimab, followed by platinum-based concurrent chemoradiation. Then participants will receive Toripalimab consolidation therapy after chemoradiotherapy with maximum 1 years or until disease progression or intolerable toxicity.
62162762|NCT05888402|ACTIVE_COMPARATOR|Induction chemotherapy followed by concurrent chemoradiotherapy|Participants will receive 2 cycles of induction platinum-based chemotherapy, followed by platinum-based concurrent chemoradiation. Then participants will receive Toripalimab consolidation therapy after chemoradiotherapy with maximum 1 years or until disease progression or intolerable toxicity.
62162763|NCT01945593|EXPERIMENTAL|Fixed BAX855 prophylaxis|45-80 IU/kg twice weekly to once per week.
62162764|NCT01945593|EXPERIMENTAL|Pharmacokinetic (PK)-tailored BAX 855 prophylaxis|PK-tailored prophylactic BAX855 regimen based on participant's individual PK profile to maintain a Factor VIII (FVIII) trough level
62162765|NCT06182527|EXPERIMENTAL|CGM Group|Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded. In addition perception of hypoglycemia and counter action will be assessed.
62535902|NCT06633471|PLACEBO_COMPARATOR|30 patients assigned to receive saline|Saline is the placebo in this study.
62535903|NCT06633471|EXPERIMENTAL|30 subjects assigned to receive Mist|Mist is one of the test formulations being evaluated for safety and efficacy in treating DED.
62535904|NCT06633471|ACTIVE_COMPARATOR|30 patients assigned to receive Systane Ultra|Systane Ultra is the approved OTC formulation used to treat DED and the comparator for Rain and Mist.
62535905|NCT04505748|EXPERIMENTAL|Self-transfusion group|Patients to whom a self-transfusion device has been used after total knee arthroplasty.
62535906|NCT04505748|NO_INTERVENTION|Control group|Patients to whom conventional drains have been used after total knee arthroplasty.
62535907|NCT06369233|EXPERIMENTAL|MegaShield®-SP|The study group is applied with MegaShield®-SP after Lumbar discectomy or laminectomy. Afterwards, they visit at 2 weeks, 12 week to conduct examinations and assess Questionnaires.
62535908|NCT06369233|ACTIVE_COMPARATOR|Guardix-SP Plus|The study group is applied with Guardix-SP after Lumbar discectomy or laminectomy. Afterwards, they visit at 2 weeks, 12 week to conduct examinations and assess Questionnaires.
62535909|NCT06002789|EXPERIMENTAL|MSI-H/MSS (dMMR/pMMR) mixed sMPCC or all-MSI-H (dMMR) sMPCC|"1. MSI-H/MSS (dMMR/pMMR) mixed sMPCC: Synchronous multiple primary colorectal cancer consist of MSI/dMMR and MSS/pMMR tumors at the same time~2. all-MSI-H (dMMR) sMPCC: Synchronous multiple primary colorectal cancer with all MSI/dMMR tumors"
62535910|NCT02212613|EXPERIMENTAL|Brexpiprazole|Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally
62535911|NCT01345487|OTHER|Low Vegetable Protein|Meal with 10 E% protein from fava beans/split peas
62535912|NCT01345487|EXPERIMENTAL|High Vegetable protein|Meal with 20 E% protein from fava beans/split peas
62162766|NCT02907502|EXPERIMENTAL|Experimental formula|Young-child formula with low protein content
62162767|NCT02907502|ACTIVE_COMPARATOR|Control formula|Young-child formula with protein content similar to that of cow's milk
62162768|NCT04042259|ACTIVE_COMPARATOR|Negative Pressure Wound Therapy|Standardized wound closure with negative pressure therapy.
62162769|NCT04042259|OTHER|Historic Cohort|Historic cohort have undergone a midline laparotomy and managed with an open abdomen for at least one day and have contaminated or dirty wound classification.
62535913|NCT01345487|EXPERIMENTAL|High Animal Protein|Meal with 20 E% protein from pork/beef
62535914|NCT02576912|EXPERIMENTAL|Active Delta-9-THC and Placebo Pregnenolone|
62535915|NCT02576912|EXPERIMENTAL|Active Delta-9-THC and Active Pregnenolone|
62535916|NCT02576912|EXPERIMENTAL|Placebo Delta-9-THC and Active Pregnenolone|
62535917|NCT02576912|PLACEBO_COMPARATOR|Placebo Delta-9-THC and Placebo Pregnenolone|
62535918|NCT05603377|OTHER|study group|
62535919|NCT06264401|EXPERIMENTAL|placepo group|"Alendronate:~the experimental and control group received (Alendronate) 70 mg 1 tab every week for 4 months."
62535920|NCT06264401|EXPERIMENTAL|exercises and alendronate group|"alendronate: the experimental and control group received (Alendronate) 70 mg 1 tab every week for 4 months.~treatment exercises: the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program which include 5 min warming up and 5 min cooling down at the end of the session each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 min including 10 min warming up and 10 min cooling down in form of stretching."
62535921|NCT05479656|EXPERIMENTAL|Training program|8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
62535922|NCT06016036|EXPERIMENTAL|SAL-0951|
62535923|NCT06016036|PLACEBO_COMPARATOR|Placebo|
62162770|NCT03734588|EXPERIMENTAL|SPK-8016|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
62162771|NCT04773522|EXPERIMENTAL|Talquetamab|Participants will receive talquetamab injection subcutaneously (SC) in 3 cohorts: Cohort 1 and Cohort 2 as 2 step-up doses and Cohort 3 as 3 step-up doses followed by a treatment dose.
62535924|NCT02036359|ACTIVE_COMPARATOR|erlotinib|Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
62535925|NCT02036359|ACTIVE_COMPARATOR|Chemotherapy|"Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.~Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.~Patients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.~If progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol."
62535926|NCT05782127|EXPERIMENTAL|Onureg + Venetoclax|"Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles.~Venetoclax will be administered orally at 400 mg once daily for 14 consecutive days on days 1 to 14, beginning on Day 1 of repeated 28-day cycles.~Patients will be treated up to 4 cycles and for a maximum of 24 cycles."
62535927|NCT05445661|EXPERIMENTAL|Injectable poly-L-lactic acid|One of the subject's arms will be treated with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).
62535928|NCT05445661|SHAM_COMPARATOR|Normal Saline|One of the subject's arms will be treated with injectable normal saline
62535929|NCT03983824|EXPERIMENTAL|Treatment (peposertib, mitoxantrone, etoposide, cytarabine)|Patients receive peposertib PO BID on days 2-21, mitoxantrone IV over 15 minutes, etoposide IV over 60 minutes and cytarabine IV over 60 minutes on days 1-5 in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO and MUGA during baseline, and blood collection and bone marrow biopsy throughout the study.
62162772|NCT06554366|EXPERIMENTAL|GentleWave|
62162773|NCT06554366|EXPERIMENTAL|EdgePro|
62162774|NCT06554366|ACTIVE_COMPARATOR|Irrisafe passive ultrasonic irrigation|
62162775|NCT02430935|EXPERIMENTAL|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a standardized approach to the use of environmental supports for improving multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia.
62535930|NCT01567475|EXPERIMENTAL|Everolimus and rituximab|
62535931|NCT02985190|EXPERIMENTAL|Azacitidine 75mg/m²/day|"Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles~* in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles~* in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria"
62535932|NCT06077383|EXPERIMENTAL|Probiotics group|Probiotics group subjects take probiotics every day for 8 weeks.
62535933|NCT06077383|PLACEBO_COMPARATOR|Placebo group|Placebo group subjects take placebo every day for 8 weeks.
62535934|NCT05237336|EXPERIMENTAL|MBCT-IPS|Mindfulness-based Cognitive Therapy (MBCT) integrated with cultural Psychology of Soul (IPS) 2-session (IPS) + standard 8-session (MBCT)
62535935|NCT05237336|ACTIVE_COMPARATOR|Mindfulness-based Cognitive Therapy|Standard 8-session Mindfulness-based Cognitive Therapy (MBCT)
62162776|NCT02430935|ACTIVE_COMPARATOR|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
62162777|NCT04169906|PLACEBO_COMPARATOR|Placebo|
62162778|NCT04169906|EXPERIMENTAL|TS-142 10 mg|
62162779|NCT04169906|EXPERIMENTAL|TS-142 20 mg|
62162780|NCT04169906|EXPERIMENTAL|TS-142 30 mg|
62162781|NCT02434484||Symbenda|Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study.
62162782|NCT00365599|EXPERIMENTAL|Vorinostat and Tamoxifen|As outlined in Intervention descriptions
62162783|NCT03590067||Heamodialysis group|
62535936|NCT05237336|OTHER|Counselling as usual|8-session Control group
62535937|NCT05726903|EXPERIMENTAL|Depo SC Home|Participants will be given instructions on home administration of DMPA SC and be provided with all necessary supplies.
62535938|NCT03641521|EXPERIMENTAL|Intervention|The intervention consisted of an enhanced Cooking Matters® for Families program that included behavioral strategies derived from behavioral economics, to be implemented by parents at home for increasing vegetable intake of low-income 9-12 year old children
62162784|NCT03590067||Kidney transplantation group|
62162785|NCT04267393|EXPERIMENTAL|Dose A BMS-986263|
62162786|NCT04267393|EXPERIMENTAL|Dose B BMS-986263|
62162787|NCT04267393|PLACEBO_COMPARATOR|Placebo|
62162788|NCT04763863||Ostomates|Ostomates with leakage issues and stoma created at least 3 months ago
62162789|NCT04763863||Stoma care nurses|Stoma care nurses from Denmark, Finland, Norway and Sweden who had agreed to participate. Invitations were sent to stoma care nurses randomly selected from among those working in relatively large stoma care clinics.
62162790|NCT06067984|EXPERIMENTAL|Arm A|Evaluate the efficacy and safety of a digital therapeutic as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
62162791|NCT05439720|EXPERIMENTAL|Exercise and ketone|Ketone ester is provided
62162792|NCT05439720|PLACEBO_COMPARATOR|Exercise and placebo|Placebo is provided
62162793|NCT05439720|PLACEBO_COMPARATOR|Non-exercise and placebo|Placebo is provided
62535939|NCT03641521|NO_INTERVENTION|Control|The control arm consisted of the enhanced Cooking Matters® for Families program alone--without lessons about the behavioral strategies for the parents
62535940|NCT02378792|EXPERIMENTAL|Vagus Verve Stimulation is on|
62535941|NCT02378792|SHAM_COMPARATOR|Placebo Vagus Verve Stimulation is off|
62535942|NCT05803174||Emmetropic subjects|Spherical equivalent (Diopter, D) to be between -0.5 and +0.5 D
62535943|NCT05803174||Low and moderate myopic subjects|Spherical equivalent (Diopter, D) to be less than -0.5 but over -6.0D
62162794|NCT00972686|EXPERIMENTAL|GSK2126458|GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
62162795|NCT06406049|ACTIVE_COMPARATOR|"I want Yo Quiero Control Group"|Participants will receive the standard of care for up to 15-months
62162796|NCT06406049|EXPERIMENTAL|"Friend Amigx Social network intervention"|Participant will receive a social network intervention for up to 15-months
62162797|NCT05530434|EXPERIMENTAL|Transpulmonary pressure guided positive end expiratory pressure|Patients in this group will have the positive end expiratory pressure on the ventilator set to a transpulmonary pressure of 0-2 cm H2O during ventilation and spontaneous breathing trials.
62162798|NCT05530434|ACTIVE_COMPARATOR|Standard positive end expiratory pressure|Patients in this groups will have the positive end expiratory pressure on the ventilator set by the clinician during ventilation and set to a standard positive end expiratory pressure of 5-8 cm H2O during spontaneous breathing trials.
62162799|NCT06104059|ACTIVE_COMPARATOR|Nociception level index (NOL™)|The nociception level index NOL will be used in order to quide intraopertaive analgesia.
62162800|NCT06104059|ACTIVE_COMPARATOR|Standard of care|Intraoperative analgesia will be based on common practice, i.e. changes in hemodynamic parameters.
62535944|NCT05803174||High myopic subjects|Spherical equivalent (Diopter, D) to be over or equal to -6.0D
62535945|NCT00872638|ACTIVE_COMPARATOR|1|
62162801|NCT05325008|EXPERIMENTAL|Immunosuppression reduction/modification + Intravenous Immunoglobulin|Receives Immunosuppression reduction/modification + Intravenous Immunoglobulin
62162802|NCT05325008|OTHER|Immunosuppression reduction/modification|Receives Immunosuppression reduction/modification as part of standard of care.
62162803|NCT02630147|EXPERIMENTAL|Vanilla, Then no vanilla night|"Participants were exposed to vanilla odor (2 mL of 2% vanillin on the bib, close to the face) on the first night (12-hour recording), and not exposed to vanilla on the third night (control night,12-hour recording)~No intervention, no recordings were made on the second night"
62162804|NCT02630147|EXPERIMENTAL|No vanilla, Then vanilla night|"Participants were exposed to the control condition on the first night, which consisted of no vanilla odor (12-hour recording), and then exposed to vanilla odor on the third night (2 mL of 2% vanillin on the bib, close to the face;12-hour recording)~No intervention, no recordings were made on the second night"
62162805|NCT02662023|EXPERIMENTAL|RIGHT side BOLUS and left side basal|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours
62535946|NCT00872638|ACTIVE_COMPARATOR|2|
62535947|NCT04500093|EXPERIMENTAL|Capsulotomy with Repair|Repair after capsulotomy in direct anterior hip arthroplasty
62535948|NCT04500093|ACTIVE_COMPARATOR|Capsuloectomy|Capsuloectomy in direct anterior hip arthroplasty
62535949|NCT06632353||Group 1|Cardiovascular diseases
62535950|NCT06632353||Group 2|Reference
62535951|NCT02679235|EXPERIMENTAL|Triheptanoin|Participant will undergo POST Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night) after a control PRE supplementation imaging protocol.
62535952|NCT05908630||Normothermic drowning patients with OHCA.|First in-hospital temperature measurement (using any probe) within 6 hours after hospital admission ≥35C.
62535953|NCT05908630||Hypothermic drowning patients with OHCA.|First in-hospital temperature measurement (using any probe) within 6 hours after hospital admission \<35C.
62535954|NCT00517556|EXPERIMENTAL|study group (CCOCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
62535955|NCT00517556|ACTIVE_COMPARATOR|control group (traditional OCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.
62535956|NCT03925350|EXPERIMENTAL|Niraparib|Patients receive niraparib PO daily
62535957|NCT05826795||Control|During the intraoperative period, both before and after CPB, the Control group received fluid, inotropic, and/or vasoactive drugs at the discretion of the attending anesthesiologists to achieve the following goals: MAP 65-90 mmHg; CVP 8-12 mmHg; urine output ≥ 0.5 mL·kg-1·h-1; SpO2 \> 95%; and hematocrit 26-30%. Arterial blood gas (ABG) and electrolytes were monitored and corrected hourly.
62714577|NCT04177355|EXPERIMENTAL|Part A, Group 2 (T2): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 5 mcg of 3M-052-AF and 500 mcg of Alum, as one IM injection at Months 0 and 2.
62162806|NCT02662023|ACTIVE_COMPARATOR|RIGHT side BASAL and left side bolus|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours. For the left catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later
62162807|NCT04890483|EXPERIMENTAL|Intervention|The ARD patients with post-acute COVID-19 will receive tDCS sessions for one week.
62162808|NCT03990376|OTHER|Blood volume assessment with Blood Volume Analyzer|Injections of 1 mL of I-131-labeled serum albumin based on each patient's height and weight - 1 pre-surgical and 1 post-surgical
62162809|NCT06198452|EXPERIMENTAL|Vision Improvement|
62162810|NCT01807845|ACTIVE_COMPARATOR|Skimmilk VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80;
62162811|NCT01807845|PLACEBO_COMPARATOR|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
62162812|NCT01807845|ACTIVE_COMPARATOR|enriched skimmilk with VD|enriched skimmilk with VD
62162813|NCT02261675|NO_INTERVENTION|control group|children undergoing selective lower abdominal surgery received saline before induction
62162814|NCT02261675|EXPERIMENTAL|D1 group|children undergoing selective lower abdominal surgery received a bolus dose of 0.5 µg/kg dexmedetomidine followed by a continuous infusion of 0.5 µg/kg /h before induction
62162815|NCT02261675|EXPERIMENTAL|D2 group|children undergoing selective lower abdominal surgery received a bolus dose of 1.0µg/kg dexmedetomidine followed by a continuous infusion of 1.0 µg/kg /h before induction
62162816|NCT04557059|ACTIVE_COMPARATOR|Interventional Cohort (Group 1): RT+ LHRHa|Participants will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization.
62162817|NCT04557059|EXPERIMENTAL|Interventional Cohort (Group 2): RT+LHRHa + Apalutamide|Participants will receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization. Participants will also receive 240 milligram (mg) of apalutamide starting within 3 days after randomization as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days.
62162818|NCT04557059|NO_INTERVENTION|Observational Cohort(Group3) PSMA-PET Negative Participants|Enrollment into this cohort will be stopped further. Participants who were PSMA-PET-negative at screening and were already enrolled in the Observational Cohort will continue in this cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year. The use of any medicinal product(s) for the treatment and management of participants will be at discretion of the treating physician.
62162819|NCT03683212|EXPERIMENTAL|Intervention period : early and comprehensive care bundle|
62162820|NCT03683212|NO_INTERVENTION|acute heart failure standard therapy|
62162821|NCT01979822||PH patients with LenusPro pump|"Patient Inclusion Criteria:~1. Patient aged ≥ 18 years;~2. diagnosed with Pulmonary Arterial Hypertension (WHO) Category Group 1~3. Patient is in stable clinical condition and~4. the previous specific PH medication has been retained unchanged during the past 3 weeks"
62162822|NCT06584591|EXPERIMENTAL|RBT + Active HD-tDCS Group|Participants will engage in balance and postural control training on a robotic balance platform called Hunova (Movendo, Italy). Before balance training, the current intensity of 2 mA will be delivered to the leg motor area identified using neuronavigated transcranial magnetic stimulation, and the stimulation will be turned ON for 20 minutes.
62162823|NCT06584591|SHAM_COMPARATOR|RBT + Sham HD-tDCS Group|Participants will engage in balance and postural control training on a robotic balance platform called Hunova (Movendo, Italy). Before balance training, the current intensity of 2 mA will be delivered to the leg motor area identified using neuronavigated transcranial magnetic stimulation, and the stimulation will be turned ON transiently for 30 s, to provide a sensation of stimulation.
62162824|NCT06584591|OTHER|SOC Control Group|The SOC control group participants will perform conventional physical therapy exercises delivered by a trained PT.
62162825|NCT06539468|EXPERIMENTAL|Part A (educational activity, survey administration)|Patients watch an educational video on AS for LR-BCC and complete a survey about comfort with AS for LR-BCC on study.
62162826|NCT06539468|ACTIVE_COMPARATOR|Part B arm 1 (active surveillance)|Patients receive no treatment and undergo active surveillance over 1 year in the absence of disease progression. Patients may choose to undergo treatment at any point on study. Patients complete a standard 1-year follow-up total body skin examination followed by a second survey.
62535958|NCT05826795||EV1000|The patients were managed to achieve similar goals: MAP 65-90 mmHg; urine output ≥ 0.5 mL·kg-1·h-1; SpO2 \> 95%; and hematocrit 26-30%, using information from the FloTrac/EV1000. The EGDT group received: fluid to maintain a SVV \< 13%; inotropic drugs to achieve a SVI of 33-65 mL·beat-1·m-2 and CI of 2.2-4.0 L·min-1·m-2; and/or vasoactive drugs to achieve a SVRI of 1600-2500 dynes·s·cm-5·m-2. ABG and electrolytes were monitored and corrected in the same manner.
62714578|NCT04177355|PLACEBO_COMPARATOR|Part A, Group 2 (P2): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
62714579|NCT04177355|EXPERIMENTAL|Part B, Group 3 (T3): BG505 SOSIP.664 gp140 + CpG 1018 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 300 mcg of CpG 1018 and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
62162827|NCT06539468|ACTIVE_COMPARATOR|Part B arm 2 (SOC)|Patients receive SOC treatment which typically includes either electrodesiccation and curettage, surgical resection, or Mohs surgery as agreed upon by patient and provider in the absence of disease progression. Patients complete a standard 1-year follow-up total body skin examination followed by a second survey.
62162828|NCT02418819|EXPERIMENTAL|PF-06412562 3mg|PF-06412562 3mg BID
62162829|NCT02418819|EXPERIMENTAL|PF-06412562 9mg|PF-06412562 9mg BID
62162830|NCT02418819|EXPERIMENTAL|PF-06412562 45mg|PF-06412562 45mg BID
62162831|NCT02418819|PLACEBO_COMPARATOR|Placebo|Placebo BID
62162832|NCT06193889|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning|Dosing with KYV-101 CAR-T cells
62162833|NCT06210178|OTHER|MRI|Noninvasive MRI is performed.
62162834|NCT06585371||Patients with intragastric balloon|Patients over 18 years old, who are overweight, have a BMI of 27 kg/m2 or greater and are going through intragastric balloon placement.
62162835|NCT00919061|EXPERIMENTAL|Gemcitabine and Cisplatin plus Sorafenib|This is a non-randomized, open label, single institution, phase II study of gemcitabine and cisplatin plus sorafenib for the treatment of patients with advanced or biliary tract carcinomas naïve to systemic therapy.
62162836|NCT03948815|EXPERIMENTAL|Intervention room|An adaptable, person-centered, birthing room that is specially designed.
62162837|NCT03948815|OTHER|Control room|A regular standard birthing room
62162838|NCT06721052||Group meta-PENG block|We performed meta-PENG block in patients who underwent hip surgery under spinal or general anesthesia
62162839|NCT01441258|EXPERIMENTAL|Dialectical Behavior Therapy Skills (DBT-S) Groups|Patients in the Dialectical Behavior Therapy Skills (DBT-S) group will receive the newly adapted 18-week group-skills training protocol, one-and-a-half hours in length, with weekly homework assignments to facilitate skill generalization.
62162840|NCT01441258|PLACEBO_COMPARATOR|Wait List-Treatment as Usual|Participants assigned to the wait-list condition will be given the opportunity to participate in a DBT skills group after their 18-week wait period has ended.
62162841|NCT05275023|EXPERIMENTAL|Arm 1: JNJ-73763989 + PD-1 Inhibitor + Nucleos(t)ide analog (NA)|Participants will receive JNJ-73763989 subcutaneous (SC) injections and single dose of programmed cell death protein receptor-1 (PD-1) inhibitor as intravenous (IV) infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, tenofovir alafenamide \[TAF\] or entecavir \[ETV\]).
62162842|NCT05275023|EXPERIMENTAL|Arm 2: JNJ-73763989 + PD-1 Inhibitor + NA|Participants will receive JNJ-73763989 SC injections and multiple doses of PD-1 inhibitor as IV infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, TAF or ETV).
62162843|NCT05874843|OTHER|Pediatric Participants|Pediatric surgery patients undergoing elective pediatric surgical cases under anesthesia will be invited to participate in this prospective laboratory test validation study. The results of the interventional test will not be used in clinical decision making for the participant.
62162844|NCT04502745|EXPERIMENTAL|Treatment Group|During clinically indicated surgery for subdural hematoma, the patient will undergo a single burr hole evacuation with the MICAS device with endoscopic assistance.
62162845|NCT05607550|EXPERIMENTAL|furmonertinib 240 mg|
62162846|NCT05607550|EXPERIMENTAL|furmonertinib 160 mg|
62162847|NCT05607550|ACTIVE_COMPARATOR|platinum-based chemotherapy|carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously
62162848|NCT02148276||Research Participants|All participants will complete two measures of social harm at monthly research appointments for a three month period. The social harms assessments will be (1) the ACASI-SHQ that was developed in Phase 1 and (2) the HIV Vaccine Trials Network (HVTN) Social Impact Assessment.
62162849|NCT02970721||Bipolar disorder-treated|Individuals in this group are taking any medication (mood stabilizer, antipsychotic, antidepressants, antianxiety) during pregnancy
62162850|NCT02970721||Bipolar Disorder-Not Treated|Individuals in this group are not taking any medications during pregnancy
62162851|NCT03313544|EXPERIMENTAL|NIVOLUMAB PATIENTS|
62162852|NCT04001582||Participants with FSHD|Patients with a confirmed or pending diagnosis of FSHD, living in the UK are eligible to join the registry. Parents/guardians can register a child under 16 years old.
62162853|NCT05861323|EXPERIMENTAL|Check-list Arm|This feasibility study will test an ICU team-based time and and check-list intervention, the Comfort Measures Only Time Out (CMOT). The CMOT is designed to improve ICU team communication and better address patient comfort at the end of life. Participants in the CMOT are intensive care unit clinicians who are caring for a patient who is about to undergo palliative withdrawal of mechanical ventilation at the end of life. Feasibility will be assessed by: recruitment rates, protocol adherence, and acceptability to clinicians. Patient level outcomes such as distressful episodes/person-time alive will also be collected as a component of routine care in this exploratory analysis. The maximum time any participant (ICU clinician or patient) will be participating in the study is about four hours.
62162854|NCT04232085|EXPERIMENTAL|PID/IDS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if \<10 kg). Day -12 20 mg (or 10 mg if \<10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.~Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
62535959|NCT04181073|ACTIVE_COMPARATOR|Jet Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Jet Nebuliser
62535960|NCT04181073|EXPERIMENTAL|Vibrating Mesh Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Vibrating Mesh Nebuliser
62535961|NCT04541316||Short term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-5 weeks post implantation
62535962|NCT04541316||Mid term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-4 months post implantation
62535963|NCT04541316||Long term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 6-8 months post implantation
62535964|NCT00054665|EXPERIMENTAL|Part A: PS-341 Alone|1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
62535965|NCT00054665|EXPERIMENTAL|Part B: PS-341 & EPOCH|"PS-341: level 1: 0.5 mg/m\^2 intravenous (IV) days 1, 4; level 2: 1.0 mg/m\^2 IV days 1, 4; level 3: 1.5 mg/m\^2 IV days 1, 4; level 4: 1.7 mg/m\^2 IV days 1, 4.~EPOCH: Etoposide: 50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion; Doxorubicin: 10 mg/m\^2 day CIV days 1-4, 96 hour infusion; Vincristine: 0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion; Cyclophosphamide: 750 mg/m\^2 day IV day 5 bolus; Prednisone: 60 mg/m\^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycles every 21 days."
62535966|NCT05346536|EXPERIMENTAL|Metastatic pancreatic cancer treatment-naive patients|Newly diagnosed major patients with metastatic pancreatic cancer, naïve of any treatment for metastatic disease
62535967|NCT05729516|EXPERIMENTAL|Immediate Treatment Group (ITG)|"ITG participants receive access to the Hope App, a newly designed immersive learning and telehealth application designed to deliver engaging diabetes care and self-management education and support for older adults with diabetes.~ITG participants also complete data collection (surveys and HbA1c measurements) at baseline, 3 months after baseline, and 6 months after baseline."
62535968|NCT05729516|NO_INTERVENTION|Wait List Control (WLC)|"WLC participants receive care as usual for 6 months. They will complete data collection (surveys and HbA1c measurements) at baseline, 3 months after baseline, and 6 months after baseline.~After 6 months, WLC participants will gain access to the Hope App and receive diabetes programming and health coaching for the remaining 6 months."
62162855|NCT04232085|EXPERIMENTAL|IBMFS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if \<10 kg). Day -12 20 mg (or 10 mg if \<10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
62535969|NCT05668078|EXPERIMENTAL|School-type 1, intervention school-1|We will test all symptomatic students, teachers, and support staff ; and track students symptoms and absenteeism
62535970|NCT05668078|EXPERIMENTAL|School-type 2, intervention school-2|We will test all students, teachers, and support staff every 3 days, irrespective of symptoms (also test whenever develops symptoms) and track students symptoms and absenteeism
62535971|NCT05668078|EXPERIMENTAL|In School-type 3, control school|We will not do any test, only track the students for symptom notification and absenteeism
62162856|NCT05943379|EXPERIMENTAL|cohort 1|BCG Naïve
62162857|NCT05943379|EXPERIMENTAL|cohort 2|BCG Unresponsive
62162858|NCT04731506|EXPERIMENTAL|Family Connection|2 in-person sessions spaced one week apart \& 10 IVR calls/6 months; delivers intervention to parents only
62162859|NCT04731506|NO_INTERVENTION|Waitlist Standard-Care|6-month delayed start (waitlist) in the FC program; receive post-randomization standard health promotion materials available at the local health department; delivers intervention to parents only
62162860|NCT01007851|EXPERIMENTAL|GnRH agonist|
62162861|NCT01007851|PLACEBO_COMPARATOR|Saline|
62162862|NCT02187120|EXPERIMENTAL|Tranexamic Acid|"As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.~As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
62162863|NCT02187120|PLACEBO_COMPARATOR|Placebo|"As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).~As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
62162864|NCT01545999|ACTIVE_COMPARATOR|PAS 25|In humans, paired associative stimulation (PAS-25) is a transcranial magnetic stimulation (TMS) protocol that has been shown to result in LTP-like plasticity (PAS-LTP) in the motor cortex (M1). PAS-LTP has been shown to be dependent on the NMDAR and to correlate significantly with performance on a motor learning task.
62162865|NCT01545999|SHAM_COMPARATOR|PAS 100|To control for non-specific effects of PAS protocol, the investigators will use a modified PAS protocol (PAS-100) that does not result in any neurophysiologic effects. Patients with schizophrenia and healthy controls will be assessed first with the N-back task and then randomized
62162866|NCT06059963||Average risk|Patients aged between 45 and 84, who are at average risk of developing colorectal cancer, and are scheduled for a standard-of-care screening colonoscopy.
62714580|NCT04177355|PLACEBO_COMPARATOR|Part B, Group 3 (P3): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
62162867|NCT01265914|PLACEBO_COMPARATOR|placebo|
62162868|NCT01265914|EXPERIMENTAL|FP-01.1|
62162869|NCT05309356|ACTIVE_COMPARATOR|Usual care (Control)|Routine COPD patient care.
62162870|NCT05309356|EXPERIMENTAL|ACCEPT Decision Intervention|Clinical prediction model (ACCEPT)-based treatment recommendations: The ACCEPT tool will display the predicted risk of exacerbations, and the corresponding treatment recommendations to the physicians. These recommendations will be provided in a non-mandatory 'directive' format where the physician can override the recommendation, but is required to provide a justification (pre-set choices and a free text).
62162871|NCT06720233|EXPERIMENTAL|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
62162872|NCT04315428||premature swaddled|the childs in this group will be wrap in a lange (swaddled)
62535972|NCT01231399|EXPERIMENTAL|Arm I|Patients receive fluorouracil IV continuously over 46 hours, leucovorin calcium IV over 2 hours, and oxaliplatin IV over 2 hours on day 1. Patients also receive oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62535973|NCT03425695|EXPERIMENTAL|Test group|"Free Gingival Graft (FGG) + Low Level Laser Therapy (LLLT) + Clinical Examination~The test group received LLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) at the FGG sites with a wavelength of 810 nm and output power of 0.1 W, for 60 s, with an energy density of 6 J/cm2 in the continuous wave mode (spot size:0.5 cm). The laser beam was directed perpendicularly toward the tissue in the noncontact mode. The laser was irradiated at the recipient sites immediately after surgery and 1, 3, 7, and 14 days later."
62535974|NCT03425695|PLACEBO_COMPARATOR|Control group|"Free Gingival Graft (FGG)+Placebo Low Level Laser Therapy (PLLLT) + Clinical Examination~The control group received PLLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) same as test group without pushing the start button"
62535975|NCT05476952||Group 1|"Patients with a normal weight between 18.5 and 24.9 BMI Groups will be divided into 2 groups by their own luck. According to DDA, rocuronium will be evaluated as DDA, and group numbers given according to TBW will be evaluated as K."
62535976|NCT05476952||Group 2|"overweight patients with a BMI between 25-29.9 Groups will be divided into 2 groups by their own luck. According to DDA, rocuronium will be evaluated as DDA, and group numbers given according to TBW will be evaluated as K."
62535977|NCT05476952||Group 3|"patients with a BMI of 30-34.9 in obesity class 1 Groups will be divided into 2 groups by their own luck. According to DDA, rocuronium will be evaluated as DDA, and group numbers given according to TBW will be evaluated as K."
62535978|NCT03547037|EXPERIMENTAL|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
62535979|NCT03547037|EXPERIMENTAL|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
62535980|NCT00711438|EXPERIMENTAL|FT|Breathlessness Intervention Service (BIS)
62535981|NCT00711438|ACTIVE_COMPARATOR|WL|Best supportive care
62535982|NCT02903030|EXPERIMENTAL|Visbiome, Then Placebo|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
62535983|NCT02903030|PLACEBO_COMPARATOR|Placebo, Then Visbiome|Placebo matched to probiotic.
62535984|NCT05326230|EXPERIMENTAL|Renal Denervation|Renal Angiogram and Renal Denervation (PRDS-001- Paradise™ System)
62535985|NCT05326230|SHAM_COMPARATOR|Sham Control|Renal Angiogram
62535986|NCT00637650|EXPERIMENTAL|B|"Experimental group: patients in whom stone dust was left for spontaneous elimination"
62535987|NCT00637650|OTHER|A|Control group: Patients in whom all fragments resulting from laser lithotripsy of ureteral stones were actively retrieved
62535988|NCT04345601|EXPERIMENTAL|Safety Run In|The study will first enroll and treat six patients with MSCs for safety run in. If no more than 2 treatment-related severe adverse events (tSAEs) are observed, the study will enroll and randomize additional patients in a ratio of 1:1 to receive either MSCs or routine/supportive care.
62535989|NCT04345601|EXPERIMENTAL|Mesenchymal stromal cells|Patients randomized to the MSC arm will be administered an intravenous infusion of MSCs at a dose of 1 x 10\^8. A second infusion will be allowed if the patient does not have improvement in respiratory parameters per discretion of the investigator, or ARDS clinically worsens, within 3-5 days following the initial infusion.
62535990|NCT04345601|OTHER|Control Group|Patients randomized to the control arm will receive supportive care or treatment designated by their treating physicians.
62535991|NCT03466255||Cardiac outpatients|Subjects referred for outpatient coronary angiography.
62535992|NCT02757573|EXPERIMENTAL|Hypercarbia|Hypercarbia: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
62535993|NCT01624701|EXPERIMENTAL|Expanded|'Ex vivo expanded cord blood cells
62535994|NCT02616965|EXPERIMENTAL|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
62535995|NCT01312571|ACTIVE_COMPARATOR|Cognitive behavior therapy via the internet|Cognitive behavior therapy via the internet with therapist support.
62535996|NCT01312571|ACTIVE_COMPARATOR|Attentional retraining|Attentional retraining as described by Nader Amir.
62162873|NCT04315428||premature no swaddled|the childs in this group will be not swaddled
62162874|NCT06367426|EXPERIMENTAL|Experimental: DDN-A-0101 for PART 1|DDN-A-0101: various single doses, administered to various cohorts
62162875|NCT06367426|EXPERIMENTAL|Experimental: DDN-A-0101 for PART 2|DDN-A-0101: various multiple doses, administered to various cohorts
62535997|NCT03024008|EXPERIMENTAL|Intervention Arm|"Clinical Interventions:~1. Blood tests: complete blood count, full blood chemistry and biochemistry including phosphate, alkaline phosphatase, calcium, renal and liver function, and coagulation. Serology tests: HIV, Hepatitis B, Hepatitis C.~2. Xray~3. Urine Test~4. CT~5. Liposuction - harvest of 50-300ml autologous adipose tissue from the subject's abdomen~6. Single transplantation of Investigational Medicinal Product BonoFill-II into long bone extra-articular comminuted fracture or large bone defect/critical gap"
62535998|NCT01615237|ACTIVE_COMPARATOR|CBP + PF|Field sites randomly assigned to Arm 2 will receive as an intervention current best practices and quarterly audits and performance feedback reports (PF) on provider delivery of cessation services using chart audit procedures that we have used successfully in prior work. Depending on what is used at the site, paper or Electronic Dental Record, we will work with the site to create a registry of patients who are tobacco users.
62535999|NCT01615237|ACTIVE_COMPARATOR|CBP + PF + P4P|Field sites randomly assigned to this implementation condition (Arm 3) will receive current best practices (CBP), quarterly audit and performance feedback reports (PF), and financial incentives (pay for performance, P4P) for every documented (documentation in patient chart of counseling, prescription, or referral to the quit-line) delivery of adherence to clinical practice guidelines.
62536000|NCT01615237|ACTIVE_COMPARATOR|Current Best Practices (CBP)|All dental field sites will receive current best practices (CBP) for training and technical assistance in promoting adoption of clinical practice guidelines for treating tobacco dependence.
62536001|NCT05828576||ECAA patient|ECAA patient recieving conservative treatment
62536002|NCT05498181|EXPERIMENTAL|sacubitril/valsartan|Participants will take sacubitril/valsartan, beginning dose of 24/26mg twice daily, with titration to target dose of 97/103 mg twice daily over the first four weeks. Patients will remain on the maximally tolerated dose for the remaining 12 weeks (total on-drug period of 16 weeks) before stopping drug and being followed for a further two weeks (total study time of 18 weeks).
62536003|NCT05498181|PLACEBO_COMPARATOR|placebo|Participants will take equivalent placebo, beginning equivalent dose of 24/26mg twice daily, with titration to target equivalent dose of 97/103 mg twice daily over the first four weeks. Patients will remain on the maximally tolerated dose for the remaining 12 weeks (total on-drug period of 16 weeks) before stopping drug/placebo and being followed for a further two weeks (total study time of 18 weeks).
62536004|NCT05575258|ACTIVE_COMPARATOR|Sequence 1: Agro (Green) - Conventional (Yellow)|"First, the agro-ecological sourced diet will be consumed.~Secondly, the conventional sourced diet will be consumed."
62536005|NCT05575258|ACTIVE_COMPARATOR|Sequence 2: Conventional (Yellow) - Agro (Green)|"First, the conventional sourced diet will be consumed.~Secondly, the agro-ecological sourced diet will be consumed."
62536006|NCT02418663|OTHER|Postoperative elective surgical patients|Patients undergoing major elective thoracic and abdominal, the latter group including upper gastrointestinal, esophageal, and colorectal procedures. In this group FR will predicted by administering a fluid challenge of 250 ml of Lactated Ringer's solution and measuring SV with the ccNexfin
62536007|NCT05423795|OTHER|Comparator Arm|Classic expertise (as routinely performed in the participating ICU)
62536008|NCT05423795|EXPERIMENTAL|Telemedicine-based intervention|Telemedicine-based expert advice.
62536009|NCT01216618|EXPERIMENTAL|Device|Subject starts with two clamps including device use follows by a clamp without device use
62536010|NCT01216618|NO_INTERVENTION|Control|Subject starts with clamps without device
62536011|NCT02390687|PLACEBO_COMPARATOR|Placebo Arm|Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
62536012|NCT02390687|EXPERIMENTAL|Probiotic Arm|L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
62536013|NCT03364868|EXPERIMENTAL|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
62714581|NCT04177355|EXPERIMENTAL|Part B, Group 4 (T4): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with either 1 mcg or 5 mcg of 3M-052-AF (the highest tolerated dose from Part A), and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
62714582|NCT04177355|PLACEBO_COMPARATOR|Group 4 (P4): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
62714583|NCT04177355|EXPERIMENTAL|Part B, Group 5 (T5): BG505 SOSIP.664 gp140 + GLA-LSQ|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with GLA-LSQ (GLA 5 mcg, and QS-21 2 mcg), as one IM injection at Months 0, 2, and 6.
62714584|NCT04177355|PLACEBO_COMPARATOR|Part B, Group 5 (P5): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
62536014|NCT03364868|PLACEBO_COMPARATOR|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
62536015|NCT01008332|EXPERIMENTAL|Cohort 1|ToleroMune HDM, subjects to receive either active or placebo comparator
62536016|NCT01008332|EXPERIMENTAL|Cohort 2|ToleroMune HDM, subjects to receive either active or placebo comparator
62536017|NCT01008332|EXPERIMENTAL|Cohort 3|ToleroMune HDM, subjects to receive either active or placebo comparator
62714585|NCT04177355|EXPERIMENTAL|Part B, Group 6 (T6): BG505 SOSIP.664 gp140 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 500 mcg of Alum, administered as one IM injection at Months 0, 2, and 6.
62536018|NCT01008332|EXPERIMENTAL|Cohort 4|ToleroMune HDM, subjects to receive either active or placebo comparator
62536019|NCT01008332|EXPERIMENTAL|Cohort 5|Toleromune HDM, subjects to receive either active or placebo comparator
62714586|NCT04177355|PLACEBO_COMPARATOR|Part B, Group 6 (P6): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
62536020|NCT04555720|EXPERIMENTAL|Interdisciplinary Care|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participant's doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
62536021|NCT04555720|NO_INTERVENTION|Standard of Care|If assigned to standard of care, group participants will have a normally scheduled visit with neurologist.
62536022|NCT02123082|OTHER|Single-Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the single lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
62714587|NCT04177355|EXPERIMENTAL|Part C, Group 7 (T7): BG505 SOSIP.664 gp140 + Alum|Participants will receive BG505 SOSIP.664 gp140, 100 mcg admixed with 3M-052-AF, 3 mcg and Alum, 500 mcg to be administered as one 0.5-mL dose intramuscularly (IM) at months 0, 2, and 6.
62714588|NCT04177355|PLACEBO_COMPARATOR|Part C, Group 7 (P7): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
62714589|NCT04177355|EXPERIMENTAL|Part C, Group 8 (T8): Trimer 4571 + Alum|Participants will receive Trimer 4571, 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as one 0.5-mL dose IM at months 0, 2, and 6.
62714590|NCT04177355|PLACEBO_COMPARATOR|Part C, Group 8 (P8): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
62714591|NCT05525741|EXPERIMENTAL|Vitiligo Group|If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
62714592|NCT05525741|OTHER|Volunteers Group|If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
62714593|NCT02118155|SHAM_COMPARATOR|Connective tissue graft (CTG)|The gingival recession defects were treated by connective tissue graft surgical procedure and received the sham application os low-intensity laser therapy.
62536023|NCT02123082|EXPERIMENTAL|Dual Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the dual lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
62536024|NCT05224310|ACTIVE_COMPARATOR|Pectoral nerve block|Starting from the lateral third of the clavicle and moving distally and laterally to the midaxillary line. The pectoral major and minor muscles will be identified and 10 mL of bupivacaine 0.25% will be injected between the 2 muscles, and then move the ultrasound probe towards the axilla until the serratus anterior is identified above the second, third, and fourth ribs then injection of 20 mL of bupivacaine 0.25% after negative aspiration into the fascial plane between pectoralis minor and serratus anterior muscles.
62536025|NCT05224310|ACTIVE_COMPARATOR|Serratus anterior plane block|"Aiming to find the serratus anterior muscle the investigator will identify the fifth rib in the midaxillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) will be detected using ultrasound.~The investigator will penetrate the serratus anterior muscle by a 23 GA, 35 mm needle in-plane to ultrasound probe from supero-anterior to postero-inferior to inject deep to it."
62536026|NCT06633822|EXPERIMENTAL|Digital plannig|
62536027|NCT06633822|ACTIVE_COMPARATOR|Analogic planning|
62536028|NCT03122080|ACTIVE_COMPARATOR|Electroacupuncture group|electroacupuncture+standard care
62536029|NCT03122080|PLACEBO_COMPARATOR|Control A group|placebo acupuncture+standard care
62536030|NCT03122080|OTHER|Control B group|standard care
62536031|NCT02575105||Pediatric Hydrocephalus|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
62536032|NCT02575105||Pediatric Control|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
62536033|NCT02575105||Adult Hydrocephalus|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
62536034|NCT02575105||Adult Control|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
62536035|NCT04257045||Observational (interview, survey)|"STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.~STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes."
62536036|NCT06000943||Lower Surgical Risk|Surgical risk stratification. All the following groups will be define according with STS and Euroscore II score and stratified based on antithrombotic strategy in all possible combinations (SAPT, DAPT, OAC, OAC+SAPT)
62536037|NCT06000943||Intermediate Surgical Risk|Surgical risk stratification. All the following groups will be define according with STS and Euroscore II score and stratified based on antithrombotic strategy in all possible combinations (SAPT, DAPT, OAC, OAC+SAPT)
62536038|NCT06000943||High Surgical Risk|Surgical risk stratification. All the following groups will be define according with STS and Euroscore II score and stratified based on antithrombotic strategy in all possible combinations (SAPT, DAPT, OAC, OAC+SAPT)
62536039|NCT03122197|EXPERIMENTAL|Letrozole|"The BN-16-01 main study treatment starting dose will be 2.5mg administered orally once daily. Daily doses up to 10mg and single doses of 30mg have been shown to be safe in prior studies and therefore we expect that letrozole doses up to 20mg in this study will be safe.~The recommended phase II dose (RP2D) will be considered the dose that results in ≥ 2uM letrozole concentration in the tumor or the highest dose achieved (20mg daily for cohort level 7) with \< 2/6 patients with DLTs. This dose will be planned for future phase II studies to determine potential efficacy."
62536040|NCT03122197|EXPERIMENTAL|Letrozole and temozolomide|Phase 1 expansion cohort of letrozole 15mg administered in combination with 50 mg/m2 metronomic temozolomide (TMZ) in patients with high grade gliomas. Letrozole 15mg will be administered orally once daily for a 7-day lead-in period. After 7 days subjects will continue letrozole in combination 50 mg/m2 TMZ administered orally once daily.
62536041|NCT03122197|EXPERIMENTAL|Previously Received letrozole and temozolomide|Phase 1 expansion cohort of two identified subjects with gliomas who previously participated in the main study UCCI-BN-16-01 who received as physician's choice of treatment 50 mg/m2 TMZ in combination with dosing of 15 mg letrozole.
62536042|NCT04641585|EXPERIMENTAL|Patients affected by Brugada Syndrome 1|Patients with spontaneous or drug-induced Brugada Syndrome 1
62536043|NCT04641585|ACTIVE_COMPARATOR|Controls|Patients with no condition associated with spontaneous or drug-induced Brugada Syndrome 1
62714594|NCT02118155|EXPERIMENTAL|Connective tissue graft plus laser (CTG+L)|The gingival recession defects were treated by connective tissue graft associated with the application of a LILT protocol
62162876|NCT06367426|PLACEBO_COMPARATOR|Placebo Comparator: Placebo for PART 1|DDN-A-0101 matching placebo: various single doses, administered to various cohorts
62536044|NCT03136965|EXPERIMENTAL|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
62536045|NCT03136965|PLACEBO_COMPARATOR|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
62536046|NCT03136965|SHAM_COMPARATOR|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
62536047|NCT01807286|EXPERIMENTAL|Pomalidomide + Melphalan + Dexamethasone|Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
62536048|NCT06470815||Standard-risk patients who underwent carotid intervention|Symptomatic or asymptomatic patients with a discrete lesion located in the internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA), who underwent carotid artery revascularization.
62162877|NCT06367426|PLACEBO_COMPARATOR|Placebo Comparator: Placebo for PART 2|DDN-A-0101 matching placebo: various multiple doses, administered to various cohorts
62162878|NCT04547101|EXPERIMENTAL|AK104|
62162879|NCT06653569|EXPERIMENTAL|antiviral treatment|baloxavir marboxil
62162880|NCT06653569|PLACEBO_COMPARATOR|placebo|Pacebo
62536049|NCT01885026|EXPERIMENTAL|eScreen|Web based self-monitoring of problematic alcohol and drug use, and Internet-based treatment for depression or anxiety
62536050|NCT01885026|EXPERIMENTAL|Control|Assessment only of alcohol and drug use and Internet-based treatment for depression or anxiety
62536051|NCT05495672|EXPERIMENTAL|Cohort 1-Arm A: the largest pulmonary nodule is less than or equal to 1 cm, ctDNA positive|ctDNA is detected before curative treatment. Subjects with ctDNA positive before treatment will receive curative treatments for pulmonary nodules such as surgery, radio frequency ablation or stereotactic body radiotherapy. ctDNA will be detected after curative treatment and then every three months until progression or 2 years. At the same time, routine post treatment follow-up will be performed.
62536052|NCT05495672|NO_INTERVENTION|Cohort 1-Arm B: the largest pulmonary nodule is less than or equal to 1 cm, ctDNA negative|Subjects with ctDNA negative will undergo routine follow-up. ctDNA will be detected every three months until progression or 2 years.
62536053|NCT05495672|EXPERIMENTAL|Cohort 2-Arm C: the largest pulmonary nodule is between 1 cm to 2 cm, ctDNA positive|"ctDNA is detected before curative treatment. Subjects with ctDNA positive before treatment will receive curative treatments for pulmonary nodules such as surgery, radio frequency ablation or stereotactic body radiotherapy.~ctDNA is rechecked following treatment. Subjects with ctDNA positive after treatment will receive chemotherapy. Subjects with ctDNA negative after curative treatment will undergo routine follow-up.~After treatment, ctDNA will be detected every three months until progression or 2 years. At the same time, routine post treatment follow-up will be performed."
62536054|NCT05495672|NO_INTERVENTION|Cohort 2-Arm D: the largest pulmonary nodule is between 1 cm to 2 cm, ctDNA negative|Subjects with ctDNA negative will undergo routine follow-up. ctDNA will be detected every three months until progression or 2 years.
62536055|NCT03151291|NO_INTERVENTION|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight)"
62536056|NCT03151291|EXPERIMENTAL|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight)"
62536057|NCT03151291|EXPERIMENTAL|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
62536058|NCT03151291|EXPERIMENTAL|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
62536059|NCT03151291|EXPERIMENTAL|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
62536060|NCT03151291|EXPERIMENTAL|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
62536061|NCT03151291|EXPERIMENTAL|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
62536062|NCT03151291|EXPERIMENTAL|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
62536063|NCT04886076||Participants with RBD|Participants with REM Sleep Behavior Disorder
62536064|NCT04886076||Participants without RBD|Age- and gender-matched controls, without REM Sleep Behavior Disorder
62536065|NCT03210714|EXPERIMENTAL|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
62536066|NCT02377427|EXPERIMENTAL|Mepolizumab 40 mg in Part A and B|Participants with bodyweight \< 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
62536067|NCT02377427|EXPERIMENTAL|Mepolizumab 100 mg in Part A and B|Participants with bodyweight \>= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
62536068|NCT02123810|OTHER|Control|The investigators measure quality of chest compressions before nightshift. Control group
62536069|NCT02123810|OTHER|OFF|The investigators measure quality of chest compressions before nightshift. After night shift group
62536070|NCT06632847|EXPERIMENTAL|IMT with device|"IMT is a therapeutic approach designed to improve respiratory muscle strength and endurance. In this trail, participants will engage in a structured regimen of inspiratory exercises with high resistance.~participants will perform inspiratory muscle exercises using the power-breathe device that provide intermediate to high resistance, with focus on both intensity and volume. The protocol involves 4 to 5 session per week."
62536071|NCT06632847|ACTIVE_COMPARATOR|Thera-band resistive training|Participant will engage in a structured training that involving Thera-band resistance training. Participants use different color of thera-band that provides different resistance. The regimen includes 3 session per week using different colors of band.
62536072|NCT02430285|OTHER|Endoscopic Ultrasound|All consecutive patients entering the emergency department due to acute abdominal pain and showing biochemical and/or radiological findings consistent with possible acute biliary pancreatitis, undergo Endoscopic Ultrasound with linear array Olympus 180 series echoendoscopes (Olympus Europa Holding, Hamburg, Germany).
62536073|NCT01798355|EXPERIMENTAL|Cognitive Behavioral Therapy|
62536074|NCT01798355|ACTIVE_COMPARATOR|Treatment as usual|
62536075|NCT04584385||Childhood epilepsy|Children with refractory tonic, myoclonic or atonic seizures
62536076|NCT05811806|EXPERIMENTAL|Neurorehabilitation of the Hand|Participants will undergo a 1-hour training session 5 days per week, over 3 weeks for a total of 15 sessions. Hand function therapy will be administered using the gamified protocol to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
62536077|NCT05050110|OTHER|chronic kidney disease patients|Evaluation of Increased fruits and vegetables consumption in chronic kidney disease patients maintaining normokalemia with patiromer
62536078|NCT03430388|ACTIVE_COMPARATOR|Rheumatic diseases patients|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
62714773|NCT06095960|ACTIVE_COMPARATOR|Enhanced Standard of Care|Enhanced standard of care (ESoC). Each patient will be provided education on the symptoms to watch for and when to call their healthcare provider. Patients will be scheduled for a comprehensive postpartum visit around 6 weeks postpartum and any additional care deemed necessary by their health care providers.
62162881|NCT03934944|EXPERIMENTAL|Phone application arm|Participants will have access to a educational video and foot alerts at weekly intervals to supplement usual Podiatry care and education.
62162882|NCT03934944|OTHER|Usual care|Participants will have Podiatry care and education.
62162883|NCT03623100|EXPERIMENTAL|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
62162884|NCT03623100|EXPERIMENTAL|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
62162885|NCT05658809|ACTIVE_COMPARATOR|Total thyroidectomy for single thyroid nodule|group of participants will be treated with total thyroidectomy
62162886|NCT05658809|ACTIVE_COMPARATOR|Hemithyroidectomy for single thyroid nodule|2nd group of participants will be treated with hemithyroidectomy
62162887|NCT01125345|EXPERIMENTAL|Hydrophobic IOL|The single piece Acrysof hydrophobic IOL model- SN60WF
62162888|NCT01125345|ACTIVE_COMPARATOR|Hydrophilic IOL|Rayner Intraocular Lenses Ltd., England, Model C-flex 570C
62162889|NCT01125345|ACTIVE_COMPARATOR|Hydrophillic IOL|Bausch and Lomb ltd, model Akreos Adapt
62162890|NCT00669149|EXPERIMENTAL|1|group without anticoagulant therapy
62162891|NCT00669149|ACTIVE_COMPARATOR|2|group with heparin
62162892|NCT00669149|ACTIVE_COMPARATOR|3|group with enoxaparin
62162893|NCT00669149|ACTIVE_COMPARATOR|4|group with bivalirudin
62162894|NCT00960284|EXPERIMENTAL|Arm I|Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62162895|NCT00960284|EXPERIMENTAL|Arm II|Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
62162896|NCT01094665|EXPERIMENTAL|Focal Laser Thermal Therapy|Thermal therapy delivered to lesion visible on MRI.
62162897|NCT05442593|EXPERIMENTAL|Pre-adolescents|Acute plyometric training
62536079|NCT03430388|ACTIVE_COMPARATOR|Healthy controls|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
62536080|NCT03002129|OTHER|fluid challenge|
62536081|NCT06322173|OTHER|NGS analysis|Residual anonymized samples stored at -80°C at the Tropica Biobank of the DITM and for which diagnostic analysis for germ infection has previously been carried out at the DITM by blood culture and MDR surveillance in routine diagnostic rectal swab will be used. DNA extraction will be carried out on these residual samples (with subsequent quality and quantification analysis of the nucleic acid) for subsequent NGS analyses.
62162898|NCT05442593|EXPERIMENTAL|Adolescents|Acute plyometric training
62162899|NCT02655536|EXPERIMENTAL|bevacizumab plus erlotinib|bevacizumab 15mg/kg every 3 weeks plus erlotinib 150mg per day
62162900|NCT02655536|ACTIVE_COMPARATOR|erlotinib|erlotinib 150mg per day
62162901|NCT06143891|EXPERIMENTAL|Belumosudil|"Participants will receive belumosudil 200 mg tablets per os(PO) once daily (QD) per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study~Note: 200mg two times a day (BID) is used in some cases, when the subject is taking a proton pump inhibitor or a strong CYP3A4 inducer)"
62162902|NCT06143891|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo tablets PO QD per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study
62162903|NCT01958047|EXPERIMENTAL|ASP3652|One single dose
62162904|NCT01268488|EXPERIMENTAL|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.
62162905|NCT02301104|EXPERIMENTAL|Mild Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
62162906|NCT02301104|EXPERIMENTAL|Moderate Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
62162907|NCT02301104|EXPERIMENTAL|Severe Hepatic Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort, if enrolled, will be determined based on the Interim Assessment of mild and moderate cohorts."
62162908|NCT02301104|EXPERIMENTAL|Normal Hepatic Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
62536082|NCT00086827|EXPERIMENTAL|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have continuing tumor response or stable disease after 6 courses receive 2 additional courses beyond best response.
62536083|NCT06593639|EXPERIMENTAL|Surgery plus (chemo)radiotherapy|Head and neck cancer patients undergoing surgery before (chemo)radiotherapy according to stage and risk factors.
62536084|NCT06593639|EXPERIMENTAL|Chemo-radiotherapy|Head and neck cancer patients undergoing definitive concomitant chemo-radiotherapy (CRT) according to stage and risk factors.
62536085|NCT00593151|EXPERIMENTAL|A, C, 320 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
62536086|NCT00593151|EXPERIMENTAL|B, C, 640 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
62536087|NCT00593151|ACTIVE_COMPARATOR|A, B, C PEG|Weekly subcutaneous injections of 1.5 ug/kg PegIntron (12 kDalton pegylated interferon alpha 2b) with oral ribavirin.
62536088|NCT02664714|ACTIVE_COMPARATOR|PFMT Individualized|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s) 4(5s/10s), 5(5s/5s), 6(5s/5s), 7(6s/6s),8(6s/6s), 9(8s/8s) 10(8s/8s), 11(10s/10s),12(10s/10s)
62536089|NCT02664714|EXPERIMENTAL|PFMT individualized with group|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
62536090|NCT02664714|ACTIVE_COMPARATOR|12 group PFMT|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
62536091|NCT04487951||Moderate|Moderate: moderate COVID -19 pneumonia
62536092|NCT04487951||Severe|_severe COVID-19 pneumonia
62536093|NCT03122925||Control|Healthy subjects
62536094|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
62536095|NCT00403507|NO_INTERVENTION|Clean Control|Probable Alzheimer's disease in the context of no excluding medical conditions.
62536096|NCT00403507|NO_INTERVENTION|CoMorbid Control|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
62536097|NCT00403507|EXPERIMENTAL|Clean Exercise|Probable Alzheimer's disease in the context no comorbid medical conditions.
62536098|NCT00403507|EXPERIMENTAL|CoMorbid Exercise|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
62536099|NCT05245318|ACTIVE_COMPARATOR|Standard clinical care control group|Standard physiotherapy program of 12 weeks (1 treatment session /week)
62536100|NCT05245318|EXPERIMENTAL|Experimental blended physiotherapy program group|Blended physiotherapy program of 12 weeks with exercises and counselling provided through a smartphone application and 6 face-to-face treatment sessions (1 physiotherapy treatment session every 2 weeks)
62536101|NCT05788614|EXPERIMENTAL|RSA-RV-30|
62536102|NCT05788614|EXPERIMENTAL|RSA-RV-0|
62714595|NCT06499129|EXPERIMENTAL|SensoryBall|"The training content prepared based on the Levine Conservation Model will be given to patients assigned to the intervention group. Training content information in line with the Levine Conservation Model; The conservation model, which is the application of nursing theoretical knowledge for practice, will focus on the applications to be made for three basic principles for the protection of energy, protection of structural integrity and protection of personal integrity.~Soft plastic sensory balls for hands and feet will be used in the management of peripheral neuropathy symptom.~In the sensory exercise for the feet, the patient will be asked to place the foot sensory ball between the floor and the foot and roll it to create a slight pressure on the sole of the foot.~Progressive Relaxation Exercises Practice Progressive relaxation exercises will be played to colorectal cancer patients who will receive chemotherapy."
62714596|NCT06499129|NO_INTERVENTION|Control|The control group patients who will receive chemotherapy treatment for the first time and who meet the inclusion criteria will not receive any intervention other than standard chemotherapy treatment and standard nursing care and will be asked to complete the Personal Information Form (only on the first day), Cancer Fatigue Scale, CIPNAT and Trait Anxiety Inventory on the first chemotherapy day, 14th day and 28th day.
62714597|NCT02317692|ACTIVE_COMPARATOR|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
62714598|NCT02317692|EXPERIMENTAL|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
62536103|NCT04260555|EXPERIMENTAL|TEST|tid PO, DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml
62536104|NCT04260555|ACTIVE_COMPARATOR|Reference 1|tid PO, Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml
62536105|NCT04260555|ACTIVE_COMPARATOR|Reference 2|tid PO, Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml
62536106|NCT02330536|EXPERIMENTAL|Flowrate A|insufflation of carbon dioxide at 8L/min, 8mmHg
62536107|NCT02330536|EXPERIMENTAL|Flowrate B|insufflation of carbon dioxide at 20 L/min, 8mmHg
62536108|NCT06002841|EXPERIMENTAL|EV group|will consist of 10 participants who will receive two infusions of 25 mL of the investigational product (Plasma-Lyte A solution containing EVs obtained from MSCs), intravenously, at intervals of 48 h.
62536109|NCT06002841|PLACEBO_COMPARATOR|Placebo group|will consist of 5 participants who will receive an equal volume of Plasma-Lyte A, intravenously, following the same schedule as the IV group: two infusions with an interval of 48 hours.
62536110|NCT06260709|EXPERIMENTAL|NNC6019-0001|Participants will receive NNC6019-0001 intravenously every 4 weeks added to the standard of care until Week 140.
62536111|NCT00482807|EXPERIMENTAL|Docetaxel, intensity-modulated radiation therapy and hormone therapy|This phase I trial is studying the side effects and best dose of docetaxel when given together with intensity-modulated radiation therapy and hormone therapy in treating patients with high-risk locally advanced prostate cancer with pelvic lymph node metastasis.
62536112|NCT04505956|EXPERIMENTAL|Moses Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique using Moses laser technology.
62536113|NCT04505956|ACTIVE_COMPARATOR|Standard Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.
62536114|NCT02845193|EXPERIMENTAL|Modified Nasoalveolar molding group|This group will receive nasoalveolar molding appliance in addition to taping for 3 Months with follow-up every 2 weeks.
62536115|NCT02845193|EXPERIMENTAL|Taping group|Tape will be used alone in this group on the upper lip segments for 3 months with follow-up every 2 weeks.
62536116|NCT02845193|NO_INTERVENTION|Control group|This group will not receive any treatment.
62714599|NCT04564989||HPV+ OPSCC Patients|Patients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.
62714600|NCT03515161|EXPERIMENTAL|Closed-loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed manually using the assisted fluid management sofware from the EV1000 monitor. A closed-loop system will automatically administer vasopressor based on the predefined target MAP chosen by the anesthesiologist in charge of the patient
62162909|NCT04803994|EXPERIMENTAL|Systemic therapy with atezolizumab + bevacizumab|"Patients receive atezolizumab 1200 mg flat dose plus bevacizumab 15 mg/kg given intravenously every 3 weeks until failure of strategy, participant request, or withdrawal of consent for a maximum of up to 24 months.~The discontinuation of one of the study drugs for toxicity reasons does not qualify as failure of treatment strategy as long as the other drug can be continued according to protocol."
62162910|NCT04803994|ACTIVE_COMPARATOR|Locoregional therapy with TACE|"Patients will receive initial TACE and - if required to achieve or improve an objective response - a second TACE after 8 weeks (±7 days window). Thereafter, additional TACE can be applied on demand until failure of strategy, participant request, or withdrawal of consent for a maximum of up to 24 months.~TACE must be discontinued in cases of technical difficulties making additional TACE impossible.~Only conventional TACE (cTACE) and drug-eluting bead TACE (DEB-TACE) approaches are accepted as TACE therapy. However, consistency in the TACE procedure and the use of the chemotherapeutic agent has to be maintained for each individual patient."
62162911|NCT05096741||OCS Liver|
62162912|NCT05096741||Control|
62162913|NCT04205500|EXPERIMENTAL|Children with juvenile idiopathic arthritis|The specific carbohydrate diet has been shown to have beneficial effects on IBD and has been implemented in Seattle Children's IBD centre, with some patients using SCD either as primary or complementary therapy. The SCD is a nutritionally balanced diet focused on removing many complex carbohydrates such as grains, dairy products except for yoghurt fermented over 24 hours, vegetables rich in starch and sugars except for monosaccharides like in honey. Participants can eat meat but since it has to be unprocessed food the investigator's experience is that the amounts of meat are not very big. Fish, eggs, sea-food is allowed. Bread is baked from nut and almond flour.
62162914|NCT06076746|EXPERIMENTAL|Experimental: Intervention(s) for ineffective coping in General Anxiety|Patients with nurse diagnosis of ineffective coping will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s).
62162915|NCT06076746|ACTIVE_COMPARATOR|Treatment-as-Usual for General Anxiety|Patients with nurse diagnosis of ineffective coping will receive the usual treatment for general anxiety.
62162916|NCT04034095||Cohort 1: ADT alone/ ADT + Bicalutamide|Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade \[CAB\]) under routine clinical practice will be observed.
62536117|NCT02845193|EXPERIMENTAL|CAD/NAM group|Computer Aided Designed Nasoalveolar molding and 3D printed.
62536118|NCT04366934||COVID-19 patients|Subject consulting in the Lariboisière hospital (Paris) in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection
62536119|NCT04366934||Control subjects|Subject consulting in the ear, nose and throat department at the Lariboisière hospital (Paris) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia
62536120|NCT02150135|EXPERIMENTAL|Oncothermia group|Patients were treated with oncothermia 2 or 3 times a week. Treatment was performed for about 1 hours per each visits.
62714601|NCT04347421|EXPERIMENTAL|Krill oil group|This group takes Krill oil for 12 weeks
62536121|NCT04810949|EXPERIMENTAL|serum vitamin D levels >20ng/ml (Group 1)|Patients with serum vitamin D levels \>20ng/ml that will receive Vitamin D supplementation
62536122|NCT04810949|EXPERIMENTAL|serum vitamin D levels >20ng/ml ( Group 2)|Patients with vitamin D levels \>20ng/ml that will receive diet and hygiene measures
62536123|NCT04810949|OTHER|serum vitamin D3 levels < 20ng/ml (Group3)|Patients with Vitamin D levels\<20ng/ml will receive vitamin D3 supplementation according to primary care discresion
62536124|NCT06296082|ACTIVE_COMPARATOR|Botulinum Toxin type A|The BTX-A group will receive onabotulinumtoxinA (Botox®, Allergan) with mandatory muscles getting 300 units and optional muscles getting up to 100 additional units (maximum dose of 400 units) (14) delivered with a 27-gauge (0.45 mm) beveled needle. Target muscles will be identified by ultrasound imaging or muscle stimulation. Local anesthesia will not be used. Patient positioning will be standardized.
62536125|NCT06296082|ACTIVE_COMPARATOR|Dry Needling|For Dry Needling group solid, filiform non-beveled 0.30 mm caliber needles will be used. Target muscles will be identified by ultrasound imaging or muscle stimulation. Local anesthesia will not be used. Patient positioning will be standardized.
62536126|NCT01659086|EXPERIMENTAL|Group A|Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo
62536127|NCT01659086|EXPERIMENTAL|Group B|Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo
62536128|NCT01659086|EXPERIMENTAL|Group C|Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo
62714602|NCT04347421|PLACEBO_COMPARATOR|Placebo group|This group takes Placebo for 12 weeks
62714603|NCT04515888||target population|The target population of the study consists of breast cancer female patients over 50 years old followed for an invasive carcinoma expressing hormone receptors, non metastatic, undergoing adjuvant hormone therapy.
62714604|NCT04515888||control population|The control group will be composed of patients followed for an in situ carcinoma treated by surgery +/- radiotherapy, without hormone therapy.
62714605|NCT06309667|EXPERIMENTAL|Cohort A1 - Single Ascending Dose|PG-102(MG12) Dose 1 (N=8) Subcutaneous injection
62714606|NCT06309667|EXPERIMENTAL|Cohort A2 - Single Ascending Dose|PG-102(MG12) Dose 2 (N=8) Subcutaneous injection
62714607|NCT06309667|EXPERIMENTAL|Cohort A3 - Single Ascending Dose|PG-102(MG12) Dose 3 (N=8) Subcutaneous injection
62536129|NCT01659086|EXPERIMENTAL|Group D|Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo
62162917|NCT04034095||Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide|Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.
62162918|NCT00769834||CKD|The cohort comprises of patients who are diagnosed to have chronic kidney disease as defined by the K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease-2002.
62162919|NCT03319472||Benign Pleural Effusion|Patients that will be diagnosed within a month from admission with any non-malignant cause of pleural effusion, including but not limited to effusions caused by common or tuberculous or fungal infection, heart failure, etc. Documentation of the etiology will be required for inclusion in this group, including but not limited to bacteriology, virology, PCR, radiology, heart echocardiogram or catheterization, as appropriate.
62714608|NCT06309667|EXPERIMENTAL|Cohort A4 - Single Ascending Dose|PG-102(MG12) Dose 4 (N=8) Subcutaneous injection
62162920|NCT03319472||Malignant Pleural Effusion|Patients that will be diagnosed within a month from admission with any malignant cause of pleural effusion, including but not limited to effusions caused by lung, breast, colon, ovary, mesothelial, hematopoietic, prostate, or any other cancer. Diagnosis will be based on verification of the presence of malignant cells in the pleural fluid or tissues. Patients with cancer and an effusion without such documentation will be assigned to the benign group if an alternative diagnosis is made. In any other case, they will be excluded.
62162921|NCT06584773|ACTIVE_COMPARATOR|standard maintenance immunosuppression|tacrolimus, mycophenolate and prednisone
62162922|NCT06584773|EXPERIMENTAL|fourth maintenance immunosuppressive|everolimus, tacrolimus, mycophenolate and prednisone
62162923|NCT03369314||Patients Receiving octaplasLG®|The data will be collected in all patients who have received at least one infusion of octaplasLG®
62162924|NCT04061772|EXPERIMENTAL|BCHEP|Bortezomib：1.3mg/m2, intravenous drip, d1,d8, every 3 weeks； Etoposide：100mg/m2,intravenous drip, d1-3, every 3 weeks； Cyclophosphamide：750mg/m2,intravenous drip, d1, every 3 weeks； Pharmorubicin：75mg/m2,intravenous drip, d1,every 3 weeks； Prednisone：100mg,tablet by mouth, d1-5, every 3 weeks.
62162925|NCT00799188|NO_INTERVENTION|1|reduction of immunosuppression
62162926|NCT00799188|EXPERIMENTAL|2|switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)
62162927|NCT03851159|PLACEBO_COMPARATOR|No Intervention: HIV-negative|HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
62162928|NCT03851159|EXPERIMENTAL|Intervention: HIV-|HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
62162929|NCT03851159|PLACEBO_COMPARATOR|No Intervention: HIV+|HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
62162930|NCT03851159|EXPERIMENTAL|Intervention: HIV+:|HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
62162931|NCT05029921|EXPERIMENTAL|Ustekinumab|Participants will receive a single dose of ustekinumab intravenously (IV) (weight-based dose approximating 6 milligrams per kilogram \[mg/kg\]) at Week 0. Participants with body weight less than or equal to (\<=) 55 kg will receive ustekinumab IV of 260 mg, greater than (\>) 55 kg and \<=85 kg will receive ustekinumab IV of 390 mg, and \>85 kg will receive ustekinumab IV of 520 mg at Week 0 in induction phase followed by ustekinumab 90 mg subcutaneously (SC) in maintenance phase from Week 8 to Week 52. For participants who achieve clinical response with ustekinumab induction dosing at Week 8, will continue to receive 90 mg ustekinumab SC every 12 weeks with final dose at Week 44. If these participants meet the criteria for loss of response from Week 16 to Week 40, dose can be adjusted to 90 mg every 8 weeks (q8w). Participants who are non-responders to ustekinumab at Week 8, and achieve clinical response at Week 16, will continue to receive ustekinumab 90 mg SC q8w from Week 16 to Week 48.
62162932|NCT06540846||STUMP cohort|Smooth muscle tumors of the uterus that do not fit the diagnostic criteria of benignity (such as leiomyomas) or malignancy (such as leiomyosarcomas) : smooth muscle tumor of uncertain malignant potential
62536130|NCT01659086|EXPERIMENTAL|Group E|Subjects will receive the investigational vaccine GSK2654909A and placebo
62536131|NCT01659086|EXPERIMENTAL|Group F|Subjects will receive the investigational vaccine GSK2654911A formulation 5
62536132|NCT01659086|EXPERIMENTAL|Group G|Subjects will receive the investigational vaccine GSK2654911A formulation 6
62162933|NCT06540846||Leiomyoma-leiomyosarcoma|Smooth muscle tumors of the uterus that do fit the diagnostic criteria of benignity (such as leiomyomas) or malignancy (such as leiomyosarcomas)
62162934|NCT01148017|EXPERIMENTAL|ACWY - 4|Subjects who had previously received 4 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their first year of life are administered one booster dose of the same vaccine at 60 months of age.
62536133|NCT01659086|EXPERIMENTAL|Group H|Subjects will receive the investigational vaccine GSK2654911A formulation 7
62536134|NCT01659086|EXPERIMENTAL|Group I|Subjects will receive the investigational vaccine GSK2654911A formulation 8
62536135|NCT01659086|EXPERIMENTAL|Group J|Subjects will receive the investigational vaccine GSK2654909A
62536136|NCT01659086|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive Placebo
62536137|NCT00806286|EXPERIMENTAL|CS-7017 with Paclitaxel and Carboplatin|
62536138|NCT00806286|PLACEBO_COMPARATOR|Paclitaxel and Carboplatin|
62536139|NCT00839254|EXPERIMENTAL|10Pn3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
62714609|NCT06309667|EXPERIMENTAL|Cohort A5 - Multiple Ascending Dose|PG-102(MG12) Dose 5 (N=8) Subcutaneous injection
62714610|NCT06309667|EXPERIMENTAL|Cohort B1 - Multiple Ascending Dose|PG-102(MG12) Dose 1 (N=6) Subcutaneous injection
62714611|NCT06309667|EXPERIMENTAL|Cohort B2 - Multiple Ascending Dose|PG-102(MG12) Dose 1\~5 (N=6) Subcutaneous injection
62714612|NCT06309667|EXPERIMENTAL|Cohort B3 - Multiple Ascending Dose|PG-102(MG12) Dose 1\~5 (N=6) Subcutaneous injection
62536140|NCT00839254|EXPERIMENTAL|10Pn2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
62536141|NCT00839254|ACTIVE_COMPARATOR|Ctrl3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
62536142|NCT00839254|ACTIVE_COMPARATOR|Ctrl2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
62536143|NCT00839254|EXPERIMENTAL|10Pn7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
62536144|NCT00839254|ACTIVE_COMPARATOR|Ctrl7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
62536145|NCT00839254|ACTIVE_COMPARATOR|10Pn12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
62536146|NCT00839254|EXPERIMENTAL|Ctrl12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
62536147|NCT02702661|EXPERIMENTAL|Procedure - FICB|Fascia Iliaca Block following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
62536148|NCT02702661|ACTIVE_COMPARATOR|Procedure - LAI|Local Anaesthetic Infiltration following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
62536149|NCT05750862|OTHER|Intervention arm|Study with one single arm. All participants will receive two interventions that will be compared to each other.
62536150|NCT06391255||Normal weight loss group|TWL between 25% and 35%
62536151|NCT02530658||Participants|"St. Jude patients with a diagnosed solid or liquid tumor (benign or malignant) and their biological parents or legally authorized representative.~Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy."
62536152|NCT05503810|EXPERIMENTAL|Intervention|Six month social support intervention following in hospital cardiac treatment
62536153|NCT05503810|NO_INTERVENTION|Control|Regular follow-up
62536154|NCT03333044|EXPERIMENTAL|CHW-led health coaching|Group sessions
62536155|NCT03333044|EXPERIMENTAL|HIT-enabled & CHW led|Supportive care enabled by mobile devices.
62536156|NCT03333044|EXPERIMENTAL|CHW & Physician Feedback|Patient setting progress communicated to physician via PHI
62536157|NCT06634394|EXPERIMENTAL|Treatment Arm APVO436 in combination with Venetoclax and Azacitidine|APVO436 at escalating dose levels in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
62536158|NCT03328195|ACTIVE_COMPARATOR|Neuro RX Gamma synchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.The synchronous device delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
62536159|NCT03328195|SHAM_COMPARATOR|Sham light therapy|Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
62714613|NCT06309667|EXPERIMENTAL|Cohort S - Multiple Ascending Dose|PG-102(MG12) Optimal Dose (N=6) Subcutaneous injection
62714614|NCT06309667|EXPERIMENTAL|Cohort C1 - Multiple Ascending Dose|PG-102(MG12) Dose 1 (N=12) Subcutaneous injection
62714615|NCT06309667|EXPERIMENTAL|Cohort C2 - Multiple Ascending Dose|PG-102(MG12) Dose 1 (N=12) Subcutaneous injection
62714616|NCT01911351|NO_INTERVENTION|standard management|Patients randomized to this arm will receive standard management alone for their minor procedure.
62714617|NCT01911351|EXPERIMENTAL|Nitrous Oxide|Patients randomized to this arm will receive nitrous oxide plus standard management for their minor procedure.
62714618|NCT00387088|OTHER|Tiotropium|Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
62714619|NCT00387088|OTHER|Placebo|Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
62536160|NCT03328195|ACTIVE_COMPARATOR|Neuro RX Gamma asynchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril. The asynchronous device alternatively delivers pulses from the intranasal and anterior LEDs vs. from the posterior LEDS.
62536161|NCT02455037|NO_INTERVENTION|Body Strengthening (Only)|All participants will complete a general resistance exercise training program.
62536162|NCT02455037|EXPERIMENTAL|Body Strengthening + Neck Strengthening|Participants assigned to the neck strengthening group will complete additional supervised exercises specifically designed to strengthen the neck.
62162935|NCT01148017|EXPERIMENTAL|ACWY - 2|Subjects who had previously received 1 or 2 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their second year of life, are administered one booster dose of the same vaccine at 60 months of age.
62714620|NCT03962855|ACTIVE_COMPARATOR|Ifetroban|Ifetroban 250 mg oral capsule administered once daily for a minimum of 4 weeks.
62162936|NCT01148017|OTHER|Naïve - 40|Control subjects, age-matched with the intervention groups subjects (40 months of age), to receive 1 optional dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
62162937|NCT01148017|ACTIVE_COMPARATOR|Naïve - 60|Control subjects, age-matched with the intervention groups subjects (60 months of age), are administered one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
62162938|NCT05824078|ACTIVE_COMPARATOR|Open procedure|"The study intervention involved in this project is the randomized allocation of the patient who requires surgical treatment of their perilunate injury to receive either an open or arthroscopic approach for the procedure.~Once the patient is in agreement to have surgery and has consented to partake in the study, they will be randomly allocated to either open perilunate surgery or arthroscopic perilunate surgery.~Both surgical approaches are well-recognized, common, standard-of-care procedures."
62536163|NCT02752087|EXPERIMENTAL|U-193 LY900014 Test|LY900014 test dose administered via subcutaneous (SC) injection
62536164|NCT02752087|ACTIVE_COMPARATOR|U-95 LY900014 Reference|LY900014 reference dose administered via SC injection
62536165|NCT04187339|EXPERIMENTAL|NGM395 Dose 1|NGM395 Subcutaneous Injection
62536166|NCT04187339|EXPERIMENTAL|NGM395 Dose 2|NGM395 Subcutaneous Injection
62536167|NCT04187339|EXPERIMENTAL|NGM395 Dose 3|NGM395 Subcutaneous Injection
62536168|NCT04187339|EXPERIMENTAL|NGM395 Dose 4|NGM395 Subcutaneous Injection
62536169|NCT04187339|EXPERIMENTAL|NGM395 Dose 5|NGM395 Subcutaneous Injection
62536170|NCT04187339|EXPERIMENTAL|NGM395 Dose 6|NGM395 Subcutaneous Injection
62536171|NCT04187339|PLACEBO_COMPARATOR|Placebo|Placebo
62536172|NCT04605224||Culinary class (intervention group)|The culinary class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
62536173|NCT04605224||Social studies class (control group)|The social studies class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
62536174|NCT06551571|EXPERIMENTAL|Intervention Group|"* In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission.~* The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations.~* The Postpartum Parenting Behavior Scale (PPBS), Breastfeeding Self-efficacy Scale (BSS), A Breastfeeding Charting System and Documentation Tool (LATCH), and Readiness for Hospital Discharge Scale-New Mother Form (RHD-NMF) were administered postpartum."
62536175|NCT06551571|NO_INTERVENTION|Control Group|"* Routine intrapartum care was provided to the pregnant woman in the hospital setting. This included taking an anamnesis, completing her file, opening an intravenous line, conducting routine blood tests, taking vital signs, recording cervical changes on the partograph via vaginal examination, applying EFM (electronic fetal monitoring) when indicated according to the attending physician's orders, listening to the fetal heart sounds (FHR) every fifteen minutes, and documenting this on the partograph.~* The mother and infant received standard postpartum care in the hospital. Breastfeeding was initiated immediately after delivery, and the infant was placed in direct contact with the mother. The uterine tone and bleeding of the mother were evaluated, and vital signs were taken every four hours. Nutrition and mobilization were ensured, and a heel prick blood sample was taken in the 24th hour after delivery. If the mother and infant were normal after 24 hours, they were discharged."
62536176|NCT02789553|EXPERIMENTAL|Meal with glucose syrup|Meal with glucose syrup : 30g of glucose mixed with 150 mL of water and dived into three 50 mL portions. It will be consumed in 15 minutes
62536177|NCT02789553|EXPERIMENTAL|Starch meal|Starch meal with 30g mixed in 120 mL of water. It will be consumed in 15 minutes and it represents 30g of glucose
62536178|NCT01475097|ACTIVE_COMPARATOR|Active Arm|
62536179|NCT01475097|ACTIVE_COMPARATOR|Comparator Arm|
62536180|NCT06451055|EXPERIMENTAL|Low-calorie diet|Participants will be placed on a low-calorie diet regimen consisting of \~1,300 kcal/day (55% carbohydrates, 13% fat, 25% protein, and 2% fiber) over 8 weeks. They will receive weekly pre-prepared meals (breakfast, lunch, and dinner) meticulously crafted by certified dieticians and expert chefs. Participants will be instructed to store the meals in the fridge or freezer and heat them using an air fryer, oven, microwave, or stovetop. They will be encouraged to consume 1-2 liters of water daily and maintain their habitual physical activity levels. A weight loss goal of at least 10% is set for the participants. Upon completion of the 8-week intervention, participants will transition back to their habitual dietary patterns while receiving guidance on portion sizes and healthy eating practices.
62536181|NCT06451055|ACTIVE_COMPARATOR|Routine dietary and physical activity habits|Control participants will be asked to maintain their routine dietary and physical activity habits.
62536182|NCT05854394|EXPERIMENTAL|Prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization#whey protein supplement#, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
62714621|NCT03962855|PLACEBO_COMPARATOR|Placebo|Matching placebo administered once daily for a minimum of 4 weeks.
62536183|NCT05854394|NO_INTERVENTION|Control group|The patients will receive the conventional clinical guidance according to The First Affiliated Hospital of Xiamen University, including drug treatment recommendations for chronic disease, quit smoking and abstinence.
62536184|NCT04053049|ACTIVE_COMPARATOR|High fat/ Semi-solid|Subject will receive a high fat/semi-solid meal.
62536185|NCT04053049|ACTIVE_COMPARATOR|High carbohydrate/ Semi-solid|Subject will receive a high carbohydrate/semi-solid meal.
62536186|NCT04053049|ACTIVE_COMPARATOR|High fat/ solid|Subject will receive a high fat/solid meal.
62536187|NCT04053049|ACTIVE_COMPARATOR|High carbohydrate/ solid|Subject will receive a high carbohydrate/solid meal.
62162939|NCT05824078|ACTIVE_COMPARATOR|Arthroscopic Procedure|"The study intervention involved in this project is the randomized allocation of the patient who requires surgical treatment of their perilunate injury to receive either an open or arthroscopic approach for the procedure.~Once the patient is in agreement to have surgery and has consented to partake in the study, they will be randomly allocated to either open perilunate surgery or arthroscopic perilunate surgery.~Both surgical approaches are well-recognized, common, standard-of-care procedures."
62162940|NCT01325519|NO_INTERVENTION|no intervention control group|control subjects
62536188|NCT02336724|EXPERIMENTAL|Famitinib|25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
62536189|NCT05360940||A|100 positive stool samples for H.pylori
62162941|NCT01325519|EXPERIMENTAL|experimental intervention group|video decision aid viewed by subjects
62162942|NCT00862225|PLACEBO_COMPARATOR|1|
62162943|NCT00862225|ACTIVE_COMPARATOR|2|
62162944|NCT00862225|EXPERIMENTAL|3|
62162945|NCT05618717||Surpoint Index Guided Ablation Group|Maximum Radiofrequency delivery duration cannot exceed Surpoint Index of 550
62162946|NCT05618717||Conventional Ablation Group|Operator determined ablation duration regardless of Surpoint Index Value
62162947|NCT05929222|ACTIVE_COMPARATOR|Standard Arm|Radiotherapy alone
62162948|NCT05929222|EXPERIMENTAL|Experimental Arm|Radiotherapy plus Obinutuzumab
62162949|NCT05556070|EXPERIMENTAL|Arm 1|
62536190|NCT05360940||B|100 negative stool samples for H.pylori
62162950|NCT05556070|EXPERIMENTAL|Arm 2|
62162951|NCT05556070|ACTIVE_COMPARATOR|Arm 3|
62162952|NCT04287036|EXPERIMENTAL|Test/Control|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Test/Control
62162953|NCT04287036|EXPERIMENTAL|Control/Test|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Control/Test.
62536191|NCT04544410|EXPERIMENTAL|Tildacerfont Group|Tildacerfont administered daily via oral tablet for 24 weeks at dose level 1; followed by open label tildacerfont for 52 weeks
62536192|NCT04544410|PLACEBO_COMPARATOR|Placebo|Placebo administered daily via oral tablet for 24 weeks; followed by open label tildacerfont for 52 weeks
62714622|NCT06124768||Mixed type DVT treated by PMT through the modified access|Anterograde venography shows patients with mixed type DVT. PMT is performed via ipsilateral distal calf venous access or contralateral femoral access.
62162954|NCT00308113|ACTIVE_COMPARATOR|1|CoenzymeQ10 taken once a day each morning by mouth.
62536193|NCT04129073||Cardiac arrest patients admitted to Intensive Care treatment|Intensive Care treatment; Utilization of neuroprognostication tools
62536194|NCT00524732||1|18 to 30 months since last prior dose of TD/Td vaccine.
62536195|NCT00524732||2|30 to 42 months since last prior dose of TD/Td vaccine.
62714623|NCT06124768||Mixed type DVT treated by PMT through the traditional access|Anterograde venography shows patients with mixed type DVT. PMT is performed via ipsilateral popliteal venous access.
62714624|NCT06124768||Central type DVT treated by PMT|Anterograde venography shows patients with central type DVT. PMT is performed via any access, such as ipsilateral femoral venous access or ipsilateral popliteal venous access.
62714625|NCT02217943|ACTIVE_COMPARATOR|Roux-en-Y gastric bypass|Subjects who receive a Roux-en-Y gastric bypass
62162955|NCT00308113|ACTIVE_COMPARATOR|2|Prednisone taken once a day each morning by mouth
62162956|NCT00308113|ACTIVE_COMPARATOR|3|CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
62162957|NCT00308113|NO_INTERVENTION|4|Enhanced standard of care.
62162958|NCT06030440|ACTIVE_COMPARATOR|Control Arm|postoperative radiotherapy of the head and neck region according to current standard including elective nodal irradiation
62162959|NCT06030440|EXPERIMENTAL|Investigational Arm|postoperative radiotherapy of the head and neck region without elective nodal irradiation
62162960|NCT03642899||Patients with anterior ischaemic optic neuropathy|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
62162961|NCT03642899||control group. Normal eyes|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
62162962|NCT03283449|EXPERIMENTAL|AV-1451 Recipients|Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
62162963|NCT02720705|ACTIVE_COMPARATOR|DEX I|active comparator receive 0.5µg/kg dexmedetomidine orally half an hour before operation
62162964|NCT02720705|PLACEBO_COMPARATOR|Saline Control|2ml oral 0.9%saline half an hour before operation
62162965|NCT02720705|ACTIVE_COMPARATOR|DEX II|active comparator receive,1µg/kg dexmedetomidine orally half an hour before operation
62162966|NCT03663699|EXPERIMENTAL|Exergaming|24 week access to the exergaming platform PlayPulse
62536196|NCT00524732||3|42 to 54 months since last prior dose of TD/Td vaccine.
62536197|NCT00524732||4|54 to 66 months since last prior dose of TD/Td vaccine.
62536198|NCT00524732||5|66 to 78 months since last prior dose of TD/Td vaccine.
62536199|NCT00524732||6|78 to 90 months since last prior dose of TD/Td vaccine.
62536200|NCT00524732||7|90 to 102 months since last prior dose of TD/Td vaccine.
62536201|NCT00524732||8|102 to 114 months since last prior dose of TD/Td vaccine.
62536202|NCT00524732||9|Control - over 114 months since last prior dose of TD/Td vaccine.
62536203|NCT06297954|EXPERIMENTAL|Metoclopramide|Patients will be randomized to receive metoclopramide 20 mg IV single dose.
62536204|NCT06297954|PLACEBO_COMPARATOR|Placebo|Patients will be randomized to receive placebo 10 ml IV single dose.
62536205|NCT04591951|ACTIVE_COMPARATOR|I2-ART Group|I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
62536206|NCT04591951|PLACEBO_COMPARATOR|Control Group|"The caregivers in the control group will receive usual care."
62536207|NCT04719962|EXPERIMENTAL|Disseminated Lyme infection|Only patients presenting with disseminated Lyme borreliosis will be part of the study.
62536208|NCT03504397|EXPERIMENTAL|Arm A (zolbetuximab plus mFOLFOX6)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
62162967|NCT03663699|NO_INTERVENTION|Control|Asked to continue with their normal daily routine
62162968|NCT04872465|ACTIVE_COMPARATOR|Experimental|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
62162969|NCT04872465|PLACEBO_COMPARATOR|Sham Comparator|Participants will receive sham (placebo) TBS treatment the same as experimental group
62162970|NCT05034393||Patients with de novo or recurrent HR-positive HER2-negative mBC|Patients diagnosed with de novo or recurrent HR-positive HER2-negative mBC from January 2018 to December 2020
62536209|NCT03504397|PLACEBO_COMPARATOR|Arm B (Placebo plus mFOLFOX6)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
62536210|NCT03825341|ACTIVE_COMPARATOR|Arm 1 Liquid Hydroxyurea|In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be \~20 mg/kg/day or the infant's usual daily dose.
62536211|NCT03825341|ACTIVE_COMPARATOR|Arm 2 Hydroxyurea Oral Capsule|In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg
62714626|NCT02217943|ACTIVE_COMPARATOR|Sleeve Gastrectomy|Subjects who receive a sleeve gastrectomy
62714627|NCT04182685||ZIKV-exposed children|Children age 5-15 with a positive Zika virus PCR test result.
62714628|NCT04182685||ZIKV-unexposed children|Children age 5-15 who have not had a Zika virus infection as determined by serological assays.
62714629|NCT04933149|EXPERIMENTAL|Ketamine Infusion Group|Subjects will receive ketamine infusion during their planned surgery and postoperatively.
62714630|NCT04933149|NO_INTERVENTION|Standard of Care Group|Subjects will receive general anesthesia as standard of care during their planned surgery
62714631|NCT04284709|EXPERIMENTAL|exercise group|exergames with simultaneous cognitive-physical training
62162971|NCT03927742|EXPERIMENTAL|Shade and application with UV message activated|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging activated
62162972|NCT03927742|ACTIVE_COMPARATOR|Shade and application without UV messaging|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging not activated
62162973|NCT03035149|EXPERIMENTAL|Weight Management Program|Obese subjects participate in a year long medically supervised weight management program.
62162974|NCT03035149|NO_INTERVENTION|Normal Weight Controls|Normal weight age and sex-matched controls. Unlike the obese subjects, the controls did not participate in the Weight Management Program. Pulmonary function, exercise performance and dyspnea results for normal weight controls were compared against the results for obese subjects.
62162975|NCT04172974|EXPERIMENTAL|Treatment for depression and anxiety|Treatment
62162976|NCT04172974|OTHER|Usual care|Usual Care
62162977|NCT03753256|ACTIVE_COMPARATOR|Transbond XT|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive a bonding primer (Transbond XT) The investigators will evaluate in this arm~1. the development of demineralization~2. its adverse effects after application"
62714632|NCT04284709|ACTIVE_COMPARATOR|control group|multicomponent exercise intervention focused on physical and cognitive training
62714633|NCT01903005|EXPERIMENTAL|Open-label BNX sublingual tablets|Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.
62714634|NCT06222203||1 - High-Risk|Participants with clinical or genetic diagnosis of NF1 AND at least one of the eligibility-required high-risk characteristics
62714635|NCT06222203||2 - Low-Risk|Participants with clinical or genetic diagnosis of NF1 AND none of the eligibility-required high-risk characteristic
62536212|NCT04510051|EXPERIMENTAL|Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)|Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
62536213|NCT05095571|OTHER|NO-ALS Extension Study High Dose EH301|
62536214|NCT04292652||EVAR group|Individuals undergoing endovascular aortic repair. n=40
62536215|NCT04292652||OR group|Individuals undergoing open repair. n=40
62536216|NCT02113189|EXPERIMENTAL|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
62536217|NCT02113189|EXPERIMENTAL|Individualized walking program|This group will receive a customized walking program.
62536218|NCT02113189|EXPERIMENTAL|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
62536219|NCT00372151|EXPERIMENTAL|L-Theanine|
62536220|NCT00372151|PLACEBO_COMPARATOR|Placebo|
62536221|NCT03696225|EXPERIMENTAL|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
62536222|NCT03696225|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
62536223|NCT03713853||Total hip arthroplasty + ORIF|Patients will receive acute primary total hip arthroplasty (THA) with open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
62536224|NCT03713853||Surgical Fixation (ORIF)|Patients will receive open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
62536225|NCT05110482|ACTIVE_COMPARATOR|syntocinon group|"in this group :5 mL syringe containing a bolus of 1 IU of oxytocin and infusion syringe which will be prepared with a 50 mL syringe containing 0.4 IU/mL of oxytocin and infusion rate of 7.5 IU/h will be administrated to the patient after delivery of the fetus shoulder, Additional bolus syringes will be prepared for use as rescue boluses if needed  which will be 5 ml syringe containing 3 IU of oxytocin"
62536226|NCT05110482|ACTIVE_COMPARATOR|carbetocin group|"in this group :5 mL syringe containing a bolus of 100 mcg of carbetocin and infusion syringe  which will be prepared with a 50 mL syringe containing normal saline will be administrated for the patient after delivery of the fetus shoulder. Additional bolus syringes will be prepared for use as rescue boluses if needed which will be 5 ml syringe containing 100 mcg of carbetocin"
62536227|NCT05890495|EXPERIMENTAL|Aqueous lidocaine|Subject issued 5 ml jar of aqueous 4% lidocaine and will dip tampon distal end into jar for 30 seconds prior to placement.
62536228|NCT05890495|PLACEBO_COMPARATOR|Saline|Subject issued 5 ml jar of sterile saline and will dip tampon distal end into jar for 30 seconds prior to placement.
62536229|NCT01675843|EXPERIMENTAL|Group A|controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI)
62536230|NCT01675843|NO_INTERVENTION|Group B|Controlled ovarian hyperstimulation (COH)+ Timed Intercourse (TI)
62536231|NCT05988684|EXPERIMENTAL|Metformin|Metformin group will be instructed to take metformin
62536232|NCT05988684|NO_INTERVENTION|control|Standard treatment and Follow-up, no metformin
62536233|NCT03713619|ACTIVE_COMPARATOR|secukinumab 1|Secukinumab 300mg every 2 weeks
62536234|NCT03713619|ACTIVE_COMPARATOR|secukinumab 2|Secukinumab 300mg every 4 weeks
62536235|NCT03713619|PLACEBO_COMPARATOR|placebo 1|Placebo group to secukinumab 300mg every 2 weeks
62536236|NCT03713619|PLACEBO_COMPARATOR|placebo 2|Placebo group to secukinumab 300mg every 4 weeks
62536237|NCT03718312|EXPERIMENTAL|Arm 1|Patients with aortic clamping withpre-conditioning
62536238|NCT03718312|NO_INTERVENTION|Arm 2|Patients with aortic clamping without pre-conditioning
62536239|NCT03924518|EXPERIMENTAL|granisetron group|3ml granisetron（3mg） will be diluted in 22 mL of 0.9% normal saline,and the granisetron diluted will be intravenously injected for at 10 minutes， every 8 hours for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
62536240|NCT03924518|PLACEBO_COMPARATOR|placebo group|Normal saline 25ml every 8h for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
62536241|NCT05705648|EXPERIMENTAL|Intervention|Medium chain triglyceride oil 15ml tid x 5 months
62536242|NCT05705648|PLACEBO_COMPARATOR|Placebo|Safflower oil 15mls tid x 5 months
62536243|NCT02996214|EXPERIMENTAL|LP group|Liposome paclitaxel(Lipusu®) plus cisplatin. Paclitaxel liposome Sterile injection powder 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
62536244|NCT02996214|ACTIVE_COMPARATOR|GP group|Gemcitabine (Gemzar®) plus cisplatin. Gemcitabine hydrochloride for injection 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
62536245|NCT03828786|ACTIVE_COMPARATOR|Endometrial scratching group|Endometrial scratching will be done with a Pipelle in uterus.
62536246|NCT03828786|NO_INTERVENTION|Control group|This group will proceed with intrauterine insemination without endometrial scratching according to clinic's standard procedure
62536247|NCT06279559|EXPERIMENTAL|clinical experimental group|pregnant women with the risk of preterm birth who will undergo music therapy intervention
62536248|NCT06279559|NO_INTERVENTION|clinical control group and non-clinical control group|pregnant women with the risk of preterm birth who will receive the usual ward care and pregnant women with pregnancy with a physiological course
62162978|NCT03753256|EXPERIMENTAL|Protecto®CaF2Nano|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Protecto®CaF2Nano).~The investigators will evaluate in this arm~1. its abrasion behavior and the development of demineralization~2. its adverse effects after the application"
62162979|NCT03753256|EXPERIMENTAL|Pro Seal®|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Pro Seal®).~The investigators will evaluate in this arm~1. its abrasion behavior and the development of demineralization~2. its adverse effects after the application"
62162980|NCT03753256|EXPERIMENTAL|Opal® Seal|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Opal®Seal).~The investigators will evaluate in this arm~1. its abrasion behavior and the development of demineralization~2. its adverse effects after the application"
62536249|NCT03993782|EXPERIMENTAL|A19010-R, B19010-O Use Group|Use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
62536250|NCT03993782|EXPERIMENTAL|B19010-O, A19010-R Use Group|Use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
62536251|NCT03553953||Patients with recording from BIS device|One hundred screened adult patients and no more than 60 valid cases who undergo elective surgery under general anesthesia with recording from the BIS device at the same time and comply with the inclusions criteria
62536252|NCT02968849|ACTIVE_COMPARATOR|ALVAC-HIV + subtype C gp120/MF59|2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
62536253|NCT02968849|PLACEBO_COMPARATOR|Placebo|2700 participants will receive Sodium Chloride for injection, 0.9% at months 0, 1, 3, 6, and 12.
62536254|NCT00963560|EXPERIMENTAL|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lens (IOL)
62536255|NCT00963560|ACTIVE_COMPARATOR|Crystalens HD|Bilateral implantation of Crystalens HD Intraocular Lens (IOL)
62536256|NCT00963560|ACTIVE_COMPARATOR|Crystalens AO|Bilateral implantation of Crystalens AO Intraocular Lens (IOL)
62536257|NCT04180631|EXPERIMENTAL|Quantitative ultrasound imaging parameter|Quantitative ultrasound imaging parameter (QUS)
62536258|NCT02748811|NO_INTERVENTION|Control group|The control group receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change in treatment or progression. If the patient has other health problems, those issues will be assessed either by the oncologist or by the general practitioner. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
62536259|NCT02748811|ACTIVE_COMPARATOR|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. They will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
62536260|NCT06052930|EXPERIMENTAL|VR group|12 consecutive weeks of physiotherapy + training with the IVR
62536261|NCT06052930|ACTIVE_COMPARATOR|Active control group|6 consecutive weeks of physiotherapy only, followed by 6 consecutive weeks of physiotherapy + training with the IVR
62536262|NCT05352347|ACTIVE_COMPARATOR|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
62536263|NCT05352347|ACTIVE_COMPARATOR|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
62536264|NCT05352347|PLACEBO_COMPARATOR|Placebo|Normal saline (NS) 100mL bid
62536265|NCT00237783|ACTIVE_COMPARATOR|standard dialysate sodium (140 mmol/L)|dialysate sodium (140 mmol/L)
62536266|NCT00237783|EXPERIMENTAL|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
62536267|NCT01646138|EXPERIMENTAL|Challenge Virus|The Ca/04/2009/H1N1 Vero Grown Challenge Virus was administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
62536268|NCT05496660|EXPERIMENTAL|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
62536269|NCT05496660|SHAM_COMPARATOR|NHE|the Nordic hamstring exercise plus taping wihout tension during 4-week consisting 12 sessions
62536270|NCT00509366|ACTIVE_COMPARATOR|Cisplatin Sensitive (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Cisplatin day 1, Gemcitabine days 1 \& 8 Non-Squamous Cell NSCLC-Cisplatin day 1, Pemetrexed day 1~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin sensitive arm, based on histology (squamous/non-squamous)."
62536271|NCT00509366|ACTIVE_COMPARATOR|Cisplatin Resistant (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Docetaxel day 1, Gemcitabine days 1 \& 8 Non-Squamous Cell NSCLC-Pemetrexed day 1, Gemcitabine days 1 \& 8~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin resistant arm, based on histology (squamous/non-squamous)."
62536272|NCT00509366|ACTIVE_COMPARATOR|Cisplatin Sensitive (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Cisplatin day 1, Gemcitabine days 1 \& 8"
62536273|NCT00509366|ACTIVE_COMPARATOR|Cisplatin Resistant (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Pemetrexed day 1, Gemcitabine days 1 \& 8"
62536274|NCT03869086|EXPERIMENTAL|SLOW anthocyanin metabolisers|Participants will be prospectively recruited to the SLOW anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
62714636|NCT06222203||3 - Caregiver|Parents or guardians of participants 8-17 years old in High-Risk or Low-Risk Cohorts
62536275|NCT03869086|EXPERIMENTAL|FAST anthocyanin metabolisers|Participants will be prospectively recruited to the FAST anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
62536276|NCT02784353|ACTIVE_COMPARATOR|Conventional|No intervention; conventional perioperative management without perioperative rehabilitation program
62536277|NCT02784353|EXPERIMENTAL|Intervention - PReHeBP|conventional perioperative management with preoperative and postoperative rehabilitation program
62162981|NCT01615523||Children/adolescents born preterm|
62162982|NCT01615523||Control children and adolescents|
62162983|NCT06647004||Inline Skaters|Amateur In-line skaters aged between 18 and 59 years, with at least one year of experience, without serious illnesses in the last six months or pharmacological treatments that could alter sports practice.
62162984|NCT02447380|EXPERIMENTAL|AZD6094 (Volitinib) in combination with docetaxel|"Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
62162985|NCT04435522|EXPERIMENTAL|Maraviroc Treatment|Maraviroc 300 mg Twice Daily
62162986|NCT04117334||Bracing AIS patients|These are patients undergoing brace treatment for AIS
62162987|NCT02637362|ACTIVE_COMPARATOR|Ankle + Sham metatarsal|Ankle block + sham metatarsal block
62162988|NCT02637362|ACTIVE_COMPARATOR|Ankle + Metatarsal|Ankle block + metatarsal block
62162989|NCT02637362|ACTIVE_COMPARATOR|Metatarsal + sham ankle|Metatarsal block + sham ankle block
62162990|NCT03109899|EXPERIMENTAL|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
62162991|NCT03109899|NO_INTERVENTION|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
62162992|NCT05453903|EXPERIMENTAL|Arm A: Relapsed/Refractory Setting|Participants with relapsed/refractory AML harboring either NPM1 or KMT2A alterations will receive bleximenib in combination with either venetoclax (VEN) (Cohort A1: bleximenib+VEN) or azacitidine (AZA) (Cohort A2: bleximenib +AZA) or VEN+AZA (Cohort A3: bleximenib+VEN+AZA) to select the recommended phase 2 dose (RP2D) of bleximenib in combination with VEN, AZA or VEN+AZA (dose selection). In dose expansion portion of the study, participants will receive bleximenib in combination with AML directed therapies at the RP2D(s).
62162993|NCT05453903|EXPERIMENTAL|Arm B: Newly Diagnosed Chemotherapy Ineligible Setting|Participants will receive bleximenib in combination with VEN+AZA as frontline chemo therapy for newly diagnosed AML participants harboring either KMT2A or NPM1 alterations who are greater than or equal to (\>=)75 years of age or \>= 18 years of age to less than (\<) 75 years of age with comorbidities that preclude the use of intensive induction chemotherapy.
62162994|NCT05453903|EXPERIMENTAL|Arm C: Newly Diagnosed Chemotherapy Eligible Setting|Participants will receive combination of bleximenib with cytarabine+daunorubicin or idarubicin chemotherapy as frontline treatment regimen for participants \>=18 to \<75 years of age with AML harboring either NPM1 or KMT2A alterations and eligible for intensive chemotherapy.
62162995|NCT06219902|EXPERIMENTAL|Treatment sequences A-C-D-B|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
62162996|NCT06219902|EXPERIMENTAL|Treatment sequences B-D-C-A|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
62162997|NCT06219902|EXPERIMENTAL|Treatment sequences C-B-A-D|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
62162998|NCT06219902|EXPERIMENTAL|Treatment sequences D-A-B-C|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).).
62162999|NCT03985228|EXPERIMENTAL|Fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks.
62163000|NCT03985228|PLACEBO_COMPARATOR|Placebo milk|The subjects assumed daily 250 ml of placebo milk for 12 weeks.
62536278|NCT06484725||Wild type patients|Patients with no mutations or VUS in Breast Cancer-related genes candidated to surgery as primary treatment and eligible for Oncotype DX assay.
62536279|NCT06484725||VUS patients|Patients with VUS in Breast Cancer-related genes candidated to surgery as primary treatment and eligible for Oncotype DX assay.
62714637|NCT04055974|EXPERIMENTAL|BeAMom|Low-risk (LR) women will receive a web-based intervention for the promotion of maternal mental health (the Be a Mom program). In addition, women will receive postpartum treatment as usually performed in primary care settings (TAU).
62714638|NCT04055974|NO_INTERVENTION|Control|Low-risk (LR) women will receive postpartum treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
62163001|NCT03809858|EXPERIMENTAL|Klue App Use then Usual Care|Subjects will use the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
62163002|NCT03809858|EXPERIMENTAL|Usual Care then Klue App Use|Subjects will begin the study without using the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
62163003|NCT02873442|EXPERIMENTAL|Precision cells combined with TACE|"Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
62163004|NCT02873442|ACTIVE_COMPARATOR|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
62163005|NCT02932280|EXPERIMENTAL|Neratinib|There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
62163006|NCT02070289|EXPERIMENTAL|Group 1: Cohort 1|
62163007|NCT02070289|EXPERIMENTAL|Group 1: Cohort 2|
62163008|NCT02070289|EXPERIMENTAL|Group 1: Cohort 3|
62163009|NCT02070289|EXPERIMENTAL|Group 2: Cohort 4|
62163010|NCT02070289|EXPERIMENTAL|Group 1 or 2: Cohort 5|
62536280|NCT06484725||Mutated patients|Patients with mutation in Breast Cancer-related genes candidated to surgery as primary treatment and eligible for Oncotype DX assay.
62536281|NCT05269979|EXPERIMENTAL|Intervention (the Vislanda district)|435 women living in Vislanda responded to a detailed survey and participated in physical exercise and received lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
62536282|NCT05269979|NO_INTERVENTION|Control (the Tingsryd/Emmaboda districts)|415 women living in Tingsryd and 395 women living in Emmaboda responded to the same detailed survey as the 435 women living in Vislanda.
62536283|NCT01804348|EXPERIMENTAL|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
62536284|NCT06399302||Lung transplant donors and recipients|Lung transplant donors and adult (18 years and up) lung transplant candidates and recipients
62163011|NCT02070289|EXPERIMENTAL|Group 1 or 2: Cohort 6|
62163012|NCT03959579||"1st cohort = derivation cohort:"|"1st cohort = derivation cohort: 1990-1998: cardiac echo + simultaneous systematic endomyocardial biopsy"
62163013|NCT03959579||"2nd cohort = validation cohort"|"2nd cohort = validation cohort: 1999-2016: only cardiac echo with same protocol (endomyocardial biopsy only in case of doubt)"
62163014|NCT03272373|OTHER|Monoblock|Subjects that receive the NexGen TM Monoblock Tibia
62163015|NCT03272373|OTHER|Modular|Subjects that receive the NexGen TM Modular Tibia
62163016|NCT06001593|EXPERIMENTAL|electircal stimulation + betahistine|
62163017|NCT06001593|SHAM_COMPARATOR|sham electircal stimulation + betahistine|
62163018|NCT06001593|OTHER|betahistine|control group
62163019|NCT05266209|EXPERIMENTAL|Experimental (coconut oil group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Moisturizers are applied to the thorax, back, arms and legs by massage, respectively, and the skin is absorbed. If it is to be applied for the first time, it is applied to a small area of the body under the control of a doctor. If there is no reaction, it is applied by massaging other areas. Since the babies to be included in the sample group are borderline and moderately premature (34-37W), 3-4 ml/kg (coconut oil)moisturizer will be applied.~Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday). Routine care will be applied to the skin of the newborns in the control group in the hospital. The control group will be evaluated using the NSCE form 3 days a week (Monday, Thursday, Sunday)."
62163020|NCT05266209|OTHER|Experimental (sunflower oil group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Moisturizers are applied to the thorax, back, arms and legs by massage, respectively, and the skin is absorbed. If it is to be applied for the first time, it is applied to a small area of the body under the control of a doctor. If there is no reaction, it is applied by massaging other areas. Since the babies to be included in the sample group are borderline and moderately premature (34-37W), 3-4 ml/kg (sunflower oil) moisturizer will be applied.~Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday)."
62163021|NCT05266209|NO_INTERVENTION|No Intervention (Control group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Routine maintenance of the intensive care unit will be implemented. Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday). Routine care will be applied to the skin of the newborns in the control group in the hospital. The control group will be evaluated using the NSCE form 3 days a week (Monday, Thursday, Sunday)"
62163022|NCT06721663|EXPERIMENTAL|study group|
62163023|NCT06721663|EXPERIMENTAL|control group|
62163024|NCT01876823|EXPERIMENTAL|es-citalopram and Memantine Treatment|concurrent es-citalopram plus memantine were administered for 48 weeks.
62163025|NCT04299581|EXPERIMENTAL|Cryoablation in combination with Camrelizumab|Cryoablation treatment starts at day 1. Camrelizumab will be initiated on day 14 after Cryoablation. Camrelizumab will be administered every three weeks (3mg/Kg, IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62163026|NCT06081010|EXPERIMENTAL|Intervention arm|Community Health Worker Intervention
62163027|NCT06081010|NO_INTERVENTION|Control Group|Usual care that includes patients visit to health facility based on felt need
62163028|NCT02158793|EXPERIMENTAL|Face Transplant recipient|Single Arm study, all participants will receive Craniomaxillofacial allotransplantation
62163029|NCT00795977|EXPERIMENTAL|dendritic cells|
62163030|NCT04827147|EXPERIMENTAL|MPP first, FPP second|Participants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period.
62163031|NCT04827147|EXPERIMENTAL|FPP first, MPP second|Participants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period.
62163032|NCT03980171|EXPERIMENTAL|Obinutuzumab+venetoclax+lenalidomide|Patients in both dose escalation and dose expansion will receive 6 cycles of induction treatment consisting of obinutuzumab (flat dose of 1000mg) and protocol defined dose levels of venetoclax and lenalidomide.
62536285|NCT05272748|EXPERIMENTAL|Conventional Exercise + Core Stabilization Exercise|Conventional exercises and core stabilization exercises will be performed with the telerehabilitation method for 8 weeks. Patients will be contacted via laptop, ipad and phones with cameras, microphones and internet connection. Exercise by telerehabilitation will be implemented with a live connection for the first 4 weeks. In the second 4 week periods, exercise videos will be given to the patients and it will be checked by phone. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.
62714639|NCT05947838|EXPERIMENTAL|Circulating tumoral DNA directed neoadjuvant therapy arm|Participants will have their circulating tumoral DNA levels measured at the onset of neoadjuvant chemotherapy and during their neoadjuvant treatment to direct the duration of therapy provided.
62714774|NCT01607281||anesthesiologists, experience|There is one arm. All participating anesthesiologists wıll fulfill the questionary survey and show the imaginary puncture site by USG bilaterally.
62536286|NCT05272748|EXPERIMENTAL|Conventional Exercise|Conventional exercises used in the treatment of knee and hip osteoarthritis will be performed by the telerehabilitation method for 8 weeks. Patients will be contacted via laptop, ipad and phones with cameras, microphones and internet connection. Exercise by telerehabilitation will be implemented with a live connection for the first 4 weeks. In the second 4 week periods, exercise videos will be given to the patients and it will be checked by phone. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
62536287|NCT04466241|ACTIVE_COMPARATOR|Lopinavir/ritonavir|Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
62536288|NCT04466241|EXPERIMENTAL|Lopinavir/ritonavir + telmisartan|"* Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10~* Telmisartan 40 mg : 1 tablet daily from Day 1 to Day 10"
62536289|NCT04466241|EXPERIMENTAL|Lopinavir/ritonavir + atorvastatin|"* Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10~* Atorvastatin 20 mg : 1 tablet daily from Day 1 to Day 10"
62536290|NCT03313063||PE|Women with a history or preeclampsia, between 18 - 50 years of age, 0.5 - 20 years postpartum
62536291|NCT03313063||Control|Age-matched women without any birth complications, between 18 - 50 years of age, 0.5 - 20 years postpartum
62536292|NCT02711735|ACTIVE_COMPARATOR|RUTI® vaccine|Intervention: Patients randomized to receive RUTI® vaccine will receive one injection of RUTI® vaccine in their right or left deltoid muscle.
62536293|NCT02711735|PLACEBO_COMPARATOR|Matching RUTI® Placebo|Intervention: Patients randomized to receive Placebo will receive one injection of Placebo in their right or left deltoid muscle.
62536294|NCT05202730|OTHER|Traditional injection site and traditional local anesthetic formulation|
62536295|NCT05202730|EXPERIMENTAL|Traditional injection site and new local anesthetic formulation|
62536296|NCT05202730|EXPERIMENTAL|New injection site and traditional local anesthetic formulation|
62536297|NCT05202730|EXPERIMENTAL|New injection site and new local anesthetic formulation|
62536298|NCT01824628||• HIV positive subjects receiving antiretroviral regimen|
62163033|NCT03003715|EXPERIMENTAL|Refractory Trigeminal Neurpathic Pain (TNP) Patients|All patients receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
62163034|NCT03003715|EXPERIMENTAL|Healthy volunteers|All volunteers receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
62163035|NCT03856294|EXPERIMENTAL|Rikkunshito|Rikkunshito: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
62163036|NCT03856294|PLACEBO_COMPARATOR|Placebo|Placebo: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
62163037|NCT06228209|EXPERIMENTAL|Tier - Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
62163038|NCT06228209|NO_INTERVENTION|Usual care|Patients will be cared for by the physician who treats their serious illness (cardiologist, oncologist, primary treating clinician) and other illnesses.
62163039|NCT03656926|EXPERIMENTAL|L-CsA treatment plus SoC|Liposomal Cyclosporine A (L-CsA) 10 mg twice daily for 48 weeks, plus Standard of Care Therapy
62163040|NCT03656926|ACTIVE_COMPARATOR|Standard of Care|This is a maintenance regimen of immunosuppressive agents
62536299|NCT01824628||• HIV negative subjects from the pre-admission surgical clinic|
62536300|NCT03872934||Turkish music group|Turkish music group (Saba or rast makam)
62536301|NCT03872934||classical western music|classical western music (vivaldi)
62536302|NCT03872934||soft rock music|soft rock music (elvis)
62536303|NCT03872934||control group (group not listening music)|control
62536304|NCT02512653|EXPERIMENTAL|1|Cupressus arizonica allergen extract at 4 different concentrations. Positive control. Negative control
62536305|NCT04365777||Awake State|OAA/S=5
62536306|NCT04365777||Sedation State|OAA/S=3
62536307|NCT04365777||Unconsciousness State|OAA/S=1
62536308|NCT06035263|EXPERIMENTAL|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
62536309|NCT06035263|ACTIVE_COMPARATOR|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
62536310|NCT06633900|EXPERIMENTAL|Intervention|Participants assigned to the intervention arm will receive naltrexone injections once a month over 6 months. The naltrexone injection (380mg) will be administered every 4 weeks in the ventrogluteal location.
62536311|NCT06633900|ACTIVE_COMPARATOR|Control|Participants in the control arm will receive usual care.
62536312|NCT04331938|EXPERIMENTAL|Open Label Arm|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion. This will be performed on both sides. Patients will be asked to rate their pain pre- and 30 minutes post-procedure on a scale of 0-10. Patients will also be asked to rate their nausea and photophobia on a similar scale. Patients will be reevaluated at 24 hours and 48 hours post procedure.
62163041|NCT03715634|EXPERIMENTAL|Depot buprenorphine (INDV-6200)|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive depot buprenorphine
62163042|NCT03715634|PLACEBO_COMPARATOR|Placebo|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive volume-matched placebo
62163043|NCT06233682|EXPERIMENTAL|Enriched environment group|25 people with stroke recruited from the acute in-patient ward of the Neurology Clinic, meeting the inclusion criteria.
62536313|NCT04321330|EXPERIMENTAL|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
62536314|NCT03240237|EXPERIMENTAL|CCM therapy|Optimizer SMART
62163044|NCT06233682|NO_INTERVENTION|No intervention|25 people with stroke recruited from the acute in-patient ward of the Neurology Clinic, meeting the inclusion criteria.
62163045|NCT02038114|EXPERIMENTAL|Instructed to read pamphlets|This group will be instructed to read patient education pamphlets.
62163046|NCT04758559|PLACEBO_COMPARATOR|Usual care|Patients receive usual care concerning dietary advice.
62163047|NCT04758559|EXPERIMENTAL|myfood24|Patients receive myfood24 a new online app to support tracking of food and nutrient intakes, and allows patients and healthcare professionals to communicate, seeing results of intakes to promote healthy dietary behaviour changes.
62163048|NCT04758559|EXPERIMENTAL|myfood24 + diet optimisation|Personalised feedback. Patients use myfood24 with an additional feature of new technology providing guidance of how to optimise their diets against targets, using information they provide about current intakes.
62163049|NCT05299099|EXPERIMENTAL|IN-C006 inj.|IN-C006 inj. 1970 mL
62163050|NCT05299099|ACTIVE_COMPARATOR|RCN301|RCN301 1820 mL
62163051|NCT06459128|EXPERIMENTAL|AI-Enabled Mobile Application (Limbic Care)|Participants are given access to Limbic Care, a smartphone application that uses conversational AI to deliver cognitive behavioral therapy interventions and psychoeducation, provide support through active listening, and help answer questions about the therapeutic material.
62163052|NCT06459128|ACTIVE_COMPARATOR|Digital Workbook (PDF)|Participants are provided with a link to the digital workbook (in PDF format) that can be accessed via the Internet. The workbook contains cognitive behavioral therapy interventions and psychoeducation material.
62163053|NCT01877720|EXPERIMENTAL|NAVA-PS|noninvasive NAVA first for 15 minutes and then PSV for 15 minutes
62163054|NCT01877720|EXPERIMENTAL|PS-NAVA|noninvasive PSV first for 15 minutes and then NAVA for 15 minutes
62163055|NCT06431126|EXPERIMENTAL|Nature and animal-assisted activities for young adults with autism|
62163056|NCT03062488|ACTIVE_COMPARATOR|opioid only|2 mcg/Kg of fentanyl
62536315|NCT02689050||Patients with lymphadenopathy|Patients ≥ 18 years of age, with (suspected) NSCLC or suspected sarcoidosis, and at least one suspected mediastinal/hilar lesion that are scheduled for standard diagnostic endosonographic workup will undergo additional needle based confocal laser endomicroscopy (nCLE) measurements of suspected lesions.
62536316|NCT01167101|OTHER|Pantoprazole|controls Pantoprazole 40mg qd for 28days
62536317|NCT01167101|ACTIVE_COMPARATOR|Pantoprazole + Rebamipde|Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days
62714640|NCT03833921|OTHER|Abiraterone acetate + prednisone|All subjects will receive abiraterone acetate and prednisone, as per standard of care. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone twice per day. Subjects will continue to take abiraterone acetate and prednisone until confirmed disease progression.
62736490|NCT01732029|OTHER|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric hypoxia by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (about 4500 m).
62163057|NCT03062488|ACTIVE_COMPARATOR|opioid plus PO analgesic|2 mcg/Kg of fentanyl plus PO acetaminophen 15 mg/Kg
62163058|NCT03062488|ACTIVE_COMPARATOR|opioid plus IV acetaminophen|2 mcg/Kg of fentanyl plus 15mg/Kg of IV acetaminophen
62163059|NCT00913562|ACTIVE_COMPARATOR|Patients with diabetes|Rosuvastatin
62163060|NCT00913562|ACTIVE_COMPARATOR|Patients with glaucoma|Rosuvastatin
62163061|NCT00913562|PLACEBO_COMPARATOR|Control patients with diabetes|Placebo
62163062|NCT00913562|PLACEBO_COMPARATOR|Control patients with glaucoma|Placebo
62163063|NCT04737499|EXPERIMENTAL|CASCADe Intervention|Intervention consisted of eight weekly sessions of health education and diabetes management. Topics covered include recognition of diabetes and its complications, risk factors, nutrition knowledge, dietary practices, exercise, behavioral self-monitoring, medication adherence, and stress management. Intervention also included a home visit for training of monitoring devices use, WeChat app and acquiring family support, and weekly WeChat follow-up on education tips, monitoring data summary, and group discussion. The monitoring system used a smartphone to coordinate cloud data transmission from a set of wireless devices to capture daily monitoring data on physical activity, body weight, blood pressure and blood glucose levels.
62163064|NCT01771081||Group1|
62163065|NCT03852381|EXPERIMENTAL|Spinal Cord Stimulation|"At baseline, the following data will be recorded: standard-of-care questionnaire scores, neuroimaging (fMRI, MEG), psychophysical testing (QST), accelerometer sleep and activity data.~The trial will proceed as follows:~Day 1-4: Paresthesia-based SCS (PB-SCS)~Day 5-8: No SCS (placebo)~Day 9-12: PF-SCS~Neuroimaging and psychophysical testing will be conducted at the end of the trial, and will be assessed 6-months post-implantation of the SCS device along with adverse effects. A decision to implant the SCS system will be made based on reduction of patient pain intensity by 50% in PB-SCS and/or PF-SCS modes, but not with placebo SCS.~Based on the response in the trial, the patient will either not be a candidate for an SCS implant, or they will receive one of the four modes upon implantation (PB-SCS, or one of the three PF-SCS: Burst, High Frequency, High Density)."
62163066|NCT02536729||Oral Sodium Phosphate - Normal preparation|Oral sodium phospate exposure with special diet (Liquid)
62536318|NCT00720252|EXPERIMENTAL|A|
62163067|NCT02536729||Oral Sodium Phosphate - Modified preparation|Oral sodium phospate exposure with special diet (Liquid), but the participant can normally lunch the day before the test
62163068|NCT02536729||polyethylene glycol + Electrolytes|polyethylene glycol + Electrolytes exosure with special diet (Liquid)
62536319|NCT05338216|EXPERIMENTAL|Traditional Ecological Momentary Assessment (Traditional EMA)|People with aphasia (PWA) in the traditional EMA arm will receive four prompts per day to complete a set of nine picture naming trials per prompt for a total of n = 36 prompts/day for three weeks.
62536320|NCT05338216|EXPERIMENTAL|Micro-Interaction Ecological Momentary Assessment (µEMA)|People with aphasia (PWA) in the µEMA condition will complete a single naming trial at a time, 36 times per day for three weeks.
62536321|NCT02029014|EXPERIMENTAL|LAmbre closure system|
62536322|NCT02845141|EXPERIMENTAL|Actifuse|Actifuse to fill bone tunnel
62163069|NCT01538056|EXPERIMENTAL|PMEG Fenestrated Graft or Company Manufactured Terumo Aortic Fenestrated TREO Graft|"Fenestrated device with PMEG fenestrations for the bilateral renal arteries, celiac and SMA. May include all three fenestrations or only one.~Company manufactured device - Terumo Aortic Fenestrated TREO Abdominal Stent Graft System fenestrated for the bilateral renal arteries, celiac and SMA. May include all three fenestrations or only one."
62163070|NCT05457972|EXPERIMENTAL|Vaginal Estrogen|Estradiol 4 mcg vaginal insert, daily for two weeks then twice weekly for ten weeks.
62163071|NCT05457972|ACTIVE_COMPARATOR|Vaginal Moisturizer|Vaginal moisturizer, daily for two weeks then twice weekly for ten weeks.
62163072|NCT06571292|ACTIVE_COMPARATOR|Control group|The control group will be trained with robotic exoskeleton for upper limbs and task specific training, 3 sessions per week for 4 weeks, for 1 hour per day.
62163073|NCT06571292|EXPERIMENTAL|Intensive group|The intensive group will be trained with robotic exoskeleton for upper limbs and task specific training, 5 sessions per week for 4 weeks, for 2 hours per day.
62163074|NCT04272099||PG1 (patients with diabetes 0-25 years of age)|Patients 0 to 25 years of age, with a diagnosis of diabetes that are either followed at Kay Mackenson Pediatric Clinic, Haiti, or who are of Haitian ancestry, defined as both maternal and paternal grandparents being born in Haiti, and attend one of the three diabetes clinics in Montreal.
62163075|NCT04272099||PG2 (patient's principal caregiver)|The patient's principal caregiver (a parent of legal guardian).
62163076|NCT02074878|EXPERIMENTAL|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200mg, twice daily and Sunitinib 25.0mg once daily
62163077|NCT02074878|EXPERIMENTAL|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
62163078|NCT02074878|EXPERIMENTAL|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
62163079|NCT06029803|EXPERIMENTAL|Adrenal Venous Sampling via Antecubital Approach|Patients in the experimental group will undergo adrenal venous sampling via antecubital vein approach.
62163080|NCT06029803|ACTIVE_COMPARATOR|Adrenal Venous Sampling via Femoral Approach|Patients in the active comparator group will undergo adrenal venous sampling via femoral vein approach.
62163081|NCT04503551|EXPERIMENTAL|PDS Arm|Participants randomized to the PDS arm will receive two intravitreal ranibizumab injections and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 36-weeks (Q36W) thereafter
62163082|NCT04503551|OTHER|Comparator Arm|Participants randomized to the comparator arm will undergo study visits every 4 weeks (Q4W) for comprehensive clinical monitoring until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q36W thereafter. Participants will be eligible to receive intravitreal ranibizumab 0.5 mg injections if treatment eligibility criteria are met.
62163083|NCT02246647||Healthy volunteers|Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
62714641|NCT05049863|EXPERIMENTAL|Phase I Dose Level 1a: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at 90 mg/m\^2 on Days 1 and 8. Cycles are 21 days.
62714642|NCT05049863|EXPERIMENTAL|Phase I Dose Level 1: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at 100 mg/m\^2 on Days 1 and 8. Cycles are 21 days.
62163084|NCT02246647||IBS-C|Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
62163085|NCT01817088|EXPERIMENTAL|New targeting procedure without electrophysiology|Patients with the high precision procedure under general anesthesia alone without electrophysiological stimulation
62163086|NCT01817088|ACTIVE_COMPARATOR|Classical neurosurgical procedure|patients with a first step of electrode implantation under awake surgery with electrophysiological control followed by a second step under general anesthesia
62163087|NCT02334202|ACTIVE_COMPARATOR|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program for adolescent military dependents."
62163088|NCT02334202|EXPERIMENTAL|Interpersonal Psychotherapy-Weight Gain|IPT-WG is designed to decrease excessive weight gain among adolescents who are at risk for adult obesity. IPT-WG involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. The IPT-WG program has been adapted to be appropriate for military dependents.
62163089|NCT05872984|EXPERIMENTAL|Intervention arm: adjustment of dry weight based on absolute blood volume measurement|Dry weight will be adjusted at the start of the intervention period in all subjects in the intervention group with a normalized blood volume below 65 ml/kg, regardless the occurrence of intradialytic hypotension associated adverse events during the baseline period. Dry weight will be adjusted once with 0,5kg.
62536323|NCT02845141|ACTIVE_COMPARATOR|bone graft|bone graft to fill bone tunnel
62714643|NCT05049863|EXPERIMENTAL|Phase II: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
62163090|NCT05872984|NO_INTERVENTION|Control arm: standard care|standard care provided by the clinician, no intervention.
62163091|NCT05616312|EXPERIMENTAL|Postoperative teach-back educational program|Patients will receive teach-back education while they fill out questionnaires.
62163092|NCT05616312|NO_INTERVENTION|Control|Patients will not receive any teach-back education while filling out questionnaires.
62536324|NCT01717716|EXPERIMENTAL|Calorie-free control|Calorie-free control
62536325|NCT01717716|EXPERIMENTAL|HFCS-55 drink|HFCS-55 drink
62536326|NCT01717716|EXPERIMENTAL|Glucose drink|Glucose drink
62536327|NCT01717716|EXPERIMENTAL|Sucrose drink|Sucrose drink
62536328|NCT00080314|ACTIVE_COMPARATOR|A1|
62536329|NCT00080314|PLACEBO_COMPARATOR|A2|
62536330|NCT01462812|ACTIVE_COMPARATOR|Sumatriptan|
62536331|NCT01462812|PLACEBO_COMPARATOR|Matching placebo|
62536332|NCT05268068|EXPERIMENTAL|Dose A of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose A and then followed for 140 days.
62536333|NCT05268068|EXPERIMENTAL|Dose B of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.
62536334|NCT05268068|EXPERIMENTAL|Dose C of Risankizumab for Intravenous (IV) Infusion|Participants will receive IV infusion of risankizumab at dose C and then followed for 140 days.
62536335|NCT03317834||Study Population|Total Knee Replacement with Navio Surgical Systems
62163093|NCT06650137|EXPERIMENTAL|Adult emergency patients with acute respiratory distress|"Subjects aged ≥ 18 years presenting to the emergency department with ARD defined by respiratory rate (RR) \> 25 and/or signs of struggle.~Every potentially eligible patient will have a right diaphragmatic ultrasound performed by a doctor trained in the technique."
62536336|NCT04933968|PLACEBO_COMPARATOR|Placebo|Placebo, visually identical to ALVR106
62536337|NCT04933968|ACTIVE_COMPARATOR|ALVR106|ALVR106, visually identical to placebo
62536338|NCT02529891||COPD Patients|Patients with COPD, within 48h after hospital admission for exacerbation.
62536339|NCT02529891||non-COPD patients|Healthy person of the entourage of COPD patients.
62536340|NCT00635232|ACTIVE_COMPARATOR|Irbesartan 300mg|Irbesartan 300 mg once daily
62536341|NCT00635232|PLACEBO_COMPARATOR|Placebo|Blinded Placebo Treatment
62536342|NCT00635232|EXPERIMENTAL|PS433540 200mg|PS433540 200mg once daily
62536343|NCT00635232|EXPERIMENTAL|PS433540 400mg|PS433540 400mg once daily
62536344|NCT00635232|EXPERIMENTAL|PS433540 800mg|PS433540 800mg once daily
62536345|NCT05568901|ACTIVE_COMPARATOR|LMC Alone|Caregivers who received standardized lethal means counseling (LMC) from the study team as well as a 1-page handout summarizing the counseling recommendations
62536346|NCT05568901|EXPERIMENTAL|LMC + Gun Locks|Caregivers who received standardized lethal means counseling (LMC) from the study team, 1-page handout summarizing the counseling recommendations, as well as the additional provision of 2 cable-style gun locks
62163094|NCT05978947|EXPERIMENTAL|Microfluidic Chip Method|The Sperm Separation Device - ZyMōt Multi 850µL device (ZyMōt Fertility, Inc) will be used. The microfluidic chamber will be used based on the manufacturer's instructions. 850 μL of the semen sample will be added to the inlet port of the device and 750 μL of fertilization media will be added to the outlet port. The device will then be incubated in 6% CO2 at 37°C. After 30 minutes, 500 μL of the prepared sample at the outlet port will be removed and pipetted into a labelled test tube. The final volume will be adjusted to 1mL for sperm counting.
62163095|NCT05978947|ACTIVE_COMPARATOR|Density Gradient Centrifugation Method|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 500 μL. The final volume will be adjusted to 1mL for sperm counting.
62536347|NCT03040557|ACTIVE_COMPARATOR|Flexible footwear|The intervention with flexible footwear in women with plantar fasciitis (MFG), acute n=12 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
62536348|NCT03040557|ACTIVE_COMPARATOR|Orthopedic insole|The intervention with orthopedic insole in women with plantar fasciitis (COIG, acute n=14 and chronic=14) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
62536349|NCT00845624||1|Preterm infants \<1500 grams or 32 weeks gestation.
62536350|NCT02777073|ACTIVE_COMPARATOR|liraglutide 1.8 mg|single dose of Victoza ( liraglutide) 1.8 mg
62536351|NCT02777073|PLACEBO_COMPARATOR|Placebo|Single dose of placebo
62536352|NCT02777073|ACTIVE_COMPARATOR|Dapagliflozin|Single dose of Dapagliflozin 10 mg oral tablet
62536353|NCT06224465|PLACEBO_COMPARATOR|control group|Antiaging diet instructions
62536354|NCT06224465|EXPERIMENTAL|intervention group|"1. aerobic exercises: walking :30 min on treadmill 30min at least three times per week for 12 weeks~2. Muscle strength Exercises:~   For upper extremity : hand grip exercise, arm flexion exercise ten repetition for each exercise three times per week.~   Theraband exercises for upper limb exercise ten repetition for each exercise three times per week.~3. Flexibility Exercise :~Curl up exercise and Seat and reach up exercises exercise ten repetition for each exercise three times per week.~Lateral flexibility exercises for ten repetition for each exercise three times per week,for 12 weeks and anti aging diet instruction"
62536355|NCT05918744|NO_INTERVENTION|Habitual Sleep|Participants will follow their normal sleep schedule for 2 weeks.
62536356|NCT05918744|EXPERIMENTAL|Sleep extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
62536357|NCT03664492|OTHER|Educational Whiteboard video|All the interested participants contacting us will be provided an info email and an internet link via email to access the study through REDCap. Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
62536358|NCT05259995|EXPERIMENTAL|Sustained Acoustic Medicine Device Group 1|Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62536359|NCT05259995|ACTIVE_COMPARATOR|Sustained Acoustic Medicine Device Group 2|Patients receive treatment from the SAM Ultrasonic Diathermy Device 2 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
62536360|NCT00922272|EXPERIMENTAL|SPD489 (Lisdexamfetamine dimesylate)|
62536361|NCT00922272|PLACEBO_COMPARATOR|Placebo|Placebo
62536362|NCT04395144|EXPERIMENTAL|Awake prone positioning|Prone positioning of patients on nasal high-flow oxygen therapy
62536363|NCT04395144|ACTIVE_COMPARATOR|Standard care|Standard decubitus positioning of patients on nasal high-flow oxygen therapy
62714644|NCT02068144|EXPERIMENTAL|Cranberry Extract|Cranberry Extract in a 15.2oz beverage daily for 8 weeks
62163096|NCT05908734|EXPERIMENTAL|Phase 1 (Combination Dose Selection)|Participants will receive amivantamab low dose or high dose intravenous (IV) infusion based on body weight from Cycle 1 Day 1, Day 2, and subsequently Day 8, Day 15, and Day 22 and then every 2 weeks from Cycle 2 in combination with cetrelimab IV infusion from Cycle 1 Day 2 (after the Day 2 infusion of amivantamab). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET).
62163097|NCT05908734|EXPERIMENTAL|Phase 2 (Dose Expansion)|Participants will receive amivantamab in combination with cetrelimab in Cohorts A and B at the RP2CD determined by the SET in Phase 1. Participants will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for discontinuation of study treatment is met.
62163098|NCT04586426|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
62163099|NCT04586426|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the recommended Phase 2 regimen (s) (RP2R\[s\]) of the study treatment identified in Part 1.
62536364|NCT06197373||Early laparoscopic cholecystectomy after ERCP|Evaluation of outcomes of early ( within 72 hours) laparoscopic cholecystectomy after ERCP
62163100|NCT04586426|EXPERIMENTAL|Part 3: Phase 2|Participants will receive teclistamab + talquetamab combination therapy, at the RP2R selected from Part 1 and Part 2.
62163101|NCT05464992|OTHER|Patients with glioma or brain metastases|
62163102|NCT05999994|EXPERIMENTAL|Ramucirumab + Cyclophosphamide + Vinorelbine (DSRCT ISA)|Ramucirumab given intravenously (IV), cyclophosphamide given orally and vinorelbine given IV in 28-day cycles for desmoplastic small round cell tumor (DSRCT) intervention-specific appendix (ISA).
62163103|NCT05999994|ACTIVE_COMPARATOR|Cyclophosphamide + Vinorelbine (DSRCT ISA)|Cyclophosphamide given orally and vinorelbine given IV in 28-day cycles for DSRCT ISA.
62163104|NCT05999994|EXPERIMENTAL|Ramucirumab + Gemcitabine + Docetaxel (SS ISA)|Ramucirumab and gemcitabine given IV in 21-day cycles for synovial sarcoma (SS) ISA.
62163105|NCT05999994|ACTIVE_COMPARATOR|Gemcitabine + Docetaxel (SS ISA)|Gemcitabine and docetaxel given IV in 21-day cycles for SS ISA.
62163106|NCT05999994|EXPERIMENTAL|Abemaciclib + Irinotecan + Temozolomide (ES ISA)|Abemaciclib given orally, irinotecan given IV, and temozolomide given orally in 21-day cycles for Ewing's sarcoma (ES) ISA.
62163107|NCT05999994|ACTIVE_COMPARATOR|Irinotecan + Temozolomide (ES ISA)|Irinotecan given IV and temozolomide given orally in 21-day cycles for ES ISA.
62163108|NCT06291597||Daily electronic cigarette users|Participants must use their vaping device everyday at time of enrollment.
62163109|NCT02332421|EXPERIMENTAL|modified dentoalveolar distractor|Canine retraction will be accomplished using a modified dentoalveolar distractor
62163110|NCT02332421|NO_INTERVENTION|conventional dentoalveolar distractor|Canine retraction will be accomplished using a conventional dentoalveolar distractor
62163111|NCT05888142|ACTIVE_COMPARATOR|"Roosevelt in clinic VR"|"During the in clinic training phase of the study, patients in this group will receive VR physical therapy exercises in clinic only (no homeworks during training). After the training phase, all patients will do VR homeworks, including VR exercises and VR mindfulness."
62536365|NCT06197373||Late laparoscopic cholecystectomy after ERCP|Evaluation of outcomes of late ( form third day up to 2months ) laparoscopic cholecystectomy after ERCP
62536366|NCT02445976|EXPERIMENTAL|Prior Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
62536367|NCT02445976|EXPERIMENTAL|Prior Abiraterone and Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
62536368|NCT03139227|EXPERIMENTAL|Supportive Care (celery-banana bread)|Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
62536369|NCT06332729|ACTIVE_COMPARATOR|effect of universal exercis unit on genu recurvatum in diplegic cerbral palsy children|Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
62714645|NCT02068144|PLACEBO_COMPARATOR|Placebo|Placebo 15.2oz beverage daily for 8 weeks
62163112|NCT05888142|EXPERIMENTAL|"Roosevelt in Clinic VR + VR homeworks"|"During the training phase, patients in this group will receive VR physical therapy exercises in clinic. In addition, during the training phase, they will also take a VR system home and will be encouraged to do VR homeworks at home. After the training phase, all patients will do VR homeworks, including VR exercises and VR mindfulness."
62163113|NCT06140823||prospective general population cohort|Males and females age \>= 40 years, without a personal history of HCC or current HCC and at least two clinical visits to their HCO, within the last year, before the study start date.
62163114|NCT06140823||Prospective cirrhosis population cohort|Males and females age \>= 40 years, with liver cirrhosis and without a personal history of HCC or current HCC, that have at least two clinical visits to their HCO, within the last year, before the study start date.
62163115|NCT06140823||Prospective no_cirrhosis population cohort|Males and females age \>= 40 years, without a personal history of HCC or current HCC and without a diagnosis of liver cirrhosis, that have at least two clinical visits to their HCO, within the last year, before the study start date.
62163116|NCT03759262|EXPERIMENTAL|Vitamin D (Cholecalciferol)|All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.
62163117|NCT06721715||Textbook outcome|Patients that achieve a textbook outcome after oesophagectomy
62163118|NCT06721715||No textbook outcome|Patients who do not achieve a textbook outcome after oesophagectomy
62163119|NCT05588661|EXPERIMENTAL|Perturbation Exercises|Perturbation Based Balance Training
62163120|NCT05588661|EXPERIMENTAL|Whole Body Vibration|Whole Body Vibration Therapy
62163121|NCT04715945||Women|12,583 women recruited when non-pregnant
62536370|NCT06332729|ACTIVE_COMPARATOR|effect of functional electrical stimulation on genu recurvatum in diplegic cerbral palsy children|Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
62536371|NCT03444376|EXPERIMENTAL|GX-188E, KEYTRUDA®|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg KEYTRUDA® : Day 1 q3 weeks/ 200mg
62163122|NCT04715945||Children|3,158 liveborn singleton offspring of women recruited to the study
62163123|NCT03205345|ACTIVE_COMPARATOR|Emricasan (25 mg)|Emricasan 25 mg
62163124|NCT03205345|ACTIVE_COMPARATOR|Emricasan (5 mg)|Emricasan 5mg
62163125|NCT03205345|PLACEBO_COMPARATOR|Placebo|Matching placebo
62163126|NCT04578691|EXPERIMENTAL|"Anatase Spine Surgery Navigation System"|"Using Anatase Spine Surgery Navigation System in pedicle screw placement in spine surgery"
62163127|NCT04578691|ACTIVE_COMPARATOR|Medtronic Stealthstation S7 Treatment Guidance System|Using Medtronic Stealthstation S7 Treatment Guidance System in pedicle screw placement in spine surgery
62163128|NCT04380688|EXPERIMENTAL|Arm 1|Acalabrutinib+ Best Supportive Care
62163129|NCT04380688|NO_INTERVENTION|Arm 2|Best Supportive Care
62163130|NCT01211717|EXPERIMENTAL|Branched Chained Amino Acids|
62163131|NCT01211717|PLACEBO_COMPARATOR|Cellulose mix|
62163132|NCT04582864|EXPERIMENTAL|Flotetuzumab|"* Will start on cycle 1 day 1 on the dose escalation ramp schedule of flotetuzumab as a continuous intravenous (IV) infusion. Patients will be initiated at 30 ng/kg/day and have their dose increased daily to a target goal of 500 ng/kg/day by day 7~* Patients will continue on flotetuzumab at 500 ng/kg/day for the remaining 21 days of the 28 day cycle.~* On cycle 1 day 28, patients will undergo bone marrow biopsy for assessment of disease status. Patients who have achieved a CR/CRi will proceed to a second cycle per protocol, while patients with a PR or SD or better may proceed to cycle 2 with permission of the investigator. Patients with available donor lymphocytes may receive DLI concurrently with flotetuzumab during Cycle 1 and/or Cycle 2."
62536372|NCT05387850||Elderly patients over the age of 65|Elderly patients over the age of 65 undergoing elective non-cardiac surgery
62536373|NCT01681407||Depressed Patients|Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
62536374|NCT01681407||Non-Depressed Controls|Controls: Volunteers that had clinical screening with no depression diagnosis.
62536375|NCT01681407||Patients Relatives|Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
62163133|NCT06516692|NO_INTERVENTION|Clinical Parameters guided assessment arm|"Participants recruited to this arm will be assessed for their hydration status and further fluid management as per usual care of assessment through~* Capillary refill time~* Presence/absence of pulmonary rales.~* Jugular venous pressure assessment by clinical methods~* Presence / absence of pedal edema"
62163134|NCT06516692|EXPERIMENTAL|Inferior Vena Cava Collapsibility and Distensibility guided assessment arm|"Participants recruited in this arm will be assessed through measurement of inferior vena cava diameter via subcostal window within 3 cm of its opening to right atrium through point of care ultrasound using a curvilinear or phased array probe.~For spontaneously breathing patients Inferior Vena Cava Collapsibility Index (IVC CI) will be calculated as:~\[(IVC diameter max-IVC diameter min)/IVC diameter max\]×100%~* IVC CI \> 50% = overt hypovolemia~* IVC CI \< 20% = no overt hypovolemia~* IVC CI of 20% to 50% will be goal~For mechanically ventilated patients Inferior Vena Cava Distensibility Index (IVC DI) will be calculated as:~\[(IVC diameter max-IVC diameter min)/IVC diameter min\]×100% IVC distensibility\>18% = hypovolemia IVC distensibility\<18% = no hypovolemia"
62163135|NCT05837624|EXPERIMENTAL|Women with an ovarian endometrioma who will take drospirenone / estetrol|Women 18 years of age or older with endometriosis who have at least one ovarian endometrioma, of at least 3 cm in diameter, who will take oral Drospirenone / Estetrol treatment for 6 months
62163136|NCT03939871|EXPERIMENTAL|Single arm|Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.
62163137|NCT06232655|EXPERIMENTAL|Cladribine plus Venetoclax|Subjects will receive cladribine at a dose of 5mg/m2 daily via intravenous infusion on days 1 through 5 of a 28 day cycle. Concomitantly, venetoclax will be administered orally at a dose of 100mg on day 1, 200mg on day 2, and 400mg daily on days 3 through 28.
62163138|NCT06232655|EXPERIMENTAL|Alternating Aza/Ven and Clad/Ven|Alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles), while those who do not respond will come off the study.
62163139|NCT01765699||Primary knee arthroplasty|Patients with osteoarthritis of the knee undergoing primary knee arthroplasty
62163140|NCT01601925|EXPERIMENTAL|neck extended group|We measured the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck.
62163141|NCT06073665|ACTIVE_COMPARATOR|Lower TSH Group|Target TSH level of 0.5-2.0 mU/L
62536376|NCT04142892|EXPERIMENTAL|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD). 3 weeks of (+/-3 days) of ONA treatment
62536377|NCT04485832|ACTIVE_COMPARATOR|Intervention|
62536378|NCT04485832|ACTIVE_COMPARATOR|Control|
62536379|NCT04444674|EXPERIMENTAL|Group 1- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10\^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
62536380|NCT04444674|PLACEBO_COMPARATOR|Group 1- placebo|Participants (HIV-negative) will receive two doses of Normal saline (0.9%) in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
62736491|NCT01540526|EXPERIMENTAL|Safety cohort|6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
62163142|NCT06073665|EXPERIMENTAL|Higher TSH group|Target TSH level of 5.5-7.0 mU/L
62163143|NCT06168994|ACTIVE_COMPARATOR|Amiodarone as comparison|50 patients \>\>Amiodarone +other treatmen
62163144|NCT06168994|EXPERIMENTAL|Eplerenone plus amiodarone|50 patients \>\>Amiodarone +other treatmen
62536381|NCT04444674|EXPERIMENTAL|Group 2a- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10\^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
62536382|NCT04444674|PLACEBO_COMPARATOR|Group 2a- placebo|Participants (HIV-negative) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
62536383|NCT04444674|EXPERIMENTAL|Group 2b- IP|Participants will receive two doses of 5-7.5x10\^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
62536384|NCT04444674|PLACEBO_COMPARATOR|Group 2b- placebo|Participants will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
62536385|NCT04444674|EXPERIMENTAL|Group 3- IP|Participants (HIV-positive) will receive two doses of 5-7.5x10\^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
62536386|NCT04444674|PLACEBO_COMPARATOR|Group 3- placebo|Participants (HIV-positive) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
62536387|NCT04808180|EXPERIMENTAL|Trial Group|Teeth from this group suffer from MIH. They will be evaluated after home oral care with BioRepair toothpaste containing microRepair®.
62536388|NCT04808180|ACTIVE_COMPARATOR|Control Group|Teeth from this group suffer from MIH. They are in the contralateral quadrants in respect to teeth from trial group. They will not be treated with the hydroxyapatite toothpaste.
62536389|NCT00899041|ACTIVE_COMPARATOR|Standard knee prosthesis|'standard' knee prosthesis (Sigma FB, J\&J, UK).
62536390|NCT00899041|ACTIVE_COMPARATOR|High flexion knee prosthesis|'high flexion' knee prosthesis (Sigma RP-F, J\&J, UK).
62536391|NCT05982288|EXPERIMENTAL|Intensive care nurses|"Type of Study: It will be conducted in a single-center, randomized controlled experimental design. A clinical trial number will be obtained before starting the study.~Location of the Study: The research will be conducted in the Anesthesiology and Reanimation Clinic of Antalya Kepez State Hospital."
62536392|NCT05345743||Positive AIR-test|Patients with a positive intraoperative AIR-test result
62536393|NCT05345743||Negative AIR-test|Patients with a negative intraoperative AIR-test result
62536394|NCT03529825|EXPERIMENTAL|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
62536395|NCT03529825|NO_INTERVENTION|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
62163145|NCT03500796|OTHER|Corneal perforation patients|"Patients who had/impeding corneal perforation due to melting of the cornea after infection with a corneal pathogen (bacterial or viral), with no previous surgical intervention.~Patients will undergo:~Platelet rich plasma clot implantation Wound closure with amniotic membrane"
62163146|NCT01518127|EXPERIMENTAL|stem cell group|intravitreal injection of autologous bone marrow stem cells
62536396|NCT02924636|EXPERIMENTAL|Intervention|personalized and online intervention. The intervention website will provide secure communication with dietician and lifestyle coaches. Women will receive emails and monthly newsletters with new content and reminder.
62536397|NCT02924636|NO_INTERVENTION|Control|standard care with oral information about the goal of nutritional needs during pregnancy and gestational weight gain guidelines according to BMI
62536398|NCT01056042|EXPERIMENTAL|A|Intramuscular depot medroxyprogesterone acetate
62536399|NCT01056042|ACTIVE_COMPARATOR|B|ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms
62536400|NCT05156905|EXPERIMENTAL|Cirmtuzumab + Docetaxel|There is only one treatment arm on this study. The combination of cirmtuzumab + docetaxel will be administered on one treatment arm. Treatment will cirmtuzumab will be administered initially as a loading dose alone on days 1, 15, and 29 of cycle 1. Following the loading, cirmtuzumab will be given on Day 1 of every 21-day cycle starting on Cycle 2 to up to Cycle 7 corresponding with concurrent docetaxel administration. Following discontinuation or completion of docetaxel, treatment with cirmtuzumab will be continued Day 1 of every 28 cycle until disease progression, toxicity or study withdrawal. Docetaxel will be administered on day 1 of every 21-day cycle starting Cycle 2 for up to 6 cycles.
62536401|NCT01922804|EXPERIMENTAL|K2 vitamin|K2 vitamin 375 microgram a day for 3 years
62536402|NCT01922804|PLACEBO_COMPARATOR|placebo|1 tablet a day for 3 years
62536403|NCT02743338|EXPERIMENTAL|Sleep Restriction followed by additional CBT-i components|Sleep Restriction treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
62536404|NCT02743338|ACTIVE_COMPARATOR|Sleep Compression followed by additional CBT-i components|Sleep Compression treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
62536405|NCT02743338|ACTIVE_COMPARATOR|Sleep Restriction followed by no intervention|Sleep Restriction treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
62536406|NCT02743338|ACTIVE_COMPARATOR|Sleep Compression followed by no intervention|Sleep Compression treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
62536407|NCT00460135|EXPERIMENTAL|RT|resistance training
62536408|NCT00460135|NO_INTERVENTION|Routine care|General counseling on increasing physical exercise
62536409|NCT03899441|NO_INTERVENTION|Control|Patients in the control arm will have pre-operative teaching from their physician and sign consent for surgery, as is the current standard of care at the investigators' institution.
62536410|NCT03899441|EXPERIMENTAL|Video arm|Patients in the intervention arm will watch two short animated video about minimally-invasive endometrial cancer surgery followed by focused pre-operative teaching from their physician. They will then sign consent for surgery.
62536411|NCT03383237|EXPERIMENTAL|Apatinib|Apatinib 500mg/d,q.d.,p.o.
62536412|NCT00872794|OTHER|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
62163147|NCT05076578|EXPERIMENTAL|Evaluate the harvesting of micografts in healthy and patients with chronic wounds|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
62163148|NCT02379078|EXPERIMENTAL|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
62163149|NCT02379078|PLACEBO_COMPARATOR|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
62163150|NCT00597779|ACTIVE_COMPARATOR|EM device|Extramedullary Device (EM)
62163151|NCT00597779|ACTIVE_COMPARATOR|IM device|Intramedullary Device (IM)
62163152|NCT05939349|ACTIVE_COMPARATOR|Intervention Group|The PPR intervention will span 6 months and will include 2 main components: produce vouchers and nutrition education.
62163153|NCT05939349|NO_INTERVENTION|Delayed Intervention Group|For participants enrolled in the delayed control group they will complete all the biometric measurements and surveys during the 9-month period while the intervention group received the 6-month intervention and completes the 3-month post intervention assessments.
62163154|NCT06720753|EXPERIMENTAL|Opposite action|Participants will be randomly assigned to this arm either first or second. All participants complete both arms.
62163155|NCT06720753|EXPERIMENTAL|GIVE|Participants will be randomly assigned to this arm either first or second. All participants complete both arms.
62163156|NCT05989243||Veterans with a transtibial amputation|20 Veterans with a transtibial amputation, 10 females and 10 males
62163157|NCT05989243||Veterans with a transfemoral amputation|20 Veterans with a transfemoral amputation, 10 females and 10 males
62163158|NCT01764204||Qingkailing Injection|
62163159|NCT01993342||Inflammatory knee osteoarthritis|We recruited patients with osteoarthritis and synovial effusion to diagnostic the effusion and to confirm that this this synovial fluid had mechanical characteristics. Now we are going to determine the adipocytokines and traditional parameters of inflammation in this synovial fluid to correlate it, and we will associate it with the ultrasound explanation of the knee that we have in our database.
62163160|NCT03974997|OTHER|serum concentration changes in cytokine TWEAK|We will perform a prospective study in which 50 patients with multiple sclerosis in the isolated clinical syndrome stage will be included over a 12-month period. Mental Cerebral MRIs will be performed for each patient at baseline (T0), month 6, and month 12. Serum dosages of TWEAK will be performed each month for each patient for one year. Patients will also be treated with soluble TNF, the leader in the TNF family of ligands, anti-TWEAK antibodies (which may interfere with the activity and dosage of TWEAK) as well as C-reactive Protein C ( search for intercurrent infectious episode). These dosages will be correlated with the clinical evolution (appearance or not of an inflammatory flare) as well as the data of the imagery (number of lesions raised or not by the gadolinium).
62536413|NCT05629897|EXPERIMENTAL|Intervention|They will perform an initial test of processing speed, attentional span and executive control. After this test, they will start the training programme. It consists of 40 sessions of cognitive stimulation, distributed over 8 weeks of treatment with a frequency of five sessions per week. In the last session, a final test will be performed, the same as the initial one.
62536414|NCT05629897|NO_INTERVENTION|Waiting list|"They will perform an initial test of processing speed, attentional span and executive control. In the last session, 8 weeks after the initial test, a final test will be performed, the same as the initial one.~They will have the opportunity to perform the same training as the experimental group after performing the final test. At 8 weeks, patients on the waiting list will be taught, if the wish, how to use the platform to perform the stimulation. They will be offered cognitive training with COPERIA-COG under the same conditions, periodicity, automatic reminders and calls from the psychologist as in the intervention group."
62163161|NCT02371278|OTHER|Higher daily protein|"Diets will provide protein intakes of 1.2 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
62163162|NCT02371278|OTHER|Lower daily protein|"Diets will provide protein intakes of 0.8 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
62163163|NCT04896827||Chronic pain|Patients with chronic pain (n=100)
62163164|NCT04896827||Healthy participants|Healthy participants (n=144)
62163165|NCT03873376|EXPERIMENTAL|Opt-in|Receive offer to order self-sampling kit
62163166|NCT03873376|EXPERIMENTAL|Opt-out|Receive self-sampling kit unsolicited
62163167|NCT03873376|EXPERIMENTAL|Control|Receive open reminder to be screened by physician
62536415|NCT05920733|EXPERIMENTAL|HealthyLifetime Group|This project is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making.
62536416|NCT00767169|EXPERIMENTAL|coated implant and control|
62536417|NCT02554565|OTHER|Tumor biopsies and blood sampling|
62536418|NCT00609518|ACTIVE_COMPARATOR|Standard Vitamin and Steroid Schedule + Pemetrexed|Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
62536419|NCT00609518|EXPERIMENTAL|Simplified Vitamin and Steroid Schedule + Pemetrexed|Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
62536420|NCT05042544||People at risk of HCV acquisition|This is an observational cohort study. Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. Participants will attend a single visit to receive point-of-care HCV testing and complete a self-administered survey. Testing will be performed using point-of-care HCV antibody testing (results within 1-20 minutes, depending on the test) and if positive, HCV RNA testing will be performed. Participants who have previously had HCV infection or previously received HCV treatment will be tested using point-of-care HCV RNA testing. Participants will not receive treatment as a part of this study. Participants who are HCV RNA detectable will be linked to standard of care for any other clinical assessments and treatment initiation.
62536421|NCT01539018|ACTIVE_COMPARATOR|Sorafenib alone.|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
62536422|NCT01539018|EXPERIMENTAL|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily continuously and UFT 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
62536423|NCT03343444|ACTIVE_COMPARATOR|Arm 1|Treatment-naïve is defined as having never received treatment for HCV with any interferon (IFN), ribavirin , or other approved or experimental HCV specific direct acting antivirals.
62536424|NCT03343444|ACTIVE_COMPARATOR|Arm 2|"Treatment-experienced is defined as:~1. IFN Intolerant~2. Non-response~3. Relapse/Breakthrough"
62536425|NCT03343444|EXPERIMENTAL|Short Track|Treatment-naïve or Treatment-experienced who achived very rapid virological responce - Negative HCV PCR after treatment with (Sofosbuvir 400mg/Ledipasvir 90mg) for 1 week
62536426|NCT03604315|EXPERIMENTAL|Treatment (FDG PET/CT, [18F]FTT PET/CT)|Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo \[18F\]FTT PET/CT over 1 hour.
62536427|NCT02290301||Type 2 Diabetes Mellitus|
62536428|NCT05390801||Patients|Any patient ≥ 18 years old with congenital aniridia, able to respond independently to a questionnaire and patients under 18 years old with congenital aniridia, whose parents can respond for their child.
62536429|NCT01930565|EXPERIMENTAL|LFCO application|We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
62536430|NCT01930565|ACTIVE_COMPARATOR|TTO application|To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
62536431|NCT02792608|EXPERIMENTAL|Mindfulness-based Therapy|5 week, manual-based group MBI treatment for depression
62536432|NCT00213135|EXPERIMENTAL|Cladribine 5.25 mg/kg|
62536433|NCT00213135|EXPERIMENTAL|Cladribine 3.5 mg/kg|
62536434|NCT00213135|PLACEBO_COMPARATOR|Placebo|
62536435|NCT05509738|EXPERIMENTAL|Group 1: Diaries - SMS|"Group 1 will be asked to complete a 2-day bladder diary + food diary during the first two weeks of the study, then will receive SMS Text reminders during the last 2 weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys)."
62536436|NCT05509738|EXPERIMENTAL|Group 2: SMS - Diaries|"Group 2 will receive SMS Text reminders during the first 2 weeks of the study, and then will be asked to complete a 2-day bladder diary + food diary during the last two weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys)."
62536437|NCT03996148|ACTIVE_COMPARATOR|Remifentanil, Propofol, and Desflurane|Study group A: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
62536438|NCT03996148|ACTIVE_COMPARATOR|Remifentanil, Dexmedetomidine, and Desflurane|Study group B: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
62536439|NCT03996148|ACTIVE_COMPARATOR|Remifentanil and Desflurane|Study group C (control group): no midazolam given; maintenance drugs started immediately after induction and airway is secured.
62536440|NCT01375686||Those at Risk for Type 2 diabetes|All subjects will be at risk for diabetes based on the American Diabetes Association (ADA) Standard of Care Guidelines.
62536441|NCT02678650|EXPERIMENTAL|volatile anesthetics group|10min after intubation, begin to sevoflurane wash-in / wash-out operation: sevoflurane administration was interrupted for at least 10 min, by washout with a high fresh gas flow (10 l/min) to achieve a MAC value below 0.2. Following the interruption, sevoflurane was again washed in with a high fresh gas flow (6 l/min) to achieve 1 MAC end-tidal concentration as soon as possible, and repeated twice periods of 10 minutes. Discontinuation of the halogenated agent for at 15 minutes during the last wash out time.
62536442|NCT02678650|PLACEBO_COMPARATOR|propofol intravenous anesthesia group|propofol infusion 3-5μg / kg / h
62536443|NCT02971735|EXPERIMENTAL|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
62536444|NCT02971735|ACTIVE_COMPARATOR|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
62536445|NCT00463697|EXPERIMENTAL|GW642444M 25mcg|Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.
62536446|NCT00463697|EXPERIMENTAL|GW642444M 100mcg|Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.
62536447|NCT00463697|EXPERIMENTAL|GW642444M 400mcg|Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.
62536448|NCT00463697|EXPERIMENTAL|GW642444H 100mcg|Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.
62536449|NCT00463697|PLACEBO_COMPARATOR|placebo|Subject will inhale single dose of Placebo via a DISKUS device in morning.
62536450|NCT03309995|EXPERIMENTAL|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
62536451|NCT03309995|PLACEBO_COMPARATOR|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
62536452|NCT01723579|EXPERIMENTAL|NOMAC-E2 2.5 mg/1.5 mg|Participants will receive combined oral contraceptive NOMAC-E2 2.5 mg/1.5 mg tablet for 13 consecutive 28-day cycles. Each 28-day cycle with consist of 24 active tablets and 4 placebo tablets taken at approximately the same time each day.
62536453|NCT03767335|EXPERIMENTAL|MEN1611|MEN1611 + Trastuzumab +/- Fulvestrant
62536454|NCT02469259|EXPERIMENTAL|Treatment|Subjects will receive either 20IU or 40IU intranasal oxytocin
62536455|NCT02469259|PLACEBO_COMPARATOR|Placebo|Subjects will receive intranasal saline spray
62536456|NCT05700370|EXPERIMENTAL|Sample collected with preceding DRE, then without|All subjects participate in the control and experimental collection event sequentially. The control group will consist of urine samples collected post-DRE, and the experimental group will consist of urine samples collected by the same subjects without preceding DRE.
62536457|NCT02266537|EXPERIMENTAL|Tamsulosin|
62536458|NCT02266537|EXPERIMENTAL|Alfuzosin|
62536459|NCT02266537|EXPERIMENTAL|Doxazosin|
62536460|NCT02266537|PLACEBO_COMPARATOR|Placebo|
62536461|NCT01085123|EXPERIMENTAL|1|PET 1: baseline, PET 2: 10 mg Zomig® Rapimelt, PET 3: 5 mg ZOMIG® Rapimelt, PET 4 2.5 mg ZOMIG® Rapimelt
62536462|NCT03049605|EXPERIMENTAL|Magnetic Therapy|Twenty five patient were exposed to low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss for 30 minutes / session for 2 times per week for 3 months .
62536463|NCT03049605|EXPERIMENTAL|Laser Therapy|Twenty five patients were treated with 24 sessions of laser therapy at a rate of two sessions / week for three months. Each patient will be exposed to Helium neon infrared laser (850 nano-meter continuous wave mode from a comfortable prone lying position.
62536464|NCT03049605|EXPERIMENTAL|Medical therapy|Fifteen patients were received only medical treatment .
62536465|NCT06470282|EXPERIMENTAL|Dose Level 1: 0.75 mg/kg Enfortumab Vedotin (Starting Dose)|Participants receive 0.75 mg/kg enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.
62536466|NCT06470282|EXPERIMENTAL|Dose Level 2: 1.0 mg/kg Enfortumab Vedotin|Participants receive 1.05 mg/kg enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.
62536467|NCT06470282|EXPERIMENTAL|Dose Level 3: 1.25 mg/kg Enfortumab Vedotin|Participants receive 1.25 mg/kg enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.
62536468|NCT06470282|EXPERIMENTAL|Dose Expansion; Recommended Phase 2 Dose (RP2D)|Participants receive RP2D of enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.
62536469|NCT02116608|ACTIVE_COMPARATOR|Group 1: Betadine|Apply locally as needed.
62536470|NCT02116608|ACTIVE_COMPARATOR|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
62536471|NCT02116608|ACTIVE_COMPARATOR|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
62536472|NCT03473769|EXPERIMENTAL|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
62536473|NCT03473769|NO_INTERVENTION|No Intervention|No intervention. Patient treated per standard of care.
62536474|NCT00005983|ACTIVE_COMPARATOR|surgery|surgery followed by observation
62536475|NCT00005983|EXPERIMENTAL|surgery followed by RT|Surgery followed by radiation therapy
62536476|NCT06010537|EXPERIMENTAL|polyglucose superparamagnetic iron oxide injection 2.5 mg/kg|Intravenous injected polysaccharide superparamagnetic iron oxide injection at 2.5 mg/kg dose;
62536477|NCT06010537|EXPERIMENTAL|polyglucose superparamagnetic iron oxide injection 3.0 mg/kg|Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3.0 mg/kg dose;
62536478|NCT02051400|EXPERIMENTAL|Intubation with the McGrath® MAC video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
62536479|NCT02051400|EXPERIMENTAL|Intubation with the GlidesScope® Ranger video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
62536480|NCT02051400|EXPERIMENTAL|Intubation with Macintosh laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
62536481|NCT02153008||Symptomatic population for GAS|This study is a diagnostic study to aid in the detection of Strep throat. No intervention or medication is a part of this study.
62536482|NCT01158092|ACTIVE_COMPARATOR|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
62536483|NCT01158092|ACTIVE_COMPARATOR|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
62536484|NCT03653910|EXPERIMENTAL|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
62536485|NCT03653910|ACTIVE_COMPARATOR|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
62536486|NCT04829110|EXPERIMENTAL|A. ETOH|5 Males and 5 Females will receive deuterated water and drink 2.15 ounces of alcohol in the form of vodka and have de novo Lipogenesis measured at 11 time points during and after.
62536487|NCT04829110|EXPERIMENTAL|ETOH + Sucrose|5 Females will receive deuterated water and drink 1.72 ounces of alcohol in the form of vodka + 7 grams of sucrose and have de novo Lipogenesis measured at 11 time points during and after.
62536488|NCT04829110|EXPERIMENTAL|C. Sucrose|5 Females will receive deuterated water and drink a solution containing water and 35 grams of sucrose, and have de novo Lipogenesis measured at 11 time points during and after.
62536489|NCT01696851||wheelchair rugby players with tetraplegia|
62536490|NCT01696851||other routine sport participants with tetraplegia|
62536491|NCT02799368|EXPERIMENTAL|CJ Plasma Solution A Injection|Before contrast media administration : CJ Plasma Solution A Injection (3mL/kg for 1 hour) After contrast media administration : CJ Plasma Solution A Injection (1.5 mL/kg/h for 4 hours)
62536492|NCT02799368|ACTIVE_COMPARATOR|CJ 0.9% Normal Saline Injection|Before contrast media administration : CJ 0.9% Normal Saline Injection (3mL/kg for 1 hour) After contrast media administration : CJ 0.9% Normal Saline Injection (1.5mL/kg/h for 4 hours)
62163168|NCT05556772|EXPERIMENTAL|Screening (biospecimen collection, cytology, interview)|Participants participate in an interview and clinical exam, lasting approximately 2 hours. Participants undergo vaginal self-sampling, cervical provider-sampling, and collection of blood and urine samples. Participants also undergo a pelvic exam. After first interview and clinical exam at enrollment, participants have two subsequent study visits over a 2 year period.
62163169|NCT06480500|EXPERIMENTAL|i-CBT and IV ketamine|Participants will receive internet-based cognitive therapy (i-CBT) for 13 weeks. During the first 4 weeks of i-CBT, participants will also be administered 6 infusions of ketamine intravenously. The first two infusions will be dosed at 0.5 mg/kg over a period of 40 mins. For infusions 3 and 4, patients will be flexibly-dosed between 0.5 mg/kg to 0.75 mg/kg, depending on clinical response to first two infusions. For infusions 5 and 6, patients will be flexibly-dosed between 0.5-0.85 mg/kg, depending on the clinical response to the first 4 infusions.
62163170|NCT06480500|ACTIVE_COMPARATOR|i-CBT and IV midazolam|Participants will receive internet-based cognitive therapy (i-CBT) for 13 weeks. During the first 4 weeks of i-CBT, participants will also be administered 6 infusions of midazolam intravenously. The first two infusions will be dosed at 0.02 mg/kg over a period of 40 mins. For infusions 3 and 4, patients will be flexibly-dosed between 0.02 mg/kg to 0.03 mg/kg, depending on clinical response to first two infusions. For infusions 5 and 6, patients will be flexibly-dosed between 0.02 mg/kg to 0.035 mg/kg, depending on the clinical response to the first 4 infusions.
62536493|NCT00823108|EXPERIMENTAL|1|Glucose-insulin-potassium
62536494|NCT00823108|NO_INTERVENTION|2|Control
62536495|NCT03269227|EXPERIMENTAL|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
62536496|NCT04186351|EXPERIMENTAL|Encounter notification service|For participants randomized to the intervention group, their encounter information stored in the eHRSS will be provided to the SCHSA via the automated notification service. Healthcare professionals of the SCHSA would access the electronic health record and provide caring support and services via telephone calls during the 12-month study period.
62536497|NCT04186351|NO_INTERVENTION|Usual care service|For participants randomized in the control group, no notification will be sent to the SCHSA. Usual care service will be provided during the 12-month study period. In addition, each control participant will receive placebo phone calls at least once every three months (e.g., the calls could be about greeting and general checking).
62536498|NCT02078765||hypertension|75 patients with hypertension and chronic kidney disease (CKD stage I-II)
62536499|NCT02078765||healthy subjects|75 healthy subjects
62536500|NCT03168581|EXPERIMENTAL|CN-105|All eligible subjects will receive study drug, CN-105
62536501|NCT05930457|EXPERIMENTAL|64Cu-FAPI-XT117 PET/CT|
62536502|NCT05739253||Transfemoral TAVR for AS|Patients undergoing transfemoral transcatheter aortic valve replacement for aortic stenosis
62536503|NCT03450174|PLACEBO_COMPARATOR|Control|this group, only placebo product will be given
62536504|NCT03450174|EXPERIMENTAL|Formative messages|this group will be received only daily formative messages on diet diversity, healthy and best nutrition practices
62536505|NCT03450174|EXPERIMENTAL|Fortified product|this group will be received only fortified product on alternate day up to 6 months
62536506|NCT03450174|EXPERIMENTAL|Fortified product plus|this group will receive fortified product along with daily messages on diet diversity and healthy nutrition practices
62536507|NCT02036775|EXPERIMENTAL|Treatment sequence 1|Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
62536508|NCT02036775|EXPERIMENTAL|Treatment sequence 2|Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
62536509|NCT02036775|EXPERIMENTAL|Treatment sequence 3|Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
62536510|NCT02036775|EXPERIMENTAL|Treatment Sequence 4|Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
62714646|NCT04994717|EXPERIMENTAL|Safety Run-in: Blinatumomab alternating with low-intensity chemotherapy|"The safety run-in will be performed prior to initiating the phase 3 randomized part of the study. This safety run-in is to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.~The safety run-in also evaluates a shorter dose step interval from (4 days instead of 7 days) and a 1-week (instead of 2-week) drug free interval between blinatumomab cycles. Blinatumomab will be infused at a lower dose for 4 days and increase to a higher dose on Day 5 of the infusion for the remainder of the infusion."
62163171|NCT04221308||single port laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
62163172|NCT04221308||Vaginal hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
62163173|NCT05500872|EXPERIMENTAL|BFR Group|Cross-education will be performed for 8 weeks with blood flow restriction in the unaffected extremity in the isokinetic system.
62163174|NCT05500872|ACTIVE_COMPARATOR|Control Group|Cross-education will be performed for 8 weeks without applying blood flow restriction in the isokinetic system.
62163175|NCT06721884|EXPERIMENTAL|artemisia annua|
62163176|NCT06721884|PLACEBO_COMPARATOR|Placebo|We have chosen dried-leaf alfalfa of equal weight and dosing to the interventional product (5 grams, 15 caps, 5/am, 5/noon, 5/pm for the 4 weeks of the intervention period plus an additional 1 week dose escalation period to match the dosing of the Artemisia product). We have chosen this as a comparator in consultation with SIBO and herbal medicine content experts as alfalfa matches the texture and color of Artemisia annua and, in the doses used, will provide no meaningful amounts of FODMAPs or antimicrobial phytochemicals. The alfalfa will be sourced from Bulk Apotherapy, LCC, and encapsulated at the same facility as the Artemisia capsules. Containers of placebo capsules will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.
62163177|NCT05959018|SHAM_COMPARATOR|Non-impregnated CVC - Arrow Three-Lumen Central Venous Catheter|Control group who receives non-impregnated CVC - Arrow Three-Lumen Central Venous Catheter
62163178|NCT05959018|EXPERIMENTAL|Antimicrobial-impregnated CVC - Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter|Group who receives antimicrobial-impregnated CVC - Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter
62163179|NCT00512473|PLACEBO_COMPARATOR|A|I.v. saline for 8 hours
62163180|NCT00512473|EXPERIMENTAL|GH|Growth hormone (0.5 mg s.c. at t = 0 hours)
62163181|NCT00512473|EXPERIMENTAL|Pegvisomant|Pegvisomant injection 30 mg 36 hours prior to the study
62536511|NCT02036775|EXPERIMENTAL|Treatment sequence 5|Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
62536512|NCT02036775|EXPERIMENTAL|Treatment Sequence 6|Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
62536513|NCT03858634|EXPERIMENTAL|KPL-716|Weekly for 8 weeks
62536514|NCT03858634|PLACEBO_COMPARATOR|Placebo|Weekly for 8 weeks
62536515|NCT00756769||1|Patients with SLE
62536516|NCT00756769||2|Related unaffected controls
62163182|NCT05959447|EXPERIMENTAL|Gemfibrozil effet on camlipixant pharmacokinetics|
62163183|NCT05959447|EXPERIMENTAL|Camlipixant effect on dabigatran etexilate pharmacokinetics|
62163184|NCT03419806|EXPERIMENTAL|Infudopa i.v.|"Infudopa i.v. in 75% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion.~From patient 6 and onwards:~Infudopa i.v. in 81% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion."
62163185|NCT03419806|EXPERIMENTAL|Infudopa s.c.|"Infudopa s.c. in the same dosage as the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion.~From patient 6 and onwards:~Infudopa s.c. in 86% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion."
62163186|NCT03419806|ACTIVE_COMPARATOR|LCIG (Duodopa)|Individually optimized dosing of LCIG (Duodopa) (delivered directly to the proximal small intestine via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to a portable infusion pump) will be delivered over a 16-h period, administered as a morning rapid constant rate administration followed by continuous infusion.
62163187|NCT06714344|EXPERIMENTAL|AMPEL group|Network physicians participating in the study are randomly assigned to the AMPEL group (access to the module).
62163188|NCT06714344|NO_INTERVENTION|non-AMPEL group|The non-AMPEL group (no access to the module) using a permuted block randomization scheme to ensure that there are the same number of patients in each study arm.
62536517|NCT00756769||3|Unrelated unaffected controls
62536518|NCT03286335|EXPERIMENTAL|Proton Radiation|"* Radiation therapy will be delivered typically five (5) days per week on weekdays~* Proton Radiation dose be determine by histology"
62536519|NCT04147923|ACTIVE_COMPARATOR|Floradapt Mature Immune Defense|A multivitamin will also be consumed.
62536520|NCT04147923|PLACEBO_COMPARATOR|Placebo|A multivitamin will also be consumed.
62714647|NCT04994717|EXPERIMENTAL|Phase 3: Blinatumomab alternating with low-intensity chemotherapy|Participants will receive blinatumomab alternating with low-intensity chemotherapy.
62714648|NCT04994717|ACTIVE_COMPARATOR|Phase 3: Standard of care (SOC) chemotherapy|Participants will receive 1 of 2 SOC chemotherapy regimens (GMALL or HyperCVAD) per investigator's choice.
62714649|NCT06396936|EXPERIMENTAL|Study Group|Calisthenic exercise program
62714650|NCT06396936|NO_INTERVENTION|Control Group|No intervention
62714651|NCT05738408|NO_INTERVENTION|Control: Usual Care|will receive standard treatment which entails referral to Vermont Quit Network. This network offers a wide range of free cessation services, including NRT and web-based modules on preparing to quit and developing a plan
62163189|NCT05959382|NO_INTERVENTION|with no magnification aid treatment|Dental caries treatment with no magnification aid
62163190|NCT05959382|ACTIVE_COMPARATOR|with x2 dental loupe|Dental caries treatment with x2 dental loupe
62163191|NCT05959382|ACTIVE_COMPARATOR|with x5 dental loupe|Dental caries treatment with x5 dental loupe
62536521|NCT03953989|EXPERIMENTAL|Patients with hypertrophic cardiomyopathy|"Thestudy is articulated into Screening visit plus other 3 visits. One visit (V2 ) for dose titration. V0 screening eligibility, consent, Medical History, physical examination, BP, ECG, Echocardiography, Biochemistry (haematology, electrolytes, glycaemia, ALS and bilirubin, creatinine and urine-analysis) V1 Baseline PET scan, physical examination, vital signs, and drug supply (500 mg bid).~V2 physical examination, safety check, biochemistry, drug compliance and up-titration (750 mg bid), drug supply.~V3 (2 months)safety check ,drug supply, drug compliance V4 (4 months, end of treatment) repeat PET scan, physical examination, BP, ECG, drug compliance, safety.~Drug of the study Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die"
62163192|NCT05959382|ACTIVE_COMPARATOR|with dental operation microscope|Dental caries treatment with dental operation microscope
62163193|NCT05776771||Low Back Pain|Subjects with Low Back Pain
62163194|NCT05776771||Neck Pain|Subjects with Neck Pain
62163195|NCT05776771||Control/Insincere|Subjects with healthy spines, who have no neck or low back pain
62163196|NCT06184321|EXPERIMENTAL|Arm I (alteplase)|Patients receive alteplase instilled into the IPC which is capped for 1-2 hours before the catheter is drained.
62163197|NCT06184321|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo instilled into the IPC which is capped for 1-2 hours before the catheter is drained. Beginning 1 week later, patients may receive alteplase as in arm I.
62163198|NCT03198481|ACTIVE_COMPARATOR|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
62163199|NCT03198481|ACTIVE_COMPARATOR|Physician Counseling Video Group|MUS video by a physician.
62163200|NCT05615753|EXPERIMENTAL|Acupuncture group|Participants will receive 2 acupuncture treatments each week for 5 weeks, for a total of 10 treatments. Each acupuncture treatment will take 30 minutes.
62163201|NCT05615753|NO_INTERVENTION|Usual care group|Participants will continue to receive their usual care.
62163202|NCT02648737|EXPERIMENTAL|Cognitive Behavioural Therapy (CBT)|Patients who will receive CBT plus clinical monitoring will receive 10 weekly individual sessions (60-75 minutes), tailored to the preferences and needs of each patient. In each session, a registered psychologist will address specified aspects of (coping with) anxiety and related concerns with a specific focus on behaviour and thoughts associated with anxiety.
62163203|NCT02648737|OTHER|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status. Patients who receive clinical monitoring only will be given the option to receive CBT once the trial is completed.
62163204|NCT01540877|EXPERIMENTAL|Capsaicin application|application of 0.6%
62163205|NCT01540877|EXPERIMENTAL|Local anesthetics application|application of EMLA
62163206|NCT01540877|EXPERIMENTAL|Combined application of 1. capsaicin 2. local anesthetics|application of 1. capsaicin 0.6% and 2. EMLA
62536522|NCT01906450|EXPERIMENTAL|Scaling and root planing plus Azithromycin|Single session of scaling and root planning. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
62536523|NCT01906450|PLACEBO_COMPARATOR|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
62536524|NCT01906450|NO_INTERVENTION|baselline screening only|Dental prophylaxis is offered
62536525|NCT04630158|PLACEBO_COMPARATOR|SAF312 Placebo|Randomized to a 1:1:1 topical eye drops, twice daily
62536526|NCT04630158|EXPERIMENTAL|SAF312 5 mg/mL|Randomized to a 1:1:1 topical eye drops, twice daily
62163207|NCT01540877|EXPERIMENTAL|Combined application of 1. local anesthetics and 2. capsaicin|application of 1. EMLA and 2. capsaicin 0.6%
62163208|NCT05862779|PLACEBO_COMPARATOR|Placebo Group|Group supplemented with maltodextrin (40g/day) and corn oil (4g/day). All groups will undergo a training program with strength exercises for 12 weeks
62163209|NCT05862779|EXPERIMENTAL|Whey Protein + Placebo|Group supplemented with isolated whey protein (40g/day) and corn oil (4g/day). All groups will undergo a training program with strength exercises for 12 weeks.
62163210|NCT05862779|EXPERIMENTAL|Omega 3 + Placebo|Group supplemented with omega-3 (4g/day) and maltodextrin (40g/day). All groups will undergo a training program with strength exercises for 12 weeks.
62163211|NCT05862779|EXPERIMENTAL|Omega 3 + Whey Protein|Group supplemented with omega-3 (4g/day) and whey protein (40g/day). All groups will undergo a training program with strength exercises for 12 weeks.
62163212|NCT05878522|EXPERIMENTAL|Treatment A|6 capsules of sisunatovir administered Q12 hours for 5 doses
62163213|NCT05878522|PLACEBO_COMPARATOR|Treatment B|6 capsules of placebo administered Q12 hours for 5 doses
62163214|NCT05878522|ACTIVE_COMPARATOR|Treatment C|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
62163215|NCT05878522|EXPERIMENTAL|Treatment D|7 capsules of sisunatovir administered Q12 hours for 5 doses
62163216|NCT06599684|EXPERIMENTAL|INV-102 0.7%|INV-102 0.7% Ophthalmic Solution given three times daily (TID) for 2 weeks followed by twice daily (BID) for the reminder of the study
62163217|NCT05582447||Disease Cohort|Age greater than one year old Direct bilirubin level of \>2 mg/dl. No known congenital red cell membrane defect
62536527|NCT04630158|EXPERIMENTAL|SAF312 15 mg/mL|Randomized to a 1:1:1 topical eye drops, twice daily
62536528|NCT06495489||Positive PLR test (PLR +)|"* Patient over 18 years old.~* Hospitalized in intensive care.~* For which the clinician in charge of the patient will need to predict the response to fluids and decide on a possible infusion of fluids, because of:~  * Acute circulatory failure with mean arterial pressure \< 65mmHg or \< 30mmHg of its baseline value for hypertensive patients.~ * And/or other signs of hemodynamic instability (tachycardia, mottling, oliguria, hyperlactatemia) :~* In mechanically ventilated patients under spontaneous mode.~* Previously equipped with an arterial catheter."
62163218|NCT05582447||Control|Age matched to disease cohort No evidence for cholestatic liver disease No known congenital red cell membrane defect
62163219|NCT01290471|EXPERIMENTAL|Part 1 Dose Escalation|Dose escalation of U3 1565 will follow a modified 3+3 study design with a starting intravenous (IV) dose of 2 mg/kg. A maximum of 2 new subjects will receive their first dose of U3-1565 per 24-hour period during the dose-escalation phase. Subsequent escalating doses of 8, 16, and 24 mg/kg are planned. Three to 6 subjects will be enrolled in 4 sequential dose level cohorts.
62163220|NCT01290471|EXPERIMENTAL|Part 2a Dose Expansion|For Part 2a, 6 or 12 subjects with advanced solid malignant tumors will be enrolled and treated at the MTD or MAD to further define the safety and tolerability of U3-1565. These additional subjects are expected to permit the detection of relatively rare toxicities that would not likely be observed during the dose escalation part of the study, whose 3+3 design implies a maximum of 6 subjects only will be treated at the MTD or MAD. Six subjects will be treated; however, if toxicities meeting the definition of DLT are observed during the first cycle of treatment, 6 more subjects will be treated for a total of 12 subjects.
62163221|NCT01290471|EXPERIMENTAL|Part 2b Dose Expansion and Anti-tumor Impact|For Part 2b, up to 30 subjects with advanced solid malignant tumors, with a preference for those with advanced ovarian cancer, will be enrolled and treated at the MTD or MAD. This number of subjects should allow demonstrating U3-1565 has anti-tumor impact by showing treatment-induced changes in pharmacodynamic biomarkers and clinical activity. Ovarian cancer may be more likely to be impacted by U3 1565 than other tumors, considering that in this cancer, high levels of HB-EGF have been associated with an unfavorable clinical outcome. Six subjects will be initially treated; at which point, a safety analysis will be conducted after these initial subjects have completed the first cycle of treatment, to allow the reevaluation of the appropriateness of the dosing level.
62163222|NCT05063162|EXPERIMENTAL|Rozanolixizumab Arm|Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints.
62163223|NCT05063162|PLACEBO_COMPARATOR|Placebo Arm|Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding.
62163224|NCT01628939||current low back pain|subjects with current low back pain (i.e. more than 30 days of low back pain in the last three months)
62163225|NCT01628939||controls|subjects with less than 30 days of low back pain in the last three months
62163226|NCT02665624|ACTIVE_COMPARATOR|Stewed apricot juice + senna group|68 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. Additional one liter of stewed apricot juice (made with dried apricot) were told to be drunken until 2 h before colonoscopy.
62163227|NCT02665624|ACTIVE_COMPARATOR|senna alone group|60 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. 1 patient was dropped out due to obstructive sigmoid colon cancer.
62163228|NCT03288480|OTHER|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
62163229|NCT04655014|EXPERIMENTAL|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
62163230|NCT02178878||Progress, Pain|Progress, Pain
62163231|NCT03785041|ACTIVE_COMPARATOR|Levobupivacaine and tramadol Preemptive|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.
62163232|NCT03785041|ACTIVE_COMPARATOR|Tramadol and levobupivacaine postoperative|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.
62163233|NCT03785041|ACTIVE_COMPARATOR|Tramadol and levobupivacaine preemptive and postoperative|20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.
62163234|NCT03785041|ACTIVE_COMPARATOR|Levobupivacaine|20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.
62714652|NCT05738408|EXPERIMENTAL|Intervention: Financial incentives and nicotine replacement therapy intervention|an intervention where patients are assigned to financial incentives and NRT of their choice; use of CO monitor to assess abstinence
62163235|NCT04515745||ILI/Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration (SSA) databases.
62536529|NCT06495489||Negative PLR test (PLR-)|"* Patient over 18 years old.~* Hospitalized in intensive care.~* For which the clinician in charge of the patient will need to predict the response to fluids and decide on a possible infusion of fluids, because of:~  * Acute circulatory failure with mean arterial pressure \< 65mmHg or \< 30mmHg of its baseline value for hypertensive patients.~ * And/or other signs of hemodynamic instability (tachycardia, mottling, oliguria, hyperlactatemia) :~* In mechanically ventilated patients under spontaneous mode.~* Previously equipped with an arterial catheter."
62536530|NCT02750748|EXPERIMENTAL|4mg Intranasal Naltrexone|Administer one 0.1 mL spray of a 40 mg/mL solution in one nostril
62163236|NCT04515745||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to SSA databases.
62163237|NCT05664711|EXPERIMENTAL|Stellate Ganglion Block|The stellate ganglion and nearby cervical sympathetic ganglia will be blocked with 10 mL 0.5 percent bupivacaine under ultrasound guidance.
62163238|NCT04441073|EXPERIMENTAL|Lignocaine|preoperative nebulization of lignocaine
62163239|NCT04441073|PLACEBO_COMPARATOR|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
62163240|NCT03756896|EXPERIMENTAL|Carfilzomib, pomalidomide, dexamethasone|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62163241|NCT00608387|EXPERIMENTAL|A|Participants will receive usual care from their healthcare providers and have access to a Web-based CVD risk-factor management program.
62163242|NCT00608387|NO_INTERVENTION|B|Participants will receive usual care from their healthcare providers.
62163243|NCT00501111|NO_INTERVENTION|1|Placebo
62163244|NCT00501111|ACTIVE_COMPARATOR|2|donepezil
62163245|NCT00501111|EXPERIMENTAL|3|AZD3480
62163246|NCT06147440|EXPERIMENTAL|Dietary pattern 1|Participants receive a standardized diet following the recommendation of DACH nutrition societies.
62163247|NCT06147440|EXPERIMENTAL|Dietary pattern 2|Participants receive a standardized diet following the recommendation of DACH nutrition societies.
62163248|NCT00037934|EXPERIMENTAL|1|Robot exercise group
62163249|NCT00037934|ACTIVE_COMPARATOR|2|Traditional exercise group
62163250|NCT03423537|EXPERIMENTAL|Group 1 [HCG (+) group]|"Group 1 will indicate the application of the protocol by adding hCG with the initiation of standard GnRH agonist protocol for IVF / ICSI with rFSH"
62163251|NCT03423537|PLACEBO_COMPARATOR|Group 2 [placebo]|"Group 2 will indicate the application of the standard GnRH agonist protocol without the addition of hCG, but placebo, instead"
62163252|NCT06448845|ACTIVE_COMPARATOR|Group A (Arm IVRA) 70 patients|After placement of the upper arm and forearm tourniquets and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the arm tourniquet cuff is inflated to a pressure of 250 mmHg. The double arm cuff pneumatic pressure tourniquet is placed immediately above the elbow crease and on the top of a circumferentially placed cotton cast padding before inflation.
62163253|NCT06448845|ACTIVE_COMPARATOR|Group F (Forearm IVRA) 70 patients|After placement of the forearm double tourniquet and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the forearm tourniquet cuff is inflated to a pressure of 250 mmHg. The forearm tourniquet will be placed 5 cm distal to the medial epicondyle of the humerus and on the top of a circumferentially placed cotton cast.
62163254|NCT04891536|EXPERIMENTAL|Patients with histologically confirmed recurrent prostate cancer after primary radiation therapy|
62163255|NCT03722732|ACTIVE_COMPARATOR|Open pancreaticoduedenectomy|will include all the patients who will undergo open pancreaticoduodenectomy
62163256|NCT03722732|ACTIVE_COMPARATOR|Laparoscopic pancreaticoduodenectomy|will include all the patients undergoing laparoscopic pancreaticoduodenectomy
62163257|NCT06416969|EXPERIMENTAL|Obesity Group|Subjects that have upper body obesity will receive somatostatin plus epinephrine
62163258|NCT06416969|EXPERIMENTAL|Lean Group|Subject wo are normal weight will receive somatostatin plus epinephrine
62163259|NCT01023022||Medtronic CareLink® Network|"Patients with implanted Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices, who will be monitored by the Medtronic CareLink® System.~The System consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website."
62163260|NCT00574106|OTHER|1|Infrared Radiation
62163261|NCT02910323||Experimental group|Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.
62163262|NCT02910323||Family/Healthy Controls|Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.
62163263|NCT02607293||Subjects undergoing ART treatment with long GnRH-a or GnRH-ant|Subjects undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol + Gn + human chorionic gonadotropin (hCG) as per routine clinical practice. No visits or intervention(s) additional to the routine practice of the Investigators will be performed during this observational study.
62536531|NCT02750748|EXPERIMENTAL|4mg Intranasal Naltrexone with Intravail|Administer 0.1 mL spray of a 40 mg/mL solution with 0.25% Intravail in one nostril
62536532|NCT02750748|EXPERIMENTAL|2mg Intramuscular Naltrexone|Administer 2 mg formulation intramuscularly
62163264|NCT01642888|EXPERIMENTAL|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
62163265|NCT01642888|ACTIVE_COMPARATOR|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
62163266|NCT04538482|EXPERIMENTAL|DASH Diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber)
62163267|NCT04538482|ACTIVE_COMPARATOR|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber)
62163268|NCT02215447|EXPERIMENTAL|NAB-Paclitaxel with carboplatin|NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle. Carboplatin (AUC=5 IVI) (d1) in three weekly cycle. Study treatment will continue until progressive disease, unacceptable toxicity, or ceased by patient or clinician preference.
62163269|NCT05788536|EXPERIMENTAL|DB-OTO - Dose Escalation|Unilateral intracochlear dosing
62163270|NCT05788536|EXPERIMENTAL|DB-OTO - Dose Expansion|Bilateral intracochlear dosing using the dose selected based on safety and efficacy data from the Dose Escalation phase (Part A).
62163271|NCT01863888|EXPERIMENTAL|teriflunomide (HMR1726)|Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.
62163272|NCT01863888|NO_INTERVENTION|Reference population|Untreated healthy subjects
62163273|NCT02961816|EXPERIMENTAL|Cohort A: Diffuse Large B-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
62536533|NCT02750748|EXPERIMENTAL|50mg Naltrexone|Administer 50mg formulation orally
62536534|NCT06388967||Patients with Pancreatic Cancer Ductal Adenocarcinoma (Training)|Individuals diagnosed with pancreatic ductal adenocarcinoma
62714653|NCT03481348|EXPERIMENTAL|Pharyngeal Electrical Stimulation|PES for 10 minutes per day on 3 consecutive days in addition to standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
62163274|NCT02961816|EXPERIMENTAL|Cohort B: Hodgkin's Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
62163275|NCT02961816|EXPERIMENTAL|Cohort C: T-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
62163276|NCT03649659|EXPERIMENTAL|Silver Diamine Fluoride (SDF)|SDF will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
62163277|NCT03649659|PLACEBO_COMPARATOR|Placebo|The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
62163278|NCT03502525|EXPERIMENTAL|Break the Cycle Intervention|All study participants are assigned to this experimental arm.
62163279|NCT03036722|EXPERIMENTAL|Flaxseed porridge group|22 volunteer will be given 80g of a pre prepared porridge meal containing 40 g of ground (flaxseed) to consume daily.
62163280|NCT03036722|PLACEBO_COMPARATOR|Placebo control porridge group|22 volunteer will be given 78.5g preprepared control porridge matched for energy and fat content to consume daily ( Matching food products: 22g MCT (medium chain Triglyceride), 5.5g pure egg white powder, 11g cream of rice).
62163281|NCT05274906|EXPERIMENTAL|Controlled HEI-2015-M diet, followed by controlled HEI-2015 diet.|Participants first complete a 21-day controlled HEI-2015 diet with red and processed meat (HEI-2015-M). After a washout period of 1 week or longer, participants then complete the same 21-day controlled HEI-2015 diet without red and processed meat (HEI-2015)
62163282|NCT05274906|EXPERIMENTAL|Controlled HEI-2015 diet, followed by controlled HEI-2015-M diet.|Participants first complete a 21-day controlled HEI-2015 diet without red and processed meat (HEI-2015). After a washout period of 1 week or longer, participants then complete the same 21-day controlled HEI-2015 diet with red and processed meat (HEI-2015-M).
62163283|NCT03741309|ACTIVE_COMPARATOR|Group I|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
62163284|NCT03741309|SHAM_COMPARATOR|Group II|dentifrice containing Calcium sodium phosphosilicate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
62163285|NCT03741309|PLACEBO_COMPARATOR|Group III|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks.
62163286|NCT02919865|OTHER|MRI perfusion imaging|Patients who have received chemoradiation for high grade gliomas and who subsequently developed progressive enhancing lesions on follow-up MR will be asked to participate in this study.
62163287|NCT01770509|ACTIVE_COMPARATOR|Standard of care|Standard of care: Dressings +Compression garments
62163288|NCT01770509|EXPERIMENTAL|Application of NMBM|Daily application of NMBM
62163289|NCT04228705||The elders|Patients aged over 59 years old
62163290|NCT04228705||The young adults|Patients aged from 18 to 59 years old
62163291|NCT06286956|EXPERIMENTAL|Treated with UNI-VEC|
62163292|NCT03750500|EXPERIMENTAL|Experimental|Participants included in this arm will benefit from a 12-week exercise program using the novel biofeedback rehabilitation device, under remote monitoring from a physical therapist
62163293|NCT03750500|PLACEBO_COMPARATOR|Standard of Care|Patients included in this arm will benefit from the standard of care currently in place in the Primary Care facility: education on risk factors for falls, medication review, visual and auditory acuity screening.
62163294|NCT05692232|EXPERIMENTAL|Group 1|Thirty participants randomly allocated to group 1. All the participants received a pressure biofeedback guided deep cervical flexor muscle strength training along wth conventional intervention.
62163295|NCT05692232|ACTIVE_COMPARATOR|Group 2|Thirty participants randomly allocated to group 2. All the participants received a manual therapy along wth conventional intervention.
62163296|NCT02560142||All Participants|Healthy participants will undergo behavioral assessment and fMRI.
62163297|NCT01029418|EXPERIMENTAL|AZD6244 and sorafenib|AZD6244+ sorafenib
62163298|NCT02538055|PLACEBO_COMPARATOR|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
62163299|NCT02538055|EXPERIMENTAL|Living Healthy Program|Participants in this arm worked with a Community Health Worker (CHW) who provided the Living Healthy Program. The Living Healthy Program was a cognitive-behavioral therapy based lifestyle modification program. Participants and CHW interacted by telephone 8 times over 3 months.
62163300|NCT05621720|EXPERIMENTAL|Intervention group|Subjects in the intervention group will receive a 3-moth community-based health-social partnership program (C-HSPP) led by a nurse case manager, and supported by social workers and community workers.
62163301|NCT05621720|OTHER|Control group|Subjects in the control group will receive usual community services and a monthly social control call from trained community workers.
62163302|NCT05361304|EXPERIMENTAL|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized into the TEST Lens for the duration of the study.
62163303|NCT05361304|EXPERIMENTAL|CONTROL Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized into the CONTROL Lens for the duration of the study.
62163304|NCT03109600|EXPERIMENTAL|Vi-DT (Bio Farma)|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
62163305|NCT03109600|ACTIVE_COMPARATOR|Vi polysaccharide vaccine|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine
62163306|NCT03109600|EXPERIMENTAL|Vi-DT (Bio Farma) ~ Children|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
62163307|NCT03109600|ACTIVE_COMPARATOR|Vi polysaccharide vaccine ~ Children|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine
62163308|NCT00946010||1|Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan
62163309|NCT06329661|ACTIVE_COMPARATOR|Cyclosporine ophthalmic solution, 0.1% (VEVYE)|Cyclosporine ophthalmic solution, 0.1%; 12 months
62163310|NCT06329661|PLACEBO_COMPARATOR|Saline solution, 0.6%|Saline solution, 0.6%; 12 months
62163311|NCT06387797|ACTIVE_COMPARATOR|Cooking Matters for Adults (CMA)|"Arm 1) CMA: 6 didactic sessions delivered once per week for 6 weeks at the UNLV Nutrition Center (in person) Baseline and post-test assessments and 6 cooking classes.~* Lesson 1: Let's Get Cooking!~* Lesson 2: Choosing Fruits, Vegetables and Whole Grains~* Lesson 3: Healthy Starts at Home~* Lesson 4: The Power of Planning~* Lesson 5: Shopping Smart~* Lesson 6: Recipes for Success"
62163312|NCT06387797|EXPERIMENTAL|Cooking Matters for Adults (CMA+)|Baseline and Post-test assessments and The CMA curriculum + Enhanced cooking classes with added components comprising cooking practices specific to diabetes prevention, online information as well as short assignments and activities regarding sleep, stress, physical activity, and sedentary behaviors. The CMA+ arm will also have the opportunity to use a continuous glucose monitor (CGM) for 10 days immediately following the baseline assessment visit. This will be an optional component and participants will not be excluded if they do not wish to use the CGM.
62163313|NCT06628167|EXPERIMENTAL|West Philadelphia|Eligible patient population lives in West Philadelphia
62163314|NCT06628167|NO_INTERVENTION|Southwest Philadelphia|Eligible patient population lives in Southwest Philadelphia
62163315|NCT06164119|EXPERIMENTAL|A1: manual treatment with osteopathic techniques and nutritional treatment in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet).
62163316|NCT06164119|EXPERIMENTAL|A2: manual treatment with osteopathic techniques in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques).
62163317|NCT06164119|EXPERIMENTAL|A3: nutritional treatment in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with nutritional treatment (personalized Mediterranean Diet).
62163318|NCT06164119|NO_INTERVENTION|A4: control group in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues receive general counselling on healthy dietary habits and lifestyle in accordance to the World Cancer Research Fund (WCRF) guidelines.
62163319|NCT06164119|EXPERIMENTAL|B1: osteopathic techniques and nutritional treatment in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors are treated with manual treatment (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet).
62163320|NCT06164119|EXPERIMENTAL|B2: manual treatment with osteopathic techniques in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques).
62163321|NCT06164119|EXPERIMENTAL|B3: nutritional treatment in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors are treated with nutritional treatment (personalized Mediterranean Diet).
62163322|NCT06164119|NO_INTERVENTION|B4: control group in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors receive general counselling on healthy dietary habits and lifestyle in accordance to the World Cancer Research Fund (WCRF) guidelines.
62163323|NCT03111849||hospitalized chronic obstructive patients|
62163324|NCT02674295|EXPERIMENTAL|Cohort 1|50 milligram (mg) of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration.
62163325|NCT02674295|EXPERIMENTAL|Cohort 2|20 mg of intravenous esketamine in 30 milliliter (mL), fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
62163326|NCT06190145|EXPERIMENTAL|Teriflunomide|Oral Teriflunomide is given at a dose of 7 mg once daily with dose adjustments for 24 weeks. Treatment was discontinued if a dose-limiting toxic effect occurred, rescue medication was used, or concomitant medication for immune thrombocytopenia was changed beyond the 10% level as defined above.
62163327|NCT05097183||Control|Transcatheter aortic valve replacement (TAVR) with standard procedure
62163328|NCT05097183||ACA|Transcatheter aortic valve replacement (TAVR) with Accurate Commissural Alignment (ACA) technique
62163329|NCT05067556|EXPERIMENTAL|Intervention|Acceptance and Commitment Therapy for Chronic Pain (ACT-CP)
62163330|NCT04549948|EXPERIMENTAL|0.017X0.025 Stainless Steel Archwire|Leveling of COS using 0.017X0.025 Stainless Steel (SS) Archwire A reverse COS using 0.017X0.025 SS was used to correct the excessive COS in the lower arch.
62163331|NCT04549948|EXPERIMENTAL|0.019X0.025 Stainless Steel Archwire|A reverse COS using 0.019X0.025 SS was used to correct the excessive COS in the lower arch.
62536535|NCT06388967||Individuals without Pancreatic Cancer Ductal Adenocarcinoma (Training)|Individuals without pancreatic ductal adenocarcinoma
62536536|NCT06388967||Patients with Pancreatic Cancer Ductal Adenocarcinoma (Validation)|Individuals diagnosed with pancreatic ductal adenocarcinoma
62536537|NCT06388967||Individuals without Pancreatic Cancer Ductal Adenocarcinoma (Validation)|Individuals without pancreatic ductal adenocarcinoma
62714654|NCT03481348|NO_INTERVENTION|Control|Standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
62714655|NCT05175846||Normal volunteers|Participants with negative COVID-19 test
62714656|NCT05175846||COVID-19|Participants with positive COVID-19 test and severe symptoms of disease
62714657|NCT01306292|EXPERIMENTAL|SonoVue|Ultrasound contrast agent under development
62714658|NCT01306292|PLACEBO_COMPARATOR|Placebo|normal saline 0.9% for injection used as the comparator
62163332|NCT04549948|EXPERIMENTAL|0.021X0.025 TMA archwire|A reverse COS using 0.021X0.025 TMA archwire was used to correct the excessive COS in the lower arch.
62163333|NCT02713217||Pre-Implementation Cohort|Eligible patients will be recruited and enrolled prior to implementation of the blended integrated care model in each study site. They will be exposed to care as usual in the CBOCs.
62163334|NCT02713217||Post-Implementation Cohort|"Eligible patients will be recruited and enrolled following implementation of the blended integrated care model in each study site. These participants are thus exposed to the intervention model."
62163335|NCT00942799|EXPERIMENTAL|Study Drug: Genz-644282 (28-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
62163336|NCT00942799|EXPERIMENTAL|Study Drug: Genz-644282 (21-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
62536538|NCT03398070||Motor Functional Neurological Disorder.|"The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.~Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.~The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:~1. Delivery of a positive rule-in diagnosis of functional neurological disorder~2. Individuals are provided with educational materials on functional neurological disorders~3. Referred to physical therapy and/or occupational therapy as clinically indicated~4. FND related cognitive behavioral therapy (CBT) referral when appropriate~5. Psychotropic medication management based on standard psychiatric care"
62536539|NCT00850434|EXPERIMENTAL|modified autoset|the modified AutoSet responds to different breathing patterns than the standard AutoSet, to treat OSA. Participants in this arm will trial the modified AutoSet for one night, and the standard AutoSet for one night, in a randomised order
62163337|NCT03391778|EXPERIMENTAL|Participants receiving ADP adoptive cell therapy|
62163338|NCT01516710|ACTIVE_COMPARATOR|Open liver resection|Patients will be operated with open liver resection
62536540|NCT00850434|ACTIVE_COMPARATOR|standard AutoSet|The standard autoset treat OSA by using pressure increases to overcome abnormal breathing patterns. Patients in this arm will use the standard AutoSet for one night and the modified AutoSet for one night, in a randomised order
62163339|NCT01516710|ACTIVE_COMPARATOR|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
62163340|NCT00755716|PLACEBO_COMPARATOR|Placebo (sugar pill)|Person receives an inactive placebo
62163341|NCT00755716|ACTIVE_COMPARATOR|Topiramate|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day for a total time of 10 weeks.
62163342|NCT00755716|ACTIVE_COMPARATOR|Topiramate and Nicotine patch|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day and one week taper for a total time of 10 weeks. On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
62163343|NCT00995618|EXPERIMENTAL|Tranilast|Tranilast tablets
62163344|NCT00995618|ACTIVE_COMPARATOR|Febuxostat|Febuxostat tablets
62163345|NCT00995618|EXPERIMENTAL|Combination|Tranilast plus febuxostat
62163346|NCT01110551|EXPERIMENTAL|Group 2: low dose ; ID|D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, D4: 2 x 10\^5 or placebo intradermally on Days 0 and 90.
62163347|NCT01110551|EXPERIMENTAL|Group 1: low dose; SC|D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, D4: 2 x 10\^5 or placebo subcutaneously on Days 0 and 90.
62163348|NCT01110551|EXPERIMENTAL|Group 4: high dose; ID|D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, D4: 3 x 10\^5 or placebo intradermally on Days 0 and 90.
62163349|NCT01110551|EXPERIMENTAL|Group 3: high dose; SC|D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, D4: 3 x 10\^5 or placebo subcutaneously on Days 0 and 90.
62163350|NCT02419664|EXPERIMENTAL|Ga-68 DOTATOC PET in pituitary adenomas|"To give Ga-68 DOTATOC in pituitary patients doing PET/CT~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease."
62536541|NCT05875792|EXPERIMENTAL|Intervention|people who have recently had a stroke and need upper limb rehabilitation
62536542|NCT01517373|PLACEBO_COMPARATOR|Placebo|Placebo to match PF-04937319 and glimepiride
62536543|NCT01517373|EXPERIMENTAL|PF-04937319 10 mg|
62163351|NCT05789407|EXPERIMENTAL|endometriosis|Women subjected to elective laparoscopy for pelvic endometriosis
62536544|NCT01517373|EXPERIMENTAL|PF-04937319 50 mg|
62536545|NCT01517373|EXPERIMENTAL|PF-04937319 100 mg|
62536546|NCT01517373|ACTIVE_COMPARATOR|Glimepiride|
62536547|NCT01451086|EXPERIMENTAL|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
62536548|NCT01451086|ACTIVE_COMPARATOR|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
62536549|NCT06262802|EXPERIMENTAL|Intervention|
62163352|NCT05789407|ACTIVE_COMPARATOR|idiopathic infertility|Women subjected to elective laparoscopy for idiopathic infertility
62163353|NCT03903185|ACTIVE_COMPARATOR|HCV-infected patients with hematological malignancy|HCV-infected patients with hematological malignancy on maintenance chemotherapy
62163354|NCT03903185|ACTIVE_COMPARATOR|Control HCV-infected patients|Control HCV-infected patients without haematological malignancy or co-morbidities.
62163355|NCT06143878|EXPERIMENTAL|JNJ-77242113|Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
62163356|NCT06143878|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
62163357|NCT06143878|ACTIVE_COMPARATOR|Deucravacitinib|Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
62163358|NCT05487131|EXPERIMENTAL|Men|Individuals will participate in 1 familiarization and 3 test sessions
62536550|NCT06262802|ACTIVE_COMPARATOR|Control|
62536551|NCT06312657|EXPERIMENTAL|Money-vs-money task|
62536552|NCT06312657|EXPERIMENTAL|Drug-vs-money task|
62536553|NCT00507130|EXPERIMENTAL|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
62536554|NCT00507130|EXPERIMENTAL|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
62536555|NCT00507130|EXPERIMENTAL|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
62536556|NCT00507130|PLACEBO_COMPARATOR|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
62536557|NCT02041065|EXPERIMENTAL|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
62536558|NCT02041065|ACTIVE_COMPARATOR|CUSA induced dissection|CUSA transection of the liver. Ultrasound based destruction of the liver parenchyma to allow separate ligation of the bile duct and intrahepatic vessels.
62536559|NCT03781284|EXPERIMENTAL|PET/MRI with bowel purgation|
62163359|NCT05487131|EXPERIMENTAL|Women|Individuals will participate in 1 familiarization and 3 test sessions
62536560|NCT03781284|EXPERIMENTAL|PET/MRI without bowel purgation|
62536561|NCT05214105||Patients with sickle cell anemia|Prospective longitudinal study of patients with sickle cell anemia
62536562|NCT06633146|EXPERIMENTAL|Nature intervention group|Participants take part in therapeutic individual and group sessions organised in nearby nature by the research worker.
62536563|NCT06633146|NO_INTERVENTION|Control group|Participants do not participate in organised sessions but are encouraged to maintain physical activity and social life.
62536564|NCT04514068|EXPERIMENTAL|Unilateral electroacupuncture of p6 acupoint|
62536565|NCT04514068|EXPERIMENTAL|Bilateral electroacupuncture of p6 acupoint|
62536566|NCT04514068|SHAM_COMPARATOR|Sham acupuncture of p6 acupoint|
62536567|NCT00700830||A|
62536568|NCT04602715|EXPERIMENTAL|MET-2 20 g|Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
62536569|NCT04602715|PLACEBO_COMPARATOR|Placebo|Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
62536570|NCT04100863||Individuals with Autism|Individuals who have been diagnosed with autism
62163360|NCT02338778|ACTIVE_COMPARATOR|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
62163361|NCT02338778|EXPERIMENTAL|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
62536571|NCT05851625|PLACEBO_COMPARATOR|Placebo|The control group was given a placebo press needle acupuncture (using plaster) with standard medical therapy for CINV prevention.
62536572|NCT05851625|EXPERIMENTAL|Acupuncture|The intervention group was given press needle acupuncture with standard medical therapy for CINV prevention.
62536573|NCT03232632|EXPERIMENTAL|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
62536574|NCT02656511|EXPERIMENTAL|Dolutegravir+Emtricitabine/Tenofovir|Dolutegravir 50 mg PO daily plus Emtricitabine 200 mg/Tenofovir alafenamide 25 mg
62536575|NCT03265418|EXPERIMENTAL|BioXmark liquid fiducial markers|Placement of 4 BioXmark liquid fiducial markers, standard treatment (chemo-radiotherapy followed by surgery or wait-and-see) with extra imaging to evaluate the behaviour of the markers before, during and after the radiotherapy
62536576|NCT01963286|OTHER|Enhanced SVT discriminators|Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)
62536577|NCT00773630|ACTIVE_COMPARATOR|A|Intake of Pletal 100 mg tablets dose together with 200 ml water
62536578|NCT00773630|EXPERIMENTAL|B|Intake of Pletal 100 mg ODT dose without water
62536579|NCT00773630|EXPERIMENTAL|C|Intake of Pletal 100 mg ODT dose together with 200 ml water
62536580|NCT00773630|ACTIVE_COMPARATOR|D|Intake of Pletal 100 mg ODT dose without water
62536581|NCT03639454|EXPERIMENTAL|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62536582|NCT03639454|ACTIVE_COMPARATOR|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
62536583|NCT02377050|ACTIVE_COMPARATOR|Higher Volume Feeding Goal|Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
62536584|NCT02377050|NO_INTERVENTION|Usual Volume Feeding Goal|Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.
62536585|NCT00144781|ACTIVE_COMPARATOR|1|0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.
62536586|NCT00144781|ACTIVE_COMPARATOR|2|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.
62536587|NCT00144781|ACTIVE_COMPARATOR|3|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
62536588|NCT00144781|ACTIVE_COMPARATOR|4|1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
62536589|NCT05505175||Breast Cancer Patients|Eligible patients including patients with a potential follow-up period of 6 months following the index date
62536590|NCT04587063|ACTIVE_COMPARATOR|Standard Email|"The standard of care email is the same as one used in prior outreach efforts at the health system, emphasizing reduced cost for medications and convenience."
62163362|NCT04893993|OTHER|Thiamine-Placebo|"12 weeks: 4 weeks with Thiamine, 4 weeks wash-out, 4 weeks placebo~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
62536591|NCT04587063|EXPERIMENTAL|Email with Healthcare Cost Savings|The email emphasizes future reductions in healthcare costs due to increased adherence with mail-order pharmacy, in addition to mentioning reduced prices for medications. It also uses fear appeals by stating the risk of hospital stays and how mail-order pharmacy could be an easily-achievable way to avoid this negative consequence.
62536592|NCT04587063|EXPERIMENTAL|Email with Endorsement|The email is a letter from a doctor at the health system's health plan--who may been seen as a trusted source of information--encouraging the benefits of using a mail-order pharmacy.
62536593|NCT04587063|EXPERIMENTAL|Email with Comparison Table|The email includes a table comparing the benefits and drawbacks of mail-order and chain pharmacies, which appeals to their sense of agency and allows them to make the choice that best suits them.
62536594|NCT04587063|NO_INTERVENTION|No Contact|Members do not receive an email.
62536595|NCT04549103|EXPERIMENTAL|Intervention Group|Intervention group will receive the 16-week Baduanjin exercise intervention.
62536596|NCT04549103|NO_INTERVENTION|Control Group|Control group will not receive the exercise intervention, but they will attend four education classes about managing their health status.
62536597|NCT02074917|EXPERIMENTAL|AM anatomical ACL reconstruction|Femoral and tibial tunnels performed in anteromedial footprint of ACL reconstruction
62536598|NCT02074917|EXPERIMENTAL|CENTRAL anatomical ACL reconstruction|Femoral and tibial tunnels performed in the center of ACL footprint
62536599|NCT05413616|NO_INTERVENTION|Standard care|
62536600|NCT05413616|EXPERIMENTAL|FITFOOD lifestyle intervention|Lifestyle intervention consisting of both a nutritional and exercise intervention.
62536601|NCT01094886|EXPERIMENTAL|001|Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
62536602|NCT03666650|OTHER|Rotem|
62536603|NCT06102083|EXPERIMENTAL|Experimental group 1|TDI01 dose A, once daily
62536604|NCT06102083|EXPERIMENTAL|Experimental group 2|TDI01 dose B, once daily
62536605|NCT06102083|PLACEBO_COMPARATOR|Control group|Placebo, once daily
62536606|NCT04800549|EXPERIMENTAL|METHOD|The power of the test in the study was calculated by using G\*Power 3.1 program. While Type I error is 0.05 and the power of the test is 0.80 (α= 0.05, 1-β= 0.80), minimal sample size was calculated as 62 children (31 children in each group). By considering the losses that may occur from the sample during the study due to any reason, it was planned to include 40 children in both experimental and control groups. Follow-up lost occurred in 5 patients from experimental group and 6 patients in the control group during the study. The study was completed with 69 paediatric patients including 34 in the experimental group and 35 in the control group.
62536607|NCT06035809|EXPERIMENTAL|Active SMART|Participants in the active SMART condition will complete 8 individual, 1-hour, weekly sessions of SMART with a therapist, as well as pre-treatment, post-treatment and 3-month follow-up assessments.
62536608|NCT06035809|NO_INTERVENTION|Wait List|Participants in the Wait List condition will receive no treatment for approximately 8 weeks, and they will be asked to complete pre-wait list, post-wait list and 3-month follow-up assessments. After all assessments have been completed, this group will be offered the same 8 individual, 1-hour, weekly sessions of SMART (no further assessments needed).
62536609|NCT01624792|EXPERIMENTAL|Healthy older adults|Healthy controls will receive each intervention (olive oil or fish oil with 3.5 g EPA+DHA) one time and for only one day per intervention .
62536610|NCT01624792|EXPERIMENTAL|COPD patients|COPD patients will receive one out of three possible interventions (olive oil or fish oil with 3.5 g EPA+DHA or fish oil and placebo with 2 g EPA+DHA) for 4 (+/- 7 days) weeks.
62714659|NCT05644002|SHAM_COMPARATOR|Control|In this condition, participants are instructed to smoke as usual while attending to control stimuli presented to them on a computer monitor.
62714660|NCT05644002|EXPERIMENTAL|Puff Topography Biofeedback Training (PTBT)|In this condition, participants are provided instructions on how to puff their cigarette via a computer-assisted paradigm.
62536611|NCT00800007|ACTIVE_COMPARATOR|ANZ-521|
62536612|NCT00800007|PLACEBO_COMPARATOR|Placebo|
62536613|NCT06505447|NO_INTERVENTION|Phase 1: standard of care|10 children will be enrolled in the first phase related to determining if using actigraphy and timed saliva melatonin samples can be a feasible way to measure the sleep and circadian rhythm of critically ill children aged 3 to 6 years old while they receive routine critical care.
62536614|NCT06505447|EXPERIMENTAL|Phase 2: Daytime light exposure|10 children will undergo the same sleep monitoring and salivary melatonin sampling as phase 1 while receiving timed exposure to a light box of 10,000 lux within 3 feet of their hospital bed for PICU days #2, 3 and 4.
62714661|NCT06544408|ACTIVE_COMPARATOR|Arm 1: active left dl-PFC accel-TMS|Acute Phase: Eligible participants will be randomized into one of the three treatment groups: active left dl-PFC accel-TMS vs. active dm-PFC accel-TMS vs. sham dl-PFC/dm-PFC accel TMS
62714662|NCT06544408|ACTIVE_COMPARATOR|Arm 2:active dm-PFC accel-TMS|Acute Phase: Eligible participants will be randomized into one of the three treatment groups: active left dl-PFC accel-TMS vs. active dm-PFC accel-TMS vs. sham dl-PFC/dm-PFC accel TMS
62714663|NCT06544408|SHAM_COMPARATOR|Arm 3 - sham accel-TMS dl-PFC|Acute Phase: Eligible participants will be randomized into one of the three treatment groups: active left dl-PFC accel-TMS vs. active dm-PFC accel-TMS vs. sham dl-PFC/dm-PFC accel TMS
62714664|NCT06544408|SHAM_COMPARATOR|Arm 4: sham accel -TMS dm-PFC|Acute Phase: Eligible participants will be randomized into one of the three treatment groups: active left dl-PFC accel-TMS vs. active dm-PFC accel-TMS vs. sham dl-PFC/dm-PFC accel TMS
62714665|NCT06544408|ACTIVE_COMPARATOR|Arm 5|Extension phase, all participants will receive active left dl-PFC accel-TMS.
62163363|NCT04893993|OTHER|Placebo-Thiamine|"12 weeks: 4 weeks placebo, 4 weeks wash-out, 4 weeks with Thiamine~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
62163364|NCT05075005|ACTIVE_COMPARATOR|Treatment Cohort|Treatment Cohort: Will utilize a minimalist shoe (Vibram® Fivefingers) and follow the training protocol described below for training on natural terrain.
62163365|NCT05075005|EXPERIMENTAL|Control Cohort|Control Cohort: Will utilize the same minimalist shoe and follow the same training schedule as the treatment group, with the modification of training on hardscapes.
62163366|NCT05319444|EXPERIMENTAL|Healthy Scalp and one treatment|Participants with healthy scalps who will receive one treatment with the device and complete one in-person follow-up.
62536615|NCT06505447|EXPERIMENTAL|Phase 3: Daytime restricted feeding|10 children will undergo the same sleep monitoring and salivary melatonin sampling as phase 1 while attempting to limit all nutrition (parental or enteral) to being provided during the normal hours that the child is awake at home on PICU days #2, 3, 4.
62536616|NCT04759053|ACTIVE_COMPARATOR|FNB|
62536617|NCT04759053|ACTIVE_COMPARATOR|Core biopsy|
62536618|NCT01955837|EXPERIMENTAL|TAS-102|
62536619|NCT01955837|PLACEBO_COMPARATOR|Placebo|
62536620|NCT06292585|EXPERIMENTAL|Intervention group|MMA embolization
62536621|NCT06292585|ACTIVE_COMPARATOR|Control group|Conservative treatment
62536622|NCT05160272|EXPERIMENTAL|AP-325 Treatment|AP-325, film-coated tablet, 50mg once daily
62536623|NCT05160272|PLACEBO_COMPARATOR|Placebo Treatment|Placebo matching AP-325 film-coated tablet, once daily
62536624|NCT00049530|EXPERIMENTAL|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
62536625|NCT06110624||Arm 1|A targeted sample of healthcare providers (HCPs) who are not specialized in palliative care (GHCPs) constitutes the study population.
62536626|NCT06367608|EXPERIMENTAL|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain called globus pallidus internus(GPi). Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
62536627|NCT05980663|EXPERIMENTAL|Active group|Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management.
62536628|NCT05980663|ACTIVE_COMPARATOR|Active control|Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).
62536629|NCT05980663|NO_INTERVENTION|Control group|Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.
62536630|NCT00401986||Alair Treatment|Alair Treated subjects from PREDECESSOR STUDY (NCT00214539).
62536631|NCT02917070||Patients|Patients who have chronic kidney diseases
62536632|NCT02917070||Healthy controls|Healthy subjects
62536633|NCT00810316|OTHER|Treatment A|
62536634|NCT00810316|OTHER|Treatment B|
62536635|NCT00810316|OTHER|Treatment C|
62536636|NCT02699060|EXPERIMENTAL|NERD patients|Patients have typical reflux syndrome without esophageal injury.
62536637|NCT02699060|EXPERIMENTAL|EE patients|Patients have erosion(s) or ulcer(s) in esophagus.
62536638|NCT02699060|EXPERIMENTAL|BE patients|Patients have esophageal specialized intestinal metaplasia.
62536639|NCT05357118|EXPERIMENTAL|One arm|The study is an one-arm pre- and post-design.
62536640|NCT05600465|EXPERIMENTAL|BA+OT intervention|Following baseline assessment, the PI, a BA-trained, licensed occupational therapist will deliver a 10-session manualized program in the participants' homes to ensure optimal uptake of the active ingredients and integration into daily life routines. This intervention occurs over 10 weeks. The intervention manual will include educational materials for the 4-step approach, and worksheets for goal setting and developing daily routines. In the 1st BA-OT session, the PI will collect baseline assessments and use Canadian Occupational Performance Measure (COPM) data to facilitate goal setting. The top 5 participant-selected goals chosen will be the subject of the 4-step process in sessions 2 - 10. At least one goal must be related to improving physical activity routines; each participant will receive a Fitbit Charge 5 to self-monitor fitness progress. The unbiased evaluator will carry out follow-up assessments at 10 weeks and 22 weeks with participants in both conditions.
62536641|NCT05600465|PLACEBO_COMPARATOR|Enhanced Usual Care|The enhanced usual care control group will receive the same assessment battery, a Fitbit Charge 5 with 1 hour training, and a handout about living with chronic conditions.
62536642|NCT06548308|EXPERIMENTAL|Corneal Incision|
62536643|NCT06548308|ACTIVE_COMPARATOR|Toric Intraocular|
62536644|NCT03268707|OTHER|Conventional follow up|Conventional follow up at physician practice
62536645|NCT03268707|EXPERIMENTAL|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
62714666|NCT01695941|EXPERIMENTAL|Treatment (alisertib, bortezomib, and rituximab)|"Patients receive alisertib PO BID on days 1-7; bortezomib SC on days 1, 8, and 15; and rituximab IV on day 1. Treatment repeats every 28 days\* in the absence of disease progression or unacceptable toxicity.~Note: \*After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity."
62714775|NCT03220022|EXPERIMENTAL|Treatment (R-da-EPOCH)|Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.
62536646|NCT04780282|EXPERIMENTAL|Scapular Stabilization Group|In the study, Adalar Water Sports Club (AWSK) takes places with its A team players; 15 players aged from 16-25 as the scapular stabilization group. The players in the scapular stabilization group will be applied scapular stabilization exercises for 8 weeks, 3 days a week in company with a physiotherapist. As stabilization exercises for the players; 1)Squatting while sliding a towel on the wall, 2)Wall push-ups with one leg extension, 3)Cross squat, 4)Pulling elastic band while squatting on one leg, 5)Double-leg squatting
62536647|NCT04780282|NO_INTERVENTION|Control group|No Intevention
62536648|NCT06506214||Study group|
62536649|NCT04708574|EXPERIMENTAL|Intervention|The intervention group attended a supervised exercise program for women only that presented Arabic music and traditional dance steps (the Lebanese Dabka) three times a week in the London Muslim Mosque Gym. The intervention lasted 12 weeks. There was also a nutrition education component that occurred once per week for the duration of the intervention. The lifestyle intervention group was instructed to walk 10,000 steps per day for the 12 weeks of the program. They were given instructions to take a 30-min walk on days when no formal exercise sessions were offered.
62536650|NCT04708574|PLACEBO_COMPARATOR|Control|The control group participants followed their typical work and leisure routines during the weeks of investigation. The women in the control group were offered the same intervention at the end of the 12 weeks.
62536651|NCT01830634|EXPERIMENTAL|Theraband with strengthening and stretching exercise|All subjects were received theraband exercises (strengthening and stretching), and then compare the measured outcomes between groups.
62536652|NCT00339092|EXPERIMENTAL|Treatment|Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
62536653|NCT00339092|ACTIVE_COMPARATOR|Control|Participants who receive standard care
62536654|NCT04707781||prospective patient cohort|patients who will undergo the prospective ILD Screening algorithm
62536655|NCT04707781||retrospective patient cohort|patients with diagnosed ILD
62536656|NCT02040779|EXPERIMENTAL|BDP 80 mcg BAI|40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.
62536657|NCT02040779|EXPERIMENTAL|BDP 160 mcg BAI|80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.
62536658|NCT02040779|PLACEBO_COMPARATOR|Placebo BAI|Placebo breath-actuated inhaler (BAI) twice daily.
62536659|NCT02991326|EXPERIMENTAL|Test Group (TG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to Osteopathic Manipulative Treatment - OMT.
62536660|NCT02991326|SHAM_COMPARATOR|Control Group (CG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to sham intervention (Osteopathic Manipulative Treatment simulated).
62536661|NCT03371459|EXPERIMENTAL|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
62536662|NCT03371459|ACTIVE_COMPARATOR|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
62536663|NCT02556229|EXPERIMENTAL|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
62714667|NCT04624984|EXPERIMENTAL|PD-1 Inhibitor or PD-1 Inhibitor with GVD|"All patients receive PD-1 Inhibitor on day 1. Treatment cycles repeat every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR or PR receive PD-1 Inhibitor for another 3 cycles. Patients with PD or SD receive PD-1 Inhibitor plus GVD (gemcitabine, vinorelbine and doxorubicin liposome) regimen every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients with PET/CT confirmed CR after 6 cycles of PD-1 Inhibitor treatment can receive radiotherapy or ASCT, which is determined by investigators. Patients with PR receive 2-4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with PD or SD receive 4 cycles of PD-1 Inhibitor plus GVD regimen.~Patients with confirmed CR or PR after PD-1 Inhibitor plus GVD regimen can receive radiotherapy or ASCT, which is determined by investigators. Patients with PD or SD quit the trial."
62714668|NCT02228538||Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system and off-the-shelf knee implant systems from various manufacturers
62714669|NCT02637986|EXPERIMENTAL|ARM A - suffered from one episode of UTI|Women who suffered from one episode of UTI during pregnancy before recruitment
62163367|NCT05319444|EXPERIMENTAL|Healthy Scalp and three treatments|Participants with healthy scalps who will receive three treatments with the device and complete one in-person follow-up.
62163368|NCT05319444|EXPERIMENTAL|Dandruff and one treatment|Participants with dandruff who will receive one treatment with the device and complete one in-person follow-up.
62163369|NCT05319444|EXPERIMENTAL|Dandruff and three treatments|Participants with dandruff who will receive three treatments with the device and complete one in-person follow-up.
62536664|NCT02172235|ACTIVE_COMPARATOR|Pioglitazone|
62714670|NCT02637986|PLACEBO_COMPARATOR|ARM A - suffered from one episode of UTI - placebo|Women who suffered from one episode of UTI during pregnancy before recruitment
62536665|NCT02172235|EXPERIMENTAL|Pioglitazone + BI 10773 low|
62536666|NCT02172235|EXPERIMENTAL|Pioglitazone + BI 10773 medium|
62536667|NCT02172235|EXPERIMENTAL|Pioglitazone + BI 10773 high|
62536668|NCT02172235|EXPERIMENTAL|Pioglitazone low + BI 10773 medium|
62536669|NCT02172235|EXPERIMENTAL|Pioglitazone + BI 10773 1 hour after Pioglitazone|
62536670|NCT06024889|EXPERIMENTAL|Furosemide|80 mg of furosemide is administered IV
62536671|NCT03165838|EXPERIMENTAL|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
62536672|NCT03165838|EXPERIMENTAL|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
62536673|NCT05252598|PLACEBO_COMPARATOR|Placebo Arm|9 placebo pills and 1 non-hallucinogenic Chaga (Inonotus obliquus) mushroom powder capsule to mimic the after-taste of active Psilocybin pills (Psilocybe cubensis)
62536674|NCT05252598|EXPERIMENTAL|1mg Psilocybin Arm|9 placebo pills and 1 capsule containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 1mg of psilocybin
62536675|NCT05252598|EXPERIMENTAL|2mg Psilocybin Arm|8 placebo pills and 2 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 2mg of psilocybin
62536676|NCT05252598|EXPERIMENTAL|5mg Psilocybin Arm|5 placebo pills and 5 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 5mg of psilocybin
62536677|NCT05252598|EXPERIMENTAL|8mg Psilocybin Arm|2 placebo pills and 8 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 8mg of psilocybin
62536678|NCT05252598|EXPERIMENTAL|10mg Psilocybin Arm|0 placebo pills and 10 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 10mg of psilocybin
62536679|NCT06632743||Sarcopenia|Diagnosed with sarcopenia according to EWGSOP (European Working Group on Sarcopenia in Older People)
62536680|NCT06632743||no sarcopenia|Not fulfilling sarcopenia criteria according to EWGSOP
62536681|NCT03651882|ACTIVE_COMPARATOR|Oxytocin|
62536682|NCT03651882|ACTIVE_COMPARATOR|Carbetocin|
62536683|NCT01154816|EXPERIMENTAL|Arm I (neuroblastoma- measurable)|Patients with measurable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536684|NCT01154816|EXPERIMENTAL|Arm II (Neuroblastoma- MIBG evaluable)|Patients MIBG evaluable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62163370|NCT05319444|EXPERIMENTAL|Hair loss disease and one treatment|Participants with hair loss disease who will receive one treatment with the device and complete one in-person follow-up.
62536685|NCT01154816|EXPERIMENTAL|Arm III (rhabdomyosarcoma)|Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536686|NCT01154816|EXPERIMENTAL|Arm IV (osteosarcoma)|Patients with osteosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536687|NCT01154816|EXPERIMENTAL|Arm V (Ewing sarcoma/peripheral PNET)|Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536688|NCT01154816|EXPERIMENTAL|Arm VI (non-RMS soft tissue sarcoma)|Patients with non-RMS soft tissue sarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536689|NCT01154816|EXPERIMENTAL|Arm VII (hepatoblastoma)|Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536690|NCT01154816|EXPERIMENTAL|Arm VIII (malignant germ cell tumor)|Patients with malignant germ cell tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536691|NCT01154816|EXPERIMENTAL|Arm IX (Wilms tumor)|Patients with Wilms tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536692|NCT01154816|EXPERIMENTAL|Arm X (acute lymphoblastic leukemia)|Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536693|NCT01154816|EXPERIMENTAL|Arm XI (acute myelogenous leukemia)|Patients acute myelogenous leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536694|NCT01154816|EXPERIMENTAL|Arm XII (rhabdoid malignancy)|Patients with rhabdoid malignancy receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62536695|NCT00684489|ACTIVE_COMPARATOR|A; B|
62536696|NCT00684489|ACTIVE_COMPARATOR|2|Arm A is assignment to a clinical hypertension specialist Arm B is assigned renin-guided therapeutics
62536697|NCT00684489|ACTIVE_COMPARATOR|A is clinical hypertension specialist|Arm A is assigned to a clinical hypertension specialist
62536698|NCT00684489|ACTIVE_COMPARATOR|Arm B is renin-guided therapeutics|This group will be assigned to renin-guided therapeutics
62163371|NCT05319444|EXPERIMENTAL|Seborrheic Dermatitis with one treatment|Participants with seborrheic dermatitis disease who will receive one treatment with the device and complete one in-person follow-up.
62536699|NCT03184155|EXPERIMENTAL|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
62536700|NCT03184155|PLACEBO_COMPARATOR|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
62536701|NCT02951091|EXPERIMENTAL|biomarker group|400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets \[Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN\] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
62536702|NCT02951091|ACTIVE_COMPARATOR|control group|Patients will be randomized to the biomarker vs control group (standard of care; paclitaxel) as 4:1 ratio.
62163372|NCT05319444|EXPERIMENTAL|Seborrheic Dermatitis and three treatments|Participants with seborrheic dermatitis who will receive three treatments with the device and complete one in-person follow-up.
62163373|NCT05319444|EXPERIMENTAL|Hair loss disease and three treatments|Participants with hair loss disease who will receive three treatments with the device and complete one in-person follow-up.
62536703|NCT05404945|EXPERIMENTAL|Fit Cohort|Three 6-week cycles of 400 mg intravenous pembrolizumab + intravenous AVD (q 2 weeks).
62536704|NCT05404945|ACTIVE_COMPARATOR|Frail Cohort|Three 6-week cycles of 400 mg intravenous pembrolizumab and concurrent (q 3 week) intravenous brentuximab vedotin (BV).
62536705|NCT05404945|ACTIVE_COMPARATOR|Unfit Cohort|Three 6-week cycles of 400 mg intravenous pembrolizumab and mini-AVD (q 2 weeks).
62536706|NCT05502081|EXPERIMENTAL|casirivimab and imdevimab|casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.
62536707|NCT05502081|EXPERIMENTAL|Remdesivir|Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes
62536708|NCT05502081|EXPERIMENTAL|Favipravir|Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours
62536709|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
62536710|NCT05487534||Sugar Swing +|Patients with type 1 diabetes with a high glucose variability (i.e., a coefficient of variation \> 36% over a 10-day continuous glucose monitoring)
62536711|NCT05487534||Sugar Swing -|Patients with type 1 diabetes with low glucose variability (i.e., a coefficient of variation \< 36% over a 10-day continuous glucose monitoring)
62536712|NCT03153761|EXPERIMENTAL|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
62536713|NCT03153761|EXPERIMENTAL|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
62536714|NCT00985179|EXPERIMENTAL|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
62536715|NCT00985179|NO_INTERVENTION|Waiting control group (WCG)|
62536716|NCT05744180|OTHER|Arm Not Applicable|
62536717|NCT04497948|OTHER|Single Arm|Single Arm
62536718|NCT05484219|EXPERIMENTAL|Surgery|Image-guided resection of brain tumors and vascular malformations
62536719|NCT02006693|OTHER|XEN® Gel Stent|The XEN®45 Gel Stent (XEN45 implant) was placed in the study eye as a standalone procedure.
62536720|NCT02006693|OTHER|XEN® Gel Stent with Cataract Surgery|The XEN® Gel Stent (XEN45 implant) with cataract surgery, occurred if the participant was diagnosed with a cataract.
62536721|NCT00746876|ACTIVE_COMPARATOR|Unipolar|15 patients randomized for treatment with a unipolar hip hemiarthroplasty
62536722|NCT00746876|ACTIVE_COMPARATOR|Bipolar|15 patients randomized for treatment with a bipolar hip hemiarthroplasty
62536723|NCT02546466|EXPERIMENTAL|Functional Star-shape taping (FST)|For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
62536724|NCT02546466|SHAM_COMPARATOR|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
62536725|NCT02546466|ACTIVE_COMPARATOR|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
62536726|NCT03468075|EXPERIMENTAL|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
62536727|NCT02632461|EXPERIMENTAL|Podcast (+Bite Counter)|Participants in this group will receive podcasts twice weekly in conjunction with using a wearable wrist device called a Bite Counter. The Bite Counter tracks the number of bites/calories per bite. (Podcasts plus Bite Counter)
62536728|NCT02632461|ACTIVE_COMPARATOR|Podcast (+Mobile App)|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile application to track their diet. (Podcasts plus Mobile Diet Application)
62714671|NCT02637986|EXPERIMENTAL|ARM B -suffered from more than one episode of UTI|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
62714672|NCT02637986|PLACEBO_COMPARATOR|ARM B -suffered from more than one episode of UTI - placebo|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
62714673|NCT02834455|ACTIVE_COMPARATOR|CE-CT scanning|Contrast-enhanced CT scan of the thorax and abdomen.
62714674|NCT02834455|ACTIVE_COMPARATOR|PET-CT scanning|Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
62163374|NCT03966027|EXPERIMENTAL|Hindfoot Offloading Braces / Immediate Weight-bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
62163375|NCT03966027|PLACEBO_COMPARATOR|No Hindfoot Offloading Braces / Delayed Weight-Bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
62536729|NCT05164887||MIRACLe patients|"Patient affected by colorectal cancer submitted to laparoscopic resection with MBP + OA + perioperative Probiotics administration.~MBP = oral polyphosphate 500ml preoperative OA = Amoxicillin/Clavulanic acid 1g x 2 + metronidazole 250mg x 3 Probiotics = Streptococcus thermophilus; Bifidobacterium breve; Bifidobacterium longum; Bifidobacterium infantis; Lactobacillus acidophilus; Lactobacillus plantarum; Lactobacillus paracasei; Lactobacillus delbrueckii subsp. Bulgaricus 4,4g x 2"
62536730|NCT05682859|ACTIVE_COMPARATOR|Roflumilast|20 of the participating patients are randomized to the active arm where systemic roflumilast 500 microgram tablets are received.
62536731|NCT05682859|PLACEBO_COMPARATOR|Placebo|20 of the participating patients are randomized to the active arm where systemic placebo tablets are received.
62163376|NCT05370352|EXPERIMENTAL|Mobile chat messaging|Standard smoking cessation treatment + Personalised chat messaging
62163377|NCT05370352|ACTIVE_COMPARATOR|SMS messaging|Standard smoking cessation treatment + Regular SMS text messaging generic information about the harms of smoking and the benefits of quitting
62536732|NCT01985113||early staged non-small cell lung cancers|patients who diagnosed as early staged non-small cell lung cancer after surgery
62536733|NCT01985113||lung benign mass patients|patients who diagnosed as lung benign mass after surgery
62536734|NCT05109338|EXPERIMENTAL|Ben-Guard user|Participants will wear the garment for up to 18 months while needing a central line catheter.
62536735|NCT05109338|NO_INTERVENTION|Retrospective match control|Matched historical control for intervention group based on age, gender and duration of use of a central venous catheter.
62536736|NCT01729455||BENLYSTA cohort|Participants with active, autoantibody-positive SLE treated with BENLYSTA at Baseline.
62536737|NCT01729455||Comparison cohort|Participants with active, autoantibody-positive SLE treated without BENLYSTA at Baseline.
62536738|NCT02868645|EXPERIMENTAL|Patients with bone fibrous dysplasia|Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
62536739|NCT02868645|NO_INTERVENTION|Control subjects|Control subjects will have no intervention
62536740|NCT03717025|ACTIVE_COMPARATOR|Mini Punch Grafting|
62536741|NCT03717025|ACTIVE_COMPARATOR|Suction Blister Epidermal Grafting|
62536742|NCT03717025|ACTIVE_COMPARATOR|Non Cultured Epidermal Cell Suspension|
62536743|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
62536744|NCT03470168|EXPERIMENTAL|Hyperbaric Oxygen Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
62536745|NCT03470168|PLACEBO_COMPARATOR|Placebo group|were also taken inside the Hyperbaric Chamber, but received only normobaric oxygen therapy for the same period of time at 1 ATA
62536746|NCT00685672|EXPERIMENTAL|1|adrenalin
62536747|NCT00685672|PLACEBO_COMPARATOR|2|placebo
62536748|NCT04128280|EXPERIMENTAL|Test Group|Test group: Patients will receive a surgery: transurethral dilation of prostate with a columnar balloon
62163378|NCT00319878|EXPERIMENTAL|1|Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
62536749|NCT04128280|ACTIVE_COMPARATOR|Control Group|Control group: Patients will receive a surgery: transurethral incision of bladder neck.
62536750|NCT02695680||Lung SBRT|Respiratory motion causes significant geometric and dosimetric errors in the administration of lung stereotactic radiotherapy (SBRT). The purpose of this study is to create and validate patient-specific motion models of the thoracic anatomy with high spatial and temporal resolution. These models will be used to develop novel four-dimensional (4D=3D+time) techniques for radiotherapy treatment planning and real-time motion-adaptive dose delivery.
62536751|NCT04067986|OTHER|Camrelizumab + Apatinib|Camrelizumab + Apatinib
62714776|NCT02704208|EXPERIMENTAL|Behavioral: Thrive With Me Intervention|Participants randomized to the TWM Intervention will gain access to a website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
62536752|NCT05784532||STERN FIX|Patients undergoing cardiothoracic surgery through median sternotomy, once the main intervention is finished, will have their sternum closed using the sternal stabilization system STERN FIX in combination with wires according to the STERN FIX instructions for use.
62536753|NCT01165827||Patients with aortic valve procedures|"All consecutive patients from participating hospitals with aortic valve defects who have received one of the following therapies:~1. surgical aortic valve replacement,~2. percutaneous transvascular (retrograde) aortic valve implantation~3. percutaneous transapical aortic valve implantation as principal indication. If the aortic valve insufficiency is concurrent with combination procedures (e.g. coronary artery bypass graft, mitral valve surgery) the aortic valve stenosis must fulfil only the criteria for indication according to the German National guidelines (see: detailed study description)."
62536754|NCT04141826|EXPERIMENTAL|Hydrolysed whey|Hydrolysed whey
62536755|NCT04141826|ACTIVE_COMPARATOR|Intact whey|Intact whey
62536756|NCT04141826|PLACEBO_COMPARATOR|Caseinate|Caseinate
62536757|NCT01502410|EXPERIMENTAL|Group 1 Relapsed/Refractory Rhabdomyosarcoma|"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
62536758|NCT01502410|EXPERIMENTAL|Group 2 Relapsed/Refractory Wilms tumor|"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
62536759|NCT01502410|EXPERIMENTAL|Group 3 Relapsed/Refractory hepatocellular carcinoma|"Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
62536760|NCT01502410|EXPERIMENTAL|Group 4 Papillary thyroid carcinoma|"Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
62163379|NCT01324011|EXPERIMENTAL|Family-based intervention|Special intervention (20 weekly group-based sessions) to be compared with a delayed intervention control group.
62163380|NCT01324011|OTHER|Delayed intervention controls|The delayed intervention controls will continue with usual care (if patients with diabetes)and at the end of the experimental period (6 months), they will receive a 6-session weight loss intervention delivered over a 2 month period.
62163381|NCT01057888|EXPERIMENTAL|Autodialer|Autodialer reminder/recall
62163382|NCT01057888|EXPERIMENTAL|Letters|Mailed reminder letters
62163383|NCT01057888|NO_INTERVENTION|Controls|Controls
62163384|NCT02645578|EXPERIMENTAL|RMNS group|Focus intervention: right median nerve stimulation plus standard management
62163385|NCT02645578|NO_INTERVENTION|Control group|Standard management
62163386|NCT01975701|EXPERIMENTAL|BGJ398X|To estimate anti-tumor efficacy of BGJ398
62163387|NCT06124599||Women who have developed menstrual staphylococcal toxic shock|"Clinical diagnosis of staphylococcal toxic shock syndrome: confirmed or probable according to CDC criteria :~The 5 CDC clinical criteria for Staphylococcal Toxic Shock are:~* a fever above 39°C,~* arterial hypotension,~* generalized scarlatiniform erythroderma~* intense desquamation of the palms or soles of the feet 7 to 14 days later,~* and systemic manifestations (at least three):~  * Digestive: vomiting, diarrhea~ * Muscular: myalgias, increased serum creatine phospho-kinase~ * Vaginal, oropharyngeal and conjunctival mucosal hyperemia~ * Renal: hyperuricemia, hypercreatininemia, leukocyturia without urinary infection,~ * Hepatic: increased transaminases~ * Hematological: thrombocytopenia (\< 100,000 platelets/mm3)~ * Neurological: excluding episodes of fever or hypotension such as disorientation or altered consciousness.~If 4 criteria are met, the case is considered probable, and if 5 criteria are met, confirmed."
62163388|NCT06124599||Control healthy women|Women over 13 years of age, menstruating and using internal sanitary protection with No history of menstrual toxic shock for controls
62163389|NCT01655498|EXPERIMENTAL|Vaginal Bowel Control|A vaginal bowel control system intended to manage fecal incontinence.
62163390|NCT00620230|EXPERIMENTAL|1|
62163391|NCT00620230|PLACEBO_COMPARATOR|2|
62163392|NCT06384742|EXPERIMENTAL|SWISH|"SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia.~Other Names:~Cognitive Behavioral Therapy for Insomnia"
62163393|NCT06384742|NO_INTERVENTION|WLC|Waitlist Control: Participants in the delayed treatment control condition will begin the SWISH intervention following completion of the posttreatment time point.
62163394|NCT05711745|EXPERIMENTAL|Myofascial induction in gastrocnemius|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
62714777|NCT02704208|PLACEBO_COMPARATOR|Behavioral: Thrive With Me Control|Participants randomized to the TWM Control group will receive HIV related content through a weekly web link. The web links will be static pages (not interactive) with information aimed at improving overall wellbeing while living with HIV, but not focused on improving ART medication adherence.
62163395|NCT05567302|EXPERIMENTAL|Manual therapy|Manual therapy, manipulative therapy, is a completely manual treatment method that includes special techniques and is known as a treatment that aims to correct bony deformities and is highly effective when combined with exercise.
62163396|NCT05567302|ACTIVE_COMPARATOR|myofascial release|Foam rollers are a popular tool for helping athletes release muscle knots or trigger points.Myofascial release is a soft tissue method that provides removal of adhesions and tissue tension in tissues due to overload and repetitive use.
62163397|NCT04018534|EXPERIMENTAL|Control group|The patients in control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society(BOS) educational goals.
62163398|NCT04018534|EXPERIMENTAL|Video assisted education group|The patients in one of the study groups received a video assisted education
62163399|NCT04018534|EXPERIMENTAL|Hands-on training group|The patients in other study group received a hands-on training.
62163400|NCT05991947||gastric cancer patients|
62163401|NCT05991947||healthy individuals|
62163402|NCT06257082|ACTIVE_COMPARATOR|Patient plus Clinician Combined Testimonials|In addition to being randomized for online survey participants, focus groups will view patient plus clinician combined testimonials.
62163403|NCT06257082|ACTIVE_COMPARATOR|Clinician Only Testimonials|
62163404|NCT06257082|ACTIVE_COMPARATOR|Patient Only Testimonials|
62163405|NCT06257082|ACTIVE_COMPARATOR|National Eye Institute video Control|
62163406|NCT06257082|ACTIVE_COMPARATOR|Pre-video questionnaire-only Control|
62163407|NCT06412315|EXPERIMENTAL|Citalopram|
62163408|NCT06412315|PLACEBO_COMPARATOR|Placebo|
62163409|NCT01544153|OTHER|WEB only|Control group receiving no additional intervention
62163410|NCT01544153|EXPERIMENTAL|WEB+SN|WEB plus social network intervention.
62163411|NCT01544153|EXPERIMENTAL|WEB+NRT|WEB plus nicotine replacement therapy product.
62163412|NCT01544153|EXPERIMENTAL|WEB+SN+NRT|WEB plus social network intervention and nicotine replacement therapy product.
62536761|NCT03886740|EXPERIMENTAL|Tympanostomy with tubes|Tympanostomy with pressure equalization tube placement with Ventilation (Tympanostomy) Tubes
62536762|NCT03886740|EXPERIMENTAL|Eustachian tube (ET) dilation|Eustachian tube (ET) dilation with ACCLARENT AERA® Eustachian Tube Balloon Dilation System
62536763|NCT03980574|EXPERIMENTAL|Crossover Group|The crossover group will be further randomly assigned (1:1) with 20 patients in each group. The two crossover arms of the study will follow the patients for 8 weeks. At the end of week 8, all crossover patients will have a 1 week wash out period. Thereafter, patients will be crossed-over to the opposing arm of the study for an additional 1+8 weeks (R Drink 8 oz 3-5x/day versus a placebo drink 8 oz 3-5x/day).
62536764|NCT03980574|EXPERIMENTAL|Non-crossover Group|The non-crossover group of the study will follow 20 patients for the entire 17 weeks and participants in this arm will not be crossed over, will not have a washout period, and will consume R Drink for the total duration of the study. If patients in this arm wish to continue on the R Drink, for 6 additional months they may do so. At the end of the optional 6 months these patients will have a repeat research transthoracic echocardiogram. Data collection will occur at baseline, week 8, and week 17. An additional 6 month data collection time point will occur for patients in the third arm opting to continue R Drink.
62536765|NCT05508841|EXPERIMENTAL|4mA Stimulation|
62536766|NCT05508841|ACTIVE_COMPARATOR|2mA Stimulation|
62536767|NCT05508841|SHAM_COMPARATOR|SHAM|
62536768|NCT03712878|EXPERIMENTAL|Treatment (TBI, DLI, chemotherapy, HSCT, tacrolimus, MMF)|"Description CONDITIONING REGIMEN: Participants undergo TBI BID on days -9 to -6.~TRANSPLANT: Participants receive donor lymphocytes IV on day -6 after the last dose of TBI.~CONDITIONING REGIMEN: Participants receive cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Participants undergo hematopoietic stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Participants receive tacrolimus IV beginning on day -1 with taper beginning on day 42 in the absence of GVHD, a suspicion of GVHD, or previous history of GVHD requiring a taper delay. Participants also receive mycophenolate mofetil IV BID beginning on day -1 through day 28 in the absence of GVHD."
62536769|NCT05453565||Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
62536770|NCT05453565||Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
62536771|NCT05228938|EXPERIMENTAL|Study group: vNOTES|Elective bilateral salpingectomy or Salpingo-oophorectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery approach
62536772|NCT05228938|OTHER|Control group: Laparoscopic|Elective bilateral salpingectomy or Salpingo-oophorectomy by conventional laparoscopy
62536773|NCT00106964|ACTIVE_COMPARATOR|1|Standard dose (20 mcg) of Hepatitis B vaccine.
62536774|NCT00106964|ACTIVE_COMPARATOR|2|40 mcg of Hepatitis B vaccine
62536775|NCT00106964|ACTIVE_COMPARATOR|3|20 mgc of Twinrix
62536776|NCT04689867|EXPERIMENTAL|CBSPp|Cognitive Behavioral Suicide Prevention for psychosis is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions.
62536777|NCT01104467|EXPERIMENTAL|Desmoteplase 70 µg/kg|
62536778|NCT01104467|EXPERIMENTAL|Desmoteplase 90 µg/kg|
62536779|NCT01104467|PLACEBO_COMPARATOR|Placebo|
62536780|NCT03908879|EXPERIMENTAL|Intraosseous (IO) catheter placement confirmation methods|All patients will undergo all three confirmation methods/procedures. Method 1 is a triage test and an index test. Method 2 is an index test. Method 3 is a reference standard. None of the procedures being performed in this study are regulated by the United States Food and Drug Administration.
62536781|NCT05783544|ACTIVE_COMPARATOR|COPD patients without any comorbidities|
62536782|NCT05783544|ACTIVE_COMPARATOR|COPD patients with chronic pulmonary aspergillosis|
62536783|NCT05783544|ACTIVE_COMPARATOR|COPD patients with ascariasis|
62536784|NCT05783544|ACTIVE_COMPARATOR|COPD patients with chronic pulmonary aspergillosis and ascariasis|
62536785|NCT05783544|ACTIVE_COMPARATOR|healthy control|
62536786|NCT02863783|EXPERIMENTAL|Fiducial Placement|EUS with Fiducial Placement into Tumor
62536787|NCT04028193|OTHER|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
62536788|NCT04028193|OTHER|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
62536789|NCT06379724|ACTIVE_COMPARATOR|Control|Prior to application of the skin graft, a thin layer of thrombin is sprayed onto the wound base. The skin graft is then applied to the recipient site and fixated in standard fashion.
62536790|NCT06379724|EXPERIMENTAL|Experimental|Tranexamic acid solution will be sprayed onto the wound base after excision and prior to skin graft appliance in the same manner as the thrombin spray in the control group
62536791|NCT03784053||Immersive virtual reality|Participants will receive eight 30-minute sessions of immersive virtual reality.
62536792|NCT04008849||Subjects treated with MGTA-456|MGTA-456 is an investigational expanded CD34+ cell therapy
62536793|NCT02592083|ACTIVE_COMPARATOR|A: Endocrine treatment|Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
62536794|NCT02592083|EXPERIMENTAL|B: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
62536795|NCT02592083|EXPERIMENTAL|C: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
62714778|NCT06717750|EXPERIMENTAL|CSCJC3456 monotherapy|"* Phase Ia: Single and Multiple Dose Escalation.~* Phase Ib: Cohort Expansion."
62536796|NCT05938907|NO_INTERVENTION|only apical surgery group|which will undergo only apical surgery (including apicoectomy, inflammation debridement, and retrofilling of the root apex)
62536797|NCT05938907|EXPERIMENTAL|bone substitute group|which will undergo apical surgery plus bone substitute
62536798|NCT05938907|EXPERIMENTAL|concentrated growth factors group|which will undergo apical surgery plus CGF (concentrated growth factors)
62536799|NCT05938907|EXPERIMENTAL|bone substitute and CGF group|which will undergo apical surgery plus bone substitute and CGF gel
62536800|NCT01838668|PLACEBO_COMPARATOR|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
62536801|NCT01838668|EXPERIMENTAL|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
62536802|NCT01838668|EXPERIMENTAL|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
62536803|NCT02040506|EXPERIMENTAL|IGN523|IGN523
62536804|NCT03619681|EXPERIMENTAL|KN026|
62536805|NCT02909283||Sickle cell disease patients|Physical exams and blood analyzes
62536806|NCT01830894|EXPERIMENTAL|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
62536807|NCT01830894|EXPERIMENTAL|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
62536808|NCT01830894|EXPERIMENTAL|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
62536809|NCT06633523|EXPERIMENTAL|Pulmonary Vein Isolation (PVI) alone|The distance between the ablation lines on the posterior wall after circumferential pulmonary vein isolation should be at least 2 centimeters to limit the portion of the posterior wall within the PVI ablation zone. PVI will be confirmed by verifying entrance and exit block at the PV orifices
62536810|NCT06633523|EXPERIMENTAL|Pulmonary Vein Isolation (PVI) + Posterior Wall Isolation (PWI)|After performing PVI, the mapping catheter will be placed on the posterior wall to assess electrical activity and guide ablation. A bottom linear ablation (25-40W) will be performed, connecting the lowest points beneath the lower PVs. A top linear ablation (25-40W) will be conducted at the top of the left atrium, connecting the highest points above the upper PVs. If posterior wall isolation is not achieved after completing the bottom and top lines, mapping and localization of the earliest activation point within the box will be performed during pacing from the coronary sinus (CS). Posterior wall isolation will be completed by identifying and ablating local potentials at the entry and exit sites.
62536811|NCT06633523|EXPERIMENTAL|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM)|After performing PVI, electrogram mapping of the posterior left atrial wall is conducted. Subsequently, PWI and EGM ablation are performed. In this group, multipolar mapping catheters are used for EGM mapping. Target EGMs include spatially discrete potentials (STPs), localized short cycle length potentials (SCLPs), and focal activities.
62536812|NCT05082792|OTHER|doppler US for native AVF in upper limb|creation of native arteriovenous fistula in upper limb in chronic kidney disease patients on hemodialysis
62536813|NCT03143426|EXPERIMENTAL|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualisation.
62536814|NCT03143426|NO_INTERVENTION|2D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 2D visualisation, the standard viewing method used during all laparoscopic surgeries currently.
62536815|NCT03985644||Fulfilling Hangzhou criteria|"Patients flfilling Hangzhou critieria:~Without macrovascular invasion Tumor burden \<=8 cm Preoperative AFP level \<=400 ng/mL Histopathologic grades I, II"
62536816|NCT03985644||Exceeding Hangzhou criteria|Patients exceeding Hangzhou critieria
62536817|NCT04626648|NO_INTERVENTION|Surgery without intraoperative pause|Surgical procedure without pause
62536818|NCT04626648|EXPERIMENTAL|Surgery with intraoperative pause|Three-minute long intraoperative pause, including a sugar-containing drink
62536819|NCT03946553||Allergic Rhinitis Group|Individuals with allergic rhinitis
62536820|NCT03946553||Control Group|Individuals without allergic rhinitis
62536821|NCT00018356|OTHER|1|
62536822|NCT03566797||SC-CIP|Patients developing SC-CIP
62536823|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
62536824|NCT05486481|EXPERIMENTAL|Phase I (venetoclax, dexamethasone, daratumumab)|All participants receive 400 mg venetoclax once a day (QD) on days 1-28 of each cycle. Depending on the number of DLTs reported for this dose-level, participants may also receive dexamethasone on days 1, 8, 15, and 22 of each cycle with or without daratumumab on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
62536825|NCT05486481|EXPERIMENTAL|Phase II (venetoclax, dexamethasone, daratumumab)|Participants will receive the RP2D of venetoclax QD on days 1-28 of each cycle, dexamethasone on days 1, 8, 15, and 22 of each cycle, and daratumumab on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity
62536826|NCT04236323|EXPERIMENTAL|not used intraoperative remifentanil infusion|Adult patients aged \< 70 years and ASA class \< III undergoing rotator cuff repair not used intraoperative remifentanil infusion
62536827|NCT04236323|NO_INTERVENTION|used intraoperative remifentanil infusion|Adult patients aged \< 70 years and ASA class \< III undergoing rotator cuff repair used intraoperative remifentanil infusion maintaining target concentration of 2-6ng/ml
62536828|NCT03681015||Cohort 1 - Parkinson's Disease Participants|Volunteers will be women and men with early, untreated Parkinson disease.
62536829|NCT03681015||Cohort 2 - Control Participants|Participants will be women and men without PD.
62536830|NCT04618640|EXPERIMENTAL|DTaP-IPV combination vaccine|DTaP-IPV 0.5ml IM boosting
62536831|NCT03729817|EXPERIMENTAL|Submaximal balloon angioplasty plus intensive medical therapy|Endovascular intervention with submaximal balloon angioplasty
62536832|NCT03654820|EXPERIMENTAL|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
62536833|NCT03654820|ACTIVE_COMPARATOR|SDF treated|Annual application of 38% SDF solution
62536834|NCT05158036|ACTIVE_COMPARATOR|Classic massage group|Classical massage will be applied to the lumbal and abdominal region 5 days a week, from the estimated date of ovulation until the next menstrual bleeding begins. The application will take approximately 15 minutes. During the massage, the physiotherapist will apply stroking and kneading movements by using baby oil. During the treatment of the lumbal region, the patient will be in the prone position; during the treatment of the abdominal region, the patient will be in the supine position.
62536835|NCT05158036|ACTIVE_COMPARATOR|Connective tissue massage group|Connective tissue massage will be applied to the lumbosacral, lower thoracic, abdominal and anterior pelvic regions 5 days a week, from the estimated date of ovulation until the onset of the next menstrual bleeding. The application will take approximately 15 minutes. During the massage, the physiotherapist will bring the tip of the middle finger of the hand into contact with the patient's skin and apply traction to the skin. During the treatment of the lumbar region, the patient will be in the sitting position, during the treatment of the abdominal and anterior pelvic region, the patient will be in the supine position.
62536836|NCT04954027||Patients with a use-related disorder weaning for a substance|
62536837|NCT02755155|EXPERIMENTAL|Continuous low dosage (CLD)|The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
62536838|NCT02755155|ACTIVE_COMPARATOR|Intermittent high dosage (IHD)|The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%
62536839|NCT04643561|EXPERIMENTAL|intervention|5 patients will recieve 5 days treatment with Travelan, blood samples will be taken prior and after intervention
62163413|NCT06550895|EXPERIMENTAL|Cohort 1: Cilta-cel + Talquetamab Consolidation Post Chimeric Antigen Receptor T cell (CAR-T)Therapy|Participants with relapsed and/or refractory multiple myeloma (RRMM) will be administered Cilta-cel followed by multiple cycles of talquetamab consolidation treatment and will be followed up until death, lost to follow-up, consent withdrawal, or study end, whichever occurs first.
62163414|NCT06550895|EXPERIMENTAL|Cohort 2: Cilta-cel + Talquetamab Consolidation Post CAR-T Therapy|Participants with newly diagnosed multiple myeloma (NDMM) will undergo daratummab, lenalidomide and dexamthasone (DRd) induction therapy followed by cilta-cel therapy and multiple cycles of talquetamab consolidation treatment and will be followed up until death, lost to follow-up, consent withdrawal, or study end, whichever occurs first.
62536840|NCT04903951|EXPERIMENTAL|ASV therapy + best medical treatment for stroke, including rehabilitation|Adaptive Servoventilation (ASV) therapy plus best medical treatment for stroke, including rehabilitation.
62536841|NCT04903951|ACTIVE_COMPARATOR|Best medical treatment for stroke, including rehabilitation|Best medical treatment for stroke, including rehabilitation.
62536842|NCT06000774|EXPERIMENTAL|Therapeutic Ketogenic Diet|A 2-week therapeutic ketogenic diet (TKD) induction will be implemented to establish nutritional ketosis (the goal are BHB blood levels of 0.5-3.0 millimoles per liter \[mmol/L\]). After establishing the ketotic state, study participants will continue TKD for 12 weeks.
62536843|NCT03745157||Patients with Type 2 Diabetes requiring insulin therapy|Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)
62536844|NCT05773833|EXPERIMENTAL|"Go Healthy Intervention Group"|"Go Healthy program"
62536845|NCT05773833|NO_INTERVENTION|Wait-list Control Group|"Monetary compensation equal in value to the Go Healthy program"
62536846|NCT01569932||chemotherapy|Patients will be assessed both before and after they undergo treatment with chemotherapy.
62536847|NCT04890301|EXPERIMENTAL|Puncture Template and CT group|Puncture Template assisted CT guided lung biopsy was performed.
62536848|NCT04890301|ACTIVE_COMPARATOR|CT group|Simple CT guided lung biopsy was performed.
62536849|NCT05699486|EXPERIMENTAL|Treatment with PDNO (placebo during baseline and washout observation periods before & after PDNO)|PDNO will be administered as an incremental intravenous infusion of respectively 15 minutes with the planned dosage: 3, 10, 30, 45 and 60 nmol/kg/min. If no effect on MPAP/PVR is seen at 60 nmol/kg/min in the first patients treated, further dose escalation up to 120 nmol/kg/min is possible, if recommended by the Internal Safety Review Committe (iSRC) following careful review of collected safety data. The iSRC will in any case review all collected data after 4, 8 and 12 patients (if applicable also after 16 and 20 patients). PDNO is administered together with a carrier buffer (NaHCO3-) flow into a central venous catheter. Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL) will be administered during the baseline and washout observation periods before and after start of IMP infusion.
62536850|NCT06077838|ACTIVE_COMPARATOR|RELAX Group 1|Participants will receive access to the RELAXaHEAD app version 1 which contains certain features for migraine self-management with written materials.
62536851|NCT06077838|ACTIVE_COMPARATOR|RELAX Group 2|Participants will receive access to the RELAXaHEAD app version 2 which contains certain features for migraine self-management with written and audio materials.
62536852|NCT01086397||1|
62536853|NCT01682486|EXPERIMENTAL|BIP ETT, Bactigaurd coated endotracheal tube|
62536854|NCT01682486|PLACEBO_COMPARATOR|Standard ETT, un-coated endotracheal tube|
62536855|NCT01675466|ACTIVE_COMPARATOR|early laparoscopy|early laparoscopy, aiming to achieve this within 12 hours
62536856|NCT01675466|PLACEBO_COMPARATOR|active observation|"standard management - the wait and see approach with serial examinations and investigations as deemed necessary"
62163415|NCT06550895|EXPERIMENTAL|Cohort 3: Tal Bridging Therapy Pre-CAR-T Therapy + Cilta-cel|Participants with RRMM will receive multiple cycles of talquetamab bridging therapy followed by cilta-cel therapy and will be followed up until death, lost to follow-up, consent withdrawal, or study end, whichever occurs first.
62536857|NCT02332954|OTHER|vortioxetine naive|vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
62536858|NCT02332954|OTHER|Switch|vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
62536859|NCT02458287|EXPERIMENTAL|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
62536860|NCT02458287|EXPERIMENTAL|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
62536861|NCT02458287|PLACEBO_COMPARATOR|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
62536862|NCT02458287|PLACEBO_COMPARATOR|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
62536863|NCT00605540||Study COPD population|Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
62536864|NCT01004003|EXPERIMENTAL|BIBF 1120|Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
62536865|NCT01004003|ACTIVE_COMPARATOR|Sorafenib|
62536866|NCT03107247||Patients receiving Tc-99m MDP studies|All patients within the specified age ranges scheduled at Boston Children's Hospital for a nuclear medicine study utilizing Tc-99m MDP will be eligible to volunteer for inclusion in this study.
62536867|NCT05256524||Patients with critical COVID-19 responding to LMWH treatment|Responders are defined as patient who achieve aFXa-levels, peak or trough, within target-range as excepted from the given dose of LMWH.
62536868|NCT05256524||Patients with critical COVID-19 not responding to LMWH treatment|Non-responders are defined as patients who do not achieve aFXa-levels, peak or trough, within target-range as excepted from the given dose of LMWH.
62536869|NCT03786718|EXPERIMENTAL|Intervention|Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.
62536870|NCT06201429|EXPERIMENTAL|Mechanical Tissue Resuscitation (MTR™)|
62536871|NCT05529667|EXPERIMENTAL|Experimental|"1. phase\>~   * INCB054828 begins with oral administration of 13.5 mg once a day.~  * Paclitaxel is administered intravenously every week at 80mg / m2. (Days 1, 8 and 15) It is one cycle of 4 weeks and it is administered until the time of disease progression.~2. phase\>~   * INCB54828 is dosed at the dose specified in phase 1.~  * Paclitaxel is administered intravenously every week at 80mg / m2. (Days 1, 8 and 15) It is one cycle of 4 weeks and it is administered until the time of disease progression"
62536872|NCT06633445|EXPERIMENTAL|3D guided botulinum toxin injection arm|
62536873|NCT06633445|ACTIVE_COMPARATOR|Electromyography botulinum toxin injection arm|
62536874|NCT05657392|EXPERIMENTAL|Inhibitory repetitive Transcranial Magnetic Stimulation|All patients will receive inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency. The contralesional primary motor cortex region will be stimulated with a Neurosoft-Neuro MS/D device. There will be a total of 10 treatment sessions over a 2-week period. Before each intervention, the resting motor threshold (rMT) value will be determined. rMT will be detected by obtaining a motor-evoked potential of \>50 μV amplitude on EMG recording of the contralateral first dorsal interosseous muscle in at least 5 out of 10 stimulations to the primary motor cortex. 90% of the motor threshold will be set in the stimulation. Each stimulation is planned for a total of 20 minutes and a total of 1200 pulses in the form of 1 Hz stimulation.
62536875|NCT00620087|OTHER|Diagnostic Arm|Women with core-biopsy proven atypia, LCIS, or radial scar who have not yet undergone surgical excision were enrolled in the diagnostic arm. A molecular breast imaging study will be obtained.
62536876|NCT00620087|OTHER|Surveillance arm|Women with a diagnosis of ADH, ALH, or LCIS within the past 5 years were enrolled in the surveillance arm. A molecular breast imaging study was done at enrollment (Year 0) and repeated at Yer 2 and Year 4. Patients continued with routine screening mammography during this time period.
62536877|NCT01422629|EXPERIMENTAL|High Intensity Focused Ultrasound (HIFU)|
62536878|NCT00378612|EXPERIMENTAL|Cypher® sirolimus eluting coronary stent|All pts were given the Cypher sirolimus eluting coronary stent in this open-label, single-arm, non-randomized trial
62536879|NCT02287818|PLACEBO_COMPARATOR|Placebo|Placebo plus Febuxostat
62536880|NCT02287818|EXPERIMENTAL|AC-201|AC-201 CR tablet plus Febuxostat
62536881|NCT04283500|EXPERIMENTAL|BUP treatment arm|Subjects will be given BUP 32mg in 2 doses, and observed for at least 90 minutes after the 2nd dose. The whole process will take a total of about 3-4 hours including the consenting process. Subjects will be asked questions and be examined repeatedly. Subjects will have 4 in-person visits and a phone call in addition to review of medical records.
62536882|NCT04706286|EXPERIMENTAL|Group 1|"1. Period 1: Treatment A~2. Period 2: Treatment B"
62536883|NCT04706286|EXPERIMENTAL|Group 2|"1. Period 1: Treatment B~2. Period 2: Treatment A"
62536884|NCT01450917||Group A|Brachial plexus injured patients with phrenic nerve dysfunction
62163416|NCT00730496|EXPERIMENTAL|1|the study group, 45 women
62163417|NCT00730496|NO_INTERVENTION|2|the control group, 45 women
62536885|NCT01450917||Group B|Brachial plexus injured patients without phrenic nerve dysfunction
62536886|NCT01450917||Group C|Non brachial plexus injured patients
62536887|NCT02675569|ACTIVE_COMPARATOR|Catheter|Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
62536888|NCT02675569|EXPERIMENTAL|Fistula|Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
62536889|NCT04384653|EXPERIMENTAL|Treatment A|Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 1 and IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 2
62536890|NCT04384653|EXPERIMENTAL|Treatment B|IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 1 and Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 2
62536891|NCT01563835|ACTIVE_COMPARATOR|Epidural (PCEA)|bupivacaine, fentanyl
62536892|NCT01563835|ACTIVE_COMPARATOR|IV PCA|Intravenous fentanyl patient controlled analgesia
62536893|NCT03483727|EXPERIMENTAL|Digital cognitive aid|The digital cognitive aid is designed as a smartphone app.
62536894|NCT03483727|EXPERIMENTAL|no digital cognitive aid|No cognitive aid in the hand of the leader during crises management.
62536895|NCT02031458|EXPERIMENTAL|Atezolizumab|
62536896|NCT04335786|EXPERIMENTAL|Active treatment arm|Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
62163418|NCT05272150|EXPERIMENTAL|Cohort A: Moderate-to-severe Plaque Psoriasis|Participants will receive either guselkumab subcutaneously (SC) or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
62163419|NCT05272150|EXPERIMENTAL|Cohort B: Moderate-to-severe Scalp Psoriasis|Participants will receive either guselkumab SC or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
62536897|NCT04335786|PLACEBO_COMPARATOR|Placebo arm|Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure
62163420|NCT05653921||Dry Eye Disease Group|Symptoms of ocular surface discomfort or dry eye disease for at least 3 months, supported by clinical exam findings. Reported quality of life is not effected by ocular pain.
62536898|NCT01879930|ACTIVE_COMPARATOR|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
62163421|NCT05653921||Neuropathic Corneal Pain Group|Symptoms of ocular surface discomfort or pain for at least 3 months, that are reported to have a significant impact on quality of life and ability to perform daily activities.
62163422|NCT05653921||Control Group|No symptoms of ocular surface discomfort or dry eye disease.
62536899|NCT01879930|PLACEBO_COMPARATOR|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
62536900|NCT01238380||Diabetes diagnosed under 30 years|Patients currently under 50 years of age diagnosed with diabetes under 30 years.
62536901|NCT04015713||TB HIV-negative|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
62536902|NCT04015713||TB HIV-positive|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
62536903|NCT06351436|EXPERIMENTAL|Mindfulness|
62536904|NCT05778487|NO_INTERVENTION|Control Group|"Standard of care for dietary instructions only.~The control group will consist of retrospectively recruited participants who have recently undergone a successful elective spine surgery, and followed the preoperative nutrition standards for their surgery, as outlined by the research institution's fasting dietary guidelines. Recruitment will include the most recent spine surgeries that meet the inclusion criteria and match prospective patient demographics."
62536905|NCT05778487|EXPERIMENTAL|Carbohydrate Group|"Standard of care for dietary instructions + carbohydrate loading.~The carbohydrate (CHO) group will consist of prospectively recruited patients scheduled to undergo an elective spine surgery. These participants will also follow the preoperative nutrition standards, however, in addition, they will be instructed to consume 710ml of a simple, commercial carbohydrate sports drink on the day of their procedure up to 2 hours prior to surgery."
62536906|NCT03697863||Noninvasive Adjusted Ventilatory Assist|
62536907|NCT03697863||Noninvasive Pressure Support|
62163423|NCT06157840|EXPERIMENTAL|mHealth application|Study participants, while being stabilized on buprenorphine, will download and engage with the developed mHealth application, completing daily electronic sleep diaries for the next 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
62163424|NCT06157840|EXPERIMENTAL|Control Group|Participants in the control group will receive a simplified version of the app with sleep hygiene (SH) instructions and will be required to complete daily electronic sleep diaries for the next 6 weeks. The SH condition will utilize the same application and entail the same daily and weekly logs, but with the didactic material replaced by detailed education about SH strategies. Each week, participants will be asked to complete a brief assessment of their experiences from the previous week and their current insomnia severity.
62163425|NCT01474265|PLACEBO_COMPARATOR|varenicline placebo|
62536908|NCT05986591|EXPERIMENTAL|Treatment A: 18 mcg of Test Product (tiotropium bromide inhalation powder)|
62536909|NCT05986591|ACTIVE_COMPARATOR|Treatment B: 18 mcg of Reference Product (Spiriva)|
62536910|NCT05986591|PLACEBO_COMPARATOR|Placebo|
62536911|NCT04479553||Qizhi Tongluo Capsules|Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.
62536912|NCT04327739|EXPERIMENTAL|Intervention 1 Exercise|Participants allocated to this group received a 10 weeks exercise programme for neck and upper limbs muscles
62536913|NCT04327739|EXPERIMENTAL|Intervention 2 Exercise and INIT|Participants allocated to this group received the same exercise programme as group 1 in combination with the integrated neuromuscular inhibition technique (INIT)
62536914|NCT04327739|EXPERIMENTAL|Intervention 3 Exercise and SMT|Participants allocated to this group received the same exercise programme as group 1 in combination with cervical manipulation
62536915|NCT04327739|PLACEBO_COMPARATOR|Control|Participants allocated to this group received general consulting instructions and a home based general exercise sheet
62536916|NCT03327792|EXPERIMENTAL|200 mg Mavoglurant|200 mg mavoglurant once daily for 7-10 days
62536917|NCT03327792|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 7-10 days
62536918|NCT04320251|EXPERIMENTAL|1|The single observational cohort
62536919|NCT00794755|ACTIVE_COMPARATOR|Vitamin K|
62536920|NCT00794755|PLACEBO_COMPARATOR|Placebo|
62536921|NCT03580083|EXPERIMENTAL|Dose 1; 1x10^10 GC/g brain mass of RGX-111|
62714779|NCT01029535|EXPERIMENTAL|Juvederm® VOLUMA™|Juvederm® VOLUMA™ injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.
62536922|NCT03580083|EXPERIMENTAL|Dose 2; 5x10^10 GC/g brain mass of RGX-111|
62536923|NCT00996138|OTHER|Arm 1|Dose ranging
62536924|NCT00996138|OTHER|Arm 2|Dose ranging
62536925|NCT03062423|EXPERIMENTAL|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
62536926|NCT03062423|ACTIVE_COMPARATOR|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
62536927|NCT03062423|ACTIVE_COMPARATOR|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
62536928|NCT04287335||High risk CRC screening group|Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer
62536929|NCT04287335||CRC group|Retrospective enrollment of subjects with confirmed colorectal cancer
62536930|NCT03207243|EXPERIMENTAL|Subjects receiving GSK3772847|Eligible subjects will receive GSK3772847 once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
62536931|NCT03207243|PLACEBO_COMPARATOR|Subjects receiving placebo drug|Eligible subjects will receive placebo once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
62536932|NCT01035983|EXPERIMENTAL|Frovatriptan 2.5 mg|Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.
62536933|NCT02923986|EXPERIMENTAL|BP1001 (varying dose) + Dasatinib|Phase 1b: BP1001 (varying dose levels) in combination with Das
62536934|NCT02923986|EXPERIMENTAL|BP1001 (fixed dose) + Dasatinib|Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
62536935|NCT01894035||Group 1|
62536936|NCT02293369|ACTIVE_COMPARATOR|Cuff closure via vaginal route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. The repair will start at one end of the vaginal cuff, taking care to incorporate the uterosacral ligament into the initial bite and will continue toward the surgeon until the other uterosacral ligament will be incorporated into the repair, using a continuous 0-Vicryl suture in the vaginal route.
62536937|NCT02293369|ACTIVE_COMPARATOR|Cuff closure via laparoscopic route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. In the laparoscopic approach, needles will be introduced through the umbilical trocar and removed through the peripheral trocars and intracorporeal knots will be utilized.
62536938|NCT02675439|EXPERIMENTAL|Dose escalation monotherapy|ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms
62536939|NCT02675439|EXPERIMENTAL|Dose escalation combination|ADU-S100 administered intratumorally on Days 1 and 8 of each 21-day cycle (starting dose 200 micrograms) and ipilimumab, i.v., (3 mg/kg) on day 1 of each 21-day cycle for the first 4 cycles. Dosing is continued until unacceptable toxicity, progressive disease and/or treatment is discontinued
62536940|NCT03877991|EXPERIMENTAL|CBD-sesame oil capsule|12 volunteers will receive a single oral dose of CBD in a sesame oil vehicle filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
62536941|NCT03877991|EXPERIMENTAL|CBD-LNL capsule|12 volunteers will receive a single oral dose of CBD-LNL formulation filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
62536942|NCT03877991|EXPERIMENTAL|CBD powder form capsule|12 volunteers will receive a single oral dose of CBD in powder form filled in a hard gelatin capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
62536943|NCT06426615|EXPERIMENTAL|Acute brain injury|Patients with acute brain injury with reduced consciousness that undergo multimodal intracranial monitoring, or with suspected seizures
62163426|NCT01474265|ACTIVE_COMPARATOR|varenicline|
62714780|NCT06399536|EXPERIMENTAL|ANH group|Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.
62163427|NCT01474265|ACTIVE_COMPARATOR|Nicorette TX|
62163428|NCT01474265|ACTIVE_COMPARATOR|Nicorette TX optional|
62163429|NCT01474265|NO_INTERVENTION|control group smokers|
62163430|NCT04630873|ACTIVE_COMPARATOR|LOW-HIGH VOLUME|Initially a low volume of the drug (100IU botulinum toxin diluted in 2 ml) after a safe washout period of 6 months the same patients will be injected with a high volume (100IU botulinum toxin in 4 ml) of the drug.
62163431|NCT04630873|EXPERIMENTAL|HIGH-LOW VOLUME|initially a high volume of the drug (100IU botulinum toxin diluted in 4 ml) after a safe washout period of 6 months the same patients will be injected with a low volume (100IU botulinum toxin in 2 ml) of the drug.
62163432|NCT06430151|EXPERIMENTAL|CUE1 users|
62163433|NCT03684018|EXPERIMENTAL|IgPro10 (dose level 1)|
62163434|NCT03684018|EXPERIMENTAL|IgPro10 (dose level 2)|
62163435|NCT01325272||preterm newborn|
62536944|NCT05563376|OTHER|TCPC completed|All patients after TCPC completion
62536945|NCT04159935|EXPERIMENTAL|iLux® treatment|The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.
62536946|NCT04159935|EXPERIMENTAL|Delayed iLux® treatment|Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.
62536947|NCT02727881|EXPERIMENTAL|Squalamine solution, 0.2% BID|Squalamine lactate ophthalmic solution, 0.2% bis in die (BID) + ranibizumab every 4 weeks
62536948|NCT02727881|PLACEBO_COMPARATOR|Placebo solution BID|Placebo ophthalmic solution BID + ranibizumab every 4 weeks
62536949|NCT00866190|EXPERIMENTAL|Cohort 1|SQ109 dose 75 mg or placebo once daily for 14 days.
62536950|NCT00866190|EXPERIMENTAL|Cohort 3|SQ109 dose 150 mg or placebo once daily for 14 days.
62536951|NCT00866190|EXPERIMENTAL|Cohort 2|SQ109 dose 150 mg or placebo once daily on Days 1-5, 9, and 14.
62536952|NCT01140555|EXPERIMENTAL|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
62536953|NCT00749021|ACTIVE_COMPARATOR|Regimen 1|Intravitreal injection of Ranibizumab monthly for 12 months.
62714781|NCT06399536|NO_INTERVENTION|Control group|Participants will be treated as the routine clinical practice. The decision of blood transfusion will be guided as the transfusion guideline.
62536954|NCT00749021|ACTIVE_COMPARATOR|Regimen 2|Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
62536955|NCT00749021|ACTIVE_COMPARATOR|Regimen 3|Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
62536956|NCT00749021|ACTIVE_COMPARATOR|Regimen 4|Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
62536957|NCT02240030|EXPERIMENTAL|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
62536958|NCT02240030|EXPERIMENTAL|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
62536959|NCT02240030|PLACEBO_COMPARATOR|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
62536960|NCT05637164|EXPERIMENTAL|Norepinephrine|
62536961|NCT03850548||Prosthetic joint infection with Cutibacterium acnes|Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
62536962|NCT05260112|EXPERIMENTAL|ERICA|ERICA is a smartphone-based educational program that teaches women newly diagnosed with interstitial cystitis evidence-based strategies to self-manage their symptoms at home. The program is designed to bridge the interval/gap between initial visit where they are diagnosed with interstitial cystitis and follow up visit. Participants received video learning modules via a secure and HIPAA-compliant text messaging system.
62536963|NCT05832567|ACTIVE_COMPARATOR|Active rTMS|The participant will receive a session of low frequency rTMS to the contralesional primary motor cortex. Low frequency rTMS stimulation will be applied according to the following parameter: intensity of 80% MT (intensity could be adjusted if not comfortable to the subject), frequency of 1 Hz, 1200 pulses as a single, continuous train lasting 20 minutes.
62536964|NCT05832567|SHAM_COMPARATOR|Sham rTMS|The investigators will place the coil in the same location, usually used for the active stimulation with the same stimulation parameters. However, the investigators will replace the active coil with a sham coil to ensure no stimulation is provided.
62536965|NCT05832567|PLACEBO_COMPARATOR|Open Placebo|"The open placebo will consist of typical prescription medicine bottle of placebo pills with a label clearly marked placebo pills take 2 pills twice daily. The placebo pills are made from Microcrystalline Cellulose."
62536966|NCT05832567|NO_INTERVENTION|No Intervention|It consists of treatment-as-usual group.
62536967|NCT06007924|EXPERIMENTAL|Radioiodine-refractory (RAIR), recurrent and/or metastatic differentiated thyroid cancer (DTC)|Patients will be treated with avutometinib 3.2 mg twice weekly and defactinib 200 mg twice daily, both 3 weeks on/1 week off.
62536968|NCT06007924|EXPERIMENTAL|Anaplastic thyroid cancer (ATC)|Patients will be treated with avutometinib 3.2 mg twice weekly and defactinib 200 mg twice daily, both 3 weeks on/1 week off.
62536969|NCT01119508|EXPERIMENTAL|Ipilimumab + Temozolomide|Induction: Ipilimumab 10 mg/kg IV over 90 minutes Day 1 + Temozolomide 200 mg/m2 PO on Days 1 - 4, every 3 weeks for 4 courses over 3 months.
62163436|NCT01325272||term newborn|
62536970|NCT01996683|ACTIVE_COMPARATOR|iron chelation|Included 25 thalassemia patients with low serum ferritin (\< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy.
62536971|NCT01996683|PLACEBO_COMPARATOR|blood transfusion only|Included 25 thalassemia patients with low serum ferritin (\< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy.
62536972|NCT06476951|NO_INTERVENTION|Standard of Care|No specific care in physical activity
62163437|NCT01690286|EXPERIMENTAL|Group 1: JNJ-38518168 3 mg/ ketoconazole|
62163438|NCT01690286|EXPERIMENTAL|Group 2: JNJ-38518168 30 mg/ ketoconazole|
62163439|NCT01690286|EXPERIMENTAL|Group 3: JNJ-38518168 10 mg/ ketoconazole (optional)|
62536973|NCT06476951|EXPERIMENTAL|Parent-Child Physical Activity Program|Parent-Child Physical Activity Program
62536974|NCT06368115|EXPERIMENTAL|Single Mailing|A combined patient/caregiver and provider educational intervention with one mailing to each.
62536975|NCT06368115|EXPERIMENTAL|Two Mailings|A combined patient/caregiver and provider educational intervention with a second identical mailing, following the first within 45 days
62536976|NCT06368115|NO_INTERVENTION|Usual Care|
62536977|NCT02640092|EXPERIMENTAL|[18F]GTP1|Participants will complete \[18F\]GTP1 PET imaging at four time points: Baseline, 6 months, 12 months and 18 months. For each \[18F\]GTP1 imaging session, the following procedure will be performed: a catheter will be placed for intravenous (IV) administration of \[18F\]GTP1. Participants will receive an IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of \[18F\]GTP1.
62536978|NCT01310270|EXPERIMENTAL|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation
62536979|NCT01310270|PLACEBO_COMPARATOR|Placebo|
62536980|NCT03675230|ACTIVE_COMPARATOR|3DCRT|This arm will be planned by 3DCRT to the treatment of the Medulloblastoma
62536981|NCT03675230|EXPERIMENTAL|Tomotherapy HD，TOMO|This arm will be planned by TOMO to the treatment of the Medulloblastoma
62536982|NCT01685450|OTHER|Intracranial pressure|
62536983|NCT05261295||Classical LMA|Patients who received general anesthesia with classical LMA
62536984|NCT05261295||i-Gel|Patients who received general anesthesia with i-Gel
62536985|NCT03521466|EXPERIMENTAL|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
62536986|NCT03521466|NO_INTERVENTION|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
62536987|NCT04269681|EXPERIMENTAL|High Flow Nasal Cannula Arm|Participants will receive HFNC if they have no delirium and signs of ARF. The device is supposed to be used continuously in the nose with some changes in flow and/or temperature according to tolerance. There is no crossover to the standar of care arm.
62536988|NCT04269681|ACTIVE_COMPARATOR|Standard respiratory support|Participants will receive standard of care with low flow oxygen catheter or mask initially. If there is any sign of clinical deterioration NIV can be offered if tolerated by the patient. There will be no cross over with HFNC arm.
62536989|NCT04105140|EXPERIMENTAL|male oxytocin group|male subjects with oxytocin treatment
62536990|NCT04105140|PLACEBO_COMPARATOR|male placebo group|male subjects with placebo treatment
62163440|NCT04829318|EXPERIMENTAL|Esketamine|Participants who were randomly assigned to the esketamine arm in Study 54135419TRD3013 (NCT04338321), had esketamine nasal spray administered through Week 30 (every 2 weeks dosing) or Week 31 (once weekly dosing), completed the maintenance phase at Week 32 will continue to receive esketamine nasal spray once weekly or every 2 weeks along with serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI) in this long-term extension (LTE) study. The duration of the study participation is 2 years or when esketamine is commercially available.
62163441|NCT03436797|EXPERIMENTAL|AK002-IV|AK002 given as monthly intravenous infusions at up to 3 mg/kg.
62163442|NCT04916847||children with controlled HIV|Children over 0 days and under 16 years old, with controlled HIV
62163443|NCT04916847||children with hematologic Malignancy treated by conventional chemotherapy|Children over 0 days and under 16 years old, with Hematologic Malignancy treated by conventional chemotherapy
62163444|NCT04916847||Children with inflammatory bowel disease treated by anti-TNF at least 6 weeks|Children over 0 days and under 16 years old, with inflammatory bowel disease treated by anti-TNF
62163445|NCT04916847||Children with idiopathic juvenile arthritis|Children over 0 days and under 16 years old, with idiopathic juvenile arthritis treated by methotrexate:
62163446|NCT04916847||Children treated by renal transplantation|Children over 0 days and under 16 years old, treated by renal transplantation from more than 3 months:
62163447|NCT04916847||Children attending consultation|"Children over 0 days and under 16 years old, without immunodepression or chronic inflammation attending consultation for :~* preoperative assessment~* -congenital abnormalities of the kidney and urinary tract:~* Nephropathies without renal impairment (eDFG \> 45mL/min/1.73m2)~* Non-inflammatory intestinal (polyposis, Chronic intestinal pseudo-obstruction, short bowel syndrome) or pancreatic (hereditary pancreatitis) pathologies This group of children will be a control group (age matched healthy children, non-immunosuppressed)."
62163448|NCT06355531|EXPERIMENTAL|FNP-223|Participants will receive FNP-223 orally (PO), 3 times daily (TID).
62163449|NCT06355531|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo, PO, TID.
62163450|NCT02592317|EXPERIMENTAL|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam \[2 milligram {mg}\], warfarin \[10 mg\], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine \[30 mg\]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
62163451|NCT06016127|ACTIVE_COMPARATOR|Cryoneurolysis|Subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine
62163452|NCT06016127|ACTIVE_COMPARATOR|Radiofrequency ablation|Subjects will receive RFA to the medial branch nerves of the lumbar spine
62163453|NCT06720116|EXPERIMENTAL|sustained natural apophysial glide|patients will receive sustained natural apophysial glide( SNAGS ) in addition to conventional therapy in the form of ( Infrared, TENS , stretching exercices, isometric exercises) for chronic mechanical neck pain ,3 sessions per week for one month
62163454|NCT06720116|EXPERIMENTAL|instrument assisted soft tissue mobilization|patients will receive instrument assisted soft tissue mobilization ( IASTM) technique in addition to conventional therapy in the form of ( Infrared, TENS , stretching exercices, isometric exercises) for chronic mechanical neck pain ,3 sessions per week for one month.
62163455|NCT06720116|ACTIVE_COMPARATOR|conventional therapy|patients will receive conventional therapy in the form of ( Infrared, TENS , stretching exercices, isometric exercises) for chronic mechanical neck pain ,3 sessions per week for one month.
62163456|NCT06636786|EXPERIMENTAL|Cyclobenzaprine HCl|Participants will be instructed to take a half dose (equivalent to 1 tablet, 2.8 mg) of placebo in the ED as part of enrollment procedures. If the time between the first half dose and the planned bedtime of the participant is less than 6 hours, participants will be instructed to take 1 tablet (half dose) the first night at bedtime. If the time between the first half dose and planned bedtime of the participant is greater than or equal to 6 hours, then participants will be instructed to take a full dose (equivalent to 2 tablets) the first night. Over the following 13 days, all participants will be instructed to take a full dose of the study drug at bedtime. Each participant will receive 29 tablets and take either 28 or 29 tablets total for the duration of study participation.
62163457|NCT06636786|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take a half dose (equivalent to 1 tablet, 2.8 mg) of placebo in the ED as part of enrollment procedures. The placebo is the same formulation as active except the Cyclobenzaprine HCl content is replaced by Mannitol to maintain the same tablet weight and dimensions. If the time between the first half dose and the planned bedtime of the participant is less than 6 hours, participants will be instructed to take 1 tablet (half dose) the first night at bedtime. If the time between the first half dose and planned bedtime of the participant is greater than or equal to 6 hours, then participants will be instructed to take a full dose (equivalent to 2 tablets) the first night. Over the following 13 days, all participants will be instructed to take a full dose of the study drug at bedtime. Each participant will receive 29 tablets and take either 28 or 29 tablets total for the duration of study participation.
62163458|NCT06106256|EXPERIMENTAL|Positive GVS During VR Flight Simulation|Subjects will receive positive galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
62163459|NCT06106256|EXPERIMENTAL|Negative GVS During VR Flight Simulation|Subjects will receive negative galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
62163460|NCT06106256|EXPERIMENTAL|No GVS During VR Flight Simulation|Subjects will not receive any galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
62163461|NCT06106256|EXPERIMENTAL|Positive GVS During 3-DOF Bertec Portable Essential's dual-balance force plate system|Subjects will receive positive galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
62536991|NCT05145179|EXPERIMENTAL|HER2-expressing Solid Tumors|SSGJ-705 Administered via intravenous (IV) infusion
62536992|NCT03206463|EXPERIMENTAL|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
62163462|NCT06106256|EXPERIMENTAL|Negative GVS During 3-DOF Bertec Portable Essential's dual-balance force plate system|Subjects will receive negative galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
62163463|NCT06106256|EXPERIMENTAL|No GVS During 3-DOF Bertec Portable Essential's dual-balance force plate system|Subjects will not receive any galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
62536993|NCT03206463|EXPERIMENTAL|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
62536994|NCT03206463|PLACEBO_COMPARATOR|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
62536995|NCT01996449|ACTIVE_COMPARATOR|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
62536996|NCT01996449|ACTIVE_COMPARATOR|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
62536997|NCT02171078||Alliance for Clinical Trials Database|Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
62536998|NCT02171078||National Cancer Database|Use existing data to evaluate the effectiveness of the latest imaging technology for detecting recurrence and improving survival in patients previously treated for breast cancer.
62536999|NCT02171078||Stakeholder Engagement|Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.
62537000|NCT04918498|PLACEBO_COMPARATOR|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
62537001|NCT04918498|EXPERIMENTAL|Experimental group|Implement early physiotherapy programs. The early physiotherapy program for VV-ECMO patients mainly includes the establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy.
62537002|NCT01229709|EXPERIMENTAL|Mindfulness Based Tinnitus Reduction|
62537003|NCT01229709|NO_INTERVENTION|Tinnitus Counseling Only Control|Control group subjects will have had treatment as usual (TAU) care from the UCSF Audiology Clinic which includes Tinnitus Counseling (TC) at least three-months prior to enty into the study.
62163464|NCT05036070|EXPERIMENTAL|Study Lens|Model C0001
62163465|NCT05036070|ACTIVE_COMPARATOR|Control Lens|Model ZCB00
62163466|NCT04768491||dacomitinib treatment|Sequential Therapy with Dacomitinib as First-line Treatment Followed by 3rd generation EGFR-TKI in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
62537004|NCT03748030||Confirmed Left-Sided Breast Cancer|T1/T2 N0, T1/T2 N1, T3/T4 and/or N2/N3 Left-Sided Breast Cancer Patients receiving standard radiation therapy will receive PET/MRI, ECG/EKG, and bloodwork before, within a month, and within a year post treatment.
62537005|NCT06437483|EXPERIMENTAL|Group A|Participants in this group will receive Sustained Natural Apophyseal Glides followed by Kinesiotaping in addition to the conventional treatment. This arm of the study will assess the synergistic effects of SNAGs and kinesiotape.
62537006|NCT06437483|ACTIVE_COMPARATOR|Group B|Participants in group B will receive Sustained Natural Apophyseal Glides along with the conventional treatment.
62537007|NCT03882528|EXPERIMENTAL|Infective controls|Controlled Human Malaria Infection (CHMI) will consist of exposure to Plasmodium falciparum sporozoites through the bites of infected mosquitoes. Beginning 5 days after the challenge, subjects will be evaluated daily for the development of malaria infection using a blood smear.
62163467|NCT05843695|EXPERIMENTAL|iTCBT-I (Intensive Transdiagnostic Cognitive Behavioral Therapy-Individual)|"Patients in this arm will receive transdiagnostic CBT delivered in an intensive individual format over 2 weeks. Intensive Transdiagnostic Cognitive Behavior Therapy-Individual (iTCBT-I): Participants randomized to this condition will receive 12 hours of treatment in four 3 hour sessions, over a 2-week period. Treatment consists of psychoeducation, cognitive restructuring, and exposure exercises.~For treatment non-responders (i.e., BAI score decrease \< 10), patients will receive 4 additional 90 minute sessions of individual therapy over a 2-week period (iTCBT-Enhanced). These sessions will identify areas where participants might benefit from more in-depth focus on specific concepts taught in the treatment."
62163468|NCT05843695|ACTIVE_COMPARATOR|iTCBT-G (Intensive Transdiagnostic Cognitive Behavioral Therapy-Group)|"Patients in this arm will receive transdiagnostic CBT delivered in an intensive group format over 2 weeks. Intensive Transdiagnostic Cognitive Behavior Therapy-Group (iTCBT-G): Participants randomized to this condition will receive 12 hours of treatment over a 2-day period (6 hrs each day). Treatment consists of psychoeducation, cognitive restructuring, and exposure exercises.~For treatment non-responders (i.e., BAI score decrease \< 10), patients will receive 4 additional 90 minute sessions of individual therapy over a 2-week period (iTCBT-Enhanced). These sessions will identify areas where participants might benefit from more in-depth focus on specific concepts taught in the treatment."
62163469|NCT05843695|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual, which may include other forms of psychotherapy and/or medication.
62163470|NCT02746783|ACTIVE_COMPARATOR|Group 1|Single dose of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
62163471|NCT02746783|EXPERIMENTAL|Group 2|Double dose of MUTAGRIP® (one dose into the right deltoid area and the other one into the left deltoid area) containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
62163472|NCT04241380|ACTIVE_COMPARATOR|Conventional treatment group|Patients in this group will received conventional treatments. Drug: None. Drug: For the high-risk patients, doctors will assess their risk factors and choose continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) if needed. Aspirin 5 mg/kg may be given every eight hours subsequently for 3 months.
62537008|NCT04549753|EXPERIMENTAL|tDCS stimulation group|Patients receive four sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system.
62537009|NCT04889287|EXPERIMENTAL|Rosuvastatin and/or elinzanetant|The participants will receive each dose of rosuvastatin and/or elinzanetant together with 240 mL of non-sparkling water in total.
62537010|NCT05297695|EXPERIMENTAL|Study group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will receive H. pylori eradication therapy.
62537011|NCT05297695|NO_INTERVENTION|Control group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will not receive H. pylori eradication therapy.
62537012|NCT05876767|EXPERIMENTAL|SAR444336|SAR444336
62537013|NCT05876767|PLACEBO_COMPARATOR|Placebo|placebo
62537014|NCT00849186|EXPERIMENTAL|Arm 1|
62537015|NCT03839823|EXPERIMENTAL|Ribociclib 600 mg|"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.~1. Ribociclib (600 mg) was dosed orally for the first 21 days out of a 28-day cycle.~2. Letrozole (2.5 mg) or anastrozole (1 mg) were dosed orally daily (28 days out of the 28-day cycle).~3. Goserelin (3.6 mg) was continuously released via a subcutaneous implant injected on Day 1 of each 28-day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days."
62537016|NCT03839823|ACTIVE_COMPARATOR|Combination Chemotherapy|Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine were administered to patients enrolled in the control group. The chemotherapy regimen was decided by the treating physician.
62537017|NCT03323437|EXPERIMENTAL|Patient|Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
62537018|NCT03323437|NO_INTERVENTION|Control|Healthy, psychosis-free controls who will not receive risperidone
62537019|NCT00892996|NO_INTERVENTION|1|Metoclopramide 10 mg intravenous
62537020|NCT00892996|NO_INTERVENTION|2|Ondansetron 8 mg intravenous
62714782|NCT01796743||Controls|Age and gender matched controls ('control' group) with acute MI with similar degree of troponin elevation who are managed based solely on the basis of clinical or angiographic data alone.
62537021|NCT00892996|ACTIVE_COMPARATOR|3|dexamethasone 5 mg and metoclopramide 10 mg
62537022|NCT00892996|ACTIVE_COMPARATOR|4|dexamethasone 5 mg and ondansetron 8 mg IV
62537023|NCT01303770|EXPERIMENTAL|Cognitive intervention group|Cognitive rehabilitation program designed to be tested in this study
62537024|NCT01303770|ACTIVE_COMPARATOR|Control group|
62537025|NCT02581397|EXPERIMENTAL|Transpulmin suppository|"It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
62537026|NCT02581397|EXPERIMENTAL|Guaiacol suppository|"It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
62537027|NCT02581397|ACTIVE_COMPARATOR|Transpulmin syrup|"It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days."
62537028|NCT01078883||Lung cancer|Patients with primary stage IIIb and IV lung cancer
62537029|NCT04063423||hemodialysis study session|"* 4h hemodialysis session using standard polysulphone dialyzer and Nikkiso dialysis monitors~* Minimal dose of unfractionated heparin (UFH) with loading dose 500IE and maintenance 500IE/h, stopped 60 minutes before session end in case of AVF use.~* Standard bicarbonate-based ultrapure dialysate. Na, K, Ca, bicarbonate concentrations according to the patient's routine dialysis prescription.~* The blood flow rate maximized as per routine nursing care.~* Dialysate flow rate fixed at 500 ml/min.~* Dialysate temperature between 35.5°C and 36.5°C.~* Ultrafiltration according to patient's dry weight and supported ultrafiltration rate.~* At the end of the dialysis session the blood will be returned (100ml/min) to the patient."
62537030|NCT01161407|PLACEBO_COMPARATOR|Placebo|Placebo control for calcium carbonate, given in same capsule form as the calcium carbonate, 3 times per day with meals.
62537031|NCT01161407|ACTIVE_COMPARATOR|Calcium Carbonate (Phosphate Binder)|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium.
62537032|NCT02826837|EXPERIMENTAL|LEAC-102 and FOLFOX+Bevacizumab/Cetuximab|"The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
62714783|NCT01796743||Cardiac MRI|Hospitalized patients with acute MI with a clinically-indicated CMR ordered will be enrolled. Data for T2 mapping will be added to the clinically prescribed cardiac MRI scan.
62537033|NCT04429438|EXPERIMENTAL|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after chemotherapy will be treated with a combination of 4SCAR gene-engineered T cells.
62537034|NCT06443411||Glaucoma group|The prospective clinical study will include at least 56 patients with NTG using non-invasive ICP waves monitoring system through a human eye orbit without applying external pressure to the eye with approximately 10 millisecond temporal resolution. It is a prospective longitudinal study of patients with normal tension glaucoma by the inclusion age from 25 to 65 years. The standard monitoring session will last 1-3 minutes. Sex: male and female. Exclusion criterion is documented neurodegenerative disorders.
62537035|NCT06443411||Control group|100 healthy subjects using non-invasive ICP waves monitoring system through a human eye orbit without applying external pressure to the eye with approximately 10 millisecond temporal resolution.
62537036|NCT06196814|EXPERIMENTAL|Cohort of EGFR Sensitve Mutant NSCLC|Efficay, Satety and Dose Escalation of AK112 plus Platinum-based Chemotherapy for EGFR Sensitive mutant NSCLC who Failed from First-Line Osimertinib.
62537037|NCT06196814|EXPERIMENTAL|Cohort of ALK Fusion NSCLC|Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for ALK fusion NSCLC who Failed from First-Line Osimertinib.
62537038|NCT06196814|EXPERIMENTAL|Cohort of ROS1 Fusion NSCLC|Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for ROS1 fusion NSCLC who Failed from First-Line Crizotinib.
62537039|NCT04277143||critical ill patient with bloodstream infections|Severe patients with bloodstream infections often have sepsis / septic shock, acute kidney injury (AKI), hypoproteinemia, and renal replacement treatment.
62537040|NCT04856423||Us-qFIT group|People in this group will detect fecal hemoglobin concentration by us-qFIT before colonoscopy.
62537041|NCT00661011|EXPERIMENTAL|A|Lobectomy followed by mediastinal concomitant chemoradiotherapy
62537042|NCT02041910|EXPERIMENTAL|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
62537043|NCT02041910|EXPERIMENTAL|Stem Cells Injection|Stem Cell Dose 3-5 Million Autologous MSCs Injected into testis.
62537044|NCT00759187|PLACEBO_COMPARATOR|A|
62537045|NCT00759187|ACTIVE_COMPARATOR|B|
62537046|NCT00759187|ACTIVE_COMPARATOR|C|
62537047|NCT00581087|EXPERIMENTAL|1|DHEA
62537048|NCT00581087|PLACEBO_COMPARATOR|2|Placebo
62537049|NCT05641090|EXPERIMENTAL|Nordic walking in water|The groups trained Nordic walking in water
62537050|NCT05641090|NO_INTERVENTION|No exercise intervention|The groups did not receive exercise
62537051|NCT05830149|EXPERIMENTAL|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
62537052|NCT05830149|ACTIVE_COMPARATOR|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
62537053|NCT00183560|EXPERIMENTAL|1|Participants will receive mindfulness based cognitive therapy
62537054|NCT00183560|ACTIVE_COMPARATOR|2|Participants will receive maintenance antidepressant pharmacotherapy
62537055|NCT00183560|PLACEBO_COMPARATOR|3|Participants will receive placebo plus clinical management
62537056|NCT03219619|EXPERIMENTAL|Cap group: Cap-EGD|Undergoing cap-assisted esophagogastroduodenoscopy
62537057|NCT03219619|ACTIVE_COMPARATOR|Duo group: Duo|Undergoing side-viewing duodenoscope
62537058|NCT06362668|EXPERIMENTAL|Reprieve Decongestion Management System|Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
62537059|NCT06362668|ACTIVE_COMPARATOR|Optimal Diuretic Therapy|Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials \[Diuretic Strategies in Patients with Acute Heart Failure Trail (DOSE), Acetazolamide in Decompensated Heart Failure with Volume Overload Trial (ADVOR), and Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure Trial (CLOROTIC)\] for patients randomized to control arm of the trial.
62163473|NCT04241380|EXPERIMENTAL|Anti-coagulant treatment|Continuous infusion heparin. Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5mg/kg will be given every eight hours subsequently for three months. Study will follow the intention-to-treat principle.
62163474|NCT06296797|EXPERIMENTAL|Comparative information on tubal sterilization and other long-acting contraceptives|A new website comparing tubal sterilization to vasectomy and long-acting reversible contraceptives
62537060|NCT00933348|ACTIVE_COMPARATOR|OPAL A plus standard wound care|
62537061|NCT00933348|PLACEBO_COMPARATOR|Placebo plus standard wound care|
62537062|NCT03632863|EXPERIMENTAL|Electronic Patient Decision Aid|Participants login to a website where they access the interactive PDA as well as access standard published information and resources.
62537063|NCT03632863|SHAM_COMPARATOR|Standard Resource Sheet|Participants login to a website where they access standard published information and resources.
62163475|NCT06296797|ACTIVE_COMPARATOR|Information on tubal sterilization|Participants will be shown an existing web page developed by Planned Parenthood for people considering tubal sterilization
62163476|NCT05032651|EXPERIMENTAL|GROUP A-AI (model) Arm Description:|Artificial intelligence assisted platform supported system for the clinical physicians to prescribe ESA dose to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
62163477|NCT05032651|EXPERIMENTAL|GROUP B-AI (model) Arm Description:|ESA dose prescribed by clinical physicians as regular care to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
62163478|NCT00802334|EXPERIMENTAL|1|
62163479|NCT02137603|EXPERIMENTAL|Fast track|Patients discharged home the same day following appendectomy
62163480|NCT02137603|NO_INTERVENTION|Admission|Patients are admitted to the inpatient unit following appendectomy for suppurative appendicitis and treated per the current standard of care.
62163481|NCT04586049||Veterans with GWI|Veterans with GWI who served in the Gulf War between 1990 and 1992
62163482|NCT04586049||Veterans without GWI (Controls)|Veterans without GWI who served in the Gulf War between 1990 and 1992
62163483|NCT00892970|EXPERIMENTAL|1|
62163484|NCT00892970|PLACEBO_COMPARATOR|2|
62163485|NCT02523417|EXPERIMENTAL|HepaSphere|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
62163486|NCT02523417|PLACEBO_COMPARATOR|control|breast cancer patients received traditional therapy
62163487|NCT01863368|EXPERIMENTAL|Systane Ultra|Systane® ULTRA lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
62163488|NCT01863368|ACTIVE_COMPARATOR|Optive|OPTIVE® lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
62163489|NCT02223299|EXPERIMENTAL|Deplin w Supplements|deplin 15mg plus L-Tyrosine 6g/d and L-Tryptophan 2g/d for 30 days
62163490|NCT02223299|PLACEBO_COMPARATOR|Deplin w placebo|deplin 15mg daily plus Placebo A and Placebo B for 30 days
62163491|NCT02249923||Pulmonary Arterial Hypertension|
62163492|NCT02301078||Percutaneous Needle Aponeurotomy|Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease
62163493|NCT02301078||Xiaflex|Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.
62163494|NCT05614843|EXPERIMENTAL|PBM group|Energy density 7.5 J / cm2
62537064|NCT03844217|EXPERIMENTAL|Macimorelin 0.5mg/kg body weight|"Visit 1: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin.~Visit 2: After a washout-phase of 1 week, participants will undergo the oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight. Study procedures are equal compared to visit 1.~Macimorelin 0.75mg/kg body weight"
62537065|NCT04990427|EXPERIMENTAL|CLBS201|CLBS201 will be administered in an open-label fashion via intra-renal-arterial infusion in 6 subjects followed by 6 months of observation.
62714784|NCT04841590|EXPERIMENTAL|Experimental Group|The experimental group (EG) will receive treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
62163495|NCT05614843|PLACEBO_COMPARATOR|Control group|The placebo control group will carry out the same protocol used in irradiated patients (including the use of protective goggles) using the same laser device to imitate a real irradiation; however, the device will be turned off and recording of the emission sounds will be used to give the patient the hearing sensation of the PBM therapy.
62163496|NCT00720629|EXPERIMENTAL|First Study Stage: Study Treatment|Visilizumab, Tacrolimus and Methotrexate.
62163497|NCT00720629|ACTIVE_COMPARATOR|Second Study Stage: Standard Treatment|Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
62163498|NCT01654289|EXPERIMENTAL|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
62163499|NCT01654289|EXPERIMENTAL|Exercise|The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
62163500|NCT01654289|NO_INTERVENTION|Wait-list control|"Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as experimental participants."
62163501|NCT04260100|EXPERIMENTAL|Intervention Group|
62163502|NCT04260100|NO_INTERVENTION|Control Group|Routine care group
62537066|NCT05231330|EXPERIMENTAL|silver nanoparticles|
62537067|NCT05231330|ACTIVE_COMPARATOR|silverdiamine fluoride|
62537068|NCT05231330|NO_INTERVENTION|no medicament|
62537069|NCT04987385|OTHER|single arm: Phase 1: protein supplementation, Phase 2: Urea|
62163503|NCT06720571|EXPERIMENTAL|Active stimulation|
62163504|NCT06720571|SHAM_COMPARATOR|Sham stimulation|
62163505|NCT04560322|EXPERIMENTAL|Venetoclax-Obinutuzumab +/- Acalabrutinib|"A treatment cycle is defined as 28 consecutive days. Participants with undetectable MRD (uMRD) at 1 year will complete an additional 1 year of VO then stop therapy.~Participants with high detectable MRD at 1 year will complete an additional 1 year of VO plus acalabrutinib then stop therapy.~Participants with low detectable MRD at 1 year will complete an additional 1 year of VO alone. If this eradicates MRD, they will stop therapy. If there is still residual MRD, they will complete an additional 1 year of IVO then stop therapy.~If progression occurs on VO, I will be added and IV will be administered indefinitely. After 2 years, V may be stopped and I continued as monotherapy at investigator discretion.~* Infused Study Drug: Obinutuzumab on Days 1, 2, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 1-6~* Oral Study Drugs: Venetoclax daily starting on Cycle 1 Day 22~* Oral Drug: acalabrutinib daily for Days 1-28 (if applicable)"
62163506|NCT04803058|EXPERIMENTAL|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
62163507|NCT06474234|EXPERIMENTAL|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
62163508|NCT06474234|PLACEBO_COMPARATOR|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
62163509|NCT05222178|EXPERIMENTAL|Low Dose Cohort|HMI-103 delivered IV one time
62163510|NCT05222178|EXPERIMENTAL|Intermediate Dose Cohort|HMI-103 delivered IV one time
62163511|NCT05222178|EXPERIMENTAL|High Dose Cohort|HMI-103 delivered IV one time
62163512|NCT00003778|EXPERIMENTAL|Arm I|Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62163513|NCT02699606|EXPERIMENTAL|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
62163514|NCT01898026|EXPERIMENTAL|PGX|samples of white bread, mashed potatoes, muffin, hot breakfast cereal with the addition of soluble fibre blend
62163515|NCT01898026|OTHER|Control|samples of white bread, mashed potatoes, muffin, hot breakfast cereal without the addition of soluble fibre blend
62163516|NCT05872958|EXPERIMENTAL|AZD3152 Dose X (IM)|Participants will receive dose X of AZD3152 on Day 1 as a single IM injection.
62537070|NCT04691726|ACTIVE_COMPARATOR|Lidocaine infusion|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 2 mg/kg IBW i.v., continuous infusion of 1% lidocaine postoperatively rate 1 mg/kg IBW i.v. for 24 hours
62537071|NCT04691726|PLACEBO_COMPARATOR|Saline infusion|equal volumes of placebo - 0,9% saline i.v.
62537072|NCT03207867|EXPERIMENTAL|NIR178 + PDR001|Part 1: NIR178 continuously in combination with PDR001 400mg every 4 weeks. The part 1 enrolled 9 different tumor types.
62163517|NCT05872958|EXPERIMENTAL|AZD3152 Dose X (IV)|Participants will receive dose X of AZD3152 on Day 1 as an IV infusion.
62163518|NCT05872958|EXPERIMENTAL|AZD3152 Dose Y (IM)|Participants will receive dose Y of AZD3152 on Day 1 as 2 sequential IM injections.
62537073|NCT03207867|EXPERIMENTAL|NIR178 BID Intermittent + PDR001|Part 2: Three different dosing schedules of NIR178 twice daily (BID) including continuous and two intermittent in combination with PDR001
62537074|NCT03207867|EXPERIMENTAL|Part 3|Further evaluation of optimal intermittent or continuous schedule of NIR178 in combination with PDR001 (if selected based on results of Part 2). A film-coated tablet of NIR178 was assessed.
62537075|NCT03207867|EXPERIMENTAL|Japanese safety run-in part|Different dosing schedules of NIR178 were explored.
62537076|NCT06292403|ACTIVE_COMPARATOR|Strength Training|Non-hemiplegic lower limb stepping forward training Non-hemiplegic upper limb pulling elastic belt in standing position repeatedly Hemiplegic lower limb stepped over an obstacle or climbed a platform The patients will stretch their arms to touch distant objects in a standing position repeatedly.
62537077|NCT06292403|EXPERIMENTAL|Mirror Therapy and strength Training Group|Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
62537078|NCT06213935|ACTIVE_COMPARATOR|group A|will receive a norepinephrine bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min
62537079|NCT06213935|ACTIVE_COMPARATOR|Group B|will receive 10 mg tablets of midodrine 1 hour before spinal anesthesia.
62537080|NCT02951975||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
62537081|NCT01318486|ACTIVE_COMPARATOR|Heparin free dialysis standard of care|Standard of care: can be either saline flushes or predilution (on-line or bags)
62537082|NCT01318486|EXPERIMENTAL|Heparin free dialysis with Evodial|
62537083|NCT03555006|OTHER|Local vs remote group|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation
62537084|NCT03555006|OTHER|Local vs local group|The examination will be interpreted by two department's radiologists
62537085|NCT00315731|EXPERIMENTAL|tositumomab and iodine I 131 tositumomab|Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy.
62537086|NCT04451681|OTHER|Ankylosing spondylitis|A total of 42 patients, who were diagnosed with AS with modified New York Criteria, and who agreed to participate in the study, will be included in this group.
62537087|NCT04451681|OTHER|Control|A total of 42 control participants between the ages of 18-65 who agreed to participate in the study will be included in this group.
62537088|NCT02167373|NO_INTERVENTION|Control|
62537089|NCT02167373|EXPERIMENTAL|Intervention|Cogito Companion Intervention. Participants will be provided with a mobile phone application that provides feedback on their mental health. The participants' clinicians will be provided with a desktop application to review their patients' results.
62537090|NCT04749238|EXPERIMENTAL|Treatment with NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm.
62537091|NCT02566356|EXPERIMENTAL|Oxytocin|40 IU Oxytocin
62537092|NCT02566356|PLACEBO_COMPARATOR|Saline Nasal Spray|Placebo Comparator
62537093|NCT04431726|EXPERIMENTAL|Emicizumab|
62537094|NCT01114932||BMI-I|Patients with BMI values between 18.5-24.9
62537095|NCT01114932||BMI-II|Patients with BMI values between 25-29.9
62163519|NCT05872958|EXPERIMENTAL|AZD3152 Dose Y (IV)|Participants will receive dose Y of AZD3152 on Day 1 as an IV infusion.
62163520|NCT05872958|EXPERIMENTAL|AZD3152 Dose Z (IV)|Participants will receive dose Z of AZD3152 on Day 1 as an IV infusion.
62163521|NCT05872958|PLACEBO_COMPARATOR|Pooled placebo|Participant will receive placebo on Day 1 either via IM injection or IV infusion.
62163522|NCT01669720|EXPERIMENTAL|Aflibercept|Patients will be randomized 2:1, to receive Aflibercept,4mg/kg IV q2weeks until progression for a maximum of 2 years
62537096|NCT01114932||BMI-III|Patients with BMI values between 30-49.9
62163523|NCT01669720|NO_INTERVENTION|Observation|Patients will be randomized 2:1 to receive Aflibercept. Patients who are randomized to observation will be followed per the study table, but will receive no intervention.
62163524|NCT01536795|EXPERIMENTAL|WR279,396 with Tegaderm dressing|24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing
62163525|NCT01536795|EXPERIMENTAL|WR279,396 with Gauze and Tape Dressing|24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).
62163526|NCT03322449|EXPERIMENTAL|Animal Diet|during this Arm, the participants will receive a diet enriched in animal products
62163527|NCT03322449|EXPERIMENTAL|Plant Diet|during this Arm, the participants will receive a diet enriched in plant products
62163528|NCT06241677|ACTIVE_COMPARATOR|IVT group|For patients enrolled into the IVT group from participating centers that allow IVT in patients with last DOAC intake 12-48 hours before presentation (PWH, QEH, QMH, UCH, TMH): Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg, intravenous infusion) or tenecteplase (0.25mg/kg, maximum dosage 25mg, intravenous infusion) will be given at discretion of the treating physician.
62163529|NCT06241677|NO_INTERVENTION|Control|For patients enrolled into the control group from participating centers that exclude eligible patients from IVT (PMH, PYNEH): no IVT will be given unless specific antidote can be administered before IVT.
62163530|NCT06577376|EXPERIMENTAL|DP303c injection, dose level 1, Q3W + simmitinib tablets, dose level 1, D1-D21, Q4W|DP303c injection, dose level 1, intravenous drip, Q3W + simmitinib tablets, dose level 1, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W
62163531|NCT06577376|EXPERIMENTAL|DP303c injection, dose level 1, Q3W + simmitinib tablets, dose level 2, D1-D21, Q4W|DP303c injection, dose level 1, intravenous drip, Q3W + simmitinib tablets, dose level 2, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W
62163532|NCT06577376|EXPERIMENTAL|DP303c injection, dose level 1, Q2W + simmitinib tablets, dose level 2, D1-D21, Q4W|DP303c injection, dose level 1, intravenous drip, Q2W + simmitinib tablets, dose level 2, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W
62163533|NCT06577376|EXPERIMENTAL|DP303c injection, dose level 2, Q3W + simmitinib tablets, dose level 2, D1-D21, Q4W|DP303c injection, dose level 2, intravenous drip, Q3W + simmitinib tablets, dose level 2, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W
62163534|NCT06577376|EXPERIMENTAL|DP303c RP2D + irinotecan liposomes RP2D|
62163535|NCT06577376|ACTIVE_COMPARATOR|Single agent chemotherapy chosen by researchers|Single agent chemotherapy chosen by researchers: paclitaxel, docetaxel, or irinotecan
62163536|NCT06286618|EXPERIMENTAL|Psychosocial or Structural Intervention|During optimization 1 phase, participants are assigned to two groups: Psychosocial or Structural Intervention. One group will receive psychosocial support for diet only and the other will receive structural support for diet only. Each group will have three modalities.
62537097|NCT06400134||Geriatric individuals|Volunteer healthy geriatric individuals aged 65 years and over
62537098|NCT06219278||Matrix Pro Applicator|Source study subjects received up to three (3) full-face treatments for wrinkles with Matrix Pro Applicator (27W)
62537099|NCT03058094|EXPERIMENTAL|AC0010|AC0010, 300mg, orally, BID with a 21-day cycle
62163537|NCT06286618|EXPERIMENTAL|Combined Psychosocial and Structural Intervention|The optimization 2 phase will be used to test a combined psychosocial and structural intervention, based on the most feasible selections from optimization 1 phase.During optimization 2 phase, participants will be assigned to two groups. One group will receive referral based delivery model for a combined psychosocial and structural intervention and the other group will receive an integrated delivery model for a combined psychosocial and structural intervention.
62163538|NCT06267326|OTHER|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years eighteen patients presented with COVID 19 and seventeen patients presented to our hospital post healing with history of using large doses of systemic corticosteroids. patients were managed by aggressive surgical debridement, antifungal drugs Amphotericin B and adjunctive treatment like local irrigation with amphotericin B and hyperbaric oxygen according to systemic conditions of patients. Hyperbaric oxygen was used in five patients post-surgically. all investigations were done with mean values of blood glucose level, hemoglobin and WBC were noticeably abnormal. The degree of severity, length of stay, and mortality rate were significantly correlated with the severity of systemic predisposing factors
62537100|NCT03058094|ACTIVE_COMPARATOR|Chemotherapy|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.
62537101|NCT02777814|EXPERIMENTAL|Prophylactic Entecavir|Entecavir is prophylactically used from the time of chemotherapy initiation at the dose of 0.5 mg p.o daily
62537102|NCT02777814|ACTIVE_COMPARATOR|Preemptive Entecavir|Entecavir is preemptively used from the time that hepatitis B virus DNA copies are more than 100 IU/ml at the dose of 0.5 mg p.o daily
62537103|NCT06167863||WHO ISUP grading high|high-grade refer to Grades 3 and 4 tumours with an unfavourable prognosis
62537104|NCT06167863||WHO ISUP grading low|low-grade refer to Grades 1 and 2 tumours with a promising prognosis
62537105|NCT02155543|EXPERIMENTAL|Cohort 1: AGN-223575 Form A/Vehicle|One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days.
62537106|NCT02155543|EXPERIMENTAL|Cohort 2: AGN-223575 Formulation A BID|One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15.
62714785|NCT04841590|SHAM_COMPARATOR|Control Group|The control group (CG) will not receive any treatment
62736492|NCT01540526|EXPERIMENTAL|Pharmacodynamic cohort|PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
62537107|NCT02155543|EXPERIMENTAL|Cohort 3: AGN-223575 Formulation B BID|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
62163539|NCT06267326|EXPERIMENTAL|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years eighteen patients presented with COVID 19 and seventeen patients presented to our hospital post healing with history of using large doses of systemic corticosteroids. patients were managed by aggressive surgical debridement, antifungal drugs Amphotericin B and adjunctive treatment like local irrigation with amphotericin B and hyperbaric oxygen according to systemic conditions of patients. Hyperbaric oxygen was used in five patients post-surgically. all investigations were done with mean values of blood glucose level, hemoglobin and WBC were noticeably abnormal. The degree of severity, length of stay, and mortality rate were significantly correlated with the severity of systemic predisposing factors
62163540|NCT04641156|EXPERIMENTAL|Low level LASER Therapy|Subjects in this group received low-level laser therapy
62163541|NCT04641156|EXPERIMENTAL|Exercise group|Subjects in this group received additional planned exercise therapy program
62163542|NCT03978299||Positive PSA result|"Men with a positive PSA test defined as:~* Serum total PSA concentration is over 10 ng/ml.~* Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is under 25%, in at least in two determinations."
62163543|NCT03978299||Negative PSA result|"Men with a negative PSA test defined as:~* Serum total PSA concentration is under 10 ng/ml.~* Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is over 25%."
62163544|NCT05327725|EXPERIMENTAL|Fatigue Reduction Diet Intervention|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol via 8 remote phone or video telehealth sessions with a registered dietitian over 3 months.
62163545|NCT01732055|ACTIVE_COMPARATOR|Partner-Assisted Interpersonal Psychotherapy|Partner-Assisted Interpersonal Psychotherapy is an 8-week series of psychotherapy sessions attended by the patient and her identified partner.
62163546|NCT01732055|OTHER|Treatment as Usual|Treatment prescribed for subjects by the UNC Perinatal Psychiatry clinic physicians according to the clinic algorithm.
62163547|NCT03467594|EXPERIMENTAL|Intervention arm|"8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.~Outcome measures assessed at baseline and follow-up (8 weeks)"
62537108|NCT02155543|EXPERIMENTAL|Cohort 4: AGN-223575 Formulation C BID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
62537109|NCT02155543|PLACEBO_COMPARATOR|AGN-223575 Vehicle BID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
62537110|NCT02155543|EXPERIMENTAL|Cohort 5: AGN-223575 Formulation C TID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C three times daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
62163548|NCT03467594|NO_INTERVENTION|Control|Outcome measures only at baseline at follow-up (8 weeks)
62163549|NCT02450279|ACTIVE_COMPARATOR|Nebulization with a vibrating-mesh nebulizer|Nebulization performed with a vibrating-mesh nebulizer
62163550|NCT02450279|ACTIVE_COMPARATOR|Nebulization with a jet nebulizer|Nebulization performed with a jet nebulizer
62163551|NCT02625636|EXPERIMENTAL|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions
62163552|NCT02625636|EXPERIMENTAL|SAR438544 dose 2|Single dose of SAR438544 given SC under fasting conditions
62163553|NCT02625636|EXPERIMENTAL|SAR438544 dose 3|Single dose of SAR438544 given SC under fasting conditions
62163554|NCT02625636|PLACEBO_COMPARATOR|Placebo|Single dose of placebo given SC under fasting conditions
62163555|NCT02625636|ACTIVE_COMPARATOR|Glucagon|Single dose of glucagon given SC under fasting conditions
62163556|NCT02625636|EXPERIMENTAL|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions
62163557|NCT01738087|EXPERIMENTAL|NEXThaler 100/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg
62163558|NCT01738087|EXPERIMENTAL|NEXThaler 200/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg
62537111|NCT02155543|PLACEBO_COMPARATOR|AGN-223575 Vehicle TID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle three times daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
62736493|NCT03560102|EXPERIMENTAL|MR-HIFU treatment|Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat\& resect model
62163559|NCT01738087|PLACEBO_COMPARATOR|NEXThaler placebo|Single dose (4 inhalations)
62163560|NCT01738087|EXPERIMENTAL|NEXThaler 100/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg
62163561|NCT01738087|EXPERIMENTAL|NEXThaler 200/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg
62163562|NCT01738087|ACTIVE_COMPARATOR|Flixotide Accuhaler 500 mcg|Single dose (2 inhalations) of fluticasone propionate
62163563|NCT00676663|EXPERIMENTAL|Exemestane 25 mg + Entinostat 5 mg|Exemestane (Aromasin®) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
62537112|NCT01941082|EXPERIMENTAL|Part A: RO6867461|Single doses
62537113|NCT01941082|EXPERIMENTAL|Part B: RO6867461|Multiple doses
62537114|NCT06324851|EXPERIMENTAL|Drospirenone/Estetrol|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
62537115|NCT06324851|EXPERIMENTAL|Nomegestrol Acetate/Estradiol|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol at any time of the menstrual cycle
62163564|NCT00676663|PLACEBO_COMPARATOR|Exemestane 25 mg + Placebo|Exemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
62163565|NCT01463397|EXPERIMENTAL|SAR292833 dose level 1|Dose level 1 twice daily immediately after breakfast/dinner
62163566|NCT01463397|EXPERIMENTAL|SAR292833 dose level 2|Dose level 2 twice daily immediately after breakfast/dinner
62163567|NCT01463397|PLACEBO_COMPARATOR|Placebo|Placebo (for SAR292833) twice daily immediately after breakfast/dinner
62163568|NCT03251833||obese|Body mass index \>30 Kilogram/m2
62163569|NCT03251833||non-obese|Body mass index \<30 Kilogram/m2
62163570|NCT05053399|EXPERIMENTAL|TECNIS Symfony Toric IOL|Model Series ZXT
62163571|NCT00930644|EXPERIMENTAL|teduglutide|0.05 mg/kg/day
62163572|NCT06093672|EXPERIMENTAL|Givinostat|
62163573|NCT06093672|ACTIVE_COMPARATOR|Hydroxyurea|
62163574|NCT04154774|EXPERIMENTAL|Group 1: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive single oral dose of apalutamide on Day 1 under fasted condition.
62163575|NCT04154774|EXPERIMENTAL|Group 2: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive single oral dose of apalutamide on Day 1 under fasted condition.
62163576|NCT06585059|EXPERIMENTAL|TQB2928 injection + Almonertinib Mesilate Tablets|Every 3 weeks constitutes one treatment cycle. For the first 2 cycles, TQB2928 is administered via infusion once a week. Starting from the 3rd cycle, TQB2928 is administered once every 3 weeks. Amivantamab is taken orally at a fixed time daily.
62163577|NCT02001207||MICU patients|
62163578|NCT00685659|ACTIVE_COMPARATOR|TAU only|Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
62163579|NCT00685659|EXPERIMENTAL|TMAC only|Adaptive telephone-based counseling
62163580|NCT00685659|EXPERIMENTAL|TMAC plus|Adaptive telephone-based counseling, plus incentives
62537116|NCT06324851|EXPERIMENTAL|Ethinylestradiol/Dienogest|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
62163581|NCT01648075|EXPERIMENTAL|Experimental: Probiotic enriched milk|150 ml of skimmed milk enriched with probiotic (Lactobacillus rhamnosus LRH08) once a day
62163582|NCT01648075|PLACEBO_COMPARATOR|Skimmed Milk|150 ml of skimmed milk once a day
62163583|NCT06317259|EXPERIMENTAL|Breathwork, music, messaging|Subjects will perform a 40 min initial breathwork/music/messaging session with a full EEG cap followed by 7 or 14 days of once daily practice of a 20 min breathwork/music/messaging session. At the end of 7 or 14 days, they will again perform the 40 min breathwork/music/messaging session with a full EEG cap.
62163584|NCT06317259|ACTIVE_COMPARATOR|Breathwork only|Subjects will perform a 40 min initial breathwork only session with a full EEG cap followed by 7 or 14 days of once daily practice of a 20 min breathwork only session. At the end of 7 or 14 days, they will again perform the 40 min breathwork only session with a full EEG cap.
62163585|NCT06317259|ACTIVE_COMPARATOR|Music and messaging|Subjects will perform a 40 min initial music/messaging session with a full EEG cap followed by 7 or 14 days of once daily practice of a 20 min music/messaging session. At the end of 7 or 14 days, they will again perform the 40 min music/messaging session with a full EEG cap.
62537117|NCT06032650|EXPERIMENTAL|Study group A (Calisthenics exercise)|Group (A) (n =30) will receive calisthenics exercise three times /week for eight weeks, patients in this group will receive four forms of calisthenics exercise (squats, curl up, push up, blank) starting free and upgrading intensity according to ability of the patients.
62537118|NCT06032650|EXPERIMENTAL|Study group B (High intensity interval training)|Group (B) (n =30) will receive high intensity interval training three times /week for eight weeks, A motorized treadmill device (KETTLER, laufband alpha run 600, German) with a minimum speed of 0.5km/hr and capability to display the distance in kilometer per hour will be used in this study. Intensity of HIIT will be measured using Bruce protocol to calculate target heart rate of each patient.
62537119|NCT02105558|EXPERIMENTAL|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
62163586|NCT06255665|EXPERIMENTAL|Part 1 (Dose Escalation): JNJ-79032421|In Part 1 (Dose escalation), participants will receive JNJ-79032421. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
62163587|NCT06255665|EXPERIMENTAL|Part 2 (Dose Expansion): JNJ-79032421|In Part 2 (Dose expansion), participants will receive JNJ-79032421 at the RP2D regimen(s) determined in Part 1.
62163588|NCT05010499|ACTIVE_COMPARATOR|Femoral nerve block|Patients will receive femoral nerve block (20 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
62163589|NCT05010499|ACTIVE_COMPARATOR|Fascia iliaca block|Patients will receive fascia iliaca block (40 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
62163590|NCT05552222|EXPERIMENTAL|Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR)|Participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide.
62163591|NCT05552222|EXPERIMENTAL|Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR)|Participants will receive talquetamab as SC injection in combination with daratumumab and lenalidomide.
62163592|NCT05552222|ACTIVE_COMPARATOR|Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)|Participants will receive daratumumab as SC injection with lenalidomide and dexamethasone.
62537120|NCT02105558|EXPERIMENTAL|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
62163593|NCT01973478|EXPERIMENTAL|DBS|"The medical device includes:~* Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~* Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is on during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7."
62163594|NCT01973478|SHAM_COMPARATOR|SHAM|"The medical device includes:~* Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~* Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is off during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7."
62163595|NCT05336409|EXPERIMENTAL|Dose Escalation: Schedule A|Lymphodepleting chemotherapy (LDC) will be followed by single dose administration of CNTY-101, alone or with supplemental human recombinant interleukin 2 (IL-2).
62163596|NCT05336409|EXPERIMENTAL|Dose Escalation: Schedule B|LDC will be followed by administration of CNTY-101, 3 times over 3 weeks, alone or with supplemental IL-2.
62163597|NCT02099656|EXPERIMENTAL|Lebrikizumab|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8.
62163598|NCT02099656|PLACEBO_COMPARATOR|Placebo|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8.
62163599|NCT03881267|EXPERIMENTAL|Human Autologous Homologous Skin Construct (SkinTE)|SkinTE, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a venous leg wound in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing and compression
62163600|NCT03881267|ACTIVE_COMPARATOR|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on venous leg wounds in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing and compression
62163601|NCT05045664|ACTIVE_COMPARATOR|Standard|Standard dose (24 Gy) involved site radiotherapy plus Rituximab
62163602|NCT05045664|EXPERIMENTAL|Experimental|ow-dose (4 Gy) involved site radiotherapy in combination with Obinutuzumab
62537121|NCT04699851|EXPERIMENTAL|Intervention|The intervention arm are participants who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey.
62163603|NCT06014788|EXPERIMENTAL|NPWTi|The whole wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg. The dressing changes were performed every 48-72 hours.
62163604|NCT06014788|ACTIVE_COMPARATOR|conventional NPWT|The wound was filled with black foam (Granufoam®, KCI) and covered with plastic folio. A continuous pressure of 125 mmHg was applied using the hospital suction system. The dressing changes were performed every 48 hours.
62163605|NCT03120949|EXPERIMENTAL|Treatment Arm 1: OKZ 64 mg q4w + MTX|Olokizumab 64 mg SC q4w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
62537122|NCT04699851|ACTIVE_COMPARATOR|Control|The control group will receive general recommendations about health prevention in a pandemic.
62537123|NCT05084716|EXPERIMENTAL|Intervention|At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
62537124|NCT05084716|NO_INTERVENTION|Pre-Intervention Standard of Care|Prior to the intervention period in the intervention community, healthcare facility staff will provide PrEP through outreach events and in local healthcare facilities according to the standard of care.
62537125|NCT05084716|NO_INTERVENTION|Comparison Community|The comparison community will receive standard of care for PrEP provision.
62163606|NCT03120949|EXPERIMENTAL|Treatment Arm 2: OKZ 64 mg q2w + MTX|Olokizumab 64 mg SC q2w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
62163607|NCT01130077|EXPERIMENTAL|HLA Restricted glioma antigen peptides plus Poly ICLC|All subjects will receive vaccine plus Poly ICLC will receive 9 injections ( once every 3 weeks)
62163608|NCT06219174|EXPERIMENTAL|Phase 1: Dose Escalation for Pembrolizumab and Difluoromethylornithine (DFMO)|"Difluoromethylornithine (DFMO) + Pembrolizumab Pre-treated or treatment naive advanced or metastatic NSCLC.~The phase I dose escalation will include a fixed dose of Pembrolizumab IV every 3 weeks and escalating doses of DFMO (three dose levels) to determine the maximum tolerated dose (MTD) to be used in the phase II portion of the trial.~DFMO level -1: Dose Level -1: 4500 mg/m2 by mouth (PO) once a day (QD).~DFMO Level 1: (start): 6750 mg/m2 PO QD~Dose Level 2: 9000 mg/m2 PO QD"
62163609|NCT06219174|ACTIVE_COMPARATOR|Phase II: Pembrolizumab and Difluoromethylornithine (DFMO)|"Difluoromethylornithine (DFMO) + Pembrolizumab~Advanced/metastatic NSCLC who are immunotherapy naïve.~Pembrolizumab IV flat dose every 3 weeks~DFMO dose to be determined (TBD) based on maximum tolerated dose (MTD) and dose limiting toxicities (DLT) in Phase I dose escalation."
62163610|NCT02526199|ACTIVE_COMPARATOR|Group BA|Bupivacaine + Adrenaline Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml
62163611|NCT02526199|EXPERIMENTAL|Group BAD|Bupivacine + Adrenaline + Dexamethasone Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml PLUS Dexamethsone 8 mg
62163612|NCT03819296|EXPERIMENTAL|Supportive Care (standard of care, sample collection, FMT)|"PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.~PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples.~PROJECT 3: Patients undergo FMT."
62163613|NCT04844294|EXPERIMENTAL|Brief Cognitive Behavioral Therapy (BCBT)|
62163614|NCT04844294|ACTIVE_COMPARATOR|Present-Centered Therapy (PCT)|
62163615|NCT03456089|OTHER|Neurogenic Bladder Patients|Patients with neurogenic bladder undergoing urodynamics testing
62163616|NCT00570804|OTHER|MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
62163617|NCT00570804|OTHER|MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
62163618|NCT04056598||Moderate to severe acne vulgaris|Determined by the acne severity grade of IGA 2 and above
62163619|NCT04056598||Mild acne vulgaris|Determined by the severity grade of IGA \<2
62163620|NCT05898802|EXPERIMENTAL|Kimchi inoculated Leuconostoc mesenteroides|3,600mg/day containing 80% Kimchi inoculated Leuconostoc mesenteroides powder (3 tablets 3 times per day after meals over the 16-week regimen)
62163621|NCT05898802|EXPERIMENTAL|Kimchi|3,600mg/day containing 80% Kimchi powder (3 tablets 3 times per day after meals over the 16-week regimen)
62163622|NCT05898802|PLACEBO_COMPARATOR|Lactose|3,600mg/day containing lactose placebo capsules to look identical. (3 tablets 3 times per day after meals over the 16-week regimen)
62163623|NCT02116582|EXPERIMENTAL|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
62163624|NCT04674033||Consumer|Participants who self-report regular consumption of non-nutritive sweeteners (\>/=5 servings/week) based on a pre-screening dietary survey.
62163625|NCT04674033||Non-Consumer|Participants who self-report no consumption of non-nutritive sweeteners (0 servings/week) based on a pre-screening dietary survey.
62163626|NCT05282316|ACTIVE_COMPARATOR|EVOO polyphenols enriched|Fifteen subjects with metabolic syndrome will be randomly enrolled each year (3 years of study planned), to the addition of 40 ml daily of healthy polyphenols enriched EVOO to their mediterranean diet for the duration of six months
62163627|NCT05282316|PLACEBO_COMPARATOR|EVOO standard|Fifteen subjects with metabolic syndrome will be randomly enrolled each year (3 years of study planned), to the addition of 40 ml daily of standard EVOO to their mediterranean diet for the duration of six months
62537126|NCT05288712|EXPERIMENTAL|Experimental: Training protocol with the cervical device for treatment (CDAT).|"Endurance and stabilization training program of deep cervical flexors with the cervical device for treatment.~Endurance and stabilization training program of deep cervical extensors with the cervical device for treatment."
62537127|NCT05288712|ACTIVE_COMPARATOR|Conventional training protocol:|"Endurance and stabilization training program of deep cervical flexors with conventional protocol.~Endurance and stabilization training program of deep cervical extensors with conventional protocol."
62537128|NCT05288712|NO_INTERVENTION|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
62163628|NCT01379989|ACTIVE_COMPARATOR|Carboplatin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
62163629|NCT01379989|EXPERIMENTAL|Trabectedin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
62163630|NCT01772381|EXPERIMENTAL|Dexamethasone|Dexamethasone, im , 12 mg twice, 12 hrs apart, 48 hrs before elective cesarean section
62163631|NCT06638710|PLACEBO_COMPARATOR|placebo|The nurse administers an oral dose of placebo to the patient
62163632|NCT06638710|EXPERIMENTAL|oral midazolam|The nurse administers an oral dose of midazolam to the patient
62163633|NCT03145142|ACTIVE_COMPARATOR|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infant at a speed of 20cm over 2 seconds.
62163634|NCT03145142|ACTIVE_COMPARATOR|Delayed Cord Clamping|Delayed clamping of the umbilical cord for at least 60 seconds.
62163635|NCT01292499|NO_INTERVENTION|Pharmacological treatment|Pharmacological treatment consists of the administration of a single antidepressant drug. The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
62163636|NCT01292499|EXPERIMENTAL|Psychotherapy|Will receive psychotherapy as well (10 sessions). Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each. Psychotherapy will begin after 4-6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective. The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient. Psychotherapists will be free to follow the approach they were trained.
62163637|NCT01292499|EXPERIMENTAL|Psychoeducation|Will receive psychoeducation as well, with phone monitoring and regular follow-ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
62163638|NCT01292499|EXPERIMENTAL|Psychoeducation and psychotherapy|Will receive both psychoeducation and psychotherapy sessions.
62537129|NCT00912912|EXPERIMENTAL|Sunitinib Malate|Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
62537130|NCT01796938|EXPERIMENTAL|Group 1: Healthy subjects|Single dose of 100 mg Lacosamide
62537131|NCT01796938|EXPERIMENTAL|Group 2: Subjects with mild renal insufficiency|Single dose of 100 mg Lacosamide
62537132|NCT01796938|EXPERIMENTAL|Group 3: Subjects with moderate renal insufficiency|Single dose of 100 mg Lacosamide
62537133|NCT01796938|EXPERIMENTAL|Group 4: Subjects with severe renal insufficiency|Single dose of 100 mg Lacosamide
62537134|NCT01796938|EXPERIMENTAL|Group 5: Subjects with end stage renal insufficiency|Single dose of 100 mg Lacosamide
62163639|NCT05085015|EXPERIMENTAL|Functional Exercise Training Group|A program including stretching, aerobics, strengthening and balance training will be implemented under the supervision of a physiotherapist with the instructions of the physiotherapist.They will apply a total of 24 sessions of exercise program for 60-80 minutes, 3 days a week, 8 weeks.
62163640|NCT05085015|EXPERIMENTAL|Home Exercise Training Group|Individuals in the home exercise training program will be asked to follow the program in accordance with the home exercise brochure given for 8 weeks, 3 days a week. The program will include stretching, aerobics, strengthening and balance training. The home exercise program will consist of a brochure prepared from a program similar to a functional exercise program.
62163641|NCT05658484|EXPERIMENTAL|Dimethyl fumarate (DMF)|Participants will receive DMF 120 mg capsules, orally, twice daily (BID) for the first 7 days, followed by 240 mg BID (maintenance dose) after 7 days for up to Week 48.
62163642|NCT04724668|OTHER|Morning light version+ Melatonin|Morning light version and melatonin 3mg capsule (3hrs before DLMO)
62163643|NCT04724668|OTHER|Morning light version+ Placebo|Morning light version and placebo capsule (3hrs before DLMO)
62163644|NCT04625023||Cohort of BC patients|Stage-mixed cohort of at least 500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.
62537135|NCT03891030|EXPERIMENTAL|Checklist Based Box system|Pregnant mothers will receive scheduled person-centered health educations starting from: they are identified as suspected pregnant mother up to attending their third PNC visit. In between the first ANC and the third PNC drop out tracing mechanisms will be applied, for mothers who fail to utilize the recommended maternal health services.
62163645|NCT03792945|ACTIVE_COMPARATOR|extracorporeal shock wave therapy|ESWT will be applied to Group 1 once a week for a total of 3 weeks. Modus ESWT device will be used. The patient's wrist will be applied at a pressure of 4 bar and 2000 Hz at a frequency of 5 Hz. Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
62163646|NCT03792945|ACTIVE_COMPARATOR|local injection|40 mg of local Depomedrol (methylprednisolone) injection will be applied to group 2 once. Injection will be made from wrist with carpal tunnel syndrome.Patients will be given a splint at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
62163647|NCT03792945|NO_INTERVENTION|carpal tunnel wrist brace|"Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day.~Participants will use the carpal tunnel wrist brace 3 months."
62163648|NCT06719843|EXPERIMENTAL|ACT-based intervention|In addition to usual community support services, participants in the intervention group will receive the face-to-face ACT-based intervention weekly for 4 weeks (each session lasting approximately 90 minutes), with each group consisting of 6-8 older adults.
62163649|NCT06719843|NO_INTERVENTION|Wait-list control|Participants in the wait-list control group will receive usual community support services (e.g. meal delivery) provided by the community centres they belong to.
62163650|NCT04543942|EXPERIMENTAL|Alcohol, then saline, then alcohol, then saline|Participants first received alcohol (60mg%) intravenously and then 24-48 hours later they received saline intravenously. Two weeks later, they again received alcohol (60mg%) intravenously and then 24 - 48 hours later they received saline intravenously.
62163651|NCT04543942|EXPERIMENTAL|Saline, then alcohol, then saline, then alcohol|Participants first received saline intravenously and then 24-48 hours later they received alcohol (60mg%) intravenously. Two weeks later, they again received saline intravenously and then 24 - 48 hours later they received alcohol (60mg%) intravenously.
62163652|NCT06012877|EXPERIMENTAL|Intervention Group|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
62163653|NCT06012877|NO_INTERVENTION|Control group|Participants in this group continued with normal activities at school and at home, just like the intervention group, so that the only difference between the two groups was taking part in the intervention. Once the post-study data had been collected from all participants, the participant in the control group also took part in the intervention, a few days later.
62537136|NCT03891030|NO_INTERVENTION|Routine maternal health care|Pregnant mothers in this arm will receive the usual routine maternal health care.
62537137|NCT02816411|EXPERIMENTAL|Protein|Milk protein isolate supplementation: orally, 20g of protein immediately post-exercise and then 20g every 3h on 3 occasions (+3, +6, +9), on the exercise day. The remaining 8 days, 20g daily with breakfast.
62537138|NCT02816411|ACTIVE_COMPARATOR|Placebo|Placebo administration: orally 500 ml, immediately post-exercise as well as at +3, +6 and +9 hours, on the exercise day. The remaining 8 days, 500 ml daily with breakfast.
62537139|NCT01899443||Total hip and knee replacement patients|This study will select up to 20 high volume (\>275 cases annually) public and private hospitals across Australia. A random sample of c.2200 patients with diagnosis of osteoarthritis undergoing primary total hip or knee replacement surgery will be recruited.
62537140|NCT01716715|EXPERIMENTAL|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28.
62537141|NCT01716715|EXPERIMENTAL|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
62537142|NCT02382055|EXPERIMENTAL|REACH|Psychotherapy
62537143|NCT02382055|ACTIVE_COMPARATOR|Supportive Psychotherapy|Psychotherapy
62537144|NCT05567146|EXPERIMENTAL|Experimental group|"Adolescents going to high school, Gamification technique is applied to the Intervention group for seven weeks.~Intervention:gamification technique with tele-nursing"
62537145|NCT05567146|NO_INTERVENTION|Control group|Adolescents going to high school
62537146|NCT00175188|ACTIVE_COMPARATOR|Cemented PIP implant|Avanta PIP
62537147|NCT00175188|ACTIVE_COMPARATOR|Uncemented PIP implant|Avanta PIP
62163654|NCT04283097|EXPERIMENTAL|Single arm|KPG-818 dose escalation
62163655|NCT03214198||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
62163656|NCT05981586|EXPERIMENTAL|SPEED|Speed tests are typically used solely to measure an athlete's linear speed capabilities. Track sprinters have been shown to accelerate continuously through at least 50m during a 100m sprint event.
62163657|NCT05981586|EXPERIMENTAL|BALANCE|"The person performing the test must maintain their balance on one leg, while using the other leg to reach as far as possible in 8 different directions. The person (standing on his/her left leg for example) must reach in 8 different positions, once in each of the following directions: anterior, antero medial, medial, posteromedial, posterior, posterolateral, lateral and anterolateral.~The reliability of the SEBT as being moderate to good"
62163658|NCT05981586|EXPERIMENTAL|AGILITY|The T-Test is one of the most important agility Test, used in a lot of different sports all around the world. The test is a combination of different sport specific pattern as forward, lateral, and backward movements
62163659|NCT05734976|EXPERIMENTAL|Electro-Acupuncture can modulate the levels of pro-inflammatory metabolites|the disproportionate inflammatory response presented by chronic and acute inflammation as is the case in patients with stroke. In addition, the evaluation of the risk factors associated with the presence of metabolites such as cholesterol and fatty acids will provide us with an adequate diagnosis of the influence that these risk factors have on the blood vessels and the vascular endothelium.This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
62163660|NCT05734976|SHAM_COMPARATOR|The design and conduct randomized clinical trial using electroacupunture|efficacy and effectiveness of electroacupuncture in a clinical trial in electroacupuncture: design of control group and treatment group (including sharm acupuncture) and develop in this study the measurements in the patients and perform everything to the highest standards in both treatment procedures and measurement of results. Randomized controlled trail: intervention strategy and implementation.Also called Sham because it does not receive real stimulation from an acupuncture point, it is 1 cm away from the meridian. All procedures were carried out to a depth of 0.5 cm with disposable needles
62163661|NCT05734976|NO_INTERVENTION|Arm type Methodological challenge in design|Electroacupuncture treatment, develops different groups study are three; electroacupuncture group or real treatment,1st control group or Participants in the sham group also received 24 sessions of acupuncture treatment; however, needling was performed 1 cm away from the real acupoints and 2nd control group or non-penetration needles. Access to medical records; to collect data and store it securely and anonymously.this group will receive treatment at 6 acupuncture points, but without penetration, without electroacupuncture, this is why it is called the control group. Use disposable needles too
62163662|NCT04337502||severe group|The severe group was designated when the patients had one of the following criteria during hospitalization issued by the Chinese National Health Committee (Version 3-5). 1) Respiratory distress with respiratory frequency ≥ 30/min; 2) Pulse Oximeter Oxygen Saturation ≤ 93% at rest; 3) Oxygenation index (artery partial pressure of oxygen/inspired oxygen fraction, PaO2/FiO2) ≤ 300 mmHg; 4) One of the conditions as following: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.
62163663|NCT04337502||non-severe group|The non-severe group was designated when the patients did not occur in the mentioned severe criteria until discharged from the hospital.
62163664|NCT03188549|ACTIVE_COMPARATOR|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
62163665|NCT03188549|ACTIVE_COMPARATOR|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
62163666|NCT03188549|ACTIVE_COMPARATOR|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
62163667|NCT05014815|EXPERIMENTAL|Arm A: Ociperlimab + tislelizumab histology-based chemotherapy|
62163668|NCT05014815|PLACEBO_COMPARATOR|Arm B: Placebo + tislelizumab + histology-based chemotherapy|
62163669|NCT06072352|EXPERIMENTAL|Chlorhexidine acetate solution|
62537148|NCT04206982|EXPERIMENTAL|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
62537149|NCT04206982|ACTIVE_COMPARATOR|Pulmonary vein isolation arm|
62537150|NCT03756506|ACTIVE_COMPARATOR|Novel Microbicidal Liquid Polymer|"All pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge,tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris. Step 3: Apply product with Q-tip on clean dry wound around (extending approximately one inch around pin site) and on the pin. The Polymer will be applied daily while in the hospital and then at a minimum of at least three times a week until pin removal."
62714675|NCT05111288|EXPERIMENTAL|Pulsed electromagnetic field (PEMF) therapy|A portable PEMF device will be utilized. For the PEMF group, the device includes adjustable magnetic field strength range (X-axis: 0.22±0.05 mT, Y-axis: 0.20±0.05 mT and Z-axis: 0.06±0.02 mT) and working frequency (30±3Hz). This magnetic strength range and frequency will be maintained during 180 days of the study period. The subjects will be instructed to use their device three times per day: providing micromagnetic emitting on both hands (palms) during morning, afternoon and evening/night sessions. Each session takes 16 min (both hands, 8 min per hand) and thus subjects are exposed to therapy for 48 min per day. Subjects will use the device as outlined continuously up through the final days of testing.
62163670|NCT06072352|ACTIVE_COMPARATOR|Normal saline|
62163671|NCT04750798||Participants Diagnosed with Cardiac Arrhythmias|Patients diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure in routine clinical practice for management of their arrhythmia with a BWI therapeutic catheter/Varipulse Catheter will be observed.
62163672|NCT02213458|EXPERIMENTAL|Navigated Care|Comprehensive longitudinal continuing care program
62163673|NCT02213458|NO_INTERVENTION|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
62163674|NCT02543294|EXPERIMENTAL|Anthracycline Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
62163675|NCT02543294|EXPERIMENTAL|Herceptin Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
62163676|NCT02543294|EXPERIMENTAL|Combination of Treatments Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
62163677|NCT03225092|EXPERIMENTAL|PRP Injection|Ultrasound-guided platelet rich plasma injection
62163678|NCT02270125||Adult patients with chronic rhino sinusitis|Group of adult patients indicated for mucotomy due to chronic hypertrophic rhinosinusitis, with or without polyposis
62163679|NCT02270125||Stillborn children|Control group of stillborn children whose nasal mucosa was not exposed to airborne particles
62163680|NCT00787345|OTHER|Surgery residents|general surgery residents undergoing evaluation and training in MBP during CVC placement as per department policy are eligible for the study.
62163681|NCT04051645|EXPERIMENTAL|Breathing through a system with adjustable flow resistance|During the experiment, the volunteers will breathe through ten adjustable flow resistances and their work of breathing will be measured.
62163682|NCT04172571|EXPERIMENTAL|AK105 and anlotinib|
62163683|NCT02475733|EXPERIMENTAL|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
62163684|NCT02475733|ACTIVE_COMPARATOR|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
62163685|NCT04067713||PARADIGM-D|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Docetaxel with androgen deprivation therapy (ADT).
62163686|NCT04067713||PARADIGM-A|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Androgen Receptor Signalling Inhibitor (ARSI) drugs with androgen deprivation therapy (ADT).
62163687|NCT04067713||PARADIGM-E|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Enzalutamide with androgen deprivation therapy (ADT).
62163688|NCT03449979|EXPERIMENTAL|alpha stimulation in participants in a depressive episode|Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
62163689|NCT03449979|PLACEBO_COMPARATOR|sham stimulation in participants in a depressive episode|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.
62163690|NCT03449979|EXPERIMENTAL|alpha stimulation in healthy participants|Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
62163691|NCT03449979|PLACEBO_COMPARATOR|sham stimulation in healthy participants|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.
62163692|NCT02638558|EXPERIMENTAL|written + oral explanation|patients will undergo both written and oral explanation for preparation with split dose
62163693|NCT02638558|EXPERIMENTAL|written explanation|patients will receive only a written explanation for preparation with split dose
62163694|NCT06283693|EXPERIMENTAL|Experimantal group:|Intervention Group : The women in this group will receive a 4-week Mindfulness-Based Stress Reduction program in addition to routine outpatient clinic follow-up at the relevant institution. Before the implementation of the Mindfulness-Based Stress Reduction program, the women in the intervention group will be administered the Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Perceived Stress Scale, DASS-21 and salivary cortisol measurements for pre-test measurements. After the mindfulness program, follow-up tests will be conducted in the 4th week. In the 8th week, the post-test will be conducted. In the post-test and follow-up test; Perceived Stress Scale, DASS-21 and salivary cortisol measurements will be applied.
62537151|NCT03756506|NO_INTERVENTION|Control group: no Novel Microbicidal Liquid Polymer|"The usual care of pin track sites will be followed as outlined belowAll pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.~Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge, tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Research participants will be instructed that the approach to pin care should occur in a step-wise fashion. Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris."
62537152|NCT00886288||Telmisartan|
62537153|NCT00886288||Telmisartan + hydrochlorothiazide|
62163695|NCT06283693|NO_INTERVENTION|Control group:|The women in this group will not be subjected to any intervention and will be followed up in the routine outpatient clinic of the relevant institution. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Perceived Stress Scale, DASS-21 and salivary cortisol measurements will be applied for the pre-test measurements of the control group women. In the study, post-test measurements will be made 4 weeks after the pre-test measurements of the control group and follow-up measurements will be made 8 weeks later. Perceived Stress Scale, DASS-21 and salivary cortisol measurements will be applied to the women in the control group for pre-test, post-test and follow-up measurements.
62163696|NCT02632045|EXPERIMENTAL|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
62163697|NCT02632045|PLACEBO_COMPARATOR|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
62163698|NCT02628613|ACTIVE_COMPARATOR|Paclitaxel plus Epirubicin|Paclitaxel plus Epirubicin for 4 cycles, paclitaxel 80 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
62163699|NCT02628613|EXPERIMENTAL|Vinorelbine plus Epirubicin|Vinorelbine plus Epirubicin for 4 cycles, vinorelbine 25 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
62163700|NCT01645397||Asthma, elevated exhaled NO|Children with asthma with elevated exhaled NO at initial evaluation (\>25ppb)
62163701|NCT05646602|EXPERIMENTAL|Collagenase Clostridium Histolyticum with LiSWT for PD Group|Subjects being treated for Peyronie's disease (PD) will have Collagenase Clostridium Histolyticum (CCH) intralesional injection with focused low-intensity shockwave therapy (LiSWT).
62163702|NCT05646602|ACTIVE_COMPARATOR|Collagenase Clostridium Histolyticum for PD Group|Subjects being treated for Peyronie's disease (PD) will have Collagenase Clostridium Histolyticum (CCH) intralesional injection
62163703|NCT05646602|ACTIVE_COMPARATOR|Radial Shockwave Therapy for ED Group|Subjects being treated for erectile dysfunction (ED) will have radial shockwave therapy.
62163704|NCT05646602|EXPERIMENTAL|Linear Shockwave Therapy for ED Group|Subjects being treated for erectile dysfunction (ED) will have linear shockwave therapy
62163705|NCT04034056||Obinutuzumab|
62163706|NCT01385683|ACTIVE_COMPARATOR|Arm A|Dabigatran then dabigatran and clarithromycin
62163707|NCT01385683|ACTIVE_COMPARATOR|Arm B|Clarithromycin and dabigatran and dabigatran
62163708|NCT02785822|ACTIVE_COMPARATOR|Fostipur|
62714676|NCT05111288|SHAM_COMPARATOR|Sham PEMF therapy|The sham PEMF devices are modified to deliver no micromagnetic field when turned on. The subjects will be instructed to use their device three times per day: providing micromagnetic emitting on both hands (palms) during morning, afternoon and evening/night sessions. Each session takes 16 min (both hands, 8 min per hand) and thus subjects are exposed to therapy for 48 min per day. Subjects will use the device as outlined continuously up through the final days of testing.
62714677|NCT01726374|EXPERIMENTAL|One cycle adjuvant BEP(500)|Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
62163709|NCT02785822|EXPERIMENTAL|Meriofert|
62163710|NCT06260059|EXPERIMENTAL|Empagliflozin 10 MG|Empagliflozin 10 mg daily will be administered for 1 year. The patient and the PI will be blinded (unaware) of the group they are assigned to.
62163711|NCT06260059|PLACEBO_COMPARATOR|Placebo|Placebo for 1 year
62163712|NCT02791009||Diagnosed Heart Failure [Prior]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
62163713|NCT02791009||Control [Prior]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
62163714|NCT02791009||Control [New]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
62163715|NCT02791009||Diagnosed Heart Failure [New]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
62163716|NCT01113541|EXPERIMENTAL|Active treatment (switch to oral Ziprasidone)|
62163717|NCT06408935|EXPERIMENTAL|Guselkumab|Participants will receive guselkumab 200 milligram (mg) intravenously (IV) at week 0, 4 and 8. Afterwards, participants will be alternately assigned at study level to 2 dose cohorts, high dose (200 mg subcutaneous (SC) every 4 weeks (Q4W) starting at week 12) through week 92 or low dose (100 mg SC every 8 weeks (Q8W) starting at week 16) through week 88. Starting at Week 24, participants in the low-dose cohort will be permitted to escalate to the 200 mg SC Q4W regimen if they are symptomatic and at the discretion of the investigator.
62163718|NCT06309771|EXPERIMENTAL|Intervention|Complex behavioral intervention based on health-related modules.
62163719|NCT06309771|NO_INTERVENTION|Control|Students from the control group will follow no modules.
62163720|NCT04601883|EXPERIMENTAL|Colchicine|Tablet colchicine 0.5 mg administered two times daily
62163721|NCT04601883|PLACEBO_COMPARATOR|Placebo|Tablet placebo administered two times daily
62163722|NCT01262794|EXPERIMENTAL|CDP6038 0.3 mg/kg|
62163723|NCT01262794|EXPERIMENTAL|CDP6038 1 mg/kg|
62163724|NCT01262794|EXPERIMENTAL|CDP6038 3 mg/kg|
62163725|NCT01262794|EXPERIMENTAL|CDP6038 6 mg/kg|
62163726|NCT01262794|PLACEBO_COMPARATOR|Placebo|
62163727|NCT02567435|EXPERIMENTAL|Regimen A (VAC/VI)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo primary site RT beginning at week 13 or metastatic site RT beginning at week 43 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
62163728|NCT02567435|EXPERIMENTAL|Regimen B (VAC/VI/temsirolimus)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
62163729|NCT02567435|EXPERIMENTAL|Regimen C (FOXO1 fusion negative, VAC/VA)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62163730|NCT04239976|EXPERIMENTAL|Supportive Care (scrambler therapy, sensory test, gait test)|Patients undergo scrambler therapy over 30-45 minutes QD Monday-Friday for 2 weeks. Patients also undergo a quantitative sensory test and a gait assessment test using a FitBit before receiving scrambler therapy, at the end of the first and second weeks of scrambler therapy, and 1 month after the last day of scrambler therapy.
62163731|NCT03745651|PLACEBO_COMPARATOR|Vehicle Control (VC) Period: Vehicle Cream BID|Participants received ruxolitinib matching vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
62163732|NCT03745651|EXPERIMENTAL|VC Period: Ruxolitinib 0.75% Cream BID|Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
62163733|NCT03745651|EXPERIMENTAL|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
62163734|NCT03745651|EXPERIMENTAL|Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62163735|NCT03745651|EXPERIMENTAL|LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62163736|NCT03745651|EXPERIMENTAL|LTS Period: Ruxolitinib 0.75% Cream BID|Participants who applied ruxolitinib 0.75% cream during the VC Period, continued applying ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62163737|NCT03745651|EXPERIMENTAL|LTS Period: Ruxolitinib 1.5% Cream BID|Participants who applied ruxolitinib 1.5% cream during the VC Period, continued applying ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62163738|NCT06266494|ACTIVE_COMPARATOR|Aim 1: Aloe Vera|Aloe Vera will be applied topically to participant's frostbitten tissues twice daily.
62163739|NCT06266494|EXPERIMENTAL|Aim 1: Long-Acting Silver Dressings|Long-Acting Silver dressings will be applied topically to participant's frostbitten tissues every 4 days.
62163740|NCT06266494|EXPERIMENTAL|Aim 2: Dalbavancin|Participants will receive one 1500mg dose of Dalbavancin intravenously.
62163741|NCT03921216||Diabetic nephropathy, on hemodialysis|
62163742|NCT03921216||Chronic kidney disease, on hemodialysis|Chronic kidney disease of other causes than Diabetes.
62163743|NCT03921216||Chronic kidney disease, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
62163744|NCT03921216||Diabetic nephropathy, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
62163745|NCT01695993|NO_INTERVENTION|Arm 1 - Standard Care Only|Patients will receive standard care only
62163746|NCT01695993|OTHER|Arm 2 - Expectancy-neutral Arm|"Patients receive:~1. Expectancy-neutral handout~2. Expectancy-neutral MP3~3. Acupressure bands"
62163747|NCT01695993|EXPERIMENTAL|Arm 3 - Expectancy-enhancing Arm|"Patients receive:~1. Expectancy-enhancing handout~2. Expectancy-enhancing MP3~3. Acupressure bands"
62163748|NCT02072889|EXPERIMENTAL|Neck Angle Measures|Subjects will position his/her neck in order to measure distance between the internal jugular and the carotid artery to determine if there is a maximal distance to target prior to cannulation
62163749|NCT05438511||Participants of focus groups|Breast cancer survivor, patient advocate or key healthcare personnel including hospital and laboratory leaders, pathologists, laboratory scientists and technicians, oncologists, nurses, and surgeons
62163750|NCT06553235|EXPERIMENTAL|Intervention group (group 1)|Participants will receive individualized digital CBT-I through an app called Hvil®. Treatment will take 6-9 weeks.
62163751|NCT06553235|ACTIVE_COMPARATOR|Active control group (group 2)|Participants will receive the sleep hygiene education component of CBT-I through Hvil®. Treatment will take 6-9 weeks.
62163752|NCT01247922|EXPERIMENTAL|Erlotinib|Participants who received erlotinib in a continuous oral dose of 85 mg/m\^2 per day until dose modification, interruption or study discontinuation occurred.
62163753|NCT03316248|EXPERIMENTAL|visual feedback|participants in the experimental group were applied usual prosthetic rehabilitation with visual feedback methods. 9 sessions for three days were applied.
62163754|NCT03316248|ACTIVE_COMPARATOR|Usual prosthetic rehabilitation|participants in the control group were applied usual prosthetic rehabilitation. 9 sessions for three days were applied.
62163755|NCT05863871||all enrolled patients|All patient who signed the consent form for participation to the study
62163756|NCT04049578|EXPERIMENTAL|Balovaptan|
62163757|NCT05586178|NO_INTERVENTION|Holdout|
62163758|NCT05586178|EXPERIMENTAL|Simple reminder|
62163759|NCT05586178|EXPERIMENTAL|Consistency reminder|
62163760|NCT05586178|EXPERIMENTAL|Uniqueness information reminder|
62163761|NCT05586178|EXPERIMENTAL|Eligibility information reminder|
62163762|NCT05586178|EXPERIMENTAL|Severity information reminder|
62163763|NCT05586178|EXPERIMENTAL|Consistency and uniqueness information reminder|
62163764|NCT01614899|EXPERIMENTAL|SM-13496 40mg|
62163765|NCT01614899|EXPERIMENTAL|SM-13496 80mg|
62163766|NCT01614899|PLACEBO_COMPARATOR|Placebo|
62163767|NCT03735368|PLACEBO_COMPARATOR|Control|placebo oral capsule+ dexmedetomidine+topical anesthesia
62163768|NCT03735368|ACTIVE_COMPARATOR|Dexmedetomidine- Pregabalin|Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia
62163769|NCT06049433|OTHER|Choice 1|Options; On-Demand (OD) alone or On-Demand (OD) with a facilitated discussion board (DB)
62163770|NCT06049433|OTHER|Choice 2|"Options:~On-Demand (OD) + Discussion board (DB) or OD + Video Conference (VC)"
62163771|NCT06049433|OTHER|Choice 3|Options; Om-Demand (OD) or On-Demand (OD) + Video Conference (VC)
62163772|NCT05663866|EXPERIMENTAL|Background Anti-cancer Therapy with Amivantamab Plus Lazertinib|Participant will receive following treatments in 4 different cohorts prior to administration of combination therapy of IV Amivantamab and oral Lazertinib (anti-cancer regimen): dexamethasone dose-1 in Cohort A; dexamethasone dose-2 in Cohort A2; montelukast in Cohort B; and methotrexate in Cohort C.
62163773|NCT02200016|EXPERIMENTAL|SAX|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
62163774|NCT02200016|ACTIVE_COMPARATOR|LAX|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
62163775|NCT04920045|ACTIVE_COMPARATOR|Liberal Transfusion Arm|Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb\>9g/dL, and this will be maintained throughout their hospitalization.
62163776|NCT04920045|ACTIVE_COMPARATOR|Restrictive Transfusion Arm|Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.
62163777|NCT04532333|EXPERIMENTAL|Bivalirudin|Bivalirudin at full dose Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
62163778|NCT04532333|ACTIVE_COMPARATOR|Heparin|Heparin first dose at 0.6mg/kg(75U/kg) Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
62163779|NCT02619045|OTHER|Solid tumors|Patients with solid tumor starting a intra venous chemotherapy with 21 days cycles.
62163780|NCT01849185|ACTIVE_COMPARATOR|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
62537154|NCT05775952||Asthma Cohort|"Subjects with well-controlled, mild-moderate asthma (≥12% post-bronchodilator reversibility or PC20 methacholine \<16mg/mL at screening or within past 5 years).~Subjects will be inoculated with a total dose of 1000 tissue culture-infective dose 50% (TCID50) of rhinovirus (HRV) 39. The inoculum is diluted as appropriate in lactated Ringer's solution and delivered via a two step procedure: 0.25 ml per nostril is administered by pipette while the subject tilts their head back. It is anticipated that subjects will develop mild to moderate symptoms that are transient (lasting 3-7 days) and typically consist of nasal congestion, throat irritation, malaise and increased mucoid secretions. Subjects will record cold symptoms twice daily, using a diary card listing 8 symptoms, each of which are scored 0 to 3 on a basis of severity.~Subjects will only be inoculated with HRV-39 once at Visit 5."
62537155|NCT05775952||Healthy, Non-asthmatic Cohort|"Healthy non-asthmatic control subjects.~Subjects will be inoculated with a total dose of 1000 tissue culture-infective dose 50% (TCID50) of rhinovirus (HRV) 39. The inoculum is diluted as appropriate in lactated Ringer's solution and delivered via a two step procedure: 0.25 ml per nostril is administered by pipette while the subject tilts their head back. It is anticipated that subjects will develop mild to moderate symptoms that are transient (lasting 3-7 days) and typically consist of nasal congestion, throat irritation, malaise and increased mucoid secretions. Subjects will record cold symptoms twice daily, using a diary card listing 8 symptoms, each of which are scored 0 to 3 on a basis of severity.~Subjects will only be inoculated with HRV-39 once at Visit 5."
62537156|NCT02087189||ICD/ CRT-D therapy|
62537157|NCT01874353|EXPERIMENTAL|Olaparib 300mg tablets|Taken orally twice daily
62537158|NCT01874353|PLACEBO_COMPARATOR|Placebo tablets|Taken orally twice daily
62537159|NCT02865421|EXPERIMENTAL|Stem cells|adipose tissue derived stromal vascular fraction was used
62163781|NCT01849185|PLACEBO_COMPARATOR|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
62163782|NCT03356145|EXPERIMENTAL|12 mL arm|"Intervention:~* Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~* 2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~* The tenaculum is immediately placed at the previously injected site~* The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~* No wait time between injection and dilator insertion"
62163783|NCT03356145|ACTIVE_COMPARATOR|20 mL arm|"Intervention:~* Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~* 2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~* The tenaculum is immediately placed at the previously injected site~* The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~* No wait time between injection and dilator insertion"
62163784|NCT05313945|EXPERIMENTAL|Passive indwelling urinary catheter removal|The passive indwelling urinary catheter removal takes place due to gravity.
62163785|NCT05313945|ACTIVE_COMPARATOR|Manual indwelling urinary catheter removal|The manual indwelling urinary catheter removal takes place by manual traction by a nurse.
62537160|NCT02865421|EXPERIMENTAL|platelet rich plasma|platelet rich plasma isolated after centrifugation from the pt was transplanted
62163786|NCT01558245|EXPERIMENTAL|Tissue kallikrein group|Patients in this group will be prescribed with intravenous infusion of TK (0.15 PNAU/d, dissolved in 100ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
62163787|NCT01558245|NO_INTERVENTION|Control group|Patients in control group will receive foundation treatment, including aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
62163788|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
62163789|NCT03018288|OTHER|1/Temozolomide + Pembrolizumab + Radiation Therapy|Standard treatment with experimental treatment (pembro) added.
62163790|NCT03018288|EXPERIMENTAL|2/Temozolomide+Pembrolizumab|Temozolomide+Pembrolizumab
62163791|NCT03018288|EXPERIMENTAL|3/Temozolomide+Pembrolizumab+ Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine|Temozolomide+Pembrolizumab+ HSPPC96 Vaccine
62163792|NCT03018288|PLACEBO_COMPARATOR|4/Temozolomide+Pembrolizumab+ Placebo|Temozolomide+Pembrolizumab+ Placebo
62163793|NCT03787693|NO_INTERVENTION|Stroke Symmetric Non-VR|In this control arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
62163794|NCT03787693|EXPERIMENTAL|Stroke Symmetric VR|In this experimental arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
62163795|NCT03787693|NO_INTERVENTION|Stroke Asymmetric Non-VR|In this control arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
62163796|NCT03787693|EXPERIMENTAL|Stroke Asymmetric VR|In this experimental arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
62163797|NCT05219409|ACTIVE_COMPARATOR|Treatment group|Sitagliptin
62163798|NCT05219409|PLACEBO_COMPARATOR|Control group|Placebo
62163799|NCT02468882|EXPERIMENTAL|Intervention group|"Watercress will be tested in its natural form as a food item that will supplement the usual diet, via the prescription of watercress as whole food added daily to the usual diet. The intervention group will be asked to consume 100 grams of watercress per day, in addition to their usual diet for the total time of RT treatment. These 100 grams of watercress per day will allow the achievement of the daily therapeutic dose."
62163800|NCT02468882|NO_INTERVENTION|Control group|The control group will receive the standard of care, thus will maintain their ad libitum diet.
62163801|NCT06721585||Open-access tecovirimat plus SOC for mpox|"Participants are provided SOC as well as open-access tecovirimat. Tecovirimat capsules are administered orally to participants for 14 days based on participant weight.~Closed to new participants in August 2024."
62163802|NCT06721585||Standard of care for mpox|Participants are provided SOC for mpox.
62163803|NCT02227888|EXPERIMENTAL|N91115|Every 12 hour oral dosing of 50 mg N91115 for 14 days
62537161|NCT04133285||Multiple Osteochondromas patients|Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).
62537162|NCT03375203|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
62537163|NCT03375203|EXPERIMENTAL|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
62537164|NCT03375203|EXPERIMENTAL|JNJ-42847922 10 mg plus Placebo|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
62163804|NCT01182285|EXPERIMENTAL|A - Phase I Radioiodine-Resistant|Drug: Valproic Acid Week 1 - 10 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
62163805|NCT01182285|ACTIVE_COMPARATOR|B1 - Phase 2 Schedule 1|Drug: Valproic Acid Week 11 - 17 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Drug: Cytomel (25 micrograms) Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Liothyronine Sodium (Cytomel) for 4 weeks (25 micrograms twice a day)
62163806|NCT01182285|ACTIVE_COMPARATOR|B2 - Phase 2 Schedule 2|Drug: Valproic Acid Week 11 - 52 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Weeks 17-52: Patients who show a response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have a decreased thyroglobulin level from Day 1 of the treatment (registered as a partial response to the treatment) will continue on valproic acid at their current dose for a total of 52 weeks.
62163807|NCT05707377|EXPERIMENTAL|Part 1 and Part 2: Zanubrutinib High dose|Participants will receive Zanubrutinib twice daily
62163808|NCT05707377|EXPERIMENTAL|Part 2: Zanubrutinib Low Dose|Participants will receive Zanubrutinib once daily
62163809|NCT05707377|ACTIVE_COMPARATOR|Tacrolimus|Participants will receive tacrolimus capsules for 64 weeks
62537165|NCT03375203|EXPERIMENTAL|JNJ-42847922 20 mg plus Placebo|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
62537166|NCT03375203|EXPERIMENTAL|Zolpidem plus Placebo|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
62714678|NCT05625217|EXPERIMENTAL|Total-body PET scan|All participants are asked to complete two study scan visits. First visit occurs before treatment and the second visit occurs 12 +/- 2 weeks after treatment. Each visit will involve a single injection of FDG, followed by three PET/CT scans that will start immediately following injection, at about 2 hours post-injection and at 5 hours post-injection, respectively and last about 60 minutes, 20 minutes and 20 minutes, respectively.
62714679|NCT03232073|EXPERIMENTAL|Ponesimod|20 mg administered orally once daily
62163810|NCT06055478|EXPERIMENTAL|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using each 0.75% ropivacaine 10mL when arthroscopic rotator cuff repair Patient Controlled Analgesia (PCA) at a low fixed dose: fentanyl-loading dose: 0.4㎍/kg, continuous dose: 0.2㎍/kg/h, nefopam-loading dose: 0.04mg/kg, continuous dose: 0.02mg/kg/h
62163811|NCT06055478|PLACEBO_COMPARATOR|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using saline|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using each 0.9% saline 10mL when arthroscopic rotator cuff repair Patient Controlled Analgesia (PCA) at a low fixed dose: fentanyl-loading dose: 0.4㎍/kg, continuous dose: 0.2㎍/kg/h, nefopam-loading dose: 0.04mg/kg, continuous dose: 0.02mg/kg/h
62163812|NCT06537063||Asymptomatic population|Asymptomatic medical examination population.
62163813|NCT05603299|NO_INTERVENTION|Control Group|The Control group treats their simulated patients using standard practice and have no introduction to the new test.
62163814|NCT05603299|EXPERIMENTAL|Intervention Group 1 - Test Results Given|Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, whether they order the test or not.
62163815|NCT05603299|EXPERIMENTAL|Intervention Group 2 - Test Results Optional|Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, only if they choose to order the test.
62163816|NCT06045221|EXPERIMENTAL|Orforglipron Dose 1|Participants will receive orforglipron orally.
62163817|NCT06045221|EXPERIMENTAL|Orforglipron Dose 2|Participants will receive orforglipron orally.
62163818|NCT06045221|ACTIVE_COMPARATOR|Semaglutide Dose 1|Participants will receive semaglutide orally.
62163819|NCT06045221|ACTIVE_COMPARATOR|Semaglutide Dose 2|Participants will receive semaglutide orally.
62163820|NCT06649981|PLACEBO_COMPARATOR|Placebo group|The first group receives a placebo (no FMT capsule)
62163821|NCT06649981|EXPERIMENTAL|FMT group|The second group receives FMT from young-trained donors
62163822|NCT04301518|EXPERIMENTAL|PTB Prevention|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the PTB Prevention arm will receive the PreTRM® test results. If high risk, women will be consented to take part in the intervention. Those not higher risk will continue on with standard of care.
62163823|NCT04301518|NO_INTERVENTION|Control|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the Control arm will not receive the PreTRM® test results. Control arm subjects will continue on with standard of care.
62163824|NCT05820256|EXPERIMENTAL|Milk Protein Isolate (MPI)|Study participants in the MPI group will consume 2 smoothies per day for 31 days, where each smoothie provides 300 kcal in total, composed of 45% from carbohydrate (maltodextrin), 20% from protein (milk protein isolate) and 35% from fat (a blend of flaxseed, safflower, and coconut oils). Each smoothie will be mixed with water up to volume of 250mL. Individuals in this group will not consume soy-containing beverages and foods during the 31-day study.
62163825|NCT05820256|EXPERIMENTAL|Soy Protein Isolate (SPI)|Study participants in the SPI group will consume 2 smoothies per day for 31 days, where each smoothie provides 300 kcal in total, composed of 45% from carbohydrate (maltodextrin), 20% from protein (soy protein isolate) and 35% from fat (a blend of flaxseed, safflower, and coconut oils). Each smoothie will be mixed with water up to volume of 250mL. Individuals in this group will not consume dairy-containing beverages and foods during the 31-day study.
62163826|NCT06645743||spread through air space positive group|The patients in this group were stage IA lung adenocarcinoma patients who met the inclusion and exclusion criteria, and the postoperative pathological results indicated the presence of spread through air space
62163827|NCT06645743||spread through air space negative group|The patients in this group were stage IA lung adenocarcinoma patients who met the inclusion and exclusion criteria, and the postoperative pathological results showed no spread through air space
62163828|NCT02592434|EXPERIMENTAL|CP-690,550|Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
62163829|NCT02592434|PLACEBO_COMPARATOR|Placebo|Control arm: matching placebo tablets or solution for tofacitinib
62163830|NCT01358643|OTHER|P90X + Sparkpeople|"For six weeks of the study participants will use the P90X tools and for the other six weeks participants will use Sparkpeople tools.~Sparkpeople is a web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight.~P90X is A DVD based home exercise program that guides the participant through a daily exercise routine."
62163831|NCT01358643|OTHER|P90X + BodyMedia Fit|"For six weeks participants will use the P90X tools and for the other six weeks participants will use the BodyMedia Fit Device.~P90X is a DVD based home exercise program that guides the participant through a daily exercise routine.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress."
62163832|NCT01358643|OTHER|BodyMedia Fit + Sparkpeople|"For six weeks participants will use the BodyMedia Fit devise and for the other six weeks participants will use the Sparkpeople program.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress.~Sparkpeople is A web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight"
62163833|NCT05324527|EXPERIMENTAL|Hand Massage Group|After the researcher and the children in study group sat on a chair facing each other, hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
62163834|NCT05324527|NO_INTERVENTION|Control group|The control group will be received routine treatment and care in the unit.
62537167|NCT04312386|EXPERIMENTAL|A new 4-week lunch menu|Optimized lunch menu with 30% lower greenhouse gas emissions, nutritionally adequate
62163835|NCT06381219|OTHER|Cow's milk allergen heat denaturation|Children with an EoE in remission AND a previous diet excluding any form of cow's milk will undergo an oral food challenge with extensively heated cow's milk (20'). Afterwards they will be instructed to ensure regular intake of 20' heated cow's milk. After 8 weeks of (re)introduction they will be assessed for potential remaining remission (\<15 eosinophils/hpf on esophagal biopsies). If remission is sustained, they will sequentially decrease the degree of heat denaturation by decreasing the cooking time: 15', 10' and 5' cooked cow's milk. At the end, parents will have the choice to add a final step of raw cow's milk. After every 8 weeks of every new step, a gastroscopy will be performed to assess maintained remission. If remission is lost, they will go back to a strict avoidance diet for at least 10 weeks.
62163836|NCT06381219|OTHER|Hen's egg allergen heat denaturation|Children with an EoE in remission AND a previous diet excluding any form of hen's egg will undergo an oral food challenge with strongly heated hen's egg (in cake). Afterwards they will be instructed to ensure regular intake of cake. After 8 weeks of (re)introduction they will be assessed for potential remaining remission (\<15 eosinophils/hpf on esophagal biopsies). If remission is sustained, they will sequentially decrease the degree of heat denaturation as follows: hard-boiled egg, omelet and soft-boiled egg. At the end, parents will have the choice to add a final step of raw egg. After every 8 weeks of every new step, a gastroscopy will be performed to assess maintained remission. If remission is lost, they will go back to a strict avoidance diet for at least 10 weeks.
62163837|NCT06385418|EXPERIMENTAL|Colonic local administration of fluorouracil with enhanced adhesion|Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
62163838|NCT00606346||Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
62163839|NCT00606346||No Biologics|Treatments will be prescribed according to investigator judgement.
62163840|NCT01157442|EXPERIMENTAL|cell phone sms messages|The experimental arm will receive the cell phone SMS text messaging intervention.
62163841|NCT01157442|NO_INTERVENTION|Control|The control group will receive the standard of care but no SMS text messages.
62163842|NCT05605899|EXPERIMENTAL|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV lymphodepletion chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0.
62163843|NCT05605899|ACTIVE_COMPARATOR|Standard of Care Therapy|"Participants will receive the investigator's choice of one of the following therapies/dosing schedules:~* Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for a total of 6 cycles (21-day cycle)~  * Rituximab 375 mg/m\^2 on Day 1~ * Cyclophosphamide 750 mg/m\^2 on Day 1~ * Doxorubicin 50 mg/m\^2 on Day 1~ * Vincristine 1.4 mg/m\^2 (maximum 2 mg) on Day 1~ * Prednisone 40 mg/m\^2 on Day 1 through Day 5~* Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) for a total of 6 cycles (21-day cycle)~  * Rituximab 375 mg/m\^2 on Day 1~ * Etoposide 50 mg/m\^2 on Days 1 to 4~ * Doxorubicin 10 mg/m\^2 on Days 1 to 4~ * Vincristine 0.4 mg/m\^2 on Days 1 to 4~ * Cyclophosphamide 750 mg/m\^2 on Day 5~ * Prednisone 60 mg/m\^2 twice daily on Days 1 to 5"
62163844|NCT02214017|ACTIVE_COMPARATOR|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
62163845|NCT02214017|EXPERIMENTAL|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
62163846|NCT04343989|EXPERIMENTAL|Clazakizumab 25 mg|
62163847|NCT04343989|EXPERIMENTAL|Clazakizumab 12.5 mg|
62163848|NCT04343989|PLACEBO_COMPARATOR|Placebo|
62163849|NCT01388309||Cohort|
62163850|NCT05352763|EXPERIMENTAL|Simufilam 100 mg|simufilam 100 mg oral tablets, b.i.d.
62163851|NCT04174170|EXPERIMENTAL|Brexpiprazole + Sertraline|3 pills: Fixed dose of up to 3 milligrams (mg) /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
62163852|NCT04174170|EXPERIMENTAL|Sertraline|3 pills: Fixed dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
62714680|NCT06434870||Patients who had undergone Elective Cesarean Surgery with anemia|"In pregnant women, haemoglobin values below 11 mg/dL in the first trimester, 11 mg/dL in the second trimester and 10.5 mg/dL in the third trimester indicate anaemia.~The group comprised patients with haemoglobin levels below 10.5 mg/dL."
62163853|NCT04174170|PLACEBO_COMPARATOR|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
62163854|NCT03317288|OTHER|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
62163855|NCT05804552|EXPERIMENTAL|Dorsal genital nerve stimulation|
62163856|NCT03973437|EXPERIMENTAL|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
62163857|NCT03973437|ACTIVE_COMPARATOR|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
62714681|NCT06434870||Patients who had undergone Elective Cesarean Surgery without anemia|"In pregnant women, haemoglobin values below 11 mg/dL in the first trimester, 11 mg/dL in the second trimester and 10.5 mg/dL in the third trimester indicate anaemia.~The group comprised patients with haemoglobin levels above 10.5 mg/dL."
62163858|NCT06721611||CATCH-US cohort|Non-hypertensive Nucor employees that accept to receive and wear continuously for 28 days an optical blood pressure monitoring device (Aktiia 24/7 device)
62163859|NCT06039566|PLACEBO_COMPARATOR|IV Placebo|Patients will receive: Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
62163860|NCT06039566|ACTIVE_COMPARATOR|IV N-acetylcysteine|Patients will receive: N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure.
62163861|NCT06266611|EXPERIMENTAL|Full-Spectrum Hemp-Derived CBD (fsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD/4mg THC)
62163862|NCT06266611|EXPERIMENTAL|Broad-Spectrum Hemp-Derived CBD (bsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD)
62163863|NCT06266611|PLACEBO_COMPARATOR|Placebo|
62163864|NCT06134986|EXPERIMENTAL|Time restricted eating (TRE)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
62163865|NCT06134986|EXPERIMENTAL|Daily calorie restriction (CR)|25% energy restriction every day Diet counseling provided
62163866|NCT06134986|NO_INTERVENTION|Control|Ad libitum food intake, eating over more than 10 hours per day
62163867|NCT05775718|EXPERIMENTAL|1-<2 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
62163868|NCT05775718|EXPERIMENTAL|2-<3 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
62163869|NCT05775718|EXPERIMENTAL|≥ 3 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
62163870|NCT04287361||Loading dose < 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam \< 0.03 mg / kg
62163871|NCT04287361||Loading dose ≥ 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam ≥ 0.03 mg / kg
62163872|NCT03833206|EXPERIMENTAL|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
62163873|NCT03833206|EXPERIMENTAL|2 PDC-1421 Capsules|2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
62163874|NCT06181435|EXPERIMENTAL|Amlitelimab dose 1|Subcutaneous injection as per protocol
62163875|NCT06181435|EXPERIMENTAL|Amlitelimab dose 2|Subcutaneous injection as per protocol
62163876|NCT06181435|PLACEBO_COMPARATOR|Placebo|Subcutaneous injection as per protocol
62163877|NCT02160548|PLACEBO_COMPARATOR|'Standard care'|Standard care= Intravenous fluids, Oxygen by face mask, Intubation if necessary, Mechanical ventilation (Engstrom Pro by GE) if necessary, Cardiac monitor (Infunix IP4050), Atropine (anti-muscarinic drug; G-Atropine) by intravenous route, Pralidoxime (acetylcholinesterase reactivating oxime drug; PAM-A) by intravenous route.
62714682|NCT05836272|ACTIVE_COMPARATOR|Early NE|The early NE arm will receive low-dose NE as soon as hypotension secondary to sepsis is observed in addition to a classic therapeutic regimen that complies with the guidelines of the 2021 Surviving Sepsis Compaign. Sepsis is defined according to the sepsis 3 consensus by a sepsis related organ failure assessment (SrOFA) score greater than 2 following an infection (documented or suspected)
62714683|NCT05836272|PLACEBO_COMPARATOR|Placebo|The placebo arm will receive only the classic therapeutic regimen that complies with the guidelines of the 2021 Surviving Sepsis Compaign.
62163878|NCT02160548|EXPERIMENTAL|'Standard care+ 2.5 mg Salbutamol'|Standard care+ 2.5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care
62163879|NCT02160548|EXPERIMENTAL|'Standard care+ 5 mg Salbutamol'|Standard care+ 5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 5 mg stat and once only with standard care
62163880|NCT03517371|EXPERIMENTAL|mHealth delivered exercise program|"Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application (app). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature."
62714684|NCT06061692|EXPERIMENTAL|Test group|Tongxinluo Capsule, 4 capsules/time, tid, p.o
62714685|NCT06061692|PLACEBO_COMPARATOR|Control group|Tongxinluo Capsule placebo, 4 capsules/time, tid, p.o
62736494|NCT04153981|EXPERIMENTAL|Insulin Glargine|Participants received insulin glargine once a day (QD) subcutaneously (SC) with a starting dose of 10 units. Participants self-titrated once or twice weekly until fasting blood glucose level was lowered to \<100 milligrams per deciliter (mg/dL). Dose was reduced by 4 units in case of hypoglycemia.
62163881|NCT03517371|ACTIVE_COMPARATOR|Exercise only|Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
62163882|NCT04454671|EXPERIMENTAL|ultrasound-guided percutaneous neuromodulation|Technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor point. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
62163883|NCT04454671|PLACEBO_COMPARATOR|Ultrasound-guided dry needling|Dry needling technique applied by ultrasound-guided but without electrical stimulation of a peripheral nerve.
62163884|NCT01636258|NO_INTERVENTION|Arm A: Control group|These participants will continue to receive their usual care from their primary medical care team.
62163885|NCT01636258|EXPERIMENTAL|Arm B|Arm includes diet instruction, exercise, stress management, and culinary education
62163886|NCT04830163|EXPERIMENTAL|PCMS during brain states reflecting strong corticospinal transmission|
62163887|NCT04830163|ACTIVE_COMPARATOR|PCMS during random brain states|
62163888|NCT04117711|EXPERIMENTAL|AT-007|AT-007 is a CNS and retina penetrant aldose reductase inhibitor.
62163889|NCT04117711|PLACEBO_COMPARATOR|Placebo Comparator|Placebo is used as a comparator to the experimental arm.
62163890|NCT05490368|EXPERIMENTAL|Bed mattress sensor system|The experimental group uses the new bed mattress sensor system for 6 months.
62163891|NCT05490368|NO_INTERVENTION|Control Group|In the control group, participants do not use any of the following bedside fall-prevention tools: bed-exit alarm system, ultra low bed, and ripple bed during the same 6-month period.
62163892|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Poor response|"If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction treatment, in many sites ifosfamide at high doses and MTP-PE (Muramyl tripeptide phosphatidylethanolamine), is incorporated in addition to adriamycin.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM (Adriamycin) 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)~All the product are used as commercial formulation~Other Names:~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
62163893|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Good response|"If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction treatment, in many centers the option of additional administration of methotrexate, CDDP (Cisplatinum) and adriamycin will be chosen.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)~All the product are used as commercial formulation~Other Names:~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
62163894|NCT04383288||No overexpression of ABCB1 / P-glycoprotein|"If there is no overexpression of ABCB1 / P-glycoprotein, the administration of methotrexate, adriamycin and cisplatin will be chosen in many sites.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total length 34 weeks~All the product are used as commercial formulation~Other Names:~methotrexate cisplatin doxorubicine"
62163895|NCT02457078|EXPERIMENTAL|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
62163896|NCT02457078|PLACEBO_COMPARATOR|Control Supplement|Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
62163897|NCT05990088|EXPERIMENTAL|Heat Cured Conventional Complete Removable Dentures based on neutral zone concept|The patient will be provided by a complete removable denture designed based on the neutral zone concept to restore his missing teeth which will be manufactured by heat curing of Polymethyl methacrylate.
62537168|NCT02470533|ACTIVE_COMPARATOR|Transarterial chemoembolization|Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
62163898|NCT05990088|ACTIVE_COMPARATOR|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patient will be provided with a complete removable denture designed according to the neutral-concept to restore his missing teeth, which will be manufactured by CAD/CAM milling of monolithic methacrylate blanks.
62163899|NCT05673616|EXPERIMENTAL|Interventional group|Mckenzie Extension Exercises
62163900|NCT06647147|ACTIVE_COMPARATOR|Study group|40 women with fibromyalgia will participate in low to moderate intensity aerobic training plus diaphragmatic breathing exercises.
62537169|NCT02470533|EXPERIMENTAL|Stereotactic body radiation therapy|Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) \< of 5%
62163901|NCT06647147|ACTIVE_COMPARATOR|Control group|40 women with fibromyalgia will only participate in diaphragmatic breathing exercises.
62163902|NCT04731428|EXPERIMENTAL|Progressive Relaxation Exercise|In individuals with normal daily circadian rhythms, cortisol levels peak at 8:00 AM, followed by a constantly declining daily cycle throughout the day. Therefore, it is important to collect blood samples taken for the measurement of serum cortisol levels approximately at the same time. Venous blood samples (3 ml) were obtained from the upper arm at 06:45 AM to evaluate the baseline and 45 minutes after Progressive Relaxation Exercise at 08:00. Vital signs and oxygen saturation were assessed at 6:30 AM before Progressive Relaxation Exercise and at 07:20 AM 5 minutes after Progressive Relaxation Exercise. Measurements were performed in the morning on the day of surgery and on postoperative days 1, 2, and 3.
62163903|NCT04731428|NO_INTERVENTION|Standard Care|In the control group, no application made during and after the surgical intervention, and routine treatment and care applied.
62163904|NCT05318716|EXPERIMENTAL|Reconstructive group|This group of patients would be undergoing fat grafting following implant-based reconstruction. We will be excluding patients that have had autologous based reconstruction, including regional and free flaps. This group will be analyzed based on volume (\<200cc or 50% and \>200cc or 50%) as well as subgroup analysis based on adjuvant chemo or radiation therapy.
62163905|NCT05318716|EXPERIMENTAL|Cosmetic augmentation group|This group of patients will be undergoing a primary or secondary augmentation for cosmesis. They will be included if this is a primary augmentation using fat grafting or a secondary augmentation with no history of fat grafting to the breasts.
62163906|NCT05912517|EXPERIMENTAL|Nipocalimab|Participants will receive nipocalimab intravenously (IV) once weekly (qw) from randomization through gestational age (GA) Week 35.
62163907|NCT05912517|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo IV qw from randomization through GA Week 35.
62163908|NCT06585189||Exposed|Patients initiating pemetrexed, cisplatin or carboplatin, and pembrolizumab as first-line treatment for metastatic NSCLC
62163909|NCT06585189||Comparator|Patients initiating pemetrexed and cisplatin or carboplatin as first-line treatment for metastatic NSCLC
62163910|NCT00108355|ACTIVE_COMPARATOR|Albumin (Control group)|"After LVP, patients in this group received:~Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)"
62163911|NCT00108355|EXPERIMENTAL|Vasoconstrictor (Study Group)|"After LVP, patients in this group received:~Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose"
62163912|NCT01064180|EXPERIMENTAL|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
62163913|NCT01064180|ACTIVE_COMPARATOR|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
62163914|NCT05092776|EXPERIMENTAL|RPH-104|"Test product group receiving RPH-104 subcutaneous (s.c.) injections:160 mg on Day 0, 80 mg on Day 7, Day 14 and every 2 weeks (q2w) thereafter.~In case marker attack does not resolve at Visit 2 - the treatment group will be unblinded: patients will receive planned RPH-104 80 mg administration.~In case of a new attack on further days of treatment period until Visit 10 inclusive - the treatment group will be unblinded: the dose of RPH-104 could be escalated to 160 mg q2w; The patients already receiving RPH-104 160 mg q2w will continue to receive RPH-104 at this dose. Further dose escalation is forbidden."
62163915|NCT05092776|PLACEBO_COMPARATOR|Placebo|"Placebo group receiving the equivalent placebo dose also as s.c. injections on Day 0, Day 7, Day 14 and q2w thereafter.~In case the marker attack does not resolve at Visit 2 - the treatment group will be unblinded: patients will be switched to active treatment with RPH-104 in SC injections at a dose of 160 mg followed by administration of 80 mg in 7 days at the Attack + 7 days Visit, and 80 mg at the next Visits.~In a case of a new attack the patients switching from placebo and receiving RPH-104 at 80 mg dose could be escalated to RPH-104 160 mg q2w; Further dose escalation is forbidden."
62163916|NCT03126188||Sertraline group|Mild and Moderate depressive episode without somatic syndrome who are treated with Sertraline. Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
62163917|NCT03126188||Dosulepin group|Mild and Moderate depressive episode with somatic syndrome who were treated with Dosulepin. Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks
62537170|NCT01138982|EXPERIMENTAL|Mentoring program|Mentor and mentee meet at least every second week, for 2-4 h on every occasion, during 1 year (i.e., for a minimum of two school semesters). Meetings take place outside school and work hours, and the pairs choose activities of their own preferences. No monetary incentives exist, and the mentors are laymen volunteers. The program objective is to establish a safe and supportive relationship, by which the youth is assumed to benefit in social, emotional, and academic development, and as a consequence, be less prone to use alcohol and drugs.
62537171|NCT01138982|NO_INTERVENTION|Control group|No intervention provided, only brief phone calls to control for attention bias
62537172|NCT00952211|ACTIVE_COMPARATOR|CPAP|CPAP at therapeutic pressure
62537173|NCT00952211|SHAM_COMPARATOR|sub-therapeutic CPAP|CPAP administered at sub-therapeutic pressure
62537174|NCT06284603|ACTIVE_COMPARATOR|Study Group 1: HBOT 3/week|The protocol comprises 10 Hyperbaric Oxygen Treatments (HBOT), 3 sessions per week.
62537175|NCT06284603|ACTIVE_COMPARATOR|Study Group 2: HBOT 6/week|The protocol comprises 10 Hyperbaric Oxygen Treatments (HBOT), 6 sessions per week.
62537176|NCT06284603|NO_INTERVENTION|Control Group|No changes to a daily routine.
62537177|NCT02425904|EXPERIMENTAL|Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine|"Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
62163918|NCT03126188||Venlafaxine group|Severe depressive episode without psychotic symptoms who were treated with Venlafaxine. Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
62163919|NCT04282863|ACTIVE_COMPARATOR|robotic-assisted laparoscopic myomectomy (RM)|After randomization, participants who are assigned to the robotic-assisted laparoscopic myomectomy (RM) agree to receive RM.
62163920|NCT04282863|PLACEBO_COMPARATOR|Conventional laparoscopic myomectomy (LM)|After randomization, participants who are assigned to the Conventional laparoscopic myomectomy (LM) agree to receive LM.
62163921|NCT04652050||lung transplants|Lung transplants on Tolsura for infection
62537178|NCT02425904|EXPERIMENTAL|LCH-related disorders + Clofarabine|"Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
62163922|NCT00794573|EXPERIMENTAL|Varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
62163923|NCT00794573|PLACEBO_COMPARATOR|Sugar pill|placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
62163924|NCT02363933|EXPERIMENTAL|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
62163925|NCT06386510|EXPERIMENTAL|real CN-NINM + UL training group|Upper limb strength training program combined to real CN-NINM
62163926|NCT06386510|PLACEBO_COMPARATOR|sham CN-NINM + UL training group|Upper limb strength training program combined to sham CN-NINM
62163927|NCT04038723|EXPERIMENTAL|Pre- and Post-HIIT|Participants will be evaluated before and after exercise training.
62163928|NCT01803854||Gulf War Era Veterans|All Veterans who served in the uniformed services during 1990-1991 who signed consent forms, completed a survey, and provided a blood sample are included in the cohort.
62163929|NCT04586010|EXPERIMENTAL|Fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
62163930|NCT04586010|ACTIVE_COMPARATOR|Teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
62163931|NCT00658177|EXPERIMENTAL|Arm 1|
62163932|NCT00658177|PLACEBO_COMPARATOR|Arm 2|
62163933|NCT04388514|EXPERIMENTAL|Blood ozonization|Blood ozonization plus BAT
62163934|NCT04388514|NO_INTERVENTION|Standard of Care|"BAT only~To note that the BAT are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days."
62163935|NCT01837199|EXPERIMENTAL|Smoking|Metronidazole plus Amoxicillin
62163936|NCT01837199|EXPERIMENTAL|Non-Smoking|Metronidazole plus Amoxicillin
62163937|NCT06720285|EXPERIMENTAL|Standard Treatment with Scalp Nerve Block|"General anesthesia induction was performed by administering fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg. Subsequently, scalp nerve block was performed with 0.5% ropivacaine.~During surgery, a sudden rise of heart rate and blood pressure higher than 20% from baseline was considered as pain, and a bolus of fentanyl was administered as rescue analgesia."
62163938|NCT06720285|ACTIVE_COMPARATOR|Standard Treatment|General anesthesia induction was performed by administering fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg. Then, continuous fentanyl infusion as analgesia maintenance as the standard treatment. During surgery, a sudden rise of heart rate and blood pressure higher than 20% from baseline was considered as pain, and a bolus of fentanyl was administered as rescue analgesia.
62163939|NCT05065580|ACTIVE_COMPARATOR|Low Somatic Symptom Score|"Patients meeting PHQ-9 (Patient health Questionnaire)-9 with score greater than 10 with Somatic Symptom Score less than 7.~These patients will receive the OMT treatment protocol and PHQ-9 and SSS scales will be recorded at 0, 4, and 8 weeks."
62163940|NCT05065580|ACTIVE_COMPARATOR|High Somatic Symptom Score|Patients meeting PHQ-9 (Patient health Questionnaire)-9 with score greater than 10 with Somatic Symptom Score 8 or greater These patients will receive the OMT treatment protocol and PHQ-9 and SSS scales will be recorded at 0, 4, and 8 weeks.
62163941|NCT01843699|EXPERIMENTAL|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
62163942|NCT01843699|PLACEBO_COMPARATOR|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
62163943|NCT05150002|EXPERIMENTAL|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
62163944|NCT05736237||Families with optic disc drusen|
62163945|NCT06540859|EXPERIMENTAL|Transcutaneous Spinal Cord Stimulation|"Device: Transcutaneous Spinal Stimulation~Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA"
62163946|NCT06540859|SHAM_COMPARATOR|Sham stimulation|"Device: Sham Stimulation~Non-invasive electrical stimulation of a lower extremity muscle group over the skin. The intensity of electrical stimulation will be briefly ramped up to a level at which the participants report perceiving the stimulation (i.e., sensory threshold), then ramped down and turned off for the remainder of the intervention."
62163947|NCT06149533|EXPERIMENTAL|The cohort 1|The cohort 1 is treated with edoxaban to prevent catheter-related thrombosis.
62163948|NCT06149533|NO_INTERVENTION|The cohort 2|The cohort 2 won't be treated with edoxaban.
62163949|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
62163950|NCT03586440||forward head rounded shoulder posture|"* craniovertebral angle (CVA) ≤ 50 degree~* distance between on table and acromion ≥ 2.5 cm"
62163951|NCT03586440||normal posture group|"1. Craniovertebral angle\> 50 degree~2. distance between on table and acromion \< 2.5 cm"
62163952|NCT05791305|EXPERIMENTAL|Intervention arm|Will be provided an intervention.
62163953|NCT05791305|NO_INTERVENTION|Controll arm|Will not be provided the intervention.
62163954|NCT05608408|EXPERIMENTAL|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 1|
62163955|NCT05608408|EXPERIMENTAL|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 2|
62163956|NCT05608408|EXPERIMENTAL|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 3|
62163957|NCT05608408|EXPERIMENTAL|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 4|
62163958|NCT03379909|EXPERIMENTAL|Treatment arm|Metformin orally at doses up to 1500 mg twice daily for 3 months.
62163959|NCT05347524||Case arm - Gastric cancer with peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants with peritoneal metastasis.
62163960|NCT05347524||Control arm - Gastric cancer without peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants without peritoneal metastasis.
62163961|NCT03816839|EXPERIMENTAL|SAR439859|administered orally once daily or twice daily as monotherapy in fasted or fed state
62163962|NCT04306445|ACTIVE_COMPARATOR|GF-IGB: Obalon Balloon|Obalon balloons are gas-filled balloons used for weight loss by taking up more space in the stomach. There are three separate balloons that are placed. They are inflated once the capsules containing the balloons are swallowed. The second balloon is swallowed two weeks after the first balloon, and the third balloon is swallowed four to eight weeks after the second balloon. All three balloons are removed six months after the first balloon is placed.
62163963|NCT04306445|ACTIVE_COMPARATOR|Medically Supervised Meal Replacement Program: My New Weigh|Meal Replacements are used for weight loss in order to achieve a very low-calorie diet that is nutritionally balanced. Four to five meal replacements are consumed per day. If only four meal replacements are consumed per day, three servings of vegetables and two servings of fruit are consumed as well. This program lasts for about five months or twenty weeks.
62163964|NCT04306445|ACTIVE_COMPARATOR|Endoscopic Sleeve Gastroplasty: ESG|Endoscopic sleeve gastroplasty (ESG) is a weight loss procedure that uses an endoscopic suturing device known as Overstitch to reduce the size of the stomach. This decreases the amount of food one can consume, which leads to the consumption of fewer calories throughout the day, resulting in weight loss.
62163965|NCT05999344|EXPERIMENTAL|Alcohol before Cannabis|Participants are randomly assigned to receive the standardized alcohol dose during the experimental session prior to going inside their residence to self-administer their preferred cannabis concentrate product.
62163966|NCT05999344|EXPERIMENTAL|Cannabis before alcohol|Participants are randomly assigned to go inside their residence to self-administer their preferred cannabis concentrate product and then receive the standardized alcohol dose.
62163967|NCT04618575|EXPERIMENTAL|Ursodeoxycholic acid combined with total glucosides of paeony|
62163968|NCT04618575|OTHER|Ursodeoxycholic acid only|
62163969|NCT04825210|EXPERIMENTAL|Integrated Behavioral Health - Prevention (IBH-P)|The IBH-P intervention addresses four areas: 1) assessment of emotional and behavioral adjustment, 2) parental education on important supports for emotional and behavioral health, 3) modeling and guidance on nurturing and responsive parenting, and 4) addressing parental concerns about and promoting child self-regulation. The primary focus of IBH-P is promoting infant self-regulation by teaching mothers how to soothe and calm their baby. Trauma-informed and relationship building methods are emphasized to acknowledge maternal experiences with violence and adversity and the desire to establish a strong working alliance. IBH-P is distinguished from Bright Futures through its emphasis on experiential learning, modeling of effective parenting skills, in-session practice and feedback, and proactive problem-solving. Families in IBH-P will receive all standard care elements of the well-child visit including pediatrician implementation of Bright Futures curriculum.
62163970|NCT04825210|ACTIVE_COMPARATOR|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|The Bright Futures control condition consists of standard of care in addressing emotional and behavioral health as provided by pediatricians. Pediatricians will follow the 4th edition of the Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents \[pocket guide\]. Guidelines are provided for topics to discuss and anticipatory guidance at each well-child visit. In contrast to IBH-P, there is an emphasis on didactic presentation, teaching mothers about developmental milestones, and responding to questions and concerns. These include discussions of crying, soothing, and feeding, although self-regulation is not a unifying theme.
62163971|NCT06010368|EXPERIMENTAL|Group 1: Tranexamic acid group|In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
62163972|NCT06010368|EXPERIMENTAL|Group 2: oxytocin group|to the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
62163973|NCT05963074|EXPERIMENTAL|Cohort 1a: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax|Participants will receive ibrutinib 420 milligrams (mg) capsule every day (QD) for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin, and venetoclax 400 mg QD will be administered with ibrutinib 420 mg QD, orally for 12 cycles through Cycle 15.
62163974|NCT05963074|EXPERIMENTAL|Cohort 1b: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax|Participants will receive ibrutinib 420 mg capsule QD for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin and ibrutinib dose will be reduced to 280 mg and will be administered QD, venetoclax 400 mg tablets QD will be administered with ibrutinib 280 mg for 12 cycles through Cycle 15.
62163975|NCT05963074|EXPERIMENTAL|Cohort 2a: Continuous Ibrutinib Monotherapy|Participants will receive ibrutinib 420 mg QD (or last tolerated dose) until disease progression (PD) or unacceptable toxicity.
62163976|NCT05963074|EXPERIMENTAL|Cohort 2b: Continuous Ibrutinib Monotherapy|Participants will receive ibrutinib 420 mg QD for 1 cycle (1 cycle = 28 days) followed by Ibrutinib 280 mg QD (or last tolerated dose) and continue until disease progression or unacceptable toxicity.
62163977|NCT06584929|EXPERIMENTAL|Intervention Condition|Weekly text and email messages referring to Smokefree.gov, NRT Starter kit, free 2-week supply of patches (Nicoderm CQ in either 21 or 14 mg nicotine) and lozenges (Nicorette Nicotine Lozenges, Mint Flavor in either 4 or 2 mg nicotine) with NRT education plus referral to where to request more NRT.
62537179|NCT00944619|EXPERIMENTAL|Closed loop (algorithm)|Subcutaneous delivery of Novorapid insulin, dose calculated by computer-driven control algorithm, based on continuous glucose sensor readings
62537180|NCT00944619|PLACEBO_COMPARATOR|Open loop|Subcutaneous delivery of Novorapid insulin according to usual pump regime
62537181|NCT02955758|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
62163978|NCT06584929|NO_INTERVENTION|Control Condition|Weekly text and email messages referring to Smokefree.gov
62163979|NCT06584929|NO_INTERVENTION|RHE - Intervention Condition|Weekly text and email messages on reduced harm or exposure (RHE) tobacco products.
62537182|NCT02202070|EXPERIMENTAL|Botox injection first, followed by placebo|50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months
62537183|NCT02202070|EXPERIMENTAL|Placebo injection first, followed Botox|Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.
62537184|NCT01925300|EXPERIMENTAL|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd|Single administration : 6 days, per oral
62537185|NCT01925300|EXPERIMENTAL|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd|Single administration : 6 days, per oral
62537186|NCT01925300|EXPERIMENTAL|Concor 5mg 2T and Crestor 20 mg 1Tab, qd|Combination administration : 6 days, per oral
62537187|NCT04431609||CAROtid WEB associated with cerebral infarction|french multicentric cohort that collects retrospectively and prospectively purely observational data on patients with cerebral infarction associated with a carotid web. Diagnostic, therapeutic or follow-up strategies will be at the discretion of the Stroke Unit taking care of the patient.
62537188|NCT00852774||1|Endometrial Cancer Patients Hysterectomy Robotic Surgery
62537189|NCT00852774||2|Endometrial Cancer Patient Hysterectomy Laparotomy Surgery
62537190|NCT03722667|PLACEBO_COMPARATOR|Technology-Based Component|A Technology-based interventions comprised of three technolgy components accessible via smartphone to support self-managing hypertension.
62537191|NCT03722667|EXPERIMENTAL|TechSupport|A Technology-based interventions comprised of three technolgy components plus positive psychological training accessible by smartphone to support self-managing hypertension.
62537192|NCT06231056|EXPERIMENTAL|Probiotic supplement group|Participants in this group received probiotic iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215) - dosage 1 sachet per day, during the 24-36 weeks of their gestation period.
62537193|NCT06231056|NO_INTERVENTION|Control group|No probiotic supplementation. Participants in this group did not received probiotic iNatal® during 24-36 weeks of their gestation period.
62537194|NCT03290703|EXPERIMENTAL|Part 1: GDC-0853 (Effect of Formulation)|Participants will receive five single oral doses of test formulations of GDC-0853 co-administered with rabeprazole in the fasted state.
62537195|NCT03290703|EXPERIMENTAL|Part 2: GDC-0853 (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of one GDC-0853 formulations selected from Part 1 of this study. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
62537196|NCT03290703|EXPERIMENTAL|Part 3: GDC-0853 Optimized (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of an optimized tablet formulations of GDC-0853. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
62537197|NCT03463382|ACTIVE_COMPARATOR|ESP Group|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
62537198|NCT03463382|ACTIVE_COMPARATOR|QLB Group|"Quadratus Lumborum Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
62537199|NCT03283761|EXPERIMENTAL|Treatment Arm|All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A on days 1 and 15 of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m\^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m\^2 and leucovorin IV 400 mg/m\^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m\^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every other cycle (starting with Cycle 3) to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
62537200|NCT05907629||CAPTIVA-MRI Group|CAPTIVA patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.
62537201|NCT00977886|PLACEBO_COMPARATOR|Placebo|
62537202|NCT00977886|EXPERIMENTAL|ELB353|
62537203|NCT02472327|NO_INTERVENTION|Typical Care|These patients will receive normal peripartum care and support.
62537204|NCT02472327|EXPERIMENTAL|Pre-operative support|These patients will receive additional emotional support prior to undergoing an unplanned cesarean section during labor.
62537205|NCT01442428|EXPERIMENTAL|Steroid+Statin|"1. Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~2. Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
62537206|NCT01442428|ACTIVE_COMPARATOR|NSAID+Statin|"1. Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~2. Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
62537207|NCT01442428|ACTIVE_COMPARATOR|Steroid+Placebo|"1. Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~2. Placebo"
62537208|NCT01442428|ACTIVE_COMPARATOR|NSAID+Placebo|"1. Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~2. Placebo"
62537209|NCT02552212|EXPERIMENTAL|Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
62537210|NCT02552212|PLACEBO_COMPARATOR|Placebo|Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.
62537211|NCT06609226|EXPERIMENTAL|Participants greater than or equal to (≥) 12 years old with sickle cell disease|Participants will receive an oral dose of Etavopivat A.
62537212|NCT06609226|EXPERIMENTAL|Participants ≥ 12 years old with sickle cell disease on chronic red blood cell (RBC) transfusions|Participants will receive an oral dose of Etavopivat A.
62537213|NCT06609226|EXPERIMENTAL|Participants ≥ 12 years old with transfusion-dependent thalassaemia|Participants will receive an oral dose of Etavopivat A.
62537214|NCT06609226|EXPERIMENTAL|Participants ≥ 12 years old with non-transfusion dependent thalassaemia|Participants will receive an oral dose of Etavopivat A.
62537215|NCT06609226|EXPERIMENTAL|Participants ≥ 11 months to less than (<) 12 years old with sickle cell disease|Participants ≥ 12 years of age will receive an oral dose of Etavopivat A and participants \< 12 years of age will receive an oral dose of Etavopivat B.
62537216|NCT01485744|EXPERIMENTAL|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|
62537217|NCT04461158|EXPERIMENTAL|Interventional Group|
62537218|NCT00371397|EXPERIMENTAL|Hatha yoga classes|Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
62537219|NCT00371397|SHAM_COMPARATOR|Movement Control|Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
62537220|NCT00371397|NO_INTERVENTION|Passive Video Control|Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
62537221|NCT04740320||Healthy Volunteers|Volunteers asked to register details on a SARS-CoV-2 specific web page UKcovidchallenge.com. They will be contacted with a short webform questionnaire to be performed prior to a follow-up telephone questionnaire or will be asked to complete a telephone questionnaire. If inclusion/exclusion criteria are met, appointment for a screening visit will be scheduled. Screening appointments will be conducted at hVIVO. Written consent for screening will be obtained prior to any history-taking, examination or tests are carried out. Medical history will be requested from GP to assess suitability. Once the SARS-CoV-2 characterization study is approved, potential participants will be given the study specific PIS detailing the full study and experimental procedures. The opportunity to discuss further and ask questions will be available prior to booking a study visit.
62537222|NCT06255158|EXPERIMENTAL|INSIGHT Program|"The design of the INSIGHT Program aligns with RNR model, the principles of cognitive behavioral therapy, and schema therapy. The intervention comprises different phases, beginning with an initial individual motivation interview intervention, and followed by a CBT-structured, ST-inspired individual program.~The core of the intervention program consists of a manualized individual program comprising 25 weekly sessions, each lasting approximately 60 minutes."
62537223|NCT06255158|OTHER|Treatment As Usual Group|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
62537224|NCT03673657|EXPERIMENTAL|The study group|"Patients in the study group received early nutritional intervention, including individualized nutrition counseling and oral nutritional supplements from the initiation of CCRT to 2 weeks after its completion. Energy goal: daily total nutritional intake of about 30 kcal/kg.~Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
62537225|NCT05436067|EXPERIMENTAL|Older adults with dizziness|Clinical trial only has one arm or participant group. All participants undergo the same experiment. They will perform exercises with the Vestibular Rehabilitation App as well as without the App. The order is randomized.
62537226|NCT04084093|EXPERIMENTAL|Surfactant Gel|
62537227|NCT03821181|EXPERIMENTAL|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
62537228|NCT03821181|SHAM_COMPARATOR|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
62537229|NCT02567643|EXPERIMENTAL|Stereotactic Radiosurgery|
62537230|NCT03112330|EXPERIMENTAL|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
62537231|NCT01160003|EXPERIMENTAL|Treatment Period 1|5mg of GW870086X or placebo will be given once daily for 14 days.
62537232|NCT01160003|EXPERIMENTAL|Treatment Period 2|GW870086X (5mg or 8.75mg) or placebo will be given once daily for 14 days. In a randomised dose escalating manor following on from treatment period 1.
62537233|NCT01160003|EXPERIMENTAL|Treatment Period 3|8.75mg of GW870086X or placebo will be given once daily for 14 days.
62537234|NCT02784873|NO_INTERVENTION|Usual care|"Usual care cardiac rehabilitation with exercise training as per current guidelines~Warm up: 15 mins, \< 40% heart rate reserve (HRR) Cardiovascular component: progress towards 20 - 40 mins continuous cardiovascular exercise at 40-70% HRR.~Muscular strength and endurance programme. Cool down: 10 mins, \< 40% HRR. Initial duration based on participant's previous and current physical activity (PA) levels and cardiopulmonary exercise test (CPEX) performance.~Duration and workload of cardiovascular component adjusted, as tolerated, within the above parameters, in response to exercising heart rate (HR), participant reported rating of perceived exertion (RPE) and symptoms."
62163980|NCT03221634|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
62163981|NCT04485793|ACTIVE_COMPARATOR|Active Comparator|Dietary supplement
62163982|NCT04485793|PLACEBO_COMPARATOR|Placebo comparator|Placebo
62163983|NCT04968249||Gold 0|Participant must be ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted.
62163984|NCT04968249||Gold 1|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \< 0.70 and FEV1 \>= 80% predicted.
62163985|NCT04968249||Gold 2|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \< 0.70 and FEV1 50-79% predicted.
62163986|NCT04968249||Preserved Ratio Impaired Spirometry (PRISm)|Participant shall be between ages 30-55 years and have: ≥10 year smoking history, post-bronchodilator of FEV1 50-79% predicted and a predicted FEV1/FVC ≥ 0.70.
62163987|NCT05697822|EXPERIMENTAL|Mobile Phone and Cloud-based Electronic Contact and Recording System|In this arm pregnant women will be given a smart mobile-phone with an application installed which will have their detailed health-related information. They will be able to use this application to input their daily symptoms. This will also contain results of examinations or investigations that they have undergone in a clinic. All this information will be stored in a cloud and the healthcare worker at the local health post will also be able to access this information in their mobile phone and keep track of the pregnant women under their care. In the event of a concerning symptom, the health worker will be flagged. The health coordinators in the rural municipality will also be able to keep track of the pregnant women in their area through a cloud-based database.
62163988|NCT05697822|NO_INTERVENTION|Usual Standard of Care Arm|Pregnant women will visit the health posts or hospitals for antenatal checks routinely as advised. Their records will be kept in paper-based forms and registers. They will not be tracked regularly by their healthcare provider by electronic means. Their daily symptoms will not be recorded anywhere. They will still be able to contact their healthcare providers or visit the health centers if necessary. They will not have a personal electronic health record. No one will keep active track of the pregnant women through electronic means.
62163989|NCT02294461|EXPERIMENTAL|Enzalutamide|Participants received 160 mg of enzalutamide orally once a day during double blind period until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer. Eligible participants who received enzalutamide during double blind and who provided consent to take part in open-label period continued to receive 160 mg of enzalutamide in open-label period orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
62163990|NCT02294461|EXPERIMENTAL|Placebo|Participants received enzalutamide matching placebo orally once a day during double-blind period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
62537235|NCT02784873|EXPERIMENTAL|High intensity interval training|"High intensity interval training within a standard cardiac rehabilitation programme.~Warm up: 15 mins total, 10 mins \<40-70% HRR, 5 mins \<70% HRR. Cardiovascular component: exercise bike interval training: 10 x high @ 85-90% peak power output (PPO) from CPEX, 10 x low @ 20-25% PPO (exercise intensity will not to be prescribed from gas exchange data i.e. %VO2 peak). Change in intensity from low to high achieved by altering cadence (rpm).~Muscular strength and endurance programme. Cool down: 10 mins, \<40% HRR. Duration of intervals and total programme duration increased in a standardised fashion.~Workload increased bi-weekly in response to participant reported RPE (only after the full 10 x 1 protocol has been achieved). If RPE \< 17 then workload will be increased."
62537236|NCT06505941|PLACEBO_COMPARATOR|placebo|1 intravenous infusion of an equal volume of cell-free placebo.
62537237|NCT06505941|EXPERIMENTAL|MSC|Name：Human umbilical cord mesenchymal stem cells Specification: 30 ml/bag Dosage: 1×106cells/kg, 5×106cells/kg, 10×106cells/kg Usage: Intravenous infusion The stem cells used in this study are human umbilical cord mesenchymal stem cells (hUC-MSCs), which are derived from umbilical cords donated by healthy mothers who have given birth in maternity hospitals. hUC-MSCs are extracted, processed, cultured and harvested from umbilical cord donors recruited by laboratories complying with the GMP standards. hUC-MSCs cell suspensions that have passed the quality control will be put into bags and transported to the hospitals for use by the subjects of the present clinical study.
62537238|NCT01467986|ACTIVE_COMPARATOR|Irinotecan, Temozolomide|Patients randomized to the control arm receive irinotecan (I) and temozolomide (T) alone.
62537239|NCT01467986|EXPERIMENTAL|Rapamycin, Dasatinib, Temozolomide, Irinotecan|Patients with rNB receive on the study arm the experimental combination of rapamycin (R)- mTOR Inhibitor, dasatinib (D)- protein kinase inhibitor irinotecan (I)- cytostatic topoisomerase-I-inhibitor and temozolomide (T)- Antineoplastic agent
62537240|NCT00056394|EXPERIMENTAL|1|Participants will receive comprehensive pain coping skills.
62537241|NCT00056394|ACTIVE_COMPARATOR|2|Participants will receive arthritis education.
62537242|NCT00056394|ACTIVE_COMPARATOR|3|Participants will receive standard care.
62537243|NCT05255796|EXPERIMENTAL|one-piece|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
62537244|NCT05255796|EXPERIMENTAL|plate-haptic|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
62537245|NCT06060379|EXPERIMENTAL|Intervention gruop|Partecipant will participate in playful encounters
62537246|NCT06060379|NO_INTERVENTION|Control group|Subjects will not partecipate in the games
62537247|NCT01816659|EXPERIMENTAL|Metformin + Colon Surgery|Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
62537248|NCT01816659|NO_INTERVENTION|Colon Surgery Alone|Patients will not receive any study drug from the time of colonoscopy until surgery.
62537249|NCT01894594|EXPERIMENTAL|Sodium Bicarbonate|Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:
62537250|NCT01191827||risperidone|
62537251|NCT01191827||clozapine|Patients with schizophrenia treated with clozapine
62537252|NCT01637727||GDM1|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
62537253|NCT01637727||GDM|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
62537254|NCT02648100||A|120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.
62537255|NCT02648100||B|510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.
62537256|NCT02648100||C|188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.
62537257|NCT02648100||D|93 patients from the clinical trial GETUG 19 (UNICANCER)
62537258|NCT05458180|EXPERIMENTAL|CMOEP|dose-escalation： Untreated Peripheral T-cell Lymphoma Patients will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine, Etoposide and Prednisone for 6 cycles (planned) (21 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 15 mg/m2.
62537259|NCT05605015|EXPERIMENTAL|ACTIVE-CR INTERVENTION|Participants will complete a 6-week remote, technology-based physical activity intervention named ACTIVE-CR, in which they will be required to wear a wrist worn monitor to measure daily physical activity. Participants will be able to view their physical activity feedback on a web-based platform and will receive three online trainer sessions across the 6 weeks to help them to understand and interpret their data.
62537260|NCT05605015|NO_INTERVENTION|CONTROL|Participants in the control group will receive usual care from their healthcare team (if relevant) and will be invited to have an assessment at baseline and 6-weeks. Control participants will not receive any form of intervention. At the end of the study, control participants will receive a summary of their physical activity data measured at baseline and 6-weeks (in a booklet format with guidance on how to interpret and use the information).
62537261|NCT05903014|EXPERIMENTAL|Experimental|3600 mg NAC per day in 12 weeks
62537262|NCT05903014|PLACEBO_COMPARATOR|Placebo|Placebo
62537263|NCT01292226|EXPERIMENTAL|Mycophenolate Mofetil Monotherapy|Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
62537264|NCT04540406|EXPERIMENTAL|NBT-NM108 + Usual Care|
62537265|NCT04540406|ACTIVE_COMPARATOR|Usual Care Only|
62537266|NCT04492644||elderly inpatients|Elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious. Elderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.
62537267|NCT04182724|EXPERIMENTAL|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib 250 mg p.o. qd Nab-paclitaxel 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
62163991|NCT02294461|EXPERIMENTAL|Placebo followed by Enzalutamide|Eligible participants who received enzalutamide matching placebo during double-blind period and who provided consent to take part in open-label period, received 160 mg of enzalutamide orally once a day during open-label period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
62163992|NCT00857311|EXPERIMENTAL|MRKAd5 HIV-1 gag vaccine 1x10^9 vp/dose|Participants administered MRKAd5 HIV-1 gag vaccine 1x10\^9 viral particles (vp)/dose (V520), on Day 1, Week 4, and Week 26.
62537268|NCT04960033||Osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
62537269|NCT04960033||women without osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was \<20% or the 10-year probability of HF was \<3%.
62537270|NCT01910012|EXPERIMENTAL|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
62537271|NCT06096922||AI frailty index establishment group|Individuals who undergo elective cardiac surgury
62537272|NCT02475330|EXPERIMENTAL|Dietary Supplement: Flaxseed|
62537273|NCT04876365||All Participants|All participants diagnosed with severe hemophilia A previous received prophylaxis regimen for Standard Half-life/Extended Half-life Factor VIII (SHL/EHL-FVIII) products will be compared to after the participants switched to regular prophylaxis with Adynovate with at least 6 months follow up.
62537274|NCT00764686|EXPERIMENTAL|1|Low disease severity group
62537275|NCT00764686|EXPERIMENTAL|2|Higher disease severity group
62537276|NCT00509795|ACTIVE_COMPARATOR|ranibizumab 0.5mg Q4|
62163993|NCT00857311|EXPERIMENTAL|MRKAd5 HIV-1 gag vaccine 1x10^10 vp/dose|"Participants were to be administered MRKAd5 HIV-1 gag 1x10\^10 vp/dose (V520) on Day 1, Week 4, and Week 26.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in the group MRKAd5 HIV-1 gag 1x10\^10 vp/dose."
62163994|NCT00857311|EXPERIMENTAL|Placebo|Participants administered placebo to MRKAd5 HIV-1 gag vaccine (V520) on Day 1, Week 4, and Week 26.
62163995|NCT00857311|SHAM_COMPARATOR|Open Label Tetanus and Diptheria Toxoids Adsorbed|"Participants were to be administered open label tetanus and diptheria toxoids adsorbed (Td) at Day 1 only.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in this group."
62163996|NCT03751280|EXPERIMENTAL|PEAR-004|Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
62163997|NCT03751280|SHAM_COMPARATOR|Sham|Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.
62163998|NCT05242471|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62163999|NCT05242471|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62164000|NCT05242471|EXPERIMENTAL|Group 3: Golimumab|Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62164001|NCT05242471|EXPERIMENTAL|Group 4: JNJ-78934804 (High-dose)|Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62164002|NCT05242471|EXPERIMENTAL|Group 5: JNJ-78934804 (Mid-dose)|Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62164003|NCT05242471|EXPERIMENTAL|Group 6: JNJ-78934804 (Low-dose)|Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
62164004|NCT03792841|EXPERIMENTAL|Part 1 Dose-exploration: acapatamab treatment|Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.
62164005|NCT03792841|EXPERIMENTAL|Part 1 Dose-expansion: acapatamab treatment|Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.
62164006|NCT03792841|EXPERIMENTAL|Part 2: acapatamab + Pembrolizumab|Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.
62164007|NCT03792841|EXPERIMENTAL|Part 3: acapatamab + Etanercept Prophylaxis|Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.
62164008|NCT03792841|EXPERIMENTAL|Part 4: acapatamab 24 Hour Monitoring|Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.
62164009|NCT03792841|EXPERIMENTAL|Part 5: acapatamab Outpatient Cohort|Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.
62164010|NCT03792841|EXPERIMENTAL|Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction|Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.
62164011|NCT04370392|ACTIVE_COMPARATOR|control group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
62164012|NCT04370392|EXPERIMENTAL|IV dexmedetomidine group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline containing dexmedetomidine 1 ug/kg over 10 minutes.
62164013|NCT04370392|EXPERIMENTAL|IP dexmedetomidine group|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25% with dexmedetomidine 1 ug/kg) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
62164014|NCT05254288|EXPERIMENTAL|Split-mouth Group A|Half of patients will be assigned to this group. Quadrants Q1/Q4 will receive ozone administration. Quadrants Q2/Q3 will receive chlorhexidine administration.
62164015|NCT05254288|EXPERIMENTAL|Split-mouth Group B|Half of patients will be assigned to this group Quadrants Q2/Q3 will receive ozone administration. Quadrants Q1/Q4 will receive chlorhexidine administration.
62537277|NCT00509795|EXPERIMENTAL|aflibercept injection 2.0mg Q4|
62537278|NCT00509795|EXPERIMENTAL|aflibercept injection 0.5mg Q4|
62537279|NCT00509795|EXPERIMENTAL|aflibercept injection 2.0mg Q8|
62537280|NCT02397187|EXPERIMENTAL|LOOP intervention|"Patients enrolled in this arm will be treated by the LOOP interventional technique.~The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
62537281|NCT02397187|ACTIVE_COMPARATOR|TAU|Patients enrolled in this arm will be TAU, which is based upon short-term supportive PT.
62164016|NCT05478200|EXPERIMENTAL|Semi-directed Therapeutical Exercise and pain education program|Patients will receive physical exercise, combined with pain education and healthy lifestyle habits: an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength 13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
62164017|NCT05478200|ACTIVE_COMPARATOR|Pain release passive therapy based on manual therapy, thermotherapy and electroanalgesia|"Patients will receive 35-40 minutes of passive analgesic techniques sessions (2 per week, over 8 weeks). The following treatment will be applied:~15 minutes of massage on the lumbopelvic musculature, lower lumbar segments and sacroiliac joints rhytmic-passive mobilization. The hip may also be mobilised at physiotherapist's discretion, 10 minutes of electrotherapy (interferential current in the lumbar region) Medium frequency current, interrupted alternating sinusoidal pulse with a frequency of up to 250 Hz and thermotherapy (10-15 minutes local in the lumbar region) with antenna electrodes placed at a distance of 20 cm from the patient's skin, at an intensity of 70 to 120 watts."
62164018|NCT00672711||C|APS
62164019|NCT00672711||B|HPS
62164020|NCT00672711||A|LPS
62164021|NCT01448408||Forme Fruste Keratoconus group (FFKG)|FFK eyes had to present a) no apparent signs of KC in clinical examination b) stage 0 in the Amsler-Krumeich scale, and c) demonstrate a KISA index value between 60-100%
62164022|NCT01448408||Normal Group (CG)|Eligibility for participation in the CG was confirmed by consecutive topographies, while all CG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography and KISA index value less than 60%, as well.
62164023|NCT06437327|EXPERIMENTAL|Experimiental Group 1|Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes Active release technique is applied (patient is prone lying with knee flexed, Pressure is applied on taut band and patient is asked to move the leg in internal rotation to achieve maximal lengthening) Repetitions 5 to 7 times hold for 5 to 20 seconds
62164024|NCT06437327|EXPERIMENTAL|Experimental Group 2|Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes Hold relax technique This technique is applied while the patient is in supine lying with one leg crossed over the other Patient is instructed to contract the piriformis against the manual resistance for 5 to 10 secs Then 15 secs of passive stretch is given repetitions x 5 times
62164025|NCT00553800|EXPERIMENTAL|Bevacizumab & Erlotinib|bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
62164026|NCT06719713|EXPERIMENTAL|Store Safely|The Store Safely arm (consisting of a community sample) will receive the Store Safely intervention, usual community-based care, and 988 suicide and crisis lifeline number and a publicly available safe storage information resource numbers.
62164027|NCT06719713|NO_INTERVENTION|Waitlist control|The waitlist control group (consisting of a community sample) will not receive the intervention during the clinical trial but will be offered 988 suicide and crisis lifeline number and a publicly available safe storage information resource numbers. Following the clinical trial they will have access to the Store Safely intervention.
62164028|NCT06208150|EXPERIMENTAL|Arm A: Talquetamab + Pomalidomide (Tal-P)|Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
62164029|NCT06208150|EXPERIMENTAL|Arm B: Talquetamab + Teclistamab (Tal-Tec)|Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
62164030|NCT06208150|ACTIVE_COMPARATOR|Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd)|Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication.
62164031|NCT01159756|EXPERIMENTAL|Travacom|Travacom ophthalmic solution
62164032|NCT02020551|PLACEBO_COMPARATOR|saline spray application|Placebo group
62164033|NCT02020551|EXPERIMENTAL|lidocaine spray application|2 puff lidocaine spray applicated before IUD insertion
62537282|NCT06105827|OTHER|Control group|Give antibiotics or diclofenac sodium suppository as needed.
62164034|NCT05913999||Anthracycline|Patients undergoing chemotherapy with an anthracycline-containing regimen.
62164035|NCT05913999||VEGF Inhibitor|Patients undergoing chemotherapy with a vascular endothelial growth factor (VEGF) inhibitor-containing regimen.
62164036|NCT05913999||Immune Checkpoint Inhibitor|Patients undergoing chemotherapy with an immune check point inhibitor-containing regimen.
62164037|NCT05186493|EXPERIMENTAL|Locally advanced pelvic cancer that requires total pelvic exenteration|Adult patients (\>18 years) with locally advanced pelvic cancer that require pelvic exenteration considered eligible for robot- assisted minimally invasive surgery by the respective multidisciplinary teams
62537283|NCT06105827|EXPERIMENTAL|Ningmitai capsule|Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day. Course of treatment: 12 weeks
62537284|NCT06105827|EXPERIMENTAL|Combined group (Ningmitai plus tamsulosin)|Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group. Course of treatment: 12 weeks
62537285|NCT02430831|ACTIVE_COMPARATOR|Reuteri group|Milk formula added with probiotic L reuterii DSM 17938
62164038|NCT04453306|PLACEBO_COMPARATOR|placebo|"Patients with the same characteristics as the intervention group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
62537286|NCT02430831|PLACEBO_COMPARATOR|Placebo|Milk formula without probiotic L reuterii DSM 17938
62537287|NCT05278728|EXPERIMENTAL|Nimotuzumab and Irinotecan|Nimotuzumab： 200, 400, 600 or 800mg weekly until progression or AEs Irinotecan：180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
62164039|NCT04453306|EXPERIMENTAL|intervention|"Patients with the same characteristics as the placebo group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
62164040|NCT01642771|ACTIVE_COMPARATOR|5-Fu/epirubicin/CTX following Docetaxel|Docetaxel for the first 3 cycles of chemotherapy followed by 3 cycles of FEC (Fluorouracil, epirubicin and cyclophosphamide) chemotherapy
62164041|NCT01642771|EXPERIMENTAL|Docetaxel/capecitabine followed by XEC|Docetaxel/ capecitabine (TX) for the first 3 cycles of chemotherapy followed by 3 cycles of capecitabine/epirubicin/cyclophosphamide (XEC) chemotherapy
62164042|NCT06721442|ACTIVE_COMPARATOR|Dapafliflozin|A total of 174 individuals were assessed for eligibility, of whom 87 were randomized to receive dapagliflozin in combination with optimized medical treatment for type 2 diabetes.
62164043|NCT06721442|NO_INTERVENTION|Control group|A total of 174 individuals were assessed for eligibility, and 87 were randomized to continue receiving optimized medical treatment for type 2 diabetes.
62164044|NCT06047795|EXPERIMENTAL|Interventional|Aerobic and respiratory endurance exercises with patient education
62164045|NCT06047795|PLACEBO_COMPARATOR|Control|Usual care (Patient Education, Home Plan)
62164046|NCT03161652|PLACEBO_COMPARATOR|DME lactose pill|Patients with DME will be randomized to take a lactose pill (placebo).
62164047|NCT03161652|EXPERIMENTAL|DME levosulpiride|Patients with DME will be randomized to take levosulpiride.
62164048|NCT03161652|PLACEBO_COMPARATOR|DR lactose pill|Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)
62164049|NCT03161652|EXPERIMENTAL|DR levosulpiride|Patients with non-proliferative DR will be randomized to take levosulpiride
62164050|NCT03161652|PLACEBO_COMPARATOR|DR, vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).
62164051|NCT03161652|EXPERIMENTAL|DR, vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.
62164052|NCT03161652|PLACEBO_COMPARATOR|DME plus ranibizumab lactose pill|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)
62164053|NCT03161652|EXPERIMENTAL|DME plus ranibizumab levosulpiride|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride
62164054|NCT03899844||Cognitively normal|896 of the 1120 enrolled will not exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
62164055|NCT03899844||Cognitively impaired|224 of the 1120 enrolled will exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
62164056|NCT06021834|ACTIVE_COMPARATOR|control group|The control group will be invited to attend the program three times per week and will engage in an endurance training program
62164057|NCT06021834|EXPERIMENTAL|experimental group|the experimental group will be invited to attend the program three times per week and will participate in a combined endurance training and cognitive training program.
62164058|NCT00683371|ACTIVE_COMPARATOR|1|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery
62164059|NCT00683371|PLACEBO_COMPARATOR|2|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery.
62537288|NCT03242200|OTHER|Mobile Health App|Participants will be prompted to complete questionnaires.
62537289|NCT00397774|ACTIVE_COMPARATOR|Exercise|Physical exercise twice a week for 8 weeks, and best supportive care
62537290|NCT00397774|OTHER|No exercise|Best supportive care, no exercise
62537291|NCT03408535|OTHER|Eriksholm Guide to Better Hearing|The Eriksholm Guide to Better Hearing is an online rehabilitation program. The program is made up of 5-weekly modules that cover different topics. Each module includes self-studies, training, and professional video coaching in hearing loss, hearing aids, and communication strategies.
62164060|NCT05966623|EXPERIMENTAL|Experimental VRI sign language interpretation|Participants will be provided with a Tablet of 14' inches with interrupted VRI in Colombian Sign Language. Professionally accredited Sign language interpreter. At the end of the hospital visit, they will complete a scale measuring Doctor-Patient-Communication
62164061|NCT05966623|NO_INTERVENTION|Experimental: primo control|Participants get welcome at the entry point of the hospital, they are not provided with VRI. At the end of the hospital visit, they will complete a scale measuring Doctor-Patient-communication
62164062|NCT04206384|EXPERIMENTAL|Treatment group|Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm\^2.
62537292|NCT04067453||Patients undergoing fatiguing protocol|patient consulting for anorectal manometry in order to explore anorectal disorders with a voluntary command on external anal sphincter
62537293|NCT01713881||post-registry|"Registry Group:~* Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry.~* Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013)."
62537294|NCT01713881||pre-registry|Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006.
62537295|NCT00522561|OTHER|1|healthy volunteers
62164063|NCT06299696|EXPERIMENTAL|VNZ/TEZ/D-IVA|Participants will be given VNZ/TEZ/D-IVA FDC to retain in their mouths for approximately 10 seconds and then expectorated.
62164064|NCT03239353|ACTIVE_COMPARATOR|1.5 mg ETV XR tablet|
62164065|NCT03239353|ACTIVE_COMPARATOR|3 mg ETV XR tablet|
62164066|NCT03239353|ACTIVE_COMPARATOR|6 mg ETV XR tablet|
62164067|NCT03239353|PLACEBO_COMPARATOR|Placebo-to-match 1.5 mg ETV XR tablet|
62164068|NCT03239353|OTHER|0.5 mg ETV IR tablet|
62537296|NCT02662283|ACTIVE_COMPARATOR|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
62537297|NCT02662283|EXPERIMENTAL|Reh-acteoside|Oral take reh-acteoside (0.4g bid) for 8 weeks
62537298|NCT02662283|EXPERIMENTAL|Reh-acteoside+Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) and reh-acteoside (0.4g bid) for 8 weeks
62537299|NCT01405716|ACTIVE_COMPARATOR|Behavioral-Mindfulness|Mindfulness Meditation
62537300|NCT01405716|PLACEBO_COMPARATOR|Behavioral-Health|Health Education Class
62537301|NCT03437226|EXPERIMENTAL|Levosimendan Arm|Patients receive 6 or 24 hours infusion depending on the site. Levosimendan 2.5 MG/M 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Levosimendan 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Levosimendan
62164069|NCT01810406|EXPERIMENTAL|Epidural Volume Extension|CSE with 10 ml EVE
62164070|NCT01810406|ACTIVE_COMPARATOR|No Epidural Volume Extension|CSE without EVE
62164071|NCT02440672||Device:JOURNEY™ II CR Total Knee System (J II CR TKS)|Subjects having TKA with JOURNEY™ II CR Total Knee System
62164072|NCT06340334|EXPERIMENTAL|Group A|oral Tegoprazan 50 mg, bid+amoxicillin 1000 mg, tid. The duration of treatment is 14 days.
62164073|NCT06340334|ACTIVE_COMPARATOR|Group B|oral Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days.
62164074|NCT01436045|EXPERIMENTAL|Insulin glulisine|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
62164075|NCT01436045|PLACEBO_COMPARATOR|Saline|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
62164076|NCT05430347|EXPERIMENTAL|TCbHPy*6|"Pyrotinib combined with docetaxel, carboplatin and trastuzumab for 6 cycles (Every three weeks).~T (Docetaxel 100 mg/m2, d1) C (Carboplatin, AUC 6, D1) H (Trastuzumab, 8 mg/kg for the first dose, 6 mg/kg for the rest, D1) Py (pyrotinib 400mg, qD, D1-21)"
62164077|NCT05430347|ACTIVE_COMPARATOR|TCbHP*6|"Pertuzumab combined with docetaxel, carboplatin and trastuzumab for 6 cycles (Every three weeks).~T (Docetaxel 100 mg/m2, d1) C (Carboplatin, AUC 6, D1) H (Trastuzumab, 8 mg/kg for the first dose, 6 mg/kg for the rest, D1) P (Pertuzumab, 840mg for the first dose, 420mg for the rest, D1))"
62164078|NCT03126266|EXPERIMENTAL|Patients receiving re-irradiation|Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
62164079|NCT02257853|NO_INTERVENTION|Control Group|No intervention group
62164080|NCT02257853|EXPERIMENTAL|Intervention|Receives stress reduction intervention introduction with daily practice
62164081|NCT00927537||Group 1|
62164082|NCT00927537||Group 2|
62164083|NCT06690996|EXPERIMENTAL|LY4005130 Part A (SAD) SC|A single-ascending dose of LY4005130 administered subcutaneously (SC)
62164084|NCT06690996|PLACEBO_COMPARATOR|Placebo Part A (SAD) SC|Placebo administered SC
62164085|NCT06690996|EXPERIMENTAL|LY4005130 Part A (SAD) IV|A single-ascending dose of LY4005130 administered intravenously (IV)
62164086|NCT06690996|PLACEBO_COMPARATOR|Placebo Part A (SAD) IV|Placebo administered IV
62164087|NCT06690996|EXPERIMENTAL|LY4005130 Part A (SAD) Optional|A single-ascending dose of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts
62164088|NCT06690996|PLACEBO_COMPARATOR|Placebo Part A (SAD) Optional|A single-ascending dose of placebo administered either SC or IV depending on emerging data from earlier cohorts
62164089|NCT06690996|EXPERIMENTAL|LY4005130 Part B (MAD) IV|Multiple-ascending doses of LY4005130 administered IV
62164090|NCT06690996|PLACEBO_COMPARATOR|Placebo Part B (MAD) IV|Placebo administered IV
62164091|NCT06690996|EXPERIMENTAL|LY4005130 Part B (MAD) SC or IV|Multiple-ascending doses of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts
62164092|NCT06690996|PLACEBO_COMPARATOR|Placebo Part B (MAD) SC or IV|Multiple-ascending doses of placebo administered either SC or IV depending on emerging data from earlier cohorts
62164093|NCT06690996|EXPERIMENTAL|LY4005130 Part B (MAD) Optional|Multiple-ascending doses of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts
62164094|NCT06690996|PLACEBO_COMPARATOR|Placebo Part B (MAD) Optional|Multiple-ascending doses of placebo administered either SC or IV depending on emerging data from earlier cohorts
62164095|NCT03254524||Patients visiting an emergency department in New York State|
62164096|NCT02630927|PLACEBO_COMPARATOR|Part 1 Single-Ascending (SAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. A single dose of AG-519 will be administered by mouth (orally).
62537302|NCT03437226|PLACEBO_COMPARATOR|Placebo Arm|Patients receive 6 or 24 hours infusion depending on the site. 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Placebo 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Placebo
62537303|NCT01796912|ACTIVE_COMPARATOR|First Lipoprotein Apheresis, then sham apheresis|Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis
62537304|NCT01796912|SHAM_COMPARATOR|First Sham Apheresis, then Lipoprotein Apheresis|Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis
62537305|NCT00928707|EXPERIMENTAL|GIVINOSTAT + MTD Hydroxyurea (HU)_1|50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
62537306|NCT00928707|EXPERIMENTAL|GIVINOSTAT + MTD Hydroxyurea (HU)_2|50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
62537307|NCT02474875|ACTIVE_COMPARATOR|Educational program Control Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: talk about medical issues (drugs, nutrition, importance of sleep...)
62537308|NCT02474875|EXPERIMENTAL|Educational program High Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
62537309|NCT02474875|EXPERIMENTAL|Educational program Diluted Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
62537310|NCT02474875|EXPERIMENTAL|Educational program Concentrated Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: educational sessions about the neurophysiology of pain
62537311|NCT03238612|EXPERIMENTAL|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
62537312|NCT03238612|PLACEBO_COMPARATOR|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
62537313|NCT00866658|EXPERIMENTAL|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
62537314|NCT00866658|PLACEBO_COMPARATOR|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
62537315|NCT04720131|EXPERIMENTAL|Camrelizumab combined with Apatinib and Capecitabine|Camrelizumab was administered 200mg iv every 3 weeks. Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle) Apatinib:A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle). The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group. The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
62537316|NCT00699283|EXPERIMENTAL|Brivaracetam (BRV) 1|50 mg daily
62537317|NCT00699283|EXPERIMENTAL|Brivaracetam (BRV) 2|100 mg daily
62537318|NCT04251520|NO_INTERVENTION|Control Group|Standard care by Palliative Medicine physician
62537319|NCT04251520|EXPERIMENTAL|Intervention Group A|Standard care by Palliative medicine physician plus pharmacist review of medications
62537320|NCT04251520|EXPERIMENTAL|Intervention Group B|Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
62537321|NCT06484699|ACTIVE_COMPARATOR|open repair of perforated peptic ulcer|group (A) includes patients with perforated peptic ulcer that will be operated by open repair approach
62537322|NCT06484699|ACTIVE_COMPARATOR|laparoscopic repair of perforated peptic ulcer|group (B) includes patients with perforated peptic ulcer that will be operated by laparoscopic repair approach
62537323|NCT00185445|EXPERIMENTAL|Arm 1|
62537324|NCT03288701|EXPERIMENTAL|Body Composition Analysis|Daily measurement of the Body Composition using electrical Bioimpedance Analysis in a scale (seca mBCA 515). Including total body water and weight.
62537325|NCT04024839|ACTIVE_COMPARATOR|Post Isometric Relaxation|Post Isometric Relaxation was applied three times a week for the duration of three weeks.
62537326|NCT04024839|EXPERIMENTAL|Active Isolated stretch|Active Isolated stretch was was applied three times a week for the duration of three weeks.
62537327|NCT01839318|EXPERIMENTAL|DAILIES AquaComfort Plus|Nelfilcon A contact lenses worn first, followed by etafilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
62537328|NCT01839318|ACTIVE_COMPARATOR|1-DAY ACUVUE MOIST|Etafilcon A contact lenses worn first, followed by nelfilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
62537329|NCT01839318|ACTIVE_COMPARATOR|Proclear 1 day|Omafilcon A contact lenses worn first, followed by etafilcon A and nelfilcon A in randomized order. Each product worn for 1 day, 12 hours.
62537330|NCT02201212|EXPERIMENTAL|Everolimus|"Everolimus~* Fixed doses orally once a day per each 28 day cycle~* Participants will stay on study as long as they do not progress for a maximum of 24 months.~* Tumor assessments will be performed after every 2 cycles for as long as they are on study."
62537331|NCT04229927|EXPERIMENTAL|Arm 1|
62537332|NCT04229927|PLACEBO_COMPARATOR|Arm 2|
62537333|NCT01320150||PPP and Non-PPP|Study Subjects with PPP and without PPP at followup
62537334|NCT04810026|ACTIVE_COMPARATOR|Group 1: Education only|Push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
62537335|NCT04810026|EXPERIMENTAL|Group 2: Education and Meals|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
62537336|NCT04810026|EXPERIMENTAL|Group 3: Education, Meals, Coaching|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, coaching program (e.g., diabetes-specific coaching and education, push notifications for lifestyle education modules, community support) for 12 weeks, and passive access to lifestyle education for final 4 weeks
62537337|NCT04668911||Controls tested PCR (-) for COVID-19|
62537338|NCT04668911||Tested PCR (+) for COVID-19, Mild - not admitted to the hospital|
62537339|NCT04668911||Tested PCR (+) for COVID-19, Severe - admitted to ICU (Intensive Care Unit)|
62537340|NCT02864810|EXPERIMENTAL|[18F]GP1 PET/CT imaging|"Maximally 10 patients with deep vein thrombosis, pulmonary embolism, or arterial thromboembolism, respectively will be enrolled in the study (plus replacements for drop-outs).~Intravenous injection and PET/CT scanning of \[18F\]GP1"
62537341|NCT00945100|ACTIVE_COMPARATOR|Control|2 hours daily patching
62537342|NCT00945100|ACTIVE_COMPARATOR|Intensified treatment|42 hours per week of patching (averaging 6 hours daily)
62736779|NCT03529838|ACTIVE_COMPARATOR|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
62537343|NCT01399567|EXPERIMENTAL|Algorithm|The NH pain management algorithm is a series of decision-making tools that begins with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain. The algorithm is coupled with intense diffusion strategies (e.g., education, consultation, boosters) to increase adoption of these evidence-based practices
62537344|NCT01399567|ACTIVE_COMPARATOR|Control|Control sites received staff education for pain assessment and management comprised of four one-hour classes
62164097|NCT02630927|PLACEBO_COMPARATOR|Part 2 Multiple-Ascending (MAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
62164098|NCT02630927|EXPERIMENTAL|Part 3 Bioavailability & Food Effect|The dose to be assessed in Part 3 will be selected based on emerging safety, tolerability and PK/PD data from preceding cohorts in Part 1 and Part 2, which will be reviewed during a dose decision meeting.
62537345|NCT02204306|OTHER|TSER *2/*2 *2/*3|Patients with TSER \*2/\*2 \*2/\*3 genotypes will be assigned to this group and receive standard chemotherapy contains fluorouracil. (FOLFOX 6/XELOX/SOX)
62537346|NCT02204306|OTHER|TSER*3/*3 (fluorouracil)|Patients with TSER\*3/\*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
62537347|NCT02204306|OTHER|TSER*3/*3 (non-fluorouracil)|Patients with TSER\*3/\*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
62537348|NCT03547076|EXPERIMENTAL|Focused ultrasound diagnostics|"Intervention: Focused ultrasound Diagnostics~All participants will first be examined twice with handheld ultrasound, With separate examinations performed by general practioners and nurses (random order). Both will utilize automatic analyses of left ventricular function and telemedicine support for best possible diagnosis of heart failure. Subsequently, reference imaging and diagnostics will be performed by experts (cardiologists). Handheld ultrasound examinations will be compared to Reference."
62537349|NCT02437240|EXPERIMENTAL|Pilates-based CPT|incorporated the concept of pilates training into cardiopulmonary physical therapy after cardiac surgery
62537350|NCT02437240|ACTIVE_COMPARATOR|Traditional CPT|usual bed side cardiopulmonary physical therapy after cardiac surgery
62537351|NCT06171724|EXPERIMENTAL|240 mg Shoden|Shoden, administered as two 120 mg capsules per dose (240 mg total)
62537352|NCT06171724|ACTIVE_COMPARATOR|480 mg Shoden|Shoden, administered as two 240 mg capsules per dose (480 mg total)
62537353|NCT01654133|EXPERIMENTAL|Endovascular TAAA Repair|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
62537354|NCT01654133|EXPERIMENTAL|Endovascular Ascending/Aortic Arch Branch Repair|Endovascular repair of aortic ascending/arch aneurysm using branched stent grafts
62537355|NCT01879163|EXPERIMENTAL|Group A|The first six volunteers will receive an intradermal injection of 1x10\^7 pfu MVA85A-IMX313 (non-randomised).
62537356|NCT01879163|ACTIVE_COMPARATOR|Group B|12 subjects receiving intradermal injection of 5x10\^7 pfu MVA85A-IMX313 (following completion of group A, subjects will be randomised to either group B or group C).
62537357|NCT01879163|ACTIVE_COMPARATOR|Group C|12 subjects receiving intradermal injection of 5x10\^7 pfu MVA85A (following completion of group A, subjects will be randomised to either group B or group C).
62537358|NCT01470495|EXPERIMENTAL|RFA+Sorafenib|to treat recurrent HCC both with RFA and Sorafenib
62537359|NCT01470495|ACTIVE_COMPARATOR|RFA group|To treat recurrent HCC with RFA
62537360|NCT05937997|ACTIVE_COMPARATOR|Group A high intensity|Physiotherapy with high intensity and no restrictions
62537361|NCT05937997|ACTIVE_COMPARATOR|Group B moderate intensity|Physiotherapy with medium intensity and some restrictions
62537362|NCT05937997|ACTIVE_COMPARATOR|Group C low intensity|Physiotherapy with low intensity and many restrictions
62164099|NCT02630927|EXPERIMENTAL|Experimental Part 4 (Subjects of Japanese Origin)|Two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3
62164100|NCT02630927|EXPERIMENTAL|Experimental Part 5 Open-label Multiple-Ascending (MAD)|Up to two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
62164101|NCT01657552|EXPERIMENTAL|Eltrombopag|Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.
62164102|NCT01657552|EXPERIMENTAL|Boceprevir|Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.
62164103|NCT01657552|EXPERIMENTAL|Telaprevir|Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.
62164104|NCT01657552|EXPERIMENTAL|Eltrombopag and Broceprevir|Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
62537363|NCT00552851|OTHER|Pegvisomant|patients with active acromegaly and impaired cardiac function
62537364|NCT02646852|EXPERIMENTAL|PLX038 Q3W|intravenous infusion once every 3 weeks
62537365|NCT02646852|EXPERIMENTAL|PLX038 QW ×2|intravenous infusion once weekly for 2 consecutive weeks of a 4-week cycle
62537366|NCT03226028|EXPERIMENTAL|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
62537367|NCT01468818|EXPERIMENTAL|Immunotherapy for Metastatic Melanoma|Patients will receive non-myeloablative lymphodepleting preparative regimen cons
62537368|NCT00772421||Responder|A subject having at least a 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase
62537369|NCT00772421||Non-responder|A subject with a less than 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase.
62537370|NCT06216223|ACTIVE_COMPARATOR|laser|laser ablation of anal diseases in inflammatory bowel patients
62537371|NCT06216223|SHAM_COMPARATOR|traditional surgery|traditional surgery for anal diseases in inflammatory bowel patients
62537372|NCT05669963|ACTIVE_COMPARATOR|study group|"study group receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotinR).~During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
62537373|NCT05669963|PLACEBO_COMPARATOR|control group|not recieving lactoferrin
62537374|NCT02784444|ACTIVE_COMPARATOR|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
62537375|NCT02784444|ACTIVE_COMPARATOR|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
62537376|NCT02784444|ACTIVE_COMPARATOR|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
62537377|NCT02784444|PLACEBO_COMPARATOR|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
62537378|NCT04318223|EXPERIMENTAL|single-arm study following a Simon's two-stage optimal design|Single-arm study with the primary objective of assessing the efficacy and safety of palbociclib in combination with fulvestrant (Faslodex) in women with HR+, HER2-negative metastatic breast cancer, regardless of their menopausal status, whose disease has progressed after prior treatment with AI plus a CDK4/6 inhibitor.
62537379|NCT03036254|EXPERIMENTAL|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
62537380|NCT03036254|SHAM_COMPARATOR|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
62537381|NCT02032095|EXPERIMENTAL|GB-0998|
62537382|NCT02216370||Cryptogenic Stroke or TIA|
62164105|NCT01657552|EXPERIMENTAL|Eltrombopag and Telaprevir|Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
62537383|NCT02216370||Healthy Volunteers|Healthy Volunteers as comparative group adjusted to investigated group by age and gender
62537384|NCT00535665|EXPERIMENTAL|1: 10 ug, 14 days|
62537385|NCT00535665|EXPERIMENTAL|2: 5 ug, 28 days|
62537386|NCT00535665|EXPERIMENTAL|3: 10 ug, 28 days|
62537387|NCT00535665|EXPERIMENTAL|4: 15 ug, 28days|
62537388|NCT04901988|NO_INTERVENTION|Arm A|In Arm A, patients and clinicians will remain blinded to the ctDNA result and will be managed as per standard of care with regular clinical review and imaging, and treated if they develop evidence of disease recurrence.
62537389|NCT04901988|EXPERIMENTAL|Arm B|Patients randomised to Arm B will not be blinded to the positive ctDNA result and will be treated with the intervention.
62537390|NCT03671889|EXPERIMENTAL|Blood Brain Barrier (BBB) Disruption|ExAblate Model 4000 Type 2.0 System
62537391|NCT04712981|EXPERIMENTAL|Intervention|HOPE intervention peer-led online community
62537392|NCT04712981|NO_INTERVENTION|Control|Online community without HOPE intervention psychological components
62537393|NCT03323047|EXPERIMENTAL|Group 1|Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
62537394|NCT03323047|ACTIVE_COMPARATOR|Group 2|Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
62537395|NCT03323047|PLACEBO_COMPARATOR|Group 3|Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia.
62164106|NCT02201368|EXPERIMENTAL|Triheptanoin|
62537396|NCT06209541|EXPERIMENTAL|Unified Protocol, support by a specific therapist|The participants receive eight weeks of ICBT, based on the treatment manual Unified Protocol by David Barlow and colleagues (2013), with weekly support by a specific therapist that follow the individual participant through all treatment weeks. During the eight weeks, the participant will receive in total eight treatment modules.
62537397|NCT06209541|EXPERIMENTAL|Unified Protocol, support by a team|The participants receive eight weeks of ICBT, based on the treatment manual Unified Protocol by David Barlow and colleagues (2013), with weekly support by a team of therapists. This arm implies that the participant will get support from different therapists each week. During the eight weeks, the participant will receive in total eight treatment modules.
62537398|NCT06209541|EXPERIMENTAL|Individually tailored treatment, support by a specific therapist|The participants receive ICBT in an individually tailored format, where they get to select which modules they want to be included in their specific treatment. The participants are recommended to select eight modules (out of 25) and work with one modules each week, but this is only recommendations. In their treatment, weekly support by a specific therapist that follow the individual participant through all treatment weeks is included.
62537399|NCT06209541|EXPERIMENTAL|Individually tailored treatment, support by team|The participants receive ICBT in an individually tailored format, where they get to select which modules they want to be included in their specific treatment. The participants are recommended to select eight modules (out of 25) and work with one modules each week, but this is only recommendations. In their treatment, weekly support by a team of therapists is included. This arm implies that the participant will get support from different therapists each week.
62736780|NCT00276939|EXPERIMENTAL|1|Low-fat, low-Glycemic Index, vegan diet
62164107|NCT02201368|ACTIVE_COMPARATOR|MCT (Medium-Chain Triglycerides)|
62164108|NCT05740709||AKI patients|Patients who suffered from AKI whilst in ICU and are awaiting discharge from hospital
62164109|NCT01132378|ACTIVE_COMPARATOR|Mini-midvastus approach|Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.
62164110|NCT01132378|ACTIVE_COMPARATOR|Medial Parapatellar Approach|Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.
62164111|NCT05854160|EXPERIMENTAL|Acquisition Stimulation Test|Single pulse stimulation will be delivered and measured prior to the rating task. Next, subjects perform the Pavlovian fear conditioning paradigm. Participants will be asked to perform a rating task automated on a PC where they continuously update a rating bar using the touchpad to indicate their confidence that a static sound is about to occur on a moment-by-moment basis (0-not confident to 100-very confident). For the stimulation experiment, research staff will explain that electrical stimulation will be applied before the rating task, in isolation, as well as on some trials at controlled time points while the patient performs the rating task
62164112|NCT05959057|EXPERIMENTAL|Enteric/Micro Order|Subjects will receive randomly two distinct formulations of ERr 731® in a 43 day trial consisting of treatment phase 1 (14-days), washout phase (14-days),treatment phase 2 (14-days): Arm 1 will receive enteric coated ERr 731® during treatment phase 1 and micro-coated ERr 731®during treatment phase 2
62164113|NCT05959057|EXPERIMENTAL|Micro/Enteric Order|Subjects will receive randomly two distinct formulations of ERr 731® in a 43 day trial consisting of treatment phase 1 (14-days), washout phase (14-days),treatment phase 2 (14-days): Arm 2 will receive micro-coated ERr 731® during treatment phase 1 and enteric coated ERr 731®during treatment phase 2
62164114|NCT01264484||Advantage prosthetic heart valve|All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.
62164115|NCT04837235|EXPERIMENTAL|75mg group|15mg/tablet. Five tablets (75mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3\~Day8 and single dose in Day9.
62164116|NCT04837235|EXPERIMENTAL|90mg group|15mg/tablet. Six tablets (90mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3\~Day8 and single dose in Day9.
62164117|NCT04837235|EXPERIMENTAL|105mg group|15mg/tablet. Seven tablets (105mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3\~Day8 and single dose in Day9.
62164118|NCT05582421|SHAM_COMPARATOR|calcium hydroxide|calcium hydroxide will be placed as intracanal medication between visits.
62164119|NCT05582421|ACTIVE_COMPARATOR|diclofenac sodium|diclofenac sodium will be placed as intracanal medication between visits
62164120|NCT04888208|EXPERIMENTAL|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
62164121|NCT04888208|NO_INTERVENTION|Control Arm|The control group will be offered sources of conventional health information (government and institutional websites) on a terminal located in the virtual world.
62164122|NCT06077695|EXPERIMENTAL|4 weeks phase A arm|"Phase A = Randomised duration of this phase : 4 weeks. each therapeutic therapeutic education sessions last 90 minutes.~Phase B = therapeutic education with tDCS for 4 weeks~Phase C = Cognitive remediation with tDCS for 4 weeks : Eight specific working memory remediation sessions will be carried out. These will be provided by a neuropsychologist. All cognitive remediation sessions will be individual, biweekly, lasting 1 hour 10 minutes for 4 weeks, for a total duration of 9 hours 20 minutes.~Phase D = follow-up"
62164123|NCT06077695|EXPERIMENTAL|5 weeks phase A arm|"Phase A = therapeutic education. Randomised duration of this phase : 5 weeks. each therapeutic therapeutic education sessions last 90 minutes.~Phase B = therapeutic education with tDCS for 4 weeks~Phase C = Cognitive remediation with tDCS for 4 weeks : Eight specific working memory remediation sessions will be carried out. These will be provided by a neuropsychologist. All cognitive remediation sessions will be individual, biweekly, lasting 1 hour 10 minutes for 4 weeks, for a total duration of 9 hours 20 minutes.~Phase D = follow-up"
62164124|NCT06077695|EXPERIMENTAL|6 weeks phase A arm|"Phase A = therapeutic education. Randomised duration of this phase : 6 weeks. each therapeutic therapeutic education sessions last 90 minutes.~Phase B = therapeutic education with tDCS for 4 weeks~Phase C = Cognitive remediation with tDCS for 4 weeks : Eight specific working memory remediation sessions will be carried out. These will be provided by a neuropsychologist. All cognitive remediation sessions will be individual, biweekly, lasting 1 hour 10 minutes for 4 weeks, for a total duration of 9 hours 20 minutes.~Phase D = follow-up"
62164125|NCT05866471|EXPERIMENTAL|Group 1: Sham taVNS + Psilocybin + taVNS|Group 1 will receive twice daily sham taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive twice-daily taVNS paired with psychedelic session contextual cues for 7 days.
62164126|NCT05866471|SHAM_COMPARATOR|Group 2: Sham taVNS + Psilocybin + Sham taVNS|Group 2 will receive twice daily sham taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive twice-daily sham taVNS paired with psychedelic session contextual cues for 7 days.
62537400|NCT04916444|ACTIVE_COMPARATOR|Active rTMS|Active rTMS will use a figure of eight TMS coil that will deliver real neurostimulation pulses to the patients.
62537401|NCT04916444|SHAM_COMPARATOR|Sham rTMS|Sham rTMS will use a sham figure of eight TMS coil that sounds and looks like a real rTMS coil, except no neurostimulation is being delivered to the patient.
62537402|NCT04235361||EVD patients|"The samples of all subjects (male, female, adults and children) meeting the WHO case definition of suspected and probable EVD case eligible for real time RT-PCR assay, according to the currently used case definition in DRC, will be tested by differential RPA."
62537403|NCT06634121|ACTIVE_COMPARATOR|MitraClip|
62537404|NCT06634121|ACTIVE_COMPARATOR|PASCAL|
62537405|NCT04460508|EXPERIMENTAL|Mecapegfilgrastim|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle.
62537406|NCT04460508|ACTIVE_COMPARATOR|rhG-CSF|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle.
62537407|NCT05809167|EXPERIMENTAL|VEN+AZA+Modified BUCY|
62537408|NCT06377033|ACTIVE_COMPARATOR|Generic BPA; no nudge|Usual care
62537409|NCT06377033|ACTIVE_COMPARATOR|Clinician nudge, order|Clinician will receive a nudge to order genetic testing for the patient.
62537410|NCT06377033|ACTIVE_COMPARATOR|Clinician nudge, refer|Clinician will receive a nudge to refer the patient for genetic testing.
62537411|NCT06377033|ACTIVE_COMPARATOR|Patient nudge|The patient will receive a text message encouraging them to speak with their clinician about genetic testing.
62736781|NCT00276939|ACTIVE_COMPARATOR|2|ADA diet
62537412|NCT06377033|ACTIVE_COMPARATOR|Clinician BPA order plus patient nudge|Clinician will receive a nudge to order genetic testing for the patient and the patient will receive a text message encouraging them to speak with their clinician about genetic testing.
62537413|NCT06377033|ACTIVE_COMPARATOR|Clinician BPA refer plus patient nudge|Clinician will receive a nudge to refer patient for genetic testing and the patient will receive a text message encouraging them to speak with their clinician about genetic testing.
62537414|NCT02365194|OTHER|Prehabilitation|physical conditioning and weight loss intervention done pre-operatively
62537415|NCT02365194|OTHER|Standard Counseling|initial clinic counseling
62537416|NCT00174954||1|Volumes/measurements of tophi determined by serial MRIs
62537417|NCT04091828||Biplar patients|diagnosed by DSM-5 and divided to manic,depressed and mixed last episod
62537418|NCT04091828||controlled subject|not have any medical or psychatric problem affect cognition
62537419|NCT01724489|ACTIVE_COMPARATOR|Growth Hormone|Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.
62537420|NCT01724489|PLACEBO_COMPARATOR|Placebo|Placebo will be provided by Pfizer Inc. It will appear identical to active growth hormone and will be administered in the same manner.
62537421|NCT04642651|EXPERIMENTAL|Dexmedetomidine group|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
62537422|NCT04642651|PLACEBO_COMPARATOR|Control group|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
62537423|NCT03832101|EXPERIMENTAL|Difficult face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
62537424|NCT03832101|EXPERIMENTAL|Easy face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Easy group will discriminate between dissimilar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
62537425|NCT03832101|ACTIVE_COMPARATOR|Control|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Control group will perform a simple face-matching exercise. This training will last for approximately 30 minutes. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
62537426|NCT05386940||PKN1 Tertile 1|
62537427|NCT05386940||PKN1 Tertile 2|
62537428|NCT05386940||PKN1 Tertile 3|
62537429|NCT05546463|EXPERIMENTAL|Intervention group|"During the suture procedure, the children in the intervention group played digital games.~Children began playing digital games about one minute before the local anesthesia procedure, continued to play digital games throughout the suturing procedure."
62537430|NCT05546463|EXPERIMENTAL|Control group|During the suture procedure, the children in the control group did not play digital games.
62537431|NCT05646043|ACTIVE_COMPARATOR|Patients with cancer of the digestive system|Patients with cancer of the digestive system (oesophageal and stomach cancer) will be enrolled in this study arm.
62537432|NCT05646043|ACTIVE_COMPARATOR|Patients with cancer of the rectum|Patients with cancer of the rectum will be enrolled in this study arm.
62537433|NCT05971303||Patient Questionnaire|Eligible patients will be matched to complete questionnaires in their specified preferred language. Questionnaire patient responses will also be in the patient's identified preferred language, and will be translated into English for study analysis by UHN Interpretation and Translation Services. The questionnaire will comprise of sections in multiple choice and free-text format, administered in an outpatient setting. Question domains will encompass patient demographics, comprehension of diagnosis and treatment, clinical trials, palliative care and overall experiences in the clinic from the perspective of a CALD oncology patient, including identification of any barriers to optimal care.
62537434|NCT05971303||Interpreter Questionnaire|Interpreters will be screened by investigators and approached for their willingness to complete the questionnaires. The questionnaire will comprise of several sections in rating scale and free-text format. Questionnaires will be delivered in English only. Question domains will encompass demographics, professional background, and overall experiences in the clinic setting from the perspective of a professional team member caring for the oncology patient with CALD background, including identification of any barriers to optimal care.
62537435|NCT05971303||Cancer Care Professional Questionnaire|Cancer Care Professionals will be screened by investigators and approached for their willingness to complete the questionnaires. The questionnaire will comprise of several sections in rating scale and free-text format. Questionnaires will be delivered in English only. Question domains will encompass demographics, professional background, and overall experiences in the clinic setting from the perspective of a professional team member caring for the oncology patient with CALD background, including identification of any barriers to optimal care.
62736782|NCT05556083|ACTIVE_COMPARATOR|sofenacine recievers group A|Group (A) will receive sildenafil 50mg tablet form as additive therapy to dapoxetine 30 mg tablet form on demand for 8 weeks.
62537436|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 100 µg Intra-tumoral (IT) Monotherapy|Participants receive MK-2118 100 µg via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537437|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 300 µg IT Monotherapy|Participants receive MK-2118 300 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537438|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 900 µg IT Monotherapy|Participants receive MK-2118 900 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537439|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 2700 µg IT Monotherapy|Participants receive MK-2118 2700 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537440|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 5400 µg IT Monotherapy|Participants receive MK-2118 5400 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537441|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 7700 µg IT Monotherapy|Participants receive MK-2118 7700 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537442|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 10000 µg IT Monotherapy|Participants receive MK-2118 10000 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537443|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 15000 µg IT Monotherapy|Participants receive MK-2118 15000 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537444|NCT03249792|EXPERIMENTAL|Arm 1 MK-2118 20000 µg IT Monotherapy|Participants receive MK-2118 20000 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537445|NCT03249792|EXPERIMENTAL|Arm 2 MK-2118 2700 µg IT + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 2700 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537446|NCT03249792|EXPERIMENTAL|Arm 2 MK-2118 5400 µg IT + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 5400 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537447|NCT03249792|EXPERIMENTAL|Arm 2 MK-2118 7700 µg IT + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 7700 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537448|NCT03249792|EXPERIMENTAL|Arm 2 MK-2118 10000 µg IT + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 10000 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537449|NCT03249792|EXPERIMENTAL|Arm 2 MK-2118 15000 µg IT + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 15000 µg via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by Q3W on Day 1 of Cycle 4 and beyond, for a total of up to \~35 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537450|NCT03249792|EXPERIMENTAL|(Not Enrolled) Arm 3 MK-2118 Visceral IT + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by Q3W on Day 1 of Cycle 3 and beyond, for a total of up to \~35 cycles (up to \~2 years) and pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for a total of up to \~35 cycles (up to \~2 years). Each cycle is 3 weeks long.
62537451|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 5000 µg Subcutaneous (SC) + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 5000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537452|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 10000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 10000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62164127|NCT05866471|ACTIVE_COMPARATOR|Group 3: Sham taVNS + Psilocybin + Psychosocial Support Alone|Group 3 will receive twice daily sham taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive psychosocial support alone, comprised of an integration session 1 day and 1-week post-psilocybin dosing. They will not receive active or sham taVNS post-psilocybin.
62164128|NCT05866471|ACTIVE_COMPARATOR|Group 4: taVNS + Psilocybin + Sham taVNS|Group 4 will receive twice daily taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive twice-daily sham taVNS paired with psychedelic session contextual cues for 7 days.
62164129|NCT06585553||atrophic gastritis|Perform Kimura-Takemoto and OLGIM staging
62164130|NCT05157464|EXPERIMENTAL|Losartan Group|
62537453|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 15000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 15000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537454|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 20000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 20000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537455|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 30000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 30000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537456|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 45000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 45000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537457|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 60000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 60000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537458|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 90000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 90000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537459|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 120000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 120000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537460|NCT03249792|EXPERIMENTAL|Arm 4: MK-2118 150000 µg SC + Pembrolizumab 200 mg IV Combination Therapy|Participants receive MK-2118 150000 µg via SC injection Q1W on Days 1 and 8 of Cycle 1 followed by Q1W on Days 1, 8 and 15 of Cycles 2-4, followed Q3W Day 1 of Cycle 5 and beyond, for a total of up to 36 cycles (up to \~2 years) and receive pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for a total of up to 36 cycles (up to \~2 years). Cycle 1 is 2 weeks long and Cycles 2 to 36 are 3 weeks long.
62537461|NCT01739348|EXPERIMENTAL|Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II]|\[Part I\] Verubecestat 12 mg once daily for 78 weeks in Study Part I (Base Study). \[Part II\] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
62537462|NCT01739348|EXPERIMENTAL|Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II]|\[Part I\] Verubecestat 40 mg once daily for 78 weeks in Study Part I (Base Study). \[Part II\] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
62537463|NCT01739348|EXPERIMENTAL|Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II]|\[Part I\] Verubecestat 60 mg once daily until the first IA in Study Part I (Base Study). Following IA, participants in this group were switched to Verubecestat 40 mg once daily, for the remainder of Study Part I (total dosing period: 78 weeks). \[Part II\] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
62537464|NCT01739348|PLACEBO_COMPARATOR|Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II]|\[Part I\] Placebo once daily for 78 weeks in Study Part I (Base Study). \[Part II\] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
62537465|NCT02804022|EXPERIMENTAL|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
62537466|NCT03684967|EXPERIMENTAL|fruquintinib|Fruquintinib treatment: administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.
62537467|NCT00070200|EXPERIMENTAL|All patients|Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (\> 12 kg 400 mg/m2/day, \< 12 kg 13.3 mg/kg/day, \< 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (\> 12 kg 1.2 mg/m2/day, \< 12 kg 0.04 mg/kg/day, \< 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (\> 12 kg 5 micrograms/kg, \< 12 kg 5 micrograms /kg, \< 2 years old 5 micrograms /kg.
62164131|NCT05157464|NO_INTERVENTION|Control Group|No additional steps in management are required for the control arm of the study.
62164132|NCT01725087|PLACEBO_COMPARATOR|Matching Placebo|Twice daily oral administration of matching placebo for 14 weeks
62164133|NCT01725087|EXPERIMENTAL|Low Dose GRT6005|Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.
62164134|NCT01725087|EXPERIMENTAL|Medium Dose GRT6005|Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.
62537468|NCT04868994|EXPERIMENTAL|ENMG and muscle analyses on whole body muscles MRI.|Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
62537469|NCT05551819|EXPERIMENTAL|Feeding Order 1|MDF then RUTF/RUSF
62164135|NCT01725087|EXPERIMENTAL|High Dose GRT6005|Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.
62537470|NCT05551819|EXPERIMENTAL|Feeding Order 2|RUTF/RUSF then MDF
62537471|NCT04987697|OTHER|Counseling and Surveys|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
62537472|NCT02419144|ACTIVE_COMPARATOR|AMI followed by campaigns|Behavioral interventions
62537473|NCT02419144|ACTIVE_COMPARATOR|Campaigns followed by AMI|Behavioral interventions
62537474|NCT01952210|EXPERIMENTAL|nutrition consultation and exercise program|individual nutritional consultation and exercise
62537475|NCT01952210|ACTIVE_COMPARATOR|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
62537476|NCT04317859|EXPERIMENTAL|Behavioural Activation (Intervention)|Originally a component of Cognitive Therapy, Behavioural Activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to modify one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations and mood symptoms.
62537477|NCT04317859|NO_INTERVENTION|Waitlist (Control)|The Control group (waitlist) will receive treatment as usual while waiting to receive BA intervention (at the end of intervention group therapy time, which will consist of 18 sessions over an 14 week period). This group will be assessed by clinical staff that offer treatment as usual for mood symptoms and quality of life measures during the waiting time.
62537478|NCT05434429|EXPERIMENTAL|Intervention|Participants have access to short-term and long-term interventions.
62537479|NCT05434429|NO_INTERVENTION|Control|Given access to all interventions at the end of the 5 weeks of the trial.
62537480|NCT05183386|NO_INTERVENTION|Control Group|The dental socket heals spontaneously
62537481|NCT05183386|EXPERIMENTAL|Experimental group|Distinct bone graft regeneration strategies (PRGF, Autologous bone and DFDBA)
62537482|NCT04488835|EXPERIMENTAL|TENS Therapy Group|patients in this group received TENS therapy in addition to routine physical therapy
62537483|NCT04488835|EXPERIMENTAL|PEMFT group|patients in this group received PEMFT therapy in addition to routine physical therapy
62537484|NCT00837772|ACTIVE_COMPARATOR|Arm 1|Usual standard cutting guide for TKA (Total Knee Arthroscopy)
62537485|NCT00837772|EXPERIMENTAL|Arm 2|Otismed MRI generated cutting guide for TKA
62537486|NCT04286711|EXPERIMENTAL|Albumin-paclitaxel Combined With Apatinib and Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day; Repeat the therapeutic schedule every 3 weeks
62537487|NCT00833001||1|GYNECARE PROLIFT+M\* Pelvic Floor Repair System
62537488|NCT05419609|EXPERIMENTAL|Office-based limited facelift|Patients will undergo a limited facelift in the office. Patients will receive local anesthesia and optionally may receive an antianxiety medication.
62537489|NCT05419609|ACTIVE_COMPARATOR|Hospital-based full facelift|Patients will undergo a full facelift in the hospital or ambulatory surgical center. Patients will receive either general anesthesia or intravenous sedation.
62537490|NCT04447950|EXPERIMENTAL|Study group|Posterior QL block with 20-40 cc of Bupivocaine in posterior border of Quadratum Lumborum muscle at the end of the operation.
62164136|NCT01725087|ACTIVE_COMPARATOR|Tapentadol|Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.
62537491|NCT04447950|PLACEBO_COMPARATOR|Placebo group|Posterior QL block with 40 cc of Saline in posterior border of Quadratum Lumborum muscle at the end of the operation.
62537492|NCT01458873|EXPERIMENTAL|sodium bicarbonate 4.2%|"sodium bicarbonate 4.2% 50 ml"
62537493|NCT01458873|EXPERIMENTAL|sodium bicarbonate 2.1%|"sodium bicarbonate 2.1% 1 50 ml"
62537494|NCT01458873|PLACEBO_COMPARATOR|normal saline|"50 ml normal saline"
62537495|NCT03387306||Patient group|This grup included 38 patients with NTG.
62537496|NCT03387306||Control group|This group included 38 healthy controls.
62537497|NCT02342639|EXPERIMENTAL|Rifaximin|Participants will receive a 10-day course of Rifaximin.
62537498|NCT02342639|PLACEBO_COMPARATOR|Placebo|Participants will receive a 10-day course of placebo.
62537499|NCT03914911|EXPERIMENTAL|Study Arm|The radiologist will perform a routine ultrasonic guided biopsy procedure using the Smart Biopsy Device, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
62537500|NCT00446901|PLACEBO_COMPARATOR|Placebo|Placebo
62537501|NCT00446901|EXPERIMENTAL|Selenium (selenized yeast)|Selenium (selenized yeast) tablets, 300 ug/day
62537502|NCT04139343||SMA cohort|Individuals who have a diagnosis of SMA who are NOT receiving Spinraza (nusinersen).
62537503|NCT04139343||SMA Spinraza cohort|Individuals who have a diagnosis of SMA who are receiving Spinraza (nusinersen).
62537504|NCT04139343||Control cohort|Control participants will only come to a baseline visit and the only tests that will be completed are the EMG Measures (MUNE, CMAP, decomposition EMG) and EIM. There will be no further testing for those participants. This visit will take approximately 30-60 minutes. A total of 40 control participants are being recruited for this study.
62537505|NCT02909946|ACTIVE_COMPARATOR|Intervention Arm|NHs randomized to the Intervention Arm will implement a new multi-modal infection control program.
62164137|NCT06422559|EXPERIMENTAL|Participants with unipolar depression|Participants with Unipolar depression will receive 30 sessions of TMS.10 sessions a week for 3 weeks
62164138|NCT06422559|EXPERIMENTAL|Participants with bipolar depression|Participants with bipolar depression will receive 30 sessions of TMS.10 sessions a week for 3 weeks
62537506|NCT02909946|NO_INTERVENTION|Control Arm|NHs randomized to the Control Arm will continue their current standard infection control practices.
62537507|NCT00124761|OTHER|Surgery + Whole Brain Radiotherapy|
62537508|NCT00124761|EXPERIMENTAL|RadioSurgery + Whole Brain Radiotherapy|
62736783|NCT05556083|PLACEBO_COMPARATOR|palcebo recievers group B|Group (B) will continue on dapoxetine 30mg tablet form with placebo tablet form of the same shap and colour of sildinafile on demand for 8 weeks.
62164139|NCT05923554|ACTIVE_COMPARATOR|Un-congruous single tooth peri implantitis|Patients were treated through non-surgical periodontal treatment for the peri-implant mucositis resolution
62164140|NCT05923554|PLACEBO_COMPARATOR|Congruous single tooth peri implantitis|Patients were treated through non-surgical periodontal treatment for the peri implant mucositis resolution
62537509|NCT01037400||Total Knee Replacement Patients|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee replacement surgery with no musculoskeletal injury requiring medical attention in the past 3 months or producing pain in the previous 2 weeks and no inflammatory disease other than osteoarthritis.
62714686|NCT02170064|EXPERIMENTAL|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
62714687|NCT02170064|EXPERIMENTAL|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
62164141|NCT03045289|EXPERIMENTAL|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
62164142|NCT03045289|NO_INTERVENTION|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
62164143|NCT03435510|OTHER|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
62164144|NCT05954780||second line and later lines therapy|Patients enrolled for second line or later lines therapy with selinexor in combination with bortezomib and dexamethasone.
62164145|NCT03371849|EXPERIMENTAL|Group 1|Reference Drug → Test Drug
62164146|NCT03371849|EXPERIMENTAL|Group 2|Test Drug → Reference Drug
62164147|NCT04457583|EXPERIMENTAL|Intervention|Procedure: Inspiratory muscle training with powerbreathe with a linear pressure resistance using an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, 30 exercises daily for 12 weeks.
62164148|NCT04457583|NO_INTERVENTION|Control|Procedure: Training with the same equipment but without load-generating resistance.
62164149|NCT05746676|ACTIVE_COMPARATOR|group 1|
62164150|NCT05746676|ACTIVE_COMPARATOR|group 2|
62164151|NCT06379451|EXPERIMENTAL|Low dose group|CAR-NK cell count 6x10\^8
62164152|NCT06379451|EXPERIMENTAL|Medium dose group|CAR-NK cell count 1x10\^9
62164153|NCT06379451|EXPERIMENTAL|High dose group|CAR-NK cell count 1.5x10\^9
62164154|NCT05489003||Patients with fatigue|Chronic pancreatitis patients with fatigue measured by professional assessment scales.
62164155|NCT05489003||Patients without fatigue|Chronic pancreatitis patients without fatigue measured by professional assessment scales.
62164156|NCT04743284||tele-assessment|The balance evaluations will be applied by the tele-assessment method.
62164157|NCT04743284||face-to-face assessment|The balance evaluations will be applied by the face-to-face assessment method in a clinical setting
62164158|NCT02599077|EXPERIMENTAL|Dienogest|the patient handling with 2 mg dienogest / day.
62164159|NCT02599077|ACTIVE_COMPARATOR|Levonorgestrel + ethinylestradiol|The patient handling with levonorgestrel + ethinylestradiol (0,10 mg - 0,02 )
62537510|NCT03354767||Wasting patients|Patients with \>10% loss of skeletal muscle one week after major aortic surgery
62537511|NCT03354767||Non-wasting patients|Patients with \<10% loss of skeletal muscle one week after major aortic surgery
62537512|NCT06017310||Replicative viruses|Presence of a replicative virus determined by viral culture
62537513|NCT06017310||Unreplicative viruses|Absence of a replicative virus determined by viral culture
62164160|NCT04542109|EXPERIMENTAL|READyR A|Group A will start the READyR intervention immediately after the baseline Session 1. The READyR program consists of a 3-session, values-based needs assessment intervention designed to match objectively-assessed in-home activity patterns with subjective reports of participants' care values. The goal of the intervention is to address unmet dementia-related care needs and help couples prepare for the future, and reduce strain on their relationship, and help maintain their health and well-being. Session 2 will occur approximately 3 weeks after Session 1, and Session 3 will occur approximately 3 weeks after Session 2. Session 3 also includes follow-up assessments.
62164161|NCT04542109|ACTIVE_COMPARATOR|READyR B (wait list comparison)|Group B - the wait list comparison group - will have a 60-minute support session (comparator intervention) about 3 weeks after the baseline Session 1. The support session will include general information about dementia-related care needs that does not take into account the individual participant's care values or objective in-home activity patterns. They will also receive a check-in call approximately 3 weeks later, with follow-up assessments. Group B will begin the READyR intervention sessions following completion of follow-up assessments.
62164162|NCT02268526|EXPERIMENTAL|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
62537514|NCT06400277|OTHER|Irreversible Hydrocolloid|Final impression taken with irreversible hydrocolloid impression material and stock tray in single step.
62537515|NCT06400277|OTHER|Zinc Oxide Eugenol|Final impression taken with zinc oxide eugenol impression material and individual tray in two steps.
62537516|NCT06400277|OTHER|Intraoral Scanner - Artificial Intelligence Off|Final impression taken with intraoral scanner in artificial intelligence mode deactivated in single step.
62537517|NCT06400277|OTHER|Intraoral Scanner - Artificial Intelligence On|Final impression taken with intraoral scanner in artificial intelligence mode activated in single step.
62537518|NCT06400277|OTHER|Intraoral Scanner - Modified|Final impression taken with intraoral scanner in two steps using occlusal rim.
62537519|NCT00483483|EXPERIMENTAL|1|Healthy Relationships Intervention (HRI)
62537520|NCT00483483|ACTIVE_COMPARATOR|Attention-control group|health education \& support
62537521|NCT05735041|EXPERIMENTAL|Cognitive digital therapy group|Computer-based cognitive training for 30 minutes at least 5 times a week for 12 weeks; At the end of the 12 weeks, the subjects were randomly divided into two groups. One group continued the training for 12 weeks, at least five times a week for 30 minutes each time, and the other group stopped the training.
62537522|NCT05735041|ACTIVE_COMPARATOR|Positive control group|Computer-based cognitive training tasks with low or no difficulty variation for 30 minutes at least five times a week for 12 weeks
62537523|NCT01250886|PLACEBO_COMPARATOR|Normal saline solution|Blood sample is obtained from patient in either forearm immediately before a Normal saline solution administered on the same site. The volume of fluid administration is calculated by means of Holliday and Segar formula.
62537524|NCT01250886|ACTIVE_COMPARATOR|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
62537525|NCT01250886|ACTIVE_COMPARATOR|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
62537526|NCT04260971|EXPERIMENTAL|Cyclical Stimulation|This group will undergo cyclical stimulation mode of stimulation
62537527|NCT04260971|ACTIVE_COMPARATOR|Continuous Stimulation|This group will undergo the standard continuous mode of stimulation
62537528|NCT02107365|EXPERIMENTAL|Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a|Quadritherapy from Day 0 to Week 24
62537529|NCT00898638||Healthy Volunteers|Non-tumor volunteers will be asked to participate at the time that they are attending a head and neck cancer screening clinic or at the time they are accompanying a patient to their appointment at the head and neck clinic. Intake sheets and biological specimens contributed by volunteers will be coded at the time of collection so that no identifiers are obtained. These specimens will not be linked to identifiers.
62537530|NCT00898638||Head and Neck Tumor patients|Eligible patients will be identified at the Vanderbilt Head \& Neck Clinic by clinical and research staff. An appropriately trained staff member will discuss the protocol with the patient (including, risks, benefits, alternatives, etc.).
62537531|NCT02288156|ACTIVE_COMPARATOR|0.1mM|
62537532|NCT02288156|EXPERIMENTAL|0.01mM|
62537533|NCT02288156|EXPERIMENTAL|0.001mM|
62537534|NCT02288156|PLACEBO_COMPARATOR|Placebo|
62714688|NCT02170064|EXPERIMENTAL|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
62537535|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
62537536|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
62537537|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
62537538|NCT05658978|EXPERIMENTAL|Neuromuscular training of male handball players|Neuromuscular training exercises focus on improving physical fitness and skills performance. Neuromuscular training targets the neuromuscular system through engagements of muscle groups as well as nerve function to optimize movements. This training has been considered an effective treatment method to enhance the neurophysiological entity of the joints for coordinated functioning. However, the present study applied neuromuscular training to elite male handball players to assess fitness level as well as skill performance. Post-test 1 will be after 6 weeks, and post-test 2 after 12 weeks to measure performance.
62537539|NCT05658978|ACTIVE_COMPARATOR|Male handball players continue previous regular exercises|Handball players as a control group will be continuing their previous regular exercises for 12 weeks.
62537540|NCT02952898|EXPERIMENTAL|Test Drug|GDC 695 gel applied topically as directed.
62537541|NCT02952898|ACTIVE_COMPARATOR|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
62537542|NCT02952898|PLACEBO_COMPARATOR|Placebo|Vehicle gel applied topically as directed.
62537543|NCT02941757|EXPERIMENTAL|Mediterranean Diet Intervention group|"In phase I, Group 1 will receive the MDNI for 12-months. Phase II: Group 1 fire houses will cross-over to self-sustained continuation, a less intense, self-directed, maintenance phase for 12 months to examine longer-term persistence of behavior change after the active 12-month MDNI. During self-sustained continuation access to some environmental changes: such as discounted food access, peer education/support, and online learning will remain; however, the stations will not receive investigator-led educational sessions"
62537544|NCT02941757|NO_INTERVENTION|Control group|"2) In phase I, Group 2 will receive usual care, consisting of existing IFD health and wellness activities, with no investigator-provided interventions. In Phase II, Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of self-sustained continuation (as described above) to examine the shorter MDNI's effect on persistence of adherence."
62537545|NCT01104779|EXPERIMENTAL|Cariprazine (3-6 mg/day)|Cariprazine once daily fixed-flexible low dose
62537546|NCT01104779|EXPERIMENTAL|Cariprazine (6-9 mg/day)|Cariprazine once daily fixed-flexible high dose
62537547|NCT01104779|PLACEBO_COMPARATOR|Placebo|Placebo
62537548|NCT05394649|EXPERIMENTAL|Intravascular lithotripsy arm|Preparation of calcified lesions by intravascular lithotripsy before stenting
62537549|NCT05394649|ACTIVE_COMPARATOR|Rotational Atherectomy arm|Preparation of calcified lesions by rotational atherectomy before stenting
62537550|NCT05022589|EXPERIMENTAL|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
62537551|NCT00658515|EXPERIMENTAL|Dalcetrapib (RO4607381)|
62537552|NCT00658515|PLACEBO_COMPARATOR|Placebo|
62537553|NCT03833401|SHAM_COMPARATOR|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation. This will serve as control group.
62537554|NCT03833401|EXPERIMENTAL|Autologous tissue transplantation|Root canal disinfection will be performed and revascularization will be induced with autologous tissue transplantation.
62537555|NCT05669183||Peripheral VA ECMO|Femoral artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
62537556|NCT05669183||Central VA ECMO|Axillary artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
62537557|NCT04869566||Athletes with traumatic knee injury|Youth athletes, aged 16-19, with traumatic knee injury
62537558|NCT06624878|EXPERIMENTAL|the esketamine group|
62537559|NCT06624878|PLACEBO_COMPARATOR|the placebo group|
62537560|NCT00209105||1|Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
62537561|NCT00780910|EXPERIMENTAL|MP-424|
62537562|NCT01683292|EXPERIMENTAL|Inhaled VR040|Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
62537563|NCT01683292|PLACEBO_COMPARATOR|Placebo|Inhaled dry powder. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
62537564|NCT01784939||HEPFER cohort|"male, aged 18 and over, hereditary hemochromatosis C282Y homozygous diagnosed and followed in the service of Liver Diseases, University Hospital of Rennes~- Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the basis of at least four previous plasma ferritin \< 50μg / L"
62537565|NCT05275920|EXPERIMENTAL|Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
62537566|NCT05275920|EXPERIMENTAL|In-Basket Message group|Providers will receive a monthly in-basket messages linking to a list of patients who have been seen in the past 2 months or will be seen in the upcoming month with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, date of last visit, and date of next visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
62537567|NCT05275920|NO_INTERVENTION|Control group|Patients who will receive the current standard practice of care (no BPA or in-basket message)
62537568|NCT02871219|EXPERIMENTAL|Treatment (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 8, and 15 of course 1 and day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR or CRu may receive up to an additional 12 cycles of lenalidomide.
62537569|NCT05460481|EXPERIMENTAL|Experimental: Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
62537570|NCT01683838|ACTIVE_COMPARATOR|fampridine-SR 50mg/day|
62537571|NCT01683838|PLACEBO_COMPARATOR|Placebo|
62537572|NCT06551441|EXPERIMENTAL|Exercise|The HIIT intervention includes three supervised sessions per week over a 24-week period i.e., 72 exercise sessions and take place at CFAS or at home with supervision
62736784|NCT03698578|EXPERIMENTAL|group 1 combat fight|Consisting of professional, high-performance paratletas. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
62537573|NCT06551441|NO_INTERVENTION|Control group|Controls will be encouraged to maintain current exercise habits for the duration of the study.
62537574|NCT03563651||Ancillary-Correlative (biospecimen collection, biopsy)|Participants undergo collection of blood and urine at baseline, on day 1 of courses 1, 2, and 3, at restaging, and at disease progression. Participants may undergo collection of stool at baseline, on day 1 of course 2, and at disease progression. Participants also undergo biopsy within 4 weeks of disease progression.
62537575|NCT02033057|EXPERIMENTAL|Muscular electrostimulation.|The interventions is muscular electrostimulation.
62537576|NCT02084602|EXPERIMENTAL|Artesunate/mefloquine|Orally administration of artesunate 4mg/Kg by three days Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
62537577|NCT01568970|EXPERIMENTAL|Return to work follow-up|Regular contact between the patient and his/her caretaker at the rehabilitation center over a 6 month period, including joint communication between patient, caretaker at the rehabilitation center and stake holders such as social security office, general practitioner and workplace.
62537578|NCT01568970|ACTIVE_COMPARATOR|Standard follow-up|Standard follow-up of the patient after ended rehabilitation by the return-to-work stakeholders, ie. the general practitioner, social security office and the employer. Limited contact between the caretaker at the rehabilitation center and the patient and stakeholders.
62537579|NCT02581722|EXPERIMENTAL|Adolescent male population|Male circumcision using the PrePex device among healthy adolescent males and contraindicated subjects due to Preputial adhesions and /or narrow foreskin/Phimosis
62537580|NCT03988283|EXPERIMENTAL|Personalized neoantigen DNA vaccine|Patients will receive the vaccine monthly (+/- 3 days) for 6 doses as a priming phase followed by booster injections quarterly Q3mo thereafter. If sufficient quantities of vaccine are available, vaccination may continue until development of intolerance or disease progression in the case of fatal high grade neoplasms or for up to one year. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease at the completion of treatment will be given the option of resuming vaccinations if they develop subsequent progression.
62537581|NCT03897803||Group (I):juvenile dermatomyositis (JDM)|"Group (I): twenty children diagnosed to have juvenile dermatomyositis (JDM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.~."
62537582|NCT03897803||Group (II):idiopathic inflammatory myopathies(IIM)|"Group (II): twenty adults diagnosed to have idiopathic inflammatory myopathies(IIM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.~* •"
62537583|NCT03897803||Group (III): juvenile control group|"20 healthy children matching age and sex as first control group to children with JDM .Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .~."
62537584|NCT03897803||Group (VI):adult control group|20 healthy adults matching age and sex as second control group to adults with IIM. Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .
62537585|NCT01716689|EXPERIMENTAL|Patients with advanced sarcoma|
62537586|NCT03307265|EXPERIMENTAL|Imbalance correction|
62537587|NCT03307265|ACTIVE_COMPARATOR|Control|
62537588|NCT05119153|PLACEBO_COMPARATOR|Placebo Comparator|Placebo composed of water and caramel color.
62537589|NCT05119153|EXPERIMENTAL|Light Roasted Coffee|12 oz light roast coffee beverage prepared at 55 g ground coffee/L water
62537590|NCT05119153|EXPERIMENTAL|Medium Roasted Coffee|12 oz medium roast coffee beverage prepared at 55 g ground coffee/L water
62537591|NCT05119153|EXPERIMENTAL|Dark Roasted Coffee|12 oz dark roast coffee beverage prepared at 55 g ground coffee/L water
62537592|NCT02906358|ACTIVE_COMPARATOR|Community-based pain self-management|Community-based pain self-management: two, one-hour meetings monthly for the first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
62537593|NCT02906358|ACTIVE_COMPARATOR|Clinic-based pain self-management|Clinic-based pain self-management: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
62537594|NCT02977897||Diarrhea on MMF|Solid organ transplant recipients on MMF who develop diarrhea while taking the drug. Fecal calprotectin will be measured in their stool and Octreotide Acetate will be used to treat their diarrhea.
62164163|NCT02268526|EXPERIMENTAL|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
62537595|NCT00552578|ACTIVE_COMPARATOR|Tapering doses of buprenorphine|Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
62537596|NCT00552578|EXPERIMENTAL|Steady doses of buprenrophine|Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.
62537597|NCT06634134||Female cyclist|"All female cyclist that consent using the data collected by JOIN cycling app and also give permission tracking thier menstrual cycle.~Natrual menstrual cycle. Hormonal contraceptive use Intra-uterine device use (hormonal vs non-hormonal)"
62537598|NCT06589505|EXPERIMENTAL|The Software as a Medical Device1|
62537599|NCT06589505|OTHER|The Software as a Medical Device2|
62537600|NCT02391480|EXPERIMENTAL|ABBV-075|Dose escalation cohorts of ABBV-075 monotherapy
62537601|NCT02391480|EXPERIMENTAL|ABBV-075 and venetoclax combination|Expansion cohorts of ABBV-075 and venetoclax combination therapy
62537602|NCT02391480|EXPERIMENTAL|ABBV-075 expansion|Expansion cohorts of ABBV-075 monotherapy
62537603|NCT06194942|EXPERIMENTAL|Treatment Group|
62164164|NCT02268526|PLACEBO_COMPARATOR|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
62537604|NCT06194942|SHAM_COMPARATOR|Control Group|
62537605|NCT03307616|EXPERIMENTAL|Arm A (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
62537606|NCT03307616|EXPERIMENTAL|Arm B (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm A. Patients also receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
62164165|NCT06416189|ACTIVE_COMPARATOR|Braces|Fixed appliance would be bonded post teeth extraction (premolars). subsequently, leveling and alignment using sequence of archwires would be followed. The measurements would be done using models each month.
62164166|NCT06416189|NO_INTERVENTION|Without braces|Extraction of premolars and only observing the case over time. The measurements would be done using models each month.
62164167|NCT05074004|NO_INTERVENTION|control group|"No intervention was applied to the control group in this process.~* be receiving treatment in Clinic Day Hospital~* Volunteering to participate in research"
62537607|NCT03307616|EXPERIMENTAL|Arm C (nivolumab, RT)|Patients receive nivolumab IV over 1 hour on days 1, 15, 29, and 43. Patients also undergo RT QD for 5 days during days 15-47 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
62537608|NCT03307616|EXPERIMENTAL|Arm D (nivolumab, ipilimumab, RT)|Patients receive nivolumab as in Arm C, ipilimumab as in Arm B, and RT as in Arm C in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
62537609|NCT02621749|ACTIVE_COMPARATOR|CRRT group|the CRRT group receives continuous renal replacement therapy for acute kidney injury
62537610|NCT02621749|ACTIVE_COMPARATOR|IRRT group|the IRRT group receives intermittent renal replacement therapy after termination of CRRT.
62537611|NCT03122288|EXPERIMENTAL|Individualized Cognitive Training|Participants randomized to this arm will receive 20 hours of computerized cognitive training in the two predominate cognitive domains in which they experience deficits that contribute to their HIV-Associated Neurocognitive Disorder diagnosis.
62537612|NCT03122288|OTHER|No-Contact Control|Participants in this arm will not receive any experimental or sham contact. They will only participate in the Baseline and Posttest assessments.
62537613|NCT03086759|EXPERIMENTAL|Platelet rich plasm group|
62537614|NCT03086759|ACTIVE_COMPARATOR|Triamcinolone Hexacetonide group|
62537615|NCT03086759|PLACEBO_COMPARATOR|Isotonic Saline Solution group|
62537616|NCT03021889|EXPERIMENTAL|Nutritional therapy group|The group nutritional therapy intervention was subjected to a protocol that included: nutritional counseling and weekly phone calls for 12 weeks.
62537617|NCT03021889|OTHER|Control group|The control group received conventional care consisting of usual medical care. The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
62537618|NCT00798148|EXPERIMENTAL|MIBG|
62537619|NCT00929890|ACTIVE_COMPARATOR|Lifestyle counseling|Patients will receive dietary counseling and a general advice on physical activity
62537620|NCT00929890|EXPERIMENTAL|Exercise training|patients will receive dietary counseling and will be enrolled in supervised exercise training
62537621|NCT05614427|ACTIVE_COMPARATOR|Anterior nasal swab|Lateral flow tests performed on anterior nasal swabs compared to routinely taken nose and throat swabs with RT-PCR
62537622|NCT05614427|ACTIVE_COMPARATOR|Buccal swab|Lateral flow tests performed on buccal swabs compared to routinely taken nose and throat swabs with RT-PCR
62537623|NCT00759850|ACTIVE_COMPARATOR|A|Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)
62537624|NCT00759850|EXPERIMENTAL|B|Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)
62537625|NCT00759850|EXPERIMENTAL|C|Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)
62537626|NCT04504305|ACTIVE_COMPARATOR|Neuropaway|
62537627|NCT04504305|PLACEBO_COMPARATOR|Microcystalline cellulose|
62537628|NCT01439009|EXPERIMENTAL|Tolvaptan|15 mg
62537629|NCT01439009|PLACEBO_COMPARATOR|Placebo|Placebo
62537630|NCT01147107|EXPERIMENTAL|Raltegravir based therapy|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
62537631|NCT01147107|ACTIVE_COMPARATOR|Efavirenz based therapy|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
62537632|NCT06006065|EXPERIMENTAL|Intervention group|Upper limb somatosensory discrimination therapy (Sense for Kids therapy)
62714689|NCT05361460||patients undergoing major elective joint replacement surgery|patients ≥60 years that are undergoing major elective joint replacement surgery Exclusion criteria: a score on the mini-mental state examination (MMSE) at screening of ≤ 22 i.e. suspected dementia; \< 60 years of age; suffering from a nervous system disease; taking tranquillisers or antidepressants; underwent a surgical procedure in the previous six months; or inability to read and speak Swedish; suffering from a severe visual or auditory disorder, alcoholism or drug dependence
62714690|NCT05820035|EXPERIMENTAL|Experiment group|Patients treated with PFA catheter.
62714691|NCT06206941||Cannabis User|Cancer patients being treated with immunotherapy and using cannabis
62537633|NCT06006065|ACTIVE_COMPARATOR|Active control group|Upper limb motor therapy
62537634|NCT03814525|ACTIVE_COMPARATOR|Photobiomodulation group|PBM will be applied after the surgeries with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
62537635|NCT03814525|PLACEBO_COMPARATOR|Control group|Participants will be attended in the same way as the PBM group. The person who is responsible for the application of the PMB will simulate the irradiations by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off.
62537636|NCT03097510|EXPERIMENTAL|Transcendental Meditation|The TM technique is a simple, natural, effortless technique that allows the mind to experience finer levels of the thinking process until the mind transcends and experiences the source of thought, a state of deep, integrated relaxation. During the meditation session, the active mind settles down to a silent yet fully awake state of awareness. TM was taught to study participants by certified instructors, using standardized procedures for teaching.
62537637|NCT03097510|NO_INTERVENTION|Wait list control|This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
62537638|NCT06299930||Neoadjuvant chemotherapy (NACT) group|Patients who administered chemotherapy before surgery
62537639|NCT06299930||Adjuvant chemotherapy (ACT) group|Patients who administered chemotherapy after surgery
62537640|NCT01160172|EXPERIMENTAL|Group A|
62537641|NCT01160172|EXPERIMENTAL|Group B|
62537642|NCT01160172|EXPERIMENTAL|Group C|
62537643|NCT01160172|EXPERIMENTAL|Group D|
62537644|NCT01160172|PLACEBO_COMPARATOR|Group E|
62537645|NCT01160172|PLACEBO_COMPARATOR|Group F|
62537646|NCT01963143|EXPERIMENTAL|Treatment Sequence 1 - Adults|Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
62537647|NCT01963143|EXPERIMENTAL|Treatment Sequence 2 - Adults|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
62537648|NCT01963143|EXPERIMENTAL|Pediatrics|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
62537649|NCT04380363|EXPERIMENTAL|Honda Walk Assist (HWA) Group|Participants utilize HWA device at home for 2 months according to prescribed settings.
62537650|NCT04380363|ACTIVE_COMPARATOR|Control Group|Participants complete prescribed exercise program at the Shirley Ryan AbilityLab gym for 2 months.
62537651|NCT01909063|EXPERIMENTAL|Arm A|200 IU vitamin D and 700 mg of calcium per day in 2 glasses of juice per day for 2 weeks
62537652|NCT01909063|EXPERIMENTAL|Arm B|"200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta carotene, and 700 mg of calcium per day in 2 glasses of juice~Vitamin D, Vitamin E, and Vitamin A"
62537653|NCT01909063|PLACEBO_COMPARATOR|Arm C|"Control, 700 mg of calcium per day in 2 glasses of juice~Control, 700 mg Calcium"
62537654|NCT01550029|EXPERIMENTAL|Counseling/Mood Management|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
62537655|NCT01550029|ACTIVE_COMPARATOR|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle."
62164168|NCT05074004|EXPERIMENTAL|Psychoeducation|"* be receiving treatment in Clinic Day Hospital~* Volunteering to participate in research"
62537656|NCT04152187|EXPERIMENTAL|Inspiratory muscle training (IMT)|Patients will receive IMT for 30 min (15x2), 7 times per week for 8 weeks using inspiratory muscle trainer device (PowerBreathe). During training, patients will be instructed to maintain diaphragmatic breathing. Inspiratory load will be set at 40-60% of maximum inspiratory pressure. Each week, six training sessions will be held at home and a training session will be supervised with physiotherapist.
62537657|NCT04152187|NO_INTERVENTION|Control|No additional intervention
62164169|NCT02515500|ACTIVE_COMPARATOR|Gradual Cessation|
62537658|NCT04639492|EXPERIMENTAL|MBS oral solution|fermented soybean extract-MBS
62537659|NCT02798432|EXPERIMENTAL|Hybrid NEXGEN LPS|Noncemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
62537660|NCT02798432|SHAM_COMPARATOR|Cemented NEXGEN LPS|Cemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
62537661|NCT04641078|EXPERIMENTAL|Arm A|SBRT + 6 months of darolutamide (600 mg b.i.d.)
62537662|NCT04641078|OTHER|Arm B|SBRT only
62537663|NCT04037774|ACTIVE_COMPARATOR|dex 5microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 5micrograms of dexmedetomidine.
62537664|NCT04037774|ACTIVE_COMPARATOR|dex 10microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 10micrograms of dexmedetomidine.
62537665|NCT04037774|PLACEBO_COMPARATOR|placebo|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of placebo.
62537666|NCT01798316|ACTIVE_COMPARATOR|IV Acetaminophen|IV Acetaminophen administered on admission to post-anesthesia care unit
62537667|NCT01798316|ACTIVE_COMPARATOR|Standard of care|Standard of care pain management regimen including opioids administered on admission to post-anesthesia care unit
62537668|NCT04074629|EXPERIMENTAL|Skin related VOCs collected by Polydimethylsiloxane patch|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis"
62537669|NCT05630690|EXPERIMENTAL|IPL with smart diagnostic handpiece|"Standard IPL module which has FDA clearance (K083733) for a wide range of indications including vascular and pigmented lesions. The Universal IPL handpiece (HP) operates at a spectrum of 400-1,200 nm with 7 different cut-off filters and 2 different notch filters that can be easily inserted into the handpiece to treat different conditions.~The SMART Camera is a novel add-on skin diagnostic (SD) tool. The SD module includes a proprietary spectral camera embedded in a handpiece, and proprietary computer vision-based algorithms designed to process the spectral information and to determine the skin attributes and optimal treatment IPL preset."
62537670|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
62537671|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
62537672|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
62537673|NCT05396521|ACTIVE_COMPARATOR|Standard of Care|
62537674|NCT05396521|EXPERIMENTAL|Blood Flow Restriction Supplemented|
62164170|NCT02515500|EXPERIMENTAL|Gradual Cessation w/ Quitbit|
62164171|NCT05921929|EXPERIMENTAL|One single oral dose per participant|
62164172|NCT03142893|EXPERIMENTAL|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule \& start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection \& last blood sample"
62164173|NCT03142893|EXPERIMENTAL|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
62537675|NCT05183152|EXPERIMENTAL|TESS BCI - Standard MI Task|Transcutaneous Electrical Spinal Stimulation (TESS) is applied for 20 minutes prior to BCI training sessions. Following TESS, BCI training is performed with visual feedback contingent to motor imagery as detected by a closed-loop BCI.
62164174|NCT03142893|EXPERIMENTAL|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill \& start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection \& last blood sample"
62537676|NCT05183152|ACTIVE_COMPARATOR|Visual BCI - Standard MI Task|Conventional BCI training is performed with visual feedback contingent to the imagination of right versus left hand movements as detected by a closed-loop BCI.
62537677|NCT05183152|EXPERIMENTAL|NMES BCI - Difficult MI Task|BCI training is performed with NMES instead of Visual feedback. NMES is delivered over the flexors/extensors of the forearm contingent to the imagination of same-hand wrist and fingers flexion versus extension as detected by a closed-loop BCI.
62537678|NCT05183152|ACTIVE_COMPARATOR|Visual BCI - Difficult MI Task|Conventional BCI training is performed with visual feedback contingent to the imagination of same-hand wrist and fingers flexion versus extension as detected by a closed-loop BCI.
62164175|NCT03142893|EXPERIMENTAL|Adrenal/Testis Condition|"10pm - Ganirelix Injection \& Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
62164176|NCT01579461|EXPERIMENTAL|mild hepatic impairment|
62164177|NCT01579461|EXPERIMENTAL|moderate hepatic impairment|
62537679|NCT06168279|ACTIVE_COMPARATOR|conventional group|hand occlusal articulation
62537680|NCT06168279|ACTIVE_COMPARATOR|study group|digital occlusal articulation
62537681|NCT03725332|EXPERIMENTAL|Telemedicine Education|This is a stratified cluster non-inferiority randomized controlled trial with randomization of participating clusters into a 'telemedicine' or 'group care' arm. Sites will be stratified into 'high volume' (\>500 deliveries/year) and 'low volume' (\<500 deliveries per year). Randomization will be within each strata. Patients attending sites randomized to telemedicine will be recruited by research staff.
62537682|NCT03725332|ACTIVE_COMPARATOR|Group Care Education|This is a stratified cluster non-inferiority randomized controlled trial with randomization of participating clusters into a 'telemedicine' or 'group care' arm. Sites will be stratified into 'high volume' (\>500 deliveries/year) and 'low volume' (\<500 deliveries per year). Randomization will be within each strata. Patients attending sites randomized to group care will be recruited by research staff.
62537683|NCT02414776|EXPERIMENTAL|hydroxychloroquine plus hormonal therapy|Add hydroxychloroquine to the current hormonal therapy
62537684|NCT06044012|EXPERIMENTAL|Patients with large Oro-antral Fistula|closure of oro-antral fistula by myomucosal flap and buccal pad of fat
62714692|NCT06206941||Cannabis non-user|Cancer patients being treated with immunotherapy and not using cannabis
62164178|NCT01579461|EXPERIMENTAL|healthy volunteers (matched with mild hepatic)|
62164179|NCT01579461|EXPERIMENTAL|healthy volunteers (matched with moderate hepatic)|
62164180|NCT03597997|EXPERIMENTAL|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
62537685|NCT00462124|OTHER|Balloon|Implantation of a biodegradable balloon spacer (absorbable perirectal spacer)
62537686|NCT02076373|EXPERIMENTAL|recombinant human Erythropoietin (Epo)|"Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
62537687|NCT02076373|PLACEBO_COMPARATOR|Control|"Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
62537688|NCT03888781||With Left Ventricular Remodeling|By Echocardiography
62714693|NCT03555877|EXPERIMENTAL|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
62714694|NCT03555877|ACTIVE_COMPARATOR|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
62714695|NCT05050903||Asthma|
62714696|NCT05050903||Healthy controls|
62537689|NCT03888781||Without Left Ventricular Remodeling|By Echocardiography
62537690|NCT00368979|ACTIVE_COMPARATOR|Dutasteride|
62537691|NCT00368979|PLACEBO_COMPARATOR|Placebo|
62537692|NCT04522323|EXPERIMENTAL|Dose Exploration|The Dose exploration Phase is made up of Part A, B and Part C. Part A will evaluate the safety and tolerability of MEDI5752 in combination with Axitinib (2 patients), and Part B and C will evaluate the safety and tolerability of MEDI5752 in combination with Lenvatinib (\~72 patients)
62537693|NCT04522323|EXPERIMENTAL|Dose Expansion|Evaluate safety and anti-tumor activity of MEDI5752 in combination with Lenvatinib (\~105 patients )
62537694|NCT06104995|EXPERIMENTAL|Interventional Educational video on back beliefs|Participants receive an educational video on back beliefs and its contributing factors.
62537695|NCT06104995|EXPERIMENTAL|Control Video Education|Participants receive a neutral video about the back (e.g. anatomy of the back).
62714697|NCT06716749|PLACEBO_COMPARATOR|Control (Intraosseous vancomycin with no morphine)|Control patients will receive 500 mg of vancomycin in 100 mL of normal saline + 10 mL of normal saline (placebo). Both with be injected intraosseously in the tibia.
62164181|NCT03597997|SHAM_COMPARATOR|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
62164182|NCT02832453|OTHER|Lifestyle counseling|This group will receive lifestyle counselling but not supervised exercise training sessions
62164183|NCT02832453|EXPERIMENTAL|Aerobic interval training|This group will receive lifestyle counselling plus supervised high intensity (80%VO2max) interval exercise training sessions
62164184|NCT02832453|ACTIVE_COMPARATOR|Traditional continous training|This group will receive lifestyle counselling plus supervised moderate intensity (60%VO2max) continous exercise training sessions
62164185|NCT06030999|ACTIVE_COMPARATOR|Study product A (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0\*1010 CFU:~* CECT7527, CECT7528, CECT7529~* Maltodextrin~* Lactobacillus acidophilus~* Fructose oligosaccharides~* Grapefruit, Lemon and Apple powder"
62537696|NCT01144507||Group A|Approximately 60 subjects with a heterogeneous echo pattern of the liver on abdominal ultrasound (HTG US).
62537697|NCT01144507||Group B|Approximately 680 subjects with a normal echo pattern on abdominal ultrasound (NL US). Of these subjects, approximately 110 will be matched 1:1 with Group A participants and followed for the duration of the study. The remaining unmatched subjects will not be followed beyond their initial visit.
62537698|NCT01144507||Group C|An estimated 30 subjects with cirrhosis pattern on abdominal ultrasound. These subjects will be followed in the study.
62537699|NCT01144507||Group D|An estimated 30 subjects with diffusely homogeneous echogenic pattern at screening ultrasound will be followed in the study.
62537700|NCT03262038|EXPERIMENTAL|Ondansetron IV|Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
62537701|NCT03262038|PLACEBO_COMPARATOR|Placebo|Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)
62537702|NCT06270186|OTHER|Type 1 myotonic dystrophy|"Type 1 myotonic dystrophy patients doing classical neuropsychological test and on Good Diag NMD software"
62537703|NCT05944614||Marfan Syndrome patients|Marfan Syndrome patients age 18-50 with a pathological FBN1 mutation
62537704|NCT05944614||Healthy volunteers|Age and gender matched healthy control patients without a history of aortic disease.
62537705|NCT01616342|ACTIVE_COMPARATOR|Comprehensive Medical Management|Comprehensive Medical Management will include analgesic management in accordance with guidelines and practices at the site.
62537706|NCT01616342|ACTIVE_COMPARATOR|Spinal Cord Stimulation (SCS)|Subjects assigned to Arm A, CMM + SCS, will be treated with electrical pulses from a surgically implanted Precision Plus® SCS System (Boston Scientific Corporation).
62537707|NCT02400853|EXPERIMENTAL|preterm infants with intracranial hemorrhage|Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
62164186|NCT06030999|ACTIVE_COMPARATOR|Study product B (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 1.0\*1010 CFU:~* Maltodextrin~* Lactobacillus acidophilus"
62164187|NCT06030999|PLACEBO_COMPARATOR|Study product C (placebo)|"2g/bottle, containing the following ingredients:~* Maltodextrin~* Grapefruit powder~* Lemon powder"
62164188|NCT04792541|PLACEBO_COMPARATOR|control group|saline solution
62164189|NCT04792541|EXPERIMENTAL|test group|HY containing gel; GUM® Afta Clear Gel, Sunstar
62164190|NCT01870687|EXPERIMENTAL|VAC BNO 1095 2x10 mg FCT|VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
62164191|NCT01870687|PLACEBO_COMPARATOR|Placebo|2 tablets in the morning, oral, 3 months treatment
62164192|NCT03151161|EXPERIMENTAL|Experimental Group|"1. Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;~2. Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
62164193|NCT03151161|ACTIVE_COMPARATOR|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
62164194|NCT03869541||Intensive care patients|Adult intensive care patients receiving vasoactive drugs
62164195|NCT03869541||Intensive care unit clinicians|Clinicians for participation in a survey on the hypothetical randomization of patient participants in a future randomized controlled trial.
62164196|NCT03869541||ICU rehabilitation clinicians|Clinicians for participation in a survey on the feasibility of an ICU physical rehabilitation adverse event tool.
62164197|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
62164198|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
62164199|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
62164200|NCT01482819|OTHER|Sequence 1|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Lotrafilcon A~2. Spectacles~3. Galyfilcon A Plus~4. Polymacon~5. Galyfilcon A"
62164201|NCT01482819|OTHER|Sequence 2|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Galyfilcon A Plus~2. Galyfilcon A~3. Lotrafilcon A~4. Polymacon~5. Spectacles"
62164202|NCT01482819|OTHER|Sequence 3|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Galyfilcon A~2. Polymacon~3. Galyfilcon A Plus~4. Spectacles~5. Lotrafilcon A"
62164203|NCT01482819|OTHER|Sequence 4|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Spectacles~2. Lotrafilcon A~3. Polymacon~4. Galyfilcon A Plus~5. Galyfilcon A"
62537708|NCT02400853|ACTIVE_COMPARATOR|preterm infants without intracranial hemorrhage|Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
62537709|NCT05665829|ACTIVE_COMPARATOR|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after intubation with microlaryngeal tube, a laryngoscope will be inserted transorally under direct vision and suspended. Laryngeal lesions are visualized with either microscope or endoscope, and removed with microsurgery instruments and sent for routine section
62164204|NCT01482819|OTHER|Sequence 5|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Polymacon~2. Galyfilcon A~3. Spectacles~4. Galyfilcon A Plus~5. Lotrafilcon A"
62164205|NCT01482819|OTHER|Sequence 6|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Galyfilcon A~2. Galyfilcon A Plus~3. Polymacon~4. Lotrafilcon A~5. Spectacles"
62537710|NCT05665829|EXPERIMENTAL|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, a transnasal channel flexible laryngoscope is used with prior trans-nasal, trans-oral and trans-laryngeal local anesthesia application. A 445nm blue laser is introduced via a working channel of laryngoscope, with a lesion-specific laser setting. Biopsy can be performed by devascularizing and thinning the lesion down to a pedicle, then removed with biopsy forcep. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. Patients are discharged on same day of procedure after close observation for 2 hours in day center.
62537711|NCT00160069|EXPERIMENTAL|Arm 1|
62537712|NCT00160069|EXPERIMENTAL|Arm 2|
62537713|NCT00160069|EXPERIMENTAL|Arm 3|
62537714|NCT03741699|EXPERIMENTAL|Arm 1 - experimental group|Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
62537715|NCT03741699|NO_INTERVENTION|Arm 2 - control (no pre-treatment) group|The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
62537716|NCT05129007||Study group|All patients
62537717|NCT05910112||Undergoing pleural intervention|Any patient undergoing a pleural procedure (eg thoracocentesis, chest drain, indwelling pleural catheter, pleural biopsies, medical thoracoscopy)
62537718|NCT03466268|EXPERIMENTAL|Dose escalation study of Gumarontinib|To determine the maximum tolerated dose (MTD) of Gumarontinib
62537719|NCT05308082|EXPERIMENTAL|Intervention group|It is proposed to have 70 participants who meet the inclusion criteria in the intervention group. Dance movement therapy will be delivered as an intervention, which consists of six sessions: (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection \& Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
62537720|NCT05308082|NO_INTERVENTION|Active control group|It is proposed to have 70 participants who meet the inclusion criteria in the active control group. Health talk will be delivered to participants which will match the length of contact and interval of contact of that in the intervention group.
62537721|NCT01327508|EXPERIMENTAL|TRIGEN SURESHOT Distal Targeting|TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
62537722|NCT01327508|ACTIVE_COMPARATOR|Standard Nailing Instrumentation.|Free-hand technique utilizes x-rays to find screw holes
62537723|NCT04182282|EXPERIMENTAL|Immediate|Immediate participants receive the intervention (online training and certification exam) during the study.
62537724|NCT04182282|EXPERIMENTAL|Control|Control participants do not receive the intervention (online training and certification exam) during the study. However, they do receive access to the intervention program (at no cost) at the conclusion of the study.
62537725|NCT04051034|EXPERIMENTAL|Omega 3 supplementation|12 weeks: Active: 1.25 g capsules/ \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
62537726|NCT04051034|EXPERIMENTAL|Placebo|12 weeks: Placebo: 1.25 g capsules/ \[1.25-gram high oleic safflower oil capsule\]with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
62537727|NCT02654860|EXPERIMENTAL|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
62164206|NCT01482819|OTHER|Sequence 7|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Polymacon~2. Spectacles~3. Galyfilcon A~4. Lotrafilcon A~5. Galyfilcon A Plus"
62164207|NCT01482819|OTHER|Sequence 8|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Galyfilcon A Plus~2. Lotrafilcon A~3. Galyfilcon A~4. Spectacles~5. Polymacon"
62164208|NCT01482819|OTHER|Sequence 9|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Lotrafilcon A~2. Galyfilcon A Plus~3. Spectacles~4. Galyfilcon A~5. Polymacon"
62537728|NCT02654860|EXPERIMENTAL|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
62537729|NCT02654860|EXPERIMENTAL|120 mg Paracetamol 3% (4mL)|120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
62537730|NCT02654860|PLACEBO_COMPARATOR|Phase II Only: Saline solution 0.9%|Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
62537731|NCT04339283|EXPERIMENTAL|Standardized Hibiscus sabdariffa tea Arm|300 mL of freshly prepared standardized Hibiscus sabdariffa tea (containing 102.49 mg/L of total monomeric anthocyanin) is administered daily to the participants for 28 days
62537732|NCT04339283|NO_INTERVENTION|Water Arm|300 mL of distilled water is administered to the participants daily for 28 days.
62537733|NCT03960203|EXPERIMENTAL|Comparator|The comparator arm will involve patients monitored by InSight.
62164209|NCT01482819|OTHER|Sequence 10|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~1. Spectacles~2. Polymacon~3. Lotrafilcon A~4. Galyfilcon A~5. Galyfilcon A Plus"
62537734|NCT04933448|EXPERIMENTAL|Prospective Intervention Group|Participants will receive standard of care for acute management of moderate to severe traumatic brain injury, together with a weight-based ketogenic diet added for up to fourteen days.
62537735|NCT04933448|NO_INTERVENTION|Historical Control Group|Medical records of past TBI patients will be used as controls matched for age, gender, socioeconomic status (type of health care coverage including private insurance vs. government-funded coverage), lowest first 24 hour post-injury Glasgow Coma Score (GCS) (\<8 or 8-12), and pre-injury school program (regular or special education).
62537736|NCT03421730|EXPERIMENTAL|AB - VR647 5 breaths, then VR647 10 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62537737|NCT03421730|EXPERIMENTAL|AC - VR647 5 breaths, then VR647 20 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62537738|NCT03421730|EXPERIMENTAL|AD - VR647 5 breaths, then Pulmicort|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
62537739|NCT03421730|EXPERIMENTAL|BA - VR647 10 breaths, then VR647 5 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62537740|NCT03421730|EXPERIMENTAL|BC - VR647 10 breaths, then VR647 20 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62537741|NCT03421730|EXPERIMENTAL|BD - VR647 10 breaths, then Pulmicort|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
62537742|NCT03421730|EXPERIMENTAL|CA - VR647 20 breaths, then VR647 5 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62537743|NCT03421730|EXPERIMENTAL|CB - VR647 20 breaths, then VR647 10 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62164210|NCT01891006|EXPERIMENTAL|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy (NPWT) is an alternative method of conservative wound management, which uses negative pressure to promote wound healing in both chronic and acute wounds. The rationale for using NPWT is that it mechanically stimulates the formation of new tissue and removes wound fluid and infectious material
62164211|NCT01891006|OTHER|A standard wound dressing|The standard wound dressing is a hydrofiber or alginate dressing, used for open wound
62164212|NCT03071900|EXPERIMENTAL|SCCHN|squamous cell carcinoma of the head and neck
62164213|NCT03071900|EXPERIMENTAL|Control|health volunteers
62164214|NCT02798861||CAP assessment|Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes
62164215|NCT05212233||Patients with MM and/or CLL|This is a non-interventional study. All enrolled patients will complete a telephone interview. A subset of patients will complete the optional follow-up interview. The clinical practice sites through which patients are being recruited and enrolled on to the study will each complete the Site Survey. Physicians at these sites who treat patients with MM or CLL will be invited to complete the Physician Survey.
62164216|NCT02375607|OTHER|Algometer|Algometer used patients
62164217|NCT01299441||OLT patients intubated with ECOM ETT|Patients undergoing liver transplantation and intubated with ECOM endotracheal tube (ETT).
62164218|NCT06313099||All participants will be evaluated|
62164219|NCT02446912|EXPERIMENTAL|Anifrolumab - higher dose|Anifrolumab
62164220|NCT02446912|PLACEBO_COMPARATOR|Placebo|Placebo
62164221|NCT02446912|EXPERIMENTAL|Anifrolumab - lower dose|Anifrolumab
62164222|NCT02916524|EXPERIMENTAL|Model-based|Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
62164223|NCT02916524|ACTIVE_COMPARATOR|Model-opposite|Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
62164224|NCT02916524|NO_INTERVENTION|Sub-Study: Computational Modeling for Bilingual Dementia and Semantic Decline|This is a sub-study aimed at building a computational model to simulate bilingual dementia and semantic decline.
62164225|NCT06285058||Training dataset|patients who were diagnosed with non-small cell carcinoma and undergo surgery after neoadjuvant chemoimmunotherapy treatment at hospital 1 (Tongji Medical College Affiliated Union Hospital)
62164226|NCT06285058||test dataset|patients who were diagnosed with non-small cell carcinoma and undergo surgery after neoadjuvant chemoimmunotherapy treatment at hospital (Zhengzhou University First Affiliated Hospital, Yichang Central Hospital, Anyang Cancer Hospital)
62164227|NCT05603546||CFA treated by endarterectomy|Common femoral artery lesions undergo endometrial decortication
62164228|NCT05603546||CFA treated by transluminal extraction-atherectomy|Common femoral artery lesions are treated intravenously
62164229|NCT04240418||Lyon University Hospital employees|
62164230|NCT06545045|EXPERIMENTAL|Metacognitive strategy training (MCST)|Each MCST session will be follow the procedures of Cognitive Orientation to daily Occupational Performance (CO-OP) intervention. There will be 10, 45-minute, weekly sessions. All sessions will be delivered in-person with a trained occupational therapist.
62164231|NCT06545045|ACTIVE_COMPARATOR|Inactive Control Group|Participants will receive a weekly phone call from study staff to maintain contact and monitor changes in activity.
62164232|NCT00276016|EXPERIMENTAL|Phenylephrine, Pseudoephedrine, Placebo|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules."
62164233|NCT00276016|EXPERIMENTAL|Pseudoephedrine, Placebo, Phenylephrine|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
62164234|NCT00276016|EXPERIMENTAL|Placebo, Phenylephrine, Pseudoephedrine|"Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
62164235|NCT00276016|EXPERIMENTAL|Phenylephrine, Placebo, Pseudoephedrine|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
62537744|NCT03421730|EXPERIMENTAL|CD - VR647 20 breaths, then Pulmicort|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
62537745|NCT03421730|EXPERIMENTAL|DA - Pulmicort, then VR647 5 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62537746|NCT03421730|EXPERIMENTAL|DB - Pulmicort, then VR647 10 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62164236|NCT00276016|EXPERIMENTAL|Pseudoephedrine, Phenylephrine, Placebo|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules."
62164237|NCT00276016|EXPERIMENTAL|Placebo, Pseudoephedrine, Phenylephrine|"Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
62537747|NCT03421730|EXPERIMENTAL|DC - Pulmicort, then VR647 20 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
62537748|NCT01188278||Patients in CP-CML treated with 2G TKI|Patients in CP-CML treated with 2G TKI (nilotinib or dasatinib) post imatinib failure
62537749|NCT03339167|EXPERIMENTAL|metabolic availability of lysine in millet|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked millet with or without lentils, which will all be provided by the investigators."
62537750|NCT02077218|EXPERIMENTAL|Diagnostic (CT and blood biomarkers)|Patients undergo cardiac CT and collection of blood samples for analysis of hs-CRP via quantitative immunoturbidimetry and Lp-PLA2 via ELISA.
62537751|NCT02424110|EXPERIMENTAL|Argon beam coagulator ablation group|In the bipolar left atrial radiofrequency ablation, when the linear ablation was performed through along the lower edge of interatrial groove incision up to the mitral annulus, there is a gap between the ends of the ablation line and the mitral annulus And in the bipolar right atrial radiofrequency ablation, when the linear ablation was performed along the lower edge of the coronary sinus ostium up to the inferoseptal commissure and through the vertical incision on anterior wall of the right atrium up to the tricuspid annulus. There also have gaps between ends of the ablation line and the tricuspid annulus. In the experimental group the investigators plan to use conventional bipolar radiofrequency ablation and use argon beam coagulator to ablate these gaps.
62537752|NCT02424110|EXPERIMENTAL|Bipolar radiofrequency ablation group|Only use conventional bipolar radiofrequency ablation and do not deal with these gaps.
62537753|NCT05822258|EXPERIMENTAL|Freezing of Gait|"Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray.~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions (normal, double physical task and double verbal task). A rest period will be observed."
62537754|NCT03407066||In-person|200 in-person healthy volunteers
62537755|NCT03407066||On-line|10,000 on-line healthy volunteers
62537756|NCT01210612|ACTIVE_COMPARATOR|Without Unilateral CAI|Individuals with no history of chronic ankle instability (CAI)
62537757|NCT01210612|EXPERIMENTAL|With Unilateral CAI|Individuals with a history of chronic ankle instability (CAI) that is affecting only one limb
62164238|NCT03110432||Standard lipid lowering therapy|Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids (and any combinations of these agents)
62537758|NCT01328665|EXPERIMENTAL|Expressive Writing|Affectionate Writing Intervention for 20 minutes per day, 2 times per week, 6 weeks.
62537759|NCT01328665|NO_INTERVENTION|No writing|Control Group -- No writing
62537760|NCT04074616|EXPERIMENTAL|High Dose|
62537761|NCT04074616|OTHER|Control|Low dose TTNS
62537762|NCT03565679|EXPERIMENTAL|Masimo SpO2 Adhesive Sensors, Adtx (1859) & (2329)|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
62537763|NCT03565679|SHAM_COMPARATOR|Covidien Nellcor SpO2 Sensor, MAX-A and MAX-N|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
62537764|NCT03703869||Insulin glargine (U300)|Insulin glargine (U300) dosage and dosing time as per local product labeling
62537765|NCT06633679|EXPERIMENTAL|Intervention group|
62537766|NCT06633679|NO_INTERVENTION|Control group|
62537767|NCT04868968|EXPERIMENTAL|DFV890|DFV890
62537768|NCT01959854|ACTIVE_COMPARATOR|carboxymethylcellulose|1 drop in each eye four times a day for 30 days
62537769|NCT01959854|EXPERIMENTAL|xanthan gum|1 drop in each eye four times a day for 30 days
62537770|NCT03510962|ACTIVE_COMPARATOR|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice."
62714698|NCT06716749|EXPERIMENTAL|Experimental (Intraosseous vancomycin with morphine)|Control patients will receive 500 mg of vancomycin in 100 mL of normal saline + 10 mg of morphine in 10 mL of normal saline. Both with be injected intraosseously in the tibia.
62537771|NCT03510962|EXPERIMENTAL|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
62537772|NCT03510962|EXPERIMENTAL|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
62537773|NCT03510962|EXPERIMENTAL|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will Brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the brushing as an intervention."
62537774|NCT03510962|EXPERIMENTAL|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
62537775|NCT03510962|EXPERIMENTAL|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
62537776|NCT06030986||ILCOR Utstein OHCA Core Outcome Positive|Respectively for all core outcomes defined.
62537777|NCT06030986||ILCOR Utstein OHCA Core Outcome Negative|Respectively for all core outcomes defined.
62537778|NCT04116762|EXPERIMENTAL|Intervention|Placement of TissuePatchDS-P™ at time of operation. No surgical drain is used.
62537779|NCT04116762|ACTIVE_COMPARATOR|Control|No use of TissuePatchDS-P™. Wound is closed with a surgical drain (Surgeon's choice) in situ.
62537780|NCT06634277|EXPERIMENTAL|NavSTAR|NavSTAR is a Patient Navigation service model to reduce internal and external barriers to recommended service engagement. It includes motivational interventions in tandem with proactive barrier resolution, targeting areas of addiction, medical, self-care, and basic needs.
62537781|NCT04776538|EXPERIMENTAL|Stem cell group|60 patients will be randomized to receive adipose-derived allogeneic stem cells
62537782|NCT04776538|PLACEBO_COMPARATOR|Placebo group|60 patients will receive placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
62537783|NCT02346266|ACTIVE_COMPARATOR|SMART|The intervention group of school-aged children will receive education on the F.A.S.T. (Face, Arm, Speech and Time) acronym, additional signs and symptoms of stroke and the need for immediate activation of Emergency Medical Services (EMS) by calling 911.
62537784|NCT02346266|NO_INTERVENTION|Usual Care|This group will not receive stroke education.
62537785|NCT06436066|EXPERIMENTAL|Intervention Group|A self-acupressure training booklet was created in line with the relevant literature. For the training booklet, expert opinions were received from 5 clinician nurses and 5 academic nurses who are experts in their fields. The training booklet includes the definition of self-acupressure, the areas in which it is used, its benefits, the purpose of the study, the points where acupressure will be applied and the application procedure. After 30 minutes of self-acupressure training was given to the patients in the intervention group, the relevant training booklet was delivered. Reminder messages will be sent to patients every week. They will be asked to do it 3 days a week and for 3 months. They were informed to come for a check-up after 3 months.
62714699|NCT06335966||Patients with suspected Barrett's Esophagus or at risk for esophageal cancer|Patients who receive primary care in a rural settings and are in need of screening for Barrett's Esophagus or esophageal cancer.
62164239|NCT03110432||PCSK9 Inhibitor [EPC]|Evolocumab or alirocumab.
62164240|NCT01332318|PLACEBO_COMPARATOR|Placebo|XP13512 Placebo + Diphenhydramine Placebo
62164241|NCT01332318|EXPERIMENTAL|XP13512 1200 mg|XP13512 1200 mg/day + Diphenhydramine Placebo
62164242|NCT01332318|EXPERIMENTAL|XP13512 1800 mg|XP13512 1800 mg/day + Diphenhydramine Placebo
62164243|NCT01332318|ACTIVE_COMPARATOR|Placebo + Diphenhydramine|XP13512 Placebo + 50 mg Diphenhydramine
62164244|NCT05248269|EXPERIMENTAL|Thermocoagulation of epileptogenic zone|
62164245|NCT00525915|EXPERIMENTAL|Arm A: Chemo with Radiation Treatment|For 5 weeks, Chemo of 5-FU 250 mg/m\^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m\^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.
62164246|NCT00525915|EXPERIMENTAL|Arm B: Pre-Op Chemo + Chemo with Radiation Treatment|Pre-Operative Chemo 5-FU 2.2 mg/m\^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m\^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)
62164247|NCT01078376|EXPERIMENTAL|Cohort 1: Healthy Adults (18 years to 45 years old)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
62537786|NCT06436066|NO_INTERVENTION|Control Group|"Routine clinical care continued to be provided to the patients in the control group.~Routine maintenance applications include the following parameters;~1. Patient Information Form~2. Neuropathic Pain Questionnaire - DN4~3. Neuropathic Pain Questionnaire - Short Form~4. Providing acupressure training to diabetic patients who wish to do so at the end of the study."
62164248|NCT01078376|EXPERIMENTAL|Cohort 1: Adolescents (≥12 to <17 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
62164249|NCT01078376|EXPERIMENTAL|Cohort 2: Children (≥6 to <12 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
62164250|NCT01078376|EXPERIMENTAL|Cohort 3: Children (≥1 to <6 years old)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
62164251|NCT01239225|EXPERIMENTAL|Abdominal ultrasound|Abdominal ultrasound
62164252|NCT06095817|EXPERIMENTAL|Intervention Condition|"Participants assigned to the intervention condition will be invited to engage with an internet-based intervention at the start of the study (12 months following their separation)~* Half of those in the intervention condition will have already received two prior IDBIs (as part of the DoD funded study) within the first 6 months of separation.~* The other half of those in the intervention condition will have received no prior IDBIs."
62164253|NCT06095817|NO_INTERVENTION|Control|"The control group will not be offered this month-12 internet-based intervention.~* Half of those in the control condition will have received two earlier IDBIs (as part of the DoD funded study) within the first 6 months of their separation.~* The other half of those in the control condition will have received no prior IDBIs."
62164254|NCT05362253|EXPERIMENTAL|experimental group|The experimental group received micro-conjunctival autograft combined with amniotic membrane transplantation.
62164255|NCT05362253|ACTIVE_COMPARATOR|control group|The control group received given routine autologous conjunctival transplantation.
62164256|NCT02045745|EXPERIMENTAL|Prolonged postoperative air leaks in risk patients.|Patients with prolonged postoperative air leaks
62537787|NCT05927948|EXPERIMENTAL|Intervention|This is a split body study. The patients will serve as their own control. The side that receives Laight therapy will be randomized. For example, if the patient receives Laight therapy on the right, then the control will be the left.
62537788|NCT05927948|NO_INTERVENTION|Control|This is a split body study. The patients will serve as their own control. The control side of the body will be randomized. For example, if the patient receives Laight therapy on the right, then the control will be the left.
62537789|NCT02434237||patients|
62537790|NCT02434237||healthy subjects|
62537791|NCT01595763||Deep Vein Thromobosis signs or symptoms|
62537792|NCT03610516|EXPERIMENTAL|CFZ533|Investigational drug CFZ533 will be administred as multiple doses
62537793|NCT03610516|PLACEBO_COMPARATOR|Placebo|Investigational drug matching placebo will be administered as multiple doses
62537794|NCT02302053|ACTIVE_COMPARATOR|New Viviscal Professional Supplement|New Viviscal Professional Strength Supplements. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
62164257|NCT05401669|EXPERIMENTAL|Trans-radial artery access|
62164258|NCT05401669|ACTIVE_COMPARATOR|Trans-femoral Artery access|
62164259|NCT03953378||"Group RA patients"|Patients with Rheumatoid Arthritis (RA) fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria.
62164260|NCT03953378||"Group PsA patients"|Patients with Psoriatic Arthritis (PsA) fulfilling the Classification for PsA (CASPAR) criteria.
62164261|NCT03953378||"Group Healthy donors"|Anonymous healthy donors from the Etablissement Français du Sang.
62164262|NCT01033097|EXPERIMENTAL|DNK333 5 mg|
62164263|NCT01033097|PLACEBO_COMPARATOR|Placebo to DNK333 5mg|
62164264|NCT01033097|EXPERIMENTAL|DNK333 25 mg|
62164265|NCT01033097|PLACEBO_COMPARATOR|Placebo to DNK333 25 mg|
62537795|NCT02302053|PLACEBO_COMPARATOR|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
62537796|NCT04307576|NO_INTERVENTION|R1 - SR standard arm|Standard risk arm receiving standard treatment (Delayed Intensification including Doxorubicin).
62164266|NCT01033097|EXPERIMENTAL|DNK333 100 mg|
62164267|NCT01033097|PLACEBO_COMPARATOR|Placebo to DNK333 100 mg|
62164268|NCT01033097|ACTIVE_COMPARATOR|Betamethasone 4 mg|
62164269|NCT01033097|EXPERIMENTAL|DNK333 1 mg|
62164270|NCT01033097|PLACEBO_COMPARATOR|placebo 1mg|
62164271|NCT04624074|EXPERIMENTAL|Teen Marijuana Checkup - adapted|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
62164272|NCT04620681|EXPERIMENTAL|Phase 1 Dose Level 1|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 1: 1X10\^6 CD4 T Cells/kg
62537797|NCT04307576|EXPERIMENTAL|R1 - SR experimental arm|Standard risk arm, receiving Delayed Intensification without Doxorubicin IV 3 x 30 mg/m2/dose.
62537798|NCT04307576|NO_INTERVENTION|R2 - IR-low standard arm|Standard treatment with Delayed Intensification including Doxorubicin and Maintenance including Vincristine+Dexamethasone pulses.
62164273|NCT04620681|EXPERIMENTAL|Phase 1 Dose Level 2|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 2: 1X10\^7 CD4 T Cells/kg
62537799|NCT04307576|EXPERIMENTAL|R2 - IR-low experimental arm A|Standard treatment with omission of Doxorubicin IV 3 x 30 mg/m2/dose in the Delayed Intensification phase.
62537800|NCT04307576|NO_INTERVENTION|R3 - IR-high standard arm|Intermediate risk high arm receiving Standard Maintenance Therapy.
62164274|NCT04620681|EXPERIMENTAL|Phase 1 Dose Level 3|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 3: 5 X10\^7 CD4 T Cells/kg
62164275|NCT04620681|EXPERIMENTAL|Phase 2 -Treatment at Maximum Tolerated Dose (MTD)|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at MTD.
62164276|NCT05812547|EXPERIMENTAL|The Lumen group|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection
62164277|NCT05812547|ACTIVE_COMPARATOR|The control group|The control group will use a mobile app to keep track of their glucose levels and will be managed in accordance with the common guidelines for GDM management. Participants of both groups will measure their fasting blood glucose levels and their postprandial blood glucose levels and record it in their mobile app
62164278|NCT00605384|EXPERIMENTAL|1|
62164279|NCT00605384|EXPERIMENTAL|2|
62164280|NCT04229706|EXPERIMENTAL|High dose group|xiangjurupining capsule ,8 capsules，tid
62164281|NCT04229706|EXPERIMENTAL|Lower dose group|xiangjurupining capsule, 4 capsules,tid, xiangjurupining capsule placebo ,4 capsules，tid，po
62164282|NCT04229706|PLACEBO_COMPARATOR|Placebo group|xiangjurupining capsule placebo ,8 capsules，tid，po
62164283|NCT02074865||newborns|
62164284|NCT03998423|EXPERIMENTAL|1 dose fecal microbiota transplant|This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.
62537801|NCT04307576|EXPERIMENTAL|R3-InO - IR-high experimental arm|Inotuzumab IV 0,5 mg/m2, given on days 253, 260, 267 and on days 274, 281, 288 before start of Standard Maintenance Therapy.
62164285|NCT03998423|EXPERIMENTAL|2 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.
62164286|NCT03998423|EXPERIMENTAL|3 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.
62164287|NCT00958633|ACTIVE_COMPARATOR|8 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s)and will be randomized to one of two treatment arms for up to 52 weeks:~Group 1 patients randomized to the 8 week arm will discontinue antidepressant treatment after 8 weeks, as recommended in current clinical practice guidelines. The antidepressant will be tapered in a double-blind manner beginning at 6 weeks, and will be substituted with placebo by 8 weeks.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
62164288|NCT00958633|ACTIVE_COMPARATOR|52 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s) and will be randomized to one of two treatment arms for up to 52 weeks:~Group 2 patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
62164289|NCT05579444||Ulcerative Colitis|Participants with ulcerative colitis.
62164290|NCT05579444||Crohn's Disease|Participants with Crohn's disease.
62164291|NCT05579444||Obesity|Participants that are obese.
62164292|NCT05579444||Colon Polyps|Participants with colon polyps.
62164293|NCT05579444||Eosinophilic esophagitis|Participants with Eosinophilic esophagitis
62537802|NCT04307576|EXPERIMENTAL|ABL-class fusions intervention|Imatinib p.o. 340 mg/m2 given daily from day 15 or 30 (depending on age) to the end of therapy (week 106) in addition to Standard IR-high chemotherapy.
62537803|NCT04307576|EXPERIMENTAL|R3-TEAM - IR-high experimental arm|6-tioguanine p.o, 2,5-12,5 mg/m2, given daily in addition to Standard Maintenance Therapy.
62537804|NCT04307576|EXPERIMENTAL|ALLTogether1 DS Blinatumomab intervention|Blinatumomab IV, 5 mcg/m2/day up to 28 mcg/day (detailed dosing in protocol) continous infusion. Two 28 day courses with a two week treatment free interval in between. Blinatumomab courses replace Consolidation 1 and Consolidation 2 in the standard protocol adapted for Down syndrome patients.
62537805|NCT04307576|EXPERIMENTAL|R2 - IR-low experimental arm B|Standard treatment with omission of monthly pulses of Vincristine IV 1,5 mg/m2/dose and 5 days of Dexamethasone p.o. 6 mg/m2/day in the Maintenance Phase.
62537806|NCT06633107|EXPERIMENTAL|experimental group|Medically relevant pharmacotherapy combined with rehabilitation exercise therapy. Continued rehabilitation exercise therapy intervention 3 months after discharge.
62537807|NCT06633107|NO_INTERVENTION|control group|Only medically relevant medications are given during hospitalization. No rehabilitation exercise therapy intervention for 3 months after discharge.
62164294|NCT05579444||Gastroesophageal Reflux Disease (GERD)|Participants with Gastroesophageal Reflux Disease (GERD).
62537808|NCT02505308|EXPERIMENTAL|DIVA-1 CCND2|Individuals carrying a genetic change in the CCND2 gene and controls matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
62537809|NCT02505308|EXPERIMENTAL|DIVA-2 Low Risk of Diabetes|Individuals carrying the fewest genetic risk alleles for diabetes and controls carrying the average number of genetic risk alleles, matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
62537810|NCT00554190|EXPERIMENTAL|1|AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
62537811|NCT00554190|ACTIVE_COMPARATOR|2|Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
62164295|NCT05579444||Gastritis|Participants with gastritis.
62164296|NCT05579444||Gastric ulcers|Participants with gastric ulcers.
62537812|NCT00990860|EXPERIMENTAL|Sorafenib|
62537813|NCT05289973|EXPERIMENTAL|TruNatomy Files|Newly introduced endodontic file
62537814|NCT05289973|EXPERIMENTAL|Hyflex EDM|Endodontic file
62537815|NCT01886196|EXPERIMENTAL|Non-steroidal anti-inflammatory drug|ibuprofen after exercise training sessions (400 mg, 3 times per week for 9 months)
62537816|NCT01886196|PLACEBO_COMPARATOR|placebo|placebo after exercise training sessions(3 times per week for 9 months)
62537817|NCT01886196|EXPERIMENTAL|resistance exercise|3 sets of 8-12 repetitions of resistance exercises focused on distal radius to be performed 3 times/week for 9 months
62537818|NCT01886196|SHAM_COMPARATOR|flexibility training|flexibility training to be performed 3 days/week for 1 hour for 9 months
62537819|NCT06450795|EXPERIMENTAL|High intensity functional electromagnetic stimulation (HIFEM) treatment group|Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists. Additionally, Participants will also receive HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.
62537820|NCT06450795|EXPERIMENTAL|Pelvic floor muscle training group|Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.
62537821|NCT01197144|ACTIVE_COMPARATOR|Adalimumab|Treatment with adalimumab 40 mg sc eow for 4 weeks
62537822|NCT01197144|PLACEBO_COMPARATOR|Placebo|Treatment with placebo s c eow for 4 weeks
62537823|NCT01197144|NO_INTERVENTION|Healthy Controls|"Healthy volunteers, age ≥18. Will perform all the same pain assessments, blood sampling and baseline fMRI as RA patients~Exclusion criteria:~For fMRI - left handedness and all forms of metallic implants.~* Fulfilling ACR criteria for fibromyalgia.~* Severe ischemic heart disease.~* Concurrent treatment for depression/anxiety with antidepressant drugs.~* Concurrent neurological disease.~* Other reason as evaluated by the P.I."
62537824|NCT02465268|EXPERIMENTAL|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
62537825|NCT02465268|EXPERIMENTAL|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
62537826|NCT02465268|PLACEBO_COMPARATOR|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
62537827|NCT06550258|EXPERIMENTAL|Hippotherapy group|Hippotherapy was applied with a physiotherapist for 2 months.
62537828|NCT06550258|ACTIVE_COMPARATOR|Control group|Classical physiotherapy was applied with the help of a physiotherapist for 2 months.
62537829|NCT06633068|PLACEBO_COMPARATOR|Group (C) control group|Patients will receive bilateral superficial cervical plexus block with 28 ml bupivacine 0.25% mixed with 2 ml saline 0.9%, to a volume of 30 ml, 15 ml on each side of the neck before induction of general anaesthesia.
62537830|NCT06633068|ACTIVE_COMPARATOR|Group (N) Perineural Nalbuphine|Patients will receive bilateral superficial cervical plexus block with 28 ml Bupivacaine 0.25% mixed with 10 mg nalbuphine in saline 0.9% to a volume of 30 ml, 15 ml on each side of the neck before induction of general anaesthesia.
62537831|NCT02598947|EXPERIMENTAL|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
62537832|NCT02598947|SHAM_COMPARATOR|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
62537833|NCT03545230|EXPERIMENTAL|"children who recieved Four Not Techniques surgery"|":Four Not Techniques"
62537834|NCT03792295|EXPERIMENTAL|Multimodal Therapy|Patients will receive scheduled ibuprofen 400mg po q 4 hours and acetominophen 1gram po q 8 hours during the post operative phase and oxycodone 5mg po q 4 to 6 hours as needed for pain control.
62537835|NCT03792295|ACTIVE_COMPARATOR|Classic/standard opiod Therapy|Patients will receive oxycodone 5mg po q 4 to 6 hours as needed during their post operative phase for pain control.
62537836|NCT04317118||Neurodevelopmental|Individuals between 8 and 17 years old with neurodevelopmental disorders
62537837|NCT01884337|EXPERIMENTAL|Apixaban (2.5 mg)|Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
62537838|NCT00245830|NO_INTERVENTION|No Hepatic Ischemic Preconditioning|donor will act as a sham control.
62537839|NCT00245830|EXPERIMENTAL|Hepatic Ischemic Preconditioning|blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
62537840|NCT05580965|NO_INTERVENTION|control group|Routine procedure
62537841|NCT05580965|EXPERIMENTAL|Group A|1 min pressure applied
62537842|NCT05580965|EXPERIMENTAL|Group B|3 min pressure applied
62164297|NCT05579444||Duodenal ulcers|Participants with duodenal ulcers.
62164298|NCT05579444||Intestinal metaplasia|Participants with intestinal metaplasia (risk factor for esophageal cancer).
62164299|NCT05579444||Gastric Cancer|Participants with gastric cancer.
62164300|NCT05579444||Lymphocytic/Microscopic Colitis|Participants with Lymphocytic/Microscopic Colitis.
62164301|NCT05579444||Celiac Sprue|Participants with Celiac Sprue.
62164302|NCT05579444||Irritable Bowel Syndrome (IBS)|Participants with IBS.
62164303|NCT05579444||Small intestinal bacterial overgrowth (SIBO)|Participants with SIBO.
62164304|NCT05579444||Non-alcoholic Fatty Liver Disease (NAFLD)|Participants with NAFLD.
62537843|NCT05580965|EXPERIMENTAL|Group C|5 min pressure applied
62537844|NCT05545384|EXPERIMENTAL|Immediate Azathioprine (1st attack)|"Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
62537845|NCT05545384|EXPERIMENTAL|Immediate Rituximab (1st attack)|"Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
62537846|NCT05545384|ACTIVE_COMPARATOR|Standard Care: delayed treatment (2nd attack)|"Patients will be treated according to standard of care after their 1st attack. In case of relapse:~* before 3 months, IV methylprednisolone (30 mg/kg/j not exceeding 1g/day) will be administered for 3 days. There won't be any change of the initial treatment which will be pursued.~* after 3 months, IV methylprednisolone (30 mg/kg/j not exceeding 1g/day) will be administered for 3 days with an oral relay of prednisolone (1mg/kg/day not exceeding 60 mg/day) during 3 months with then a slowly tapered dose (reduction of 25% every week for 4 weeks). Azathioprine or Rituximab might be proposed as per local clinician experience"
62537847|NCT04835623|EXPERIMENTAL|Cyclosporine|Participants receive Cyclosporine 0.09% Ophthalmic Solution (Cequa), 1 drop, each eye, twice a day for 12 weeks
62164305|NCT05579444||Gallstone disease|Participants with Gallstone disease.
62164306|NCT00788632|EXPERIMENTAL|educational materials|Patient educational DVD and brochure
62537848|NCT03813953|EXPERIMENTAL|Local Anaesthetic Wound Infiltration|Wound catheter delivering local anaesthetic for 48 hours post-operatively following liver resection
62537849|NCT03813953|ACTIVE_COMPARATOR|Epidural|Conventional practice following liver resection
62537850|NCT04096755||DVT group|40 patients with a confirmed deep venous thrombosis (DVT) on Duplex ultrasound will be recruited into this group. All patients will have serum and urine samples for analysis.
62537851|NCT04096755||Control Group|40 volunteers without a DVT will be recruited for the control group. They will have urine and serum samples taken for analysis.
62537852|NCT01560650|EXPERIMENTAL|high dose (35ml/kg/h)|\> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 35 mL/kg/h.
62537853|NCT01560650|EXPERIMENTAL|low dose (25ml/kg/h)|\> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 25 mL/kg/h.
62537854|NCT00960635|ACTIVE_COMPARATOR|calcitriol|
62537855|NCT00960635|PLACEBO_COMPARATOR|pill without agent|
62537856|NCT01189487|EXPERIMENTAL|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV
62537857|NCT05351671|EXPERIMENTAL|Arm A|RLS-0071 lower dose group
62537858|NCT05351671|EXPERIMENTAL|Arm B|RLS-0071 higher dose group
62537859|NCT05351671|PLACEBO_COMPARATOR|Arm C|Placebo group
62537860|NCT03805711|EXPERIMENTAL|Aortic Valve Replacement with HLT® Transcatheter System|Replacement of aortic valve using the HLT® Transcatheter System (HLT System) comprised of The Meridian® II Valve with TriVent™ Anticalcification Treatment and The Pathfinder® II Delivery System
62164307|NCT00788632|OTHER|physician education|Physician web modules
62537861|NCT02106897|EXPERIMENTAL|Part 1, Cohort 1: BIIB059 0.05 mg/kg IV|BIIB059 0.05 mg/kg IV dose, Once on Day 1
62537862|NCT02106897|EXPERIMENTAL|Part 1, Cohort 2: BIIB059 0.3 mg/kg IV|BIIB059 0.3 mg/kg IV dose, Once on Day 1
62537863|NCT02106897|EXPERIMENTAL|Part 1, Cohort 3: BIIB059 1 mg/kg IV|BIIB059 1 mg/kg IV dose, Once on Day 1
62537864|NCT02106897|EXPERIMENTAL|Part 1, Cohort 4: BIIB059 3 mg/kg IV|BIIB059 3 mg/kg IV dose, Once on Day 1
62537865|NCT02106897|EXPERIMENTAL|Part 1, Cohort 5: BIIB059 10 mg/kg IV|BIIB059 10 mg/kg IV dose, Once on Day 1
62537866|NCT02106897|EXPERIMENTAL|Part 1, Cohort 6: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
62537867|NCT02106897|EXPERIMENTAL|Part 1, Cohort 7: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Once on Day 1
62537868|NCT02106897|PLACEBO_COMPARATOR|Part 1, Cohort 1-6: Placebo IV|Matching placebo IV dose, Once on Day 1
62164308|NCT00788632|EXPERIMENTAL|System intervention|Self-referral letter with toll-free number provided
62164309|NCT02899676|EXPERIMENTAL|Healthy subjects aged 18 to 24|Subjects without neurological or psychiatric history
62164310|NCT02899676|EXPERIMENTAL|Healthy subjects aged 8 to 11|Subjects without neurological or psychiatric history
62164311|NCT02899676|EXPERIMENTAL|Healthy subjects aged 12 to 14|Subjects without neurological or psychiatric history
62164312|NCT01219153|EXPERIMENTAL|Extended high dose letrozole regimen /GnRH antagonist|
62164313|NCT01219153|ACTIVE_COMPARATOR|Short low dose letrozole regimen /GnRH antagonist|
62537869|NCT02106897|PLACEBO_COMPARATOR|Part 1, Cohort 7: Placebo SC|Matching placebo SC dose, Once on Day 1
62537870|NCT02106897|EXPERIMENTAL|Part 2, Cohort 8: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
62537871|NCT02106897|PLACEBO_COMPARATOR|Part 2, Cohort 8: Placebo IV|Matching placebo IV dose, Once on Day 1
62537872|NCT02106897|EXPERIMENTAL|Part 3a, Cohort 9: BIIB059 20 mg SC|BIIB059 20 mg SC dose, Every 4 weeks for 2 doses
62537873|NCT02106897|EXPERIMENTAL|Part 3a, Cohort 10: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
62537874|NCT02106897|EXPERIMENTAL|Part 3a, Cohort 11: BIIB059 150 mg SC|BIIB059 150 mg SC dose, Every 4 weeks for 2 doses
62537875|NCT02106897|EXPERIMENTAL|Part 3a, Cohort 12: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
62537876|NCT02106897|PLACEBO_COMPARATOR|Part 3a, Cohort 9-12: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
62537877|NCT02106897|EXPERIMENTAL|Part 3b, Cohort 13: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
62537878|NCT02106897|EXPERIMENTAL|Part 3b, Cohort 14: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
62537879|NCT02106897|PLACEBO_COMPARATOR|Part 3b, Cohort 13-14: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
62537880|NCT04434300|OTHER|Dapto SC-IV|"First stage :~* Subcutaneous injection of daptomycin 10mg/kg~* Subcutaneous injection of placebo (physiological serum)~Second stage :~- Intravenous injection of daptomycin 10mg/kg"
62537881|NCT04434300|OTHER|Dapto IV-SC|"First stage :~- Intravenous injection of daptomycin 10mg/kg~Second stage :~* Subcutaneous injection of daptomycin 10mg/kg~* Subcutaneous injection of placebo (physiological serum)"
62537882|NCT04831463|EXPERIMENTAL|experimental group|The experimental (N = 49) received a short-term IHAPIM program by one-on-one interview (5 week, 1 hr per week, 10 hr in total).
62537883|NCT04831463|NO_INTERVENTION|control group|Firstly, Pre-tests were applied to the men in the control group. No intervention was applied to this group. Post-tests were made 3 months after finished intervention which applied to experimental group.
62537884|NCT01004653|EXPERIMENTAL|H1N1 influenza A Vaccine (Split virion), Inactivated|15 μg H1N1 influenza A Vaccine (Split virion), Inactivated
62537885|NCT01939574|EXPERIMENTAL|Chemoradiation & Adjuvant Therapy:|"* Concurrent chemoradiation Therapy:~  * Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~ * Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~ * Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.~* Adjuvant Therapy:~  * Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events\> grade 2 are noted.~ * Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg."
62537886|NCT05377892|EXPERIMENTAL|Intervention|Subjects receiving high protein followed by reduced protein diet
62537887|NCT04123561|EXPERIMENTAL|TLC599|TLC599 (1mL) IA injection
62537888|NCT04123561|ACTIVE_COMPARATOR|Dexamethasone sodium phosphate|DSP 4mg (1mL) IA injection
62537889|NCT04123561|PLACEBO_COMPARATOR|Normal Saline|Normal saline (1mL) IA injection
62537890|NCT01555671|ACTIVE_COMPARATOR|meperidine administration group|Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
62537891|NCT01555671|PLACEBO_COMPARATOR|plasebo group|Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
62537892|NCT02887456|ACTIVE_COMPARATOR|Vitapex|Endodontic treatment using Vitapex
62537893|NCT02887456|EXPERIMENTAL|MTA paste|Endodontic treatment using MTA paste
62537894|NCT01997216|OTHER|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
62537895|NCT01997216|OTHER|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
62537896|NCT03426163|EXPERIMENTAL|VR group|Application of virtual reality 12 hours before arthroscopic surgery
62537897|NCT03426163|NO_INTERVENTION|Non-VR group|Application of knee MRI 12 hours before arthroscopic surgery
62537898|NCT04440670|EXPERIMENTAL|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after birth. Cell dose for all patients was targeted at 5×107 cells per kilogram.
62537899|NCT04440670|PLACEBO_COMPARATOR|control group|Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume.
62537900|NCT06076083||ankylosing spondylitis patients|Ankylosing spondylitis Cohort consists of individuals aged 19 to 60 who, at the time of providing consent, have received a diagnosis of ankylosing spondylitis in accordance with the Modified New York criteria and meet the 2010 diagnosis of spondyloarthritis. These individuals have voluntarily chosen to participate in the study, having fully comprehended its details, and have agreed to adhere to the required precautions.
62537901|NCT06076083||ankylosing spondylitis patients their families|Those who are between the ages of 19 and 65 A primary immediate family member (parent/brother/sister) who is related to the patient and has never developed ankylosing spondylitis, and who lives with the patient 3) Those who, after listening to the explanation of this study and fully understanding it, voluntarily decided to participate and agreed to comply with the precautions
62537902|NCT06075953|ACTIVE_COMPARATOR|chemoprevention therapy per investigator choice|a. For premenopausal women: 20 mg or 5 mg tamoxifen orally b. for postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3 times per week orally i. For postmenopausal women who are not tolerating an AI, low dose (5 mg) or standard dose (20 mg) of tamoxifen There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years.
62537903|NCT06075953|EXPERIMENTAL|Testosterone + Anastrazole (T+Ai)|White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.
62537904|NCT06075953|EXPERIMENTAL|Elacestrant|Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years.
62537905|NCT06075953|EXPERIMENTAL|Endoxifen|(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.
62537906|NCT01073137||Diabetic Subjects|
62537907|NCT01073137||Non diabetic subjects|
62537908|NCT04516759|EXPERIMENTAL|AZD1656 (plus Usual Hospital Care)|50mg film-coated tablets at a dose of 100mg BID
62537909|NCT04516759|PLACEBO_COMPARATOR|Matched Placebo (plus Usual Hospital Care)|Matched placebo tablets
62537910|NCT02068235|EXPERIMENTAL|Pilot Phase|Subjects will receive a single intravenous (i.v.) dose of 5 mg ponesimod dissolved in 50 mL sterile 0.9% sodium chloride (NaCl) solution as a 3-hour infusion in the fasted state in the morning (infusion rate: 0.028 mg/min).
62537911|NCT02068235|EXPERIMENTAL|Treatment A/Treatment B|"Subjects will receive Treatment A followed by Treatment B.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
62537912|NCT02068235|EXPERIMENTAL|Treatment B/Treatment A|"Subjects will receive Treatment B followed by Treatment A.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
62537913|NCT01685840|EXPERIMENTAL|Usual Care|Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
62537914|NCT01685840|EXPERIMENTAL|Biomarker-Guided Care|Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
62537915|NCT06111352|EXPERIMENTAL|Group A|"Patients will be treated with Atropine plus pralidoxime~Pralidoxime: Dosage:1gram; Dosage form: Intravenous infusion; Frequency: 8 hourly~Atropine:"
62537916|NCT06111352|OTHER|Group B|Patients will be treated with only atropine
62537917|NCT03414086||Myositis in Remission|Subjects who are in remission with their myositis diagnosis.
62537918|NCT03414086||Healthy Controls|Subjects who do not have a myositis diagnosis.
62537919|NCT01400802|EXPERIMENTAL|Listro Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Listro Mix75/25®; 100 U/mL), DispoPen 3.0 mL.
62537920|NCT01400802|ACTIVE_COMPARATOR|Humalog Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Humalog® Mix75/25TM; 100 U/mL), Humalog Mix 75/25® Kwik PenTM 3.0 mL.
62537921|NCT00846534||Post operative atrial fibrillation|To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.
62537922|NCT00080873|EXPERIMENTAL|Receive Traumeel S|
62537923|NCT00080873|PLACEBO_COMPARATOR|Receive placebo|
62537924|NCT02422589|EXPERIMENTAL|Ceritinib|
62537925|NCT01711892|ACTIVE_COMPARATOR|Soccer Training|12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
62537926|NCT01711892|NO_INTERVENTION|Control group|Usual care
62537927|NCT03021863|ACTIVE_COMPARATOR|Group A Reminder|Tone of reminder email (duty 14 days followed by duty for non-responders 28 days)
62537928|NCT03021863|ACTIVE_COMPARATOR|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement for non-responders 28 days)
62537929|NCT03021863|ACTIVE_COMPARATOR|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
62537930|NCT03021863|ACTIVE_COMPARATOR|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
62537931|NCT03021863|ACTIVE_COMPARATOR|Group E Reminder|Tone of reminder email (generic reminders at 14 days followed by generic for non-responders 28 days)
62537932|NCT03021863|ACTIVE_COMPARATOR|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
62537933|NCT03021863|ACTIVE_COMPARATOR|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
62537934|NCT03021863|ACTIVE_COMPARATOR|Group H Reminder|Tone of reminder email (duty 14 days followed by generic for non-responders 28 days)
62537935|NCT03021863|ACTIVE_COMPARATOR|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic for non-responders 28 days)
62537936|NCT06273267||Patients|AP-HP patients followed by the pediatric palliative care teams of Ile de France (metropolitan area of Paris) between January 2020 and December 2022 and suffering from a serious non-progressive neurological disease.
62537937|NCT04801381|ACTIVE_COMPARATOR|Aquablation therapy|Aquablation therapy: Computer-assisted transurethral ablation of prostate tissue using a high-pressure water jet. Subsequent removal of residual ablated tissue at the bladder neck and haemostasis by transurethral electroresection (TUR).
62537938|NCT04801381|ACTIVE_COMPARATOR|Transurethral laser enucleation|Transurethral laser enucleation of the prostate using thulium laser (ThuLEP) or holmium laser (HoLEP).
62537939|NCT04429347|EXPERIMENTAL|Tizanidine 2mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
62537940|NCT04429347|EXPERIMENTAL|Gabapentin 300mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
62537941|NCT04429347|PLACEBO_COMPARATOR|Placebo|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
62714700|NCT05661552|EXPERIMENTAL|Evolocumab treatment group|The experimental group will receive Rosuvastatin 5 mg, Ezetimibe 10 mg, and evolocumab by subcutaneous injection. Evolocuumab will be administered at a dose of 140 mg once during the study period.
62537942|NCT04880863|EXPERIMENTAL|NAP in combination with docetaxel following obinutuzumab pretreatment|Subjects will receive obinutuzumab, 1,000 mg, administered by IV infusion on Days -13 and -12 of the first treatment cycle in order to reduce the titer of anti-drug antibodies to NAP. NAP will be administered in a daily dose of 10 μg/kg by IV bolus on Days 1 - 4 of treatment cycles 1-6, followed by docetaxel, 75 mg/m2 on Day 5. Treatment cycles with the combination NAP/docetaxel will be 21 days in duration. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1 and docetaxel on Day 2, in 21 days treatment cycles. Once NAP is given as monotherapy and not earlier than C7, cycles will be of 28 days of duration.
62537943|NCT02361242|EXPERIMENTAL|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate and 1 white capsule containing 6 mg of baclofen are taken orally b.i.d during 24 weeks.
62537944|NCT02361242|EXPERIMENTAL|PXT00864 Dose 2|1 orange capsule containing 1 mg of acamprosate and 1 white capsule containing 15 mg of baclofen are taken orally b.i.d during 24 weeks.
62537945|NCT02361242|EXPERIMENTAL|PXT00864 Dose 3|1 orange capsule containing 20 mg of acamprosate and 1 white capsule containing 12 mg of baclofen are taken orally b.i.d during 24 weeks.
62537946|NCT00143923|ACTIVE_COMPARATOR|1|Intervention: 6 months of individualized advice regarding Nutrition, Exercise, Stress Management Counseling for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 1
62537947|NCT00143923|PLACEBO_COMPARATOR|2|Intervenition: 6 months of Usual care for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 2. No active Nutrition, Exercise, Stress Management Counseling
62537948|NCT00143923|NO_INTERVENTION|3|No intervention for all participants who are at low Framingham risk for CVD or have preexisting CVD prior to study entry/ No active Nutrition, Exercise, Stress Management Counseling
62537949|NCT03302026|EXPERIMENTAL|Real-time neurofeedback training group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
62537950|NCT03302026|NO_INTERVENTION|No-feedback control group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
62537951|NCT01056315|EXPERIMENTAL|A GRT3983Y|Participants randomly assigned to receive GRT3983Y.
62537952|NCT01056315|PLACEBO_COMPARATOR|B Placebo|Participants randomly assigned to placebo.
62537953|NCT05811897|EXPERIMENTAL|Self-Managed Online Treatment|Participants manage their treatment online without the assistance of a therapist.
62537954|NCT05811897|ACTIVE_COMPARATOR|Therapist-Assisted Online Treatment|Participant will be assisted through the process by a therapist who will provide support and encouragement for 15-20 minutes of contact per week for the duration of the treatment. Supportive contacts are not psychotherapy. They are intended to answer questions about the content of the platform, to review adherence to the exercises and to provide encouragement; they also allow for the rapid identification and referral of participants in case of need (e.g., suicidal crisis).
62537955|NCT03781037|EXPERIMENTAL|GIVE module|The GIVE module consists of one 50-minute treatment session and a second partial session (15-20 minutes) embedded within a larger cognitive behavioral treatment (CBT) protocol for anxiety or depression. The GIVE module uses cognitive behavioral principles to target youth's beliefs that they are a burden or drain on others.
62537956|NCT00787059|EXPERIMENTAL|Ad5.hAC6|Will receive intracoronary adenovirus encoding human adenylyl cyclase type 6
62537957|NCT00787059|PLACEBO_COMPARATOR|sucrose solution|Will receive intracoronary sucrose solution
62537958|NCT06174597|EXPERIMENTAL|UCA-PSCs/bFGF group|Clusters of umbilical cord artery-derived perivascular stem cells (Dose: 1.2 x 10\^8 cells+20ng bFGF /20mL/vial)
62537959|NCT06174597|ACTIVE_COMPARATOR|bFGF group|(Dose: 20ng bFGF /20 mL/vial)
62537960|NCT04297033|EXPERIMENTAL|Lovastatin intervention|combination of 40mg/d 12m lovastatin and symptomatic treatment drugs as a treatment strategy for BAVM .
62537961|NCT04297033|PLACEBO_COMPARATOR|placebo|combination of placebo and symptomatic treatment drugs as a treatment strategy for BAVM
62537962|NCT01635218|EXPERIMENTAL|Individualized homeopathic treatment|Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
62537963|NCT01635218|EXPERIMENTAL|Fluoxetine|Selective serotonin reuptake inhibitor.
62537964|NCT01635218|PLACEBO_COMPARATOR|Placebo|Fluoxetine placebo plus individualized homeopathic placebo
62537965|NCT06453252||ICAD group|includes ICAD-related stroke made when a smooth-bordered lesions leading to delayed perfusion on conventional-angiography (without competing stroke etiology) or when irregular-surfaced lesions involving the target vessel during mechanical thrombectomy were unveiled (with or without competing stroke etiology).
62537966|NCT06453252||Non-ICAD cases (controls)|Non-ICAD cases (controls) includes patients with posterior circulation stroke attributed to stroke etiologies other than ICAD.
62537967|NCT05055583|EXPERIMENTAL|Toripalimab in Combination With Platinum-based Chemotherapy|Participants receive totally 3-4 cycles of toripalimab combined with platinum-based chemotherapy neoadjuvant treatment during preoperative period. After the last treatment (Day 21 of Cycle 4), surgery will be performed within 4-6 weeks. Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention was to receive maintenance therapy within 6-12 weeks of the MDT assessment.
62537968|NCT02553759|EXPERIMENTAL|Effective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement to each side, first 10 times towards the right and then 10 times towards the left. The movement will be performed effectively over the entire course of the cervical path, approximately 80º
62537969|NCT02553759|ACTIVE_COMPARATOR|Ineffective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement ineffectively, without achieving the maximum cervical travel, performing approximately 40º. First, 10 movements towards the right will be performed and then 10 towards the left
62537970|NCT01028924|EXPERIMENTAL|Teduglutide 5 mg|Treatment A, subcutaneous injection
62537971|NCT01028924|EXPERIMENTAL|Teduglutide 20 mg|Treatment B, subcutaneous injection
62537972|NCT01028924|PLACEBO_COMPARATOR|Placebo|subcutaneous injection
62537973|NCT01028924|ACTIVE_COMPARATOR|Moxifloxacin|400 mg, oral
62537974|NCT04061525||Patients with coronary bifurcation lesions|Patients from 18 to 90-years old with coronary bifurcation lesions with significant \>50% diameter stenosis artery scheduled for intervention of the main vessel (Medina types: 1x1, x11, 111)
62537975|NCT05026996|EXPERIMENTAL|Mild hepatic impairment patients|Participants with mild hepatic impairment
62537976|NCT05026996|EXPERIMENTAL|Healthy participants|Matched healthy participants with normal hepatic function
62537977|NCT01655576|NO_INTERVENTION|Routine clamping|After delivery of the newborn, umbilical cord at mothers end, will be left clamped until delivery of the placenta.
62537978|NCT01655576|EXPERIMENTAL|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
62537979|NCT05794360|EXPERIMENTAL|ACCELERATION|Both study arms occurred during participants' PE class, once a week for 45 minutes for 10 weeks. The ACCELERATION curriculum is designed to improve children's MVPA through learning and practicing new and challenging sport skills in a fun and free-will learning environment that includes not only school but also home environment. The ACCELERATION focuses on introducing the ball to the child at a basic level. Ball mastery is a soccer term that simply refers to the ability to manipulate and play with the ball using all parts of the foot. Since this program was an individual pursuit, not a team endeavor, it was imperative that each student has their own ball during the PE class. The trained undergraduate interns assisted PE teachers to deliver this program to classrooms assigned into the treatment arm. The program trains parents via virtual workshops on delivering the program at home.
62537980|NCT05794360|NO_INTERVENTION|Standard PE|Classrooms assigned to the control group received a 45-minute weekly regular PE curriculum for 10 weeks designed to meet state-mandated requirements. For the same research school, a standard PE curriculum was also delivered by the same PE teacher who delivered the intervention curriculum. However, additional training and support were not provided to PE teachers for the implementation of a regular PE curriculum.
62537981|NCT03881423|ACTIVE_COMPARATOR|Deep block|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
62537982|NCT03881423|ACTIVE_COMPARATOR|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
62537983|NCT00788138|EXPERIMENTAL|1|Vitamin D3 250,000 PO Once
62537984|NCT00788138|PLACEBO_COMPARATOR|2|Matching Placebo
62537985|NCT04988087|EXPERIMENTAL|SjS participants: MHV370|SjS participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
62537986|NCT04988087|PLACEBO_COMPARATOR|SjS participants: Placebo|SjS participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
62537987|NCT04988087|EXPERIMENTAL|MCTD participants: MHV370|MCTD participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
62537988|NCT04988087|PLACEBO_COMPARATOR|MCTD participants: Placebo|MCTD participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
62537989|NCT03357653|EXPERIMENTAL|Losartan group|Losartan 50 mg daily
62537990|NCT03357653|PLACEBO_COMPARATOR|Placebo group|Placebo 1 pill daily which has same size, color and taste with losartan
62537991|NCT05323279|EXPERIMENTAL|novices with AI-assisted system|The novice doctors are assisted in colonoscopy with an artificial intelligence system that can indicate abnormal lesions and the speed of withdrawal in real-time, as well as feedback on the percentage of overspeed.
62537992|NCT05323279|NO_INTERVENTION|experts without AI-assisted system|The expert doctors perform routine colonoscopy without artificial intelligence assistance system and no special tips
62537993|NCT05323279|NO_INTERVENTION|novice without AI-assisted system|The novice doctors perform routine colonoscopy without artificial intelligence assistance system and no special tips
62537994|NCT03457935||Non-IPF ILD|non-IPF ILD diagnosis
62537995|NCT03457935||IPF|Naive patients with no IPF treatment
62537996|NCT03457935||Control|no lung diseases
62537997|NCT05739279||Lipedema Group|Patients between the ages of 18-85, diagnosed with lipedema, accepted to participate in the study, and at the appropriate sociocultural level to participate in the study are included in this group.
62537998|NCT05739279||Control Group|Those between the ages of 18-85, in an age group similar to the lipoedema group, who agreed to participate in the study, and who were at the appropriate sociocultural level to participate in the study are included in this group.
62537999|NCT02572245|ACTIVE_COMPARATOR|PF-06410293 PFS (Prefilled Syringe)|PF-06410293 40 mg administered by Prefilled Syringe (PFS)
62538000|NCT02572245|ACTIVE_COMPARATOR|PF-06410293 PFP (Prefilled Pen)|PF-06410293 40 mg administered by Prefilled pen
62538001|NCT03581409|EXPERIMENTAL|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg \& prasugrel 5mg) treatment continued for 3 months through study completion.
62714701|NCT05661552|ACTIVE_COMPARATOR|Group not receiving evolocumab|The control group receives Rosuvastatin 5 mg and Ezetimibe 10 mg.
62714702|NCT04947722|EXPERIMENTAL|PREVENT Program|
62714703|NCT04947722|NO_INTERVENTION|Control Group|Residents in homes allocated to the control group will receive usual care as provided within their home.
62538002|NCT03581409|EXPERIMENTAL|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
62538003|NCT06462560|EXPERIMENTAL|Vivo Online Exercise program|
62538004|NCT06462560|ACTIVE_COMPARATOR|Medbridge Home Exercise Program|
62538005|NCT00465465|ACTIVE_COMPARATOR|1|Dose of 1 x 10\^7
62538006|NCT00465465|ACTIVE_COMPARATOR|2|Dose of 1 x 10\^8
62538007|NCT06632977|EXPERIMENTAL|Arm A (genetic testing, valemetostat tosylate)|Patients undergo genetic testing on previously-collected tissue samples. Patients receive valemetostat tosylate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and bone scan throughout the trial. Patients may also undergo optional FDG or PSMA PET, as well as optional blood collection throughout the trial.
62538008|NCT06632977|EXPERIMENTAL|Arm B (genetic testing, carboplatin, cabazitaxel)|Patients undergo genetic testing on previously-collected tissue samples. Patients receive carboplatin IV over 30 minutes and cabazitaxel IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and bone scan throughout the trial. Patients may also undergo optional FDG or PSMA PET, as well as optional blood collection throughout the trial.
62538009|NCT06632977|EXPERIMENTAL|Arm C (genetic testing, physician choice treatment)|Patients undergo genetic testing on previously-collected tissue. Patients receive one of the following treatment regimens per treating physician: 1)Cabazitaxel IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. 2)Abiraterone acetate PO QD on days 1-28 of each cycle and prednisone PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. 3) Enzalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. 4) Lutetium Lu 177 vipivotide tetraxetan IV on day 1 of each cycle. Treatment repeats every 42 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and bone scan throughout the trial. Patients may also undergo optional FDG or PSMA PET, as well as optional blood collection throughout the trial.
62538010|NCT01630577|EXPERIMENTAL|responder to fluid challenge|fluid challenge
62538011|NCT04416165|EXPERIMENTAL|Experimental: 68Ga-DOTA-FAPI-04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
62538012|NCT01543295||Known Positive Syphilis Infection|Individuals known to have a clinical diagnosis of Syphilis
62538013|NCT01543295||High Risk for Syphilis Infection|Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis.
62538014|NCT01543295||Pregnant Women (High Risk and Low Risk)|"1st or 3rd trimester from either High Risk (see description above) or Low Risk population.~Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc..."
62538015|NCT04126590|EXPERIMENTAL|KN044 0.03 mg/kg dose group|KN044 0.03 mg/kg dose group,once every 3 weeks，a total of four cycles
62538016|NCT04126590|EXPERIMENTAL|KN044 0.1 mg/kg dose group|KN044 0.1 mg/kg dose group,once every 3 weeks，a total of four cycles
62538017|NCT04126590|EXPERIMENTAL|KN044 0.3mg/kg dose group|KN044 0.3mg/kg dose group,once every 3 weeks，a total of four cycles
62538018|NCT04126590|EXPERIMENTAL|KN044 1 mg/kg dose group|KN044 1 mg/kg dose group,once every 3 weeks，a total of four cycles
62538019|NCT04126590|EXPERIMENTAL|KN044 3 mg/kg dose group|KN044 3 mg/kg dose group,once every 3 weeks，a total of four cycles
62538020|NCT04126590|EXPERIMENTAL|KN044 6mg/kg dose group|KN044 6mg/kg dose group,once every 3 weeks，a total of four cycles
62538021|NCT04126590|EXPERIMENTAL|KN044 10mg/kg dose group|KN044 10mg/kg dose group,once every 3 weeks，a total of four cycles
62538022|NCT05444530|EXPERIMENTAL|Dose Escalation|Participants with essential thrombocythemia (ET) and myelofibrosis (MF) will receive VAC85135 target dose intramuscular (IM) injection in the safety lead-in cohort (Cohort 0). Participants in subsequent cohorts will receive VAC85135 target dose IM injection along with ipilimumab intravenous (IV) infusion. Ipilimumab dose may be escalated based on dose limiting toxicity (DLT) observations.
62538023|NCT05444530|EXPERIMENTAL|Dose Expansion|Participants with polycythemia vera (PV) or post-polycythemia vera myelofibrosis, ET and MF will receive VAC85135 target dose IM injection with ipilimumab IV infusion at the dose(s) determined by study evaluation team (SET).
62538024|NCT05603312|EXPERIMENTAL|AAV-GAD Dose 1 treatment group|Eligible participants will receive bilateral infusion of AAV-GAD Dose 1 into the STN
62538025|NCT05603312|EXPERIMENTAL|AAV-GAD Dose 2 treatment group|Eligible participants will receive bilateral infusion of AAV-GAD Dose 2 into the STN
62538026|NCT05603312|SHAM_COMPARATOR|Sham treatment group|Eligible participants will undergo a sham surgical procedure
62538027|NCT05297578|EXPERIMENTAL|VAX-24 Low Dose|Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.
62538028|NCT05297578|EXPERIMENTAL|VAX-24 Mid Dose|Participants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1.
62538029|NCT05297578|EXPERIMENTAL|VAX-24 Mixed Dose|Participants will receive a single dose of VAX-24 2.2 mcg/4.4 mcg administered as an intramuscular injection on Day 1.
62538030|NCT05297578|ACTIVE_COMPARATOR|PCV20|Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
62538031|NCT02754856|EXPERIMENTAL|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.
62538032|NCT02665845|EXPERIMENTAL|5-ASA group|Patients will receive corticosteroids with optimized 5-ASA.
62538033|NCT02665845|ACTIVE_COMPARATOR|Control group|Patients will receive corticosteroids alone.
62538034|NCT03621501|PLACEBO_COMPARATOR|Staged complete revascularization|• Culprit only + staged (within six weeks after index procedure) complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Control arm)
62538035|NCT03621501|ACTIVE_COMPARATOR|Immediate complete revascularization|• Immediate complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Experimental arm)
62538036|NCT05346926|EXPERIMENTAL|3D-printed cast|Treatment of distal radius fracture with 3D-printed forearm cast.
62538037|NCT05346926|ACTIVE_COMPARATOR|Conventional cast|Treatment of distal radius fracture with conventional plaster cast.
62538038|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
62538039|NCT04297319|EXPERIMENTAL|1 - Laser intervention|Laser diiodo treatment, 3 procedures of 5-10 minutes at intervals of 4 weeks
62538040|NCT04297319|PLACEBO_COMPARATOR|2 - Laser placebo|Only the laser speculum is placed in the vagina but the laser is not activated. 3 procedures of 5-10 minutes at intervals of 4 weeks
62538041|NCT04312516||Controls|Participants scheduled for surgery with MoCA score ≥ 26 preoperatively
62538042|NCT04312516||Patients|Participants scheduled for surgery with MoCA score \< 26 preoperatively
62538043|NCT00103610|EXPERIMENTAL|G-CSF plus plerixafor|
62538044|NCT00103610|PLACEBO_COMPARATOR|G-CSF plus placebo|
62538045|NCT02521376|EXPERIMENTAL|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
62538046|NCT02521376|EXPERIMENTAL|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
62538047|NCT02521376|EXPERIMENTAL|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
62538048|NCT01917981|EXPERIMENTAL|Personal Heart Rhythm Monitor|Intermittent cardiac monitoring with a Personal Heart Rhythm Monitor for three months.
62538049|NCT06041152|EXPERIMENTAL|Amnestic Mild Cognitive Impairment Participants Receiving Psilocybin|Receiving 2 doses of 25mg of psilocybin separated by 1 week.
62538050|NCT06041152|EXPERIMENTAL|Healthy Participants Receiving Psilocybin|Receiving 2 doses of 25mg of psilocybin separated by 1 week.
62538051|NCT06041152|PLACEBO_COMPARATOR|Amnestic Mild Cognitive Impairment Participants Receiving Placebo|Receiving 2 doses of placebo separated by 1 week.
62538052|NCT06041152|PLACEBO_COMPARATOR|Healthy Participants Receiving Placebo|Receiving 2 doses of placebo separated by 1 week.
62538053|NCT04156958|OTHER|Fruquintinib Arm|Fruquintinib, 5 mg once daily for 21 days, followed by 7 days off (28 days/cycle) treatment until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
62538054|NCT02586246|EXPERIMENTAL|CDP870 group from Study 275-08-002|Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870
62538055|NCT02586246|EXPERIMENTAL|CDP870 group from Study 275-08-004|Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870
62538056|NCT06500624|NO_INTERVENTION|Control group|Each subject will be given 10-20mg Escitalopram with depressive disorder.
62538057|NCT06500624|EXPERIMENTAL|Treatment group|Each subject will be given 10-20mg of escitalopram with 0.5mg pizotifen with depressive disorder.
62538058|NCT04292665|EXPERIMENTAL|Classical Massage|Patients will receive a total of fourteen individual applied classical massage sessions, twice daily for seven days, each session lasting 30 minutes.
62538059|NCT04292665|EXPERIMENTAL|Relaxation|Patients will receive a total of fourteen individual counseling sessions, in a quiet room, twice daily for seven days, each session lasting 20 minutes.
62538060|NCT04292665|OTHER|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
62538061|NCT05043441|EXPERIMENTAL|Acceptance and commitment therapy (ACT) group|10 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
62538062|NCT05043441|SHAM_COMPARATOR|Psychoeducation control group|Care as usual with psychoeducation materials provided
62538063|NCT00737152|EXPERIMENTAL|1|All subjects will take RAS 130 administered orally in tablet form at a starting dose of 4 mg once a day or 2 mg tablets twice a day.
62538064|NCT05769257|EXPERIMENTAL|Single Arm|Single Arm Safety and Feasibility Study of IS-001 with 20 mg in Multiple Injections
62538065|NCT06628947|EXPERIMENTAL|50 μg KIO-301|50 μg KIO-301 or placebo administered by IVT injection bilaterally (OU) once every 6 weeks for 3 administrations per participant.
62538066|NCT06628947|EXPERIMENTAL|100 μg KIO-301|100 μg KIO-301 or placebo administered by IVT injection OU once every 6 weeks for 3 administrations per participant.
62538067|NCT01814553|EXPERIMENTAL|Afatinib 40 mg + Loperamide (Cohort 1)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
62538068|NCT01814553|EXPERIMENTAL|Afatinib 40 mg + loperamide prophylactic (Cohort 2)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
62538069|NCT03628625|EXPERIMENTAL|Study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
62538070|NCT03628625|PLACEBO_COMPARATOR|Control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
62714704|NCT02359903|EXPERIMENTAL|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
62714705|NCT02359903|ACTIVE_COMPARATOR|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
62538071|NCT02449096|OTHER|ORIF group|"No arthroscope ORIF = Open reduction and internal fixation~All Patients will be operated following a standardized protocol of our foot and ankle department:~Posterior malleolus: ORIF of the posterior malleolus fractures will be performed using a one-third tubular plate in an antiglide-technique.~Lateral malleolus: If the patients suffer a fracture of the posterior and lateral malleolus, a posterolateral approach will be performed. After posterior fracture fixation a lag screw and a one-third tubular plate will be used laterally. In special cases a locking plate will be used. If the patient only suffers a lateral malleolus fracture, we utilize the standard lateral incision.~Medial malleolus: We perform a curved incision and two cannulated leg screws/tension wiring or locking plate for fixation.~Syndesmotic complex: After all, the stability of the syndesmotic complex is tested and reduction will be performed if necessary."
62538072|NCT02449096|ACTIVE_COMPARATOR|AORIF group|Arthroscope AORIF = Arthroscopically assisted open reduction and internal fixation Our standard operative protocol is described above. Intervention: In case of randomization to the AORIF group, the arthroscopic procedure will be performed as the first step during the surgery before internal fixation. No distraction device will be used for the ankle. To avoid lesions of the cartilage and soft tissue, the joint will first be inflated with saline, and the portals will be created by blunt dissection. A 2.7mm, 30° arthroscope will be inserted into the ankle through a standard anteromedial portal. Fluid will be aspirated and the cavity filled with water. Afterwards the standard anterolateral portal will be performed in the same way. A standardized systematic examination as described by Ferkel and Fasulo will be performed to inspect the internal structures. At this stage loose bodies and disrupted ligaments extending into the joint will be removed.
62538073|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:~* 6 months to 1 year ago~* 1 year to 3 years ago~* 3 years ago or more"
62538074|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:~* 6 months to 1 year ago~* 1 year to 3 years ago~* 3 years ago or more"
62538075|NCT05645159|EXPERIMENTAL|Physiotherapy students|The participants performed an 8-week heart disease blended learning program.
62538076|NCT01103830|EXPERIMENTAL|Group 1|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal."
62538077|NCT01103830|ACTIVE_COMPARATOR|Group 2|"4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.~Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal."
62538078|NCT01103830|OTHER|Group 3|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
62538079|NCT01103830|EXPERIMENTAL|Group 4|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal."
62538080|NCT01103830|EXPERIMENTAL|Group 5|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fasting condition."
62538081|NCT01103830|OTHER|Group 6|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fasting condition.~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
62538082|NCT04576923|EXPERIMENTAL|Velacur by Sonic Incytes|Patients with known or suspected Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) will be scanned with Velacur for assessment of liver fibrosis.
62538083|NCT02356432||NOACs group|Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.
62538084|NCT02356432||Warfarin group|Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.
62538085|NCT04956432|EXPERIMENTAL|Treatment group A|SHR4640+Allopurinol Placebo；once a day, orally, for 52 weeks
62538086|NCT04956432|ACTIVE_COMPARATOR|Treatment group B|Allopurinol+ SHR4640 Placebo；once a day, orally, for 52 weeks.
62538087|NCT04380090|ACTIVE_COMPARATOR|Drug: Docusate Sodium|Docusate sodium one pill to be taken twice a day by mouth for 28 days
62538088|NCT04380090|EXPERIMENTAL|Drug: Propylene Glycol|One standard dose (17 grams) of propylene glycol by mouth on postoperative day one
62538089|NCT05923463|EXPERIMENTAL|precision-enhanced feedback email messages|Providers receive an enhanced monthly email containing precision audit and feedback (A\&F).
62538090|NCT05923463|ACTIVE_COMPARATOR|standard feedback email messages|"Providers receive the standard one size fits most A\&F monthly email."
62538091|NCT01602718|NO_INTERVENTION|Physical Function/Activity|"cross-sectional comparison study of physical function/activity, frailty and inflammation measures in prevalent home Dx and prevalent in-center hemodialysis patients.~Subjects: Forty-five prevalent home dialysis patients will be recruited and tested once for all outcome measures. Forty-five prevalent in-center hemodialysis patients will be identified from prevalent patients in the University of Utah in-center dialysis system who are matched for gender, age, comorbidities and time on dialysis as the home dialysis patients who have been tested. Consenting patients will be tested for all outcome measures once and compared to the home dialysis group."
62538092|NCT01602718|NO_INTERVENTION|Incident Patients|"Study 2: is a longitudinal cohort study of incident patients starting either home dialysis or in-center hemodialysis.~Consenting patients will be tested upon initiation of dialysis therapy and every 6 months for 18 months to track physical functioning /activity, frailty and inflammation over time."
62538093|NCT01602718|OTHER|Independent Home Exercise|pilot study of independent home exercise training in home dialysis (PD only) patients. Consenting patients will be tested at baseline, then randomized into exercise training or usual care (no prescribed change in activity levels) and retested after 3 months.
62538094|NCT00753857|EXPERIMENTAL|1|Participants received 2 ads for drugs to reduce cardiovascular risk with drug facts boxes second pages.
62538095|NCT00753857|ACTIVE_COMPARATOR|2|Participants receive the same 2 advertisements for drugs to reduce cardiovascular risk with the standard second page (i.e., brief summary)
62538096|NCT00678886|EXPERIMENTAL|otelixizumab|otelixizumab
62538097|NCT00678886|PLACEBO_COMPARATOR|placebo|Placebo
62538098|NCT06552052||Cohort 1 (29 days - 6 years of age)|"1. Patient is between the ages of 29 days - 6 years old~2. Confirmed ACTA2 pathogenic variant~3. Available medical records since birth that permit documentation of disease characteristics and developmental milestone~4. Have two parents and/or legal guardians who are English speaking and are able to read, understand, and sign the informed consent~5. Able to tolerate travel to study site"
62538099|NCT06552052||Cohort 2 (7 - 18 years of age)|"1. Patient is between the ages of 7 - 18 years old~2. Confirmed ACTA2 pathogenic variant~3. Available medical records since birth that permit documentation of disease characteristics and developmental milestone~4. Have two parents and/or legal guardians who are English speaking and are able to read, understand, and sign the informed consent~5. Able to tolerate travel to study site"
62538100|NCT06552052||Cohort 3 (19 - 99 years of age)|"1. Patient is between the ages of 19 - 100 years old~2. Confirmed ACTA2 pathogenic variant~3. Available medical records since birth that permit documentation of disease characteristics and developmental milestone~4. Patient, parent and/or legal guardian is English speaking is able to read, understand, and sign the informed consent~5. Able to tolerate travel to study site"
62538101|NCT06552052||Cohort 4 (Retrospective - All Ages)|"1. Patient of any age, alive or deceased~2. Confirmed ACTA2 pathogenic variant~3. Available medical records since birth that permit documentation of disease characteristics and developmental milestone~4. Patient, parent and/or legal guardian is English speaking and able to read, understand, and sign the informed consent"
62538102|NCT00492024|EXPERIMENTAL|Moxifloxacin 400 mg|Moxifloxacin 400mg once daily for 5 days
62538103|NCT00492024|PLACEBO_COMPARATOR|Placebo|Matching placebo for 5 days
62538104|NCT06358235|EXPERIMENTAL|Music Therapy|The Patient Identification Form, Modified Borg Scale, Vital Signs Record Chart, and Blood Test Results Record Chart will be completed when the patient is first admitted to the ward. Music therapy intervention will be administered between 6:00 AM and 12:00 PM. Before the music therapy session, the patient will lie on their back at a 30-45 degree angle and rest for 5 minutes. The Modified Borg Scale and Vital Signs Record Chart will be completed just before the music therapy session begins. During the session, the patient will receive the music therapy intervention through headphones for 30 minutes. At the end of the 30-minute music session, the Modified Borg Scale and Vital Signs Record Chart will be completed again. Thirty minutes after the end of the music therapy intervention, the Modified Borg Scale and Vital Signs Record Chart will be completed once more.
62538105|NCT06358235|OTHER|No Music Therapy|When the patient is admitted to the ward, the Patient Identification Form, Modified Borg Scale, Vital Signs Record Chart, and Blood Test Results Record Chart will be completed. Music therapy will not be applied to this group; however, patients will be provided with headphones to maintain consistent conditions. When the patient is ready, between 6:00 AM and 12:00 PM, they will lie on their back at a 30-45 degree angle and rest for 5 minutes. The Modified Borg Scale and Vital Signs Record Chart will be completed just before the patient puts on the headphones. Once the session begins, the patient will quietly spend 30 minutes with headphones. After 30 minutes, the Modified Borg Scale and Vital Signs Record Chart will be filled out again. Thirty minutes after the end of the session, the Modified Borg Scale and Vital Signs Record Chart will be completed again.
62538106|NCT00469144|EXPERIMENTAL|Fixed-Dose Busulfan + Fludarabine|Busulfan Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days. Fludarabine 40 mg/m\^2 IV Daily Over 1 Hour x 4 Days.
62538107|NCT00469144|EXPERIMENTAL|Adjusted Dose Busulfan + Fludarabine|Busulfan Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day. Fludarabine 40 mg/m\^2 IV Daily Over 1 Hour x 4 Days.
62538108|NCT06226012|EXPERIMENTAL|Group A|Group (A) received Pulsed magnetic field therapy in addition to traditional exercise program
62538109|NCT06226012|EXPERIMENTAL|Group B|Group (B) received Low level laser therapy in addition to traditional exercise program
62538110|NCT04610372|ACTIVE_COMPARATOR|standard|External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks
62538111|NCT04610372|EXPERIMENTAL|High dose rate brachytherapy|A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.
62538112|NCT04610372|EXPERIMENTAL|Permanent seed implant brachytherapy|A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate
62538113|NCT04610372|EXPERIMENTAL|Stereotactic body radiotherapy|36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.
62538114|NCT02762461||Exposed group|Women with peritoneal/ovarian endometriosis and DIE (rectovaginal and rectosigmoid endometriosis) undergoing ART (IVF or ICSI).
62538115|NCT02762461||Reference group 1|Women with infertility because of factors other than endometriosis, e.g. male factor, undergoing ART (IVF or ICSI).
62538116|NCT02762461||Reference group 2|Women with medically treated endometriosis not undergoing ART.
62538117|NCT06353568|EXPERIMENTAL|Photobiomodulation Group|The PBM Group will use a boot with 1344 LEDs once daily for 6 minutes, over a period of 60 days, and will receive therapeutic education.
62538118|NCT06353568|SHAM_COMPARATOR|Control Group|The Control Group will use a non-therapeutic LED boot (placebo) for 6 minutes once daily for 60 days and will also receive therapeutic education.
62538119|NCT03278392|EXPERIMENTAL|Psychosocial challenge task|Participants will be assigned to complete the Trier Social Stress Test (TSST) immediately after consuming a standardized breakfast drink
62538120|NCT03278392|SHAM_COMPARATOR|Placebo challenge task|Participants will be assigned to complete the placebo non-stress task immediately after consuming a standardized breakfast drink
62538121|NCT04808336|ACTIVE_COMPARATOR|PRP injection group|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
62538122|NCT04808336|ACTIVE_COMPARATOR|surgical group..|Group 2: thirty patients underwent surgery
62538123|NCT03557879||Hearing impaired families|Samples from families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
62538124|NCT04603235|EXPERIMENTAL|Intervention|This is a quasi-experimental study
62538125|NCT02897583|EXPERIMENTAL|YAG vitreolysis|A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician. Only one treatment session will be performed.
62538126|NCT02897583|SHAM_COMPARATOR|Sham YAG vitreolysis|Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
62538127|NCT06163924||PCa receiving ADT|prostate cancer patients receiving androgen deprivation therapy
62538128|NCT04135326|EXPERIMENTAL|Supportive care (tDCS)|Patients undergo tDCS QD over 20 minutes 5 days each week (Monday-Friday) for 3 weeks.
62538129|NCT05949710|EXPERIMENTAL|aerobic exercise(AE), normal weight|3 times a week, normal weight
62538130|NCT05949710|EXPERIMENTAL|aerobic exercise(AE) , overweight/obese|3 times a week, overweight/obese
62538131|NCT06227572|EXPERIMENTAL|Intervention Group|The CATNAP MI intervention consists of 3 Motivational Interviewing sessions to address obstructive sleep apnea (OSA), positive airway pressure (PAP) adherence, and risk of Alzheimer's disease and related dementias (ADRD) in American Indians and electronic messaging to support PAP adherence, and usual care. Data will be collected at baseline, 3-months, and 9-months.
62538132|NCT06227572|NO_INTERVENTION|Waitlist Control Group|Usual care, consisting of an in-service on how to operate the PAP machine, and a mask fitting to select the most comfortable, effective mask for the individual. After 4-6 weeks of use, the participant will be contacted by Missouri Breaks Durable Medical Equipment to review objective adherence data and address any challenges or barriers to therapy such as treatment-emergent central apneas. Data will be collected at baseline, 3-months, and 9-months.
62538133|NCT04232280|EXPERIMENTAL|mRNA-1647 Dose Level A|Participants will receive mRNA-1647 vaccine at Dose Level A by intramuscular (IM) injection on Day 1, Day 56, and Day 168.
62538134|NCT04232280|EXPERIMENTAL|mRNA-1647 Dose Level B|Participants will receive mRNA-1647 vaccine at Dose Level B by IM injection on Day 1, Day 56, and Day 168.
62538135|NCT04232280|EXPERIMENTAL|mRNA-1647 Dose Level C|Participants will receive mRNA-1647 vaccine at Dose Level C by IM injection on Day 1, Day 56, and Day 168.
62538136|NCT04232280|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to the mRNA-1647 vaccine dose by IM injection on Day 1, Day 56, and Day 168.
62538137|NCT05403255||Multiple or isolated pituitary hormone deficiency group|Patient with multiple pituitary deficiency or isolated pituitary deficiency diagnosed for at least 6 months.
62538138|NCT03573778|EXPERIMENTAL|iHEAL|10-18 visits (over 6 months) with a Registered Nurse
62538139|NCT03573778|ACTIVE_COMPARATOR|Usual Care|Information about Community Services
62538140|NCT01796418|EXPERIMENTAL|Beraprost sodium|Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks
62538141|NCT01796418|PLACEBO_COMPARATOR|Placebo|Placebo capsule by mouth every 12 hours for 12 weeks
62538142|NCT05733221|EXPERIMENTAL|3D Model Generated|Patient will undergo an Open Reduction and Internal Fixation preformed by a surgeon who had pre-operative access to a 3D model printed to help pre-bend hardware.
62538143|NCT05733221|NO_INTERVENTION|Normal Standards of Care without Aide of Model|Patient will undergo standard Open Reduction and Internal Fixation by a surgeon who did not have a pre-operative 3D model.
62538144|NCT02212379|EXPERIMENTAL|raltegravir and etravirine|
62538145|NCT06200324||Ready-to-Use Parenteral Nutrition|Numeta G13E
62538146|NCT06200324||Individualized parenteral nutrition|Individualized parenteral nutrition
62538147|NCT05899491|ACTIVE_COMPARATOR|ARMA Group|All patients in this group will undergo Anti-reflux mucosal ablation using upper gastrointestinal endoscopy. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
62538148|NCT05899491|SHAM_COMPARATOR|Sham Group|UGI Endoscopy will be performed under Propofol based sedation with scope kept inside for at least 5 minutes.
62538149|NCT05144490|EXPERIMENTAL|Bodyweight Exercise|"A standardized 11-minute bodyweight exercise session that involves a 1-minute warm-up followed by 5, 1-minute bouts of exercise at a self-selected challenging pace, interspersed with 1-minute periods of low-intensity exercise for recovery."
62538150|NCT05144490|NO_INTERVENTION|Non-Exercise Control|An 11-minute period of quiet sitting.
62538151|NCT03900897|EXPERIMENTAL|Prospective|Detailed interventions and outcome measures refer to the prospective, experimental study arm. The prospective arm is active but not enrolling.
62538152|NCT03900897|OTHER|Retrospective|Study identification, sponsor/collaborators, oversight, purpose, indications, and primary endpoints for the retrospective, observational study arm align with the prospective study arm. The retrospective arm will be enrolling by invitation for chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020. The specific devices and outcome measures will vary slightly for retrospective subjects, based on what was clinically available and used at the time of implantation.
62538153|NCT04177784|EXPERIMENTAL|Intervention (I)|This arm was randomized to a 20 min video that emphasized information about factors other than individual behaviors that influence weight, weight loss and ability to maintain weight. It also indirectly addressed weight bias by explaining how to have conversation about weight and health with a patient with obesity that is free of biases.
62538154|NCT04177784|ACTIVE_COMPARATOR|Weight Control (C1)|This arm was randomized to a 20 min video that emphasized the controllable aspects of weight and gave dietitians an overview of a tool to help plan and monitor weight loss.
62538155|NCT04177784|PLACEBO_COMPARATOR|Weight Neutral Control (C2)|The arm was randomized to a 20 min video about the role dietitians play in society, that made no mention of weight or obesity.
62538156|NCT05801952|EXPERIMENTAL|Aerobika OPEP Therapy|Bronchial drainage session with the Aerobika OPEP device consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique. This cycle is repeated at least three times. The maximum number of cycles is five considering the need. The size of the applied expiratory resistance is selected individually. The pressure is 5 - 20 cm H2O and the oscillation frequency is up to about 15 Hz. Duration of the session: 10 - 20 min. Duration of the program: 4 days. Frequency: twice a day.
62538157|NCT05801952|EXPERIMENTAL|Flutter O-PEP Therapy|Bronchial drainage session with the Flutter O-PEP device consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique. This cycle is repeated at least three times. The maximum number of cycles is five considering the need. The size of the applied expiratory resistance is selected individually. The pressure is 5 - 20 cm H2O and the oscillation frequency is up to about 15 Hz. Duration of the session: 10 - 20 min. Duration of the program: 4 days. Frequency: twice a day.
62538158|NCT05801952|EXPERIMENTAL|PEP Therapy|Bronchial drainage session with the PEP device consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique. This cycle is repeated at least three times. The maximum number of cycles is five considering the need. The size of the applied expiratory resistance is selected individually. The pressure is 10-20 cmH2O during exhalation. Duration of the session: 10 - 20 min. Duration of the program: 4 days. Frequency: twice a day.
62538159|NCT05942625|EXPERIMENTAL|HS-10390|Single or multiple dosing of HS-10390 in a fastingstate
62538160|NCT05942625|EXPERIMENTAL|Placebo|Single or multiple dosing of placebo in a fastingstate
62538161|NCT01006135||COPD patients|
62538162|NCT02293863|EXPERIMENTAL|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
62538163|NCT02293863|EXPERIMENTAL|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
62538164|NCT02293863|PLACEBO_COMPARATOR|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
62538165|NCT04365218|EXPERIMENTAL|Cohort 1 (Dose A)|6 subjects will be randomized to receive MEDI8367 Dose A and 2 subjects will be randomized to receive placebo.
62538166|NCT04365218|EXPERIMENTAL|Cohort 2 (Dose B)|6 subjects will be randomized to receive MEDI8367 Dose B and 2 subjects will be randomized to receive placebo.
62538167|NCT04365218|EXPERIMENTAL|Cohort 3 (Dose C)|6 subjects will be randomized to receive MEDI8367 Dose C and 2 subjects will be randomized to receive placebo.
62538168|NCT04365218|EXPERIMENTAL|Cohort 4 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D and 2 subjects will be randomized to receive placebo.
62538169|NCT04365218|EXPERIMENTAL|Cohort 5 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 2 subjects will be randomized to receive placebo.
62538170|NCT04365218|EXPERIMENTAL|Cohort 6 (Dose D)|15 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 15 subjects will be randomized to receive placebo.
62538171|NCT00855179|ACTIVE_COMPARATOR|Antistax film-coated tablets 360 mg|Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
62538172|NCT00855179|PLACEBO_COMPARATOR|Placebo|Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
62538173|NCT06027385|EXPERIMENTAL|Tested Newborns|Tested for three mutations in the CTNS gene and one mutation in the SMN1 gene.
62538174|NCT03335215|EXPERIMENTAL|cognitive remediation|The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
62538175|NCT03335215|NO_INTERVENTION|usual care|
62538176|NCT02481362|ACTIVE_COMPARATOR|Order 1|Order for sessions: Cake, apricots
62538177|NCT02481362|ACTIVE_COMPARATOR|Order 2|Order for sessions: apricots, Cake
62538178|NCT03578666|EXPERIMENTAL|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
62538179|NCT03578666|EXPERIMENTAL|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
62538180|NCT03578666|NO_INTERVENTION|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
62538181|NCT02707445|EXPERIMENTAL|GENIUS|All comer patients who had undergone percutaneous coronary intervention with administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months
62538182|NCT00482586||Image-guided Therapy|Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
62538183|NCT02161315||Observation group|Steroid Aromatase Inhibitors
62538184|NCT02161315||Control group|Non-Steroid Aromatase Inhibitor
62538185|NCT01275430|EXPERIMENTAL|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
62538186|NCT01275430|ACTIVE_COMPARATOR|"Blind Placement"|"PICCs will be placed blindly, without the use of any tip location/positioning device."
62538187|NCT06341829|EXPERIMENTAL|Right prismatic adaptation|This group will undergo right prismatic adaptation
62538188|NCT06341829|EXPERIMENTAL|Left prismatic adaptation|This group will undergo left prismatic adaptation
62538189|NCT06341829|SHAM_COMPARATOR|Neutral prismatic adaptation|This group will undergo neutral lenses
62538190|NCT00513279|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334. The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
62538191|NCT00513279|EXPERIMENTAL|Cohort 2|Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
62538192|NCT05384171|EXPERIMENTAL|Intervention Group|MBTA, MBTA satisfaction measures, and other assessment measures at T1 (baseline); MBTA and other assessment measures at T2 (three month follow-up)
62538193|NCT05384171|ACTIVE_COMPARATOR|Active Control Group|assessment measures only at T1 (baseline); MBTA, MBTA satisfaction measures, and other assessment measures at T2 (three month follow-up)
62538194|NCT06089434|EXPERIMENTAL|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would limit the number of TEE clips per case.
62538195|NCT06089434|OTHER|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
62538196|NCT01806766|ACTIVE_COMPARATOR|Ceramic on Ceramic|Ceramic on Ceramic bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
62538197|NCT01806766|ACTIVE_COMPARATOR|Ceramic on HXPE|Ceramic on HIghly crosslinked polyethylene bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
62538198|NCT04913948||Pregnant|Pregnant women with confirmed COVID-19 at any point during pregnancy or suspected (as identified at local hospital) of COVID-19 at time of delivery, who will be delivering at a participating hospital within Ontario
62538199|NCT03906578|ACTIVE_COMPARATOR|Probiotic|Two sachets Vivomixx® containing 8 strains of life bacteria (9 x 10\^11 CFU) in the evening for 8 weeks
62538200|NCT03906578|PLACEBO_COMPARATOR|Placebo|Two sachets placebo in the evening for 8 weeks
62538201|NCT05162014||Pooled Empagliflozin|Patients with type 2 diabetes mellitus (T2DM) and new initiators of empagliflozin on a background of metformin, between 1-Aug-2014 and the latest data-cut available in IBM MarketScan Commercial Claims and Encounters (CCAE)/ Medicare Supplemental (MDCR) 30-Sep-2020 and Optum Clinformatics® Data Mart (CDM) 31-Mar-202, who were enrolled for a minimum of 6 months in the US claims databases before index treatment initiation
62538202|NCT05162014||Pooled Sulfonylureas (SUs)|Patients with type 2 diabetes mellitus (T2DM) and new initiators of Sulfonylureas (SUs) on a background of metformin, between 1-Aug-2014 and the latest data-cut available in IBM MarketScan Commercial Claims and Encounters (CCAE)/ Medicare Supplemental (MDCR) 30-Sep-2020 and Optum Clinformatics® Data Mart (CDM) 31-Mar-202, who were enrolled for a minimum of 6 months in the US claims databases before index treatment initiation
62538203|NCT04594317|EXPERIMENTAL|low level laser therapy|970 ± 15-nm diode laser (Biolase Epic X, Biolase, Irvine, California, USA)will be activated at 0.5 W and 10 Hz at a distance of approximately 10 mm to the tissue around the apex of the root. A circular movement will be performed during application. Pulse duration will be 0.5 s, and pulse pause will be 50%. Total application time will be30 s for the tooth. For this application, a 200-μm optical tip will be used.
62538204|NCT04594317|ACTIVE_COMPARATOR|Calcium hydroxide intracanal medication|calcium hydroxide paste (Metapaste, Meta Biomed Co., Ltd, Korea) will be inserted in the canal using disposable plastic tip and placed at a distance 1 or 2 mm less than the working length.
62538205|NCT00642278|EXPERIMENTAL|Canagliflozin 50 mg daily|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
62538206|NCT00642278|EXPERIMENTAL|Canagliflozin 100 mg daily|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
62538207|NCT00642278|EXPERIMENTAL|Canagliflozin 200 mg daily|Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
62538208|NCT00642278|EXPERIMENTAL|Canagliflozin 300 mg daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
62538209|NCT00642278|EXPERIMENTAL|Canagliflozin 300 mg twice daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
62538210|NCT00642278|ACTIVE_COMPARATOR|Sitagliptin 100 mg daily|Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
62538211|NCT00642278|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo twice daily for 12 weeks.
62538212|NCT00835965|ACTIVE_COMPARATOR|Active Comparator|Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting
62538213|NCT00835965|PLACEBO_COMPARATOR|Placebo Comparator|Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting
62538214|NCT03337243|EXPERIMENTAL|HAM and HUMCWJ Injections (Group 1)|Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
62538215|NCT03337243|NO_INTERVENTION|Control (Group 2)|Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months.
62736785|NCT03698578|EXPERIMENTAL|group 2 combat fight|Constituted by amateur paratroopers. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
62736786|NCT01457963||pulmonary embolism, deep venous thrombosis|
62538216|NCT00790335|EXPERIMENTAL|A-Intervention|PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
62538217|NCT00790335|NO_INTERVENTION|B-Control|Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
62538218|NCT00991419|EXPERIMENTAL|A|\[18F\]4694
62538219|NCT03357835||Normal Triage|Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
62538220|NCT03357835||Software Triage|"triage maintenance / evaluation will be done with computer software called Trauma Decision System (TraumaDS) developed by us. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes. According to this scoring, patients who need urgent care and who should not wait will be considered red code, patients who should wait less than 15 minutes will be considered orange coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded."
62538221|NCT05478512|EXPERIMENTAL|VenObi+Ven or VenObi+VenZan|Patients will receive VenObi combination followed by Venetoclax single agent or Venetoclax+zanubrutinib, according to MRD.
62538222|NCT05450601|EXPERIMENTAL|Experimental|HCP2102
62538223|NCT05450601|ACTIVE_COMPARATOR|Active Comparator|RLD2106
62538224|NCT04032236|OTHER|smoking group|35 smoking case
62538225|NCT04032236|OTHER|nonsmoking group|35 nonsmoking case
62538226|NCT02151877|EXPERIMENTAL|Nitric oxide on CPB|neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
62538227|NCT02151877|PLACEBO_COMPARATOR|control|neonates not receiving inhaled NO into the cardiopulmonary bypass
62538228|NCT06608537|EXPERIMENTAL|neoadjuvant SCRT followed by Sintilimab plus CAPOX|Patients received neoadjuvant treatment consisting of SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
62538229|NCT05124392||Individuals with a family history of Prion disease|Individuals with a family history of Prion disease
62538230|NCT04996550||Carvedilol group|Treated with Carvedilol
62538231|NCT04996550||Metoprolol succinate group|Treated with Metoprolol succinate
62538232|NCT04809051|NO_INTERVENTION|Condition 1: Combined Transplant Pictograph|"Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a survival rate pictograph corresponding to all patients at the center who received transplants."
62538233|NCT04809051|EXPERIMENTAL|Condition 2: Stratified Transplant Pictograph|"Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of survival rate pictographs corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
62538234|NCT04809051|EXPERIMENTAL|Condition 3: Combined Transplant SRTR|"Participants randomized to Condition 3 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a quintile score corresponding to all patients at the center who received transplants."
62538235|NCT04809051|EXPERIMENTAL|Condition 4: Stratified Transplant SRTR|"Participants randomized to Condition 4 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of quintile scores corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
62538236|NCT06633172|ACTIVE_COMPARATOR|laparoscopic ventral mesh rectopexy|performing laparoscopic ventral mesh rectopexy for group of patients to find out its efficacy
62538237|NCT06633172|ACTIVE_COMPARATOR|Trans vaginal repair|performing trans vaginal repair for the 2nd group to find out its efficacy.
62538238|NCT05258097||Boys|Child sex based on parent report on a screening questionnaire
62538239|NCT05258097||Girls|Child sex based on parent report on a screening questionnaire
62538240|NCT04308707||Surgical specialties|
62538241|NCT04308707||Anesthesiology|
62538242|NCT01005277||Ancillary-Correlative (genetic polymorphisms)|Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.
62538243|NCT06213493||Non end-stage heart failure|Measurement of tissutal RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
62538244|NCT06213493||ACS patients|Measurement of circulating RNAs in acute coronary syndrome (ACS) patients treated with percutaneous angioplasty and undergoing to ventricle remodelling
62538245|NCT06213493||HF patients|Measurement of circulating RNAs in heart failure patients
62538246|NCT06213493||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
62538247|NCT04737096|EXPERIMENTAL|tDCS+DAOIB|
62538248|NCT04737096|PLACEBO_COMPARATOR|tDCS+placebo|
62538249|NCT06141967|EXPERIMENTAL|WITHINGS Sleep Analyzer|The sleep apnea screening device used is a medical screening device WITHINGS Sleep Analyzer (WSA)
62538250|NCT06422910|EXPERIMENTAL|Intervention Group|
62538251|NCT06422910|ACTIVE_COMPARATOR|Control Group|
62538252|NCT01181362|OTHER|Endoscopy|
62538253|NCT06598878|EXPERIMENTAL|PD patients|AR gait training
62538254|NCT06598878|NO_INTERVENTION|PD patients (Control)|Control Group
62538255|NCT00127218|EXPERIMENTAL|1|any statin plus niacin
62538256|NCT00127218|PLACEBO_COMPARATOR|2|any statin plus placebo
62538257|NCT04820530|EXPERIMENTAL|LNP023|Participants receive LNP023 at a dose of 200 mg orally b.i.d
62538258|NCT04241315|EXPERIMENTAL|Near-Infrared Imaging group|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
62538259|NCT04241315|OTHER|No Imaging Group|All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.
62538260|NCT02662660|EXPERIMENTAL|Port-sites infiltration:Bupivacaine0,25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
62538261|NCT02662660|EXPERIMENTAL|Epidural analgesia:Levobupivacaine0.125%|"Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.~Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours."
62538262|NCT02662660|ACTIVE_COMPARATOR|Metamizole and Acetaminophen iv|Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
62538263|NCT06262932|ACTIVE_COMPARATOR|Repeated amiodarone bolus dosing regimen|An Initial 150 mg IV amiodarone bolus should be given over a 15-minute period. If the heart rate is still over 110 minutes after the initial treatment, provide an additional 150 mg IV amiodarone bolus over a 15-minute period. During the first 24 hours, this bolus may be administered up to three times in total. Within 24 hours of finishing the first bolus dosage, 900 mg of amiodarone will be administered intravenously.
62538264|NCT06262932|ACTIVE_COMPARATOR|Standard dosing regimen|An Initial 150 mg IV amiodarone bolus should be given over a 15-minute period, then a 24-hour amiodarone loading infusion 900 mg over 24 hours
62538265|NCT02115438||Occupational Stress|
62538266|NCT04181723|EXPERIMENTAL|Drug - Trofinetide|Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
62538267|NCT04181723|PLACEBO_COMPARATOR|Placebo|Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
62538268|NCT05695131|EXPERIMENTAL|Virtual Reality Delivered Therapy + Standard Clinical Care|The GlenXRose virtual reality therapies will be delivered to participants using a head-mounted device to allow vocal therapy and practice. Participants will also receive routine clinical care provided by speech-language pathologists.
62538269|NCT05695131|NO_INTERVENTION|Standard Clinical Care|Participants will receive routine clinical care provided by speech-language pathologists.
62538270|NCT05266339|EXPERIMENTAL|Cross-education group|Each subject in the cross-education group will receive a treatment protocol consisting of cross-education (training of the contralateral limb) and standard exercise program applied after arthroscopic rotator cuff repair.
62538271|NCT05266339|ACTIVE_COMPARATOR|Standard exercise group|Each subject in the standard exercise group will receive a treatment protocol consisting of standard exercise program applied after arthroscopic rotator cuff repair.
62538272|NCT05812443|EXPERIMENTAL|Shabad Kriya Meditation|87 participants (intervention group) will be trained to perform Shabad Kriya meditation for 30 minutes, daily, before going to sleep, for 8 weeks
62538273|NCT05812443|ACTIVE_COMPARATOR|Relaxing reading|87 participants (control group) will perform relaxing reading for 30 minutes, daily, before going to sleep, for 8 weeks
62538274|NCT03083080|EXPERIMENTAL|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
62538275|NCT03480386|EXPERIMENTAL|Pulmonary Rehabilitation Program Intervention|Subjects will receive 12 weeks home pulmonary rehabilitation (PR) with health coaching.
62538276|NCT03480386|NO_INTERVENTION|Usual Care|Subjects will receive 12 weeks of usual care.
62538277|NCT03990597|EXPERIMENTAL|Supportive care (StrataXRT, placebo)|Beginning first day of CSI proton radiation therapy, caregivers apply StrataXRT gel to half of the patient's forehead and one ear and placebo to the other half of the forehead and the other ear BID until the last day of radiation therapy.
62538278|NCT01987479|EXPERIMENTAL|Tocilizumab Alone or in Combination with Methotrexate or DMARD|Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
62538279|NCT02358135|OTHER|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
62538280|NCT02358135|EXPERIMENTAL|CCH Model|The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes. Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
62538281|NCT00662623|EXPERIMENTAL|1|
62538282|NCT00662623|ACTIVE_COMPARATOR|2|Usual Care (Standard Care)
62538283|NCT04928092||Active research group|Patients undergoing intravascular imaging guided, low contrast PCI procedure as part of standard care
62538284|NCT02128061|ACTIVE_COMPARATOR|R-miniCHOP|"All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² Day 1 (D1) DOXORUBICINE IV : 25 mg/m² D1 VINCRISTINE IV : 1 mg Total Dose (TD) D1 PREDNISONE PO : 40 mg/m² D1 to D5 RITUXIMAB SC\* : 1400 mg TD D1~\*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
62538285|NCT02128061|EXPERIMENTAL|R2-miniCHOP|"All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC\* : 1400 mg TD D1 LENALIDOMIDE PO\*\* :10 mg TD D1 to D14~\*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
62538286|NCT05773248||Standard care|
62538287|NCT05773248||ERAS|
62538288|NCT02051361||Clopidogrel treated patients|Patients pre and post operatively following stent implantation treated with clopidogrel and aspirin
62538289|NCT05986253|PLACEBO_COMPARATOR|Control|0.6g/kg body mass maltodextrin in solution
62538290|NCT05986253|EXPERIMENTAL|Protein|0.6g/kg body mass maltodextrin PLUS 0.15g/kg body mass protein from Biodulse, in solution
62538291|NCT01110135|EXPERIMENTAL|Treatment (chemotherapy and colony-stimulating factor)|"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until \> 5 x 10\^6 CD34+/kg has been collected.~."
62538292|NCT04340596|EXPERIMENTAL|Arm A: N-803 only|Participants will receive N-803 6 mcg/kg 1 week after Step 2 entry and then every 3 weeks for a total of eight doses.
62538293|NCT04340596|EXPERIMENTAL|Arm B: N-803 in combination with 10-1074 and VRC07-523LS|"Participants will receive N-803 in combination with 10-1074 and VRC07-523LS as follows:~* At Step 2 entry:~  * VRC07-523LS 20 mg/kg~ * 10-1074 30 mg/kg~* At Step 2, week 1: N-803 6 mcg/kg every 3 weeks for eight doses~* At Step 2, week 9: 10-1074 30 mg/kg"
62538294|NCT05102812|EXPERIMENTAL|Breakfast Group Intervention|The intervention will be piloted at Sheffield Teaching Hospitals for 1-2 weeks. Then will be refined and piloted at tow further stroke wards (Rotherham Hospitals NHS Foundation Trust and Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust)
62538295|NCT06028321|EXPERIMENTAL|Part 1 Group1 (AB)|"Part 1 Group1 Subjects were randomised to two treatment regimens (A and B) and received treatment sequence AB in a 2-period cross over.~Regimen A = 15 mg ACM-001.1 and matching placebo. Regimen B = 30 mg pindolol."
62538296|NCT06028321|EXPERIMENTAL|Part 1 Group 1 (BA)|"Subjects were randomised to two treatment regimens (A and B) and received treatment sequence BA in a 2-period cross over.~Regimen B = 30 mg pindolol. Regimen A = 15 mg ACM-001.1 and matching placebo."
62538297|NCT06028321|EXPERIMENTAL|Part 1 Group 2 (C)|"Subjects were non-randomised; received regimen C in parallel with Group 1 in a single period.~Regimen C = 15 mg pindolol."
62538298|NCT06028321|EXPERIMENTAL|Part 2 Group D|Subjects received one of the four regimens over a four day treatment period. Regimen D = 20 mg pindolol BID (bis in die) for four days.
62538299|NCT06028321|EXPERIMENTAL|Part 2 Group E|Subjects received one of the four regimens over a four day treatment period. Regimen E = 5 mg ACM-001.1 and placebo BID for four days.
62538300|NCT06028321|EXPERIMENTAL|Part 2 Group F|Subjects received one of the four regimens over a four day treatment period. Regimen F = 10 mg ACM-001.1 and placebo BID for four days.
62538301|NCT06028321|EXPERIMENTAL|Part 2 Group G|Subjects received one of the four regimens over a four day treatment period. Regimen G = 15 mg ACM-001.1 and placebo BID for four days.
62538302|NCT00244478|EXPERIMENTAL|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
62538303|NCT00244478|PLACEBO_COMPARATOR|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
62538304|NCT03548831||MLH|Minilaparotomy Hysterectomy
62538305|NCT03548831||LAVH|Laparoscopic Assisted Vaginal Hysterectomy
62538306|NCT03103139|ACTIVE_COMPARATOR|Transpapillary Stents|Stent placement across the Papilla (with a short plastic stent) for biliary leak
62538307|NCT03103139|EXPERIMENTAL|Stent across bile leak|Stent placement across the bile leak (with a longer stent) for biliary leak
62538308|NCT06633510||Massimo group|The patient is not given fluids until the Massimo PVI score is \>25, a 300 cc fluid bolus is given when the PVI is above 25, and fluid loading is performed at an average rate until the PVI falls below 25. If the patient's Massimo PVI is below 25, restrictive fluid therapy is applied.
62538309|NCT06633510||standart group|intraoperative fluid deficit is calculated according to the 4-2-1 rule by summing up the hourly basal fasting level, intraoperative losses depending on the degree of tissue trauma (1-2mlt/kg/h in small-sized surgeries, 2-4mlt/kg/h in medium-sized surgeries, 4-8mlt/kg/h in large-sized surgeries), blood losses, urine and losses from the nasogastric tube. Fluid is given in this way.
62538310|NCT01177475|ACTIVE_COMPARATOR|natural milk|
62538311|NCT01177475|EXPERIMENTAL|pasteurized milk|
62538312|NCT03243058|ACTIVE_COMPARATOR|Treatment Arm|ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.
62538313|NCT03243058|EXPERIMENTAL|Treatment-Placebo Arm|Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.
62538314|NCT03243058|PLACEBO_COMPARATOR|Placebo|Participants in this group will receive a placebo injection for two years.
62538315|NCT03902730|OTHER|Back Squat Variation One|In a randomized order, traditional back squat will be completed.
62538316|NCT03902730|OTHER|Back Squat Variation Two|In a randomized order, barefoot back squat will be completed.
62538317|NCT03902730|OTHER|Back Squat Variation Three|In a randomized order, box squat will be completed.
62538318|NCT03902730|OTHER|Back Squat Variation Four|In a randomized order, traditional back squat with chains will be completed.
62538319|NCT02837614|ACTIVE_COMPARATOR|Group A (intramuscular dexamethasone)|In Group A patients, 1 ml of dexamethasone (4mg) administered in the deltoid muscle before commencement of surgical procedure
62164314|NCT05294380||oncologic|"Be between the ages of 2-18 years Being under pediatric oncology outpatient/clinical follow-up Being able to stand unaided without using a cane/walker Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
62538320|NCT02837614|EXPERIMENTAL|Group B (submucosal dexamethasone)|In Group B patients, 1 ml of dexamethasone was administered in submucosa after local anesthesia
62538321|NCT02837614|PLACEBO_COMPARATOR|Group C (control)|Group C patients continued without receiving any preoperative medication.
62538322|NCT06260124|EXPERIMENTAL|Pre-menopausal women|Pre-menopausal healthy, inactive women that will participate in a random order in three dancing sessions (Greek traditional dancing) of different tempo on non-consecutive days.
62538323|NCT06260124|EXPERIMENTAL|Post-menopausal|Post-menopausal healthy, inactive women that will participate in a random order in three dancing sessions (Greek traditional dancing) of different tempo on non-consecutive days.
62538324|NCT03760185|EXPERIMENTAL|Brimonidine Tartrate 0.2%|One eye was treated with Brimonidine Tartrate 0.2% after a 20-day washout period. Patients will treat right eye 3 times per day for 7 days of treatment.
62538325|NCT03760185|NO_INTERVENTION|Control - untreated|The left eye will serve as the control for the study and will not receive the Brimonidine Tartrate 0.2% treatment
62538326|NCT04475835|EXPERIMENTAL|Bivalirudin|Bivalirudin with prolonged full dose infusion during PCI
62538327|NCT04475835|ACTIVE_COMPARATOR|Heparin|Heparin 100U/kg
62538328|NCT02529215|EXPERIMENTAL|Just-in-time training (JITT) group|Receive a 20min just-in-time simulation-based teaching session targeting: (1) CPR quality and (2) medication administration within 3 hours of the scheduled in situ simulation.
62538329|NCT02529215|NO_INTERVENTION|No additional training (control) group|Control group who receives no additional training.
62538330|NCT05209152|EXPERIMENTAL|Part 1A - AMG 176 Monotherapy (Dose Exploration)|Two dose levels of AMG 176 will be tested in Part 1A to find the optimal biological dose/minimum safe biologically effective dose (OBD/MSBED).
62538331|NCT05209152|EXPERIMENTAL|Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration)|After the OBD is found in Part 1A, two dose levels of AMG 176 in combination with azacitidine will be tested in Part 1B to find the OBD/MSBED.
62538332|NCT05209152|EXPERIMENTAL|Part 2 - AMG 176 and Azacitidine Combination Therapy (Dose Expansion)|"After the completion of Part 1, the Part 2 dose expansion phase will begin at the OBD/MSBED identified in Part 1.~Venetoclax-naïve and venetoclax-exposed R/R HR-MDS participants after HMA failure will be enrolled along with participants with newly diagnosed HR-MDS/CMML."
62538333|NCT03276078|EXPERIMENTAL|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
62538334|NCT04637932|ACTIVE_COMPARATOR|Use of endotracheal tube During Percutaneous Dilatation Tracheostomy|Group 1 was determined as endotracheal tube
62538335|NCT04637932|ACTIVE_COMPARATOR|Use of Pro-seal LMA and Bronchoscopy During Percutaneous Dilatation Tracheostomy|group 2 as pro-seal laryngeal mask group.
62538336|NCT03679182|EXPERIMENTAL|Olanzapine|Olanzapine 5 mg at 0, 12, 24 and 36 hours
62538337|NCT01594710||Apparently Health People|
62538338|NCT02227446|EXPERIMENTAL|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
62538339|NCT02227446|NO_INTERVENTION|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
62538340|NCT01812681||Low vitamin D level|The premature infants with low cord blood vitamin D level
62538341|NCT01812681||Normal Vitamin D|The premature infants with normal vitamin D level
62538342|NCT05079581|OTHER|Intervention group|Pelvic floor exercises
62538343|NCT05079581|NO_INTERVENTION|Control group|Education session
62538344|NCT05314816|EXPERIMENTAL|Blood culture identification panel|BioFire BCID2 (Blood culture identification panel) will be performed on positive blood culture specimens.
62538345|NCT05314816|NO_INTERVENTION|Concurrent control|Standard blood culture process will be performed concurrently on select positive blood culture specimens during the study period. BCID2 will NOT be performed on these specimens.
62538346|NCT05314816|NO_INTERVENTION|Retrospective control|Standard blood culture process was performed prior to the study period.
62538347|NCT01865942|ACTIVE_COMPARATOR|open surgery|One arm receives open surgery. In our department open surgery is considered as the standard procedure since all spine surgeons are preforming this operation.
62538348|NCT01865942|ACTIVE_COMPARATOR|Minimal access surgery|We compare to well-known types of surgery for metastatic spinal cord compression. The other arm receive open surgery. In our department minimal access surgery is considered as a standard procedure but it is not preformed by all spine surgeons.
62538349|NCT06421077|ACTIVE_COMPARATOR|Transauricular Vagal Nerve Stimulation|
62538350|NCT06421077|SHAM_COMPARATOR|Transauricular Vagal Nerve sham Stimulation|
62538351|NCT05279300|EXPERIMENTAL|Dose escalation|
62538352|NCT05279300|EXPERIMENTAL|Dose expansion|
62538353|NCT04095312|EXPERIMENTAL|pancreaticobiliary disease|10 pancreaticobiliary disease cases
62538354|NCT04095312|EXPERIMENTAL|Urinary tract disease|13 urinary tract disease cases
62538355|NCT04095312|EXPERIMENTAL|Colon disease|10 colon disease cases
62538356|NCT03192423||Expert|The physicians in the Expert-group will perform a LP following local standard procedure protocol.
62538357|NCT03192423||Intermediate|The physicians in the Intermediate-group will perform a LP following local standard procedure protocol.
62538358|NCT03192423||Novice|The physicians in the novice-group will perform a LP following local standard procedure protocol.
62538359|NCT04058067|EXPERIMENTAL|Brolucizumab 6 mg|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
62538360|NCT04058067|ACTIVE_COMPARATOR|Aflibercept 2 mg|5 x every 4 weeks loading then every 8 weeks maintenance
62538361|NCT04864314|PLACEBO_COMPARATOR|Control group|Group supplemented with a daily dose of placebo
62538362|NCT04864314|EXPERIMENTAL|Experimental group|Group supplemented with a daily dose of TetraSOD®
62538363|NCT01114100|ACTIVE_COMPARATOR|sertraline, panic education|treatment with sertraline after panic education
62538364|NCT01114100|PLACEBO_COMPARATOR|placebo after panic education|treatment with placebo after panic education
62538365|NCT01114100|NO_INTERVENTION|care as usual|patient received no diagnosis an no panic education, they had a 24 weeks follow up with a visit at 12 weeks and 24 weeks to evaluate their complaints
62538366|NCT06484842|EXPERIMENTAL|The combined intervention group|The combined intervention group will receive the combined psychological resilience and self-efficacy intervention.
62538367|NCT06484842|EXPERIMENTAL|The single intervention group|The single intervention group will receive the mindfulness intervention.
62538368|NCT06484842|NO_INTERVENTION|The control group|The control group will receive routine care. Routine care mainly includes postoperative precautions, management of postoperative complications, and postoperative dietary care such as the type, time, and amount of food required, etc. In addition, we will add the patients' WeChat and send relevant health knowledge to the patients regularly. The control group theoretically will not receive any additional psychological interventions. However, they will be entitled to receive either the combined psychological resilience and self-efficacy intervention or the psychological resilience intervention once the combined and single intervention groups have completed the intervention.
62538369|NCT00400816|EXPERIMENTAL|Temozolomide|Temozolomide, 150 mg/m2/d x days 1-7 and 15-21
62538370|NCT03149445|EXPERIMENTAL|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
62538371|NCT03149445|PLACEBO_COMPARATOR|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
62538372|NCT04990700|NO_INTERVENTION|Control Group|Includes patients undergoing routine thoracotomy
62538373|NCT04990700|EXPERIMENTAL|Intervention Group|The group that will undergo 1 cm partial rib resection during thoracotomy.
62714706|NCT03628209|EXPERIMENTAL|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
62538374|NCT03340207|EXPERIMENTAL|Pneumaglide|After induction of anesthesia Pneumaglide device will be placed in the mouth of the pneumaglide assigned patients.
62538375|NCT03340207|NO_INTERVENTION|non-pneumaglide|The patients in non-pneumaglide will not have Pneumaglide insertion prior to intubation.
62538376|NCT05091021||University of Colorado Health New Nurses (Day Shift Workers)|Day shift work group nurses have greater than 50% of their shifts as day shifts.
62538377|NCT05091021||University of Colorado Health New Nurses (Night Shift Workers)|Night shift work group nurses have greater than 50% of their shifts as night shifts.
62538378|NCT01704794|ACTIVE_COMPARATOR|Folic Acid + Paludrine +Jobelyn (500mg)|Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
62538379|NCT01704794|ACTIVE_COMPARATOR|Folic Acid + Paludrine +Jobelyn (250mg.)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily
62538380|NCT01704794|ACTIVE_COMPARATOR|Folic Acid + Paludrine + Jobelyn (2mg)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily
62538381|NCT05642845|OTHER|Sequence TR|25 subjects assigned to the sequence TR will receive a single 40 mg dose of the test product Atorvastatin (1 x 40 mg film-coated tablet), marked as T in the sequence, in Period 1 and Period 3, and a single 40 mg dose of the reference product Liprimar® (1 x 40 mg film-coated tablet), marked as R in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62538382|NCT05642845|OTHER|Sequence RT|25 subjects assigned to the sequence RT will receive a single 400 mg dose of the reference product Liprimar® (1 x 40 mg tablet), marked as R in the sequence, in Period 1 and Period 3 and a single 40 mg dose of the test product Atorvastatin (1 x 40 mg tablet), marked as T in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
62538383|NCT03097848|EXPERIMENTAL|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
62538384|NCT03097848|ACTIVE_COMPARATOR|RFA group|for eligible cases, RFA will be given only.
62538385|NCT02817945|EXPERIMENTAL|68Ga-NOTA-3P-TATE-RGD PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-3P-TATE-RGD in one dose intravenously and underwent PET/CT scan 45-60 min later.
62714707|NCT03160625|ACTIVE_COMPARATOR|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
62538386|NCT05076240||Adults with ventilator associated pneumonia in COVID-19 ARDS|Patient hospitalized in intensive care unit for acute respiratory distress related to a Sars-Cov2 infection having contracted ventilator associated pneumonia. The diagnosis was made by culture but also with a FilmArray® multiplex PCR analysis.
62538387|NCT04368689|EXPERIMENTAL|Floating|Participants have 3 Floatation sessions that last up to 90 minutes. Each spaced about a week apart.
62538388|NCT06228599|EXPERIMENTAL|Molecular Tumor Board (MTB)-recommended matched therapy|The MTB, a multidisciplinary group composed of medical oncologists (including those with expertise in precision oncology), surgical oncologists, and a pathologist, convenes periodically to discuss and recommend an individualized treatment plan that targets specific molecular alterations (e.g., genomic mutations) found in the patient's cancer while considering patient clinical and laboratory factors.
62164315|NCT05294380||control|"Be between the ages of 2-18 years Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
62164316|NCT05434533|EXPERIMENTAL|preoperative|1 gm of Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) 30 mins before the operation
62538389|NCT04197050|EXPERIMENTAL|sacubitril/valsartan group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. sacubitril/valsartan will be given.
62538390|NCT04197050|NO_INTERVENTION|control group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. Valsartan will be given.
62538391|NCT06124495|EXPERIMENTAL|Reference group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
62538392|NCT06124495|EXPERIMENTAL|Test group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
62538393|NCT00089024|EXPERIMENTAL|treatment|see interventions
62538394|NCT05517811||Cancer|new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma
62538395|NCT05517811||Control|Patients undergoing major surgery
62538396|NCT06584422|EXPERIMENTAL|Empower@Home supported by aging service providers|Participants will be provided with access to a 9-session online program called Empower@Home, a self-help intervention based on cognitive behavioral therapy principles. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. Participants will have up to 12 weeks to try to complete the program with the support of a trained coach.
62538397|NCT06584422|OTHER|Attention call with friendly visitors|Participants will receive enhanced care as usual, including care as usual from their social service provider and a psycho-educational handout. In addition, they will receive telephone friendly calls from a research staff every other week to mimic the human interactions provided by coaches in the experimental group.
62538398|NCT04680858|NO_INTERVENTION|Standard Communication|Endoscopic procedures performed by skilled endoscopic team with standard communication (no headset)
62538399|NCT04680858|EXPERIMENTAL|DECT enhanced Communication|Endoscopic procedures performed by skilled endoscopic team with enhanced communication tools ( DECT headset)
62538400|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
62538401|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
62538402|NCT06128070|EXPERIMENTAL|Prevention (Ruxolitinib, tacrolimus, methotrexate)|Patients receive ruxolitinib PO BID from day -1 to day +100, tacrolimus IV on day -1, and methotrexate IV on days +1, +3, +6, and +11, and undergo HCT on day 0. Patients also undergo chest CT and ECHO/MUGA at screening and undergo collection of blood samples throughout the trial.
62538403|NCT05546112|EXPERIMENTAL|Experimental group|Transcutaneous trigeminal nerve stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
62538404|NCT05546112|SHAM_COMPARATOR|Control group|Sham stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
62538405|NCT02257385|EXPERIMENTAL|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
62538406|NCT02257385|PLACEBO_COMPARATOR|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
62538407|NCT02456935|EXPERIMENTAL|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
62538408|NCT02456935|ACTIVE_COMPARATOR|Esomeprazole 40 mg QD|Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks
62538409|NCT04199871|EXPERIMENTAL|Group1|dichoptic 3D movies
62538410|NCT04199871|SHAM_COMPARATOR|Group 2|dichoptic standard movies
62538411|NCT05169450|EXPERIMENTAL|Diterpene ginkgolides meglumine injection|The intervention group received daily single infusions of 25 mg diterpene ginkgolides meglumine injection (DGMI) diluted with 250 ml of 0.9% sodium chloride injection for 14 days.
62164317|NCT05434533|EXPERIMENTAL|uterine incision|1 gm of Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) directly before uterine incision
62164318|NCT05434533|NO_INTERVENTION|placebo|1ml of normal saline will be given
62538412|NCT05169450|ACTIVE_COMPARATOR|Ginaton|The control group received once or twice a day infusion of 35-60mg Ginaton diluted with 250 ml of 0.9% sodium chloride injection for 14 days.
62164319|NCT02595593|ACTIVE_COMPARATOR|Rib Fixation System|This group of subjects will receive a surgical rib plating procedure after trauma
62164320|NCT02595593|NO_INTERVENTION|Critical Care and Pain Control|This group will receive critical care and pain control after trauma
62164321|NCT02080143|EXPERIMENTAL|Air Activated Heat Patch|The experimental air activated heat patch will be worn by the subjects for 8 hours.
62164322|NCT02080143|ACTIVE_COMPARATOR|Marketed ThermaCare Air Activated Heat Patch|The marketed air activated heat patch will be worn by the subjects for 8 hours.
62538413|NCT04784533|EXPERIMENTAL|Part A: Period 1 - CTP-543 8 mg BID|Participants received CTP-543 8 milligrams (mg) tablets, orally, twice daily (BID) for up to 24 weeks.
62538414|NCT04784533|EXPERIMENTAL|Part A: Period 1 - CTP-543 12 mg BID|Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
62538415|NCT04784533|EXPERIMENTAL|Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID|Participants who received CTP-543 8 mg during Period 1 of Part A and achieved an absolute severity of alopecia tool (SALT) score of ≤20 at Week 24, received CTP-543 4 mg tablets, orally, BID, for up to 24 weeks.
62164323|NCT02416973|OTHER|Sham of Provant|Sham of Provant
62164324|NCT02416973|OTHER|Active Treatment|Active Provant Treatment
62538416|NCT04784533|EXPERIMENTAL|Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID|Participants who received CTP-543 12 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.
62538417|NCT04784533|PLACEBO_COMPARATOR|Part A: Period 2 - CTP-543 8 mg BID to Placebo|Participants who received CTP-543 8 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 matched placebo tablets, orally, BID, for up to 24 weeks.
62538418|NCT04784533|PLACEBO_COMPARATOR|Part A: Period 2 - CTP-543 12 mg BID to Placebo|Participants who received CTP-543 12 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 matched placebo tablets, orally, BID, for up to 24 weeks.
62538419|NCT04784533|EXPERIMENTAL|Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID|Participants who received CTP-543 8 mg during Period 1, followed by CTP-543 4 mg during Period 2 of Part A and met the criteria for loss of regrowth maintenance (LOM) (absolute SALT score of \> 20), received re-treatment with CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.
62538420|NCT04784533|EXPERIMENTAL|Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID|Participants who received CTP-543 12 mg during Period 1, followed by CTP-543 8 mg during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 12 mg tablets, orally, BID, for up to 24 weeks.
62538421|NCT04784533|EXPERIMENTAL|Part B: CTP-543 8 mg BID to Placebo to 8 mg BID|Participants who received CTP-543 8 mg during Period 1, followed by CTP-543 matched placebo during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.
62538422|NCT04784533|EXPERIMENTAL|Part B: CTP-543 12 mg BID to Placebo to 12 mg BID|Participants who received CTP-543 12 mg during Period 1, followed by CTP-543 matched placebo during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 12 mg tablets, orally, BID, for up to 24 weeks.
62164325|NCT02416973|OTHER|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
62164326|NCT05271799|EXPERIMENTAL|Participants receiving gepotidacin powder for oral suspension followed by tablet|
62164327|NCT05271799|EXPERIMENTAL|Participants receiving gepotidacin tablet followed by powder for oral suspension|
62164328|NCT00685347|EXPERIMENTAL|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
62164329|NCT00685347|ACTIVE_COMPARATOR|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
62164330|NCT04252794|EXPERIMENTAL|Patients who undergo GIM|If inclusion criteria are met, after randomisation, these group of patients will undergo splenic artery ligation (graft inflow modulation)
62164331|NCT04252794|ACTIVE_COMPARATOR|No splenic artery ligation|If inclusion criteria are met, after randomisation, these group of patients will not undergo splenic artery ligation (graft inflow modulation)
62164332|NCT02115542|EXPERIMENTAL|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
62538423|NCT03587324|EXPERIMENTAL|Experimental: aspirin, clopidogrel|Perioperative measurement of ASA and clopidogrel resistance in patients undergoing vascular treatment
62538424|NCT00896480|EXPERIMENTAL|GSK2132231A Group|Subjects, male or female, 18 years of age or older, received up to 24 doses of GSK2132231A intramuscularly in 4 cycles. In Cycle 1 (ending Week 13) 6 doses were administered at 2-week intervals; in Cycle 2 (ending Week 32) 6 doses at 3-week intervals; in Cycle 3 (ending Week 54) 4 doses at 6-week intervals and in Cycle 4 4 doses at 12-week intervals, starting 12 weeks after end of Cycle 3, followed by, after an interruption of treatment of 6 months, 4 doses at 24-week intervals.
62538425|NCT02132858||Ancillary-Correlative (genetic mutation analysis)|Patients undergo collection of blood and tissue samples for analysis via sequencing.
62538426|NCT03615859||Healthy volunteers|Healthy volunteers whose data represents a negative control
62538427|NCT03615859||Prednisolone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of prednisolone
62538428|NCT03615859||Hydrocortisone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of hydrocortisone
62538429|NCT03615859||New adrenal insufficiency group|Participants who have recently been given a new diagnosis of adrenal insufficiency
62538430|NCT03615859||High dose steroids groups|Participants who are treated with high dose steroids for management of any medical condition to serve as a positive control
62538431|NCT03696238|EXPERIMENTAL|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
62538432|NCT03696238|PLACEBO_COMPARATOR|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
62538433|NCT05405348|NO_INTERVENTION|Control|The control group received routine care (T0)
62538434|NCT05405348|EXPERIMENTAL|Intervention|Same patients, one week after T0, T1 was applied in middialysis. In T1, patients did not consume food at least half an hour before coming to hemodialysis. They also did not consume any food during hemodialysis.
62538435|NCT03477903|EXPERIMENTAL|Group A: TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
62538436|NCT03477903|EXPERIMENTAL|Group B: TAK-954 0.3 mg|TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
62538437|NCT03477903|EXPERIMENTAL|Group C: TAK-954 1.0 mg|TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
62538438|NCT03477903|ACTIVE_COMPARATOR|Group D: Metoclopramide 10 mg|Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.
62538439|NCT04055038|EXPERIMENTAL|Platinum-based chemotherapy|"This is an experimental arm of this study. Allowed therapeutic options:~1. Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);~2. Gemcitabine 1000 mg/m2 d 1, 8 + cisplatin 75 mg/m2 1 every 3 weeks;~3. Doxorubicin 40-50 mg/m2 d 1 + carboplatin AUC5 or cisplatin 60-75 mg/m2 d 1 every 3 weeks;~4. Topotecan 0.75 mg/m2 d 1-3 + cisplatin 60-75 mg/m2 or carboplatin AUC 4-5 d 1 every 3 weeks;~5. Etoposide 100 mg once daily orally d 1-7 + cisplatin 60-75 mg/m2 d1 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
62538440|NCT04055038|ACTIVE_COMPARATOR|Non-platinum monochemotherapy|"This is a control arm of this study. Allowed therapeutic options:~1. Paclitaxel 60-80 mg/m2 weekly (or day 1, 8, 15 every 4 weeks schedule);~2. Gemcitabine 1000 mg/m2 d 1, 8, 15 every 4 weeks;~3. Doxorubicin 50-60 mg/m2 d 1 every 3 weeks;~4. Topotecan 1,2-1,5 mg/m2 d 1-5 every 3 weeks;~5. Etoposide 100 mg once daily orally d 1-10 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
62538441|NCT01449448|EXPERIMENTAL|NSAID|Test Group: This group was given subacromial injections of Ketorolac.
62538442|NCT01449448|ACTIVE_COMPARATOR|Steroid|This group was given a subacromial injection triamcinolone.
62538443|NCT04676659|EXPERIMENTAL|Group 1 (rhTNK-tPA 0.10 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.10 mg/kg IV bolus over 5-10 seconds.
62538444|NCT04676659|EXPERIMENTAL|Group 2 (rhTNK-tPA 0.25 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.25 mg/kg IV bolus over 5-10 seconds.
62538445|NCT04676659|EXPERIMENTAL|Group 3 (rhTNK-tPA 0.32 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.32 mg/kg IV bolus over 5-10 seconds.
62538446|NCT04676659|ACTIVE_COMPARATOR|Group 4 (rt-PA 0.9 mg/kg)|10% of rt-PA 0.9 mg/kg administered as an initial IV bolus followed by the remaining 90% as an IV infusion over the next 1 hour.
62538447|NCT06172621|ACTIVE_COMPARATOR|SCAP alone|After a run-in phase of 2-4 months to determine individualized stimulation parameters, participants will be randomized into a comparator group of two weeks (6 sessions) of SCAP intervention alone.
62538448|NCT06172621|EXPERIMENTAL|SCAP plus task-oriented exercise|After a run-in phase of 2-4 months to determine individualized stimulation parameters, participants will be randomized into a comparator group of two weeks (6 sessions) of SCAP intervention plus upper extremity task-oriented exercise.
62538449|NCT01246063|EXPERIMENTAL|Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)|Dose Level 0: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (27 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.
62538450|NCT01246063|EXPERIMENTAL|Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)|"Dose Level 1: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (36 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.~Dose Level 1: Carfilzomib IV (1 dose level above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (1 dose level above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (1 dose level above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.~Dose Level 2: Carfilzomib IV (2 dose levels above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (2 dose levels above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (2 dose levels above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib."
62538451|NCT01246063|EXPERIMENTAL|Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)|Dose Level 2: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (45 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.
62538452|NCT01246063|EXPERIMENTAL|Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)|Dose Level 3: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (56 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.
62538453|NCT01246063|EXPERIMENTAL|Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)|Cohort 0: Carfilzomib IV (56 mg/\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
62538454|NCT01246063|EXPERIMENTAL|Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)|Carfilzomib IV (56 mg/\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
62538455|NCT04229173|OTHER|MSA patients|"Patients with multiple system atrophy will be examined at baseline, 6 months and 12 months via the following procedures performed at all 3 visits:~* a clinical examination;~* blood and cerebrospinal fluid (CSF) (optional) sampling for the assessment of selected fluid biomarkers;~* MRI for the assessment of brain volume, white matter integrity and cerebral iron deposition; DAT-SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography) for the assessment of presynaptic dopaminergic function"
62538456|NCT04229173|OTHER|Healthy volunteers|healthy. Controls will undergo an MRI scan at baseline, 6 months and 12 months, and a DAT-SPECT(Dopamine Transporter, Single Photon Emission Computed Tomography) scan at baseline and 12 months.
62538457|NCT04293796|EXPERIMENTAL|TNBC group|A group with TNBC in neoadjuvant therapy will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then 12 cycles of neoadjuvant polychemotherapy according to the paclitaxel 60-100 mg / m² scheme in 1 day + carboplatin AUC 2 1 p in 7 days. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
62538458|NCT04293796|EXPERIMENTAL|HER2-positive breast cancer group|ER + - / HER2 + will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then docetaxel 75-100 mg / m² on the 1st day + trastuzumab 6 mg / kg (loading dose of 8 mg / kg) on the 1st day + pertuzumab 420 mg (loading dose of 840 mg) on the 1st day; 4 cycles, 1 time in 21 days and surgical treatment. In adjuvant therapy, a group of patients with HER2-positive breast cancer will receive trastuzumab for up to one year and hormone therapy with an antiestrogen (tamoxifen) or aromatase inhibitors in ER + / HER2 + tumors. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
62538459|NCT05645705|EXPERIMENTAL|Arm 1: Brush/ LISTERINE Cool Mint Antiseptic Mouthwash|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
62538460|NCT05645705|EXPERIMENTAL|Arm 2: Brush / Listerine Advanced Gum Alcohol|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
62538461|NCT05645705|EXPERIMENTAL|Arm 3: Brush / Listerine Advanced Gum Zero|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
62538462|NCT05645705|EXPERIMENTAL|Arm 4: Brush / LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
62538463|NCT05645705|OTHER|Arm 5: Brush Only|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
62538464|NCT05094856||Effect of volume expansion by albumin on the correction of peripheral tissue hypoperfusion|Effect of volume expansion by albumin on the correction of peripheral tissue hypoperfusion by measuring the proportion of patients who normalized their cutaneous re-coloring time (CRT) measured at the index level, defined by a value \<3 seconds at H1. The clinical measurement method has been standardized in the participating departments and has been used for several years in clinical practice.
62538465|NCT05094856||Effect of volume expansion by saline on the correction of peripheral tissue hypoperfusion|Effect of volume expansion by saline on the correction of peripheral tissue hypoperfusion by measuring the proportion of patients who normalized their cutaneous re-coloring time (CRT) measured at the index level, defined by a value \<3 seconds at H1. The clinical measurement method has been standardized in the participating departments and has been used for several years in clinical practice.
62538466|NCT02089035|EXPERIMENTAL|MUFA-rich dairy products|"Subjects are asked to exchange habitual dairy products for modified MUFA-rich experimental dairy products for a 12 week period.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
62538467|NCT02089035|EXPERIMENTAL|Conventional dairy products|"Subjects are asked to consume habitual non-modified dairy products for a period of 12 weeks.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
62538468|NCT04304040|EXPERIMENTAL|Single Arm|
62538469|NCT04331574||covid-19 patients|Patients with certified diagnosis of COVID-19 recruited in Italian hospitals
62538470|NCT02704403|EXPERIMENTAL|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
62538471|NCT02704403|PLACEBO_COMPARATOR|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
62714708|NCT03160625|ACTIVE_COMPARATOR|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
62714709|NCT06381336|EXPERIMENTAL|Experimental Group|Use of TRAK-SILVER platform as a treatment methodology.
62714710|NCT06381336|NO_INTERVENTION|Control Group|They did not have access to the platform and were instructed to continue with the standard care program through exercise sheets.
62538472|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I \& II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
62538473|NCT05470283|EXPERIMENTAL|OBX-115 plus Acetazolamide|Participants will receive chemotherapy to prepare your body for the study drug combination, then you will receive OBX-115 and acetazolamide.
62538474|NCT02176785|SHAM_COMPARATOR|Sham tDCS|tDCS will be applied, but then turned off after 30 seconds.
62538475|NCT02176785|EXPERIMENTAL|Anodal tDCS 2mA 10 Minutes|Anodal tDCS will be applied bi-frontally for 10 minutes at 2mA
62538476|NCT02176785|EXPERIMENTAL|Cathodal tDCS 2mA 10 Minutes|Cathodal tDCS will be applied Bi-Frontally for 10 minutes at 2mA
62538477|NCT02188173||dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
62538478|NCT03448497||Advanced Melanoma patients who intiated first-line therapy|patients who initiated any first-line therapy for advanced melanoma and had not previously received treatment for their advanced disease
62538479|NCT03303196|EXPERIMENTAL|Bihormonal bionic pancreas admission|Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.
62538480|NCT03303196|NO_INTERVENTION|Standard care admission|Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.
62538481|NCT05864963||Intervention group|18 patients treated with medial tab-type fasciocutaneous flaps
62538482|NCT05864963||Control group|46 patients were randomly chosen, through Propensity Score Matching (PSM) the matching was performed with the age variable. The types of flaps considered were: 15 cases with sural flap, 18 with soleus flap, and 13 with a gastrocnemius flap
62538483|NCT00815360|EXPERIMENTAL|Treatment group|"1. single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)~2. peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography"
62538484|NCT00815360|ACTIVE_COMPARATOR|Control Group|"1. single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)~2. macular laser per treatment criteria"
62538485|NCT05823324|EXPERIMENTAL|Therapeutic play|The therapeutic play method with the teddy bear during PIVC was applied in this group
62538486|NCT05823324|NO_INTERVENTION|Control|The standard procedure of the clinic was applied in the control group. The routine invasive procedure of the clinic, the mothers accompany their children and are involved in the procedure
62538487|NCT04702308|EXPERIMENTAL|Intervention Group|The intervention will contain two components: 1) a non-interruptive best practice advisory (BPA) in the Epic Storyboard and 2) a default suggested calculator tab in the MDCalc Connect app. Six clinical decision rules will be included: Canadian CT Head Rule, Canadian C-spine Rule, HEART Score, PERC Rule, Wells' PE Criteria and Wells' DVT Criteria. Predefined criteria based on chief complaint, patient age and vital signs will be used to determine when a decision rule may be relevant in a patient encounter. When a patient meets all of the predefined criteria, the intervention will be triggered.
62538488|NCT04702308|NO_INTERVENTION|Control Group|The control group will be usual care. Specifically, providers in the control group will not receive the clinical decision rule alert or the default suggested calculator tab in the MDCalc Connect app. The control group providers will have access to the MDCalc Connect app in its standard form and functionality.
62538489|NCT00907010||Group I|11 to 18 years - composed of 12 adolescent with six women and six men
62538490|NCT00907010||Group II|20 to 26 years - composed of 12 young with six women and six men
62538491|NCT00907010||Group III|45 to 60 years - composed of 12 adult with six women and six men
62538492|NCT00907010||Group IV|66 - 82 years - composed of 12 aged with six women and six men
62538493|NCT04953936|EXPERIMENTAL|HMB|The participants will receive oral HMB-enriched nutritional supplements (65 g once daily)
62538494|NCT04953936|PLACEBO_COMPARATOR|Placebo|The participants will receive a placebo (maltodextrin 65 g once daily) with the same package as the intervention.
62538495|NCT05159167|EXPERIMENTAL|Intervention group|Participants in the intervention group received two months of Baduanjin exercise training provided by the specialist coach 3 days per week in Hubei Cancer Hospital, and they were also required to do Baduanjin exercise at home for the remaining 4 days each week for at least 20 min per day. All the participants are requested to monitor and record adverse effects during their exercise sessions.
62538496|NCT05159167|PLACEBO_COMPARATOR|Control group|Participants in the control group were requested to maintain their original daily physical activity for no less than 20 min per day over the following 6-month period and record their daily activity at home by themselves. These data were collected by a researcher during the participants' time in the study and at the 6-month follow-up at the hospital. After the 6-month follow-up, the participants were provided with 1-month professional Baduanjin exercise guidance by the trial's specialist coach for free if they wished.
62538497|NCT01371383|EXPERIMENTAL|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
62538498|NCT01371383|PLACEBO_COMPARATOR|Placebo|Soybean oil
62538499|NCT03994783|ACTIVE_COMPARATOR|Standard of Care (SOC)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants)
62714711|NCT03994016|EXPERIMENTAL|WiseGuyz Participant|Individuals in this arm will receive the WiseGuyz program in their grade 9 year.
62538500|NCT03994783|EXPERIMENTAL|Standard of Care plus Rituximab (SOCR)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants) Rituximab (375 mg/m2 max 1 g (no dose adjustment for paediatric participants), n=2 14 days +/- 2 days apart)
62538501|NCT05258448||COLA 1: Locally advanced non-small-cell lung cancer|Patients with locally advanced non-small-cell lung cancer treated with radiotherapy alone or in combination with chemotherapy with curative intent. Patients are included before initiation of the treatment. A Cardiac MR and ECG are performed at the beginning of the treatment, and at 6, 12, and 24 months after radiotherapy.
62538502|NCT05258448||COLA 2 Locally advanced non-small-cell lung cancer|Patients with locally advanced non-small-cell lung cancer treated with radiotherapy alone or in combination with chemotherapy with curative intent. Patients not included in COLA 1 cohort are offered one cardiac MR and ECG between 12-24 months after radiotherapy treatment.
62538503|NCT00000116|EXPERIMENTAL|Docosahexaenoic acid + Vitamin A|Participants randomized to this arm received 1200 mg/d docosahexaenoic acid and 15000 IU/d Vitamin A as retinyl palmitate
62538504|NCT00000116|PLACEBO_COMPARATOR|Control fatty acid + Vitamin A|Patients randomized to this arm received 500 mg/d of fatty acid with no docosahexaenoic acid and 15000 IU/ Vitamin A as retinyl palmitate
62538505|NCT01903135|OTHER|[HCO3-] >= 27 mmol/L (Group 1)|All obese patients with plasmatic\[HCO3-\] \>= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS
62538506|NCT01903135|OTHER|[HCO3-]< 27mmol/L+pneumologist (Group 2)|Among obese patients with serum \[HCO3-\]\< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.
62538507|NCT01903135|OTHER|[HCO3-]< 27 mmol/L (Group 3)|Obese patients with a \[HCO3-\]\<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)
62538508|NCT04326621|EXPERIMENTAL|PRT group|pressure Release Technique and exercises
62538509|NCT04326621|ACTIVE_COMPARATOR|Exercises group|Only exercises
62538510|NCT01900951|EXPERIMENTAL|Temozolomide|"Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study"
62538511|NCT03906552|EXPERIMENTAL|acupressure group|"2 neonates did not calm down before heel lancing; oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well.~Acupressure was performed when the mother was holding the neonate on her arm. For two minutes, acupressure was performed in the acupressure points (Kun Lun (UB60) and Taixi (K3). Each point was applied acupressure for 60 seconds, and heel lancing was performed right after this procedure. The acupuncture points that Kun Lun (UB60) and Taixi (K3) are on the side of the ankle."
62538512|NCT03906552|EXPERIMENTAL|masssage group|"oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~Foot massage was performed when the mother was holding the neonate on her arm. Each neonate was given foot massage for two minutes, and heel lancing was performed right after the massage."
62538513|NCT03906552|NO_INTERVENTION|control group|"oxygen saturation and heart rate values of 1 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~No application was made to theneonates in the control group before heel lancing procedure"
62538514|NCT00625053|EXPERIMENTAL|1|Laparoscopic repair
62538515|NCT00625053|ACTIVE_COMPARATOR|2|Open repair
62538516|NCT03837002|EXPERIMENTAL|foot care protocol|foot examination at the first interview, foot care and training once a month and weekly follow-up for 3 months, foot examination at the last interview (six month)
62538517|NCT03837002|NO_INTERVENTION|Control|foot examination at the first interview, foot examination at the last interview (six month)
62538518|NCT06259188|EXPERIMENTAL|Personalized Breathing Exercise Device Group|In the personalized respiratory exercise device group, the initial pressure load will be set to the resistance level corresponding to 40% of the MIP and MEP measurements. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. Participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. As the progression progresses, the perceived exertion level will be increased by 5-10% on a weekly basis, to be in the range of 4-6 according to the Modified Borg scale.
62714712|NCT03994016|NO_INTERVENTION|Comparison Participant|Individuals in this arm will not receive any intervention in their grade 9 year, and will be used to create a matched comparison group for individuals in Arm 1 (WiseGuyz Participants).
62714713|NCT06710210|EXPERIMENTAL|Hybrid PCI strategy|Hybrid percutaneous coronary intervention with a bioresorbable scaffold and drug-coated balloon(s)
62714714|NCT06710210|ACTIVE_COMPARATOR|Conventional PCI strategy|Percutaneous coronary intervention with drug-eluting stent(s)
62714786|NCT03352765|EXPERIMENTAL|rituximab, bendamustine & melphalan and ASCT|This is a phase I study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts. Patients who are deemed inevaluable will be replaced for the primary objective. Patients will be considered inevaluable if they don't receive one dose of conditioning regimen and are removed from the study.
62714787|NCT03721250||thoracic epidural|patients receiving thoracic epidural
62538519|NCT06259188|ACTIVE_COMPARATOR|Respiratory Muscle Training Group|Respiratory muscle training will be done with Threshold® IMT and Threshold™ PEP devices. Training intensity will be set to 40% of MIP and MEP measurements in the first week. For inspiratory muscle training, participants will be asked to rest after 5 breathing repetitions and repeat the training for 10 sets. Participants will be asked to rest after 5 exhalation repetitions for expiratory muscle training and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. As the progression progresses, the perceived exertion level will be increased by 5-10% on a weekly basis, to be in the range of 4-6 according to the Modified Borg scale. At this point, if the training threshold exceeds the upper pressure limits of Threshold® IMT + Threshold™ PEP devices, the training intensity will continue at the upper limit.
62538520|NCT05228535|NO_INTERVENTION|Control|Continue current NICU feeding protocol, introducing human milk fortifier at 8 days
62538521|NCT05228535|EXPERIMENTAL|Intervention|Introducing human milk fortifier at 1 day
62538522|NCT04338204||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
62538523|NCT05347212|EXPERIMENTAL|Nivolumab+Relatlimab|nivolumab 480 mg IV plus relatlimab 480 mg IV every 4 weeks for up to 2 years
62538524|NCT03326713|EXPERIMENTAL|Telephone Counseling & Navigation (TCN)|Telephone Counseling
62538525|NCT03326713|ACTIVE_COMPARATOR|Mailed Targeted Print (TP)|Mailed Targeted Print
62538526|NCT03326713|OTHER|Usual Care (UC)|Control
62538527|NCT06397027|EXPERIMENTAL|Dose-escalation + Dose-expansion of Ziftomenib|The first group of 3 participants will receive the starting dose of ziftomenib. If no intolerable side effects are seen, the rest of the study participants will receive a higher dose of ziftomenib. If intolerable side effects were seen at the starting dose, the next group of 3 participants will receive a lower total dose given for a shorter time period. If needed for safety, an even lower total dose schedule can be assigned to the next group of participants.
62538528|NCT05938608|EXPERIMENTAL|Regimen 1 (Oral primaquine), 2(IV primaquine phosphate), 3(IV carboxyprimaquine)|"Regimen 1 (Oral primaquine): Primaquine 15 mg base orally once~Regimen 2 (IV primaquine phosphate): Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously~Regimen 3 (IV carboxyprimaquine): Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously"
62538529|NCT02445274|EXPERIMENTAL|Capsule-reserved surgical procedure|"In this group, the anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.~Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group."
62538530|NCT02445274|NO_INTERVENTION|Conventional surgical procedure|In this group, the anterior lens capsule was not reserved or attached onto the posterior lens capsule.
62538531|NCT01173081|EXPERIMENTAL|Teriparatide|Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
62538532|NCT01173081|PLACEBO_COMPARATOR|Placebo Control|Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
62538533|NCT06628557|EXPERIMENTAL|The Effect of Mandala Art Therapy on Anxiety in Patients Undergoing Total Hip Replacement|"Between May 22, 2024, and December 30, 2024, patients undergoing total hip replacement surgery at Samsun Gazi State Hospital's Orthopedic Surgery Clinic will be informed about the study. Between May 22, 2024, and December 30, 2024, patients undergoing total hip replacement surgery at Samsun Gazi State Hospital's Orthopedic Surgery Clinic will be informed about the study. Those who agree to participate will complete an Informed Consent Form, Patient Introduction Form, Pain Assessment Scale, and State-Trait Anxiety Inventory (STAI-I). One group will engage in mandala coloring activities using a coloring book on the second day post-surgery, while the other group will not receive this intervention. The same questionnaires will be administered again after the intervention.~Data Analysis Data evaluation will utilize frequency, percentage, mean, standard deviation, Student's t-test, analysis of variance, and Pearson correlation analysis."
62538534|NCT06628557|EXPERIMENTAL|The Effect of Mandala Art Therapy on Pain in Patients Undergoing Total Hip Replacement|"Between May 22, 2024, and December 30, 2024, patients undergoing total hip replacement surgery at Samsun Gazi State Hospital's Orthopedic Surgery Clinic will be informed about the study. Between May 22, 2024, and December 30, 2024, patients undergoing total hip replacement surgery at Samsun Gazi State Hospital's Orthopedic Surgery Clinic will be informed about the study. Those who agree to participate will complete an Informed Consent Form, Patient Introduction Form, Pain Assessment Scale, and State-Trait Anxiety Inventory (STAI-I). One group will engage in mandala coloring activities using a coloring book on the second day post-surgery, while the other group will not receive this intervention. The same questionnaires will be administered again after the intervention.~Data Analysis Data evaluation will utilize frequency, percentage, mean, standard deviation, Student's t-test, analysis of variance, and Pearson correlation analysis."
62538535|NCT05713383|NO_INTERVENTION|Walking|Walking normally without restriction
62538536|NCT05713383|EXPERIMENTAL|Walking Quietly|Participants instructed to make little noise while walking.
62538537|NCT02242032|EXPERIMENTAL|P-321|P-321 Ophthalmic Solution
62538538|NCT02242032|PLACEBO_COMPARATOR|P-321 Ophthalmic Solution Placebo|P-321 Ophthalmic Solution Placebo
62538539|NCT03661697|EXPERIMENTAL|Lytera Arm|4 week washout period with skin care regimen including Lytera 2.0 followed by 2 laser treatments.
62714788|NCT05817461|EXPERIMENTAL|AZD0780|In Part 1, one oral dose of AZD0780 and one intravenous dose of \[14C\]AZD0780. In Part 2, one oral dose of \[14C\]AZD0780
62714789|NCT03703388|EXPERIMENTAL|Arctigenin 250mg|Arctigenin 250mg will be administered for 28 days.
62714790|NCT03703388|EXPERIMENTAL|Arctigenin 400mg|Arctigenin 400mg will be administered for 28 days.
62714791|NCT03703388|EXPERIMENTAL|Arctigenin 500mg|Arctigenin 500mg will be administered for 28 days.
62538540|NCT03661697|ACTIVE_COMPARATOR|Laser only arm|4 week washout period with a basic skin care regimen, no Lytera 2.0, followed by 2 laser treatments.
62538541|NCT00517127|ACTIVE_COMPARATOR|1|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
62538542|NCT00517127|ACTIVE_COMPARATOR|2|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
62538543|NCT05440123||bronchopulmonary cancer|"The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation.~For subjects presenting with anomalies suggestive of PBC on the STBD, a consultation in pneumo-oncology will be planned with management corresponding to routine care."
62538544|NCT05438914|EXPERIMENTAL|Reverse Shoulder Arthroplasty with subscapularis repair|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
62538545|NCT05438914|NO_INTERVENTION|Reverse Shoulder Arthroplasty without subscapularis repair|The subscapularis will not be repaired.
62538546|NCT06633484||Migraine patients|
62538547|NCT06633484||Healthy Controls|
62538548|NCT06053684|ACTIVE_COMPARATOR|Standard Non-Invasive Mechanical Servo Ventilation Arm|This arm will utilize a standard mode of non-invasive ventilation within protocol parameters.
62538549|NCT06053684|EXPERIMENTAL|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation Arm|This arm with utilize a NAVA mode of non-invasive ventilation within protocol parameters.
62538550|NCT03247192|EXPERIMENTAL|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
62538551|NCT03247192|EXPERIMENTAL|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
62538552|NCT03247192|PLACEBO_COMPARATOR|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
62538553|NCT05705765|EXPERIMENTAL|Suspension|Exercise with suspension devices.
62538554|NCT05705765|ACTIVE_COMPARATOR|Balance|Exercise over instability surfaces.
62538555|NCT05895955|EXPERIMENTAL|TetraFluvac TF vaccine|20 participants in phase I study and 200 participants in phase II study will receive a prefilled single dose of 0.5 ml of TetraFluvac TF vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
62538556|NCT05895955|ACTIVE_COMPARATOR|Vaxigrip vaccine|20 participants in phase I study and 50 participants in phase II study will receive a prefilled single dose of 0.5 ml Vaxigrip vaccine (Commercially available seasonal quadrivalent split, manufactured by Sanofi Pasteur, Ltd. France) will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
62538557|NCT05307510|ACTIVE_COMPARATOR|Intervention A - prefabricated splint|A prefabricated splint is provided to the client
62538558|NCT05307510|EXPERIMENTAL|Intervention B - custom orthosis|a custom orthosis (wrist splint with thumb spica) is fabricated by an occupational therapist
62538559|NCT06582849|EXPERIMENTAL|Standard Assistance + Enhanced Assistance|In the time period that patients are receiving radiotherapy, study participants will receive standard plus enhanced financial assistance for unmet essential needs.
62538560|NCT02873741||Validation Study|Participants will undergo a perianal and digital anorectal exam, a high resolution anoscopy, and cervical and anal swabs to determine the best method to identify women at high risk for anal cancer.
62538561|NCT05372653|EXPERIMENTAL|OPA-15406|
62538562|NCT06550973|NO_INTERVENTION|EUS-guided biliary drainage|EUS-guided biliary drainage will be performed using a bi-flanged lumen apposing metal stent (LAMS) mounted on an electrocautery-enhanced delivery. After EUS identification of the dilated CBD, a place without interposing vessels will be found by the endosonographer. Transduodenal puncture of the CBD will be performed directly with the LAMS that will be used to cautery the tract and enter the CBD. The diameter and length of the stent and the modality of placing the stent (under complete EUS view or with endoscopic or fluoroscopic guidance) will be chosen at the discretion of the endoscopist performing the procedure.
62538563|NCT06550973|EXPERIMENTAL|Rescue techniques|Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.
62538564|NCT03966183||UVFP patients post thyroplasty|Patients in this group are adults who have undergone type I medialization thyroplasty (with Montgomery implant, silicone implant, follow-up of more than 3 months) as a definitive procedure following unilateral vocal fold paralysis.
62538565|NCT03966183||Control participants|The people in this group are control subjects of the same age, sex and manual laterality as the patients.
62538566|NCT02332837|EXPERIMENTAL|Digital informed consent|"Traditional digitally signed text based informed consent~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
62538567|NCT02332837|EXPERIMENTAL|Multi-media informed consent|"Informed consent with images, text and auditory presentation~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
62538568|NCT02332837|EXPERIMENTAL|Test to train informed consent|"Informed consent with images, text, auditory presentation and test to train feature where participants get feedback on comprehension responses throughout the consent and can change them~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
62538569|NCT01404078|ACTIVE_COMPARATOR|SD Polycap without potassium|Single dose polycap without pottasium
62538570|NCT01404078|EXPERIMENTAL|DD Polycap plus potassium|Double Dose polycap with potassium
62538571|NCT03101644|OTHER|Darunavir|All patients treated with darunavir
62538572|NCT01897038|EXPERIMENTAL|Cohort 1 (Onartuzumab)|
62538573|NCT01897038|EXPERIMENTAL|Cohorts 2/3 (Onartuzumab + Sorafenib)|
62538574|NCT03429010|EXPERIMENTAL|"New guideline"|"New guideline anesthesia strategy team (Group A)"
62538575|NCT03429010|NO_INTERVENTION|Current strategy|Current anesthesia strategy team (Group B)
62538576|NCT05886387||High PEEP + Recruitment Maneuvers|Patients who received intraoperatively high PEEP (10-12 cmH2O) after a recruitment maneuvers as per the original study protocol
62538577|NCT05886387||Standard PEEP|Patients who received intraoperatively standard PEEP (0-5 cmH2O) without recruitment maneuvers
62538578|NCT05147324|EXPERIMENTAL|"MyPlan - Individualized Planned Eating Pattern"|All youth enrolled in the study will receive the 6-month MyPlan behavioral intervention. Youth and their guardian will be paired with a dietitian to individualize the eating pattern and receive support in setting and refining action plans focused on adhering to the five eating behavior goals that define the eating pattern.
62538579|NCT01653301|EXPERIMENTAL|XELOX-RT|"* Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
62538580|NCT01653301|ACTIVE_COMPARATOR|XELAC-RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
62538581|NCT04201691|EXPERIMENTAL|conventional group|Conventional group is received conventional rehabilitation program.
62538582|NCT04201691|EXPERIMENTAL|mobilization group|Mobilization group is received cervical mobilization in addition to conventional rehabilitation program.
62538583|NCT03996135|EXPERIMENTAL|Experimental : Cannulation with AccuVein AV400|Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation
62538584|NCT03996135|NO_INTERVENTION|Control|Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.
62538585|NCT04591223|EXPERIMENTAL|TAU + six weekly sessions of competency-based module (CbM)|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider as well as a well-designed, one on one structural physical workout module to be offered by a licensed senior physical trainer in public sports ground or gymnasium.
62538586|NCT04591223|NO_INTERVENTION|TAU|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider.
62538587|NCT00822406|ACTIVE_COMPARATOR|1|This arm received individualized homeopathic medicine during 6 months (initial phase), and completed three years (second phase)
62538588|NCT00822406|PLACEBO_COMPARATOR|2|This arm received placebo during 6 months. After this period, all patients received individualized homeopathic medicine for three years.
62538589|NCT03766412||School start time 8:30 AM or later|These are high schoolers with migraine who attend a school that begins at 8:30 AM or later (i.e. follows AAP recommendation re: high school start time).
62538590|NCT03766412||School start time earlier than 8:30|These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
62538591|NCT01708148|ACTIVE_COMPARATOR|Lactobacilli|30 Participants with verum
62538592|NCT01708148|PLACEBO_COMPARATOR|Placebo|30 Participants
62538593|NCT02820649|EXPERIMENTAL|Exercise training|7 weeks of exercise training
62538594|NCT02820649|SHAM_COMPARATOR|Control|Sedentary group
62538595|NCT02021357|EXPERIMENTAL|Hyperbolid combined with tongue exercises on the palate|The proprioceptive treatment protocol if run in the use of exercises with hyperboloid based on studies of Biasotto-Gonzalez (2005), for each exercise will be held 6 sets of 6 reps. Between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain, and after that period you will be asked to volunteer the proprioceptive exercise of ´ ´ tongue on the hard palate ´ ´ Biasotto-Gonzalez-based (2005), which consists of the language supported in the hard palate, you must open and close the mouth, having as the principle language as a physical reference.
62538596|NCT02021357|ACTIVE_COMPARATOR|Hyperbolid|"The proprioceptive treatment protocol if run in the use of the hyperboloid, based on studies of Biasotto-Gonzalez (2005), but without the proprioceptive exercise of language in ´ ´ hard palate ´ ´.~For each exercise will be held 6 series of 6 repetitions, and between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain."
62538597|NCT02021357|NO_INTERVENTION|Control|The individuals in control group did not receive any type of intervention, being offered proprioceptive treatment after the study period.
62538598|NCT05310695|ACTIVE_COMPARATOR|NSAC rapid: treatment at the NSAC at- or within 4 weeks|NSAC service delivered according to ordinary procedures, 4 weeks after referral.
62538599|NCT05310695|ACTIVE_COMPARATOR|NSAC ordinary: treatment at the NSAC after 10-14 weeks|NSAC service delivered according to ordinary procedures, 10-14 weeks after referral, by and large equivalent to current waiting time
62538600|NCT05310695|ACTIVE_COMPARATOR|NSAC - active control|Monodisciplinary examination at the NSAC close to diagnosis-specific deadline for examination as suggested by guidelines (8-26 weeks, the majority at the end of this interval)
62538601|NCT06232473|EXPERIMENTAL|Patient Education|The patient education program consists of three individual sessions (consultations with the participant's doctor, one to one and a half hour duration each) and one group session (three hours in groups of up to 16 participants). The program focuses on providing patients with a positive and evidence-based understanding of their illness by providing an individualized bio-psycho-social explanation of multisystem functional somatic disorder.
62538602|NCT06232473|ACTIVE_COMPARATOR|Enhanced Usual Care|Inclusion consultation and final visit at end of treatment (week 12) are the only contacts provided to participants randomized to receive enhanced usual care.
62538603|NCT06232473|EXPERIMENTAL|Duloxetine and Enhanced Usual Care|"Duloxetine will be given as capsules orally once daily. Participants will commence with 2 weeks of 30 mg duloxetine and then increase the dose to 60 mg duloxetine (two capsules). If participants are unable to increase in dose due to adverse events, but still tolerate the initial dose of 30 mg duloxetine, this dose is kept for the remaining part of the trial. Treatment will continue for 8 weeks on highest dosis until primary endpoint (end of treatment). The dose is then reduced to 30 mg duloxetine for 1 week after which the study drug is discontinued.~In addition, participants will recieve enhanced usual care as described above."
62538604|NCT06232473|PLACEBO_COMPARATOR|Placebo and Enhanced Usual Care|"Participants will recieve the active placebo benztropine mesylate 0,5 mg. In order to best mimic the dosage increase of the duloxetine treatment program a passive placebo RAP will be added for the 8 weeks of high dosage treatment. Benztropine mesylate and passive placebo will be given as capsules orally, and will be re-encapsulated by the hospital pharmacy to assure identical appearance to the duloxetine capsules. Participants will commence with 2 weeks of 0.5 mg benztropine mesylate (one capsule) and continue with 0.5 mg benztropine mesylate and passive placebo RAP (two capsules) for 8 weeks. This will be end of treatment. Participants will then be asked to reduce to one capsule (0.5 mg benztropine mesylate) for 1 week after which the study drug is discontinued.~In addition, participants will recieve enhanced usual care as decribed above."
62538605|NCT06232473|EXPERIMENTAL|Patient Education and Duloxetine|Participants in this arm will recieve patient education as described above. In addition, participants will recieve duloxetine as described above.
62538606|NCT06232473|EXPERIMENTAL|Patient Education and Placebo|Participants in this arm will recieve patient education as described above. In addition, participants will recieve the placebo treatment as described above.
62538607|NCT02902367|EXPERIMENTAL|Intervention:|Outdoor walking and strength exercise, Three months, daily SMS.
62538608|NCT02902367|OTHER|Control group|Usual care; no restriction for exercise, Three months
62538609|NCT02495259|EXPERIMENTAL|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
62164333|NCT03023878|EXPERIMENTAL|Blinatumomab|"Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time.~An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days.~There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death."
62164334|NCT04108208|EXPERIMENTAL|Apalutamide 240 milligram (mg) plus ADT|Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
62164335|NCT04108208|PLACEBO_COMPARATOR|Placebo plus ADT|Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
62164336|NCT00788671|EXPERIMENTAL|Treatment (levonorgestrel-releasing intrauterine system)|Patients undergo placement of a levonorgestrel-releasing intrauterine system.
62538610|NCT02495259|ACTIVE_COMPARATOR|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
62538611|NCT02495259|ACTIVE_COMPARATOR|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
62538612|NCT05943808||Book reading|Test subjects in this group are given a page range within a traditional acupuncture text book to study for 30 minutes.
62538613|NCT05943808||VR pre-recorded video watching|Test subjects in this group are given a video which was pre-recorded with our Virtual reality system to study for 30 minutes.
62538614|NCT06360055|EXPERIMENTAL|D-mannose and dabigatran etexilate|Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on day 1 and day 16 of the trial period. And they will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
62538615|NCT04655430|EXPERIMENTAL|3-second SDF application|3-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62538616|NCT04655430|EXPERIMENTAL|5-second SDF application|5-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62538617|NCT04655430|EXPERIMENTAL|10-second SDF application|10-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62538618|NCT04655430|EXPERIMENTAL|15-second SDF application|15-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62538619|NCT04655430|EXPERIMENTAL|30-second SDF application|30-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62538620|NCT04655430|EXPERIMENTAL|45-second SDF application|45-second application time of silver diamine fluoride (38% SDF) in arresting tooth decay (dental caries) in the primary teeth of preschool children.
62538621|NCT04655430|EXPERIMENTAL|60-second SDF application|60-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62164337|NCT01854372|EXPERIMENTAL|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
62538622|NCT04655430|EXPERIMENTAL|120-second SDF application|120-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62164338|NCT05716971||RD: (study case group A)|Redetachment under Densiron
62538623|NCT04655430|EXPERIMENTAL|180-second application time|180-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
62538624|NCT05865730|EXPERIMENTAL|Phase 2 - NSCLC|Oncobax-AK (1 capsule) will be administered daily until PD\< excessive toxicity or withdrawal of consent
62538625|NCT05865730|EXPERIMENTAL|Phase 2 -RCC|Oncobax-AK (1 capsule) will be administered daily until PD\< excessive toxicity or withdrawal of consent
62538626|NCT01001624|EXPERIMENTAL|A|Melanil facial cream
62538627|NCT01001624|ACTIVE_COMPARATOR|B|Hydroquinone 2% cream
62538628|NCT00394524|EXPERIMENTAL|Computer assisted IV insulin infusion|Subjects in this group will receive continuous intravenous (IV) Insulin Infusion using glucommander computer guided system. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
62538629|NCT00394524|ACTIVE_COMPARATOR|Standard insulin infusion algorithm|Subjects in this group will receive Insulin using Standard insulin infusion algorithm. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
62164339|NCT05716971||RA : (control group B)|reattachment under Densiron
62164340|NCT06156488|ACTIVE_COMPARATOR|Anorganic bovine bone|Maxillary sinus floor augmentation grafted with anorganic bovine bone
62164341|NCT06156488|EXPERIMENTAL|Anorganic bovine bone + polynucleotides and hyaluronic acid|Maxillary sinus floor augmentation grafted with anorganic bovine bone + polynucleotides and hyaluronic acid
62538630|NCT03968978|EXPERIMENTAL|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
62538631|NCT03968978|EXPERIMENTAL|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
62538632|NCT05471492|EXPERIMENTAL|Treatment Group 1|PF-06480605 150 mg
62538633|NCT05471492|PLACEBO_COMPARATOR|Treatment Group 2|Placebo
62538634|NCT05623618|EXPERIMENTAL|Intervention (PACE labelling)|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
62538635|NCT05623618|NO_INTERVENTION|Control (usual practice)|PACE labelling not implemented. Secondary schools continue with their usual practice.
62538636|NCT06403280|EXPERIMENTAL|Interventional Day|Participants will receive vodka with rum flavored orange juice with a target blood alcohol of 0.4 ‰ 30 minutes after alcohol consumption. The required amount of vodka will be calculated with the Widmark formula.
62538637|NCT06403280|PLACEBO_COMPARATOR|Placebo Day|Participants will receive a non-alcoholic rum flavored orange juice.
62538638|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 1|100 mg GDC-0810 once daily (QD) in fasting state.
62538639|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 2|200 mg GDC-0810 QD in fasting state.
62164342|NCT02278822|EXPERIMENTAL|Low dose oral liposomal glutathione|Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.
62164343|NCT02278822|EXPERIMENTAL|High dose oral liposomal glutathione|Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.
62538640|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 3|400 mg GDC-0810 QD in fasting state.
62538641|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 4|600 mg GDC-0810 QD in fasting state.
62538642|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 5|600 mg GDC-0810 QD in non-fasting state.
62538643|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 6|300 mg GDC-0810 twice daily (BID) in fasting state.
62538644|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 7|800 mg GDC-0810 QD in fasting state.
62538645|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 8|800 mg GDC-0810 QD in non-fasting state.
62538646|NCT01823835|EXPERIMENTAL|Phase Ia - Cohort 9|400 mg GDC-0810 BID in fasting state.
62538647|NCT01823835|EXPERIMENTAL|Phase IIa - Cohort A1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).
62538648|NCT01823835|EXPERIMENTAL|Phase IIa - Cohort A2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.
62538649|NCT01823835|EXPERIMENTAL|Phase IIa - Cohort B1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤1 prior therapy with an aromatase inhibitor (AI).
62538650|NCT01823835|EXPERIMENTAL|Phase IIa - Cohort B2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤1 prior therapy with an AI.
62538651|NCT01823835|EXPERIMENTAL|Phase Ib - Cohort C1|400 mg GDC-0810 + 125 mg Palbociclib QD.
62164344|NCT01562288||Observational|Previously collected serum and DNA from peripheral blood mononuclear cell samples are analyzed for HER2-specific antibodies and FcγR genotype by ELISA and PCR.
62164345|NCT03581344|NO_INTERVENTION|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
62538652|NCT01823835|EXPERIMENTAL|Phase Ib - Cohort D1|≤600 mg GDC-0810 QD + LHRH agonist once monthly.
62538653|NCT05958888|EXPERIMENTAL|Front of package food label|4 labels (3 sodium labels, 1 control barcode label) are shown on an image of a soup can
62164346|NCT03581344|EXPERIMENTAL|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
62164347|NCT04771624||Patients|Subjects who have been Covid positive by RT-PCR at least 60 days ago and not having any symptoms of Covid-19 at the moment
62164348|NCT04771624||Healthy|Subjects who do not have any general medical, neurological or psychiatric disorder
62164349|NCT04096261||Healthy controls|Healthy controls recruited through public advertisement.
62164350|NCT04096261||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement
62538654|NCT03259659||irritable bowel disease patient|Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
62538655|NCT03259659||healthy control|Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
62538656|NCT02368951|EXPERIMENTAL|BAY1187982|"Dose-escalation phase:~Approximately 30 subjects will participate in the dose-escalation phase The total number of subjects will depend on the number of cohorts necessary to identify the MTD.~MTD expansion phase:~Once the MTD has been determined, two expansion cohorts in FGFR2 expressing indications are planned:~Cohort 1: Triple negative breast cancer (TNBC). This cohort will enroll 80 subjects (N=40 with low to moderate FGFR2 expression and N=40 with high FGFR2 expression) Cohort 2: Other indications expressing FGFR2. This cohort 40 subjects will be enrolled."
62538657|NCT02398383|EXPERIMENTAL|CF with Normal Glucose Tolerance|Individuals with CF without cystic fibrosis related diabetes
62538658|NCT02398383|EXPERIMENTAL|Cystic Fibrosis Related Diabetes|Individuals with cystic fibrosis and cystic fibrosis related diabetes
62538659|NCT02398383|ACTIVE_COMPARATOR|Control|Age matched control subjects
62538660|NCT01802450|EXPERIMENTAL|Dasatinib (Sprycel)|Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib
62538661|NCT01497808|EXPERIMENTAL|Ipilimumab and Radiotherapy (8 Gy x 2)|
62538662|NCT01497808|EXPERIMENTAL|Ipilimumab and Radiotherapy (8 Gy x 3)|
62538663|NCT01497808|EXPERIMENTAL|Ipilimumab and Radiotherapy (6 Gy x 2)|
62538664|NCT01497808|EXPERIMENTAL|Ipilimumab and Radiotherapy (6 Gy x 3)|
62538665|NCT04131738|EXPERIMENTAL|Baricitinib 2 mg Dose Level|"* On Day 0 the allograft will be infused per standard institutional practice~* Baricitinib will be administered PO at a starting dose of 2 mg daily from Day -3 to Day 100~* After Day 100, for patients already dose reduced to 2 mg daily, reduce baricitinib to 2 mg every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
62538666|NCT04131738|EXPERIMENTAL|Baricitinib 4 mg Dose Level|"* On Day 0 the allograft will be infused per standard institutional practice~* Baricitinib will be administered PO at a starting dose of 4 mg daily from Day -3 to Day 100~* After Day 100, for patients at a dose of 4 mg daily, reduce baricitinib to 2 mg daily for one month, then every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
62538667|NCT05643053|EXPERIMENTAL|thomas fixation|
62538668|NCT05643053|EXPERIMENTAL|elastic band|
62538669|NCT05643053|EXPERIMENTAL|normal fixation adhesive tape|
62538670|NCT05643053|EXPERIMENTAL|reinforced adhesive tape fixation|
62538671|NCT03850314|EXPERIMENTAL|Glycine|Glycine total daily dose of 150mg/kg divided three times daily with meals (powder dissolved in 1 cup of water) for 12 weeks.
62538672|NCT06237439|EXPERIMENTAL|Move with HaRT|Move with HaRT is a 12-session, weekly, manualized mental health intervention led by trained paraprofessionals. It is delivered in groups of 8-12 individuals and includes breathwork, yoga poses, guided meditations, and discussions aligned with weekly themes. Group discussions include topics such as noticing how we feel in our bodies, recognizing and allowing all emotions, practicing self-acceptance, and developing deeper connections with others with whom we feel safe.
62538673|NCT06237439|ACTIVE_COMPARATOR|Services as Usual|Services as usual are ongoing activities provided by anti-trafficking agencies that include basic counseling, vocational training, games and entertainment (e.g., movies and social activities).
62538674|NCT03019159||Tele-consulting|One visit out of two takes place with teleconsulting and the other is a face-to-face consultation
62538675|NCT03019159||No tele-consulting|
62538676|NCT03910387|EXPERIMENTAL|Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl)|Patients receive gemcitabine/nab-paclitaxel combination chemotherapy on days 1, 8 and 15, and telotristat ethyl PO QD, BID, or TID on days 1 and 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62538677|NCT03910387|ACTIVE_COMPARATOR|Group 2 (gemcitabine/nab-paclitaxel)|Patients receive gemcitabine/nab-paclitaxel chemotherapy (at the discretion of the investigator) on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62538678|NCT01382654|EXPERIMENTAL|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
62538679|NCT01382654|EXPERIMENTAL|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
62538680|NCT01382654|EXPERIMENTAL|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
62538681|NCT01382654|EXPERIMENTAL|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
62538682|NCT01382654|ACTIVE_COMPARATOR|azelastine 0.1%|nasal spray 2 sprays in each nostril for a total of 3 doses
62538683|NCT02173314|EXPERIMENTAL|Treatment|
62538684|NCT02173314|NO_INTERVENTION|Comparison|
62538685|NCT04819841|EXPERIMENTAL|nula-cel Drug Product|nula-cel Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.
62538686|NCT05326776|EXPERIMENTAL|Order 1|Participants will receive 4mcg/2ml oxytocin during Session 1 and 2ml isotonic saline during Session 2, injected into the forearm.
62538687|NCT05326776|EXPERIMENTAL|Order 2|Participants will receive 2ml isotonic saline during Session 1 and 4mcg/2ml oxytocin during Session 2, injected into the forearm.
62538688|NCT04808310|ACTIVE_COMPARATOR|Angiography|The indication to further coronary intervention will be based on angiographic diameter stenosis.
62538689|NCT04808310|EXPERIMENTAL|Quantitative flow ratio (QFR)|The indication to further coronary intervention will be based on QFR.
62538690|NCT06102681|NO_INTERVENTION|control group|Patients who are in the control group will receive standard clinical care and these patient will be stand up 1. day after operation.
62538691|NCT06102681|EXPERIMENTAL|experimental group|Patients who are in the experimental group will receive standard clinical care and they will stand up 8. hours after operation.
62538692|NCT05179538|EXPERIMENTAL|Single Arm Treatment|Cued picture naming therapy will be delivered to all participants. There will be four cohorts of participants based on BDNF and ApoE genotypes.
62538693|NCT00444379|ACTIVE_COMPARATOR|PI-based HAART regimen|PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)
62714715|NCT05359250||Patients with evidence of myocardial injury related to vaccination with a SARS-CoV-2 mRNA vaccine|Patients who present with new symptoms of chest pain within 2-10 days following SARS-CoV-2 mRNA vaccination will be recruited up to 180 days following diagnosis. Patients will be screened using multiple methods and then provided informed consent. If patients are unable to consent, health care decision makers of patients who meet initial inclusion criteria will be approached for consent. Following informed consent, a cardiac MRI will be performed (if not performed prior) to assess myocardial function and potential damage. Patients will qualify on the basis of the presence of late-gadolinium enhancement and/or abnormal T1 mapping on MRI. The patient will then be taken to the cardiac catheterization lab where he/she will undergo endomyocardial biopsy and right heart catheterization (RHC) for candidate gene analysis. A blood sample will be collected to analyze circulating biomarkers associated with myocardial injury.
62714716|NCT01074125|EXPERIMENTAL|1 g/day|1 g/day KRX-0502 (ferric citrate)
62538694|NCT00444379|ACTIVE_COMPARATOR|non-nucleoside reverse transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)
62538695|NCT02600689|EXPERIMENTAL|Physical exercise training|Combined aerobic and resistance exercise for 30 or more minutes at least 3 times per week for 12 weeks using the Wii Fit Plus
62538696|NCT02600689|ACTIVE_COMPARATOR|Cognitive exercise training|Cognitive, brain-training, video gaming \~30 minutes per session, 3 times per week for 12 weeks
62538697|NCT01363882|ACTIVE_COMPARATOR|Standard NIV|Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of \<50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
62538698|NCT01363882|EXPERIMENTAL|Sleep study titrated NIV|ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) \<50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.
62538699|NCT04775849|EXPERIMENTAL|Intraoperative Berger Space Imaging|Intraoperative OCT imaging of the space between the posterior capsule and the anterior hyaloid
62538700|NCT06552143|OTHER|Stone needle therapy follows the Belt channel|"generic name: Stone needle therapy frequency: Neuromuscular Electrical Stimulation (NMES) for a total of 10 sessions, with the addition of massage therapy after the 3rd, 6th, and 9th NMES sessions, and stone needle therapy after each massage session for a total of 3 sessions.~dosage: Thirty minutes at a time, three times in total."
62538701|NCT06552143|OTHER|control group|"generic name: Neuromuscular Electrical Stimulation combined with massage therapy frequency: Neuromuscular Electrical Stimulation (NMES) for a total of 10 sessions, with the addition of massage therapy after the 3rd, 6th, and 9th NMES sessions.~dosage: Thirty minutes at a time, three times in total."
62164351|NCT04096261||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
62538702|NCT06359106|PLACEBO_COMPARATOR|Control: 80% Oxygen|Before anesthesia induction, the participants inhaled 100% oxygen through the mask for 3 minutes. After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute. All patients will receive treatment through the lung-protective ventilation strategy. The respiratory parameters are VT: 6-8mL/kg, positive end-expiratory pressure (PEEP), 6-8 cmH2O; RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation. Blood will be collected for blood gas analysis within 48 hours after surgery.
62538703|NCT06359106|EXPERIMENTAL|Experimental: 40% Oxygen|Before anesthesia induction, the participants inhaled 100% oxygen through the mask for 3 minutes. After successful anesthesia induction, FiO2 will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute. All patients will receive treatment through the lung-protective ventilation strategy. The respiratory parameters are VT: 6-8mL/kg, positive end-expiratory pressure (PEEP), 6-8 cmH2O; RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation. However, when intraoperative oxygen saturation is less than 94%, the manual lung recruitment maneuver will also be performed. Patients should transfer to 80% Oxygen group if intraoperative oxygen saturation less than 85%.Blood will be collected for blood gas analysis within 48 hours after surgery.
62538704|NCT05408585|ACTIVE_COMPARATOR|"SIFIB with concentration A"|"The patients were placed in a supine position, and their skin was disinfected and draped. A linear ultrasonography probe was positioned parasagittally and slightly medially on the anterior superior iliac spine. The sartorius, iliacus, internal oblique muscles and deep circumflex iliac artery were visualized. A 80-mm peripheral nerve block needle was advanced, using the in-plane technique, from cranial to caudal until the tip was positioned between the internal oblique and iliacus muscles. Suprainguinal fascia iliaca block will be performed with concentration A."
62538705|NCT05408585|ACTIVE_COMPARATOR|"SIFIB with concentration B"|"The patients were placed in a supine position, and their skin was disinfected and draped. A linear ultrasonography probe was positioned parasagittally and slightly medially on the anterior superior iliac spine. The sartorius, iliacus, internal oblique muscles and deep circumflex iliac artery were visualized. A 80-mm peripheral nerve block needle was advanced, using the in-plane technique, from cranial to caudal until the tip was positioned between the internal oblique and iliacus muscles.Suprainguinal fascia iliaca block performed with concentration B"
62538706|NCT06045923||Outpatient|15 outpatients will be recruited from a single pre-determined clinical site (Columbia University)
62538707|NCT06045923||Inpatient|Up to 85 hospitalized patients will be recruited from other participating clinical sites
62538708|NCT02531750||Achilles tendon rupture|Patients with acute Achilles tendon rupture.
62538709|NCT01322867|ACTIVE_COMPARATOR|Reference Drug|
62538710|NCT01322867|ACTIVE_COMPARATOR|Test Drug|
62538711|NCT05918406|EXPERIMENTAL|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
62538712|NCT00785460|EXPERIMENTAL|Benfotiamine and Smoking|
62538713|NCT00785460|PLACEBO_COMPARATOR|Smoking alone|
62538714|NCT03004287|EXPERIMENTAL|Study Treatment|"Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).~Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 1: Daratumumab.~Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).~ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 2: Daratumumab.~Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.~Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician."
62538715|NCT04590638|ACTIVE_COMPARATOR|Tumescent with adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution containing adrenaline.
62164352|NCT04096261||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
62164353|NCT04096261||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
62538716|NCT04590638|ACTIVE_COMPARATOR|Tumescent without adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution not containing adrenaline.
62538717|NCT03887494|EXPERIMENTAL|Y-Strut Implant|Single interventional arm
62538718|NCT03987321|EXPERIMENTAL|Denali Group|Those who received Denali filter placement
62538719|NCT03987321|EXPERIMENTAL|Celect Group|Those who received Celect filter placement
62538720|NCT04202003|EXPERIMENTAL|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
62538721|NCT05707754|ACTIVE_COMPARATOR|High dose with unilateral administration|High dose (3ml) with unilateral administration of bupivacaine
62714717|NCT01074125|EXPERIMENTAL|6 g/day|6 g/day KRX-0502 (ferric citrate)
62714718|NCT01074125|EXPERIMENTAL|8 g/day|8 g/day KRX-0502 (ferric citrate)
62714719|NCT04883476||Chronic Low Back Pain and Neck Pain|
62538722|NCT05707754|ACTIVE_COMPARATOR|High dose with bilateral administration|High dose (3ml) with bilateral administration of bupivacaine
62538723|NCT05707754|ACTIVE_COMPARATOR|Low dose with unilateral administration|Low dose (1ml) with unilateral administration of bupivacaine
62538724|NCT05707754|ACTIVE_COMPARATOR|Low dose with bilateral administration|Low dose (1ml) with bilateral administration of bupivacaine
62538725|NCT02299115|EXPERIMENTAL|Prednisolone|Single center, prospective, observational, open trial using high-dose oral prednisolone as first-line treatment for newly diagnosed Infantile Spasms (non-Tuberous Sclerosis)
62538726|NCT02299115|ACTIVE_COMPARATOR|Vigabatrin|Retrospective controls composed of our cohort of non-Tuberous Sclerosis Infantile Spasms patients from January 2010- September 2013 who received Vigabatrin as first-line treatment.
62538727|NCT05594264|EXPERIMENTAL|Pilot Study|The objective of the second phase of the study was to conduct a 6-week pilot study of the web-based storytelling approach
62538728|NCT05594264|NO_INTERVENTION|Feasibility Phase|The objective of the feasibility phase was to assess participant views of the stories and the study website, and obtain feedback for the design of a future trial.
62538729|NCT02556463|EXPERIMENTAL|Escalation MEDI9197|MEDI9197
62538730|NCT02556463|EXPERIMENTAL|Escalation MEDI9197 with durvalumab|MEDI9197 in combination with durvalumab
62538731|NCT02556463|EXPERIMENTAL|Escalation MEDI9197 durvalumab radiation|MEDI9197 in combination with durvalumab and palliative radiation
62538732|NCT02556463|EXPERIMENTAL|MEDI9197 with palliative radiation|MEDI9197 in combination with palliative radiation
62164354|NCT05324384|EXPERIMENTAL|Low dose of sirolimus|The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 6 months. Then, The plasma trough concentration of sirolimus is maintained within the range of 5-8 ng/ml by adjusting sirolimus dose, for 6 months.
62538733|NCT00927394|EXPERIMENTAL|Combination Therapy: Aliskiren + Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks
62538734|NCT00927394|ACTIVE_COMPARATOR|Monotherapy: Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks.
62538735|NCT06079346|ACTIVE_COMPARATOR|OT-101 + mFOLFIRINOX|OT-101 IV dosed on Days 4-7 plus mFOLFIRINOX (dl-LV 400 mg/m2, irinotecan 180 mg/m2 and oxaliplatin 85 mg/m2 followed by a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycle
62538736|NCT06079346|PLACEBO_COMPARATOR|mFOLFIRINOX Only|mFOLFIRINOX (dl-LV 400 mg/m2, irinotecan 180 mg/m2 and oxaliplatin 85 mg/m2 followed by a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycle
62538737|NCT06633029||Prismaflex HF20 cohort|"Data collected from this study~Pediatrics (weighing between 8 and 20 kg) who received CRRT with Prismaflex HF20 between 2008 to current in Canada or between 2020 to current in the US"
62538738|NCT06633029||Prismaflex M60 cohort|"Data from ppCRRT registry used for comparison~Pediatrics (weighing between 8 and 20 kg) who received CRRT with Prismaflex M60 sets"
62538739|NCT01247883|ACTIVE_COMPARATOR|single dose PF-04634817 tablet|subjects receive a single dose of PF-04634817 as a tablet
62538740|NCT01247883|ACTIVE_COMPARATOR|single dose PF-04634817 solution|subjects receive a single dose of PF-04634817 as a solution
62538741|NCT02684630|EXPERIMENTAL|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
62538742|NCT02684630|EXPERIMENTAL|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
62538743|NCT06112496||smart phone addict|
62538744|NCT06112496||smart phone non addict|
62538745|NCT04458792|EXPERIMENTAL|Experimental: Biological collection|"For all the patients include in the study :~* Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue)~* MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery~* circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery~* radiotherapy toxicity : Blood samples collected before the radiotherapy~In parallel to this biological collection, standardized clinical data will be entered into a database"
62538746|NCT01401556|EXPERIMENTAL|Case Manager Intervention|Osteoporosis case-managers will identify older fracture patients in Emergency Departments and Fracture Clinics; arrange bone mineral density (BMD) tests; meet with patients to counsel them and go over their results; and then offer and prescribe bisphosphonate treatment to those with low BMD.
62714720|NCT05556434||patients with postoperative complications|Patients who experienced postoperative complications were divided into the first group. The complications were defined according to the Clavien-Dindo classification system.
62164355|NCT05324384|ACTIVE_COMPARATOR|Regular dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
62164356|NCT03677102|ACTIVE_COMPARATOR|higher chloride solutions|higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)
62538747|NCT01401556|ACTIVE_COMPARATOR|Multifaceted quality improvement intervention|Active-comparator control consisting of telephone-based education for patients and treatment guidelines with reminders for family physicians
62538748|NCT02013674|EXPERIMENTAL|Group 1: 20 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10\^8 (20 million) Allo-hMSCs.
62538749|NCT02013674|EXPERIMENTAL|Group 2: 100 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10\^8 (100 million) Allo-hMSCs.
62538750|NCT06046794|EXPERIMENTAL|metastatic pancreatic adenocarcinoma patients|Analyze of GemCore status
62538751|NCT00447993|EXPERIMENTAL|Low Dose NT-501|"NT-501 Low Dose Implant: encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina~Sham Implant in Fellow Eye"
62538752|NCT00447993|EXPERIMENTAL|High Dose NT-501|"NT-501 High Dose Implant: encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina~Sham Implant in Fellow Eye"
62538753|NCT04581369|ACTIVE_COMPARATOR|Direct Intervention|"Initial Evaluation: Prior to discharge, the care coordinator will review the hospital discharge plan, obtain the approval of the patient's physicians to co-manage the patient's care, and schedule a visit with the patient at their place of discharge.~Participants in this arm will receive direct interaction with a care coordinator to develop an individualized care plan. Frequent assessments, at least once every two weeks, will occur to continue to follow or to modify the care plan based on the needs of the patient.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians and their participation in this study will be ended."
62538754|NCT04581369|SHAM_COMPARATOR|Standard of Care|Prior to hospital discharge, the care coordinator will identify the primary care and/or hepatology provider of patients in the usual care group and will ensure follow up appointments at the time of hospital discharge. The coordinator will compose and send a letter to the primary care and/or hepatology provider summarizing the patient's diagnosis, hospital course, discharge medications, and the plan of follow-up care. If the patient does not already have a primary care or hepatology provider, the coordinator will work with the patient to identify a new provider. Subjects in this group will receive no further intervention.
62538755|NCT04581369|PLACEBO_COMPARATOR|Caregiver|The caregivers of people with cirrhosis will be enrolled in the study. They will complete the assessments at baseline, 3 months and 6 months.
62538756|NCT05668130|EXPERIMENTAL|Sacrospinous Ligament Fixation Arm|Women randomized to this arm will undergo sacrospinous ligament fixation for apical suspension procedure during pelvic organ prolapse surgery.
62538757|NCT05668130|EXPERIMENTAL|Uterosacral Liganemt Suspension Arm|Women randomized to this arm will undergo uterosacral ligament suspension for apical suspension procedure during pelvic organ prolapse surgery.
62538758|NCT04495036||dermatology patients|
62538759|NCT04495036||physicians and medical staff|
62538760|NCT02910063|EXPERIMENTAL|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
62538761|NCT04839692|OTHER|Young females (21-30 years old)|young healthy females (21-30 years old) from all phototypes who have thin or moderately thick lips
62538762|NCT04839692|OTHER|post menopausal females|post menopausal females from all phototypes who have thin or moderately thick lips
62538763|NCT00745784||1|Young spouses/domestic partners (20-49 years old) of cancer patients who have died from cancer.
62538764|NCT05691088|EXPERIMENTAL|Group A|Paracetamol injection
62538765|NCT05691088|NO_INTERVENTION|Group B|Equivalent physiological saline
62538766|NCT05530187|NO_INTERVENTION|Control|
62538767|NCT05530187|EXPERIMENTAL|Intervention|
62538768|NCT04898855|EXPERIMENTAL|OncoSleep intervention (internet-delivered cognitive-behavioral treatment for insomnia)|Participants assigned to the experimental group receive immediate access to the OncoSleep program, a web-based self-guided cognitive-behavioral intervention for insomnia consisting of 6 weekly sessions. A certified psychologist will monitor the participant's progress and provide feedback.
62538769|NCT04898855|NO_INTERVENTION|waitlist control|Participants assigned to the waitlist control group receive access to the OncoSleep program after 8 weeks.
62538770|NCT00956800|EXPERIMENTAL|telemedicine/study group|
62538771|NCT00956800|ACTIVE_COMPARATOR|control group|
62538772|NCT00681590|ACTIVE_COMPARATOR|1|vitamin D (cholecalciferol) 400 IU daily orally - low dose
62538773|NCT00681590|ACTIVE_COMPARATOR|2|vitamin D (cholecalciferol) 2000 IU daily orally - high dose
62538774|NCT01734200|EXPERIMENTAL|Eriobotyra Japonica Lindley Extract|
62164357|NCT03677102|ACTIVE_COMPARATOR|lower chloride solutions|lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)
62164358|NCT04827602||Allergy tested group|Patients who have completed penicillin allergy testing
62538775|NCT01734200|PLACEBO_COMPARATOR|Placebo|
62538776|NCT02643355|EXPERIMENTAL|Standard of Care - Olanzapine|Drug of interest in the study - Olanzapine
62538777|NCT02643355|ACTIVE_COMPARATOR|Standard of Care - Clonidine|Standard of care - clonidine
62538778|NCT05631197|EXPERIMENTAL|Trial group|
62538779|NCT05631197|ACTIVE_COMPARATOR|Control group|
62538780|NCT06498869|ACTIVE_COMPARATOR|Ketamine Group|This group will receive ketamine (0.25-0.50 mg/kg) in addition to midazolam and propofol during the colonoscopy procedure
62538781|NCT06498869|NO_INTERVENTION|Control Group|For this group, midazolam and propofol will be administered during the colonoscopy procedure. Ketamine will not be administered additionally.
62538782|NCT04296084||healthy individuals|Volunteer healthy individuals who are between the ages of 20-40 and who do not have any medical condition to affect gait or arm swing.
62538783|NCT00991705|OTHER|Group B|Atorvastatin (7 days) → Fimasartan + Atorvastatin (7 days)
62538784|NCT00991705|OTHER|Group A|Fimasartan (7 days) → Fimasartan + Atorvastatin (7 days)
62538785|NCT04918589|EXPERIMENTAL|Tranexamic Acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
62538786|NCT04918589|PLACEBO_COMPARATOR|Normal Saline|40 mL topical of 0.9% normal saline
62538787|NCT05097235||t0, t1|acute low back pain, inclusion criteria.
62538788|NCT03608865|EXPERIMENTAL|experimental group|Drug:Durvalumab + tremelimumab Dose/Potency:Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental
62538789|NCT04878848|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation Group|"Participants in the proprioceptive neuromuscular facilitation group will be given a treatment protocol consisting of rhythmic initiation, repeated stretch and hold-relax PNF techniques for upper extremity flexion-abduction-external rotation pattern and the scapular patterns of anterior elevation, posterior depression, anterior depression, posterior elevation for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks."
62538790|NCT04878848|EXPERIMENTAL|Conventional Rehabilitation Group|Participants in the conventional rehabilitation group will be given a treatment protocol consisting of stretching, strengthening exercises and joint mobilization techniques for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks.
62538791|NCT05001217|EXPERIMENTAL|Chinese herbal medicine treatment plus conventional medication|"Participants will receive integrated medicine treatment combining Chinese herbal treatment, given in the form of granules, and conventional medication for 32 weeks. Patients will be differentiated into 4 subgroups based on their Chinese medicine pattern, and receive herbal treatment accordingly. An existing clinical pathway will guide the diagnosis and treatment of the Chinese medicine patterns. The four pattern subgroups are as follows:~1) the Phlegm-heat stirring Wind subgroup; 2) the Spleen-and Kidney-Yang subgroup; 3) the Internal Stirring of Yang and Wind subgroup; and 4) the Qi deficiency and stasis of Blood subgroup~To resemble actual clinical practice, minor adjustment of herbal treatment will be possible and also adhere to the mentioned clinical guideline. The dosage of each herbal drug will follow the instructions of China Pharmacopeia."
62538792|NCT05001217|ACTIVE_COMPARATOR|Conventional medication|Conventional medication for Parkinson's disease include levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
62538793|NCT02186834|EXPERIMENTAL|Selinexor, Liposomal Doxorubicin and Dexamethasone|"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D).~After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg along with dexamethasone for 1 day. One week later, patients will receive weekly selinexor at a starting dose from 60 mg once a week to 80 mg twice a week in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone 40 mg orally weekly."
62538794|NCT01794897|EXPERIMENTAL|Valacyclovir treatment|Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
62538795|NCT01794897|PLACEBO_COMPARATOR|Placebo|Placebo comparator: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
62538796|NCT04437459|EXPERIMENTAL|Abbreviated Fat Tolerance Test|
62538797|NCT04437459|ACTIVE_COMPARATOR|Oral Glucose Tolerance Test|
62538798|NCT00820443|EXPERIMENTAL|Ceramic on metal prosthesis|Ceramic on metal prosthesis
62538799|NCT06632665|EXPERIMENTAL|Group A: Transcutaneous vagus nerve stimulation+Virtual Reality+Routine physical therapy|Patients will undergo a 60-minute session for two weeks, consisting of 30 minutes of vagus nerve stimulation, 15 minutes of virtual reality training, and 15 minutes of routine physiotherapy for 4 weeks
62538800|NCT06632665|EXPERIMENTAL|Group B: Transcutaneous Vagus Nerve Stimulation +Routine physical therapy|Patients will undergo a 60-minute session for two weeks, which includes 30 minutes of vagus nerve stimulation and 30 minutes of routine physiotherapy per session for 4 weeks.
62538801|NCT05549323|EXPERIMENTAL|Treatment Group 1|Oral PF-07054894
62164359|NCT06057532|EXPERIMENTAL|UCAN SuperStarch study drinks|Intervention group will receive UCAN SuperStarch study drinks. 100g carbohydrate will be consumed the night before surgery and 50g carbohydrate will be consumed 2 - 3 hours before surgery.
62538802|NCT05549323|PLACEBO_COMPARATOR|Treatment Group 2|Matched Placebo
62538803|NCT00813800|EXPERIMENTAL|Varenicline|Open-label; subjects will receive a behavioral intervention in addition to Varenicline.
62538804|NCT01649401|ACTIVE_COMPARATOR|Standard nubulizer|"Nebulizer sessions for the patients in this arm will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
62538805|NCT01649401|EXPERIMENTAL|Experimental nebulizer|"Nebulizer sessions for the patients in this arm will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
62538806|NCT03201432|OTHER|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
62538807|NCT03201432|EXPERIMENTAL|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R\&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
62538808|NCT04826692|EXPERIMENTAL|Metformin|Therapeutic group: Biguanidines (antidiabetic) Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
62538809|NCT04826692|PLACEBO_COMPARATOR|Placebo|Therapeutic group: NA Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
62538810|NCT02058550|NO_INTERVENTION|Arm I (no intervention)|Patients receive no additional reminders.
62538811|NCT02058550|EXPERIMENTAL|Arm II (email survey)|Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
62538812|NCT02058550|EXPERIMENTAL|Arm III (email surveys and phone calls)|Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
62538813|NCT04496115|EXPERIMENTAL|Mindfulness Intervention|Mindfulness training
62538814|NCT04496115|NO_INTERVENTION|Control|Standard of Care
62538815|NCT05952518|EXPERIMENTAL|Peripheral Nerve Stimulation|Peripheral nerve stimulation (PNS) is a procedure used to relieve chronic back pain by targeting the nerves responsible for transmitting pain signals from the back to the brain. It is a minimally invasive approach that aims to disrupt the pain signals and provide pain relief.
62538816|NCT05952518|ACTIVE_COMPARATOR|Radiofrequency Ablation|Radiofrequency ablation (RFA) is the current standard of care for facet joint pain. It is a minimally invasive procedure used to relieve chronic back or neck pain caused by issues with the small joints in the spine called facet joints.
62538817|NCT04730037|ACTIVE_COMPARATOR|Edoxaban group|
62538818|NCT04730037|ACTIVE_COMPARATOR|Warfarin group|
62538819|NCT03724214|NO_INTERVENTION|Pre-intervention|Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
62538820|NCT03724214|ACTIVE_COMPARATOR|Post-intervention|Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
62538821|NCT04521582|EXPERIMENTAL|Active Group|Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within \~1 week and measure blood pressure again. If found high, the participant will be referred to the nearest Health Post. At the Health Posts, if FB-CHWs confirms the diagnosis of hypertension, they will prescribe amlodipine 5 mg/d according to the study protocol and ask the patient to return in \~2 weeks. If blood pressure is controlled (\<140/90 mmHg) after \~2 weeks, FB-CHWs will refill amlodipine 5 mg/d for 3 months. If not, FB-CHWs will increase the dose to 10 mg/d and follow up in \~2 weeks. If still not controlled with amlodipine 10 mg, FB-CHWs will refer the patient to the Regional Hospital in Pokhara. In addition, FCHVs will visit patients' homes 3 times (at 3-, 6-, and 9-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment.
62538822|NCT04521582|ACTIVE_COMPARATOR|Comparison Group|"Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within a week or so and measure the blood pressure again. If found high, the participant will be referred to a healthcare facility (the usual care) which can diagnose and manage hypertension. In addition, FCHVs will visit patients' homes once (around 3-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment."
62538823|NCT02697240|EXPERIMENTAL|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
62538824|NCT03462979|EXPERIMENTAL|Open Results with home testing|Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 8 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 8 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine samples and complete a questionnaire.Additionally, participants will be given 4 stool test kits, with instructions that they may use these at times of their choosing and will report results and reasons for test use, if any. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
62538825|NCT03462979|NO_INTERVENTION|Blinded (sample collection only)|Participants in the blinded arms will not be given a test kit but will be given sample collection materials. During the period from week 8 to week 30 of the study, participants will be contacted a total of 6 times at random intervals, instructed to collect urine samples, and complete a questionnaire. Participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit. After completion of sample collection, all participants will be unblinded and notified of the results once the samples have been processed.
62538826|NCT05105412|EXPERIMENTAL|Lenalidomide and Gemcitabine|Lenalidomide and Gemcitabine
62538827|NCT06634186|EXPERIMENTAL|Dietary intervention|The studied patients will receive a dietary intervention. This intervention includes a dietary counselling, that enables our patients to establish a fiber-enriched diet. This adapted diet will be supplemented by the short-chain-fatty-acid propionate, that functions as fiber-surrogate.
62538828|NCT05742763|ACTIVE_COMPARATOR|Ibuprofen and PRP|Weight based Ibuprofen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
62538829|NCT05742763|ACTIVE_COMPARATOR|Acetaminophen and PRP|Weight based Acetaminophen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
62538830|NCT05742763|PLACEBO_COMPARATOR|Placebo and PRP|Placebo provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
62538831|NCT03330054||Group A|50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
62538832|NCT03330054||Group B|25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
62538833|NCT03330054||Group C|25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
62538834|NCT06600126|EXPERIMENTAL|Coping Skills Training|
62538835|NCT06600126|EXPERIMENTAL|COPD Education|
62538836|NCT02360176|EXPERIMENTAL|Sleeve gastrectomy single port|Sleeve gastrectomy single port
62538837|NCT02360176|ACTIVE_COMPARATOR|Sleeve gastrectomy multi trocar|Sleeve gastrectomy multi trocar
62538838|NCT00886405|EXPERIMENTAL|Nytroglicerin|
62538839|NCT05670535||pSS group (Study group)|"* Women with the diagnosis of pSS for at least 3 years.~* At reproductive age (without menopause).~* Receiving only hydroxychloroquine sulfate treatment.~* Presence of the symptoms of vaginitis."
62538840|NCT05670535||Women without pSS (Control group)|"* Women without any known disease.~* At reproductive age (without menopause).~* Presence of the symptoms of vaginitis."
62714721|NCT05556434||patients without postoperative complications|Patients who didn't experience postoperative complications were divided into the second group.
62714722|NCT02113319|EXPERIMENTAL|dasatinib|
62164360|NCT06057532|ACTIVE_COMPARATOR|Gatorade study drinks|Active Control group will receive Gatorade study drinks. 100g carbohydrate will be consumed the night before surgery and 50g carbohydrate will be consumed 2 - 3 hours before surgery.
62538841|NCT01773837|EXPERIMENTAL|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
62538842|NCT01773837|PLACEBO_COMPARATOR|placebo|the same number of pills (p.o.) than methylphenidate for six days
62538843|NCT06492278|EXPERIMENTAL|SMART-3RP|This is an adapted 8-session group program of the Relaxation Response Resiliency Program (3RP) for parents of children with LAD.
62538844|NCT06492278|ACTIVE_COMPARATOR|Health Education Program|This is an adapted 8-session group program to provide health behavior education.
62538845|NCT02131961|EXPERIMENTAL|Study arm|Collagenase ointment topical application, once daily for 14 days, modified Contact Cast System, applied at days 0,3, and 7.
62538846|NCT00603837|EXPERIMENTAL|Blanket|This arm includes those Extremely low gestational age newborns (ELGANs) who are to be placed on a sodium acetate warming blanket after delivery.
62538847|NCT00603837|EXPERIMENTAL|Wrap|This arm includes those ELGANs randomized to be wrapped in polyethylene after delivery.
62538848|NCT05055050|EXPERIMENTAL|UGN-201 Pre Radical Cystectomy|UGN-201 200 mg/50ml
62538849|NCT06007911|EXPERIMENTAL|Cladribine-Low Dose Cytarabine Backbone Dose Level -1|Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
62538850|NCT06007911|EXPERIMENTAL|Cladribine-Low Dose Cytarabine Backbone Dose Level 0|This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
62538851|NCT06007911|EXPERIMENTAL|Cladribine-Low Dose Cytarabine Backbone Dose Level 1|This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
62538852|NCT06007911|EXPERIMENTAL|Cladribine-Low Dose Cytarabine Backbone Dose Level 2|This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
62538853|NCT06007911|EXPERIMENTAL|Cladribine-Low Dose Cytarabine Backbone Dose Maximum Tolerated Dose (MTD)|The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.
62538854|NCT06007911|EXPERIMENTAL|CLAG-M Backbone Level -1|Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
62538855|NCT06007911|EXPERIMENTAL|CLAG-M Backbone Level 0|This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and granulocyte colony-stimulating factor (G-CSF).
62164361|NCT02127892|OTHER|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
62164362|NCT02127892|OTHER|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
62164363|NCT02127892|OTHER|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
62164364|NCT02127892|OTHER|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
62538856|NCT06007911|EXPERIMENTAL|CLAG-M Backbone Level 1|This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
62538857|NCT06007911|EXPERIMENTAL|CLAG-M Backbone Level 2|This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
62538858|NCT06007911|EXPERIMENTAL|CLAG-M Backbone Maximum Tolerated Dose|The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.
62538859|NCT02969265|EXPERIMENTAL|TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks."
62538860|NCT02969265|EXPERIMENTAL|Amlodipine 5 mg|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks."
62164365|NCT01469429|PLACEBO_COMPARATOR|Arm I (Lozenge placebo)|Patients receive lozenge placebo PO QID.
62538861|NCT02138058|PLACEBO_COMPARATOR|Placebo|a 12 week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention
62538862|NCT02138058|EXPERIMENTAL|topiramate|a 12 week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention
62164366|NCT01469429|EXPERIMENTAL|Arm II (LBR lozenge)|Patients receive lyophilized black raspberries lozenge PO (8gms/day)
62164367|NCT01469429|PLACEBO_COMPARATOR|Arm III (Saliva Substitute placebo)|Patients receive Saliva Substitute placebo PO QID.
62164368|NCT01469429|EXPERIMENTAL|Arm IV (LBR Saliva Substitute)|Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
62538863|NCT05044312|OTHER|Sleep Disturbances|Difficulty Sleeping
62538864|NCT05596565|EXPERIMENTAL|Experimental group 1|Supervised Exercise by a physiotherapist via face to face Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face. The exercises will focus on breathing exercises, passive range of motion exercises and strengthening exercises.
62538865|NCT05596565|EXPERIMENTAL|Experimental group 2|Supervised Exercise by a physiotherapist via video conference Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference. The exercises will focus on breathing exercises, passive range of motion exercises and strengthening exercises.
62538866|NCT05596565|NO_INTERVENTION|Control group|No Intervention: Control group: Unsupervised exercise Home based exercises will be explained to the patients and they will be asked to perform these exercises 2 days a week for 6 weeks.
62538867|NCT06430359||Group 1 - DP|Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with D-Pencillamine
62538868|NCT06430359||Group 2 - Trientine|Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Trientine
62538869|NCT06430359||Group 3 - ZINC|Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Zinc.
62538870|NCT01290562|EXPERIMENTAL|Stereotactic Body Radiotherapy (SBRT)|Cohort 1: Patients with spinal metastases and no prior radiation Cohort 2: Patients with spinal metastases in a previously radiated field Cohort 3: Post-operative patients with spinal metastases
62538871|NCT06409208|EXPERIMENTAL|Intervention, mHealth intervention (video and reminder SMSs)|Intervention group of postnatal mothers will get mHealth intervention package which will include video on postnatal care and 13 reminder short text messages (SMS) which will be delivered to women different days of postnatal period. Reminder SMSs will be focused on Postnatal visits, post partum family planning and exclusive breast feeding practice.
62538872|NCT06409208|NO_INTERVENTION|Control arm|Routine antenatal and postnatal care
62538873|NCT03489109|EXPERIMENTAL|Intermittent Fasting diet|HIV positive subjects with body mass index ≥30 kg/m2 (obese) consume approximately 25% of their daily calories for 2 non-consecutive days per week, normal diet for the other 5 days, and receive healthy lifestyle counseling for 12 weeks.
62538874|NCT03489109|ACTIVE_COMPARATOR|Standard of Care diet|HIV positive subjects with body mass index ≥30 kg/m2 (obese) receive nutritional and healthy lifestyle counseling for 12 weeks.
62538875|NCT02648932|OTHER|Haplo-Cord Search|If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
62538876|NCT02648932|OTHER|Matched Unrelated Donor Search (MUD)|If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
62538877|NCT03597529|EXPERIMENTAL|Low-Dose Melatonin (mg)|melatonin 2mg (equal to or over 40kg) melatonin 1mg (under 40kg) Melatonin: melatonin
62538878|NCT03597529|EXPERIMENTAL|High-Dose Melatonin (mg)|melatonin 8mg (equal to or over 40kg) melatonin 4mg (under 40kg) Melatonin: melatonin
62538879|NCT05798026|EXPERIMENTAL|EU103: Dose Escalation Cohort|Participants with advanced solid tumors will receive EU103 intravenously once every 3 weeks (3 weeks = 1 cycle) with escalating doses starting from 1 milligrams per kilogram (mg/kg) for each cohort and increasing to 3, 6, 12 or 24 mg/kg until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
62538880|NCT05798026|EXPERIMENTAL|EU103: Dose Escalation Cohort 1|1 mg/kg
62538881|NCT05798026|EXPERIMENTAL|EU103: Dose Escalation Cohort 2|3 mg/kg
62538882|NCT05798026|EXPERIMENTAL|EU103: Dose Escalation Cohort 3|6 mg/kg
62538883|NCT05798026|EXPERIMENTAL|EU103: Dose Escalation Cohort 4|12 mg/kg
62538884|NCT05798026|EXPERIMENTAL|EU103: Dose Escalation Cohort 5|24 mg/kg
62538885|NCT05798026|OTHER|Backfill cohort|Additional subjects can be registered at doses confirmed to be safety
62538886|NCT01413607|EXPERIMENTAL|Quill knotless tissue-closure device|During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
62538887|NCT01413607|ACTIVE_COMPARATOR|2-0 absorbable vicryl suture|Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.
62538888|NCT03893565|EXPERIMENTAL|GSK2831781-Double blind phase|Eligible participants will receive GSK2831781 intravenously in the double blind induction phase at different dose levels. Participants identified as Responders at Week 10 will then receive GSK2831781 subcutaneously during the double-blind ETP from Week 14 until Week 26
62538889|NCT03893565|EXPERIMENTAL|GSK2831781- Open label phase|Eligible participants will receive GSK2831781 intravenously in the open label induction phase. Participants identified as Non-Responders at Week 10 will receive GSK2831781 from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
62538890|NCT03893565|PLACEBO_COMPARATOR|Placebo matching GSK2831781- Double blind phase|Eligible participants will receive Placebo in the double blind induction phase Participants identified as Responders at Week 10 will continue to receive Placebo subcutaneously during the double-blind ETP from Week 14 until Week 26.
62538891|NCT04799938|ACTIVE_COMPARATOR|İntevention group|Prediabetic patients with age 30-50 and overweight Standart recommendations Exercise intervention will be made.
62538892|NCT04799938|NO_INTERVENTION|Control group|Prediabetic patients with age 30-50 and overweight Only Standart recommendations
62538893|NCT04799938|NO_INTERVENTION|Metformin Group|Prediabetic patients who received metformin Standart recommendations
62538894|NCT04150263|OTHER|Traditional IOL repositioning|Intraocular lens (IOL) ab externo scleral suture fixation
62538895|NCT04150263|OTHER|Modification of traditional IOL repositioning|Modified intraocular lens (IOL) ab externo scleral suture fixation
62538896|NCT05010616|EXPERIMENTAL|Three-dimensional digital simulation with fixed appliance|The records will be obtained at the first visit, which will be one week before placing brackets. At the second visit, the orthodontic appliances will be applied; then assessments will be taken after 15 minutes of showing the patient the digital simulation of their teeth alignment at the end of orthodontic treatment.
62538897|NCT02542553|EXPERIMENTAL|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
62538898|NCT00529139|ACTIVE_COMPARATOR|A|
62538899|NCT00529139|ACTIVE_COMPARATOR|B|
62538900|NCT05160857|EXPERIMENTAL|test group|
62538901|NCT01890135|ACTIVE_COMPARATOR|endothelin receptor antogonist|10 mg of zibotentan
62714723|NCT00656682|ACTIVE_COMPARATOR|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian. Registered Dietitian Counseling Alone
62538902|NCT01890135|PLACEBO_COMPARATOR|placebo|matched placebo
62538903|NCT04267029||Cases: CRTR (cardiorespiratory transfusion reaction)|Respiratory/cardiovascular disturbances after transfusion (\>/=2 of respiratory distress, pulmonary edema, cardiovascular system changes, fluid shifts, cardiac strain indicators), with or without accompanying (or pre-existing) fever
62538904|NCT04267029||Controls: HRFTR (high risk febrile transfusion reactions)|Post-transfusion fevers requiring laboratory investigation (Tmax\>/=39C, or lesser deflections if accompanied by chills/rigors), without respiratory features (hypoxia or dyspnea)
62538905|NCT05756283|EXPERIMENTAL|Multimodal Prehabilitation|Participants in the intervention group will undergo, in addition to the standard of care, 6+/-1 weeks of a personalized multimodal prehabilitation program. The interventions included will be patient-centered, aiming to optimize patients' preoperative health status while enhancing their empowerment and engagement.
62538906|NCT05756283|NO_INTERVENTION|Control group (standard of care)|Participants in the control group will receive the standard of care. This will include comorbidity optimization, anemia correction and smoking cessation advice if deemed appropriate.
62538907|NCT04385303|EXPERIMENTAL|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1.
62538908|NCT04385303|PLACEBO_COMPARATOR|Vehicle|Healthcare professional-administered intra-articular injection; performed on Day 1.
62538909|NCT00224419|ACTIVE_COMPARATOR|1 - CBT Counseling|Participants in this arm received a tailored CBT (TCBT) intervention that included: a written self-help guide, feedback about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session.
62538910|NCT00224419|EXPERIMENTAL|2 - Counseling + NRT|Women in this arm received the TCBT described in Arm 1, plus their choice of NRT. To minimize fetal exposure to nicotine for women in the TCBT+NRT arm, the dose of NRT are customized to the woman's current level of smoking. Women who smoke 5-10 cigarettes a day will be given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smokes per day. Those who smoke 11 cigarettes or more per day will be given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smokes per day, not to exceed 15 lozenges or pieces of gum per day.
62538911|NCT06148584|EXPERIMENTAL|Intervention Barbershops Group|Participants recruited from intervention barbershops will receive the barbershop-based HIV prevention initiative. The trained barber will provide the following services during regular haircut services: general, status-neutral HIV education, HIV self-test kits, and information about where to receive HIV prevention services. The barber will also lead peer support group education every two months for clients enrolled in the study.
62538912|NCT06148584|ACTIVE_COMPARATOR|Control Barbershops Group|Participants recruited from control barbershops will receive standard-of-care HIV prevention services which include facility-based HIV risk reduction counseling and testing and providing information about facility distributed HIV self-test kits.
62538913|NCT04032249|ACTIVE_COMPARATOR|Control Group (CG)|Education and modifying diet
62538914|NCT04032249|EXPERIMENTAL|Intervention Group (IG)|Education, modifying diet and Indications to record self-weighing with a frequency of 2 times per week
62538915|NCT05856643|EXPERIMENTAL|SZ011 CAR-NK|
62538916|NCT03515590|EXPERIMENTAL|Emulsion with solid droplets|Emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
62538917|NCT03515590|EXPERIMENTAL|Emulsion with liquid droplets|Emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
62538918|NCT03936712|EXPERIMENTAL|Red Bull drink (RB)|Over the study, three participants were unable to complete all test sessions due to muscle pain or injury . Thus, 19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg) completed all test sessions
62538919|NCT03936712|PLACEBO_COMPARATOR|Placebo drink|19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg)
62538920|NCT04888559|ACTIVE_COMPARATOR|Whole grain breakfast product|
62538921|NCT04888559|PLACEBO_COMPARATOR|Reference|
62538922|NCT01531543|EXPERIMENTAL|VAC-laparostomy|Primary use of Vacuum Assisted Closure (VAC) laparostomy after surgical revision because of severe peritonitis
62538923|NCT01531543|NO_INTERVENTION|Primary abdominal closure|The abdominal wall is primary closed after the surgical revision because of severe peritonitis
62538924|NCT05804916|EXPERIMENTAL|SGRT+DIBH group|Patients with left breast cancer treated with SGRT combined with DIBH technique
62538925|NCT05804916|NO_INTERVENTION|common+Free breath group|Patients with left breast cancer treated with traditional laser alignment with free breathing treatment
62164369|NCT05516836|EXPERIMENTAL|Multicomponent exercise program + Telemedicine|"The multicomponent exercise program lasted 6 weeks with sessions twice a week for a total of 12 sessions. It will have a duration of forty minutes in which the first five and the last five will be performed at a constant load of 5% of its maximum load corresponding to the warm-up and return to calm. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed.~A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence"
62538926|NCT02841163||Lumbar/cervical disc herniation group|Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.
62538927|NCT05368311|EXPERIMENTAL|Group receiving dietary recommendations including protein enriched bars .|Experimental group will consume two protein enriched bars per day during 12 weeks. First bar will be consumed 45 minutes before lunch and second bar will be consumed 45 minutes before dinner.
62538928|NCT05368311|PLACEBO_COMPARATOR|Group receiving dietary recommendations without protein enriched bars.|Placebo group will follow just dietary recommendations during 12 weeks.
62538929|NCT03146962|EXPERIMENTAL|Cohort A: Vitamin C + Surgery|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks.
62538930|NCT03146962|EXPERIMENTAL|Cohort B: Vitamin C Only|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for up to 6 months.
62538931|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 1|Vitamin C will be administered at a dose of 0.5 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.
62538932|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 2|Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C.
62538933|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 3|Vitamin C will be administered at a dose of 0.75 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.
62538934|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 4|Vitamin C will be administered at a dose of 1 g/kg intravenously for 4 days /week for 1-2 weeks prior to and following Y90 therapy for a total of 4 weeks of vitamin C. A single dose of Vitamin C at 0.5g/kg will also be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment.
62538935|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 5|A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
62538936|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 6|A single dose of Vitamin C at 0.75g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
62538937|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 7|A single dose of Vitamin C at 1g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
62538938|NCT03146962|EXPERIMENTAL|Cohort C: Vitamin C + Y-90 Dose Level 8|A single dose of Vitamin C at 1.25g/kg will be administered on the day of Y90 radioembolization, administered prior to or within 24 hours of a Y90 treatment. Vitamin C will also be administered at a dose of 1.25 g/kg intravenously for 4 days/week for 1-2 weeks following Y90 therapy.
62538939|NCT01221363|ACTIVE_COMPARATOR|Lifestyle counselling|Theory based individually tailored lifestyle counselling aimed at reduction of sitting time during leisure time and at work. Four individual sessions over a six months period.
62538940|NCT01221363|NO_INTERVENTION|Control group|No intervention control group
62538941|NCT04465695|EXPERIMENTAL|IFN beta-1b and clofazimine|A 3-day course of 3 doses of subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) consecutively on day 1 to day 3 and oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
62538942|NCT04465695|ACTIVE_COMPARATOR|Clofazimine|A 3-day course of oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
62538943|NCT04465695|NO_INTERVENTION|Control|Standard care alone
62538944|NCT03031886|EXPERIMENTAL|high GI|Cereal, milk, tea, cheese, steamed glutinous rice with chicken, carrots, bread, strawberry jam, margarine, high GI sweetener (sucrose).
62538945|NCT03031886|EXPERIMENTAL|Low GI|Cereal, milk, tea, steamed basmati rice with chicken, spinach, bread, strawberry jam, low GI sweetener (isomaltulose).
62538946|NCT04917042|EXPERIMENTAL|tazemetostat|
62538947|NCT04494880|EXPERIMENTAL|Treatment Group (Marcaine 1 Breast)|Marcaine will be injected into one randomized breast and saline into the other in the treatment group.
62538948|NCT04494880|NO_INTERVENTION|Control Group (Marcaine 2 Breasts)|Marcaine will be injected into both breasts as is currently the standard of care.
62538949|NCT02908048||Hepatocellular Carcinoma|Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
62538950|NCT02908048||Biliary Tract Cancer|Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
62538951|NCT02908048||Cirrhosis|Blood samples will be collected during regular intervals over a three year period.
62538952|NCT02908048||Chronic Liver Disease without Cirrhosis|A single blood sample will be collected at entry into the study
62538953|NCT00170664|EXPERIMENTAL|Paclitaxel, Carboplatin|
62538954|NCT04371094|ACTIVE_COMPARATOR|stylet|The stylet is a device that is put inside the endotracheal tube to facilitate its insertion into the trachea
62538955|NCT04371094|ACTIVE_COMPARATOR|bougie|The bougie is a device that is inserted into the trachea and an endotracheal tube is loaded over it and is slide into the trachea
62538956|NCT03173326|EXPERIMENTAL|Subarachnoid block|
62538957|NCT03173326|ACTIVE_COMPARATOR|General anesthesia|
62538958|NCT03295981|NO_INTERVENTION|Control group|The surgical procedure for all patients will include extensive curettage of the lesion to remove macroscopic tumor, high-speed burring of the residual cavity, adjuvant treatment to the residual cavity, followed by packing of the cavity with either polymethylmethacrylate (PMMA) bone cement (Simplex P; Stryker, Mahwah, New Jersey) alone or bone cement with subchondral allograft bone graft. The choice of cavity reconstruction will be at the discretion of the treating surgeon. Traditional local adjuvants (argon beam coagulation, phenol, ethanol, or cryotherapy) will be used depending on surgeon preference. In addition to the above standard treatment, the patients will be randomized into one of two study arms. In Arm 1, the control group, no additional local therapy will be utilized.
62538959|NCT03295981|EXPERIMENTAL|Bisphosphonate group|In Arm 2, the bisphosphonate group, 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement.
62538960|NCT03219190|EXPERIMENTAL|LST High School Online|Provided with the prevention program, consisting of e-learning modules and classroom sessions.
62538961|NCT03219190|NO_INTERVENTION|Treatment as Usual (Control)|Standard health education
62538962|NCT04516993|EXPERIMENTAL|Tenecteplase arm|
62538963|NCT04516993|OTHER|Best treatment arm (e.g. Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|The best treatment selected by local doctors
62538964|NCT02217254|ACTIVE_COMPARATOR|two 3-minute cryoablations|two 3-minute cryoablations per pulmonary vein during an atrial fibrillation ablation procedure
62538965|NCT02217254|ACTIVE_COMPARATOR|One 3-minute cryoablation|One 3-minute cryoablation per pulmonary vein during an atrial fibrillation ablation procedure
62538966|NCT04734405|EXPERIMENTAL|ProF-001 Group|"ProF-001 Group:~• During induction period: app. 5 g of ProF-001 for 6 days (twice daily app. 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of app. 2.5 g of ProF-001 at bedtime and 1 placebo capsule on days 1, 4, and 7 and~• During maintenance period: 2 doses of app. 2.5 g of ProF-001 per week for 22 weeks (total of 44 single doses) and 1 placebo capsule per week for 24 weeks"
62538967|NCT04734405|ACTIVE_COMPARATOR|Fluconazole Group|"Fluconazole Group:~* During induction period:~  1 Fluconazole 150 mg capsule on days 1, 4, and 7 and a daily dose of app. 5 g of placebo cream for 6 days (twice daily 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of 2.5 g of placebo cream at bedtime and~* During maintenance period:~  1. capsule of fluconazole 150 mg per week for 24 weeks and two doses of 2.5 g of placebo cream per week for 22 weeks (total of 44 single doses)"
62538968|NCT01971957||Sjogren-Larsson syndrome|There are no cohorts for this study.
62538969|NCT02552732|EXPERIMENTAL|NHF with or without Oxygen|NHF with or without oxygen will be delivered to COPD patients using myAIRVO™ 2 for 30 days post hospital discharge
62538970|NCT06195488||Group D|Group Diabetic
62538971|NCT06195488||Group Control|Non-diabetic patients
62538972|NCT02115932|EXPERIMENTAL|Strength & Balance Training Intervention|Subjects in this arm will undergo once weekly home-based strength and balance training for a period of 8 weeks.
62538973|NCT02115932|NO_INTERVENTION|Control|Subjects in this arm will not undertake any procedures or activities related to the study. They will continue with their prescribed medication and other medical advice from their treating physician as per usual.
62538974|NCT05267730|EXPERIMENTAL|Modern board and card games group|"Conectar Jugando Game Program: The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl \& Weir, 2018), Kaleidos Junior (Albertarelli, 1997), Sherlock Express (Kermarrec, 2019), Alles Kanone! (Knizia, 2007), Halli Galli (Shafir, 1990), Bananazul (Warsch, 2019), Blurble (Bernard, 2013), La Morada Maldita (Ortiz, 2020), Dice Academy (Gobert, 2019) and Streams (Itsubaki, 2011). Play sessions will be held in subgroups of 3-5 children within the class group. In each session, each subgroup will play two games. The games used in the program have an average duration of approximately 20-30 minutes (filler games).~All subgroups will play all games in the program the same number of times with the same rules. The game program will be the same in all participating centers to guarantee the homogeneity of its implementation"
62538975|NCT05267730|NO_INTERVENTION|Wait-list group|Wait-list. They will do the usual classes without modern board games. At the end of the postintervention evaluation, the Conectar Jugando Game Program will be implemented under the same conditions as the experimental group.
62538976|NCT05180357||SEA+NP Patients on FASENRA (benralizumab)|SEA+NP Patients on FASENRA (benralizumab)
62538977|NCT02186626|EXPERIMENTAL|WN/DEN4Δ30 Vaccine|Participants will receive one dose of the WN/DEN4Δ30 vaccine at study entry and one dose at Day 180.
62538978|NCT02186626|PLACEBO_COMPARATOR|Placebo|Participants will receive one dose of the placebo at study entry and one dose at Day 180.
62538979|NCT00788320|PLACEBO_COMPARATOR|Placebo|Placebo three times a week for 8 weeks
62538980|NCT00788320|EXPERIMENTAL|Cholecalciferol|Vitamin D3 50,000 IU three times a week for 8 weeks
62538981|NCT05127512|NO_INTERVENTION|Control Group|Control participants will only complete the knowledge questionnaire in addition to a non-validated survey created by the investigators to collect demographic information as well as attitudes towards treatments of pelvic floor disorders.
62538982|NCT05127512|EXPERIMENTAL|Video Group|These participants will be administered the study intervention, which entails viewing an education video on pelvic floor disorders.
62538983|NCT01265810|OTHER|sodium chloride -> supersaturated calcium-phosphate|Patients in this arm start first with sodium chloride 0.9% mouth rinses and go crossover to supersaturated calcium-phosphate mouth rinses.
62538984|NCT01265810|OTHER|supersaturated calcium-phosphate -> sodium chloride|Patients in this arm start first with supersaturated calcium-phosphate mouth rinses and go crossover to sodium chloride 0.9% mouth rinses.
62538985|NCT01399879||Healthy Volunteers|
62538986|NCT03292159|EXPERIMENTAL|RAVANS|
62714724|NCT00656682|EXPERIMENTAL|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based diabetes prevention lifestyle intervention offered by the community. Dietitian Counseling Plus Community Group Lifestyle Intervention.
62164370|NCT05516836|ACTIVE_COMPARATOR|Multicomponent exercise program|"The multicomponent exercise program lasted 6 weeks with sessions twice a week for a total of 12 sessions. It will have a duration of forty minutes in which the first five and the last five will be performed at a constant load of 5% of its maximum load corresponding to the warm-up and return to calm. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
62538987|NCT03292159|SHAM_COMPARATOR|Sham stimulation|
62538988|NCT04856410|EXPERIMENTAL|2-Month Arm|Astronauts on 2-month International Space Station missions will be exposed to spaceflight for a duration of 2 months. Biometric and cognitive data will routinely be collected.
62538989|NCT04856410|EXPERIMENTAL|6-Month Arm|Astronauts on 6-month International Space Station missions will be exposed to spaceflight for a duration of 6 months. Biometric and cognitive data will routinely be collected.
62538990|NCT04856410|EXPERIMENTAL|12-Month Arm|Astronauts on 12-month International Space Station missions will be exposed to spaceflight for a duration of 12 months. Biometric and cognitive data will routinely be collected.
62538991|NCT04856410|EXPERIMENTAL|No Intervention|Subjects matched to 12-month astronauts that stay on Earth and are investigated at similar time points.
62538992|NCT03155945|EXPERIMENTAL|Olorinab 25 mg TID|Participants received olorinab 25 milligrams (mg) tablet by mouth, three times daily (TID) for 8 weeks
62538993|NCT03155945|EXPERIMENTAL|Olorinab 100 mg TID|Participants received olorinab 100 mg oral tablets TID for 8 weeks
62538994|NCT06022900|NO_INTERVENTION|Control group|During the study period, this group participated in the standard breast cancer screening program, which is a nationwide health initiative implemented throughout the country to promote early detection and prevention of breast cancer.
62538995|NCT06022900|EXPERIMENTAL|Online training group|Alongside the standard breast cancer screening services, participants in this group were offered comprehensive online health education that emphasized both breast cancer awareness and prevention strategies. Additionally, they received a digital educational brochure designed to enhance their understanding of the disease. Four weeks after their enrollment in the study, participants were contacted via phone to reinforce the significance of regular screenings and to provide them with a summary of essential information regarding the benefits of early detection.
62538996|NCT06022900|EXPERIMENTAL|Face-to-face training group|In addition to the standard breast cancer screening services, individuals in this group received tailored in-person health education regarding breast cancer and its prevention through comprehensive home visits, which included a well-designed training brochure. At the conclusion of the fourth week following their enrollment in the study, participants were contacted via phone to emphasize the critical importance of regular screening. During this call, they were provided with a concise summary of key information aimed at reinforcing the benefits of early detection and encouraging ongoing participation in screening programs.
62538997|NCT02990780|ACTIVE_COMPARATOR|Conventionally fractionated CRT|Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
62538998|NCT02990780|EXPERIMENTAL|Accelerated hypofractionated CRT|Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
62538999|NCT01205984|ACTIVE_COMPARATOR|oral methylprednisolone|
62539000|NCT01205984|PLACEBO_COMPARATOR|placebo|
62539001|NCT04122144|EXPERIMENTAL|Intervention|ENHANCED-SPS intervention implemented
62539002|NCT04122144|NO_INTERVENTION|Control|Standard of care maintained. These are procedures conducted during the routine HIV care visits at the health facilities include ART card documentation as required, general/routine counseling, and adherence counseling to the non suppressors, ART drug supply based on the clinicians prescription and laboratory monitoring.
62539003|NCT00405808|EXPERIMENTAL|1|Administration of one tablet containing 20 mg of Rimonabant
62539004|NCT00405808|PLACEBO_COMPARATOR|2|Administration of one Rimonabant placebo tablet.
62539005|NCT04386486|EXPERIMENTAL|bathe group|The patients were divided into two equal groups randomly first group is BATHE anamnesis group.
62539006|NCT04386486|SHAM_COMPARATOR|standart anamnesis group|The patients were divided into two equal groups randomly second group is standart anamnesis group.
62539007|NCT03563911|EXPERIMENTAL|Brief Mindfulness-Based Intervention|Those assigned to the Brief Mindfulness-Based Intervention (BMBI) Arm will receive BMBI.
62539008|NCT03563911|ACTIVE_COMPARATOR|Control/Nutrition Education|Those assigned to the Control/Nutrition Education Arm will receive the nutrition education intervention.
62539009|NCT01852500|EXPERIMENTAL|Sham OMT|patients under standard medical care plus sham OMT
62539010|NCT01852500|OTHER|Control|patients under standard medical care plus only osteopathic evaluation
62539011|NCT05597735|EXPERIMENTAL|Tecovirimat|
62539012|NCT05597735|PLACEBO_COMPARATOR|Placebo|
62539013|NCT03460639|ACTIVE_COMPARATOR|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
62539014|NCT03460639|SHAM_COMPARATOR|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
62539015|NCT03460639|OTHER|Control group|In this group, no treatment will be done, we will only induce fatigue, for evaluation.
62539016|NCT03503526|EXPERIMENTAL|Music therapy treatment|"An intervention consisting of 12 weekly sessions of trauma-focused treatment in form of group music and imagery therapy.~Receptive music therapy."
62539017|NCT03503526|NO_INTERVENTION|Wait List Control|No treatment for approximately 12 weeks.
62539018|NCT00525798|ACTIVE_COMPARATOR|1|SMC021 - Oral Calcitonin
62539019|NCT00525798|PLACEBO_COMPARATOR|SMC021- Placebo|SMC021 - placebo
62539020|NCT04029753|EXPERIMENTAL|Walk out from operating room|Patients will return to the ward after surgery by walking.
62539021|NCT04029753|NO_INTERVENTION|Leave operating room by transporting bed|Patients will return to the ward after surgery by lying on the transporting bed.
62539022|NCT00927732|EXPERIMENTAL|hydroquinidine|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
62539023|NCT00927732|PLACEBO_COMPARATOR|capsules of sugar|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
62539024|NCT06632314|ACTIVE_COMPARATOR|Feeding continued arm|Enteral feeding will continue during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
62539025|NCT06632314|ACTIVE_COMPARATOR|Feeding restricted arm|Enteral feeding will be withhold during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
62539026|NCT06168630|EXPERIMENTAL|Manual Lymph Drainage|
62539027|NCT06168630|OTHER|Control group|
62539028|NCT01781481||Children and youth with IBD|Children/youth (ages 8-17) with confirmed diagnoses of IBD.
62539029|NCT00770081|EXPERIMENTAL|1|50mg qd vildagliptin
62539030|NCT00770081|ACTIVE_COMPARATOR|2|sitagliptin (25mg qd)
62539031|NCT04780568|EXPERIMENTAL|Treatment (osimertinib, tegavivint)|Patients receive osimertinib PO QD on days 1-28 and tegavivint IV on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive osimertinib PO QD on days 1-28. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
62539032|NCT01333774||Group 1|
62539033|NCT04943276|EXPERIMENTAL|Embr Watch|Participants will receive the device and a technical onboarding video 3 days prior to study start to allow time for familiarization with the device and troubleshooting any technical questions or problems prior to study start. The study will consist of baseline measurements prior to using the Embr device and weekly outcome assessments at Week 1, 2, 3, and 4
62539034|NCT04410237|EXPERIMENTAL|Med-Jet|"The Med-Jet injector is a novel needle-free drug-delivery system, which we believe may be a solution to the impracticalities of ILTA for mild-to-moderate psoriasis. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region.12 The drug-delivery device is highly configurable allowing adjustable depth and volume parameters.12 In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas"
62539035|NCT04410237|ACTIVE_COMPARATOR|Traditional Syringe|TAC will be injected on a half-plaque while the control half of the plaque will be untreated. A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
62539036|NCT04239027|EXPERIMENTAL|RTH258/Brolucizumab|This is a single-arm study in which all patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment from Week 16/Week 20 up to Week 40/Week 44.
62539037|NCT02955823|EXPERIMENTAL|1 arm for all patient: Ritux-Dexame-Lena|Rituximab-Dexamethasone-Lenalidomide
62539038|NCT03701854||Heart failure patients with pacemakers|Functional (6-Minute Walking test (6-MWT)) and maximal exercise capacity (Incremental Shuttle Walking test (ISWT)), respiratory (MIP, MEP; Mouth pressure device) and peripheral muscle strength (Dynamometer), pulmonary function (Spirometry) dyspnea (Modified Medical Research Council Dyspnea scale) (MMRC)), and fatigue (Fatigue Severity scale (FSS)) were evaluated in 50 patients.
62539039|NCT03701854||Healthy controls|Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
62539040|NCT03696953|EXPERIMENTAL|Probiotic|"Florajen3 Combination Probiotic Product 15 billion CFU per capsule~1 capsule daily from 28 weeks until the time of birth."
62539041|NCT03696953|NO_INTERVENTION|Placebo|Microcrystalline Cellulose
62539042|NCT03594058|EXPERIMENTAL|Solabegron modified release tablets low dose|
62539043|NCT03594058|EXPERIMENTAL|Solabegron modified release tablets high dose|
62539044|NCT03594058|PLACEBO_COMPARATOR|Placebo Comparator|
62539045|NCT03263975|EXPERIMENTAL|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
62539046|NCT03263975|EXPERIMENTAL|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
62539047|NCT02278055|EXPERIMENTAL|Radium-223|Radium Ra 223 dichloride will be administered as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles. The dosage of Radium Ra 223 dichloride after implementation of the new 2015 NIST standard is 55kBq/kg body weight.
62539048|NCT03495349||Diabetic foot infection|All of the patients followed for a diabetic foot infection in Hospices Civils of Lyon
62539049|NCT02441764||Halaven|Participants who are prescribed with Halaven per approved prescribing information of Halaven.
62539050|NCT03017612|EXPERIMENTAL|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
62539051|NCT06349590|EXPERIMENTAL|Dietary Intervention Participants|Subjects will be provided 21 days of standardized plant-based low fat/ high-fiber meals and complete a food diary up until lunch on the day prior to surgery.
62539052|NCT04730648|EXPERIMENTAL|pcsk9 inhibitor group|patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.
62539053|NCT04730648|NO_INTERVENTION|control group|Patients with comparable age, sex ratio, and BMI, but coronary arteries are relatively normal evaluated by coronary angiography. their blood and urine would be collected as the control group.
62539054|NCT01664130|EXPERIMENTAL|Treatment (SBRT)|Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.
62539055|NCT06016491|EXPERIMENTAL|Acupressure group|Before the acupressure application, the woman to be applied was informed in a quiet room for ease of application, and then she was ensured to be in a comfortable position. Women were taught to practice on a total of two points, the kidney meridian (Yong Quan-KD1) and the spleen meridian (Sanyinjiao-SP6). Since the symmetry of the selected two different points on the other extremity will also be applied, a total of 8 minutes of compression was applied to each point, provided that it was two minutes. Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each patient, and then the patients were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks. To remind the session day, information was given by the researcher via short message.
62539056|NCT06016491|SHAM_COMPARATOR|Sham acupressure group|"After all the preparations (suitability of sound and environment and information) before the application to the acupressure group were made in the sham group, the sham acupressure points determined parallel to the KD1 and SP6 points (approximately 1-1.5 cm away) were put on the bone area where the meridians do not pass has been applied.~Similar to the acupressure group, the sham acupresuure group was treated with symmetrical extremities and for similar durations."
62539057|NCT01339338|EXPERIMENTAL|warm media|Subjects undergo HSG using a warm media heated with a 37℃ water-bathing
62539058|NCT01339338|NO_INTERVENTION|cold media|the contrast media under room temperature without heat
62539059|NCT05293912|EXPERIMENTAL|SG2501|SG2501 monotherapy intravenous (IV) infusion - Weekly doses
62539060|NCT06097455|EXPERIMENTAL|ARI0003|ARI0003 will be administered intravenously under a split regime. A total dose between 0.5 and 5 x106 cell/Kg will be administered in 3 administrations (fractions):
62539061|NCT06160700||Immunotherapy Only|Subjects who are currently receiving immunotherapy only.
62539062|NCT06160700||Chemo-Immunotherapy Control Arm|Subjects who are receiving chemo-immunotherapy.
62539063|NCT06160700||No Active Therapy Control Arm|Subjects who are no currently receiving active therapy.
62539064|NCT00919854|EXPERIMENTAL|Darunavir (DRV)+Ritonavir (rtv)|Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg. After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg. Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
62539065|NCT05776251|EXPERIMENTAL|PTLD - active taVNS|Participants with Post-treatment Lyme Disease (PTLD) will start with 40 sessions (i.e., 4 weeks of Monday to Friday, twice daily treatments that last 1 hour each session) to receive transcutaneous auricular Vagus Nerve Stimulation (taVNS). If compliance is less than 70% in at least 3 of the first 4 open label treated participants, then the investigators will modify the treatment design accordingly.
62539066|NCT02079779|EXPERIMENTAL|Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of robotic-assisted therapy.
62539067|NCT02079779|ACTIVE_COMPARATOR|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of classical rehabilitation.
62539068|NCT04645836|EXPERIMENTAL|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
62539069|NCT04645836|NO_INTERVENTION|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
62539070|NCT03578575|EXPERIMENTAL|Danggui Buxue Tang group|Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
62164371|NCT05642663||Treated patients|Patients with grade II (with one or more associated comorbidities) and grade III obesity who went through sleeve, bypass and revisional bariatric surgery procedure with the use of Altus Powered Stapler
62164372|NCT02032134|OTHER|Patients with severe thrombocytopenia|Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System
62539071|NCT03578575|PLACEBO_COMPARATOR|Placebo group|Use Placebo 5g/time, 3 times a day, for 12 weeks.
62539072|NCT01308905|EXPERIMENTAL|FLT-PET|"Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment.~1. Low risk patients: observation only.~2. Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection.~3. High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin.~PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection)."
62539073|NCT06632730||Spinal Muscular Atrophy (SMA) Cohort|Pediatric patients with SMA type I, SMA type II, or presymptomatic SMA.
62539074|NCT03589040|OTHER|Ripivirine arm|All subjects will be administered oral ripilvirine 25mg once daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
62539075|NCT03589040|OTHER|Darunavir arm|All subjects will be administered oral DRV/r 600/100mg twice daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
62539076|NCT00387556|EXPERIMENTAL|Ketamine + Ondansetron|ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
62539077|NCT00387556|PLACEBO_COMPARATOR|Ketamine + Placebo|ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo
62539078|NCT06619769|ACTIVE_COMPARATOR|CBT - Navigator|"Participants will complete the CBT arm of eSense with support from a treatment navigator"
62539079|NCT06619769|ACTIVE_COMPARATOR|CBT - No navigator|"Participants will complete the CBT arm of eSense without support from a treatment navigator"
62539080|NCT06619769|ACTIVE_COMPARATOR|MBT - Navigator|"Participants will complete the MBT arm of eSense with support from a treatment navigator"
62539081|NCT06619769|ACTIVE_COMPARATOR|MBT - No navigator|"Participants will complete the MBT arm of eSense without support from a treatment navigator"
62539082|NCT01265433|EXPERIMENTAL|Galinpepimut-S + Montanide + GM-CSF|Galinpepimut-S emulsified with Montanide adjuvant (1:1 ratio) 1 mL and GM-CSF 70 mcg
62164373|NCT02085590|ACTIVE_COMPARATOR|BCG vaccine|BCG vaccine SSI, 0.75mg/ml, injection 0.1 cc intradermal
62164374|NCT02085590|PLACEBO_COMPARATOR|NaCl 0.9%|injection 0.1 cc intradermal
62539083|NCT01265433|PLACEBO_COMPARATOR|Montanide + GM-CSF|Montanide adjuvant 1 mL and GM-CSF 70 mcg
62539084|NCT03051932|ACTIVE_COMPARATOR|Ofiramev®( IV Acetaminophen)|Patients randomized to the treatment arm will receive 1 g (100 mL) intravenous acetaminophen infused over 15-minutes every 6 hours for 4 doses total.
62539085|NCT03051932|PLACEBO_COMPARATOR|Placebo IV administration|Patients randomized to the placebo arm will receive 100 mL of normal saline infused over 15 minutes every 6 hours for 4 doses total
62539086|NCT05868512|OTHER|Dry needling|
62539087|NCT05868512|EXPERIMENTAL|therapeutic ultrasound|
62539088|NCT06187090|EXPERIMENTAL|PEA Arm|
62539089|NCT01211938|ACTIVE_COMPARATOR|single-fraction radiotherapy with concomitant 5FU and Hydrea|six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
62539090|NCT01211938|EXPERIMENTAL|hyperfractionated radiotherapy with concomitant Cetuximab|Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
62539091|NCT00792935|EXPERIMENTAL|MK-0941|
62539092|NCT00792935|ACTIVE_COMPARATOR|Glimepiride|
62539093|NCT05736653|EXPERIMENTAL|Task-specific PCMS, PCMS-rest, Task-specific sham-PCMS|"During Task-specific paired corticospinal-motor neuronal stimulation (PCMS) participants will receive PCMS \[Transcranial Magnetic Stimulation (TMS) + Peripheral Nerve Stimulation (PNS)\] with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
62539094|NCT05736653|EXPERIMENTAL|Task-specific PCMS, Task-specific sham-PCMS, PCMS-rest|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
62539095|NCT05736653|EXPERIMENTAL|PCMS-rest, Task-specific PCMS, Task-specific sham-PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
62539096|NCT05736653|EXPERIMENTAL|PCMS-rest, Task-specific sham-PCMS, Task-specific PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
62539097|NCT05736653|EXPERIMENTAL|Task-specific sham-PCMS, Task-specific PCMS, PCMS-rest|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
62539098|NCT05736653|EXPERIMENTAL|Task-specific sham-PCMS, PCMS-rest, Task-specific PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
62539099|NCT01746459|ACTIVE_COMPARATOR|Low Low|Low Intensity, Low Frequency Reminder System
62539100|NCT01746459|ACTIVE_COMPARATOR|Low, High|Low Intensity, High Frequency Reminder System
62539101|NCT01746459|ACTIVE_COMPARATOR|High, Low|High Intensity, Low Frequency Reminder System
62539102|NCT01746459|ACTIVE_COMPARATOR|High, High|High Intensity, High Frequency Reminder System
62539103|NCT05881746|EXPERIMENTAL|anatomical resection group|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) is defined as the resection of one or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination thereof.
62539104|NCT05881746|ACTIVE_COMPARATOR|nonanatomical resection group|nonanatomical resection (NAR), also called as wedge resection, is defined as the resection of the tumor with a margin of normal parenchyma regardless of the hepatic anatomy.
62539105|NCT00599963|EXPERIMENTAL|1|paricalcitol 1 mg/day for 12 weeks, followed by a washout period of 4 weeks, then crossed over to no treatment for another 12 weeks
62539106|NCT00599963|ACTIVE_COMPARATOR|2|no treatment for 12 weeks, followed by a washout period of 4 weeks, then crossed over to paricalcitol for another 12 weeks
62539107|NCT02188186|ACTIVE_COMPARATOR|Conventional treatment|"Initial dual combination therapy with sulfonylurea and metfomin. Dose of sulfonylurea (glimepride 2-8 mg) and metfomin (500-2550 mg) can be ecalated at investigator's discreition at every visit.~Insulin therpy can be added as a rescue therapy at investigator's discreition."
62539108|NCT02188186|EXPERIMENTAL|Initial triple combination treatment|"Initial dual combination therapy with metformin, sitagliptin (Januvia 100 mg), and lobeglitazone (Duvie 0.5 mg).~Insulin therpy can be added as a rescue therapy at investigator's discreition."
62539109|NCT04523935|PLACEBO_COMPARATOR|Placebo-Sequence 1|The placebo contained fructose powder in packets identical to the medicines.
62539110|NCT04523935|ACTIVE_COMPARATOR|Drug-Sequence 2|GABA-B agonists, muscarinic acetylcholine receptor antagonists, inhibitors of the vesicular monoamine transporter, benzodiazepines, antiepileptics, and tricyclic antidepressants were used.
62539111|NCT04264026|EXPERIMENTAL|Open Label|Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 40 mg MDMA.
62714725|NCT03593590||Ocrelizumab|Participants with relapsing or primary progressive MS receiving ocrelizumab under routine clinical care.
62714726|NCT02230345|EXPERIMENTAL|Probiotic yogurt|Daily administration, during two weeks, of two probiotic yogurts (200 mL each)
62539112|NCT03121287||Lung or Esophageal Patients|Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test \& 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
62539113|NCT02097680|EXPERIMENTAL|Letrozole|
62539114|NCT02097680|PLACEBO_COMPARATOR|Placebo comparator|
62539115|NCT06300320|EXPERIMENTAL|TQ05105 Tablets|TQ05105 Tablets administered twice-daily. 28 days as a treatment cycle.
62539116|NCT05456555|EXPERIMENTAL|Flapless with Enamel Matrix Derivatives (EMD)|Closed non-surgical treatment of periodontal intrabony defects with the combined use of Enamel Matrix Derivatives (EMD).
62539117|NCT05456555|ACTIVE_COMPARATOR|Flapless alone|Closed non-surgical treatment of periodontal intrabony defects without any adjunct.
62539118|NCT02045147|EXPERIMENTAL|Grp 1a: Low Cognition, Low Activation|Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
62539119|NCT02045147|EXPERIMENTAL|Grp 2a: Low Cognition, High Activation|Subjects will receive an 8 week care transition intervention with an APRN-NP and CNA. The APRN-NP will guide the care transition intervention. This group will receive an intense intervention.
62539120|NCT02045147|EXPERIMENTAL|Grp 3a: Normal Cognition, Low Activation|Subjects will receive an 4 week care transition intervention with a Registered Nurse (RN) Coach. This group will be evaluated at four weeks, if the patient activation levels are still low, they will be referred to the 4 week APRN-NP and CNA.
62539121|NCT02045147|EXPERIMENTAL|Grp 4a: Normal Cognition, High Activation|Subjects will receive the least intensive intervention delivered by a RN coach.
62539122|NCT02045147|NO_INTERVENTION|Grp 1b: Low Cognition, Low Activation Usual Care|Comparison group to 1a intervention group
62539123|NCT02045147|NO_INTERVENTION|Grp 2b Low Cognition, High Activation Usual Care|Comparison group to 2a intervention group
62164375|NCT04264416|EXPERIMENTAL|Whole-Body Electromyostimulation|16 weeks of dynamic WB-EMS: one supervised session per week, 20 min session; impulse-frequency: 85 Hz; impulse breadth 350 µs; intermittent 4-6 s; of impulse - 4 s of impulse break; impulse intensity RPE 7 (hard+ to very hard) on Borg CR 10 Scale.
62164376|NCT04264416|NO_INTERVENTION|Non exercising control|...maintained physical activity and exercise habits during the study period.
62164377|NCT04983147|EXPERIMENTAL|health belief model based training manuel|"A training manual entitled Do Not Stay Silent Towards Obesity was prepared by the researcher to guide women in obesity management by affecting their beliefs on obesity in a positive way."
62539124|NCT02045147|NO_INTERVENTION|Grp 3b: Normal Cognition, Low Activation Usual Care|Comparison group to 3a intervention group
62539125|NCT02045147|NO_INTERVENTION|Grp 4b: Normal Cognition, High Activation Usual Care|Comparison group to 4a intervention group
62539126|NCT02182635|EXPERIMENTAL|Ba253BINEB|
62539127|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
62539128|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
62164378|NCT04983147|EXPERIMENTAL|powerpoint presentation with computer|The presentation prepared based on the Health belief model was used in group training.
62164379|NCT04983147|EXPERIMENTAL|video for obesity based on health beliefs|In the literature; It is explained that the educator's use of representations such as video is more effective than verbal expression and reading, and facilitates learning both by hearing and seeing.For this reason, videos that will create awareness about the subject in the trainings were prepared by the researcher and used in the trainings.
62164380|NCT04983147|EXPERIMENTAL|successful patients in obesity management|Real-life stories of people who could manage obesity before and thought themselves healthier compared to their previous condition were shared with the group. People were invited to the trainings who had obesity before and managed to lose weight and trainings were given in the affective field.
62164381|NCT04983147|EXPERIMENTAL|Post-training follow-up|"After the trainings given to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days.It will be made by phone call."
62539129|NCT00541879|EXPERIMENTAL|I|Elementary school children -grades 2-6 participating in Program ENERGY
62539130|NCT00541879|SHAM_COMPARATOR|II|Elementary school children in grades 2-6 matched to the intervention classes not receiving any intervention
62539131|NCT05585879|OTHER|Pure-Vu EVS|"Rate of incomplete colonoscopies due to inadequate preparation salvaged to adequate colonoscopies with the use of the Pure-Vu EVS System.~Inadequate OCs defined as such if any of the following are met:~* BBPS \< 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~* Inability to identify \> 5mm polyps The estimated rate of salvaged preparations will be calculated and presented with exact one-sided 95% confidence interval: Number of preps inadequate with SOC and adequate after Pure-VU EVS System / Number of preps inadequate with SOC.~The lower bound will be compared to a 35% performance goal."
62539132|NCT03583684|EXPERIMENTAL|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
62539133|NCT03583684|NO_INTERVENTION|Delayed Treatment Group (DTG)|Child continues stable treatments as usual in the community.
62539134|NCT04823975|EXPERIMENTAL|HIEP intervention|Participants will be given the health insurance intervention from Utah Health Policy Project staff, a 60 minute long, educational learning session.
62539135|NCT01283035|EXPERIMENTAL|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
62539136|NCT04762498|EXPERIMENTAL|Pegloticase 16mg cohort|16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly
62539137|NCT04762498|EXPERIMENTAL|Pegloticase 24/32mg cohort|24 to 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly
62539138|NCT05875311|EXPERIMENTAL|telemonitoring|Patients in the intervention group will come to the ambulatory centre 2 times, undergoing mobile application training and the same educational talks as in the control group. Subsequently, they will follow the scheduled physical activities and adherence to the risk factor management according to individualised guidelines in their App, until the end of the study period. All data generated are recorded on the professional website. The degree of compliance with the objectives set is monitored by means of 7 coloured icons, which vary according to the target achievement.
62539139|NCT05875311|OTHER|control follow-up|Patients in the control group will come to the ambulatory centre only once. The same educational talks as to the intervention group will be given. A conventional outpatient follow-up by primary care and the corresponding specialist will be carried out.
62539140|NCT03194841|EXPERIMENTAL|Heart Failure Application|A mobile application that allowed for input of physiologic data, qualitative questions about symptoms and education
62539141|NCT05148260|EXPERIMENTAL|LTP+|"The LTP+ is divided into two components:~First, underpinned by Piaget's theory of cognitive development (Piaget, 1952; Sidik, 2020) and Bowlby's theory of attachment (Bowlby, 1980; Granqvist \& Duschinsky, 2021), the central focus here is a pictorial calendar devised for parents, depicting eight successive stages of child development from birth to 3 years, with illustrations of parent-child play and other activities that promote parental involvement, learning, and mum-baby attachment.~Second, well-grounded in the standard framework of cognitive-behavioural theory (Bernal et al., 2009) and uses techniques of active listening, changing negative thinking, guided discovery, behavioural tasks, and homework (i.e. trying things out between sessions, putting what has been learnt into practice), while educating participating mums about depression/anxiety, correlates and management, social support, and practical advice on using appropriate healthcare (Bernal et al., 2009)."
62539142|NCT05148260|ACTIVE_COMPARATOR|Psychoeducation|This is the comparative group with a primary aim of monitoring participating mums to ensure their postnatal depression does not degenerate. However, supportive, and postnatal educational components are provided. These psychoeducation sessions are grounded on the theory and philosophy of group psychosocial support (with basic but relevant topics on postnatal mental healthcare advice and discussions).
62539143|NCT06251492|EXPERIMENTAL|Experimental Group|Stereotactic body radiotherapy of 8 Gray (Gy) x 3 on targeted metastasis determined by MDT + Adebrelimab 20mg/kg IV every 3 weeks (Q3W) for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
62539144|NCT04540679|ACTIVE_COMPARATOR|Inpatient - Standard Care Delayed Platform|Patient will receive standard inpatient care and provided access to the platform 6 weeks after inpatient discharge with support provided by the VIP coach.
62539145|NCT04540679|ACTIVE_COMPARATOR|Inpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the inpatient program
62539146|NCT04540679|ACTIVE_COMPARATOR|Outpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the outpatient program. If patient is transitioning from the inpatient program, their access to the platform will be guided by which group they were originally assigned to (i.e. if a 6 week delay is applicable).
62539147|NCT05528471|EXPERIMENTAL|Intervention group|Iso-caloric and low fructose /low HFCS diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) (n=35)
62539148|NCT05528471|NO_INTERVENTION|Control group|Iso-caloric with higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) (n=35)
62539149|NCT02516943|ACTIVE_COMPARATOR|Control|The patient were retrospectively included according to the last digit of their admission number (odd number). The had arterial blood gas analysis every 4 hour during the ICU stay.
62714727|NCT02230345|ACTIVE_COMPARATOR|Acidified milk|Daily administration, over two consecutive weeks, of an isocaloric dose (compared to probiotics) of unfermented acidified milk
62539150|NCT02516943|ACTIVE_COMPARATOR|Guideline|The patient were prospectively included and they had arterial blood gas analysis following the pathological- based guidelines for arterial blood gas analysis in patients aftercardiac surgery
62539151|NCT04201886|OTHER|RA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
62539152|NCT04201886|OTHER|OA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
62539153|NCT01977274|EXPERIMENTAL|gynecological cancer|blood and tumor samples
62714728|NCT05788445|EXPERIMENTAL|nrTMS treatment|using nrTMS coli to stimulate the contralateral Broca's area on the right hemisphere with high freqency stimulation.
62164382|NCT01358175|EXPERIMENTAL|Secukinumab 10 mg/kg i.v. / 75 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
62164383|NCT01358175|EXPERIMENTAL|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
62164384|NCT01358175|PLACEBO_COMPARATOR|Placebo|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
62714729|NCT05788445|SHAM_COMPARATOR|nrTMS sham|using nrTMS sham-coli to stimulate the contralateral Broca's area on the right hemisphere with high frequency stimulation.
62714730|NCT06717932||Safety and efficacy assessments|Safety evaluations,disease-specific assessments,and assessments to monitor for long-term complications of autologous transplant
62714731|NCT04074564|EXPERIMENTAL|Part A|Subgroup 1: MASCT-I A+Camrelizumab+Apatinib combination therapy; Subgroup 2: MASCT-I B+Camrelizumab+Apatinib combination therapy
62714732|NCT04074564|EXPERIMENTAL|Part B|MASCT-I (based on the administration schedule selected from part A) in combination with Apatinib
62164385|NCT02177058|EXPERIMENTAL|Immediate INTERACT implementation|INTERACT Quality improvement program training and implementation between APR 2013 and MAR 2014
62539154|NCT02083718|EXPERIMENTAL|PBSC & MSCs|PBSC will be intravenously infused at a dose of 2×10\^8/kg. MSCs will be intravenously infused at a dose of 1×10\^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
62539155|NCT06165601|OTHER|Dapagliflozine|For prospective cohort, an additional follow-up at D14 and M1 will be carried out.
62539156|NCT05734430||GAP Social|Individuals ages 18+ years with an appendix cancer diagnosis in the United States.
62539157|NCT05734430||GAP Vanderbilt|Individuals ages 18+ years with an appendix cancer diagnosis seen at Vanderbilt.
62539158|NCT05734430||GAP Parent|Biological parents of active GAP (Social and Vanderbilt) Study participants.
62539159|NCT05833698||Patients with failure of conservative treatment|
62164386|NCT02177058|ACTIVE_COMPARATOR|Delayed intervention with reporting|Quarterly surveys/data reporting between APR 2013 and MAR 2014. They receive INTERACT training starting on MAR 2014.
62164387|NCT02177058|NO_INTERVENTION|Delayed intervention not reporting|No data collected from these nursing homes for one year since baseline. They receive INTERACT training starting on MAR 2014.
62164388|NCT02640326|ACTIVE_COMPARATOR|Active Comparator|The catheterized arm will have Standard of care Foley urinary catheter insertion according to usual institutional care pathways in the operating room prior to surgery initiation. The urinary catheter will be assessed for removal on the morning of post-operative day 1, and patients will be monitored for urinary complications once catheter is removed until patient has successfully voided spontaneously within 8 +/- 2 hours.
62164389|NCT02640326|EXPERIMENTAL|Experimental Arm|The non-catheterized arm will have standard of care Foley urinary catheter insertion, with no Foley Urinary Catheter inserted prior to, during, or after surgery unless the patient is showing signs of urinary retention after surgery. Patient will be monitored for urinary complications starting in the recovery room until patient has successfully voided spontaneously within 8 +/- 2 hours
62164390|NCT03600506|ACTIVE_COMPARATOR|Dexmedetomidine|Intervention drug of the study
62164391|NCT03600506|PLACEBO_COMPARATOR|Placebo|Normal Saline (Placebo)
62164392|NCT04282200|NO_INTERVENTION|Standard of Care|Patients receiving standard of care pain management including opioids.
62164393|NCT04282200|ACTIVE_COMPARATOR|Ketorolac|Patients will receive standard of care pain management plus intravenous ketorolac.
62164394|NCT04640376|EXPERIMENTAL|Paracetamol UNIFLASH 125mg|1 sachet Paracetamol UNIFLASH 125mg + 2 placebo capsule
62164395|NCT04640376|PLACEBO_COMPARATOR|Placebo|1 Placebo sachet + 2 placebo capsule
62164396|NCT04640376|ACTIVE_COMPARATOR|Paracetamol 500mg|1 Placebo sachet + 1 placebo capsule + 1 capsule Panadol 500mg
62164397|NCT04640376|ACTIVE_COMPARATOR|Paracetamol 1000mg|1 Placebo sachet + 2 capsules Panadol 500mg
62539160|NCT05833698||Patients without failure of conservative treatment|
62539161|NCT02218801||Colorectal adenocarcinoma liver metastasis|Unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer
62164398|NCT01812707|PLACEBO_COMPARATOR|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
62164399|NCT01812707|EXPERIMENTAL|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
62164400|NCT01812707|EXPERIMENTAL|Alirocumab 75 mg Q2W|Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
62539162|NCT02676583|ACTIVE_COMPARATOR|Billateral tonsil fossa closure|tonsillectomy
62539163|NCT02676583|ACTIVE_COMPARATOR|No closure of tonsil fossa|tonsillectomy
62539164|NCT02676583|ACTIVE_COMPARATOR|Unilateral tonsil fossa closure|tonsillectomy
62539165|NCT01504529||Neupro Treatment|Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
62539166|NCT04618783|EXPERIMENTAL|Low-dosage experimental group|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
62539167|NCT04618783|EXPERIMENTAL|Medium-dosage experimental group|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
62539168|NCT04618783|EXPERIMENTAL|High-dosage experimental group|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
62539169|NCT04618783|ACTIVE_COMPARATOR|Control wIPV group|Three doses of control wIPV, vaccinated within one-month interval between doses
62539170|NCT04618783|ACTIVE_COMPARATOR|Control sIPV group|Three doses of control sIPV, vaccinated within one-month interval between doses
62539171|NCT02926482|NO_INTERVENTION|Control|This arm will include 35 organizations who receive access to the Prescriber Recruitment Bundle (PRB) materials online via a secure website.
62539172|NCT02926482|EXPERIMENTAL|PRB: organizations implementing the PRB|This arm will include 35 organizations that will implement the intervention, the Prescriber Recruitment Bundle (PRB) using the NIATx Organizational Change Model (a model developed by our center research team).
62539173|NCT01200992|EXPERIMENTAL|EN3348|8 mg mixed with sterile water for injection for a total volume of 50mL
62539174|NCT01200992|ACTIVE_COMPARATOR|Mitomycin C|40 mg powder will be reconstituted with sterile water for injection to a total volume of 40 mL
62539175|NCT04932057|EXPERIMENTAL|Self-Action Observation (s-AO Group)|Participants will watch their own actions during an upper extremity functionality test.
62164401|NCT01812707|PLACEBO_COMPARATOR|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
62164402|NCT01124916|ACTIVE_COMPARATOR|Laparoscopic Abdominal Sacrocolpopexy (LASC)|Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC)
62539176|NCT04932057|EXPERIMENTAL|Action Observation (AO Group)|Participants will watch a person while performing an upper extremity functionality test.
62539177|NCT04932057|ACTIVE_COMPARATOR|Action Practice|Participants will perform an upper extremity task 4 more times.
62539178|NCT04932057|PLACEBO_COMPARATOR|Observation|Participants will watch a slide show which will only contain landscapes.
62539179|NCT04932057|NO_INTERVENTION|Control|Participants will wait without any performance till the second assesment.
62539180|NCT05792579|ACTIVE_COMPARATOR|early closure of stoma|Detection complications of early closure of stoma in pateints with colorectal injures
62539554|NCT04355065|EXPERIMENTAL|Cognitive Training with Therapeutic chess|"The training in Therapeutic chess consists of four sections:~Video tutorial: Weekly videos have been recorded in which a chess board and the image of the psychologist explaining the lesson appear. Each week a chess concept will be explained.~Traditional chess exercises Therapeutic chess exercises: The exercises use the elements of chess but it is not necessary to know how to play chess to perform them. The purpose of the exercise is to work on a specific cognitive area each week.~Playing online games: The patient must play a minimum of 2 online games on the chess platform chess24.es . The psychologist will follow the progress of each patient.~At the end of the week, the patient should send an email to the psychologist with the completed exercises and then they will receive a personalised email. This group carries out all the treatment online from their home."
62539555|NCT04355065|ACTIVE_COMPARATOR|Control Group|This group corresponds to the control group. The control group continues with their prescribed pharmacological treatment without any cognitive intervention. The participants of this group are contacted by telephone once a week to follow up on possible difficulties and/or side effects.
62539556|NCT00866879|ACTIVE_COMPARATOR|Control|Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.
62539557|NCT00866879|EXPERIMENTAL|Transition to Sirolimus Group|Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus
62539558|NCT00866879|OTHER|Donors|Data and blood samples from the donors are collected in this study to contribute to the general knowledge to be used in assessing the two donor recipient groups, which are the target of this study.
62539559|NCT01476332|EXPERIMENTAL|Group 1: Cis-UCA 0.5% eye drops|
62539560|NCT01476332|EXPERIMENTAL|Group 2: Cis-UCA 2.5% eye drops|
62539561|NCT01476332|PLACEBO_COMPARATOR|Group 3: Placebo for cis-UCA, eye drops|
62539562|NCT05189444|EXPERIMENTAL|Vonoprazan group|Vonoprazan + Amoxicillin + Bismuth potassium citrate Drug: Vonoprazan 20mg bid Other Names: no Drug: Amoxicillin 0.75g tid Other Names: no Drug: Bismuth potassium citrate 0.22g bid Other Names: no
62539563|NCT05189444|ACTIVE_COMPARATOR|control group: quadruple therapy|Drug: Esomeprazole 20mg bid Other Names: no Drug: Amoxicillin 1.0g bid Other Names: no Drug: Clarithromycin 0.5g bid Other Names:no Drug: Bismuth potassium citrate 0.22g bid Other Names:no
62539564|NCT06332495||Assessment of pain during pelvic positioning|48-hour follow-up of patients included in the study, with data collected on two pelvis fittings per 24 hours of follow-up (one fitting = one installation and one removal).
62539565|NCT02634359|OTHER|IVF Treatments- Frozen Embryo transfer|Consenting women that arrive to IVF clinic for frozen embryo transfer on spontaneous cycle Study Intervention: Ultrasound and Blood test to detect Ovulation. At home, HR, RR and movements will be contactlessly measured using EarlySense home device
62539566|NCT02634359|OTHER|IVF Treatments- Clinical Evaluation|"Consenting women that arrive for cycle evaluation or insemination on spontaneous cycle (infertile women).~Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device"
61977731|NCT01712854|EXPERIMENTAL|Symbicort|A combination of budesonide + long acting beta agonist (Symbicort): Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
62539567|NCT02634359|OTHER|No IVF|Healthy women volunteers with regular menstrual cycles - not using contraceptives Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device
62539568|NCT00205803|EXPERIMENTAL|13vPnC|
62539569|NCT00205803|ACTIVE_COMPARATOR|7vPnC|
62539570|NCT00338312|PLACEBO_COMPARATOR|1|Placebo patch
62539571|NCT00338312|EXPERIMENTAL|2|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
62539572|NCT02391129||Hyperion Prosthesis|Patients treated with the second generation long-stem revision prosthesis
62539573|NCT02391129||Helios Prosthesis|Patients treated with the first generation long-stem revision prosthesis
62539574|NCT02391129||Locking compression plate|Patients treated with LCP
62539575|NCT01186484|EXPERIMENTAL|001|JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
62539576|NCT02594085|EXPERIMENTAL|Patch 3/Patch4 + Patch1/patch2 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 1 and Patch 2 Test period 3: Patch 5 and Patch 6"
62539577|NCT02594085|EXPERIMENTAL|Patch 1/Patch2 + Patch3/patch4 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
62539578|NCT02594085|EXPERIMENTAL|Patch 1/Patch2 + Patch5/patch 6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
61977732|NCT01712854|PLACEBO_COMPARATOR|Budesonide only|Budesonide 80 mcg (Entocort EC) only
62539579|NCT02594085|EXPERIMENTAL|Patch 3/Patch4 + Patch5/patch6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 5 and Patch 6 Test period 3: Patch 1 and Patch 2"
62734432|NCT03993444|EXPERIMENTAL|communication and problem solving|Three smal group sessions (separate for employees (length 2 hours each) and for supervisors (length 2,5 hours each)) focused on training communication and problem solving skills.
62734433|NCT03993444|ACTIVE_COMPARATOR|psychoeducation|Two, 1 hour, lectures, one on the topic of pain and one on the topic of stress (for employees and supervisors combined).
61977687|NCT02184182|EXPERIMENTAL|VLS ablation/portal ligation/hepatectomy|"Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight \> 0.5~- laparoscopic/laparotomic right trisectionectomy"
62539580|NCT02594085|EXPERIMENTAL|Patch 5/Patch 6 + Patch 3/patch 4 + patch 1/patch 2|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 5 and Patch 6 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 1 and Patch 2"
62539581|NCT02594085|EXPERIMENTAL|Patch 5/Patch 6 + Patch1/patch2 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
62539582|NCT04719455|EXPERIMENTAL|Intervention treatment experienced patients|AIMS
62539583|NCT04719455|EXPERIMENTAL|Intervention starting patients|AIMS
62539584|NCT04719455|OTHER|Control group treatment experienced patients|Regular care
62539585|NCT04719455|OTHER|Control group starting patients|Regular care
62539586|NCT05011747|ACTIVE_COMPARATOR|single-site VT group|Viscotrabeculotomy is performed through a superonasal triangular scleral flap.
62539587|NCT05011747|ACTIVE_COMPARATOR|two-site VT group|Viscotrabeculotomy is performed through a superonasal and an inferotemporal triangular scleral flap.
61977688|NCT04060550||Normal controls|No history of skin disease and atopy
61977689|NCT04060550||ADEH-|Atopic dermatitis without a history of eczema herpeticum
61977690|NCT04060550||ADEH+|Atopic dermatitis with a history of eczema herpeticum
62539588|NCT05742932||Study group|Male and female, major or minor patients. The patients have maxillary, mandibular, maxillomandibular fracture with/without annex face or skull fracture, and will be treated by trauma surgery.
62539589|NCT06349174|EXPERIMENTAL|Endobronchial valve group|The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
62539590|NCT06621004|ACTIVE_COMPARATOR|propranolol|1 mg propranolol will be prepared in a 10 ml syringe (100 ug/ml). Propranolol will be given 200-300 ug bolus followed by increments of 100 ug until MABP becomes 50-60 mmHg and HR 50 - 70 b/ m.
62539591|NCT06621004|ACTIVE_COMPARATOR|propranolol and magnesium sulphate|1g MgSo3 ampoule (10ml) will be prepared in a syringe pump to be given at a rate of 40 ml/hr in the group and 1 mg propranolol will be prepared in a 10 ml syringe (100 ug/ml). Propranolol will be given 200-300 ug bolus followed by increments of 100 ug until MABP becomes 50-60 mmHg and HR 50 - 70 b/ m.
62539592|NCT05524961|EXPERIMENTAL|Timed-Bright light therapy (BLT group)|10,000lux bright light
62539593|NCT05524961|ACTIVE_COMPARATOR|Timed-inactivated negative ion generator (Active-control group)|Inactivated negative ion generator
62539594|NCT05524961|PLACEBO_COMPARATOR|Random-time inactivated negative ion generator (placebo group)|Inactivated negative ion generator
62539595|NCT02264912||stent-PCI patients|Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.
62539596|NCT02329535|EXPERIMENTAL|Treatment group|Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
62539597|NCT02329535|NO_INTERVENTION|No treatment|No treatment. Regular follow up
62539598|NCT06633575|EXPERIMENTAL|exercise intervention|
62539599|NCT06632717|EXPERIMENTAL|HAIC-Cisplatin+5-fluorouracil in combination with lipiodol embolization|hepatic arterial infusional cisplatin and 5-fluorouracil will be given followed by lipiodol embolization
62539600|NCT04511598|EXPERIMENTAL|Bellus 3D Face Camera Pro|"Every single patient will be diagnosed using 3D imaging system Bellus 3D Face Camera Pro to be compared to the direct measurements obtained from direct anthropometry."
62539601|NCT04511598|EXPERIMENTAL|Planmeca ProMax 3D Proface|"Every single patient will be diagnosed using 3D imaging systems Planmeca ProMax 3D Proface to be compared to the direct measurements obtained from direct anthropometry."
62539602|NCT03640286|ACTIVE_COMPARATOR|VeSTAL - active device|The VeSTAL device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
62539603|NCT03640286|SHAM_COMPARATOR|Sham device|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
62539604|NCT06633770||(case group):|"Consists of 70 neonates, whose blood culture results were positive and indicative of known sepsis-causing pathogens and neonates whose clinical and laboratory findings were indicative of probable sepsis despite negative blood culture results.~Clinical and laboratory findings were indicative of probable sepsis :~* Fever or low temperature.~* Fast or slow heart rate.~* Fast breathing or shortness of breath.~* Vomiting.~* Diarrhea.~* Reduced sucking/difficulty feeding.~* Swollen belly (abdomen).~* Cold hands and feet.~* Leukocyte (\<5000 or ≥20000 wbcs/ µL), absolute neutrophil (\>60%) a~* Thrombocytopenia:"
62539605|NCT06633770||control group|30 healthy neonates who had no signs of sepsis in clinical, radiographic, or laboratory findings or whose symptoms could be characteristic of another disease.
62539606|NCT02382861|EXPERIMENTAL|NAVA group|Management of the difficult weaning from mechanical ventilation by the NAVA.
62539607|NCT02382861|ACTIVE_COMPARATOR|Control group|Conventional management of the difficult weaning from mechanical ventilation, with the pressure ventilation.
62539608|NCT02326441|EXPERIMENTAL|KX2-361|
62539609|NCT03916783|EXPERIMENTAL|Combination intervention|"Selected families will be assigned to the treatment condition (delivered over 9 months) to receive BSC plus a family EE intervention comprising of a matched family development account (FDA) for health-related expenses, including transport to UCI, food/nutrition, and health insurance. Combined with the Family EE will be four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education. The sessions will be conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use.~\*Due to insufficient sample size, the open clinical trial is not being conducted."
62539610|NCT04708548||Oligodendroglioma (Grade II and III) Patients|Patients diagnosed with a WHO Grade II or III Oligodendroglioma
62539611|NCT00103220|EXPERIMENTAL|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62539612|NCT01208636||Sun exposed people|Sun exposure \>3 hours daily for at least 5 days weekly for the last 3 months.
62539613|NCT02195661|ACTIVE_COMPARATOR|Melatonin sleep EEG induced group|"All children who were referred to the neurophysiology department who were either unable to keep still for their EEG, or required a sleep EEG as part of their epilepsy work-up and whose caregivers agreed to the administering of sedation with melatonin. Melatonin by mouth (3mg for children \< 15kg, 6mg for those \> 15kg) 1 hour before the scheduled EEG by the unit nurse. Children who can swallow the capsules directly, those who cannot are given the contents of the powder in the capsule mixed in a few millilitres of water. If the child fails to fall asleep within one hour of administration of the melatonin then a second dose 3mg is given) ."
62539614|NCT02195661|OTHER|Comparison group for children sedated using previous practice|Since the choral hydrate had been withdrawn a direct comparison group was not possible. However a study performed the previous year in the department measured a several parallel useful outcomes. This study had addressed the usefulness of electroencephalograms in a South African population. A proportion of this group screened in 2012 in our unit underwent sleep studies, sedated with chloral (n=22). These patients were drawn from the same regional pool, with the same disease demographics, and the same sleep deprivation and procedural techniques to the current group. This group was screened for several common denominators to the current study themes, and comparison will be made between these, namely the proportion of patients with successful attainment of sleep studies, the proportion of studies with excessive artifact (precluding interpretation) and the usefulness of the data attained detailing whether the studies were able to assist or alter patient management.
62539615|NCT04851873|EXPERIMENTAL|OAV101|Participants received a single IV dose administration of OAV101
62539616|NCT00905710|NO_INTERVENTION|1|Conventional colonoscopy
62539617|NCT00905710|EXPERIMENTAL|2|Colonoscopy using chromoendoscopy
62539618|NCT02473523|EXPERIMENTAL|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
62539619|NCT05194098|EXPERIMENTAL|Major Depression Disorder Group: iTBS-EEG|Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: intermittent theta stimulation (iTBS): the investigators will stimulate a dorsomedial prefrontal cortex target at the scalp location (0x 60y 60z). Standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes, per session; total session length, including setup is 10-15 min.
62539620|NCT05194098|SHAM_COMPARATOR|Major Depression Disorder Group: SHAM-EEG|"Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: sham stimulation (SHAM): Sham stimulation will entail the same procedures for the active stimulation day, but with the sham side of the DB-80 A/P placed exactly on the same anatomical target in the same position and duration, but without any active stimulation.~\*Note, iTBS and SHAM stimulation sessions will occur on separate days scheduled one week apart (counterbalanced, across subjects). The two stimulation visits follow identical procedures (with the sole difference being active vs. sham rTMS stimulation), with each followed directly by post-stimulation EEG assessment with SLOT and MID tasks."
62715108|NCT03885401|EXPERIMENTAL|Enhanced care planning|The intervention consists of two components - enhanced care planning and clinical-community linkages. The enhanced care plan is created using MOHR (https://myownhealthreport.org). MOHR screens patients for unhealthy behaviors, mental health needs, and social needs. Patients identify the needs they would like to address and create a care plan, which they update quarterly. A clinical navigator and community health worker (CHW) help patients address their care plans using clinical-community linkages, which has four components. First, clinicians and clinical navigators have a resource registry identifying community programs and support - No Wrong Door (NWD) and https://navigator.aafp.org/. Second, MOHR shares information (care plans, patient narrative, and patient progress) across clinical and community team members. Third, MOHR supports messaging and video visits for team members and patients. Finally, MOHR sends care team members quarterly patient progress updates.
61977691|NCT01846507|EXPERIMENTAL|Tranexamic acid|Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
61977692|NCT02522026||Healthy volunteers|
61977693|NCT02522026||Healthy smokers|
61977694|NCT02522026||COPD GOLD1|
61977695|NCT02522026||COPD GOLD2|
61977696|NCT02522026||COPD GOLD3/4|
61977697|NCT02429947||INC Contact Registry Participants|Adult CMT patients who have self-registered at the Inherited Neuropathies Consortium (INC) Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
62539621|NCT05194098|NO_INTERVENTION|Baseline Evaluation (Major Depressive Disorder and Healthy Control Groups)|"HC and MDD participants will have visits for clinical assessment and a baseline EEG session to complete reward processing tasks (SLOT AND MID). The SLOT task is a 288-trial EEG task developed in our laboratory. Design features mimic structural characteristics common to real-word slot machines, including sound effects and visualizations, and the display consists of 3 sequentially populated slot reels. Participants initiate each trial via button press, after which timing of the slot reels is automated, such that reward outcome is independent of task performance.~The MID task is a 130-trial EEG task designed to model anticipatory and consummatory sub-stages of reward processing in the context of participants being rewarded based on their response times to a cued target detection task."
62539622|NCT04257149|EXPERIMENTAL|Hemorrhagic stroke group (group A)|Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
62539623|NCT04257149|EXPERIMENTAL|Ischemic stroke group (group B)|Patient group B is defined as patients that are diagnosed with ischemic stroke.
62539624|NCT04257149|EXPERIMENTAL|Stroke mimic group (group C)|Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
62539625|NCT00598572|EXPERIMENTAL|1|All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
62539626|NCT03037437|EXPERIMENTAL|No prior systemic treatment|Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
62539627|NCT03037437|EXPERIMENTAL|Progress on sorafenib|As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
62539628|NCT01775449|EXPERIMENTAL|polyamines depleted diet|• in the group with a polyamines depleted diet : 2-4 cans per day of Polydol® (oral alimentation without polyamines), associated to predefined menus low in polyamines, according to the chemotherapy cycle and for 107 days
62539629|NCT01775449|OTHER|normal polyamines containing diet|• in the control group with a normal polyamines containing diet: 1 can per day of Polydol® associated with predefined menus with normal average in polyamines and for 107 days.
62539630|NCT02837848|EXPERIMENTAL|Coactivation strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
62539631|NCT02837848|ACTIVE_COMPARATOR|Regular strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
62539632|NCT00735306|EXPERIMENTAL|1|Avastin, Tarceva and Radiation Therapy
62539633|NCT04790708|EXPERIMENTAL|Midgut NETs|75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
62539634|NCT04790708|EXPERIMENTAL|Pancreatic NETs|75 patients affected by non-functional and functional NETs arising from Pancreas.
62539635|NCT04790708|EXPERIMENTAL|Bronchial NETs|25 patients affected by non-functional and functional Bronchial NETs.
62539636|NCT04790708|EXPERIMENTAL|Sympathetic-Adrenergic axis NEts|25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
62539637|NCT04790708|EXPERIMENTAL|Other Nets|25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
62539638|NCT04790708|EXPERIMENTAL|Cancers of Unknown Primary Origin (CUP) NETs|25 patients affected by non-functional and functional unknown primary NETs
62539639|NCT04061031|EXPERIMENTAL|Parent-Child Interaction Therapy|
62539640|NCT04061031|ACTIVE_COMPARATOR|Child-Centered Therapy with Parent Education|
61977698|NCT04827329||Patients with a sleep disorder|Patients with a sleep disorder recording performed in the Sleep Unit in Montpellier University Hospital.
61977699|NCT04827329||Patients with a narcolepsy|Patients with a narcolepsy (type 1 or type 2) / a idiopathic hypersomnia or a restless legs syndrome.
62539641|NCT04922320|EXPERIMENTAL|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
62539642|NCT04922320|PLACEBO_COMPARATOR|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. UC participants will not receive any additional preparation
62539643|NCT06296927|EXPERIMENTAL|Intervention Group|Emotional Freedom Technique will be applied to women in the intervention group applying for mammography screening 30-40 minutes before the procedure.
62539644|NCT06296927|NO_INTERVENTION|Control Group|Women in the control group applying for mammography screening will not receive any intervention other than routine mammography screening.
61977700|NCT04425707|EXPERIMENTAL|A ivermectin alone|ivermectin will be administarted alone to COVID 19 patients
61977701|NCT04425707|EXPERIMENTAL|B standard care alone|standard care will be administarted alone
62539645|NCT03902886||cerebral palsy infants|gait analysis
62539646|NCT03902886||typically developed infants|gait analysis
62539647|NCT04608123||DBS Patients with NFS|Patients with PD treated with STN DBS between 2016 and 2019 who underwent NFS testing in pre and post-op conditions
62539648|NCT04496284|EXPERIMENTAL|Vitrification via slush nitrogen|Blastocyst stage embryos will be vitrified via slush nitrogen
62539649|NCT04496284|NO_INTERVENTION|Vitrification via liquid nitrogen|Blastocyst stage embryos will be vitrified via conventional liquid nitrogen. This is the current standard of care.
61977702|NCT04425707|ACTIVE_COMPARATOR|C ivermectin added to standard of care|ivermectin will be administarted in adition to standard care
62539650|NCT05290727|OTHER|0.15% Aquoral Lipo (Esteve) and 0.15% Hyabak (Thea)|Dosage form: topical administration multidose ophthalmic eye drops Product usage order will be determined through randomization Duration: 15 days + 15 days Frequency: dosage between 3 and 6 drops per day
62539651|NCT05290727|OTHER|0.15% Hyabak (Thea) and 0.15% Aquoral Lipo (Esteve)|Dosage form: topical administration multidose ophthalmic eye drops Product usage order will be determined through randomization Duration: 15 days + 15 days Frequency: dosage between 3 and 6 drops per day
62539652|NCT03578367|EXPERIMENTAL|Asciminib 60mg QD + Imatinib 400mg QD|Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
62539653|NCT03578367|EXPERIMENTAL|Asciminib 40mg QD + Imatinib 400mg QD|Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
62539654|NCT03578367|ACTIVE_COMPARATOR|Imatinib 400mg QD|Imatinib 400 mg taken once daily
62539655|NCT03578367|ACTIVE_COMPARATOR|Nilotinib 300mg BID|Nilotinib 300 mg taken twice daily
62539656|NCT03578367|EXPERIMENTAL|Asciminib 80mg QD|Asciminib 80 mg taken once daily
62539657|NCT04821700||Patients with Carotid stenosis|Ischemic stroke patients with atrial fibrillation and carotid stenosis
62539658|NCT04821700||Patients without Carotid stenosis|Ischemic stroke patients with atrial fibrillation without carotid stenosis
62539659|NCT05551663|EXPERIMENTAL|Isometric exercise training|
62539660|NCT05551663|NO_INTERVENTION|Control group|
62539661|NCT04087681||Elderly 60+ preferably those with increased risk of IED|Study participants are aged 60 years or older in stable health, preferably with a history of urinary tract infection in the previous 10 years.
62539662|NCT02723747||Healthy volunteers|Healthy subjects with normal 12-lead electrocardiogram at rest.
62539663|NCT00237640|PLACEBO_COMPARATOR|1|
62539664|NCT00237640|ACTIVE_COMPARATOR|2|
62539665|NCT03363386|EXPERIMENTAL|Proprioceptive Exercise Group (PG)|Aerobic Exercise Proprioceptive Exercises
62539666|NCT03363386|ACTIVE_COMPARATOR|Resistive Exercise Group (RG)|Aerobic Exercise Resistive Exercises
62539667|NCT05396235|EXPERIMENTAL|MT-3921|Intravenous (IV)
62539668|NCT05396235|PLACEBO_COMPARATOR|Placebo|Intravenous (IV)
62539669|NCT03251339|EXPERIMENTAL|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
62539670|NCT03251339|EXPERIMENTAL|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
62539671|NCT03013855|ACTIVE_COMPARATOR|FIT-SOC|Fecal immunochemical test performed on spontaneously passed stool as noted in the standard instructions.
62539672|NCT03013855|EXPERIMENTAL|FIT-DRE|Fecal immunochemical test completed with stool collected during digital rectal exam.
62539673|NCT00904579||1|Cancer patients who have had organ transplants identified through the transplant and cancer registries.
62539674|NCT01790477|EXPERIMENTAL|Auricular Acupuncture|Use of auricular acupuncture in bilateral ears
62539675|NCT01790477|NO_INTERVENTION|Control|
62539676|NCT03815734|NO_INTERVENTION|control group|Non intervention group
62539677|NCT03815734|EXPERIMENTAL|intervention group|motor imagery group
62539678|NCT06322602|EXPERIMENTAL|Ommaya reservoir placement|Patients undergo Ommaya reservoir placement during standard of care biopsy. Patients then undergo extraction of CSF while on study. Patients may also undergo lumbar puncture while on study. Patients also undergo CT on study.
62539679|NCT04204291|EXPERIMENTAL|All|
62539680|NCT04471129|OTHER|High-Flow Oxygen Therapy, followed by Non-Invasive Ventilation|oxygenation first by High-Flow Oxygen Therapy, then by O2C, then by Non-Invasive Ventilation
61977703|NCT05069454|ACTIVE_COMPARATOR|Exposure group|Healthcare workers vaccinated by any of the available COVID19 vaccine;
62539681|NCT04471129|OTHER|Non-Invasive Ventilation, followed by High-Flow Oxygen Therapy|oxygenation first by Non-Invasive Ventilation, then by O2C, then by High-Flow Oxygen Therapy
62539682|NCT05612373|EXPERIMENTAL|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
62539683|NCT05612373|EXPERIMENTAL|Message offering free round trip ride to the pharmacy|This condition will use a text message offering a free round trip ride to the pharmacy to get a COVID vaccination.
62539684|NCT01824043|EXPERIMENTAL|vitreous hemorrhage group|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
62539685|NCT00409448|EXPERIMENTAL|CAPS|Participants will receive the Internet-based counselor-assisted problem-solving group treatment
62539686|NCT00409448|ACTIVE_COMPARATOR|IRC|Participants will receive the Internet resource comparison group treatment
62539687|NCT05255848|EXPERIMENTAL|Intervention|Heparin sodium will be administered as a nebulised aerosol dose of 5000 IU heparin three times a day (TDS) via an ai compressor nebuliser plus standard of care treatment
62539688|NCT05255848|NO_INTERVENTION|No Intervention|Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin
61977704|NCT05069454|ACTIVE_COMPARATOR|Control group|Have not received any doses of any form of COVID-19 vaccine
62539689|NCT02668588|EXPERIMENTAL|LF-PB 30 mg|extended release of octreotide
62539690|NCT02668588|PLACEBO_COMPARATOR|Placebo|extended release of placebo
62539691|NCT00908310|OTHER|Omniscan|
62539692|NCT00901212|ACTIVE_COMPARATOR|LV Pacing|left univentricular pacing
62539693|NCT00901212|ACTIVE_COMPARATOR|BV Pacing|biventricular pacing
62539694|NCT01385449|EXPERIMENTAL|interscalene block|interscalene block
62539695|NCT01385449|EXPERIMENTAL|interscalene catheter|interscalene catheter
62539696|NCT06290908||RPE-P/TLIF|The clinical manifestation is intermittent claudication accompanied by lower back pain. Patients with lumbar spinal canal stenosis indicated by MRI and/or CT, and instability of the responsible segment of the lumbar spine shown by X-ray in the over extension and over flexion position, with severe symptoms that affect daily life and work, and poor conservative treatment effect, should undergo RPE-P/TLIF single or double segment surgical treatment.
62539697|NCT01090752|PLACEBO_COMPARATOR|Pioglitazone|placebo-controlled, randomized, cross-over study
62539698|NCT01090752|PLACEBO_COMPARATOR|Metformine|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
62539699|NCT05052047|EXPERIMENTAL|Brisk Walking Group|Brisk walking as training for 4 weeks
62539700|NCT05052047|ACTIVE_COMPARATOR|Conventional Breathing Exercise Group|Conventional Breathing exercise for 4 weeks
62539701|NCT02916667|ACTIVE_COMPARATOR|CNdiet|CNdiet includes chrono nutritional dietary guidelines
62539702|NCT02916667|PLACEBO_COMPARATOR|GDMdiet|GDMdiet includes regular GDM diet
62539703|NCT02338804|ACTIVE_COMPARATOR|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
62539704|NCT02338804|EXPERIMENTAL|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
62539705|NCT04467450|EXPERIMENTAL|Botox injection|half of the hemiplegic patients will be injected by botulinum toxin A in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
62539706|NCT04467450|ACTIVE_COMPARATOR|methyl prednisolonate injection|the other half of the hemiplegic patients will be injected by methylprednisolonate in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
62539707|NCT05375071|EXPERIMENTAL|Conventional rehabilitation plus blood flow restriction (BFR) therapy|Following standard of care surgery, subjects will immediately be started in standard of care physical therapy. Additionally, a BFR Cuff will be applied during physical therapy.
62539708|NCT05375071|ACTIVE_COMPARATOR|Conventional rehabilitation|Following standard of care surgery, subjects will immediately be started in standard of care physical therapy.
62539709|NCT01679717|ACTIVE_COMPARATOR|Early mobilisation after CMC1-surgery|Mobilisation at two weeks after operation. The participants will wear a soft splint for six weeks.
62539710|NCT01679717|OTHER|Conservative treatment after CMC1-surgery|Current standard procedure: Mobilisation at six weeks after operation. The participants will wear a rigid splint for six weeks.
62539711|NCT00642252|EXPERIMENTAL|B|226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
62539712|NCT00642252|ACTIVE_COMPARATOR|A|ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
62539713|NCT00134004|EXPERIMENTAL|Mini-haplo Transplant|Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
62539714|NCT03645707|EXPERIMENTAL|CAR Training and Psychoeducational Sessions|"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group.~In this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."
62539715|NCT04766164||Males and Females ages 18-26|Participants between the ages of 18-26 will complete a survey
62539716|NCT04766164||Males and Females ages 27-45|Participants between the ages of 27-45 will complete a survey
62539717|NCT02489253||polygenic hypercholesterolemia|patients with high cholesterol level where no mutation was found in their FH-causing genes and had to gene score in their six LDL-C raising gene score undergo a carotid ultrasound, a CT coronary angiogram and a blood test
61977705|NCT03402789|EXPERIMENTAL|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
62539718|NCT02489253||monogenic FH|patients with a mutation in FH-causing gene undergo a carotid ultrasound, a CT coronary angiogram and a blood test
62539719|NCT04138823|EXPERIMENTAL|Part A: 100 mg BI 891065 QD|
62539720|NCT04138823|EXPERIMENTAL|Part A: 200 mg BI 891065 QD|
62539721|NCT04138823|EXPERIMENTAL|Part A: 200 mg BI 891065 BID|
62539722|NCT02687529||Low Risk|Tested with CST001
62539723|NCT02687529||Known Risk|Tested with CST001
62539724|NCT03909269||Haemodialysis and type 2 diabetes|On chronic haemodialysis and type 2 diabetes
62539725|NCT03909269||Control group|Type 2 diabetes and with eGFR above 60ml/min
62539726|NCT02558530|OTHER|Low carbohydrate diet|Isocaloric diet, \<20 g carbohydrates per day
62539727|NCT06579534|NO_INTERVENTION|Device: Oral Explanation of Paper-Based Health Education|Before the patient is discharged from the hospital, the nurse orally informs the patient about the precautions for preventing falls after discharge using a discharge health education leaflet.
62539728|NCT06579534|EXPERIMENTAL|Device: Multimedia Video Health Education on Fall Prevention|Multimedia audio-visual health education tools: Taking fall risk factors, self-health management and fall prevention measures as the main teaching plan, investigators produce multimedia digital audio-visual teaching materials in Chinese version for adults, Chinese version for children, and English version for adults, with built-in AI patented artificial intelligence automatic dubbing, and matching Chinese or English subtitles and lively 3D virtual lecturers are presented on the screen to explain the course, and pictures, physical photos, short videos, etc. are used as the main content, allowing viewers to quickly and conveniently grasp the key points and absorb knowledge.
62539729|NCT02787408|EXPERIMENTAL|EW Tricuspid Transcatheter Repair System|Edwards (EW) Tricuspid Transcatheter Repair System
62539730|NCT05249452||Adult transplant-eligible SCD patients with a MSD|Sickle cell disease patients aged 16 years and older with an available matched sibling donor.
62734434|NCT03035864|EXPERIMENTAL|rhNGF 20 µg/ml|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
62734435|NCT03035864|PLACEBO_COMPARATOR|Vehicle|Vehicle eye drops six times daily
62734436|NCT04051294|EXPERIMENTAL|Intervention group 1: commercial kombucha|8oz
62539731|NCT06522633|OTHER|patients under treatment with opioids referred for study of non-obstructive dysphagia for esophageal|In patients with dysphagia referred for esophageal manometry as part of routine clinical practice, if esophageal dysfunction associated with opioid use is diagnosed, such as type III achalasia, esophagogastric junction outflow obstruction, esophageal spasm, or hypercontractile esophagus, the opioid is discontinued and replaced with another analgesic for 7 days. Esophageal manometry is then repeated to determine if the opioid-induced esophageal dysfunction (OIED) has resolved or persists.
62539732|NCT05349643|EXPERIMENTAL|AMB-05X|Subjects will receive an injection of AMB-05X once every 4 weeks for 24 weeks (for 6 treatments total). Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose.
62539733|NCT05656872|ACTIVE_COMPARATOR|TAP Block|Transversus abdominus plane (TAP) block will be used as postoperative analgesia
62539734|NCT05656872|ACTIVE_COMPARATOR|IIIH Block|Ilioinguinal-iliohypogastric (IIIH) block will be used as postoperative analgesia
62539735|NCT05467696|EXPERIMENTAL|Sequence 1 Fed:Fasted|Period 1: CTP-543 12 mg fed Period 2: CTP-543 12 mg fasted
62539736|NCT05467696|EXPERIMENTAL|Sequence 2 Fasted:Fed|Period 1: CTP-543 12 mg fasted Period 2: CTP-543 12 mg fed
62539737|NCT01578616||3 / non-CAD, ACS with or without TCFA|ACS patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
62539738|NCT01578616||non-CAD, ACS without TCFA, ACS with TCFA|Acute coronary syndrome (ACS) patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
62539739|NCT05496491|EXPERIMENTAL|Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy|"The experimental group will receive the standard 5-week neoadjuvant chemoradiotherapy (CRT). Thereafter, all patients will commence consolidation chemotherapy. At the 6th week after the end of CRT, patients will undergo MRI re-staging: In case of non-response (mrTRG 5) they will be submitted immediately to surgery, and, subsequently, excluded from the trial.~In case of response (mrTRG 2-4) they will receive consolidation chemotherapy for the whole waiting period between the end of CRT and surgery - 12 weeks."
62539740|NCT05496491|ACTIVE_COMPARATOR|Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy|The control group will receive the standard 5-week neoadjuvant chemoradiotherapy regimen. Six weeks after completion the patient will be re-staged with rectal MRI and depending on the response will be operated (TME): immediately in case of non-response (mrTRG 5) or after an additional 6-week delay (overall 12 weeks after the end of chemoradiotherapy) in case of partial response (mrTRG 2-4). Adjuvant chemotherapy will be, also, administered.
62539741|NCT04711902|EXPERIMENTAL|Arm 1|Participants received 150 mg dose (dose level 1) of Secukinumab
62539742|NCT04711902|PLACEBO_COMPARATOR|Arm 2|Participants received Placebo of the study drug.
62539743|NCT04711902|ACTIVE_COMPARATOR|Arm 3|Participants who received Placebo and switched to dose level 1 (150 mg) of secukinumab.
62539744|NCT04711902|ACTIVE_COMPARATOR|Arm 4|Participants who received Placebo and switched to dose level 2 (300 mg) of secukinumab.
61976416|NCT05230810|EXPERIMENTAL|Ib Safety Cohort /II Expansion Cohort|In phase Ib, the tolerability of tucatinib and alpelisib combination will be confirmed and maximum tolerated dose determined. Therapy will be administered in 28 day cycles of tucatinib 300 mg PO BID and alpelisib 250 mg PO daily (dose level 1). Treatment will continue until unacceptable toxicity, disease progression, withdrawal of consent, or study closure. Fulvestrant will also be administered in patients with HR+/HER2+ metastatic breast cancer. Once RP2D is determined, the study will be continued to phase II, and new patients will enroll at RP2D. All patients in phase IB part, who are remaining on study at the time of initiation of phase II, will be rolled over to phase II. At that time, their study drug doses will be modified as follows: (1) if a patient is on the drug doses lower than RP2D, doses will not be increased; (2) if a patient is on a higher doses compared to RP2D, doses of study drugs will be changed to RP2D.
61976417|NCT05503641|EXPERIMENTAL|Experimental group|This group receives training in cognitive and psychomotricity stimulation activities.
62539745|NCT04208958|EXPERIMENTAL|VE800 combination treatment with nivolumab|Subjects received 5 days of oral vancomycin, followed by daily VE800 in combination with nivolumab every 4 weeks.
62539746|NCT04839484|EXPERIMENTAL|Lumina|Lumina Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
61976418|NCT05503641|NO_INTERVENTION|Control group|This group does not receive any treatment.
62539747|NCT04839484|ACTIVE_COMPARATOR|Restylane Defyne|Restylane Defyne Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
62539748|NCT02826512|EXPERIMENTAL|Niraparib|niraparib 300 mg QD continuously
62539749|NCT03749486|EXPERIMENTAL|ArcScan|High resolution immersion ultrasound measurement before Cataract surgery
62539750|NCT04605874|EXPERIMENTAL|2 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 2 cigarillos per pack.
62539751|NCT04605874|EXPERIMENTAL|4 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 4 cigarillos per pack.
62539752|NCT02565537|ACTIVE_COMPARATOR|iDesign WFG LASIK|Wavefront-guided LASIK
62539753|NCT02565537|ACTIVE_COMPARATOR|Wavelight WFO LASIK|Wavefront-optimized LASIK
62539754|NCT06376851||Group 1: No AI-QCPA|This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. No AI-QCPA will be provided.
62539755|NCT06376851||Group 2: Delayed AI-QCPA|This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. Ninety days following the CCTA, an AI-QCPA report will be provided to the CCTA reader who will in turn provide it to the treating clinician. The treating clinician will decide if changes to medical management are required to effectively treat the patient and if so, treating clinician will contact the patient with the new treatment plan.
62539756|NCT06376851||Group 3: Stress Test Only|This group includes symptomatic patients who previously had non-invasive stress testing only with no CCTA and no prior revascularization. No AI-QCPA will be provided.
62734437|NCT04051294|EXPERIMENTAL|Intervention group 2: brewed kombucha|8oz
62734438|NCT04051294|ACTIVE_COMPARATOR|Control group 1: tea|8oz
62539757|NCT06376851||Group 4: Prospective AI-QCPA, symptomatic without prior revascularization|This group includes newly scanned, symptomatic patients with plaque detected and no prior revascularization. Patients in this group will have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.
62539758|NCT06376851||Group 5: Prospective AI-QCPA, prior PCI|This group includes newly scanned patients with plaque detected. Patients in this group can by symptomatic or asymptomatic and will have had prior PCI in only one vessel territory (CABG patients are not eligible). CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.
62539759|NCT06376851||Group 6: Prospective AI-QCPA, asymptomatic without prior revascularization|This group includes newly scanned, asymptomatic patients with plaque detected and no prior revascularization. Patients in this group will not have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.
62539760|NCT06410235|EXPERIMENTAL|Thoracic manipulation and exercise program|Thoracic manipulation and exercise program
62539761|NCT06410235|ACTIVE_COMPARATOR|exercise program|exercise program
62539762|NCT05856630|EXPERIMENTAL|LY01022|
62539763|NCT05856630|ACTIVE_COMPARATOR|Zoladex®|
62539764|NCT03214393||Pre-Eclampsia|pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler
62539765|NCT02304133|ACTIVE_COMPARATOR|Intervention|participating in a four-hour course in abdominal POC US
62539766|NCT02304133|PLACEBO_COMPARATOR|Control|no training
62539767|NCT05939583|EXPERIMENTAL|Treatment Group|The treatment group will receive US, TENS, IR and exercises in addition to shock waves therapy. Patients will receive 3 sessions per week for 4 weeks
62539768|NCT05939583|EXPERIMENTAL|Control Group|Control group will receive US, TENS, IR and exercises. Patients will receive 3 sessions per week for 4 weeks
62539769|NCT02213289|EXPERIMENTAL|ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)|"For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:~Immuno-oncology included PD-L1 IHC combined positivity score \>10, high microsatellite instability, tumor mutation burden \>15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab."
62539770|NCT02213289|EXPERIMENTAL|ITT-PTS: Personalized Treatment Strategy (HER2 amplified)|HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
62539771|NCT02213289|EXPERIMENTAL|ITT-PTS: Personalized Treatment Strategy (EFGR amplified)|EGFR amplified. These patients received ABT-806.
62539772|NCT02213289|EXPERIMENTAL|ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)|FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
62539773|NCT02213289|EXPERIMENTAL|ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)|MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
62539774|NCT02213289|EXPERIMENTAL|ITT-PTS: Personalized Treatment Strategy (EGFR expressing)|EGFR expressing. These patients received standard cytotherapy plus ABT 806.
62539775|NCT02213289|EXPERIMENTAL|ITT-PTS: Personalized Treatment Strategy (All negative)|All negative. These patients received standard cytotherapy plus Ramucirumab.
62539776|NCT02213289|OTHER|Non-ITT: Standard Therapy|Patients without monoclonal antibodies available received standard cytotherapy.
62539777|NCT02602600|EXPERIMENTAL|Liraglutide|Liraglutide up to 3.0 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks followed by 2 weeks of weight maintenance diet. Before initiating treatment participants will serve as their own controls for 4 weeks.
62539778|NCT00850863||A|20 healthy individuals not susceptible for COPD (age 18-40 years, 0 \< pack years \> 10, FEV1/FVC \>70% , FEV1 \>85% predicted)
62539779|NCT00850863||B|30 healthy individuals susceptible for COPD (age 40-75years, pack years \>20, FEV1/FVC \> 70%, FEV1 \> 85% predicted)
62539780|NCT00850863||C|20 healthy individuals very susceptible for COPD (age 18-40 year, 0 \< pack years \> 10, FEV1/FVC \> 70%, FEV1 \> 85% predicted)and high prevalance of COPD in smoking family members older than 45 years
62539781|NCT00850863||D1|30 COPD patients with GOLD stage I (age 40-75 years, Pack years \> 10, FEV1/FVC ≤ 70%, FEV1 \> 80% predicted)
62539782|NCT00850863||D2|30 COPD patients with GOLD stage II (age 40-75 years, Pack years \> 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)
62539783|NCT00850863||D3|30 COPD patients with GOLD stage III (age 40-75 years, Pack years \> 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)
62539784|NCT00850863||D4|30 COPD patients with GOLD stage IV (age 40-75 years,Pack years \> 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)
62539785|NCT00850863||E|20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 \< Pack years \> 10, FEV1/FVC \>70%, FEV1 \> 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
62539786|NCT00850863||F|30 COPD patients who are highly susceptible (age \> 53 years with Pack years \> 10 , FEV1/FVC ≤ 70% and FEV1 \< 40% predicted) or (age \>18 years with 0 \< pack years \> 5, FEV1/FVC ≤ 70% and FEV1 \< 80% predicted)
62539787|NCT00195338||1|This is an open label, observational study.This is a post-marketing surveillance study in rheumatology practice patients in Luxemburg.Rheumatologists will be asked to document safety and adherence to therapy of Enbrel when given to adults with active rheumatoid arthritis.All patients initiated with Enbrel will be observed.
62539788|NCT02709291|OTHER|Community Health Workers|Community health workers will complete a 5-day interventionist training to deliver a behavioral parent training intervention.
62539789|NCT02709291|OTHER|Parent-Child Dyads|Parents and children will receive a behavioral parent training intervention delivered by community health workers.
62734439|NCT04051294|PLACEBO_COMPARATOR|Control group 2: water|8oz
62734440|NCT01506557|EXPERIMENTAL|choecalciferol|
62734441|NCT01506557|PLACEBO_COMPARATOR|placebo|
62734442|NCT05464238|ACTIVE_COMPARATOR|Exercise training|
62734443|NCT05464238|PLACEBO_COMPARATOR|Standard treatment (waiting group)|
62539790|NCT06549712|EXPERIMENTAL|identify the main common genetic determinants|The purpose of the entire project is to identify genetic determinants of the predisposition to develop respiratory failure in persons infected by SARS-CoV-2; knowledge of these factors may educate the biological understanding of the development of severe lung disease in SARS-CoV-2 infection. Such an understanding may inform treatment trials of potential utility towards more effective management of this patient group. A polygenic risk score may also be useful in identifying high/low risk patients, e.g. amongst health-care providers and vulnerable individuals with significant comorbidities.
62539791|NCT00351884|EXPERIMENTAL|vildagliptin am|
62539792|NCT00351884|EXPERIMENTAL|vildagliptin pm|
62539793|NCT00351884|PLACEBO_COMPARATOR|placebo|
62539794|NCT01593943|NO_INTERVENTION|Control Condition|
62539795|NCT01593943|EXPERIMENTAL|CHARM Intervention|CHARM will be conducted via three 30-minute counseling sessions delivered in a rural setting, with the first session being required and the subsequent sessions being optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
62539796|NCT02076490|EXPERIMENTAL|Software Supported Mirror Therapy|First experimental condition Physical/Occupational Therapy
62539797|NCT02076490|EXPERIMENTAL|Traditional mirror therapy|Second experimental condition Physical/Occupational Therapy
62539798|NCT02076490|ACTIVE_COMPARATOR|Sensomotor exercises without mirror|Control condition Physical/Occupational Therapy
62539799|NCT06633198|EXPERIMENTAL|Passive Heating of lower limbs|The lower limbs will be immersed in warm circulating water for 60 minutes.
62539800|NCT06498635|EXPERIMENTAL|Arm I (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT and blood sample collection throughout the trial.
62539801|NCT06498635|ACTIVE_COMPARATOR|Arm II (active survallence)|Patients undergo active surveillance for 12 months on study. Patients undergo CT and blood sample collection throughout the trial.
62539802|NCT03609320|EXPERIMENTAL|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
62539803|NCT04808219||Driver|Ambulance driver who was involved in a traffic collision - video analysis of the collision records and in-depth interview aiming to find the cause of the collision.
62539804|NCT03915418|EXPERIMENTAL|Connected tools|1 night at home with connected tools only and 1 night at hospital with connected tools and PSG.
62539805|NCT02518672|ACTIVE_COMPARATOR|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
62539806|NCT02518672|PLACEBO_COMPARATOR|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
62539807|NCT01140399|ACTIVE_COMPARATOR|Infusional drug treatment|Diuretics or diuretics plus fixed low dose dopamine infusion
62539808|NCT01140399|EXPERIMENTAL|Ultrafiltration|Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion
62539809|NCT05287256|PLACEBO_COMPARATOR|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
62539810|NCT05287256|EXPERIMENTAL|Oral administration of 10mg D-8-THC|Single acute administration of cannabis containing 10mg Delta-8-THC baked into a brownie
62539811|NCT05287256|EXPERIMENTAL|Oral administration of 20mg D-8-THC|Single acute administration of cannabis containing 20mg Delta-8-THC baked into a brownie
62539812|NCT05287256|EXPERIMENTAL|Oral administration of 40mg D-8-THC|Single acute administration of cannabis containing 40mg Delta-8-THC baked into a brownie
62539813|NCT05287256|EXPERIMENTAL|Oral administration of 20mg D-9-THC|Single acute administration of cannabis containing 20mg Delta-9-THC baked into a brownie
62539814|NCT05287256|PLACEBO_COMPARATOR|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
62539815|NCT05287256|EXPERIMENTAL|Administration of vaporized 10mg D-8-THC|Single acute administration of placebo cannabis containing 10mg Delta-8-THC via commercial vaporizer
62539816|NCT05287256|EXPERIMENTAL|Administration of vaporized 20mg D-8-THC|Single acute administration of placebo cannabis containing 20mg Delta-8-THC via commercial vaporizer
62539817|NCT05287256|EXPERIMENTAL|Administration of vaporized 40mg D-8-THC|Single acute administration of placebo cannabis containing 40mg Delta-8-THC via commercial vaporizer
62539818|NCT05287256|EXPERIMENTAL|Administration of vaporized 20mg D-9-THC|Single acute administration of placebo cannabis containing 20mg Delta-9-THC via commercial vaporizer
62539819|NCT05708092|ACTIVE_COMPARATOR|NeuroResource Facilitation|As part of the NRF intervention group, participants will receive specialized care management, both in prison and after the participant goes home. While in the State Correctional Institution (SCI), participants will meet weekly to monthly depending on resource needs, and how close participant is to release with a NeuroResource Facilitator in person who will help participants to understand more about their challenges. Participants may also be referred to a group run by the Facilitator in conjunction with staff from the prison. The facilitator will also tell the participant about resources that are available to help after the participant's release and help participants get connected to them.
62539820|NCT05708092|NO_INTERVENTION|Standard of Care|As part of the SoC, participants will receive the re-entry services normally receive if not in the study including (but not limited to) Treatment Services, Educational and Vocational Training, Mental Health Management, Reentry and Transitional Services, Population Management and Community Corrections.
62539821|NCT06336395|EXPERIMENTAL|Standard risk (SR)|"1. No anthracycline throughout the treatment.~2. CNS consolidation using Capizzi type low dose methotrexate (LDMTX) x 2 courses to replace pre-existing high dose methotrexate (HDMTX) 2.5g #3/4"
61976419|NCT01029574|EXPERIMENTAL|Rotator cuff repair plus PRP|Conventional arthroscopic repair of rotator cuff with application of PRP.
61976420|NCT01029574|PLACEBO_COMPARATOR|Rotator cuff repair alone|Conventional arthroscopic repair of rotator cuff without application of PRP
62164581|NCT06071715|EXPERIMENTAL|Cryoneurolysis first, then optional sham crossover treatment|"Initial treatment: Cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.~Optional sham crossover treatment: Sham cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis."
62539822|NCT06336395|EXPERIMENTAL|Intermediate risk (IR)|Those with CD20 ≥ 20% expression on diagnostic blasts by flow immunophenotyping will receive additional dose of rituximab on day 1 of each delayed intensification (DI) phases: phase III (2 courses) and V (1 course) for total 3 infusions
62539823|NCT06336395|EXPERIMENTAL|High risk (HR)|Provisional HR patients will be offered CAR-T cell immunotherapy or HSCT
62539824|NCT05127915|EXPERIMENTAL|Therapeutic|The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
62539825|NCT05127915|EXPERIMENTAL|Prophylactic - Test|The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
62539826|NCT05127915|ACTIVE_COMPARATOR|Prophylactic - Control|The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.
62164582|NCT06071715|EXPERIMENTAL|Sham Comparator first, then optional cryoneurolysis treatment|"Initial treatment: Sham cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.~Optional active crossover treatment: Cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis."
62164583|NCT03754686|ACTIVE_COMPARATOR|Oseltamivir|best medical care and oral oseltamivir 75 mg twice daily for five days.
62539827|NCT05174195|ACTIVE_COMPARATOR|ESI (Implanon NXT® subdermal implant)|In this group, the implant was inserted immediately after thorough explanations of the potential side effects and possible adverse events
62539828|NCT05174195|EXPERIMENTAL|DSG + ESI(Desogestrel +Implanon NXT® subdermal implant)|In this group, patients were given a 3 months' supply of 75µg of DSG to be started immediately after which insertion of an ESI was proposed. Similarly, explanations of the potential side effects and possible adverse events were presented to the patient before treatment initiation.
62539829|NCT00506792|EXPERIMENTAL|1|QAU145
62164584|NCT03754686|ACTIVE_COMPARATOR|Paracetamol|best medical care and oral paracetamol twice daily for five days.
62539830|NCT00506792|PLACEBO_COMPARATOR|2|Placebo
62539831|NCT02974179||Subjects who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
62539832|NCT05636514|EXPERIMENTAL|Decitabine/cedazuridine + defactinib|"Decitabine/cedazuridine taken days 1-5 of each 28 day treatment cycle, cycle 1 to 6~Defactinib taken on days 1-5 of each 28 treatment day cycle from cycle 2 to cycle 6."
62539833|NCT00168818|EXPERIMENTAL|dabigatran etexilate 75 mg|daily dose 150 mg once daily, half a dose on the day of surgery
62539834|NCT00168818|EXPERIMENTAL|dabigatran etexilate 110 mg|daily dose 220 mg once daily, half a dose on the day of surgery
62539835|NCT00168818|ACTIVE_COMPARATOR|enoxaparin|40 mg once daily
62539836|NCT05386030|EXPERIMENTAL|saypha® VOLUME Lidocaine|"For injection, either a needle (27G ½'') or cannula (25G 1½) may be used. Randomization will be stratified by injection equipment in a 1:1 ratio.~The volume administered is at the discretion of the treating investigator and depends on the severity of the midface volume deficit to be corrected. However, the maximum volume (left and right side of the midface together) must not exceed 10 mL in total per treatment (initial and repeat-treatment) or 20 mL per 60 kg (130 lbs) body mass per year."
62736623|NCT05376059|EXPERIMENTAL|How and why incentive receive|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives), including an incentive if they seek out mental health treatment (if they visit a therapist within 30 days, they will receive a gift card).
61976421|NCT03012958||Health control group|"Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
61977706|NCT03402789|PLACEBO_COMPARATOR|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
62539837|NCT05386030|ACTIVE_COMPARATOR|Juvéderm® Voluma™ XC|"For injection, either a needle (27G ½'') or cannula (25G 1½) may be used. Randomization will be stratified by injection equipment in a 1:1 ratio.~The volume administered is at the discretion of the treating investigator and depends on the severity of the midface volume deficit to be corrected. However, the maximum volume (left and right side of the midface together) must not exceed 10 mL in total per treatment (initial and repeat-treatment) or 20 mL per 60 kg (130 lbs) body mass per year."
62164585|NCT00672347|ACTIVE_COMPARATOR|B|compare caudal anesthesia with bupivacaine alone or in addition to morphine, clonidine or both
62539838|NCT02635113|EXPERIMENTAL|PD Shoe|40 subjects will wear the shoe in order to test abnormal gait patterns that increase likelihood of falls and the effectiveness of a gait synchronized vibration system to plantar surface to reduce fall risk.
62539839|NCT04462211|EXPERIMENTAL|Management pharmacological protocol and bundle's|"The elaboration of the protocol according to the evidence-based approach, updated evidence found from both search engines such as MEDLINE, EMBASE, Cochrane Library, OVID and ScIELO will be used through the research question using the PICO method (Patient interest, Intervention, Comparation and Outcome).~the ready-made protocol will be adjusted to the pharmacological options that are available in the hospital."
62539840|NCT01059344|EXPERIMENTAL|Mesalamin|4.8g Mesalamin (800mg tablet)
62539841|NCT01059344|PLACEBO_COMPARATOR|Placebo|4.8g Placebo to Mesalamin (800 mg tablet)
62539842|NCT01797237|EXPERIMENTAL|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
62539843|NCT01797237|EXPERIMENTAL|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
62539844|NCT01085201|EXPERIMENTAL|Stage 1|12-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
62539845|NCT01085201|EXPERIMENTAL|Stage 2|24-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
62539846|NCT01085201|EXPERIMENTAL|Stage 3|24-hour infusion to adults with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
62539847|NCT01085201|EXPERIMENTAL|Stage 4|24-hour infusion to children with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
62539848|NCT01085201|EXPERIMENTAL|Stage 2B|48-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
62539849|NCT01729403|EXPERIMENTAL|Aleglitazar|
62539850|NCT01729403|PLACEBO_COMPARATOR|Placebo|
62539851|NCT04086407|EXPERIMENTAL|Forehead sensor recording precision head pitch and roll angle|During an overnight polysomnography, participants were coached by sleep research technologists to sleep with their head in positions hypothesized to minimize apnea severity ≤20⁰ or ≥160⁰, and those hypothesized to maximize apnea severity between 30⁰ and 150⁰. Head roll angles were measured and recorded by the participant's forehead sensor attached with adhesive and tape. Extreme head positions were attempted with the torso in both supine and non-supine positions so show insensitivity to torso position. A custom interface was developed to maintain compatibility with specific bedside polysomnography recorder auxiliary inputs. Sleep epochs were considered those where the subject slept for at least 10 minutes. Each head position epoch was analyzed for apnea hypopnea index and oxygen desaturation.
62539852|NCT02287155|EXPERIMENTAL|occupation based health promotion|"The description of the health promotion intervention is provided in the detailed description of the study. It's a single arm study."
62539853|NCT06633315|EXPERIMENTAL|High dose dexmedetomidine|received high dose dexmedetomidine,received dexmedetomidine 3 μ g/kg nasal drops,Record the success rate of the first dose of nasal sedation, the onset time of sedation, the time of sedation recovery, the quality of recovery, and the satisfaction of the examining physician. Record the vital signs of three groups of patients during the examination process, including before sedation (T0), after successful sedation (T1), after the end of the examination (T2), and upon awakening (T3). Compare the incidence of adverse reactions during sedation, including bradycardia, nausea and vomiting, nystagmus, postoperative agitation, and delayed awakening, among the three groups of patients.
62539854|NCT06633315|EXPERIMENTAL|Dexmedetomidine and esketamine|received dexmedetomidine plus esketamine ,received dexmedetomidine 2 μ g/kg nasal drops plus esketamine 0.5 mg/kg nasal drops.Record the success rate of the first dose of nasal sedation, the onset time of sedation, the time of sedation recovery, the quality of recovery, and the satisfaction of the examining physician. Record the vital signs of three groups of patients during the examination process, including before sedation (T0), after successful sedation (T1), after the end of the examination (T2), and upon awakening (T3). Compare the incidence of adverse reactions during sedation, including bradycardia, nausea and vomiting, nystagmus, postoperative agitation, and delayed awakening, among the three groups of patients.
62735174|NCT02964273|PLACEBO_COMPARATOR|Phase A: Placebo|Participants received matching-placebo tablets, orally as a split-dose (with the first dose taken upon awakening and second dose taken approximately 8 hours later), and starting dose based on their weight as per the following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.
61977707|NCT02405845|OTHER|CT Angiogram|A research CTA scan may be required if there is no change of the imaging on the 3 CTA scans prior.
62164586|NCT00672347|ACTIVE_COMPARATOR|C|compare caudal anesthesia with bupivacaine plus clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or morphine plus clonidine
62164587|NCT00672347|ACTIVE_COMPARATOR|M|compare caudal anesthesia with bupivacaine plus morphine with caudal anesthesia with bupivacaine alone or in addition to clonidine or morphine plus clonidine
62164588|NCT00672347|ACTIVE_COMPARATOR|CM|compares caudal anesthesia with bupivacaine, morphine and clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or clonidine
61977708|NCT00697203|EXPERIMENTAL|Dalcetrapib 300mg|
62164589|NCT05315817|EXPERIMENTAL|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
62164590|NCT06647108|ACTIVE_COMPARATOR|Food Supplement|The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium.
62539855|NCT06633315|EXPERIMENTAL|Low dos dexmedetomidine|received dexmedetomidine 2.5 μ g/kg nasal drops, Record the success rate of the first dose of nasal sedation, the onset time of sedation, the time of sedation recovery, the quality of recovery, and the satisfaction of the examining physician. Record the vital signs of three groups of patients during the examination process, including before sedation (T0), after successful sedation (T1), after the end of the examination (T2), and upon awakening (T3). Compare the incidence of adverse reactions during sedation, including bradycardia, nausea and vomiting, nystagmus, postoperative agitation, and delayed awakening, among the three groups of patients.
62539856|NCT05808920||Group 1|Participants with previous diagnosis of H\&N SCC treated with radiotherapy. Recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx treated with salvage surgery
62539857|NCT01499459|EXPERIMENTAL|autologous mesenchymal stem cell transplantation|
62539858|NCT06043687|EXPERIMENTAL|Dentifrice containing Jasmate formulation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Jasmate formulation toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 24 weeks for assessment of the efficacy and safety in periodontitis patients.
62539859|NCT06043687|ACTIVE_COMPARATOR|Dentifrice containing Biomin formulation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Biomin formulation toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 24 weeks for assessment of the efficacy and safety in periodontitis patients.
62539860|NCT06043687|PLACEBO_COMPARATOR|Dentifrice containing placebo formulation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Placebo formulation toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 24 weeks for assessment of the efficacy and safety in periodontitis patients.
62539861|NCT02954991|EXPERIMENTAL|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
62539862|NCT02954991|EXPERIMENTAL|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
62539863|NCT02954991|EXPERIMENTAL|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
62539864|NCT06194760|OTHER|myopic eyes with macular hole and only posterior retinal detachment|
62539865|NCT05801718||chronic cardiac patients|patients with chronic cardiac diseases affecting their groth parameters \& body mass index
62539866|NCT05801718||chronic renal patients|patients with chronic renal diseases affecting their growth parameters \& body mass index
62539867|NCT05801718||chronic respiratory diseases|patients with chronic respiratory diseases affecting their growth parameters \& body mass index
62539868|NCT05801718||chronic metabolic diseases|patients with chronic metabolic diseases affecting their growth parameters \& body mass index
62539869|NCT05801718||chronic neurological diseases|patients with chronic neurological diseases affecting their growth parameters \& body mass index
62539870|NCT05801718||chronic haematological diseases|patients with chronic haematological diseases affecting their growth parameters \& body mass index
62539871|NCT05801718||chronic gastro-intestinal diseases|patients with chronic gastro-intestinal diseases affecting their growth parameters \& body mass index
62539872|NCT04667754|EXPERIMENTAL|10 week ICBT|CBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
62539873|NCT06359288|EXPERIMENTAL|Group receiving QR code supported training|Training sessions in the training class run three days a week for two weeks. 6. During the training process, QR codes were integrated into the sections related to the care of the newborn in the guide in order to provide mothers with the opportunity to watch the video simultaneously while reading the guide in practices requiring skills related to hygienic care of the newborn and nutrition / communication / sleep, and to allow them to watch it repeatedly as long as they feel the need. In these videos, the application steps were shown one by one. URL addresses of the videos were obtained and then QR Codes were created. When the code is scanned with a smartphone, it automatically redirects the user to the specified URL. The difference between the groups was that videos on newborn care were shown and QR Code training guides with the same content as the SC group created by the researchers on newborn care were distributed.
61977709|NCT00697203|EXPERIMENTAL|Dalcetrapib 600mg|
61977710|NCT00697203|EXPERIMENTAL|Dalcetrapib 900mg|
61977711|NCT00697203|PLACEBO_COMPARATOR|Placebo|
62164591|NCT06647108|PLACEBO_COMPARATOR|Placebo|Placebo
62539874|NCT06359288|NO_INTERVENTION|Recommendations to start care|In the training class, mothers who are preparing for discharge are currently given training on the appearance, feeding, care, vaccinations, sleep and health checks of the premature infant, and the care of the newborn is carried out practically.
62164592|NCT06345924|NO_INTERVENTION|Control Group|Patients who receive the treatment program, will previously constitute their own control group (waiting list control group).
62539875|NCT02483208|EXPERIMENTAL|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
62539876|NCT02483208|OTHER|Advate|Advate infusion to analyze pharmacokinetics.
62539877|NCT01931696|EXPERIMENTAL|Verum acupuncture|Verum acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
62539878|NCT01931696|SHAM_COMPARATOR|Sham acupuncture|Sham acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
62539879|NCT02008435|EXPERIMENTAL|Enriched GLB|This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
62539880|NCT02008435|ACTIVE_COMPARATOR|Standard GLB|This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
62539881|NCT04060095||β1-adrenergic antagonists|Patients who have been treated for more than 3 months with β1-adrenergic antagonists
62539882|NCT00911027|EXPERIMENTAL|SonoVue guided biopsy|
62539883|NCT00911027|OTHER|Systematic biopsy|
62539884|NCT06632249|EXPERIMENTAL|HIIT VR|The virtual reality (VR) exergame 'Move Sapiens®' will be implemented through the VR headset Oculus Quest 2 (Meta®, Menlo Park, USA). The game's objective is to take as much life from the drone as possible while avoiding being hit to preserve their own life, the drone not only moves erratically but also can attack, having a defined amount of life, just like the player. Participants will use a virtual exoskeleton to interact with the environment, and their main task is to aim and punch a drone that moves unpredictably. The exergame incorporates a short HIIT model, consisting of 12 cycles that include 16 seconds of maximum effort followed by 20 seconds of rest. This structured format is intrinsic to the game's design, aiming for a balance between effort and recovery. Essential factors for the simulation design include an engaging sensory experience of enhanced physical skills and the application of powerful punches in the game design.
62539885|NCT06632249|SHAM_COMPARATOR|Sedentary VR|Participants will play an adapted version of the 'Move Sapiens®' exergame in VR, which maintains the immersive environment of the original game but excludes any physical exercise component. In this version, interaction will be carried out exclusively through joystick manipulation, without requiring physical activity from the participants.
62539886|NCT04617522|EXPERIMENTAL|Advanced or Metastatic Solid Tumor and Moderate Liver Impairment|Participants with advanced solid tumor and moderate hepatic impairment will receive an escalating dose of sacituzumab govitecan-hziy on Days 1 and 8. The dose-escalation plan will start at 5 mg/kg and escalate to 7.5 mg/kg, and finally 10 mg/kg, if deemed to be safe. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
62539887|NCT04617522|EXPERIMENTAL|Advanced or Metastatic Solid Tumor and Normal Liver function|Participants with advanced or metastatic solid tumor and normal hepatic function will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
62539888|NCT02341391|EXPERIMENTAL|TissueGene-C(Low dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10\^6 cells
62539889|NCT02341391|EXPERIMENTAL|TissueGene-C(Medium dose)|Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10\^7 cells
62539890|NCT02341391|EXPERIMENTAL|TissueGene-C(High dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10\^7 cells
62539891|NCT06632808|EXPERIMENTAL|deep cervical flexor muscle exercises|deep cervical flexor muscle exercises program
62539892|NCT06632808|NO_INTERVENTION|Control|no intervention
62539893|NCT06498440|EXPERIMENTAL|Ketorolac Alone|Participants in this arm will receive ketorolac 0.5% eye drops administered twice daily for one week following Selective Laser Trabeculoplasty (SLT). Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that helps reduce inflammation and alleviate pain. The purpose of this intervention is to assess the efficacy and safety of ketorolac alone in managing postoperative inflammation and patient comfort compared to other treatment strategies.
62736624|NCT05376059|EXPERIMENTAL|How and why incentive holdout|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives). This group is eligible for an incentive but not randomly assigned to it.
62167970|NCT06358339|EXPERIMENTAL|Routine Tracker and Achievement & Rewards|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker and Achievement \& Rewards."
62539894|NCT06498440|EXPERIMENTAL|Ketorolac with Fluorometholone|Participants in this arm will receive a combination of ketorolac 0.5% eye drops administered twice daily and fluorometholone 0.1% eye drops administered four times daily for one week following Selective Laser Trabeculoplasty (SLT). Fluorometholone is a corticosteroid that reduces inflammation by stabilizing capillary permeability and inhibiting inflammatory cell activation. This arm aims to evaluate the combined efficacy and safety of ketorolac and fluorometholone in postoperative care.
62539895|NCT06498440|NO_INTERVENTION|No Treatment Control|Participants in this arm will not receive any postoperative treatment following Selective Laser Trabeculoplasty (SLT). This control group is included to provide a baseline for comparison against the treatment groups receiving ketorolac alone or a combination of ketorolac and fluorometholone. The purpose is to assess the natural course of postoperative inflammation and patient comfort without intervention.
62539896|NCT00676780|EXPERIMENTAL|ECGC Extract|Single arm for a phase II study
62715109|NCT03885401|NO_INTERVENTION|Usual medical care|"Clinicians randomized to the control condition will continue to provide usual care. This includes current non-systematic assessment of health behaviors, mental health needs, and social needs. Neither clinicians nor patients will be eligible to receive CHW support or have access to NWD. Clinicians may refer some control patients to community programs as part of their current usual care. Control clinicians will be blinded as to which patients are included in the study. At the end of the study, the investigators will share with control clinicians our lessons learned, access to MOHR, and lists of useful community resources."
62715110|NCT05912621|EXPERIMENTAL|2.5 mg (up to 15 mg) Tirzepatide|Patients assigned to tirzepatide will undergo dose titration starting with 2.5 mg per day with an increase every four weeks if tolerated by nausea. During the first 6 weeks, weight loss must be matched with the dietary weight loss arm at 0.6 kg/week. Participants will be seen every two weeks to review diet and physical activity, evaluate tolerability/side effects, and obtain morning weight. If weight loss is greater than 0.6 kg/week, recommendations to increase caloric intake will be made through the week 6 visits that repeat baseline testings (biopsy, metabolic tests, and regional fat scans). After the 6th week, weight loss can occur naturally without any restrictions (no further matching to the dietary weight loss group is required). Starting at week 8 the visits are decreased to every 4 weeks. Biopsies, metabolic tests, and regional fat scans are completed at baseline, week 6, and end of study (week 22).
62715111|NCT05912621|NO_INTERVENTION|Diet-controlled|The group assigned to dietary weight loss will undergo intensive dietary counseling with initial 3 day food diary evaluation followed by specific dietary recommendations that include macronutrient balanced, healthful and calorie-restricted diet, weekly dietitian visits, alternating between video and in person, use of a mobile app for food logging, weekly weights at home and biweekly weights, and review of these data by the study dietitian who will give individualized feedback at the weekly visits in order to attain targeted weight loss of 0.6 kg per week. The goal is to match weight loss in the tirzepatide and diet groups for the first six weeks. Any residual differences in weight loss at 6 weeks will be adjusted statistically. At six weeks all baseline tests (biopsy, metabolic tests, and regional fat scans) will be repeated, after which no further attempts for matching for weight loss will occur. At the end of the study (week 22), all baseline testing will occur again.
62715112|NCT03534388|OTHER|Prospective Subjects|
62715113|NCT03111030|EXPERIMENTAL|ProacTive SCI|Individualized physical activity coaching sessions
62715114|NCT03111030|NO_INTERVENTION|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
62715115|NCT05195489|EXPERIMENTAL|Active Intervention|Family members participate in Connectors by phone and receive a packet of resources
62715116|NCT05195489|NO_INTERVENTION|Comparison|Family members receive a pack of resources
62715117|NCT06715176||Periodontal Health|This group showed PD ≤ 3 mm with BOP \< 10 % in the entire mouth as well as no interproximal CAL or radiographic bone loss.
62715118|NCT06715176||Gingivitis|This group exhibited PD ≤ 3 mm with BOP ≥ 30 % in the entire mouth as well as no interproximal CAL or radiographic bone loss.
62715119|NCT06715176||Stage III, Grade B Periodontitis|This group had interproximal CAL ≥ 5 mm along with PD ≥ 6 mm and radiographic bone loss extending to the middle or apical third of the root radiographically at 30 % of the teeth or more. CAL was not caused by trauma-related gingival recession, dental caries extending into the cervical areas of the teeth, endodontic lesions draining through the marginal periodontium, and the distal bone loss in adjacent second molars due to extractions of third molars. They had ≤ 4 teeth lost owing to periodontitis. % of radiographic bone loss/age value was between 0.25 and 1.0.
62539897|NCT00701961|EXPERIMENTAL|1|Pregnat women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
62539898|NCT00701961|ACTIVE_COMPARATOR|2|Non-pregnant women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
62539899|NCT05005312|EXPERIMENTAL|Cohort 1|Healthy Volunteer
62539900|NCT05005312|EXPERIMENTAL|Cohort 2|Hepatic Impairment
62539901|NCT02167854|EXPERIMENTAL|LJM716, BYL719 AND TRASTUZUMAB|A treatment cycle will consist of 28 days. Treatment doses for trastuzumab and LJM716 will be fixed at trastuzumab 2mg/kg weekly, and LJM716 20mg/kg weekly. The exception to this is if dose de-escalation results in treatment of patients at dose level 1, where LJM will be dosed at 10mg/kg weekly. On Arm A, BYL719 was administered orally once daily continuously at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. On Arm B, BYL719 will be administered orally once daily during 4 of 7 days in a week, at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. This means BYL719 will be given to patients on Arm B during days 1-4, 8-11, 15-18, and 22-25 of each cycle. The dose-finding phase will follow a Continuous Reassessment Methods (CRM) phase I biostatistical design.
62539902|NCT01053000|EXPERIMENTAL|Lt. Arm Tazorac/Rt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Left arm only and then receive ALA- PDT Treatment to both arms
62539903|NCT01053000|EXPERIMENTAL|Rt. Arm Tazorac/Lt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Right arm only and then receive ALA- PDT Treatment to both arms
62539904|NCT01496300|SHAM_COMPARATOR|Manual|Manual Implantation of THA
62539905|NCT01496300|EXPERIMENTAL|Navigated|Navigated Implantation of THA
62539906|NCT06149806||efficacy and tolerability of Sacubitril/Valsartan|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
62539907|NCT06633692|EXPERIMENTAL|Simulated microgravity|Pre- and post-assessment of pelvic blood flow in response to simulated microgravity will be performed in the same participant.
62715120|NCT06715176||Stage III, Grade C Periodontitis|This group had interproximal CAL ≥ 5 mm along with PD ≥ 6 mm and radiographic bone loss extending to the middle or apical third of the root radiographically at 30 % of the teeth or more. CAL was not caused by trauma-related gingival recession, dental caries extending into the cervical areas of the teeth, endodontic lesions draining through the marginal periodontium, and the distal bone loss in adjacent second molars due to extractions of third molars. They had ≤ 4 teeth lost owing to periodontitis. % of radiographic bone loss/age were value was higher than 1.0.
62539908|NCT06633432|EXPERIMENTAL|Acupuncture group|The acupuncture group administered medication three times at each acupoint: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. Acupuncture and moxibustion stimulation was applied to four pairs of acupoints: bilateral Shenmen (HT7), Neiguan (PC6), Zusanli (ST36) and Zhaohai (KI6), and the penetration depth was 10-20mm. Select the specific depth based on the subject's body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.
62539909|NCT06633432|SHAM_COMPARATOR|Sham-acupuncture group|"The sham acupuncture group received non skin breaking comfort needles at corresponding points for acupuncture and moxibustion the night before the operation, the night of the operation and the first night after the operation, and kept the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin."
62539910|NCT01942889|ACTIVE_COMPARATOR|Antioxidant Supplementation|Vitamin antioxidant and trace elements combination that won't exceed the maximal nutritional dose recommended in France (Vit E, vit C, Selenomethionine, Zinc gluconate).
62539911|NCT01942889|PLACEBO_COMPARATOR|Placebo|Placebo
62539912|NCT02454127|ACTIVE_COMPARATOR|Atkins Diet|Atkins Diet (dietary counseling)
62539913|NCT02454127|ACTIVE_COMPARATOR|Zone Diet|Zone Diet (dietary counseling)
62539914|NCT02454127|ACTIVE_COMPARATOR|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
62539915|NCT02454127|ACTIVE_COMPARATOR|Ornish Diet|Ornish Diet (dietary counseling)
62539916|NCT05853744|EXPERIMENTAL|Group C|patients receiving aromatherapy using cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
62539917|NCT05853744|ACTIVE_COMPARATOR|Group M|- Group M: inhaled three drops of lavender oil through a facemask. These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer. A cotton ball soaked with water was put 10 cm next to the patient.
62539918|NCT05853744|PLACEBO_COMPARATOR|Group P|Placebo group: inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
62539919|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
62539920|NCT05180916|ACTIVE_COMPARATOR|Brivaracetam + Transcutaneous vagal nerve stimulation|Start of Brivaracetam (treatment as usual), combined with tVNS in the first 3 months of treatment
62539921|NCT05180916|NO_INTERVENTION|Brivaracetam|Start of Brivaracetam (treatment as usual)
62539922|NCT05738317|EXPERIMENTAL|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|"Adebrelimab: 20 mg/kg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Albumin Paclitaxel: 100 mg/m2 Albumin Paclitaxel is given on days 1, 8, and 15 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
62539923|NCT04855149||WALANT|anesthesia performed with WALANT technique
62539924|NCT04855149||BAx|anesthesia performed with axillary block under ultrasound control
62539925|NCT05713851|EXPERIMENTAL|Dapaglifozin group|Dapagliflozin 10 mg, will be administered orally or by nasogastric tube every 24 h for 21 days.
62539926|NCT05713851|PLACEBO_COMPARATOR|Standard of care|Without receiving any of the interventional drugs.
62539927|NCT01194817|OTHER|Cemented fixation|Nexgen High-Flexion Knee Replacement System using Cemented Fixation
62539928|NCT01194817|OTHER|Cementless fixation|Nexgen High-Flexion Knee Replacement System using Cementless Fixation
62539929|NCT03803787|EXPERIMENTAL|QT/RT + Budesonide|Patients are receiving chemotherapy (QT) and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
62539930|NCT03803787|NO_INTERVENTION|QT/RT + No medication|Patients are receiving chemotherapy (QT) and radiotherapy (RT) without intervention therapy and followed during 12 months.
62539931|NCT03803787|EXPERIMENTAL|Target drug/RT + Budesonide|Patients are receiving target therapy and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
62539932|NCT03803787|NO_INTERVENTION|Target drug/RT + No medication|Patients are receiving target treatment and radiotherapy (RT) without intervention therapy and followed during 12 months.
62539933|NCT06633614|NO_INTERVENTION|Control|Participants in the control group (uSEP) will receive the standard PREPARE program provided by the hospital, which includes preoperative physiotherapy education and a home exercise booklet (Supplementary Material: Educational Materials). This unsupervised, home-based programme consists of full-body aerobic, resistance, and respiratory exercises that participants will perform independently at home. Additionally, participants with a Maximal Inspiratory Pressure (MIP) of less than 100 cmH₂O will be given an Inspiratory Muscle Trainer (IMT) to enhance respiratory function.
62539934|NCT06633614|EXPERIMENTAL|Intervention|Participants in the intervention group (swSEP) will receive standard preoperative physiotherapy education in addition to a Fitbit Aspire 3 wearable device, which will track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalised exercise program that is remotely supervised by a physiotherapist via telemedicine twice a week. The exercise regimen will consist of 20-minute sessions, at least three times per week, and will include three core components: strength training, aerobic exercise, and flexibility exercises. Strength training will involve 2-3 sets of full-body exercises, including combinations of upper body, lower body, and abdominal movements. Aerobic exercises will be performed at a minimum intensity of 40% of the participant's maximal heart rate (HRmax) for up to 20 minutes. Flexibility training will include six stretches, each held for 20 seconds and repeated twice, targeting the chest, arms, legs, and trunk.
62539935|NCT02091466|ACTIVE_COMPARATOR|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
62715121|NCT04944147|EXPERIMENTAL|Anodal tDCS + cognitive training|"device: anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: intensive cognitive training intensive cognitive training of letter memory updating task (20 minutes), 9 sessions"
62539936|NCT02091466|NO_INTERVENTION|Control|Patients received no active warming before the anesthesia procedure in control groups
62539937|NCT03443271|EXPERIMENTAL|Group T (TAP Block with Bupivicaine)|Ultrasound guided TAP block will be performed in this group. Bupivicaine 0.25 % 20 ml will be administered in the block on either side.
62539938|NCT03443271|PLACEBO_COMPARATOR|Group C (TAP Block with Placebo drug)|Ultrasound guided TAP block will be performed in this group. 0.9 % Saline 20 ml will be administered in the block on either side.
62539939|NCT00763061|EXPERIMENTAL|Travoprost 0.004%|Travoprost 0.004%
62539940|NCT00763061|ACTIVE_COMPARATOR|Timolol 0.5%|Timolol 0.5%
62539941|NCT03558061|EXPERIMENTAL|Active|ALK4290 800 mg daily
62539942|NCT05806294|EXPERIMENTAL|Single-arm pilot trial|The Digital Metabolic Rehabilitation is a single-arm pilot trial that assesses Canadian Digital Technology's feasibility in preventing and managing MetS in patients living with COPD for a 6-month program.
62539943|NCT02933255|EXPERIMENTAL|Lead-in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Cohort|Prostate-specific antigen (PSA)-TRICOM vaccinia (PROSTVAC)-V on week 0 followed by booster injection called PROSTVAC-F on week 2, 4, and 8. Nivolumab will be administered on week 2, 4, 6, 8 and 10. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo restaging scans on week 12. If no progressive disease (PD), option to continue treatment with nivolumab every 2 weeks and PROSTVAC-F every 4 weeks until intolerance or progression. Option to extend nivolumab interval to 4 weeks for participants who remain on protocol beyond 1 year.
62539944|NCT02933255|EXPERIMENTAL|Neoadjuvant Cohort|Prostate-specific antigen (PSA)-TRICOM vaccinia (PROSTVAC)-V on week 0 followed by booster injection called PROSTVAC-fowlpox (F) on 2, 4 and 8 weeks. Nivolumab will be administered on week 2, 4, and 8. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo prostatectomy on week 9.
62715122|NCT04944147|PLACEBO_COMPARATOR|Sham tDCS + cognitive training|"device: sham transcranial direct current stimulation (tDCS), 9 sessions with 30 seconds stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: intensive cognitive training intensive cognitive training of letter memory updating task (20 minutes), 9 sessions"
62715123|NCT04944147|ACTIVE_COMPARATOR|Sham tDCS + Progressive Muscle Relaxation training|"device: sham transcranial direct current stimulation (tDCS), 9 sessions with 30 seconds stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: progressive muscle relaxation (PMR) standardized instructed PMR (20 minutes), 9 sessions"
62715124|NCT05035238|ACTIVE_COMPARATOR|Arm 1|3 μg / 0.5 mL
62715125|NCT05035238|ACTIVE_COMPARATOR|Arm 2|4,5 μg / 0.5 mL
62715126|NCT06206850|EXPERIMENTAL|neoadjuvant osimertinib|Osimertinib 80 mg QD
62539945|NCT02642848|ACTIVE_COMPARATOR|HTO with micro fracture|High tibial osteotomy(HTO) with micro fracture is an common treatment for the correction of malalignment of the knee treating osteoarthritis.
62715127|NCT03364647|EXPERIMENTAL|Arm A - Blood flow restriction training|Group will use blood flow restriction training and standard of care
62715128|NCT03364647|SHAM_COMPARATOR|Arm B - standard of care plus sham|Group will receive standard of care plus a sham version of blood flow restriction training
62715129|NCT05905536|EXPERIMENTAL|Vitalstream|Device placed on the subject preoperatively in the holding room and continued postoperatively into the Cardiac Intensive Care Unit (ICU).
62715130|NCT04760873|EXPERIMENTAL|Cryotherapy for GAVE|Subjects will undergo cryotherapy for GAVE
62539946|NCT02642848|EXPERIMENTAL|HTO with bone marrow stem cell|High tibial osteotomy(HTO) with transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone.
62539947|NCT02642848|EXPERIMENTAL|HTO with adipose derived stem cell|High tibial osteotomy(HTO) with autologous adipose-derived stromal vascular fraction transplantation using LipoSculptor collecting from abdominal fat tissue.
62539948|NCT04697095|EXPERIMENTAL|early / intermediate AMD without neovessels and without macular atrophy|
62539949|NCT04697095|EXPERIMENTAL|Late exsudative AMD with neovessels|
62539950|NCT04697095|EXPERIMENTAL|Late AMD with macular atrophy without neovessels|
62539951|NCT04697095|SHAM_COMPARATOR|Patientes with No AMD|
62539952|NCT06338124||survivor group|About 50 patients whom will be relifed from the sepsis and will be discharged from the Intensive Care Unit
62539953|NCT06338124||non-survivor group|About 50 patients whom will be died from the sepsis in the Intensive Care Unit
62539954|NCT06588842|EXPERIMENTAL|Cluster Set Resistance Training|Participants in this group will receive high-speed resistance training 2 times a week for 12 consecutive weeks.
62539955|NCT06588842|ACTIVE_COMPARATOR|Traditional Set Resistance Training|Participants in this group will receive traditional set resistance training 2 times a week for 12 consecutive weeks.
62539956|NCT02940132|EXPERIMENTAL|SC10914|SC10914 Dose Escalation： Dose Level 1：30mg(QD) Dose Level 2：60mg(QD) Dose Level 3：120mg(QD) Dose Level 4：200mg(QD) Dose Level 5：100mg(BID) Dose Level 6：300mg(QD) Dose Level 7：150mg(BID) Dose Level 8：400mg(QD) Dose Level 9：200mg(BID) Dose Expansion： Receiving SC10914 in one of three dosage regimens(low, middle or high dose-level and QD or BID) based on the assessment of dose escalation study.
62539957|NCT05062889|EXPERIMENTAL|Arm B FOLFOXIRI, part 1 (adjuvant)|FOLFOXIRI Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluoruracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. In the case of oxaliplatin and/or irinotecan interruption because of adverse events, patient's refusal or investigator's choice, the continuation of the other drugs until 12 cycles is recommended.
62715131|NCT05105321|PLACEBO_COMPARATOR|Placebo Group|Placebo plus healthy lifestyle intervention. Placebo with same appearance of berberine tablet will be orally taken twice daily and maintained until the last subject completes 3-year intervention.
62715132|NCT05105321|EXPERIMENTAL|Berberine Group|Berberine plus healthy lifestyle intervention. Berberine dose is 500mg twice daily and maintained until the last subject completes 3-year intervention.
62539958|NCT05062889|ACTIVE_COMPARATOR|Arm A mFOLFOX6 or CAPOX (at investigator's choice), part 1 (adjuvant)|"mFOLFOX6 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. The continuation of 5FU/leucovorin until 12 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.~CAPOX Oxaliplatin 130 mg/sqm iv over 2 hours, day 1; Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14; to be repeated every 3 weeks until 8 cycles. The continuation of Capecitabine until 8 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.~Pending the results of ct-DNA analysis, up to 2 cycles of FOLFOX/CAPOX before randomization are allowed to start the adjuvant treatment within 8-10 weeks after surgery"
62539959|NCT05062889|EXPERIMENTAL|Trastuzumab and Tucatinib plus mFOLFOX6, part 1 target-driven (adjuvant)|"Tucatinib 300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal); Trastuzumab 4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes), followed by~mFOLFOX6 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. In the case of oxaliplatin and/or trastuzumab and/or tucatinib interruption because of adverse events, patient's refusal or investigator's choice, the prosecution of the other drugs until 12 cycles is recommended.~Pending the results of ct-DNA analysis, up to 2 cycles of FOLFOX/CAPOX before randomization are allowed to start the adjuvant treatment within 8-10 weeks after surgery"
62539960|NCT05062889|EXPERIMENTAL|Arm B Trifluridine/Tipiracil, part 2 (post-adjuvant)|Trifluridine/Tipiracil: 35 mg/ m2/bid per os days 1-5 and 8-12 to be repeated every 4 weeks until 6 cycles.
62539961|NCT05062889|NO_INTERVENTION|Arm A Observation, part 2 (post-adjuvant)|Follow-up
62539962|NCT04769414|EXPERIMENTAL|Chemotherapy|"Participants will receive the test protocol Gem-5FU on biweekly basis for 6 months with interim evaluation~Doses as follows:~Gemcitabine 1000 mg/m2, infusion over 30 min, D1, D15 Leucovorin 400 mg/m2 infusion over 30 min , D1, D15 5FU 400 mg/m2 I.V. shot D1, D15 5FU 2000 mg/m2 infusion over 46 hours D1 , D15"
62539963|NCT06558149|ACTIVE_COMPARATOR|Analgesic use according to hemodynamics patients to be treated|Procedure/Surgery: Pericapsular nerve group block(PENG) Before the general anesthesia induction, Peng block will be performed between the psoas tendon and the ilium with 0.25% bupivacaine (20 mL) using ultrasound and will be adjusting opioid infusion rate according to hemodinamic parameters
62539964|NCT06558149|ACTIVE_COMPARATOR|Patients who will use analgesics according to NOL monitoring|Procedure/Surgery: Pericapsular nerve group block(PENG) Before the general anesthesia induction, Peng block will be performed between the psoas tendon and the ilium with 0.25% bupivacaine (20 mL) using ultrasound and will be adjusting opioid infusion rate according to NOL monitoring.
62715133|NCT05958914|EXPERIMENTAL|Arm 1|"women with regular ovarian cycle. Patients, as per normal clinical practice, will undergo three blood draws in the follicular, ovulatory and luteal phases.~Biological samples will be analyzed for the concentration of neuropeptides (enkephalins, CGRP, SP and VIP)"
62539965|NCT00083603|EXPERIMENTAL|1|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
62539966|NCT00083603|PLACEBO_COMPARATOR|2|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
62539967|NCT00083603|EXPERIMENTAL|3|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
62539968|NCT00083603|PLACEBO_COMPARATOR|4|Empty TBC-MVA vector administered in each deltoid on Days 0, 28; empty TBC-FPV vector administered in each deltoid on Days 84, 140, and 196
62539969|NCT00083603|EXPERIMENTAL|5|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
62539970|NCT00083603|PLACEBO_COMPARATOR|6|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
62539971|NCT00083603|EXPERIMENTAL|7|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
62539972|NCT00083603|PLACEBO_COMPARATOR|8|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
62539973|NCT00083603|EXPERIMENTAL|9|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
62715134|NCT05958914|EXPERIMENTAL|Arm 2|"non-PCOS women undergoing ovarian stimulation and ICSI treatment. Patients will undergo ovarian stimulation treatment with gonadotropins and egg retrieval. As part of this process, as per clinical practice, blood and follicular fluid sampling will be performed.~Biological samples will be analyzed for the concentration of neuropeptides (enkephalins, CGRP, SP and VIP)"
62736625|NCT05376059|EXPERIMENTAL|How and why incentive ineligible|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives). This group is not eligible for an incentive.
62539974|NCT00083603|PLACEBO_COMPARATOR|10|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
62539975|NCT00083603|EXPERIMENTAL|11|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
62715135|NCT05958914|EXPERIMENTAL|Arm 3|"PCOS women undergoing ovarian stimulation and ICSI treatment. Patients will undergo ovarian stimulation treatment with gonadotropins and egg retrieval. As part of this process, as per clinical practice, blood and follicular fluid sampling will be performed.~Biological samples will be analyzed for the concentration of neuropeptides (enkephalins, CGRP, SP and VIP)"
62539976|NCT00083603|PLACEBO_COMPARATOR|12|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
62539977|NCT00083603|EXPERIMENTAL|13|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
62539978|NCT00083603|PLACEBO_COMPARATOR|14|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
62539979|NCT00083603|EXPERIMENTAL|15|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
62539980|NCT00083603|PLACEBO_COMPARATOR|16|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
62539981|NCT02542605|OTHER|PACAP-38 Challenge Agent|In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
62539982|NCT02542605|PLACEBO_COMPARATOR|Placebo|Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
62539983|NCT02542605|EXPERIMENTAL|Erenumab|Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
62539984|NCT03423017|OTHER|Pierre Robin sequence|"Infants with PRS : retrognathism, glossoptosis, cleft palate~Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease"
62539985|NCT03423017|OTHER|Superior airway obstruction, AWO|Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
62539986|NCT03423017|OTHER|Healthy infants|Healthy infants : siblings of sudden unexpected death of the infant
62539987|NCT05850806|EXPERIMENTAL|KmAsthma self-management smart phone app intervention|Participants assigned to the intervention arm will be given a link to download the self-management app on their Android smartphone or iPhone
62539988|NCT05850806|NO_INTERVENTION|Control arm|Will emulate standard access to asthma self-management information
62539989|NCT05053334|EXPERIMENTAL|BP11 (Proposed biosimilar)|Subcutaneous injection of Omalizumab developed by CuraTeQ.
62539990|NCT05053334|ACTIVE_COMPARATOR|US-Xolair|Subcutaneous injection of Omalizumab licensed for use in USA
62539991|NCT05053334|ACTIVE_COMPARATOR|EU-Xolair|Subcutaneous injection of Omalizumab approved for use in Europe.
62539992|NCT06548815|EXPERIMENTAL|GZR4|s.c, single dose
62539993|NCT06548815|PLACEBO_COMPARATOR|Placebo|s.c, single dose
62539994|NCT02069431|EXPERIMENTAL|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
62539995|NCT02069431|PLACEBO_COMPARATOR|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
62539996|NCT01025115|EXPERIMENTAL|A|Diamel
62539997|NCT01025115|PLACEBO_COMPARATOR|B|Placebo
62539998|NCT06632899|EXPERIMENTAL|intervention group|
62539999|NCT06632899|NO_INTERVENTION|control group|
62540000|NCT01621477|EXPERIMENTAL|Treatment|"All study participants.~Interventions: clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, tacrolimus, mycophenolate mofetil"
62540001|NCT06157736||Cases|Children with newly diagnosed T1D
62540002|NCT06157736||Controls|Healthy siblings of cases
62540003|NCT05651789|EXPERIMENTAL|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
62540004|NCT05651789|ACTIVE_COMPARATOR|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
62540005|NCT06355791|OTHER|Surgical Group|patient treated with interspinous fusion device for degenerative conditions of the lumbar spine
62540006|NCT02183181|EXPERIMENTAL|Meloxicam capsule|Capsules 15 mg
62540007|NCT02183181|ACTIVE_COMPARATOR|Meloxicam tablet|Tablets 15 mg
62540008|NCT05021718|EXPERIMENTAL|Intervention group (IG)|A total of 35 patients in IG received different back and hip strengthening exercises five times a week for six weeks. They were also instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
62540009|NCT05021718|ACTIVE_COMPARATOR|Control group (CG)|The remaining 35 patients were allocated to CG. The patients in CG were treated with Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks, followed by hot moist compression for the next three weeks. Moreover, they were instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
62540010|NCT06050343|EXPERIMENTAL|Rinsulin® R|Single subcutaneous administration of Insulin at a dose 0.3 IU / kg
62540011|NCT06050343|ACTIVE_COMPARATOR|Humulin® Regular|Single subcutaneous administration of Insulin at a dose 0.3 IU / kg
62540012|NCT04962152|EXPERIMENTAL|Group Naldebain|ultrasound-guided intramuscular injection of Naldebain 150mg after the induction anesthesia immediately
62540013|NCT04962152|PLACEBO_COMPARATOR|Group Placebo|ultrasound-guided intramuscular injection of sesame oil (placebo) 2mL after the induction anesthesia immediately
62164593|NCT06345924|EXPERIMENTAL|Experimental group|The study will commence with an initial evaluation (T1) one week after the patients' admission to the hospital. After an equal amount of time has passed without receiving any treatment, patients will undergo a re-evaluation (T2). Subsequently, patients will receive the music therapy treatment protocol, which consists of three sessions. Finally, patients will undergo a third evaluation (T3) after completing the treatment. Patients will undergo assessment before and after each music therapy session. Before the session, they will report their physical and emotional state, as well as their memory of the previous session's effects. After the session, they will be evaluated on their physical and emotional state, as well as the perceived effects of the current session. The therapy will consist of three individual sessions.
62540014|NCT02730026|EXPERIMENTAL|Surgery with Ketoprofen|Fifty healthy volunteers underwent removal one of lower third molar, will be treated to control pain, swelling and trismus with ketoprofen 100 mg
62540015|NCT02730026|EXPERIMENTAL|Surgery with Ketoprofen and Omeprazole|Fifty healthy volunteers underwent removal the other lower third molars, will be treated to control pain, swelling and trismus with ketoprofen 200 mg associated with Omeprazole 20 mg
62540016|NCT03499210|EXPERIMENTAL|Investigational group|All subjects will participate in study procedures involving use of the ReWalk ReStore device.
62540017|NCT01145508|EXPERIMENTAL|Arm A (vaccine therapy and chemotherapy)|Patients receive rilimogene-galvacirepvec SC on day 1 of course 1 and fowlpox-PSA-TRICOM vaccine SC on days 15, 29, 43, and 57 of course 1. Beginning on day 85 (day 1 of course 2), patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment with docetaxel and prednisone repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62540018|NCT01145508|ACTIVE_COMPARATOR|Arm B (docetaxel, prednisone)|Patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62540019|NCT00952731|EXPERIMENTAL|oral placebo, afimoxifene|4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.
62540020|NCT00952731|ACTIVE_COMPARATOR|tamoxifen citrate, placebo gel)|Placebo gel applied to the breasts daily. 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules).
62540021|NCT06012461|EXPERIMENTAL|Bilateral STN DBS Modulation|Participants will be implanted with bilateral STN DBS using PINS 106RS system. DBS stimulation will be initiated one month post surgery. Follow-up visits will be conducted 1/3/6/9/12/15 months post surgery with clinical evaluation, STN LFP recording and resting state functional MRI testing. During the 6-15 month's visit, short-term closed-loop DBS modulation (from 24hours to 72hours ) will be conducted to test the safety and efficacy of closed-loop DBS therapy.
62540022|NCT04920500|EXPERIMENTAL|Daunorubicin Cytarabine liposome for injection|Induction 1: Daunorubicin Cytarabine liposome for injection \[100 U/m²\] i.v. (120 min±10min) d1,3,5 Induction 2: Daunorubicin Cytarabine liposome for injection \[100 U/m²\] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection \[65 U/m²\] i.v. (\>90 min) d1,3
62540023|NCT04920500|ACTIVE_COMPARATOR|Vyxeos + Daunorubicin Cytarabine liposome for injection|Induction 1: Vyxeos\[100 U/m²\] i.v. (120 min) d1; Daunorubicin Cytarabine liposome for injection \[100 U/m²\] i.v. (120 min±10min) d3,5 Induction 2: Daunorubicin Cytarabine liposome for injection \[100 U/m²\] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection \[65 U/m²\] i.v. (\>90 min) d1,3
62540024|NCT01128608|ACTIVE_COMPARATOR|Control Group - Healthy Subjects|Healthy volunteers with normal EGD.
62540025|NCT01128608|ACTIVE_COMPARATOR|NERD Group|Subjects with NERD. Heartburn symp x2 wk for 3 months. Normal EGD and abnormal 24 hour pH.
62540026|NCT05653284|EXPERIMENTAL|AK130|Each subject will receive a single dose of AK130 every 3-week cycle (Q3W) or every 2-week cycle (Q2W). Participants may continue on study drug until unacceptable toxicity, or other withdrawal criteria is met.
62540027|NCT02394704|EXPERIMENTAL|Graded sensory attention training|Sensory stimuli will begin at a maximal tolerable intensity and decrease in intensity throughout the training, to shift from involuntary to voluntary attentional focus.
62715136|NCT05444881|EXPERIMENTAL|Intervention|"10-20 minutes a day of mindfulness meditation practice through the Headspace app.~Participants will receive daily reminders to participate and receive weekly calls to assess adherence.~Participants will be briefed on the telephone on how to use the app and receive recommendations of possible meditations they can engage with throughout the 6 weeks of participation."
62715137|NCT05444881|NO_INTERVENTION|Waitlist Control|Waitlist Control
62164594|NCT03460444|EXPERIMENTAL|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days while consuming a diet similar to the recommended health guidelines (40-50% carbohydrate; 30-40% fat; 20-25% protein).
62164595|NCT00586807|OTHER|Infliximab|Subjects on infliximab
62540028|NCT02394704|ACTIVE_COMPARATOR|Non-graded sensory attention training|Sensory stimuli will begin and be maintained at a minimal detectable intensity to maximize voluntary attentional training.
62540029|NCT03349086|ACTIVE_COMPARATOR|Voice Exercise|Randomized participants in this group will undergo 45 minutes of voice exercise, including sustained pitches and pitch glides on a variety of different vocal facilitators.
62540030|NCT03349086|NO_INTERVENTION|Voice Rest|Randomized participants in this group will undergo 45 minutes of voice rest.
62540031|NCT01723618|EXPERIMENTAL|CRD007 10 mg|CRD007, 10 mg tablet, single dose
62540032|NCT01723618|EXPERIMENTAL|CRD007 25 mg|CRD007, 25 mg tablet, single dose
62540033|NCT01723618|EXPERIMENTAL|CRD007 40 mg|CRD007, 40 mg tablet, single dose
62540034|NCT04688905||Dyspnea explained by heart failure with preserved ejection fraction|All patients fulfilling invasive criteria for heart failure with preserved ejection fraction
62540035|NCT04688905||Dyspnea not explained by heart failure with preserved ejection fraction|All patients not fulfilling invasive criteria for heart failure with preserved ejection fraction
62715138|NCT06530277|EXPERIMENTAL|Intervention, no intervention (AB)|Beginning with the digital multimodal intervention (REMINDer) and then transitioning to a no intervention phase (sequence: AB).
62540036|NCT05720065|ACTIVE_COMPARATOR|Botulinum toxin|Single bilateral injection into three standardized points of the masseter muscles and two of the anterior temporalis muscle. The total dose administered is 100 U (10 U/point) which is dissolved in 1 mL of isotonic saline. Thus, 0.1 ml of botulinum toxin solution is injected in each point.
62540037|NCT05720065|PLACEBO_COMPARATOR|Isotonic saline|Single injection of 1 mL isotonic saline (0.9 mg/mL) into the same five points per side in a similar manner as for botulinum toxin.
62540038|NCT02292173|EXPERIMENTAL|Trametinib plus Sorafenib|"Dose Escalation Followed by Dose Expansion.~Trametinib: Daily (To start on day 8 during cycle 1 and on day 1 from cycle 2 onwards), according to dose level upon entry.~Sorafenib: Twice daily, according to dose level upon entry.~Each cycle is repeated every 28 days."
62540039|NCT06019598|EXPERIMENTAL|Licorice|2 weeks of licorice corresponding to 20 mg of glycyrrhizic acid followed by 2 weeks of licorice corresponding to 50 mg of glycyrrhizic acid.
62540040|NCT02942641|EXPERIMENTAL|Indwelling urethral catheterization (Foley)|Foley catheter as the intervention.
62540041|NCT02942641|EXPERIMENTAL|Clean intermittent catheterization (CIC)|CIC as the intervention .
62540042|NCT03421795|EXPERIMENTAL|Let's Talk About Pain Training|Participants complete pre-, post- and follow-up measures, and receive a pain training program. The pain assessment and management training will be based on a training previously developed and piloted by Genik et al. (2017). The training will be facilitated by the same researcher (L.G.) throughout the study.
62540043|NCT03421795|SHAM_COMPARATOR|Family Centered Care Training|Participants complete all of the same measures as those in the intervention, but receive a training about family centered care. This training will be facilitated by Andrea Cross (PhD Candidate) from CanChild and will be related to the F-words of childhood disability (function, family, fitness, fun, friends, future; Rosenbaum \& Gorter, 2012) .
62540044|NCT02618135|EXPERIMENTAL|Intervention Group|10 child participants in the intervention group will take part in a total of 24 sessions spread over an 8-week period, and a final follow-up review 1 month after the completion of the training session. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy.
62540045|NCT02618135|OTHER|Control Group|10 child participants in the control group will not receive BCI training during the first 8 weeks of their study participation; they will act as controls. At week 9, subjects in this group will go through the BCI training similar to the intervention group. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy. They will take part in a total of 24 sessions spread over an 8-week period, followed by a final follow-up review 1 month after the completion of the training sessions.
62540046|NCT04717557|EXPERIMENTAL|Hyperbaric Oxygen Plus Regular Care|Hyperbaric oxygen (2 hours at 2 atmospheres absolute) to be administered 1-2 times daily for up to 10 treatments after amputation. Usual care for patients with amputation will be administered in parallel.
62540047|NCT04717557|NO_INTERVENTION|Regular Care|Usual care for patients with amputation.
62540048|NCT06624644|EXPERIMENTAL|LNS8801 Monotherapy|125 mg LNS8801 by mouth every day
62540049|NCT06624644|EXPERIMENTAL|LNS8801 + Pembrolizumab|125 mg LNS8801 by mouth every day plus 200 mg Pembrolizumab by IV infusion once every 3 weeks.
62540050|NCT06624644|ACTIVE_COMPARATOR|Physician's Choice|patients may receive chemotherapy or immunotherapy as determined by physician.
62540051|NCT03190902|EXPERIMENTAL|specific computer training (ST) - POMS|
62540052|NCT03190902|ACTIVE_COMPARATOR|nonspecific computer training (n-ST) - POMS|
62540053|NCT03190902|EXPERIMENTAL|specific computer training (ST) - ADHD|
62540054|NCT03190902|ACTIVE_COMPARATOR|nonspecific computer training (n-ST) - ADHD|
62540055|NCT05649930||Spastic paresis|Children with spastic paresis
62540056|NCT06536140||NSCLC patients 1-3 months after lung resection surgery with or without (neo-)adjuvant therapy|This study will include twenty persons who underwent surgery for early stage I-IIIA NSCLC (with or without (neo-) adjuvant chemotherapy/radiotherapy/immunotherapy) one to three months before inclusion and their carers significant other(s). This can be one person or multiple persons (e.g. partner, parent, child, brother, sister).
62540057|NCT04608435||Male Group|
62540058|NCT04608435||Female Group|
62540059|NCT03207737|EXPERIMENTAL|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 5-days post baseline testing before beginning a one-year telehealth program.
62540060|NCT03207737|ACTIVE_COMPARATOR|Telehealth Only|This group will complete baseline and 5-days post baseline testing before beginning a one-year telehealth program.
62540061|NCT03177213||pemphigus vulgaris patients|20 pemphigus vulgaris patients will be included in the study, either newly diagnosed or recurrent. Patients will be recruited on admission from Dermatology department and Outpatient Clinic, Assiut University Hospitals
62540062|NCT03177213||Healthy controls|10 healthy age and sex matched subjects will be included as controls.
62540063|NCT01833819|OTHER|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
62540064|NCT01833819|OTHER|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
62540065|NCT04328961|PLACEBO_COMPARATOR|Ascorbic Acid|Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days
62540066|NCT04328961|EXPERIMENTAL|Hydroxychloroquine|Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days
62540067|NCT04020289|EXPERIMENTAL|"BalancingMySwing"|"Psychoeducational Program BalancingMySwing for bipolar disorder"
62540068|NCT04020289|OTHER|treatment as usual (TAU)|Patients received treatment as usual
62715139|NCT06530277|EXPERIMENTAL|No intervention, intervention (BA)|Starting with a no intervention phase and subsequently moving to the digital multimodal intervention (REMINDer) (sequence: BA).
61977712|NCT03137472|EXPERIMENTAL|Active Treatment|Participants will receive active TMS in the target area once daily for two days
62540069|NCT04184505|ACTIVE_COMPARATOR|Standard clinical treatment|"If BM-blasts \>= 10%: Conventional chemotherapy: induction one cycle (3+7 protocol) and one optional consolidation cycle, followed by HSCT if a suitable sibling or unrelated donor is available versus~If BM blasts are \<10%: HSCT upfront"
62540070|NCT04184505|EXPERIMENTAL|Experimental treatment|"If BM-blasts \>= 10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available~If BM blasts are \<10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available"
62540071|NCT03351465|EXPERIMENTAL|CALM|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive-behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living that directly incorporates our previously optional modules for depression into the main program. The computerized/internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed. Participants in the intervention group will be visited by the calm specialist weekly between 6 and 8 times prenatally;postpartum visits will vary based on continuing assessment of symptoms.
62540072|NCT03351465|NO_INTERVENTION|Treatment as Usual|Participants will receive pre-natal care as usual, and will be visited at 4 time points by the graduate student researchers: baseline, 12 weeks post baseline, and 10 weeks postpartum.
62715140|NCT06645886|EXPERIMENTAL|Monotherapy Dose Escalation|
62715141|NCT06645886|EXPERIMENTAL|Combo Therapy Dose Escalation|
62540073|NCT02573844|ACTIVE_COMPARATOR|A: Proklama ( 1 sachet/ day)|"15 patients belonging to group A will receive drug A (Proklama: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group A, starting from visit 5, will receive drug B ( Placebo: 1 sachet/day)."
62540074|NCT02573844|PLACEBO_COMPARATOR|B: Placebo ( 1 sachet/ day)|"15 patients belonging to group B will receive drug B (Placebo: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group B, starting from visit 5, will receive drug A ( Proklama: 1 sachet/day)."
62540075|NCT05893810|EXPERIMENTAL|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares prior to treatment with radiotherapy (RT) for patients with nasopharyngeal carcinoma, can prevent radiation-induced oral mucositis(RIOM) and improve quality of life.
62540076|NCT05893810|NO_INTERVENTION|Control|Patients in the control arm will be treated according to standard of care.
62540077|NCT05744141|EXPERIMENTAL|Intervention Group|Elderly individuals undergoing relaxation exercises before cataract surgery
62540078|NCT05744141|NO_INTERVENTION|Control Group|Standard care
62540079|NCT04942743||control group|patients with normal TMJ
62540080|NCT04942743||Study group|patients with TMJ internal derangement
62540081|NCT05719792||Those who had lumbar radicular pain|Patients with lumbar radicular pain identified by inclusion and exclusion criteria
62540082|NCT02826538|EXPERIMENTAL|patient specific guides|fracture fixation with 3D planning and use of patient-specific instruments
62540083|NCT02826538|ACTIVE_COMPARATOR|standard procedure|standard procedure of fracture Fixation without 3D planning and without use of patient-specific instruments
62540084|NCT06160193|EXPERIMENTAL|Brief behavioral parent training with optional care as usual|A brief, individualized, three-session parent training that exists of two (bi)weekly individually tailored training sessions of 120 minutes, and a third session of 60 minutes. Parents and children may receive care as usual as well. Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
62540085|NCT06160193|ACTIVE_COMPARATOR|Care as usual only|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
62540086|NCT05576883|OTHER|Emotion Regulation Intervention and Control Intervention|"Participants will be asked in the morning and in the evening at their self-selected time to evaluate their emotional state through ecological momentary assessment (EMA) and will be prompted to engage in an ER intervention (60% likelihood) or to read health information (40% likelihood). Upon completion they will evaluate the likability and helpfulness of the exercise or the article and re-evaluate their emotional state (post-EMA).~The intervention consists of 20 ER exercises and 20 health facts. The ER intervention is based on different therapeutic approaches targeting various underlying transdiagnostic factors such as rumination, self-referential thoughts etc. The 20 health facts will act as a placebo intervention with no effect on emotion regulation and keep participants engaged in the post-EMA evaluation when they are not randomized to an exercise.~The interventions and the control intervention materials were developed by the research team for the purposes of this study."
62540087|NCT06629831||Patients undergoing cytoreduction surgery for ovarian cancer|Patients undergoing cytoreduction surgery for ovarian cancer
62540088|NCT05149859||BED+ : Participants with obesity and binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 positive score and a Binge Eating Scale score \>16
62540089|NCT05149859||BED-: Participants with obesity but without binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 negative score and a Binge Eating Scale score \< 12
62715142|NCT06645886|EXPERIMENTAL|Combo Therapy Dose Expansion - RP2D|
62715143|NCT06645886|EXPERIMENTAL|Combo Therapy Dose Expansion - RP2D-1|
62715144|NCT06645886|EXPERIMENTAL|Monotherapy Dose Expansion - RP2D|
62715145|NCT06645886|EXPERIMENTAL|Monotherapy Dose Expansion - RP2D -1|
62736626|NCT03996681|EXPERIMENTAL|TACE plus methylcantharidimide tablets|Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment. Every 6 weeks is a cycle.
62164596|NCT03643770|NO_INTERVENTION|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
62540090|NCT04038983||Observational|"ER2 is a simple and standardized clinical tool composed of two sequential components: an assessment followed by recommendations for intervention. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies (21-24). Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
62540091|NCT03107221|EXPERIMENTAL|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
62540092|NCT03107221|NO_INTERVENTION|Control|Usual treatment from a specialist eating disorder service
62540093|NCT02101593|EXPERIMENTAL|ADI-PEG 20|
62540094|NCT02505087|ACTIVE_COMPARATOR|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months, then N-Acetylcysteine (NAC) for 6 months.
62540095|NCT02505087|EXPERIMENTAL|N-Acetylcysteine followed by Placebo|Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
62540096|NCT02505087|NO_INTERVENTION|Healthy volunteers|The purpose of this group is to collect reference values for biochemical markers.
62540097|NCT06486805|PLACEBO_COMPARATOR|control|received the same volume of normal saline as placebo
62540098|NCT06486805|ACTIVE_COMPARATOR|NAC|received 150 mg/kg NAC in 200 ml of 5% glucose over 15 min through the central line after induction of anesthesia and intubation followed by 50 mg/kg of NAC in 500 ml of 5% glucose over 4 h
62540099|NCT04278716||Utilization of a safe return to play checklist|Athletes who were treated for a capsulolabral tear who have undergone arthroscopic capsulolabral repair surgery will be evaluated using an objective checklist prior to being allowed to return to their sport. The utilization and outcome of using this checklist will be evaluated
62540100|NCT06246214|ACTIVE_COMPARATOR|BlueLT|Participants with depressive and/or anxiety symptoms that will receive the interventional light (BlueLT)
62540101|NCT06246214|SHAM_COMPARATOR|ControlLT|Participants with depressive and/or anxiety symptoms that will receive the placebo light (ControlLT)
62540102|NCT06246214|NO_INTERVENTION|Healthy control|Participants without depressive and/or anxiety symptoms
62540103|NCT02527538||Pleth|The masimo probe is attached on the index fingertip and cover with black cover in all patients. Record the pleth variability index and blood pressure
62540104|NCT00151346|ACTIVE_COMPARATOR|CSE|"Subjects assigned to this group will receive combined spinal-epidural (CSE) to relieve pain during labor. For CSE, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer directly into the spinal canal (a smaller amount than is given for traditional epidural), followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. CSE is not experimental."
62540105|NCT00151346|ACTIVE_COMPARATOR|Traditional Epidural|"Subjects assigned to this group will receive traditional epidural to relieve pain during labor. For the traditional epidural, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer into the epidural space, followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. The traditional epidural is not experimental."
62540106|NCT05657119|EXPERIMENTAL|FSN Lethal Means Reduction|"\* Participants will be screened into the lethal-means reduction-focused FSN program if they answer yes to one or more of the following questions:~1. In the past two months, has anyone in your household been going through a rough time?~2. In the past two months, has someone in your home seemed down, sad, or depressed?~3. Are you worried that someone in your home is at risk of suicide?~Participants are then assigned to either the MI FSN intervention or the Scripted FSN intervention"
62540107|NCT05657119|ACTIVE_COMPARATOR|General Firearm Safety Comparison|"General Firearm Safety~\* Participants will be screened into the general firearm safety arm of the program if they do not answer yes to any of the following questions:~1. In the past two months, has anyone in your household been going through a rough time?~2. In the past two months, has someone in your home seemed down, sad, or depressed?~3. Are you worried that someone in your home is at risk of suicide?~Participants are then assigned to either the General Firearm Safety Intervention or General Firearm Comparison"
62540108|NCT04939376||Group A|Women with hysteroscopically or ultrasonographic detected uterine anomalies(adenomyosis,fibroid) intracavitary lesions ( like polyp, adhesion or septum) and those with detected endometrial abnormalities (like hypervascularization,pale endometrium) ,cervical lesion and cervical canal lesion or pelvic lesion
62164597|NCT03643770|ACTIVE_COMPARATOR|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
62540109|NCT04939376||Group B|Matched women (eg. Age,parity, BMI, ovarian reserve....) with no uterine or ovarian abnormalities assessed by hysteroscopy or ultrasonography.
62540110|NCT05551871|ACTIVE_COMPARATOR|Simvastatin|the patient will receive simvastatin 40mg
62540111|NCT05551871|PLACEBO_COMPARATOR|Placebo|the patient will receive placebo drug
62540112|NCT05819710|EXPERIMENTAL|5 mg of TS-142|Low dose of TS-142
62540113|NCT05819710|EXPERIMENTAL|10 mg of TS-142|High dose of TS-142
62164598|NCT03643770|ACTIVE_COMPARATOR|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
62164599|NCT03643770|NO_INTERVENTION|Sham AIH therapy|Sham hypoxia
62164600|NCT02596542|EXPERIMENTAL|Water temperature|
62540114|NCT05819710|EXPERIMENTAL|7.5 mg of Zopiclone|Comparator.
62715146|NCT05859178|EXPERIMENTAL|Exercise group|Each participant in the exercise group will undergo hand grip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks. To activate the ulnar nerve innervated muscles, the exercise will be done using an electronic hand grip device with adjustable resistance individualized to the strength of each participant.
62715147|NCT05859178|EXPERIMENTAL|Control group|Participants will carry out a stretch exercise routine that is not known to have any effect on nerve regeneration.
62715148|NCT02804061|ACTIVE_COMPARATOR|Full NELIP|This group will receive the full Nutrition and Exercise Lifestyle Intervention Program (two behavior changes) from enrollment until birth and serves as the comparator control (Group A).
62715149|NCT02804061|EXPERIMENTAL|Nutrition followed by Exercise (N+E)|Intervention - Nutrition component only (one behaviour) until 24 week assessment, then the addition of the second behavior change (Exercise component) at 25 weeks, with both behaviours followed until birth (Group B).
62715150|NCT02804061|EXPERIMENTAL|Exercise followed by Nutrition (E+N)|Intervention - Exercise component only (one behaviour) until 24 week assessment, after which there will be the addition of the second behaviour change (Nutrition component), with both behaviours followed until birth (Group C).
62715151|NCT01136369||OSNA Breast Cancer System|
62540115|NCT05819710|EXPERIMENTAL|Placebo|Placebo.
62540116|NCT02876107|EXPERIMENTAL|Group A (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 1 hour on day 1 of cycle 0 and over 30 minutes on days 1, 8, and 15 of cycles 1-4. Patients also receive paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1 of cycles 1-4. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
62540117|NCT02876107|EXPERIMENTAL|Group B (paclitaxel, carboplatin)|Patients receive paclitaxel, carboplatin, doxorubicin, and cyclophosphamide as in Group A. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
62540118|NCT06374758|EXPERIMENTAL|Accelerate Model of Care|"Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider."
62540119|NCT01864395|EXPERIMENTAL|Control (CF)|Centrifugation Method (CF): currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
62540120|NCT01864395|EXPERIMENTAL|Online MUF|Online MUF: hemofilter is used online while the heart-lung machine is connected to the patient.
62540121|NCT01864395|EXPERIMENTAL|Offline MUF|Offline MUF: hemofilter is used offline when the heart-lung machine is not connected to the patient.
62540122|NCT03452878||Aggressive refractory patient|A pre defined group of individuals will be included in the study. This group is considered aggressive refractory patient and will be submitted to the bilateral amygdalotomy surgery.
62540123|NCT04547842|ACTIVE_COMPARATOR|Group M: patients receive Mirtazapine|the patient will receive an oral disintegrating tablet (ODT) of mirtazapine 30 mg with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 min as a placebo 1 h preoperatively
62540124|NCT04547842|ACTIVE_COMPARATOR|Group D: patients receive Dexamethasone|the patient will receive a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 min, 1 h preoperatively.
62540125|NCT03764098|EXPERIMENTAL|Guanfacine ER|Guanfacine extended release (6mg/day ER). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
62540126|NCT03764098|PLACEBO_COMPARATOR|Placebo|Administered orally twice a day at 8:00 AM and 8:00 PM Days 1-23, then orally once a day at 8:00 PM.
62540127|NCT04112186|EXPERIMENTAL|Behavioral group therapy 1|8-weeks of group therapy
62540128|NCT04112186|ACTIVE_COMPARATOR|Behavioral group therapy 2|8-weeks of group therapy
62540129|NCT02816008|EXPERIMENTAL|Cognitive rehabilitation group|Cognitive rehabilitation training with RGS in the clinic.
62540130|NCT02816008|ACTIVE_COMPARATOR|Passive control group|Passive/conventional cognitive training at home.
62540131|NCT06634173|EXPERIMENTAL|FAPI PET/CT|Patients will undergo an additional diagnostic FAPI PET/CT scan within four weeks after PSMA PET/CT and within four weeks before planned treatment.
62540132|NCT06474273|EXPERIMENTAL|Lower dose IV methylprednisolone x Lower dose oral prednisone|Lower dose IV MP (250 mg daily x 3 days in adults or 150 mg/m² daily x 3, or to a max 250 mg/dose in children (\<18 years), with lower dose (25mg daily x 7 days, or 15mg/m2 for those \< 18 years ) vs higher dose (50mg daily x 7 days, or or 30mg/m2 for those \< 18 years) oral prednisone augmentation.
62540133|NCT06474273|EXPERIMENTAL|Lower dose IV methylprednisolone x Higher dose oral prednisone|Lower dose IV MP (250 mg daily x 3 days in adults or 150 mg/m² daily x 3, or to a max 250 mg/dose in children (\<18 years), with higher dose (50mg daily x 7 days, or or 30mg/m2 for those \< 18 years) oral prednisone augmentation.
62715152|NCT04795531|EXPERIMENTAL|Once weekly insulin icodec + once daily placebo|Participants will get once daily and once weekly injections
62715153|NCT04795531|EXPERIMENTAL|Once weekly placebo and once daily insulin degludec|Participants will get once daily and once weekly injections
62715154|NCT06717451||Control-IQ Technology v1.5|Real-world use of Control-IQ technology v1.5 for 12 months.
62540134|NCT06474273|ACTIVE_COMPARATOR|Higher dose IV methylprednisolone x lower dose oral prednisone|Higher dose IV MP (500 mg daily x 3 days in adults or 300 mg/m² daily x 3 or to a max 500 mg/dose in children (\<18 years), with lower dose (25mg daily x 7 days, or 15mg/m2 for those \< 18 years) oral prednisone augmentation.
62540135|NCT06474273|ACTIVE_COMPARATOR|Higher dose IV methylprednisolone x higher dose oral prednisone|Higher dose IV MP (500 mg daily x 3 days in adults or 300 mg/m² daily x 3 or to a max 500 mg/dose in children (\<18 years), with higher dose (50mg daily x 7 days, or 30mg/m2 for those \< 18 years) oral prednisone augmentation.
62540136|NCT04940559|EXPERIMENTAL|Group 1: Sequence 1|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 3: Danicopan as a tablet under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
62540137|NCT04940559|EXPERIMENTAL|Group 1: Sequence 2|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 2: Danicopan as a tablet under fasted conditions. Period 3: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
62540138|NCT04940559|EXPERIMENTAL|Group 1: Sequence 3|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. Period 3: Danicopan as a tablet under fed (medium-fat meal) conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
62540139|NCT04940559|EXPERIMENTAL|Group 2: Sequence 1|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a softgel capsule under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
62540140|NCT04940559|EXPERIMENTAL|Group 2: Sequence 2|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as a softgel capsule under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
62540141|NCT05674851|EXPERIMENTAL|Healthy Volunteer MRI|
62540142|NCT01713452|ACTIVE_COMPARATOR|Purse string closure|Patients undergo a purse string closure of their old stoma site.
62540143|NCT01713452|ACTIVE_COMPARATOR|Primary closure|Patients have their stoma sites close primarily with staples.
62540144|NCT01893346|EXPERIMENTAL|CAZ-AVI|This arm will include 4 cohorts. Patients will be stratified by age.
62540145|NCT02026440||Smokers|Those who smoke at least one cigarette a day.
62540146|NCT02026440||Non smokers|Those who have not smoked for at least one week when the sample is collected.
62540147|NCT06164093|OTHER|Subjects once received LPCs transplantation treatment|The patients who have participated in the clinical trial of autologous transplantation of P63+ LPCs for treatment of bronchiectasis, and actually received LPCs transplantation treatment. (n = 15)
62540148|NCT06164093|OTHER|Subjects providing samples of surgically resected bronchiectasis lesions|The bronchiectasis patients who could provide samples of surgically resected lung lesions. (n = 5)
62540149|NCT04012151||Pregnant cohort|Parturients of gestational age \>= 32 weeks will have measurements of arm length, MAC, proximal arm circumference, distal arm circumference, finger circumference to generate the conicity index.
62540150|NCT05353387|EXPERIMENTAL|Intervention Group- Motivational Interviewing|Standard protocols and participation in Motivational Interviews
62540151|NCT05353387|NO_INTERVENTION|Control Group|Standard protocols
62540152|NCT04914455||Fluid responsiveness groups (responders and non-responders)|Fluid responsiveness is defined as an increase in stroke volume of 10% and more form baseline.
62540153|NCT01002937||Tumour tissue, renal cell carcinoma|\> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
62540154|NCT04187417|EXPERIMENTAL|Topical tetracaine|Topical tetracaine hydrochoride 1%
62540155|NCT04187417|PLACEBO_COMPARATOR|Balanced artificial tear solution|Balanced artificial tear solution (Systane)
62540156|NCT01960712|NO_INTERVENTION|Continued external drainage|Continued external drainage alone.
62540157|NCT01960712|ACTIVE_COMPARATOR|Continued external drainage + transpapillary stent|External drainage + transpapillary plastic stent (7-10 Fr).
62540158|NCT03954834|EXPERIMENTAL|5 mg Tirzepatide|Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
62540159|NCT03954834|EXPERIMENTAL|10 mg Tirzepatide|Participants received 10mg of tirzepatide as subcutaneous injection once a week.
62540160|NCT03954834|EXPERIMENTAL|15 mg Tirzepatide|Participants received 15mg of tirzepatide as subcutaneous injection once a week.
62540161|NCT03954834|PLACEBO_COMPARATOR|Placebo|Participants received placebo as subcutaneous injection once a week.
61977713|NCT03137472|SHAM_COMPARATOR|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
62540162|NCT06579781|ACTIVE_COMPARATOR|Control Condition|Adult participants in the control condition will receive access to an online general health guide for parents that was adapted for this study from a pre-existing health guide.
62540163|NCT06579781|EXPERIMENTAL|Treatment Condition|Adult participants in the treatment condition will receive access to the Parent Toolkit 2.0 intervention, which includes an online interactive guide, four videos modeling parent-teen communication around sex and contraception, and two group-based, virtual sessions with other parents and caregivers.
62540164|NCT02598856|EXPERIMENTAL|Intranasal naloxone 1x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
62540165|NCT02598856|ACTIVE_COMPARATOR|Intranasal naloxone 2x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
62540166|NCT02598856|ACTIVE_COMPARATOR|Intravenous naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
62540167|NCT02598856|ACTIVE_COMPARATOR|Intramuscular naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
62540168|NCT02113553|EXPERIMENTAL|Triptorelin|Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy
62540169|NCT01324531|ACTIVE_COMPARATOR|Bankart repair|
62540170|NCT01324531|ACTIVE_COMPARATOR|Bankart repair and remplissage|
62540171|NCT02345837|ACTIVE_COMPARATOR|clomiphene and endometrial sampling|Couples who will undergo endometrial sampling in the luteal phase of the cycle preceding ovulation induction by clomiphene citrate.
62540172|NCT02345837|ACTIVE_COMPARATOR|clomiphene citrate|Couples who will undergo ovulation induction with clomiphene citrate.
62540173|NCT00609999|EXPERIMENTAL|Stratum A|Pts not on EIAEDs
62540174|NCT00609999|EXPERIMENTAL|Stratum B|Pts on EIAEDs
62540175|NCT04810637|EXPERIMENTAL|GX-I7|Patients randomised on experimental arm will receive GX-I7 drug
62540176|NCT04810637|PLACEBO_COMPARATOR|GX-I7 vehicle|Patients randomised on comparator arm will receive placebo
62540177|NCT01374074||White GERD|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with gastroesophageal reflux disease and do not have Barrett's esophagus."
62540178|NCT01374074||African American GERD|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with gastroesophageal reflux disease and do no have Barrett's esophagus."
62540179|NCT01374074||White BE|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with Barrett's Esophagus."
62540180|NCT01374074||African American BE|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with Barrett's Esophagus."
62540181|NCT05987319|EXPERIMENTAL|General Treatment|Subjects will receive treatment on the face, neck and/or body for conditions such as but not limited to wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks or loose skins.
62540182|NCT05987319|EXPERIMENTAL|Split-face treatment|Subjects will receive split-face treatments where each side of the face may be treated with different tips.
62540183|NCT01307111|EXPERIMENTAL|Misoprostol|Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.
62540184|NCT01307111|PLACEBO_COMPARATOR|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
62540185|NCT02191761|EXPERIMENTAL|SM04755|
62540186|NCT02918253|EXPERIMENTAL|Tumour visible on MRI|Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
62540187|NCT02918253|ACTIVE_COMPARATOR|No tumour visible on MRI|Whole-gland HDR Brachytherapy
62540188|NCT06066294|EXPERIMENTAL|Regimen 1|WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
62540189|NCT06066294|ACTIVE_COMPARATOR|Regimen 2|Government of India currently recommended PrEP Schedule, 0.1ml 3 visits, on day 0, day 7 and day 28
62540190|NCT04480710|EXPERIMENTAL|CRV431 75mg|CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions
62540191|NCT04480710|PLACEBO_COMPARATOR|Placebo, 75mg|Placebo, softgel capsule, QD, 28 days, fasted conditions
62540192|NCT04480710|EXPERIMENTAL|CRV431 225mg|CRV431, softgel capsule, 225mg, QD, 28 days, fasted conditions
62540193|NCT04480710|PLACEBO_COMPARATOR|Placebo, 225mg|CRV431, 3 softgel capsules, 225mg, QD, 28 days, fasted conditions
62715155|NCT00929214|EXPERIMENTAL|Standard Therapy + Local Therapy|Systemic Standard Therapy (chemotherapy and/or endocrine therapy) + Local Therapy (surgery and/or radiation)
62540194|NCT04696289|EXPERIMENTAL|Standardized catheterization assessment|Assessment of pulmonary veins including angiography, intravascular ultrasound, pressure assessment and compliance testing.
62540195|NCT06389799|EXPERIMENTAL|Pemigatinib + Retifanlimab|Patients will be treated with pemigatinib monotherapy for an induction phase of 6 weeks. This period is a safety measure to assess and manage adverse events of pemigatinib before start of combination treatment. Pemigatinib will be given daily as a 3-weekly cycle (2 weeks on followed by one week off) for 2 cycles. After 6 weeks, patients will receive combination treatment with retifanlimab (Q3W) and pemigatinib also as a 3-weekly cycle (2 weeks on followed by one week off).
62540196|NCT02907255|EXPERIMENTAL|Oximetry monitor|"* Standard care plus~* Wireless respiratory monitoring~  * Covidien~ * Alarm triggers:~SpO2 ≤89% (heart rate) HR \< 50 or \> 120"
62540197|NCT02907255|NO_INTERVENTION|Standard of Care|"• Standard care:~* 1:4 patient to nurse ratio~* Vital signs every 4 hours~* Respiratory rate and sedation scores every 2 hours for patients on the Acute Pain Service"
62540198|NCT05950750||All Patients|Non interventional observational
62540199|NCT06122376|EXPERIMENTAL|U-shaped power toothbrush|U-shaped power toothbrush with fluoride toothpaste
62540200|NCT06122376|PLACEBO_COMPARATOR|Manual Toothbrush|soft manual toothbrush with fluoride toothpaste
62540201|NCT03745716|EXPERIMENTAL|Experimental arm: APR-246 + azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):
62540202|NCT03745716|EXPERIMENTAL|Control arm: Azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):
62715156|NCT05807568|EXPERIMENTAL|NCAEM EM-SART Pre-Screen|
61977714|NCT01594125|EXPERIMENTAL|Group I|patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
62540203|NCT03879434||Ostenil® Mini|1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.
62540204|NCT03914092|EXPERIMENTAL|study group|female patients with vocal fold nodules undergoing intralesional steroid injection
62715157|NCT00713687|EXPERIMENTAL|1|Treatment by combination of photodynamic therapy and chemotherapy
62736997|NCT03719001|EXPERIMENTAL|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm.
62540205|NCT03914092|ACTIVE_COMPARATOR|control group|female patients with vocal fold nodules undergoing Smith Accent voice therapy
62540206|NCT04628793|EXPERIMENTAL|Cohort 1|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
62540207|NCT04628793|EXPERIMENTAL|Cohort 2|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
62540208|NCT04628793|EXPERIMENTAL|Cohort 3|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
62540209|NCT05850585|EXPERIMENTAL|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
62540210|NCT05850585|PLACEBO_COMPARATOR|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
62540211|NCT02657265|EXPERIMENTAL|SpineJack® system|Spine fracture management
62540212|NCT02657265|ACTIVE_COMPARATOR|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
62540213|NCT03571412|EXPERIMENTAL|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
62540214|NCT03571412|EXPERIMENTAL|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
62540215|NCT00735605|ACTIVE_COMPARATOR|1:BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
62540216|NCT00735605|ACTIVE_COMPARATOR|2 BTX A|Injected with BTX-A in the left lateral position; anesthesia was not required
62540217|NCT00735605|ACTIVE_COMPARATOR|3: PDPR|Inner half of puborectalis sling was divided on each side by using a scalpel NO
62540218|NCT04314648|ACTIVE_COMPARATOR|START|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid and alcohol use disorders, and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor"
62540219|NCT04314648|NO_INTERVENTION|Usual Care|Usual care for people with alcohol or opioid use disorder.
62540220|NCT00771459|ACTIVE_COMPARATOR|Ropivacaine|
62540221|NCT00771459|PLACEBO_COMPARATOR|Placebo|
62540222|NCT01651897||Delirious in the ED|Patients who were delirious in the ED at either the 0-hour or 3-hour delirium assessment.
62540223|NCT01651897||Non-Delirious in the ED|Patients who were non-delirious in the ED at both the 0-hour or 3-hour delirium assessment.
62540224|NCT01504958|ACTIVE_COMPARATOR|Active rTMS with real cognitive training|High frequency rTMS stimulation to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
62540225|NCT01504958|SHAM_COMPARATOR|Sham rTMS with real cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
62540226|NCT01504958|SHAM_COMPARATOR|Sham rTMS with sham cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent sham cognitive training.
62540227|NCT03231566|ACTIVE_COMPARATOR|Usual education control group (CG)|The CG received the traditional hospital preoperative program, which was consistent with current preoperative TKA protocols. The CG received education covering anatomy of the knee joint, information about the joint replacement surgery, what to expect when they were admitted for surgery, what to expect immediately after surgery, pain medications, postoperative rehabilitation/physical therapy, etc. The CG received a hospital-based booklet with this information.
62540228|NCT03231566|EXPERIMENTAL|Experimental group (EG)|The EG underwent an additional 30-minute group PNE program, followed by the usual preoperative education program from the hospital. The PNE program used in this TKA study was an adaptation of the PNE program developed for LS. The educational program was designed to be delivered by a physical therapist in a group session to patients prior to their TKA.
62540229|NCT06632587|ACTIVE_COMPARATOR|Early cranioplasty|Cranioplasty procedure performed prior to 8 weeks following the initial decompressive hemicraniectomy.
62540230|NCT06632587|PLACEBO_COMPARATOR|Standard-of-care cranioplasty|Cranioplasty procedure performed after 3 months following the initial decompressive hemicraniectomy.
62540231|NCT02121392|SHAM_COMPARATOR|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
62540232|NCT02121392|EXPERIMENTAL|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
61977715|NCT01594125|EXPERIMENTAL|Group II|patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
62167971|NCT06358339|EXPERIMENTAL|Routine Tracker and Social Connectivity|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker and Social Connectivity."
62540233|NCT03239223|EXPERIMENTAL|Dose 1 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
62540234|NCT03239223|EXPERIMENTAL|Dose 2 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
62540235|NCT04198259|ACTIVE_COMPARATOR|interventional devascularization|Interventional devascularization includes BRTO and similar procedure. Several variations of the technique exist, such as balloon-occluded antegrade transvenous obliteration or occlusion of the collateral by the placement of a vascular plug or coils.
62540236|NCT04198259|EXPERIMENTAL|Transjugular intrahepatic portosystemic shunt|TIPS is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein.
62540237|NCT01398514|EXPERIMENTAL|Active medication|Escitalopram 10mg/day
62540238|NCT01398514|PLACEBO_COMPARATOR|Placebo|Matched pill placebo
62540239|NCT01596660|EXPERIMENTAL|Bupivacaina|20 cc of bupivacaine 0.5% in 20 cc de saline solution and it is infiltrated 20 cc each side.
62540240|NCT01596660|PLACEBO_COMPARATOR|saline solution|20 cc of saline solution 0.9% to infiltrate each side.
62540241|NCT02971098|EXPERIMENTAL|Reduced activity|participants will undergo a reduced physical activity period (75% step reduction) for two weeks.
62540242|NCT02591186|EXPERIMENTAL|Acupuncture arm|Participants receiving acupuncture during IVF process
62540243|NCT02591186|NO_INTERVENTION|Control|Control arm not receiving acupuncture during IVF process
62540244|NCT04746794|EXPERIMENTAL|Point of Care|For clinics in the point of care (POC) arm, patients will be approached at the time they come in to the clinic for a routine visit with their primary care provider. We will screen patients for familial cancer risk using electronic tablets in the waiting room or, in the case of a telehealth visit, through telephone contact before the visit. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
62540245|NCT04746794|EXPERIMENTAL|Direct Patient Engagement|"For clinics in the direct patient engagement (DPE) arm, patients will be identified by reviewing clinic records to create an active patient list (i.e., those who have had a visit in the past year). We will contact patients by postal mail and email to provide a link to the online risk screening tool. The patient outreach is not tied to a specific visit and the online screening can be completed at any time. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers."
62540246|NCT04746794|NO_INTERVENTION|Stakeholder Interviews and Surveys|Samples of patients, providers, and clinic leaders will be assessed at several points throughout the study - baseline and follow-up. We will use a mixed methods approach, with both quantitative assessments (surveys) and qualitative assessments (interviews). Baseline assessments will provide initial data on the patient population and current clinic functioning and help in implementation planning. The final assessments will provide estimates of change in patients, providers, and clinic leaders as a result of the implementation.
62540247|NCT00026299|EXPERIMENTAL|Phase 2: Oxaliplatin plus ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
62540248|NCT00026299|EXPERIMENTAL|Phase 2: Oxaliplatin alone|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.
62540249|NCT00026299|EXPERIMENTAL|Phase I: Oxaliplatin with ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.
62540250|NCT03840369|EXPERIMENTAL|rTMS to the Right Dorsolateral Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsolateral Prefrontal Cortex (DLPFC). The right DLPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
62540251|NCT03840369|EXPERIMENTAL|rTMS to the Right Dorsomedial Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsomedial Prefrontal Cortex (DMPFC). The right DMPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
62540252|NCT06494462|EXPERIMENTAL|game based virtual reality|"24 hours after the theoretical lecture, students will be given a demonstrative presentation of the application in the laboratory environment by the instructor (researcher).~All students will perform the application on low-fidelity models (task trainers) under the supervision of the instructor.~After the laboratory application, students will be required to play a gamified virtual reality experience using Oculus 2 Interactive Virtual Reality Headsets within 7 days before the clinical application."
62540253|NCT06494462|EXPERIMENTAL|Video|"24 hours after the theoretical lecture, students will be given a demonstrative presentation of the application in the laboratory environment by the instructor (researcher).~All students will perform the application on low-fidelity models (task trainers) under the supervision of the instructor.~After the laboratory application, students will be shown a video recording prepared by the researchers via VR Box non-interactive virtual reality headsets within 7 days before the clinical application."
62540254|NCT06494462|NO_INTERVENTION|Control|"24 hours after the theoretical lecture, students will be given a demonstrative presentation of the application in the laboratory environment by the instructor (researcher).~All students will perform the application on low-fidelity models (task trainers) under the supervision of the instructor."
62540255|NCT01831401|EXPERIMENTAL|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) \& standard straight acetabular component introducer without alignment guide.
62540256|NCT01831401|EXPERIMENTAL|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) \& modified 35° acetabular component introducer.
62540257|NCT01831401|EXPERIMENTAL|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) \& standard straight acetabular component introducer without alignment guide.
62736998|NCT03254706|ACTIVE_COMPARATOR|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
62164601|NCT05119231|EXPERIMENTAL|Pulmonary Vein Isolation|"Pulmonary Vein Isolation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standards:~Trial participants will assigned to the PVI-arm will undergo catheter ablation within 48 hours after baseline evaluation, with the aim to achieve isolation of all pulmonary veins and restore sinus rhythm.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
62540258|NCT01831401|EXPERIMENTAL|7° Head Down & Standard Introducer.|Operating table position 7° head down \& standard straight acetabular component introducer without alignment guide.
62540259|NCT01831401|EXPERIMENTAL|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down \& modified 35° acetabular component introducer.
62540260|NCT01831401|EXPERIMENTAL|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down \& inclinometer-assisted acetabular component introducer.
62164602|NCT05119231|SHAM_COMPARATOR|Sham Control Arm|"Sham Pulmonary Vein Isolation~Trial participants will assigned to the SHAM-arm will undergo their procedure within 48 hours after baseline evaluation. The Sham procedure will include deep sedation according to the respective PVI protocol for at least one hour, femoral vein/artery puncture with introduction of sheaths and an electrical cardioversion in presence of persistent atrial fibrillation.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
62164603|NCT03613454|ACTIVE_COMPARATOR|Splenic artery embolization with vascular embolic coils|
62164604|NCT03613454|ACTIVE_COMPARATOR|Splenic artery embolization with vascular embolic plugs|
62164605|NCT06269900|EXPERIMENTAL|dexamethasone + standard of care|"* Dexamethasone 0.2mg.kg-1.day-1 intravenous for a minimal duration of 5 days, and a maximal duration of 7 days in case of persistence of ARDS criteria (PaO2/FiO2 ratio \< 200).~* Standard of care: antimicrobial therapy in compliance with European guidelines. Briefly, intravenous antimicrobial therapy with the narrowest spectrum to cover at-risk and/or identified pathogens for 7-8 days."
62164606|NCT06269900|PLACEBO_COMPARATOR|Placebo + Standard of care|"* Placebo 0.2mg.kg-1.day-1 intravenous for 5 days and a maximal duration of 7 days in case of persistence of ARDS criteria (PaO2/FiO2 ratio \< 200).~* Standard of care: antimicrobial therapy in compliance with European guidelines. Briefly, intravenous antimicrobial therapy with the narrowest spectrum to cover at-risk and/or identified pathogens for 7-8 days."
62164607|NCT04238130||Perioperative ctDNA Dynamic Monitoring Group|Samples were obtained at multiple pre-specified time points including before surgery (plasma samples)，during surgery after tumor resection (tumor samples) and after surgery(plasma samples were obtained every 6 months from ctDNA positive patients at baseline in the following 2 years)
62164608|NCT05057767|EXPERIMENTAL|Pre-induction Group (I)|will receive intravenous midazolam premedication 2mg in a volume of 3 ml, 15 minutes before induction of anesthesia
62164609|NCT05057767|EXPERIMENTAL|Pre-extubation Group (II)|will receive intravenous midazolam 2mg in a volume of 3 ml 30 minutes before extubation at the end of surgery
62164610|NCT05057767|PLACEBO_COMPARATOR|Control Group (III)|will receive 3 ml normal saline 15 minutes before induction of anesthesia plus 3 ml normal saline 30 minutes before extubation at the end of surgery.
62164611|NCT06369987|EXPERIMENTAL|Dailies Total1 Multifocal, ACUVUE OASYS MAX 1-Day Multifocal|Fit participant with Dailies Total1 Multifocal first, and with ACUVUE OASYS MAX 1-Day Multifocal second.
62164612|NCT06369987|EXPERIMENTAL|ACUVUE OASYS MAX 1-Day Multifocal, Dailies Total1 Multifocal|Fit participant with ACUVUE OASYS MAX 1-Day Multifocal first, and with Dailies Total1 Multifocal second.
62164613|NCT05376735|EXPERIMENTAL|Purrble intervention + Single Session Intervention|"The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~The Single Session Intervention has been co-produced with university students and clinical experts (Prof Jessica Schleider), combining the theories of emotion regulation with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~1. Initial guided reflection exercise~2. Short interactive psychoeducation~3. Personalised action plan~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
62164614|NCT05376735|NO_INTERVENTION|Treatment as usual / Waiting list|Participants in the control group will be given a Purrble \& access to the online SSI intervention before the academic term ends, after 4 week follow-up questionnaires are completed.
62164615|NCT00511147|EXPERIMENTAL|IGIV3I Grifols 10% (All Subjects)|All subjects with Chronic ITP
62164616|NCT00005908|EXPERIMENTAL|Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine|Docetaxel 75 mg/m\^2 intravenous day 1, capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
62540261|NCT01831401|EXPERIMENTAL|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) \& standard straight acetabular component introducer without alignment guide.
62540262|NCT01831401|EXPERIMENTAL|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) \& modified 35°acetabular component introducer.
62540263|NCT01831401|EXPERIMENTAL|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) \& inclinometer-assisted acetabular component introducer.
62540264|NCT01307176|EXPERIMENTAL|Home exercise program|Balance and walking exercise program
62540265|NCT04702243||Affected Participants|Subjects who have suppurative lung disease without a known genetic diagnosis
62540266|NCT04702243||Unaffected Family Members|Unaffected family members may be enrolled in the study for collection of DNA only
62540267|NCT01707719||Alzheimer's disease|
62540268|NCT01707719||Non demented subjects|
62540269|NCT03005912|PLACEBO_COMPARATOR|Conventional acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
62540270|NCT03005912|ACTIVE_COMPARATOR|Conventional bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
62540271|NCT03005912|ACTIVE_COMPARATOR|VoIP acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
62540272|NCT03005912|ACTIVE_COMPARATOR|VoIP bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
62540273|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
62540274|NCT01405014|EXPERIMENTAL|Relationship enhancement group|One group, all involved in the intervention
62540275|NCT00338728|EXPERIMENTAL|Treatment (imatinib mesylate, letrozole)|Participants receive imatinib mesylate PO BID and letrozole PO QD for 8 weeks in the absence of disease progression or unacceptable toxicity.
62540276|NCT04963543|EXPERIMENTAL|FID123238|FID123238 applied to the ocular surface, 1 application per day, for five consecutive days
62540277|NCT01192763|EXPERIMENTAL|Arm I|Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.
62540278|NCT06365918|EXPERIMENTAL|Intraperitoneal VG2025|"Participants will receive VG2025 intraperitoneally over about 5 minutes on Days 1-3 of each 21-day cycle. Participants will be watched for side effects for about 2 hours after each dose.~Up to 3 dose levels of VG2025 will be tested. At least 3 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of VG2025 given intraperitoneally is found."
62540279|NCT04651413||Covid-19 Ct Value|All patients enrolled onto the ISARIC COVID-19 trial at The University Hospitals of North Midlands NHS Trust between the period 1st February 2020 to 1st July 2020 will be included in this study, provided that a laboratory cycle threshold (Ct) value is available.
62540280|NCT04460560|OTHER|Open-Label Terlipressin|All prospective patients receive open-label Terlipressin.
62540281|NCT01261091|EXPERIMENTAL|Early Tracheostomy|Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 3 days from intubation.
62540282|NCT01261091|ACTIVE_COMPARATOR|Prolonged Intubation|Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy between days 7 to 14 from intubation.
62540283|NCT06516003|EXPERIMENTAL|Virtual Reality|Patients randomized to receive virtual reality goggles in addition to the standard of care.
62540284|NCT06516003|ACTIVE_COMPARATOR|Standard of Care|Patients that are randomized to receive the standard of care including other distraction techniques and child life specialist.
62540285|NCT04777149|EXPERIMENTAL|transcranial Random Noise Stimulation (tRNS)|Participants in this group will receive a combined intervention (3 days of tRNS during functional task practice and 3 days of sham-stimulation during functional task practice).
62540286|NCT04777149|ACTIVE_COMPARATOR|transcranial Direct Current Stimulation (tDCS)|Participants in this group will receive a combined intervention (3 days of tDCS during functional task practice and 3 days of sham-stimulation during functional task practice).
62540287|NCT01688492|EXPERIMENTAL|ipilimumab|This multi-institution open label study has a Phase 1 and Phase 2 component. The Phase 1 dose escalation stage is to establish the tolerability of ipilimumab to be used in combination with the standard clinical dose of abiraterone acetate plus prednisone in chemotherapy and immunotherapy-naïve patients with progressive metastatic CRPC. Due to the overlapping potential hepatic toxicity between abiraterone and ipilimumab, a Lead in Therapy with abiraterone plus prednisone for 2 cycles will assess for adverse events related to the abiraterone plus prednisone. Patients, who tolerate well the Lead in therapy as defined by Grade 1 or less AEs, will pursue Combination Therapy. Patients with AEs Grade ≥ 2 after Lead in Therapy will be excluded and replaced. The Phase 2 stage will assess efficacy and confirm an acceptable safety profile of the recommended dose.
62540288|NCT05369728|OTHER|First line coronary scanner group|The patient will benefit from a coronary CT scan in 1st line (evaluation of the coronary anatomy), then according to the result it will be managed according to the CAD-RADS decision algorithm.
62540289|NCT05369728|OTHER|First line functional test strategy group|The patient benefits from a functional test in 1st line (search for myocardial ischemia by myocardial scintigraphy: SPECT, stress echography, or MRI), then according to the result he will be managed in accordance with the European recommendations.
62540290|NCT06079567|EXPERIMENTAL|New COMs for FSHD2 patients|
62540291|NCT01832779||Achalasia subjects|Information about teh subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after the subject's medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
62540292|NCT00776750|EXPERIMENTAL|influenza vaccination|All participants received a standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection. The vaccine contained 15 μg hemagglutinin of each of the following influenza strains: A/ New Caledonia/20/99 (H1N1), A/ Panama/2007/99 (H3N2), and B/Shangdong/7/97, recommended by WHO as components of the influenza vaccine for the epidemic season 2003/2004.
62164617|NCT00005908|EXPERIMENTAL|Dose B-Cohort 2-Arm 2 Reduced dose-Docetaxel & Capecitabine|Docetaxel 60 mg/m\^2 intravenous day 1, capecitabine 937.5 mg/m\^2 orally twice daily day 2-15 for 4 cycles
62164618|NCT04173273|EXPERIMENTAL|Etrasimod Dose A|
62164619|NCT04173273|EXPERIMENTAL|Etrasimod Dose B|
62164620|NCT04173273|PLACEBO_COMPARATOR|Placebo|
62164621|NCT03322475|EXPERIMENTAL|Facial skin rejuvenation|Facial skin rejuvenation using PiQo4 laser system
62164622|NCT06149338|EXPERIMENTAL|Patients being intubated using Macintosh laryngoscope|
62164623|NCT06149338|EXPERIMENTAL|Patients being intubated using Vie Scope laryngoscope|
62164624|NCT00781209|EXPERIMENTAL|Exp|Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI \& Mini Mental Status Examination
62164625|NCT03865940|EXPERIMENTAL|Lidocaine then Lidocaine + Guanfacine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine."
62164626|NCT03865940|EXPERIMENTAL|Lidocaine + Guanfacine then Lidocaine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine."
62164627|NCT06108752|EXPERIMENTAL|Scapular Stabilization Exercises|Scapular stabilization exercises along with the hot pack and cervical active range of motion exercises
62164628|NCT06108752|EXPERIMENTAL|Thoracic Extension Exercises|Thoracic extension exercises along with the hot pack and cervical active range of motion exercises
62164629|NCT06646900|EXPERIMENTAL|culturally adapted CaCBT manual|
62164630|NCT06646900|EXPERIMENTAL|standard CBT manual|
62164631|NCT04463888|EXPERIMENTAL|Robot training with Smart Home-based Exoskeleton Robot System|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based robot assisted tenodesis-grip training per day, 5 days a week, for 4 weeks .
62164632|NCT04463888|ACTIVE_COMPARATOR|control group|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based specific motor task training per day, 5 days a week, for 4 weeks .
62164633|NCT05566626|EXPERIMENTAL|Camera test group|The Principal Investigator will take a hyperspectral image of all subjects, both healthy volunteers and patients.
62164634|NCT00533182||Immunocompromised|Immunocompromised individuals
62540293|NCT00946816|ACTIVE_COMPARATOR|Anorexia Nervosa|
62540294|NCT00946816|ACTIVE_COMPARATOR|Obesity|
62540295|NCT00946816|ACTIVE_COMPARATOR|Healthy volunteers|
62540296|NCT06210919|EXPERIMENTAL|TRTP-101|Micro-Block (MiB) manufactured from autologous Adipose-derived Mesenchymal Stem Cells
62540297|NCT02647827|ACTIVE_COMPARATOR|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization.
62540298|NCT02647827|ACTIVE_COMPARATOR|Acupuncture + lifestyle management|Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
62540299|NCT02647827|ACTIVE_COMPARATOR|Metformin + lifestyle management|Oral metformin 500 mg three times daily, in total 1500 mg per day.
62540300|NCT04400682|EXPERIMENTAL|FAVIRA then AVIGAN|Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
62540301|NCT04400682|EXPERIMENTAL|AVIGAN then FAVIRA|Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
62540302|NCT02820207||Vulnerable plague|The patients suffering from carotid artery stenosis were identified as the vulnerable plague group by Contrast Enhanced Ultrasound whose plagues were found intraplaque neovascularization
62540303|NCT05445583|EXPERIMENTAL|Motivational Enhancement System (MES) and Physical Activity Tracking (PAT)|MES is a web-based, mobile asthma management intervention delivered to participants' personal mobile devices. There are 4 sessions, completed over 10 weeks, with each session taking approximately 15-20 minutes. During Session 1, participants will identify asthma-related problems they may encounter and will receive asthma information and motivation. Between Session 1 and Session 2, participants will be asked to complete an electronic daily diary for 7 days. Session 2 allows participants to select up to 2 goals to address. Session 3 occurs over the course of 4 weeks and provides tailored messages based on problem and goal selection. The final session (Session 4), asks participants for feedback on how well they feel they accomplished their goal. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
62540304|NCT05445583|EXPERIMENTAL|Supportive Accountability (SA) and PAT|SA is an asthma management intervention delivered by asthma nurses trained in targeted MI skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). Sessions with the nurse will be approximately 15-20 minutes in length and will focus on ways to improve asthma care. There are 4 sessions with the nurse, over the course of 10 weeks. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
62540305|NCT05445583|EXPERIMENTAL|Text Messaging (SMS) and PAT|SMS will target asthma knowledge. One-way SMS messages will be sent to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Text messages will be sent twice a week for the first 5 weeks and once a week for the last 5 weeks. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
62164635|NCT00533182||Non-Immunocompromised|Non-immunocompromised individuals
62164636|NCT00533182||Pregnant|Pregnant women
62164637|NCT00739024|ACTIVE_COMPARATOR|Active Treatment|Ramelteon once daily (double-blind assignment)
62164638|NCT00739024|PLACEBO_COMPARATOR|Placebo|Placebo tablet, once daily (double-blind assignment)
62164639|NCT05057078|EXPERIMENTAL|Intervention group|A mindfulness-based stress reduction program will be done once a week for eight weeks
62540306|NCT05445583|EXPERIMENTAL|MES_SMS_PAT|Participants will receive a combination of the MES and SMS interventions. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
62540307|NCT05445583|EXPERIMENTAL|SA_SMS_PAT|Participants will receive a combination of the SA and SMS interventions. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
62540308|NCT05445583|NO_INTERVENTION|Usual Care_PAT|Participants will continue to receive standard clinical asthma care. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
62540309|NCT01755767|EXPERIMENTAL|Tivantinib 240 mg BID Cohort|The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.
62540310|NCT01755767|EXPERIMENTAL|Tivantinib 120 mg BID Cohort|Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).
62540311|NCT01755767|PLACEBO_COMPARATOR|Placebo Matching 240 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
62540312|NCT01755767|PLACEBO_COMPARATOR|Placebo Matching 120 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
62540313|NCT02072304|EXPERIMENTAL|web-based CBT|Web-based CBT group : The intervention is made up of 8 internet modules based on behavioral activation, cognitive behavioral therapy
62540314|NCT02072304|ACTIVE_COMPARATOR|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks
62540315|NCT01229579|EXPERIMENTAL|Zinc Supplement|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc
62540316|NCT01229579|PLACEBO_COMPARATOR|Placebo|2.5 ml supplement syrup daily without elemental zinc
62540317|NCT06217211|EXPERIMENTAL|Remolacha|beet juice
62540318|NCT06217211|PLACEBO_COMPARATOR|Placebo|
62540319|NCT01920581||volunteers|
62540320|NCT03361930|EXPERIMENTAL|CP participants|Single-day data collection for walking conditions; barefoot, with plain ankle-foot orthosis (flat foot plate) on involved side, with tone-reducing ankle-foot orthosis on involved side.
62540321|NCT03460392||Neurological and behavioral disorders|Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
62540322|NCT03460392||Subjects affected by bone diseases|Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
62540323|NCT03460392||Dysmetabolic and/or endocrine disorders|Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
62540324|NCT03460392||Subjects performing agonistic activity|Subjects performing physical activity at agonistic level are enrolled.
62540325|NCT03460392||Gastroenteric disorders|Subjects affected by gastric and/or enteric disorders are enrolled.
62540326|NCT03460392||Prolonged antibiotic therapy|Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
62540327|NCT03460392||Healthy subjects|Subjects without any known ongoing disease are enrolled.
62540328|NCT04430309|EXPERIMENTAL|Baduanjin exercise group|"The intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements.~The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks"
62540329|NCT04430309|ACTIVE_COMPARATOR|Control group|The control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
62540330|NCT04197661|ACTIVE_COMPARATOR|Elderly groupⅠ|Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486
62540331|NCT04197661|ACTIVE_COMPARATOR|Elderly group Ⅱ|Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486
62540332|NCT04197661|ACTIVE_COMPARATOR|Elderly group Ⅲ|Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486
62540333|NCT04197661|ACTIVE_COMPARATOR|Non-elderly group IV|Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486
62540334|NCT04627987||Main study|Patients with severe, symptomatic aortic stenosis will be recruited and followed up with primary outcome of heart failure death and hospitalisation (n=192). Of these, 170 will have an implantable cardiac monitor placed to detect presence and burden of non-sustained VT.
62540335|NCT03058289|EXPERIMENTAL|Monotherapy With >=40% Total Tumor Burden Dosed (Cohorts A1/B1/EA/EC/EC2/EC3)|"Dosing: \>=40% Total Tumor Burden~A1:INT230-6 injections into only superficial tumors, low starting dose, low concentration per tumor.~B1:INT230-6 injections into deep tumors, low starting dose, low drug concentration per tumor~Dosing schedule for A1 and B1 is every 28 days for 5 sessions~EA:INT230-6 injections into superficial tumors, medium starting dose, low drug concentration per tumor~EC:INT230-6 injections into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor~EC2:INT230-6 injections into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC.~EC3:INT230-6 injections at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.~Dosing schedule for EA, EC, EC2 and EC3 is every 2 weeks for 5 sessions~Completed Cohorts"
62715158|NCT06065124|ACTIVE_COMPARATOR|Bariatric surgery strategy|The intervention group will receive bariatric surgery including an intensive pre- and postoperative treatment scheme
62715159|NCT06065124|NO_INTERVENTION|Standard of Care|The control group will receive standard of care
62715160|NCT06090344|NO_INTERVENTION|Usual care|Usual care from healthcare providers
62715161|NCT06090344|EXPERIMENTAL|Traditional video format|Multimedia videos formatted as traditionally found online
62715162|NCT06090344|EXPERIMENTAL|Evidence-informed video format|Multimedia videos formatted as per evidence advice
62715163|NCT04124627|EXPERIMENTAL|Single arm study|Ultrasound plus radiographic guidance
62715164|NCT03334006|NO_INTERVENTION|Control arm|Standard of Care treatment
62715165|NCT03334006|ACTIVE_COMPARATOR|Verum arm|Standard of Care treatment + Pentaglobin®
62540336|NCT03058289|EXPERIMENTAL|Monotherapy With <40% Total Tumor Burden Dosed (Cohorts A1/B1/EA/EC/EC2/EC3)|"Dosing: \<40% Total Tumor Burden~A1:INT230-6 injections into only superficial tumors, low starting dose, low concentration per tumor.~B1:INT230-6 injections into deep tumors, low starting dose, low drug concentration per tumor~Dosing schedule for A1 and B1 is every 28 days for 5 sessions~EA:INT230-6 injections into superficial tumors, medium starting dose, low drug concentration per tumor~EC:INT230-6 injections into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor~EC2:INT230-6 injections into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC.~EC3:INT230-6 injections at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.~Dosing schedule for EA, EC, EC2 and EC3 is every 2 weeks for 5 sessions~Completed Cohorts"
62540337|NCT03058289|EXPERIMENTAL|INT230-6 Combined With Pembrolizumab (Cohorts DEC/DEC2)|"DEC: INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody KEYTRUDA® (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.~Completed Cohort~DEC2:INT230-6 per the dosing of cohort EC3 combined with KEYTRUDA® (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.~Completed Cohort"
62540338|NCT03058289|EXPERIMENTAL|INT 230-6 Combined With Ipilimumab (Cohort FEC)|"FEC: INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.~Completed Cohort anti-CTLA-4 antibody: The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC."
62540339|NCT04522115|EXPERIMENTAL|aerobic training|Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.
62540340|NCT04522115|EXPERIMENTAL|Resistance training|Resistance exercise training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.
62540341|NCT05176795||Experimental|Child under 10 years old newly diagnosed with JIA, IBD or T1DM
62540342|NCT05176795||Active Comparator: Healthy control|Brother/sister of child with pediatric onset inflammatory disease (same age category - same environment: food, living space)
62540343|NCT06357806|ACTIVE_COMPARATOR|Peg-IFNα group|180 ug Peg-IFNα-2b subcutaneous injection once/week for 48 weeks NAs
62540344|NCT06357806|ACTIVE_COMPARATOR|PD-1 antibody group|1.5 mg/kg Sintilimab intravenous injection once per 3 weeks for 24 weeks NAs
62540345|NCT06357806|EXPERIMENTAL|PD-1 antibody combined Peg-IFNα group|1.5 mg/kg Sintilimab intravenous injection once per 3 weeks for 24 weeks 180 ug Peg-IFNα-2b subcutaneous injection once/week for 48 weeks NAs
62540346|NCT01751737|EXPERIMENTAL|Prostate Cancer Imaging|"Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.~In addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.~Patients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
62540347|NCT01377987|EXPERIMENTAL|Acetazolamide|
62540348|NCT01377987|PLACEBO_COMPARATOR|Sugar pill|
62164640|NCT05057078|NO_INTERVENTION|Control group|During study process, no application will be made to the control group.
62164641|NCT05567224||Pilot Group|This group of TennCare recipients will be referred to VUMC primary care services and will be allowed to utilize these services for at least two years. Those referred to VUMC primary care services will be those who belong to the two of state's three Medicaid Managed Care plans who have agreed to participate in this pilot.
62540349|NCT05543408|EXPERIMENTAL|EXERCISE|
62540350|NCT05543408|NO_INTERVENTION|CONTROL|
62540351|NCT03683030|EXPERIMENTAL|Treatment Group|Ablation using Multi-electrode Radiofrequency (RF) Balloon Catheter (HELIOSTAR).
62540352|NCT06532851|EXPERIMENTAL|Progressive Resistance Exercise (PRE)|Participants will perform progressive resistance exercises focusing on strengthening the quadriceps muscles. The exercises will be adjusted based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique.
62540353|NCT06532851|EXPERIMENTAL|Aerobic Exercise|Participants will engage in aerobic exercise sessions using a stationary bike, aimed at improving cardiovascular fitness and knee joint mobility.
62540354|NCT06532851|ACTIVE_COMPARATOR|Control|Participants will receive standard of care, including general strength and balance exercises as per current clinical guidelines.
62540355|NCT06233331|EXPERIMENTAL|Level 1|Initial three study participants will be enrolled in Dose Level 1, 2.5% ACU-D1 twice daily for 4 weeks.
62540356|NCT06233331|EXPERIMENTAL|Level 2|If there are no DLTs to Dose Level 1 then, 3 new study participants will proceed to Dose Level 2 at 5% ACU-D1.
62540357|NCT06233331|EXPERIMENTAL|Level 3|If there are no DLTs to Dose Level 2 then, 3 new study participants will proceed to Dose Level 3 at 10 % ACU-D1.
62540358|NCT05253963|NO_INTERVENTION|Control|During the first and second study nights, subjects will undergo baseline polysomnography.
62715166|NCT01101451|ACTIVE_COMPARATOR|Arm I (EBRT, IMRT)|Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
61977716|NCT06454110|EXPERIMENTAL|Cohort 1|All subjects will be administered 17 mg/kg of NM8074 intravenously every week, for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
61977717|NCT05575167||single Zol group|postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive a single zoledronate infusion (5mg) at 6 months after the last denosumab dose
61977718|NCT05575167||double Zol group|postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive two zoledronate infusions (5mg) at 6 and 12 months after the last denosumab dose
62540359|NCT05253963|EXPERIMENTAL|Continuous Positive Airway Pressure|Baseline polysomnography will be perfomed during the first study night and CPAP titration polysomnography will be performed during the second study night.
62540360|NCT01878461|PLACEBO_COMPARATOR|Vehicle|Proper quantity twice a day
62540361|NCT01878461|EXPERIMENTAL|M518101|Proper quantity twice a day
62540362|NCT05855122|EXPERIMENTAL|Tocilizumab|
62540363|NCT05855122|NO_INTERVENTION|no-Tocilizumab|
62540364|NCT05134337|EXPERIMENTAL|Part 1 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
62540365|NCT05134337|EXPERIMENTAL|Part 1 Period 2 (Itraconazole + LOXO-305)|Itraconazole + LOXO-305 co-administered orally
62540366|NCT05134337|EXPERIMENTAL|Part 2 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
62540367|NCT05134337|EXPERIMENTAL|Part 2 Period 2 (Rifampin + LOXO-305)|Rifampin + LOXO-305 co-administered orally
62540368|NCT04518293|EXPERIMENTAL|Triple - TAI|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
62540369|NCT04518293|ACTIVE_COMPARATOR|Dual - TA|Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
62540370|NCT04518293|ACTIVE_COMPARATOR|Dual - TI|Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
62540371|NCT04518293|ACTIVE_COMPARATOR|Dual - AI|Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
62540372|NCT03878667|PLACEBO_COMPARATOR|No Diet|No diet or exercise or calcium intervention
62540373|NCT03878667|EXPERIMENTAL|High Calorie Diet|High calorie (2,600 calorie) diet and exercise and calcium
62540374|NCT03878667|EXPERIMENTAL|Low Carbohydrate/High Protein Diet|Low carbohydrate (63% protein, 7% carbohydrate, 30% fat) diet and exercise and calcium
62540375|NCT03878667|EXPERIMENTAL|High Carbohydrate/Low Protein|High carbohydrate (15% protein, 55% carbohydrate, 30% fat) diet and exercise and calcium
62540376|NCT00499421||CT Scan|CT Scan with Fiducial markers + external beam radiation therapy
62540377|NCT03749083||Tumor Sequencing|"* Quality of life assessments will be collected using The Functional Assessment of Cancer Therapy- Colorectal~* Blood for circulating tumor DNA will be collected"
62540378|NCT00741286|PLACEBO_COMPARATOR|Asprin (100mg) plus placebo|Asprin (100mg) plus placebo
62540379|NCT00741286|ACTIVE_COMPARATOR|Asprin (100mg) plus cilostazol (200mg)|Asprin (100mg) plus cilostazol (200mg)
62540380|NCT05521659|EXPERIMENTAL|Standardized oral care protocol|Intervention: Patients in experimental group were given oral care 3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate.
62540381|NCT05521659|NO_INTERVENTION|Control Group|Routine oral care (usual oral care with the same appliances and solution but applied twice a day without following a protocol)
62540382|NCT06381713|EXPERIMENTAL|High intensive speech therapy|To investigate the (cost-)effectiveness of speech therapy for children with a cleft palate (with of without a cleft lip), we will provide a high-intensive speech intervention.
62540383|NCT06381713|ACTIVE_COMPARATOR|Low intensive speech therapy|To investigate the (cost-)effectiveness of speech therapy for children with a cleft palate (with of without a cleft lip), we will provide a low-intensive speech intervention.
62540384|NCT00660400|EXPERIMENTAL|Combined Therapy|5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
61976422|NCT03012958||Deployment-related lung disease|"Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
62540385|NCT02612259|EXPERIMENTAL|TRYPTOPHAN|"tryptophan 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
62540386|NCT02612259|PLACEBO_COMPARATOR|PLACEBO|"lactose capsules 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
62540387|NCT05499949||FONS group|Patients with morbid obesity enrolled for bariatric surgery in the Franciscus Gasthuis, Rotterdam, the Netherland
62540388|NCT00306930|OTHER|A|Acetabular cup replacement with total hip arthroplasty
62540389|NCT02101307||RA Patients on RoActemra/Actemra treatment|
61976423|NCT01606345|EXPERIMENTAL|Phase I Dose Escalation|Dose escalation: 200 mg/75 ml effluent, 400 mg/75 ml effluent, 800 mg/75 ml effluent
61976424|NCT04993456||POAF group|the patients will have atrial fibrillation following the cardiac surgery
61976425|NCT04993456||non-POAF group|the patients will have no atrial fibrillation following the cardiac surgery
62540390|NCT05866185|ACTIVE_COMPARATOR|Therapy|Standard regular therapy.
62540391|NCT05866185|EXPERIMENTAL|Therapy + Adhere.ly|Standard regular therapy, enhanced with Adhere.ly
62540392|NCT02346591|EXPERIMENTAL|Jauntly|Mobile app designed to take advantage of the known connections between positive emotions, stress reduction and stress resilience; goal was to lead users through research-proven positive emotion enhancing exercises and relevant educational materials. Intervention activities covered five well-being generating content areas: 1) promoting the experience and recognition of gratitude; 2) encouraging positive social relationships and feelings of social support; 3) improving stress resilience via mindfulness and other relaxation-focused activities; 4) focusing and capitalizing on individual strengths (as opposed to limitations and weaknesses); and 5) general positive mood inducing activities.
62540393|NCT02346591|ACTIVE_COMPARATOR|Online stress management information|The control participants were emailed links to vetted online information about stress and encouraged to visit the websites.
62540394|NCT01282008||Focus Groups|Focus Groups about smoking messages
62540395|NCT01354379|ACTIVE_COMPARATOR|Fluzone 15 mcg HA 200 mcl IN by Pipette|
62540396|NCT01354379|EXPERIMENTAL|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette|
62540397|NCT01354379|ACTIVE_COMPARATOR|Fluzone 15 mcg HA 200 mcl IN by Nasal Spray|
62540398|NCT01354379|EXPERIMENTAL|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray|
62540399|NCT01354379|EXPERIMENTAL|NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray|
62540400|NCT03358186||revision of periprosthetic fracture|patients with surgically treated periprosthetic femur fracture
62540401|NCT02492659|EXPERIMENTAL|trial group|the trial group underwent femtosecond laser-assisted cataract surgery
62540402|NCT02492659|OTHER|control group|the control group underwent conventional phacoemulsification
62540403|NCT03040700|NO_INTERVENTION|Clinical|Regular medical visits every 6 months.
62540404|NCT03040700|EXPERIMENTAL|Myocardial Perfusion Scan|Myocardial perfusion stress test using cardiac scintigraphy (Sestamibi) at rest and during pharmacological stress (dipyridamole)
62540405|NCT03040700|EXPERIMENTAL|Coronary CTA|Coronary computed tomography angiography
62540406|NCT04670094||Covid19 infection related patients|"Patients over the age of 18 hospitalized for SARS-CoV-2 up to end of June 2020 in the San Gerardo Hospital and other centers will be included.~Patients are followed until discharge from hospital or death."
62540407|NCT02383810|ACTIVE_COMPARATOR|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
62540408|NCT02383810|ACTIVE_COMPARATOR|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
62540409|NCT02383810|ACTIVE_COMPARATOR|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
62540410|NCT02383810|PLACEBO_COMPARATOR|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
62540411|NCT02383810|ACTIVE_COMPARATOR|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
61976426|NCT04801160|EXPERIMENTAL|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
62540412|NCT02383810|ACTIVE_COMPARATOR|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
62540413|NCT02383810|ACTIVE_COMPARATOR|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
62540414|NCT02383810|PLACEBO_COMPARATOR|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
62540415|NCT00575887|EXPERIMENTAL|1|
62540416|NCT06039189|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive guselkumab by subcutaneous injection with placebo as needed to maintain the blind.
62540417|NCT06039189|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive placebo by subcutaneous injection then receive guselkumab by subcutaneous injection.
62540418|NCT01639196|EXPERIMENTAL|Self-compassion writing|
62540419|NCT01639196|ACTIVE_COMPARATOR|Self-efficacy writing|
62540420|NCT04400032|EXPERIMENTAL|Panel 1|25 million cells/unit dose (cumulative dose: 75 million MSCs)
62540421|NCT04400032|EXPERIMENTAL|Panel 2|50 million cells/unit dose (cumulative dose: 150 million MSCs)
62540422|NCT04400032|EXPERIMENTAL|Panel 3|up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)
62540423|NCT03543436|EXPERIMENTAL|Intravenous temocillin|Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h)
62540424|NCT03543436|ACTIVE_COMPARATOR|Intravenous meropenem or imipenem|Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy
62540425|NCT01922440||Natpar(a)|Participants receiving parathyroid hormone (rhPTH(1-84) (Natpar\[a\]) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.
62540426|NCT01922440||Conventional Therapy|Participants receiving conventional therapy/standard of care (including calcium supplements, active vitamin D, vitamin D) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.
62540427|NCT01336452|OTHER|CCRTx|consecutive patients who plan to undertake CCRTx due to advanced hepatocellular carcinoma
62540428|NCT05249673|EXPERIMENTAL|global postural reeducation|"global postural reeducation (GPR) interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
62540429|NCT05249673|ACTIVE_COMPARATOR|neck stabilization training|Each exercise session will be comprised of 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient.
62164642|NCT05567224||Control Group|This group of TennCare recipients will not be referred to VUMC primary care services and will receive care as usual. Those not referred to VUMC primary care services will be those who belong to one of the state's three Medicaid Managed Care plans who has not agreed to participate in this pilot.
62540430|NCT03450252|EXPERIMENTAL|Active pacing|Active ventricular pacing. The pacemaker is set-up with a short atrio-ventricular delay to allow for appropriate pacing capture of the ventricle.
62540431|NCT03450252|SHAM_COMPARATOR|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
62736999|NCT03254706|EXPERIMENTAL|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
61976427|NCT04801160|ACTIVE_COMPARATOR|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
61976428|NCT04484792|EXPERIMENTAL|Group A|
61976429|NCT04484792|EXPERIMENTAL|Group B|
61976430|NCT04484792|PLACEBO_COMPARATOR|Group C|
62164643|NCT03470701|NO_INTERVENTION|Control - usual care|This arm will receive usual care.
62540432|NCT05054478|EXPERIMENTAL|Experimental Arm|"4 days of dexamethasone. According to local practice, one dose of doxorubicine (30 mg/m2 IV) or cyclophosphamide (750 mg/m2 IV) may also be added~Induction Treatment (4 months): Subject will receive 4 x 28 days cycles of Dara-VRD induction:~Daratumumab sc 1800 mg on D1 D8 D15 D22 for cycle1 \& 2 and D1 D15 for cycle 3 \& 4 Bortezomib sc 1.3 mg/m2 on D1 D4 D8 D11 for each cycle Lenalidomide po 25 mg on D1 to D21 for each cycle Dexamethasone po 20 mg on D1 D2 D8 D9 D15 D16 D22 D23 for each cycle~High dose melphalan 200mg/m2 as conditioning therapy and first ASCT~First consolidation : 2 cycles of Dara-VRd~* Daratumumab 1800 mg s.c D1 D15~* Bortezomib 1.3 mg/m2 s.c D1 D8 D15 D22~* Lenalidomide 25 mg p.o from D1 to D21~* Dexa 20 mg p.o D1 D8 D15 D22~High dose melphalan 200mg/m2 as conditioning therapy and second ASCT Second consolidation : 6 cycles of Dara-VRd (every 2 months for 2 years) Then maintenance: Lenalidomide every 28 days (25 mg from D1 to D21) for 1 year"
62540433|NCT01449812|EXPERIMENTAL|INFANRIX+HIB/POLIORIX 1 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
62540434|NCT01449812|EXPERIMENTAL|INFANRIX+HIB/POLIORIX 2 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
62540435|NCT01449812|ACTIVE_COMPARATOR|CONTROL GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
62540436|NCT06633653|EXPERIMENTAL|exercise intervention|
62540437|NCT02720874|EXPERIMENTAL|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
62540438|NCT02720874|ACTIVE_COMPARATOR|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
62540439|NCT04799301|EXPERIMENTAL|Diet with 20% of carb intake from soda|This group will receive a weight-maintaining diet with 20% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
62540440|NCT04799301|EXPERIMENTAL|Diet with 50% of carb intake from soda|This group will receive a weight-maintaining diet with 50% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
62540441|NCT04799301|EXPERIMENTAL|Diet with no soda|This group will receive a weight-maintaining diet without soda. All 50% of carbohydrates will originate from sources other than corn and sugar cane.
62540442|NCT01045538|EXPERIMENTAL|Vorinostat plus XP|Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
62540443|NCT03006302|EXPERIMENTAL|Part 1: Dose Level 1|Epacadostat/Pembrolizumab/CY/GVAX/CRS-207
62540444|NCT03006302|EXPERIMENTAL|Part 1: Dose Level 2|Epacadostat/Pembrolizumab/CY/GVAX/CRS-207
62540445|NCT03006302|EXPERIMENTAL|Part 1X: Dose Level 2|Epacadostat/Pembrolizumab/CRS-207
62540446|NCT03006302|EXPERIMENTAL|Part 1X: Dose Level 3|Epacadostat/Pembrolizumab/CRS-207
62540447|NCT03006302|EXPERIMENTAL|Part 2: Dose Expansion|Epacadostat/Pembrolizumab/CRS-207
62540448|NCT02712580|ACTIVE_COMPARATOR|First investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light."
62540449|NCT02712580|ACTIVE_COMPARATOR|Second investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light."
62540450|NCT02712580|PLACEBO_COMPARATOR|ES Wetling W200 with white light|Placebo device - 'ES Wetling W200 Placebo with white light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
62164644|NCT03470701|EXPERIMENTAL|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
62540451|NCT02712580|PLACEBO_COMPARATOR|ES Wetling W200 with red light|Placebo device - 'ES Wetling W200 Placebo with red light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
61976431|NCT00132145|OTHER|Intervention|Behavioural
61976432|NCT01518166|EXPERIMENTAL|Trial period A|
61976433|NCT01518166|EXPERIMENTAL|Trial period B|
61976434|NCT02659631|EXPERIMENTAL|PF-06671008|
62164645|NCT02633345|EXPERIMENTAL|Probiotic|The probiotic tablets contain Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2 at a dose of 1 \* 109 CFU/tablet. The participants will take two tablets a day for four weeks.
62164646|NCT02633345|PLACEBO_COMPARATOR|Control|Placebo tablets. The participants will take two tablets a day for four weeks.
62540452|NCT01258712|EXPERIMENTAL|1|
62540453|NCT01258712|PLACEBO_COMPARATOR|2|
62540454|NCT04562155|EXPERIMENTAL|BAY1817080 dose A BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
62540455|NCT04562155|EXPERIMENTAL|BAY1817080 dose B BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
62540456|NCT04562155|EXPERIMENTAL|BAY1817080 dose C BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
62540457|NCT04562155|PLACEBO_COMPARATOR|Placebo|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
62540458|NCT05996562|EXPERIMENTAL|Pulmonary Artery Denervation (PADN)|
62540459|NCT04286451|EXPERIMENTAL|Sleep Restriction|Women will undergo 4 nights of sleep restriction treatment.
62540460|NCT04286451|EXPERIMENTAL|Habitual Sleep|Women will undergo 4 nights of habitual sleep treatment.
62540461|NCT01484327||Carvedilol, LVEF, Heart Failure|Patients with Heart Failure on carvedilol therapy measured for their LVEF value
62540462|NCT01288144|EXPERIMENTAL|Intervention|Quality improvement initiative using computerized decision support
62540463|NCT01288144|NO_INTERVENTION|Usual care|In control clinics, women will continue to receive usual care.
62540464|NCT00933361|EXPERIMENTAL|ghrelin|Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS) receptor. When administered peripherally it stimulates growth hormone secretion, food intake, triggers a positive energy balance, produces weight gain through a central mechanism involving hypothalamic neuropeptides and has anti-inflammatory effects
62540465|NCT02628327||Glaucoma subjects|Survey given to all glaucoma subjects agreening to study.
62540466|NCT02335918|EXPERIMENTAL|Varlilumab and Nivolumab|
62540467|NCT03267563|EXPERIMENTAL|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
62540468|NCT03267563|EXPERIMENTAL|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
62540469|NCT03267563|EXPERIMENTAL|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
62540470|NCT00729573||1|Participants in MTN-003. Participants will remain a part of their assigned MTN-003 study groups.
62540471|NCT03125980|EXPERIMENTAL|Perioperative chemotherapy with CapOX regimen|
62540472|NCT03125980|ACTIVE_COMPARATOR|Postoperative chemotherapy with CapOX regimen|
62540473|NCT05434637|EXPERIMENTAL|Individualized Physiotherapy|Individuals randomized to this group will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
62540474|NCT05434637|ACTIVE_COMPARATOR|Sound-based Therapy|Individuals randomized to this group will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
62540475|NCT05434637|EXPERIMENTAL|Combination Therapy|Individuals randomized to this group will receive both individualized physical therapy and sound-based therapy.
62715167|NCT01101451|EXPERIMENTAL|Arm II (cisplatin, EBRT, IMRT)|Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62715168|NCT04861584|EXPERIMENTAL|Toripalimab+Gemcitabine/Cisplantin（GC）|Subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. . Toripalimab is given every 21 days for 4 doses starting C1D1. Subjects will then have consolidative surgery to remove their primary tumor within 6 weeks after their last dose of neoadjuvant therapy.
62540476|NCT01915758|EXPERIMENTAL|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel
62540477|NCT01915758|PLACEBO_COMPARATOR|occlusive patch 200uL of vehicle gel|occlusive patch 200uL of vehicle gel
62540478|NCT04686552|EXPERIMENTAL|cinnamon|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served with 6 g of ground cinnamon.
62540479|NCT04686552|NO_INTERVENTION|control|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served without 6 g of ground cinnamon
62540480|NCT04688892|ACTIVE_COMPARATOR|Intervention Group|The type of cupping therapy will be dry-cupping with moving-cupping (dynamic cupping therapy). The participants will remain in the supine position on a massage table (Posturarte® Olympic), without inclination. Cupping therapy will be performed with a plastic suction cup (5.08 cm in diameter) (K.S. Choi Corp®) and with a pistol for dosing pumps (K.S. Choi Corp®). Prior to the cupping therapy, a small amount of massage cream (ATL®) will be applied throughout the median nerve pathway in order to facilitate the sliding of the suction cup. The cupping therapy will performed with the suction cup sliding with a slow rhythm, insufflation of the suction cup with two pumps for 5 minutes along the median nerve path.
62540481|NCT04688892|NO_INTERVENTION|Control Group|The participants will remain at rest in a supine position on a massage table (Posturarte® Olympic) without inclination for 5 minutes.
62540482|NCT05831241|EXPERIMENTAL|Ashwagandha|"KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.~After enrollment in the study, 50% participants will be randomly assigned to take one capsule of KSM 66 Ashwagandha (300 mg) two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
62737000|NCT03254706|ACTIVE_COMPARATOR|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
61976435|NCT04771507|EXPERIMENTAL|Intermittent ibrutinib|Intermittent treatment with ibrutinib.
62540483|NCT05831241|PLACEBO_COMPARATOR|Placebo|"Placebo means that the capsules will not contain Ashwagandha but some other inactive substance. By using placebo, investigators will know whether the positive results are because of Ashwagandha or are because of psychological factors. For example, the subject may feel that her condition is improved because she is expecting the capsules to be helpful.~After enrollment in the study, 50% participants will be randomly assigned to take one capsule of placebo two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
62540484|NCT04530435|EXPERIMENTAL|Treatment group|"The participants will be handed three airway resistances equivalent to a resistance of 10-20 cm H2O alongside one PEP flute. Two videos will guide the participants in use of the PEP flute; one with instructions of the rationale and how to use the flute, including how to choose the suitable resistance and one video, which gives instructions of hygienic maintenance.~Participants in the intervention group will be advised to continue use of their PEP flute in the active intervention period of 30 days or at least if they still have respiratory symptoms. They will receive daily text-messages to prompt their reporting and to use the PEP flute according to instructions."
62540485|NCT04530435|NO_INTERVENTION|Control group|The participants in the control group will receive daily text-messages to prompt their reporting of CAT-scores. To avoid attrition of the trial due to early recovery of symptoms, the project manager will call the participants by phone at day 15 to ask them about their present condition (i.e. CAT-score) and address potential concerns of continued participation of the trial. Otherwise, they will only receive usual care.
62540486|NCT05418504|ACTIVE_COMPARATOR|Non- Tramadol|the control group represented by dental patients who are not a tramadol addict
62540487|NCT05418504|ACTIVE_COMPARATOR|Tramadol|The study group with patients seeking dental service but also are tramadol addict.
62540488|NCT06397417||Patients|All patients over 18 years of age who will benefit from an installation or an attempt at an ECMO installation following a non-traumatic refractory cardiac arrest care by the ECMO TEAM of the Paris SAMU over a period of 20 years old. Patients' medical data will be collected for one year after their care.
62540489|NCT02359994|EXPERIMENTAL|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps \> 2mm and large needle holes \> 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
62540490|NCT02359994|EXPERIMENTAL|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels \> 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels \> 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
62540491|NCT02359994|EXPERIMENTAL|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels \> 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels \> 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
62540492|NCT05343546|ACTIVE_COMPARATOR|Group 1: Early insertion|Early insertion will refer to Group 1 where a post abortion intrauterine device will be placed within seven days of giving medical management of first trimester incomplete abortion
62540493|NCT05343546|ACTIVE_COMPARATOR|Group 2: Standard insertion|Standard insertion will refer to Group 2 where a post abortion intrauterine device will be inserted in the recommended 2-4 weeks after medical management of first trimester incomplete abortion
62540494|NCT05212389|ACTIVE_COMPARATOR|Femicept|3x28 days of treatment with Femicept. Each cycle consists of 21 days of active pill (Femicept) and 7 days of placebo pill.
62540495|NCT05212389|PLACEBO_COMPARATOR|Placebo|3x28 days of treatment with placebo
62540496|NCT03891745||prone group|prone extubation
62540497|NCT03891745||supine group|supine extubation
62540498|NCT02547090||CP who underwent PSF by two attendings in 2012|
62540499|NCT02547090||CP who underwent PSF by a single surgeon from 2008-2010|
62540500|NCT01565057|EXPERIMENTAL|sedimenting meal|To assess whether rates of gastric emptying of a specifically formulated emulsion drink are significantly different from a control drink and that this in turn leads to differences in satiation (cessation in the desire to eat) and satiety (desire to limit further food intake) as measured by visual analogue scale (VAS) satiety questionnaire and blood CCK.
62540501|NCT03972735|EXPERIMENTAL|NECT + follow up|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2 hours sessions are conducted by two trained facilitators.
62540502|NCT03972735|PLACEBO_COMPARATOR|TAU|"* Drug treatment (antipsychotic, mood stabilizing) for people with schizophrenia or with bipolar disorder~* Support in day-care hospital~* No intervention specifically targeting self-stigma reduction or improvements in social functioning (social cognitive remediation or social skills training)"
62540503|NCT06256107|EXPERIMENTAL|Intervention|The intervention period will last 4 weeks where participants will be required to use the VR set and document the time of use in a daily diary
62164647|NCT02648061||After cardiac arrest syndrome (ACAS)|adult patients after out-of-hospital cardiac arrest
62540504|NCT00828737|EXPERIMENTAL|Arm 1|
62540505|NCT03620968|NO_INTERVENTION|Group 1|Control, no intervention
62164648|NCT01116830|PLACEBO_COMPARATOR|Placebo|
62164649|NCT01116830|EXPERIMENTAL|RO4917838|
62164650|NCT04861571|EXPERIMENTAL|Very Low Calorie Diet Arm|We plan to perform a controlled, non-randomized, open-label, pilot clinical trial to evaluate the effect of an 8-week VLCD intervention on NAFLD.
62164651|NCT04861571|OTHER|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
62164652|NCT01599455||Inpatient|Youths admitted for inpatient rehabilitation training
62164653|NCT01599455||Outpatient|Youths visiting outpatient clinics
62164654|NCT01599455||Urodynamic study|Youths who undergo scheduled urodynamic study
62164655|NCT02078778|EXPERIMENTAL|Treatment|Patients with hypertension and moderate to severe OSA is treated with CPAP for 3 months.
62164656|NCT00599599|EXPERIMENTAL|1|Prolonged Exposure Therapy.
62164657|NCT00599599|NO_INTERVENTION|2|Weekly monitoring/Waitlist Control Group.
62164658|NCT06647953|EXPERIMENTAL|Group I, Arm 1 (VAC1200/VA regimen)|Patients undergo surgery on study. Patients receive vincristine IV on days 1, 8, and 15 of cycles 1-3 and 5-7, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of each cycle, and cyclophosphamide IV over 30-60 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT and ultrasound throughout the study.
62164659|NCT06647953|ACTIVE_COMPARATOR|Group I, Arm 2 (observation)|Patients undergo surgery on study. Patients undergo observation on study.
62164660|NCT06647953|EXPERIMENTAL|Group II, Arm 3 (VTC400, IVADo, VTC250, VAC1200 regimens)|See Detailed Description for Group II, Arm 3.
62164661|NCT06647953|EXPERIMENTAL|Group II, Arm 4 (VTC400, IVADo, IVA regimens)|See Detailed Description for Group II, Arm 4.
62164662|NCT02332122||COPD patients with bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
62164663|NCT02332122||COPD patients without bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
62164664|NCT06055400|NO_INTERVENTION|standard US|The participants underwent CVC placement using standard ultrasound guidance.
62164665|NCT06055400|EXPERIMENTAL|AR-US|The participants underwent CVC placement using AR-HMD ultrasound guidance.
62164666|NCT06102005|EXPERIMENTAL|Lunsekimig Dose1 interval 1|Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 1
62164667|NCT06102005|EXPERIMENTAL|Lunsekimig Dose 1 interval 2|Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 2
62164668|NCT06102005|EXPERIMENTAL|Lunsekimig Dose 2 interval 1|Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 1
62164669|NCT06102005|EXPERIMENTAL|Lunsekimig Dose 2 interval 2|Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 2
62164670|NCT06102005|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo (subcutaneous injection) according to established dosing intervals corresponding to Dose 1 and Dose 2
62164671|NCT01827176||Recurrent Acute Rhinosinusitis|Recurrent Acute Rhinosinusitis is defined as acute rhinosinusitis more than 3 times/6 months or more than 4 times/year
62164672|NCT03800745|NO_INTERVENTION|No Medication|No intervention is assigned in Arm A.
62164673|NCT03800745|EXPERIMENTAL|Colace|This is Arm B. Docusate sodium(Colace) is prescribed as100mg twice daily orally. Patients will be instructed to begin taking this the evening of surgery through postoperative day five.
62164674|NCT03800745|EXPERIMENTAL|Miralax|This is Arm C. Miralax 17 grams oral powder pack daily is prescribed to be taken with breakfast. Patients will be instructed to begin taking this the morning after surgery through postoperative day five.
62540506|NCT03620968|EXPERIMENTAL|Group 2|Intervention before surgery (cognitive training)
62540507|NCT03620968|EXPERIMENTAL|Group 3|Intervention Before and after surgery (cognitive training)
62540508|NCT04263324|EXPERIMENTAL|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
62540509|NCT04263324|NO_INTERVENTION|Control group|No intervention
62540510|NCT00827437|OTHER|1|
62164675|NCT06145971|NO_INTERVENTION|Baseline phase|Randomly allocated baseline phase (no intervention) of 5, 7, or 9 days.
62164676|NCT06145971|EXPERIMENTAL|Intervention - bCBTi|Two sessions of brief Cognitive Behavioural Therapy for insomnia (bCBTi). This will involve a clinical psychologist meeting with the participant for two sessions, three days apart, to provide bCBTi, which will involve a cognitive and a behavioural therapy technique.
62164677|NCT04201847|ACTIVE_COMPARATOR|Infertile women with normal ovarian reserve|Infertile women with normal ovarian reserve will be included.
62164678|NCT04201847|ACTIVE_COMPARATOR|Infertile women with high ovarian reserve|Infertile women with high ovarian reserve will be included.
62164679|NCT04201847|ACTIVE_COMPARATOR|Infertile women with poor ovarian reserve|Infertile women with poor ovarian reserve will be included.
62164680|NCT06585319|EXPERIMENTAL|Collagen-polyvinylpyrrolidone|Collagen-PVP ml intramuscular q24 h
62164681|NCT06585319|ACTIVE_COMPARATOR|Pirfenidone|Pirfenidone 1,200 mg of oral q12 h
62164682|NCT06585319|NO_INTERVENTION|Control|Standard treatment with dexamethasone (intravenously) and 40 or 60 mg of enoxaparin (subcutaneously, according to the patient's weight) once daily and 1 g of paracetamol
62164683|NCT01592422|EXPERIMENTAL|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every month
62164684|NCT01592422|ACTIVE_COMPARATOR|Best Supportive Care|Best Supportive Care
62164685|NCT01294358|EXPERIMENTAL|Gemcitabine Dose Escalation|gemcitabine dose escalation
62164686|NCT02709265|EXPERIMENTAL|Cohort 1|amikacin/fosfomycin (30/12 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
62540511|NCT06393517|EXPERIMENTAL|Sequence 1|"Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:~Formulation 1 , Formulation 2, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively."
62540512|NCT06393517|EXPERIMENTAL|Sequence 2|"Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:~Formulation 2, Formulation 3, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively."
62540513|NCT06393517|EXPERIMENTAL|Sequence 3|"Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:~Formulation 3, Formulation 1, and Formulation 2, under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively."
62540514|NCT06393517|EXPERIMENTAL|Sequence 4|"Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:~Formulation 3, Formulation 2, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively."
62540515|NCT06393517|EXPERIMENTAL|Sequence 5|"Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:~Formulation 1, Formulation 3, and Formulation 2 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively."
62540516|NCT06393517|EXPERIMENTAL|Sequence 6|"Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:~Formulation 2, Formulation 1, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively."
62540517|NCT03294720|EXPERIMENTAL|Bio ACL Reconstruction|Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.
62540518|NCT01696058|EXPERIMENTAL|Olodaterol andTiotropium|2 puffs Olodaterol from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
62540519|NCT01696058|OTHER|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
62540520|NCT05279313|EXPERIMENTAL|Centanafadine Hydrochloride|"* Adolescents (13 to 17 years of age, inclusive) to receive 328.8 mg daily.~* Children (4 to 12 years of age, inclusive) will receive weight-based doses of centanafadine ranging from 82.2 mg to 328.8 mg daily"
62540521|NCT01535092|EXPERIMENTAL|silibinin|Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
62540522|NCT01535092|PLACEBO_COMPARATOR|Placebo|Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
62540523|NCT01404923|EXPERIMENTAL|meteospasmyl|
62540524|NCT01404923|ACTIVE_COMPARATOR|standard of care|
62540525|NCT04837924|EXPERIMENTAL|B (FICB)|Participants receiving fascia iliaca compartment block (FICB)
62164687|NCT02709265|EXPERIMENTAL|Cohort 2|amikacin/fosfomycin (60/24 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
62540526|NCT04837924|SHAM_COMPARATOR|A (PLACEBO)|Participants receiving sham injection matching fascia iliaca compartment block (FICB)
62540527|NCT01446328|ACTIVE_COMPARATOR|Amisulpride|
62540528|NCT01446328|ACTIVE_COMPARATOR|Aripiprazole|
62164688|NCT02709265|EXPERIMENTAL|Cohort 3|amikacin/fosfomycin (90/36 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
62164689|NCT02709265|EXPERIMENTAL|Cohort 4|amikacin/fosfomycin (90/36 mg) delivered via the PARI LC Sprint Nebulizer (single dose)
62164690|NCT02709265|EXPERIMENTAL|Cohort 5|amikacin/fosfomycin (Dose and Nebulizer to be chosen based on results from Cohorts 1 - 4)
62164691|NCT02232009|OTHER|3.0 T Neonatal Scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
62164692|NCT00183599|EXPERIMENTAL|1|
62164693|NCT00183599|EXPERIMENTAL|2|
62164694|NCT00183599|EXPERIMENTAL|3|
62540529|NCT01446328|ACTIVE_COMPARATOR|Olanzapine|
62540530|NCT04127630||mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
62540531|NCT00351533|EXPERIMENTAL|1|Enteral fish oil
62540532|NCT00351533|PLACEBO_COMPARATOR|2|Enteral saline
62540533|NCT06489626|EXPERIMENTAL|Intraoperative and Post-operative steroid|Patients in this groups will receive intraoperative intravenous dexamethasone as well as a 6-day post-operative methylprednisolone taper
62540534|NCT06489626|ACTIVE_COMPARATOR|Intraoperative Steroid|Patients randomized to this group will only receive intraoperative intravenous dexamethasone
62540535|NCT00869336|EXPERIMENTAL|Luliconazole Cream 1% - 2 wks|Daily treatment with Luliconazole Cream 1% for 2 weeks
62540536|NCT00869336|EXPERIMENTAL|Luliconazole Cream 1% - 4 wks|Daily treatment with Luliconazole Cream 1% for 4 weeks
62540537|NCT00869336|PLACEBO_COMPARATOR|Placebo Comparator - 2 wks|Daily treatment with Vehicle Cream for 2 weeks
62540538|NCT00869336|PLACEBO_COMPARATOR|Placebo Comparator - 4 wks|Daily treatment with Vehicle Cream for 4 weeks
62540539|NCT00925366|OTHER|Shoulder rotator cuff tear|Shoulder rotator cuff tear
62540540|NCT05177302||Individuals with hip and/ or groin pain|The young to middle-aged physically active individuals with hip and/ or groin pain, which symptoms lasting for 2 to 6 month.
62540541|NCT06132932|EXPERIMENTAL|WX390|Participants will receive WX390 continuous oral dosing (1.1 mg once a day).
62540542|NCT05753995|OTHER|single arm|for diagnostic
62540543|NCT05326243|EXPERIMENTAL|CD19-targeted chimeric antigen receptor T-cell|Patients will receive a lymphodepletion chemotherapy with fludarabine plus cyclophosphamide for three consecutive days(Day -5 to Day -3) before infusion of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T). Patients will receive the CD19 CAR-T(also known as PL001) infusion on Day 0.
62737001|NCT03254706|EXPERIMENTAL|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
62164695|NCT02741297|EXPERIMENTAL|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
62540544|NCT03478527|EXPERIMENTAL|verum condition probiotics|The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.
62540545|NCT03478527|PLACEBO_COMPARATOR|placebo condition|In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.
62164696|NCT05979987|EXPERIMENTAL|Control Reminder|Eligible, randomized participants will receive a generic text message reminding them to close their outstanding health gap.
62164697|NCT05979987|EXPERIMENTAL|Anecdote-based Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
62167972|NCT06358339|EXPERIMENTAL|Routine Tracker and Mind Care|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker and Mind Care."
62540546|NCT01932723|EXPERIMENTAL|Lumbar Stabilization Exercises & Control|Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
62540547|NCT05354739||Emla Group|"Emla Cream~1 gm of EMLA cream contains lidocaine 25 mg, prilocaine 25 mg, and macrogol glycerol hydroxy stearate. Act as a surface anesthetic of the skin. Will apply ½ tube (approximately 2 gram) per 10 square cm and covered with occlusive dressing. Applied for 30-45 minutes for children needing IV catheter placement or blood extraction based on the treating physician decision depending on the patient's need"
62715169|NCT03573024|EXPERIMENTAL|Azacitidine and Venetoclax|Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
62715170|NCT02345239|EXPERIMENTAL|Pantoprazole|Pantoprazole
62715171|NCT06717009|EXPERIMENTAL|3D trial group|The three-dimensional reconstruction data of patients will be synthesized according to renal enhanced CT/MRI within 48 hours before surgery. The surgeon/researcher will conduct surgical planning according to the results of the three-dimensional reconstruction and perform robot-assisted laparoscopic nephron sparing surgery.
62167973|NCT06358339|EXPERIMENTAL|Routine Tracker and Achievement & Reward|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker and Achievement \& Reward."
62167974|NCT06358339|EXPERIMENTAL|Routine Tracker|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker only."
62167975|NCT06358339|EXPERIMENTAL|Mind Care, Social Connectivity, and Achievement & Rewards|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Mind Care, Social Connectivity, and Achievement \& Rewards."
62167976|NCT06358339|EXPERIMENTAL|Mind Care and Social Connectivity|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group~The TEEM app with the intervention condition of Mind Care and Social Connectivity."
62167977|NCT06358339|EXPERIMENTAL|Mind Care and Achievement & Rewards|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Mind Care and Achievement \& Rewards."
62167978|NCT06358339|EXPERIMENTAL|Mind Care|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Mind Care only."
62167979|NCT06358339|EXPERIMENTAL|Social Connectivity and Achievement & Rewards|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Social Connectivity and Achievement \& Rewards."
62167980|NCT06358339|EXPERIMENTAL|Social Connectivity|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Social Connectivity only."
62167981|NCT06358339|EXPERIMENTAL|Achievement & Rewards|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Achievement \& Rewards only."
62167982|NCT06358339|EXPERIMENTAL|Brief contact intervention|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~Participants will receive care as usual (receiving brief contact intervention which mention in the study NCT04907669)"
62167983|NCT06358339|EXPERIMENTAL|Optimized TEEM|"At the confirmation phase, participants will be assigned into Group 17 to Group 18 randomly, with 160 participants in each group.~The TEEM app with the optimized intervention condition from the optimization phase."
62167984|NCT06358339|EXPERIMENTAL|Care as usual|"At the confirmation phase, participants will be assigned into Group 17 to Group 18 randomly, with 160 participants in each group.~Participants will receive care as usual (receiving brief contact intervention which mention in the study NCT04907669)"
62167985|NCT01209936|EXPERIMENTAL|deuterium oxide and BC3|Testing of total body water on the BC3 compared to total body water measured by deuterium oxide.
62167986|NCT06640075|EXPERIMENTAL|Community co-produced action|Participatory workshops will be conducted with community members by a multidisciplinary team with the aim to co-develop a strategy for cervical cancer screening adapted to the local setting (including primary HPV screening, triage of HPV-positive patients and treatment of patients triaged positive).
62167987|NCT06640075|ACTIVE_COMPARATOR|Standard screening strategy|Recruitment of study participants will be coordinated centrally at district level (from the Bafoussam Regional Hospital) following procedures previously established in a cervical cancer screening program in the health district of Dschang.
62540548|NCT05354739||Buzzy Device Group|"Buzzy Device~The vibration cold device (BUZZY) is 8.4 cm X 5.3 cm X 2.9 cm dimensions, exist in different but the investigators will choose the most attractive color, and can be handled by the child prior the procedure~It composed of two parts:~* The main body which can be operated by a switch. It generates vibration using two AAA batteries.~* Removable ice wings. The ice wings are reusable for about 100 times, both wings weighing 18 grams. It stays frozen at room temperature for around 10 minutes. The research nurse will follow the manufactures recommendations (MMJ labs, Atlanta, Georgia, USA)."
62540549|NCT03678285|EXPERIMENTAL|HIFRT Workout|Consecutive completion of; 1 mile run, 100 pull ups, 200 push-ups, 300 bodyweight squats, 1 mile run.
62540550|NCT00737763|EXPERIMENTAL|A|This group will receive weekly efalizumab injections for 6 months
62540551|NCT00737763|PLACEBO_COMPARATOR|B|This group will receive placebo injections for 6 months
62540552|NCT05093361|ACTIVE_COMPARATOR|Operative Treatment|Total Hip Arthroplasty
62540553|NCT05093361|ACTIVE_COMPARATOR|Conservative Treatment|Physical therapy
62540554|NCT04237935||Clopidogrel 75 mg|Reference group
62540555|NCT04237935||Ticagrelor 90 mg|Exposure group
62540556|NCT02114385|EXPERIMENTAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
62540557|NCT02114385|ACTIVE_COMPARATOR|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
62540558|NCT04919018||Primary Ciliary Dyskinesia (PCD)|Subjects with a confirmed diagnosis of PCD
62540559|NCT04919018||Primary Immune Deficiency (PID)|Subjects with a confirmed diagnosis of PID
62540560|NCT02874885||Ancillary-Correlative (biospecimen collection)|Patients and healthy participants undergo collection of blood sample at baseline. Patients may also undergo collection of blood sample collections during tumor surgery, 4 weeks after surgery or after completion of treatment if you are not surgery, 8 weeks after the last dose of chemotherapy, 1 year after surgery or 1 year after completion of treatment if not having surgery, 2 years after surgery or 2 years after completion of treatment if not having surgery, and within 6 years after treatment or at the end of the 6 year follow-up if the disease gets worse with treatment or comes back.
62540561|NCT05523024|ACTIVE_COMPARATOR|Probiotic|"Individuals receive Probiotics (9 strains: B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19, and Lactococcus lactis W58) in dose: 1x109 colony forming units (CFU), daily, for 12 weeks.~Intervention: Dietary Supplement: Probiotic"
62540562|NCT05523024|ACTIVE_COMPARATOR|Berberine|"Individuals receive Berberine (Berberine hydrochloride 97% extract of Berberis aristata) in dose: 1500 mg/day, for 12 weeks.~Intervention: Dietary Supplement: Berberine"
62540563|NCT05523024|PLACEBO_COMPARATOR|Placebo|Individuals receive placebo daily, for 3 months. Intervention: Dietary Supplement: Placebo
62540564|NCT05523024|ACTIVE_COMPARATOR|Probiotics and Berberine|"Individuals receive: Probiotics (9 strains: B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19, and Lactococcus lactis W58) in dose: 1x109 colony forming units (CFU), daily and Berberine (Berberine hydrochloride 97% extract of Berberis aristata) in dose: 1500 mg/day, for 12 weeks.~Intervention: Dietary Supplement: Probiotic and Berberine"
62540565|NCT05090488|EXPERIMENTAL|Received Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
62540566|NCT05090488|ACTIVE_COMPARATOR|Received Diabetes Education in Group|Diabetes education in group, with trained educator team from primary health care
62540567|NCT02905747|EXPERIMENTAL|Medical Exercise Therapy|Medical Exercise Therapy (MET) developed by Oddvar Holten
62540568|NCT04483206|EXPERIMENTAL|Treatment (Melphalan-based autologous transplant)|Patients receive high dose (100 mg/m2) melphalan IV over 30 minutes on day -3 and PK-directed melphalan IV over 30 minutes on day -1 to achieve set cumulative melphalan exposure levels. Patients then undergo stem cell infusion on day 0.
62540569|NCT04034407|EXPERIMENTAL|Damage control surgery|In the damage control surgery (DCS) group the surgeon was asked to perform rapid source control by stapling the perforated segment leaving blind ends or suturing the perforation site if possible, doing a thorough lavage of the abdominal cavity and placing an intra-abdominal negative pressure system avoiding the retraction of the abdominal wall with dynamic sutures as published. The second-look operation was scheduled for a time 24-48 hours after primary surgery that would be during regular working hours with a colorectal surgeon on hand to make the decision for either anastomosis or ostomy.
62540570|NCT04034407|ACTIVE_COMPARATOR|Control group|In the conventional treatment group (Group C), the decision to reconstruct the colon or perform a Hartmann procedure was made by the surgeon during the emergency operation. After performing the anastomosis or the Hartmann procedure, patients with advanced peritonitis received an intraabdominal negative pressure system at the discretion of the operating surgeon.
62540571|NCT05129605||Cohort A|Documented germline known pathogenic or likely pathogenic mutation in a prostate cancer related risk gene
62540572|NCT05129605||Cohort B|Family history suggestive of high genetic risk for prostate cancer with clinical genetic testing negative for known pathogenic or likely pathogenic mutations in prostate cancer-related risk genes
62540573|NCT05129605||Cohort C|Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry
62540574|NCT03550001|EXPERIMENTAL|Injection CNP before NAT|Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.
62540575|NCT03550001|NO_INTERVENTION|No injection|Do not inject carbon nanoparticle during the treatment.
62540576|NCT04952909|EXPERIMENTAL|ShortCut™|
61976436|NCT05728307||Intervention Group|The intervention group consists of patients admitted to the 4 neonatal subunits where neoGuard was installed: the preterm units (category A and category B), and the high dependence units (HDU-1 and HDU-2).
62540577|NCT00863018||Control|Eyes with glaucoma and on anti-glaucoma medication but without glaucoma surgery
62540578|NCT00863018||Implant surgery|Eyes underwent Ahmed glaucoma valve implantation
62540579|NCT00863018||Trabeculectomy|Eyes underwent conventional trabeculectomy with mitomycin-C
62540580|NCT01243437|EXPERIMENTAL|ciprofloxacin|
62540581|NCT01243437|ACTIVE_COMPARATOR|doxycycline|
62540582|NCT04855578|NO_INTERVENTION|Usual Medical Care|During the control period, patients admitted to the study sites who qualify for the trial will receive a pharmacy medication reconciliation as part of usual medical care. Study participants will be informed that the goal of the trial is to evaluate medication use and medication changes after discharge, but they will not be informed that gabapentinoids are specifically being targeted. Medical staff will not receive specific information about the trial, or particular instructions with regards to deprescription during the control period.
62540583|NCT04855578|EXPERIMENTAL|In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid Prescription|During the intervention period, patients admitted to the study sites who qualify for the trial will receive an in-hospital educational brochure. Additionally, the medical team will attend an educational session about gabapentinoid prescription.
62540584|NCT02051062|EXPERIMENTAL|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration, but within a maximum of 32 hours after administration.
62540585|NCT00856375|EXPERIMENTAL|NKTR-102|NKTR-102 IV every 3 weeks
62540586|NCT00856375|ACTIVE_COMPARATOR|irinotecan|irinotecan IV every 3 weeks
62540587|NCT05686226|EXPERIMENTAL|E7 TCR-T cells|Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.
62540588|NCT02851693|EXPERIMENTAL|Optical Coherence Tomography (OCT)|
62540589|NCT04665466||Group A|QFR≤0.80 vessels with PCI strategy and low PPG index
62540590|NCT04665466||Group B|QFR≤0.80 vessels with PCI strategy and high PPG index
62540591|NCT04665466||Group C|QFR≤0.80 vessels with conservative strategy
62540592|NCT06378398|EXPERIMENTAL|Intervention|Two 20 mg/day omeprazole tablets and two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
62540593|NCT06634082||O-TEP Symphysial Plating Cohort|This cohort consists of 15 patients with pubic symphysis diastasis (PSD) who underwent total extraperitoneal endoscopic symphysial plating (O-TEP) between March 2022 and May 2024. The interventions include a minimally invasive plating procedure aimed at evaluating clinical outcomes, such as postoperative pain, functional recovery, and complications
62164698|NCT05979987|EXPERIMENTAL|Anecdote-based Reminder without link|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
62540594|NCT00577395|EXPERIMENTAL|2|one 150 mg risedronate once a month, orally
62164699|NCT05979987|EXPERIMENTAL|Research-based Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will mention that research has shown promptly closing health gaps saves lives. The message will contain a link to an official website that supports the statement.
62164700|NCT05401149||IV rt-PA cohort|Acute Ischaemic Stroke (AIS) patients aged \> 80 years who received intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) (Alteplase) within 4.5 hours of symptom onset
62540595|NCT00577395|PLACEBO_COMPARATOR|1|Placebo tablet once a month, orally
62540596|NCT03071939|OTHER|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
62540597|NCT04049136||Healthy pregnant women with BMI <30|
62540598|NCT04049136||Healthy pregnant women with BMI >=30|
62540599|NCT01769560|NO_INTERVENTION|Centers for Disease Control and Prevention (CDC) Fact Sheet|Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
62540600|NCT01769560|EXPERIMENTAL|MeFirst Intervention|Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
62540601|NCT03674255||1|Participants in group 1 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained, in addition to venous blood samples obtained from the cannula inserted as part of the standard clinical procedure. These blood samples will be collected before and after the stress echocardiogram. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
62540602|NCT03674255||2|Participants in group 2 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
62540603|NCT03674255||3|Participants in group 3 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
62540604|NCT03674255||4|Participants in group 4 will be recruited at their stress echocardiogram appointment, regardless of the type of investigation. A simplified data set and an anonymised version of the stress echocardiography report will be collected as a part of this registry phase. Participants will be followed up over a 10-year period.
62715172|NCT06717009|NO_INTERVENTION|Conventional group|The patients will not undergo preoperative 3D reconstruction. The surgeon will arrange robot-assisted laparoscopic nephron sparing surgery according to routine CT/MRI.
62164701|NCT05401149||Non-reperfusion cohort|Acute Ischaemic Stroke (AIS) patients aged \> 80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatments
62164702|NCT01320514||Fibrin Sealant (Artiss)|
62164703|NCT05800704|EXPERIMENTAL|Nagasin®|consumption of Nagasin® (synbiotic food supplement) once per day for four weeks
62164704|NCT05800704|PLACEBO_COMPARATOR|Comparator|consumption of the comparator (maltodextrin) once per day for four weeks
62164705|NCT00688337||1|Patients with newly diagnosed breast cancer. Clinically nodal negative.
62164706|NCT04547504|ACTIVE_COMPARATOR|Pembrolizumab|Pembrolizumab
62164707|NCT04547504|ACTIVE_COMPARATOR|Chemotherapy-Pembrolizumab|Chemotherapy and Pembrolizumab
62164708|NCT05872906|EXPERIMENTAL|Acupuncture|All subjects will receive acupuncture at LI11, ST36, SP10, SP9, SP6, ST34, BL39, KI10, LIV8, LI10, HT3, SI8, LI4, PC6, HT7, GB34, GB40, KI3, BL2, GB20, LIV3, BL62, KI6, BI57, ST40, KI7 and be recorded with simultaneous ultrasound imaging, external video, and required to fill out sensation sheets. Pulse diagnosis will be taken after de qi is achieved.
62164709|NCT00003934|EXPERIMENTAL|Arm I|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin every 12 hours on days 1-7 and daunorubicin IV on days 1-2 or days 1-3, depending on age. Patients may receive an additional course. Treatment begins no earlier than 2 weeks and no later than 4 weeks after hematopoietic recovery."
62164710|NCT00003934|EXPERIMENTAL|Arm II|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin as in arm I above. Patients also receive oral mercaptopurine once a day and oral methotrexate once weekly for up to 1 year."
62164711|NCT00521807|NO_INTERVENTION|A 1|
62164712|NCT00521807|EXPERIMENTAL|A 2|Treatment group
62164713|NCT01102985|EXPERIMENTAL|aerobic resistance|12 month aerobic resistance exercise at a fitness center
62164714|NCT01102985|ACTIVE_COMPARATOR|home based physical activity|national recommendations for physical activity for adults
62164715|NCT06358040|ACTIVE_COMPARATOR|Standard Opioid Pill Bottle with App|
62164716|NCT06358040|EXPERIMENTAL|Opioid-Dispensing Device with App|
62164717|NCT05630794|EXPERIMENTAL|Prevention (ONC201, biopsy, sigmoidoscopy, colonoscopy)|Patients receive ONC201 PO QW or Q3W for 12 weeks. Patients also undergo collection of blood, tissue biopsy, and sigmoidoscopy/colonoscopy throughout the study.
62164718|NCT03521076|EXPERIMENTAL|Virtual Reality for distraction|The application of VR during the putative painful treatment (botulinum toxin injections) will provide a) active and engaging distraction during the procedure, and will b) block the view and auditory noise related to the procedure.
62164719|NCT03521076|NO_INTERVENTION|Standard of Care|Patients will receive the standard of care for the putative painful treatment (botulinum toxin injections).
62164720|NCT00437086|EXPERIMENTAL|PS-341|Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
62164721|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
62164722|NCT05340426|EXPERIMENTAL|Porcine Kidney (UKidney) transplant|In this phase I single arm study patients with acute renal failure will be transplanted with a porcine xenograft versus a human allograft-after transplantation the best practice standard of care will be followed for monitoring and immunosuppression with the exception of additional monitoring for potential porcine transmitted infections
62164723|NCT05415644|EXPERIMENTAL|Bioequivalence study part|
62540605|NCT01873183|EXPERIMENTAL|The IGDT group|"30 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will be consecutively enrolled for the study.~The individualized goal-directed therapy (IGDT) with focus on level of venous return will be implemented in two steps in the intervention group. First, preoperative optimizing of venous return will be performed 45 minutes before surgery in a preoperative room with TTE. Second, after induction of anaesthesia perioperative fluid therapy will be implemented by utilizing the FloTrac-device."
62540606|NCT01873183|NO_INTERVENTION|The control group|20 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will consecutively be enrolled for the study. Conventional monitoring will be conducted perioperatively.
62540607|NCT04234932|EXPERIMENTAL|Netarsudil alone|Topical application of netarsudil 0.02%
62540608|NCT04234932|ACTIVE_COMPARATOR|Netarsudil plus latanoprost|Topical application of netarsudil 0.02% with latanoprost 0.005%
61977719|NCT05575167||ALN group|postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive alendronate 70mg orally weekly for 12 months
61977720|NCT02066974||Hepatoma, Circulating tumor genome|Hepatoma requiring radiotherapy
61977721|NCT00502177||Quality of Life Questionnaire|Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their parents/caregivers.
61977722|NCT01430156|ACTIVE_COMPARATOR|Heme arginate (Normosang)|This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
61977723|NCT01430156|PLACEBO_COMPARATOR|0.9% saline|The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.
61977733|NCT02716064|EXPERIMENTAL|TAP-CM Intervention|Patients in this arm will be encouraged to complete the Healthy Lifestyle App modules and use McMaster PHR to self manage their chronic disease. Participants will also be completing the health and life goals using the App. The TAPESTRY-CM reports generated will then be reviewed by the clinic huddle teams
61977734|NCT04683536||control group|Patients underwent TUR-BT under spinal anesthesia
62540609|NCT00613886|EXPERIMENTAL|Comparison for patients of lumbar drain and shunt surgery|"Subjective comparisons made for patients - before and after external lumbar drain, before and after shunt surgery.~Device: Programmable Shunt Insertion (Codman Medtronic)~Behavioral: Assessments in physical therapy, occupational therapy, and speech therapy~Follow-up testing to be administered by trained physician assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, mini-mental status exam, 9-hole grooved pegboard, motor visual perception test (MVPT), modified rankin score (MRS)"
62540610|NCT03552068|PLACEBO_COMPARATOR|Patients under placebo|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
62540611|NCT03552068|ACTIVE_COMPARATOR|Patient under clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
62540612|NCT02064985|EXPERIMENTAL|Ticagrelor 45mg|A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
62540613|NCT02064985|EXPERIMENTAL|Ticagrelor 60mg|A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
62540614|NCT02064985|EXPERIMENTAL|Ticagrelor 90mg|A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
62540615|NCT00587028||Oral Omnipaque MCA|Ten participant minimum: for stool tagging two days preceding the CT colonography, if applicable, with oral Omnipaque. This cohort at Scottsdale Mayo Clinic only.
62540616|NCT00587028||IV Iodine MCR|Ten participant minimum: for intravenous iodine contrast dye. This cohort at Rochester Mayo Clinic only.
62540617|NCT00587028||NO oral and no IV MCR|Five participant minimum for no oral or IV contrast.
62540618|NCT00587028||Replacement Group|Five participant minimum for either cohorts 1, 2, or 3 as above should there be poor imaging results. A like prepped participant will replace that who had poor quality imaging to meet 25 imaging data sets.
62540619|NCT03115216|ACTIVE_COMPARATOR|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
62540620|NCT03115216|ACTIVE_COMPARATOR|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
62164724|NCT05415644|EXPERIMENTAL|Food impact study part|
62164725|NCT06385288|OTHER|Single-arm trial|Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
62540621|NCT03904589||Coronary Heart Disease|
62540622|NCT00519688|EXPERIMENTAL|Thalidomide plus Tegafur/Uracil1|Thalidomide plus Tegafur/Uracil
62540623|NCT04854889|EXPERIMENTAL|Decitabine|Subjects will receive low-dose decitabine for 4 cycles and for another 6 cycles in extension study for patients achieving response during the first 4 cycles.
62540624|NCT05256719|EXPERIMENTAL|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg single dose usage
62540625|NCT05256719|EXPERIMENTAL|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg single dose usage
62540626|NCT05256719|EXPERIMENTAL|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg single dose usage
62540627|NCT05256719|EXPERIMENTAL|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg single dose usage
62164726|NCT02684942|ACTIVE_COMPARATOR|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
62167988|NCT03635047|ACTIVE_COMPARATOR|AL002|AL002 by intravenous (IV) infusion
62167989|NCT03635047|PLACEBO_COMPARATOR|Saline Solution|placebo by intravenous (IV) infusion
62540628|NCT05256719|EXPERIMENTAL|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg single dose usage
62540629|NCT05256719|PLACEBO_COMPARATOR|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
62540630|NCT05256719|PLACEBO_COMPARATOR|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg, i.v. single dose usage.
62540631|NCT05256719|PLACEBO_COMPARATOR|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
62540632|NCT05256719|PLACEBO_COMPARATOR|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
62540633|NCT05256719|PLACEBO_COMPARATOR|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
62540634|NCT02669030|EXPERIMENTAL|Suvorexant|suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment
62540635|NCT02669030|PLACEBO_COMPARATOR|Placebo|no augmentation of FDA-approved antidepressant treatment
62540636|NCT02437435|EXPERIMENTAL|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
62540637|NCT02437435|PLACEBO_COMPARATOR|Placebo Intervention|The researcher puts his right hand on the right shoulder of the patient for 20 times Metronome.
62715173|NCT02530268||Ankylosing Spondylitis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
62540638|NCT01822366|NO_INTERVENTION|Usual Care Comparison Condition|Half of the participating children/guardian dyads will receive no intervention (usual care) to serve as a control.
62540639|NCT01822366|EXPERIMENTAL|Trauma-focused CBT group therapy|Half of the participating children/guardian dyads will receive the 12-week Trauma-focused Cognitive Behavioral Therapy (TF-CBT) group treatment.
62540640|NCT00591981||Primary|All patients 70 years old and above scheduled for a thoracic oncologic surgery (typically esophageal or lung cancer) will be approached for entry into this study
62540641|NCT01609712||Patient with vertebral compression fracture|RF kyphoplasty is standard of care in our hospital for patients with osteoporortic compression fractures. We are intersetd, if it also can improve the lung function.
62540642|NCT05612672|EXPERIMENTAL|GeoHAI Use|Participants will use the GeoHAI tool
62540643|NCT00656266|PLACEBO_COMPARATOR|tacrolimus & corticosteroids|Standard post-transplant immunosuppression medications: tacrolimus and corticosteroids
62540644|NCT00656266|EXPERIMENTAL|low-dose tacrolimus + steroids + MMF|Comparison arm: low-dose tacrolimus + steroids + MMF
62540645|NCT05667675|EXPERIMENTAL|Community Support Worker|Participants in the intervention group will have a structured review of their financially related needs and resources with a trained CSW, who will have a thorough understanding of potential income supports and community support agencies. The CSW will use a structured approach to identify financial needs and benefits for which the family is eligible The CSW will work intensively with families in the intervention arm to identify and meet their goals. They will conduct weekly meetings to complete forms, and provide advocacy (in person and by telephone) as needed up to six meetings as needed for system navigation.
62540646|NCT05667675|ACTIVE_COMPARATOR|Control|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. For this proposal, participants in the comparator group will receive Usual care, defined as: Participants in both groups will receive a written summary of available resources.
62540647|NCT02525237|EXPERIMENTAL|Apatinib plus S-1|Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
62540648|NCT03854682|EXPERIMENTAL|Surgical|Radiofrequency microtenotomy (RF): A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
62540649|NCT03854682|ACTIVE_COMPARATOR|Non-surgical|Strength training: Consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
62540650|NCT02474056||trauma patients|patients with decreased blood volume
62540651|NCT02474056||surgical patients|patients with decreased blood volume
62540652|NCT02474056||non surgical patients|patients with decreased blood voloume
62540653|NCT05908292|EXPERIMENTAL|Episiotomy and Vaginal/Perineal Tear Self-Scar Massage|This Arm will be instructed in and perform self-scar massage to their pelvic floor scar tissue.
62540654|NCT05908292|NO_INTERVENTION|Standard Postnatal Care|This Arm will not be instructed in or perform self-scar massage to their pelvic floor scar tissue.
61977735|NCT04683536||Study group|Patients underwent TUR-BT under spinal anesthesia combined with ultrasound guided obturator nerve blockade
62540655|NCT00338455|EXPERIMENTAL|001|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
62540656|NCT00338455|PLACEBO_COMPARATOR|002|Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
62540657|NCT04798131|EXPERIMENTAL|Active|The visual feedback will correspond to instructions, adapted to the current hallucinatory state and decoded online from the fMRI signal.
62540658|NCT04798131|SHAM_COMPARATOR|Sham|The visual feedback will correspond to random instructions independently of the fMRI signal.
62540659|NCT05597748|ACTIVE_COMPARATOR|Class II type A malocclusion - proclination of upper incisors indicated - No TADs|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
62540660|NCT05597748|ACTIVE_COMPARATOR|Class II type B malocclusion - proclination of upper incisors not indicated - No TADs|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
62540661|NCT05597748|EXPERIMENTAL|Class II type A malocclusion - proclination of upper incisors indicated - TADs|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
62167990|NCT05770193|EXPERIMENTAL|pursed lip breathing and CBT in addition to kinesio tape.|patients will receive pursed lip breathing and cognitive-behavioral therapy in addition to kinesio tape.
62540662|NCT05597748|EXPERIMENTAL|Class II type B malocclusion - proclination of upper incisors not indicated - TADs|CA modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines.
62540663|NCT05443568||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
62540664|NCT06633458||Study group (observation only)|Adolescent inpatients at the child and adolescent psychiatry, age 14-17 years.
62540665|NCT05076019|EXPERIMENTAL|Atorvastatin 80 mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
62540666|NCT05076019|PLACEBO_COMPARATOR|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
62540667|NCT01384955||exercise|subjects diagnosed and treated in the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between 1983 and 1994, with scoliosis - specific exercise program
62540668|NCT01384955||control|age and condition - matched subjects, who were diagnosed at the same time, in the same clinic, and by the same physician, and prescribed the same method of physiotherapy, but did not start the exercise treatment
62540669|NCT02002286|EXPERIMENTAL|TwHF extract + cART|Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
62540670|NCT02002286|OTHER|cART control|Continue current cART regimen
62540671|NCT00644852||001|
62540672|NCT02112487|EXPERIMENTAL|Macitentan|10 mg once daily
62540673|NCT06552156|PLACEBO_COMPARATOR|Placebo|The intervention was delivered through three daily brownies. These were 'plain' brownies without any further addition next to the basic ingredients.
62540674|NCT06552156|EXPERIMENTAL|Carrageenan|Brownies that contained k-CGN (375 mg daily, Modernist Pantry, Eliot, ME, USA)
62540675|NCT06552156|EXPERIMENTAL|Carboxymethyl Cellulose (CMC)|Brownies that contained carboxymethyl cellulose (2.75 g daily, Modernist Pantry, Eliot, ME, USA)
62540676|NCT06552156|EXPERIMENTAL|Polysorbate-80 (P80)|Brownies that contained polysorbate-80 (1.350 mg daily, Sigma-Aldrich, Darmstad, Germany)
62540677|NCT06552156|EXPERIMENTAL|Soy Lecithin|Brownies that contained soy lecithin (3.55 g daily, Modernist Pantry, Eliot, ME, USA)
62540678|NCT06552156|EXPERIMENTAL|Native Rice Starch|Brownies that contained native rice starch (8.72 g daily, Remy B7, BENEO-Remy N.V., Wijgmaal-Leuven, Belgium)
62540679|NCT03279692|EXPERIMENTAL|Pembrolizumab|"* Pembrolizumab will be administered every 3 weeks~* Pembrolizumab will be administered through IV infusion"
62167991|NCT05770193|EXPERIMENTAL|pursed lip breathing and CBT in addition to diaphragmatic breathing exercise.|patients will receive pursed lip breathing and cognitive-behavioral therapy in addition to diaphragmatic breathing exercise
62167992|NCT05770193|ACTIVE_COMPARATOR|pursed lip breathing and CBT.|patients will receive pursed lip breathing and cognitive-behavioral therapy.
62540680|NCT03456453|EXPERIMENTAL|NIDA Standard via Facebook|Participants will receive the NIDA Standard via Facebook
62540681|NCT03456453|NO_INTERVENTION|Re-entry services as usual|Participants will receive standard re-entry services available in the community and through the criminal justice system
62540682|NCT04462887|EXPERIMENTAL|Nursing intervention program|The nursing intervention program consisting of 3 parts: (1) Structural Informational (SI) booklet, (2) Nursing Telephone Support (NTS) protocol, and (3) Nurse Pager 24/7.
62540683|NCT04462887|NO_INTERVENTION|Usual Care Group|Usual care participants received treatment as usual from their health care providers.
62540684|NCT01547130|ACTIVE_COMPARATOR|BLS and Yoga exercise|Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
61976437|NCT05728307||Comparison Group|The comparison group consists patients admitted 4 subunits where neoGuard was not installed: the neonatal intensive care unit (NICU), the KMC/category C room, the isolation room and the stable full-term room. These subunits will receive the standard-of-care/current practice, which consists of either a bedside cardiac monitor or intermittent monitoring every 3 hours using manual equipment such as hand-held pulse oximeters for pulse rate and oxygen saturation, digital axillary thermometers for temperature, and manual counting of breaths for respiratory rate.
61976438|NCT02240199|EXPERIMENTAL|Pregabalin/Lidocaine|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Infusion
62540685|NCT01547130|ACTIVE_COMPARATOR|PEG (HalfLytely)|Patients followed the preparation method according to the manufacturer's standard instructions.
62540686|NCT03671616|EXPERIMENTAL|IPV-Al SSI|Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination
62540687|NCT04792762|EXPERIMENTAL|GIP(1-42)|
62540688|NCT04792762|EXPERIMENTAL|GIP(1-30)NH2|
62167993|NCT05835037|EXPERIMENTAL|Zinc treatment|Research subjects administered zinc gluconate for 1 year (one 30 mg tablet per day)
62167994|NCT05835037|PLACEBO_COMPARATOR|Placebo|Research subjects administered placebo for 1 year (1 tablet per day)
62167995|NCT03771534|EXPERIMENTAL|Oxygen gas|10-15 L/min of oxygen by face mask for up to 45 minutes for the MRI and up to 30 minutes for the echocardiogram.
62167996|NCT06315647|ACTIVE_COMPARATOR|Patients enrolled for double guide wire technique.|
62167997|NCT06315647|ACTIVE_COMPARATOR|Patients enrolled for trans - pancreatic sphincterotomy technique.|
62167998|NCT06315647|ACTIVE_COMPARATOR|Patients enrolled for needle knife precut technique or fistulotomy technique.|
62540689|NCT04792762|PLACEBO_COMPARATOR|Placebo|
62540690|NCT01667835|EXPERIMENTAL|Yoga Intervention|
62540691|NCT01667835|NO_INTERVENTION|Control|
62540692|NCT04504123|EXPERIMENTAL|Doxycycline|Participants received doxycycline hyclate 50 mg capsule orally once a day for 6 months
62540693|NCT04504123|PLACEBO_COMPARATOR|Placebo|Participants received placebo (inactive) capsule orally once a day for 6 months
62540694|NCT03831165|EXPERIMENTAL|melatonin 3mg + Acyclovir 400mg|Group I - melatonin 3mg + Acyclovir 400mg
62540695|NCT03831165|ACTIVE_COMPARATOR|Acyclovir 400mg|Group II - Acyclovir 400mg twice a day
62540696|NCT03831165|PLACEBO_COMPARATOR|placebo + melatonin 3mg|Group III - placebo + melatonin 3mg
62540697|NCT01450527||Patient fulfilling the criteria of ARDS|
62540698|NCT01121848|ACTIVE_COMPARATOR|5-FU & LV|"* Day 1: LV 400 mg/m2 (given as a 2-hour infusion)~* Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.~* This chemotherapy regimen will be administered each two weeks."
62540699|NCT01121848|EXPERIMENTAL|XELOX or modified FOLFOX-6|"XELOX:~* Day 1: Oxaliplatin 130 mg/m2 (2 hours infusion)~* This chemotherapy regimen will be administered each two weeks.~OR modified FOLFOX-6:~* Day 1: Oxaliplatin 85 mg/m2 (given as a 2-hour infusion)~* Day 1: LV 400 mg/m2 (given as a 2-hour infusion simultaneous to oxaliplatin)~* Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours (Day 1 and 2)~* This chemotherapy regimen will be administered each two weeks."
62540700|NCT02244814|EXPERIMENTAL|Choosing Healthy Options in Carbohydrate Energy|60% carbohydrate/25% fat/15% protein diet
62540701|NCT02244814|ACTIVE_COMPARATOR|Low Carbohydrate/Conventional|40% carbohydrate/45% fat/15% protein
62540702|NCT02849938|NO_INTERVENTION|Control Group|Usual care
62540703|NCT02849938|EXPERIMENTAL|Telemedicine Group|TytoCare Device
62540704|NCT01663883|EXPERIMENTAL|Healthy subjects|
62540705|NCT04473066||Adenotonsillectomy (AT)|Children diagnosed with moderate-to-severe OSA (OAHI ≥3/h) and tonsillar hypertrophy (tonsil grade ≥2) at the age of 5-12 years old and underwent AT since 2012.
62540706|NCT04473066||Refused AT|Children diagnosed with moderate-to-severe OSA and tonsillar hypertrophy but refused AT in the same period.
62540707|NCT04473066||Normal control|Children reported to have no habitual snoring (less than 3 nights per week) and confirmed to have no OSA (OAHI \<1/h) by overnight sleep study in the same period.
62540708|NCT06108076|EXPERIMENTAL|Ketone Ester administration|"1. Monitored administration of oral Ketone monoester at 400mg/kg dosed twice on visit 2 (cardiac MRI day)~2. Self administered oral β-hydroxybutyrate (BOHB) at 400mg/kg/day for a period of 6 days"
62540709|NCT05816538|ACTIVE_COMPARATOR|Group 1 PVB|Group 1 will receive paravertebral block (PVB) as analgesia for breast surgery. PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
62540710|NCT05816538|EXPERIMENTAL|Group 2 PECS|Group 2 will receive Pectoralis and Serratus Plane Nerve blocks (PECS 2) as analgesia for breast surgery. PECS 2 block is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
62540711|NCT01892280|EXPERIMENTAL|Teenwork Group|Teen/family will receive the Teenwork intervention at each quarterly study visit.
62540712|NCT01892280|EXPERIMENTAL|Teenwork/Text Message Group|Teen/family will receive the Teenwork intervention at each quarterly study visit. Teen will receive text message reminders to check blood glucose levels at self-selected times.
62540713|NCT01892280|EXPERIMENTAL|Text Message Group|Teen will receive text message reminders to check blood glucose levels at self-selected times.
62540714|NCT01892280|NO_INTERVENTION|Usual Care Group|Teen/family will receive routine clinical care for the first year of the study (the time period for assessment of primary outcomes). After year 1, teen/family will receive the Teenwork intervention at each remaining study visit and teen will receive text message reminders to check blood glucose levels at self-selected times.
62540715|NCT05965973|EXPERIMENTAL|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
62540716|NCT05965973|EXPERIMENTAL|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
62540717|NCT04819334|PLACEBO_COMPARATOR|Commercially Available Sports Drink A|A commercially available flavored electrolyte solution, The Coca-Cola Company
62540718|NCT04819334|EXPERIMENTAL|Commercially Available Sports Drink B|A commercially available flavored electrolyte solution, PepsiCo
62540719|NCT04819334|EXPERIMENTAL|Commercially Available Sports Drink A with added Amino Acids|he same as sports drink A above (a commercially available flavored electrolyte solution, The Coca-Cola Company), but with the addition of a small amount of amino acids (\~2.6 g/100 ml).
62540720|NCT05365724|EXPERIMENTAL|subjects aged 18-59 years old|
62540721|NCT05365724|EXPERIMENTAL|subjects aged 60 years old and above|
62540722|NCT05395286|EXPERIMENTAL|Innovation Lab Group|Randomized to attend the Innovation Lab
62540723|NCT05395286|NO_INTERVENTION|Control Group|Randomized to NOT attend the Innovation Lab
62540724|NCT04421300|EXPERIMENTAL|smile exercise|smile exercise, 4 times a day，8 weeks
62540725|NCT04421300|ACTIVE_COMPARATOR|0.1% Sodium Hyaluronate Eye Drops|0.1% sodium hyaluronate, 4 times a day, 8 weeks.
62540726|NCT00561418|EXPERIMENTAL|Vorinostat (SAHA)|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.
62540727|NCT05142397||Treated women|HPV positive，pathology result indicate cervical intraepithelial neoplasia
62540728|NCT05142397||Healthy controls|HPV negative, normal cytology
62540729|NCT03715504|EXPERIMENTAL|Single Arm TP-3654|TP-3654 by oral administration
62540730|NCT01747746|ACTIVE_COMPARATOR|Rivaroxaban|Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days
61978101|NCT02415751||self-care education|All patients in the study will receive self-care education
62540731|NCT01747746|OTHER|Warfarin and Enoxaparin|Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
62540732|NCT02227511|ACTIVE_COMPARATOR|fruit|Participants are given +7kCal/kg body weight of fruit to be eaten as snack in between regular meals
62540733|NCT02227511|ACTIVE_COMPARATOR|nuts|Participants are given +7kCal/kg body weight of nuts to be eaten as snack in between regular meals
62540734|NCT03629756|EXPERIMENTAL|Dose Escalation|3+3 design, including a DLT evaluation period. Etrumadenant RP2D will be determined in this part with escalating doses of oral etrumadenant in combination with a fixed dose of IV zimberelimab.
62540735|NCT03629756|EXPERIMENTAL|Dose Expansion-advanced clear-cell RCC|Etrumadenant at RP2D + zimberelimab
62540736|NCT03629756|EXPERIMENTAL|Dose Expansion-mCRPC|Etrumadenant at RP2D + zimberelimab
62540737|NCT02154295|ACTIVE_COMPARATOR|Eagle Eye Platinum|Eagle Eye Platinum Catheter as the comparator.
62540738|NCT02154295|ACTIVE_COMPARATOR|Revolution|Revolution Catheter as the comparator
62540739|NCT02154295|ACTIVE_COMPARATOR|TVC Insight 40MHz|TVC Insight as comparative catheter.
62540740|NCT02154295|ACTIVE_COMPARATOR|Atlantis Pro|Atlantis Pro catheter as comparator
62540741|NCT02187146||ART population|Patients undergoing IVF/ICSI/FET treatment at the Birmingham Womens Fertility Centre 2013-2014
62540742|NCT01014793||Responders to cabergoline|patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
62540743|NCT00428116|NO_INTERVENTION|Interrupted HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
62540744|NCT00428116|ACTIVE_COMPARATOR|Continued HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.
62540745|NCT00985101||diabetes no complications|
62540746|NCT00985101||diabetes with complications|
62540747|NCT03283384|OTHER|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of \<1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
62540748|NCT03283384|ACTIVE_COMPARATOR|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
62540749|NCT03283384|EXPERIMENTAL|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
62540750|NCT06632470|EXPERIMENTAL|Secretome injection|patient will receive secretome injection every two weeks for four months
62540751|NCT06632470|PLACEBO_COMPARATOR|Vitamin B12|patient will receive 1 ampule of vitamin b12 every two weeks for 4 months
62540752|NCT06500611|EXPERIMENTAL|GROUP A (Sensory Integration and Vestibular Exercise with Routine Physical Therapy)|"Sensory Integration Exercise:~Week 1-2~1. Eyes Open Standing for 5 minutes.~2. Sitting position for 5 minutes.~Week 3-4~1. Eyes Closed Standing for 5 minutes.~2. Sit to stand for 5 minutes.~Week 5-6~1. Tandem Walk for 4 minutes.~2. Walk Obstacle Course for 4 minutes.~Vestibular Exercise~Week 1-2~1. Head Movements for 5 minutes~2. Gaze Stabilization for 5 minutes.~Week 3-4~1. Single Leg Stance for 5 minutes.~2. Rotation Exercises for 5 minutes.~Week 5-6~1. Walking Patterns for 4 minutes.~2. Pendulum Exercise for 4 minutes.~3. Catch and Throw for 4 minutes.~Routine Physical Therapy for 20 minutes."
62540753|NCT06500611|EXPERIMENTAL|GROUP B (Vestibular Exercise with Routine Physical Therapy)|"Vestibular Exercise~Week 1-2~1. Head Movements for 10 minutes~2. Gaze Stabilization for 10 minutes.~Week 3-4~1. Single Leg Stance for 10 minutes.~2. Rotation Exercises for 10 minutes.~Week 5-6~1. Walking Patterns for 5 minutes.~2. Pendulum Exercise for 5 minutes.~3. Catch and Throw for 10 minutes.~Routine Physical Therapy for 20 minutes."
62540754|NCT03300843|EXPERIMENTAL|Peptide loaded dendritic cell vaccine|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
62540755|NCT05227963|EXPERIMENTAL|Experimental Group(Group A)|Experimental Group received soft tissue mobilization with neck isometric strengthening exercises.
62540756|NCT05227963|OTHER|Control group (Group B)|Control group received neck isometric strengthening exercises alone.
62540757|NCT00006348|EXPERIMENTAL|Arm 1: ondansetron + placebo|Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.
62540758|NCT00006348|EXPERIMENTAL|Arm 2: ondansetron + placebo|Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.
62540759|NCT03167463|EXPERIMENTAL|choanoplasty with flap|flap surgery
62540760|NCT06634225||Volunteers|Volunteers without pathology
62540761|NCT06634225||Patient with multiple sclerosis|Patient with multiple sclerosis
61976439|NCT02240199|ACTIVE_COMPARATOR|Pregabalin Placebo/Lidocaine|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Infusion
62540762|NCT04778488|OTHER|NIRS diagnostics|NIRS measurement
62540763|NCT01753557|EXPERIMENTAL|Treatment-Naive|
62540764|NCT01753557|EXPERIMENTAL|Treatment-Relapsed|
62540765|NCT05113433|EXPERIMENTAL|group a|15 minute on standing frame .
62540766|NCT05113433|EXPERIMENTAL|group b|30 minute on standing frame .
62540767|NCT05113433|EXPERIMENTAL|group c|45 minute on standing frame.
62540768|NCT05113433|EXPERIMENTAL|group d|60 minute on standing frame.
62540769|NCT04974203|EXPERIMENTAL|CT Value <25|Patients with CT value \<25
62540770|NCT04974203|EXPERIMENTAL|CT Value 25+|Patients with CT value of 25 or higher
62540771|NCT04974203|EXPERIMENTAL|Negative|Patients with negative PCR test result
62540772|NCT04484259|EXPERIMENTAL|Ticagrelor|ticagrelor 60 mg bid monotherapy
61393485|NCT05840419||Airseal group (A)|Patients operated with Airseal
61393486|NCT05840419||Standard group (S)|Patients operated with standard insufflation
62540773|NCT04484259|ACTIVE_COMPARATOR|Aspirin plus Clopidogrel|aspirin 81 mg qd plus clopidogrel 75 mg qd
62540774|NCT04484259|ACTIVE_COMPARATOR|Aspirin plus Ticagrelor|aspirin 81 mg qd plus ticagrelor 60 mg bid
62540775|NCT04546880|EXPERIMENTAL|Group 1:Breathing and Stabilization Exercise Group|Breathing exercises combined with stabilization exercises
62540776|NCT04546880|ACTIVE_COMPARATOR|Group 2: Stabilization Exercise Group|Only Stabilization exercises therapy
62540777|NCT04635527|EXPERIMENTAL|IBI318 combined with conventional TACE (cTACE)|
62540778|NCT04635527|PLACEBO_COMPARATOR|Placebo combined with conventional TACE (cTACE)|
61976440|NCT02240199|ACTIVE_COMPARATOR|Pregabalin/Lidocaine Placebo|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Placebo Infusion
62540779|NCT02810379|PLACEBO_COMPARATOR|written informed consent|participants read the written informed consent documents befor ERCP
62540780|NCT02810379|EXPERIMENTAL|video+written informed consent|participants watch a video about the ERCP and read the written informed consent documents before ERCP
62540781|NCT02365116|EXPERIMENTAL|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will include components such as hope and belongingness.
62540782|NCT02365116|ACTIVE_COMPARATOR|Enhanced Usual Care|Patients will continue to receive usual care which typically consists of referral to an outpatient psychiatrist. Participants will also receive a phone call within 24-72 hours from a member of the inpatient unit clinical staff to assess barriers to follow-up care and safety. The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
62540783|NCT04482673|EXPERIMENTAL|COVID-19 Negative Active Treatment|Participants will be randomized to vitamin D3 (6000 IU) per day for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
62540784|NCT04482673|PLACEBO_COMPARATOR|COVID-19 Negative Placebo|Participants in this arm would receive placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
62540785|NCT04482673|EXPERIMENTAL|COVID-19 Positive Active Treatment|Participants will be randomized to vitamin D3 as a bolus (20,000 IU) per day for 3 days followed by high dose vitamin D (6000 IU) per dayfor 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
62540786|NCT04482673|PLACEBO_COMPARATOR|COVID-19 Positive Placebo|Participants in this arm would receive placebo as a bolus followed by daily placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
62540787|NCT01279720|EXPERIMENTAL|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
62540788|NCT03957070|EXPERIMENTAL|Liver Incyte|Patients with successfully treated HCV, or NASH Healthy volunteers with no history of liver disease. Patients and Volunteers will be scanned with FibroScan and Liver Incyte.
62540789|NCT04880473|EXPERIMENTAL|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
62540790|NCT06354452||Patients with a diagnosis of sepsis|All patients with a diagnosis of sepsis admitted to the hospitals of the public hospital network of Catalonia, Spain, were included.
62540791|NCT04279236||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and an additional follow-up visit after surgery.
62540792|NCT00912613|NO_INTERVENTION|Discussion with nurse|Brief discussion with ICU follow-up nurse about the patients' critical illness
62540793|NCT00912613|EXPERIMENTAL|ICU Diary|Receipt of ICU Diary at 1 month post critical illness
62540794|NCT03597464|EXPERIMENTAL|Voclosporin|Voclosporin
62540795|NCT03597464|PLACEBO_COMPARATOR|Placebo Oral Capsule|Placebo
62540796|NCT05422625|ACTIVE_COMPARATOR|Active PTNS|Once a week induction consisting of active PTNS treatments for 30 minutes for 12 consecutive weeks.
62540797|NCT05422625|PLACEBO_COMPARATOR|Sham PTNS|Once a week induction consisting of Sham PTNS treatments for 30 minutes for 12 consecutive weeks.
62540798|NCT05296135||Main Cohort|
62540799|NCT01192867|EXPERIMENTAL|RO4917838 20 milligrams (mg)|Participants, on stable antipsychotics, will receive RO4917838 orally at 20 mg once daily (QD) up to 56 weeks followed by an optional treatment extension for up to 3 years.
62540800|NCT01192867|EXPERIMENTAL|RO4917838 10 mg|Participants, on stable antipsychotics, will receive RO4917838 orally at 10 mg QD up to 56 weeks followed by an optional treatment extension for up to 3 years.
61976441|NCT02240199|PLACEBO_COMPARATOR|Pregabalin Placebo/Lidocaine Placebo|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Placebo Infusion
62540801|NCT01192867|PLACEBO_COMPARATOR|Placebo|Participants, on stable antipsychotics, will receive RO4917838 matching placebo orally QD up to 56 weeks.
62540802|NCT02437903|OTHER|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
62540803|NCT02593253|EXPERIMENTAL|Intervention Audit and Feedback Bundle|Access to the electronic dashboard and weekly feedback rounds
61976442|NCT04040478||Abdominal|80 patients undergoing surgery for abdominal cancer. Data review for interim analysis will be conducted after the participation of 40 patients to evaluate the requirement for further enrollment.
61976443|NCT04040478||Vascular|20 patients undergoing femoral endarterectomy.
62540804|NCT02593253|ACTIVE_COMPARATOR|Bi-weekly audit and feedback emails|Access to biweekly feedback emails with performance on selected quality measures (current practice).
62540805|NCT02863055|EXPERIMENTAL|Nintedanib|200 mg twice a day per os
62540806|NCT02863055|PLACEBO_COMPARATOR|Placebo|Placebo match twice a day per os
62540807|NCT04648696|ACTIVE_COMPARATOR|continuous infusions (CI) group|CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge
62540808|NCT04648696|ACTIVE_COMPARATOR|Intermittent infusion (II) group|Inpatient study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
62540809|NCT04622319|EXPERIMENTAL|Trastuzumab deruxtecan (T-DXd)|Participants who will be randomized to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg.
62540810|NCT04622319|ACTIVE_COMPARATOR|Trastuzumab ematansine (T-DM1)|Participants who will be randomized to receive trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.
62715174|NCT02530268||Psoriatic Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
62540811|NCT02996487|PLACEBO_COMPARATOR|Placebo|Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.
62540812|NCT02996487|ACTIVE_COMPARATOR|vancomycin|Vancomycin 125 mg by mouth every 6 hours
62540813|NCT05946616|EXPERIMENTAL|Active non-invasive brain stimulation during behavioral memory interference|Non-invasive brain stimulation with transcranial alternating current stimulation will be applied during a memory interference intervention.
62540814|NCT05946616|SHAM_COMPARATOR|Sham stimulation during behavioral memory interference|Inactive (sham) stimulation will be applied during a memory interference intervention.
62540815|NCT06353542|EXPERIMENTAL|AI software examination (A)|In arm A, the visual acuity, refraction status and the ancillary tests will be performed. The obtained optic disc retinography will be analyzed by the AI software to determine whether the patient was a glaucomatous, suspect or healthy patient.
62540816|NCT06353542|ACTIVE_COMPARATOR|Ophthalmic examination (B)|In arm B, the visual acuity, refraction status and the ancillary tests will be performed, and then the patients (and the test) will be examined by a glaucoma specialist who will determine the status of the patient (glaucomatous, suspect or healthy).
62540817|NCT03939715|ACTIVE_COMPARATOR|DermaPure|
62540818|NCT03939715|ACTIVE_COMPARATOR|Native Tissue|
62540819|NCT03585634|OTHER|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
62540820|NCT03200912|ACTIVE_COMPARATOR|Picato|Picato® (ingenol mebutate) gel, 0.15% (Leo Pharma Inc.) \[Reference Listed Drug (RLD)\]
62540821|NCT03200912|EXPERIMENTAL|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.15% \[Test\]
62540822|NCT03200912|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle gel of the test product
62540823|NCT06632223|EXPERIMENTAL|Sensory-motor training group|This group will include 35 patients with foot burns. Patients will receive sensorimotor training exercise in addition to a traditional physical therapy program in the form of stretching exercises, strengthening exercises and scar management. Exercises will be applied for 3 times a week for 8 consecutive weeks.
62540824|NCT06632223|ACTIVE_COMPARATOR|Traditional physical therapy group|This group will include 35 patients with foot burns. Patients will receive the traditional physical therapy program only in the form of stretching exercises, strengthening exercises and scar management. Exercises will be applied for 3 times a week for 8 consecutive weeks.
61976444|NCT03120819|ACTIVE_COMPARATOR|Oncologist Recommendation only|Medical providers in this study provide a standardized brief recommendation for exercise to a consenting patient during a clinical visit. Patients randomized to this arm receive a packet that contained a study information sheet and standard published exercise information materials. The standard materials consisted of publicly available exercise recommendations for cancer survivors from the American Cancer Society (ACS). The packet of exercise information intended to represent general information about exercise and cancer that would be readily available to patients through the internet, a medical clinic, or cancer support services.
62540825|NCT02935621|EXPERIMENTAL|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
62540826|NCT02935621|ACTIVE_COMPARATOR|Support Group|Participants will attend a support group weekly for eight weeks.
62540827|NCT02103504|OTHER|DePuy Attune TKA|DePuy Attune posterior stabilized fixed bearing total knee replacement
62540828|NCT05260580|EXPERIMENTAL|Two-hour sessions per week for 18 weeks|The classroom learning of study subjects and clinical care experience of in-service students are both very important in this intervention course. The teaching method will primarily focus on empowerment strategies, with support from the school's digital action learning platform for teaching-related activities.
62540829|NCT01269931||Group 1 (EBUS-TBNA simulator training)|Group 1 (EBUS-TBNA simulator training): pulmonary medicine trainees with \>30 bronchoscopy procedures experience, \>nine months of pulmonary fellowship training and no clinical EBUS-TBNA experience (n=4).
62540830|NCT01269931||Group 2 (Clinical EBUS-TBNA training)|Group 2 (Clinical EBUS-TBNA training): pulmonary medicine trainees in the 2nd half of their final year of pulmonary training or recent graduates (within one year), with \>50 bronchoscopy procedures experience who completed a one-month elective with the Interventional Pulmonary Medicine (IPM) service with ≥15 and ≤25 EBUS-TBNA procedures experience (n=4).
62540831|NCT04667286|EXPERIMENTAL|Oxygen and Prone Position (PP)|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96% plus PP for a minimum of 10 hrs a day
62540832|NCT04667286|ACTIVE_COMPARATOR|Oxygen|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96%
62540833|NCT01548118|EXPERIMENTAL|Adult Group 1, HPV vaccine 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
62540834|NCT01548118|PLACEBO_COMPARATOR|Adult Group 1, Placebo 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
62540835|NCT01548118|EXPERIMENTAL|Adult Group 2, HPV vaccine 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
62540836|NCT01548118|PLACEBO_COMPARATOR|Adult Group 2, Placebo 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
62540837|NCT01548118|EXPERIMENTAL|Children Group 1, HPV vaccine 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
62540838|NCT01548118|PLACEBO_COMPARATOR|Children Group 1, Placebo 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
62540839|NCT01548118|EXPERIMENTAL|Children Group 2, HPV vaccine 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
62540840|NCT01548118|PLACEBO_COMPARATOR|Children Group 2, Placebo 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
61978102|NCT01337947||exercise training|12 weeks of exercise treatment/program for DM1 subjects
62540841|NCT03244683|OTHER|Intervention|Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
62540842|NCT03244683|OTHER|Nutrition Counseling alone|Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.
62715175|NCT06719128|EXPERIMENTAL|Olomorasib (Mild Hepatic Impairment)|Olomorasib administered orally.
61978103|NCT02773355||Saxenda®|
62164727|NCT02684942|ACTIVE_COMPARATOR|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
62164728|NCT02684942|ACTIVE_COMPARATOR|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
62540843|NCT01069874|PLACEBO_COMPARATOR|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
62164729|NCT02684942|ACTIVE_COMPARATOR|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
62540844|NCT01069874|ACTIVE_COMPARATOR|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
62540845|NCT06633276||Nanopore sequencing|All adult patients at with suspected diagnosis of breast cancer undergoing biopsy or surgical resection will be offered to participate in the study. After informed written consent excess tissue is preserved for DNA extraction using commercial spin column kits and will be further analyzed.
62540846|NCT06634290|EXPERIMENTAL|Cemented|Patients diagnosed of pertrochanteric hip fracture treated with intramedullary nailing WITH cephalic augmentation using bone cement
62540847|NCT06634290|ACTIVE_COMPARATOR|Not Cemented|Patients diagnosed of pertrochanteric hip fracture treated with intramedullary nailing WITHOUT cephalic augmentation
62540848|NCT00754715|EXPERIMENTAL|AZD2516|
62540849|NCT00754715|PLACEBO_COMPARATOR|Placebo|
62540850|NCT05135403||ASSURE Registry Patients|Patient prescribed the ASSURE WCD who have also consented to participate in the ASSURE Patient Registry. Patients include those with reduced left ventricular ejection fraction (LVEF) and recent myocardial infarction, recent coronary revascularization, or new onset heart failure (HF) to allow for optimization of medical therapy and re-evaluation of cardiac function. Additional indications include ICD explant due to infection, postponed ICD implant, and pending heart transplant.
62540851|NCT04563546|OTHER|MI Patients in northern Tanzania|Patients presenting to KCMC emergency department with acute MI
62540852|NCT02796794|ACTIVE_COMPARATOR|Genistein|Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
62540853|NCT02796794|OTHER|control|Control group are the patients receiving enteral nutrition
62540854|NCT06551779|EXPERIMENTAL|Grupo experimental:|Experimental Group: Patients who meet the inclusion and exclusion criteria, to whom perineural injection with dextrose and conventional physical therapy will be applied for the treatment of Bell's palsy.
62540855|NCT06551779|NO_INTERVENTION|Control:|Control Group: Patients who meet the inclusion and exclusion criteria, to whom only conventional physical therapy will be applied for Bell's palsy.
62540856|NCT04972110|EXPERIMENTAL|Phase Ib Dose Escalation|Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with niraparib and/or Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with olaparib
62540857|NCT04972110|EXPERIMENTAL|Phase 2 Expansion Cohorts|Expansion cohort with RP-3500 (camonsertib) + niraparib and/or Expansion cohort RP-3500 (camonsertib) + olaparib
62540858|NCT02782806|EXPERIMENTAL|Test group|All subjects are enrolled into the test group and receive Masimo Rad-67 Pulse Oximeter for measurement of hemoglobin.
62540859|NCT03134092|NO_INTERVENTION|Generalized Risk Communication (GRC)|Generalized Risk Communication (GRC): Participants in this arm will receive standard discharge instructions similar to instructions they would receive during usual care. This arm represents a standardized way of communicating post-discharge risk-benefit information about treatment options for patients with back pain and renal colic. The GRC, includes a standardized discharge information sheet about the clinical condition of interest and a written overview of population based evidence describing comparative benefits and side effects of alternative classes of medication acute pain.
62540860|NCT03134092|ACTIVE_COMPARATOR|Probabilistic Risk Communication (PRT)|Probabilistic Risk Communication (PRT): The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
62540861|NCT03134092|ACTIVE_COMPARATOR|Narrative Enhanced Risk Tool (NERT)|Narrative Enhanced Risk Tool (NERT): Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale related to prolonged opioid use. Narrative videos are developed from actual patient stories - put into a in a structured format of \~ 2-minute length and recorded.
62540862|NCT03613727|EXPERIMENTAL|IV Vitamin C followed by oral Vitamin C|All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
62540863|NCT00000378|ACTIVE_COMPARATOR|sertaline|patients randomized to sertraline 12 week trial does up to 200mgs
62540864|NCT00000378|ACTIVE_COMPARATOR|nortriptyline|patients randomized to nortriptyline dose adjusted to therapeutic level
62540865|NCT01827865|ACTIVE_COMPARATOR|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
62540866|NCT01827865|EXPERIMENTAL|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
62540867|NCT01272479||HCV (+)|Hemodialysis patients with chronic hepatitis C
62540868|NCT01272479||HCV (-)|Hemodialysis patients without chronic hepatitis C
62540869|NCT01272479||Control|Healthy volunteers
62540870|NCT02308566|ACTIVE_COMPARATOR|Conventional Extracorporeal Circulation Technique|Conventional Extracorporeal Circulation Technique
62540871|NCT02308566|EXPERIMENTAL|Minimized Extracorporeal Circulation Technique|Minimized Extracorporeal Circulation Technique
62540872|NCT05648188||NSCLC patients|Patients with proven stage IA-IIB non-small cell lung cancer (NSCLC).
62540873|NCT02425163|ACTIVE_COMPARATOR|suspicious for Prostate Cancer|"PSA \>4ng/ml or PSA-Velocity \>0.75ng/ml/a or suspicious rectal examination or Status after external beam therapy of the prostate in prostate cancer.~Patients who are able for transrectal ultrasound examination. Transrectal shear wave elastography of the prostate for Transrectal random biopsy of the prostate."
62540874|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
62540875|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
62540876|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
62540877|NCT03190213|EXPERIMENTAL|Pembrolizumab, all patients|
62540878|NCT03483363|EXPERIMENTAL|topical irrigation with the antibiotic plus intravenous (IV) prophylactic antibiotic|"Fractures will be topically irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.~\[previously, this arm involve topical irrigation with bacitracin topical antibiotic (50,000 units), but in April of 2020 the study was modified to use gentamycin rather than bacitracin, after the FDA warning of the toxic side effects of bacitracin and because the hospital where the study was conducted removed bacitracin from its formulary.\]"
62540879|NCT03483363|ACTIVE_COMPARATOR|topical irrigation with sterile normal saline (NS) plus intravenous (IV) prophylactic antibiotic|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
62540880|NCT03747510|EXPERIMENTAL|CarpX Device|Transverse carpal ligament release with CarpX Device
62540881|NCT02771535|EXPERIMENTAL|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
62540882|NCT02771535|ACTIVE_COMPARATOR|Health Training Group|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
62540883|NCT06350916||SeamlessMD Mobile Application|"Participants enrolling in SeamlessMD will be prompted by the mobile app to electronically complete a validated quality-of-life assessment, the Quality of Recovery (QoR-15) evaluation over 30 days. Participants will also be prompted by the app to record their daily narcotic consumption via an Opioid Tracker page that requests participants enter the number of doses taken for each narcotic medication in the last 24 hours."
62540884|NCT06350916||Non-App User Study Participant|Participants will receive on postoperative day one (POD1) in the hospital a one-page paper survey of the same questions prompted by the SeamlessMD app regarding completion of preoperative ERAS metrics.
62540885|NCT00513591||1|Women with lupus
62540886|NCT00513591||2|Health women who are matched to women with lupus by age and race
62540887|NCT00513591||3|Women with other autoimmune diseases
62540888|NCT05096832|EXPERIMENTAL|V-01 COVID-19 Vaccine|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
62540889|NCT05096832|PLACEBO_COMPARATOR|Placebo control|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
62540890|NCT05772247||PS application|
62540891|NCT05772247||non-PS application|
62540892|NCT05168683|EXPERIMENTAL|Part One|Four Study Treatments will be dosed during Part One of the study with radiolabelled ALLN-346 tablets (in 12 subjects): Treatment A ALLN-346 enteric coated (EC) fast release tablet; Treatment B ALLN-346 fast release capsule; Treatment C ALLN-346 EC slow release tablet; Treatment D ALLN-346 slow release capsule. Subjects will be dosed in a lightly fed state.
61978104|NCT03579589|ACTIVE_COMPARATOR|Sugammadex|"* If spontaneous recovery has reached second twitch after TOF: 2 mg/kg~* If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg~* When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg"
62540893|NCT05168683|EXPERIMENTAL|Part Two|Following completion of Part One of the study, study treatment (one or both of those administered in Part One) and dosing requirements will be confirmed for dosing in Part Two, to be administered in fasted and/or fed states (in 12 subjects).
62540894|NCT04584762|SHAM_COMPARATOR|Sham treatment|"The AVPI device software is set in sham mode which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
62540895|NCT04584762|EXPERIMENTAL|Active Treatment|"The AVPI device software is set in active mode which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
62540896|NCT00695305|PLACEBO_COMPARATOR|placebo|placebo to match
62540897|NCT00695305|ACTIVE_COMPARATOR|rilapladib|250 mg/day
62540898|NCT01649960|OTHER|Rapamycin|Oral rapamycin was given during the nonrandomized phase of the study. The doses that were used of rapamycin were 0.5mg, 1mg, or 2mg.
62540899|NCT03580486||Patients with Parkinson's Disease|Parkinson's Disease (Hoehn and Yahr stage 1-4)
62540900|NCT03580486||Healthy controls|Healthy people
62540901|NCT04604886|EXPERIMENTAL|Passive Leg Raising|Passive leg raising (PLR) test is used to predict fluid responsiveness, which is performed by raising the legs of the patient to 45°. Cardiac output will be collected from both PAC and LiDCO before and after PLR.
62540902|NCT04604886|EXPERIMENTAL|Dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It \[\<10 ug/(kg.min)\] can effectively increase myocardial contractility.
62715176|NCT06719128|EXPERIMENTAL|Olomorasib (Moderate Hepatic Impairment)|Olomorasib administered orally.
62715177|NCT06719128|EXPERIMENTAL|Olomorasib (Severe Hepatic Impairment)|Olomorasib administered orally.
62540903|NCT06552013|EXPERIMENTAL|Sham filter|"Participants in this arm will receive a sham filter for their box fans. These filters receive a MERV rating of 1 and only filter very large particles and debris such as lint, hair and insects. These particles have little to no impact on asthma symptoms. MERV stands for minimum efficiency reporting value and a filter receives a MERV rating as determined by the American Society of Heating, Refrigeration, and Air-Conditioning Engineers."
62540904|NCT06552013|EXPERIMENTAL|MERV 13 filter|Participants in this arm will receive a MERV 13 filter for their box fans. MERV 13 filters trap the majority of small particles, as small as 1 micron. It also traps up to 75% of particles that are as small as 0.3 microns.
62540905|NCT01422187|EXPERIMENTAL|Taliglucerase alfa 30 units/kg|Subjects randomized to receive 30 units/kg
62540906|NCT01422187|EXPERIMENTAL|Taliglucerase alfa 60 units/kg|Subjects randomized to 60 units/kg
62540907|NCT02339662|ACTIVE_COMPARATOR|gabapentin|900 mg per day total, 3 pills of 300mg.
62167999|NCT00006006|EXPERIMENTAL|Arm I|Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.
62540908|NCT02339662|ACTIVE_COMPARATOR|amitriptyline|20 mg total, 1pill
62540909|NCT05911880|EXPERIMENTAL|Subjets with rheumatoid arthritis treated with a plant-based diet for 14 days|"The present study focuses on a dietary intervention in human subjects who have been diagnosed with rheumatoid arthritis for at least one year. The intervention consists of an individualized nutritional plan, isocaloric, and modifies the percentage of plant-based proteins to 80%, for 14 days, to evaluate if a plant-based diet affects the disease activity.~The calorie intake given to each subject is calculated based on the average of 3 24-hour recalls and the basal energy expenditure using the Harris \& Benedict formula. No medication modifications are made three months before and during the intervention.~Fasting blood samples of blood are collected via venipuncture before and after the intervention to analyze the blood chemistry of six elements, a complete blood count, as well as to analyze the expression of microRNAs related to the disease and pro-inflammatory cytokines.~In addition, body measurements (weight, body fat, visceral fat, and muscle) are taken using bioimpedance."
62540910|NCT01635283|EXPERIMENTAL|Treatment (tumor lysate-pulsed autologous dendritic cells)|Patients receive autologous glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 0, 14, and 28.
62540911|NCT00303459|EXPERIMENTAL|A|Bosentan
62540912|NCT00303459|PLACEBO_COMPARATOR|B|Placebo
62540913|NCT04774848|ACTIVE_COMPARATOR|High Frequency Jet Ventilation (HFJV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to high frequency oscillating ventilator.
62540914|NCT04774848|ACTIVE_COMPARATOR|High Frequency Jet Ventilation (HFJV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to high frequency oscillating ventilator.
62540915|NCT04774848|ACTIVE_COMPARATOR|High Frequency Oscillatory Ventilation (HFOV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to HFJV.
62540916|NCT04774848|ACTIVE_COMPARATOR|High Frequency Oscillatory Ventilation (HFOV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to HFJV.
62540917|NCT06168110|ACTIVE_COMPARATOR|TENS|
62540918|NCT06168110|SHAM_COMPARATOR|Sham TENS|
62540919|NCT00782405|EXPERIMENTAL|1|quetiapine
62540920|NCT00782405|ACTIVE_COMPARATOR|2|mirtazapine
62540921|NCT01406444|ACTIVE_COMPARATOR|rhIGF-1 followed by Risedronate|Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
62540922|NCT01406444|ACTIVE_COMPARATOR|Risedronate|Risedronate 35mg PO once weekly for 12 months
62540923|NCT01406444|PLACEBO_COMPARATOR|Placebo|Placebo for 12 months
62540924|NCT02305160|EXPERIMENTAL|Butantan|The new pulmonary surfactant produced by Butantan Institute. Butantan Surfactant: 100 mg/kg, IT, maximum of 3 doses.
62540925|NCT02305160|ACTIVE_COMPARATOR|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
62540926|NCT04502212|EXPERIMENTAL|Insonification|All subjects enrolled will receive a 3-day, 15 minute per day ultrasound insonification targeting the portis hepatis (liver).
62540927|NCT01386983||Early 5ARI Initiation|Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
62540928|NCT01386983||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)
61978105|NCT03579589|ACTIVE_COMPARATOR|Neostigmine|50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.
61978106|NCT01953120|EXPERIMENTAL|Belatacept|Survival and rejection in patients switched to belatacept.
61978107|NCT01681732|EXPERIMENTAL|Personalized Care Plan|A personalized plan based on baseline clinic visit data
62540929|NCT00902317|ACTIVE_COMPARATOR|Boston Scientific|The PolarCath peripheral balloon catheter (CryoVascular Systems, Inc., Los Gatos, CA) is a novel angioplasty system that simultaneously dilates and cools the plaque and vessel wall in the area of treatment. Cooling is achieved by inflating the balloon with nitrous oxide rather than the usual saline/contrast mixture.
62715178|NCT06719128|EXPERIMENTAL|Olomorasib (Normal Hepatic Function)|Olomorasib administered orally.
62715179|NCT06003166|EXPERIMENTAL|4AP then placebo (Group A)|Subjects randomized to this group will receive the study drug (4AP) followed by the placebo.
61978108|NCT01681732|ACTIVE_COMPARATOR|Control|This arm will be standard care
62540930|NCT00902317|ACTIVE_COMPARATOR|Spectranetics|The excimer laser has unique properties that make it ideally suited to debulk atheromatous and thrombotic arterial blockages. LASER is an acronym for Light Amplification by Stimulated Emission of Radiation. However, there are many types of lasers, each distinguished by the wavelength of the emitted light, the effective power of the light beam, and whether the light is pulsed (like a flashbulb) or continuous (like a light bulb). The effectiveness of a given laser for intraarterial applications depends on how the light interacts with tissue inside an artery.
62540931|NCT00902317|ACTIVE_COMPARATOR|Fox Hollow|"The SilverHawk peripheral catheter system and cutter driver (FoxHollow Technologies, Redwood City, CA) are designed for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries. The catheter consists of a flexible shaft designed to track over a 0.014 guidewire. At the distal end of the catheter is a small cutting assembly comprised of a rotating inner blade contained within a tubular housing. The proximal end of the catheter contains a connector and Positioning Lever designed to fit into a small, disposable, battery-driven Cutter Driver which powers the device."
62540932|NCT00902317|ACTIVE_COMPARATOR|WL Gore|Viabahn Endoprosthesis (W.L. Gore \& Associates, Flagstaff, AZ) is a flexible self-expanding endoluminal device consisting of expanded polytetrafluoroethylene (ePTFE) lining with an external Nitinol (NiTi=Nickel:Titanium) support extending along its entire length. The device is compressed and attached to a catheter delivery system. The Gore Viabahn Endoprosthesis is available in a wide range of diameters and lengths.
57964634|NCT06718166|EXPERIMENTAL|AI-based chatbot|A chatbot that was developed using information related to HPV vaccines from authoritative sources such as the Japanese Ministry of Health, Labour, and Welfare, World Health Organization, Centers for Disease Control and Prevention, and other reputable public health organizations and validated survey questions from published research.
57964635|NCT06718166|ACTIVE_COMPARATOR|Leaflet|A leaflet which is a publicly accessible HPV vaccination document prepared by the Ministry of Health, Labour, and Welfare.
62540933|NCT00902317|PLACEBO_COMPARATOR|Control Group, Guidant|Balloon angioplasty is a treatment that uses a catheter with a tiny balloon mounted on the end. The balloon is positioned through the narrowing/blockage in your leg artery, and then it is inflated to push the narrowing apart and restore a channel for blood flow. The balloon is then deflated and removed from your body. A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface. The FDA has approved the use of certain stents for the treatment of narrowing in the leg arteries. Stents have been widely used in various parts of the body, including blocked blood vessels in the arms, legs, heart (coronary arteries), and kidneys (renal arteries).
62540934|NCT06201156|ACTIVE_COMPARATOR|Group A / Nebulizer Group|Group A/ Nebulizer group will receive 3 puffs of a placebo MDI with a spacer, followed immediately by a standard dose of 0.15 mg/kg of salbutamol in 3 mL of isotonic sodium chloride solution delivered by an oxygen-driven nebulizer at a flow rate of 6 L/min.
61978109|NCT04055142|ACTIVE_COMPARATOR|Electrocoagulation|This procedure will be implemented following the Standard of Care (SoC) on weeks: 0, 8 and 16 calculated since the day the patient is included into the trial.
62540935|NCT06201156|EXPERIMENTAL|Group B / MDI with Spacer Device Group|Group B/ MDI with Spacer Group will receive 3 puffs (90 pg per puff) of salbutamol MDI with a spacer, followed by 3 mL of nebulized isotonic sodium chloride solution. All treatments will be given at 20-minute intervals.
62540936|NCT03426137|ACTIVE_COMPARATOR|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
62540937|NCT03426137|PLACEBO_COMPARATOR|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
62540938|NCT03426137|PLACEBO_COMPARATOR|C (Control)|Participants in this group will receive NSAIDs and placebo pills
62540939|NCT06619626||Group 1, lung protective ventilation with alveolar recruitment|In mechanical ventilation volume controlled ventilation (VCV) mode, tidal volume (TV) is 6-8 ml/kg according to ideal body weight, positive end expiratory pressure (PEEP): 8 cmH2O, end tidal carbon dioxide pressure (etCO2): 35-45 mmHg, the number of breaths will be adjusted and ventilation will be started. After 10 minutes of ventilation, alveolar recruitment manoeuvre will be started by switching the mechanical ventilator to pressure controlled ventilation (PCV) mode in patients in whom alveolar recruitment strategy (ARS) will be applied. PEEP will be 30 cmHg with 2 unit increases in PEEP for 2 minutes each ventilation will be applied until PEEP reaches 20. When the mean arterial pressure decreases more than 20%, recruitment will be terminated. PEEP will be restored when PEEP 20 is reached. Mechanical ventilation will be switched to VCV mode.
62540940|NCT06619626||Group 2, lung protective ventilation without alveolar recruitment|In mechanical ventilation volume controlled ventilation (VCV) mode, tidal volume (TV) is 6-8 ml/kg according to ideal body weight, positive end expiratory pressure (PEEP): 8 cmH2O, end tidal carbon dioxide pressure (etCO2): 35-45 mmHg, ventilation will be provided by adjusting the number of breaths.
62540941|NCT03357718|EXPERIMENTAL|Dexmedetomidine|2 µg/kg Precedex
62540942|NCT03357718|ACTIVE_COMPARATOR|Midazolam|0.5 mg/kg dormicum
62540943|NCT04854044|EXPERIMENTAL|Arm I (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks, and receive ONC201 PO daily on days 1, 2, 8, and 9. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. Beginning 7 days from last pre-surgery dose of ONC201, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
62540944|NCT04854044|EXPERIMENTAL|Arm II (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. After recovery from surgery, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
62715180|NCT06003166|EXPERIMENTAL|Placebo then 4AP (Group B)|Subjects randomized to this group will receive the placebo first followed by the study drug (4AP)
61978110|NCT04055142|EXPERIMENTAL|Sinecatechins (10%)|Topical ointment wich contains 2 grams of active principle (sinecatechins 10%) at each administration. It will be taken three times per week during 8 weeks of treatment.
62540945|NCT02730299|EXPERIMENTAL|NiCord® (omidubicel)|"NiCord® is a cryopreserved stem/progenitor cell based product comprised of:~1. ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))~2. the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation."
62540946|NCT02730299|ACTIVE_COMPARATOR|Unmanipulated CBU(s)|
62164730|NCT02684942|ACTIVE_COMPARATOR|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
62164731|NCT02684942|ACTIVE_COMPARATOR|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
62164732|NCT02066389|PLACEBO_COMPARATOR|Placebo|Participants received placebo capsules twice daily for 12 weeks.
62164733|NCT02066389|EXPERIMENTAL|Upadacitinib 3 mg BID|Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.
62164734|NCT02066389|EXPERIMENTAL|Upadacitinib 6 mg BID|Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.
62164735|NCT02066389|EXPERIMENTAL|Upadacitinib 12 mg BID|Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.
62164736|NCT02066389|EXPERIMENTAL|Upadacitinib 18 mg BID|Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.
62164737|NCT02066389|EXPERIMENTAL|Upadacitinib 24 mg QD|Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.
62164738|NCT05812209||SGB Patients for Long COVID 19|Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics.
62164739|NCT04086576|EXPERIMENTAL|Commercial Smartphone-paired breathalyzers-Set 1|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
62164740|NCT04086576|EXPERIMENTAL|Commercial Smartphone-paired breathalyzers-Set 2|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: BACtrack Vio, Drinkmate, and Floome which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
62164741|NCT03538834|EXPERIMENTAL|Cod meal from residual material|Dietary supplement: cod meal from residual material, 8 g protein daily for 8 weeks
62164742|NCT03538834|PLACEBO_COMPARATOR|Control|Control group receive tablet containing fillers and no protein
62164743|NCT02305797|EXPERIMENTAL|EDG004|EDG004 - Extended release lorazepam capsules
62164744|NCT02305797|PLACEBO_COMPARATOR|Placebo|Placebo
62164745|NCT00730392|EXPERIMENTAL|1 drug, 2 placebo|"1. Etanercept~2. Placebo"
62164746|NCT06381297|ACTIVE_COMPARATOR|MS group|Study group (MS patients)
62164747|NCT06381297|PLACEBO_COMPARATOR|Control group|Control group ( Healty individuals)
62164748|NCT00784277|EXPERIMENTAL|001|Tapentadol IR (CG5503) 50mg for 14 days
62164749|NCT00784277|EXPERIMENTAL|002|Tapentadol IR (CG5503) 75mg for 14 days
62164750|NCT00784277|ACTIVE_COMPARATOR|003|oxycodone IR 10mg for 14 days
62164751|NCT00784277|PLACEBO_COMPARATOR|004|placebo 1 capsule for 14 days
62540947|NCT01767324|EXPERIMENTAL|Injection to deltoid|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
62540948|NCT01767324|EXPERIMENTAL|Injection to forearm|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
62164752|NCT00784277|EXPERIMENTAL|005|Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
62164753|NCT00784277|ACTIVE_COMPARATOR|006|oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
62164754|NCT00784277|PLACEBO_COMPARATOR|007|placebo Tablets and capsules 2 x a day for 28 days
62164755|NCT03444155|ACTIVE_COMPARATOR|Natural Panmol-B-Complex first, then synthetic Vitamin B-complex|Participants first received a Natural Vitamin B-complex, i.e., Panmol-B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
62164756|NCT03444155|ACTIVE_COMPARATOR|Synthetic Vitamin B-complex first, then Natural Panmol-B-Complex|Participants first received a Synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a natural Vitamin B-complex, i.e., Panmol-B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
62164757|NCT05492578|EXPERIMENTAL|Amlitelimab|Subcutaneous injection
62164758|NCT01388088|ACTIVE_COMPARATOR|Spironolactone|Increases the level of potassium
62540949|NCT01767324|EXPERIMENTAL|Injection to thigh|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
62540950|NCT05093764|OTHER|VIV TAVR with BVF using TCEP|All subjects will receive the intervention.
62164759|NCT01388088|ACTIVE_COMPARATOR|Amiloride|Increases the level of potassium
62540951|NCT04697082|PLACEBO_COMPARATOR|Group A|The open surgical method and a moist gauze (with saline) were applied to patients in group A
62540952|NCT04697082|EXPERIMENTAL|Group B|Open surgery and then PRP application were performed on patients in group B. After the cavity was filled with PRP, the wound was covered with a dry gauze.
62540953|NCT04697082|EXPERIMENTAL|Group C|PRP was applied to the patients in group C after curettage of the sinus cavity. And again the wound was covered with a dry gauze.
62540954|NCT04283968|EXPERIMENTAL|Treatment arm|All patients will receive 4 fecal microbial transplantations from healthy donors each 2 weeks apart
62540955|NCT04283968|PLACEBO_COMPARATOR|Placebo followed by treatment arm|All patients will receive 4 placebo fecal transplantations followed by 4 fecal microbial transplantations from healthy donors each 2 weeks apart
62540956|NCT04113863|ACTIVE_COMPARATOR|ARM A - Anastrozole|Anastrozole at the dosage of 1 mg/die. Treatment will last 28 days
62164760|NCT01388088|PLACEBO_COMPARATOR|Placebo|
62540957|NCT04113863|EXPERIMENTAL|ARM B - Anastrozole + ATRA|Anastrozole at the dosage of 1mg/die in combination with ATRA at the total dosage of 45mg/m2/die (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
62540958|NCT00843479||Elderly NGT|Normoglycemic subjects 65-80 years old
62540959|NCT00843479||Middle-age NGT|Middle-age normoglycemic subjects 35 to 50 years old.
62540960|NCT06633185|ACTIVE_COMPARATOR|Topical anal phenytoin cream application|local application of phenytoin cream on anal wound post internal sphincterotomy for chronic anal fissure.
62540961|NCT06633185|ACTIVE_COMPARATOR|control arm|includes those with internal sphincterotomy but without application of topical phenytoin cream
62540962|NCT06328062|EXPERIMENTAL|Mirogabalin|Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
62540963|NCT06328062|ACTIVE_COMPARATOR|Pregabalin|Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
62540964|NCT05852561|ACTIVE_COMPARATOR|Group Superficial+Deep Serratus Anterior Plan Block|Superficial+Deep Serratus Anterior Plan Block after Video-Assisted Thoracic Surgery
62540965|NCT05852561|ACTIVE_COMPARATOR|Group Deep Serratus Anterior Plan Block|Deep Serratus Anterior Plan Block after Video-Assisted Thoracic Surgery
62540966|NCT02640690|EXPERIMENTAL|Trauma Center Trauma-Sensitive Yoga (TCTSY)|10-weekly 1-hour TCTSY Sessions
62540967|NCT02640690|ACTIVE_COMPARATOR|Cognitive Processing Therapy (CPT)|12-weekly 1.5 hour CPT Sessions
62540968|NCT04005365|EXPERIMENTAL|Prop+neochemo|
62540969|NCT00926783|ACTIVE_COMPARATOR|(1) targeted CFAE ablation|
62540970|NCT00926783|ACTIVE_COMPARATOR|(2) generalized CFAE ablation|
62540971|NCT06247371|EXPERIMENTAL|Decision aid|Patients will be presented with a decision aid featuring personalized cost information, as well as other information about angiotensin receptor neprilysin inhibitor (ARNI) and angiotensin-converting enzyme inhibitor (ACEI) medications. These patients will then be tasked to choose a preferred medication and reflect on which attribute holds the most significance for them. The preferred medication will be communicated to the clinicians during the clinic session.
62540972|NCT06247371|NO_INTERVENTION|Usual care|Patients are managed as per usual clinical routine without the decision aid.
62540973|NCT01707771|ACTIVE_COMPARATOR|Roux-en-Y gastric bypass|Both sexes, age between 30 and 60 years, BMI =/\> 35 kg/m2
62540974|NCT01707771|ACTIVE_COMPARATOR|diet and lifestyle modifications|Both sexes, age between 30 and 60 years, BMI =/\> 35 kg/m2
62540975|NCT03460080||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
62540976|NCT03460080||Hepatic hemangioma patients|
62540977|NCT03630107|EXPERIMENTAL|WO 5101 Shampoo for Scalp and Hair|WO 5101 is used in subjects with chronically itchy scalp
62540978|NCT04191499|EXPERIMENTAL|Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib, palbociclib, and fulvestrant.
62540979|NCT04191499|PLACEBO_COMPARATOR|Placebo + Palbociclib + Fulvestrant|Participants will receive placebo, palbociclib, and fulvestrant.
62540980|NCT00176423|EXPERIMENTAL|galantamine|galantamine, 24mgs, p.o., qday
62540981|NCT00176423|PLACEBO_COMPARATOR|placebo|placebo, 3 tablets, p.o., qday
62540982|NCT04163510|EXPERIMENTAL|Reading Intervention Group|A group of parents and their children will participate in this single arm, pre-/post-intervention study. This 10-week study will include 10 sets of parents of low-reading elementary school children, recruited from Harlem Grown Community Center. Intervention will be implemented in a 9-week period, with data collection during the first intervention week and one week post-intervention. Three large-group sessions will be held in a central location (at Harlem Grown Community Center), to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. The reading program will help parents identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading.
62164761|NCT05681845|EXPERIMENTAL|Arm 1 (Pilot part)|Participants will receive a single dose of Mim8 using a 32G, 4 mm pen-needle with the DV3407-C1 pen injector.
62540983|NCT01982448|EXPERIMENTAL|Arm A: Cisplatin|Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
62540984|NCT01982448|EXPERIMENTAL|Arm B: Paclitaxel|Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
62540985|NCT05333731||Cesarean section group|In the cesarean section group, all the pregnant women had only one prior cesarean section.
62540986|NCT05333731||Non-cesarean section group|In the non-cesarean section group, all the pregnant women are primipara, and never had a cesarean section.
62540987|NCT05547620|EXPERIMENTAL|Low Intensity Focused ultrasound|NeuroFUS device stimulation with 4 channel transducer Stimulation target = Cerebellum
62540988|NCT04315571|ACTIVE_COMPARATOR|Group A|Routine Large Volume Paracentesis (LVP) with albumin infusion
62540989|NCT04315571|ACTIVE_COMPARATOR|Group B|Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
62540990|NCT04733261|ACTIVE_COMPARATOR|Diaphragmatic mobility|The patient will be in supine, supported on one/two pillows under her head, and a bolster under her knees.
62540991|NCT04733261|EXPERIMENTAL|Chest Physiotherapy|Give passive ROM exercise to all joints of the upper and lower extremities.
62540992|NCT01438996|EXPERIMENTAL|NVGH Vi-CRM/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study
62540993|NCT01438996|EXPERIMENTAL|Vi-PS/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study
62540994|NCT01438996|EXPERIMENTAL|NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults
62540995|NCT01420471|ACTIVE_COMPARATOR|Saline-impregnated spacer|Saline-impregnated spacers are actively being used as the standard of care. It does not contain any active ingredients.
62540996|NCT01420471|EXPERIMENTAL|Triamcinolone-impregnated spacer|This study arm receives the experimental treatment, a Triamcinolone-impregnated spacer.
62540997|NCT06249815|ACTIVE_COMPARATOR|Foley catheter + misoprostol|-cervical ripening with transcervical Foley catheter 22 F for 16 hours, then sequentially 25 μg oral misoprostol once every 2 hour.Max 200 μg
62540998|NCT06249815|ACTIVE_COMPARATOR|misoprostol|25 μg oral misoprostol alone once every 2 hour, Max 200 μg.
62540999|NCT02366429|EXPERIMENTAL|ICBT|Internet-based CBT for antenatal depression
62541000|NCT02366429|ACTIVE_COMPARATOR|TAU|Treatment as usual provided at antenatal clinics and other health care instances
62541001|NCT03587116|OTHER|Standard of Care FIX replacement therapy|
62541002|NCT03587116|OTHER|Standard of Care FVIII replacement therapy|
62541003|NCT00788944|OTHER|1|
62541004|NCT03007992|EXPERIMENTAL|Vinorelbine Oral|Test product: Navelbine® 20 mg / 30 mg soft capsules
62541005|NCT00976417||1. Patients in the control group|
62541006|NCT00976417||2. Patients in the intervention group|
62541007|NCT06484478||Adults with Fabry disease|
62541008|NCT06574360|EXPERIMENTAL|S1R agonist (S1RA) plus NMDAE|An S1R agonist plus an NMDA enhancer
62541009|NCT06574360|PLACEBO_COMPARATOR|S1R agonist (S1RA) plus placebo|An S1R agonist plus placebo
62541010|NCT00422500||Chemotherapy Symptoms|Study participants with advanced-stage lung cancer.
62541011|NCT02031718|NO_INTERVENTION|Online Education|
62541012|NCT02031718|EXPERIMENTAL|Online Education & Virtual Counseling|Online virtual counseling
62541013|NCT01125371|EXPERIMENTAL|Computerized Brief Alcohol Intervention + IVR|Computer-delivered brief alcohol intervention (CBI) with booster phone calls delivered by IVR+ text messages (TM)
62541014|NCT01125371|ACTIVE_COMPARATOR|Computerized Brief Alcohol Intervention|Computerized Brief Alcohol Intervention only (CBI)
62541015|NCT01125371|PLACEBO_COMPARATOR|Attention Control|Attention control
62541016|NCT04305353|EXPERIMENTAL|ICU Diary Group|Patients randomized to this group receive the ICU diary, along with PTSD education
62541017|NCT04305353|OTHER|PTSD Education-only Group|Control Group: patients randomized to this group only receive PTSD education
62541018|NCT01811316|ACTIVE_COMPARATOR|Probiotics Lozenge (twice a day)|Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
62541019|NCT01811316|ACTIVE_COMPARATOR|Probiotics Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
62541020|NCT01811316|PLACEBO_COMPARATOR|Placebo Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
62541021|NCT01243112|EXPERIMENTAL|Lidocaine w/ Epi|0.2ml 1% Lidocaine with Epinephrine (1:100,000)
62541022|NCT01243112|EXPERIMENTAL|Bupivacaine with epi|0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
62541023|NCT01243112|EXPERIMENTAL|Low dose Lido and Bupi w/ Epi|0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
62541024|NCT01243112|EXPERIMENTAL|High Dose Lido and Bupi with epi|0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
62541025|NCT01044264|ACTIVE_COMPARATOR|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Test product
62541026|NCT01044264|ACTIVE_COMPARATOR|DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Reference product
62541027|NCT01044264|PLACEBO_COMPARATOR|Placebo|
62541028|NCT00516373|EXPERIMENTAL|KU-0059436|KU-0059436 administered orally twice daily
62541029|NCT03239743|EXPERIMENTAL|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
62541030|NCT03239743|ACTIVE_COMPARATOR|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
62541031|NCT03777163|OTHER|Butantan Trivalent Influenza Vaccine|"Butantan Institute Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
62541032|NCT03777163|OTHER|Sanofi Trivalent Influenza Vaccine|"Sanofi Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
62541033|NCT04986384|ACTIVE_COMPARATOR|Active Treatment Group|Patients will be instructed to use the anti-pruritic spray for four weeks starting from the day which informed consent was signed in active treatment group. A follow-up visit will be on week 2 for a mid-term review.
62541034|NCT04986384|ACTIVE_COMPARATOR|Wait-list Control Group|Patients will be instructed to start the treatment after two weeks from the day which consent was signed and for a duration of two weeks in wait-list control group. A follow-up visit will be on week 2 for a mid-term review and for the dispense of treating material.
62541035|NCT00626392|EXPERIMENTAL|NER 500; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)
62541036|NCT00626392|EXPERIMENTAL|NER 500; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)
62541037|NCT00626392|EXPERIMENTAL|NER 500; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)
62541038|NCT00626392|EXPERIMENTAL|NER 1000; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)
62541039|NCT00626392|EXPERIMENTAL|NER 1000; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)
62541040|NCT00626392|EXPERIMENTAL|NER 1000; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)
62541041|NCT00206323|PLACEBO_COMPARATOR|placebo/sugar pill|Placebo or sugar pill
62541042|NCT00206323|ACTIVE_COMPARATOR|Topiramate|Topiramate 25 mg to 200 mg
62541043|NCT04492592|EXPERIMENTAL|Workshop Only|2 session weekend face:face workshop for adolescent-mother pairs
62541044|NCT04492592|EXPERIMENTAL|Workshop + SMS/Texting|2 session weekend face:face workshop for adolescent-mother pairs followed by 8 weeks of supplementary text messages (NOTE: there was no 'SMS/texting-only' arm of this study)
62541045|NCT04492592|NO_INTERVENTION|Control|No intervention provided.
62541046|NCT06549283|ACTIVE_COMPARATOR|NIPPV group|Nasal intermittent positive pressure ventilation (NIPPV) was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation). Appropriately-sized bi-nasal cannulae were placed prior to laryngoscopy as interface for NIPPV implementation. Non-synchronized NIPPV was implemented. NIPPV was initiated prior to intubation, with the peak inspiratory pressure set to 16-20 cmH2O (selected according to the infant's birth weight and chest wall expansion), positive-end expiratory pressure set to 6 cmH2O, breathing rate set to 40-50 breaths/min, inspiratory time set to 0.40-0.45 s, and flow rate set to 8-12 L/min. After the first successful intubation attempt, NIPPV was discontinued. Prior to laryngoscopy, the fraction of inspired oxygen (FiO2) was adjusted to maintain SpO2 above 90%.
62541047|NCT06549283|NO_INTERVENTION|Standard-care group|The intubation attempt proceeded without NIPPV or supplemental oxygen.
62541048|NCT00567905|EXPERIMENTAL|A|Green tea extract
62541049|NCT00567905|PLACEBO_COMPARATOR|B|
62541050|NCT06634056|PLACEBO_COMPARATOR|Control Arm|Participants in the control arm will start one placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.
62541051|NCT06634056|EXPERIMENTAL|Experimental Arm|Participants in the experimental arm will start Pentoxifylline 400 mg orally three times a day and α-Tocopherol 400 IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
62541052|NCT01464931|EXPERIMENTAL|Denosumab|Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
62541053|NCT06148415|EXPERIMENTAL|Fetal Heartbeat Monitoring Group|"The prospective fathers will be trained by the investigators on how to perform the 1st and 2nd leopold maneuvers using visual materials. Each couple will be provided with a stethoscope to listen to the fetal heartbeat and will be given a schedule to listen to the fetal heartbeat together for 5-10 minutes at least once a day for 15 days.~1. Leopold maneuver (Posture): The first maneuver is performed to determine the height of the fundus and the part that is located on the fundus.~2. Leopold's maneuver (Position: back right, back left): This maneuver is used to determine which side the fetal back is on. On palpation, the side with the baby's back is flat and firmer, and the other side feels bumpy."
62541054|NCT06148415|NO_INTERVENTION|Control|Standard care group without fetal heart rate monitoring
61976445|NCT03120819|EXPERIMENTAL|Oncologist Recommendation + DVD|Participants in this arm receive the same oncologist's recommendation and written materials as the comparator group and also received an instructional yoga DVD. Inclusion of the video is intended to provide patients with a tool for following the oncologist's exercise recommendation. The instructional video contains a brief introduction from a breast cancer survivor, who was also featured in the exercise portion of the DVD, and safety information about lymphedema from a lymphedema therapist. The exercise program is a 30-minute, low intensity, restorative yoga program to improve whole body flexibility and to be safe for participants who were in active treatment for cancer and/or who had metastatic disease. Women are encouraged to use the DVD at least 3 times per week.
62164762|NCT05681845|EXPERIMENTAL|Arm 2 (Pilot part)|Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.
62541055|NCT02647385|EXPERIMENTAL|General Anesthesia|Interventions: include pain assessment, inflammatory response and opioid consumption.
62541056|NCT02647385|EXPERIMENTAL|General Anesthesia SAM and PEC I block|Interventions: include pain assessment, inflammatory response and opioid consumption.
62541057|NCT04731246|EXPERIMENTAL|Parkinson's disease (mild to moderate stage)|
62541058|NCT04249869|EXPERIMENTAL|Group A|Group A will receive VGH-AD1 two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 8 weeks. Post-follow up will be 4 weeks later.
62541059|NCT04249869|PLACEBO_COMPARATOR|Group B|Group B will receive placebo two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the VGH-AD1 for another 8 weeks. Post-follow up will be 4 weeks later.
62541060|NCT04701164|EXPERIMENTAL|ANX005 Treatment Group - Dose 1|Participants will receive a single IV infusion of ANX005 (Dose 1) on Day 1.
62541061|NCT04701164|EXPERIMENTAL|ANX005 Treatment Group - Dose 2|Participants will receive a single IV infusion of ANX005 (Dose 2) on Day 1.
62541062|NCT04701164|PLACEBO_COMPARATOR|Placebo Group|Participants will receive a single IV infusion of placebo on Day 1.
61976446|NCT04532957|EXPERIMENTAL|Group 1|Multiple doses 100mg Healthy subjects receive multiple doses of KBP-7072 (100mg) or Placebo (100mg) QD capsules daily for a total of 10 days
62541063|NCT06029179|ACTIVE_COMPARATOR|Group A|40 patients will receive sodium zirconium cyclosilicate (SZC)
62541064|NCT06029179|ACTIVE_COMPARATOR|Group B|40 patients will receive sodium polystyrene sulfonate
62541065|NCT04258033|EXPERIMENTAL|PLB1001|Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
62541066|NCT01957735|EXPERIMENTAL|BP31510 monotherapy|"* Starting dose level of BPM31510 will be 66 mg/kg administered by IV infusion over 48 hours 2 times per week of each 28-day cycle.The 2 doses will be administered over 4 consecutive days.The study drug will be administered undiluted via a central venous access device and the infusion rate will be controlled by a programmable ambulatory infusion pump.~* first dose of each week of the cycle a loading dose will be infused over 1 hour with the remainder of the dose volume infused over 47 hours.At each dose level of Arm 1 and Arm 2, patients will be treated for either 8 hours at minimum of outpatient monitoring or inpatient monitoring for the first 24-hrs of the first infusion of Cycle 1.~* second dose of each week of the cycle, the total dose volume given over 48 hours with no loading dose."
62541067|NCT01957735|ACTIVE_COMPARATOR|BP31510 in combination with chemotherapy|"standard 3+3 design will be used for Arm 2 of the study. BPM31510 will be started at one dose level below the dose that has been studied and determined to be safe in the monotherapy portion of the trial. Arm 2 patients will be enrolled onto one of 3 chemotherapies, gemcitabine, 5-FU, or docetaxel according to the dose levels below:~* Gemcitabine IV once weekly at a starting dose of 600 mg/m2 ;~* 5-Fluorouracil (5-FU) IV once weekly at a starting dose of 350 mg/m2 with leucovorin (LV) 100 mg/m2; OR~* Docetaxel IV once weekly at a starting dose of 20 mg/m2.~* Note:Both BPM31510 and the chemotherapy agent can escalate simultaneously in Cohorts 3 and 4 only if there are no DLTs observed in the previous cohorts. If one or more DLTs are observed, then intermediate dose levels will be added where one agent is escalated."
62541068|NCT00464438|EXPERIMENTAL|1|
62541069|NCT00464438|ACTIVE_COMPARATOR|2|
62541070|NCT04731792|EXPERIMENTAL|Virtual Reality group|
62541071|NCT04731792|NO_INTERVENTION|control group|
62541072|NCT01819610|EXPERIMENTAL|SPRIX|Subjects will be administered open label SPRIX according to subject weight.
62541073|NCT03076580||cardiomyopathy|Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
62541074|NCT03076580||disease control|Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
62541075|NCT03076580||healthy control|Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
62541076|NCT02340052||Frederiksberg Hospital|100 patients undergoing planned total hil arthroplasty
62541077|NCT02340052||Koege hospital|100 patients undergoing planned total hil arthroplasty
62541078|NCT02340052||Naestved Hospital|100 patients undergoing planned total hil arthroplasty
62541079|NCT02340052||Hilleroed Hospital|100 patients undergoing planned total hil arthroplasty
62541080|NCT02340052||Nykoebing Falster Hospital|100 patients undergoing planned total hil arthroplasty
62541081|NCT00530218|EXPERIMENTAL|All Study Participants|Ganciclovir IV 5 mg/kg/bid x 7 days followed by Ganciclovir Oral 1000 mg tid 7 days per week x 5 weeks
62541082|NCT01970800|EXPERIMENTAL|Growth hormone, injections|Growth hormone injection 0.3mg/kg/week dailY
62541083|NCT01888770||Normotensive Term|Infants born at term (\>37 weeks) to Normotensive pregnancies
62541084|NCT01888770||Term Preeclampsia|Infants born at term (\>37 weeks gestation) and exposed to a preeclamptic pregnancy
62541085|NCT01888770||Preterm Normotensive|Infants born to Normotensive pregnancies at \<37 weeks gestation
62541086|NCT01888770||Preterm Hypertensive|Infants born to hypertensive pregnancies at \<37 weeks completed gestation
61976447|NCT04532957|EXPERIMENTAL|Group 2|Multiple doses 200mg Healthy subjects receive multiple doses of KBP-7072 (200mg) or Placebo (200mg) QD capsules daily for a total of 10 days
61976448|NCT04532957|EXPERIMENTAL|Group 3|Multiple doses dose tbd Healthy subjects receive multiple doses of KBP-7072 (tbd) or Placebo(tbd) QD capsules daily for a total of 10 days
62541087|NCT01888770||Term Pregnancy-induced Hypertension|Infants born at term (\>37 weeks gestation) and exposed to pregnancy-induced hypertension
62541088|NCT04842786|EXPERIMENTAL|Coconut oil at 5 mg/Kg body weight twice daily|Coconut oil (Parachute Brand) is a marketed product that is routinely used for daily massage after birth for infants in India. An amount of 5 mg/Kg body weight will be applied twice daily by the health care provider from enrollment until discharge, or until day of life 28, whichever occurs first.
62541089|NCT04842786|NO_INTERVENTION|No intervention|Subjects assigned to this arm will have their skin gently stroked twice daily for the time that would be required to apply an oil. This will simulate the stroking received by the intervention arm subjects. This will occur from enrollment until discharge, or until day of life 28, whichever occurs first.
62541090|NCT01596309|PLACEBO_COMPARATOR|control group, placebo|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added
62541091|NCT01596309|EXPERIMENTAL|Intervention group, cocoa extract|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
62541092|NCT04005014|EXPERIMENTAL|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SE and presence of high myopia in the subsequent 10 years.
62541093|NCT04005014|NO_INTERVENTION|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
62541094|NCT05498779||Non-resectable hepatocellular carcinoma|Patients treated with ablation therapy as first treatment for non-resectable hepatocellular carcinoma.
62541095|NCT02777398|EXPERIMENTAL|Trans-Quadrant Channel Surgery|Patients in the experimental arm (experimental group, i.e. microsurgery through trans-Quadrant channel pathway) will be operated using Quadrant channel system. All the tumor resection will be operated through the Quadrant channel with assistance of microsurgical techniques.
62541096|NCT02777398|ACTIVE_COMPARATOR|Conventional Open Surgery|Patients in the active comparator arm (control group, i.e. conventional open surgery) will be operated using the conventional open surgery. All the tumor resection will be operated directly with conventional procedures. More posterior structures of spine will be removed.
62715181|NCT02707341||Psoriasis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
62715182|NCT03291340||Cognitively normal elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
62541097|NCT01216787|EXPERIMENTAL|Treatment (gamma-secretase inhibitor RO4929097, surgery)|Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Within 35-56 days after completion of therapy, patients with stable or responsive disease undergo surgery. Patients may continue RO4929097 for 28 days after surgery in the absence of disease progression or unacceptable toxicity.
62541098|NCT05604989|EXPERIMENTAL|Neovascular AMD patients with anti-VEGF treatment, oral probiotics supplement|"Neovascular AMD patients will be allocated. Regular intravitreal anti-VEGF injection treatment will be done. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~Oral probiotics (The Perfect Probiotics®) supplement will be given to the participants for 6 months."
62541099|NCT05604989|SHAM_COMPARATOR|neovascular AMD patients with anti-VEGF treatment, no oral probiotics supplement|"Neovascular AMD patients will be allocated. Regular intravitreal anti-VEGF injection treatment will be done. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~No Oral probiotics (The Perfect Probiotics®) supplement in this group."
62541100|NCT05604989|NO_INTERVENTION|Control patients, no oral probiotics supplement|"Healthy, no retinal disease patients will be allocated. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~No Oral probiotics (The Perfect Probiotics®) supplement in this group."
62541101|NCT04837131|EXPERIMENTAL|Ixazomib in patients with scleroderma-interstitial lung disease (ILD)|Participants will be administered oral ixazomib for six cycles (each cycle is 28 days duration).
62541102|NCT04223557|EXPERIMENTAL|FPU treatment|Transcutaneous non-invasive ultrasound will be administered to the peri-renal fat for one time via a focused power ultrasound system (FPU) device.
62541103|NCT04223557|SHAM_COMPARATOR|Sham treatment|Partcipates will receive the same procedure as those in experimental arm except that the device will not be activated.
62541104|NCT02882308|EXPERIMENTAL|Monotherapy with olaparib|Patients in the monotherapy arm will be treated with olaparib until the 21st -28th day depending on the day of surgery, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
62541105|NCT02882308|EXPERIMENTAL|Combination of cisplatin and olaparib|Patients in the cisplatin - olaparib combination arm will receive treatment until the 5th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day.
62541106|NCT02882308|NO_INTERVENTION|No treatment arm|"Patients in the no treatment arm will wait to be operated or have a second biopsy on the 23rd - 29th day.Optionally, patients who have a baseline FDG-PET/CT scan may be re-examined on the 22nd -28th day by the same modality to assess metabolic response."
62541107|NCT02882308|EXPERIMENTAL|Combination of durvalumab and olaparib|Patients in the durvalumab - olaparib combination arm will receive treatment until the 21th-28th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
62541108|NCT02602444||STEMI|ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
62541109|NCT02602444||NSTEMI|non-ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
62541110|NCT02565212|EXPERIMENTAL|GROUP 1|montelukast sodium and mometasone
62541111|NCT02565212|ACTIVE_COMPARATOR|Group 2|montelukast
62541112|NCT02565212|ACTIVE_COMPARATOR|Group 3|mometasone furoate
62541113|NCT03590769|EXPERIMENTAL|PET/MR using FDG-18 radiotracer|Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.
62541114|NCT04727047|ACTIVE_COMPARATOR|Neuromuscular Electrical Stimulation|"Neuromuscular electrical stimulation will be applied to the calf muscles. The level of stimulation will be increased weekly from 10 to 30 mA during the first 6 weeks after surgery.~In addition, patients will follow standard therapy for Achilles tendon repair."
62541115|NCT04727047|NO_INTERVENTION|Control|Patients will follow standard therapy for Achilles tendon repair.
62541116|NCT02656888|EXPERIMENTAL|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
62541117|NCT02656888|PLACEBO_COMPARATOR|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
62541118|NCT00010114||Newly diagnosed embryonal tumors|The participants in this study are infants (\< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
62541119|NCT01866046|EXPERIMENTAL|RESPECT-IPV|Rapid HIV testing and risk prevention intervention for victims of intimate partner violence
62541120|NCT03399825||Healthy controls|Children without eye disease
62541121|NCT03399825||Retinopathy of prematurity (ROP)|Previously preterm children with a history of ROP
62715183|NCT03291340||Cognitive impaired elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
61976449|NCT04081311|EXPERIMENTAL|water flosser|patient will be provided with Waterpik Water Flosser and instructed to water floss around the implant once a day, preferably at nighttime
61976450|NCT04081311|ACTIVE_COMPARATOR|dental floss|patient will be instructed to floss with TePe Bridge and Implant Floss once a day, preferably at nighttime
61976451|NCT05497674|EXPERIMENTAL|rongliflozin and/or rifampicin|on Day 1, subjects will receive a single dose administration of rongliflozin, followed by a washout period of 4 days. Starting On Day 5, subjects will administer rifampicin once a day (QD) for 10 consecutive days ( Day 5 to Study Day 14) , comprising of a single dose administration of rongliflozin on Study Day 11.
61976452|NCT05497674|EXPERIMENTAL|rongliflozin and/or probenecid|on Day 1, subjects will receive a single dose administration of rongliflozin, followed by a washout period of 4 days. Probenecid will be administrated twice a day from Day 5 to Day 9, and another single dose administration of rongliflozin on Day 6.
62715184|NCT06552429|EXPERIMENTAL|Peginterferon α-2b 135 mcg dose group|
62164763|NCT05681845|EXPERIMENTAL|Arm 3 (Bioequivalence part)|Participants will receive a single dose of Mim8 using a 29G, 4 mm pen-needle with the DV3407-C1 pen injector.
62164764|NCT05681845|EXPERIMENTAL|Arm 4 (Bioequivalence part)|Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.
62541122|NCT03399825||Diabetic retinopathy|Children with diabetes
62541123|NCT01403857|EXPERIMENTAL|Whole Grain|Whole grain products as defined by the American Association of Cereal Chemists (AACC) given in a market basket that contains eight commonly used grain products over six weeks.
62541124|NCT01403857|PLACEBO_COMPARATOR|Refined Grains|Time control compared to experimental intervention.
62541125|NCT06470178||Cohort 1 : neoadjuvant treatment|
62541126|NCT06470178||Cohort 2:conversion treatment|
62541127|NCT05949411|OTHER|Screening|D-42 to D-7
62541128|NCT05949411|OTHER|Lactulose|D0
62164765|NCT01000584|OTHER|1|Group A: One dose of the licensed H1N1 vaccine and one dose of the seasonal influenza vaccine given concurrently
62164766|NCT01000584|OTHER|2|Group B: One dose of seasonal influenza vaccine given 3 weeks after administration of one dose of the licensed H1N1 vaccine
62164767|NCT00301015|EXPERIMENTAL|1|Malaria diagnosis aided with rapid diagnostic test
62164768|NCT00301015|ACTIVE_COMPARATOR|2|Malaria diagnosis based on clinical judgement only
62164769|NCT03944499|EXPERIMENTAL|FS-1502|"Phase Ia:~Patients enrolled on the 1.2 and 2.0 regimens: FS-1502 monotherapy every 4 weeks with intravenous drip, 28 days as a cycle; Patients enrolled on the 3.0 regimens: starting from the 1.0mg/kg dose group, FS-1502 monotherapy every 3 weeks with intravenous drip, 21 days as a cycle;~Phase Ib:~FS-1502 monotherapy, the dose and frequency of administration for Stage Ib will be obtained according to Phase Ia (RP2D). All patients will continue treatment until no clinical benefit occurs, or intolerable toxicity occurs, or death occurs, or the investigator decides, or patients voluntarily withdraw from the study.~Study end is defined as the last patient's treatment ended or 2 years after the last patient's treatment began(depending on which happens earlier)."
62164770|NCT01531478||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
62164771|NCT02411071||Patients starting cART|Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
62164772|NCT02411071||Patients with cART|Patients with cART. Grouping in patients without and with low-level-viremia (LLV) defined as two consecutive viral loads between 40 copies/ml and 200 copies/ml, 400 copies/ml, 500 copies/ml and 1000 copies/ml, respectively.
62164773|NCT03727334|EXPERIMENTAL|Treatment|For the treatment arm, the participants will complete the intervention protocol following the first in-person study visit 7 months post-injury. The intervention involves 16 weeks of online, in-home spatial navigation training. During the 16 weeks, the participant will complete exercises for 1 hour/day, 5 days a week.
62164774|NCT03727334|NO_INTERVENTION|Control|The control arm participants will receive their typical standard of care; they will not complete the intervention but will complete all of the in-person visits at the same post-injury time-points as the treatment group.
62164775|NCT05639946|EXPERIMENTAL|Experimental group|Participants with severe neuropathic pain will receive brivaracetam treatment
62164776|NCT05639946|PLACEBO_COMPARATOR|Control group|Participants with severe neuropathic pain will receive placebo drug
62164777|NCT05793827|EXPERIMENTAL|Adapted Hatha Yoga|
62164778|NCT05793827|ACTIVE_COMPARATOR|Low-Impact Exercise|
62164779|NCT05145088|NO_INTERVENTION|Control Group|The participants in this group are under control and not perfoming any exercise, and their life style is NOT consistent with any kind of submaximal exercise training designed as per protocol.
62164780|NCT05145088|EXPERIMENTAL|Experimental group|"the particpants are made to perform submaximal exercise testing according to ACSM guidelines for 03 weeks.~For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate.~The data will be calculated at two times in the form of pre and post testing."
62541129|NCT05949411|OTHER|Meal 1|D14+/-7
62541130|NCT05949411|OTHER|Meal 2|D16+/-7
62541131|NCT05949411|OTHER|Meal 3|D18+/-7
62164781|NCT03721900|EXPERIMENTAL|SHX-001 Active Low Dose|Ketamine transdermal patch
62164782|NCT03721900|PLACEBO_COMPARATOR|Placebo|placebo transdermal patch
62541132|NCT02462291|EXPERIMENTAL|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
62541133|NCT02462291|NO_INTERVENTION|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
62541134|NCT06632405|EXPERIMENTAL|Camrelizumab+Nab-Paclitaxel+Levocetirizine|Camrelizumab 200mg(3mg/kg for patient whose weight is below 50kg) iv, d1, q3w, plus Nab-Paclitaxel 100mg/m2, iv, d1,8,15 q4w, and Levocetirizine 5mg, po, 3 days before 1st administration
62541135|NCT06632405|PLACEBO_COMPARATOR|Camrelizumab+Nab-Paclitaxel+Placebo|Camrelizumab 200mg(3mg/kg for patient whose weight is below 50kg) iv, d1, q3w, plus Nab-Paclitaxel 100mg/m2, iv, d1,8,15 q4w, and Placebo 5mg, po, 3 days before 1st administration
62541136|NCT06430931|ACTIVE_COMPARATOR|Polypropylene mesh|Polypropylene mesh (Prolene, PMN3, Ethicon Inc Johnson \& Johnson, Amersfoort, The Netherlands; weight 78 g/m2)
62541137|NCT06430931|EXPERIMENTAL|OviTex 1S permanent mesh|OviTex Reinforced BioScaffold, Permanent Polymer composed of ovine (sheep) forestomach extracellular matrix (ECM) and polypropylene.
62541138|NCT03571386||Mild to Moderate Depression|Patients who currently have mild to moderate severity of depression symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
62541139|NCT03571386||Mild to Moderate Anxiety|Patients who currently have mild to moderate severity of anxiety symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
62541140|NCT03571386||High Stress|Patients with a history of reported stress who are receiving Mindfulness-Based Stress Reduction (MBSR) in a group setting as standard of care will be recruited for this study. All patients are eligible.
62541141|NCT02493192|ACTIVE_COMPARATOR|Meperidine|Use pethidine and haloperidol injection as a pain relief.
62541142|NCT02493192|EXPERIMENTAL|birth ball|Use birth ball as a pain relief.
62715185|NCT06552429|EXPERIMENTAL|Peginterferon α-2b 180 mcg dose group|
62541143|NCT03083652|SHAM_COMPARATOR|Control|Conventional physiotherapy with NMEs device not activated
62541144|NCT03083652|EXPERIMENTAL|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
62541145|NCT03196635|EXPERIMENTAL|All Study Participants|All subjects will undergo their regularly scheduled full-field digital mammogram, consisting of bilateral, 2-view (craniocaudal \[CC\] and mediolateral oblique \[MLO\]) image acquisition. In addition, a study-specific, unilateral 2-view image set will obtained, utilizing the PA breast compression mode.
62541146|NCT01882972|EXPERIMENTAL|Exercise|Exercise 12 week home-based resistance exercise training intervention. Participants will be coached to engage in resistance training 3 days per week and aerobic exercise for 30 minutes at least 5 days per week for 12 weeks.
62541147|NCT01882972|PLACEBO_COMPARATOR|control|Participants in the attention control arm will not be asked to cease activity they already participate in but will be instructed not to begin a new exercise program for 12 weeks. Participants will receive a meditation CD to use daily to account for the time intervention arm participants are engaged in exercise.
62541148|NCT06163391|EXPERIMENTAL|SOT201|SOT201 will be administered intravenously once every 21 days
62541149|NCT04767191|ACTIVE_COMPARATOR|artemether lumefantrine|The drug is approved and in use by the Kenya Ministry of Health as the 1st line treatment for malaria. The study is to assess the continued efficacy of the drug.
62541150|NCT04767191|ACTIVE_COMPARATOR|dihydroartemisinin piperaquine|The drug is approved and in use by the Kenya Ministry of Health as the 2nd line treatment for malaria. The study is to assess the continued efficacy of the drug.
62541151|NCT05896644|EXPERIMENTAL|Eat Well|The experimental group will participate in the Eat Well Produce Prescription program, receiving an $80 monthly benefit for eligible produce for 12 months and diabetes education materials through email, including curated nutrition and diet information from the Diabetes Resource Page, consistent with standard of care at Duke University Health System.
62541152|NCT05896644|NO_INTERVENTION|Control|The control group will receive usual care (including diabetes educational materials) without the prescription benefit.
62541153|NCT03925259|ACTIVE_COMPARATOR|Full-ACT|Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of eight modules in the Full-ACT arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all eight mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; self-as-context; values; and committed action.
62541154|NCT03925259|EXPERIMENTAL|ACT-SAC|"Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of seven modules in the ACT-SAC arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; values; and committed action.~The ACT-SAC condition removed the self-as-context module; therapists were instructed to avoid any reference to self-as-context or to support discussions regarding this process."
62541155|NCT06379685|EXPERIMENTAL|PRO-190|"Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.~Dosage: 1 drop QID \[4\] (4 times per day, at least three hours apart between doses) for 7 days in both eyes,~Route of administration: Ophthalmic."
61978111|NCT04055142|EXPERIMENTAL|cidofovir (1%)|Topical ointment wich contains 2 grams of active principle (cidofovir 1%) at each administration. It will be taken three times per week during 8 weeks of treatment.
62541156|NCT06379685|ACTIVE_COMPARATOR|Systane Ultra®|"Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.~Dosage: 1 drop QID \[4\] (4 times per day, at least three hours apart between doses) for 7 days in both eyes,~Route of administration: Ophthalmic."
62541157|NCT00501098|EXPERIMENTAL|I|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
62541158|NCT06600269|EXPERIMENTAL|SCA training group|Long-term training
62541159|NCT06600269|NO_INTERVENTION|SCA Control group|Control group
62541160|NCT03372291|EXPERIMENTAL|Psychological app|"Psychological intervention consist of four components~* Supportive psychotherapy interventions to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance;~* Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social supports;~* Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty;~* Self-care to promote positive health behaviors and enhance patients' sense of control especially as they transition from the hospital to outpatient care.~* The psychological intervention will consist of four sessions (20-25 minutes each) that patients will start during their first week of admission for intensive chemotherapy and continue weekly"
62541161|NCT03372291|ACTIVE_COMPARATOR|Usual Care|"* Participants receiving usual care will not have access to the psychological intervention app. -They will receive usual leukemia care with all the supportive care measures instituted by the leukemia team.~* Patients in usual care will also meet with the leukemia social worker based on their request or at the discretion of the treating leukemia team"
62541162|NCT05972174|EXPERIMENTAL|Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 1|Participants will receive mRNA-1018 for H5N8 at dose level 1 by intramuscular (IM) injection on Day 1 and Day 22.
62164783|NCT03721900|EXPERIMENTAL|SHX-001 Active high dose|ketamine transdermal patch
62164784|NCT01446822|EXPERIMENTAL|Bipolar transurethral resection|
61978112|NCT03330808|EXPERIMENTAL|Epidural with general anesthesia|Epidural anesthesia with 0.2% ropivacaine 10 ml
62164785|NCT01446822|ACTIVE_COMPARATOR|Monopolar transurethral resection|
62164786|NCT06253689|EXPERIMENTAL|Defecation Posture Modification Device|
62164787|NCT06253689|NO_INTERVENTION|Control|
62541163|NCT05972174|EXPERIMENTAL|Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 2|Participants will receive mRNA-1018 for H5N8 at dose level 2 by IM injection on Day 1 and Day 22.
62541164|NCT05972174|EXPERIMENTAL|Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 3|Participants will receive mRNA-1018 for H5N8 at dose level 3 by IM injection on Day 1 and Day 22.
62541165|NCT05972174|EXPERIMENTAL|Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 1|Participants will receive mRNA-1018 for H5 only at dose level 1 by IM injection on Day 1 and Day 22.
62541166|NCT05972174|EXPERIMENTAL|Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 2|Participants will receive mRNA-1018 for H5 only at dose level 2 by IM injection on Day 1 and Day 22.
62541167|NCT05972174|EXPERIMENTAL|Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 3|Participants will receive mRNA-1018 for H5 only at dose level 3 by IM injection on Day 1 and Day 22.
62541168|NCT05972174|EXPERIMENTAL|Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 1|Participants will receive mRNA-1018 for H7N9 at dose level 1 by IM injection on Day 1 and Day 22.
62541169|NCT05972174|EXPERIMENTAL|Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 2|Participants will receive mRNA-1018 for H7N9 at dose level 2 by IM injection on Day 1 and Day 22.
62541170|NCT05972174|EXPERIMENTAL|Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 3|Participants will receive mRNA-1018 for H7N9 at dose level 3 by IM injection on Day 1 and Day 22.
62541171|NCT05972174|EXPERIMENTAL|Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 1|Participants will receive mRNA-1018 for H7 only at dose level 1 by IM injection on Day 1 and Day 22.
62541172|NCT05972174|EXPERIMENTAL|Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 2|Participants will receive mRNA-1018 for H7 only at dose level 2 by IM injection on Day 1 and Day 22.
62541173|NCT05972174|EXPERIMENTAL|Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 3|Participants will receive mRNA-1018 for H7 only at dose level 3 by IM injection on Day 1 and Day 22.
62541174|NCT05972174|EXPERIMENTAL|Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 1|Participants will receive mRNA-1018 for H5 Only-CG at dose level 1 by IM injection on Day 1 and Day 22.
62541175|NCT05972174|EXPERIMENTAL|Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 2|Participants will receive mRNA-1018 for H5 Only-CG at dose level 2 by IM injection on Day 1 and Day 22.
62541176|NCT05972174|EXPERIMENTAL|Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 3|Participants will receive mRNA-1018 for H5 Only-CG at dose level 3 by IM injection on Day 1 and Day 22.
62541177|NCT02609074|EXPERIMENTAL|CPC/rhBMP-2|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC/rhBMP-2 microffolds (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
62541178|NCT02609074|ACTIVE_COMPARATOR|CPC|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC paste (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
62541179|NCT04679701||Recruited Amputees|The amputee participants will be recruited over the course of 6 months. Once a patient is recruited and has given consent, they will be fitted with a prosthesis using the Confidence Socket technology and be administered an initial survey. A follow-up meeting for one month after the fitting is scheduled. At the follow-up appointment adjustments to the prosthesis are made as needed and the patient is administered another survey.
62541180|NCT04030715|OTHER|the successful group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
62541181|NCT04030715|OTHER|the failure group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
62541182|NCT03638726|EXPERIMENTAL|Atropine sulfate and Epinephrine|Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).
62541183|NCT03638726|OTHER|Topical cyclopentolate and phenylephrine|Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.
62541184|NCT02568839|ACTIVE_COMPARATOR|A standard treatment|"docetaxel + trastuzumab sc + pertuzumab. Treatment with all three drugs is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm B.~Postoperatively, patients receive 2 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
62541185|NCT02568839|EXPERIMENTAL|B experimental treatment|"trastuzumab emtansine. Treatment is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm A.~Postoperatively, patients receive 4 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
61976453|NCT02348827|EXPERIMENTAL|Family psychoeducation|The intervention consists of group-based family psychoeducation-program aimed at the patients' relatives. Each group will consist of 5 participants and the patients will not be present at group sessions. The program consists of four weekly sessions each consisting of both short lectures on relevant topics as well as interactive séances designed to give participants problem-solving skills.
62715186|NCT02258802|EXPERIMENTAL|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
62715187|NCT02258802|NO_INTERVENTION|Usual food practices|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
62541186|NCT05060744|ACTIVE_COMPARATOR|Intervention (Antacid)|"An Antacid, a CE marked medical device under normal conditions of use.~Sodium alginate (reduces reflux) (250 mg/tablet) Calcium carbonate (reduces acidity) (80 mg/tablet) Magnesium carbonate (reduces acidity) (144 mg/tablet) Hyaluronic acid (mucosal protector) (6.15 mg/tablet) Aloe vera extract without anthraquinones (mucosal protector) (40 mg/tablet)~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
62541187|NCT05060744|PLACEBO_COMPARATOR|Control|"The control will consist of a placebo based on excipients without active ingredients that will be formulated so that the tablet has the same appearance as the test product, with three different colour layers.~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
62541188|NCT02153463|EXPERIMENTAL|Activity Counselling|Physical Activity Counselling weekly for 8 weeks
62541189|NCT02153463|NO_INTERVENTION|Standard Care|Standard care with no change in medications for 8 weeks
62541190|NCT05002439|EXPERIMENTAL|Group multicomponent physical exercise program and a nutritional intervention|Group multicomponent physical exercise program and a nutritional intervention. The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
62541191|NCT05002439|NO_INTERVENTION|Control group|Control group will receive usual care by their Primary Care Physicians. Healthy lifestyle recommendations including exercise and nutritional recommendations will be offered
62541192|NCT00002678|ACTIVE_COMPARATOR|Melphan plus prednisone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.
62541193|NCT00002678|ACTIVE_COMPARATOR|Melphan, prednisone pluse dexamethasone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression
62541194|NCT04810065|OTHER|SingStrong for Pulmonary Fibrosis|"This arm of the project explores Singing as an intervention for people suffering from Pulmonary Fibrosis specifically.~It is a 10 week programme. All other aspects of the intervention are the same in terms of delivery and length of classes.~Different outcome measures, namely the St Georges Respiratory Questionnaire is used in this trial. This is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations."
62541195|NCT05123183|ACTIVE_COMPARATOR|Acupressure group|Acupressure will be applied to ST36 and CV17 points.
62541196|NCT05123183|ACTIVE_COMPARATOR|Back Massage|Back massage will be applied.
62541197|NCT05123183|ACTIVE_COMPARATOR|Control Group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
62541198|NCT03709979|ACTIVE_COMPARATOR|C-MAC with folded towel position|Children will be intubated by C-MAC videolaryngoscope with placing a folded towel under the shoulder.
62541199|NCT03709979|PLACEBO_COMPARATOR|C-MAC with flat position|Children will be intubated by C-MAC videolaryngoscope with flat position (non-inserted a folded towel)
62541200|NCT01119664|EXPERIMENTAL|No prior chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously untreated with chemotherapy
62541201|NCT01119664|EXPERIMENTAL|Patients with prior Pemetrexed-based chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously treated with chemotherapy
62541202|NCT05418244|EXPERIMENTAL|Inhaled Isopropyl Alcohol|If the subject is assigned to receive the isopropyl alcohol pad group, an isopropyl alcohol pad (Covidien Webcol 2 ply prep pad, saturated with 70% isopropyl alcohol) will be given to the subject, or the legal guardian. The alcohol pad will be held 1-2 cm under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed during the Emergency Department (ED) stay.
62541203|NCT05418244|ACTIVE_COMPARATOR|Oral Ondansetron|If the subject is assigned to receive ondansetron treatment, subject will be provided with 4 mg ondansetron oral disintegrating tablet (ODT) for treatment.
62541204|NCT05418244|PLACEBO_COMPARATOR|Inhaled Placebo|If the subject is assigned to receive the inhaled placebo, a normal saline pad (Hygea sterile saline wipe) will be given to the subject or the legal guardian. The saline wipe will be held under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed.
62164788|NCT03902327|EXPERIMENTAL|NAC group|NAC for 12 weeks, 1.6 mg/day, 4x400 mg; a diet based on general recommendations for people with carbohydrate metabolism disorder
62164789|NCT03902327|ACTIVE_COMPARATOR|Control group|Placebo for 12 weeks and a diet based on general recommendations for people with carbohydrate metabolism disorder
62164790|NCT06138522||Adolescents|Participants in consultations specialising in the treatment of psychotrauma at the Maison de Solenn
62164791|NCT06138522||Parents|Participants in consultations specialising in the treatment of psychotrauma at the Maison de Solenn
62164792|NCT06138522||Professionals|Participants in consultations specialising in the treatment of psychotrauma at the Maison de Solenn
62164793|NCT05432258|EXPERIMENTAL|Bulk-fill composite resin|Bulk-fill Ormocer composite resin restorations on the mandibular first molars applied in layers of 4 mm depth
62164794|NCT05432258|ACTIVE_COMPARATOR|Nano-fill composite resin|Nano-fill composite resin restorations on the mandibular first molars were applied in layers of 2 mm depth
62164795|NCT01252199|EXPERIMENTAL|cαStx1/cαStx2|
62164796|NCT01252199|PLACEBO_COMPARATOR|Control|
62164797|NCT00607789|EXPERIMENTAL|Duloxetine Group|Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.
62164798|NCT00607789|PLACEBO_COMPARATOR|Placebo Group|Sugar pill with matching dosage as Duloxetine
62541205|NCT02193334|ACTIVE_COMPARATOR|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
61978113|NCT03330808|NO_INTERVENTION|General anesthesia alone|Sevoflurane and nitrous oxide.
62164799|NCT03151551|EXPERIMENTAL|Ixekizumab|"160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps."
62164800|NCT03151551|ACTIVE_COMPARATOR|Adalimumab|"80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps."
62164801|NCT03012321|ACTIVE_COMPARATOR|Arm I: Abiraterone + Prednisone|Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
62541206|NCT02193334|PLACEBO_COMPARATOR|Placebo|Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times
62541207|NCT03490760|EXPERIMENTAL|Durvalumab plus Radiation Therapy|Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
62541208|NCT02027428|EXPERIMENTAL|Abraxane + Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
62541209|NCT02027428|OTHER|Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
62541210|NCT06633952|EXPERIMENTAL|MediTrain|
62541211|NCT06633952|EXPERIMENTAL|Worder|
61978114|NCT01707186||Group 1A|Early phase, requiring change in treatment
61978115|NCT01707186||Group 2|Established phase, stable treatment
61978116|NCT01707186||Group 2A|Established phase, requiring a change in treatment
61978117|NCT01707186||Group 1|Early phase, stable treatment
61978118|NCT05068557|ACTIVE_COMPARATOR|Intervention group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with fish oil (3 capsules daily. Containing EPA+DHA: 1.8 g). (n=40)
61978119|NCT05068557|PLACEBO_COMPARATOR|Control group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with chia/linseed oil (3 capsules daily. Containing ALA 1.6 g). (n=40)
61978120|NCT01172457|ACTIVE_COMPARATOR|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
61978121|NCT01172457|PLACEBO_COMPARATOR|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
61978122|NCT03967964|EXPERIMENTAL|Group 1: AVD|Vaginal ring with 2.2 grams dehydroepiandrosterone (DHEA), wearing time 72 hours
61978123|NCT03967964|EXPERIMENTAL|Group 2: AVT|Vaginal ring with 35 mg testosterone, wearing time 72 hours.
61978124|NCT03967964|EXPERIMENTAL|Group 3: AVD+T|Vaginal ring with 1.5 grams DHEA and 25 mg testosterone, wearing time 72 hours.
61978125|NCT03967964|ACTIVE_COMPARATOR|Group 4: DHEA capsule|Capsules with 25 mg DHEA, oral administration every 8 hours for a 72-hour period.
61978126|NCT03967964|ACTIVE_COMPARATOR|Group 5: Testosterone transdermal gel|Testosterone transdermal gel with dosing valve (pump): administration of 3 pump actuations (equivalent to 5 mg of testosterone each) per day (total daily dose 15 mg), on 3 consecutive days (72 hours).
61978127|NCT02105792||Responders|Patients with Type 2 diabetes about to commence a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors or Glitazone or insulin).
61978128|NCT02105792||Progressors|Patients with Type 2 diabetes that progress to requiring insulin treatment ≤10 years from diagnosis or have no requirement for insulin treatment \>10 years from diagnosis.
61978129|NCT01626560|OTHER|Daptomicina|
61978130|NCT01626560|OTHER|Vancomycin|
61978131|NCT01209364|EXPERIMENTAL|Durolane|intraarticular hyaluronic acid
61978132|NCT01209364|ACTIVE_COMPARATOR|methylprednisolone|intraarticular injection
61978133|NCT03750812|ACTIVE_COMPARATOR|Highly fit older adults - Exercise|This will receive an aerobic exercise intervention
61978134|NCT03750812|ACTIVE_COMPARATOR|Poorly fit older adults - Exercise|This arm will receive an aerobic exercise intervention
61978135|NCT03750812|ACTIVE_COMPARATOR|Highly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
61978136|NCT03750812|ACTIVE_COMPARATOR|Poorly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
61978137|NCT03750812|ACTIVE_COMPARATOR|Highly fit older adults - TV|This arm will sit at rest and watch television
61978138|NCT03750812|ACTIVE_COMPARATOR|Poorly fit older adults - TV|This arm will sit at rest and watch television
61978139|NCT03750812|ACTIVE_COMPARATOR|Highly fit young adults - TV|This arm will sit at rest and watch television
61978140|NCT03750812|ACTIVE_COMPARATOR|Poorly fit young adults - TV|This arm will sit at rest and watch television
61978141|NCT05105061|EXPERIMENTAL|Ketamine (1) then Placebo (2)|Participants will receive an intramuscular injection of racemic ketamine, followed the next day by an intramuscular injection of saline (placebo)
61978142|NCT05105061|PLACEBO_COMPARATOR|Placebo (1) then Ketamine (2)|Participants will receive an intramuscular injection of saline (placebo), followed the next day by an intramuscular injection of racemic ketamine
61978143|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
61978144|NCT03676933|EXPERIMENTAL|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
62541212|NCT01357148||Participants treated with sitagliptin phosphate/metformin HCl|
62541213|NCT05517538|EXPERIMENTAL|Palpation-guided|injected with the Palpation Method of neurotoxin adminstration
62541214|NCT05517538|EXPERIMENTAL|EMG-guided|injected with the EMG-guided Method of neurotoxin adminstration
62541215|NCT02950649||Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed and the data will be used for comparison with routine subjective preoperative assessment assessment.
62541216|NCT02950649||No Hemodynamic Monitored Guided Assesment|This group will have subjective assessment by the provider and this data will be compared to the device assessment of cardiac index..
62541217|NCT03601130|OTHER|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
62541218|NCT03601130|ACTIVE_COMPARATOR|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
62541219|NCT04392427|ACTIVE_COMPARATOR|INTERVENTION|"\*Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :"
62541220|NCT04392427|NO_INTERVENTION|CONTROL|"B) Control group: will not receive nothing~* Data collection will include: sociodemographic data, clinical history, results of follow up (daily or according to clinical situation )~* Follow-up: to record any side effects of drugs, swab will be taken for PCR"
62541221|NCT04893018|EXPERIMENTAL|Treatment (efineptakin alfa)|Patients receive efineptakin alfa IM on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
62541222|NCT04735926|PLACEBO_COMPARATOR|Group 1A|Subjects corresponding to Cohort 1 (25-OH-D baseline level \> 10 to \< 20 ng/mL)
62541223|NCT04735926|EXPERIMENTAL|Group 1B|Subjects corresponding to Cohort 1 (25-OH-D baseline level \> 10 to \< 20 ng/mL)
62541224|NCT04735926|EXPERIMENTAL|Group 1C|Subjects corresponding to Cohort 1 (25-OH-D baseline level \> 10 to \< 20 ng/mL)
62541225|NCT04735926|PLACEBO_COMPARATOR|Group 2A|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
62541226|NCT04735926|EXPERIMENTAL|Group 2B|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
62541227|NCT04735926|EXPERIMENTAL|Group 2C|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
62541228|NCT05263310|EXPERIMENTAL|Educational Video and Action Plan handout|"Patients in the intervention arm will be given access to an educational video (Prepare for Your Diabetes Care) and will be supported in viewing the video and the Action Plan handout.~This program will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps with the participant's primary care provider."
62541229|NCT05263310|ACTIVE_COMPARATOR|Usual Care|Patients in the control arm will continue with usual care and also complete baseline, 6-month, and 12-month surveys
62541230|NCT02583958|EXPERIMENTAL|Device Urgo 3103166|Soft-adherent hydro-desloughing dressing
62541231|NCT02583958|ACTIVE_COMPARATOR|Device Aquacel Extra|Hydrofibre dressing
62541232|NCT03981692|ACTIVE_COMPARATOR|Consecutive Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. Immediately after these trainings, they should expected to find the letters Z in the mixed letters, search for the five words you read on the previous page, find the similarities between the concepts, find the letter in the given tables, derive the fruit names starting with the letter, count the days of the week etc. Attention, memory and arithmetic training will be given the ability to run.
62541233|NCT03981692|ACTIVE_COMPARATOR|Integrated Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. They will be done similar cognitive activities during with this simple balance trainings.
62541234|NCT00435812|EXPERIMENTAL|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
62164802|NCT03012321|ACTIVE_COMPARATOR|Arm II: Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
62541235|NCT00435812|ACTIVE_COMPARATOR|Engerix-B|1.0 mL Engerix-B
62541236|NCT06338462|EXPERIMENTAL|Mobile Health and Oral Testing|to adapt an automated conversation agent (Chatbot) and oral testing as a novel multi-component strategy for implementing TB contact investigation over three phases of participatory co-design
62541237|NCT03287843|EXPERIMENTAL|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
62541238|NCT03287843|EXPERIMENTAL|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
62541239|NCT02563392|EXPERIMENTAL|Uterine arteries occlusion|Laparoscopic myomectomy with preventive uterine arteries occlusion
62541240|NCT02563392|ACTIVE_COMPARATOR|No uterine arteries occlusion|Laparoscopic myomectomy without preventive uterine arteries occlusion
62541241|NCT02985671|EXPERIMENTAL|Experimental Drug & Voltaren Placebo|"Orphenadrine + acetaminophen + caffeine + diclofenac sodium \& Placebo of Voltaren~01 tablet of experimental drug (orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg) + 01 tablet of placebo of Voltaren, to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
62541242|NCT02985671|ACTIVE_COMPARATOR|Voltaren® + Experimental Drug Placebo|"Voltaren \& Placebo of Orphenadrine + acetaminophen + caffeine + diclofenac sodium~01 tablet of Voltaren + 01 tablet of placebo of experimental drug (orphenadrine, acetaminophen, caffeine and diclofenac sodium), to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
62541243|NCT06361875|EXPERIMENTAL|Quadrivalent Influenza mRNA Vaccine MRT5421 Dose 1|participants will receive a single dose of QIV mRNA vaccine MRT5421
62541244|NCT06361875|EXPERIMENTAL|Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 1|participants will receive a single dose of QIV mRNA vaccine MRT5429
62541245|NCT06361875|EXPERIMENTAL|Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 2|participants will receive a single dose of QIV mRNA vaccine MRT5429
62541246|NCT06361875|EXPERIMENTAL|Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 3|participants will receive a single dose of QIV mRNA vaccine MRT5429
62541247|NCT06361875|EXPERIMENTAL|Quadrivalent Influenza mRNA Vaccine MRT5429 Dose 4|participants will receive a single dose of QIV mRNA vaccine MRT5429
62541248|NCT06361875|EXPERIMENTAL|Quadrivalent Influenza mRNA Vaccine MRT5424 Dose 1|participants will receive a single dose of QIV mRNA vaccine MRT5424
62541249|NCT06361875|EXPERIMENTAL|Quadrivalent Influenza mRNA Vaccine MRT5424 Dose 2|participants will receive a single dose of QIV mRNA vaccine MRT5424
62541250|NCT06361875|ACTIVE_COMPARATOR|Quadrivalent Influenza SD Vaccine|participants will receive a single dose of QIV-SD vaccine
62541251|NCT06361875|ACTIVE_COMPARATOR|Quadrivalent Influenza HD Vaccine|participants will receive a single dose of QIV -HD vaccine (for adults ≥ 65 years of age only)
62541252|NCT06361875|ACTIVE_COMPARATOR|Quadrivalent Influenza RIV4 Vaccine|participants will receive a single dose of RIV4 vaccine
62541253|NCT00381914|EXPERIMENTAL|1|400 IU / day vitamin D
62541254|NCT00381914|EXPERIMENTAL|2|800 IU / day vitamin D
62541255|NCT00381914|EXPERIMENTAL|3|1200 IU / day vitamin D
62541256|NCT05248165||Coronary artery disease requiring percutaneous coronary intervention|Chronic or acute coronary syndrome requiring percutaneous myocardial revascularization.
62541257|NCT03486366|OTHER|Workpackage1 WP1|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach 1998), aged up to 4 years, diagnosis of epilepsy established on the basis of clinical seizures or epileptiform changes on EEG within 1-7 days prior to baseline. We plan to enroll 60 TSC patients into WP1 to Epimarker in 12 months.
62541258|NCT03486366|OTHER|Workpackage2 WP2|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach criteria: Roach 1998) and epilepsy, aged up to 16 years, seizure free, in whom a decision to withdraw antiepileptic drugs was made. We plan to enroll 60 TSC patients into WP2 to Epimarker in 12 months. The data obtained in children seizure free at the end of follow-up and patients with recurrent seizures will be compare.
62541259|NCT00792350||Group 1|
62541260|NCT01023048|EXPERIMENTAL|PGD testing|
62541261|NCT03132779|EXPERIMENTAL|One armed|One group of patient will take Intralipid for all
62541262|NCT01919788|PLACEBO_COMPARATOR|Control|"No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded.~Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice."
62541263|NCT01919788|EXPERIMENTAL|Insulin|Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
62541264|NCT01919788|EXPERIMENTAL|Insulin and glucose|"Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm.~Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice"
62541265|NCT04899544|EXPERIMENTAL|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|A 16-week center-based PRT intervention (PRT-C) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
62541266|NCT04899544|EXPERIMENTAL|Home-Based Pivotal Response Treatment (PRT) Intervention (PRT-H)|A 16-week home-based PRT intervention (PRT-H) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
62541267|NCT04899544|NO_INTERVENTION|Treatment As Usual (TAU)|This is a control group that consists of children who are receiving treatment as usual (TAU) for a 16-week period. These families will be invited to participate in PRT after completing the 16-week TAU phase.
62541268|NCT06423807|EXPERIMENTAL|Group S (Ondansetron lozenge)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery as a study group.
62541269|NCT06423807|NO_INTERVENTION|Group C (Control)|Patients will not receive ondansetron as a control group.
62541270|NCT01568554||Group 1|Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
62541271|NCT01568554||Group 2 (Not Yet Enrolling)|Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
62541272|NCT01568554||Group 3|"Subjects in Group 3 will participate in the Follow Up Sub-Study. This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit."
62541273|NCT06452667|EXPERIMENTAL|platelet-rich fibin|Each case will receive 3 sessions of therapies with one month interval. We will apply 1-2ml PRF to the photoaging areas in one side of the cheek of patients by using microneedling.
62541274|NCT06452667|ACTIVE_COMPARATOR|platelet-rich palsma|Each case will receive 3 sessions of therapies with one month interval. We will apply 1-2ml PRP to the photoaging areas in one side of the cheek of patients by using microneedling.
62541275|NCT01774708||Bed Exit|"Participants will be up to 60 ambulatory Budd Terrace residents.~Inclusion/Exclusion:~Inclusion:~1. Ambulatory patient able to leave the bed.~2. Willingness to consent and participate in a 30-night study~Exclusion:~1. Lack of capacity to consent, without an identifiable surrogate.~2. Terminal Prognosis~3. Unstable health, as determined by the principal investigator, medical doctor, or registered nurse."
62541276|NCT01657812|EXPERIMENTAL|dexmedetomidine|Drug:dexmedetomidine,dexmedetomidine 1.0μg/kg intravenous injection within 15 minutes before the induction of general anesthesia and followed by Dex 0.4μg/kg/h until 40min before the end of surgery
62541277|NCT01657812|ACTIVE_COMPARATOR|epidural|Epidural:continuous epidural block (T8-9) 4 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery
62541278|NCT01657812|PLACEBO_COMPARATOR|control|Drug: normalsaline
62541279|NCT00000620|EXPERIMENTAL|Glycemia Trial: intensive control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels \<6.0%.
62541280|NCT00000620|ACTIVE_COMPARATOR|Glycemia Trial: standard control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.
62541281|NCT00000620|EXPERIMENTAL|BP Trial: intensive control|Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to \<120 mmHg.
62541282|NCT00000620|ACTIVE_COMPARATOR|BP Trial: standard control|Open label administration of multiple anti-hypertensive agents to maintain SBP level \<140 mm Hg.
62541283|NCT00000620|EXPERIMENTAL|Lipid Trial: fenofibrate|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 in combination with open label simvastatin.
62541284|NCT00000620|PLACEBO_COMPARATOR|Lipid Trial: placebo|Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR \<50 mL/min/1.73m2 in combination with open label simvastatin.
62541285|NCT01154361|EXPERIMENTAL|Arm A|
62541286|NCT01154361|ACTIVE_COMPARATOR|Arm B|
62541287|NCT04063150|ACTIVE_COMPARATOR|IPV at 14 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 14 weeks and 9 months of age.
62541288|NCT04063150|ACTIVE_COMPARATOR|IPV at 6 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 6 weeks and 9 months of age.
62541289|NCT04063150|ACTIVE_COMPARATOR|fIPV ID at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
62541290|NCT04063150|ACTIVE_COMPARATOR|fIPV ID at 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
62541291|NCT04063150|ACTIVE_COMPARATOR|fIPV IM at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
62541292|NCT04063150|ACTIVE_COMPARATOR|fIPV 0.1mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
62541293|NCT04063150|ACTIVE_COMPARATOR|fIPV 0.2mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.2 mL) of IPV at 14 weeks and 9 months of age.
62541294|NCT05379673|ACTIVE_COMPARATOR|"Conservative O2 Supplementation"|Oxygen administration will be titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
62541295|NCT05379673|EXPERIMENTAL|"Liberal O2 Supplementation"|Oxygen administration will be titrated to an SpO2 \> 96%.
62541296|NCT02018380|EXPERIMENTAL|Shock Absorbing Insoles vs. Athletic shoes|
62541297|NCT05339334|EXPERIMENTAL|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days to adult Chinese healthy volunteers
62541298|NCT03437031|NO_INTERVENTION|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
62541299|NCT03437031|EXPERIMENTAL|Latent-Virtual Reality (VR)|Patients in the latent phase of labor who will receive the Virtual Reality (VR) intervention.
62541300|NCT05856006|ACTIVE_COMPARATOR|Stretching Group|upper trapezius stretching plus neck isometrics
62541301|NCT05856006|EXPERIMENTAL|Stretching plus strengthening Group|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics
62541302|NCT00384930|PLACEBO_COMPARATOR|1|placebo tablet
62541303|NCT00384930|ACTIVE_COMPARATOR|2|2.5 mg tadalafil tablet
62541304|NCT00384930|ACTIVE_COMPARATOR|3|5 mg tadalafil tablet
62541305|NCT00384930|ACTIVE_COMPARATOR|4|10 mg tadalafil tablet
62541306|NCT00384930|ACTIVE_COMPARATOR|5|20 mg tadalafil tablet
62541307|NCT06467799|EXPERIMENTAL|Experimental arm|Two cycles of FOLFOX-HAIC combined with tislelizumab as neoadjuvant therapy, followed by surgical resection and four cycles of adjuvant tislelizumab.
62541308|NCT00506584|EXPERIMENTAL|Group 1, arm 1|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day, where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
62541309|NCT00506584|EXPERIMENTAL|Group1, Arm 2|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 40 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
62541310|NCT00506584|ACTIVE_COMPARATOR|Group 1, Arm 3|Human breast milk + bovine-based human milk fortifier (initiated when nutrition volume reaches 100 mL/kg/day) + pre-term formula (as needed)
62541311|NCT00506584|EXPERIMENTAL|Group 2, Arm 1|Prolact20/Neo20 + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
62541312|NCT00506584|ACTIVE_COMPARATOR|Group 2, Arm 2|Pre-term/term formula (minimum 20 cal/oz)
62541313|NCT03496610|ACTIVE_COMPARATOR|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
62541314|NCT03496610|ACTIVE_COMPARATOR|Surgical wound infiltration|Patients will receive 266 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
62715188|NCT06165991|ACTIVE_COMPARATOR|Group A: Bupivacaine|Group A: Participants were treated with 0.5% bupivacaine 20mL thoracic paraverteal block combined with Patient-controlled intravenous analgesia (PCIA) analgesia;
62715189|NCT06165991|ACTIVE_COMPARATOR|Group B: Bupivacaine with drainage tube|Group B: 0.5% bupivacaine 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA;
62715190|NCT06165991|EXPERIMENTAL|Group C: Liposomal bupivacaine|Group C: 1.33% liposomal bupivacaine 20mL thoracic paravertebral nerve block complex PCIA;
62715191|NCT06165991|EXPERIMENTAL|Group D: Liposomal bupivacaine with drainage tube|Group D: 1.33% liposomal bupivacaine 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA.
62715192|NCT06131788|ACTIVE_COMPARATOR|Intervention Arm|"The intervention among people who inject drugs (PWID) from the intervention arm consist in : i) educational hand washing training (fingertips first model), ii) supply of single use alcohol-based hand rub (called MONO-RUB).~Only staff from the 11 harm reduction (HR) centres in the intervention arm will be trained in the educational hand-washing intervention."
61976454|NCT02348827|ACTIVE_COMPARATOR|Social support group|Relatives in the social support group will attend the same number of sessions of the same duration, as the relatives in the intervention group (family psychoeducation). The psychiatric nurse who will be in charge of the social support group will not give any psychoeducational intervention.
62164803|NCT03012321|ACTIVE_COMPARATOR|Arm III: Abiraterone + Prednisone + Olaparib|Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
62164804|NCT03012321|ACTIVE_COMPARATOR|Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
62164805|NCT00282711||1|Standard Exercise treadmill test
62164806|NCT00282711||2|Exercise treadmill testing with nuclear imaging
62164807|NCT04562571|EXPERIMENTAL|Charter & patient information leaflets|A public commitment charter promoting antibiotic stewardship, signed by the general practitioner (GP) and displayed in the practice waiting room; a non-prescription pad, to be distributed to patients when an antibiotic is not needed; and a patient information leaflet to be used when antibiotics were prescribed
62164808|NCT04562571|NO_INTERVENTION|Control|No intervention, eligible general practitioners randomised in the control group not informed of the intervention
62164809|NCT02552706|EXPERIMENTAL|probiotics group|Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
62737002|NCT05254951|EXPERIMENTAL|Patients enrolled in the protocol|Patients will receive a tidal volume challenge to assess fluid responsiveness and then a volume expansion bolus to classify them into responders and not responders
61976455|NCT04737343|ACTIVE_COMPARATOR|Azathioprine treatment arm|Patients will be treated with Azathioprine 100mg QD for 18 months combined with rednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period.All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intoleran.t
61976456|NCT04737343|EXPERIMENTAL|Leflunomide treatment arm|Patient will be treated with Leflunomide 30mg QD for 18 months combined with prednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period. All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intolerant.
61976457|NCT02823288|EXPERIMENTAL|Sonke CHANGE intervention condition|This arm (n=9 clusters) will receive the Sonke CHANGE intervention for 12 months.
61976458|NCT02823288|NO_INTERVENTION|Control condition|In this arm (n=9 clusters), no activities will take place during the trial period outside of data collection.
61976459|NCT01822340|EXPERIMENTAL|Cohort 1|Once weekly HM10560A
61976460|NCT01822340|EXPERIMENTAL|Cohort 2|Once weekly HM10560A
61976461|NCT01822340|EXPERIMENTAL|Cohort 3|Once weekly HM10560A
61976462|NCT01822340|EXPERIMENTAL|Cohort 4|Biweekly HM10560A
61976463|NCT01822340|ACTIVE_COMPARATOR|Cohort 5|Once daily Genotropin
61976464|NCT05789147|ACTIVE_COMPARATOR|active tVNS|Patients randomized to active treatment will be instructed to receive the stimulation at the tragus
61976465|NCT05789147|PLACEBO_COMPARATOR|sham tVNS|Patients randomized to active treatment will be instructed to receive the stimulation at the ear lobe
61976466|NCT00464087|ACTIVE_COMPARATOR|Heparin|Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
61976467|NCT00464087|ACTIVE_COMPARATOR|Bivalirudin|Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
61976468|NCT05793476|EXPERIMENTAL|Fotona Dynamis Er:YAG Laser System Arm|Non-ablative thermal-only Er:YAG laser treatment using R11 and PS03 handpieces
61976469|NCT05793476|SHAM_COMPARATOR|Fotona Dynamis Er:YAG Laser System with Sham handpience|The same procedure is applied but with a sham handpiece.
61976470|NCT04471012|EXPERIMENTAL|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~The experimental group was given a Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet during their first counseling session."
61976471|NCT04471012|NO_INTERVENTION|Standard Care|The progress of the participants in the control group was tracked routinely without any specific implementation. At the end of the study, the control group was also given the same booklet.
61976472|NCT05268939|EXPERIMENTAL|Nasal Swab|Nasal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
61976473|NCT05268939|EXPERIMENTAL|Nasopharyngeal Swab|Nasopharyngeal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
61976474|NCT02651727|EXPERIMENTAL|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 1- IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
61976475|NCT02651727|EXPERIMENTAL|Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 2- IV treatment for the first 2 cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15), followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
61976476|NCT02651727|EXPERIMENTAL|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
61976477|NCT03485768|EXPERIMENTAL|percutaneous disc decompression with coblation nucleoplasty|PDCN will be performed in patients who are allocated to this group by using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA)
62541315|NCT04638075|NO_INTERVENTION|Group A Bottle Supplementation|Group A will supplement using the bottle. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the bottle per standard of care. The mother will breastfeed for up to 25 minutes and then will offer a bottle to supplement breastfeeding for at least 5 minutes. Time at the breast and with the bottle might vary based on the neonate's ability to stay awake at the breast and to sustain a latch at the breast. The type of supplementation will be either Expressed Breast Milk (EBM), Donor Human Milk (DHM), formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of bottle use will be determined by the neonate's physician. The mother will return the neonate to their crib then pump and hand express after feeding sessions per the IBCLC's recommendation. The mother will document each feeding session in the feeding log provided at the bedside.
62541316|NCT04638075|EXPERIMENTAL|Group B SNS Supplementation|Group B will supplement using the SNS. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the SNS per standard of care. The mother will assemble the SNS, place it clamped and in position at the nipple prior to breastfeeding (see SNS instructions for use). The mother will initiate breastfeeding for up to 5 minutes and then unclamp the SNS to begin supplementation for up to 25 minutes. The SNS will contain either EBM, DHM, formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of SNS use will be determined by the neonate's physician. The mother will pump and hand express after feeding sessions per the IBCLC's recommendation. Them mother will document each feeding session in the feeding log provided at the bedside.
62541317|NCT00086281|EXPERIMENTAL|1|Xyrem 9 grams given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later
62541318|NCT00086281|ACTIVE_COMPARATOR|2|Zolpidem 10 mg + placebo were given at bedtime and placebo given 2.5 to 4 hours later.
62541319|NCT00086281|EXPERIMENTAL|3|Xyrem 9 g + modafinil 200 mg (Xyrem 9 g was given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later; modafinil was given at 8 am on the morning of Xyrem treatment).
62541320|NCT00086281|PLACEBO_COMPARATOR|4|Placebo was given at bedtime and again 2.5 to 4 hours later.
62541321|NCT04215276|ACTIVE_COMPARATOR|Valsalva Maneuver|Patient will do valsalva maneuver for 20 seconds
62541322|NCT04215276|PLACEBO_COMPARATOR|control|Patient will do nothing
62541323|NCT05778903|ACTIVE_COMPARATOR|Ultrasound guided Suprazygomatic Maxillary Nerve Block|An ultasound guided SMNB is admitted on one half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.
62541324|NCT05778903|ACTIVE_COMPARATOR|Landmark guided Suprazygomatic Maxillary Nerve Block landmark|A langmark guided SMNB is admitted on the other half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.
62541325|NCT01161134|EXPERIMENTAL|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
62541326|NCT01161134|ACTIVE_COMPARATOR|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
62541327|NCT01233739|PLACEBO_COMPARATOR|Placebo|
62541328|NCT01233739|EXPERIMENTAL|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
62541329|NCT02987452|EXPERIMENTAL|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
62541330|NCT02987452|ACTIVE_COMPARATOR|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
62541331|NCT02987452|ACTIVE_COMPARATOR|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
62541332|NCT06355102||SSNHL with Tinnitus|Patients diagnosed with sudden sensorineural hearing loss accompanied with acute occuring tinnitus symptoms.
62541333|NCT06355102||SSNHL without Tinnitus|Patients diagnosed with sudden sensorineural hearing loss without acute occuring tinnitus symptoms.
62541334|NCT06355102||Health Control|Healthy subjects with normal hearing and no tinnitus.
62541335|NCT06125808|EXPERIMENTAL|1050 mg HRO350|1050 mg HRO350 daily given as 3 capsules of HRO350 (350 mg) in the morning and 3 capsules of placebo in the evening. Total of 6 capsules daily.
62541336|NCT06125808|EXPERIMENTAL|2100 mg HRO350|2100 mg HRO350 daily given as 3 capsules of HRO350 in the morning and 3 capsules of HRO350 in the evening. Total of 6 capsules daily.
62541337|NCT06125808|PLACEBO_COMPARATOR|Placebo|Placebo given as 3 capsules of placebo in the morning and 3 capsules of placebo in the evening, Total of 6 capsules daily.
62541338|NCT00627861|EXPERIMENTAL|Aliskiren and metoprolol succinate|
62164810|NCT02552706|PLACEBO_COMPARATOR|control group|control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
62541339|NCT06007833|EXPERIMENTAL|physical therapy and rehabilitation program in addition to conservative treatment|Orthoses and positioning will be applied to the experimental group as a conservative treatment, following post-surgical plastering. In addition, they will receive a physical therapy and rehabilitation program
62541340|NCT06007833|ACTIVE_COMPARATOR|Conventional Group|As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning will be applied
62164811|NCT03771378|EXPERIMENTAL|Effective of rhTPO|After enrollment, all subjects receive rhTPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
62168000|NCT05018949||Patients who have undergone LL angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
62737003|NCT03774043|EXPERIMENTAL|Single session of Acute Intermittent Hypoxia (AIH)|
62168001|NCT01379521|EXPERIMENTAL|everolimus + TACE|everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
62168002|NCT01379521|PLACEBO_COMPARATOR|placebo + TACE|Placebo by mouth + transcatheter arterial chemoembolization (TACE)
62541341|NCT06602960|ACTIVE_COMPARATOR|Control Group|"All arms receive identical instructions during the onboarding session, which includes information about the study's purpose and the use of Fitbit and NextSense brain-sensing earbuds. Participants are provided with a Fitbit and NextSense brain-sensing earbuds upon enrollment in the study and are instructed to wear them during weeks 3-4. Throughout the 4 weeks, participants complete short daily surveys and longer weekly surveys. At the end of the study, participants complete an offboarding survey.~In this arm, participants will receive accurate feedback about their sleep data."
62541342|NCT06602960|EXPERIMENTAL|Intervention Group 1|"All arms receive identical instructions during the onboarding session, which includes information about the study's purpose and the use of Fitbit and NextSense brain-sensing earbuds. Participants are provided with a Fitbit and NextSense brain-sensing earbuds upon enrollment in the study and are instructed to wear them during weeks 3-4. Throughout the 4 weeks, participants complete short daily surveys and longer weekly surveys. At the end of the study, participants complete an offboarding survey.~In this arm, participants will receive inflated feedback about their sleep data, suggesting better sleep quality than detected by Fitbit (actual sleep hours +10%)."
62541343|NCT06602960|EXPERIMENTAL|Intervention Group 2|"All arms receive identical instructions during the onboarding session, which includes information about the study's purpose and the use of Fitbit and NextSense brain-sensing earbuds. Participants are provided with a Fitbit and NextSense brain-sensing earbuds upon enrollment in the study and are instructed to wear them during weeks 3-4. Throughout the 4 weeks, participants complete short daily surveys and longer weekly surveys. At the end of the study, participants complete an offboarding survey.~In this arm, participants will receive deflated feedback about their sleep data, suggesting poorer sleep quality than detected by Fitbit (actual sleep hours -10%)."
62541344|NCT06602960|EXPERIMENTAL|Intervention Group 3|"All arms receive identical instructions during the onboarding session, which includes information about the study's purpose and the use of Fitbit and NextSense brain-sensing earbuds. Participants are provided with a Fitbit and NextSense brain-sensing earbuds upon enrollment in the study and are instructed to wear them during weeks 3-4. Throughout the 4 weeks, participants complete short daily surveys and longer weekly surveys. At the end of the study, participants complete an offboarding survey.~In this arm, participants will receive accurate feedback about their sleep data along with sleep-related educational information."
62541345|NCT02766933||hepatitis B cohort|CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening
62541346|NCT05520515|EXPERIMENTAL|Aquatic training plus health education group|Aerobic exercise training program in the aquatic environment twice a week plus health education program once a week
62541347|NCT05520515|EXPERIMENTAL|Land training plus health education group|Aerobic exercise training program in the land environment twice a week plus health education program once a week
62541348|NCT05520515|ACTIVE_COMPARATOR|Health education group|Health education program once a week
62541349|NCT02207712|ACTIVE_COMPARATOR|Standard Arm|Those receiving only their prescribed ranibizumab treatment only
62541350|NCT02207712|EXPERIMENTAL|Intervention Arm|Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
62541351|NCT02194348|EXPERIMENTAL|BIBN 4096 BS - in single rising doses|
62541352|NCT02194348|PLACEBO_COMPARATOR|Placebo|
62541353|NCT04880603|ACTIVE_COMPARATOR|A - Standard of Care|
62541354|NCT04880603|EXPERIMENTAL|B - Restrata Graft|
62541355|NCT02572414|EXPERIMENTAL|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention consisted of three, 3-hour weekly small-group intervention sessions led by a trained facilitator using a detailed, scripted manual designed to increase adherence to guidelines for physical activity, 5-a-Day diet, and colon cancer screening.
62541356|NCT02572414|ACTIVE_COMPARATOR|Health Awareness Control|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
62541357|NCT02888587||Control group|no gastrointestinal symptoms
62541358|NCT02888587||Symptomatic group|Patients with Visceral hypersensitivity
62541359|NCT05204082|NO_INTERVENTION|Standard IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have standard IV insertion
62541360|NCT05204082|OTHER|SU-VEID assisted IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have IV insertion using SU-VEID device
62541361|NCT06352918|EXPERIMENTAL|Experimental group|Along with the NICU PICC care application procedures, palmar grasp reflex stimulation was performed on all babies by the same researcher, starting one minute before the procedure.
61976478|NCT03485768|ACTIVE_COMPARATOR|Manual Therapy|Participants who are allocated to this group will undergo manual therapy treatments containing two kinds: sustained natural apophyseal glides (SNAGs) plus passive joint mobilisations (PJMs)
62541362|NCT06352918|NO_INTERVENTION|Control Group|Without any intervention to the control group, the necessary data were recorded in accordance with the NICU's PICC care application procedures.
62715193|NCT06131788|NO_INTERVENTION|Control Arm|The 11 control arm HR centres will be the placebo group. People who inject drugs (PWID) in this group will receive standard HR services, including to reduce abscesses if necessary. MONO-RUBs will not be made available in these HR centres during the intervention period.
62737004|NCT03774043|PLACEBO_COMPARATOR|Single session of Sham Acute Intermittent Hypoxia (Sham AIH)|
62737005|NCT03774043|EXPERIMENTAL|Two successive sessions of AIH|
61976479|NCT04626297|EXPERIMENTAL|Lebrikizumab|Participants received a loading dose of 500 milligram (mg) lebrikizumab injection administered subcutaneously (SC) at baseline and week 2, and 250 mg once every two weeks (Q2W) from week 4 to 14.
61976480|NCT04626297|PLACEBO_COMPARATOR|Placebo|Participants received placebo SC injection Q2W from baseline to week 14.
61978145|NCT03676933|PLACEBO_COMPARATOR|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
62541363|NCT04932161|EXPERIMENTAL|Titanium Granules as a bone graft in intrabony defects|In test group, after reflection of flap and degranulation, bone graft i.e., titanium particles will be placed in the void created by the defect and sutures will be placed.
62541364|NCT04932161|ACTIVE_COMPARATOR|Hydroxyapatite as a bone graft in intrabony defects|In control group, after reflection of flap and degranulation, bone graft i.e., hydroxyapatite will be placed in the defect and sutures will be placed.
62541365|NCT05213039||1/Children with diparetic and hemiparetic cerebral palsy|1/Children with diparetic and hemiparetic cerebral palsy whose Gross Motor Function Classification System (GMFCS) Level ≤ 2 will be evaulated by two different observers.
62541366|NCT01728129|EXPERIMENTAL|Concussed|Subjects who are diagnosed with a concussion by a clinician will be assessed with the MACE and DANA Rapid every 24 hours for up to 72 hours post-injury.
62541367|NCT01728129|ACTIVE_COMPARATOR|Non-concussed|Subjects will have been exposed to a potentially concussive event but be clinically evaluated and found not to have sustained a concussion. Control subjects from this arm will take both the MACE and DANA Rapid twice: once within 24 hours of potentially concussive event, and again on the day of return to duty.
62541368|NCT04645537||FinACAF cohort|The study cohort consists of all patients with AF diagnosis (ICD-10 I48) living in Finland during 1.1.2004-31.12.2018. The study cohort is obtained from data of Finnish national registries. Patients with permanent residence in Finland less than 12 months prior to index date and patients with age below 18 years at index date are excluded from the study.
62541369|NCT05629975|EXPERIMENTAL|Intervention group|"In addition to the normal diet in the hospital, patients in the intervention group received a package of nutritional powder in the morning and evening of every day, and each package was diluted with 500 ml of water.~Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days."
62541370|NCT05629975|NO_INTERVENTION|Control group|Patients in the control group received normal diet provided by the hospital.
62168003|NCT01282983|ACTIVE_COMPARATOR|fiber|
62541371|NCT04925193|EXPERIMENTAL|Arm 1 SPd|"* Selinexor 60 mg PO days 1, 8, 15~* Pomalidomide 4 mg PO on days 1-21~* Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22~* 28 day treatment cycles"
62541372|NCT04925193|EXPERIMENTAL|Arm 2 SDd|"* Selinexor 80 mg PO days 1, 8, 15~* Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \>6~* Dexamethasone 40 mg PO or IV days 1, 8, 15, 22~* 28 day treatment cycle"
62541373|NCT04925193|EXPERIMENTAL|Arm 3 SKd|"* Selinexor 80 mg PO days 1, 8, 15~* Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.~* Dexamethasone 40 mg IV or PO days 1, 8, 15, 22~* 28 day treatment cycle"
62541374|NCT01371812|EXPERIMENTAL|Cohort 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 150mg, to 600mg, to 1200mg and 1200mg with a FDA high fat/high calorie meal, will be administered over the 13 week long study allowing adequate washout period between doses.
62541375|NCT01371812|EXPERIMENTAL|Cohort 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 300mg, to 900mg, and 1500mg, will be administered over the 13 week long study allowing adequate washout period between doses.
62541376|NCT01520870|EXPERIMENTAL|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end. Patients at first recurrence will be enrolled onto 1 of 2 cohorts that will be recruited and analysed independently. Cohort A will include patients who have EGFRvIII mutations. Cohort B will include patients who have EGFR gene amplification but no EGFRvIII mutations.
62541377|NCT01900561|EXPERIMENTAL|IVR Intervention|The intervention will consist of two components, both with content design based on established theories for self-management support: 1) automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach, and 2) personally tailored newsletters that incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Intervention-group participants will receive four automated assessment and self-management support calls over a 3-month period (at baseline, 1-month, 2-month, 3-months). Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
62541378|NCT01900561|NO_INTERVENTION|Enhanced Usual Care|Because of the strong evidence documenting symptom burden in PC survivors, the investigators believe that providing control subjects with some information about symptom self-management is warranted. The investigators further believe, based on the investigators' prior experience conducting RCTs, that offering some type of educational material for Veterans randomized to the control arm will increase their willingness to enroll in the study (as opposed to a pure usual care arm where they would not receive any such materials). Therefore, survivors randomized to the control condition will receive written material at the time of enrollment designed to educate them about PC symptoms and symptom management. Material will be approximately six pages in length, also written at or below an 8th grade reading level, and will include a summary of common symptoms experienced by prostate cancer survivors.
62541379|NCT04646005|EXPERIMENTAL|Cemiplimab+ISA101b|
62541380|NCT00323466|EXPERIMENTAL|IMRT|
62541381|NCT05615831|EXPERIMENTAL|Young adult (19-30 years)|Individuals aged 19-30 who are not physically active will participate in resistance training combined with blood flow restriction.
62541382|NCT05615831|EXPERIMENTAL|Older adults adult (aged 65 years and older)|Individuals aged 65 years and older who are not physically active will participate in resistance training combined with blood flow restriction.
62715194|NCT04641221|ACTIVE_COMPARATOR|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
62737006|NCT03774043|PLACEBO_COMPARATOR|Two successive sessions of Sham AIH|
62168004|NCT01282983|PLACEBO_COMPARATOR|Placebo|
62168005|NCT05165563|EXPERIMENTAL|Workflows|Digital and conventional workflows for treatment of implant single crowns
62168006|NCT05165563|EXPERIMENTAL|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
62541383|NCT02904824|EXPERIMENTAL|ADRC, adipose derived regenerative cells|Biological: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
62541384|NCT02904824|ACTIVE_COMPARATOR|CAF, centrifuged autologous fat|Biological: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.
62541385|NCT06233903|EXPERIMENTAL|Neural crest tumors and sympathetically innervated organs undergoing tissue sampling|All subjects who undergo histopathologically established diagnosis of neuroblastoma and a scheduled clinical biopsy or surgery procedure within 21 days after 18F-mFBG PET imaging procedure; or be scheduled to have a clinical biopsy or surgery procedure that will yield a tissue specimen from an adrenergically-innervated organ or a non-neuroblastoma neural crest tumor within 21 days after 18F-mFBG PET imaging.
62541386|NCT01860352|OTHER|Fish Oil|
62541387|NCT01577589|EXPERIMENTAL|A|600 mg ceftaroline fosamil in 50 ml infusion volume
62541388|NCT01577589|PLACEBO_COMPARATOR|B|Placebo in 50 ml infusion volume
62541389|NCT01577589|EXPERIMENTAL|C|600 ceftaroline fosamil in 250 ml infusion volume
62541390|NCT01577589|PLACEBO_COMPARATOR|D|Placebo in 250 ml infusion volume
62541391|NCT01577589|EXPERIMENTAL|E|600 mg ceftaroline in 100 ml infusion volume
62541392|NCT01577589|PLACEBO_COMPARATOR|F|Placebo in 100 ml infusion volume
62541393|NCT05884294|EXPERIMENTAL|PowerGlide Pro Midline catheter.|The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
62541394|NCT05884294|NO_INTERVENTION|Introcan Safety Deep Access long peripheral venous catheter.|The control group will be subjected to the same selection criteria as the patients in the intervention group; however, they will receive an ultrasound-guided insertion of a long peripheral venous catheter Introcan Safety Deep Access 20G (6.4 cm).
62541395|NCT03521843|EXPERIMENTAL|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
62541396|NCT03521843|EXPERIMENTAL|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
62541397|NCT04026386|EXPERIMENTAL|Center Based or In-Home Early Intervention Program|
62541398|NCT06632288||Prospective Observational Cohort|Patient and family caregiver dyads will be recruited for a prospective cohort observation for at least 24 hours and a maximum of seven days. At inclusion, baseline and self-reported data from admission until inclusion will be collected. After inclusion, data will be collected every 24 hours on self-reported outcomes of the last 24 hours. Patients and family caregiver dyads will be followed until discharge, transfer to another department, death or a maximum of seven days of follow-up. If dyads stay longer than seven days, daily follow-up is ended and they are called once 14 days later to collect outcome data.
62541399|NCT06632288||Time and Motion|Nurses and doctors will be recruited for time-and-motion observations by a trained non-participant observer during their shift on the medicine ward. Observers will use a REDCap to record where, what, for how long and how health workers perform tasks and interactions during their shifts. Observations will take place in sets of two hours each. Approximate equal amounts of observations will be done on all medicine wards. Observations will occur on different days of the week, at different shifts during the day, and at different times during a shift to collect data from different care contexts. Baseline data of the shift is recorded at the start of the observation.
62541400|NCT06632288||Qualitative|The qualitative arm of the study involves interviews and focus group discussions with patients, family caregivers, nurses, doctors and hospital administrators. The FGDs and interviews will be performed in English, Twi or Ga by a local researcher experienced in qualitative research. An interview guide is used to define themes for the conversations, however, the interviewer is encouraged to follow the flow of the conversation by changing the order of topics or asking additional questions. The main themes of the interview guide are (1) the role of family participation in hospital care, (2) the perceived effect of family participation, (3) the barriers and facilitators for family participation in hospital care, and (4) the opportunities for improving family caregiver participation in hospital care.
62541401|NCT02538965|EXPERIMENTAL|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
62541402|NCT01722201|EXPERIMENTAL|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
62541403|NCT01722201|ACTIVE_COMPARATOR|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
62541404|NCT03938623||Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
62541405|NCT03938623||Control|General Practitioners not using the patient-centered approach
62541406|NCT04924257|EXPERIMENTAL|Intranasal Esketamine|
62541407|NCT04924257|ACTIVE_COMPARATOR|ECT|
62541408|NCT01582152|EXPERIMENTAL|TPI 287 + Bevacizumab|"Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.~Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.~Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I."
62715195|NCT04641221|ACTIVE_COMPARATOR|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
62715196|NCT04641221|ACTIVE_COMPARATOR|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
62715197|NCT04641221|ACTIVE_COMPARATOR|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
62715198|NCT04641221|ACTIVE_COMPARATOR|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
62541409|NCT01582152|EXPERIMENTAL|Bevacizumab Group|"Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.~Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone."
62541410|NCT06015763|OTHER|Relation between gastritis and H.pylori|Endoscopic
62541411|NCT04141930|OTHER|Study Drug Eligible|Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant
62541412|NCT06548178|EXPERIMENTAL|Arm A|T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.
62541413|NCT06548178|PLACEBO_COMPARATOR|Arm B|Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.
62541414|NCT00659958|EXPERIMENTAL|1|
62541415|NCT01012310|EXPERIMENTAL|Cohort 1|
62541416|NCT01012310|EXPERIMENTAL|Cohort 2|
62541417|NCT01012310|EXPERIMENTAL|Cohort 3|
62541418|NCT01012310|EXPERIMENTAL|Cohort 4|
62541419|NCT01256944||Control|The normal reproductive-aged women
62541420|NCT01256944||PCOS|"Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:~1. Oligo- or anovulation~2. Clinical and/or biochemical signs of hyperandrogenism~3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)"
62541421|NCT03257865|EXPERIMENTAL|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
62541422|NCT03257865|PLACEBO_COMPARATOR|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind
62541423|NCT01199016||1|
62541424|NCT03844386|EXPERIMENTAL|MVA.tHIVconsv3 (M3)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv3 (M3) given IM at Day 0
62541425|NCT03844386|EXPERIMENTAL|MVA.tHIVconsv4 (M4)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv4 (M4) given IM at Day 0
62541426|NCT03844386|EXPERIMENTAL|MVA.tHIVconsv3 (M3)+MVA.tHIVconsv4 (M4)|Participants in this arm receive a single combined dose containing each vaccine type MVA.tHIVconsv4 (M3) + MVA.tHIVconsv4 (M4) given IM at Day 0
62541427|NCT03844386|PLACEBO_COMPARATOR|Placebo|Participants in this arm receive one saline (placebo) dose given IM at Day 0
62541428|NCT02985216|EXPERIMENTAL|YHD1119|YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150\~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
62541429|NCT02985216|ACTIVE_COMPARATOR|Lyrica|Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150\~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
62541430|NCT01352416|ACTIVE_COMPARATOR|CABG surgery with Ranolazine|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
62541431|NCT01352416|PLACEBO_COMPARATOR|CABG surgery with placebo|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
62541432|NCT01352416|ACTIVE_COMPARATOR|Heart Valve surgery with Ranolazine|Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
62541433|NCT01352416|PLACEBO_COMPARATOR|Heart Valve surgery with placebo|Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.
62541434|NCT03510026|OTHER|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
62541435|NCT05786209|EXPERIMENTAL|Whole-body Balm + Wash and Shampoo|Parent participant will be instructed to apply the whole-body balm on the newborn baby's whole body (excluding the mouth, eyes, diaper area, and scalp) two times per day (morning and evening), and to cleanse the newborn baby with the wash and shampoo at least once per week and no more than three times per week up to Day 28.
62737007|NCT05959655||Glean Urodynamics System|Wireless, catheter-free urodynamics system
62541436|NCT01680003|EXPERIMENTAL|Hepar-P|Hepar-P: Two capsules (250mg x 2), three times daily, orally
62541437|NCT01680003|PLACEBO_COMPARATOR|Placebo for Hepar-P|Placebo: Two capsules, three times daily, orally
62541438|NCT04616430|PLACEBO_COMPARATOR|Control|Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
62541439|NCT04616430|ACTIVE_COMPARATOR|Topical Endoxifen 10mg/breast/day|10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
62541440|NCT04616430|ACTIVE_COMPARATOR|Topical Endoxifen 20mg/breast/day|20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
62541441|NCT00916760|EXPERIMENTAL|1|A Subcutaneous Depigmented and Polymerized Allergen extract of Parietaria Judaica 1000 DPP/ml. Depigoid Parietaria judaica 1000 DPP/ml.
62541442|NCT00916760|PLACEBO_COMPARATOR|2|
62164812|NCT03771378|ACTIVE_COMPARATOR|Effective of eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
62164813|NCT00884793|EXPERIMENTAL|intensification with raltegravir +/- NNRTI or PI|Intensification with raltegravir 400mg PO BID +/- a study PI or NNRTI
62164814|NCT06407193||Poor weight loss group|Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with TWL \< 25%
62164815|NCT06407193||Successful weight loss group|Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with TWL \> 35%
62164816|NCT06646562|EXPERIMENTAL|CAB LA + RPV LA|the proportion of participants ≥60 years on stable oral ART that switch to CAB LA + RPV LA with plasma HIV-1 RNA ≥50 copies/mL at month 12 in the intention-to- treat exposed (ITT-E) population
62164817|NCT05043298|EXPERIMENTAL|IBI360|
62164818|NCT05043298|EXPERIMENTAL|IBI 360 + Sintilimab|
62164819|NCT00425906|EXPERIMENTAL|Nicotine inhaler|
62164820|NCT00425906|PLACEBO_COMPARATOR|Placebo inhaler|
62168007|NCT05741294|EXPERIMENTAL|Tirbanibulin 2.5 milligrams (mg) ointment|Participants will apply tirbanibulin ointment- topically at a dose of 2.5 mg once daily for 5 consecutive days- on the face or scalp.
62715199|NCT04641221|ACTIVE_COMPARATOR|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
61976481|NCT02302781||Subfertile couples|Couples referred to one of the four participating hospitals with any type of subfertility for work up and/ or treatment will be screened for inclusion. Couples have not visited only other clinic yet.
61976482|NCT06315439||pancreatic solid lesions|
61976483|NCT03315208|EXPERIMENTAL|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
61976484|NCT03315208|ACTIVE_COMPARATOR|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
61976485|NCT03061838|ACTIVE_COMPARATOR|MabThera®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
61976486|NCT03061838|EXPERIMENTAL|Ritumax®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
61976487|NCT05829889|EXPERIMENTAL|FFR-guided Left Main PCI|
61976488|NCT05829889|ACTIVE_COMPARATOR|Angiography-Guided PCI|
61976489|NCT04233554|EXPERIMENTAL|Intervention Arm - Implementing Patient Priorities Care|Practice staff and providers will be trained on how to identify patient health priorities. Staff and clinicians will implement Patient Priorities Care, document priorities in EHRs, and align patient priorities with health care decisions.
61976490|NCT04233554|NO_INTERVENTION|Control Arm|Control arm practices will receive no intervention and patients will receive usual care.
61976491|NCT03921086|OTHER|Hypertensive patients|Newly diagnosed or poorly controlled hypertensive patients will be initiated on appropriate therapy as per a specific algorithm.
61976492|NCT03285620|EXPERIMENTAL|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral dose of AL-034 (oral solution) (the starting dose in Cohort 1 of Part 1 will be 0.2 milligram \[mg\]) or matching placebo under fasted condition (Cohorts 1 to 5 or optional Cohort 7) on Day 1. Participants may receive AL-034 in a fed state (Cohort 6) to evaluate the effect of food on the pharmacokinetics (PK) of AL-034.
61976493|NCT03285620|EXPERIMENTAL|Part 2: Multiple-Dose Administration (MAD)|Participants will receive multiple oral doses of AL-034 or matching placebo for 4 consecutive weeks either once weekly (Qwk - for 4 doses) or every two weeks (Q2wk - for 3 doses) under fed or fasted conditions. The starting dose for Part 2 will be determined based on the initial PK and safety/tolerability data from Part 1.
61976494|NCT02329249|EXPERIMENTAL|Smokefree Partners: 21 Days to Freedom|Smoking cessation website program with live personal coach
61976495|NCT02329249|OTHER|Wait-list control|120-day wait-list and then provided access to the smoking cessation website
61976496|NCT06420453||Exposed to prolonged labor duration|
61976497|NCT06420453||Not exposed to prolonged labor duration|
61976498|NCT04610944|EXPERIMENTAL|Intervention|Intervention nursing homes will receive the training and control nursing homes will complete assessments, but not receive the training.
61976499|NCT04610944|ACTIVE_COMPARATOR|Waitlist Control|After the intervention nursing homes complete the training, the waitlist control nursing homes will crossover and complete the training.
61976500|NCT01196923|EXPERIMENTAL|HeartLight Ablation|
61976501|NCT03445338|EXPERIMENTAL|Cohort 1|
61976502|NCT03445338|EXPERIMENTAL|Cohort 2|
61976503|NCT03445338|EXPERIMENTAL|Cohort 3|
61976504|NCT04106921|EXPERIMENTAL|Universal Health Coverage Mode|The NGOs Muso and Medic Mobile have partnered to develop Universal Health Coverage Mode, a smartphone app tool that provides visual cues to help CHWs track the quantity of household visits they have conducted at each household in a given month.
61976505|NCT04106921|NO_INTERVENTION|Work as usual|For the control arm, all households within the CHW's household list in the app will have the same appearance. There will be no visual differentiation between households on the list to indicate the frequency of home visits.
61976506|NCT03236740|ACTIVE_COMPARATOR|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
61976507|NCT03236740|ACTIVE_COMPARATOR|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
61976508|NCT04178499||smokers|active smokers
61976509|NCT04178499||non-smokers|never smokers
61978146|NCT01204164|EXPERIMENTAL|TG02 in AL|Single agent TG02 citrate in acute leukemia patients
62541443|NCT03568097|EXPERIMENTAL|Avelumab + Standard 1st line Chemotherapy|Administration of cisplatin or carboplatin + etoposide every 3 weeks with phased avelumab administered every 2 weeks until disease progression.
62541444|NCT03223844|EXPERIMENTAL|Healthy subjects|Measurement of Dextroamphetamine Sulfate-induced dopamine release and synthesis before and after amphetamine sensitization.
62541445|NCT01577940|EXPERIMENTAL|Infusion of local anesthetic|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours.
62541446|NCT01577940|PLACEBO_COMPARATOR|Infusion of saline|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of saline 5 ml/h 24 hours.
62541447|NCT00240565|EXPERIMENTAL|Arm 1|Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
62541448|NCT04748965||Tibial Vessel Involvement in Patients with peripheral artery disease and CLI|The primary goal is to establish a protocol for performing optimal OCT in below-the-knee vessels. OCT images will be analyzed for lesion characteristics, lesion sizing pre- and post-intervention. This will be analyzed against QVA and IVUS (latter if applicable).
62541449|NCT00753662|ACTIVE_COMPARATOR|1|15 patients in group 1 will be treated with 1Hz frequency
62541450|NCT00753662|ACTIVE_COMPARATOR|2|15 patients in group 2 will be treated with 1Hz frequency 10Hz
62541451|NCT00753662|SHAM_COMPARATOR|3|15 patients in group 3 will be treated with SHAM (1Hz/10Hz)
62541452|NCT02522715|EXPERIMENTAL|Treatment (cabazitaxel, enzalutamide)|Patients receive cabazitaxel IV over 1 hour on day 1 and enzalutamide PO QD on days 1-21 (days 2-21 of cycle 1). Patients also receive prednisone PO BID as standard of care with cabazitaxel. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue enzalutamide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
62541453|NCT01226407|EXPERIMENTAL|Single Arm for CG200745|any progrossive solid cancer
62541454|NCT06121934|EXPERIMENTAL|Carica Papaya Leaf Extract|"The study patients will be followed for clinical and laboratory endpoints in the hospital until study day 5 (or daily as outpatients from discharge to day 5) and reviewed at an outpatient visit at week 2 after discharge.~The patients will be assigned to one of the two treatment arms after randomization:~1) Active drug: Carica papaya leaf extract (CPLE) 500mg 2 capsule t.i.d for 5 days~The oral capsule of CPLE and placebo will be provided by the Institute of Technology Transfer and Innovation (ITTI), an institute in Bangladesh Council of Scientific and Industrial Research (BCSIR), with appropriate masking for a double-blind study. On receipt, the medications will be stored in a secure area by the manufacturer's recommendation."
62541455|NCT06121934|PLACEBO_COMPARATOR|Placebo|"The study patients will be followed for clinical and laboratory endpoints in the hospital until study day 5 (or daily as outpatients from discharge to day 5) and reviewed at an outpatient visit at week 2 after discharge.~The patients will be assigned to standard treatment with placebo after randomization:~Placebo: visually matched placebo 2 capsule t.i.d for 5 days~The oral capsule of CPLE and placebo will be provided by the Institute of Technology Transfer and Innovation (ITTI), an institute in Bangladesh Council of Scientific and Industrial Research (BCSIR), with appropriate masking for a double-blind study. On receipt, the medications will be stored in a secure area by the manufacturer's recommendation."
62541456|NCT03451552|NO_INTERVENTION|Control (211 services)|Patients allocated to the control arm will be directed to the Ontario 211 navigation service, which is already available to the general public free of charge. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use existing navigation services provided by Ontario 211 to help them access the CR referred to them by their PHCP. The research assistant will instruct patients to dial 2-1-1 to obtain additional information on the nature of this service.
62541457|NCT03451552|EXPERIMENTAL|Intervention (Patient Navigator)|Patients allocated to the intervention arm will be offered the services of the ARC Patient Navigator. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use the services offered by the ARC patient navigator to help them access the CR referred to them by their PHCP. Following a brief description of the services provided by the navigator (e.g., arrange transportation, make appointments, fill out forms, etc.), patients will be offered to be contacted by the navigator by telephone or to meet with the navigator in person on a day and time that is most convenient for them.
62541458|NCT06633809||Immediate Endovascular Therapy|The immediate endovascular therapy is performed immediately after stroke onset with any thrombectomy device usually used.
62541459|NCT06633809||Best Medical Therapy|The best medical therapy is standard medical therapy, including intravenous fibrinolysis, anticoagulants or antiplatelet, but NOT including any endovascular therapies. The rescue endovascular therapies may be performed in case of acute neurological deterioration.
62541460|NCT01908907|ACTIVE_COMPARATOR|DHA oil|DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
62541461|NCT01908907|PLACEBO_COMPARATOR|(MCT) control oil|MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
62541462|NCT04590352||Index case and household contacts|"* nasophryngeal and throat swab at day 0.~* collection of mucosal lining fluid: day 0, 7, 14, 28 for index case and day 0, 3, 6, 28 for household contacts.~* fingerprick at day 28 (optional).~* daily record of symptoms from day 0-28."
62541463|NCT00721227|ACTIVE_COMPARATOR|Anterior Curve|Reduction Gastroplasty by Gastric Plication on Anterior Curve
62541464|NCT00721227|ACTIVE_COMPARATOR|Greater Curve|Reduction Gastroplasty by Gastric Plication on Greater Curve
62541465|NCT01326650|EXPERIMENTAL|Vitamin D|daily vitamin D supplement
62715200|NCT04641221|ACTIVE_COMPARATOR|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
61978147|NCT01204164|EXPERIMENTAL|TG02 in MM|Single Agent TG02 citrate in multiple myeloma patients
62164821|NCT03469258|EXPERIMENTAL|Zenpep|"* Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.~* Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
62164822|NCT00248794|EXPERIMENTAL|CRT + Skills Training|"The intervention is call Cognitive Remediation Therapy (CRT) with a skill development group. Participants receive 15 weeks of cognitive training (with intake, 15 and 30 week assessment). This intervention is reliant upon didactic exchanges between trainer and participant, minimizing error, and behavioral modeling with the goal of developing better meta-cognitive skills. Procedures include paper and pencil activities (memory, planning and cognitive flexibility training) which are organized by difficulty. Sessions are organized to have a discussion between the trainer and the participant about the task and strategies, trainer modeling with articulation of strategy a participant attempts the task, talking aloud the steps, and finally the participant practices the task covertly. The trainer has the role of error catcher and model. All subjects randomized to this condition also are receiving the weekly skills group (SDG)offered to participants in all experimental conditions."
62168008|NCT02490878|EXPERIMENTAL|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be treated as per treating MD."
62541466|NCT01326650|PLACEBO_COMPARATOR|placebo|daily placebo supplement
62541467|NCT03171974|EXPERIMENTAL|treatment group|The treatment group will be injected with dexamethasone instracapsular under US according to our built protocol.
62541468|NCT03638544|ACTIVE_COMPARATOR|Reduced Gluten-Normal Gluten|
62541469|NCT03638544|ACTIVE_COMPARATOR|Normal Gluten-Reduced Gluten|
62541470|NCT06197165|EXPERIMENTAL|Shiatsu|"Comfort Shiatsu: 39~Targeted Shiatsu: 39"
62541471|NCT06197165|ACTIVE_COMPARATOR|without Shiatsu|patients with cardiac amyloidosis with severe symptoms
62541472|NCT05567276||Group 1|Group : Non-Violent Resistance parental training (NVR)
62541473|NCT05567276||Group 2|Group 2 : Treatment as usual (TAU) = Control
62541474|NCT06002581|EXPERIMENTAL|the early treatment group|stage1+stage2 real stimulation
62541475|NCT06002581|OTHER|the control group (delayed treatment group)|stage1 sham stimulation + stage2 real stimulation
62541476|NCT04787679||Osteoporotic patients|Osteoporotic patients, age \> 18 years old
62541477|NCT04787679||Non osteoporotic patients|Non osteoporotic patients, age \> 18 years old
62541478|NCT06223386|PLACEBO_COMPARATOR|Traditional model|Designed course A with 3-month consultation with the dietitians
62541479|NCT06223386|EXPERIMENTAL|Multi-oriented lifestyle education|Designed course B with 3-month consultation with the dietitians
62541480|NCT06223386|EXPERIMENTAL|Multi-oriented lifestyle education with dietary assessment|Designed course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians
62541481|NCT06223386|EXPERIMENTAL|Multi-oriented lifestyle education with longer period of dietary assessment|Designed course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians
62541482|NCT01013558|ACTIVE_COMPARATOR|remifentanil|
62541483|NCT01013558|PLACEBO_COMPARATOR|saline|
62541484|NCT05673811|ACTIVE_COMPARATOR|Arm 1-SoC|Nab-paclitaxel and gemcitabine as SoC.
62541485|NCT05673811|EXPERIMENTAL|Arm 2 -VCN-01 + SoC|A maximum of two (2) doses of VCN-01 administrated as a single IV infusion in combination with nab-paclitaxel and gemcitabine as SoC.
62541486|NCT03507647|EXPERIMENTAL|Mindfulness Based Cognitive Therapy added to usual care|Patients in the MBCT arm will be invited to participate in MBCT added to their usual care.
62541487|NCT03507647|ACTIVE_COMPARATOR|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse).
62541488|NCT00843635|EXPERIMENTAL|Arm A - Tadalafil 10mg|Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
62541489|NCT00843635|EXPERIMENTAL|Arm B - Tadalafil 20mg|Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
62541490|NCT00843635|PLACEBO_COMPARATOR|Arm C - Placebo|Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
62541491|NCT03741712|EXPERIMENTAL|SHR2554|Participants will receive SHR2554 orally
62541492|NCT03741712|EXPERIMENTAL|SHR2554+SHR3680|Participants will receive SHR2554 combined with SHR3680 orally
62541493|NCT04106661|EXPERIMENTAL|Tai Chi Intervention 1|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
62541494|NCT04106661|EXPERIMENTAL|Tai Chi Intervention 2|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
62541495|NCT06398275|EXPERIMENTAL|1|
62541496|NCT06398275|PLACEBO_COMPARATOR|2|
62541497|NCT01867203||Statin users|
62541498|NCT06499740|ACTIVE_COMPARATOR|Treatment as usual|Arm 1 entails months 1-2 of this study. Treatment as usual will be delivered by providers to adolescent patients in their clinics during the first two months of this study. Treatment as usual will be defined by each individual clinic based on their existing clinic protocols.
62541499|NCT06499740|EXPERIMENTAL|SAFETY-A Based Adapted Intervention|Arm 2 entails months 3-4 of this study. Participating providers will deliver the adapted intervention for the second half (months 3-4) of the pilot trial. The intervention will be based on the evidence-based SAFETY-Acute protocol and will be adapted based on information from potential users prior to piloting. It is anticipated that both adolescent patients and their parents/caregivers will be involved in the intervention. Anticipated components of the intervention include safety planning, lethal means restriction, communication, identifying adolescent and family strengths, and linking to longer term care.
62541500|NCT03486691|EXPERIMENTAL|preoperative left lobe measurement|routine preoperative left lobe measurement
62541501|NCT03486691|ACTIVE_COMPARATOR|Control group|Control group without routine measurement of left lobe
62541502|NCT03423186|EXPERIMENTAL|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
62541503|NCT03423186|EXPERIMENTAL|Dose group 2|SOBI003 dose 10 mg/kg once weekly for 24 weeks
62541504|NCT01830790|ACTIVE_COMPARATOR|Healthy Controls|Healthy individuals \>65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
62541505|NCT01830790|EXPERIMENTAL|AMD patients|Age-related macular degeneration (AMD) patients \>65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
62541506|NCT03039270|ACTIVE_COMPARATOR|Control (Without sonic activation)|Desensitizing gel applied without sonic activation, for 10 minutes, previously to the in-office bleaching.
62541507|NCT03039270|EXPERIMENTAL|With sonic activation (SMART Device®)|Desensitizing gel applied with sonic activation, 30 seconds per tooth, previously to the in-office bleaching.
62541508|NCT05436314|EXPERIMENTAL|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.
62541509|NCT05436314|SHAM_COMPARATOR|Sham Group|Sham Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.
62541510|NCT01130597|EXPERIMENTAL|patiromer|spironolactone + patiromer
62541511|NCT04779554|EXPERIMENTAL|Flat Dose Mitomycin C|Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
62541512|NCT04779554|EXPERIMENTAL|Weight-Based Mitomycin C|Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
62541513|NCT06197269|EXPERIMENTAL|Short duration antibiotic|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
62541514|NCT06197269|ACTIVE_COMPARATOR|Standard duration antibiotic|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
62541515|NCT06626295|EXPERIMENTAL|exercise-snack group|"Exercise program:~Adolescents in the exercise-snacks group will perform 4 exercise-snacks sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity."
62541516|NCT06626295|NO_INTERVENTION|control group|only the multidimensional care program without 'exercise-snacks'
62541517|NCT04593576|EXPERIMENTAL|Structured physical activity/outdoor sports.|Out door sports and structured physical activity protocol will be administered on children with Autism.
62541518|NCT04593576|ACTIVE_COMPARATOR|Intensive table teaching control group|Control group will only be exposed to intensive table teaching instead of physical activity protocol.
62541519|NCT03164538|EXPERIMENTAL|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
62541520|NCT03164538|ACTIVE_COMPARATOR|Diabetes Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet).
62541521|NCT04166565|EXPERIMENTAL|Daratumumab/bortezomib/cyclophospamide/dexamethasone (daraVCD)|"Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.~Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.~Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
62541522|NCT02159079|NO_INTERVENTION|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
62541523|NCT02159079|EXPERIMENTAL|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
62541524|NCT04234659||Individuals Receiving Mechanical Circulatory Device Support|Individuals receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
62541525|NCT04234659||Individuals Without Mechanical Circulatory Device Support|Individuals not receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
62541526|NCT02695537|EXPERIMENTAL|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
62541527|NCT04001946|OTHER|G-button Securement Device|Subjects will be provided instructions and a 12-week supply of test devices, sufficient to change the gauze dressing at least once per day.
62541528|NCT04001946|NO_INTERVENTION|Standard Dressing|Subjects will be provided instructions and a 12-week supply of tape and gauze (current standard of care), sufficient to change the gauze dressing at least once per day.
62541529|NCT01365312|EXPERIMENTAL|Ethanol|Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.
62541530|NCT01365312|PLACEBO_COMPARATOR|Heparinized saline|Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.
62541531|NCT01910246|EXPERIMENTAL|Metformin, Insulin Resistance, Cardiac Function,|Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
62541532|NCT02242045|EXPERIMENTAL|Idelalisib|Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.
62541533|NCT03069326|EXPERIMENTAL|Cohort A: Ruxolitinib and Thalidomide|After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
62541534|NCT03069326|EXPERIMENTAL|Cohort B: Ruxolitinib and Thalidomide|"A cohort expansion, for patients with baseline thrombocytopenia, will enroll 35 additional patients~After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs."
62541535|NCT00819637|EXPERIMENTAL|Arformoterol 3 doses|
62541536|NCT00819637|EXPERIMENTAL|Arformoterol 1 dose, placebo 2 doses|
62541537|NCT00819637|ACTIVE_COMPARATOR|Levalbuterol 3 doses|
62541538|NCT03316547|NO_INTERVENTION|Control|The control group received standard hospital care.
62541539|NCT03316547|EXPERIMENTAL|Intervention|Parents in the sensory-based intervention group were educated to provide daily sensory-based interventions across the length of hospitalization as outlined in the manualized intervention (the SENSE Program). A sensory support team completed the doses of sensory exposures when parents were unable.
62541540|NCT05950178|OTHER|Clinical brain death|The protocol is based on performing two consecutive apnea tests on a patient in clinical brain death in intensive care unit. The first apnea test will be conducted under standard oxygen therapy and confirms clinical brain death (standard procedure). The second apnea test (for the study) will be conducted under high-flow oxygen therapy. Only patients whose apnea test is initially validated under standard oxygen therapy will have the second apnea test under high-flow oxygen therapy.
62541541|NCT02032056|EXPERIMENTAL|probiotic (10^9 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10\^9 cfu/day, provided as powder in a sachet which can be added to food or drink.
62541542|NCT02032056|EXPERIMENTAL|probiotic (10^8 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10\^8 cfu/day, provided as powder in a sachet which can be added to food or drink.
62541543|NCT02032056|PLACEBO_COMPARATOR|Placebo|provided as powder in a sachet which can be added to food or drink.
62541544|NCT01027338|EXPERIMENTAL|Tai Chi Exercise|
62541545|NCT01027338|NO_INTERVENTION|Usual Care|
62541546|NCT04573114||Stroke subjects|
62541547|NCT04573114||Healthy|
62541548|NCT03541980|ACTIVE_COMPARATOR|Intervention|Patients allocated to receive IV acetaminophen
62541549|NCT03541980|PLACEBO_COMPARATOR|Placebo|Patients allocated to receive IV normal saline placebo
62541550|NCT06452979||Cases|Children aged 6-11 years old with habitual snoring (≥3 nights per week) and PSG confirmed OSA (OAHI of ≥1/hour)
62541551|NCT06452979||Controls|Non-OSA age, sex and BMI-matched control with PSG confirmed absence of OSA (OAHI \< 1 event/h)
62541552|NCT05543343|EXPERIMENTAL|Ntaphylococcus albicans tablets|Participants received High-dose Staphylococcus albicans tablets (0.3 mg/tablet, 8 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days) or Normal-doseStaphylococcus albicans tablets (0.3 mg/tablet, 4 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days)+ placebo (4 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days).
62541553|NCT05543343|PLACEBO_COMPARATOR|Placebo|Participants received placebo (8 tablets each time, 3 times a day, Shandong Qilu Pharmaceutical Co., Ltd., course of treatment 90 days).
62541554|NCT04900519|EXPERIMENTAL|STI-6643|STI-6643 will be provided in a single use 10-mL high borosilicate type 1 glass vial at a concentration of 500mg/10 mL (50 mg/mL) administered intravenously weekly for 4 weeks, then biweekly for Cycles 2 and up.
62715201|NCT04641221|ACTIVE_COMPARATOR|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
62541555|NCT05603533|EXPERIMENTAL|Intervention group|On top of the regular physical therapy, the participants in the intervention group will receive a music and video-based group exercise therapy in small groups of 5. On a big screen, a video of an older woman performing exercises will be shown, the participants will have to copy these exercises. In the beginning of each session, the participants will be able to choose the music they want to move to.
62541556|NCT05603533|NO_INTERVENTION|Control group|The participants in the control group will receive no additional therapy.
62541557|NCT05970666|EXPERIMENTAL|Single arm|
62541558|NCT01724450|ACTIVE_COMPARATOR|Carvedilol|
62541559|NCT01724450|PLACEBO_COMPARATOR|Control|
62541560|NCT06620133|EXPERIMENTAL|Pain education and patient-led goal setting|Pain education and patient-led goal setting
62541561|NCT06620133|EXPERIMENTAL|Supervised group exercise|Supervised group exercise
62541562|NCT00396643|EXPERIMENTAL|A|
62541563|NCT00396643|PLACEBO_COMPARATOR|B|Coconut oil
62541564|NCT03783429|ACTIVE_COMPARATOR|Intervention group|The intervention group will receive low-dose digoxin
62541565|NCT03783429|PLACEBO_COMPARATOR|Placebo group|The placebo group will receive a matching placebo
62541566|NCT01590277|EXPERIMENTAL|Active Ethanol and Active Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
62541567|NCT01590277|EXPERIMENTAL|Active Ethanol and Placebo Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
62541568|NCT01590277|EXPERIMENTAL|Placebo Ethanol and Active Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
62541569|NCT01590277|PLACEBO_COMPARATOR|Placebo Ethanol and Placebo Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
62541570|NCT01105715||Rheumatoid Arthritis (RA) Case Subjects|"* Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA~* Have currently active disease as assessed by Clinical Disease Activity Index (CDAI) score of \>10~* Have \> or = 3 swollen joints"
62541571|NCT01105715||Control Subjects|"* Age, sex, and 5-year age categories matched to cases~* No historical diagnosis of RA and other primary autoimmune or inflammatory disorders"
62541572|NCT01132924||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
62541573|NCT00340678|EXPERIMENTAL|Normoalbuminuria Losartan|Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
62541574|NCT00340678|PLACEBO_COMPARATOR|Normoalbuminuria Placebo|Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.
62541575|NCT00340678|EXPERIMENTAL|Microalbuminuria Losartan|Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
62541576|NCT00340678|PLACEBO_COMPARATOR|Microalbuminuria Placebo|Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.
62541577|NCT03458260|EXPERIMENTAL|Experimental|Pixantrone plus rituximab, ifosfamide and etoposide.
62541578|NCT03629080|EXPERIMENTAL|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
62541579|NCT03629080|PLACEBO_COMPARATOR|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
62541580|NCT03629080|EXPERIMENTAL|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
62541581|NCT03629080|PLACEBO_COMPARATOR|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
62541582|NCT03629080|EXPERIMENTAL|HB-101 vaccine: CMV (+) patients-Prophylactic Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
62715202|NCT04641221|ACTIVE_COMPARATOR|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
62715203|NCT04641221|ACTIVE_COMPARATOR|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
62541583|NCT03629080|EXPERIMENTAL|HB-101 vaccine: CMV (+) patients-Preemptive Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
62541584|NCT02842138|EXPERIMENTAL|CD19 CAR T cells|A standard dose escalation approach aimed to assess the safety and efficacy of autologous anti-CD19 CAR T cells will be applied.
62541585|NCT03359954|EXPERIMENTAL|Treatment (radiation therapy, surgery)|Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.
62541586|NCT06277232|OTHER|All participants|"Through the Diet4painrelief platform, the dietician will follow up the progress of each participant in different timepoints during pain rehabilitation process: 4 weeks before the Interdisciplinary Pain Rehabilitation Program (IPRP), 1-2 meetings with patients as well as other professionals integrated in IPRP, and 4 weeks after IPRP rehabilitation (via chat function).~The IPRP is conducted in groups of six to nine participants and is based on cognitive behavioral treatment principles and included physiotherapy, ergonomics, training in coping strategies, occupational therapy, and education in pain management. An IPRP delivers a group-treatment format by an interdisciplinary team (i.e., physician in rehabilitation, a physiotherapist, an occupational therapist, and a psychologist). The IPRP lasts for 12 weeks."
62541587|NCT04716868|EXPERIMENTAL|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 week.
62541588|NCT04716868|EXPERIMENTAL|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 gf once a day for 8 week.
62541589|NCT04716868|EXPERIMENTAL|Maltodextrin 10 g + Agave Fructans 5 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 week.
62541590|NCT04716868|ACTIVE_COMPARATOR|Psyllium plantago 15 g|Psyllium plantago 15 g once a day for 8 week.
62541591|NCT01008189|ACTIVE_COMPARATOR|Self study comparison group|Caregivers and children and adolescents each received three books about coping with grief after the death of a loved one and a syllabus to guide reading
62541592|NCT01008189|EXPERIMENTAL|Family Bereavement Program|12- session group for caregivers and bereaved children and adolescents plus 2 individual sessions
62541593|NCT03149757|EXPERIMENTAL|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
62541594|NCT03149757|ACTIVE_COMPARATOR|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
62541595|NCT06021626|EXPERIMENTAL|CRD3874-SI|Phase 1a: starting dose of 0.1 mg/kg, Phase 1b: RP2D determined during Phase 1a. Cycle 1 \& 2: once weekly infusion x 4 (Days 1, 8, 15, 22) over 28-day cycle. Cycle 3 onwards: weekly infusion x 3 (Days 1, 8, 15) over 28-day cycle
62541596|NCT00143247|EXPERIMENTAL|Exubera® (inhaled insulin)|Open label, no comparator
62541597|NCT04962386||Perimenopausal women who did not undergo HRT|Perimenopausal women who did not undergo HRT at baseline. And they did not receive any other drugs
62541598|NCT04962386||Perimenopausal women who did undergo HRT|Perimenopausal women who did undergo HRT received estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV. Weesp, The Netherlands).Take this medicine once a day. A course of treatment was defined as 28 days of continuous treatment.
62541599|NCT03309527|EXPERIMENTAL|e-aid Cognitive Behavior Therapy|Participants receive e-aid cognitive behavior therapy. Every week, this group will receive researcher guided individual customized sleep restriction and stimulus control therapy.
62541600|NCT03309527|ACTIVE_COMPARATOR|e-aid Sleep Hygiene Education|Participants receive e-aid sleep hygiene education which consists of general sleep health education and the guidance on questionnaires. Every week, this group will receive researcher guided sleep hygiene.
62541601|NCT06067269|EXPERIMENTAL|Treatment (apalutamide, SBRT)|Patients receive apalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 or 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo SBRT for 5 fractions over 1-2 weeks beginning on day 1 of cycle 1. Patients also undergo multiparametric MRI and collection of blood samples throughout the trial. Patients undergo PSMA-PET/CT scans during screening and follow up.
62541602|NCT01068262|EXPERIMENTAL|Panel A - Odanacatib|Panel A - Healthy male subjects receiving Odanacatib
62541603|NCT01068262|PLACEBO_COMPARATOR|Panel A - Placebo|Panel A - Healthy male subjects receiving placebo
62541604|NCT01068262|EXPERIMENTAL|Panel B - Odanacatib|Panel B - Healthy female subjects receiving Odanacatib
62541605|NCT01068262|PLACEBO_COMPARATOR|Panel B - Placebo|Panel B - Healthy female subjects receiving placebo
62541606|NCT01402635|EXPERIMENTAL|POCT lab|The patient group whose laboratory test perform by POCT chemistry analyzer.
62541607|NCT01402635|ACTIVE_COMPARATOR|central laboratory group(CLT)|The patients group whose laboratory test perform by central laboratory.
62541608|NCT04386616|PLACEBO_COMPARATOR|All Placebo|Participants randomized to this arm received one intravenous (IV) infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo on Day 1. A second IV infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo (same placebo as the first infusion) was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
62541609|NCT04386616|EXPERIMENTAL|MSTT1041A|Participants randomized to this arm received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
62541610|NCT04386616|EXPERIMENTAL|UTTR1147A|Participants randomized to this arm received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
62541611|NCT04691154|EXPERIMENTAL|L606|
62541612|NCT04225910|EXPERIMENTAL|mCRPC for PSMA RLT|225Ac-PSMA 100KBq/kg, iv. Totally 2 doses, every 8 weeks.
62541613|NCT06251245|EXPERIMENTAL|Experimental Group (Oral Injector)|Children who use oral injectors to give oral medication will constitute the experimental group.
62541614|NCT06251245|OTHER|Control group (Spoon)|Children who use spoons to give oral medication will constitute the control group.
62541615|NCT05913505|EXPERIMENTAL|OSC+|Twenty-five participants will complete five weeks of heart rate variability biofeedback using emWave software (HeartMath®Institute, 2020). Participants will receive a weekly 30-minute heart rate variability biofeedback session for five weeks at the University Parkway Center, Brigham Young University. The heart rate variability biofeedback protocol will be based on Lehrer et al., 2013 and Yoo et al., 2022. This format will aid participants in implementing and learning breathing and heart rate variability biofeedback skills (Lehrer et al., 2020). All participants will wear an ear sensor to measure their pulse. The heart rate variability biofeedback will focus on autonomic balance through slow breathing at a resonance frequency of approximately 6 breathes per minute. The best approximate breathing pace for resonance frequency will be estimated and participant's resonance frequency will be provided and used for their homework and subsequent training sessions.
62541616|NCT05913505|SHAM_COMPARATOR|OSC-|"Twenty-five participants will complete five weeks of Osc-. Similarly, for the Osc- procedures, the client will be required to complete a five-week intervention. During the weekly session, participants will also be wearing an earlobe monitor with HeartMath. Participants will be administered the Scale of Positive and Negative Experience at the beginning of each session to assess for mood. Participants will also be administered the 3-item Rivermead Post Concussion Symptoms Questionnaire at the beginning of each session. Participants will be instructed that the purpose of this portion of the study is to decrease their breathing oscillations. A program was designed by Yoo and colleagues (2022) that gives feedback regarding a calmness score which reflects a better score (i.e., higher) when participants breath in a pattern that elicits less variability (i.e., less oscillations)."
62541617|NCT05186675|EXPERIMENTAL|Superselective adrenal arterial embolization|For patients with bilateral idiopathic hyperaldosteronism confirmed by adrenal venous sampling, Superselective adrenal arterial embolization（SAAE）shall be given according to the patient's wishes. The blood pressure, plasma aldosterone and potassium levels, and adverse events were assessed after SAAE. The primary endpoint was the change in home blood pressure at one months, compared with baseline.
62541618|NCT02068092|EXPERIMENTAL|Hydroxytyrosol|Hydroxytyrosol 25 mg orally once daily for 1 year.
62541619|NCT00186940||1|
62541620|NCT00894829|EXPERIMENTAL|1|Heparin sodium - Eurofarma
62541621|NCT00894829|ACTIVE_COMPARATOR|2|Heparin APP
62541622|NCT04614753|ACTIVE_COMPARATOR|Dealcoholized Muscadine Wine|Participants in this arm will receive 300ml of dealcoholized muscadine wine daily for six weeks. After a 7- day run-in period, participants will receive dealcoholized muscadine wine daily for six weeks
62541623|NCT04614753|ACTIVE_COMPARATOR|Control Beverage|Participants in this arm will receive 300 ml of sugar water and acid content for six weeks. After a 7-day run in period, participants will receive sugar water for six weeks.
62541624|NCT03513055|EXPERIMENTAL|inject premixed insulin|patients inject premixed insulin themselves then nurse inject premixed insulin
62541625|NCT05458882|EXPERIMENTAL|educational Booklet|Receive intervention- educational booklet describing the day to day social activities and eating out habits of children with established food allergy in Ireland
62541626|NCT05458882|ACTIVE_COMPARATOR|Routine education|This group will receive routine education in the allergy group.
62541627|NCT03712514|OTHER|Rugby players|Destabilization of the upper cervical spine with Cervistab
62541628|NCT03712514|OTHER|Healthy non rugby players|Destabilization of the upper cervical spine with Cervistab
62541629|NCT04820660|EXPERIMENTAL|Task oriented Strength training group|Standing and reaching in different directions Sit-to-stand Stepping forward and backward Stepping sideways onto blocks
62541630|NCT04820660|EXPERIMENTAL|Balance Training|Stepping forward, backward, and sideways on the exercise step; Stepping over blocks of various heights; Standing up from a chair, From a sitting position on a 65-cm Swiss ball, Arms; bending the trunk forward and side to side); Performing double-legged stance Performing tandem stance Rising from a chair without the use of the arms; Walking forward and backward with a tandem walking pattern Performing single- legged stance
62541631|NCT02538380|EXPERIMENTAL|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
62541632|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
62541633|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
62541634|NCT04874805|EXPERIMENTAL|Major patient admitted to the ICU for COVID|
62541635|NCT00043810|EXPERIMENTAL|Gelonin Purging of ASCT|Gelonin Purging of Autologous Stem Cells for Transplantation (ASCT) + Fludara/Busulfan
62541636|NCT00229723|PLACEBO_COMPARATOR|1|Radiation + cisplatin; followed by placebo as maintenance therapy
62541637|NCT00229723|EXPERIMENTAL|2|250 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
62541638|NCT00229723|EXPERIMENTAL|3|500 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
62541639|NCT00229723|EXPERIMENTAL|4|gefitinib 250 mg + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
62541640|NCT00229723|EXPERIMENTAL|5|gefitinib 500 mg + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
62541641|NCT00229723|PLACEBO_COMPARATOR|6|placebo + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
62541642|NCT00229723|PLACEBO_COMPARATOR|7|placebo + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
62541643|NCT01192048||Study Subjects|Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.
62541644|NCT00738114||1|group without hyperglycemia (fasting blood glucose below 126mg/dl) approximately 1000 patients
62541645|NCT00738114||2|group with hyperglycemia (fasting blood glucose above 125 mg/dl) or history of diabetes approximately 500 patients
62541646|NCT00200408||smokers|college students who smoke
62541647|NCT00200408||non smokers|college students who don't smoke
62541648|NCT00877162|EXPERIMENTAL|1|Providing parents with a group teaching intervention (2 hours long). The teaching session is followed by 2 weeks of phone calls twice a week to offer parents support for their use of the strategies described in the teaching session and to clarify any questions about the teaching session content. The arm will have baseline data collected one week prior to the teaching session. Follow-up data will be collected at 6 and 24 weeks post intervention. A pamphlet on infant safety will be distributed to the intervention arm following the 6 week data collection point. A pamphlet on managing behavioural sleep problems will distributed to the control group following the 6 week data collection point.
62541649|NCT01753297|ACTIVE_COMPARATOR|Triptorelin, 11.25 mg|Triptorelin, powder and solvent for suspension (prolonged released form)
62541650|NCT01753297|NO_INTERVENTION|Active surveillance|Active surveillance after radical prostatectomy (RP)
62541651|NCT03813810||Normal|People without any chronic pulmonary diseases.
62541652|NCT03813810||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease.
62541653|NCT03813810||Asthma|Patients with asthma
62541654|NCT03813810||Idiopathic pulmonary fibrosis|Patients with idiopathic pulmonary fibrosis
62541655|NCT00593905||Group 1|"GROUP 1~1. Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.~2. WHO Group 1 Pulmonary arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis."
62541656|NCT00593905||Group 2|"Group 2~1. Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months.~2. WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis."
62541657|NCT00143390|EXPERIMENTAL|1|
62541658|NCT00143390|EXPERIMENTAL|2|
62541659|NCT06632548|ACTIVE_COMPARATOR|milled titanium secondary coping|group I patients received primary and secondary coping made of milled titanium
62541660|NCT06632548|EXPERIMENTAL|3D printed cobalt chromium secondary coping|group II patients received primary coping made of milled titanium and secondary coping made of 3D printed cobalt chromium
62541661|NCT06632548|EXPERIMENTAL|milled poly ether ketone ketone secondary coping|group III patients received primary coping made of milled titanium and secondary coping made of milled poly ether ether ketone
62541662|NCT03276130||Part A: Retrospective register study|To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population.
62541663|NCT03276130||Part B1: Survey to HTC|The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts.
62541664|NCT03276130||Part B2: Survey to PwH|All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey.
62541665|NCT02354794|EXPERIMENTAL|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention: see below"
62541666|NCT02109653|EXPERIMENTAL|LGX818|Adult patients, with confirmed diagnosis of BRAF V600E mutant advanced or metastatic NSCLC who have progressed on or after at least one prior systemic anticancer therapy.
62541667|NCT06633939|OTHER|Move & Eat 2 Live|5, 1-hour sessions with an education and motivational component and focused on nutrition, physical activity and healthy weight.
62541668|NCT04836897|EXPERIMENTAL|Treatment|Transcatheter aortic valve replacement
62541669|NCT06626464|EXPERIMENTAL|Carbon-14 radiolabeled [14C] MK-8189|Participants receive a dose of 4.5-mg immediate release (IR) (\~ 50 μCi) orally on Day 1.
61978148|NCT01204164|EXPERIMENTAL|TG02 + CFZ in MM|TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients
62541670|NCT03048552|NO_INTERVENTION|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
62541671|NCT03048552|EXPERIMENTAL|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
62541672|NCT01562561|EXPERIMENTAL|Rep + NPH|
62541673|NCT01562561|ACTIVE_COMPARATOR|NPH|
62541674|NCT01708551|ACTIVE_COMPARATOR|Group A|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
62541675|NCT01708551|ACTIVE_COMPARATOR|Group B|Subjects who were non-responders to a prior Ultherapy™ treatment for hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
62541676|NCT01708551|ACTIVE_COMPARATOR|Group C|Subjects will receive one double-density Ulthera System treatment; dual depth treatment at 4.5mm and 3.0mm.
62541677|NCT01708551|ACTIVE_COMPARATOR|Group D|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and standard energy level.
62715204|NCT04641221|ACTIVE_COMPARATOR|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
62715205|NCT04641221|ACTIVE_COMPARATOR|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
62715206|NCT04641221|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
62715207|NCT04641221|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
62715208|NCT04641221|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
62715209|NCT04641221|ACTIVE_COMPARATOR|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
62715210|NCT05421676|EXPERIMENTAL|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
62715211|NCT05140239||AbroSkib Cohort|Adult patients with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare (n=20). The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.
62715212|NCT05595746|EXPERIMENTAL|equicrestally placement with higher vertical mucosa|Implants with a vertical mucosal height greater than 2 mm (A) and placed equicrestally (I) are in group A-I.
62715213|NCT05595746|EXPERIMENTAL|subcrestally placement with higher vertical mucosa|Implants with a vertical mucosal height greater than 2 mm (A) and placed subcrestally (II) are in group A-II.
62715214|NCT05595746|EXPERIMENTAL|equicrestally placement with less vertical mucosa|Implants with a vertical mucosal height of 2 mm or less (B) and placed equicrestally (I) are in group B-I.
62715215|NCT05595746|EXPERIMENTAL|subcrestally placement with less vertical mucosa|Implants with a vertical mucosal height of 2 mm or less (B) and placed subcrestally (II) are in group B-II.
62715216|NCT04364555|ACTIVE_COMPARATOR|Active/active|The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
62715217|NCT04364555|ACTIVE_COMPARATOR|Placebo/active|The bottle for use in the morning contains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
62541678|NCT01708551|ACTIVE_COMPARATOR|Group E|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and adjusted energy level.
62541679|NCT03270878|EXPERIMENTAL|Glasdegib Oral tablet then IV|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
62541680|NCT03270878|EXPERIMENTAL|Glasdegib IV solution followed by Oral tablet|Subjects will receive a 50 mg IV solution will be infused over approximately 1.25 hours in the fasted condition followed by washout in the first study period . Then in the second period, a single 100 mg oral tablet of glasdegib will be administered under fasted conditions
62541681|NCT05583305||Patients diagnosed with APS|"Investigators shall recruit patients with the following criteria:~1. Diagnosed with APS who fulfilled the modified Sapporo criteria:~   1. at least one clinical criterion (vascular thrombosis or pregnancy morbidity); and~  2. laboratory criteria (aPL positivity twice, 12 weeks apart):~   i. Lupus anticoagulant positivity requires screening, mixing, and confirmation test as per International Society of Thrombosis and Hemostasis guidelines (11).~   ii. Anticardiolipin antibodies positivity requires a medium to high titer IgG and/or IgM level by ELISA assays.~   iii. Anti-β2 glycoprotein antibodies positivity requires a \>99th titer IgG and/or IgM level by ELISA assays.~2. Patients age ≥18 years~3. Patients who are able to provide an informed consent to study procedures"
62541682|NCT05583305||Controls|From the ongoing prospective Brain Health Longitudinal study which contained stroke- and dementia free participants (CREC Ref. No: 2018.148), investigators shall identify age- and gender-matched individuals without aPLs as controls
62541683|NCT06331767|EXPERIMENTAL|mSYNC|mHealth psychosocial-behavioral intervention
62541684|NCT03904264|EXPERIMENTAL|Hearing Aid Study|Measure the reduction in tinnitus handicap when mild amplification through receiver-in-the-canal hearing aids is provided to adults with bothersome tinnitus and normal hearing thresholds.
62541685|NCT03904264|NO_INTERVENTION|VA Clinician Interviews|Document the opinions, procedures, and rationale used clinically to make decisions regarding fitting mild amplification for tinnitus on Veterans with bothersome tinnitus and normal hearing thresholds. The data for this arm of the study will be collected via telephone interview.
62715218|NCT04364555|PLACEBO_COMPARATOR|Placebo/placebo|Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
62737141|NCT05308355||OFA : Opioid Free Anesthesia|Opioid-free surgery. Analgesia provided by attenuation analgesic 1, dexmedetomidine, ketamine and general anesthesia by propofol. Regional loco anesthesia is performed in the OFA group and possible in the OBA group. It's local service protocol used since 1 year.
62737142|NCT05308355||OBA : Opioid Based Anesthesia|Conventional anesthesia with Propofol and Sufentanil boli with the possibility of regional loco anesthesia.
62541686|NCT05173857|ACTIVE_COMPARATOR|Drug Eluting Balloon (DEB)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Drug Eluting Balloon Technology.~Drug: Paclitaxel (PTX). Name of Device: Advance PTX"
62541687|NCT05173857|PLACEBO_COMPARATOR|Plain Old Balloon Angioplasty (POBA)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Plain Old Balloon Angioplasty.~Drug: None. Name of Device: Advance LP (Low Profile)"
62541688|NCT06629844|EXPERIMENTAL|Virtual Reality Program|The experiment group will receive the VR dementia education program, which will be conducted once for each participant.
62541689|NCT06629844|ACTIVE_COMPARATOR|Standard Course Material|The control group will receive the standard course material through the university's e-learning platform.
62541690|NCT05232266|EXPERIMENTAL|Caralluma fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
62541691|NCT05232266|PLACEBO_COMPARATOR|Placebo comparator capsule - Microcrystalline cellulose|A comparator capsule taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
62541692|NCT06550466|EXPERIMENTAL|Breakfast only|Breakfast only without the exercise protocol
62541693|NCT06550466|EXPERIMENTAL|FAST|Participants will be exercised 90 minutes following a 12-hour overnight fast
62541694|NCT06550466|EXPERIMENTAL|FED|Participants will be exercised 90 minutes after a meal
62541695|NCT04684043||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
62541696|NCT04570787|ACTIVE_COMPARATOR|No Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. Bladder catheterization is not performed.
62541697|NCT04570787|ACTIVE_COMPARATOR|Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. The bladder is to be drained with the urethral catheter in all cases.
62541698|NCT03787134|EXPERIMENTAL|2016-0500-Healthy YoungAdults|working memory and attention
62541699|NCT02687217|NO_INTERVENTION|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
62541700|NCT02687217|EXPERIMENTAL|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
62541701|NCT01867983|ACTIVE_COMPARATOR|Control|Behavioral: Smoking cessation
62541702|NCT01867983|EXPERIMENTAL|Simultaneous|Behavioral: Weight gain prevention and smoking cessation
62541703|NCT01867983|EXPERIMENTAL|Sequential|Behavioral: Weight gain prevention and smoking cessation
62541704|NCT03417687|ACTIVE_COMPARATOR|Arm 1|Subjects will undergo hyperpolarized 129Xe MRI first, followed by 133Xe scintigraphy
62541705|NCT03417687|ACTIVE_COMPARATOR|Arm 2|Subjects will undergo 133Xe scintigraphy first, followed by hyperpolarized 129Xe MRI
62541706|NCT06359639|EXPERIMENTAL|Cognitive restructuring|
62541707|NCT06359639|ACTIVE_COMPARATOR|Supportive counselling|
62541708|NCT04602546|ACTIVE_COMPARATOR|Sevoflurane alone|"Sevoflurane will be administered in steps to achieve a loss of consciousness via a tight-face mask by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until MOAA/S scales at values less than 2 is reached.~The equilibration time for each targeted concentration will be approximately 12 minutes to maintain a constant ETSEVO. The BIS™ value, MOAA/S score and picture recall test will be assessed when the patient is awake and at the different ETSEVO concentrations.~ETSEVO is decreased by the same steps until consciousness is regained."
62541709|NCT04602546|ACTIVE_COMPARATOR|Sevoflurane with Remifentanil Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, an initial IV bolus of remifentanil will be given followed by the start of an infusion. Approximately within 7 minutes, the infusion rate of remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml.~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of less than 2 is reached.~ETSEVO is decreased by the same steps until consciousness is regained."
62541710|NCT04602546|ACTIVE_COMPARATOR|Sevoflurane with Fentanyl Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of fentanyl of 2 ng/mL, an initial IV bolus of fentanyl will be given followed by the start of an infusion. Approximately within 10 minutes, the infusion rate of fentanyl may be adjusted to maintain the effect-site concentration of fentanyl of 2 ng/ml.~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of equal to or less than 2 is reached.~ETSEVO is decreased by the same steps until consciousness is regained."
62541711|NCT04602546|ACTIVE_COMPARATOR|Desflurane Group|"Due to desflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve laryngeal mask (LMA) insertion, will be administered 15-20 minutes prior to desflurane. Once correct LMA placement has been confirmed, there will be an equilibrium time of approximately 15-20 minutes to allow the effect site concentration of propofol to reach a level consistent with a pharmacodynamic effect of consciousness as measured by a MOAA/S score of 2 or 3. Desflurane will then be administered via a tight-face mask at the targeted end-tidal concentration (ETDES) of 2, 5, 7, 8, 9, 10 %, or higher until an MOAA/S score of less than 2 is reached.~The BIS™ value will be correlated with desflurane ETDES concentration. ETDES is decreased by the same steps until consciousness is regained."
62737143|NCT06385379|EXPERIMENTAL|WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system|Participants will be treated with WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system
62737144|NCT05922943|EXPERIMENTAL|Harmony & Health program|Participants will take part in the Harmony \& Health program or participants will attend in-person group health education sessions 2 times a week for 8 weeks.
62737145|NCT03586024|EXPERIMENTAL|Cohort 1|cohort 1: NK/T-cell lymphoma;
62541712|NCT04602546|ACTIVE_COMPARATOR|Isoflurane Group|"Due to isoflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to isoflurane.Isoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness (MOAA/S of 0,1) by increasing the end-tidal concentration of Isoflurane (ETISO). Targeted concentration for ETISO are 0.25, 0.5, 0.75, 1, 1.5% or higher until MOAA/S scales at values less than 2 is reached.~The BIS™ value will be correlated with desflurane ETISO concentration. ETISO is decreased by the same steps until consciousness is regained."
62541713|NCT04704570|EXPERIMENTAL|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
62541714|NCT04704570|OTHER|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
62541715|NCT04704570|OTHER|Remotely assessment Group-Face to Face Assessment Group|First, a remote evaluation and then a face to face evaluation will be made.
62541716|NCT04704570|OTHER|Face to Face Assessment Group-Remotely assessment Group|First, a facet o face evaluation and then a remote evaluation will be made.
62541717|NCT04867174|PLACEBO_COMPARATOR|Control Arm|No messaging about COVID-19 vaccination
62541718|NCT04867174|EXPERIMENTAL|Emotional message|Participants view an emotional video from the state of California about getting back to normal.
62541719|NCT04867174|EXPERIMENTAL|Safety and effectiveness message|Participants view a video with information about the safety and effectiveness of the COVID-19 vaccines
62541720|NCT04867174|EXPERIMENTAL|Consequences message|Participants view a video with information about the consequences of not getting vaccinated against COVID-19.
62541721|NCT00339144|EXPERIMENTAL|Dasatinib (100 mg)|
62541722|NCT00339144|EXPERIMENTAL|Dasatinib (150 mg)|
62541723|NCT00339144|EXPERIMENTAL|Dasatinib (200 mg)|
62541724|NCT01350570|EXPERIMENTAL|acupuncture group 1|Acupoints ST25 and BL25 will be used in the group. ST25 locate at the abdomen, while BL25 locate at the back.
62541725|NCT01350570|EXPERIMENTAL|acupuncture group 2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
62541726|NCT01350570|EXPERIMENTAL|acupuncture group 3|All acupoints used in acupuncture group1 and acupuncture group2 will be used in this group.
62541727|NCT01350570|ACTIVE_COMPARATOR|Loperamide|Loperamide will be used as an active comparator to the acupuncture groups.
62541728|NCT06188624|EXPERIMENTAL|TQB2922 for injection|TQB2922 for injection, 28 days as a treatment cycle
62541729|NCT02374775||Group A (Culprit lesion)|The plaque in the culprit vessel of acute myocardial infarction will be defined the Group A.
62541730|NCT02374775||Group B (Non-culprit lesion)|The plaque in the non-culprit vessel of acute myocardial infarction will be defined as internal control, Group B.
62541731|NCT03361774|EXPERIMENTAL|Test dentifrice|Participants in this arm will receive experimental dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 parts per million \[ppm\] fluoride).
62541732|NCT03361774|ACTIVE_COMPARATOR|Control dentifrice|Participants in this arm will receive comparator dentifrice containing 0.454% SnF2 (1100ppm fluoride).
62541733|NCT04015908|EXPERIMENTAL|multi-modal|"3 Different Non-opioid pain medication taken every 6 hours~Celecoxib 100mg~Acetaminophen 325mg~Pregabalin 50 mg~Plus, for breakthrough pain~oxycodone 5-10 mg will be taken every 4 hours as needed for pain."
62541734|NCT04015908|ACTIVE_COMPARATOR|Control|7 day supply of Percocet (oxycodone 5mg/acetaminophen 325 mg) to be taken 1-2 by mouth every 4 hours as needed for pain.
62541735|NCT02180737|EXPERIMENTAL|Dexmeditomedine|Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.
62541736|NCT05151783|ACTIVE_COMPARATOR|conventional physiotherapy|routine physical therapy for adhesive capsulitis
62541737|NCT05151783|EXPERIMENTAL|PNF techniques|PNF techniques along with conventional physiotherapy
62541738|NCT02104115|OTHER|Gluten free white bread|Sliced loaf of gluten free white bread
62541739|NCT02104115|OTHER|Normal gluten content white wheat bread|Sliced loaf of normal gluten content white wheat bread
62541740|NCT02104115|OTHER|High gluten content white wheat bread|Sliced loaf of high gluten content white wheat bread
62541741|NCT05308628|ACTIVE_COMPARATOR|Post-Transplant-Liver Allograft Fibrosis|Pediatric patients who have undergone liver transplantation , the occurrence of graft fibrosis necessitates hospitalization for biopsy and treatment to assess the degree of fibrosis and its underlying causes.
62541742|NCT05308628|SHAM_COMPARATOR|Post-Transplant-Liver Allograft regular recovery|Pediatric patients who have undergone liver transplantation and have recovered normally typically undergo liver biopsy around 3 to 5 years postoperatively and around 10 years postoperatively to evaluate the presence of potential subclinical rejection. This assessment guides the long-term application of immunosuppressive medications.
62541743|NCT05056662||Group 1|Patients with negative invasive functional evaluation
62541744|NCT05056662||Group 2|Patients with positive invasive functional evaluation undergoing PCI
62541745|NCT05056662||Group 3|Patients with positive invasive functional evaluation undergoing PCI and subsequent retest of functional indexes
62541746|NCT02593110|ACTIVE_COMPARATOR|Telmisartan + Supervised Treadmill Exercise Therapy|Participants in this group will receive both daily telmisartan and supervised treadmill exercise three days weekly for six months.
62541747|NCT02593110|ACTIVE_COMPARATOR|"Telmisartan + No Exercise Control Group"|Participants in this group will receive daily telmisartan and attend weekly educational lectures at the medical center for six months.
62541748|NCT02593110|ACTIVE_COMPARATOR|Placebo + Supervised Treadmill Exercise Therapy|Participants randomized to this group will receive daily placebo and supervised treadmill exercise three times weekly for six months.
62541749|NCT02593110|PLACEBO_COMPARATOR|"Placebo + No Exercise Control Group"|Participants randomized to this group will receive daily placebo and health education lectures weekly for six months.
62541750|NCT03787862||Hyperspectral Imaging (HSI)|Patients scheduled for foot surgery will be imaged using the HSI device. Data will be gathered from the electronic medical record for one year to determines the outcomes of the surgery, any complications, re-hosptializations, re-ulcerations or amputation.
62715219|NCT00508482|EXPERIMENTAL|deep needling group|Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20\~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1\~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
62715220|NCT00508482|ACTIVE_COMPARATOR|lactulose group|Lactulose Oral Solution was taken orally at the dose of 20\~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
62715221|NCT00508482|ACTIVE_COMPARATOR|shallow needling group|Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5\~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.
62715222|NCT03321799|ACTIVE_COMPARATOR|Sterile Antimicrobial Dressings|Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
62715223|NCT03321799|EXPERIMENTAL|Negative pressure wound therapy (NPWT)|"Experimental group. Negative pressure wound therapy bandage applied intra-operatively by a physician on the treatment team.~The dressing will be removed after 7 days postoperatively, or if the battery power stops earlier."
62715224|NCT03561155|EXPERIMENTAL|Robot assisted treatment|The experimental group (EG) will undergo a robot-assisted arm training using Amadeo® (Tyromotion-Austria).
62715225|NCT03561155|ACTIVE_COMPARATOR|Conventional treatment|The conventional group (CG) will undergo robot unassisted treatment (Conventional treatment).
62715226|NCT05194150|EXPERIMENTAL|Rayone EMV|Patient will receive the non-diffractive monofocal IOL during cataract surgery
62715227|NCT05194150|EXPERIMENTAL|Acrysof IQ Vivity|Patient will receive the standard EDOF IOL during cataract surgery
62715228|NCT03934866||Group A (LDCT)|"25,000 individuals who are at high-risk for lung cancer due to a significant smoking history.~Participants will receive at least 1 LDCT scan at baseline."
62715229|NCT03836040|EXPERIMENTAL|Dose level 1|Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
62715230|NCT03836040|EXPERIMENTAL|Dose level 2|Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
62715231|NCT03836040|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to a placebo comparator.
62715232|NCT05741476|EXPERIMENTAL|DBPC Treatment Period: DBV712 250 mcg|Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
62715233|NCT05741476|PLACEBO_COMPARATOR|DBPC Treatment Period: Placebo|Participants will apply DBV712 matching placebo epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
62715234|NCT05741476|EXPERIMENTAL|Open Label Extension Period: DBV712 250 mcg|Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 2 additional years if they were randomized DBV712 250 mcg or for 3 years if they were randomized placebo. After 12 months of open-label treatment with DBV712 250 mcg, (i.e., at the end of Month 24), participants will undergo a peanut DBPCFC according to the following schedule: 3, 10, 30, 100, 300, 600, 1000, and 2000 mg (4043 mg cumulative dose). Participants who were randomized to placebo will also undergo an additional peanut DBPCFC after 24 months of open-label treatment with DBV712 250 mcg, (i.e., at the end of Month 36).
62715235|NCT03789981||At diagnosis|Immunogenic profile in patients affected by primary or secondary AML at diagnosis
62715236|NCT03789981||At relapse|Immunogenic profile in patients affected by primary or secondary AML at relapse
62715237|NCT04175600|EXPERIMENTAL|Selexipag|Participants will receive selexipag based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Selexipag will be uptitrated during the first 12 weeks until the participants reaches the individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline body-weight category is achieved. Uptitration is followed by a maintenance period after Week 12 until end of treatment (EOT), at the maximum tolerated dose.
62715238|NCT04175600|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo based on the body weight on Day 1 and will continue thereafter with twice daily dosing.
62715239|NCT04699344||Pre-tissue biopsy patients|Pre-tissue biopsy patients with suspected prostate carcinoma will be the experimental group to determine the sensitivity and specificity of PROUD analysis, the result will be compared with histological results and PCA3 test.
62715240|NCT04699344||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of PROUD analysis.
62715241|NCT02622191|EXPERIMENTAL|Open-angle glaucoma|Participants with primary open-angle glaucoma and an abnormal visual field defect in one eye. Spectral domain Optical Coherence Tomography will be obtained from the effected eye and fellow eye of each glaucoma patient.
62715242|NCT02622191|EXPERIMENTAL|Healthy Controls|Participants without glaucoma and no other eye diseases. Spectral domain Optical Coherence Tomography will be obtained from eyes of each healthy control.
62737146|NCT03586024|EXPERIMENTAL|Cohort 2|EBV-associated diffuse large B cell lymphomas
61978149|NCT01204164|EXPERIMENTAL|TG02 + CFZ + DEX in CFZ refractory MM|TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients
62541751|NCT04881019||Type 2 Diabetes|Individuals who have been diagnosed with Type 2 diabetes.
62541752|NCT04881019||Non type 2 diabetes|Individuals who have not been diagnosed with Type 2 diabetes.
62541753|NCT05158088|ACTIVE_COMPARATOR|Borescope group|Using an Endotracheal tube mounted over Borescope with the aid of conventional laryngoscope for intubation
62541754|NCT05158088|ACTIVE_COMPARATOR|Videolaryngoscope group|Using videolaryngoscope for intubation
62541755|NCT01329783||EuroSIDA sub-cohort|HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)
62541756|NCT00950131|EXPERIMENTAL|Directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs.~This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record."
62541757|NCT00950131|EXPERIMENTAL|Non-directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs.~This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market."
62541758|NCT00950131|EXPERIMENTAL|No new drug warning|Survey contains information about when the drug was approved by the FDA (2009) only.
62541759|NCT02147964|EXPERIMENTAL|Acyline; T Gel; placebo dutasteride, placebo ketoconazole|"All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months"
62541760|NCT02147964|EXPERIMENTAL|Acyline; T gel; Ketoconazole; placebo|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months"
62541761|NCT02147964|EXPERIMENTAL|Acyline; Tgel; Ketoconazole; Dutasteride|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months"
62541762|NCT02147964|EXPERIMENTAL|Acyline; Tgel; HCG|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months."
62541763|NCT06310304|EXPERIMENTAL|Cohort 1: Dose Treatment A|Ruxolitinib IR will be administered at protocol defined dose.
62541764|NCT06310304|EXPERIMENTAL|Cohort 1: Dose Treatment B|Ruxolitinib XR will be administered at protocol defined dose.
62541765|NCT06310304|EXPERIMENTAL|Cohort 2: Dose Treatment A|Ruxolitinib IR will be administered at protocol defined dose.
62541766|NCT06310304|EXPERIMENTAL|Cohort 2: Dose Treatment B|Ruxolitinib XR will be administered at protocol defined dose.
62541767|NCT03391726|EXPERIMENTAL|Arm 1|CART-19 cells treat
62541768|NCT05730569||Small Vulnerable Newborns|"* Low birth weight: \<2500g; and/or,~* Preterm: born between the 34th and 37th week of pregnancy; and/or,~* Small for Gestational Age: \<10 percentile of INTERGROWTH-21st birthweight standards."
62541769|NCT05730569||Healthy Community Controls|"* Born after the 37th week of pregnancy; and,~* Birth weight ≥2500g; and,~* ≥10 percentile of INTERGROWTH-21st birthweight standards."
62541770|NCT05319210|EXPERIMENTAL|Buzzy application|It is fixed on the right upper arm area of the child one minute before the procedure. After cleaning the skin with the appropriate solution, venous catheter placement will be performed. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
62541771|NCT05319210|EXPERIMENTAL|Virtual Reality Glasses|A dinosaur movie suitable for the 7-12 age group will be watched 2-3 minutes before the venous catheter insertion. In this process, after cleaning the skin with the appropriate solution, a venous catheter will be inserted. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
62541772|NCT05319210|NO_INTERVENTION|No intervention|The routine venous catheter placement protocol in the institution where the study is conducted will be applied. An evidence-based non-pharmacological method is not used to reduce pain during venous catheter insertion in children in the institution. A venous catheter is inserted by attaching a tourniquet to the child. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
62541773|NCT04228835|EXPERIMENTAL|ICGFC-LC|ICG fluorescence cholangiography assisted laparoscopic cholecystectomy (ICGFC-LC) arm patients received intravenous bolus of 2.5mg of ICG before the induction of anaesthesia. Near infrared laparoscopic light camera was utilized intermittently during dissection of Calot's triangle until critical view of safety was achieved.
62541774|NCT04228835|NO_INTERVENTION|Conventional LC|Conventional laparoscopic cholecystectomy (LC) arm patients underwent standard white light laparoscopic cholecystectomy without fluorescence cholangiography.
62541775|NCT00022334|EXPERIMENTAL|Treatment|See intervention description.
62541776|NCT04399486|EXPERIMENTAL|Aquatic Physical Therapy|
62541777|NCT04399486|ACTIVE_COMPARATOR|Land-based Physical Therapy|
62541778|NCT01269541|ACTIVE_COMPARATOR|Mupirocin|Topical treatment
62541779|NCT01269541|ACTIVE_COMPARATOR|Rifampicin+Clindamycine or Trimethoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
62541780|NCT03750292|EXPERIMENTAL|HEPAirX air filter|
62541781|NCT03750292|PLACEBO_COMPARATOR|Control air filter|
62541782|NCT01872286|EXPERIMENTAL|Pillcam SB2 first|patients were assigned to swallow PSB first, followed by the AKE
62541783|NCT01872286|EXPERIMENTAL|AKE-1 first|patients were assigned to swallow AKE first, followed by the PSB
62541784|NCT01885195|EXPERIMENTAL|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
62737147|NCT01677416||Rheumatoid Arthritis Group|RA with at least one year since diagnosis, asymptomatic feet, and age between 18 and 65 years
62737148|NCT01677416||Control group|Absence of known osteoarticular disease
62737149|NCT01999842|EXPERIMENTAL|Formulation 1 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
62164823|NCT00248794|EXPERIMENTAL|ICBCR and Skills Training|This intervention is Individualized Computer Based Cognitive Remediation (ICBCR) and skills development group (SDG). Participants receive 15 weeks of computerized training (with intake, 15 and 30 week assessments). This intervention relies upon intense, frequent, repetition of tasks being made incrementally more challenging. Computer tasks are organized so that the initial trials are easily completed and more challenging levels are then attempted. Parameters such as duration of task, task speed, and intra-task variables all be are manipulated. A trainer will be present at each session to help set up the computer tasks and answer questions. Besides the first two sessions that will be orientation sessions, the trainer has little involvement during the training sessions. The role of the trainer is to help organize, support, and provide feedback to each participant. All subjects randomized to this condition also are receiving the weekly skills group (SDG).
62541785|NCT05150847|OTHER|Prone Positioning|Patients will be ventilated in volume-controlled mode with Vt at 6 ml/kg of predicted body weight. Prone positioning will be performed over periods of 16 hours when PaO2/FiO2 was persistently lower than 150 mm Hg. Flow, volume, and airway pressure will bw measured by ventilators. Measurements of oxygenation and respiratory mechanics were performed at 5 and 15 cmH20 PEEP levels and will be repeated every season as before first period of prone positioning, before supine positioning, and again before second period of prone positioning. Total PEEP and plateau pressure will be measured by a short end-expiratory and an end-inspiratory occlusion respectively. Complete airway closure will be assessed by performing a low-flow (4 L/min) inflation( PV tool) (9). The potential for lung recruitment will be assessed by means of the R/I ratio (10).
62541786|NCT04040192|EXPERIMENTAL|Crisaborole 2%|Crisaborole 2% ointment applied once daily (QD)
62541787|NCT04040192|PLACEBO_COMPARATOR|Vehicle|Vehicle ointment applied once daily (QD)
62541788|NCT02230774||medical staff|Nurses and doctors oncall
62541789|NCT02268968|EXPERIMENTAL|Lidocaine|Intervention: Topical lidocaine gel 2% (0.3 ml/kg) will be applied once only to the nostrils and nasal CPAP prong 5 minutes prior to the application of nasal CPAP
62541790|NCT02268968|NO_INTERVENTION|Control|No topical lidocaine will be used prior to application of nasal CPAP
62541791|NCT02692144|EXPERIMENTAL|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
62541792|NCT02692144|PLACEBO_COMPARATOR|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
62541793|NCT02692144|PLACEBO_COMPARATOR|White-bread|47g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
62541794|NCT03095638|EXPERIMENTAL|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B in Part 1 and will receive A: conventional 10 mg DTG tablet (5 tablets) in Period 1 and B: conventional 50 mg DTG tablet in Period 2, administered directly to mouth.
62541795|NCT03095638|EXPERIMENTAL|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A in Part 1 and will receive B: conventional 50 mg DTG tablet in Period 1 and A: conventional 10 mg DTG tablet (5 tablets) in Period 2, administered directly to mouth.
62541796|NCT03095638|EXPERIMENTAL|Treatment sequence C/D/E: Part 2|Eligible subjects will be randomized in sequence C/D/E in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
62541797|NCT03095638|EXPERIMENTAL|Treatment sequence D/E/C: Part 2|Eligible subjects will be randomized in sequence D/E/C in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
62541798|NCT03095638|EXPERIMENTAL|Treatment sequence E/C/D: Part 2|Eligible subjects will be randomized in sequence E/C/D in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
62541799|NCT03095638|EXPERIMENTAL|Treatment sequence C/E/D: Part 2|Eligible subjects will be randomized in sequence C/E/D in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
62541800|NCT03095638|EXPERIMENTAL|Treatment sequence D/C/E: Part 2|Eligible subjects will be randomized in sequence D/C/E in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
62541801|NCT03095638|EXPERIMENTAL|Treatment sequence E/D/C: Part 2|Eligible subjects will be randomized in sequence E/D/C in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
62541802|NCT06359028|EXPERIMENTAL|Test toothpaste|Participants will dose the toothbrush with a ribbon of toothpaste, across the full brush head and will brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening), for approximately 56 days making sure to brush the sensitive areas of the two 'test teeth' carefully first. Participants who wish to rinse after brushing will be instructed to rinse with 10 milliliter (ml) water using graduated rinsing cup provided.
62541803|NCT06359028|ACTIVE_COMPARATOR|Reference toothpaste (Negative control)|Participants will dose the toothbrush with a ribbon of toothpaste, across the full brush head and will brush the entire dentition thoroughly for at least 1-timed minute, twice daily (morning and evening) for approximately 56 days. Participants who wish to rinse after brushing will be instructed to rinse with 10 ml water using graduated rinsing cup provided.
62541804|NCT00682357|EXPERIMENTAL|1|Methylprednisone 80 mg and Lidocaine 20 mg
62541805|NCT00682357|EXPERIMENTAL|2|Methylprednisolone 16 mg and Lidocaine 20 mg
62541806|NCT00682357|PLACEBO_COMPARATOR|3|Placebo and Lidocaine 20 mg
62541807|NCT06548945|EXPERIMENTAL|GZR18|
62541808|NCT06548945|PLACEBO_COMPARATOR|Placebo|
62168009|NCT02490878|EXPERIMENTAL|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
62541809|NCT05651607|EXPERIMENTAL|Cannabidiol (Epidyolex)|
62541810|NCT03063918|EXPERIMENTAL|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
62541811|NCT02792699|EXPERIMENTAL|ABP 798 / ABP 798|Participants received ABP 798 on days 1 and 15 (dose 1) and a second dose of ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
62541812|NCT02792699|ACTIVE_COMPARATOR|Rituximab (US) / ABP 798|Participants received rituximab (United States \[US\] formulation) on days 1 and 15 (dose 1) and transitioned to receive ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
62541813|NCT02792699|ACTIVE_COMPARATOR|Rituximab (EU) / Rituximab (EU)|Participants received rituximab (European Union \[EU\] formulation) on days 1 and 15 (dose 1) and a second dose of rituximab (EU formulation) at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
62541814|NCT06382610|ACTIVE_COMPARATOR|Oral tablet|3 mg Tablets (Nature Made). Participants will need to fast for 2 hours prior to consumption and 2 hours after consumption.
62541815|NCT06382610|EXPERIMENTAL|Lotion|Dr. Teal's Sleep Lotion with Melatonin, Lavender, and Chamomile. 3 g lotion applied to one arm (without washing for at least 4 hours).
62541816|NCT06382610|EXPERIMENTAL|Bubble bath|Dr. Teal's Sleep Bath with Melatonin, Lavender, and Chamomile. 40L warm tap water maintained between 36.5 - 40 degrees C (98 - 104 degrees F) and 2 ml bubble bath. Participants will soak their feet and legs in the cooler for 15 minutes and then dry off (without rinsing or washing for at least 4 hours).
62541817|NCT00749892|EXPERIMENTAL|Treatment (erlotinib hydrochloride)|Participants receive erlotinib hydrochloride PO QD for 3-5 weeks in the absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose, participants undergo cystectomy.
62541818|NCT05435937|EXPERIMENTAL|P4C-Swe intervention|Pupils in participating classes will receive the Partnering for change (P4C) intervention
62541819|NCT05435937|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
62541820|NCT04543890|ACTIVE_COMPARATOR|Hyperfrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
62541821|NCT04543890|EXPERIMENTAL|Hypofrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/15 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
62541822|NCT02794870|EXPERIMENTAL|RSV LID ΔM2-2 1030s vaccine|Participants received a single dose of the RSV LID ΔM2-2 1030s vaccine at study entry (Day 0).
62541823|NCT02794870|PLACEBO_COMPARATOR|Placebo|Participants received a single dose of placebo at study entry (Day 0).
62541824|NCT06104943||Index patients|All individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County in Sweden.
62541825|NCT06104943||First degree relatives to index patients|Parents and the siblings to the index patients by interlinkage of personal identification numbers via the Swedish Multi-Generation register.
62541826|NCT00318877|EXPERIMENTAL|After school sports|After school team sports
62541827|NCT00318877|ACTIVE_COMPARATOR|Health and Nutrition Education|Health and Nutrition Education Active Placebo Control
62541828|NCT04384835||Mild to moderate asthma|low or medium dose of inhaled steroids according to GINA guidelines
62541829|NCT04384835||Severe asthma|criteria described by the ATS / ERS guidelines (for the recruitment of severe patients)
62541830|NCT01866098|EXPERIMENTAL|Naltrexone 50mg|Oral Naltrexone 50mg capsule taken once daily for 52 weeks
62541831|NCT01866098|PLACEBO_COMPARATOR|Placebo|Oral placebo capsule taken once daily for 52 weeks
62541832|NCT01866098|EXPERIMENTAL|Naltrexone 25mg|Oral Naltrexone 25mg capsule taken once daily for 52 weeks
62541833|NCT04614948|EXPERIMENTAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1 and Day 57. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
62541834|NCT04614948|PLACEBO_COMPARATOR|Placebo|Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
62541835|NCT00887991||Electric Pump 1 (ISIS Duo iQ Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
62715243|NCT05566561|ACTIVE_COMPARATOR|Group PSCB = Parasartorial compartment block group|After placing the linear ultrasound probe in the middle of the anterior superior line to the patella and spina drug, the probe will be advanced cephalad to visualize the intermediate femoral cutaneous nerve over the satrorious. Then the block will be applied. Three injections will be made with a single needle entry in the same imaging. The procedure will be completed by applying the first injection to the femoral triangle (10 ml of local anesthetic solution), the second injection to the subsartorial region (10 ml of local anesthetic solution) lateral to the femoral artery, and the third injection to the suprasartorial region (10 ml of local anesthetic solution) (total 30 ml of 0.25% solution). concentration bupivacaine). The block location will be confirmed by injecting 2 ml of saline in every three injections.
62715244|NCT05566561|ACTIVE_COMPARATOR|Group C = Control group|Wound infiltration will be applied by the surgical team
62715245|NCT02805140|EXPERIMENTAL|Virtual exercise and mobile apps|Participants randomized to the intervention arm will join a virtual group convenient for them. They will plan and participate in 8 weeks (every week day) of virtual exercise sessions. Sessions will all be under 30 minutes and include a brief check in amongst participants. The investigators will provide links to information on physical activity and links to online resources for being active.
62715246|NCT02805140|ACTIVE_COMPARATOR|Exercise resources and information|The investigators will provide links to information on physical activity and links to online resources for being active. Women will be invited to join the exercise groups at the end of the 8 weeks.
62715247|NCT06717477||Retrospective (Pre-Intervention)|Participants in this arm were treated for carpal tunnel syndrome before the Carpal Tunnel Plus Pathway was implemented.
62715248|NCT06717477||Prospective (Post-Intervention)|Participants in this arm were treated for carpal tunnel syndrome after the Carpal Tunnel Plus Pathway was implemented.
62715249|NCT06615050|EXPERIMENTAL|Dose Finding Run-In Group 1: Tac/MTX/Ruxolitnib Dose 1|Tacrolimus/ methotrexate/ ruxolitinib (Tac/MTX/Rux) at the protocol defined doses.
62715250|NCT06615050|EXPERIMENTAL|Dose Finding Run-In Group 2: Tac/MTX/Ruxolitnib Dose 2|Tacrolimus/ methotrexate/ ruxolitinib (Tac/MTX/Rux) at the protocol defined doses.
62715251|NCT06615050|EXPERIMENTAL|Main Study Group A: Tac/MTX/Ruxolitnib|Tacrolimus/ methotrexate/ ruxolitinib (Tac/MTX/Rux) at the protocol defined doses.
62715252|NCT06615050|ACTIVE_COMPARATOR|Main Study Group B: PTCy/Tac/MMF|Post-transplant cyclophosphamide/ tacrolimus/ mycophenolate mofetil (PTCy/Tac/MMF) at the protocol defined doses.
62715253|NCT05936424|ACTIVE_COMPARATOR|Non-Exercise Control (CON)|This condition will serve as a non-exercise control and will not be performing resistance exercise training (RET)
62715254|NCT05936424|EXPERIMENTAL|Follicular Based Training (FOL)|This condition will have high volume of RET (20 weekly sets) during the follicular phase and low volume during the luteal phase of the participant's menstrual cycle.
62715255|NCT05936424|EXPERIMENTAL|Luteal Based Training (LUT)|This condition will have high volume of RET (20 weekly sets) during the luteal phase and low volume during the follicular phase of the participant's menstrual cycle.
62715256|NCT05936424|EXPERIMENTAL|Exercise Control (EX)|This condition will have consistent training volume (12 weekly sets) throughout the duration of the study, regardless of what phase of the menstrual cycle the participant is in.
62715257|NCT04138095|OTHER|Virtual Reality|As this is a within subject design, participants will act as their own control. Participants will have access to their baseline opioids and benzodiazepines for pain and anxiety. Every second day they will have access to virtual reality as an adjunct to their opioids and benzodiazepines to manage their symptoms
62715258|NCT04764526|EXPERIMENTAL|Protein-enriched ice cream|Two protein-enriched ice cream daily (afternoon and evening) in two days in addition to the normal menu
62715259|NCT04764526|NO_INTERVENTION|Control|Standard menu in two days
62715260|NCT06705569|EXPERIMENTAL|Test tablet followed by Reference capsule|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62715261|NCT06705569|EXPERIMENTAL|Reference capsule followed by Test tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
62168010|NCT01370161|EXPERIMENTAL|TIPS treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
62541836|NCT00887991||Electric Pump 2 (Medela Symphony Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
62541837|NCT04107792|EXPERIMENTAL|Experimental|Parents of children with sensory processing issues who attend Workshop 1
62715262|NCT04345055|EXPERIMENTAL|Fascial treatment|Treatment the lumbar fasciae
62715263|NCT04345055|PLACEBO_COMPARATOR|Placebo group|Introduce in a machine off
62715264|NCT05122546|EXPERIMENTAL|Arm 2 (CBM588, nivolumab, cabozantinib S-malate)|Patients receive CBM588 PO BID, nivolumab IV over 30 minutes on day 1, and cabozantinib S-malate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62715265|NCT05122546|ACTIVE_COMPARATOR|Arm I (nivolumab, cabozantinib S-malate)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib S-malate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62715266|NCT00457392|EXPERIMENTAL|1|
62715267|NCT00457392|ACTIVE_COMPARATOR|2|
62715268|NCT01580228|EXPERIMENTAL|Dinaciclib|
62715269|NCT01580228|ACTIVE_COMPARATOR|Ofatumumab|
62715270|NCT00477984|EXPERIMENTAL|A|alcohol and placebo
62715271|NCT02751944|EXPERIMENTAL|NEM Treatment|NEM, 500 mg, once daily, orally for 2 weeks
62715272|NCT02751944|PLACEBO_COMPARATOR|Placebo|Placebo, 500 mg, once daily, orally for 2 weeks
62715273|NCT04760769|EXPERIMENTAL|Tavapadon|Participants will receive a Tavapadon tablet at a dose of 5 milligrams (mg) to 15 mg once daily (QD) orally during 58-week treatment period.
62715274|NCT06577337|EXPERIMENTAL|Part A and Part B: M5542|
62715275|NCT06577337|PLACEBO_COMPARATOR|Part A and Part B: Placebo|
62715276|NCT05473507||Participant with Basal Cell Carcinoma/BCC|Participants have been diagnosed with at least 1 Basal Cell Carcinoma/BCC based on clinical, dermoscopy, RCM (reflectance confocal microscopy) and OCT (optical coherence tomography)
62715277|NCT00339716||Belarus in utero|subjects exposed to I131 in utero
62715278|NCT00339716||Main BelAm|subjects exposed to I131 at age less than 18 year
62715279|NCT04663074||IVUS Group|Patients treated by BEVAR/CHEVAR/FEVAR due to a thoracoabdominal aneurysm.
62715280|NCT05086393|EXPERIMENTAL|Duloxetine|Patients randomized to the experimental arm of the study will receive 30 mg of duloxetine and will be advised to consume the medication orally (per os \[PO\]) daily starting one week prior to surgery and to continue until 6 weeks following surgery. The dose of 30 mg was selected as that has been used as that is the largest starting dose used in other RCTs without requiring a preceding adjustment period at a lower dosage.
62715281|NCT05086393|PLACEBO_COMPARATOR|Control|Patients randomized to the control arm will receive PO-matched placebo tablets and advised to consume their medication similar to the treatment arm. Both groups of patients will receive their medications from the pharmacy at Rush Medical Center, which will be responsible for providing patients with the appropriate regimen. All patients will receive the same postoperative multimodal analgesic regimen that is normally administered as part of conventional care to patients undergoing TKA at Rush University Medical Center.
62715282|NCT06450886|EXPERIMENTAL|Ulviprubart (ABC008) 2.0 mg/kg SC|All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
62715283|NCT04565990|EXPERIMENTAL|Selexipag|Participants will receive selexipag tablets twice daily with the dose strength corresponding to their individual maximum tolerated dose (iMTD) from the parent study.
62715284|NCT00727116|EXPERIMENTAL|State-wide|All parents of newborns in Pennsylvania hospitals will receive the parent education materials
62715285|NCT00727116|EXPERIMENTAL|Central PA|All of Central PA new parents will receive the state-wide hospital-based intervention. In half of the 31 central PA counties, all primary care providers having offices in those counties provide an office-based booster intervention to new parents. The other half of central PA counties will receive the state-wide, hospital-based intervention, but not the office-based booster intervention.
62715286|NCT02761135||Side-fire|Using side-fire technique during transrectal ultrasound.
62715287|NCT02761135||End-fire|Using end-fire technique during transrectal ultrasound.
62715288|NCT06676280|EXPERIMENTAL|Aspirin and High-intensity statin|Patients will take aspirin 100 mg/day and high-intensity statin therapy. Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.
62715289|NCT06676280|EXPERIMENTAL|No aspirin and High-intensity statin|Patients will take no aspirin and high-intensity statin therapy. Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.
62715290|NCT06676280|ACTIVE_COMPARATOR|No aspirin and guideline-directed statin|Patients will take no aspirin and guideline-directed statin therapy.
62715291|NCT06676280|EXPERIMENTAL|Aspirin and guideline-directed statin|Patients will take aspirin 100 mg/day and guideline-directed statin therapy.
62715292|NCT05278520||OA cases|Fifty adult patients who have hip osteoarthritis.
62715293|NCT05278520||RA cases|Forty adult patients who have rheumatoid arthritis in the hip joint.
62541838|NCT04107792|NO_INTERVENTION|Waitlist Control|parents of children with sensory processing issues who attend Workshop 2
62715294|NCT05278520||Non-arthritic controls|Twenty adult patients who go through trauma-based emergency total hip arthroplasty and do not have arthritis.
62715295|NCT06717542|OTHER|Organ donors|organ donors (legally deceased, brain death or cardiac death)
62715296|NCT06717542|OTHER|Organ recipients|Organ recipients
62715297|NCT00761345|EXPERIMENTAL|radiotherapy and chemotherapy|gemcitabine will be administered at 1000mg/m2 IV on days 1 and 8 of each 21 day cycle. erlotinib at either 100mg (cohort 1-3) or 150mg (cohort 4) PO daily. Low dose fractionated radiotherapy (LDRT) will be given BID on days 1 and 2 and 8 and 9 of each 21 day cycle
62715298|NCT06447545|OTHER|Low Pressure Pneumoperitoneum|low-pressure pneumoperitoneum in which the pressure is (6-10 mmHg)
62715299|NCT06447545|OTHER|High Pressure Pneumoperitoneum|High-pressure pneumoperitoneum, involving insufflation pressures typically ranging from 12 to 15 mmHg or higher
62715300|NCT01378117|EXPERIMENTAL|Sitagliptin + SSI prn|Sitagliptin once daily plus supplemental doses of lispro if needed using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with GFR 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
62715301|NCT01378117|EXPERIMENTAL|Sitagliptin and glargine+ SSI|Sitagliptin 50-100 mg per oral once a day and SubCutaneous (SQ) glargine insulin once daily + correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with glomerular filtration rate (GFR) 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
62715302|NCT01378117|ACTIVE_COMPARATOR|Glargine and Lispro + SSI|Glargine once daily and lispro before meals supplemental insulin lispro as needed for elevated blood glucose using sliding scale insulin (SSI)
62715303|NCT06718127|OTHER|People with an indication for primary immunization against yellow fever and typhoid|People with an indication for primary immunization against yellow fever and typhoid and whose vaccination schedule includes two appointments 7 days apart
62715304|NCT05231278|EXPERIMENTAL|nCLE aided RANB biopsy|Single arm study
62715305|NCT06713031|PLACEBO_COMPARATOR|Cannulated compression screws + iliac bone graft group|
62715306|NCT06713031|EXPERIMENTAL|DCS + medial support plate + iliac bone graft group|
62715307|NCT01444105|ACTIVE_COMPARATOR|iStent|implantation of two iStent devices
62715308|NCT01444105|ACTIVE_COMPARATOR|SLT|Laser treatment
62715309|NCT03783871|EXPERIMENTAL|Single-arm|Subjects will be treated with microwave ablation.
62715310|NCT06644040|EXPERIMENTAL|TeriQ Patch|
62715311|NCT06644040|ACTIVE_COMPARATOR|Teribone Injection|
62715312|NCT06644040|ACTIVE_COMPARATOR|Forteo Injection|
62715313|NCT06713590|EXPERIMENTAL|Cohort A|Axatilimab will be administered at a protocol defined starting dose administered as an IV infusion.
62715314|NCT06713590|EXPERIMENTAL|Cohort B|Axatilimab will be administered at a protocol defined starting dose administered as an SC injection.
62715315|NCT06713590|EXPERIMENTAL|Cohort C|Axatilimab will be administered at a protocol defined starting dose administered as an SC injection.
62715316|NCT06713590|EXPERIMENTAL|Cohort D|Axatilimab will be administered at a protocol defined starting dose administered as an SC injection.
62715317|NCT06274983|OTHER|IVR platform trial|8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform.
62715318|NCT05541848|NO_INTERVENTION|Control group|Participants in the control group will not receive any intervention and will continue with their normal combat and flight exercise activities. They will be asked not to take medication or seek alternative treatments.
62715319|NCT05541848|EXPERIMENTAL|Experimental group|Participants in the experimental group will follow a supervised ELGF program. Subsequently, they will receive an intervention based on manual therapy combined with electrical stimulation called electro-massage.
62715320|NCT04929210|EXPERIMENTAL|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.
62715321|NCT04929210|EXPERIMENTAL|Group 2: Guselkumab|Participants will receive guselkumab SC.
62715322|NCT04929210|EXPERIMENTAL|Group 3: Placebo followed by Guselkumab|Participants will receive matching placebo and will cross over to receive guselkumab SC.
62715323|NCT03239457||Heberprot P treatment|Patients with diabetic foot ulcers treated with Heberprot P
62715324|NCT05780879|EXPERIMENTAL|Venetoclax + FLAG or CLAG induction chemotherapy|Induction chemotherapy with FLAG starting on day 1 and venetoclax given on days 3-16. The G-CSF component of FLAG will continue until count recovery (ANC at least \> 1000). FLAG dosing will be standard and uniform for all patients and venetoclax dosing will be determined according to institutional guidelines based on the prophylactic antifungal therapy chosen for use during induction therapy. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
62715325|NCT04855357|EXPERIMENTAL|Smoke-free home permanent supportive housing (PSH) resident intervention + Staff Intervention|Study staff will deliver a one hour, one-on-one counseling to PSH residents that includes: (1) a step-by-step guide on how to voluntarily adopt a smoke-free home, (2) information on second hand smoke (SHS) and third-hand smoke, alternative combustible tobacco and nicotine product use, cannabis-tobacco co-use, effects of SHS on kids and pets,(3) a worksheet on calculating personal costs related to tobacco use, and (4) pledges to designate one's home smoke-free. At follow-up assessments, the study team will ask participants whether they had a chance to view the intervention materials in between visits and will offer an opportunity for participants to discuss conflicts that they had experienced around smoke-free home adoption and will provide strategies to address these roadblocks.
62715326|NCT04855357|OTHER|Wait-List Control (Usual Care) then crossover to Smoke-free home PSH resident intervention|The current standard of care includes no interventions for smoke-free home adoption or referrals to smoking cessation resources. Wait-list group receives Smoke-Free Home (SFH) intervention after intervention group complete 6-month follow-up
62715327|NCT00655837|EXPERIMENTAL|1|
62715328|NCT02896309|EXPERIMENTAL|Sodium bicarbonate|Oral sodium bicarbonate tablets three times daily 1000mg
62715329|NCT02896309|ACTIVE_COMPARATOR|Sodium chloride|Oral sodium chloride capsules two times daily 1000mg
62715330|NCT02896309|NO_INTERVENTION|No treatment|No treatment
62715331|NCT06141083|PLACEBO_COMPARATOR|Placebo chewable tablets|
62715332|NCT06141083|EXPERIMENTAL|TCI188 Probiotic chewable tablets|
62541839|NCT05317338|EXPERIMENTAL|Intervention group|Participants randomized to this group will be enrolled to a multicomponent training for 5-7 consecutive days and will continue to receive usual hospital care. The training program consists of strength, balance and gait exercises performed within the hospital.
62715333|NCT03390504|EXPERIMENTAL|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-\[L\] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events \[AEs\]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision.
62715334|NCT03390504|EXPERIMENTAL|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-\[L\] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m\^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system.
62715335|NCT03390504|EXPERIMENTAL|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-\[L\] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision.
62541840|NCT05317338|NO_INTERVENTION|Control group|Participants randomized to the control group will receive only the usual hospital care and rehabilitation, without performing multicomponent exercises.
62715336|NCT03390504|EXPERIMENTAL|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-\[L\] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first.
62715337|NCT06715111|EXPERIMENTAL|laser acupuncture|included twenty-seven participants whom have postnatal pelvic girdle pain received laser acupuncture over specific acupoints, plus conventional pelvic floor exercises; 30minutes, 3 times/week for consecutive 12 sessions for four weeks
62715338|NCT06715111|ACTIVE_COMPARATOR|conventional pelvic floor exercises|included twenty-seven participants whom have postnatal pelvic girdle pain received conventional pelvic floor exercises; 30minutes, 3 sessions per week consecutive 12 sessions for four weeks
62715339|NCT05745155|EXPERIMENTAL|Senti-Wear with Senti-AI|Participants will wear the Senti-Wear smart garment up to twice per day (as tolerated) and complete a study journal detailing issues with the device and changes to their respiratory illness.
62715340|NCT05414175|EXPERIMENTAL|Mavacamten|
62715341|NCT06414668|EXPERIMENTAL|Cycling group|The intervention will include two Bikeability sessions and encouragements strategies will be carried out to complete the eight-weeks intervention based on cycling to and from school
62715342|NCT06414668|NO_INTERVENTION|Control group|The control group will keep their usual mode of commuting to and from school.
62715343|NCT05130294|ACTIVE_COMPARATOR|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides.
62715344|NCT05130294|PLACEBO_COMPARATOR|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
62715345|NCT02121093|NO_INTERVENTION|alpha band of the EEG and electromyographic activity|- 20 will be in the evaluation group (EG); then review the alpha band of EEG and EMG activity.
62715346|NCT02121093|EXPERIMENTAL|Vibration|"* • 20 vai participar no grupo de baixa freqüência de vibração estimulação (LFVS);~* 20 no grupo de estimulação da vibração de média freqüência (MFVS);~* 20 vai participar no grupo de alta freqüência de vibração estimulação (HFVS). then review the alpha band of EEG and EMG activity."
62715347|NCT01538121||Cases-Early Severe Preeclampsia|Patients with severe preeclampsia before 34 weeks of gestation
62715348|NCT01538121||Controls|Patients with normal pregnancies at term.
62715349|NCT05751759|EXPERIMENTAL|Cohort 1|8 participants with mild hepatic impairment (Child-Pugh A) will be given Dose A of mitiperstat.
62715350|NCT05751759|EXPERIMENTAL|Cohort 2|8 participants with moderate hepatic impairment (Child-Pugh B) will be given Dose A of mitiperstat.
62715351|NCT05751759|EXPERIMENTAL|Cohort 3|6-8 participants with severe hepatic impairment (Child-Pugh C) will be given Dose A of mitiperstat.
62715352|NCT05751759|EXPERIMENTAL|Cohort 4|8-12 participants with normal hepatic function will be given Dose A of mitiperstat.
62715353|NCT05653700|EXPERIMENTAL|Arena Strive|The experimental intervention employed in this study will be a 12-week, multi-phased approach involving an asynchronous learning and coaching experience (6 weeks), and exploration phase (6 weeks).
62715354|NCT05653700|OTHER|Control Cohort|Participants randomized into the control cohort - survey at baseline and end of the study
62715355|NCT06506110||Patients who received intravenous PCA following surgery at the UHN|Patients who received intravenous PCA following surgery at the UHN from the period of June 4, 2022 to December 31, 2023.
62715356|NCT04258852|EXPERIMENTAL|Low Strength, High Strength|
62715357|NCT04258852|EXPERIMENTAL|High Strength, Low Strength|
62715358|NCT06278922|EXPERIMENTAL|Seeking Safety + Signs of Safety toolkit|Experimental participants will be offered 12 one-hour, weekly individual therapy sessions of Seeking Safety delivered with the Signs of Safety toolkit. Sessions will occur virtually via National Deaf Therapy's (NDT) secure HIPAA-compliant video chat platform. Length of treatment is limited to six months; number of completed sessions will be tracked as a measure of participant adherence.
62715359|NCT06278922|ACTIVE_COMPARATOR|Treatment as usual|Participants assigned to the active comparison condition will receive therapy as usual - i.e., general, open-ended, non-manualized supportive counseling provided by an NDT therapist. In the absence of any evidence-based therapies available for Deaf clients, this unstructured therapy approach is the current standard of care in the field of Deaf mental health. All NDT therapists are Deaf, fluent in ASL, and specialize in issues common to Deaf individuals seeking mental health care. Like the experimental condition, participants will receive 12 one-hour, weekly individual therapy sessions via NDT's secure virtual therapy platform. Length of treatment is limited to six months; number of completed sessions will be tracked as a measure of participant adherence.
62737150|NCT01999842|EXPERIMENTAL|Formulation 2 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
62541841|NCT04639804|ACTIVE_COMPARATOR|Tegoprazan 50 mg|Multiple doses of tegoprazan alone once daily (QD) for 7 days
62541842|NCT04639804|ACTIVE_COMPARATOR|NSAIDs|Multiple doses of NSAIDs alone twice daily (BID) for 7 days
62737151|NCT01999842|EXPERIMENTAL|Formulation 3 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
62737152|NCT01999842|EXPERIMENTAL|Formulation 4 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
62541843|NCT04639804|ACTIVE_COMPARATOR|Tegoprazan 50 mg + NSAIDs|Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days
62541844|NCT00191165|EXPERIMENTAL|1|Doubled dosage
62541845|NCT00191165|ACTIVE_COMPARATOR|2|In-label dosage
62715360|NCT06278922|NO_INTERVENTION|No treatment|Participants in states with no NDT therapists and who prefer to be placed on NDT's waitlist instead of being referred outside of NDT for therapy will be automatically assigned to the no-treatment control condition. At the time of this submission, there are approximately 200 individuals on the NDT waitlist; individuals remain on the waitlist until a licensed therapist from their state joins the NDT team. Participants in the control condition will be prompted to complete assessments at baseline, week 6, week 12 (to approximate immediate post-treatment), week 25 (to approximate three-month follow-up), and week 38 (to approximate six-month follow-up). Such repeated assessment in the control arm will allow us to quantify and control for participants' natural change over time and any potential assessment reactivity.
62715361|NCT01281111|EXPERIMENTAL|BG00012 plus ASA|
62715362|NCT01281111|EXPERIMENTAL|BG00012 plus ASA matching placebo|
62541846|NCT04951986|EXPERIMENTAL|High dose Rifampicin plus Levofloxacin|Standard TB treatment plus additional Rifampicin 35 mg/kg/day PLUS Levofloxacin for 14 days
62541847|NCT04951986|EXPERIMENTAL|Prednisone|Prednisone 1.5 mg/kg for 14 days
62541848|NCT04951986|ACTIVE_COMPARATOR|Standard TB treatment|High dose rifampicin/levofloxacin comparator
62541849|NCT04951986|PLACEBO_COMPARATOR|Placebo|Prednisone comparator
62541850|NCT02849483|EXPERIMENTAL|Ramosetron|2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)
62541851|NCT02849483|PLACEBO_COMPARATOR|Control|dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA
62541852|NCT00381160|EXPERIMENTAL|1|Provision of non-caloric beverages to home
62541853|NCT00381160|NO_INTERVENTION|2|
62541854|NCT06449144|EXPERIMENTAL|mindfulness education with pre-test group|24 hours before surgery, patients will be administered the sociodemographic information form, the fear of pain scale and the cognitive intrusion of pain scale. Subsequently, awareness training will be given to the patients. 24 hours after surgery, surgical information form, fear of pain scale and cognitive intrusion of pain scale will be administered.
62541855|NCT06449144|EXPERIMENTAL|mindfulness education without pre-test group|24 hours before surgery awareness training will be given to the patients. 24 hours after surgery, surgical information form, fear of pain scale and cognitive intrusion of pain scale will be administered.
62541856|NCT06449144|NO_INTERVENTION|control with pre-test group|24 hours before surgery, patients will be administered the sociodemographic information form, the fear of pain scale and the cognitive intrusion of pain scale. 24 hours after surgery, surgical information form, fear of pain scale and cognitive intrusion of pain scale will be administered.
62541857|NCT06449144|NO_INTERVENTION|control without pre-test group|24 hours after surgery, surgical information form, fear of pain scale and cognitive intrusion of pain scale will be administered.
62541858|NCT05454670|EXPERIMENTAL|Test group|The intervention will be primary cleft palate repair using resorbable collagen matrix graft as superpositional graft during approximation of the nasal mucosa and muscular layer in cleft palate repair. The collagen graft with be inserted between the nasal mucosa/ muscular layer and the oral mucosa layer during two-flap palatoplasty.
62541859|NCT05454670|ACTIVE_COMPARATOR|Control group|The intervention will be primary cleft palate repair using two-flap palatoplasty technique without collagen graft
62541860|NCT02430038||Acceptability|To assess acceptability of intervention. Some patients from this group also participated in the other groups.
62541861|NCT02430038||Feasibility|Is it possible for ultrasound to measure labour parameters, where vaginal examinations are best avoided e.g. vaginismus or contraindicated (PPROM) with controls. Some patients from this group also participated in the other groups.
62541862|NCT02430038||Predictive Model|Nulliparous term labouring women with cephalic presentation. Some patients from this group also participated in the other groups.
62541863|NCT03020537|OTHER|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
62541864|NCT03020537|OTHER|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
62541865|NCT00636389|OTHER|HD-C4 First, then 210H|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
62541866|NCT00636389|OTHER|210H First, then HD-C4|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux 210H dialyzer. Following the third treatment, the subjects will be switched to the Polyflux HD-C4 dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
62541867|NCT06282783|EXPERIMENTAL|Men|Sex assigned at birth, male Single dose of 400mg topiramate
62541868|NCT06282783|EXPERIMENTAL|Women|Sex assigned at birth, female Single dose of 400mg topiramate
62541869|NCT06211543||LMV cohort|Patients will receive oral or intravenous (if available ) LMV at a dose of 480mg/day. For patients receiving concomitant cyclosporine treatment, the LMV dose will be 240mg/day. LMV will be administered daily through week 14 after transplantation for up to 8 weeks (\~Day 100) beginning
62541870|NCT06211543||Historical cohort|An historical control cohort for comparison purposes will be used. Historical data will be obtained from a national CMV data base (GETH-GRUCINI), that includes stem cell transplant recipients from September 2014 to December 2022
62715363|NCT01281111|PLACEBO_COMPARATOR|BG00012 Placebo plus ASA|
62541871|NCT04693897||Overactive bladder with Mirabegron|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Mirabegron 50mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
62541872|NCT04693897||Overactive bladder with Solifenacin|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Solifenacin 5mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
62541873|NCT04693897||Urinary tract infection|Urinary samples for beta-3 adrenoceptor concentration of 100 patients with urinary tract infection.
62715364|NCT01281111|EXPERIMENTAL|BG00012 Placebo plus ASA matching placebo|
62715365|NCT01281111|EXPERIMENTAL|BG00012|modified dose regimen
62715366|NCT06247735|PLACEBO_COMPARATOR|Placebo + K-877 (Group A)|Placebo for 12 Weeks followed by K-808 (Dose A) for 52 Weeks
62541874|NCT04693897||Control|Urinary samples for beta-3 adrenoceptor concentration of 100 patients without lower urinary tract symptoms.
62541875|NCT01531439|ACTIVE_COMPARATOR|Naloxone infusion 0.5 mcg/kg/hr|
62541876|NCT01531439|EXPERIMENTAL|Naloxone 2.5 mcg/kg/hr|Naloxone infusion 2.5 mcg/kg/hr
62541877|NCT00576446|EXPERIMENTAL|1|
62541878|NCT04378738|OTHER|Cohort|the healthy people who accepted to participate in the study
62541879|NCT06633159||prospective|The prospective part of the study will include patients who have undergone hospitalization for the purpose of surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets.
62541880|NCT06633159||retrospective|The retrospective part of the study will include patients who underwent surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets.
62541881|NCT02274831|EXPERIMENTAL|Email Group|Includes receiving standard of care discharge instructions plus an email after being discharged home from the emergency department, reinforcing their discharge instructions. Included in the email is their physician's name and recommended timing of follow-up visit.
62541882|NCT02274831|NO_INTERVENTION|Standard of Care|Includes standard of care discharge instructions after being discharged from the emergency department. This included receiving paper copies of their discharge instructions.
62541883|NCT06041789|EXPERIMENTAL|Donepezil|
62541884|NCT06041789|PLACEBO_COMPARATOR|Placebo|
62541885|NCT06495112|OTHER|Soft contact lens with lathe cut technique Lathe|
62541886|NCT06495112|EXPERIMENTAL|Soft contact lens with cast molding technique|
62541887|NCT00025259|EXPERIMENTAL|Arm I (Patients off-therapy before callback-Induction only)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
62541888|NCT00025259|EXPERIMENTAL|Arm II (RER with CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
62541889|NCT00025259|EXPERIMENTAL|Arm III (RER with CR [ABVE-PC])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
62541890|NCT00025259|EXPERIMENTAL|Arm IV (RER with less than CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
62541891|NCT00025259|EXPERIMENTAL|Arm V (RER with PD)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
62541892|NCT00025259|EXPERIMENTAL|Arm VI (SER [DECA, ABVE-PC, IFRT])|Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, and cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 and 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 and G-CSF SC beginning on day 3 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
62541893|NCT00025259|EXPERIMENTAL|Arm VII (SER [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
62541894|NCT03548337|ACTIVE_COMPARATOR|13vPnC with 2-PE from a MDV|Multi Dose Vial with preservative
62715367|NCT06247735|PLACEBO_COMPARATOR|Placebo + K-877 (Group B)|Placebo for 12 Weeks followed by K-808 (Dose B) for 52 Weeks
62715368|NCT06247735|EXPERIMENTAL|K-808 Group A|K-808 (Dose A) for 64 Weeks
62715369|NCT06247735|EXPERIMENTAL|K-808 Group B|K-808 (Dose B) for 64 Weeks
62715370|NCT03156829|EXPERIMENTAL|Splint alone|
62715371|NCT03156829|EXPERIMENTAL|Cortico-steroid alone|
62715372|NCT03156829|EXPERIMENTAL|Splint and cortico-steroid combined|
62715373|NCT02485015|OTHER|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
62715374|NCT02485015|EXPERIMENTAL|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
62715375|NCT05378113|EXPERIMENTAL|Ondansetron premedication Group|The ondansetron group will receive ondansetron 0.15mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.
62715376|NCT05378113|ACTIVE_COMPARATOR|Lidocaine premedication Group|The lidocaine group will receive lidocaine 2% 1mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.
62715377|NCT06657105|EXPERIMENTAL|Period 1: Ethinyl estradiol/Levonorgestrel (EE/LNG)|Participants will receive oral dose of EE/LNG in the fasted state on Day ,1 followed by PK sampling of EE/LNG for 120 hours (EE 72 hours and LNG 120 hours).
62715378|NCT06657105|EXPERIMENTAL|Period 2: Baxdrostat|Participants will self-administer the baxdrostat tablet once a day from Day 6 to Day 16.
62715379|NCT06657105|EXPERIMENTAL|Period 3: Baxdrostat + EE/LNG|Participants will receive baxdrostat once daily on Day 17 to Day 22 and will receive EE+LNG in the fasted state on Day 18, followed by oral dose of EE/LNG PK sampling for 120 hours (EE=72 hours and LNG=120 hours).
62715380|NCT04211363|EXPERIMENTAL|Rofumilast Cream 0.3%|Participants receive roflumilast cream 0.3% once daily for 8 weeks.
62715381|NCT04211363|PLACEBO_COMPARATOR|Vehicle cream|Participants receive vehicle cream once daily for 8 weeks.
62715382|NCT02495285||Gelofusine 4%|Children age ≤ 12 years
62715383|NCT02495285||Gelaspan 4%|Children age ≤ 12 years
62715384|NCT00845702|EXPERIMENTAL|Dotarem|Each subject will receive one injection of Dotarem 0.2 ml/kg.
62715385|NCT00845702|OTHER|Time Of Flight Magnetic Resonance Angiography|Each subject undergo a TOF MRA
62715386|NCT03637400|EXPERIMENTAL|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (\<40 kg), we will use weight based liquid medications for children \< 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (\>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
62715387|NCT03637400|EXPERIMENTAL|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (\<40 kg), we will use weight based liquid medications for children \< 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (\>100 kg) and four additional placebo tabs will be given to subjects \> 100 kg randomized to doxycycline.
62715388|NCT03613064|EXPERIMENTAL|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
62715389|NCT03613064|EXPERIMENTAL|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
62715390|NCT03457077|EXPERIMENTAL|Brief Intervention|Participants will receive a brief intervention at week 0
62715391|NCT03457077|OTHER|Delayed Intervention|Participants will receive a brief intervention at 6 months
62715392|NCT03586518||Haemodialysis patients|"The plans for patient recruitment were developed in partnership with our local haemodialysis patient participation and involvement group. Patients will be identified from the supportive care register established for haemodialysis patients in Leicester in 2008.~Inclusion:~* Prevalent haemodialysis patient (more than 3 months)~* Active on the supportive care register with anticipated death in the subsequent 12 months~* Able to give informed consent~* Consent to donation of heart for research following death~* Able to understand written and verbal explanations in English~Exclusion:~* Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)~* Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)~* Unable to give informed consent~* Unable to understand written and verbal explanations in English"
62168011|NCT01370161|ACTIVE_COMPARATOR|Medical treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.
62168012|NCT00924209|EXPERIMENTAL|Stage IIIA lung cancer patients|Non-squamous cell non small cell lung cancer treated with 1250 mg/m\^2 gemcitabine dose for two doses on day 1 and day 8 every 21 days,80 mg/m\^2 cisplatin day 1 every 21 days for 3 cycles, 7.5 mg/kg bevacizumab on day 1 every 21 days for first 2 cycles only, and 100 mg/m\^2 intravenous, and 100 mg/m\^2 etoposide intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
62168013|NCT01935349||Diabetes mellitus (DM) and hypertension (HT)|Diabetes mellitus (DM) and/or hypertension (HT) patients in Hong Kong
62168014|NCT00847223|EXPERIMENTAL|ZARNESTRA (Tipifarnib)|
62168015|NCT03966014|ACTIVE_COMPARATOR|EM-amoxicillin 3 x 10 days|
62715393|NCT00893360|EXPERIMENTAL|Cardiac Stem Cell Treatment - Group 1|Autologous stem cell infusion of 12.5 MIL CDCs via intracoronary infusion.
62715394|NCT00893360|EXPERIMENTAL|Cardiac Stem Cell Treatment -Group 2|Autologous stem cell infusion of 25 MIL CDCs via intracoronary infusion.
62715395|NCT00893360|NO_INTERVENTION|Observation (Control Group)|Observation of myocardial recovery after usual medical management.
62715396|NCT06417671|EXPERIMENTAL|Postbiotics supplementation|Supplementation of postbiotics for 4 weeks
62715397|NCT06417671|PLACEBO_COMPARATOR|Placebo supplementation|Supplementation of placebo for 4 weeks
62715398|NCT06715527|EXPERIMENTAL|Treatment|Women with PCOS under oral supplementation with myo-inositol and D-chiro-inositol in 40:1 ratio
62715399|NCT06715527|ACTIVE_COMPARATOR|Comparator|Women with PCOS under oral supplementation with myo-inositol and D-chiro-inositol in 3.6:1 ratio
62715400|NCT06173505|EXPERIMENTAL|Vudalimab + Carboplatin + Pemetrexed|
62715401|NCT06173505|ACTIVE_COMPARATOR|Pembrolizumab + Carboplatin + Pemetrexed|
62715402|NCT04815564|EXPERIMENTAL|Intervention|Subjects with a PAR score between 15 and 50 and fulfilling the other eligibility criteria will be offered participation in the trial.
62715403|NCT04815564|NO_INTERVENTION|Natural History|Subjects with a PAR score outside of 15-50 will be offered the opportunity to remain on study for the Natural History arm.
62715404|NCT02476448|ACTIVE_COMPARATOR|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
62715405|NCT02476448|EXPERIMENTAL|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
62715406|NCT02476448|EXPERIMENTAL|Phenazopyridine|Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
62715407|NCT02476448|EXPERIMENTAL|Sodium Fluorescein|Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
62715408|NCT04020640||Exclusive breastfeeding (EBF)|provision of breast milk only, allowing only receiving oral rehydration salts (ORS), drops and syrups (vitamins, minerals, medicines) as necessary
62715409|NCT04020640||Predominant breastfeeding (PBF)|providing breast milk plus other liquids (water and water-based drinks, fruit juice) and ORS, drops and syrups (vitamins, minerals, medicines)
62715410|NCT04020640||Partial breastfeeding (PartBF)|provision of breast milk plus infant formula or cow milk or other solid/semi-solid complementary foods
62715411|NCT06654037|EXPERIMENTAL|Treatment (abemaciclib, 5-FU)|Patients receive abemaciclib PO BID on days 1-28 and 5-FU IV over 46 hours on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection throughout the study and may additionally undergo a tissue biopsy before treatment and on cycle 1 day 16.
62715412|NCT04660760|EXPERIMENTAL|Arm A (TAS-102, ramucirumab)|Patients receive TAS-102 PO BID on days 1-5 and 8-12, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
62715413|NCT04660760|ACTIVE_COMPARATOR|Arm B (paclitaxel, ramucirumab)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
62715414|NCT06510816|EXPERIMENTAL|ANX007|Participants will receive ANX007 IVT injections every month during the 24-month treatment period.
62715415|NCT06510816|SHAM_COMPARATOR|Sham Group|Participants will receive Sham IVT injections every month during the 24-month treatment period.
62715416|NCT05162586|PLACEBO_COMPARATOR|Cohort A: Placebo|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (Cutaneous Lupus Erythematosus Disease Area and Severity Index \[CLASI-A\] greater than or equal to \[\>=\] 8) will be enrolled in Cohort A to receive placebo matched to Enpatoran.
62715417|NCT05162586|EXPERIMENTAL|Cohort A: Enpatoran low dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A \>= 8) will be enrolled in Cohort A to receive low dose of Enpatoran.
62715418|NCT05162586|EXPERIMENTAL|Cohort A: Enpatoran medium dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A \>= 8) will be enrolled in Cohort A to receive medium dose of Enpatoran.
62715419|NCT05162586|EXPERIMENTAL|Cohort A: Enpatoran high dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A \>= 8) will be enrolled in Cohort A to receive high dose of Enpatoran.
62715420|NCT05162586|PLACEBO_COMPARATOR|Cohort B (Part 1 + Part 2): Placebo|Participants with active SLE who have moderate to high systemic disease activity (British Isles Lupus Assessment Group \[BILAG A/2B\]) with 1 or 2 of the following: CLASI-A \>= 8 and/or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) \>= 6 will be enrolled in Cohort B to receive placebo matched to Enpatoran .
62715421|NCT05162586|EXPERIMENTAL|Cohort B (Part 1 + Part 2): Enpatoran high dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A \>= 8 and/or SLEDAI \>= 6 will be enrolled in Cohort B to receive high dose of Enpatoran.
62715422|NCT05162586|EXPERIMENTAL|Cohort B (Part 2): Enpatoran low dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A \>= 8 and/or SLEDAI \>= 6 will be enrolled in Cohort B to receive low dose of M5049.
62715423|NCT05162586|EXPERIMENTAL|Cohort B (Part 2): Enpatoran medium dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A \>= 8 and/or SLEDAI \>= 6 will be enrolled in Cohort B to receive medium dose of Enpatoran.
62715424|NCT02873078|EXPERIMENTAL|Internet-delivered CBT|Children and parents will receive 10 weekly modules of cognitive behavior therapy (CBT). Parents will also receive 10 weekly modules. Main components in the children's modules are exposure for abdominal symptoms, feared stimuli and situations in which the children are afraid of having symptoms. The parental receive information on how they can support their children in the treatment and how to reinforce health y behaviors and decrease attention to pain behaviors. Therapist support is provided through written messages within the secure platform.
62737153|NCT01999842|EXPERIMENTAL|Formulation 5 Group|Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
62715425|NCT02873078|NO_INTERVENTION|Waiting list|This is a wait-list control where the children and parents are allowed to carry on with any contacts within the health-care system, exempt for psychological treatments.
62715426|NCT04047446|EXPERIMENTAL|Liposomal bupivacaine & standard bupivacaine|
62541895|NCT03548337|ACTIVE_COMPARATOR|13vPnC without 2-PE in a PFS|Pre Filled Syringe without preservative
62715427|NCT04047446|ACTIVE_COMPARATOR|Standard bupivacaine & dexamethasone|
62541896|NCT06523660|EXPERIMENTAL|Intervention Group|Children will receive the EF training intervention, which will be delivered in a telehealth format across 10 sessions (1 1-hour session per week for 10 weeks), targeting core EF components including inhibitory control, attention shifting, and working memory. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.
62541897|NCT06523660|ACTIVE_COMPARATOR|Control Group|Group-based parent psychoeducation will be provided to the control group. This program will also be delivered in a telehealth format across 10 sessions (1 1-hour session per week for 10 weeks) and will cover a broad range of information relevant to ASD.
62541898|NCT01061476|OTHER|Single arm - Sleep apnea|"Participants with sleep apnea will be recruited for the study. Each participant will undergo 3 sleep studies to assess the effect of the Provent™ device. Participants will only use the device while they are in the sleep laboratory. They will not use the device at home between sleep studies .~1. Baseline sleep study (No device) - Assess the effects of no Provent™ on sleep apnea severity.~2. Treatment sleep study (Provent™ device used) - Assess the effects of Provent™ on sleep apnea severity~3. Physiology sleep study (Provent™ on/off) - Assess the physiological effects of the Provent™ device on breathing during sleep."
62541899|NCT06551766|EXPERIMENTAL|Photosensitive hydrogel|The photosensitive hydrogel is composed of tetra-armed poly(ethylene glycol) (4aPEGNB)and methacrylate-modified hyaluronic acid (HAMA).The hydrogel can be rapidly photocured under light induction at 395nm.
62541900|NCT06551766|ACTIVE_COMPARATOR|Suture fixation|The suture is fixed with 6-0 absorbable thread.
62541901|NCT02094911|EXPERIMENTAL|Combined lifestyle intervention|Lifestyle counselling (nutrition and physical activity) by dietician and physiotherapist during 10-month intervention period
62541902|NCT02094911|OTHER|Usual care group|Subjects receive brochures on healthy lifestyle at baseline, and during the 10-month intervention period only usual care as provided by their own general practitioner.
62541903|NCT00015873|NO_INTERVENTION|A no VIMARAM|No VIMARAM preceding maintenance treatment
62541904|NCT00015873|EXPERIMENTAL|B - VIMARAM|VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days
62541905|NCT02722915|EXPERIMENTAL|fMRI Neurofeedback up-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
62541906|NCT02722915|EXPERIMENTAL|fMRI Neurofeedback down-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
62541907|NCT05329259|EXPERIMENTAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (13vPnC)
62541908|NCT02197910|ACTIVE_COMPARATOR|High content of wheat bioactive peptides|100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)
62541909|NCT02197910|PLACEBO_COMPARATOR|Low dose of wheat bioactive peptides|100 gr pasta/day, containing around 3 mg bioactive peptides
62541910|NCT06348615|EXPERIMENTAL|Single arm: 1 bottle (cream-gel) 400ml|"Each study subject applies the medical device (one cream-gel of 400ml) on both buttocks and thighs affected by cellulite (II or III degree) massaging with circular movements following the direction of the lymphatic flow, twice a day for 4 weeks ( intermediate visit) and for another 8 weeks (final visit).~If the device is finished during the study, a new device may be provided, always one cream-gel of 400 ml."
62541911|NCT02988635|EXPERIMENTAL|Early Palliative Care|Subjects receive standard of care with early palliative care.
62541912|NCT02988635|NO_INTERVENTION|Standard of Care|Subjects receive standard of care.
62541913|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery online/phone survey.
62541914|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery online/phone survey.
62541915|NCT03645239||Control (non-Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Twenty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
62541916|NCT03645239||Experimental (Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Fifty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
62541917|NCT04722146|EXPERIMENTAL|Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide|Participants will receive teclistamab plus daratumumab plus pomalidomide.
62715428|NCT03551782|EXPERIMENTAL|Cohort 1|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer \[t-SCNC\]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
62541918|NCT04722146|EXPERIMENTAL|Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 21-day cycles.
62541919|NCT04722146|EXPERIMENTAL|Treatment Regimen C: Teclistamab + Nirogacestat|Participants will receive teclistamab plus nirogacestat.
62541920|NCT04722146|EXPERIMENTAL|Treatment Regimen D: Teclistamab + Lenalidomide|Participants will receive teclistamab plus lenalidomide.
62737154|NCT01999842|PLACEBO_COMPARATOR|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
62715429|NCT03551782|EXPERIMENTAL|Cohort 2|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1.
62715430|NCT03551782|EXPERIMENTAL|Cohort 3|Biomarker-positive participants who progressed on AA-P will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
62715431|NCT03551782|EXPERIMENTAL|Cohort 4|Biomarker-positive participants who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
62715432|NCT03551782|EXPERIMENTAL|Cohort 5|Biomarker-negative participants with t-SCNC who progressed on treatment with AA-P, apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
62715433|NCT03978845|EXPERIMENTAL|Phrenic Nerve Blockade|All patients will be submitted to bilateral phrenic nerve block on its cervical portion.
62715434|NCT02341066||Rheumatoid Arthritis|Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT
62715435|NCT02013609|EXPERIMENTAL|Brexpiprazole|Up to 3mg/day, once daily dose, tablets, orally
62715436|NCT06032390|EXPERIMENTAL|Intervention arm|AI assisted mammography screening interpretation
62715437|NCT06032390|ACTIVE_COMPARATOR|Control arm|Standard mammography screening interpretation (standard procedure)
62715438|NCT04286178|EXPERIMENTAL|Treatment|patients in this arm will be treated with creatine and coenzyme Q10 supplements
62715439|NCT04286178|PLACEBO_COMPARATOR|Placebo|patients in this arm will be given placebo supplements that look and taste identical to the active supplements
62715440|NCT03760172||Prevalence of NAFLD in patients with IMID|To analyze the global prevalence of NAFLD in patients with an immune-mediated inflammatory disease IMID
62715441|NCT03760172||Prevalence of High-risk NASH in patients with IMID|To evaluate the prevalence of high-risk NASH (NASH with advanced fibrosis) in patients with IMID through clinical, radiological and histological evaluation
62715442|NCT03760172||Immunophenptypic characterization|To investigate the existence of common and differential immunophenotypes between the subjects with NASH with and without IMID, and patients with IMID without liver involment
62715443|NCT03760172||Genetic and Molecular characterization|Liver molecular characterization of NASH associated to IMID
62715444|NCT06675461|ACTIVE_COMPARATOR|Treatment As Usual|Access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
62715445|NCT06675461|EXPERIMENTAL|Gold Card Intervention|A 4-session manualized intervention consisting of weekly scheduled 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support.
62715446|NCT02563782|SHAM_COMPARATOR|Control group|Sham surgery and placebo immunosuppressive therapy (IMT)
62715447|NCT02563782|ACTIVE_COMPARATOR|Active Group|Sub-retinal transplantation of MA09-hRPE cells and IMT
62715448|NCT02885142|EXPERIMENTAL|Transanal endoscopic microsurgery group|
62168016|NCT03966014|ACTIVE_COMPARATOR|EM-amoxicillin 3 x 14 days|
62715449|NCT02885142|ACTIVE_COMPARATOR|endoscopic submucosal dissection group|
62715450|NCT06033287||CDK4/6 inhibitors treatment|All HR+/HER2- metastatic breast cancer patients using CDK4/6 inhibitors
62715451|NCT00017914||Healthy Volunteer|Healthy subject who has not received anti-inflammatory medications and should not has undergone surgery or any major trauma within the 8 weeks prior to enrollment.
62715452|NCT00017914||Myositis Patient|Patient should have documented evidence that he/she meets criteria for an idiopathic inflammatory myopathy (IIM)
62715453|NCT00017914||Non-Myositis Patient|Patients with other myopathies/autoimmune diseases/complications similar to myositis patients. Close relatives of IIM patients (affected or unaffected siblings, children, parents, grandparents)
62715454|NCT06020261|EXPERIMENTAL|Parent Management Training|12 sessions of manualized Parent Management Training.
62715455|NCT06481670|EXPERIMENTAL|Preoperative carbohydrate drink|Participants randomized into this group will receive a carbohydrate drink before surgery.
61978150|NCT06049745|NO_INTERVENTION|hysteroscopic myomectomy without misoprostol|Patients undergoing hysteroscopic myomectomy that will be randomized to no intervention before the procedure.
62168017|NCT03966014|ACTIVE_COMPARATOR|EM-amoxicillin 2 x 14 days|
62168018|NCT03966014|OTHER|Controls|
62168019|NCT06038578|EXPERIMENTAL|Arm A: TRK-950(5 mg/kg)+Ramucirumab+Paclitaxel|Participants who will be randomized to receive a 5 mg/kg intravenous(IV) dose of TRK-950 on days 1, 8, 15 and 22 in combination with 8 mg/kg IV dose of ramucirumab on days 1 and 15 and 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
62541921|NCT04722146|EXPERIMENTAL|Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide|Participants will receive teclistamab plus daratumumab plus lenalidomide.
62715456|NCT06481670|NO_INTERVENTION|Preoperative fasting|Participants randomized into this group will be fasting/nothing by mouth (NPO) before surgery.
62715457|NCT04971928|EXPERIMENTAL|Participants with Moderate (CP-B) hepatic impairment|
62715458|NCT04971928|EXPERIMENTAL|Participants with Mild (CP-A) hepatic impairment|
62715459|NCT04971928|EXPERIMENTAL|Healthy participants|
62715460|NCT06717243||Extensive-Stage Small Cell Lung Cancer (ES-SCLC) patients|This cohort includes adults with extensive-stage small cell lung cancer (ES-SCLC) receiving standard-of-care chemo-immunotherapy, such as platinum-based chemotherapy (cisplatin or carboplatin) combined with immune checkpoint inhibitors (atezolizumab or durvalumab). The study collects biospecimens, including blood (for circulating tumor DNA and circulating tumor cells) and tumor tissue, at baseline, during treatment, and at progression. These samples are analyzed to identify genomic, epigenetic, and transcriptomic signatures associated with treatment resistance. Insights gained will improve understanding of resistance mechanisms and guide personalized treatment strategies for ES-SCLC.
62715461|NCT06717243||Large Cell Neuroendocrine Carcinoma (LCNEC) patients|"This cohort includes adults diagnosed with metastatic large cell neuroendocrine carcinoma (LCNEC). Participants will receive standard-of-care systemic therapies, such as platinum-based chemotherapy (cisplatin or carboplatin), with or without immune checkpoint inhibitors, based on physician discretion.~Biospecimens, including blood (for circulating tumor DNA and circulating tumor cells) and tumor tissue, will be collected at baseline, during treatment, and upon disease progression. These samples will undergo molecular analysis to identify genomic, epigenetic, and transcriptomic changes associated with treatment resistance and progression."
62715462|NCT06524375|EXPERIMENTAL|Venetoclax Added to cBTKi (Commercially Prescribed)|"Participants will receive venetoclax, orally, once daily (QD) as ramp-up dosing at a starting dose of 20 milligrams (mg) on Day 1 of Cycle 1 (cycle length= 28 days) with weekly dose increases until the target dose of 400 mg is reached. Thereafter, participants will continue receiving venetoclax at 400 mg, orally, QD from Day 1 of Cycle 2 up to Day 28 of Cycle 12.~Participants will continue receiving cBTKi-monotherapy (i.e. ibrutinib or acalabrutinib, or zanubrutinib) as previoulsy prescribed by the investigator in accordance with its prescribing label for up to 12 months."
62715463|NCT02138825|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
62715464|NCT02138825|PLACEBO_COMPARATOR|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
62541922|NCT04722146|EXPERIMENTAL|Treatment Regimen F: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 28-day cycles.
62541923|NCT03159338|ACTIVE_COMPARATOR|treatment group|One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation
62541924|NCT03159338|PLACEBO_COMPARATOR|Control group|In control site , placebo gel will be placed before rigid fixation
62541925|NCT06447129|EXPERIMENTAL|NMES with Exercise|Each subject in Group 2 will receive a treatment protocol consisting of stretching exercises, strengthening exercises, functional exercises for the knee and hip, and NMES application for the quadriceps femoris muscle.
62541926|NCT06447129|ACTIVE_COMPARATOR|Exercise|Each subject in Group 2 will receive a treatment protocol consisting of stretching exercises, strengthening exercises, functional exercises for the knee and hip.
62541927|NCT02628886|EXPERIMENTAL|maternal group|13-valent pneumococcal conjugate vaccine \[Prevenar13®\] (PCV13) vaccine, 0.5ml, once, stat, plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
62541928|NCT02628886|PLACEBO_COMPARATOR|control group|placebo sterile 0.9% sodium chloride, 0.5ml, once, stat plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
62541929|NCT02628886|EXPERIMENTAL|neonatal group|tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV 13 0.5ml at birth, 8 weeks and 16 weeks
62541930|NCT06448260||Patient with ATCT|Patient with tibiocalcaneal arthrodesis with talectomy amputation
62541931|NCT01326923|OTHER|Single arm|Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
62541932|NCT00637767|EXPERIMENTAL|radio-labelled anti-CD66 monoclonal antibody|Up to 4mg radio-labelled anti-CD66 monoclonal antibody. Plus standard treatment
62541933|NCT00637767|ACTIVE_COMPARATOR|No IMP - standard treatment|No IMP - standard treatment
62541934|NCT06050304||Crack-cocaine Use Disorder users|Observation of behaviour in ecological conditions in patients with crack-cocaine dependence
62541935|NCT04251572|EXPERIMENTAL|HCV reinfection after DAA therapy in PWID|Hepatitis C virus reinfection after directly acting antiviral treatment in persons who inject drugs. DAA therapy is an inclusion criteria, not an intervention.
62541936|NCT03349983|EXPERIMENTAL|MVA-BN-Brachyury/ FPV-Brachyury|
62541937|NCT06633367|NO_INTERVENTION|Control group receiving standard health information|This group will receive information about health benefits in nature.
62541938|NCT06633367|ACTIVE_COMPARATOR|Intervention Group receiving standard health information + incentives to increase time outdoors|This group will receive information on the health benefits of time outdoors, a request to increase their time outdoors, eligibility to receive a prize, and information on peer performance.
62541939|NCT01291771|OTHER|comparator|One group of patients with no myocardial ischemia on non invasive testing will be followed up for 2 years
62541940|NCT01291771|EXPERIMENTAL|coronary angiography group|One group of patients with myocardial ischemia on non invasive testing will undergo coronary angiography and measure of FFR + CFR to detect myocardial microvascular disease
62541941|NCT04478812|EXPERIMENTAL|Single Group Assignment|
62541942|NCT01763190|EXPERIMENTAL|SAR302503|single treatment of 300 mg oral dose of SAR302503
62541943|NCT05576077|EXPERIMENTAL|Breast Cancer|Patients with locally advanced or metastatic breast cancer that has failed or is intolerant to standard of care therapies. Includes, HER2+, HER 2-, TNBC.
62541944|NCT05576077|EXPERIMENTAL|Colorectal carcinoma|Patients with advanced, metastatic colorectal adenocarcinoma who have failed or are intolerant to at least one line of therapy that included either irinotecan or oxaliplatin.
62541945|NCT05576077|EXPERIMENTAL|Uveal Melanoma|Patients with advanced, metastatic uveal melanoma.
62715465|NCT05268757|EXPERIMENTAL|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
62715466|NCT05268757|PLACEBO_COMPARATOR|Placebo|In this group participants will receiveplacebo twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
62715467|NCT05425017||Low back pain group|Participants currently experiencing low back pain will have small accelerometers taped along spine, Ultrasound (US) Clinician will place an US transducer at the right L4/L5 Z joint. Participants will complete a range of motions while accelerometers are recording back sounds. Subsequently, they will receive a chiropractic adjustment, then repeat the range of motions
62737155|NCT05276336|EXPERIMENTAL|Intervention Group|Subjects will receive radiofrequency turbinate reduction done in the outpatient clinic, followed by pharmacology treatment (intranasal steroid and AH-1) for 8 weeks.
62541946|NCT05576077|EXPERIMENTAL|Cutaneous Melanoma|Patients with cutaneous melanoma who have experienced disease progression following a PD-1 or PD-L1 inhibitor.
62541947|NCT05576077|EXPERIMENTAL|Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer who have experienced disease progression following platinum containing chemotherapy and/or PD-1 or PD-L1 inhibitor.
62541948|NCT05576077|EXPERIMENTAL|Head and Neck Squamous Cell Carcinoma|"* Patients with head and neck squamous cell carcinoma who have received no prior therapy for metastatic disease~* Patients with head and neck squamous cell carcinoma who are PD-1/PD-L1 inhibitor naïve at the time of TIL harvest and will be treated with TBio-4101 at the time of progression, inadequate response or intolerance to the PD-1/PD-L1 inhibitor-based standard of care regimen given on study."
62541949|NCT05331807|EXPERIMENTAL|Group (A)|Participants will be received daily omega-3 fatty acid (two capsules of 1000mg fish oil daily). Each soft gel capsule contains 300 mg of omega-3 fatty acids in the bioactive triglyceride (TG) and 180mg EPA and 120 mg DHA. (Omega3 complex, Jamieson Laboratories, Canada)
62541950|NCT05331807|EXPERIMENTAL|Group (B)|Participants will be received only vitamin D (one capsule of 50,000IU weekly). Each film coated tablet of vitamin D contains 50,000 IU Vitamin D3 (Cholecalciferol). (J-Dee, Jerusalem Pharmaceutical Company, West bank, Palestine).
62541951|NCT05331807|EXPERIMENTAL|Group (C)|Participants will be received both omega-3 fatty acids capsules and vitamin D3 capsule. (one capsule of D3 50,000 IU weekly + two omega-3 fatty acids capsules daily (each capsule contains 300 mg of omega-3 fatty acids)
62541952|NCT05331807|NO_INTERVENTION|Group (D)|Participants will not be received any supplements and just receive oncology treatment as an usual oncology patient.
62541953|NCT06498167||Upadatacinib Arm|Patients exposed to upadacitinib (Rinvoq™)
62541954|NCT05456230||Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
62541955|NCT05456230||Non-Midazolam|Midazolam was not given during the operation.
62541956|NCT01447277|EXPERIMENTAL|Femoral and Sciatic Block|Administration of preoperative femoral and sciatic nerve blocks
62541957|NCT01447277|OTHER|Femoral Block Only|Administration of a femoral nerve block prior to surgery
62541958|NCT06632535|EXPERIMENTAL|Combined chiropractic care and group medical visits|Participants will attend 8 weekly chiropractic visits (40-minutes for initial visit, 20-minutes for remaining 7). Participants will simultaneously enroll in 8 weekly 90-minute virtual group medical visits.
62541959|NCT06218576||acute cerebral and/or cerebellar CMI|Patients with acute cerebral and/or cerebellar CMI
62541960|NCT06427707|ACTIVE_COMPARATOR|Group PLM (propofol-lidocaine-magnesium)|intravenous infusion of propofol, lidocaine and magnesium sulfate.
62541961|NCT06427707|ACTIVE_COMPARATOR|Group KLM (ketamine-lidocaine-magnesium)|intravenous infusion of Ketamine, lidocaine and magnesium sulfate
62541962|NCT06427707|ACTIVE_COMPARATOR|Group DLM (Dexmeditomidine-lidocaine-magnesium)|Intravenous infusion of Dexmeditomidine, lidocaine and magnesium sulfate
62541963|NCT04333030||Psychiatry|patients who come for psychiatric consultation
62541964|NCT04333030||addictology (other than tabacco)|patients who come for addictology consultation
62541965|NCT04333030||endocrinology|patients who come for endocrinology consultation
62541966|NCT06522217|ACTIVE_COMPARATOR|Conventional Group A|10 neonates receiving conventional nasoalveolar molding appliances
62541967|NCT06522217|ACTIVE_COMPARATOR|Digital Group B|10 neonates receiving CAD- nasoalveolar molding appliances
62541968|NCT04258319|EXPERIMENTAL|Affected (Lymphedema)|Subjects affected lymphedema extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
62541969|NCT04258319|ACTIVE_COMPARATOR|Unaffected (Control)|Subjects unaffected extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
62541970|NCT02901548|EXPERIMENTAL|Durvalumab Plus Cystoscopy|Durvalumab: Fixed dose level IV infusion every 4 weeks for 13 study treatment cycles/infusions over 12 months/1 year. Cystoscopy with biopsy will be performed every 3 months to monitor the treatment response during this one year of treatment phase. It will be performed every 6 months during year 2 of the surveillance phase.
62541971|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
62541972|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
62541973|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
62541974|NCT04139759|EXPERIMENTAL|hand massage group|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
62541975|NCT04139759|EXPERIMENTAL|Foot massages group|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
62541976|NCT04139759|NO_INTERVENTION|control group|The patients in the control group (n = 28) were not administered except nursing interventions in the HD unit.
62541977|NCT04743492|EXPERIMENTAL|CBT group|cognitive behavioral therapy (CBT)+routine medical care
62541978|NCT04743492|EXPERIMENTAL|exercise therapy group|physiotherapy-exercise therapy+routine medical care
62541979|NCT04743492|EXPERIMENTAL|breathe training group|using biofeedback devices to train breathing speed+routine medical care
62541980|NCT04743492|NO_INTERVENTION|usual care|accepting only routine medical care
62715468|NCT05425017||Healthy group|Participants without low back pain will have small accelerometers taped along spine. Ultrasound (US) Clinician will place a US transducer at the right L4/L5 Z joint. Participants will perform a range of motions while accelerometers are recording back sounds. Subsequently, they will receive a chiropractic adjustment, then repeat the range of motions
62715469|NCT02576873||Hemodiafiltration|End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months
62715470|NCT05634408|EXPERIMENTAL|TEST Lens|Eligible subjects will bilaterally wear the TEST Lens for the duration of the study.
62715471|NCT04832347|EXPERIMENTAL|Exercise group|Exercise group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
62715472|NCT04832347|EXPERIMENTAL|Vagus group|Vagus therapy will be applied to Group 2 for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
62715473|NCT04832347|NO_INTERVENTION|Control group|Control group will be followed as a control group and no application will be made.
62715474|NCT05248490|EXPERIMENTAL|Patients with pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization.
62168020|NCT06038578|EXPERIMENTAL|Arm B: TRK-950(10 mg/kg)+Ramucirumab+Paclitaxel|Participants who will be randomized to receive a 10 mg/kg intravenous(IV) dose of TRK-950 on days 1, 8, 15 and 22 in combination with 8 mg/kg IV dose of ramucirumab on days 1 and 15 and 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
62168021|NCT06038578|ACTIVE_COMPARATOR|Arm C: Ramucirumab+Paclitaxel|Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
62541981|NCT04011163|EXPERIMENTAL|VPIA analgesia|VPIA pump will be connected to patients after surgery for up to three days. The vital signs (oxygen saturation, respiratory rate, heart rate) will be closely monitored when patients are using VPIA pump. Intravenous medication (morphine) will be given intravenously.
62541982|NCT01542151|ACTIVE_COMPARATOR|Morning|Women randomized to a labor induction in the morning between 0600 and 1000.
62541983|NCT01542151|EXPERIMENTAL|Evening|Women randomized to a labor induction begun in the evening between 1700-2100
62541984|NCT01349777|EXPERIMENTAL|Pregrel®|clopidogrel
62541985|NCT01349777|ACTIVE_COMPARATOR|Plavix®|clopidogrel
62541986|NCT01992718|ACTIVE_COMPARATOR|Evaluation of MRI, US for pelvic conditions|MRI and ultrasound imaging will be used clinically to evaluate pelvic pain and abnormal uterine bleeding. The goal is to determine which exams are most helpful to the clinician in providing an accurate diagnosis as well as evaluating patient preference.
62541987|NCT01992718|ACTIVE_COMPARATOR|Patient preference MRI vs. US|We are asking subjects to evaluate patient preference between MRI (magnetic resonance imaging) and ultrasound to determine which they would rather undergo.
62541988|NCT02352935|EXPERIMENTAL|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
62541989|NCT02352935|NO_INTERVENTION|Control|The patients without any treatment
62541990|NCT02764151|EXPERIMENTAL|PF-06840003|Daily Oral PF-06840003
62715475|NCT05248490|NO_INTERVENTION|Patients without pharmaceutical interview|Control group without interview
62715476|NCT01709357|EXPERIMENTAL|Muscle energy technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the muscle energy technique of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
62715477|NCT01709357|EXPERIMENTAL|Ischemic compression technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed ischemic compression technique on the latent trigger point.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
62541991|NCT01181557||rectal cancer with stoma|rectal cancer submitted to rectal anterior resection with stomia (RARS). Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month after stoma reconversion
62541992|NCT01181557||rectal cancer without stoma|rectal cancer submitted to rectal anterior resection (RAR) Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month later
62541993|NCT01181557||anterior resection of rectum|patients with rectal cancer submitted to RAR and patients with rectal cancer submitted to RARS
62541994|NCT00589927|EXPERIMENTAL|cilostazol|Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
62541995|NCT00589927|PLACEBO_COMPARATOR|placebo|Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
62541996|NCT06551376|PLACEBO_COMPARATOR|Early Follicular Phase ovarian stimulation|Twenty patients started controlled ovarian stimulation (COS) after spontaneous menses
62168022|NCT03344913|ACTIVE_COMPARATOR|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
62541997|NCT06551376|ACTIVE_COMPARATOR|Late Luteal Phase ovarian stimulation|Twenty patients started stimulation on the Friday previous to a spontaneous menses (at the end of late luteal phase), regardless of cycle day.
62541998|NCT03574350|EXPERIMENTAL|KS in Kangaroo Position (KSKP)|KS is performed while the infant is in Kangaroo Position using a lycra band to maintain the position.
62541999|NCT03574350|ACTIVE_COMPARATOR|KS in incubator (KSI)|The infant is in the incubator, unclothed with diaper.
62542000|NCT02895828|EXPERIMENTAL|Core Stabilization Exercise (CSE)|The participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
62542001|NCT02895828|EXPERIMENTAL|General Strengthening Exercise (GSE)|The participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks.
62715478|NCT01709357|EXPERIMENTAL|Passive stretching technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the passive stretching of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
62542002|NCT02399319|EXPERIMENTAL|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal fixator.
62542003|NCT02399319|EXPERIMENTAL|Randomized to Symphyseal Plate|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal plating of the symphysis.
62542004|NCT02399319|ACTIVE_COMPARATOR|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and the treating physician selected the internal fixator intervention based on their opinion of how best to treat the specific case.
62542005|NCT02399319|ACTIVE_COMPARATOR|Observational - Symphyseal Plate|Patient signed consent but did not want to randomize their procedure and the treating physician selected internal plating of the symphysis based on their opinion of how best to treat the specific case.
62542006|NCT02862561|EXPERIMENTAL|Precision Cell Immunotherapy|"Precision Cells combined with Chemotherapy treatment: Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. Precision Cells：once per 3 weeks with a total of three periods."
62542007|NCT02862561|ACTIVE_COMPARATOR|Chemotherapy|"Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood."
62542008|NCT00818987|OTHER|Operative|Treatment arm - intervention = Open Reduction Internal Fixation or Reduction \& Immobilization
62542009|NCT00818987|NO_INTERVENTION|Non Operative|Placebo arm
62542010|NCT01208987|EXPERIMENTAL|Intervention (with Medication History)|these patient visits generated a medication history
62542011|NCT01091324|ACTIVE_COMPARATOR|Dextromethorphan|
62542012|NCT01091324|ACTIVE_COMPARATOR|Silymarin|
62542013|NCT01091324|PLACEBO_COMPARATOR|sugar pill|
62542014|NCT03838497|ACTIVE_COMPARATOR|HIV-infected subjects with CD4 T-cell counts <350 cells/µL|Intervention to be administered: Prevenar13
62542015|NCT03838497|ACTIVE_COMPARATOR|HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL|Intervention to be administered: Prevenar13
62542016|NCT05468931|EXPERIMENTAL|Prostate stimulation device arm|Participants will be asked to use our prostate stimulation device.
62542017|NCT02865460|EXPERIMENTAL|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
62542018|NCT02865460|PLACEBO_COMPARATOR|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x 200 mg for 4 months) with food each morning-upon waking
62542019|NCT02564887|OTHER|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
62715479|NCT01709357|SHAM_COMPARATOR|Sham technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, for the sham technique, the therapist only contacted with his hands the head and the shoulder of the subject, without executing any movement, for 30 seconds.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
62715480|NCT01709357|NO_INTERVENTION|No intervention group|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next,the subject was lying for 30 seconds, without intervention.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
62715481|NCT06252376|EXPERIMENTAL|Supine cognitive testing first|Participants will undergo a computerized cognitive battery in the supine position, followed by a similar battery with alternate test versions in the upright position while on a head-up tilt table.
62715482|NCT06252376|EXPERIMENTAL|Upright cognitive testing first|Participants will undergo a computerized cognitive battery in the upright position, followed by a similar battery with alternate test versions in the supine position while on a head-up tilt table.
62715483|NCT00748631|EXPERIMENTAL|1|balloon Kyphoplasty
62715484|NCT06629454|EXPERIMENTAL|Single arm proof of concept study of a digital incentive spirometer|This single-arm proof-of-concept research study aims to assess the effect of a digital incentive spirometer (IS) device and a companion mobile-based app on incentive spirometry adherence in patients post-surgery. The digital IS utilizes a sensor to measure inspiratory breaths, and these data are transmitted wirelessly to a secure cloud database. The spirometer and app include a patient reminder system, exercise gamification strategies, progress tracking, and additional features designed to promote patient IS use.
62542020|NCT02564887|EXPERIMENTAL|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
62542021|NCT03940131|EXPERIMENTAL|Single Arm|Panitumumab with FOLFOX6/FOLFIRI
62542022|NCT01027195|PLACEBO_COMPARATOR|Standard Bovie Electrocautery|Standard Bovie electrocautery \[Valleylab, Boulder, Colorado\] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.
62542023|NCT01027195|EXPERIMENTAL|Bipolar Radiofrequency|Aquamantys 6.0 bipolar sealer \[Salient Surgical Technologies, Portsmouth, New Hampshire\] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (\<100 degrees Celsius) than standard Bovie electrocautery.
62542024|NCT02520297|EXPERIMENTAL|TRV130|Drug: TRV130
62542025|NCT03668392|EXPERIMENTAL|Patients on Oncospar|
62542026|NCT04272749|EXPERIMENTAL|Dairy and non-dairy milks|Questionnaires and consumption behaviors of dairy and non-dairy milks
62542027|NCT00548470|EXPERIMENTAL|varenicline|open label varenicline 2mg/day
62542028|NCT05976126||High environmental pollution group (HIGH)|subjects living in area characterized by high environmental pollution, as defined by Pizzolante et al. \[Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).\]
62542029|NCT05976126||Medium environmental pollution group (MEDIUM)|subjects living in area characterized by medium environmental pollution, as defined by Pizzolante et al. \[Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).\]
62542030|NCT05976126||Low environmental pollution group (LOW)|subjects living in area characterized by low environmental pollution, as defined by Pizzolante et al. \[Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).\]
62542031|NCT02931929|OTHER|68Ga-NeoBOMB1|68Ga-NeoBOMB1, 2-vial kit for radiolabelling. I.v. Administration after radiolabelling
62542032|NCT02376816|EXPERIMENTAL|Cohort 1: Low Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 3E11 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
62542033|NCT02376816|EXPERIMENTAL|Cohort 2: High Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 1E12 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
62542034|NCT02455518|ACTIVE_COMPARATOR|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
62542035|NCT02455518|ACTIVE_COMPARATOR|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen (5 mg/300 mg)
62542036|NCT02455518|ACTIVE_COMPARATOR|Codeine/acetaminophen|Codeine/acetaminophen (30 mg/300 mg)
62542037|NCT02455518|ACTIVE_COMPARATOR|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/1000 mg)
62542038|NCT05405582|EXPERIMENTAL|community-based differentiated biosocial HIV prevention (incl. PrEP) with SRH|The intervention is available to all 15-30 year olds residing in the intervention cluster. Area based peer navigators mobilise all young people living in their cluster. They provide sexual health promotion, condoms, HIV self-tests, pregnancy test, and conduct structured psychosocial and health needs assessment with the young people they support. Based on the needs assessment they develop a tailored plan which includes, varying degrees of peer-mentorship and psychosocial support, lay-counselling and ART/PrEP adherence support. The peer navigators refer young people to mobile SRH services. The mobile SRH services provide gender and HIV status neutral nurse-led HIV testing, Individualised risk assessments for HIV care and PrEP, contraception and wider SRH services. The nurses liaise with the peer navigators to provide ongoing support for 3-monthly follow-ups with repeat HIV testing, adherence support and PrEP/ART/contraception refills.
62542039|NCT05405582|ACTIVE_COMPARATOR|Standard of Care|SOC is available to all young people in the delayed clusters. Care is provided in a nurse led Primary Health Clinics (PHC) to young people who attend the clinic. This includes HIV counselling and point of care testing, immediate initiation of ART if positive and PrEP if negative and eligible according to South African National PrEP guidelines. This is followed by a 3-monthly follow-up with repeat HIV testing, safety bloods, clinic-based counselling and adherence support and PrEP/ART refills. Clinic attendees are offered family planning support and syndromic management for STIs (as per South African National Department of Health Guideline).
62542040|NCT06234943|OTHER|Participants requesting test(s) and treatment assessment for CT and NG infection|Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) self-swab(s) and urine collection for asymptomatic testing by a pharmacist. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and prescription(s) will be issued for treatment as appropriate.
62542041|NCT06448806|OTHER|Lifestyle modification through m-health|Individuals recruited will be followed for a year and offered lifestyle intervention
62542042|NCT05916274|OTHER|Patients with samples|"Blood and fecal samples, and colonic biopsies will be analysed and compared between 3 groups of participants :1/ Active IBD; 2/Inactive IBD; 3/Controls non-IBD."
62542043|NCT02127385||IUGR|
62542044|NCT04917471|ACTIVE_COMPARATOR|Nitrate-rich beet root juice|Nitrate-rich Beet root juice 70 ml bid
62542045|NCT04917471|PLACEBO_COMPARATOR|Placebo|Nitrate-depleted beet root juice 70 ml bid
62715485|NCT02979574|ACTIVE_COMPARATOR|Electro-Acupuncture (EA) Procedure|Participants will receive 10 treatment of EA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
62715486|NCT02979574|ACTIVE_COMPARATOR|Battle Field Acupuncture (BFA) Procedure|Participants will receive 10 treatment of BFA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
62737156|NCT05276336|ACTIVE_COMPARATOR|Control Group|Subjects in the control group will receive only the pharmacology treatment for 8 weeks.
62542046|NCT06525103|EXPERIMENTAL|Group (A): Fifteen patients will receive whole body vibration|
62542047|NCT06525103|EXPERIMENTAL|Group (B): Fifteen patients will receive pulsed electromagnetic field (PEMF)|
62542048|NCT01823601|ACTIVE_COMPARATOR|Seminars in Health|This group of volunteers will attend to seminars in health. Each seminar will last about 120 minutes, a similar period of time used for training experimental group.
62542049|NCT01823601|EXPERIMENTAL|Behavioral Management Program|"Behavioral Management Program consists in to teach to the volunteers procedures which involve autogenic muscle relaxation, progressive self-focus meditation and cognitive-behavioral training to change thoughts, beliefs and behavior in order to control emotions. This program will consist in 10 weekly sessions of about 120 minutes each."
62542050|NCT06625892|EXPERIMENTAL|the interventions group|The experimental group undergoes a 12-week multidimensional interventions.
62542051|NCT06625892|NO_INTERVENTION|the control group|the control group receives no intervention.
62715487|NCT02979574|ACTIVE_COMPARATOR|Wait List Control (WLC) Usual Care Procedure|Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
62715488|NCT06716775|EXPERIMENTAL|TTF+Best Standard of Care|
62715489|NCT06716775|ACTIVE_COMPARATOR|Best Standard of Care|
62715490|NCT06311682|EXPERIMENTAL|Tralokinumab + TCS for subjects aged 2 to <12 years|Dose and dosing frequency for each subject will depend on the subject's body weight.
62715491|NCT06311682|EXPERIMENTAL|Placebo + TCS for subjects aged 2 to <12 years|Dose and dosing frequency for each subject will depend on the subject's body weight.
62715492|NCT06311682|EXPERIMENTAL|Tralokinumab + TCS for subjects aged 6 months to <2 years|Dose and dosing frequency for each subject will depend on the subject's body weight.
62715493|NCT00776789|EXPERIMENTAL|skin to skin contact|Infants randomized to this group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. Mothers in both the groups received support for initiating breastfeeding, if required. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
62715494|NCT00776789|EXPERIMENTAL|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
62715495|NCT06716567|ACTIVE_COMPARATOR|Pregnant women|Pregnant women receive one dose of influenza-containing vaccine during pregnancy.
62715496|NCT06716567|ACTIVE_COMPARATOR|Non-pregnant women|Non-pregnant women receive one dose of influenza-containing vaccine.
62715497|NCT03170375|EXPERIMENTAL|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
62715498|NCT03170375|ACTIVE_COMPARATOR|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
62715499|NCT03170375|EXPERIMENTAL|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
62715500|NCT03170375|PLACEBO_COMPARATOR|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
62715501|NCT04042805|EXPERIMENTAL|Sintilimab Plus Lenvatinib|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day (QD) plus sintilimab 200 mg intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
62715502|NCT02772029|EXPERIMENTAL|Apatinib Mesylate Tablets|Apatinib (Apatinib Mesylate Tablets) 750 mg is administered orally daily, until disease progression or intolerable toxicity.
62715503|NCT02670902|EXPERIMENTAL|Critical Time Intervention-Residential|CTI-R is a 9-month, assertive outreach and linkage program.
62715504|NCT02670902|ACTIVE_COMPARATOR|Enhanced Usual Discharge-Residential|The enhanced usual discharge condition includes usual discharge services plus enhanced transition services.
62715505|NCT06098690|EXPERIMENTAL|Treatment|A tailored HPV psychoeducational multimedia intervention
62715506|NCT06098690|ACTIVE_COMPARATOR|Active Control|General/standard multimedia materials on HPV and HPV vaccine
62715507|NCT06162624|EXPERIMENTAL|ACT workbook|
62715508|NCT06162624|ACTIVE_COMPARATOR|Control workbook|
62715509|NCT06719141|EXPERIMENTAL|LP352|Participants will be titrated up to highest tolerated dose of LP352 during the Titration period (Visit 2 - Visit 5), followed by maintenance period (Visit 5 - Visit 8) and then taper/down titration period.
62715510|NCT06719141|PLACEBO_COMPARATOR|Placebo|Placebo for LP352
62715511|NCT01701388|EXPERIMENTAL|Ekso Safety and Efficacy|Observational study on the first time use of a robotic exoskeleton.
62715512|NCT06479239|EXPERIMENTAL|EGFR Fresh Peripheral Blood Mononuclear Cells|Participants will undergo apheresis to collect cells to make EGFR fresh peripheral blood mononuclear cells (FPBMC). These cells will be activated in the lab to fight against pancreas cancer. About 3-4 days after apheresis, participants will start receiving infusions of EGFR FPBMC. Throughout treatment, participants will have blood taken for labs, to check disease status and also to look at immune response. Study treatment will stop if the participant has disease progression. Participants that have disease progression after the first 8 infusions may receive chemotherapy and then continue study treatment with the other 8 infusions.
62715513|NCT02169011|ACTIVE_COMPARATOR|Latissimus Dorsi Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the Latissimus Dorsi flap and if needed an implant.
62715514|NCT02169011|ACTIVE_COMPARATOR|TAP Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the TAP-flap and if needed an implant in combination with an acellular dermal matrix.
62715515|NCT06717100|EXPERIMENTAL|DDI Cohort|All participants will receive the same interventions at the same schedule
62715516|NCT06689553|EXPERIMENTAL|Intraperitoneal implanted device|Implantation and activation of an automated continual water removal system
62737157|NCT02761681|EXPERIMENTAL|ACT-CL Web-based guided self-help|Behavioral: Experimental Web-based guided self-help Program This intervention will involve counselor training and student use of the developed program. Counselors will complete training and invite students to participate, and will monitor and guide students in completing the series of 8 web-based sessions based on Acceptance and Commitment Therapy.
62168023|NCT03344913|ACTIVE_COMPARATOR|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
62715517|NCT05753215|EXPERIMENTAL|omadacycline|Omadacycline will be administered 300 mg orally daily without the loading dose. We chose to omit the loading dose given that many of the enrolled subjects would have received an IV therapy prior to omadacycline initiation and notable gastrointestinal intolerabilities (nausea/vomiting) based on Phase-3 trial data. Subjects receiving omadacycline will be counseled on appropriate timing of administration (fast for 4 hours before dosing and no food for 2 hours after dosing) in light of the known food effects on drug absorption. They will be instructed to avoid use of products containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations such as dairy, antacids, and multivitamins for 4 hours post-dosing.
62715518|NCT05753215|OTHER|standard of care antibiotic|Standard of care as determined by primary care team
62715519|NCT00030147|EXPERIMENTAL|Raloxifene|Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks
62715520|NCT00030147|EXPERIMENTAL|Rimostil|Rimostil (phytoestrogen) 1000 mg twice a day and placebo skin patch for eight weeks
62715521|NCT00030147|ACTIVE_COMPARATOR|Transdermal estradiol|17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks
62715522|NCT00030147|PLACEBO_COMPARATOR|Placebo|Placebo skin patch and placebo tablets for eight weeks.
62542052|NCT02264860|OTHER|Nutritional Supplements Zinc and SAMe|All men subjects will be started on 30 mg/day and women will be started on 25mg of elemental zinc plus 1600 mg/day of SAMe.
62542053|NCT04785755|ACTIVE_COMPARATOR|Group I|The control group (n=15) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
62542054|NCT04785755|EXPERIMENTAL|Group II|The hypertonic saline solution (HSS) group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the start of the study to the end of the study) with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
62542055|NCT04785755|EXPERIMENTAL|Group III|The etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
62542056|NCT04785755|EXPERIMENTAL|Group IV|The hypertonic saline solution (HSS) + Etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg100mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days, and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
62542057|NCT02781038|EXPERIMENTAL|Interventional|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given a teaching intervention and receive another attitude survey.
62542058|NCT02781038|OTHER|Control|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will receive another attitude survey.
62542059|NCT00748384||1|Self trained subjects
62542060|NCT00748384||2|supervised trained subjects
62542061|NCT04283604|EXPERIMENTAL|ADHD with MPH|ADHD participants, taking MPH before the second session
62542062|NCT04283604|NO_INTERVENTION|ADHD no MPH|ADHD participants will perform motor tests in both session, without any intervention, for evaluation of learning effect among ADHD participants.
62542063|NCT04283604|NO_INTERVENTION|Healthy participants|Non-ADHD participants will serve as a control group for learning effect on motor tests
62542064|NCT03502434|EXPERIMENTAL|90 mg/mL SM04755 in water|90 mg/mL SM04755 in water applied via patches
62542065|NCT03502434|EXPERIMENTAL|90 mg/mL SM04755 in aqueous Vehicle|90 mg/mL SM04755 in aqueous Vehicle applied via patches
62542066|NCT03502434|EXPERIMENTAL|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches
62542067|NCT03502434|OTHER|Vehicle|Aqueous Vehicle applied via patches
62542068|NCT03502434|OTHER|White petrolatum|White petrolatum (Negative control) applied via patches
62542069|NCT03502434|OTHER|Sodium lauryl sulfate|Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches
62542070|NCT05954286|EXPERIMENTAL|Early Treatment: Upamostat 400 mg|400 mg (2 x 200 mg) capsules administered orally once daily for 14 days
62542071|NCT05954286|PLACEBO_COMPARATOR|Early Treatment: Placebo Oral Capsule|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way.
62542072|NCT06456853||Visual Analog Scale Score|The Visual Analog Scale (VAS) pain score is a simple and effective method used to measure patients' pain levels. This method is typically represented by a line ranging from 0 to 10, where 0 indicates no pain and 10 indicates the most severe pain. Patients are asked to mark a point on the line that corresponds to their level of pain.
62715523|NCT06578247|EXPERIMENTAL|Arm A: Quizartinib + Chemotherapy|Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive quizartinib at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)
62715524|NCT06578247|PLACEBO_COMPARATOR|Arm B: Placebo + Chemotherapy|Participants will receive placebo at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)
62542073|NCT06456853||Images maded by Artificial Intelligence|Pain assesment maded by images which is created from ChatGPT/DALLE
62542074|NCT00237393|EXPERIMENTAL|1|Quetiapine
62542075|NCT00237393|PLACEBO_COMPARATOR|2|
62715525|NCT06578247|EXPERIMENTAL|Arm C: Quizartinib + Chemotherapy then Placebo Maintenance|Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)
62715526|NCT05286710|EXPERIMENTAL|modified access group|modified access: PMT was performed via distal calf venous access or contralateral femoral access
62715527|NCT05286710|ACTIVE_COMPARATOR|traditional access group|traditional access: PMT was performed via ipsilateral popliteal venous access
62715528|NCT00577200|NO_INTERVENTION|Control|Control group subjects are not undergoing any surgical procedures and will not be randomized to any anesthetic drug group.
62715529|NCT00577200|EXPERIMENTAL|Midazolam + Sufentanil + Propofol|"Midazolam 0.03 mg/kg + Sufentanil 0.1 µg/kg + Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.~For subjects who are chronic pain patients undergoing minor surgical procedures."
62715530|NCT00577200|EXPERIMENTAL|Midazolam and Sufenatnil|"Midazolam 1-5 mg in holding area + Sufentanil 5-10 mcg.~For subjects who are chronic pain patients undergoing minor surgical procedures."
62715531|NCT03388372|EXPERIMENTAL|Nimotuzumab plus RT and temozolomide.|Nimotuzumab, administered once a week intravenously in addition to radiotherapy with concomitant and adjuvant temozolomide (TMZ) after surgery.
62715532|NCT05178186|OTHER|Thyroid carcinoma|Patients with thyroid carcinoma submitted to thyroidectomy
62715533|NCT06587386|EXPERIMENTAL|the dose of bupivacaine liposome|First patient's use of bupivacaine liposome and next patient's use of bupivacaine liposome
62715534|NCT04767711|ACTIVE_COMPARATOR|L. reuteri|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 30 days, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day. Oral glucocorticoid 25 mg daily for 7 days.
62715535|NCT04767711|PLACEBO_COMPARATOR|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 30 days.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day. Oral glucocorticoid 25 mg daily for 7 days.
62715536|NCT05149820|ACTIVE_COMPARATOR|Nudge Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
62715537|NCT05149820|ACTIVE_COMPARATOR|Nudge Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
62715538|NCT05149820|ACTIVE_COMPARATOR|Preference Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
62715539|NCT05149820|ACTIVE_COMPARATOR|Preference Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
62715540|NCT01952938||LINK SL|Patients
62715541|NCT01952938||EnduRo|Patients
62715542|NCT05212428|EXPERIMENTAL|Screening (biospecimen collection, genetic analysis)|Participants receive a saliva kit, register with Helix then undergo collection of saliva sample which is returned o Helix. Participants also receive an online link to complete the About Me family history. Once sequencing is completed by Helix, ancestry/trait information and genetic findings are shared with participants and their primary provider, if applicable. Participants with positive results are offered genetic counseling and are encouraged to seek clinical confirmatory testing. Following clinical confirmation, results are scanned into the electronic health record. Participants may also undergo the collection of blood, urine, and stool samples for future studies.
62715543|NCT05991427|EXPERIMENTAL|Experimental vaccine group, low dose, Intramuscular injection(IM)|2 doses of ChAdOX1-VZV vaccine (1 × 10\^10 vp) on Day 0 and Month 4
62715544|NCT05991427|ACTIVE_COMPARATOR|Control vaccine group, low dose, IM|2 doses of Shingrix vaccine (0.5ml) on Day 0 and Month 4
62715545|NCT05991427|EXPERIMENTAL|Experimental vaccine group, high dose, IM|2 doses of ChAdOX1-VZV vaccine (5 × 10\^10 vp) on Day 0 and Month 4
62715546|NCT05991427|ACTIVE_COMPARATOR|Control vaccine group, high dose, IM|2 doses of Shingrix vaccine (0.5ml) on Day 0 and Month 4
62715547|NCT05991427|EXPERIMENTAL|Experimental vaccine group, Aerosol, Inhalation(IH)|2 doses of ChAdOX1-VZV vaccine (2 × 10\^10 vp) on Day 0 and Month 4
62715548|NCT05991427|PLACEBO_COMPARATOR|Saline group, Aerosol, IH|2 doses of saline (0.2ml) on Day 0 and Month 4
62715549|NCT03824951|EXPERIMENTAL|Anti-CD19 iCAR NK Cells|
62715550|NCT04372875|EXPERIMENTAL|SHS-derived CDS|All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.
62715551|NCT04372875|NO_INTERVENTION|Usual care|All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.
62715552|NCT05237583|EXPERIMENTAL|Prehabilitation|Multimodal prehabilitation program
62715553|NCT04167527|EXPERIMENTAL|Immediate mechanical thrombectomy(iMT)|Treatment initiation within 8 hours of symptom onset. Arterial puncture and revascularization will be performed using EmboTrap II Retriever. The procedure will be completed within two hours of arterial access.
62715554|NCT04167527|ACTIVE_COMPARATOR|Initial medical management (iMM)|Standard medical therapy based on current AHA (American Heart Association) guidelines. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.
62715555|NCT02003222|EXPERIMENTAL|Arm I (blinatumomab, chemotherapy)|See Detailed Description
62715556|NCT02003222|ACTIVE_COMPARATOR|Arm II (chemotherapy)|See Detailed Description
62715557|NCT06480201|ACTIVE_COMPARATOR|Healthy Controls|Healthy controls will receive one saline and ketamine infusion.
62715558|NCT06480201|ACTIVE_COMPARATOR|Major Depressive Disorder|Major Depressive Disorder participants will receive one saline and ketamine infusion.
62715559|NCT06480201|ACTIVE_COMPARATOR|Treatment Resistant Depression|Treatment Resistant Depression participants will receive 8 ketamine infusions where their first and fourth infusions are a saline and ketamine infusion.
62715560|NCT00994864|OTHER|adjuvant FOLFOX (1 pre-operative cycle)|One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
62715561|NCT06716112|EXPERIMENTAL|Active VNS first, then Sham VNS|"Patients will undergo two 6-week intervention blocks, receiving active VNS first and sham VNS second.~Blocks consist of three 90-minute sessions per week with a licensed occupational therapist (OT). During these sessions, patients will perform rehabilitation training activities paired with active VNS during the first block and paired with sham VNS during the second block."
62715562|NCT06716112|EXPERIMENTAL|Sham VNS first, then Active VNS|"Patients will undergo two 6-week intervention blocks, receiving sham VNS first and active VNS second.~Blocks consist of three 90-minute sessions per week with a licensed occupational therapist (OT). During these sessions, patients will perform rehabilitation training activities paired with sham VNS during the first block and paired with active VNS during the second block."
62715563|NCT06141512|EXPERIMENTAL|Reduced-exertion high-intensity interval training (REHIT)|"All participants complete 6 weeks (3 sessions/week) of an exercise intervention labelled 'REHIT'.~Exercise sessions involve 10 minutes of unloaded cycling interspersed with 2 x 20 sec 'all-out' sprints against a resistance of 7.5% of participant's body weight. Sprints begin at 1:40 min and 5:40 min."
62715564|NCT00594789|EXPERIMENTAL|1 (physician-only)|Physician(s) connected with a fracture that meets study inclusion criteria.
62715565|NCT00594789|EXPERIMENTAL|2 (physician/patient)|Physician(s) and patient connected with a fracture that meets study inclusion criteria.
62715566|NCT00594789|NO_INTERVENTION|Control|Usual care.
62715567|NCT05720455|EXPERIMENTAL|Fexofenadine HCL + pseudoephedrine HCL|Participants will take a tablet containing fexofenadine 60 mg and pseudoephedrine 120 mg twice daily for 10 days (+/- 3 days based on investigator's clinical judgement)
62715568|NCT01823289|EXPERIMENTAL|Itraconazole Sequential Therapy|
62715569|NCT01841996|EXPERIMENTAL|ME1111 solution|
62715570|NCT01841996|PLACEBO_COMPARATOR|Vehicle Solution|
62715571|NCT05290766|ACTIVE_COMPARATOR|Control group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on 4 implants that were placed according to the All on four concept."
62715572|NCT05290766|ACTIVE_COMPARATOR|Study group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on two implants placed according to All On two concept."
62715573|NCT05227170|EXPERIMENTAL|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (2 capsules) once daily for 8 weeks.
62715574|NCT05227170|PLACEBO_COMPARATOR|Heat-killed placebo control|Subjects will consume potato starch (2 capsules) once daily for 8 weeks.
62715575|NCT05114746|EXPERIMENTAL|177Lu-PSMA-617|PSMA positivity will be confirmed by PET/CT scan after administration of 68Ga-PSMA-11. All eligible participants will receive recommended dose of 177Lu-PSMA-617 via intravenous injection every 6 weeks (+/- 1 week) for a maximum of 6 cycles.
62715576|NCT06717789|EXPERIMENTAL|High Frequency TENS|"Based on the diagnosis and the type of pain , subjects will be assigned to the High Frequency TENS (gate control principle at 50-150 Hz) treatmet group, which includes the following preset programs:~* Pain management TENS~* Epicondylitis~* Tendinitis."
62715577|NCT06717789|EXPERIMENTAL|Low frequency TENS|"Based on the diagnosis and the type of pain , subjects will be assigned to the Low Frequency TENS (endorphinic TENS at 5 Hz) treatmet group, which includes the following preset programs:~* Muscle pain~* Neck pain~* Back pain"
62715578|NCT05910047|EXPERIMENTAL|Supplement|One tablet of supplement before breakfast and dinner
62715579|NCT05910047|PLACEBO_COMPARATOR|Placebo|One tablet of inert compound before breakfast and dinner
62542076|NCT02836314|EXPERIMENTAL|PRF and ABBM|Intervention: Anorganic Bovine Bone Mineral and Platelet Rich fibrin is applied to the periodontal intrabony defects
62542077|NCT02836314|ACTIVE_COMPARATOR|Anorganic Bovine Bone Mineral|Intervention: Anorganic Bovine Bone Mineral is applied to the periodontal intrabony defects
62542078|NCT05171608|EXPERIMENTAL|Ultrasound-based protocol group (USP)|Preoperative intravenous (IV) fluid therapy is order according to the result of the preoperative ultrasound scans of the inferior vena cava and the lungs (2 hours and 30 minutes before surgery)
62542079|NCT05171608|NO_INTERVENTION|Conventional fluid therapy|Preoperative IV fluid therapy (isotonic, balanced crystalloid infusion, if any) is determined by the discretion of the attending anesthesiologist.
62715580|NCT06717373|OTHER|Single Arm|There is no investigational device being used. Devices to be used are Vscan Air and Venue Ultrasound systems
62715581|NCT06098326|EXPERIMENTAL|CyFluATG|Patients who receive with cyclophosphamide, fludarabine, and antithymocyte globulin (CyFluATG) for allogeneic hematopoietic cell transplantation
62715582|NCT02268383|EXPERIMENTAL|Luspatercept Extension population|Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
62715583|NCT05733689|EXPERIMENTAL|Neoadjuvant chemotherapy with ctDNA testing|"The patients will be treated with one of the standard neoadjuvant protocols (FLOT or FOLFOX.) If no decline in ctDNA detected after 4 cycles, treatment will be switched to a different chemotherapy backbone (e.g. irinotecan based regimen, or taxane based if not used upfront).~ctDNA will be re-evaluated after 3 cycles (if a 21 day regimen) or 4 cycles (if a 14 day regimen) of the 2nd line regimen. If ctDNA is lower than the previous measurement, then the same regimen continues for 3-4 more cycles (depending on 14 day or 21 day cycle), followed by gastrectomy. Adjuvant treatment is given based on the investigator's discretion."
62715584|NCT01286597|EXPERIMENTAL|dietary|
62737158|NCT02761681|ACTIVE_COMPARATOR|Control Web-based guided self-help|Behavioral: Control Web-based guided self-help program This intervention will be created for the current study. It will involve psycho-education on how students might get the most out of counseling. Counselors will go through the psycho-education session before inviting students to participate.
62164824|NCT00248794|EXPERIMENTAL|Skills Group Control|The control intervention is call the skills development group (SDG) and is augmented with up to five individual contacts with research staff. The Skills Group (SDG) control is standard care group which will receive 15 weeks of the skills development group (SDG) similar to that offered as a clinical service at the VA Medical Center. During the 15 weeks participants will attend 1.5 hours of skills group per week. The 15 sessions will include skills training related to: a) cooking and food preparation, b) negotiating the local transportation system, c) shopping, and d) planning leisure activities. The training activities are a blend of didactic learning, modeling and finally in vivo practice. Participants in this group will also be offered up to five weekly contacts with staff to balance out factors related to meeting with staff in the other conditions.
62164825|NCT04885478||Healthy health care workers|"≥ 18 years of age~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.~To be a health care professional worker infected or exposed to SARS-CoV-2~RT-PCR (SARS-CoV2), negative at baseline or follow up~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), negative positive at baseline or follow up"
62542080|NCT01858272|EXPERIMENTAL|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
62542081|NCT06093438|EXPERIMENTAL|Induction immunotherapy and chemotherapy|Patients enrolled in this arm would receive neoadjuvant immunotherapy and chemotherapy before definitive chemoradiation
62542082|NCT02421224|ACTIVE_COMPARATOR|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
62542083|NCT02421224|EXPERIMENTAL|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
62542084|NCT02421224|EXPERIMENTAL|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
62542085|NCT02421224|EXPERIMENTAL|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
62542086|NCT02421224|EXPERIMENTAL|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
62542087|NCT02421224|EXPERIMENTAL|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
62542088|NCT02421224|EXPERIMENTAL|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
62542089|NCT02421224|EXPERIMENTAL|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
62542090|NCT02421224|EXPERIMENTAL|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
62164826|NCT04885478||Infected health care workers|"≥ 18 years of age~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.~To be a health care professional worker infected or exposed to SARS-CoV-2~RT-PCR (SARS-CoV2), positive at baseline or follow up~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), positive at baseline or follow up"
62164827|NCT00515112|EXPERIMENTAL|A|Twenty subjects will receive testosterone gel
62164828|NCT00515112|PLACEBO_COMPARATOR|B|Twenty subjects will receive the placebo
62164829|NCT00095251|ACTIVE_COMPARATOR|Dexmedetomidine group|Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
62164830|NCT00095251|ACTIVE_COMPARATOR|Lorazepam group|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
62164831|NCT02632747|EXPERIMENTAL|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
62164832|NCT02632747|EXPERIMENTAL|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
62164833|NCT06020495|EXPERIMENTAL|DDAVP|"DDAVP 4µg/ml IV Additional doses may be administrated every 6h for a maximum of 48h~- Standard hyponatremia treatment : Presence of neurological symptoms : sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
62542091|NCT05263830||Patient with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
62542092|NCT02448368|EXPERIMENTAL|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
62542093|NCT02448368|EXPERIMENTAL|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
62542094|NCT02448368|EXPERIMENTAL|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
62542095|NCT02448368|EXPERIMENTAL|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
62542096|NCT02448368|EXPERIMENTAL|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
62542097|NCT02448368|EXPERIMENTAL|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
62542098|NCT02448368|EXPERIMENTAL|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
62542099|NCT02448368|EXPERIMENTAL|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
62542100|NCT02121873||Women with and without breast cancer|Nipple aspirator, ductal lavage microcatheter, blood draw
62542101|NCT01596738|EXPERIMENTAL|Tranexamic Acid group|"1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
62542102|NCT01596738|PLACEBO_COMPARATOR|Placebo group|"1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
62542103|NCT06304168||Observational|Patients undergo blood, urine, and/or residual tissue sample collection and have their medical records reviewed on study.
62542104|NCT00436865|OTHER|PCOS|PCOS women receiving weight loss intervention
62542105|NCT00436865|OTHER|Control|Non-PCOS women receiving weight loss intervention
62542106|NCT05555823|EXPERIMENTAL|Experimental: ATR-002|In the SAD part, study participants will receive IMP orally once (except for the first cohort), or twice (two single doses separated by an adequate washout period of at least 10 days for the FDI cohort, which will be conducted according to a two-period fixed-sequence design with all subjects receiving the treatment sequence 'fasted-fed'). In each of the periods of the MAD Part, study participants will receive the IMP for seven consecutive days. Dosing will start at 600 mg (SAD part) and 900 mg (MAD part) in the first cohort and follow the dose escalation schedule that is given in the study protocol.
62542107|NCT05555823|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|"In the SAD part, study participants will receive IMP orally once (except for the first cohort), or twice (two single doses separated by an adequate washout period of at least 10 days for the FDI cohort, which will be conducted according to a two-period fixed-sequence design with all subjects receiving the treatment sequence 'fasted-fed'). In each of the periods of the MAD Part, study participants will receive the IMP for seven consecutive days.~In the DDI period with repaglinide two doses of ATR-002 will be given, and in the DDI period with celecoxib, four doses of ATR-002 will be given."
62542108|NCT05795322||Tuning for Health|Community based group 'Tuning for Health' was set up to provide chronic condition self-management support to people. Trained, experienced therapist-led group used half an hour of sound healing in virtual session.
62542109|NCT05842044|EXPERIMENTAL|Group 1: NSAID|Participants in this group will be prescribed NSAIDs instead of the standard of care treatment. Participants will be in this group for approximately 21 days.
62542110|NCT05842044|ACTIVE_COMPARATOR|Group 2: No-NSAID|Participants in this group will follow standard of care treatment. Participants will be in this group for approximately 21 days.
62542111|NCT01956305|EXPERIMENTAL|Cohort A 10mg DS-7309|DS-7309 10 mg twice daily
62542112|NCT01956305|EXPERIMENTAL|Cohort B 20mg DS-7309|DS-7309 20 mg twice daily
62542113|NCT01956305|EXPERIMENTAL|Cohort C DS-7309 40 mg|DS-7309 40 mg twice daily
62542114|NCT01956305|EXPERIMENTAL|Cohort D DS-7309 75 mg|DS-7309 75 mg twice daily
62542115|NCT01956305|EXPERIMENTAL|Cohort E DS-7309 150 mg|DS-7309 150 mg twice daily
62164834|NCT06020495|ACTIVE_COMPARATOR|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms : sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
62542116|NCT01956305|EXPERIMENTAL|Cohort F DS-7309 150 mg with escalating metformin doses|DS-7309 150 mg twice daily with escalating metformin doses
62542117|NCT01956305|PLACEBO_COMPARATOR|Placebo|placebo to match DS-7309
62542118|NCT03482258|EXPERIMENTAL|Treatment Prebiotic|3 week daily dose of Vivinal-GOS (galacto-oligosaccharide)
62542119|NCT03482258|PLACEBO_COMPARATOR|Placebo|3 week daily dose of Maltodextrin
62542120|NCT00724828||1|
62542121|NCT00275574|EXPERIMENTAL|acupuncture|four acupuncture treatments over a period of two weeks
62542122|NCT03626688|EXPERIMENTAL|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
62542123|NCT03626688|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets (oral)
62542124|NCT04553016|EXPERIMENTAL|1: Vaccine|"At Week 0, volunteers receive 5.0 x 10\^10 virus particles (vp) of ChAdOx1.tHIVconsv1 (C1) administered intramuscularly (IM). The dose is divided in 2 and administered in the deltoid muscle of each arm.~At week 4,1.0 x 10\^8 Plaque forming units (PFU) of MVA.tHIVconsv3 (M3) administered IM and 0.9 x 10\^8 PFU of MVA.tHIVconsv4 (M4) are administered IM simultaneously, one into the deltoid muscle of each arm."
62715585|NCT04302116|EXPERIMENTAL|Combination therapy with vigabatrin and prednisolone|"Vigabatrin (tablet of 500 mg) dose based on weight divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment. Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks.~Prednisolone (tablet of 5 mg), 40 mg of prednisolone (10 mg oral 4 times a day) for 14 days. Prednisolone will be increased to 60 mg/day (20 mg oral 3 times a day) if seizures still occur at Day 7 or recur within Day 8 - 14. Then, prednisolone will be reduced every 5 day until completely off within 1 month. Total prednisolone duration is 1 month."
62164835|NCT05698888|EXPERIMENTAL|VP301 (Dose Escalation)|Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
62715586|NCT04302116|ACTIVE_COMPARATOR|Vigabatrin alone|"Vigabatrin (500 mg/tab) dose will be calculated on weight basis divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment.~Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks."
62542125|NCT04553016|PLACEBO_COMPARATOR|2. Placebo|Normal sterile saline (0.9% Sodium Chloride solution) administered IM as Placebo, the volume is matched to that of the vaccines and administered in the deltoid muscle of each arm at Week 0 and at week 4 .
62542126|NCT05134857|EXPERIMENTAL|ZON+ST|Zonisamide (ZON) plus standard treatment (ST)
62542127|NCT05134857|PLACEBO_COMPARATOR|PLO+ST|Placebo (PLO) plus standard treatment (ST)
62542128|NCT01015937|ACTIVE_COMPARATOR|Turmeric|"diabetic nephropathy patient~more than 300 mg/proteinuria"
62542129|NCT01015937|ACTIVE_COMPARATOR|ACE inhibitor + ATI blocker|"diabetic nephropathy~more than 300 mg/day proteinuria"
62542130|NCT04130750|ACTIVE_COMPARATOR|treatment of physician's choice|Patients in this arm will receive neoadjuvant chemotherapy according physician's choice.
62542131|NCT04130750|EXPERIMENTAL|treatment of drug screening|Patients in this arm will receive neoadjuvant chemotherapy according results of drug screening vitro.
62542132|NCT05198518|EXPERIMENTAL|Microcurrent TENS device|A handheld micro-current TENS emitter device, which applies a small current of electricity to the forehead and maxillary region
62542133|NCT05198518|SHAM_COMPARATOR|Sham device|The sham device appears identical to the active device while emitting no therapeutic microcurrent.
62542134|NCT06423092|EXPERIMENTAL|Music therapy songwriting + standard care|The music therapy songwriting is a method frequently employed in music therapy sessions. This method involves the collaborative creation of lyrics and/or music with the participants. The intervention will consist of nine sessions, each of which will last approximately 30 to 45 minutes. Three sessions will be conducted per week until a minimum of six and a maximum of nine sessions are achieved.
62542135|NCT06423092|NO_INTERVENTION|Standard care|Standard care is the usual care provided to parents of newborns hospitalized in a neonatal intensive care unit (NICU). This care includes providing information about the baby's health status and recommendations during contact with the baby. Additionally, when a health professional identifies symptoms of mental health disturbance in the parents, they are referred to a mental health professional for appropriate management.
62542136|NCT06200545|ACTIVE_COMPARATOR|Standard of care PrEP services|Standard of care (SOC) PrEP services include PrEP eligibility assessment, rapid HIV antibody testing prior to provision and/or refill of PrEP, and PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines. Specifically, SOC services do not generally include point of contact STI testing (with the exception of rapid syphilis and Hepatitis B antigen testing, if kits are available, at PrEP initiation) nor tracing for missed PrEP visits. Participants randomized to the SOC condition will receive these standard PrEP services.
62542137|NCT06200545|EXPERIMENTAL|Intervention package PrEP services|"The intervention package is integrated into PrEP visits and includes evaluation of barriers and facilitators to ongoing PrEP use, point of contact STI testing to inform counseling regarding ongoing PrEP care engagement, tracing for any missed PrEP visits, and offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period. Recognizing increasingly cyclical PrEP use patterns, navigators serve as a direct entry point to retain or re-engage participants in HIV prevention care."
62542138|NCT00711321||2|AFFITOPE AD02 with adjuvant
62542139|NCT00711321||1|AFFITOPE AD02 without adjuvant
62542140|NCT06463002||OSA treated|Patients with OSA treated with CPAP for at least six months
62542141|NCT06463002||OSA untreated|Patients with OSA not treated with CPAP
62542142|NCT06463002||non-OSA|Patients underwent a sleep study and were diagnosed not to have OSA
62542143|NCT04207463|EXPERIMENTAL|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
62542144|NCT05385549|EXPERIMENTAL|5 years of adjuvant imatinib treatment|
62542145|NCT06469632|ACTIVE_COMPARATOR|Experimental Group 1|There will be 12 individual sessions guided by a physiotherapist specialized in Women's Health. The approximate duration will be 45 minutes/session, 2 times a week for 6 weeks. The intervention will consist of a multimodal physiotherapy treatment based on therapeutic patient education, specific PFM exercises, and conservative and invasive treatment of the MPS. Pre- and post-intervention assessments will be carried out, and at 3 and 6 months after the intervention, by an examining physiotherapist who will be blinding for the intervention group.
62542146|NCT06469632|EXPERIMENTAL|Experimental Group 2|There will be 12 individual sessions guided by a physiotherapist specialized in Women's Health. The approximate duration will be 45 minutes/session, 2 times a week for 6 weeks. The intervention will consist of a multimodal physiotherapy treatment based on therapeutic patient education, specific PFM exercises, conservative and invasive treatment of the MPS and non-ablative radiofrequency. Pre- and post-intervention assessments will be carried out, and at 3 and 6 months after the intervention, by an examining physiotherapist who will be blinding for the intervention group.
62542147|NCT02667067|OTHER|Anterior cervical discectomy & fusion (ACDF)|
62542148|NCT02667067|EXPERIMENTAL|Simplify Disc|Simplify Disc
62542149|NCT06473012|EXPERIMENTAL|CBT Experimental Group|Group intervention based on Cognitive Behavioral Therapy, lifestyle intervention, and effective communication.
62542150|NCT06473012|ACTIVE_COMPARATOR|Active Control Group|The session focused on education about lifestyle and communication.
62542151|NCT06329427|ACTIVE_COMPARATOR|Intervention - Dragon Ambient eXperience (DAX)|Clinicians interacted with DAX Copilot
62542152|NCT06329427|NO_INTERVENTION|No Intervention - Control group|Clinicians with standard care
62542153|NCT04795596|EXPERIMENTAL|surgery + chemotherapy|surgical resection for recurrent platinum resistant ovarian cancer followed by second line chemotherapy as per the investigator's choice
62542154|NCT04795596|ACTIVE_COMPARATOR|chemotherapy alone|second line chemotherapy according to investigator's choice
62715587|NCT04027647|EXPERIMENTAL|Treatment|Daily administration of oral Dacomitinib
62715588|NCT06716138|EXPERIMENTAL|ANS03 monotherapy|
62715589|NCT06719310|EXPERIMENTAL|Participant group 1|Stage one: ACC017 (Dose 1) Stage two: ACC017 (Dose 1)+FTC/TAF (200mg/25mg) QD
62715590|NCT06719310|EXPERIMENTAL|Participant group 2|Stage one: ACC017 (Dose 2) Stage two: ACC017 (Dose 2)+FTC/TAF (200mg/25mg) QD
62715591|NCT06719310|EXPERIMENTAL|Participant group 3|Stage one: ACC017 (Dose 3) Stage two: ACC017 (Dose 3)+FTC/TAF (200mg/25mg) QD
62715592|NCT06719310|PLACEBO_COMPARATOR|Participant group 4|Stage one: Placebo
62715593|NCT05185947|EXPERIMENTAL|1/ IP Catheter Placement and Bidirectional Chemotherapy|IP and IV paclitaxel administration with oral nilotinib
62715594|NCT02989181|EXPERIMENTAL|Continues Positive Airway Pressure|Use of Continues Positive Airway Pressure (CPAP) mask every night under six months period.
62715595|NCT02989181|NO_INTERVENTION|Consultation of conservative measures|Study participants with DCM and OSA (no-CPAP), participants receive consultation of conservative measures such as avoiding alcohol before bedrest, sleeping on the side...
62715596|NCT05710952|OTHER|Braces|Patients will receive an orthodontic treatment with fixed braces for 12 to 24 months
62715597|NCT01566240|ACTIVE_COMPARATOR|Chemoradiation|Radiotherapy (external beam and brachytherapy) plus concurrent Cisplatin weekly for 5 weeks
62715598|NCT01566240|EXPERIMENTAL|Induction Chemotherapy + Chemoradiation|6 cycles of weekly Paclitaxel and Carboplatin followed by Chemoradiation as per Active Comparator
62715599|NCT05555446|EXPERIMENTAL|Bovine colostrum|Participant will receive 18g of bovine colostrum with apple sauce and 1g of gluten.
62715600|NCT05555446|PLACEBO_COMPARATOR|Placebo|Participant will receive 18g of placebo with apple sauce and 1g of gluten.
62715601|NCT06199232|EXPERIMENTAL|Treatment Arm|HAIC combined with targeted therapy and PD-1 inhibitor
62715602|NCT02114177|EXPERIMENTAL|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
62715603|NCT02114177|EXPERIMENTAL|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
62715604|NCT05348811|EXPERIMENTAL|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, Day 1, every 3 weeks (Q3W). The maximum of 6 times.~Sintilimab will be given on Day 1, 200 mg i.v. Q3W.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment."
62715605|NCT03759990|ACTIVE_COMPARATOR|insertion time|
62715606|NCT03759990|ACTIVE_COMPARATOR|intubation time|
62715607|NCT06718543|EXPERIMENTAL|SCRT followed by CapeOX regimen combined with AK112|"Patients will receive short-course radiotherapy (SCRT) followed by chemotherapy (CapeOX regimen) combined with AK112:~In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7-day interval, patients will receive 2 cycles of CapeOX chemotherapy combined with AK112 (every 3 weeks; Day 1: Oxaliplatin, 130 mg/m², IV infusion; Day 1: AK112, 20 mg/kg, IV infusion; Day 1 to Day 14: Capecitabine, 850-1000 mg/m², BID, orally)."
62715608|NCT06718543|EXPERIMENTAL|SCRT followed by AK112|"Patients will receive short-course radiotherapy (SCRT) followed by AK112:~In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7-day interval, patients will receive 2 cycles of AK112 treatment (Day 1: AK112, 20 mg/kg, IV infusion)."
62715609|NCT05738330|ACTIVE_COMPARATOR|SMaRRT-HD (Symptom Monitoring on Renal Replacement Therapy - Hemodialysis)|Dialysis clinics randomized to SMaRRT-HD will implement the SMaRRT-HD symptom monitoring system. SMaRRT-HD consists of 1) tablet-based symptom reporting using a patient reported outcome measure (PROM) and 2) supported clinician follow-up consisting of symptom alerts, guidances for symptom management, and symptom tracking reports that are shared with patients. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
62715610|NCT05738330|ACTIVE_COMPARATOR|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
62715611|NCT04893863|ACTIVE_COMPARATOR|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
62715612|NCT04893863|EXPERIMENTAL|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
62715613|NCT06225115|EXPERIMENTAL|SAD Cohort 1|Single-Ascending Dose Cohort 1. Intervention: KYN-5356 A mg or placebo, single dose, oral tablet
62715614|NCT06225115|EXPERIMENTAL|SAD Cohort 2|Single-Ascending Dose Cohort 2. Intervention: KYN-5356 B mg or placebo, single dose, oral tablet
62715615|NCT06225115|EXPERIMENTAL|SAD Cohort 3|Single-Ascending Dose Cohort 3. Intervention: KYN-5356 C mg or placebo, single dose, oral tablet
62715616|NCT06225115|EXPERIMENTAL|SAD Cohort 4|Single-Ascending Dose Cohort 4. Intervention: KYN-5356 D mg or placebo, single dose, oral tablet
62715617|NCT06225115|EXPERIMENTAL|SAD Cohort 5|Single-Ascending Dose Cohort 5. Intervention: KYN-5356 E mg or placebo, single dose, oral tablet
62715618|NCT06225115|EXPERIMENTAL|MAD Cohort 1|Multiple-Ascending Dose Cohort 1. Intervention: KYN-5356 G mg or placebo, oral tablets for 7 days
62715619|NCT06225115|EXPERIMENTAL|MAD Cohort 2|Multiple-Ascending Dose Cohort 2. Intervention: KYN-5356 H mg or placebo, oral tablets for 7 days
62715620|NCT06225115|EXPERIMENTAL|MAD Cohort 3|Multiple-Ascending Dose Cohort 3. Intervention: KYN-5356 I mg or placebo, oral tablets for 7 days
62715621|NCT06225115|EXPERIMENTAL|Food Effect Cohort|Intervention: KYN-5356 J mg, single dose, oral tablets in fasted or fed state.
62715622|NCT05710887|ACTIVE_COMPARATOR|Treatment; Nitrous Oxide 50%|A single 45-minute session of inhaled 50% nitrous oxide.
62715623|NCT05710887|PLACEBO_COMPARATOR|Control; Oxygen-air mixture|A single 45-minute session of inhaled Oxygen-air mixture
62715624|NCT06619899|EXPERIMENTAL|PAP exercise with 0% body mass|The participants will perform 6 x 30m sprints. A pre-conditioning exercise (2 sets x 4 countermovement jumps with 0% body mass).
62715625|NCT06619899|EXPERIMENTAL|PAP exercise with 20% body mass|The participants will perform 6 x 30m sprints. A pre-conditioning exercise (2 sets x 4 countermovement jumps with 20% body mass).
62542155|NCT05805215|EXPERIMENTAL|Active TIS of the hippocampus|Participants will undergo Active TIS of the hippocampus as one of the 3 conditions within the trial in randomized order.
62542156|NCT05805215|EXPERIMENTAL|Active TIS of the precuneus|Participants will undergo Active TIS of the precuneus as one of the 3 conditions within the trial in randomized order.
62542157|NCT05805215|PLACEBO_COMPARATOR|High-frequency stimulation|High frequency \>1Khz stimulation; Assumption: The intrinsic low-pass filtering of electrical signals by the neural membrane prevents neural electrical activity from following very high-frequency oscillating (e.g., \> 1 kHz) electric fields.
62542158|NCT00873457|EXPERIMENTAL|Perifosine|Perifosine 50 mg twice a day for a total of six 28-day cycles.
62542159|NCT04358952||COVID + patients|Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR
62542160|NCT04556071|EXPERIMENTAL|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until disease progression
62542161|NCT06158555|EXPERIMENTAL|Single Arm|Patients will receive fluid and vasopressor challenges and the macro and microvascular responses will be recorded using the IKORUS monitor alongside conventional haemodynamic monitoring
61976510|NCT01565785|EXPERIMENTAL|Discharge Prepartion with The FSM-DPI|25 families on each of 2 units will receive the will receive the Family Self-Management-Discharge Preparation Intervention (FSM-DPI). This scripted theory-based intervention is delivered by the study nurse using a e-mobile device. Eight elements of discharge preparation are addressed, the nurse assesses the family status and documents the additional care provided.
62542162|NCT02974712|EXPERIMENTAL|Fentanyl|After routine Induction, fentanyl was administrated.
62542163|NCT02974712|PLACEBO_COMPARATOR|Saline|After routine Induction, same volume saline was administrated.
62542164|NCT05260060|ACTIVE_COMPARATOR|Usual Treatment (Control)|Participants allocated to the control group will receive treatment as usual under the child and adolescent mental health service.
62542165|NCT05260060|EXPERIMENTAL|Group MCT (Intervention)|Participants allocated to the intervention group will receive group metacognitive therapy sessions.
62542166|NCT00311324|EXPERIMENTAL|Special Intervention|One individual counseling visit, twelve group sessions, three postcards, and twelve telephone calls.
62542167|NCT00311324|EXPERIMENTAL|Delayed Intervention|"Direct mailing of two American Dietary Association pamphlets (Healthy Eating and Staying Alive) and three bimonthly newsletters providing general health information and study updates."
62542168|NCT03364543||Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs. This group will also have access to access to a social worker and a community worker.
62542169|NCT03364543||Usual Care|Access to a social worker and a community worker, but no systematic process for addressing health-harming legal needs.
62542170|NCT02942030||ADHD|Children diagnosed with ADHD after a complete psychiatric evaluation.
62542171|NCT02942030||Non-ADHD|Children diagnosed with other mental conditions after a complete psychiatric evaluation.
62542172|NCT03819894|EXPERIMENTAL|Intervention|The intervention is the introduction of a lower female threshold. In cluster-randomized trials, the cluster (i.e., hospital) is the unit of randomization.
62542173|NCT03819894|NO_INTERVENTION|Control|The control phase will be standard of care, with the use of an overall population hs-cTn T and I threshold, for both men and women, to identify those with myocardial injury/infarction.
62542174|NCT00492986|EXPERIMENTAL|Arm 1|
62542175|NCT03369197|EXPERIMENTAL|Intervention: Nasal Mask|Nasal anesthesia mask with positive pressure
62542176|NCT03369197|ACTIVE_COMPARATOR|Control: Nasal cannula|Nasal Cannula with standard care
62542177|NCT01740245|ACTIVE_COMPARATOR|Chlorhexidine|
62542178|NCT01740245|EXPERIMENTAL|Polyhexamethylene biguanide|
62542179|NCT06107803|EXPERIMENTAL|Treatment Phase 1|Roluperidone 64 mg monotherapy administered as an oral dose daily for 7 days on Days 1-7.
62542180|NCT06107803|EXPERIMENTAL|Treatment Phase 2|Roluperidone 64 mg oral and olanzapine 10 mg oral administered at the same time daily for 10 days on Days 8-17.
62542181|NCT04856501|EXPERIMENTAL|PALS intervention condition|
62542182|NCT04856501|ACTIVE_COMPARATOR|Control condition|
62542183|NCT00337181||Vaccine Group|Received vaccination in RV144
62542184|NCT00337181||Placebo Group|Received placebo in RV144
62542185|NCT00930163|EXPERIMENTAL|1|
62542186|NCT00930163|PLACEBO_COMPARATOR|2|
62542187|NCT06432374|EXPERIMENTAL|Written Exposure Therapy|WET is a trauma-focused therapy for PTSD. It includes five writing sessions.
62542188|NCT05962762|EXPERIMENTAL|Human Umbilical Cord Mesenchymal Stem Cell Injection|The trial was divided into three dose groups： Low-dose group: 1000000 cells/kg Medium-dose group: 3000000 cells/kg High-does group: 5000000 cells/kg
62542189|NCT04435184|EXPERIMENTAL|Crizanlizumab|Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
62542190|NCT04435184|ACTIVE_COMPARATOR|Placebo Saline|0.9% saline 100 ml IV once.
62542191|NCT01722422|PLACEBO_COMPARATOR|normoxia and isotonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
62542192|NCT01722422|ACTIVE_COMPARATOR|normoxia and 3% hypertonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days.
62542193|NCT01722422|ACTIVE_COMPARATOR|hyperoxia and isotonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with isotonic saline during 3 days."
62542194|NCT01722422|ACTIVE_COMPARATOR|hyperoxia and 3% hypertonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
62542195|NCT04284540|EXPERIMENTAL|Adjuvant Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have undergone surgery
62542196|NCT04284540|EXPERIMENTAL|Definitive Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have not had surgery
62715626|NCT06619899|PLACEBO_COMPARATOR|No PAP exercise|The participants will perform only 6 x 30m sprints. No pre-conditioning exercise will be performed.
62715627|NCT06715605|EXPERIMENTAL|Intradermal arm: tolerogenic dendritic cells (tolDC)|Each vaccine (15x106cells in 500 µL NaCl 0.9% solution supplemented with 5% human albumin) will be administered through intradermal injection at 5 sites (100 µL/site) in the posterior neck region to ensure lymphatic drainage to superficial and deep cervical lymph nodes (5-10 cm from the cervical lymph nodes). Injection sites will alternate between left and right sides
62715628|NCT06715605|ACTIVE_COMPARATOR|Control arm: standard-of-care|Participants who receive standard-of-care, on first-line treatment (interferon-beta, glatiramer acetate, teriflunomide, dimethylfumarate, ponesimod, ozanimod). They will follow the same assessments as the interventional arms
62715629|NCT01302002|EXPERIMENTAL|Metformin Pre-Surgery|Patients will take metformin twice a day for three weeks prior surgery
62715630|NCT05434234|EXPERIMENTAL|Dose escalation|All participants enrolled in the dose escalation part
62715631|NCT05434234|EXPERIMENTAL|Dose expansion|All participants enrolled in the dose expansion part
62715632|NCT06717061||Harvesting of study samples during planned intervention|"Patients who are troubled by gallstone disease and are referred for laparoscopic surgery of the gallbladder at the surgical center Västerbotten in Skellefteå will receive oral and written information and will be asked to participate in the study.~Once the blood samples have been taken, a research nurse will be on site in Skellefteå to collect the samples for centrifugation, pipetting and freezing. Serum and plasma will be shipped frozen to Umeå for analysis. Pieces of tissue are placed in formalin in the operating room and sent to the laboratory."
62715633|NCT05056896|EXPERIMENTAL|Low Dose Aspirin|Participants will be randomly assigned to aspirin group and receive a daily low dose aspirin (81 mg) for the duration of the study up to 12 weeks.
62715634|NCT05056896|EXPERIMENTAL|Placebo|Participants will be randomly assigned to placebo group and receive a daily placebo capsule for the duration of the study up to 12 weeks.
62715635|NCT06360419|EXPERIMENTAL|Solriamfetol 300 mg|Up to 6 weeks
62715636|NCT06360419|PLACEBO_COMPARATOR|Placebo|Up to 6 weeks
62715637|NCT04442893|EXPERIMENTAL|Experimental group|The experimental group would be provided with a 6- session RFCBT program for 12 weeks (60-90 mins, once every two weeks).
62715638|NCT04442893|OTHER|Control group|The control group would receive a 6- session Health Education program for 12 weeks (60-90 mins, once every two weeks)
62715639|NCT01120405|EXPERIMENTAL|Xenon|0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
62715640|NCT01120405|ACTIVE_COMPARATOR|sevoflurane|0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)
62715641|NCT06716164|EXPERIMENTAL|Administration of Metabolically Armed CD19 CAR-T cells|Patients or donors undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
62715642|NCT02034643|OTHER|patients with single-lumen tube|Patients who required intraoperative TEE and single-lumen tube; balloon pressure adjustment before TEE probe insertion
62715643|NCT02034643|OTHER|patients with double-lumen tube|Patients who required intraoperative TEE and double-lumen tube; balloon pressure adjustment before TEE probe insertion
62715644|NCT06718504|ACTIVE_COMPARATOR|Intervention Group|During the procedure, patients in the intervention group watched videos of their choice, either in a relaxing natural setting or without any violent content, using virtual reality glasses.
62715645|NCT06718504|NO_INTERVENTION|Control Group|No intervention was applied to the patients in the control group.
62715646|NCT01068184|EXPERIMENTAL|1|
62715647|NCT01068184|PLACEBO_COMPARATOR|2|
62715648|NCT04271800|EXPERIMENTAL|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
62715649|NCT03051958|EXPERIMENTAL|Internet mindfulness&exposure treatment|A 12-week treatment where the main treatment components are mindfulness, exposure and response prevention, a form of cognitive behavior therapy. The treatment entails methods to increase acceptance and non-reactivity to aversive thoughts and emotions associated with AD. The treatment is delivered via the Internet and comprises 10 modules, each with a specific theme. Throughout treatment, the patient is given structured exercises to work with on a daily basis.
62715650|NCT03051958|ACTIVE_COMPARATOR|Treatment as usual|"Participants receive information about moisturizer and anti-inflammatory lotion treatment which is treatment as usual.~After 12 weeks, patients in this arm are crossed over to treatment."
62715651|NCT05850247|EXPERIMENTAL|[18F]DPA-714 PET|
62715652|NCT05904028|EXPERIMENTAL|Treat and Extend|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
62715653|NCT05904028|EXPERIMENTAL|Home optical coherence tomography-Guided Treatment|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
62715654|NCT01865487|PLACEBO_COMPARATOR|2-Dose Placebo|Placebo QFT Neg and Pos, 2 Doses, days 0,56
62715655|NCT01865487|EXPERIMENTAL|2-Dose 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 2 Doses, days 0,56
62715656|NCT01865487|EXPERIMENTAL|2-Dose 15/500 H56ug/IC31nmol|15/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
62715657|NCT01865487|EXPERIMENTAL|2-Dose 50/500 H56ug/IC31nmol|50/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
62715658|NCT01865487|PLACEBO_COMPARATOR|3-Dose, Placebo|Placebo QFT Neg and Pos, 3 doses, days 0, 56, 112
62715659|NCT01865487|EXPERIMENTAL|3-Dose, 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 3 Doses, days 0, 56, 112
61976511|NCT01565785|NO_INTERVENTION|control group|25 parents on each unit receiving standard of care in discharge preparation.
62715660|NCT05809388|EXPERIMENTAL|Experimental Group (EG)|The EG will perform a standard Parent Training program. This PT will be supplemented with virtual reality sessions. Each pair of parents will perform a total of 12 treatment sessions fortnightly.
62715661|NCT05809388|ACTIVE_COMPARATOR|Control Group (CG)|The CG will perform a standard Parent Training program plus two follow up sessions. Each pair of parents will perform a total of 12 treatment sessions fortnightly.
62715662|NCT01250054|OTHER|Lotrafilcon B / Comfilcon A|Lotrafilcon B multifocal contact lenses worn first, with comfilcon A multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
62715663|NCT01250054|OTHER|Comfilcon A /Lotrafilcon B|Comfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
62542197|NCT02553447|EXPERIMENTAL|Arm I (high-dose cholecalciferol)|Patients receive high-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
62542198|NCT02553447|EXPERIMENTAL|Arm II (low-dose cholecalciferol)|Patients receive low-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
62715664|NCT01153035|OTHER|Surgery followed by RFA|
62715665|NCT05203380||Part A|Assessed in a single visit and no study-related treatment will be given.
62715666|NCT05203380||Part B|Patients in Part A may also enroll in Part B provided they meet the eligibility criteria.
62715667|NCT00089492|EXPERIMENTAL|1|
62715668|NCT00089492|ACTIVE_COMPARATOR|2|
62715669|NCT05382338|EXPERIMENTAL|Treatment (chemoradiotherapy, maintenance)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy on weeks 1-7 and receive vincristine IV once weekly on weeks 2-7 in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 4 weeks after chemoradiotherapy, patients receive lomustine PO on day 1 of cycles 1, 2, 4, 5, 7, and 8, cisplatin IV over 6 hours on day 1 of cycles 1, 2, 4, 5, 7, and 8, sodium thiosulfate IV over 15 minutes on day 1 of cycles 1, 2, 4, 5, 7, and 8, cyclophosphamide IV over 30-60 minutes on days 1 and 2 of cycles 3, 6, and 9, and mesna IV over 15-30 minutes TID on days 1 and 2 of cycles 3, 6, and 9. Patients also receive vincristine IV on days 1, 8, and 15 of cycles 1, 2, 4, 5, 7, and 8, and on days 1 and 8 of cycles 3, 6, and 9. Treatment repeats every 6 weeks (cycles 1, 2, 4, 5, 7 and 8) or every 4 weeks (cycles 3, 6, and 9) for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
62715670|NCT03648710|NO_INTERVENTION|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
62715671|NCT03648710|EXPERIMENTAL|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
62542199|NCT02553447|NO_INTERVENTION|Arm III (control)|Patients receive no intervention.
62542200|NCT02341898|EXPERIMENTAL|Updated original programme|Educational programme for all nurses (90 min. single information session); training and structured support for nominated key nurses (one-day training workshop); provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
62542201|NCT02341898|EXPERIMENTAL|Concise updated programme|Training and structured support for nominated key nurses (one-day training workshop); nurses' training will be carried out by key nurses as facultative option; key nurses receive an additional train-the-trainer module to apply the educational programme; provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
62542202|NCT02341898|ACTIVE_COMPARATOR|Optimized usual care|Provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives) only
62542203|NCT04710979|EXPERIMENTAL|Yoga Intervention Group|
62715672|NCT03648710|EXPERIMENTAL|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
62715673|NCT05134649|EXPERIMENTAL|BOTOX|BOTOX (OnabotulinumtoxinA) will be injected into the platysma muscle for up to 3 Cycles during study M21-323
62715674|NCT04461353|ACTIVE_COMPARATOR|Hydroxychloroquine Sulfate|The study drug AHCQ will be administered by inhalation through the mouth. The starting dose will be 20 mg (Cohort A1) with a proposed subsequent dose of 50 mg (Cohort A2). At each dose level 8 participants (including at least 3 female participants and 3 participants older than 50 years old) will be enrolled. Six participants will receive the active study drug and 2 participants will receive placebo.
62715675|NCT04461353|PLACEBO_COMPARATOR|Placebo|Placebo will be administered by inhalation through the mouth. It will be administered in both Cohort A1 and Cohort A2. Six participants will receive the active study drug and 2 participants will receive placebo.
62715676|NCT04875520|ACTIVE_COMPARATOR|Weekly Screening testing plus symptomatic testing|Among 16 middle and high schools, 8 will be randomized to offer students and staff weekly SARS-CoV-2 testing. Additionally, these schools will offer testing for symptomatic students, staff, household members in all age groups.
61976512|NCT01870960|OTHER|right control|the patient is his own control The right side will be treated as normal while the left side will also receive the emdogaim
62542204|NCT04710979|NO_INTERVENTION|Control Group|Control participants will receive no guidance from the research staff to change their behavior.
62542205|NCT03762044|EXPERIMENTAL|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|10 sessions of 30 minutes, twice a week in a total 5 week period of Activity-oriented Proprioceptive Antiedema Therapy (TAPA in Spanish)
62542206|NCT03762044|ACTIVE_COMPARATOR|Complete Decongestive Therapy (CDT)|10 sessions of 30 minutes, twice a week in a total 5 week period of complete decongestive therapy (CDT).
62542207|NCT01625832|EXPERIMENTAL|1|CSO first
62542208|NCT01625832|EXPERIMENTAL|2|CSO second
62715677|NCT04875520|ACTIVE_COMPARATOR|Symptomatic testing|All 16 schools will have testing available for individuals that have symptoms or need a test for other reasons.
62715678|NCT01677260|EXPERIMENTAL|Group I|500 mg metformin hydrochloride extended release caplet (PT Ferron Par Pharmaceuticals)
62715679|NCT01677260|ACTIVE_COMPARATOR|Group II|500 mg metformin hydrochloride prolonged release tablet (PT Merck Pharmaceuticals)
62715680|NCT00200200|ACTIVE_COMPARATOR|1|Bevacizumab in addition to HAI plus systemic chemotherapy
62715681|NCT00200200|EXPERIMENTAL|2|HAI plus systemic chemotherapy alone
62715682|NCT02606630|EXPERIMENTAL|ABT-555|ABT-555 will be administered at Visit 4 for Part 2 only
62715683|NCT00023049||1|patients with known SNHL and/or peripheral vestibular dysfunction
62715684|NCT00477815|EXPERIMENTAL|Rituximab + Zevalin|Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.
62715685|NCT04753489|OTHER|Sequence TR|17 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
62715686|NCT04753489|OTHER|Sequence RT|17 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
62715687|NCT06716437|EXPERIMENTAL|Prehabilitation arm|Patients will receive the prehabilitation program
62715688|NCT06718751|EXPERIMENTAL|PO 650mg TXA tablet|650mg tablets of TXA will be prescribed to be taken orally, once daily for 21 weeks.
62715689|NCT06718751|PLACEBO_COMPARATOR|PO 650mg placebo tablet|650mg placebo tablet will be prescribed to be taken orally, once daily for 21 weeks.
62715690|NCT01441388|EXPERIMENTAL|Dose Escalation|Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
62715691|NCT01441388|EXPERIMENTAL|Expansion Population 1|Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
62715692|NCT01441388|EXPERIMENTAL|Expansion Population 2|Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
62715693|NCT01441388|EXPERIMENTAL|Expansion Population 3|Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
62715694|NCT01441388|EXPERIMENTAL|Expansion Population 4|Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
62715695|NCT06712095|EXPERIMENTAL|Videocapsule investigation|
62715696|NCT05501548|EXPERIMENTAL|Olaparib and Vitamin C|Olaparib will be administered at 300 mg by mouth, twice daily; ascorbate will be administered at 1 g/kg IV twice weekly at least 24 hours apart, until objective disease progression or unacceptable toxicities or patient withdrawal for other reasons.
62715697|NCT06719206|EXPERIMENTAL|Intervention|Participants receive a digital self-management intervention
62715698|NCT06719206|NO_INTERVENTION|Control|Control condition. Individuals receive the care as usual provided by the healthcare only.
62715699|NCT03667105|EXPERIMENTAL|CAF+XDM|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous dermal collagen matrix graft (AXDM - Mucoderm®, Botiss,) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
62715700|NCT03667105|EXPERIMENTAL|CAF+MC|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Mucograft®, Geistlich Pharma) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
62715701|NCT03667105|ACTIVE_COMPARATOR|CAF|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Then, the flap will be coronally positioned and sutured to completely cover the graft. This group will be the control group.
62715702|NCT05335967|EXPERIMENTAL|Self-management group|The experimental group will receive the self-management program for 12 weeks.
61976513|NCT01870960|OTHER|left control|the patient is his own control The left side will be treated as normal while the right side will also receive the emdogaim
61976514|NCT01845350|OTHER|M2 macrophages|M2 macrophage introduction
62715703|NCT05335967|OTHER|Information group|The control group will receive an information package on a healthy diet.
62715704|NCT05230498|ACTIVE_COMPARATOR|Cochlear Implant (CI) with default fitting then anatomy-based fitting|Cochlear Implant with default fitting first during 6 weeks then with anatomy-based fitting during 6 weeks
62715705|NCT05230498|ACTIVE_COMPARATOR|Cochlear Implant (CI) with anatomy-based fitting then default fitting|Cochlear Implant with anatomy-based fitting during 6 weeks then with default fitting during 6 weeks
62715706|NCT04051606|EXPERIMENTAL|Regorafenib|160 mg regorafenib 3 weeks on/ one week off in participants with Avastin refractory Glioblastoma, continued until progression or toxicity. Participants will receive an MRI every 8 weeks.
61976515|NCT06474364|EXPERIMENTAL|Health facilty delivery model|AYA will be randomized to access CABLA at the health facility.
62715707|NCT05504707|EXPERIMENTAL|Dendritic Cell Vaccine dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of HER2- and HER3- primed DC1 study vaccines. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
62542209|NCT05389631||Trifecta VinV|VinV TAVI procedure in patients who have previously received a Trifecta valve
62542210|NCT05389631||Epic VinV|VinV TAVI procedure in patients who have previously received an Epic valve
62542211|NCT05826535|EXPERIMENTAL|Phase I Dose Level I CAR T experienced cohort|Phase I 3+3 design Dose level 1: 1×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
62542212|NCT05826535|EXPERIMENTAL|Phase I Dose Level II CAR T experienced cohort|Phase I 3+3 design Dose level 2: 3×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
62542213|NCT05826535|EXPERIMENTAL|Phase II CAR T experienced cohort|Single dose determined during Phase I.
62542214|NCT05826535|EXPERIMENTAL|Phase I Dose Level I CAR T naïve cohort|Phase I 3+3 design Dose level 1: 1×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
62542215|NCT05826535|EXPERIMENTAL|Phase I Dose Level II CAR T naïve cohort|Phase I 3+3 design Dose level 2: 3×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
62542216|NCT05826535|EXPERIMENTAL|Phase II CAR T naïve cohort|Single dose determined during Phase I.
62542217|NCT05826535|EXPERIMENTAL|Phase I Dose Level I Refractory disease or relapse within one year of first line therapy|Phase I 3+3 design Dose level 1: 1×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
62542218|NCT05826535|EXPERIMENTAL|Phase I Dose Level II Refractory disease or relapse within one year of first line therapy|Phase I 3+3 design Dose level 2: 3×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
62542219|NCT05826535|EXPERIMENTAL|Phase II Refractory disease or relapse within one year of first line therapy|Single dose determined during Phase I.
62542220|NCT02047734|EXPERIMENTAL|Ozanimod 0.5 mg|Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
62542221|NCT02047734|EXPERIMENTAL|Ozanimod1 mg|Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
62542222|NCT02047734|ACTIVE_COMPARATOR|Interferon β-1a|interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.
62542223|NCT05693974||stage I-II ovarian cancer|30 patients with stage I-II ovarian cancer
62542224|NCT05693974||stage III-IV ovarian cancer|30 patients with stage III-IV ovarian cancer
62542225|NCT05693974||benign ovarian cancer|40 patients with benign ovarian cancer
62542226|NCT05693974||healthy people|30 healthy people
62542227|NCT04669301|ACTIVE_COMPARATOR|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
62542228|NCT04669301|EXPERIMENTAL|MAAT-G intervention|The MAAT-G intervention will be delivered by a trained psychology fellow at the University of Rochester Medical Center. The intervention will be delivered through televideoconferencing and participants will be provided a tablet equipped with a HIPPA compliant televideoconferencing application to use for the MAAT-G workshop sessions. We will use the University of Rochester Zoom application which is HIPPA compliant. A tablet instruction manual will be given to patients to help guide them through how to use a tablet and how to navigate the Zoom application. A unique meeting ID number will be given to each patient to log in to the Zoom application. If participants do not have access to wireless internet, the tablet will be equipped with a data package for participant use for the purposes of this study
62542229|NCT03471000|EXPERIMENTAL|Short implants Treatment|Group 2 (G2; n=15 patients) had short implants (OsseoSpeed ™ L6mm Ø4 mm) \[DENTSPLY Implants, Waltham, MA, USA\] placed without sinus lift and augmentation procedure.
62542230|NCT03471000|ACTIVE_COMPARATOR|Regular Implants Treatment|Group 1 (G1; n=15 patients) had conventional dental implants (OsseoSpeed ™ L11 Ø4 mm and L13 Ø4 mm) \[DENTSPLY Implants, Waltham, MA, USA\] placed, preceded by the sinus lift procedure from a lateral window approach with the application of the xenogeneic bone graft Geistlich Bio-Oss® \[Geistlich AG, Wolhusen, Switzerland\]. The lateral window approach sinus lift surgery was performed 6 weeks prior to the implant placement by the same surgeon.
62542231|NCT04380961|EXPERIMENTAL|Sirukumab|Participants will receive single intravenously (IV) dose infusion of sirukumab on Day 1 along with standard of care treatment.
62542232|NCT04380961|PLACEBO_COMPARATOR|Placebo|Participants will receive IV single dose infusion of placebo on Day 1 along with standard of care treatment.
62542233|NCT02733380|EXPERIMENTAL|Chidamide combined with VDDT regimen|Chidamide 30mg，Oral twice a week with an interval of no less than 3 days combined with regimen：VDDT（Vinorelbine，Liposomal doxorubicin or mitoxantrone ，Dexamethasone and Thalidomide）：repeated every 14 days ，up to 12 cycles
62542234|NCT01343316||Transgastric tube|Nasogastric (NG tube)
62542235|NCT01343316||Transpyloric tube - Tiger2|Self-propelled by paristaltic waves of the stomach
62542236|NCT01343316||Transpyloric tube - Syncro BlueTube|Magnetically placed
62542237|NCT02234219|EXPERIMENTAL|Heart-shaped anastomosis|Heart shaped anastomosis
62542238|NCT02234219|ACTIVE_COMPARATOR|Circle anastomosis|Soave anastomosis
62715708|NCT01657305|EXPERIMENTAL|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
62542239|NCT05742035|EXPERIMENTAL|Hereditary hemochromatosis|Individual with ferritin \>500 ng/mL and documented homozygous or compound heterozygous HFE-gen mutation.
62542240|NCT05742035|EXPERIMENTAL|secondary hyperferritinemia|Individual with ferritin \>500 ng/mL, not fulfilling the criteria for hereditary hemochromatosis.
62715709|NCT01657305|OTHER|Non-adhesive wound dressing only|A STSG donor site wound \>15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
62715710|NCT06718829|EXPERIMENTAL|Core Stability Exercises + Traditional physical therapy program|This group will be composed of 30 patients with lower limb burns. Patients will receive core stability exercises in addition to a traditional physical therapy program in the form of stretching exercises, strengthening exercises and scar management. Exercises will be applied for 3 times a week for 8 consecutive weeks.
62715711|NCT06718829|EXPERIMENTAL|Sensorimotor Training Exercises + Traditional physical therapy program|This group will be composed of 30 patients with lower limb burns. Patients will receive sensorimotor training exercise in addition to traditional physical therapy program in the form of stretching exercises, strengthening exercises and scar management. Exercises will be applied for 3 times a week for 8 consecutive weeks.
62715712|NCT06718829|EXPERIMENTAL|Core Stability Exercises + Sensorimotor Training Exercises + Traditional physical therapy program|This group will be composed of 30 patients with lower limb burns. Patients will receive core stability exercises and sensorimotor training exercise in addition to traditional physical therapy program in the form of stretching exercises, strengthening exercises and scar management. Exercises will be applied for 3 times a week for 8 consecutive weeks.
62715713|NCT02054169||pre-test group|All patients aged 65 or older presenting to the ED during the pre-test period
62715714|NCT02054169||post-test period|All patients aged 65 or older presenting to the ED in the post-test period
62715715|NCT06462313|EXPERIMENTAL|Dobutamine, norepinephrine|Patients will be initiated on Dobutamine at 5 mcg/kg/min while continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 65mmHg or more
62715716|NCT06462313|OTHER|Norepinephrine|Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more
62715717|NCT04240691||60-Minutes-For-Health|60-Minutes-for Health: this is a psychological intervention which seeks to correct factors underlying decisions to delay or avoid HIV care and strengthen abilities to overcome HIV care utilization barriers. This is achieved through assistance identifying and reducing misinformation guiding HIV care attendance decisions; enhancing motivation to maintain HIV care via personal health goals; building skills for coping with negative feelings related to living with HIV; and increasing self-efficacy for navigating structural barriers and maintaining HIV care amidst competing priorities.
62715718|NCT04240691||Time-and-Attention Control Session|60 Minute diet \& nutrition control session
62715719|NCT04317144|ACTIVE_COMPARATOR|Web-based follow-up programme|Participant randomized to the Web-based follow-up programme receive access to web-portal called www.1177.se
62715720|NCT04317144|ACTIVE_COMPARATOR|No follow-up.|Participants does not receive the web-based follow-up programme. e-questionnaires are sent out.
62715721|NCT04734860|EXPERIMENTAL|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
62715722|NCT04734860|PLACEBO_COMPARATOR|Placebo|A single injection of placebo will be administered
62715723|NCT05559099|EXPERIMENTAL|Tecovirimat|Tecovirimat capsules administered orally to participants for 14 days plus SOC.
62715724|NCT05559099|PLACEBO_COMPARATOR|Placebo|Matching placebo capsules administered orally to participants for 14 days plus SOC.
62715725|NCT05913401|EXPERIMENTAL|Aerobic Exercise|Exercise sessions will be 20 minutes of moderate-intensity aerobic exercise on a treadmill. A treadmill is located on D1A within the space shared by the Butler Hospital TMS Clinic and the COBRE-support Neuromodulation Research Facility. A research staff member will monitor their heart rate and blood pressure to ensure safety and that activity is occurring at a moderate intensity (i.e., 64-76% of age predicted maximal heart rate). Participants will be asked to rate their affect and rating of perceived exertion (RPE) during exercise sessions. Sessions will include a 5-min warm-up and a 5-min cool-down to ensure safe exercise procedures. Participants will be asked to answer questions about affect before, during, and after exercise. These sessions will be supervised (i.e., they provide onsite coverage) by an exercise physiologist or medical staff member (e.g., nurse or physician) to ensure safety.
62715726|NCT05913401|OTHER|Video Condition|In this condition, participants will be asked to sit and watch various documentaries or educational videos on topics NOT related to physical activity. These will last approximately 20 minutes and will occur before each TMS session.
62542241|NCT05742035|OTHER|healthy blood donor with normal ferritin value.|Healthy comparator.
62542242|NCT00985491|EXPERIMENTAL|Device|All patients will be implanted with the Endobarrier Liner device.
62542243|NCT04275986|EXPERIMENTAL|Experimental arm|Endoscopic resection+ concurrent chemoradiotherapy
62542244|NCT04887155|ACTIVE_COMPARATOR|Cognitive behavioral therapy (CBT)_no app|
62542245|NCT04887155|EXPERIMENTAL|Cognitive behavioral therapy (CBT) with mobile app|
62715727|NCT06590675|EXPERIMENTAL|≥34 Week Neonates & ≥1.4 kg|"Phase 1 of a step-wise enrollment strategy in which chlorhexidine gluconate (CHG) bathing will be administered as follows:~1. 1% CHG administered twice (2) a week (N=10)~2. 1% CHG administered five times (5) a week (N=10)~3. 2% CHG administered twice (2) a week (N=10)~4. 2% CHG administered five times (5) a week (N=10)"
62542246|NCT04144361|EXPERIMENTAL|sleeve without plication|sleeve gastrectomy on bougie 36 without plication
62542247|NCT04144361|ACTIVE_COMPARATOR|sleeve with plication|sleeve gastrectomy on bougie 42 without plication
62542248|NCT02897310||critically ill patients|critically ill patients with acute kidney failure requiring renal replacement therapy
62542249|NCT03847298||Pacemaker|
62542250|NCT03847298||Control|
62542251|NCT01855828|EXPERIMENTAL|Chemo plus Pertuzumab,Trastuzumab|During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
62715728|NCT06590675|EXPERIMENTAL|≥32 Week Neonates &/or 1.2 kg - 1.4 kg|"Phase 2 of a step-wise enrollment strategy in which chlorhexidine gluconate (CHG) bathing will be administered as follows:~1. 1% CHG administered twice (2) a week (N=20)~2. 1% CHG administered five times (5) a week (N=20)~3. 2% CHG administered twice (2) a week (N=20)~4. 2% CHG administered five times (5) a week (N=20)"
62715729|NCT06590675|EXPERIMENTAL|≥28 Week Neonates &/or 1.0 kg - 1.2 kg|"Phase 3 of a step-wise enrollment strategy in which chlorhexidine gluconate (CHG) bathing will be administered as follows:~1. 1% CHG administered twice (2) a week (N=30)~2. 1% CHG administered five times (5) a week (N=30)~3. 2% CHG administered twice (2) a week (N=30)~4. 2% CHG administered five times (5) a week (N=20)"
62715730|NCT06590675|NO_INTERVENTION|Feasibility Assessment|Semi-structured, qualitative Interviews will be performed with caregivers (N=10) of neonates enrolled in the interventional arms and with healthcare workers (N=20) who care for these neonates in the neonatal unit (NNU) and intensive care unit (ICU).
62542252|NCT01346787|EXPERIMENTAL|Carfilzomib Cyclophosphamide Dexamethasone|The treatment period includes administration of Carfilzomib Cyclophosphamide Dexamethasone for 9 courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled carfilzomib administration. The response will be assessed after each cycle.
62542253|NCT04219826|EXPERIMENTAL|CK-3773274 - Cohort 1 (Obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
62542254|NCT04219826|PLACEBO_COMPARATOR|Placebo - Cohort 1 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
62542255|NCT04219826|EXPERIMENTAL|CK-3773274 - Cohort 2 (Obstructive HCM)|Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
62542256|NCT04219826|PLACEBO_COMPARATOR|Placebo - Cohort 2 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
62542257|NCT04219826|EXPERIMENTAL|CK-3773274 & disopyramide - Cohort 3 (Obstructive HCM)|Subjects will receive doses 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
62542258|NCT04219826|EXPERIMENTAL|CK-3773274 - Cohort 4 (non-obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
62542259|NCT03007238|EXPERIMENTAL|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
62542260|NCT05842174|EXPERIMENTAL|Transarterial Embolization with Hydroxychloroquine|Intra-arterial hydroxychloroquine in Lipiodol + transarterial embolization followed by oral hydroxychloroquine
62542261|NCT05842174|PLACEBO_COMPARATOR|Transarterial Embolization without Hydroxychloquine|Intra-arterial Lipiodol + transarterial embolization followed by oral placebo
62542262|NCT05251610|ACTIVE_COMPARATOR|PROPRANOLOL GROUP|Participants will receive 20mg of oral propranolol 10 minutes prior to initiation of augmentation or induction of labor with oxytocin
62542263|NCT05251610|PLACEBO_COMPARATOR|OXYTOCIN ONLY GROUP|Participants had outright augmentation or induction of labor with oxytocin only
62542264|NCT05018312|EXPERIMENTAL|Modified Collaborative Assessment (MCA)|The patients allocated to this arm will receive assessment inspired by therapeutic/collaborative assessment, as a pre-treatment to the standard psychotherapeutic treatment they will receive in the clinic.
62542265|NCT05018312|ACTIVE_COMPARATOR|Assessment as usual (AAU)|The patients allocated to this arm will receive standard assessment offered in the clinic, before proceeding to the standard psychotherapeutic treatment they will receive in the clinic.
62542266|NCT06487208|PLACEBO_COMPARATOR|Placebo|No intervention
62542267|NCT06487208|EXPERIMENTAL|AnticipaMax|The subjects will be instructed to use the 5 minutes to consider potential complications, prioritize them, and anticipate their management. The facilitators will have a neutral role with pre-determined standardized responses and will ensure the correct use of the Max tool during this time period
62542268|NCT00289120|EXPERIMENTAL|Cola beverage|Subjects will be given 500cc of Cola twice daily.
62542269|NCT00289120|PLACEBO_COMPARATOR|Deionized water|Subjects will be given 500cc of deionized water.
62542270|NCT05298761|EXPERIMENTAL|Lignocain|I/V lignocain 1.5mg per kg given to participants in state dose
62542271|NCT05298761|EXPERIMENTAL|nalbuphine|I/v nalbuphine 0.1mg per kg given to participants in stat dose
62542272|NCT00863772|EXPERIMENTAL|Tanezumab 5 mg|
61976516|NCT06474364|EXPERIMENTAL|Community venue delivery model|AYA will be randomized to receive Cabotegravir from a community pharmacy/drop-in center.
62542273|NCT00863772|EXPERIMENTAL|Tanezumab 10 mg|
62542274|NCT00863772|PLACEBO_COMPARATOR|Placebo|
62542275|NCT05597150|EXPERIMENTAL|Experimental Group|
62542276|NCT06130423|EXPERIMENTAL|Music intervention and NRT|The rhythm of the music sessions will be 2 per week in the first month, 1 per week in the second month and 1 every 15 days in th third month, music intervention will be associated to NRT.
62542277|NCT06130423|ACTIVE_COMPARATOR|NRT Group|Nicotine Patch, Nicotine Gum as in the intervention group, the physician will adapt the type of NRT according to the patient's smoking profile.
62542278|NCT05351658|EXPERIMENTAL|Temporary Cardiac Pacing with Active-Fixation Leads|
62542279|NCT03578549||Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
62738087|NCT00998452|NO_INTERVENTION|MOVE!|Participants will receive the usual VA MOVE! Program. These elements include a baseline assessment, brief clinic counseling session about weight, printed targeted health information on weight management and behaviors, and opportunities to participate in group sessions at the VA site and telephone follow-up from MOVE! clinic staff.
62542280|NCT06137625|EXPERIMENTAL|Cerebral Palsy|Children with Cerebral Palsy
62542281|NCT06137625|ACTIVE_COMPARATOR|Typical developing|Typical developing children
62542282|NCT00769938|ACTIVE_COMPARATOR|Aspirin + clopidogrel + oral anticoagulation|
62715731|NCT06314425|EXPERIMENTAL|Immediate loading of ceramic implants|Tooth/teeth are extracted with minimally invasive approach using piezo surgery and when necessary sectioning after local anesthesia (Articaine 40 mg/mL with epinephrine 10 μg/mL; or Lidocaine 20mg/ml with 10 ug/ml). Extraction sockets are thoroughly degranulated to remove all remnants of soft tissue and residual restorations or material which may have extended beyond the tooth apex. After copious irrigation, the socket condition is recorded, which includes, thickness and location of buccal/facial crestal alveolar bone.
62715732|NCT00961038|EXPERIMENTAL|Arm 1|
62715733|NCT00961038|EXPERIMENTAL|Arm 2|
62715734|NCT00961038|PLACEBO_COMPARATOR|Arm 3|
62715735|NCT05411497|EXPERIMENTAL|Treatment (cyclophosphamide, MUC1-activated T-cells)|"LD CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes on days -5, -4, -3.~ASCT: Patients receive MUC1-activated T-cells IV over 10 minutes to 1 hour on day 0."
62715736|NCT02325063|EXPERIMENTAL|PRP-L Group|"Patients randomized to this group will be treated with an injection of Leukocyte and Platelet Rich Plasma (PRP-L).~Intervention: PRP-L Injection"
62715737|NCT02325063|ACTIVE_COMPARATOR|Botox Group|"Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).~Intervention: Botox injection"
62715738|NCT02325063|ACTIVE_COMPARATOR|Corticoid Group|"Patients randomized to this group will be treated with an injection of Corticoids.~Intervention: Corticoid injection"
62164836|NCT05698888|EXPERIMENTAL|VP301 (Dose Expansion)|Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will receive the maximum tolerated dose or recommended phase 2 dose during the Dose Expansion period of the study.
62164837|NCT05126199|EXPERIMENTAL|Time restricted eating|"Time-restricted eating using 18:6 protocol (12 weeks)~Washout Period (4 weeks)~Crossover to Normal ad libitum diet (12 weeks)"
62715739|NCT05211323|EXPERIMENTAL|Arm A (atezolizumab, bevacizumab, gemcitabine, cisplatin)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV on days 1 and 8. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients undergo blood specimen collection on study.
62715740|NCT05211323|ACTIVE_COMPARATOR|Arm B (atezolizumab, gemcitabine, cisplatin)|Patients receive atezolizumab IV over 30-60 minutes on day 1, and gemcitabine IV over 30 minutes and cisplatin IV on days 1 and 8. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or magnetic resonance imaging MRI throughout the trial. Patients undergo blood specimen collection on study.
62715741|NCT06717438|EXPERIMENTAL|BPN14770|"Participants will receive a weight adjusted dose of BPN14770 twice daily (BID) during the 24-week Double-blind Period.~Participants in the BPN14770 arm who complete the Double-blind Period will have the opportunity to continue in the Open-label Extension Period. Participants will receive a weight adjusted dose of BPN14770 BID during the 24-week Open-label Extension Period."
62715742|NCT06717438|PLACEBO_COMPARATOR|Placebo|"Participants will receive BPN14770 matching placebo BID during the 24-week Double-blind Period.~Participants in the placebo arm who complete the Double-blind Period will have the opportunity to continue in the Open-label Extension Period. Participants will receive a weight adjusted dose of BPN14770 BID during the 24-week Open-label Extension Period."
62715743|NCT01472731|EXPERIMENTAL|GC1008 imaging and treatment|"Part 1: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake.~Part 2: 89Zr-GC1008 PET imaging in patients with relapsed malignant glioma and phase II extension study with therapeutic GC1008 in these patients"
62715744|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA\<34 weeks) with severe thrombocytopenia
62715745|NCT05484128|EXPERIMENTAL|Gastrus|"86 patients Gastrus sachets/chewable caps: 2x108 CFU Lactobacillus reuteri DSM 17938 + 2x108 CFU Lactobacillus reuteri ATCC PTA 6475.~Placebo sachets/chewable caps: Identical in shape, colour and taste to Gastrus capsules but without the Lactobacillus reuteri components.~Both study products are delivered in identical containers. Dosing: Two sachets/cps twice a day. Length of treatment: Gastrus or placebo will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus and placebo."
62715746|NCT05484128|PLACEBO_COMPARATOR|Placebo|"86 patients Gastrus sachets/chewable caps: 2x108 CFU Lactobacillus reuteri DSM 17938 + 2x108 CFU Lactobacillus reuteri ATCC PTA 6475.~Placebo sachets/chewable caps: Identical in shape, colour and taste to Gastrus capsules but without the Lactobacillus reuteri components.~Both study products are delivered in identical containers. Dosing: Two sachets/cps twice a day. Length of treatment: Gastrus or placebo will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus and placebo."
62715747|NCT06294821|ACTIVE_COMPARATOR|4-aminopyridine|Study drug: dalfampridine (generic) 10mg ER capsule
62164838|NCT05126199|ACTIVE_COMPARATOR|Normal ad libitum diet|"Normal ad libitum dietary patterns without defined eating window, fasting or restrictions on types of food or drink consumed (12 weeks)~Washout Period (4 weeks)~Crossover to time-restricted eating using 18:6 protocol (12 weeks)"
62542283|NCT00769938|ACTIVE_COMPARATOR|Oral anticoagulants + clopidogrel|
62715748|NCT06294821|PLACEBO_COMPARATOR|Placebo|Placebo-1 capsule
62715749|NCT03305484||Symptomatic Contact Lens Wearers|Contact lens wearers who present to the eye care practitioner's office with a symptomatic red eye
62715750|NCT01555060|EXPERIMENTAL|Iron supplements|Subjects who are randomized to receive daily iron supplements after donating blood
62715751|NCT01555060|NO_INTERVENTION|Control|Subjects who are randomized not to receive daily iron supplements after donating blood
62715752|NCT05192421|ACTIVE_COMPARATOR|Level 1|Wellness Education
62715753|NCT05192421|EXPERIMENTAL|Level 2|Wellness Education + Pre-recorded Exercise Videos
62715754|NCT05192421|EXPERIMENTAL|Level 3|Wellness Education + Livestream Exercise Classes
62715755|NCT04128709|EXPERIMENTAL|Neurogenic Bladder Patient|Patients with neurogenic bladder
62715756|NCT03937479|EXPERIMENTAL|RPL554 0.375 mg twice daily|RPL554 0.375 mg twice daily
62715757|NCT03937479|EXPERIMENTAL|RPL554 0.75 mg twice daily|RPL554 0.75 mg twice daily
62715758|NCT03937479|EXPERIMENTAL|RPL554 1.5 mg twice daily|RPL554 1.5 mg twice daily
62715759|NCT03937479|EXPERIMENTAL|RPL554 3.0 mg twice daily|RPL554 3.0 mg twice daily
62715760|NCT03937479|PLACEBO_COMPARATOR|Placebo twice daily|Placebo twice daily
62715761|NCT04098705|NO_INTERVENTION|Pre-intervention|Pre-intervention period
62715762|NCT04098705|EXPERIMENTAL|Post-intervention|Post-intervention period
62715763|NCT05027074|EXPERIMENTAL|MK-2060 Low Dose|MK-2060 low dose administered via intravenous (IV) infusion as a loading dose: Every other day (QOD) during week 1 (3 administrations), then once a week (QW) after week 1
62715764|NCT05027074|EXPERIMENTAL|MK-2060 High Dose|MK-2060 high dose administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then QW after week 1
62715765|NCT05027074|PLACEBO_COMPARATOR|Placebo|Placebo (normal saline) administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then once a week after week 1
62715766|NCT03392181|EXPERIMENTAL|18F-DCFPyL|
62715767|NCT05578976|EXPERIMENTAL|Epcoritamab and R-CHOP|Participants will receive subcutaneous epcoritamab combined with intravenous rituximab, cyclophosphamide, doxorubixin hydrochloride, vincristine and oral prednisone (R-CHOP) followed by epcoritamab in 21-day cycles.
62715768|NCT05578976|EXPERIMENTAL|R-CHOP and Rituximab|Participants will receive intravenous rituximab, cyclophosphamide, doxorubixin hydrochloride, vincristine and oral prednisone (R-CHOP) followed by intravenous rituximab in 21-day cycles.
62715769|NCT06718569||Patients who initiate or switch biological or targeted synthetic DMARD|All patients initiate or switch biological or targeted synthetic DMARD
62542284|NCT03311750|EXPERIMENTAL|Panitumumab|On day 1 of each cycle patients will receive panitumumab followed by 5-fluorouracil and leucovorin in combination with either irinotecan (FOLFIRI regimen) or oxaliplatin (FOLFOX regimen) or followed by irinotecan monotherapy. This treatment will be repeated every 2 weeks for FOLFIRI and FOLFOX regimens and every 3 weeks for irinotecan monotherapy.
62542285|NCT04660240|ACTIVE_COMPARATOR|Abluminus Sirolimus Eluting Stent System (ASES)|The Abluminus sirolimus eluting stent manufactured by Envision and distributed by Concept Medical.
62542286|NCT04660240|EXPERIMENTAL|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|The Orsiro sirolimus eluting stent manufactured by Biotronik.
62542287|NCT04906421|EXPERIMENTAL|TVB-2640 50 mg|Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.
62542288|NCT04906421|PLACEBO_COMPARATOR|Placebo|Subjects will receive matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.
62542289|NCT02226471||NW-NBP group|normal weight and blood pressure subjects
62715770|NCT05827887||Ubrogepant|Participants will receive ubrogepant as prescribed by their physician in routine clinical practice.
62715771|NCT05827887||Atogepant|Participants will receive atogepant as prescribed by their physician in routine clinical practice.
62715772|NCT02172729|EXPERIMENTAL|ACB with lidocaine 5 mg/ml|Adductor canal block (ACB) with 20 ml lidocaine 5 mg/ml, single bolus
62715773|NCT02172729|EXPERIMENTAL|ACB with lidocaine 15 mg/ml|Adductor canal block with 20 ml lidocaine 15 mg/ml, single bolus
62715774|NCT06717360|EXPERIMENTAL|AG2304T|
62715775|NCT06717360|ACTIVE_COMPARATOR|AG2304R|
62715776|NCT06718725||Patients undergoing EUS-FNA and ROSE|Patients ≥18 years with pancreatic, bile duct, hepatic, or lymph node lesions accepted EUS-FNA and ROSE.
62542290|NCT02226471||NW-HTN group|Normal weight with hypertension subjects
62715777|NCT06623019||Device 1, Device 2 and Jamar®|As this is a validation study, both criterion, inter-observer and intra-observer validation will be performed. Initially, three repetitions will be performed with each device, leaving between 3 and 5 minutes of rest between devices. 20-30 minutes later, the same process will be repeated but with another researcher giving the orders (interobserver reliability). A few days later the same process is repeated with the first investigator (intra-observer reliability). No person will receive any treatment.
62715778|NCT02412150|EXPERIMENTAL|Dexmedetomidine (Group D)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3."
62715779|NCT02412150|PLACEBO_COMPARATOR|Normal Saline (Group N)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3."
62542291|NCT02226471||OB-NBP group|obese-normal blood pressure subjects
62715780|NCT00781547|EXPERIMENTAL|Recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
62715781|NCT00781547|PLACEBO_COMPARATOR|Placebo|
62715782|NCT04562311|EXPERIMENTAL|Chidamide with Immunotherapy|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
62738088|NCT00998452|ACTIVE_COMPARATOR|MOVE*VETS|Participants will receive the same MOVE! program as the control group plus 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from volunteer veteran peer counselors.
62738089|NCT00431444|ACTIVE_COMPARATOR|Zoledronic Acid|Zoledronic acid 5 mg (single i.v. infusion) + daily oral placebo for 6 months (zoledronic acid group)
62542292|NCT02226471||OB-HTN group|Obese-hypertension subjects
62715783|NCT02374229|EXPERIMENTAL|The study group|"Procedure: mitral valve surgery, surgical ablation of ganglion plexus pulmonary artery.~Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. During the operation, a standard surgical procedure for the treatment of heart valve disease will be complemented by the ablation zone of bifurcation of the pulmonary artery, surgical ablation of ganglion plexus pulmonary artery.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement.~Procedure will be considered effective in the face of declining average pressure in the pulmonary artery for invasive monitoring of 10mm Hg and more."
62715784|NCT02374229|ACTIVE_COMPARATOR|The control group|"Procedure:mitral valve surgery. Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. Patients will be made standard procedure correction mitral valve disease without pulmonary artery denervation.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement only."
62715785|NCT02783274|OTHER|Actis Total Hip System|The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
62715786|NCT06122441|EXPERIMENTAL|Complex lifestyle intervention|Receives a complex lifestyle intervention, a wrist-worn activity tracker, and access to national recommendations on physical activity.
62715787|NCT06122441|ACTIVE_COMPARATOR|Active control|Receives a wrist-worn activity tracker and access to national recommendations on physical activity.
62715788|NCT03200002|EXPERIMENTAL|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
62715789|NCT03200002|EXPERIMENTAL|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
62715790|NCT05870345|OTHER|Ultrasound Exam|"The Study consists of two parts, a feasibility part and an active part.~Participants in the feasibility part of the study only undergo a pocket-sized ultrasound exam and are distinct (unique) group with no overlap or involvement with the active part.~Participants in the active part of the study undergo a pocket-sized ultrasound exam and continue with normal clinically indicated medical care in the ED. The comparison to the ultrasound images is either a X-ray if fracture is suspected or bedside nursemaid reduction if subluxation is suspected (participants will act as their own comparison based on their routine ED clinical management). There is no participation overlap with the feasibility part."
62715791|NCT06293937|EXPERIMENTAL|Numerical label|
62715792|NCT06293937|EXPERIMENTAL|Interpretive text-only label|
62715793|NCT06293937|EXPERIMENTAL|Interpretive magnifying glass icon label|
62542293|NCT05924607|EXPERIMENTAL|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position.Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions)
62715794|NCT06293937|EXPERIMENTAL|Separated interpretive magnifying glass icon label|
62715795|NCT04106115|EXPERIMENTAL|Durvalumab + S-488210/S-488211|Trial treatment for up to 24 weeks of Durvalumab (1500 mg IV infusion every 4 weeks for up to 7 doses) in combination with S-488210/S-488211 vaccine (given as 2 subcutaneous injections of S-488210/Montanide and S-488211/Montanide starting day after first durvalumab dose, then weekly for the first 6 weeks, and then every 2 weeks for a further 9 doses).
62715796|NCT02418520|EXPERIMENTAL|Miswak chewing|Chewing Sticks
62715797|NCT02418520|NO_INTERVENTION|H.Pylori|Oral H.Pylori
62542294|NCT05924607|EXPERIMENTAL|Targeted VMO strengthening|The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
62542295|NCT04807647|EXPERIMENTAL|music band|"The starting person will first talk about white noise and explain how he can direct breastfeeding, and fill the Informed Volunteer Form, Patient Identification Form and Application Registration Form. The mother and baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. During the second breastfeeding, 30 newborn group Orhan OSMAN's Kolik album will be played on the music player Your Baby Don't Cry. After the process is completed, a written response will be received for the data Premature Baby Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form."
62715798|NCT02425397||patients with grade 3 or 4 Brock ototoxicity|
62715799|NCT02425397||patients controls with no signs of ototoxicity|
62715800|NCT03883139|ACTIVE_COMPARATOR|JASPER|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing JASPER. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined \& enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified JASPER for 4 hours a week (4 days, 1 hour per day)."
62715801|NCT03883139|ACTIVE_COMPARATOR|DTT|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing DTT. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined \& enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified DTT for 4 hours a week (4 days, 1 hour per day)."
62715802|NCT06716502|EXPERIMENTAL|Healthy elderly individuals|The performance and easiness to use of the device will be evaluated in patients' self-experience conditions, with elderly participants self-applying the device.
62715803|NCT06716502|EXPERIMENTAL|Patients with mild oxygenation impairment|The efficacy of the device will be assessed in patients with mild oxygenation impairment.
62715804|NCT06561152|EXPERIMENTAL|Dose level 1 (DL1)|DL1 will consist of cladribine 5mg/m2 IV once daily on days 1-3, cytarabine 20mg/m2 IV daily days 1-5, and tagraxofusp 12 mcg/kg IV daily days 4-6. If a DLT is encountered in the first 2 participants, 3 more will be enrolled at the same dose.
62715805|NCT06561152|EXPERIMENTAL|Dose level 2 (DL2)|DL2 will consist of cladribine 5mg/m2 IV once daily on days 1-4, cytarabine 20mg/m2 IV daily days 1-7, and tagraxofusp 12 mcg/kg IV daily days 4-6. If a DLT is encountered in the first 2 participants, 3 more will be enrolled at the same dose.
62164839|NCT05534451|EXPERIMENTAL|video rigid laryngoscope group|Similarly during intubation, the patient should be placed in the supine position with the neutral head. The endoscopic body of video rigid laryngoscope covered by a lubricated endotracheal tube enters the airway through the nasal cavity, then proceeds under visual conditions. When the epiglottis is exposed, if necessary, gently lift the patient's lower jaw so that the glottis is fully visible. The tube is pushed to approach and pass the glottis. Withdraw the endoscopic body while adjusting the depth of tube in the trachea. The intubation ends with tube fixation.
62542296|NCT04807647|NO_INTERVENTION|control|First, the mother will be informed about the study. Then the appropriate position will be given. The informed volunteer form, the Patient Identification Form and the Application Registration Form will be filled. The mother and the baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. No intervention will be applied during the second breastfeeding. After the procedure is completed, a written response will be received with the data Premature Infant Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form.
62542297|NCT02032797|EXPERIMENTAL|A: 7 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
62542298|NCT02032797|PLACEBO_COMPARATOR|B: 5 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
62542299|NCT03946280|OTHER|Fluoroscopy Group|Patient undergoing common flutter (AFL) ablation procedure using conventional X-ray based fluoroscopy for for catheter tracking
62542300|NCT03946280|EXPERIMENTAL|3D Group|Patient undergoing common flutter (AFL) ablation procedure using the low X-ray 3D navigation technique for for catheter tracking
62542301|NCT01727726|PLACEBO_COMPARATOR|Placebo + ADT|Matching Placebo and assigned ADT
62542302|NCT01727726|EXPERIMENTAL|Brexpiprazole + ADT|Brexpiprazole, flexible dose and assigned ADT
62542303|NCT01727726|ACTIVE_COMPARATOR|Seroquel XR + ADT|Seroquel XR, flexible dose and assigned ADT
62542304|NCT00740012|ACTIVE_COMPARATOR|Even, low numbers|They start with a alarm- clock night. No venous blood drawing.
62542305|NCT00740012|ACTIVE_COMPARATOR|Even, high numbers|They start with a nurse performing blood glucose determination. No venous blood drawing.
62542306|NCT00740012|ACTIVE_COMPARATOR|Uneven, low numbers|They start with an alarm- clock night and have venous blood drawing.
62542307|NCT00740012|ACTIVE_COMPARATOR|Uneven, high numbers|They start with a nurse performing blood glucose determination and have venous blood drawing.
62542308|NCT00620399|EXPERIMENTAL|1|brace
62542309|NCT00620399|PLACEBO_COMPARATOR|2|no brace
62542310|NCT06584292|ACTIVE_COMPARATOR|Caudal block|Caudal Block (CB) will applied to the patients.
62542311|NCT06584292|ACTIVE_COMPARATOR|Retrolaminar Block|Retrolaminar Block (RL) will applied to the patients.
62738090|NCT00431444|ACTIVE_COMPARATOR|Raloxifene|Placebo (single i.v. infusion) + oral raloxifene 60 mg/day for 6 months (raloxifene group)
62542312|NCT01410643|ACTIVE_COMPARATOR|Reduced Carbohydrate|42% carbohydrate macronutrient modification
62542313|NCT01410643|ACTIVE_COMPARATOR|STandard Carbohydrate|60% carbohydrate macronutrient modification
62164840|NCT05534451|EXPERIMENTAL|video laryngoscope group|First of all, participants will be asked to take supine position with neutral head. The operator will insert a lubricated endotracheal tube through the nasal cavity into the oropharynx, while he/she holds the handle of video laryngoscope in his/her left hand. Laryngoscope blade can be placed into oral cavity along the right corner of the patient's mouth, and the tongue is pushed to the left by moving the handle. Blade should arrive at a suitable depth to fully expose the epiglottis and glottis. After that, the operator can push the catheter with the right hand to approach and pass the glottis, sometimes Magill forceps are necessary. Finally, the tube is inserted into the trachea to the appropriate depth and fixed firmly.
62168024|NCT04514289||assesment SLND with enjection by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The first group in which the cervix is injected superficially with 1 mL of ICG ( indocyanine green) at 4 and 8 o'clock quadrans.
62168025|NCT04514289||assesment SLND with hysterescopy by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The second one which ICG has injected the uterine cavity during hysteroscopy. Our aim is to assess and compare the performance two approaches for sentinel lymph node ( SLND) biopsy.
62542314|NCT01434810|EXPERIMENTAL|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
62542315|NCT01434810|ACTIVE_COMPARATOR|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
62542316|NCT03108053|ACTIVE_COMPARATOR|Guidewire used|Patients whose semirigid ureteroscopy procedure is conducted with the use of safety guidewire
62542317|NCT03108053|EXPERIMENTAL|No guide wire used|Patients whose semirigid ureteroscopy procedure is conducted without the use of safety guidewire
62542318|NCT01164696||Group 1|
62715806|NCT06561152|EXPERIMENTAL|Dose level 3 (DL3)|DL3 will consist of cladribine 5mg/m2 IV once daily on days 1-5, cytarabine 20mg/m2 IV daily days 1-10, and tagraxofusp 12 mcg/kg IV daily days 4-6. If a DLT is encountered in the first 2 participants, 3 more will be enrolled at the same dose.
62715807|NCT06561152|EXPERIMENTAL|Dose Level -1 (DL-1)|DL -1 will consist of cladribine 5mg/m2 IV once daily on days 1-2, cytarabine 20mg/m2 IV daily days 1-4, and tagraxofusp 12mcg/kg IV daily days 4-6.
62715808|NCT04255615|OTHER|3D Ultrasound with AI|AI tool to assess antral follicle count using 3 D Ultrasound
62715809|NCT06415487|EXPERIMENTAL|ACE2016 ONLY: 1 DOSE|ACE2016 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE2016.
62715810|NCT06415487|EXPERIMENTAL|ACE2016 ONLY: 3 DOSES|ACE2016 recommended dose, monotherapy. Lymphodepleting regimen followed by recommended dose of ACE2016.
62715811|NCT06415487|EXPERIMENTAL|ACE2016 AND PEMBROLIZUMAB: 3 DOSES|ACE2016 recommended dose, in combination with pembrolizumab. Lymphodepleting regimen followed by recommended dose of ACE2016, giving in combination with pembrolizumab.
62715812|NCT05383911|EXPERIMENTAL|Shared Decision Making Toolkit including VR|
62715813|NCT05383911|EXPERIMENTAL|Shared Decision Making Toolkit without VR|
62715814|NCT06032884|EXPERIMENTAL|IHD Group|A central venous access (uncuffed nontunneled catheter, preferentially in the right jugular vein or femoral vein), a biocompatible membrane and bicarbonate dialysate will be used. The investigators will plan at least 3 sessions of 4 to 6 hours each per week with blood flow \> 200ml/min, dialysate flow\>500ml/min, high sodium concentration (\>145 mmol/L) and low temperature (35°C) in the dialysate. the investigators will recommend urea reduction ratio \> 65% for each session.
62542319|NCT03997617|OTHER|Personalized Functional Profiling|
62542320|NCT05321641|EXPERIMENTAL|Text SMS|Adherence messages presented in both text form.
62542321|NCT05321641|EXPERIMENTAL|Graphic SMS|Adherence messages presented in graphic form.
62542322|NCT05321641|EXPERIMENTAL|Both text and graphic|Adherence messages presented in both text and graphic form.
62542323|NCT05321641|PLACEBO_COMPARATOR|Control|Messages on public health promotion not related to epilepsy
62542324|NCT05575206||Patients with rare genetic variant in ELAPOR1 or ELAPOR2|Patients undergo several examinations. Beside anthropometric measurements, bioelectrical impedance analysis, an 2h-oral glucose tolerance test (OGTT) and a hyperglycemic clamp is performed.
62542325|NCT02691143|EXPERIMENTAL|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
62542326|NCT02691143|NO_INTERVENTION|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
62542327|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
62542328|NCT03513133|EXPERIMENTAL|working memory training|Patients with severe TBI will receive a hierarchical training of working memory according to a previously described methodology. They will receive 3 sessions per week during three months (each session=1 h approximately)
62542329|NCT00875797|ACTIVE_COMPARATOR|parentral glutamine|parenteral glutamine given in central venous line in dose up to 30 g par day
62542330|NCT00875797|EXPERIMENTAL|entral glutamine|enteral glutamine given through gastric tube in a dose up to 30 g per day
62542331|NCT01141855|EXPERIMENTAL|Champix plus counselling|varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service
62715815|NCT06032884|EXPERIMENTAL|CRRT group|A central venous access (uncuffed nontunneled catheter, preferentially in the right jugular vein or femoral vein) and a biocompatible membrane will be used with a change of membrane every 72 hours (unless clotting occurs before). Choice between continuous veno-venous hemodialysis (CVVHD), continuous veno-venous hemofiltration (CVVHF), or continuous veno-venous hemodiafiltration (CVVHDF) will be left at physician discretion. The investigators will recommend a minimum delivered dose of dialysis of 20-25 ml/Kg/h of effluent by filtration and/or diffusion.
62715816|NCT03505983|ACTIVE_COMPARATOR|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
62715817|NCT03505983|ACTIVE_COMPARATOR|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
62715818|NCT03505983|ACTIVE_COMPARATOR|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
62715819|NCT06122779|EXPERIMENTAL|BMS-986435|
62715820|NCT06122779|PLACEBO_COMPARATOR|Placebo|
62168026|NCT04717362|EXPERIMENTAL|Standard Reboot with Natesto|Standard Reboot Protocol + Natesto
62542332|NCT01141855|ACTIVE_COMPARATOR|counselling alone|5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).
62542333|NCT05734248|EXPERIMENTAL|Intervention group|"This test region (right or left cheek) will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFL) with a 100 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a operator- and subject- blinded fashion. A lidocaine and tetracaine mixture cream will be applied at each cheek at t1.Ten minutes after cream application (incubation time), the facial filler injections will be performed.~Interventions: AFL Device: AFL Drug: anesthetic mixture cream"
62715821|NCT02616731|ACTIVE_COMPARATOR|Tranexamic acid|
62715822|NCT02616731|ACTIVE_COMPARATOR|Diosmin|
62715823|NCT04670809|EXPERIMENTAL|Clevidipine Butyrate Injection|
62715824|NCT04670809|ACTIVE_COMPARATOR|Ncardipine Hydrochloride Injection|
62715825|NCT05419856|EXPERIMENTAL|4P-004 at 0.3 mg or placebo|4P-004 at 0.3 mg or placebo is administered once intraarticularly in the target knee joint
62715826|NCT05419856|EXPERIMENTAL|4P-004 at 1 mg or placebo|4P-004 at 1 mg or placebo is administered once intraarticularly in the target knee joint
62715827|NCT05419856|EXPERIMENTAL|4P-004 at 3mg or placebo|4P-004 at 3 mg or placebo is administered once intraarticularly in the target knee joint
62715828|NCT05419856|EXPERIMENTAL|4P-004 at 2 mg or placebo|4P-004 at 2 mg or placebo is administered once intraarticularly in the target knee joint
62715829|NCT06510036||test group|Post processing patient data using energy spectrum CT
62715830|NCT06510036||control group|Collect traditional CT data that can correspond to spectral CT since the establishment of PACS database to form a comparison
62715831|NCT00984503|EXPERIMENTAL|Intradermal Juvista|
62715832|NCT00984503|PLACEBO_COMPARATOR|Placebo|
62715833|NCT00984503|EXPERIMENTAL|Intradermal and topical Juvista|
62715834|NCT00984503|PLACEBO_COMPARATOR|Intradermal and topical placebo|
62715835|NCT04172766||Cohort|Participants will be asked to read and sign the study ICF within the app if they agree and are willing to participate. After providing informed consent to participate, participants will be directed to select which data they want to share from the Health App via HealthKit and SensorKit to the Research app. All Research app users are asked to complete contact information and demographic questions that may be common across multiple Research app studies, such as age, race, sex, location of residence, and socioeconomic status. Participants will be asked to complete surveys approximately every other month for a total of about 1.5 hours over the entire year. Participants will be asked to complete three types of hearing tests 2-6 times per year; Interactive Tinnitus Tasks, Pure Tone Audiometry, and Speech in Noise. Participants will also be requested to complete brief on-demand surveys following high sound level measurements from headphones or the watch, at most monthly.
62715836|NCT02655887|EXPERIMENTAL|VENOVO™ Venous Stent.|Implant of the VENOVO™ Venous Stent
62715837|NCT06719284|ACTIVE_COMPARATOR|High frequency oscillation at the settings applied prior to the study|
62715838|NCT06719284|ACTIVE_COMPARATOR|High frequency oscillation with volume targeted ventilation|
62715839|NCT04640142|EXPERIMENTAL|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion
62715840|NCT01572337|EXPERIMENTAL|NIV|Non-invasive ventilation
62715841|NCT01572337|OTHER|Best available treatment|
62715842|NCT00641693|EXPERIMENTAL|1|Nasal Spray
62715843|NCT00641693|PLACEBO_COMPARATOR|2|
62715844|NCT05374109|ACTIVE_COMPARATOR|SYV: Sauti ya Vijana (The Voice of Youth intervention)|"Sessions 1 to 3 - youth name their worries, discuss coping strategies, practice relaxation and breathing exercises, and learn components of cognitive behavioral therapy. Sessions 4 to 6 are dedicated to reflection and processing trauma. Caregivers (supportive adults) are invited at the discretion of enrolled youth to participate in Sessions 1 and 6. Session 7 - youth name their support network and any changes. Sessions 8 and 9 - youth consider stigma, disclosure, reproductive health, condom use, and gender-based violence. Sessions 9 and 10 expand the overall client-centered approach to emphasizing autonomy rather than imposing ideas about what the youth should do. In a final individual meeting, youth revisit their personal values, goals, and strategies for the next 6 months and review their support networks. A final gathering is used to review all session content, to celebrate all that has been shared and learned together, and to distribute certificates of completion."
62715845|NCT05374109|NO_INTERVENTION|SOC - Standard of Care|"Participants in the SOC will not meet in study groups, thus are more at risk for attrition. They will be contacted by the study team on a monthly basis to check in and ensure their documented contact information remains accurate. SOC may vary by site depending on clinic structure, referral systems, and group activities. These differences could potentially dilute the SYV intervention effect and introduce content spillover whereby participants randomized to the intervention discuss intervention content with participants randomized to SOC. As part of the study survey, participants will be asked if they had friends who attended the SYV intervention and if they discussed content. Additionally, as part of the implementation science outcomes (Aim 3), the SOC group structure, adherence counseling, and any mental health referrals offered as part of SOC will be documented."
62715846|NCT05880147|EXPERIMENTAL|App-based consent|Prototype consent app based on REDCap eConsent module
62715847|NCT05880147|ACTIVE_COMPARATOR|Traditional paper-based consent|Traditional paper-based consent
62715848|NCT06520397|EXPERIMENTAL|Dual-target Therapy Group|Participants in this group will receive the standard maintenance dosage of Ustekinumab administered subcutaneously, combined with the addition of Upadacitinib administered orally.
62715849|NCT06520397|ACTIVE_COMPARATOR|Intensified Ustekinumab Monotherapy Group|Participants in this group will receive an additional induction dose of Ustekinumab administered intravenously, followed by maintenance therapy with Ustekinumab.
62715850|NCT02768207|EXPERIMENTAL|Treatment Phase: Vemurafenib+Cobimetinib|Participants with BRAF V600 mutation will receive vemurafenib 960 milligrams (mg) tablets orally twice daily (BID) on Days 1 to 28 along with cobimetinib 60 mg tablets orally once daily (OD) for 21 consecutive days (Days 1 to 21) of each 28-day cycle until disease progression, consent withdrawal, or the development of unacceptable toxicity.
62715851|NCT05639881|EXPERIMENTAL|Experimental: Intervention|Subjects receive a brief intervention to improve their immune health literacy and self-management skills.
62715852|NCT05639881|ACTIVE_COMPARATOR|Services as Usual|Subjects receive routine mental health care.
62715853|NCT04401462|ACTIVE_COMPARATOR|Operative group|tension band wiring or plate fixation
62715854|NCT04401462|ACTIVE_COMPARATOR|Non-operative group|conservative treatment
62715855|NCT06715735|EXPERIMENTAL|Theory-based health behaviour change intervention group|Participants will be enrolled via WeChat and undergo 8 intervention sessions over 12 weeks. The 8 intervention sessions contain two online individual education sessions, two online group music-paced brisk walking training, two group discussions, and two telephone follow-ups. Besides, participants in the intervention group will be required to perform self-music-paced brisk walking 150 minutes/week for three months.
62715856|NCT06715735|NO_INTERVENTION|Control group|Usual care.
62738091|NCT01338519||PCOS and hirsutism|
62715857|NCT04047056|PLACEBO_COMPARATOR|Ergonomic Guidelines Manual|A manual of ergonomic occupational and daily living guidelines will be given to both control and labor kinesiotherapy groups, which is the only approach for the control group initially.
62715858|NCT04047056|ACTIVE_COMPARATOR|Labor Kinesiotherapy in group|The intervention will be performed by a physical therapist, which will consist of preparatory labor kinesiotherapy, which aims to prepare the workers' osteo-articular system for the beginning of the work activity, acting more specifically on those muscle groups that will be most required during the journey which will be identified in the evaluation. Labor kinesiotherapy will be performed in the workplace before the workday and will last 20 minutes, 3 times a week, for 12 weeks.
62715859|NCT04868292|EXPERIMENTAL|SPR206|Healthy subjects meeting eligibility criteria will receive a total of three 100 mg SPR206 intravenous doses administered every 8 hours.
62715860|NCT06719037|EXPERIMENTAL|Endo-Surgi Plus endoscopic group|
62715861|NCT06719037|EXPERIMENTAL|Unilateral biportal endoscopic group|
62715862|NCT06719037|ACTIVE_COMPARATOR|Microdiscectomy group|
62715863|NCT05215002|EXPERIMENTAL|Telephone call|Patient will receive a telephone call in the evening of the day of the surgery or one day after surgery
62715864|NCT05215002|EXPERIMENTAL|No telephone call|Patient will not receive a telephone call in the evening of the day of the surgery or one day after surgery
62715865|NCT06605508||Intracavernosal Injection of Autologous Adipose Stem Cells for Erectile Dysfunction Treatment|In this arm of the study, participants will receive intracavernosal injections of autologous adipose tissue-derived stem cells (ADSC). The ADSC are collected from the participant's own body fat through a minimally invasive liposuction procedure. After processing, the stem cells will be injected directly into the erectile tissue of the penis. This treatment aims to improve erectile function by stimulating tissue regeneration and enhancing blood flow. Participants will be monitored for safety and efficacy, including erectile function assessments using the International Index of Erectile Function (IIEF) and penile hemodynamics measured by Doppler ultrasound. Follow-up evaluations will occur at 3, 6, 9, and 12 months post-treatment.
62715866|NCT06605508||Intracavernosal Injection of Stem cell-derived exosomes|In this arm of the study, participants will receive intracavernosal injections of stem cell-derived exosomes. These exosomes, which are nano-sized extracellular vesicles obtained from cultured stem cells, are rich in growth factors and bioactive molecules that facilitate tissue repair and regeneration. Unlike stem cell therapy, this cell-free approach minimizes potential risks associated with live cell transplantation while still delivering therapeutic benefits. Participants will be monitored for safety and efficacy, including erectile function assessments using the International Index of Erectile Function (IIEF) and penile hemodynamics measured by Doppler ultrasound. Follow-up evaluations will occur at 3, 6, 9, and 12 months post-treatment.
62715867|NCT06090669|EXPERIMENTAL|Dose Escalation|Escalating doses of imatinib to determine the MTD
62715868|NCT06090669|EXPERIMENTAL|Dose Expansion|Imatinib at the MTD
62715869|NCT06090669|NO_INTERVENTION|No Treatment|Collection of blood or marrow only. No treatment.
62715870|NCT06715059|EXPERIMENTAL|Tele-rehab group|The participants who performed exercise program via online platform.
62715871|NCT06715059|EXPERIMENTAL|Home-based group|The participants who performed exercise program in the home.
62715872|NCT03795493|EXPERIMENTAL|Intervention Group|Standard chemotherapy treatment and oncology care plus short-term diet and exercise intervention.
62715873|NCT03795493|NO_INTERVENTION|Control Group|Standard chemotherapy treatment and oncology care.
62715874|NCT05758324|EXPERIMENTAL|Trace elements|Nutri PNEA in a single dose (4 sequences of 10 tablets). Nutri PNEA is a complex of trace elements with the status of a food supplement.
62715875|NCT05758324|PLACEBO_COMPARATOR|Placebo|4 sequences of 10 tablets containing only excipients
62715876|NCT04476576|EXPERIMENTAL|Aerobic|3 months program, 3 times/week aerobic ambulatory program.
62715877|NCT04476576|ACTIVE_COMPARATOR|Flexibility|3 months program, 3 times/week flexibility ambulatory program
62715878|NCT01313507|EXPERIMENTAL|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).
62715879|NCT06411301|EXPERIMENTAL|225Ac-DOTATATE|Dose escalation study to assess the safety and determine the recommended phase II dose, based on time-to-event Bayesian optimal interval design, with a target toxicity rate of 30%. Three dose levels are planned to be evaluated: 5 MBq (starting dose), 7.5 MBq and 10 MBq (maximum dose allowed). The cohort size will be 3, with a maximum of 10 participants within a same dose level, and a maximum of 18 evaluable participants in total. Participants are planned to receive two cycles of intravenous infusion of 225Ac-DOTATATE every 6 weeks (Q6W). Each dose escalation and potential de-escalation step will be decided based on the dose-limiting toxicities (DLT) rate observed during the study treatment period (84 days following the first infusion), in the current dose cohort.
62715880|NCT05536297|EXPERIMENTAL|avacincaptad pegol|Participants will receive avacincaptad pegol 2 mg monthly from Month 1 to Month 17.
62715881|NCT05845112||Cameroon: Primary healthcare clinics|Country with a high burden of HIV associated TB with recruitment to the study occurring at the PHC.
62715882|NCT05845112||Cameroon: District Hospital|Country with a high burden of HIV associated TB with recruitment to the study occurring at the District Hospital.
62715883|NCT05845112||Cameroon: Informal settlements/rural poor active case finding (ACF)|Country with a high burden of HIV associated TB with recruitment to the study occurring through ACF in rural areas and informal settlements.
62715884|NCT05845112||Cameroon: children|Country with a high burden of HIV associated TB with recruitment to the study occurring only in children, an under represented cohort in TB studies.
62715885|NCT05845112||Nigeria: Primary healthcare clinics|Country with a high burden of drug resistant TB infections with recruitment to the study occurring at the PHC.
62715886|NCT05845112||Nigeria: District Hospitals|Country with a high burden of drug resistant TB infections with recruitment to the study occurring at the District Hospital.
62715887|NCT05845112||Nigeria: Nomads|Country with a high burden of drug resistant TB infections with recruitment to the study occurring through ACF targeting Nomad populations.
62715888|NCT05845112||Nigeria: Internally displaced people (IDP)/refugees|Country with a high burden of drug resistant TB infections with recruitment to the study occurring through ACF targeting Internally displaced people (IDP)/refugees.
62715889|NCT05845112||Kenya: Primary healthcare clinics|Country with a high burden of HIV associated TB with recruitment to the study occurring at the PHC.
62715890|NCT05845112||Kenya: District Hospital|Country with a high burden of HIV associated TB with recruitment to the study occurring at the District Hospital.
62715891|NCT05845112||Bangladesh: Primary healthcare clinics|Country with a high TB burden in the general population with recruitment to the study occurring at the PHC.
62715892|NCT05845112||Bangladesh: District Hospitals|Country with a high TB burden in the general population with recruitment to the study occurring at the District Hospital.
62715893|NCT05845112||Bangladesh: Informal settlements active case finding|Country with a high TB burden in the general population with recruitment to the study through active case finding targeting informal settlements.
62715894|NCT05845112||Brazil: Primary healthcare clinics Aracaju|Country with a high burden of HIV associated TB with recruitment to the study occurring at the Primary healthcare clinics in Aracaju.
62715895|NCT05845112||Brazil: Primary healthcare clinics Maceio|Country with a high burden of HIV associated TB with recruitment to the study occurring at the Primary healthcare clinics in Maceio.
62715896|NCT05845112||Viet Nam: Primary healthcare clinics|Country with a high burden of drug resistant TB infections with recruitment to the study occurring at Primary healthcare clinics.
62715897|NCT05845112||Viet Nam: Informal settlements active case finding|Country with a high burden of drug resistant TB infections with recruitment to the study occurring through ACF targeting informal settlements.
62715898|NCT05845112||Viet Nam: Children|Country with a high burden of drug resistant TB infections with recruitment to the study occurring only in children, an under represented cohort in TB studies.
62715899|NCT05845112||Malawi: Primary healthcare clinics|Country with a high burden of HIV associated TB with recruitment to the study occurring at the Primary healthcare clinics in Blantyre, Malawi.
62715900|NCT03781674|ACTIVE_COMPARATOR|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg(4 tablets) daily beginning at 18-22 weeks gestational age
62715901|NCT03781674|ACTIVE_COMPARATOR|progesterone 200mg plus placebo to progesterone 200 mg|Women received vaginal progesterone suppositories in a dose of 200 mg(2 tablets) daily beginning at 18-22 weeks gestational age plus 2tablets placebo to vaginal progesterone
62715902|NCT03781674|PLACEBO_COMPARATOR|placebo to progesterone 400 mg|Women received 4 tablets placebo to vaginal progesterone suppositories
62715903|NCT06716047|PLACEBO_COMPARATOR|placebo|resistant dextrin
62715904|NCT06716047|EXPERIMENTAL|probiotics|lactobacillus
62715905|NCT06718946|EXPERIMENTAL|Oncolytic Virus injection(IDOV-SAFETM)|"Intravenous administration of IDOV-SAFETM every 3 weeks for patients with advanced solid tumors.~Dose cohorts: 3x10\^8 PFU、7x10\^8 PFU 、1x10\^9 PFU、3x10\^9 PFU、7x10\^9 PFU 、1x10\^10 PFU and 3x10\^10 PFU"
62715906|NCT06718582|EXPERIMENTAL|Supine Limb Occlusion Pressure|In the supine LOP session, the BFR cuffs will be pressurized to 60% of the supine LOP. After inflation of the BFR cuffs, four sets of dumbbell wall squats will be performed to failure with a 2-seconds concentric and 2-seconds eccentric cadence, at 20% of their 1RM using 60% of the LOP with 1-minute rest intervals.
62715907|NCT06718582|EXPERIMENTAL|Seated Limb Occlusion Pressure|In the seated LOP session, the BFR cuffs will be pressurized to 60% of the seated LOP. After inflation of the BFR cuffs, four sets of dumbbell wall squats will be performed to failure with a 2-seconds concentric and 2-seconds eccentric cadence, at 20% of their 1RM using 60% of the LOP with 1-minute rest intervals.
62715908|NCT06718582|EXPERIMENTAL|Standing Limb Occlusion Pressure|In the standing LOP session, the BFR cuffs will be pressurized to 60% of the standing LOP. After inflation of the BFR cuffs, four sets of dumbbell wall squats will be performed to failure with a 2-seconds concentric and 2-seconds eccentric cadence, at 20% of their 1RM using 60% of the LOP with 1-minute rest intervals.
62715909|NCT06718582|PLACEBO_COMPARATOR|No BFR cuff|Four sets of dumbbell wall squats will be performed to failure with a 2-seconds concentric and 2-seconds eccentric cadence, at 20% of their 1RM using 60% of the LOP with 1-minute rest intervals with no BFR cuffs
62715910|NCT06715982|EXPERIMENTAL|JAK inhibitors|treated with JAK inhibitors orally for 28 days
62715911|NCT03324789|EXPERIMENTAL|Single Implant Partial Over-denture|The design will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
62715912|NCT03324789|ACTIVE_COMPARATOR|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
62715913|NCT06715644||group 1|patients with respiratory failure treated with high flow nasal cannula
62715914|NCT06715644||group 2|patients with respiratory failure treated with noninvasive ventilation in
62164841|NCT05534451|EXPERIMENTAL|video fiberoptic scope group|It is suggested to apply paraffin oil to the surface of the insertion tube of video fiberoptic scope, where the friction with the inner wall of the endotracheal catheter will be reduced. The insertion tube together with a lubricated endotracheal tube will be placed into the nasopharynx through the nasal cavity of patient who takes supine position with neutral head. Push the insertion tube slowly and continuously along the airway until cuff passes through the glottis. Next carefully, the endotracheal tube can be delivered into the trachea, and the insertion tube can be withdrawn from the trachea. At last, the tracheal catheter can be fixed after the depth is adjusted to an appropriate level.
62715915|NCT04008914||readmission at 30 days|
62164842|NCT01838629||thyroid nodule|
62715916|NCT04008914||readmission at 90 days|
62715917|NCT03130569|NO_INTERVENTION|Control Group|Will simply complete surveys at baseline and at the three-month follow-up.
62164843|NCT02835209||Work of breathing during SBT|Ventilated premature infants born 24 to 34+6 weeks gestational age.
62715918|NCT03130569|EXPERIMENTAL|Web-based Module Group|Participants will complete surveys at baseline. Participants in this arm will be provided with information to access and complete a web-based educational module (AKA the intervention), at the end of which will be given the opportunity to request and complete genetic testing for skin cancer. Participants who elect to complete the genetic testing will receive their genetic testing results along with a two-week follow-up call. All participants will also complete the survey at the three month follow-up.
62715919|NCT03082924|EXPERIMENTAL|Control group|Neither cycle training nor inspiratory muscle training.
62715920|NCT03082924|EXPERIMENTAL|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
62715921|NCT03082924|EXPERIMENTAL|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
62542334|NCT05734248|PLACEBO_COMPARATOR|Control|"A pass with the same fractional carbon dioxide laser with a 100 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to the test region on the other to the intervention cheek (sham AFL) at t0 in a operator- and subject-blinded fashion.~A lidocaine and tetracaine mixture cream will be applied at each cheek at t1.Ten minutes after cream application (incubation time), the facial filler injections will be performed.~Interventions: sham AFL Device: sham AFL Drug: anesthetic mixture cream"
62542335|NCT04093375|EXPERIMENTAL|Radical Prostatectomy|Patients with locally advanced prostate adenocarcinoma receives Radical Prostatectomy with or without enlarged lymph node dissection
62715922|NCT03082924|EXPERIMENTAL|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
62715923|NCT04162548||cardio-relay|"Cardio-relay is a novel collaboration model between hospital-based specialists and primary care, to provide high-quality care to frail patients, relieving their burden to attend multiple hospital specialist visits.~Using telemedicine, it is possible to make measurements where the patient is (at the family clinic at the patient's home). Data are available for all the involved. That is, primary the patient, the relatives and caregivers that the patient wishes help from and health professionals from the family clinics and the hospital. Thereby, the hospital-based specialist supports the family clinic with expert knowledge, the need for attending the hospital facilities reduced to focus on what is strictly needed as specialized provider. Ultimately, the patient can be reached for high-quality care, relieving the patient's burden to attend multiple hospital specialist visits."
62715924|NCT06639386||Parents of children 12-24 months|30 birthing parents and their 12-24 month old infants will be enrolled into the study. Study activities (enrollment and interviews) can be conducted with participants in English, Haitian Creole, or Spanish.
62715925|NCT06639386||Clinicians|35 clinicians at BMC will be recruited to participate in anonymous, one-time interviews. The sample will include 20 Community Health Workers, 10 pediatric/family Medicine clinicians, and 5 Obstetricians. Recruitment will focus on clinicians who have a history of successful vaccine-specific Evidence-Based Interventions (EBIs) beyond BMC and its affiliated CHCs.
62715926|NCT06639386||Evidence Based Intervention (EBI) Experts|15 EBI Experts will be identified from a literature review of published peer-review articles in the fields of vaccine EBIs, implementation science, and prenatal genetic counseling.
62715927|NCT06032754||First group : SSC with PSVD|medical file analysis of patients affected by SSC and PSVD
62715928|NCT06032754||Second group : PSVD without SSC|medical file analysis of patients affected by PSVD only
62715929|NCT06032754||Third group : SSC without PSVD|medical file analysis of patients affected by SSC only
62715930|NCT02842593|EXPERIMENTAL|Resistance exercise training|Whole-body resistance exercise training 4x/week for 12 weeks. Either 'lower-repetition, heavier-load' or 'higher-repetition, lighter-load' intervention.
62715931|NCT02842593|NO_INTERVENTION|Non-exercising control|Continue habitual physical activity for 12 weeks.
62715932|NCT06614036|EXPERIMENTAL|Remimazolam|Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
62715933|NCT06614036|ACTIVE_COMPARATOR|Midazolam|Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
62715934|NCT06376682|EXPERIMENTAL|Interventional arm|Patients treated by percutaneous CT-guided procedures in the bone with the EPIONE® device
62715935|NCT06433700||BAS group|Patients who received bariatric surgery prior to their knee arthroplasty
62715936|NCT06433700||Non-BAS group|Patients who did not receive bariatric surgery prior to their knee arthroplasty
62715937|NCT06202469|EXPERIMENTAL|Supplement 1|Creatine monohydrate
62715938|NCT06202469|EXPERIMENTAL|Supplement 2|Creatine monohydrate plus ubiquinol
62715939|NCT06202469|PLACEBO_COMPARATOR|Placebo|Inulin
62542336|NCT04093375|ACTIVE_COMPARATOR|Radical Radiotherapy|Patients with locally advanced prostate adenocarcinoma receives Radical Radiotherapy with adjuvant androgen deprivation therapy
62542337|NCT00776087|EXPERIMENTAL|1 = Home Monitoring|Remote monitoring of ICD and CRT-D function and patient status
62715940|NCT03672630|ACTIVE_COMPARATOR|2-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
62715941|NCT03672630|ACTIVE_COMPARATOR|3-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
62715942|NCT02375074|EXPERIMENTAL|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
62715943|NCT02375074|EXPERIMENTAL|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment.
62715944|NCT01840033|ACTIVE_COMPARATOR|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
62715945|NCT01840033|EXPERIMENTAL|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
62542338|NCT00776087|ACTIVE_COMPARATOR|2 = No Home Monitoring|Home Monitoring option is switched off
62542339|NCT01617252|EXPERIMENTAL|Optiflow|
62542340|NCT01617252|EXPERIMENTAL|Facial mask|
62542341|NCT03086551|EXPERIMENTAL|Experimental|Application of active continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
62542342|NCT03086551|PLACEBO_COMPARATOR|Control|Application of sham continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
62542343|NCT04210050|OTHER|Usual care|Usual care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
62542344|NCT04210050|ACTIVE_COMPARATOR|Usual care plus NIPPV group only|Usual care for COPD based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines plus use of nocturnal ventilator device using the Breas VIVO 50 home ventilator, Breas Medical (or any newer models as available).
62542345|NCT01795911|EXPERIMENTAL|Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir|"Pegylated Interferon Lambda 180 μg Solution, Subcutaneous Once weekly for 12 weeks;~Ribasphere 1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg oral tablets per day \[subjects should take either 400 mg for subjects \< 75 kg or 600 mg ≥ 75 kg in the morning with food and 600 mg in the evening with food\] for 12 weeks;~Daclatasvir 60 mg oral tablet Once daily for 12 weeks"
62542346|NCT03834285||Cirrhosis in pregnancy|Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.
62542347|NCT03834285||Pregnancy-associated liver diseases|Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.
62542348|NCT03531138|EXPERIMENTAL|Pulmonary rehabilitation group|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week.
62542349|NCT05689957|EXPERIMENTAL|deep neuromuscular block group|Group 1 (Induction with Rocuronium 0.6mg/kg + maintenance with intravenous Rocuronium rocuronium 8-12mcg/kg/minute (0.48-0.72 mg/kg/hour maintain PTC 0-1(deep block). (Study Group) intraoperatively
62542350|NCT05689957|ACTIVE_COMPARATOR|moderate neuromuscular block group|Group 2 (Induction with intravenous Rocuronium 0.6mg/kg + maintenance with intermittent intravenous Rocuronium 0.2mg/kg bolus. maintain PTC \>1, TOF 0-2). Moderate block. (Control Group) intraoperatively
62542351|NCT05616637||Pes Planus|Participants with unilateral pes planus aged 18-40 years will be included in the study.
62542352|NCT03484143|ACTIVE_COMPARATOR|Active Neuro RX Gamma device|Neuro RX Gamma device delivers low-energy near-infrared light, through 5 diodes, to the brain transcranially and intranasally
62542353|NCT03484143|SHAM_COMPARATOR|Sham Neuro RX Gamma device|Sham Neuro RX Gamma device is identical in appearance and sound as the active Neuro RX Gamma device but does not emit low-energy near infrared light
62542354|NCT02750826|OTHER|Arm 1: Health Education Program|Patients will receive a standardized intervention focusing on healthy living. This will include mailings at study entry and one year later describing healthy lifestyle behaviors. All participants will also receive a 2-year subscription to a health magazine. In addition, all study participants will be invited to join twice-yearly Webinars/teleconferences that focus on breast cancer and other health topics, such as treatment updates in breast cancer, management of menopausal side effects, general cancer screening, etc. Finally, the study will also provide birthday and holiday greeting cards and a twice-yearly study newsletter with study updates and other general breast cancer news.
62542355|NCT02750826|OTHER|Arm 2: Health Education Program + Weight Loss Intervention|Patients will receive a standardized intervention focusing on healthy living as described in the Arm 1 (Health Education Program). In addition, patients will utilize a standardized, 2-year, telephone-based weight loss intervention. The intervention will include individual weight loss, caloric restriction, and physical activity goals for each participant. It will be administered through semi-structured phone calls delivered by trained coaches at the BWEL call center and supplemented through print and on-line materials. The intervention will utilize a toolbox approach that will allow for tailoring for the individual participant.
62542356|NCT00704847|ACTIVE_COMPARATOR|1|SMC021 Oral Calcitonin
62542357|NCT00704847|PLACEBO_COMPARATOR|2|SMC021 Placebo
62542358|NCT06551714|EXPERIMENTAL|Control Group|Phase 1 cardiac rehabilitation
62542359|NCT06551714|ACTIVE_COMPARATOR|Study Group|Neurophysiological facilitation techniques in addition to phase 1 cardiac rehabilitation techniques
62542360|NCT05329324||Study Group - Lipedema|Questionnaire for study group
62542361|NCT05329324||Control Group - Acute Subacromial Impingement|Questionnaire for control group
62542362|NCT03893097|ACTIVE_COMPARATOR|Praziquantel|Participants in this arm will receive one dose of PZQ at baseline at 40 mg/kg.
62542363|NCT03893097|EXPERIMENTAL|Artesunate-Mefloquine|Participants in this arm will receive the Artesunate-Mefloquine (fixed-drug)combination at 4 mg/kg artesunate and 8 mg/kg mefloquine at 3 consecutive days. This will be repeated twice; at week 6 and week 12.
62542364|NCT02203331|PLACEBO_COMPARATOR|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
62542365|NCT02203331|EXPERIMENTAL|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
62542366|NCT02203331|EXPERIMENTAL|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
62542367|NCT02203331|EXPERIMENTAL|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
62542368|NCT02203331|EXPERIMENTAL|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
62164844|NCT02800512|ACTIVE_COMPARATOR|Sacrocolpopexy|Robotic sacrocolpopexy
62542369|NCT02203331|ACTIVE_COMPARATOR|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
62715946|NCT06434337||Research Group|Standard-of-care (SOC) procedures will be performed as part of the routine visit, and the provider will collect up to two additional cervical swabs for research. One research cervicovaginal swab may also be self-collected by the patient (optional procedure) in the clinic during the routine visit. All research swab samples, in addition to residual material from standard of care HPV testing, will be transferred to Rice University team for testing and some will be tested on site at the provider facility as described below.
62715947|NCT04122378|EXPERIMENTAL|Treatment Arm|Acupuncture will be provided up to once daily for one or more days till the day of discharge or 5 days, whichever occurs first. Patients will continue to receive their standard pain management regime including IV opioids, ketorolac and fluids. Minimum number of sessions received by the acupuncture group will be one.
62715948|NCT04122378|NO_INTERVENTION|Control Arm|Standard of care for SCD patients who are hospitalized for acute pain and typically includes IV opioids, ketorolac and fluids.
62715949|NCT02913963|ACTIVE_COMPARATOR|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
62715950|NCT02913963|PLACEBO_COMPARATOR|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
62715951|NCT06311591|NO_INTERVENTION|Enhanced Treatment as Usual (ETAU) Historical Control Group|Enhanced Treatment As Usual (ETAU) Historical Control is defined as the treatment provided as part of routine clinical care in the participating EDs during a period of time when Jaspr was not being implemented.
62715952|NCT06311591|EXPERIMENTAL|Jaspr Implementation Group|"This group will receive the enhanced treatment as usual (ETAU) provided as part of routine clinical care at the participating EDs. They will also be considered by their treating team for administration of Jaspr. Jaspr administers a Suicide Status Interview (SSI), Safety Planning, and Lethal means counseling, and allows open access to the Jaspr resource library. They can sign up to receive Jaspr at Home mobile app.~Electronic Health Records (EHR) will be used to assess the outcomes in the 12 months following the index visit."
62715953|NCT02389244|EXPERIMENTAL|Regorafenib|"For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .~For children Age ≥10 years to \<18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent."
62715954|NCT02389244|PLACEBO_COMPARATOR|placebo|Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
62715955|NCT05812339||Motility Disorder Patients|Adults with history of confirmed motility disorder.
62715956|NCT05812339||Healthy Controls|Adults meeting all inclusion and exclusion criteria with no symptoms or history of motility disorder.
62715957|NCT05810519|EXPERIMENTAL|Experimental group|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting.
62715958|NCT05810519|ACTIVE_COMPARATOR|Control group|Participants assigned to the control group will receive an self-care recommendations book.
62715959|NCT02832414|NO_INTERVENTION|Regular program|
62715960|NCT02832414|ACTIVE_COMPARATOR|Intensive weight loss program|
62715961|NCT04907071|EXPERIMENTAL|Malperfusion Primary Cohort|"Patients presenting to hospital with AAD meeting criteria for malperfusion syndrome preoperatively which includes both components:~* Imaging findings indicating reduced flow to the Celiac Trunk, Superior mesenteric artery, either renal artery or either iliac artery~* Clinical stigmata of end organ ischemia (abdominal pain, distended abdomen, oliguria/anuria, reduced pulses, signs of limb ischemia) OR Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte abnormalities)"
62715962|NCT04907071|EXPERIMENTAL|Malperfusion Secondary Cohort:|"Patients who develop new clinical signs or laboratory results indicating distal malperfusion after proximal repair of the AAD is complete and proximal blood flow is redirected into the true lumen.~* New Clinical signs include: Loss of femoral pulses, distended abdomen, reduced urine output, dusky extremities~* New Laboratory signs include: Rising lactate (\>50% above baseline), Rising Creatinine, Metabolic Acidosis, Rising LFTs"
62715963|NCT04907071|EXPERIMENTAL|No Malperfusion Cohort|Patients presenting with AAD with no evidence of malperfusion syndrome preoperatively and postoperatively.
62715964|NCT06243068|EXPERIMENTAL|Educate and Engage|Patients accrued and making treatment decisions while the clinic treating them is implementing Approach 1.
62715965|NCT06243068|EXPERIMENTAL|Educate and Engage Plus Kidney Supportive Care Program|Patients accrued and making treatment decisions while the clinic treating them is implementing Approach 2.
62715966|NCT06593210|EXPERIMENTAL|RSV vaccine group|Single arm open label study of RSV vaccine to all adult transplant participants enrolling into the study.
62715967|NCT06305754|EXPERIMENTAL|Sacituzumab tirumotecan|Participants receive 4 mg/kg sacituzumab tirumotecan via intravenous (IV) infusion every 2 weeks (Days 1, 15, and 29 of every 6-week cycle) until discontinuation criteria is met.
62715968|NCT06305754|ACTIVE_COMPARATOR|Pemetrexed Plus Carboplatin|Participants receive, via IV infusion, 500 mg/m2 pemetrexed every 3 weeks (Days 1 and 22 of every 6-week cycle) plus area under the curve (AUC) 5 mg/mL\*min carboplatin every 3 weeks (Days 1 and 22 of every 6-week cycle for 4 doses), then 500 mg/m2 pemetrexed every 3 weeks until discontinuation criteria is met.
62715969|NCT06163287|EXPERIMENTAL|Supplement|One tablet of hydrogen-rich supplement before breakfast and dinner
62715970|NCT06163287|PLACEBO_COMPARATOR|Placebo|One tablet of hydrogen-free supplement before breakfast and dinner
62715971|NCT02178579||Multiple Myeloma (MM) treatment with bortezomib|No intervention planned.
62715972|NCT02178579||Multiple Myeloma (MM) treatment with carfilzomib|No intervention planned.
62715973|NCT03926455|EXPERIMENTAL|Typhax 0.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
62715974|NCT03926455|EXPERIMENTAL|Typhax 2.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
62715975|NCT03926455|EXPERIMENTAL|Typhax 10 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
62164845|NCT02800512|ACTIVE_COMPARATOR|HUSLS|Vaginal high uterosacral ligament suspension
62164846|NCT06256484|EXPERIMENTAL|ATA3219 Dose Level 1|Participants will receive a single IV infusion of ATA3219 Dose Level 1 on Day 1.
62164847|NCT06256484|EXPERIMENTAL|ATA3219 Dose Level 2|Participants will receive a single IV infusion of ATA3219 Dose Level 2 on Day 1.
62164848|NCT06256484|EXPERIMENTAL|ATA3219 Dose Level 3|Participants will receive a single IV infusion of ATA3219 Dose Level 3 on Day 1.
62164849|NCT06256484|EXPERIMENTAL|ATA3219 Dose Level 4|Participants will receive a single IV infusion of ATA3219 Dose Level 4 on Day 1.
62164850|NCT01585597|EXPERIMENTAL|Mild Hypothermia|Reduction of body temperature to 34 degrees centigrade. This will be accomplished using the Zoll Coolguard .
62164851|NCT01823926|ACTIVE_COMPARATOR|Control Group|Noninvasive ventilation + jet nebulizer
62542370|NCT01243775|EXPERIMENTAL|Belotaxel plus Belloxa|Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)
62542371|NCT06413043|ACTIVE_COMPARATOR|ADD on Selenium|Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
62542372|NCT06413043|NO_INTERVENTION|Placebo|Vitamin B Complex supplementation with Standard Treatment for Grave's Disease
62542373|NCT05992766|EXPERIMENTAL|Reformer Pilates|Reformer Pilates were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). The exercises of the Reformer Pilates were given as individual sessions by the physiotherapist. Reformer Exercises were explained by the physiotherapist in detail to understand the movement and starting position correctly, and the participants were then asked to perform the movements.
62542374|NCT05992766|EXPERIMENTAL|Hammach Yoga|Hammock Yoga were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). Hammock Yoga were given as individual sessions by the physiotherapist.
62542375|NCT05992766|ACTIVE_COMPARATOR|Mat|Traditional mat exercises were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). The mat exercises were applied as a home program. The exercises were visually given with detailed explanations on a piece of paper, and they were checked by telephone every week.
62542376|NCT01559389|EXPERIMENTAL|Female Partners|This arm comprises female partners who receive up to 16 weeks of solifenacin treatment for their UUI symptoms
62542377|NCT01559389|NO_INTERVENTION|Male Partners|This arm comprises healthy male partners
62542378|NCT04529837||Pregnant individuals with Dilapan-S only|22 women received Dilapan-S rods without gauze at start of induction.
62542379|NCT04529837||Pregnant individuals with Dilapan-S plus gauze placement|22 women received Dilapan-S rods with 1 gauze at start of induction.
62542380|NCT02776137|EXPERIMENTAL|Docetaxel Group|Concurrent Chemoradiotherapy With Docetaxel
62542381|NCT06206629||ALS patients|Patients with ALS (Awaji criteria)
62542382|NCT06206629||Non-ALS patients|Patients referred to the neurophysiology unit for a suspicion of ALS du to motor weakness, but in whom the diagnosis is ruled out.
62542383|NCT06206629||Healthy volunteers|Healthy volunteers who will undergo a blink reflex evaluation on ENMG.
62542384|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
62542385|NCT06216678|EXPERIMENTAL|Healthy Diet + Cottonseed Oil (CSOD)|Healthy dietary pattern containing 40g/day/2000 kcal of cottonseed oil (CSO)
62164852|NCT01823926|EXPERIMENTAL|Experimental Group|Noninvasive ventilation + vibrating mesh nebulizer
62164853|NCT05361954|EXPERIMENTAL|STI-1386|A dose-escalation standard 3+3 design will be utilized and a total of 3 dosing cohorts are planned, receiving up to 4 mL of 1 x 10\^6 / 1 mL, 1 x 10\^7 / 1 mL, or 1 x 10\^8 / 1 mL.
62164854|NCT05106023|EXPERIMENTAL|SHR-1701 combined with temozolomide|SHR-1701 combined with temozolomide
62542386|NCT06216678|ACTIVE_COMPARATOR|Healthy Diet + Fatty Acid-Matched Plant Oils (FAMD)|Healthy dietary pattern containing 40g/day/2000 kcal of a blend of plant oils comprising a fatty acid profile that matches the CSOD but devoid of CSO
62542387|NCT06216678|ACTIVE_COMPARATOR|Healthy Diet + PUFA:SFA Ratio-Matched Plant Oil (P:S-MD)|Healthy dietary pattern containing 40g/day/2000 kcal of plant oil that is lower in polyunsaturated fatty acids (PUFA) and saturated fatty acids (SFA) than the CSOD, but with a matched PUFA:SFA ratio and devoid of CSO.
62542388|NCT01666392|EXPERIMENTAL|Fish oil (Omega-3 fatty acid)|2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA
62542389|NCT01666392|PLACEBO_COMPARATOR|Soybean oil|2 capsules/day
62164855|NCT02523443|ACTIVE_COMPARATOR|IV PCA after surgery|general anesthesia with post-operative IV PCA with a standard demand pump
62164856|NCT02523443|EXPERIMENTAL|PCEA during and after surgery|general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump
62164857|NCT04741984|EXPERIMENTAL|MT-201-GBM monocyte vaccine|pp65 monocyte vaccines (MT-201-GBM) - cohorts of patients will receive increasing doses (dose escalation) of MT-201-GBM followed by a dose expansion cohort at the maximum tolerated dose. Patients will receive a total of 3 intravenous vaccines every 4 weeks after completing standard radiation therapy (XRT) and temozolomide (TMZ) and a single course of dose-intensified TMZ.
62542390|NCT01129687||ANSRS group|Patients qualifying for the study.
62542391|NCT04167540|EXPERIMENTAL|Earlier stage PD|
62542392|NCT04167540|EXPERIMENTAL|Later stage PD|
62542393|NCT03203850|EXPERIMENTAL|Deferasirox FCT Arm|An initial dose of deferasirox FCT 7 mg/kg/day was used for 3 months (12 weeks), then was adjusted according to the serum ferritin (SF) level. Deferasirox was interrupted when the study-defined target SF ≤ 100 μg/L was achieved. Deferasirox was to be reinitiated when SF ≥ 300 μg/L, according to deferasirox label.
62715976|NCT03926455|ACTIVE_COMPARATOR|Typhim Vi 25 mcg|Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
62715977|NCT03926455|PLACEBO_COMPARATOR|Placebo (saline)|Placebo control was administered IM Days 0 and 28 ( n=9)
62715978|NCT05269004|EXPERIMENTAL|Ocrelizumab|Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046). Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.
62715979|NCT05000372|EXPERIMENTAL|Feasibility and safety of 68Ga-grazytracer|The purpose of the study is to evaluate the safety and early predictive performance of 68Ga-grazytracer for immunotherapy.
62715980|NCT05906771|PLACEBO_COMPARATOR|CONTROL GROUP|Nutraceutical placebo intake group
62715981|NCT05906771|EXPERIMENTAL|EXPERIMENTAL GROUP|Intake of natural herbal dietary supplement composed of a combination of Hibiscus sabdariffa flowers and Lippia citriodora leaves.
62542394|NCT03203850|ACTIVE_COMPARATOR|phlebotomy|Phlebotomy was conducted at a frequency determined by the physician. Phlebotomy was interrupted when the study-defined target SF ≤ 100 μg/L was achieved. Phlebotomy was to be reinitiated when SF \> 100 μg/L, based on standard of care practice.
62542395|NCT03353883|ACTIVE_COMPARATOR|(Group A) Midluteal Triptorelin depot|infertile women with impaired ovulation who will be subjected to Triptorelin sustained release(Decapeptyl depot 375 mg one injection )at D-21 of previous menstrual cycle Hormon Replacement Therapy (HRT)Cyclo-Progynova (estradiol, norgestrel)(Group A). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-HCG level and was confirmed 2-weeks later by TVU.
62542396|NCT03353883|ACTIVE_COMPARATOR|(Group B)first day Triptorelin depot|infertile women with impaired ovulation who will be subjected toTriptorelin sustained release(Decapeptyl depot 375 mg one injection) at D-1 of menses then Cyclo-Progynova (estradiol, norgestrel) (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-Human Chorionic Gonadotropin level and was confirmed 2-weeks later by TVU.
62542397|NCT02943135|ACTIVE_COMPARATOR|lidocaine in-situ|Self-administered gel 10 min before intrauterine device insertion
62542398|NCT02943135|PLACEBO_COMPARATOR|placebo|Self-administered gel 10 min before intrauterine device insertion
62542399|NCT06455540|EXPERIMENTAL|Nerve block|The superior hypogastric plexus block in this group will contain 20 mL of 0.75% ropivacaine hydrochloride.
62542400|NCT06455540|PLACEBO_COMPARATOR|Placebo block|The superior hypogastric plexus block in this group will contain 20 mL of 0.9% normal saline.
62542401|NCT00794508|EXPERIMENTAL|Retroviral-mediated ADA gene transfer|Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.
62542402|NCT05418114|NO_INTERVENTION|Group B|Patients will be given local infiltration with 9 ml (180 mg) of 2% lignocaine only.
62542403|NCT05418114|ACTIVE_COMPARATOR|Group A|Patients will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate
62542404|NCT01746030||Questionnaires|No treatment
62542405|NCT00627510||A|all patients consecutively admitted to psychiatric inpatient treatment (naturalistic sample from routine psychiatric hospital intake)
62542406|NCT06440993|EXPERIMENTAL|systemic plus ID-RFA|"systemic treatment: - combination treatment for 8 cycles (Q3W):~* Gemcitabine, 1,000 mg/m2 IV, on day 1 and 8,~* Cisplatin, 25 mg/m2 IV, on day 1 and 8~* Durvalumab, 1,500 mg IV, on day 1 followed by~* Durvalumab maintenance, 1,500 mg IV, PLUS • 2 endoscopic intraductal RFA"
62542407|NCT02458859|ACTIVE_COMPARATOR|PICO|PICO Negative Pressure Wound Therapy (NPWT) system
62542408|NCT02458859|NO_INTERVENTION|Standard care|Standard care
62542409|NCT00950365|ACTIVE_COMPARATOR|Arm A (pemetrexed)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62542410|NCT00950365|EXPERIMENTAL|Arm B (pemetrexed disodium, erlotinib hydrochloride)|Patients receive pemetrexed disodium IV as in Arm A and erlotinib hydrochloride PO QD on days 2-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62542411|NCT04128683|EXPERIMENTAL|Healthy Controls|Healthy Control Subjects
62542412|NCT04128683|EXPERIMENTAL|Anorexia Nervosa|Anorexia Nervosa Subjects
62715982|NCT06674473|EXPERIMENTAL|Robot-assisted Rehabilitation|In this clinical trial, 7 patients who meet the inclusion criteria will be enrolled in the experimental group to undergo rehabilitation using a portable isokinetic device.
62715983|NCT06674473|ACTIVE_COMPARATOR|None-robot-assisted Rehabilitation|The control group will consist of 7 patients who meet the inclusion criteria and will undergo traditional bodyweight rehabilitation
62715984|NCT03070678|EXPERIMENTAL|SAR439954 with or without mefenamic acid|Period 1: single oral dose of 400 mg sotagliflozin Period 2: initial loading dose of 500 mg in the morning of Day 1, followed by 250 mg from Day 1 H6 to Day 7 of mefenamic acid and a single oral dose of sotagliflozin on Day 2
62715985|NCT01162551|EXPERIMENTAL|Sirolimus and Methotrexate|"Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days"
62715986|NCT06252909|EXPERIMENTAL|Interpersonal Psychotherapy for Couples|
62715987|NCT06252909|ACTIVE_COMPARATOR|Interpersonal Psychotherapy (Individual)|
62715988|NCT06629688|EXPERIMENTAL|T2DM subjects before and at week 10 of semaglutide therapy|Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
62715989|NCT00546481|EXPERIMENTAL|Correction Phase: CERA|
62715990|NCT00546481|ACTIVE_COMPARATOR|Correction Phase: Epoetin Beta|
62715991|NCT06717191|EXPERIMENTAL|Introduction of Basaglar to insulin treatment regimen|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
62715992|NCT06718140|EXPERIMENTAL|Focused Ultrasound to Location A|Focused Ultrasound will be administered to location A as condition 1. Stimulation will last 1-10 minutes
62715993|NCT06718140|EXPERIMENTAL|Focused Ultrasound to Location B|Focused Ultrasound will be administered to location B as condition 2. Stimulation will last 1-10 minutes
62715994|NCT06718140|EXPERIMENTAL|Focused Ultrasound to Location C|Focused Ultrasound will be administered to location C as condition 3. Stimulation will last 1-10 minutes
62715995|NCT06718140|SHAM_COMPARATOR|Focused Ultrasound to Location D|Focused Ultrasound will be administered to location D as condition 4. Stimulation will last 1-10 minutes
62715996|NCT05320406|ACTIVE_COMPARATOR|Arm I (radiation therapy alone)|Patients undergo definitive radiation therapy alone (IMRT, SBRT, proton therapy, brachytherapy) in the absence of disease progression or unacceptable toxicity.
62715997|NCT05320406|EXPERIMENTAL|Arm II (radiation therapy plus leuprolide)|Patients undergo radiation therapy as in Arm I and receive leuprolide SC or IM every 3 or 6 months. Treatment continues for 6 to 12 months (depending on risk) in the absence of disease progression or unacceptable toxicity.
62715998|NCT05320406|EXPERIMENTAL|Arm III (radiation therapy plus relugolix)|Patients undergo radiation therapy as in Arm I and receive relugolix PO QD. Treatment continues for 6 to 12 months (depending on risk) in the absence of disease progression or unacceptable toxicity.
62715999|NCT01818687|EXPERIMENTAL|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
62716000|NCT03669796|EXPERIMENTAL|supplementary Marine protein hydrolysate|20 mg powder per kg body weight of Marine protein hydrolysate (MPH)
62716001|NCT03669796|PLACEBO_COMPARATOR|control|20 mg powder per kg body weight of casein/maltodextrin
62716002|NCT04494048||Endoscopic Bariatric Therapies (EBT).|patients undergoing Endoscopic Bariatric Therapies
62716003|NCT00760162||HSCB, Brooklyn, NY|State University of New York Brooklyn, NY 11203
62542413|NCT01004744|EXPERIMENTAL|Presurgical oral anastrozole|1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.
62542414|NCT04608110|EXPERIMENTAL|Azacitidine + Cedazuridine|"Drug: Azacitidine~Tablets or capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration~Drug: Cedazuridine~Tablets for oral administration"
62542415|NCT01809782||Study group:20 patients undergoing two stage liver-operation|Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
62542416|NCT01809782||Control group: 20 patients (ASA class II/III)|Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
62542417|NCT01241747|EXPERIMENTAL|Supervised Exercise|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes at an exercise intensity of 40% of exercise capacity.
62542418|NCT01241747|ACTIVE_COMPARATOR|Control|Light resistance training without any walking
62542419|NCT00841828|EXPERIMENTAL|Experimental|Epirubicin + Cyclophosphamide -\> Docetaxel + Lapatinib
62542420|NCT00841828|ACTIVE_COMPARATOR|Control|Epirubicin + Cyclophosphamide -\> Docetaxel + Trastuzumab
62716004|NCT00760162||2. Nephrology Associates,|Scarborough, ON CANADA, LI H IC5
62716005|NCT00760162||3.New York Harbor VA Medical Center|NYU School of Medicine New York, NY.10010
62716006|NCT00760162||4.Hospital Juarez De Mexico|Madero, Mexico, D.FC.P. 07760
62168027|NCT02042170|EXPERIMENTAL|Sr-hGH 0.5 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.5 mg/kg/wk every week himself/herself.
62168028|NCT02042170|EXPERIMENTAL|Sr-hGH 0.7 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.7 mg/kg/wk every week himself/herself.
62542421|NCT03450044|EXPERIMENTAL|Vaccinated|Transfer of autologous dendritic cells interspersed with chemotherapy doses
62716007|NCT00760162||5. Hospital Italiano de Buenos Aires|Buenos Aires, Argentina.
62716008|NCT00760162||6. National Hospital|Abuja, Nigeria
62716009|NCT06718868||Group 1|Patients in Group 1 were defined as those who received PECSII Block in addition to intravenous analgesia.
62716010|NCT06718868||Group 2|Patients in Group 2 were defined as patients who received intravenous analgesia only.
62716011|NCT06411990|EXPERIMENTAL|Endovascular Aneurysm Repair|Fenestrated Endovascular Aneurysm Repair using the LIFE Device System
62716012|NCT05366712|EXPERIMENTAL|Trident® II HA coated shells|Patients will receive a Trident® II acetabular component as part of primary total hip arthroplasty at the study centre. This component is CE marked and widely available for use by UK surgeons. The Trident® II shells are HA coated, cementless, press-fit acetabular shells composed of a Titanium (Ti-6Al-4V) substrate featuring a CpTi roughened surface with PureFix™ HA.
62716013|NCT06718205|EXPERIMENTAL|nimotuzumab|Nimotuzumab+sindilimab+chemotherapy
62716014|NCT06691126|EXPERIMENTAL|Single arm|n=15, single oral dose of 200mg of food-grade terpinolene in 5ml of olive oil
62716015|NCT05304585|EXPERIMENTAL|Regimen M (positive mutation)|Patients receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 2-4, 7-8, and 11-12 and dactinomycin IV over 1-5 minutes or 10-15 minutes on day 1 of cycles 2-5 and 8-14. Patients also receive cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 12-13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo radiation therapy at cycle 5. Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study.
62716016|NCT05304585|EXPERIMENTAL|Regimen VA (VLR RMS)|Patients with VLR RMS receive vincristine intravenously (IV) on day 1 of each cycle and days 8 and 15 of cycles 1, 3, 5, and 7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study.
62716017|NCT05304585|EXPERIMENTAL|Regimen VAC/VA (VL RMS)|Patients with LR RMS receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 1-3. Patients also receive dactinomycin IV over 1-5 minutes or 10-15 minutes and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 5-7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Radiation therapy (if needed) will be administered at cycle 5.Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study.
62716018|NCT04607343|EXPERIMENTAL|Assigned Interventions|Patients will undergo a conventional flexible nasopharyngeal laryngoscopy in which the degree of obstruction and the laryngopharyngeal sensitivity during wakefulness will be determined. Electrostimulation will be applied at different submandibular points with increasing intensity until the contraction of the dilation muscles of the airway or until the patient cannot tolerate the electrostimulation. The presence of contraction of stimulated muscles will be determined by external and endoscopic inspection.
62716019|NCT05615402|EXPERIMENTAL|Training group|Group A: strength training 3x/week + nutrition optimalisation
62542422|NCT03450044|NO_INTERVENTION|Control|Control patients who follow their basic treatment with chemotherapy with the A/C scheme
62716020|NCT05615402|EXPERIMENTAL|Nutrition group|Group B: nutrition optimalisation
62716021|NCT06410144|ACTIVE_COMPARATOR|Program A|Kidney therapy education and support with kidney therapy decision-making.
62716022|NCT06410144|EXPERIMENTAL|Program B|Behavioral: CKD-EDU Palliative care-based decision-support intervention for support with kidney therapy decision-making
62716023|NCT00379678||Information not available|
62542423|NCT03289273||uHCC patients treated with regorafenib|Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)
62542424|NCT05709197|EXPERIMENTAL|Braun anastomosis|Open pancreatoduodenectomy with Braun enteroenterostomy
62542425|NCT05709197|OTHER|Standard Child reconstruction|Open pancreatoduodenectomy only
62542426|NCT03769207|OTHER|Ambulatory ECG|
62542427|NCT03115268|EXPERIMENTAL|Immediate|Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
62542428|NCT03115268|ACTIVE_COMPARATOR|Wait list control|Participants allocated to the wait list control arm will receive 6 months of usual care after randomisation. They will be re-assessed in month 7, and will then receive 6 months of social support groups delivered in EVA Park, with reassessment in month 14.
62542429|NCT06457893|EXPERIMENTAL|Control Group|The study includes with a total of 121 students, 60 in the experimental group and 61 in the control group. No intervention will be made to the students in the control group
62542430|NCT06457893|EXPERIMENTAL|Experimental Group|The study includes with a total of 121 students, 60 in the experimental group and 61 in the control group. The health belief model-based exercise training program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
62542431|NCT03735004|EXPERIMENTAL|TES 60 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 60 Hz) current
62542432|NCT03735004|ACTIVE_COMPARATOR|TES 100 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 100 Hz) current
62542433|NCT03735004|SHAM_COMPARATOR|TES with DC current|Transcranial electrostimulation (TES) with direct current (DC) only
62542434|NCT00670202|EXPERIMENTAL|Drug: Fasudil hydrochloride|Fasudil hydrochloride 40 mg three times a day X 14 days
62542435|NCT00670202|PLACEBO_COMPARATOR|Drug: Placebo oral tablet|Placebo 1 tablet three times daily x 14 days
62542436|NCT02652611|EXPERIMENTAL|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
62542437|NCT02652611|EXPERIMENTAL|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
62542438|NCT04204473|EXPERIMENTAL|TY-9591|Find maximum tolerated dose of TY-9591 given orally. Escalating doses of TY-9591 starting at 20mg daily.
62542439|NCT03526783|OTHER|Failed sleeve gastrectomy - RNYGB|Intervention: Roux en Y gasric bypass (RNYGB)
62542440|NCT03526783|OTHER|Failed sleeve gastrectomy - MGB/OAGB|Inervention: Mini/One anastomosis gasic bypass (MGB/OAGB)
62542441|NCT05231005|EXPERIMENTAL|4th dose BNT162b2 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (30 microgram) of the BNT162b2 vaccine
62542442|NCT05231005|NO_INTERVENTION|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
62542443|NCT01316315|EXPERIMENTAL|Active|N6022 - 5 mg
62542444|NCT01316315|PLACEBO_COMPARATOR|Placebo|Placebo
62542445|NCT01781195||Advagraf-based immunosuppression|50 patients after liver transplantation (25 with a MELD-score ≤20 and 25 patients with a MELD-score \>20) under CNI-based immunosuppression with Advagraf
62542446|NCT01152619|EXPERIMENTAL|1|
62542447|NCT01152619|EXPERIMENTAL|2|
62542448|NCT01152619|PLACEBO_COMPARATOR|3|
62542449|NCT01152619|PLACEBO_COMPARATOR|4|
62542450|NCT01693510|EXPERIMENTAL|Exercise and Nutrition Intervention|Nutrition intervention: The proposed nutrition plan is a high protein (25% energy) diet providing low fat dairy foods and individualized to energy needs. Dairy foods are accepted by women during pregnancy as a healthy choice (from pilot study) and in our recent birth cohort study, women consumed an average of 3 or more servings of dairy per day. Exercise intervention: Most previous studies and published guidance focus on aerobic exercise such as walking as it is the easiest physical activity to implement in pregnancy in terms of setting goals of steps and monitoring of adherence using accelerometer-type devices. Walking is also the most practical since women reduced moderate and vigorous physical activity during pregnancy but levels of walking were maintained.
62542451|NCT01693510|NO_INTERVENTION|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health. In addition, women will have the opportunity to attend one focus group session exploring women's experiences with nutrition, exercise, and weight gain in pregnancy.
62542452|NCT00750581|PLACEBO_COMPARATOR|Standard dose group|The infants randomized to the standard dose group will receive indomethacin (0.1 mg/kg) at 24 hr intervals for 5 days. These infants will also receive 5 extra doses of normal saline infusion of similar volume at 12 hrly intervals between the indomethacin schedules to match the Escalating dose Indomethacin Schedule
62542453|NCT00750581|ACTIVE_COMPARATOR|Escalating dose group|The infants randomized to the Escalating dose group will receive indomethacin started at 0.2 mg/kg/dose every 12 hours for 2 doses with stepwise increment in indomethacin dose by 0.1 mg/kg/dose every 24 hours upto maximum dose of 0.6 mg/kg/dose
62542454|NCT03523299|EXPERIMENTAL|Cryoablation|Participants in this arm will receive cryoablation of their breast tumor two weeks before their routine lumpectomy. They will undergo two blood draws: one before cryoablation (at the time of consent) and one after cryoablation (at the time of surgery).
62542455|NCT03523299|NO_INTERVENTION|Control|Participants in this arm will undergo a blood draw at the time of consent and then will continue with their scheduled lumpectomy (standard of care).
62542456|NCT03927014||Preeclampsia|The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
62542457|NCT03927014||Control|The control groups' samples will obtain during the routine obstetrical care examination in the third trimester of pregnancy.
62542458|NCT03815526|EXPERIMENTAL|Dynamic tape|
62542459|NCT03815526|EXPERIMENTAL|Kinesio tape|
62542460|NCT03815526|EXPERIMENTAL|Sport tape|
62542461|NCT03464630|EXPERIMENTAL|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
62542462|NCT03464630|ACTIVE_COMPARATOR|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
62542463|NCT02790515|EXPERIMENTAL|Treatment|"Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.~Cells for infusion are prepared using the CliniMACS System."
62542464|NCT03485352||Bariatric Surgery patients|Patients attending a private clinic specialized in the treatment of obesity and bariatric surgery. Patients to be analyzed should have a medical indication for bariatric surgery.
62542465|NCT01953978|ACTIVE_COMPARATOR|Dexamethasone|"* Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation~* Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~* Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~* Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
62542466|NCT01953978|PLACEBO_COMPARATOR|Placebo|"* Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation~* Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~* Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~* Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
62716024|NCT00894387|EXPERIMENTAL|Aliskiren|Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.
62716025|NCT00894387|PLACEBO_COMPARATOR|Placebo|Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
62716026|NCT05289752|ACTIVE_COMPARATOR|Group I|GroupI: The retentive caps will be picked up by the indirect method on the cast first, then by the direct method.
62716027|NCT05289752|ACTIVE_COMPARATOR|Group II|GroupII: The retentive caps will be picked up by the direct method on the cast first, then by the indirect method.
62716028|NCT00402987|EXPERIMENTAL|celecoxib 50 mg/50 mg|
62716029|NCT00402987|EXPERIMENTAL|celecoxib 100 mg/placebo|
62716030|NCT00402987|EXPERIMENTAL|celecoxib 100 mg/50 mg|
62716031|NCT00402987|PLACEBO_COMPARATOR|Placebo|
62716032|NCT04623541|EXPERIMENTAL|Epcoritamab in R/R CLL/SLL|In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.
62716033|NCT04623541|EXPERIMENTAL|Epcoritamab in RS|Only in expansion phase.
62542467|NCT04718948||Patients Positive for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention~The group of cases will consist of patients who meet the inclusion and exclusion criteria in the operative note for:~* Transurethral Resection of Bladder Neoplasia (TURBT)~* Radical Cystectomy for Bladder Neoplasia~* Diagnostic ureterorenoscopy and / or laser treatment of ureteral and / or renal pelvis neoplasia~* Segmental ureterectomy with or without ureteral reimplantation~* Nephroureterectomy with or without bladder cuff excission"
62542468|NCT04718948||Patients Negative for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention~The control group will consist of patients who meet the inclusion and exclusion criteria in the operative note for:~* Transurethral Resection of Prostate (TURP)~* Other endoscopic treatments of Benign Prostatic Hyperplasia (BPH)~* Open interventions of prostatic adenomectomy~* Endoscopic lithotripsy interventions of bladder stones or cystotomy with removal of bladder stones~* Rigid and / or flexible ureterorenoscopy for the treatment of kidney and / or ureteral stones~* Placement of ureteral catheter for ureteral and / or renal stones~* Bladder Neck Incision (TUIP)~* Endoscopic urethrotomy"
62542469|NCT04693416|EXPERIMENTAL|Intrapersonal Stigma Reduction|The intervention will include education about substance use disorders (diagnosis, prognosis, and treatment), goal setting to assist the individual in preparing for change, and decisional balance to assist the individual in measuring the costs and benefits about disclosure of mental health problems and exercises to practice how to disclose. Facilitation of an intake assessment for treatment will be offered (with assistance in making the appointment, getting transportation and childcare, and securing a pro-bono status at a outpatient treatment facility).
62542470|NCT04693416|EXPERIMENTAL|Interpersonal Stigma Reduction|The intervention for family members and support persons of enrolled intrapersonal participants will include education about substance use disorders (diagnosis, prognosis, and treatment), stigma reduction, and how to provide support for someone with substance use disorder.
62542471|NCT03486665||Diagnosed with Multiple Sclerosis|Patients previously diagnosed with Multiple Sclerosis
62542472|NCT03486665||Newly Diagnosed with Multiple Sclerosis|Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
62542473|NCT03486665||Healthy Volunteers|Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
62542474|NCT03218124|EXPERIMENTAL|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
62542475|NCT02695810|EXPERIMENTAL|Dapagliflozin|Dapagliflozin, 10 mg per day
62542476|NCT02695810|ACTIVE_COMPARATOR|Metformin|Metformin, 2 x 850 mg per day
62542477|NCT02695810|ACTIVE_COMPARATOR|Exercise|Exercise, interval training
62542478|NCT02695810|NO_INTERVENTION|Control|No intervention
62542479|NCT06633627||Experimental|Patients with dentine sensitivity
62542480|NCT06633627||Control|Patients without dentine sensitivity
62716034|NCT04623541|EXPERIMENTAL|Epcoritamab + Venetoclax in R/R CLL/SLL|In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.
62716035|NCT04623541|EXPERIMENTAL|Epcoritamab + Lenalidomide in RS|Only in expansion phase.
62716036|NCT04623541|EXPERIMENTAL|Epcoritamab + R-CHOP in RS|Only in expansion phase.
62716037|NCT00905229|ACTIVE_COMPARATOR|PO (by mouth)|2.5 mg P.O Vitamin K
62716038|NCT00905229|ACTIVE_COMPARATOR|IV (intravenous )|0.5 mg IV Vitamin K
62716039|NCT06712810|EXPERIMENTAL|Treatment (Q702)|Patients receive Q702 PO QD on days 1-7 and 15-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients who have not progressed/relapsed may continue on therapy at their current dose at MD/patient discretion for an additional 6 cycles. Patients undergo blood and urine sample collection and may undergo PET scan/CT scan or MRI and bone marrow aspiration and biopsy throughout the study.
62716040|NCT04103476|EXPERIMENTAL|BZA/CE|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
62716041|NCT04103476|PLACEBO_COMPARATOR|Placebo|Oral matching placebo
62716042|NCT06718790|ACTIVE_COMPARATOR|Menstrual cup users|Women who will use menstrual cups will be trained on the use of the product and a menstrual cup will be provided for them to use. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd and 6th menstrual cycles and asked to answer questions about their menstrual cup use by sharing an online form.
62716043|NCT06718790|ACTIVE_COMPARATOR|Menstrual pad users|For women in the group who will use menstrual pads, the average number of pads they have used in their previous menstrual cycles will be asked and an appropriate number of menstrual pads will be provided. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd and 6th menstrual cycles and asked to answer questions about their menstrual pad use by sharing an online form.
62542481|NCT03744429|EXPERIMENTAL|Mediterranean Meal Plan|This is a single arm study in which participants will receive meals that follow a Mediterranean diet plan for 4 weeks. Breast milk samples will be collected before, during, and after the intervention period.
62542482|NCT01178710|EXPERIMENTAL|treatment|
62542483|NCT01178710|NO_INTERVENTION|untreated|control
62542484|NCT05088811||Liver cirrhosis|Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT.
62542485|NCT05088811||Hepatocellular Carcinoma|Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination
62542486|NCT05088811||Control|Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2.
62542487|NCT03581591|EXPERIMENTAL|Primary; open label|Injection of Burosumab every two to three weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
62542488|NCT06251050|EXPERIMENTAL|0.03 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid. In this group, 10 ml of 0.03 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
62542489|NCT06251050|EXPERIMENTAL|0.06 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid.. In this group, 10 ml of 0.06 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
62542490|NCT06251050|EXPERIMENTAL|0.10 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid,transparent colorless liquid. In this group, 10 ml of 0.10 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
62542491|NCT06251050|EXPERIMENTAL|0.15 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid. In this group, 10 ml of 0.15 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
62542492|NCT06251050|EXPERIMENTAL|0.21 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid. In this group, 10 ml of 0.21 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
62542493|NCT06251050|ACTIVE_COMPARATOR|Lithium mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions.
62542494|NCT06251050|PLACEBO_COMPARATOR|Placebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid.
62542495|NCT03931525|EXPERIMENTAL|Radiofrequency therapy with drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
62542496|NCT03931525|ACTIVE_COMPARATOR|Radiofrequency Therapy without drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
62542497|NCT03931525|EXPERIMENTAL|Radiofrequency therapy with drug delivery 15 days|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
62542498|NCT03931525|ACTIVE_COMPARATOR|Radiofrequency therapy without drug delivery 15 days|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
62542499|NCT01038362|ACTIVE_COMPARATOR|Almonds|National Cholesterol Education Program Step I diet plus almonds for 6 weeks
62542500|NCT01038362|PLACEBO_COMPARATOR|No Almonds|National Cholesterol Education Program Step 1 diet without almonds for 6 weeks
62542501|NCT01117493|OTHER|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
62542502|NCT01117493|EXPERIMENTAL|Expert Patient Programme|Receives a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
62542503|NCT04556851|EXPERIMENTAL|HSK7653 10 mg|
62542504|NCT04556851|EXPERIMENTAL|HSK7653 25 mg|
62542505|NCT04556851|PLACEBO_COMPARATOR|Placebo|
62542506|NCT03700385|EXPERIMENTAL|IOWA Approach Endocardial Ablation|Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.
62542507|NCT03301571|OTHER|All patients|"All patients will receive the treatment (CABG) and postoperatively three different interventions:~1. Change in preload and afterload~2. Change in inspired oxygen~3. Change in pacemaker modes"
62542508|NCT06091540|EXPERIMENTAL|Feasibility and Efficacy of Individual SH+ Intervention|The first phase of the study involves executing a pilot randomized controlled trial (RCT) with an earthquake-adapted iteration of the SH+ intervention. This phase will introduce modifications to the traditional SH+ approach. Unlike the conventional SH+ manual, which includes audio elements and paired discussions centered around specific topics, the adapted version will omit the audio components. Instead, the intervention will be delivered directly by the psychologist on a one-on-one basis. Additionally, while the original SH+ format involves paired discussions within a group setting, this study will focus on individual sessions. The intervention aims to provide a more personalized approach, promoting a more individualized and humane dimension to the healing process.
62716044|NCT02359565|EXPERIMENTAL|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo standard MRI, DCE permeability MRI, DTI, DSC perfusion MRI, MR diffusion imaging and may undergo MR spectroscopy as well as CSF and blood sample collection during screening and on study.
62542509|NCT06091540|NO_INTERVENTION|Treatment as Usual|Participants will undergo random assignment to either the treatment as usual (TAU) condition or the intervention condition. Upon completion of all measurements, the control condition will be given the opportunity to receive the intervention.
62542510|NCT03494101||Non-typhoid Salmonella infection|Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
62542511|NCT03494101||Acute, infectious diarrhea|Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
62542512|NCT03494101||Healthy individuals|Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.
62542513|NCT02432157|EXPERIMENTAL|Hypertonic saline (HTS)|A protocol of prophylactic 3% HTS as a volume expander with bolus (over 30 minutes) of 3% HTS at a dose of 250 ml every 6 hours for 7 days. This will be given through a central line as soon as possible and within 72 hours of onset of SAH symptoms.
62542514|NCT02432157|ACTIVE_COMPARATOR|Standard fluid|Routine fluid management strategy as pre-specified by our SAH management protocol at Jefferson University Hospital according to the American Heart Association and Neurocritical Care Guidelines for the management of SAH (this includes conventional intravenous fluids or normal saline solutions to maintain a normal hydration status and guided by the treating doctor and daily assessments of fluid balance).
62542515|NCT05018546|EXPERIMENTAL|Gravity Irrigation|RIRS under Gravity irrigation
62542516|NCT05018546|EXPERIMENTAL|Pressure Irrigation|RIRS under Pressure irrigation.
62542517|NCT05063032|EXPERIMENTAL|High-density mapping guided ablation|High-density map and return-cycles map in order to localize the protected isthmus with precision for focal/minimal ablation.
62542518|NCT05063032|ACTIVE_COMPARATOR|Empirical linear ablation|Empirical predefined set of linear ablation.
62542519|NCT01799369|NO_INTERVENTION|Control|Routine post-operative care
62542520|NCT01799369|EXPERIMENTAL|Intervention|Post-operative care influenced by the Surgical Apgar Score
62542521|NCT00282919|EXPERIMENTAL|Azithromycin plus chloroquine|Single Arm, Open label study
62542522|NCT03672045|ACTIVE_COMPARATOR|Carbetocin 10mcg|Patient is given 10 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62542523|NCT03672045|ACTIVE_COMPARATOR|Carbetocin 20mcg|Patient is given 20 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62542524|NCT03672045|ACTIVE_COMPARATOR|Carbetocin 40mcg|Patient is given 40 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62542525|NCT03672045|ACTIVE_COMPARATOR|Carbetocin 60mcg|Patient is given 60 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62542526|NCT03672045|ACTIVE_COMPARATOR|Carbetocin 80mcg|Patient is given 80 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62542527|NCT03672045|ACTIVE_COMPARATOR|Carbetocin 100mcg|Patient is given 100 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
62542528|NCT02875691|ACTIVE_COMPARATOR|green tea extract|Patients were given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules (500 mg) for three months.
62542529|NCT02875691|PLACEBO_COMPARATOR|Placebo|Patients in placebo group received daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
62542530|NCT06155695|EXPERIMENTAL|Auditory Control Enhancement (ACE)|tDCS + ACCT
62542531|NCT06155695|SHAM_COMPARATOR|Sham tDCS + ACCT|Sham tDCS + ACCT
62542532|NCT01888510|EXPERIMENTAL|Diagnostic (imaging studies)|Patients undergo conventional free breathing CT, 4D CT, ABC CT, ABC CBCT, and free breathing CBCT before undergoing radiation therapy.
62542533|NCT04771975|EXPERIMENTAL|MatchQEP group|"Phase 1: All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors \[16-18\]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.~Participants in the MatchQEP group will receive exercise information and program sessions tailored by a qualified exercise professional (QEP) specifically for each BCS in the dyad. Dyads will meet with the QEP via Zoom once per week for 10 weeks for up to 60 minutes. For four weeks following the 10-week intervention period, the QEP will be available for consultation (i.e., a post-intervention tapering period) as needed by the MatchQEP group participants.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group."
62542534|NCT04771975|ACTIVE_COMPARATOR|Match group|"Phase 1: All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors \[16-18\]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.~Participants in the Match (control) group will independently communicate and support each other around exercise for 10 weeks. They will not have any contact with a QEP during this time.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group."
62716045|NCT05567835|EXPERIMENTAL|Arm A: FLOT-TNT ( Investigational Arm)|Arm A is the investigational arm with all 4 cycles of FLOT given as total neoadjuvant chemotherapy prior to surgery. Each cycle is 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in Arm A is 8. Every effort will be made to have surgery in week 20 ( -1 to +2 weeks), 4 weeks post C4 on arm A.
62542535|NCT02506283|EXPERIMENTAL|cooling intervention|subjects in this study receive a single pre-exercise (3x MVC) or post-exercise intervention (3x 30 counter movement jumps), consisting of an external cooling application (Zamar Therapy CT clinic) applied to both thighs. Both interventions have a duration of 20 minutes and a temperature of 8°C
62542536|NCT02506283|SHAM_COMPARATOR|thermoneutral intervention|subjects in the control group receive a single pre-exercise (3x MVC) or post-exercise (3x 30 counter movement jumps) sham intervention, consisting of a 20 minute external thermoneutral application (Zamar Therapy CT clinic) applied to both thighs. Both sham interventions have a duration of 20 minutes and a temperature of 32°C.
62542537|NCT04670276|EXPERIMENTAL|Experimental arm|Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction
62542538|NCT03079635|ACTIVE_COMPARATOR|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
62542539|NCT03079635|ACTIVE_COMPARATOR|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
62542540|NCT03886415|EXPERIMENTAL|Jaktinib hydrochloride tablets 1|This is the dose group was given once a day. Jaktinib hydrochloride tablets 1 200mg qd dose group
62542541|NCT03886415|EXPERIMENTAL|Jaktinib hydrochloride tablets 2|This is the dose group was given twice a day. Jaktinib hydrochloride tablets 2 100mg bid dose group
62542542|NCT05222698|ACTIVE_COMPARATOR|Group A|Segmental free latissimus muscle trasfer to the face.
62542543|NCT05222698|ACTIVE_COMPARATOR|Group B|Free gracillis muscle trasfer to the face.
62542544|NCT02309138|ACTIVE_COMPARATOR|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of \>130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
62542545|NCT02309138|ACTIVE_COMPARATOR|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
62542546|NCT06634303|EXPERIMENTAL|Post-Mechanical Cerebral Cooling|Acute ischemic stroke patients undergoing mechanical thrombectomy.
62542547|NCT06410313|EXPERIMENTAL|ChampioNIR™ Ridaforolimus Eluting Peripheral Stent System|ChampioNIR™ Ridaforolimus Eluting Peripheral Stent System
62542548|NCT06625567|NO_INTERVENTION|Control group|Patients undergoing hysteroscopy without anesthesia. Patients will receive the standard education regarding the procedure.
62542549|NCT06625567|EXPERIMENTAL|Intervention group|Patients undergoing hysteroscopy without anesthesia. Patients will receive the standard education regarding the procedure and will also watch a short educational video.
62542550|NCT05439083|EXPERIMENTAL|Immunosuppressed Group|"N=90 Immunosuppressed patients, consisting of HIV-infected children and adolescents, hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant (SOT) recipients and post-chemotherapy patients (PCT) under follow up at Hospital La Paz in Madrid Spain.~9-valent HPV vaccine: three-dose schedule: Months 0-2-6."
62542551|NCT05439083|OTHER|Control Group|N=30 Healthy controls aged 9-14 9-valent HPV vaccine: two-dose schedule: Months 0-6.
62542552|NCT01966588||Metabolic Arm|Blood samples for whole genomic/transcriptomic sequencing; administration of the UKU Side Effect Rating Scale.
62542553|NCT01966588||Neutropenia/Immune System Arm|Blood samples for whole genomic/transcriptomic sequencing
62542554|NCT01994291|ACTIVE_COMPARATOR|Arm 1|Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
62542555|NCT01994291|EXPERIMENTAL|Arm 2|Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
62542556|NCT06069115||Main cohort group|All participants will be included in the same group, with no subgrouping within this study.
62542557|NCT05013437|EXPERIMENTAL|Evomela (Melphalan)|Participants will receive Evomela 16 mg/m2 on day 1 of the study only. Evomela will be given as IV infusion over 30 minutes after administration of 500 cc normal saline as pre-hydration and pre-medications Prochlorperazine, Acetaminophen, and Diphenhydramine.
62542558|NCT03337958|NO_INTERVENTION|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
62542559|NCT03337958|EXPERIMENTAL|INTERVENTION GROUP|The group received the standard medical and pharmacological care provided by the hospital. In addition, an educational program on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program, furthermore, the technique of inhaler use was trained.
62542560|NCT03140371|EXPERIMENTAL|High energy high protein peptide feed|"This is a one-arm study. Each patient recruited onto the study will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
62542561|NCT05501990|EXPERIMENTAL|Health intervention based on intelligent applet|Health interventions using electronic applet, including nutrition, psychology, and patient self-management components.
62542562|NCT02897245||Patient with intentionally stop|
62542563|NCT03103841||Children and young people with epilepsy|Sleep studies \[Polysomnography\] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
62542564|NCT03103841||Healthy controls|Sleep studies \[Polysomnography\] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
62542565|NCT00933647|EXPERIMENTAL|Yerba Mate Tea|Subjects will drink 1000ml/day of yerba mate tea for 8 weeks.
62542566|NCT00933647|ACTIVE_COMPARATOR|Green Tea|Subjects will drink 1000ml/day of green tea for 8 weeks.
62542567|NCT00933647|PLACEBO_COMPARATOR|Apple Tea|Subjects will drink 1000ml/day of apple tea for 8 weeks.
62542568|NCT05795647|EXPERIMENTAL|Pentoxifylline|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
62542569|NCT01345578|EXPERIMENTAL|Hepatocyte Transplantation|See Below
62542570|NCT05360485|ACTIVE_COMPARATOR|Fitbit-Only Self-Monitoring|Control participants will be sent a Fitbit and study-provided account and will self-monitor physical activity for the duration of the study period (2 months).
62542571|NCT05360485|EXPERIMENTAL|MOV'D plus Fitbit Self-Monitoring|Treatment participants will be sent a Fitbit and study-provided account, and assigned to a private, study-created Twitter support group of 10 participants. Within the private group of 10, each participant is also further paired with a peer to be that person's peer coach, setting weekly exercise snack goals and practicing behavior change techniques.
62542572|NCT03734315||Ostenil®|3-5 injections of sodium hyaluronate 1 % (20 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
62542573|NCT01697553|EXPERIMENTAL|Home automation pack coupled to teleassistance service|
62542574|NCT01697553|ACTIVE_COMPARATOR|Home without automation pack coupled to teleassistance service|
62542575|NCT05349552||Chest Wall Type|The lesion is directly adjacent (less than 1cm) or overlapped with the chest wall.
62542576|NCT05349552||Peripheral Type|The lesion is more than 1cm away from the chest wall and more than 2cm away from the bronchial tree.
62542577|NCT05349552||Central Type|The lesion is less than 2cm away from the bronchial tree.
62542578|NCT05349552||Ultral-central Type|The lesion is directly adjacent or overlapped with the mediastinal structure.
62542579|NCT05209165|EXPERIMENTAL|Semaglutide|
62542580|NCT05209165|PLACEBO_COMPARATOR|Placebo|
62542581|NCT01862484|EXPERIMENTAL|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
62542582|NCT01862484|SHAM_COMPARATOR|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet.
62542583|NCT01453179|EXPERIMENTAL|Aldara 5% Cream|
62542584|NCT01453179|ACTIVE_COMPARATOR|Solaraze 3% Gel|
62542585|NCT02794597|NO_INTERVENTION|Opioid Medication-Assisted Treatment only|Usual care - Opioid Medication Assisted Treatment
62164858|NCT06509477|EXPERIMENTAL|Lunaphil Ultra (by Espad Pharmed Co.)|Lunaphil Ultra (by Espad Pharmed Co.) will be administered over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs. In case of suboptimal correction of NLFs at week 2 after the initial treatment, the treating investigator will be directed to retreat the under corrected NLF(s).
62542586|NCT02794597|EXPERIMENTAL|Intervention|Peer led, behavioral sexual health intervention: Sexual Health Initiative for Navigation and Empowerment (SHINE).
62542587|NCT05057806|EXPERIMENTAL|Empagliflozin Group|Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months
62542588|NCT05057806|PLACEBO_COMPARATOR|Placebo group|Subjects will be randomized to receive the empagliflozin placebo for 3 months
62542589|NCT05164783|EXPERIMENTAL|Participants|Intervention: use of SCP
62542590|NCT02714426|ACTIVE_COMPARATOR|Brain Health|In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop), Positive and Negative Affect Scale (PANAS), Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS), Five Facet Mindfulness Questionnaire (FFMQ), Emotion Regulation Questionnaire (ERQ), State-Trait Anxiety Inventory (STAI), and Starkstein Apathy Scale (AS). In weeks 4-11, participants receive the Brain Health control instruction.
62542591|NCT02714426|EXPERIMENTAL|Mindfulness-inspired Treatment/Testing|"Participants receive all of the same measures as the active comparator Brain Health condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment"
62542592|NCT05422638|EXPERIMENTAL|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
62542593|NCT05422638|ACTIVE_COMPARATOR|PCT|8-week health promotion group focused on providing support and facilitating problem solving
62542594|NCT02174289|ACTIVE_COMPARATOR|Active Bi-ventricular Pacing|
62542595|NCT02174289|PLACEBO_COMPARATOR|No Biventricular pacing|
62542596|NCT03619200||Fallers|"Participants who reported at least one fall in the 12-months follow-up period were categorized as fallers."
62542597|NCT03619200||Non-Fallers|"Participants who did not report any fall in the 12-months follow-up period were categorized as non-fallers."
62542598|NCT03714828|EXPERIMENTAL|Treatment (talimogene laherparepvec)|The subject participation period will be approximately 48 weeks. This will include a screening visit, 4 injection visits and 5 follow up visits. Total length of study/patient is 8.5 to 10.5 months. TVEC will be administered by injection with a needle directly into one or more tumors.
62542599|NCT03922776|EXPERIMENTAL|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~* at diagnosis, before chemotherapy (pre-CT)~* after chemotherapy (post-ct)~Intervention : Collection of two blood samples (5mL)~* before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~* and then, after chemotherapy (post-CT), up to 3 months after enrollment"
62542600|NCT04762277|EXPERIMENTAL|Spesolimab|
62542601|NCT04762277|PLACEBO_COMPARATOR|Placebo|
62542602|NCT03651830|EXPERIMENTAL|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
62716046|NCT05567835|EXPERIMENTAL|Arm B: FLOT-POP ( Standard Arm)|Arm B us the standard perioperative arm with 2 cycles of pre-operative FLOT ( 4 treatment sessions) and 2 cycles ( 4 treatment sessions) of post-operative FLOT. Post-surgery FLOT will start 4-6 weeks post surgery. Each cycle of chemotherapy consists of 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in arm B is 8. Every effort should be done to have surgery done in week 12 ( -1 to +2 weeks) post completion of cycle 2 on ARM B.
62716047|NCT03092180||Idiopathic inflammatory myopathies 1|Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset
62716048|NCT03092180||Idiopathic inflammatory myopathies 2|Intravenous infusion with methyprednisolone at disease onset
62716049|NCT05791864|EXPERIMENTAL|Cohort 1: Main Treatment Arm|2×10\^10 GC/eye
62716050|NCT05791864|EXPERIMENTAL|Cohort 2: Main Treatment Arm|6×10\^10 GC/eye
62716051|NCT05791864|EXPERIMENTAL|Expansion Cohort: Early Treatment Arm|Dose level to be determined based on Independent Data Monitoring Committee review.
62716052|NCT05791864|EXPERIMENTAL|Expansion Cohort: Main Treatment Arm|Dose level to be determined based on Independent Data Monitoring Committee review.
62716053|NCT05791864|EXPERIMENTAL|Expansion Cohort: Late Treatment Arm|Dose level to be determined based on Independent Data Monitoring Committee review.
62716054|NCT05305924|EXPERIMENTAL|Fulvestrant plus Abemaciclib Arm with Fulvestrant Run-In|"A 1-month (28 days) run-in of fulvestrant will precede fulvestrant plus abemaciclib treatment. Fulvestrant at a dose of 500 mg will be administered intramuscularly (IM) into the buttocks slowly (1-2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of the run-in period.~After the fulvestrant run-in, fulvestrant plus abemaciclib will be administered in 28-day cycles until disease progression or unacceptable toxicity. Fulvestrant (500 mg IM) will be administered on Day 1 of each 28-day cycle. Abemaciclib at a dose of 150 mg will be given p.o. BID on Days 1-28 of each cycle"
62716055|NCT01193101|EXPERIMENTAL|LCZ696 100 mg|LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
62716056|NCT01193101|EXPERIMENTAL|LCZ696 200 mg|LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
62716057|NCT01193101|EXPERIMENTAL|LCZ696 400 mg|LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.
62716058|NCT01193101|PLACEBO_COMPARATOR|Placebo|Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.
62716059|NCT00265850|ACTIVE_COMPARATOR|Arm A: FOLFOX or FOLFIRI + bevacizumab|Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
62716060|NCT00265850|EXPERIMENTAL|Arm B: FOLFOX or FOLFIRI + cetuximab|Patients receive cetuximab 400mg/m\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
62716061|NCT00265850|EXPERIMENTAL|Arm C: FOLFOX or FOLFIRI + cetuximab + bevacizumab|Patients receive cetuximab 400mg/m\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
62716062|NCT05901649||Apalutamide Plus Androgen Deprivation Therapy (ADT)|Participants with metastatic hormone-sensitive prostate cancer (mHSPC) will be observed who are being treated with apalutamide under clinical practice setting. Only data available per routine clinical practice will be collected within this study.
62716063|NCT05901649||Enzalutamide Plus Androgen Deprivation Therapy (ADT)|Participants with metastatic hormone-sensitive prostate cancer (mHSPC) will be observed who are being treated with enzalutamide under clinical practice setting. Only data available per routine clinical practice will be collected within this study.
62716064|NCT06241300|EXPERIMENTAL|Chicago Parent Program|Half of the dyads will be randomized to participant in the Chicago Parent Program (CPP), an evidence-based parenting preventive intervention for urban poor parents with children between the ages of 2-8 with behavior problems. The Chicago Parent Program consists of 12 groups sessions (11 weekly, 1 booster session). The groups are co-facilitated by two certified group leaders. Parents learn positive parenting and effective child behavior management skills, strategies to support the child's attention, literacy, and social skills, and stress management and problem solving techniques. Skill building is accomplished through watching videos of real-life parents and children during parent-child interactions, group discussion, role-playing, and weekly homework assignments.
62716065|NCT06241300|NO_INTERVENTION|Control Condition|Half of the dyads will be randomized to the no intervention arm.
62716066|NCT04062058|EXPERIMENTAL|Total Neoadjuvant Chemoradiotherapy|Total neoadjuvant chemoradiotherapy arm receives intensity-modulated neoadjuvant chemoradiotherapy (45Gy in 25 fractions) concurrently with oral S-1(40-60mg/m2, orally twice daily every weekday) followed by six cycles of SOX neoadjuvant chemotherapy and surgery
62716067|NCT01173679|OTHER|dasatinib, rituximab, fludarabine|Single-arm, open-label
62716068|NCT06719466|EXPERIMENTAL|linoleic acid (LA)|diet intervention（diet guidance with low linoleic acid (LA) ）
62716069|NCT06155357|EXPERIMENTAL|Lifestyle Interventions Pre-Procedure|Subjects with paroxysmal or persistent atrial fibrillation (AF) who are scheduled to undergo elective catheter ablation of AF will participate in a 12-week multicomponent lifestyle intervention program.
62716070|NCT06155357|NO_INTERVENTION|Standard of Care|Subjects who have previously undergone catheter ablation of atrial fibrillation (AF) as part of their standard of care will have medical chart review completed to gather information.
62168029|NCT02042170|ACTIVE_COMPARATOR|Daily hGH 0.37 mg/kg/wk|Patients inject Eutropin (daily hGH) 0.37 mg/kg/wk everyday for the first 6days a week himself/herself.
62716071|NCT06252597|EXPERIMENTAL|education and training|After implementation of the pre-interview and determination/performance of necessity, education and training at a regularly scheduled occupational therapy clinic visit will be performed with handouts, verbal education, hands-on training, and video training.
62716072|NCT03571971|EXPERIMENTAL|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
62716073|NCT03571971|ACTIVE_COMPARATOR|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
62716074|NCT05775510||Pilot Phase Cohort|
62716075|NCT05775510||Data at Scale Phase Cohort|
62716076|NCT02403544|EXPERIMENTAL|CCRT Arm|Patients recruited will be treated by concurrent chemoradiotherapy with IGRT and two cytotoxic agents: capecitabine and oxaliplatin. Capecitabine will be taken orally twice a day, from D1 to D14 while oxaliplatin will be given intravenously on D1 and D8, every 21 days. The doses of the two drugs will be escalated alternatively in each level group. The radiation will be given by IGRT and the dose is between 45 to 54Gy, 1.8-3Gy per fraction.
62716077|NCT03179761|EXPERIMENTAL|Group I (HD-TIV)|Patients received HD-TIV intramuscularly once at baseline (day 0) and again between 28-42 days later.
62716078|NCT03179761|ACTIVE_COMPARATOR|Group 2(SD-QIV)|Patients received SD-QIV intramuscularly once at baseline (day 0) and again between 28-42 days later.
62716079|NCT06709287||fixed orthodontic treatment|The patients in this group were treated with conventional braces.The patients were treated with 0.018-inch slot metal Roth brackets. Pretreatment (T0) digital lateral cephalometric radiographs were taken from the patients to compare pretreatment characteristics between the groups.The digital periapical radiographs taken with the paralleling technique were obtained.The digital periapical radiographs taken with the paralleling technique were obtained from the maxillary and mandibular incisors at the beginning of the treatment (T0) and after 6 months (T2).Probing depth, plaque index, and bleeding on probing were record at T0, after 3 months of treatment(T1), and at 6months(T2) to evaluate the periodontal status of the patients.A 5-question survey was used to evaluate pain levels, and a 9-question survey was used to evaluate chewing performance.
62716080|NCT06709287||clear aligners|The patients in this group were treated with clear aligners. Anterior teeth movement started from the first pair of aligners. Microfill and brace paste primers were used for bonding the attachments. Pretreatment (T0) digital lateral cephalometric radiographs were taken from the patients to compare pretreatment characteristics between the groups.The digital periapical radiographs taken with the paralleling technique were obtained.The digital periapical radiographs taken with the paralleling technique were obtained from the maxillary and mandibular incisors at the beginning of the treatment (T0) and after 6 months (T2).Probing depth, plaque index, and bleeding on probing were record at T0, after 3 months of treatment(T1), and at 6months(T2) to evaluate the periodontal status of the patients.A 5-question survey was used to evaluate pain levels, and a 9-question survey was used to evaluate chewing performance.
62716081|NCT06360575|EXPERIMENTAL|Treatment (Crizotinib)|Patients receive crizotinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy on study and undergo radiologic evaluation and blood sample collection throughout the study.
62716082|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
62716083|NCT05117996|ACTIVE_COMPARATOR|Standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
62716084|NCT05117996|EXPERIMENTAL|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
62716085|NCT02878876|EXPERIMENTAL|Sequence A1-A2|Dietary Supplement: Oral consumption of milk with sequence A1-A2
62716086|NCT02878876|EXPERIMENTAL|Sequence A2-A1|Dietary Supplement: Oral consumption of milk with sequence A2-A1
62716087|NCT01461525|EXPERIMENTAL|Sphincter preservation surgery|Temporary ileostomy with anal sphincter preservation
62716088|NCT01461525|EXPERIMENTAL|Abdominoperineal Resection|Permanent colostomy with total anal sphincter sacrifice
62716089|NCT01697709|PLACEBO_COMPARATOR|Placebo|Placebo medication
62716090|NCT01697709|EXPERIMENTAL|quetiapine|Quetiapine treatment
62716091|NCT06412107|EXPERIMENTAL|True acupressure group|True self-acupressure plus routine methods of treatment and care.
62716092|NCT06412107|SHAM_COMPARATOR|Sham acupressure group|Same dose as the true acupressure group but on the sham acupoints plus routine methods of treatment and care.
62716093|NCT06412107|OTHER|Usual care group|Routine methods of treatment and care.
62716094|NCT03766984|EXPERIMENTAL|Diclofenac 25 mg|Participants receive 1 tablet of diclofenac sodium 25 mg with 250 milliliters of purified water.
62716095|NCT03766984|EXPERIMENTAL|Tramadol 25 mg|Participants receive 1 tablet of tramadol hydrochloride 25 mg with 250 milliliters of purified water.
62716096|NCT03766984|EXPERIMENTAL|Diclofenac/Tramadol 25 mg/25 mg FDC|Participants receive 1 fixed-dose combination tablet of diclofenac sodium 25 mg/tramadol hydrochloride 25 mg with 250 milliliters of purified water.
62716097|NCT05023460|ACTIVE_COMPARATOR|Paresthesia-free (burst) ONS|"Implanted lead and impulse generator (IPG), paresthesia-free (burst) active stimulation.~Lead implanted subcutaneously over greater occipital nerves. Implanted IPG capable of providing paresthesia-free stimulation continuously."
62716098|NCT05023460|PLACEBO_COMPARATOR|Placebo|Implanted lead and IPG, deactivated.
62716099|NCT00069641|EXPERIMENTAL|Idursulfase weekly (0.5 mg/kg)|
62716100|NCT00069641|EXPERIMENTAL|Idursulfase every other week (0.5 mg/kg)|
62716101|NCT00069641|PLACEBO_COMPARATOR|Placebo|
62716102|NCT06715462|EXPERIMENTAL|N0750|"* Phase 1 of the Dosage Titration: 3 capsules/day~* Phase 2 of the Dosage Titration: 5 capsules/day~* Treatment: 4 capsules/day~* Withdrawal: 4 capsules/day"
62716103|NCT06715462|ACTIVE_COMPARATOR|Cymbalta®|"* Phase 1 of the Dosage Titration: 3 capsules/day~* Phase 2 of the Dosage Titration: 5 capsules/day~* Treatment: 4 capsules/day~* Withdrawal: 4 capsules/day"
62716104|NCT06715462|ACTIVE_COMPARATOR|Lyrica®|"* Phase 1 of the Dosage Titration: 3 capsules/day~* Phase 2 of the Dosage Titration: 5 capsules/day~* Treatment: 4 capsules/day~* Withdrawal: 4 capsules/day"
62716105|NCT04841993|EXPERIMENTAL|Oral formulation: Cannabis decoction|From a standardized preparation cannabis Cannabis FM2 (THC) (\~ 6%) and (CBD) (\~ 8%) ,cannabis decoction will be prepared at the moment by putting female inflorescences in cold water brought to a boil, boiling for 15 minutes and using 500 mg of medicinal cannabis for 500 ml of water.
62716106|NCT04841993|EXPERIMENTAL|Oral formulation: Cannabis oil|From a standardized preparation cannabis Cannabis FM2 (THC) (\~ 6%) and (CBD) (\~ 8%), cannabis oil is prepared the day before the experimental session with 500 mg of female inflorescences in 5 ml of olive oil from the European Pharmacopoeia, heating in a water bath (approximately 98 ° C) for 120 minutes and cooling the oil samples. at room temperature.
62716107|NCT04841993|EXPERIMENTAL|Vaporized formulation: Cannabis vaporized|From a standardized preparation cannabis Cannabis FM2 (THC) (\~ 6%) and (CBD) (\~ 8%), 100 mg of Cannabis inflorescences of FM2 standardized cannabis were administered through Volcano vaporizer .
62716108|NCT01127919||Low Commitment|Group 1 participants will take a 1-credit hour course that involves exercise training only.
62716109|NCT01127919||High Commitment|Group 2 participants will take a 3-credit hour course that involves exercise training plus an online cognitive component that provides information on fitness and health topics and includes quizzes and other written course work
62716110|NCT01127919||Non-Exercise|Group 3 participants will take the cognitive component of the formal course but will not partake in the formalized exercise program for a period of 35 weeks.
62716111|NCT06505187|EXPERIMENTAL|Celecoxib for pain management|Participants receive celecoxib in addition to Tylenol and oxycodone
62716112|NCT06505187|SHAM_COMPARATOR|Placebo for pain management|Participants receive placebo in addition to Tylenol and oxycodone
62716113|NCT06556485|ACTIVE_COMPARATOR|Ablation group|Primary prophylactic ablation
62716114|NCT06556485|ACTIVE_COMPARATOR|Control group|Optimal medical therapy
62542603|NCT03651830|ACTIVE_COMPARATOR|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
62542604|NCT01056354||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
62716115|NCT04991857|EXPERIMENTAL|The technology-based family-centered empowerment program for heart failure (T-FAME-HF)|The T-FAME-HF is a 16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits. The Program includes 3 four-week phases, which followed by 2 bi-weekly telephone visits. Each phase is designated with a specified goal of care to guide the disease management activities. Commenced with the home visit by the team nurse for each phase, patients' condition and self-care will be assessed. A goal-setting approach will be used to enhance disease monitoring, symptom recognition and response, and treatment compliance. A mobile apps (T-FAME) will be installed in participants' smart-phone and supports the prescribed actions for goal attainment.
62716116|NCT04991857|ACTIVE_COMPARATOR|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by another team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
62716117|NCT04337242|EXPERIMENTAL|Blended Dynamic Interpersonal Therapy (B-DIT)|B-DIT is based on the same treatment principles as face-to-face Dynamic Interpersonal Therapy (DIT) and has the same structure of treatment consisting of three phases: (a) an exploration and engagement phase, (b) a middle or working through phase, and (c) an ending phase. B-DIT consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
62716118|NCT04337242|EXPERIMENTAL|Blended Cognitive Behavioral Therapy (B-CBT)|B-CBT is based on the same treatment principles as face-to-face Cognitive Behavioral Therapy (CBT). These include (a) psycho-education about depression, (b) cognitive restructuring (i.e., identifying and challenging maladaptive thoughts and beliefs, fostering problem solving capacities), (c) mindfulness and acceptance based approaches, and (d) relapse prevention. B-CBT in this trial consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
62716119|NCT04337242|ACTIVE_COMPARATOR|Dynamic Interpersonal Therapy (DIT)|DIT is a short-term, integrative psychodynamic, 16 weekly sessions individual therapy for depression. DIT formulates the presenting symptoms of depression as responses to interpersonal difficulties or perceived threats to attachments (loss/separation) and hence also as threats to the self.
62738092|NCT01775163||Self Directed Exercise|Participants randomized to the self-directed group will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss. Participants will not be given a specific exercise recommendation in terms of weekly energy expenditure.
62542605|NCT01056354||Novel respiratory virus-1|MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus)
62542606|NCT01056354||Novel respiratory virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
62542607|NCT04875936|EXPERIMENTAL|Motor Imagery and Contingent Neurofeedback (NFB)|This group will receive real-time fMRI NFB on the bases of participant's own brain activity
62542608|NCT04875936|SHAM_COMPARATOR|Motor Imagery and Non-contingent Neurofeedback (NFB)|This group will receive group will receive fMRI NFB based on another participant's brain activity
62542609|NCT05340829|EXPERIMENTAL|ThisCART19A 2×10^6 cells/kg for dose level 1|Patients will receive 2×10\^6 cells/kg of ThisCART19A
62542610|NCT05340829|EXPERIMENTAL|ThisCART19A 3×10^6 cells/kg as dose level 2|Patients will receive 3×10\^6 cells/kg of ThisCART19A
62542611|NCT05340829|EXPERIMENTAL|Patients will receive 4×10^6 cells/kg as dose level 3|Patients will receive 4×10\^6 cells/kg of ThisCART19A
62716120|NCT04337242|ACTIVE_COMPARATOR|Cognitive Behavioral Therapy (CBT)|CBT is a brief talking therapy that consists of a maximum of 16 sessions, offered over 4 to 6 months. CBT is based on the assumption that depression is directly related to patterns of thinking. Specifically, dysfunctional and often automatic patterns of thinking are assumed to be related to the onset and maintenance of depression.
62716121|NCT06716723||male kidney donors|Male kidney donors who had a laparoscopic nephrectomy between April 1, 2002 and March 31, 2023 at transplant centres in the province of Ontario, Canada. Each donor's nephrectomy date will serve as their cohort entry date.
62716122|NCT06716723||male healthy nondonors|"Before nephrectomy, living donors undergo rigorous health screening. We will select a similarly healthy segment of the general population using restriction and matching. We will randomly assign a cohort-entry date (simulated nephrectomy date) to all male citizens in Ontario, according to the distribution of cohort-entry dates among donors (between April 1, 2002 and March 31, 2023).~We will identify baseline illnesses and measures of healthcare access using baseline records available before the cohort entry date. We will then restrict the sample to eligible nondonors without a recorded medical condition that could preclude donation. These restrictions will leave only a portion of citizens from the original sample as eligible nondonors.~We will then match 10 eligible nondonors to each donor based on baseline characteristics that might be associated with the risk of scrotal surgery. Each nondonor can only be selected once."
62716123|NCT00757068|ACTIVE_COMPARATOR|SBT|Women assigned to SBT (blue) will receive a six month program that offers to help them stay quit after having a baby.
62716124|NCT00757068|EXPERIMENTAL|CBT|Women assigned to CBT (pink) will receive a six month treatment designed to provide support and address the concerns of women who have just had a baby and do not want to resume smoking.
62716125|NCT02640937||Orthopaedic device related infections|"Inclusion Criteria:~* infections after fracture fixation or prosthetic joint surgery~* Affected bone or joint: Long bones of the lower extremity; hip joint, knee joint;~* Bacterial growth of S. epidermidis at the site of interest~* Written consent~* Age: 18 and older"
62716126|NCT06719401|OTHER|F-H Group|Participants in this group perform training and testing using the foot chest compression (FCC) method first, followed by training and testing using the hand chest compression (HCC) method.
62716127|NCT06719401|OTHER|H-F Group|Participants in this group perform training and testing using the hand chest compression (HCC) method first, followed by training and testing using the foot chest compression (FCC) method.
62716128|NCT01932788|ACTIVE_COMPARATOR|Vitamin D 4000 IU|Subjects randomized into this arm will receive supplementation with 4000 IU/day vitamin D3 in gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3.
62716129|NCT01932788|PLACEBO_COMPARATOR|placebo gummy vitamin|Supplementation with placebo gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3)
62716130|NCT06711042||Control Group (Implant Placement Within Functional Safe Zone - FSZ)|This group will consist of patients who have previously undergone total hip arthroplasty (TKA) with implant placement within the functional safe zone (FSZ).
62716131|NCT06711042||Experimental Group (Implant Placement Outside Functional Safe Zone - FSZ)|This group will consist of patients who have previously undergone total hip arthroplasty (TKA) but have implant placement outside the functional safe zone (FSZ).
62716132|NCT06319820|EXPERIMENTAL|Group A: TAR-210|Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year.
62716133|NCT06319820|ACTIVE_COMPARATOR|Group B: MMC or Gemcitabine|Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year.
62716134|NCT06431425|EXPERIMENTAL|Digital care path (eCG Family Clinic)|Individuals included in the intervention group (eCG Family Clinic), will receive an invitation to the DNA-poli platform after the proband adds their email address to the digital clinic at risk relatives list. The eCG Family Clinic serves as the pre-test counseling, afterwards counseling by a healthcare professional can be requested. Subsequently the at-risk relative decides whether to get genetically tested and if the results are communicated via the DNA-poli platform or via telephone.
62716135|NCT06431425|NO_INTERVENTION|Current clinical practice|Individuals included in the control group, will receive the family letter via the proband. The relative needs to contact their general practitioner to get a referral to the genetic department. The relative sets up an appointment with a genetic counselor. The relative has a face-to-face session with a healthcare professional and will decide during this conversation whether to get genetically tested. When results are in, another face-to-face appointment is set to discuss the result and if applicable, follow-up steps will be discussed.
62716136|NCT03820830|EXPERIMENTAL|Palbociclib plus standard endocrine therapy|Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.
62716137|NCT03820830|ACTIVE_COMPARATOR|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
62716138|NCT06718439|EXPERIMENTAL|Restrictive transfusion strategy|The restrictive transfusion strategy will consist of administering red blood cell transfusion when the participant's hemoglobin level is measured below 70 g/L or to maintain a hemoglobin target range of 70-80 g/L.
62716139|NCT06718439|EXPERIMENTAL|Liberal transfusion strategy|The liberal transfusion strategy will consist of administering red blood cell transfusion when the participant's hemoglobin level is measured below 90 g/L or to maintain a hemoglobin target range of 90-100 g/L.
62716140|NCT04683913|EXPERIMENTAL|Immediate Intervention: Telerehabilitation|Immediate entry into the gait modification intervention delivered using teleconferencing methods
62716141|NCT04683913|EXPERIMENTAL|Delayed Intervention: Telerehabilitation|Delayed (6 weeks) entry into the gait modification intervention delivered using teleconferencing methods
62716142|NCT04845256||SOMAVAC 100 Sustained Vacuum System|New sustained vacuum system
62716143|NCT06715826|EXPERIMENTAL|Trop2/HER2-targeted immunoPET imaging|Enrolled patients will undergo a Trop2/HER2-targeted immunoPET/CT scanning.
62716144|NCT01659450|EXPERIMENTAL|Low energy dense|Diet of the LED group contained 30%fat, 15% protein and 55% carbohydrate. Most of the consumed carbohydrates in the LED diet group were fruits, vegetables and whole grains. In addition, this group received more servings of vegetables groups daily in the form of liquid diets or some menus contain more vegetables
62716145|NCT01659450|EXPERIMENTAL|control|In the group with a control diet, 35% of the energy was provided by fat, 15% by protein and 50% by carbohydrate
62716146|NCT03384875|EXPERIMENTAL|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
62716147|NCT03384875|PLACEBO_COMPARATOR|Control|Standard of care
62716148|NCT03895190|NO_INTERVENTION|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
62716149|NCT03895190|EXPERIMENTAL|Experimental: Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
62716150|NCT02150239||postoperative pain|
62716151|NCT06340230|EXPERIMENTAL|Arm 1 (PD-L1 Positive) SHR-A1811 Injection + Adebrelimab Injection|SHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
62716152|NCT06340230|EXPERIMENTAL|Arm 2 (PD-L1 Negative) SHR-A1811 Injection + Adebrelimab Injection|SHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
62716153|NCT06340230|EXPERIMENTAL|Arm 3 SHR-A1811 Injection|SHR-A1811 Injection Drug: SHR-A1811 Injection
62716154|NCT04910269|EXPERIMENTAL|Treatment Group|Participants in this group will receive the investigational treatment in addition to standard of care.
62716155|NCT04910269|PLACEBO_COMPARATOR|Placebo Group|Participants in this group will receive a placebo in addition to standard of care.
62716156|NCT06345768|EXPERIMENTAL|Intervention|Data will be collected in the waiting room before cholecystectomy surgery. A pre-test will be performed 30 minutes before the patient enters the operation. General Comfort Scale, Surgical Fear Scale and VAS-A will be applied 30 minutes before the operation. Stress ball application will be made to the patient for 15 minutes. At the end of the stress ball application, General Comfort Scale, Surgical Fear Scale and VAS-A will be applied to the patients again.
62716157|NCT06345768|NO_INTERVENTION|Control|Patients in the control group will not undergo any intervention other than the standard care protocol.
62716158|NCT06452732||MRD monitoring|
62716159|NCT05455580|EXPERIMENTAL|N-TORM Intervention|This is a non-randomized, non-blinded, quasi-experimental, pre- and post-test phase I feasibility design pilot study.
62716160|NCT06613880|EXPERIMENTAL|p-ALG+Romiplostim N01+CsA|The maximum screening period was 4 weeks, and after entering the treatment period, the patients were treated with p-ALG combined with cyclosporine and Romiplostim N01. Symptomatic leukocyte elevation, blood transfusion support, and anti-infective therapy are allowed during this period, according to the patient's blood routine. If a patient has a serious adverse event during treatment, it will be treated according to the criteria for suspension and recovery.
62716161|NCT04343092|EXPERIMENTAL|Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)|Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily
62716162|NCT02710539|ACTIVE_COMPARATOR|Free combination|Perindopril 10 mg/daily, indapamide 2,5 mg/daily, and amlodipine 10 mg/daily will be given according to a free combination strategy
62716163|NCT02710539|ACTIVE_COMPARATOR|Tripliam|fixed combination of perindopril 10 mg/daily, indapamide 2,5 mg/daily, amlodipine 10 mg/daily
62716164|NCT01830985|EXPERIMENTAL|Single Arm VX-509|
62716165|NCT04103021|EXPERIMENTAL|Port-a-cath|Ultrasound guided Port-a-cath insertion
62716166|NCT03168802|EXPERIMENTAL|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
62716167|NCT03168802|ACTIVE_COMPARATOR|Radiofrequency ablation facet treatment|Radiofrequency ablation for facet joint pain once at Lumbar spine
62716168|NCT03794349|ACTIVE_COMPARATOR|Regimen A (chemotherapy, dinutuximab, sargramostim)|Patients receive temozolomide PO, via NG, or G tube on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12 of a 21-day cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62716169|NCT03794349|EXPERIMENTAL|Regimen B (eflornithine, chemotherapy, dinutuximab)|Patients receive eflornithine PO, via NG, or G tube on days -6 to 7 and days 15-21 of cycle 1 and days 1-7 and 15-21 of subsequent cycles, temozolomide PO, via NG, or G tube on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12. Treatment duration is 28 days for cycle 1 and then every 21 days in subsequent cycles for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62716170|NCT05291650|ACTIVE_COMPARATOR|glucocorticoid injection into infrapatellar fat pad|
62716171|NCT05291650|PLACEBO_COMPARATOR|placebo injection into infrapatellar fat pad|
62168030|NCT06057259||Inclinometer|Measuring Wrist Joint Position Sense with a Inclinometer
62716172|NCT00454116|PLACEBO_COMPARATOR|1|FOLFIRI + placebo vandetanib
62716173|NCT00454116|EXPERIMENTAL|2|FOLFIRI + low dose vandetanib
62716174|NCT00454116|EXPERIMENTAL|3|FOLFIRI + high dose vandetanib
62716175|NCT02812914|EXPERIMENTAL|Phase 1|In Phase I, 25 pregnant women will receive a low-cost gas stove and will be taught by peer educators in group classes how to safely use gas stoves and how to reduce exposure to air pollution.
62168031|NCT06057259||Goniometer|Measuring Wrist Joint Position Sense with a Goniometer
62716176|NCT02812914|EXPERIMENTAL|Phase 2|In Phase 2, the investigators will assess a more resource-intensive behavioral intervention approach with a different group of 25 women who will follow the same study procedures described in Phase I.
62735825|NCT03976024|EXPERIMENTAL|DHBN-FN arm|"Recruitment is planned in traditional hospitalization for DHBN-FN patients. Evaluation of streptococcal carriage by swab, pharyngeal, anal and perineal in patients hospitalized for a DHBN-FN at the end of hospitalization and 1 month after discharge from hospital during the reassessment consultation. Swabs made by the dermatologist.~The carriage of streptococcus in patients living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index"
62716177|NCT03179917|EXPERIMENTAL|Pembrolizumab and Involved Site Radiation Therapy|Following a PET/CT simulation to evaluate the extent of disease, pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Fourteen to 21 days after the completion of therapy, a PET/CT simulation will be repeated. Pts with complete response will proceed to 20 Gy of ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these ps will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these pts will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts with new sites of disease or progression on imaging will have a repeat biopsy, per treating physician's discretion \& then be treated off study.
62716178|NCT02530177||Patients having CYTOTOXIC CHEMOTHERAPY|Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.
62716179|NCT02530177||Patients having ENDOCRINE THERAPY|Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits.
62716180|NCT02530177||COMPARATOR (menopausal women)|Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort.
62716181|NCT02176148||Lupus control standard-of-care|Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
62716182|NCT00494182|EXPERIMENTAL|Treatment (carboplatin, paclitaxel, sorafenib)|Participants receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1, and sorafenib PO BID on days 2-19. Treatment repeats every 21 days for up to 6 courses. Starting with course 7, participants receive sorafenib PO daily in the absence of disease progression or unacceptable toxicity.
62716183|NCT03144167|OTHER|Patients, aged 18-88, with glioblastoma|
62716184|NCT06396741|EXPERIMENTAL|Quadricepsl muscle dry needling|The Quadriceps muscle will be punctured with ultrasound control
62716185|NCT04615546|EXPERIMENTAL|Remote Phase: Post-Bariatric Hypoglycemia Patients|Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days.
62716186|NCT04615546|NO_INTERVENTION|In-Clinic Phase: Post-Bariatric Hypoglycemia Patients|Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. This may include participants from the Remote Phase or newly enrolled participants.
62716187|NCT04615546|NO_INTERVENTION|In-Clinic Phase: Surgical Controls|Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions.
62716188|NCT04615546|NO_INTERVENTION|In-Clinic Phase: Nonsurgical Controls|Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions.
62716189|NCT04615546|NO_INTERVENTION|In-Clinic Phase: Post-Bariatric Hypoglycemia Patients with indwelling gastrostomy tube|Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed.
62716190|NCT06107530|EXPERIMENTAL|Semi structured interview|
62716191|NCT01370187|NO_INTERVENTION|Control|Control group
62716192|NCT01370187|EXPERIMENTAL|Montelukast|4mg Montelukast daily for 2 months
62716193|NCT06479174|EXPERIMENTAL|CHAMPS-TR|Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training.
62716194|NCT06479174|EXPERIMENTAL|CHAMPS TR plus remotely supervised transcranial direct current stimulation (RS-tDCS)|Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training. Persons with stroke will also receive RS-tDCS.
62716195|NCT06715449|EXPERIMENTAL|Intervention group: Empagliflozin + usual stroke care|Patients randomised in this group will be taking the SLGT2 inhibitor (empagliflozin 10mg OD) in addition to usual stroke care
62716196|NCT06715449|NO_INTERVENTION|Control group: Usual stroke care alone|Patients randomised in this group will continue to have their guideline directed stroke care
62716197|NCT01242514|EXPERIMENTAL|A|Oral treatment
62716198|NCT01242514|EXPERIMENTAL|B|Oral treatment
62716199|NCT01242514|EXPERIMENTAL|C|Oral treatment
62716200|NCT01977365|EXPERIMENTAL|Growth promotion based on child centered approach|
62716201|NCT01977365|NO_INTERVENTION|Control|
62716202|NCT04736472|EXPERIMENTAL|DPYD/UGT1A1 pharmacogenetic testing|"All patients will be screened for twelve single nucleotide polymorphisms (SNPs) in DPYD: DPYD\*2A, \*5, \*6, \*8, \*9A, \*10, \*12, \*13, rs2297595, rs115232898, rs67376798, HapB3.~All patients will be screened for two SNPs in UGT1A1: UGT1A1\*6, \*28."
62716203|NCT00686673|EXPERIMENTAL|A|Providing Videotape-based material \& tailored workbook to make informed choice of disclosing terminal illness to patients
62716204|NCT00686673|OTHER|B|"Attention control arm:~Providing videotape-based material \& non-tailored workbook about pain control"
62716205|NCT04972253|EXPERIMENTAL|Infigratinib|"* Infigratinib daily dosage per protocol 3-week on/1-week off schedule. 4 weeks will constitute 1 cycle of therapy.~* Participants will receive 2 cycles (i.e. 8 weeks) and the treatment will be administered as an outpatient.~* After completion of therapy, patients will undergo a CT of the chest, abdomen and pelvis (within 2 weeks of the last dose of therapy) and then proceed to Radical cystectomy 2-4 weeks after the last dose of therapy."
62716206|NCT06717022|EXPERIMENTAL|CHT102 allogeneic CAR T cells|In the dose escalation phase of this study, one alternative dose and 4 dose groups (calculated by the number of CAR-positive T cells) were planned, each treatment lasted 28 days, and UCAR-T cells were transfused three times, respectively on D1, D5, and D9. The single dose within the group was fixed, and the dose between the groups was escalating dose. Each infusion dose was 2.5×106/kg (optional), 5×106/kg, 1×107/kg, 2×107/kg, and 3×107/kg, with a dose error of 20% allowed.
62716207|NCT04097990|OTHER|healthy participants|healthy participants
62716208|NCT04097990|OTHER|hypertriglyceridemia without prior pancreatit|
62716209|NCT04097990|OTHER|hypertriglyceridemia and at least one case of|
62716210|NCT00928343|EXPERIMENTAL|GLPG0187|Single dose
62716211|NCT00928343|PLACEBO_COMPARATOR|Placebo|
62716212|NCT06585891|EXPERIMENTAL|Group 1|5 mg/kg IV- single administration
62716213|NCT06585891|EXPERIMENTAL|Group 2|5 mg/kg SC- single administration
62716214|NCT06585891|EXPERIMENTAL|Group 3|20 mg/kg IV- single administration
62716215|NCT06585891|EXPERIMENTAL|Group 4|40 mg/kg IV- single administration
62716216|NCT06585891|EXPERIMENTAL|Group 5|5 mg/kg SC- repeat dosing
62716217|NCT06585891|EXPERIMENTAL|Group 6|20 mg/kg IV-repeat dosing
62716218|NCT03097289|EXPERIMENTAL|Platelets stored in InterSol|Platelets collected on the Trima Accel system and stored in 65% InterSol/35% plasma
62716219|NCT06438991|EXPERIMENTAL|All participants|"Baseline: participants will undergo lower extremity muscle strength testing, electromyography, spine and brain MRI, and complete a battery of questionnaires~All participants will undergo a clinically indicated spinal cord stimulator implanted for refractory chronic pain.~SCS Optimization phase consists of weekly research visits for 1 month. SCS parameters will be optimized for voluntary control of lower extremity muscles.~Individualized Neurorehabilitation phase consists of 4 x weekly visits for 5-months. With the SCS settings turned on for muscle activation, participants will undergo progressive neurorehabilitation by a spinal cord specialized physical therapist.~All participants who complete the 6-month timepoint will be invited to continue long-term follow up."
62716220|NCT02382354|EXPERIMENTAL|i-gel|I-gel insertion was attempted during propofol and remifentanil anesthesia .
62716221|NCT02382354|ACTIVE_COMPARATOR|laryngeal mask airway|LMA insertion was attempted during propofol and remifentanil anesthesia .
62716222|NCT03126916|EXPERIMENTAL|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
62716223|NCT03126916|EXPERIMENTAL|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
62716224|NCT03126916|EXPERIMENTAL|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description. Closed to accrual as of 12/17/20.
62716225|NCT03126916|EXPERIMENTAL|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
62716226|NCT03126916|EXPERIMENTAL|Arm E (lorlatinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
62716227|NCT05302063|EXPERIMENTAL|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
62716228|NCT05957042|EXPERIMENTAL|Contrast Enhanced Ultrasound (with Lumason)|
62716229|NCT06531538|EXPERIMENTAL|PG4 1-Dose Group|Participants to receive a single injection of Multivalent Pneumococcal Vaccine
62716230|NCT06531538|EXPERIMENTAL|PG4 2-Dose Group|Participants to receive two injections of Multivalent Pneumococcal Vaccine
62716231|NCT06531538|ACTIVE_COMPARATOR|20-valent pneumococcal conjugate vaccine (20vPnC)|Participants to receive a single injection of 20-valent pneumococcal conjugate vaccine (20vPnC).
62716232|NCT06715956||Inflammatory Subtype A|Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
62716233|NCT06715956||Inflammatory Subtype B|Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
62716234|NCT06715956||Inflammatory Subtype C|Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
62716235|NCT06715956||Inflammatory Subtype D|Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
62716236|NCT05625399|EXPERIMENTAL|Nivolumab + Relatlimab FDC SC|
62716237|NCT05625399|ACTIVE_COMPARATOR|Nivolumab + Relatlimab FDC IV|
62716238|NCT06279312|PLACEBO_COMPARATOR|Placebo drink|consume 1 drink per day for 4 weeks
62716239|NCT06279312|EXPERIMENTAL|Adaptogen Elixir drink|consume 1 drink per day for 4 weeks
62716240|NCT00888147||Fiber formula|This group will receive tube feeding formula that contains fiber.
62716241|NCT00583219|EXPERIMENTAL|Botox/DMSO Solution|"Subjects received Botulinum-A toxin and Dimethyl sulfoxide solution. The first 3 subjects in Phase 1 underwent bladder instillation of 50 cc of the solution utilizing 200 units of botulinum-A toxin and 50cc DMSO. The next 6 subjects in the Phase 1 trial received 300 units of botulinum-A toxin and 50cc DMSO.~All subjects in the Phase 2 trial received 300 units of botulinum-A toxin and 50cc DMSO."
62716242|NCT03096886|EXPERIMENTAL|Early CCBT|"Intervention: Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
62716243|NCT03096886|EXPERIMENTAL|Late CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to be waitlisted for up to 4 weeks and will receive CCBT within 4 weeks; imaging data will also be collected pre--treatment, following waitlist, and post-treatment of CCBT.~This arm will serve as the equivalent of a placebo comparator arm during the waitlist; and then as an experimental arm when receiving 8 weeks of CCBT treatment."
62716244|NCT03096886|NO_INTERVENTION|Matched Comparison|"No Intervention: Matched Comparison~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
62716245|NCT05225103|EXPERIMENTAL|SAFETY-A Implementation Sites|New Brief Trauma-Informed Intervention (based on SAFETY-A) in addition to Enhanced Usual Care in Juvenile Detention Sites
62716246|NCT04679454|EXPERIMENTAL|Preoperative Radiation Treatment|Preoperative Radiation treatment with CyberKnife
62716247|NCT06088329|EXPERIMENTAL|Mindful Walking|All participants will belong to the experimental mindful walking arm for our single arm feasibility study.
62716248|NCT03367884|EXPERIMENTAL|Neck dissection group|Neck dissection followed by radiotherapy(50Gy) according to risk factors
62716249|NCT03367884|ACTIVE_COMPARATOR|Radiotherapy group|Definitive radiotherapy (70Gy)
62716250|NCT06068374|EXPERIMENTAL|Break dual task|Subjects will remain seated for three hours; however, every 30 minutes the subjects will be instructed to stand and take short walks with low intensity and perform a cognitive task
62716251|NCT06068374|ACTIVE_COMPARATOR|Standard break|Subjects will remain seated for three hours, however, every 30 minutes the subjects will be instructed to stand and take short walks at low intensity for two minutes,
62716252|NCT06068374|NO_INTERVENTION|Control session|Subjects will remain seated for three hours
62716253|NCT06715410|OTHER|CO2 data collection|To collect data from CO2
62716254|NCT06714136||PAH (idiopathic pulmonary hypertension)|Patients with idiopathic pulmonary hypertension
62716255|NCT06714136||IPF-PH (idiopathic pulmonary fibrosis and pulmonary hypertension)|Patients with idiopathic pulmonary fibrosis and pulmonary hypertension
62716256|NCT06714136||COPD-PH (COPD and pulmonary hypertension)|Patients with COPD and pulmonary hypertension
62716257|NCT06685198|EXPERIMENTAL|Group O|Titrated administration of propofol to an OAA/S score of 1 as the endpoint.
62716258|NCT06685198|EXPERIMENTAL|Group T|Titrated administration of propofol to an OAA/S score of 2 as the endpoint.
62716259|NCT06685198|ACTIVE_COMPARATOR|Group B|Titrated administration of propofol to a BIS value ≤ 60 as the endpoint.
62716260|NCT04214067|ACTIVE_COMPARATOR|Arm I (EBRT, brachytherapy)|Patients undergo pelvic EBRT daily for 5-6 weeks and vaginal brachytherapy completed within 7 days after completion of EBRT in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT scans, MRI scans, or x-ray imaging throughout the trial.
62716261|NCT04214067|EXPERIMENTAL|Arm II (EBRT, brachytherapy, pembrolizumab)|Patients undergo EBRT and brachytherapy as in Arm I. Within 7 days prior to the start of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 6 weeks for up to 1 year (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT scans, MRI scans, or x-ray imaging throughout the trial.
62716262|NCT06539754|NO_INTERVENTION|No music|Participants who undergo cesarean delivery will not have music available to listen to during the procedure.
62716263|NCT06539754|EXPERIMENTAL|Music|Participants who undergo cesarean delivery will have music of their choice played through bone conduction headphones.
62716264|NCT06278051||Xarelto (Rivaroxaban, BAY59-7939)|
62716265|NCT06278051||Warfarin|
62716266|NCT03300206||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging.
62716267|NCT03300206||Standard of Care|Each of the participating sites will currently be using a vacuum assisted breast biopsy system along with a specimen radiography system (or other specimen imaging system).
62716268|NCT05489887|EXPERIMENTAL|Subjects with ALK Wildtype or Unknown|"5 cycles of standard of care induction + naxitimab~Naxitimab on Days 1, 3, and 5 of each cycle"
62716269|NCT05489887|EXPERIMENTAL|Subjects with ALK aberration|"5 cycles of standard of care induction + naxitimab + ceritinib~Naxitimab on Days 1, 3, and 5 of each cycle Ceritinib once daily on every day of study"
62716270|NCT06715254||Ankylosing Spondylitis (AS) Cohort|Adult patients diagnosed with AS who were treated with secukinumab.
62716271|NCT06715254||Psoriatic Arthritis (PsA) Cohort|Adult patients diagnosed with PsA who were treated with secukinumab.
62716272|NCT06715254||Psoriasis (PsO) Cohort|Adult patients diagnosed with PsO who were treated with secukinumab.
62716273|NCT06715254||Overall Cohort|Adult patients diagnosed with AS, PsA, or PsO who were treated with secukinumab.
62716274|NCT06218823|ACTIVE_COMPARATOR|Low-Intensity Standard Smoking Cessation Treatment|2 weeks of nicotine patch therapy, 3 telephone counseling sessions, and information about quitline and National Cancer Institute text messaging support services (SmokefreeTXT)
62716275|NCT06218823|EXPERIMENTAL|High-Intensity, Cancer-Targeted Smoking Cessation Treatment|12 weeks of varenicline therapy, 7 counseling sessions targeted to cancer patients, and information about quitline and SmokefreeTXT services
62716276|NCT04375527|EXPERIMENTAL|Treatment (binimetinib, nivolumab)|Patients receive binimetinib PO BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62716277|NCT00479063||Cases|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Cases had been referred for a lumbar MRI for LBP lasting \> 90 days.
62716278|NCT00479063||Controls|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Controls were headache patients who had been referred for a cranial MRI, which turned out to be normal, and who either had no history of LBP or had only experienced one episode in their life, which had lasted for less than 7 days.
62716279|NCT06289400|EXPERIMENTAL|Study Group|Conventional treatment+ Magnetic field application
62716280|NCT06289400|ACTIVE_COMPARATOR|Control Group|Conventional treatment
62716281|NCT06135584|EXPERIMENTAL|Pioglitazone metformin tablets|Pioglitazone metformin tablets 15mg/500mg (To control the fasting blood glucose below 7.0mmol/l, adjust the dose and dosage according to the blood glucose)
62716282|NCT06135584|ACTIVE_COMPARATOR|Other drug|Chinese patent medicine or Hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin and GLP1 ((To control the fasting blood glucose below 7.0mmol/l)
62716283|NCT06135584|OTHER|Drug-free|Drug-free
62716284|NCT05587491|OTHER|Gastric mucosal ablation|Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid argonplasma.
62716285|NCT06112860|OTHER|OTC Hearing Aid First|Participants will be provided a pair of OTC hearing aids (experimental) with typical directions and use for 4 weeks before outcome measures will be assessed. After which, participants will then receive the communication strategies information/counseling (control) and have outcome measures assessed after 4 weeks.
62716286|NCT06112860|OTHER|Communication Strategies First|Participants will receive the communication strategies information/counseling intervention (control) first. Outcome measures will be assessed at 4 weeks. After which, participants will then be given a pair of OTC hearing aids (experimental) with typical directions and use for four weeks before having outcome measures assessed.
62716287|NCT06711484|EXPERIMENTAL|SPEAKİNG UP TRAİNİNG GROUP|A pre-test will be administered to all participants seven days before the training program begins. A language training program consisting of four modules will be given to the experimental group participants. The final test of the scales and the training program evaluation form will be administered to the experimental group participants seven days after the training program is completed.
62716288|NCT06711484|NO_INTERVENTION|NON-TRAİNİNG GROUP|A pre-test will be applied to all participants seven days before the training program begins. No intervention will be made to the control group participants. The post-test of the scales will be applied to the control group again seven days after the training program of the experimental group participants is completed.
62716289|NCT06692361|EXPERIMENTAL|Escitalopram + FMT|The experimental group will receive escitalopram + FMT capsules (using Oral capsules derived from healthy human fecal microbiota)
62716290|NCT06692361|PLACEBO_COMPARATOR|Escitalopram + placebo|The control group will be treated with escitalopram + placebo (using capsules containing only corn starch)
62716291|NCT00419692|EXPERIMENTAL|Sequence WAXBYZCDE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).
62716292|NCT00419692|EXPERIMENTAL|Sequence WAXBYZCED|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
62716293|NCT00419692|EXPERIMENTAL|Sequence WAXBYZDCE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).
62716294|NCT00419692|EXPERIMENTAL|Sequence WAXBYZDEC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).
62716295|NCT00419692|EXPERIMENTAL|Sequence WAXBYZECD|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
62716296|NCT00419692|EXPERIMENTAL|Sequence WAXBYZEDC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).
62716297|NCT06361134|EXPERIMENTAL|SAFE Early Intervention Group|A sensory-based, activity-focused early intervention program was implemented in an enriched environment (SAFE Early intervention). Children in the intervention group received home visits once a month and their families were coached. Families were informed about how to support their children. Home visits were made once a month for 10 weeks.
62716298|NCT06361134|EXPERIMENTAL|Control Group|Home-based NDT program was applied to the control group. The babies in the group were examined in a clinic environment and the families were given booklets to support their children's development.
62716299|NCT05013554|EXPERIMENTAL|SAR443216-Dose Escalation|Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive SAR443216 as intravenous (IV) infusion or subcutaneous (SC) injection.
62716300|NCT05013554|EXPERIMENTAL|SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort A|Participants with metastatic breast cancers with HER2 high expression (with amplification) will receive SAR443216 as intravenous (IV) infusion.
62716301|NCT05013554|EXPERIMENTAL|SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort B|Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
62716302|NCT05013554|EXPERIMENTAL|SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort C|Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
62716303|NCT05013554|EXPERIMENTAL|SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort D|Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive SAR443216 as intravenous (IV) infusion.
62716304|NCT06653101|EXPERIMENTAL|Probiotic group|Akk capsule, 4 billion AFU/day, before meals
62716305|NCT06653101|PLACEBO_COMPARATOR|Placebo group|Placebo capsule, four capsules/day, before meals
62716306|NCT04411849|EXPERIMENTAL|Group I (intervention)|Participants receive the HPV self-testing intervention consisting of mailed HPV self-test devices. Participants also receive an information about cervical cancer. Participants who do not return their self-test within a few weeks receive telephone-based patient navigation.
62716307|NCT04411849|ACTIVE_COMPARATOR|Group II (usual care continued)|Participants receive usual care consisting of a reminder letter to get a clinic-based cervical cancer screening test and information about cervical cancer.
62716308|NCT03204760|EXPERIMENTAL|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
62168032|NCT06057259||Joint position sense goniometer|Measuring Wrist Joint Position Sense with a joint position sense goniometer
62164859|NCT06509477|ACTIVE_COMPARATOR|Juvederm Ultra 4® (by Allergan Co.)|Juvederm Ultra 4® (by Allergan Co.) will be administered over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs. In case of suboptimal correction of NLFs at week 2 after the initial treatment, the treating investigator will be directed to retreat the under corrected NLF(s).
62542612|NCT00905970||1|Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.
62542613|NCT00905970||2|Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.
62542614|NCT00905970||3|Patients with LTBI diagnosed time ago.
62542615|NCT00905970||4|Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.
62542616|NCT06355544||Not clinically at-risk|Individuals with BMI between 18.5 kg/m2 (included) and 25 kg/m2 (excluded) and without risk factors for metabolic syndrome
62542617|NCT06355544||Clinically at-risk|Individuals with BMI between 25 (included) and 35 kg/m2 (excluded) with or without metabolic syndrome and without treated type-2 diabetes mellitus
62542618|NCT01054404|ACTIVE_COMPARATOR|Furosemide|Furosemide 0.3 mg/kg
62542619|NCT01054404|PLACEBO_COMPARATOR|Placebo|Up to 5 mL saline
62542620|NCT06291415|EXPERIMENTAL|Dose escalation|Part 1 will consist of the following 3 dose levels: 300, 400, and 500 mg once daily (QD).
62542621|NCT06291415|EXPERIMENTAL|Dose optimization stage|In part 2 subjects will be randomized in a 1:1 ratio between the 2 dose levels selected at the end of part 1.
62542622|NCT02077361|EXPERIMENTAL|Open Label|"Patients will receive a subretinal injection of 0.10 ml of the rAAV2.REP1 vector drug substance. It is a colourless opalescent frozen liquid with no visible particles. Each patient will be given a one-time dose in one eye.~It is the same vector used in the United Kingdom Phase I/II trial logged at: http://clinicaltrials.gov/ct2/show/NCT01461213."
62542623|NCT01404130|EXPERIMENTAL|Isotretinoin therapy|0.5-1mg /kg titrated by clinical need and tolerance of each patient according to normal clinical practice
62542624|NCT00508131|ACTIVE_COMPARATOR|A|Milk fortified with, iron, zinc and vitamin C
62542625|NCT00508131|PLACEBO_COMPARATOR|B|Milk not fortified
62542626|NCT03704415|ACTIVE_COMPARATOR|Extended|Extended sinus surgery including all sinuses
62164860|NCT03500835|EXPERIMENTAL|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
62164861|NCT03500835|EXPERIMENTAL|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
62542627|NCT03704415|ACTIVE_COMPARATOR|Limited|Limited sinus surgery with partial ethmoidectomy
62542628|NCT03585920|ACTIVE_COMPARATOR|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
62542629|NCT03585920|EXPERIMENTAL|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (\<8 g oil per 40 g snack)
62542630|NCT03585920|EXPERIMENTAL|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (\<8 g oil, matched sensory signals)
62542631|NCT02558348|EXPERIMENTAL|AL3818|"Part 1 (Phase 1b): Cohort 1 will initiate at a dose of 12 mg/day of AL3818, for 21-Day cycles (14 days of AL3818 treatment followed by 7 days of rest). After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818 for the same 21-day cycles.~Part 2 (Phase 2a): Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818 treatment followed by 7 days of rest)."
62542632|NCT05378594|EXPERIMENTAL|House dust mite nasal allergen challenge|House dust mite allergic patients to undergo nasal allergen challenge with house dust mite extract
62542633|NCT05378594|EXPERIMENTAL|Silver birch pollen nasal allergen challenge|Silver birch pollen allergic patients to undergo nasal allergen challenge with silver birch pollen extract
62542634|NCT06380881|EXPERIMENTAL|SHR-2017|
62542635|NCT03555292|EXPERIMENTAL|PD without dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
62542636|NCT03555292|EXPERIMENTAL|PD with MCI|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
62542637|NCT03555292|EXPERIMENTAL|PD with dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
61976517|NCT06474364|OTHER|SEARCH-YOUTH|Virally unsuppressed or likely to be unsuppressed AYA, Youth living with HIV will receive the SEARCH-YOUTH intervention in addition to the standard MoH HIV care package.
62164862|NCT03500835|EXPERIMENTAL|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
62168033|NCT03847389|OTHER|clobetasol propionate topical oil|clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
62168034|NCT00659152||1: ALI/ARDS|
62542638|NCT03555292|EXPERIMENTAL|dementia with Lewy bodies|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
62542639|NCT03555292|EXPERIMENTAL|healthy control|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
62542640|NCT03975231|EXPERIMENTAL|Treatment (dabrafenib, trametinib, IMRT)|See Detailed Description
62716309|NCT03204760|EXPERIMENTAL|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
62716310|NCT05640479|ACTIVE_COMPARATOR|pregabalin group|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. Patients will receive IV saline as placebo with the same rate of dexmedetomidine.
62716311|NCT05640479|ACTIVE_COMPARATOR|dexmedetomidine group|patients in the dexmedetomidine group will receive after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h. Patients will receive placebo 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. If patients are hemodynamically unstable, the bolus dose will be omitted. The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Dexmedetomidine infusion will be not discontinued before extubation.
62716312|NCT05973903|EXPERIMENTAL|Single Arm|Single-arm: participants will be treated with TTFields (200 kHz) + intravenous pembrolizumab 200 mg every three weeks and oral lenvatinib 20 mg once daily until evident progressive disease by Response Assessment in Neuro-Oncology (RANO) criteria, unacceptable toxicity, withdrawal of consent, or until completion of 35 treatment cycles (approximately 2 years) with pembrolizumab. Participants who complete treatment with pembrolizumab after 35 cycles (approximately 2 years) or CR will continue to receive lenvatinib and TTF until disease progression, development of unacceptable toxicity, or withdrawal of consent.
62716313|NCT01147302|EXPERIMENTAL|C1 Esterase Inhibitor (Human)|Subjects were to receive C1 esterase inhibitor intravenously at a rate of approximately 1 mL per minute as tolerated. Subjects were to receive a total of 7 doses over a 2-week period: an initial IV infusion of 5000 U (not to exceed 100 U/kg) on Day 1, followed by 2500 U (not to exceed 50 U/kg) IV on Days 3, 5, 7, 9, 11, and 13
62716314|NCT01147302|PLACEBO_COMPARATOR|Normal Saline|placebo infused as above
62542641|NCT00805961|EXPERIMENTAL|Intervention|"Combined Modality Treatment and Systemic Therapy~Combined Modality Therapy - Radiation Therapy: 2 Gy/fraction, single daily fractions Monday-Friday, to total of 60 Gy Temozolomide: 75 mg/m2 by mouth daily Bevacizumab: 10 mg/kg IV every 2 weeks (Weeks 1, 3, 5, and 7)~After the last dose of radiation, patients exhibiting an objective response, stable disease on MRI scan, or have stable/improved tumor-related symptoms will begin systemic therapy~Systemic Therapy - Bevacizumab: 10 mg/kg IV every 2 weeks Everolimus: 10 mg by mouth daily"
62542642|NCT02201277|EXPERIMENTAL|Denali|Denali IVC Filter
62542643|NCT02201277|EXPERIMENTAL|Option|Option Elite IVC Filter
62542644|NCT05358509|EXPERIMENTAL|IV iron intervention arm 1|Intervention arm 1 involves a single dose of an IV iron formulation - ferric carboxymaltose - given during pregnancy.
62542645|NCT05358509|EXPERIMENTAL|IV iron intervention arm 2|Intervention arm 2 involves a single dose of an IV iron formulation - iron isomaltoside - given during pregnancy.
62542646|NCT05358509|ACTIVE_COMPARATOR|Active comparator|Participants randomly assigned to the active comparator arm will receive oral iron tablets to take daily, which is the current standard of care.
62542647|NCT02390024||Critically ill patients|Mechanical Ventilation
62542648|NCT02813265|ACTIVE_COMPARATOR|KPI-121 0.25% Ophthalmic Suspension|
62542649|NCT02813265|PLACEBO_COMPARATOR|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
62542650|NCT02186288||Adult ICU patients|
62542651|NCT04194294|ACTIVE_COMPARATOR|Liocaine|Group Lid
62542652|NCT04194294|ACTIVE_COMPARATOR|Na CL 0.9%|group C
62542653|NCT04806048||Hospitalized patients and outpatients|There may be different types of patients with differing follow-up plan but all will bie considered one group regarding on whether they receive their recommended follow-up plan
62542654|NCT00655343|EXPERIMENTAL|ATG-F|"ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)~cyclosporine A (target trough level \> 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
62542655|NCT00655343|NO_INTERVENTION|non-ATG-F|"cyclosporine A (target trough level \> 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
62542656|NCT01025453|EXPERIMENTAL|Pts getting Temsirolimus and Sorafenib|We propose a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). A maximum of 36 subjects will be evaluated during the study. Restaging scans, with evaluation of response, will be done every 2 cycles (8 weeks of treatment). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay \> 4 weeks, or at the discretion of the treating physician or patient.
62542657|NCT00567684|EXPERIMENTAL|CTU + IVU|CTU = Computed Tomography Urography + IVU = Intravenous Urography
62542658|NCT02650843||Patients with parkinsonism|Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland
62542659|NCT00264550|PLACEBO_COMPARATOR|Group 1: Placebo + Methotrexate|Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62542660|NCT00264550|EXPERIMENTAL|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62542661|NCT00264550|EXPERIMENTAL|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62542662|NCT00264550|EXPERIMENTAL|Group 4: Golimumab 100 mg + Methotrexate|Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
62542663|NCT02283008|NO_INTERVENTION|Standard care|This arm will receive standard care which involves informal education on how to use metered dose inhalers
62716315|NCT04106245|EXPERIMENTAL|Supportive care (PACK health coach, survey)|Patients are contacted once weekly by a health coach by text message, phone call, email, or a mobile application, for 3 months. The total time interacting with the health coach is about 3.5-4.5 hours across the study. Patients also complete surveys over 30 minutes each time at baseline and every 30 days for 3 months.
62716316|NCT03375320|EXPERIMENTAL|Arm I (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.
62716317|NCT03375320|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.
62716318|NCT04363164|EXPERIMENTAL|Arm A: Enzalutamide|Patients randomized to Arm A will receive continuous therapy with standard dose Enzalutamide (160 mg oral daily).
62716319|NCT04363164|EXPERIMENTAL|Arm B: Sequential Testosterone and Enzalutamide|Patients in Arm B will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 (i.e. cycle 1). On Day 1 of cycle 2, patients will stop testosterone and begin enzalutamide 160 mg po q day for 56 days. Each cycle is 56 days. On Day 1 of cycle 3, patient will not take enzalutamide and will again receive injection of testosterone. Patients will continue to alternate one cycle of testosterone (2 injections) with one cycle of 56 days of enzalutamide.
62716320|NCT04363164|EXPERIMENTAL|Arm C: Variable Sequential Testosterone and Enzalutamide|Patients in Arm C will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 injections per cycle. Each cycle is 56 days. Patients with PSA progression will stop T injection and begin Enzalutamide. Patients on T with initial PSA decline will remain on high dose T for additional cycles of 2 injections until PSA progression occurs (≥25% increase in PSA from PSA nadir on current BAT cycle). These patients will then be started on Enzalutamide. Patients with PSA progression will stop Enzalutamide and will restart injections of T with 2 injections/cycle. Patients on enzalutamide with initial PSA decline after one 56-day cycle will continue on Enzalutamide until PSA progression occurs (≥25% increase in PSA from PSA nadir on current Enzalutamide cycle). These cycles of switching between T and Enza with onset of PSA progression will continue until clinical and/or radiographic progression occurs.
62716321|NCT05176158|EXPERIMENTAL|Morning dosage|Dexketoprofen pill at morning; Placebo at night
62716322|NCT05176158|EXPERIMENTAL|Night dosage|Placebo pill at morning; Dexketoprofen at night
62716323|NCT06452771|EXPERIMENTAL|Ascending Dose|Multiple Dose Level (DL) Cohorts, with 1 Optional DL or Repeat DL
62716324|NCT06452771|EXPERIMENTAL|Optional Expansion|Multiple Optional Expansion Cohorts, activation will be determined by the Sponsor
62716325|NCT04505761|EXPERIMENTAL|Intervention group|Participants will receive Virtual Reality as an add-on to standard physiotherapy after COVID-19.
62716326|NCT03212976|OTHER|Study Phase 1|Patients with an intracranial pressure monitor will undergo phase contrast magnetic resonance imaging to measure their ICP.
62716327|NCT03212976|OTHER|Study Phase 2|Patients with shunts or CSF access devices such as Ommaya reservoir, etc will undergo phase contrast magnetic resonance imaging
62716328|NCT06358495|EXPERIMENTAL|Cognitive-Behavioural Therapy Group|Participants will receive a 6 week online Cognitive behavioural therapy for insomnia (CBT-I) evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Their parents will also be invited to participant in 1 virtual psychoeducation session.
62716329|NCT06358495|ACTIVE_COMPARATOR|Treatment as Usual waitlist with Psychoeducational Pamphlet|Control group participants will receive a pamphlet providing information on sleep hygiene that matches the information in CBT-I arm (e.g., having a bedtime routine, maintaining a sleep schedule, avoiding exercise within several hours of bed, avoiding bright screens before bed). Otherwise, they will be encouraged to continue with treatment they are receiving, if any. After the 19 week follow-up assessment, participants have the option of receiving the digitized CBT-I intervention.
62716330|NCT03898284||Impulse Oscillometry|Patients with Idiopathic Pulmonary Fibrosis. The objective is to determine whether another lung function technique, impulse oscillometry, is of interest to identify disease progression before changes in forced vital capacity can be ascertained.
62716331|NCT04445662|ACTIVE_COMPARATOR|Control (n=90)|"* Varenicline~* Tobacco coaching~* Saliva cotinine monitoring with fixed payments ($10) regardless of results"
62716332|NCT04445662|EXPERIMENTAL|Financial incentives (n=90)|"* Varenicline~* Tobacco coaching~* Saliva cotinine monitoring with escalating payments ($25-70) for levels \<30 ng/ml"
62716333|NCT06491563|EXPERIMENTAL|BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα|Participants will receive BRII-179 of a longer dose interval, followed by BRII-835 and PEG-IFNα combination therapy.
62716334|NCT06491563|EXPERIMENTAL|BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα|Participants will receive BRII-179 of a shorter dose interval, followed by BRII-835 and PEG-IFNα combination therapy.
62716335|NCT00105534|EXPERIMENTAL|AzaSite|
62716336|NCT00105534|SHAM_COMPARATOR|Vehicle|
62716337|NCT04724330|EXPERIMENTAL|Healthy for Two/Healthy for You (H42/H4U)|Those assigned to the intervention group will receive the H42/H4U health coaching intervention during pregnancy and 12 weeks postpartum.
62716338|NCT04724330|NO_INTERVENTION|Usual Care Comparison Group: Maintain Health in Pregnancy (mHIP)|Those assigned to the Usual Care comparison group, mHIP, will receive typical, evidence- and guideline-based experience in the prenatal care clinics.
62716339|NCT03512093||Retrospective chart review|
62716340|NCT03512093||Focus Group Discussion (FGD) of the medical staff|
62716341|NCT03512093||Interviews of mothers|
62735826|NCT03976024|ACTIVE_COMPARATOR|Control arm (Erysipelas)|"Recruitment is planned in traditional hospitalization for patients with erysipelas.~The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission)."
61976518|NCT01096264|OTHER|Healthy volunteer|"Healthy volunteer undergoing two imagery evaluation :~* SSI technique for local PWV and arterial stiffness evaluation~* SphygmoCor® for aortic PWV."
61976519|NCT01096264|OTHER|vEDS patients|"vEDS patients undergoing two imagery evaluations:~* SSI technique for local PWV and arterial stiffness evaluation~* SphygmoCor® for aortic PWV."
62716342|NCT06139653|ACTIVE_COMPARATOR|Group 1 - IMT CB|"Moment 1: IMT and moment 2: CardioBreath. Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
62716343|NCT06139653|ACTIVE_COMPARATOR|Group 2 - CB IMT|"Moment 1: CardioBreath and moment 2: IMT. Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
62716344|NCT03950427|ACTIVE_COMPARATOR|game-based Physical Activity Group|"The game-based physical activity group, will play active games using the Kinect for Xbox 360 game system or outdoors in a public park. Each game group will be facilitated by the study coordinator, the principal investigator or other study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
62716345|NCT03950427|PLACEBO_COMPARATOR|Sedentary Videogame Group|"The sedentary videogame group will play games while seated using the Xbox 360 game system (without the Kinect sensor) or seated outdoors in a public park. Each sedentary videogame group will be facilitated by study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
62716346|NCT06627751|EXPERIMENTAL|Treatment - MeziKD|Patients receive mezigdomide PO QD on days 1-21 of each cycle, carfilzomib IV over 30 minutes on days 1, 8, and 15 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles of study treatment, patients showing a response to therapy may continue the treatment regimen as part of standard of care per physician's discretion. Additionally, patients undergo ECHO, PET/CT, MRI, CT guided tumor biopsy, bone marrow aspiration and biopsy, and blood and saliva sample collection throughout the study,
62542664|NCT02283008|ACTIVE_COMPARATOR|Structured education|This arm will receive structured education on the use of inhalers. At 6 weeks post education inhaler technique will be re-assessed. Participants who fail to achieve a set level of competence may be chosen for semi structured interview.
62716347|NCT06007027|EXPERIMENTAL|Active laser group|In the active laser group, participants are treated intravaginally with the fractional microablative CO2 laser system (SmartXIDE2V2LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting; dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μs and the smart stack parameter from 2 to 3. At the level of the vaginal introitus, the dot power decreases to 20 Watt.
62716348|NCT06007027|SHAM_COMPARATOR|Sham laser group|In the sham laser group, participants are treated intravaginally with the fractional microablative CO2 laser system (SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy), using the following setting; dot power 0,5 watt, dwell time 100 μs, dot spacing 2000 μs and the smart stack parameter from 1 to 1
62716349|NCT05692999|EXPERIMENTAL|Pulse Arm|
62716350|NCT05692999|ACTIVE_COMPARATOR|Control Arm|
62716351|NCT04459416|EXPERIMENTAL|Usual Care plus Acupuncture|Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. to prevent severe pain. If acupuncture does not prevent severe pain, the participant will receive opioid medication as backup pain relief.
62716352|NCT04459416|ACTIVE_COMPARATOR|Usual Care|Will receive only the usual pain management approach, which includes opioid medication when needed for severe pain, according to the routine guidelines for their care.
62716353|NCT02343302|OTHER|Soft Pancreatic Gland|This arm will be patients with glands felt to have a soft texture during surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
62716354|NCT02343302|OTHER|Hard Pancreatic Gland|This arm will include patients felt to have a hard gland tecture at the time of surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
62716355|NCT00530881|PLACEBO_COMPARATOR|4|
62716356|NCT00530881|PLACEBO_COMPARATOR|3 active, 1 placebo|
62716357|NCT04658862|EXPERIMENTAL|TAR-200 + Cetrelimab|Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with intravenous (IV) Cetrelimab.
62735827|NCT03764319|ACTIVE_COMPARATOR|Intervention group|Ultra-protective ventilator settings in patients with ARDS and ECMO.
62542665|NCT02980289||Patients|Patients over 18 years old with advanced cancer defined as metastatic disease, no curable treatment options. The patients may not have received chemotherapy or irradiation within 4 weeks, no operations within 2 weeks and no general anesthesia within 4 days.
62542666|NCT03128021|ACTIVE_COMPARATOR|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
61976520|NCT05505903||Vaginal delivery|Newborn Infants born by vaginal delivery.
61976521|NCT05505903||Regular Cesarean section|Newborn infants born by regular Cesarean section
62716358|NCT04658862|ACTIVE_COMPARATOR|Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy|Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray \[Gy\], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.
62716359|NCT04908150|EXPERIMENTAL|Core Group|The Core Group carried out core stability exercises. Their training consisted of the following exercises: bridge, Klapp, front plank and lateral plank
62542667|NCT03128021|PLACEBO_COMPARATOR|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
62542668|NCT03128021|OTHER|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
62542669|NCT03128021|ACTIVE_COMPARATOR|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
62542670|NCT05373628|EXPERIMENTAL|Gradient and pulse imaging|All subjects used standardized breast MRI scanning schemes, including T2 weighted imaging (T2WI), T1 weighted imaging (T1WI), diffusion weighted imaging (DWI), PGSE, OGSE and contrast dynamic enhancement (DCE). Three quantitative parameters of VIN, DEX and D are derived on MATLAB software
62542671|NCT04129229|EXPERIMENTAL|LTR Treatment|Eligible subjects will undergo insertion of the LTR device in their tongue. Initiation of treatment will occur 7 days post insertion procedure and will be monitored over the course of 1 year.
62542672|NCT04603157|NO_INTERVENTION|Standard of Care Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will continue to follow the treatment recommendations of the primary care physician
62716360|NCT04908150|ACTIVE_COMPARATOR|Abdominal Group|The Abdominal Group performed traditional exercises: trunk flexion or abdominal crunch, trunk extensions, lower abdominals with hip lifts and crunch with crossed legs
62716361|NCT05457556|EXPERIMENTAL|Arm A (halploHCT)|Patients receive a myeloablative conditioning regimen with PTCy or alpha beta T cell depletion at the discretion of the treating provider. Patients then undergo haploHCT on day 0. Patients undergoing myeloablative conditioning regimen with PTCy also receive GVHD prophylaxis on days 3-5. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
62716362|NCT05457556|EXPERIMENTAL|Arm B (MUD-HCT)|Patients receive a TBI-based or chemotherapy-based myeloablative conditioning regimen between days -9 and -2, followed by MUD-HCT on day 0. Patients then receive GVHD prophylaxis regimen on days 1-11. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
62716363|NCT05457556|EXPERIMENTAL|Arm C (haploHCT)|Patients who only have a haplo donor receive a myeloablative conditioning regimen with PTCy or alpha beta T cell depletion at the discretion of the treating provider. Patients then undergo haploHCT on day 0. Patients undergoing myeloablative conditioning regimen with PTCy also receive GVHD prophylaxis on days 3-5. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
62716364|NCT04401774|EXPERIMENTAL|Nivolumab Maintenance|All patients will undergo cerebrospinal fluid (CSF) and blood collection as well as MRI imaging as standard of care prior to (- 21 days) first-line treatment initiation, during first-line therapy (before initiation of the 5th methotrexate dose (+/- 7 days)), at completion of first-line chemotherapy therapy (+/- 7 days) as well as 60, 180, and 360 days after enrollment into maintenance or observation (+/- 7 days). Those patients with persistent cfDNA in the CSF after completion of first-line chemotherapy and either complete or partial response on imaging will be enrolled into the nivolumab maintenance treatment arm. All other patients (no persistent cfDNA in the CSF and either complete or partial response on imaging) are followed with observation. Patients who do not respond to first-line therapy are not eligible for nivolumab maintenance and will no longer be followed in the biospecimen and clinical data collection cohort.
62735828|NCT03764319|ACTIVE_COMPARATOR|Control group|Standard ventilator settings in patients with ARDS and ECMO.
62735829|NCT05088330|EXPERIMENTAL|D-VRD|treatment with D-VRD in NDMM
62164863|NCT04605471||PMS I study|"'PMS I' was conducted in contrast-enhanced X-ray examination between June 1999 and November 2003 in 27 countries in Europe, Africa and Asia and comprised 74,717 patients of which 2,172 were children and 32,103 were elderly patients.~Ref. Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol. 2008;49(8):902-11."
62168035|NCT06268600|EXPERIMENTAL|Modified neck target volume delineation|For patients with negative lymph nodes in regions III and IVa, a modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
62542673|NCT04603157|EXPERIMENTAL|Hybrid Exercise Training Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will follow a hybrid exercise training program
62542674|NCT02681211|EXPERIMENTAL|Auricular Acupuncture|If assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint.
62735830|NCT02905539|EXPERIMENTAL|Iron Isomaltoside 1000|Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
62164864|NCT04605471||IMAGE study|"'IMAGE' consists of 44,835 patients with contrast-enhanced X-ray examination and was conducted in 21 European and Asian countries from February 2008 to September 2009, 1,451 patients were children, and 15,654 were elderly patients.~Ref. Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon ST, Zhang SX, et al. Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE). Acta Radiol. 2012;53(2):179-86."
62542675|NCT02681211|ACTIVE_COMPARATOR|Medication and Fluid|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
62542676|NCT02317289|EXPERIMENTAL|Detection of freezing|freezing parkinsonian patients
62542677|NCT04022408|EXPERIMENTAL|Liquid based cytology|.Liquid-based cytology (LBC), enables cells to be suspended in a monolayer. LBC makes better cytological assessment possible with improved sensitivity and specificity, since fixation is better and nuclear details are well preserved in the technique. Preneoplasticand neoplastic cells are not obscured by other cells, such as normal epithelial and inflammatory cells. LBC techniques are currently applied to cytological samples from several tissues or fluids. They include uterine cervix , endometrium, aspirates from breast , thyroid tumors, ascites and pleural effusion, and urine , LBC technology is suggested as an appropriate diagnostic method for metastatic tumors in cerebrospinal fluid .
62542678|NCT04022408|ACTIVE_COMPARATOR|Conventional cytology|It is a gold standard for histopathological diagnosis of pancreatobiliary malignancies till date
62542679|NCT05042258|EXPERIMENTAL|Dupilumab administration|dupilumab administered in weight based dosage for 12 weeks. The drug will be administered once a week during this time through a subcutaneous injection.
62542680|NCT05853042||Cohort|Study population: Prospective, observational cohort study of consecutive patients (goal, 1500 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
62542681|NCT02929524|EXPERIMENTAL|Ketamine group|This group was used intranasal ketamine, syringes were made with 4 ml of the drug (50mg/ml), 1 randomized per patient. The validity stability and were 7 days after drawing the solution. The drug began to take effect in 10 minutes and lasted about 40 minutes.
62542682|NCT02929524|PLACEBO_COMPARATOR|Placebo Group|This group was used intranasal saline, syringes were made with 4 ml of liquid 1 per patient randomized. The validity stability and were 7 days after drawing the solution.
62542683|NCT04895982|EXPERIMENTAL|BNT162b2|Intramuscular Injection
62542684|NCT03887793|EXPERIMENTAL|VACs intervention|Integrated healthcare delivery systems randomly assigned to this arm will participate in the Vaccinate Adolescents against Cancers (VACs) model for HPV vaccine QI. Specific QI activities will be chosen by healthcare system leadership and healthcare providers on the systems' QI teams.
62542685|NCT03887793|NO_INTERVENTION|Wait list control|Integrated healthcare delivery systems randomly assigned to this arm will be placed on a waiting list to receive the intervention after the conclusion of the study period.
62542686|NCT02226601|ACTIVE_COMPARATOR|Aprepitant|"Aprepitant~* 40 mg IV pre-operatively~* 40 mg PO post-op day #1~* 40 mg PO post-op day #2"
62542687|NCT02226601|PLACEBO_COMPARATOR|Placebo|"* electrolyte (0.9% NaCl) infusion) pre-operatively~* capsule without medication on post-op day #1~* capsule without medication on post-op day #2"
62735831|NCT02905539|ACTIVE_COMPARATOR|Ferric Carboxymaltose|Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
62735832|NCT02479958|EXPERIMENTAL|Control|
62542688|NCT06076460|EXPERIMENTAL|Early Total Enteral Feeding|Mom's milk or donor milk at 80 ml/kg/day after randomization within the first 2 hours
62542689|NCT06076460|ACTIVE_COMPARATOR|Conventional Enteral Feeding|Mom's milk or donor milk at 20 ml/kg/day and rest of the requirement as Total parenteral nutrition after randomization within the first 2 hours.
62542690|NCT04981327|EXPERIMENTAL|Experimental|After a conventional course of 7 days of Apixaban 10mg BID, Apixaban 2.5mg BID during 3 months.
62542691|NCT04981327|ACTIVE_COMPARATOR|Standard|After a conventional course of 7 days of Apixaban 10 mg BID, Apixaban 5 mg BID during 3 months.
62542692|NCT05238454|EXPERIMENTAL|Cohort 1: SCTV01C|
62542693|NCT05238454|ACTIVE_COMPARATOR|Cohort 1: Sinopharm inactivated COVID-19 vaccine|
62542694|NCT05238454|EXPERIMENTAL|Cohort 2: SCTV01C|
62542695|NCT05238454|ACTIVE_COMPARATOR|Cohort 2: Comirnaty|
62542696|NCT02495623|ACTIVE_COMPARATOR|Low Dose|21 mg SYN-010
62542697|NCT02495623|ACTIVE_COMPARATOR|High Dose|42 mg SYN-010
62542698|NCT02495623|PLACEBO_COMPARATOR|Placebo|Placebo
62542699|NCT05984186|EXPERIMENTAL|FiO2=100% with Flow=5LPM|"The study is a repeated measures model that will collect data on the participants with the designated HVT at four specified settings (Flow/FiO2) during the Wingate exercise test and during the recovery interval. The Wingate exercise test configuration, equipment and procedures will be repeated for each HVT setting for a matched dataset.~The study will include four study arms, corresponding to four therapy settings being tested: (1) FiO2=100% with Flow=5LPM, (2) FiO2=21% with Flow=25-35LPM, (3) FiO2=100% with Flow=25-35LPM, (4) FiO2=21% with Flow=5LPM. The participants will wear the appropriately sized nasal cannula interface during the exercise and recovery."
62542700|NCT05984186|EXPERIMENTAL|FiO2=21% with Flow=25-35LPM|"The study is a repeated measures model that will collect data on the participants with the designated HVT at four specified settings (Flow/FiO2) during the Wingate exercise test and during the recovery interval. The Wingate exercise test configuration, equipment and procedures will be repeated for each HVT setting for a matched dataset.~The study will include four study arms, corresponding to four therapy settings being tested: (1) FiO2=100% with Flow=5LPM, (2) FiO2=21% with Flow=25-35LPM, (3) FiO2=100% with Flow=25-35LPM, (4) FiO2=21% with Flow=5LPM. The participants will wear the appropriately sized nasal cannula interface during the exercise and recovery."
62735833|NCT02479958|EXPERIMENTAL|APDT 1|
62735834|NCT02479958|EXPERIMENTAL|APDT 2|
62735835|NCT01720004|EXPERIMENTAL|Repeated Use of Hands-and-Knees|The intervention was repeated use of hands-and-knees position during labour. Participants were asked to try it for at least 15 minutes every hour, from randomization until delivery. They were not required to use it for delivery.
62542701|NCT05984186|EXPERIMENTAL|FiO2=100% with Flow=25-35LPM|"The study is a repeated measures model that will collect data on the participants with the designated HVT at four specified settings (Flow/FiO2) during the Wingate exercise test and during the recovery interval. The Wingate exercise test configuration, equipment and procedures will be repeated for each HVT setting for a matched dataset.~The study will include four study arms, corresponding to four therapy settings being tested: (1) FiO2=100% with Flow=5LPM, (2) FiO2=21% with Flow=25-35LPM, (3) FiO2=100% with Flow=25-35LPM, (4) FiO2=21% with Flow=5LPM. The participants will wear the appropriately sized nasal cannula interface during the exercise and recovery."
62542702|NCT05984186|EXPERIMENTAL|FiO2=21% with Flow=5LPM|"The study is a repeated measures model that will collect data on the participants with the designated HVT at four specified settings (Flow/FiO2) during the Wingate exercise test and during the recovery interval. The Wingate exercise test configuration, equipment and procedures will be repeated for each HVT setting for a matched dataset.~The study will include four study arms, corresponding to four therapy settings being tested: (1) FiO2=100% with Flow=5LPM, (2) FiO2=21% with Flow=25-35LPM, (3) FiO2=100% with Flow=25-35LPM, (4) FiO2=21% with Flow=5LPM. The participants will wear the appropriately sized nasal cannula interface during the exercise and recovery."
62542703|NCT01920022|EXPERIMENTAL|Etonorgestrel and mifepristone|Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
62542704|NCT01920022|ACTIVE_COMPARATOR|mifepristone|Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion
62542705|NCT01716975|PLACEBO_COMPARATOR|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
62542706|NCT01716975|EXPERIMENTAL|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
62542707|NCT01716975|EXPERIMENTAL|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
62542708|NCT04409314||Diagnostic (18F-FAZA PET scan)|Prior to CAR T-cell therapy, patients receive administration of 18F-FAZA IV. Patients will then undergo a vertex-thigh PET scan approximately 2 hours after injection of 18FFAZA lasting 30-45 minutes.
62542709|NCT06381557|EXPERIMENTAL|Experimental Group|
62542710|NCT06381557|PLACEBO_COMPARATOR|Control Group|
62542711|NCT03244644|PLACEBO_COMPARATOR|Placebo|Placebo is an suspension of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
62542712|NCT03244644|EXPERIMENTAL|RBX2660|RBX2660 is a rectally administered microbiota suspension in a 0.9% sodium chloride irrigation United States Pharmacopeia (USP) solution and cryoprotectant
62542713|NCT03307629|EXPERIMENTAL|NOX66 + Radiation treatment (combined) in cohorts 1-3|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 treatment given to 3 cohorts of 4 patients as 1 of 3 doses, 400mg, 800mg and 1200 mg.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
62542714|NCT03307629|EXPERIMENTAL|NOX66 + Radiation treatment (combined) in cohort 4|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 dose will be either one of 3 doses 400mg, 800mg and 1200 mg based on interim analyses of safety data and tumour response at WEEK 6 of 3 dose cohorts of 12 total patients. The Safety Steering Committee will inform on dose for cohort expansion.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
62542715|NCT04623086|EXPERIMENTAL|Insulin Glargine and Insulin Degludec|Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
62542716|NCT04623086|PLACEBO_COMPARATOR|Insulin Degludec and placebo|Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
62735836|NCT01720004|NO_INTERVENTION|Usual care|Participants were asked to refrain from using hands-and-knees position at any time from randomization to delivery. They were free to use any other position.
62542717|NCT00564330|ACTIVE_COMPARATOR|esomeprazole|Esomeprazole 20mg twice daily
62542718|NCT00564330|PLACEBO_COMPARATOR|placebo|Placebo tablet twice daily
61976522|NCT05505903||Friendly Cesarean section|Newborn infants born by friendly Cesarean section
62164865|NCT04605471||TRUST study|"'TRUST' assessed the safety and tolerability of Ultravist in patients undergoing cardiac catheterization. It was conducted from August 2010 to September 2011 in China and included 17,513 patients of which 12 were children and 8,918 were elderly patients.~Ref. Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, et al. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Int J Cardiovasc Imaging. 2015;31(7):1281-91."
62164866|NCT04605471||Ultravist in CT study|"'Ultravist in CT' was performed with focus on contrast-enhanced CT examination between November 2006 and December 2008 and included 15,168 patients in Germany, Iran, Romania and Saudi Arabia. A total of 417 patients were children, 7,453 were elderly patients.~Ref. Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014;55(6):707-14."
62542719|NCT06634433|EXPERIMENTAL|Training of Trainers (ToT) Program Group|Participants in this group will receive a two-phase Training of Trainers Program (TTP) aimed at improving their skills in interprofessional education. The first phase includes three days of online theoretical training covering topics such as interprofessional communication, teamwork, and scenario-based learning. The second phase consists of two days of face-to-face practical sessions, where participants will engage in scenario-based group work and role-playing activities to reinforce skills in collaborative healthcare practices. To evaluate the effectiveness of the training program, all participants will complete a pre-test before the training and a post-test after the training
62542720|NCT05289297|ACTIVE_COMPARATOR|Karydakis Flap Procedure|Vertical eccentric elliptical incision down to the post-sacral fascia, complete removal of unhealthy tissue, and normal tissue around the cyst and sinus tracts. Mobilization of the medial wound edge and advancement of the skin. Flap along the midline to the post-sacral fascia and suturing its margin to the lateral wound margin.
62542721|NCT05289297|ACTIVE_COMPARATOR|Burow's Triangle Advancement Flap Procedure|The flap is incised along the base of the wedge-shaped defect, and a small Burow's triangle is excised on the opposite side. The skin is mobilized and shifted in the direction of the arrow to close the defect. Excising the small Burow's triangle eliminates a dog ear at the base of the flap.
62735837|NCT00770627|PLACEBO_COMPARATOR|Placebo caps|
62735838|NCT00770627|ACTIVE_COMPARATOR|Omega 3 caps|
62716365|NCT05841498|ACTIVE_COMPARATOR|Immunoadsorption|"Immunoadsorption will be conducted with the Plasauto Sigma extracorporeal therapy system in combination with the TR-350 adsorber (Addendum February 2024: or with the Miltenyi Life-21 system in combination with the Ig-Omni adsorber) over 7 days (3 times daily, 2 times every other day). During each session 2-2.5 times the participant's plasma volume will be treated. This therapy regimen is proven by studies with groups of patients suffering from other autoimmune diseases (Boedecker, Luessi et al. 2022). The material needed for the immunoadsorption is provided by Diamed, the provider of Plasauto Sigma and TR-350 adsorber (Addendum February 2024: or by Miltenyi Biotec, the Provider of Life-21 and IgOmni) . To exclude possible beneficial or adverse effects of heparin on participants' symptoms, regional anticoagulation will be performed using citrate.~This is a cross-over study: Each participant will receive immunoadsorption and sham treatment with a wash-out period of 8 weeks in between."
62716366|NCT05841498|SHAM_COMPARATOR|Sham-apheresis|The sham procedure will also be conducted with the Plasauto Sigma extracorporeal therapy system (Addendum February 2024: or the Miltenyi Life-21 therapy system) without an inserted adsorber. To ensure that sham treatment is indistinguishable from immunoadsorption for the subjects, the therapy regimen is identical except for the missing adsorber. For both verum therapy and sham procedure, the devices are placed behind a portable wall and covered with a curtain not visible to the patient. However, since the setup of the machines differs depending on the procedure, it is not possible to blind the supervising staff as well. To exclude possible beneficial or adverse effects of heparin on participants' symptoms, regional anticoagulation will be performed using citrate. If a subject does not have sufficiently large peripheral veins, a large-bore central venous catheter will be placed for both IA and sham treatments.
62716367|NCT06356168|EXPERIMENTAL|Social Virtual Reality|Social Virtual Reality will be delivered using virtual reality glasses for 30-45 minutes during dialysis sessions. Groups of 3 participants will watch a movie or program together through the glasses. They will be able to talk and interact during the session.
62716368|NCT06356168|ACTIVE_COMPARATOR|Individual Virtual Reality|Individual Virtual Reality will be delivered using virtual reality glasses for 30-45 minutes during dialysis sessions. Those randomized to this arm will watch a movie or program alone through the glasses.
62716369|NCT00240851|EXPERIMENTAL|001|acetaminophen extended release
62716370|NCT04388163|EXPERIMENTAL|Gentian Violet Treatment|A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.
62716371|NCT06690307|ACTIVE_COMPARATOR|sulfentanil group|Participants in the active comparator group will receive sulfentanil for PCIA.
62716372|NCT06690307|EXPERIMENTAL|oxycodone group|Participants in the experimental group will receive oxycodone for PCIA.
62716373|NCT01792167|EXPERIMENTAL|Second Step|Second Step Curriculum
62716374|NCT01792167|NO_INTERVENTION|Stories of Us|Stories of Us was provided to schools
62716375|NCT06717035|ACTIVE_COMPARATOR|Children on clear DIMS lenses|202 children will be recruited at 6 institutions following the rules of inclusion and exclusion criteria. Based on a randomization process defined from the study coordinator, children will be allocated to 2 groups: DIMS and PDIMS. The study will be single blinded, meaning that the investigators are not aware of which type of treatment will be associated with which subjects. Subjects cannot be blinded due to the darkening of PDIMS that allows recognition on the type of lens.
62716376|NCT06717035|ACTIVE_COMPARATOR|Children on photochromic DIMS lenses|202 children will be recruited at 6 institutions following the rules of inclusion and exclusion criteria. Based on a randomization process defined from the study coordinator, children will be allocated to 2 groups: DIMS and PDIMS. The study will be single blinded, meaning that the investigators are not aware of which type of treatment will be associated with which subjects. Subjects cannot be blinded due to the darkening of PDIMS that allows recognition on the type of lens.
62716377|NCT06467682|OTHER|12-week intervention tele-exercise program|tele-exercise and tele-rehabilitation
62716378|NCT06713278||fibromyalgia with tension type headache|fibromyalgia with tension type headache
62716379|NCT06713278||fibromyalgia without tension type headache|fibromyalgia without tension type headache
62716380|NCT06713278||control group|control group
62716381|NCT04375800|EXPERIMENTAL|Doravirine + 2 NRTIs|Participants receive DOR (3.2 mg to 100 mg based on weight) in combination with 2 NRTIs (based on local label) for 96 weeks.
62716382|NCT04640623|EXPERIMENTAL|Cohort 1: TAR-200 and Cetrelimab|TAR-200 is placed into the bladder through a urinary placement catheter in participants with carcinoma in situ (CIS), with or without papillary disease, on Day 0 and will be dosed every 3 weeks (Q3W) for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2). In addition, Cetrelimab will be dosed Q3W through Week 78 (18 months).
62716383|NCT04640623|EXPERIMENTAL|Cohort 2: TAR-200|TAR-200 is placed into the bladder through a urinary placement catheter in participants with CIS, with or without papillary disease, on Day 0 and will be dosed Q3W for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2).
62716384|NCT04640623|EXPERIMENTAL|Cohort 3: Cetrelimab|Participants with CIS, with or without papillary disease, will receive Cetrelimab which will be dosed Q3W through Week 78 (18 months).
62716385|NCT04640623|EXPERIMENTAL|Cohort 4: TAR-200 (Participants with Papillary Disease only)|TAR-200 is placed into the bladder through a urinary placement catheter in participants with papillary disease only, on Day 0 and will be dosed Q3W for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2).
62716386|NCT03767257|EXPERIMENTAL|Participants with Myeloma|Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea
62164867|NCT03532568|EXPERIMENTAL|CKD-aP patients|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue and their response to narrow band ultraviolet B
62164868|NCT03532568|EXPERIMENTAL|CKD patients without pruritis|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
62164869|NCT03532568|EXPERIMENTAL|normal healthy participants|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
62164870|NCT00579475|PLACEBO_COMPARATOR|Placebo|
61976523|NCT06167044|ACTIVE_COMPARATOR|thoracic mobilization group|which will include 17 patients who will receive thoracic manual mobilization exercises in addition to selected physical therapy .The treatment will conducted for 45 minutes, 3 sessions per week for 6 weeks.
62716387|NCT06718465||Sudden Cardiac Death Victim with coronary artherosclerosis|Sudden Death victims (\>18 years old) who have died in the community and there is supportive evidence of myocardial infarction on autopsy.
62716388|NCT06718465||Sudden Death Victim without coronary artherosclerosis|Sudden Death victims (\>18 years old) who have died in the community with no evidence of coronary atherosclerosis or myocardial infarction on autopsy.
62716389|NCT03247829||Group A: Patients with CardioMEMS PA Sensor and HeartMate LVAD prior to study enrollment|Patients with CardioMEMS PA Sensor and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS HF System
62716390|NCT03247829||Group B: Patients with existing HeartMate LVAD implanted with CardioMEMS PA Sensor post enrollment|Patients with a HeartMate LVAD prior to study enrollment who are implanted with a CardioMEMS PA Sensor within 72 hours of study enrollment, will receive hemodynamic management using CardioMEMS HF System
62716391|NCT04429464|EXPERIMENTAL|Non-randomized|All subjects will be treated using the Acutus Medical's AcQBlate Force Sensing Ablation Catheter in combination with the Qubic Force Sensing Module (AcQBlate Force Sensing System) to treat their arrhythmia.
62716392|NCT06716203|EXPERIMENTAL|Experimental: 5 mg BGM0504|Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
62542722|NCT03834454|ACTIVE_COMPARATOR|Bupivacaine 5 mg|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
62542723|NCT03834454|ACTIVE_COMPARATOR|Bupivacaine 7.5 mg|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
62542724|NCT03376061|ACTIVE_COMPARATOR|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
62542725|NCT03376061|ACTIVE_COMPARATOR|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
62542726|NCT01741883|NO_INTERVENTION|Standard Medical Care and Information|Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
62542727|NCT01741883|EXPERIMENTAL|Side effect prevention training (SEPT)|Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
62542728|NCT01741883|ACTIVE_COMPARATOR|Attention Control group (ACG)|Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.
62542729|NCT00557089|OTHER|1|This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
62716393|NCT06716203|EXPERIMENTAL|Experimental: 10 mg BGM0504|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
62716394|NCT06716203|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
62716395|NCT04633447|EXPERIMENTAL|Guselkumab|Participants will receive guselkumab subcutaneously (SC) every 4 weeks from Week 0 through Wweek 48. This will be in combination with a protocol specified 26-week GC taper. Participants of the long-term extension (LTE) period will continue to receive subcutaneous (SC) injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a Giant cell arteritis (GCA) flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
62716396|NCT04633447|EXPERIMENTAL|Placebo|Participants will receive matching placebo SC every 4 weeks from Week 0 through Week 48. This will be in combination with a protocol-specified 26-week GC taper. Participants of the LTE period will continue to receive SC injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a GCA flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
62735839|NCT01804933|NO_INTERVENTION|conventional neuromuscular blockade|No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement
62164871|NCT00579475|ACTIVE_COMPARATOR|I|Mifepristone (Mifegyne) 50 mg every other day for 3 months
62542730|NCT00557089|OTHER|2|This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.
62542731|NCT00109408|EXPERIMENTAL|1|
62542732|NCT00109408|ACTIVE_COMPARATOR|2|
62542733|NCT02343783|EXPERIMENTAL|Healthy + Atopic Dermatitis + Allergic Asthmatic Participants|Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. Participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed for the use of induced skin blisters after allergic skin reaction (ASR).
62542734|NCT04685408|EXPERIMENTAL|TargEted MAnageMent Intervention (TEAM)|This arm will receive the experimental intervention, TargEted MAnageMent Intervention (TEAM)
62542735|NCT04685408|ACTIVE_COMPARATOR|Enhanced treatment as usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
62542736|NCT01006018|EXPERIMENTAL|Sitagliptin + Pioglitazone PLACEBO|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone PLACEBO daily by mouth"
62542737|NCT01006018|EXPERIMENTAL|Sitagliptin + Pioglitazone|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone (TZD) 15 mg daily by mouth"
62542738|NCT01006018|PLACEBO_COMPARATOR|PLACEBO|"Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth~+ pioglitazone (TZD) PLACEBO daily by mouth"
62542739|NCT06054165|NO_INTERVENTION|Standard-of-care|
62542740|NCT06054165|ACTIVE_COMPARATOR|Best-practice|
62542741|NCT02140385|ACTIVE_COMPARATOR|Abdominoplasty-Scarpa's fascia preservation|Scarpa's fascia preservation Lymphoscintigraphy 3D imaging Abdominal ultrasound
62542742|NCT02140385|ACTIVE_COMPARATOR|Abdominoplasty-Scarpa's fascia ablation|Scarpa's fascia ablation Lymphoscintigraphy 3D imaging Abdominal ultrasound
62542743|NCT04614415|EXPERIMENTAL|Treatment group|group 1 will be treated with autocrosslinked Hyaluronic acid
62542744|NCT04614415|PLACEBO_COMPARATOR|control group|group 2 treated with placebo (isotonic saline solution).
62735840|NCT01804933|ACTIVE_COMPARATOR|optimal neuromuscular blockade|Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively
62542745|NCT01374269|EXPERIMENTAL|Excercise|One group will be assigned to protocolized back pain exercise, three times a week for 4 weeks. This program is carried out by physiotherapists from participating institutions who wish to participate in research and who will be given a training which will standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. Treatment, type of exercises, exercise tolerance and adverse reactions will be registered
62542746|NCT01374269|ACTIVE_COMPARATOR|NSAID|Naproxen 500 mg per day by 10 days or Celecoxib 200 mg per day by 10 days and Acetaminophen 1,5 a 2 g as rescue
62542747|NCT01343446||Patients with Diabetes|Patients with diabetes suffer from sleep impairment or not
62542748|NCT04423185|EXPERIMENTAL|Almonertinib-EGFR mutation|Administration: 110 mg oral qd, to disease progression or intolerable adverse effects.
62542749|NCT04423185|EXPERIMENTAL|Dacomitinib-EGFR mutation|Administration: 45 mg oral qd, to disease progression or intolerable adverse effects.
62542750|NCT04423185|EXPERIMENTAL|Alectinib-ALK fusion|Administration: 600 mg oral qd, to disease progression or intolerable adverse effects.
62542751|NCT04423185|EXPERIMENTAL|Crizotinib-ALK fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
62542752|NCT04423185|EXPERIMENTAL|Vemurafenib-BRAF mutation|Administration: 960 mg oral bid, to disease progression or intolerable adverse effects.
62542753|NCT04423185|EXPERIMENTAL|Niraparib-BRCA mutation or HRD|Administration: 200/300 mg oral qd, to disease progression or intolerable adverse effects.
62542754|NCT04423185|EXPERIMENTAL|Pyrotinib-HER-2 overexpression/amplification|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
62542755|NCT04423185|EXPERIMENTAL|Imatinib-CKIT mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
62542756|NCT04423185|EXPERIMENTAL|Palbociclib-CDKN2A mutation|Administration: 125 mg oral qd for 21 days q28d, to disease progression or intolerable adverse effects.
62542757|NCT04423185|EXPERIMENTAL|Crizotinib-ROS-1 fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
62542758|NCT04423185|EXPERIMENTAL|Crizotinib-C-MET amplification|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
62542759|NCT04423185|EXPERIMENTAL|Crizotinib-C-MET mutation|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
62542760|NCT04423185|EXPERIMENTAL|Pyrotinib-HER-2 mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
62542761|NCT04423185|EXPERIMENTAL|Sintilimab-PD-1|Administration: 200mg q21d, to disease progression or intolerable adverse effects.
62542762|NCT04423185|EXPERIMENTAL|Combination ARM-Niraparib & Sintilimab|Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
62542763|NCT04423185|EXPERIMENTAL|Combination ARM-Vemurafenib & Atezolizumab|Vemurafenib (960 mg oral bid) \& Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
62542764|NCT04423185|EXPERIMENTAL|Combination ARM-Palbociclib & Atezolizumab|Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
62542765|NCT04117919|EXPERIMENTAL|chinese medicine medicated bath|we used the leaf of paper mulberry as chinese medicine medicated bath. Two packs per day ,and the period of treatment will be two month.
62542766|NCT04117919|ACTIVE_COMPARATOR|control group|Topical steroids
62542767|NCT05885984|EXPERIMENTAL|ACT group|Participants in the intervention group will receive ACT intervention, consisting of six online sessions via video conferencing platform (The first two sessions for patient only, the third and fourth sessions for caregiver only, and the last two sessions for patient-caregiver dyads) of 60-90 min each (once/week), in addition to health education.
62542768|NCT05885984|OTHER|Health eduction control group|Participants randomised to the health education control group will receive six weekly health education by a video-conferencing platform. The topics mainly include treatments and daily care during admission, medication instructions and side effects, diet and exercise advice, and retest recommendations when discharged.
62542769|NCT06634355|EXPERIMENTAL|ex-vivo placenta perfusion|Measurement of placental transfer.
62542770|NCT03909880|NO_INTERVENTION|Control|Without Kinesio tape on the forearm
62542771|NCT03909880|PLACEBO_COMPARATOR|Kinesio taping with neutral tension|Kinesio tape with neutral tension on the forearm
62542772|NCT03909880|EXPERIMENTAL|Kinesio taping with additional 20% tension|Kinesio tape with 20% additional tension on the forearm
62542773|NCT05007821|EXPERIMENTAL|Arm A|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm A participants will take linezolid (LZD) once a day for the entire treatment period.~* Weeks 1-26: LZD 600 mg once daily (QD)~* Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~* Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~* Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
61976524|NCT06167044|NO_INTERVENTION|control group|which will include 17 patients who will receive selected physical therapy.The treatment will conducted for 45 minutes, 3 sessions per week for 6 weeks.
62542774|NCT05007821|EXPERIMENTAL|Arm B|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm B participants will take a higher dose of linezolid (LZD) once a day for 4 weeks and then continue taking that higher dose of LZD just three times a week for the rest of the treatment period.~* Weeks 1-4: LZD 1200 mg once daily (QD)~* Weeks 5-26: LZD 1200 mg three times per week (TIW)~* Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~* Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~* Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
62542775|NCT00710866|EXPERIMENTAL|1|2 doses 0.5mL VAXIGRIP® at months 0, 1
62542776|NCT00710866|ACTIVE_COMPARATOR|2|2 doses 0.25mL VAXIGRIP® at months 0, 1
62542777|NCT03769961||ET (DBS-, Ataxia+)|Essential Tremor without DBS with Ataxia on examination
62542778|NCT03769961||ET (DBS-, Ataxia-)|Essential Tremor without DBS and without Ataxia on examination
62542779|NCT03769961||ET (DBS+, Ataxia+)|Essential Tremor with DBS with Ataxia on examination
62542780|NCT03769961||ET (DBS+, Ataxia-)|Essential Tremor with DBS without Ataxia
62542781|NCT05382585||Head neck cancer|Histologically diagnosed cases of head and neck cancer
62542782|NCT06549855|EXPERIMENTAL|PD-1 Inhibitor Combined With Progesterone Treatment|All participants
62716397|NCT05544084|EXPERIMENTAL|Adapted Patient Navigation Program|Adaptation of a patient navigation approach to effect change in cervical cancer screening uptake in Kedougou and Dakar, Senegal. Conduct a stepped-wedge randomized pragmatic trial in three districts in the Kedougou Region and three districts in Dakar to evaluate the impact of The Adapted Program. In order to conduct this trial, investigators will deploy The Adapted Program and evaluate the impact of The Adapted Program on screening uptake and time to treatment initiation (for those with abnormal screening results) within the various contexts across clusters. Investigators will also explore the effect of The Adapted Program on intrapersonal- and community-level barriers. Finally, evaluate the implementation outcomes of The Adapted Program within the context of these rural and urban districts, whereby clusters serve as their own controls as they cross over from the control to intervention group.
62716398|NCT05544084|NO_INTERVENTION|Control|Standard of care
62716399|NCT05626426|EXPERIMENTAL|Active SASm|Patients will receive active treatment with the device every other day over 8 weeks.
62716400|NCT06102655|EXPERIMENTAL|treatment group（Jiajian Guishen Formulation）|Jiajian Guishen Formulation is a traditional Chinese medicine, it will be used in POI patients for three menstrual cycles; their blood samples are collected before and after treatment.
62716401|NCT06102655|NO_INTERVENTION|no-treatment control group|healthy people
62716402|NCT06341881|EXPERIMENTAL|Intervention Group|A total of 30 participants would be exposed to the nursing care training (intervention) randomly.
62716403|NCT06341881|NO_INTERVENTION|Control Group|A sample of 30 study participants would not be exposed to the training and would be kept in the control group. They would be a group who would receive usual care and routine awareness by their health care professionals.
62716404|NCT04752722|EXPERIMENTAL|Phase 1|Dose escalation phase
62716405|NCT04752722|EXPERIMENTAL|Phase 2|"Cohort 1: Recommended Phase 2 dose (RP2D) with eligible BCG-unresponsive NMIBC patients, up to 4 cycles of treatment with EG-70~Cohort 2: RP2D with eligible high-risk NMIBC patients who have been incompletely treated with BCG or are BCG-naïve"
62716406|NCT06357975|EXPERIMENTAL|Subprotocol C1 (MET amplification)|Patients receive crizotinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation and collection of blood samples throughout the study. Patients may undergo biopsy at screening, on study, and/or at end of treatment.
62716407|NCT04992026|EXPERIMENTAL|ADT plus abiraterone + surgery|After 6 cycles of first-line treatment (Androgen deprivation therapy + abiraterone acetate along with prednisone) , patients will receive robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection (ePLND) within 9 months of being diagnosed. The ADT+abiraterone treatment will be maintained after surgery.
62716408|NCT04992026|ACTIVE_COMPARATOR|ADT plus abiraterone|Patients will be only treated with Androgen deprivation therapy + abiraterone acetate along with prednisone. Prostatectomy won't be performed.
62716409|NCT05121025||Helicobacter pylori patients|Patients with gastric biposies which was positive for Helicobacter pylori in culture
62716410|NCT05121025||Helicobacter pylori asymptomatic carriers|Healthy controls who are positive for Helicobacter pylori antigen in stool and have no symptoms of gastritis
62716411|NCT05121025||Healthy controls|Healthy controls who are negative for Helicobacter pylori antigen in stool and have no symptoms of gastritis
62716412|NCT03910621|EXPERIMENTAL|Miglustat|Miglustat is administered three times a day as an oral capsule
62716413|NCT04684368|EXPERIMENTAL|Plan A (chemotherapy, WVSCI, second-look surgery if needed)|See Outline in Detailed Description.
62716414|NCT04684368|EXPERIMENTAL|Plan B (chemotherapy, HDCSCR, second-look surgery if needed)|See Outline in Detailed Description.
62716415|NCT04443088|OTHER|Dose Escalation|"Phase 1a: Subjects will receive escalating doses of INV-1120 orally once a day until un-acceptable toxicity or disease progression. Three to six patients will be enrolled per cohort to evaluate the safety and pharmacokinetics for each dose level. After the last patient in each cohort completes Cycle 1 (DLT observation period of 28 days), the Safety Evaluation Team (SET) will evaluate the safety data and pharmacokinetic collected from Cycle 1, and make the decision whether to escalate the dose before opening the second cohort.~Phase 1b: Subjects will receive escalating and de-escalating doses of INV-1120 orally once a day in combination with pembrolizumab until un-acceptable toxicity or disease progression, and DLT observation period of 21 days."
62716416|NCT02668666|EXPERIMENTAL|Investigational Treatment|"Subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.~Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.~Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously)."
62716417|NCT06719375||Degenerative Cervical Myelopathy (DCM) Patients|Patients diagnosed with Degenerative Cervical Myelopathy (DCM) scheduled for surgery. This group will undergo gait analysis and clinical assessments at three time points: 10 days pre-surgery, 10 days post-surgery, and 30 days post-surgery.
62716418|NCT05989568|EXPERIMENTAL|BASIS-T|BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
62716419|NCT05989568|PLACEBO_COMPARATOR|Attention Control|Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
62735841|NCT01804933|EXPERIMENTAL|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
61976525|NCT04508868|EXPERIMENTAL|Brief Behavioral Activation with Mental Imagery|Four weekly sessions of Brief Behavioral Activation with Mental Imagery.
61976526|NCT04508868|PLACEBO_COMPARATOR|Minimal Attention Control Intervention|Four weeks with weekly follow-up calls.
62716420|NCT05714007|EXPERIMENTAL|Treatment group|"Iron to be administered as intravenous ferric derisomaltose:~Where Hb (hemoglobin) ≥100 g/L, dosage according to body weight is as follows:~Body weight \<50 kg: 500mg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 1500 mg.~Where Hb \<100 g/L, dosage according to body weight is as follows:~Body weight \<50 kg: 500mg; Body weight 50 to \<70 kg: 1500mg; Body weight ≥70 kg: 2000 mg.~The maximial dose should not exceed 20mg/kg body weight, rounded off to the nearest 100mg"
62542783|NCT06172426||MarketScan® secukinumab, other biologics/apremilast, and any biologics/apremilast cohort|
62542784|NCT06172426||BADBIR secukinumab cohort|
62542785|NCT00451646|EXPERIMENTAL|1|SMOFlipid
62542786|NCT00451646|ACTIVE_COMPARATOR|2|Intralipid
62542787|NCT03951025|ACTIVE_COMPARATOR|Melatonin oral administration|Consumption of one tablet with 1 mg of melatonin orally
62542788|NCT03951025|EXPERIMENTAL|Melatonin sublingual administration|Consumption of one tablet with 1 mg of melatonin sublingually
62542789|NCT03207386|EXPERIMENTAL|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
62542790|NCT03288181|EXPERIMENTAL|Muscle Stretch Group|This is the group who applies the splint to stretch the calf muscles as per the described protocol for 4 weeks.
62542791|NCT03288181|NO_INTERVENTION|Control Arm|This is the group who has undergone no splint for 4 weeks.
62542792|NCT04159870|EXPERIMENTAL|Intervention Group|Rifaximin 1200 mg/day in 3 doses
62542793|NCT04159870|ACTIVE_COMPARATOR|Control Group|Norfloxacin 400 mg/day in one dose
62542794|NCT03133650|EXPERIMENTAL|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
62542795|NCT01955083|EXPERIMENTAL|Pillar implant|"Arm 1- Pillar implant (Study group):~15 subjects undergo pillar implant surgery of the soft palate for the treatment of snoring."
62542796|NCT01955083|ACTIVE_COMPARATOR|Radiofrequency|"Arm 2- Radiofrequency (control group):~15 subjects undergo radiofrequency of the soft palate for the treatment of snoring."
62542797|NCT01793948|EXPERIMENTAL|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62542798|NCT01793948|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
62542799|NCT06634238||Masked Group|Participants who performed the Incremental Shuttle Walk Test (ISWT) while wearing a face mask.
62542800|NCT06634238||Unmasked Group|Participants who performed the Incremental Shuttle Walk Test (ISWT) without wearing a face mask.
62542801|NCT06632574|EXPERIMENTAL|Experimental arm|Patients with advanced solid tumors received arterial infusion chemotherapy with paclitaxel cationic liposomes, at a dosage range of 33 mg/m\^2 to 66 mg/m\^2.
62542802|NCT05503511|EXPERIMENTAL|Part A; Cohort 1|QD dosing of 10mg (1 day)
62542803|NCT05503511|EXPERIMENTAL|Part A; Cohort 2|QD dosing of 50mg (1 day)
62542804|NCT05503511|EXPERIMENTAL|Part A; Cohort 3|QD dosing of 160mg (1 day)
62542805|NCT05503511|EXPERIMENTAL|Part B; Cohort 1|Every 12-hour dosing of 20mg (7 days)
62542806|NCT05503511|EXPERIMENTAL|Part B; Cohort 2|Every 12-hour dosing of 40mg (7 days)
62542807|NCT05503511|EXPERIMENTAL|Part B; Cohort 3|Every 12-hour dosing of 80mg (7 days)
62542808|NCT00685776|EXPERIMENTAL|Anacetrapib|Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
62716421|NCT05714007|ACTIVE_COMPARATOR|Control group|"Iron to be administered as oral ferrous succinate:~1 tablet (100 mg) tid (three times daily), starting on the first postoperative day and continuing for 4 weeks."
62735842|NCT01188902|EXPERIMENTAL|walnut|western type diet with 48 g walnut per day
62735843|NCT01188902|NO_INTERVENTION|control|
62542809|NCT00685776|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.
62542810|NCT04382287|EXPERIMENTAL|REMIN paste|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
62542811|NCT04382287|EXPERIMENTAL|MI PASTE PLUS|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
62542812|NCT04382287|ACTIVE_COMPARATOR|COLGATE Total|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
62542813|NCT02018575|EXPERIMENTAL|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
62716422|NCT04281784|EXPERIMENTAL|EHR-based Clinician Jumpstart|The EHR-based Jumpstart Guide will be developed by extracting data from the EHR using automated methods with both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation and patients' code status.
62716423|NCT04281784|NO_INTERVENTION|Usual Care|The clinicians (hospital teams) for patients in the control group will not receive Jumpstart guides. These subjects will receive usual care.
62716424|NCT06717282|EXPERIMENTAL|Intervention to improve ophthalmic compliance|
62716425|NCT04656587|OTHER|Standard Therapy (Control)|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
62716426|NCT04656587|EXPERIMENTAL|Standard Therapy plus BPAP|Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
62716427|NCT06317636|ACTIVE_COMPARATOR|Ketamine|A one-time intravenous infusion of ketamine (0.5 mg/kg)
62716428|NCT06317636|PLACEBO_COMPARATOR|Saline|A one-time intravenous infusion of normal saline
62716429|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
62716430|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
62716431|NCT02835586|EXPERIMENTAL|paclitaxel delivery in femoropopliteal artery|
62716432|NCT06405386|EXPERIMENTAL|ReCharge|Participants randomized to ReCharge will participate in an emotions-focused intervention facilitated by a mental health professional.
62716433|NCT06405386|EXPERIMENTAL|TakeCharge|Participants randomized to TakeCharge will participate in a problem-solving focused intervention facilitated by a diabetes care professional.
62716434|NCT06255808||Ultrasonic group|
62716435|NCT02030132|ACTIVE_COMPARATOR|Feedback 50th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
62716436|NCT02030132|EXPERIMENTAL|Feedback 75th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
62716437|NCT02030132|EXPERIMENTAL|Feedback 50th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the average team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
62716438|NCT02030132|EXPERIMENTAL|Feedback 75th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
62716439|NCT06062017|EXPERIMENTAL|Water and Potassium|N=40, 20 males, 20 females. Following the two-week habitual run-in period, this group will receive 2000mg potassium supplementation/day for 14 days. This will be achieved by taking capsules filled with potassium citrate powder.
62716440|NCT06062017|NO_INTERVENTION|Habitual consumption|N=40, 20 males, 20 females. All participants will be monitored after two weeks of habitual water and potassium prior to being assigned into two weeks of water and potassium.
62716441|NCT01595087|EXPERIMENTAL|Osteodex, infusion|Osteodex
62716442|NCT06719102|PLACEBO_COMPARATOR|MAGIC-SAFE|Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc. The intervention is delivered via virtual visits, binder, website and newsletters.
62716443|NCT06719102|EXPERIMENTAL|MAGIC-FEED|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines. The intervention is delivered via virtual visits, binder, website and newsletters.
62716444|NCT02150421||e-book|study the course materials by using e-book
62542814|NCT02053337|EXPERIMENTAL|Self adhesive foam dressing|Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
62716445|NCT05063552|ACTIVE_COMPARATOR|Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
62716446|NCT05063552|EXPERIMENTAL|Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
62735844|NCT03763812|OTHER|Endovascular Aneurysm Repair (EVAR)|Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
62735845|NCT03763812|OTHER|Endovascular Aneurysm Sealing (EVAS)|Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
62735846|NCT00811291|PLACEBO_COMPARATOR|1|
62542815|NCT02053337|ACTIVE_COMPARATOR|Comparator self adhesive foam dressing|Non Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
62542816|NCT04778085||IMR patients|Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
62542817|NCT04778085||IMR therapists and other staff|Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
62542818|NCT03131804|EXPERIMENTAL|Interventional Participants|Patients will represent their own controls (pre and post intervention), in the HD unit of Al Qassimi Hospital, Sharjah, United Arab Emirates.
62542819|NCT05277662|EXPERIMENTAL|Precision diagnostics profiling|The study will involve subjects with endoscopically, laboratory and clinically confirmed diagnoses of organic and functional intestinal pathology or none of the above (healthy volunteers). All diagnoses are defined in accordance with the validated criteria presented in the clinical guidelines for the diagnosis and treatment of functional bowel pathology (Irritable Bowel Syndrome), 2020, Crohn's Disease (approved by the Ministry of Health of the Russian Federation, 2020), Ulcerative Colitis (approved by the Ministry of Health of the Russian Federation, 2020), in accordance with international criteria of ECCO-ESGAR Guidelines, 2018, 2019. After the initial screening and inclusion in the study, intestinal biopsy samples are taken in accordance with the applied endoscopic examination technique during the endoscopic examination. These biopsy samples will be further used for molecular and immunological diagnostics.
62542820|NCT04513288|EXPERIMENTAL|Experimental group|Enteral administration of citrulline for 5 days. L-citrulline (Protéocit®). This commercial form consists only of L-citrulline. Each patient will receive 10 grams per day in 2 doses (1 stick/ 12H = 5 grams / 12H). These sticks contain a powder to be resuspended in 50 mL of water for injection (ppi) for 1 stick. They will be delivered in a 50 mL syringe allowing administration of the product through the nasogastric tube. The solution will be prepared just before administration.
62542821|NCT04513288|PLACEBO_COMPARATOR|Control group|Enteral administration of iso-nitrogenous placebo for 5 days. The placebo used will consist of a mixture of 4 non-essential amino acids. 5 g of L-citrulline provides 1.2 g of nitrogen. For the mixture to be iso-nitrogenous, each of the 4 amino acids will need to provide 0.3 g of nitrogen. The mixture will therefore consist of 21.6% alanine, 32.3% aspartate, 18.2% glycine and 27.9% proline for a total of 8.83 g of amino acids per sachet. 2 administrations (2 sticks) daily for 5 days.
62542822|NCT01377012|EXPERIMENTAL|AIN457 10mg/kg-75mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
62542823|NCT01377012|EXPERIMENTAL|AIN457 10mg/kg-150mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
62542824|NCT01377012|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (\>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24
62542825|NCT03197181|EXPERIMENTAL|anodal transcranial direct current stimulation|anodal transcranial direct current stimulation (current strength: 1 mA, duration: 20 min) over the frontopolar cortex
62542826|NCT03197181|SHAM_COMPARATOR|sham transcranial direct current stimulation|sham transcranial direct current stimulation (current strength: 1 mA, duration: 0.5 min) over the frontopolar cortex
62542827|NCT00235404|EXPERIMENTAL|Intermediate community hospital|
62542828|NCT00235404|ACTIVE_COMPARATOR|Usual care|
62542829|NCT04538625|PLACEBO_COMPARATOR|Placebo|Subjects randomized to the placebo arm, will receive oral doses of matching placebo tablets twice daily with or without food.
62542830|NCT04538625|EXPERIMENTAL|Crofelemer|Subjects randomized to the crofelemer arm, will receive oral doses of crofelemer 125mg delayed-release tablets twice daily with or without food.
62542831|NCT02759692|ACTIVE_COMPARATOR|Group 1 (Test/Control/Test)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL / TEST wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
62542832|NCT02759692|ACTIVE_COMPARATOR|Group 2 (Control/Test/Control)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST / CONTROL wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
62542833|NCT01089894||18F-FLT 1|18F-FLT in differentiating benign from malignant pulmonary nodules
62542834|NCT01089894||18F-FLT 2|18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The chemotherapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
62542835|NCT01089894||18F-FLT 3|18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors (The target therapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
62542836|NCT04666389|PLACEBO_COMPARATOR|Control group|No statins being used for prevention
62542837|NCT04666389|ACTIVE_COMPARATOR|Low-dose statin therapy|Atorvastatin 40 mg
62542838|NCT04666389|ACTIVE_COMPARATOR|High-dose statin therapy|Atorvastatin 80 mg
62542839|NCT01021280||Type II BS|Adolescents and young adults with type II Bartter syndrome
62542840|NCT01021280||Type IV BS|Adolescents and adults with type IV Bartter syndrome
62542841|NCT01021280||Controls|Age and sex- matched controls
62542842|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
62542843|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
62542844|NCT01191944|EXPERIMENTAL|pramipexole Extended release|subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement
62542845|NCT01191944|ACTIVE_COMPARATOR|pramipexole Immediate release|subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement
62542846|NCT03848390|EXPERIMENTAL|Modified Time-restricted Feeding|
62542847|NCT03848390|ACTIVE_COMPARATOR|Conventional diet|
62735847|NCT00811291|ACTIVE_COMPARATOR|2|folic acid and B-vitamin supplement
62735848|NCT04438759|EXPERIMENTAL|investigational group|Virtual Reality
62716447|NCT05063552|EXPERIMENTAL|Phase II, Arm C (Bevacizumab, Atezolizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
62716448|NCT05063552|EXPERIMENTAL|Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
62716449|NCT05063552|EXPERIMENTAL|Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)|Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
62716450|NCT05155423||group 1|patient using mask for immobilization
62716451|NCT05155423||group 2|patients using Elekta BodyFix
62716452|NCT06495892|EXPERIMENTAL|PVP-Guided|Peripheral venous pressure guided diuretic therapy arm
62716453|NCT06495892|ACTIVE_COMPARATOR|Control|Standard dıuretic therapy arm
62716454|NCT02234765|ACTIVE_COMPARATOR|Sleep Unit|Patients diagnosed and followed up in the Sleep Unit.
62716455|NCT02234765|EXPERIMENTAL|Primary Care|Patients diagnosed and followed up in the Primary Care.
62716456|NCT06029127|EXPERIMENTAL|Stage 1: BGB-A445 + Docetaxel|BGB-A445 + Docetaxel
62716457|NCT06029127|EXPERIMENTAL|Stage 1: BGB-A445 + BGB-15025|BGB-A445 + BGB-15025
61976527|NCT03187093|ACTIVE_COMPARATOR|Vortioxetine|
62542848|NCT05769010|EXPERIMENTAL|Arm 1|HER2-positive: SHR-A1811
62542849|NCT05769010|EXPERIMENTAL|Arm 2|HER2-positive: SHR-A1811 and pyrotinib
62542850|NCT05769010|EXPERIMENTAL|Arm 3|HER2-positive: SHR-A1811 and bevacizumab
62542851|NCT05769010|EXPERIMENTAL|Arm 4|HER2-low: SHR-A1811
62542852|NCT05769010|EXPERIMENTAL|Arm 5|HER2-low: SHR-A1811 and bevacizumab
62542853|NCT02686736|OTHER|Internet-based educational intervention|The Internet-based educational intervention will include four educational sessions that will be provided during a four-week period. The follow up will last three-months.
62542854|NCT02686736|NO_INTERVENTION|Control group|In the control group, teens will continue the usual school provided sexual education and will be invited to answer the internet-based self-applied questionnaire at the same time as the intervention group.
62542855|NCT05352412|ACTIVE_COMPARATOR|Baseline Counseling As Usual|Patients randomized to the baseline counseling as usual arm will receive provision of one of 3 MAT options, prescription and referral to community providers; overdose prevention education and access to naloxone kits; harm reduction counseling (e.g safe injection practices, referral to PrEP); lab testing for HIV, HBV, HCV infection, and routine vaccinations (e.g. Hepatitis A). That includes wrap-around services modeled on the Ryan White Program, with access to social worker, case manager, and mental health counselor who follow up with patients, enroll them in insurance as eligible, and provide ongoing support. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.
62542856|NCT05352412|ACTIVE_COMPARATOR|Shared Decision Making Aid|Patients randomized to the decision aid arm will receive all of the above as well as a shared decision making aid. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.The provider will have access to then have access to this summary in making final care decisions with the patient.
62542857|NCT05352412|NO_INTERVENTION|Assessing Stigma of Providers|Providers who provide care for patients enrolled in this project will be asked to participate in a survey to assess their stigma in regards to taking care of patients with opioid use disorder. This will be a 10-minute tablet- or web-based in-person survey administered by one of our wraparound care service team members.
62542858|NCT02938377|ACTIVE_COMPARATOR|No dx of alcohol use disorder, panic or depre|Computerized Brief Intervention (CBI)- a video about alcohol abuse
62542859|NCT02938377|ACTIVE_COMPARATOR|Risky drinking, no dx of AUD, has panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy
62716458|NCT06029127|EXPERIMENTAL|Stage 2: BGB-A445 + selected investigational agent(s) from Stage 1|BGB-A445 + selected investigational agent(s) from Stage 1 (either Docetaxel or BGB-15025)
62716459|NCT06029127|OTHER|Docetaxel + Ramucirumab|Reference to Stage 2: Ramucirumab + Docetaxel
62716460|NCT04753775|EXPERIMENTAL|22 patients were assigned to Group-A|22 patients were assigned to Group-A
62716461|NCT04753775|PLACEBO_COMPARATOR|22 patients were assigned to Group-B|22 patients were assigned to Group-B
62716462|NCT00352300|EXPERIMENTAL|Treatment (carboplatin, paclitaxel, pegfilgrastim)|Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
62716463|NCT06173531|EXPERIMENTAL|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
62716464|NCT06173531|PLACEBO_COMPARATOR|Placebo|Placebo
62716465|NCT06247982||DCB de novo PCI|All patients who received a de novo DCB PCI
62716466|NCT06247982||BOS PCI|All patients who received a stent after DCB treatment of de novo coronary lesion because of high grade dissection or recoil more than 30%
62716467|NCT01541371|EXPERIMENTAL|Paliperidone ER|
61976528|NCT03187093|ACTIVE_COMPARATOR|Escitalopram|
61976529|NCT05131074|EXPERIMENTAL|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions.
62716468|NCT01317992|EXPERIMENTAL|Ibudilast|To receive ibudilast 40mg twice daily for 8 weeks.
62716469|NCT01317992|PLACEBO_COMPARATOR|Placebo|To receive placebo twice daily for 8 weeks.
62716470|NCT05330182|EXPERIMENTAL|Sentinel Cohort|
62716471|NCT05330182|ACTIVE_COMPARATOR|LMN-201|
62716472|NCT05330182|PLACEBO_COMPARATOR|Placebo|
62716473|NCT04326790|EXPERIMENTAL|Intervention|Colchicine, on top of standard treatment
62716474|NCT04326790|ACTIVE_COMPARATOR|Control|Standard treatment, including all medications recommedned by the National Public Health Organization
62716475|NCT05061368|EXPERIMENTAL|Sildenafil|Participants will be administered a 25 mg oral dose of sildenafil.
62716476|NCT05061368|PLACEBO_COMPARATOR|Placebo|Participants will be administered an oral placebo indistinguishable from the sildenafil pill.
62716477|NCT03849105|EXPERIMENTAL|Single administration of 131I-IPA (1f group)|Study participants with GBM receive a single administration of 4-L-\[131I\]iodo-phenylalanine (131I-IPA), followed by 18 cycles of external radiotherapy, each cycle being of 2 Gy.
62716478|NCT03849105|EXPERIMENTAL|Three administrations of 131I-IPA (3f-parallel group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above, 1- 3 days prior to 1st XRT. The 2nd and 3rd 131I-IPA fractions will be administered after 5-9 XRT fractions (subject to investigator's discretion and day of IMP administration) following the previous 131I-IPA fraction. The remainder of XRT fractions will be given following the 3rd 131I-IPA fraction.
62716479|NCT03849105|EXPERIMENTAL|Three administrations of 131I-IPA (3f-sequential group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above 1- 3 days prior to 1st XRT. The 2nd 131I-IPA fraction will be administered after all 18 XRT fractions have been completed, and the 3rd 131I-IPA fraction will be administered 1 week after the 2nd 131I-IPA fraction.
62716480|NCT03849105|EXPERIMENTAL|Dose escalation of fractionated dosing|Dose escalation will be made in steps of 2.0 GBq, i.e. 4.0 (3\*1.33 GBq), 6.0 GBq (3\*2.0 GBq), up to 8.0 GBq (3\*2.67 GBq) until the maximum tolerated dose (MTD) is reached, using cohorts of N=3 patients.
62716481|NCT01336777||Insulin resistant group|there is no intervention
62716482|NCT01336777||Insulin sensitive group|There is no intervention
62716483|NCT01847755|EXPERIMENTAL|120 Hyperbaric treatments at 1.5 ATA|Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
62716484|NCT05690425|EXPERIMENTAL|BC3402 treatment group|BC3402 as a single agent via intravenous infusion once every 3-weeks
62716485|NCT01130792|EXPERIMENTAL|Lactobacillus GG|LGG once daily for 4 weeks
62716486|NCT01130792|PLACEBO_COMPARATOR|Inulin|
62716487|NCT01339507||Bepreve|Subjects with a history of allergic conjunctivitis.
62716488|NCT01339507||Lastacaft|Subjects with a history of allergic conjunctivitis.
62716489|NCT02275507||Women Undergoing Scheduled Cesarean Delivery|We will be recruiting women who are scheduled for an elective repeat or primary cesarean delivery.
62716490|NCT04814914||KB109 + Self Supportive Care (SSC)|
62716491|NCT04814914||Self Supportive Care (SSC) Alone|
62716492|NCT01411033||Newly diagnosed diabetes mellitus type 1|
62716493|NCT03496116|EXPERIMENTAL|ECIG Session: 0.5 Ohms, 3 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 3 mg
62716494|NCT03496116|EXPERIMENTAL|ECIG Session 0.5 Ohms, 8 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 8 mg
62164872|NCT04376255|EXPERIMENTAL|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
62164873|NCT03258905|EXPERIMENTAL|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
62716495|NCT03496116|EXPERIMENTAL|ECIG Session 1.5 Ohms, 3 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 3 mg
62716496|NCT03496116|EXPERIMENTAL|ECIG Session 1.5 Ohms, 8 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 8 mg
62716497|NCT06602791||Video Group|Patients will be taken to the preoperative preparation unit, where those in the video group will watch short videos of their choice on a phone or tablet for 20 minutes under the guidance of their parents.
62716498|NCT06602791||Control Group (Standard)|The control group will undergo standard preoperative preparation. Patients in this group will not watch any videos.
62716499|NCT06718777|EXPERIMENTAL|0.1% polyhexanide|0.1% polyhexanide solution was applied 3 times at 48-hour intervals for pressure ulcer care.
62716500|NCT06718777|EXPERIMENTAL|0.9% NaCl|0.9% sodium chloride solution was applied three times at 48-hour intervals for pressure ulcer care.
62716501|NCT03346525|EXPERIMENTAL|BPG Arm|Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days
62716502|NCT03346525|NO_INTERVENTION|Control Arm|No prophylaxis
62716503|NCT06714942|EXPERIMENTAL|Treatment Group|One capsule of Proprietary Blend of Ashwagandha 300 mg twice a day, orally with water.
62716504|NCT06714942|EXPERIMENTAL|Comparator Group|One capsule of KSM-66 Ashwagandha 300mg two times a day, orally with water
62164874|NCT03258905|ACTIVE_COMPARATOR|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
62164875|NCT02857309|OTHER|Device implant|Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
62716505|NCT06714942|PLACEBO_COMPARATOR|Control Group|One capsule of Placebo two times a day, orally with water
62716506|NCT05196308|EXPERIMENTAL|Xeomin® receivers|Patients will receive Xeomin®.
62716507|NCT05196308|PLACEBO_COMPARATOR|Placebo receivers|Patients will receive placebo injection instead of Xeomin®.
62716508|NCT01690754|NO_INTERVENTION|Control|This arm will receive the regular standard of care given by TB clinics.
62716509|NCT01690754|EXPERIMENTAL|Interactive Reminders|Patients randomized to this arm will receive Interactive SMS reminders daily.
62716510|NCT05160545|EXPERIMENTAL|GNC-035|Patients receive GNC-035 intravenous infusion (IV, QW) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles
62716511|NCT04188951|OTHER|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|
62735849|NCT04438759|NO_INTERVENTION|reference group|standard of care
62542860|NCT02938377|ACTIVE_COMPARATOR|Dx of AUD with or without panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy plus a recommendation for Alcohol Pharmacotherapy (APT). The drugs recommended in the APT are all standard of care drugs for alcohol treatment and are not under study in this protocol.
62542861|NCT03170531||Custom MR spine coil|
62542862|NCT01613313|EXPERIMENTAL|Dose #1|single injection 0.058 mg Collagenase Clostridium Histolyticum
62542863|NCT01613313|EXPERIMENTAL|Dose #2|single injection 0.15 mg Collagenase Clostridium Histolyticum
62542864|NCT01613313|EXPERIMENTAL|Dose #3|single injection 0.29 mg Collagenase Clostridium Histolyticum
62542865|NCT01613313|EXPERIMENTAL|Dose #4|single injection 0.44 mg Collagenase Clostridium Histolyticum
62542866|NCT04228497|ACTIVE_COMPARATOR|clear fluids fasting for one hour|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml one hour before surgery
62542867|NCT04228497|PLACEBO_COMPARATOR|clear fluids fasting for two hours|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml two hours before surgery
62542868|NCT05301595|ACTIVE_COMPARATOR|TAP block|"All patients will have paravertebral (PV) blocks of the chest performed prior to induction of general anesthesia.~Patients in this group will have bilateral sham blocks performed after PV block is complete. 2ml of normal saline will be injected under the skin bilaterally near the insertion site of a typical QL block.~TAP block will be performed intraoperatively by the surgeon. The anesthesiologist will provide the surgeon with 40ml of LA mixture (ropivacaine 0.25%, epinephrine 100mcg and dexamethasone 4mg) for patients in this group. The surgeon will be blinded to the injectate content. The TAP block is performed once the abdominal flap has been harvested. The triangle of Petit is landmarked by the iliac crest inferiorly, the latissimus dorsi muscle posteriorly and the external oblique muscle anteriorly. A blunt tip needle is advanced through the external oblique fascia and internal oblique fascia. A total volume 20mL of the LA mixture will be injected per side."
62542869|NCT05301595|ACTIVE_COMPARATOR|QL block|"All patients will have paravertebral (PV) blocks of the chest performed prior to induction of general anesthesia.~Patients in this group will have QL block performed after PV block is complete. This will be performed with patients in the prone position using the transverse in-plane technique. With realtime U/S guidance, the quadratus lumborum muscle is identified before a short-bevel needle is advanced into the plane between the quadratus lumborum and psoas major muscles. Needle tip position is confirmed by separation of quadratus lumborum and psoas major upon injection. 20ml of ropivacaine 0.25%, epinephrine 50mcg and dexamethasone 2mg will be injected per side.~TAP block is performed intraoperatively similar to above but with 40mL of normal saline to perform a sham block. The anesthesiologist will provide the surgeon with 40ml of normal saline in this group. The surgeon will be blinded to the injectate content."
62542870|NCT04423887|ACTIVE_COMPARATOR|Control|
62542871|NCT04423887|EXPERIMENTAL|Creatine Supplementation|
62542872|NCT01180426|EXPERIMENTAL|Tosedostat|
62542873|NCT04222972|EXPERIMENTAL|Pralsetinib|Participants randomized to the Experimental Arm will receive Pralsetinib
62542874|NCT04222972|ACTIVE_COMPARATOR|Platinum-based chemotherapy with or without pembrolizumab|"Participants randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology)~Nonsquamous histology~* Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance.~* Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance.~Squamous histology~* Carboplatin or cisplatin / gemcitabine~* Carboplatin with paclitaxel/nab-paclitaxel and pembrolizumab"
62542875|NCT05243446||Study group|Hypotensive treatment including Losartan
62542876|NCT05243446||Control group|Hypotensive treatment without renin-angiotensin-aldosteron system blockers.
62542877|NCT05659693|EXPERIMENTAL|Experimental Group|Digital literacy education specific to menopause will be given to this group.
62542878|NCT05659693|NO_INTERVENTION|Control Group|no intervention will be applied to this group.
62542879|NCT01886079|EXPERIMENTAL|Dexmedetomidine group|
62542880|NCT01886079|PLACEBO_COMPARATOR|Saline group|
62164876|NCT02857309|ACTIVE_COMPARATOR|Optimal medical therapy|Patients randomized to the control group will receive optimal medical therapy for heart failure.
62542881|NCT06111261|EXPERIMENTAL|Albumin-massive transfusion protocol|At the initiation of MTP, 200ml of 20% albumin will be infused followed by transfusion of packed RBC:FFP:Platelet concentrate with ratio of 1:1:1.
62542882|NCT06111261|ACTIVE_COMPARATOR|Conventional-massive transfusion protocol|At the initiation of MTP, Balanced crystalloid will be infused followed by transfusion of packed RBC:FFP:Platelet concentrate with ratio of 1:1:1. Albumin will be transfused according to the serum albumin level.
62542883|NCT05289947|PLACEBO_COMPARATOR|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks
62542884|NCT05289947|ACTIVE_COMPARATOR|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
62542885|NCT05289947|ACTIVE_COMPARATOR|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
62542886|NCT02540850||CRC group|stage 0-IV CRC subjects
62542887|NCT02540850||precancerous disease group|subjects with adenoma or polyps
62542888|NCT02540850||other disease group|subjects with other bowel diseases, other cancers, and subjects with no evidence of disease
62542889|NCT00576108|EXPERIMENTAL|KD7040 topical gel|
62542890|NCT00576108|PLACEBO_COMPARATOR|Placebo gel|
62716512|NCT02076945|ACTIVE_COMPARATOR|Healthy patients|Patients without diabetes and without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus \<19.01 mm2)
62716513|NCT02076945|EXPERIMENTAL|Diabetic patients without neuropathy|Patients with diabetes but without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus \<19.01 mm2)
62164877|NCT03613571|EXPERIMENTAL|ILB|ILB treatment
62164878|NCT02585752|EXPERIMENTAL|Single centre, single arm|Noninvasive ventilation with expiratory modulation. Assessment of comfort and blood gases.
62716514|NCT02076945|EXPERIMENTAL|Diabetic patients with neuropathy|Patients with diabetes and with peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus \> 19.01 mm2)
62716515|NCT01619917|ACTIVE_COMPARATOR|Proximal|location of the scar proximal to heart
62716516|NCT01619917|EXPERIMENTAL|Distal|location of scar distal to heart
62716517|NCT02572531|ACTIVE_COMPARATOR|L. reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 2 weeks
62716518|NCT02572531|PLACEBO_COMPARATOR|Placebo|Placebo lozenges three times daily for 2 weeks
62716519|NCT03217266|EXPERIMENTAL|Step 1 (tumor tissue testing, navtemadlin)|Patients undergo tumor tissue testing for p53 gene status and receive navtemadlin PO on days 2-4, days 2-5, or days 1-5 of weeks 1 to 5 in the absence of disease progression or unacceptable toxicity.
62716520|NCT03217266|EXPERIMENTAL|Step 2, Group I (navtemadlin, radiation therapy, surgery)|Starting with week 2, patients receive navtemadlin as in Step 1 and undergo RT daily for 5 weeks in the absence of disease progression or unacceptable toxicity, followed by surgery 5-8 weeks after RT completion.
62716521|NCT03217266|EXPERIMENTAL|Step 2, Group II (radiation therapy, surgery)|Starting with week 2, patients undergo radiation therapy daily for 5 weeks in the absence of disease progression or unacceptable toxicity, followed by surgery 5-8 weeks after RT completion.
62716522|NCT04903626|EXPERIMENTAL|Participants Treated With Glecaprevir/Pibrentasvir for 8 weeks|Participants treated once daily with oral tablets of glecaprevir/pibrentasvir for 8 weeks.
62716523|NCT01915212|EXPERIMENTAL|HSV529|1 x 107 pfu/dose of HSV529 in 10 mM L-histidine buffer containing 50 mM potassium glutamate, 160 mM sodium chloride, and 10% (w/v) sucrose
62542891|NCT06398119|ACTIVE_COMPARATOR|Traditional Treatment Arm|The traditional therapy program consisted of one hour provided three times a week for three months. The components of traditional therapy included weight-bearing exercises for the upper limbs, protective extensor push to activate the upper limbs' protective reactions, and passive stretching for the flexors of the wrist and elbow. In order to strengthen the muscles that oppose the spastic muscles, such as the elbow and wrist extensors, various toys were used, along with incentives to motivate the children to complete the exercises. Basic reach, grab, carry, and release techniques, in-hand manipulation techniques, and bilateral hand use are exercises that help with hand abilities.
62716524|NCT01915212|PLACEBO_COMPARATOR|Placebo|Sodium Chloride 0.9%
62716525|NCT06716866|EXPERIMENTAL|Temporally-Interfering Electrical Field Central Nervous System Stimulation|Participants in this arm receive temporally-interfering electric fields stimulation.
62716526|NCT03394989|EXPERIMENTAL|Test|Fluticasone propionate/salmeterol 100/50 µg
62716527|NCT03394989|ACTIVE_COMPARATOR|Comparator|Fluticasone propionate/salmeterol 100/50 µg
62716528|NCT03394989|OTHER|Placebo|Test Placebo
62716529|NCT04527835||patients suspected for viral myocarditis|All patients admitted with unexplained heart failure in the last 3 months will be investigated for viral myocarditis by the use of 12 lead ECG, echocardiography, Cardiac MRI , coronary angiography, Endomyocardial biopsy ( optional ), serological tests including ELIZA,Extraction of nucleic acid, Determination of viral genome by using PCR., Quantitative real-time PCR to assess viral load, Immunohistochemistry analysis of EMB.
62716530|NCT02286726|EXPERIMENTAL|Arm I (lower-dose (50 units/m^2) CPX-351)|Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5 of a 28-day course. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
62716531|NCT02286726|EXPERIMENTAL|Arm II (intermediate-dose (75 units/m^2) CPX-351)|Patients receive intermediate-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
62716532|NCT02286726|EXPERIMENTAL|Arm III (standard-dose (100 units/m^2) CPX-351)|Patients receive standard-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
62716533|NCT05221645|ACTIVE_COMPARATOR|Control Arm A|"Patients will receive three cycles of R-ICE. Each cycle is 21 days +/- 3 days Rituximab 375mg/m2 Ifosfamide 5,000mg/m2 Carboplatin AUC = 5 (max dose 800mg) Etoposide 100mg/m2~All patients who are deemed to be in CR or PR on the post treatment PET-CT scan will undergo autologous stem cell transplant (ASCT) within 4 weeks of completing R-ICE treatment. BEAM (carmustine, etoposide, cytarabine and melphalan) conditioning will be employed according to institutional protocol."
62716534|NCT05221645|EXPERIMENTAL|Experimental Arm B|"Pembrolizumab 200mg Rituximab 375mg/m2 Ifosfamide 5,000mg/m2 Carboplatin AUC = 5 (max dose 800mg) Etoposide 100mg/m2 Patients will receive up to 3 cycles of: P+R-ICE, where each cycle is 21 days long +/-_3 days.~All patients who are deemed to be in CR or PR on the post treatment PET-CT scan will undergo autologous stem cell transplant (ASCT) within 4 weeks of completing P+R-ICE treatment. BEAM (carmustine, etoposide, cytarabine and melphalan) conditioning will be employed according to institutional protocol.~These patients will then be offered maintenance pembrolizumab every 3 weeks for one year."
62716535|NCT04303858|EXPERIMENTAL|Eciskafusp Alfa as a Single Agent|Part 1: Dose-escalation of eciskafusp alfa as a single agent. eciskafusp alfa will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.
62716536|NCT04303858|EXPERIMENTAL|Eciskafusp Alfa in Combination with Atezolizumab|Part 2: Dose-escalation of eciskafusp alfa in combination with atezolizumab.
62716537|NCT04303858|EXPERIMENTAL|Eciskafusp Alfa as a Single Agent and/or with Atezolizumab|Part 3: Extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab.
61976530|NCT05131074|EXPERIMENTAL|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions.
61976531|NCT05131074|NO_INTERVENTION|Control Group|Patients will not receive the Collabree application.
61976532|NCT05678309||patient library|Patient with pruritus sine materia
61978151|NCT06049745|EXPERIMENTAL|Misoprostol group|Patients undergoing hysteroscopic myomectomy will be randomized to 400 mcg of misoprostol sublingual before the procedure.
62716538|NCT06397911|EXPERIMENTAL|FB825|
62716539|NCT06397911|PLACEBO_COMPARATOR|Placebo|
62716540|NCT04261088||Experts in Swiss assisted suicide|Persons in Switzerland who are experts in how assisted suicide is practiced. We will beexamining already collected interviews.
62716541|NCT05588440|EXPERIMENTAL|Phase 1: Dose Escalation|Patients will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by ONCT-808 IV infusion escalated sequentially with a target dose consistent with the dose required by cohort being enrolled to determine Phase 2 dose (RP2d) regimen(s). Participants may receive bridging therapy that is appropriate to the subject's disease and treatment history if clinically indicated to maintain disease stability.
62716542|NCT05588440|EXPERIMENTAL|Phase 2: Dose Expansion|Patients with LBCL or MCL will receive ONCT-808 for each RP2D regimen determined in Phase 1.
62716543|NCT04537741|EXPERIMENTAL|NSTEMI scheduled for angiography|
62716544|NCT03792516|EXPERIMENTAL|Artesunate ointment 40%, 1 cycle|Patients enrolled in this treatment group will receive one 5-day cycle of artesunate ointment applied topically to the vulva at week 0.
62716545|NCT03792516|EXPERIMENTAL|Artesunate ointment 40%, 2 cycles|Patients enrolled in this treatment group will receive two 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0 and 2.
62716546|NCT03792516|EXPERIMENTAL|Artesunate ointment 40%, 3 cycles|Patients enrolled in this treatment group will receive three 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0, 2, and 4.
62716547|NCT02821325||MRI|Radiology
62716548|NCT00891150|ACTIVE_COMPARATOR|oxytocin|group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
62716549|NCT00891150|ACTIVE_COMPARATOR|oxytocin2|group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
62716550|NCT00891150|ACTIVE_COMPARATOR|oxytocin3|group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
62716551|NCT06473701|EXPERIMENTAL|Dronabinol 20 mg, then placebo|In this arm, the study subject will first receive dronabinol 2.5 mg capsules. For two weeks the subject will titrate dose with one capsule corresponding to 2.5 mg dronabinol every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 20 mg daily treatment over a period of 2 weeks. After a wash out period of 2 weeks, study subject will receive placebo capsules (matching dronabinol 2.5 mg capsules). For two weeks the subject will titrate with one capsule every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 8 daily placebo capsules over a period of 2 weeks.
62716552|NCT06473701|PLACEBO_COMPARATOR|Placebo, then dronabinol 20 mg|In this arm, the study subject will first receive placebo capsules (matching dronabinol 2.5 mg capsules). For two weeks the subject will titrate with one capsule every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 8 daily placebo capsules over a period of 2 weeks. After a wash out period of 2 weeks, study subject will receive dronabinol 2.5 mg capsules. For two weeks the subject will titrate dose with one capsule corresponding to 2.5 mg dronabinol every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 20 mg daily treatment over a period of 2 weeks.
62716553|NCT04707092|EXPERIMENTAL|Antibiotic at induction|Patients will receive one single dose of Antibiotic at induction
62716554|NCT04707092|EXPERIMENTAL|Antibiotic one week|Patients will receive one single dose of Antibiotic at induction, plus a 7 day treatment with oral Antibiotic
62716555|NCT06589713|EXPERIMENTAL|Control Group 1 (Normal Renal Function)|
62716556|NCT06589713|EXPERIMENTAL|Group 2 (Impaired Renal Function)|
62716557|NCT05293340|EXPERIMENTAL|Hispanic/Latino adults with or at risk of T2D- Active Group|Eligible participants receive vouchers for free avocados.
62716558|NCT05293340|NO_INTERVENTION|Hispanic/Latino adults with or at risk of T2D- Control Group|Eligible participants will not receive vouchers for free avocados.
62716559|NCT06715332|EXPERIMENTAL|Endoscopic submucosal dissection with SpydrBlade Flex|This group of patient would undergo endoscopic submucosal dissection with the use of the novel SpydrBlade Flex knife
62716560|NCT05404958|EXPERIMENTAL|Intervention clinics that implement the Systems Analysis and Improvement Approach|Mombasa County public health staff will facilitate SAIA
62716561|NCT05404958|NO_INTERVENTION|Usual procedures|
62716562|NCT02652221|EXPERIMENTAL|Study cohort|Acoustic Radiation Force Imaging
62716563|NCT06543485|EXPERIMENTAL|adults with metacarpal fractures|intramedullary screw fixation of metacarpal fractures
62164879|NCT04883606||All Participants|Retrospective data will be collected from participants who followed up at least 6 months before teduglutide initiation or intestinal failure associated with SBS-IF diagnosis and at least 6 months of follow-up after teduglutide treatment initiation.
62542892|NCT06398119|EXPERIMENTAL|Virtual Reality Treatment Arm|For virtual reality training, the Pablo system was utilized. In both one- and two-dimensional modules, it is a game-based kind of rehabilitation. Based on the concepts of motor learning, this apparatus is used to train users. Using sensors to operate the games, the Pablo system features several boards, multiball, and handheld devices. The virtual reality program consisted of 45 minutes provided three times a week for three months.
62716564|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
62716565|NCT01371058|ACTIVE_COMPARATOR|routine dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically； clopidogrel 75mg/d for 1year.
62716566|NCT01371058|EXPERIMENTAL|high maintenance clopidogrel|aspirin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 150mg/d for 1 month followed by 75mg/d for at least 1 year.
62716567|NCT01371058|EXPERIMENTAL|policosanol plus dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 75mg/d for at least 1 year; Policosanol 40mg/d for 6months.
62716568|NCT06389123|EXPERIMENTAL|[177Lu]Lu DOTA-ABM-5G single dose therapy study|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy.
62542893|NCT00683345|ACTIVE_COMPARATOR|Anakinra|Anakinra self-administered s.c. in a dose of 100mg daily
62542894|NCT00683345|PLACEBO_COMPARATOR|Placebo|Placebo self-adminsitered s.c in a dose 0.67ml daily
62542895|NCT01051947|EXPERIMENTAL|Nebivolol|Nebivolol therapy for 2-6 weeks depending on blood pressure readings
62716569|NCT03245918|OTHER|Aprepitant Capsule Study Period #1|
62716570|NCT03245918|OTHER|Aprepitant Oral Suspension Study Period#1|
62716571|NCT02977078|SHAM_COMPARATOR|Control|Inhaler use monitored by device but no feedback to participants (control); this group is unaware of the second arm receiving feedback on inhaler use.
62716572|NCT02977078|EXPERIMENTAL|Active|Inhaler use monitored with feedback to participants (active); participants randomized to this group sign an additional consent to receive feedback on inhaler use
62716573|NCT06414044||Episodic migraine|Patients affected by migraine with an episodic pattern (\< 15 monthly migraine days) with or without aura according to ICHD-III criteria.
62716574|NCT06414044||Chronic migraine|Patients affected by chronic migraine (\> 15 monthly headache days with at least 8 days with migraine features) according to ICHD-III criteria.
62716575|NCT06345001|EXPERIMENTAL|Part 1 - Total mass dose selection|Participants with HCC or other select solid tumors will receive a single dose of BAY3630942 after intravenous (IV) administration of a specified dose of BAY3547922. Up to 5 total mass dose levels may be tested.
62716576|NCT06345001|EXPERIMENTAL|Part 2 - Actinium-225 Dosimetry Estimates|Participants with HCC or other select solid tumors will receive the total mass dose level selected in Part 1.
62716577|NCT06714682|ACTIVE_COMPARATOR|Ultrasound-Guided Modified Pectoral Plane Block group|first group 10 patients
62716578|NCT06714682|ACTIVE_COMPARATOR|Erector Spinae Plane Block group|second group 10 patients
62716579|NCT06226051||PEAPOD device|Premature babies will be evaluated using the PEAPOD Infant Body Composition measuring device
62716580|NCT03533010|ACTIVE_COMPARATOR|Ca500mg + VitD800IU|Daily Supplementation with 500mg Calcium plus 800IU Vitamin D3
62716581|NCT03533010|PLACEBO_COMPARATOR|Placebo|Dietary Supplement: Placebo
62716582|NCT06671756|EXPERIMENTAL|Fructose First, Glucose Second (10 participants)|Participants will first consume 75g of fructose in 225ml of water. Blood samples will be taken at specific intervals to measure metabolic responses. After 2 weeks, they will consume 75g of glucose in 225ml of water, with blood samples taken at the same intervals.
62716583|NCT06671756|EXPERIMENTAL|Glucose First, Fructose Second (10 participants)|Participants will first consume 75g of glucose in 225ml of water, followed by the same blood sampling schedule. After 2 weeks, they will switch to 75g of fructose, with blood samples taken at the same intervals.
62716584|NCT06691867|EXPERIMENTAL|I-STRONG - Early Start|Youth and caregivers will receive the I-STRONG for SCD intervention in addition to standard care.
62716585|NCT06691867|OTHER|Enhanced Usual Care (EUC)|Participants randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months. After completing the 6-month follow-up assessment, participants will have the opportunity to start the I-STRONG SCD intervention.
62716586|NCT03430349|EXPERIMENTAL|Novel OPV2 Candidate 1|Participants received one vaccination with novel OPV2 candidate 1 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units \[CCID50\]).
62716587|NCT03430349|EXPERIMENTAL|Novel OPV2 Candidate 2|Participants received one vaccination with novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
62716588|NCT06716086|EXPERIMENTAL|SMA group|Participants in the SMA group will use the shape memory alloy-based orthosis. They will undergo a 30-minute home-based training program 3-4 times a day, 7 days a week, for 8 weeks.
62716589|NCT06716086|ACTIVE_COMPARATOR|Stretching group|Participants in the Stretching group will receive conventional stretching program as a home program. They will undergo a 30-minute home-based training program 3-4 times a day, 7 days a week, for 8 weeks.
62716590|NCT05465525|PLACEBO_COMPARATOR|Control group|Patients will be operated under general anesthesia.
62716591|NCT05465525|ACTIVE_COMPARATOR|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block type III bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
62716592|NCT05465525|ACTIVE_COMPARATOR|Erector Spinae Plane Block Group|Patients will receive ultrasound-guided erector spinae plane block bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
62716593|NCT06368570||Cesarean delivery with neuraxial anesthesia.|Patients who have a scheduled cesarean delivery with neuraxial anesthesia.
62716594|NCT04519931|EXPERIMENTAL|Stress ball|
62716595|NCT04519931|NO_INTERVENTION|Control group|
62716596|NCT06477848|NO_INTERVENTION|Primary Care Practice As Usual|Data are collected regarding standard primary care practice and outcomes before implementation of SUD resources within the Integrated Behavioral Health System.
62716597|NCT06477848|EXPERIMENTAL|Integrated Behavioral Health with SUD Resources|Participating clinics receive a system-level intervention, an Integrated Behavioral Health System with SUD Resources, designed to improve youth connection to substance use treatment.
62716598|NCT05673200|EXPERIMENTAL|Treatment (ASTX727, paclitaxel, pembrolizumab)|Patients receive ASTX727 PO on days 1-4, paclitaxel IV over 1 hour on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples and CT and/or MRI throughout the trial. Patients in the dose-expansion phase also undergo a tumor biopsy during screening and day 1 of the treatment cycle 2 of the study. Patients will be followed every 3 months for 2 years after treatment and then every 6 months for an additional 3 years or until death, whichever occurs first.
62716599|NCT05554315||1|Male or female, aged 18 or greater in good general health as evidenced by medical history
62716600|NCT01142440|EXPERIMENTAL|behavioral intervention|
62716601|NCT01142440|NO_INTERVENTION|convention dental treatment|
62716602|NCT02474979|EXPERIMENTAL|CBPM-system|CBPM-system (Continuous Bedside Pressure Mapping System): the bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure. The CBPM-system will be used in addition to standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
62716603|NCT02474979|EXPERIMENTAL|Control|Standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
62716604|NCT06717594||Patients with Carbapenem-resistant Enterobacterales (CRE) infection treated with CAZ/AVI ± FOS|Adult patients treated for ≥ 48 hours with CAZ/AVI or CAZ/AVI plus FOS for a microbiologically documented CRE infection
62716605|NCT04861714|ACTIVE_COMPARATOR|Regeneten|Standard subscapularis repair with Regeneten augmentation group
62716606|NCT04861714|OTHER|Standard repair|Standard subscapularis repair
62716607|NCT05221866|NO_INTERVENTION|Control|UControlPain App with only data collection function. No provider-facing prescription intervention.
62716608|NCT05221866|ACTIVE_COMPARATOR|UControlPain educational app only|UControlPain app with education components. No provider-facing prescription intervention.
62542896|NCT01051947|EXPERIMENTAL|Metoprolol|Metoprolol therapy for 2-6 weeks depending on blood pressure readings
62542897|NCT03155516|EXPERIMENTAL|GPM Ward|Good Pain management ward
62164880|NCT03594786|EXPERIMENTAL|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
62168036|NCT06268600|NO_INTERVENTION|Routine neck target volume delineation|For patients with negative lymph nodes in regions III and IVa, the inner boundary of regions III and IVa is defined as the inner edge of the common carotid artery or the outer edge of the thyroid.
62542898|NCT03155516|ACTIVE_COMPARATOR|Control Ward|Current practice controlled ward
62542899|NCT05154461|EXPERIMENTAL|GLP-1 in relation to the 2 major BHB release sites|The magnitude of plasma GLP-1 following an OGTT (75g glucose per os) when beta-hydroxybutyrate (BHB) is released either at an upper gastrointestinal site (alginate encapsulation), or at distal gastrointestinal site (pea-protein encapsulation). BHB is given per-os in a single dose of 18g, plus 2 g encapsulation material; totally 20 g.
62542900|NCT04655001|EXPERIMENTAL|MORPH|Participants engage in 12 weeks of group and 1-on-1 coaching meant to promote physical activity throughout the day and caloric restriction. Participants engage with a custom smartphone application, use a smart scale and physical activity monitor, and meet using video conference software. At the end of 12 weeks, participants are provided with tools to continue meeting virtually on their own if desired, and will be followed for an additional 12-week maintenance phase.
62542901|NCT04655001|NO_INTERVENTION|Control|This condition receives the wearable activity monitor and simply asked to use it and continue in their daily lives for 24 weeks.
62542902|NCT01296997|EXPERIMENTAL|calcium phosphate|
62542903|NCT01296997|PLACEBO_COMPARATOR|placebo|
62542904|NCT02021513|EXPERIMENTAL|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
62542905|NCT02021513|PLACEBO_COMPARATOR|Placebo|Olive Oil
62542906|NCT04585230|ACTIVE_COMPARATOR|Group 1: (CBD + MO cohort)|Roll on stick containing CBD and mineral oils (CBD + MO cohort)
62542907|NCT04585230|ACTIVE_COMPARATOR|Group 2: (MO cohort)|Roll on stick containing mineral oils only (MO cohort)
62542908|NCT04585230|ACTIVE_COMPARATOR|Group 3: (CBD Cohort)|Roll on stick containing CBD only (CBD cohort)
62542909|NCT04585230|PLACEBO_COMPARATOR|Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)|Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)
62542910|NCT00970827|ACTIVE_COMPARATOR|1|Leg postconditioning
62542911|NCT00970827|ACTIVE_COMPARATOR|2|Arm postconditioning
62542912|NCT00970827|PLACEBO_COMPARATOR|3|Control group
62542913|NCT04589663|EXPERIMENTAL|MF followed by QMF149|Single inhaled dose of mometasone furoate on Day 1 delivered via TH inhaler followed by 4-7 days of washout. On Day 6-9, single inhaled dose of QMF149 delivered via C1 inhaler.
62542914|NCT02581644||Patients survey|Adult patients treated with belatacept for renal transplantation
62542915|NCT02581644||HCP survey|HCP with at least 1 patient taking belatacept
62542916|NCT02581644||Retrospective chart review study|Adult patients treated with belatacept for renal transplantation
62542917|NCT01969786|EXPERIMENTAL|Corneal ulcer prevention program|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to the corneal ulcer prevention arm will be trained to diagnose and treat corneal abrasions with antifungal (itraconazole) and antibiotic (chloramphenicol) ointments. FCHVs will promote their new services to their communities and encourage villagers who experience ocular trauma to present to them within 24 hours.
62542918|NCT01969786|NO_INTERVENTION|Control|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to control (no intervention) will not receive additional training and will not undertake a promotional campaign in their communities.
62542919|NCT06010186|EXPERIMENTAL|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~* Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~* Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
62542920|NCT03883802|EXPERIMENTAL|Foxy-5|Arm will receive Foxy-5 as neo-adjuvant therapy prior to surgical removal of tumour and afterwards until initiation of FOLFOX 6 months regimen
62542921|NCT03883802|ACTIVE_COMPARATOR|Standard therapy|Surgical removal of tumour followed by 6 months FOLFOX regimen
62542922|NCT03201445|EXPERIMENTAL|Filgotinib|Participants received filgotinib up to Week 13 in the DB phase (Part A). At Week 13, participants who were IBD responders, without meeting pre-specified sperm decrease thresholds, continued DB treatment up to Week 26 (Part B). Participants who were IBD non-responders at Week 13 or had disease worsening after Week 13 and prior to Week 26, and whose sperm parameters did not meet a prespecified decrease threshold, entered the OL Phase and received OL filgotinib for up to Week 13. At Week 26/OL Week 13, participants who were IBD responders and who had not experienced disease worsening, and whose sperm parameters did not meet a prespecified decrease threshold, continued receiving the same study drug they were responding to as part of the LTE for up to 195 weeks. Participants who met pre-specified sperm decrease threshold(s) at any postbaseline visit discontinued study drug and switched to a standard of care (SOC) regimen selected by the investigator and entered the MP for up to 52 weeks.
62716609|NCT05221866|ACTIVE_COMPARATOR|UControlPain app AND provider facing tool|UControlPain app with education components and provider-facing prescription intervention.
62716610|NCT05221866|ACTIVE_COMPARATOR|Provider facing tool only|UControlPain App with only data collection function. Provider-facing prescription intervention.
62716611|NCT04716894|EXPERIMENTAL|Sequence: BI 474121 alone (Reference) - Itraconazole + BI 474121 (Test)|"Period 1:~Reference (R) treatment: Healthy subjects received a single dose of 0.5 milligram (Powder for oral solution, 0.5 milligram (mg)/milliliter (mL) formulation) BI 474121 on day 1 of period 1.~Period 2:~Test (T) treatment: Healthy subjects received a daily dose of 200 milligram (oral solution, 10 mg/mL) Itraconazole for 14 days (days -3 - 11 of period 2) and a single dose of 0.5 milligram (Powder for oral solution, 0.5 milligram mg/mL formulation) BI 474121 on day 1 of period 2.~BI 474121 administrations in treatment R and treatment T were separated by a wash-out period of at least 10 days.~Administration of trial medication with 240 mL of water was performed after subjects had fasted overnight; fasting was to start no later than 10 hours before the scheduled dosing of BI 474121 or 9 hours before itraconazole administration."
62716612|NCT01362101|ACTIVE_COMPARATOR|Traditional behavioral intervention|
62716613|NCT01362101|ACTIVE_COMPARATOR|Mindfulness behavioral intervention|
62716614|NCT06135948|EXPERIMENTAL|Intervention Group|Hypothyroidism patients who received an increased dose of L-thyroxine, 25 mcg, n = 50
62716615|NCT06135948|NO_INTERVENTION|Control Group|Hypothyroidism patients who received standard/regular dose of L-thyroxine, n = 46
62716616|NCT05513859|EXPERIMENTAL|Diagnostic (qOBM)|Patients undergo craniotomy with intraoperative ex vivo and in situ tumor assessment with qOBM. Patients then undergo postoperative exam with CT or MRI any of days 1-5 after surgery.
62716617|NCT06110403|EXPERIMENTAL|Experimental group|Symptomatic COPD patients in stable condition treated with BGF 160 (Trixéo Aerosphere®), a combination of budesonide, formoterol and glycopyrronium in a metered dose inhaler, taken twice a day
62716618|NCT00590967|EXPERIMENTAL|Treatment Group 1|"Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin 40 mg/m\^2"
62716619|NCT00590967|EXPERIMENTAL|Treatment Group 2|"Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m\^2)"
62716620|NCT04122001|EXPERIMENTAL|Active HD-tDCS+word intervention then Sham+word intervention|Participants will receive active HD-tDCS + Word List Learning Intervention (WordLLI) and then receive Sham + WordLLI after a three-month washout period.
62716621|NCT04122001|EXPERIMENTAL|Sham+word intervention then active HD-tDCS+word intervention|Participants will receive Sham + Word List Learning Intervention (WordLLI) and then active HD-tDCS + WordLLI after a three-month washout period.
62716622|NCT06072196||Novel hormonal therapy cohort|Patients initiating novel hormonal therapy (abiraterone, apalutamide or enzalutamide) for mCSPC
62716623|NCT04435743||DLBCL|Treatment-naive or relapsed/refractory CD20+ diffuse large B-cell lymphoma patients who receive induction therapy containing lenalidomide.
62716624|NCT04435743||FL/MCL/MZL|Treatment-naive or relapsed/refractory CD20+ follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma patients who receive induction therapy containing lenalidomide.
62716625|NCT04435743||Maintenance|B-cell non-Hodgkin lymphoma patients who achieve complete or partial remission after induction therapy and receive maintenance therapy containing lenalidomide.
62716626|NCT05670912|EXPERIMENTAL|active group|"Take 2 tablets each time (study drug), 3 times a day, a total of 0.9g per day. Take it with warm water half an hour before meals.~Specifications: 0.15g/ pill (42mg sodium ferulate dihydrate, 42mg rhamnose monohydrate, 66mg chrysin)"
62716627|NCT05670912|PLACEBO_COMPARATOR|control group|"Take 2 tablets of the control drug (placebo) each time, 3 times a day, 0.9g a day. Take it with warm water half an hour before meals.~Specification: 0.15g/ grain (microcrystalline cellulose)"
62716628|NCT06576466|EXPERIMENTAL|Creatine monohydrate|Creatine monohydrate. Guinama brand with CE marking. Code 89823.
62716629|NCT06576466|PLACEBO_COMPARATOR|Dextromaltose|Dextrinomaltose. Guinama brand with CE marking. Code 91146.
62716630|NCT05008705|EXPERIMENTAL|Intervention|Patients allocated to this arm will be submitted to intervention (protein supplementation plus neuromuscular electrostimulation).
62716631|NCT05008705|PLACEBO_COMPARATOR|Placebo|Patients allocated to this arm will be submitted to a placebo intervention (isocaloric supplement plus sham for neuromuscular electrostimulation).
62716632|NCT01276106|EXPERIMENTAL|AC-201, 25mg|25mg BID for 24 weeks
62716633|NCT01276106|EXPERIMENTAL|AC-201, 50mg|50mg BID for 24 weeks
62716634|NCT01276106|EXPERIMENTAL|AC-201, 75mg|75mg BID for 24 weeks
62716635|NCT01276106|PLACEBO_COMPARATOR|Placebo|Placebo BID for 24 weeks
62716636|NCT06635148|EXPERIMENTAL|Arm A: JNJ-81201887 Low Dose|Study participants who were enrolled and received treatment with low dose JNJ-81201887 in parent clinical studies (81201887MDG2001 \[NCT05811351\]; 81201887MDG1003) will enter this long-term extension (LTE) study. No study intervention will be administered as part of this study.
62716637|NCT06635148|EXPERIMENTAL|Arm B: JNJ-81201887 High dose|Study participants who were enrolled and received treatment with high dose JNJ-81201887 in parent clinical studies (81201887MDG2001 \[NCT05811351\]; 81201887MDG1003) will enter this LTE study. No study intervention will be administered as part of this study.
62716638|NCT06635148|SHAM_COMPARATOR|Arm C: Sham Procedure|Participants randomized to the sham arm in parent study 81201887MDG2001 (NCT05811351) may have the option to receive JNJ-81201887 open-label treatment under a separate protocol after unmasking of that study; and will enter this LTE study. No intervention will be administered as part of this study.
62716639|NCT05618444|EXPERIMENTAL|Automated Management (AM)|Receipt of text-based behavioral intervention
62716640|NCT05618444|NO_INTERVENTION|Usual Care|Control group receiving usual care for obstructive sleep apnea
62542923|NCT03201445|PLACEBO_COMPARATOR|Placebo|Participants received placebo (matched to filgotinib) up to Week 13 in the DB phase (Part A). At Week 13, participants who were IBD responders, without meeting pre-specified sperm decrease thresholds, continued DB treatment up to Week 26 (Part B). Participants who were IBD non-responders at Week 13 or had disease worsening after Week 13 and prior to Week 26, and whose sperm parameters did not meet a prespecified decrease threshold, entered the OL Phase and received OL filgotinib for up to Week 13. At Week 26/OL Week 13, participants who were IBD responders and who had not experienced disease worsening, and whose sperm parameters did not meet a prespecified decrease threshold, continued receiving the same study drug they were responding to as part of the LTE for up to 195 weeks. Participants who met pre-specified sperm decrease threshold(s) at any postbaseline visit discontinued study drug and switched to SOC regimen selected by the investigator and entered the MP for up to 52 weeks.
62542924|NCT05931978|EXPERIMENTAL|CKD dashboard + Routine CKD care|Filled out PROMs before consultation and discussed the CKD consultation dashboard together with their clinician in the (already scheduled) routine care follow up consultation.
62542925|NCT05931978|NO_INTERVENTION|Routine CKD care|In the period of the study PROMs and the dashboard are not yet implemented for this group of patients.
62542926|NCT02766283||Iodinated contrast agents|children age 0-3 years (inclusive), who underwent a iodine contrast enhanced radiological examination.
62542927|NCT01043224|EXPERIMENTAL|Clobetasol propionate plus calcipotriol|
62542928|NCT03047629|EXPERIMENTAL|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
62542929|NCT03047629|PLACEBO_COMPARATOR|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
62542930|NCT04036110|EXPERIMENTAL|Intervention 1|Vitamin C 500 mg taken daily for 3 months
62542931|NCT04036110|EXPERIMENTAL|Intervention 2|Vitamin C 1000 mg taken daily for 3 months
62542932|NCT04036110|PLACEBO_COMPARATOR|Control|Placebo tablets taken daily for 3 months
62542933|NCT03677583|EXPERIMENTAL|Duckweed|daily lunch with 150-180g wet weight duck weed
62542934|NCT03677583|ACTIVE_COMPARATOR|Spinach|daily lunch with 150-180g wet weight spinach
62542935|NCT04820205|EXPERIMENTAL|intranasal dexmedetomdine and kemtaine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
62542936|NCT04820205|ACTIVE_COMPARATOR|oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
62542937|NCT02347150||ICU LOS>24h|30-110 patients discharged from the ICU
62168037|NCT06482502||6-MPRT Group|There is 1 group in the study. All assessments are made on the same group.
62542938|NCT05173441|EXPERIMENTAL|High Dose Group|Standard of care (SOC)+high dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
62542939|NCT05173441|EXPERIMENTAL|Low Dose Group|Standard of care (SOC)+low dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
62542940|NCT05173441|PLACEBO_COMPARATOR|Control Group|Standard of care (SOC)+placebo (0.9% sodium chloride). Placebo will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
62542941|NCT02198963|EXPERIMENTAL|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
62542942|NCT02198963|ACTIVE_COMPARATOR|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
62542943|NCT02198963|PLACEBO_COMPARATOR|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
62542944|NCT01796652||Home and hospital treatment groups|Patients were randomized into either home or hospital groups after a brief hospitalization(≤24 hours. Hospital patients were followed 5 days in hospital.Home patients were visited on 2nd,3rd and 5th days by a staff nurse and the vital signs, symptoms, and general condition were recorded and transmitted back to the attending physician. On the 7th, 14th and 30th days, the home and hospital group patients were requested to return for a follow-up clinic visit at Bezmialem, at which time an assessment of their symptoms, physical examination, and laboratory evaluation was conducted.
61978152|NCT03445572|EXPERIMENTAL|Group I (MSB)|Participants are instructed on the MSB technique and then perform MSB over 15 minutes BID for 28 days.
62542945|NCT01017796|EXPERIMENTAL|A. Experimental|1200mg acetylcysteine and 2g ascorbic acid at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
62542946|NCT01017796|PLACEBO_COMPARATOR|B. Control|200ml 0,9% normal saline IV
62542947|NCT01667237|EXPERIMENTAL|Pulmonary rehabilitation|
62716641|NCT02151929|EXPERIMENTAL|Bioresorbable Vascular Scaffold|Implantation of of an everolimus eluting bioresorbable scaffold in patients with STEMI treated with primary PCI
61978153|NCT03445572|EXPERIMENTAL|Group II (IK meditation)|Participants are instructed on the 3 steps of IK meditation and then perform IK meditation over 15 minutes BID for 28 days.
62168038|NCT06051097||OSA with metabolic syndrome|sleep study
62168039|NCT06051097||OSA without metabolic syndrome|sleep study
62168040|NCT02145195|EXPERIMENTAL|Vitamin D (10 microgram/day)|Tablets with 10 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
62168041|NCT02145195|EXPERIMENTAL|Vitamin D (20 microgram/day)|Tablets with 20 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
62168042|NCT02145195|PLACEBO_COMPARATOR|Placebo control|Tablets with 0 microgram vitamin D daily for 20 weeks.
62168043|NCT01275872|EXPERIMENTAL|Guided Imagery and Progressive Muscle Relaxation|
62716642|NCT02151929|ACTIVE_COMPARATOR|Everolimus Eluting stent|Implantation of of an everolimus eluting stent in patients with STEMI treated with primary PCI
62716643|NCT04255914|EXPERIMENTAL|Root coverage procedure along with orthodontic treatment|subepithelial connective tissue graft and orthodontic levelling and alignment
62716644|NCT04255914|ACTIVE_COMPARATOR|Root coverage procedure only|sub epithelial connective tissue graft procedure for recession coverage
62716645|NCT06653842|EXPERIMENTAL|Single-arm, open-label|
62716646|NCT00344331||Patients with a diagnosis of Niemann-Pick type C (NPC) of either sex and any age|Participants may range from neurologically asymptomatic to severe and may have liver disease or unrelated comorbidities, but must be stable enough to safely travel and tolerate medical evaluations.
62716647|NCT05027568|EXPERIMENTAL|IOA-289 daily oral dosing plus gemcitabine and nabpaclitaxel every 3 weeks starting on Day 8|
62716648|NCT01344148|EXPERIMENTAL|Anti- TB therapy HAART|
62716649|NCT01489904|EXPERIMENTAL|Botulinum Toxin|Botulinum Toxin type-A
62716650|NCT01489904|NO_INTERVENTION|Control Treatment|No intervention
62716651|NCT06718426|ACTIVE_COMPARATOR|Fertitonex group|Patients in this group will receive Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.
62716652|NCT06718426|PLACEBO_COMPARATOR|Placebo group|Patients in this group will receive placebo capsule twice daily for 3 months.
62164881|NCT04818047|EXPERIMENTAL|Experimental: VID-KIDS Intervention Program Group|Experimental: VID-KIDS Intervention Program Group RN review photos of infant engagement/ disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
62716653|NCT06646484||Patients hospitalized due to subarachnoid hemorrhages|Each patient eligible for the study hospitalized due to subarachnoid hemorrhages
62716654|NCT01383005||Kaletra (LPV/r) QD as First Kaletra Treatment|HIV-infected participants treated with lopinavir/ritonavir once daily (LPV/r QD) from ≥3 months to \<2 years who had not been treated with any of the following: LPV/r twice daily (BID), a protease inhibitor, or a ritonavir-boosted protease inhibitor.
62716655|NCT01383005||Kaletra (LPV/r) QD from Kaletra BID|HIV-infected participants treated with LPV/r from ≥3 months to \<2 years who had initiated on LPV/r BID and at any time within this period (but at least 3 months before inclusion in the study) had changed dosing from BID to QD.
62716656|NCT00644839|EXPERIMENTAL|CP-945,598|
62716657|NCT04478942|ACTIVE_COMPARATOR|oral misoprostol|At time of delivery, participants randomly assigned to either oral misoprostol will receive 50 mcg of Misoprostol every 4 hours up to 6 doses, OR until simplified Bishop score \>6 (whichever is achieved first).
62716658|NCT04478942|ACTIVE_COMPARATOR|intravenous oxytocin|At time of delivery, participants randomly assigned to intravenous oxytocin, will be administered the drug per standard of labor and delivery titrations.
62716659|NCT04207320|EXPERIMENTAL|Stage I|Stage I will include eligible subjects between the ages of 10-25 years.
62716660|NCT04207320|EXPERIMENTAL|Stage II|Stage II will include eligible subjects between the ages of 2-25 years.
62716661|NCT06119854|EXPERIMENTAL|Attitudinal inoculation intervention|"Participants randomized to this arm will view a brief video addressing one anti-vaccine meta-narrative or issue (e.g., concerns about the vaccine not working) most salient to the entire CHASING COVID study population (per recent historical data) and focused on bolstering resistance to mis/disinformation."
62716662|NCT06119854|EXPERIMENTAL|Cognitive behavioral therapy-informed intervention|Participants randomized to this arm will view a brief video using a CBT-informed approach and focused on addressing barriers to vaccination, with no inoculation messaging.
62716663|NCT06119854|ACTIVE_COMPARATOR|Conventional public health messaging|Participants randomized to this arm will view a brief video conveying conventional public health messaging adapted from a review of public health public service announcements, with no inoculation or CBT-informed messaging.
62716664|NCT06126497|EXPERIMENTAL|Ropanicant 45 mg qd|The participant will take 1 tablet/day in the morning (for qd dosing)
62716665|NCT06126497|EXPERIMENTAL|Ropanicant 30 mg bid|The participant will take 2 tablets/day (\~12 hours apart for bid dosing).
62716666|NCT06126497|EXPERIMENTAL|Ropanicant 45 mg bid|The participant will take 2 tablets/day (\~12 hours apart for bid dosing).
62716667|NCT00765219|EXPERIMENTAL|1|CBT with ACS
62716668|NCT00765219|EXPERIMENTAL|2|CBT with Counselor
62716669|NCT00765219|ACTIVE_COMPARATOR|3|Usual Care
62716670|NCT06663319|EXPERIMENTAL|JNJ-89402638|Participants with unresectable metastatic colorectal adenocarcinoma (mCRC) will receive JNJ-89402638 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially until the recommended Phase 2 Dose(s) (RP2D) have been identified. Participants in Part 2 (Dose expansion) will receive JNJ-89402638 at the RP2D(s) determined in Part 1.
62716671|NCT06719323|EXPERIMENTAL|Experimental group|Experimental group: a 12-week Family WISH program
62716672|NCT06719323|SHAM_COMPARATOR|Comparison group|Comparison group: a family walking health education sheet received
62716673|NCT03338985|EXPERIMENTAL|"Group cases patients"|patients with endometrial hyperplasia or endometrial cancers
62716674|NCT05004662|ACTIVE_COMPARATOR|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with Florida Quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
62735850|NCT03066960|ACTIVE_COMPARATOR|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
62735851|NCT03066960|SHAM_COMPARATOR|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
62716675|NCT05004662|EXPERIMENTAL|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
62716676|NCT06482775||dexmedetomidine|Infusion of dexmedetomidine 4 microgram/mL.
62716677|NCT06716346||Forward head posture group|-Craniovertebral angle \<50
62716678|NCT06716346||control|-Craniovertebral angle \>50
62164882|NCT01504919|EXPERIMENTAL|Health Education (HE)|HE of brief counseling and self-help materials addressing 3 risk behaviors, referrals to available resources, and a home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed.
62542948|NCT06125730|EXPERIMENTAL|DIME Beauty Eyelash Boost Serum|Participants will use the eyelash serum twice daily in the morning and evening. The serum will be applied to the base of the top and bottom lashes.
62542949|NCT05917600|EXPERIMENTAL|Interventional group|The interventional group meets an Advanced Practice Nurses (APN) between the ambulatory hospitalization (AH) and the MD consultation
62542950|NCT05917600|NO_INTERVENTION|Control group|The control group of patients keeps a traditional follow-up (ambulatory hospitalization (AH) then consultation with a MD)
62542951|NCT06088030|EXPERIMENTAL|Arsenic trioxide combined chemotherapy|Patients with p53-mutated pediatric cancer should initially undergo the corresponding first-line chemotherapy regimen. If the patient is evaluated as PD/SD, arsenic trioxide (ATO) will be administered in conjunction with previous conventional chemotherapy on the third day of each treatment cycle.
62542952|NCT02054689|OTHER|Fractionated Stereotactic Radiosurgery|24 to 36 Gy in 3 fractions (8-12 Gy/fx).
62542953|NCT01959295|EXPERIMENTAL|ASP2151|
62542954|NCT01959295|PLACEBO_COMPARATOR|ASP2151 placebo|
62542955|NCT02646761|EXPERIMENTAL|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
62542956|NCT02646761|OTHER|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
62542957|NCT03195179||Suprapubic tube placement|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will have a suprapubic tube placed to manage the acute urethral injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
62542958|NCT03195179||Urethral realignment|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will undergo urethral realignment with a combined antegrade / retrograde approach within 7 days of injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
62542959|NCT05727826|EXPERIMENTAL|stroke patients|individuals with hemiplegia after Hemorrhagic or Infarction stroke
62542960|NCT03138655|EXPERIMENTAL|UC: <30 kg Participants, Vedolizumab 100 mg|Participants with UC having baseline weight of \<30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542961|NCT03138655|EXPERIMENTAL|UC: <30 kg Participants, Vedolizumab 200 mg|Participants with UC having baseline weight of \<30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542962|NCT03138655|EXPERIMENTAL|CD: <30 kg Participants, Vedolizumab 100 mg|Participants with CD having baseline weight of \<30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542963|NCT03138655|EXPERIMENTAL|CD: <30 kg Participants, Vedolizumab 200 mg|Participants with CD having baseline weight of \<30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542964|NCT03138655|EXPERIMENTAL|UC: >=30 kg Participants, Vedolizumab 150 mg|Participants with UC having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542965|NCT03138655|EXPERIMENTAL|UC: >=30 kg Participants, Vedolizumab 300 mg|Participants with UC having baseline weight of \>=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542966|NCT03138655|EXPERIMENTAL|CD: >=30 kg Participants, Vedolizumab 150 mg|Participants with CD having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542967|NCT03138655|EXPERIMENTAL|CD: >=30 kg Participants, Vedolizumab 300 mg|Participants with CD having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
62542968|NCT00208845||adult ED patients|
62542969|NCT02784041|EXPERIMENTAL|single adductor-canal-block|Patients in this group will receive ultrasound guided single adductor-canal- block with 0.35% ropivacaine 25ml.
62542970|NCT02784041|EXPERIMENTAL|periarticular infiltration|patients in this group will receive periarticular infiltration of local anesthetic.
62542971|NCT00751556|EXPERIMENTAL|Arm 1|
62542972|NCT00751556|ACTIVE_COMPARATOR|Arm 2|
62716679|NCT06718608|EXPERIMENTAL|Only one arm|
62716680|NCT06167486|EXPERIMENTAL|SG2918|SG2918 monotherapy
62716681|NCT03222674|EXPERIMENTAL|Single arm|CAR T cells to treat AML
61978154|NCT03445572|ACTIVE_COMPARATOR|Group III (waitlist)|Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.
62168044|NCT06138132|EXPERIMENTAL|KYV-101 CAR-T cells with lymphodepletion conditioning|Dosing with KYV-101 CAR T cells
62168045|NCT02442232||Normotensive|
62716682|NCT00087217|EXPERIMENTAL|Treatment (tanespimycin, paclitaxel)|Patients receive 17-AAG IV over 1 hour on days 1\*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
62716683|NCT01805284|EXPERIMENTAL|Linezolid|
62716684|NCT06716307|EXPERIMENTAL|Treatment sequence 1|Participants will receive a single subcutaneous (s.c.) dose of CagriSema (cagrilintide B and semaglutide I) in DV3384 pen-injector in period 1 followed by a single s.c. dose of CagriSema A in PDS290 pen-injector in period 2 separated by a wash out period of minimum 7 weeks.
62716685|NCT06716307|EXPERIMENTAL|Treatment sequence 2|Participants will receive a single s.c. dose of CagriSema A in PDS290 pen-injector in period 1 followed by a single s.c. dose of CagriSema (cagrilintide B and semaglutide I) in DV3384 pen-injector in period 2 separated by a wash out period of minimum 7 weeks.
62716686|NCT00797719|EXPERIMENTAL|All|This is a single arm study. All patients enrolled will be in this arm.
62716687|NCT06440252|ACTIVE_COMPARATOR|Grape Seed Extract|Grape seed extract 600mg per day - 1 capsule per day
62716688|NCT06440252|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin - 1 capsule per day
62716689|NCT04306328|EXPERIMENTAL|Neurostimulation|
62716690|NCT06255353|EXPERIMENTAL|The observation group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure."
62716691|NCT06255353|ACTIVE_COMPARATOR|The control group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding."
62716692|NCT06715800|ACTIVE_COMPARATOR|H1 Thyme honey group|The group who applied with the complaint of sore throat was cultured and given thyme honey in addition to drug treatment.
62716693|NCT06715800|ACTIVE_COMPARATOR|H2 Yuksekova honey group|The group who applied with the complaint of sore throat was cultured and given Yuksekova honey in addition to drug treatment.
62716694|NCT06715800|ACTIVE_COMPARATOR|H3 Chestnut honey group|The group who applied with the complaint of sore throat was cultured and given chestnut honey in addition to drug treatment..
62716695|NCT06715800|ACTIVE_COMPARATOR|H4 Linden honey group|The group who applied with the complaint of sore throat was cultured and given linden honey in addition to drug treatment.
62716696|NCT06715800|ACTIVE_COMPARATOR|H5 Pine honey group|The group who applied with the complaint of sore throat was cultured and given pine honey in addition to drug treatment.
62716697|NCT06715800|PLACEBO_COMPARATOR|H6 Plasebo group|The group who applied with the complaint of sore throat was cultured and given plasebo in addition to drug treatment.
62716698|NCT06560476||Study Arm|This is the data collection study arm. There is no other arm in the study.
62716699|NCT06033534|EXPERIMENTAL|STIMULAN DEVICE USED|Patients allocated to this arm will receive an extended-release antibiotic device, STIMULAN, as a prophylactic measure against bacterial infection post-fracture repair surgery. The device is designed to release antibiotics in a controlled manner over a specified period of time.
62542973|NCT03951324||Expert Endoscopists|Experienced Endoscopists with significant user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
62542974|NCT03951324||None-Expert Endoscopists|Experienced Endoscopists with non-significant or beignner user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
62542975|NCT05516979|EXPERIMENTAL|100 mg AP1189|Treatment period of 12 weeks given as 1 tablet daily
62542976|NCT05516979|PLACEBO_COMPARATOR|Placebo|Treatment period of 12 weeks given as 1 tablet daily
62542977|NCT03616145|EXPERIMENTAL|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
62716700|NCT06033534|NO_INTERVENTION|STIMULAN DEVICE NOT USED|Patients in this arm will undergo the surgical repair of their open fracture but will not receive any antibiotic device for prophylaxis against bacterial infections.
62716701|NCT06716320||Group gestational diabetes mellitus, Group Healthy pregnant women|"Group gestational diabetes mellitus (GDM): GDM was diagnosed according to the criteria of The International Association of Diabetes and Pregnancy Study Groups when one or more abnormal plasma glucose values were obtained (fasting ≥ 92 mg/dL, 1 h ≥ 180 mg/dL, 2 h ≥ 153 mg/dL). In pregnant women who could not achieve normoglycemia with diet, insulin treatment was started and fasting blood sugar and 1st and 2nd hour postprandial blood sugar threshold values were determined as 95 mg/dL, 140 mg/dL and 120 mg/dL, respectively.~Group Healthy pregnant women: In the healthy pregnant women group, 40 pregnant women were considered normoglycemic because their 75-g OGTT tests matched the study group in terms of age, BMI, and gestational age. Pregnant women in this group who did not have any complications were included.~All groups were followed until the end of birth."
62716702|NCT06719024|ACTIVE_COMPARATOR|Ruxolitinib cream|a thin layer of the assigned topical to the selected lesions twice daily
62716703|NCT06719024|PLACEBO_COMPARATOR|Aqueous cream|a thin layer of the assigned topical to the selected lesions twice daily
62716704|NCT04565509|ACTIVE_COMPARATOR|General Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.
62716705|NCT04565509|ACTIVE_COMPARATOR|Focus/Targeted Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.
62716706|NCT04565509|ACTIVE_COMPARATOR|Best Message Alone|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.
62716707|NCT04565509|ACTIVE_COMPARATOR|Best Message + Augmented Message or Implementation Strategy|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
62716708|NCT06715306|NO_INTERVENTION|Standard Care|Standard intravenous treatment in accordance with local or national procedures
62716709|NCT06715306|ACTIVE_COMPARATOR|Oral treatment|Oral treatment
62716710|NCT01391702||Labouring woman with epidural in situ|Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
62716711|NCT03698019|EXPERIMENTAL|Arm I (adjuvant pembrolizumab)|Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
62716712|NCT03698019|ACTIVE_COMPARATOR|Arm II (adjuvant and neoadjuvant pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
62716713|NCT06717568||participant|"BHD Measurement: Each participant undergoes two measurements by two different assessors, with a 5-minute interval between each measurement. The average value is taken.~ATR Measurement: The trunk rotation angle (ATR) is measured using a Scoliometer. Two assessors each perform two measurements, with a 5-minute interval between each, and the average value is taken.~Cobb Angle Measurement: Two experienced spinal specialists independently measure the Cobb angle, with each performing two measurements. The average value is taken. If their measurements differ by 5° or more, a third senior physician is required to perform a review."
62716714|NCT04227028|EXPERIMENTAL|Treatment (brigatinib, bevacizumab)|Patients receive brigatinib PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Patients also receive bevacizumab IV on day 8 of cycle 1 and day 1 of subsequent cycles. Starting cycle 2, cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62716715|NCT04055753||Doxorubicin|
62716716|NCT04055753||Doxil|
62716717|NCT00405288||Proctofoam-HC®|Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
62716718|NCT00405288||Control|Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
62716719|NCT02478489|EXPERIMENTAL|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
62716720|NCT02478489|ACTIVE_COMPARATOR|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
62716721|NCT02462226|ACTIVE_COMPARATOR|Arm Precaution|"Patients assigned to Education #1 will receive arm precaution self-care strategies. The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. Exercises to promote limb mobility will also provided. Only the patients in the control group will be given access to Arm Precautions section.~Patients will be given access to the website to learn about the arm precaution program."
62716722|NCT02462226|EXPERIMENTAL|The-Optimal-Lymph-Flow|"The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.~Patients will be given the access to the website to learn about the The-optimal-Lymph-Flow program"
62716723|NCT06715631|EXPERIMENTAL|Hands-free exoskeleton|
62716724|NCT06712680|EXPERIMENTAL|Test product HYP-6589|HYP-6589 should be administered orally at the recommended dosage
62735852|NCT06089863|EXPERIMENTAL|PAMPERO program group|This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity.
62735853|NCT06089863|NO_INTERVENTION|Usual Care intervention group|"Usual Rehabilitation of the patient after the inclusion. 0 to 2 physical therapy sessions and 0 to 2 Speech therapy sessions each week usually constitute this program.~This rehabilitation highly depends on the patients usual preferences. Some patients have no rehabilitation in the daily care while some have more."
62735854|NCT00391053|EXPERIMENTAL|Study Group 1|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1
62542978|NCT03616145|SHAM_COMPARATOR|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
62542979|NCT03616145|NO_INTERVENTION|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
62542980|NCT06081179|ACTIVE_COMPARATOR|Psilocybin|40 participants will receive psilocybin
62542981|NCT06081179|ACTIVE_COMPARATOR|MDMA|40 participants will receive MDMA
62542982|NCT06081179|ACTIVE_COMPARATOR|Methylphenidate|40 participants will receive methylphenidate
62542983|NCT03576079|EXPERIMENTAL|Laser therapy|12 laser sessions over 3 months
62542984|NCT03576079|ACTIVE_COMPARATOR|anterior re-positioning splint therapy|anterior re-positioning splint worn for 8 hours during night time for 3 months
62542985|NCT03576079|PLACEBO_COMPARATOR|inactive laser therapy|placebo laser for 12 sessions over 3 months
62542986|NCT06550284|EXPERIMENTAL|Carpal Tunnel Syndrome|Age 18-65 years with unilateral carpal tunnel syndrome.
62542987|NCT06456034|NO_INTERVENTION|Baseline group|Receives care as usual after severe perinatal diagnosis
62542988|NCT06456034|EXPERIMENTAL|Perinatal palliative care group|Receives a new perinatal palliative care intervention after severe perinatal diagnosis
62542989|NCT06052280|EXPERIMENTAL|Telerehabilitation Exercise group (TrE arm)|
62542990|NCT06052280|ACTIVE_COMPARATOR|Home Self-Exercise group (HSE arm)|
62542991|NCT06550570||Conventional epidural anesthesia (=before revision of the usual practice of the maternity ward)|A local anesthetic and an opioid are administered into the epidural space, as per department protocol (usual practice).
62542992|NCT06550570||Ambulatory epidural anesthesia (=after revision of the usual practice of the maternity ward)|Low doses of local anesthetic and an opioid are administered into the epidural space to allow the patient to walk around while being monitored, as per department revised protocol (usual practice)
62542993|NCT02072603|EXPERIMENTAL|Intervention Hospitals|HITSystem implementation at hospital and its affiliated laboratory
62542994|NCT02072603|ACTIVE_COMPARATOR|Control Hospitals|Existing standard of EID care
62542995|NCT01987310|ACTIVE_COMPARATOR|Statin|statin therapy (atorvastatin 20 mg/d) for 6 months
61976533|NCT03888547|EXPERIMENTAL|OT-HAWP|"The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules:~Week 1: Sleep Hygiene Week 2: Fatigue Management Week 3: Cancer-related cognitive impairments Week 4: Stress Management Each session will last 1.5 hours (45 minutes of group education and 45 minutes of individual modifications and strategy recommendations."
61978155|NCT03264209|EXPERIMENTAL|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
62168046|NCT02442232||Hypertensive taking ACEi|
62542996|NCT01987310|NO_INTERVENTION|usual care|follow up group with no intervention
62542997|NCT01987310|ACTIVE_COMPARATOR|lifestyle counseling|lifestyle modification by dietician counseling and follow-up
62735855|NCT00391053|EXPERIMENTAL|Study Group 2|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2
62168047|NCT02442232||Hypertensive not taking ACEi|
62542998|NCT05755347||Single Arm|Subjects with metastatic breast carcinoma have been receiving treatment at the study center and responding to survey questionnaires.
62542999|NCT02218554|EXPERIMENTAL|Study Group|Subject has been diagnosed with BRONJ
62543000|NCT02218554|NO_INTERVENTION|Control Group|Subject has not developed any signs or symptoms of BRONJ
62543001|NCT00760734|EXPERIMENTAL|Hyperbaric oxygen therapy-TBI/PCS|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
62543002|NCT00760734|EXPERIMENTAL|Hyperbaric Oxygen Therapy-PCS/PTSD|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
62543003|NCT04293900||Study cohort|24-hour dietary recall, hand grip strength, accelerometer, International Physical Activity Questionnaire (IPAQ), Patient-reported outcomes survey (NCI-PRO-CTCAE), Pittsburgh Sleep Quality Index (PSQI), Functional Assessment of Cancer Treatment - Lymphoma (FACT-lym), urine sample (optional), fecal sample (optional)
62543004|NCT04446923|EXPERIMENTAL|Hand antisepsis by scrub|Hand antisepsis by scrub using propan-ol-1 60%
62543005|NCT04446923|ACTIVE_COMPARATOR|Hand antisepsis by rub|Hand antisepsis by rub using propan-ol-1 60%
62543006|NCT03551288|EXPERIMENTAL|Food Effect Cohort|Twelve healthy male subjects 18 to 45 years of age, inclusive, will be administered a single oral dose of SUVN-911 on Day 1 (Period 1) and Day 8 (Period 2) with and without food in a crossover manner.
62543007|NCT03551288|EXPERIMENTAL|Gender Effect Cohort|Eight healthy female subjects 18 to 45 years of age, inclusive, will be administered a single dose of SUVN-911.
62543008|NCT03551288|EXPERIMENTAL|Age Effect Cohort|Eight healthy male subjects ≥ 65 years of age will be administered a single oral dose of SUVN-911.
62543009|NCT03491657|EXPERIMENTAL|virtual reality distraction (Yes VR)|In addition to their standard pain medications, patients will play a virtual realty game named SnowWorld during some portions of their burn wound cleaning procedure, on each study day.
62543010|NCT03491657|ACTIVE_COMPARATOR|music distraction (No VR condition)|In addition to their standard pain medications, patients will listen to music during comparable portions of their burn wound cleaning procedure, on each study day.
62543011|NCT03706937||Paramedical professionals|Paramedical professionals of the Lucien Neuwirth Cancer Institute
62735856|NCT00391053|EXPERIMENTAL|Study Group 3|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3
62716725|NCT05589194|EXPERIMENTAL|Intervention Group|After the first interview with the patients in the intervention group, a phone call will be made for regarding the implementation of nursing interventions based on the Comfort Theory, and they will be informed about the planned dates for the implementation. The implementation phase of nursing interventions based on Comfort Theory will be carried out for 6 weeks at the Communication Laboratory of the Faculty of Nursing of Akdeniz University on the planned dates with the patients. In addition, a handbook will be given to the patients at the beginning of the practice, and the Home Yoga Diary in the handbook will be expected to be filled in daily by the patients during the research. Immediately after the implementation of the nursing interventions based on Comfort Theory (week 6), patients will be asked to fill in ISI, IQO-L, and the Urinary Incontinence and Frequency Comfort Scale. During this whole process, patients will continue their planned routine care and treatment.
62716726|NCT05589194|NO_INTERVENTION|Control Group|After the first interview with the patients in the control group, the routine care and treatment practices planned by the polyclinic physician and nurse will continue. No additional intervention is planned for the patients in this group. A new interview will be planned with the patients in the control group 6 weeks after the first interview, and they will be asked to fill in the ISI, IQO-L, and the Urinary Incontinence and Frequency Comfort Scale.
62716727|NCT02122380|EXPERIMENTAL|Sitagliptin, then Placebo|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
62716728|NCT02122380|EXPERIMENTAL|Placebo, then Sitagliptin|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
62716729|NCT06715423||Pediactric ICU Hospitalized children 1mo to 5 yo|Prescription of HFNO therapy
62716730|NCT00437398|EXPERIMENTAL|Islet Transplant|Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.
62716731|NCT02765048|EXPERIMENTAL|GAIN Program|Subjects randomly assigned to receive the GAIN Program intervention
62543012|NCT01960049|PLACEBO_COMPARATOR|MOTAP Catheter with Saline and IV PCA|Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours
62543013|NCT01960049|ACTIVE_COMPARATOR|MOTAP catheter with ropivocaine and IV PCA|20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours
62543014|NCT01289379|EXPERIMENTAL|HFJV|
62543015|NCT01168752|EXPERIMENTAL|schedule A|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
62543016|NCT01168752|EXPERIMENTAL|schedule B|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as a daily schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
62543017|NCT01338870|PLACEBO_COMPARATOR|Placebo|Placebo for PF-04991532 and sitagliptin
62543018|NCT01338870|EXPERIMENTAL|25 mg PF-04991532|
62543019|NCT01338870|EXPERIMENTAL|75 mg PF-04991532|
62716732|NCT02765048|NO_INTERVENTION|Usual Care|Subjects randomly assigned to receive community-based services as part of their usual care
62543020|NCT01338870|EXPERIMENTAL|150 mg PF-04991532|
62543021|NCT01338870|EXPERIMENTAL|300 mg PF-04991532|
62543022|NCT01338870|ACTIVE_COMPARATOR|Sitagliptin 100 mg|
62543023|NCT05968417||Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder|Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.
62543024|NCT06408506|OTHER|6 Implants in edentulous mandible|Placement of 6 Implants in the lower jaw, Two of which are remained to heal submucosal, two transmucosal, and two by immediate loading with removable gold bar retained dentures
62543025|NCT04332393|EXPERIMENTAL|metformin group|
62543026|NCT04332393|NO_INTERVENTION|No treatment group|
62543027|NCT05324410|EXPERIMENTAL|Part A: VX-840|Participants will be randomized to receive single dose of one of different dose levels of VX-840.
62543028|NCT05324410|PLACEBO_COMPARATOR|Part A: Placebo|Participants will receive placebo matched to VX-840.
62543029|NCT05324410|EXPERIMENTAL|Part B: VX-840|Participants will be randomized to receive multiple doses of one of different dose levels of VX-840. The dose levels will be determined based on the data from Part A.
62543030|NCT05324410|PLACEBO_COMPARATOR|Part B: Placebo|Participants will receive placebo matched to VX-840.
62543031|NCT04408235|ACTIVE_COMPARATOR|Low-Dose LMWH|Enoxaparin 4000 IU daily
62543032|NCT04408235|EXPERIMENTAL|High-Dose LMWH|Enoxaparin 70 IU/kg twice daily
62543033|NCT01442688|EXPERIMENTAL|Amoxicillin + MMX placebo|
62543034|NCT01442688|EXPERIMENTAL|Amoxicillin + MMX mesalazine/mesalamine|
62543035|NCT01736969|EXPERIMENTAL|RD047-023|RD-047-023
62543036|NCT01736969|ACTIVE_COMPARATOR|Predicate Device|legally marketed predicate device
62543037|NCT01425411|EXPERIMENTAL|Valsartan treatment|
62543038|NCT04604795|EXPERIMENTAL|Part A:GSK3915393 DLs 1,3,4,intravenous (IV) microdose and placebo (Sequence A)|In Part A, participants will receive dose levels (DLs) 1, 3, 4, IV microdose of GSK3915393, and placebo in a pre-determined sequence (Sequence A). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data.
62716733|NCT05083078|EXPERIMENTAL|Part 1: Healthy Participants-Coadministration|Healthy participants will receive a single co-administered dose of risankizumab and guselkumab subcutaneously (SC) on Day 1.
62716734|NCT05083078|EXPERIMENTAL|Part 2: Psoriatic Arthritis (PsA) Participants-Coadministration|Participants with PsA will receive a single co-administered dose of risankizumab and guselkumab SC on Day 1 and Day 29.
62716735|NCT05083078|EXPERIMENTAL|Part 3: PsA Participants-Separate Administration|Participants with PsA will receive a single dose of either risankizumab or guselkumab SC on Day 1 and Day 29.
62735857|NCT00391053|ACTIVE_COMPARATOR|Group 4|Participants will receive the Standard Fluzone® vaccine
62164883|NCT01504919|EXPERIMENTAL|Motivation and Problem Solving (MAPS)|HE counseling, self-help materials, and resource referrals, and home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed. Plus 9 proactive, telephone counseling sessions over the 18 month period.
62164884|NCT02274350||radiation therapy|Patients treated with either external beam radiation therapy or brachie therapy for localized prostate cancer
62164885|NCT05586308|OTHER|Active control|Participants in this arm will receive an evidence-based text-messaging support.
62164886|NCT05586308|ACTIVE_COMPARATOR|Media literacy|Participants will receive media literacy e-learning lessons and an evidence-based text-messaging support.
62543039|NCT04604795|EXPERIMENTAL|Part A:GSK3915393 DLs 1,2,4,IV microdose and placebo (Sequence B)|"In Part A, participants will receive dose levels 1, 2, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence B).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
62543040|NCT04604795|EXPERIMENTAL|Part A:GSK3915393 DLs 1,2,3,IV microdose and placebo (Sequence C)|"In Part A, participants will receive dose levels 1, 2, 3, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence C).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
62543041|NCT04604795|EXPERIMENTAL|Part A:GSK3915393 DLs 2,3,4,IV microdose and placebo (Sequence D)|"In Part A, participants will receive dose levels 2, 3, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence D).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
62543042|NCT04604795|EXPERIMENTAL|Part B: Cohort 1: Participants receiving GSK3915393 DL X|Participants will receive GSK3915393 dose level X twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A.
62543043|NCT04604795|PLACEBO_COMPARATOR|Part B: Cohort 1: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level X during Part B of the study.
62543044|NCT04604795|EXPERIMENTAL|Part B: Cohort 2: Participants receiving GSK3915393 DL Y|Participants will receive GSK3915393 dose level Y twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
62543045|NCT04604795|PLACEBO_COMPARATOR|Part B: Cohort 2: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Y twice daily during Part B of the study
62543046|NCT04604795|EXPERIMENTAL|Part B: Cohort 3: Participants receiving GSK3915393 DL Z|Participants will receive GSK3915393 dose level Z twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
62543047|NCT04604795|PLACEBO_COMPARATOR|Part B: Cohort 3: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Z twice daily during Part B of the study.
62543048|NCT04604795|EXPERIMENTAL|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+water/GSK3915393+GFJ/GSK3915393+ITZ (Sequence A)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and itraconazole (ITZ) in period 2. Participants will then receive oral GSK3915393 plus water in period 3, oral GSK3915393 plus grape fruit juice (GFJ) in period 4 and oral GSK3915393 plus ITZ in period 5.
62543049|NCT04604795|EXPERIMENTAL|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+GFJ/GSK3915393+water/GSK3915393+ITZ (Sequence B)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and ITZ in period 2. Participants will then receive oral GSK3915393 plus GFJ in period 3, oral GSK3915393 plus water in period 4 and oral GSK3915393 plus ITZ in period 5.
62543050|NCT01455298|OTHER|Transient elastography and fibrotest|
62164887|NCT05586308|ACTIVE_COMPARATOR|Financial incentive|Participants will receive financial incentive intervention and an evidence-based text-messaging support.
62164888|NCT05586308|EXPERIMENTAL|Combined|Participants will receive media literacy e-learning lessons, financial incentive, and an evidence-based text-messaging support program.
62543051|NCT01111825|EXPERIMENTAL|Temsirolimus plus Neratinib|This is an open-label, single arm, dose-escalation phase I-II study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma. Patients with trastuzumab-refractory HER2-amplified disease or triple negative disease will be enrolled in both phases of this clinical trial.
62543052|NCT02976987|EXPERIMENTAL|Cidofovir|Women receiving an aqueous gel containing 2% (w/w) cidofovir, administrated directly on cervix exhibiting high grade squamous intraepithelial lesion (CIN 2 and 3).
62543053|NCT01236911||Calcium after moderate-severe TBI|Patients with moderate -severe TBI with less as 24 hrs , admitted in emergency. We will measure seric calcium to compare the differences between both groups
62164889|NCT05159778|EXPERIMENTAL|Experimental|
62716736|NCT00551083|EXPERIMENTAL|CDSS-D|Computer Decision Support System for Depression (CDSS-D) - This arm provided physicians with a computerized treatment algorithm and a decision support system to treat their patients suffering Major Depressive Disorder
62164890|NCT01636778|EXPERIMENTAL|SB-497115-GR|investigational product for thrombocytopenia
62164891|NCT02093078||CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
62164892|NCT02093078||Control Arm|
62164893|NCT02286427|ACTIVE_COMPARATOR|Standard Dressing|J0 to J42 : once a week, primary dressing with Mepitel®
62543054|NCT05609630|EXPERIMENTAL|Cohort 1 Upadacitinib|Participants will receive upadacitinib for 52 weeks.
62543055|NCT05609630|ACTIVE_COMPARATOR|Cohort 1 Tocilizumab|Participants will receive tocilizumab for 52 weeks.
62543056|NCT05609630|EXPERIMENTAL|Cohort 2 Upadacitinib|Participants will receive upadacitinib for 52 weeks.
62543057|NCT02037386|EXPERIMENTAL|H-side branch stent|H-side branch stent group
62543058|NCT04726176||COVID-19|"Participants who were admitted to the intensive care unit due to COVID-19 or participants who exhibited mild symptoms due to COVID-19 but needed to be hospitalized."
62716737|NCT00551083|ACTIVE_COMPARATOR|UC|Usual Care (UC) - This group of physicians treated their patients suffering from Major Depressive Disorder with their standard treatment as usual, and received no algorithm support with regard to treatment decisions
62543059|NCT04726176||Healthy control group|Healthy matched participants who never had COVID-19.
62543060|NCT06113302|EXPERIMENTAL|Cohort 1|Participants with lower risk MDS patients who have symptomatic anemia that are transfusion independent (TI). Participants will be asked to come to the study clinic weekly for the first 3 weeks and then 1 time every 3 weeks after that to have tests and procedures (such as physical exams and blood draws). Luspatercept will be administered once every 3 weeks.
62543061|NCT06113302|EXPERIMENTAL|Cohort 2|Participants with lower risk MDS that are transfusion dependent (TD). Participants will be asked to come to the study clinic weekly for the first 3 weeks and then 1 time every 3 weeks after that to have tests and procedures (such as physical exams and blood draws). Luspatercept will be administered once every 3 weeks.
62543062|NCT04204538||Urban|Young adults living in urban communities of Rwanda
62543063|NCT04204538||Rural|Young adults living in rural communities of Rwanda
62543064|NCT05678543||Mothers|Pregnant women with pre existing diabetes.
62543065|NCT05678543||Partners|Partners to pregnant women with pre existing diabetes.
62543066|NCT05678543||Offspring|Offspring born to women with pre existing diabetes
62543067|NCT03904108|EXPERIMENTAL|Ramucirumab|Ramucirumab 10 mg/kg IV day 1, every 3 weeks for 4 cycles
62543068|NCT01045135||first time delivery|Women giving birth to their first child
62543069|NCT01958073|EXPERIMENTAL|Conjugated Estrogen Vaginal Cream|Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
62543070|NCT01958073|EXPERIMENTAL|Estradiol Ring|Estradiol Ring per vagina every 3 months
62543071|NCT01958073|PLACEBO_COMPARATOR|Placebo|Per vagina
62543072|NCT00961402|EXPERIMENTAL|Wellness Control|Participants will receive health and wellness information and no exercise information.
62543073|NCT00961402|EXPERIMENTAL|Exercise Intervention|Intervention will include motivational telephone-based intervention to increase exercise to 5 days per week for 30 minutes or more each session.
62543074|NCT03296878|OTHER|Own-Price Elasticity|"The price of eggs will vary (own-price elasticity) while the price of other foods in the mock grocery store will remain constant."
62543075|NCT03296878|OTHER|Cross-Price Elasticity|"The eggs will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
62543076|NCT00580515|EXPERIMENTAL|1|6 sessions of Family Focused Group Therapy
62543077|NCT00580515|EXPERIMENTAL|2|10 Sessions of Family Focused Group Therapy
62543078|NCT00580515|ACTIVE_COMPARATOR|3|Standard Care- Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request
62543079|NCT01404286|EXPERIMENTAL|physical exercise|Experimental group: physical exercise Control group: no physical exercise
62543080|NCT01404286|NO_INTERVENTION|Control group|
62543081|NCT02379572|EXPERIMENTAL|iMRI-guided surgery|Resection of Glioblastomas with iMRI-guidance
62543082|NCT02379572|ACTIVE_COMPARATOR|5-ALA-guided surgery|Resection of Glioblastomas with 5-ALA-fluorescence-guidance
62543083|NCT05012826|EXPERIMENTAL|Osteopathic Manipulative Treatment (OMT)+ Physiotherapy (PT) Group|Participants in this group will receive OMT in addition to the same interventions of PT group for the same 2- month period. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
62716738|NCT06716554|EXPERIMENTAL|Shatavari|One capsule of Shatavari 300 mg (contains Shatavari extract) once a day, orally with water.
62735858|NCT05201885||laparoscopic surgery|Different surgical methods for rectal cancer resection
62543084|NCT05012826|ACTIVE_COMPARATOR|Physiotherapy Group (PT)|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 2 months. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council. the treatment provided will be registered on each participant's clinical notes and a summary of main interventions will be reported.
62543085|NCT03168230||PVE|Patients who required PVE prior to the attempt of liver resection.
62543086|NCT03168230||No-PVE|Patients who received upfront surgery (no PVE prior to the intervention)
62543087|NCT04094727|EXPERIMENTAL|Presumptive treatment and enhanced vector control|"For all eligible HRPs in intervention areas, after obtaining informed consent, presumptive treatment for malaria will be carried out using artemether-lumefantrine (AL) at two time points.~Enhanced vector control activities will include: (1) a mop up indoor residual spraying (IRS) campaign and (2) distribution of long-lasting insecticide-treated nets (LLINs) and/or vector control packs with topical repellent.~The intervention arm will also receive the standard of care in Namibia."
62543088|NCT04094727|NO_INTERVENTION|Standard of care|The control arm will receive the standard of care in Namibia: passive case detection through health facilities and health extension workers, routine indoor residual spraying (IRS), and reactive case detection (RACD) accompanied by reactive IRS.
62543089|NCT06324435|EXPERIMENTAL|Apremilast|Apremilast (60mg/day). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Day 1 10mg AM; Day 2 10mg AM, 10mg PM; Day 3 10mg AM, 20mg PM; Day 4 20mg AM, 20mg PM; Day 5 20mg AM, 30mg PM; Day 6 30mg AM, 30mg PM. Once at steady state, administration is orally twice daily at 8:00 AM (30mg) and 8:00 PM (30mg).
62716739|NCT06716554|EXPERIMENTAL|Shatavari + Ashwagandha|One capsule of Shatavari (300mg) + Ashwagandha (250mg) (contains Shatavari + Ashwagandha root extract) once a day, orally with water.
62543090|NCT02110784|EXPERIMENTAL|Eurartesim tablets|Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.
62543091|NCT05914688|EXPERIMENTAL|LY3209590 (Formulation 1)|Single dose of LY3209590 as formulation 1 administered subcutaneously (SC).
62543092|NCT05914688|EXPERIMENTAL|LY3209590 (Formulation 2)|Single dose of LY3209590 as formulation 2 administered SC.
62543093|NCT06551831||Young Patients With Advanced Cancer|"1. The patient has a solid tumor.~2. The age at initial cancer diagnosis is between 15 and 39 years.~3. The patient is at least 18 years old at the time of enrollment.~4. The patient has cancer with metastasis, either present at initial diagnosis or occurring after treatment or follow-up.~5. After metastasis, the first-line curative treatment is ineffective."
62543094|NCT02939053||Single-arm|All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.
62543095|NCT02939625|ACTIVE_COMPARATOR|muscle training|participants will breathing exercises for 20 min, then 40 min training with Threshold IMT therapy will be held in 7 sessions
62543096|NCT02939625|ACTIVE_COMPARATOR|bilevel positive airway pressure|participants will breathing exercises for 20 min, then 40 min bilevel (IPAP and EPAP 12 = 8 cm H2O), the therapy will be held in 7 sessions
62543097|NCT02939625|ACTIVE_COMPARATOR|Continue Positive Airway Pressure|participants will breathing exercises for 20 min, then 40 min CPAP (8 cm H2O) therapy will be held in 7 sessions
62543098|NCT04479644|EXPERIMENTAL|Cohort 1|BRII-198 dose level 1 or placebo
62543099|NCT04479644|EXPERIMENTAL|Cohort 2|BRII-198 dose level 2 or placebo
62543100|NCT04479644|EXPERIMENTAL|Cohort 3|BRII-198 dose level 3 or placebo
62543101|NCT05238714|EXPERIMENTAL|[14C] venglustat|Single dose of \[14C\] venglustat Oral Solution under fasting conditions
62543102|NCT02753920|ACTIVE_COMPARATOR|Retrograde fill voiding trial method|"1. Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~2. Catheter is removed~3. Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~4. The patient will subjectively quantify their force of stream via visual analog scale (VAS) scale (however this information will only be used for research purposes).~5. If she voids \>/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids \<200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial."
62543103|NCT02753920|ACTIVE_COMPARATOR|Force of Stream (FAST) voiding trial method|"1. Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~2. Catheter is removed~3. Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~4. The patient will subjectively quantify their force of stream via VAS scale.~5. If VAS scale \>/=50 (\>/=50%) the catheter will remain out, patient is discharged home without measuring a PVR~6. If VAS scale is from 0-49 (=0-49%) a PVR will be checked via bladder scan. If PVR is \<500cc, the patient will be discharged without a catheter; if PVR is \>/=500cc, the patient will be discharged with a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days."
62543104|NCT02137486||sequential ballooning|include BMS or DES
62543105|NCT02137486||final kissing ballooning|include BMS or DES
62543106|NCT01689727|OTHER|Technetium Tc 99m EC20|
62543107|NCT01851330|EXPERIMENTAL|LDV/SOF 8 Week|Participants will receive LDV/SOF FDC for 8 weeks.
62543108|NCT01851330|EXPERIMENTAL|LDV/SOF+RBV 8 Week|Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
62543109|NCT01851330|EXPERIMENTAL|LDV/SOF 12 Week|Participants will receive LDV/SOF FDC for 12 weeks.
62543110|NCT04803305|EXPERIMENTAL|Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 Treatment|subcutaneous injection
62543111|NCT04803305|PLACEBO_COMPARATOR|Double-Blind Placebo Treatment followed by Open-Label PF-06946860 Treatment|subcutaneous injection
62543112|NCT06223087||control|group not practicing winter swimming
62543113|NCT06223087||winter swimmers|group practicing winter swimming
62543114|NCT01141205|EXPERIMENTAL|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
62543115|NCT01141205|PLACEBO_COMPARATOR|Saline|Saline
62543116|NCT06500208|EXPERIMENTAL|Adebrelimab and chemotherapy|Adebrelimab 1200 mg Q3W combined with nab-paclitaxel (100 mg/m2 Q1W) for 4 cycles followed by epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) Q3W for 4 cycles.
62543117|NCT00609180|EXPERIMENTAL|1|Participants will receive initial minimal (trophic) enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
62543118|NCT00609180|EXPERIMENTAL|2|Participants will receive initial full-calorie enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
62543119|NCT00609180|EXPERIMENTAL|3|Participants will receive initial minimal (trophic) enteral feeding and the placebo supplement
62543120|NCT00609180|PLACEBO_COMPARATOR|4|Participants will receive initial full-calorie enteral feeding and the placebo supplement
62716740|NCT06716554|PLACEBO_COMPARATOR|Placebo|One capsule of Placebo 300 mg (contains starch extract) once a day, orally with water.
62716741|NCT04340518|EXPERIMENTAL|Post-scleral lens wear|Normal subjects without ocular diseased who have worn scleral lenses for at least 8 hours.
62716742|NCT06716073|EXPERIMENTAL|Endoscopic breast-conserving surgery (E-BCS) group|
62543121|NCT04244383|EXPERIMENTAL|chronic hepatitis C virus patients|50 chronic hepatitis C virus patients taking will be trated with direct acting antiviral treatment with three months regimen (Sofosbuvir + Daclatasvir).
62543122|NCT04244383|EXPERIMENTAL|treated chronic hepatitis C virus patients|the selected 50 chronic hepatitis C virus patients received direct acting antivirals: Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virological response at 12 weeks following the end of treatment (SVR12).
62543123|NCT02165878||Children and adolescent|children and adolescent CKD patients of any etiology
62543124|NCT04283019|EXPERIMENTAL|CBD without THC|oral formulation containing 100mg CBD and 0mg THC
62543125|NCT04283019|EXPERIMENTAL|CBD with 3.7 mg THC|oral formulation containing 100mg CBD and 3.7mg THC
62716743|NCT06716073|NO_INTERVENTION|Conventional breast-conserving surgery (C-BCS) group|
62543126|NCT04283019|EXPERIMENTAL|CBD with 2.8 mg THC|oral formulation containing 100mg CBD and 2.8 mg THC
62543127|NCT02842073|EXPERIMENTAL|Naltrexone and Buproprion|Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
62543128|NCT02252406|EXPERIMENTAL|Ranolazine|Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
62543129|NCT02252406|PLACEBO_COMPARATOR|Placebo|Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.
62543130|NCT02630979||No treatment|Clinical and medical oncology physicians.
62543131|NCT03591497|EXPERIMENTAL|Intervention Group|"Instrument to be used:~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.~Programme schedule:~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
62543132|NCT03591497|NO_INTERVENTION|Control Group|Virtual reality sessions were not provided.
62543133|NCT02627651|EXPERIMENTAL|brain injury|children post brain injury
62164894|NCT02286427|EXPERIMENTAL|Amniotic Membrane|J0 to J42: once a week, Mepitel® and amniotic membrane (one or several depending on the graft size, so that the ulcer was completely covered with MAH). The last amniotic membrane is left in place.
62543134|NCT02627651|ACTIVE_COMPARATOR|controls|children typically developed age matched
62543135|NCT03685422|EXPERIMENTAL|Virtual Reality|"Patients will be given a VR Gear Headset fitted with a smartphone, and will be offered to choose the calming scenario they wish to experience from a set of predefined scenarios before the surgery. They will be given time to experience VR for up to 25 mins. After the VR session, patients will be given questionnaires, satisfaction with VR, and pain scores.~After the surgery is completed, patient will be transferred to recovery room. Patients may resume VR session for up to 25 mins. After the use of VR, they will be asked on their satisfaction towards the VR experience, and also fill in questionnaires.~On the same day of surgery (0-24 hours post-op), patients will be asked to have another two more VR sessions (up to 25 mins per session), with questionnaire filled in after the sessions.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given.~All the headsets will be disinfected following the hospital's infection control guideline."
62543136|NCT03685422|NO_INTERVENTION|Non Virtual Reality|"Before the surgery, only questionnaires and pain scores will be documented. After the surgery is completed, patient will be transferred to recovery room. Only questionnaires and pain scores will be documented.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given."
62543137|NCT00553176||Patients with Crohn's disease|The Registry is an observational research program featuring clinical, economic, and humanistic measures characterizing the treatment of Crohn's disease
62716744|NCT00399035|PLACEBO_COMPARATOR|FOLFOX + placebo Cediranib|FOLFOX + placebo Cediranib
62164895|NCT05942833|EXPERIMENTAL|Group A (Early)|Early left hemicolectomy immediately up to a maximum of 2 days after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
62543138|NCT01871571|EXPERIMENTAL|Treatment (bevacizumab, mFOLFOX7)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.
62543139|NCT02008812|EXPERIMENTAL|Ad sensor|virus detection
62543140|NCT02851745|EXPERIMENTAL|Linagliptin|Linagliptin 5 mg daily for 48 weeks
62543141|NCT02851745|PLACEBO_COMPARATOR|Placebo|Placebo 5 mg daily for 48 weeks
62543142|NCT05096260|EXPERIMENTAL|Intervention|Enrolled study participants receive Motivational Interviewing based SMS/MMS messages to increase COVID-19 vaccine uptake, and complete Baseline and Follow-up surveys.
62543143|NCT05096260|NO_INTERVENTION|Control|Enrolled study participants receive a simple website and complete a Baseline and Follow-up survey, after which they will receive the interventional Motivational Interviewing based SMS/MMS messages to increase COVID-19 vaccine uptake.
62543144|NCT02513030||Replacement of defibrillator|
62543145|NCT06611280||MS group|People with relapse remitting multiple sclerosis
62543146|NCT06611280||HC group|Healthy control participant who are age- and sex-matched to the MS group
62543147|NCT05461196|EXPERIMENTAL|Mobile App + BP|Patients use a mobile application in addition to electronic monitoring blister packs for pain medications.
62543148|NCT05461196|NO_INTERVENTION|BP|Patients' pain medication is in electronic monitoring blister packs.
62716745|NCT00399035|PLACEBO_COMPARATOR|Xelox + placebo Cediranib|Xelox + placebo Cediranib
62543149|NCT05461196|EXPERIMENTAL|Mobile App Only|Patients use a mobile application.
62543150|NCT05461196|NO_INTERVENTION|Control|
62543151|NCT04521101|OTHER|VAST Course|
62543152|NCT05578183|EXPERIMENTAL|high dose TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
62716746|NCT00399035|EXPERIMENTAL|FOLFOX + Cediranib|FOLFOX + Cediranib
62716747|NCT00399035|EXPERIMENTAL|XELOX + Cediranib|XELOX + Cediranib
62735859|NCT05201885||Transanal endoscopic surgery|Different surgical methods for rectal cancer resection
62735860|NCT02188940|ACTIVE_COMPARATOR|Exercise, dietary and behavioral therapy|The interventions of active comparator will be education program, dietary and behavioral therapy and exercise training.
62735861|NCT02188940|SHAM_COMPARATOR|Dietary and behavioral therapy|The intervention in sham comparator will be education program, dietary and behavioral therapy and stretching and breathing exercise.
62735862|NCT03001193|EXPERIMENTAL|DF01 low dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in low dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
62543153|NCT05578183|EXPERIMENTAL|low dose TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
62543154|NCT05578183|SHAM_COMPARATOR|high dose sham TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
62543155|NCT05578183|SHAM_COMPARATOR|low dose sham TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
62543156|NCT05176444|EXPERIMENTAL|Music therapy intervention|Music therapy
62543157|NCT05176444|NO_INTERVENTION|Control group - standard care|Standard care for residents with cognitive impairment. Staff will not receive music therapy training.
62543158|NCT03417635|EXPERIMENTAL|Guided focused attention|"Participants will take part in a guided focused attention practice led by the researcher. This will include strategies used in meditations where participants focus on their breathing. More specifically, they will be instructed to close their eyes and focus on the sensation of breathing in one area of the body for the entire session. They will be given reminders throughout the session to remain on task (focusing on the breath) and not to let their thoughts wander.~Participants will be asked to either sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much that they might fall asleep."
62543159|NCT03417635|ACTIVE_COMPARATOR|Acoustic music|"Participants will be instructed to listen to a prepared soothing acoustic music track. The sessions will be led by a researcher. Participants will be asked to close their eyes and relax while listening to the music.~Participants will be asked to sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much they might fall asleep This group is used as active control group to control for socialization in group settings and any effects of consciously relaxing for the meetings."
62543160|NCT04992208|EXPERIMENTAL|Experimental Group|All of the participants(N=33000) will receive two doses inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
62543161|NCT03458182|EXPERIMENTAL|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
62543162|NCT03458182|NO_INTERVENTION|No intervention|No added exercise period (normal exercise test).
62543163|NCT02793505||Pregnant patient exposed to metformin|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to metformin (Anatomical Therapeutic Chemical A10BA02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (LMP)).
62543164|NCT02793505||Reference group|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to any drug not known as a major teratogen or fetotoxicant and different than metformin, insulin or any other hypoglycaemic agent.
62543165|NCT04577664|ACTIVE_COMPARATOR|TT group|
62543166|NCT04577664|ACTIVE_COMPARATOR|ST group|
62543167|NCT01635816|ACTIVE_COMPARATOR|JE Vaccine existing facilities|will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
62543168|NCT01635816|ACTIVE_COMPARATOR|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
62543169|NCT01635816|ACTIVE_COMPARATOR|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
62543170|NCT01635816|ACTIVE_COMPARATOR|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
62543171|NCT02390128||mothers and babies|pregnant mothers (UK resident) and their babies (observational, not an intervention)
62543172|NCT04379791||case cohort|Patients with a surgical site infection or a wound complication after surgical treatment of an ankle fracture. The time horizon for wound complication was set to maximally 4 weeks after surgery.
62543173|NCT04379791||control cohort|Patients without a surgical site infection or a wound complication (normal wound-healing and suture or staple removal) after surgical treatment of an ankle fracture.
62543174|NCT06321679||WB-MRI|Each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
62735863|NCT03001193|EXPERIMENTAL|DF01 medium dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in medium dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
62543175|NCT01062347|EXPERIMENTAL|zinc supplementation (20 mg/d, for 7 d)|
62543176|NCT05443178|EXPERIMENTAL|Cohort 1|100 mg Nivaquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
62543177|NCT05443178|EXPERIMENTAL|Cohort 2|200 mg Chloroquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
62543178|NCT05443178|EXPERIMENTAL|Cohort 3|300 mg Chloroquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
62543179|NCT05443178|EXPERIMENTAL|Dose extension group|Dose escalation: XX mg Chloroquine (depending on results) and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
62543180|NCT06021418|EXPERIMENTAL|DKB-119|Injecting to one side crow's feet
62543181|NCT06021418|ACTIVE_COMPARATOR|Control|Injecting to one side crow's feet
62543182|NCT05946499||Group A|30 ICU-admitted SARS-CoV-2- infected individuals with ARDS or in need of oxygen supplementation
62543183|NCT05946499||Group B|30 ward-admitted SARS-CoV-2-infected individuals not suffering from ARDS and not in need of oxygen supplementation
62543184|NCT05946499||Group C|30 sex and age-matched normal individuals
62543185|NCT01654172|EXPERIMENTAL|High Flavanol Cocoa|"Cocoa drink containing \~450mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
62543186|NCT01654172|PLACEBO_COMPARATOR|Low Flavanol Cocoa|"Cocoa drink containing \~25mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
62543187|NCT05810688|EXPERIMENTAL|Eating rehabilitation training group|The intervention group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education
62716748|NCT03516279|EXPERIMENTAL|Treatment (pembrolizumab, dasatinib, imatinib, nilotinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and dasatinib, imatinib mesylate, or nilotinib PO as clinically indicated per the treating physician. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients with detectable MRD after course 18 continue pembrolizumab and dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity. Patients with UMRD at any time before course 18 discontinue pembrolizumab after course 18 and continue dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity.
62716749|NCT01342926|EXPERIMENTAL|GSK933776 3 mg/kg|3 mg/kg administration of GSK933776 via intravenous infusion
62164896|NCT05942833|OTHER|Group B (Late)|Elective left hemicolectomy 6 to 8 weeks after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
62543188|NCT05810688|NO_INTERVENTION|Control group|The control group will receive only usual care.
62543189|NCT04752059|EXPERIMENTAL|T-DXd 5.4 mg|Single arm phase II trial
62543190|NCT05070026|EXPERIMENTAL|uni-portal VATS group|
62543191|NCT05070026|EXPERIMENTAL|three port VATS group|
62543192|NCT00233402|ACTIVE_COMPARATOR|Standard White Light Cystoscopy|
62543193|NCT00233402|EXPERIMENTAL|Standard White Light and Hexvix Fluorescence Cystoscopy|
62543194|NCT03086382|EXPERIMENTAL|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
62543195|NCT03086382|EXPERIMENTAL|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
62543196|NCT06632912|EXPERIMENTAL|18-26 years old 3 doses group|
62543197|NCT06632912|EXPERIMENTAL|9-17 years old 3 doses group|
62543198|NCT06632912|EXPERIMENTAL|9-14 years old 2 doses group|
62543199|NCT01322230|EXPERIMENTAL|Control|Screen shots with voiceover and no interactivity
62543200|NCT01322230|EXPERIMENTAL|WISEMD Original|Learner control of pacing through multi-media content
62543201|NCT01322230|EXPERIMENTAL|Social Networking|social networking features (Forum and Social Presence)
62543202|NCT01322230|EXPERIMENTAL|Social Networking plus Emotional Design|Social networking features plus user interface enhancements
62543203|NCT01008735||women with hodgkin lymphoma treated with chemotherapy|
62543204|NCT04131348|OTHER|CSG|patients underwent open CST (component separation group or CSG)
62543205|NCT04131348|OTHER|BTG|patients with preoperative BT administration and following open RSR (botulinum toxin group or BTG).
62164897|NCT01919255|ACTIVE_COMPARATOR|Picolight + Coolprep (Day-Prior)|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\]
62164898|NCT01919255|ACTIVE_COMPARATOR|Picolight + Clicolon (Day-Prior)|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\]
62164899|NCT01919255|ACTIVE_COMPARATOR|Picolight + Coolprep (Split-Dose)|Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
62543206|NCT04421235|OTHER|Childbirth Support|Women who enroll in the intervention portion of this study will receive the childbirth support elements for which they are eligible in and elect to participate. Possible program elements include prenatal education classes, support group, lactation program, doula support, and parenting classes.
62543207|NCT03378752||Atelectasis formation using HFJV|Computed tomography scans are performed every 15 minute during the first 45 minutes during general anaesthesia using high frequency jet ventilation.
62543208|NCT06413511|EXPERIMENTAL|Belantamab|
62543209|NCT02570594|OTHER|healthy volunteers|
62543210|NCT05999487|ACTIVE_COMPARATOR|patients who will recieve dobutrex|patient presenting with acute heart failure , who will recieve dobutrex as a result of their randomixation , startng dose will be 5 mic , assesing their need for tittration of dose , the need for addition of another inotrope , the prescence of any side effects and the duration of inotropic use for reaching hemodynamically stable state
62543211|NCT05999487|EXPERIMENTAL|patients who will recieve milirinone|patient presenting with acute heart failure , who will recieve milirinone as a result of their randomixation , startng dose will be 0.25 mic , assesing their need for tittration of dose , the need for addition of another inotrope , the prescence of any side effects and the duration of inotropic use for reaching hemodynamically stable state
62543212|NCT06632938|EXPERIMENTAL|ABBV-382 Dose A|Participant will receive a single dose of ABBV-382 Dose A on Day 1 and will be confined to the study site and supervised for approximately 9 days. Participants will be followed-up for approximately 20 weeks.
62543213|NCT06632938|PLACEBO_COMPARATOR|ABBV-382 Dose A Placebo|Participant will receive a single dose of ABBV-382 Dose A placebo on Day 1 and will be confined to the study site and supervised for approximately 9 days. Participants will be followed-up for approximately 20 weeks.
62543214|NCT06632938|EXPERIMENTAL|ABBV-382 Dose B|Participant will receive a single dose of ABBV-382 Dose B on Day 1 and will be confined to the study site and supervised for approximately 5 days. Participants will be followed-up for approximately 20 weeks.
62543215|NCT06632938|PLACEBO_COMPARATOR|ABBV-382 Dose B Placebo|Participant will receive a single dose of ABBV-382 Dose B placebo on Day 1 and will be confined to the study site and supervised for approximately 5 days. Participants will be followed-up for approximately 20 weeks.
62543216|NCT00138554|EXPERIMENTAL|vildagliptin 50 mg qd + pioglitazone 45 mg qd|vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks
62543217|NCT00138554|EXPERIMENTAL|vildagliptin 50 mg bd+ pioglitazone 45 mg qd|vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks
62543218|NCT02101580|EXPERIMENTAL|ADI-PEG 20|
62543219|NCT01608061|EXPERIMENTAL|DBS-f on|DBS-f on
62543220|NCT01608061|SHAM_COMPARATOR|DBS-f off|DBS-f off
62543221|NCT02293980|EXPERIMENTAL|Part 1: MK-3795|Participants with advanced ccRCC receive MK-3795 at an initial dose level of 100mg orally, twice daily (BID) up to approximately 3 weeks. Dose levels will be escalated to identify the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for MK-3795. Each escalated dose will be continued for up to approximately 3 weeks before escalating a dose again until a dose limiting toxicity (DLT) is experienced. Thereafter, participants receive RP2D dose of MK-3795 for up to 2 cycles (each cycle length = 28 days) for up to approximately 1 year. Participants may continue to receive MK-3795 beyond 1 year at the discretion of the Sponsor.
62543222|NCT02293980|EXPERIMENTAL|Part 2: MK-3795 + Nivolumab + Belzutifan|Participants with advanced ccRCC in the expansion phase receive the RP2D of MK-3795 orally in combination with nivolumab 240mg by IV infusion over \~60 minutes every 2 weeks for up to \~1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later. As per Amendment 09 (29 March 2024), participants will not receive MK-3795. Participants receive nivolumab 240mg by IV infusion over \~60 minutes every 2 weeks in combination with belzutifan 120 mg once daily (QD) for up to \~1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later. If participants experience an adverse event, then nivolumab will be discontinued and participants will continue to receive belzutifan 120 mg QD alone for up to \~1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later.
62543223|NCT02293980|EXPERIMENTAL|Part 3: MK-3795 + Cabozantinib|Participants with advanced ccRCC in the expansion phase receive the RP2D of MK-3795 in combination with cabozantinib 20mg up to 60mg orally QD for up to approximately 1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later.
62543224|NCT05369312|EXPERIMENTAL|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-442096 administered, once daily (QD).
62543225|NCT05369312|EXPERIMENTAL|Dose Expansion|Oral tablets administered at MTD/RP2D defined dose. Each treatment cycle will be 21 days in duration with BPI-442096 administered, once daily (QD)
62543226|NCT04207489||endoscopic submucosal injection of indocyanine green|
62543227|NCT02613182|EXPERIMENTAL|Open Label|Open Label Study Drug NEOD001
62543228|NCT01917916|EXPERIMENTAL|BI 655064 dose group 1 - 80 mg|
62543229|NCT01917916|EXPERIMENTAL|BI 655064 dose group 2 - 120 mg|
62543230|NCT01917916|EXPERIMENTAL|BI 655064 dose group 3 - 180 mg|
62543231|NCT01917916|EXPERIMENTAL|BI 655064 dose group 4 - 240 mg|
62543232|NCT01917916|PLACEBO_COMPARATOR|Placebo matching BI 655064|
62543233|NCT02607267||laparoscopic Roux en Y Gastric Bypass|patients undergoing LRYGB, being the first surgical treatment for severe obesity
62543234|NCT02607267||laparoscopic Sleeve Gastrectomy|patients undergoing LSG, being the first surgical treatment for severe obesity
62543235|NCT03122977|EXPERIMENTAL|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
62543236|NCT03122977|ACTIVE_COMPARATOR|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
62543237|NCT01954745|EXPERIMENTAL|Cabozantinib|Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
61978156|NCT03264209|NO_INTERVENTION|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
62543238|NCT06206135||low-dose group|initial dose 1.5 g/day
62543239|NCT06206135||standard-dose group|initial dose 4 g/day
62543240|NCT01102556||Surgery Patients/High-risk Patients|Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
62543241|NCT03886883|EXPERIMENTAL|Exercise-induced hypoalgesia (EIH)|Exercise-induced hypoalgesia - isometric muscle contractions of the hand flexors
61978157|NCT05098925|EXPERIMENTAL|Intervention|Study of Thermoregulatory Processes in Ultra-endurance Runners in a Hot and Humid Environment
62543242|NCT03886883|ACTIVE_COMPARATOR|Static stretch (SS)|A static stretch of the knee flexors
62543243|NCT03886883|SHAM_COMPARATOR|Rest|No intervention
62543244|NCT03886883|EXPERIMENTAL|Conditioning painful stimulus (CPM)|Conditioned pain modulation - cold pressure test
62543245|NCT03905720|NO_INTERVENTION|Treatment As Usual|Participants will receive routine care consisting of usual analgesic medications for pain in adults with cancer.
62543246|NCT03905720|ACTIVE_COMPARATOR|Acupuncture|Along with routine pain medications, participants will be offered daily acupuncture treatments for up to four days.
62543247|NCT03905720|ACTIVE_COMPARATOR|Pain Counseling|Along with routine pain medications, participants will receive evidence-based psychosocial support through education and counseling provided by qualified study staff.
62543248|NCT03905720|ACTIVE_COMPARATOR|Acupuncture and Pain Counseling|Along with routine pain medications, participants will be offered daily acupuncture treatments and pain counseling for up to four days as described above.
62543249|NCT06006390|EXPERIMENTAL|Intravenous of CD70-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62543250|NCT06006390|EXPERIMENTAL|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg
62543251|NCT05264129|EXPERIMENTAL|Atogepant + Ubrogepant|Participants will receive atogepant for 12 weeks followed by atogepant + ubrogepant for 12 weeks.
62716750|NCT01342926|EXPERIMENTAL|GSK933776 6 mg/kg|6 mg/kg administration of GSK933776 via intravenous infusion
61978158|NCT03913650|ACTIVE_COMPARATOR|Nerve block(+)|patient accept nerve block for post-op pain control
62543252|NCT01381315|OTHER|Sentinel lymph node biopsy|During surgery, 1.0 mCi of technetium-99m sulfur colloid will be injected into sub-dermal subareolar aspect of the affected breast. The KUMC Nuclear Medicine Department will be responsible for performing the injection of the isotope and dilution of the isotope using saline to a final volume of 4.0 ml or less.
62543253|NCT01381315|OTHER|Axillary lymph node biopsy|
62543254|NCT05758233|EXPERIMENTAL|Grup 1: Transversalis Fascia Plane Block (TFPB)|Transversalis Fascia Plane Block (TFPB)
62543255|NCT05758233|EXPERIMENTAL|Grup 2: Transversus Abdominis Plane Block (TAPB)|Transversus Abdominis Plane Block (TAPB)
62543256|NCT05840679|EXPERIMENTAL|3% NaOCl concentration group|Participants in this group will receive endodontic irrigation with lower conc 3% sodium hypochlorite
62543257|NCT05840679|EXPERIMENTAL|6% NaOCl concentration group|Participants in this group will receive endodontic irrigation with higher conc 6% sodium hypochlorite
62543258|NCT05321368|EXPERIMENTAL|LINKED-HEARTS Program|"Patients in the LINKED-HEARTS Program will be trained to measure their blood pressure with an Omron 10 series device using the Sphygmo telemonitoring app. The physician, pharmacist and Community Health Worker will have access to transmit data.~Community Health Workers will provide education on managing blood pressure; reinforce positive blood pressure self-management behaviors; deliver knowledge and skills to promote healthy chronic conditions; assist with linking clinical and administrative services; and link participants with community resources.~The study pharmacist will conduct telehealth visits, optimize pharmacologic therapy. The pharmacists will assess and address medication adherence to improve hypertension and diabetes control."
62543259|NCT05321368|NO_INTERVENTION|Enhanced Usual Care|Patients in the Enhanced Usual Care Arm, will receive care as usual from their primary care provider and will be trained to measure their blood pressure with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
62543260|NCT00124124|EXPERIMENTAL|1|KLH and peptide pulsed DCs
62543261|NCT00124124|EXPERIMENTAL|2|KLH, peptides plus Montanide
62543262|NCT00832156|EXPERIMENTAL|1|wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
62543263|NCT00832156|OTHER|2|control wound site; application of mesh graft alone
62543264|NCT00807716|EXPERIMENTAL|walking skill group|weight-bearing 12 times, 70 minutes
62543265|NCT00807716|ACTIVE_COMPARATOR|usual physiotherapy care|partial weight-bearing, 12 times, 40 minutes
62543266|NCT06205329|EXPERIMENTAL|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo
62543267|NCT06205329|EXPERIMENTAL|WPV01 Dose 5-8|WPV01 Dose 5-8 co-administrated with ritonavir or Placebo
62543268|NCT06205329|EXPERIMENTAL|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo
62543269|NCT06205329|EXPERIMENTAL|WPV01 Dose 13-15|WPV01 Dose 13-15 or Placebo
62543270|NCT06205329|EXPERIMENTAL|WPV01 Dose 16|WPV01 Dose 16(with high fat meal) or WPV01 Dose 16 (fed)
62543271|NCT03495921|EXPERIMENTAL|Group A: Vigil + Irinotecan and Temozolomide|"Participants randomized to Group A received oral temozolomide 100 mg/m2 daily (Days 1-5), total dose 500 mg/m2/cycle) and oral irinotecan 50 mg/m2 daily (Days 1-5, total dose 250 mg/m2/cycle). Vigil immunotherapy was administered at a concentration of 1 X 10e6 cells/dose given via intradermal injection on Day 15 of each cycle. 1 cycle = 21 days~Participants continued treatment for a maximum of 12 cycles, or until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study."
62543272|NCT03495921|ACTIVE_COMPARATOR|Group B: Irinotecan and Temozolomide|"Participants randomized to Group B received oral temozolomide 100 mg/m2 daily (Days 1-5), total dose 500 mg/m2/cycle) and oral irinotecan 50 mg/m2 daily (Days 1-5, total dose 250 mg/m2/cycle).~1 cycle = 21 days~Participants continued treatment for a maximum of 12 cycles, or until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study."
62543273|NCT03495921|OTHER|Cross-Over: Vigil monotherapy|Participants randomized to Group B were able to receive Vigil immunotherapy at a concentration of 1 X 10e6 cells/dose given via intradermal injection on Day 15 of each cycle. Confirmation of progression by central radiologist and pre-approval from sponsor was required. 1 cycle = 21 days
62543274|NCT00477633|EXPERIMENTAL|Norethindrone/ethinyl estradiol|1 tablet per day
62543275|NCT04637555|EXPERIMENTAL|LCZ696 (sacubitril/valsartan)|Following start of treatment, patients will receive LCZ696. Possible doses are level 1, 2, and 3 (50, 100 and 200 mg twice daily respectively)
62543276|NCT02268578|ACTIVE_COMPARATOR|Transcranial Direct Current Stimulation|Subjects will receive a total of 5 sessions on consecutive days. During each session, 2 mA of tDCS will be applied for 20 minutes over the left DLPFC (active or sham). The electrodes will have the size of 35cm2 each. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes and delivered b y a specially developed, battery driven, constant current stimulator with a maximum output of 2mA.
62543277|NCT02268578|SHAM_COMPARATOR|Sham TDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds - this is a reliable method of sham stimulation as sensations arising from tDCS treatment occur only at the beginning of application as also demonstrated by a randomized study (Gandiga et al. 2006).
62543278|NCT04760496|EXPERIMENTAL|Experimental group|The experimental group will receive oxytocin at 4 mIU/mL
62543279|NCT04760496|ACTIVE_COMPARATOR|Control group|The control group will receive oxytocin at 2 mIU/mL
61978159|NCT03913650|SHAM_COMPARATOR|Morphine|patient received morphine for post-op pain control
62543280|NCT05184543|ACTIVE_COMPARATOR|Control Group|Participants in the control group will continue their routine warm-up programs.
62543281|NCT05184543|EXPERIMENTAL|Core Stability Group|A warm-up program including core stability exercises will be applied to the participants.
62543282|NCT05184543|EXPERIMENTAL|Neuromuscular Exercise Group|A warm-up program including dynamic neuromuscular exercises will be applied to the participants.
62543283|NCT04220970||BIA-ALCL|
62543284|NCT04600258|EXPERIMENTAL|Chocolate Group|Administration of 40g dark chocolate per day, for 2 months
62543285|NCT04600258|NO_INTERVENTION|Control Group|No intervention and analysis will be performed before and after 2 months
62543286|NCT06033092|ACTIVE_COMPARATOR|Low dose tamoxifen|Tamoxifen 10 mg (1 tablet) every other day for 6 months.
62716751|NCT01342926|PLACEBO_COMPARATOR|Placebo|Placebo via intravenous infusion
62716752|NCT01342926|EXPERIMENTAL|GSK933776 15 mg/kg|15 mg/kg administration of GSK933776 via intravenous infusion
62543287|NCT06033092|ACTIVE_COMPARATOR|Low dose tamoxifen + Intermittent Caloric Restriction|Tamoxifen 10 mg (1 tablet) every other day for 6 months + 5:2 diet (5 days/week at regular energy intake+2 days a week at an average 75% energy deficit)
62543288|NCT06033092|PLACEBO_COMPARATOR|Lifestyle intervention|Step counter device
62543289|NCT06033092|ACTIVE_COMPARATOR|Lifestyle Intervention + Intermittent Caloric Restriction|Step counter device + 5:2 diet (5 days/week at regular energy intake+2 days a week at an average 75% energy deficit)
62543290|NCT06501716||ICG Group|Eligible participants are those diagnosed with suprasellar lesions undergoing ICG angiography during endoscopic endonasal resection.
62543291|NCT01550679||Smokers or ex-smokers|Smokers or ex-smokers 40-65 years of age with a smoking history of at least 20 pack-years with no diagnosis of COPD or asthma
62543292|NCT04999891||Surgical Cohort|Elderly patients aged 65 and above who are planned for hip fracture surgery.
62543293|NCT00878176|EXPERIMENTAL|1|(Crossover study)
62543294|NCT06474208|EXPERIMENTAL|Intervention sequence 1|Subjects will receive 5 different formulations in sequence No. 1. The intervention administrations will be separated by a washout phase of 24 h.
62543295|NCT06474208|EXPERIMENTAL|Intervention sequence 2|Subjects will receive 5 different formulations in sequence No. 2. The intervention administrations will be separated by a washout phase of 24 h.
62543296|NCT06474208|EXPERIMENTAL|Intervention sequence 3|Subjects will receive 5 different formulations in sequence No. 3. The intervention administrations will be separated by a washout phase of 24 h.
62543297|NCT06474208|EXPERIMENTAL|Intervention sequence 4|Subjects will receive 5 different formulations in sequence No. 4. The intervention administrations will be separated by a washout phase of 24 h.
62543298|NCT06474208|EXPERIMENTAL|Intervention sequence 5|Subjects will receive 5 different formulations in sequence No. 5. The intervention administrations will be separated by a washout phase of 24 h.
62543299|NCT06509503|ACTIVE_COMPARATOR|the COCs group|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency. HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months. We will assess the phenotypic features of migraine.
62543300|NCT06509503|ACTIVE_COMPARATOR|the non-hormonal contraception group|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are not receiving any hormonal contraception and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency. HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months. We will assess the phenotypic features of migraine.
62543301|NCT00396812|EXPERIMENTAL|Rituximab|
62543302|NCT01973595|EXPERIMENTAL|Almonds then no almonds|Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.
62543303|NCT01973595|OTHER|No almonds then almonds|No almonds will be consumed by participants for 3 weeks.
62543304|NCT01061268|EXPERIMENTAL|BLINK™ tears|
62543305|NCT01061268|NO_INTERVENTION|No topical artificial tear|
62543306|NCT06181708||Primary care practitioners|A one off questionnaire to be sent to primary care practitioners via qualtrics to determine the current practice in primary care for venous leg ulcer management and availability of services to onward referral.
61978160|NCT01831544|EXPERIMENTAL|MVAD® Pump|Implant of HeartWare MVAD® System
62543307|NCT06181708||Vascular Scientists|A Delphi Consensus questionnaire will be performed via Qualtrics to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the UK
62543308|NCT02149147||Physical Activity Variety|participants will complete the Self-Efficacy questionnaire, the Physical Activity Enjoyment Scale, the Behavioral Regulation in Exercise-2 questionnaire, and an Outcome Expectations questionnaire. Participants will be instructed to wear the SenseWear® armband which will measure physical activity-related energy expenditure for the course of the study. The armband will be worn every day for at least 10 hours per day. In addition, participants will be asked to complete a physical activity diary to record their physical activity as well as additional information about the environment in which the physical activity was conducted. Participants will be instructed to engage in their normal physical activity regimen, wear the armband, and complete the physical activity diary for 3 weeks.
62543309|NCT01261923|EXPERIMENTAL|Alitretinoin - Hepatic Insufficiency|metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency
62543310|NCT01261923|EXPERIMENTAL|Alitretinoin - Hepatic Insufficiency Controls|metabolism of 30 mg alitretinoin single dose in 8 healthy controls.
62543311|NCT01146756|EXPERIMENTAL|AZD6244 & Thoracic Radiotherapy|AZD6244 in combination with thoracic radiotherapy (RT)- the aim is to determine the recommended phase II dose (RP2D).
62716753|NCT03461471|EXPERIMENTAL|Intervention Group|Exercise intervention
62716754|NCT05486390|EXPERIMENTAL|Intervention|
62716755|NCT05486390|NO_INTERVENTION|Control|
62716756|NCT06413732|EXPERIMENTAL|Group I|The dual-task training program combined with conventional physiotherapy was applied to both groups for approximately 1 hour, 5 days a week.
62716757|NCT06413732|OTHER|Group II|Only conventional physiotherapy was applied to both groups for approximately 1 hour, 5 days a week.
62716758|NCT06716827|EXPERIMENTAL|Conventional|In this group, 14 patients (7 with fixed appliances and 7 with clear aligners) underwent conventional whitening procedures during the treatment process. As the whitening agent, an in-office bleaching system containing 35% hydrogen peroxide (Whiteness HP, FGM) was chosen.
62716759|NCT06716827|EXPERIMENTAL|Laser-assisted bleaching|In this group, 14 patients (7 with fixed appliances and 7 with clear aligners) underwent laser whitening with a 940 nm diode laser and a 35% hydrogen peroxide gel (Whiteness HP, FGM).
62716760|NCT06716827|EXPERIMENTAL|Home bleaching|In the home whitening group, 14 patients (7 with fixed appliances and 7 with clear aligners) underwent a 14-day home whitening treatment during the treatment process using a 16% carbamide peroxide gel (Opalescence PF, Ultradent Products Inc., South Jordan, UT, USA).
62716761|NCT06716827|EXPERIMENTAL|Control|The 14 patients randomly selected (7 with fixed appliances and 7 with clear aligners) served as the control group. No whitening procedures were performed on the patients in this group.
62716762|NCT06666699|EXPERIMENTAL|RIVOS|
62716763|NCT06073704|EXPERIMENTAL|Antimicrobial Photodynamic therapy adjunct to scaling and root planing|Treatment of scaling and root planing followed by antimicrobial photodynamic therapy with methylene blue (100 micrograms/ml) and red laser
62716764|NCT06073704|ACTIVE_COMPARATOR|Control|Treatment of scaling and root planing.
62716765|NCT01155557|ACTIVE_COMPARATOR|Specific Strength Training|10 weeks of specific strength training of neck and shoulder muscles using elastic resistance.
62716766|NCT01155557|ACTIVE_COMPARATOR|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
62716767|NCT01804452||Subjects with a diagnosis of PSP or CBD|
62716768|NCT00154349|EXPERIMENTAL|imatinib mesylate|
62716769|NCT06716151|ACTIVE_COMPARATOR|Active Comparator: HB0034 dose group 1|6 subjects receive a single-dose of HB0034 and 2 subjects receive a single-dose placebo
62716770|NCT06716151|ACTIVE_COMPARATOR|Active Comparator: HB0034 dose group 2|6 subjects receive a single-dose of HB0034 and 2 subjects receive a single-dose placebo
62716771|NCT06716151|ACTIVE_COMPARATOR|Active Comparator: HB0034 dose group 3|6 subjects receive a single-dose of HB0034 and 2 subjects receive a single-dose placebo
62716772|NCT06716151|ACTIVE_COMPARATOR|Active Comparator: HB0034 dose group 4|6 subjects receive a single-dose of HB0034 and 2 subjects receive a single-dose placebo
62716773|NCT06716151|ACTIVE_COMPARATOR|Active Comparator: HB0034 dose group 5|6 subjects receive a single-dose of HB0034 and 2 subjects receive a single-dose placebo
62716774|NCT06716151|ACTIVE_COMPARATOR|Active Comparator: HB0034 dose group 6|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
62716775|NCT06716151|ACTIVE_COMPARATOR|Active Comparator: HB0034 dose group 7|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
62716776|NCT05407103|EXPERIMENTAL|Cold Acupressure Group|"Personal information form (PIF ) , Labor Monitoring Form (LMF), Visual Analog Scale (VAS), and Childbirth Comfort Questionnaire (CCQ) as pre-test during the latent phase before going about the cold acupressure. Next, she applied the cold acupressure pouches on the respective cold group on their LI 4 point for ten minutes, during the active and transition phases. The application was then suspended for one hour, and then repeated three more times.~Last, posttest took place. Cold group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after cold group to monitor how they were feeling."
62716777|NCT05407103|EXPERIMENTAL|Warm Acupressure Group|"PIF, LMF, VAS, and CCQ as pre-test during the latent phase before going about the warm acupressure. Next, she applied the warm acupressure pouches on the respective warm groups on their LI 4 point for ten minutes, during the active and transition phases. The application was then suspended for one hour, and then repeated three more times.~Last, posttest took place. Warm group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after warm group to monitor how they were feeling."
62716778|NCT05407103|NO_INTERVENTION|Control Group|The researcher ran PIF, LMF, VAS, and CCQ as pre-test during the latent phase. No intervention was applied to the control group. Last, posttest took place. Control group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after warm group to monitor how they were feeling.
62716779|NCT02102243|EXPERIMENTAL|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
62716780|NCT02102243|EXPERIMENTAL|Initial Saline Infusion|"We will perform the following procedures:~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
62543312|NCT01902225|EXPERIMENTAL|Istodax, Doxil|"Istodax; Intravenous; 8-14 mg/m2; Days 1, 8, and 15; over 4 hours~Doxil; Intravenous; 20 mg/m2; Day 1; over 1 hour"
62716781|NCT02811848||Barbers|Barbers that service African American clientele mainly will be recruited for this study; there is no intervention.
62716782|NCT04607629|EXPERIMENTAL|Genolar® + Symbicort®|omalizumab \& inhalation of budesonide+formoterol
62716783|NCT04607629|ACTIVE_COMPARATOR|Xolair® + Symbicort®|omalizumab \& inhalation of budesonide+formoterol
62716784|NCT06719453||The Trøndelag Health Study (The HUNT Study)|"(I) All participants from the HUNT4 70+ cohort (conducted 2017-2019, N=9,963) who have a blood sample (N=8,949). Participants underwent cognitive evaluation.~(II) Selection of 3,948 participants from the HUNT3 cohort (conducted 2006-2008, n=8,548.). Selection criteria: Later participation in the HUNT4 70+ cohort or HUNT4 70+ AiT cohort and having an available blood sample in HUNT3. The 3,948 participants were further selected to include all those with a dementia diagnosis in HUNT4 70+ (N=approx. 1,100). Of the remaining HUNT3 participants included, 1/3 should have a diagnosis of normal cognition in HUNT4 70+, and 2/3 should have a diagnosis of mild cognitive impariment in HUNT4 70+.~(III) All participants from the HUNT AiT cohort (Conducted 2021-2023, N=5,710) who have a blood sample. All HUNT4 70+ participants were invited to participate in HUNT4 AiT 4 years later. Participants underwent cognitive evaluation."
62716785|NCT01850953|PLACEBO_COMPARATOR|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
62716786|NCT01850953|ACTIVE_COMPARATOR|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
62716787|NCT01100112|EXPERIMENTAL|Budesonide|Budesonide-MMX 9 mg tablet
62716788|NCT06017492|NO_INTERVENTION|Hospital Patient Education Method|"Control Group:~Implementation will be carried out in 2 phases; Phase 1(intervention): participants will receive hospital-based patient education method(printouts, verbal instruction). This intervention will be carried out in a 2 weeks period; starting 2 weeks before day surgery and ending after day surgery has been carried out.~Phase 2 (post test): In this part, participants will be asked to answer questions in the in the descriptive data, the Quality of Discharge Teaching Scale (QDTS) and Patient Satisfaction with Nursing Care Quality Questionnaire (PSNCQQ). The questionnaire will be printed and distributed to participants after Day Surgery. The questionnaire will also be in Google form format and sent to emails of participants who are not physically present at the clinic."
62716789|NCT06017492|EXPERIMENTAL|Audio-Visual Patient Education Method|"Implementation will be carried out in 2 phases; Phase 1(intervention): participants will recieve video assisted teaching as patient education method. Series of short videos will be played for the participants to watch and also sent to their phones through Whatsapp application or email. This intervention will be carried out in a 2 weeks period; starting 2 weeks before day Surgery and ending after day Surgery has been carried out.~Phase 2(post test): In this part, participants will be asked to answer questions in the in the descriptive data, the Quality of Discharge Teaching Scale (QDTS) and Patient Satisfaction with Nursing Care Quality Questionnaire (PSNCQQ). The questionnaire will be printed and distributed to participants after Day Surgery. The questionnaire will also be in Google form format and sent to emails of participants who are not physically present at the clinic."
62716790|NCT06715137|EXPERIMENTAL|Exercise arm|Each participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines.
62716791|NCT06715137|NO_INTERVENTION|Conventional care arm|In the conventional care arm, patients did not receive explicit exercise advice but were provided with general information regarding a healthy lifestyle, in accordance with current physical activity guidelines during the first study visit.
62716792|NCT00720993||1|Control group - patients scheduled for routine colonoscopy procedures with no self or family history or other GI conditions.
62716793|NCT00720993||2|Case group - patients with confirmed colorectal carcinoma scheduled for surgery or observed during routine colonoscopy screening.
62716794|NCT02918526|EXPERIMENTAL|Laryngeal Mask|laryngeal mask (LMA)
62716795|NCT02918526|ACTIVE_COMPARATOR|Oro Tracheal Intubation|oro tracheal intubation
62716796|NCT01493089|EXPERIMENTAL|Zegerid|Treatment of heartburn with Zegerid
62716797|NCT01493089|ACTIVE_COMPARATOR|Losec|Treatment of heartburn with Losec
62716798|NCT06715215|ACTIVE_COMPARATOR|age and sex matched thrombocytopenic patients other than ITP.|Causes of decreased platelets count other than immune thrombocytopenia
62716799|NCT06715215|ACTIVE_COMPARATOR|acute ITP patients|Patients diagnosed as acute thrombocytopenia
62716800|NCT06715215|ACTIVE_COMPARATOR|chronic ITP patients .|Patients diagnosed as chronic thrombocytopenia
62716801|NCT04591119|ACTIVE_COMPARATOR|Transversus Thoracic Muscle Plane Block (TTMPB) Group|At the TTMPB group, the block will be performed by the surgeon before the closure of the sternum by visualizing the muscles and identifying them. In the TTMPB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between internal intercostal muscle and transversus thoracic muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space.
62716802|NCT04591119|ACTIVE_COMPARATOR|Parasternal Intercostal Block (PSIB) Group|At the PSIB group, the block will be performed by ultrasound guidance after completion of surgery. PSIB Blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesist.In PSIB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally.
62716803|NCT04591119|NO_INTERVENTION|Control Group|At the control group, no intervention for pain management will be done.
62716804|NCT05823896|ACTIVE_COMPARATOR|Nirmatrelvir/ritonavir|Oral nirmatrelvir/ritonavir (Paxlovid) 300/100 mg twice daily for 15 days
62716805|NCT05823896|PLACEBO_COMPARATOR|Placebo/ritonavir|Oral placebo/ritonavir 100 mg twice daily for 15 days
62716806|NCT04681144||Radium-223-dichloride (Xofigo, BAY88-8223)|Patients with metastatic castration-resistant prostate cancer (mCRPC)
62716807|NCT04411303|EXPERIMENTAL|Reducing interlimb asymmetry with biofeedback post-stroke|We will use a randomized crossover design to determine the performance and retention effects following single-day training sessions with biofeedback of three different gait variables (i.e., step length, propulsive force, and interlimb asymmetry) in 25 individuals with chronic stroke.
62716808|NCT04411303|EXPERIMENTAL|Evaluating capacity for biofeedback use at varied intensities|We will use a within-session randomized crossover design to test the capacity of persons post-stroke (second cohort; n=25) to reduce their interlimb asymmetry using the biofeedback variable found to be the most effective for the group in Aim 1 while walking in three aerobic intensity zones: low, moderate, and vigorous (30-40%, 50-60%, and 70-80% of heart rate reserve, respectively).
62716809|NCT03321071|EXPERIMENTAL|Healthy Summer Learners|Similar to typical summer day camp procedures, students attending Healthy Summer Learners will be dropped-off and picked-up at camp. The physical activity component of the program was designed with the expertise and input from B\&G Club youth program staff. The academic component was informed by school district personnel. The program was also designed to be analogous to typical summer day camp program in terms of operating weeks (10 weeks) length of program day (i.e., 8am-5pm), and program component time blocks (\~45min-1hr time blocks).
62716810|NCT03321071|ACTIVE_COMPARATOR|21st Century Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
62716811|NCT03321071|NO_INTERVENTION|Passive control|Children in this condition will not attend a summer program.
62735864|NCT03001193|EXPERIMENTAL|DF01 high dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in high dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
62543313|NCT04389957||Providers|The quantitative surveys will be delivered to the identified local quality stewards (N=73) and providers (N=657) for each enrolled site via the Research Electronic Data Capture (REDCap) platform at baseline (prior to VA-EQuIP) and 12 months following completion of the VA-EQuIP intervention. We will incorporate established methods of maximizing web survey responses, including multiple, carefully-timed, integrated email contacts.
62543314|NCT04389957||Patients|We expect 69 sites with 571 providers seeing 135,517 patients/year, corresponding to 95 providers/wave and 59 patients/provider/quarter. Patient data is retrospective and informs the primary outcome of provider adenoma detection rate. There is not a direct intervention for patients.
62543315|NCT03362606|EXPERIMENTAL|OC-CTLs|Autologous ovarian cancer specific cytotoxic lymphocytes
62543316|NCT03619265|EXPERIMENTAL|Prickly pear juice|Prickly pear juice, 3 oz daily for 8 weeks.
62543317|NCT03619265|PLACEBO_COMPARATOR|Pear-flavored juice|Pear-flavored juice, 3 oz daily for 8 weeks.
62543318|NCT00993421|PLACEBO_COMPARATOR|placebo|
62543319|NCT00993421|EXPERIMENTAL|LY377604 (75 mg)|
62543320|NCT00993421|ACTIVE_COMPARATOR|sibutramine (30 mg)/metoprolol (200 mg)|
62543321|NCT00993421|EXPERIMENTAL|LY377604 (40 mg)/sibutramine (30 mg)|
62543322|NCT00993421|EXPERIMENTAL|LY377604 (75 mg)/sibutramine (30 mg)|
62543323|NCT00993421|EXPERIMENTAL|LY377604 (15 mg)/sibutramine (30 mg)|
62543324|NCT00993421|EXPERIMENTAL|LY377604 (75 mg)/sibutramine (15 mg)|
62543325|NCT02600533|NO_INTERVENTION|Standard care/control group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the standard of care group will be provided standard educational resources (booklet and DVD), with no additional instructions. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
62543326|NCT02600533|EXPERIMENTAL|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
62543327|NCT04393324||Transferred patients|A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds
62543328|NCT04393324||Matched Non-transferred patients|A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables
62543329|NCT03988686|EXPERIMENTAL|Intervention Group|Radical prostatectomy plus standard care
62543330|NCT03988686|ACTIVE_COMPARATOR|Comparator Group|Standard care, currently ADT +/- other systemic therapies.
62543331|NCT01546454|EXPERIMENTAL|Non-steroidal effects|Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
62543332|NCT01546454|EXPERIMENTAL|Contraceptive effects|Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
62543333|NCT01546454|EXPERIMENTAL|Steroid effects|Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
62543334|NCT05517083|EXPERIMENTAL|Ultrathin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure for EGFR mutation (including T790M positivity) evaluation.
62543335|NCT06414226|EXPERIMENTAL|Krill group|Krill oil ((n=17), (EPA=340 mg, DHA=180 mg)), The duration of the intervention was 8 weeks.
62543336|NCT06414226|EXPERIMENTAL|Fish group|2) fish oil ((n=17)), (EPA=360 mg, DHA=240 mg), The duration of the intervention was 8 weeks.
62543337|NCT06414226|PLACEBO_COMPARATOR|Placebo|Placebo capsule ( (n=16), (EPA=0 mg, DHA=0 mg)). The duration of the intervention was 8 weeks.
62543338|NCT00425373|EXPERIMENTAL|Valsartan + amlodipine 40/2.5 mg|
62543339|NCT00425373|EXPERIMENTAL|Valsartan + amlodipine 40/5 mg|
62543340|NCT00425373|EXPERIMENTAL|Valsartan + amlodipine 80/2.5 mg|
62543341|NCT00425373|EXPERIMENTAL|Valsartan + amlodipine 80/5 mg|
62543342|NCT00425373|ACTIVE_COMPARATOR|Valsartan 40 mg|
62543343|NCT00425373|ACTIVE_COMPARATOR|Valsartan 80 mg|
62543344|NCT00425373|ACTIVE_COMPARATOR|Amlodipine 2.5 mg|
62543345|NCT00425373|ACTIVE_COMPARATOR|Amlodipine 5 mg|
62543346|NCT00425373|PLACEBO_COMPARATOR|Placebo|
62543347|NCT03999749|EXPERIMENTAL|Induction Phase, Maintenance Phase|"Induction Phase: 2 induction treatment cycles of 42 days (6 weeks) each, of which the first cycle of 6 weeks is the dose-limiting toxicity (DLT) period.~Maintenance Phase: Consists of treatment cycles of 84 days (12 weeks) each, and may extend up to 1 year."
62543348|NCT05924269||Cardiac Surgery|Patients undergoing cardiac surgery
62543349|NCT01761760|EXPERIMENTAL|Contingent|"Patients will earn game-based incentives contingent on meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
62543350|NCT01761760|ACTIVE_COMPARATOR|Non-contingent|"Patients will earn game-based incentives independent of meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
62543351|NCT00782704||1|questionnair for Patients
62543352|NCT00782704||2|questionnaire for Nurses
62543353|NCT00782704||3|questionnaire for Physicians
62543354|NCT05938504|PLACEBO_COMPARATOR|Control group|Subjects will receive two packs of placebo ONS (ONS_320275) orally daily
62543355|NCT05938504|EXPERIMENTAL|Test group|Subjects will receive two packs of test ONS (ONS_211567) orally daily
62543356|NCT03810326|EXPERIMENTAL|Intervention|
62543357|NCT00085384|EXPERIMENTAL|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
62543358|NCT00085384|EXPERIMENTAL|Arm II|Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
62716812|NCT05899114|EXPERIMENTAL|Transitional Multidisciplinary Pharmacotherapeutic Care (TMPC)|The participants in hospitals allocated to the intervention arm will receive TMPC, which will be executed by a Pharmacotherapy-team and will take place during the index hospital stay. This Pharmacotherapy-team will be composed of a physician and a hospital pharmacist, preferably registered as clinical pharmacologists.
62716813|NCT05899114|NO_INTERVENTION|Usual care|The comparator in this study is usual care, which refers to the entire spectrum of medication-related interventions by different healthcare providers (physician, pharmacist, nurse etc.) which the patient undergoes during hospital admission.
62716814|NCT00582478||1|women with breast cancer
62716815|NCT06127433|EXPERIMENTAL|intervention group|Intervention：insulin pump intensive therapy
62716816|NCT06127433|ACTIVE_COMPARATOR|control group|basal insulin and oral antidiabetic drugs
62716817|NCT03846661|ACTIVE_COMPARATOR|Physiomesh|Patients undergoing laparoscopic incisional hernia repair reinforced with a Physiomesh.
62716818|NCT03846661|NO_INTERVENTION|other mesh|Patients undergoing laparoscopic incisional hernia repair reinforced with other meshes than Physiomesh.
62716819|NCT03829111|ACTIVE_COMPARATOR|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62716820|NCT03829111|EXPERIMENTAL|Arm II (CBM588, nivolumab, ipilimumab)|Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62716821|NCT02160015|EXPERIMENTAL|Treatment (lenalidomide, ibrutinib, rituximab)|Patients receive rituximab IV on day 1 (up to 6 cycles), lenalidomide PO QD on days 1-21 (up to 12 cycles), and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECG on screening and CT scan or MRI, bone marrow biopsy and blood sample collection throughout the study.
62716822|NCT02221973|EXPERIMENTAL|milk with 1.2g/d sterols and 8g/d hawthorn powder|
62716823|NCT02221973|EXPERIMENTAL|milk with 1.8g/d sterols and 8g/d hawthorn powder|
62543359|NCT00085384|EXPERIMENTAL|Arm III|Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
62543360|NCT01875640||Usual Care|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will not utilize the Decision Support Tool. A qualitative analysis of these recordings will assess quality assurance and provide guidance for the development of the Decision Support Tool.
62543361|NCT01875640||Use of Decision Support Tool|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will utilize the Decision Support Tool (DST). A qualitative analysis of these recordings will assess the practicality of use and possible benefits of the DST's implementation.
62543362|NCT05738044||COPD patients|"Patient meets diagnose of COPD refering to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2022 will be included."
62543363|NCT05738044||Bronchiectasis patients|Patients diagnosed with bronchiectasis (according to the Chinese consensus, patient's previous chest CT examination must show bronchiectasis)
62543364|NCT03016819|EXPERIMENTAL|Indication A: ASPS AL3818 Arm - CLOSED|All subjects with ASPS will be assigned to the open-label AL3818 arm to receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62543365|NCT03016819|EXPERIMENTAL|Indication B: LMS AL3818 Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62543366|NCT03016819|ACTIVE_COMPARATOR|Indication B: LMS Dacarbazine Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m\^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
62543367|NCT03016819|EXPERIMENTAL|Indication C: SS AL3818 Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
62543368|NCT03016819|ACTIVE_COMPARATOR|Indication C: SS Dacarbazine Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m\^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
62543369|NCT03016819|PLACEBO_COMPARATOR|Indication D: LMS AL3818 or Placebo Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or placebo in a double-blind manner. AL3818 or placebo will be administrated as one 12 mg capsule orally once daily in 21-day cycles for 14 days on treatment (Days 1-14) and 7 days off treatment (Days 15-21).
62716824|NCT02221973|ACTIVE_COMPARATOR|milk without sterols and hawthorn powder|
62543370|NCT01883349||ESRD patients|ESRD patients awaiting renal transplantation
62543371|NCT01883349||Control Arm|Subjects without kidney disease. No intervention with control group.
62543372|NCT05577195|EXPERIMENTAL|Impella + VA-ECMO|
62716825|NCT01200576||1|healthy volunteers
62716826|NCT05900076||Patient group|This group corresponds to patients who have just suffered a miscarriage and are undergoing curettage for the evacuation of the product of conception.
62716827|NCT04418895|EXPERIMENTAL|Single Arm: Standard of Care|Investigator's choice of total neoadjuvant therapy (TNT) comprised of neoadjuvant chemotherapy and chemoradiation followed by surgical resection; or neoadjuvant chemoradiation followed by surgical resection and then adjuvant chemotherapy.
62716828|NCT03793621|EXPERIMENTAL|BI 730357|
62716829|NCT03793621|PLACEBO_COMPARATOR|Placebo|
62716830|NCT01643460|EXPERIMENTAL|98% Ethanol with Paclitaxel injection|
62716831|NCT01171677|EXPERIMENTAL|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
62716832|NCT01171677|NO_INTERVENTION|Treatment as Usual|
62716833|NCT05691933|ACTIVE_COMPARATOR|Block group|Patients will be subjected to bilateral external oblique intercostal plane block
62716834|NCT05691933|ACTIVE_COMPARATOR|Opioid group|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
62716835|NCT05545748|EXPERIMENTAL|Zero (0) Tolerance Program Group|"The intervention to this group consists of four parts.~1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score and color scale mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~2. Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~3. Informative Materials (Information Notes and Brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~4. Informative Telephone Text Messages: Reminder phone messages related to SHS and THS"
62716836|NCT05545748|ACTIVE_COMPARATOR|Exposure Feedback Group|This group will receive only exposure feedback Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score and color scale mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
62543373|NCT05577195|ACTIVE_COMPARATOR|VA-ECMO only|
62543374|NCT06174467|EXPERIMENTAL|First group to receive the intervention|This cluster of classes of different scholls will be instructed in the social emotional and ethical learning training (SEELearning) and being tested trought questionaries.
62543375|NCT06174467|EXPERIMENTAL|Second group to receive the intervention|The cluster of classes of different scholls forming the second group, will not be instructed in the social emotional and ethical learning training (SEELearning) in the first semester, but will answer the questionaries during this period. Than, in next semester they will receive the Training.
62543376|NCT05786664||Observational (survey, biospecimen collection, record review)|Patients complete surveys, undergo collection of blood samples, and review of medical records on study.
62543377|NCT00535405|EXPERIMENTAL|1|Each patient will receive 1 active treatment dose \& 2 Placebo (Pbo) doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
62543378|NCT00535405|EXPERIMENTAL|2|Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
62543379|NCT00535405|EXPERIMENTAL|3|Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
62543380|NCT00535405|EXPERIMENTAL|4|Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
62543381|NCT00535405|EXPERIMENTAL|5|Each patient will receive 1 active treatment dose \& 2 Pbo doses or 2 active treatment doses \& 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
62543382|NCT02767986||Spanish-speaking Latinas|Women who speak Spanish as their primary language
62543383|NCT05645952||Patients diagnosed with DCMP during study period|Patients newly diagnosed with DCMP between January 2015 and December 2020
62543384|NCT04831424|EXPERIMENTAL|Healthy controls|No diagnosis of mitochondrial disease
62543385|NCT04831424|EXPERIMENTAL|Mutation|Participants carrying the m.3243A\>G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
62543386|NCT04831424|EXPERIMENTAL|Mutation with MELAS|Participants carrying the m.3243A\>G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
62543387|NCT04831424|EXPERIMENTAL|Deletion|Participants carrying a single, large-scale mtDNA deletion
62543388|NCT01644630|ACTIVE_COMPARATOR|Cemented single crowns|Cemented single crown: zirconia abutment (Straumann Cares abutment) with an all-ceramic lithium disilicate crown
62543389|NCT01644630|ACTIVE_COMPARATOR|Screw-retained single crown|Screw-retained single crown: zirconia abutment (Straumann Cares abutment), directly veneered with veneering ceramic
62543390|NCT00588458|EXPERIMENTAL|single arm|All patients with PSC in will have CT cholangiography.
62543391|NCT01967914||Women undergoing cesarean delivery under spinal anesthesia|
62543392|NCT05817682|EXPERIMENTAL|Intervention group|
62543393|NCT05817682|NO_INTERVENTION|Control group|
62543394|NCT04439617||sepsis patient|
62543395|NCT04439617||Sepsis-free patient|
62716837|NCT05171166|EXPERIMENTAL|HAIC-TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with hepatic arterial infusion chemotherapy that consists of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. After 2-4 cycles of HAIC treatment, the sequential TACE therapy would be performed.
62716838|NCT05171166|ACTIVE_COMPARATOR|TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with cTACE or DEB-TACE that mixed with EPI.
62716839|NCT03351946|ACTIVE_COMPARATOR|ZEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) until start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan and immediately before start of emergence preoxygenation, this group will have the PEEP exchanged for zero PEEP (ZEEP). ZEEP will remain until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
62716840|NCT03351946|ACTIVE_COMPARATOR|PEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) even after start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan, this group will have PEEP remained until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
62716841|NCT03333356|EXPERIMENTAL|Experimental Arm|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
62716842|NCT03333356|NO_INTERVENTION|Standard Arm|Surveillance
62716843|NCT06124157|ACTIVE_COMPARATOR|Arm I (dasatinib, standard chemo)|See detailed description.
62716844|NCT06124157|EXPERIMENTAL|Arm II (blinatumomab)|See detailed description.
62716845|NCT02392988|PLACEBO_COMPARATOR|Group receives sham treatment|Sham treatment will be given on points on the back, points that are not acupuncture points, so that the patient will not be able to know whether she is receiving sham treatment or a real treatment. The treatment will be every 48-72 hours, a maximum of three treatments.
62716846|NCT02392988|EXPERIMENTAL|Group receives acupuncture treatment|The women in this group will receive acupuncture treatment every 48-72 hours, a maximum of three treatments.
62716847|NCT02392988|NO_INTERVENTION|Group doesn't receive any treatment|The women in this group will come for a follow-up check a week later, unless a spontaneous birth will develop.
62716848|NCT06279611|EXPERIMENTAL|LY007|The CAR T cell preparation to be evaluated in this study is LY007, developed and produced by Shanghai Longyao Biotechnology Co., LTD Cell injection. LY007 cell injection is a chimeric antigen receptor targeting CD20 genetically modified using lentiviral vectors (CAR) Autologous T cells are CD20 CAR-T independently developed by Shanghai Longyao Biotechnology Co., LTD., in the CAR facility The independent co-stimulatory signal receptor OX40 was introduced to increase the proliferation and killing function of CAR-T cells. Table of CAR gene The frame comprises the following elements: (1) MSCVEF1α fusion promoter; (2) Single-chain antibody CD20 scFv targeting CD20; (3) CD8 junction and transmembrane region; (4) Intracellular region of 4-1BB; (5) CD3ζ intracellular region; (6) P2A self-shearing peptide; (7) Co-stimulated receptor OX40
62716849|NCT05848778|ACTIVE_COMPARATOR|Acute Intermittent Hypoxia|Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive acute intermittent hypoxia
62716850|NCT05848778|PLACEBO_COMPARATOR|Normoxia control|Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive normoxia
62716851|NCT04735458|EXPERIMENTAL|Treatment|Parkinson's Disease Patients receiving DBS electrodes
62716852|NCT04735458|NO_INTERVENTION|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
62716853|NCT03523858|EXPERIMENTAL|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion.
62716854|NCT04970069|ACTIVE_COMPARATOR|Analgesic education|
62716855|NCT04970069|PLACEBO_COMPARATOR|General perioperative education|
62716856|NCT05362292|ACTIVE_COMPARATOR|Anticholinergic bladder medication plus behavioral self-management education|Tolterodine tartrate is a muscarinic receptor antagonist designed to treat urgency incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression.
62716857|NCT05362292|ACTIVE_COMPARATOR|Beta-3-adrenergic agonist medication plus behavioral self-management education|Mirabegron, currently sold under the brand name Mybetriq by Astellas Pharma, is a selective beta-3-adrenergic receptor agonist approved for treatment of urgency urinary incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression.
62716858|NCT05362292|PLACEBO_COMPARATOR|Placebo medication plus behavioral self-management education|Microcrystalline cellulose placebo encapsulated to appear identical to tolterodine and mirabegron medication will be prepared by a compounding pharmacy. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression.
62716859|NCT05753462|EXPERIMENTAL|Phase 1|Participants will receive single escalating doses of 2, 4, 6, 10, 16 and 25 mg/kg by intravenous infusion of SQY51 every 2 weeks.
62716860|NCT05753462|EXPERIMENTAL|Phase 2a - Treatment arm (Dose 1)|Non randomized participants will receive by IV dose 1 of SQY51 in 4 blocks of 4-weeks.
62716861|NCT05753462|EXPERIMENTAL|Phase 2a - Treatment arm (Dose 2)|Non randomized participants will receive by IV dose 2 of SQY51 in 4 blocks of 4-weeks.
62716862|NCT05753462|EXPERIMENTAL|Phase 2a - Treatment arm (Dose 3)|Non randomized participants will receive by IV dose 3 of SQY51 in 4 blocks of 4-weeks.
61978161|NCT05560997||biopsy-proved NAFLD cohort|NAFLD is defined as the presence of at least 5% steatosis based on histological examination.
62716863|NCT02746302|EXPERIMENTAL|HS-20004|One dose of HS-20004(0.02,0.04,0.05,0.06,0.08,0.1mg) Injected s.c. (under the skin) once for one subject.
62716864|NCT02746302|PLACEBO_COMPARATOR|Placebo|Placebo Injected s.c. (under the skin) once for one subject.
62716865|NCT05023057|EXPERIMENTAL|Multidomain intervention|The participants in the intervention arm will receive all five components of the intervention: (1) monitoring and management of metabolic and vascular risk factors; (2) cognitive training and social activity; (3) physical exercise; (4) nutritional guidance; and (5) motivational training.
62716866|NCT05023057|NO_INTERVENTION|Control|At baseline, the participants in the control group will meet a study doctor, be prescribed medication when necessary, and receive educational booklets corresponding to their risk factors and a booklet on lifestyle guidelines to prevent dementia. They will receive usual care during the study period and be informed that they could participate in the multidomain intervention program after this study end.
62716867|NCT04275076|EXPERIMENTAL|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate
62716868|NCT04275076|EXPERIMENTAL|bipolar transurethral enucleation of the prostate|bipolar transurethral enucleation of the prostate
62716869|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
62716870|NCT03206372||Case group|The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.
62716871|NCT03206372||Control group|The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure
62716872|NCT03496168|EXPERIMENTAL|mavacamten (MYK-461)|
62716873|NCT02665325||TSHsuppressive therapy group|TSH-suppressive therapy group: newly diagnosed differentiated thyroid carcinoma and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
62716874|NCT02665325||Negative control group|Healthy volunteers (normal T3,T4,FT3,FT4,TSH, TG-ab,TPO-ab,TG) are recruited to match the patients with age, gender, education level, ect.
62716875|NCT02665325||Positive control group|Newly diagnosed nodular goiter and undergone thyroidectomy according to the China thyroid association guidelines for the management of thyroid nodule and thyroid cnacer; followed by L-T4 replacement therapy 6/12 months.
62716876|NCT03071965|EXPERIMENTAL|Cohort 1|Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
62716877|NCT03071965|EXPERIMENTAL|Cohort 2|Participants completed protocol NTMT-02. Participants received surgery to implant NT-501 or sham surgery to mimic implant procedure. Participants that received NT-501 implant were exposed to ciliary neurotrophic factor (CNTF).
62716878|NCT06719154||Treated group|"120 subjects will be treated~Healthy subjects Male and Female subjects. Age : between 35 and 55 year"
62716879|NCT06719154||Not treated group|"44 subjects will be not treated~Healthy subjects Male and Female subjects. Age : between 35 and 55 year"
62716880|NCT06423391|EXPERIMENTAL|Tested intervention (NeuOst treatment)|"The tested treatment is a manual therapy-based intervention, drawing on core manual therapy components and integrating psychologically informed approaches to pain management and elements from diabetes education, foot care, and exercise rehabilitation. This intervention is called 'Augmented manual therapy for people with painful diabetic neuropathy', or NeuOst. NeuOst components will be taught to fully qualified UK-registered osteopaths who then deliver the intervention according to a treatment manual in 1:1 appointments, lasting 45-60 minutes each (90 mins first appointment). Up to 5 treatment sessions will be provided per patient, at weekly intervals and at maximum over 10n weeks.~The treatment manual specifies obligatory and optional elements for each of the 5 study treatment sessions. Exercise components will be rehearsed in the clinic with providers. Participants will then be encouraged to complete a progressive home-exercise programme according to the manual."
62716881|NCT06423391|SHAM_COMPARATOR|Control intervention|"The objectives of the control intervention are to replicate the contextual elements of the test intervention (to test efficacy), and to blind participants to group allocation. Trial providers will be trained in its delivery. As per CoPPS guidance, the control intervention will resemble the tested intervention in all aspects but for the components whose effect the trial is designed to study. These excluded components of interest, and their respective adaptations in the control intervention, are specified in the detailed pre-registered protocol.~Control intervention components will be taught to fully qualified UK-registered osteopaths who then deliver the intervention according to a treatment manual in 1:1 appointments, lasting 45-60 minutes each (90 mins first appointment). Up to 5 treatment sessions will be provided per patient, at weekly intervals and at maximum over 10 weeks."
62716882|NCT06423391|OTHER|Usual care comparator|Participants randomized to this study arm will only undergo baseline and follow-up assessments but will receive no further attention as part of this trial. As in all other trial arms, they are free to continue their usual medical care but will be encouraged to not change their analgesic regime or nonpharmacological management as far as possible.
62716883|NCT06058962|EXPERIMENTAL|Suramin 10 mg/kg|50 mg test dose of suramin (upon first administration), then suramin 10 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5.
62716884|NCT06058962|EXPERIMENTAL|Suramin 20 mg/kg|50 mg test dose of suramin (upon first administration), then suramin 20 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5.
62716885|NCT06058962|PLACEBO_COMPARATOR|Placebo|Test dose of saline placebo, then saline placebo infusion of 50 mL administered over 30 minutes was given at Visits 2, 4, and 5.
62716886|NCT00659035||IT|Subjects receiving 1-10 mg/day of morphine or its equivalent doses of opioid medications through intrathecal route. Intrathecal medications are administered through a catheter in spinal cord
62543396|NCT06634095|EXPERIMENTAL|Moulage group|"It will consist of students trained with standardized patient simulation supported by a model."
62543397|NCT06634095|NO_INTERVENTION|Contol group|Students in the control group will receive standard care.
62543398|NCT00451048|EXPERIMENTAL|Arm I|Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
62543399|NCT01509703|EXPERIMENTAL|High flow therapy|
62716887|NCT00659035||Oral|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone), but not also receiving anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
62716888|NCT00659035||Oral + Anticonvulsant|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone) and anticonvulsants (gabapentin, pregabalin, topiramate), but not also receiving muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
62716889|NCT00659035||Control -Pain|Subject not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
62716890|NCT00659035||Control -No Pain|Age-matched volunteers (NO PAIN) not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
62716891|NCT04940728|EXPERIMENTAL|Creative Thinking Group|"Nursing students who took the Self-Knowledge and Communication Techniques course for the first time in March and agreed to participate in the study were divided into experimental (30) and control (30) groups using a simple randomization method.~Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were administered to the participants who volunteered to participate in the research using the Online Questionnaire System.~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups.~An intervention program based on creative thinking techniques was applied to the experimental group and post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
62543400|NCT04759768|EXPERIMENTAL|Intranasal Nalmefene|Nalmefene hydrochloride nasal spray, 3mg, 1 spray
62543401|NCT04759768|ACTIVE_COMPARATOR|Intramuscular Nalmefene|Nalmefene injection, 1mg, 1 injection
62543402|NCT02735785|EXPERIMENTAL|intervention|behavioral intervention
62543403|NCT02735785|NO_INTERVENTION|control|control
62543404|NCT02022748|EXPERIMENTAL|Sequence 1|hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.
62543405|NCT02022748|EXPERIMENTAL|Sequence 2|hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.
62543406|NCT02022748|EXPERIMENTAL|Treatment H|Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment
62543407|NCT06173271|OTHER|Exercise only|Exercise only (60 min/times, 3 times/wk)
62543408|NCT06173271|ACTIVE_COMPARATOR|plant protein group|Soymilk (230ml) and sweet potato (60g) supplementation after exercise (3 times/wk) plus nutrition education (once a wk)
62543409|NCT06173271|ACTIVE_COMPARATOR|animal protein group|Milk (240ml) and sweet potato (60g) supplementation after exercise (3 times/wk) plus nutrition education (once a wk)
62543410|NCT06173271|NO_INTERVENTION|Control|No exercise and no nutrition education intervention
62543411|NCT06173271|ACTIVE_COMPARATOR|Exercise and Nutrition Education group|Exercise 60 min/times and three times per week Nutrition education 30 min/week
62543412|NCT00936247|EXPERIMENTAL|1|HES 130/0.42 + Sterofundin ISO
62543413|NCT00936247|ACTIVE_COMPARATOR|2|Albumin + NaCl 0.9%
62543414|NCT02015065|EXPERIMENTAL|Vandetanib in Children|Children with measurable localized or metastatic wt-GIST
62543415|NCT02015065|EXPERIMENTAL|Vandetanib in Adults|Adults with measurable localized or metastatic wt-GIST
62543416|NCT06456905|EXPERIMENTAL|Contingency Management + Treatment As Usual|An experimental approach examining the effectiveness of contingency management for promoting a decrease in drinking through increasing rewards for positive behavior. Participants will be given positive reinforcement messaging regardless of the sample's results.
62543417|NCT06456905|NO_INTERVENTION|Non-Contingent Management + Treatment As Usual|Participants will be given a flat amount for submitting samples on time, and there is no increasing scale for maintaining samples at 0.00%BAC. Participants will be given positive reinforcement messaging regardless of the sample's results.
62543418|NCT06142318|EXPERIMENTAL|Pirfenidone group|Calculate from 2 weeks before the start of radiotherapy: week 1: pirfenidone 200mg, tid; week 2: pirfenidone 400mg tid; during radiotherapy: pirfenidone 600mg tid.
62543419|NCT06142318|PLACEBO_COMPARATOR|Control group|Calculate from 2 weeks before the start of radiotherapy: week 1: placebo 200mg, tid; week 2: placebo 400mg tid; during radiotherapy: placebo 600mg tid.
62543420|NCT00242632|EXPERIMENTAL|ApoE Non-Carriers|Subjects in this group did not carry the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
62543421|NCT00242632|EXPERIMENTAL|ApoE Carriers|Subjects in this group carried the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
62543422|NCT03138590|EXPERIMENTAL|Active tDCS|Active transcranial Direct Current Stimulation targeting the trigeminal nerve
62543423|NCT03138590|SHAM_COMPARATOR|Sham tDCS|Sham transcranial Direct Current Stimulation targeting the trigeminal nerve
62543424|NCT02458209|ACTIVE_COMPARATOR|Treatment A|150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Pfizer Andover
62543425|NCT02458209|EXPERIMENTAL|Treatment B|• Treatment B: 150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma
62735865|NCT03001193|PLACEBO_COMPARATOR|PL1|The subjects will receive intravenous infusion of placebo as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
62735866|NCT02417610|EXPERIMENTAL|Polynucleotide - PNHA - Newart|50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid
62735867|NCT02417610|ACTIVE_COMPARATOR|Hyaluronic acid - HA - Ialart|50 patients will be enrolled and treated with three weekly injections of hyaluronic acid
62543426|NCT02458209|EXPERIMENTAL|Treatment C|150 mg SC dose administered in a prefilled pen using drug substance manufactured at Pfizer Andover.
62543427|NCT01890447||Questionnaire design group|A focus group (group of experts) such as physicians, nurses, or other professionals invited by the investigator.
62543428|NCT01890447||Adaptive questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the adaptive choice based conjoint (ACBC) technique.
62543429|NCT01890447||Standard questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the standard discrete choice experiment (DCE) technique.
62543430|NCT05110820||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin \>5% (\>10% in smokers).
62543431|NCT05296863|EXPERIMENTAL|Non-concentrated ADSC-CM|2 ml intradermal injection of non-concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
62543432|NCT05296863|EXPERIMENTAL|Concentrated ADSC-CM|2 ml intradermal injection of concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
62543433|NCT04445597|OTHER|COVID-19 positive or negative patients|Hospitalised patients with or without COVID-19 (with or without olfactory dysfunctions)
62543434|NCT02633748|OTHER|Intervention|The twenty participants in the intervention arm will undergo a pre-assessment, post assessment, and a three month follow-up assessment. The pre and post assessments will ask participants to 1) fill out questionnaires to measure lifestyle, stress, meditations habits, and sleep impairment, 2) take a blood sample, 3) use a BodyMedia's Sensewear® armband for a week, and 4) provide salivary cortisol levels. The three month follow-up will repeat everything done if the first two assessments, excluding the blood sample. The intervention arm will also attend the weekly two and a half hour Mindfulness-Based Cancer Survivorship (MBSC) four-week program between the pre and post assessments.
62543435|NCT02633748|NO_INTERVENTION|Control|The twenty participants in the control arm will undergo the same pre assessment as the intervention arm, receive a presentation on breathing exercises, and undergo the same post and three-month follow-up assessments. The control arm will also be offered the same Mindfulness-Based Cancer Survivorship program given to the intervention arm following the three month follow-up.
62543436|NCT01097512|EXPERIMENTAL|Regimen 1: AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle
62543437|NCT01097512|EXPERIMENTAL|Regimen 2: AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle
62543438|NCT05848947|OTHER|99mTc-MAA Injection|Patients enrolled in the study will have 3 imaging scans taken after 99mTc-MAA Injection with the final scan occurring 18-24 hours after injection.
62543439|NCT05746598||1|NSCLC patients Who developed Toxicity to Chemotherapeutic agents
62543440|NCT05746598||2|NSCLC patients Who did not developToxicity to Chemotherapeutic agents
62543441|NCT01534130|EXPERIMENTAL|acupuncture|
62543442|NCT01534130|SHAM_COMPARATOR|sham acupuncture|
62543443|NCT01319500||Yasmin|"Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC Yasmin"
62543444|NCT01319500||Other OCs|"Users of OCs except Yasmin (Other OCs)"
62543445|NCT04648800|NO_INTERVENTION|Group I|with positive RT23 test reading, not randomised and not vaccinated against tuberculosis
62543446|NCT04648800|ACTIVE_COMPARATOR|Group II|with negative RT23 test reading, receiving BCG-10 Vaccine
62543447|NCT04648800|PLACEBO_COMPARATOR|Group III|with negative RT23 test reading, receiving placebo
62543448|NCT04314895|EXPERIMENTAL|NanoPac|Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.
62543449|NCT04775615|EXPERIMENTAL|Treatment group A|
62543450|NCT04775615|EXPERIMENTAL|Treatment group B|
62543451|NCT04775615|EXPERIMENTAL|Treatment group C|
62543452|NCT02394093|EXPERIMENTAL|Aspirin dry powder|500 mg Acetylsalicylic Acid (ASA) dry powder
62543453|NCT02394093|ACTIVE_COMPARATOR|Aspirin coated tablet|500 mg ASA coated tablet
62543454|NCT02394093|ACTIVE_COMPARATOR|Aspirin effervescent tablet|500 mg ASA effervescent tablet
62543455|NCT06239857|EXPERIMENTAL|Epidural pulsed radiofrequency treatment|All patients diagnosed with failed back surgery syndrome will receive epidural pulsed radiofrequency treatment.
62543456|NCT05258903|EXPERIMENTAL|Ulnar artery|Ulnar artery cannulation under USG-guidance
62543457|NCT05258903|ACTIVE_COMPARATOR|Radial artery|Radial artery cannulation under USG-guidance
62543458|NCT00253721|EXPERIMENTAL|All subjects|
62543459|NCT00768547||By protocol|Where the test are predefined
62543460|NCT00768547||By degression|The group where the doctor decided which test are to be taken.
62543461|NCT04617912|EXPERIMENTAL|PennPET Explorer|"All subjects will be scanned in the CT scanner and then the scanner bed will be moved into position in the PennPET Explorer for initiation of the PET scan. For all PET scans a radioactive imaging drug is used.~The radiotracer injection may be performed according to one of the following scenarios:~1. As part of a clinical standard-of-care (SOC) PET/CT or PET/MRI scan (using an FDA-approved radiotracer; the PennPET Explorer cannot yet accommodate a study that requires a commercially available 510(k)-approved instrument for clinical results, subjects in this group will be scanned on both a commercial instrument (PET/CT or PET.MRI) and the PennPET Explorer),~2. As part of another research study (using either an FDA-approved radiotracer or an investigational radiotracer),~3. As a research injection designed specifically to utilize the PennPET Explorer (using an FDA-approved radiotracer)."
62543462|NCT04877457|EXPERIMENTAL|Ocrelizumab|Three courses of ocrelizumab will be administered over the course of the study.
62543463|NCT04877457|PLACEBO_COMPARATOR|Placebo|Three courses of placebo will be administered over the course of the study.
62716892|NCT04940728|NO_INTERVENTION|Standart Group|"Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were applied to the participants who volunteered to participate in the study by using the Online Questionnaire System.~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills of the 4 main topics in the course; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups by using the Online Questionnaire System.~After the interim tests were applied, no intervention was made to the control group until the end of the period. At the end of the semester, post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
62716893|NCT05788601|PLACEBO_COMPARATOR|Placebo (4 mg and 6 mg)|Abdominal s.c. self-administration of placebo content once weekly for 12 weeks. To ensure double-blinding, the placebo arm is divided into a 4-mg and 6-mg arm. But both placebo arms are pooled during data analysis.
62716894|NCT05788601|ACTIVE_COMPARATOR|4 mg dapiglutide|Abdominal s.c. self-administration of 4 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks until the remaining nine weeks of treatment (12 weeks in total)
62716895|NCT05788601|ACTIVE_COMPARATOR|6 mg dapiglutide|Abdominal s.c. self-administration of 6 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks to 4 mg and again to 6 mg after six weeks until the remaining six weeks of treatment (12 weeks in total)
62716896|NCT01909544|EXPERIMENTAL|Oxygen|
62716897|NCT01909544|SHAM_COMPARATOR|Room air|
62716898|NCT01135472|EXPERIMENTAL|Nexium|ARM 1: NEXIUM 40MG ONCE DAILY, ARM 2: NEXIUM 40MG TWICE DAILY, ARM 3: NEXIUM 80MG TWICE DAILY
62716899|NCT06040541|EXPERIMENTAL|RMC-9805 monotherapy arm|Dose exploration and dose expansion
62716900|NCT06040541|EXPERIMENTAL|RMC-9805 plus RMC-6236 combination arm|Dose exploration and dose expansion
62716901|NCT00678730|ACTIVE_COMPARATOR|1|"* Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or joint.~* Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or joint.~* Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or joint."
62716902|NCT00678730|PLACEBO_COMPARATOR|2|small amount of ethanol, (quarter teaspoon), with no THC
62716903|NCT05198258|EXPERIMENTAL|Implementation study - experimental group|Physiotherapists in the experimental group (group A) will receive on-line theoretical education including three hours of practical training by the project leaders. The standardized theoretical education includes three 45 minutes on-line lectures. The theoretical education will be followed by three hours practical training including clinical examination in patients with neck disability and instructions how to perform the neck-specific exercises.To facilitate the implementation process, group A will receive additional support; the physiotherapists can contact the project leader via e-mail, phone, online meetings and/or outreach visits
62716904|NCT05198258|ACTIVE_COMPARATOR|Implementation study - control group|Physiotherapists in the control group (group B) will receive the same theoretical and practical training as group A but without additional support from the research group or education after the first three theoretical on-line lectures and the three hours practical education.
62716905|NCT03581487|EXPERIMENTAL|Arm I (intermittent selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-7 and 15-21 and durvalumab intravenously (IV) over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62716906|NCT03581487|EXPERIMENTAL|Arm II (continuous selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-28 and durvalumab IV over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62716907|NCT00886730|EXPERIMENTAL|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
62716908|NCT00886730|EXPERIMENTAL|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
62716909|NCT00886730|EXPERIMENTAL|Physicians endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
62716910|NCT02850588||TCAR treatment|All patients, both high risk and standard risk surgical patients undergoing transcarotid revascularization with a carotid stent during carotid artery flow reversal in hospitals that participate in the Carotid Artery Stent Registry of the Society for Vascular Surgery Patient Safety Organization
62735868|NCT00330980|EXPERIMENTAL|1|Participants will receive 20 mg of simvastatin for 6 months.
62543464|NCT05976165|EXPERIMENTAL|Breath Test Evaluation for SIBO|Subjects with symptoms of gastroesophageal reflux disease (GERD) treated with a short course of proton pump inhibitors (PPI) clinically will undergo breath testing evaluating for small intestinal bacterial overgrowth (SIBO).
62543465|NCT06034782||patients with salivary gland tumors|patients with salivary gland tumors
62543466|NCT00368017|ACTIVE_COMPARATOR|1|
62543467|NCT00368017|PLACEBO_COMPARATOR|2|
62543468|NCT01971437|EXPERIMENTAL|Cystodistension & Cystoscopy Arm|This is the Arm receiving cystodistension and cystoscopy due to refractory OAB.
62543469|NCT01971437|PLACEBO_COMPARATOR|Cystoscopy Arm|This is the arm that receives cystoscopy only in women with refractory OAB.
62716911|NCT02850588||CEA treatment|All patients undergoing carotid endarterectomy in hospitals that participate in the Carotid Endarterectomy Registry of the Society for Vascular Surgery Patient Safety Organization
62716912|NCT05722587|EXPERIMENTAL|Pain education day|Pain education day, lecture and experiential
62716913|NCT05722587|NO_INTERVENTION|Control|No intervention
62716914|NCT06289868||At-risk and/or signs and symptoms patients of HAV infection and/or HAV test ordered patients|"Frozen leftover serum samples from adult and pediatric patients:~* From subjects exhibiting either jaundice or elevated total bilirubin or elevated serum ALT enzymes and one or more primary signs and symptoms of hepatitis infection, and/or~* From subjects at-risk of HAV infection, and/or~* From subjects for whom laboratory testing for hepatitis A was ordered by their healthcare providers."
62716915|NCT06289868||Known anti-HAV IgM positive patients|"Frozen serum or EDTA retrospective known anti-HAV IgM positive leftover samples procured from sample vendors .~These samples are known Positive for HAV IgM AND at least one of the following :~* Positive HAV PCR result (within the last 28 days) OR~* Jaundice (clinical assessment OR Total bilirubin result \>3.0 mg/dL) OR~* Elevated ALT result (\> 200 IU/L)"
62716916|NCT06289868||HAV Pre- and post-vaccinated patients|Frozen serum leftovers. A first sample was collected, and the US licensed and CE-marked vaccination series administered. A second sample was collected four (4) to ten (10) weeks after the complete vaccination series has been administered according to vaccine dosing instructions.
62716917|NCT06692894||Adults with Myelodysplastic syndromes|All participants will be in one group. Participants will by adults with Myelodysplastic syndromes. Blood will be taken at regular appointments that are part of standard care.
62716918|NCT04051177|EXPERIMENTAL|parents living with HIV intervention group|Parents living with HIV in this group received five two-hour parent HIV disclosure intervention, delivered one session per week for five weeks in the clinics where the parents are recruited. The intervention curriculum is modeled after the TRACK program with supplemental materials from TALC.
62716919|NCT04051177|OTHER|Parents living with HIV control group|"Parents living with HIV in this group received five two-hour nutrition education curriculum in same delivery way. The nutrition curriculum is modeled after the Simply Good Eating: curriculum developed at University of Minnesota."
62716920|NCT06718400|EXPERIMENTAL|Sentinel Skin Flap|Willing participants who will be receiving an intestinal transplantation will receive a sentinel skin flap on their forearm from the same donor
62716921|NCT06719167||Treatment|All group and individual therapy will be in line with the Trauma Informed Stabilization Treatment (TIST) model, developed by dr Janina Fisher. Patients will be admitted for in-patient pre-planned treatment over 11 weeks in an open door psychiatric hospital. Patients will be summoned for 6 day follow-up 8 months after discharge.
62716922|NCT04185350|EXPERIMENTAL|68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 60 min later.
62716923|NCT02742129|EXPERIMENTAL|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
62716924|NCT02742129|PLACEBO_COMPARATOR|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
62716925|NCT05736393|EXPERIMENTAL|Exosuit Augmented Physical Therapy|participants will attend an in person screening, initial visit (1), 10 (2-11) sessions of physical therapy and a discharge visit (12). Participants will undergo a comprehensive biomechanical analysis on visits 1, 3, 6, 9 and 12, completing an extensive battery of surveys at visits 1, discharge, and 1-month post-discharge. Treatment will incorporate evidence-based physical therapy care based on clinical presentation to include manual therapy, therapeutic exercise, and functional therapeutic activities. A portion of each session will include exosuit use.
62716926|NCT03492177|EXPERIMENTAL|open label selexipag|The first dose of selexipag (Uptravi) will be administered in the evening of Day 1 and will be based on the body weight. Thereafter selexipag will be administered twice daily (morning and evening). Selexipag will be up-titrated during the first 12 weeks, with weekly increments equal to the starting dose until the participants reach their individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline weight category is achieved (which will be 8-fold of the corresponding starting dose). Up-titration is followed by a stable maintenance treatment period from Week 12 to Week 16, at the maximum tolerated dose. Thereafter, participants will be treated with selexipag as long as the treatment is beneficial to the participants, as per investigator's decision.
62716927|NCT04236271|EXPERIMENTAL|patient|interventional group
62716928|NCT01632033||Investigation for lower limb arteries|Patients referred for investigation of assumed peripheral artery disease (PAD)
62716929|NCT02175186|EXPERIMENTAL|ALBIS|Albis Tab 2 tab twice a day 12weeks
62716930|NCT02175186|PLACEBO_COMPARATOR|Placebo|placebo Tab 2 tab twice a day 12weeks
62716931|NCT05759338|EXPERIMENTAL|Intervention|Using the Revian Red All LED cap 10 minutes each day for 6 months
62716932|NCT02764411|EXPERIMENTAL|Onreltea ( Brimonidine)|All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).
62716933|NCT06718933|EXPERIMENTAL|SHR-A1811+pyrotinib|In phase Ib, enrolled subjects will received SHR-A1811 combined with pyrotinib at different doses to confirm RP2D and evaluate the safety and tolerance.
62716934|NCT06718933|EXPERIMENTAL|SHR-A1811+pyrotinib+bevacizumab|In phase II, enrolled subjects will received SHR-A1811 combined with pyrotinib and bevacizumab to evaluate the efficacy and safety.
62735869|NCT00330980|EXPERIMENTAL|2|Participants will receive 40 mg of pravastatin for 6 months.
62716935|NCT02996396||1|Patients diagnosed with AAA who are considered candidates for Endovascular Repair and meet the study eligibility criteria and sign the Informed consent may be subsequently enrolled in the study.
62716936|NCT06557759|EXPERIMENTAL|Music|Participants will be asked to listen to the brief music demo and the 30-minute music session. The pre- and post-assessments will require participants to complete a 5-10-minute online survey.
62716937|NCT00565565|EXPERIMENTAL|BAY60-4552, 1 mg|Subjects were planned to receive 1 mg of BAY60-4552 as solution
62716938|NCT00565565|EXPERIMENTAL|BAY60-4552, 2.5 mg|Subjects were planned to receive 2.5 mg of BAY60-4552 as tablet
62716939|NCT00565565|EXPERIMENTAL|BAY60-4552, 5 mg|Subjects were planned to receive 5.0 mg of BAY60-4552 as tablet
62716940|NCT00565565|EXPERIMENTAL|BAY60-4552, 7.5 mg|Subjects were planned to receive 7.5 mg of BAY60-4552 as tablet
62716941|NCT00565565|EXPERIMENTAL|BAY60-4552, 10 mg|Subjects were planned to receive 10 mg of BAY60-4552 as tablet
62716942|NCT05291533|OTHER|Patients using VR Mindfulness Program|Participants are inpatients on any NYP/WCM unit that use VR mindfulness programs; any patient referred for a psychological or neuropsychological evaluation by their treatment team will have the opportunity to complete the VR program. The study is seeking to evaluate the feasibility and preliminary efficacy of the VR mindfulness intervention.
62716943|NCT00646126|ACTIVE_COMPARATOR|1|1:Active comparator sulfadoxine-pyrimethamine plus artesunate
62716944|NCT00646126|PLACEBO_COMPARATOR|2|2:placebo comparator
62716945|NCT00707473|EXPERIMENTAL|Treatment (docetaxel, cisplatin, and fluorouracil)|"INDUCTION CHEMOTHERAPY: Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 30-180 minutes or carboplatin IV on day 1, and fluorouracil IV continuously on days 1-4. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~Patients who achieve CR or PR receive 1 additional course of treatment and undergo chemoradiotherapy over 6-7 weeks. Patients who have SD or PD to induction therapy, or less than a complete response to chemoradiotherapy undergo surgery and radiation therapy."
62716946|NCT06201676|EXPERIMENTAL|Standard of Care (SOC) + Ketorolac|The treatment arm will receive 15 mg of intravenous (IV) ketorolac every 6 hours during the first five hospital days, in addition to standard of care (SOC) multimodal analgesia according to each site's institutional protocol.
62716947|NCT06201676|PLACEBO_COMPARATOR|Standard of Care (SOC)|The placebo arm will receive 2 mL of intravenous (IV) saline every 6 hours during the first five hospital days, in addition to standard of care (SOC) multimodal analgesia according to each site's institutional protocol.
62716948|NCT01911455|ACTIVE_COMPARATOR|acamprosate|The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh \< 50 kg.
62716949|NCT01911455|PLACEBO_COMPARATOR|Placebo|Placebo will be prescribed with the same frequency and duration as the acamprosate group.
62716950|NCT01459692|NO_INTERVENTION|Control group - No Music Exposure|Subjects that were assigned to the control group of the study were not exposed to music.
62716951|NCT01459692|EXPERIMENTAL|Music Exposure|The treatment subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
62716952|NCT06353815|EXPERIMENTAL|Group I (Experimental group) 4% articaine infiltration|
62716953|NCT06353815|ACTIVE_COMPARATOR|Group II (Control group) 4% articaine inferior alveolar nerve block|
62716954|NCT04940468|ACTIVE_COMPARATOR|Arm 1: Diet Intervention|Based on participant food preferences, diet higher in fiber and lower in fat than the participant's typical diet will be provided.
62716955|NCT04940468|NO_INTERVENTION|Arm 2: No Diet Intervention|No diet changes will be made for participants
62716956|NCT06434324|EXPERIMENTAL|Saline Irrigation Group|Subjects will receive twice daily fibrinolytic therapy in addition to daily saline irrigation through their chest tube until the treating physician determines that the pleural space has been adequately evacuated
62716957|NCT06434324|NO_INTERVENTION|Standard of Care Group|Subjects will receive twice daily fibrinolytic therapy through their chest tube until the treating physician determines that the pleural space has been adequately evacuated
62716958|NCT03907397|ACTIVE_COMPARATOR|Treatment|Ingests peanut - . Depending upon reaction threshold, participants may begin with different starting amounts of store bought peanut butter measured with study-supplied kitchen measuring spoons.
62716959|NCT03907397|OTHER|Avoidance|Avoids peanut, standard care
62716960|NCT00185887|ACTIVE_COMPARATOR|Terbutaline|
62716961|NCT00185887|ACTIVE_COMPARATOR|Nitroglycerine|
62716962|NCT02833883|EXPERIMENTAL|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day \& enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day \& enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional in the expansion phase treated at 7.5 mg BID. Amended to treat expansion group with 5mg BID of CC-115.
62543470|NCT06141603||Lower Extremity Group|"The first test is the cardiopulmonary exercise test (CPET), which evaluates the maximal exercise capacity of the lower extremities and will be performed on a treadmill.~During the test, the muscle oxygen of the individuals will be measured with a near-infrared spectrometer, and their energy consumption will be measured with a multisensory physical activity monitor."
62716963|NCT06715007||Patients with recent small subcortical infarct|Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),
62735870|NCT00330980|PLACEBO_COMPARATOR|3|Participants will receive placebo for 6 months.
62735871|NCT02209792|PLACEBO_COMPARATOR|Placebo|
61978162|NCT05560997||longitudinal physical examination cohort|The diagnosis of NAFLD was based on imaging evaluation.
62716964|NCT06715007||Patients with Whiter matter changes|White matter hyperintensities with a 2-3 grading on Fazekas scale will be recruited. Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),
62716965|NCT04086316||Depression Group|Naturally cycling women with a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
62716966|NCT04086316||Healthy Group|Naturally cycling women without a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
62716967|NCT00308334|EXPERIMENTAL|Domperidone|Domperidone
62716968|NCT00308334|PLACEBO_COMPARATOR|placeob- Sugar pill|
62716969|NCT06714890|EXPERIMENTAL|Transcranial Electrical Stimulation Group|visual training combined with transcranial electrical stimulation
62716970|NCT06714890|ACTIVE_COMPARATOR|Visual Training Group|visual training
62716971|NCT04937192||Kidney stone former|
62716972|NCT00002766|EXPERIMENTAL|"ARA-C/High-Dose Mitoxantrone(All-2)"|See detail description
62716973|NCT00002766|ACTIVE_COMPARATOR|"Standard Vincristine/Prednisone (L-20)"|See detail description
62716974|NCT02964377|EXPERIMENTAL|Cohort 1|8-weeks open-label (+)- Epicatechin at 25mg/day twice per day,
62716975|NCT02964377|EXPERIMENTAL|Cohort 2|8-weeks open-label (+)- Epicatechin at 25mg/day three times per day
62716976|NCT02964377|EXPERIMENTAL|Cohort 3|8-weeks open-label (+)- Epicatechin at 75mg/day at two times per day
62716977|NCT03263403|EXPERIMENTAL|Test Group|"44 participants will be randomly assigned to the test group for receiving the locally produced meningococcal vaccine Ingovax ACWY (Incepta)."
62716978|NCT03263403|ACTIVE_COMPARATOR|Comparator Group|44 participants will be randomly assigned to the comparator group for receiving 'Quadri Meningo' (BiO-MeD Private Limited).
62716979|NCT01310010|EXPERIMENTAL|Dasatinib|
62716980|NCT02054637|EXPERIMENTAL|Lanreotide|Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)
62716981|NCT03179878|EXPERIMENTAL|SYNB1020|SYNB1020
62716982|NCT03179878|PLACEBO_COMPARATOR|Placebo|100 mL masking solution
62716983|NCT06663332|EXPERIMENTAL|Guselkumab (Every 8 weeks)|Participants treated with guselkumab in one of the three primary studies (CNTO1959PUC3001 \[NCT06260163\], CNTO1959PBCRD3007 \[NCT05923073\], CNTO1275JPA3001 \[NCT05092269\]) will be enrolled in this long-term extension (LTE) study, if in the investigator's opinion, the participant will benefit from continued guselkumab therapy. Participants will have continued access to guselkumab (every 8 weeks \[q8w\]). Participants coming from double-blinded arm of the primary studies will be assigned to q8w dosing. Based on investigator's discretion and participant's clinical status, all participants on q8w dosing have the option to switch to q4w once during the LTE study. Participants coming from the jPsA primary study (CNTO1275JPA300) will continue the same dosing regimen from the primary study (q8w) and cannot increase their dose during the LTE study.
62716984|NCT06663332|EXPERIMENTAL|Guselkumab (Every 4 weeks)|Participants treated with guselkumab in one of the three primary studies (CNTO1959PUC3001 \[NCT06260163\], CNTO1959PBCRD3007 \[NCT05923073\], CNTO1275JPA3001 \[NCT05092269\]) will be enrolled in this LTE study, if in the investigator's opinion, the participant will benefit from continued guselkumab therapy. Participants will have continued access to guselkumab (q4w). Participants coming from the open-label arm of the primary studies will be assigned to q4w dosing. Participants coming from the jPsA primary study (CNTO1275JPA300) will continue the same dosing regimen from the primary study (q4w) and cannot increase their dose during the LTE study.
62716985|NCT06715722|EXPERIMENTAL|hexed non hexed|a 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using hexed and non hexed abutments
62716986|NCT06715722|ACTIVE_COMPARATOR|non hexed non hexed|a 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using two non-hexed abutments
62716987|NCT00956293|ACTIVE_COMPARATOR|Control group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.
62716988|NCT00956293|EXPERIMENTAL|Everolimus group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.
62716989|NCT06391892|EXPERIMENTAL|ctDNA guided|"All patients included into the study are recommended to go for upfront surgery (localized and resectable tumor in CT and CA19-9 \<500kU/l) by tumor board.~If preoperative ctDNA in peripheral blood is positive, we assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead."
62716990|NCT06391892|OTHER|Standard of care|Patient get the gold standard treatment at physicians choice, independent to study participation (here the study is just observational).
62716991|NCT02790502|OTHER|Intervention|Intervention Group
62716992|NCT06401421||Participants with High Risk Early Breast Cancer|Participants with High Risk Early Breast Cancer
62716993|NCT01679483|EXPERIMENTAL|FloSeal group|This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
62716994|NCT01679483|NO_INTERVENTION|No FloSeal group|All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.
62716995|NCT06718478|EXPERIMENTAL|Genicular Artery Embolization (GAE)|Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
62735872|NCT02209792|EXPERIMENTAL|BIRB 796 BS, low dose|2 x 5 mg b.i.d.
62735873|NCT02209792|EXPERIMENTAL|BIRB 796 BS, medium dose 1|20 mg b.i.d.
62735874|NCT02209792|EXPERIMENTAL|BIRB 796 BS, medium dose 2|2 x 5 mg + 20 mg b.i.d.
62735875|NCT02209792|EXPERIMENTAL|BIRB 796 BS, high dose|3 x 20 mg b.i.d.
62716996|NCT03507582|ACTIVE_COMPARATOR|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
62716997|NCT03507582|ACTIVE_COMPARATOR|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
62716998|NCT04203316|EXPERIMENTAL|Treatment (enasidenib)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and/or biopsy and collection of blood on study.
62716999|NCT04099277|EXPERIMENTAL|Part A: 10 milligrams (mg) LY3435151|Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
62717000|NCT04099277|EXPERIMENTAL|Part B: LY3435151 + Pembrolizumab Dose Escalation|Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
62717001|NCT04099277|EXPERIMENTAL|Part C: LY3435151 Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
62717002|NCT04099277|EXPERIMENTAL|Part D: LY3435151 + Pembrolizumab Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
62717003|NCT06607991|EXPERIMENTAL|Blinatumomab Treatment|
62717004|NCT02982330|EXPERIMENTAL|Low Carbohydrate Breakfast|Breakfast composition containing \<10% carbohydrate, 75% fat, 15% protein Matched calories
62717005|NCT02982330|ACTIVE_COMPARATOR|Guidelines Breakfast|Breakfast composition containing 55% carbohydrate, 30% fat, 15% protein Matched calories
62717006|NCT03493958|EXPERIMENTAL|Feasibility and acceptability of Sleep Healthy Using the Internet (SHUTi) for CBT-I|Individuals with alcohol use disorder (AUD) in recovery with insomnia completed six online classes that include interactive educational content and case studies about insomnia and its precipitating factors. These sessions are designed to parallel traditional (in-person) cognitive behavioral therapy for insomnia (CBT-I) sessions and are tracked and customized. New sessions are available seven days after completion of the previous session. The program includes a variety of interactive features, including goal setting, feedback based on user-identified symptoms, animations, quizzes, vignettes, and video-based expert explanations. Participants have maximum of 9-11 weeks to complete the six sessions.
62717007|NCT06158867||FMD WK|
62717008|NCT06158867||Placebo|
62717009|NCT04946695|EXPERIMENTAL|Telefisio India|Feasibility and efficacy of the use of Telephysiotherapy for improving functional independence and quality of life in children and young people with lower limb fracture in a low resource setting in Anantapur (India).
62717010|NCT06715124|EXPERIMENTAL|Part 1a: QTX3544 monotherapy dose escalation|QTX3544 will be administered at protocol defined dose based on cohort assignment
62717011|NCT06715124|EXPERIMENTAL|Part 1b: QTX3544 dose escalation in combination with cetuximab|QTX3544 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
62717012|NCT06715124|EXPERIMENTAL|Part 2: QTX3544 monotherapy dose expansion|QTX3544 will be administered at protocol defined dose based on cohort assignment
62717013|NCT06715124|EXPERIMENTAL|Part 3: QTX3544 dose expansion in combination with cetuximab|QTX3544 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
62717014|NCT03152123|EXPERIMENTAL|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
62717015|NCT03152123|EXPERIMENTAL|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
62717016|NCT03152123|ACTIVE_COMPARATOR|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
61978163|NCT02402543|PLACEBO_COMPARATOR|Control Arm|In pre-op, the subject is administered four placebo pills PO containing confectioners sugar, which are matched in color, size, and shape to the active pills.
62717017|NCT03152123|PLACEBO_COMPARATOR|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
62717018|NCT02365597|EXPERIMENTAL|Erdafitinib (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram \[mg\] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants enrolled in DDI substudy will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression. Participants who completed the DDI substudy and continue to benefit from erdafitinib treatment, will continue to receive erdafitinib in long-term extension (LTE) phase.
62717019|NCT02999607|EXPERIMENTAL|active transcranial direct current stimulation|Stimulation at three different intensities during FDG-PET scan
62717020|NCT02999607|SHAM_COMPARATOR|Sham tDCS|Comparator to active arm
62717021|NCT01985022|ACTIVE_COMPARATOR|Group-ESI|Infants 12 months of age at risk of developing ASD who are randomized to receive the Group-ESI intervention for 9 months.
62717022|NCT01985022|EXPERIMENTAL|Individual-ESI plus Group-ESI|Infants 12 months of age at risk of developing ASD who are randomized to receive Individual-ESI intervention in addition to the Group-ESI intervention for 9 months.
62717023|NCT04382443|EXPERIMENTAL|Oral Colchicine +BMS implantation|This group will receive after BMS and Colchicine, at the time of PCI, 0,5 mg twice a day during the first three months after stent implantation
62717024|NCT04382443|NO_INTERVENTION|Second generation Drug eluting stent (DES)|"This group will receive DES at the moment of randomization and will be treated as standard of care.~All second generation DES should be approved by ANMAT for clinical use."
62717025|NCT06589596|EXPERIMENTAL|Phase 1a: Dose Escalation and Safety Expansion|Sequential cohorts of increasing dose levels of BGB-58067 as monotherapy will be evaluated.
62717026|NCT06589596|EXPERIMENTAL|Phase 1b: Dose Expansion and Optimization|Recommended Dose(s) for Expansion (RDFE\[s\]) of BGB-58067 as monotherapy will be evaluated for selected indications based on emerging data.
62717027|NCT02539550|PLACEBO_COMPARATOR|Placebo|Placebo
62717028|NCT02539550|EXPERIMENTAL|PF-06266047|PF-06266047
62717029|NCT06716411|EXPERIMENTAL|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
62717030|NCT06716411|ACTIVE_COMPARATOR|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
62717031|NCT00827957|ACTIVE_COMPARATOR|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
62717032|NCT00827957|ACTIVE_COMPARATOR|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
62717033|NCT02115321|EXPERIMENTAL|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
62717034|NCT02115321|EXPERIMENTAL|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
62717035|NCT02115321|EXPERIMENTAL|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
62717036|NCT02115321|EXPERIMENTAL|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
62717037|NCT05158413|EXPERIMENTAL|High dose|Experimental: high dose of sesame 20 patients
62717038|NCT05158413|ACTIVE_COMPARATOR|Low dose|Active Comparator: low dose of sesame 20 patients
62717039|NCT06548568||OZURDEX|Participants with diabetic macular edema prescribed OZURDEX in routine clinical practice are observed from the first dose for up to 24 months.
62717040|NCT01293812|EXPERIMENTAL|sucrose po|"88% sucrose solution (Syrup B.P.). The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution."
62717041|NCT01293812|PLACEBO_COMPARATOR|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
62717042|NCT05161871|ACTIVE_COMPARATOR|Cathodal transcranial direct current stimulation|
62717043|NCT05161871|SHAM_COMPARATOR|Sham transcranial direct current stimulation|
62717044|NCT06618274|EXPERIMENTAL|Cohort 1|Cohort 1 will enroll patients with new cancer appointments within genitourinary (GU) or thoracic cancers. These clinics have not yet implemented the central navigation program.
62717045|NCT06618274|EXPERIMENTAL|Cohort 2|Cohort 2 will enroll participants with new cancer appointments within gastrointestinal (GI), hematology, and breast cancer (clinics where the central navigation program was implemented). These individuals will be randomized to receive standard of care, which for these cancer types includes central oncology navigation or the intervention of oncology research navigator in addition to SOC.
62717046|NCT02311725|EXPERIMENTAL|aTAU + sTVi|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Storytelling Video Intervention (sTVi): We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
62717047|NCT02311725|ACTIVE_COMPARATOR|aTAU + Attention Control Videos|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Attention Control Videos: Control participants will view videos about general mental health and well-being. Specifically, we plan to give participants 4 30-minute videos on topics including nutrition, stress reduction, movement and recreation, and becoming an educated patient. The series comes with an accompanying course guidebook. We will provide videos on the same schedule as sTVi."
62717048|NCT03419429|EXPERIMENTAL|Simvastatin/Occlusive membrane|open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .
62717049|NCT03419429|EXPERIMENTAL|Simvastatin/perforated membrane|open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.
62717050|NCT03419429|EXPERIMENTAL|EDTA/Simvastatin/Occlusive membrane|open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.
62717051|NCT03419429|EXPERIMENTAL|EDTA/Simvastatin/perforated membrane|open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.
62717052|NCT05918978|EXPERIMENTAL|Efgartigimod|Receive efgartigimod IV 10mg/kg infusions during a treatment period of 48 weeks
62717053|NCT06712836|EXPERIMENTAL|MET097 Active|MET097 will be administered at four different dose levels subcutaneously once-weekly without titration.
62717054|NCT06712836|PLACEBO_COMPARATOR|Placebo|Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
62717055|NCT06714825|EXPERIMENTAL|Investigational Product|HS235 Subcutaneous Injection
62717056|NCT06714825|PLACEBO_COMPARATOR|Placebo|Subcutaneous Injection
62717057|NCT00647543|EXPERIMENTAL|High Risk|
62717058|NCT00647543|EXPERIMENTAL|Low Risk|
62717059|NCT00647543|EXPERIMENTAL|Medium Risk|
62717060|NCT02379052|EXPERIMENTAL|Dupilumab 300 mg QW|Participants received SC dupilumab 300 mg during the 12-week double-blind treatment phase. Participants received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
62717061|NCT02379052|EXPERIMENTAL|Placebo|Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.
62717062|NCT03483389|EXPERIMENTAL|Alcohol, placebo|Alcohol, ethyl - Placebo
62717063|NCT03483389|EXPERIMENTAL|Alcohol, low dose|Alcohol, ethyl - Low dose
62717064|NCT03483389|EXPERIMENTAL|Alcohol, moderate dose|Alcohol, ethyl - Moderate dose
62717065|NCT04565288|EXPERIMENTAL|Atomoxetine|Atomoxetine (40 mg/day for 3 days then 80 mg/day thereafter) during a 6-week medication trial
62717066|NCT04565288|PLACEBO_COMPARATOR|Placebo|Identical matching placebo capsules
62717067|NCT02142088|OTHER|Glucose Monitoring|Each patient will undergo simultaneous Glucose monitoring with 2 devices. One is GlySure's intervascular continuous measurement sensor (test device) introduced through a CVC, and the other measures glucose intermittently from repeated venous blood samples drawn through an indwelling ventflon style catheter
62717068|NCT04278703|ACTIVE_COMPARATOR|15 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
62717069|NCT04278703|ACTIVE_COMPARATOR|25 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
62717070|NCT04278703|ACTIVE_COMPARATOR|35 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
62717071|NCT03776630|OTHER|Control|Patients undergoing surgery for benign pelvic lesions
62717072|NCT03776630|OTHER|Ovarian Cancer|
62717073|NCT03776630|OTHER|Endometrial Cancer|
62717074|NCT02321228|EXPERIMENTAL|Salpingectomy with delayed oophorectomy|Female BRCA mutation carriers can opt for early salpingectomy upon completion of childbearing, followed by second stage oophorectomy delayed for five years beyond current guideline ages for risk-reducing salpingo-oophorectomy (i.e. age 40-45 for BRCA1 mutation carriers and 45-50 for BRCA mutation carriers).
62717075|NCT02321228|ACTIVE_COMPARATOR|Risk-reducing salpingo-oophorectomy|Female BRCA mutation carriers can opt for standard risk-reducing salpingo-oophorectomy at current guideline ages (age 35-40 for BRCA1 mutation carriers and age 40-45 for BRCA2 mutation carriers).
62717076|NCT03609424|EXPERIMENTAL|PDR001 plus Imatinib|
62717077|NCT05964179|EXPERIMENTAL|time restricted feeding|total feeding time (from the first meal or snack to the last) is assigned as 8 hours/day.
62717078|NCT05964179|EXPERIMENTAL|time extended feeding|total feeding time (from the first meal or snack to the last) is assigned as 14 hours/day.
62717079|NCT06715943|EXPERIMENTAL|HRS-5965 capsule|
62717080|NCT06719271|ACTIVE_COMPARATOR|Robotic assisted gait training: participants in this group with receive gait training on the Lokomat|
62717081|NCT06719271|ACTIVE_COMPARATOR|Body Weight Supported Treadmill Training: participants in this group receive training on Treadmill|
62717082|NCT04168931|EXPERIMENTAL|Interventional|Use of trastuzumab combination chemotherapy in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue but positive in CTC.
62717083|NCT05089370|EXPERIMENTAL|Oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Mucosal Melanoma|
62717084|NCT05921110|ACTIVE_COMPARATOR|PENG Block %0,25|PENG Block will be applied with 0.25% bupivacaine in 20 ml volume under ultrasound guidance.
62717085|NCT05921110|ACTIVE_COMPARATOR|PENG Block %0,16|PENG Block will be applied with 0.16% bupivacaine in 20 ml volume under ultrasound guidance.
62717086|NCT05921110|NO_INTERVENTION|Control Group|Control
62717087|NCT06163326|EXPERIMENTAL|Arm 1|"Participants who previously received 1 ritlecitinib 50 mg capsule QD orally from BL to Week 52 in Study B7981040.~Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned."
62717088|NCT06163326|EXPERIMENTAL|Arm 2|Participants who previously received 1 placebo 50 mg capsule QD orally from BL to Week 52 in Study B7981040 Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned
62717089|NCT06108570|OTHER|Study methodology|This is an intra-individual comparison study.
62717090|NCT03271866|OTHER|metformin treatment|
62717091|NCT03271866|NO_INTERVENTION|non-metformin treatment|
62717092|NCT06624800|EXPERIMENTAL|Shoulder chuna treatment|During the hospitalization period, Chuna therapy for the shoulder joint will be performed once a day for a total of 10 to 15 minutes, including before, during, and after the treatment. The practitioner will assess the condition and select one of three techniques-posterior displacement, anterior displacement, or lateral displacement-to apply Chuna therapy
62717093|NCT06624800|ACTIVE_COMPARATOR|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
62717094|NCT00725088|EXPERIMENTAL|1|exercise training group
62717095|NCT00725088|NO_INTERVENTION|2|control group
62717096|NCT04294355|EXPERIMENTAL|Artificial intelligence-Assisted colonoscopy|Tandem colonoscopy of proximal colon assisted with artificial intelligence followed by conventional colonoscopy
62717097|NCT04294355|ACTIVE_COMPARATOR|Conventional colonoscopy|Tandem conventional colonoscopy of proximal colon followed by usual conventional colonoscopy
62717098|NCT06446583|EXPERIMENTAL|Preoperative chewing gum group|Upon arrival at the preoperative preparation room, patients begin chewing sugar-free gum provided by the preoperative nurse. They continue chewing until they enter the operating room (for at least 15 minutes). Before entering the operating room, it is confirmed that the gum has been discarded.
62717099|NCT06446583|NO_INTERVENTION|No preoperative chewing gum group|After arriving at the preoperative preparation room, patients wait without chewing gum until they enter the operating room.
62717100|NCT00818493|EXPERIMENTAL|1|Q8003, flexible ascending dose
62717101|NCT00818493|EXPERIMENTAL|2|Low dose Q8003
62717102|NCT00818493|ACTIVE_COMPARATOR|3|Percocet (oxycodone and acetaminophen)
62717103|NCT03697850|EXPERIMENTAL|atezolizumab|Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.
62717104|NCT01642303|EXPERIMENTAL|vodcasting|students who listen to downloaded vodcasting
62717105|NCT01642303|NO_INTERVENTION|control|listen to the student book listening file
62717106|NCT06650384|NO_INTERVENTION|Group (1): colistin only|Group1 (n=60): will receive (IV) colistin 300 mg CBA loading dose, followed 12 hours later by a maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation .
62717107|NCT06650384|EXPERIMENTAL|Group(2): colistin and N-Acetylcysteine|Group2 (n=60): will receive (IV) colistin 300mg CBA loading dose followed by a maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice/day (acetylcysteine 600mg sachets produced by South Egypt Drug Industries Company, SEDICO)
62717108|NCT06650384|EXPERIMENTAL|Group(3): colistin and Alpha-lipoic acid|Group3 (n=60): will receive (IV) colistin 300mg CBA loading dose followed by a maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice daily (thiotacid 600mg produced by EVA PHARM) before meals .
62717109|NCT05281913|EXPERIMENTAL|Intervention Group|A web-based Simulation Game concerning marital positive skills in remarriage, positive co-parenting strategies and positive stepparent-stepchild relationship skills.
62717110|NCT05281913|NO_INTERVENTION|Control|No intervention
62717111|NCT00741169|EXPERIMENTAL|Treatment Sequence ABC|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence will consist of Treatment A (TMC435350 200 mg once daily for 7 days), Treatment B (rifampin 600 mg once daily for 7 days), and Treatment C (TMC435350 200 mg once daily+rifampin 600 mg once daily for 7 days). Participants will receive 1 treatment (A, B, or C) during each treatment session. There will be 3 treatment sessions, each treatment session will be separated by 10 days.
62717112|NCT00741169|EXPERIMENTAL|Treatment Sequence BCA|
62717113|NCT00741169|EXPERIMENTAL|Treatment Sequence CAB|
62717114|NCT00741169|EXPERIMENTAL|Treatment sequence CBA|
62717115|NCT00741169|EXPERIMENTAL|Treatment Sequence BAC|
62717116|NCT00741169|EXPERIMENTAL|Treatment Sequence ACB|
62717117|NCT05311033|EXPERIMENTAL|Samples Without DNA|Healthy males aged 20-40 years with at risk of post-inflammatory hyperpigmentation: phototype IV or V according to the Fitzpatrick scale (1) and having a colorimetric individual typology angle (ITA°) between -20° and 28° and/or having already had post-inflammatory pigmentation or hyperpigmentation (e.g. acne scars, melasma)
62717118|NCT01965613|EXPERIMENTAL|open label-Xilonix|Open label-Xilonix
62717119|NCT03132285|OTHER|PrePex Day 0 foreskin removal|Day 0 foreskin removal
62717120|NCT06716424|EXPERIMENTAL|iGlarLixi|iGlarLixi will be administered to study participants subcutaneously
62717121|NCT02298959|EXPERIMENTAL|Treatment (pembrolizumab and ziv-aflibercept)|Patients receive pembrolizumab intravenously (IV) over approximately 30 minutes and ziv-aflibercept IV over 1-2 hours on day 1. Cycles repeat every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, blood sample collection and tumor biopsy throughout the study.
62717122|NCT01641484|EXPERIMENTAL|local control 19.8Gy|local control at 19.8 Gy, at Day 14
62717123|NCT02850978||Spiolto|Patient with COPD to received Spiolto
62717124|NCT00503984|EXPERIMENTAL|Phase 1 - Aza + Doc|Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).
62543471|NCT06141603||Upper Extremity Group|"In the second test, the maximal exercise capacity for the upper limb will again be evaluated by CPET and performed on the arm ergometer.~The second test will be conducted 48 hours after the lower extremity exercise test.~During the test in the second group, as in the first test, muscle oxygen will be measured with a near-infrared spectrometer, and energy expenditure with a multisensory physical activity monitor."
62717125|NCT00503984|EXPERIMENTAL|Phase 2 - Aza + Doc RPTD|Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel; and Prednisone; with optional growth factor support (pegfilgrastim/filgrastim).
62717126|NCT06259357|EXPERIMENTAL|Protocolized protective mechanical ventilation in prone position|
62717127|NCT06259357|NO_INTERVENTION|Protocolized protective mechanical ventilation in supine position|
62717128|NCT03703505|EXPERIMENTAL|AG-348|On Day 1, participants fasting for at least 10 hours the night before will receive oral AG-348 followed by intravenous (IV) \[13C6\]AG-348, 1 hour post-oral dose.
62717129|NCT05142306|EXPERIMENTAL|COVID-HIG Intramuscular|"Eligible subjects will be randomized to receive an 8.5mL dose of COVID-HIG by IM injections.~COVID-HIG: COVID-HIG is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2."
62717130|NCT05142306|EXPERIMENTAL|COVID-HIG Subcutaneous|"Eligible subjects will be randomized to receive an 8.5mL dose of COVID-HIG by SC injections.~COVID-HIG: COVID-HIG is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2."
62717131|NCT05142306|EXPERIMENTAL|COVID-HIG Intravenous|"Eligible subjects will be randomized to receive an 8.5mL dose of COVID-HIG by IV infusion.~COVID-HIG: COVID-HIG is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2."
62717132|NCT05894057||Group 1 (reference: midazolam oral syrup or rectal suppository formulations)|Oral syrup or rectal suppository formulation of midazolam prescribed in the Anesthesiology Unit or Emergency Unit of UKBB as current reference formulations in clinical routine.
62717133|NCT05894057||Group 2 (alternative: midazolam oro- dispersible mini-tablet (OMDT) formulation)|ODMT formulation of midazolam prescribed in the Anesthesiology or Emergency Unit at UKBB as a recently introduced alternative formulation in clinical routine.
62717134|NCT06690775|EXPERIMENTAL|Cohort 1|Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
62717135|NCT06690775|EXPERIMENTAL|Cohort 2|Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
62717136|NCT06690775|EXPERIMENTAL|Cohort 3|Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
62717137|NCT03058133|OTHER|fMRI study|
62717138|NCT02554994|ACTIVE_COMPARATOR|Intervention|"ASPRA (Aging Study of PyeongChang Rural Area) cohort is a population-based, prospective cohort study of older adults living in PyeongChang County of South Korea. This cohort study is supported by public health center, named PyeongChang Health Center and Country Hospital managed by government, to improve the quality of aged public health services.~All participants will be recruited from ASPRA cohort. After 6 months of usual care period, eligible participants are screened by characteristics of ASPRA database, and are assigned to a multifactorial intervention arm."
62717139|NCT02554994|ACTIVE_COMPARATOR|usual care|The other participants enrolled to ASPRA cohort are acted as a control arm. The usual care according to ASPRA protocol will be maintained.
62717140|NCT04904835||Unselected blood donors|leftover samples from unselected blood donors from at least 2 donation centers. Leftover samples to be tested by Access HBV serological marker assays and CE-marked (european compliance marked) predicate assays
62717141|NCT04904835||Hospitalized patients|Leftover samples to be tested by Access HBV serological marker assays and CE-marked predicate assays
62717142|NCT04904835||Presumed HBsAg positive patients|"Leftover samples from patients at different stages of HBV infection (acute and chronic, minimum 10 per stage of infection), HBsAg positive by a Confirmatory testing of a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling), and minimum 20 high positive samples (\>26 IU/mL) and minimum 20 samples in the cut-off range. If not enough samples in the cut-off range are obtained during the clinical trial, additional HBsAg specimens in the cut-off range will be tested by Research \&Development to fit with Common Technical Specification requirements.~Leftover samples to be tested by Access HBsAg assays and CE-marked predicate assays"
62717143|NCT04904835||Patients having recovered from natural HBV infection, presumed Anti-HBs positive|"Leftover samples from Patients positive for Anti-HBs and Anti-HBc Total by CE-marked assays. Target is to have at least ¾ of them recovered without HBV antiviral treatment.~Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays"
62717144|NCT04904835||Patients having received HBV vaccination, presumed Anti-HBs positive|Leftover samples Confirmed as vaccinated by testing at the time of enrollment (i.e. positive for Anti-HBs and negative for Anti-HBc by CE-marked assays).Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays
62717145|NCT04904835||Presumed Anti-HBc Total positive patients|"Leftover samples from Patients at different stage of infection (acute, chronic or recovered, minimum 10 per stage of infection) positive for Anti-HBc Total by a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling).~Leftover samples to be tested by Access anti-HBc Total and CE-marked predicate assays"
62717146|NCT04904835||Presumed Anti-HBc IgM positive patients|"left over samples from Patients with acute/recent HBV infection, positive for Anti-HBc IgM by a CE-marked assay.~Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assays"
62717147|NCT04904835||Presumed HBeAg positive patients|"Leftover samples from Patients at different stages of infection (acute and chronic, minimum 5 per stage of infection), positive for HBeAg by a CE-marked assay.~Leftover samples to be tested by Access HBeAg assay and CE-marked predicate assays"
62717148|NCT04904835||Presumed Anti-HBe positive patients7|"Leftover samples from Patients at different stages of infection (chronic and recovered, minimum 5 per stage of infection), positive for Anti-HBe by a CE-marked assay.~Leftover samples to be tested by Access anti-HBe assay and CE-marked predicate assays"
62717149|NCT04904835||Patients with chronic HBV infection|Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assay
62717150|NCT05964569|ACTIVE_COMPARATOR|Standard treatment plan|Model-based NTCP is calculated after plan approval, however, no further adjustments are to be made to the approved treatment plan
62717151|NCT05964569|EXPERIMENTAL|Optimized treatment plan|"Allocated to Control Calculation of normal tissue complication probability (NTCP) Model-guided replanning. Replanning is performed with Raysearch Raystation. Optimizations objectives are:~1. the optimization objectives that control the maximum dose in the target volume employ a variable, LETd-dependent model for RBE that allows us to include the RBE-variations predicted by the NTCP model~2. the periventricular volume, defined as the volume closer than 4 mm to the ventricular wall, is included into the optimization with a constraint on its Equivalent Uniform Dose (EUD) and with the variable RBE model described above. Thereby, the combined effect of the RBE variation and increased sensitivity of the periventricular volume, as predicted by the NTCP model, is included.~The effectiveness of the re-planning is verified by a second NTCP computation."
62717152|NCT04596592||Transgender|
62543472|NCT03939663|PLACEBO_COMPARATOR|placebo group|2 tablets vaginally
62717153|NCT04596592||Cisgender|
62717154|NCT06719050||online + offline integrated management in the Internet hospital|
62543473|NCT03939663|EXPERIMENTAL|misoprostol group|400 mcg vaginally
62543474|NCT00030225|EXPERIMENTAL|ELAD|Treatment with ELAD, extracorporeal liver assist system and standard of care
62543475|NCT00030225|OTHER|Standard of care (Control)|Standard of care for patients with fulminant hepatic (liver) failure
62543476|NCT05191537|EXPERIMENTAL|spinal mobilization with arm movement|conventional treatment and of spinal mobilization with arm movement
62543477|NCT05191537|ACTIVE_COMPARATOR|positional SNAGs|conventional treatment and positional SNAGs
62717155|NCT06719050||Routine offline management mode|
62717156|NCT01474967|EXPERIMENTAL|Lower metformin dose group|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
62717157|NCT01474967|ACTIVE_COMPARATOR|Higher metformin dose group|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
62717158|NCT06270407|ACTIVE_COMPARATOR|Tranexamic acid arm|Anonymous ampoule containing 5 ml of 100 mg/ml Tranexamic Acid. If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
62717159|NCT06270407|PLACEBO_COMPARATOR|Placebo arm|Anonymous ampoule containing 5 ml of 0.9% NaCl. If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
62717160|NCT05965336|ACTIVE_COMPARATOR|Able-Bodied Participants|Able-bodied participants will complete a total of three study sessions. The three sessions include a clinical evaluation, gait biomechanics, and gait biofeedback for comparison with participants with DPN.
62717161|NCT05965336|EXPERIMENTAL|Plantar Pressure Biofeedback Gait Training Followed by Propulsion Biofeedback Gait Training|Participants with DPN will complete a total of seven study sessions. The first three sessions include a clinical evaluation, gait biomechanics, and gait biofeedback for comparison with able bodied participants. Sessions four through seven involve two different biofeedback training sessions followed by a retention gait analysis test 24-48 hours after training. Participants in this study are are randomized to receive plantar pressure biofeedback gait training first and propulsion biofeedback gait training at least three weeks later.
62717162|NCT05965336|EXPERIMENTAL|Propulsion Biofeedback Gait Training Followed by Plantar Pressure Biofeedback Gait Training|Participants with DPN will complete a total of seven study sessions. The first three sessions include a clinical evaluation, gait biomechanics, and gait biofeedback for comparison with able bodied participants. Sessions four through seven involve two different biofeedback training sessions followed by a retention gait analysis test 24-48 hours after training. Participants in this study are are randomized to receive propulsion biofeedback gait training first and plantar pressure biofeedback gait training at least three weeks later.
62717163|NCT03646357|ACTIVE_COMPARATOR|Betablocker|Patients receiving a betablocker. Any other treatment or management is to be given as per usual care.
62717164|NCT03646357|EXPERIMENTAL|Non-Betablocker|No betablocker is given to this arm. Any other treatment or management is to be given as per usual care.
62717165|NCT05811351|EXPERIMENTAL|Arm A: JNJ-81201887 Low Dose|Participants will receive a single low dose intravitreal injection of JNJ-81201887 in the study eye on Day 4. In addition, participants will receive a 20-day oral prednisone course starting on Day 1 and a single, long acting periocular triamcinolone (corticosteroid injection) on Day 4 for prophylaxis of intraocular inflammation.
62717166|NCT05811351|EXPERIMENTAL|Arm B: JNJ-81201887 High dose|Participants will receive a single high dose intravitreal injection of JNJ-81201887 in the study eye on Day 4. In addition, participants will receive a 20-day oral prednisone course starting on Day 1 and a single, long acting periocular triamcinolone (corticosteroid injection) on Day 4 for prophylaxis of intraocular inflammation.
62717167|NCT05811351|SHAM_COMPARATOR|Arm C: Sham Procedure|Participants will receive sham procedure that matches the single JNJ21801887 injection on Day 4, a sham procedure that matches the long acting periocular corticosteroid injection (triamcinolone) on Day 4 and a 20-day placebo matching oral prednisone starting on Day 1.
62717168|NCT04372108||Ustekinumab New User Cohort|Participants with crohn's disease (CD) or ulcerative colitis (UC) with no prior exposure to ustekinumab, at least 1 year of enrollment records immediately prior to the new use will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
62717169|NCT04372108||Other Biologics Comparator Cohort|Participants with CD or UC with no prior exposure to the individual drugs (for example, infliximab, adalimumab, or vedolizumab) in question, at least 1 year of enrollment records immediately prior to the new use of the comparator biologic will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
62717170|NCT02781441|ACTIVE_COMPARATOR|Control group|Patients will receive only the education brochure of GFM
62717171|NCT02781441|EXPERIMENTAL|General QPL group|Patients will receive the brochure and the newly developed QPL (general version)
62717172|NCT02781441|EXPERIMENTAL|Targeted QPL group|Patients will receive the brochure and the newly developed QPL (general version)
62717173|NCT06184997|PLACEBO_COMPARATOR|CONTROL GROUP|Volunteer participants who will drink water
62717174|NCT06184997|EXPERIMENTAL|ISOTONIC DRINK GROUP|Volunteer participants who will drink Natural isotonic drink based on 20% Atlantic sea water, mixed with lemon and stevia.
62717175|NCT03960047|EXPERIMENTAL|Intervention: Virtual Reality Training|Uses virtual reality to train children to cross streets
62717176|NCT03960047|EXPERIMENTAL|Intervention: Streetside Training|Train children to cross streets using real traffic in curbside locations
62717177|NCT03960047|NO_INTERVENTION|Control|Receives no intervention
62717178|NCT06327789||Multiple Sclerosis|Patients who were 18-50 years old, diagnosed with RRMS by a experienced neurologist, and with an EDSS score ≤ 3 were included in this study. Patients with orthopedic or sensory additional problems in the lower extremity, who had an interventional procedure in the last six months, and had an attack in the last three months were excluded from the study.
62717179|NCT06621654|EXPERIMENTAL|Experimental vaccine group 1A|Subjects aged 18-59 years
62717180|NCT06621654|EXPERIMENTAL|Experimental vaccine group 2A|Subjects aged 1-5 years
62717181|NCT06621654|ACTIVE_COMPARATOR|Control vaccine group 2B|Subjects aged 1-5 years
62717182|NCT06621654|EXPERIMENTAL|Experimental vaccine group 3A|Subjects aged 6-11 months
62717183|NCT06621654|ACTIVE_COMPARATOR|Control vaccine group 3B|Subjects aged 6-11 months
62717184|NCT06621654|EXPERIMENTAL|Experimental vaccine group 4A|Subjects aged 2 months
62717185|NCT06621654|ACTIVE_COMPARATOR|Control vaccine group 4B|Subjects aged 2 months
62717186|NCT01299389|EXPERIMENTAL|Paliperidone palmitate|
62717187|NCT01299389|PLACEBO_COMPARATOR|Placebo|
62717188|NCT03861182|OTHER|Adult Healthy Volunteers|
62717189|NCT03861182|OTHER|Neonates|
62717190|NCT04372303|EXPERIMENTAL|Short-term Compassion Fatigue Resiliency Program|Experimental I received a short-term program (five hours per day for two days, ten hours in total).
62717191|NCT04372303|EXPERIMENTAL|Long-term Compassion Fatigue Resiliency Program|Experimental II received a long-term program (five weeks, two hours per week, ten hours in total).
62717192|NCT04372303|NO_INTERVENTION|Control|No intervention was applied to the control group.
62717193|NCT01740869|EXPERIMENTAL|Experimental: Patients|Children who will receive intrathecal autologous stem cells
62717194|NCT01740869|OTHER|Control/Crossover|We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
62543478|NCT06040151||Users of mobile-based medication-reconciliation app|Adult patients (18 years or older) who are asked to complete medication reconciliation before a planned admission to the clinical ward of selected pilot departments in Erasmus Medical Center
62543479|NCT00157924|EXPERIMENTAL|1|1. simvastatin/ezetimibe 10/20mg
62543480|NCT00157924|ACTIVE_COMPARATOR|2|2. atorvastatin 10mg
62543481|NCT06468436|EXPERIMENTAL|Dexmedetomidine-Esketamine Combination|Sedation-analgesia is provided with dexmedetomidine-esketamine combination for up to 14 days or until discharge from the ICU. The formulation consists of dexmedetomidine 200 μg/2 ml and esketamine 100 mg/4 ml, diluted with normal saline to a total volume of 50 ml, resulting in a dexmedetomidine concentration of 4 μg/ml and an esketamine concentration of 2 mg/ml.
62543482|NCT06468436|ACTIVE_COMPARATOR|Dexmedetomidine|Sedation-analgesia is provided with dexmedetomidine for up to 14 days or until discharge from the ICU. The formulation consists of dexmedetomidine 200 μg/2 ml, diluted with normal saline to a total volume of 50 ml, resulting in a dexmedetomidine concentration of 4 μg/ml.
62543483|NCT04290143|ACTIVE_COMPARATOR|Colored healing water|Colored medical water in a bath tub. A single 20 minutes-long treatment will be performed.
62543484|NCT04290143|PLACEBO_COMPARATOR|Placebo - Colored tap water|Colored tap water. The temperature and the pH of the tap water will be adjusted to the temperature pH of the healing water. A single 20 minutes-long treatment will be performed.
62543485|NCT06633783|EXPERIMENTAL|Semaglutide injection|Semaglutide：0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg
62543486|NCT06633783|ACTIVE_COMPARATOR|Wegovy®|Wegovy®：0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg
62543487|NCT00900822|EXPERIMENTAL|Straumann Bone Ceramic|StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures
62543488|NCT00900822|ACTIVE_COMPARATOR|BioOss|BioOss is used as a bone grafting material in sinus augmentation procedure
62543489|NCT01529710|EXPERIMENTAL|Mirazid|Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®). It originates from Myrrh a medicinal herb that has been used for thousands of years. Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
62543490|NCT01529710|ACTIVE_COMPARATOR|Praziquantel|Tablets
62543491|NCT01775189|PLACEBO_COMPARATOR|Treatment A|
62543492|NCT01775189|EXPERIMENTAL|Treatment B|
62543493|NCT01775189|PLACEBO_COMPARATOR|Treatment C|
62543494|NCT01775189|ACTIVE_COMPARATOR|Treatment D|
62543495|NCT02814890|EXPERIMENTAL|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
62543496|NCT02814890|ACTIVE_COMPARATOR|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
62543497|NCT05052476|EXPERIMENTAL|Open label Bactecal® D Liquid 1 dose|Patients will receive 1 dose of Bactecal® D Liquid by day which corresponds to 2 ml of product
62543498|NCT05052476|EXPERIMENTAL|Open label Bactecal® D Liquid 2 doses|Patients will receive 2 doses of Bactecal® D Liquid by day which correspond to 4 ml of product.
62543499|NCT01480362|EXPERIMENTAL|Negative Pressure Wound Therapy|The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment,using a sealed wound dressing connected to a vacuum pump.
62543500|NCT01480362|ACTIVE_COMPARATOR|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
62543501|NCT05026827|EXPERIMENTAL|Iyengar Yoga|Participants will engage in 10 weekly IY classes
62543502|NCT05026827|ACTIVE_COMPARATOR|Socialization Control|Participants will engage in 10 weekly socialization control group sessions
62543503|NCT05026827|NO_INTERVENTION|Healthy Comparison Group|A group of participants will also be followed for 10 weeks
62543504|NCT02480348|EXPERIMENTAL|Polymer-free DES (Drug Eluting Stent)|
62543505|NCT05410587|OTHER|Fracture Monitor T1 (implantable device class III)|
62543506|NCT01449370|EXPERIMENTAL|Arm A|TAK-117 administered once a day orally
62543507|NCT01449370|EXPERIMENTAL|Arm B|TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
62543508|NCT01449370|EXPERIMENTAL|Arm C|TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
62543509|NCT02286258|EXPERIMENTAL|Inuline - Calcium EDTA|Calcium EDTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
62543510|NCT02286258|EXPERIMENTAL|Inuline - Gd-DOTA|Gd-DOTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
62543511|NCT01823432||BAV Cohort|Patients with bicuspid or unicuspid aortic valves, regardless of surgical status.
62543512|NCT03389815|EXPERIMENTAL|WX-0593 Tablets|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
62543513|NCT00641225|EXPERIMENTAL|1|SBI-087
62543514|NCT02594670|EXPERIMENTAL|DU20 and HT7 combination|combination of two acupoints based on location and Heart meridian, including Baihui (DU20) and Shenmen(HT7).
62543515|NCT02594670|OTHER|DU20 and SP6 combination|combination of two acupoints based on location and Spleen meridian, including Baihui (DU20) and Sanyinjiao(SP6).
62543516|NCT02594670|SHAM_COMPARATOR|DU20 and SA combination|combination of local acupoint Baihui (DU20) and a sham acupoint (SA) not belonging to any regular meridian or acupoint.
62543517|NCT05790603|EXPERIMENTAL|Intervention group|PHD-band Group
62543518|NCT05790603|ACTIVE_COMPARATOR|Control group|TR-band Group
62543519|NCT00755443|EXPERIMENTAL|2|
62543520|NCT00755443|PLACEBO_COMPARATOR|1|Bare metal stent
62543521|NCT04217616||Headache Resistant Participants|Male participants who have never had a headache.
62543522|NCT04217616||Non-Resistant Participants|Male participants who have experienced headache. Age matched.
62717195|NCT02972710|ACTIVE_COMPARATOR|Supine thoracic spine manipulation|Supine thoracic spine thrust manipulation (lying face-up on the treatment table) will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
62717196|NCT02972710|ACTIVE_COMPARATOR|Seated thoracic spine manipulation|Seated thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
62717197|NCT06717113|EXPERIMENTAL|68Ga-BC1 PET/CT diagnosis|
62717198|NCT06717113|ACTIVE_COMPARATOR|18F-FDG PET/CT diagnosis|
62717199|NCT04327440||Nyambi, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (\>18 months, \< 10 years of age)~The duration of the cohort is six months."
62543523|NCT01178528|EXPERIMENTAL|Ivabradine|7.5 mg bd
62717200|NCT04327440||Nyambi, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (\>18 months, \< 10 years of age)~The duration of the cohort is six months."
62717201|NCT04327440||Kalembo, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (\>18 months, \< 10 years of age)~The duration of the cohort is six months."
62717202|NCT04327440||Kalembo, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (\>18 months, \< 10 years of age)~The duration of the cohort is six months."
62717203|NCT06706167|ACTIVE_COMPARATOR|stainless steel crown|Participants in this arm will receive stainless steel crowns for primary teeth.
62717204|NCT06706167|EXPERIMENTAL|zirconia crown|Participants in this arm will receive zirconia crowns for primary teeth.
62717205|NCT06706167|EXPERIMENTAL|Bioflx crown|Participants in this arm will receive Bioflex crowns for primary teeth.
62717206|NCT01529229|EXPERIMENTAL|Desloratadine + Prednisolone|Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.
62717207|NCT01529229|ACTIVE_COMPARATOR|Dexchlorpheniramine + Betamethasone|Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.
62717208|NCT06421051|EXPERIMENTAL|high-frequency vagus nerve electrical stimulation|
62543524|NCT01178528|ACTIVE_COMPARATOR|Carvedilol|up to 25 mg bd
62717209|NCT06421051|PLACEBO_COMPARATOR|low-frequency vagus nerve electrical stimulation|
62717210|NCT06344637|EXPERIMENTAL|10% lidocaine spray without adrenaline|4 puffs of 10% lidocaine spray without adrenaline apply on cervical os before manual vacuum aspiration
62717211|NCT06344637|PLACEBO_COMPARATOR|Placebo|4 puffs of normal saline apply on cervical os before manual vacuum aspiration
62717212|NCT01644643|EXPERIMENTAL|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
62717213|NCT01644643|ACTIVE_COMPARATOR|Best Available Therapy|IV treatment
62717214|NCT02701764|EXPERIMENTAL|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
62717215|NCT02701764|PLACEBO_COMPARATOR|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
62717216|NCT05973006|EXPERIMENTAL|Group-A NVX-CoV2601|The Monovalent NVX-CoV2601 of 5 μg of antigen with 50 μg of Matrix-M adjuvant
62717217|NCT05973006|ACTIVE_COMPARATOR|Group-B Bivalent NVX CoV2373 + NVX CoV2601|The Bivalent NVX CoV2373 + NVX CoV2601 of 5 μg of each antigen with a total of 50 μg of Matrix-M adjuvant
62717218|NCT04985084|EXPERIMENTAL|The intervention group|A 4-week dietary behavioral intervention provided by a registered nurse who has received nutrition training.
62717219|NCT04985084|OTHER|Usual care|General dietary advice provided by the ward nurses.
62543525|NCT01178528|EXPERIMENTAL|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
62543526|NCT02643667|EXPERIMENTAL|Phase I: Ibrutinib|"* Ibrutinib 840 mg by mouth once daily for 2 weeks.~* Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib."
62543527|NCT02643667|EXPERIMENTAL|Safety Run-In and Phase II: Ibrutinib|"* Ibrutinib 840 mg by mouth once daily for 4 weeks.~* Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
62543528|NCT05465655|EXPERIMENTAL|Patients undergoing TAVR|Study subjects will be studied during the TAVR procedure and their 12 lead ECGs collected and analyzed notifying for New-Onset Conduction Disturbances (NOCD) using Cara Monitor.
62543529|NCT01947998||Rivaroxaban / Cohort 1|Patients who have been prescribed Rivaroxaban for the first time
62543530|NCT01947998||Standard of care / Cohort 2|Patients who have been prescribed Standard of care for the first time
62717220|NCT03960684|EXPERIMENTAL|Levita Magnetic Surgical System|Levita Magnetic Surgical System
62717221|NCT00735150||1|25 female and 5 male BRCA carriers
62717222|NCT06006871|EXPERIMENTAL|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|"The Secret Trail of Moon is a therapeutic video game that has been created for the cognitive training of patients with ADHD. Five mechanisms have been designed to work on five cognitive functions that are deficient in ADHD: sustained attention, working memory, reasoning, planning and visuospatial ability. Aspects of rewards and music therapy have been added to this enhanced version of the game.~In this second clinical trial, the impact has been extended to twice a week during 20 sessions. There are two platforms of the same version of the game: computer (7-11 years old) and virtual reality (12-18 years old). Patients have to come to the hospital twice a week for training sessions of about 20-30 minutes duration for 10 weeks. Subsequently, they are given the computer version of the video game on a USB so that they can play it at home for another 10 weeks (twice a week).~Participants are monitored for possible difficulties and/or side effects."
62717223|NCT06006871|ACTIVE_COMPARATOR|Control Group|"This group corresponds to the control group (n=76). The control group continues with their prescribed pharmacological treatment without any cognitive intervention.~The participants of this group are contacted by telephone once a week to follow up on possible difficulties and/or side effects."
62717224|NCT06062329|EXPERIMENTAL|Symphony Thrombectomy system|Mechanical thrombectomy using the Symphony Thrombectomy system for the treatment of acute pulmonary embolism.
62717225|NCT04302025|EXPERIMENTAL|ALK Cohort|Participants will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with alectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of alectinib.
62717226|NCT04302025|EXPERIMENTAL|ROS 1 Cohort|Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.
62717227|NCT04302025|EXPERIMENTAL|NTRK Cohort|Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.
62717228|NCT04302025|EXPERIMENTAL|BRAF Cohort (Enrollment closed, no participants enrolled)|"Participants will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with vemurafenib plus cobimetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of of vemurafenib plus cobimetinib.~Enrollment closed."
62717229|NCT04302025|EXPERIMENTAL|RET Cohort (Enrollment closed)|"Participants will receive up to 8 weeks of pralsetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with pralsetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of pralsetinib.~Enrollment closed."
62717230|NCT04302025|EXPERIMENTAL|PD-L1 Cohort|Participants with positive PD-L1 in ≥1% tumor cells will receive 4 cycles of atezolizumab neoadjuvant treatment. During neoadjuvant Cycle 1 of atezolizumab, patients will also receive low-dose SBRT (8Gy X 3). Adjuvant treatment consists of SOC treatment as determined by the investigator, per NCCN guidelines
62717231|NCT04302025|EXPERIMENTAL|KRAS G12C Cohort|Participants will receive up to 8 weeks of divarasib as neoadjuvant treatment before undergoing surgical resection per standard of care. PD-L1 negative patients whose tumors have pathological response or lack radiographic progression will be have the option of continuing divarasib for up to 2 years as adjuvant therapy. For patients who test positive PD-L1, they will have the option to receive Atezolizumab for up to 16 cycles.
62717232|NCT06078475|ACTIVE_COMPARATOR|Group M-TAPA (Modified Perichondral Approach Thoracoabdominal Nerve block group)|In group M-TAPA, M-TAPA block will be performed with patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine(Buvasin %5 flakon) (total 40 ml for both sides) will be injected bilaterally.
62717233|NCT06078475|ACTIVE_COMPARATOR|Group C (Control group)|In the control group, analgesics will be administered according to the protocol in postoperative analgesia management.
62717234|NCT05784181|OTHER|patients prostatic volume more than 80 gm turp by bipolar resection|pt with 80gm prostate size underwent bipolar resection
62717235|NCT05784181|OTHER|patients prostatic volume more than 80 gm turp by Laser enaculation by holmium: YAG laser|pt with 80gm prostate size underwent Laser enaculation by holmium: YAG laser
62717236|NCT05801913|EXPERIMENTAL|Treatment (CMV-specific CD19-CAR T cells, triplex vaccine)|Patients undergo leukapheresis on day -30 and receive lymphodepleting chemotherapy on days -10 to -3 per SOC on study. Patients then receive CMV-specific CD19-CAR T cells IV on day 0 and CMV-MVA triplex vaccine IM on days 28 and 56 in the absence of unacceptable toxicity on study. Patients also undergo x-ray during screening and on study, as well as PET, CT, MRI, blood sample collection, and bone marrow biopsy on study and during follow-up.
62717237|NCT06119503|EXPERIMENTAL|Elongating Time HOrizons for Reentry (ETHoR)|Episodic Future Thinking (EFT) utilizes participant-generated descriptions of future events to elongate an individual's temporal horizon. In EFT paradigms, the participant is asked to create and envision vivid descriptions of specific, positively valanced, events that could happen in the future. Recent research suggests that directing EFTs to focus on specific goals (i.e. evoking images of oneself engaging in activities consistent with a desired future outcome) are associated with stronger decreases in undesirable health behaviors. Thus, as part of the ETHoR condition, participants will be asked to verbally describe and imagine four specific events reflecting positive activities in which the participant engages in substance and incarceration-free activities, corresponding to predetermined future timepoints. The PRC will encourage participants to include as many contextual and emotional details as possible.
62735876|NCT02064049|EXPERIMENTAL|Hepatitis C treatment|All prisoners (in participating correctional centres) with hepatitis c, as identified during the hepatitis C surveillance phase of the study will be offered treatment for hepatitis C. The treatment course is sofosbuvir/velpatasvir 400/100mg for 12 weeks (1 tablet once daily).
62164900|NCT01919255|ACTIVE_COMPARATOR|Picolight + Clicolon (Split-Dose)|Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
62164901|NCT05903573|EXPERIMENTAL|Intervention Group: Cognitive Training|Participants will complete computerized cognitive training via Posit Science Brain HQ. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
62164902|NCT05903573|ACTIVE_COMPARATOR|Active Control Group: Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
62164903|NCT01156818||Children|Age 8-21 years
62164904|NCT01156818||Adult|Age 21-80 years
62164905|NCT00524693|ACTIVE_COMPARATOR|1|4mg Singulair© sachets
62164906|NCT00524693|PLACEBO_COMPARATOR|2|
62164907|NCT05020886||Healthy|
62717238|NCT06119503|ACTIVE_COMPARATOR|Standardized Recent Thinking (ERT)|Individuals in the control group utilizes SET; an approach that controls for activation of episodic thinking but does not engage prospection (the hypothesized mechanism of episodic future thinking, future outcome) are associated with stronger decreases in undesirable health behaviors. Thus, as part of the SET condition, participants will be asked to verbally describe and imagine four current events reflecting positive activities in which the participant engages in substance and incarceration-free activities, corresponding to current experiences. The PRC will encourage participants to include as many contextual and emotional details as possible.
62717239|NCT02280993|EXPERIMENTAL|DHAP-BV|Brentuximab Vedotin with DHAP chemotherapy follow by Autologous Peripheral Blood Stem Cell Transplantation
62717240|NCT04858399||Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
62717241|NCT04858399||Moderate Severity OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.
62717242|NCT04858399||High Severity OSAS|Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour
62717243|NCT06433479|EXPERIMENTAL|Dapagliflozin|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
62717244|NCT06433479|NO_INTERVENTION|Control|No intervention
62717245|NCT01278264|ACTIVE_COMPARATOR|iTAP-group|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
62717246|NCT01278264|ACTIVE_COMPARATOR|aTAP-group|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
62717247|NCT06131658|EXPERIMENTAL|Functional motor control excercise|Functional motor control exercise Includes side plank with clamshell, Side plank with hip abduction, Side-lying hip abduction, Lateral monster walk, Hip hikes, Single leg squat, TKE with T-band-hip abduction All exercises done with 2 sets of 10 reps with 3 sessions per week for 6 weeks
62717248|NCT06131658|EXPERIMENTAL|conventional exercise|The conventional exercise included 4 stages of self-myofascial techniques, strengthening, and integration techniques. In the first phase, individuals did fascial release exercises using foam rolls, focusing on tensor fascia latae, iliotibial band, and hip adductor muscles, and tennis balls for the quadratus lumborum. The exercises were performed at high-intensity maximum pain tolerance for 30 seconds or low-intensity minimum pain tolerance for 90 seconds.
62717249|NCT06603558||Atogepant|Participants will receive atogepant as prescribed by their physician according to the local label.
62717250|NCT06715657|EXPERIMENTAL|Group A|Patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection 15 min before the end of surgery
62717251|NCT06715657|EXPERIMENTAL|Group B|Patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection just before intrathecal anaesthesia
62717252|NCT06715657|PLACEBO_COMPARATOR|Group C|patients will receive intrathecal anaesthesia with morphine without other intervention
62717253|NCT00602693|EXPERIMENTAL|UCB post-transplant Treg Cell Infusion|Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.
62717254|NCT05778656|EXPERIMENTAL|Mediterranean diet without red and/or processed meat|They will receive motivation and behavioral support through a study specific website which will be accessed after randomization. The research team will give participants further information on the use of this website. One of the features of the website will allow participants to collect and self-monitor their dietary intakes using 24h dietary recalls. Participants will be instructed to fill in as many recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. Other features of the website include specific indications to eliminate red and processed meat in the context of a healthy Mediterranean dietary pattern, considering the key elements proposed in the dietary guidelines to improve cardiovascular health. The website will also provide them general information about the Mediterranean diet, as well as recipes, tips, and alternatives to replace meat when cooking at home or eating out. The rest of the clinical care will be as usual.
62717255|NCT05778656|NO_INTERVENTION|General advice based on the Mediterranean diet|The control group will be guided to use the same website although they will only have access to a restricted version of it, with the dietary recall feature plus general information about the Mediterranean diet. They will not receive specific recommendations to reduce red and processed meat or any other support or advice. Participants will be instructed to fill in as many 24h dietary recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. The rest of the clinical care will be as usual.
62717256|NCT02719392|ACTIVE_COMPARATOR|Minocycline|Patients in the minocycline group will take 1 minocycline (100mg) and 2 NAC placebo capsules in the morning and 1 minocycline (100mg) and 2 NAC placebo capsules in the evening for a total of 6 capsules per day over the course of the study.
62717257|NCT02719392|ACTIVE_COMPARATOR|N-acetylcysteine|Patients in the NAC group will take 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the morning and 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
62717258|NCT02719392|ACTIVE_COMPARATOR|Minocycline + N-acetylcysteine|Patients in the minocycline NAC combination group will take 2 NAC (500mg) and 1 minocycline (100mg) capsule in the morning and 2 NAC (500mg) and 1 minocycline (100mg) capsule in the evening for a total of 6 capsules per day over the course of the study.
62717259|NCT02719392|PLACEBO_COMPARATOR|Placebo Control|Patients in the placebo control group will take 2 NAC placebo capsules and 1 minocycline placebo capsule in the morning and 2 NAC placebo capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
62717260|NCT06592911|NO_INTERVENTION|CONTROL|1 session of speech and reading therapy weekly, no use of the medical device Poppins Clinical
62717261|NCT06592911|EXPERIMENTAL|EXPERIMENTAL|Reduced speech and reading therapy sessions (1 session every 2 weeks) and use of the medical device Poppins Clinical
62717262|NCT02116179|EXPERIMENTAL|DVD Intervention|DVD Intervention presented at one 90 minute group session
62717263|NCT02116179|NO_INTERVENTION|Wait list Control Group|Group will get no intervention until after 90 day follow up
62717264|NCT04849637|EXPERIMENTAL|Standard of care plus adjunctive virgin coconut oil supplementation|Standard of care plus virgin coconut oil
62717265|NCT04849637|NO_INTERVENTION|COVID-19 Standard of care treatment|Standard of care
62717266|NCT00708409||1|Autograft operations with the subcoronary technique
62717267|NCT00708409||2|Autograft operations with the root replacement technique
62717268|NCT01605357|ACTIVE_COMPARATOR|Standard Care|Patients will be managed to maintain a goal serum sodium of \> 135 mmol/L , a well recognized value in the management of severe traumatic brain injury.
62717269|NCT01605357|EXPERIMENTAL|Induced Hypernatremia|Patients will be treated with induced, sustained hypernatremia for 5 days following injury by using hypertonic saline to target a goal serum sodium of 150-160 mmol/L
62717270|NCT06203210|EXPERIMENTAL|Ifinatamab deruxtecan (I-DXd)|Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the protocol.
62717271|NCT06203210|ACTIVE_COMPARATOR|Treatment of Physician's Choice (TPC)|Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criterion is met as specified in the protocol.
62717272|NCT03568812|EXPERIMENTAL|Probiotics Rillus®|Rillus®, Chewing tablet containing viable cell 1.0 x 10\^9 colony forming unit (Lactobacillus plantarum 8.55 mg, Streptococcus thermophilus 8.55 mg, Bifidobacterium bifidum 2.55 mg, fructooligosaccharide 480 mg), isomalt, xylitol, milk flavour, vanilla flavour Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
62717273|NCT03568812|PLACEBO_COMPARATOR|Placebo|Placebo: Chewing tablet with identical flavour, colour, smell, and size as investigational drug Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
62717274|NCT05145413|EXPERIMENTAL|Drug: KarXT|
62717275|NCT05145413|PLACEBO_COMPARATOR|Placebo|
62717276|NCT02388906|EXPERIMENTAL|Ipilimumab and Placebo matching Nivolumab|
62717277|NCT02388906|EXPERIMENTAL|Nivolumab and Placebo matching Ipilimumab|
62717278|NCT01334918|EXPERIMENTAL|Single Photon Emission Computed Tomography (SPECT)|"Resting SPECT imaging was performed prior to regadenoson stress SPECT~imaging. Imaging was conducted with one of two radiotracers (99mTc sestamibi or tetrofosmin). Regadenoson 0.4 mg was administered prior to stress SPECT as a single bolus injection."
62717279|NCT01334918|EXPERIMENTAL|Multidetector Computed Tomography (MDCT)|Multidetector Computed Tomography (MDCT), composed of CCTA and regadenoson CTP. Regadenoson stress CTP was performed prior to rest CCTA/CTP imaging. Regadenoson 0.4 mg was administered prior to stress CTP as a single bolus injection. The rest CCTA/CTP was performed at least 30 minutes after completion of the stress CTP, after resolution of any symptoms brought on by the regadenoson infusion and after the participant's heart rate had returned to baseline.
62717280|NCT01402869|EXPERIMENTAL|Prilocaine|30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
62717281|NCT01402869|EXPERIMENTAL|Lidocaine|30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
62717282|NCT01402869|NO_INTERVENTION|No local anesthetic|30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control
62717283|NCT02793583|EXPERIMENTAL|Umbralisib + Ublituximab|Umbralisib oral daily dose in combination with Ublituximab intravenous administration
62717284|NCT02793583|EXPERIMENTAL|Umbralisib|Umbralisib oral daily dose
62717285|NCT02793583|EXPERIMENTAL|Umbralisib + Ublituximab + Bendamustine|Umbralisib oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration
62717286|NCT03983447|EXPERIMENTAL|School-based intervention to promote Physical Activity (PA)|"This intervention included :~1. Physical (Environmental) adaptation of playground~2. Time adaptation of lunch breaks~3. Curriculum-based program of children~4. Workshops and newsletters for parents~5. Meetings for teachers"
62717287|NCT03983447|NO_INTERVENTION|Control|Nothing has changed in the school.
62717288|NCT05547412||Cohort X|Phase 0 will include up to 20 subjects in Cohort X (TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
62717289|NCT05547412||Cohort Y|Phase 0 will include up to 20 subjects in Cohort Y (No TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
62717290|NCT05547412||Cohort A|Both Phase 1 and Phase 2 of the study will enroll Cohort A (LVO TCD). Cohort A will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
62717291|NCT05547412||Cohort B|Both Phase 1 and Phase 2 of the study will enroll Cohort B (Non-LVO TCD). Cohort B will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
62164908|NCT05020886||Stroke|
62164909|NCT06393712|EXPERIMENTAL|ALN-APP|Participants will be administered multiple doses of ALN-APP during the double-blind treatment period and optional open-label extension period.
62543531|NCT01859910|EXPERIMENTAL|compression|compression and scrub of lid margin for 5 circles before cataract surgery
62543532|NCT01859910|ACTIVE_COMPARATOR|control|no compression or scrub of lid margin
62717292|NCT05547412||Cohort C|Both Phase 1 and Phase 2 of the study will enroll Cohort C (LVO No-TCD). Cohort C will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
62717293|NCT05547412||Cohort D|Both Phase 1 and Phase 2 of the study will enroll Cohort D (Non-LVO No-TCD). Cohort D will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
62717294|NCT04884607|EXPERIMENTAL|Study group|Study group will receive subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes.
62717295|NCT02705092|EXPERIMENTAL|Subliminal priming with subliminal reward stimuli|"This intervention consisted of five presentations \[three cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal priming (displayed for 17 ms), and positive words as subliminal reward (displayed for 17 ms)\].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
62717296|NCT02705092|EXPERIMENTAL|Subliminal priming with supraliminal reward stimuli|"This intervention consisted of four presentations \[two cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal prime (displayed for 17 ms), and positive words as supraliminal reward (displayed for 150 ms)\].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
62717297|NCT02592421|ACTIVE_COMPARATOR|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
62717298|NCT02592421|PLACEBO_COMPARATOR|Placebo|10 subjects will receive placebo
62717299|NCT05988736|EXPERIMENTAL|Group A|
62717300|NCT05988736|ACTIVE_COMPARATOR|Group B|
62717301|NCT01098747|EXPERIMENTAL|Treatment A|
62717302|NCT01098747|ACTIVE_COMPARATOR|Treatment B|
62717303|NCT01098747|ACTIVE_COMPARATOR|Treatment C|
62717304|NCT01098747|PLACEBO_COMPARATOR|Treatment D|
62717305|NCT05887791|EXPERIMENTAL|Collagen hydrolysate dose 1|Source: porcine; standardized to 10 g provided as single dose. Orally applied in flavoured water.
62717306|NCT05887791|EXPERIMENTAL|Collagen hydrolysate dose 2|Source: porcine; standardized to 5 g provided as single dose. Orally applied in flavoured water.
62717307|NCT05887791|PLACEBO_COMPARATOR|Placebo|Flavoured water
62717308|NCT00615576|EXPERIMENTAL|Subjects receiving SB-656933|Eligible subjects will be randomized to receive once daily doses of 100 milligrams of SB- 656933 for 14 days.
62717309|NCT00615576|PLACEBO_COMPARATOR|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 14 days.
62717310|NCT03997864|ACTIVE_COMPARATOR|Treatment - prazosin|Participants randomized to this group will receive the medication prazosin.
62717311|NCT03997864|PLACEBO_COMPARATOR|Control - placebo|Participants randomized to this group will receive placebo .
62717312|NCT06718114|EXPERIMENTAL|immediate removal of urinary catheter|The urinary catheter will be removed immediately after surgery.
62717313|NCT06718114|OTHER|early removal of urinary catheter|The urinary catheter will be kept after surgery and be removed within 48 hours after surgery.
62717314|NCT01058252||Letrozole, recFSH, INVOCell, Monitoring|Infertile couple following MSP with INVO IVF
62717315|NCT02422979|EXPERIMENTAL|PART 1 - Cohort 1|3-6 patients
62717316|NCT02422979|EXPERIMENTAL|PART 1 - Cohort 2|3-6 patients
62717317|NCT02422979|EXPERIMENTAL|PART 1 - Cohort 3|3-6 patients
62717318|NCT02422979|EXPERIMENTAL|PART 2 - Cohort 1|Number of patients depend on Part 1
62717319|NCT02422979|EXPERIMENTAL|PART 2 - Cohort 2|Number of patients depend on Part 1
62543533|NCT04554940|EXPERIMENTAL|Vosoritide + Standard of Care|Standard of Care treatment for cervicomedullary compression and once daily subcutaneous injection of recommended dose of vosoritide based on weight-band dosing.
62717320|NCT02422979|EXPERIMENTAL|PART 3|Up to 30 patients
62717321|NCT00038844|EXPERIMENTAL|Campath in Nonmyeloablative Transplantation|Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.
62717322|NCT06262438|EXPERIMENTAL|Quizartinib|Quizartinib will be administered for 14 days following the completion of standard of care chemotherapy for up to 3-5 cycles of induction and consolidation. After high dose chemotherapy or allo-Stem Cell Transplantation (allo-SCT), patients will receive continuation treatment with quizartinib for six 28-day courses
62717323|NCT03563092|EXPERIMENTAL|Lap Inguinal Hernia repair with Drain|A (14 French sizes) closed suction drain will be placed in preperitoneal space after laparoscopic inguinal hernia (TEP/TAPP) surgery.
62717324|NCT03563092|ACTIVE_COMPARATOR|Lap Inguinal Hernia repair without Drain|No drain will be placed after laparoscopic inguinal hernia (TEP/TAPP) surgery.
62717325|NCT04000061||acute coronary syndrome (ACS)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed.
62717326|NCT04000061||acute heart failure (AHF)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed.
62717327|NCT06121648|EXPERIMENTAL|Water Group|Static and dynamic balance, breathing, combined breathing and movement activities.
62717328|NCT06121648|ACTIVE_COMPARATOR|Land Group|Intervention program focused on balance and gait.
62717329|NCT06483854|NO_INTERVENTION|Standard of Care|people who receive HIV testing in this arm through standard programs provided by clinics.
62717330|NCT06483854|EXPERIMENTAL|Healer-provided|Traditional healers will provide HIV counseling and testing services to their clients
62717331|NCT04781816|EXPERIMENTAL|SAR443122|SAR443122 for 12 weeks
62543534|NCT04554940|NO_INTERVENTION|Standard of Care Alone|Institutional standard of care monitoring and treatment for cervicomedullary compression
62543535|NCT06067503|EXPERIMENTAL|Participants with ER/PR+ metastatic lobular breast cancer (LBC)|
62717332|NCT04781816|PLACEBO_COMPARATOR|Placebo|Matching placebo
62717333|NCT03015493|EXPERIMENTAL|Neural mobilization and traction|Patients in this group are treated with neural mobilization techniques combined with cervical traction
62717334|NCT03015493|EXPERIMENTAL|Traction group|Patients in this group are treated with cervical traction
62717335|NCT03015493|NO_INTERVENTION|Control group|Patients in this group comprise the control group and are not treated with any intervention
62717336|NCT06005987|EXPERIMENTAL|Mobile App arm|Patient will input their daily blood glucose levels (fasting and 2 hours after breakfast, lunch and dinner) into the OneTouch Reveal app
62717337|NCT06005987|NO_INTERVENTION|Paper Log Arm|Patients will input their daily blood glucose levels onto paper logs which is the current process in the prenatal clinic.
62717338|NCT04095052|EXPERIMENTAL|Methyl Folate|Participants will receive a capsule containing 1,000 mcg methyl folate and microcrystalline cellulose orally once per day for 15 days.
62717339|NCT04095052|PLACEBO_COMPARATOR|Placebo|Participants will receive a microcrystalline cellulose capsule orally once per day for 15 days.
62717340|NCT06716268||Twenty healthy female university students|They will be selected from the faculty of physical therapy ,Cairo university
62717341|NCT05914194|EXPERIMENTAL|NLS-2|Participants will receive a single NLS-2 tablet orally once daily from Day 1 to Day 56 (until the end of Week 8).
62717342|NCT05914194|PLACEBO_COMPARATOR|Placebo|Participants will receive a single NLS-2 placebo matching tablet orally once daily from Day 1 to Day 56 (until the end of Week 8).
62717343|NCT03343561|NO_INTERVENTION|Control|Subjects would have subjects' own diet as usual
62717344|NCT03343561|EXPERIMENTAL|Intervention diet 1|Nutrition advice will be given to subjects to consume a healthy diet and select food with Polyunsaturated fatty acids like fish and nuts to replace subjects' own food in high fat
62717345|NCT03343561|EXPERIMENTAL|Intervention diet 2|Nutrition advice will be given to subjects to consume a healthy diet and select food with whole grains to replace subjects own food in carbohydrate
62717346|NCT03343561|EXPERIMENTAL|Intervention diet 3|Nutrition advice will be given to subjects to consume a healthy diet and select food with healthy choices in fat and carbohydrate to replace subjects' own food choice
62543536|NCT06633380|EXPERIMENTAL|Standard Physical Activity - Fasted|Participants will perform 30 minutes of walking at a self-selected pace 15 minutes prior to consumption of first meal in the morning (including cream/sugar/milk in coffee or tea).
62543537|NCT06633380|EXPERIMENTAL|Standard Physical Activity - Post-Meal|Participants will perform 30 minutes of walking at a self-selected pace 30 minutes after the start of the first meal in the morning.
62543538|NCT06633380|EXPERIMENTAL|Dispersed Physical Activity|Participants will perform 10 minutes of walking at a self-selected pace 30 minutes after the start of each main meal throughout the day (i.e., three bouts total).
62543539|NCT06633380|EXPERIMENTAL|Physical Activity Snacks|Participants will perform 2 minutes of walking or marching on the spot at a self-selected pace every 30 minutes throughout the day for 7.5 waking hours.
62543540|NCT06633380|EXPERIMENTAL|Muscle Strengthening|Participants will perform 30 minutes of muscle strengthening exercises targeting the major muscle groups of the whole body performed by following along with a video, to start 30 minutes after the start of the first meal in the morning.
62543541|NCT02698033||Low dose challenge passed|Individuals who tolerated without dose limiting symptoms the screening food challenge for a parent interventional trial
62543542|NCT01587170||Uninjured control subjects|Uninjured, control subjects who are not taking any of the contraindicated drugs.
62543543|NCT01587170||Spinal-cord injured subjects|Patients who have suffered a spinal cord injury (\>1year ago).
62543544|NCT03443830|EXPERIMENTAL|0.2 mg/kg|Subject will be administered with 0.2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62543545|NCT03443830|EXPERIMENTAL|0.5 mg/kg|Subject will be administered with 0.5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62543546|NCT03443830|EXPERIMENTAL|1 mg/kg|Subject will be administered with 1 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62543547|NCT03443830|EXPERIMENTAL|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62543548|NCT03443830|EXPERIMENTAL|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62543549|NCT03443830|EXPERIMENTAL|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
62543550|NCT06633120|EXPERIMENTAL|Biphasic IVM Treatment|Biphasic IVM of oocytes
62543551|NCT02679638||Kaplan Hospital|Breast cancer survivors recruited at the Kaplan Medical Center
62543552|NCT02679638||Rambam Hospital|Breast cancer survivors recruited at the Rambam Medical Center
62543553|NCT02679638||Sheba|Breast cancer survivors recruited at the Sheba Medical Center
62543554|NCT02679638||Barzilai|Breast cancer survivors recruited at the Barzilai Medical Center
62543555|NCT02237703||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
62543556|NCT02237703||Trauma Control (TC)|Trauma Control (TC)
62543557|NCT02237703||Healthy Control (HC)|Healthy Control (HC)
62543558|NCT06418516|EXPERIMENTAL|Capsule-sponge|"This part of the study will have an active prospective recruitment of patients. Recruitment will involve three patient populations:~1. Patients with ESCC~2. Patients at high risk for ESCC~3. Healthy controls~Following inclusion in the study, subjects will be asked to complete a behavior questionnaire, have blood collected, and undergo a capsule-sponge procedure followed by diagnostic gastroscopy using advanced imaging with biopsies. During gastroscopy, additional tissue samples will be collected for research purposes. These samples, along with cytological specimens from the capsule-sponge, will be analyzed to assess the diagnostic accuracy of biomarkers in the diagnosis of esophageal squamous neoplasia."
62543559|NCT01740050|ACTIVE_COMPARATOR|Roux- and Y bypas surgery (RYGB)|"One subject group will lose 10% of initial body weight using RYGB. RYGB is an operation that first divides the stomach into a small upper pouch and a much larger lower remnant pouch and then re-arranges the small intestine to connect to both, in this way bypassing part of the small intestine."
62543560|NCT01740050|ACTIVE_COMPARATOR|Laparoscopic adjustable gastric banding (LAGB)|One subject group will lose 10% of initial body weight using LAGB. With LAGB an inflatable band is placed around the upper part of the stomach to create a smaller stomach pouch. This slows and limits the amount of food that can be consumed at one time giving the opportunity for the sense of satiety to be met. It does not decrease gastric emptying time.
62543561|NCT01740050|ACTIVE_COMPARATOR|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
62543562|NCT01791270||OSA versus Control subjects.|sleep apnea-hypopnea syndrome and control
61978164|NCT02402543|EXPERIMENTAL|Experimental Arm|In pre-op, the subject is administered four pills PO containing a total of 1000 mg of acetaminophen and 600 mg of gabapentin, which are matched in color, size, and shape to the placebo pills.
62543563|NCT01791270||OSA patients before and after treatment, CPAP|Continuous positive pressure CPAP
62543564|NCT06467110|EXPERIMENTAL|transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)|The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
62543565|NCT00998868||hemiplegia|patients with hemiplegia, without other musculoskeletal disorders of the shoulder
62543566|NCT04322565|EXPERIMENTAL|Colchicine|Administration of Colchicine 1mg (or 0.5 mg in CKD)/day + standard of care for COVID-19 pneumonia
62543567|NCT04322565|NO_INTERVENTION|Standard of care|Standard of care for COVID-19 pneumonia
62543568|NCT00555152|EXPERIMENTAL|Arm I (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
62543569|NCT00555152|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
62543570|NCT00754546|ACTIVE_COMPARATOR|Arformoterol tartrate|Bronchodilator therapy with arformoterol solution 15 mcg
62717347|NCT04276025||German cohort Bayreuth|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
62717348|NCT04276025||German cohort Hof|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
62717349|NCT04276025||Chinese cohort Beijing|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
62717350|NCT04163939|EXPERIMENTAL|Collar|This group will wear a cervical collar for at least 30 minutes per day, 5 out of 7 days of the week
62717351|NCT04163939|PLACEBO_COMPARATOR|Control|This group will not wear the cervical collar
62717352|NCT05685784|EXPERIMENTAL|Healthy volunteer|"* 20 Healthy volunteers required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots~* 15 Non-MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots"
62717353|NCT05685784|EXPERIMENTAL|People with MS|"* 20 patients with MS required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots~* 15 MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots"
62717354|NCT02717650|EXPERIMENTAL|A-STEP|Study A) A-STEP Study Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).
62717355|NCT02717650|EXPERIMENTAL|A-STEP (New Protocol)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
62717356|NCT02717650|ACTIVE_COMPARATOR|CPET cycle ergometer (Gold Standard)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
62717357|NCT04919434|OTHER|Intervention|Women will be asked NOT to use their own personal care product during the intervention. They will only have to use the substitute one given by the research team
62717358|NCT03041935|ACTIVE_COMPARATOR|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
62717359|NCT03041935|EXPERIMENTAL|Ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
62717360|NCT02255019||IBD, CD, UC|All patients should either have a known IBD diagnose or suspect of having IBD.
62717361|NCT05225909||Patients who Undergo ERCP procedure with aScope|This will be patients who undergo ERCP procedure using aScope.
62717362|NCT06219252|EXPERIMENTAL|ORA group|the intraocular lens calculation in this group will be optimized by the intraoperative aberrometer (ORA)
62717363|NCT06219252|ACTIVE_COMPARATOR|Control group|Barrett universal II will be used in the control group.
62717364|NCT03390725|EXPERIMENTAL|A Healthy School Start Plus intervention|The intervention consists of 4 components given to all participants in the experimental group: 1) A health information brochure regarding child's health; 2) Motivational Interviewing with the parents by the school nurse concerning the child; 3) classroom activities for the children with home assignments; and 4) a web-based self-test of type-2 diabetes risk by parents with recommendation to contact primary health care in case of elevated risk.
62717365|NCT03390725|ACTIVE_COMPARATOR|Control|Treatment as usual in school health services plus the health information brochure regarding child's health (component 1 of the intervention)
62717366|NCT04616937|ACTIVE_COMPARATOR|Galacto-oligosaccharides (GOS) Group|Daily dose of GOS over 4 weeks
62717367|NCT04616937|PLACEBO_COMPARATOR|Placebo group|Daily dose of maltodextrin over 4 weeks
62717368|NCT05600413|EXPERIMENTAL|L-Citrulline|L-Citrulline: 6 grams/day
62717369|NCT05600413|PLACEBO_COMPARATOR|Placebo|Crystalline Cellulose
62717370|NCT00467376|EXPERIMENTAL|1|Administration of Insulin Glulisine
62717371|NCT00467376|ACTIVE_COMPARATOR|2|Administration of Lispro
62717372|NCT06333548||Appropriate for gestational age|Appropriate for gestational age
62717373|NCT06333548||small for gestational age|small for gestational age
62717374|NCT06333548||large for gestational age|large for gestational age
62717375|NCT06333548||Baby of mother diagnosed with GDM|Baby of mother diagnosed with gestational diabetes mellitus
62717376|NCT00682149|PLACEBO_COMPARATOR|Group 1|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
62717377|NCT00682149|ACTIVE_COMPARATOR|Group 2|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
62717378|NCT05522738|EXPERIMENTAL|study group|Fruquintinib combined with FOLFIRI
62717379|NCT01015521|EXPERIMENTAL|Aminoflavone Prodrug|Aminoflavone to treat ER positive breast cancer patients
62717380|NCT01015521|EXPERIMENTAL|Aminoflavone Prodrug with pretreatment|Aminoflavone Prodrug to treat Triple Negative Breast Cancer
62717381|NCT00608062|EXPERIMENTAL|Pre1|Premenopausal - GnRHant plus estradiol
62717382|NCT00608062|PLACEBO_COMPARATOR|Pre2|Premenopausal - GnRHant plus placebo
62717383|NCT00608062|EXPERIMENTAL|Peri1|Perimenopausal (early) - GnRHant plus estradiol
62717384|NCT00608062|PLACEBO_COMPARATOR|Peri2|Perimenopausal (early) - GnRHant plus placebo
62717385|NCT00608062|EXPERIMENTAL|Peri3|Perimenopausal (late) - GnRHant plus estradiol
62717386|NCT00608062|PLACEBO_COMPARATOR|Peri4|Perimenopausal (late) - GnRHant plus placebo
62717387|NCT00608062|EXPERIMENTAL|Post1|Postmenopausal - GnRHant plus estradiol
62717388|NCT00608062|PLACEBO_COMPARATOR|Post2|Postmenopausal - GnRHant plus placebo
62717389|NCT02999009|OTHER|Trident II Tritanium Acetabular Shell|
62717390|NCT01069913|ACTIVE_COMPARATOR|BG00012|BG00012 Standard Formulation
62717391|NCT01069913|ACTIVE_COMPARATOR|BG00012 API|BG00012 API
62717392|NCT03539757||Fontan patients|Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.
62717393|NCT03507127|ACTIVE_COMPARATOR|Varenicline|
62717394|NCT03507127|PLACEBO_COMPARATOR|Placebo|
62717395|NCT00693888|EXPERIMENTAL|interventional group|individual comprehensive primary advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
62717396|NCT00693888|NO_INTERVENTION|Control group|only informative flyer, no further advice in any direction
62717397|NCT05341310|EXPERIMENTAL|ADHDCoach|Participants in the experimental group will have access to an individually-tailored Internet intervention developed for the present study. The intervention in clinician-guided and it consists of nine modules delivered for four weeks. The Internet Intervention, called ADHDCoach, is based on an existent Behavioral Parent training protocol, an intervention that was previously tested in a randomized controlled trial with Romanian children. The contents for parent modules were developed according to Rational Emotive and Behavioral Therapy.
62717398|NCT05341310|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual at the outpatient clinic
62717399|NCT05272189|EXPERIMENTAL|Experiment|All participants are tested in all conditions of this experiment.
62717400|NCT02224534|EXPERIMENTAL|Ticagrelor and Clopidogrel.|The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
62717401|NCT02224534|ACTIVE_COMPARATOR|Clopidogrel|The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
62717402|NCT02196753||CIED related infection|"All patients will undergo standard diagnostic process that will consist of: medical interview, physical examination, laboratory tests, blood cultures (3 sets, 1 hour apart, repeated after 24 hours and -if applicable - with fever peak above 38°C); imaging studies (echocardiography: transthoracic, and if there are no contraindications transesophageal, in case of negative or equivocal result repeated after 7-10 days, or in series if necessary, computed tomography scan for pulmonary embolism if indicated); if there are abnormalities in other systems, decisions concerning further diagnostics will be made by the physician in charge.~Apart from standard diagnostic procedures patients will undergo whole body PET CT scan to localize infection or inflammation.~Then the investigators team will make a decision concerning further treatment (antibiotics and complete device removal vs conservative treatment)."
62717403|NCT02196753||Non-infective|Control group consisting of 20 pts with implanted CIEDs who underwent PET CT due to non infectious indications and have no data for infectious process in follow-up
62717404|NCT03670108||patients receiving an individualized SMS|
62717405|NCT03670108||patients receiving a standard SMS|
62717406|NCT04235543||autistic children aged 6:12 years|show the occurrance of traumatic dental injury compared to normal children
62717407|NCT04235543||normal children aged 6:12 years|show the occurrance of traumatic dental injury
62717408|NCT02015403|EXPERIMENTAL|Standard Care + NAC (N-ACETYLCYSTEINE) infusion|
62717409|NCT02015403|ACTIVE_COMPARATOR|Standard Care|
62717410|NCT06717581||people with HIV (PLWH) aged 60 years and older|people with HIV (PLWH) aged 60 years and older on stable antiretroviral therapy who switch to bictegravir/tenofovir alafenamide/emtricitabine.
62717411|NCT02965638|ACTIVE_COMPARATOR|Oxygen Group|The mothers will be asked to be on 4 liter of oxygen through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
62717412|NCT02965638|NO_INTERVENTION|Control Group|These mothers will not undergo CMH therapy
62717413|NCT05162690|ACTIVE_COMPARATOR|The Drug Arm|"Dapagliflozin 10 milligram Once a day~1 year"
62717414|NCT05162690|PLACEBO_COMPARATOR|The Placebo Arm|Metformin 1gram Per Oral Twice a day Glimepiride 2 milligram oral twice a day Dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors)
62717415|NCT06716762||Open Surgery Group, OSG|This group consists of pediatric patients diagnosed with congenital choledochal cyst (CCC) who underwent open surgery, which involved open cyst excision and Roux-en-Y hepaticojejunostomy. A total of 60 patients were assigned to this group.
62717416|NCT06716762||Laparoscopic Surgery Group, LSG|This group includes pediatric patients diagnosed with CCC who underwent laparoscopic surgery, which involved laparoscopic cyst excision and Roux-en-Y hepaticojejunostomy. A total of 12 patients were assigned to this group.
62717417|NCT01824290|EXPERIMENTAL|Tadalafil|"Period 1: 20 mg or 40 mg administered orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final tadalafil doses for Period 1 (6-month double-blind) were assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431).Tadalafil doses would range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to \<40 kg: administered orally by tablets once a day. Light weight cohort \<25 kg: administered orally by suspension once a day.~Participants receiving tadalafil in Period 1 continued to receive tadalafil during Period 2 (2-year open-label extension)."
62735877|NCT03877614||Cardiovascular high-risk (disease) group|A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
61978165|NCT00988455|EXPERIMENTAL|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
62717418|NCT01824290|PLACEBO_COMPARATOR|Placebo|"Period 1: Participants received placebo orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final placebo dose for Period 1 (6-month double-blind) was be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort.~Participants receiving placebo in Period 1 Period 2 (2-year open-label extension) would receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group."
62717419|NCT02562781|ACTIVE_COMPARATOR|Supplemental Oxygen|Inspired oxygen fraction \> 0.5 and SpO2 = 98-100%
62717420|NCT02562781|EXPERIMENTAL|Air or supplemental oxygen|Air or lowest possible inspired concentration of oxygen to maintain SpO2 \> 90%
62717421|NCT04592341|EXPERIMENTAL|Gantenerumab|Participants will receive gantenerumab by subcutaneous (SC) injection at a dose of 120 mg every 4 weeks (Q4W) for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg every 2 weeks (Q2W) for another 12 weeks, followed by the target dose 255 mg once weekly (Q1W) for up to Week 103. Participants who complete Week 104 visit will be given an option to take part in 2-year extension of the study to receive gantenerumab 255 mg Q1W for up to Week 207.
62717422|NCT01085526|ACTIVE_COMPARATOR|alutard phl prat. treatment group|18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
62717423|NCT01085526|NO_INTERVENTION|control group|control
62717424|NCT01085526|ACTIVE_COMPARATOR|alutard phl.prat., treatment group2|basophil activity, basophil biology measured
62717425|NCT01852643|ACTIVE_COMPARATOR|Spreader graft|
62717426|NCT01852643|ACTIVE_COMPARATOR|Lateral crural overlay|
62717427|NCT01606579|EXPERIMENTAL|Part I|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
62717428|NCT01606579|EXPERIMENTAL|Part II|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
62717429|NCT01606579|EXPERIMENTAL|Part III Arm A|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age."
62717430|NCT01606579|EXPERIMENTAL|Part III Arm B|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC."
62717431|NCT01606579|EXPERIMENTAL|Part III Arm C|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP."
62717432|NCT02761642|EXPERIMENTAL|Epoetin Beta|Anemic breast cancer participants will receive epoetin beta treatment for 12 weeks.
62717433|NCT06715553|EXPERIMENTAL|Interventional group|"Participants will be randomly assigned to the intervention group~Six types of intervention will be done on the patients as follows:~* Psychoeducational intervention program prepared and will be applied by a psychologist~* Art therapy program will be done by a psychologist~* Bibliotherapy program will be done by a neuroscience person~* Nutrition program will be done a nutritionist~* Sport activity will be held by a physical trainee~* Ping Pong activity will be done by a ping pong trainer"
62717434|NCT06715553|NO_INTERVENTION|Control Group|This group will follow the standard care provided by the hospital without any type of intervention
62717435|NCT02404714||CF/CRMS|"Subject's with a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis will receive the institution's standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
62717436|NCT02404714||NON CF/CRMS|"Subject's without a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis but referred to the sweat test lab on a clinical observation basis by a physician will receive standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
62717437|NCT05042206|EXPERIMENTAL|Cellgram-CKD|"Subjects receive a safety evaluation at 1 month, 3 months, 6 months, 9 months and 12 months after intravenous infusion of Cellgram-CKD 10mL at intervals of 2 weeks (14 days) 3 times.~In the case of Cellgram-CKD, a milky white cell suspension solution is filled in a colorless and transparent plastic syringe, and the syringe tip is fixed with an obturator."
62717438|NCT04179110|EXPERIMENTAL|Pembrolizumab and Ramucirumab|Patients with progressive transitional cell carcinoma after treatment with an immune checkpoint inhibitor will receive Pembrolizumab and Ramucirumab.
62717439|NCT06717984||Women who undergo biopsy for suspected abnormal cell growth in the breast|"The cohort includes women who have undergone a biopsy due to suspected abnormal cell growth in the breast. This cohort captures a wide range of potential diagnoses, including benign conditions, noninvasive (in situ) breast cancers, and invasive breast cancers. All participants have histopathological samples collected for analysis, which serve as the basis for determining the presence and type of abnormal cell growth. The cohort will be studied using deep learning techniques to classify the biopsy samples into specific categories (normal, benign, in situ, or invasive), with the goal of improving diagnostic accuracy and efficiency in detecting breast cancer.~By focusing on women undergoing biopsy, this study aims to address the diagnostic challenges faced in distinguishing between various breast tissue abnormalities, contributing to earlier detection and better clinical outcomes."
62717440|NCT04384614||COVID (+)|Patients COVID19(+) confirmed by PCR
62717441|NCT04384614||COVID (-)|Patients COVID19 (-) who had been in contact with COVID-19 (+) confirmed by PCR
62164910|NCT06393712|PLACEBO_COMPARATOR|Placebo/ALN-APP|Participants will be administered multiple doses of placebo during the double-blind treatment period. Participants who continue into the optional open-label extension period will be administered multiple doses of ALN-APP.
62543571|NCT00754546|PLACEBO_COMPARATOR|Normal saline|Placebo using normal saline
62717442|NCT05128565||Females under 40|females from 18 years old to 40 years old
62164911|NCT01953406|EXPERIMENTAL|The 5-fluorouracil/mitomycin group|Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
62164912|NCT02713698||Group 1 (≥18 years, BMI<35kg/m2)|Patients with 18 or more years presenting for inpatient nose and ear surgery.
62543572|NCT06571513|EXPERIMENTAL|Written Exposure Therapy|Five sessions of remotely-delivered written exposure therapy.
62543573|NCT06571513|PLACEBO_COMPARATOR|Unemotional Writing|Five sessions of remotely-delivered non-emotional writing.
62543574|NCT06173856|ACTIVE_COMPARATOR|Phototherapy group|LED phototherapy (430-470nm)
62543575|NCT06173856|EXPERIMENTAL|phototherapy with probiotics group|In group B, LED phototherapy (430-470nm) with probiotics (125mg Saccharomyces boulardii, twice a day, orally mixed in 5cc of milk whichever the neonate is taking).
62543576|NCT01708967|EXPERIMENTAL|Catheter-free method|"We explored success rate, side effects, and vital signs in patients with catether-free method.~Intervention: one-time spray of epinephrine (1cc) plus 4% lidocaine (4cc)"
62543577|NCT01708967|EXPERIMENTAL|Catheter insertion method|We explored success rate, side effects, and vital signs in patients with catether insertion method : use both spray and catheter
62543578|NCT02803658|EXPERIMENTAL|infertile couples|smoking behavior
62543579|NCT02803658|ACTIVE_COMPARATOR|Fertile couples|smoking behavior
62543580|NCT04817020|EXPERIMENTAL|Klorheksidin|
62543581|NCT04817020|EXPERIMENTAL|Alchol|
62543582|NCT02483546|EXPERIMENTAL|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
62543583|NCT02483546|ACTIVE_COMPARATOR|traditionally teaching|students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
62543584|NCT04533997|ACTIVE_COMPARATOR|Intravenous furosemide|
62543585|NCT04533997|EXPERIMENTAL|Hypertonic saline solution plus intravenous furosemide|
62543586|NCT06006377|ACTIVE_COMPARATOR|conventional|conventional physiotherapy methods
62543587|NCT06006377|EXPERIMENTAL|backup|Physiotherapy applied with backup device
62543588|NCT02478203|PLACEBO_COMPARATOR|normal|intubation of a normal airway pediatric manikin with direct laryngoscopy, airtraq , glidescope
62543589|NCT02478203|ACTIVE_COMPARATOR|tongue edema|intubation of a tongue edema simulated pediatric manikin with diract laryngoscopy, glidescope and airtraq
62543590|NCT02478203|ACTIVE_COMPARATOR|face-to-face intubation|intubation of an entrapped pediatric manikin with diract laryngoscopy, glidescope and airtraq
62543591|NCT04032717|EXPERIMENTAL|Open-label Q-GRFT enema|Open-label Q-GRFT enema administered rectally once as a single dose (Arm 1)
62543592|NCT04032717|EXPERIMENTAL|Randomized, blinded Q-GRFT enema|Blinded Q-GRFT enema administered rectally once as a single dose (Arm 2)
62543593|NCT04032717|PLACEBO_COMPARATOR|Randomized, blinded placebo enema|Blinded placebo enema administered once as a single dose (Arm 3)
62543594|NCT05961501|EXPERIMENTAL|Study Group|Participants with facial pain and headache of muscular origin which last for more than 3 months. Each of the participants in this group will receive the aqueous solution of CBD and CBN to drink in home every day for 60 days in a specific dose determined by the attending physician
62717443|NCT05128565||Males under 40|males from 18 years old to 40 years old
62717444|NCT05128565||Females above 40|females older than 40 years old
62717445|NCT05128565||Males above 40|males older than 40 years old
62717446|NCT02447185|EXPERIMENTAL|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
62164913|NCT02713698||Group 2 (≥18 years, ≥35kg/m2)|Patients with 18 or more years presenting for inpatient bariatric surgery.
62543595|NCT05961501|PLACEBO_COMPARATOR|Control group|Participants with facial pain and headache of muscular origin which last for more than 3 months. Each of the participants in this group will receive the placebo to drink in home every day for 60 days in a specific dose determined by the attending physician
62543596|NCT01692366|EXPERIMENTAL|SAR302503 300mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
62543597|NCT01692366|EXPERIMENTAL|SAR302503 400 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
62543598|NCT01692366|EXPERIMENTAL|SAR302503 500 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
62735878|NCT03877614||Cardiovascular Low-risk (control) group|Patient with only risk factors with ASCVD score\<10% will be recognized as the comparison group
62717447|NCT02447185|ACTIVE_COMPARATOR|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetonide group will receive Triamcinolone Acetonide 4mg/0.1 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
62717448|NCT05434819|EXPERIMENTAL|Surgical Atrial Fibrillation Ablation Group|Surgeon will perform left atrial ablation during patient's cardiac surgery procedure.
62717449|NCT05434819|NO_INTERVENTION|No Surgical Atrial Fibrillation Ablation Group|Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure.
62717450|NCT04868916||Participants with X-Linked Retinitis Pigmentosa (XLRP)|Participants with confirmed diagnosis of XLRP associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR) in the Japanese population will be enrolled in the study and the data will be collected and observed. The primary data source for this study will be the medical records of each participant.
62717451|NCT06718192|ACTIVE_COMPARATOR|Bleomycin Group|
62717452|NCT06718192|OTHER|cryotherapy|
62717453|NCT06719297|EXPERIMENTAL|Personalized cognitive-sensorimotor VR/MR training|Thinking task integrated walking and balance training program
62543599|NCT03977714|EXPERIMENTAL|Group A - test implant and abutment|Zirconia implant and G3-coated abutment (test implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
62543600|NCT03977714|EXPERIMENTAL|Group B - test implant and control abutment|"Zirconia implant and control abutment (test implant, negative control abutment).~Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons."
62543601|NCT03977714|EXPERIMENTAL|Group C - control implant and test abutment|Titanium implant and G3-coated abutment (control implant, test abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
62543602|NCT03977714|ACTIVE_COMPARATOR|Group D - control implant and abutment|Titanium implant and control abutment (negative control implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
62543603|NCT03977714|EXPERIMENTAL|Group E - test and control implants|"Zirconia implant and titanium implant for histological and histomorphometric evaluation.~This study will be performed in the area of the wisdom teeth (a non useful site that will not interfere with the rest of the study or with the patient's life), so it can only be performed in patients who no longer have these teeth. The procedure will match the procedures described for Groups A-B-C-D. Group E implants will only remain in the mouth for 2 months, after which they will be removed for further analysis. The removal of these implants, for the patient, has exactly the same implications as a normal molar extraction."
62543604|NCT05204498|EXPERIMENTAL|Education plan|"Education plan and adherence to exercise Educational talk about the importance of exercise as an important strategy to change dyspnea at the start of the study.~Twice a week, corresponding to the days that do not attend the sessions of pulmonary rehabilitation, calls will be made with a duration of 15 minutes each, in the calls will encourage and guide the practice of physical activity and breathing exercises"
62543605|NCT05204498|NO_INTERVENTION|control|"A survey will be conducted at week 8 of monitoring where adherence to exercise is measured during the 8-week study.~At the end of week 8, patients will be referred to the pulmonary rehabilitation unit in order to evaluate the anthropometric parameters, assess dyspnea with the modified Medical Research Council scale, the hospital anxiety and depression scale, the Saint George respiratory questionnaire, the pulmonary information needs questionnaire and the 6-minute walk test again."
62543606|NCT04362553||Adults|Adults scheduled to receive a TTE (Trans-esophogeal echocardiogram)
62543607|NCT02813980||High SUDEP-7 score|Patients with epilepsy who have a high SUDEP-7 score
62543608|NCT02813980||Low SUDEP-7 score|Patients with epilepsy who have a low SUDEP-7 score
62543609|NCT02296931|ACTIVE_COMPARATOR|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
62717454|NCT06719297|ACTIVE_COMPARATOR|Standard of Care|Standard walking and balance training
62717455|NCT02121509|EXPERIMENTAL|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
62717456|NCT02121509|EXPERIMENTAL|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
62717457|NCT02121509|EXPERIMENTAL|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
62717458|NCT02121509|EXPERIMENTAL|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
62717459|NCT05110573||Laparoscopic pancreatoduodenectomy|Cohort of patients that underwent a Whipple-procedure through a laparoscopic approach.
62717460|NCT05110573||Open pancreatoduodenectomy|Cohort of patients that underwent a Whipple-procedure through a traditional open approach.
62717461|NCT01459666|EXPERIMENTAL|Dysport (abobotulinumtoxinA)|Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry.
62543610|NCT02296931|EXPERIMENTAL|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
62543611|NCT04114487|NO_INTERVENTION|control 1|The control 1 group will not be subjected to any application except education.
62543612|NCT04114487|ACTIVE_COMPARATOR|control 2|The control 2 group will be the control group and will be taken to the balance training in addition to normal education.
62543613|NCT04114487|EXPERIMENTAL|intervention|In theintervention group, dual task balance training will be applied within the scope of cognitive rehabilitation.
62543614|NCT01589497|ACTIVE_COMPARATOR|RHZE-RHZE|Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.
62543615|NCT01589497|ACTIVE_COMPARATOR|RHZE-RZE|Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.
62543616|NCT01589497|ACTIVE_COMPARATOR|RHZE-RMZE|Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.
62543617|NCT01589497|ACTIVE_COMPARATOR|RZE-RZE|Participants were administered only RZE from Day 1 through Day 14.
62543618|NCT00385008|OTHER|Arm 1|open-label active drug
62543619|NCT00385008|OTHER|Arm 2|open-label active drug
62543620|NCT05593419||Immunotherapy Group|
62543621|NCT06434623||patients record|
62543622|NCT03126500||Malnourished|malnourished, geriatrics patients at hospital discharge
62543623|NCT05884684|NO_INTERVENTION|Post-Procedural Images Not Discussed with Participants|"During a lumbar epidural steroid injection under fluoroscopic guidance, images are taken as part of the procedure. Following the procedure, the surgeon who performed it will not discuss the images with the participants in this arm.~If participants request an explanation of the images, they will not be included in the analysis."
62543624|NCT05884684|OTHER|Post-Procedural Images Discussed with Participants|During a lumbar epidural steroid injection under fluoroscopic guidance, images are taken as part of the procedure. Following the procedure, the surgeon who performed it will discuss the images with the participants in this arm.
62543625|NCT01249573|EXPERIMENTAL|fascia therapy|arm where fascia therapy is used as a treatment for an acute ankle distortion
62543626|NCT01249573|EXPERIMENTAL|transcutaneous fibrolysis|arm where transcutaneous fibrolysis is used as a treatment for an acute ankle distortion
62543627|NCT01249573|PLACEBO_COMPARATOR|placebo|arm where placebo therapy is used as a treatment for an acute ankle distortion
62543628|NCT04844944||Heart Failure|Hospitalized patients diagnosed with Heart Failure. No Intervention.
62543629|NCT04844944||Coronary Artery Disease|Hospitalized patients diagnosed with Coronary Artery Disease. No Intervention.
62543630|NCT04844944||Atrial Fibrillation|Hospitalized patients diagnosed with Atrial Fibrillation. No Intervention.
62543631|NCT03249831|EXPERIMENTAL|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.~The minimally manipulated transplant product is manufactured using the CliniMACS device."
62543632|NCT02374138|ACTIVE_COMPARATOR|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
62543633|NCT02374138|EXPERIMENTAL|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
62543634|NCT02304666|EXPERIMENTAL|Crohn disease's Patients|Patients with Crohn disease or presenting an ulcerative colitis
62543635|NCT02304666|OTHER|Control patient|Patients with programmed colonoscopy screening for familial colon cancer history, polyps or for irritbale bowel syndrome
62543636|NCT06570187|EXPERIMENTAL|Dexmedetomidine|Participants will receive the standard sepsis and septic shock treatment with dexmedetomidine, which is to be administered with an initial dose of 0.2 μg/kg/hour, and the infusion rate is to be titrated based on response for at least 24 hours.
62543637|NCT06570187|ACTIVE_COMPARATOR|Control|Participants will receive the standard sepsis and septic shock treatment and the standard sedatives without dexmedetomidine.
62543638|NCT06057402|EXPERIMENTAL|Elranatamab|Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
62543639|NCT03951220||Group 1- Myeloma|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
62543640|NCT03951220||Group 2- MGUS|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
62543641|NCT03951220||Group 3- Healthy Volunteers|Participants will have the experimental combined MR imaging.
62543642|NCT03624309|EXPERIMENTAL|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
62543643|NCT03624309|ACTIVE_COMPARATOR|Docetaxel|Docetaxel (75mg/m2 IV d1)
62543644|NCT06251089|EXPERIMENTAL|0.07% CPC mouthwash|"Brush your teeth twice a day with fluoride toothpaste, after meals. Then rinse for 1 minute with 15 ml of the test mouthwash for 1 minute. If feasible on the part of the volunteer, they will be asked to do 30 seconds of gargling and 30 seconds of mouthwash.~If the volunteers are unable to rinse, the health professionals who care for them will be asked to perform the application of the product using sterile gauze soaked with the product, passing it through the oral mucous membranes and tongue, twice a day"
62717462|NCT01459666|PLACEBO_COMPARATOR|Placebo|
62717463|NCT01999933|ACTIVE_COMPARATOR|CCRT with cisplatin(DDP) weekly|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation
62717464|NCT01999933|EXPERIMENTAL|CCRT with TP|concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation
62717465|NCT01999933|EXPERIMENTAL|concurrent and adjuvant TP|2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation
62717466|NCT04661033|EXPERIMENTAL|Part A: Cohort 1: Isatuximab 140 mg SC Q2W x2|Participants received 2 doses of Isatuximab 140 milligrams (mg) (1 milliliter \[mL\]) via subcutaneous (SC) injection every 2 weeks (Q2W) on Day 1 and Day 15.
62717467|NCT04661033|EXPERIMENTAL|Part A: Cohort 2: Isatuximab 280 mg SC Q2W x6|Participants received 6 doses of Isatuximab 280 mg (2 mL) via SC injection Q2W through Day 71.
62717468|NCT04661033|EXPERIMENTAL|Part A: Cohort 3: Isatuximab 560 mg SC Q2W x6|Participants received 6 doses of Isatuximab 560 mg (4 mL) via SC injection Q2W through Day 71.
62717469|NCT04661033|EXPERIMENTAL|Part B: Isatuximab up to 560 mg SC Q2W x6|Participants were planned to receive 6 doses of Isatuximab up to 560 mg (4 mL) via SC injection Q2W through Day 71
62717470|NCT00329030|ACTIVE_COMPARATOR|Rituxan/BEAM|Autologous transplantation using rituxan/BEAM
62717471|NCT00329030|EXPERIMENTAL|Bexxar/BEAM|Autologous transplantation using Bexxar/BEAM
62543645|NCT06251089|PLACEBO_COMPARATOR|comparator|"Brush your teeth twice a day with fluoride toothpaste, after meals. Then rinse for 1 minute with 15 ml of the control product for 1 minute. If feasible on the part of the volunteer, they will be asked to do 30 seconds of gargling and 30 seconds of mouthwash.~If the volunteers are unable to rinse, the health professionals who care for them will be asked to perform the application of the product using sterile gauze soaked with the product, passing it through the oral mucous membranes and tongue, twice a day"
62717472|NCT03974269|ACTIVE_COMPARATOR|Hypnosis arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
62717473|NCT03974269|PLACEBO_COMPARATOR|Sedation arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
62717474|NCT05173376|EXPERIMENTAL|Larger portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 100% portion. All other foods are identical across conditions (e.g. sides, seconds, breakfast, dessert, snacks).
62717475|NCT05173376|EXPERIMENTAL|Smaller portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 66% portion (i.e. reduced portion size). All other foods are identical across conditions (e.g. sides, seconds, breakfast, dessert, snacks).
62717476|NCT04133168|EXPERIMENTAL|Cryoablation|Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System
62717477|NCT01159093|EXPERIMENTAL|Family Decision Support|Families will receive informational vaccine reminder telephone calls.
62717478|NCT01159093|EXPERIMENTAL|Clinical Decision Support|In this treatment arm, clinicians receive the decision support at the point of care within an electronic health record.
62543646|NCT01933646||Cohort 1|
62543647|NCT06632119|ACTIVE_COMPARATOR|HILT|high-intensity laser therapy (HILT)
62543648|NCT06632119|PLACEBO_COMPARATOR|Sham_HILT|Sham-HILT, the HILT without laser release
62543649|NCT03624907|OTHER|Consecutive Daily Treatment|Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
62543650|NCT03624907|OTHER|Non-Consecutive Daily Treatment|Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days
62543651|NCT05210010|OTHER|Algorithm|All participating cardiologists.
62543652|NCT05019950|EXPERIMENTAL|NIM-1324|Once daily oral tablet
62543653|NCT05019950|PLACEBO_COMPARATOR|Placebo|Once daily oral tablet
62543654|NCT02369302|EXPERIMENTAL|DWC20141|multiple dose of DWC20141
62717479|NCT01159093|EXPERIMENTAL|Family DS+ Clinician DS|Families will receive informational vaccine reminder calls and their clinicians will receive electronic health record-based decision support for immunizations.
62717480|NCT01159093|OTHER|Control|This group will receive regular primary care with no decision support.
62717481|NCT01387750|PLACEBO_COMPARATOR|Mentholated Cream|
62717482|NCT01387750|ACTIVE_COMPARATOR|Mentholated Cream with OGT|
62717483|NCT06521216||patients will receive oral iron in alternate day regimen|50 patients will receive oral ferrous sulphate in alternate day regimen
62543655|NCT02369302|EXPERIMENTAL|DWC20142|multiple dose of DWC20142
62543656|NCT02369302|EXPERIMENTAL|DWC20141+DWC20142|multiple dose of DWC20141 and DWC20142
62543657|NCT02052011|EXPERIMENTAL|Intervention Group|Subjects will take extended release Ranolazine for 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
62543658|NCT02052011|PLACEBO_COMPARATOR|Placebo Control|Subjects will take placebo pill twice daily for 4 weeks.
62717484|NCT06521216||patients will receive oral iron in single daily dose regimen|50 patients will receive oral ferrous sulphate in single daily dose regimen
62543659|NCT00789997|EXPERIMENTAL|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later prednisone placebo po daily for 10 days Levofloxacin 750 mg po daily for 10 days.
62543660|NCT00789997|ACTIVE_COMPARATOR|Prednisone|prednisone 40 mg daily for 10 days etanercept placebo subcutaneous given on the day of randomization and one week later Levofloxacin 750 mg daily for 10 days.
62543661|NCT06222320|EXPERIMENTAL|Kinesiotaping group|Kinesiotaping will be applied to patients in this group in addition to painkillers.
62717485|NCT06521216||patients will receive oral iron in thrice daily dose regimen|50 patients will receive oral ferrous sulphate in thrice daily dose regimen
62717486|NCT01779414|NO_INTERVENTION|Enhanced Usual Care|Participants in this arm of the study will receive a standard, usual care psychological risk assessment by a social worker and then recommended to a mental health referral.
62717487|NCT01779414|EXPERIMENTAL|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
62717488|NCT02481414|EXPERIMENTAL|PepCan|Four injections (one every 3 weeks) of PepCan
62717489|NCT02481414|ACTIVE_COMPARATOR|Candin|Four injections (one every 3 weeks) of Candin
62717490|NCT03401203|EXPERIMENTAL|rotational atherectomy followed by balloon angioplasty|
62717491|NCT03401203|ACTIVE_COMPARATOR|balloon angioplasty|
62717492|NCT01853709|EXPERIMENTAL|Multidisciplinary approach|"The multidisciplinary approach will include:~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
62717493|NCT01853709|ACTIVE_COMPARATOR|Conventional approach|"The conventional approach will include:~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
62717494|NCT06143956|EXPERIMENTAL|LY3305677 Obesity ISA OXA1|"Participants will receive LY3305677 or placebo subcutaneously (SC).~Each ISA will detail the intervention specific analysis."
62717495|NCT06143956|EXPERIMENTAL|LY3841136 Obesity ISA LAA1|"Participants will receive LY3841136 or placebo SC.~Each ISA will detail the intervention specific analysis."
62717496|NCT06143956|EXPERIMENTAL|LY3841136 Obesity ISA LAA2|"Participants will receive LY3841136, tirzepatide and placebo SC.~Each ISA will detail the intervention specific analysis."
62717497|NCT06143956|EXPERIMENTAL|LY3549492 Obesity ISA GN01|"Participants will receive LY3549492 orally.~Each ISA will detail the intervention specific analysis."
62717498|NCT06191276|EXPERIMENTAL|STEP@Home Intervention|This arm involves participants undergoing the 20-week STEP@Home multi-component exercise training program. The program is designed to recondition the functional status of older adults in the post-discharge period and develop long-term exercise engagement.
62717499|NCT06191276|ACTIVE_COMPARATOR|Usual care|Participants in this group receive the usual post-discharge care provided in the hospital setting, including general education on medication, disease-related self-care, and regular medical follow-ups.
62717500|NCT04591002|ACTIVE_COMPARATOR|Osemertinib|
62717501|NCT04591002|NO_INTERVENTION|Observation|
62717502|NCT02673944|EXPERIMENTAL|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
62717503|NCT06717048|EXPERIMENTAL|Red light: 2.0 mW/twice daily|
62717504|NCT06717048|EXPERIMENTAL|Red light: 2.0 mW/once daily|
62717505|NCT06717048|EXPERIMENTAL|Red light: 1.0 mW/twice daily|
62717506|NCT06717048|EXPERIMENTAL|Red light: 1.0 mW/once daily|
62717507|NCT06717048|EXPERIMENTAL|Red light: 0.5 mW/twice daily|
62717508|NCT06717048|EXPERIMENTAL|Red light: 0.5 mW/once daily|
62717509|NCT06717048|EXPERIMENTAL|Red light: 0.3 mW/twice daily|
62717510|NCT06717048|EXPERIMENTAL|Red light: 0.3 mW/once daily|
62717511|NCT06717048|SHAM_COMPARATOR|Red LED: twice daily|
62717512|NCT06716814|EXPERIMENTAL|Efanesoctocog alfa phrophylaxis|Patients who have completed a previous study with efanesoctocog alfa may continue to be treated with a prophylactic dose of 50 IU/kg efanesoctocog alfa once weekly.
62717513|NCT00641732|EXPERIMENTAL|TAK-442 40 mg QD|
62717514|NCT00641732|EXPERIMENTAL|TAK-442 80 mg QD|
62717515|NCT00641732|EXPERIMENTAL|TAK-442 10 mg BID|
62717516|NCT00641732|EXPERIMENTAL|TAK-442 20 mg BID|
62717517|NCT00641732|EXPERIMENTAL|TAK-442 40 mg BID|
62717518|NCT00641732|EXPERIMENTAL|TAK-442 80 mg BID|
62717519|NCT00641732|ACTIVE_COMPARATOR|Enoxaparin 30 mg BID|
62717520|NCT04270422|EXPERIMENTAL|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial, twice a week, 12 sessions
62717521|NCT04270422|ACTIVE_COMPARATOR|Usual physiotherapy|Usual evidence based physiotherapy, twice a week, 12 sessions
62717522|NCT04552002|EXPERIMENTAL|Synbiotic group|"Intervention group:~Will receive synbiotic supplements: one capsule/day. Each capsule contains 20 billion CFU multi-strain probiotics + prebiotics (inulin and oligosaccharides) for a duration of 6 months."
62717523|NCT04552002|NO_INTERVENTION|Placebo group|Will receive a placebo. The placebo will be similar to the synbiotic supplements in appearance.
62717524|NCT02299310|EXPERIMENTAL|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
62717525|NCT02299310|ACTIVE_COMPARATOR|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
62717526|NCT04787003|EXPERIMENTAL|Oncolytic virus (OVV-01) injection for patients with advanced solid tumors|Oncolytic virus (OVV-01) injection combined with or without immune checkpoint inhibitors in the treatment of patients with advanced solid tumors.
62717527|NCT06717308|ACTIVE_COMPARATOR|Single use post surgical NPWT drape application|Aim 1 description: A comparison of performance of Comfort Release® drapes with V.A.C. drapes in single-use NPWT applications in a randomized controlled trial. Post-surgical patients (n=200) with a prescribed treatment of Negative Pressure Wound Therapy (NPWT), will be enrolled at Weill Cornell under PI. Dr. Robert Winchell and at Columbia Presbyterian hospital under co-Principal Investigator Dr. Jarrod Bogue for single-use NPWT. Patients will be randomized to a single use control (V.A.C. drape) or intervention (Comfort Release® drape). All other components of the NPWT device including but not limited to the pump, tubing, foam or dressing insert and will be identical. Randomize patients- 1/2 of the patients to receive KCI drape and 1/2 to receive the intervention - Comfort Release drape. The intervention is a change in a component in the NPWT treatment kit.
62735879|NCT03444103|ACTIVE_COMPARATOR|Clazakizumab / Clazakizumab|Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
62717528|NCT06717308|ACTIVE_COMPARATOR|Multi-use chronic wound NPWT drape application|"Aim 2: A comparison of performance of Comfort Release® drapes with V.A.C. drapes in serial-use NPWT applications in a randomized controlled trial. Chronic wound patients (n=100) with prescribed NPWT will be enrolled at Weill Cornell Medical Center under Principal Investigator Dr. Robert Winchell. All patients will undergo 3 NPWT drape changes per week. Patients will be randomized to control (V.A.C. drape.) or intervention (Comfort Release® drape) for the duration of their study enrollment. All other components of the NPWT device including but not limited to the pump, tubing, foam or dressing insert will be identical.~Randomize patients- 1/2 of the patients to receive KCI drape and 1/2 to receive the intervention- Comfort Release drape. The intervention is a change in a component in the NPWT treatment kit."
62717529|NCT05391230|EXPERIMENTAL|Intervention Arm : Arm that received permethrin-treated lesu|Intervention Arm is the group that receives permethrin-treated lesu for use. The lesus of participants in the intervention group will be treated and subsequently retreated each month with 0.5% permethrin (Sawyer Products, Safety Harbor, FL).
62717530|NCT05391230|SHAM_COMPARATOR|Control Arm: Arm that received none permethrin-treated lesu|The lesus of participants in the control group will undergo sham treatment and re-treatment in which the cloth is soaked in water for a period of time similar to that of the intervention group. Participants and clinical staff (but not administrative staff) will be blinded to group assignments.
62717531|NCT06715189||MASLD patients with hepatic fibrosis|MASLD with hepatic fibrosis with type 2 diabetes mellitus
62717532|NCT06715189||MASLD without hepatic fibrosis|MASLD with out hepatic fibrosis with type 2 diabetes mellutis
62717533|NCT02598037|OTHER|FTO gene polymorphism|test meal after fasting for 12 hours
62717534|NCT03172143|ACTIVE_COMPARATOR|Mesenteric sparing ileocolic resection|Ileocolic resection without removal of the lymph nodes in the mesentery.
62717535|NCT03172143|ACTIVE_COMPARATOR|High ligation ileocolic resection|Ileocolic resection with removal of lymph nodes in the mesentery
62717536|NCT02099825|EXPERIMENTAL|Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
62717537|NCT02099825|ACTIVE_COMPARATOR|Non-Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
62717538|NCT03264144|EXPERIMENTAL|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
62717539|NCT03264144|NO_INTERVENTION|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
62717540|NCT03764969|ACTIVE_COMPARATOR|standard smoking cessation program (SCP)|standard smoking cessation program
62717541|NCT03764969|EXPERIMENTAL|SCP + CRT|SCP plus cognitive remediation treatment (CRT)
62717542|NCT03764969|EXPERIMENTAL|SCP + ICHT|SCP plus an implicit computer-based habit-modifying training (ICHT)
62543662|NCT06222320|ACTIVE_COMPARATOR|Routine treatment group|Patients in this group will be administered painkillers routinely in the hospital.
62543663|NCT04890912|ACTIVE_COMPARATOR|Conventional Fractionation Pelvic Radiation|Patients randomized to the conventional fractionation arm will be treated with intensity-modulated or volumetric arc therapy technique as per standard protocol.
62543664|NCT04890912|EXPERIMENTAL|Stereotactic Hypofractionated Radiation|Patients randomized to hypofractionation will be treated the stereotactic hypofractionated technique.
62543665|NCT05475327|OTHER|Conventional Physical Therapy|Heat therapy and education regarding back care management.
62717543|NCT03166930|EXPERIMENTAL|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
62717544|NCT03166930|ACTIVE_COMPARATOR|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management.
62717545|NCT00487981|OTHER|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
62543666|NCT05475327|EXPERIMENTAL|Relaxation exercises|Progressive relaxation exercises along with Deep Breathing exercises.
62543667|NCT01062711|OTHER|Control group 0 g protein|Control group in which a placebo drink containing no protein is given following unilateral knee extension exercise
62543668|NCT01062711|EXPERIMENTAL|10g whey|10g whey protein given following unilateral knee extension exercise
62543669|NCT01062711|EXPERIMENTAL|20g whey|20g whey protein given following unilateral knee extension exercise
62543670|NCT01062711|EXPERIMENTAL|30g whey|30g whey protein given following unilateral knee extension exercise
62543671|NCT01062711|EXPERIMENTAL|40g whey|40g whey protein given following unilateral knee extension exercise
62543672|NCT01062711|EXPERIMENTAL|20g soy|20g soy protein given following unilateral knee extension exercise
62543673|NCT01062711|EXPERIMENTAL|40g soy|40g soy protein given following unilateral knee extension exercise
62717546|NCT02636296|EXPERIMENTAL|Pilates|Group received 12 week of inspired-Pilates intervention (2 days/week, 60 minutes duration).
62717547|NCT02636296|OTHER|Control|Control group was oriented to maintain the habitual activities during 12 weeks
62717548|NCT03109405|EXPERIMENTAL|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
62717549|NCT03109405|OTHER|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
62717550|NCT05809089|ACTIVE_COMPARATOR|(High flow nasal cannula (HFNC)|"This arm should have the interventionHigh flow nasal cannula (HFNC) assigned to it."
62717551|NCT05809089|ACTIVE_COMPARATOR|Noninvasive ventilation (NIV)|"This arm should have the intervention Noninvasive ventilation (NIV) assigned to it."
62717552|NCT03816189||Diffuse SSc|Recruitment of 20 patients with diffuse SSc
62717553|NCT03816189||Limited SSc|Recruitment of 20 patients with limited SSc
62717554|NCT03816189||Healthy subjects|Recruitment of 20 healthy subjects (control)
62717555|NCT03237806|NO_INTERVENTION|Baseline|In this phase, patients were sedated to the level of Ramsay 6 before Deep sedated or Light sedated
62717556|NCT03237806|EXPERIMENTAL|Deep sedation|In this Arm, patients were sedated to the level of Ramsay 5(Deep sedated) by Midazolam IV continuously
62717557|NCT03237806|EXPERIMENTAL|Light sedation|In this Arm, patients were sedated to the level of Ramsay 3(Light sedated)by Midazolam IV continuously
62543674|NCT04005612|EXPERIMENTAL|vitamin d3 group|weekly Dietary Supplement: Vitamin D3 50,000 IU Vitamin D3 / week for 8 weeks
62543675|NCT04005612|EXPERIMENTAL|omega3-Fatty Acid group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
61978166|NCT03704272|NO_INTERVENTION|Control|Families in the control group will receive treatment as usual, which includes reporting to child welfare agencies when appropriate.
62543676|NCT04005612|EXPERIMENTAL|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3 FA) once daily
62543677|NCT04005612|NO_INTERVENTION|Control group|NO INTERVENTION
62543678|NCT02295540|EXPERIMENTAL|Treatment (hypofractionated IMRT, surgery)|Patients undergo hypofractionated IMRT every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment.
62543679|NCT03148665||Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
62543680|NCT03148665||Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
62543681|NCT03915509|EXPERIMENTAL|Bioactive group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
62543682|NCT03915509|ACTIVE_COMPARATOR|Sandblasted group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
62543683|NCT03976544|NO_INTERVENTION|Natural cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH), on the first or second day of the menstrual cycle. If these serum hormonal values are considered basal for the beginning of the follicular phase, patients are asked to come back on day 10 to 12 of the cycle for blood sample and transvaginal ultrasound scan in order to assess follicular growth.~The timing of ovulation is determined based on a combination of ultrasonography features (the presence of a dominant follicle and adequate endometrium) and endocrine hormonal values in serum blood samples. Ovulation is generally defined as an, at least, 180% increase of LH compared to the mean level in the previous 24h.~Frozen-warmed blastocyst transfer will take place six days following the spontaneous LH surge."
62717558|NCT06715839|EXPERIMENTAL|ImmunoPET imaging in patients with digestive system carcinoma|Enrolled patients will undergo a targeted-specific immunoPET/CT scanning.
62717559|NCT05526755|EXPERIMENTAL|Osimertinib|Participants will receive osimertinib (AZD9291).
62717560|NCT00256126|EXPERIMENTAL|Turner Syndrome (TS)|
62717561|NCT00256126|EXPERIMENTAL|Growth Hormone Deficiency (GHD)|
62717562|NCT02343315|EXPERIMENTAL|TENS|Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
62717563|NCT02343315|EXPERIMENTAL|SMCE|Participants will receive SMCE and UHEP. Six sessions of supervised Motor control exercises will be provided over the period of two weeks.
62717564|NCT02343315|ACTIVE_COMPARATOR|UHEP|Unsupervised home exercise program will be prescribed with home exercise leaflet and education leaflet in the form of back book on first treatment session.
62717565|NCT05538806||Group 1|all patients will receive routine clinical care and TTFields
62717566|NCT04911491|EXPERIMENTAL|IMST|This group will perform high-resistance (75% of maximal inspiratory pressure) inspiratory muscle strength training (IMST), 30 inhalations/session, 6 days/week.
62717567|NCT04911491|SHAM_COMPARATOR|Control|This group will perform low-resistance (15% of maximal inspiratory pressure) inspiratory muscle strength training, 30 inhalations/session, 6 days/week.
62717568|NCT06715475|ACTIVE_COMPARATOR|Plasmalogen|Take 1 mg/day of plasmalogen
62717569|NCT06715475|PLACEBO_COMPARATOR|Placebo|Take 0 mg/day of plasmalogen
62717570|NCT02086695||Cancer Group|All subjects with cancer who will be treated with anyone of the following chemotherapy drugs; Pazopanib, Sutent or Bevacizumab
62717571|NCT04391712|EXPERIMENTAL|Experimental|Participants will receive MLS laser treatment along with regular inpatient medical care.
62717572|NCT04391712|ACTIVE_COMPARATOR|Control Group|Participants will receive regular inpatient medical care.
62717573|NCT02250417|EXPERIMENTAL|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
62717574|NCT02250417|EXPERIMENTAL|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
62717575|NCT06389058||Severe Asthma|Patients with Severe or Uncontrolled Asthma
61978167|NCT03704272|EXPERIMENTAL|Treatment|SunBrite
62717576|NCT02794571|EXPERIMENTAL|Phase Ia Dose-Escalation Stage: Tiragolumab|Cohorts of at least 3 participants each will be treated with escalating doses of tiragolumab.
62717577|NCT02794571|EXPERIMENTAL|Phase Ia Dose-Expansion Stage: Tiragolumab|Participants will be treated with tiragolumab at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the study.
62717578|NCT02794571|EXPERIMENTAL|Phase Ib Q3W Dose-Escalation Stage: Tiragolumab+Atezolizumab|A minimum of 3 participants will be treated for each dose level of tiragolumab in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
62717579|NCT02794571|EXPERIMENTAL|Phase Ib Q3W Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 3 weeks (Q3W) with tiragolumab at or below the MTD or MAD in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
62717580|NCT02794571|EXPERIMENTAL|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A|In Cohort A, carboplatin or cisplatin and pemetrexed chemotherapy will be administered after atezolizumab and tiragolumab intravenous (IV) infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin and pemetrexed on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab in combination with pemetrexed on Day 1 of each 21-day cycle.
62717581|NCT02794571|EXPERIMENTAL|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B|In Cohort B, carboplatin and paclitaxel chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin and paclitaxel on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle (participants enrolled under protocol version 4) or Day 1 of each 28-day cycle (participants enrolled under protocol version 5).
62717582|NCT02794571|EXPERIMENTAL|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C|In Cohort C, carboplatin or cisplatin and etoposide chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin on Day 1 of each 21-day cycle and etoposide on Day 1 to 3 of each 21-day cycle for 4 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 28-day cycle.
62717583|NCT02794571|EXPERIMENTAL|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort D|In Cohort D, participants will receive atezolizumab and tiragolumab on Day 1 and capecitabine on Day 1-14 of each 21-day cycle.
62717584|NCT02794571|EXPERIMENTAL|Phase Ib Q4W Sequential Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 4 weeks (Q4W) with fixed doses of tiragolumab and atezolizumab with tiragolumab being administered prior to atezolizumab.
62717585|NCT02794571|EXPERIMENTAL|Phase Ib Q4W Coinfusion Expansion Cohort Tiragolumab+Atezolizumab|Participants will be treated Q4W with fixed doses of tiragolumab and atezolizumab mixed and administered in one IV bag.
62717586|NCT02794571|EXPERIMENTAL|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC1|In Cohort NC1, participants will receive atezolizumab and tiragolumab in combination with bevacizumab on Day 1 of each 21-day cycle.
62717587|NCT02794571|EXPERIMENTAL|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC2|In Cohort NC2, participants will receive tiragolumab in combination with pembrolizumab on Day 1 of each 21-day cycle.
62717588|NCT03894891|EXPERIMENTAL|Induction Docetaxel (T)+Cisplatin (P)+Nivolumab (N) then Radioimmunotherapy (IMRT+N) then adjuvant N|"Participants received 3 cycles of induction with docetaxel, cisplatin and nivolumab (TPN) every 3 weeks (or 21 days): docetaxel 75 mg/m2 IV day 1, cisplatin 100 mg/m2 IV day 1, and nivolumab 240 mg IV flat dose day 1.~Induction was followed by clinical and radiologic assessment of response. Participants without partial response or better based on RECIST 1.1 were offered salvage laryngectomy and/or pharyngectomy. Participants with partial or complete response per RECIST 1.1 proceeded with immunoradiotherapy concurrently with nivolumab. Intensity-modulated radiotherapy (IMRT) was preferred and proton beam radiotherapy not permitted. Nivolumab 240 mg IV flat dose day 1 was repeated every 2 weeks concurrently with IMRT (for a total of 3-4 doses).~Participants then received adjuvant nivolumab (480 mg IV flat dose day 1) every 4 weeks within 3-8 weeks from the last day of IMRT for up to 6 cycles or until disease progression or recurrence."
62717589|NCT02374125|EXPERIMENTAL|Fibrolysis Group|Actual Diacutaneous Fibrolysis and protocolized physiotherapy
62543684|NCT03976544|EXPERIMENTAL|Hormone replacement therapy cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) on the first or second day of the menstrual cycle. If these values are considered basal for the beginning of the follicular phase, estrogen supplementation (Estradiol valerate, Progynova® 3x2mg/day) is started to induce proliferation of the endometrium. Blood sample and transvaginal ultrasound are thereafter performed ten to fourteen days later. If the endometrium is considered adequate (generally considered if triple line and above 6,5 mm thickness), embryo transfer is scheduled on the sixth day of progesterone (vaginal micronized progesterone, Utrogestan® 2x200mg twice a day) supplementation.~In case of escape spontaneous ovulation embryo transfer will be performed considering the presumable time of ovulation."
62717590|NCT02374125|EXPERIMENTAL|Pressure Group|Trigger Point Pressure Release and protocolized physiotherapy
62717591|NCT02374125|ACTIVE_COMPARATOR|Control Group|Protocolized physiotherapy
62717592|NCT02475421|EXPERIMENTAL|Healthy, lean subjects|Healthy subjects with BMI \< 27 kg/m\^2
62543685|NCT00596076|EXPERIMENTAL|1|Workers with low back pain
62717593|NCT02475421|EXPERIMENTAL|Healthy, obese subjects|Healthy subjects with BMI \> 33 kg/m\^2
62717594|NCT02475421|EXPERIMENTAL|Diabetic, lean subjects|Diabetic subjects with BMI \< 27 kg/m\^2
62543686|NCT05607420|EXPERIMENTAL|Dose finding part|"UCART20x22 tested at several dose levels until the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) is identified.~Dose expansion part: UCART20x22 administered at the RP2D determined during the dose finding part"
62543687|NCT04613492|EXPERIMENTAL|Single dose MEDI9253, sequential Durvalumab|Various dose level cohorts for single dose MEDI9253 with sequential Durvalumab dosing
62717595|NCT02475421|EXPERIMENTAL|Diabetic, obese subjects|Diabetic subjects with BMI \> 33 kg/m\^2
62717596|NCT04584047|EXPERIMENTAL|Intervention group|This arm has blood collected either at the time of CVS.
62717597|NCT05249686|EXPERIMENTAL|Manual Therapy + Dry Needling|
62164914|NCT02713698||Group 3 (≥65 years)|Patients with 65 or more years presenting for orthopaedic surgery.
62717598|NCT05249686|ACTIVE_COMPARATOR|Manual Therapy|
62717599|NCT05249686|NO_INTERVENTION|Control|The control group received only the dentist´s usual advice after endodontic surgery.
62717600|NCT01758094||Hypogonadotropic hypogonadism patients|Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
62717601|NCT01027429|ACTIVE_COMPARATOR|procaine penicillin and gentamicin|Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
62717602|NCT01027429|EXPERIMENTAL|Amoxicillin and gentamicin|Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
62717603|NCT01027429|EXPERIMENTAL|procaine penicillin, gentamicin, and amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
62717604|NCT02315092||Diabetic foot ulcers|Patients who present with diabetic foot ulcers will undergo fluorescence imaging.
62717605|NCT02868853|EXPERIMENTAL|Photo App|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile dietary tracking application(Photo App). This Photo App allows participants to track meals by taking photos.
62717606|NCT02868853|ACTIVE_COMPARATOR|Diet App|Participants in this group will receive podcasts twice weekly in conjunction with an app (Diet App) to track their diet by entering in foods and beverages consumed.
62717607|NCT01336816|EXPERIMENTAL|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
62717608|NCT01336816|PLACEBO_COMPARATOR|Placebo Wintergreen|Subjects allow study placebo lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
62717609|NCT01526629||ICD patients with remote follow-up|Patients implanted with a fully automatic ICD and remotely followed-up.
62717610|NCT01601184|EXPERIMENTAL|combination of vismodegib with temozolomide|"In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive~- Arm A: the combination of vismodegib (150 mg/day continuously) with temozolomide (150 mg/m2 during Cycle 1 \[day 1 to day 5/ 28 day-cycle\] and 200 mg/m2 during subsequent cycles) (6 patients)"
62717611|NCT01601184|ACTIVE_COMPARATOR|temozolomide alone|In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive Arm B: temozolomide alone (150 mg/m2 day1 to day 5/ 28 day-cycle during Cycle 1 and 200 mg/m2 day 1 to day 5/ 28 day-cycle during subsequent cycles) (3 patients).
62717612|NCT01601184|OTHER|vismodegib alone|Considering the rarity of the disease, the few therapeutic options available and the promising results reported with vismodegib in adult medulloblastoma : the Sponsor will consider (on case by case basis) the enrolment of patients previously treated by temozolomide in a 3rd independent and parallel study arm
62717613|NCT05799118||Cohort|Individuals with hemoglobinopathies
62717614|NCT02550015|EXPERIMENTAL|Training|Supervised high intensity interval training (uphill treadmill walking 4 x 4 min at 90-95% of peak heart rate) 3 times weekly for 8 weeks
62717615|NCT02550015|OTHER|standard care|Standard clinical follow-up care, including general information about importance of physical activity as part of a healthy lifestyle
62717616|NCT02962921|EXPERIMENTAL|Diabetic patients|"Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons.~Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading"
62717617|NCT03557125|ACTIVE_COMPARATOR|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
62717618|NCT03557125|PLACEBO_COMPARATOR|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
62717619|NCT04468373|EXPERIMENTAL|WA-NG (NG-IMT) Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
62717620|NCT03101800|EXPERIMENTAL|Azathioprine and Allopurinol|
62717621|NCT03101800|ACTIVE_COMPARATOR|Azathioprine|
62717622|NCT02213029|EXPERIMENTAL|Oxytocin or Placebo challenge (Cohort 1)|Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered.
62717623|NCT02213029|EXPERIMENTAL|Epelsiban or Placebo (Cohort 2)|Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (\<150mg) and Cohort 2C (\>200mg) with repeated oxytocin challenges.
61976534|NCT01203150|EXPERIMENTAL|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, \< 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
62543688|NCT04613492|EXPERIMENTAL|Multiple dose MEDI9253, sequential Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with sequential Durvalumab dosing;
62543689|NCT04613492|EXPERIMENTAL|Multiple dose MEDI9253, concurrent Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with concurrent Durvalumab dosing.
62543690|NCT05770895|EXPERIMENTAL|Cohort 1: GS-2829 Dose A or Placebo|Healthy participants will receive GS-2829 Dose A or placebo for GS-2829.
62543691|NCT05770895|EXPERIMENTAL|Cohort 2: GS-6779 Dose B or Placebo|Healthy participants will receive GS-6779 Dose B or placebo for GS-6779.
62543692|NCT05770895|EXPERIMENTAL|Cohort 3: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo|Healthy participants will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.
62543693|NCT05770895|EXPERIMENTAL|Cohort 4: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Healthy participants will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
62543694|NCT05770895|EXPERIMENTAL|Cohort 5: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo|Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.
62543695|NCT05770895|EXPERIMENTAL|Cohort 6: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
62543696|NCT05770895|EXPERIMENTAL|Cohort 7: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Participants with CHB who are virally suppressed will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
62543697|NCT05770895|EXPERIMENTAL|Cohort 8: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Healthy participants will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
62543698|NCT02108093|EXPERIMENTAL|RAP (retrograde autologous priming) group|In the RAP (retrograde autologous priming) group, the priming solution is partially replaced by the patient's own circulating blood, before initiation of CPB. After initiation of cardiopulmonary bypass the priming volume is approximately 900 ml.
62543699|NCT02108093|NO_INTERVENTION|Control group|In the control group, the priming volume of the arterial and venous line will not be replaced by patient's own blood. The priming volume of cardiopulmonary bypass is 1300 ml in the control group.
62543700|NCT04735978|EXPERIMENTAL|Dose escalation of RP3 - superficial and/or deep/visceral tumors|Dose escalation of RP3 alone in 2 cohorts with intratumoral (IT) injections including use of imaging guided injection for deep tumors.
62543701|NCT04735978|EXPERIMENTAL|Dose combination of RP3 and anti-PD1 therapy - superficial and/or deep/visceral tumors|Dose combination of RP3 and anti-PD1 therapy. IT injections of RP3 including use of imaging guided injection for deep tumors.
62543702|NCT04735978|EXPERIMENTAL|Seronegative cohort|Doses of RP3 (IT) in HSV seronegative participants.
62543703|NCT02191644|PLACEBO_COMPARATOR|Refined rice|
62543704|NCT02191644|EXPERIMENTAL|Whole grains and legumes|
62543705|NCT02466685|EXPERIMENTAL|JNJ-18038683|Subjects will be randomized to receive JNJ-18038683 or placebo after the completion of the baseline assessments. Subjects randomized to JNJ-18038683 will receive 10 mg for one week, then titrate to 20 mg for the duration of the trial, with the provision for a single, downward dose adjustment for intolerance, based upon investigator judgment.
62543706|NCT02466685|PLACEBO_COMPARATOR|Placebo|Placebo treatment for 8 weeks.
62543707|NCT02594865|ACTIVE_COMPARATOR|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
62543708|NCT02594865|ACTIVE_COMPARATOR|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
62543709|NCT03986411|OTHER|Feasibility study of physiotherapy for UI in athletic women|A mixed methods study with 3 distinct but related phases to explore the feasibility of conducting an RCT of physiotherapy as management of urinary incontinence in athletic women
62543710|NCT01591343|EXPERIMENTAL|Depigoid® (500 DPP/ml)|Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).
62543711|NCT03857282|ACTIVE_COMPARATOR|Aerobic Exercises|Bicycling Exercise (lower Limb)
62543712|NCT03857282|EXPERIMENTAL|Tai Chi Exercises|Tai Chi Exercises (yang 24 Postures)
62543713|NCT02614274|EXPERIMENTAL|Nutraceutical joint health formulation|A Proprietary Blend
62543714|NCT00224289|OTHER|1|All participants will be taking Latanoprost; This study compares efficacy within age groups.
62543715|NCT02965586|ACTIVE_COMPARATOR|intravenous dexmedetomidine group|intrathecal 2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and will receive intravenous dexmedetomidine infusion as prepared. Dexmedetomidine will be diluted to a volume of 50 ml (4 mg ml-1) and presented as coded syringes by an anesthesiologist. I.V. bolus of dexmedetomidine 1 ug kg-1 administered by a syringe pump over a 10-min period followed by an infusion of 0.4 ug kg-1h-1 dexmedetomidine during the surgery. Just after intrathecal injection, all drugs were infused intravenously. The infusions will be stopped at the end of surgery.
62543716|NCT02965586|ACTIVE_COMPARATOR|intrathecal dexmedetomidine group|intrathecal2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and dexmedetomidine (10µg) and will receive an equal volume of saline intravenously
62543717|NCT02965586|PLACEBO_COMPARATOR|control group|intrathecal 2.5 ml of heavy bupivicaine0.5% pulse 0.5 mg morphine and will receive an equal volume of saline intravenously
62543718|NCT03962283|ACTIVE_COMPARATOR|Rifaximin|ASA daily + misoprostol + Rifaximin (Rifaximin group)
62543719|NCT03962283|PLACEBO_COMPARATOR|Rifaximin Placebo|ASA daily + misoprostol + Placebo Rifaximin (Placebo group)
62543720|NCT06452901|EXPERIMENTAL|Group I|Will receive the complete structured and progressive training program involving specific micro-surgical skills, VA, and AAOR.
62543721|NCT06452901|ACTIVE_COMPARATOR|Group II|Will only receive VA and AAOR training.
62543722|NCT06452901|ACTIVE_COMPARATOR|Group III|Will only receive AAOR training.
62717624|NCT02213029|EXPERIMENTAL|Biopsy cohort (Cohort 3)|Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies.
62543723|NCT02760745||Febrile Shivering|
62543724|NCT02760745||Fever without Shivering|
62543725|NCT02473926|EXPERIMENTAL|Physical Activity Program Intervention|"The intervention seeks to increase physical activity and improve strength by addressing individual , behavioral, and social/environmental factors. Health promotion clinic staff will deliver counseling by phone on a bi-weekly basis - a clinic physician assistant will coordinate with the counselor during in-person clinic visits, teach participants to perform strengthening exercise, and assess for safety concerns associated with type 2 diabetes.~In addition to behavioral counseling targeting social cognitive theory constructs, counselors will assist participants in the intervention group to set specific goals for physical activity in a paper log and on an electronic FitBit activity tracking device.Health promotion clinic staff will encourage participants to advance goals towards meeting U.S. physical activity guidelines of 150 minutes/week of moderate intensity activity and 2-3 days/week of strength activities."
62543726|NCT02473926|OTHER|Usual Care Group|Participants in the usual care arm will receive three mailings (Intervention Questionnaires) during the intervention phase. Health promotion clinic staff will mail materials from the Center for Disease Control and Prevention website that address general health aging topics.
62543727|NCT00400699|OTHER|REview|
62543728|NCT00579566||1|Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
62543729|NCT01352780|NO_INTERVENTION|usual care|Motivational interviewing
62543730|NCT00362466|ACTIVE_COMPARATOR|A|50-180 mg once daily (QD)
62543731|NCT00362466|ACTIVE_COMPARATOR|B|200-800 mg QD
62543732|NCT04971187|EXPERIMENTAL|Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)|Patients receive bintrafusp alfa IV over 1 hour on day 1 and pemetrexed IV over 10 minutes on day 1. Patients also receive carboplatin IV over 15 minutes or cisplatin IV over 6-8 hours at the physician's discretion on day 1 of cycles 1-4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62717625|NCT03794973|EXPERIMENTAL|TOL-3021|TOL-3021 2 mg/mL
62543733|NCT03838900||Cohort A|Individuals who have not started Loop or who have been on Loop fewer than 7 days at the time of enrollment.
62543734|NCT03838900||Cohort B|Participants who have been using Loop 7 or more days at the time of enrollment.
62543735|NCT05734612|EXPERIMENTAL|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
62543736|NCT05734612|PLACEBO_COMPARATOR|Placebo|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
62543737|NCT01853800|EXPERIMENTAL|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
62543738|NCT01853800|EXPERIMENTAL|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
62543739|NCT01853800|EXPERIMENTAL|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
62543740|NCT01853800|EXPERIMENTAL|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
62543741|NCT01171755|EXPERIMENTAL|Gemcitabine, Ts-1|Gemcitabine : 1000/m2 will be administered on days 1 and 8 at every 3 weeks . TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
62543742|NCT01960023|EXPERIMENTAL|Arm 1: Cetuximab and Neratinib|Cetuximab 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV plus neratinib per oral daily until disease progression
62543743|NCT05139810|EXPERIMENTAL|Donidalorsen: Cohort A|Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
62543744|NCT05139810|EXPERIMENTAL|Donidalorsen: Cohort B|Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
62543745|NCT05139810|PLACEBO_COMPARATOR|Placebo: Cohort A|Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
62543746|NCT05139810|PLACEBO_COMPARATOR|Placebo: Cohort B|Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
62717626|NCT03794973|PLACEBO_COMPARATOR|TOL-3021 Placebo|TOL-3021 Placebo
62543747|NCT03123276|EXPERIMENTAL|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
62543748|NCT02171780|EXPERIMENTAL|BI 1744 CL single rising doses|
62543749|NCT02171780|PLACEBO_COMPARATOR|Placebo|
62717627|NCT03059784|EXPERIMENTAL|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
62717628|NCT03059784|NO_INTERVENTION|control|usual care without APP
62717629|NCT03534050|EXPERIMENTAL|postoperative adjuvant RT|In this prospective observational study, all potentially eligible patients are clinically indicated for receiving postoperative adjuvant RT. Namely, partial cranial irradiation will be initiated within one month approximately after enrollment. Prescription dose will be 5000 - 6000 cGy in 25 - 30 fraction during 5 - 7 weeks.
62717630|NCT01263327|EXPERIMENTAL|HPV 16/18|Participants in this arm would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
62717631|NCT02512380|EXPERIMENTAL|SLOT group|4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
62717632|NCT02512380|ACTIVE_COMPARATOR|SOX group|3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
62717633|NCT01883024|OTHER|Type 1 diabetes|
62717634|NCT04280003|EXPERIMENTAL|Treatment group|15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.
62717635|NCT04280003|PLACEBO_COMPARATOR|Placebo group|15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group.
62717636|NCT06559462|OTHER|Physician Focus Group|To develop patient- and clinician-directed nudges that will address biases to DPYD testing. Clinicians will be engaged to provide input on developing the content and design of the nudges that address biases that impact the decision to order DPYD testing. Feedback will be elicited for nudges based on relevancy, nudge timing, and appropriateness. We will also develop/refine patient- and clinician-focused educational materials and test results based on input from our focus groups.
62717637|NCT06559462|OTHER|Patient Focus Group|To develop patient-directed nudges that will address biases to DPYD testing. Patients will be engaged to provide input on developing the content and design of the nudges that address biases that impact the decision to order DPYD testing. Feedback will be elicited for nudge content, clarity, and perceived urgency. We will also develop/refine patient-focused educational materials and test results based on input from our focus groups.
62717638|NCT06559462|EXPERIMENTAL|Physician Discrete Choice|To pilot test clinician-nudges using discrete choice experiments, we will test the degree each nudge is associated with the perceived intention to order testing (clinician). Clinicians will be shown a series of nudges, and asked to choose which of each pair is the better nudge. The location/timing of the nudge in their workflow will be presented as part of the discrete choice.
62717639|NCT06559462|EXPERIMENTAL|Patient Discrete Choice|To pilot test patient-nudges using discrete choice experiments, we will test the degree each nudge is associated with perceived likelihood to prompt discussion regarding testing. Patients will be shown a series of nudges, and asked to choose which of each pair is the better nudge.
62717640|NCT02823002|EXPERIMENTAL|Slow, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
62717641|NCT02823002|EXPERIMENTAL|Rapid, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
62717642|NCT02823002|EXPERIMENTAL|Slow, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
62717643|NCT02823002|EXPERIMENTAL|Rapid, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
62717644|NCT02823002|EXPERIMENTAL|Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
62717645|NCT02823002|PLACEBO_COMPARATOR|Non-Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
62717646|NCT04409834|EXPERIMENTAL|Full-dose anticoagulation (FDAC)|"* Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an activated partial thromboplastin time (aPTT) of 1.5-2.5 times the control as per institutional therapeutic target for treatment of venous thrombotic events (VTE)~* Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours~* With or without anti-platelet therapy: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily on subsequent days"
62717647|NCT04409834|ACTIVE_COMPARATOR|Standard-dose prophylactic anticoagulation (SDPAC)|"* Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if creatinine clearance CrCl \<30 ml/min)~* Heparin 5,000 units administered subcutaneous three times daily~* With or without anti-platelet therapy: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily on subsequent days"
62717648|NCT05398016|EXPERIMENTAL|Low-intensity behavioral intervention|Brief behavioral intervention for mild-to-moderate symptoms of anxiety. Delivered by a trained lay counselor.
62717649|NCT01665313||participants|Full-time faculty with morning and afternoon outpatient clinics on the same day in SNUH
62717650|NCT05754957|EXPERIMENTAL|Milvexian|Participants enrolled within 7 days of an acute coronary syndrome (ACS), who have undergone cardiac catheterization with percutaneous intervention (PCI) or who are being managed conservatively with or without catheterization, and who are receiving antiplatelet therapy standard-of-care (single antiplatelet therapy \[SAPT\] or dual antiplatelet therapy \[DAPT\]) as determined by the investigator will receive milvexian 25 milligrams (mg), orally, twice daily.
62717651|NCT05754957|PLACEBO_COMPARATOR|Placebo|Participants enrolled within 7 days of an ACS, who have undergone cardiac catheterization with PCI or who are being managed conservatively with or without catheterization, and who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) as determined by the investigator will receive placebo orally, twice daily.
62717652|NCT02311803|EXPERIMENTAL|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
62717653|NCT02311803|ACTIVE_COMPARATOR|Excision of Denonvilliers Fascia|Excision of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
62717654|NCT01111643||I|
62717655|NCT04608877|PLACEBO_COMPARATOR|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
62717656|NCT04608877|EXPERIMENTAL|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
62735175|NCT02964273|EXPERIMENTAL|Phase B: Prior Tolvaptan|Qualified participants (defined as those who were willing to continue in the trial and who did not have any adverse events \[AEs\] that would require investigational medicinal product \[IMP\] discontinuation) who received tolvaptan and completed Phase A were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting dose based on their body weight as per following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.
62543750|NCT02870010|EXPERIMENTAL|non-metastatic hepatocellular carcinoma|"* Radiation : Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection~* Biological : blood samples (5 ml) will be taken"
62543751|NCT04794036|EXPERIMENTAL|Experimental Group|Telerehabilitation asynchronous programme at home
62543752|NCT04794036|ACTIVE_COMPARATOR|Control Group|Rehabilitation programme with an explanatory booklet at home
62543753|NCT04611529|EXPERIMENTAL|Oral ibuprofen + topical diclofenac|Oral ibuprofen 400mg Topical diclofenac 4gm
62543754|NCT04611529|ACTIVE_COMPARATOR|Oral ibuprofen + topical placebo|Oral ibuprofen 400mg Topical placebo
62543755|NCT04611529|ACTIVE_COMPARATOR|Oral placebo + topical diclofenac|Oral placebo Topical diclofenac 4gm
62543756|NCT04214626|EXPERIMENTAL|R-CHOP regimen Combined With Lenalidomide|"Experimental: R-CHOP regimen Combined With Lenalidomide Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.~Patients will exit and receive salvage treatment for the following situations: disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles.~PS: Methotrexate, 1g/m2, Intravenous administration on day 3 of each 3-week cycle, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system."
62543757|NCT03101865|EXPERIMENTAL|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
62543758|NCT03101865|ACTIVE_COMPARATOR|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
62543759|NCT02713919|EXPERIMENTAL|Intervention Group|Adapted German PRO-SELF© Plus Pain Control Program
62543760|NCT02713919|NO_INTERVENTION|Control Group|No intervention
62543761|NCT03900520||Pneumonia group (PREVAIL-Pneumo)|Children aged 1-35 months with pneumonia or lower respiratory tract infection hospitalized or recommended for hospitalization
62543762|NCT03900520||Community group (PREVAIL-Community)|Children aged 1-35 years living in the community with no known systemic illness
62543763|NCT03900520||Economic group (PREVAIL-Econ)|PREVAIL-Pneumo-enrolled children hospitalized for pneumonia
62543764|NCT01242722||1|Two experimental and/or intervention groups under 1 arm.
62543765|NCT01034956||Facial Soft Tissue Filler Patients|Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years
62543766|NCT05412355||Incomplete ERAS|Incomplete ERAS was defined as ERAS compliance \< 70%.
62543767|NCT05412355||Non-ERAS|non-ERAS was defined as not executing any ERAS programs.
62543768|NCT00489827|ACTIVE_COMPARATOR|Intravenous glutamate|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
62543769|NCT00489827|PLACEBO_COMPARATOR|Saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
62543770|NCT06632366|EXPERIMENTAL|Sexual Dysfunction in the Postpartum Period|"In the research, Awareness-Based Self-Compassion Training sessions will be held with the women in the experimental group twice a week for 3 weeks, six times in total.Women in the postpartum period included in the control group will be interviewed twice in total. In the first interview, the Personal Information Form, Sexual Life Quality Scale-Female and Male Compatibility Scale will be applied and pre-test data will be obtained. Eight weeks after the pre-test data is obtained, post-test data will be obtained by applying the Arizona Sexual Experiences Scale-Female, Sexual Quality of Life Scale-Female and Dutch Compatibility Scale."
62543771|NCT06632366|NO_INTERVENTION|control|"Women in the postpartum period included in the control group will be interviewed twice in total. In the first interview, the Personal Information Form, Sexual Life Quality Scale-Female and Male Compatibility Scale will be applied and pre-test data will be obtained. Eight weeks after the pre-test data is obtained, post-test data will be obtained by applying the Arizona Sexual Experiences Scale-Female, Sexual Quality of Life Scale-Female and Dutch Compatibility Scale."
62543772|NCT02143076||Sickle Cell Disease|Participants will complete three questionnaires during the course of the study: Demographic Questionnaire, Medical Adherence Measure Questionnaire, and Acceptability Questionnaire. All questionnaires will be completed in a private clinic room.
62543773|NCT06106165|EXPERIMENTAL|In-person delivery|Participants will attend the workshops in a mosque or community centre.
62543774|NCT06106165|EXPERIMENTAL|Online delivery|Participants will join the workshops via a web conferencing platform The content of the online workshops is identical to the content of in-person workshops.
62543775|NCT06536959|EXPERIMENTAL|VA-PD1i|Patients are treated with PD-1 inhibitor combined with venetoclax and decitabine/azacytidine.
62543776|NCT05248802|PLACEBO_COMPARATOR|Control|Placebo DLBS2411 2 x 1 caplet daily, given everyday for 4 weeks of study period
62543777|NCT05248802|EXPERIMENTAL|DLBS2411|DLBS2411 caplet 2 x 250 mg daily, given everyday for 4 weeks of study period
62543778|NCT05668585|EXPERIMENTAL|Phase 1: Arm A: CFT1946|Approximately 40 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma, ATC)
62543779|NCT05668585|EXPERIMENTAL|Phase 1: Arm B: CFT1946 + trametinib|Approximately 28 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma)
62543780|NCT05668585|EXPERIMENTAL|Phase 2: Arm A1: CFT1946|Approximately 30 subjects with V600 melanoma or NSCLC (post BRAF inhibitor)
62543781|NCT05668585|EXPERIMENTAL|Phase 2: Arm B1: CFT1946 + trametinib|Approximately 20 subjects with V600 melanoma or NSCLC (post BRAF Inhibitor)
62543782|NCT05668585|EXPERIMENTAL|Phase 1: Arm C: CFT1946 + cetuximab|Approximately 30 subjects with CRC (post BRAF inhibitor)
62543783|NCT05668585|EXPERIMENTAL|Phase 2: Arm C1: CFT1946 + cetuximab|Approximately 40 subjects with CRC (post BRAF inhibitor)
62717657|NCT06251414|EXPERIMENTAL|Blood Flow Restriction Training，BFRT|Blood Flow Restriction Training (BFRT) is a special training technique aimed at limiting blood flow by using cuffs or elastic bands on the limbs to promote muscle growth and improve strength. BFRT was originally designed for rehabilitation injured athletes as it can improve muscle strength while reducing load, helping to avoid further injuries during the rehabilitation process. But as research deepens, it is gradually being applied to a wider range of fitness and training fields. One major advantage of BFRT is that it allows for efficient training under relatively light loads, reducing the burden on joints and tendons, making it suitable for people who find it difficult to withstand high-intensity training due to injuries or other reasons. Meanwhile, BFRT also has the characteristic of achieving muscle growth and strength growth in a short period of time, and it is considered a time-saving training method. BFRT can not only be used for strength training, but also for rehabilitation, i
62717658|NCT06251414|EXPERIMENTAL|Instrument-Assisted Soft Tissue Mobilization，IASTM|Instrument Assisted Soft Tissue Mobilization (IASTM) is a physical therapy technique that utilizes specially designed tools (such as metal or plastic scraping boards) to assist in the treatment of soft tissue problems. Mainly used in rehabilitation medicine, sports medicine, and plastic surgery, it is used to handle tension, adhesion, pain, and motor dysfunction of muscles, fascia, and tendons. The edge design of IASTM special tools can loosen adhesions in tissues, improving their elasticity and plasticity. Regulating pathological areas through neural pathways, reducing pain and improving neurological function. And different types of treatment tools improve the accuracy of treatment, promote blood circulation, accelerate the rehabilitation process, improve tissue elasticity, expand joint range of motion, and have lower risks and complications compared to invasive surgery.
62543784|NCT06547411|EXPERIMENTAL|PC Ventilation mode group|Group I patients received mechanical ventilation using the PC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%.
62543785|NCT06547411|EXPERIMENTAL|VC Ventilation mode group|Group II patients received mechanical ventilation in VC mode. The tidal volume during regulated breathing was determined based on the ideal body weight (IBW): 6-8 ml/kg (IBW for males: 50 + 0.91 × (height \[cm\] - 152.4); IBW for females: 45.5 + 0.91 × (height \[cm\] - 152.4). The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%
62543786|NCT06547411|EXPERIMENTAL|PRVC Ventilation mode group|Group III patients received mechanical ventilation using the PRVC mode.The tidal volume during regulated breathing was determined based on the ideal body weight (IBW): 6-8 ml/kg (IBW for males: 50 + 0.91 × (height \[cm\] - 152.4); IBW for females: 45.5 + 0.91 × (height \[cm\] - 152.4). The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%
62543787|NCT05393479|EXPERIMENTAL|Intervention Arm: Thinking Healthy Programme|"Perinatal women identified with depression in intervention arm will be engaged in 2 modules, one during pregnancy and one during postnatal. Each module has 3 sessions each focusing on a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. Altogether 8 sessions (including 1 introductory session, 6 THP sessions, and 1 closing session) each lasting 30 minutes to 1 hour will be provided to intervention arm participants. In the third session of each module that deals with the mother's relationship with others, family members will be engaged as well. Questionnaire evaluation will be conducted at baseline, post-Module 1 (after 2 months from recruitment date) and at 3 months post delivery after completing Module 2 and closing session."
62543788|NCT05393479|NO_INTERVENTION|Control Arm: Usual Care|Subjects in the control arm will receive usual care, where perinatal women identified with depression, are provided with psychoeducation about their condition and about the availability of services at the health facility and other health information. They will be then referred to the health facility where trained health workers are available.
62543789|NCT02046486|ACTIVE_COMPARATOR|Ticagrelor 180mg whole tablets|Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
62543790|NCT02046486|EXPERIMENTAL|Ticagrelor 180mg crushed and dispersed|Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position
62543791|NCT00717483||Type 1 diabetes|children with type 1 diabetes
62543792|NCT04352868|ACTIVE_COMPARATOR|Toric soft contact lens|Toric soft contact lens
62543793|NCT04352868|EXPERIMENTAL|Multifocal toric soft contact lens|A multifocal toric soft contact lens with a +2.00 D add.
62543794|NCT04226950|ACTIVE_COMPARATOR|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers.
62543795|NCT04226950|EXPERIMENTAL|Pegylated Interferon Alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
62543796|NCT05745597||HSIL (CIN2,3) women or cervical carcinoma in situ or early invasive carcinoma confirmed by pathology|In this study, women with pathologically confirmed HSIL(CIN2, 3) or women with cervical carcinoma in situ or early invasive cancer will be included. All participants will have four follow-up visits at enrollment and at months 6, 12, and 24.
62543797|NCT03638414|EXPERIMENTAL|Group 1 - Interventional Treatment|This group will be given the ePainQ questionnaire and an interview.
62543798|NCT03638414|NO_INTERVENTION|Group 2 - Usual care|This group will be receiving normal routine care without the study intervention
62543799|NCT02713555|EXPERIMENTAL|Roux-en-Y Gastric Bypass group|Morbidly obese patients with type 2 diabetes mellitus will be examined before and after the Roux-en-Y Gastric Bypass procedure
62543800|NCT02713555|EXPERIMENTAL|Gastric sleeve group|Morbidly obese patient with type 2 diabetes Mellitus will be examined before and after the Gastric Sleeve procedure
62543801|NCT02713555|NO_INTERVENTION|Method /control group|Healthy normal weight participants matched by age and gender to the intervention study will be examined with the same methods as the intervention groups and serve as participants in a method study and as a metabolic normal reference group.
62717659|NCT06251414|PLACEBO_COMPARATOR|Tuinal|Tuinal is an important physical therapy method in traditional Chinese medicine, which can be traced back to the Shang Dynasty around 2700 BC. With the continuous development of social economy and cultural exchange, Tuinal technology based on traditional Chinese medicine ethics and guided by modern scientific theories gradually emerged. The technical treatment methods are mainly relaxation techniques, supplemented by movement techniques. Following the principle of combining movement and stillness, emphasizing both muscles and bones, and progressing step by step, massage has significant therapeutic effects on skeletal muscle diseases. In clinical practice, massage therapists use various techniques to apply to specific parts or acupoints of the human body, keeping the nerves and muscle tissues in a good state, improving the unblocking of meridians, relaxing soft tissues, restoring flexibility, and relieving symptoms such as muscle spasms and pain.
62717660|NCT01394380|EXPERIMENTAL|artificially sweetened beverages|subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
62717661|NCT01394380|NO_INTERVENTION|regular sodas|subjects will continue their usual consumption of sweetened sodas
62717662|NCT00465426||1|HIV Positive men and women 18-65 years of age
62717663|NCT00465426||2|HIV negative men and women 18-65 years of age
62717664|NCT02442050|EXPERIMENTAL|del Nido solution|Administering of cardioplegia using del Nido solution in eligible patients.
62717665|NCT02442050|ACTIVE_COMPARATOR|Blood-based cardioplegia|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol.
62717666|NCT00692003|ACTIVE_COMPARATOR|Zonisamide|
62717667|NCT00692003|PLACEBO_COMPARATOR|Placebo|
62717668|NCT03180229|ACTIVE_COMPARATOR|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
62717669|NCT03180229|NO_INTERVENTION|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
62717670|NCT02928861|EXPERIMENTAL|18F-FDG PET/CT-based prognostic model|The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
62717671|NCT06715969|ACTIVE_COMPARATOR|myofasyal indiction treatment|"MIT will be applied to the lumbal region by a physiotherapist trained and experienced in fascial treatments to patients in the MIT group. Applications 2 sessions per week, a total of 8 sessions will be applied, with an average of 20-25 minutes. The application principles of this technique will be as follows.~* Induction of the lumbal interfacial triangle region (stroke application) (3 min)~* Induction of the lumbal interfacial triangle region (deep induction application) (3 min)~* Cross-hands myofascial induction (3 min)"
62717672|NCT06715969|ACTIVE_COMPARATOR|classıcal phsyotherapy|15 sessions of mictowave diathermy (MDD), Vacuum Interference, Infraruj and Classic waist exercise program will be applied to patients in this group.
62717673|NCT06715969|ACTIVE_COMPARATOR|Myofacial ReleaseTechniques|Separate techniques will be applied to the parts of the thoracolumbal fascia that surround the erector spina, quadratus lumborum, latissimus dorsi muscles and extend in that direction to patients in the MFR group. Techniques will continue for 180 seconds, tissue shift will be carried further as relaxation is achieved. Applications Total 8 sessions will be applied twice a week by an experienced physiotherapist.
62717674|NCT05910567|OTHER|Focused Assessment with Sonography for Trauma (FAST) Examination Arm|Patients in this arm will under the FAST examination (abdominal ultrasound) for diagnostic purposes to detect the presence of blood in injured patients with blunt abdominal trauma.
62717675|NCT05910567|OTHER|No Intervention - Standard of Care - Without the FAST Examination|Institution will use their standard operating procedures to deliver the usual care for injured patients with blunt abdominal/torso trauma.
62717676|NCT04140617|EXPERIMENTAL|E-cigarette aerosol exposure in a room|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a 25 m3 room.
62717677|NCT04140617|EXPERIMENTAL|E-cigarette aerosol exposure in a car|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a car.
62717678|NCT01473030||Dutasteride|No PCa at Year 2 or Year 4
62717679|NCT01473030||Placebo|No PCa at Year 2 or Year 4
62717680|NCT03119168|EXPERIMENTAL|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations ( 4L Polyethyleneglycol)
62717681|NCT03119168|ACTIVE_COMPARATOR|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation (4L Polyethylenglycol)
62717682|NCT01605669||Aortic stenosis patients|Patients with varying degrees of aortic stenosis without significant additional valvular disease will be considered eligible for this study. All participants will recieve a transthoracic echocardiogram and recorded cardiac auscultation.
62717683|NCT05604261|EXPERIMENTAL|Anaprazole sodium 40 mg QD|
62543802|NCT01137994|EXPERIMENTAL|Lapatinib plus Chemotherapy|Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
62168048|NCT00513461|EXPERIMENTAL|Arm I (SAMe)|Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
62717684|NCT05604261|EXPERIMENTAL|Anaprazole sodium 60 mg QD|
62717685|NCT05604261|ACTIVE_COMPARATOR|Rabeprazole sodium 20 mg QD|
62717686|NCT06132178|EXPERIMENTAL|Full dose COMP360 with active aiTBS rTMS|25mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.
62717687|NCT06132178|ACTIVE_COMPARATOR|Full dose COMP360 with sham aiTBS rTMS|25mg of COMP360 with sham iTBS delivered over 10 sessions daily for 5 consecutive days.
62717688|NCT06132178|ACTIVE_COMPARATOR|Low dose comparator with active aiTBS rTMS|1mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.
62717689|NCT06132178|SHAM_COMPARATOR|Low dose comparator with sham aiTBS rTMS|1mg of COMP360 with with sham iTBS delivered over 10 sessions daily for 5 consecutive days.
62717690|NCT06717126|EXPERIMENTAL|Arm 1 - Roginolisib 80mg|IOA-244: 80 mg (corresponding to 72 mg roginolisib) daily
62717691|NCT06717126|ACTIVE_COMPARATOR|Arm 2 - Investigator choice of standard of care|Investigator´s choice of therapy
62717692|NCT06717126|EXPERIMENTAL|Arm 3 - Roginolisib 40mg|IOA-244: 40 mg (corresponding to 36 mg roginolisib) daily
62717693|NCT03859557||4-Quadrant Random Forceps Biopsy|Random sampling within a quadrant of esophageal tissue using forceps.
62717694|NCT03859557||WATS biopsies|Wide area transepithelial sampling with computer aided pathologic interpretation of tissue.
62717695|NCT05670327||Bilateral lung recipients|Adult patients undergoing bilateral LT, not requiring invasive mechanical ventilation before surgery, were eligible for inclusion in the study only when they met the predefined 'readiness-to-wean' criteria on daily screening and were therefore deemed ready to undergone a first 30-min weaning trial.
62717696|NCT02169310|EXPERIMENTAL|1|up to 40 adult TBI patients between the ages of 18 and 60
62717697|NCT02169310|ACTIVE_COMPARATOR|2|up to 40 adult healthy volunteers between the ages of 18 and 60
62717698|NCT05677100|EXPERIMENTAL|Treatment Arm|Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management. Randomization will be stratified by ejection fraction.
62717699|NCT05677100|NO_INTERVENTION|Control Arm|The Control arm should receive standard of care therapy as per the study directed Diuretic Care Treatment Algorithm.
62717700|NCT05677100|EXPERIMENTAL|Advanced HF Registry|For the Advanced HF registry, all eligible enrolled subjects will receive Aortix system support.
62717701|NCT06714877|ACTIVE_COMPARATOR|prism treatment group|prism treatment
62717702|NCT06714877|EXPERIMENTAL|botulinum toxin group|botulinum toxin injection
62717703|NCT06714968|NO_INTERVENTION|Control 1|No intervention was applied to the students in the control group, and 2 weeks after the pre-test application, the post-test interface was activated for the students in this group and the students were enabled to perform the post-test application.
62717704|NCT06714968|NO_INTERVENTION|control 2|No intervention was applied to the students in the control group, and 2 weeks after the pre-test application, the post-test interface was activated for the students in this group and the students were enabled to perform the post-test application.
62717705|NCT06714968|EXPERIMENTAL|Digital game|After the pre-test application is completed, the students in the experimental group will be allowed to install the designed game application on their phones. After the installation process, students will be allowed to play the game for 2 weeks. After 2 weeks from the date of downloading the game, access to the game will be automatically blocked. After completing the application steps, when the student thinks that he/she is ready to apply the post-test, he/she will be able to perform the post-test application. In the post-test application, there will be no repeated return of the student to the questions or multiple answer submission. Two weeks after the application is completed, the knowledge test will be applied to the students again in order to objectively evaluate the learning. In this process, students will be prevented from accessing the application.
62717706|NCT02373618|EXPERIMENTAL|Experimental: DN and Conventional PT|
62717707|NCT02373618|ACTIVE_COMPARATOR|Active Comparator: Conventional PT|
62717708|NCT06563310|EXPERIMENTAL|Veritable-NF|
62717709|NCT06563310|ACTIVE_COMPARATOR|Sham-NF|
62717710|NCT06252714|EXPERIMENTAL|Defecation Posture Modification Device|Patients will be given a Squatty Potty Device
62717711|NCT02747147|NO_INTERVENTION|A- Control|Group A will have their PIVs assessed daily and record kept of PIV dislodgement or replacement
62717712|NCT02747147|EXPERIMENTAL|B - Device Intervention|patients will have their PIVs assessed daily and record kept of PIV displodgement or replacement. patients will additionally have a single blood collection attempted using the study device
62717713|NCT01101607|ACTIVE_COMPARATOR|Pediatric Emergency Physician|Patients randomized to Pediatric Emergency Physician Group will have their fracture reduced by a Pediatric Emergency Physician
62717714|NCT01101607|ACTIVE_COMPARATOR|Orthopaedic physician|Patients to be randomized to Orthopaedic physician Group will have their fracture reduced by an Orthopaedic Physician
62717715|NCT06718842|EXPERIMENTAL|group I|this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
62717716|NCT06718842|NO_INTERVENTION|Group II|this Group II will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will act a waitlisted children
62717717|NCT03212352|PLACEBO_COMPARATOR|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
62717718|NCT03212352|EXPERIMENTAL|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
62717719|NCT01507701|EXPERIMENTAL|Clonidine|
62717720|NCT00981721|EXPERIMENTAL|1|cediranib 20mg
62717721|NCT00981721|EXPERIMENTAL|2|cediranib 30mg
62717722|NCT00527228|ACTIVE_COMPARATOR|A|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm B
62717723|NCT00527228|PLACEBO_COMPARATOR|B|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm A
62717724|NCT05224661||Adult patients with AML in complete remission undergoing alloHCT|Adult patients with AML in complete remission undergoing alloHCT
62717725|NCT04902391|EXPERIMENTAL|Acute Mental Health Care Bundle|We developed an evidence-based bundle of care to address current gaps in care. The bundle: 1) brings together multiple evidence-based assessment tools (ASQ, HEADS-ED) to ensure efficient, high-value ED-based care; 2) removes barriers to assessment and builds connections to care: Assessments are conducted by a mental health care provider and families have access to urgent follow-up care; and 3) prioritizes family engagement: A shared decision-making framework (Choice and Partnership) is used to promote children and youth as stewards of their care and support partnership between EDs and follow-up services with the duration of care determined collaboratively by the patient and their provider.
62735880|NCT03444103|PLACEBO_COMPARATOR|Placebo / Clazakizumab|Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
62735881|NCT03073811|EXPERIMENTAL|PeriHab|Provided nutrition counseling and prescribed to consume 1.6 g/kg/body weight as well as provided 30 grams of high quality protein three times per day for two weeks before and four weeks after surgery.
62717726|NCT04902391|NO_INTERVENTION|Usual ED-Based Mental Health Care|Local standards of ED-based mental health care will be delivered at control sites. Site leads have determined that this care does not involve the 3 specific core innovations in the bundle. Local care standards are similar across study sites and include use of CTAS score at triage (but no mental health risk assessment tool), ED physician medical clearance and assessment of consultation need, and no consistent mental health follow-up plan. Sites that are randomized to the control arm will not adopt core bundle elements.
62735882|NCT03073811|ACTIVE_COMPARATOR|PoshControl|Provided nutrition counseling and prescribed to consume 1.0 g/kg/body weight in the form of educational handouts explained by a Registered Dietitian and one oral nutrition supplement per day for two weeks before surgery.
62735883|NCT04107740|EXPERIMENTAL|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
62543803|NCT01137994|EXPERIMENTAL|Trastuzumab plus Chemotherapy|Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
62543804|NCT06340386||Patients with breast cancer and age <=50 years|Patients with diagnosis of breast cancer and age \<=50 years
62543805|NCT06340386||Patients with breast cancer and age >50 years|Patients with diagnosis of breast cancer and age \>50 years
62543806|NCT05233111|PLACEBO_COMPARATOR|Treatment as Usual|Participants in the Treatment as Usual (TAU) group will not receive Prolonged Exposure therapy, but will instead receive the standard clinical treatment received by all persons with spinal cord injury (SCI) at the rehabilitation facility. TAU participants will complete questionnaires/interviews at 1, 3, and 6 months from Baseline.
62543807|NCT05233111|EXPERIMENTAL|Brief Prolonged Exposure|Experimental: Brief Prolonged Exposure Participants will receive Brief PE. Subjects in the Brief Prolonged Exposure (BPE) intervention group will additionally receive 3 total therapy sessions, each lasting about 60 minutes spaced about 1-7 days apart. Sessions include education about common reactions to trauma, breathing retraining, identification of self-care tasks and prolonged (repeated) imaginal exposure to trauma memories. Any missed sessions will be made up by scheduling multiple sessions in subsequent weeks. Individuals in the BPE group will complete a screener and then survey questionnaires/ interviews at 1, 3, and 6 months from Baseline.
62543808|NCT05416788|EXPERIMENTAL|Cervical manipulation group|high-velocity, low-amplitude cervical manipulation
62543809|NCT05416788|SHAM_COMPARATOR|Control group|placebo manipulation, the cervical spine will be tilted and rotated without reaching the end feel or the pump
62543810|NCT02300155|EXPERIMENTAL|PregVit®|Women will be randomized to the '35 mg' group, who will start supplementation with PregVit® (low iron content, small size)
62543811|NCT02300155|ACTIVE_COMPARATOR|Orifer F®|Women will be randomized to the '60 mg' group, who will start supplementation with Orifer F® (high iron content, small size).
62543812|NCT01927198|EXPERIMENTAL|RDEA3170 5 mg qd|No titration.
62543813|NCT01927198|EXPERIMENTAL|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
62543814|NCT01927198|EXPERIMENTAL|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
62543815|NCT01927198|PLACEBO_COMPARATOR|Placebo|Placebo group
62543816|NCT01869855|ACTIVE_COMPARATOR|110 patients with cSDH assigned to subdural drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
62543817|NCT01869855|ACTIVE_COMPARATOR|110 patients with cSDH assigned to subperiosteal drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
62543818|NCT04965077|EXPERIMENTAL|MIL97|
62543819|NCT03687411|EXPERIMENTAL|ULTRA-SINE (phases 1-4)|"There will be four phases in this proposed uSINE system. In first phase attending anaesthetist will use the automated spinal landmark system for neuraxial needle insertion to place the neuraxial anaesthesia in non-obese patients.~For the second phase, obese patients will have ultrasound scan of their lumbar back and no needle insertion is involved.~In third phase, conventional ultrasonography is used prior to the needle insertion, and needle insertion is conducted manually as per routine practice. The images collected in the system will be used for annotation and evaluation which serves as training material for uSINE to optimize its algorithm to improve landmark identification for obese patients. The fourth phase will have uSINE system used prior to the needle insertion, with the neuraxial needle insertion conducted manually as per routine practice. The identification accuracy and first-attempt puncture success rate of uSINE will be determined."
62543820|NCT01378247|NO_INTERVENTION|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in heart failure.
62543821|NCT01378247|EXPERIMENTAL|Family Focused Nursing|Family Focused Nursing and treatment as usual
62543822|NCT06453850|EXPERIMENTAL|FLEXIGO delivery catheter|
62543823|NCT06543173|EXPERIMENTAL|Prophylactic Catheter-based VT Ablation|Subjects receive catheter-based ventricular tachycardia (VT) ablation within 3 months of primary ICD implantation.
62543824|NCT06543173|NO_INTERVENTION|Continued Medical Management|Subjects undergo continued medical management after primary ICD implantation without prophylactic VT ablation.
62543825|NCT02012348|PLACEBO_COMPARATOR|Control soap|Forearms of subjects in this arm will be washed with control (non-antibacterial) soap
62543826|NCT02012348|EXPERIMENTAL|Antibacterial soap with triclocarban|The forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
62543827|NCT02012348|ACTIVE_COMPARATOR|Antibacterial soap + benzalkonium chloride|The forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
62543828|NCT02132806|EXPERIMENTAL|OFD with piezosurgery|Open flap debridement with Piezosurgery
62543829|NCT02132806|EXPERIMENTAL|OFD with piezosurgery+biomaterial|Open flap debridement with Piezosurgery with biomaterial mp3
62543830|NCT02132806|EXPERIMENTAL|OFD with piezosurgery+mp3+bracket|Open flap debridement with Piezosurgery with biomaterial mp3 + bracket
62543831|NCT01620294|EXPERIMENTAL|triclosan|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
62543832|NCT01620294|EXPERIMENTAL|uncoated|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
62735884|NCT04107740|PLACEBO_COMPARATOR|Placebo (0mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
62543833|NCT05056038|ACTIVE_COMPARATOR|Lateral Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
62543834|NCT05056038|ACTIVE_COMPARATOR|Posterior Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the posterior border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
62543835|NCT03390426|EXPERIMENTAL|Mepivacaine Block Group|Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
62543836|NCT03390426|PLACEBO_COMPARATOR|Saline Sham Group|Injection of salt water (saline) above and beside the femoral artery.
62543837|NCT03166137|EXPERIMENTAL|Carbon dioxide laser group|(group A): thirty patients will be treated by application of carbon dioxide laser.
62543838|NCT03166137|ACTIVE_COMPARATOR|Cryotherapy group|(group B): thirty patients will be treated by cryotherapy application.
62543839|NCT06385548|EXPERIMENTAL|Lurbinectedin and Dostarlimab Combination Therapy|
62543840|NCT05639075|EXPERIMENTAL|Gait analysis|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
62543841|NCT01756079|EXPERIMENTAL|PegIFN-2b + RBV+ boceprevir|Participants will receive PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) for 4 weeks and then will receive 44 additional weeks of treatment with PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) + boceprevir (capsules, orally, 800 mg three times per day).
62543842|NCT04290195|EXPERIMENTAL|ziv aflibercept patients|20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO
62543843|NCT03636997|ACTIVE_COMPARATOR|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
62543844|NCT03636997|ACTIVE_COMPARATOR|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
62543845|NCT02329626||Study population|"The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.~Intervention: PET CT 18 FDG"
62543846|NCT03172494|EXPERIMENTAL|Insulin degludec/liraglutide|
62543847|NCT03172494|ACTIVE_COMPARATOR|Insulin degludec|
62543848|NCT03172494|ACTIVE_COMPARATOR|Liraglutide|
62543849|NCT04357080||Case|Patients with urethral stricture recurrence
62543850|NCT04357080||Control|Patients with normal, patent urethra
62543851|NCT03566615|ACTIVE_COMPARATOR|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
62543852|NCT03566615|EXPERIMENTAL|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
62543853|NCT03566615|EXPERIMENTAL|CAP-daisy|"A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.~Note:~IRB Approval date for the use of Endocuff at St. Barbara Hospital, Iglesias (CA), Italy, was obtained on 3/8/2017.~IRB Approval date for the use of Endocuff at Evergreen General Hospital, Taipei, Taiwan, was obtained on 3/18/2021."
62543854|NCT02125877|ACTIVE_COMPARATOR|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
62543855|NCT02125877|EXPERIMENTAL|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
62543856|NCT04204057|EXPERIMENTAL|Tenalisib|Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles
62717727|NCT06486181|NO_INTERVENTION|Unresolved Deep Venous Thrombosis Patients continuing with systemic anticoagulation|"Patients presenting to emergency department with the following criteria:~over 18 years of age, who have diagnosis of acute femoropopliteal acute deep venous thrombus, placed on anticoagulation treatment and failed to resolve the DVT in 1 week (+/- 3 days) follow up Doppler US study. In control arm the treatment will be the continuation of current anticoagulation treatment, which is standard of care for 12 months unless crossover between groups is needed."
62735885|NCT05117567|EXPERIMENTAL|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and mobile and migrant population-tailored behavioural change communication (BCC) package
62543857|NCT01767948|EXPERIMENTAL|Patients with mild hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
62543858|NCT01767948|EXPERIMENTAL|Patients with moderate hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
62735886|NCT05117567|NO_INTERVENTION|Control|No personal protection package
62543859|NCT01767948|EXPERIMENTAL|Patients with severe hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
62543860|NCT01767948|EXPERIMENTAL|Patients with normal hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
62543861|NCT03196219|EXPERIMENTAL|Arm 1: Open-Enrollment Multiple Dose C16G2 Varnish|Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.
62543862|NCT03196219|EXPERIMENTAL|Arm 2A: Single-Blind C16G2 Varnish|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish applications over 7 days (Days 0, 2, 5 \& 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
62543863|NCT03196219|PLACEBO_COMPARATOR|Arm 2B: Single-Blind Placebo|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive Placebo applications over 7 days (Days 0, 2, 5 \& 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
62543864|NCT03196219|EXPERIMENTAL|Arm 3: Open-Enrollment Single Dose C16G2 Varnish|If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.
62543865|NCT02148471||Healthy controls|Healthy living liver donors with healthy liver on imaging and/or liver histology
62543866|NCT02148471||Simple steatosis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis
62543867|NCT02148471||Nonalcoholic steatohepatitis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis
62543868|NCT02148471||Minimal findings|Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.
62543869|NCT05006547||Young adults|18\<age\<35
62543870|NCT05006547||Middle aged adults|50\<age\<65
62543871|NCT03328975|ACTIVE_COMPARATOR|Dexamethasone|Group 1 will receive an injection of 4mg of dexamethasone 4 mL of 1% lidocaine.
62543872|NCT03328975|PLACEBO_COMPARATOR|Placebo|Group 2 will receive an injection of 5 mL of 1% lidocaine (placebo).
62543873|NCT00242684||Group 1|older patients admitted to a TCU unit
62543874|NCT05232812|EXPERIMENTAL|Administration of 3-[11C]-OHB|All participants will first be injected with 200 MBq 3-\[11C\]-OHB followed by an oral ingestion of 100 MBq 3-\[11C\]-OHB.
62543875|NCT01305044|EXPERIMENTAL|Tai Chi Chih|The Tai Chi Chih classes were 60 minutes sessions, held three times a week, over twelve weeks. The classes were led by an instructor who was certified and licensed in the Tai Chi Chih form.
62543876|NCT01305044|ACTIVE_COMPARATOR|Health Education Classes|Health Education classes were 60 minute sessions that occurred three times a week, over twelve weeks. These classes were taught by specialists in the class topic and focused on topics related to aging (e.g., sleep quality, nutrition, pain, etc.).
62543877|NCT00709488|EXPERIMENTAL|Litx™ BPH Therapy|
62543878|NCT01831258|EXPERIMENTAL|SensAwake On|The comfort feature 'SensAwake' will be turned on
62543879|NCT01831258|ACTIVE_COMPARATOR|SensAwake Off|The comfort feature 'SensAwake' will be turned off
62543880|NCT02143921|EXPERIMENTAL|Training Intervention|One service provider group received training
62543881|NCT02143921|NO_INTERVENTION|Control|Control group service providers did not received intervention training
62543882|NCT01162707|EXPERIMENTAL|Pressure Measurement System|CardioMEMS HF Pressure Measurement System
62543883|NCT04366687|ACTIVE_COMPARATOR|PAT-AU|Parents randomized to this arm (i.e., group) receive Parents as Teachers (PAT) services as usual (AU).
62543884|NCT04366687|EXPERIMENTAL|PAT+CSA|Parents randomized to this arm (i.e., group) receive the added CSA-focused session (Smart Parents - Safe and Healthy Kids) added to typical Parents as Teachers (PAT).
62543885|NCT02836210|ACTIVE_COMPARATOR|Angled incision|Patients in this arm will undergo 27-gauge vitrectomy wound construction using angled (tunnel-like) incisions for trocar entry.
62735887|NCT03365687|ACTIVE_COMPARATOR|Vitamin D|Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
62735888|NCT03365687|PLACEBO_COMPARATOR|Placebo|Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
62543886|NCT02836210|ACTIVE_COMPARATOR|Straight Incision|Patients in this arm undergo 27-gauge vitrectomy wound construction using straight (perpendicular) incisions for trocar entry.
62543887|NCT03829787||Bipolar without Anxiety or Substance Use Disorder|Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
62543888|NCT03829787||Bipolar disorder with a current anxiety disorder only|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
62543889|NCT03829787||Bipolar disorder with a current anxiety disorder and a current|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
62543890|NCT03829787||Bipolar disorder with a current substance use disorder only|Subjects who are diagnosed with bipolar disorder \& a substance use disorders but not a current anxiety disorder
62543891|NCT03829787||Healthy Volunteers|
62543892|NCT03583086|EXPERIMENTAL|Escalation|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
62543893|NCT03583086|EXPERIMENTAL|Dose Expansion - Non Small-Cell-Lung Cancer Acquired Resistance|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
62735889|NCT03316716|NO_INTERVENTION|Control Group|Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
62717728|NCT06486181|EXPERIMENTAL|Unresolved Deep Venous Thrombosis Patients managed by interventional therapies.|"Patients presenting to emergency department with the following criteria:~over 18 years of age, who have diagnosis of acute femoropopliteal acute deep venous thrombus, placed on anticoagulation treatment and failed to resolve the DVT in 1 week (+/- 3 days) follow up Doppler US study. In intervention arm, patients will undergo either CDT or MT procedures both of which have been cleared by FDA for the treatment of acute DVT. FDA-cleared endovascular devices currently available at our institution will be used for both procedures. The choice of procedure will be based on operator's preference, availability of device and the patient's bleeding risk. The endovascular procedure will be scheduled within 15 days of the initial symptoms."
62717729|NCT03151031|EXPERIMENTAL|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
62717730|NCT03151031|NO_INTERVENTION|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
62717731|NCT06443892||PENG Group|Participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia and receiving postoperative pericapsular nerve block (PENG).
62717732|NCT06443892||SFICB Group|Participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia and receiving postoperative suprainguinal fascia iliaca compartment block (SFICB).
62717733|NCT00419055||1 Control|Patients are discharged the day after PCI
62717734|NCT00419055||2 Study group|Patients will be discharged 4-6 hrs after PCI
62717735|NCT06718153|EXPERIMENTAL|Resected HCC patients|patients resected for HCC with NGS data, and paraffin material for immunohistochemistry analysis.
62717736|NCT01829568|EXPERIMENTAL|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 1 and once weekly at weeks 13, 21, 29, and 37.
62717737|NCT06358521|EXPERIMENTAL|Physiotherapist-led primary care model for hip and knee pain|The index intervention will incorporate a PT within the primary care team and make them available at the first point of contact for people with hip or knee pain. There will be 4 key components of this intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need (e.g., no insurance coverage for PT).
62717738|NCT06358521|ACTIVE_COMPARATOR|Usual physician-led primary care model for hip and knee pain|Participants will be seen by a primary care physician or a nurse practitioner, depending on the current practice at the clinic. Participants in both groups will be permitted to seek additional care outside of the primary care clinic.
62717739|NCT05960357|EXPERIMENTAL|Informed group during Ultrasound Examination|Before starting the detailed USG examination for the experimental group, Personal Information Form and State-Anxiety Inventory will be filled. While informing about the fetus during the USG examination, the pregnant woman will be informed by using the physical images of the fetus (hand, arm, face, heartbeat, information about the internal organs, etc.) using the USG screen. After the USG is completed, the State-Anxiety Inventory will be filled again as a final test.
62717740|NCT05960357|NO_INTERVENTION|Control group|In the control group, the Personal Information Form and the State-Anxiety Inventory will be filled before the USG procedure, and only the State-Anxiety Inventory after the USG procedure. After the data collection process is completed, the pregnant woman will be informed about the USG results.
62717741|NCT05518461|EXPERIMENTAL|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
62717742|NCT06716905|EXPERIMENTAL|Part 1:ACT500 Tablets|
62717743|NCT06716905|PLACEBO_COMPARATOR|Part 1: Placebo|
62717744|NCT06716905|EXPERIMENTAL|Part 2:ACT500 Tablets|
62717745|NCT06716905|PLACEBO_COMPARATOR|Part 2: Placebo|
62717746|NCT03950635|EXPERIMENTAL|Group I (fiber-rich diet)|Patients consume a whole-foods, fiber-rich diet for 6 weeks.
62717747|NCT03950635|EXPERIMENTAL|Group II (ketogenic diet)|Patients consume a high fat, low carbohydrate (ketogenic) diet for 6 weeks.
62717748|NCT03761056|EXPERIMENTAL|Axicabtagene Ciloleucel|"Participants will receive cyclophosphamide 500 mg/m\^2/day intravenously (IV) and fludarabine 30 mg/m\^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\^8 anti-CD19 CAR T cells will be administered.~Participants who achieve partial response or complete response and subsequently experience disease progression will have an option to receive second course of conditioning chemotherapy therapy and axicabtagene ciloleucel. Participants will receive the same axicabtagene ciloleucel regimen as the original target dose anytime during the study."
62717749|NCT05465954|EXPERIMENTAL|Treatment (efineptakin alfa, pembrolizumab)|"BEFORE SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1. Patients then undergo surgery 1 week later.~AFTER SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1 of each cycle. Cycles repeat every 42 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo MRI or CT at baseline and on study. Patients also undergo tumor biopsy at baseline and blood sample collection on study."
62717750|NCT04934683|ACTIVE_COMPARATOR|Routine Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
62717751|NCT04934683|ACTIVE_COMPARATOR|Routine Pressure Management with propofol induction|Propofol will be used as an induction agent.
62717752|NCT04934683|ACTIVE_COMPARATOR|Tight Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
62717753|NCT04934683|ACTIVE_COMPARATOR|Tight Pressure Management with propofol induction|Propofol will be used as an induction agent.
62717754|NCT04076267||Patients with cancer|
62717755|NCT06619821|ACTIVE_COMPARATOR|Psychoeducation group （PsyE）|Psychoeducation consists of parent and adolescent psychoeducation. The content includes an introduction to stress, emotional distress and mental disorders.
62717756|NCT06619821|EXPERIMENTAL|Psychoeducation + Emotional Skills (PsyE+EmoS)|"Psychoeducation includes sessions for both parents and adolescents, offering the same content as the control group, which introduces stress, emotional distress, and mental disorders.~In addition, the emotional skills enhancement sessions provide online materials focused on emotional awareness and emotion regulation strategies, along with tasks related to the content. Participants will also be required to complete a weekly writing assignment, upload their written contents, and assess their level of subjective discomfort following each writing exercise."
62717757|NCT06619821|EXPERIMENTAL|Psychoeducation + emotional skills + PCE (PsyE+EmoS+PoCE)|In comparison to the PsyE+EmoS group, this group additionally requires parents to complete a weekly parent-child communication task aimed at fostering positive childhood experiences. Parents are also expected to document and upload the details of these tasks each week.
62717758|NCT02332928|ACTIVE_COMPARATOR|20 mg Melatonin|RT (as clinically indicated) + melatonin (Subjects will receive 20-mg oral melatonin the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
62717759|NCT02332928|PLACEBO_COMPARATOR|Placebo|RT (as clinically indicated) + placebo (Subjects will receive 20-mg oral placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
62717760|NCT03249402|EXPERIMENTAL|Oral Contraceptive Tablet + JNJ-42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
62717761|NCT06713265||With freezing of gait|"During patient enrollment, the following assessments will be conducted:~* The Unified Parkinson's Disease Rating Scale (UPDRS);~* Timed Up \& Go (TUG) Test;~* New Freezing of Gait Questionnaire (NFOG-Q);~* BAASTA Battery;~* Clinical swallowing assessment. All assessments will be conducted during the patient's OFF phase.~At the end of the motor assessment (NFOG-Q and TUG), the patients will be divided into two groups: the first group will consist of patients exhibiting freezing of gait, while the second group will consist of those not presenting freezing. The procedure for the assessments will remain the same for both groups.~If, during the clinical speech therapy swallowing assessment, signs indicative of swallowing disorders are detected, the patient will be referred for a pharyngography to specify the nature of these disorders."
62717762|NCT06713265||Without freezing of gait|"During patient enrollment, the following assessments will be conducted:~* The Unified Parkinson's Disease Rating Scale (UPDRS);~* Timed Up \& Go (TUG) Test;~* New Freezing of Gait Questionnaire (NFOG-Q);~* BAASTA Battery;~* Clinical swallowing assessment. All assessments will be conducted during the patient's OFF phase.~At the end of the motor assessment (NFOG-Q and TUG), the patients will be divided into two groups: the first group will consist of patients exhibiting freezing of gait, while the second group will consist of those not presenting freezing. The procedure for the assessments will remain the same for both groups.~If, during the clinical speech therapy swallowing assessment, signs indicative of swallowing disorders are detected, the patient will be referred for a pharyngography to specify the nature of these disorders."
62717763|NCT04390399|ACTIVE_COMPARATOR|Cohort A Control Treatment Arm|SBRT + gemcitabine + nab-paclitaxel
62717764|NCT04390399|EXPERIMENTAL|Cohort A Experimental Treatment Arm 1|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin HCl + N-803
62717765|NCT04390399|EXPERIMENTAL|Cohort A Experimental Treatment Arm 2|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
62717766|NCT04390399|ACTIVE_COMPARATOR|Cohort B Control Treatment Arm|Irinotecan liposome + 5-FU/leucovorin
62717767|NCT04390399|EXPERIMENTAL|Cohort B Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
62717768|NCT04390399|EXPERIMENTAL|Cohort C Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin + N-803 + PD-L1 t-haNK
62717769|NCT06187324|EXPERIMENTAL|periopaper|periopaper used to collect GCF
62717770|NCT06489366|ACTIVE_COMPARATOR|Ho: YAG lithotripsy|Ho; YAG laser therapy device is used. The patient adopts lithotomy position. After general anesthesia, a semi-rigid ureteroscope is used to enter the bladder through the urethra to observe the ureteral opening, and then a hydrophilic guide wire is inserted into the ureter on the affected side. After the semi-rigid ureteroscope slowly enters along the hydrophilic guide wire and reaches the bottom of the stone, the laser optical fiber of the laser therapy device is inserted into the working channel of the ureteroscope so that the end of the optical fiber is exposed in the field of view of the ureteroscope. After the laser therapy device sets the lithotripsy parameters, the optical fiber is aimed at the stone for laser lithotripsy.
62717771|NCT06489366|EXPERIMENTAL|Thulium Fiber laser (TFL) lithotripsy|The patient adopts lithotomy position. After general anesthesia, a semi-rigid ureteroscope is used to enter the bladder through the urethra to observe the ureteral opening, and then a hydrophilic guide wire is inserted into the ureter on the affected side. After the semi-rigid ureteroscope slowly enters along the hydrophilic guide wire and reaches the bottom of the stone, the laser fiber of the laser therapy machine is inserted into the working channel of the ureteroscope so that the end of the fiber is exposed to the field of view of the ureteroscope. Using the TFL laser therapy device, after setting the lithotripsy parameters, the fiber is aimed at the stone for laser lithotripsy.
62717772|NCT01695018||p16 methylation positive|48 patients with mild or moderate oral epithelial dysplasia containing methylated p16.
62717773|NCT01695018||p16 methylation negative|104 patients with p16 mild or moderate oral epithelial dysplasia NOT containing methylated p16.
62717774|NCT06190834||The patients with coronary heart disease diagnosed by coronary angiography|The patients with coronary heart disease diagnosed by coronary angiography in the department of cardiology of Beijing Tsinghua Changgeng Hospital. Except patients with severe valvular disease, severe myocarditis, severe hepatic and renal insufficiency, thyroid insufficiency, severe infectious or systemic inflammatory diseases, severe blood diseases, malignant tumors, etc.
62717775|NCT05963438|OTHER|Two-step retraction group (control group)|In this group, immediately after placement of mini-implant and extractions of upper first premolars, heavy ligation will be done from mini-implant to maxillary second premolar and first molar. Canine will be retracted by sliding mechanics and the four anterior teeth will be retracted by loop mechanics. Loops will be activated every three weeks by 1 mm.
62717776|NCT05963438|EXPERIMENTAL|En-masse retraction group(experimental group)|After placement of mini-implants and extraction of maxillary first premolar, rectangular stainless steel arch wire with anterior 8mm height crimpable hooks distal to the lateral incisors will be inserted and force will be applied using elastic chains attached between the mini-implant and the hooks for conducting en-masse retraction. Elastic chains will replace after every three weeks
62717777|NCT05524831|EXPERIMENTAL|groupA(Kinesiotape)|kinesio tape on orbicularis oris muscle for 45 minute /3times per week for 2 successive months
62717778|NCT05524831|EXPERIMENTAL|group B(oromotor training)|oromotor training for 45 minute/ 3 times per week for 2 successive months
62717779|NCT01302925|EXPERIMENTAL|PEP005 Gel 0.05%/2 days|Subjects will be exposed to investigational product for 2 consecutive days.
62717780|NCT01302925|EXPERIMENTAL|PEP005 Gel 0.015%/3 days|Subjects will be exposed to investigational product for 3 consecutive days.
62717781|NCT01011114|ACTIVE_COMPARATOR|Cincalcet|cinacalcet will be titrated as needed to achieve serum phosphorus of \> 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at \~ 2.5 mg/l.
62717782|NCT01011114|PLACEBO_COMPARATOR|Control|"subjects will receive placebo pill titrated as needed to achieve phosphorus \> 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at \~ 2.5 mEq/l."
62717783|NCT00003816|EXPERIMENTAL|Regimen 1|Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
62717784|NCT00003816|EXPERIMENTAL|Regimen 2|Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
62717785|NCT00003816|EXPERIMENTAL|Regimen 3|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
62717786|NCT00003816|EXPERIMENTAL|Regimen 4|Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
62717787|NCT00003816|EXPERIMENTAL|Regimen 5|Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
62717788|NCT00003816|EXPERIMENTAL|Regimen 6|Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
62717789|NCT00003816|EXPERIMENTAL|Regimen 7|Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
62717790|NCT00003816|EXPERIMENTAL|Regimen 8|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
62717791|NCT00003816|EXPERIMENTAL|Regimen 9|Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
62717792|NCT02605408||Cataract surgery|Phacoemulsification and artificial IOL implantation with and without LenSx® laser system
62164915|NCT00938041|EXPERIMENTAL|Retreatment of NHL with Iodine-131 Anti-B1 Antibody|Patients with non-Hodgkin's lymphoma who previously responded with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy will undergo two phases of study. In the first phase, patients will receive a dosimetric dose of unlabeled Anti-B1 Antibody (450 mg) followed by Anti-B1 Antibody (35 mg) which has been radiolabeled with 5 mCi of Iodine-131. Whole body gamma camera scans will be obtained after the dosimetric dose and data from three imaging time points will be used to calculate a patient-specific dose to deliver the desired total body dose of radiotherapy. In the second phase, patients will receive the therapeutic dose of unlabeled Anti-B1 Antibody (450 mg) followed by 35 mg of Anti-B1 Antibody labeled with the patient-specific dose to deliver the desired whole body dose of radiation. Patients will be treated with thyroid blocking medication at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion.
62717793|NCT02947191|EXPERIMENTAL|Collagen membrane + HUC-MSCs|
62717794|NCT03026244|ACTIVE_COMPARATOR|Nutritional intervention product|Milk protein, prebiotics, vitamin D
62717795|NCT03026244|PLACEBO_COMPARATOR|Placebo product|placebo product
62717796|NCT06670378||Nemaline myopathy patients|Patients of any age and ability with a genetic and clinical diagnosis of Nemaline myopathy with no significant comorbidities. All patients will be evaluated for the natural clinical progression of the disease using scales and questionnaires for the assessment of motor function, breathing, swallow function and Quality of life and fatigue. In addition it will collect data on continuous movement and gait analysis using real world data and wearable sensors (Syde and Maiju), blood samples for future genetic and proteomic analysis and respiratory analysis using ventilatory and thoraco-abdominal pattern for some paediatric participants.
62717797|NCT06715085|EXPERIMENTAL|Experimental: Plasma Rich in Growth Factors (PRGF)|The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.
62717798|NCT06715085|ACTIVE_COMPARATOR|Control: Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.|The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.
62164916|NCT05538156|OTHER|Control group|The internal limiting membrane is not removed
62717799|NCT05883202|EXPERIMENTAL|Connect®|Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.
62717800|NCT05883202|ACTIVE_COMPARATOR|Multi-unit|Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
62717801|NCT03490929|EXPERIMENTAL|Contrast-enhanced ultrasound arm|contrast-enhanced ultrasound
62717802|NCT05385211||People living with type 1 diabetes|Participants will be separated into two groups based on the levels of their exocrine pancreatic enzymes levels.
62735890|NCT03316716|EXPERIMENTAL|active warming group|Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.
62164917|NCT05538156|OTHER|Intervention group|The internal limiting membrane of the posterior pole is removed
62717803|NCT04255784|EXPERIMENTAL|Active iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days. Each session will deliver 1800 pulses of active iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
62717804|NCT04255784|SHAM_COMPARATOR|Sham iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days, using a sham coil that reproduces auditory and tactile sensations of stimulation and has an identical external appearance. Each session will deliver 1800 pulses of sham iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
62717805|NCT05641402|OTHER|Experienced acceptability study|The final study in this research will involve people with type 2 diabetes receiving the text messages
62717806|NCT03695887|EXPERIMENTAL|Nitrous Oxide Inhalant Product|Nitrous oxide
62717807|NCT03695887|PLACEBO_COMPARATOR|Placebo|placebo comparator
62717808|NCT01643681|EXPERIMENTAL|AdMSC|Autologous Adipose Tissue derived Mesenchymal Stem Cells
62717809|NCT03851640|EXPERIMENTAL|HC-1119|80mg;
62717810|NCT03851640|PLACEBO_COMPARATOR|placebo|80mg;
62717811|NCT01894490||Jejunostomy|Patients who received a jejunostomy
62717812|NCT01894490||Nasojejunal catheter|Patients who received a nasojejunal catheter
62717813|NCT05592301||Surgical patients|Patients undergoing major non-cardiac, non-vascular, and non-brain surgery who will be examined for a presence of PFO
62717814|NCT04953611||Group A in GOLD|CAT\<10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year\<2；
62717815|NCT04953611||Group B in GOLD|CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year\<2
62717816|NCT04953611||Group C in GOLD|CAT\<10、mMRC 0-1、 FEV1%\<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
62717817|NCT04953611||Group D in GOLD|CAT≥10、mMRC≥2、FEV1%\<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
62717818|NCT04953611||Control Group|not COPD
62717819|NCT02012218|EXPERIMENTAL|ADT and Brexpiprazole|ADT and Brexpiprazole
62717820|NCT05454280|ACTIVE_COMPARATOR|Control Arm: Standard Perioperative Management|Patients in the Control Arm will receive standard post-discharge surveillance (i.e., usual care).
62717821|NCT05454280|EXPERIMENTAL|Intervention Arm: Intensified Post-Discharge Surveillance|"Patients in the Intervention and Control Arms will be monitored~* Through PDD 30 for postoperative deaths and complications (as defined by ACS NSQIP) and/or adverse events (as defined by CTCAE)~* Through the end of the index hospitalization for ICU admission, postoperative LOS, return to operating room, and discharge to home.~* Through PDD 90 for hospital readmission, QOL, and receipt of anti-neoplastic therapy"
62717822|NCT06172582|EXPERIMENTAL|Intervention|Participants will be randomized to intervention and will receive the 12-week program.
62717823|NCT06172582|ACTIVE_COMPARATOR|Delayed Intervention Control|Participants will be randomized to delayed intervention control and will receive the same 12-week program.
62717824|NCT04218812|ACTIVE_COMPARATOR|No electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data without ESI
62717825|NCT04218812|EXPERIMENTAL|Automated Electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data with ESI
62717826|NCT02022709|ACTIVE_COMPARATOR|Selective Serotonin Reuptake Inhibitor|In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
62717827|NCT02022709|ACTIVE_COMPARATOR|Exposure and Response Prevention|Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
62717828|NCT06716931|ACTIVE_COMPARATOR|Group A|Exercise under the supervision of physical therapist in clinic during the first 3 months, then self-directed exercise routine for the last 3 months
62717829|NCT06716931|ACTIVE_COMPARATOR|Group B|Exercise under the supervision of physical therapist virtually during the first 3 months, then self-directed exercise routine for the last 3 months
62717830|NCT06716931|ACTIVE_COMPARATOR|Group C|Self-directed exercise routine for the first 3 months, then exercise routine under the supervision of physical therapist virtually during the last 3 months
62717831|NCT03809273|EXPERIMENTAL|Yangxinshi|
62717832|NCT03809273|ACTIVE_COMPARATOR|Trimetazidine|
62717833|NCT06646952||68Ga-NOTA-MAL-NB147|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-NOTA-MAL-NB147 PET/CT scan.
62717834|NCT06719193|EXPERIMENTAL|Enhanced community-wide TB intervention|Enhanced community-wide TB intervention strategy with intensive screening and health education
62717835|NCT06719193|ACTIVE_COMPARATOR|Routine TB program activities|TB standard of care per Ethiopia's national guidelines
62717836|NCT05468502|EXPERIMENTAL|Dose escalation|Four different doses were set, and three subjects in each dose plan received human umbilical cord mesenchymal stem cell injection successively. Each subject received a single dose of 6.0\*10\^6, 3.0\*10\^7, 6.0\*10\^7, and 9.0\*10\^7 cells / person.
62717837|NCT04494360||Healthy Participants|Healthy participants (men and women) who have, or are likely to have, NAFLD will be enrolled in the study.
62717838|NCT04683705||patients without shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the asymptomatic shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
62717839|NCT04683705||patients with shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the painful shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
62735891|NCT03687294||Group I|patients suffering from malignant salivary gland tumors.
62735892|NCT03687294||Group II|patients suffering from benign salivary gland tumors.
62735893|NCT01501890|ACTIVE_COMPARATOR|Progesterone|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
62164918|NCT00304278|EXPERIMENTAL|RADPLAT and Tarceva|"All patients will receive RADPLAT and Tarceva:~Drug: Erlotinib (Tarceva)~150 mg daily X 7 weeks~Other Names:~Tarceva~Drug: Intra-arterial Cisplatin (PLAT)~1 dose (150 mg/sq) per week X 4 weeks~Other Names:~Cisplatin~Radiation: Radiation Therapy (RAD)~5 days per week X 7 weeks"
62164919|NCT05166317||Liver Cirrhosis|All the consecutive patients of cirrhosis admitted to Intensive care unit of Hepatology department of ILBS.
62164920|NCT02014402|EXPERIMENTAL|IG1202-A (Vascular)|
62164921|NCT02014402|EXPERIMENTAL|IG1202-B (Hepatic)|
62164922|NCT02014402|EXPERIMENTAL|IG1202-C (Soft Tissue)|
62543894|NCT03583086|EXPERIMENTAL|Dose Expansion - Non Small-Cell-Lung Cancer Naive|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
62543895|NCT03583086|EXPERIMENTAL|Dose Expansion - Non Small-Cell-Lung Cancer Primary Refractory|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
62543896|NCT03583086|EXPERIMENTAL|Dose Expansion - Small Cell Lung Cancer - Progressed on Platinum-based Chemotherapy|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
62543897|NCT03583086|EXPERIMENTAL|Dose Expansion - Thymic Carcinoma|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
62543898|NCT05801224|EXPERIMENTAL|Electrical Impedance Tomography|"A total of 60 subjects (cohort 1) will receive an inhaled nitric oxide (iNO) challenge (20 ppm) for 15 min. The investigators will measure ventilation and perfusion distributions using EIT before iNO (OFF1), after 15 min on iNO (ON), and after 15 min washout (OFF2) to confirm baseline stability."
62543899|NCT05801224|EXPERIMENTAL|Electrical Impedance Tomography and Dual-Energy Computed Tomography|In a subset of 10 subjects (cohort 2), EIT and DECT will be performed in a row at the same type of bed and body position. In cohort 2, the measurements will be before nitric oxide (iNO) and during iNO. The OFF-ON fashion for DECT imaging is to minimize the subject's exposure to radiation and reduce the time spent in the CT room.
62543900|NCT05948176||Urban group1|150 boys
62543901|NCT05948176||Urban group2|150 girls
62543902|NCT05948176||Rural group 3|150 boys
62543903|NCT05948176||Rural group 4|150 girls
62543904|NCT00845078||1|Immediate reconstruction followed by radiation therapy
62543905|NCT00845078||2|Radiation therapy followed by delayed reconstruction
62543906|NCT01499433|EXPERIMENTAL|caspofungin|
62543907|NCT01368315|EXPERIMENTAL|CT327|Cream
62543908|NCT01368315|PLACEBO_COMPARATOR|Placebo|Cream (Vehicle only)
62543909|NCT01368315|ACTIVE_COMPARATOR|Active comparator|Cream
62543910|NCT01368315|NO_INTERVENTION|No intervention|
62543911|NCT05871034|OTHER|Control group|Control group who have cataract without Open Angle glaucoma Will under go phacoemulsification cataract surgery
62543912|NCT05871034|OTHER|Open Angle glaucoma group|patients who have cataract and Open Angle glaucoma Will undergo phacoemulsification cataract surgery
62543913|NCT06265194|EXPERIMENTAL|Intervention (TAU and EMDR)|Intervention Group: Received TAU and EMDR Therapists delivering EMDR Therapy provided psychotherapeutic services to clients in the experimental group using the EMDR Fibromyalgia Treatment.
62543914|NCT06265194|ACTIVE_COMPARATOR|Control (TAU)|Control Group: TAU Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
62543915|NCT01509014|EXPERIMENTAL|Pharmacy Intervention Arm|All patients receiving statins from pharmacies allocated to the pharmacist intervention arm of the study
62543916|NCT01509014|NO_INTERVENTION|Usual Care|Pharmacies not allocated to the intervention arm will serve as the control. They received no training on the CPATCH intervention and provide usual care to patients at their pharmacy.
62543917|NCT02113618|ACTIVE_COMPARATOR|Cogmed Training|Cogmed® working memory training is a computer program that will be administered online. The program consists of 7 verbal and non-verbal working memory tasks and gives immediate performance feedback to the subject undergoing training.
62543918|NCT02113618|PLACEBO_COMPARATOR|Standard training|Individuals randomised to the placebo arm will receive a standard training online program from Cogmed also consisting of 90 trials to be performed 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level.
62543919|NCT01559883||all eligible patients|there is only 1 Cohort in which all patients participating in this NIS are included
62543920|NCT02794246|EXPERIMENTAL|Single Arm|
62735894|NCT01501890|PLACEBO_COMPARATOR|Placebo|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
62164923|NCT02014402|EXPERIMENTAL|IG1202-D (Spinal)|
62164924|NCT05513417||Intervention|These programs will cover participants with pelvic floor conditions which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these conditions.
62164925|NCT03379688||Cardiac surgery patients|Patients undergoing cardiac surgery at Charité Campus Mitte
62164926|NCT05450939||Ruptured group|Group of subarachnoid hemorrhage after rupture of intracranial aneurysm
62543921|NCT01794559|EXPERIMENTAL|Informed by PEER Interactive Report|"The PEER Interactive Report -This study is prospective in nature. For subjects in the experimental group, the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication.~The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days.~The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health."
62543922|NCT01794559|NO_INTERVENTION|No Report|This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health.
62717840|NCT05691192|EXPERIMENTAL|Cognitive Leisure Activities|"Participants in the intervention group will engage in cognitive leisure activities for 12 weeks and will be instructed to track their daily activity level in minutes through a daily online questionnaire. To maintain motivation and improve adherence to the study protocol, participants will also receive regular follow-up phone calls from a member of the research team every 2 weeks.~After the initial 12 weeks, the groups will be crossed over and the study will continue for another 12 weeks."
62717841|NCT05691192|NO_INTERVENTION|Passive control|Participants in the passive control group will not receive information regarding the intervention and cognitive leisure activities. They will instead be instructed to carry on as usual and to expect active participation in the study in 12 weeks from the time of enrolment.
62717842|NCT06719115|EXPERIMENTAL|UClear|UClear contains 1.5g of D-Mannose. Participants will be instructed to take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit). The product should be completely dissolved in a full glass of water and participants are instructed to take one dose in the morning and one dose in the afternoon. If a dose was missed participants were instructed to take the missed dose as soon as they remembered. Participants were advised not to exceed two doses daily.
62717843|NCT06719115|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).The product should be completely dissolved in a full glass of water and participants are instructed to take one dose in the morning and one dose in the afternoon. If a dose was missed participants were instructed to take the missed dose as soon as they remembered. Participants were advised not to exceed two doses daily.
62717844|NCT05993741|EXPERIMENTAL|AR group (EG-AR)|Behavioral: AR intervention For the EG-AR, the AR dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.
62717845|NCT05993741|EXPERIMENTAL|AR-health consulting group (EG-ARHC)|"AR intervention For the EG-B, the ARHC dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.~The health counseling will also provide professional oral health related courses (including oral care for diabetes and periodontal disease, etc.)"
62717846|NCT05993741|NO_INTERVENTION|Control group (CG)|the control group(CG) only have standard oral hygiene education
62717847|NCT04781140|PLACEBO_COMPARATOR|Placebo|Placebo, qd
62717848|NCT04781140|EXPERIMENTAL|SPN-812|SPN-812, qd
62717849|NCT01800786|ACTIVE_COMPARATOR|OSA-CPAP group|OSA patient will use CPAP for 3 months
62717850|NCT01800786|NO_INTERVENTION|OSA -no CPAP|newly diagnosed OSA patient will not wear CPAP for 3 months
62164927|NCT05450939||Unruptured group|Group of inexperience of aneurysmal rupture during specific period
62717851|NCT06226961|EXPERIMENTAL|Intervention group|For the dynamic cupping protocol, the participants will be instructed to remain seated on the massage table with their feet supported, and the technique will applied to the entire shoulder (anterior, lateral and posterior face) and surrounding muscles (upper trapezius and pectoralis major). The cupping will be performed using a plastic cupping cup (5,08 cm in diameter) (K.S. Choi Corp®) and a pistol grip hand pump (K.S. Choi Corp®). The dynamic cupping will be performed for ten minutes, at a slow pace, and consists of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
62717852|NCT06226961|NO_INTERVENTION|Control group|Participants in the CG group will remain at rest, sitting on the massage table for 10 minutes.
62717853|NCT05658328|EXPERIMENTAL|Intervention Group|Caregivers (MCI or healthy) randomized into this group walk 3x/week for 16 weeks with their care-partner (person living with early-stage dementia - PLWD) and their caregiver support person (MCI or healthy). Caregivers (and optionally for PLWD), wears an actigraphy watch, uses an under-the-mattress sleep sensor, and on a weekly basis completes weight and a health update survey. Mid- and end-study focus groups evaluate program effectiveness and needed adaptations.
62717854|NCT05658328|ACTIVE_COMPARATOR|Waitlist Control|Caregivers (MCI or healthy) randomized into this group first complete baseline measures for 16 weeks, consisting of wearing an actigraphy watch, using an under-the-mattress sleep sensor, and, on a weekly basis, completing weight and a health update survey. These baseline measures are optional for PLWD. After 16 weeks of baseline data collection, the primary caregiver continues these measures while walking 3x/week for 16 weeks with their triad. The PLWD optionally completes measures and optionally wears the watch and sleep sensor. Mid- and end-study focus groups during the walking phase evaluate program effectiveness and needed adaptations.
62717855|NCT06042426|EXPERIMENTAL|Patients receiving intravenous dexamethasone|
62717856|NCT06042426|ACTIVE_COMPARATOR|Patients receiving intravenous morphine and oral oxycodone|
62168049|NCT00513461|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
62168050|NCT03194789|ACTIVE_COMPARATOR|Traditional Pelvic Floor Therapy|up to six sessions, with one session every alternate week.
62717857|NCT00577278|EXPERIMENTAL|Treatment (chemo, monoclonal antibody therapy, transplant)|REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
62543923|NCT05980572|EXPERIMENTAL|App intervention group|Patients will receive instructions on performing the seven sets of frozen shoulder exercises mentioned earlier. The APP intervention group will be guided through the exercises using the mobile app. Each set of exercises will involve 10 repetitions, and it is recommended to perform four sessions per day.
62543924|NCT05980572|ACTIVE_COMPARATOR|Conventional group|patients will receive instructions on performing the seven sets of frozen shoulder exercises mentioned earlier. The conventional group will be provided with a printed pamphlet illustrating the exercises. Each set of exercises will involve 10 repetitions, and it is recommended to perform four sessions per day.
62543925|NCT01392625|ACTIVE_COMPARATOR|Autologous hMSCs|Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
62543926|NCT01392625|ACTIVE_COMPARATOR|Allogeneic hMSCs|Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
62543927|NCT04389892|EXPERIMENTAL|study participants|After a careful endoscopic ultrasound examination in B mode of the entire pancreas, contrast enhancement was administrated to the participants. The uptake and the wash-out of the agent were followed and then a morphological diagnose was established. EUS-fine needle aspiration of the cyst wall, septa or solid components was guided by the enhancing pattern.
62543928|NCT04185623||Group A (immediate denudation)|Oocytes were denudated immediately after oocyte retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
62543929|NCT04185623||Group B ( 2hs denudation after ovum pickup)|Oocytes were denudated 2 hours after retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
62543930|NCT03990610|EXPERIMENTAL|Treatment (vascularized lymph node transfer)|Patients undergo vascularized lymph node transfer during standard of care breast reconstructive surgery.
62543931|NCT03147625|EXPERIMENTAL|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
62543932|NCT03147625|NO_INTERVENTION|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
62717858|NCT06317662|EXPERIMENTAL|Arm A|See Detailed Description for Arm A.
62717859|NCT06317662|EXPERIMENTAL|Arm B, Cohort 1|See Detailed Description for Arm B, Cohort 1.
62717860|NCT06317662|EXPERIMENTAL|Arm B, Cohort 2|See Detailed Description for Arm B, Cohort 2.
62164928|NCT04479176||Drip-method group|Transnasal SPGB was performed by a single pain clinician. After the patient was placed in a supine and neck-extended position, 2 mL of 2% mepivacaine was placed in a syringe connected to a 16-gauge Angiocath sheath. The sheath of the Angiocath was inserted through the nostril, and 2% mepivacaine was dripped into the nostrils with the patient in a supine position. The mepivacaine drip on the nasal pharynx was maintained for 10 min. A drip of 2% mepivacaine was delivered to the nostril, where the pain was dominant. In cases of bilateral pain, mepivacaine drip was administered to both nostrils.
62164929|NCT04479176||Topical-method group|Transnasal SPGB was performed by a single pain clinician. The posture was the same as that in the drip method. A cotton tip applicator soaked with 2% mepivacaine was inserted vertically into the nostril. After the cotton tip applicator made contact with the posterior wall of the middle turbinate, the cotton tip applicator was fixed for 10 min. A cotton tip applicator was inserted into the nostril, where the pain was dominant. In cases of bilateral pain, two applicators were inserted into both nostrils.
62164930|NCT05798754|ACTIVE_COMPARATOR|Group LOR|The thoracic epidural space will be identified by the loss of resistance technique.
62164931|NCT05798754|ACTIVE_COMPARATOR|Group C|The thoracic epidural space will be identified by the CompuFlo® technology.
62164932|NCT00281983|EXPERIMENTAL|Allogeneic stem cell transplantation|"1. Cytoreductive therapy for inducing a state of partial remission:~   FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)~2. Conditioning regimen:~   FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)~3. allogeneic-PBSCT (from HLA-identical donor)~4. GVHD prophylaxis: CSA + MTX or MMF~5. +/- DLI (Donor lymphocyte infusions)"
62164933|NCT02559479|ACTIVE_COMPARATOR|18%-Protein diet|Energy-restricted diet wit the following composition: 18% protein, 30% fat and 52% carbohydrates
62164934|NCT02559479|ACTIVE_COMPARATOR|35%-Protein diet|Energy-restricted diet wit the following composition: 35% protein, 30% fat and 35% carbohydrates
62168051|NCT03194789|EXPERIMENTAL|FGBMM plus Traditional pelvic floor therapy|Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
62717861|NCT06317662|EXPERIMENTAL|Arm B, Cohort 3|See Detailed Description for Arm B, Cohort 3.
62717862|NCT06317662|EXPERIMENTAL|Arm B, Cohort 4|See Detailed Description for Arm B, Cohort 4.
62717863|NCT06317662|EXPERIMENTAL|Arm C|See Detailed Description for Arm C.
62168052|NCT03806218|ACTIVE_COMPARATOR|TICW-RFA|Bipolar RFA using twin internally cooled-wet electrodes
62717864|NCT06317662|EXPERIMENTAL|Safety Phase Cohort|See Detailed Description for Safety Phase Cohort.
62717865|NCT06317662|EXPERIMENTAL|Steroid Prephase (prednisone, prednisolone)|All patients receive prednisone or prednisolone PO or NG TID for 7 days prior to the start of induction therapy (on days 1-7).
62717866|NCT02866812|EXPERIMENTAL|patient with endovascular treatment for intracranial aneurysm|
62717867|NCT02289469|EXPERIMENTAL|PictureRx|PictureRx medication history platform
62717868|NCT02289469|NO_INTERVENTION|Usual care|Usual medication history process
62717869|NCT00800800|ACTIVE_COMPARATOR|1|Rosuvastatin 40 mg
62717870|NCT00800800|PLACEBO_COMPARATOR|2|placebo
62717871|NCT02903290|OTHER|cerebellar ataxia|Evaluation ataxia according SARAs; measuring the quality of life through SF36 Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®
62168053|NCT03806218|ACTIVE_COMPARATOR|SC-RFA|Switching monopolar RFA using separable clustered electrodes
62543933|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
62543934|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
62543935|NCT06582043|ACTIVE_COMPARATOR|SCARCr tester 1|"The subjects will apply the product concomitantly with the topical medical treatment for 56 days, followed by 28 days applying the SCARCr tester 1 alone.~Instructions for topical medical treatment and study product application:~1. Application of the topical treatment (metronidazole twice daily, morning and night, or ivermectin daily at night)~2. After 5 minutes, application of the study product starting on the eye area followed by the whole face and neck, twice a day, morning and evening.~Subjects must keep their usual habits during the clinical study (hygiene products, sunscreen, make-up). If the application of sunscreen"
62543936|NCT06582043|PLACEBO_COMPARATOR|SCARCr tester 2|"The subjects will apply the product concomitantly with the topical medical treatment for 56 days, followed by 28 days applying the SCARCr tester 2 alone.~Instructions for topical medical treatment and study product application:~1. Application of the topical treatment (metronidazole twice daily, morning and night, or ivermectin daily at night)~2. After 5 minutes, application of the study product starting on the eye area followed by the whole face and neck, twice a day, morning and evening.~Subjects must keep their usual habits during the clinical study (hygiene products, sunscreen, make-up). If the application of sunscreen"
62543937|NCT03492086|EXPERIMENTAL|Rosemary and alkylglycerol capsules|
62543938|NCT03492086|PLACEBO_COMPARATOR|Control capsules|
62543939|NCT05306509|EXPERIMENTAL|Nurse-initiated conversations for early integration of palliative care (NiCE)|Participants will receive nurse-initiated conversations facilitating early integration of palliative care in pediatric oncology.
62543940|NCT05306509|OTHER|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
62543941|NCT01845727|EXPERIMENTAL|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
62543942|NCT01845727|EXPERIMENTAL|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
62543943|NCT00431483|OTHER|Pharmaceutical counseling|
62543944|NCT02971020|OTHER|Surgical Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
62543945|NCT02971020|OTHER|Transcatheter Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
62543946|NCT03804814|ACTIVE_COMPARATOR|Motivational Interviewing Training|Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
62543947|NCT03804814|NO_INTERVENTION|Standard Clinical Encounter|Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.
62543948|NCT04023227|EXPERIMENTAL|Sacubitril/valsartan|"Sacubitril/valsartan 200 mg b.i.d.~Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug~Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively"
62717872|NCT06546085|NO_INTERVENTION|Lean with Normal Glucose Tolerance|Participants will not receive the study intervention and will be healthy controls.
62717873|NCT06546085|EXPERIMENTAL|Obesity with Normal Glucose Tolerance|Participants with obesity and normal glucose tolerance will participate in 3 supervised exercise training sessions at 85% VO2max that expends \~400 kcal for 16 weeks.
62717874|NCT06546085|EXPERIMENTAL|Obesity with Type 2 Diabetes|Participants with obesity and type 2 diabetes will participate in 3 supervised exercise training sessions at 85% VO2max that expends \~400 kcal for 16 weeks.
62717875|NCT06719518||ViTrack device|
62717876|NCT03376516|EXPERIMENTAL|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
62717877|NCT00628381|EXPERIMENTAL|AA|24 ICU patients with severe sepsis will get a L-citrulline 8 h enteral supplementation.
62543949|NCT04023227|ACTIVE_COMPARATOR|Enalapril|"Enalapril 10 mg b.i.d.~Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily)."
62543950|NCT02181790|EXPERIMENTAL|First Group|excimer laser treatment to one palm and/or one sole
62543951|NCT02181790|EXPERIMENTAL|Second Group|excimer laser treatment to both palms and/or soles
62543952|NCT01589718|EXPERIMENTAL|0.3mg Pegaptanib Sodium, Macugen|will receive Macugen intravitreal injection prior to surgery
62543953|NCT01589718|SHAM_COMPARATOR|Sham injection|will receive a sham injection
62543954|NCT00702988||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) (60 μg, 120 μg and 180 μg)
62543955|NCT00702988||Experimental Group 2|150 IU recFSH
62543956|NCT00002825|EXPERIMENTAL|Arm I|All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
62543957|NCT04621019|EXPERIMENTAL|Non-invasive lipolysis and circumference reduction of the abdomen|The treatment administration phase consists of four (4) treatment visits, delivered at least 1 week apart. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
62543958|NCT05959252|ACTIVE_COMPARATOR|Bivalirudin|Bivalirudin protocol with target activated thromboplastin time (aPTT) of 50-70 seconds
62543959|NCT05959252|ACTIVE_COMPARATOR|Unfractionated Heparin|Unfractionated heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
62543960|NCT00550030|EXPERIMENTAL|left/right|half-body comparison
62543961|NCT04774744|EXPERIMENTAL|Group I (digital health coaching program)|Patients receive the PACK Health digital health coaching program over 3 months consisting of communication initiated by either the PACK Health coach or the patient through either text, e-mail, or phone call, to provide education and support related to a specific topic such as fatigue, nutrition, or exercise.
62543962|NCT04774744|ACTIVE_COMPARATOR|Group II (standard of care support services)|Patients receive standard of care support services consisting of a telephone triage line that patients may call when experiencing physical or psychological concerns, or with any other questions related to their disease or treatment.
62543963|NCT02922738|EXPERIMENTAL|Intervention - VisualDx Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
62543964|NCT02922738|NO_INTERVENTION|Control - Usual Care Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to control, did not refer to VisualDx but could refer to other information sources or none per usual care. Their patients were assigned to the control group and interviewed about the outcomes of their treatment
62543965|NCT06202612|EXPERIMENTAL|SHR0302 quick release tablet and sustained-release tablet|
62543966|NCT06202612|EXPERIMENTAL|SHR0302 sustained-release tablet and quick release tablet|
62543967|NCT03020589|EXPERIMENTAL|CYP3A5 based tacrolimus dosing|Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5\*1/\*1 and CYP3A5\*1/\*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5\*3/\*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.
62543968|NCT03020589|NO_INTERVENTION|Control|Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
62543969|NCT00668694|NO_INTERVENTION|1|Anemia without stimulation.
62543970|NCT00668694|EXPERIMENTAL|2|Anemia with stimulation
62543971|NCT00668694|NO_INTERVENTION|3|Non-anemic group: Hb \>80-109 g/L ferritin levels \>12 μg/L and TfR \<6 will be enrolled without stimulation
62543972|NCT00668694|NO_INTERVENTION|4|Non-anemic group: Hb \>80-109 g/L ferritin levels \>12 μg/L and TfR \<6 will be enrolled with stimulation
62543973|NCT04102189|EXPERIMENTAL|Semaglutide|2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly
62543974|NCT04102189|PLACEBO_COMPARATOR|Placebo|Placebo injected s.c. once weekly .
62543975|NCT03694899|EXPERIMENTAL|one|acetaminophen 650 mg three times/day ibuprofen 600 mg three times/day opioid dose based on use in hospital day prior to discharge
62543976|NCT03905616|EXPERIMENTAL|healthy subjects|25 healthy subjects with a normal/corrected vision fitting to all of the inclusion/exclusion criteria. All the subjects will be tested on the same visual stimuli, leading to intrasubject comparison analyses of functional magnetic resonance imaging (fMRI) activity between conditions.
62543977|NCT05348447|EXPERIMENTAL|Cryoanalgesia with standard of care pain control|subjects will receive standard of care pain control + cryoanalgesia in the intercostal spaces during routine surgery
62543978|NCT05348447|ACTIVE_COMPARATOR|Standard of care pain control|subjects will receive standard of care pain control only
62543979|NCT00375895|EXPERIMENTAL|Ciclosporin|
62543980|NCT05998629|EXPERIMENTAL|Healthy control subjects experimental device|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels for healthy control subjects
62543981|NCT05998629|ACTIVE_COMPARATOR|Healthy control subjects standard of care|standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for measurement of sweat chloride concentrations for healthy control subjects
62543982|NCT05998629|EXPERIMENTAL|Cystic Fibrosis Subjects experimental device|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels for cystic fibrosis subjects
62543983|NCT05998629|ACTIVE_COMPARATOR|Cystic Fibrosis Subjects standard of care|standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for measurement of sweat chloride concentrations for cystic fibrosis subjects
62543984|NCT00497913|ACTIVE_COMPARATOR|A|
62543985|NCT00497913|PLACEBO_COMPARATOR|B|
62543986|NCT04590040|ACTIVE_COMPARATOR|Toothpaste 1|Toothpaste 3 containing 5% potassium nitrate (KNO3) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
62717878|NCT00628381|ACTIVE_COMPARATOR|AB|24 ICU patients with severe sepsis will get an alternative isocaloric amino acid supplementation (L-alanine) during 8 hours
62717879|NCT06495957|EXPERIMENTAL|Electroacupuncture group|Needles will be inserted at 11 acupoints. Acupoints will be added electrical stimulation via a low-frequency neural regulator (electrical stimulator) respectively with a disperse-dense wave after insertion of all needles. Twenty-minute treatments will be delivered three times weekly for 8 weeks.
62717880|NCT06495957|OTHER|Micro-acupuncture group|11 needles will be inserted at acupoints with 1-3 mm in depth. The acupoints will then be connected to the electrical stimulator in accordance with the electroacupuncture group. The frequency of the electroacupuncture is the same as that of the electroacupuncture group, which is briefly energized at the beginning for 30s.Twenty-minute treatments will be delivered three times weekly for 8 weeks.
62717881|NCT04617080|ACTIVE_COMPARATOR|SUPRACOR Regular|
62717882|NCT04617080|EXPERIMENTAL|SUPRACOR Strong|
62717883|NCT04265131|EXPERIMENTAL|Experimental group|art therapy is delivered on top of treatment as usual (TAU). TAU means that individual verbal therapy takes place on a regular basis, whereby the frequency varies depending on the severity of the eating disorder and the patient's request for help. Cognitive-behavioral therapy is provided with elements of dialectical behavioral therapy, and there is also the possibility of family or couple counseling by a family-based therapist.
62717884|NCT06681649|EXPERIMENTAL|Intervention|"The intervention group will receive follow-up care through the specialized post-ICU follow-up clinic at KHSC at approximately 1- and 3-months following ICU discharge. Caregivers will also be invited to participate in the follow-up clinic along with the ICU survivor participant.~In addition to receiving specialized follow-up clinical care, ICU survivor participants and their caregivers will also receive the following additional items as part of a bundled care intervention program (see Appendix):~* Informational pamphlet on critical illness and expectations following ICU discharge~* Flyer on critical illness and expectations following ICU discharge (brief version, which may be placed on the participant's refrigerator or other location at home as a consistent reminder)~* Diaries in which the healthcare team, family members, and the patient themselves are able to journal their experiences, updates, progress, and barriers in the ICU and following discharge"
62717885|NCT06681649|NO_INTERVENTION|Control|The control group will receive generalized standard of care follow-up through their primary care provider. This follow-up is highly variable depending on the patient and their primary care provider.
62717886|NCT05698394|EXPERIMENTAL|Esketamine group|For women in this group, study drug (esketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
62717887|NCT05698394|PLACEBO_COMPARATOR|placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
62717888|NCT00943761|EXPERIMENTAL|Vaniprevir 300 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 300 mg twice daily (b.i.d.) in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
62717889|NCT00943761|EXPERIMENTAL|Vaniprevir 600 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 600 mg b.i.d. in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
62717890|NCT01384318||Cuffed ETT|Patients intubated with cuffed endotracheal tubes.
62717891|NCT06718660|EXPERIMENTAL|Study Group|
62543987|NCT04590040|ACTIVE_COMPARATOR|Toothpaste 2|Toothpaste 2 containing 15% nano-HAP will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
62717892|NCT03101319|EXPERIMENTAL|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a tablet containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
62717893|NCT03101319|PLACEBO_COMPARATOR|Antipsychotic and B Complex|Subjects randomised to the B Complex arm will receive a tablet of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
62717894|NCT03344341|EXPERIMENTAL|Dapagliflozin|Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
62717895|NCT03344341|ACTIVE_COMPARATOR|Acarbose|Acarbose is started from 50 mg once a day at dinner during the first week, titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
62717896|NCT04025892|EXPERIMENTAL|Tracking group|Participants will be asked to track weight daily for six weeks
62717897|NCT03893526|PLACEBO_COMPARATOR|Placebo|Participants are subjected to a standardized meal
62717898|NCT03893526|ACTIVE_COMPARATOR|Entrestro|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
62717899|NCT03893526|ACTIVE_COMPARATOR|Sitagliptin|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
62717900|NCT03893526|ACTIVE_COMPARATOR|Entrestro + sitagliptin|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
62717901|NCT03893526|ACTIVE_COMPARATOR|Valsartan|206mg valsartan as one single dose followed by a standardized meal
62717902|NCT02184676|OTHER|Children born to mother/father with type 1 diabetes|
62717903|NCT00882024|EXPERIMENTAL|1 Tranilast|Tranilast, 300 mg/day
62717904|NCT00882024|EXPERIMENTAL|2 Tranilast|Tranilast, 150 mg/day
62717905|NCT00882024|PLACEBO_COMPARATOR|3|Placebo
62717906|NCT05443971|EXPERIMENTAL|Treatment (durvalumab, grid therapy)|Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo grid therapy on day 1. Beginning 7-14 days after grid therapy, patients also undergo palliative radiation therapy for 5 fractions. Additionally, patients undergo blood sample collection at baseline and throughout study.
62717907|NCT02869724|ACTIVE_COMPARATOR|Weekly divided delivery|Hospitalized for voluntary drug intoxications.
62717908|NCT02869724|ACTIVE_COMPARATOR|Monthly divided delivery|Hospitalized for voluntary drug intoxications.
62543988|NCT04590040|PLACEBO_COMPARATOR|Toothpaste 3|Toothpaste 1 containing 0% nano-hydroxyapatite (HAP) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
62543989|NCT01564264|EXPERIMENTAL|Sentinel Node Biopsy|Each participant will have both measurements, the new diagnostic test (sentinel node biopsy) and the gold standard (complete lymphadenectomy)
62543990|NCT01415102|EXPERIMENTAL|Cohort 1|Subjects will be assigned to receive either PF-05212372 or placebo in each period
62543991|NCT01415102|EXPERIMENTAL|Cohort 2|Subjects will be assigned to receive either PF-05212372 or placebo in each period
62543992|NCT03666286||Intensive Care Patients|Patients \>24h on intensive care
62543993|NCT00224471|EXPERIMENTAL|Group A|
62543994|NCT00224471|EXPERIMENTAL|Group B|
62543995|NCT00224471|EXPERIMENTAL|Group C|
62543996|NCT02422134|ACTIVE_COMPARATOR|Cytokine plus Hyalurinan embryo transfer arm|To monitor the pregnancy and implantation of the patients in this arm after adding Cytokine to the embryo transfer medium.
62543997|NCT02422134|NO_INTERVENTION|Hyalurinan embryo transfer group|To transfer the embryos using a Hyaluronan enriched medium only
62543998|NCT06581055||Luspatercept|Adult participants treated with and discontinued Luspatercept treatment while enrolled in the COMMANDS trial (NCT03682536).
62543999|NCT06581055||Epoetin alfa|Adult participants treated with and discontinued Epoetin alfa treatment while enrolled in the COMMANDS trial (NCT03682536).
62544000|NCT05780476|ACTIVE_COMPARATOR|Control group|Psychoeducational program.
62544001|NCT05780476|EXPERIMENTAL|Experimental group|Psychoeducational program combined with virtual reality.
62544002|NCT05076214|EXPERIMENTAL|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer.~The group training session will begin with a 3-5 minutes check-in round followed by a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied"
62544003|NCT05076214|ACTIVE_COMPARATOR|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together.
62544004|NCT03889080||SCN9A-group|Patients with SCN9A-associated small fiber neuropathy
62544005|NCT03889080||Skin biopsy|Patients with SFN confirmed with a decreased intra-epidermal nerve fiber density (IENFD)
62544006|NCT03889080||Control|Age- and gender-matched healthy controls
62544007|NCT05388513||Colon|The patients who are operated with colon cancer
62544008|NCT05388513||Rectum|The patients who are operated with rectum cancer
62544009|NCT06008275|EXPERIMENTAL|neratinib + ruxolitinib|There is only one arm
62544010|NCT06229548|EXPERIMENTAL|SYH2053 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of SYH2053 on Day 1.
62544011|NCT06229548|PLACEBO_COMPARATOR|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
62544012|NCT05866419|EXPERIMENTAL|ThecaFlex DRx Port and Catheter System|Subjects who meet all of the inclusion and none of the exclusion would be eligible to receive the ThecaFlex DRx Port and Catheter System.
62544013|NCT01738451|EXPERIMENTAL|Part 1(Cohort 1): GSK2118436 225 mg|GSK2118436 (3 capsules of 75 mg) will be administered orally at the dose of 225 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal.
62717909|NCT04619004|EXPERIMENTAL|Study Group 1: Patritumab deruxtecan 5.6 mg/kg|Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks (Q3W)
62544014|NCT01738451|EXPERIMENTAL|Part 1(Cohort 2): GSK2118436 300 mg|GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
62544015|NCT01738451|EXPERIMENTAL|Part 2: GSK2118436 300 mg (or highest tolerated dose)|Subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single dose on the 9th day. There will be 1 day when a placebo will be given. All doses will be administered under fasted conditions, either 1 hour before or 2 hours after a meal.
62544016|NCT03763357|EXPERIMENTAL|Heat Therapy|Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.
62544017|NCT05798910|ACTIVE_COMPARATOR|Conventional Training Group (15 Participants)|The members of the conventional group had to complete pretest at the beginning of the study. Afterwards they had to take part at an interactive classroom based lecture about Advanced Life Support. The next step was the skills training with task trainers in order to teach them compression skills. Afterwards, the conventional group was divided into three blue code teams consisting of each 5 participants for the simulation session. Two independent instructors evaluated the video recordings in terms of technical and nontechnical skills. The final stage of the study were completing the post-test.
62717910|NCT04619004|EXPERIMENTAL|Study Group 2: Patritumab deruxtecan Up-Titration|Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV every 3 weeks (Q3W)
62717911|NCT01252082|ACTIVE_COMPARATOR|Scalig and Rootplaning|patients will receive scaling and root planing therapy
62717912|NCT01252082|NO_INTERVENTION|control|patients in control group will not receive periodontal treatment in the time period of the study
62717913|NCT06159504|ACTIVE_COMPARATOR|Arm 1 - simplified care model|Arm 1 will receive DAA medication at the second appointment following the return of RNA HCV results. They will receive sofosbuvir (400mg) and velpatasvir (100mg).
62717914|NCT06159504|EXPERIMENTAL|Arm 2 - short read time|Arm 2 will begin DAA treatment after the first appointment following a shortened RDT read time of 5 minutes rather than 20 minutes. They will receive sofosbuvir (400mg) and velpatasvir (100mg).
62717915|NCT03313414|EXPERIMENTAL|Treatment with Sofosbuvir/Velpatasvir|14 days of treatment with Sofosbuvir/Velpatasvir tablet
62717916|NCT06020521|OTHER|Group of healthy volunteers|This research will take place at the hospital and at the UFR Simone Veil-Santé with single sessions on the same day of approximately 10 minutes and 1 hour respectively. A list of healthy volunteers has already been established at the faculty. A provisional schedule for passing the various examinations provided for in the protocol is also scheduled. The experiments conducted at the UFR Simone Veil - Santé will take place within the Department of Health Biotechnology. This Department already has all the resources necessary for the successful completion of the study, in particular within the mass spectrometry platform which has the instruments (high resolution mass spectrometer Q-Exactive) and human resources (2 analytical science engineers, 1 data science engineer + technical staff and interns) required.
62717917|NCT06717074|EXPERIMENTAL|Low dose group, active|Participants will receive RBD4059 as subcutaneous injections
62717918|NCT06717074|PLACEBO_COMPARATOR|Low dose group, placebo|Participants will receive placebo as subcutaneous injections
62717919|NCT06717074|EXPERIMENTAL|High dose group, active|Participants will receive RBD4059 as subcutaneous injections
62717920|NCT06717074|PLACEBO_COMPARATOR|High dose group, placebo|Participants will receive placebo as subcutaneous injections
62717921|NCT02296476|EXPERIMENTAL|Birabresib 80 mg|Participants received 80 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
62717922|NCT02296476|EXPERIMENTAL|Birabresib 120 mg|Participants received 120 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
62717923|NCT02296476|EXPERIMENTAL|Birabresib 160 mg|Participants received 160 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
62717924|NCT05065658||Critically-ill COVID-19 patients receiving posaconazole prophylaxis|
62717925|NCT05065658||Critically-ill COVID-19 patients without antifungal prophylaxis|
62717926|NCT01175343|EXPERIMENTAL|Treatment (RO4929097)|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected."
62717927|NCT06324474|EXPERIMENTAL|scaling and root planning with Hyaluronic acid application|patients will receive Hyaluronic acid topical gel after scaling and root planning at first week and receive the gel after one week
62717928|NCT06324474|EXPERIMENTAL|scaling and root planning only|patients will receive scaling and root planning only
62717929|NCT03730610|EXPERIMENTAL|Exercise intervention|Six months of exercise training
62717930|NCT05121961|EXPERIMENTAL|Platelet-rich Plasma|Patients will receive an intra-articular injection 3 mL of autologous platelet-rich plasma in the sacroiliac joint.
62717931|NCT05121961|ACTIVE_COMPARATOR|Steroid/Anesthetic|Patients will receive an intra-articular injection 40 mg Depo-medrol mixed with 2 mL 0.25% bupivicaine in the sacroiliac joint.
62717932|NCT02098135|EXPERIMENTAL|ArmeoSenso|The ArmeoSenso system is an easy to set up and use upper limb rehabilitation system for the home environment. It consists of a motion capture system based on wearable sensors in combination with a personal computer as well as a therapy software that provides an ergonomic user interface, therapy games and automated assessments.
62717933|NCT04954534|EXPERIMENTAL|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood-derived mesenchymal stem cells High dose: 3 x 10\^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
62717934|NCT06307613|EXPERIMENTAL|Efgartigimod arm|Participants with active, moderate-to-severe TED receiving Efgartigimod PH20 SC (subcutaneously) via pre-filled syringe (PFS)
62717935|NCT06307613|PLACEBO_COMPARATOR|Placebo arm|Participants with active, moderate-to-severe TED receiving Placebo PH20 SC (subcutaneously) via pre-filled syringe (PFS)
62717936|NCT06717828|EXPERIMENTAL|Tai Chi Exercise|Tai Chi Exercise program, five times a week .
62717937|NCT06717828|EXPERIMENTAL|Regular Physical Activity|Each exercise session lasts for 60 minutes, five days a week.
62717938|NCT06717828|OTHER|Control|Conduct health education on fatty liver once every two months.
62717939|NCT04289779|EXPERIMENTAL|Treatment Arm|Cabozantinib 40 mg orally daily x 9 weeks plus Atezolizumab 1200 mg every 3 weeks x 3 doses
62717940|NCT04826237|EXPERIMENTAL|Statin|"Methylprednisolone+statin (identity and dose to be determined before Trial Begins) Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day;~Oral statin 1 dose per day for 7 days, beginning with the first dose of methylprednisolone:~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
62717941|NCT04826237|PLACEBO_COMPARATOR|Placebo|"Methylprednisolone+ placebo. Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral placebo 1 dose per day for 7 days, beginning with the first dose of methylprednisolone~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
62717942|NCT00752414|EXPERIMENTAL|1|MP-376 Inhalation Solution
62717943|NCT00752414|PLACEBO_COMPARATOR|2|Placebo
62717944|NCT01298336|EXPERIMENTAL|Clarithromycin|
62544018|NCT05798910|ACTIVE_COMPARATOR|VR Group (14 Participants)|The members of the VR group had to complete pretest at the beginning of the study. Afterwards they had to play with the VR based serious game module for Advanced Life Support. The next step was the skills training with task trainers in order to teach them compression skills. Afterwards, the conventional group was divided into three blue code teams consisting of each 5 participants for the simulation session. Two independent instructors evaluated the video recordings in terms of technical and nontechnical skills. The final stage of the study were completing the post-test. The aprticipants of this group were also asked to fill a survey about their VR experience during the study.
62544019|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
62544020|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
62544021|NCT04860609|ACTIVE_COMPARATOR|Conventional Physiotherapy|It includes the pre-physiotherapy session by conventional physiotherapy
62544022|NCT04860609|EXPERIMENTAL|Lumber spinal decompression|It includes the pre-physiotherapy session iby lumber spinal decompression along with conventional therapy.
62544023|NCT03685201|ACTIVE_COMPARATOR|Orange Juice1|100% orange juice
62544024|NCT03685201|EXPERIMENTAL|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
62544025|NCT03685201|PLACEBO_COMPARATOR|Raw Orange|raw orange
62544026|NCT02000765|EXPERIMENTAL|GSK2140944 for Injection and Capsule|Each subject will receive a single 1000 milligram (mg) IV dose of GSK2140944 containing \[14C\]-GSK2140944 of approximately 22.5 microcurie \[μCi\] (approximately 0.8 megabecquerel \[MBq\]) of radioactivity given as a 2 hour infusion on Day 1 of treatment period 1 and 2000 mg oral dose of GSK2140944 containing \[14C\]-GSK2140944 of approximately 45 μCi (approximately 1.7 MBq) of radioactivity on Day 1 of treatment period 2. Each treatment period will be followed with washout of atleast 8 Days.
62544027|NCT06632327|EXPERIMENTAL|Arm 1 (surgery, adjuvant therapy)|"SURGERY: Patients undergo surgery within 28 days of registration.~ADJUVANT THERAPY: Patients receive platinum-based doublet chemotherapy (cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and/or vinorelbine) for up to 4 cycles and immune checkpoint inhibitor therapy (nivolumab, pembrolizumab, and/or atezolizumab) for up to 1 year in the absence of disease progression or unacceptable toxicity according to current approved guidelines.~Patients also undergo CT throughout the study and may undergo MRI and/or PET/CT at screening."
62544028|NCT06632327|EXPERIMENTAL|Arm 2 (neoadjuvant therapy, surgery, adjuvant therapy)|"NEOADJUVANT THERAPY: Within 28 days of registration, patients receive platinum-based doublet chemotherapy (cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and/or vinorelbine) for up to 4 cycles in combination with immune checkpoint inhibitor (nivolumab, pembrolizumab, and/or atezolizumab) according to current approved guidelines.~SURGERY: Patients undergo surgery.~ADJUVANT THERAPY: Patients receive immune checkpoint inhibitor therapy (nivolumab, pembrolizumab, and/or atezolizumab) for up to 1 year in the absence of disease progression or unacceptable toxicity according to current approved guidelines.~Patients also undergo CT throughout the study and may undergo MRI and/or PET/CT at screening."
62544029|NCT04588025|ACTIVE_COMPARATOR|Healthy Volunteers|
62544030|NCT04588025|ACTIVE_COMPARATOR|Pancreatic Cancer Participants|
62544031|NCT04191850|ACTIVE_COMPARATOR|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
62544032|NCT04191850|EXPERIMENTAL|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
62544033|NCT05461326|ACTIVE_COMPARATOR|Quad tendon|ACL graft harvested from the quadriceps tendon
62544034|NCT05461326|ACTIVE_COMPARATOR|BTB tendon|ACL graft harvested from the patellar tendon
62544035|NCT03263897|EXPERIMENTAL|Active|Receiving insufflation during an acute episode of migraine in both visits
62544036|NCT03263897|SHAM_COMPARATOR|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
62544037|NCT04558918|EXPERIMENTAL|LNP023 200mg b.i.d.|Iptacopan 200mg b.i.d. hard gelatin capsule. After 24 weeks of LNP023 200mg b.i.d. treatment in the Randomized Treatment Period, participants had the option to enter the Extension Treatment Period to receive an additional 24 weeks of LNP023 200mg b.i.d.
62544038|NCT04558918|ACTIVE_COMPARATOR|Anti-C5 antibody|In the Randomized Treatment Period patients randomized to receive Anti-C5 antibody continued with the same stable regimen of Anti-C5 antibody therapy as they had received prior to randomization. For eculizumab (administered as intravenous infusion every 2 weeks), the maintenance dose was a fixed dose, whereas for ravulizumab (administered as intravenous infusion every 8 weeks), the maintenance dose was based on body weight. After 24 weeks of Anti-C5 antibody treatment in the Randomized Treatment Period, participants had the option to enter the Extension Treatment Period to receive 24 weeks of LNP023 200mg b.i.d.
62544039|NCT02513212|OTHER|oxalate liquid, SnF2 paste, manual toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Manual toothbrush
62544040|NCT02513212|OTHER|oxalate liquid, SnF2 paste, power toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Power toothbrush
62544041|NCT06057272||Forensic Medicine|Individuals with unilateral lower extremity fractures who apply to the Department of Forensic Medicine for disability rate determination and reporting
61976535|NCT01203150|PLACEBO_COMPARATOR|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
62544042|NCT06057272||Orthopedic|In individuals with unilateral lower extremity fractures who apply to the Department of Orthopedics and Traumatology
62544043|NCT06057272||Healthy|The healthy counterparts of the patients in the forensic medicine and orthopedic population group.
62717945|NCT01298336|EXPERIMENTAL|Moxifloxacin|
62717946|NCT05916300||Standard physiotherapy group|Patients will be treated with standard physiotherapy according to the recommendation of the referring physician without modification of the treatment based on the output of the diagnostic ultrasonography examination.
62164935|NCT06584994||Individuals and Families affected by disease predisposition syndromes|"We will work with collaborators to identify cohorts of families in which one or more members suffer with a cancer predisposition syndromes such as LFS. The affected individual/s act as an index participant and their unaffected family members act as controls. This may include immediate family (father, mother and affected/non-affected siblings) and extended family members (grandparents, maternal/paternal uncles and aunts) where practical.~We wish to collect blood samples, buccal swabs, skin swabs, saliva and/ or urine samples. Adult males (affected and unaffected) may (cohort dependant) also be asked to collect a semen sample for use in the study.~We will ask affected individuals if we can access any leftover tumour biopsies and/or material from medical procedures for use in the study.Material will only be accessed once it is not required for diagnostic purposes."
62164936|NCT06584994||Individuals attending fertility clinics with or without fertility problems|For males who are attending fertility clinics we will require blood or saliva samples along with a semen sample as a minimum to take part in this arm of the study.
62164937|NCT06584994||Individuals receiving treatment for cancers in the reproductive system|These participants will have to agree to donate a blood sample (and a semen sample for adult male participants) both before and after their treatment. If any participants do not wish to give a blood sample, we may be able to collect a saliva sample or buccal swab instead.
62164938|NCT06537570|EXPERIMENTAL|Guided Imagery Practice|Pregnant women in the experimental group were administered pre-tests (Personal Information Form, Psychosocial Health Assessment Scale in Pregnancy and Wijma Birth Expectancy/ Experience Scale - A Version) just before watching the guided imagery video. In the first interview with pregnant women, video viewing days and hours were determined by giving information about the guided imagery video. Pregnant women were then shown the guided imagery video consisting of a total of 12 weeks, once a day for 15 minutes and 50 seconds. Immediately after the 12-week period was completed, post-tests (Psychosocial Health Evaluation Scale in Pregnancy and Wijma Birth Expectancy/ Experience Scale - A Version) were administered to the pregnant women.
62544044|NCT04302636|EXPERIMENTAL|The hypoglycemic index diet group|"Patients in the experimental group ate two portions of food each day.This diet will last for 12 weeks.~1. Food provided by the canteen: one egg for breakfast;Lunch and dinner are 50g of rice with all the dishes.~2. Dietary nutrition and supplementary food: according to the weight and height of the patient, the daily energy required was calculated, which was divided into six levels: 1400kcal, 1600kcal, 1800kcal, 2000kcal, 2200kcal and 2400kcal.The six corresponding nutritional auxiliary food powders are: 20g-30g-40g-50g-60g-70 g.The suspension was prepared in the proportion of 160ml warm water poured into 55 grams and given to the patient."
62544045|NCT04302636|NO_INTERVENTION|General diet group|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
62544046|NCT02901977|EXPERIMENTAL|ACE inhibitor|Ramipril tablets 10 mg od for 12 weeks
62544047|NCT02901977|ACTIVE_COMPARATOR|Alpha receptor blocker|Doxazosin tablets 8 mg od for 12 weeks
62544048|NCT05776823|EXPERIMENTAL|Pharmacist Narcan Training|Pharmacist-led intervention
62544049|NCT05776823|ACTIVE_COMPARATOR|Substance Use Counselor Narcan Training|Non-clinician intervention
62544050|NCT05776823|EXPERIMENTAL|Brief Intervention and Referral to Treatment (BIRT)|BIRT intervention
62544051|NCT05776823|ACTIVE_COMPARATOR|Standard Medication Counseling (SMC)|SMC intervention
62544052|NCT02056912|OTHER|Lipodystrophie Héréditaire|
62544053|NCT04968184|PLACEBO_COMPARATOR|Placebo|"Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period.~Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period~Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period~Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52.~Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56."
62544054|NCT04968184|EXPERIMENTAL|KBP-5074|"Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period.~Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period~Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period~Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52.~Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56."
62544055|NCT02925104|EXPERIMENTAL|INC280|
62544056|NCT05912270|EXPERIMENTAL|Orchestra in Class|"Children will receive music practice lessons in groups, Orchestra in Class (4 different string instruments, violin, viola, cello, double bass) in school class size groups over 2 full years. Interventions, given by 2 professional teachers per class, take place for 1 hour and 30 minutes per week, completed by daily homework (20-30 minutes)."
62544057|NCT05912270|EXPERIMENTAL|Visual Arts|Children will receive visual arts lessons in school class size groups over 2 full years. Interventions, given by 2 professional teachers per class, take place for 1 hour and 30 minutes per week, completed by daily homework (20-30 minutes).
62544058|NCT05912270|PLACEBO_COMPARATOR|Culture|The children will receive six cultural outings per year (museums, concerts, theatre, etc.) and pass all measurements
62544059|NCT06493006||Long-term group|University members who use mainly one transport mode to get to the work place
62544060|NCT06493006||Short-term group|University members who alternate their transport habits between physically active and passive commuting
62168054|NCT01378481|EXPERIMENTAL|Treatment (vorinostat, surgery, FSRT)|Patients receive high-dose vorinostat PO at 48, 27, and 3 hours prior to surgery. Beginning 2-6 weeks later, patients receive vorinostat PO QD on days 1-3 in weeks 1-2and undergo fractionated stereotactic body radiation therapy on days 1-5 in weeks 1-2. Treatment continues in the absence of disease progression or unacceptable toxicity.
62164939|NCT06537570|NO_INTERVENTION|group|Pregnant women in the control group were administered pre-tests (Personal Information Form, Psychosocial Health Assessment Scale in Pregnancy and Wijma Birth Expectancy/ Experience Scale) and post-tests (Psychosocial Health Assessment Scale in Pregnancy and Wijma Birth Expectancy/ Experience Scale - A Version) 12 weeks later and no practice was performed except routine practices during outpatient follow-up.
62164940|NCT05993832|EXPERIMENTAL|Referential cues to object|Each object pair that is presented to the child is accompanied by 1) gaze only (3 trials); 2) novel label only (3 trials); or 3) conflicting gaze and novel label (3 trials)
62164941|NCT01015794|EXPERIMENTAL|Adrenergic agonist|
62164942|NCT02891018|EXPERIMENTAL|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
62164943|NCT02891018|EXPERIMENTAL|paclitaxel release coronary balloon catheter|Patients treated with paclitaxel release coronary balloon catheter
62544061|NCT01410656|NO_INTERVENTION|Standard PA Recommendation|Received the standard physical activity recommendation.
62544062|NCT01410656|EXPERIMENTAL|Telephone Implementation Intention|Behavioural Telephone Assisted Implementation Intention Intervention
62544063|NCT01410656|EXPERIMENTAL|Self-completed implementation intention|Self-administered implementation intention intervention.
62544064|NCT03391414|EXPERIMENTAL|hypertonic bicarbonate|subjects will be administered a solution of 8.4% hypertonic bicarbonate by nebulizer
62544065|NCT03391414|ACTIVE_COMPARATOR|hypertonic saline|subjects will be administered a solution of 7% sodium chloride by nebulizer
62544066|NCT05544279|EXPERIMENTAL|Intervention group that given education|"7 interviews are held. 3 meaurements are explored. In the first measurement (first interview) Personal information form, Zarit Burden Interview (ZBI), STAI-S and STAI-T are filled in preoperatively within 24-48 hours, and the planned training and booklet are given. Second measurement (4th interview) is done on the phone within the 1st week after discharge. Third measurement (7th interview) is explored within the 4th week after discharge. In the interim interviews, the training is repeated and the questions about the places that were not understood are answered."
62544067|NCT05544279|NO_INTERVENTION|Control group|"1. Interview (pre-test): 1st interview: Personal information form, ZBI, STAI were filled in preoperatively within 24-48 hours. They receive routine care at the hospital 2nd interview (on the phone within the 1st week after discharge): ZBYÖ, STAI-S and Education follow-up form are filled.~3rd interview (post-test): ZBYÖ, STAI-S and Education follow-up forms were filled on the phone within the 4th week after discharge. A pdf format of the training material was sent to the mothers in the control group via whatsapp application."
62544068|NCT05727618|EXPERIMENTAL|pituitrin group|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
62544069|NCT05727618|PLACEBO_COMPARATOR|normal saline group|Intravenous infusion of normal saline at the same dose and speed
62544070|NCT01148615|EXPERIMENTAL|Aflibercept/ docetaxel|"Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks"
62544071|NCT01605812||high myopia|high myopia (axial length\>26mm)
62544072|NCT01605812||emmetropia|emmetropia (22\<axial length\<25mm) as control group.
62544073|NCT01233895|EXPERIMENTAL|AVE1642/ AVE1642 with Velcade|
62544074|NCT02127346||Chronic Periodontitis|"1. Male patients~2. Patients are suffering from chronic periodontitis~3. Patients do not have any systemic diseases~4. Subjects should have 20 teeth at least~5. Age: 30 years or greater"
62544075|NCT02127346||Healthy Volunteers|"1. Males~2. Healthy with no systemic diseases or periodontitis~3. 30 years old at least~4. 20 teeth are present at least"
62544076|NCT05489666|ACTIVE_COMPARATOR|Treatment Group|Participants in this group will be administered an oral Vitamin D3 supplement; 5,000 IU/ day. The participants will take the supplement themselves, orally, once per day, for 8 weeks.
62544077|NCT05489666|PLACEBO_COMPARATOR|Control Group|Participants in this group will be administered an oral, soft-gel, lookalike placebo. The participants will take the supplement themselves, orally, once per day, for 8 weeks.
62544078|NCT04813783||Control group|The first group of 26 volunteers who meet the inclusion criteria of the study will form the control group. These participants will be given clinical routine training about mucositis care.
62544079|NCT04813783||Intervention Group|In the study, in order to prevent/minimize the flow of information between the control and intervention groups, the data of the control group will be collected first. Data collection will be suspended in the clinic for three months after the control group data is completed. After this period, data of the enterprise group will be collected. Participants in the intervention group will be provided with mucositis training within the scope of the Mucositis Care Protocol in line with the MASCC / ISOO 2019 Recommendations.
62164944|NCT04967521|EXPERIMENTAL|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
62164945|NCT04967521|PLACEBO_COMPARATOR|Placebo Arm|Patients will be randomized 1:1 and will receive placebo if they are randomized to the placebo arm of the study. Each cycle is 28 days.
62164946|NCT05420701|NO_INTERVENTION|Left Atrial Appendage Occlusion|
62164947|NCT05420701|ACTIVE_COMPARATOR|Left Atrial Appendage Closure,|
62164948|NCT04855396||Patients with Severe Traumatic Brain Injury|Participants will be enrolled in the HOBIT trial
62168055|NCT02936193|EXPERIMENTAL|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy with Pylorus-preservation
62544080|NCT02315274|EXPERIMENTAL|Single arm, remote contact.|Between visit remote contact.
62544081|NCT03482115|EXPERIMENTAL|Comatose patient|Subject with coma of traumatic or anoxic aetiology : PET examination with radiopharmaceutical drug \[18F\] DPA-714, MRI examination and Blood samples.
62717947|NCT05916300||Diagnostic ultrasonography-guided physiotherapy group|Patients will undergo modified treatment techniques, the application of which will be indicated based on the initial diagnostic ultrasonographic examination.
62717948|NCT06315192|EXPERIMENTAL|Stroke Alarm use|The patients are provided with Stroke Alarm and instructed to use it in accordance with the IFU for a 3 months period.
62717949|NCT04846387||Females with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A urinary pouch will be used to collect the participant's urine while in the scanner."
62717950|NCT04846387||Males with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A condom catheter will be used to collect the participant's urine while in the scanner."
62717951|NCT02522039|EXPERIMENTAL|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
62717952|NCT02522039|EXPERIMENTAL|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
62717953|NCT02522039|EXPERIMENTAL|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
62717954|NCT02522039|NO_INTERVENTION|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
62717955|NCT05155033|EXPERIMENTAL|1 - Pembro and IL-2|Course 1: pembrolizumab (200 mg IV) on Day 1 of each cycle with aldesleukin (600,000 IU/kg intravenous bolus every eight hours) continuing for up to 4 days (maximum 10 doses) for 2 cycles (each 21 days). Course 2: pembrolizumab (200 mg IV) on Day 1 of each cycle for 2 cycles (each 21 days).
62717956|NCT04340154|EXPERIMENTAL|chimeric antigen receptor T cell treatment|
62717957|NCT04630821|EXPERIMENTAL|Treatment with Dilute Sodium Hypochlorite solution|Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.
62717958|NCT06630533|EXPERIMENTAL|Baduanjin Exercise Group|The experimental group received Baduanjin training for 8 weeks (5 days a week). Baduanjin training was given face-to-face 3 days a week by a physiotherapist who is a Baduanjin trainer. Participants practiced it at home as a home exercise 2 days a week.
62717959|NCT06630533|NO_INTERVENTION|Control Group|No intervention will be applied to the control group.
62717960|NCT03680807||Older adults with knee osteoarthritis (>50 years)|
62717961|NCT03680807||Healthy older adults (> 50 years)|
62717962|NCT03702179|EXPERIMENTAL|Durvalumab + Tremelimumab|"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.~Two weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder."
62168056|NCT02936193|ACTIVE_COMPARATOR|Distal gastrectomy|Patients undergo Laparoscopic Gastrectomy procedure detailing in distal gastrectomy with D2 lymphadenectomy
62544082|NCT03482115|OTHER|control volunteers|subject control : PET examination with radiopharmaceutical drug \[18F\] DPA-714, MRI examination and Blood samples.
62717963|NCT04122976||Men with nmCRPC|Men with nmCRPC for whom a decision to treat with darolutamide has been made before enrollment, and who have signed informed consent, will be eligible for the study.
62717964|NCT02153489|EXPERIMENTAL|Aclidinium bromide|Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
62717965|NCT02153489|PLACEBO_COMPARATOR|Placebo|Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
62717966|NCT06181981||incidental Leukoaraiosis (LA)|Eligible patients in the incidental LA group will be pre-identified by the radiologist at the time of the 3T MRI or CT scan, and recruited by the neurologist at their first routine neurology consultation in the days following the MRI.
62717967|NCT06181981||LA and ischemic stroke|Eligible patients in the LA + ischemic stroke group will be recruited by the neurologist during hospitalization for ischemic stroke
62168057|NCT04130373||Women receiving autologous fat grafting|Women who received breast reconstruction and autologous fat grafting.
62168058|NCT04130373||Control|Women who received breast reconstruction only.
62544083|NCT04977531||6 months less|Stroke onset less than 6 months
62168059|NCT02942628|EXPERIMENTAL|Vegetarian - Meat|4 weeks of vegetarian diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of meat-containing diet
62544084|NCT04977531||6 months to 2 years|Stroke onset between 6 months and 2 years
62544085|NCT04977531||over 2 years|Stroke onset over 2 years
62544086|NCT03352466|EXPERIMENTAL|NasoShield very low dose|Single intranasal spray (Part A)
62544087|NCT03352466|EXPERIMENTAL|NasoShield low dose|Single intranasal spray (Part A)
62717968|NCT06181981||LA and intracerebral hemorrhage|Eligible patients in the LA + intracerebral hemorrhage group will be recruited by the neurologist during hospitalization
62717969|NCT01881815||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
62717970|NCT03888248|ACTIVE_COMPARATOR|Exercises|Daily muscle-strengthening exercises
62717971|NCT03888248|EXPERIMENTAL|Whole-body vibration + exercises|Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
62544088|NCT03352466|EXPERIMENTAL|NasoShield medium dose|Single intranasal spray (Part A)
62717972|NCT06194305|EXPERIMENTAL|CBIT group|Participants with chronic TICs
62717973|NCT05304442|EXPERIMENTAL|Intravenous Ferric Derisomaltose|One single dose of ferric derisomaltose, 1000 mg Intravenous over at least 20 minutes.
62717974|NCT05304442|ACTIVE_COMPARATOR|Oral Iron|ferrous sulfate 65 mg once daily for 42 days.
62717975|NCT00659282||A|biphasic insulin aspart
62717976|NCT03528317|EXPERIMENTAL|Alternate day fasting|Alternate day fasting with a high protein diet
62717977|NCT05837234|EXPERIMENTAL|ULF SCS|Participants with chronic low back pain that is refractory to conservative care will undergo temporary trial stimulation with the ULF SCS system. Those receiving at least 50% pain relief of their chronic back pain will be eligible for a permanent device implant and followed for 24 months.
62717978|NCT05227976|ACTIVE_COMPARATOR|Theory only|Once weekly for 10 weeks
62717979|NCT05227976|ACTIVE_COMPARATOR|Theory and physical training|Once weekly for 10 weeks
62717980|NCT05227976|ACTIVE_COMPARATOR|Theory and mindfulness/medical yoga|Once weekly for 10 weeks
62544089|NCT03352466|EXPERIMENTAL|NasoShield high dose|Single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
62544090|NCT03352466|PLACEBO_COMPARATOR|Placebo|Normal saline, single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
62544091|NCT03352466|ACTIVE_COMPARATOR|BioThrax|Three intramuscular injections 15 days apart (Part A)
62544092|NCT06633094|NO_INTERVENTION|In-person management|In-person group will be followed with standard-of-care clinic visits scheduled with an pediatric orthopaedic Surgeon at Carilion Clinic Institute for Orthopaedics and Neurosciences. Participants will complete a pediatric PROMIS assessment at baseline and 6 weeks for . Patients/guardians will complete a satisfaction survey.
62544093|NCT06633094|EXPERIMENTAL|Home management|Home-management group will be given access to an educational video explaining the nature of buckle fractures and treatment. all participants will enroll in MyChart to allow for asynchronous messages. Participants will complete a pediatric PROMIS assessment at baseline and 6 weeks. Patients/guardians will complete a satisfaction survey.
62544094|NCT03876626|OTHER|Provider Participants|Employees who work with medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as providers. Provider participants will receive access to a web based system that allows them to view information for their enrolled clients, securely message clients, and track medication refills. Providers will be asked to participate in a 30-day usability interview and a end-of-study assessment.
62544095|NCT03876626|OTHER|Patient Participants|Clients who receive medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as patients. Patient participants will be provided access to a mobile app that allows them to track their mood, stress, and medication adherence, access an anonymous online community, securely message providers, and receive medication refill alerts
62544096|NCT00638053|EXPERIMENTAL|1|
62544097|NCT05622240|EXPERIMENTAL|99mTc-MIRC213 Dosimetry study|about 6 patients were injected with 11.1-14 (MBq) per kilogram body weight of 99mTc-MIRC213 in one dose intravenously and underwent wholebody scan at 5min、20min、40min、60min、90min、120min、180min、240min, then analysis of dosimetric distribution of radiopharmaceuticals in human body by HERMES software.
62544098|NCT05622240|EXPERIMENTAL|99mTc-MIRC213 wholebody and SPECT/CT scan|About 30 patients were injected with 11.1-14 (MBq) per kilogram body weight of 99mTc-MIRC213 in one dose intravenously and underwent wholebody scan 1 \\2\\3h later and underwent SPECT/CT scan at 2h.
62544099|NCT02989324|EXPERIMENTAL|Vaginal Misoprosto|Vaginal Misoprosto for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Section
62544100|NCT02989324|ACTIVE_COMPARATOR|Misoprostol Plus Foley Catheter|Misoprostol Plus Foley Catheter for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Sections
62544101|NCT03259412|EXPERIMENTAL|Fish Oil|Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
62544102|NCT03259412|PLACEBO_COMPARATOR|Placebo|Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
62544103|NCT05151289|EXPERIMENTAL|Patients consulting in one of the participating centers for intra uterine growth restriction.|All included patients
62544104|NCT02811432|EXPERIMENTAL|Kangaroo mother care|Skin-to-skin care initiated as soon as possible following randomisation
62544105|NCT02811432|ACTIVE_COMPARATOR|Standard care|Incubator or radiant warmer
62717981|NCT05543499||Monochorionic Pregnancy Group|Participants with complicated monochorionic pregnancies (MC) will be followed prospectively beginning at the time of the mother's evaluation for a complication related to monochorionic (MC) multiple pregnancies through delivery of the child and follow-up of the child to 12 months of life.
62717982|NCT05490758|EXPERIMENTAL|sensorimotor training|sensorimotor training group did sensorimotor activities e.g play with dough,peg games 5 days a week for 4 weeks.
62717983|NCT05490758|EXPERIMENTAL|constraint induced movement therapy|constraint induced movement therapy group in which affected arm was constraint for 6 hours a day for 5 days a week for 4 weeks.
62717984|NCT02996812|ACTIVE_COMPARATOR|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
62717985|NCT02996812|ACTIVE_COMPARATOR|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
62717986|NCT02996812|ACTIVE_COMPARATOR|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
62717987|NCT02996812|ACTIVE_COMPARATOR|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
62717988|NCT06573008|EXPERIMENTAL|GP681 tablet 40mg|Patients in the GP681 tablet 40mg group will receive a single oral dose of GP681 tablet 40mg.
62717989|NCT06573008|PLACEBO_COMPARATOR|Placebo group|Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg.
62717990|NCT01010607|EXPERIMENTAL|Vibraton Mirror (VM)|subjects will receive tendon vibration AND mirror therapy
62717991|NCT01010607|ACTIVE_COMPARATOR|Mirror (M)|Subjects will receive treatment only with Mirror, together with sham vibration (over bone instead of tendon)
62717992|NCT01010607|SHAM_COMPARATOR|Sham (S)|Opaque board instead of mirror, bone vibration instead of tendon vibration
62717993|NCT03224039|EXPERIMENTAL|Intranasal sufentanil|"Treatment arm to include~1. Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose~2. Normal saline 1ml intravenous (IV) push x 1 dose"
62717994|NCT03224039|ACTIVE_COMPARATOR|Intravenous morphine|"b. Treatment B:~1. Normal saline 0.3 mL IN x 1 dose~2. Morphine 0.1 mg/kg IV push x 1 dose"
62717995|NCT06104137|EXPERIMENTAL|MOOC group|If a patient chooses to take part and is randomly allocated to the MOOC group, a member of research team will issue them with details of how to access the course. Three to six weeks later the research team will contact them to test their recall over the phone of some important information about bariatric surgery. At six week's after the procedure, the research team will send them a copy of the SDM Q9 questionnaire to complete and send back. This is a questionnaire that asks about satisfaction with the shared decision making process.
62717996|NCT06104137|ACTIVE_COMPARATOR|non MOOC group|If a patient is randomly allocated to the non MOOC group, they will also receive a recall test and a questionnaire after the consultant appointment in order to compare the two groups.
62717997|NCT06301646|EXPERIMENTAL|comprehensive rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The experimental group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
62717998|NCT06301646|ACTIVE_COMPARATOR|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The control group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
62717999|NCT06482086|EXPERIMENTAL|Organoid-guided targeted therapeutic group|Patients who take the recommended drugs regularly based on sensitivity analysis.
62718000|NCT00765414|EXPERIMENTAL|1|
62718001|NCT01469039|EXPERIMENTAL|ALKS 9072|
62718002|NCT01469039|PLACEBO_COMPARATOR|Placebo|
62718003|NCT02669498|ACTIVE_COMPARATOR|Surgery with fallopian tube removal|Patients receiving routine fallopian tube removal during pelvic surgery after randomization.
62718004|NCT02669498|NO_INTERVENTION|Surgery without fallopian tube removal|Fallopian tubes are not removed during pelvic surgery after randomization.
62718005|NCT06664554||Preterm birth|Pregnancy with delivery before 37 weeks of gestational age
62718006|NCT06664554||Term birth control|Pregnancy with delivery at 37 weeks or later of gestational age
62718007|NCT06298227|ACTIVE_COMPARATOR|Group ESPB = Erector spinae plane block group|ESPB will be performed
62718008|NCT06298227|ACTIVE_COMPARATOR|Group QLB = Quadratus lumborum block group|QLB will be performed
62718009|NCT05007548|EXPERIMENTAL|Ga68-Dolacga Injection|Ga68-Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
62718010|NCT06719440|ACTIVE_COMPARATOR|Radiotherapy with standard irradiation volume|Radiotherapy with standard irradiation volume CTV=15mm
62718011|NCT06719440|EXPERIMENTAL|Radiotherapy with reduced irradiation volume|Radiotherapy with standard irradiation volume CTV=10mm
62718012|NCT03383042|EXPERIMENTAL|Cohort 1|Single-ascending cohort 1
62718013|NCT03383042|EXPERIMENTAL|Cohort 2|Single-ascending cohort 2
62718014|NCT03383042|EXPERIMENTAL|Cohort 3|Single-ascending cohort 3
62718015|NCT03383042|EXPERIMENTAL|Cohort 4|Single-ascending cohort 4
62718016|NCT03383042|EXPERIMENTAL|Cohort 5|Single-ascending cohort 5
62718017|NCT03383042|EXPERIMENTAL|Cohort 6|Multiple-ascending cohort 1
62718018|NCT03383042|EXPERIMENTAL|Cohort 7|Multiple-ascending cohort 2
62168060|NCT02942628|ACTIVE_COMPARATOR|Meat - Vegetarian|4 weeks of meat-containing diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of vegetarian diet
62168061|NCT04798508|OTHER|Whole group|"The whole group listen successively the 3 paradigms :~* P3 own-name recorded by listening to a smiling voice~* P3 own-name recorded by listening to a neutral voice~* P3 own-name recorded by listening to a rough voice"
62718019|NCT03383042|EXPERIMENTAL|Cohort 8|Multiple-ascending cohort 3
62718020|NCT03383042|EXPERIMENTAL|Cohort 9|Multiple-ascending cohort 4
62718021|NCT06121895||Video Laryngeal Mask|Patients who are intubated using Video Laryngeal Mask for intubation purposes will be included.
62718022|NCT06121895||Fastrack Laryngeal Mask|Patients who are intubated using Fastrack Laryngeal Mask for intubation purposes will be included.
62718023|NCT05561647||GATTEX: Participants|Participants who have taken GATTEX in the 60 days prior to survey implementation are eligible to participate in this Risk Evaluation and Mitigation Strategy (REMS) survey for up to 10 years via internet, telephone, and paper.
62718024|NCT05561647||GATTEX: Healthcare Providers (Prescribers)|HCPs (adult and pediatric) in the United States (US) who have prescribed GATTEX at least once regardless of their completion of the voluntary GATTEX REMS training are eligible for participation in this REMS survey for up to 10 years via internet, telephone, and paper.
62718025|NCT01667341|EXPERIMENTAL|Low Dose GEN-003 with Matrix M-2|10µg GEN-003, 50µg Matrix M-2 Adjuvant
62718026|NCT01667341|EXPERIMENTAL|Mid Dose GEN-003 with Matrix M-2|30µg GEN-003, 50µg Matrix M-2 Adjuvant
62718027|NCT01667341|EXPERIMENTAL|High Dose GEN-003 with Matrix M-2|100µg GEN-003, 50µg Matrix M-2 Adjuvant
62718028|NCT01667341|EXPERIMENTAL|Low Dose GEN-003 Only|10µg GEN-003
62718029|NCT01667341|EXPERIMENTAL|Mid Dose GEN-003 Only|30µg GEN-003
62718030|NCT01667341|EXPERIMENTAL|High Dose GEN-003 Only|100µg GEN-003
62718031|NCT01667341|PLACEBO_COMPARATOR|Placebo|0.5 mL phosphate buffered saline
62718032|NCT01952509||Cohort|
62718033|NCT04710030|ACTIVE_COMPARATOR|Valacyclovir|Oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day (total dose: 4 grams per day) for 52 weeks.
62718034|NCT04710030|PLACEBO_COMPARATOR|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day for 52 weeks.
62718035|NCT05301543|EXPERIMENTAL|Behavioral approach 1|This includes sleep hygiene and other elements to serve as an experimental arm; subjects will receive a clinically proven therapeutic intervention.
62718036|NCT05301543|ACTIVE_COMPARATOR|Behavioral approach 2|This includes sleep hygiene and other elements to serve as an active comparator; subjects will receive a clinically proven therapeutic intervention.
62718037|NCT06357845|OTHER|Residents effected by the Derailment event|Eligible residents must be adult participants from Columbiana County, Ohio, Mahoning County, Ohio, Beaver County, Pennsylvania, or Lawrence County, Pennsylvania.
62718038|NCT06719349||Single level decompression and LLIF|Patients with single-segment L1-L4 spine discopathy treated with lumbar spine fusion modified by the authors were included in this study
62544106|NCT02758639|EXPERIMENTAL|W & W Intervention|Wonders \& Worries Psychosocial intervention is a 6 week group or individual sessions for children who have a parent with cancer focusing on psycho-educational information about cancer, treatment and its side effects, feelings expression, positive coping strategies, and family communication about the illness.
62544107|NCT02758639|OTHER|Wait list control|Wait list group will complete baseline, 6 week and 8 week follow up measures and then will be enrolled to receive W \& W intervention.
62544108|NCT01998841|EXPERIMENTAL|Mutation Carriers: Crenezumab|"Study Period A: Participants will receive Crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: Participants will be offered the opportunity to continue to receive blinded study drug until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
62544109|NCT01998841|PLACEBO_COMPARATOR|Mutation Carriers: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All mutation carriers entering Study Period B will, receive Crenezumab until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
62544110|NCT01998841|PLACEBO_COMPARATOR|Non-carriers of Mutation: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All non-mutation carriers entering Study Period B will continue to receive Placebo, until the results of the study are known and post trial access to Crenezumab is started or development of Crenezumab is discontinued."
62544111|NCT04061148|OTHER|Non-Depressed Controls|"Volunteers who have screened by a clinical psychiatrist, to exclude depression and other major psychiatric and neurocognitive disorders.~They will undergo NIRSIT testing to measure frontal blood oxygenation up to 3 times, with an interval of 3 weeks between each measurement."
62544112|NCT04061148|ACTIVE_COMPARATOR|Depressed Patients|Patients diagnosed with Major Depressive Disorder by a clinical psychiatrist. They will undergo NIRSIT testing to measure frontal blood oxygenation up to 5 times, with an interval of 3 weeks between each measurement, over the course of their clinical therapy for Major Depressive Disorder.
62544113|NCT01850251|EXPERIMENTAL|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
62544114|NCT01850251|ACTIVE_COMPARATOR|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
62544115|NCT04168008|EXPERIMENTAL|Adherence|Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for Antiretroviral therapy (ART) adherence and engagement in HIV care.
62544116|NCT04168008|ACTIVE_COMPARATOR|Parenting|Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.
62544117|NCT01179711|OTHER|glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
62544118|NCT00789243|ACTIVE_COMPARATOR|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, local ischaemic preconditioning will be induced by inflating a cuff around the non-dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
62544119|NCT00789243|ACTIVE_COMPARATOR|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
62718039|NCT02406222|ACTIVE_COMPARATOR|Pomalidomide and Dexamethasone|"Pomalidomide and Dexamethasone will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~* Pomalidomide 4mg orally on days 1-21~* Dexamethasone 40mg orally on days 1, 8, 15 and 22"
62718040|NCT02406222|EXPERIMENTAL|Pomalidomide Dexamethasone Cyclophosphamide|"Pomalidomide, Dexamethasone and Cyclophosphamide will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~* Pomalidomide 4mg orally on days 1-21~* Dexamethasone 40mg orally on days 1, 8, 15 and 22~* Cyclophosphamide 500mg orally on days 1, 8 and 15"
62718041|NCT04870151|EXPERIMENTAL|Anterolateral approach|"The minimally invasive anterolateral approach (Watson-Jones approach) is performed with the patient in supine position. An oblique incision is made from just dorsal to the anterior superior iliac spine, and extended distally to the greater trochanter. After the fascia is incised, deep dissection continues in the plane between the tensor fasciae latae and the gluteus medius muscles. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the fascia, subcutis and skin is closed in separate layers with sutures."
62544120|NCT00789243|PLACEBO_COMPARATOR|3|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, sham will be performed by inflating a cuff to 10 mmHg for 5 mins followed by 5 mins of deflation. This cycle will be repeated 3 times.
62544121|NCT06156332|EXPERIMENTAL|surufatinib combined with serplulimab|"surufatinib: 250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab: 300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy."
62544122|NCT03997851|EXPERIMENTAL|Topical 5% acetaminophen gel|Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
62544123|NCT03997851|EXPERIMENTAL|Topical 2.5% acetaminophen gel|Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
62544124|NCT03997851|EXPERIMENTAL|Topical 1% acetaminophen gel|Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
62544125|NCT03997851|PLACEBO_COMPARATOR|Topical vehicle gel|Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
62544126|NCT01328379|ACTIVE_COMPARATOR|Dalfampridine-ER 5mg|5mg, twice daily
62544127|NCT01328379|ACTIVE_COMPARATOR|Dalfampridine-ER 10mg|10mg, twice daily
62544128|NCT01328379|PLACEBO_COMPARATOR|Placebo|placebo, twice daily
62544129|NCT04597697|EXPERIMENTAL|Subjects with normal hepatic function|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
62544130|NCT04597697|EXPERIMENTAL|Subjects with mild hepatic impairment, child-pugh grade A|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
62544131|NCT04597697|EXPERIMENTAL|Subjects with moderate hepatic impairment, child-pugh grade B|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
62544132|NCT04597697|EXPERIMENTAL|Subjects with severe hepatic impairment, child-pugh grade C|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
62544133|NCT04977479|ACTIVE_COMPARATOR|Blinded Active Vaccine 2|Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly followed by a wash out period of 24 hours then crossover to receive placebo (0.3 mL normal saline) intramuscularly.
62544134|NCT04977479|PLACEBO_COMPARATOR|Blinded Placebo|Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the placebo (0.3 mL normal saline) intramuscularly followed by a wash out period of 24 hours then crossover to receive the active mRNA COVID-19 vaccine (0.3mL) intramuscularly.
62544135|NCT04977479|EXPERIMENTAL|Open-Label Booster Vaccine|Participants who did not suffer from a COFAR grade 3 or higher reaction after blinded active vaccine 2 were offered to receive booster dose of the active mRNA COVID-19 vaccine (0.3 mL) intramuscularly 5 months later.
62544136|NCT02443987|EXPERIMENTAL|Received intravenous fluids|The patient will receive 500ml of 0.9% NaCl fluid intravenously during the operation.
62544137|NCT02443987|NO_INTERVENTION|Control Arm|The patient will receive no intravenous fluid as per current routine protocol
62544138|NCT00970593|PLACEBO_COMPARATOR|OAP-189|
62544139|NCT00970593|PLACEBO_COMPARATOR|2|
62544140|NCT05881525|EXPERIMENTAL|dose escalation|"This study uses the 3+3 dose escalation method. The initial dose is Dose 1, the maximum dose that patients can tolerate is determined as the phase II recommended dose (RPIID), and at least 6 patients are receiving RPIID treatment. If patients develop intolerance in Dose 1 (≥3 subjects with DLT), then the subsequent enrolled patients will receive Dose -1 infusion.~Interventions:~Biological: TCR-T cells Drug: IL-2 Drug: Fludarabine Drug: Cyclophosphamide Drug: Nab-Paclitaxel"
62544141|NCT06500169|EXPERIMENTAL|Supportive care (golf program)|Patients participate in the golf training program composed of group sessions over 1-2 hours with a PGA professional two times per week for ten weeks. Training consists of complimentary/warm up exercises integrated with pelvic floor muscle training, golf instruction, golf practice, and golf play on a Par 3 public golf course. Patients also wear an activity tracker and undergo blood sample collection on the study.
62544142|NCT04615650|ACTIVE_COMPARATOR|Surgical treatment|Patients randomised to operative treatment will have their surgery performed by an orthopaedic surgeon or by orthopaedic trainees under the supervision of a consultant, when fit for surgery. The surgical technique and choice of implants will be decided by the surgeon in order to closely resemble everyday clinical practice. The syndesmosis must be reduced (closed or open) and fixed. Postoperatively, the patients will be treated with an ankle orthosis for six weeks with weight-bearing as tolerated.
62544143|NCT04615650|EXPERIMENTAL|Non-surgical treatment|Patients randomised to non-operative treatment are treated with an ankle orthosis for six weeks with weight-bearing as tolerated. Other types of casts can be used if preferred by the treating orthopaedic surgeon, but the cast must allow full weight-bearing and must prevent equinus position.
62735895|NCT01671709|EXPERIMENTAL|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
62735896|NCT01671709|ACTIVE_COMPARATOR|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp \& Dohme Ltd., USA
62718042|NCT04870151|ACTIVE_COMPARATOR|Direct lateral approach|"The direct lateral approach (Hardinge approach) is performed with the patient in a lateral decubitus position. A straight or curved longitudinal incision is made over the greater trochanter, and the fascia is incised longitudinally. The anterior aspect of the gluteus medius and minimus muscles are separated from the greater trochanter. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the gluteus medius and minimus muscles are reinserted using osteosutures. The fascia, subcutis and skin is closed in separate layers with sutures."
62718043|NCT01176617|NO_INTERVENTION|Conventional Monitoring Strategy|Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.
62718044|NCT01176617|OTHER|Reveal XT|Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
62718045|NCT01249001|EXPERIMENTAL|Group 1|This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
62718046|NCT01249001|EXPERIMENTAL|Group 2|This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.
62718047|NCT06716944|ACTIVE_COMPARATOR|self-acupuncture plus usual care|Participants will be taught to do self-acupuncture to manage their migraines. They can also do all the other things they normally do to manage their migraines apart from having acupuncture elsewhere.
62718048|NCT06716944|NO_INTERVENTION|usual care|Participants can do all the other things they normally do to manage their migraines apart from having acupuncture elsewhere.
62718049|NCT04707079|EXPERIMENTAL|Duvelisib|Eligible subjects will be given duvelisib (15mg, 25mg), orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
62718050|NCT06714994|EXPERIMENTAL|Study group|Children at Intervention schools will receive free spectacles of a design they select, based on the child's measured refractive power and dispensed at school by the teacher. All students will be advised to wear glasses as much as possible during the study to ensure clear vision.
62718051|NCT06714994|NO_INTERVENTION|Control group|Children at Control schools will receive a glasses prescription and letter to the parents informing them of the refractive status of their child, with free glasses provided only at the end of the trial. Service offered to the Control group exceeds standard care, in that no school-based programs of vision screening and refraction currently exist in the study area, or in most of rural China.
62718052|NCT02603757|ACTIVE_COMPARATOR|Group A|Standard-dose of 2,000 IU Vitamin D3, daily
62718053|NCT02603757|EXPERIMENTAL|Group B|Higher-dose of 50,000 IU of Vitamin D3, weekly
62718054|NCT06524089|EXPERIMENTAL|Pilates|Fifteen patients will receive Pilates exercises
62718055|NCT06524089|EXPERIMENTAL|eccentric|Fifteen patients will receives eccentric training
62718056|NCT00669006||1|New patients with a diagnosis of Neuropathic Pain
62718057|NCT05034328||Healsea® Children: isotonic seawater based nasal spray supplemented with natural Symbiofilm® extract|Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed.
62718058|NCT05034328||Conventional therapies|Children will receive conventional therapies for common cold as needed, nasal irrigation excluded
62718059|NCT05905783|EXPERIMENTAL|Group 1|Participants will receive placebo as a subcutaneous (SC) injection every week (QW) from Day 1 to Week 15. Participants will then receive izokibep as a SC injection QW from Week 16 to Week 51.
62718060|NCT05905783|EXPERIMENTAL|Group 2|Participants will receive izokibep QW from Day 1 to Week 51.
62718061|NCT05622942|EXPERIMENTAL|Recombinant Pneumococcal Protein Vaccine（PBPV）|Subjects received 1 dose of PBPV
62718062|NCT05622942|ACTIVE_COMPARATOR|Pneumococcal Polysaccharide Vaccine-23-valent (PPV23)|Subjects received 1 dose of PPV23
62718063|NCT05724082|EXPERIMENTAL|Clean air intervention|See detailed description
62718064|NCT02063451|OTHER|Obese, Weight Loss, Very Low Calorie Diet|Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
62718065|NCT02063451|NO_INTERVENTION|Lean, baseline measure|MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
62718066|NCT04488133|EXPERIMENTAL|Nusinersen 12 mg|Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.
62718067|NCT00649350|EXPERIMENTAL|1|Metformin Hydrochloride ER Tablets 750 mg
62718068|NCT00649350|ACTIVE_COMPARATOR|2|Glucophage XR 750 mg
62718069|NCT02136914|EXPERIMENTAL|ADS-5102|ADS-5102 (amantadine HCl extended release)
62718070|NCT02136914|PLACEBO_COMPARATOR|Placebo|Placebo
62718071|NCT06718816||The subjects received AL-001 ophthalmic injection|Evaluate long-term safety and efficacy
62718072|NCT01047189|EXPERIMENTAL|1|Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
62718073|NCT01047189|ACTIVE_COMPARATOR|2|Generic clindamycin 1% gel plus tretinoin 0.025% cream
62718074|NCT03480984|ACTIVE_COMPARATOR|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
62718075|NCT03480984|ACTIVE_COMPARATOR|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
62718076|NCT04016857|EXPERIMENTAL|RIPC Group|Remote ischemic preconditioning
62718077|NCT04016857|SHAM_COMPARATOR|Control Group|Sham remote ischemic preconditioning
62718078|NCT03440073|EXPERIMENTAL|Mulligan Concept Intervention|Mulligan Concept Intervention, including Mobilizations with Movement intervention is administered. Up to 30 minutes total treatment time.
62718079|NCT03440073|SHAM_COMPARATOR|Sham Mulligan Concept Treatment|Assessment procedures of the Mulligan Concept are followed, but no manual pressure is applied to the participant during treatment to provide a sham Mulligan Concept Treatment.
62544144|NCT03857269|EXPERIMENTAL|Acupoint Massage group|Choose Chinese medicine acupuncture points： Shenting, Baihui, Sishencong, Diwei, Chengling, Fengchi, Fengfu，Zusanli and Sanyinjiao，32 points per acupressure.32 times per acupoint.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
62544145|NCT03857269|EXPERIMENTAL|Aromatherapy group|Make a 5x5cm bag and put a cotton ball in the bag and the bag is clipped to the patient's collar.Dispense 10% lavender essential oil, 2-3 drops a day in cotton balls.Cotton ball replacement daily. Intervention frequency will be monday to saturday per week for 6 months.（n=30）
62544146|NCT03857269|EXPERIMENTAL|Acupoint Massage and Aromatherapy group|At the same time as the acupressure, the essential oil is applied to the collar and begins to sniff.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
62544147|NCT03857269|NO_INTERVENTION|Blank control group|The group selects elderly people with MCI who do not receive intervention after informed.Participate in routine activities of Nursing homes.
62544148|NCT05976230||Entresto|Patients administered Entresto by prescription
62544149|NCT00851435|EXPERIMENTAL|KBPA-101, a monoclonal antibody|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
62544150|NCT03944824|EXPERIMENTAL|Exercise (Intervention) Arm|The 25 patients in this arm will receive an interventional exercise plan using resistance bands and once weekly visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
62544151|NCT03944824|PLACEBO_COMPARATOR|Control|The 25 patients in the control arm will not receive an interventional exercise plan or visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
62544152|NCT02205190|OTHER|Treatment AB|"Treatment A (1 day) → wash-out(7days) → Treatment B (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
62544153|NCT02205190|OTHER|Treatment BA|"Treatment B (1 day) → wash-out(7days) → Treatment A (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
62544154|NCT04832009|EXPERIMENTAL|Glucose Infusion|Hyperglycemia (glucose infusion) will receive an I.V. Glucose infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
62544155|NCT04832009|EXPERIMENTAL|Lipid Infusion|Hyperlipidemia (lipid infusion) will receive an I.V. Lipid infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
62544156|NCT00476775|EXPERIMENTAL|After school ethnic dance and home-based screen time reduction|After school ethnic dance classes and home-based screen time reduction intervention
62544157|NCT00476775|ACTIVE_COMPARATOR|Health and Nutrition Education|Health and nutrition education active placebo control intervention
62544158|NCT06361121|ACTIVE_COMPARATOR|mid-point transverse process to pleura (MTP) block|In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL
62544159|NCT06361121|ACTIVE_COMPARATOR|Thoracic Paravertebral (TPV) Block|In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
62544160|NCT00890604|OTHER|Standard interventions for temperature control used in protocolized, stepwise fashion|Normothermia Protocol- use of standard interventions in protocolized fashion (physical cooling, antipyretics)
62544161|NCT00890604|NO_INTERVENTION|Standard fever management/prevention interventions used in ad hoc fashion|standard interventions for fever prevention used in ad hoc fashion based on nurse decision making
62544162|NCT01807247||Hemiparetic|Intensive lower limbs muscles strengthening
62544163|NCT01807247||Spinal cord injury|Intensive lower limbs muscles strengthening
62544164|NCT01807247||Multiple sclerosis|Intensive lower limbs muscles strengthening
62544165|NCT06038162|ACTIVE_COMPARATOR|VA-ECMO patients with parallel connection|Patients undergoing VA ECMO with indication for concomitant RRT, assigned to parallel connection group.
62544166|NCT06038162|ACTIVE_COMPARATOR|VA-ECMO patients with integrated connection|Patients undergoing VA ECMO with indication for concomitant RRT, assigned to integrated connection group.
62544167|NCT02953977|EXPERIMENTAL|Diabetes Intervention|Diabetes Prevention Program
62544168|NCT02953977|OTHER|Delayed Intervention|Diabetes Prevention Program
62544169|NCT06048263|EXPERIMENTAL|Intervention Interpersonal psychotherapy plus ketamine|Five sessions of interpersonal psychotherapy (IPT) and pre-, and post-, ketamine sessions b) Two doses of subcutaneous (SC) ketamine in the first 4 post-cesarean days
62544170|NCT01342757|EXPERIMENTAL|Arm I|"Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study."
62718080|NCT05016089|EXPERIMENTAL|Simplified Pilates exercise group (SPEG)|The participants in the SPEG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks. Each participant will undertake a total of 24 exercise sessions.
62735897|NCT04475419|ACTIVE_COMPARATOR|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe)
62718081|NCT05016089|OTHER|Wait-list control group (WLCG)|The participants in the WLCG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks after two scheduled assessment sessions and a waiting period of 12 weeks in between. Each participant will undertake a total of 24 exercise sessions.
62718082|NCT04343560||patients with MACS|Patients with adrenal adenoma and dexamethasone suppression test \>1.8 mcg/dl
62718083|NCT04343560||healthy controls|no history of adrenal and pituitary disease, no exogenous steroids
62718084|NCT06715046||GVHD patients|This group gathers all the patients that eventually develop GVHD
62718085|NCT06715046||Control patients|This group gathers all the patients that will not develop post-HSCT complications and show no signs of relapse.
62544171|NCT04792424|EXPERIMENTAL|No monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.~Citrate dose start at 4 mmol/L and no adjustment of citrate dose. Post-filter ionized calcium result will blind for physician.~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
62544172|NCT04792424|PLACEBO_COMPARATOR|Monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.~Citrate dose start at 4 mmol/L with adjustment of citrate dose to acheive post-filter ionized calcium at 0.25-0.35 mmol/L.~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
62544173|NCT04974749|EXPERIMENTAL|REPLAGAL|Participants received REPLAGAL 0.2 milligrams per kilogram (mg/kg) body weight, intravenous (IV) infusion, every other week (EOW) from Day 1 (Week 0) up to Week 52.
62544174|NCT05142280|EXPERIMENTAL|Active choice|This intervention contains information and an assignment to foster an active choice regarding coping with an increased CVD risk. Participants will be presented a hypothetical 'heart age' of 16 years older than their actual age. They will be asked to imagine that this heart age really applies to them. Next, participants will receive information about the meaning of the risk, including its causes and potential consequences, and about four coping strategies: changing one's lifestyle; taking medication; doing both; or changing nothing. The pros and cons of each strategy will be presented, followed by a value-clarification exercise.
62544175|NCT05142280|OTHER|Control|The control group will receive online information and advice that resembles GP's usual care. The information contains a hypothetical CVD risk: a risk of 31% to get CVD within 10 years. They will be asked to imagine that this risk really applies to them. Participants will read about an imaginary GP who advices to change one's lifestyle (i.e., quitting smoking; healthy diet; more physical activity), and to use medication to decrease the risk.
62544176|NCT03713632|ACTIVE_COMPARATOR|Secukinumab 1|Secukinumab 300mg every 2 weeks
62544177|NCT03713632|ACTIVE_COMPARATOR|Secukinumab 2|Secukinumab 300mg every 4 weeks
62544178|NCT03713632|PLACEBO_COMPARATOR|Placebo 1|Placebo group to secukinumab 300mg every 2 weeks
62544179|NCT03713632|PLACEBO_COMPARATOR|Placebo 2|Placebo group to secukinumab 300mg every 4 weeks
62544180|NCT06377514|EXPERIMENTAL|Test IOL|DEN00V
62544181|NCT06377514|ACTIVE_COMPARATOR|Control IOL|DCB00
62544182|NCT04123626|EXPERIMENTAL|QR-1123 Single dose - dose level 1|Open label Single dose cohort: dose level 1
62544183|NCT04123626|EXPERIMENTAL|QR-1123 Single dose - dose level 2|Open label Single dose cohort: dose level
62544184|NCT04123626|EXPERIMENTAL|QR-1123 Single dose - dose level 3|Open label Single dose cohort: dose level 3
62544185|NCT04123626|EXPERIMENTAL|QR-1123 Single dose - dose level 4|Open label Single dose cohort: dose level 4
62544186|NCT04123626|EXPERIMENTAL|QR-1123 Single dose - dose level 5|Open label Single dose cohort: dose level 5
62544187|NCT04123626|EXPERIMENTAL|Repeat dose cohort 1|Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.
62544188|NCT03660306||opioid anesthesia|classical anesthesia using sufentanil to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
62544189|NCT03660306||opioid free anesthesia|anesthesia using non opioids like dexmedetomidine, lidocaine, magnesium and ketamine to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
62544190|NCT06089200|EXPERIMENTAL|Transversus Abdominis Plane Block|Twenty two subjects were given postoperative block administration in the transversus abdominis area on each side with ultrasonography (USG) guidance
62544191|NCT06089200|ACTIVE_COMPARATOR|Spinal Morphine|Twenty two subjects were given additional morphine 100 µg intrathecally
62544192|NCT04069338|ACTIVE_COMPARATOR|Device Storz Modulith SLX-F2|Patients receive standard of care treatment for their urolithiasis using the Device Storz Modulith SLX-F2
62544193|NCT04069338|ACTIVE_COMPARATOR|Dornier Delta III Treatment|Patients receive standard of care treatment for their urolithiasis using the Dornier Delta III lithotripter
62544194|NCT05782881|EXPERIMENTAL|Protocol treatment group|Strictly intervene blood glucose, blood pressure and blood lipids
62718086|NCT06715046||Infection patients|This group gathers all the patients that develop post-HSCT infections
62718087|NCT06715046||Relapse patients|This group gathers all the patients that relapse after HSCT
62718088|NCT06715046||TAD/SOS patients|This goup gathers patients presenting with transplant associated microangiopathy or sinusoidal obstruction.
62718089|NCT00503490|EXPERIMENTAL|1|Inhaled Levofloxacin
62718090|NCT00503490|PLACEBO_COMPARATOR|2|Placebo
62718091|NCT02117778|ACTIVE_COMPARATOR|Interscalene|Continuous Interscalene Nerve Block
62718092|NCT02117778|ACTIVE_COMPARATOR|Supraclavicular|Continuous Supraclavicular Nerve Block
62718093|NCT02117778|ACTIVE_COMPARATOR|Suprascapular|Continuous Suprascapular Nerve Block
62718094|NCT02457026|EXPERIMENTAL|Adjunctive PDT + Aflibercept|Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3. At Study Visit 4, participants will have repeat assessment of disease activity. If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections. If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6. Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months. If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
62718095|NCT02457026|ACTIVE_COMPARATOR|Aflibercept Alone|"Participants in this group will receive intravitreal aflibercept at Study Visits 1, 2, and 3. At Study Visit 4, participants will have repeat assessment of disease activity. From Study Visit 4 onwards, aflibercept will be administered according to a treat-and-extend strategy. If disease activity is considered to be resolved or trivial, then the interval between treatments can be initially extended from every 28 days to every 42 days. If disease activity remains stable, treatments can be extended in 14-day increments, up to 10 weeks between treatments. For individuals who have PDA that remains unresolved, aflibercept will continue to be administered every days, but if disease quiescence is achieve at a later time point, the treatment period can be extended at that time."
62718096|NCT02326727|ACTIVE_COMPARATOR|General Anesthesia|Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery
62718097|NCT02326727|ACTIVE_COMPARATOR|Combined anesthesia|Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery
62718098|NCT06717646||Inpatient|Patients warded under National Heart Centre Singapore
62718099|NCT06717646||Outpatients|Patients scheduled for 24-hour Ambulatory Blood Pressure Monitoring at National Heart Centre Singapore
62718100|NCT03362268|EXPERIMENTAL|Ilaprazole|
62718101|NCT03362268|ACTIVE_COMPARATOR|omeprazole|
62718102|NCT03709966|EXPERIMENTAL|FitBit|Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.
62718103|NCT03709966|ACTIVE_COMPARATOR|Routine|Physical activity promotion supported by a kinesiologist
62718104|NCT02423486|EXPERIMENTAL|Electromagnetic stimulation therapy|Electromagnetic stimulation therapy group
62718105|NCT02423486|EXPERIMENTAL|Electromagnetic stimulation therapy with biofeedback|Electromagnetic stimulation therapy with biofeedback group
62718106|NCT06716489|EXPERIMENTAL|6-Week Aerobic Exercise Program for Migraine Management|This arm of the study is a 16-week aerobic exercise program designed to assess the effects of regular physical activity on sensory perception, musculoskeletal changes, and psychosocial factors in women with migraine. Participants will engage in treadmill sessions three times per week, with intensity tailored to individual cardiovascular assessments. The primary focus will be to assess how aerobic exercise affects headache disability, neck pain, sensory thresholds, and overall quality of life. The intervention aims to provide insight into non-pharmacological treatment options for managing migraine symptoms.
62718107|NCT02366325|EXPERIMENTAL|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
62718108|NCT02366325|EXPERIMENTAL|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
62718109|NCT02366325|EXPERIMENTAL|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
62718110|NCT06714760|EXPERIMENTAL|patient|The study will involve patients referred to the Department of Maxillofacial Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna who require simple reconstruction following parcellar resections of the mandibular gingival region. It is planned to recruit during the above period 5 patients who meet the following inclusion and exclusion criteria.
62718111|NCT04275999|OTHER|Control Group|In the control group, all subjects will receive ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea. Subjects will not receive any follow-up intervention from the study team.
62718112|NCT04275999|EXPERIMENTAL|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their use ivermectin generated by Causa Research; in addition to receiving ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
62718113|NCT04275999|EXPERIMENTAL|GPSkin group|The GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin once daily. Subjects also are receiving the ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
62718114|NCT05287243|OTHER|Inspiratory Muscle Training|involves the intervention portion of the study to improve strength of the cardiopulmonary system
62718115|NCT02670473|NO_INTERVENTION|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
62718116|NCT02670473|EXPERIMENTAL|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
62718117|NCT06717529|EXPERIMENTAL|Hyaluronic acid injection|This arm will receive a hyaluronic acid injection in the knee joint.
62718118|NCT06717529|ACTIVE_COMPARATOR|Steroid injection|This arm will receive steroid injection in the knee joint.
62718119|NCT06718959|EXPERIMENTAL|treatment group|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add used the test product (Jet Floss EX) twice a day.
62718120|NCT06718959|ACTIVE_COMPARATOR|control group|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add auxiliary product (interdental brush) twice a day.
62718121|NCT03653182||normal|A normal constitution condition in TCM.
62718122|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
62718123|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
62718124|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
62718125|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
62718126|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
62718127|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
62718128|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
62718129|NCT03653182||Special|One of an abnormal constitution condition in TCM.
62718130|NCT06712914|EXPERIMENTAL|Theta-burst stimulation (TBS)|Theta-burst stimulation (a form of transcranial magnetic stimulation) targeting the right frontal pole.
62718131|NCT06714838|EXPERIMENTAL|Single arm: all patients receive rituximab|All patients will receive rituximab at baseline (1000 mg) and after two weeks (1000 mg). Then, depending of whether the patient shows improvement in the following three to six months, the patient will receive another dose of rituximab (500 mg) at six months.
62718132|NCT02545439|EXPERIMENTAL|ALKS 5461|Sublingual tablet
62718133|NCT06713538|EXPERIMENTAL|Experimental group|The experimental setup corresponds to a standardized and progressive program of 12 sessions (2 sessions of 90 minutes per week for 6 weeks) of ground work with the horse. These sessions will be protocolized and themed, addressing psycho-behavioral issues commonly found in traumatic brain injury patients (emotion management, strategy development, problem-solving, analysis and interpretation of others' behavior, etc.).
62718134|NCT06713538|ACTIVE_COMPARATOR|Control group|"The control setup is based on global recommendations for physical activity for health (WHO), which advise 150 to 300 minutes of moderate endurance activity per week for a positive impact on physical, cognitive, and psychological health for the 18-65 age group.~Following these recommendations, the subjects will independently carry out 12 sessions (2 sessions of 90 minutes per week for 6 weeks) of moderate-intensity physical activity. The endurance activity should be performed according to the patient's capabilities and fatigue levels."
62718135|NCT00639951|ACTIVE_COMPARATOR|A Normal dose Group|20 vials up front in a Single Dose of Antivipmyn in 500 ml of solution IV, administered in 60 minutes. After 12 hours, it has to be perfomed a clinical evaluation of the patient. Each patient is going to have clinical studies of coagulation time and also the fibrinogen measures, this at 2, 4, 6, 8, 10, 12, 48, 72, 96 hours.All patients who have received at least one dose of medication study will be contacted by telephone to investigate the presence of symptoms suggestive of continuing with effect snake venom, or the presence of an adverse event, or any signs or symptoms indicating the presence of a hypersensitivity response to Antivipmyn® including serum sickness. If symptoms suggestive of an adverse event were discovered, the patient will referred for appropriate treatment.
62718136|NCT00639951|PLACEBO_COMPARATOR|B Placebo Group|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®. The treatment schedule for each subject is a dose of 5 vials Antivipmyn® every 2 hours to complete 20 vials, the total duration is 6 hours of the treatment. Each dose IV shall apply in physiological solution 250ml, and finish its application in 15 minutes. For pediatric patients the volume administered should not exceed the recommended fluid volume according to your body weight. After the assessment at 12 hours, it can be administered at the discretion of more antivenom attending by the physician.
62718137|NCT06715293|EXPERIMENTAL|Hemopill to detect the presence of active bleeding in the upper GI tract|Hemopill to detect the presence of active bleeding in the upper GI tract
62718138|NCT06715293|ACTIVE_COMPARATOR|OGD to diagnose and treat active beleeding in the upper GI tract|ogd will be performed to compare the results with that of the hemopill
62718139|NCT05935176|EXPERIMENTAL|Vaccine Group A|2 dose of ACYW135 group meningococcal polysaccharide conjugate vaccine(MCV4) (0.5ml)
62718140|NCT05935176|EXPERIMENTAL|Vaccine Group B|2 dose of (MCV4) (0.5ml)
62718141|NCT04271475|EXPERIMENTAL|Macitentan|Participant will receive macitentan at a dose of 10 milligram (mg) once daily (OD) for 4 weeks, followed by a dose of macitentan 37.5 mg for another 4 weeks and continue with the target dose of macitentan 75 mg. Participants who have reached the target dose of 75 mg, completed the Double-blind (DB) period up to Week 28 (either on treatment or in Post-treatment observation period \[PTOP\]) at minimum, may be eligible for transitioning into the Open label (OL) extension period once all participants have completed the DB part of the study, or earlier if they experienced a Clinical event committee (CEC) confirmed clinical worsening event.
62718142|NCT04271475|EXPERIMENTAL|Placebo|Participants will receive placebo tablets matching the macitentan 10 mg, macitentan 37.5mg and macitentan 75 mg tablets, respectively. Participants who completed the DB period as per protocol either on treatment or in PTOP are eligible for transitioning to the OL extension period and will receive macitentan 75 mg after an 8-week double-dummy uptitration (macitentan 10 mg for 4 weeks, followed by 37.5 mg for another 4 weeks).
62718143|NCT00001486||Normal Controls|Male and female adult healthy volunteers
62718144|NCT00001486||Parents|Parents of Probands and siblings for the purposes of DNA collection
62718145|NCT00001486||Probands|Adult Subjects with Schizophrenia Spectrum Disorders
62718146|NCT00001486||Siblings|Adult siblings of Probands
62718147|NCT06622434|EXPERIMENTAL|A52-Mel/A49-Mel/Li28|One month after completion of concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide with subcutaneous injections of the vaccine formulation (D0, W2, W4, W6, and then every 2 months until progression) consisting of 2 tumor antigens (TERT and PTPRZ1) adjuvanted with synthetic melanin and a TLR9 agonist (CpG-ODN).
62718148|NCT06567002|EXPERIMENTAL|Sequence 1: (Treatment A) → (Treatment B) → (Treatment C) → (Treatment B) → (Treatment C)|Period 1: Participants receive MK-6552 Treatment A single dose administered orally under fasted conditions (Period 1 = 4 days). Period 2: Participants receive MK-6552 Treatment B single dose administered orally under fasted conditions (Period 2 = 4 days). Period 3: Participants receive Treatment C single dose administered orally under fasted conditions (Period 3 = 4 days). Period 4: Participants receive MK-6552 Treatment B single dose administered orally under fed conditions (Period 4 = 4 days). Period 5: Participants receive MK-6552 Treatment C single dose administered orally under fed conditions (Period 5 = 4 days). There will be a minimum 3-day washout between periods.
62735898|NCT04475419|ACTIVE_COMPARATOR|preformed metal crowns|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
62718149|NCT06567002|EXPERIMENTAL|Sequence 2: (Treatment B) → (Treatment C) → (Treatment A) → (Treatment B) → (Treatment C)|Period 1: Participants receive MK-6552 Treatment B single dose administered orally under fasted conditions (Period 1 = 4 days). Period 2: Participants receive MK-6552 Treatment C single dose administered orally under fasted conditions (Period 2 = 4 days). Period 3: Participants receive MK-6552 Treatment A single dose administered orally under fasted conditions. (Period 3 = 4 days). Period 4: Participants receive MK-6552 Treatment B single dose administered orally under fed conditions (Period 4 = 4 days). Period 5: Participants receive MK-6552 Treatment C single dose administered orally under fed conditions (Period 5 = 4 days). There will be a minimum 3-day washout between periods.
62544195|NCT05782881|PLACEBO_COMPARATOR|Conventional treatment group|Treatment and management according to the guidelines
62544196|NCT00997204|EXPERIMENTAL|Icatibant- Naive Treatment Phase|Single subcutaneous injection of icatibant, 30 mg
62544197|NCT00997204|EXPERIMENTAL|icatibant- Self administration Phase|Single subcutaneous injection of icatibant, 30 mg
62544198|NCT05256394|ACTIVE_COMPARATOR|Pain Manager + tailored implementation support Pain Manager|Pain Manager is a decision support tool. All study clinics will begin the trial with Pain Manager integrated and available in their EHR. Consistent with the stepped-wedge design, intensive implementation support (e.g, administrative support, technical support)will be provided to two clinics at once by a multidisciplinary team.
62544199|NCT05256394|NO_INTERVENTION|Pain Manager implementation in EHR|Pain Manager is a decision support tool. All study clinics will begin the trial with Pain Manager integrated and available in their EHR. The other 6 clinics will have no additional tailor support.
62544200|NCT00741507|ACTIVE_COMPARATOR|1|No alcohol drinking
62544201|NCT00741507|ACTIVE_COMPARATOR|2|Mild alcohol drinking
62544202|NCT00741507|ACTIVE_COMPARATOR|3|Moderate alcohol drinking
62544203|NCT00741507|ACTIVE_COMPARATOR|4|Severe over alcohol drinking
62544204|NCT00741507|ACTIVE_COMPARATOR|5|Alcohol-dependent
62544205|NCT00610610|EXPERIMENTAL|A|Paroxetine - Controlled Release
62544206|NCT00610610|PLACEBO_COMPARATOR|B|Same colour, shape placebo
62544207|NCT05071976|EXPERIMENTAL|Participants undergoing a pelvic or abdominal wall reconstruction procedure|Women undergoing a pelvic or abdominal wall reconstruction procedure after radical gynecologic surgery for any indication at Memorial Sloan Kettering Cancer Center
62544208|NCT05167799||Cardiac Amyloidosis patients|"Patients with established diagnosis of amyloid TTR Cardiomyopathy, baseline ejection fraction ≥25% and ≤45%, at least one hospitalization due to worsening heart failure over the year before entry into the registry.~Already implanted with ICD or PM if needed, fullfilling the indication for CCM implantation."
62544209|NCT02349867|EXPERIMENTAL|Treatment (chemotherapy, chemoradiation)|Participants receive gemcitabine IV infusion over 30 minutes (200 mg/m2 weekly) x 6, concurrent administration of oral sorafenib and oral vorinostat (both per dose-escalation schema), and concurrent RT( 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy) administered at 1.8-Gy fractions to a total dose of 50.4 Gy over 5 ½ weeks (28 daily fractions).
62544210|NCT05666245|OTHER|Donors|Donors are persons naturally infected with influenza.
62544211|NCT05666245|EXPERIMENTAL|Intervention Recipients|Intervention recipients are participants who do not have influenza and will use personal protective equipment.
62544212|NCT05666245|NO_INTERVENTION|Control Recipients|Control recipients are participants who do not have influenza and will not be using personal protective equipment.
62544213|NCT03961659|ACTIVE_COMPARATOR|Liraglutid|Liraglutid will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutid could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
62544214|NCT03961659|ACTIVE_COMPARATOR|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but dapagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
62544215|NCT03961659|ACTIVE_COMPARATOR|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to100mg three times daily if appropriate. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but acarbose could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
62544216|NCT00261781|EXPERIMENTAL|Treadmill training|Home-based treadmill training
62544217|NCT00261781|NO_INTERVENTION|Usual care|Control group
62544218|NCT04140162|EXPERIMENTAL|Dara-Rd followed by Dara-RVd|"* Induction regimen with Daratumumab, Lenalidomide and Dexamethasone (Dara-Rd) in all study subjects, weeks 1-24~* Consolidation regimen with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (Dara-RVd) in post-induction MRD+ population, weeks 25-36~* Maintenance regimen with Daratumumab and Lenalidomide (Dara-R) in all study subjects, weeks 37-88~* Maintenance regimen with lenalidomide (R) until progression or intolerance"
62544219|NCT02040441|ACTIVE_COMPARATOR|Spironolactone|High-risk pattern: Spironolactone 25 mg once daily + Standard care
62544220|NCT02040441|PLACEBO_COMPARATOR|Placebo|High-risk pattern: One placebo tablet once daily + Standard care
62544221|NCT02040441|OTHER|Observational|Low-risk pattern: Standard care
62544222|NCT06622642|ACTIVE_COMPARATOR|Group A will undergo transoral technique for mandibular angle fracture reduction|In Group A transoral approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. A 5-hole 2mm miniplate with 2 holes anterior and 2 holes posterior to fracture line will be screwed to external oblique ridge and MMF will be removed and incision line will be closed
62718150|NCT06567002|EXPERIMENTAL|Sequence 3: (Treatment C) → (Treatment A) → (Treatment B) → (Treatment B) → (Treatment C)|Period 1: Participants receive MK-6552 Treatment C single dose administered orally under fasted conditions (Period 1 = 4 days). Period 2: Participants receive MK-6552 Treatment A single dose administered orally under fasted conditions. (Period 2 = 4 days). Period 3: Participants receive MK-6552 Treatment B single dose administered orally under fasted conditions (Period 3 = 4 days). Period 4: Participants receive MK-6552 Treatment B single dose administered orally under fed conditions (Period 4 = 4 days). Period 5: Participants receive MK-6552 Treatment C single dose administered orally under fed conditions (Period 5 = 4 days). There will be a minimum 3-day washout between periods.
62718151|NCT06567002|EXPERIMENTAL|Sequence 4: (Treatment A) → (Treatment C) → (Treatment B) → (Treatment C) → (Treatment B)|Period 1: Participants receive MK-6552 Treatment A single dose administered orally under fasted conditions (Period 1 = 4 days). Period 2: Participants receive MK-6552 Treatment C single dose administered orally under fasted conditions (Period 2 = 4 days). Period 3: Participants receive MK-6552 Treatment B single dose administered orally under fasted conditions (Period 3 = 4 days). Period 4: Participants receive MK-6552 Treatment C single dose administered orally under fed conditions (Period 4 = 4 days). Period 5: Participants receive MK-6552 Treatment B single dose administered orally under fed conditions (Period 5 = 4 days). There will be a minimum 3-day washout between periods.
62718152|NCT06567002|EXPERIMENTAL|Sequence 5: (Treatment B) → (Treatment A) → (Treatment C) → (Treatment C) → (Treatment B)|Period 1: Participants receive MK-6552 Treatment B single dose administered orally under fasted conditions (Period 1 = 4 days). Period 2: Participants receive MK-6552 Treatment A single dose administered orally under fasted conditions. (Period 2 = 4 days). Period 3: Participants receive MK-6552 Treatment C single dose administered orally under fasted conditions (Period 3 = 4 days). Period 4: Participants receive MK-6552 Treatment C single dose administered orally under fed conditions (Period 4 = 4 days). Period 5: Participants receive MK-6552 Treatment B single dose administered orally under fed conditions (Period 5 = 4 days). There will be a minimum 3-day washout between periods.
62718153|NCT06567002|EXPERIMENTAL|Sequence 6: (Treatment C) → (Treatment B) → (Treatment A) → (Treatment C) → (Treatment B)|Period 1: Participants receive MK-6552 Treatment C single dose administered orally under fasted conditions (Period 1 = 4 days). Period 2: Participants receive MK-6552 Treatment B single dose administered orally under fasted conditions (Period 2 = 4 days). Period 3: Participants receive MK-6552 Treatment A single dose administered orally under fasted conditions. (Period 3 = 4 days). Period 4: Participants receive MK-6552 Treatment C single dose administered orally under fed conditions (Period 4 = 4 days). Period 5: Participants receive MK-6552 Treatment B single dose administered orally under fed conditions (Period 5 = 4 days). There will be a minimum 3-day washout between periods.
62718154|NCT06631768|EXPERIMENTAL|Treatment arm with casual labor voucher program|Eligible members (pregnant and/or mother of at least one child aged 1 years or younger) of 1AF in the randomly selected treatment districts receive vouchers for a set number of days of free work from casual laborers employed by local 1AF offices. This is in addition to standard 1AF programming.
62718155|NCT06631768|NO_INTERVENTION|Control arm|Eligible members will only receive standard 1AF programming in randomly selected control districts. They will not receive the labor subsidy during the study period.
62718156|NCT05167812||Prospective cohort of couples with RPL|
62718157|NCT05167812||Retrospective cohort op couples with RPL|
62718158|NCT06519682|ACTIVE_COMPARATOR|Domain 1 - Upfront ICI|Initially 12 eligible patients will be enrolled for upfront ICI. At 12 week assessment if \>6 patients have response (NO radiation for recurrence/progression), an additional 6 patients will be enrolled for upfront ICI. All patients will be assessed at 12 weeks from the start of ICI. If 6 or fewer patients have response (NO radiation for progression/recurrence), no more patients will be recruited to this domain.
62718159|NCT06519682|ACTIVE_COMPARATOR|Domain 2 - Radiation + ICI → maintenance ICI|All the patients experiencing tumor progression on domain 1 will be eligible for domain 2 and will receive a combination of radiation and nivolumab followed by maintenance nivolumab for 2 years. To be eligible for domain 2 post recurrence patients will need surgery/biopsy at recurrence. If 6 RRD-glioblastoma will recur/progress at 12 weeks on domain 1 then 8 additional eligible patients may be directly enrolled in domain 2.
62718160|NCT06715514|OTHER|Menopausal Hormone Therapy|"Oestrogel®: once daily 1.5mg of transdermal E2~Utrogestan®\*: once daily 200mg of micronized progesterone (in women with intact uterus)"
62718161|NCT06715514|ACTIVE_COMPARATOR|GLP-1 Receptor Agonist|Wegovy®: injected once weekly, starting dose 0.25mg, with dose increments every four weeks reaching the maintenance dose of 1mg after eight weeks
62718162|NCT06715514|EXPERIMENTAL|Combined Menopausal Hornome Therapy and GLP-1 Receptor Agonist|Wegovy®: injected once weekly, starting dose 0.25mg, with dose increments every four weeks reaching the maintenance dose of 1mg after eight weeks Oestrogel®: once daily 1.5mg of E2 Utrogestan®\*: once daily 200mg of micronized progesterone (in women with intact uterus)
62718163|NCT06049173|EXPERIMENTAL|NEXAP group|The ventilator mode was changed from SIMV to PSV before LRM. After that, the abdominal pressure cardiopulmonary resuscitation (CPR-LW100) instrument was adopted and adsorbed on the epigastrium of patients. The LRM was performed by pulling up (tension of 20-30 kg) and compressing downward (tension\<10 kg) alternately on the abdomen of the patients with a frequency of 12 times per minute to support and maintain breathing. The whole LRM procedure lasted for 3 minutes in total . After LRM, the ventilator mode was changed to its baseline settings.
62718164|NCT06049173|ACTIVE_COMPARATOR|PEEP group|The ventilator mode was changed from SIMV to PSV before LRM. After that, PEEP was increased gradually (every 3-5cmH2O per 30s) from baseline (5-8 cmH2O) to 20cmH2O. The PEEP level was maintained at 20cmH2O for 60s, followed by decrements to baseline PEEP (every 3-5cmH2O per 30s). After LRM, the ventilator was changed to the baseline settings.
62718165|NCT05715060|ACTIVE_COMPARATOR|stainless steel wire closure|conventional closure of median sternotomy by stainless steel wire
62718166|NCT05715060|ACTIVE_COMPARATOR|PDS sternal closure|closure of median sternotomy by PDS
62718167|NCT05152511||All male children who had penile ischaemia after circumcision were included in the study|It is a cohort prospective study. All male children who had penile ischaemia after circumcision were included in the study between April 2017 and October 2020.
62718168|NCT02831660|EXPERIMENTAL|idarucizumab|
62718169|NCT06384170||Interventional|Patients identified with post-stroke pain due to spasticity. Patients will be evaluated for spinal cord stimulation trial. The trial will be for 7 days.
62718170|NCT05973201|EXPERIMENTAL|interventional arm|Fibroscopy performed under local anesthesia with immersion in a virtual reality scenario
62718171|NCT05973201|NO_INTERVENTION|Conventional arm|Fibroscopy performed under local anesthesia without immersion in a virtual reality scenario
62718172|NCT00587041|PLACEBO_COMPARATOR|Placebo|Participants received placebo for 6 weeks: 1 placebo packet daily and 1 placebo capsule twice daily
62718173|NCT00587041|ACTIVE_COMPARATOR|Oxadrop|Participants received Oxadrop for 6 weeks: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis)
62718174|NCT00587041|ACTIVE_COMPARATOR|Agri-King Synbiotic|Participants received AKSB for 6 weeks: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
62718175|NCT01070342||Chidren ages 6 to 18|Children ages 6 to 18 years will be available for participation in this multicenter study. Subjects will be enrolled from community based general pediatric clinics and other well-child care areas within participating hospitals and clinics of the four participating sites. Enrollment will continue until a total of 85 subjects from each age category (6-\<12 years and ≥12- \<18 years) successfully complete the study.
62718176|NCT06077994|ACTIVE_COMPARATOR|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|6 or 8 weeks BEPR+ program
62718177|NCT06077994|EXPERIMENTAL|digital Remote Patient Monitoring + BEPR+ (dRPM+)|6 or 8 weeks BEPR+; daily vitals readings (blood pressure, heart rate, oximetry, body temperature, and body weight) and an additional 12 weeks of dRPM reading once the BEPR+ program concludes
62718178|NCT01732536|EXPERIMENTAL|S8 Sinus Implant|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
62718179|NCT01732536|SHAM_COMPARATOR|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
62718180|NCT03017443|EXPERIMENTAL|Nutrisystem My Way|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem My Way plan.
62718181|NCT03017443|EXPERIMENTAL|Nutrisystem Turbo 10|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem Turbo 10 plan.
62718182|NCT03017443|EXPERIMENTAL|Nutrisystem DASH|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem DASH plan.
62718183|NCT03017443|ACTIVE_COMPARATOR|Dieting on Your Own (DIY) - DASH|All subjects provided publically available information on the DASH diet and instructed to follow a reduced calorie DASH diet meal plan on their own.
62718184|NCT02255929|EXPERIMENTAL|Gamma Knife Radiosurgery|Gamma Knife treatment is conducted in one day and takes approximately 70 to 90 minutes.
62718185|NCT02812745||patients|"patients presenting an indication for general anaesthesia during elective cardiac surgery and being monitored for sedation depth~* recording of cardiac output~* other parameters"
62718186|NCT01923883|ACTIVE_COMPARATOR|Negative-pressure syringe|EUS-FNA with negative-pressure suction with syringe
62718187|NCT01923883|EXPERIMENTAL|Capillary sampling with slow-pull|EUS-FNA with capillary sampling with stylet slow-pull technique
62718188|NCT01478932|EXPERIMENTAL|Diaphragmatic Breathing Retraining|In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
62718189|NCT01478932|PLACEBO_COMPARATOR|Health Promotion|In-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
62718190|NCT01732614|EXPERIMENTAL|Topcon Endpoint Management Laser|
62718191|NCT04160104||Training cohort|This cohort was used to establish the bowel preparation score (BPS).
62718192|NCT04160104||Validation cohort|This cohort was used to verify the bowel preparation score (BPS).
62718193|NCT02582879||Patient with CLL/SLL|Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.
62718194|NCT03652714|EXPERIMENTAL|Local anesthetic|
62718195|NCT03652714|PLACEBO_COMPARATOR|Isotonic NaCl|
62718196|NCT00598650|EXPERIMENTAL|1|
62718197|NCT04236999|EXPERIMENTAL|YSLQQ group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Unplugged in its original name, but the adaptation made by the research team for Chile is called Yo Sé Lo Que Quiero (YSLQQ). 12 one-hour sessions taught once a week by class teachers, previously trained in a 3-day course. Each session will be delivered during the time of Orientation lessons."
62718198|NCT04236999|NO_INTERVENTION|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
62718199|NCT00519727|EXPERIMENTAL|A|50 mg ISIS 325568 vs Placebo, s.c. injection
62718200|NCT00519727|EXPERIMENTAL|B|100 mg ISIS 325568 vs Placebo , s.c. injection
62718201|NCT00519727|EXPERIMENTAL|C|200 mg ISIS 325568 vs Placebo , s.c. injection
62718202|NCT00519727|EXPERIMENTAL|D|400 mg ISIS 325568 vs Placebo, s.c. injection
62718203|NCT00519727|EXPERIMENTAL|AA|50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
62718204|NCT00519727|EXPERIMENTAL|BB|100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
62718205|NCT00519727|EXPERIMENTAL|CC|200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
62718206|NCT00519727|EXPERIMENTAL|DD|400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
62164949|NCT05572697|EXPERIMENTAL|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|"In addition to the standard rehabilitation program, participants will receive the sleep intervention delivered via a smartphone app. We will use a Norwegian a program named Assistert Selvhjelp (In English: Assisted Self-Help). The app is fully automated and requires no contact with healthcare personnel. It can also be assessed on computers, but in the present project we will use the app-delivered version. It is based on the principles from face-to-face CBT-I including several modules consisting of sleep hygiene, stimulus control sleep restriction, cognitive therapy, and relaxation training. The modules also consist of learning material (e.g., quizzes and materials explaining and educating the patients about important sleep dimensions)."
62544223|NCT06622642|EXPERIMENTAL|Group B will undergo transbuccal technique for mandibular angle fracture reduction|In Group B tranbuccal technique approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF after which extraorally a stab incision will be made with scalpel blade parallel to relaxed resting skin tension lines through which the cannula with a trocar will be inserted through facial tissue down to bone. Transbuccal instrument system will cionsist of transbuccal guide, mountable retractor, drill sleeve, drill guide, and 2mm drill bit. A 2mm titanium miniplate will be placed along buccal cortex and screwed through trocar system. MMF will be removed and incision line closed
62544224|NCT05468424|EXPERIMENTAL|FarmVille|tablet (iPad or android) based role-playing game (FarmVille)
62544225|NCT05468424|ACTIVE_COMPARATOR|puzzle games|selection of tablet (iPad or android) based word puzzles (Word Search Ultimate and Word Cookies) and image puzzles (Flow Free and Jigsaw HD)
62544226|NCT04017650|EXPERIMENTAL|Treatment (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV over 1 hour on days 1 and 15, and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62544227|NCT03509857|PLACEBO_COMPARATOR|normal standard of care infusion of propofol without analgesia|normal standard of care infusion of propofol without analgesia
62544228|NCT03509857|EXPERIMENTAL|infusion of propofol with application of vibration analgesia|infusion of propofol with application of vibration analgesia
62544229|NCT06157190||patients with knee replacement|"The knee replacement patient cohort in this study consists of individuals who underwent Total Knee Arthroplasty (TKA) and utilized the moveUP digital application for at least six weeks post-surgery. The criteria include:~Total Knee Arthroplasty (TKA): Individuals who had surgical intervention for total knee replacement.~moveUP Digital Application Usage: Patients actively engaged with the moveUP digital therapies platform, using the associated application for rehabilitation. The application aids and monitors the recovery process.~Post-Surgery Duration of Six Weeks: To be part of the study, patients in this cohort used the digital application for a minimum of six weeks after knee replacement surgery. This duration aims to evaluate the effectiveness of technology-assisted rehabilitation during the critical early recovery phase."
62544230|NCT06157190||patients with hip replacement|"The hip replacement cohort likely comprises individuals who had total hip arthroplasty. Similar to the knee replacement cohort, inclusion criteria may involve using the moveUP digital application for at least six post-surgery weeks. Characteristics include:~Total Hip Arthroplasty (THA): Patients underwent surgical intervention for total hip replacement.~moveUP Digital Application Usage: Cohort members actively engaged with the moveUP digital therapies platform, utilizing the associated app for post-surgery rehabilitation.~Post-Surgery Duration of Six Weeks: To join the study, patients likely used the digital application for a minimum of six weeks post-hip replacement surgery. This period helps assess technology-assisted rehabilitation effectiveness during early recovery."
62544231|NCT00766779|EXPERIMENTAL|Transplant Arm|Hematopoietic cell transplantation after Reduced Intensity Conditioning
62544232|NCT00766779|ACTIVE_COMPARATOR|Conventional Chemotherapy|The non-transplant treatment approach for consolidation
62544233|NCT05017597|EXPERIMENTAL|Fatigue management|"Prescribed exercises by Physical Therapy Problem-Solving Sessions to resume activities that ther person needs to do, wants to do or is expected to do.~Four online educational modules: What is Cancer-Related Fatigue? Nutrition, Sleep Hygiene and Exercise"
62544234|NCT03225872||Osteosarcoma patients and family members|Osteosarcoma patients and family members
62718207|NCT02782442|EXPERIMENTAL|Structured Cognitive Training & PRIME|Structured cognitive training consists of social cognition and auditory exercises.
62718208|NCT02782442|ACTIVE_COMPARATOR|Computer Games Control & PRIME|Computer games control condition comes in the official PositScience wrapper.
62168062|NCT02552693|EXPERIMENTAL|Experimental Facility|"Enhanced training, supervision and support for MOHCC Standard Operating Procedure (SOP) implementation of identifying, tracing and returning to care (tracking and tracing) defaulting mother/infant pairs.~Facilities in the experimental group will receive additional training, supervision and support in identifying, tracing and returning to care defaulting mother/infant pairs."
62544235|NCT05404334||Breast Cancer|Patients with histologically proven breast cancer
62544236|NCT05404334||Benign breast disease|Patients with benign breast diseases undergoing surgical resection
62544237|NCT03150407|ACTIVE_COMPARATOR|VR101 Device|Subjects assigned to use randomly-assigned VR101 devices. Each device is to be used for 7 consecutive days, then replaced with a fresh device. Four each VR101 devices will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 Shams, each for 7 days.
62544238|NCT03150407|SHAM_COMPARATOR|Sham Control Ring|Subjects assigned to use randomly-assigned Sham rings. Each Sham is to be used for 7 consecutive days, then replaced with a fresh sham. Four each Shams will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 VR101 Devices, each for 7 days.
62544239|NCT03150407|OTHER|Long-term Safety Evaluation|13-week investigation of the safety of the use of VR101 Devices
62544240|NCT01393886|EXPERIMENTAL|Laparoscopic Greater Curvature Plication|Only one treatment arm
62544241|NCT05094089||SYNECOR IP Device|Hernia mesh repair with GORE® SYNECOR Intraperitoneal Biomaterial
62544242|NCT05094089||SYNECOR PRE Device|Hernia mesh repair with GORE® SYNECOR Preperitoneal Biomaterial
62544243|NCT04975191|OTHER|Resources Program (RP)|
62544244|NCT04975191|ACTIVE_COMPARATOR|Personalized Feedback Program (PFP)|
62544245|NCT04975191|ACTIVE_COMPARATOR|Brief motivational intervention (BMI)|
62718209|NCT06718920||Patients referred to the Multiple Sclerosis Center of the Agostino Gemelli IRCCS|Patients diagnosed with multiple sclerosis between 2014 and 2024, referring to the Multiple Sclerosis Center of the Agostino Gemelli IRCCS
62544246|NCT04975191|ACTIVE_COMPARATOR|Combined PFP+BMI|
62544247|NCT05062213|EXPERIMENTAL|Moisturizer Body Lotion|All participants will receive the product and use it at home.
62544248|NCT06080854|EXPERIMENTAL|Concurrent radiochemotherapy combined with immunotherapy|Participants will receive toripalimab plus gemcitabine and nab-paclitaxel in cycles of 21 days. Non-progressors will plus concurrent radiotherapy during the 3rd cycle of chemotherapy. After 4-6 cycles treatment, Multiple disciplinary team (MDT) will evaluate whether to undergo radical surgery.
62544249|NCT03167983||dementia|patients with dementia
62544250|NCT03167983||control|healthy control
62544251|NCT02318303|PLACEBO_COMPARATOR|GSP 301 Placebo NS|
62544252|NCT02318303|EXPERIMENTAL|GSP 301-1 NS (QD)|
62544253|NCT02318303|EXPERIMENTAL|GSP 301-2 NS (BID)|
62544254|NCT02318303|ACTIVE_COMPARATOR|Olopatadine HCl-1 NS (QD)|
62544255|NCT02318303|ACTIVE_COMPARATOR|Olopatadine HCl-2 NS (BID)|
62544256|NCT02318303|ACTIVE_COMPARATOR|Mometasone Furoate-1 NS (QD)|
62544257|NCT02318303|ACTIVE_COMPARATOR|Mometasone Furoate-2 NS (BID)|
62544258|NCT05456503|EXPERIMENTAL|Cognitively and neurologically normal seniors (CN)|One PET imaging scan using the PI-2620 tracer
62544259|NCT05456503|EXPERIMENTAL|Non-amnestic Alzheimer's Disease (AD)|One PET imaging scan using the PI-2620 tracer
62544260|NCT05456503|EXPERIMENTAL|Frontotemporal lobar degeneration from tauopathy (FLTD-tau)|One PET imaging scan using the PI-2620 tracer
62544261|NCT05456503|EXPERIMENTAL|Frontotemporal lobar degeneration from TDP-43 (FLTD-TDP)|One PET imaging scan using the PI-2620 tracer
62544262|NCT05456503|EXPERIMENTAL|Frontotemporal lobar degeneration from mutation in the MAPT gene (genetic FLTD-tau)|One PET imaging scan using the PI-2620 tracer
62544263|NCT05456503|EXPERIMENTAL|Frontotemporal lobar degeneration from mutation in the GRN gene or frame 72 of chromosome 9|One PET imaging scan using the PI-2620 tracer
62544264|NCT05456503|EXPERIMENTAL|Amnestic Mild Cognitive Impairment Alzheimer's Disease (MCI/aAD)|One PET imaging scan using the PI-2620 tracer
62544265|NCT03333265|EXPERIMENTAL|100mg Berberine hydrochloride group|Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
62544266|NCT03333265|EXPERIMENTAL|300mg Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
62544267|NCT03333265|PLACEBO_COMPARATOR|Placebo oral tablets|identical-appearing placebo tablets by mouth, two times per day for 6 months
62544268|NCT03593018|EXPERIMENTAL|Oral Azacitidine|Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
62544269|NCT03593018|ACTIVE_COMPARATOR|Investigator's choice therapy|Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
62718210|NCT02932826|EXPERIMENTAL|Treg Treatment + Insulin|subjects will be treated with Umbilical Cord Blood Regulatory T cells Therapy and insulin according to routine clinical practice at the discretion of the treating physician
62544270|NCT01680107|EXPERIMENTAL|d-cycloserine|oral, capsule, 250 mg, once
62544271|NCT01680107|PLACEBO_COMPARATOR|sugar pill|oral, capsule, once
62544272|NCT04539652|EXPERIMENTAL|Experimental group|
62544273|NCT05414344|EXPERIMENTAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
62544274|NCT05414344|EXPERIMENTAL|Trauma-Informed and Peer-Supported Brief Intervention (TIPS-BI)|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
62544275|NCT05414344|EXPERIMENTAL|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
62544276|NCT06003296|OTHER|Screw fixation|Calcaneocuboid arthrodesis in triple arthrodesis by Screw fixation
62544277|NCT02940808|OTHER|Caffeine first, placebo second|"Caffeine consumption during session 1, placebo consumption during session 2 (after baseline session 0)."
62544278|NCT02940808|OTHER|Placebo first, caffeine second|"Placebo consumption during session 1, caffeine consumption during session 2 (after baseline session 0)."
62544279|NCT05424458|EXPERIMENTAL|single-arm|"Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.~In the first month after definitive prosthesis placement, patients were recalled to complete the MDAS, OES and OHIP questionnaires for the second time. Changes of overall MDAS, OSE and OHIP score were defined as the score after definitive prosthesis placement minus that before the treatment. Negative score changes indicated score decrease of the second questionnaire compared to the first one. Positive score changes indicated score increase."
62718211|NCT02932826|ACTIVE_COMPARATOR|Insulin|subjects will be treated with insulin according to routine clinical practice at the discretion of the treating physician
62718212|NCT04940130|EXPERIMENTAL|Arm 1 (PfSPZ Vaccine)|134 children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10\^5 PfSPZ) via DVI at 1, 8, and 29 days
62718213|NCT04940130|PLACEBO_COMPARATOR|Arm 2 (normal saline)|134 children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days
62718214|NCT03766061|ACTIVE_COMPARATOR|Onlay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with onlay mesh hernioplasty in which we placed mesh on the anterior rectus sheath
62718215|NCT03766061|ACTIVE_COMPARATOR|Sublay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with sublay mesh hernioplasty in which we placed mesh in the retromuscular space
62718216|NCT04301648|ACTIVE_COMPARATOR|Common Practice|Patients included in the phase before will receive common practice.
62718217|NCT04301648|EXPERIMENTAL|STAR Nurse|Patients included in the phase after will receive care by a STAR Nurse.
62718218|NCT06716684|EXPERIMENTAL|Intervention group|In the study, a 6-session psychoeducation programme on coping with anger was given to the intervention group.
62718219|NCT06716684|NO_INTERVENTION|Control group|No intervention was applied to the control group in the study.
62718220|NCT04548206|EXPERIMENTAL|Pilates training|60 minutes of Pilates training will be performed for 8 weeks.
62718221|NCT04548206|PLACEBO_COMPARATOR|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
62718222|NCT03376932|EXPERIMENTAL|Subjects receiving FF/UMEC/VI (100/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FF/UMEC/VI (100/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol metered dose inhalers (MDIs) as a rescue medication throughout the study.
62718223|NCT03376932|EXPERIMENTAL|Subjects receiving FF/UMEC/VI (200/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FF/UMEC/VI (200/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
62718224|NCT03376932|ACTIVE_COMPARATOR|Subjects receiving FP/SAL(250/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FP/SAL (250/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
62718225|NCT03376932|ACTIVE_COMPARATOR|Subjects receiving FP/SAL(500/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FP/SAL (500/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily given in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
62168063|NCT02552693|NO_INTERVENTION|Control Facility|Facilities in the control group will be operating as described in the MOHCC SOP. (Standard practice in tracking and tracing of defaulting mother/infant pairs)
62718226|NCT01977378|EXPERIMENTAL|Sustained-Release Desvenlafaxine Hydrochloride|50-100mg/d
62718227|NCT01977378|ACTIVE_COMPARATOR|Sustained-Release Venlafaxine Hydrochloride|75-225mg/d
62718228|NCT05891171|EXPERIMENTAL|Dose Escalation Cohort 1|Participants will receive AB598 intravenous (IV) infusion once every 3 weeks
62718229|NCT05891171|EXPERIMENTAL|Dose Escalation Cohort 2|Participants will receive AB598 IV infusion once every 3 weeks
62718230|NCT05891171|EXPERIMENTAL|Dose Escalation Cohort 3|Participants will receive AB598 IV infusion once every 3 weeks
62718231|NCT05891171|EXPERIMENTAL|Dose Escalation Cohort 4|Participants will receive AB598 IV infusion once every 3 weeks
62718232|NCT05891171|EXPERIMENTAL|Pharmacodynamic Cohort 1|Participants will receive AB598 IV infusion once every 3 weeks
62718233|NCT05891171|EXPERIMENTAL|Pharmacodynamic Cohort 2|Participants will receive AB598 IV infusion once every 3 weeks
62718234|NCT05891171|EXPERIMENTAL|Pharmacodynamic Cohort 3|Participants will receive AB598 IV infusion once every 3 weeks
61976536|NCT06423820|EXPERIMENTAL|Group S (Ondansetron lozenge)|Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery as a study group.
62168064|NCT00083122|EXPERIMENTAL|Group 1|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62718235|NCT05891171|EXPERIMENTAL|Dose Expansion Gastric/GEJ Cancer (phase 1b)|Participants will receive AB598 IV infusion every 2 weeks in combination with zimberelimab and FOLFOX (oxaliplatin, leucovorin, fluorouracil)
62718236|NCT03995160|ACTIVE_COMPARATOR|Total knee replacement with use of closed suction drainage|Use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
62718237|NCT03995160|ACTIVE_COMPARATOR|Total knee replacement without use of closed suction drainage|Without the use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
62718238|NCT04929964||Breast cancer|
62718239|NCT01900886||Pegasys, injection subcutaneous|Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)
62718240|NCT06714903||Experimental group|sintilimab + fruquintinib
62718241|NCT06714903||Control group|fruquintinib
62718242|NCT06718257||Control group|Patients initially received GP/GEMOX regimen.
62718243|NCT06718257||Experimental group|Patients initially received GP/GEMOX combined with PD-1/L1 and TKI inhibitors regimen.
62718244|NCT05528575|EXPERIMENTAL|Polyphenol|Consume polyphenol combination for two weeks
62718245|NCT05528575|EXPERIMENTAL|Prebiotic|Consume prebiotic combination for two weeks
62718246|NCT05528575|EXPERIMENTAL|prebiotic and polyphenol|Combination of prebiotics and polyphenols for two weeks
62718247|NCT05528575|PLACEBO_COMPARATOR|Placebo|maltodextrin placebo for two weeks
62718248|NCT04161534|ACTIVE_COMPARATOR|Arm Sling Group|
62718249|NCT04161534|EXPERIMENTAL|KT Tape Group|
62718250|NCT05987982|EXPERIMENTAL|Group with oral management|The investigators taught and monitored patients or caregivers to oral health care plus oral exercises such as salivary glands massage methods after meals and before sleep.
62718251|NCT05987982|EXPERIMENTAL|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
62718252|NCT05987982|NO_INTERVENTION|Group with standard of care|Only provided oral care education.
62718253|NCT05157087||Commercial Population|Individuals with at least one omalizumab prescription in the Marketscan commercial claims during the identification period (07/07/2016 - 12/31/2018)
62718254|NCT05157087||Medicaid Population|Individuals with at least one omalizumab prescription in the Truven Medicaid claims during the identification period (07/07/2016 - 12/31/2018)
62718255|NCT02711501|EXPERIMENTAL|Laser irradiation|laser-assisted surgery with the following parameters: Wavelength:810 nanometer, power: 3 W, pulse mode,pulse length 100 µs, pulse interval 200 µs
62718256|NCT02711501|EXPERIMENTAL|blade|conventional surgery by blade
62718257|NCT02347085|EXPERIMENTAL|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
62718258|NCT02347085|PLACEBO_COMPARATOR|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
62718259|NCT05321329|EXPERIMENTAL|Single Arm|Capecitabine will be taken orally at dose of 1250 mg/m2 PO BID on days 1→14 every 3 weeks Cycles are to be repeated every 21 days for a total of 8 cycles
62718260|NCT04167254|EXPERIMENTAL|Sit Down and Play|
62718261|NCT04167254|NO_INTERVENTION|Usual Care|
62718262|NCT06160323|ACTIVE_COMPARATOR|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"Patient would undergo a EUS diagnostic procedure with or without a biopsy. Patient would be blinded to the group they were assigned. The procedure will be performed with a linear array echoendoscope (EUS) under conscious sedation or monitored anaesthesia care.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
62718263|NCT06160323|ACTIVE_COMPARATOR|Conventional step-up approach|"Patient would undergo a EUS diagnostic procedure with or without a biopsy. Patient would be blinded to the group they were assigned. The concept of the conventional step-up approach is to follow ESMO clinical practice guidelines for cancer pain.~In case of inadequate pain control, the analgesics will be stepped up according to the guidelines. After 4 weeks, if patient's VAS score more than 7 or VAS score fails to improve by 20% despite optimal oral analgesics, patients are given the option of EUS-guided CGN/ CPN."
62718264|NCT04848402|EXPERIMENTAL|On-Body Delivery System (OBDS)/Multiple Bolus Injector|On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).
62718265|NCT04848402|EXPERIMENTAL|Single Auto Injector|Single auto injector used to administer placebo SC.
62718266|NCT06550882||All Participants|Participants with AHA who are receiving OBIZUR injection or initiate OBIZUR Injection treatment for the first time will be enrolled. Both retrospective and prospective participants data will be collected. Retrospective data will be collected from the date of first treatment with OBIZUR injection after the marketing authorization in Korea but before date of signed informed consent and prospective data will be collected from the date of signed informed consent. The treatment and follow up of the participants will be determined by the treating physicians according to her/his routine practice.
62718267|NCT04442568|ACTIVE_COMPARATOR|ERAS|all patients in this group will be performed LSG under a specified anesthesia protocol. This protocol includes non-opioid analgesia and sedation. Also short-acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the second hour postoperatively, also will be started oral intake between second and fourth hours.
62718268|NCT04442568|NO_INTERVENTION|no ERAS|all patients in this group will be performed LSG under a conventional anesthesia protocol which is depended on the anesthesiologist . This protocol includes opioid analgesia and sedation. Also short and long acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the fourth hour postoperatively, also will be started oral intake in the next day morning after surgery.
62718269|NCT00827229|OTHER|LaborPro, active Labor, Vaginal Examination|
62718270|NCT03055091|EXPERIMENTAL|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
62718271|NCT03055091|PLACEBO_COMPARATOR|Placebo|Participants in the placebo arm will receive sorbitol syrup.
62718272|NCT05726149|EXPERIMENTAL|Real UHCDS a-TDCS + Therapeutic Exercise|Real unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise
62718273|NCT05726149|SHAM_COMPARATOR|Sham UHCDS a-TDCS + Therapeutic Exercise|Sham unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise
62718274|NCT05726149|ACTIVE_COMPARATOR|Therapeutic Exercise|Therapeutic exercise.
62718275|NCT06708338|ACTIVE_COMPARATOR|Bevel-up group|AVF puncture will be performed with the needle bevel facing up for the entire duration of the patient's participation.
62718276|NCT06708338|EXPERIMENTAL|Bevel-down group|AVF puncture will be performed with the needle bevel facing down for the entire duration of the patient's participation
62718277|NCT05525910|ACTIVE_COMPARATOR|Treatment A: Nirmatrelvir/ritonavir|Nirmatrelvir and ritonavir tablets
62718278|NCT05525910|EXPERIMENTAL|Treatment B: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
62718279|NCT05525910|EXPERIMENTAL|Treatment C: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
62718280|NCT05525910|EXPERIMENTAL|Treatment D: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
62718281|NCT05525910|EXPERIMENTAL|Treatment E: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
62718282|NCT03423121|EXPERIMENTAL|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
62718283|NCT03423121|PLACEBO_COMPARATOR|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
62544280|NCT00735397|EXPERIMENTAL|Perampanel|Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.
62544281|NCT00216138|ACTIVE_COMPARATOR|1|Docetaxel + Capecitabine
62544282|NCT06124937|EXPERIMENTAL|Intervention group|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
62544283|NCT06124937|PLACEBO_COMPARATOR|Comperator|The comparator group will receive a matching placebo
62544284|NCT04274231||TKI best effect group|TKI best effect was defined achieve complete cytogenetic response (CCyR)after 3 months of treatment and the level of BCR/ABL\<10% after 3 months of treatment,the level of BCR/ABL\<1% .
62544285|NCT04274231||TKI resistance group|TKI resistance was defined as the lack of a complete hematologic response (CHR) after 3 months of TKI treatment, the lack of any cytogenetic response after 6 months of treatment, the lack of major cytogenetic response (MCyR) (Ph-positive cells \> 35%) after 12 months of treatment, an increase of white blood cell (WBC) count in at least two consecutive samplings (with a doubling of the count from the nadir to ≥ 20×109/L or an absolute increase of ≥ 50×109/L), or a relapse after a CHR or MCyR.
62544286|NCT04274231||TKI intolerance group|TKI intolerance was defined as at least grade 3 nonhematologic toxicity or grade 4 hematologic toxicity persisting for more than 7 days, related to TKIs at any dose.
62544287|NCT00865371|EXPERIMENTAL|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
62164950|NCT05572697|ACTIVE_COMPARATOR|Usual care|Participants randomized to usual care will receive the standard inpatient rehabilitation program. This is a traditional rehabilitation program consisting of physical activity, mindfulness excises, psychoeducation and acceptance and commitment therapy. One of the educational sessions is about sleep. Although this educational session overlaps with some of the content included in the intervention (e.g., sleep hygiene, stimulus control), it does not include any of the interactive features of the app.
62164951|NCT00850993|EXPERIMENTAL|Cohort 1: Stannsoporfin 1.5 mg/kg|Participants receive a single dose of 1.5 mg/kg by intramuscular (IM) injection, along with PhotoTherapy (PT) if and when needed.
62164952|NCT00850993|EXPERIMENTAL|Cohort 2: Stannsoporfin 3.0 mg/kg|Participants receive a single dose of 3.0 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
62544288|NCT00865371|ACTIVE_COMPARATOR|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
62544289|NCT02845700|ACTIVE_COMPARATOR|Perceptual Retraining Treatment (PRT)|"The Perceptual Retraining Treatment will involve systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor). Each training session will consist of 4 training blocks."
62544290|NCT02845700|PLACEBO_COMPARATOR|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the PRT. Following the one-month assessment, they will be given the option to complete the PRT.
62544291|NCT00742118|EXPERIMENTAL|2|patient with chronic inflammatory intestinal disease
62544292|NCT00742118|OTHER|3|patient having no symptoms
62544293|NCT00742118|EXPERIMENTAL|1|patient with irritable bowel syndrome
62544294|NCT01670591|EXPERIMENTAL|PS - Prevention in School|Teachers learn to use the core program components (defining and teaching school rules and the handling of rule breakings, principles of positive behavior support)with help from external consultants during approximately 1.5 years.
62544295|NCT01670591|NO_INTERVENTION|Business as usual|
62544296|NCT06508320|EXPERIMENTAL|Group 1: mRNA-1083 Lot A|Participants will receive mRNA-1083 Lot A as a single injection on Day 1.
62544297|NCT06508320|EXPERIMENTAL|Group 2: mRNA-1083 Lot B|Participants will receive mRNA-1083 Lot B as a single injection on Day 1.
62544298|NCT06508320|EXPERIMENTAL|Group 3: mRNA-1083 Lot C|Participants will receive mRNA-1083 Lot C as a single injection on Day 1.
62544299|NCT06508320|EXPERIMENTAL|Group 4: mRNA-1083 Lot D|Participants will receive mRNA-1083 Lot D as a single injection on Day 1.
62544300|NCT02006329|EXPERIMENTAL|Intervention group - dietary consultation - Medit|
62544301|NCT02006329|NO_INTERVENTION|Control group - dietary consultation - Mediterranean diet|
62544302|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
62544303|NCT05608473|EXPERIMENTAL|Exercise Group|A 10-minute video consisted of 14 exercises was uploaded to the computers of the participants in the exercise group. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
62544304|NCT05608473|NO_INTERVENTION|Control Group|The control group was given one session of training on postural correction.
62544305|NCT05681715|EXPERIMENTAL|Rozanolixizumab Sequence 1: Syringe Driver - Manual Push|Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.
62544306|NCT05681715|EXPERIMENTAL|Rozanolixizumab Sequence 2: Manual Push - Syringe Driver|Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.
62544307|NCT03430765|EXPERIMENTAL|Acceptance and Commitment Therapy|Standard breast cancer treatment plus a single 2 hour individual Acceptance and Commitment Therapy coping skills session.
62544308|NCT03430765|NO_INTERVENTION|Treatment as Usual|Standard breast cancer treatment.
62544309|NCT03973307||Participants with bladder cancer|50 participants with histologically confirmed evidence of malignancy for bladder cancer following routine cystoscopy and biopsy.
62544310|NCT03973307||Participants without bladder cancer|50 participants with negative biopsy for bladder cancer following routine cystoscopy and biopsy.
62544311|NCT02213510|EXPERIMENTAL|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
62544312|NCT02213510|ACTIVE_COMPARATOR|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
62544313|NCT03338725|ACTIVE_COMPARATOR|Patients without intervention|Patients without follow-up by clinical pharmacy model
62544314|NCT03338725|EXPERIMENTAL|Patients with intervention|Patients who are being monitored by a clinical pharmacy model
62544315|NCT06550700||laparoscopic hybrid surgery (LHS) cohort|Routine colorectal surgery is performed first, followed by liver surgery. The LHS cohort first performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
62544316|NCT06550700||totally open surgery (TOS) cohort|Routine colorectal surgery is performed first, followed by liver surgery. The blood vessel detachment, bowel detachment, the distal bowel of the tumor in the TOS cohort were accomplished by open surgery through the mid-abdominal incision approach. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
62544317|NCT04490616|EXPERIMENTAL|RR-GR|MCI patients with social cognition deficits will receive 4 weeks of rTMS stimulation
62544318|NCT04490616|OTHER|SR-GR|MCI patients with social cognition deficits will receive 2 weeks of placebo treatment, followed by 2 weeks of real rTMS stimulation
62544319|NCT03374007|EXPERIMENTAL|GB226 1mg/kg single-dose|Geptanolimab, 1mg/kg, i.v., single-dose
62544320|NCT03374007|EXPERIMENTAL|GB226 3 mg/kg single-dose|Geptanolimab, 3mg/kg, i.v., single-dose
62544321|NCT03374007|EXPERIMENTAL|GB226 10mg/kg single-dose|Geptanolimab 10mg/kg, i.v., single-dose
62544322|NCT03374007|EXPERIMENTAL|GB226 1mg/kg multiple dosing, every 2 weeks|Geptanolimab, 1mg/kg, i.v., q2w\*6
62544323|NCT03374007|EXPERIMENTAL|GB226 3mg/kg multiple dosing,every 2 weeks|Geptanolimab, 3mg/kg, i.v., q2w\*6
62544324|NCT03374007|EXPERIMENTAL|GB226 10mg/kg multiple dosing, every 2 weeks|Geptanolimab,10mg/kg, i.v., q2w\*6
62544325|NCT03374007|EXPERIMENTAL|GB226 280mg multiple dosing|Geptanolimab, 280mg, i.v., q3w
62544326|NCT03374007|EXPERIMENTAL|GB226 3mg/kg multiple dosing|Geptanolimab, 3mg/kg, i.v., q2w
62544327|NCT05019599|NO_INTERVENTION|normal controls|subjects with normal renal function
62544328|NCT05019599|EXPERIMENTAL|CKD_Low protein diet|CKD patient with low protein diet (\<0.8g/kg/BW)
62544329|NCT05019599|ACTIVE_COMPARATOR|CKD_normal protein diet|CKD patient with normal protein diet
62544330|NCT01307748|EXPERIMENTAL|stress reducing aroma|aroma with reported stress reducing effects
62544331|NCT01307748|PLACEBO_COMPARATOR|Placebo aroma 1|
62544332|NCT01307748|PLACEBO_COMPARATOR|Placebo aroma 2|
62544333|NCT04800679|ACTIVE_COMPARATOR|intravitreal bevacizumab injections and then rescue|
62544334|NCT04800679|ACTIVE_COMPARATOR|PRP group|
62544335|NCT04800679|ACTIVE_COMPARATOR|IVB injections and a modified laser|
62544336|NCT04429308|ACTIVE_COMPARATOR|Photodynamic Therapy|One upper arm will be exposed to blue light therapy
62544337|NCT04429308|ACTIVE_COMPARATOR|Chemical Peels|One upper arm will be exposed to Jessner's Solution AND 35% Trichloroacetic acid peel
62544338|NCT00735618|EXPERIMENTAL|Guided Relaxation|Heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation program
62544339|NCT06370481|EXPERIMENTAL|Patients living with HIV and substance use|Patients living with HIV and substance use, aged 18 and over. These participants are receiving services at HIV clinics in Alabama and must have reported opioid and/or stimulant misuse.
62544340|NCT05189834|OTHER|Treatment sequence A|"Patients will follow the following treatment sequence:~1. Treatment with Gelsectan® (30 days)~2. Washout period (15 days)~3. Treatment with placebo (30 days)"
62544341|NCT05189834|OTHER|Treatment sequence B|"Patients will follow the following treatment sequence:~1. Treatment with placebo (30 days)~2. Washout period (15 days)~3. Treatment with Gelsectan® (30 days)"
62544342|NCT05350605|EXPERIMENTAL|Experimental: Laid back breastfeding position education group|Breastfeeding education will be given to pregnant women in the laid-back breastfeeding position group, which includes the laid back breastfeeding position with a lactation simulation model.
62544343|NCT05350605|EXPERIMENTAL|Experimental: Upright breastfeeding position education group|Breastfeeding education will be given to pregnant women in the upright breastfeeding position group, which includes the upright breastfeeding position with a lactation simulation model.
62544344|NCT05350605|NO_INTERVENTION|No Intervention: Control Group|Mothers in the control group will receive routine hospital care
62544345|NCT00562523|EXPERIMENTAL|Arm 1|
62544346|NCT00631657|EXPERIMENTAL|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
62544347|NCT00631657|PLACEBO_COMPARATOR|Placebo|Participants receive placebo tablets, administered once a day for 6 months
62544348|NCT03039426|EXPERIMENTAL|Group Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
62544349|NCT03039426|ACTIVE_COMPARATOR|Group Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
62544350|NCT00822978|ACTIVE_COMPARATOR|ACHN-490 Injection|ACHN-490 Injection in escalating doses
62544351|NCT00822978|PLACEBO_COMPARATOR|2|Placebo is normal saline
62544352|NCT05122559|ACTIVE_COMPARATOR|N-acetyl cysteine|N-acetyl cysteine (NAC) 1200mg t.i.d.
62544353|NCT05122559|PLACEBO_COMPARATOR|Placebo|Placebo 1200mg t.i.d.
62718284|NCT06715592|EXPERIMENTAL|ECT Electrochemotherapy|The ways in which ECT treatment will be applied have been codified at European level from the 2006 ESOPE study
62718285|NCT03988946|EXPERIMENTAL|Transcatheter Mitral Valve Replacement|Replacement valve delivered through a transfemoral access and transseptal approach
62544354|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
62164953|NCT00850993|EXPERIMENTAL|Cohort 3: Stannsoporfin 4.5 mg/kg|Participants receive a single dose of 4.5 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
62164954|NCT00850993|PLACEBO_COMPARATOR|Cohort 4: Placebo|Participants receive a single dose of placebo (sterile saline solution) by IM injection, along with PT if and when needed.
62164955|NCT02535598|ACTIVE_COMPARATOR|Normal presentation|Standard internet based CBT presentation.
62164956|NCT02535598|EXPERIMENTAL|Enhanced presentation|Enhanced internet CBT presentation.
62164957|NCT02535598|ACTIVE_COMPARATOR|Normal support|Standard internet based CBT support.
62164958|NCT02535598|EXPERIMENTAL|Enhanced support|Enhanced internet CBT support.
62164959|NCT03348800|EXPERIMENTAL|Test Side|The side in which computer controlled anesthetic delivery system will be used as dental anesthesia before dental surgery
62544355|NCT04935229|EXPERIMENTAL|SD-101|3 weekly doses of SD-101 given via hepatic artery infusion over 2 cycles
62544356|NCT04150770|EXPERIMENTAL|Patients with Childhood Uveitis|5mg/kg/dose of infliximab IV initially two weeks, then 4 weeks and then every 6-8 weeks
62544357|NCT03510598|EXPERIMENTAL|Treatment for Submental Fat Reduction withCoolSculpting System followed by Kybella|CoolSculpting followed by Kybella treatments. Kybella supplied in 2mL vials.
62544358|NCT05326282|EXPERIMENTAL|Multi-parametric and micro ultrasound|Transrectal ultrasound imaging in men with suspected or known low grade prostate cancer using both standard and micro-ultrasound technology
62544359|NCT06402760|ACTIVE_COMPARATOR|Western medicine group|Treatment will be stratified according to the severity of psoriasis in patients, with therapeutic methods limited to the traditional treatment approaches outlined in the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 Simplified Version). The treatment duration will be 16 weeks, followed by a 24-week follow-up period during which patients will not be restricted in their treatment modalities.
61976537|NCT06423820|NO_INTERVENTION|Group C (Control)|Pediatric patients will not receive ondansetron as a control group.
62164960|NCT03348800|ACTIVE_COMPARATOR|Control Side|The side in which conventional syringe will be used as dental anesthesia before dental surgery
62164961|NCT02831439|EXPERIMENTAL|Intervention|Participating health systems in Wisconsin. Interventions include: Basic public reporting and the enhanced intervention (app)
62164962|NCT02831439|OTHER|Control|Health systems in comparison states. Control includes: Cost savings comparison
62164963|NCT01746199|EXPERIMENTAL|cotrimoxazole daily prophylaxis|cotrimoxazole daily prophylaxis
62164964|NCT01746199|ACTIVE_COMPARATOR|Intermittent Preventive sulphadoxine-pyrimethamine Treatment|Referent treatment given according WHO recommendations
62544360|NCT06402760|EXPERIMENTAL|TCM comprehensive treatment group|In addition to the Western medicine treatment prescribed in the guidelines, patients are required to take fish oil orally and Taodan Granules, and engage in moderate to high-intensity aerobic exercise weekly.
62544361|NCT03864887||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by Optical monitor for hemodynamic parameter.
62544362|NCT03864887||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by Optical monitor for hemodynamic parameter.
62164965|NCT05587361|PLACEBO_COMPARATOR|Placebo Patch/Placebo Propranolol|Placebo Nicotine Patch Placebo Propranolol
62544363|NCT03864887||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by Optical monitor for hemodynamic parameter.
62544364|NCT03864887||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ\[Hb\] and Δ\[HbO2\] time courses were collected by Optical monitor for hemodynamic parameter.
61976538|NCT03542968|EXPERIMENTAL|4D magnetic resonance imaging|MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).
61976539|NCT03542968|SHAM_COMPARATOR|2D magnetic resonance imaging|MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI
61976540|NCT00607529||1|Patients having a creatinine drawn
61976541|NCT03358290|EXPERIMENTAL|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
61976542|NCT03358290|EXPERIMENTAL|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
61976543|NCT03358290|EXPERIMENTAL|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
61976544|NCT03358290|EXPERIMENTAL|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
61976545|NCT03358290|EXPERIMENTAL|Placebo|One dose of study drug by mouth daily for 12 weeks
61976546|NCT04688762||Group without the e-consult tool|standard consultation
61976547|NCT04688762||Group with the e-consult tool|The e-consult tool is a digital application developed and designed by the Center François Baclesse, This tool is a consultation support to explain the surgical management of the patient.
61976548|NCT00719251|EXPERIMENTAL|HVG|The patients received standard nursing care and HVPC
61976549|NCT00719251|EXPERIMENTAL|LG|These patients received standard nursing care and LLLT
61976550|NCT00719251|ACTIVE_COMPARATOR|CG|The control group only was treated with standard nursing care
61976551|NCT01444326|EXPERIMENTAL|Dairy diet|
61976552|NCT01444326|PLACEBO_COMPARATOR|Control diet|
61976553|NCT01248377||Cephalosporins allergic patients|
61976554|NCT04034420|EXPERIMENTAL|Online training|To receive self-paced online training and learning materials
61976555|NCT04893603|EXPERIMENTAL|Severe Aortic Valve Stenosis|Patients will be treated with Transcatheter Aortic Valve Systerm
61976556|NCT05548166||Pediatric Patients|Pediatric patients with celiac disease.
62718286|NCT02011269|ACTIVE_COMPARATOR|7500 TSO|7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
62164966|NCT05587361|EXPERIMENTAL|Placebo Patch/Active Propranolol|Placebo Nicotine Patch Active Propranolol (40 mg, immediate release)
62164967|NCT05587361|EXPERIMENTAL|Active Patch/Placebo Propranolol|Active Nicotine Patch (14 mg) Placebo Propranolol
62164968|NCT05587361|EXPERIMENTAL|Active Patch/Active Propranolol|Active Nicotine Patch (14 mg) Active Propranolol (40 mg, immediate release)
62718287|NCT02011269|ACTIVE_COMPARATOR|15000 TSO|15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
62164969|NCT06240403|PLACEBO_COMPARATOR|Placebo|Two capsules of placebo taken orally per day for three months
62164970|NCT06240403|EXPERIMENTAL|Digoxin|Two capsules containing 62.5mcg digoxin taken orally per day for three months
62164971|NCT06585007|NO_INTERVENTION|Standard of care therapy|The standard of care can consist of surveillance (which means the continuation of the ongoing systemic treatment without any change) or initiation of NEST. The decision which option is considered must be decided at the multidisciplinary urologic oncology meeting (obligatory). MDT is not allowed in this arm. Options for NEST in this trial are abiraterone acetate, enzalutamide, apalutamide, darolutamide, olaparib, talazoparib, niraparib, cabazitaxel and docetaxel, radium-223, luthetium-177-PSMA.
62164972|NCT06585007|EXPERIMENTAL|Progression-directed therapy|PDT (metastasectomy or SBRT) while continuing current systemic therapy: androgen-deprivation (ADT) alone, or ADT in combination with abiraterone acetate, enzalutamide, apalutamide and patients who had received docetaxel in the past. Patients under current treatment with docetaxel are not allowed, because the hypothesized interaction between docetaxel and radiotherapy concerning toxicity. In case of oligoprogression after PDT, repeated PDT to the new lesions is mandatory.
62544365|NCT03306446|EXPERIMENTAL|Adalimumab in monotherapy|Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.
62544366|NCT05327231|EXPERIMENTAL|IN10018 Monotherapy|Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
62718288|NCT02011269|PLACEBO_COMPARATOR|Non-active treatment|The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product.
62718289|NCT05562115|EXPERIMENTAL|Patients treated for an ocular malformation linked to a PAX6 mutation.|
62718290|NCT02167789|NO_INTERVENTION|PhD|
62718291|NCT05973864|EXPERIMENTAL|Experimental arm : Pembrolizumab and capecitabine|"* Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles at adjuvant phase of the treatment;~* Capecitabine will be administrated at a dose of 1250 mg/m² twice a day (BID) (14 days on / 7 days off) for a total of 8 cycles, with a dose reduction at 825 mg/m² BID during radiotherapy if indicated~* Local radiotherapy will be performed as per standard practice if indicated."
61976557|NCT05548166||Caregivers and parents|Caregivers and parents of pediatric patients with celiac disease
61976558|NCT05548166||Experts|Group of experts in pediatric celiac disease to provide feedback on scale development.
61976559|NCT00539331|PLACEBO_COMPARATOR|1|Paclitaxel/Carboplatin
61976560|NCT00539331|EXPERIMENTAL|2|Paclitaxel/Carboplatin + AZD2171
61976561|NCT05517928|EXPERIMENTAL|Lactobacillus rhamnosus GG Group|Subjects will receive omeprazole daily for 56 days. After 28 days, subjects will receive Lactobacillus rhamnosus GG two capsules daily taken with a meal.
61976562|NCT05517928|PLACEBO_COMPARATOR|Placebo Group|Subjects will receive omeprazole daily for 56 days. After 28 days, subjects will receive placebo two capsules daily taken with a meal.
61976563|NCT00938379|EXPERIMENTAL|20% deet insect repellent|experimental intervention
62544367|NCT05327231|EXPERIMENTAL|IN10018 Combination with Docetaxel|Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours. Docetaxel 75mg/m2 every 21 days a cycle.
62544368|NCT05952674|EXPERIMENTAL|Vagus Nerve Stimulation (VNS) + Best Medical Treatment (BMT)|Along with the Optimal Medical Treatment for resistant depression, the VNS + BMT arm will be implanted a medical device of VNS.
62544369|NCT05952674|ACTIVE_COMPARATOR|Best Medical Treatment|The BMT arm will only receive the Optimal Medical Treatment for resistant depression.
62718292|NCT05973864|OTHER|Standard of care (SOC) treated external cohort|A standard of care treated external cohort with patients treated with pembrolizumab as postoperative treatment for localized TNBC without pCR after NAC, and with similar eligibility criteria will be registered in an ambispective way, allowing comparisons between the experimental arm and this external cohort. All the centres involved in the study will participate the registration of the needed information concerning this cohort.
61976564|NCT00938379|PLACEBO_COMPARATOR|lotion without repellent active|
62718293|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
62718294|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
62718295|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.~Inclusion before initiation of anticoagulation."
62718296|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
62718297|NCT02199756||Cesarean section|Women with cesarean section
62718298|NCT05993793|EXPERIMENTAL|Fototherapy|
62735899|NCT01713582|EXPERIMENTAL|AL 10 mg QD 14-21|Participants received 10 mg birabresib/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.
62164973|NCT00587899|OTHER|1|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
62164974|NCT00587899|NO_INTERVENTION|2|The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation
62164975|NCT06102538|ACTIVE_COMPARATOR|Morbid obese adolescents with comorbidity|A weekly intervention of physical education, group psychological support, and nutrition education.
62164976|NCT06102538|NO_INTERVENTION|Obese children who do not participate in this intervention|This group of adolescents will continue the routine treatment in the clinic
62164977|NCT01586494|EXPERIMENTAL|Group 1|
62164978|NCT01586494|EXPERIMENTAL|Group 2|
62164979|NCT02039596|EXPERIMENTAL|vegetarian breakfast|Diet: Vegetarian food items
62718299|NCT05562505|ACTIVE_COMPARATOR|Venovenous ECMO|Patients allocated to the ECMO strategy be initiated on V-V ECMO and on anticoagulation (blood thinning medication to prevent clot formation) within 24 hours of being allocated into the intervention group. Anticoagulant medication to prevent clot formation will be initiated as per current local practice for each site. Sites are encouraged to use best practice ECMO management that includes de-sedation, extubation, commencement of physiotherapy and rehabilitation,
62164980|NCT02039596|EXPERIMENTAL|Swedish Breakfast|Diet: Swedish food items
62164981|NCT02039596|EXPERIMENTAL|English breakfast|Diet: English food items
62718300|NCT05562505|NO_INTERVENTION|Standard care|Patients allocated to the standard care arm will receive routine intensive care for hypoxic respiratory failure, including mechanical ventilation as per local practices, weaning of sedation and assessment for extubation. Patients who continue to deteriorate will be eligible for initiation of V-V ECMO if they meet the ECMO to rescue lung injury in severe ARDS (EOLIA) criteria: Partial pressures of arterial oxygen (PaO2):Fraction of inspired oxygen (FiO2)\<50 for 3 hours, PaO2:FiO2\<80 for 6 hours, pH\<7.25 with PaCO2 \>60 for \>6 hours.
62718301|NCT05747274||The Divat COHORT|"The DIVAT cohort (Computerized and Validated Data in Transplantation) developed by the Immunology and Nephrology Department of the University Hospital of Nantes (France) , is a biocollection database linked to clinical data and plasma, serum, blood cells and urines of all kidney recipients from Nantes, Paris-Necker, and Lyon centres. The clinical and biological parameters are collected at 3 months, 6 months, 1 year and then every year.~All available specimens in the DIVAT cohort that:~* meet inclusion and exclusion criteria of this study AND~* are usable in terms of quality, integrity, and quantity. will be analysed for this study in order to maximise the power and generalisability of the results."
62718302|NCT06376864|EXPERIMENTAL|Activity Breaks intervention|The intervention arm will receive the Activity Breaks intervention.
62718303|NCT06376864|NO_INTERVENTION|The control group|The control arm will continue to receive their normal instruction.
62164982|NCT02039596|EXPERIMENTAL|Lacto-vegetarian breakfast|Diet: Lacto-vegetarian food items
62164983|NCT02039596|EXPERIMENTAL|Swedish omnivore breakfast|Diet: Swedish breakfast with meat items
62164984|NCT04246099||Group opioid free anesthesia|Patient benefit of the opioid free anesthesia protocol
62164985|NCT04246099||Group opioid based anesthesia|Patient don't benefit of the opioid free anesthesia protocol
62164986|NCT03999398||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
62164987|NCT03999398||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
62164988|NCT04538378|EXPERIMENTAL|1/Arm 1|Combination of durvalumab and olaparib
62164989|NCT03093233||VKA- and NOAC-related ICH|"1. Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)~2. Association of hematoma evacuation surgery with clinical outcomes~3. Associations of antithrombotic management with ischemic and hemorrhagic complications~4. Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
62164990|NCT04839289|EXPERIMENTAL|A-B-A|"Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument A Hearing instrument B Hearing instrument A"
62164991|NCT04839289|EXPERIMENTAL|B-A-B|"Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument B Hearing instrument A Hearing instrument B"
62164992|NCT05114629||Active|Individuals in the active group will meet or exceed the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
62164993|NCT05114629||Inactive|Individuals in the inactive group are those who do not meet the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
62164994|NCT05144854|EXPERIMENTAL|ONO-4538 + ipilimumab + chemotherapy|
62164995|NCT05144854|ACTIVE_COMPARATOR|Chemotherapy|
62164996|NCT01121497|EXPERIMENTAL|Physostigmine|Colonoscopy sedation with or without physostigmine
62164997|NCT02524951|EXPERIMENTAL|MSI-1436C (Trodusquemine) 20 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 20 mg/m2. Drug infusions will last approximately 2 hours.
62164998|NCT02524951|EXPERIMENTAL|MSI-1436C (Trodusquemine) 26 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 26 mg/m2. Drug infusions will last approximately 2 hours.
62164999|NCT02524951|EXPERIMENTAL|MSI-1436C (Trodusquemine) 34 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 34 mg/m2 . Drug infusions will last approximately 2 hours.
62165000|NCT02524951|EXPERIMENTAL|MSI-1436C (Trodusquemine) 44 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 44 mg/m2 . Drug infusions will last approximately 2 hours.
62718304|NCT03511001|EXPERIMENTAL|E-Cigarette|6 weeks of JUUL electronic cigarettes
62718305|NCT03511001|ACTIVE_COMPARATOR|Assessment Only|6 weeks of smoking as usual
62718306|NCT04496479|EXPERIMENTAL|LYG-LIV0001|Open label group of subjects with end stage liver disease receiving increasing doses of the experimental therapy.
62718307|NCT04841954|EXPERIMENTAL|Prick-test|
62718308|NCT05626933|EXPERIMENTAL|Buccinator myomucosal flap with Furlow palatoplasty|
62718309|NCT01760070|EXPERIMENTAL|Hybrid knife|O-type Hybrid knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
62718310|NCT01760070|ACTIVE_COMPARATOR|IT knife|IT knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
62718311|NCT05233514|EXPERIMENTAL|Aerobic exercise group (AEM)|The AEM group performed aerobic exercise three times a week for 12 weeks in addition to Metformin treatment.
62718312|NCT05233514|ACTIVE_COMPARATOR|Metformin group (M)|The M group received Metformin only
62718313|NCT00820547|EXPERIMENTAL|(FEC / Docetaxel) + Bevacizumab|Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year
62718314|NCT03431597|EXPERIMENTAL|oral nutritional supplementation|Daily novel micronutrient supplement: 800 μg folic acid, 5.2 μg cyanocobalamin (B12), 2.8 mg Riboflavin-5'- phosphate (B2), 4g trimethylglycine (betaine) in drink powder form. The drink will be dissolved in 200ml of water and taken daily for 12 weeks
62718315|NCT03431597|ACTIVE_COMPARATOR|oral nutritional supplementation, UNIMMAP|The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
62718316|NCT03431597|NO_INTERVENTION|control|no treatment will be given to this group observation only (no placebo)
62718317|NCT04273165|ACTIVE_COMPARATOR|Etravirine Dose 1|Etravirine dose 200 mg per diem(100+100)
62718318|NCT04273165|ACTIVE_COMPARATOR|Etravirine Dose 2|Etravirine dose 400 mg per diem (200+200)
62718319|NCT04034264||Afebrile close contact|Lived in the same household or worked in the same enclosed workspace daily with a febrile enrollee at the time they got sick with a known highly morbid and/or transmissible pathogen.
62718320|NCT04034264||Febrile patient|Patients between 2 months and 65 years old who present with fever, or diagnosed with a highly morbid and/or transmissible pathogen by clinically validated tests.
62718321|NCT05171153||IBD group|Subjects over 21 years old, with inflammatory bowel disease (both ulcerative colitis and Crohn's disease), diagnosed by clinical, biochemical, endoscopic and anatomo-pathological criteria.
62718322|NCT05171153||Control group|Subjects over 21 years old, without IBD or known metabolic bone disease, recruited voluntarily in the Endocrinology and Nutrition, Digestive System and Rheumatology departments of the Ruber Juan Bravo Hospital, during routine health control visits
62718323|NCT01641107|EXPERIMENTAL|Ponatinib|
62718324|NCT01572974||No Barrett's esophagus|Subject without columnar lined esophagus
62718325|NCT01572974||Nondysplastic BE|Subject with columnar lined esophagus and absence of dysplasia
62718326|NCT01572974||Low grade dysplastic BE|subject with columnar lined esophagus and presence of low grade dysplasia
62718327|NCT01572974||High grade dysplastic BE|subject with columnar lined esophagus and presence of high grade dysplasia
62718328|NCT02663310|EXPERIMENTAL|Surgery with Rehabilitation|Surgically removed cysts, and collected intracystic fluids and cerebrospinal fluid for histological and molecular analyses. Samples will be collected during the surgery and will be cryo-protected for further analyses. All subjects will enroll for intensive rehabilitation 60 days after surgery.
62718329|NCT02663310|ACTIVE_COMPARATOR|Rehabilitation|All subjects will enroll for intensive rehabilitation everyday as instruction.
62718330|NCT02171026|EXPERIMENTAL|Dabigatran etexilate + Amiodarone|
62718331|NCT02171026|ACTIVE_COMPARATOR|Amiodarone|
62718332|NCT01478984|ACTIVE_COMPARATOR|one staged PCI|the patient randomized to this arms complete the myocardial revascularization in one stage PCI, the investigators treat all lesions.
62718333|NCT01478984|ACTIVE_COMPARATOR|multistaged PCI|the patients randomized to this arms in the first stage the investigators treat only the culprit lesion and in second stage the investigators treat the other vessels
62718334|NCT05148741||Group 1|implanted with the C-loop haptic intraocular lens
62718335|NCT05148741||Group 2|implanted with the plate haptic intraocular lens
62718336|NCT06179680||Alzheimer's Disease Group|"Description: Individuals diagnosed with Alzheimer's disease. Inclusion Criteria: Participants meeting established criteria for Alzheimer's disease diagnosis, which may include cognitive and memory deficits along with functional impairment.~Exclusion Criteria: Exclusion of participants with significant comorbidities that could affect cognitive function and those with other forms of dementia."
62718337|NCT06179680||Amnestic Mild Cognitive Impairment (aMCI) Group|"Description: Individuals diagnosed with amnestic mild cognitive impairment. Inclusion Criteria: Participants displaying cognitive decline beyond what is expected for their age but not meeting criteria for a diagnosis of Alzheimer's disease.~Exclusion Criteria: Exclusion of participants with other neurological conditions that might mimic or contribute to cognitive impairment."
62718338|NCT06179680||Control Group (Healthy Controls)|"Description: Individuals without cognitive impairment or neurological disorders.~Inclusion Criteria: Participants with normal cognitive function for their age, absence of memory complaints, and no history of neurological or psychiatric disorders.~Exclusion Criteria: Exclusion of individuals with any cognitive impairment, psychiatric disorders, or significant medical conditions affecting cognition."
62718339|NCT02552576|EXPERIMENTAL|Voncento|The frequency and dose of Voncento administration will be determined by the investigator using the information included in the Voncento Summary of product characteristics (SmPC)
62718340|NCT01148667|ACTIVE_COMPARATOR|Infants drink formula added with LGG|Infants have been randomized (1:1) to get casein hydrolysate with or without LGG
62718341|NCT01148667|PLACEBO_COMPARATOR|Infants drink casein hydrolysate without LGG|Infants get extensively hydrolysed casein formula
62718342|NCT06715202|EXPERIMENTAL|Experimental: Patient Education Booklet|Patients will be informed about URS, DJ stents and possible problems in the early postoperative period with an education booklet and the patient's questions will be answered.
62718343|NCT06332586|EXPERIMENTAL|The learning effect of applying diversified teaching in emergency triage and classification|
62718344|NCT05549661|EXPERIMENTAL|Treatment (onvansertib)|Patients receive onvansertib PO QD on study. Patients also undergo bone marrow aspiration and biopsy, collection of blood samples, and ultrasound imaging during screening and throughout the trial.
62718345|NCT03475602||Cyclophosphamide|Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
62718346|NCT03475602||Cyclosporin|Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
62718347|NCT05833711|EXPERIMENTAL|Froniglutide 50 mg|Froniglutide (PF1801) 50 mg will be administered subcutaneously once a week.
62718348|NCT05833711|EXPERIMENTAL|Froniglutide 70 mg|Froniglutide (PF1801) 70 mg will be administered subcutaneously once a week.
62718349|NCT05833711|PLACEBO_COMPARATOR|Placebo|Matching placebo will be administered subcutaneously once a week.
62718350|NCT05195203|EXPERIMENTAL|HS-10353|Capsules；Single dose: only one administration; Multiple doses: continuous administration for 7 days
62718351|NCT05195203|PLACEBO_COMPARATOR|Placebo|Capsules；Single dose: only one administration; Multiple doses: continuous administration for 7 days
62718352|NCT00818090|EXPERIMENTAL|TP|paclitaxel and cisplatin every 3 weeks
62718353|NCT03807583|NO_INTERVENTION|Control group|
62718354|NCT03807583|ACTIVE_COMPARATOR|AMINOVEN® 10%|"The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.~The product is administered per os during the first hour of dialysis sessions for the duration of the study."
62718355|NCT03807583|EXPERIMENTAL|RENORAL®|"The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.~The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins."
62718356|NCT01783444|EXPERIMENTAL|Capecitabine 1250 mg/m2|Capecitabine (1250 mg/m2 twice daily) for two weeks, followed by one week rest period in 3-weeks cycles (investigational arm).
62718357|NCT01783444|EXPERIMENTAL|Everolimus 10 mg|Everolimus (10 mg daily) (investigational arm).
62718358|NCT01783444|ACTIVE_COMPARATOR|Everolimus 10 mg + Exemestane 25 mg|Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).
62718359|NCT00689806|PLACEBO_COMPARATOR|Placebo|
62718360|NCT00689806|ACTIVE_COMPARATOR|Lovastin|
62718361|NCT06159257|OTHER|Steatohepatitis (NASH)|
62718362|NCT00948688|EXPERIMENTAL|Vorinostat, 5-FU, Radiation Therapy|Vorinostat at varying doses; orally, days 1-7, weeks 1-6 5-FU 225 mg/m2/day; intravenous; days 1-5, weeks 1-6 until completion of radiation therapy; Radiation therapy; 180cGy daily Monday-Friday; 28 days of treatment (6 weeks)
62718363|NCT06717490|ACTIVE_COMPARATOR|MS group|The patients allocated to this group will receive an intravenous bolus of magnesium sulfate (50 mg/kg) followed by a continuous infusion (15 mg/kg/h) Blood coagulation parameters will be assessed pre- and post- magnesium administration using thromboelastometry.
62718364|NCT06717490|PLACEBO_COMPARATOR|NS group|The patients allocated to this group will receive an equivalent volume of normal saline proportionally to the active comparator group. Blood coagulation parameters will be assessed pre- and post-magnesium administration using thromboelastometry.
62718365|NCT06012851|EXPERIMENTAL|Mobile BPT with in-the-moment feedback|Participants will be randomized multiple times per day to receive a push notification that provides feedback about parenting.
62718366|NCT06012851|EXPERIMENTAL|Mobile BPT with in-the-moment suggestions|Participants will be randomized multiple times per day to receive a push notification that provides a suggestion for a parenting behavior.
62718367|NCT06012851|OTHER|Mobile BPT only|Participants will be randomized multiple times per day to receive no push notification.
62165001|NCT02524951|EXPERIMENTAL|MSI-1436C (Trodusquemine) 57 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 57 mg/m2. Drug infusions will last approximately 2 hours.
62165002|NCT02524951|EXPERIMENTAL|MSI-1436C (Trodusquemine) 74 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 74 mg/m2 . Drug infusions will last approximately 2 hours.
62718368|NCT05987124|EXPERIMENTAL|Defibrotide|7.1.1 HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought (see 7.2 for definition of response) (Maximum of 4 dose levels) (7.1.2):
62718369|NCT04025944||chronic hepatitis B|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
62718370|NCT04025944||chronic hepatitis C|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
62718371|NCT02252315|ACTIVE_COMPARATOR|Written Education|
62718372|NCT02252315|ACTIVE_COMPARATOR|Verbal Education|
62718373|NCT01711528|EXPERIMENTAL|Schedule I (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62718374|NCT01711528|EXPERIMENTAL|Schedule II (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62718375|NCT04446312|EXPERIMENTAL|BLI4900|Experimental bowel preparation solution for oral ingestion
62718376|NCT04446312|ACTIVE_COMPARATOR|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
62718377|NCT03407092||Stentriever Cohort|
62718378|NCT03407092||ADAPT cohort|
62718379|NCT04366856|EXPERIMENTAL|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
62718380|NCT04366856|OTHER|2: No instruction regarding positioning|the control group will get no instruction regarding positioning
62718381|NCT01583673|EXPERIMENTAL|Amino Acid Formula|Hypoallergenic baby formula
62718382|NCT01583673|ACTIVE_COMPARATOR|Amino Acid commercial formula|Hypoallergenic commercial amino acid formula
62718383|NCT05361265|EXPERIMENTAL|Experimental Group|pregnant women were trained about fetal movements and fetal movement counting was taught. The training was given verbally. Pregnant women were asked to perform ten fetal movements by counting once a day after any meal, lying in the left side position for one hour. When ten fetal movements could not be reached within the first hour, pregnant women were instructed to count the fetal movements for one hour after walking for five minutes. When ten fetal movement counts could not be obtained at the end of two hours, they were asked to apply to the hospital immediately. Pregnant women were expected to perform fetal movement counting after the same meal every day (breakfast, lunch or dinner) and record the start and end times of the ten movements on the Fetal Movement Monitoring Card.
62718384|NCT05361265|NO_INTERVENTION|Control Group|Routine follow up
62718385|NCT05951647|PLACEBO_COMPARATOR|Scaling|12 patients will be managed by scaling only
62718386|NCT05951647|ACTIVE_COMPARATOR|Scaling and Chlorohexidine mouthwash|Patients will be managed by scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
62718387|NCT05951647|EXPERIMENTAL|Scaling and Chamomile extract mouthwash|Patients will be managed by scaling and will use 5% chamomile extract mouthwash in a dose of 15 ml twice daily.
62718388|NCT05951647|EXPERIMENTAL|Scaling and Pomegranate peel extract mouthwash|Patients will be managed by scaling and will use 5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
62718389|NCT05951647|EXPERIMENTAL|Scaling and Chamomile extract mixed with Pomegranate peel extract mouthwash|Patients will be managed by scaling and will use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
62718390|NCT00050583|EXPERIMENTAL|1|10 Session modified CBT (including a relaxation component) administered by trained mental health clinicians at the primary care setting
62718391|NCT00050583|NO_INTERVENTION|2|"Treatment as Usual, defined as the use of a consultation letter and traditional primary care management."
62718392|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
62718393|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
62718394|NCT06704100|EXPERIMENTAL|Oral Fosamprenavir-Sodium Alginate (FOS-SA)|"Eight weeks of:~1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID, at least 1 hour before or 2 hours after the morning and evening meals, approximately 12 hours apart"
62718395|NCT06704100|PLACEBO_COMPARATOR|Oral Placebo|"Eight weeks of:~15 ml oral solution containing 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate administered BID at least 1 hour before or 2 hours after the morning and evening meals, approximately 12 hours apart"
62718396|NCT03730584|EXPERIMENTAL|Patient with Hereditary Epidermolysis Bullosa|
62718397|NCT02565992|EXPERIMENTAL|CAVATAK and pembrolizumab|Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.
62718398|NCT06701565||Controlled type 2 diabetes|
62718399|NCT06701565||Uncontrolled type 2 diabetes|
62718400|NCT05534893|EXPERIMENTAL|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
62718401|NCT05534893|PLACEBO_COMPARATOR|Placebo powder group|Participants in the placebo group will receive an isocaloric placebo powder.
62718402|NCT05636202||Survival group|Patients who survived sepsis
62718403|NCT05636202||Death group|Patients who died of sepsis
62718404|NCT04362306|EXPERIMENTAL|Planned Intervention|Patients will be scheduled for CT (computed tomography ) simulation for radiation treatment planning. Prior to simulation, patients will be asked to complete anxiety and patient satisfaction questionnaires. Following completion of the questionnaires, each patient will receive the first intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic. The patient will then be asked to complete a second set of anxiety and patient satisfaction questionnaires and will then undergo the planned simulation.
62718405|NCT04362306|ACTIVE_COMPARATOR|No Planned Intervention|After patients are enrolled into this study, they will be scheduled for CT simulation for radiation treatment planning. Prior to simulation, patients will receive anxiety and patient satisfaction questionnaires to complete
62718406|NCT05198401||1|(previous covid-19 positive) n. =88
62718407|NCT05198401||2|(covid-19 negative) n.=91
62718408|NCT01816048|EXPERIMENTAL|TAK-700|"TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles.~The most common way of assessing bone metastasis is planar bone scintigraphy or single photon emission computed tomography (SPECT), though both lack high spatial resolution and thus make small metastases detection inaccurate. Positron emission tomography (PET) is a successful imaging modality with a higher resolution than SPECT, but has not been widely adopted in bone imaging. One of the most promising PET imaging agents for detection of bone metastasis is 18F-Sodium Fluoride (Fluorine F 18 Sodium Fluoride, or NaF). NaF uptake is characterized by high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ration in a short time."
62718409|NCT01936233|EXPERIMENTAL|Aspirin AND Lamivudine|
62718410|NCT01936233|ACTIVE_COMPARATOR|Lamivudine|
62735900|NCT01713582|EXPERIMENTAL|AL 20 mg QD 14-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62544370|NCT02254434|EXPERIMENTAL|Eltrombopag 50 mg|Each volunteer will receive orally, single dose of tablet eltrombopag 50 mg under fasting conditions
62718411|NCT02194114|EXPERIMENTAL|Dietary Protein Intake|One treatment Arm; Protein Diet: All patients will be fed the following five diets, in random order, each for 17-19 days: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
62718412|NCT02273921|NO_INTERVENTION|EEG|A non-invasive EEG recording
62718413|NCT00000134|EXPERIMENTAL|intravenous foscarnet|intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
62718414|NCT00000134|ACTIVE_COMPARATOR|intravenous ganciclovir|intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
62718415|NCT00000134|ACTIVE_COMPARATOR|combination therapy|combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
62718416|NCT04161209|EXPERIMENTAL|Drug: Citalopram|20mg oral dose of citalopram (tablet encapsulated in opaque capsule)
62718417|NCT04161209|PLACEBO_COMPARATOR|Placebo|Lactose placebo (tablet encapsulated in opaque capsule)
62718418|NCT02579434|EXPERIMENTAL|Male young adults|Arm 1: Male healthy volunteers aged from 20 to 45 years Midazolam (IV) on day 1
62718419|NCT02579434|EXPERIMENTAL|Male elderly adults|Arm 2: Male healthy volunteers aged over 45 years Midazolam (IV) on day 1
62718420|NCT02579434|EXPERIMENTAL|Female elderly adults|Arm 3: Female healthy volunteers aged over 45 years Midazolam (IV) on day 1
62718421|NCT02579434|EXPERIMENTAL|Female young adults|Arm 4: Female healthy volunteers aged 20 to 45 years Midazolam (IV) on day 1, Day 15
62718422|NCT01720030|PLACEBO_COMPARATOR|Conventional therapy|Standard of care as protocolized locally
62718423|NCT01720030|EXPERIMENTAL|Levosimendan|The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.
62718424|NCT05895994|EXPERIMENTAL|RD13-02 cell infusion|
62718425|NCT03099122|EXPERIMENTAL|Thymoglobuline|"A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice.~Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies."
62718426|NCT04769206|EXPERIMENTAL|Galantamine|"Galantamine 16mg/day~- titrating: 4mg once a day for 2 weeks, titrate to 8mg once a day for 2 weeks, then 8mg twice a day for 8 more weeks"
62718427|NCT04769206|PLACEBO_COMPARATOR|Placebo|"placebo (micro crystalline cellulose)~- 1 pill once daily for 4 weeks, then 2 pills daily for 8 weeks"
62718428|NCT01144000|EXPERIMENTAL|Daptomycin|High dose Daptomycin in hip, knee and shoulder prosthesis infections
62718429|NCT05535114|EXPERIMENTAL|Yoga-resistance exercise (YRE) group|"The YRE group will perform breathing exercises, flexibility, resistance exercises and relaxation. It will be carried out for about 30 to 45 minutes in the first two hours of each hemodialysis session, three times weekly for 12 weeks. The intensity of resistance exercise will be adjusted individually at week 3, week 7, and week 11 to the rate of perceived exertion of somewhat hard (on the Borg scale 6-20). The intensity of resistance exercise will be increased gradually by changing the different colors of elastic bands."
62718430|NCT05535114|NO_INTERVENTION|Control group|Participants in the control group will receive only usual care. They will be able to receive the YRE protocol after completing the study.
62165003|NCT02524951|EXPERIMENTAL|MSI-1436C (Trodusquemine) 96 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 96 mg/m2 . Drug infusions will last approximately 2 hours.
62165004|NCT03612258|EXPERIMENTAL|Functional Magnetic Resonance Imaging|
62544371|NCT05698225|EXPERIMENTAL|Inoculation with Streptococcus pneumoniae serotype 6B|Participants will be inoculation with a controlled concentration of full sequenced, fully antibiotic sensitive Streptococcus pneumonia serotype 6B
62165005|NCT03071874|EXPERIMENTAL|AZD2014|"* AZD2014 will be administered orally at a pre-determine dose~* Twice daily for two consecutive days out of every seven days~* Cycles will last 28 days"
62165006|NCT04607837|EXPERIMENTAL|Etrasimod 2 mg|
62165007|NCT04607837|PLACEBO_COMPARATOR|Placebo|
62165008|NCT05283642|EXPERIMENTAL|DCI|Oral supplementation with D-chiro-inositol once a day
62544372|NCT01873378|EXPERIMENTAL|GnRH agonist pretreatment|triptorelin 3.75 mg, im, monthly, three times
62544373|NCT01873378|NO_INTERVENTION|No pharmacological treatment|
62544374|NCT06633055|EXPERIMENTAL|JH013 injections 75mg|6 subjects receive JH013 at a dose of 75 mg and 2 subjects receive the same volume placebo
62718431|NCT02559648|ACTIVE_COMPARATOR|Denosumab|In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
62718432|NCT02559648|PLACEBO_COMPARATOR|Placebo|In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
62718433|NCT04174859||NVAF patients|Start treatment with rivaroxaban at the discretion of physician.
62718434|NCT01366573|EXPERIMENTAL|GSK1521498 &amp; alcohol|GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)
62718435|NCT01366573|EXPERIMENTAL|GSK1521498 & orange juice|GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour
62718436|NCT01366573|EXPERIMENTAL|Placebo &amp; alcohol|Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)
62718437|NCT01366573|PLACEBO_COMPARATOR|Placebo &amp; orange juice|Placebo and orange juice approximately matching alcoholic beverage for volume and colour
62718438|NCT04249401||Reduced dose NOAC|Participants with NVAF initiating treatment with reduced doses of individual non-vitamin K antagonist oral anticoagulants (NOACs)
62544375|NCT06633055|EXPERIMENTAL|JH013 injections 150mg|6 subjects will receive JH013 injections 150mg，2 subjects receive the same volume placebo
62718439|NCT04249401||Vitamin K antagonists (VKA)|Participants with NVAF initiating treatment with vitamin K antagonists (VKA)
62718440|NCT01669902||Cohort|
62718441|NCT01440361|EXPERIMENTAL|Belimumab|Reconstituted solution for intravenous infusion
62718442|NCT01440361|PLACEBO_COMPARATOR|Normal saline|Solution for intravenous infusion
62718443|NCT02514343|EXPERIMENTAL|Magnesium sulfate|Will administrate 1 ml of magnesium sulfate 10% and 1.5 mL of sterile water
62718444|NCT02514343|EXPERIMENTAL|Bupivacaine|Will administrate 1 ml of magnesium sulfate 10% and 1.5 ml of bupivacaine (5mg/ml)
62718445|NCT05070130||dPR and FFR|Subjects with aortic stenosis who are considered for TAVR will undergo a physiological assessment and prediction of ischemic coronary lesions pre- and post-TAVR by using Opsens non-hyperemic dPR and/or Opsens FFR
62718446|NCT01143402|EXPERIMENTAL|Arm I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are unable to be treated with temozolomide may be treated with dacarbazine IV every 3 weeks (with approval from the Principal Investigator). Patients who experience disease progression may crossover to arm II.
62718447|NCT01143402|EXPERIMENTAL|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62718448|NCT02505425|EXPERIMENTAL|Active Intervention|"Behavioral: behavioral support~Usual HF Care + ENABLE CHF-PC"
62718449|NCT02505425|ACTIVE_COMPARATOR|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
62718450|NCT02132403|EXPERIMENTAL|IMPRIME PGG, BTH1704, & Gemcitabine|Imprime PGG with BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day cycle with Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day cycle.
62718451|NCT05924139|EXPERIMENTAL|Omega-3 fatty acid|Nordic Naturals (Ultimate Omega) will be used as the intervention at a dose of 4 grams/day (3840 mg total fish oil with 1950 mg EPA and 1350 mg DHA
62718452|NCT05924139|PLACEBO_COMPARATOR|Coconut oil|dose of 4 grams/day
62718453|NCT01425476|PLACEBO_COMPARATOR|Placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
62718454|NCT01425476|ACTIVE_COMPARATOR|Placebo & cholecalciferol 2,000 IU|
62718455|NCT01425476|EXPERIMENTAL|celecoxib 400 mg & cholecalciferol 2,000 IU|
62718456|NCT02448966||Traditional open esophagectomy|Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.
62718457|NCT02448966||Minimally invasive eophagectomy|treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.
62718458|NCT03817489|EXPERIMENTAL|Intervention: Baduanjin qigong|This arm of participants will be receiving the Baduajin qigong intervention.
62718459|NCT03817489|EXPERIMENTAL|Intervention: Mindfulness meditation|This arm of participants will be receiving the Mindfulness meditation intervention.
62718460|NCT03817489|NO_INTERVENTION|Control|This arm of participants will not receive any intervention and are allocated as a Wait-list Control group.
62718461|NCT04704024|EXPERIMENTAL|Pregnant Women - Tenofovir|Women will be randomized to early initiation (enrollment at 14-28 weeks pregnant) vs standard initiation (at 28 weeks pregnant) of tenofovir disoproxil fumarate (TDF) 300 mg daily oral medication until delivery.
62718462|NCT04704024|PLACEBO_COMPARATOR|Newborn Infants - Lamivudine|Infants exposed to HBV at birth will be randomized to receive oral lamivudine post-exposure prophylaxis or matching placebo. Medication will be administered twice daily for 6 months.
62718463|NCT04457986|EXPERIMENTAL|Erector spina plane block (ESP)|Patients will receive Erector spina plane block (ESP) with bupivacaine for postoperative analgesia
62718464|NCT04457986|EXPERIMENTAL|Modified thoracolumbar interfacial plane block (MTI)|Patients will receive Modified thoracolumbar interfacial plane block (MTI) with bupivacaine for postoperative analgesia
62718465|NCT04457986|ACTIVE_COMPARATOR|Intravenous patient controlled analgesia (IV-PCA)|Patients will receive Intravenous patient controlled analgesia (IV-PCA) with tramadol for postoperative analgesia
62718466|NCT05572840|EXPERIMENTAL|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (PowerPoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (PowerPoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
62718467|NCT00896012|EXPERIMENTAL|1. Low-dose tacrolimus arm|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months). All patients will undergo a second protocol biopsy at 12 months.
62718468|NCT00896012|EXPERIMENTAL|2. Rapamune conversion arm:|Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy. Tacrolimus will be withdrawn progressively over a period of 7-10 days. Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued. Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
62718469|NCT01951053|EXPERIMENTAL|Sequence 1|Participants will receive the study medications in the sequence of placebo, citalopram, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
62718470|NCT01951053|EXPERIMENTAL|Sequence 2|Participants will receive the study medications in the sequence of placebo, JNJ-40411813, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
62735901|NCT01713582|EXPERIMENTAL|AL 40 mg QD 14-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62165009|NCT01588379|EXPERIMENTAL|Girls and mothers dance together|African-American girls AND their mom's will participate in the Afro-centric dance program together and also receive weekly newsletter that focuses on health related issues.
62165010|NCT01588379|EXPERIMENTAL|Girls, alone|African-American girls will participate in the Afro-centric dance program alone. Girls and mom's will receive weekly newsletter that focuses on health related issues
62165011|NCT01588379|ACTIVE_COMPARATOR|No dancing|African-American girls and their mom's will only receive weekly newsletter that focuses on health related issues.
62165012|NCT05685212||Group Hypotension.|patients who developed hypotension defined as a decrease in systolic arterial pressure more than 20% of the baseline
62165013|NCT05685212||Group Normotension|patients who did not experience a hypotensive event.
62165014|NCT03029611|EXPERIMENTAL|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. After completion of 3 cycles, patients then undergo cytoreductive surgery.
62165015|NCT00841945|ACTIVE_COMPARATOR|1|"Chemotherapy + Radiotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone~* Radiotherapy 40 gray on initial nodes"
62165016|NCT00841945|EXPERIMENTAL|2|"Chemotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone"
62544376|NCT06633055|EXPERIMENTAL|JH013 injections 300mg|6 subjects receive JH013 at a dose of 300 mg and 2 subjects receive the same volume placebo
62544377|NCT06633055|EXPERIMENTAL|JH013 injections 500mg|6 subjects receive JH013 at a dose of 500 mg and 2 subjects receive the same volume placebo
62544378|NCT03403075|ACTIVE_COMPARATOR|Usual Care|"Control Group will be offered usual care (UC), plus two sessions of therapeutic education delivered in small groups. In these educational sessions, patients are provided with useful information on communication strategies, problem solving strategies, recognition and management of symptoms and the management of any aids/orthoses provided in everyday life, etc. In the meetings, it will be emphasized the importance of maintaining an active lifestyle as much as possible by encouraging involvement in physical activity even during the cancer treatment period.~Written information material that summarizes the concepts addressed during group meetings will be provided."
62544379|NCT03403075|EXPERIMENTAL|ETAF: Therapeutic Education Physical Activity|"Intervention group will perform UC, and the two sessions of therapeutic education delivered in small group, as for the Control Group. The Intervention group will also provided for 6 individual sessions of therapeutic education and physical activity held by physiotherapists dedicated to the study, according to the patients' needs and objectives.~In these sessions, the topics discussed in group will be deepened, personalizing them according to the patient's characteristics. Furthermore, personalized physical activity is planned, taking into account the context of execution, the clinical condition and the patient's preferences. The patient will be trained to build an action plan aimed at self-plan physical activities and a diary will be provided to monitor the physical activity carried out autonomously.~Written information material that summarizes the concepts addressed during group and individual sessions will be provided."
62544380|NCT01510626|EXPERIMENTAL|One|
62544381|NCT00141778|PLACEBO_COMPARATOR|Placebo|matched placebo pills daily beginning 4-7 days before surgery and continuing through discharge
62544382|NCT00141778|EXPERIMENTAL|Ramipril|Ramipril daily (2.5mg, increased to 5mg) beginning 4 to 7 days before surgery and continuing through discharge
62544383|NCT00141778|EXPERIMENTAL|Spironolactone|Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge
62544384|NCT03035929|EXPERIMENTAL|Healthy|"10 Healthy subjects will undergo study procedures at four study visits.~All subjects will undergo the same procedures and interventions."
62544385|NCT02803424|EXPERIMENTAL|Volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
62544386|NCT02803424|ACTIVE_COMPARATOR|Autoflow-volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, Autoflow-volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
62544387|NCT03183596|ACTIVE_COMPARATOR|Deep Serratus Anterior Block|"Patients in the deep Serratus Anterior Block (DSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone deposited deep to the serratus. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
62544388|NCT03183596|ACTIVE_COMPARATOR|Superficial Serratus Anterior Block|"Patients in the superficial Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
62165017|NCT01754545|EXPERIMENTAL|Octaplas infusion and placebo (group 1)|Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.
62165018|NCT01754545|EXPERIMENTAL|Octaplas infusion and placebo (group 2)|Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks
62165019|NCT02498418|EXPERIMENTAL|Generic Rifaximin 200 mg Tablets|Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
62165020|NCT02498418|ACTIVE_COMPARATOR|Xifaxan 200 mg Tablets|Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
62165021|NCT02498418|PLACEBO_COMPARATOR|Placebo|Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
62165022|NCT00591084|EXPERIMENTAL|ginsenoside-Rd 10mg|both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
62165023|NCT00591084|PLACEBO_COMPARATOR|placebo|2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
62165024|NCT00591084|EXPERIMENTAL|ginsenoside-Rd 20mg|2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
62165025|NCT06096142|EXPERIMENTAL|AVF Treatment|Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.
62165026|NCT06096142|SHAM_COMPARATOR|AVF Control|Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) alone.
62165027|NCT06096142|EXPERIMENTAL|AVG Treatment|Participants on dialysis via AV graft will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.
62165028|NCT03605745|EXPERIMENTAL|Treatment|Prostatic Vapor Ablation with Rezum
62165029|NCT05553353|EXPERIMENTAL|Active rTMS|Active repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling.
62544389|NCT01906515|NO_INTERVENTION|Control Group|Control Group received standard anesthesia care including intraoperative blood sampling when estimated blood loss was ≥15% of total blood volume and transfusion when hemoglobin was ≤10 g/dL.
62718471|NCT01951053|EXPERIMENTAL|Sequence 3|Participants will receive the study medications in the sequence of citalopram, placebo, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
62718472|NCT01951053|EXPERIMENTAL|Sequence 4|Participants will receive the study medications in the sequence of citalopram, JNJ-40411813, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
62718473|NCT01951053|EXPERIMENTAL|Sequence 5|Participants will receive the study medications in the sequence of JNJ-40411813, placebo, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
62718474|NCT01951053|EXPERIMENTAL|Sequence 6|Participants will receive the study medications in the sequence of JNJ-40411813, citalopram, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
62718475|NCT05687227|EXPERIMENTAL|EXPERIMENT GROUP|The trainings were held in groups of 4-6 people. The trainings, which were held in three sessions, were held on the days and times that were convenient for the participants. Since the participants were required to attend all sessions, additional session/sessions were held in case of not being able to attend the trainings. Participants in the control and experimental groups were called and the day they would come for the control was determined, and they went to the gynecology outpatient clinic. The post-test questionnaire was applied to the participants in the control and experimental groups in the first 3 months. Until the end of the research, the participants were told that they could reach the researcher at any time and ask questions. Finally, at the 6th month, a post-test form was applied to the participants.
62718476|NCT05687227|NO_INTERVENTION|CONTROL GROUP|No training or counseling was given to the control group. Participants in the control and experimental groups were called and the day they would come for the control was determined, and they went to the gynecology outpatient clinic. The post-test questionnaire was applied to the participants in the control and experimental groups in the first 3 months. Finally, at the 6th month, a post-test form was applied to the participants.
62718477|NCT05739292|EXPERIMENTAL|EuNmCV-5|Healthy adults received 0.5mL single intramuscular dose on Day 0.
62718478|NCT05739292|ACTIVE_COMPARATOR|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
62718479|NCT06416228|EXPERIMENTAL|Two active doses of beetroot juice|2 active (nitrate containing) doses of Beet-it Pro 400
62718480|NCT06416228|ACTIVE_COMPARATOR|One active dose of beetroot juice and one placebo dose of beetroot juice|1 active (nitrate containing) dose of Beet-it Pro 400 and one placebo (nitrate-depleted) dose of beetroot juice
62718481|NCT06416228|PLACEBO_COMPARATOR|Two placebo doses of beetroot juice|2 placebo (nitrate-depleted) doses of beetroot juice
62718482|NCT00251836||Left-sided donor nephrectomy|Left-sided laparoscopic hand-assisted donor nephrectomy
62718483|NCT00251836||Right-sided donor nephrectomy|Right-sided laparoscopic hand-assisted donor nephrectomy
62718484|NCT06354673|EXPERIMENTAL|SD group|Stellate ganglion block and 1 ug/kg/h intravenous Dexmedetomidine infusion
62718485|NCT06354673|EXPERIMENTAL|SK group|Stellate ganglion block and 0.5 mg/kg/h intravenous ketamine infusion.
62718486|NCT04631809|ACTIVE_COMPARATOR|invasive Coronary Angiography alone|
62718487|NCT04631809|EXPERIMENTAL|CT-Coronary Angiography + invasive Coronary Angiography|
62718488|NCT06455722|EXPERIMENTAL|[68Ga]Ga-P15-041; PET/CT|Perform PET/CT after injecting \[68Ga\]Ga-P15-041
62718489|NCT01451411|EXPERIMENTAL|Conivaptan hydrochloride|
62718490|NCT01451411|PLACEBO_COMPARATOR|Placebo|
62165030|NCT05553353|SHAM_COMPARATOR|Sham rTMS|Sham repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling, but a sham treatment coil will be used; thus, no active treatment will be administered.
62718491|NCT05850767|EXPERIMENTAL|Sleep deprivation|Participants will stay fully awake for 24 hours.
62718492|NCT05850767|NO_INTERVENTION|Normal sleep|Participant will sleep a normal night sleep.
62718493|NCT02856022|EXPERIMENTAL|Electrical ilioinguinal nerve stimulation|
62718494|NCT02856022|ACTIVE_COMPARATOR|Intravesical Irrigation|
62735902|NCT01713582|EXPERIMENTAL|AL 20 mg BID 21-21|Participants received 20 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
62735903|NCT01713582|EXPERIMENTAL|AL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62735904|NCT01713582|EXPERIMENTAL|AL 40 mg BID 14-21|Participants received 40 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.
62165031|NCT02465944|EXPERIMENTAL|FFP104 - 2.5 mg/kg|FFP104
62165032|NCT02465944|EXPERIMENTAL|FFP104 - 5.0 mg/kg|FFP104
62165033|NCT02465944|PLACEBO_COMPARATOR|Placebo|Placebo
62165034|NCT04966247||Patients with Aortic Arch Pathology|Patients undergoing aortic arch surgery for aortic arch pathologies, such as aortic aneurysm and aortic dissection.
62165035|NCT05005572|EXPERIMENTAL|Treatment|
62165036|NCT05005572|NO_INTERVENTION|Control|
62718495|NCT05295628|EXPERIMENTAL|EMBLOK™ Embolic Protection System|"Device Description:~The EMBLOK™ Embolic Protection System (EMBLOK EPS) is a sterile, single use system designed to capture and remove debris (e.g., thrombus, calcium, atheroma) dislodged during transcatheter aortic valve replacement (TAVR) procedures. The device is currently for investigational use only.~When Device Will Be Used:~Roll-in: Prior to enrollment of the first randomized subject at each site, each site will enroll 2 Roll-In subjects, who will not be randomized but will receive the EMBLOK EPS during TAVR.~Randomized: Up to 422 subjects meeting eligibility criteria will be randomized 1:1. The experimental intervention arm is utilizing EMBLOK EPS during TAVR (up to 211 subjects).~Nested registry: Up to 50 subjects who meet clinical eligibility criteria and are anatomically suitable for the EMBLOK EPS, but whose anatomy precludes the use of the SENTINEL CPS."
62718496|NCT05295628|ACTIVE_COMPARATOR|SENTINEL™ Cerebral Protection System|"Device Description:~The control comparator is the commercially-available SENTINEL™ Cerebral Protection System (SENTINEL CPS) (Boston Scientific Corp., Marlborough, MA, US), a dual-filter protection device designed to capture and remove debris dislodged during TAVR procedures.~The SENTINEL CPS is indicated for use as an embolic protection device to capture and remove thrombus/debris while performing TAVR procedures. The diameters of the arteries at the site of filter placement should be between 9.0 mm - 15.0 mm for the brachiocephalic and 6.5 mm - 10.0 mm in the left common carotid.~When Device Will Be Used:~In the randomized cohort, up to 422 subjects meeting eligibility criteria will be randomized 1:1 (stratified by operative risk and study site). The active comparator control arm is utilizing SENTINEL CPS during TAVR (up to 211 subjects)."
62718497|NCT00057057|OTHER|Arm 1|
62718498|NCT05771532|EXPERIMENTAL|The experimental group|"The experimental group (n=33) received a gender-sensitive and transtheoretical model (TTM)-based sexual health education program, which includes a 10-15-minute individual sexual health education and a sexual health pamphlet. The TTM-based sexual health education program was performed by a nurse educator with more than one year of clinical experience in gynecological nursing, who received formal training through enrollment in a course entitled  a gender-sensitive and transtheoretical model (TTM)-based sexual health education training program."
62718499|NCT05771532|NO_INTERVENTION|The control group|"The control group (n=30) received a 10-15-minute routine sexual health education and a sexual health pamphlet without a gender-sensitive and theoretically based design. Both were provided by nursing staff with no formal training in  a gender-sensitive and transtheoretical model (TTM)-based sexual health education training program."
62718500|NCT02927795||Spiolto Respimat|QOL measurement of COPD patients taking Spiolto Respimat
62544390|NCT01906515|EXPERIMENTAL|SpHb Group.|Continuous non-invasive hemoglobin monitoring (SpHb monitoring) was provided to the anesthesiologist to influence administration of care
62718501|NCT03790644|EXPERIMENTAL|exoskeleton assist|walking with assist of a powered exoskeleton
62718502|NCT04945486|EXPERIMENTAL|Peer-mentoring|The patients (mentees) are matched with a peer-mentor i.e. a person with a similar life situation or health problem as one self
62718503|NCT04945486|NO_INTERVENTION|Usual care|Usual care provided by professional healthcare workers
62718504|NCT02991339|EXPERIMENTAL|Dexamethasone|Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
62718505|NCT02991339|NO_INTERVENTION|control|Patients are not treated with glucocorticoids.
62718506|NCT02544854|EXPERIMENTAL|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
62718507|NCT02544854|EXPERIMENTAL|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
62718508|NCT02544854|EXPERIMENTAL|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
62718509|NCT04677998||Personalized surveillance and intervention protocol|
62718510|NCT00893841|PLACEBO_COMPARATOR|1|Quetiapine XR 300mg + Placebo
62718511|NCT00893841|EXPERIMENTAL|2|Quetiapine XR 300mg + Pramipexole 0.25mg
62718512|NCT00893841|EXPERIMENTAL|3|Quetiapine XR 300mg + Pramipexole 0.50mg
62718513|NCT02093260|EXPERIMENTAL|Vaccine|"Vaccine~Flubio (Influenza HA) vaccine~2 doses for infants and children (6 months - 8 years old)~1 doses for children (9-11 years old)~The vaccine will be given intramuscularly"
62718514|NCT02292537|EXPERIMENTAL|Nusinersen|Nusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.
62718515|NCT02292537|SHAM_COMPARATOR|Sham procedure|Sham comparator on Days 1, 29, 85 and 274.
62718516|NCT05927116|EXPERIMENTAL|Immediate intervention|Both groups will be assessed at baseline on the outcome measurements, after which the immediate intervention group will begin the 6-week intervention
62718517|NCT05927116|NO_INTERVENTION|Waitlist control|Both groups will be assessed at baseline on the outcome measurements, after which the the waitlist control group will receive usual care in the following six weeks. Afterwards, the waitlist control group will complete outcome assessment once again, before receiving the 6-week intervention
62718518|NCT06005909|EXPERIMENTAL|Cawthorne-Cooksey|These exercises, which are designed to reduce vertigo, stabilize the gaze and improve balance by stimulating or operating the vestibular system during daily activities, consist of a series of eye, head, trunk and balance movements that provoke vestibular symptoms and whose difficulty increases. The degree of difficulty of the exercises was increased with the improvement of the patient. Head and trunk movements while sitting, standing and walking were added to the exercises that initially started with simple eye-head movements in bed.
62718519|NCT06005909|EXPERIMENTAL|Mechanical Hippotherapy|Before being taken to the device, the patients were informed about the working principle of the device, the exercises to be performed on the device, and that the exercise would be terminated in case of a possible health problem. After being placed on the device, the patient was given time until the initial balance was achieved. When the patient felt ready, a 15-minute hippotherapy session was applied at the 5th level of the 20-stage speed level by the physiotherapist.
62718520|NCT02012803|EXPERIMENTAL|Operative treatment|
62718521|NCT02012803|ACTIVE_COMPARATOR|conservative treatment|
62718522|NCT04149496|EXPERIMENTAL|All|Patients requiring IVF treatment with PCOS or a PCO pattern in their ovaries who wish to undertake IVM (as a variant of their IVF procedure)
62165037|NCT00198666|EXPERIMENTAL|Treatment|Children with severe pneumonia were randomly assigned to receive supplementation with elemental zinc.
62544391|NCT01474200|EXPERIMENTAL|Aquapheresis (AQ) - isolated veno-venous ultrafiltration|Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
62544392|NCT01474200|ACTIVE_COMPARATOR|IV Loop Diuretics (LD)|Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment
62544393|NCT04268199|OTHER|Self Injection of Bortezomib|Subcutaneous self administration of bortezomib
62544394|NCT01538082||Patients without stress|Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
62544395|NCT01538082||Patients with stress|Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
62544396|NCT03947944|ACTIVE_COMPARATOR|manifest refraction planning group|The subjects underwent SMILE using manifest refraction planning.
62544397|NCT03947944|ACTIVE_COMPARATOR|vector planning group|The subjects underwent SMILE using vector planning.
62544398|NCT01589289|EXPERIMENTAL|Phase 3 RDTs|The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. \[To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated\].
62544399|NCT03173287|EXPERIMENTAL|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
62544400|NCT05523791|EXPERIMENTAL|WPS|Patients continued their standard therapy, received a standard protein redistribution dietary regimen plus a whey protein-based oral formula twice a day
62544401|NCT05523791|ACTIVE_COMPARATOR|Mg|Patients continued their standard therapy, received a standard protein redistribution dietary regimen plus 2.250g of magnesium pidolate twice a day
62544402|NCT03240263|EXPERIMENTAL|Inspiratory muscle training|High intensity inspiratory muscle training
62544403|NCT03240263|SHAM_COMPARATOR|Sham endurance training|Sham inspiratory muscle training at low intensity
62544404|NCT05852223|EXPERIMENTAL|experimental arm A|N° 20 patients: patients will receive pembrolizumab 200 mg Every Three Weeks (Q3W) for 2 courses, followed by thyroidectomy +/- radioiodine according to the risk class
62544405|NCT05852223|NO_INTERVENTION|control group B|N° 5 patients: patients will be treated for clinical practice with upfront thyroidectomy followed by +/- radioiodine according to the risk class
62544406|NCT00796055|EXPERIMENTAL|1|MEDI-547
62544407|NCT01144247|EXPERIMENTAL|alloreactive CTL arm|
61978168|NCT02190084|ACTIVE_COMPARATOR|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
61978169|NCT02190084|SHAM_COMPARATOR|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 20 treatments identical in duration will be administered over a four week period.
61978170|NCT00240253|ACTIVE_COMPARATOR|Pramlintide|
62544408|NCT01213277|ACTIVE_COMPARATOR|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
62544409|NCT01213277|ACTIVE_COMPARATOR|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
62544410|NCT02064517|PLACEBO_COMPARATOR|Conventional technique|Apical MTA barrier
62544411|NCT02064517|EXPERIMENTAL|Revascularisation pulpaire|hydroxide of calcium
62544412|NCT04521972|ACTIVE_COMPARATOR|Group 1|Natural non-augmented labor with room lights ON. This is what is currently done in the hospital, and thus does not change any current medical practices.
62544413|NCT04521972|ACTIVE_COMPARATOR|Group 2|Augmented labor with room lights ON. This group will be a subgroup of Group 1 (Natural non-augmented labor with room lights ON), as labor-augmentation cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
62544414|NCT04521972|EXPERIMENTAL|Group 3|Natural non-augmented labor with reduced or red room lights.
62544415|NCT04521972|EXPERIMENTAL|Group 4|Augmented labor with reduced or red room lights. This group will be a subgroup of Group 3, as augmented labor cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
62544416|NCT06283732|EXPERIMENTAL|Dietary Supplement: Greens powder|Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
62544417|NCT04566289||PiCSO treatment group|PiCSO treatment as per IFU
62544418|NCT04874155|ACTIVE_COMPARATOR|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation - Phase 1
62544419|NCT04874155|SHAM_COMPARATOR|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation - Phase 1
62544420|NCT04874155|ACTIVE_COMPARATOR|Open-Label|Open-Label - Phase 2 lasting 4-wks, during which all subjects will receive open-label Active treatment
62544421|NCT03516513|ACTIVE_COMPARATOR|Problem Solving Therapy as Usual|"Clinicians in this arm of care will have access to the Case Management Tracking System which is already in use.~Intervention: unguided PST"
62544422|NCT03516513|EXPERIMENTAL|Assisted Problem Solving Therapy|"This arm will be designed and finalized in Phase 1 and 2 of the project. We anticipate that the intervention will leverage clinical notes required to be completed by clinicians and will provide information to clinicians to help patients improve over time, as well as help clinicians implement PST to high quality.~Intervention: guided PST"
62718523|NCT02739958|ACTIVE_COMPARATOR|Propofol group|Patients receive only intravenous anesthetics
62544423|NCT06400524||Healthy controls|
62544424|NCT06400524||Mutation carriers|
62544425|NCT06400524||Mild hypertrophy|
62544426|NCT06400524||Overt hypertrophy|
62544427|NCT00812448|EXPERIMENTAL|tea catechin extracts containing mask|wearing the tea catechin extracts containing mask
62718524|NCT02739958|PLACEBO_COMPARATOR|Isoflurane group|Patients receive isoflurane /fentanyl anesthesia
62718525|NCT01964183|EXPERIMENTAL|treatment group|
62718526|NCT01303692||A|Total of 250 prostate cancer patients receiving GnRH agonist
62718527|NCT01303692||B|Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
62165038|NCT00198666|NO_INTERVENTION|Control|Children with severe pneumonia were randomly assigned to receive supplementation with placebo tablets.
62165039|NCT03588676|NO_INTERVENTION|Normoxia|Participants will sleep in room air and receive no melatonin.
62544428|NCT02429284||Patients newly diagnosed with CTEPH|Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.
62544429|NCT05437315|EXPERIMENTAL|bi-4SCAR-GD2/PSMA T Cell Therapy for GD2 and PSMA positive tumor|
62544430|NCT01505582|EXPERIMENTAL|Inspiratory muscle training|
62544431|NCT01505582|SHAM_COMPARATOR|Sham inspiratory muscle training|
62544432|NCT01159080|ACTIVE_COMPARATOR|routine dose tacrolimus and less myfortic|
62544433|NCT01159080|EXPERIMENTAL|reduced dose tacrolimus and conventional myfortic|
62544434|NCT05690490|EXPERIMENTAL|endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Then, using an endoscopic needle, a solution will be injected into the submucosa to remove the neoplasm. Using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
62544435|NCT05690490|ACTIVE_COMPARATOR|endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Then, using an endoscopic needle, a solution will be injected into the submucosa to remove the neoplasm. Using an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe), the lesion will be resected through the submucosal plane using the eb-block principle, after which the patient will be monitored.
62544436|NCT02497638|EXPERIMENTAL|Metformin and Atorvastatin|Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
62544437|NCT02497638|PLACEBO_COMPARATOR|Placebo|One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
62544438|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
62544439|NCT03229135||Group B|Group B (40 mL/min≤CLcr\<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
62544440|NCT03229135||Group C|Group C (CLcr\<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
62544441|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
62544442|NCT00423371|EXPERIMENTAL|EUFLEXXA™|
62544443|NCT00423371|PLACEBO_COMPARATOR|Placebo|
62544444|NCT06060431|EXPERIMENTAL|Experimental group|The experimental group will carry out the sessions of the specific Pain Sciences program. This intervention is based on two educational sessions of 90 and 60 minutes each, separated by one week.
62544445|NCT06060431|NO_INTERVENTION|Control Group|The control group will not perform any specific intervention and will follow their usual academic curriculum.
62544446|NCT06240195||patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan|The availability of at least one tumor tissue sample to be transferred to the coordinating center will be essential for enrollment in the study. For patients for whom a new sampling is scheduled biopsy of the tumor (primary or metastasis) as per clinical practice, the feasibility of the development will be assessed tumor organoids and the execution of single-cell sequencing on tumor tissue. In these cases, the order of priority in dividing the sampled tissue will be: sufficient quota to carry out the histological examination that will have to be carried out naturally confirm the diagnosis of triple-negative breast cancer. Quota to be prepared as a fresh preparation for the two experiments of feasibility indicated above; quota to be considered as a second sample, to be analyzed at the end of the study.
62544447|NCT06442787|EXPERIMENTAL|control group|Orthognathic surgery will be performed (n=20) (control group)
62544448|NCT06442787|ACTIVE_COMPARATOR|group 2|Orthognathic surgery will be performed (n=20)
62544449|NCT06442787|ACTIVE_COMPARATOR|group 3|Orthognathic surgery will be performed (n=20)
62544450|NCT02035358|EXPERIMENTAL|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
62544451|NCT03887312|EXPERIMENTAL|t-CETA|Telephone-delivered Common Elements Treatment Approach (t-CETA). t-CETA sessions of up to 30 minutes will be delivered 1-2 times per week for approximately 8-12 weeks. The number and content of sessions will be tailored to each child, thus there will be some variation.
62544452|NCT03887312|ACTIVE_COMPARATOR|Médecins du Monde treatment as usual|Treatment as usual provided by Médecins du Monde. The number and content of sessions will vary depending on the needs of the child.
62544453|NCT00660907|EXPERIMENTAL|1|dapagliflozin plus metformin
62544454|NCT00660907|ACTIVE_COMPARATOR|2|glipizide plus metformin
62718528|NCT04827316||Patients undergoing clinically indicated CCTA|Patients undergoing clinically indicated CCTA
62735905|NCT01713582|EXPERIMENTAL|AL 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62735906|NCT01713582|EXPERIMENTAL|AL 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
62165040|NCT03588676|PLACEBO_COMPARATOR|Hypoxia and Placebo|5mg placebo before sleep study
62165041|NCT03588676|EXPERIMENTAL|Hypoxia and Melatonin|5mg melatonin before sleep study
62165042|NCT06721013|EXPERIMENTAL|Pirtobrutinib Phase 1|Pirtobrutinib administered orally
62544455|NCT04663230||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
62544456|NCT04663230||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
62544457|NCT04663230||Control|Patients with invasive exclusion of pulmonary hypertension (mean pulmonary arterial pressure below 25 mmHg) undergoing diagnostic CMRI due to the evaluation of dyspnoea.
62718529|NCT01008618|EXPERIMENTAL|Fentanyl (Titration period)|One-day adhesive transdermal patch containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will be continued for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
62718530|NCT01008618|EXPERIMENTAL|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
62718531|NCT01008618|PLACEBO_COMPARATOR|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
62718532|NCT04473001||Surgical patients|Adult patients admitted for major abdominal-, orthopedic or arterial vascular surgery.
62718533|NCT06154018|ACTIVE_COMPARATOR|0.8:1|This arm will receive an initial administration of 0.8mg of protamine per 100IU of totally given heparin.
62718534|NCT06154018|ACTIVE_COMPARATOR|0.6:1|This arm will receive an initial administration of 0.6mg of protamine per 100IU of totally given heparin.
62718535|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
62718536|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
62718537|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
62718538|NCT04703140|EXPERIMENTAL|nasopharyngeal swabs|One patient will have 2 nasopharyngeal for PCR and COVIDISC
62718539|NCT04029207||African Surgical OutcomeS-2 Trial|The ASOS-2 Trial is a cluster randomised trial purposively recruiting hospitals across Africa. To be eligible for inclusion a hospital must perform at least 20 cases of adult in-patient surgery with anaesthesia per week, have local ethics approval for the trial, have local hospital management approval and have established a local hospital study team. The trial excludes hospitals with lower surgical volume. The trial aims to include all consecutive adult in-patient surgical cases at participating hospitals (both elective and emergency surgery). Patients under the age of 18 and patients who have already been recruited into the trial are excluded from recruitment. Follow-up is in-hospital, censored at 30 days.
62718540|NCT01889394|ACTIVE_COMPARATOR|limberg flap|primary wound closure using a limberg flap
62718541|NCT01889394|ACTIVE_COMPARATOR|secondary wound healing|secondary wound healing
62718542|NCT03154021|EXPERIMENTAL|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
62718543|NCT03154021|PLACEBO_COMPARATOR|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
62718544|NCT00372957|PLACEBO_COMPARATOR|Placebo|Participants received two capsules of matching placebo orally once daily in the morning with 150 milliliter (mL) of water at least 15 minutes prior to breakfast for 7 Days.
62718545|NCT00372957|EXPERIMENTAL|GW823093C 15 mg|Participants received one 15 milligrams (mg) of GW823093C capsule and one placebo capsule orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
62165043|NCT06721013|EXPERIMENTAL|Pirtobrutinib Phase 2|Pirtobrutinib administered orally
62165044|NCT06721013|PLACEBO_COMPARATOR|Placebo Phase 2|Placebo administered orally
62165045|NCT01442207|ACTIVE_COMPARATOR|Placement of Cervical Cerclage|Cervical Cerclage is to be placed in an inpatient hospital setting within 24 to 72 hours of being assigned to this treatment group
62168065|NCT00083122|EXPERIMENTAL|Group 2|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
62168066|NCT03314389|EXPERIMENTAL|Cochet bonnet esthesiometer|To examine sensation
62544458|NCT00987779|EXPERIMENTAL|Period I: Tablet(400 mg single dose)|Period I: Tablet in fasting state, Period II: Liquid formulation in fasting state, Period III: Liquid formulation in fed state
62544459|NCT00987779|EXPERIMENTAL|Period I: Liquid formulation(400 mg single dose)|Period I: Liquid formulation in fasting state, Period II: Tablet in fasting state, Period III: Liquid formulation in fed state
62544460|NCT02908087|ACTIVE_COMPARATOR|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
62544461|NCT02908087|PLACEBO_COMPARATOR|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
62544462|NCT05169632|ACTIVE_COMPARATOR|Control group (CTR)|Computerized Gaming Rehabilitation Program 1
62544463|NCT05169632|EXPERIMENTAL|Intervention group (INT)|Computerized Gaming Rehabilitation Program 2
62544464|NCT01586793|EXPERIMENTAL|High Frequency rTMS|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
62544465|NCT01586793|EXPERIMENTAL|Low Frequency rTMS|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
62544466|NCT00773474|EXPERIMENTAL|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
62544467|NCT03929991||Case|"All women admitted or already hospitalized with suspected or confirmed infection after C/S will be screened for inclusion in the study as a case. Case confirmation will be clinically established by an infectious disease expert.SSI post C/S will be classified as:~* Superficial incisional surgical site infection,~* Deep incisional surgical site infection,~* Organ/space surgical site infection."
62544468|NCT03929991||Control|For each case, 3 patients undergoing the C/S on the same day and admitted to the same ward but not presenting Surgical Site Infection
62544469|NCT04646876|ACTIVE_COMPARATOR|intervention arm ( Group A )|"including 30 patients Group A was given magnesium Sulphate~Administration regimen of Mgso4 was as following:~Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs."
62544470|NCT04646876|PLACEBO_COMPARATOR|Placebo arm (Group B )|including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate
61978171|NCT02630355|SHAM_COMPARATOR|Control|Inflation of blood pressure cuff in lower limb to 40mmHg for four cycles of 5 minutes inflation and then deflation
62544471|NCT02199886|EXPERIMENTAL|BIBH 1|dose escalation: 0.5, 2, 10 or 20mg/m\*\*2, 7 days prior to surgery
62544472|NCT01551875||subjects who are meeting the inclusion criteria|
62544473|NCT04819763|EXPERIMENTAL|Physical training of the lateral pterygoid muscle|Static stretching and isometric contraction exercises of the lateral pterygoid muscle are used to strengthen and restore a physiological lateral movement of the mandible.
62544474|NCT04819763|ACTIVE_COMPARATOR|Stabilization appliance therapy|Hard acrylic splint with anterior canine guidance for the lower jaw.
62544475|NCT00590512|ACTIVE_COMPARATOR|High Sodium|High sodium
62544476|NCT00590512|ACTIVE_COMPARATOR|Low sodium|Low sodium
62544477|NCT03816943|NO_INTERVENTION|Control|control group with no intervention
62544478|NCT03816943|EXPERIMENTAL|Whatsapp|intervention group receiving a Whatsapp instant text message with encouraging words after bond up of fixed appliances
62544479|NCT03816943|EXPERIMENTAL|Call|intervention group receiving a phone cal with encouraging words after bond up of fixed appliances
62544480|NCT05969249|EXPERIMENTAL|Experimental|"Each patient will go on a treatment with 24 sections, and each section is 60 minutes.~The experimental group received 30 minutes of effective vibration intervention with a vibration frequency of 30 Hz and an amplitude of 5 mm on the affected upper limb. The vibration duration was 1 minute, and there was also a 1-minute rest interval. After completion, 30 minutes of traditional clinical rehabilitation training was also performed."
62544481|NCT05969249|ACTIVE_COMPARATOR|Active Comparator:|"Each patient will go on a treatment with 24 sections, and each section is 60 minutes.~During the intervention, it is necessary to wear an upper limb vibration device on the affected limb, and perform a sham vibration intervention (sham vibration) with a vibration frequency of 1 Hz (excluding the effective vibration frequency range of 4-50 Hz proposed in previous studies) and an amplitude of 5 mm for 30 minutes. The duration of the vibration is 1 minute, and there is a rest interval of 1 minute. After completion, 30 minutes of traditional clinical rehabilitation training will be performed."
62544482|NCT03364842|EXPERIMENTAL|F group|Furosemide group
62544483|NCT03364842|NO_INTERVENTION|C group|Control group
62544484|NCT03348735|EXPERIMENTAL|Lidocaine patch 5%|Lidocaine 5% medicated plasters will be applied daily, during 12 consecutive hours.
62544485|NCT03348735|EXPERIMENTAL|Capsaicin 8% patch|Capsaicin 8% patches need to applied in a hospital setting during 1 hour. Re-application of these capsaicin patches will be performed upon re-occurrence of painful symptoms (mostly after 12 weeks - so not after a fixed time interval). Application of capsaicin patches will be carried out in a hospital setting (+/- 3 hours procedure).
62544486|NCT03348735|ACTIVE_COMPARATOR|Pregabaline|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe. In European clinical practice, up-titration of the dose is often carried out over a longer time-period. This study thus includes up-titration schedule for pregabalin over a period of 4 weeks. If patients develop side-effects during the intake/uptitration of pregabalin this treatment can be stopped and switched to gabapentin (300mg capsules). Gabapentin will always be the back-up treatment for failed systematic treatment with pregabalin. Dose of gabapentin will be uptitrated to maximum 1200mg per day.
62544487|NCT05372965|EXPERIMENTAL|Experimental: periodontitis|Our study will include 42 people with periodontitis patients and these two groups will be divided into two as smokers (21) and non-smokers (21).
62544488|NCT05372965|ACTIVE_COMPARATOR|Control: clinical healthy|Our study will include 42 people with clinical healthy patients and these two groups will be divided into two as smokers (21) and non-smokers (21).
62544489|NCT05620537||Gastrointestinal cancer patients cohort|
61978172|NCT02630355|ACTIVE_COMPARATOR|Low Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for two cycles of 5 minute inflation and then deflation.
61978173|NCT02630355|ACTIVE_COMPARATOR|Standard Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and then deflation.
62718546|NCT00372957|EXPERIMENTAL|GW823093C 30 mg|Participants received 30 mg (2x15 mg) of GW823093C capsules orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
62718547|NCT04422431|EXPERIMENTAL|ALXN1840|Participants will receive ALXN1840.
62718548|NCT03882281|EXPERIMENTAL|A group|Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.
62718549|NCT03882281|EXPERIMENTAL|B group|Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.
62718550|NCT04229888|EXPERIMENTAL|Subject Treatment|All subjects will receive light based (sham) treatment, then all subjects will receive LipiFlow treatment.
62718551|NCT01794910|EXPERIMENTAL|Plevic floor muscle therapy|The pelvic floor muscle therapy to women with vaginal or cesarean deliveries involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions.
62718552|NCT01794910|NO_INTERVENTION|Controll group|Women with vaginal or cesarean deliveries did not did not undergo muscle training
62718553|NCT06715566|EXPERIMENTAL|ActForStroke|A combination of high-intensity gait training and coaching to encourage physical and social activity.
62718554|NCT06715566|ACTIVE_COMPARATOR|Standard care|Standard care usually provided
62718555|NCT01203033||AML patients|newly diagnosed or relapsed AML patients
62718556|NCT04116593|EXPERIMENTAL|Intervention|
62718557|NCT04116593|NO_INTERVENTION|Control|
62718558|NCT00207220||3|subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls
62718559|NCT01989429|ACTIVE_COMPARATOR|Daivonex|topical application
62718560|NCT01989429|PLACEBO_COMPARATOR|vehicle|topical application
62718561|NCT01989429|EXPERIMENTAL|M518101|topical application
62718562|NCT04414293|EXPERIMENTAL|Treatment|All the patients will be treated with low dose lung radiation
62718563|NCT04802603|OTHER|Radiotherapy|Cohort 1 (De novo) No Prior radiotherapy Cohort 2 (Prior radiotherapy) Prior radiotherapy
62718564|NCT02806011||no Intervention|Long-term follow up of no intervention group
62718565|NCT02806011||1-time injection group|Long-term follow up of 1-time injection group
62718566|NCT02806011||2-time injection group|Long-term follow up of 2-time injection group
62718567|NCT05106348||Wheelchair Rugby Group|wheelchair rugby players, elite athletes, national team athletes
62718568|NCT03574961|EXPERIMENTAL|e-Support Group|Participants in this arm will receive the treatment, 12 weeks of 1-hr weekly moderated e-Support sessions.
62718569|NCT03574961|PLACEBO_COMPARATOR|e-Journaling Placebo|Participants in this arm will complete 12 weeks of 1-hr weekly online journaling activities.
62718570|NCT03710421|EXPERIMENTAL|Treatment (leukapheresis, chemotherapy, CS-1 CAR T therapy)|Patients undergo leukapheresis over 2-4 hours. Beginning 3-4 weeks, patients receive cyclophosphamide IV on days -4 and/or -3 or fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients then undergo CS1-CAR T therapy over 10-15 minutes on day 0.
62718571|NCT02800733|EXPERIMENTAL|saffron|450 mg of saffron capsule once a day for 6 weeks
62718572|NCT02800733|PLACEBO_COMPARATOR|placebo|placebo capsule once a day for 6 weeks
62718573|NCT03092310|EXPERIMENTAL|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
62718574|NCT01926132|EXPERIMENTAL|ascorbic acid 10g/20ml|Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation
62718575|NCT01926132|ACTIVE_COMPARATOR|Normal Saline 150ml|Normal Saline 150ml, covered bottle
62718576|NCT00947219|ACTIVE_COMPARATOR|HairMax LaserComb 2009, 12 Beam|Low Level Laser Medical Device 2009 with 12 laser beams
62718577|NCT00947219|ACTIVE_COMPARATOR|HairMax LaserComb 2009 9 Beam|Low Level Laser Mecial Device 2009 with 9 laser beams
62718578|NCT00947219|ACTIVE_COMPARATOR|Control device|The control device appears identical to the active device, but utilizes 9 LED lights instead of laser lights. The randomized devices are blinded to the study investigator and distributed in a blinded manner to the participants.
62168067|NCT01763489|EXPERIMENTAL|ASSIST tool group|Surgeons will assess the applicability of a trial using the ASSIST
62718579|NCT03196830|EXPERIMENTAL|Treatment group|the group of patients who received CAR-T treatment
62718580|NCT02814058|EXPERIMENTAL|Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
62718581|NCT02814058|EXPERIMENTAL|Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
62718582|NCT00499525|EXPERIMENTAL|Arm I|Patients receive paclitaxel IV over 1 hour once weekly for 3 weeks. Patients also receive oral sorafenib tosylate twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62718583|NCT00499525|ACTIVE_COMPARATOR|Arm II|Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
62718584|NCT03532022|EXPERIMENTAL|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
62718585|NCT03532022|ACTIVE_COMPARATOR|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
62718586|NCT01757665|EXPERIMENTAL|Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M|Aortic/Mitral valve replacement therapy
62718587|NCT01012284|EXPERIMENTAL|Panel A|8 patients with moderate hepatic impairment classified as moderate as per the Child Pugh Classification.
62165046|NCT01442207|PLACEBO_COMPARATOR|Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids \> 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, Premature rupture of the membranes (PROM) \> 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
62165047|NCT05023304|EXPERIMENTAL|Group A Dextenza|
62544490|NCT01270191|EXPERIMENTAL|Exenatide|In the exenatide therapy group, subjects will be instructed in the techniques for injection and be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months. If FPG still greater than 200 mg/dL after 4 weeks of exenatide treatment, they will use insulin for rescue therapy and will be withdrawn from this study.
62544491|NCT01270191|ACTIVE_COMPARATOR|Humulin-N|In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
62544492|NCT00200044|SHAM_COMPARATOR|Sham|This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
62544493|NCT00200044|ACTIVE_COMPARATOR|Treatment|The treatment arm has the Gatekeeper devices implanted.
62544494|NCT06550232|ACTIVE_COMPARATOR|papaverine arm|IV-papaverine 80 mg in 100 ml 0.9% saline, once
62544495|NCT06550232|PLACEBO_COMPARATOR|Control arm|I.V 100 ml 0.9% saline
62544496|NCT03901976|OTHER|Bed Exit Detection On|prevention of fall by a true bed exit detection
62544497|NCT06582940|EXPERIMENTAL|The study group|Patients in the study group will receive MRI-guided adaptive stereotactic radiotherapy (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. The MRI-linac is used for the delivery of radiotherapy.
62544498|NCT06582940|ACTIVE_COMPARATOR|The control group|Patients in the study group will receive conventional standard stereotactic radiotherapy (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. The conventional linac is used for the delivery of radiotherapy.
62544499|NCT02488954|EXPERIMENTAL|Probiotics|Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks
62544500|NCT02655705|ACTIVE_COMPARATOR|Cyclosporine A|Cyclosporine 200 mg/day (male) and 150 mg/day (female) orally, divided twice daily for 16 weeks
62544501|NCT02655705|ACTIVE_COMPARATOR|Methotrexate|Methotrexate was started with 10 mg/week orally as a single dose, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
62544502|NCT06633978|EXPERIMENTAL|MediTrain|
62544503|NCT03532373|NO_INTERVENTION|Control|None- normal care
62544504|NCT03532373|EXPERIMENTAL|Intervention|Patients will use a preference elicitation tool to determine their preferences for diagnosis and treatment of CTS
62544505|NCT03337269|OTHER|Control|Subject does not receive an educational intervention
62544506|NCT03337269|OTHER|Educational video|Subject watches an educational video
62544507|NCT03337269|OTHER|Educational handout|Subject reads an educational handout
62544508|NCT05285904||Ofatumumab|Population under routine medical care prescribed Ofatumumab in an early Relapsing Multiple Sclerosis
62544509|NCT04422041|ACTIVE_COMPARATOR|Early discharge|Discharge between 24 and 48 hours
62544510|NCT04422041|EXPERIMENTAL|Very early discharge|Discharge in less than 24 hours
62544511|NCT05009511|EXPERIMENTAL|Traumatic Brain Injury (TBI)|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13.
62544512|NCT05009511|EXPERIMENTAL|Traumatic Brain Injury (TBI) with MDD|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13. In addition, individuals will have a diagnosis of major depressive disorder (MDD) as per DSM-5.
62544513|NCT05009511|EXPERIMENTAL|Major Depressive Disorder (MDD)|Individuals meeting criteria for major depressive disorder (MDD) including qualifiers 'in partial remission' or 'in full remission' if they are actively in treatment for the condition and still carry the depression diagnosis.
62544514|NCT05009511|EXPERIMENTAL|Healthy Individuals|Healthy individuals without psychiatric and neurological conditions.
62544515|NCT00549679|EXPERIMENTAL|25 mcg|25 microgram inhaled once daily
62544516|NCT00549679|EXPERIMENTAL|87.5 mcg|87.5 microgram inhaled once daily
62544517|NCT00549679|PLACEBO_COMPARATOR|Placebo|Placebo inhaled once daily
62544518|NCT03254498|ACTIVE_COMPARATOR|Endocuff assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
62544519|NCT03254498|PLACEBO_COMPARATOR|Cap assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
62544520|NCT01887769||Lung cancer patient at diagnosis|
62544521|NCT00706862|EXPERIMENTAL|1|Talactoferrin, Carboplatin, Paclitaxel
62544522|NCT00706862|PLACEBO_COMPARATOR|2|Placebo, Carboplatin, Paclitaxel
62544523|NCT06160219|ACTIVE_COMPARATOR|Group (OH CO)|Group (OH CO): 30 patients will receive hydroxycobolamin (Cyanokit) 5 gm intravenously(iv) through the central venous catheter as bolus over 15 min reconstituted in 200 ml of NS.
62544524|NCT06160219|PLACEBO_COMPARATOR|Group (C) control|Group (C) control: 30 patients will receive 200ml of NS over 15 min iv.
62544525|NCT04260087||New Daily Persistent Headache|"This cohort will consist of participants diagnosed with New Daily Persistent Headache (NDPH). New daily persistent headache (NDPH) is a primary headache syndrome which can mimic chronic migraine and chronic tension-type headache. The headache is daily and unremitting from very soon after onset (within 3 days at most), usually in a person who does not have a history of a primary headache disorder.~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
62165048|NCT05023304|ACTIVE_COMPARATOR|Group B Topical Prednisolone|
62165049|NCT05065008|EXPERIMENTAL|Cranberry juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) of cranberry juice daily for 3 weeks.
62544526|NCT04260087||Chronic Migraine|"This cohort will consist of participants diagnosed with chronic migraine. Chronic migraine is defined as headache occurring on 15 or more days per month for more than three months, which, on at least 8 days per month, has the features of migraine headache. Chronic migraine occurs in approximately 1% of the population. Studies estimate that about 2.5% of people with episodic migraine will transition to chronic migraine each year.~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
62544527|NCT04260087||Healthy Volunteers|"This cohort will consist of healthy volunteers who have not been diagnosed with either NDPH or chronic migraine.~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
62544528|NCT05125965|EXPERIMENTAL|Patient undergoing immunotherapy with an indication for cardiac MRI|Patient undergoing immunotherapy with an indication for cardiac MRI for suspected myocarditis or myocarditis or other cardiovascular complications
62544529|NCT05011318|EXPERIMENTAL|Fatigue Manipulation|
62544530|NCT01890434|EXPERIMENTAL|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
62544531|NCT06023459|EXPERIMENTAL|Injectable extended-release buprenorphine (XR-BUP)|Participants will be randomly assigned to XR-BUP, with approximately 96 in the XR-BUP condition. The XR-BUP condition will use Brixadi/CAM2038 injectable, extended-release buprenorphine (Braeburn Pharmaceuticals, Inc.). After titrating to a stable dosage in approximately two weeks using weekly injection dosages as clinically indicated to relieve cravings and withdrawal symptoms, the target monthly dosage (128mg) of XR-BUP will be administered by injection at approximately Day 14 and approximately four weeks later in Week 6, with a third injection in Week 10. Dosage adjustments will be made as indicated for tolerability.
62544532|NCT06023459|ACTIVE_COMPARATOR|Sublingual buprenorphine-naloxone (SL-BUP)|Participants will be randomly assigned to SL-BUP with approximately 48 in the SL-BUP condition. The SL-BUP condition will use sublingual buprenorphine-naloxone, with a target maintenance daily dose range of 16-24mg as recommended for clinical practice. Titration to maintenance dosage will be attempted within the first two weeks of the SL-BUP condition. During the initial stabilization weeks, SL-BUP will be flexibly dosed as clinically indicated to relieve cravings and withdrawal symptoms, after which dosage adjustments will be based on clinical decisions by the site clinicians. The maintenance dosage of SL-BUP will be dispensed on a schedule similar to the XR-BUP injections (i.e., at approximately Day 14, Week 6, and Week 10).
62544533|NCT04388553|EXPERIMENTAL|Treatment|lumbar ESP block is performed. Before proceeding to ESP block, the back is cleaned with aseptic technique and draped. 40 mL of 0.25% levobupivacaine (or maximum of 2mg/kg body weight made up to same volume) is injected into the ESP.
62544534|NCT04388553|NO_INTERVENTION|Control|no regional anaesthesia is performed nor saline is injected into the ESP
62544535|NCT05205694||Late COVID-19 and PERIO|Participants in the late convalescent stage of COVID-19 with diagnosed periodontitis
62544536|NCT05205694||PERIO non COVID-19|Participants with diagnosed periodontitis and no history of COVID-19
62544537|NCT05205694||Late COVID-19 non PERIO|Participants in the late convalescent stage of COVID-19 without periodontitis
62544538|NCT05205694||Non PERIO non COVID-19|Participants with no history of COVID-19 and without periodontitis
62544539|NCT00506701|EXPERIMENTAL|Tadalafil treatment 40 mg|
62544540|NCT01406587|EXPERIMENTAL|PP4001 50 mg|
62544541|NCT01406587|EXPERIMENTAL|PP4001 100 mg|
62544542|NCT01406587|EXPERIMENTAL|PP4001 200 mg|
62544543|NCT01406587|PLACEBO_COMPARATOR|Placebo|
62544544|NCT00769873|ACTIVE_COMPARATOR|Lovenox|Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days after laparoscopic splenectomy
62544545|NCT00769873|NO_INTERVENTION|No Lovenox|Patients do NOT receive Lovenox post laparoscopic splenectomy
62544546|NCT00448383|EXPERIMENTAL|1|Open-label adalimumab
62544547|NCT06623474||Patients diagnosed with hepatocellular carcinoma|Patients diagnosed with hepatocellular carcinoma according to the guidelines for the diagnosis of primary liver cancer
62544548|NCT06623474||Patients diagnosed with non-hepatocellular carcinoma otherwise requiring hepatic resection|Patients who can be excluded from the diagnosis of hepatocellular carcinoma according to the guidelines for the diagnosis of primary liver cancer but required hepatic resection for other liver diseases
62544549|NCT01131468|EXPERIMENTAL|N-acetylcysteine|N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
62544550|NCT01131468|NO_INTERVENTION|Controls|Vancomycine and/or amikacin alone
62544551|NCT01528007|PLACEBO_COMPARATOR|Placebo pill.|
62544552|NCT01528007|ACTIVE_COMPARATOR|50mg Naltrexone when needed|
62544553|NCT05753878|EXPERIMENTAL|HH-120 nasal spray, Part A cohort 1|Nasal endoscopic examination is performed at 3min (±2 min), 30min (±5 min), 1h (±10 min), and 2h (±10 min) after dosing.
62544554|NCT05753878|EXPERIMENTAL|HH-120 nasal spray, Part A cohort 2-7|Nasal/nasopharyngeal samples are collected at 3min (±2 min) , 1h (±10 min) ,2h (±10 min),4h (±30 min),8h (±30 min),24h (±30 min).
62544555|NCT05753878|EXPERIMENTAL|HH-120 nasal spray, Part A cohort 8-9|Nasal/nasopharyngeal samples are collected at 4h (±30 min) , 8h (±30 min).
62544556|NCT05753878|EXPERIMENTAL|HH-120 nasal spray, Part B|
62544557|NCT05753878|PLACEBO_COMPARATOR|Placebo nasal spray, Part B|
62544558|NCT00802932||Partial Breast Radiation|1. Patients receiving Partial breast radiation
62544559|NCT00802932||Whole Breast Radiation|2. Patients receiving whole breast radiation
62168068|NCT01763489|ACTIVE_COMPARATOR|Synopsis Group|Surgeons will assess the applicability of a trial using the synopsis presented in a case vignette
62544560|NCT00939016|ACTIVE_COMPARATOR|High SD/ Low DR|This group contains females that exhibit characteristics of high social desirability and low dietary restraint.
62544561|NCT00939016|ACTIVE_COMPARATOR|High SD/ High Dr|This group contains females that exhibit characteristics of high social desirability and high dietary restraint.
62718588|NCT01012284|EXPERIMENTAL|Panel B|8 healthy participants who will match to patients with hepatic impairment in Panel A with regards to sex, age (more or less to 5 years), and body mass index.
62718589|NCT02799550|EXPERIMENTAL|allogeneic CART-19|infusions of allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
62718590|NCT05378412|EXPERIMENTAL|3Cs|
62718591|NCT05378412|NO_INTERVENTION|Control|
62718592|NCT06350448|EXPERIMENTAL|Washed Microbiota Transplantation|Patients undergo once WMT a day for three consecutive days
62718593|NCT02136225|EXPERIMENTAL|Counseling|Intervention: Means restriction counseling. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun in the home where youth are present.
62718594|NCT02136225|EXPERIMENTAL|Counseling and locking devices|Intervention: Means restriction counseling and locking devices. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present. Parents will also receive locking devices to store their guns securely.
62718595|NCT02136225|NO_INTERVENTION|Control group|Youth in the control group will receive usual care.
62718596|NCT03064932|ACTIVE_COMPARATOR|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (\<1g/day for all diets).~Post prandial test meal will be contain minimal amounts of spice."
62718597|NCT03064932|EXPERIMENTAL|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (\~3g/day in the 2100kcal diet).~Post prandial test meal will be contain a moderate amount of spice."
62718598|NCT03064932|EXPERIMENTAL|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).~Post prandial test meal will be contain a culinary amount of spice."
62718599|NCT04095065|EXPERIMENTAL|itMatters|Participants will have access to content focused on general knowledge and injunctive and descriptive norms for a period up to 3 weeks.
62718600|NCT04095065|EXPERIMENTAL|itMatters and itMatters Sexual Violence Prevention|Participants will have access to content focused on general knowledge and injunctive and descriptive norms related to alcohol use and sex. Additionally, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
62718601|NCT04095065|EXPERIMENTAL|itMatters Well-being and itMatters Sexual Violence Prevention|Participants will have access to content focused on basic information related to sleep wellness and time management. In Addition, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
62718602|NCT04095065|EXPERIMENTAL|itMatters Well-being|Participants will have access to content focused on basic information related to sleep wellness and time management. This content will be available for a period up to 3 weeks.
62718603|NCT03424395|OTHER|Personalized dietary and wellness program|An integrated personalized nutrition program which includes a combination of dietary and wellness advice/counseling on wellness and meals, or dietary and wellness advice/counseling alone, each for 10 weeks.
62718604|NCT02844985||Addict Group|In-patient and out-patient adult men and women who meet diagnostic criteria for sexual addiction.
62718605|NCT02844985||Control Group|Individuals from the general community and college student populations who have no history of identifiable psychopathology.
62718606|NCT01028235||Obstructive Dysphagia|Patients who complained of dysphagia, which had an obstructive etiology for their symptoms at the time of endoscopy (ring, mass, stricture, etc)
62718607|NCT01028235||Non-obstructive Dysphagia|Patients whose endoscopy was normal and without any obvious etiology for their symptoms noted.
62718608|NCT01049373|EXPERIMENTAL|Lymphdiaral Basistropfen (HDC)|HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
62718609|NCT01049373|PLACEBO_COMPARATOR|Placebo Solution|10 drops t.i.d. for 15 weeks
62718610|NCT01306747|EXPERIMENTAL|Chronic Pain Self-Management|
62718611|NCT01306747|NO_INTERVENTION|Control group|
62718612|NCT00998010|EXPERIMENTAL|Experimental|Patients receive bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide on days 1-42.Patients undergo external-beam fractionated regional radiotherapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.2-6 weeks after radiotherapy, patients receive bortezomib IV on days 1, 4, 8, and 11 and oral temozolomide on days 1-5.Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62718613|NCT02965625||open elective cardiac surgery patients|Including coronary artery bypass graft and valve replacement surgery patients
62718614|NCT06543875||Women incarcerated at the Penitentiary Center of French Guiana|
62718615|NCT00003645|EXPERIMENTAL|Arm I - Leuprolide + Flutamide|Arm I: Patients receive leuprolide intramuscularly once every 3 months and oral flutamide three times daily for 1 year.
62718616|NCT00003645|NO_INTERVENTION|Arm II - No Treatment|Arm II: Patients receive no initial treatment.
62718617|NCT03961802|EXPERIMENTAL|systematic early rehabilitation|systematic early rehabilitation
62718618|NCT03961802|NO_INTERVENTION|without systematic rehabilitation|without systematic rehabilitation
62718619|NCT04067232|EXPERIMENTAL|Patients with posttraumatic forearm impairment|All patients with a one-sided posttraumatic impairment of forearm pro- and/or supination at least 3 months after injury
62718620|NCT01025557|EXPERIMENTAL|Chocolate milk|
62718621|NCT01025557|EXPERIMENTAL|Milk|
62718622|NCT01025557|EXPERIMENTAL|Infant formula|
62718623|NCT01025557|EXPERIMENTAL|Soy beverage|
62718624|NCT01025557|EXPERIMENTAL|Water|
62718625|NCT05860764||vascular amputees and healthcare professionals|participants who have undergone an amputation due to peripheral arterial disease and healthcare professionals who treat these participants
62718626|NCT02633735|EXPERIMENTAL|Appy CDS|The Appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The intervention is administered to providers in this arm.
62718627|NCT02633735|NO_INTERVENTION|Usual Care|
62718628|NCT01426061|EXPERIMENTAL|Reflexology plus conventional treatment|
62718629|NCT01426061|EXPERIMENTAL|Homeopathy plus conventional treatment|
62718630|NCT01426061|NO_INTERVENTION|Conventional treatment|
62718631|NCT06007417|EXPERIMENTAL|GenSci004|
62718632|NCT06007417|ACTIVE_COMPARATOR|Genotropin|
62718633|NCT03830580|EXPERIMENTAL|Sung voice|
62718634|NCT03830580|NO_INTERVENTION|Control|
62718635|NCT00985647|ACTIVE_COMPARATOR|3TC 300mg/150mg|Group 1: Participants will be administered 3TC 300 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 150 mg once daily for 10 days
62718636|NCT00985647|ACTIVE_COMPARATOR|3TC 150mg/300mg|Group 2: Participants will be administered 3TC 150 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 300 mg once daily for 10 days
62718637|NCT04361500||COVID-19 patients with Seraph 100 therapy|
62718638|NCT04818905|EXPERIMENTAL|Helichrysum italicum infusion|1 g of milled plant material (Helichrysum italicun) immersed in hot water (200 mL, 100 °C) for 10 minutes.
62718639|NCT04818905|PLACEBO_COMPARATOR|Hot water|The control beverage contained only hot water (200 mL, 100 ˚C).
62718640|NCT04601116|ACTIVE_COMPARATOR|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg tablets per day for 2 years
62718641|NCT04601116|PLACEBO_COMPARATOR|Placebo|Placebo tablets 1 per day for 2 years.
62718642|NCT05465070|EXPERIMENTAL|Heat therapy|Patients will be provided with water-circulating trousers, a water heater, and a water tank coupled to a water pump. The heater will be adjusted to warm up the water to 42ºC. Participants will be asked to apply the therapy daily for 90 min while seated or in the supine position.
62718643|NCT05465070|ACTIVE_COMPARATOR|Sham Control|Patients will be provided with water-circulating trousers, a water heater, and a water tank coupled to a water pump. The heater will be adjusted to warm up the water to 33ºC. Participants will be asked to apply the therapy daily for 90 min while seated or in the supine position.
62718644|NCT04044963|EXPERIMENTAL|Exercise Group|All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The exercise intervention is prescribed based on the FITT principle: frequency, intensity, time and type. The 10-point Rating of Perceived Exertion (RPE) scale, which has been well correlated to target HR levels, will be used to monitor exercise intensity levels throughout the intervention, with participants instructed to maintain their intensity level at 3-5 during exercise sessions. Participant progression will be individualized and based on their subjective perceived intensity level using the RPE scale. In person instruction, from a member of the research team with standard first aid and CPR-C training, and an instructional handout and exercise log will be provided, as well as exercise resistance bands to perform resistance exercises.
62718645|NCT04044963|NO_INTERVENTION|Control Group|This will consist of regular care, which is standard procedure.
62718646|NCT02367963|EXPERIMENTAL|Intervention|A Training period and a Peer-group intervention are asigned to this arm. Peer-group intervention is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
62718647|NCT02367963|OTHER|Control|"A Training period intervention is asigned to this arm. Once the workshops have been carried out, the control group will be provided with written and visual documentation of risk factors and overall health habits. The members of this group will have access to the study website, where they will be able to find information on risk factors and health habits and links to the same websites related to health as the intervention group.~They won't participate in the sessions of peer education group dynamics for a period of 12 months."
62718648|NCT04435314|EXPERIMENTAL|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
62718649|NCT04435314|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo TID.
62718650|NCT02961244|NO_INTERVENTION|Control Group|Perioperative management and warming was not performed according to a standard normothermia protocol, with our clinic's traditional methods except prewarming.
62718651|NCT02961244|ACTIVE_COMPARATOR|Intervention Group|Perioperative management and warming was performed according to a standard normothermia protocol with active prewarming.
62718652|NCT02961036|EXPERIMENTAL|Group 1 Information|Group 1 Information about the prize draw incentive for 100% of an Amazon gift (or currency equivalent) in the invitation letter.
62718653|NCT02961036|ACTIVE_COMPARATOR|Group 2 Information|Group 2 Information about the prize draw incentive for 75% of an Amazon gift (or currency equivalent) in the invitation letter.
62718654|NCT02961036|ACTIVE_COMPARATOR|Group 3 Information|Group 3 Information about the prize draw incentive for 50% of an Amazon gift (or currency equivalent) in the invitation letter.
62718655|NCT02961036|ACTIVE_COMPARATOR|Group 4 Information|Group 4 Information about the prize draw incentive for 25% of an Amazon gift (or currency equivalent) in the invitation letter.
62718656|NCT02961036|ACTIVE_COMPARATOR|Group 5 No Information|Group 5 No Information incentive for an Amazon gift certificate (or currency equivalent) in the invitation letter.
62718657|NCT02961036|EXPERIMENTAL|Group A reminder|One survey reminder at 14 days
62718658|NCT02961036|ACTIVE_COMPARATOR|Group B reminders|Two survey reminders 14 days and 28 days
62718659|NCT00784862|ACTIVE_COMPARATOR|1|Arimidex 1mg + Nolvadex placebo
62718660|NCT00784862|ACTIVE_COMPARATOR|2|Arimidex placebo + Nolvadex 20mg
62718661|NCT00784862|ACTIVE_COMPARATOR|3|Arimidex 1mg + Nolvadex 20mg
62165050|NCT05065008|EXPERIMENTAL|Apple juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) apple juice with matching sugar and calories daily for 3 weeks.
62718662|NCT01819272|EXPERIMENTAL|600 mg DR|600 mg delayed-release metformin once daily in the morning
62165051|NCT02084589|ACTIVE_COMPARATOR|PCEA of continuous background infusion with demand dose|PCEA with background infusion of 5 ml/h and demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
62168069|NCT01666717||Healthy controls (HC)|HC
62718663|NCT01819272|EXPERIMENTAL|800 mg DR|800 mg delayed-release metformin once daily in the morning
62718664|NCT01819272|EXPERIMENTAL|1000 mg DR|1000 mg delayed-release metformin once daily in the morning
62718665|NCT01819272|ACTIVE_COMPARATOR|1000 mg XR|1000 mg extended-release metformin once daily in the evening
62718666|NCT01819272|ACTIVE_COMPARATOR|2000 mg XR|2000 mg extended-release metformin once daily in the evening
62718667|NCT01819272|PLACEBO_COMPARATOR|Placebo|Placebo once daily in the morning
62718668|NCT01301677|ACTIVE_COMPARATOR|Hydrocortisone|
62718669|NCT01301677|EXPERIMENTAL|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
62718670|NCT01301677|EXPERIMENTAL|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
62718671|NCT01822665|ACTIVE_COMPARATOR|Paracetamol Tablet|Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
62718672|NCT01822665|ACTIVE_COMPARATOR|Ibuprofen Tablet|Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
62718673|NCT01822665|PLACEBO_COMPARATOR|Placebo Tablet|Placebo tablets, 2 tablets QID administered with water.
62718674|NCT01822665|ACTIVE_COMPARATOR|Ibuprofen Capsule|Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water
62718675|NCT02507154|EXPERIMENTAL|Cetuximab + NK cells|During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo. Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks. During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart. Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1. This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
62718676|NCT02045784|EXPERIMENTAL|Infant formula milk 60 µg iodine/day|Infant formula containing 57 µg/100 g powder, providing approximately 60 µg iodine/day (i.e. 55% of the current AI). Unrestricted consumption during 11 days.
62718677|NCT02045784|EXPERIMENTAL|Infant formula milk 110 µg iodine/day|Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
62718678|NCT02045784|EXPERIMENTAL|Infant formula 220 µg iodine/day|Infant formula containing 217 µg/100 g powder, providing approximately 220 µg iodine/day (i.e. 200% of the current AI). Unrestricted consumption during 11 days.
62718679|NCT02045784|OTHER|Breast milk|Unrestricted consumption during 4 days
62718680|NCT02568722|ACTIVE_COMPARATOR|Standard RRT initiation|RRT initiation will be guided by the presence of one or more clinical indications. Even in the absence of one of these indications, RRT may be commenced at the discretion of the treating physician.
62718681|NCT02568722|EXPERIMENTAL|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of the patient meeting the eligibility criteria.
62718682|NCT01535287|ACTIVE_COMPARATOR|Dexmedetomidine|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
62718683|NCT01535287|PLACEBO_COMPARATOR|Placebo|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
62718684|NCT01336244|EXPERIMENTAL|GLPG0778 ascending doses|Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.
62718685|NCT01336244|PLACEBO_COMPARATOR|Placebo|Twice daily for 13 days, matching the scheme of the multiple ascending dose.
62718686|NCT04330209||LowGI/nutrigenetic|"114 overweight (n=1) and obese (n=113) subjects (M = 55, F = 59, age 24-56y, all of Romanian heritage and similar socio-economic status), who were patients at a weight management clinic (Bucharest, Romania), gave written informed consent for their weight loss data to be prospectively analysed for this study.~Upon enrolment at the weight management clinic, the subjects self-selected either a ketogenic diet or a low-GI nutrigenetic diet. 61 subjects (34 female; age 42.0 ± 6.7y) selected the low-GI nutrigenetic diet plan."
62718687|NCT04330209||Ketogenic|As above + Fifty-three subjects (25 female; age 43.0 ± 7.2y) selected the ketogenic diet plan
62718688|NCT03852784||Bone and joint infection with Streptococcus peumoniae|Patients having had an osteoarticular infection with Streptococcus peumoniae
62718689|NCT01228214|EXPERIMENTAL|Amiloride,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
62718690|NCT01228214|PLACEBO_COMPARATOR|Placebo,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
62718691|NCT04556344|EXPERIMENTAL|Emotional skills|3 individual sessions in which patients are going to learn how to identify, understand, express and regulate emotions
62718692|NCT04556344|SHAM_COMPARATOR|Short free talk and relaxation|3 individual sessions in which patients are going to follow relaxation instructions after a non-directive talk about their current or past experience of cancer.
62718693|NCT02527395|OTHER|Clinical pain models|Brief thermal sensitization. Heat pain detection threshold. Pain during 1 min. thermal stimulation
62718694|NCT06452693|EXPERIMENTAL|TQA3038 injection/placebo|"100/0mg\~400/0mg, subcutaneous injection, 2 weeks\~8 weeks as a cycle, a total of 2 doses.~Nucleotide drugs: Oral, once a day, orally administered with food, for 16 weeks."
62718695|NCT06452693|ACTIVE_COMPARATOR|Nucleotide drugs Control group|Nucleotide drugs: Oral, once a day, orally administered with food, for 48weeks.
62718696|NCT01486303|EXPERIMENTAL|Facial Cosmetic Acupuncture|28 Patients with grade III to IV wrinkling on the face, according to the Glogau classification system, were treated with Facial Cosmetic Acupuncture.
62718697|NCT04389073|EXPERIMENTAL|Arm 1 (PD-1+NVB)|"The treatments received are:~* Vinorelbine (40 mg/day, tiw, per os)~* Toripalimab (240 mg every 3 weeks, intravenously \[IV\])."
62718698|NCT04389073|EXPERIMENTAL|Arm 2 (PD-1+NVB+Bev)|"The treatments received are:~* Vinorelbine (40 mg/day, tiw, per os)~* Toripalimab (240 mg every 3 weeks, intravenously \[IV\])~* Bevacizumab (5 mg/kg every 3 weeks, intravenously \[IV\])."
62718699|NCT04389073|EXPERIMENTAL|Arm 3 (PD-1+NVB+DDP)|"* Vinorelbine (40 mg/day, tiw, per os)~* Toripalimab (240 mg every 3 weeks, intravenously \[IV\])~* Cisplatin (50mg/m2 every 3 weeks, intravenously \[IV\])."
62735907|NCT01713582|EXPERIMENTAL|AL 160 mg QD 14-21|Participants received 160 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62718700|NCT04389073|EXPERIMENTAL|Arm 4 (PD-1+VEX)|"* Vinorelbine (40 mg/day, tiw, per os)~* Toripalimab (240 mg every 3 weeks, intravenously \[IV\])~* Cyclophosphamide (50 mg/day, qd, per os)~* Capecitabine (500 mg, tid, per os)"
62718701|NCT04389073|ACTIVE_COMPARATOR|Arm 5 (NVB)|• Vinorelbine (40 mg/day, tiw, per os)
62718702|NCT03845829|EXPERIMENTAL|Patients with TBAD treated with TEVAR|In situ laser assisted fenestration for the left subclavian artery during the TEVAR procedure for TBAD.
62718703|NCT03764111||large mobile ultrasound system|the ultrasound transducer is based on piezoelectric technology.
62718704|NCT03764111||handheld ultrasound machine|The handheld device utilizes Capacitive micro-machined ultrasound transducers (CMUTs) instead of piezoelectric technology
62718705|NCT02023619||Keratoconus|Eyes with confirmed keratoconus diagnosis
62718706|NCT02023619||Astigmatism >2.0 D|Healthy eyes with astigmatism \>2.0 D
62718707|NCT02734329|EXPERIMENTAL|Zero Ischemia group|Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
62718708|NCT02734329|ACTIVE_COMPARATOR|Conventional group|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
62718709|NCT02061475|ACTIVE_COMPARATOR|Lidocaine Patches|
62718710|NCT02061475|PLACEBO_COMPARATOR|Placebo Patches|
62718711|NCT03177538|ACTIVE_COMPARATOR|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
62718712|NCT03177538|ACTIVE_COMPARATOR|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
62718713|NCT06101303||Pelvic pain|Patients with pelvic pain with and without endometriosis scheduled for an operative laparoscopic surgery for endometriosis diagnosis and/or treatment
62718714|NCT00755170|EXPERIMENTAL|1|Vinorelbine metronomic + bevacizumab
62718715|NCT04924621|EXPERIMENTAL|THRIVE group|Patients in group T received mask ventilation(oxygen concentration: 100%, flow rate: 6L /min, head height: 30°) for 5 minutes, and then THRIVE device (device model: Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher \& Paykel Healthcare, Inc.) was set 100% oxygen, flow rate 30L /min, temperature 34℃.
62718716|NCT04924621|PLACEBO_COMPARATOR|Control group|The Control Group will receive mask ventilation (oxygen concentration: 100%, flow rate: 6L /min, head height: 30°) for 5 minutes
62718717|NCT03775993|ACTIVE_COMPARATOR|GHD|
62718718|NCT03775993|PLACEBO_COMPARATOR|Placebo|
62718719|NCT03069378|EXPERIMENTAL|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
62718720|NCT02147821|NO_INTERVENTION|Standard|Standard treatment will be defined as current practice whereby two mediastinal chest tubes are used for drainage, as well as an additional pleural tube if the pleura is opened during surgery. As part of current standard practice, the pleural and mediastinal spaces will be suctioned during the achievement of hemostasis prior to the insertion of chest tubes.
62718721|NCT02147821|EXPERIMENTAL|Intervention|The treatment arm of the study will involve standard placement of the mediastinal tubes with the exclusion of the pleural tube.
62718722|NCT03433976|OTHER|Hyperbaric Bupivacaine|spinal anesthesia for planned cesarean sections control group
62718723|NCT03433976|ACTIVE_COMPARATOR|Hyperbaric Prilocaïne|spinal anesthesia for planned cesarean sections
62718724|NCT03940560|EXPERIMENTAL|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
62718725|NCT05748821|ACTIVE_COMPARATOR|Autoregulated blood flow restriction|Autoregulated BFR expands as the muscle progresses into the stretch-shortening cycle.
62718726|NCT05748821|ACTIVE_COMPARATOR|Non-autoregulated blood flow restriction|Non-autoregulated BFR does not expand as the muscle progresses into the stretch-shortening cycle.
62718727|NCT05748821|ACTIVE_COMPARATOR|No blood flow restriction|This group serves as the control group for this study
62718728|NCT00410475||U.S. radiologic technologists|Radiologic technologists certified by the American Registry of Radiologic Technologists (ARRT) during 1923-1980 and residing in any U.S. state or territory.
62718729|NCT05978336|EXPERIMENTAL|Health Coaching (HC)|The health coaching program will be delivered by trained and certified kinesiologists utilizing Brief Action Planning (BAP) principals. The BAP behavior change approach utilizes the following 4 techniques: 1) goal-setting; 2 )action planning; 3) self-monitoring; and 4) feedback. Participants will utilize daily physical activity diaries to enable self-monitoring, and BAP coaches will provide feedback on progress toward individualized physical activity goals.
62718730|NCT05978336|ACTIVE_COMPARATOR|Health Education Program (ED)|This program is an attention control group, which consists of general health education. Education sessions will be delivered either by zoom or in person. The education sessions will cover the following topics: 1) falls prevention; 2) sleep; 3) healthy eating; 4) cognitive health; and 5) mental and emotional health.
62718731|NCT04792385|EXPERIMENTAL|E4/DRSP 15/3 mg|Single treatment arm will receive E4/DRSP 15/3 mg
62718732|NCT03753022|SHAM_COMPARATOR|Group G5|Patients submitted to CABG and peep 5
62718733|NCT03753022|EXPERIMENTAL|Group G10|Patients submitted to CABG and peep 10
62718734|NCT03753022|EXPERIMENTAL|Group G15|Patients submitted to CABG and peep 15
62718735|NCT01627691|EXPERIMENTAL|Lotus Valve System|Patients enrolled will receive the Lotus Valve.
62168070|NCT01666717||Inflammatory Bowel Disease (IBD) patients|Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
62718736|NCT03807388|EXPERIMENTAL|ReMindCare Intervention Group|"Patients from First Episode of Psychosis Unit who will use ReMindCare app.~ReMindCare is an user-friendly app which conducts daily evaluations of the health status of patients with psychosis by some quick questions that patients will have to answer."
62718737|NCT03807388|OTHER|Treatment as Usual|Patients from First Episode of Psychosis Unit who will follow psychiatric usual care.
62718738|NCT03348124|EXPERIMENTAL|Intervention|"Educational lessons based on the conversational material Toolkit Children - what does it involve?, will be delivered in the classroom at school and caring for the RCB simulator during three days and nights."
62718739|NCT03348124|NO_INTERVENTION|Control|Education as usual.
62735908|NCT01713582|EXPERIMENTAL|AML de novo 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62735909|NCT01713582|EXPERIMENTAL|AML/MDS 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62718740|NCT02030821|ACTIVE_COMPARATOR|Tranexamic Acid (TXA)|"TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
62718741|NCT02030821|ACTIVE_COMPARATOR|Epsilon-aminocaproic acid (Amicar)|"Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
62718742|NCT06715098|EXPERIMENTAL|RoboGait group|Robotic walking training 3 days a week, 30 minutes a day for 4 weeks
62718743|NCT06715098|EXPERIMENTAL|RehaWalk group|Walking training on treadmill with body weight support for 30 minutes a day, 3 days a week for 4 weeks
62718744|NCT06715098|ACTIVE_COMPARATOR|Conventional Group|Conventional walking training for 30 minutes a day, 3 days a week for 4 weeks
62718745|NCT00690326|EXPERIMENTAL|A|"treatment type: behavioral(lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
62718746|NCT00690326|PLACEBO_COMPARATOR|B|Arm B given placebo comparator ie pamphlets
62718747|NCT02986074|EXPERIMENTAL|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
62718748|NCT02986074|EXPERIMENTAL|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
62718749|NCT06271824|EXPERIMENTAL|Intervention|Live, online socio-emotional group course
62718750|NCT01730872|EXPERIMENTAL|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
62718751|NCT01730872|PLACEBO_COMPARATOR|Placebo|Tears Naturale II Ophthalmic Solution, 1%
62718752|NCT04941690||Men seen for preconception physicals|Ready to conceive, i.e. not having contraception and not having children for less than 1 year
62718753|NCT04941690||Men seen for infertility|Couples who have not used contraception and have not had children for more than 1 year
62718754|NCT04941690||Men who visited the clinic for their wives' miscarriage|Couples whose wives were previously pregnant but terminated the pregnancy due to fetal abortion, spontaneous abortion, biochemical pregnancy, fetal malformation or ectopic pregnancy
62718755|NCT06487780|EXPERIMENTAL|Lifestyle-focused Occupational Therapy (OT) Intervention|Participants in the intervention group will engage in telemedicine sessions led by trained occupational therapists.
62718756|NCT06487780|ACTIVE_COMPARATOR|Education|Participants in the control group will receive standard education on foot self-care and offloading treatment aimed at preventing foot ulcer recurrence.
62718757|NCT00819429|EXPERIMENTAL|1|"Omega-3 + Standard treatment~Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure."
62718758|NCT00819429|EXPERIMENTAL|2|"Social skills + Omega-3 placebo + Standard treatment~Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. They will also undergo a manualised group social problem solving skills training protocol of 12 weekly 1-hour sessions (Ang \& Ooi, 2003a, 2003b). There will be booster sessions scheduled at 3-week intervals after the initial treatment period of 12 weeks, for a total of 4 booster sessions."
62544562|NCT00939016|ACTIVE_COMPARATOR|Low SD/ High DR|This group contains females that exhibit characteristics of low social desirability and high dietary restraint.
62544563|NCT00939016|ACTIVE_COMPARATOR|Low SD/ Low DR|This group contains females that exhibit characteristics of low social desirability and low dietary restraint.
62718759|NCT00819429|EXPERIMENTAL|3|"Omega-3 + Social skills + Standard treatment~Children in this group will receive omega-3 supplement and social skills training on top of standard treatment. Procedures for administration of Omega-3 supplement are similar to those stated in (1) and (2)."
62718760|NCT00819429|PLACEBO_COMPARATOR|4|"Omega-3 placebo + Standard treatment.~Children in this group will receive placebo as well as a course of the standard treatment. Procedure for administering the placebo capsules is similar to that outlined in (2)."
62718761|NCT02901886|EXPERIMENTAL|Intensive smoking cessation intervention|"The intervention includes 1) Individual motivational counseling in combination with 2) nicotine replacement therapy.~The intervention consists of five individual motivational counselling sessions, each lasting 20 to 40 minutes over a period of six weeks with a trained smoking cessation counsellor. The principles of motivational counselling are based on the trans theoretical model of change. The smoking cessation counsellor has also been trained in motivational counselling techniques specific to this intervention.~2. Nicotine replacement therapy The participants in the intervention group will be offered nicotine replacement therapy (NRT) free of charge and if accepted it will be tailored individually according to the Fagerström's Test for Nicotine Dependence.~The participants will note their tobacco and NRT consumption in a smoking diary."
62735910|NCT01713582|EXPERIMENTAL|OHM 10 mg QD 21-21|Participants received 10 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
62544564|NCT05332873|EXPERIMENTAL|Rivet Shunt Therapy|
62544565|NCT06625918|EXPERIMENTAL|Single arm|"Single group~Treatment"
62544566|NCT06399575|EXPERIMENTAL|Apnea Following Isocapnic Hypoxia|
62544567|NCT04208750|EXPERIMENTAL|R-Refraction|
62544568|NCT04208750|ACTIVE_COMPARATOR|S-Refraction|
62544569|NCT03960125|EXPERIMENTAL|4% Imipramine Cream on Upper Forearm Site|Base cream will be applied to the lower forearm site.
62544570|NCT03960125|EXPERIMENTAL|4% Imipramine Cream on Lower Forearm Site|Base cream will be applied to the upper forearm site.
62544571|NCT03179423|EXPERIMENTAL|GNbAC1|Monthly IV repeated dose
62544572|NCT03179423|PLACEBO_COMPARATOR|Placebo|Monthly IV repeated dose
62544573|NCT03267901|EXPERIMENTAL|Walnut-Control|
62544574|NCT03267901|EXPERIMENTAL|Control-Walnut|
62718762|NCT02901886|NO_INTERVENTION|Control|The control group will receive the standard treatment and care in the rheumatology outpatient clinic. The participants will be encouraged to write a diary describing their tobacco use during the trial period. If participants in the control group express an interest in receiving smoking cessation counselling, they will be informed about municipal programs.
62718763|NCT05221008|EXPERIMENTAL|group A|Experimental: SHR6508 Placebo Comparator: normal saline
62718764|NCT05221008|EXPERIMENTAL|group B|Experimental: SHR6508 Placebo Comparator: normal saline
62718765|NCT05221008|EXPERIMENTAL|group C|Experimental: SHR6508 Placebo Comparator: normal saline
62718766|NCT05221008|EXPERIMENTAL|group D|Experimental: SHR6508 Placebo Comparator: normal saline
62718767|NCT00606489|PLACEBO_COMPARATOR|1|
62718768|NCT00606489|EXPERIMENTAL|2|
62718769|NCT01400009|PLACEBO_COMPARATOR|Placebo|Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
62544575|NCT06630169|OTHER|Arm 1|Endothelial polishing zone 1
62165052|NCT02084589|ACTIVE_COMPARATOR|PCEA with demand dose only|PCEA with demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
62544576|NCT06630169|OTHER|Arm 2|Endothelial polishing zone 2
62544577|NCT06630169|OTHER|Arm 3|Endothelial polishing zone 3
62544578|NCT04228016|EXPERIMENTAL|Experimental: Device : nasal airway stent|All patients consulting for predominantly nocturnal nasal obstruction who have benefited from Nasal Respiratory Functional Exploration with detection of pathological resistance in the decubitus.
62544579|NCT01016470|PLACEBO_COMPARATOR|B|Placebo
62544580|NCT01016470|EXPERIMENTAL|A|VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
62544581|NCT04627428|EXPERIMENTAL|50,000 cells|Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.
62544582|NCT04627428|EXPERIMENTAL|150,000 cells|Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.
62544583|NCT04627428|EXPERIMENTAL|250,000 cells|Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.
62544584|NCT02682927|EXPERIMENTAL|ZX008 - 0.8 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
62544585|NCT02682927|EXPERIMENTAL|ZX008 - 0.2 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
62544586|NCT02682927|PLACEBO_COMPARATOR|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
62718770|NCT01400009|ACTIVE_COMPARATOR|Vitamin D|Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
62718771|NCT04992468|EXPERIMENTAL|GnRH-a+rhCG|Ovulation triggering with GnRH-a+rhCG
62718772|NCT04992468|ACTIVE_COMPARATOR|GnRH-a|Ovulation triggering with GnRH-a
62718773|NCT04398576|NO_INTERVENTION|Support as usual|"There will be no interventions, only support as usual. All GPs receive an information package by post or via e-mail containing:~* Belgian guidelines on the management of hazardous and harmful alcohol use~* A summary card about EIBI for hazardous and harmful alcohol consumption.~* Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider."
62718774|NCT04398576|ACTIVE_COMPARATOR|Training and support|"All GPs receive an information package by post or via e-mail containing:~* Belgian guidelines on the management of hazardous and harmful alcohol use~* A summary card about EIBI for hazardous and harmful alcohol consumption.~* Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider.~There shall be tailored training and support for the general practioners. At the start of the study, this group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months."
62165053|NCT05634083|EXPERIMENTAL|Uremic Pateints group|Patients with end-stage renal failure with itching
62165054|NCT04713878|ACTIVE_COMPARATOR|Group 1|Intubated without comorbidity
62544587|NCT00493415|EXPERIMENTAL|1|nitroglycerine iv
62544588|NCT00493415|PLACEBO_COMPARATOR|2|nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
62544589|NCT02645903|ACTIVE_COMPARATOR|transversus abdominis plane block|"Patients who received a tranversus abdominis plane block with ultrasound after standard general anesthesia represented Group 1.~The tranversus abdominis plane block was performed bilaterally by obtaining an image with real time ultrasound guidance with a 6-13 MHz linear probe.~The block was placed with a 22 G 80 mm needle while obtaining real-time images via an in-plane technique.~Two 20 mL syringes were prepared after preparing a local anesthetic concentration of 1.5 mg/kg of 0.5% bupivacaine to 40 mL with saline. These were administered to the left and right abdominal walls.~Postoperative analgesia was administered through a morphine the patient-controlled analgesia device."
62544590|NCT02645903|PLACEBO_COMPARATOR|nonblocked|Patients who received standard general anesthesia alone made up Group 2. Postoperative analgesia was administered through a morphine the patient-controlled analgesia device.
62544591|NCT03387566|EXPERIMENTAL|HB002.1M 0.3mg|Participants received a 0.3mg dose of HB002.1M via intravitreal (IVT) injection.
62544592|NCT03387566|EXPERIMENTAL|HB002.1M 0.5mg|Participants received a 0.5mg dose of HB002.1M via intravitreal (IVT) injection.
62544593|NCT03387566|EXPERIMENTAL|HB002.1M 1.0mg|Participants received a 1.0mg dose of HB002.1M via intravitreal (IVT) injection.
62544594|NCT03387566|EXPERIMENTAL|HB002.1M 2.0mg|Participants received a 2.0mg dose of HB002.1M via intravitreal (IVT) injection.
62544595|NCT03387566|EXPERIMENTAL|HB002.1M 3.0mg|Participants received a 3.0mg dose of HB002.1M via intravitreal (IVT) injection.
62718775|NCT04398576|ACTIVE_COMPARATOR|Training and support and community actions|In this group, GPs receive the same training and support as in the second arm (training and support). There will also be embedded community-based actions within a local strategy.
62544596|NCT06259305|EXPERIMENTAL|Creation of a memory track combined with the baby's heartbeat|"A memory track will be created by the music therapist with the family and this will be overlaid with a recording of the baby's heartbeat, provided by the family.~This recording will be placed inside a memory bear and given to the family to keep.~This will be offered to form part of the memory making process alongside existing processes."
62544597|NCT06282146|EXPERIMENTAL|Open-label aiTBS to posterior parietal cortex|10 iTBS treatment sessions per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses total). In the unlikely event that a participant is late for an hourly treatment, then the treatment will be delayed accordingly. The minimum gap between treatments will be 25 minutes. Each iTBS treatment will consist of 60 cycles of 10 bursts of three pulses at 50 Hz delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation will be delivered at 90% resting motor threshold (rMT), adjusted for depth of the identified functional connectivity target.
62544598|NCT03741426|EXPERIMENTAL|Arm 1- Cediranib|Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
62544599|NCT03741426|EXPERIMENTAL|Arm 2- Olaparib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy.
62544600|NCT03741426|ACTIVE_COMPARATOR|Arm 3- Olaparib and Cediranib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy AND Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
62544601|NCT03741426|EXPERIMENTAL|Arm 4- Durvalumab|Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
62544602|NCT03741426|ACTIVE_COMPARATOR|Arm 5- Olaparib and Durvalumab|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy. Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
62544603|NCT02028741|EXPERIMENTAL|symptomatic intervention group|Paitients with mechanical neck pain were treated with transverse vertebral pressures
62544604|NCT02028741|SHAM_COMPARATOR|aymptomatic non-intervention group|Sham treatment to aymptomatic subjects
62544605|NCT06525207||Anal incontinence group|Women with anal incontinence and no symptoms of constipation
62544606|NCT06525207||Obstructive defecation group|Women with constipation and predominant symptoms of obstructive defecation, without symptoms of anal incontinence
62544607|NCT06525207||Healthy volunteer group|Women without any defecation disorders
62544608|NCT00551668|EXPERIMENTAL|1|Operative
62544609|NCT00551668|EXPERIMENTAL|2|Nonoperative
62544610|NCT04087434||Retrospective|retrospective review of 300 records of patients following concussive diagnosis to track recovery and adherence to progressive return to activity recommendations.
62544611|NCT04087434||Prospective|300 prospective patients enrolled following concussive diagnosis to track recovery, clinical diagnosis and brain gauge performance.
62544612|NCT04087434||Control Group|75-100 Healthy Controls recruited by Fort Bragg to assess performance in a healthy population for brain gauge performance.
62544613|NCT00976911|ACTIVE_COMPARATOR|Chemotherapy|Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 milligrams per square meter (mg/m\^2) as a 1-hour intravenous (IV) infusion on Days 1, 8, 15, and 22 every 4 weeks (q4w) OR topotecan 4 mg/m\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\^2 dose could have been administered over 30 minutes on Days 1-5 every 3 weeks \[q3w\]) OR pegylated liposomal doxorubicin (PLD) 40 mg/m\^2 as a 1 milligram per minute (mg/min) infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices.
62544614|NCT00976911|EXPERIMENTAL|Chemotherapy + Bevacizumab|Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion. Depending on chosen chemotherapy, pre-medication was implemented according to local practices. The chosen chemotherapy was combined with bevacizumab 10 milligrams per kilogram (mg/kg) IV every 2 weeks (q2w; or bevacizumab 15 mg/kg q3w if used in combination with topotecan 1.25 mg/m\^2 on Days 1-5 on a q3w schedule). The initial bevacizumab infusion was over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes, as tolerated.
62544615|NCT01653717|EXPERIMENTAL|T-Cell Infusion + Chemotherapy|Peripheral blood mononuclear cells (PBMC) collected via venipuncture or steady state leukapheresis after enrollment. Clinically successful T-cell production defined as amount of T-cells required for dose level for which the patient is enrolled. Fludarabine 25 mg/m2 by vein on Days -5 to Day -3. Cyclophosphamide 250 mg/kg by vein on Days -5 to -3. Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
62544616|NCT05232188|EXPERIMENTAL|22French (Fr)|After renal access, dilatation is provided up to 22Fr with a dilatator set, and fragmentation is started with a 19Fr nephroscope.
62544617|NCT05232188|EXPERIMENTAL|28F|After renal access, dilatation is provided up to 28Fr with a dilatator set, and fragmentation is started with a 25Fr nephroscope.
62544618|NCT05857852|EXPERIMENTAL|Low-Intensity Focused Ultrasound (LIFU)|All subjects to receive LIFU and Sham in a randomized order.
62735911|NCT01713582|EXPERIMENTAL|OHM 20 mg QD 21-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
62544619|NCT05857852|SHAM_COMPARATOR|Sham LIFU|All subjects to receive LIFU and Sham in a randomized order.
62544620|NCT04751071|ACTIVE_COMPARATOR|Roflumilast|Roflumilast 500 µg tablet plus standard therapy
62544621|NCT04751071|PLACEBO_COMPARATOR|Placebo|placebo tablet plus standard therapy
62544622|NCT04363827|EXPERIMENTAL|Group 1: Hydroxychloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1, followed by a weekly dose of Hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, covering a total of 1 month of treatment.
62165055|NCT04713878|ACTIVE_COMPARATOR|Group 2|Intubated with comorbidity
62718776|NCT01624714|EXPERIMENTAL|Alemtuzumab Naive|Alemtuzumab Subjects (30) with prior treatment refractoriness and treatment experience EDSS 3.0-7.0 inclusive, without contraindications to alemtuzumab
62718777|NCT01624714|EXPERIMENTAL|Alemtuzumab Experienced|Subjects with treatment refractory MS and prior alemtuzumab therapy (30)
62718778|NCT01555866|EXPERIMENTAL|Part 1 Subjects with End Stage Renal Disease (ESRD)|
62718779|NCT01555866|EXPERIMENTAL|Part 1 Healthy Subjects|
62718780|NCT01555866|EXPERIMENTAL|Part 2 Subjects with Mild Renal Impairment|
62718781|NCT01555866|EXPERIMENTAL|Part 2 Subjects with Moderate Renal Impairment|
62718782|NCT01555866|EXPERIMENTAL|Part 2 Subjects with Severe Renal Impairment|
62718783|NCT01555866|EXPERIMENTAL|Part 2 Subjects with no Renal Impairment|
62718784|NCT06718231|ACTIVE_COMPARATOR|Group T|the electrodes will be fixed at acupointsShenmen,Neiguan,Hegu,Chize,Anmian bilaterally
62718785|NCT06718231|SHAM_COMPARATOR|Group S|the electrode pads will be fixed at the bilateral sham acupoints
62718786|NCT00382174|PLACEBO_COMPARATOR|1|0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
62718787|NCT00382174|ACTIVE_COMPARATOR|2|3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
62165056|NCT04713878|ACTIVE_COMPARATOR|Group 3|No intubated
62718788|NCT03147183||candidates for renal transplant|
62718789|NCT02405988|EXPERIMENTAL|Intravenous naloxone|0,4 mg/ml Naloxone B Braun 2,5 ML intravenously
62718790|NCT03510273|OTHER|Thermocoagulation treatment|Acceptability of Liger Medical Thermocoagulator treatment
62718791|NCT04638751||NSCLC|Stage 3 or stage 4 non-small cell lung cancer patients, being administered checkpoint inhibitor therapy for the first time. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62718792|NCT04638751||Triple-negative breast cancer|Stage 3 or stage 4 metastatic triple-negative breast cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62718793|NCT04638751||Colorectal cancer|Stage 3 or stage 4 colorectal cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62735912|NCT01713582|EXPERIMENTAL|OHM 40 mg QD 21-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
61978174|NCT02630355|ACTIVE_COMPARATOR|High Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and deflation on weekly basis for four consecutive weeks.
61978175|NCT05791851||HIV infected|
61978176|NCT05791851||HIV uninfected|
61978177|NCT03164096|EXPERIMENTAL|intrathecal bupivacaine|intrathecal bupivacaine hydrochloride 0.5%,12.5mg
62165057|NCT05094947|EXPERIMENTAL|intermittent catheterization (group B)|Procedure/Surgery: The acute urinary retention in group B is managed by clean intermittent catheterization along with alpha-blockers during 3 period. After 3 days the ability of spontaneous voiding is assessed and registered as an outcome.
62544623|NCT04363827|NO_INTERVENTION|Group 1: Observation|observation only
62544624|NCT04363827|EXPERIMENTAL|Group 2: Hydroxycloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1 followed by 200 mg twice daily for a total of at least 5-7 days according to clinical evolution.
62544625|NCT04363827|NO_INTERVENTION|Group 2: Observation|Observation only
62544626|NCT06028880|EXPERIMENTAL|Experimental group|1 pre-session + 12 sessions
62544627|NCT06634264|EXPERIMENTAL|Intervention Arm (Soft Oral Appliance)|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
62544628|NCT06634264|NO_INTERVENTION|Control Arm (Nasal Hygiene)|Parents and Participants of this group will be reminded the nasal hygiene procedures (depending on the site; for example application of saline in each nostril three times a day,few simple breathing exercises), and given a diary to report daily use.
62544629|NCT00953251||patients with acute coronary syndrome|patients with acute coronary syndrome
62544630|NCT00953251||Non-STEMI and unstable angina|
62544631|NCT05327673||patients who accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)|
62544632|NCT05327673||patients who did not accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)|
62544633|NCT05705037|SHAM_COMPARATOR|Group A (CPP-ACPF mousse + sham light therapy)|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
62544634|NCT05705037|PLACEBO_COMPARATOR|Group B (placebo mousse + PBMT)|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
62718794|NCT04638751||Pancreatic cancer|Stage 3 or stage 4 pancreatic cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
62165058|NCT05094947|ACTIVE_COMPARATOR|Catheter Foley (group A)|The acute urinary retention in group A is managed by trial without catheter along with alpha-blockers during 3 period. After 3 days the indwelling Foley catheter is removed and ability of spontaneous voiding is assessed and registered as an outcome.
62165059|NCT03437902|EXPERIMENTAL|Rutin C group|patients will receive Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks..
62165060|NCT03437902|EXPERIMENTAL|Vitamin C group|patients will receive vitamin C 500 mg once daily in addition to usual antidiabetic treatment for 8 weeks.
62544635|NCT05705037|EXPERIMENTAL|Group C (CPP-ACPF + PBMT)|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
62544636|NCT03535389|EXPERIMENTAL|Pathologic group|Patients addressed to our imaging department for the realization of a knee scanner as part of routine care and presenting clinical PFI syndrome (Patellofemoral instability diagnosis based on physical examination, history and Kujala score)
62544637|NCT03535389|ACTIVE_COMPARATOR|Control group|"Patients addressed to our imaging department for osteo-articular pathologies other than patellofemoral instability (non-fracture trauma, vascular pathologies, degenerative or soft tissues).~* Does not have any clinical PFI syndrome~* Matched (1: 1 ratio) to PFI patients by age (+/- 40 years) and sex"
62544638|NCT00243412|EXPERIMENTAL|Arm A: 500 mg Rituximab|"Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18).~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
62544639|NCT00243412|EXPERIMENTAL|Arm B: 1000 mg Rituximab|"Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered.~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
62544640|NCT00551018|EXPERIMENTAL|Vicriviroc + Reyataz + ritonavir|vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
62544641|NCT00551018|ACTIVE_COMPARATOR|Truvada® + Reyataz + ritonavir|Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
62544642|NCT01707979||Diabetic neuropathy|Male participants, type1 diabetic with diabetic neuropathy
62544643|NCT01707979||Diabetes without neuropathy|Male participants, type1 diabetic without diabetic neuropathy
62544644|NCT01707979||Non diabetic control|Male participants, control group non diabetic
62544645|NCT01188291||Sleep Apnea / Hypopnea syndrome|Study group composed of patients with Obstructive Sleep Apnea / Hypopnea syndrome
62544646|NCT03938285|ACTIVE_COMPARATOR|High Flux Hemodialysis|High Flux Hemodialysis with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment.
62544647|NCT03938285|ACTIVE_COMPARATOR|Extended Hemodialysis|Extended Hemodialysis with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment.
62544648|NCT03938285|ACTIVE_COMPARATOR|On Line Hemodiafiltration|On Line Hemodiafiltration with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
62544649|NCT03938285|ACTIVE_COMPARATOR|On Line Hemodiafiltration with an MCO membrane|On Line Hemodiafiltration with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
62718795|NCT04638751||High risk for colorectal cancer|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening considered at high risk for CRC due to either 1) one or more first degree relatives with a history of CRC, or 2) a personal history of colorectal cancer, advanced adenoma as defined by USMSTF guidelines on colorectal cancer, or 3 or more non-advanced adenomas in a single screening or surveillance encounter (synchronous).
62165061|NCT03437902|NO_INTERVENTION|Control group|patients will receive their usual antidiabetic treatment only for 8 weeks.
62165062|NCT04822025|EXPERIMENTAL|High Dose|High-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62165063|NCT04822025|EXPERIMENTAL|Mid Dose|Mid-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
62544650|NCT04842292|EXPERIMENTAL|Nebulized heparin|Nebulized heparin 25,000 units in 3 mL inhalation every 6 hours
62544651|NCT04842292|PLACEBO_COMPARATOR|Nebulized placebo|Sodium chloride 0.9% 5 mL inhalation every 6 hours
62544652|NCT02156167|EXPERIMENTAL|CP810 and Codacs™Test System|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
62544653|NCT02568605|EXPERIMENTAL|Prebiotic Fibre|The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
62544654|NCT02568605|PLACEBO_COMPARATOR|Placebo|The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
62544655|NCT02568605|OTHER|Weight Loss|All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.
62544656|NCT04495881|EXPERIMENTAL|sitagliptin|sitagliptin 100mg
62544657|NCT04031755|EXPERIMENTAL|Minocycline versus Placebo|"Phase 1: 4 weeks of daily minocycline 100mg BID dosing~2-week washout period~Phase 2: 4 weeks of daily placebo dosing"
62735913|NCT01713582|EXPERIMENTAL|OHM 80 mg QD 21-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
62165064|NCT01995149|EXPERIMENTAL|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
62165065|NCT04560192|ACTIVE_COMPARATOR|Intervention group|Treatment with the mindfulness based emotion regulation therapy (MBERT) in block 1, no study-treatment in block 2 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy).
62165066|NCT04560192|OTHER|Treatment as usual (TAU)|No study-treatment in block 1 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy), treatment with the mindfulness based emotion regulation therapy (MBERT) in block 2.
62165067|NCT04560192|NO_INTERVENTION|Control condition|Healthy subjects will get a single TSST session.
62165068|NCT04826393|EXPERIMENTAL|ASP8374 and Cemiplimab-Cohort 1|"A 3+3 dose escalation design will be used to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when combined with cemiplimab.~Participants will receive ASP8374 and Cemiplimab every 3 weeks for up to 2 years. ASP8374 will be available until October 31, 2022. Subjects may continue treatment with cemiplimab alone after that date."
62168071|NCT01537120|EXPERIMENTAL|Placebo → Vildagliptin|Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily
62544658|NCT04031755|EXPERIMENTAL|Placebo versus Minocycline|"Phase 1: 4 weeks of daily placebo dosing~2-week washout period~Phase 2: 4 weeks of daily minocycline 100mg BID dosing"
62544659|NCT06634017|EXPERIMENTAL|EXPERIMENTAL|Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
62544660|NCT06634017|PLACEBO_COMPARATOR|CONTROL|On control side saline was injected using a 27 mm gauged needle. During the first application the saline was injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
62544661|NCT04264676|ACTIVE_COMPARATOR|Metronidazole|supplement of metronidazole 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6(6 treatments totally),and every 6 weeks for CapeOX (4 treatments totally).
62544662|NCT04264676|PLACEBO_COMPARATOR|Placebo|supplement of identical-appearing placebo 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6 (6 treatments totally),and every 6 weeks for CapeOX 4 treatments totally).
62544663|NCT00879411||arterial hypertension|
62544664|NCT04419012||Patients with AF treated with VKA|
62544665|NCT04419012||Patients with AF treated with NOAC|
62544666|NCT04538183|EXPERIMENTAL|WO 5000|Body lotion pH 4 for topical application
62544667|NCT04538183|EXPERIMENTAL|WO 5001|Body lotion pH 5.8 for topical application
62544668|NCT04538183|NO_INTERVENTION|No product use|Untreated control area
62544669|NCT04976413|EXPERIMENTAL|Experimental|Experimental arm will receive eight phase EMDR treatment using standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12 -14 weeks . Follow up will be conducted after 12 weeks of treatment completion.
62544670|NCT04976413|ACTIVE_COMPARATOR|Control|Control group will receive treatment as usual (supportive counselling) for 12 -14 weeks
62544671|NCT00270907|EXPERIMENTAL|CT-2103 + Gemcitabine|CT-2103 135 mg/m\^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m\^2 IV on Day 1 and 8.
62544672|NCT01492920|EXPERIMENTAL|Arm I (acetyl-L-carnitine hydrochloride)|Patients receive ALC PO BID on days 1-21 (during chemotherapy treatment).
62544673|NCT01492920|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID on days 1-21 (during chemotherapy treatment) (maximum of 8 courses).
62544674|NCT02654119|EXPERIMENTAL|Treatment (cyclophosphamide, paclitaxel, trastuzumab)|"SYSTEMIC THERAPY: Patients receive cyclophosphamide IV over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.~Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard NCCN guidelines."
62544675|NCT05128760||Patients with COVID-19 and aPL positivity|Patient with COVID-19 and aPL test positivity
62544676|NCT05128760||Patients with COVID-19 without aPL positivity|
62544677|NCT05128760||APS patients|
62544678|NCT05128760||Healthy control|
62544679|NCT05128760||Disease control|
62718796|NCT04638751||Low risk for colorectal cancer|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening, who are not considered high risk for CRC based on family history or prior colonoscopy findings.
62718797|NCT01178840|OTHER|WC then FC2|The couples will use 4 PATH Woman's Condom then 4 FC2 female condom.
62718798|NCT01178840|OTHER|FC2 then WC|The couples will use 4 FC2 female condom then 4 PATH Woman's Condom.
62718799|NCT05542459||Non-IBD control group|A control group in which patients are not diagnosed as inflammatory bowel disease.
62718800|NCT05542459||CD group|A group in which patients are diagnosed as crohn's disease
62718801|NCT05542459||UC group|A group in which patients are diagnosed as ulcerative colitis
62718802|NCT02629926||Patients to receive GH replacement|30 patients will be recruited to the study who wishes to continue receiving growth hormone replacement, all of whom will receive NutorpinAq Recombinant growth hormone
62718803|NCT02629926||Patients who will not receive GH replacement|An additional 30 patients who elect not to receive growth hormone replacement will provide a parallel control data.
62718804|NCT01125579||Children aged 6-12|"Children suffering from nervous restlessness, e.g. in agitated depression (ICD 10, F3 and DSM IV affective disorders), aged 6-12 years"
62718805|NCT04830046||Multiple Myeloma-MM patients|People with Multiple Myeloma-MM receiving covid 19 vaccine
62718806|NCT04830046||Waldenstrom's macroglobulinemia-WM patients|People with Waldenstrom's macroglobulinemia-WM receiving covid 19 vaccine categorized by treatment naïve, actively receiving BTK inhibitor,currently or previously treated.
62718807|NCT05595200||Study Group|All subjects diagnosed with pulmonary hypertension by right heart catheterization agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
62718808|NCT02448199|EXPERIMENTAL|Kit 1 ( ML + CG ) + P|One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
62718809|NCT02448199|ACTIVE_COMPARATOR|Kit 2 ( ML + P)|One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
62718810|NCT02448199|ACTIVE_COMPARATOR|Kit 3 ( P+ GC)|One sachet of glucosamine and one tablet placebo once a day for 12 weeks
62718811|NCT01861847|PLACEBO_COMPARATOR|Placebo Group|Placebo Comparator
62718812|NCT01861847|ACTIVE_COMPARATOR|Drug group|7 Keto-DHEA
62718813|NCT05447689|EXPERIMENTAL|Integrative-Mind-Body Skills Group|Treatment group
62718814|NCT05447689|NO_INTERVENTION|Control|Control group: Treatment-As-Usual (TAU) and mind-body skills reading materials.
62718815|NCT02295462|EXPERIMENTAL|Person-centered Care|Medication Review + Person-centered Care
62718816|NCT02295462|ACTIVE_COMPARATOR|Optimised Treatment|Medication Review
62718817|NCT02525926|EXPERIMENTAL|denervation|
62718818|NCT02525926|SHAM_COMPARATOR|control group|
62718819|NCT01667250|ACTIVE_COMPARATOR|GammaCore Active Device|Subjects will use an Active GammaCore Device
62718820|NCT01667250|SHAM_COMPARATOR|GammaCore Sham Device|Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study.
62718821|NCT05292001|EXPERIMENTAL|Treatment|Single infusion of low molecular weight Iron Dextran
62718822|NCT05292001|PLACEBO_COMPARATOR|Placebo|Single infusion of normal saline
62718823|NCT03714438|EXPERIMENTAL|Medicago sativa|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
62718824|NCT03714438|PLACEBO_COMPARATOR|Placebo|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
62718825|NCT00411424|EXPERIMENTAL|1|
62718826|NCT00411424|PLACEBO_COMPARATOR|2|
62718827|NCT06353503|EXPERIMENTAL|bone marrow injection|intra articular injection of autologous bone marrow aspirate concentrate 4cc in the injured knee under local anesthesia and ultrasound guide
62718828|NCT00532844|EXPERIMENTAL|Sapropterin dihydrochloride|Sapropterin dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
62718829|NCT00532844|EXPERIMENTAL|Sapropterin dihydrochloride+Vitamin C|Sapropterin dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
62718830|NCT02923154|EXPERIMENTAL|MT-3995|
62718831|NCT02923154|PLACEBO_COMPARATOR|Placebo|
62718832|NCT03767543|EXPERIMENTAL|iGlarlixi DAILY|Titration Group 1: Addition of 1 unit per day until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
62718833|NCT03767543|ACTIVE_COMPARATOR|iGlarlixi WEEKLY|Titration Group 2: Algorithm of weekly adjustment until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
62718834|NCT03567707|EXPERIMENTAL|C-section -Vaginal seeding|"Pregnant women who undergo C-section and (neonate) vaginal seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with gauze containing their mother's vaginal microbiota just after delivery."
62718835|NCT03567707|EXPERIMENTAL|C-section - Placebo Seeding|"Pregnant women who undergo C-section and (neonate) placebo seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with sterile gauze (placebo)."
62718836|NCT03567707|ACTIVE_COMPARATOR|standard care|"Pregnant women who undergo spontaneous vaginal delivery (of neonate) .~Pregnant women who undergo spontaneous vaginal delivery and (neonate) receives standard care."
62718837|NCT03692403|EXPERIMENTAL|Quinagolide 360 µg|Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
62718838|NCT03692403|EXPERIMENTAL|Quinagolide 720 µg|Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
62718839|NCT03692403|EXPERIMENTAL|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
62718840|NCT03692403|PLACEBO_COMPARATOR|Placebo|Vaginal ring containing matching placebo
62718841|NCT02053844|EXPERIMENTAL|lottery and enhanced promotion of tool|tool users in the intervention arm will be eligible to enter a monthly lottery to win one of two monthly drawings of a $500 gift card, and will receive enhanced promotion of the tool (mailed promotion, promotional message on the member web portal, and promotion through employers to employees)
62718842|NCT02053844|NO_INTERVENTION|usual promotion of the tool|Routine promotion of the tool through newsletter and on health plan web site
62718843|NCT02318017|ACTIVE_COMPARATOR|Methylphenidate|Methylphenidate 0.5mg/kg - once
62718844|NCT02318017|PLACEBO_COMPARATOR|Placebo|Placebo - once
62718845|NCT00099021|EXPERIMENTAL|Prevention (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.
62718846|NCT05926063|EXPERIMENTAL|Short treatment group|"Empirical broad-spectrum antibiotics (EBAT) as per local protocol:~* Meropenem 3 x 1(/2) g IV; OR~* Piperacilline-Tazobactam 4 x 4 g IV; OR~* Cefepime 3 x 2 g IV; OR~* Ceftazidim 3 x 2 g IV~Short treatment group: EBAT will be discontinued:~* After 3x24 hours;~* Irrespective of presence of fever; AND~* If no clinical of microbiological infection is documented."
62718847|NCT05926063|ACTIVE_COMPARATOR|Extended treatment group|"Empirical broad-spectrum antibiotics (EBAT) as per local protocol:~* Meropenem 3 x 1(/2) g IV; OR~* Piperacilline-Tazobactam 4 x 4 g IV; OR~* Cefepime 3 x 2 g IV; OR~* Ceftazidim 3 x 2 g IV~Extended treatment arm: EBAT will be continued:~* At least 5x24 hours;~* Until afebrile (TMT\<38.0°C) for at least 5 consecutive days; OR~* Until resolution of neutropenia (ANC \>0,5 x109/L); OR~* Until they have been treated 10 days, whatever comes first."
62718848|NCT05572879|EXPERIMENTAL|Test group(EuCorVac-19) - Cohort A|Cohort A - Immunogenicity cohort
62718849|NCT05572879|ACTIVE_COMPARATOR|Comparator group(ChAdOx1) - Cohort A|Cohort A - Immunogenicity cohort
62718850|NCT05572879|EXPERIMENTAL|Test group(EuCorVac-19) - Cohort B|Cohort B - Safety cohort
62718851|NCT05572879|ACTIVE_COMPARATOR|Comparator group(ChAdOx1) - Cohort B|Cohort B - Safety cohort
62718852|NCT00186628|EXPERIMENTAL|Prophylactic Rituximab|Rituximab will be infused after a non-myeloablative transplantation regimen of total lymphoid irradiation (TLI) + anti-thymoglobulin (ATG), with the intention of reducing chronic graft-vs-host disease (cGvHD)
62718853|NCT03905915|OTHER|Preoperative virtual reality session|Amsterdam Anxiety score recorded before VR session is followed by a 15 min VR session and finally Amsterdam Anxiety score is recorded after VR session
62718854|NCT05431647|ACTIVE_COMPARATOR|İntervention group: Physiotherapy and Sensory Integration Therapy|"Physiotherapy program~8 weeks 2 days in a week 45 minutes per session Conventional physiotherapy~Sensory integration therapy program~8 weeks 2 days in a week 45 minutes per session Sensory integration therapy"
62718855|NCT05431647|ACTIVE_COMPARATOR|Control group only Physiotherapy|"Physiotherapy program~8 weeks 2 days in a week 45 minutes per session Conventional physiotherapy"
62718856|NCT02350218|EXPERIMENTAL|Eglandin 720㎍|Eglandin® (Alprostadil) 720㎍
62718857|NCT02350218|ACTIVE_COMPARATOR|Eglandin 360㎍|Eglandin® (Alprostadil) 360㎍
62718858|NCT02062736||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
62718859|NCT06488924|EXPERIMENTAL|JR-446|
62718860|NCT06565468|EXPERIMENTAL|Cold water immersion phase.|
62718861|NCT06565468|NO_INTERVENTION|Control phase.|
62718862|NCT02097784|OTHER|cirrhosis with portal hypertension,ascite and acute kidney|
62718863|NCT01453166|EXPERIMENTAL|Group 1|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
62718864|NCT01453166|EXPERIMENTAL|Group 2|Group B received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
62718865|NCT01453166|EXPERIMENTAL|Group 3|Group C received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
62718866|NCT03693495|EXPERIMENTAL|ellume·lab Group A Streptococcus Test|"ellume·lab Group A Streptococcus Test~Pharyngeal samples from participants will be tested with:~ellume.lab Group A Streptococcus Test; Polymerase Chain Reaction (PCR) and bacterial culture."
62718867|NCT04087356||RMD+ Patients|Age-related macular degeneration patients with reticular macular disease
62718868|NCT04087356||RMD- Patients|Age-related macular degeneration patients without reticular macular disease
62718869|NCT04321616|ACTIVE_COMPARATOR|Hydroxychloroquine|
62718870|NCT04321616|ACTIVE_COMPARATOR|Remdesivir|
62718871|NCT04321616|ACTIVE_COMPARATOR|Control group - SoC|
62718872|NCT03826043|EXPERIMENTAL|Experimental arm|Hospitalized patient
62718873|NCT03965403|EXPERIMENTAL|Arm motor function retraining with BURT|All participants will receive 1 hour sessions, 2-3x/week for 6 weeks (total 18 sessions). Sessions will be organized with 30 minutes of robotic-assisted training and 30 minutes of hands-on training with a research therapist to work on the baseline goals of the subject. Hands-on training will be done with routinely employed techniques in therapy to transfer the skills gained with the robotic device in everyday life activities.
62718874|NCT04461496|ACTIVE_COMPARATOR|Hybrid revascularization|50 hybrid procedure
62718875|NCT04461496|EXPERIMENTAL|Full metall jacket|50 total endovascular interventions
62718876|NCT03250143|ACTIVE_COMPARATOR|group A|Oral cyclosporine 3mg/kg/day (200mg/day) will be started.If there is no improvement in 1 week then escalating the dose maximum upto 5mg/kg/day.
61976565|NCT03886012|EXPERIMENTAL|Otoband efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to the effective power level. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
62718877|NCT03250143|ACTIVE_COMPARATOR|group B|Oral azathioprine will be started at 1mg/kg/day.If there is no improvement in 1 week then escalating the dose maximum upto 100mg/day
62718878|NCT02234726|EXPERIMENTAL|Early Childhood Development Program|"Treatment clusters will be assigned a trained Child Development Agent (CDA) who will have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases including malaria, diarrhea, and pneumonia and referral for diagnosis and treatment; and 4) organization and mentoring of biweekly caregiver meetings to discuss parenting and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
62165069|NCT04826393|EXPERIMENTAL|ASP8374 and Cemiplimab-Cohort 2|"Upon determination of the MTD/RP2D of ASP8374 plus cemiplimab in Cohort 1, a dose expansion will be performed in which eligible participants who are candidates for surgical resection will enroll to Cohort 2 and will be randomized into one of two treatment groups (2A-2B).~Group 2A: IV ASP8374 plus cemiplimab within 14± 5 days prior to surgery at the MTD/RP2D established in Cohort 1.~Group 2B: No immune checkpoint therapy prior to surgery.~Post-operatively, all Cohort 2 participants will receive ASP8374 plus cemiplimab every 3 weeks administered at the MTD/RP2D established by Cohort 1"
62165070|NCT04782596|EXPERIMENTAL|One-centimeter resection|In the study subjects enrolled into this study arm, one-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
62165071|NCT04782596|EXPERIMENTAL|Two-centimeter resection|In the study subjects enrolled into this study arm, two-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
62544680|NCT04223375|EXPERIMENTAL|Nutrition Group|"After the health status of the mothers in the experimental group was stabilized, approximately 20-30 minutes of nutritional education was given at the first interview before the hospital discharge. After nutrition education, motivational messages were sent to women's phones once a week. In addition, mothers were given nutritional counseling during their home visits during the 1st and 3rd months, and their questions and problems regarding nutrition were evaluated. The mother was supported where she needed it.~In nutritional education, information was given such as adequate and balanced nutrition in the postpartum period, adequate fluid intake, consumption and importance of prebiotic and probiotic foods, the importance of healthy microbiota for infant health and the amount of nutrients equivalent to one serving. In addition, the handbook which contains the educational content is given to the mothers to facilitate the recall."
62544681|NCT04223375|NO_INTERVENTION|Control Group|No intervention was made to the control group.
62544682|NCT05300828||Genexol PM|Genexol PM/carboplatin combination treatment is performed as an adjuvant treatment after cytoreductive surgery for newly diagnosed ovarian cancer.
62544683|NCT00717379|ACTIVE_COMPARATOR|1|steroid regimen 1
62165072|NCT04984980|EXPERIMENTAL|combined treatment group|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab Gemcitabine: 1000mg/m\^2, iv, d1, d8, q3w Oxaliplatin: 100mg/m\^2, iv, d1, q3w Sintilimab: 200mg, iv, d1, q3w Bevacizumab: 5mg/kg, d1, q3w
62165073|NCT04029727|EXPERIMENTAL|Combination of Plant Extracts (BSL_EP025)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP025)
62165074|NCT04029727|PLACEBO_COMPARATOR|Placebo|The volunteers will take two capsules daily with maltodextrin.
62544684|NCT00717379|EXPERIMENTAL|2|steroid regimen 2
62544685|NCT04391504|EXPERIMENTAL|transesophageal echocardiography guidance|
62544686|NCT04391504|EXPERIMENTAL|intracardiac echocardiography guidance|
62544687|NCT03308812|ACTIVE_COMPARATOR|Health360x|Participants will use the Health360x application for 6 months.
62544688|NCT03308812|EXPERIMENTAL|Health360x plus health coach|Participants will use the Health360x application and received personalized health coaching for 6 months.
62544689|NCT05835908||Patient who contacted the Emergency Call Center and were referred to an Unscheduled Care Center|
62718879|NCT02234726|NO_INTERVENTION|Control|Children residing in comparison health zones will only receive baseline and end line evaluations of their health and developmental status. There will be no active intervention in the comparison areas during the course of the study.
62735914|NCT01713582|EXPERIMENTAL|OHM 40 mg BID 21-21|Participants received 40 mg birabresib/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
62165075|NCT00442026|EXPERIMENTAL|1|DG
62165076|NCT00442026|EXPERIMENTAL|2|G
62165077|NCT01257698|ACTIVE_COMPARATOR|Dorzolamide-timolol topical drops|
62544690|NCT01331629|EXPERIMENTAL|ART-THERAPIE|supported in art therapy with other supportive care available in the facility
62544691|NCT01331629|NO_INTERVENTION|standard group|standard care (supportive care available in each facility)
62544692|NCT04400422|EXPERIMENTAL|Lipano MCT formula|Kanso Lipano will be consumed daily for 3 months each to assess tolerability and compliance
62544693|NCT01123915|EXPERIMENTAL|Opal-HIV-Gag(c)|Opal-HIV-Gag(c) administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
62544694|NCT01123915|PLACEBO_COMPARATOR|Diluent|Administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
62544695|NCT05705076|PLACEBO_COMPARATOR|Placebo without anticoagulation|Without any anticoagulation
62544696|NCT05705076|ACTIVE_COMPARATOR|Low Dose Direct Oral Anticoagulation|Apixaban 2.5 mg twice Rivaroxaban 10 mg plus placebo
62544697|NCT04554446|EXPERIMENTAL|T-MSAT(Motion style acupuncture treatment using Traction)|T-MSAT group receives 3 sessions of T-MSAT; on 2nd, 3rd, 4th day after hospitalization. A trained doctor of Korean medicine with clinical experience conducted the T-MSAT. And T-MSAT group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
62544698|NCT04554446|ACTIVE_COMPARATOR|Korean medicine treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
62544699|NCT05602883|EXPERIMENTAL|Experimental group|Experimental: Experimental group Pregnant women in this group will listen to a music of their choice for 30 minutes before going to bed at night.
62544700|NCT05602883|NO_INTERVENTION|Control group|Women in the control group will not be interfered with and will be followed in line with the routine follow-up protocol of the clinic.
62718880|NCT02370472|NO_INTERVENTION|control group|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes proficiency noted final evaluation
62544701|NCT01509768||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIB to identify endpoints that may be used for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures
62544702|NCT00641615|EXPERIMENTAL|Phase 1|
62544703|NCT01686230|EXPERIMENTAL|acupoints on specific meridian|Acupuncture plus foundation treatment。 We Select specific acpupoints on the heart and pericardium meridian.
62544704|NCT01686230|ACTIVE_COMPARATOR|acupoints on the other meridian|Acupuncture plus foundation treatment。We choose the acupoints on the other meridian。
62544705|NCT01686230|SHAM_COMPARATOR|sham acupoints|Acupuncture plus foundation treatment。We use sham acupoints。
62544706|NCT01686230|OTHER|waiting-list|wait for the treatment，Only basic treatment, We will not treat the participants until they complete all the observations.
62544707|NCT02871544|SHAM_COMPARATOR|Low BNP and Low NGAL Group|BNP≤100pg/ml and NGAL≤153pg/ml
62544708|NCT02871544|ACTIVE_COMPARATOR|High BNP and Low NGAL Group|BNP\>100pg/ml and NGAL≤153pg/ml
62544709|NCT02871544|ACTIVE_COMPARATOR|Low BNP and High NGAL Group|BNP≤100pg/ml and NGAL\>153pg/ml
62544710|NCT02871544|ACTIVE_COMPARATOR|High BNP and High NGAL Group|BNP\>100pg/ml and NGAL\>153pg/ml
62544711|NCT05972148|ACTIVE_COMPARATOR|Intraoral Scanning|
62544712|NCT05972148|EXPERIMENTAL|Photogrammetry Scanning|
62544713|NCT03161340|EXPERIMENTAL|Treatment group|Rapamycin group
62544714|NCT03161340|NO_INTERVENTION|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
62544715|NCT04206969|EXPERIMENTAL|Transcultural psychotherapy|In addition to usual care, the participants in the treatment group receive transcultural psychotherapy in the inclusion centers, which consists of 5 sessions every 7 weeks (W6, W13, W20, W27, and W34). During all the research process, participants from both groups continue their usual care provided by the referent medical team outside the inclusion center.
62544716|NCT04206969|NO_INTERVENTION|standard care|usual care provided by the referent medical team
62544717|NCT03775044|EXPERIMENTAL|Experimental: Medherent Device|All participants get the Medherent device. There is only one arm to this study.
62544718|NCT02890784|ACTIVE_COMPARATOR|A. Standard arm|100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)
62544719|NCT02890784|EXPERIMENTAL|B. Study arm|100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)
62718881|NCT02370472|EXPERIMENTAL|Experimental|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes - subjects will use tool developed using cameras and a computer to visualize hand and needle movements as well as the position of the transducers along with the image from the ultrasound on a computer screen proficiency belief noted final evaluation
62718882|NCT01482858|EXPERIMENTAL|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
62165078|NCT01257698|NO_INTERVENTION|Standard of care|
62544720|NCT00855907||cases|IBD patients above the age of 18 years old, suffering from the disease for at least one year.
62544721|NCT03041428|EXPERIMENTAL|Recruited patients|Ultraprotective ventilation
62544722|NCT02685683|EXPERIMENTAL|GED-0301 Induction (160mg) followed by intermittent 160 mg|"GED-0301 160 mg by mouth (PO) daily (QD) for 12 weeks, followed by alternating GED 0301 160 mg QD for 4 weeks and no IP for 4 week, up to Week 100"
62544723|NCT03022097|EXPERIMENTAL|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
62544724|NCT03022097|EXPERIMENTAL|Experimental 2|Aclidinium bromide 400 μg
62544725|NCT03022097|ACTIVE_COMPARATOR|Comparator|Formoterol fumarate 12 μg
62544726|NCT03022097|PLACEBO_COMPARATOR|Placebo|Placebo
62544727|NCT04170010||Conservatively managed group|Individuals with conservatively managed obesity
62718883|NCT01482858|PLACEBO_COMPARATOR|Placebo|Gelatin capsules, each containing 500 mg \[comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose\] for oral use as placebo
62735915|NCT01713582|EXPERIMENTAL|OHM 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
62735916|NCT01713582|EXPERIMENTAL|OHM 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62735917|NCT01713582|EXPERIMENTAL|OHM 120 mg QD 5-7|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.
62544728|NCT04170010||Surgically managed group|Individuals with a past history of bariatric surgery (Roux-en-Y gastric bypass/Sleeve gastrectomy) for the management of obesity
62544729|NCT03044626|EXPERIMENTAL|study group A|"Patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
62544730|NCT03044626|OTHER|study group B|"Patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w)."
62544731|NCT03931109||PHPT w/ Osteoporosis|Primary hyperparathyroidism patients with osteoporosis undergoing parathyroidectomy
62544732|NCT03931109||PHPT w/o Osteoporosis|Primary hyperparathyroidism patients without osteoporosis undergoing parathyroidectomy
62544733|NCT03931109||Thyroid w/ Osteoporosis|Thyroid disease patients with osteoporosis undergoing thyroidectomy
62544734|NCT01853332||Cross-Sectional|New participant: The purpose of the study is to learn about physical health in midlife and how it has been influenced by experiences and relationships. The study specifically targets health differences and the development of heart disease and diabetes.
62544735|NCT01853332||Longitudinal|Former participants (or the partner of a former participant) of the Adolescent and Family Development Project, Young Adult Development Project, Across Generations Project, and/or Paths Over Time Project may already know that this research shows how people grow, individually and as part of a familial and social network, throughout the course of life. This study focuses on learning about former participants' physical health in midlife and how it has been influenced by their experiences and relationships.
62544736|NCT06226181|ACTIVE_COMPARATOR|Conventional dacryocystorhinostomy|Patients undergoing conventional dacryocystorhinostomy using external approach.
62544737|NCT06226181|EXPERIMENTAL|Dacryocystorhinostomy using amniotic membrane|Patients undergoing conventional dacryocystorhinostomy using external approach and adding amniotic membrane over the osteotomy, fixed with sutures.
62544738|NCT03277924|EXPERIMENTAL|Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS|"Stage 1:~IP d1-14 sunitinib 37.5mg/d then MP sunitinib 37.5mg/d+nivolumab 3mg/kg ev 2w.~Stage 2:~C1-6: IP d1-14 sunitinib 37.5mg/d then MP sunitinib 25mg/d+nivolumab 240mg ev 2w. C7a level 0: Epirubicin 60mg/m2/d, d1,2, ifosfamide 3g/m2/d d1-3 and nivolumab 360mg. 3 or more DLTs level -1 same treatment than in level 0, but nivolumab 240mg. C7b level 0: Doxorubicin 75mg/m2/d, d1, dacarbazine 400mg/m2/d (also on d2) and nivolumab 360mg. 3 or more DLTs level -1 same tratment than in level 0, but nivolumab 240mg. GCSF support is mandatory. 1-year maintenance of nivolumab. C8 level 0: In the IP, CDDP 120mg/m2 (d1-2), doxorubicin 75mg/m2 in (d3-4 and d36-39), nivolumab 240mg (d5), and on d18,39,53 and methotrexate 12g/m2 on d22,29,57,64, surgery and MP with nivolumab on d210, every 2 weeks up to d364. 3 or more DLTs level -1, with nivolumab 360mg on d4,36, surgery and MP with nivolumab on d210, ev 3 weeks up to d364."
62544739|NCT02964572|ACTIVE_COMPARATOR|Glimepiride|Glimepiride (anti-diabetic drug) as a comparison group
62544740|NCT02964572|EXPERIMENTAL|Empagliflozin|Empagliflozin (anti-diabetic drug) as a study group
62544741|NCT02473198|ACTIVE_COMPARATOR|Femoral Nerve Block (Group 1)|"In group1 (standard group) all patients receive the standard current perioperative pain management protocol for TKR.~The patient will then undergo an ultrasound guided femoral nerve block with bupivacaine 0.25% 20 cc. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint. Postoperatively patients will receive narcotic pain medication on a PRN basis."
62165079|NCT03508882|ACTIVE_COMPARATOR|Preseptal-pretarsal|The Preseptal-pretarsal group will receive injections of Botulinum Toxin Type A 100Unit/Vial (Product) in the preseptal site (Injection pattern A) and Saline Solution for Injection (placebo control) in the pretarsal site for 2 cycles at 3 months apart. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
62544742|NCT02473198|EXPERIMENTAL|Exparel (Group 2)|Group 2 will receive standard perioperative pain management for TKR; will undergo placebo femoral nerve block under ultrasound guidance with normal saline (NS) 20 cc. Following femoral bone cuts they will receive local anesthetic injection mixture of 30cc 0.25% bupivicaine with epinephrine 20 cc of preservative free normal saline, 30mg of toradol and 10 mg of morphine sulfate into the periarticular tissues including periosteum, joint capsule and posterior capsule of the knee joint and collateral ligaments and subcutaneous tissues. Prior to cementing prosthesis, a second injection with mixture of 20mL 1.3% Exparel and 40mL normal saline solution will be injected into the same tissues, joint capsules and collateral ligaments.
62544743|NCT04598386|EXPERIMENTAL|PR Lotion Topical Solution|Approximately 50 grams of PR Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. This lotion will be applied once during the 4th of session of their PR Lotion Phase and will remain on the skin for approximately 4.5 hours.
62544744|NCT04598386|PLACEBO_COMPARATOR|Placebo Lotion Topical Solution|Approximately 50 grams of the Placebo Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. The only difference in ingredients for this Placebo Lotion will be the exclusion of the sodium bicarbonate ingredient. This lotion will be applied once during the 4th of session of their Placebo Lotion Phase and will remain on the skin for approximately 4.5 hours.
62544745|NCT03151304|EXPERIMENTAL|Stage 1a and 1b open-label pracinostat plus azacitidine|"open-label single arm pracinostat plus azacitidine. Pracinostat: 45 mg administered orally 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.~In later cycles (i.e., after Cycle 4), pracinostat dose reduction to 45 mg orally 3 days each week × 2 weeks (instead of 3 weeks) or dose interruption is allowed to manage toxicity such as fatigue, gastrointestinal toxicity, or myelosuppression.~Azacitidine: 75 mg/m2 for 7 days of each 28-day cycle. Administration will occur by subcutaneous (SC) injection, or IV infusion if SC injections are not tolerated, on one of two schedules:~* Schedule 1 - daily therapy on Days 1 through 7~* Schedule 2 - 5-2-2 schedule in which subjects receive azacitidine for 5 consecutive days (Days 1 through 5) with rest on Days 6 and 7, and resume azacitidine dosing the first two days of the next week (Days 8 and 9) of each 28-day cycle"
62544746|NCT02257697|EXPERIMENTAL|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
62544747|NCT02257697|ACTIVE_COMPARATOR|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
62544748|NCT00898287|EXPERIMENTAL|P276-00 plus Gemcitabine|"Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/m2/day x 5 q 3 weeks Level 2 - 140 mg/m2/day x 5 q 3 weeks Level 3 - 185 mg/m2/day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.~Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity."
62735918|NCT01713582|EXPERIMENTAL|OHM 120 mg QD 7-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle
62735919|NCT01713582|EXPERIMENTAL|OHM/DLBCL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
62718884|NCT04034992||Retrospective CKD cohort|Retrospective (secondary) data refers to patient data extracted from existing electronic health records (EHRs)/registries/databases. It represents existing real-world data, regardless of reason for collection or location of storage and is analogous to those represented in the study protocol for which feasibility assessments are conducted. Retrospective data will be collected from registries, databases, and EHRs. The aim is to identify and extract clinical data retrospectively from a minimum of 100000 (no set maximum) CKD patients via existing databases/registries/EHRs across geographies. The retrospective data will be captured beginning 1 January 2008 through the most currently available data.
62718885|NCT04034992||Prospective CKD cohort|Prospective (primary and secondary) data refers to manual collection/extraction of data in a de novo manner for the purpose of addressing study objectives. Collection/extraction of patient data in the prospective cohort will be done via electronic case report form, questionnaires, and mobile phone/tablet application. The initial aim is to identify and collect/extract data from approximately 1000 (no set maximum) enrolled CKD patients until the decision to stop the study is taken, with the possibility of prospective follow-up for a minimum of approximately 1 year up to a maximum of approximately 3 years. The patient specific data in the prospective cohort will be collected by utilizing Rapid Assessment of Physical Activity (RAPA) questionnaire, Work Productivity and Activity Impairment (WPAI) questionnaire, Short Form (SF)-36 questionnaires, simple food diary, and other patient reported outcomes - including a set of questions to collect patient symptoms.
62165080|NCT03508882|ACTIVE_COMPARATOR|Pretarsal-preseptal|The Pretarsal-preseptal group will initially receive injections Botulinum Toxin Type A 100Unit/Vial (Product) in the reverse with the intervention at the pretarsal site (Injection pattern B) for 2 cycles at 3 months apart. Groups 1 and 2 will crossover and receive the alternative intervention. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
62165081|NCT01543009|NO_INTERVENTION|Emla + no additional intervention|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) without warming
62165082|NCT01543009|EXPERIMENTAL|Emla + Local Warming|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) plus warming with a heating pad at 40°C for 5 minutes
62544749|NCT02740114|ACTIVE_COMPARATOR|Bupivacaine Group|"Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
62544750|NCT02740114|EXPERIMENTAL|Liposomal Bupivacaine + Bupivacaine Group|"Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
62544751|NCT01619566|NO_INTERVENTION|Control|Control subjects undergo a skin biopsy.
62544752|NCT01619566|EXPERIMENTAL|Treatment|Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
62544753|NCT02797197|EXPERIMENTAL|patient undergoing to chemotherapy during 6 months|
62544754|NCT05446259||DCM group|Subjects diagnosed with degenerative cervical myelopathy.
62544755|NCT05446259||Control group|Subjects diagnosed with cervical spinal disease without myelopathic symptoms.
62544756|NCT05188677|EXPERIMENTAL|Group 1a (primary series: Comirnaty)|participants will receive one dose of SCB-2019 vaccine on Day 1
62544757|NCT05188677|ACTIVE_COMPARATOR|Group 1b (primary series: Comirnaty)|participants will receive one dose of Comirnaty vaccine on Day 1
62544758|NCT05188677|EXPERIMENTAL|Group 2a (primary series: Vaxzevria)|participants will receive one dose of SCB-2019 vaccine on Day 1
62544759|NCT05188677|ACTIVE_COMPARATOR|Group 2b (primary series: Vaxzevria)|participants will receive one dose of Vaxzevria vaccine on Day 1
62544760|NCT05188677|EXPERIMENTAL|Group 3a (primary series: CoronaVac)|participants will receive one dose of SCB-2019 vaccine on Day 1
62544761|NCT05188677|ACTIVE_COMPARATOR|Group 3b (primary series: CoronaVac)|participants will receive one dose of CoronaVac vaccine on Day 1
62544762|NCT05188677|EXPERIMENTAL|Group 4a (primary series and booster dose CoronaVac)|participants will receive one dose of SCB-2019 vaccine on Day 1
62544763|NCT05188677|ACTIVE_COMPARATOR|Group 4b (primary series and booster dose CoronaVac)|participants will receive one dose of CoronaVac on Day 1;
62544764|NCT05188677|EXPERIMENTAL|Group 4c (primary series and booster dose CoronaVac)|participants will receive a half dose of SCB-2019 vaccine on Day 1
62544765|NCT05188677|EXPERIMENTAL|Group 5a (primary series: CoronaVac)|participants will receive a dose of 2-vial presentation of SCB-2019 vaccine
62544766|NCT05188677|EXPERIMENTAL|Group 5b (primary series: CoronaVac)|participants will receive a dose of 3-vial presentation of SCB-2019 vaccine
62544767|NCT05706883||Experimental group|Patients with advanced lung cancer featuring cervical and/or supraclavicular lymph node metastasis
62544768|NCT05706883||Control group|Patients with advanced lung cancer NOT featuring cervical and/or supraclavicular lymph node metastasis
62544769|NCT04624477||Active Surveillance|Patients under active surveillance choose to not have immediate thyroid surgery. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if received). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
62718886|NCT03707886|EXPERIMENTAL|Pain SMART (Intervention Arm)|The Intervention Arm will be invited to participate in a one-time group intervention, Pain SMART
62718887|NCT03707886|PLACEBO_COMPARATOR|Minimally Enhanced Usual Care|The Minimally Enhanced Usual Care group will receive educational information via mail.
62718888|NCT05415488|ACTIVE_COMPARATOR|IBS dietary advice according to the NICE guidelines|The traditional dietary advice according to the NICE guidelines and the systematic reviews performed by the British dietetic association (BDA) include having regular meals and to take time to eat, not to skip meals or eat too much at ones. The diet also limits intake of known trigger foods, such as coffee, alcohol, fizzy drinks, spicy foods, fatty foods etc. People who experience loose stools are recommended to avoid sweeteners (-ol), and people with wind/bloating are recommended to eat soluble fibers such as oats and flaxseeds.
62165083|NCT02305667|PLACEBO_COMPARATOR|Macintosh|Double lumen tube intubation using Macintosh laryngoscope
62718889|NCT05415488|SHAM_COMPARATOR|A healthy diet according to the Swedish dietary guidelines|This diet includes eating 500 grams of vegetables and fruits/day, fish approximately 3 times/week, 70 grams of wholegrain/day and to limit intake of red meat.
62718890|NCT05981326|EXPERIMENTAL|cohort: triple negative breast cancer|"Standard drug: Neoadjuvant treatment : Weekly paclitaxel + carboplatin + pembrolizumab (TCP) followed by EC90 \*4 pembrolizumab~Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite"
62718891|NCT05981326|EXPERIMENTAL|cohort: HER2+ breast cancer|"Standard drug:~EC100 followed by docetaxel + trastuzumab or EC100 followed by paclitaxel + trastuzumab Docetaxel + carboplatin + trastuzumab \*6 folowed by trastuzumab alone~Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite"
62718892|NCT05981326|EXPERIMENTAL|cohort: ER/PR+ /HER2- breast cancer|"Standard drug: EC100 paclitaxel or EC100 docetaxel~Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite"
62718893|NCT05081362|OTHER|COVID-severe|patient recovered from severe COVID desease
62718894|NCT05081362|OTHER|COVID-moderate|patient recovered from moderate COVID desease
62718895|NCT05081362|OTHER|COVID-mild|patient recovered from mild COVID desease
62718896|NCT04960124|EXPERIMENTAL|Part 1: Cohort 1 (JNJ-42847922)|Participants with normal hepatic function will receive Dose 1 of JNJ-42847922 on Day 1.
62718897|NCT04960124|EXPERIMENTAL|Part 1: Cohort 2 (JNJ-42847922)|Participants with mild hepatic impairment will receive Dose 1 of JNJ-42847922 on Day 1.
62718898|NCT04960124|EXPERIMENTAL|Part 1: Cohort 3 (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 2 of JNJ-42847922 on Day 1.
62718899|NCT04960124|EXPERIMENTAL|Part 2: Cohort 4 (Optional) (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 1 (depending on the results of Cohort 3) of JNJ-42847922 on Day 1.
62718900|NCT04960124|EXPERIMENTAL|Part 2: Cohort 5 (Optional) (JNJ-42847922)|Participants with severe hepatic impairment will receive Dose 2 or Dose 3 (depending on the results of Part 1) of JNJ-42847922 on Day 1.
62718901|NCT05211180|ACTIVE_COMPARATOR|Vida Sana|Vida Sana is a cultural-adaption of Group Lifestyle Balance, a 12-month intervention that targets at least 5% weight loss and at least150 minutes per week of moderate-to-vigorous physical activity. Health coaches will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
62718902|NCT05211180|EXPERIMENTAL|Vida Sana y Completa|Vida Sana y Completa is an obesity intervention with integrated treatment for food insecurity. This arm includes all the activities described for the active comparator arm (Vida Sana) as well as a weekly food box delivery for the first 12 weeks of the intervention. The food box will contain approximately 40 pounds of food including proteins and dairy, whole grains, and produce. Just like the Vida Sana active comparator arm, the Vida Sana y Completa group will include health coaches who will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
62718903|NCT05253404|NO_INTERVENTION|Anesthesia remove endotracheal tube|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at MAC 2-3%, at the same time we perform suction secretions in endotracheal tube and oral cavity and give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
62718904|NCT05253404|EXPERIMENTAL|Switching endotracheal tube to laryngeal mask|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at 2.63%-2.97%, we perform suction secretions in endotracheal tube and oral cavity, then switching endotracheal tube to laryngeal mask. Then we discontinue inhalation anesthestic sevoflurane and support oxygen at the rate of 6L/min. At the same time, give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when sevofulrane at MAC 0.4, spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
62718905|NCT02710188|EXPERIMENTAL|HTL0009936 modified release (MR) Formulation|Intervention: 5 different modified release formulations of HTL0009936, as a single dose
62718906|NCT02710188|ACTIVE_COMPARATOR|HTL00009936 immediate release (IR) fasted|Intervention: 1 immediate release formulation of HTL0009936, as a single dose in the fasted state
62718907|NCT01060787||Fluocinolone Acetonide 0.59 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 0.59 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
62165084|NCT02305667|ACTIVE_COMPARATOR|Glidescope®|Double lumen tube intubation using Glidescope® videolaryngoscope
62165085|NCT02305667|ACTIVE_COMPARATOR|Airtraq®|Double lumen tube intubation using Airtraq® videolaryngoscope
62165086|NCT02305667|ACTIVE_COMPARATOR|King Vision™|Double lumen tube intubation using King Vision™ videolaryngoscope
62718908|NCT01060787||Fluocinolone Acetonide 2.1 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 2.1 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
62718909|NCT04096417|EXPERIMENTAL|Treatment (pemigatinib)|Patients receive pemigatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
62718910|NCT01576783|EXPERIMENTAL|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
62718911|NCT01576783|PLACEBO_COMPARATOR|Placebo|Corn oil supplement
62165087|NCT00860522|EXPERIMENTAL|Phase I|Three patients will be enrolled at dose Level 1. If the patient does not completed the three infusion of JVRS-100 during cycle 1 for reason other than toxicity, another patient will be accrued at the same dose level.
62165088|NCT00860522|EXPERIMENTAL|Phase II|3 patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity, an additional 3 patients will be enrolled at the given dose level. If the 1st 2 subjects enrolled and treated at a given dose experience dose limiting toxicities, no additional subjects will be enrolled at that dose. Dose escalation may proceed if \< 2/6 patients at a given dose level experience a LDT. If ≥ 2/6 patients experience a DLT at a given dose level, the next lower dose level will be considered the RP2D. If a patient does not complete the 3 infusions of JVRS-100 during Cycle 1 for reasons other than toxicity, another patient will be accrued at the same dose level. Once the RP2D is established, the cohort will be expanded to a total of 12 patients.
62718912|NCT04709510|OTHER|AllPatients|There is only one cohort in this study. They all received the same follow up and ultrasound protocol.
62718913|NCT02249403|EXPERIMENTAL|Talsaclidine, 6 mg tid|
62165089|NCT01396122|EXPERIMENTAL|PROSIMA group|Reconstructive surgeries with GYNECARE PROSIMA\* were performed in all patients.
62544770|NCT04624477||Immediate Thyroid Surgery (total or partial thyroidectomy)|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
62544771|NCT01898273|EXPERIMENTAL|Single|I-124-CLR1404, open-label
62544772|NCT00796107|EXPERIMENTAL|R1507 in Combination With Letrozole|Participants received a full daily dose of 2.5 mg of orally administered Letrozole along with 16 mg/kg of intravenous R1507 administered q3w, and observed for dose limiting toxicity for the first 2 cycles of treatment.
62544773|NCT01842997|EXPERIMENTAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
62544774|NCT04109729|EXPERIMENTAL|Treatment: all patients|
62544775|NCT03649347|EXPERIMENTAL|AR Therapy Intervention for Spider Phobia|AR Therapy Intervention participants first complete a behavioral approach test (BAT). They approach a live spider to get as close as they comfortably can. This BAT provides a baseline measure of the degree of fear of spiders; the BAT is not a form of exposure therapy. Participants then complete exposure therapy using an augmented reality (AR) headset. A therapist controls the AR paradigm, placing virtual spiders in a participant's real environment as a method of exposure therapy. Once a participant's anxiety is reduced to low, stable levels (as measured by the participant's subjective units of distress assessed at intervals during session), the participant then completes a second BAT to measure their degree of fear immediately following AR therapy. The difference between the first and second BAT are used to assess the efficacy of the AR exposure therapy treatment. One month later, the AR Therapy Intervention participants complete a third BAT to assess for treatment efficacy over time.
62544776|NCT03649347|NO_INTERVENTION|No Treatment Control Group for Spider Phobia|The No Treatment Control group participants do not receive any AR exposure therapy for the duration of the study. These participants complete a behavioral approach test (BAT) at their first study visit, during which they approach a live spider as close as they comfortably can. This BAT provides a baseline measure of the degree of fear of spiders; the BAT is not a form of exposure therapy. One month later, the No Treatment Control group participants return for a second BAT to assess the degree to which their fear has changed as a function of time, in the context of NOT receiving any exposure therapy. After completion of the second BAT at this one-month follow-up visit, these participants are offered the opportunity for some form of exposure therapy following the conclusion of the study.
62544777|NCT03649347|EXPERIMENTAL|AR Therapy Intervention for Snake Phobia|Augmented reality (AR) exposure therapy involves placing virtual objects in the participant's real environment as a method of exposure therapy. The AR therapy intervention group will complete an exposure therapy session using an augmented reality headset. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The exposure therapy session will be as long as needed to reduce anxiety to low and stable levels, as measured by the participant's subjective units of distress.
62544778|NCT03649347|NO_INTERVENTION|No Treatment Control Group for Snake Phobia|This will be a waitlist control group that will receive no treatment for the duration of the study, however they will be offered the opportunity for some form of exposure therapy following the conclusion of the study (1 month).
62544779|NCT00959218|EXPERIMENTAL|Dronabinol|
62544780|NCT00959218|PLACEBO_COMPARATOR|Placebo|
62544781|NCT01669603|EXPERIMENTAL|Bifidobacterium animalis lactis Bl-04|Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
62544782|NCT01669603|PLACEBO_COMPARATOR|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
62544783|NCT02885766|EXPERIMENTAL|PF-114|"PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied.~When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor.~Orally, once daily"
62544784|NCT00791895|EXPERIMENTAL|A|
62544785|NCT04277962|EXPERIMENTAL|Patients having vaginal delivery|EBL will be estimated visually vs quantitatively at time of vaginal delivery.
62544786|NCT06235827|EXPERIMENTAL|Green tea group|Patients in Group A will have to consume two cup (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes.
62544787|NCT06235827|EXPERIMENTAL|Control Group|Patients in Group B will not consume green tea for 6 months during study period.
62718914|NCT02249403|EXPERIMENTAL|Talsaclidine, 12 mg tid|
62718915|NCT02249403|EXPERIMENTAL|Talsaclidine, 24 mg tid|
62718916|NCT02249403|EXPERIMENTAL|Talsaclidine, 36 mg tid|
62718917|NCT02249403|EXPERIMENTAL|Talsaclidine, 36 mg bid|
62165090|NCT05279417|EXPERIMENTAL|ATI-450 20 mg BID plus Methotrexate|ATI-450 20 mg oral tablet twice daily (BID) with a stable weekly dose of methotrexate for 12 weeks
62165091|NCT05279417|EXPERIMENTAL|ATI-450 50 mg BID plus Methotrexate|ATI-450 50 mg oral tablet BID with a stable weekly dose of methotrexate for 12 weeks
62165092|NCT05279417|PLACEBO_COMPARATOR|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of methotrexate for 12 weeks
62544788|NCT01121562|EXPERIMENTAL|Sunitinib arm|
62544789|NCT02303821|EXPERIMENTAL|Phase 1b: Dose Escalation 1|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine.~Subjects will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle.~Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
62544790|NCT02303821|EXPERIMENTAL|Phase 1b: Dose Escalation 2|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy and then have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
62544791|NCT02303821|EXPERIMENTAL|Phase 2: Aged ≥ 12 months at screening|"All subjects aged ≥ 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 4 week cycle of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine) if subjects showed no disease progression at the end of the Induction Cycle."
62544792|NCT02303821|EXPERIMENTAL|Phase 2: Aged < 12 months at screening|"All subjects aged \< 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a modified 5 week cycle (based on Interfant-06) of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 5 week cycle (modified based on Interfant-06) of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if subjects showed no disease progression at the end of the Induction Cycle."
62544793|NCT05985135|EXPERIMENTAL|Type 1 Diabetes Mellitus (T1DM) Insulin Deprived|Subjects will have their insulin infusions replaced with saline and have blood draws to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
62544794|NCT05985135|EXPERIMENTAL|Type 1 Diabetes Mellitus (T1DM) Insulin Treated|Subjects will continue their baseline insulin infusion while maintaining a target blood glucose range. Blood draws will be obtained to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
62544795|NCT05985135|EXPERIMENTAL|Type 1 Diabetes Mellitus (T1DM) Insulin-Treated with Hyperglycemia|Subjects will be continue their baseline insulin infusion for 2 hours and then receive an intravenous dextrose infusion to maintain elevated blood sugar levels. Blood draws will be obtained to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
62544796|NCT05985135|OTHER|Non-Diabetic Controls|Subjects will have blood draws to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
62544797|NCT05985135|EXPERIMENTAL|Diabetes after Total Pancreatectomized (DATP) Insulin Treated|Subjects will continue their baseline insulin infusion while maintaining a target blood glucose range. Blood draws will be obtained to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
62544798|NCT05985135|EXPERIMENTAL|Diabetes after Total Pancreatectomized (DATP) Insulin Deprived|Subjects will have their insulin infusions replaced with saline and have blood draws to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
62544799|NCT05185765|ACTIVE_COMPARATOR|Brown bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544800|NCT05185765|ACTIVE_COMPARATOR|Wholemeal bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544801|NCT05185765|ACTIVE_COMPARATOR|Wholemeal bread without crust (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544802|NCT05185765|ACTIVE_COMPARATOR|White bread, water based (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544803|NCT05185765|ACTIVE_COMPARATOR|White hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
62544804|NCT05185765|ACTIVE_COMPARATOR|Brown hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
62544805|NCT05185765|ACTIVE_COMPARATOR|White soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
62544806|NCT05185765|ACTIVE_COMPARATOR|Brown soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
62718918|NCT02249403|PLACEBO_COMPARATOR|Placebo|
62718919|NCT00163644|ACTIVE_COMPARATOR|Aerobic exercise plus resistance|Aerobic exercise plus resistance exercise for 6 weeks
62718920|NCT00163644|ACTIVE_COMPARATOR|Aerobic exercise|Aerobic exercise for 6 weeks
62718921|NCT00163644|OTHER|Control|No formal exercise and weekly phone calls
62718922|NCT01500317|ACTIVE_COMPARATOR|Tapentadol|75 mg tapentadol tid
62168072|NCT06443541|EXPERIMENTAL|Students|Students in either randomization group will become active consumers of GlobalConsent with an email introduction to the program, process, delivery schedule, data collection procedures, and consent.
62718923|NCT01500317|ACTIVE_COMPARATOR|Oxycodone|5 mg oxycodone tid
62718924|NCT01500317|PLACEBO_COMPARATOR|Placebo|Placebo tid
62718925|NCT06192914||Food Anaphylaxis Patients|Patients with anaphylaxis to legumes, tree nuts, seeds, cereals and pseudocereals within the last 12 months
62718926|NCT05081921|EXPERIMENTAL|MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI \> 30) will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
62718927|NCT05081921|ACTIVE_COMPARATOR|Control Patients with type 2 diabetes and obesity|The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI \> 30) will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
62718928|NCT05081921|EXPERIMENTAL|MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with obesity (BMI \> 30), but with no type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
62718929|NCT05081921|ACTIVE_COMPARATOR|Control Patients without type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with obesity (BMI \> 30), but with no type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
62718930|NCT05081921|EXPERIMENTAL|MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity|The patients with osteoarthritis of knee, with no obesity (BMI \< 30) nor type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
62718931|NCT05081921|ACTIVE_COMPARATOR|Control Patients without type 2 diabetes and without obesity|The patients with osteoarthritis of knee, with no obesity (BMI \< 30) nor type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
62718932|NCT05805137|EXPERIMENTAL|Study subject with venous ulcer|The subjects will be monitored using the WoundWatch wound management system two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
62718933|NCT04097821|EXPERIMENTAL|Part 1 Arm 1: Ruxolitinib + Siremadlin|Dose escalation of siremadlin added to existing stable dose of ruxolitinib
62718934|NCT04097821|EXPERIMENTAL|Part 1 Arm 2: Ruxolitinib + Crizanlizumab|Safety run-in of crizanlizumab added to existing stable dose of ruxolitinib
62718935|NCT04097821|EXPERIMENTAL|Part 1 Arm 3: Ruxolitinib + Sabatolimab|Safety run-in of Sabatolimab added to existing stable dose of ruxolitinib
62718936|NCT04097821|EXPERIMENTAL|Part 2 Arm 1: Ruxolitinib + Siremadlin|Siremadlin added to existing stable dose of ruxolitinib
62718937|NCT04097821|EXPERIMENTAL|Part 2 Arm 2: Ruxolitinib + Crizanlizumab|Crizanlizumab added to existing stable dose of ruxolitinib
62718938|NCT04097821|EXPERIMENTAL|Part 2 Arm 3: Ruxolitinib + Sabatolimab|Sabatolimab added to existing stable dose of ruxolitinib
62718939|NCT04097821|ACTIVE_COMPARATOR|Part 2 Arm 6: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 2
62718940|NCT04097821|EXPERIMENTAL|Part 3 Arm 1: Ruxolitinib + Compound X|Compound from Part 2 (to be confirmed) added to existing stable dose of ruxolitinib
62718941|NCT04097821|EXPERIMENTAL|Part 3 Arm 2: Ruxolitinib cessation|Compound from Part 2 added to existing stable dose of ruxolitinib for 3 cycles followed by compound monotherapy
62718942|NCT04097821|ACTIVE_COMPARATOR|Part 3 Arm 3: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 3
62718943|NCT04097821|EXPERIMENTAL|Part 1 Arm 4: Ruxolitinib + Rineterkib|Dose escalation of Rineterkib added to existing stable dose of ruxolitinib
62718944|NCT04097821|EXPERIMENTAL|Part 1 Arm 5: Ruxolitinib + NIS793|Safety run-in of NIS793 added to existing stable dose of ruxolitinib
62718945|NCT04097821|EXPERIMENTAL|Part 2 Arm 4: Ruxolitinib + Rineterkib|Rineterkib added to existing stable dose of ruxolitinib
62718946|NCT04097821|EXPERIMENTAL|Part 2 Arm 5: Ruxolitinib + NIS793|NIS793 added to existing stable dose of ruxolitinib
62718947|NCT00203385|EXPERIMENTAL|Divalproex|Divalproex; oral up to 2000mg/d; open label
62718948|NCT04032821|EXPERIMENTAL|Alkotinib（300mg）First empty stomach, after the meal|Alkotinib（300mg），Subjects need to be fasting overnight for at least 10 hours before being warmed to 240 mL on an empty stomach Water service, lunch 4 hours later, dinner 10 hours later.
62718949|NCT04032821|EXPERIMENTAL|Alkotinib（300mg）After eating first, after fasting|Alkotinib（300mg），Subjects need to be fasting for at least 10 hours overnight, starting 30 min before taking the medication A standard meal (800-1000 CAL) can be taken before taking the medicine, and 240 mL warm water can be taken after the meal Lunch hours later, dinner 10 hours later.
62168073|NCT06443541|EXPERIMENTAL|Faculty|Faculty will receive access to educational material based on the university randomization implementation strategies group.
62718950|NCT03709901|EXPERIMENTAL|Active Allograft|Injection of viable allograft
62718951|NCT03709901|PLACEBO_COMPARATOR|Placebo|Injection of saline
62718952|NCT03709901|NO_INTERVENTION|Conservative Care|Continued conservative care treatment
62718953|NCT04817202|EXPERIMENTAL|Group A1 (hzVSF-v13 50mg, intravenous, single dose)|Single administration (intravenous) of 50mg hzVSF-v13 on Day 1.
62718954|NCT04817202|EXPERIMENTAL|Group A2 (hzVSF-v13 100mg, intravenous, single dose)|Single administration (intravenous) of 100mg hzVSF-v13 on Day 1.
62718955|NCT04817202|EXPERIMENTAL|Group A3 (hzVSF-v13 200mg, intravenous, single dose)|Single administration (intravenous) of 200mg hzVSF-v13 on Day 1.
62718956|NCT04817202|EXPERIMENTAL|Group A4 (hzVSF-v13 400mg, intravenous, single dose)|Single administration (intravenous) of 400mg hzVSF-v13 on Day 1.
62718957|NCT04817202|EXPERIMENTAL|Group A5 (hzVSF-v13 800mg, intravenous, single dose)|Single administration (intravenous) of 800mg hzVSF-v13 on Day 1.
62718958|NCT04817202|EXPERIMENTAL|Group A6 (hzVSF-v13 1200mg, intravenous, single dose)|Single administration (intravenous) of 1200mg hzVSF-v13 on Day 1.
62718959|NCT04817202|EXPERIMENTAL|Group A7 (hzVSF-v13 100mg, subcutaneous, single dose)|Single administration (subcutaneous) of 100mg hzVSF-v13 on Day 1.
62718960|NCT04817202|EXPERIMENTAL|Group B1 (hzVSF-v13 100mg, intravenous, multiple dose)|Multiple administration (intravenous) of 100mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
62718961|NCT04817202|EXPERIMENTAL|Group B2 (hzVSF-v13 400mg, intravenous, multiple dose)|Multiple administration (intravenous) of 400mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
62718962|NCT04817202|PLACEBO_COMPARATOR|Placebo (intravenous, single dose)|Single administration (intravenous) of placebo on Day 1.
62718963|NCT04817202|PLACEBO_COMPARATOR|Placebo (subcutaneous, single dose)|Single administration (subcutaneous) of placebo on Day 1.
62718964|NCT04817202|PLACEBO_COMPARATOR|Placebo (intravenous, multiple dose)|Multiple administration (intravenous) of placebo on Day 1, Day 15, Day 29, Day 43, Day 57.
62718965|NCT06086743|EXPERIMENTAL|Experimental Group|"10 min of warm up exercises will be performed.~* Arm swings~* Jogging on the spot~* Walks on treadmill The following exercises will be performed along with EMS after warm up exercises.~* Bicep curls~* Triceps dips~* Squats~* Quadriceps chair~The following cool down exercises will be performed after resistance exercises along with EMS.~* Light jogging and walking~* Upper body stretches~* Knee to chest pose Galvanic current would be administer, with intensity of 100 A."
62718966|NCT06086743|ACTIVE_COMPARATOR|Control Group|"10 min of warm up exercises will be performed.~* Arm swings~* Jogging on the spot~* Walks on treadmill The following exercises will be performed after warmups.~* Bicep curls~* Triceps dips~* Squats~* Quadriceps chair~The following cool down exercises will be performed after resistance exercises.~* Light jogging and walking~* Upper body stretches~* Knee to chest pose"
62718967|NCT04420676|ACTIVE_COMPARATOR|Probiotic|Group 1: receiving a probiotic mixture (Omni-Biotic® 10 AAD) twice a day
62718968|NCT04420676|PLACEBO_COMPARATOR|Placebo|Group 2: receiving a similar looking and tasting placebo without bacteria twice a day
62718969|NCT02283034|EXPERIMENTAL|With feedback|Participants compress the chest of the manikin with CPR feedback device.
62718970|NCT02283034|EXPERIMENTAL|Without feedback|Participants compress the chest of the manikin without CPR feedback device
62718971|NCT06255405|EXPERIMENTAL|Experimental: Intervention group|Dyadic parent-child self-compassion program will be provided.
62718972|NCT06255405|NO_INTERVENTION|Waitlist control group|Participants in the control group will be instructed to live their lives as usual, no intervention will be imposed during study period. They will be provided with the program after the study.
62718973|NCT06056180|EXPERIMENTAL|Balance Training+ Action Observation Training + Motor İmagery Training|The study group (23 cases) will be given motor imagery training and virtual reality-based balance training along with action observation.
62718974|NCT06056180|ACTIVE_COMPARATOR|Balance Training|Only virtual reality-based balance training will be given to the control group (23 cases).
62718975|NCT03004885|EXPERIMENTAL|Minimal Distension|Tidal volume 4 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R
62718976|NCT03004885|EXPERIMENTAL|Maximal Recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain plateau pressure between 23 - 25 cmH2O + ECCO2R
62718977|NCT03004885|ACTIVE_COMPARATOR|Standard|Tidal volume 6 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R
62718978|NCT04804124|EXPERIMENTAL|Short Sleepers|Reported nightly sleep time of ≤6 hours
62718979|NCT04804124|EXPERIMENTAL|Long Sleepers|Reported nightly sleep time of ≥9 hours
62718980|NCT04804124|EXPERIMENTAL|Average Duration Sleepers|Reported nightly sleep time of 7-8 hours
62718981|NCT02047448|NO_INTERVENTION|Control Group|The control group will receive the current standard of care including medication reconciliation during hospitalization performed by a nurse or physician and education about discharge medications provided by the inpatient nurse. There will not be a pharmacist discharge care plan developed for this group. The patients will not be required to choose a participating community pharmacist and no counseling and education appointments will be scheduled. Any medication-related problems identified by the pharmacists and will be communicated as appropriate and resolved as is the standard of care. Any other interaction between the patient and their pharmacist will be according to the current standard of care.
62718982|NCT02047448|EXPERIMENTAL|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
62718983|NCT04123730|ACTIVE_COMPARATOR|Fixed dose oxygen|O2Matic deliver the usual fixed-dose oxygen treatment during walking.
62718984|NCT04123730|EXPERIMENTAL|Automated oxygen titration|O2Matic deliver a variable oxygen dosage set at an SpO2-target of 90 to 94 % and a O2-flow of 0 - 15 liters/min during walking.
62718985|NCT01802788||Cohort A|Patients implanted with a Portico valve after CE mark
62718986|NCT01802788||Cohort B|Patients implanted in previous SJM-sponsored premarket studies
62718987|NCT02441842|ACTIVE_COMPARATOR|Group A : Atenolol|oral atenolol (50mg)
62718988|NCT02441842|PLACEBO_COMPARATOR|Group C: Placebo|glucose tablet (10mg)
62718989|NCT02441842|ACTIVE_COMPARATOR|Group L: Lisinopril|oral lisinopril (5mg)
62718990|NCT05386225||Standardized follow-up|Participants who chose to continue guideline-prescribed, standardized follow-up one year after HNC treatment.
62718991|NCT05386225||Individualized follow-up|Participants who chose to switch to individualized follow-up one year after HNC treatment. Follow-up visits will only be scheduled based on clinical symptoms and questions, initiated by the patient.
62718992|NCT01149746|EXPERIMENTAL|Tamsulosin|0.4 mg Capsule
62718993|NCT01149746|ACTIVE_COMPARATOR|Flomax®|0.4 mg Capsule
62718994|NCT03999580|EXPERIMENTAL|Experimental Arm:|"Experimental: Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day~3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)."
62718995|NCT03999580|ACTIVE_COMPARATOR|Control Arm:|"Active Comparator: Vitamin D3 600 UI/day then 600 UI/day~600 UI/day as induction therapy for 4 weeks, then 600 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
62718996|NCT02717325|EXPERIMENTAL|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application fo test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application
62718997|NCT05920174|EXPERIMENTAL|single|"Patients with motor disability（Complete or incomplete quadriplegia due to spinal cord injury, brain stem stroke, amyotrophic lateral sclerosis and other motor neuron disorders).~Implantation of NEO device."
62718998|NCT00746525|EXPERIMENTAL|Brain Computer Interface Training Stroke Experimental Group|Individuals in the stroke experimental group received treatment with BCI, FES, and motor learning targeted at their upper extremity motor deficits following stroke.
62718999|NCT00901303|OTHER|Early Stage Disease|Group A
62719000|NCT00901303|OTHER|Advance Stage Disease|Group B
62719001|NCT01043718|EXPERIMENTAL|More-Intensive|
62719002|NCT01043718|ACTIVE_COMPARATOR|Less-Intensive|
62719003|NCT01332214|EXPERIMENTAL|AZD2820|
62719004|NCT01332214|PLACEBO_COMPARATOR|Placebo|
62719005|NCT02015247|OTHER|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
62719006|NCT01497834|EXPERIMENTAL|Daclatasvir + Asunaprevir|
62719007|NCT01282866|EXPERIMENTAL|HS treatment|Treatment with HS handpiece
62719008|NCT01485848|ACTIVE_COMPARATOR|Paclitaxel|A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
62719009|NCT01485848|EXPERIMENTAL|Paclitaxel + EP-100|Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
62719010|NCT03382912|EXPERIMENTAL|Pegilodecakin+Nivolumab|"Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
62719011|NCT03382912|ACTIVE_COMPARATOR|Nivolumab|Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
62719012|NCT01530373|EXPERIMENTAL|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
62719013|NCT01530373|ACTIVE_COMPARATOR|clonidine|oral clonidine 0.1 mg daily for 3 weeks
62719014|NCT05713461|EXPERIMENTAL|obese women without metabolic syndrome|Women with obesity and without metabolic syndrome
62719015|NCT05713461|EXPERIMENTAL|obese women with metabolic syndrome|Women with obesity and with metabolic syndrome
62719016|NCT06467630||Post-extraction socket preservation group|The 30 eligible patients are any male and female, adult patients with the following dental treatment to be done with the study device: Post-extraction socket preservation (not done concomitantly to implant placement).
62719017|NCT06467630||Alveolar ridge augmentation group|The 30 eligible patients are any male and female, adult patients with the following dental treatment to be done with the study device: Alveolar ridge augmentation (not done concomitantly to implant placement).
62719018|NCT06467630||Guided Tissue Regeneration (GTR) during immediate implant placement group|The 30 eligible patients are any male and female, adult patients with the following dental treatment to be done with the study device: Guided Tissue Regeneration (GTR) during immediate implant placement
62719019|NCT02663154|EXPERIMENTAL|Aromatherapy|Aromatherapy inhaler (QueaseEASE, Soothing Scents Inc, Enterprise, AL) applied to nauseous post surgical paediatric patients in the postanesthetic care unit
62719020|NCT02663154|PLACEBO_COMPARATOR|Placebo|Saline inhaler applied to nauseous post surgical paediatric patients in the postanesthetic care unit
62719021|NCT06716918||patients took antenatal corticosteroids prior to planned cesarean section|
62719022|NCT06716918||patients didnt't take antenatal corticosteroids prior to planned cesarean section|
62719023|NCT00297869|NO_INTERVENTION|1|
62719024|NCT00297869|EXPERIMENTAL|2|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
62719025|NCT04757311||Metastatic Colorectal Cancer Patients|All RAS wild type metastatic colorectal cancer patients
62719026|NCT03744338||Group 1|
62719027|NCT02300233|PLACEBO_COMPARATOR|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
62719028|NCT02300233|EXPERIMENTAL|Volanesorsen 300 mg weekly|Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks.
62719029|NCT02300233|EXPERIMENTAL|Volanesorsen 300 mg biweekly, post Week 13|Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.
62719030|NCT03492047|ACTIVE_COMPARATOR|control|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
62719031|NCT03492047|EXPERIMENTAL|high dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
62719032|NCT03492047|EXPERIMENTAL|low dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.
62719033|NCT02756403|ACTIVE_COMPARATOR|Azithromycin|500 mg of Azithromycin
62719034|NCT02756403|ACTIVE_COMPARATOR|Doxycycline|200 mg of Doxycycline
62719035|NCT02756403|ACTIVE_COMPARATOR|Metronidazole|500 mg of Metronidazole
62719036|NCT02756403|PLACEBO_COMPARATOR|Placebo|Inactive Ingredient
62719037|NCT01900665|EXPERIMENTAL|Solanezumab|Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.
62719038|NCT01900665|PLACEBO_COMPARATOR|Placebo|Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
62719039|NCT06328842|ACTIVE_COMPARATOR|Nasogastric Tube Feeding|the control group was given enteral nutritional support with nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation.
62719040|NCT06328842|EXPERIMENTAL|Intermittent Oro-esophageal Tube Feeding|the group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the relevant guidelines.
62719041|NCT05778695|EXPERIMENTAL|Parkinson Disease|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) three times daily (TID) as tolerated. KE dose will be titrated down to a tolerated level if necessary.
62719042|NCT05778695|EXPERIMENTAL|Parkinson Disease Dementia/Lewy Body Dementia|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.
62719043|NCT05778695|EXPERIMENTAL|Healthy Controls|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.
62719044|NCT00185302|EXPERIMENTAL|Histone Deacetylase Inhibitor, 3 mg|Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity
62719045|NCT00185302|EXPERIMENTAL|Histone Deacetylase Inhibitor, 7 mg|Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity
62719046|NCT02404168|ACTIVE_COMPARATOR|lamotrigine brand tablet1|lamotrigine tablet Lamictal
62719047|NCT02404168|EXPERIMENTAL|lamotrigine generic tablet1|lamotrigine tablet Teva
62719048|NCT02404168|ACTIVE_COMPARATOR|lamotrigine brand tablet2|lamotrigine tablet Lamictal
62719049|NCT02404168|EXPERIMENTAL|lamotrigine generic tablet2|lamotrigine tablet Teva
62719050|NCT00370292|EXPERIMENTAL|Pemetrexed - Before Protocol Amendment|
62544807|NCT05185765|ACTIVE_COMPARATOR|Ciabatta (commercially available)|Participants consume half a mini ciabatta, and masticate and expectorate half of 1 cm thick slice
62544808|NCT05185765|ACTIVE_COMPARATOR|Croissant (commercially available)|Participants consume half a croissant, and masticate and expectorate half of 1 cm thick slice
62719051|NCT00370292|EXPERIMENTAL|Pemetrexed - After Protocol Amendment|
62719052|NCT06266000|EXPERIMENTAL|Saw palmetto extract|Saw palmetto extract taken as 2 capsules per day
62719053|NCT06266000|ACTIVE_COMPARATOR|Comparator saw palmetto extract|Commercial saw palmetto extract taken as 2 capsules per day
62719054|NCT06266000|PLACEBO_COMPARATOR|Placebo|Palm oil taken as 2 capsules per day
62719055|NCT01138475|ACTIVE_COMPARATOR|Paricalcitol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules,cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
62719056|NCT01138475|ACTIVE_COMPARATOR|cholecalciferol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
62719057|NCT01138475|PLACEBO_COMPARATOR|placebo|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
62719058|NCT03737552||Children and adolescents with ADHD|Children and Adolescents with ADHD children or Adolescents, male or female, ages 6-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
62719059|NCT03737552||Healthy control children and adolescent|children or Adolescents, male or female, ages 6-17,medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
62719060|NCT02443701|EXPERIMENTAL|Exercise|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).
62738423|NCT05469425|NO_INTERVENTION|Control Group|"Patients allocated to this group will receive usual care and must complete the outcome measures.~In addition, a physical therapist will carry out weekly telephone calls with all participants to monitor adverse events."
62544809|NCT05185765|ACTIVE_COMPARATOR|Whole wheat bread produced by bakery, proofing time 65 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544810|NCT05185765|ACTIVE_COMPARATOR|Whole wheat bread produced by bakery, proofing time 85 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544811|NCT05185765|ACTIVE_COMPARATOR|Whole wheat bread produced by bakery, proofing time 105 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544812|NCT05185765|ACTIVE_COMPARATOR|Whole wheat bread produced by bakery, proofing time 65 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62165093|NCT04854616|EXPERIMENTAL|CoSTED Intervention|"CoSTED is an opportunistic smoking cessation intervention comprising three elements:~1. brief smoking cessation advice~2. the provision of an electronic cigarette (e-cigarette) and training in its use~3. referral to stop-smoking services"
62719061|NCT02443701|EXPERIMENTAL|NEMES|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).The healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation, medium frequency current (1kHz), modulated at 70Hz, cycle Work 10%, intensity used will vary according to the capacity and tolerable for each individua. The stimulated muscle group will be the quadriceps femoris
62719062|NCT02443701|EXPERIMENTAL|Phototherapy|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump). The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. Phototherapy will be conducted through a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J. The application sites will be six points on the belly of the quadriceps femoris muscles bilaterally.
62719063|NCT05236036|EXPERIMENTAL|Group 1 (TMZ, MMF)|Patients who have already undergone surgery or biopsy followed by chemoradiation receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
62719064|NCT05236036|EXPERIMENTAL|Group 2 (TMZ, MMF, radiation therapy)|Patients with unmethylated glioblastoma who have already undergone surgery or biopsy receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Starting at the same time as TMZ and MMF administration, patients also receive radiation therapy daily, 5 days per week, for 6 weeks.
62719065|NCT05236036|EXPERIMENTAL|Group 3 (TMZ, MMF, radiation therapy)|Patients who have already undergone surgery or biopsy receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Starting at the same time as TMZ and MMF administration, patients also receive radiation therapy daily, 5 days per week, for 6 weeks.
62719066|NCT05236036|EXPERIMENTAL|Group S (pre-surgical MMF, TMZ)|Patients planning to undergo surgery receive MMF PO BID and TMZ PO QD for 5 days prior to surgery in the absence of disease progression or unacceptable toxicity.
62719067|NCT03358030|PLACEBO_COMPARATOR|Placebo|Participants received placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
62719068|NCT03358030|EXPERIMENTAL|Cohort A: ISIS 416858, 200 mg|Participants received ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
62719069|NCT03358030|EXPERIMENTAL|Cohort B: ISIS 416858, 250 mg|Participants received ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
62719070|NCT03358030|EXPERIMENTAL|Cohort C: ISIS 416858, 300 mg|Participants received ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
62719071|NCT01302184|EXPERIMENTAL|Experimental Group|Lokomat®
62719072|NCT01302184|ACTIVE_COMPARATOR|Control Group|Treadmill training
62719073|NCT04942431|EXPERIMENTAL|Interventiongroup|60 min per day school based Physical activity program (for one year)
62719074|NCT04942431|NO_INTERVENTION|Waitinggroup|Intervention starts after one year.
62719075|NCT06280248|OTHER|Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst|
62719076|NCT02239926|ACTIVE_COMPARATOR|Ranolazine|tablet, 1000 mg twice daily for four weeks
62719077|NCT02239926|PLACEBO_COMPARATOR|Placebo|Placebo
62719078|NCT04037228||KneeAlign 2|Those of the group will be adopt KneeAlign 2: accelerometer-based navigation system at total knee arthroplasty.
62719079|NCT01639469|EXPERIMENTAL|Structured exercise|Structured exercise instruction by smartphone
62719080|NCT01639469|ACTIVE_COMPARATOR|lifestyle exercise|Lifestyle exercise program taught via smartphone
62719081|NCT01205503|OTHER|Cycle 1 Saline; Cycle 2 Mesna|Saline infused over 15 minutes administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
62165094|NCT04854616|NO_INTERVENTION|Treatment as Usual|Signposting to NHS smoking cessation services through provision of written information about local services.
62165095|NCT01204775|EXPERIMENTAL|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
62165096|NCT01204775|PLACEBO_COMPARATOR|Placebo|Placebo matching saxagliptin tablet
62719082|NCT01205503|OTHER|Cycle 1 Mesna; Cycle 2 Saline|Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Saline administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
62738786|NCT01422785|ACTIVE_COMPARATOR|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|
62165097|NCT05261100|PLACEBO_COMPARATOR|Active group|Conventional Physical therapy
62165098|NCT05261100|EXPERIMENTAL|Experimental group|Conventional Physical therapy with Core stability
62738787|NCT01422785|ACTIVE_COMPARATOR|clindamycin / tretinoin gel plus benzoyl peroxide|
62165099|NCT05559164|EXPERIMENTAL|Anti-HER2 targeted therapy + Lipitor 40mg daily|Participants will receive Lipitor 40 mg PO daily while receiving anti-HER2 therapy.
62719083|NCT05856955|ACTIVE_COMPARATOR|Enhanced Usual Care|The active comparison group will receive a smartphone with the WebMD® health information application preloaded and a BP monitor. After recruitment, participants will receive a confirmatory interview, informed consent, and baseline device training via telephone, delivered by an experienced research assistant. Participants will be encouraged to complete 1 morning BP reading daily, irrespective of study arm. BP readings are automatically uploaded via Bluetooth to a centralized, secure platform to be accessible to the study PI.
62165100|NCT06352034|EXPERIMENTAL|Empathy Training|The Empathy training consists of five sessions. Each session contains psychoeducation, three-role group exercises, and Q\&A. The interval between every session is 5-14 days. Sessions are scheduled for 1.5 hours, including 30 minutes of psychoeducation, 45 minutes of three-role group exercises, and 15 minutes of Q\&A.
62165101|NCT06352034|NO_INTERVENTION|Wait-List|The participants in the wait-list group will not receive the empathy training or other similar training until all the groups finish their one-month follow-up measurements.
62165102|NCT05655715|EXPERIMENTAL|A SBRT + ipi/nivo|Stereotactic body radiotherapy of 8 Gray (Gy) x 3 on one soft tissue or bone metastasis + Nivolumab 3mg/kg IV every 3 weeks (Q3W) + Ipilimumab 1mg/kg IV Q3W for four doses, then Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks treatment in total
62544813|NCT05185765|ACTIVE_COMPARATOR|Whole wheat bread produced by bakery, proofing time 85 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544814|NCT05185765|ACTIVE_COMPARATOR|Whole wheat bread produced by bakery, proofing time 105 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
62544815|NCT00582660|ACTIVE_COMPARATOR|study drug BID for 7 days before surgery|400 mg Celecoxib the study drug will be given for 7 days before surgery
62544816|NCT00582660|PLACEBO_COMPARATOR|Placebo for 7 days before surgery|Placebo in a one to one randomization prior to surgery
62544817|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
62544818|NCT01593046|EXPERIMENTAL|Run-in Period|Oral GSK1265744 30mg once daily for 14 days
62544819|NCT01593046|EXPERIMENTAL|Cohort 1|GSK1265744 LAP injection given subcutaneously once a month for 4 months
62544820|NCT01593046|EXPERIMENTAL|Cohort 2|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
62544821|NCT01593046|EXPERIMENTAL|Cohort 3|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
62544822|NCT01593046|EXPERIMENTAL|Cohort 4|GSK1265744 LAP injection given intramuscularly once every 12 weeks.
62544823|NCT04274257|PLACEBO_COMPARATOR|Double-Blind Placebo|Participants will receive double-blind matching placebo from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
62544824|NCT04274257|EXPERIMENTAL|Double-Blind Rituximab|Participants will receive double-blind rituximab from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
62544825|NCT04727801||Febrile (n=50)|Febrile is defined as having sublingual temperatures of 37.5 °C or above. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
62544826|NCT04727801||Afebrile (n=50)|Afebrile is defined as having sublingual temperatures of less than 37.5 °C. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
62544827|NCT02029157|EXPERIMENTAL|ARQ 197|Daily oral dose
62544828|NCT02029157|PLACEBO_COMPARATOR|Placebo|Daily oral dose
62544829|NCT01772797|EXPERIMENTAL|LDK378 and AUY922|
62544830|NCT00644930|EXPERIMENTAL|1|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated.
62544831|NCT00644930|ACTIVE_COMPARATOR|2|Patients in the standard therapy group without indications for urgent intubation were only given standard medical therapy (such as oxygen, antibiotics, and bronchodilators), and IMV through an endotracheal tube was applied when intubation criteria were met.
62544832|NCT02122692|EXPERIMENTAL|Lu AE58054 30 mg + itraconazole 200 mg|
62165103|NCT05655715|EXPERIMENTAL|B ipi/nivo|Nivolumab 3mg/kg IV Q3W + Ipilimumab 1mg/kg IV Q3W for four doses, then Nivolumab 480 mg IV Q4W for up to 52 weeks treatment in total
62165104|NCT00323895|EXPERIMENTAL|1|group with intra-Cypher™ restenosis
62544833|NCT06247410|OTHER|Sequence: Reference-Test-Reference-Test (RTRT)|"Once daily patch application of one patch of Test or Reference over 4 days, i.e. a total of 4 alternating applications with RTRT sequence. Each patch remains applied for 24 h. Treatments may be directly switched without washout phase.~Period 1: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application~Period 2: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application~Period 3: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application~Period 4: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application"
62544834|NCT06247410|OTHER|Sequence: Test-Refrence-Test-Reference|"Once daily patch application of one patch of Test or Reference over 4 days, i.e. a total of 4 alternating applications with TRTR sequence. Each patch remains applied for 24 h. Treatments may be directly switched without washout phase.~Period 1: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application~Period 2: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application~Period 3: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application~Period 4: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application"
62544835|NCT02798588|EXPERIMENTAL|Comatose patients in ICU|
62544836|NCT05106608|EXPERIMENTAL|Group PBM_1|Energy density 7.5 J / cm2 for group PBM_1
62544837|NCT05106608|EXPERIMENTAL|Group PBM_2|Energy density 3 J / cm2 for group PBM_2
62719084|NCT05856955|EXPERIMENTAL|Behavioral mHealth Coaching Intervention|Those randomized to the intervention group will receive a smartphone with the intervention program preloaded in addition to a BP monitor. After recruitment, participants will receive a confirmatory interview, informed consent, and baseline device training via telephone, delivered by an experienced research assistant. Participants will be encouraged to complete 1 morning BP reading daily, irrespective of study arm, however, only the intervention group will receive reminders from the mHealth coaching intervention to check BP daily. BP readings are automatically uploaded via Bluetooth to a centralized, secure platform to be accessible to the study PI.
62719085|NCT03425916||Primiparous women|Women after normal, not operative, vaginal one-child delivery
62544838|NCT05106608|PLACEBO_COMPARATOR|Placebo Control|The placebo control group will carry out the same protocol used in irradiated patients (including the use of protective glasses) using the same laser device to imitate a real irradiation; however, the device will be turned off and a recording of the emission sounds will be used to give the patient the hearing sensation of the laser therapy.
62544839|NCT04682522|ACTIVE_COMPARATOR|Metronidazole|Metronidazole 250 mg three times a day
62544840|NCT04682522|NO_INTERVENTION|Standard care|Standard post-operative care, which may or may not include post-operative antibiotics
62544841|NCT05005897|EXPERIMENTAL|Screening - treatment|From 6 weeks of age, infants will be screened for elevated plasma total homocysteine concentrations. Those who have a concentration above the defined cut-off will be treated with cobalamin (vitamin B12).
62544842|NCT05005897|NO_INTERVENTION|Control|The control-group sample will be stored and analyzed when the child is 12 months old. Those with elevated tHcy will contribute to the control group.
62544843|NCT03785327|EXPERIMENTAL|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
62544844|NCT03785327|SHAM_COMPARATOR|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
62544845|NCT03785327|EXPERIMENTAL|Autism Training Program|Training program designed to increase autism understanding followed by behavioral testing Intervention:Training program
62544846|NCT03785327|NO_INTERVENTION|Social interaction without intervention|Control condition: Behavioral testing without an intervention component
62544847|NCT05096429|EXPERIMENTAL|Intervention|Within these cities/towns, the health department will work with stakeholders to prioritize overdose prevention interventions to neighborhoods with the highest probability of future overdose deaths, as predicted by the PROVIDENT model.
62544848|NCT05096429|NO_INTERVENTION|Control|Cities/towns assigned to the control arm will continue to work with the health department and distribute these interventions at existing resource levels, but without receiving information on predicted probability of overdose risk for specific neighborhoods.
62544849|NCT03918460|EXPERIMENTAL|Intervention|All patients enrolled are intended to be treated
62544850|NCT04988919|EXPERIMENTAL|4D dietary supplement|Multi-ingredient supplement containing a proprietary blend with 150mg of caffeine, and other ingredients including vitamins, electrolytes, and BCAA blend (150mg).
62544851|NCT04988919|PLACEBO_COMPARATOR|placebo|flavored water (raspberry lemonade Crystal Light®)
62544852|NCT04187547|ACTIVE_COMPARATOR|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
62544853|NCT04187547|PLACEBO_COMPARATOR|AC-SD-03P|Placebo formulation, twice daily. Administered orally
62544854|NCT03101176|EXPERIMENTAL|Experimental: Single Arm|All consenting patients will undergo mpUS imaging prior to surgery with the ultrasound contrast agent Sonovue for the CEUS specific mode.
62544855|NCT03685812||patients with patellofemoral pain syndrome , Auto Cad software|Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
62544856|NCT01911897|EXPERIMENTAL|MobiusHD|MobiusHD
62544857|NCT02847871|OTHER|Multimodal Intervention|The multimodal intervention on mobility will consist of the implementation of a care pathway dedicated in primary care. It will include awareness and training of general practitioners for easy identification, a care associating a dedicated geriatric consultation to rule out underlying pathology, teaching exercises by MAPA (+/- taken care in the presence of MAPA) and nutritional counseling by a dietician. Close collaboration between general practitioners, geriatrician, MAPA and dietician will be established.
62544858|NCT02847871|NO_INTERVENTION|Non interventional|Patients received treatment as part of their standard care: at the discretion of the general practitioner patients
62544859|NCT04859205|EXPERIMENTAL|Intervention|"All participants partaking the SUPPORT-Pro study will receive the full intervention for 3 months which implies: (1) Full access to the platform (2) a newsletter sent by email every 2 weeks to inform them on the new blogs posted on the platform.~During the following 9 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase)."
62544860|NCT03004339|EXPERIMENTAL|SOR007 Ointment 2.0%|Topical application once daily during a 12-day treatment period (10 treatments)
62544861|NCT03004339|EXPERIMENTAL|SOR007 Ointment 1.0%|Topical application once daily during a 12-day treatment period (10 treatments)
62544862|NCT03004339|EXPERIMENTAL|SOR007 Ointment 0.3%|Topical application once daily during a 12-day treatment period (10 treatments)
62544863|NCT03004339|EXPERIMENTAL|SOR007 Ointment 0.15%|Topical application once daily during a 12-day treatment period (10 treatments)
62544864|NCT03004339|PLACEBO_COMPARATOR|SOR007 Ointment Placebo|Topical application once daily during a 12-day treatment period (10 treatments)
62544865|NCT03004339|ACTIVE_COMPARATOR|Taclonex® Ointment|Topical application once daily during a 12-day treatment period (10 treatments)
62544866|NCT01174043|EXPERIMENTAL|Erlotinib|
62544867|NCT02986477|OTHER|Contrast Ultrasound|Patients with vesicoureteral reflux will receive contrast ultrasound via Foley catheter for study of vesicoureteral reflux.
62719086|NCT03425916||Nulliparous women|Women without any child or pregnancy, age-matched
62719087|NCT00705705|EXPERIMENTAL|1|Participating social networks will receive standard HIV risk-reduction counseling and network leadership training on HIV prevention.
62544868|NCT04669561|EXPERIMENTAL|Single /arm|All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
62719088|NCT00705705|ACTIVE_COMPARATOR|2|Participating social networks will receive standard HIV risk-reduction counseling.
62719089|NCT02028845|ACTIVE_COMPARATOR|Loop guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with loop guidewire.
62719090|NCT02028845|ACTIVE_COMPARATOR|Straight guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with straight guidewire.
62719091|NCT02125955|EXPERIMENTAL|Prebiotic fiber|The intervention group will consume an 8 gram dose of prebiotic fiber one time per day approximately 30 minutes prior to their evening meal.
62719092|NCT02125955|PLACEBO_COMPARATOR|Placebo|The placebo group will consume an isocaloric dose of placebo (maltodextrin; 3.3 grams) one time per day approximately 30 minutes prior to their evening meal.
62719093|NCT01868828|EXPERIMENTAL|PAD Followed by ASCT|"Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
62719094|NCT01868828|EXPERIMENTAL|VCD Followed by ASCT|"Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
62719095|NCT00700648||A|
62719096|NCT06216158|ACTIVE_COMPARATOR|Arm A: Iberdomide|36 months of oral iberdomide administration; In cycle 1, dexamethasone is added as pre-medication
62719097|NCT06216158|EXPERIMENTAL|Arm B: Iberdomide plus isatuximab|36 months of oral iberdomide plus subcutaneous isatuximab administration; In cycle 1, dexamethasone is added as pre-medication
62544869|NCT05477108|EXPERIMENTAL|Treatment A: BGF MDI HFO 160/7.2/4.8 μg ex-actuator with oral activated charcoal|Subjects will receive Test formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
62544870|NCT05477108|EXPERIMENTAL|Treatment B: BGF MDI HFA 160/7.2/4.8 μg ex-actuator with oral activated charcoal|Subjects will receive Reference formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
62719098|NCT03929003|EXPERIMENTAL|Contingent|Participants in this arm will be required to meet CO goals in order to earn game-based rewards.
62719099|NCT03929003|ACTIVE_COMPARATOR|Non-contingent|Participants in this arm will submit CO verifications but will earn game-based rewards independent of meeting CO goals.
62719100|NCT03381118|EXPERIMENTAL|Ara-C+HaploLymphocyte+Nivo|"Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:~\[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0~+ Nivolumab 40 mg D+5\] х 2-3 cycles"
62165105|NCT00323895|ACTIVE_COMPARATOR|2|group with intra-Taxus™ restenosis
62165106|NCT00323895|ACTIVE_COMPARATOR|3|group with intra-BMS restenosis
62165107|NCT03133455|OTHER|Patient with Fibromyalgia|
62719101|NCT03381118|EXPERIMENTAL|Ara-C+ Nivo|"Patients treated with nivolumab and intermediate dose cytarabine:~\[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1\] х 2-3 cycles"
62719102|NCT03310944|ACTIVE_COMPARATOR|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
62719103|NCT03310944|EXPERIMENTAL|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
62719104|NCT03310944|EXPERIMENTAL|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
62719105|NCT03310944|EXPERIMENTAL|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
62719106|NCT00586794|ACTIVE_COMPARATOR|A|
62719107|NCT00586794|PLACEBO_COMPARATOR|B|from the 26th weeks on open-label, all patients were treated with Sildenafil
62719108|NCT04831840||Female participants with recurrent urinary tract infections (RUTI).|Patients with RUTIs (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
62719109|NCT04831840||Female control patients without RUTIs|Patients without RUTIs (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
62719110|NCT06353477|ACTIVE_COMPARATOR|EPs® 7630 group|The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \>12 years of age)\] for 7 days.
62165108|NCT03640754|ACTIVE_COMPARATOR|Experimental: G-CSF|Intervention: G-CSF given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Filgrastim
62165109|NCT03640754|PLACEBO_COMPARATOR|Comparator: Placebo/Saline|Intervention: Placebo/saline given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Saline
62165110|NCT02444884|EXPERIMENTAL|Stratum A1|Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
62719111|NCT06353477|NO_INTERVENTION|control grup|Control group did not receive any herbal medication.
62719112|NCT03484728|PLACEBO_COMPARATOR|High-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
62719113|NCT03484728|OTHER|Low-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
62719114|NCT01871389||cholecalciferol|
62165111|NCT02444884|EXPERIMENTAL|Stratum A2|MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
62165112|NCT02444884|EXPERIMENTAL|Stratum B|Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
62165113|NCT01323309||Individual Meaning-Centered Psychotherapy (IMCP)|
62165114|NCT01323309||standard Individual Supportive Psychotherapy (ISP)|
62719115|NCT01871389||usual treatment|
62719116|NCT00159926|EXPERIMENTAL|1|With cell saver
62719117|NCT00159926|ACTIVE_COMPARATOR|2|Without cell saver
62719118|NCT02785328|EXPERIMENTAL|obstructive sleep apnoea|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from obstructive sleep apnoea syndrome.
62719119|NCT02785328|EXPERIMENTAL|narcolepsy|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from narcolepsy.
62719120|NCT02785328|EXPERIMENTAL|BECTS (Benign epilepsy with centro-temporal spikes)|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from BECTS.
62719121|NCT02785328|EXPERIMENTAL|high intellectual potential|The objective of this task is to evaluate the sleep-dependent consolidation abilities in children with high intellectual potential.
62719122|NCT02785328|EXPERIMENTAL|healthy children|The objective of this task is to evaluate the sleep-dependent consolidation abilities in healthy children.
62719123|NCT05439733||Exposed group|Women with a history of cesarean section and with a base-line attempt after planned cesarean section (TVBAC).
62719124|NCT05439733||Non-exposed group|Women with a history of cesarean section and scheduled cesarean section after cesarean section (CPAC).
62719125|NCT00529672|ACTIVE_COMPARATOR|1|Surgery: crossectomy plus short stripping
62719126|NCT00529672|ACTIVE_COMPARATOR|2|ultrasound guided sclerotherapy with foam (3% polidocanol)
62719127|NCT00529672|ACTIVE_COMPARATOR|3|Endovenous laser therapy (940 nm, about 70 J/cm)
62719128|NCT04023942|ACTIVE_COMPARATOR|Low carb - App-based group|Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
62719129|NCT04023942|ACTIVE_COMPARATOR|Low carb - Newsletter-based group|"Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
62719130|NCT04023942|ACTIVE_COMPARATOR|Low fat - App-based group|Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
62719131|NCT04023942|ACTIVE_COMPARATOR|Low fat - Newsletter-based group|"Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
62719132|NCT03431454|ACTIVE_COMPARATOR|home-based vision orthoptic therapy (HBVOT) group|In the home-based vision orthoptic therapy (HBVOT) group, patients were trained to do the pencil push-ups procedure 15 minutes per day, five days a week
62719133|NCT03431454|ACTIVE_COMPARATOR|office-based vision orthoptic therapy (OBVOT) group|In the office-based vision orthoptic therapy (OBVOT) group, 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed
62719134|NCT03431454|ACTIVE_COMPARATOR|augmented office-based vision orthoptic therapy (AOBVOT) group|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
62719135|NCT03902964||women treated for breast cancer in 2017 (cohort A)|all patients who completed breast cancer treatment between January 1 and May 31, 2017. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
62719136|NCT03902964||women treated for breast cancer in 2015 (cohorte B)|all patients who completed breast cancer treatment between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
62719137|NCT02253043|EXPERIMENTAL|Deep Brain Stimulation|DBS Implant and stimulation
62719138|NCT03842735|EXPERIMENTAL|exercise and rehabilitation counselling|Subjects enrolled in exercise group make physical exercises and receive rehabilitative counselling indications
62719139|NCT03842735|OTHER|rehabilitation counselling|Subjects enrolled in exercise group only receive rehabilitative counseling indications.
62719140|NCT02217618|EXPERIMENTAL|LY2409021|Single oral dose of 20 milligrams (mg) LY2409021.
62719141|NCT06719492|EXPERIMENTAL|Nutrition education|Participants randomized to this group will receive an additional 15 minutes of nutrition education focused on nutrition for surgical recovery. They will be offered an additional nutrition beverage if they choose it.
62719142|NCT06719492|NO_INTERVENTION|Control group with typical clinic education and care|Participants randomized to this group will receive typical clinic education and care. They will be offered an additional nutrition beverage if they choose it.
62719143|NCT05341947|EXPERIMENTAL|Activated T cells|
62719144|NCT02071771|OTHER|DACP T, Then 1DAM A|Nelfilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
62719145|NCT02071771|OTHER|1DAM A, Then DACP T|Etafilcon A toric contact lenses worn first, with nelfilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
62719146|NCT04436341||Patients with Alzheimer's disease|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
62165115|NCT01323309||enhanced usual care (EUC)|
62165116|NCT01970072|EXPERIMENTAL|1.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight
62165117|NCT01970072|EXPERIMENTAL|2.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight
62544871|NCT02229474|EXPERIMENTAL|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
62544872|NCT02229474|NO_INTERVENTION|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
62544873|NCT04545320|PLACEBO_COMPARATOR|Usual care control group|Subjects in the usual care control group will receive a health education program to provide the usual care information. This program will include 3-month biweekly sessions (70 minutes each session, total 6 sessions) for obesity-related health briefing, dietary caloric restriction advice, lifestyle counselling/consultation and stretching exercise.
62544874|NCT04545320|EXPERIMENTAL|HIIT group|A 3-month intervention of HIIT will be given to participants allocated to this group. The once-a-week HIIT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform brisk walking for four 4-min bouts at 85%-95% maximal heart rate (HRmax) with a 3-min active recovery walk at 50%-70% HRmax between each session. There will be a 5-min warm-up and cool-down in each exercise session. The duration of each exercise session will be 35 minutes. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
62544875|NCT04545320|EXPERIMENTAL|MICT group|A 3-month intervention of MICT will be given to participants allocated to this group. The once-a-week MICT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform mild walking exercise for \~47 minutes at an intensity of 65-75% HRmax. This exercise volume matches the HIIT volume. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
62544876|NCT01098487|EXPERIMENTAL|Open Label|Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).
62544877|NCT03132233|ACTIVE_COMPARATOR|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
62544878|NCT03132233|PLACEBO_COMPARATOR|Placebo|Receives a matched placebo powder to the IMP.
62544879|NCT00653900||1|All patients undergoing elective, invasive cardiac procedure on plavix prior to admission
62544880|NCT01966874||Study population|"All study participants will receive 200 mg of the mifepristone product Zacafemyl, followed 24-48 hours later by 800 mcg of misoprostol."
62544881|NCT06344585||Drop out|Women who had their first access from 2012 to 2021 and never returned back
62544882|NCT06344585||Non drop out|Women who had their first access from 2012 to 2021 and returned back for subsequent treatment
62544883|NCT03289819|EXPERIMENTAL|Pembrolizumab/Nab-Paclitaxel|"This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.~All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.~After the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.~Clinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent."
62544884|NCT03786458|EXPERIMENTAL|Cancer and Fertility Decision making|Cancer and Fertility Decision aid
62544885|NCT03356288||Asthma|20 Participants with moderate to severe asthma, as defined by British Thoracic Society (BTS) guidelines
62544886|NCT03356288||Chronic heart failure|10 Participants with a diagnosis of chronic heart failure
62544887|NCT03356288||Breathing Pattern Disorder|10 Participants with a diagnosis of Breathing Pattern Disorder
62544888|NCT03356288||Pneumonia|10 participants with a radiologically confirmed diagnosis of pneumonia
62544889|NCT03356288||Motor Neurone Disease|10 participants with a diagnosis of motor neurone disease with known hypercapnic failure.
62544890|NCT03356288||Healthy|10 Participants who have no known lung, cardiac or neuromuscular condition.
62544891|NCT06250946|EXPERIMENTAL|Group A|Subjects will receive escalated dose of HRS-7535 administered orally
62544892|NCT06250946|EXPERIMENTAL|Group B|Subjects will receive escalated dose of HRS-7535 administered orally
62544893|NCT06250946|EXPERIMENTAL|Group C|Subjects will receive escalated dose of HRS-7535 administered orally
62544894|NCT06250946|EXPERIMENTAL|Group D|Subjects will receive escalated dose of HRS-7535 administered orally
62544895|NCT06250946|PLACEBO_COMPARATOR|Group E|Subjects will receive Placebo administered orally
62544896|NCT04495335|EXPERIMENTAL|Test Group (TG)|The study included test group with Photobiomodulation treatment after dental implant surgery
62544897|NCT04495335|ACTIVE_COMPARATOR|Control Group (CG)|The control group consisted of laser application without energy delivery to the tissue.
62165118|NCT01970072|EXPERIMENTAL|3.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight
62165119|NCT01970072|EXPERIMENTAL|4.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight
62544898|NCT01212289||Primary cardiac surgery|Pediatric patients receiving primary cardiac surgery
62544899|NCT01212289||Reoperation|Pediatric patients receiving cardiac surgery reoperation
62719147|NCT04436341||Patients with Lewy body dementia|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
62165120|NCT01970072|EXPERIMENTAL|5.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight
62165121|NCT01970072|EXPERIMENTAL|6.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight
62165122|NCT01970072|EXPERIMENTAL|7.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight
62165123|NCT01970072|EXPERIMENTAL|8.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight
62165124|NCT01970072|EXPERIMENTAL|9.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight
62165125|NCT01970072|EXPERIMENTAL|10.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight
62165126|NCT01970072|ACTIVE_COMPARATOR|11.Midazolam|Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight
62168074|NCT06443541|EXPERIMENTAL|Leaders|Leaders will receive site-specific (University) invitations and material based on the implementation strategies group.
62168075|NCT06443541|EXPERIMENTAL|Implementation Team Members|Implementation team members will receive passive access to web-based materials and training according to the university-specific implementation strategies group.
62544900|NCT00799825|EXPERIMENTAL|Cervarix group|Female subjects who previously received the active control i.e. Hepatitis A vaccine in the primary study (NCT00122681) and who received the Cervarix vaccine in the current study. The Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1 and 6 months schedule.
62544901|NCT01469078|ACTIVE_COMPARATOR|100 mg Monofer®|
62544902|NCT01469078|ACTIVE_COMPARATOR|200 mg Monofer®|
62544903|NCT01469078|ACTIVE_COMPARATOR|500 mg Monofer®|
62544904|NCT04877821|EXPERIMENTAL|Sintilimab + Anlotinib + Chemotherapy|Experimental: Sintilimab + Anlotinib + Chemotherapy Participants receive Sintilimab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + (Nab paclitaxel weekly + carboplatin (Q3W) x 4 cycles followed by epirubicin + cyclophosphamide Q3W x 4 cycles) as neoadjuvant therapy prior to surgery. After surgery, the subjects will continue to receive sintilimab treatment until one year has elapsed since the start of neoadjuvant therapy (that is, they will receive sintilimab treatment at least 17 times).
62544905|NCT02089659|EXPERIMENTAL|Part 1: Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
62544906|NCT02089659|EXPERIMENTAL|Part 1: Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
62544907|NCT02089659|EXPERIMENTAL|Part 2: Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
62544908|NCT01857479|ACTIVE_COMPARATOR|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]
62544909|NCT01857479|EXPERIMENTAL|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision."
62544910|NCT00583388||A|42 healthy subjects aged 18 to 60 will be be randomly assigned to 6 different treatment sequences.
62544911|NCT04011670|ACTIVE_COMPARATOR|Caffeine group|Participants will receive a caffeine tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
62544912|NCT04011670|PLACEBO_COMPARATOR|Placebo group|Participants will receive a placebo tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
62544913|NCT03883503|EXPERIMENTAL|Beer alone|Consumption of beer (correlated for weight to reach a blood alcohol concentration of 0.8) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
62544914|NCT03883503|ACTIVE_COMPARATOR|Beer and water|Consumption of beer and additional water (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of water, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
62544915|NCT03883503|ACTIVE_COMPARATOR|Beer and stock|Consumption of beer and additional stock(correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
62544916|NCT03883503|PLACEBO_COMPARATOR|Water alone|Consumption of water alone (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
62544917|NCT01563497|EXPERIMENTAL|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
62719148|NCT04436341||Healthy controls|No treatment interventions. Investigations: physical examination, ear-EEG cranial MR, cognitive tests, blood samples
62719149|NCT02679378||ClearSight™ System|To assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery when compared to histopathological assessment.
62719150|NCT02575443|EXPERIMENTAL|Moderate block (MB) group|
62168076|NCT01564134|EXPERIMENTAL|HepB 5ug|receive the vaccine with 5ug HBsAg
62719151|NCT02575443|EXPERIMENTAL|Deep block (DB) group|
62719152|NCT06174207|PLACEBO_COMPARATOR|Placebo Group|Start with Constant Work Rate Exercise Test with 5l/min room air applied via nasal cannula.
62719153|NCT06174207|EXPERIMENTAL|Experimental Group|Start with Constant Work Rate Exercise Test with 5l/min Oxygen Therapy applied via nasal cannula.
62719154|NCT02319486|EXPERIMENTAL|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
62719155|NCT03986125|EXPERIMENTAL|Emotional Awareness & Expression Therapy|Participants will attend three individual sessions focused on becoming aware of and expressing avoided or conflicted emotions.
62719156|NCT03986125|EXPERIMENTAL|Mindfulness Meditation Training|Participants will attend three individual sessions focused on increasing equanimity and compassion and reducing self-judgement.
62719157|NCT03986125|NO_INTERVENTION|Wait-List Control|Participants will receive the intervention of their choice following assessment at four and eight weeks after randomization.
62719158|NCT01960881||Prostate Cancer Patients|Prostate Cancer Patients
62719159|NCT06716372|EXPERIMENTAL|DSiHy Silicone Hydrogel Soft Contact Lens|New Daily disposable contact lenses
62719160|NCT06716372|ACTIVE_COMPARATOR|Daily Silicone Hydrogel Contact Lenses (oB)|Daily disposable contact lens products already on the market
62719161|NCT04575519|ACTIVE_COMPARATOR|Control group|Standard of Care (SoC) TB treatment + placebo twice daily during first 4 weeks of TB treatment followed by placebo once daily for an additional 4 weeks.
62719162|NCT04575519|EXPERIMENTAL|SoC TB + ASA group|Standard of Care (SoC) TB treatment + acetylsalicylic acid 300mg twice daily during first 4 weeks of TB treatment followed by aspirin 300mg once daily for an additional 4 weeks.
62719163|NCT04575519|EXPERIMENTAL|SoC TB + IBU group|Standard of Care (SoC) TB treatment + ibuprofen 400mg twice daily during first 4 weeks of TB treatment followed by ibuprofen 400mg once daily for an additional 4 weeks
62719164|NCT06718764|ACTIVE_COMPARATOR|NSICU Patients with Acute Neurological Injuries (ANI)|ANI are participants having Acute Ischemic Stroke (AIS), Intracerebral Hemorrhage, Subarachnoid Hemorrhage (SAH), Status Epileptics, Traumatic Brain Injury (TBI), Brain Tumors, Meningitis/encephalitis, post cardiac arrest hypoxic ischemic encephalopathy. All participants will be set up with the Neurosteer bedside monitoring system.
62719165|NCT06718764|ACTIVE_COMPARATOR|NSICU Patients without Acute Neurological Injuries (ANI)|Participants without ANI to have neuromuscular disorders such as myasthenia gravis, spine surgery, septic shock, acute respiratory distress syndrome, and Hemorrhagic shock ex. from gastrointestinal bleeding. All participants will be set up with the Neurosteer bedside monitoring system.
62719166|NCT03827811||PandrTB cohort|endTB and endTB-Q study participants on experimental regimen
62719167|NCT04364087||Infertile PCOS women|All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.
62719168|NCT06717412|ACTIVE_COMPARATOR|Conbercept 0.25 mg/0.025mL|intravitreal injection in both eyes on Day 0, with up to 1 re-treatment allowed for each eye if required
62719169|NCT06717412|EXPERIMENTAL|Conbercept 0.15 mg/0.015mL|intravitreal injection in both eyes on Day 0, with up to 1 re-treatment allowed for each eye if required
62168077|NCT01564134|EXPERIMENTAL|HepB 10ug|receive the vaccine with 10ug HBsAg
62719170|NCT06218810|EXPERIMENTAL|single arm|This study includes only on experimental arm
62719171|NCT03434223||Single Cohort|
62719172|NCT01809665||ICD/CRT-P therapy|Standard indication for ICD or triple-chamber pacemaker therapy
62719173|NCT02024854|EXPERIMENTAL|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
62719174|NCT02024854|ACTIVE_COMPARATOR|standard care|after birth the baby is transferred to the neonatal intensive care unit
62719175|NCT02832570|EXPERIMENTAL|Sildenafil|Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
62719176|NCT02832570|PLACEBO_COMPARATOR|Placebo|Single placebo intake approximately 2 hours before the treadmill test.
62719177|NCT05288023|ACTIVE_COMPARATOR|Programmatic azithro 1-11|Biannual oral azithromycin administration to children aged 1-11 months distributed by community health workers
62719178|NCT05288023|NO_INTERVENTION|no intervention|No additional intervention.
62719179|NCT00611390|ACTIVE_COMPARATOR|1|treatment with spray containing aromatic essential oils of some herbal plants.
62719180|NCT00611390|PLACEBO_COMPARATOR|2|spray containing placebo.
62719181|NCT04589169||Positive cohort|Patients who develop delirium
62719182|NCT04589169||Experimental control group|Patients who do not develop delirium
62168078|NCT01564134|EXPERIMENTAL|HepB 20ug|receive the vaccine with 20ug HBsAg
62168079|NCT01564134|EXPERIMENTAL|HepB 60ug|receive the vaccine with 60ug HBsAg
62719183|NCT01248793|EXPERIMENTAL|Placebo|
62719184|NCT01248793|EXPERIMENTAL|Golimumab|
62168080|NCT03200171||Group I|HCC patients who received DAAs for chronic HCV previously (either responders or not)
62168081|NCT03200171||Group II|HCC patients who are naive to DAAs.
62719185|NCT01728142|ACTIVE_COMPARATOR|Non-concussed|Control group; individuals assigned to this group will be either healthy volunteers or individuals sustaining an injury that does not involve concussion. Participants will take both the ANAM and DANA Brief twice at minimum.
62719186|NCT01728142|EXPERIMENTAL|Concussed|Individuals who have been diagnosed with a concussion by a clinician. Participants will take both the DANA and ANAM twice at minimum.
62719187|NCT01497197|EXPERIMENTAL|Gonal-f®+Luveris®|GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 1 until required recombinant human chorionic gonadotropin (r-hCG) level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
62719188|NCT01497197|EXPERIMENTAL|Gonal-f® Followed by Luveris®|GONAL-f® 300 IU per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 6 until required r-hCG level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
62719189|NCT06468787|EXPERIMENTAL|Anatomical Object Labeling and View Identification Comparison|Labeling and identification comparative assessment
62719190|NCT04283188|EXPERIMENTAL|Adolescents with bipolar disorder|25 adolescents aged 14 to 21 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
62719191|NCT02947828||T2D patients|600 type 2 diabetes (T2D) patients recruited from the DD2 cohort
62719192|NCT02947828||Gender- and age-matched healthy controls|100 healthy subjects
62719193|NCT05477654||Parkinson's disease patients|Patients with an early diagnosis of Parkinson's disease
62719194|NCT05477654||Healthy controls|Healthy controls who are age-matched
62719195|NCT02020590|EXPERIMENTAL|ALLOB® Implantation|One arm: ALLOB® Implantation
62719196|NCT00788814|OTHER|Control|Control group
62719197|NCT05009095|EXPERIMENTAL|The Listening Program® with bone conduction headphones|"The Listening Program ® Spectrum music requires a person listen to psycho-acoustically modified classical music online using specialized Waves ™ headphones. The headphones transmit sound through bone conduction which provides another mode of perceiving sound (https://advancedbrain.com). The Listening Program ® can be carried out in the home environment with either the base schedule, two fifteen minute sessions at least 30 minutes apart, or a condensed schedule for 30 minutes.~Bone conduction allows the listening experience to go deeper into the vestibular system which is purported to reduce stress, help regulate the fight or flight response, and allow the listener to achieve a state of calm and relaxed alertness. This theory is based on the function of the vagus nerve, the 10th cranial nerve, which has branches that extend to the eardrum. Stimulation of the vagus nerve stimulates the parasympathetic nervous system (Allen, 2008)."
62719198|NCT01497847||travelers to tropical destinations|
62719199|NCT05011253|EXPERIMENTAL|Intervention|The group which will receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria and makes recommendations for follow-up.
62719200|NCT05011253|NO_INTERVENTION|Control|The group which will not receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria. (Standard practice)
62719201|NCT00960544|EXPERIMENTAL|Capecitabine|Capecitabine - Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
62719202|NCT03130829|EXPERIMENTAL|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
62719203|NCT03130829|PLACEBO_COMPARATOR|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
62544918|NCT01563497|EXPERIMENTAL|PF-05089771 TS formulation fasted|Tablets TS formulation- fasted
62544919|NCT01563497|EXPERIMENTAL|PF-05089771 TS formulation fed|Tablets TS formulation- fed
62544920|NCT05235516|EXPERIMENTAL|treatment arm|
62719204|NCT00244621|EXPERIMENTAL|1|0.05 mg/kg Atacand oral liquid dose
62719205|NCT00244621|EXPERIMENTAL|2|0.20 mg /kg Atacand oral liquid dose
62719206|NCT00244621|EXPERIMENTAL|3|0.40 mg /kg Atacand oral liquid dose
62719207|NCT01897493|ACTIVE_COMPARATOR|Digoxin|0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
62719208|NCT01897493|EXPERIMENTAL|Evacetrapib + Digoxin|130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15
62719209|NCT04169464|OTHER|group I|A group of HCV infected patients treated with DAA therapy including Sofospovir
62719210|NCT04333615|SHAM_COMPARATOR|Control Session|The control session will consist of resting on the treadmill for 30 min. It will be recommended that the patient do cycles in which he / she stands for 3 to 5 minutes and sits for 2 to 3 minutes in between, aiming to minimize the effect of body positioning on cardiovascular responses.
62719211|NCT04333615|EXPERIMENTAL|Self-selected Session|In the self-selected exercise session, individuals will perform 30 min of exercise with self-selected intensity. This means that the duration of the series and the intensity (speed) of the treadmill are at the discretion of the patient. The important thing is that in the end it totals 30 minutes of exercise. This choice of intensity and duration of the series can be made regardless of the occurrence of pain.
62719212|NCT04333615|ACTIVE_COMPARATOR|Walking with pain|In the exercise until maximum pain session (current recommendation of walking exercise prescription for patients with PAD), individuals will perform series of 3 to 5 minutes with adjusted intensity so that they feel moderate to maximum pain. This means that the patient will start walking and the Physical Education professional, experienced and able to prescribe exercises for patients with PAD, will adjust the treadmill speed so that the patient walks with moderate pain or even maximum pain. There will be rest intervals of 2 to 3 minutes. The patient will be encouraged to complete a total of 30 minutes of exercise.
62719213|NCT04444089|EXPERIMENTAL|conventional group, CG|receives Ringer's lactate solution at a rate of 4 ml/kg/h for the first-10 kg of body weight, 2 ml/kg/h for the second-10 kg of body weight, and 1 ml/kg/h for each further kg of body weight. The deficit volume is calculated as the maintenance volume multiplied by fasting hours and given as follows: 50% of the volume in the first hour, 25% of the volume in the second hour, and 25% of the volume in the third hour, in addition to the aforementioned maintenance volume
62719214|NCT04444089|EXPERIMENTAL|restricted group, RG|Patients in the RG receives Ringer's lactate solution at a rate of 3 ml/kg/h from the start to the end of surgery.
62719215|NCT02795494||Perthes Group|Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
62719216|NCT02795494||Fracture Control Group|Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline.
62719217|NCT05362994|ACTIVE_COMPARATOR|Plain old balloon (POB) arm|"Balloon catheter used in the POB arm will be the Medtronic Euphora Rapid Exchange Balloon Dilatation Catheter, with diameters from 1.5 mm to 4.0 mm, and length from 6 to 30 mm,"
62544921|NCT05235516|PLACEBO_COMPARATOR|placebo arm|
62719218|NCT05362994|EXPERIMENTAL|Drug-eluting balloon (DEB) arm|The Selution SLR™ sirolimus-eluting balloon catheter system comprises of a semi-compliant polyamide balloon catheter with low tip profile coated with sirolimus drug (concentration: 1.00 μg/mm2 of balloon surface). Selution sustained limus release (SLR™) sirolimus-eluting balloon provides controlled and 90-day sustained release of sirolimus given its MicroReservoir technology made from biodegradable polymer intermixed with sirolimus. The balloon platform is the percutaneous transluminal coronary angioplasty (PTCA) rapid exchange catheter, with diameters from 2.0 to 4.5 mm and length from 15 to 30 mm.
62719219|NCT04486690|EXPERIMENTAL|propofol group|"* Propofol infusion, 25-150mic/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min"
62719220|NCT04486690|ACTIVE_COMPARATOR|ketofol group|"* Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min"
62719221|NCT01317303|EXPERIMENTAL|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
62719222|NCT01317303|EXPERIMENTAL|cTBS-PAS|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
62719223|NCT01317303|EXPERIMENTAL|iTBS|190 seconds of intermittent theta-burst stimulation
62719224|NCT01317303|EXPERIMENTAL|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
62719225|NCT02604459|ACTIVE_COMPARATOR|Usual general anesthesia care|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
62719226|NCT02604459|EXPERIMENTAL|Optimized general anesthesia care|The subjects will have general anesthesia with propofol, fentanyl, sevoflurane. In addition the subjects will be monitored with a depth of anesthesia monitor (BIS) and a cerebral oximeter (Foresight). These additional monitors will be used to direct care. BP management: Systolic BP will be maintained within 20% of baseline systolic BP variables.
62719227|NCT02604459|ACTIVE_COMPARATOR|Mini Mental State Exam|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
62719228|NCT02604459|OTHER|Tested and Excluded|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
62719229|NCT05908162||Patients with sepsis on day 1|
62719230|NCT05908162||Patients with sepsis on day 7|
62719231|NCT05908162||Patients with severe bacterial infection|
62719232|NCT05908162||Patients with severe viral infection|
62719233|NCT03421184|EXPERIMENTAL|Patient with Systemic Lupus Erythematosus|30 women with SLE
62719234|NCT03421184|ACTIVE_COMPARATOR|Patients with other autoimmune diseases|20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia
62719235|NCT03421184|ACTIVE_COMPARATOR|Healthy control|30 healthy control women
62719236|NCT03308682|EXPERIMENTAL|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
62719237|NCT05948189|ACTIVE_COMPARATOR|intervention group|a 6-week exercise program
62719238|NCT05948189|NO_INTERVENTION|Controls|a brochure to read
62719239|NCT05439980||CKD aged 8-<13 years|8-\<13 years n = 25
62719240|NCT05439980||CKD aged 13-18 years|13-18 years n = 25
62719241|NCT05439980||Parents/caregivers|Parent/caregivers of children and young people with CKD 4-5D n=50
62719242|NCT01482130|EXPERIMENTAL|Training group|All participants in the training group will pursue a 12 weeks of strength training.
62719243|NCT01482130|OTHER|Controls|The control group will be encouraged to follow a training program according to recommended exercise guidelines
62719244|NCT03309982|EXPERIMENTAL|Plant polyphenol blend|The study product (4 g) consists of 3 g of a mix a maltodextrins, and 1 g of anthocyanin-rich plant polyphenol blend containing: 1) 100 mg bilberry extract; 2) 300 mg black currant extract; and 3) 600 mg black rice extract.
62719245|NCT03309982|PLACEBO_COMPARATOR|Placebo|The placebo (4 g) consists of a mix of maltodextrins (3.85 g) and Red Dye No. 40 (0.125 g) and Blue Dye No. 1 (0.025 g).
62719246|NCT03368781|EXPERIMENTAL|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
62719247|NCT04197284|ACTIVE_COMPARATOR|Control group|In control group subjects will undergo individual kinesitherapy- isometric exercise for strengthening of the quadriceps muscle.
62719248|NCT04197284|ACTIVE_COMPARATOR|Biofeedback group|Biofeedback group will perform physical therapy using biofeedback device for better activation control of the quadriceps muscle with audio and visual signal. They will also perform isometric exercise.
62719249|NCT04197284|ACTIVE_COMPARATOR|Electrical stimulation|Electrical stimulation group will receive electrical stimulation of the quadriceps muscle and they will also perform isometric exercise.
62168082|NCT04351100||Diacerein group|Osteoarthritis and dry eye patients treated with Diacerein
62168083|NCT04384692|EXPERIMENTAL|Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)|See detailed description.
62719250|NCT04772209|ACTIVE_COMPARATOR|Sodium bicarbonate Arm|In this arm, the catheter lock solution is sodium bicarbonate
62719251|NCT04772209|ACTIVE_COMPARATOR|Heparin arm|In this arm, classic heparin will be used as a reference catheter lock solution (standard lock solution)
62719252|NCT01044030|EXPERIMENTAL|Xylitol syrup|
62719253|NCT01044030|PLACEBO_COMPARATOR|Placebo|
62719254|NCT06632626|EXPERIMENTAL|Task oriented training group|This group included 30 patients suffering from taxanes induced peripheral neuropathy who received 30 minutes of task-oriented exercises, three sessions per week for four weeks along with 30 minutes of the traditional physical therapy.
62719255|NCT06632626|ACTIVE_COMPARATOR|Traditional physical therapy group|This group included 30 patients suffering from taxanes induced peripheral neuropathy who received 30 minutes of the traditional physical therapy only, three sessions per week for four weeks.
62719256|NCT02834429||endoscopy patients|We will recruit patients (n=1000) from the endoscopy department at the Royal Hallamshire Hospital, Sheffield, United Kingdom (UK).
62719257|NCT02332473|ACTIVE_COMPARATOR|Arm A|Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
62719258|NCT02332473|EXPERIMENTAL|Arm B|Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
62719259|NCT00894595|EXPERIMENTAL|Intervention group|The clubs in the intervention group are instructed to perform a warm-up program at two training sessions per week throughout the entire 2009 competitive season.
62165127|NCT04277442|EXPERIMENTAL|Treatment (nivolumab, decitabine, venetoclax)|"INDUCTION: Patients receive nivolumab IV over 30 minutes on day 15 of cycle 1 and days 1 and 15 of subsequent cycles, decitabine IV over 60 minutes on days 1-10 of induction cycle 1 (and cycles 2 and 3 if needed), and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a CR or CRi receive nivolumab IV over 30 minutes on days 1 and 15, decitabine IV over 60 minutes on days 1-5, and venetoclax PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62165128|NCT03612453|EXPERIMENTAL|Intervention group|
62165129|NCT03612453|ACTIVE_COMPARATOR|Control group|
62165130|NCT01906255||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender, pregnancy) who are participating in observational or clinical studies on FTC/TDF for PrEP
62165131|NCT01304953|PLACEBO_COMPARATOR|P+P|
62165132|NCT01304953|EXPERIMENTAL|P+T|
62165133|NCT01304953|PLACEBO_COMPARATOR|S+P|
62165134|NCT01304953|EXPERIMENTAL|S+T|
62165135|NCT03640793|EXPERIMENTAL|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
62165136|NCT02676739|PLACEBO_COMPARATOR|Placebo|Capsule with no active medical ingredients to be taken orally once a day for 12 weeks.
62165137|NCT02676739|ACTIVE_COMPARATOR|Adderall XR 10mg|10mg Adderall XR capsule to be taken orally once a day for 12 weeks.
62719260|NCT00894595|ACTIVE_COMPARATOR|Control group|The clubs in the control group are instructed to train and play as usual throughout the 2009 season
62165138|NCT02676739|ACTIVE_COMPARATOR|Adderall XR 20mg|20mg Adderall XR capsule to be taken orally once a day for 12 weeks.
62165139|NCT01552642|ACTIVE_COMPARATOR|Intervention Group|Intervention Group
62165140|NCT01552642|NO_INTERVENTION|Control Group|Control Group
62165141|NCT03877133|OTHER|Regional oxygen saturation group|Near-infrared spectroscopy application to the skin near the kidney
62165142|NCT03094520|EXPERIMENTAL|Anodal tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with anodal stimulation
62544922|NCT02677350|EXPERIMENTAL|Pilot|Twenty (20) subjects will be treated with 20 million (2 x 10\^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection.
62544923|NCT04637802|ACTIVE_COMPARATOR|Pre-operative and Post-operative Education intervention|This arm receives access to Patient Education intervention in the pre- and post-operative phases.
62165143|NCT03094520|SHAM_COMPARATOR|Sham tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with sham stimulation
62544924|NCT04637802|EXPERIMENTAL|Pre-operative CBT intervention (SurgeryPal), Post-operative Education intervention|This arm receives access to CBT intervention in the pre-operative phase and Patient Education in the post-operative phase.
62544925|NCT04637802|EXPERIMENTAL|Pre-operative Education intervention, Post-operative CBT intervention (SurgeryPal)|This arm receives access to Patient Education intervention during the pre-operative period and CBT intervention during the post-operative period.
62544926|NCT04637802|EXPERIMENTAL|Pre-operative and Post-operative CBT intervention (SurgeryPal)|This arm receives access to CBT intervention during the pre-operative and post-operative period.
62544927|NCT06063057|EXPERIMENTAL|low-dose experimental group|phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ：6\~71 months old
62544928|NCT06063057|EXPERIMENTAL|medium-dose experimental group|phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ：6\~71 months old
62544929|NCT06063057|EXPERIMENTAL|high-dose experimental group|phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ：6\~71 months old
62719261|NCT04595786|ACTIVE_COMPARATOR|TXA group|The TXA group will receives Tranexamic acid intraoperative.
62719262|NCT04595786|PLACEBO_COMPARATOR|Placebo group|The TXA group will receives 0.9% saline intraoperative.
62165144|NCT03325829||Patients with colonic diverticula|No interventional study
62165145|NCT05908149|EXPERIMENTAL|HEMIPLEGIC PATIENTS|HEMIPLEGIC PATIENTS WITH PES EQUINUS WILL BE EXAMINED BY GAIT ANALYSIS WITH AND WITHOUT THE INSOLE SPLINT, RANDOMLY
62165146|NCT06585280||orthosis users|
62165147|NCT06585280||prosthesis users|
62165148|NCT01840696|EXPERIMENTAL|Regadenoson|
62165149|NCT06225050|EXPERIMENTAL|HSC Recipient|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
62165150|NCT05650580|EXPERIMENTAL|Dose Escalation and Expansion|Participants with relapsed/Refractory Non-Hodgkin's Lymphoma or Advanced solid tumor will receive TR115 at escalating and expansion dose levels.
62165151|NCT03258983||The Diet, Cancer and Health cohort|
62165152|NCT01884376|EXPERIMENTAL|Neuromaix implantation|Implantation of Neuromaix during an diagnostic nerve biopsy
62165153|NCT06388876|EXPERIMENTAL|Exercise|Exercise group did aerobic exercise during 6 weeks. Also this group took advice including lifestyle.
62165154|NCT06388876|EXPERIMENTAL|control|Control group only took advice including lifestyle.
62165155|NCT01556087|EXPERIMENTAL|Distress Tolerance|7 sessions aimed at increasing distress tolerance skills
62165156|NCT01556087|PLACEBO_COMPARATOR|Health Education|7 didactic health education sessions
62165157|NCT03296007|EXPERIMENTAL|Mindfulness Meditation App|Participants randomized to this arm will use a smartphone app to practice mindfulness meditation for 12 minutes.
62165158|NCT03296007|ACTIVE_COMPARATOR|Mindfulness Meditation No App|Participants randomized to this arm will not use a smartphone app, but will receive instructions to practice mindfulness meditation for 12 minutes.
62165159|NCT01601821|ACTIVE_COMPARATOR|Arm A (CsA+Rapamune+CS)|
62165160|NCT01601821|EXPERIMENTAL|Arm B (CsA+MMF+CS)|
62168084|NCT01792206|ACTIVE_COMPARATOR|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
62168085|NCT01792206|PLACEBO_COMPARATOR|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
62168086|NCT01435499|EXPERIMENTAL|Cohort A|Cohort A will receive four doses of vaccine, each containing 5E7 melanoma GVAX cells.
62719263|NCT03768427|EXPERIMENTAL|EZ 10 mg/Ator 10 mg|Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
62719264|NCT03768427|ACTIVE_COMPARATOR|Atorvastatin 20 mg|2 atorvastatin 10 mg tablets administered orally, QD for 84 days
62719265|NCT03768427|EXPERIMENTAL|EZ 10 mg/Ator 20 mg|Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
62719266|NCT03768427|ACTIVE_COMPARATOR|Atorvastatin 40 mg|2 atorvastatin 20 mg tablets administered orally, QD for 84 days
62719267|NCT00945659|ACTIVE_COMPARATOR|Standard Care|"Standard Care constitutes intensified diabetes management, an enrollment criterion for the study, consisting of either continuous subcutaneous insulin infusion (insulin pump) or multiple daily injections using a basal-bolus approach. All patients must be using carbohydrate counting and have prescribed correction factors for targeted insulin bolus dose adjustments."
62719268|NCT00945659|ACTIVE_COMPARATOR|Continuous Glucose Sensor|Patients will have the same diabetes management regimen as those in the Standard Care group. In addition they will be given a continuous glucose sensor, receive expert instruction in its use, and be guided by a physician and diabetes educator in achieving glycemic benefits through retrospective and real-time interpretation of CGS results and by learning to respond judiciously to the various CGS alarms.
62719269|NCT00945659|EXPERIMENTAL|CGS + Behavior Therapy|Patients in the use group will receive the same medical management as the Continuous Glucose Sensor group above. In addition, they will have 6 scheduled encounters with a behavior therapist that are designed to reduce or eliminate typical behavioral and/or psychological barriers to optimal use of CGS as part of diabetes care.
62719270|NCT04482725|EXPERIMENTAL|S1|"Day 1: Trial products 1-2-12-3-11-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 10-5-9-6-8-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719271|NCT04482725|EXPERIMENTAL|S2|"Day 1: Trial products 2-3-1-4-12-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 11-6-10-7-9-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719272|NCT04482725|EXPERIMENTAL|S3|"Day 1: Trial products 3-4-2-5-1-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 12-7-11-8-10-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719273|NCT04482725|EXPERIMENTAL|S4|"Day 1: Trial products 4-5-3-6-2-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 1-8-12-9-11-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719274|NCT04482725|EXPERIMENTAL|S5|"Day 1: Trial products 5-6-4-7-3-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 2-9-1-10-12-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719275|NCT04482725|EXPERIMENTAL|S6|"Day 1: Trial products 6-7-5-8-4-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 3-10-2-11-1-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719276|NCT04482725|EXPERIMENTAL|S7|"Day 1: Trial products 7-8-6-9-5-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 4-11-3-12-2-1-given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719277|NCT04482725|EXPERIMENTAL|S8|"Day 1: Trial products 8-9-7-10-6-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 5-12-4-1-3-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719278|NCT04482725|EXPERIMENTAL|S9|"Day 1: Trial products 9-10-8-11-7-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 6-1-5-2-4-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719279|NCT04482725|EXPERIMENTAL|S10|"Day 1: Trial products 10-11-9-12-8-1 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 7-2-6-3-5-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719280|NCT04482725|EXPERIMENTAL|S11|"Day 1: Trial products 11-12-10-1-9-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 8-3-7-4-6-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719281|NCT04482725|EXPERIMENTAL|S12|"Day 1: Trial products 12-1-11-2-10-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 9-4-8-5-7-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
62719282|NCT05505461|EXPERIMENTAL|Neoadjuvant therpy|Neoadjuvant chemoradiation plus SOX and PD-1 antibody
62719283|NCT03087175|EXPERIMENTAL|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
62719284|NCT03087175|ACTIVE_COMPARATOR|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
62719285|NCT05771129|EXPERIMENTAL|Pulsed Electric Field Ablation System was used in treating chronic bronchitis|All participants meet inclusion and exclusion criteria and signed the ICF will be enrolled to experimental arm.
62719286|NCT04960007||Group A|Sarcopenia patients.
62719287|NCT04960007||Group B|Dynapenia patients.
62719288|NCT04960007||Group C|Age and gender matched non-sarcopenia and non-dynapenia patients.
62168087|NCT01435499|EXPERIMENTAL|Cohort B|Cohort B will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells.
62168088|NCT01435499|EXPERIMENTAL|Cohort C|Cohort C will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells. One day prior to each vaccination, patients in cohort C will receive a single, low dose of intravenous cyclophosphamide.
62719289|NCT06714695|OTHER|Pediatric patients before and after using chitosan mouthwash|pediatric patients with black stains will be recruited in the study. Scaling and polishing will be done then followed up for 3 months, then scaling and polishing will be repeated after follow up period and the patient will be given chitosan mouthwash to be used for additional 3 months.
62719290|NCT03293121|EXPERIMENTAL|Strength and Coordination Training|The strength and coordination group will perform a progression of exercises utilizing body weight and resistance bands as resistance. Exercises include squats, lunges, jumps etc. typical of a normal strength training program.
62719291|NCT03293121|ACTIVE_COMPARATOR|Walking|The walking group will be instructed to walk 3x/week, progressing from 30 to 45 min over 8 weeks.
62719292|NCT05821660|EXPERIMENTAL|Five-day hypocaloric and ketogenic programme|The group will receive a five-day remotely delivered hypocaloric and ketogenic programme followed by a four-day food reintroduction period
62719293|NCT05821660|NO_INTERVENTION|Control|The group will maintain their habitual diet
62719294|NCT03637491|EXPERIMENTAL|Avelumab and binimetinib|Open label
62719295|NCT03637491|EXPERIMENTAL|Avelumab, binimetinib and talazoparib|Open label
62719296|NCT03637491|EXPERIMENTAL|Binimetinib and talazoparib.|Open label.
62719297|NCT02805543||diabetes group|34 T2DM patients without vascular complications as diabetes group
62719298|NCT02805543||control group|32 healthy people were recruited as control group
62719299|NCT01306526||Moderate to Severe OSA|
62719300|NCT01291108|EXPERIMENTAL|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.
62719301|NCT01291108|EXPERIMENTAL|AGN-210669 + bimatoprost|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.
62719302|NCT01291108|EXPERIMENTAL|AGN-210669 + bimatoprost vehicle|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
62719303|NCT01291108|ACTIVE_COMPARATOR|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.
62719304|NCT01291108|EXPERIMENTAL|bimatoprost + AGN-210669|bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.
62719305|NCT01291108|OTHER|bimatoprost + bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
62719306|NCT05556889|EXPERIMENTAL|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
62719307|NCT05556889|OTHER|Traditional auriculotemporal nerve blockade|The traditional method of auriculotemporal nerve block is to inject the needle 1\~1.5 cm vertically at the level of tragus and posterior of superficial temporal artery, and inject 2-3 ml of local anesthetics after pumping back without blood
62719308|NCT03670160|ACTIVE_COMPARATOR|Phenobarbital|Phenobarbital loading dose 20mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital continued throughout the infants hospitalization.
62719309|NCT03670160|ACTIVE_COMPARATOR|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be continued to achieve control of NAS symptoms. Clonidine may be weaned after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
62719310|NCT06461039|EXPERIMENTAL|NNC0487-0111|Participants will receive oral dosing of NNC0487-0111 and gradually will escalate from dose 1 to dose 2. The oral NNC0487-0111 treatment will be followed by s.c. NNC0487-0111 treatment with dose escalating from dose 3 to dose 4.
62719311|NCT01299506||Trabectedin|The administration of chemotherapy regimen with trabectedin will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
62719312|NCT01299506||Conventional care|This includes other palliative chemotherapy or biological therapy or best supportive care.
62719313|NCT04460781||1|Pregnant women from the VAP00003 Study and their offspring - Pregnant women from the VAP00003 Study (NCT03694392) between September 2018 and May 2020 (2 influenza seasons), and infants born from this cohort of pregnant women
62719314|NCT03070990|EXPERIMENTAL|Arm A: Enfortumab vedotin 1.0 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
62719315|NCT03070990|EXPERIMENTAL|Arm B: Enfortumab vedotin 1.25 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
62719316|NCT03520309|EXPERIMENTAL|International Dental Federation|Dental Treatment: according to the decision based on the International Dental Federation (FDI) criteria
62168089|NCT04120064|EXPERIMENTAL|Large bolus|
62168090|NCT04120064|ACTIVE_COMPARATOR|Standard|
62168091|NCT02135588|EXPERIMENTAL|Active Treatment|Intra-pleural deoxyribonuclease 5mg and intra-pleural Alteplase 10mg, every 12 hours over 72 hours (total of 6 treatments)
62719317|NCT03520309|EXPERIMENTAL|Caries Around Restorations System|Dental Treatment: according to the decision based on the Caries Around Restorations System (CARS) and treatment decision proposed by the International Caries Classification and Management System (ICCMS)
62719318|NCT00795028|ACTIVE_COMPARATOR|1|Standard Care for people after a hip fracture
62719319|NCT00795028|EXPERIMENTAL|2|Standard Care + exercise intervention
62719320|NCT05067868|EXPERIMENTAL|Replagal|Participants with fabry disease will receive Replagal 0.2 milligram per kilogram (mg/kg) intravenous infusion on Day 1 and every 2 weeks up to Week 51.
62719321|NCT05804929||Control|21.5≤BMI\<25, age between 25-40 years old, 200subjects.
62719322|NCT05804929||Superlean|BMI≤18.5, age between 25-40 years old, 200 subjects.
62719323|NCT01326299|ACTIVE_COMPARATOR|Nutritional ingredient|Dissolve in water and consume with meal
62719324|NCT01326299|PLACEBO_COMPARATOR|Carbohydrate|dissolve in water and consume with meal
62719325|NCT01326299|EXPERIMENTAL|#1 Nutrtitional ingredient + Fiber|Dissolve in water and consume with meal
62719326|NCT01326299|EXPERIMENTAL|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
62719327|NCT01326299|EXPERIMENTAL|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
62719328|NCT02320864||Non-surgical group|Adults who have knee osteoarthritis, but do not elect to have a total knee replacement surgery.
62719329|NCT02320864||Surgical group|Adults who have knee osteoarthritis and elect to have total knee replacement surgery.
62719330|NCT05412992|ACTIVE_COMPARATOR|DMTS Patch|DMTS applied to upper outer arm
62719331|NCT05412992|PLACEBO_COMPARATOR|Placebo Patch|Placebo system (with no drug) to match DMTS applied to the upper arm
62719332|NCT00998257||Group 1|
62719333|NCT05795270||Sleep apnea syndrome with excessive daytime sleepiness|
62719334|NCT03820011|EXPERIMENTAL|PEM-Plus Group|For Aim 1, 6 parents of young children were recruited to perform tasks related to navigating the PEM+ interface. Data on completion rate and time, as well as user satisfaction, were analyzed to guide PEM+ improvements. For Aim 2, we recruited 27 participants to enroll in a feasibility trial of PEM+. Caregivers who completed the YC-PEM e-PRO to evaluate their child's participation clicked on a weblink to begin PEM+, whereby they built on their YC-PEM responses for the purpose of creating a participation-focused care plan to share with their child's rehabilitation team. Caregivers were instructed to complete the PEM+ over a two-week (14 day) period because it mimics what would be provided in routine care.
62719335|NCT04982991|EXPERIMENTAL|SAR443820|Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods
62719336|NCT00509327|ACTIVE_COMPARATOR|1|bisacodyl 10mg twice daily from one day preoperative to day three postoperative
62719337|NCT00509327|PLACEBO_COMPARATOR|2|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
62719338|NCT03366363|EXPERIMENTAL|Electro-acupuncture|"5 compulsory acupoints (ST35、EX-LE5、LR8、GB33 and Ashi) and 3 optional matching acupoints (stomach meridian syndrome：ST34、ST36、ST32、ST40、EX-LE2；gallbladder meridian syndrome：GB31、GB36、GB34、GB39、GB41；bladder meridian syndrome：BL39、BL40、BL57、BL60；San Yin meridian syndrome：LR7、SP9、SP10、KI10、SP4、SP6、LR3、KI3) will be chosen. Needles will be stimulated manually to achieve De Qi sensation and an electrical apparatus (Nanjing Jisheng Medical Co., Ltd., wave of 2/100Hz) will be then connected to the needles with alligator clips in pairs LR8-GB33 and two other matching acupoints. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity. Patients will receive 30-minute, 24 sessions intervention over eight weeks."
62719339|NCT03366363|EXPERIMENTAL|manual acupuncture|Participants in the manual acupuncture group have the same schedule as the Electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
62719340|NCT03366363|SHAM_COMPARATOR|sham acupuncture|Those in the sham acupuncture group receive shallow acupuncture at non-acupoints without manipulation，Deqi or actual current output.
62719341|NCT02774434|EXPERIMENTAL|JM-105|Within 15 minutes of each ordered blood sample 2 TcB measurements will be performed using the JM-105 on the sternum and forehead. Subject's participation will end after a 10 day period.
62719342|NCT00692887||1|Subjects diagnosed as new CNV or treated CNV
62168092|NCT03403556|EXPERIMENTAL|Rosuvamibe ® Tab.|Rosuvastatin 10mg/Ezetimibe10mg
62168093|NCT03403556|ACTIVE_COMPARATOR|Monorova ® Tab.|Rosuvastatin 20mg
62719343|NCT03389308|EXPERIMENTAL|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
62719344|NCT06275230||chronic obstructive pulmonary disease|Patients with COPD undergoing bronchoscope.
62719345|NCT03842267|ACTIVE_COMPARATOR|Gemigliptin 50mg|
62719346|NCT03842267|PLACEBO_COMPARATOR|Gemigliptin Placebo|
62719347|NCT04603001|EXPERIMENTAL|Dose Escalation Arm A (Monotherapy)|Patients not requiring a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
62719348|NCT04603001|EXPERIMENTAL|Dose Escalation Arm B (Monotherapy)|Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.
62719349|NCT04603001|EXPERIMENTAL|Dose Escalation Arm C (LY3410738, Venetoclax, and Azacitidine)|Patients with no prior venetoclax therapy and not requiring a strong CYP3A4 inhibitor for active treatment within 7 days of starting LY3410738.
62719350|NCT04603001|EXPERIMENTAL|Cohort 1|Patients with relapsed/refractory (R/R) AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.
62719351|NCT04603001|EXPERIMENTAL|Cohort 2|Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.
62719352|NCT04603001|EXPERIMENTAL|Cohort 3|Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation.
62719353|NCT04603001|EXPERIMENTAL|Cohort 4|Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.
62719354|NCT04603001|EXPERIMENTAL|Cohort 5|Patients with newly diagnosed AML, R/R AML, or other advanced hematologic malignancy harboring IDH1 and/or IDH2 mutations with no prior venetoclax therapy. Strong CYP3A4 inhibitor allowed but not required.
62719355|NCT04162106|ACTIVE_COMPARATOR|Ultravision™ System|Smoke management during laparoscopic cholecystectomy performed with the Ultravision™ System
62719356|NCT04162106|ACTIVE_COMPARATOR|Airseal® iFS|Smoke management during laparoscopic cholecsystectomy performed with the Airseal® iFS
62544930|NCT06063057|ACTIVE_COMPARATOR|Active control group|phase Ⅰ: 6\~71 months old; phase Ⅱ：6\~71 months old
62719357|NCT04596722|ACTIVE_COMPARATOR|Assigned Interventions|oral active pomella taken by mouth once per day
62719358|NCT04596722|PLACEBO_COMPARATOR|Placebo|oral placebo taken by mouth once per day
62719359|NCT05660603|PLACEBO_COMPARATOR|control group|patients will be operated on under general anesthesia
62544931|NCT05798455|EXPERIMENTAL|Intervention arm|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
62544932|NCT02460146|ACTIVE_COMPARATOR|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
62544933|NCT02460146|PLACEBO_COMPARATOR|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
62544934|NCT02552901|EXPERIMENTAL|LFT Dye Detection Monitor|
62544935|NCT02552901|ACTIVE_COMPARATOR|Serial Blood Draws|
62544936|NCT04736225|EXPERIMENTAL|ISTE Group|This program includes a 60-min small-group lesson, a 20-min individual instruction. The education program's goal is to teach patients to self-titrate their insulin doses every six days to maintain their six-day average blood glucose levels \< 120 mg/dl
62544937|NCT04736225|PLACEBO_COMPARATOR|Non-ISTE Group|The usual care (a 15-min individual education) was giving at the Diabetes Health Education Center. They were taught how to self-inject insulin and test and record their before-breakfast and before-dinner blood glucose levels daily at home.
62544938|NCT00004263|EXPERIMENTAL|Cytarabine + UCN-01|
62544939|NCT02317029|EXPERIMENTAL|"1 (Standard: Oxygen / LIFEPAK 20)"|"1. Intervention: Cardioversion with a biphasic truncated exponential waveform~2. Intervention: Hyperoxia during cardioversion"
62544940|NCT02317029|ACTIVE_COMPARATOR|2 (room air / LIFEPAK 20)|"1. Intervention: Cardioversion with a biphasic truncated exponential waveform~2. Intervention: Normoxia during cardioversion"
62544941|NCT02317029|ACTIVE_COMPARATOR|3 (Oxygen / Schiller Defigard 5000)|"1. Intervention: Cardioversion with a pulsed biphasic waveform~2. Intervention: Hyperoxia during cardioversion"
62544942|NCT02317029|ACTIVE_COMPARATOR|4 (Room air / Schiller Defigard 5000)|"1. Intervention: Cardioversion with a pulsed biphasic waveform~2. Intervention: Normoxia during cardioversion"
62544943|NCT04414774|EXPERIMENTAL|using app first|The experimental group will immediately start using the GGSI app, for a period of 15 days (T1). After 15 days (T2) the experimental group ceases its use of the app. The end of this period is marked T3. The research team will contact the experimental group on T1, T2 and T3 in order to fill out questionnaires regarding suicide ideation and related risk factors.
62544944|NCT04414774|ACTIVE_COMPARATOR|waiting list|During the first 15 days, the control group is inactive (T1). After 15 days (T2) the control group will start using GGSI app for additional 15 days (T3). Participants will fill questionnaires about suicide ideation and related risk factors three time during the study on: T1, T2 and T3.
62544945|NCT01109147|ACTIVE_COMPARATOR|aripiprazole|"Imagery: A fMRI session is conducted on schizophrenic patients under aripiprazole (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
62544946|NCT01109147|ACTIVE_COMPARATOR|risperidone|"Imagery: A fMRI session is conducted on schizophrenic patients under rsiperidone (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
62544947|NCT01109147|OTHER|control|Imagery: A fMRI session is conducted on healthy volunteers. Genetic: pharmacogenetic sampling. One sample was collected for each subject.
62544948|NCT02029196|EXPERIMENTAL|e-vapour product (EVP)|Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).
62544949|NCT02029196|ACTIVE_COMPARATOR|Conventional cigarette (CC)|Subjects who continue smoking their usual conventional cigarette (CC) brand.
62544950|NCT03526159|EXPERIMENTAL|Gentamicin Sulfate|"IV Arm:~7.5 mg/kg gentamicin once daily for 14 days.~Topical Arm:~0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites."
62544951|NCT03331835|EXPERIMENTAL|Brodalumab|"Kyntheum® (brodalumab)~pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.~First 3 injections are administered weekly, and hereafter every two weeks (Q2W)."
62544952|NCT03331835|ACTIVE_COMPARATOR|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)~Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)~Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
62544953|NCT02376400|EXPERIMENTAL|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
62544954|NCT02376400|EXPERIMENTAL|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
62544955|NCT02376400|EXPERIMENTAL|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
62544956|NCT02376400|EXPERIMENTAL|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
62544957|NCT05986695|ACTIVE_COMPARATOR|Peer Comparison Report|Clinicians assigned to peer comparison, will receive messages by secure email every two weeks regarding their SGLT2i and MRA prescribing performance.
62544958|NCT05986695|ACTIVE_COMPARATOR|Alert|Clinicians in the alert arm will receive an alert two business days prior to a patient's upcoming appointment. Clinicians will receive approximately two alerts per week.
62544959|NCT05986695|ACTIVE_COMPARATOR|Alert and Peer Comparison|The combined alert and peer comparison arm will receive both interventions.
62544960|NCT05986695|NO_INTERVENTION|Control|No alert or peer comparison
62168094|NCT01509040|ACTIVE_COMPARATOR|Control|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
62544961|NCT01048372||Early HIV infection|HIV infected adults with early evidence of suppressed cell-mediated immunity but whose disease has not progressed far enough to indicate antiretroviral therapy.
62544962|NCT01048372||Control|Healthy adults without HIV infection.
62544963|NCT00747032|ACTIVE_COMPARATOR|1|NYC 0462 Ointment
62544964|NCT00747032|PLACEBO_COMPARATOR|2|Placebo
62544965|NCT05107596|ACTIVE_COMPARATOR|Post ST Elevation Myocardial Infarction/ Heart Attack|Image patients who have had a heart attack
62719360|NCT05660603|ACTIVE_COMPARATOR|LSP group (lumbar and sacral plexus block)|patients will receive ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of 0.25% of bupivacaine.
62719361|NCT05660603|ACTIVE_COMPARATOR|CP group (circum-psoas block)|patients will receive ultrasound-guided circum-psoas blocks with 40 ml of 0.25% of bupivacaine.
62719362|NCT01727934|EXPERIMENTAL|Miravirsen sodium|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg.
62719363|NCT01305187|EXPERIMENTAL|Hyaluronic Acid Filler - Medical Device|
62719364|NCT05150678|EXPERIMENTAL|removal of cs scar|gruop 1 will remove the scar
62719365|NCT05150678|EXPERIMENTAL|non removal of the scar|gruop2 will not remove the scar
62719366|NCT03423511|EXPERIMENTAL|MiStent II Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
62719367|NCT03423511|ACTIVE_COMPARATOR|Xience or Promus Coronary Artery Stents|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
62719368|NCT00204529|EXPERIMENTAL|PegIFN|pegylated interferon-alpha-2a
62719369|NCT00204529|ACTIVE_COMPARATOR|IFN|interferon-alpha-2a
62719370|NCT02935192|EXPERIMENTAL|Vaccine Arm|Seasonal trivalent split, inactivated influenza vaccine
62719371|NCT02935192|PLACEBO_COMPARATOR|Placebo Arm|Phosphate buffered saline
62719372|NCT01269684|EXPERIMENTAL|1|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
62719373|NCT05174585|EXPERIMENTAL|Arm A, JAB-BX102 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-BX102 will be administered as monotherapy to determine the MTD and RP2D.
62719374|NCT05174585|EXPERIMENTAL|Arm B, JAB-BX102 combination with pembrolizumab, Phase 2a, Dose Expansion|JAB-BX102 will be administered in combination with pembrolizumab in specific solid tumor patients to evaluate the preliminary antitumor activity.
62719375|NCT03368066|EXPERIMENTAL|Hospitalized cirrhosis patients|Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency
62719376|NCT06718023|EXPERIMENTAL|Nordic walking|Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. The primary focus is on utilizing a specialized pole for engaging in cross-country walking. This regimen entails approximately 10 minutes of warm-up exercises, followed by around 40 minutes of brisk walking, and concluding with a period of relaxation stretching lasting between 5 to 8 minutes.
62719377|NCT06718023|NO_INTERVENTION|Daily life|The individuals engaged in routine daily tasks, while being advised against incorporating any supplementary physical exertion.
62719378|NCT06718023|EXPERIMENTAL|Strength training|Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
62719379|NCT06718023|EXPERIMENTAL|Bungy Pump Exercises|The training lasts approximately 60 minutes each time, 3 times a week, for a period of 12 weeks. The main emphasis is placed on the use of a specialist Bungy Pump pole. Bungy Pump training allows participants to combine aerobic and strength training. Bungy Pump poles contain a built-in shock absorber (RSA) in the form of an elastic band. The additional resistance generated by the stretched band increases the overall intensity of the exercise and increases calorie consumption. The program classes will include approximately 10 minutes of warm-up exercises, followed by approximately 40 minutes of brisk walking, and at the end a period of relaxation stretching lasting from 5 to 8 minutes.
62719380|NCT06253715|ACTIVE_COMPARATOR|Regimen 1: Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E)|8 weeks of daily HRZ(E) followed by either 16 or 24 weeks of daily HR, per local standard of care
62719381|NCT06253715|EXPERIMENTAL|Regimen 2: Isoniazid (H), Rifapentine (P), Pyrazinamide (Z), Moxifloxacin (M)|8 weeks of daily HPZM
62719382|NCT01248325|EXPERIMENTAL|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
62719383|NCT01248325|ACTIVE_COMPARATOR|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
62719384|NCT02814188|EXPERIMENTAL|Carbohydrate Beverage|
62719385|NCT02814188|PLACEBO_COMPARATOR|Placebo Beverage|
62719386|NCT03006588|EXPERIMENTAL|EUS-FNA for RPLN in NPC patients|Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
62719387|NCT02107534|EXPERIMENTAL|parent training (dyslexia)|Participants take part in parent training, five two-hour sessions held biweekly.
62719388|NCT02107534|NO_INTERVENTION|wait list control group|Participants of the waiting list control group had the possibility to take part in the parent training after the follow-up was completed.
62719389|NCT06715280|OTHER|Patients with Chronic Thromboembolic Pulmonary Hypertension|Patients with Chronic Thromboembolic Pulmonary Hypertension under Sildenafil treatment
62719390|NCT06368817|EXPERIMENTAL|Stratum I (carboplatin, etoposide, 3D-CRT, IMRT, surgery)|See Detailed Description.
62719391|NCT06368817|EXPERIMENTAL|Stratum II (carboplatin, etoposide, 3D-CRT, IMRT)|Patients receive carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 90-120 minutes on days 1-3 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with localized germinoma achieving PR with normalization of markers who do not undergo second-look surgery undergo 3DRT or IMRT QD 5 days a week for 20 days. Patients undergo MRI and optional blood and tissue sample collection throughout the study. Patients may undergo LP for CSF sample collection during screening and follow up.
62738788|NCT01114087|EXPERIMENTAL|1|Patients presenting with chronic myeloid leukaemia or malignant GIST and receiving for the first time a treatment by imatinib, a tyrosin-kinase inhibitor, preceded or not by hydroxyurea therapy for less than one month.
62719392|NCT06368817|EXPERIMENTAL|Stratum III (carboplatin, etoposide, 3D-CRT, IMRT)|Patients receive carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 90-120 minutes on days 1-3 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with localized germinoma with normalization of markers who fail to achieve CR or PR who do not undergo second-look surgery undergo 3DRT or IMRT QD 5 days a week for 24 days. Patients undergo MRI and optional blood and tissue sample collection throughout the study. Patients may undergo LP for CSF sample collection during screening and follow up.
62738789|NCT01807169|EXPERIMENTAL|Colonic polypectomy or endoscopic mucosal resection|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
62544966|NCT05107596|ACTIVE_COMPARATOR|Sarcoidosis|Image patients who have Sarcoidosis
62544967|NCT05107596|ACTIVE_COMPARATOR|Myocarditis|Image patients with Myocarditis
62544968|NCT05107596|ACTIVE_COMPARATOR|Cardiomyopathy|Image patients with cardiomyopathy
62544969|NCT05107596|ACTIVE_COMPARATOR|Infected Cardiovascular Implantable Electronic Devices|Image patients with cardiovascular implanted medical devices
62544970|NCT05107596|ACTIVE_COMPARATOR|Healthy Volunteers|Image healthy volunteers
62544971|NCT05465109|EXPERIMENTAL|TACSI|
62544972|NCT05465109|NO_INTERVENTION|Usual care control group|The usual care control group would have continued receipt of standard services at either the Mayo Clinic or the MVAHCS. In addition, staff will offer participants the opportunity to request supportive/educational resources as needed after randomization.
62544973|NCT05847829|EXPERIMENTAL|Intervention|The study is open label all participants get the same intervention
62544974|NCT05518188|EXPERIMENTAL|Treatment Arm|MELPIDA, a gene therapy product
62544975|NCT03793127|OTHER|Young group|20-40 years of age
62544976|NCT03793127|OTHER|Old group|60-80 years of age
62544977|NCT04936711|EXPERIMENTAL|Back Massager Device + Standard Pain Treatment|"Resteck Shiatsu Neck and Back Massager (brand name), with recommended use for at least every 2 hours for at least 15 minutes on the first post-operative day and then every 4 hours for 2 days and then as needed.~Standard pain treatment:~1. Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~2. Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~3. Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~4. Tylenol 650 mg Tab: oral administration every 6 hours"
62544978|NCT04936711|ACTIVE_COMPARATOR|Marcaine spray + Standard Pain Treatment|"30cc of 0.25% Marcaine spray on the diaphragm at the end of surgery.~Standard pain treatment:~1. Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~2. Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~3. Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~4. Tylenol 650 mg Tab: oral administration every 6 hours"
62544979|NCT04936711|NO_INTERVENTION|Standard Pain Treatment|"will receive standard pain treatment include local anesthetic agent at the incision sites + oral Tylenol and oral or IV opioid as breakthrough pain treatment postoperatively as needed.~Standard pain treatment:~1. Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~2. Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~3. Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~4. Tylenol 650 mg Tab: oral administration every 6 hours"
62544980|NCT00791544|EXPERIMENTAL|Dose Level -1|0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
62544981|NCT00791544|EXPERIMENTAL|Dose Level 1|1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
62544982|NCT00791544|EXPERIMENTAL|Dose Level 2|3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
62544983|NCT00791544|EXPERIMENTAL|Dose Level 3|6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
62544984|NCT00791544|EXPERIMENTAL|Dose Level 4|12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
62544985|NCT00791544|EXPERIMENTAL|Dose Level 5|18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
62544986|NCT00791544|EXPERIMENTAL|Combination cohort 1|AVE1642 selected dose in combination with sorafenib
62544987|NCT00791544|EXPERIMENTAL|Combination cohort 2|AVE1642 selected dose in combination with erlotinib
62544988|NCT06362863|EXPERIMENTAL|Enteral nutrition biscuits|Addition of enteral nutritional biscuits to existing pharmacological treatment.
62544989|NCT06362863|NO_INTERVENTION|Conventional drug therapy|No nutritional intervention, use of existing medication.
61976566|NCT03886012|SHAM_COMPARATOR|Otoband sham efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to an ineffective power level, serving as a placebo. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
61976567|NCT01986985|OTHER|Single arm PET MRI|single group evaluation of PET/MRI system scan for diagnostic quality of image
61976568|NCT02441777|EXPERIMENTAL|Control: Healthy|Polarization Sensitive Optical Coherence Tomography (PS-OCT) Imaging will be used to look at the nerve fiber layer (NFL) in the healthy retina.
61976569|NCT03072628|EXPERIMENTAL|Nicotine: use e-cig with nicotine|One time exposure to e-cig with nicotine
62544990|NCT03097146|OTHER|comprehensive multidisciplinary stroke care|
61976570|NCT03072628|EXPERIMENTAL|no nicotine: use e-cig without nicotine|One time exposure to e-cig without nicotine
61976571|NCT03072628|EXPERIMENTAL|Nicotine inhaler: use a nictoine inhaler|One time exposure to nicotine inhaler
61976572|NCT03072628|SHAM_COMPARATOR|Sham control|Use an empty e-cigarette
62544991|NCT06582966|OTHER|DoxyDOT single arm|Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.
62165161|NCT03711799|NO_INTERVENTION|Resource Only Group|Families randomized to the resource only condition will have access to training materials in web-based and paper formats. The will receive the internet address to access web-based trainings, handouts and materials, including instructions for each activity and they will receive a binder that includes the information that is available on line so they can access the information even if they do not have internet access. Families in the resource only condition will not have access to a peer coach through the program. They will not have access to the on-line support community.
62165162|NCT03711799|EXPERIMENTAL|Peer Coaching Group|Families randomized to peer coaching will receive assistance with navigating the training program and accessing the system from a trained peer parent coach. Peer coaches will, as much as possible, be culturally and language-matched with the participant family.
62165163|NCT02879448|EXPERIMENTAL|Amulet|Amulet left atrial appendage occluder
62165164|NCT02879448|ACTIVE_COMPARATOR|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
62719393|NCT06368817|EXPERIMENTAL|Stratum IV (carboplatin, etoposide, 3D-CRT, IMRT, surgery)|Patients receive carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 90-120 minutes on days 1-3 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with metastatic germinoma achieving CR undergo 3DRT or IMRT QD 5 days a week for 20 days. Patients with metastatic germinoma and normalization of markers who fail to achieve CR may undergo second-look surgery. Patients found to have mature teratoma or non-viable tumor undergo 3DRT or IMRT QD 5 days a week for 20 days. Patients undergo MRI and optional blood and tissue sample collection throughout the study. Patients may undergo LP for CSF sample collection during screening and follow up.
62738790|NCT02833584|EXPERIMENTAL|Paracetamol|Eligible patients will be randomised to receive Paracetamol prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
62165165|NCT04457011|EXPERIMENTAL|High dose group|High dose Susu Xiao'er Zhike Granules, 1 bag, bid
62165166|NCT04457011|EXPERIMENTAL|Middle dose group|Middle dose Susu Xiao'er Zhike Granules, 1 bag, bid
62544992|NCT06013826|EXPERIMENTAL|Experimental|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated. D-FISQ was repeated to the patients when they came to the hospital for control.
62544993|NCT06013826|NO_INTERVENTION|Control|Patients who were randomly assigned to the control group were informed about the method of the study. Telehealth service in the control group was not applied. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. D-FISQ was repeated to the patients when they came to the hospital for control.
62544994|NCT03577782|EXPERIMENTAL|Single group|HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
62544995|NCT05676515|ACTIVE_COMPARATOR|culture media of fabricant A|use of culture media of fabricant A
62544996|NCT05676515|ACTIVE_COMPARATOR|culture media of fabricant B|use of culture media of fabricant B
62544997|NCT05676515|ACTIVE_COMPARATOR|culture media of fabricant C|use of culture media of fabricant C
62544998|NCT03092973||Epistaxis Group|
62544999|NCT03092973||Control Group|
62545000|NCT05944926|EXPERIMENTAL|Healthy Activity Program (HAP)|HAP is a brief psychological treatment adapted from behavioral activation therapy, an empirically supported psychological treatment recommended by WHO.
62545001|NCT05944926|EXPERIMENTAL|Antidepressant medication (fluoxetine)|Fluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression. It is a routinely used medication and part of the Essential Drug List (EDL) in India.
62545002|NCT00125515|PLACEBO_COMPARATOR|Placebo|Placebo plus oral naltrexone
62545003|NCT00125515|ACTIVE_COMPARATOR|Memantine 30 mg bid|Memantine 30 mg bid plus oral naltrexone
62545004|NCT00125515|ACTIVE_COMPARATOR|Memantine 15 mg bid|memantine 15 mg bid plus oral naltrexone
62165167|NCT04457011|PLACEBO_COMPARATOR|Extremely-low dose group|Extremely-low dose Susu Xiao'er Zhike Granules, 1 bag, bid
62545005|NCT05115487||Sjögren's syndrome|Subjects diagnosed with primary sjögren's syndrome according to the 2016 ACR/EULAR primary sjögren classification criteria will be included in the study.
62545006|NCT05115487||Healthy controls|
62545007|NCT04556786|EXPERIMENTAL|Transitions of care|The study participants in this aim received usual care plus medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist.
62738791|NCT02833584|PLACEBO_COMPARATOR|Placebo|Eligible patients will be randomised to receive Placebo prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
62545008|NCT04556786|NO_INTERVENTION|Usual care|The study participants in this arm received usual care.
62545009|NCT01783912|EXPERIMENTAL|Cognitive/Motivational Intervention Group|"This arm of the project will address the following questions:~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?"
61976573|NCT02189746|ACTIVE_COMPARATOR|Continuous Kangaroo Mother Care to 1 hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
62168095|NCT01509040|EXPERIMENTAL|Low Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/h, ultrafiltration 45 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
62545010|NCT01783912|ACTIVE_COMPARATOR|Attention Control Group|"This arm of the project will address the following question:~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate that those who are in the experimental treatment group?~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Cognitive/Motivational Intervention Group?"
62545011|NCT01783912|NO_INTERVENTION|Motivated Smokers Comparison Group|"This arm of the project will address the following question:~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~Participants will not receive any intervention but will be consented and enrolled into this group and assessed for utilization of the tobacco quit line services."
62545012|NCT06171828|NO_INTERVENTION|Control Group (Traditional Training)|This arm of the study involves participants who will engage in a traditional learning process. After an initial pre-survey, they will start the ultrasound training phase. During this phase, participants will utilize pre-made educational videos for learning. Then participants will perform an ultrasound on an abdominal ultrasound phantom using a handout based on the pre-made video. When assistance is needed, participants will physically move to a different location to seek help from a supervisor. This face-to-face interaction allows for direct guidance and feedback. After completing the training sessions, participants will take a post-survey, which includes NASA-TLX, System Usability Scale (SUS), and a self-confidence assessment, to evaluate the training experience and measure the perceived workload, system usability, and confidence level changes due to the training.
62545013|NCT06171828|EXPERIMENTAL|Experimental Group (Remote Training)|In this arm, participants will undergo a remote learning process. Similar to the control group, they begin with a pre-survey followed by the training phase using the same educational videos. Participants view a handout on a head-mounted display(HMD) and perform an ultrasound on an abdominal ultrasound phantom. The key difference is that when they require assistance, they will use a HMD to communicate with a supervisor remotely. This allows the supervisor to provide guidance without being physically present, utilizing the HMD and potentially other remote communication tools for real-time interaction. The training phase is intended to mimic the in-person guidance as closely as possible through technological means. Following the training, the participants will also complete the same post-survey as the control group to assess the impact of remote training on their learning experience.
62545014|NCT03612349|OTHER|Condition 1: All Products|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, all tobacco products are available in menthol and non-menthol flavors.
62738986|NCT04610619||RYR1 related malignant hyperthermia/rhabdomyolysis|
62738987|NCT02220153|EXPERIMENTAL|UCB7665 Intravenous 1|Single dose calculated based on body weight for 60 minutes intravenous infusion.
61976574|NCT02189746|SHAM_COMPARATOR|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
61976575|NCT02189746|ACTIVE_COMPARATOR|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
61976576|NCT02189746|SHAM_COMPARATOR|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
61976577|NCT01555294||community-based cohort|"The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.~In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed."
62165168|NCT04609579|EXPERIMENTAL|SNX281 Monotherapy|"SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 66 participants will take part in this arm of the study.~Subjects enrolled in the dose expansion phase of this arm may be eligible to add pembrolizumab (KEYTRUDA®) to their SNX281 therapy following identification of the maximum tolerated dose (MTD) or optimal dose of SNX281 in combination with pembrolizumab (KEYTRUDA®). Subjects must, in the opinion of the Investigator, have demonstrated tolerance to SNX281 and have experienced sub-optimal response to therapy (i.e., disease stability for 4 cycles or progression on treatment with SNX281 at any time)."
62165169|NCT04609579|EXPERIMENTAL|SNX281 in Combination with pembrolizumab (KEYTRUDA®)|SNX281 will be administered in 3 of the 4 weeks in Cycle 1 and then once every 3 weeks of each cycle thereafter. Participants will also receive pembrolizumab (KEYTRUDA®) once every cycle for up to 6 cycles. The combination of SNX281 and pembrolizumab (KEYTRUDA®) will be given for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 and pembrolizumab (KEYTRUDA®) (or SNX281 alone) beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 68 participants will take part in this arm of the study.
62165170|NCT00214162|OTHER|1|internet access and computer for 1 year
62165171|NCT00214162|EXPERIMENTAL|2|computer and Full CHESS
62165172|NCT00792402||1 control group|Computerized data collection of outcome measures in usual care
62165173|NCT00792402||2 intervention group|Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.
62165174|NCT06090318|EXPERIMENTAL|Milademetan (RAIN-32) in Combination With Atezolizumab|"Milademetan (RAIN-32): 260 mg orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.~Atezolizumab: Atezolizumab IV infusion is to be administered on Day 1 of each 28- day cycle."
62165175|NCT04793555|EXPERIMENTAL|Experimental_Arm|Assessment of behavior during day and night by unobtrusive sensors
62165176|NCT01170871|EXPERIMENTAL|Experimental|Escalating doses of Ixabepilone and Pemetrexed
62165177|NCT02497547|EXPERIMENTAL|Oxytocin 400 IU|Oxytocin 400 IU vaginal gel (1 x 1mL/400 IU oxytocin daily for 12 weeks)
62165178|NCT02497547|EXPERIMENTAL|Oxytocin 200 IU|Oxytocin 200 IU vaginal gel (1 x 1mL/200 IU oxytocin daily for 12 weeks)
62165179|NCT02497547|PLACEBO_COMPARATOR|Placebo|Placebo vaginal gel (1 x 1mL daily for 12 weeks)
62165180|NCT03174470|EXPERIMENTAL|TENS stimulator|Single day Transcutaneous electrical nerve stimulations utilizing a commercial TENS stimulator (TensMed S82 ENRAF-NONIUS)
62165181|NCT00473512|EXPERIMENTAL|Abiraterone acetate|Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
62165182|NCT03126721|EXPERIMENTAL|oral midazolam alone|single dose of oral midazolam administered alone in period 1
62165183|NCT03126721|EXPERIMENTAL|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
62165184|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
62165185|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
62165186|NCT06645522|EXPERIMENTAL|Edaravone dexborneol group|Edaravone dexborneol injection 37.5mg every 12 hours for 7 days and a sublingual dose of edaravone dexborneol 36 mg twice a day for 21 days.
62165187|NCT06645522|PLACEBO_COMPARATOR|Placebo group|Placebo injection every 12 hours for 7 days and a sublingual dose of placebo drug twice a day for 21 days.
62165188|NCT06539390||Is Sedation Necessary for Transforaminal Epidural Injections|
62165189|NCT02765347|OTHER|Metformin and Insulin|MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g bid or tid) for 24 weeks
62165190|NCT02765347|OTHER|Insulin|Accept insulin for 24 weeks
62165191|NCT04013347||Early Surgery|Surgery after ≤ 42 days from the end of neoadjuvant radio-chemotherapy
62719394|NCT06368817|EXPERIMENTAL|Stratum V (carboplatin, etoposide, 3D-CRT, IMRT)|Patients receive carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 90-120 minutes on days 1-3 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with metastatic germinoma with normalization of markers who fail to achieve CR who do not undergo second-look surgery undergo 3DRT or IMRT QD 5 days a week for 24 days. Patients undergo MRI and optional blood and tissue sample collection throughout the study. Patients may undergo LP for CSF sample collection during screening and follow up.
62165192|NCT04013347||Late Surgery|Surgery after 43-56 days from the end of neoadjuvant radio-chemotherapy
62165193|NCT04013347||Very Late Surgery|Surgery after 57 or more days from the end of neoadjuvant radio-chemotherapy
62165194|NCT06113822||Control Group|Without Anxiety - Normal BMI 15 patient nonanxiety group (HAD scores ranging from 0 to 10) body mass index is normal between 18.5-24.9
62165195|NCT06113822||1st working group|High BMI \& Anxiety Normal 19 Patient nonanxiety group (HAD scores ranging from 0 to 10) Those with a high body mass index are between 25 and 29.9.
62165196|NCT06113822||2st working group|Normal BMI \& High Anxiety (15 patients) having anxiety group (HAD scores ranging from 11 to 21) body mass index is normal between 18.5-24.9
62165197|NCT06113822||3st working group|High BMI \& High Anxiety (19 patients) having anxiety group (HAD scores ranging from 11 to 21) Those with a high body mass index are between 25 and 29.9.
62165198|NCT03741283|EXPERIMENTAL|Optimisation of nutrition and medication|"N=approx.~65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition."
62165199|NCT03741283|NO_INTERVENTION|Standard care|N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.
62738988|NCT02220153|EXPERIMENTAL|UCB7665 Intravenous 2|Single dose calculated based on body weight for 60 minutes intravenous infusion.
62165200|NCT06719596|EXPERIMENTAL|Probiotics combined with enteral nutrition reduces postoperative infectious complications in PD|enteral nutrition+Pre-operative + one week post-operative Oral Bifidobacterium bifidum live triple capsule, 4 capsules Oral BID
62165201|NCT06719596|NO_INTERVENTION|Control group|Conventional postoperative treatment of the pancreas combined with enteral nutrition
62165202|NCT04213625|NO_INTERVENTION|Control Group|Information sheet with only their surgeon's educational background.
62165203|NCT04213625|EXPERIMENTAL|Intervention|Experimental group will receive an information sheet with their surgeon's educational and personal background.
62165204|NCT02092285|EXPERIMENTAL|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight \<80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
62165205|NCT05682040|OTHER|Active|
62165206|NCT00647699|ACTIVE_COMPARATOR|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
62165207|NCT00647699|SHAM_COMPARATOR|Control Group|riboflavin ophthalmic solution without UVA irradiation.
62165208|NCT04303598|EXPERIMENTAL|FNC Treatment Group|FNC 3mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;3TC placebo 1 tablet;daily oral before bedtime
62165209|NCT04303598|ACTIVE_COMPARATOR|3TC control group|3TC 300mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;FNC placebo 1 tablet;daily oral before bedtime
62165210|NCT00609245|EXPERIMENTAL|Placebo then Valproic Acid (VPA)|all patients will have placebo on day 1 and VPA infusion on day 2
62165211|NCT00005843|EXPERIMENTAL|Arm I|Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
62165212|NCT04770571||Vuepoint II OCT|
62165213|NCT04770571||Reline-C|
62165214|NCT03127475|EXPERIMENTAL|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
62165215|NCT03127475|SHAM_COMPARATOR|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
62165216|NCT06129656||Cardiac Amyloidosis|Patients with diagnosed cardiac amyloidosis being treated at Leipzig University Hospital.
62165217|NCT06355037|EXPERIMENTAL|quercetin and dasatinib|
62165218|NCT01257386|EXPERIMENTAL|Asacol®|Import Mesalazine
62165219|NCT01257386|ACTIVE_COMPARATOR|Mesalazine|Marketed Mesalazine
62165220|NCT00432445|EXPERIMENTAL|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
62165221|NCT03768986|ACTIVE_COMPARATOR|Treatment Group A|Standard referral for HIV testing and online HIV risk reduction training
62165222|NCT03768986|EXPERIMENTAL|Treatment Group B|Standard referral for HIV testing and online HIV risk reduction training plus reinforcement
62165223|NCT03628612|EXPERIMENTAL|AUTO CAR T cell therapy|Patients who received previous treatment with AUTO CAR T Cell Therapy
62165224|NCT00043368|EXPERIMENTAL|1|Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
62165225|NCT04301609|ACTIVE_COMPARATOR|ImmunoVita®|250 mg Yeast beta-glucan + 3.75 microg Vitamin D3 + 1.05 mg Vitamin B6 + 7.5 mg zinc)
62165226|NCT04301609|PLACEBO_COMPARATOR|Placebo|473,2 mg microcristalline cellulose + 0,06 mg Brown Oxide dye + 0,27 mg yellow A oxide dye
62165227|NCT01341418|ACTIVE_COMPARATOR|Suprapatellar approach|surgical approach for intramedullary nailing of the tibia
62165228|NCT01341418|ACTIVE_COMPARATOR|Infrapatellar approach|surgical approach for intramedullary nailing of the tibia
62165229|NCT05315076|EXPERIMENTAL|Thoracic Manipulation Posterior anterior and conventional therapy|Thoracic Manipulation Posterior anterior and conventional therapy
62165230|NCT05315076|EXPERIMENTAL|Muscle Energy Technique (PIR) and conventional treatment|Muscle Energy Technique (PIR) and conventional treatment
62165231|NCT04533334||Pediatric|FOB measurement of the distance between carina and right upper lobe bronchus and carina and labium oris in pediatric population
62165232|NCT00246129|ACTIVE_COMPARATOR|Campath-Tacrolimus|Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
62165233|NCT00246129|EXPERIMENTAL|Daclizumab-Tacrolimus-Mycophenolate|Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy
62165234|NCT03583944|EXPERIMENTAL|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
62165235|NCT06049888|NO_INTERVENTION|Naturalistic Social Media|In this control condition, participants will have no study-imposed restrictions on social media use.
62165236|NCT06049888|EXPERIMENTAL|Restricted Social Media|Participants will have social media apps on their phones blocked for three months.
62165237|NCT02672345||Sevoflurane Group|Group of patients receiving sevorane during extracorporeal circulation period.
62165238|NCT02672345||Not Sevoflurane Group|Group of patients who did not receive the sevorane during extracorporeal circulation period.
62165239|NCT01774929|EXPERIMENTAL|Transdermal Therapeutic System (TTS)-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
62165240|NCT02362100|PLACEBO_COMPARATOR|nonoperative management|"Treatment will consist of sling immobilization for a period of 6 weeks. Details and treatment timeline as follows:~* 0 - 3 weeks: immobilization with a shoulder sling, range of motion of elbow, hand and wrist~* 3 - 6 weeks: same as 0-3 weeks, with addition of pendulum exercises every two hours~* After 6 weeks: Active mobilization and removal of sling. Light activity permitted and physiotherapy for range of motion permitted as tolerated.~* After 6 months: no further restriction will be placed. Full home and work activity permitted."
62165241|NCT02362100|ACTIVE_COMPARATOR|locking plate surgical fixation|"Standardized operative management protocol as follows:~* Pre-operative medical clearance established via anesthesia consults if required for medically complex patients.~* Provision of pre-operative intravenous (IV) antibiotic prophylaxis:~* Administration of general anesthetic.~* Patient positioning and preparation:~  * Patient is carefully placed in the beach-chair position,~ * Deltopectoral approach Fracture reduction and fixation with confirmation with intraoperative fluoroscopy images."
62165242|NCT05399667||Early stimulation|Skin-to skin care by mother, kangaroo care, breastfeeding policy plus massage therapy are made by the mothers until hospital discharge. After discharge, they receive standard follow up care plus orientation for a continuous global simulation at home (total of 10 home visits independently of the standard evaluation and care that will be performed; visits promoting guidance and supervision sessions).
62165243|NCT05399667||Conventional care|Standard care according to the routine care of the Neonatal Intensive Care Unit (NICU) (skin-to skin care by mother, kangaroo care, and breast feeding policy) and their needs in the follow up program (motor, and cognition evaluations and interventions).
62165244|NCT05399667||Control group|Term born children to obtain reference values for the variables evaluated in the present study.
62165245|NCT05194631|EXPERIMENTAL|Regeneration Capacity of Satellite Cells|In vitro Regeneration Capacity of Satellite Cells from the Quadriceps Compared to That of the Diaphragm isolated From one patient
62165246|NCT02261922|EXPERIMENTAL|ticagrelor|ticagrelor treatment
62165247|NCT02261922|ACTIVE_COMPARATOR|prasugrel|prasugrel treatment
62165248|NCT06577103|EXPERIMENTAL|Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)|Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.
62165249|NCT06577103|EXPERIMENTAL|Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)|Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
62165250|NCT04966351|EXPERIMENTAL|Circadian misalignment (Condition A)|Participants will eat meals during the biological nighttime while remaining awake to mimic overnight work shifts.
62545015|NCT03612349|OTHER|Condition 2: No menthol LCCs|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, the online tobacco marketplace does not include menthol flavored little cigars and cigarillos.
62545016|NCT04097873|EXPERIMENTAL|Diaphragm biofeedback reeducation plus inspiratory training|
62545017|NCT04097873|ACTIVE_COMPARATOR|Isolated high-intensity inspiratory muscle training|
62545018|NCT06136000|ACTIVE_COMPARATOR|SACRAL EREKTÖR SPİNAE PLANE BLOK|
62545019|NCT06136000|ACTIVE_COMPARATOR|RİNG BLOCK|
62545020|NCT03198676|ACTIVE_COMPARATOR|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
62545021|NCT03198676|ACTIVE_COMPARATOR|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
62545022|NCT03198676|ACTIVE_COMPARATOR|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
62545023|NCT03198676|PLACEBO_COMPARATOR|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
62545024|NCT01515917|EXPERIMENTAL|Citicoline and Omega-3|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
62545025|NCT01515917|PLACEBO_COMPARATOR|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
62545026|NCT05797844|EXPERIMENTAL|Experimental Group|Nurses included in experimental group were trained through a 4-hour presentation (passive implementation strategy) prepared in the presence of evidence-based guidelines and literature, in addition, they were given a brochure about cuff pressure measurement and a brochure about cuff pressure was hung in the intensive care units where there are handwashing sinks. In addition, 4 follow-up visits (active strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days.
62545027|NCT05797844|ACTIVE_COMPARATOR|Control Group|Nurses included in control group were trained through a 4-hour presentation (passive implementation strategy) prepared in the presence of evidence-based guidelines and literature, in addition, they were given a brochure about cuff pressure measurement and a brochure about cuff pressure was hung in the intensive care units where there are handwashing sinks.No follow-up visits were made to this group
62719395|NCT06368817|EXPERIMENTAL|Stratum VI (carboplatin, etoposide, 3D-CRT, IMRT, surgery)|Patients receive carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 90-120 minutes on days 1-3 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with basal ganglia and thalamic germinoma achieving CR undergo 3DRT or IMRT QD 5 days a week for 20 days. Patients with basal ganglia and thalamic germinoma and normalization of markers who fail to achieve CR may undergo second-look surgery. Patients found to have mature teratoma or non-viable tumor undergo 3DRT or IMRT QD 5 days a week for 20 days. Patients undergo MRI and optional blood and tissue sample collection throughout the study. Patients may undergo LP for CSF sample collection during screening and follow up.
62545028|NCT01320384|ACTIVE_COMPARATOR|O2 conventional : standard low flow therapy|in order to obtain a SpO2\>92%
62545029|NCT01320384|EXPERIMENTAL|O2-HNF : high flow nasal oxygen therapy|set between 30 to 50 l/min,adjusted in order to obtain a SpO2 \>92%.
62545030|NCT01320384|EXPERIMENTAL|O2-HFN/NPPV|cycling of NIV and O2-HDN
62165251|NCT04966351|EXPERIMENTAL|Circadian misalignment with time-restricted feeding (Condition B)|Participants will fast during the biological nighttime while remaining awake to mimic overnight work shifts.
62165252|NCT00002540|NO_INTERVENTION|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
62165253|NCT00002540|ACTIVE_COMPARATOR|Prostate Screening|Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.
62165254|NCT04503889|EXPERIMENTAL|Real taVNS intervention|taVNS will be administered to cymba conchae of both ears using ECO2-TENS device
62165255|NCT04503889|SHAM_COMPARATOR|Sham|aVNS will be administered to lobes of both ears using ECO2-TENS device
62165256|NCT00841165|EXPERIMENTAL|1|Participants in this arm are treated with Continuous Positive Airway Pressure at 5cm H2O and 100% oxygen
62165257|NCT00841165|ACTIVE_COMPARATOR|2|Participants in this arm receive standard of care therapy- oxygen via a non-rebreather mask
62165258|NCT04940533||Participants receiving CFTR modulator therapy - Trikafta|This is a single arm study. Participants in this study are receiving CFTR modulator therapy.
62165259|NCT04968314||ChiPP Groups|Parents enroll in Chicago Parent Program groups offered at their child's school
62165260|NCT01084408|ACTIVE_COMPARATOR|Sequent®Please|
62165261|NCT01084408|ACTIVE_COMPARATOR|Taxus™Liberté™|
62165262|NCT06529068|ACTIVE_COMPARATOR|Isometric exercise without BFR cuff (control)|
62165263|NCT06529068|EXPERIMENTAL|Isometric exercise with narrow-elastic BFR band|
62165264|NCT06529068|EXPERIMENTAL|Isometric exercise with wide-rigid BFR cuff|
62165265|NCT04883619|PLACEBO_COMPARATOR|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) from Week 0 through Week 50 along with standard-of-care treatment of mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved complete renal response (CRR) may have the option to participate in the long-term extension (LTE) until unblinding of the study.
62165266|NCT04883619|EXPERIMENTAL|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
62165267|NCT04883619|EXPERIMENTAL|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
62165268|NCT04027673|EXPERIMENTAL|Treatment|Participants in the treatment group complete interactive modules. They will be asked to complete one module per week, for a total of eight weeks.
62165269|NCT04027673|NO_INTERVENTION|Control|Participants in the control group will have no active study requirements for the eight weeks following Survey Session 1.
62165270|NCT05332522|EXPERIMENTAL|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation
62165271|NCT05736458|EXPERIMENTAL|High regional controllability TMS target in non-symptomatic participants|We will administer TMS to an individualized target of high regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
62165272|NCT05736458|ACTIVE_COMPARATOR|Low controllability TMS target in non-symptomatic participants|We will administer TMS to an individualized target of low regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
62165273|NCT05736458|EXPERIMENTAL|High regional controllability TMS target in ADHD participants|We will administer TMS to an individualized target of high regional controllability while patient completes a working memory task inside the MRI scanner.
62165274|NCT02615041|EXPERIMENTAL|1 g by bolus injection|1 g of meropenem with bolus injection every 8 h regimen
62165275|NCT02615041|EXPERIMENTAL|1 g by 3 h infusion|1 g of meropenem with 3 h infusion every 8 h regimen
62165276|NCT02615041|EXPERIMENTAL|2 g by 3 hinfusion|2 g of meropenem with 3 h infusion every 8 h regimen
62165277|NCT04927299|EXPERIMENTAL|Group A: Losartan + chlorthalidone|Administered orally, one tablet a day, for 2 months.
62165278|NCT04927299|ACTIVE_COMPARATOR|Group B: Losartan + hydrochlorothiazide|Administered orally, one tablet a day, for 2 months.
62165279|NCT06032702|EXPERIMENTAL|3 week interval|3 week orthodontic interappointment interval
62165280|NCT06032702|EXPERIMENTAL|6 week interval|6 week orthodontic interappointment interval
62165281|NCT03520088|EXPERIMENTAL|Inferior mesenteric Vein dissection|To improve and preserve the rectal nerve in the total mesorectal excision, its starts the dissection from the inferior mesenteric vein to the inferior mesenteric artery and through the pelvis
62165282|NCT03520088|ACTIVE_COMPARATOR|Inferior mesenteric Artery dissection|As standard, the dissection starts straight in the inferior mesenteric artery and through the pelvis
62165283|NCT06415383|EXPERIMENTAL|Vitamin-B6|Participants will consume one high-dose Vitamin B6 100 mg tablet orally once daily for one month. Vitamin B6 will be provided as Pyridoxal-5'-Phosphate (PLP).
62165284|NCT06415383|PLACEBO_COMPARATOR|Placebo|Participants will consume a Placebo tablet matching the appearance of the Vitamin B6 tablets in the Experimental arm orally once daily for one month.
62165285|NCT04824456|EXPERIMENTAL|bilateral sagittal split osteotomy using chisels.|The final split is completed with Smith forceps and flag separators
62165286|NCT01287624|EXPERIMENTAL|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin)
62165287|NCT01287624|ACTIVE_COMPARATOR|Gemcitabine, Paclitaxel|GT (gemcitabine and paclitaxel combination)
62165288|NCT02159456|EXPERIMENTAL|Continuous enteral feeding|Continuous enteral feeding via infusion pump is applied for at least 7 days after the start of enteral feeding
62165289|NCT02159456|ACTIVE_COMPARATOR|Intermittent enteral feeding|Intermittent enteral feeding via gravity-based infusion is applied for at least 7 days after the start of enteral feeding.
62165290|NCT01545271|EXPERIMENTAL|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
62165291|NCT01545271|ACTIVE_COMPARATOR|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
62165292|NCT03598023|ACTIVE_COMPARATOR|Group 1|Cytal® Burn Matrix
62545031|NCT05607654|ACTIVE_COMPARATOR|active iTBS|The active group of TRD will receive the accelerated intermittent TBS(iTBS).The iTBS cycles including 10 bursts of three pulses at 50 Hz were delivered in 2-second trains. Each iTBS session comprised 60 x 2 second trains, with an 8-second intertrain interval and total duration of 10-minutes.Treatment sessions were administered hourly 10 times a day totaling 18,000 pulses/day. Patients received this treatment protocol for 5 consecutive days (90,000 pulses in total).
62545032|NCT05607654|SHAM_COMPARATOR|sham rTMS|The sham group of TRD will receive sham rTMS stimulation.
62165293|NCT03598023|ACTIVE_COMPARATOR|Group 2|EZ-Derm® Porcine Xenograft
62165294|NCT02440919|OTHER|Hyperoxygenation - 100% FiO2|Hyperoxygenation involved supplying 100% fraction of inspired oxygen (FIO2).
62165295|NCT02440919|OTHER|Hyperoxygenation - 20% FiO2|Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
62165296|NCT02440919|OTHER|Hyperinflation - Basal FiO2|Ventilator hyperinflation, with keeping the oxygen already offered to the patient.
62165297|NCT02440919|OTHER|Hyperinflation - 20% FiO2|Ventilator hyperinflation and hyperoxygenation involved supplying 20% oxygen.
62165298|NCT02325258|EXPERIMENTAL|Telephone call|Telephone call to physicians in charge of patients who have just had blood cultures drawn. Diagnostic and therapeutic recommendations to physicians in charge.
62165299|NCT02325258|NO_INTERVENTION|No telephone call|control arm: no intervention
62165300|NCT06111183|EXPERIMENTAL|AUP1602-C|AUP1602-C is administered topically during the treatment period.
62165301|NCT06111183|PLACEBO_COMPARATOR|Placebo|Placebo is administered topically during the treatment period.
62165302|NCT02690025|EXPERIMENTAL|ZP1848 High dose|s.c. administration of high dose
62165303|NCT02690025|EXPERIMENTAL|ZP1848 Medium dose|s.c. administration of medium dose
62165304|NCT02690025|EXPERIMENTAL|ZP1848 Low dose|s.c. administration of low dose
62165305|NCT02146300|EXPERIMENTAL|Allergen and xylometatsolin|Two separate exposure sessions: 1) nasal birch pollen exposure 2) nasal xylometazoline exposure
62165306|NCT04946097|EXPERIMENTAL|study group|received the conventional selected exercise program in addition to gross Myofascial Release
62545033|NCT02983747|EXPERIMENTAL|PRP Treatment(P)|PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
62545034|NCT02983747|ACTIVE_COMPARATOR|Medication Treatment(M)|NSAIDs medication(Loxoprofen Sodium tablets) therapy only.
62545035|NCT06008873||One group only|No intervention.
62165307|NCT04946097|EXPERIMENTAL|control group|the control group which received the conventional selected exercise program
62165308|NCT02586961|PLACEBO_COMPARATOR|0.9% saline solution - oral betamethasone placebo|Control arm: 0.9% saline solution - oral betamethasone placebo
62165309|NCT02586961|EXPERIMENTAL|adrenaline - oral betamethasone|Experimental arm : adrenaline and betamethasone
62165310|NCT04855708|EXPERIMENTAL|Virtual visit|Patients will have 2-week post-operative virtual visit
62165311|NCT04855708|ACTIVE_COMPARATOR|Office visit|Patients will return to the office for a 2-week post-operative visit
62165312|NCT02239666||Moderate to Severe Plaque Psoriasis|Prospective cohort study of usual care for subjects initiating therapy for plaque psoriasis on approved biologic agents. A non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
62165313|NCT05494099||Group A (1st 25 patients)|The middle meatal mega-antrostomy approach.
62165314|NCT05494099||Group B (2nd 25 patients)|The endoscopic modified medial maxillectomy approach.
62165315|NCT05494099||Group C (3rd 25 patients)|The endoscopic prelacrimal recess approach.
62165316|NCT00591188|EXPERIMENTAL|1|All patients will receive capecitabine and interferon-alpha.
62165317|NCT02539602|EXPERIMENTAL|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
62165318|NCT02539602|NO_INTERVENTION|Counterfactual|The counterfactual condition received no intervention.
62165319|NCT04143802|EXPERIMENTAL|LY3437943|LY3437943 administered subcutaneously (SC)
62165320|NCT04143802|ACTIVE_COMPARATOR|Dulaglutide|Dulaglutide administered SC
62165321|NCT04143802|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62165322|NCT02080117||patients who underwent kidney transplantation|patients who underwent living or deceased donor kidney transplantation between 2008 and 2013
62165323|NCT03463291||Study group|All patients with bony lesions
62165324|NCT02618200|EXPERIMENTAL|3D prostate ultrasound|3D prostate ultrasound will be performed in patients the day before radical prostatectomy
62545036|NCT00810511|EXPERIMENTAL|Lotrafilcon A|Investigational, spherical, silicone hydrogel contact lenses
62545037|NCT00810511|ACTIVE_COMPARATOR|Comfilcon A|Commercially marketed, spherical, silicone hydrogel contact lenses
62545038|NCT06303843|EXPERIMENTAL|Intervention group|Transfer to the operating theatre with an electric ride-on car
62545039|NCT06303843|NO_INTERVENTION|Controlled group|Transfer to the operating theatre with a paediatric trolley
62545040|NCT01181570|EXPERIMENTAL|Adalimumab|
62545041|NCT01181570|PLACEBO_COMPARATOR|Placebo|
62545042|NCT05537974|OTHER|Open Suction|Endotracheal aspiration will perform after the patient disconnect from mechanical ventilation
62545043|NCT05537974|OTHER|Closed Suction|Endotracheal aspiration will perform without disconnection from mechanical ventilation
62165325|NCT03045549|EXPERIMENTAL|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
62165326|NCT03045549|ACTIVE_COMPARATOR|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
62165327|NCT01306409|EXPERIMENTAL|A|Sequential application of different ESA
62165328|NCT02789098|OTHER|STEMI|All patients included in this study (1 arm)
62165329|NCT05480202|EXPERIMENTAL|Thoracic block technique and designed chest physical therapy program|Manual compression on healthy lung for 20 seconds and rest for 20 seconds, total time 20 minutes and percussion,vibration , postural drainage one session time for 35 minutes every day for ten days
62165330|NCT05480202|ACTIVE_COMPARATOR|Designed chest physical therapy program|Percussion, vibration and postural drainage for 30 minutes every day for ten days
62165331|NCT03452735||patients diagnosed before age 40|Patient between 18 and 50 years-old with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism who will answer to a questionnaire about fertility
62165332|NCT03452735||Control Group|Patient between the ages of 18 and 50 years, not diagnosed with Chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology, presenting no chronic pathology, having no chemo or radiotherapy or immunosuppressive therapy, or pelvic surgery before age 40 years who will answer to a questionnaire about fertility
62165333|NCT00647452|EXPERIMENTAL|1|Healthy male volunteers
62545044|NCT03907657|EXPERIMENTAL|Perflutren Lipid Microsphere or Lumason|Patients with Von-Hippel Lindau disease will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
62545045|NCT00940316|EXPERIMENTAL|Arm A: Erlotinib + Panitumumab + Irinotecan|Patients receive oral erlotinib hydrochloride once daily on days 1-14, panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
62165334|NCT00647452|EXPERIMENTAL|2|Healthy female volunteers
62165335|NCT04156256|EXPERIMENTAL|CD123-CD33 cCAR T cells|C123-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs
62165336|NCT03559452|NO_INTERVENTION|Control|Immobilisation without prior exercise
62165337|NCT03559452|EXPERIMENTAL|Muscle damage|300 bilateral knee extensor eccentric contraction performed immediately prior to immobilisation
62165338|NCT00762853|PLACEBO_COMPARATOR|A|fluoride toothpaste from Thailand
62165339|NCT00762853|ACTIVE_COMPARATOR|B|fluoride/triclosan/copolymer toothpaste
62165340|NCT05395078|EXPERIMENTAL|Group A|Thoracic extension exercises
62165341|NCT05395078|EXPERIMENTAL|Group B|Thoracic Stabilization exercises
62165342|NCT01662661|EXPERIMENTAL|Arm AB|Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension followed by Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet, administered on Day 1.
62165343|NCT01662661|EXPERIMENTAL|Arm BA|Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet followed by Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension, administered on Day 1.
62165344|NCT01717755|NO_INTERVENTION|Best medical management.|"Best medical management consists of the standard of care of patients with acute ischemic stroke according to existing local protocols and guidelines, and may include IV thrombolysis.~If treated with IVT as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO."
62165345|NCT01717755|EXPERIMENTAL|Additional intra-arterial treatment.|Best medical management followed by intra-arterial treatment and best medical management
62545046|NCT00940316|EXPERIMENTAL|Arm B: Erlotinib + Panitumumab|Patients receive oral erlotinib hydrochloride once daily on days 1-14 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients receive irinotecan hydrochloride as in arm A.
62545047|NCT00940316|EXPERIMENTAL|Arm C: Erlotinib + Panitumumab|Patients receive erlotinib hydrochloride and panitumumab as in arm B.
62545048|NCT03900052|NO_INTERVENTION|Naïve|Conventional cane with no instruction given
62545049|NCT03900052|ACTIVE_COMPARATOR|Scale training|Conventional cane, scale training, and instruction on proper cane use
62545050|NCT03900052|ACTIVE_COMPARATOR|Scale recall|Conventional cane with no further instruction or practice given
62545051|NCT03900052|EXPERIMENTAL|Haptics training|Haptic biofeedback cane with explanation and training.
62545052|NCT03900052|EXPERIMENTAL|Haptics recall|Haptic biofeedback cane with no further instruction or practice given.
62165346|NCT01550822|ACTIVE_COMPARATOR|HEALS|Intervention group which will receive group clinics addressing smoking cessation, healthy eating, physical activity, and the risk factors of stroke.
62165347|NCT01550822|NO_INTERVENTION|Usual Care|This group will receive usual care for stroke survivors
62165348|NCT01699802|EXPERIMENTAL|Inhaled anaesthetic agent|The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
62165349|NCT04728659|EXPERIMENTAL|Desogestrel Group|Ovulation inhibition will be performed using Desogestrel (75 mcg) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first
62165350|NCT04728659|ACTIVE_COMPARATOR|GnRH antagonist|Ovulation inhibition will be performed using ganirelix (Orgalutran, 0.25 mg/die) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first.
62165351|NCT06585410|EXPERIMENTAL|Experimental Arm|Investigational treatment
62165352|NCT06585410|OTHER|Control Arm|Standard of care treatment
62165353|NCT02815709|EXPERIMENTAL|Treatment 1 Oliceridine|
62165354|NCT02815709|EXPERIMENTAL|Treatment 2 Oliceridine|
62165355|NCT02815709|EXPERIMENTAL|Treatment 3 Oliceridine|
62165356|NCT02815709|PLACEBO_COMPARATOR|Placebo|
62165357|NCT02815709|ACTIVE_COMPARATOR|Morphine|
62545053|NCT05772026||POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
62545054|NCT05772026||non-POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
62165358|NCT04520685|EXPERIMENTAL|Arm 1: 12 weeks of study drug then 15 weeks of placebo|Subjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks.
62165359|NCT04520685|EXPERIMENTAL|Arm 3: 15 weeks of placebo then 12 weeks of study drug|Subjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks.
62165360|NCT04520685|EXPERIMENTAL|Arm 3: 27 weeks of study drug|Subjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment.
62165361|NCT02819271|EXPERIMENTAL|CXL-1427 (BMS-986231)|Experimental
62165362|NCT02819271|PLACEBO_COMPARATOR|Placebo|Placebo
62165363|NCT00464737|PLACEBO_COMPARATOR|Placebo|Placebo
62165364|NCT00464737|EXPERIMENTAL|Rotigotine 4 mg|4 mg/24 hrs
62165365|NCT00464737|EXPERIMENTAL|Rotigotine 8 mg|8 mg/24 hrs
62165366|NCT02389335||Group 1a|Patients with type 1 diabetes who have undetectable c-peptide ( ≤0.1 ng/mL) levels after mixed meal tolarance test: group 1a
62165367|NCT02389335||Group 1b|Patients with type 1 diabetes who have c-peptide levels between 0.1-0.8 ng/mL after mixed meal tolerance test: group 1b
62165368|NCT02389335||Group 1c|Patients with type 1 diabetes who have c-peptide levels ≥0.8ng/mL after mixed meal tolerance test: group 1c
62545055|NCT02690987|EXPERIMENTAL|Overweight/obese subjects|Overweight/obese volunteers with BMI 28.0-50.0 kg/m2, otherwise healthy. This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design.
62545056|NCT02690987|EXPERIMENTAL|Ex-smokers|"Abstinent tobacco dependent individuals who score at least moderately on tobacco dependence as measured retrospectively using the Fagerström Test for Nicotine Dependence (FTND), and who have been in stable tobacco abstinence for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
62545057|NCT02690987|EXPERIMENTAL|Ex-alcohol dependent subjects|"Abstinent alcohol dependent individuals who score at least moderately alcohol dependent as measured retrospectively using the Severity of Alcohol Dependence Questionnaire (SADQ), and who have been abstinent for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
62165369|NCT02389335||Control|Healthy subjects
62165370|NCT02721420|OTHER|Drug + short message(SMS) reminder|dihydroartemesinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with SMS reminders prior to each treatment course
62545058|NCT04936035|PLACEBO_COMPARATOR|Placebo|Participants received zilebesiran matching placebo, subcutaneous (SC) injection, once every 3 months (Q3M), with re-randomization at Month 6 to 1 of the initial 4 zilebesiran regimens. Participants will continue their respective zilebesiran regimen up to Month 12 in the DB period and up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed.
62545059|NCT04936035|EXPERIMENTAL|Zilebesiran 150 Milligrams (mg) Once Every 6 Months (Q6M)|Participants receive zilebesiran, 150 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.
62545060|NCT04936035|EXPERIMENTAL|Zilebesiran 300 mg Q6M|Participants receive zilebesiran, 300 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.
62545061|NCT04936035|EXPERIMENTAL|Zilebesiran 300 mg Q3M|Participants receive zilebesiran, 300 mg, SC injection, Q3M, during the 12-month DB period. Participants continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed.
62719396|NCT06368817|EXPERIMENTAL|Stratum VII (carboplatin, etoposide, 3D-CRT, IMRT)|Patients receive carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 90-120 minutes on days 1-3 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with basal ganglia and thalamic germinoma with normalization of markers who fail to achieve CR who do not undergo second-look surgery undergo 3DRT or IMRT QD 5 days a week for 24 days. Patients undergo MRI and optional blood and tissue sample collection throughout the study. Patients may undergo LP for CSF sample collection during screening and follow up.
62719397|NCT00181844|EXPERIMENTAL|Lamotrigine|
62165371|NCT02721420|OTHER|Drug + no short message(SMS) reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) without SMS reminders prior to each treatment course.
62165372|NCT02721420|OTHER|Drug+ Health worker reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with Health surveillance assistants reminders prior to each treatment course.
62165373|NCT02721420|OTHER|Drug at hospital + SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department without an SMS reminders prior to each treatment course.
62165374|NCT02721420|OTHER|Drug at Hospital+no SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department with a short message reminder prior to each treatment course
62165375|NCT04105764|ACTIVE_COMPARATOR|DEEP BLOCK|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
62165376|NCT04105764|ACTIVE_COMPARATOR|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
62165377|NCT00974402|EXPERIMENTAL|Patients with PTSD Symptoms|Patients with Post-Traumatic Stress Disorder (PTSD) symptoms willing to undergo Cognitive Behavioral Therapy in a primary care setting.
62165378|NCT06645990||ECMELLA group|VA-ECMO + Impella implemented before or within 24 h of ECMO initiation
62165379|NCT06645990||ECMO+IABP group|VA-ECMO + IABP implemented before or within 24h of ECMO initiation
62719398|NCT02588157|ACTIVE_COMPARATOR|İnsertion time|handling the device till the glottic visualisation of Macintosh, McGrath MAC X-Blade and Glidescope
62719399|NCT02588157|ACTIVE_COMPARATOR|intubation time|handling the device till seeing the endotracheal tube entering from the vocal cords Macintosh, McGrath MAC X-Blade and Glidescope
62719400|NCT03423407||PET/MR|"* Participants will be scanned on a PET-MRI scanner which is FDA-approved and will operate within FDA-approved guidelines.~* Participants will be asked to lie still within the scanner for up to 90 minutes"
62719401|NCT02266303|EXPERIMENTAL|With checklist|Doctors will initiate insulin with the aid of a checklist
62719402|NCT02266303|NO_INTERVENTION|Without checklist|Doctors will initiate insulin without the use of the checklist
62719403|NCT02700672||Institutionalized older adults|Observational study
62719404|NCT02700672||Non-institutionalized older adults|Observational study
62719405|NCT00947128|EXPERIMENTAL|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
62719406|NCT00947128|ACTIVE_COMPARATOR|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
62719407|NCT00920556|EXPERIMENTAL|Treatment|"5.0 g SRT501 will be administered for 20 consecutive days in a 21 day cycle for a maximum of 12 cycles. SRT501 will be administered at the same time each morning (approximately 15-30 minutes after breakfast) on all dosing days. No SRT501 administration will occur on Day 21 of each cycle.~After the first two cycles of SRT501, any subject who exhibits stable disease or better with SRT501 monotherapy (5.0 g/day) will continue for an additional two cycles. If, after the first two cycles, a subject exhibits PD, that subject will receive bortezomib (1.3 mg/m2 on Day 1, Day 4, Day 8, and Day 11 in a 21 day cycle) in conjunction with SRT501. Bortezomib will be administered prior to breakfast and SRT501 administration.~If after two additional cycles of SRT501 monotherapy (4 cycles total), the subject exhibits a MR or better, they they will remain on SRT501 therapy. If PD or SD are exibited, they are to undergo bortezomib regiment listed above."
62719408|NCT02501993||Screening cohort|All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
62719409|NCT03868410|ACTIVE_COMPARATOR|cPMD rTMS + Training|New Approach
62719410|NCT03868410|ACTIVE_COMPARATOR|iM1 rTMS + Training|Conventional Approach
62719411|NCT01814956|EXPERIMENTAL|1|i.v. lipid emulsion for parenteral nutrition
62719412|NCT01814956|ACTIVE_COMPARATOR|2|i.v. lipid emulsion for parenteral nutrition
62719413|NCT04086355|EXPERIMENTAL|Effect of electrical stimulation on dysphagia in cp|the study group that was treated by selected oromotor exercise program in addition to neuromuscular electrical stimulation, Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
62719414|NCT04086355|EXPERIMENTAL|effect of oromotor exercise on dysphagia in cp|the control group was treated by the same oromotor exercise program in addition to placebo effect of neuromuscular electrical stimulation. Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
62719415|NCT01038505|ACTIVE_COMPARATOR|Tacrolimus and Myfortic|Immunosuppressive
62719416|NCT01038505|ACTIVE_COMPARATOR|Tacrolimus and Sirolimus|Immunosuppressive
62719417|NCT00905190|EXPERIMENTAL|Fed|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast
62719418|NCT00905190|EXPERIMENTAL|Fasting|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
62719419|NCT04118829|EXPERIMENTAL|Group one|The Group 1 patients will be taking PER up to 14 days following surgical intervention as per discretion of the treating neurosurgeon.
62719420|NCT04118829|EXPERIMENTAL|Group Two|The Group 2 patients will be taking PER as part of their maintenance AED regimen and will continue on the same maintenance dosage postoperatively.
62719421|NCT06362109|ACTIVE_COMPARATOR|Routine rehabilitation group|This group is going to receive Routine rehabilitation once a day.
62719422|NCT06362109|EXPERIMENTAL|Routine rehabilitation + Intermittent Oro-esophageal Tube Feeding group|This group is going to receive Routine rehabilitation once a day and Intermittent Oro-esophageal Tube Feeding once a day.
62719423|NCT03859076|EXPERIMENTAL|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
62719424|NCT03859076|ACTIVE_COMPARATOR|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
62719425|NCT00182143|ACTIVE_COMPARATOR|LMWH (Fragmin, dalteparin)|Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose
62719426|NCT00182143|ACTIVE_COMPARATOR|2|Unfractionated Heparin 5000IU BID
62719427|NCT03240107|ACTIVE_COMPARATOR|levator resection|20 patients who will undergo levator aponeurosis resection technique
62719428|NCT03240107|ACTIVE_COMPARATOR|levator tucking|20 patients who will undergo two point fixation levator tucking technique
62719429|NCT00057564|EXPERIMENTAL|A (Thalidomide & Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
62719430|NCT00057564|PLACEBO_COMPARATOR|B (Dexamethasone and placebo)|Dexamethasone and placebo
62719431|NCT02432430|EXPERIMENTAL|quality improvement technical support|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
62719432|NCT02432430|ACTIVE_COMPARATOR|pay for performance|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and are informed of a tiered incentives structure. Practices receive bonuses for both improvement in individual practice coverage as well as improvement in coverage for all practices allocated to this study arm.
62719433|NCT02805452|EXPERIMENTAL|Succinate of Solifenacin|1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.
62719434|NCT02805452|PLACEBO_COMPARATOR|Placebo of Succinate of Solifenacin|1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.
62719435|NCT04257019|EXPERIMENTAL|Lavender|Lavender mask before and during procedure
62719436|NCT04257019|ACTIVE_COMPARATOR|Almond|Almond oil mask before and during procedure
62719437|NCT04257019|SHAM_COMPARATOR|Water|Water mask before and during procedure
62719438|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
62719439|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
62719440|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
62719441|NCT06334809||Cohort A:patients with high risk localized prostate cancer|"Cohort A:150 patients with high risk localized prostate cancer (defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVIat mpMRI), with tissue available from diagnostic biopsy/prostatectomy undergoing or who underwent curative treatment (prostatectomy/radical radiotherapy) but have not started a FU pathway.~Patients within Cohort A will be followed up with PSA every 3 months for 3 years and early scans. They will also receive a blood sample for ctDNA/CTC before (when feasible) and after radical treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression"
62719442|NCT06334809||Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC)|Cohort B: 100 patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) with tissue available from diagnostic biopsy of the primary and when possiblepossible, from a metastatic site. Patients must either have not started a standard treatment or have started for not longer than 3 months;Patients within Cohort B will be followed up with PSA and scans every 3 months. They will also receive a blood sample before (when feasible) or after the start of systemic treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression
62719443|NCT06334809||Cohort C:Patients with metastatic castration resistant prostate cancer (mCRPC) progressing|Cohort C:100-150 patients with metastatic castration resistant prostate cancer tissue (mCRPC) progressing on a standard treatment with available from biopsy of a metastatic site, and when possiblepossible, from the primary.Patients within Cohort C will be followed up with PSA monthly and scans every 3 month. They will also receive a blood sample for ctDNA/CTC before (when feasible) or after the start of systemic treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression.
62719444|NCT01760577|EXPERIMENTAL|The Botulinum Toxin A group|The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.
62719445|NCT01760577|ACTIVE_COMPARATOR|The hyaluronate group (Hyalgan, Italy)|The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .
62719446|NCT01808378|EXPERIMENTAL|Autologous Stem Cells|Autologous expanded adipose-derived stem cells
62719447|NCT04217109|EXPERIMENTAL|Odour sampling|Odour collection will be obtained by positioning a compress on the breast concerned during the night preceding the day of samplings. The compress, once removed, will be placed in specific envelope for the study. Envelope will be given to the investigating centre during the appointment of percutaneous samples and then sent to the sponsor center (Institute Curie Paris).
62719448|NCT02745873|EXPERIMENTAL|Arm A|Ascorbic Acid 250 mg in tablet form was used.
62719449|NCT02745873|EXPERIMENTAL|Arm B|Ascorbic Acid 500 mg in tablet form was used.
62165380|NCT03303547|EXPERIMENTAL|MRI-Pathology N1c matching group|MRI mapping will be used to guide pathologists to sample areas of the mesorectum where tumour deposits are likely to be present.
62719450|NCT01423552||Post-heart transplant|All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
62719451|NCT02189798|EXPERIMENTAL|Newly Implanted Group|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness. Patients retaining considerable low frequency acoustic hearing after the surgery, will be fitted with the EAS sound processor.
62719452|NCT02189798|EXPERIMENTAL|Existing Implanted Group|Adults unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness will be fitted with the EAS sound processor.
62165381|NCT01339156|EXPERIMENTAL|P3914|
62165382|NCT01339156|PLACEBO_COMPARATOR|Placebo|
62545062|NCT04936035|EXPERIMENTAL|Zilebesiran 600 mg Q6M|Participants receive zilebesiran, 600 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.
62719453|NCT02189798|EXPERIMENTAL|EAS Extended Use Arm|Adults who are unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness and completed the 12 Month visit using the EAS sound processor in either the Newly Implanted Group or Existing Implanted Group.
62719454|NCT01080417|ACTIVE_COMPARATOR|Cellcept® 250 mg Capsule|
62719455|NCT01080417|EXPERIMENTAL|Mycophenolate Mofetil Capsule 250 mg|
62719456|NCT03092479|EXPERIMENTAL|Behavioral Intervention|4-month bi-weekly comprehensive postoperative behavioral support program addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
62719457|NCT03092479|NO_INTERVENTION|Usual Care|Usual postoperative follow-up per the GHS Center for Nutrition and Weight Management guidelines.
62719458|NCT02137070||Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss at local surgical centers or UFHEALTH \& Shands Hospital.
62719459|NCT02137070||Non surgical/Community volunteers|Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss
62719460|NCT01682356|PLACEBO_COMPARATOR|Beetroot juice without nitrate|Patients will be studied before and after ingestion of beetroot juice without nitrate
62719461|NCT01682356|ACTIVE_COMPARATOR|Beetroot juice with nitrate|Patients will be studied before and after ingestion of beetroot juice with nitrate.
62719462|NCT04712747||Cases - patients with stroke|Ophthalmological examinations : At the inclusion visit and 3 months after their stroke Blood pressure measurement at rest : At the inclusion visit
62719463|NCT04712747||Controls - Individuals with no history of stroke|Ophthalmological examinations : At the inclusion visit Blood pressure measurement at rest : At the inclusion visit
62719464|NCT02927444|EXPERIMENTAL|NBP606|13-valent pneumococcal conjugate vaccine
62719465|NCT02927444|ACTIVE_COMPARATOR|Prevnar13|13-valent pneumococcal conjugate vaccine
62719466|NCT02984670|EXPERIMENTAL|Behavior Therapy|
62719467|NCT02984670|EXPERIMENTAL|Cognitive Therapy|
62719468|NCT02984670|OTHER|Waitlist|
62719469|NCT04028648||elderly|150 elderlies (\>60 years): community dwelling or living in old
62719470|NCT01686113|EXPERIMENTAL|NEFA|Participants swish and spit 5 mL of an oleic acid solution everyday for 10 days.
62719471|NCT01686113|ACTIVE_COMPARATOR|Control|Participants swish and spit 5 mL of sucrose solution everyday for 10 days.
62719472|NCT00707993|EXPERIMENTAL|Alogliptin 25 mg QD|
62719473|NCT00707993|ACTIVE_COMPARATOR|Glipizide 5 mg QD|
62719474|NCT03363178|EXPERIMENTAL|GC3107|BCG Vaccine, 0.1mL
62165383|NCT03079284|EXPERIMENTAL|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
62165384|NCT02718053||spasticity|patients affected by spasticity of the lower limbs
62165385|NCT02718053||controls|healthy subjects
62165386|NCT02916745|EXPERIMENTAL|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
62165387|NCT01064856|EXPERIMENTAL|Double-blind (DB) Adalimumab|Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.
62719475|NCT01767896|EXPERIMENTAL|ASP7374 group|cell-culture-derived vaccine group
62719476|NCT01767896|ACTIVE_COMPARATOR|TIV group|approved egg-derived TIV group
62719477|NCT05342948||pRPL|Primary RPL patients: no prior birth ≥22 weeks
62719478|NCT05342948||sRPL with a first born boy|Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only boy(s)
62719479|NCT05342948||sRPL with a first born girl|Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only girl(s)
62719480|NCT04034134|EXPERIMENTAL|Jaktinib Hydrochloride Tablets 50mg bid|Oral tablet for 24 weeks
62719481|NCT04034134|EXPERIMENTAL|Jaktinib Hydrochloride Tablets 150mg qd|Oral tablet for 24 weeks
62719482|NCT04034134|EXPERIMENTAL|Jaktinib Hydrochloride Tablets 200mg qd|Oral tablet for 24 weeks
62719483|NCT03563482|EXPERIMENTAL|Experimental|Biopsy and PET scan
62719484|NCT06632782|EXPERIMENTAL|intervention|Breath Awareness using pyramid in people with T2DM and symptoms of depression and anxiety
62719485|NCT06632782|NO_INTERVENTION|control|Control group or the wait list group will continue usual treatment recommended by the physician.
62719486|NCT01240863|PLACEBO_COMPARATOR|Placebo|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
62719487|NCT01240863|EXPERIMENTAL|Hydrocodone ER|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
62719488|NCT06714981|EXPERIMENTAL|opioid free anesthesia|patients received opioid free anesthesia
62719489|NCT06714981|ACTIVE_COMPARATOR|opioid based anesthesia|patients received opioid based anesthesia
62719490|NCT06341400|EXPERIMENTAL|Experimental group|Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
62719491|NCT04127526|ACTIVE_COMPARATOR|Baseline Period of 2 weeks|2 participants will be randomly allocated to a baseline of 2 weeks before commencing CONNECT intervention.
62719492|NCT04127526|ACTIVE_COMPARATOR|Baseline Period of 3 weeks|2 participants will be randomly allocated to a baseline of 3 weeks before commencing CONNECT intervention.
62719493|NCT04127526|ACTIVE_COMPARATOR|Baseline Period of 4 weeks|2 participants will be randomly allocated to a baseline of 4 weeks before commencing CONNECT intervention.
62719494|NCT04831671|ACTIVE_COMPARATOR|Infra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an infra-patella approach.
62719495|NCT04831671|EXPERIMENTAL|Supra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an supra-patella approach.
62719496|NCT04909554||the training cohort|From January 2019 to December 2020, 140 patients from Guangdong Province People's Hospital with complete clinicopathological information and available images of MRI before treatment and after 1st-NAT were retrospectively recruited for the training cohort
62719497|NCT04909554||the internal validation cohort|From June 2021 and December 2023, 120 patients from Guangdong Province People's Hospital were prospectively recruited for the internal validation cohort.
62719498|NCT04909554||the external validation cohort|From June 2021 and December 2023, 41 patients from Shantou Central Hospital, The First Affiliated Hospital of Guangdong Pharmaceutical University and The First People's Hospital of Foshan were prospectively recruited for the external validation cohort.
62719499|NCT02714660||Participants with Type 2 Diabetes|Adults with type 2 diabetes will be enrolled in this mixed methods observational study.
62719500|NCT03569189|EXPERIMENTAL|High Fat Diet|Participants will consume a high-fat, high-calorie diet for 7 days (i.e. westernised diet) following a 3-day weight maintenance diet. Measurements will be made pre- and post-high fat diet intervention.
62719501|NCT00820989|EXPERIMENTAL|A|Time points after IV Endotoxin administration compared to baseline (immediately before Endotoxin administration).
62719502|NCT05158920|EXPERIMENTAL|Intervention Group|Participants in the intervention group received Mindfulness-Based Cognitive Therapy in addition to their treatment as usual.
62719503|NCT05158920|NO_INTERVENTION|Control Group|Participants in the control group received their treatment as usual.
62719504|NCT06389214|EXPERIMENTAL|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days|
62719505|NCT06389214|PLACEBO_COMPARATOR|Vehicle Ophthalmic Solution administered six times over two consecutive days|
62719506|NCT04419467|EXPERIMENTAL|CSL346 (low dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
62719507|NCT04419467|EXPERIMENTAL|CSL346 (high dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
62165388|NCT01064856|PLACEBO_COMPARATOR|Double-blind Placebo|Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.
62719508|NCT04419467|PLACEBO_COMPARATOR|Placebo|Administered as a single IV loading dose followed by SC infusions
62719509|NCT02886130|PLACEBO_COMPARATOR|Placebo|Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
62719510|NCT02886130|EXPERIMENTAL|Alpha-GPC|Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
62719511|NCT02160288|ACTIVE_COMPARATOR|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
62719512|NCT02160288|PLACEBO_COMPARATOR|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
62719513|NCT04754763|EXPERIMENTAL|Propolis|Propolis was applied by disposable micro brush on particular sensitive teeth and left undisturbed for 60 seconds to let it dry. Followup was done at 7th, 15th and 30th day
62719514|NCT04754763|ACTIVE_COMPARATOR|Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE)|Application of Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE) on sensitive surfaces was applied single coated for 20 seconds, gently applied air for 5 seconds and cured for 10 seconds (as per manufacturer's instructions). Followup was done at 7th, 15th and 30th day
62719515|NCT00636181|ACTIVE_COMPARATOR|Auto Aflex|auto adjusting positive pressure therapy with AFLEX
62719516|NCT00636181|ACTIVE_COMPARATOR|Auto CPAP|auto adjusting positive pressure therapy
62719517|NCT00636181|ACTIVE_COMPARATOR|CPAP|continuous positive airway pressure
62719518|NCT06086964|EXPERIMENTAL|Group A|15 autistic child will receive gluten and casein free diet.
62719519|NCT06086964|EXPERIMENTAL|Group B|15 autistic child will receive physical therapy program.
62719520|NCT06086964|EXPERIMENTAL|Group C|15 autistic child will receive combination of gluten and casein free diet with physical therapy program.
62719521|NCT06086964|NO_INTERVENTION|Group D|the group of no intervention as a control group.
62719522|NCT02803203|EXPERIMENTAL|osimertinib and bevacizumab|"Phase 1:~3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks~Phase 2:~Use MTD determined during phase 1"
62719523|NCT06487871|ACTIVE_COMPARATOR|Fucoidan extracted from Undaria pinnatifida (UPF)|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
62719524|NCT06487871|PLACEBO_COMPARATOR|Placebo|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
62719525|NCT05419752|EXPERIMENTAL|endo sequence bioceramic sealer|obturation using Endo-sequence BC sealer
62719526|NCT05419752|EXPERIMENTAL|MTA fill apex calcium silicate base sealer|obturation using calcium-silicates based MTA fill-apex sealer
62165389|NCT01064856|EXPERIMENTAL|Double-blind Adalimumab / Open-label Adalimumab|Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.
62545063|NCT02445963|ACTIVE_COMPARATOR|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
62719527|NCT05419752|EXPERIMENTAL|AH plus resin sealer|obturation using AH Plus sealer
62719528|NCT02896257|OTHER|Proactive patient-tailored electronic consult (E-consult)|Primary care clinicians receive patient-tailored guideline concordant treatment recommendations, including orders and rationale to discontinue inhaled corticosteroids.
62719529|NCT02896257|NO_INTERVENTION|Usual care|Standard practice (usual care). Primary care providers treat their patients as usual.
62719530|NCT06717737|EXPERIMENTAL|Team-Based Training Intervention for Firefighter Fitness and Adherence|This arm involves a six-month team-based training intervention designed to improve firefighters' physical fitness and exercise adherence. The program includes aerobic, resistance, and functional exercises tailored to the demands of firefighting tasks. Sessions are conducted in small groups to foster teamwork and peer support, with participants receiving real-time feedback and guidance from certified professionals. The aim is to enhance cardiovascular fitness, strength, endurance, and overall health behaviors, while reducing injury risks. Participants track their progress using the Gymsmart (Pro X) app to monitor activity levels and adjust intensity for optimal results.
62719531|NCT06717737|EXPERIMENTAL|Control group|The control group maintained their old habits
62719532|NCT01657370|PLACEBO_COMPARATOR|Placebo|MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
62719533|NCT01657370|EXPERIMENTAL|MK-1602 1 mg|MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
62719534|NCT01657370|EXPERIMENTAL|MK-1602 10 mg|MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
62719535|NCT01657370|EXPERIMENTAL|MK-1602 25 mg|MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
62719536|NCT01657370|EXPERIMENTAL|MK-1602 50 mg|MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
62719537|NCT01657370|EXPERIMENTAL|MK-1602 100 mg|MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
62719538|NCT03134326|EXPERIMENTAL|Test group|All subjects will be enrolled in the test group and will receive both R1-25 and R2-25 Pulse Oximeter Sensors
62719539|NCT03374020||Intermediate AMD|
62719540|NCT03374020||Advanced AMD|
62719541|NCT03374020||DR without macular edema|
62719542|NCT03374020||DR with macular edema|
62719543|NCT02273102|EXPERIMENTAL|TCP Dose Level 1|20mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
62719544|NCT02273102|EXPERIMENTAL|TCP Dose Level 2|40mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
62719545|NCT02273102|EXPERIMENTAL|TCP Dose Level 3|60mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
62719546|NCT03408990||Sleep study for clinical reasons|Children referred to sleep study for clinical reasons
62719547|NCT03408990||Healthy|Healthy children, no relevant pathologies
62719548|NCT03596671|EXPERIMENTAL|Treatment arm|RENOVA iStim™ System implanted patients
62719549|NCT01014702|EXPERIMENTAL|Laser Treatment|
62719550|NCT01014702|ACTIVE_COMPARATOR|Phacoemulsifcation|
62719551|NCT00512278|EXPERIMENTAL|Infliximab|Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
62719552|NCT00512278|PLACEBO_COMPARATOR|Placebo|Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
62719553|NCT04549480|EXPERIMENTAL|Bosutinib capsule|Bosutinib pediatric capsule to healthy participants
62719554|NCT04549480|ACTIVE_COMPARATOR|Bosutinib tablet|Bosutinib tablet to healthy participants
62719555|NCT00881894|EXPERIMENTAL|Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)|Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
62719556|NCT00881894|EXPERIMENTAL|Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)|Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days
62719557|NCT03186768|EXPERIMENTAL|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
62719558|NCT03186768|NO_INTERVENTION|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
62719559|NCT06134817|EXPERIMENTAL|Patients with Post TKA Knee Pain|Patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA) will receive geniculate artery embolization (GAE) using Embozene Color-Advanced Microspheres. Treatment will be completed during one interventional session.
62719560|NCT02731287|EXPERIMENTAL|Timolol|Timolol maleate 0.5% topical solution; 50% of the patients treated (randomized)
62719561|NCT02731287|PLACEBO_COMPARATOR|Placebo|Saline topical solution; 50% of the patients treated (randomized)
62719562|NCT03454230|EXPERIMENTAL|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
62719563|NCT03454230|NO_INTERVENTION|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
62719564|NCT03985280|EXPERIMENTAL|Cooled radiofrequency|The procedure will be performed under regimen of major ambulatory surgery, it will be done under guidance of combined X-ray and ultrasound. . The nerves will be located b, after applying AL (Lidocaine 1%), a RF needle will be placed in the objective position.After verifying the positive sensitive and negative motor responses the cooled radiofrequency will proceed (previous application of local anesthesia (lidocaine 2%)). Cooled RF will be performed for 2:30 minutes at 60 degrees.
62719565|NCT03985280|ACTIVE_COMPARATOR|Intraarticular local anesthetic and steroids injections|An intraarticular injection will be done in ambulatory surgery regimen with a 22 Gauge needle. Intraarticular injection will be done under Fluoroscopic guidance (X-rays) with intra articular position confirmation by infusion of iodine contrast (Omnipaque 240). Once the needle position has been verified we will administer 10 mg of bipuvacaine, and 40 mg triamcinolone hexacetonide.
62719566|NCT03435068|EXPERIMENTAL|Ceramic rotary bur|For the ceramic bur group(Meisenger gingivectomies, ceramic rotary burs were used with 400-rpm rotary systems and with no serum irrigation, per the manufacturer's recommendation.
62719567|NCT03435068|EXPERIMENTAL|Diode laser|In the laser group (LG), a diode laser was applied to the operation sites in accordance with the manufacturer's guidelines (2.8 W continuous wave mode, wavelength 980 nm). The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power. The laser never made contact with the gingival tissue. The practice distance did not affect the laser spot size, which was 0.5 cm-1 cm. Smoke associated with the laser application was aspirated from the surgical site.
62719568|NCT03435068|ACTIVE_COMPARATOR|Scalpel|In the scalpel group following the local anesthetic administration, the gingivectomy was performed with a #15 scalpel. Subsequent to the operation, the borderline of gingiva was determined via the use of a pointer dental tweezers, and excessive gingival tissue was then removed with Gracey curettes
62719569|NCT01654939|EXPERIMENTAL|rifaximin|All patients will be taking rifaximin 550 mg twice daily
62719570|NCT00560300|EXPERIMENTAL|1|Doxercalciferol + Calcium Carbonate
62719571|NCT00560300|EXPERIMENTAL|2|Doxercalciferol + Sevelamer
62719572|NCT00560300|EXPERIMENTAL|3|Calcitriol + Calcium Carbonate
62719573|NCT00560300|EXPERIMENTAL|4|Calcitriol + Sevelamer
62719574|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
62719575|NCT03139461|EXPERIMENTAL|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
62719576|NCT03139461|NO_INTERVENTION|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
62719577|NCT04994223|EXPERIMENTAL|Group A(combined anticoagulation plus antithrombotic therapy group)|group A patients would be receiving rivaroxaban and aspirin as experimental group to see the efficacy of rivaroxaban in peripheral arterial disease.
62719578|NCT04994223|ACTIVE_COMPARATOR|Group B( antithrombotic therapy alone group)|group B patients would be those receiving traditional antithrombotic therapy as usually given n Peripheral Arterial Disease.
62719579|NCT01114737|EXPERIMENTAL|Sapropterin dihydrochloride|
62719580|NCT01114737|PLACEBO_COMPARATOR|Tablet without active ingredient|
62719581|NCT01385592|EXPERIMENTAL|AFQ056 100 mg|
62719582|NCT01385592|PLACEBO_COMPARATOR|Placebo|
62719583|NCT06715995|ACTIVE_COMPARATOR|endogenous gamma light|This device is an LED light source table lamp with a vertical surface measuring 16 cm by 22 cm. It will be positioned within arm's reach, approximately 50 cm from the participant, to ensure continuous exposure to the light stimulation. The active device delivers endogenous gamma light stimulation.
62719584|NCT06715995|SHAM_COMPARATOR|Sham (70Hz) gamma light|The sham device is identical in appearance to the active device. It will be positioned within arm's reach, approximately 50 cm from the participant, to ensure continuous exposure to the light stimulation. The sham device delivers 70 Hz light stimulation.
62719585|NCT05570032|EXPERIMENTAL|virtual reality training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
62165390|NCT01064856|PLACEBO_COMPARATOR|Double-blind Placebo / Open-label Adalimumab|Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.
62165391|NCT02188784|ACTIVE_COMPARATOR|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
62165392|NCT02188784|PLACEBO_COMPARATOR|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
62165393|NCT02173561|EXPERIMENTAL|Group Cognitive Processing Therapy-Cognitive Only|
62165394|NCT02173561|EXPERIMENTAL|Individual Cognitive Processing Therapy-Cognitive Only|
62165395|NCT04297423|EXPERIMENTAL|Plenvu|Plenvu split dose
62165396|NCT04297423|ACTIVE_COMPARATOR|Citrafleet|citrafleet in split dose
62165397|NCT06562244|EXPERIMENTAL|HAT On, Peer Support On, High Engagement|"HAT component: On - Two interactive sessions using UNICEF's Helping Adolescents Thrive comics, covering recognizing emotions, stress management, conflict resolution, and relationship building.~Peer Support: On - Half-day workshop from UNICEF's I Support My Friends program, teaching adolescents to identify distress in peers, develop listening skills, and seek additional support.~Engagement booster: High - Includes refreshments, certificates, and vouchers (10 EUR for adolescents, 5 EUR for caregivers)."
62545064|NCT02445963|ACTIVE_COMPARATOR|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
62545065|NCT02445963|ACTIVE_COMPARATOR|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
62719586|NCT04035889|EXPERIMENTAL|Group 1|Participants assigned to Group 1 will take 2 weeks of melatonin followed by 2 weeks of placebo
62719587|NCT04035889|EXPERIMENTAL|Group 2|Participants assigned to Group 2 will take 2 weeks of placebo followed by 2 weeks of melatonin.
62719588|NCT05590247|EXPERIMENTAL|Intermittent Fasting Group|Patients in this group will do intermittent fasting dieting for 12 weeks, meaning they will only eat for 8 hours per day. They may choose whichever 8 hours they want. Only water can be consumed during the fasting period. For the last 12 weeks of the study, they will resume their normal diet.
62719589|NCT05590247|NO_INTERVENTION|Standard Routine Diet Group|Patients will continue with their normal diets for the 24 week duration of the study.
62719590|NCT06191042|EXPERIMENTAL|si-544|
62165398|NCT06562244|EXPERIMENTAL|HAT On, Peer Support Off, High Engagement|"HAT component: On - Two interactive sessions using UNICEF's Helping Adolescents Thrive comics, covering recognizing emotions, stress management, conflict resolution, and relationship building.~Peer Support: Off~Engagement booster: High - Includes refreshments, certificates, and vouchers (10 EUR for adolescents, 5 EUR for caregivers)."
62719591|NCT06191042|PLACEBO_COMPARATOR|Placebo|
62719592|NCT02752347|EXPERIMENTAL|unilateral crossbite|unilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
62719593|NCT02752347|NO_INTERVENTION|control|the surface Electromyography (surface EMG device) device will be used to examine the muscle activities on normal patients
62719594|NCT02752347|EXPERIMENTAL|Bilateral crossbite|Bilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
62719595|NCT03557866|EXPERIMENTAL|pronated group|individuals with pronated foot
62719596|NCT03557866|ACTIVE_COMPARATOR|control group|individuals with normal foot posture
62545066|NCT02445963|ACTIVE_COMPARATOR|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
62545067|NCT00582010|EXPERIMENTAL|1. Experimental|iNO administration
62545068|NCT00582010|PLACEBO_COMPARATOR|2. Placebo|Placebo (nitrogen)
62545069|NCT00408083|EXPERIMENTAL|1|MultiHance MRI contrast agent
62545070|NCT00408083|ACTIVE_COMPARATOR|2|Magnevist contrast agent for MRA
62545071|NCT01769456|EXPERIMENTAL|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
62545072|NCT02965040|EXPERIMENTAL|Roxadustat: subjects with normal renal function|Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m\^2. Single dose of roxadustat
62719597|NCT05534984|EXPERIMENTAL|Arm A|
62719598|NCT05534984|PLACEBO_COMPARATOR|Arm B|
62719599|NCT05534984|EXPERIMENTAL|Arm C|
62719600|NCT03594110|EXPERIMENTAL|Empagliflozin 10 mg|Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily 10 milligram (mg) film-coated tablets of empagliflozin.
62719601|NCT03594110|PLACEBO_COMPARATOR|Placebo|Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily film-coated tablets of placebo to match empagliflozin.
62545073|NCT02965040|EXPERIMENTAL|Roxadustat: subjects with severely impaired renal function|Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m\^2. Single dose of roxadustat
62545074|NCT02965040|EXPERIMENTAL|Roxadustat: subjects with ESRD on CAPD or APD|ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
62545075|NCT02965040|EXPERIMENTAL|Roxadustat: subjects with ESRD on HD or HDF|ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
62545076|NCT00002704|EXPERIMENTAL|Arm I|Single Agent Chemotherapy. TSPA or DTC101. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 2-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. ARA-C/ASP; plus TIT. 4-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. CTX/MP/MTX/VP-16; with CF; plus TIT. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 6-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. ARA-C/ASP/CTX/MP/MTX/VP-16; with CF; plus TIT. Radiotherapy plus 3-Drug Combination Chemotherapy. Craniospinal irradiation using x-rays with energies of 4-6 MV (electrons acceptable for spinal cord irradiation); plus ASP/DM/VCR. 2-Drug Combination Chemotherapy Alternating with 2-Drug Combination Chemotherapy. MP/MTX; alternating with CTX/VCR.
62719602|NCT04373421|ACTIVE_COMPARATOR|chlorhexidine gluconate plus benzydamine hydrochloride|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects. The most common side effect of chlorhexidine is oral discoloration, taste changes and allergic responses. Furthermore, it has been reported that chlorhexidine has cytotoxic effect on gingival fibroblasts, epithelial cells, neutrophils and red blood cells; also shows incremental trend in genotoxicity as the duration of usage is increased. Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that elicits anti-inflammatory, analgesic, anesthetic and antimicrobial effects. It is often used in addition to the topical application of chlorhexidine.. However, side effects such as urticaria, erythema, pruritus, photosensitivity, bronchospasm and renal problems can be observed associated with the use of benzydamine.
62719603|NCT04373421|ACTIVE_COMPARATOR|St. John's wort oil|St. John's Wort (Hypericum perforatum) is a European medicinal plant with a history of more than 2000 years which possessing a variety of important constituents including phloroglucinols (hyperforin and adhyperforin), naphthodianthrones (hypericin and pseudohypericin), xanthones, essential oil, biflavones (biapigenin and amentoflavone), flavonol derivatives and phenolic compounds. The important components of St. John's Wort such as hypericin and hyperforin exert anti-inflammatory, antimicrobial, anticancer effects as well as stimulating tissue growth and differentiation. Hypericin exhibits anti-inflammatory effects by inhibiting the production of interleukin-12; whereas hyperforin reveals this effect by inhibiting the mechanisms of cyclooxygenase 1, 5-lipoxygenase and prostaglandin E2. St. John's Wort oil is extracted by maceration of the hypericum herb in carrier oil, such as virgin olive oil.
62738989|NCT02220153|EXPERIMENTAL|UCB7665 Intravenous 3|Single dose calculated based on body weight for 60 minutes intravenous infusion.
62719604|NCT04373421|ACTIVE_COMPARATOR|Virgin olive oil|The olive oil, a product extracted from the fruit of Olea europaea, exerts also antioxidant and anti-inflammatory effects due to its important contents including oleic acids, phenolic acids, secoiridoids and flavonoids. The oral application of olive oil has been shown to have protective anti-inflammatory effects and accelerated epithelial healing.
62719605|NCT00059631|EXPERIMENTAL|Bortezomib + Mitoxantrone|"Bortezomib starting dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.~Mitoxantrone starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles."
62719606|NCT06716996|EXPERIMENTAL|rTMS|
62719607|NCT06716996|PLACEBO_COMPARATOR|sham treatment|
62719608|NCT06180525||Retrospective part|Patients for whom follow-up data up to at least 1 year after surgery is available at the start of the study.
62719609|NCT06180525||Prospective part|Both for patients not yet undergoing treatment intervention, at the start of the study, according to the inclusion criteria, both regarding those in follow-up for whom data are not available according to the time of observation required (1 year), will begin once all necessary authorizations have been obtained administrative requests
62719610|NCT02431325|EXPERIMENTAL|Teduglutide|Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration
62165399|NCT06562244|EXPERIMENTAL|HAT On, Peer Support On, Low Engagement|"HAT component: On - Two interactive sessions using UNICEF's Helping Adolescents Thrive comics, covering recognizing emotions, stress management, conflict resolution, and relationship building.~Peer Support: On - Half-day workshop from UNICEF's I Support My Friends program, teaching adolescents to identify distress in peers, develop listening skills, and seek additional support.~Engagement booster: Low - Refreshments and certificates."
62165400|NCT06562244|EXPERIMENTAL|HAT On, Peer Support Off, Low Engagement|"HAT component: On - Two interactive sessions using UNICEF's Helping Adolescents Thrive comics, covering recognizing emotions, stress management, conflict resolution, and relationship building.~Peer Support: Off~Engagement booster: Low - Refreshments and certificates."
62545077|NCT04718454||Equator attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,Equator Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
62545078|NCT04718454||ball attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,ball Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
62545079|NCT04891003||Patients Diagnosed with Endometriosis (or endometrioma alone)|Nulliparous patients who had diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
62545080|NCT04891003||Patients With No Gynecological Pathology|Nulliparous patients who had not diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
62545081|NCT05349045||an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group|
62545082|NCT02467478|PLACEBO_COMPARATOR|Placebo|Matching placebo 1 pill daily for 12 weeks
62545083|NCT02467478|ACTIVE_COMPARATOR|Linagliptin|Linagliptin 5mg once daily for 12 weeks
62545084|NCT02982837|EXPERIMENTAL|PEG-IFN & NUCLEOTIDE ANALOGUES|Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.
62545085|NCT02982837|ACTIVE_COMPARATOR|NUCLEOTIDE ANALOGUES|Nucleoside same dose as they started the study.
62545086|NCT01267487|ACTIVE_COMPARATOR|Fixed doses plus PO protamine|"Intraoperative fixed dose schemes (as in fixed doses plus placebo group) plus continuous infusion of 25mg/hour of protamine during first 6 PO hours"
62545087|NCT01267487|ACTIVE_COMPARATOR|Titrated doses plus PO protamine|"Same as titrated doses arm, plus continuous infusion of 25mg/ hour of protamine during first 6 PO hours"
62719611|NCT02431325|PLACEBO_COMPARATOR|Placebo|Placebo, subcutaneous injection, 6 months duration
62719612|NCT03375333||20GPs|20 general practitioners, who use ultrasound in the examination of patients.
62719613|NCT03174327|OTHER|Hepatic Transplantation|
62719614|NCT00628524||1|\> 500 consecutive patients with coronary artery disease fulfilling eligibility criteria.
62545088|NCT01267487|NO_INTERVENTION|Fixed doses plus placebo|"Before CPB, fixed heparin dose of 400 Units per kg of body weight to achieve an Activated Coagulation Time (ACT) \> 480 seconds.~Reversal of heparin after CPB using 1 : 1 ratio (1 mg of protamine for each 100 units (1mg) of heparin), plus 0.8 mg/kg of protamine at the end of the surgery.~Continuous infusion of placebo (saline 0.9%) during the first 6 PO hours."
62545089|NCT01267487|ACTIVE_COMPARATOR|Titrated doses plus placebo|"Titrated doses of heparin before and during CPB and reversal with protamine after CPB calculated by the construction of individualized Bull's dose-response curve.~Continuous infusion of placebo (saline 0.9%) during first 6 PO hours."
62719615|NCT02799589|EXPERIMENTAL|Remifentanil-dexmedetomidine and caudal|Anesthesia will be induced with inhaled sevoflurane which will be discontinued once IV access is obtained and the airway is secured with an endotracheal tube. Patients will receive remifentanil loading dose of 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min) and dexmedetomidine load at 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr) A caudal block with 0.2% ropivacaine will be performed in all patients for intraoperative and postoperative pain control.
62545090|NCT05812274|EXPERIMENTAL|Intervention Arm|Participants are provided with ApricityRx digital solution with pulse oximeters and 24/7 C.A.R.E. (Cancer Adverse event Rapid Evaluation) to monitor and capture ePRO, identify onset or progression of symptoms verified by nurse triage, trigger intervention by the study team.
62545091|NCT05812274|NO_INTERVENTION|Control Arm|Clinicians will monitor NSCLC patients on ICIs for irAEs as a standard of care using routine practices.
62719616|NCT01951664|EXPERIMENTAL|Modified Yoga Program for HNC Survivors|Following the completion of baseline study measures, participants will be randomized to either do go directly into a Yoga program or to an 8 week wait-list control group. Those in the yoga program will undergo an initial Yoga Evaluation. Patients will receive customized yoga guided practice program, a home practice plan with ongoing modifications. Instructors will assess compliance. A satisfaction assessment is conducted at study-end.
62719617|NCT01951664|ACTIVE_COMPARATOR|Wait list control|Those in the wait list group will have the same assessments as those in the yoga program over the same period of time.
62719618|NCT05973162|ACTIVE_COMPARATOR|Virtual Reality training|Virtual Reality + Conventional PT
62719619|NCT05973162|EXPERIMENTAL|Transverse friction massage (TFM)|Transverse friction massage (TFM)+ Conventional PT
62719620|NCT05365100|EXPERIMENTAL|Phase1dose escalation|Phase1 Dose Escalation Multiple dose levels of BN102 to be evaluated; determination of MTD/Phase 2 recommended dose(RP2D)
62719621|NCT05365100|EXPERIMENTAL|Phase2 expansion in R/R MCL with BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group
62719622|NCT05365100|EXPERIMENTAL|Phase2 expansion in R/R MCL without BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should without BTK inhibitor, approximate 12-23 patients this group
62165401|NCT06562244|EXPERIMENTAL|HAT Off, Peer Support On, High Engagement|"HAT component: Off~Peer Support: On - Half-day workshop from UNICEF's I Support My Friends program, teaching adolescents to identify distress in peers, develop listening skills, and seek additional support.~Engagement booster: High - Includes refreshments, certificates, and vouchers (10 EUR for adolescents, 5 EUR for caregivers)."
62165402|NCT06562244|EXPERIMENTAL|HAT Off, Peer Support Off, High Engagement|"HAT component: Off~Peer Support: Off~Engagement booster: High - Includes refreshments, certificates, and vouchers (10 EUR for adolescents, 5 EUR for caregivers)."
62719623|NCT05365100|EXPERIMENTAL|Phase2 expansion in R/R CLL/SLL with BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group
62719624|NCT05365100|EXPERIMENTAL|Phase2 Expansion in R/R CLL/SLL without BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group
62719625|NCT05365100|EXPERIMENTAL|Phase2 Expansion in other R/R B-NHL with BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should with BTK inhibitor, approximate 12-23 patients this group
62719626|NCT05365100|EXPERIMENTAL|Phase2 Expansion in other R/R B-NHL without BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group
62719627|NCT03488329|EXPERIMENTAL|Intervention|"Intervention group~Individual nutritional therapy"
62719628|NCT03488329|NO_INTERVENTION|Control|"Control group~Standard treatment"
62719629|NCT06084364|EXPERIMENTAL|Intraarticular corticosteroid injection (IACS)|A single ultrasound-guided intraarticular injection of 0.50 ml of 40 mg/ml triamcinolone acetonide at baseline. A smaller dosage can be considered if there is increased resistance during injection. The same injection procedure will be repeated after 12 weeks if there is pain (NRS≥3) and inflammation (grey scale synovitis grade 1-3) present in the CMC-1 joint.
62719630|NCT06084364|PLACEBO_COMPARATOR|Saline injection|A single ultrasound-guided intraarticular injection of 0.50 ml of sodium chloride 9 mg/ml at baseline. A smaller dosage can be considered if there is increased resistance during injection. The same injection procedure will be repeated after 12 weeks if there is pain (NRS≥3) and inflammation (grey scale synovitis grade 1-3) present in the CMC-1 joint.
62719631|NCT06084364|EXPERIMENTAL|Occupational Therapy intervention|Patient education, instructions about hand exercises and training in the Happy Hands app. Administration of day and night orthosis. The Happy Hands app involves a 12 week intervention.
62719632|NCT06718062|PLACEBO_COMPARATOR|Aliskiren Group|Participants in this group will receive Aliskiren (240 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., with the approval number National Drug Approval No. H20138002. The patients will take Aliskiren orally once a day for 3 months. The primary objective is to assess the non-inferiority of Aliskiren in lowering serum uric acid levels, as well as its effects on blood pressure and kidney function.
62719633|NCT06718062|ACTIVE_COMPARATOR|Losartan Group|Participants in this group will receive Losartan (100 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be provided by Zhejiang Huahai Pharmaceutical Co., Ltd., with the approval number National Drug Approval No. H20143030. The patients will take Losartan orally once a day for 3 months. The goal is to compare the efficacy of Losartan in reducing serum uric acid levels with Aliskiren and evaluate its impact on blood pressure and kidney function.
62719634|NCT06714708|EXPERIMENTAL|Low Dose Radiotherapy combined with Sintilimab and Chemotherapy|Neoadjuvant treatment：two cycles of sintilimab and platinum based chemotherapy，simultaneously undergoing radiotherapy 30Gy/15F
62165403|NCT06562244|EXPERIMENTAL|HAT Off, Peer Support On, Low Engagement|"HAT component: Off~Peer Support: On - Half-day workshop from UNICEF's I Support My Friends program, teaching adolescents to identify distress in peers, develop listening skills, and seek additional support.~Engagement booster: Low - Refreshments and certificates."
62165404|NCT06562244|EXPERIMENTAL|HAT Off, Peer Support Off, Low Engagement|"HAT component: Off~Peer Support: Off~Engagement booster: Low - Refreshments and certificates"
62545092|NCT04077190|EXPERIMENTAL|adipose-derived stem cell injection|Ultrasound guided injection of 5cc adipose derived stem cells
62545093|NCT04077190|ACTIVE_COMPARATOR|cortisone injection|Ultrasound guided injection of cortisone
62719635|NCT06714708|ACTIVE_COMPARATOR|Sintilimab in combination with Chemotherapy|Neoadjuvant treatment：two cycles of sintilimab and platinum based chemotherapy
62719636|NCT04344184|ACTIVE_COMPARATOR|Infusion|L-Ascorbic Acid (Vitamin C), intravenous infusion
62719637|NCT04344184|PLACEBO_COMPARATOR|Placebo|Dextrose 5% Water
62719638|NCT02696603|EXPERIMENTAL|Participants with Parkinson disease|People who report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
62738990|NCT02220153|EXPERIMENTAL|UCB7665 Intravenous 4|Single dose calculated based on body weight for 60 minutes intravenous infusion.
62719639|NCT02696603|EXPERIMENTAL|Participants without Parkinson disease|People who do not report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
62545094|NCT05931653|EXPERIMENTAL|Multimodal Physical Therapy|Multimodal Physical therapy/Traditional Physical therapy
62545095|NCT05931653|EXPERIMENTAL|Proprioceptive training along with Multimodal Physical Therapy|Proprioceptive training along with Multimodal Physical Therapy
62545096|NCT03277755|EXPERIMENTAL|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
62545097|NCT03277755|EXPERIMENTAL|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
62719640|NCT06021808|EXPERIMENTAL|LAA clipping group|In this arm, participants are performed thoracoscopic LAA clipping.
62719641|NCT06021808|ACTIVE_COMPARATOR|NOACs group|Patients randomized to NOAC therapy will begin long-term oral administration of NOACs immediately after enrollment.
62719642|NCT02793661|EXPERIMENTAL|RenalGuard Arm|In order to prevent patients from acute kidney injury, patients will receive the RenalGuard Therapy delivered by the RenalGuard system from one hour before the cardiovascular intervention to 4 hours after the intervention.
62719643|NCT02793661|ACTIVE_COMPARATOR|Control Arm|Patient will received standard treatment, as per ESC Guidelines 2014, to prevent from acute kidney injury.
62545098|NCT03620045|EXPERIMENTAL|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
62719644|NCT00100802|EXPERIMENTAL|Treatment (lomustine, temozolomide, radiation therapy)|Patients receive oral temozolomide once daily on days 1-42. Patients also undergo concurrent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-40. Patients who did not undergo prior gross total resection also undergo boost radiotherapy once daily on days 43-47. Four weeks after completion of chemoradiotherapy, patients receive oral temozolomide once daily on days 1-5 and oral lomustine on day 1. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62719645|NCT05275673|EXPERIMENTAL|Group A - NFE2L2 Mutation, Dosing Cohort 1|sapanisertib 3 mg once daily (QD)
62719646|NCT05275673|EXPERIMENTAL|Group A - NFE2L2 Mutation, Dosing Cohort 2|sapanisertib 2 mg twice daily (BID)
62719647|NCT05275673|EXPERIMENTAL|Group B - NFE2L2 Wild-Type, Dosing Cohort 1|sapanisertib 3 mg QD
62719648|NCT05275673|EXPERIMENTAL|Group B - NFE2L2 Wild-Type, Dosing Cohort 2|sapanisertib 2 mg BID
62545099|NCT03620045|NO_INTERVENTION|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
62719649|NCT01979614|EXPERIMENTAL|Serelaxin|Serelaxin was administered at a dose of 30 μg/kg/24h by intravenous infusion for 48 hours
62719650|NCT01979614|PLACEBO_COMPARATOR|Placebo|Placebo was administered by intravenous infusion for 48 hours
62719651|NCT04478903||primary caregiver of patients aged 70 and over|
62545100|NCT05751343|EXPERIMENTAL|TACE-HAIC plus atezolizumab-bevacizumab|transartery chemoembolization and hepatic artery infusion of FOLFOX, simultaneously followed by intravenous of 1200mg atezolizumab plus bevacizumab (15mg/kg)
62545101|NCT03624959|EXPERIMENTAL|Treatment Group A - Ozanimod 0.46mg|A single dose of ozanimod 0.46 mg on Day 1
62545102|NCT03624959|EXPERIMENTAL|Treatment Group B - Ozanimod plus Gemfibrozil|Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
62545103|NCT03624959|EXPERIMENTAL|Treatment Group C - Ozanimod 0.92mg|A single dose of ozanimod 0.92 mg on Day 1.
62719652|NCT02003482||Postop IMRT for Head/Neck cancer|CT for Radiation Treatment Planning
62719653|NCT02003482||Chemo/IMRT for bulky Head/Neck cancer|CT for Radiation Treatment Planning
62719654|NCT03225482|EXPERIMENTAL|ME-CCT|8-week Motivationally Enhanced Compensatory Cognitive Training group
62719655|NCT03225482|ACTIVE_COMPARATOR|SC|8-week Goal-focused Supportive Contact group
62719656|NCT03157895|EXPERIMENTAL|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
62719657|NCT03157895|NO_INTERVENTION|Comparison group|This group receives Children's Administration services as usual.
62719658|NCT04480229|EXPERIMENTAL|Intervention Group|After the first treatment, every week the patients were called and consulted by telenursing. During the next there chemotherapy treatments, Edmonton Symptom Assessment System and General Comfort Questionnaire were filled. The study ended with the fourth cycle chemotherapy. A total of six telephone calls and 3 face-to-face follow-ups were done with each of the intervention group patients. Face-to-face follow-up with patients during chemotherapy treatments lasted for about 20-30 minutes, and patients were evaluated three times in terms of symptom severity and comfort level.
62737435|NCT01843673|EXPERIMENTAL|in-room imaging systems|Patients undergo FBCT once before treatment and once weekly for a total of 6-7 scans, dual CBCT up to 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian kV OBI 5 times weekly for a total of 33-35 scans, 2-D x-ray with Brain Lab ExacTrac 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian MV OBI once weekly for a total of 6-7 scans, and EPID imaging up to 5 times weekly for a total of 33-35 scans while undergoing IGART.
62165405|NCT03196180|EXPERIMENTAL|Treatment (topical fluorouracil, imiquimod)|Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.
62165406|NCT06471413||Group BOAT +|"The middle schools in the experimental group will benefit from the BOAT+ intervention, which involves training the school's educational team in the use of the BOAT®. Training is provided each year of the study to 5 members of the BOAT+ college educational team, in the form of e-learning supplemented by two half-day face-to-face sessions.~Trained professionals will use the BOAT® in real-life ecological conditions, according to their needs and educational projects."
62165407|NCT06471413||Group BOAT -|"No intervention will be carried out in the colleges of the control group, except to inform parents and educational teams about the research. The educational teams will not be trained to use the BOAT when the study is set up.~These middle schools will benefit from the same annual evaluations (school, students and educational teams) as the BOAT+ middle schools.~If the effect of the BOAT® structured prevention program is positive, the educational teams in the control group (BOAT-) will receive training in the use of the BOAT® at the end of the study."
62165408|NCT02232958|EXPERIMENTAL|Hyperbaric Oxygen treatment|administration of 100% Oxygen at 2 Atmospheres Absolute for 1 hour 1 daily, 5 days a week for 2 weeks
62545104|NCT03624959|EXPERIMENTAL|Treatment Group D - Ozanimod plus Itraconazole|Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
62545105|NCT03624959|EXPERIMENTAL|Treatment Group E - Ozanimod plus Rifampin|Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
62545106|NCT02521272|EXPERIMENTAL|air pocket|Breathing in the simulated avalanche snow.
62545107|NCT05957744||Group with colorectal cancer and malnutrition|
62545108|NCT05957744||Group with colorectal cancer without malnutrition|
62545109|NCT00750685|OTHER|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
62545110|NCT02813941|EXPERIMENTAL|Alternative GRADE SoF table|Two SoF tables (alternative GRADE SoF table and EPC SoF table) will be used in this randomized controlled non-inferiority trial as an intervention. The alternative GRADE SoF table format will be developed from a user-testing survey.
62545111|NCT02813941|EXPERIMENTAL|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published.
62545112|NCT02813941|ACTIVE_COMPARATOR|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
62545113|NCT01371539|OTHER|Lotrafilcon B / Comfilcon A|Lotrafilcon B contact lenses worn first, with comfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
62545114|NCT01371539|OTHER|Comfilcon A / Lotrafilcon B|Comfilcon A contact lenses worn first, with lotrafilcon B contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
62545115|NCT02279108|EXPERIMENTAL|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
62545116|NCT02279108|ACTIVE_COMPARATOR|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
62545117|NCT00994578|NO_INTERVENTION|Internet Only|Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
62545118|NCT00994578|EXPERIMENTAL|CHESS|Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
62545119|NCT00994578|EXPERIMENTAL|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
62545120|NCT00994578|EXPERIMENTAL|CHESS/COPE|Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
62545121|NCT02468856|ACTIVE_COMPARATOR|Armodafinil|Armodafinil 250 mg tablets, one time administration per study session in the morning of day 2
62545122|NCT02468856|PLACEBO_COMPARATOR|Placebo|one time administration per study session in the morning of day 2
62545123|NCT04153903||Patients with intermediate lesions|Imaging cohort will be performed invasive angiography and optical coherence tomography (or Coronary CT angiography) with FFR(Fractional Flow Reserve) values of the intermediate lesions (50-70% stenosis)
62545124|NCT02806024|EXPERIMENTAL|Treatment Arm (Tranexamic Acid, or TXA)|Patients will be randomized to treatment or placebo arms preoperatively. In our treatment arm of pregnant patients with suspected placenta accreta or at high risk for placenta accreta, patients will receive 1 gram intravenous TXA administered over 10 minutes immediately after delivery of the infant. The drug will be prepared and ready to hang at the beginning of the case. The study drug will be administered only once.
62165409|NCT01973179||Radiation therapy|Radiotherapy with protons in patients with head and neck carcinoma
62165410|NCT00489697|EXPERIMENTAL|1 (single arm)|patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
62165411|NCT05234008|EXPERIMENTAL|home therapy group|one group of 15 participants (i.e. persons with CLBP) performing a six-week HIT exercise intervention with a total of 12 rehabilitation sessions (two sessions per week).
62165412|NCT01107912|EXPERIMENTAL|5 milligrams (mg) prasugrel|
62165413|NCT01107912|ACTIVE_COMPARATOR|10 mg prasugrel|
62719659|NCT04480229|NO_INTERVENTION|No Intervention: Control Group|"During their first treatment the Patient Identification Form was filled and they were trained, which is the routine practice of the clinic. Patients were informed about the Symptom follow-up form, asked to mark the symptoms and signs they experienced due to the disease and treatment in the form between the two chemotherapy treatments and to note when they experienced and how they resolved this symptom. When the patients came to the second treatment, the first follow-up of the patients was done. The investigator filled Edmonton Symptom Assessment System and General Comfort Questionnaire forms via face-to-face interviews. The Symptom Follow-up Form given to the patients in the previous chemotherapy treatment was collected and the same new form was given. They were requested to bring this form in their next treatment. The same protocol was followed during the third and fourth chemotherapy treatment"
62719660|NCT02668289|OTHER|interventional|consent, screening, xrays, PVS impressions, photographs, CBCT, anesthesia, extraction, clinical measurements
62719661|NCT06715930||ISS group|Patients presenting with in-stent stenosis (ISS) at imaging follow-up. ISS was defined as a growth process exceeding the limits of metal mesh, as evidenced by a visible gap between the contrast-filled vascular lumen and the internal contours of the pipeline embolization device.
62719662|NCT06715930||Non-ISS group|Patients withou in-stent stenosis (ISS) at imaging follow-up. ISS was defined as a growth process exceeding the limits of metal mesh, as evidenced by a visible gap between the contrast-filled vascular lumen and the internal contours of the pipeline embolization device.
62735920|NCT06513130|EXPERIMENTAL|Group with geriatric assessment|"Patients will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following.~In addition to the first visit in the group without geriatric assessment, will be collected:~* Living conditions (home, proxy, home support)~* Quality of life (SF-36)~* Covi test and 4-item Geriatric Depression Scale~* Katz-ADL and IADL~* History of fall, mobility assessment~* Nutritional status (BMI, albuminemia, Mini Nutritionnal Assesment)~* Cognitive assessment (Mini-mental State Examination)~The visit at month 6 will be the same in both groups"
62737436|NCT00943098|EXPERIMENTAL|Diclofenac HPBCD s.c. 75mg/ml|
62165414|NCT01107912|ACTIVE_COMPARATOR|75 mg clopidogrel|
62545125|NCT02806024|PLACEBO_COMPARATOR|Placebo Arm|Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
62545126|NCT02348255|EXPERIMENTAL|Treatment (bevacizumab, carmustine, NovoTTF-100A)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.
62545127|NCT05430217|EXPERIMENTAL|Buspirone, sustained-release tablets, 15 mg|15 mg/day
62545128|NCT05430217|PLACEBO_COMPARATOR|Placebo|1 placebo tablet/day
62545129|NCT03504683|EXPERIMENTAL|Early TRE|
62545130|NCT03504683|EXPERIMENTAL|Mid-day TRE|
62545131|NCT03504683|PLACEBO_COMPARATOR|Control Schedule|
62545132|NCT00435760|ACTIVE_COMPARATOR|Tiotropium|1 puff, 1 day treatment
62545133|NCT00435760|PLACEBO_COMPARATOR|Placebo|Tiotropium or Aclidinium Placebo, 1 day treatment
62545134|NCT00435760|EXPERIMENTAL|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
62545135|NCT06115083|EXPERIMENTAL|Pelvic floor muscle re-education|Intervention with pelvic floor re-education using bio-feedback and home training for 6 months, with a follow up visit after an additional period of 6 months
62545136|NCT06115083|NO_INTERVENTION|Standard Care|No intervention during 6 months after inclusion. After the 6 month follow-up evaluation the study subjects are offered to participate in the interventional arm.
62545137|NCT05258383||Lung Neoplasm patients|Lung Neoplasm patients (adults)
62545138|NCT05258383||Pelvic Neoplasm patients|Pelvic Neoplasm patients (adults)
62545139|NCT05258383||Breast Cancer patients|Breast Cancer patients(adults)
62545140|NCT05258383||Ear Nose and Throat (ENT) Cancer patients|Ear Nose and Throat (ENT) Cancer patients (adults)
62545141|NCT05258383||Pediatric Cancer patients|Pediatric cancer patients (under 18 years-old) : neurologic cancer , abdomen cancer, Thorax cancer, Ear Nose and Throat (ENT) Cancer
62545142|NCT05513391|EXPERIMENTAL|RIV4 cohort|RIV4 single injection at Day 1
62165415|NCT01545245||Treated|Palivizumab treated
62165416|NCT01545245||Untreated|Palivizumab untreated
62165417|NCT06593288|ACTIVE_COMPARATOR|Spontaneous breathing trial with pressure support|Spontaneous breathing trial with pressure support
62545143|NCT05513391|ACTIVE_COMPARATOR|IIV4 cohort|IIV4, single injection at Day 1
62545144|NCT01044108|EXPERIMENTAL|Trial, part 1 (males only)|
62545145|NCT01044108|EXPERIMENTAL|Trial, part 2 (males and females)|
62545146|NCT03637387|EXPERIMENTAL|BIIB074|Administered orally three times daily (TID)
62545147|NCT03637387|PLACEBO_COMPARATOR|Placebo|Placebo matching BIIB074
62545148|NCT06552182|EXPERIMENTAL|After a single dose of HUC2-344, co-administration of HUC2-344-R1 and HUC2-344-R2|Take 2 pills of comparative drugs first, and take 1 pill of IP after a 1 week of the break.
62545149|NCT06552182|EXPERIMENTAL|After co-administering HUC2-344-R1 and HUC2-344-R2 once, take single dose of HUC2-344 once.|Take 1 pill of IP first, and take 2 pills of comparative drugs after a 1 week of the break.
62545150|NCT03874728||Older people at risk of falls|Older people at risk of falls
62545151|NCT02214537|EXPERIMENTAL|MACS|Patients with MACS Selection
62545152|NCT03002701|NO_INTERVENTION|Control - standard care|Prior to implementation of the intervention package the current standard of care will be maintained.
62545153|NCT03002701|ACTIVE_COMPARATOR|Intervention group|After implementation the intervention package will be implemented as standard care.
62545154|NCT06469203|PLACEBO_COMPARATOR|Placebo|Participants will receive 100 ml of saline alone.
62545155|NCT06469203|EXPERIMENTAL|Oxytocin|Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
62545156|NCT01118975|EXPERIMENTAL|Pilot Phase - Vornistat 200 to 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and escalating doses of vorinistat (200mg run-up, 300mg, and 400mg 4 days on 3 days off)
62165418|NCT06593288|ACTIVE_COMPARATOR|Spontaneous breathing trial without pressure support|Spontaneous breathing trial without pressure support ( CPAP)
62719663|NCT03294005||Subjects with nodular goiter|Enrolled subjects with nodular goiter had thyroid sonography and thyroidectomy from 2002 January to 2016 December in CMUH. Total enrolled subject about 2000. These subjects were confirmed by pathology. Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients. Gray scale ultrasonography was routinely performed in every subject. Color Doppler ultrasonography for blood flow and thyroid fine needle aspiration was not absolute done in routine procedure. All data at least was interpreted by 3 endocrinologists under the blind method. Each subject was analyzed under thyroid echogenicity, margin, calcification, inclusion, grooving change and size \& ratio size of tall and transverse.
62719664|NCT00501644|EXPERIMENTAL|Chemoimmunotherapy|GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days
62719665|NCT05783752|EXPERIMENTAL|Stair-Stepping then Control|Participants start with stair-stepping 15 minutes after meals on day 1 followed by no exercise on day 2. Sequence continues throughout the 10 days.
62719666|NCT05783752|EXPERIMENTAL|Control then Stair-Stepping|Participants start with no exercise on day 1 followed by stair-stepping 15 minutes after meals on day 2. Sequence continues throughout the 10 days.
62719667|NCT04375436|ACTIVE_COMPARATOR|NTRX-07-SDD|NTRX-07-SDD at 0.3-8mg/kg; single dose
62165419|NCT00847847|OTHER|2|control subjects with muscle biopsy
62165420|NCT00847847|OTHER|1|ALS patients with muscle biopsy
62165421|NCT06326281|ACTIVE_COMPARATOR|External oblique intercostal plane block group|Before general anaesthesia, Ultrasound guided unilateral external oblique intercostal plane block group block will perform with 20 ml of 0.25% bupivacaine .Patient controlled analgesia with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
62165422|NCT06326281|ACTIVE_COMPARATOR|Oblique subcostal transversus abdomınıs plane block group|Under general anaesthesia, Ultrasound guided unilateral oblique subcostal transversus abdomınıs plane block will perform with 20 ml of 0.25% bupivacaine. Patient controlled analgesia with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours
62165423|NCT06326281|ACTIVE_COMPARATOR|Local anesthetic infiltration group|4 trocars will be used by the surgical team during the operation, and these trocars will be placed 10 mm infraumbilical, 10 mm in the middle epigastrium, 5 cm below the xiphoid, 5 mm in the midclavicular line and in the right subcostal region, and 5 mm in the anterior axillary line. Before trocar placement, 0.25% bupivacaine will be applied to the skin, fascia, muscle and preperitoneal area in accordance with the infiltration rules. A total of 20 mL of 0.25% bupivacaine will be used, 6 mL for 10 mm trocar sites and 4 mL for 5 mm trocar sites. Patient controlled analgesia with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours
62165424|NCT06326281|SHAM_COMPARATOR|Control Group|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) Patient controlled analgesia protocols were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
62165425|NCT05911191|NO_INTERVENTION|Control|Both groups will receive a first session in which they will be instructed to carry out the unsupervised home EBPrehab program, consisting of respiratory training, ventilatory training, strengthening of the respiratory muscles, aerobic endurance exercise through continuous walking, and a series of recommendationss on post-surgical care
62165426|NCT05911191|EXPERIMENTAL|Experimental|Addittionally, a preoperative musculoskeletal and cardiopulmonary rehabilitation program focused on peripheral resistance training, will be implemented in the experimental group
62165427|NCT04161872|ACTIVE_COMPARATOR|Uricemin|
62165428|NCT04161872|PLACEBO_COMPARATOR|Placebo|
62165429|NCT03534778||patients undergoing neck dissection|all patients undergoing neck dissection
62165430|NCT04462653|EXPERIMENTAL|use two kinds of device successively|the same participant use a Wearable Dynamic ECG Recorder and 12-lead ECG to record heart rate and atrial fibrillation
62165431|NCT02473913|EXPERIMENTAL|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
62165432|NCT02473913|PLACEBO_COMPARATOR|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
62165433|NCT04299698||Carbohydrate reduction group|Participants chose to control their body fat mass by reducing their carbohydrate intake through observation study periods.
62545157|NCT01118975|EXPERIMENTAL|Phase II - Vorinistat 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and vorinostat 400 mg 4 days on 3 days
62545158|NCT04687683|EXPERIMENTAL|Post Isometric Relaxation Group|The participants in this group will receive post isometric relaxation stretching in modified cross body position.
62545159|NCT04687683|EXPERIMENTAL|Isolytic Stretching Group|The participants in this group will receive isolytic stretching in modified cross body position.
62719668|NCT04375436|PLACEBO_COMPARATOR|Control|Placebo control
62719669|NCT02382588|EXPERIMENTAL|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
62545160|NCT04687683|EXPERIMENTAL|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position.
62545161|NCT00612664|ACTIVE_COMPARATOR|Arm 1|0.1 mg/kg every 3 weeks
62545162|NCT00612664|ACTIVE_COMPARATOR|Arm 2|1 mg/kg every 3 weeks
62545163|NCT00612664|ACTIVE_COMPARATOR|Arm 3|1 mg/kg every 6 weeks
62545164|NCT00612664|ACTIVE_COMPARATOR|Arm 4|5 mg/kg every 3 weeks
62719670|NCT02382588|PLACEBO_COMPARATOR|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
62719671|NCT00783432|EXPERIMENTAL|1|Astepro Nasal Spray (0.1% azelastine hydrochloride)
62719672|NCT00783432|ACTIVE_COMPARATOR|2|Astelin Nasal Spray (0.1% azelastine hydrochloride)
62719673|NCT03242226|EXPERIMENTAL|two spectacles|
62165434|NCT04299698||Fat reduction group|Participants chose to control their body fat mass by reducing their fat intake through observation study periods.
62165435|NCT04299698||Intense exercise group|Participants chose to control their body fat mass by vigorously increasing the time and intensity of exercise through observation study periods.
62719674|NCT03242226|ACTIVE_COMPARATOR|single vision spectacles|
62719675|NCT02950103|EXPERIMENTAL|Synthetic phosphoethalonamine|Phosphoethanolamine PO daily
62719676|NCT06717165|ACTIVE_COMPARATOR|active tACS+exposure based CBT|The exposure and response prevention (ERP) treatment concurrently with an anode transcranial alternating current stimulation over the mPFC will be applied 8 times (tACS+ERP, 8 sessions) in the whole treatment.
62719677|NCT06717165|SHAM_COMPARATOR|sham tACS +exposure based CBT|the exposure and response prevention (ERP) treatment concurrently with an sham transcranial alternating current stimulation over the mPFC will be applied 8 times (sham tACS+ERP, 8 sessions) in the whole treatment.
62719678|NCT06717165|NO_INTERVENTION|waiting list|The patients in the waiting list will wait for two months after MRI and EEG collection. After this period, they could choose to receive either active tACS stimulation combined with ERP treatment or only active tACS stimulation treatment.
62719679|NCT04477616|EXPERIMENTAL|Experimental: Experimental/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 (chemotherapy day was recorded as day 1). If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
62719680|NCT04477616|ACTIVE_COMPARATOR|Comparator: Comparator/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 (chemotherapy day was recorded as day 1). If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
62719681|NCT04082130|EXPERIMENTAL|(XCM)+(CAF)|"Surgical protocol for test treatment with CAF + XCM:~After local anesthetizing the recipient site,CAF elevation will be done using (De Sanctis \& Zucchelli 2007) design.Horizontal incisions will be done at the recession site,another two slightly divergent vertical incisions will be done at the end of previous incisions extending to the mucogingival junction.The resulting flap will be split thickness in the surgical papillae area,then will be full thickness exposing 3-4 mm of the bone apically of the dehiscence and after that it will be split thickness in the apical direction,all the muscle insertions will be eliminated,the root surface will be prepared by curettes and chemically treated with 24% EDTA gel.De-epithelialization of the interdental papillae will be done.The XCM will be trimmed and fix onto the root surface 1-2mm coronally of the CEJ using absorbable sutures,and the flap will be coronally advanced to fully cover the XCM and then sutured to the de-epithelialized papillae."
62719682|NCT04082130|ACTIVE_COMPARATOR|(SCTG)+(CAF)|"The surgical protocol in the control group will be identical with test group protocol with these exceptions:~1. The entire flap will be elevated as split thickness instead of split-full-split thickness flap.~2. A SCTG harvested from the palate will be used to cover the exposed denuded root surface in lieu of placement of XCM in the test group. And absorbable sutures will be used to stabilize it 2 mm coronally from the CEJ.~3. As in the test group the mucosal flap will coronally advanced to completely cover the SCTG then sutured to the de-epithelialized papillae."
62165436|NCT04299698||Moderate exercise group|Participants chose to control their body fat mass by moderately increasing the time and intensity of exercise through observation study periods.
62165437|NCT01622088|EXPERIMENTAL|Dexpramipexole|Dexpramipexole open-label
62165438|NCT02100189|EXPERIMENTAL|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
62165439|NCT01854164|EXPERIMENTAL|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
62545165|NCT06236841|EXPERIMENTAL|XH-S004|Participants will receive XH-S004 as per assigned treatment regimen on scheduled days. Starting dose in single asceding dose: 5 mg.
62545166|NCT06236841|PLACEBO_COMPARATOR|XH-S004 placebo tablet|Participants will receive matching placebo as per assigned treatment regimen on scheduled days.
62545167|NCT05785884|EXPERIMENTAL|Non-Hispanic Black|Black adults ages 40-75 with knee OA.
62719683|NCT01201980||1|Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
62736211|NCT05291546|EXPERIMENTAL|Part B|Selected doses of REGN5381 or matching placebo given by IV administration followed by selected doses of REGN9035 and/or matching placebo via IV infusion
62165440|NCT01854164|PLACEBO_COMPARATOR|Placebo|Placebo for 8 weeks
62165441|NCT02984787|EXPERIMENTAL|3D Laparoscopic total gastrectomy|Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
62165442|NCT02984787|ACTIVE_COMPARATOR|2D Laparoscopic total gastrectomy|Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
62736212|NCT03831178|EXPERIMENTAL|DHA|Participants will take 11 capsules per day containing DHA-enriched triglyceride oil (1 g capsules containing at least 400 mg DHA) for a total of 5 g DHA/day divided into three times daily with meals or as tolerated.
62737437|NCT00943098|ACTIVE_COMPARATOR|Voltarol 75mg/3ml i.m.|
62737438|NCT01819207|EXPERIMENTAL|TEG group|
62165443|NCT03788941||LAAC plus Catheter ablation|Patients will receive both left atrial appendage closure and catheter ablation of atrial fibrillation for treatment.
62545168|NCT05785884|EXPERIMENTAL|Non-Hispanic White|White adults ages 40-75 with knee OA.
62545169|NCT02889523|EXPERIMENTAL|DLBCL cohort|"RCHOP + tazemetostat:~- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days~* Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~* Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID"
62165444|NCT01817127||Main Study|Women enrolled in this cohort of the study will collect their breast milk, infant urine and stool, and their urine and stool samples. Blood and saliva will be collected from these participants by study personnel.
62165445|NCT01817127||Gestational Diabetes Mellitus Cohort|Women who have been diagnosed with gestational diabetes mellitus, type 2 diabetes mellitus or impaired glucose tolerance will be enrolled in this cohort. Participants will be asked to report their fasting and postprandial blood glucose levels if they are monitoring these outcomes at home with a glucometer.
62165446|NCT01817127||Fresh Milk Cohort|Women enrolled in this cohort will provide fresh milk samples (stored in the refrigerator and picked up by study personnel within 1 hour of collection) for analysis of glycan composition and gene expression of glycan metabolizing enzymes of somatic cells in milk.
62165447|NCT01817127||RNA Milk Fat Cohort|Women enrolled in this cohort must have given birth to sons and will collect a fresh milk sample for transcriptomic analysis compared against non-human primate milk.
62165448|NCT01817127||Skin Study|This cohort includes mothers and their infants who will provide milk and infant stratum corneum cells to act as the control group for a different study designed to investigate skin function in premature infants.
62165449|NCT01817127||BMMI Project|Subjects enrolled in this cohort will be part of the control group for the BMMI Project.
62165450|NCT06338891||FMF patients|Patients, of both sexes, aged between 6 months and 80 years, affected by FMF, classified according to the Eurofever/PRINTO criteria
62165451|NCT06338891||Control subjects|"Subjects of the vaccination center of the University Hospital 'Paolo Giaccone' of Palermo, Italy"
62165452|NCT01398345|ACTIVE_COMPARATOR|Exercise and Respiratory Training|
62165453|NCT05728619|EXPERIMENTAL|Phase 1b|Escalating doses of HTMC0435 and Temozolomide
62165454|NCT05728619|EXPERIMENTAL|Phase 2|Recommended phase 2 dose (RP2D) of HTMC0435 and Temozolomide
62165455|NCT04851444|EXPERIMENTAL|SI-F019|SI-F019 administered intravenously (IV).
62545170|NCT02889523|EXPERIMENTAL|FL cohort|"RCHOP + tazemetostat:~Induction~* RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):~  6 cycles, every 21 days~* Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~* Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID~Maintenance~* Tazemetostat : 6 months (every 8 weeks)~* Rituximab : 24 months (every 8 weeks)"
62545171|NCT04117802|EXPERIMENTAL|Maple|
62545172|NCT04117802|PLACEBO_COMPARATOR|Placebo|
62545173|NCT02836691|ACTIVE_COMPARATOR|EKG to Control subjects|healthy controls without asthma or other respiratory disease.
62545174|NCT02836691|ACTIVE_COMPARATOR|EKG monitoring Mild asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
62545175|NCT02836691|ACTIVE_COMPARATOR|EKG monitoring severe control asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
62545176|NCT02836691|ACTIVE_COMPARATOR|EKG monitoring severe uncontrolled asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
62545177|NCT00380744|EXPERIMENTAL|Part A LY2189102 0.1 mg/kg/wk|"Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV)~Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV"
62545178|NCT00380744|EXPERIMENTAL|Part A LY2189102 0.3 mg/kg/wk|"Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV~Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV"
62545179|NCT00380744|EXPERIMENTAL|Part A LY2189102 1.0 mg/kg/wk|"Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV~Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV"
62545180|NCT00380744|EXPERIMENTAL|Part A LY2189102 2.5 mg/kg/wk|"Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV~Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV"
62545181|NCT00380744|PLACEBO_COMPARATOR|Placebo|IV, once weekly x 4 wks
62545182|NCT01007045||"Clinically likely"|Subjects deemed clinically likely to have DVT based on modified Well's criteria
62545183|NCT01007045||"Clinically unlikely"|Subjects deemed clinically unlikely to have DVT based on modified Well's criteria
62165456|NCT02023099|EXPERIMENTAL|Substudy 1, Arm A: DB 2-DAA|Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents \[2-DAA\]) once daily (QD) for 12 weeks in participants without cirrhosis
62165457|NCT02023099|PLACEBO_COMPARATOR|Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA|DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
62165458|NCT02023099|EXPERIMENTAL|Substudy 2, Arm C: OL 2-DAA|OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis
62165459|NCT04416256||France|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62545184|NCT05046743|EXPERIMENTAL|Colonic gas load|
62545185|NCT05046743|SHAM_COMPARATOR|Sham|
62545186|NCT02002559||NBI Magnify Endoscopy|Detection of esphageal neoplasia through recognition of brownish discolored area via NBI and characterize the lesion using IPCL upon magnifying endoscopy
62545187|NCT02002559||Lugol Chromoendoscopy|Detection of esophageal neoplasia through recognition of discolored area
62545188|NCT00952354||research group|60 children aged from 3 to 10 years, both genders, observed in a symbolic play situation with their language therapists
62545189|NCT02216097|EXPERIMENTAL|Treatment|
62545190|NCT02216097|PLACEBO_COMPARATOR|Placebo|
62545191|NCT01911286||Standard group|Apnea test according to the recommendation
62545192|NCT01911286||CPAP group|Apnea test with CPAP connection
62545193|NCT03629197|EXPERIMENTAL|Communication skills training|Intervention clinicians will receive 2 standardized patient visits. The first visit will consist of an 8 minute video on the development of 5 key communication skills, a 10-12 minute role-play session to practice using these skills, and 8-10 minutes of constructive feedback. The 2nd visit will include only the role-play and feedback components. Clinicians will also get a printed pocket card and pamphlet explaining the targeted communication skills in more detail.
62165460|NCT04416256||Spain|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165461|NCT04416256||Portugal|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165462|NCT04416256||Croatia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165463|NCT04416256||Germany|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165464|NCT04416256||Italy|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165465|NCT04416256||Netherlands|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165466|NCT04416256||Austria|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165467|NCT04416256||US|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62545194|NCT03629197|ACTIVE_COMPARATOR|Control|Control clinicians will receive a written summary of the 2016 CDC opioid prescribing guidelines, which include recommendations for best practices for use of opioids to treat chronic non-cancer pain. CDC guidelines will serve as an attention control.
62545195|NCT03484650|PLACEBO_COMPARATOR|Control|Patients will receive standard care plus infusion of placebo
62545196|NCT03484650|EXPERIMENTAL|Lidocaine|Patients will receive lidocaine infusions peri-operatively
62545197|NCT06551870|EXPERIMENTAL|Experimental group 1 (Xbox Kinect Sports)|The programs were then designed for a duration of 12 weeks (36 sessions), with a 10-minute warm-up consisting of low-intensity aerobic activities and joint mobility, a 40-minute main part and a 10-minute cool-down with static flexibility exercises. The main part of the training sessions included active exergames of volleyball, bowling, boxing, and table tennis, each lasting 8 minutes, with 2 minutes of rest between games. In these active exergames, playing the games will require standing in front of a sensor on a camera under the TV screen in a 3.5-meter-wide range of motion (Li et al., 2021; Marotta et al., 2022).
62545198|NCT06551870|EXPERIMENTAL|Experimental group 2 (Nintendo Switch Sports)|The programs were then designed for a duration of 12 weeks (36 sessions), with a 10-minute warm-up consisting of low-intensity aerobic activities and joint mobility, a 40-minute main part and a 10-minute cool-down with static flexibility exercises. In Nintendo Switch Sports in order to run the games of these active exergames you will have to have a controller in your hand that has no cable because it connects via Bluetooth to the console, as in Xbox Kinect Sports you have to play in front of the TV screen (Ramolete et al., 2020). In Nintendo Switch Sports, there will be active exergames of volleyball, bowling, fencing and tennis in the main part, each of 8 min duration, with 2 minutes of rest between games.
62545199|NCT06551870|NO_INTERVENTION|Control group|The control group, the individuals will participate in the assessments (initial and final) and only played board games twice a week for 60 minutes.
62545200|NCT00437359|OTHER|Fareston|Toremifene citrate: 40-mg tablets by mouth once daily.
62545201|NCT00437359|OTHER|Arimidex|Anastrozole: 1-mg tablets by mouth once daily.
62545202|NCT06390709||JAK/T-cell/IL-6|
62545203|NCT01221389|ACTIVE_COMPARATOR|Colloid Control|Patients will receive 2 units of 250 ml of hydroxyethylated starch solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
62545204|NCT01221389|ACTIVE_COMPARATOR|Plasma|Patients will receive 2 units of AB+ plasma once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
62545205|NCT00786409|OTHER|Gardasil|30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.
62545206|NCT04625244|NO_INTERVENTION|Group 1: In-person therapy|Standard of care, in-person therapy with a Certified Hand Therapist (CHT)
62545207|NCT04625244|EXPERIMENTAL|Group 2: Home therapy program|Participants will be sent video links to three therapy videos demonstrating postoperative recovery exercises, starting 4 weeks after surgery.
62545208|NCT00281957|EXPERIMENTAL|Arm I (sorafenib, temsirolimus)|Patients receive oral sorafenib twice daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
62545209|NCT00281957|EXPERIMENTAL|Arm II (sorafenib, tipifarnib)|Patients receive oral sorafenib as in arm I and oral tipifarnib twice daily on days 1-21
62165468|NCT04416256||Canada|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165469|NCT04416256||Mexico|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165470|NCT04416256||Brazil|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165471|NCT04416256||Uruguay|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165472|NCT04416256||Argentina|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165473|NCT04416256||Chile|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62545210|NCT02265926|EXPERIMENTAL|N95|Intervention: N95 mask material
62545211|NCT05998148|NO_INTERVENTION|standard in-person appointment visits|Randomly selected participants will receive standard in-person post-operative appointment visits at 6 week, 12 week, and 6 months after surgery.
62545212|NCT05998148|EXPERIMENTAL|virtual phone appointment visits|Randomly selected participants will receive virtual telemedicine post-operative appointment visits at 6 week, 12 week, and 6 months after surgery.
62545213|NCT01650584|EXPERIMENTAL|ISTA Tears|Sterile ophthalmic solution
62545214|NCT01650584|ACTIVE_COMPARATOR|Systane|Sterile ophthalmic solution
62165474|NCT04416256||Australia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165475|NCT04416256||Belgium|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165476|NCT04416256||Finland|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
62165477|NCT05153161|EXPERIMENTAL|Persons with ADRD living in a residential care facility|Each consented participant will receive the current Memesto device and will be provided formal and informal training instructions. After consent and screening, a two-week training period with a Memesto device will be followed by ten weeks of data collection. An experienced research assistant will administer the baseline NPI in order to collect the agitation ratings by the family caregiver, and the professional caregiver will be collected by a trained research assistant and captured in an electronic case report form designed using REDCap.14,15 Then, participants will undergo evaluation of the NPI agitation domain at 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 10 weeks. Adverse events related to the device will be collected from the family and professional caregivers. Human centered system designers will work with the operations team to enhance participant engagement and maintain high quality data collection.
62165478|NCT06539936|EXPERIMENTAL|Multiple Baseline|Participants act as their own controls. Participants are fit with a prosthesis system, which includes IBT's Core2 controller, IBT Electrodes, FlexCell batteries, and prosthetic componentry chosen by the patient and their clinical team. The provided controller can operate in two modes of operation: (1) in Direct Control (or DC); and (2) using the Glide control strategy. Participants progress through an AB multiple baseline protocol, where they use the provided prosthesis system for four evaluation periods (totaling 24-weeks in duration). During the A-phase, participants use the system with DC and during the B-phase, participants use the system with the Glide control strategy. For both interventions, the required hardware is the same, while the control software will differ.
62165479|NCT04945356|EXPERIMENTAL|upper limb virtual training|6-week virtual training of the affected upper limb using the Physiotec application
62165480|NCT00543634|ACTIVE_COMPARATOR|1|
62165481|NCT00543634|ACTIVE_COMPARATOR|2|
62165482|NCT06310278||Normal-hearing|
62165483|NCT05971186|ACTIVE_COMPARATOR|Ibuprofen|"Fifteen participants were randomly selected to form the third intervention group. Each subject in this arm received a single tablet of Ibuprofen, with a dosage of 400 mg. Similar to the other arms, they were given a 15-minute window to take the Ibuprofen tablet.~Prior to administering the Ibuprofen, the pain intensity of the participants was measured using the standardized Numeric Rating Scale (NRS). Additionally, the pain intensity was measured again two hours after the consumption of the Ibuprofen tablet, using the same Numeric Rating Scale (NRS)."
62165484|NCT05971186|ACTIVE_COMPARATOR|Young Coconut Water|"Fifteen participants were randomly selected to join the intervention group. Each subject in this arm received a single dose of 330 ml of young coconut water. To ensure uniformity, they were given a 15-minute window to consume the entire 330 ml of the young coconut water intervention.~Before administering the young coconut water, the pain intensity of the participants was measured using a standardized Numeric Rating Scale (NRS). Additionally, the pain intensity was reevaluated two hours after the consumption of the young coconut water, using the same Numeric Rating Scale (NRS)."
62165485|NCT05971186|ACTIVE_COMPARATOR|Dark Chocolate Bar|"Fifteen participants were also randomly chosen for the second intervention group. In this arm, each subject received a single 70% dark chocolate bar weighing 35 grams. Similar to Arm 1, they were given a 15-minute timeframe to consume the entire dark chocolate bar intervention.~Prior to giving the dark chocolate bar, the pain intensity of the participants was measured using the Numeric Rating Scale (NRS). Subsequently, the pain intensity was reassessed two hours after the consumption of the dark chocolate bar, using the same Numeric Rating Scale (NRS)."
62165486|NCT02067000||Obstructive Sleep Apnea|
62165487|NCT02788305||non obese|BMI\<30. Misoprostol is given for induction of labour according to Bishop score
62165488|NCT02788305||obese|BMI\>30. Misoprostol is given for induction of labour according to Bishop score
62165489|NCT04928235||All Participants|All participants will have thermal imaging of their lower extremities. The temperature values will be shared with the attending physician. The physician will be asked questions about their diagnostic confidence before and after seeing the temperature values.
62165490|NCT04026022|PLACEBO_COMPARATOR|Standard pain management|Besides the standard pain management a placebo TTS (normal wound plaster) will be administered in the Emergency Room (ER) or Post Anaesthesia Care Unit (PACU)
62545215|NCT05184881|ACTIVE_COMPARATOR|Group medial branch block|cervical medial branch block will done at the affected dermatomal level using 1 mL of a mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml).
62545216|NCT05184881|ACTIVE_COMPARATOR|Group retrolaminar block|cervical retrolaminar block was done using 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) for each affected dermatomal level.
62545217|NCT03640416|OTHER|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit® Charge HR smart watch
62545218|NCT06241469|EXPERIMENTAL|Experimental Arm|Sintilimab combined with nab-paclitaxel and tegio
62165491|NCT04026022|EXPERIMENTAL|Modified pain management|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial i.v. treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day
62165492|NCT01034683|EXPERIMENTAL|Esophageal Carcinoma|
62545219|NCT03500380|EXPERIMENTAL|RC48-ADC|Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
62545220|NCT03500380|ACTIVE_COMPARATOR|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.
62737439|NCT06349265|ACTIVE_COMPARATOR|Group 1|Mild Carpal Tunnel syndrome
62165493|NCT02750371|EXPERIMENTAL|Patients with brain tumors treated by radiotherapy|"Patients with:~- meningioma of the cavernous sinus for which radiotherapy is planned~Or~- a pituitary adenoma for which radiotherapy is planned"
62165494|NCT03473912||RA patients|before or after medication
62165495|NCT03473912||Systemic sclerosis patients|before or after medication
62165496|NCT03473912||IgG4 RD patients|before or after medication
62165497|NCT03473912||Lupus patients|before or after medication
62165498|NCT03899285|EXPERIMENTAL|Citalopram increase (group A)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of citalopram 20 mg for a length of 14 days. The total dose of citalopram will be 40 mg once daily.~Follow up will last 8 weeks in total."
62165499|NCT03899285|PLACEBO_COMPARATOR|Placebo (group B)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of placebo (a capsule without medication) for a length of 14 days. The total dose of citalopram will be 20 mg once daily.~Follow up will last 8 weeks in total."
62165500|NCT03899285|NO_INTERVENTION|Observational arm (group c)|"Eligible patients to this arm are responders to citalopram. A diminution of at least 30% of the symptoms from baseline with the MADRS is required to enter this arm. At the end of the first phase, these patients will pursue their citalopram 20 mg for the rest of the study (=6 weeks). It's possible that in this group, the treatment approach may vary depending the physician.~Follow up will last 8 weeks in total."
62165501|NCT04815707|OTHER|Surgery|Occult hernia found will be repaired at the same time as the initial inguinal hernia
62165502|NCT04815707|NO_INTERVENTION|Expectant Management|No surgery will be done if an occult hernia is found during the initial inguinal hernia surgery
62165503|NCT01634620||FeNO|Participants with chronic obstructive pulmonary disease (COPD) will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
62165504|NCT03569891|EXPERIMENTAL|AMT-061|"Single infusion of AMT-061~Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing."
62165505|NCT03569891|ACTIVE_COMPARATOR|FIX replacement (Lead-in Period)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
62165506|NCT05820542||Group M (n=42), Miller laryngoscope|The effect of direct epiglottis lifting method on the percentage of glottic patency in Miller and McGraht laryngoscopy.
62165507|NCT05820542||Group V (n= 43), McGrath MAC videolaryngoscope|The effect of direct epiglottis lifting method on the percentage of glottic patency in Miller and McGraht laryngoscopy.
62165508|NCT02115945|EXPERIMENTAL|epidural block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
62165509|NCT02115945|ACTIVE_COMPARATOR|femoral block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
62165510|NCT03556345|EXPERIMENTAL|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
62165511|NCT03195699|EXPERIMENTAL|Dose escalation study|Participants will receive up to 4 dose levels of TTI-101 to determine RP2D
62165512|NCT03195699|EXPERIMENTAL|Dose expansion study|Enrollment in the dose expansion may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101
62165513|NCT03195699|EXPERIMENTAL|Food effect study|Participants will be treated with TTI-101 at the RP2D under fed and fasted conditions to assess the bioavailability of TTI-101 and to determine the best conditions for taking the study drug
62165514|NCT03195699|EXPERIMENTAL|Dose expansion, cross-over study|Participants will be administered different formulations of TTI-101 to compare bioavailability.
62165515|NCT01090232|EXPERIMENTAL|chronic HEV infection|in kidney-transplant recipients with chronic HEV infection
62165516|NCT01090232|ACTIVE_COMPARATOR|control|the host responses in kidney-transplant recipients without viral infection (controls)
62719684|NCT05200312|EXPERIMENTAL|Treatment-naive DLBCL|Treatment-naive high-risk DLBCL patients will be enrolled. R/R2-CHOP were allowed in cycle 1 due to poor physical condition or liver and renal failure caused by lymphoma progression. Patients achieving Complete Remission (CR) or Partial Remission (PR) after 2 cycles will receive another 2 cycles. Patients achieving CR or PR after 4 cycles will finish 6 cycles. Patients achieving CR after 6 cycles with double-hit/triple-hit/double-expression/median to high risk aaIPI will undergo Autologous Stem Cell Transplantation (ASCT). Other patients will be administered rituximab for another 2 cycles and then turn to follow-up. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for another 3 years. Patients achieving Stable Disease (SD) or PD (Progression Disease) after 2 or 4 cycles will quit the study. After 6 cycles, patients achieving SD or PD will quit the study and patients achieving PR will receive second-line therapy.
62165517|NCT06092879||Asciminib|Adult patients with Ph+ CML-CP previously treated with two or more tyrosine kinase inhibitors
62165518|NCT06600815|EXPERIMENTAL|preemptive stepwise infiltration anaesthesia(PSIA) group|Drugs：A cocktail of anaesthetics (30 mg of ropivacaine, 0.3 mg of adrenaline) will be prepared, diluted with normal saline to 120 mL, and divided into two equal parts(Cocktail A\[CA\] and Cocktail B\[CB\]), with CB containing 8 mg of added betamethasone (each 1 ml of the compound contains 5 mg betamethasone dipropionate \[calculated as betamethasone\] and 2 mg of betamethasone sodium phosphate \[calculated as betamethasone\]).
62165519|NCT06600815|ACTIVE_COMPARATOR|postoperative local infiltration analgesia(PLIA) group|Drugs: the same preoperative preparation and treatment with the anaesthesia cocktail formulation as those in the PSIA group.
62165520|NCT03694249|EXPERIMENTAL|Group 1 (ifetroban)|ifetroban capsule (250mg) will be taken by mouth daily.
62165521|NCT03694249|PLACEBO_COMPARATOR|Group 2 (placebo)|Placebo capsule (250mg) will be taken by mouth daily.
62165522|NCT01243086|PLACEBO_COMPARATOR|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
62165523|NCT01243086|ACTIVE_COMPARATOR|Ranibizumab and OZURDEX|Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
62719685|NCT02005744|EXPERIMENTAL|Child Pugh A|CKD-501 will be administered to patients who are included Child Pugh A
62165524|NCT06510946|EXPERIMENTAL|Intervention group|Intervention group: health education, use of mobile phones, personalized dosage system.
62165525|NCT06510946|NO_INTERVENTION|Control group|Routine follow-up.
62545221|NCT06598241||Diabetic Foot Ulcer Treatment Group|Male or female between ≥ 18 years and ≤ 80 years of age that are scheduled to receive treatment of the commercially available borate-based bioactive glass fiber matrix will be enrolled in the study
62545222|NCT04493567|EXPERIMENTAL|Part A: 1 x BMS-986036 via auto-injector or pre-filled syringe|
62545223|NCT04493567|EXPERIMENTAL|Part B: 2 x BMS-986036 via auto-injector or pre-filled syringe|
62545224|NCT03299946|EXPERIMENTAL|Arm 1|
62545225|NCT03106389|ACTIVE_COMPARATOR|Misoprostol|This group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours.
62545226|NCT03106389|EXPERIMENTAL|Misoprostol/Transcervical catheter|This group will receive the same regimen, but will have in addition a transcervical balloon (Foleys') catheter that is inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix
62545227|NCT04113785||Klassic TKA|Subjects implanted with a Klassic TKA. Subjects will undergo flouoroscopic evaluation during a deep knee bend evaluation and the postoperative kinematics will be reported.
62545228|NCT02391987|ACTIVE_COMPARATOR|Tele-Monitoring|Tele-monitoring and health coaching in addition to standard health care
62545229|NCT02391987|NO_INTERVENTION|Standard Care|Standard care is defined as Heart Failure (HF) care based on current American College of Cardiology (ACC) and American Heart Association (AHA) HF guidelines implemented and orchestrated by a cardiologist and support staff at the participating institution.
62545230|NCT06632652|EXPERIMENTAL|Pre- and post-intervention design|After enrollment patients receive 'Health Education'. Then patients receive weekly follow up monitoring over phone call for 3 months. After 3 months, patients are requested to visit the Primary Health Care Center (PHC) for follow-up by physician and lab test. From 4-6 months, they receive bi-weekly follow up over phone call and at the end of 6 month, group evaluation for 1 hour and endline data will be collected by the nurses at the PHC.
62545231|NCT02198183||Near-infrared spectroscopy|Casmed Fore-Sight Elite and Non-invasive Cardiac Output Monitor (NICOM)
62719686|NCT02005744|EXPERIMENTAL|Child Pugh B|CKD-501 will be administered to patients who are included Child Pugh B
62719687|NCT02005744|EXPERIMENTAL|Subject who are matched Child Pugh A|CKD-501 will be administered to the Subjects who are matched Child Pugh A
61976578|NCT01555294||Familial Combined Hyperlipidemia|FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
61976579|NCT04906044|EXPERIMENTAL|Total Neoadjuvant Treatment combined with Sintilimab|
61976580|NCT01717807||lung cancer; advanced pancreatic cancer|
62165526|NCT02889809|EXPERIMENTAL|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams \[mg\] for subjects who are 5 years old and 5 mg for subjects who are \>= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol \[inhalation aerosol or nebuliser\]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
62545232|NCT05529446|EXPERIMENTAL|intervention|This group will consist of twenty women with mild to moderate osteoarthritis suffering from pain. These women will perform strengthening exercises in addition to combination therapy 10 minutes for each session, 3 times per week, for 3 weeks.
62545233|NCT05529446|SHAM_COMPARATOR|control|This group will consist of twenty women with mild to moderate osteoarthritis suffering from pain.These women will perform the same strengthening exercises as intervention group and receive sham combination therapy 10 minutes for each session, 3 times per week, for 2 weeks.
62545234|NCT02234492|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin 10mg once daily for 6 months.
62545235|NCT02234492|NO_INTERVENTION|No rosuvastatin|No rosuvastatin- this group will continue with their current medical therapy for 6 months.
62545236|NCT01820234|OTHER|In-person dermatology evaluation|Health care modality
62545237|NCT01820234|OTHER|Store-and-forward teledermatology evaluation|Health care modality
62545238|NCT02645331|EXPERIMENTAL|Remind-to-move|RTM involved a wristwatch device worn on more-affected arm which emitted sensory cueing continuously to remind the children to use the more-affected hand to engage in daily activities or complete bimanual tasks intensively, 5 hour per day, 5 days every week, for 3 consecutive weeks.
62719688|NCT02005744|EXPERIMENTAL|Subject who are matched Child Pugh B|CKD-501 will be administered to the subjects who are matched Child Pugh B
62719689|NCT00696878|EXPERIMENTAL|Corifollitropin alfa 150 µg|Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin (\[rec\]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after \[rec\]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.
62719690|NCT04402710|ACTIVE_COMPARATOR|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Action-Coping Planning and Monitoring Physical Activity Session 4: Goal re-visitation and adjustment and building self-efficacy. Session 5: Physical Activity Enjoyment and Barriers/Solutions. Session 6: Relapse prevention and commitment to exercise. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, antibiotic use, oral health, osteoporosis and vitamin D).
62719691|NCT04402710|EXPERIMENTAL|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Learn about fear of self-compassion and the benefits of self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Dealing with difficult emotions, loving Kindness and Self-Compassionate motivation. Session 6: Living deeply, self-appreciation and stages of progress.
62719692|NCT05691387|EXPERIMENTAL|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
62719693|NCT05691387|ACTIVE_COMPARATOR|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
62719694|NCT03030456|NO_INTERVENTION|Control Group|Elderly women receiving a list of general health orientations through an 8 week period
62719695|NCT03030456|EXPERIMENTAL|Power Plate®|Power Plate®: training of elderly women
62719696|NCT06710535|EXPERIMENTAL|Manual manipulation|Experimental group, subject to manipulation performed by the same Physiotherapist, using the techniques described by Shadmehr, A. et al (2018).
62719697|NCT06710535|SHAM_COMPARATOR|Sham Manipulation|Sham group, subjected only to a simulation of manipulation, using the same gestures, but without manipulating, used as a placebo group.
62719698|NCT06710535|NO_INTERVENTION|Control Group|Control group, which will not be subject to any intervention.
62719699|NCT02863237||weaning failure group|Patients reconnected to the ventilator within 48 hours after SBT will be designated the weaning failure group
62719700|NCT02863237||weaning success group|Patients who pass the SBT and breathing without ventilator support within 48 hours are designated the weaning success group
62719701|NCT02434211|EXPERIMENTAL|Questionnaire and Focus group|The children complete the questionnaire to better know their knowledge and cancer individual conceptions. Then, they will be interviewed during one hour in groups for the pre-testing phase. And after, for the testing phase, they just complete the questionnaire.
62719702|NCT03662282|EXPERIMENTAL|Drug - Omegaven®|Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.
62719703|NCT04266522|ACTIVE_COMPARATOR|Arm I (printed materials)|Patients receive printed materials describing the technical aspects of their treatment.
62719704|NCT04266522|EXPERIMENTAL|Arm II (printed materials, physicist interaction)|Patients receive printed materials as in Arm I. Patients also receive a minimum of 2 direct physicist interactions to describe the technical aspects of their treatment either immediately prior to or immediately after treatment simulation.
62719705|NCT01674790|EXPERIMENTAL|AEROBIC group|6-week program of one 20-min session of aerobic training and one 20-min session of ROM exercise 5 days/week.
62719706|NCT01674790|EXPERIMENTAL|COGNITIVE group|6-week program of one 20-min session of cognitive training and one 20-min session of ROM exercise 5 days/week.
62719707|NCT01674790|EXPERIMENTAL|AEROBIC + COGNITIVE group|6-week program of one 20-min session of aerobic training and one 20-min session of cognitive training 5 days/week.
62719708|NCT01674790|EXPERIMENTAL|CONTROL group|6-week program of one 20-min session of ROM exercise and one 20-min session of unstructured mental activity 5 days/week.
62719709|NCT00660803||1|Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
62165527|NCT02889809|PLACEBO_COMPARATOR|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams \[mg\] for subjects who are 5 years old and 5 mg for subjects who are \>=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol \[inhalation aerosol or nebuliser\]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
62165528|NCT01112163|EXPERIMENTAL|Enhanced external counter pulsation|One session of enhanced external counter pulsation (60 minutes)
62165529|NCT04320602|EXPERIMENTAL|Ravulizumab|Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).
62165530|NCT05849220|EXPERIMENTAL|Dapagliflozin+Standard of Care|Dapagliflozin
62165531|NCT05849220|ACTIVE_COMPARATOR|Standard of Care|Standard of Care
62165532|NCT04971889|ACTIVE_COMPARATOR|Diabetes MNT plus MI|--Group-based dietary/dietary motivation intervention
62165533|NCT04971889|ACTIVE_COMPARATOR|Diabetes MNT|-Group-based dietary intervention
62545239|NCT02645331|ACTIVE_COMPARATOR|Modified constraint induced movement therapy (mCIMT)|children were encouraged to wear a customer-made volar resting splint that extended from below the elbow to the fingertips on their noninvolved hands for 5 hour daily except for toileting, writing and specific physical sports, for 3 weeks. Each child was supervised by one therapist to complete structured unimanual practice with the affected hand during the supervised session, 5 days every week, for 3 consecutive weeks.
62545240|NCT02645331|PLACEBO_COMPARATOR|Conventional rehabilitation|Conventional splinting, muscle strengthening, stretching, and neurodevelopmental facilitation techniques for 1hr daily, 2 day per week for 3 weeks.
62545241|NCT06125977||Cohort 1|Intermediate AMD group, Original Cohort
62545242|NCT06125977||Cohort 2|Atrophic AMD and/or previous treatment group, Extended Cohort
62165534|NCT03703999||type 1 diabetic patients freestyle Libre|group of type 1 diabetic patients that will be selected to use Freestyle libre on the basis of clinicians decisions and reimbursement criteria
62165535|NCT03130699|EXPERIMENTAL|Dulce Digital|The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
62165536|NCT03130699|EXPERIMENTAL|Dulce Digital-Me (Automated Delivery)|The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
62545243|NCT04498117|EXPERIMENTAL|Cohort 1- Surgery Active|Six (6) 21-day cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
62545244|NCT04498117|PLACEBO_COMPARATOR|Cohort 1 - Primary Surgery Control|Six (6) 21-day cycles of chemotherapy with placebo comparator given with chemotherapy at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
62545245|NCT04498117|EXPERIMENTAL|Cohort 2 - NACT + Interval Surgery Active|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
62545246|NCT04498117|PLACEBO_COMPARATOR|Cohort 2 - NACT + Interval Surgery Control|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with placebo comparator given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
62545247|NCT01741168|ACTIVE_COMPARATOR|TLSO|TLSO brace 8-10 weeks
62545248|NCT01741168|EXPERIMENTAL|No Orthosis|No Orthosis
62545249|NCT04557033|EXPERIMENTAL|Mindful Meditation|"* The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.~* The My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media~* Participants will be asked to complete brief surveys before and after the intervention activity."
62545250|NCT06488339|EXPERIMENTAL|Protein and oil supplement|Take 1 sachet/day replaced dinner
62545251|NCT06488339|NO_INTERVENTION|Normal dietary meal|Take normal dietary meal for dinner
62545252|NCT05015283|EXPERIMENTAL|Laparoscopic One-anastomosis gastric bypass|In this group, the bariatric procedure is laparoscopic one-anastomosis gastric bypass, all operations follow the same standard operating procedure.
62545253|NCT05015283|ACTIVE_COMPARATOR|Laparoscopic Roux-en-Y gastric bypass|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass, all operations follow the same standard operating procedure.
62545254|NCT03656588|ACTIVE_COMPARATOR|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by|
62545255|NCT03656588|ACTIVE_COMPARATOR|b. Iodine scrub and ChloraPrep alone|
62719710|NCT01160809|EXPERIMENTAL|Mosquito repellent and LLINs group vs. LLINs group only|This study is based on two population groups: 1) a group of households that use LLINs alone (control) and 2) a group of households that use both mosquito repellent and LLINs (repellent group).
62719711|NCT00664950|ACTIVE_COMPARATOR|SHS|sliding hip screw
62545256|NCT05823012|EXPERIMENTAL|XP-8121|XP-8121 100 to 1500 μg subcutaneous injection
62719712|NCT00664950|ACTIVE_COMPARATOR|InterTAn IM Nail|interTAN IM nail
62719713|NCT04926116|EXPERIMENTAL|AK3280 Cohort 1|Eligible subjects will be administered a single oral dose of 200 mg AK3280 under fasted conditions on Day 1. A multiple dosing period follows with daily 200 mg AK3280 b.i.d. administered with a concurrent low-fat meal intake from Day 4 to Day 16 and a 200 mg AK3280 q.d. dosing on Day 17.
62736213|NCT03831178|PLACEBO_COMPARATOR|Placebo|Participants will take 11 capsules per day containing corn/soy oil blend capsules divided into three times daily with meals or as tolerated.
62736214|NCT01091038|PLACEBO_COMPARATOR|Routine Care|Usual care of patients in the ambulatory setting
62165537|NCT03130699|EXPERIMENTAL|Dulce Digital-Me (Medical Assistant)|The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
62165538|NCT05281419|EXPERIMENTAL|Intralesional triamcinolone injection with whole breast detection radical surgery|
62165539|NCT05281419|ACTIVE_COMPARATOR|Whole breast detection radical surgery|
62165540|NCT02064309|EXPERIMENTAL|Human islets in Beta-Air device|
62545257|NCT03928067|EXPERIMENTAL|TREK Study Abroad Program|On-screen personalized normative feedback (PNF) will contain information on the drinking behavior and attitudes about gender- and country-specific study abroad peers. Participants will view text-based tips and strategies and watch clips of prior student abroad students discussing how they met their cultural engagement goals while abroad (Sojourner Adjustment Feedback or SAF). Content focuses around the four aspects of positive sojourner adjustment (social interaction with host nationals, cultural understanding and participation, language development and use, host culture identification) and the two negative sojourner adjustment factors while abroad (i.e., social interaction with co-nationals, homesickness/feeling out of place). The intervention will also contain text- and video-based tips and strategies for protective strategies used abroad to limit experience of risk sex and sexual violence victimization.
62165541|NCT03296176|EXPERIMENTAL|presymptomatic|
62165542|NCT03296176|EXPERIMENTAL|symptomatic|
62165543|NCT03296176|OTHER|controls|
62165544|NCT06379321||Primary|Triathlon Hinge Femoral Component + Revision Baseplate
62165545|NCT06379321||Revision|Triathlon Hinge Femoral Component+ Revision Baseplate
62165546|NCT06379321||TS Revision|Triathlon TS Femoral Component+ Revision Baseplate
62165547|NCT06379321||Revision (Maximum of 80 subjects)|Triathlon TS Femoral Component + Revision Baseplate
62165548|NCT06379321||MRH Revision|MRH Femoral Component + Revision Baseplate
62165549|NCT06379321||GMRS Primary or Revision|GMRS Femoral Component + Revision Baseplate
62165550|NCT03563131|ACTIVE_COMPARATOR|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
62165551|NCT03563131|ACTIVE_COMPARATOR|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
62545258|NCT03928067|NO_INTERVENTION|Control|"Control participants will receive a link to a general website offering study abroad advice (www.studyabroad.com) and will be asked to spend at least 20 to 30 minutes reviewing their institution's study abroad website content, including policies for drinking abroad. This control condition was selected as a form of treatment as usual as our conversations with study abroad personnel indicate this is the extent of typical information students receive about alcohol use abroad."
62545259|NCT01739660|EXPERIMENTAL|Pegloticase|Pegloticase 8 mg single intraveneous dose
62736215|NCT01091038|EXPERIMENTAL|Basic Clinical Decision Support|Providers use basic clinical decision support
62165552|NCT02551926|EXPERIMENTAL|mobile text messaging|Patients will receive some SMS in a regular interval.
62165553|NCT02551926|EXPERIMENTAL|virtual communities|Patients will receive some messages by a virtual community in a regular interval.
62165554|NCT02551926|EXPERIMENTAL|brochures|Patients will receive some messages by as a printed media
62165555|NCT02551926|ACTIVE_COMPARATOR|Control|control group will be included without any intervention
62165556|NCT06313606|EXPERIMENTAL|Dietary fat with negative control supplement|Dietary fat-containing meal plan with a specific supplement that should not modify fat metabolism
62165557|NCT06313606|EXPERIMENTAL|Dietary fat with positive control supplement|Dietary fat-containing meal plan with a specific supplement that may modify fat metabolism
62165558|NCT04619420|EXPERIMENTAL|JNJ-63733657 Low-dose|Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.
62165559|NCT04619420|EXPERIMENTAL|JNJ-63733657 High-dose|Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.
62165560|NCT04619420|PLACEBO_COMPARATOR|Placebo|Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period.
62165561|NCT03404440|ACTIVE_COMPARATOR|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
62165562|NCT03404440|PLACEBO_COMPARATOR|Placebo|Placebo one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
62165563|NCT02359552|PLACEBO_COMPARATOR|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
62736216|NCT01958528||Cohort 1 Progressors|
62736217|NCT01958528||Cohort 2 - Non-Progressors|
62736218|NCT02508584|EXPERIMENTAL|Intervention|This is a single patient treatment IND
62165564|NCT02359552|ACTIVE_COMPARATOR|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
62165565|NCT01532024|EXPERIMENTAL|Healthy Volunteers|Delivery of intrapulmonary NAP Dose escalation from 5 mcgs to 80mcgs
62165566|NCT01532024|EXPERIMENTAL|Pulmonary Infiltrate in ICU|Delivery of NAP (80mcgs) to ventilated patients with pulmonary infiltrates
62165567|NCT01532024|EXPERIMENTAL|Patients with Bronchiectasis|Delivery of NAP (80mcgs) to patients with bronchiectasis
62545260|NCT03129555|ACTIVE_COMPARATOR|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62545261|NCT03129555|ACTIVE_COMPARATOR|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62545262|NCT03129555|ACTIVE_COMPARATOR|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62545263|NCT03129555|ACTIVE_COMPARATOR|Apixaban|After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
62545264|NCT01085357|EXPERIMENTAL|CyPass Micro-Stent + Cataract Surgery|Subjects receive the CyPass Micro-Stent at the conclusion of their cataract surgery
62545265|NCT01085357|ACTIVE_COMPARATOR|Cataract Surgery Only|Subjects do not receive the CyPass Micro-Stent at the conclusion of their cataract surgery
62545266|NCT03874273|EXPERIMENTAL|crizotinib +|Patients with unresectable, relapsed or refractory inflammatory myofibroblastic tumor, receiving crizotinib
62545267|NCT05186792||myco well participants|Retrospective analysis of patient records. No new patients recruited.
62545268|NCT03936595|EXPERIMENTAL|Core exercises protocol|Participants will perform 4 core exercises
62165568|NCT00006747|EXPERIMENTAL|chemotherapy + stem cell transplantation|"Patients receive carmustine, etoposide, cytarabine and melphalan on day -1. Patients undergo allogeneic peripheral blood stem cell (PBSC) transplantation on day 0. Patients also receive tacrolimus on day -2 and then orally twice daily until day 120 and methotrexate on days 1, 3, and 6 as graft-versus-host disease (GVHD) prophylaxis. Patients receive sargramostim daily beginning on day 7 and continuing until blood counts recover.~Patients with no active GVHD who have persistent disease on day 150 or progressive disease at any time after PBSC transplantation receive donor lymphocytes IV over 2 hours. Patients may receive additional donor lymphocytes at least 8 weeks later if disease persists.~Patients are followed at 6 and 12 months post-transplantation and then annually for 4 years."
62165569|NCT03330197|EXPERIMENTAL|Arm 1 - Closed|Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
62165570|NCT03330197|EXPERIMENTAL|Arm 2 - Open|Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
62165571|NCT00495612|EXPERIMENTAL|Omalizumab|Patients received omalizumab via subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. The dose administered and the dosing interval were determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
62545269|NCT03936595|EXPERIMENTAL|Structural exercises protocol|Participants will perform 4 structural (Olympic lifting) exercises
62165572|NCT00495612|PLACEBO_COMPARATOR|Placebo|Patients received placebo as a subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. Patients received injections at the same time intervals as the omalizumab group.
62165573|NCT04233411|ACTIVE_COMPARATOR|Milk|Acute ingestion of 20 g milk protein
62165574|NCT04233411|EXPERIMENTAL|20g|Acute ingestion of 20 g mycoprotein
62165575|NCT04233411|EXPERIMENTAL|40g|Acute ingestion of 40 g mycoprotein
62165576|NCT04233411|EXPERIMENTAL|60g|Acute ingestion of 60 g mycoprotein
62165577|NCT04233411|EXPERIMENTAL|80g|Acute ingestion of 60 g mycoprotein
62165578|NCT02382913|EXPERIMENTAL|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
62165579|NCT02382913|EXPERIMENTAL|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
62165580|NCT02382913|EXPERIMENTAL|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
62165581|NCT02382913|EXPERIMENTAL|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
62165582|NCT02382913|EXPERIMENTAL|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62165583|NCT02382913|EXPERIMENTAL|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62545270|NCT03936595|EXPERIMENTAL|Accentuated eccentric load exercises protocol|Participants will perform 4 exercises with eccentric loading
62545271|NCT03936595|OTHER|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
62545272|NCT06223776|NO_INTERVENTION|Normal sleep|The night before the experimental session, where participants will follow their habitual sleep-wake routines.
62545273|NCT06223776|EXPERIMENTAL|Sleep restriction|The night before the experimental session (with sleep restrictions (SR)), where participants will experience acute sleep restriction the night before the test session (i.e., 3 h of early sleep restriction versus normal sleep).
62737440|NCT06349265|ACTIVE_COMPARATOR|Group 2|Moderate Carpal Tunnel Syndrome
62545274|NCT01313585||IPDA salbutamol MDI|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
62545275|NCT01313585||IPDA salbutamol EB|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
62545276|NCT01313585||IPDI salbutamol EB|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
62545277|NCT01313585||IPDI salbutamol MDI|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
62545278|NCT04338269|EXPERIMENTAL|Atezo+Cabo|Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.
62545279|NCT04338269|ACTIVE_COMPARATOR|Cabozantinib|Participants will receive cabozantinib every day.
62545280|NCT05972330|EXPERIMENTAL|VRx MyBiotics Oral Lozenges|Participants will receive a 30 day supply of their personalized oral biotic lozenges.
62545281|NCT03316274|EXPERIMENTAL|Nivolumab (Cohort A-Safety)|Participants will receive a 10mg (or 1 mL) injection into a single KS lesion in the skin, every 2 weeks for 4 doses.
62545282|NCT03316274|EXPERIMENTAL|Nivolumab (Cohort B-Expansion)|Participants from Cohort A with at least 1 lesion that is left untreated and additional participants receive injections in into up to 2 KS lesions in the skin, every 2 weeks for 4 doses. The injected volume will not exceed 10 mg (or 1 mL) each time. Lesions will be evaluated at week 26, and participants with lesion improvement may enroll in Cohort B-PLUS to receive additional injections.
62545283|NCT03316274|EXPERIMENTAL|Nivolumab (Cohort B-PLUS)|Participants in Cohort B whose injected lesions achieved partial response or complete response by week 26 and who did not experience any serious adverse events, are permitted to receive additional injections up to 4 residual KS lesions (total volume 10 mg in 1 mL) every 2 weeks for up to 4 additional doses. Lesions will be assessed again after 26 weeks.
62545284|NCT05102552|ACTIVE_COMPARATOR|Cohort 1|BIS-001: Treatment A and SPN-817: Treatment B
62545285|NCT05102552|ACTIVE_COMPARATOR|Cohort 2|BIS-001: Treatment A and SPN-817: Treatment C
62545286|NCT01653912|EXPERIMENTAL|GSK2110183, carboplatin and paclitaxel|Subjects will be treated with a maximum of six doses of carboplatin + paclitaxel in combination with continuous daily GSK2110183 followed by single agent GSK2110183 at the single-agent MTD of 125 mg or above oral daily.
62545287|NCT05547841||Trial group|A total of 680 singleton pregnant women in the first trimester (gestational age of 6-13 weeks + 6 days), who had normal results in various examinations and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 34 centers, with 20 cases in each center.
62545288|NCT00616070|EXPERIMENTAL|1|Difluprednate
62545289|NCT00616070|PLACEBO_COMPARATOR|2|Vehicle
62545290|NCT06484686|EXPERIMENTAL|Experimental Group|Subjects will be collected venous blood at 6 and 10 years after booster immunization.
62545291|NCT00230178|EXPERIMENTAL|Arm A|Rasburicase alone given as a single agent for 5 days
62545292|NCT00230178|EXPERIMENTAL|Arm B|Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
62719714|NCT04926116|EXPERIMENTAL|AK3280 Cohort 2|The dose level of AK3280 for Cohort 2 will be determined by the SRC (Safety Review Committee) based on the safety and PK data gleaned in Cohort 1. Subjects will receive AK3280 following the same dosing schedule as that in Cohort 1, i. e., a single oral dose of AK3280 under fasted conditions on Day 1, multiple AK3280 b.i.d. administration with a concurrent low-fat meal intake from Day 4 to Day 16, and an AK3280 q.d. dose on Day 17.
62545293|NCT00230178|ACTIVE_COMPARATOR|Arm C|Oral allopurinol alone given as a single agent for 5 days
62545294|NCT00920790|EXPERIMENTAL|KW-0761|
62545295|NCT05489250||HCC (Hepatocellular cancer)|Hepatocellular cancer patients with NGS based molecular tumor profiling
62545296|NCT05489250||CCA/GBCA (Intra-, extrahepatic cholangiocellular carcinoma or gallbladder cancer)|Intra-, extrahepatic cholangiocellular carcinoma or gallbladder cancer patients with NGS based molecular tumor profiling
62545297|NCT05489250||PanCa (Pancreatic cancer)|Pancreatic cancer patients with NGS based molecular tumor profiling
62545298|NCT05489250||EC/GC (Oesophagogastric cancer)|Oesophagogastric cancer patients with NGS based molecular tumor profiling
62545299|NCT05538078|EXPERIMENTAL|intervention|Ozone gel
62545300|NCT05538078|ACTIVE_COMPARATOR|active comparator|nonsurgical periodontal treatment(scaling)
62545301|NCT02439970|ACTIVE_COMPARATOR|Treatment 1|100 mg brincidofovir (BCV; 1 tablet) administered orally twice weekly, plus valganciclovir (vGCV) placebo (2 tablets) administered orally once daily.
62545302|NCT02439970|ACTIVE_COMPARATOR|Treatment 2|900 mg valganciclovir (vGCV; two 450 mg tablets) administered orally once daily, plus brincidofovir (BCV) placebo (1 tablet) administered orally twice weekly.
62545303|NCT05446584|ACTIVE_COMPARATOR|Active left frontal HD-tDCS|Electrodes will be placed in a 4x1 ring configuration over the frontal region in accordance with the International 10-10 EEG system. Stimulation will consist of a ramp up period in which the electrical current is gradually increased, 30 minutes of stimulation at 2 mA, and a ramp down period during which the electrical current is gradually removed. Stimulation will be applied back-to-back over three consecutive days.
62545304|NCT05446584|ACTIVE_COMPARATOR|Active left temporal HD-tDCS|Electrodes will be placed in a 4x1 ring configuration over the left temporal region in accordance with the International 10-10 EEG system. Stimulation will consist of a ramp up period in which the electrical current is gradually increased, 30 minutes of stimulation at 2 mA, and a ramp down period during which the electrical current is gradually removed. Stimulation will be applied back-to-back over three consecutive days.
62545305|NCT05446584|SHAM_COMPARATOR|Sham HD=tDCS|Electrodes will be placed in the same 4x1 ring configuration over the frontal region as the active left frontal condition to ensure a useful control condition. Stimulation will consist of a 30-second ramp up period until reaching 2 mA, followed immediately by a 30-second ramp down, and off for 29 minutes. The same ramp up and down process will be repeated in the final minute of the session to help preserve masking of conditions. Sham stimulation will be applied back-to-back over three consecutive days.
62545306|NCT02896790||Stage 1|Patients without therapeutic education
62719715|NCT04926116|EXPERIMENTAL|AK3280 Optional Cohort|This is an optional dose cohort that the SRC will determine depending on the results of Cohorts 1 and 2, including the proposed dose level. Potential subjects in this cohort will also follow the same dosing scheme as those for Cohorts 1 and 2.
62545307|NCT02896790||Stage 2|Patients with therapeutic education
62545308|NCT03852537|ACTIVE_COMPARATOR|Usual Care|Usual care as determined by the patient's primary team.
62545309|NCT03852537|EXPERIMENTAL|Biomarker-adjusted Steroid Dosing|Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP \< 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level \> 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).
62545310|NCT00073697|EXPERIMENTAL|1|Interpersonal Psychotherapy
62545311|NCT00073697|EXPERIMENTAL|2|Escitalopram
62545312|NCT00073697|EXPERIMENTAL|3|Escitalopram plus IPT
62545313|NCT03907878|EXPERIMENTAL|Ligelizumab 120 mg per 1 mL qw4|Subjects received one subcutaneous injection every 4 weeks at 13 visits during the treatment period
62545314|NCT03209557|NO_INTERVENTION|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
62545315|NCT03209557|EXPERIMENTAL|SmokeBeat Intervention|"25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.~A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.~A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking."
62545316|NCT04537832||SCN1A-positive Dravet Syndrome|Participants aged between 6 and 60 months of age who have SCN1A-positive Dravet Syndrome. Clinical, neurocognitive, laboratory, the burden of disease, and health care resource utilization will be assessed.
62545317|NCT05668546|EXPERIMENTAL|surgical knee group|This study analyzed 58 knees of 29 unilateral TKA candidates, divided into the surgical and non-surgical knee groups
62545318|NCT05668546|EXPERIMENTAL|non surgical knee group|This study analyzed 58 knees of 29 unilateral TKA candidates, divided into the surgical and non-surgical knee groups
62545319|NCT02886624|EXPERIMENTAL|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
62545320|NCT05566184|EXPERIMENTAL|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure and the data will be collected.
62545321|NCT05566184|NO_INTERVENTION|Without modified pacifier|Data will be collected without giving the child in the control group a modified pacifier during the procedure.
62545322|NCT06235684||Single Arm study|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion
62545323|NCT04308057||Aquatic Exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., \<140/90 mm Hg). Specifically for this group, we include participants engaging in swimming or other aquatic, primarily aerobic-based, training regimes for more than 2 times a week, for more than 6 months, at the time of the assessments.
62545324|NCT04308057||Land-based exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., \<140/90 mm Hg). Specifically for this group, we include participants engaging in land-based, primarily aerobic training regimes (e.g. aerobic exercise) for more than 2 times a week, for a period longer than 6 months, at the time of the assessments.
62545325|NCT04308057||Mixed exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., \<140/90 mm Hg). Specifically for this group, we include participants engaging in both land-based and aquatic, primarily aerobic, exercise regimes on an equal basis, for more than 6 months.
62545326|NCT04308057||Sedentary.|General inclusion criteria included being over 55 years of age and normotensive (e.g., \<140/90 mm Hg). Specifically for this group, we include participants who are sedentary (e.g., defined as undertaking less than 60 min of structured/planned physical activity per week), for a period longer than 6 months.
62545327|NCT05812066|EXPERIMENTAL|all ceramic single-retainer resin bonded fixed partial denture using the upper canine abutment|
62545328|NCT05812066|ACTIVE_COMPARATOR|all ceramic single-retainer resin bonded fixed partial denture using the upper central incisor|
62545329|NCT01976884||Severe sepsis|Patients with severe sepsis
62545330|NCT01976884||Infectious kidney stone|Patients with sepsis after PCNL for infectious kidney stone
62545331|NCT01976884||Tumor|Patients with pancreatic cancer
62545332|NCT01976884||Volunteer|
62719716|NCT04926116|PLACEBO_COMPARATOR|Control Arm|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
62545333|NCT05771844|EXPERIMENTAL|Deep Sleep Enhancement with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
62545334|NCT04080544|EXPERIMENTAL|Follow up DLBS participants|Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
62545335|NCT03762694|EXPERIMENTAL|Electroacupuncture (EA) and Auricular Acupuncture (AA)|12 sessions acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization.
62545336|NCT03762694|NO_INTERVENTION|Wait-list control|No treatment except routine care will be given at the first 6 weeks, followed by 12 sessions treatment as Acupuncture group.
62545337|NCT01396915||High or Normal Dietary Protein Intake|
62545338|NCT03261011|EXPERIMENTAL|AK-104|Single-arm
62545339|NCT06501326|ACTIVE_COMPARATOR|lifestyle intervention + orlistat group|The control group was treated with lifestyle intervention + orlistat until the end of follow-up.
62719717|NCT02169648|EXPERIMENTAL|ranibizumab|Experimental: Intravitreal injection of Ranibizumab
62545340|NCT06501326|EXPERIMENTAL|lifestyle intervention + liraglutide group|Trial group 1 was treated with lifestyle intervention + liraglutide.
62545341|NCT06501326|EXPERIMENTAL|lifestyle intervention + liraglutide + orlistat group|Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
62545342|NCT03928210|EXPERIMENTAL|Digoxin|Digoxin 0.125 mg or 0.25 mg administered once daily for 7 days or until symptoms of toxicity Generic e.g. DIGOXIN Juvisé or Lenoxin Mite
62545343|NCT06505798|NO_INTERVENTION|The optimal medical therapy as per standard of care|Participants randomised to the optimal medical therapy arm will receive optimal medical therapy according to the most contemporary ESC HF guidelines.
62545344|NCT06505798|OTHER|The catheter ablation|Catheter ablation is an established therapeutic strategy in patients without HF that aims to convert AF to sinus rhythm in symptomatic, drug-refractory AF in patients.
62545345|NCT06361719|EXPERIMENTAL|Experimental Group (EG)|Starter infant formula supplemented with two HMOs. Following the intervention period, the infants will consume a standard infant follow-up formula (non-trial formula).
62545346|NCT06361719|ACTIVE_COMPARATOR|Control Group (CG)|Starter infant formula not supplemented with two HMOs. Following the intervention period, the infants will consume a standard infant follow-up formula (non-trial formula).
62545347|NCT06361719|NO_INTERVENTION|Breastfed Group (BG)|Breast Milk
62545348|NCT04497012|ACTIVE_COMPARATOR|Low Iron Sulfate Supplementation|Participants will be given 2 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
62545349|NCT04497012|ACTIVE_COMPARATOR|High Iron Sulfate Supplementation|Participants will be given 6 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
62545350|NCT02963233||Non-operative Group|Patients treated within the non-operative group will be treated with gentle reduction by the orthopaedic surgery team in the emergency department under procedural sedation. Immobilization and maintenance of reduction will be obtained through either taping of the elbow in a flexed (100-110 degree) and pronated position or through long-arm casting at 90 degrees of flexion. Immobilization type and position will be noted.
62545351|NCT02963233||Operative Group|Patients treated operatively will be largely treated with closed reduction and percutaneous pinning with 2-3 laterally-based k-wires, followed by long-arm immobilization. Immobilization type and position will be noted.
62719718|NCT06151626|EXPERIMENTAL|virtual-reality based rhythmic skill training|Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
62719719|NCT06151626|ACTIVE_COMPARATOR|rhythmic skill training with visual feedback|The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
62165584|NCT02382913|EXPERIMENTAL|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62165585|NCT02382913|EXPERIMENTAL|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
62165586|NCT02382913|EXPERIMENTAL|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
62165587|NCT02382913|ACTIVE_COMPARATOR|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
62165588|NCT03965481|EXPERIMENTAL|Diagnostic (CECT, PET-MRI)|Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30 days before laparoscopy or cytoreduction. Patients who do not undergo cytoreduction based on diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after completion of chemotherapy and before cytoreduction.
62165589|NCT00839306|EXPERIMENTAL|1|
62165590|NCT00839306|ACTIVE_COMPARATOR|2|
62165591|NCT05906056|EXPERIMENTAL|Continuous passive motion (CPM)|"10 ICU patients receiving CPM at HO joints that continuously stretches slowly the joint passively at a constant velocity in a painless range and for a substantial amount of time until there is evidence both laboratory (bone alkaline phosphatase) and radiographically (CT), that osteogenesis has entered a quiescent state. Conventional PT will also be performed.~Plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made."
62719720|NCT06151626|ACTIVE_COMPARATOR|strengthening group|The patients receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
62719721|NCT05317598|EXPERIMENTAL|Intervention group|Students in the intervention group will be given a 5-week positive psychotherapy-based kindness and honesty psychoeducation.
62737441|NCT06349265|ACTIVE_COMPARATOR|Group 3|Severe Carpal Tunnel Syndrome
62165592|NCT05906056|ACTIVE_COMPARATOR|Physiotherapy (PT)|10 ICU patients receiving the conventional PT, plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.
62165593|NCT06633133|EXPERIMENTAL|Virtual ileostomy|A pre-stage ileostomy, anchored under the abdominal wall by a vascular sling or rubber tape through the mesenteric window, is delivered to the outside of the abdomen, where the VI is pulled through the abdominal wall.
62545352|NCT01707264|EXPERIMENTAL|NEOD001|NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
62165594|NCT06633133|NO_INTERVENTION|Diverting ileostomy|Diverting ileostomy (DI) is a common fecal diversion procedure performed in patients undergoing total mesorectal excision (TME) procedure for rectal cancer to protect the anastomosis and reduce the risk of complications.
62165595|NCT05658445||cases|Female with recurrent unexplained abortion
62165596|NCT05658445||control|female with normal labour
62165597|NCT04632264|EXPERIMENTAL|Pre-placental group|"Oxytocin will be initiated immediately after delivery of the neonatal anterior shoulder (within 15 seconds). This is our intervention group. Saline placebo will be initiated post placenta delivery (within 15 seconds)."
62165598|NCT04632264|OTHER|Post-placental group|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds). Oxytocin will be initiated immediately after placenta delivery (within 15 seconds).
62165599|NCT06471842||Children with Inherited Metabolism Disease (IMD) with dietary treatment|Children with Inherited Metabolism Disease (IMD) with dietary treatment planning to come for a hospital visit (in or out patient) as part of their standard care.
62165600|NCT00687128|EXPERIMENTAL|1|Low-intensity aerobic exercise
62165601|NCT00687128|EXPERIMENTAL|2|Moderate-intensity aerobic exercise
62165602|NCT00687128|ACTIVE_COMPARATOR|3|Non-aerobic stretching exercise
62165603|NCT06230692|EXPERIMENTAL|Inspiratory Muscle Training (IMT)|Participants will be asked to perform inspiratory muscle training (breathing exercise) 5 days per week for 6 weeks at home.
62165604|NCT05951777|EXPERIMENTAL|Treatment|Autologous Adipose Derived Mesenchymal Stem Cells
62165605|NCT05951777|PLACEBO_COMPARATOR|Placebo|Normal Saline
62165606|NCT01375777|PLACEBO_COMPARATOR|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
62165607|NCT01375777|PLACEBO_COMPARATOR|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
62165608|NCT01375777|ACTIVE_COMPARATOR|Ezetimibe|Participants received 10 mg ezetimibe orally once a day for 12 weeks.
62165609|NCT01375777|EXPERIMENTAL|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62165610|NCT01375777|EXPERIMENTAL|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62165611|NCT01375777|EXPERIMENTAL|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
62165612|NCT01375777|EXPERIMENTAL|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62165613|NCT01375777|EXPERIMENTAL|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62165614|NCT01375777|EXPERIMENTAL|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
62165615|NCT00639639|EXPERIMENTAL|Arm I (first randomization)|Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
62165616|NCT00639639|EXPERIMENTAL|Arm II (first randomization)|Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
62165617|NCT00639639|EXPERIMENTAL|Arm I (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
62165618|NCT00639639|EXPERIMENTAL|Arm II (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.
62165619|NCT01651650|OTHER|Inhalation of Placebo Dry Powder|Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
62719722|NCT05317598|NO_INTERVENTION|control group|Students in the control group will not receive any intervention during the 5-week period.
62165620|NCT01495754|EXPERIMENTAL|coffee3|
62165621|NCT01495754|EXPERIMENTAL|coffee6|
62165622|NCT01495754|PLACEBO_COMPARATOR|water|
62165623|NCT03456206||"Diet, Cancer and Health cohort"|"Participants from the Diet, Cancer and Health (DCH) cohort with no CID diagnosis at entry to the DCH study. The number of persons developing a CID (defined as at least one of the mentioned CIDs) during follow up (1993/1997 - 2018) and the number of persons not developing a CID will be investigated.~Based on the participants reporting of dietary habits in the Food Frequency Questionnaire (FFQ) from the DCH study, the exposure intake of red and processed meat and fibres will be investigated in both CID cases and non-cases.~Other exposure variables are Lifestyle factors independently or combined and are also obtained from the data in the DCH cohort."
62165624|NCT01125436|EXPERIMENTAL|Cholecalciferol|Nutritional supplement
62165625|NCT01125436|PLACEBO_COMPARATOR|placebo|Weekly placebo plus 800 calcium daily
62165626|NCT05078450|EXPERIMENTAL|Graduate Student Program|This is the graduate student version of the program. The original program has been tailored to this population to meet its specific needs and address its specific concerns.
62165627|NCT05078450|EXPERIMENTAL|Young Professional Program|This is the young professional version of the program. The original program has been tailored to this population to meet its specific needs and address its specific concerns.
62165628|NCT05078450|NO_INTERVENTION|Waitlist|This is the waitlist. Participants may be randomly assigned here first. After the typical period fo the intervention on the waitlist (12 weeks), these participants will be invited to join the arm which they are most appropriate for (i.e., graduate student or young professional).
62165629|NCT01818245|EXPERIMENTAL|LY2605541: Cohort A (Injection site: Abdomen)|Participants ≤55 years of age will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
62165630|NCT01818245|EXPERIMENTAL|LY2605541: Cohort A (Injection site: Upper Arm)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
62545353|NCT05065255||Patients|Adult subjects with neurogenic or non-neurogenic urinary tract disorders, newly initiated to ASI, and users of the SpeediCath line of catheters.
62545354|NCT03796052|EXPERIMENTAL|Avena Sativa Skincare Regimen|Avena sativa-containing body wash, body cream, and anti-itch balm
62545355|NCT03062046|EXPERIMENTAL|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
62545356|NCT05890534|EXPERIMENTAL|Pycnogenol®|People with post COVID-19 condition randomly allocated to the Pycnogenol® arm will take 4 capsules of Pycnogenol® per day (4x50mg capsules, 200mg total) over a period of 12 weeks.
62545357|NCT05890534|PLACEBO_COMPARATOR|Placebo|People with post COVID-19 condition randomly allocated to the Placebo arm will take 4 capsules of Placebo per day (4x50mg capsules, 200mg total) over a period of 12 weeks.
62545358|NCT00354692|EXPERIMENTAL|Experimental|
62545359|NCT01566227|EXPERIMENTAL|number of implants|number of implants (1,2 or 3) used to retained an overdenture
62545360|NCT04948892||Father/partner present, Kolding hospital|All father/partners, mothers and hospital staff involved in hyperacute cesarean section category 1 in general anesthesia (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) in Kolding Hospital, where the father is present in the OR during the cesarean section category 1
62545361|NCT04948892||Father/partner not present, Aabenraa hospital|"All father/partners and mothers involved in hyperacute cesarean section category 1 in general anesthesia in Aabenraa hospital, where the father is not present in the OR during the cesarean sectio category 1.~All relevant hospital staff, who sometimes participates in cesarean sectio category 1 (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) will be asked to fill in a questionnaire on their thoughts and opinions on having the father/partner present during hyperacute cesarean sectio category 1."
62545362|NCT01263938|OTHER|Atorvastatin|
62545363|NCT01632397|EXPERIMENTAL|CBT-based counseling|Cognitive behavioral based intervention to promote PrEP adherence.
62545364|NCT01632397|ACTIVE_COMPARATOR|Health education and supportive counseling|Time matched supportive counseling
62545365|NCT01590303|EXPERIMENTAL|Vitamin C|Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
62545366|NCT01590303|PLACEBO_COMPARATOR|placebo|placebo vehicle administered in same fashion as active treatment
62545367|NCT01128309|EXPERIMENTAL|Stress Reduction Intervention|Stress Reduction Intervention
62545368|NCT01128309|ACTIVE_COMPARATOR|Active Control Condition|
62545369|NCT00306995|EXPERIMENTAL|SB218352_15 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
62545370|NCT00306995|EXPERIMENTAL|SB218352_8 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
62545371|NCT00306995|EXPERIMENTAL|SB218352_4 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
62545372|NCT00306995|EXPERIMENTAL|SB218352_2 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
62545373|NCT00306995|EXPERIMENTAL|SB218352_8AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
62545374|NCT00306995|EXPERIMENTAL|SB218352_4AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
62545375|NCT00306995|EXPERIMENTAL|SB218352_2AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
62545376|NCT04357548||Feedback system|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
62719723|NCT02665533|ACTIVE_COMPARATOR|Dexamethasone|Dexamethasone 8 mg, one capsule single preoperative dose.
62719724|NCT02665533|EXPERIMENTAL|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg, one capsule single preoperative dose.
62719725|NCT03855943|EXPERIMENTAL|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
62545377|NCT06233773|EXPERIMENTAL|Kinesio Taping Group|In this project, Kinesio Taping will be applied to the Kinesio Taping group to reduce pain and support circulation. In this study, space correction method to reduce pain and lymphatic correction technique to support circulation will be applied from Kinesio Taping methods. In the study, in order to determine the susceptibility to allergy to kinesio tape, a five cm application will be made on the outer lateral region of the arms of pregnant women and waited for 10 minutes. Before the application, the physiotherapist will clean the application area with volatile alcohol for correct and good adhesion of the tape. Four bands of 10 cm each will be cut for the application. In order to protect the tape during the movement of the person, all corners will be oval shaped and the kinesio tape will be adhered to the BL-40 and BL-57 points bilaterally using 25-50% tension with the space correction method.
62719726|NCT02072954|EXPERIMENTAL|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
62719727|NCT02072954|ACTIVE_COMPARATOR|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
62719728|NCT00805584|EXPERIMENTAL|Arm 1|
62737442|NCT02565758|EXPERIMENTAL|Arm A4 (ABBV-085)|ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson
62545378|NCT06233773|EXPERIMENTAL|Manual Lymph Drainage Group|Before the application, the pregnant woman will open both lower extremities, including the knee area, in a semi-sitting position. The other body parts will be covered with a sheet/sweater so that the leg area is open. Without applying anything (oil, vaseline, cream) to the leg, the physiotherapist will perform Manual Lymph Drainage using his/her hands. The pregnant woman will be asked to do 10 repetitions of diaphragmatic breathing exercise. Popliteal lymph nodes will be stimulated manually 7 times. The anterior and medial knee will be stimulated 7 times each with circular movements. Manual Lymph Drainage will be performed on the front of the leg with the pumping technique and on the back of the leg with the scooping movement. The procedure will be repeated 3 times to provide drainage in the same area. The ankle will be stimulated 7 times with circular movements. The inferior and posterior parts of both the medial malleolus and lateral malleolus will be stimulated.
62545379|NCT06233773|EXPERIMENTAL|Kinesio Taping and Manual Lymph Drainage Group|In this group, Kinesio Taping and Manual Lymph Drainage will be performed together to support circulation and reduce pain. All of the procedures performed in the Kinesio Taping Group and the Manual Lymph Drainage Group will be performed in parallel. After Kinesio Taping, Manual Lymph Drainage will be performed for 6 days. The kinesio tape will be renewed on the fourth day and will remain for three more days.
62545380|NCT06233773|ACTIVE_COMPARATOR|Control Group|Pregnant women in the control group will not be subjected to any intervention other than routine follow-up and care at the hospital.
62545381|NCT02879903|EXPERIMENTAL|biofilm tobacco effect|Group smokers - patients will receive periodontal treatment and biofilm will be collected.
62545382|NCT02879903|EXPERIMENTAL|biofilm non smoker effect|Group Non Smokers - patients will receive periodontal treatment and biofilm will be collected.
62545383|NCT01887171|EXPERIMENTAL|Tacrolimus + HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
62545384|NCT01887171|NO_INTERVENTION|HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.
62545385|NCT01912378|EXPERIMENTAL|Oxytocin Nasal Spray|40 IUs of Oxytocin nasal spray will be administered to both parents at one time during the lab visit.
62545386|NCT01912378|PLACEBO_COMPARATOR|Placebo nasal spray|40 IUs of Placebo nasal spray will be administered to both parents at one time during the lab visit.
62545387|NCT03245866||Aneurysmal Subarachnoid hemorrhage|Patients suffering from a ruptured cerebral aneurysm are included in the study.
62545388|NCT01703624|EXPERIMENTAL|glycopyrronium bromide 12.5mcg|glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
62545389|NCT01703624|EXPERIMENTAL|glycopyrronium bromide 25mcg|glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
62545390|NCT01703624|EXPERIMENTAL|glycopyrronium bromide 50mcg|glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
62545391|NCT01703624|EXPERIMENTAL|glycopyrronium bromide 100mcg|glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
62545392|NCT01703624|PLACEBO_COMPARATOR|placebo|placebo single dose via pressurised metered dose inhaler (pMDI)
62545393|NCT02447601|EXPERIMENTAL|Simvastatin and PEX168(200µg)|Simvastatin: 40mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
62545394|NCT02593292|ACTIVE_COMPARATOR|PROSPERO group (intervention group)|
62165631|NCT01818245|EXPERIMENTAL|LY2605541: Cohort A (Injection site: Thigh)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
62165632|NCT01818245|EXPERIMENTAL|LY2605541: Cohort B (Injection site: Abdomen)|Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.
62545395|NCT02593292|PLACEBO_COMPARATOR|control group|
62545396|NCT03761940||Disease free|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires are disease free.
62545397|NCT03761940||Local recurrences|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with local recurrence and may be undergoing treatment for this.
62545398|NCT03761940||Distant disease|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with distant disease and may be undergoing treatment for this.
62545399|NCT03761940||Mastectomy|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have undergone a mastectomy.
62545400|NCT06550765|NO_INTERVENTION|Control group|The tumor lesion area is exposed using conventional surgery methods, and the tumor segment is resected according to the principles of tumor-free operation. Electrocautery and suture ligation are used to handle the tumor bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
62719729|NCT03420365|EXPERIMENTAL|Type of intervention|A single bout of aerobic exercise, or a single bout of balance and coordination exercise, or reading a magazine
62719730|NCT06472037|EXPERIMENTAL|Gemcitabine and Nab-paclitaxel combined with Cadonilimab and Sequential Short-course Radiotherapy|Cadonilimab 10mg/kg Q3W；Gemcitabine 1000mg/m2 Q4W；Nab-paclitaxel 125mg/m2 Q4W； Short-course Radiotherapy
62719731|NCT05882396|ACTIVE_COMPARATOR|Rood's approach group|Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.
62719732|NCT05882396|ACTIVE_COMPARATOR|Traditional physical therapy program group|Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.
62719733|NCT04859998|NO_INTERVENTION|Control group|Participants in this group will simply continue with their daily living and therapies. They will be assessed before and after the 10 week program but will not take part in it.
62165633|NCT06453304|ACTIVE_COMPARATOR|Calcium Hydroxide|
62165634|NCT06453304|ACTIVE_COMPARATOR|Leddermix|
62165635|NCT06453304|ACTIVE_COMPARATOR|Glycirrhizin|
62545401|NCT06550765|EXPERIMENTAL|Magnesium metal closure clips|The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
62545402|NCT01098630||Group I (limited participation)|Patients do not complete any questionnaires at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
62545403|NCT01098630||Group II (full participation)|Patients complete the Patient Registration Survey and Patient Questionnaire at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
62545404|NCT06164366|EXPERIMENTAL|0 Degrees Group|dentures will be printed at a 0 degrees build angle
62545405|NCT06164366|ACTIVE_COMPARATOR|45 Degrees Group|dentures will be printed at a 45 degrees build angle
62545406|NCT02441660|EXPERIMENTAL|Investigational Capsacin, Then Control Capsacin|Qutenza, Capsaicin 8% Patch will be used for 12 weeks followed by capsacin 0.025% Well Patch
62545407|NCT02441660|EXPERIMENTAL|Control Capsacin, Then Investigational Capsacin|Active control with low dose capsaicin 0.025% Well Patch used for 12 weeks followed by Qutenza 8% Patch
62545408|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
62545409|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
62545410|NCT01859663||Women with a history of irregular menstrual cycles|We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
62545411|NCT01944111|EXPERIMENTAL|Plication|Prospective clinical trial comparing Standard Adustable Gastric Banding versus experimental Adjustable Gastric Banding
62545412|NCT06342115|EXPERIMENTAL|Intervention|"In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.~Colonized patients will be considered those identified through positive routine rectal swabs and/or positive culture of a clinical sample) or at risk of infection by an ESBL-producing pathogen due to use of 3rd/4th gen cephalosporin or piperacillin/tazobactam for at least 48 hours. in the last 30 days."
62545413|NCT06342115|ACTIVE_COMPARATOR|Control|"The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.~Colonized patients will be considered those identified through positive routine rectal swabs and/or positive culture of a clinical sample) or at risk of infection by an ESBL-producing pathogen due to use of 3rd/4th gen cephalosporin or piperacillin/tazobactam for at least 48 hours. in the last 30 days."
62545414|NCT03714919|EXPERIMENTAL|Non-opiod pain relief|Subjects will receive preoperative oral dextromethorphan \& acetaminophen and intraoperative intravenous dexmedetomidine \& ketamine.
62545415|NCT05291611|EXPERIMENTAL|Treatment with cbt|Treatment for 26 patients with obsessive-compulsive disorder, 14 sessions, each about 90 minutes.
62545416|NCT02333656|NO_INTERVENTION|Control group|Usual care. The participants enrolled in the control period will receive OA treatment as it is currently offered in primary health care services.
62545417|NCT02333656|EXPERIMENTAL|Intervention group|New OA model. Health professionals attend an interactive workshop, implementation of international recommendations for OA care, multidiciplinary collaboration
62545418|NCT01711463|EXPERIMENTAL|FF/VI|50/25 mcg, 100/25 mcg or 200/25 mcg
62545419|NCT01711463|PLACEBO_COMPARATOR|Placebo|matching placebo
62545420|NCT05391386|NO_INTERVENTION|conventional|
62545421|NCT05391386|EXPERIMENTAL|modified|
62545422|NCT04952818||RANK/RANKL low expression|
62165636|NCT03552471|EXPERIMENTAL|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62165637|NCT03323814||short-sleepers|subset of participants will be recruited who report less than typical work/ weekday sleep in order to examine whether enhancing sleep with stimulation will reduce the amount of extra sleep subjects usually get on the weekends.
62545423|NCT04952818||RANK/RANKL high expression|
62545424|NCT06257381||COPD-patients|We aim to include 16 patients with COPD across the FEV1% of predicted spectrum, ranging from mild to severe COPD. Participants will undergo lung function test and VO2max
62719734|NCT04859998|EXPERIMENTAL|Experimental group|Participants in this group will take part in the 20 session dog-assisted therapy. This therapy will be added to their usual daily living and therapies. They will be assessed before and after the 10 week program.
62736219|NCT06346509|EXPERIMENTAL|PORT-77|Healthy adult participants in each cohort will receive a single oral dose of PORT 77 or matching placebo on Day 1.
62545425|NCT06257381||Matched healthy volunteers|We aim to include 16 healthy matched controls (sex +-3year age).
62545426|NCT04065360|EXPERIMENTAL|Cognitive behavioural family intervention|
62545427|NCT04065360|ACTIVE_COMPARATOR|Usual group psychoeducation|
62545428|NCT06329609|EXPERIMENTAL|Intervention|This arm will receive the study intervention
62545429|NCT03490656|EXPERIMENTAL|Healthy volunteer population|
62545430|NCT03490656|EXPERIMENTAL|Patient population|
62545431|NCT03544944|EXPERIMENTAL|TJP-008-1|
62545432|NCT03544944|EXPERIMENTAL|TJP-008-2|
62545433|NCT03544944|ACTIVE_COMPARATOR|Coolprep powder|
62545434|NCT05860114|EXPERIMENTAL|Givinostat (single-dose and multiple-dose)|On day 1, givinostat 50 mg as oral suspension was administered as a single dose, in the morning. On Days 5-12 givinostat 50 mg as oral suspension was administered twice-daily, in the morning and in the evening, as a multiple dose. On day 13 givinostat 50 mg as oral suspension was administered as a single dose, in the morning.
62545435|NCT06550960|EXPERIMENTAL|SureCore Plus biopsy needle|Prostate biopsy of subject with BPH with a SureCore biopsy needle
62545436|NCT06550960|ACTIVE_COMPARATOR|Standard of Care biopsy needle|Prostate biopsy of subject with BPH with a standard of care (SOC) biopsy needle
62545437|NCT01679509|EXPERIMENTAL|Single-port surgery group|Single-port laparoscopic adnexal surgery
62545438|NCT01679509|ACTIVE_COMPARATOR|Three-port surgery group|Three-port laparoscopic adnexal surgery
62545439|NCT05088785|EXPERIMENTAL|Part A: dynamic FES PET imaging|All patients included in part A will receive a dynamic FES PET/CT scan.
62545440|NCT05088785|EXPERIMENTAL|Part B: whole body static FES PET imaging|All patients included in part B will receive a whole body static FES PET/CT scan twice within 1 week.
62545441|NCT02737904|ACTIVE_COMPARATOR|Control group|Usual care - conventional, personalised in-patient rehabilitation 4 weeks duration
62545442|NCT02737904|EXPERIMENTAL|Intervention group|Usual care - conventional, personalised in-patient rehabilitation - plus APT cycling programme 4 weeks duration
62545443|NCT00998309||Azithromycin SR|Patients taking Azithromycin.
62545444|NCT01026311|PLACEBO_COMPARATOR|placebo|
62545445|NCT01026311|ACTIVE_COMPARATOR|Coenzyme Q10|200mg of coenzyme Q10
62545446|NCT02551484|EXPERIMENTAL|Procedure 1|Measures with 60 minutes interval during the consultation of equipment, functional testing, receuil pain.
62545447|NCT02551484|EXPERIMENTAL|Procedure 2|Measuring J15, J30 J 45 and after the different settings functional amputation, pain and tissue oxygenation.
62545448|NCT03360955||Total Intravenous Anesthesia|Patients with total intravenous anesthesia during the cardiac surgery
62545449|NCT03360955||Spinal Anesthesia|Patients with spinal anesthesia with minimal opioid dose.
62545450|NCT02108184|EXPERIMENTAL|Sequential therapy 10 days|1.(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 5 days
62545451|NCT02108184|ACTIVE_COMPARATOR|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days
62545452|NCT02108184|ACTIVE_COMPARATOR|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 10 days
62545453|NCT02108184|ACTIVE_COMPARATOR|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days
62545454|NCT00474266|EXPERIMENTAL|Nimenrix + Priorix-Tetra Group|Subjects received 1 dose of Nimenrix vaccine and 1 dose of Priorix-Tetra vaccine on Day 0 and a second dose of Priorix-Tetra vaccine on Day 84.
62545455|NCT00474266|EXPERIMENTAL|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
62545456|NCT00474266|ACTIVE_COMPARATOR|Priorix-Tetra Group|Subjects received 1 dose of Priorix-Tetra vaccine on Day 0, 1 dose of Meningitec vaccine on Day 42 and a second dose of Priorix-Tetra vaccine on Day 84.
62545457|NCT00474266|ACTIVE_COMPARATOR|Meningitec Group|Subjects received 1 dose of Meningitec vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
62545458|NCT03527953|ACTIVE_COMPARATOR|Tetric EvoCeram BulkFill resin|Randomly applied
62545459|NCT03527953|ACTIVE_COMPARATOR|Surefil SDR Flowable bulk-fill resin|Randomly applied
62719735|NCT04681989|EXPERIMENTAL|MOVE-ABC intervention arm|"MOVE-ABC interventional group participants receive usual care plus the MOVE-ABC education instruction and materials. After the participant completes the baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. instructions on the education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment. The follow-up phone calls are expected to take 20 - 30 minutes each time. During these follow-ups research staff will review material, and answer any questions the participant may have. All documentation of phone calls and questions asked by participants during these reviews will be captured in REDCap."
62545460|NCT03527953|ACTIVE_COMPARATOR|everX fiber-reinforced resin|Randomly applied
62545461|NCT00901576|EXPERIMENTAL|SPD503|
62545462|NCT00901576|ACTIVE_COMPARATOR|Concerta|
62545463|NCT00901576|ACTIVE_COMPARATOR|SPD503 + Concerta|
62545464|NCT04928976||Arm 1: MCI amyloid positive|"* Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62545465|NCT04928976||Arm 2: MCI amyloid negative|"* Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)"
62545466|NCT04928976||Arm 3: CN amyloid positive|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62545467|NCT04928976||Arm 4: CN amyloid negative|"* Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)"
62545468|NCT05762692|EXPERIMENTAL|HFNO Group|Intra-operative oxygenation will be administered by the high-flow nasal oxygenation device. The flow rate is 2L/kg.(upper limit 30L/min)
62545469|NCT03616717|ACTIVE_COMPARATOR|modafinil 100 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
62545470|NCT03616717|ACTIVE_COMPARATOR|modafinil 200 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
62545471|NCT03616717|PLACEBO_COMPARATOR|placebo|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
62545472|NCT05083897||30 patients in 1 group|measuring the effect of isometric hip adduction with knee extension on the peak torque of knee extensors
62545473|NCT06013748|EXPERIMENTAL|VR-VOICES|7-10 sessions of 45-60 minutes of individual VR assisted therapy and two booster sessions, in addition to TAU. Participants allocated to VR-VOICES create together with their therapist a VR digital representation (avatar with face, body and voice) of the voice that bothers them most. Patients have dialogues with the avatar, voiced by the therapist. As indicated in the treatment protocol, over the sessions the avatar will become less hostile and the participant will gain more power and resilience over the avatar.
62545474|NCT06013748|OTHER|Treatment as usual|TAU as described in the current Dutch treatment guidelines, which generally exists of pharmacological treatment, supportive counseling, and psychological interventions such as CBT and coping strategies. This will vary per individual.
62545475|NCT00703872|EXPERIMENTAL|1|Oral HDV-Interferon
62545476|NCT00703872|EXPERIMENTAL|2|Injectable HDV-Interferon + ribavarin
62545477|NCT05478252|EXPERIMENTAL|Semaglutide J|Participants will initially receive 0.25 milligrams (mg) subcutaneous injections of semaglutide J once weekly (OW) and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.
62545478|NCT05478252|ACTIVE_COMPARATOR|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.
62545479|NCT03352258|NO_INTERVENTION|Observation|Subjects in this arm will only be followed and not treated (observational arm)
62545480|NCT03352258|EXPERIMENTAL|Treatment arm|Subjects will receive a low dose brain radiotherapy
62545481|NCT05907239|EXPERIMENTAL|Treatment group|Treatment group will undergo treatment with focal shock wave therapy for 5 weeks, with weekly sessions and guidance by a trained physiotherapist on habits, stretching and exercises for adequate strengthening and ergonomic guidelines to promote a better quality of life
62545482|NCT05907239|PLACEBO_COMPARATOR|Placebo|Patients in the placebo group will undergo treatment with placebo focal shockwave therapy (using a dummy applicator) for 5 weeks and guidance by a trained physiotherapist on habits, stretching and exercises for adequate strengthening and ergonomic guidelines to promote a better quality of life
62545483|NCT02290223|EXPERIMENTAL|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
62545484|NCT02290223|NO_INTERVENTION|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
62545485|NCT00258128|EXPERIMENTAL|Treatment|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the salsalate 4.0 g/d arm.
62545486|NCT00258128|PLACEBO_COMPARATOR|Placebo|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the placebo arm.
62545487|NCT01652547|EXPERIMENTAL|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs), switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
62719736|NCT04681989|NO_INTERVENTION|Control/Usual Care arm|Control group participants will be measured at baseline and at 1 month follow-up. They receive usual care. Usual care does not include specialized, physical therapy-based education on recovery from breast cancer.
62719737|NCT03783780|EXPERIMENTAL|INVSENSOR00031|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00031 sensor during motion and non-motion.
62719738|NCT01577602|NO_INTERVENTION|Standard practice|
62719739|NCT01577602|EXPERIMENTAL|Printed list intervention|Providing patients a list of their current medications before they see medical assistant and begin their visit.
62719740|NCT01577602|EXPERIMENTAL|Open ended question intervention|"Medical assistants begin the medication review with a scripted, open ended question (i.e., tell me about your medications)"
62719741|NCT01577602|EXPERIMENTAL|Combined intervention|
62165638|NCT03323814||shift-workers|An additional subset of participants will be recruited who work evening shifts to see if enhanced sleep can counteract some of the effects of schedule shifting.
62736220|NCT06346509|PLACEBO_COMPARATOR|Placebo|Healthy adult participants in each cohort will receive a single oral dose of PORT 77 or matching placebo on Day 1.
62165639|NCT03323814||normal-sleepers|The first cohort will be used to optimize the the type and duration of sensory stimuli that will optimally enhance slow-waves.
62545488|NCT01652547|EXPERIMENTAL|Pasireotide long acting release|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
62545489|NCT00727597|EXPERIMENTAL|Arm A : Boosted Lexiva plus Epzicom|Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).
62545490|NCT00727597|EXPERIMENTAL|Arm B: Efavirenz plus Epzicom|QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
62545491|NCT05682651||Tracheal Stenosis with Covid-19|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
62545492|NCT05682651||Tracheal Stenosis with Non-Covid-19|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
62545493|NCT01049646|ACTIVE_COMPARATOR|Angiotensin II|
62545494|NCT01049646|PLACEBO_COMPARATOR|Saline infusion|
62545495|NCT05100160|EXPERIMENTAL|Gabapentin|used as part of a multimodal pain regimen (combination of drugs used to control pain
62545496|NCT05100160|EXPERIMENTAL|Placebo|designed to be compared with a study drug to learn if the study drug has any real effect
62545497|NCT02876757||5ARI Users|
62545498|NCT02876757||Non 5ARI users|
62545499|NCT01499446|EXPERIMENTAL|GW685698X (fluticasone furoate) 100mcg Morning|
62545500|NCT01499446|EXPERIMENTAL|GW685698X (fluticasone furoate) 100mcg Evening|
62545501|NCT01499446|EXPERIMENTAL|GW685698X (fluticasone furoate) 250mcg Evening|
62545502|NCT01499446|PLACEBO_COMPARATOR|Placebo|
62545503|NCT06490679|EXPERIMENTAL|Hand and ultrasonic scalers and curettes|Hand and ultrasonic scalers and curettes will be used for supra- and subgingival instrumentation.
62545504|NCT06490679|ACTIVE_COMPARATOR|Electro Medical Systems AIRFLOW® Prophylaxis Master Device With Erythritol Powder|Prophylaxis Master Device With Erythritol Powder An erythritol powder will be used by Electro Medical Systems AIRFLOW® Prophylaxis Master Device.
62545505|NCT05886868|EXPERIMENTAL|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
62545506|NCT05565079|EXPERIMENTAL|Coronally positioned tunnel with AlloDerm RTM and Enamel Matrix Derivative|12 patients will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm RTM, BioHorizons) and a porcine derived enamel matrix derivative (Emdogain, Straumann).
62545507|NCT05565079|ACTIVE_COMPARATOR|Coronally positioned tunnel with AlloDerm RTM|12 patients will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm RTM, BioHorizons).
62545508|NCT05441501|EXPERIMENTAL|Part 1: Dose Escalation|Participants will receive JNJ-80038114. The dose levels will be escalated based on the dose limiting toxicities (DLTs) evaluation by the study evaluation team (SET).
62545509|NCT05441501|EXPERIMENTAL|Part 2: Dose Expansion|Participants will receive JNJ-80038114 at the recommended Phase 2 dose (RP2D) determined in Part 1.
62545510|NCT02928445|EXPERIMENTAL|RVT-101 35 mg|RVT-101 35 mg once daily
62545511|NCT02928445|EXPERIMENTAL|RVT-101 70 mg|RVT-101 70 mg once daily
62545512|NCT05357066|ACTIVE_COMPARATOR|Treatment; Nitrous Oxide 50%|A single 60-minute session of inhaled 50% nitrous oxide.
62545513|NCT05357066|PLACEBO_COMPARATOR|Control; Oxygen-air mixture|A single 60-minute session of inhaled Oxygen-air mixture
62719742|NCT02765399|EXPERIMENTAL|Liraglutide|"Liraglutide subcutaneous injection once daily with following dose escalation:~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months."
62545514|NCT04261101|EXPERIMENTAL|Block A|Test intervention with questions regarding diabetes and adrenal
62719743|NCT02765399|PLACEBO_COMPARATOR|Placebo|"Placebo subcutaneous injection once daily with following dose escalation:~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months."
62719744|NCT04847440|EXPERIMENTAL|ATI-2173 and Viread|ATI-2173 + Tenofovir disoproxil fumarate (Viread)
62719745|NCT04847440|ACTIVE_COMPARATOR|Placebo and Viread|ATI-2173 Placebo + Tenofovir disoproxil fumarate
62545515|NCT04261101|ACTIVE_COMPARATOR|Block B|Test intervention with questions regarding thyroid and hypophysis
62545516|NCT03174379|PLACEBO_COMPARATOR|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
62545517|NCT03174379|ACTIVE_COMPARATOR|Treatment Group|60-minute treatment session twice a week for three weeks
62545518|NCT01287026|EXPERIMENTAL|1|Open Label
62545519|NCT03590054|EXPERIMENTAL|Dose Escalation: (abexinostat, pembrolizumab)|Participants receive abexinostat PO BID on days -7 to -4 of the lead-in period, and days 1-4, 8-11 of each treatment cycle and pembrolizumab over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62545520|NCT03590054|EXPERIMENTAL|Cohort A: Dose Expansion (abexinostat, pembrolizumab)|Participants with primary resistance to prior anti-PD-1/PD-L1 will receive abexinostat PO BID on days -7 to -4 of the lead-in period, and days 1-4, 8-11 of each treatment cycle and pembrolizumab over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62545521|NCT03590054|EXPERIMENTAL|Cohort B: Dose Expansion (abexinostat, pembrolizumab)|Participants with acquired resistance, defined as treatment duration on prior CPI for greater than 6 months with evidence of clinical benefit (tumor regression or disease stabilization) with subsequent disease progression will receive abexinostat PO BID on days -7 to -4 of the lead-in period, and days 1-4, 8-11 of each treatment cycle and pembrolizumab over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62545522|NCT03413579|EXPERIMENTAL|Nimotuzumab|"Injection of 200 mg of Nimotuzumab (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~The objective of the present study is to assess the overall survival of patients after administration of Nimotuzumab hR3 monoclonal antibodies (combined with a chemotherapy) in the treatment of patients with cervix epithelial tumors as first-line treatment.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
62545523|NCT03413579|PLACEBO_COMPARATOR|Placebo|"Injection of the Placebo in the same procedures (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
62545524|NCT00364000|ACTIVE_COMPARATOR|I|Calcium acetate 670 mg tablets
62165640|NCT06006780|ACTIVE_COMPARATOR|Coronally advanced flap (CAF)|
62545525|NCT00364000|EXPERIMENTAL|II|label sevelamer (RenagelR) 800 mg tablets
62545526|NCT06435910|EXPERIMENTAL|DCvac cells to treat MM|
62545527|NCT00681031|EXPERIMENTAL|All Enrolled|Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)
62545528|NCT00478244|EXPERIMENTAL|Epidermolysis Bullosa (EB) Patients|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant.
62545529|NCT03221244|EXPERIMENTAL|VR Treatment|"The VR distractor condition is an adaptive training, experimental treatment. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context. Distractors will be presented intermittently throughout the test session. During training sessions, distractor saliency and frequency will increase or decrease based on performance on the tests.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect a decrease in distraction after adaptive distractor exposure in the VR classroom."
62545530|NCT03221244|ACTIVE_COMPARATOR|VR Active Control|"The VR classroom with no distractors presented is an active control group. This group will undergo the same training regimen, only their virtual classroom environment will not contain adaptive distractors. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect no change in response to distraction in the ADHD group after control exposure to the VR classroom."
62545531|NCT01150812|EXPERIMENTAL|1|
62545532|NCT01590797|EXPERIMENTAL|Sitagliptin|Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
62545533|NCT01590797|PLACEBO_COMPARATOR|Placebo|Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
62545534|NCT00101283|EXPERIMENTAL|Pemetrexed/Carboplatin|Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle.
62545535|NCT00101283|EXPERIMENTAL|Pemetrexed/Gemcitabine|Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
62545536|NCT05637203|EXPERIMENTAL|THRIVE + Discharge / Safety Planning|"Participants assigned to the intervention condition will receive THRIVE Crisis Recovery and Care Transition Program, which consists of group-based reflections on giving and belonging and a plan for community connection and treatment, followed by 3-4 coaching calls to reinforce and troubleshoot the plans."
62545537|NCT05637203|ACTIVE_COMPARATOR|Discharge / Safety Planning Alone|Participants assigned to the control condition will receive Discharge/Safety Planning as it is practiced by Connections Health Solutions per industry best practices.
62545538|NCT05021432|EXPERIMENTAL|Virtual Reality Group|Virtual Reality group will receive video based games training.
62545539|NCT05021432|ACTIVE_COMPARATOR|Circuit Training Group|They will receive Task-oriented Circuit training exercise program
62545540|NCT04143243|ACTIVE_COMPARATOR|ACT on Life|"Acceptance and Commitment Therapy plus Education, Resources and Support ('ACT on Life').~The ACT+ERS intervention will include: 1) Acceptance and Mindfulness Training (2-3 hours); 2) Committed Action Training (2-3 hours) involving helping Veterans clarify what matters most to them and what they want to stand for in life, how they want to behave, and what sorts of strengths and qualities they want to develop; and; 3) Education, Resources, and Support (1 hour)."
62719746|NCT04847440|EXPERIMENTAL|ATI-2173, Viread and AB-729|ATI-2173 + Tenofovir disoproxil fumarate (Viread) + AB-729
62719747|NCT04847440|ACTIVE_COMPARATOR|Placebo, Viread and AB-729 Placebo|ATI-2173 Placebo + Tenofovir disoproxil fumarate (Viread) + AB-729 Placebo
62719748|NCT04781530|EXPERIMENTAL|Intervention (Device)|"Diagnostic Test: BioFire~A molecular rapid syndromic testing platform, using the following panel:~BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) In addition to standard of care"
62719749|NCT04781530|NO_INTERVENTION|Control (Standard of Care)|Standard of Care
62719750|NCT04635137|EXPERIMENTAL|Ablation and Cementoplasty|All patients undergoing thermal ablation and cementoplasty procedure for one or more painful bone lesion
62736221|NCT04320056|ACTIVE_COMPARATOR|Control group|"Usual care will be provide to patients concerning their medical management.~In the Control Group usual, oxygen will be delivered as per usual local practices"
62165641|NCT06006780|EXPERIMENTAL|Coronally advanced flap associated with the porcine acellular dermal matrix (CAF+ PADM)|
62719751|NCT00551096|EXPERIMENTAL|Gemcitabine, capecitabine and ZD6474|"Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.~Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off .~ZD6474 administered orally at 300 mg/day once daily. One cycle will consist of 28 days."
62545541|NCT04143243|PLACEBO_COMPARATOR|Education, Resources, and Support|Information provided in the ERS workshop was compiled from existing VHA and community resources. Veterans will be educated about 1) symptoms of depression, anxiety and PTSD and how these conditions do and do not impact daily life and functional ability; 2) common difficulties and challenges with reintegration into civilian life; 3) mild TBI, differences between civilian and Veteran TBIs, shared/crossover symptoms (for example, memory and concentration difficulties, sleep disturbance, irritability can be symptoms of depression, PTSD, and mild TBI); 4) chronic pain; how it is often often misinterpreted as on-going damage, leading to fear of physical activities and resulting in increased sedentary behavior and declines in physical functioning; and 5) treatment options and resources. Basic resource counseling will include guidance on the evidence-based treatments available at VHA. Problem solving, relaxation, and deep breathing techniques will be covered
62545542|NCT02128672|ACTIVE_COMPARATOR|Conventional SCS lead|Conventional Thoracic-lumbar SCS lead placement
62545543|NCT02128672|EXPERIMENTAL|SCS Experimental Lead Placement|Experimental SCS lead placement in a novel position
62545544|NCT03336528|EXPERIMENTAL|Degludec inpatient|Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting aspart insulin before meals.
62545545|NCT03336528|ACTIVE_COMPARATOR|Glargine U100 inpatient|Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as basal bolus regimen with glargine once daily plus rapid-acting aspart insulin before meals.
62545546|NCT00606164|PLACEBO_COMPARATOR|Placebo|
62545547|NCT00606164|EXPERIMENTAL|10 ug/m2 Bryostatin|
62545548|NCT00606164|EXPERIMENTAL|15 ug/m2 Bryostatin|
62545549|NCT03555110|ACTIVE_COMPARATOR|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
62545550|NCT03555110|ACTIVE_COMPARATOR|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:~* Three evaluation and preparation sessions,~* Eight EMDR sessions weekly with variable length of 60 minutes and~* One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
62545551|NCT01461447|EXPERIMENTAL|MVA|Volunteers who were primed with 3 HIVIS DNA and further boosted with 2 MVA vaccine will receive a third MVA there shall not be an comparator for this study.
62545552|NCT05721976|EXPERIMENTAL|"With Love, Grandma (Con Cariño, Abuelita) Group"|"Cancer survivor-Daughter dyads randomized to the With Love, Grandma (Con Cariño, Abuelita) group will access a digital lifestyle program that includes 8 modules of didactic, behavioral, and family communication/parenting/grandparenting content from smartphones over the course of 10-12 weeks."
62545553|NCT05721976|NO_INTERVENTION|Control Group|This group is intended to reflect typical services cancer survivors and family members receive from healthcare providers.
62545554|NCT01115478|ACTIVE_COMPARATOR|Vitamin A|
62545555|NCT01115478|ACTIVE_COMPARATOR|Zinc|
62545556|NCT01115478|ACTIVE_COMPARATOR|Vitamin A + Zinc|
62545557|NCT01115478|PLACEBO_COMPARATOR|Placebo|
62545558|NCT04110379|EXPERIMENTAL|Virtual Reality (VR)|Child behavior management will be done using virtual reality glasses distraction (Remax Fantasy Land virtual reality glasses (Schenzen Remax Co.,Ltd))
62545559|NCT04110379|ACTIVE_COMPARATOR|Conventional Behavior Management|Child behavior management will be done using conventional behavior management techniques
62545560|NCT04585880|EXPERIMENTAL|Virtual Collaborative Care Clinic|The Virtual Collaborative Care Clinic arm participants use a home blood pressure monitor and routine blood pressure measurements will be uploaded to a dashboard monitored by clinical pharmacists. Blood pressure will be managed aggressively by the clinical pharmacists in coordination with Primary Care Physicians.
62545561|NCT04585880|NO_INTERVENTION|Control Intervention|The control intervention will consist of providing the participant with educational material and a home blood pressure monitor. The patients in the control group will not have support from Virtual Collaborative Care Clinic pharmacists. Routine blood pressure measures using their device will not be collected via the dashboard and will not be available for pharmacist review. Participants will continue to see their physicians for their usual care for blood pressure management.
62719752|NCT05125003|EXPERIMENTAL|FITBI|Reinforcement-based learning procedures delivered via telehealth in 16 remote-delivered treatment sessions - 13 weekly and 3 booster treatment sessions over 6 month period.
62719753|NCT05125003|ACTIVE_COMPARATOR|Parent Education|Information relevant to parenting a young child with ASD (e.g. parent advocacy, developmental changes in ASD, treatment options) delivered via telehealth in 15 remote-delivered treatment sessions -12 weekly and 3 booster treatment sessions over 6 month period.
62719754|NCT06211699|ACTIVE_COMPARATOR|Omentopexy with Laparoscopic Sleeve Gastrectomy|Patients who underwent continuous through-and-through omentopexy of the omentum to the remnant stomach staple line after resection during Laparoscopic Sleeve Gastrectomy (omentopexy group).
62719755|NCT06211699|ACTIVE_COMPARATOR|Clips with Laparoscopic Sleeve Gastrectomy|Patients who underwent consecutive clippping along the staple line of the remnant stomach during Laparoscopic Sleeve Gastrectomy (clips group)
62545562|NCT02135471|EXPERIMENTAL|acellular dermal matrix graft|
62545563|NCT02135471|EXPERIMENTAL|enamel matrix derivative|
62545564|NCT02609438|ACTIVE_COMPARATOR|Short breaks|Participants instructed to stand/move for 1-2 minutes every half hour throughout the workday
62545565|NCT02609438|ACTIVE_COMPARATOR|Long breaks|Participants instructed to take two 15-minute activity breaks during each workday
62545566|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
62545567|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
62545568|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
62545569|NCT00695058|EXPERIMENTAL|1|Women with stress incontinence treated with active TMNS (vibration)
62545570|NCT00695058|PLACEBO_COMPARATOR|2|Women with stress incontinence treated with placebo TMNS (vibration)with an amplitude of 0
62719756|NCT05214937|EXPERIMENTAL|Intervention|Participants will be provided with a FitBit Inspire 2 and assigned a movement specialist. They will be asked to monitor their daily steps over the 12-week intervention period. Participants will attend 6 remotely-delivered behaviour change sessions (4 one-on-one sessions with their movement specialist, 2 group-based webinars). Sessions will be delivered bi-weekly and last \~30 minutes.
62165642|NCT04712500|EXPERIMENTAL|AND017: Fasted - Fed|Subjects were randomized to receive single dose of AND017 under fasted condition in Period 1 and under fed condition in Period 2
62165643|NCT04712500|EXPERIMENTAL|AND017: Fed - Fasted|Subjects were randomized to receive single dose of AND017 under fed condition in Period 1 and under fasted condition in Period 2
62165644|NCT01690871|EXPERIMENTAL|BEZ235|BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
62165645|NCT01061775|EXPERIMENTAL|Exenatide|5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
62165646|NCT02570971|NO_INTERVENTION|Control|Patients will receive supportive care measures.
62165647|NCT02570971|EXPERIMENTAL|Investigational|Patients will receive 500mL of 20% mannitol
62165648|NCT04923893|EXPERIMENTAL|Arm A: VRd+Rd (Standard Therapy)|Participants will receive bortezomib, lenalidomide, and dexamethasone (VRd) regimen for 6 cycles before randomization. Following randomization, participants in Arm A will receive 2 more cycles of VRd. In VRd treatment, participants will receive bortezomib 1.3 milligram per meter square (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each cycle (Cycles 1 to 8), oral lenalidomide 25 mg on Days 1 to 14 of each cycle (Cycles 1 to 8) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle (Cycles 1 to 8). Each cycle will consist of 21 days. After 8 cycles of VRd, treatment will continue with lenalidomide and dexamethasone (Rd) maintenance therapy. In Rd treatment, participants will receive oral lenalidomide 25 mg on Days 1 to 21 of each cycle and oral dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle. Each cycle will consist of 28 days. Participants will continue to receive Rd until confirmed progressive disease or unacceptable toxicity.
62165649|NCT04923893|EXPERIMENTAL|Arm B: VRd+Ciltacabtagene Autoleucel (Cilta-cel)|Participants will receive VRd regimen for 6 cycles before randomization. Following randomization, participants in Arm B will undergo apheresis and receive two more cycles of VRd as bridging therapy. In VRd treatment, participants will receive bortezomib 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each cycle for Cycles 1 to 8; oral lenalidomide 25 mg on days 1 to 14 of each cycle for Cycles 1 to 8 and oral dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle for Cycles 1 to 8. Each cycle will consist of 21 days. After 8 cycles of VRd, participants will receive a conditioning regimen (cyclophosphamide 300 mg/m\^2 intravenous \[IV\] and fludarabine 30 mg/m\^2 IV daily for 3 days) and Cilta-cel infusion 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg).
62165650|NCT03082638||Control|served in Gulf War during 1990 - 1991 and have no symptoms of Gulf War Illness based on criteria
62165651|NCT03082638||Case|Served in Gulf War during 1990 -1991 and have Gulf War Illness
62165652|NCT06608459|EXPERIMENTAL|Adult participants with confirmed OUD|
62165653|NCT05440578||olaparib plus bevacizumab treatment group|olaparib plus bevacizumab maintenance therapy in clinical practice and will be conducted in patients with tBRCAwt newly diagnosed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy following the standard of care from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required) at tertiary-referral university hospitals and main cancer centers in China.
62165654|NCT04453709|EXPERIMENTAL|Problem Management Plus for Immigrants at family settings|PMP-I intervention aims to develop skills in coping adaptively in a new culture, seeking help and support for mental health problems, and other life skills opportunities that can help to improve their quality of life. PMP-I intervention includes stress management through breathing exercises and yoga, problem solving, behavioral activation, and skills to strengthen social support.
62165655|NCT04453709|ACTIVE_COMPARATOR|Talk program with Community Support Service Pamphlet (CSS)|Family receives pamphlet including list of community support service institutions that provide various health and well-being services.
62165656|NCT01914302||Delica Lancing Device|Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood
62165657|NCT01914302||Freestyle Flash Lancing Device|Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood
62165658|NCT01914302||Easy Touch Lancing Device|Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood
62165659|NCT01914302||Glucoject Lancing Device|Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood
62165660|NCT01914302||Microlet Lancing Device|Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood
62545571|NCT00695058|EXPERIMENTAL|3|Women with overactive bladder syndrome treated with active TMNS (vibration)
62545572|NCT00695058|PLACEBO_COMPARATOR|4|Women with overactive bladder syndrome treated with placebo TMNS (vibration)with an amplitude of 0
62545573|NCT00695058|EXPERIMENTAL|5|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with active TMNS (vibration)
62545574|NCT00695058|PLACEBO_COMPARATOR|6|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with placebo TMNS (vibration)with an amplitude of 0
62545575|NCT04169152||Internal hemorrhoids and rectal prolapse|Participants were treated with Cap-assisted endoscopic sclerotherapy (CAES).
62545576|NCT03864016|OTHER|Standard group|
62545577|NCT03864016|EXPERIMENTAL|Pupillometry group|
62545578|NCT00555841|EXPERIMENTAL|ALC|I g three times daily
62545579|NCT00555841|PLACEBO_COMPARATOR|Placebo|1 g three times daily
62545580|NCT05858112||Patients with suspected MI|
62545581|NCT06526624|EXPERIMENTAL|HS-20093|Patients with LS-SCLC who have not progressed following CRT. Patients in this arm will be administrated HS-20093 intravenously at a dose of 8.0 mg/kg, Q3W continuously until disease progression or until other criteria for discontinuation of treatment are met.
62545582|NCT06526624|NO_INTERVENTION|Active surveillance|Patients with LS-SCLC who have not progressed following CRT. Patients in this arm will receive active surveillance until disease progression or until other criteria for discontinuation of active surveillance are met.
62545583|NCT03647670|OTHER|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
62545584|NCT03647670|OTHER|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
62545585|NCT02986867|EXPERIMENTAL|SAbR|SAbR treatment of lesions
62545586|NCT04168879|ACTIVE_COMPARATOR|bupivacaine group|
62165661|NCT01914302||Multiclix Lancing Device|Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood
62165662|NCT01914302||Fastclix Lancing Device|Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood
62165663|NCT01914302||Reli-On Lancing Device|Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood
62165664|NCT03652064|ACTIVE_COMPARATOR|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m\^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
62165665|NCT03652064|EXPERIMENTAL|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m\^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
62165666|NCT02345421||At risk population|
62165667|NCT05532319|EXPERIMENTAL|HAIC sequential TAE combined with lenvatinib and tislelizumab|The aim of this phase II trial is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with unresectable hepatocellular carcinoma (HCC), and to explore the optimal benefit population.
62165668|NCT05626920|PLACEBO_COMPARATOR|Placebo|Placebo medication
62165669|NCT05626920|ACTIVE_COMPARATOR|Disulfiram|Disulfiram medication
62165670|NCT06439537||Single-group for all hip fracture patients|Single-group cohort for all hip fracture patients who are candidates for an operation
62165671|NCT04551469|EXPERIMENTAL|Treatment Arm|30 minutes of listening to music
62165672|NCT04551469|NO_INTERVENTION|Standard of Care|actual sounds of the intensive care unit environment
62165673|NCT02469493|EXPERIMENTAL|Acupuncture 1|In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
62165674|NCT02469493|EXPERIMENTAL|Acupuncture 2|In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
62165675|NCT02469493|SHAM_COMPARATOR|Sham acupuncture|In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist. S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
62165676|NCT02469493|NO_INTERVENTION|Waitinglist control|In this group, patients received no electroacupuncture
62545587|NCT04168879|PLACEBO_COMPARATOR|saline group|
62545588|NCT05284266|ACTIVE_COMPARATOR|Standard conservative treatment|"Standard conservative treatment consisting of:~* Physical therapy, including compression garment and exercise program~* Self-care program~* Individual counseling from a clinical dietician"
62719757|NCT05214937|ACTIVE_COMPARATOR|Fitbit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living (e.g., 24-hour movement guidelines).
62165677|NCT04382807||Subjective, chronic tinnitus|Tinnitus patients who received internet-based psycho-educational counseling
62165678|NCT04121949|NO_INTERVENTION|Control group|"The control group will receive standard-of-care treatment recommended by current ESC guidelines for patients with low to intermediate likelihood of stable CAD using the Diamond-Forrester (DF) score only: Rule-out if DF-score \<15%; NIT if DF-score 15-85%.~As per January 2020 the protocol was updated according to the 2019 ESC Guidelines on Chronic Coronary Syndrome:~The control group will receive standard-of-care treatment recommended by current ESC guidelines based on the patients likelihood of stable CAD using the Pre-test Probability score (PTP): Rule-out if PTP≤5%, NIT may be considered if PTP 6-15%, NIT if PTP\>15%"
62545589|NCT05284266|EXPERIMENTAL|Standard treatment plus additional lymphedema treatment|"Standard conservative treatment consisting of:~* Physical therapy, including compression garment and exercise program~* Self-care program~* Individual counseling from a clinical dietician Additional lymphedema treatment consisting of intermittent pneumatic compression (IPC)"
62719758|NCT02487966|EXPERIMENTAL|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
62719759|NCT02487966|EXPERIMENTAL|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
62165679|NCT04121949|EXPERIMENTAL|Intervention group|"The intervention group will undergo a modified diagnostic pathway where a CAD-score \<30 rules out stable CAD in the group of patients having a DF-score \<15% and a CAD-score ≤20 rules out stable CAD in the group of patients having a DF-score in the range 15-85%, and thus not tested with NIT. Otherwise NIT is performed.~As per January 2020 the protocol was updated according to the 2019 ESC Guidelines on Chronic Coronary Syndrome:~The intervention group will undergo a modified diagnostic pathway where a CAD-score ≤20 rules out stable CAD. If CAD-score \>20 NIT is performed."
62165680|NCT03550014|ACTIVE_COMPARATOR|Low Back Only|Participants randomized to the Low Back Only arm will receive physical therapy as directed by the treating physical therapist targeting the lower back.
62165681|NCT03550014|ACTIVE_COMPARATOR|Low Back+Hip|Participants randomized to the Low Back+Hip arm will receive physical therapy as directed by the treating physical therapist targeting the lower back. In addition to that treatment, participants will received hands-on and exercise physical therapy interventions directed at the hip(s).
62165682|NCT05360706||CSL220|AAV5 containing a codon-optimized human factor IX gene
62165683|NCT02395588||Guideline based care|"Prior to discharge. Survey data will include descriptive characteristics, depression, heart failure knowledge. After patient education is complete prior to discharge patients will complete a readiness for discharge scale and heart failure self-care survey.~Phone call 48 hours after discharge. Discharge instructions will be reinforced.~Phone call 7 days after discharge. Survey data will include self management, complications, and satisfaction care.~Secondary data 30 days post discharge. The hospital electronic medical record system will be queried to determine if the patient has been readmitted within 30 days of discharge for heart failure or non-heart failure causes."
62165684|NCT03921164||Patients scheduled for a neuroradiology procedure|Interventional neuroradiology procedure under general anesthesia requiring a continuous monitoring of mean arterial pressure and cardiac output, including electrocardiogram, pulsated oxygen saturation, endtidal CO2, respiratory rate, tidal volume and monitoring of neuromuscular function. In addition, for all patients, data from trans-oesophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.
62165685|NCT01189136|SHAM_COMPARATOR|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
62165686|NCT01189136|EXPERIMENTAL|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
62165687|NCT01400217||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
62165688|NCT01400217||IPDI SP HFA-BDP|Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
62165689|NCT01400217||IPDA SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
62165690|NCT01400217||IPDA EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
62165691|NCT01400217||IPDS SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
62165692|NCT01400217||IPDS EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date
62165693|NCT03868930|EXPERIMENTAL|STEP-Home|The STEP-Home Arm involves a skills-based intervention focused on Emotional Regulation, Problem Solving, and Attention Training strategies.
62165694|NCT03868930|ACTIVE_COMPARATOR|PCGT|The Present Center Group Therapy (PCGT) Arm involves a nonspecific, supportive intervention, focused on identifying and discussing current life stressors.
62165695|NCT03856645|EXPERIMENTAL|OKG-0301 0.012% w/v|
62165696|NCT03856645|EXPERIMENTAL|OKG-0301 0.03% w/v|
62165697|NCT03856645|PLACEBO_COMPARATOR|Vehicle Control|
62165698|NCT00117650|ACTIVE_COMPARATOR|Low Dose|2 x 10\^9 vp (viral particles)
62165699|NCT00117650|ACTIVE_COMPARATOR|Middle Dose|2 x 10\^10 vp
62165700|NCT00117650|ACTIVE_COMPARATOR|High Dose|2 x 10\^11 vp
62165701|NCT00117650|PLACEBO_COMPARATOR|Placebo|(PBS + 10% sucrose + 0.02% polysorbate 80)
62165702|NCT04028128|EXPERIMENTAL|Cocoa group|The cocoa was provided in 5 g sachets. The intervention last 10 weeks. Cocoa was provided in a single daily dose of 5 g, which provided 425 mg of flavonoids
62165703|NCT04028128|PLACEBO_COMPARATOR|Placebo group|Maltodextrin (5 g) was supplied as placebo in sachets identical to those provided for cocoa.
62165704|NCT00714688|EXPERIMENTAL|001|prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
62165705|NCT00714688|EXPERIMENTAL|002|prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
62165706|NCT00714688|PLACEBO_COMPARATOR|003|Placebo 2xplacebo once daily for 13 weeks
62165707|NCT02247141|EXPERIMENTAL|Subgam®|
62545590|NCT05284266|EXPERIMENTAL|Surgical group: Liposuction|Early liposuction, 6-9 months after inclusion in study.
62165708|NCT01174147||Hospital Candida Cases|People who developed a positive blood culture for Candida while hospitalized
62165709|NCT04011995|EXPERIMENTAL|Intermittent caloric restriction|
62165710|NCT04011995|ACTIVE_COMPARATOR|Low carbohydrate diet|
62165711|NCT03878147|OTHER|HIV infected|HIV infected children
62165712|NCT03878147|OTHER|HIV exposed uninfected|HIV exposed, uninfected children
62165713|NCT03878147|ACTIVE_COMPARATOR|HIV unexposed uninfected|HIV unexposed uninfected children (community controls)
62165714|NCT06647173||Blued App|A three-month run-in period with the standard of care followed by the Blued+ intervention with participants for 12 months.
62545591|NCT05284266|ACTIVE_COMPARATOR|Surgical group: Control|Late liposuction, 18-21 months after inclusion. This group functions as a control group for 1 year before enrolment in the Liposuction group.
62719760|NCT02487966|EXPERIMENTAL|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
62545592|NCT02401997|ACTIVE_COMPARATOR|sexual abstinence period group I|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group I male partners have sexual abstinence period of 2 days or less.
62545593|NCT02401997|ACTIVE_COMPARATOR|sexual abstinence period group II|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of 2 to 4 days.
62545594|NCT02401997|ACTIVE_COMPARATOR|sexual abstinence period group III|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of more than 4 days
62545595|NCT06359912|EXPERIMENTAL|Treatment (clinical standard treatment, EPCs)|Patients receive clinical standard treatment and EPCs IV with a single dose
62545596|NCT06359912|OTHER|clinical standard treatment|Patients receive clinical standard treatment
62545597|NCT03456388|EXPERIMENTAL|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts . Each cohort will be administered in different dose once for 7 days.
62545598|NCT03456388|ACTIVE_COMPARATOR|Placebo Enteric-coated Tablets|There will be 7 ascending cohorts. placebo enteric-coate tablets to mimic Ammoxetine Hydrochloride Enteric-coated tablets.
62545599|NCT01711515|EXPERIMENTAL|Treatment (cisplatin, radiation therapy, and ipilimumab)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36, undergo extended beam radiation therapy 5 days a week for 6 weeks, and then undergo intracavitary brachytherapy for approximately 2 weeks. Within 2 weeks, patients receive ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks.
62545600|NCT05092984|EXPERIMENTAL|Spironolactone|
62545601|NCT05092984|PLACEBO_COMPARATOR|Placebo|
62545602|NCT03447743|OTHER|XR-NTX services as usual|Participants will receive on-going XR-NTX injections in a local community clinic
62545603|NCT01785277||SCIM scores for patients with SCI|All patients with SCI included in the study
62545604|NCT06550427||aggressive B cell lymphoma|Pathology proven aggressive B-cell lymphoma
62545605|NCT02944773|EXPERIMENTAL|facilitated tucking device (FTD)|20 infants use a FTD in the procedure of daily weight
62545606|NCT02944773|NO_INTERVENTION|without FTD|20 infants use not a FTD in the procedure of daily weight
62545607|NCT06416956||Preterm infant|Preterm infants receiving caffeine (prescribed clinically) will be studied
62545608|NCT01654003|ACTIVE_COMPARATOR|CONTROL|"In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
62545609|NCT01654003|ACTIVE_COMPARATOR|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
62545610|NCT00559806|EXPERIMENTAL|1|9 healthy elderly males
62545611|NCT00559806|EXPERIMENTAL|2|11 healthy young males
62545612|NCT00288730|EXPERIMENTAL|001|nesiritide
62545613|NCT06200051||High-risk group|
62719761|NCT02487966|SHAM_COMPARATOR|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
62719762|NCT06036199|EXPERIMENTAL|Focused Ultrasound Pallidotomy|Pediatric and young adult patients between ages of 8 and 22 years with pharmaco-resistant secondary dystonia due to dyskinetic cerebral palsy who have Focused Ultrasound Pallidotomy
62719763|NCT05291754|OTHER|Cranioplasty PEEK|
62545614|NCT06200051||Moderate-risk group|
62545615|NCT06200051||Low-risk group|
62545616|NCT01000948|EXPERIMENTAL|ZD4054|The study had only one arm: intervention
62545617|NCT03718650|EXPERIMENTAL|Scans, Surgical Resection and Assessment|Pre-surgery scans, surgical resection and post-surgery pathological assessment. All patients will receive standard of care imaging and blood tests. If suitable, non-standard of care abdominal MRI imaging will be done. 16-24 hours prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 pimonidazole (HydroxyProbe).
62545618|NCT00314951|EXPERIMENTAL|fidaxomicin|Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours \[q12h\] regimen) with intermittent matching placebo to fidaxomicin
62545619|NCT00314951|ACTIVE_COMPARATOR|Vancomycin|Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours \[q6h\] regimen).
62545620|NCT00153972|ACTIVE_COMPARATOR|Levodopa|Levodopa 300 mg per day orally.
62545621|NCT00153972|ACTIVE_COMPARATOR|Cabergoline|Cabergoline 3 mg per day orally.
62545622|NCT01356212|EXPERIMENTAL|Regimen A: Ketorolac tromethamine (Gentle Sniff - Upright)|Gentle sniff-inhalation with the volunteer upright for dosing and imaging
62545623|NCT01356212|EXPERIMENTAL|Regimen B: Ketorolac tromethamine (Vigorous Sniff - Upright)|Vigorous sniff-inhalation with the volunteer upright for dosing and imaging
62545624|NCT01356212|EXPERIMENTAL|Regimen C: Ketorolac tromethamine (Gentle Sniff - Semi-supine)|Gentle sniff-inhalation with the volunteer semi-supine for dosing and imaging
62545625|NCT06006429|EXPERIMENTAL|Patients|
62545626|NCT05024357|EXPERIMENTAL|Dasatinib for 1 year|After the allo-HSCT treatment, the patients in this group will continue to take dasatinib orally for 1 year.
62719764|NCT01041430|ACTIVE_COMPARATOR|Day Surgery Group|discharge planned on day of surgery, inguinal hernia repair
62719765|NCT01041430|ACTIVE_COMPARATOR|Inpatient Group|overnight admission at the hospital, inguinal hernia repair
62719766|NCT04645173||CanGaroo Envelope|Participants who received a CanGaroo envelope during CIED implantation
62545627|NCT05024357|EXPERIMENTAL|Dasatinib for 6 months|After the allo-HSCT treatment, the patients in this group will receive dasatinib for 6 months.
62545628|NCT04302714|ACTIVE_COMPARATOR|cervical injection|Fluorescent SLN Imaging With Indocyanine Green (ICG), using near-infrared fluorescence imaging, will be used as a dye for SLN mapping. Injections will be performed intraoperative. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room, and 4 mL is injected directly into the cervix. This solution was injected intracervically at 3 and 9 o'clock positions, both submucosally and deep into the cervical stroma. A spinal needle 18-gauce is used to inject the ICG. The 4 mL can be divided into 4 separate injections (1 mL each). The ICG should be injected slowly, at a rate of 5 to 10 seconds per quadrant.
62545629|NCT04302714|EXPERIMENTAL|hysteroscopic injection|hysteroscopy is performed using an operative hysteroscope. Uterine distension is obtained by means of saline solution. Usually, the fluid bag is placed 50 cm above the patient's plane so that the intracavitary pressure does not exceed 40 mm Hg. After visualization of uterine cavity a 22-gauce, 40-mm needle was introduced into the operative port and IGC is injected peritumorally. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room. The injection is performed subendometrially around the lesion, or, if the uterine cavity was totally involved by disease, at 3, 6, 9, and 12 o'clock . The depth of needle placement is modulated by visualizing endometrial elevation during injection.
62545630|NCT04201626|EXPERIMENTAL|ERAS|
62545631|NCT04201626|NO_INTERVENTION|Control|
62545632|NCT03293316|SHAM_COMPARATOR|Sham Transcranial Random Noise Stimulation|The sham tRNS condition involves 30 seconds of 1.5 mA tRNS, with a ramping period of 30 seconds at the onset and offset. This procedure ensures that, in both the Active and Sham conditions, participants experience the sensations associated with the onset of transcranial electrical stimulation (e.g., tingling sensation)
62545633|NCT03293316|EXPERIMENTAL|1mA Transcranial Random Noise Stimulation|The 1mA tRNS condition consists of 1 mA peak-to-peak (-.5 mA to .5 mA) high frequency noise (100-500 Hz), with amplitude values that are normally distributed and have a mean of zero. The stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
62545634|NCT03293316|EXPERIMENTAL|2mA Transcranial Random Noise Stimulation|The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
62545635|NCT02090166|OTHER|lung cancer diagnosis|"4 arms will be included in the study:~The groups sample size is as follows:~Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects~A blood test will be taken from each patient."
62545636|NCT04848727||Atelectasis or Pneumothorax|Infants with asymmetric lung disease (i.e. atelectasis or pneumothorax) confirmed by chest radiograph
62545637|NCT02623985|EXPERIMENTAL|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia which is rapid test.
62545638|NCT02623985|EXPERIMENTAL|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue which is rapid test.
62545639|NCT02623985|EXPERIMENTAL|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture which is gold standard.
62545640|NCT05403086|EXPERIMENTAL|Psilocybin|A single moderate-to-high dose of oral psilocybin, plus 4-5 sessions of a brief, existential psychotherapy.
62545641|NCT05403086|ACTIVE_COMPARATOR|Ketamine|A single low-to-moderate dose of oral liquid ketamine, plus 4-5 sessions of a brief, existential psychotherapy.
62545642|NCT01700231||Liver resection ,Liver Dysfunction|100 patients will be monitored perioperatively, in a subset of 40 patients hepatic venous pressure gradient will be monitored
62545643|NCT01739127||Aripiprazole|Participants receiving treatment with at least 10mg aripiprazole per day, as prescribed to them by their psychiatrists.
62545644|NCT01739127||Risperidone/Quetiapine|Participants receiving treatment with either risperidone or quetiapine, as prescribed to them by their psychiatrists.
62545645|NCT01739127||Control|Healthy participants who are not taking any antipsychotic medications.
62545646|NCT04797221||Veteran study group|The investigators will recruit approximately 20 Veterans who were identified as having elevated suicide risk while being treated in a VA Emergency Department.
62545647|NCT06501430|EXPERIMENTAL|Autogenic Inhibition|Group 1 will receive Autogenic inhibition with conventional treatment. Autogenic inhibition will be applied to the muscles of the anterior tibial compartment, including Tibialis anterior, extensor hallucis longus, extensor digitorum longus (Perform Dorsi-Flexion), Lateral Tibial Muscles (Peronei), and posterior tibial muscles including, gastrocnemius, soleus and plantaris (Perform Plantarflexion).
62545648|NCT06501430|EXPERIMENTAL|Reciprocal Relaxation|Group 2 will receive reciprocal inhibition with conventional treatment. Reciprocal inhibition will be applied to the muscles of the anterior tibial compartment, including Tibialis anterior, extensor hallucis longus, extensor digitorum longus (Perform Dorsi-Flexion), Lateral Tibial Muscles (Peronei), and posterior tibial muscles including, gastrocnemius, soleus and plantaris (Perform Plantarflexion).
62545649|NCT06469502|EXPERIMENTAL|Group 1-Stretching Group|Exercise program consisting of supervised stretching exercises
62545650|NCT06469502|EXPERIMENTAL|Group 2-Strengthening Group|Exercise program consisting of supervised strengthening exercises
62719767|NCT04645173||TYRX Envelope|Participants who received a TYRX envelope during CIED implantation
62719768|NCT04645173||No Envelope|Participants who did not receive an envelope during CIED implantation
62545651|NCT02583490|EXPERIMENTAL|Low Pulse Amplitude ECT (LAP)|Right Unilateral LAP ECT
62545652|NCT02583490|ACTIVE_COMPARATOR|standard Right Unilateral ECT|standard Right Unilateral ECT
62545653|NCT03912545||Trauma patients|Subjects experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
62719769|NCT00527618|ACTIVE_COMPARATOR|Standard-dose acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
62719770|NCT00527618|EXPERIMENTAL|High-dose valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
62719771|NCT02639247|EXPERIMENTAL|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
62719772|NCT02639247|EXPERIMENTAL|SOF/VEL|SOF/VEL for 12 weeks
62545654|NCT03912545||Obstetric hemorrhage patients|Subjects experiencing obstetric hemorrhage such that viscoelastic testing is performed as standard of care is performed to assess coagulopathy.
62545655|NCT02637531|EXPERIMENTAL|Part A/B: IPI-549 Dose Escalation|Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
62545656|NCT02637531|EXPERIMENTAL|Part C: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545657|NCT02637531|EXPERIMENTAL|Part D: IPI-549 Monotherapy|Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.
62545658|NCT02637531|EXPERIMENTAL|Part D Annex: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545659|NCT02637531|EXPERIMENTAL|Part E: NSCLC: IPI-549 and nivolumab|Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545660|NCT02637531|EXPERIMENTAL|Part E: Melanoma: IPI-549 and nivolumab|Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545661|NCT02637531|EXPERIMENTAL|Part E: SCCHN: IPI-549 and nivolumab|Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545662|NCT02637531|EXPERIMENTAL|Part F: TNBC: IPI-549 and nivolumab|Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545663|NCT02637531|EXPERIMENTAL|Part G: ACC: IPI-549 and nivolumab|Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545664|NCT02637531|EXPERIMENTAL|Part G: Mesothelioma: IPI-549 and nivolumab|Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545665|NCT02637531|EXPERIMENTAL|Part H: High-circulating MDSCs: IPI-549 and nivolumab|Participants with high-circulating MDSCs receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
62545666|NCT02487303|ACTIVE_COMPARATOR|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
62545667|NCT02487303|ACTIVE_COMPARATOR|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
62545668|NCT02487303|NO_INTERVENTION|No acetaminophen|(group 3) no acetaminophen
62545669|NCT06222073||Postmenopausal + Hot Flush (P+HF)|Postmenopausal women who regularly experience hot flushes.
62545670|NCT06222073||Postmenopausal + Hot Flush (P-HF)|Postmenopausal women who do not experience hot flushes.
62545671|NCT06222073||Premenopausal|Premenopausal women who experience regular menstruation.
62545672|NCT05440890|ACTIVE_COMPARATOR|Control group|Standard protocol rehabilitation programme for an anterior cruciate ligament repair based on VAN MELICK N, et al 2016.
62545673|NCT05440890|EXPERIMENTAL|Cross-education group|"Standard protocol rehabilitation programme for an anterior cruciate ligament repair based on VAN MELICK N, et al 2016.~Additionally a contralateral lower limb strength training."
62545674|NCT05014841|EXPERIMENTAL|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 20-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
62545675|NCT03782051|ACTIVE_COMPARATOR|Phacovisco group|group had combined phacoemulsification and viscocanalostomy
62545676|NCT03782051|ACTIVE_COMPARATOR|OloPhacovisco group|group had combined phacoemulsification and viscocanalostomy and Ologen
62545677|NCT05195801||Group with local anesthesia|The group that did not apply general anesthesia
62545678|NCT05195801||Group with Sevoflurane|The Sevoflurane used for maintenance of general anesthesia
62545679|NCT05195801||Group with Propofol|The Propofol (IV) used for maintenance of general anesthesia
62545680|NCT06172634|EXPERIMENTAL|DC + ICI|
62545681|NCT04868500|EXPERIMENTAL|Massachusetts General Hospital (MGH) Participants|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
62545682|NCT04868500|EXPERIMENTAL|Massachusetts General Hospital (MGH) Clinical Site Staff|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
62545683|NCT03203681|OTHER|Natesto|Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.
62545684|NCT03545893|ACTIVE_COMPARATOR|Ibuprofen|
62545685|NCT03545893|ACTIVE_COMPARATOR|Ibuprofen + Oxycodone|
62545686|NCT02914353|EXPERIMENTAL|Experimental - EP-7041|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.01 mg/kg to 1.0 mg/kg~Multiple Ascending Dose: 0.01 mg/kg/h - 5 x 24 h continuous infusion up to 0.6 mg/kg/h - 5 x 24 h continuous infusion"
62545687|NCT02914353|PLACEBO_COMPARATOR|Placebo - Sterile Saline|"Single Ascending Dose: Single IV dose for each cohort;~Multiple Ascending Dose: 5 x 24 h continuous infusion for each cohort"
62545688|NCT03885583|ACTIVE_COMPARATOR|thoracic epidural group|patients in this group will receive ultrasound guided thoracic epidural block preoperatively for pain management, continuous infusion of 0.5% bupivacaine through epidural catheter during operation and early post-operative period
62545689|NCT03885583|ACTIVE_COMPARATOR|paravertebral group|patients in this group will receive ultrasound guided pararvertebral block preoperatively for pain management, continuous infusion of paravertebral bupivacaine 0.5% through paravetebral catheter during operation and early post-operative period
62545690|NCT06323148|PLACEBO_COMPARATOR|ct-DNA-positive patients receiving no adjuvant osimertinib|ct-DNA-positive patients receiving no adjuvant osimertinib
62545691|NCT06323148|EXPERIMENTAL|ct-DNA-positive patients receiving adjuvant osimertinib|ct-DNA-positive patients receiving adjuvant osimertinib
62545692|NCT00582049||1|Cases: retinoblastoma patients
62737443|NCT02565758|EXPERIMENTAL|Arm A3 (ABBV-085)|ABBV-085 will be administered at every cycle (28-day cycles).
62545693|NCT00582049||2|Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).
62545694|NCT03364946||High Nasal Flow Therapy|Every patient in the ICU that requires High Nasal Flow Therapy
62545695|NCT02274506|EXPERIMENTAL|T-Cell Administration|"Cyclophosphamide 60 mg/kg by vein for 2 consecutive days, followed by Fludarabine at 25 mg/m2/day by vein for 5 consecutive days. Fludarabine dose calculated per adjusted ideal body weight.~T-cell product divided into 2 portions. Up to 25% of the genetically modified cells given on first day, with plan to infuse up to 75% of the remaining T-cell dose no sooner than 24 hours after completion of first portion. Second portion should not be given later than 72 hours after first portion. First group of 3 participants receive lowest dose of T-cells. Each new group receive a higher dose of T-cells than the group before it, if no intolerable side effects were seen. Up to 6 dose levels of T-cells will be tested."
62545696|NCT04913012|EXPERIMENTAL|Aerobic training booster group|Will receive 12 weeks of aerobic training followed by booster sessions + standard care in the 40 follow up period
62545697|NCT04913012|ACTIVE_COMPARATOR|Aerobic training control group|Will receive 12 weeks of aerobic training followed by standard care in the 40 follow up period
62545698|NCT04913012|EXPERIMENTAL|Resistance training booster group|Will receive 12 weeks of resistance training training followed by booster sessions + standard care in the 40 follow up period
62545699|NCT04913012|ACTIVE_COMPARATOR|Resistance training control group|Will receive 12 weeks of resistance training followed by standard care in the 40 follow up period
62545700|NCT04913012|NO_INTERVENTION|Control group|Will receive standard care throughout the study
62545701|NCT02715570|EXPERIMENTAL|Single dose - healthy volunteers|
62545702|NCT02715570|EXPERIMENTAL|Repeat dose - healthy volunteers|
62545703|NCT02715570|EXPERIMENTAL|Single dose - asthmatic patients|
62545704|NCT04807400|ACTIVE_COMPARATOR|Control+ BS|Participants continued to receive their background lipid lowering therapy plus behavioural support (BS).
62719773|NCT05018494|EXPERIMENTAL|Group A|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
62165715|NCT05707689|EXPERIMENTAL|Gaming|Gaming intervention with entertainment video games will be run in small groups (6-10 players) closely monitored by trained gaming facilitators. Pre-scheduled gaming sessions, about 60 minutes each, will be run twice a week over 10 weeks (totally 20 hours).
62165716|NCT05707689|NO_INTERVENTION|Treatment as usual (TAU)|Participants will join usual practices as planned in community services. No specific activities will be organized to them by the research team.
62545705|NCT04807400|EXPERIMENTAL|Inclisiran|Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).
62545706|NCT04807400|EXPERIMENTAL|Inclisiran + BS|Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.
62545707|NCT03741400|EXPERIMENTAL|Standard Occupational Therapy + Smart Glove|Subjects randomized to this arm will be expected to use the Neofect Rapael Smart Glove for a minimum of 20-30 minutes per day, 5 days per week, in addition to prescribed occupational therapy.
62545708|NCT03741400|NO_INTERVENTION|Standard Occupational Therapy|Subjects in the control arm will undergo standard of care occupational therapy as prescribed by their care team.
62165717|NCT05384522||Parkinson's Disease subjects|Subjects with Parkinson Disease aged 65 years or more at Hoehn and Yahr stage ≤3
62165718|NCT06611657|EXPERIMENTAL|Anlotinib hydrochloride|Subjects received antirotinib hydrochloride capsules, 1 capsule (12mg) once a day.
62165719|NCT00702520||Corifollitropin alpha 100 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily subcutaneous (SC) injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous luteinizing hormone (LH) and follicle stimulating hormone (FSH) was confirmed by estradiol (E2) and progesterone (P) measurements, a single dose of corifollitropin alpha 100 μg was administered in participants weighing \<= 60 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recombinant follicle stimulating hormone (recFSH) injections (maximally 200 IU) up to and including the day of administration of human chorionic gonadotprophin (hCG). No study medications were administered in the present P05783 study (38834, NCT00702520).
62545709|NCT00633243|EXPERIMENTAL|Modified Directly Observed Therapy (mDOT)|Hepatitis C Virus (HCV) Treatment in Modified Directly Observed Therapy (mDOT) in Methadone Maintenance Treatment (MMT)
62545710|NCT00633243|ACTIVE_COMPARATOR|Self-Administered Therapy at Liver Specialty Clinic (SAT)|Hepatitis C virus (HCV) at a liver specialty clinic as self-administered therapy
62545711|NCT06176651|EXPERIMENTAL|Experimental Arm|This is a single arm open label study with no randomization or control group. All participants will receive the Miebo eye drop for use while enrolled in the study.
62545712|NCT06353269|EXPERIMENTAL|Estrogen cream|Participants in this arm will receive the vaginal estrogen cream (Estrace 0.01%) for treatment. Participants will apply 0.5gm twice per week for the duration of the study.
62545713|NCT06353269|EXPERIMENTAL|Estrogen tablet|Participants in this arm will receive the vaginal estrogen tablets (Vagifem) for treatment. Participants will place one tablet (10 mcg) into the vagina twice per week for the duration of the study.
62719774|NCT05018494|ACTIVE_COMPARATOR|Group B|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
62719775|NCT02452073||CRE group|patients with chronic radiation enteritis
62545714|NCT06353269|EXPERIMENTAL|Estrogen drug-eluting ring|Participants in this arm will receive the vaginal estrogen drug-eluting ring (Estring) for treatment. Participants will have the ring placed by a provider at their clinical visit. The ring will be exchanged every 12 weeks.
62545715|NCT00486031|OTHER|balsalazide disodium tablets,3.3 g BID,|
62719776|NCT02452073||malignancy group|patients with some kinds of malignant tumors but had not previously received radiotherapy
62719777|NCT02452073||control group|age-matched healthy volunteers
62719778|NCT00842387||1|Patients with symptoms suggestive of GERD, managed according to a new structured and implemented pathway
62719779|NCT00842387||2|Patients with symptoms suggestive of GERD, managed according to usual clinical practice.
62719780|NCT00327912|EXPERIMENTAL|1|Laparoscopic Biliopancreatic diversion with Duodenal switch
62545716|NCT01632280|ACTIVE_COMPARATOR|Active tDCS|In this arm, participants will receive active tDCS (2mA, 20 min per session). The anode electrode will be placed over the right inferior frontal gyrus, defined as F8 (10-20 EEG system), with the cathode electrode placed over the contralateral supraorbital area, above the left eyebrow. During each session they will also perform a computerized task designed to engage the inhibitory control circuit when confronted with food stimuli.
62545717|NCT01632280|SHAM_COMPARATOR|Sham tDCS|Participants will receive sham tDCS sessions with the same duration and electrode montage as in the real tDCS arm. In this case, current will be applied for 30 s only according to standard procedures, and participants will perform a control task where they will observe and provide responses for the same food and non-food pictures as in the active group task, but without requirement of inhibitory control for performance.
62545718|NCT04311671|EXPERIMENTAL|Moxidectin|In onchocerciasis endemic areas: Moxidectin 8 mg per oral on Day 0
62545719|NCT04311671|ACTIVE_COMPARATOR|Ivermectin|In onchocerciasis endemic areas: Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0
62545720|NCT04311671|EXPERIMENTAL|Moxidectin with concomitant Albendazole|In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Moxidectin 8 mg per oral with concomitant albendazole 400 mg per oral on Day 0
62545721|NCT04311671|ACTIVE_COMPARATOR|Ivermectin with concomitant Albendazole|In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Ivermectin treatment with approximately 150 microgram/kilogram (μg/kg) per oral determined based on height with concomitant albendazole 400 mg per oral on Day 0
62545722|NCT03089710|EXPERIMENTAL|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.~Applied colloid: hydroxyethyl starch"
62545723|NCT05830344|PLACEBO_COMPARATOR|Placebo|Placebo treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, without any emission of therapeutic dose. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
62545724|NCT05830344|EXPERIMENTAL|Active|Active treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, with a dose of 8.02 J per site. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments.
62545725|NCT02132793|ACTIVE_COMPARATOR|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
62545726|NCT02132793|EXPERIMENTAL|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
62545727|NCT03448887|EXPERIMENTAL|Study group|Extended HD with MCO dialyzer
62545728|NCT03448887|ACTIVE_COMPARATOR|Control group|Online hemodiafiltration
62545729|NCT02012426|EXPERIMENTAL|Intervention Group|Participants enrolled in commercial weight management program
62545730|NCT02012426|ACTIVE_COMPARATOR|Control group|Participants enrolled in standard care weight management provision
62719781|NCT00327912|ACTIVE_COMPARATOR|2|Laparoscopic Roux-en-Y Gastric Bypass
61976581|NCT05030974|ACTIVE_COMPARATOR|stratum A1 - one extra dose of mRNA-1273|Patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m)
62545731|NCT01935518|EXPERIMENTAL|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
62545732|NCT06412679|ACTIVE_COMPARATOR|In-Person Life Skills Education (LSE) Peer Support Groups|Participants will receive a culturally-adapted LSE intervention delivered through weekly in-person peer support group sessions for 12 weeks. The LSE curriculum covers topics such as stress management, communication skills, problem-solving, emotion regulation, health and hygiene, social skills, gender norms and safety, education and livelihoods, and community mobilization. Each peer support group will consist of 10-12 participants, separated by gender and age bands (12-17 and 18-24 for youth, 18+ for women), and will meet weekly for approximately 2 hours in a private, safe space within the IDP camp. Sessions will be co-facilitated by a trained IDP peer leader and a local mental health provider, following a structured format with interactive activities, discussions, and skill practice.
62545733|NCT06412679|ACTIVE_COMPARATOR|WhatsApp-Enabled LSE Virtual Peer Support Groups|Participants will receive the same culturally-adapted LSE curriculum as those in the In-person arm, but delivered through WhatsApp for 12 weeks. Participants will be added to a moderated WhatsApp group chat with other IDP youth or women in their camp, where they will receive three LSE-related messages per week. These messages will include brief psychoeducational content, practice exercises, reflection prompts, and reminders to engage with the virtual support group. The WhatsApp group will provide a platform for participants to discuss the LSE topics, share experiences and coping strategies, and provide emotional support to one another, with trained IDP peer facilitators moderating the chats to ensure a safe and supportive environment. Participants will also receive regular push notifications with motivational messages, links to further resources, and reminders to practice the LSE skills.
62545734|NCT02862730|EXPERIMENTAL|Predictive Low Glucose Suspend Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient. The predictive low glucose suspend system will run through the artificial pancreas controller in predictive low glucose suspend mode and utilize the patient's optimized basal rates, correction factor, and carb ratio, but it will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
62719782|NCT02267434|EXPERIMENTAL|Low dose AFFITOPE® PD03A + Adjuvant|"4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
62545735|NCT02862730|EXPERIMENTAL|Dual Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in dual hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
62545736|NCT02862730|EXPERIMENTAL|Single Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
62545737|NCT02862730|ACTIVE_COMPARATOR|Sensor Augmented Pump Therapy arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient with subject's insulin pump and glucose sensor, if he/she typically uses one. Subjects will still wear a heart rate monitor uploading to a smart phone.
62545738|NCT04005352|EXPERIMENTAL|Brolucizumab 6 mg|3 x 4-week injections and one 8-week Intra-vitreal injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62.
62545739|NCT04005352|ACTIVE_COMPARATOR|Aflibercept 2 mg|3 x 4-week injections and one 8-week Intra-vitreal injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62
62545740|NCT05659212|ACTIVE_COMPARATOR|Group D|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
62545741|NCT05659212|ACTIVE_COMPARATOR|Group M|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
62545742|NCT05659212|PLACEBO_COMPARATOR|Group L|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
62545743|NCT06453369|EXPERIMENTAL|root coverage using novel Y shaped Tunnel with Connective tissue graft|Sulcular incision will be performed using 15c blade . Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. Micro periosteal elevator will be used to elevate the buccal aspect of both mesial and distal papillae of the affected tooth. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG will be inserted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.
62545744|NCT06453369|ACTIVE_COMPARATOR|root coverage using MCAT with Connective tissue graft|The tunnel will be prepared with a full-thickness incision up to MGJ and as a split-thickness beyond MGJ using tunneling instruments to obtain a tension-free tunnel, allowing the insertion of the CTG, a delicate incision is performed at the level of interdental papillae and raised without detaching the tip of the papillae. The papillary regions will be detached in their buccal aspects. The adjacent papillae of the neighboring teeth will be involved in the preparation to ensure a coronal positioning of the flap. After planing, the graft will be inserted into the tunnel by a specific suture technique. The first suture will be inserted through the most distal recession part and the needle exits in the most medial part of the recession, second suture will be placed at the opposite side and the needle exits at the same medial recession. The buccal flap will be advanced coronally to cover CTG and secured with sling sutures. The donor CTG will stabilized to the underlying CT interproximally.
62545745|NCT01246310|EXPERIMENTAL|Inositol|
62545746|NCT01246310|PLACEBO_COMPARATOR|Placebo|
62545747|NCT03016975|EXPERIMENTAL|Randomized - Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
62545748|NCT03016975|ACTIVE_COMPARATOR|Randomized - Control|Guideline directed medical therapy (GDMT)
62545749|NCT03016975|EXPERIMENTAL|Roll-In - Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
62545750|NCT01577550|EXPERIMENTAL|i.v. BI 655066|A subject to receive a single i.v. dose of BI 655066
62545751|NCT01577550|PLACEBO_COMPARATOR|i.v. placebo|A subject to receive a single i.v. dose of placebo
62545752|NCT01577550|EXPERIMENTAL|s.c. BI 655066|A subject to receive a single s.c. dose of BI 655066
62545753|NCT01577550|PLACEBO_COMPARATOR|s.c. placebo|A subject to receive a single s.c. dose of placebo
62545754|NCT01944163|NO_INTERVENTION|Usual care|GP provide care as usual to their CLBP patients.
62719783|NCT02267434|EXPERIMENTAL|High dose AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
62545755|NCT01944163|OTHER|Referral arm|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
62545756|NCT06551818|EXPERIMENTAL|SesZen-Bio Low Dose 1 (350 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: capsule Frequency: One time daily after meal Rout of administration: Oral"
62719784|NCT02267434|PLACEBO_COMPARATOR|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
62719785|NCT03988426|EXPERIMENTAL|Octanorm|Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center \[during first training sessions and then for every 4th administration\] or at home by the patient or caregiver). The initial weekly dose was determined based on subjects' previous IVIG treatment.
62736222|NCT04320056|EXPERIMENTAL|Intervention group|"Usual care will be provide to patients concerning their medical management.~In the Intervention group, automated oxygen administration will be delivered with FreeO2"
62737659|NCT01127464|PLACEBO_COMPARATOR|Placebo|sterile saline
62737660|NCT01127464|EXPERIMENTAL|poly-ICLC alone|1.6 mg of poly-ICLC alone
62545757|NCT06551818|EXPERIMENTAL|SesZen-Bio Low Dose 1 (150 mg liposomal)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: capsule Frequency: One time daily after meal Rout of administration: Oral"
62545758|NCT06551818|EXPERIMENTAL|SesZen-Bio High Dose 1 (500 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: capsule Frequency: One time daily after meal Rout of administration: Oral"
62545759|NCT06551818|PLACEBO_COMPARATOR|Placebo|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: capsule Frequency: One time daily after meal Rout of administration: Oral"
62545760|NCT02404116|EXPERIMENTAL|Metacognitive Therapy|12 weeks of Metacognitive Therapy
62545761|NCT02404116|OTHER|Wait List Control|The Waiting list control will control for time and repeated assessments during an initial 12 week period
62545762|NCT04401215|OTHER|Technology Augmented Treatment group|Intervention Group
62545763|NCT04401215|NO_INTERVENTION|Control group|After the baseline visit the control arm participants will receive no additional follow-up beyond usual care until the 30 days' end. Surveys at the end of 30 days.
62545764|NCT06387524|EXPERIMENTAL|Interventional group|There will be only one group in the study. After application of Mc Connell taping, patients will perform eccentric exercises taught by the therapist for 6 weeks. Mentioned below are detailed protocols for the treatment of patellofemoral pain syndrome.
62545765|NCT02930759|EXPERIMENTAL|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
62545766|NCT01783886|EXPERIMENTAL|Intravitreal Aflibercept Injection 2Q4|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF \[vascular endothelial growth factor\] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
62545767|NCT01783886|EXPERIMENTAL|Intravitreal Aflibercept Injection 2Q8|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
62545768|NCT01783886|ACTIVE_COMPARATOR|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.
62545769|NCT03169231|EXPERIMENTAL|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
62545770|NCT03169231|EXPERIMENTAL|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
62545771|NCT03169231|EXPERIMENTAL|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
62545772|NCT03169231|EXPERIMENTAL|Study Group D|Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
62545773|NCT03169231|PLACEBO_COMPARATOR|Study Group E|Single peripheral IV infusion of placebo.
62545774|NCT01254383|ACTIVE_COMPARATOR|Treatment A|Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
62545775|NCT01254383|EXPERIMENTAL|Treatment B|Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
62545776|NCT01254383|EXPERIMENTAL|Treatment C|Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.
62545777|NCT05044559|EXPERIMENTAL|Continuous Positive Air Way Group|"Day 1: Use of CPAP between 10 and 12 cmH2O according to tolerance for 20 minutes two time a day at first day of post surgery bed mobility chest physiotherapy ,active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise. and vital was record after exercise.~Day 2: Active ROM exercise progress of 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time was increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
62545778|NCT05044559|ACTIVE_COMPARATOR|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
62545779|NCT01675648|EXPERIMENTAL|Lofexidine & Diazepam Placebo|"Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm."
62545780|NCT01675648|ACTIVE_COMPARATOR|Diazepam & Lofexidine Placebo|"The initial dosage of Diazepam is 10 mg per day on Day 1\&2, the dosage will be increased to 15 mg per day on Day 3\&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6\&7, 2mg per day on Day 8\&9\&10.~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm."
62545781|NCT00925639|EXPERIMENTAL|Isoflavone|Patients will receive daily doses of 150 mg of concentrated extract of soy per os
62737661|NCT03419637|NO_INTERVENTION|Control - Standard of Care|The standard of care consists of in-clinic counseling, informational handouts, and access to patient medical records
62545782|NCT00925639|PLACEBO_COMPARATOR|Control|Patients will receive daily placebo pills
62545783|NCT00459043|ACTIVE_COMPARATOR|1|Docetaxel Alone
62545784|NCT00459043|ACTIVE_COMPARATOR|2|Docetaxel with ZD6474
62545785|NCT05990985|EXPERIMENTAL|RCMOP|RiTUXimab Injection+Cyclophosphamid+Mitoxantrone hydrochloride liposome injection+Vincristine+Prednisolone, 4 cycles of treatment
62545786|NCT05792111|EXPERIMENTAL|Group C|Group C; caudal epidural steroid injection (10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space).
62545787|NCT05792111|ACTIVE_COMPARATOR|Group CT|Group CT; trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
62738991|NCT02220153|EXPERIMENTAL|UCB7665 Intravenous 5|Single dose calculated based on body weight for 60 minutes intravenous infusion.
62545788|NCT03008174|EXPERIMENTAL|Intervention|"1. Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.~2. Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~3. Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
62545789|NCT03008174|NO_INTERVENTION|Control|"1. Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~2. Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
62545790|NCT01577771|ACTIVE_COMPARATOR|Child|1 dose of Prevnar13 at 2 to 4 years of age
62545791|NCT01577771|EXPERIMENTAL|Toddler 1 dose|Single dose of Prevnar13 at 12-15 months of age
62545792|NCT01577771|ACTIVE_COMPARATOR|Toddler 2 dose|2 doses of Prevnar13 2 months apart beginning at 12-15 months of age
62545793|NCT01577771|EXPERIMENTAL|Infants 2+1|Infants receiving Prevnar13 at 6 weeks, 14 weeks and 9 months. Note: This infant immunization schedule is used in many European countries and in South Africa and has been shown to be immunogenic and effective. However, few head-to-head comparisons of the 2+1 and 3+0 schedules have been conducted.
62719786|NCT06438198|EXPERIMENTAL|Mechanically ventilated adults|"Switch from controlled to assisted mechanical ventilation when PaO2/FiO2-ratio \> 200 mmHg.~Before switch (on controlled ventilation) participants will undergo an electrical impedance tomography (EIT) perfusion measurement as well as a photon-counting CT (PCCT) scan to assess lung perfusion and ventilation/perfusion mismatch. From 15 minutes before until 4 hours after switch and 30 minutes twice daily for 72 hours or until switch failure participants will be monitored continuously using EIT, esophageal pressure and gastric pressure."
62545794|NCT01577771|ACTIVE_COMPARATOR|Infants 3+0|Infants receiving Prevnar13 at 6, 10 and 14 weeks
62545795|NCT01065402|PLACEBO_COMPARATOR|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
62545796|NCT01065402|EXPERIMENTAL|PPB-R-203-Based Meal|"PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. RS intake is associated with several changes in metabolism which may confer some health benefits.~PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition."
62545797|NCT01635348|EXPERIMENTAL|motor skill gait exercise arm|motor skill gait exercise intervention: stepping and walking patterns, and speed interval treadmill-assisted walking to enhance timing and coordination in walking
62545798|NCT01635348|ACTIVE_COMPARATOR|aerobic gait exercise arm|aerobic gait exercise intervention: treadmill-assisted and overground walking exercise to enhance walking practice and improve endurance in walking
62545799|NCT01649986|ACTIVE_COMPARATOR|Non-pharmacologic intervention|Patients assigned by their own general practitioner to have non-pharmacologic intervention and prevention strategies will be given details on lifestyle approaches and dietary strategies
62545800|NCT01649986|ACTIVE_COMPARATOR|Nutraceuticals|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
62545801|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
62545802|NCT01611857|EXPERIMENTAL|Maximum Tolerated Dose|Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer.
62545803|NCT02676765|EXPERIMENTAL|sublingual allergen tablets|Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.
62545804|NCT02676765|PLACEBO_COMPARATOR|Placebo|Subjects will be administered placebo sublingual tablets
62545805|NCT01688557|EXPERIMENTAL|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus).
62545806|NCT01688557|ACTIVE_COMPARATOR|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
62545807|NCT01966250|EXPERIMENTAL|Electroacupuncture and Usual care|15 minutes of electroacupuncture and usual care. Usual care contains 15 minutes ICT(Interferential Current Therapy), 10 minutes hot pack or ice pack and education of patients.
62545808|NCT01966250|ACTIVE_COMPARATOR|usual care|15 minutes ICT, 10 minutes hot pack or ice pack and education of patients
62545809|NCT04170465|EXPERIMENTAL|Metformin group|Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
62545810|NCT04170465|ACTIVE_COMPARATOR|Control group|Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)
62719787|NCT03745768|EXPERIMENTAL|Active iTBS Treatment|Participants received Intermittent theta burst stimulation to the dorsolateral prefrontal cortex for 6 weeks
62719788|NCT03745768|SHAM_COMPARATOR|Sham Stimulation|Participants received Sham stimulation to the dorsolateral prefrontal cortex for 6 weeks.
62719789|NCT04403308|EXPERIMENTAL|ONO-7913 as a Single Agent|
62719790|NCT00654537|EXPERIMENTAL|1|Rosuvastatin
62719791|NCT00654537|ACTIVE_COMPARATOR|2|Atorvastatin
62719792|NCT00654537|ACTIVE_COMPARATOR|3|Pravastatin
62719793|NCT00654537|ACTIVE_COMPARATOR|4|Simvastatin
62719794|NCT03929666|EXPERIMENTAL|ZW25 + FP|ZW25 plus fluorouracil (5-FU) and cisplatin
62719795|NCT03929666|EXPERIMENTAL|ZW25 + mFOLFOX6|ZW25 plus 5-FU, leucovorin, and oxaliplatin
62719796|NCT03929666|EXPERIMENTAL|ZW25 + XELOX|ZW25 plus capecitabine and oxaliplatin
62719797|NCT03929666|EXPERIMENTAL|ZW25 + mFOLFOX6 with bevacizumab|ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab
62719798|NCT03929666|EXPERIMENTAL|ZW25 + CisGem|ZW25 plus cisplatin and gemcitabine
62719799|NCT04473612||Neuromuscular low physical status group|Patients diagnosed of Neuromuscular disease with low physical status
62719800|NCT04473612||Neuromuscular high physical status group|Patients diagnosed of Neuromuscular disease with high physical status
62545811|NCT02653833|EXPERIMENTAL|Healthy Controls (HC)|Healthy men currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. This is repeated at baseline and shortly after taking beetroot juice extract.
62545812|NCT02653833|EXPERIMENTAL|Becker Muscular Dystrophy (BMD)|"currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. Using a lower body negative pressure (LBNP) chamber, the subjects are tested for impaired exercise induced vasodilation to the skeletal muscle or functional sympatholysis. This is repeated at baseline and shortly after taking beetroot juice extract."
62545813|NCT03103516|EXPERIMENTAL|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
62545814|NCT03103516|EXPERIMENTAL|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
62545815|NCT03493256||type 2 neurological complications present|The group of patients diagnosed with postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
62545816|NCT03493256||type 2 neurological complications absent|The group of patients without neurological complications.
62545817|NCT05370469|EXPERIMENTAL|Cohort A|Subjects who, at enrollment, have been on a TKI for less than 4 weeks will be monitored with the Sensus smartphone application, Fitbit Sense, RX Cap, and paper surveys. Visits will be at: Screening, Baseline, 1 Week, 2 Weeks, 4 Weeks, 8 Weeks, 16 weeks, and 24 weeks.
62545818|NCT05370469|EXPERIMENTAL|Cohort B|Subjects who, at enrollment, have been on a TKI for 4 weeks or more will be monitored with the Sensus smartphone application, Fitbit Sense, RX Cap, and paper surveys. Visits will be at: Screening, Baseline, Week 1, and then every 8 weeks for 24 weeks.
62545819|NCT06257095|EXPERIMENTAL|Treatment|
62545820|NCT06257095|ACTIVE_COMPARATOR|Usual Care|
62545821|NCT02125864|EXPERIMENTAL|Aflibercept|There is only one arm. Plasma VEGF is investigated in the same patient before and after intravitreal Aflibercept injection.
62545822|NCT01632657|EXPERIMENTAL|Sumatriptan|Subcutaneous injection of sumatriptan (6 mg)
62545823|NCT01632657|PLACEBO_COMPARATOR|Placebo|Matching placebo (0.9% saline)
62545824|NCT04202055||Neuromyelitis optica with anti-MOG|
62545825|NCT04202055||Patients with Neuromyelitis optica with anti-AQP4|
62545826|NCT04202055||Seronegative patients with Neuromyelitis optica|
62545827|NCT04202055||Patients with recurrent-remitting multiple sclerosis|Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement
62545828|NCT04202055||Progressive multiple sclerosis patients|
62545829|NCT04202055||Symptomatic controls|
62545830|NCT05163392|EXPERIMENTAL|SilverD|"The SIlverD arm includes:~1. For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly.~2. For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly."
62545831|NCT05163392|ACTIVE_COMPARATOR|ControlD|"The ControlD arm includes:~1. For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours.~2. For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr."
62545832|NCT05297773|EXPERIMENTAL|Aerobic Training|Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform moderate-intensity cycling exercise.
62545833|NCT05297773|EXPERIMENTAL|Resistance training|Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform weight-machine strength exercises of the upper and lower body.
62545834|NCT05297773|ACTIVE_COMPARATOR|Control Group|One session per week of relaxation/stretching.
62545835|NCT00520117||negative pap-smear|
62545836|NCT00520117||positive pap-smear|
62545837|NCT03555643||transient ischemic attack (TIA)|Patients with transient ischemic attack
62545838|NCT03555643||transient neurological attack (TNA)|Patients with transient neurological attack
62545839|NCT05453097||Perioperative Myocardial Injury Occured|Patients with troponin elevation from the preoperative basal level do not meet the criteria for myocardial infarction according to the fourth universal myocardial infarction guideline, do not describe active anginal complaints, and underwent surgery in the operating room.
62545840|NCT05453097||Perioperative Myocardial Injury Not Occured|Patients without troponin elevation from the preoperative basal level, do not describe active anginal complaints, and underwent surgery in the operating room.
62545841|NCT06578143|PLACEBO_COMPARATOR|Control|
62545842|NCT06578143|EXPERIMENTAL|Synbiotics|
62545843|NCT01661062|EXPERIMENTAL|Cone Beam CT|All patients will be included in the treatment arm of this study. For the purposes of this study patients will get CT scans every day for the length of their radiation therapy (in order to assess if CT every day provides additional information compared with CT scans performed less frequently). Although the exact amount of radiation patients get will be determined by their doctor, it is expected that they will get approximately 7 weeks, approximately 35 total cone beam CT scans.
62545844|NCT03190031|EXPERIMENTAL|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
62545845|NCT03190031|ACTIVE_COMPARATOR|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
62545846|NCT03765788|EXPERIMENTAL|Secukinumab|Participants received secukinumab at a dose of 300 milligrams (mg) as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
62719801|NCT04473612||Control group|Healthy subjects
62719802|NCT01987466||Post cardiac arrest patient|
62719803|NCT01381770|EXPERIMENTAL|Platelet-derived repairing factors|
62545847|NCT03765788|PLACEBO_COMPARATOR|Placebo|Participants received placebo as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
62545848|NCT01510782|EXPERIMENTAL|BI 655064 subcutaneous|Escalating single dose as solution for subcutaneous injection
62545849|NCT01510782|PLACEBO_COMPARATOR|Placebo to BI 655064 subcutaneous|Escalation single dose as solution for subcutaneous injection (Placebo)
62545850|NCT01510782|EXPERIMENTAL|BI 655064 intravenous|Escalating single dose as solution for intravenous infusion
62545851|NCT01510782|PLACEBO_COMPARATOR|Placebo to BI 655064 intravenous|Escalating single dose as solution for intravenous infusion (Placebo)
62545852|NCT02694328|EXPERIMENTAL|ALKS 3831|Administered as a coated bilayer tablet
62545853|NCT02694328|ACTIVE_COMPARATOR|Olanzapine|Administered as a coated bilayer tablet
62545854|NCT01897805|EXPERIMENTAL|Heart-protecting Musk Pill|Patients will get standard treatment for coronary artery disease plus 2 Heart-protecting Musk Pills each time, three times a day by mouth for 24 months
62545855|NCT01897805|PLACEBO_COMPARATOR|Placebo|Patients will get standard treatment for coronary artery disease plus 2 placebo pills each time, three times a day by mouth for 24 months
62545856|NCT04252092|EXPERIMENTAL|Sensory Group|15 patients who will be applied 15 sessions of sensory training
62545857|NCT04252092|EXPERIMENTAL|Electrical Stimulation Group|15 patients who will be applied 15 sessions of electrical stimulation
62545858|NCT02713412|EXPERIMENTAL|Glucose|75g glucose and 150mg C13-acetate in 300ml water
62545859|NCT02713412|PLACEBO_COMPARATOR|Control|300ml water
62545860|NCT02695784|EXPERIMENTAL|Probiotic continuation|This Group will Continue probiotics Beyond 34 weeks corrected Gestational agent standard practice
62545861|NCT02695784|NO_INTERVENTION|Standard treatment Group|This group will continue current standard practice of stopping probiotics at 34 weeks corrected gestational age
62545862|NCT05114278|EXPERIMENTAL|Oral Iron + IV Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year.
62545863|NCT05114278|ACTIVE_COMPARATOR|Oral Iron only|Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
62545864|NCT05755971|EXPERIMENTAL|study group|Receive combination taping in addition to conventional physiotherapy
62719804|NCT00976716|EXPERIMENTAL|Celecoxib|
62545865|NCT05755971|OTHER|control group|Receive conventional physiotherapy
62545866|NCT02003950|OTHER|Chocolate pre-restriction|
62545867|NCT02003950|OTHER|Chocolate Baseline|
62545868|NCT02003950|OTHER|Chocolate post-restriction|
62545869|NCT02003950|OTHER|Salty Snacks|
62545870|NCT02003950|OTHER|Sweet Non-Chocolate Snacks|
62545871|NCT02003950|OTHER|Dried Fruit|
62545872|NCT01359891||Cohort 1|"All patients \>18 years admitted to the University Hospital Graz, Austria, with positive blood cultures tested in the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz, or the Institute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, are screened for study inclusion. Patients eligible for the study have to have Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Klebsiella pneumoniae or medically relevant fungi / viral pathogens identified as causative pathogen.~The estimated total number of patients included in this first study cohort will be 500."
62545873|NCT01359891||Cohort 2|"All patients \>18 years admitted to the University Hospital Graz, Austria, will be screened for study inclusion if the attending emergency department physicians on the very first visit suspects bacteremia/fungemia/sepsis and consecutively orders blood cultures. Patients will be included in this second cohort if these initially taken blood culture turns positive (n=200) or stays negative (n=50) at the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz. As soon as the number of 50 is reached for the control group enrollment will be stopped for this group.~As soon as the proposed number of 250 patients is reached enrolment for this second cohort will be stopped. Patients enrolled in cohort 2 may also be consecutively enrolled in cohort 1."
62545874|NCT01359891||Validation Cohort|To verify the employed Presage™ST2 assay established in our study laboratory for its intended use, a total number of 70 left over plasma samples obtained from septic patients which have prior been tested for sST2 with the same assay at the Department of Laboratory Medicine, Barmherzige Brueder Linz, Austria, will be retested. This cohort therefore serves as a validation cohort.
62545875|NCT04302038|EXPERIMENTAL|Potato protein|Participants will be provided with 25 g of potato protein twice per day in addition to a diet set at the recommended daily allowance. Total protein intake for this group will be 1.6 g/kg/day
62719805|NCT02784392|EXPERIMENTAL|Active|Ulimorelin
62719806|NCT02784392|ACTIVE_COMPARATOR|Comparator|Metoclopramide
62719807|NCT05367869|EXPERIMENTAL|Intraoperative Spraying Methylene Blue In Thyroidectomy|
62545876|NCT04302038|PLACEBO_COMPARATOR|Control group|This group will consume protein from food sources set at 0.8 /kg/day including 2 pudding placebo cups per day.
62545877|NCT04108624|EXPERIMENTAL|MRD2STOP ARM|
62545878|NCT04420494|EXPERIMENTAL|Patients treated with umbilical cord blood|
62545879|NCT04972357||Standard RYGB|
62545880|NCT04972357||Banded RYGB|
62545881|NCT04972357||Extended pouch RYGB|
62545882|NCT00696787|PLACEBO_COMPARATOR|Placebo|In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.
62545883|NCT00696787|EXPERIMENTAL|DVS SR|In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
62545884|NCT00696787|ACTIVE_COMPARATOR|Pregabalin|In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.
62545885|NCT02914860|EXPERIMENTAL|Volunteers|Healthy volunteers
62545886|NCT02914860|ACTIVE_COMPARATOR|PAF|Patients with paroxysmal atrial fibrillation
62719808|NCT00429754|OTHER|aprepitant|Aprepitant treatment
62545887|NCT02914860|ACTIVE_COMPARATOR|Pers AF|Patients with persistent atrial fibrillation
62545888|NCT02914860|ACTIVE_COMPARATOR|L-s Pers AF|Patients with long-standing persistent atrial fibrillation
62545889|NCT03414476|EXPERIMENTAL|ET group|Sampling : Hair follicles sampling on the scalp in women with Telogene Effluvium
62545890|NCT03414476|EXPERIMENTAL|Control group|Sampling: Hair follicles sampling on the scalp in women without Telogene Effluvium
62545891|NCT05434689|EXPERIMENTAL|Iberdomide, Daratumumab and Dexamethasone (Regimen A)|Iberdomide dosed according to cohort assignment days 1-21. Dexamethasone 40 mg oral or intravenously (20 mg for participants 70 or older) on days 1,8,15 and 22 Darartumumab and hyalurnonidase-fihj 1,800mg/30,000 units subcutaneously on days 1,8,15,22 (cycles 1,2) or on days 1,15 (cycles 3-6)
62545892|NCT05434689|EXPERIMENTAL|Iberdomide, Carfilzomib, Daratumumab and Dexamethasone (Regimen B)|Iberdomide dosed according to cohort assignment days 1-21. Dexamethasone 40 mg oral or intravenously (20 mg for participants 70 or older) on days 1,8,15 and 22 Darartumumab and hyalurnonidase-fihj 1,800mg/30,000 units subcutaneously on days 1,8,15,22 (cycles 1,2) or on days 1,15 (cycles 3-6) Carfilzomib dosed intravenously dosed according to cohort assignment on days 1, 8, 15 (Consistent with standard practice, the very first dose of carfilzomib (cycle 1 day 1) must be 20 mg/m\^2).
62545893|NCT06581783|NO_INTERVENTION|control|Normal endoscopic patients with out medication is required to compare with active groups.
62545894|NCT06581783|EXPERIMENTAL|simethicone plus NAC combination time interval greater than 30 minutes|Premixed medication (150mg) simethicone and 600mg nac with 100ml of water has to be given \>30minutes for 273 patients.
62545895|NCT06581783|EXPERIMENTAL|simethicone plus NAC 10 to 20 minutes|Premixed medication (150mg) simethicone and 600mg nac with 100ml of water has to be given 10-20 minutes time interval for 273 patients.
62545896|NCT06581783|EXPERIMENTAL|simethicone plus NAC 20 to 30 minutes|Premixed medication (150mg) simethicone and 600mg nac with 100ml of water has to be given 20-30minutes for 273 patients.
62545897|NCT01687972|ACTIVE_COMPARATOR|Sutures|
62545898|NCT01687972|ACTIVE_COMPARATOR|Insorb Staples|
62545899|NCT06418347|OTHER|Control|This group will include 75 PCOS participants who will receive the standard treatment letrozole and the other commonly provided PCOS care (lifestyle modification, diet and exercise education, any other non-pharmacological method of management) according to the PCOS guidelines .Treatment with letrozole will begin after the baseline visit and for three cycles.
62545900|NCT06418347|EXPERIMENTAL|Intervention|"this will include 75 PCOS participants who will receive the standard treatment as letrozole with the same schedule of the control group and the other commonly provided PCOS care as previously described in addition to ALA, (Thiotacid®, EVAPHARMA, Egypt) in a dose of one tablet 600 mg three times per day Each patient in the test group will start the ALA from day 3 of the menstrual period then daily until the day of human chorionic gonadotropin (HCG) injection"
62545901|NCT01808573|EXPERIMENTAL|neratinib plus capecitabine|neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
62719809|NCT04240431||Epiphora|Adult patients suffering from watering of the eye included in the study to detect level of obstruction
62719810|NCT03387956|ACTIVE_COMPARATOR|Atropine group|Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.
62719811|NCT03387956|ACTIVE_COMPARATOR|Dexamethasone group|Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).
62719812|NCT03387956|ACTIVE_COMPARATOR|Dexamethasone and Atropine group|Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.
62719813|NCT03345277||Continuous Temperature monitoring|All residents of a long-term care facility will be considered for the study over the predetermined timeframe. Residents who choose not to participate or are determined, by their care providers, to be inappropriate for inclusion will be excluded.
62719814|NCT03914989|EXPERIMENTAL|Experimental group|Individuals in this group receive exposure to a higher concentration of essential oil fragrances nightly.
62719815|NCT03914989|PLACEBO_COMPARATOR|Active control group|Individuals in this group receive exposure to a lower concentration of essential oil fragrances nightly.
62545902|NCT01808573|ACTIVE_COMPARATOR|lapatinib plus capecitabine|lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
62545903|NCT06206798|EXPERIMENTAL|experimental group|"1. Subjects were randomly assigned to the experimental or the control group.~2. There were 20 members in the experimental group who received 6-week intervention activities.~3. Each subject was asked to fill out the questionnaires three times in total. The first time was before the intervention; the second time was right after the intervention; and the last time was four weeks later of the intervention."
62545904|NCT06206798|NO_INTERVENTION|control group|"1. There were 20 members in the control group who accepted chronic nursing care as usual without any nursing intervention.~2. Each subject was asked to fill out the questionnaires three times in total. The first time was the same time as the experimental group; the second time was 6 weeks after the first test; and the last time was four weeks after the second test."
62545905|NCT00990925|EXPERIMENTAL|Weight Loss Education Group|Involvement in weekly manualized, educational group on nutrition and lifestyle modifications to help with weight loss.
62545906|NCT00990925|OTHER|Usual Care|Treatment as usual
62545907|NCT00295061|EXPERIMENTAL|1 Alpha-1 MP|Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP
62719816|NCT05962281|ACTIVE_COMPARATOR|Individualized tDCS|Each participant will be screened according to their brain scan, they will receive individualized dose of tDCS currents.
62719817|NCT05962281|ACTIVE_COMPARATOR|Fixed currents tDCS|All of the participant will receive standardized dose of tDCS currents intensity of 2 mA.
62545908|NCT00295061|ACTIVE_COMPARATOR|2 Prolastin|Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP
62545909|NCT01696279|EXPERIMENTAL|Lanthanum Carbonate|Participants will receive lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided and mixed equally between in three meals.
62545910|NCT01696279|ACTIVE_COMPARATOR|Calcium Carbonate|Participants will receive calcium carbonate orally at a total daily dose adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
62545911|NCT03237507||Chemotherapy Group|chemotherapy treatment（S-1 and Oxaliplatin） for patients until disease progress
62545912|NCT03237507||Chemotherapy plus HIPEC Group|Hyperthermic Intraperitoneal chemoperfusion（HIPEC）with Paclitaxel more than 2 cycles and plus chemotherapy
62545913|NCT04577209|EXPERIMENTAL|Pediatric Patients|Participants undergoing anesthesia-related aerosol generating medical procedures (AGMPs) and pediatric otolaryngologic surgeries will have a local exhaust ventilation system to the exposure seen by the medical providers during the AGMPs and surgeries.
62545914|NCT00717041||Presenting to the ED|Patients who present to the ED
62545915|NCT05847348|EXPERIMENTAL|Treatment (68Ga-PSMA-11)|"111 \~ 259 MBq 68Ga-PSMA-11 will be administered intravenously to participants over 3- 5 minutes.~After 50-100 minutes post 68Ga-PSMA-11 injection, participants will be scanned (PET/CT or PET/MRI) from the mid-thigh to the apex of the skull. Participants will be placed in a supine position with the arms raised overhead."
62545916|NCT05794503|ACTIVE_COMPARATOR|Neostigmine|One type of Neuromuscular Blockade Reversal Drug
62545917|NCT05794503|ACTIVE_COMPARATOR|Sugammadex|One type of Neuromuscular Blockade Reversal Drug
62545918|NCT03094637|EXPERIMENTAL|Treatment (azacitidine, pembrolizumab)|Patients receive azacitidine Intravenous (IV) over 10-40 minutes or Subcutaneous (SC) on days 1-7, and pembrolizumab IV over 30 minutes every 3 weeks. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62545919|NCT05410964||Single Arm|
62545920|NCT06011707|EXPERIMENTAL|OPT-IN intervention|
62545921|NCT06011707|ACTIVE_COMPARATOR|Psychoeducational control|
62545922|NCT02089607|EXPERIMENTAL|Thoracoabdominal Aortic Aneurysm Arm|The TAAA study arm will include patients treated by endovascular aortic repair of thoracoabdominal aortic aneurysms (Extent I to IV) using either an off-the-shelf Zenith t-Branch or patient-specific stent-graft with a combination of fenestrations and/or branches. The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
62545923|NCT02089607|EXPERIMENTAL|Aortic Arch Aneurysm Arm|Aortic Arch study arm will include patients with aortic arch aneurysms treated by Patient-specific stent-grafts with one to three inner branches or a scallop. The study will include patients with thoracoabdominal and/or aortic arch aneurysms due to degenerative aneurysms or chronic aortic dissections. The stent-graft design for this study will be individually selected based on anatomy at the discretion of the principal investigator, including an off-the-shelf stent-graft (t-Branch stent-graft) or patient-specific stent-graft with a combination of fenestrations and/or branches.
62545924|NCT02673814|EXPERIMENTAL|Arm A (durvalumab)|10 mg/kg durvalumab alone every two weeks
62545925|NCT02673814|EXPERIMENTAL|Arm B (bavituximab + durvalumab)|3 mg/kg bavituximab weekly in combination with 10 mg/kg durvalumab every two weeks
62545926|NCT02673814|EXPERIMENTAL|Arm C (bavituximab + durvalumab)|3 mg/kg bavituximab in combination with 10 mg/kg durvalumab both every two weeks
62545927|NCT05473143|EXPERIMENTAL|Protocolized fluid removal|
62545928|NCT05473143|ACTIVE_COMPARATOR|Usual care|
62545929|NCT05537636|EXPERIMENTAL|Regional Interdepence Intervention for the upper quarter|Physical therapist will perform interventions to the entire uppper extremity and spine to treat elbow pain. Physical therapy intervention will include manual therapy and soft-tissue massage to the shoulder, cervical, and thoracic spine. Participants will be prescribed specific exercises using a phased approach.
62545930|NCT03009773|EXPERIMENTAL|multitasking walking|Multitasking Group: rehabilitation multitasking walking.
62545931|NCT03009773|ACTIVE_COMPARATOR|walking simple task|Simple task group : Traditional walking rehabilitation
62545932|NCT03685344|EXPERIMENTAL|ADCT-402|"Dose escalation phase: Ascending doses of Loncastuximab tesirine will be administered using a traditional 3+3 design. Dose level 1: 90 µg/kg, every 3 weeks (Q3W). Dose level 2: 120 µg/kg, Q3W. Dose level 3: 150 µg/kg, Q3W. Loncastuximab tesirine will be given for 2 doses, 3 weeks apart.~Dose expansion phase: Loncastuximab tesirine will be administered at the recommended dose determined in the dose escalation phase. Durvalumab will also be administered at a dose of 1500 mg once every 4 weeks (Q4W) throughout the dose escalation phase and dose expansion phase."
62545933|NCT05741177||bronchiolitis|children with bronchiolitis
62545934|NCT04036838|EXPERIMENTAL|Indication for H.pylori testing|Walk in basis: Symptomatic patients of H.pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test in addition to at least 2 other diagnostic tools from one obtained biopsy as comparison.
62545935|NCT01924559|ACTIVE_COMPARATOR|Direct Laryngoscopy & standard clothing|Residents will intubate manikin using DL while wearing standard clothing.
62545936|NCT01924559|ACTIVE_COMPARATOR|Direct Laryngoscopy & Biohazard Gear|Residents will intubate manikins using DL while in Biohazard gear.
62545937|NCT01924559|EXPERIMENTAL|Glidescope & standard clothing|Residents will intubate manikins using Glidescope while wearing standard clothing.
62545938|NCT01924559|ACTIVE_COMPARATOR|Glidescope & Biohazard Gear|Residents will intubate manikins using Glidescope while wearing Biohazard gear.
62545939|NCT01924559|ACTIVE_COMPARATOR|Supraglottic Airway & standard clothing|Residents will intubate manikins using Supraglottic Airway while wearing standard clothing.
62545940|NCT01924559|ACTIVE_COMPARATOR|Supraglottic Airway and Biohazard gear|Residents will intubate manikins using Supraglottic airway while wearing biohazard gear.
62719818|NCT05962281|SHAM_COMPARATOR|Sham tDCS|The electrodes will applied to the cortical areas, however none of all of the participant will receive the current dose of tDCS.
62719819|NCT05187260||5q SMA type I|
62719820|NCT05187260||5q SMA type II|
62719821|NCT05187260||5q SMA type III|
62719822|NCT05187260||Non-5q SMA|
62545941|NCT04475172|EXPERIMENTAL|Fusio™ Flowable Self-Adhesive Flowable Composite|"2-Cavity preparation steps:~* patients will be given local anesthesia as required,the operative field will be isolated with rubber dam before starting.~* Conventional design Class V cavity will be prepared on the buccal surface of tooth by No. #330 bur (0.8 mm in diameter and 1.6 mm in length) , tooth surfaces will be kept moist to protect them against dehydration.~* 2% chlorhexidine gluconate disinfecting solution .~* wash the dentin surface with water spray and air dry with maximum air pressure for 5 s.~A) Intervention: Fusio™ Flowable (Self adhesive flowable composite):~* Simply syringe into the preparation 1 mm increments, agitate with tip or brush for 20 s, and light-cure.No need for an etchant or an adhesive."
62545942|NCT04475172|ACTIVE_COMPARATOR|Conventional flowable composite [Tetric Evo Flow (FF)].|"Tetric Evo Flow (Conventional flowable composite):~* After cleaning cavities, apply conditioning material (phosphoric acid etching 37% ) and apply bonding agent (ExciTE® F) according to the instructions for use of the product.~* Apply Tetric EvoFlow in layers of 1mm. Polymerize each layer separately following the instructions for use of this product. . Hold the light emission window as closely as possible to the surface of the restorative material.~All 20 Class V restorations will be prepared, restored, finished, and polished by one operator. Each of the 10 patients had one (FL) restoration and the other restoration will be filled with (FF)."
62545943|NCT03935438|EXPERIMENTAL|Patients after ACS|Patients after acute coronary syndrome undergoing cardiac rehabilitation.
62545944|NCT03446807|EXPERIMENTAL|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
62545945|NCT03446807|PLACEBO_COMPARATOR|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
62545946|NCT03844256|EXPERIMENTAL|Regimen A|"Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
62545947|NCT03844256|EXPERIMENTAL|Regimen B|"Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
62545948|NCT03844256|EXPERIMENTAL|Regimen C|"Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
62545949|NCT03653884||Pregnancy with fetal intra-abdominal umbilical vein.|All women with a pregnancy with a partially intra-abdominal umbilical vein aneurysm isolated or associated with other abnormalities découvert lors d'une ultrasonic monitoring.
62545950|NCT06447194|EXPERIMENTAL|Intervention (RECK)|"The arm of patients who will be administered RECK local anesthesia cocktail:~Ropivacaine 0.125g Clonidine 80 mcg Epinephrine 0.5 mg Ketorolac 30 mg In sterile water 73 mL (total volume of compound is 100 mL)~Given through paraspinal muscle injection once intraoperatively."
62545951|NCT06447194|PLACEBO_COMPARATOR|Control Group (Placebo)|"The arm of patients who will be administered a placebo injection:~100 mL Normal Saline~Given through paraspinal muscle injection once intraoperatively."
62545952|NCT04573894||Positives blood cultures|Collection of clinical and biological data of patients with blood cultures positives for potential contaminants, as well as PCT levels measurements, from January 2016 to May 2019 at the Nancy CHRU
62545953|NCT05523583||Patients newly diagnosed with lung cancer or head & neck cancer|Patients newly diagnosed with lung cancer or head \& neck cancer (International Classification of Diseases 10: C76, C34) who undergo front-line treatment and who had at least one episode of smoking within the past 30 days before diagnosis
62545954|NCT06444178|ACTIVE_COMPARATOR|Arm 1: Aspirin|Randomized 1:1:1:1
62545955|NCT06444178|EXPERIMENTAL|Arm 2: Aspirin + REGN9933|Randomized 1:1:1:1
62545956|NCT06444178|EXPERIMENTAL|Arm 3: Aspirin + REGN7508|Randomized 1:1:1:1
62545957|NCT06444178|ACTIVE_COMPARATOR|Arm 4: Aspirin + Rivaroxaban|Randomized 1:1:1:1
62545958|NCT04642404|EXPERIMENTAL|Epidiolex 10mg/kg single dose|After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
62545959|NCT04642404|EXPERIMENTAL|Epidiolex 20mg/kg single dose|The 20mg/kg dose is the maximum recommended daily dose from the manufacturer. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
62719823|NCT05187260||Non-SMA subjects|Including asymptomatic carriers of SMA, relatives of SMA patients and carriers, and patients undergoing clinical standard lumbar puncture
62719824|NCT03925363|ACTIVE_COMPARATOR|Active|Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)
62719825|NCT03925363|SHAM_COMPARATOR|Control|Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).
62545960|NCT04642404|PLACEBO_COMPARATOR|Placebo group|Placebo drug will be a solution with the same taste, texture and color as the drug. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
62545961|NCT04194645|PLACEBO_COMPARATOR|SRD: Placebo matching BI 474121 oral solution (OS)|This arm comprises all placebo treated participants of the single rising dose (SRD) part treated with an oral solution (placebo treated participants of the two lowest dose group (DG)s). Participants receiving placebo were equally distributed across dose groups. A single dose of BI 474121 matching placebo powder for oral solution was administered after an overnight fast together with 240 milliliter (mL) of water to participants who were in a standing position.
62545962|NCT04194645|PLACEBO_COMPARATOR|SRD: Placebo matching BI 474121 tablet (T)|This arm comprises all placebo treated participants of the SRD part treated with a tablet (placebo treated participants of the five upper DGs). Participants receiving placebo were equally distributed across dose groups. A single dose of BI 474121 matching placebo tablet was administered after an overnight fast together with 240 mL of water to subjects who were in a standing position.
62545963|NCT04194645|EXPERIMENTAL|SRD: 0.25 milligram (mg) BI 474121 - OS|A single dose of 0.25 mg BI 474121 was solved in 0.5 mL of water and was administered after an overnight fast together with 240 mL of water to participants who were in a standing position.
62545964|NCT04194645|EXPERIMENTAL|SRD: 1 mg BI 474121 - OS|A single dose of 1 mg BI 474121 was solved in 2mL of water and was administered after an overnight fast together with 240 mL of water to participants who were in a standing position.
62545965|NCT04194645|EXPERIMENTAL|SRD: 2.5 mg BI 474121 - T|A single dose of 2.5 mg BI 474121 was administered as 1 uncoated 2.5 mg tablet after an overnight fast together with 240 mL of water to participants who were in a standing position.
62545966|NCT04194645|EXPERIMENTAL|SRD: 5 mg BI 474121 - T|A single dose of 5.0 mg BI 474121 was administered as 2 uncoated 2.5 mg tablets after an overnight fast together with 240 mL of water to participants who were in a standing position.
62545967|NCT04194645|EXPERIMENTAL|SRD: 10 mg BI 474121 - T|A single dose of 10.0 mg BI 474121 was administered as 1 uncoated 10.0 mg tablet after an overnight fast together with 240 mL of water to participants who were in a standing position.
62545968|NCT04194645|EXPERIMENTAL|SRD: 20 mg BI 474121 - T|A single dose of 20.0 mg BI 474121 was administered as 2 uncoated 10.0 mg tablets after an overnight fast together with 240 mL of water to participants who were in a standing position.
62545969|NCT04194645|EXPERIMENTAL|SRD: 40 mg BI 474121 - T|A single dose of 40.0 mg BI 474121 was administered as 4 uncoated 10.0 mg tablets after an overnight fast together with 240 mL of water to participants who were in a standing position.
62545970|NCT04194645|EXPERIMENTAL|BA: BI 474121 10 mg as: OS fasted (Reference (R)) / T fasted (T2) / T fed (T1)|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (Reference (R)), in period 2 as 1 uncoated tablet with 240 mL of water after an overnight fast (Test 2 (T2)) and in period 3 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (Test 1 (T1)). Between periods was a wash-out period of at least 7 days.
62545971|NCT04194645|EXPERIMENTAL|BA: BI 474121 10 mg as: R / T1 / T2|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R), in period 2 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1) and in period 3 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2). Between periods was a wash-out period of at least 7 days.
62545972|NCT04194645|EXPERIMENTAL|BA: BI 474121 10mg as: T2 / R / T1|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2), in period 2 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R) and in period 3 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1). Between periods was a wash-out period of at least 7 days.
62545973|NCT04194645|EXPERIMENTAL|BA: BI 474121 10mg as: T2 / T1 / R|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2), in period 2 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1) and in period 3 as oral solution solved in 20 mL water with 240 mL of water after an overnight fast (R). Between periods was a wash-out period of at least 7 days.
62545974|NCT04194645|EXPERIMENTAL|BA: BI 474121 10mg: T1 / R / T2|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1), in period 2 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R) and in period 3 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2). Between periods was a wash-out period of at least 7 days.
62545975|NCT04194645|EXPERIMENTAL|BA: BI 474121 10mg: T1 / T2 / R|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1), in period 2 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2) and in period 3 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R). Between periods was a wash-out period of at least 7 days.
62545976|NCT00307021|ACTIVE_COMPARATOR|Group A|
62545977|NCT00307021|EXPERIMENTAL|Group B|
62545978|NCT06187805||Up to 15 patients|Patients who have had a transcrestal elevation using autogenous bone supporting an OSSIX Volumax collagen scaffolding.
62545979|NCT03912597|EXPERIMENTAL|Virtual Reality [A]|Participants watch a 4-minute virtual reality video, on top of reading a brochure, then answer post-intervention questionnaires.
62545980|NCT03912597|ACTIVE_COMPARATOR|Brochure Waitlist Control [A]|Participants read an informational brochure about depression, then answer post-intervention questionnaires. After that, they will be given a chance to watch the VR video at the end of their participation session.
62545981|NCT03912597|ACTIVE_COMPARATOR|Standard Video Control [B]|Participants watch a 4-minute standard video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
62545982|NCT03912597|EXPERIMENTAL|Virtual Reality [B]|Participants answer pre-questionnaires, then watch a 4-minute virtual reality video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
62545983|NCT02068703|ACTIVE_COMPARATOR|Intervention|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools (face mask, ear plugs and white noise machine) to improve sleep.
62545984|NCT02068703|PLACEBO_COMPARATOR|Inert Control|Same 10 min time exposure and tool delivery to subjects in this arm WITHOUT demonstration.
62545985|NCT04825782||Pregnant Women exposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
62545986|NCT04825782||Pregnant Women unexposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
62545987|NCT01630070|EXPERIMENTAL|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
62545988|NCT04521127|ACTIVE_COMPARATOR|Kinesio Taping Group|Kinesio taping will be applied to trapezius muscle
62545989|NCT04521127|ACTIVE_COMPARATOR|Dry needling Group|Dry needling will be applied to trigger point on trapezius muscle
62545990|NCT04521127|NO_INTERVENTION|Control Group|Control group will not receive any additional intervention
62545991|NCT05092152|ACTIVE_COMPARATOR|Propofol|
62545992|NCT05092152|EXPERIMENTAL|Esketamina|
62545993|NCT05108402|EXPERIMENTAL|Bottle of water|"After inclusion in the study, the patients are phenotyped between V1 and V4. Following this, they will be separated into 2 groups: NaCl sensitive patients and non-NaCl sensitive patients. The non-sensitive group will drop out of the study, while the others will be randomized to one of the 2 treatment arms: bottle of water or sachet of salt."
62545994|NCT05108402|ACTIVE_COMPARATOR|Salt sachet|"After inclusion in the study, the patients are phenotyped between V1 and V4. Following this, they will be separated into 2 groups: NaCl sensitive patients and non-NaCl sensitive patients. The non-sensitive group will drop out of the study, while the others will be randomized to one of the 2 treatment arms: bottle of water or sachet of salt."
62545995|NCT05108402|OTHER|No treatment|"After inclusion in the study, the patients are phenotyped between V1 and V4. Following this, they will be separated into 2 groups: NaCl sensitive patients and non-NaCl sensitive patients. The non-sensitive group will drop out of the study, while the others will be randomized to one of the 2 treatment arms: bottle of water or sachet of salt."
62545996|NCT03669185|PLACEBO_COMPARATOR|Placebos|Placebos, 2 times daily 1 tablet, intake max. 133 days
62545997|NCT03669185|ACTIVE_COMPARATOR|Pentalong|Pentalong, 2 times daily 1 tablet, intake max. 133 days
62545998|NCT05065710|EXPERIMENTAL|ZL-1211 monotherapy|
62545999|NCT03050138||Dabigatran|In the RE-COVER- and RE-COVER II studies, one group of DVT and/or PE patients were randomized to receive 6 months of treatment with dabigatran (150 mg twice daily). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
62546000|NCT03050138||Warfarin|In the RE-COVER- and RE-COVER II studies, the other group of DVT and/or PE patients were randomized to receive 6 months of treatment with warfarin (once daily to maintain international normalized ratio (INR) 2.0-3.0). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
62546001|NCT02970448|EXPERIMENTAL|LITT with Radiation and Temozolomide|Laser interstitial thermal therapy (LITT) followed by Radiation therapy, three-dimensional conformal radiotherapy (3D-CRT) or intensity modulation radiation therapy (IMRT), 60 Gy/30 fractions. Radiation given with chemotherapy Temozolomide
62546002|NCT03254264|EXPERIMENTAL|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
62546003|NCT03254264|ACTIVE_COMPARATOR|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
62546004|NCT06112847|EXPERIMENTAL|Treatment (lenalidomide and epcoritamab)|Patients receive lenalidomide PO QD on days 1-21 of each cycle and epcoritamab SC on days 1, 8, 15, and 21 of cycles 1-3 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients may be re-treated with study treatment at any point during the follow-up period as long as they did not progress during treatment or stop due to unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI as well as bone marrow biopsy throughout the trial. Patients undergo blood sample collection on trial and during follow-up.
62546005|NCT05510284|ACTIVE_COMPARATOR|Doula Coordinated-Care Arm|Postpartum care will be doula-coordinated. The doula will meet with the mother at least once a week during their infant's NICU stay, with a minimum of 3 meetings. Participants will be given the option of seeing the study nurse midwife or their own provider. If the participant opts to see the nurse midwife, they can meet in a private office located in the NICU. The doula, as typical of the doula role, will coordinate any needed community services in the transition to home.
62719826|NCT04707105||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
62719827|NCT04707105||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
62719828|NCT04707105||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
62719829|NCT04324892||Treat to target|The study has only 1 cohort with treat-to-target strategy
62546006|NCT05510284|NO_INTERVENTION|Standard Postpartum Care Arm|In this arm participants will receive usual postpartum care. They will be discharged from the hospital while their baby is still in the NICU and a plan will be made to for follow-up with their provider as an outpatient at some point in the next 6 weeks. The study coordinator will provide the participant with a community postpartum resources list.
62546007|NCT04774497|EXPERIMENTAL|Oxygen inhalation treatment group|"1. Patients receive chemotherapy for breast cancer.~2. Patients are randomly divided into inhalation treatment group. Oxygen inhalation is started on the first day of chemotherapy, and the oxygen inhalation volume is 2 L / min, 8 hours / day for 3 consecutive days.（d1，d2，d3）.~3. Blood samples are collected before and after chemotherapy（d0，d3）.~4. CIS and BFI are measured before chemotherapy（d0, d3 chemotherapy regimen/ d0, d3， chemotherapy regimen）."
62546008|NCT04774497|PLACEBO_COMPARATOR|Oxygen non-inhalation treatment group|"1. Patients receive chemotherapy for breast cancer.~2. Patients are randomly divided into non-inhalation treatment group.~3. Blood samples are collected before and after chemotherapy（d0，d3）.~4. CIS and BFI are measured before chemotherapy（d0, d3，chemotherapy regimen/ d0, d3， chemotherapy regimen）."
62719830|NCT04528238|EXPERIMENTAL|Relaxing Visual Immersion|The patients will benefit a Relaxing Visual Immersion during the intravenous treatment for their cancer.
62719831|NCT04528238|NO_INTERVENTION|No sensitive stimulation|The patients will not receive Relaxing Visual Immersion during the intravenous treatment for their cancer.
62719832|NCT05045716|EXPERIMENTAL|Lecanemab 10 mg/kg|Participants will receive lecanemab 10 milligram per kilogram (mg/kg), as single dose IV infusion over approximately 1 hour on Day 1.
62719833|NCT05045716|EXPERIMENTAL|Lecanemab 700 mg|Participants will receive lecanemab 700 milligram (mg), as single fixed dose SC injection in the abdomen on Day 1.
62546009|NCT02323828|EXPERIMENTAL|Investigational product|"The investigational products are RS starch cookies (40 g resistant starch) from high amylose maize starch.~Nine young healthy volunteers (males and females) consumed RS rich cookies (40 g RS) in two separate occasions."
62546010|NCT02323828|PLACEBO_COMPARATOR|Placebo|The placebo products are common wheat-maize cookies (2 g RS). Nine young healthy volunteers (males and females) consumed placebo in two separate occasions.
62546011|NCT01010113|PLACEBO_COMPARATOR|Test formula 1|Standard formula with prebiotics
62546012|NCT01010113|EXPERIMENTAL|test product|Infant formula with synbiotics
62546013|NCT05052112|ACTIVE_COMPARATOR|E-PR-01 200mg|Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to 7 days
62546014|NCT05052112|PLACEBO_COMPARATOR|E-PR-02 200mg|Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to7 days
62546015|NCT03226535|EXPERIMENTAL|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
62546016|NCT03226535|NO_INTERVENTION|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
62546017|NCT00534404|EXPERIMENTAL|NRT Patch, Phone Counseling, Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
62546018|NCT00534404|ACTIVE_COMPARATOR|Nicotine Patches and Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
62546019|NCT00534404|PLACEBO_COMPARATOR|Internet|Research participants in this arm will have free access to internet-assisted tobacco treatment (iQuit Smoking website).
62546020|NCT02590965|PLACEBO_COMPARATOR|Control Group|Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.
62546021|NCT02590965|EXPERIMENTAL|Treatment Group|The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent
62546022|NCT04455321|ACTIVE_COMPARATOR|Vicryl|Single layer locked uterine closure with vicryl suture material
62546023|NCT04455321|EXPERIMENTAL|rapide vicryl|Single layer locked uterine closure with rapide vicryl suture material
62546024|NCT03743155|EXPERIMENTAL|treatment with mesenchymal stem cells|xerostomy using mesenchymal stem cells adult autologous bone marrow
62546025|NCT04365192||I-gel|
62546026|NCT04365192||Self-pressurized air-Q|
62546027|NCT03827720|EXPERIMENTAL|Control|Healthy volunteers monitored with Sense Device
62546028|NCT03827720|EXPERIMENTAL|Intracranial Hemorrhage|Intracranial hemorrhage patients monitored with Sense Device
62546029|NCT03827720|EXPERIMENTAL|Acute Ischemic Stroke with LOV|Acute Ischemic Stroke patients that have large vessel occlusion monitored with SENSE Device
62546030|NCT03827720|EXPERIMENTAL|AIS without LOV|Ischemic Stroke patients that do not have large vessel occlusion monitored with SENSE device
62546031|NCT05102747|EXPERIMENTAL|Hypofractionated SRT (stereotactic radiotherapy)|
62719834|NCT05878717|EXPERIMENTAL|Belimumab|Participants will receive belimumab in addition to standard therapy.
62719835|NCT05878717|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo in addition to standard therapy.
62719836|NCT02613195|EXPERIMENTAL|Hydrogen-rich Celsior solution|Using aging liver grafts（≥60 years old)，lavaged and cold stored with hydrogen-rich Celsior solution for 2-4 hours.
62546032|NCT05102747|ACTIVE_COMPARATOR|Historical single-dose SRS (stereotactic radiosurgery)|
62546033|NCT05277584||Patients with hyponatremia|
62546034|NCT06363903||Included patients|Patients included with index operation that are referred to a participating outpatient clinic and who present with ASIA Syndrome-like complaints occurring after PP implant placement.
62546035|NCT02724228|EXPERIMENTAL|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study, initially up to 30 μg/kg. BMN 111 will be administered by weight-band dosing regimen.
62546036|NCT02786225|EXPERIMENTAL|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a Vanderbilt University Medical Center (VUMC) perinatologist and a Vanderbilt University School of Nursing (VUSN) nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
62546037|NCT02786225|ACTIVE_COMPARATOR|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
62546038|NCT00852722|EXPERIMENTAL|1. Low fat study diet|The low fat study diet arm will receive low fat diet training and followed for 12 months on the diet.
62546039|NCT00852722|NO_INTERVENTION|2. Regular diet group|The regular diet arm will be a wait-listed group that will receive no training in diet and will be advised to continue their regular (usual) diet as was prior to entry into the study, for the duration of the study. They will have a similar clinic follow up schedule as the treatment group. The regular diet group will be given identical instructions to exercise regularly similar to the treatment group.
62546040|NCT05456958|EXPERIMENTAL|Amygdala|PTSD participants will receive a neurofeedback signal reflecting amygdala activity.
62719837|NCT02613195|NO_INTERVENTION|Celsior solution|Using aging liver/kidney grafts（≥60 years old）, lavaged and cold stored with common Celsior solution for 2-4 hours.
62719838|NCT04966325|EXPERIMENTAL|Treatment T (Therapeutic dose)|Single oral dose of 200 mg LC350189 (1 × 200 mg tablet) and 2 × placebo tablets.
62719839|NCT04966325|EXPERIMENTAL|Treatment ST (Supratherapeutic dose)|Single oral dose of 600 mg LC350189 (3 × 200 mg tablets).
62719840|NCT04966325|PLACEBO_COMPARATOR|Treatment P (Placebo)|Single oral dose of 3 × placebo tablets.
62719841|NCT04966325|ACTIVE_COMPARATOR|Treatment M (positive control)|Single oral dose of moxifloxacin 400 mg (1 × 400 mg tablet; open label)
62719842|NCT01749488|NO_INTERVENTION|Control intensive care wards|This is a randomized cluster trial. The centers randomized into this arm will serve as controls. No interventions will be implemented for these centers.
62719843|NCT01749488|EXPERIMENTAL|Experimental intensive care wards|"This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.~Intervention: Designated dietitian for the ward"
62719844|NCT03816787|EXPERIMENTAL|dry cupping for patients of low back pain|Patients will receive four consecutive dry cupping therapy application in one month.
62719845|NCT03816787|ACTIVE_COMPARATOR|dry cupping for health people|Health people will receive four consecutive dry cupping therapy application in one month.
62719846|NCT04793516|EXPERIMENTAL|VR-based spatial retraining|Game-like therapy activities will be taken place in a virtual environment, provided through an immersive head-mounted display.
62719847|NCT00641108|EXPERIMENTAL|ADAM SPECT|Participants with depression will undergo ADAM SPECT scans and cognitive behavioral therapy.
62719848|NCT00641108|ACTIVE_COMPARATOR|Control|Healthy subjects without depression will undergo ADAM SPECT scans.
62719849|NCT05285579||TKI+ICI|Therapeutic combination tyrosine kinase inhibitor (TKI) + immune checkpoint inhibitors (ICI)
62719850|NCT05285579||ICI+ICI|Therapeutic combination with different immune checkpoint inhibitors (ICI)
62546041|NCT05456958|EXPERIMENTAL|Posterior cingulate cortex (PCC)|PTSD participants will receive a neurofeedback signal reflecting PCC activity.
62546042|NCT05456958|EXPERIMENTAL|Sham-control|PTSD participants will receive a sham neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
62546043|NCT05056623|EXPERIMENTAL|Dyadic pain management program|The DPM is an 8-week group-based program. The DPM included 4 weeks of center-based, face-to-face activities and 4 weeks digital-based activities delivered via a WhatsApp group.
62546044|NCT05056623|OTHER|Usual care and pain management pamphlet|The participants in the control group will receive the usual care and a pain management pamphlet.
62546045|NCT03766386||Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are currently alive (including patients who may or may not have undergone heart transplantation).
62719851|NCT02402595|EXPERIMENTAL|Sequence 1 - Period 1|AVP-923 and placebo matching AVP-786- BID Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
62719852|NCT02402595|EXPERIMENTAL|Sequence 1 - Period 2 (after 3-week washout)|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
62719853|NCT02402595|EXPERIMENTAL|Sequence 2 - Period 1|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
62719854|NCT02402595|EXPERIMENTAL|Sequence 2 - Period 2 (after 3-week washout)|AVP-923 and placebo matching AVP-786- BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
62719855|NCT02985411|ACTIVE_COMPARATOR|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
62719856|NCT02985411|ACTIVE_COMPARATOR|Delayed Gardening Intervention|Individuals in this group will serve as their own control
62719857|NCT01252615|EXPERIMENTAL|patient only|Patient with the ICD is involved in the intervention
62719858|NCT01252615|EXPERIMENTAL|patient and partner|patient with the ICD and intimate partner are involved in the intervention
62719859|NCT02091076|EXPERIMENTAL|Silk with bioactive coated dressing|Silk fibroin coated with bioactive layer, apply once only
62719860|NCT02091076|ACTIVE_COMPARATOR|Control|Bactigras wound dressing, apply once only
62719861|NCT06546475|EXPERIMENTAL|NAC add-on 1|NAC add-on with 1200 mg/d
62719862|NCT06546475|ACTIVE_COMPARATOR|NAC add-on 2|NAC add-on with 2400 mg/d
62719863|NCT03322982|EXPERIMENTAL|MS Diet|34 people with MS following low-fat diet
62719864|NCT03322982|NO_INTERVENTION|MS Wait-List|34 people with MS following usual diet
62719865|NCT03322982|NO_INTERVENTION|Diet Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Diet group
62719866|NCT03322982|NO_INTERVENTION|Wait-List Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Wait-List group
62719867|NCT01370876|EXPERIMENTAL|Oxaliplatin/5-FU|
62546046|NCT03766386||Deceased Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are deceased (including patients who may or may not have undergone heart transplantation).
62546047|NCT02352012|EXPERIMENTAL|Autologous blood group A|Autologous blood was perfused to the target pulmonary segment
62719868|NCT00790049|EXPERIMENTAL|ARRY-371797|
62719869|NCT00790049|PLACEBO_COMPARATOR|Placebo|
62719870|NCT01211561|EXPERIMENTAL|Selenium, selenomethionine|
62719871|NCT01211561|ACTIVE_COMPARATOR|placebo|
62546048|NCT02352012|EXPERIMENTAL|Bronchial plug group B|Bronchial plug was placed to the target pulmonary segment
62546049|NCT02352012|NO_INTERVENTION|control group|Control group was given to continuous negative pressure drainage
62719872|NCT00766116|EXPERIMENTAL|Phase 1 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m\^2 5-Aza 2 days then GO at 3 mg/m\^2"
62719873|NCT00766116|EXPERIMENTAL|Phase 1 Dose Level 2|"5-Azacitidine, Gemtuzumab ozogamicin~75mg/m\^2 5-Aza for 4 days then GO at 6 mg/m\^2"
62546050|NCT05597319||ERAS-in|Patients who completed ERAS program
62719874|NCT00766116|EXPERIMENTAL|Phase I Dose Level 3|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m\^2 5-Aza for 6 days then GO at 6 mg/m\^2"
62719875|NCT00766116|EXPERIMENTAL|Phase 2 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m\^2 5-Aza for 6 days then GO at 6 mg/m\^2"
62719876|NCT01349673|EXPERIMENTAL|Budesonide Foam|Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
62719877|NCT05746390|EXPERIMENTAL|Home Alone Intervention|"Home Alone is a semi-structured intervention, tailored to address the individual needs and concerns of the older adult. The participant will engage in about seven psychoeducational coaching sessions, each lasting approximately one hour.~The intervention has two key foci:~1. increasing or maintaining home safety and comfort~2. increasing scheduled social engagements and activities.~Sessions are also designed to identify formal and informal services and supports to improve to increase assistance and ability to live independently for as long as safely possible. The sessions take place either in-person or remotely (via secure video conferencing or telephone). Ad hoc/ongoing sessions may be provided as needed."
62719878|NCT06100757|ACTIVE_COMPARATOR|Conventional pacing|24 patients underwent the implantation of a conventional VVI pacing system (Medtronic) with placement of a ventricular pacing lead Medtronic 5076-58 in the right ventricle.
62719879|NCT06100757|EXPERIMENTAL|leadless pacing|27 patients underwent the implantation of a leadless pacing system Micra TPS
62719880|NCT06716515||Males|"Forty-one males will be evaluated using digital inclinometer in an open kinetic chain position. The JPS testing is conducted in the sitting position without feet floor contact, at a quiet place with closed eyes . Investigator will perform all the knee joint position sense assessments in the dominant extremity. The digital inclinometer is stabilized to the middle third of the subjects' leg (15 cm distal from the apex of the fibular head) with a strap. The starting position of the test is 90° flexion. The proprioception evaluation angle is defined at 30°. Participants are asked to extend their tested knee to the target angle of 30° from the initial position (90° knee flexion) then to return to their initial position after 5 seconds in this position ,The participant indicated by saying YES when they thought they reach the target, and the reposition accuracy will be measured as the joint position error (JPE) in degrees, as displayed on the digital inclinometer screen"
62719881|NCT06716515||Females|Forty-one females will be assessed the same as group A , Then compare Results To investigate the impact of gender difference on knee proprioception among non specific low back pain young adults
61976582|NCT05030974|ACTIVE_COMPARATOR|stratum A2 - one extra dose of mRNA-1273 with discontinuation of MMF/MPA|patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the extra dose
62719882|NCT00846846|EXPERIMENTAL|Endeavor® Zotarolimus Eluting Coronary Stent|Endeavor® Zotarolimus Eluting Coronary Stent System
62719883|NCT00991809|EXPERIMENTAL|Alfentanil|Subjects received a series of acute alfentanil administrations each session (15 mcg/kg IM per session), with sessions spaced at 3-4 day intervals.
62719884|NCT00991809|ACTIVE_COMPARATOR|Diphenhydramine|Subjects received a series of acute diphenhydramine administrations each session (25 mg IM per session), with sessions spaced at 3-4 day intervals.
62719885|NCT04441697||continuous apomorphine delivery|apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day
62719886|NCT04441697||continous levodopa/carbidopa delivery|levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day
61976583|NCT05030974|ACTIVE_COMPARATOR|stratum B1 - 3rd dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)
62546051|NCT05597319||ERAS-out|Patients who dropped-out from ERAS program
62546052|NCT02052193|EXPERIMENTAL|Dabrafenib|Dabrafenib 150mg BID orally
62546053|NCT02052193|ACTIVE_COMPARATOR|Vemurafenib|Vemurafenib 960mg orally BID
62546054|NCT00996892|EXPERIMENTAL|Dose Escalation Stage 1: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams \[mg\]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
62546055|NCT00996892|EXPERIMENTAL|Dose Escalation Stage 1A: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
62165720|NCT00702520||Corifollitropin alpha 150 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing \>= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
61976584|NCT05030974|ACTIVE_COMPARATOR|statum B2 - 3rd double dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms
62546056|NCT00996892|EXPERIMENTAL|Dose Escalation Stage 1B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
62546057|NCT00996892|EXPERIMENTAL|Dose Expansion Stage 2: Cobimetinib + Pictilisib|Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
62165721|NCT05510102|EXPERIMENTAL|Treatment group|Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
62165722|NCT05510102|ACTIVE_COMPARATOR|Control group|Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
62165723|NCT04120623|EXPERIMENTAL|Dapagliflozin combined with CSII|Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.
62165724|NCT04120623|ACTIVE_COMPARATOR|CSII alone|Aspart infused by CSII alone as glucose lowering therapy.
62165725|NCT05382390|EXPERIMENTAL|lderly Patients With Acute Myeloid Leukemia DCTAG|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
62546058|NCT00996892|EXPERIMENTAL|Dose Expansion Stage 2A: Cobimetinib + Pictilisib|Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.
62546059|NCT00996892|EXPERIMENTAL|Dose Expansion Stage 2B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.
62546060|NCT01611779|EXPERIMENTAL|Tongue suspension|Tongue-based suspension
62546061|NCT03394157|OTHER|Diabetes Mellitus Type 2 in Obese patients|obese patients had metabolic surgery for the treatment for DMT2 .Preoperative data , which including SASI bypass , MGB and Sleeve gastrectomy
62546062|NCT05063851|EXPERIMENTAL|Memantine hydrochloride|
62546063|NCT05063851|PLACEBO_COMPARATOR|Placebo|
62546064|NCT06292221|EXPERIMENTAL|Experimental|For this group of participants: The study clinicians will receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch' via a secure clinician portal
62546065|NCT06292221|OTHER|Control|For this group of participants: The study clinicians will NOT receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch'
62546066|NCT04414345|EXPERIMENTAL|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
62165726|NCT05382390|OTHER|lderly Patients With Acute Myeloid Leukemia|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
62165727|NCT01765439|EXPERIMENTAL|CD resected|Patients with Crohn´s disease with the history of single resection (\<60 cm) of distal leum.
62165728|NCT01765439|EXPERIMENTAL|UC unoperated|Patients with ulcerative colitis without history of gut resection.
62165729|NCT01765439|EXPERIMENTAL|UC IPAA|Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).
62165730|NCT01765439|EXPERIMENTAL|Healthy volunteers|Subjects without any sign of disease of the digestive tract.
62165731|NCT02339506|ACTIVE_COMPARATOR|Cosyntropin|Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
62165732|NCT02339506|PLACEBO_COMPARATOR|Normal saline (Placebo)|Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
62165733|NCT01050699|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine plus saline
62165734|NCT01050699|ACTIVE_COMPARATOR|Usual Care|Midazolam and Fentanyl
62168096|NCT01509040|EXPERIMENTAL|High Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/kg/h, ultrafiltration 90 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
62546067|NCT04414345|PLACEBO_COMPARATOR|Matching Placebo|"Administration: Oral~Dosage: 2 bottles daily"
62546068|NCT04003896|EXPERIMENTAL|Abemaciclib|Abemaciclib will be given as a single oral agent A sample size of 10 subjects is determined to be minimally sufficient for these pilot study objectives. The starting dose will be 200 mg twice daily. Dosing will continue daily for 28 days, this being one cycle. There will be no protocol scheduled hiatus and daily dosing will be continuous unless there is unacceptable toxicity, disease progression, or death.
62546069|NCT05740618|EXPERIMENTAL|Inhaled Mannitol|All study participants will receive the same study treatment. Study treatment will be dry powder mannitol 400 mg twice a day by oral inhalation (the contents of 10 capsules administered individually) for 14 days +/- 2 days.
62719887|NCT04441697||deep brain stimulation|bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings
62546070|NCT04477070|EXPERIMENTAL|Air-polishing with ultrasonic debridement|Air-polishing with ultrasonic debridement
62546071|NCT04477070|ACTIVE_COMPARATOR|Conventional scaling and root planing.|Conventional scaling and root planing.
62546072|NCT01194063|EXPERIMENTAL|Omegaven|Administration of intravenous Omega-3 fish oil lipid emulsion 1 g/kg continuous infusion over 12-24 hrs
62546073|NCT03260725|EXPERIMENTAL|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
62546074|NCT03260725|ACTIVE_COMPARATOR|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
62546075|NCT05833087|EXPERIMENTAL|Schema therapy|The participants in this arm will receive up to 30 individual, weekly sessions of consecutive Schema Therapy (ST). A treatment manual for ST has been written for the study, based on former studies of ST on chronic depression as well as the manual for a major clinical trial on ST for avoidant personality disorder.
62546076|NCT05833087|ACTIVE_COMPARATOR|Treatment as Usual|Patients with moderate-severe depression in the Danish secondary psychiatric sector are treated according to standard 'treatment packages', in the 'Main Function' offering from 6 to 16 weekly sessions of psychotherapy, in group or individually, typically Cognitive Behavioral Therapy, psychodynamic or interpersonal therapy or other evidence-based therapies.
62546077|NCT01207895|EXPERIMENTAL|[18F]-FLT PET scans|
62546078|NCT04004416|PLACEBO_COMPARATOR|Healthy Controls|
62546079|NCT04004416|EXPERIMENTAL|Early Psychosis patients|
62546080|NCT04004416|EXPERIMENTAL|Schizophrenia or Schizoaffective disorder patients|
62719888|NCT03584906|EXPERIMENTAL|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
62546081|NCT04004416|EXPERIMENTAL|Bipolar disorder patients|
62546082|NCT01890863|EXPERIMENTAL|Sequence 1|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
62546083|NCT01890863|EXPERIMENTAL|Sequence 2|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): BAAB, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
62546084|NCT04472676|EXPERIMENTAL|LY3473329 (Part A)|LY3473329 administered orally.
62546085|NCT04472676|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered orally.
62546086|NCT04472676|EXPERIMENTAL|LY3473329 (Part B)|LY3473329 administered orally.
62546087|NCT04472676|EXPERIMENTAL|Placebo (Part B)|Placebo administered orally.
62719889|NCT03584906|EXPERIMENTAL|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
62546088|NCT01777230||All patients|Alle subjects included retain in one cohort.
62546089|NCT01638598|EXPERIMENTAL|BI 1021958 dose group 1|subject to receive a tablet containing dose group 1 BI 1021958 single dose
62546090|NCT01638598|EXPERIMENTAL|BI 1021958 dose group 2|subject to receive a tablet containing dose group 2 BI 1021958 single dose
62546091|NCT01638598|EXPERIMENTAL|BI 1021958 dose group 3|subject to receive a tablet containing dose group 3 BI 1021958 single dose
62546092|NCT01638598|EXPERIMENTAL|BI 1021958 dose group 4|subject to receive a tablet containing dose group 4 BI 1021958 single dose
62546093|NCT01638598|EXPERIMENTAL|BI 1021958 dose group 5|subject to receive a tablet containing dose group 5 BI 1021958 single dose
62546094|NCT02997748|NO_INTERVENTION|Observational group|No intervention, standard care
62546095|NCT02997748|SHAM_COMPARATOR|Sham RIPC|Three cycles of 5- min upper limb sham ischemia
62546096|NCT02997748|EXPERIMENTAL|RIPC-Group 1|Three cycles of 5- min upper limb ischemia
62719890|NCT03584906|EXPERIMENTAL|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
62737662|NCT03419637|EXPERIMENTAL|Intervention - Mobile app|The mobile app, or app, is used to document before and after photos of the excised skin areas and to document related diagnoses. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
62546097|NCT02997748|EXPERIMENTAL|RIPC-Group 2|Three cycles of 7-min upper limb ischemia
62546098|NCT02997748|EXPERIMENTAL|RIPC-Group 3|Three cycles of 10-min upper limb ischemia
62546099|NCT02997748|EXPERIMENTAL|RIPC-Group 4|Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia
62719891|NCT03584906|EXPERIMENTAL|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
62546100|NCT03518645|EXPERIMENTAL|OPN strategy|The OPN NC Super High Pressure PTCA Balloon will be used as the study device for lesion preparation for BVS Absorb implantation - OPN strategy of lesion preparation. This balloon has a twin layer balloon construction, which allows a very high pressure resistance of 35 bar. The balloon has a 0.016'' lesion entry profile and is available in sizes between 1.5 and 4.5 mm and lengths of 10, 15 and 20 mm.
62546101|NCT03518645|ACTIVE_COMPARATOR|standard strategy|Predilatation with standard coronary balloon will be performed for lesion preparation for BVS Absorb implantation - standard strategy of lesion preparation.
62546102|NCT05652595|EXPERIMENTAL|TR Sequence|first Intervention period - subjects are administered test medecine (GP40141) and in seconde Intervention period subjects are administered reference medecine (Nplate)
62546103|NCT05652595|EXPERIMENTAL|RT Sequence|first Intervention period subjects are administered reference medecine (Nplate) and in seconde Intervention period subjects are administered test medecine (GP40141)
62719892|NCT02560220|EXPERIMENTAL|Intervention arm|Patients receive MIC cell therapy together with standard immunosuppressive therapy
62719893|NCT01392573|EXPERIMENTAL|IDegLira + metformin|IDegLira was injected subcutaneously once daily for 26 weeks.
62719894|NCT01392573|EXPERIMENTAL|IDeg + metformin|IDeg was injected subcutaneously once daily for 26 weeks.
62719895|NCT04416243|EXPERIMENTAL|Recumbent Stepping, High-Intensity Interval Training|
62719896|NCT06715345|NO_INTERVENTION|Control Group|Local autologous bone
62719897|NCT06715345|EXPERIMENTAL|Experimental Group 1|Dose 1
62719898|NCT06715345|EXPERIMENTAL|Experimental Group 2|Dose 2
62546104|NCT00758966|EXPERIMENTAL|NF (Naltrexone+Fluoxetine)|Naltrexone SR 32 mg and fluoxetine 60 mg
62546105|NCT00758966|ACTIVE_COMPARATOR|Fluoxetine|Fluoxetine 60 mg
62546106|NCT00758966|ACTIVE_COMPARATOR|Naltrexone|Naltrexone SR 32 mg
62546107|NCT03010683|ACTIVE_COMPARATOR|liraglutide|
62546108|NCT03010683|ACTIVE_COMPARATOR|Metformin|
62546109|NCT03366441|EXPERIMENTAL|Telephone group|The telephone group received telephone calls. All non-response and refusing donors were included for further follow-up. Donors who answered the phone call and agreed to be interviewed were asked the reasons why they had stopped donating according to a pre-designed questionnaire. All of the responsed donors were re-recruited by altruistic appeal.
62546110|NCT03366441|EXPERIMENTAL|SMS group|"The SMS intervention group received the following text message:Dear donors, Thank you for your donation through which your love brought hope to those helpless patients and your donated blood reignited the fire in their lives. If you can, please consider donating blood again to save a life. Thank you again for your support! . All donors either receiving or not receiving the message were included for further follow-up."
62546111|NCT03366441|NO_INTERVENTION|Control group|No intervention will be giving to this group.
62546112|NCT00074828|EXPERIMENTAL|A|
62546113|NCT00074828|ACTIVE_COMPARATOR|B|
62546114|NCT01708018|NO_INTERVENTION|Control group|Prior and post intervention period (on days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). Survey concerning birth.
62546115|NCT01708018|EXPERIMENTAL|Intervention group|Prior and post intervention (days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). After the second intervention(day 4): qualitative questionnaire for intervention-group only. Survey concerning birth.
62546116|NCT04909229|EXPERIMENTAL|PEAR-003b PDT Intervention|Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
62546117|NCT04909229|PLACEBO_COMPARATOR|Control Arm|Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
62546118|NCT05937737|EXPERIMENTAL|Type 2 Diabetes|Individuals with type 2 diabetes were followed for 12 weeks with an appropriate diet specific to their type 2 diabetes condition, and necessary measurements were taken at the beginning, 4th week, and 12th week.
62719899|NCT06715345|EXPERIMENTAL|Experimental Group 3|Dose 3
62719900|NCT02947633|EXPERIMENTAL|Continuous sciatic PNB|If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
62719901|NCT02947633|ACTIVE_COMPARATOR|Single-injection sciatic PNB|Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
62719902|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
62719903|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
62719904|NCT02128087|NO_INTERVENTION|Control group|This study arm will receive care as usual.
61976585|NCT05030974|ACTIVE_COMPARATOR|stratum B3 - Ad26.COV2.S vaccine|patients treated with any combination of immunosuppressive drugs, receiving a 3rd COVID vaccination with Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)
61976586|NCT05609045|EXPERIMENTAL|test product group|
62546119|NCT05937737|NO_INTERVENTION|Healthy Controls|No dietary intervention was made for the control group, and necessary measurements were taken at the beginning and 12th week.
62546120|NCT04271917|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|"Participants will receive a 5-day supply of acetaminophen 500mg and ibuprofen 200mg.~Instructions for use: Take one tablet of each medication at the same time every 4-6 hours as needed for pain."
62719905|NCT02128087|EXPERIMENTAL|Two-way SMS intervention group|"Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages (We hope you are feeling well today. Reply 1 if well, 2 if unwell) to request a follow-up call from the clinic."
62546121|NCT04271917|PLACEBO_COMPARATOR|Placebo|"Participants will receive a 5-day supply (15mL) of inactive placebo in a dropper vial.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
62546122|NCT04271917|EXPERIMENTAL|CBD 17mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 17mg/mL.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
62546123|NCT04271917|EXPERIMENTAL|CBD 37 mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 37mg/mL.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
62546124|NCT02457923|EXPERIMENTAL|Mobile phone counselling|"The intervention will include:~* An App for real time data collection of mothers by ASHAs, data transfer, and, display of counselling messages and health video during ASHAs monthly home visit.~* Weekly voice and text messages from server at a prescribed time to provide targeted information on infant feeding counselling.~* Server generated reminders and alerts, delivered to the mother, ASHA and ANM.~* An App for field supervisor to monitor ASHAs~* Women will receive fortnightly mobile phone counselling calls by an ANM at times they recommend. Need based counselling will also be provided"
62546125|NCT02457923|NO_INTERVENTION|Usual health care services|The control clusters to receive usual health care services at PHC. The existing data collection methods will be continued in these clusters. Routine IYCF counseling is provided in existing level of care and its frequency is consistent with the visit schedule described in the intervention group: at antenatal clinics; at delivery; and at immunization clinics postnatal.
62546126|NCT05102227||LBBAP|Patients implanted with a dual-chamber DF-1 cardioverter-defibrillator. Ventricular tachy sensing is performed via an IS-1 pacing lead placed in the interventricular septum.
62546127|NCT02389231|EXPERIMENTAL|Low doses of Interleukine-2|Low doses of Interleukine-2 over a 9 week treatment period
62546128|NCT04280640||Metastatic Cancer Pts Receiving Molecularly Targeted Therapy|Metastatic cancer patients (with liver and/or lung metastasis) who will receive molecularly targeted therapy based on genomic testing data
62546129|NCT04280640||GI Cancer Pts|Gastrointestinal cancer patients (with liver and/or lung metastasis) who will receive 3rd line treatments or enrolled on a targeted therapy treatment trial
62546130|NCT04280640||Bladder Cancer Pts|Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment
62546131|NCT05358080|EXPERIMENTAL|Entelon Tab. 50mg|
62546132|NCT05358080|PLACEBO_COMPARATOR|Placebo|
62546133|NCT01391897||in- and out-patient psychotherapy patients|All included patients are highly selected in- and outpatients in a department of psychosomatic medicine (Germany) undergoing high dose psychotherapy (e.g. group therapy, creative therapy, cbt and psychodynamic psychotherapy).
62546134|NCT05013307|EXPERIMENTAL|CASE|In this prospective study the investigators aim to quantify participants' responses to physical activity. Participants will be asked to engage in physical activity, to identify any provocation of symptoms in adolescents ranging from ages 10 to 22 years. Responses to physical activity will be measured through physiologic markers (e.g., blood pressure, heart rate, oxygen saturation, rate of perceived exertion, dyspnea). Additionally, participants will be monitored for any changes in symptoms that occur during or after physical activity as measured by the modified PCSS symptom inventory.
62546135|NCT06416046|EXPERIMENTAL|Intraoral photobiomodulation (PBM)|"A gallium-aluminum arsenide diode laser (Gemini® manufactured by Azena Medical, LLC, distributed by Ultradent Products, Inc.) with double wavelength 810 + 980 nm. The equipment will be programmed with 0,3W of power. The application of PBM will be carried out for at least 03 alternate days within 01 week by a trained professional. Patients who still have an ulcerated lesion on the 7th day will be assessed every 2 days until complete healing. During each irradiation, the applicator and patients will wear specific protective goggles and the instruments will be disinfected with an antiseptic solution (Chlorhexidine 2%).~Points of application:~Equidistant points (0.5cm) along the length of the lesion and in contact with the lesion."
62546136|NCT06416046|PLACEBO_COMPARATOR|Placebo|The application of placebo will be carried out for at least 03 alternate days within 01 week (3x within 07 days) by a trained professional. Patients who still have an ulcerated lesion on the 7th day will be assessed every 2 days until complete healing. The device will not be activated and the applicator and patients will wear specific protective goggles and the instruments will be disinfected with antiseptic solution (Chlorhexidine 2%).
62546137|NCT04325932|EXPERIMENTAL|Urinary Kallikrein group|Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
62546138|NCT04325932|NO_INTERVENTION|control group|with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
62546139|NCT01934426||Admission High Risk|Admission High Risk
62719906|NCT02128087|EXPERIMENTAL|One-way SMS intervention group|"Clients will receive a weekly one-way SMS with the message We hope you are feeling well today. There will be no prompt for response."
62719907|NCT02197572|EXPERIMENTAL|Sapanisertib|Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
62719908|NCT00473109|EXPERIMENTAL|Dialysis without systemic heparinization|Dialysis without systemic heparinization
62737663|NCT02181491|EXPERIMENTAL|P943 PET Scan|
61976587|NCT05609045|PLACEBO_COMPARATOR|placebo group|
61976588|NCT02452398|EXPERIMENTAL|Treatment Group|Hair removal treatment using Venus Versa IPL energy
62546140|NCT04128501|EXPERIMENTAL|Treatment (azacitidine, venetoclax)|Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
62546141|NCT06328179|EXPERIMENTAL|VHEA regimen in the treatment of ND-AML and RR-AML with MLL gene abnormalities.|"Venetoclax 100 mg d1，200 mg d2，400 mg d3-14； homoharringtoine, HHT 2 mg/m2，qd，d1-7； Etoposide 0.1 g，qd，d1-5； Cytarabine 100 mg/m2，qd，d1-7~The patient meets the criteria for autologous hematopoietic stem cell transplantation (ASCT) during the treatment process, they can undergo ASCT.If the patient meets the criteria for transplantation and there is a suitable donor, they can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT)."
62546142|NCT03490578|EXPERIMENTAL|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P\&S Mechanics Co. Ltd., Seoul, Korea)
62546143|NCT03490578|ACTIVE_COMPARATOR|Intensive treadmill training|Intensive treadmill training using an usual treadmill
62719909|NCT04355650|EXPERIMENTAL|Clinical decision tool|Launch of clinical decision support tool at baseline visit with study clinician.
62719910|NCT06716385|EXPERIMENTAL|MSiHy Silicone Hydrogel Soft Contact Lens|New Monthly disposable contact lenses
62546144|NCT03403647|EXPERIMENTAL|Vitamin D deficient|Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
62546145|NCT03403647|NO_INTERVENTION|No vitamin D deficiency|Regular and routine monitoring
62546146|NCT06632821||University Students|Evaluation of university students' health literacy, physical activity, back pain and posture habits.
62546147|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
62546148|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546149|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546150|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546151|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546152|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546153|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546154|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546155|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
62546156|NCT05440201|EXPERIMENTAL|First test session|For each patient, the anticoagulant Clexane 50IE/kg is administered in the venous line of the dialysis circuit once blood is detected by the dialysis machine.
62719911|NCT06716385|ACTIVE_COMPARATOR|Monthly Silicone Hydrogel Contact Lenses (oA)|Monthly disposable contact lens products already on the market
62719912|NCT00484341|EXPERIMENTAL|A: low-dose NGR-hTNF|0.8 mcg/m² of NGR-hTNF
62719913|NCT00484341|EXPERIMENTAL|B: high-dose NGR-hTNF|45 mcg/m² of NGR-hTNF
62719914|NCT00484341|EXPERIMENTAL|C: low-dose NGR-hTNF + doxorubicin|0.8 mcg/m² of NGR-hTNF + doxorubicin
62719915|NCT00484341|EXPERIMENTAL|D: high-dose NGR-hTNF + doxorubicin|45 mcg/m² of NGR-hTNF + doxorubicin
62719916|NCT00325143|EXPERIMENTAL|Infanrix Hexa Group|Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
62719917|NCT05579730|EXPERIMENTAL|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combination ophthalmic solution, n = 75|
62546157|NCT05440201|EXPERIMENTAL|Second test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
62546158|NCT05440201|EXPERIMENTAL|Third test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
62546159|NCT05440201|EXPERIMENTAL|Fourth test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
62546160|NCT05870618|EXPERIMENTAL|Group A|Group with DTap vaccination produced by Wuhan Institute of Biological Products Co., Ltd
62546161|NCT05870618|EXPERIMENTAL|Group B|Group with DT vaccination
62719918|NCT05579730|EXPERIMENTAL|Ketotifen fumarate ophthalmic solution 0.035% (n = 75)|
61976589|NCT02452398|PLACEBO_COMPARATOR|No intervention|Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
61976590|NCT02105428|NO_INTERVENTION|Sedentary Control|Participants will be randomized to an exercise training program or sedentary control group. The sedentary will not perform any structured physical activity or exercise. Participants will be encouraged to maintain their sedentary lifestyle and will be monitored by an accelerometer to track physical activity.
62546162|NCT05149326|EXPERIMENTAL|Experimental arm|
62546163|NCT05149326|PLACEBO_COMPARATOR|Control arm|
62546164|NCT05017961|ACTIVE_COMPARATOR|Autograft|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group an autograft will be used to fill the void. For the purpose of autologous grafting, cancellous strips of bone will be harvested from the posterior superior iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s). This will be the control arm.
62546165|NCT05017961|OTHER|Allograft only|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) will be used to fill the void. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
62719919|NCT05579730|EXPERIMENTAL|Brimonidine tartrate ophthalmic solution 0.025% (n = 75)|
62719920|NCT05579730|EXPERIMENTAL|Vehicle ophthalmic solution (n = 75)|
62737664|NCT03572231||mirabegron|Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice.
62738992|NCT02220153|EXPERIMENTAL|UCB7665 Subcutaneous 1|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
62738993|NCT02220153|EXPERIMENTAL|UCB7665 Subcutaneous 2|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
61976591|NCT02105428|EXPERIMENTAL|Aerobic Exercise Training|Participants will perform 12-weeks of aerobic exercise training
61976592|NCT02398851|OTHER|TacTIC care model|Compare the 30-day readmission rate in adult patients who receive care in a trans-disciplinary chronic disease continuity of care model with integrated technology (mobile devices such as tablets, iPads and smartphones)
61976593|NCT02398851|OTHER|Standard of Care|Compare standard practice (patient-centered, coordinated care model without the integration of technology
61976594|NCT00508625|OTHER|C|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
61976595|NCT00508625|EXPERIMENTAL|E|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
61976596|NCT00508625|EXPERIMENTAL|B|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.
61976597|NCT00508625|OTHER|A|40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only
61976598|NCT00508625|EXPERIMENTAL|D|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
61976599|NCT01105195|ACTIVE_COMPARATOR|DuraPrep|
61976600|NCT01105195|ACTIVE_COMPARATOR|ChloraPrep|
61976601|NCT01051024|EXPERIMENTAL|A|Diamel
61976602|NCT01051024|PLACEBO_COMPARATOR|B|Placebo
61976603|NCT03114813||Clinically indicated primary prophylaxis|"Approach all those who have had a portal pressure measurement (HVPG) as part of their routine clinical care.~At baseline participants will consent to have an additional MRI scan before undergoing clinical screening Endoscopy.~All participants found to have oesophgeal varices that require primary prophylaxis, will be started on Carvedilol 6.25mg.~After 1 week, participants will return for dose optimisation~After 4-12 weeks of treatment, participants will have:~* repeat one hour MRI scan~* repeat HVPG to evaluate treatment response"
61976604|NCT04078061|ACTIVE_COMPARATOR|MABA|
61976605|NCT04078061|ACTIVE_COMPARATOR|EIBI|
61976606|NCT01074866|NO_INTERVENTION|Pressure support|Non invasive ventilation under pressure support (PS)
61976607|NCT01074866|ACTIVE_COMPARATOR|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally Adjusted ventilatory Assist
61976608|NCT01563003|EXPERIMENTAL|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 16 weekly CBT sessions. This intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposures to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases
61976609|NCT01563003|ACTIVE_COMPARATOR|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
62546166|NCT05017961|OTHER|Allograft combined with BMAC|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) combined with BMAC will be used to fill the void. For the purpose of BMAC preparation, bone marrow will be collected from iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
62719921|NCT02579811|EXPERIMENTAL|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
62719922|NCT03054714|ACTIVE_COMPARATOR|group A|exchange of the infected catheter with a new one over a guidewire
62719923|NCT03054714|ACTIVE_COMPARATOR|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
62719924|NCT05480228|EXPERIMENTAL|NRD135S.E1 80mg/day|NRD135S.E1 as a potential treatment for moderate to severe painful diabetic peripheral neuropathy (PDPN). While the activity of NRD135S.E1 has been extensively studied, its molecular target is not known, though it does not appear to work through any of the opioid receptors or molecular pathways currently targeted by available analgesics. The best evidence suggests it may act, at least in part, through modulating the Lyn kinase signaling pathway In clinical studies, NRD135S.E1 has been well tolerated at all dose levels tested in single-dose (up to 1,200 mg) and repeat-dose regimens (up to 300 mg/day over 5 days or 150 mg over 3 weeks), and it has been shown to have predictable pharmacokinetics with dose-dependent increases in exposure.
62546167|NCT05328219|EXPERIMENTAL|Chewing gums with PEG solution|The investigator provide the chewing gums with PEG solution to the experimental group.
62546168|NCT05328219|ACTIVE_COMPARATOR|Standard of Care|Care provided as per the standard existing routine.
62546169|NCT04196140|EXPERIMENTAL|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
62546170|NCT03458299|EXPERIMENTAL|Motivational Interviewing|The MI intervention will incorporate open-ended questions, personalized feedback, and discussion about participants' alcohol use and drug, associated risk behaviors (e.g., drinking and driving), and the consequences of these behaviors. Individual MI procedures will incorporate the core principles of MI described by Miller and Rollnick, including expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. Therapist interventions will be tailored to the participants' readiness to change/current stage of change (pre-contemplation, contemplation, preparation, action, maintenance, and relapse).
62546171|NCT03458299|EXPERIMENTAL|Psychoeducation|The Psychoeducation session will consist of therapist assisted viewing and discussion of four educational DVDs about adolescent alcohol use, drug use, and driving under the influence provided by Human Relations Media, Mount Kisco, NY (hrmvideo.com).
62546172|NCT06505070|NO_INTERVENTION|Control group|Individuals in the control group continued their daily routines. They were chosen from another nursing home to avoid interaction with the experimental group.
62546173|NCT06505070|EXPERIMENTAL|Experimental group|Participants in the intervention group engaged in bingo, matching pairs, word challenges, and hot-and-cold games, organized into groups of eight individuals. They adhered to the game instructions and participated in sessions twice a week for 2 months, totalling 16 sessions. In each session, all individuals played all four games, so one played 64 games in 16 sessions. Sessions are planned to last 45 minutes.
62546174|NCT01912261|ACTIVE_COMPARATOR|FeraMax|FeraMax Polysaccharide iron complex oral iron supplement 150mg one capsule orally daily
62546175|NCT01912261|PLACEBO_COMPARATOR|Placebo|one capsule orally daily
62546176|NCT01638585|NO_INTERVENTION|standard therapy|patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
62546177|NCT01638585|ACTIVE_COMPARATOR|urokinase|patients receiving urokinase short infusions in addition to standard therapy
62546178|NCT05142956||Smokers|Current smokers are defined as cigarettes smoking within one year before surgery.
62546179|NCT01715571|EXPERIMENTAL|Viberect treatment|Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly
62546180|NCT04181606|ACTIVE_COMPARATOR|Esmolol Infusion|Drug: Esmolol Hydrochloride Dosage form: Intravenous Infusion Dosage/Frequency: 0.5 mg/(kg Fat Free Mass·min) for 3 min followed by a maintenance infusion of 0.25 mg/(kg Fat Free Mass·min) for remainder of trial, up to a maximum of 1 hour.
62546181|NCT04181606|PLACEBO_COMPARATOR|Saline Infusion|Saline infusion volume/rate matched to the calculated dose of esmolol.
62546182|NCT05314101|EXPERIMENTAL|TAS-102 combined with bevacizumab and tislelizumab|TAS-102 combined with bevacizumab and tislelizumab third-line or above in the treatment of liver metastasis in colorectal cancer
62546183|NCT03909282|ACTIVE_COMPARATOR|Surgical Excision|Surgical excision of ductal carcinoma
62546184|NCT03909282|EXPERIMENTAL|Neoadjuvant partial breast irradiation|Partial breast irradiation will be delivered once a day for 5 days before surgery. The planned daily dose is 6 Gy.
62546185|NCT01184079|EXPERIMENTAL|12 months|Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
62546186|NCT01184079|ACTIVE_COMPARATOR|6 month|Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine
62719925|NCT05480228|PLACEBO_COMPARATOR|Matching placebo|A matching placebo comparator will be used.
61976610|NCT01569178|NO_INTERVENTION|standard care|optimal standard care post myocardial infarction
62719926|NCT03946969|EXPERIMENTAL|Sintilimab + Liposomal Paclitaxel + Cisplatin + S-1|Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.
61976611|NCT01569178|EXPERIMENTAL|Intracoronary Reinfusion of Cells|Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells
61976612|NCT00847054|EXPERIMENTAL|MORAb-004|
62719927|NCT03122938|EXPERIMENTAL|Lactoferrin Group|lactoferrin-supplemented formula
62546187|NCT03106987|EXPERIMENTAL|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
62546188|NCT03106987|PLACEBO_COMPARATOR|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
62546189|NCT00559065||Benzene Cohort|Benzene exposed and unexposed workers.
62546190|NCT06463522|EXPERIMENTAL|Tumor-infiltrating Lymphocytes Therapy|Autologous Tumor-infiltrating Lymphocytes Therapy, 2.0\*10\^7/Kg, single intravenous infusion.
62546191|NCT03794479||Travellers|Adults planning for travel
62546192|NCT04539912|EXPERIMENTAL|angulated screw-retained group(AG)|
62546193|NCT04539912|ACTIVE_COMPARATOR|cemented group (CG)|
62546194|NCT01114607|EXPERIMENTAL|Treatment sequence ABCDE|Eligible subjects will be randomized in sequence ABCDE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
62546195|NCT01114607|EXPERIMENTAL|Treatment sequence ABDEC|Eligible subjects will be randomized in sequence ABDEC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
62546196|NCT01114607|EXPERIMENTAL|Treatment sequence ABECD|Eligible subjects will be randomized in sequence ABECD and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
62546197|NCT01114607|EXPERIMENTAL|Treatment sequence ABCED|Eligible subjects will be randomized in sequence ABCED and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= a film coated tablet of GSK1605786 GSK formulation 500 mg once daily and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
62546198|NCT01114607|EXPERIMENTAL|Treatment sequence ABDCE|Eligible subjects will be randomized in sequence ABDCE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
62546199|NCT01114607|EXPERIMENTAL|Treatment sequence ABEDC|Eligible subjects will be randomized in sequence ABEDC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
62546200|NCT01114607|EXPERIMENTAL|Treatment sequence BACDE|Eligible subjects will be randomized in sequence BACDE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
62546201|NCT01114607|EXPERIMENTAL|Treatment sequence BADEC|Eligible subjects will be randomized in sequence BADEC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
62546202|NCT01114607|EXPERIMENTAL|Treatment sequence BAECD|Eligible subjects will be randomized in sequence BAECD and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
62546203|NCT01114607|EXPERIMENTAL|Treatment sequence BACED|Eligible subjects will be randomized in sequence BACED and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
62546204|NCT01114607|EXPERIMENTAL|Treatment sequence BADCE|Eligible subjects will be randomized in sequence BADCE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
62546205|NCT01114607|EXPERIMENTAL|Treatment sequence BAEDC|Eligible subjects will be randomized in sequence BAEDC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
62546206|NCT05635032||IPF|Patients with Idiophatic Pulmonary Fibrosis (IPF), serving as a prototype of a progressive fibroproliferative disorder.
62546207|NCT05635032||Progressive Pulmonary Fibrosis (non-IPF)|Patients with non-IPF interstitial lung diseases, presenting a progressive fibrosing phenotype, or acute exacerbations.
62546208|NCT05635032||Non-Progressive Pulmonary Fibrosis (non-IPF)|Patients with fibrotic non-IPF interstitial lung diseases that are stable during a minimum follow-up of 24 months.
62546209|NCT02075307|EXPERIMENTAL|Blueberry Powder|The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
62546210|NCT02075307|PLACEBO_COMPARATOR|Placebo Powder|The placebo group will receive placebo powder in the same amounts for the same duration.
62546211|NCT01721304|EXPERIMENTAL|Adaptive Conjoint Analysis|Computerized survey to elicit preferences
62546212|NCT01721304|NO_INTERVENTION|Usual care|Patients are counseled by their physician as usual
62546213|NCT05624398|EXPERIMENTAL|Treatment Group|Subjects implanted with the Vivity IOL undergoing concurrent implantation of the Hydrus Microstent
62546214|NCT02422524|EXPERIMENTAL|Child-Pugh A (Mild hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
62546215|NCT02422524|EXPERIMENTAL|Child-Pugh B (Moderate hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
62546216|NCT02422524|EXPERIMENTAL|Child-Pugh C (Severe hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
62546217|NCT02422524|EXPERIMENTAL|Non-hepatically impaired controls|18 matched Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
62546218|NCT00693043|NO_INTERVENTION|Standard anesthesia group|Patients randomized to arm 1 received standard of care anesthesia for pleuroscopy. Duration of the procedure will be recorded. Pain management will be monitored prior to, intraoperatively and at the end of the procedure.
62546219|NCT00693043|EXPERIMENTAL|Lidocaine Group|Patients randomized to arm two will receive a reduced topical dose of lidocaine of 2mg/kg and additional lidocaine 3mg/kg infused into the pleura cavity. Duration of procedure will be monitored from the time initial dose of intradermal lidocaine until the start of surgical wound closing, pain scale will be administered prior to the procedure and at the end of the procedure. Lidocaine serum levels will be monitored at 30, 60, and 120 minutes after initial intradermal administration of lidocaine.
62546220|NCT04482387|OTHER|Subjects recruited to visual acuity testing|All recruited subjects will have the intervention (Digivis visual acuity self-testing) and the standard clinical visual acuity assessment in clinic.
62546221|NCT03997279|EXPERIMENTAL|S.boulardi|Quadruple eradication therapy with S. boulardi
62546222|NCT03997279|PLACEBO_COMPARATOR|Placebo|Quadruple eradication therapy without S. boulardi
62546223|NCT02006225|EXPERIMENTAL|Plerixafor|The use of plerixafor as additive measurment for the conventional stem cell collection protocol.
62546224|NCT05968118|EXPERIMENTAL|investigational product|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
62546225|NCT05968118|PLACEBO_COMPARATOR|Placebo|Patients in this group will receive normal saline respective in D0、14、28
62546226|NCT02018965|OTHER|ER niacin followed by ART alone|For Arm 1, ER niacin administration begins Week 0 and ends Week 24 (defined as 'immediate use' arm).
62546227|NCT02018965|OTHER|ART alone followed by ER niacin|For Arm 2, ER niacin administration begins after the Week 24 Visit and ends Week 48 (defined as 'deferred use' arm).
62546228|NCT04521387|EXPERIMENTAL|N1 Platelet Rich Plasma (PRP)|2ml of autologous platelet rich plasma injection
62546229|NCT04521387|ACTIVE_COMPARATOR|N2 Corticosteroid (CS)|2ml of 7mg Betamethasone injection
62546230|NCT04521387|ACTIVE_COMPARATOR|N3 Hyaluronic Acid (HA)|2ml of 40mg hyaluronic acid with mannitol injection
62546231|NCT04521387|PLACEBO_COMPARATOR|N4 Saline (NaCl)|2ml saline (0,9%NaCl) injection
62546232|NCT04151043|OTHER|Verbal suggestion|
61976613|NCT05789446|EXPERIMENTAL|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.~These children also complete pre- and post-intervention assessments, as well as 6-month and 12-month follow-up assessments."
61976614|NCT05789446|NO_INTERVENTION|Control|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 6-month and 12-month follow-up assessments. No intervention.
61976615|NCT02447549|ACTIVE_COMPARATOR|WBRT|Standard dose whole bladder radiotherapy
62546233|NCT04151043|OTHER|No suggestion|
62546234|NCT01333397|EXPERIMENTAL|Dysport RU 20 U|
62546235|NCT01333397|EXPERIMENTAL|Dysport RU 50 U|
62546236|NCT01333397|EXPERIMENTAL|Dysport RU 75 U|
62546237|NCT01333397|ACTIVE_COMPARATOR|Dysport (Azzalure) 50 U|
62546238|NCT01333397|PLACEBO_COMPARATOR|Placebo|
62546239|NCT04583189|OTHER|Test rapid antigenic and Test RT-PCR|
62546240|NCT06546774|EXPERIMENTAL|Melatonin group|Patients received melatonin supplementation for at least a two-month period prior to IVF cycles
62546241|NCT06546774|NO_INTERVENTION|Control group|Patients did not receive melatonin supplementation and proceeded directly to IVF cycles
62546242|NCT06633601|EXPERIMENTAL|Treatment Arm|All biopsy confirmed breast cancer patients undergoing MRI-Ultrasound Stimulated Microbubble Radiation Treatment plus Radiation Therapy.
62546243|NCT04391296|EXPERIMENTAL|I (Prepectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
62546244|NCT04391296|ACTIVE_COMPARATOR|II (Subpectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
62546245|NCT05801588|EXPERIMENTAL|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
62719928|NCT03122938|PLACEBO_COMPARATOR|Control Group|formula without lactoferrin supplementation
62546246|NCT05801588|ACTIVE_COMPARATOR|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
62546247|NCT04167592|ACTIVE_COMPARATOR|Benzydamine Hydrochloride Group|Subjects who were allocated in benzydamine group would gargle with 15 of ml benzydamine hydrochloride 0.15% before sedation started.
62546248|NCT04167592|PLACEBO_COMPARATOR|Control Group|Subjects who were allocated in control group would gargle with 15 ml of water before sedation started.
62546249|NCT05708989|ACTIVE_COMPARATOR|Caudal Block|Patients will receive a caudal block prior to surgery.
61976616|NCT02447549|EXPERIMENTAL|SART|Standard dose Adaptive tumour focused radiotherapy (SART)
62546250|NCT05708989|EXPERIMENTAL|Pudendal Block|Patients will receive a pudendal block prior to surgery.
62546251|NCT05554081|PLACEBO_COMPARATOR|Clean catch BMI < 30|Standard of care urine collection
62546252|NCT05554081|PLACEBO_COMPARATOR|Clean catch BMI > 30|Standard of care urine collection
62546253|NCT05554081|EXPERIMENTAL|PEEZy collection BMI < 30|PEEZY device for urine collection
62546254|NCT05554081|EXPERIMENTAL|PEEZY collection BMI > 30|PEEZY device for urine collection
62546255|NCT00840489|EXPERIMENTAL|Ribavirin|Ribavirin 1000-1200 mg qd
62546256|NCT00840489|ACTIVE_COMPARATOR|Colchicine|Colchicine 0.5 mg bd
62546257|NCT04020783||Observation group|sequential
62546258|NCT01121367||Emphysema-alone|
62546259|NCT01121367||CPFE group|
62546260|NCT01121367||IPF-alone|
62546261|NCT01121367||smokers|
62546262|NCT01121367||nonsmokers|
62546263|NCT04351633||osteoporosis patient|
62546264|NCT03727880|EXPERIMENTAL|Arm A - Pembrolizumab and Defactinib|
62546265|NCT03727880|EXPERIMENTAL|Arm B - Pembrolizumab|
62546266|NCT04740697|OTHER|Patient with localized breast cancer.|
62546267|NCT03784027|EXPERIMENTAL|Automated closed loop insulin delivery (intervention arm)|"Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 16 weeks.~Intervention: Device: CamAPS FX"
62546268|NCT03784027|ACTIVE_COMPARATOR|Sensor augmented pump therapy (control arm)|Sensor augmented pump therapy over 16 weeks.
62546269|NCT05845502|EXPERIMENTAL|SZ003 CAR-NK|
62546270|NCT05873933|EXPERIMENTAL|Acne and Eczema group|Participants who experience regular acne, pimples, eczema, or blemishes. Must use the test products as prescribed. In addition, must be willing to maintain the following skincare routine during the study: (1)Daily cleansing or rinsing of their face in the morning or the evening is sufficient. (2) The option to wear sunscreen if the sunscreen brand is pre-approved - a person who does not wear sunscreen is more desirable. The test product does contain some sun protection (3) Must NOT use any moisturizer besides our oil. Must use the test product in the morning and the evening daily. Must not be using retinoids and must not start using retinoids during the study. Must NOT use oral anti-acne medications/prescriptions.
62546271|NCT05873933|EXPERIMENTAL|Anti-Aging group|"Participants who experience early-stage wrinkles not treated by topical or oral prescription drugs/medication or over-the-counter products.~Must use the test products as prescribed. In addition, must be willing to maintain the following skincare routine during the study: (1)Daily cleansing or rinsing of their face in the morning or the evening is sufficient. (2) The option to wear sunscreen if the sunscreen brand is pre-approved - a person who does not wear sunscreen is more desirable. The test product does contain some sun protection (3) Must NOT use any moisturizer besides our oil. Must use the test product in the morning and the evening daily. Must not be using retinoids and must not start using retinoids during the study. Must NOT use oral anti-acne medications/prescriptions."
61976617|NCT02447549|EXPERIMENTAL|DART|Dose escalated Adaptive tumour boost radiotherapy (DART)
61976618|NCT02328755|EXPERIMENTAL|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
62546272|NCT03484546||folicular|Women who will undergo endometrioma cystectomy in her follicular phase of menstrual period.
62546273|NCT03484546||ovulatory|Women who will undergo endometrioma cystectomy in her ovulatory phase (12-14th day of mestrual period cycle for women regular period) of menstrual cycle.
62546274|NCT03484546||luteal|Women who will undergo endometrioma cystectomy in her luteal phase of menstrual period.
62546275|NCT03082144|ACTIVE_COMPARATOR|Group 1: RT-Intra-MTX|Intrathecal chemotherapy: MTX 15 mg, plus dexamethasone 5 mg, via lumbar puncture,once per week, 4 weeks in total.
62546276|NCT03082144|EXPERIMENTAL|Group2: RT-Intra-Ara-C|Intrathecal chemotherapy:Ara-C 50 mg, plus dexamethasone 5 mg, via lumbar puncture, once per week, 4 weeks in total.
62546277|NCT00493896|EXPERIMENTAL|Fondaparinux|Fondaparinux treatment - one standard of care option
62719929|NCT02569346|ACTIVE_COMPARATOR|Triumeq whole|Single-dose Triumeq as a whole tablet in a fasted state
62719930|NCT02569346|EXPERIMENTAL|Triumeq crushed + breakfast|Single-dose crushed and suspended Triumeq in a fasted state
62546278|NCT00493896|ACTIVE_COMPARATOR|2|Enoxaparin
62546279|NCT02800642|EXPERIMENTAL|Intravitreal (IVT) aflibercept|Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept
62546280|NCT02774642|EXPERIMENTAL|CBTI-PE|Integrates the core components of CBT-I and PE in 14 90-minute weekly sessions.
62546281|NCT02774642|ACTIVE_COMPARATOR|Hygiene-PE|Uses non-active sleep hygiene to account for the dose response of experimental condition before starting PE. Uses 14 90-minute weekly sessions.
62546282|NCT01820975|EXPERIMENTAL|High protein intake|High protein intake: large bolus of protein in teh diet the day before testing
62546283|NCT01820975|PLACEBO_COMPARATOR|No protein intake|No protein in the diet the day before testing
62546284|NCT02286687|EXPERIMENTAL|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62719931|NCT02569346|EXPERIMENTAL|Triumeq crushed + drip feed|250 ml drip feed (Nutrison) followed by a single-dose crushed and suspended Triumeq
62719932|NCT02095756|EXPERIMENTAL|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of melasma
62719933|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
62546285|NCT04258462|EXPERIMENTAL|Diagnostic (HP 13C pyruvate with MRI)|Participants receive HP 13C pyruvate IV and then undergo 13C MRI scan 1-2 minutes post HP 13C pyruvate injection. Participants may receive an optional second HP 13C pyruvate injection and undergo 13C pyruvate MRI scan 15 to 30 minutes following completion of the first scan or at a return visit 1-2 weeks from the first HP C13 MRI
62546286|NCT04258462|EXPERIMENTAL|Diagnostic (Combined (co-polarized) HP 13C pyruvate and 13C, 15N2 Urea with MRI)|Participants receive HP 13C pyruvate and 13C 15N2 urea IV and then undergo an MRI scan 1-2 minutes post injection. Participants may receive an optional second HP 13C pyruvate with 13C 15N2 urea injection and undergo a second MRI scan 15 to 30 minutes following completion of the first scan or at a return visit 1-2 weeks from the first HP C13 MRI
62546287|NCT05656261||Adults of African or sub-Saharan ancestry|The study focuses on those who are at risk of having the APOL1 renal risk variants, which homozygous or compound heterozygous variants have been shown to lead to Chronic Kidney Disease in some of the population. Those who are found to have this mutations are of African or sub-Saharan ancestry. This study will include those aged 18-90 of this population.
62546288|NCT02461160|PLACEBO_COMPARATOR|SRD Cohorts 1-3: Placebo|TAK-915 placebo-matching suspension, orally, once on Day 1.
62546289|NCT02461160|EXPERIMENTAL|SRD Cohort 1 TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1.
62546290|NCT02461160|EXPERIMENTAL|SRD Cohort 2: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1.
62546291|NCT02461160|EXPERIMENTAL|SRD Cohort 3: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1.
62546292|NCT02461160|PLACEBO_COMPARATOR|MRD Cohorts 4-6|TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.
62546293|NCT02461160|EXPERIMENTAL|MRD Cohort 4: TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.
62546294|NCT02461160|EXPERIMENTAL|MRD Cohort 5: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.
62546295|NCT02461160|EXPERIMENTAL|MRD Cohort 6: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.
62546296|NCT02461160|EXPERIMENTAL|DDI Cohort 7: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).
62546297|NCT02461160|EXPERIMENTAL|BA/FE Cohort 8 Group 1: A,B,C|Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.
62546298|NCT02461160|EXPERIMENTAL|BA/FE Cohort 9 Group 1: B,C,A|Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.
62546299|NCT02461160|EXPERIMENTAL|BA/FE Cohort 10 Group 1: C,A,B|Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.
62546300|NCT02461160|EXPERIMENTAL|ESSD Cohort 11: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
62546301|NCT06633861|EXPERIMENTAL|In-patients with routine spot-check monitoring of vital signs|In-patients with routine spot-check monitoring of vital signs
62546302|NCT04496518||Patients with ICD/CRT device with iATP programmed on|Patients implanted with an iATP-capable device with iATP on in at least one device detection zone will be enrolled in the iATP PAS. Patients must also be enrolled in the CareLink network for remote monitoring. All patients must have provided signed informed consent.
62546303|NCT01526473|EXPERIMENTAL|AVX901|AVX901 at 4 x 108 IU intramuscularly, given every 2 weeks for a total of three doses.
62546304|NCT01038297|EXPERIMENTAL|EXC 001|
62546305|NCT01038297|PLACEBO_COMPARATOR|Placebo|
62546306|NCT03377101|ACTIVE_COMPARATOR|Arm I (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
62546307|NCT03377101|EXPERIMENTAL|Arm I (fulvestrant, palbociclib, copanlisib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
62546308|NCT05283564|OTHER|Administration of Percussive ventilation breathhold (PVB) technique in healthy volunteers|The healthy patient will execute the Percussive ventilation breathhold technique
62546309|NCT05283564|OTHER|Administration of the PVB-SABR in lung cancer patients|Lung cancer patients will execute a PV breathhold and a verification cone-beam CT scan.
62546310|NCT01998724|NO_INTERVENTION|Standard Care|No intervention
62546311|NCT01998724|EXPERIMENTAL|Tai Chi Exercise|24 week Tai Chi intervention designed for individuals with COPD
62546312|NCT01998724|EXPERIMENTAL|Group Walking Exercise|24 week group walking intervention
62719934|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
62719935|NCT06178367|EXPERIMENTAL|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid|Participants receive moisturizer containing 0,1% low molecular weight (7 kDa) hyaluronic acid on 7 cm x 7 cm area on the right or left leg based on the randomization, twice a day for 1 month
61976619|NCT04197089|EXPERIMENTAL|Vitamin D treatment|Treatment with 10.000 IU or 50.000 IU Vitamin D weekly during 4 weeks
62546313|NCT01231204|PLACEBO_COMPARATOR|Placebo Infusion|Patients will be randomized to receive a continuous infusion of Normal Saline via a Paravertebral Nerve Block.
62546314|NCT01231204|ACTIVE_COMPARATOR|Ropivicaine 0.4% Infusion|Patients will be randomized to receive a continuous infusion of 0.4% Ropivicaine via a Paravertebral Nerve Block.
62546315|NCT01059578|EXPERIMENTAL|Active|GSK206136 once daily
62546316|NCT01059578|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62546317|NCT02875223|EXPERIMENTAL|CC-90011 and Rifampicin|
62546318|NCT02875223|EXPERIMENTAL|CC-90011 and Itraconazole|
62546319|NCT05702229|EXPERIMENTAL|Substudy 1|Volrustomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
62546320|NCT05702229|EXPERIMENTAL|Substudy 2|Rilvegostomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
62546321|NCT05702229|EXPERIMENTAL|Substudy 3|AZD0901 plus volrustomig and 5-fluorouracil or capecitabine
62546322|NCT05702229|EXPERIMENTAL|Substudy 4|AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine
62546323|NCT05702229|EXPERIMENTAL|Substudy 5|AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
62546324|NCT05702229|EXPERIMENTAL|Substudy 6|AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine
62546325|NCT01459042||primary aldosteronism|
62546326|NCT01459042||essential hypertension|
62546327|NCT06633705|EXPERIMENTAL|GUS-estriol|Patients with GUS symptoms and examination findings, who are treated with vaginal oestrogen cream
62546328|NCT06633705|NO_INTERVENTION|GUS-control|Patients with GUS symptoms and examination findings
62546329|NCT06633705|NO_INTERVENTION|Control M|Patients in menopause who doesn't have any GUS symptoms nor examination findings
62546330|NCT06633705|NO_INTERVENTION|Control AV|Patients in menopause who doesn't have any GUS symptoms but have examination findings
62546331|NCT02859142|EXPERIMENTAL|Augmented Treatment|"Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.~* Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions~* Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
62546332|NCT02859142|ACTIVE_COMPARATOR|Standard Treatment w/ placebo|"Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits in addition to placebo pills identical in appearance to varenicline~* Placebo pills (identical to varenicline)~* NicodermCQ (Nicotine Patches): Administered according to package insert directions~* Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
62546333|NCT03729726|EXPERIMENTAL|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model will include: a mandatory school-year program that offers after-school programming 4 days a week, including 120 hours of education (direct instruction \& homework support), 30 hours of health (social emotional learning \& sexual health), and 15 hours of student advocacy; an optional, 4-week summer program that offers 120 hours of programming each summer, including 16 hours of health (social emotional learning - service learning), 104 hours of project-based learning and enrichment (project-based learning in STEM - 64 hours) and enrichment (i.e., field trips, career speakers, and arts and crafts opportunities- 40 hours); and an optional parent engagement program, which will offer monthly parent workshops and quarterly events.
62719936|NCT06178367|ACTIVE_COMPARATOR|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid|Participants receive moisturizer containing 0,1% high molecular weight (1.800 kDa) hyaluronic acid on 7 cm x 7 cm area on the right or left leg based on the randomization, twice a day for 1 month
62546334|NCT03729726|NO_INTERVENTION|Control|
62546335|NCT06451211|EXPERIMENTAL|Tislelizumab + SOX/XELOX|Patients with borrmann type 4 or large type 3 (over 8 cm) gastric cancer, who are deemed to be surgically resectable, are treated with neoadjuvant Tislelizumab (200 mg) and oxaliplatin (150 mg) intravenously on day 1 plus capecitabine (2500 mg) or S-1 (40 mg) orally on day 1-14 in each 21-day cycle. Radical gastrectomy will be performed after 6 cycles, followed by adjuvant chemotherapy (capecitabine or S-1).
62546336|NCT03283267|EXPERIMENTAL|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
62546337|NCT03283267|EXPERIMENTAL|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
62546338|NCT06093230|EXPERIMENTAL|Group A|mild liver function impairment group
62546339|NCT06093230|EXPERIMENTAL|Group B|moderate liver function impairment group
62546340|NCT06093230|EXPERIMENTAL|Group C|normal liver function subject group
62546341|NCT06035978|EXPERIMENTAL|Patients with Heart Failure with Reduced Ejection Fraction|Patients with heart failure with reduced ejection fraction, aged 18+, dispensary at the Cardiology Outpatient Clinic for Heart Failure University Hospital Ostrava, who are orally administered tablets one of the evaluated medicinal products or their combination as indicated by the attending physician (Nebivolol, Valsartan and Sacubitril, Carvedilol, Bisoprolol, Metoprolol, Spironolactone).
62546342|NCT00967460|NO_INTERVENTION|Control group: No intervention|No intervention, regular childcare program
62719937|NCT06178367|PLACEBO_COMPARATOR|Vehicle|Participants receive vehicle on 7 cm x 7 cm area on the right or left leg based on the randomization, twice a day for 1 month.
62719938|NCT05456529|EXPERIMENTAL|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
62719939|NCT00272792|EXPERIMENTAL|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
62738994|NCT02220153|PLACEBO_COMPARATOR|Intravenous Placebo|Single dose placebo comparator for each active arm of intravenous infusion.
61976620|NCT01961323|EXPERIMENTAL|Nebivolol|Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
62546343|NCT00967460|EXPERIMENTAL|Intervention group|Promoting unstructured spontaneous PA through an adaptation of the built environment and the provision of a supportive social environment
62546344|NCT03846583|EXPERIMENTAL|Dose Escalation|"* Tucatinib is administered orally twice daily~* Abemaciclib is administered orally twice daily~* Trastuzumab is adminidtered intravenously once every three weeks~* Aromatase Inhibitor is administered orally once daily"
62546345|NCT03846583|EXPERIMENTAL|Arm A: Active Brain Metastases|"* Tucatinib is administered orally twice daily~* Abemaciclib is administered orally twice daily~* Trastuzumab is adminidtered intravenously once every three weeks~* Aromatase Inhibitor is administered orally once daily"
62546346|NCT03846583|EXPERIMENTAL|Arm B: Surgical Resection Needed|"* Tucatinib is administered orally twice daily~* Abemaciclib is administered orally twice daily~* Trastuzumab is adminidtered intravenously once every three weeks~* Aromatase Inhibitor is administered orally once daily"
62546347|NCT03846583|EXPERIMENTAL|Arm C: Progressive Extracranial Disease|"* Tucatinib is administered orally twice daily~* Abemaciclib is administered orally twice daily~* Trastuzumab is adminidtered intravenously once every three weeks~* Aromatase Inhibitor is administered orally once daily"
62546348|NCT02960490|EXPERIMENTAL|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
62546349|NCT02960490|EXPERIMENTAL|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
62546350|NCT02960490|EXPERIMENTAL|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
62546351|NCT02960490|EXPERIMENTAL|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
62546352|NCT05022212|ACTIVE_COMPARATOR|LACTIN-V|"LACTIN-V contains a naturally occurring human vaginal strain of Lactobacillus (L.) crispatus CTV- 05. At a potency of 2 x 109 cfu/dose, it is preserved in powder formulation, and applied by a vaginal applicator.~Women will receive the study product for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
62546353|NCT05022212|PLACEBO_COMPARATOR|Placebo|"A matching placebo formulation without L. crispatus CTV-05 is supplied in an identical applicator containing just the powder formulation.~Women will receive the placebo for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
62546354|NCT04625491||Location on lower limb|Proximal (thigh) Medium (leg) Distal (ankle and foot)
62546355|NCT04335539|EXPERIMENTAL|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg of cefiderocol and participants ≥34 kg will receive 2000 mg.
62546356|NCT04335539|EXPERIMENTAL|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered via IV every 8 hours on Day 1 and continuing for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg of cefiderocol and participants ≥34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
62546357|NCT00683579||1|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA \>1,000 copies/ml who are initiating HAART with possibility of de-intensification (early treatment).
62546358|NCT00683579||2|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA \>1,000 copies/ml who are not initiating treatment.
62546359|NCT00683579||3|Participants with CD4+ T cells \< 350 cells/mm3 who are initiating treatment.
62546360|NCT00683579||4|Participants with CD4+ T cells \< 350 cells/mm3 who are not initiating treatment.
62546361|NCT04731363|EXPERIMENTAL|Xylitol, 30g|oral xylitol, a potent artificial sweetener
62546362|NCT04731363|EXPERIMENTAL|Erythritol, 30g|oral erythritol, a potent artificial sweetener
62546363|NCT04731363|EXPERIMENTAL|Xylitol, 5g|oral xylitol, a potent artificial sweetener
62546364|NCT04731363|ACTIVE_COMPARATOR|Glucose, 30g|oral glucose, delivered as dextrose
62546365|NCT02224157|EXPERIMENTAL|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
62546366|NCT02224157|ACTIVE_COMPARATOR|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
62546367|NCT05767320|ACTIVE_COMPARATOR|open approach for perforated pectic ulcer|repair of perforated peptic ulcer by open technique (exploration)
62546368|NCT05767320|ACTIVE_COMPARATOR|lap. approach for perforated peptic ulcer|repair of perforated peptic ulcer by laparoscopy
62546369|NCT01555697|ACTIVE_COMPARATOR|Memantine/high|memantine 20 mg
62546370|NCT01555697|PLACEBO_COMPARATOR|Placebo/high|placebo comparator for memantine 20 mg
62546371|NCT01555697|ACTIVE_COMPARATOR|Memantine/low|memantine 10 mg
61976621|NCT01522989|EXPERIMENTAL|PD-0332991, 5-FU and oxaliplatin|PD-0332991 with 5-FU and oxaliplatin
61976622|NCT01157949|ACTIVE_COMPARATOR|Study withdrawn|Study withdrawn
61976623|NCT01157949|PLACEBO_COMPARATOR|Withdrawn|Study withdrawn
62546372|NCT01555697|PLACEBO_COMPARATOR|Placebo/low|placebo comparator for memantine 10 mg
62546373|NCT04529954|EXPERIMENTAL|Open-Label Safety|Participants roll-over from DA071976 or CLN100P.02
62546374|NCT05390593|EXPERIMENTAL|iTBS-1800|The active group will receive 1800 pluse of intermittent theta-bursts in the left dorsolateral prefrontal cortex.
62546375|NCT05390593|EXPERIMENTAL|iTBS-1200|The active group will receive 1200 pluse of intermittent theta-bursts in the left dorsolateral prefrontal cortex.
62546376|NCT02125721|EXPERIMENTAL|CBTD Patients|Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period
62546377|NCT05640258|EXPERIMENTAL|seasickness susceptibility and vestibular time constant|"All study participants underwent rotatory chair testing in a velocity step protocol to determine the Vestibular time constant.~testing were preformed at baseline, before commencing active duty on a ship, 3 month and 6 month follow up after the beginning of active sailing."
62546378|NCT03656744|EXPERIMENTAL|500mg HTD1801, bid|
62546379|NCT03656744|EXPERIMENTAL|1000mg HTD1801, bid|
62546380|NCT03656744|PLACEBO_COMPARATOR|placebo, bid|
62546381|NCT04595422|EXPERIMENTAL|Call center staff (educational intervention)|Participants undergo training consisting of a 60-minute educational session.
62546382|NCT04595422|EXPERIMENTAL|Callers substudy (LCS educational materials, questionnaire)|Participants are referred to lung cancer screening educational materials. Participants also complete questionnaires at 1 week and 6 months after referral to educational materials.
62546383|NCT06583473|EXPERIMENTAL|Interactive digital health care|"The Intelligent Interactive Personal Management System for Heart Failure and Bluetooth-enabled devices for remote monitoring of blood pressure and weight."
62546384|NCT06583473|NO_INTERVENTION|Standard care|The control group will continue to receive standard medical care.
62546385|NCT04218578||Device group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with MitraClip
62546386|NCT04218578||Control group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with optimal medical treatment
62546387|NCT04236882|EXPERIMENTAL|Focus group and interview (focus group, interview)|Participants attend either a focus group or interview about the sleep intervention and sleep-related problems over 90 minutes.
62546388|NCT04236882|EXPERIMENTAL|Group I (sleep intervention, health coaching session)|Participants receive a web-based sleep intervention weekly during weeks 1-4. Participants then receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out during weeks 5-9. Participants may optionally complete an interview over 1 hour at week 9.
62546389|NCT04236882|EXPERIMENTAL|Group II (health coaching session, sleep intervention)|Participants receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out during weeks 1-4. Participants then receive a web-based sleep intervention weekly during weeks 5-9. Participants may optionally complete an interview over 1 hour at week 9.
62546390|NCT04236882|ACTIVE_COMPARATOR|Group III (health education material, counseling session)|Participants receive educational material on healthy homes. Participants also receive 2 web-based counseling sessions over 30-45 minutes consisting of topics such as indoor air quality, CPR and first aid, and emergency preparedness at weeks 1 and 3. Participants may optionally complete an interview over 1 hour at week 9.
62719940|NCT00272792|PLACEBO_COMPARATOR|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
62546391|NCT06628804|EXPERIMENTAL|Artemisia and green tea extracts group|This group takes Artemisia and green tea extracts for 8 weeks.
62546392|NCT06628804|PLACEBO_COMPARATOR|Placebo group|This group takes a placebo for 8 weeks.
62546393|NCT01321827|EXPERIMENTAL|Itraconazole group|Itraconazole 200 mg BD for 4 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
62546394|NCT01321827|ACTIVE_COMPARATOR|Glucocorticoid group|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
62546395|NCT01272492|EXPERIMENTAL|Computer Use|Participants use the computer with the infant/toddler nutrition/feeding education modules
62546396|NCT01272492|NO_INTERVENTION|Control|Only answers survey questions.
62546397|NCT05739149|EXPERIMENTAL|Microvessel Ultrasound Imaging for Chronic Ulcers|Subjects with chronic diabetic ulcers and venous ulcers will undergo wound debridement and treatment as standard of care and receive research microvessel ultrasound examination and two skin biopsies
62546398|NCT04082156|ACTIVE_COMPARATOR|Active TENS|
62719941|NCT04860115|EXPERIMENTAL|Block group|Patients in a Block group will be anesthetized and receive PECS II+PIFB with dexmetomidine prior to their surgery.
62546399|NCT04082156|SHAM_COMPARATOR|Sham TENS|
62546400|NCT05329662|ACTIVE_COMPARATOR|AD-MSCs infusions, then Placebo|Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 ± 7
62546401|NCT05329662|PLACEBO_COMPARATOR|Placebo, then AD-MSCs infusions|Patients in group B will receive two autologous AD-MSC administrations on day 180 ± 14 and day 270 ± 14
62546402|NCT03431545|EXPERIMENTAL|PALS and BEECH|Play and Learning Strategies (PALS) and Beginning Education: Early Childcare at Home (BEECH) include web-based parent and teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.
62546403|NCT03431545|ACTIVE_COMPARATOR|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
62738995|NCT02220153|PLACEBO_COMPARATOR|Subcutaneous Placebo|Single dose placebo comparator for each active arm of subcutaneous infusion.
62546404|NCT02032680|EXPERIMENTAL|Web-based family psycho-education treatment|The e-health/web-based intervention provides: three therapist facilitated group forums; a function to send facilitators questions; a library of previously answered questions; and a library of educational materials.
62546405|NCT02032680|ACTIVE_COMPARATOR|In-persons Multi-Family Group Psycho-Education treatment|This arm provides the evidence based multi-family psychoeducational treatment, termed Multi-Family Group Psycho-Education (MFG) that is the standard of care in the VA.
62546406|NCT02032680|OTHER|Treatment as Usual|The Treatment as usual (TAU) group provides a benchmark against which to measure the impact of the two individual interventions (MFG \& DSW) independent from each other. Through enhancements of TAU, such as regular monitoring which will be done in the assessment process and by the provision of information to VA psychiatrist when there are concerns or problems with the psychiatric status of their patients, we will be taking reasonable steps to ensure the safety of the participants who are assigned to TAU.
62546407|NCT02011477|EXPERIMENTAL|Neural glide|This technique involves two movements, initial and final. It consists of going from one to the other constantly. The therapist took the subject's head by putting his hands on the suboccipital and front region. In the initial movement, the therapist perform craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject perform dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as perform plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject. The session lasted 7 minutes.
62546408|NCT02011477|PLACEBO_COMPARATOR|Placebo|The model of the ultrasound (ENRAF-NONIUS, P.O. Box 12080, 3004 GB Rotterdam, The Netherlands). The subject was placed in a prone position, with arms along the body and the head in the hole of the examining couch. The therapist applied a non-therapeutic dose of ultrasound for 7 minutes with no break all over the cervical area and trapezius, in circles.
62546409|NCT02011477|ACTIVE_COMPARATOR|Neural Stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
62546410|NCT06633835|ACTIVE_COMPARATOR|2024-25 updated Novavax COVID-19|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
62546411|NCT06633835|ACTIVE_COMPARATOR|Pfizer mRNA COVID-19|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
62546412|NCT02351141|OTHER|Asthma Patients|All enrolled asthma patients will undergo hyperpolarized noble gas MRI with Helium-3 and/or Xenon-129, Pulmonary Function Tests, Quality of Life Questionnaires, dyspnea scales in two visits over three years.
62546413|NCT02975778|EXPERIMENTAL|Aged, 65 and over|
62546414|NCT05921552|EXPERIMENTAL|Tele Health Exercise Prehabilitation|Participants will take part in an exercise program in which they will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week until they undergo surgery (Approximately 2-4 weeks). Participants will also be encouraged to perform moderate aerobic exercise such as brisk walking or using stationary aerobic equipment at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
62546415|NCT01105871|ACTIVE_COMPARATOR|naloxone|4 mg in 10 ml saline iv bolus
62546416|NCT01105871|PLACEBO_COMPARATOR|saline placebo|10 ml of normal saline iv bolus
62546417|NCT04368351||Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
62546418|NCT04368351||bacteriotherapy|Dietary Supplement: SivoMixx (200 billion) plus Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), and hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
62546419|NCT00229177|PLACEBO_COMPARATOR|P|
62546420|NCT00229177|EXPERIMENTAL|E1|
62719942|NCT04860115|NO_INTERVENTION|Control group|Patients in a Control group will receive a standard general anesthesia the same way as patients in the interventional group but without regional anesthesia.
62546421|NCT00229177|EXPERIMENTAL|E2|
62546422|NCT05097365|EXPERIMENTAL|Supplemented Normal Weight Group|Patients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive supplementation.
62546423|NCT05097365|EXPERIMENTAL|Supplemented Excess Body Weight Group|Patients with excess body weight (BMI \> 25 kg/m²) that will receive supplementation.
62546424|NCT05097365|PLACEBO_COMPARATOR|Control Normal Weight Group|Patients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive placebo.
62546425|NCT05097365|PLACEBO_COMPARATOR|Control Excess Body Weight Group|Patients with excess body weight (BMI \> 25 kg/m²) that will receive placebo.
62546426|NCT02655783|ACTIVE_COMPARATOR|control|normal saline, 250 ml/h, until expulsion of placental
62546427|NCT02655783|EXPERIMENTAL|intervention|normal saline + 5% dextrose, 250 ml/h, until expulsion of placental
62719943|NCT00901225|EXPERIMENTAL|G-CSF plus Plerixafor|Patients who were unable to mobilize a minimum number of cells (CD34+ cell count \<20 cells/ul)following 5 days of G-CSF mobilization.
62719944|NCT01663311|EXPERIMENTAL|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
61976624|NCT03929575|PLACEBO_COMPARATOR|Placebo of calcium|Participants will consume 250 mg of calcium
62546428|NCT01772485|EXPERIMENTAL|Cognitive Training|Training group participants will engage in 30 hours of at-home online training on the novel neuroplasticity-based cognitive training program ('Rewired') in 30 minute sessions completed approximately 3-5 days per week, for a total training period lasting 12-20 weeks. Both visual and auditory exercise forms will be practiced daily. Level progression criteria will be flexibly set to assure that almost all individuals can reach them in a reasonable time. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely, and analyzed over secure online servers to assure that subjects are completing their training as scheduled and to deal with any unexpected road-blocks in training.
62546429|NCT01772485|ACTIVE_COMPARATOR|Active Control|The active control group shall engage in an at-home computer game suite, as used in a prior cognitive training trial in a psychiatric population (Fisher et al., 2009), for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with clinical research personnel and monetary rewards. Compliance will be monitored via an online data portal.
62546430|NCT03883308|EXPERIMENTAL|Treatment|Treatment group will receive 6 months of online, computerized, multi-domain cognitive training at home.
62546431|NCT03883308|ACTIVE_COMPARATOR|Active Control|The Active Control group will receive 6 months of online, computerized cross-word puzzles at home using the same platform as for the Treatment group.
62546432|NCT03461731|SHAM_COMPARATOR|Control|Participant will receive a sham treatment that consists of just the 660-nm aiming beam
62546433|NCT03461731|EXPERIMENTAL|800 nm laser|800 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
62546434|NCT03461731|EXPERIMENTAL|combination laser|905 nm and 800 nm will be applied at 4.4 joules per square cm with a total of 8.8 Joules per square cm during 40 repetitive handgrips.
62546435|NCT03461731|EXPERIMENTAL|905 nm laser|905 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
62546436|NCT02208739|EXPERIMENTAL|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy was given to all patients at baseline
62546437|NCT02208739|ACTIVE_COMPARATOR|Oral hygiene instructions|Oral hygiene instructions were given to all patients at baseline
62546438|NCT01360463|EXPERIMENTAL|Behavioral and Drug Risk Counseling|Participants assigned to this arm will receive bi weekly Behavioral and Drug Risk Counseling (BDRC) counseling for six months.
62546439|NCT01360463|ACTIVE_COMPARATOR|Treatment as Usual|Participants assigned to this arm will receive methadone treatment without and alterations.
62546440|NCT02208804|EXPERIMENTAL|Surefire Infusion System|Hepatic arterial administrations using the Surefire Infusion System
62546441|NCT02208804|ACTIVE_COMPARATOR|Standard End-hole Microcatheter|Hepatic arterial administrations using the standard end-hole microcatheter
62546442|NCT02256436|ACTIVE_COMPARATOR|Control|Participants receive paclitaxel 175 mg/m\^2 intravenously (IV) or docetaxel 75 mg/m\^2 IV or vinflunine 320 mg/m\^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experience disease progression may be able to switch over to receive pembrolizumab 200 mg Q3W for up to 35 treatment administrations (up to approximately 2 years).
62546443|NCT02256436|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg IV on Day 1 Q3W. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to approximately 1 additional year).
62546444|NCT04851392|EXPERIMENTAL|THC condition|"THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC. A 75kg person receives 8mg of THC.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in \< 18 minutes."
62546445|NCT04851392|EXPERIMENTAL|THC+CBD condition|"THC+CBD condition: Cannabis with THC and CBD (i.e. THC+CBD condition). 0.107mg/kg of THC and 0.320mg/kg of CBD. A 75kg person receives 8mg of THC and 24mg of CBD.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in \< 18 minutes."
62546446|NCT04851392|PLACEBO_COMPARATOR|PLA condition|"PLA condition: Placebo cannabis with no THC or CBD.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in \< 18 minutes."
62546447|NCT06151769|EXPERIMENTAL|Pomegranate seed oil|In addition to the routine care of patients, pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days.
62546448|NCT06151769|ACTIVE_COMPARATOR|Sesame oil|In addition to the routine care of patients, Sesame oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days.
62546449|NCT06151769|NO_INTERVENTION|Control group|Patients will not be interfered with in their routine care. Patient monitoring will be done every afternoon for 6 days.
62546450|NCT04575311|ACTIVE_COMPARATOR|Active: Dose Escalation|Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 will be random.
62546451|NCT04575311|PLACEBO_COMPARATOR|Placebo: Dose Escalation|Participants will receive matching placebo as a single oral dose. Assignment to receive matching placebo will be random.
62546452|NCT06254456|EXPERIMENTAL|Prone patients|
62546453|NCT04292288||Foreign body granuloma|men injecting paraffin oil
62546454|NCT03436056|OTHER|Dose escalation cohort - DOSE LEVEL 1|Intervention: One dose pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
62546455|NCT03436056|OTHER|Dose escalation cohort - DOSE LEVEL 2|Intervention: One dose of pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
62737665|NCT03572231||Antimuscarinics|Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
62546456|NCT03436056|OTHER|Part B - Expansion cohort|Intervention: One dose of pembrolizumab 200 mg (week 1) followed in by lung Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose determined in Part A in week 3, dosed at the maximum tolerated dose determined in Part A. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
62546457|NCT02405130|ACTIVE_COMPARATOR|epinephrine|intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg
62546458|NCT02405130|OTHER|no intracoronary epinephrine|no epinephrine
62546459|NCT05967884|ACTIVE_COMPARATOR|Arm A: Cemiplimab|Arm A: Cemiplimab (n=10), 350mg IV x 1 dose administered prior to surgery.
62546460|NCT05967884|EXPERIMENTAL|Arm B: Cemiplimab + Dupilumab|Arm B: Cemiplimab + Dupilumab (n=10), Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery.
62546461|NCT00286026|EXPERIMENTAL|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); will be treated with Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
62546462|NCT00286026|EXPERIMENTAL|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with Azithromycin; will receive a second dose of Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
62546463|NCT04657211||Group A|Participants will receive treatment from settled general practitioners (GPs) (GPs, primary care, practitioner/registered doctor).
62546464|NCT04657211||Group B|Participants will receive treatment from settled pulmonologists (specialists, primary or secondary care).
62546465|NCT04657211||Group C|Participants will receive treatment at outpatient lung centers (clinics, ambulances, acute care centers).
62546466|NCT02827695|EXPERIMENTAL|SMASK|Subjects will receive electronic pill tray with reminder functions activated and Bluetooth blood pressure monitor and phone app.
62546467|NCT02827695|OTHER|EnhancedSC|Subjects will receive daily attention control texts with healthy lifestyle information and continue to use the pill tray without reminder functions.
62546468|NCT00922740|PLACEBO_COMPARATOR|Sugar pill|
62546469|NCT00922740|EXPERIMENTAL|VA106483 1 mg|
62546470|NCT00922740|EXPERIMENTAL|VA106483 2 mg|
62546471|NCT00922740|EXPERIMENTAL|VA106483 4 mg|
62546472|NCT06550752|EXPERIMENTAL|Mixture UC-MSCs and PRP|A mixture of UCSCs and PRP will be injected into the corpora cavernosa of the penis of each patient. The injection will be done at four points along the shaft on both sides of the penis. The injection procedure will be performed once per month for a total duration of three months. Each patient received a dosage of 10 million cells per injection session.
62546473|NCT06344767||FES positive in MBC|Patients who did not present with any ER-positive lesions in primary cancer were characterized as with any positive ER expression in the metastatic stage
62546474|NCT03511092|EXPERIMENTAL|HMB-FA|
62719945|NCT01663311|EXPERIMENTAL|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
62546475|NCT03511092|EXPERIMENTAL|HMB-Ca|
62546476|NCT03511092|EXPERIMENTAL|alfa-HICA|
62546477|NCT03511092|PLACEBO_COMPARATOR|Placebo|
62719946|NCT04303975||Group 1: Patients with neoadjuvant chemotherapy|"The patients of group1 will receive one of the following treatments:~1. neoadjuvant chemotherapy \& concurrent chemoradiotherapy~2. neoadjuvant chemotherapy \& radiotherapy~3. neoadjuvant chemotherapy \& radiotherapy \& adjuvant chemotherapy"
62719947|NCT04303975||Group 2: Patients without neoadjuvant chemotherapy|"The patients of group2 will receive one of the following treatments:~1. concurrent chemoradiotherapy~2. concurrent chemoradiotherapy \& adjuvant chemoradiotherapy~3. radiotherapy \& adjuvant chemotherapy"
62719948|NCT00371371|EXPERIMENTAL|BM-MNC|autologous bone marrow-derived mononuclear cells
62546478|NCT05593497|EXPERIMENTAL|Single Arm|neoadjuvant capivasertib combined with androgen receptor pathway therapy (leuprolide + abiraterone) prior to radical prostatectomy
62719949|NCT00371371|PLACEBO_COMPARATOR|Placebo|Placebo
62546479|NCT03803982|EXPERIMENTAL|Deep Neuromuscular Blockade, Sugammadex|All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
62546480|NCT03803982|NO_INTERVENTION|Standard Anesthetic|Patients in the standard anesthetic (or control group) will also receive anesthetic induction as per routine using a combination of propofol, opioids, dexamethasone, and rocuronium, with a lidocaine infusion. Patient monitoring will be similar to the experimental group, with electrocardiography, blood pressure, heart rate, and bispectral index monitoring. Patients in the control group will receive rocuronium 30 mg intravenous prior to intubation, followed by repeated 10 mg doses to reach a TOF of 1-2 twitches.
62546481|NCT04107909|OTHER|3 ports|3port operation
62546482|NCT04107909|OTHER|4 port|4 port operation
62546483|NCT02042456||Main Cohort|Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
62546484|NCT03579381||Immune Controllers|Patients with very low or undetectable levels of viremia without treatment
62546485|NCT03579381||Acute Infection|Early infection, i.e. within 2 weeks of infection
62719950|NCT00535418|EXPERIMENTAL|Letrozole|
62737666|NCT05503095||patients who develop cardiac rupture following acute myocardial infarction|
62546486|NCT00041132|EXPERIMENTAL|Hyper-CVAD + MTX/Ara-C + Rituximab|"21-day cycles of Hyper-CVAD and high-dose methotrexate/cytarabine are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.~Hyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m\^2 on day 1, mesna 600 mg/m\^2 on days 2-4, cyclophosphamide 300 mg/m\^2 on days 2-4, doxorubicin 16.6 mg/m\^2/day on days 5-7, vincristine 1.4 mg/m\^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and filgrastim 5 ug/kg on days 8-21.~Methotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m\^2 on day 1, methotrexate 1000 mg/m\^2 over days 2-3, Ara-C 12 g/m\^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21."
62546487|NCT04045483|EXPERIMENTAL|VR based cognitive training|Participants perform the VR based cognitive training under the supervision of a research nurse or psychologist for 30 min per session, twice per week, over the 6-week intervention period.
62546488|NCT04045483|NO_INTERVENTION|Usual care|Participants take some medication for risk factors and cognitive impairment and receive health advice as a usual care.
62546489|NCT01522612|EXPERIMENTAL|5-fluorouracil/leucovorin plus cetuximab|
62546490|NCT01522612|ACTIVE_COMPARATOR|5-fluorouracil/leucovorin alone|
62546491|NCT05124886|ACTIVE_COMPARATOR|Healthy Controls|
62546492|NCT05124886|EXPERIMENTAL|Enteric Hyperoxaluria|
62546493|NCT04169945|EXPERIMENTAL|Ultrasonic instrumentation and Air Polishing|All participants will receive full mouth conventional ultrasonic subgingival debridement, followed by air-polishing with erythritol powder which include activating device for 5 seconds of each surface (Petersilka 2003). Subsequently, Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth \>4mm. Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth \>4mm
62546494|NCT04169945|ACTIVE_COMPARATOR|Ultrasonic instrumentation|All participants will receive full mouth conventional ultrasonic subgingival debridement only. No time limit (Flemmig 2012), until dental surfaces feel smooth.
62546495|NCT04514484|EXPERIMENTAL|Treatment (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
62546496|NCT06192056|ACTIVE_COMPARATOR|Intervention group|The RNT-focused web based self-help program will be given to the intervention group.
62546497|NCT06192056|NO_INTERVENTION|Waitlist group|Waitlist group will be given only pre and post test measures at the same time with the intervention group.
62546498|NCT06633289|OTHER|Experimental formula-Control formula|"Blinded cross-over oral food challenge sequence starting by Experimental formula followed by Control.~Following the crossover phase, children who passed the oral food challenge will consume the open label experimental formula at home during 7 days."
62546499|NCT06633289|OTHER|Control formula-Experimental formula|"Blinded cross-over oral food challenge sequence starting by Control followed by Experimental formula.~Following the crossover phase, children who passed the oral food challenge will consume the open label experimental formula at home during 7 days."
62546500|NCT04409483|ACTIVE_COMPARATOR|Standard Care|Standard care for COVID-19 according to the national guidelines of Niger
62546501|NCT04409483|EXPERIMENTAL|Standard Care plus lopinavir/ritonavir|Standard care for COVID-19 according to the national guidelines of Niger plus lopinavir/ritonavir
62546502|NCT01128179|EXPERIMENTAL|Lanthanum carbonate|
62546503|NCT01128179|PLACEBO_COMPARATOR|Placebo|
62546504|NCT02413567|EXPERIMENTAL|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
62546505|NCT01249560||raltegravir|"To illustrate the cause and effect relationship between the abnormalities of the distribution(casting) of the molecules of co-activation and the rate of apoptose, we compare also 2 groups: a first group of patients with a rate of apoptose normal ( n=10 ), and another group of patients having a rate of apoptose aggravated ( n=10 ).~20 eligible patients will receive their treatment to J1 and will be estimated for the residual concentration of the raltegravir ®, the antiretroviral activity, the tolerance and the observance at the treatments of the study in the visits of evaluation of M1, M2, M3, M6, M12, and / or in case of premature stop(ruling) of the try(essay). Every visit will give rise to a clinical evaluation of the patient. The arisen of unwanted events"
62546506|NCT04380597||Patients with nail psoriasis|Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
62546507|NCT04714073|EXPERIMENTAL|Reference: BI 706321 alone|First treatment period
62546508|NCT04714073|EXPERIMENTAL|Test: BI 706321 + Itraconazole|Second treatment period
62546509|NCT01266031|EXPERIMENTAL|Bevacizumab|10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.
62546510|NCT01266031|EXPERIMENTAL|Vorinostat and Bevacizumab|"Vorinostat: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.~Bevacizumab: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle."
62546511|NCT01443897|PLACEBO_COMPARATOR|Group 1|Untreated mushrooms plus placebo capsule.
62546512|NCT01443897|EXPERIMENTAL|Group 2|UVB-treated mushrooms (400 IU vitamin D2 per serving) plus placebo capsule.
62546513|NCT01443897|EXPERIMENTAL|Group 3|UVB-treated mushrooms (1,000 IU vitamin D2 per serving) plus placebo capsule.
62546514|NCT01443897|EXPERIMENTAL|Group 4|Untreated mushrooms plus 1,000 IU Vitamin D2 in capsule
62546515|NCT01727037|EXPERIMENTAL|BIABI arm|Patients will undergo intrabullous autologous blood instillation
62546516|NCT03926520|EXPERIMENTAL|ECT+UC group|ECT with Usual Care
62546517|NCT01792687|EXPERIMENTAL|Treatment|ARN-509 when combined with the approved dose of abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily).
62546518|NCT05042895|ACTIVE_COMPARATOR|PCO women|Group A will consist of 100 PCO infertile women
62546519|NCT05042895|ACTIVE_COMPARATOR|unexplained infertile cases|group B will consist of 50-unexplained infertility.
62546520|NCT00100880|EXPERIMENTAL|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 2-3 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which an estimated 25% of patients experience dose-limiting toxicity."
62546521|NCT02671929|EXPERIMENTAL|self-help program + feedback|Patients in this arm receive access to the internet-based self-help program and get feedback on their progress in the program.
62546522|NCT02671929|ACTIVE_COMPARATOR|self-help program|Patients in this arm receive access to the internet-based self-help program and don't get any therapeutic feedback
62546523|NCT04799496||Kynteles Injection (Vedolizumab)|Participants with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-α) antagonist or participants with pouchitis, who have undergone proctocolectomy and IPAA for UC, and have had an inadequate response with, or lost response to antibiotic therapy and have initiated Kynteles injection (Vedolizumab) treatment in a routine clinical practical setting in South Korea, will be observed prospectively.
62546524|NCT04683679|EXPERIMENTAL|Arm A|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT + olaparib
62546525|NCT04683679|EXPERIMENTAL|Arm B (the study is amended to pause Arm B)|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT only
62546526|NCT04683679|EXPERIMENTAL|Arm C (activate new arm)|Participants will have metastatic ER+ breast cancer (ER+ MBC) Treatment will be pembro/SBRT/Olaparib)
62546527|NCT04521738|EXPERIMENTAL|SAR441255|Single dose, subcutaneous, escalating dose
62546528|NCT04521738|PLACEBO_COMPARATOR|Placebo|Single dose, subcutaneous, matched volume
62546529|NCT03552848|EXPERIMENTAL|Mesenchymal stem cell|Patients in the MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.
62546530|NCT03552848|NO_INTERVENTION|Control|Patients in the control arm will not be given MSC.
62546531|NCT03906422|EXPERIMENTAL|"A: 0.016 Nitinol"|"0.016 Nitinol (3M Unitek, Monrovia, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
62546532|NCT03906422|EXPERIMENTAL|"B: 0.016 Ormco 27oC NiTi"|"0.016 Ormco 27oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
62546533|NCT03906422|EXPERIMENTAL|"C: 0.016 Ormco 35oC NiTi"|"0.016 Ormco 35oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
62546534|NCT02129608|ACTIVE_COMPARATOR|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
62546535|NCT02129608|ACTIVE_COMPARATOR|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
62546536|NCT02129608|ACTIVE_COMPARATOR|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
62546537|NCT05114876|NO_INTERVENTION|Standard of Care|Standard of care
62546538|NCT05114876|ACTIVE_COMPARATOR|Intervention|Multicomponent delirium-risk prevention bundle
62546539|NCT02771470|EXPERIMENTAL|Probiotic|Microbial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
62546540|NCT02771470|PLACEBO_COMPARATOR|Placebo|Microbiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
62546541|NCT03437070|EXPERIMENTAL|TDO Dose Level|Trabectedin \[T\], Doxorubicin \[D\], and Olaratumab \[O\]
62546542|NCT02681835|EXPERIMENTAL|Position 1|Standard position during intubation. Intubator is behind head of the victim, propped up on both elbows
62546543|NCT02681835|EXPERIMENTAL|Position 2|Intubator is behind head of the victim, lies on the left side
62546544|NCT02681835|EXPERIMENTAL|Position 3|Intubator stands astride the victims, intubated using the face-to-face
62546545|NCT04952350|ACTIVE_COMPARATOR|Atorvastatin|"All patients will be randomized to receive atorvastatin 40 mg once daily orally for a maximum of 28 days. All patients will receive the standard of care according to recent local hospital protocol. Antiviral treatment will be allowed and will be reported.~Administration in unconscious or ventilated patients: The patients will receive the drug (divided into 4 quadrants) through a nasogastric tube."
62546546|NCT04952350|PLACEBO_COMPARATOR|Control|"All patients will be randomized to receive the placebo once daily orally for a maximum of 28 days. All patients will receive the standard of care according to recent local hospital protocol. Antiviral treatment will be allowed and will be reported.~Administration in unconscious or ventilated patients: The patients will receive the drug through a nasogastric tube.~Placebo will resemble the original drug as regards the drug package, the tablet color, consistency, and size."
62546547|NCT05446012||women diagnosed with ectopic pregnancy (n: 40)|thyroid function tests (TSH, sT3, sT4, TT3, TT4, thryoglobulin, Anti-Peroxidase Antibody, Anti- thryoglobulin Antibody, TSH receptors antibody levels) will be done in women diagnosed with ectopic pregnancy
62719951|NCT04067492|EXPERIMENTAL|RPH - 4 mg|Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.
62719952|NCT04067492|EXPERIMENTAL|RPH - 20 mg|Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.
62719953|NCT04067492|EXPERIMENTAL|RPH - 40 mg|Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.
62546548|NCT05446012||Control group pregnants (n:40)|thyroid function tests (TSH, sT3, sT4, TT3, TT4, thryoglobulin, Anti-Peroxidase Antibody, Anti- thryoglobulin Antibody, TSH receptors antibody levels) will be done in pregnant women in early pregnancy week.
62719954|NCT04067492|EXPERIMENTAL|RPH - 80 mg|Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.
62546549|NCT04411914|EXPERIMENTAL|Clavulanic Acid|Participants will receive 10 days of CLAV-- Period 1: 500 mg/day for days 1-3; Period 2: 750 mg/day for days 4-6; Period 3: 1000 mg/day for days 7-10.
62546550|NCT04411914|PLACEBO_COMPARATOR|Placebo|"Participants will receive 10 days of placebo and will have a dose escalation at the same time as the experimental group. They will be given additional placebo pills to match the number given to the experimental group (i.e. 2 PBO capsules/day for days 1-3, 3 PBO capsules/day days 4-6 and 4 PBO capsules/day for days 7-10)."
62546551|NCT06032000|ACTIVE_COMPARATOR|LEM-mR203|"Drug: LEM-mR203~An intramuscular single injection prepared by mixing mRNA and DegradaBALL before administration"
62546552|NCT06032000|PLACEBO_COMPARATOR|Placebo|"Drug: 0.9% Sodium Chloride Solution~An intramuscular single injection prepared before administration"
62546553|NCT01392235|EXPERIMENTAL|Drug: Famitinib|
62546554|NCT04078997||PCV13-vaccinated,15-24 months of age|"Recruitment for carriage surveillance (primary endpoint) will take place at randomly selected households within each of the catchment areas (zones) of the 20 selected health centers.~Sampling: Random sampling from populations will occur preferentially around the health centers and not from the population on the zonal interfaces. Researchers will designate two geographic sampling areas within each zone around each health center that allows a buffer against zonal borders. If the recruitment target within first sampling area is not met, sampling will move into the second area."
62546555|NCT04078997||PCV13-vaccinated, 5-10 years of age|"Six schools will be selected: three located centrally in each of the 3+0 zones, and three in the 2+1 zones.~Sampling: Children will be randomly chosen and recruited from each school. NP swab collection will occur during two surveys, starting 21 and 34 months after the switch to 2+11.~Mapping analysis from our current surveillance activities shows good clustering of recruited children living around the school, suggesting limited movement and thus low risk of contamination between zones with different vaccination schedules."
62546556|NCT04078997||PCV13-unvaccinated HIV-infected adults on ART 18 - 40 years of|"Adults will be recruited from the Queen Elizabeth Central Hospital (QECH), Lighthouse ART clinic in Blantyre.~Sampling: Mapping analysis from current surveillance activities shows good distribution throughout the Blantyre area, suggesting it is possible to achieve balance between those adults residing in 2+1 vs 3+0 areas. Sample collection will be on a rolling basis throughout the study period, starting 18 months after switch to 2+1."
62546557|NCT04078997||PCV13-vaccinated, 9 months of age|"Recruitment will take place at vaccination centers.~Sampling: A convenience sample of NP swabs will be collected at the 9-month (measles-1) visit. Sample collection will occur 9 months after the switch to 2+1 schedule."
62546558|NCT01931878|PLACEBO_COMPARATOR|Placebo , saline|The subject may be randomly assigned to receive Placebo, saline
62546559|NCT01931878|ACTIVE_COMPARATOR|IncobotulinumtoxinA Treatment|The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)
62546560|NCT04975295|EXPERIMENTAL|LY3361237|LY3361237 administered subcutaneously (SC).
62546561|NCT04975295|PLACEBO_COMPARATOR|Placebo|Placebo administered SC.
62546562|NCT00928044||control groups|They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded.
62546563|NCT00928044||operation group|1. They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded. 2. Operations were performed for benign ovarian tumors, leiomyoma or adenomyosis
62546564|NCT01357083||Major Depression Disorder|This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
62546565|NCT04152863|EXPERIMENTAL|IV Gebasaxturev + Pembrolizumab|Participants receive gebasaxturev at a dose of 1 X 10\^9 TCID50 by IV infusion on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Gebasaxturev will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
62546566|NCT04152863|EXPERIMENTAL|ITu Gebasaxturev + Pembrolizumab|Participants receive gebasaxturev at a dose of 3 X 10\^8 TCID50 by ITu injection on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Gebasaxturev will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
62546567|NCT04152863|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
62546568|NCT02393352|EXPERIMENTAL|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
62546569|NCT02393352|ACTIVE_COMPARATOR|Electrical Stimulation Therapy|Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.
62546570|NCT05537350|EXPERIMENTAL|Lumenato|1 Lumenato soft gel once a day
62546571|NCT05537350|PLACEBO_COMPARATOR|Placebo|1 Soft gels without active ingredients once a day
62546572|NCT04303780|EXPERIMENTAL|AMG 510|
62546573|NCT04303780|ACTIVE_COMPARATOR|Docetaxel|
62546574|NCT02193217|EXPERIMENTAL|MT-1303-Low|MT-1303-Low dose
62546575|NCT02193217|EXPERIMENTAL|MT-1303-High|MT-1303-High dose
62546576|NCT02193217|ACTIVE_COMPARATOR|Fingolimod|Fingolimod
62546577|NCT02193217|PLACEBO_COMPARATOR|Placebo|Placebo
62546578|NCT01105624|EXPERIMENTAL|azithromycin ophthalmic solution, 1%|
62546579|NCT01105624|EXPERIMENTAL|rewetting drops|
62546580|NCT00761657|EXPERIMENTAL|Roxadustat 0.7 mg/kg BIW|Participants will receive roxadustat 0.7 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
62546581|NCT00761657|EXPERIMENTAL|Roxadustat 0.7 mg/kg TIW|Participants will receive roxadustat 0.7 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
62546582|NCT00761657|EXPERIMENTAL|Roxadustat 1.0 mg/kg BIW|Participants will receive roxadustat 1.0 mg/kg BIW orally with doses administered at least 72 hours apart for 29 days.
62737667|NCT05503095||patients with acute ST-elevation myocardial infarction not complicated by cardiac rupture|
62546583|NCT00761657|EXPERIMENTAL|Roxadustat 1.0 mg/kg TIW|Participants will receive roxadustat 1.0 mg/kg TIW orally with doses administered at least 48 hours apart for 26 days.
62546584|NCT00761657|EXPERIMENTAL|Roxadustat 1.5 mg/kg BIW|Participants will receive roxadustat 1.5 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
62546585|NCT00761657|EXPERIMENTAL|Roxadustat 1.5 mg/kg TIW|Participants will receive roxadustat 1.5 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
62546586|NCT00761657|EXPERIMENTAL|Roxadustat 2.0 mg/kg BIW|Participants will receive roxadustat 2.0 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
62546587|NCT00761657|EXPERIMENTAL|Roxadustat 2.0 mg/kg TIW|Participants will receive roxadustat 2.0 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
62546588|NCT00761657|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo orally, matching to the roxadustat dose, number of days per week, and duration.
62546589|NCT04526847|EXPERIMENTAL|Intervention|"Intermittent energy restricted (IER) group:~IER group will receive 5:2 diet pattern (5 day without energy restriction and 2 days with 75% energy restriction, net weekly energy deficit \~25%)"
62546590|NCT04526847|ACTIVE_COMPARATOR|Calorie Restricted Diet (CER)|"Continuous energy restricted (CER) group:~CER group with a low-calorie diet (daily energy deficit \~25%) over the course of six months."
62546591|NCT00811928|ACTIVE_COMPARATOR|Posaconazole|Posaconazole oral suspension 200 mg three times a day (TID)
62546592|NCT00811928|ACTIVE_COMPARATOR|Fluconazole|Fluconazole 400 mg once daily (QD)
62546593|NCT03817541|EXPERIMENTAL|Bariatric surgery|Patients due for bariatric surgery, BMI \> 30
62546594|NCT03817541|EXPERIMENTAL|Cholecystectomy|Normal weight patients due for cholecystectomies
62546595|NCT01783795|OTHER|Genetic Analysis|Genetic Analysis
62546596|NCT02499484|ACTIVE_COMPARATOR|GTN and eccentric exercises|Participants will complete a 12 week eccentric exercise program and use 0.5cm of glyceryl trinitrate ointment daily for 24 weeks
62546597|NCT02499484|PLACEBO_COMPARATOR|Placebo and eccentric exercises|Participants will use a placebo ointment with no active ingredient for 24 weeks and complete an eccentric exercise program for 12 weeks
62546598|NCT02240615|EXPERIMENTAL|Sinopsys Lacrimal Stent|All enrolled patients will receive a Sinopsys Lacrimal Stent inserted from the caruncle to the ethmoid sinus. Discharge instructions will include administration of sterile saline and ophthalmic drops as well as assessments for device patency.
62546599|NCT05803239|EXPERIMENTAL|EBUS-TBMC via a tunnel first group|After completing the routine bronchoscopy examination, under the EBUS guidance, combined with the results of chest CT to determine the location of puncture. Then, a disposable puncture dilation catheter (BroncTru AK-91-55; Broncus Inc., Hangzhou, China) was inserted through the working channel of the ultrasound bronchoscope and built a tunnel between the airway wall and targeted lymph node. The 1.1-mm cryoprobe (Erbe 20402-401; ERBE, Tübingen, Germany) was inserted into the target lymph node through the tunnel under direct EBUS monitoring, and the distance between the tip of the cryoprobe and the border of the target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds and freezing 3 times to obtain 3 pieces of sample. At the end of TBMC via a tunnel, EBUS-TBNA is performed in the same lymph node, and the tissue is aspirated repeatedly for 5 strokes (one stroke is 30 round trips).
62546600|NCT05803239|EXPERIMENTAL|EBUS-TBNA first group|Completion of routine bronchoscopy, determination of the puncture position under EBUS guidance, combined with the results of chest CT, and application of the EBUS-TBNA needle to repeatedly aspirate the tissue for 5 strokes (one stroke is 30 round trips ). At the end of the puncture, EBUS-TBMC via a tunnel was then performed with a freezing time of 5-9 seconds (1.1-mm cryoprobe), and frozen 3 times to obtain 3 pieces of samples.
62546601|NCT05575232|EXPERIMENTAL|Application Group (GA)|Participants undergoing the GA will be instructed on how to download the application and how to use it. From there, all personal data must be entered into the application so that alerts, tips and incentives can be issued to each one, individually.
62546602|NCT05575232|NO_INTERVENTION|Control Group (GC)|The GC, in turn, will participate in a single lecture, in the first week of the intervention, with basic guidelines related to the key points of the treatment of SAH, including the importance of medication adherence, monitoring of blood pressure values and/or capillary glucose, lifestyle modifications linked to physical activity, eating habits, smoking cessation, stress management and moderate alcohol consumption.
62546603|NCT03632018|ACTIVE_COMPARATOR|Standard Cardiac Rehabilitation|Participants in the STANDARD condition will receive the standard of care cardiac rehabilitation, consisting of 36 sessions across 12 weeks of prescribed, supervised exercise sessions.
62546604|NCT03632018|EXPERIMENTAL|HEART-PLAY|Participants in the HEART-PLAY will receive standard CR and additionally receive pedometers, resistance bands, and the National Institute of Aging (NIA) exercise guide. They will further receive counseling from peer health coaches, social support from group education sessions, and supplemental educational materials. After the 12 weeks of prescribed, supervised exercise sessions, HEART-PLAY group participants will continue to receive support from peers and clinic staff with check-in calls, feedback on pedometer goals, and twice weekly group events including walks and/or resistance band group exercise classes.
62546605|NCT02597127|EXPERIMENTAL|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
62546606|NCT02597127|EXPERIMENTAL|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
62546607|NCT02597127|EXPERIMENTAL|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
62546608|NCT02597127|PLACEBO_COMPARATOR|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
62546609|NCT02597127|EXPERIMENTAL|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
62546610|NCT02597127|EXPERIMENTAL|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
62546611|NCT02597127|EXPERIMENTAL|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
62546612|NCT02597127|PLACEBO_COMPARATOR|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
62546613|NCT05994885|OTHER|Root surface debridement|Periodontal pockets with PPD of 4 to 6mm are treated with root surface debridement only and assessed after 3 months for success/failure of treatment.
62546614|NCT02524457||Premenopausal|Premenopausal women going through gynecological surgery
62546615|NCT02524457||Postmenopausal|Postemnopausal women going through gynecological surgery
62546616|NCT02524457||Postmenopausal + HT|Postmenopausal women going through gynecological surgery who has been taking hormone treatment through the past year (as a minimum)
62546617|NCT04871672|EXPERIMENTAL|pilates and home exercises (PAH) group|these subjects will receive pilates and home exercises.
62546618|NCT04871672|ACTIVE_COMPARATOR|control home exercises group (COH)|these subjects will receive only home exercises.
62546619|NCT02535793|OTHER|laboratory workers with symptoms in presence of drosophila|
62546620|NCT02699073|EXPERIMENTAL|Regorafenib|dose of regorafenib : 160mg once daily
62546621|NCT04218734|EXPERIMENTAL|metformin hydrochloride+DBPR108|metformin hydrochloride 500 mg+DBPR108 100 mg
62546622|NCT04218734|PLACEBO_COMPARATOR|metformin hydrochloride+placepo|metformin hydrochloride 500 mg+placebo 100 mg
62719955|NCT04067492|EXPERIMENTAL|RPH - 160 mg|Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)
62168097|NCT02985255|EXPERIMENTAL|Neoadjuvant Arm|Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.
62546623|NCT05311579|EXPERIMENTAL|Ovarian cancer patients with increased CA125|Patients with CA125 \>35 U/ml or increased to 2 x nadir, and with no evidence of imaging recurrence after completion of 1st-line platinum-based chemotherapy
62546624|NCT04465981||Patients with lab-confirmed COVID-19|Subject has lab-confirmed diagnosis of COVID-19 by RT-PCR
62546625|NCT04465981||Patients who are suspected to have or are confirmed to not have COVID-19|Subject has suspected COVID-19 according to medical evaluation, but does not yet have lab-confirmed diagnosis of COVID-19 (results outstanding, or has tested negative by RT-PCR)
62546626|NCT03825718|EXPERIMENTAL|CAR-T treatment group|The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
62546627|NCT04348695|EXPERIMENTAL|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days."
62546628|NCT04348695|OTHER|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
62546629|NCT01009502|EXPERIMENTAL|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
62546630|NCT04738695||Nursing home residents/staff members|Follow-up of seroprevalence
62546631|NCT02418832|OTHER|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
62546632|NCT02929056|PLACEBO_COMPARATOR|SOC alginate dressing|SOC absorptive alginate primary dressing in conjunction with a class II multi-layer compression wrap and standard debridement
62546633|NCT02929056|EXPERIMENTAL|AmnioExCel dressing|AmnioExCel dressing in conjunction with a class II multilayer compression wrap and standard debridement
62546634|NCT06170697|EXPERIMENTAL|Camrelizumab+（Cisplatin or Carboplatin or Lobaplatin or Nedaplatin）+radiotherapy|patients with short-term postoperative progression receive camrelizumab and platin-based chemotherapy concurrent with radiotherapy.
62546635|NCT03074786|EXPERIMENTAL|Vaginal Matrix Ring|Dapivirine vaginal ring containing 25 mg of dapivirine to be replaced each month.
62546636|NCT03074786|EXPERIMENTAL|Oral Emtricitanbine/Tenofovir Disoproxil|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to be taken orally daily
62546637|NCT00618332|ACTIVE_COMPARATOR|1|2 weeks of treatment
62546638|NCT00618332|PLACEBO_COMPARATOR|2|2 weeks of treatment
62546639|NCT04638101|EXPERIMENTAL|Intervention group (RCT)|Participants from the intervention group participated in the mindfulness-based intervention between Time 1 and Time 2.
62546640|NCT04638101|EXPERIMENTAL|Waiting group (RCT)|Participants from the waiting group took part in the mindfulness-based intervention between Time 2 and Time 3.
62546641|NCT02565940||diabetic patient with foot infection|
61976625|NCT03929575|EXPERIMENTAL|Rhodiola|Participants will consume 250 mg of Rhodiola
61976626|NCT03929575|EXPERIMENTAL|Rhodiola and Cordyceps|Participants will consume a combination of 250 mg of Rhodiola and 225 mg of Cordyceps
61976627|NCT03914781|EXPERIMENTAL|SPIN-SELF program|Offered access to the online SPIN-SELF program in addition to usual care
61976628|NCT03914781|NO_INTERVENTION|Not Offered the SPIN-SELF program|Usual care
62546642|NCT03046641|EXPERIMENTAL|continuous training group|With the continuous training program
62546643|NCT03046641|EXPERIMENTAL|interval training group|With the interval training program
62546644|NCT05299528|EXPERIMENTAL|Direct Feedback|On approximately study day 97, surgeon participants will receive procedure-specific direct feedback through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
62546645|NCT05299528|NO_INTERVENTION|No Direct Feedback|Surgeon participants randomized to No Direct Feedback will not be contacted directly at any time in the study and will not receive feedback about patients' opioid consumption-to-prescription ratio.
62546646|NCT06291714|ACTIVE_COMPARATOR|Interventional group|GDT-therapy guided hemodynamic management based on Clearsight system
62546647|NCT06291714|NO_INTERVENTION|Control group|Clearsight-monitor is blinded but records standard hemodynamic care
62546648|NCT01093092|EXPERIMENTAL|Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)|Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62719956|NCT04067492|ACTIVE_COMPARATOR|Voltaren® (diclofenac)|Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)
62719957|NCT02213614|EXPERIMENTAL|Spring Lithium Water|"The Long term goal of this research project is the implementation of an effective, inexpensive therapy in communities with high risk of violence. Therapy will be based on a daily dietary supplement LIWA at appropriate doses.~The short-term objective is to prove that Lithium water (LIWA) as a daily supplement is an intervention that prevents gun violence from occurring, and is a factor that decrease the violence for gun in our communities Gun violence poses a serious threat to America's children and youth. Existing data clearly point to the need for improved strategies for keeping guns out of the hands of children and youth and those who would harm them."
62546649|NCT03389347|EXPERIMENTAL|Device feasibility (high-throughput assay, sequencing)|Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.
62546650|NCT03112642|ACTIVE_COMPARATOR|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
62546651|NCT03112642|EXPERIMENTAL|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
62546652|NCT01428154|EXPERIMENTAL|Darbepoetin alfa|
62546653|NCT06501677|NO_INTERVENTION|Identify CP communication behaviors that elicit or inhibit DP drinking using EMA|"Couples (N=50 dyads) with one CP and one DP will be recruited from social media. Both partners will independently complete baseline and follow-up surveys. Both the CP and DP will independently complete a 21-day EMA with three daily reports on their communication and DP's drinking (craving, motives, consumption, problems). We will identify specific CP communication behaviors as proximal and long-term predictors of the DP's drinking and non-drinking.~Hyp1: CP punishing drinking (e.g., yelling) will relate to increases in DP drinking.~Hyp2: CP rewarding drinking (e.g., bringing alcohol home) will relate to increases in DP drinking.~Hyp3: CP rewarding sobriety (e.g., planning non-drinking activities) will relate to decreases in DP drinking."
62546654|NCT06501677|EXPERIMENTAL|Develop and evaluate the feasibility and acceptability of a WBI providing personalized feedback|We will use the Behavioral Intervention Technology Model framework to iteratively develop a four-session WBI that includes CRAFT principles and education about communication patterns learned in Aim 1. During the WBI, CPs will receive personalized feedback based on their baseline data on how their communication may influence their DP's drinking. We will evaluate the WBI's feasibility and acceptability with 15 CPs to iteratively improve the WBI.
62546655|NCT06501677|ACTIVE_COMPARATOR|Perform a pilot randomized controlled trial (RCT) comparing WBI to psychoeducation control|"Outcomes include DP drinking (primary), CP well-being (e.g., depression, anxiety, social support), and relationship functioning (e.g., relationship distress). Although the WBI will target CPs, we will collect data from both partners (N=80 couples) at baseline and 1-month follow-up to evaluate effects.~Hyp4: DP, CP, and relationship outcomes will show greater improvement in the WBI compared to control."
62546656|NCT02506829|ACTIVE_COMPARATOR|Usual care|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.
62546657|NCT02506829|EXPERIMENTAL|Financial Incentives|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).
62546658|NCT01107197|ACTIVE_COMPARATOR|Isonitrogenous isocaloric formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula isonitrogenous isocaloric to the experimental one
62546659|NCT01107197|EXPERIMENTAL|Enriched nutrition formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula enriched in arginine, zinc and antioxidant oligoelements
62546660|NCT01045330|NO_INTERVENTION|Usual Care Group|Usual care consists of standard hospital services provided by physicians, nurses, and support staff (e.g., physical therapist, dietitian) in the general surgery units.
62546661|NCT01045330|EXPERIMENTAL|Experimental Group|The intervention consisted of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
62546662|NCT00048737|EXPERIMENTAL|90Y Zevalin in ASCT|Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
62546663|NCT02220062|ACTIVE_COMPARATOR|EUS-CPN group|Group that be performed by Endoscopic ultrasound guided bilateral celiac plexus neurolysis
62546664|NCT02220062|EXPERIMENTAL|EUS-CGN group|Group that be performed by Endoscopic ultrasound guided celiac ganglia neurolysis
62719958|NCT02213614|EXPERIMENTAL|Placebo: Natural Spring water|This group will be drink natural spring water for 4 months in tres cicles
62719959|NCT04792190|ACTIVE_COMPARATOR|Intervention Management Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
62719960|NCT04792190|PLACEBO_COMPARATOR|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
62168098|NCT02504034|EXPERIMENTAL|Transhepatic portosystemic shunt|Patients with cavernous transformation of portal vein undergo transhepatic portalsystemic shunt and other interventional radiology treatment
62546665|NCT03694756|OTHER|Pre-biopsy patients (Cohort A)|"Patients identified by a radiologist at the time of diagnostic evaluation. Upon consent, TMEM-MRI will be scheduled. After TMEM-MRI, the patient will undergo core biopsy as per usual radiology procedure, with additional FNA preceding the core biopsy). MenaINV and MenaCalc will be calculated from the FNA material. After the breast biopsy confirms the suspected diagnosis of invasive breast carcinoma, the patient will be referred to breast surgery and a treatment plan devised, as per NCCN/ASCO guidelines.~No patients were enrolled into this arm/group and Cohort A has been removed by protocol amendment. This was intended to be a cohort for patients before breast biopsy in the event the biopsy procedure created a hematoma which would, in turn, affect measurement of TMEM-MRI activity. Since this effect was not observed in the first set of patients enrolled, Cohort A was removed from the study and only patients post-breast biopsy were enrolled (Cohort B)."
62546666|NCT03694756|OTHER|Post-biopsy patients (Cohort B)|Patients after breast biopsy. Once consent is obtained, patients will undergo TMEM-MRI. The patients will undergo definitive breast surgery and will receive adjuvant treatments as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be evaluated in final surgical specimen. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
62546667|NCT03694756|OTHER|Post-neoadjuvant therapy patients (Cohort C)|Patients status post neoadjuvant therapy. Patients who received neoadjuvant will be enrolled into Cohort C to understand the correlation between TMEM MRI activity and TMEM doorway density following after neoadjuvant chemotherapy. Only patients with residual palpable mass on physical exam will be included (≥ 1cm). Patients will undergo TMEM-MRI after neoadjuvant therapy is completed. Patients will also have CTCs and ctDNA measured on the same day of TMEM-MRI (+/- 3 days). TMEM density, MenaCalc and MenaINV will be evaluated in breast surgical specimen (after pre-operative therapy). Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV after pre-operative therapy.
62546668|NCT03697031||REKOVELLE®|Follitropin Delta
62546669|NCT04234971|EXPERIMENTAL|Intervention group (DBM/BMP)|Patient undergoes Alveolar bone graft with DBM/BMP
62546670|NCT04234971|ACTIVE_COMPARATOR|Control group(autologous ICBG)|Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.
62546671|NCT05282563|OTHER|The safety of esophagojejunostomy in total gastrectomy for gastric cancer|The safety of esophagojejunostomy depends on the integrity of the anastomosis, sufficient blood supply and satisfactory tension. Early tight mucosal anastomosis and the proliferation of mucosal epithelial cells can reduce the stimulation of digestive fluid to the anastomotic wound.Professor Zhao Yuzhou surgical team proposed double and a half layered esophagojejunal anastomosis to improve the safety of anastomosis. This method is simple and has no special requirements for the selection of instruments and sutures. It can be carried out in all levels of hospitals. In order to verify the value of this method in gastrointestinal reconstruction of gastric cancer, Professor Zhao Yuzhou surgical team plans to carry out a multicenter, randomized controlled study throughout the province.
62546672|NCT04352725|EXPERIMENTAL|experimental procedure|"* end-expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o~* incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
62546673|NCT03862924|EXPERIMENTAL|Active condition|Participants in the active condition will be provided with the Standardized Research Electronic Cigarette (SREC) and will be encouraged to use the SREC whenever they would normally smoke a cigarette.
62546674|NCT03862924|NO_INTERVENTION|Standard Condition|Participants in this condition will be asked to continue to smoke their usual brand of cigarettes.
62546675|NCT02876718||Rivaroxaban, BAY59-7939|It is a single-arm study in which only patients who switched from a VKA to a NOAC treatment will be included.
62546676|NCT00098423|EXPERIMENTAL|Treatment (chemotherapy)|"Patients receive induction therapy comprising cytarabine IV continuously on days 1-5 and tanespimycin IV over 1 hour on days 3 and 6.~Patients achieving a morphologic complete response with CRi or partial response may be eligible to receive a second induction course of therapy after day 21 at the discretion of the principal investigator. Patients achieving a CR receive up to 4 courses of consolidation therapy with cytarabine and tanespimycin. Consolidation therapy repeats approximately every 60 days in the absence of disease progression or unacceptable toxicity. Patients who achieve CR and remain in remission for â¥ 6 months may be retreated with cytarabine and tanespimycin (at the current dose level or the MTD) at the time of relapse. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months."
62546677|NCT05906524|EXPERIMENTAL|Phase 1：KD6001+Tislelizumab|KD6001 combined with Tislelizumab in patients with solid tumors（hepatocellular carcinoma, esophageal squamous cell carcinoma, MSI-H or dMMR solid tumors are preferentially included）
62546678|NCT05906524|EXPERIMENTAL|Phase 2：KD6001+Tislelizumab±Bevacizumab|KD6001 combined with Tislelizumab±Bevacizumab in patients with advanced HCC
62546679|NCT00610246|EXPERIMENTAL|Sorafenib and Radiation|Eligible patients (not candidates for curative treatment) will have measurable lesions in the anatomic thorax, abdomen or pelvis (any histology) amenable to palliative radiation treatment (30 Gy in 10 fractions). Patients receive sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. If full oral dose (400 mg po bid) is reached in a given cohort (dose level three) then an additional dose level will open where sorafenib treatment (400 mg bid) is extended following radiation for a total of eight weeks.
62546680|NCT03744299|OTHER|Intervention|Patients and caregivers are asked to complete a questionnaire
62546681|NCT03404739|EXPERIMENTAL|Single-dose group|Ceftazidime 2g at the start of POEM
62546682|NCT03404739|ACTIVE_COMPARATOR|Multiple-dose group|Ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure
62546683|NCT03461601|ACTIVE_COMPARATOR|HCG uterine flushing group|Uterine flushing was done one day before Intrauterine insemination (IUI) with HCG (500 IU) in 10 ml of saline followed by Intrauterine insemination (IUI).
62546684|NCT03461601|PLACEBO_COMPARATOR|IUI alone group|Intrauterine insemination alone plus vaginal flushing with 10 ml normal saline
62546685|NCT04042844|EXPERIMENTAL|Active Treatment- BRTX-100|BRTX-100 consists of a population of hypoxic-cultured bone marrow mononuclear cells highly enriched in mesenchymal stem cells from autologous bone marrow with autologous platelet lysate.
62546686|NCT04042844|PLACEBO_COMPARATOR|Saline|Isotonic saline will be used as a control in this study. Drug: saline (0.9% sodium chloride).
62546687|NCT05952531|EXPERIMENTAL|68Ga-FAPI|Inject 68Ga-FAPI and then perform PET/CT scan
62546688|NCT03666273|EXPERIMENTAL|Dose escalation_Monotherapy|Patients with solid tumor types considered immunosensitive
62546689|NCT03666273|EXPERIMENTAL|Dose escalation_Combination therapy|Patients with solid tumor types considered immunosensitive
62546690|NCT03666273|EXPERIMENTAL|Expansion HNSCC_Combination therapy|Patients with head and neck squamous cell carcinoma (HNSCC)
62546691|NCT01970774|EXPERIMENTAL|MTM and PGx|Participants attend two MTM sessions and have PGx testing
62546692|NCT01644383|EXPERIMENTAL|Treatment arm (logotherapy)|Participants in Arm I will attend the logotherapy group sessions by the trained psychologist for 4 visits (see Table II, III). The number of participants in group sessions will be 20 participants per group.
62546693|NCT01644383|NO_INTERVENTION|Control arm (general health education)|Participants in Arm II will attend the routine health education by the nurse. The number of participants in group session will be 20 participants per group.
62546694|NCT03997773|EXPERIMENTAL|Intervention|Will receive the intervention
62546695|NCT03997773|NO_INTERVENTION|Usual care|Will receive usual care - will be the control group
62546696|NCT04647903|EXPERIMENTAL|Oral Placebo + Intranasal manipulated ADAIR|Oral Placebo + Intranasal manipulated ADAIR 30 mg
62546697|NCT04647903|ACTIVE_COMPARATOR|Oral Placebo + Intranasal crushed dextroamphetamine sulfate|Oral Placebo + Intranasal crushed dextroamphetamine sulfate IR 30 mg
62546698|NCT04647903|EXPERIMENTAL|Oral ADAIR + Intranasal Placebo|Oral ADAIR 30 mg + Intranasal Placebo
62546699|NCT04647903|PLACEBO_COMPARATOR|Oral Placebo + Intranasal Placebo|Oral Placebo + Intranasal Placebo
62546700|NCT05511311|ACTIVE_COMPARATOR|Control|12-week of Standard Therapy using elastic-band
62546701|NCT05511311|EXPERIMENTAL|Intervention|12-week of Resistance Training developed by RSCM using sand-bag
62546702|NCT06468241|EXPERIMENTAL|Progressive relaxation exercise group|progressive relaxation exercise intervention and measurement with scales and wearable technology
62546703|NCT06468241|EXPERIMENTAL|Music group|music listening intervention and measurement with scales and wearable technology
62546704|NCT06468241|NO_INTERVENTION|Control group|No intervention and measurement with scales and wearable technology
62546705|NCT01403220|ACTIVE_COMPARATOR|Group 1 (hemodiafiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
62546706|NCT01403220|ACTIVE_COMPARATOR|Group 2 (hemofiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
62546707|NCT01899612||Symptomatic postmenopausal women|Postmenopausal women with vulvovaginal symptoms
62168099|NCT00946998|ACTIVE_COMPARATOR|Sertraline|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
62546708|NCT01899612||Asymptomatic postmenopausal women|Postmenopausal women without vulvovaginal symptoms
62546709|NCT03893019|EXPERIMENTAL|Dose Level 1: 1x10e5 MB-CART20.1 cells|3+3 patients will be treated with 1x10e5 MB-CART20.1 cells per kg body weight administered intravenously
62546710|NCT03893019|EXPERIMENTAL|Dose Level 2: 1x10e6 MB-CART20.1 cells|3+3 patients will be treated with 1x10e6 MB-CART20.1 cells per kg body weight administered intravenously
62546711|NCT03893019|EXPERIMENTAL|Dose Level 3: 1x10e7 MB-CART20.1 cells|3+3 patients will be treated with 1x10e7 MB-CART20.1 cells per kg body weight administered intravenously
62546712|NCT03266939|PLACEBO_COMPARATOR|Placebo|
62546713|NCT03266939|ACTIVE_COMPARATOR|Active Medication|
62168100|NCT00946998|PLACEBO_COMPARATOR|Placebo|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
62546714|NCT04862910|EXPERIMENTAL|Kinect Based Virtual Reality Training|Kinect-Based Virtual Reality Training 30 Minutes walk outdoor Routine Medication and routine diet will be continued.
62546715|NCT04862910|OTHER|Control Group|30 Minutes walk outdoor Regular active life style Routine diet and routine Medication
62546716|NCT01756430|EXPERIMENTAL|Carvedilol SR 32mg, 64mg|•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.
62546717|NCT01756430|ACTIVE_COMPARATOR|Carvedilol IR 25mg|•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.
62168101|NCT06474442|EXPERIMENTAL|Group 1|BD111 combining triple-drugs therapy Group.
62168102|NCT06474442|ACTIVE_COMPARATOR|Group 2|BD111 sham injection combining triple-drugs therapy group.
62546718|NCT04677101||Subjects with NASH documented by liver biopsy|One hundred subjects with NASH documented by liver biopsy and no evidence of another form of liver disease with a BMI ≥30 and ≤55 kg/m2.
62546719|NCT04677101||Healhy Donor|Fifty subjects with normal liver who underwent laparoscopic elective cholecystectomy, but otherwise in healthy conditions, will be used as controls.
62546720|NCT01019668|ACTIVE_COMPARATOR|verteporfin PDT, half-dose|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
62546721|NCT01019668|ACTIVE_COMPARATOR|verteporfin PDT, half-fluence|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
62546722|NCT00625872|ACTIVE_COMPARATOR|Treatment Group|Somatropin for 12 months
62546723|NCT00625872|OTHER|Control Group|In the first 6 months no intervention, afterwards Somatropin for 12 months
62546724|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
62546725|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
62546726|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
62546727|NCT01831102||Mexican American|Mexican American ancestry
62546728|NCT05333705|EXPERIMENTAL|immune cell arm|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were cultured. NK cell production will be infused after chemotherapy.
62546729|NCT02945969|EXPERIMENTAL|Low Sodium Diet|Behavioral modification to decrease dietary sodium intake to ≤2,300 mg/day for 24 weeks. The intervention program consists of two phases. An initial 12-week intensive phase will include weekly individual and group sessions. This will be followed by a 12-week maintenance phase that includes telephone counseling sessions every 2 weeks.
62168103|NCT01060163|EXPERIMENTAL|group ET|Patients receiving early CABG \<=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
62168104|NCT01060163|PLACEBO_COMPARATOR|group EP|Patients receiving early CABG \<= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
62168105|NCT01060163|EXPERIMENTAL|group LT|Patients receiving late CABG \>7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
62168106|NCT01060163|PLACEBO_COMPARATOR|group LP|Patients receiving late CABG \>7 days of the cessation of clopidogrel, treated with placebo(saline solution)
62168107|NCT01060163|EXPERIMENTAL|group BT|Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
62168108|NCT01060163|PLACEBO_COMPARATOR|group BP|Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)
62168109|NCT03924778|EXPERIMENTAL|DASH diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber
62168110|NCT03924778|ACTIVE_COMPARATOR|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber
62168111|NCT05733000|EXPERIMENTAL|COHORT 1 (Devimistat, 5-FU, HCQ)|Patients with colorectal cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
62168112|NCT05733000|EXPERIMENTAL|COHORT 2 (Devimistat, 5-FU, HCQ)|Patients with pancreatic cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
62168113|NCT05733000|EXPERIMENTAL|COHORT 3 (Devimistat, 5-FU, HCQ, Gemcitabine)|Patients with gastroesophageal cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients with urothelial, ovarian, or non-small cell lung cancer receive devimistat IV, gemcitabine IV, plus HCQ PO on study. Patients with biliary tumors receive devimistat IV and gemcitabine IV or HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
62168114|NCT05758922|PLACEBO_COMPARATOR|Placebo|Participant will receive placebo once daily during the course of the study (12 weeks).
62168115|NCT05758922|EXPERIMENTAL|AZ-3102 (Dose 1)|Participant will receive AZ-3102 (Dose 1) once daily during the course of the study (12 weeks) and the study extension (if applicable).
62168116|NCT05758922|EXPERIMENTAL|AZ-3102 (Dose 2)|Participant will receive AZ-3102 (Dose 2) once daily during the course of the study (12 weeks) and the study extension (if applicable).
62168117|NCT04796948|EXPERIMENTAL|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|"1. irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion.~2. oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial.~3. 5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.~4. LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution."
62168118|NCT06647381||Sinus lifting|Patients from a previous cohort of patients that received dental implants with sinus augmentation procedures
62168119|NCT03265262|EXPERIMENTAL|Children receiving OFC during a diagnost|paediatric patients attending food allergy
62168120|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle \> or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
62168121|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle \< 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
62168122|NCT01885377|EXPERIMENTAL|Specific exercise group|A progressive program of strength-endurance exercises for the rotator cuff and scapula stabilizing muscles combined with mobilization of the joint capsule when needed
62168123|NCT01885377|ACTIVE_COMPARATOR|Control exercise group|General movements for the neck and shoulder and self-stretching. No progression some addition of exercises during the three month period.
62168124|NCT03942276|PLACEBO_COMPARATOR|Control|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks without perform exercise training.
62168125|NCT03942276|EXPERIMENTAL|Alternative training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of high intensity interval training.
62546730|NCT02945969|NO_INTERVENTION|Usual Diet|No dietary intervention.
62546731|NCT03168334|EXPERIMENTAL|IDP-123 Lotion|Tazarotene 0.045% Lotion
62546732|NCT03168334|PLACEBO_COMPARATOR|IDP-123 Vehicle Lotion|Vehicle Lotion
62168126|NCT03942276|EXPERIMENTAL|Conventional training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of moderate intensity continuous training
62168127|NCT02931916||healthy group|recruited for evaluation of system reliability
62168128|NCT02931916||Chronic Ankle Instability group|recruited for evaluation of system validity
62546733|NCT02322203|EXPERIMENTAL|Niacin ER in healthy participants and its effects on lipoprotein composition and function|Niacin extended release (ER) to be given as follows: 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks in healthy participants.
62546734|NCT06140446|EXPERIMENTAL|FeverApp group|Use af a self-care FeverApp (containing fever advices and a monitoring function for their child with an uncomplicated URTI), additional to standard advices of the GP.
62546735|NCT06140446|EXPERIMENTAL|DMT group|Use of a self-care decision making tool (to choose a herbal medicinal product for their child with an uncomplicated URTI), additional to standard advices from their GP.
62546736|NCT06140446|NO_INTERVENTION|Control group|Just standard advices from the GP for their child with an uncomplicated URTI.
62546737|NCT05131828|EXPERIMENTAL|Research arm: metformin and clemastine|
62546738|NCT05131828|PLACEBO_COMPARATOR|Control arm: placebos for both metformin + clemastine|
62546739|NCT00359801|EXPERIMENTAL|Exubera|
62546740|NCT00359801|ACTIVE_COMPARATOR|Usual Diabetes Care|
62546741|NCT01308502|EXPERIMENTAL|Probe|Children with airway obstruction
62546742|NCT02297256|ACTIVE_COMPARATOR|BMAC & Allograft|Subjects will be treated with bone marrow aspirate concentrate (BMAC) and allograft during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, 12 teaspoons of bone marrow will be taken (aspirated) from one side of hip bone. This may be repeated on the other side of hip bone for a total of 12, 24, or 36 teaspoons of bone marrow total taken from your hip bone depending on the decision made by the surgeon. The bone marrow will then be concentrated with a machine for 15 minutes to a final volume of 2, 4, or 6 teaspoons of BMAC. BMAC will be combined with packed allograft bone chips using another machine to produce two or three constructed bone logs. The bone logs will be laid along the backside of the spine and between each vertebral body.
62546743|NCT02297256|ACTIVE_COMPARATOR|Iliac Crest Bone Graft|Subjects who are in the Iliac Crest Bone Graft arm will be treated with Iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, the surgeon will make an incision to expose the iliac crest (hip bone), and cutting out the segments of the bone that will be needed, based on the decision of the surgeon. The bone chips will be laid along the backside of the spine and also between each vertebral body where the bone will fuse into place. When the bone becomes solid/fused, there is no movement in the fused spine.
62546744|NCT01915745|NO_INTERVENTION|Usually health care|85 patients receive the usually health care. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
62546745|NCT01915745|EXPERIMENTAL|Short Message Service - SMS|85 patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in the Emergency Department emergencies. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
62546746|NCT06632964|EXPERIMENTAL|VT-101|The registered patients will receive oncolytic adenovirus VT-101 therapy for the non-muscle invasive bladder cancer by intravesical instillation.
62546747|NCT04108026|EXPERIMENTAL|Immunotherapy|Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.
62546748|NCT03915405|EXPERIMENTAL|KHK2455 in Combination with Avelumab|
62546749|NCT06185881|EXPERIMENTAL|Short fiber reinforced resin modified glass ionomer restorations (GC Europe)|
62546750|NCT06185881|ACTIVE_COMPARATOR|Resin modified glass ionomer restoration. (Fugi II LC, GC Europe)|
62546751|NCT00790348||1|Patients who on Januvia
62546752|NCT00790348||2|Patients on Janumet (Combination of Januvia and Metformin)
62546753|NCT00790348||3|Patients on Metformin
62546754|NCT02918812|EXPERIMENTAL|Intracervical lidocaine|This group will comprise of patients that will receive the intracervical block. The study group will receive a total of 60 mg (6 mL) of 1% lidocaine to be injected at four points (12, 4, 6, and 8 o'clock) circumferentially into the cervix (1.5 mL at each point) 5 minutes before proceeding with the hysterosalpingogram.
62546755|NCT02918812|ACTIVE_COMPARATOR|Intramuscular Diclofenac|This group will comprise of patients that will receive intramuscular diclofenac potassium 75mg 30 minutes before proceeding with the hysterosalpingogram.
62546756|NCT03912935|NO_INTERVENTION|Sniffing position|Subject will be maintained in standard intubation position which is supine position with head elevation with head rest (foam donut).
62546757|NCT03912935|EXPERIMENTAL|Bed up head elevation position|Subject will be maintained at bed up 20-30 degree aiming alignment between the external auditory meatus with sternal notch
62546758|NCT05746832|ACTIVE_COMPARATOR|One session application of (ERCP) in the management of common bile duct stones.|One session application of endoscopic stenting retrograde cholangiopancreatography (ERCP) in the management and clearance of difficult common bile duct stones and assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large \[≥ 20 mm\] or multiple \[≥ 3 sized ≥ 15 mm\] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
62719961|NCT04656405|EXPERIMENTAL|Online real-time CPR training program|Online real-time quality measurement and feedback video-based CPR training will be provided to participants
62546759|NCT05746832|ACTIVE_COMPARATOR|Two sessions application of (ERCP) in the management of common bile duct stones.|Two sessions application of endoscopic stenting retrograde cholangiopancreatography (ERCP) in the management and clearance of difficult common bile duct stones.and assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large \[≥ 20 mm\] or multiple \[≥ 3 sized ≥ 15 mm\] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
62719962|NCT04656405|ACTIVE_COMPARATOR|Online real-time CPR training without quality measurement program|Online real-time feedback video-based CPR training without quality measurement will be provided to participants
62719963|NCT04656405|PLACEBO_COMPARATOR|Conventional CPR training program|Conventional CPR training will be provided to participants
62719964|NCT01244386||Inflammatory bowel disease|Patients with inflammatory bowel disease requiring CT for clinical purposes will be studied.
62546760|NCT02497911|EXPERIMENTAL|Adductor Canal Catheter|Postoperatively, patients will be brought to the PACU. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. A sterile field will be utilized and the femoral artery is identified with a high frequency linear transducer proximal to the operative knee. 18g insulated Tuohy needle will be inserted in an out-of-plane approach through the sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 15 cc's of 0.5% ropivicaine will be injected through the needle under visualization. A 20-g multi-orifice catheter will be inserted approximately 4 cm beyond the needle tip and secured.
62546761|NCT02497911|EXPERIMENTAL|Intraarticular Catheter|Intra-articular catheters will be placed by the surgeon at the end of the procedure, before wound closure. A bupivacaine 0.5% infusion will be admin through the On-Q system and continued for 48 hours postoperatively.
62546762|NCT06105723|EXPERIMENTAL|Path-HA care|A 14-week care initiative comprising two phases is provided, which are the 2-week ICOPE-based personalized care planning phase, and the 12-week healthy aging empowerment phase.
62546763|NCT06105723|NO_INTERVENTION|Control|No care intervention will be provided.
62546764|NCT03410394||registry of endocrine tumors|"* Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.~* Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23~* Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24~* Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
62546765|NCT02565511|EXPERIMENTAL|Cohort I (CAD106)|CAD106 (450 µg) + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
62546766|NCT02565511|PLACEBO_COMPARATOR|Cohort I (CAD106 Placebo)|Placebo to CAD106 + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
62546767|NCT02565511|EXPERIMENTAL|Cohort II (CNP520)|CNP520 (50 mg) capsules taken orally once daily
62546768|NCT02565511|PLACEBO_COMPARATOR|Cohort II (CNP520 Placebo)|Matching Placebo to CNP520 capsules taken orally once daily
62546769|NCT00420732|EXPERIMENTAL|Vaccine Group|
62546770|NCT04427072|EXPERIMENTAL|Capmatinib|400mg of capmatinib tablets, administered orally twice daily
62546771|NCT04427072|ACTIVE_COMPARATOR|Docetaxel|Docetaxel 75 mg/m2 solution administered by intravenous infusion on Day 1 of every 21-day cycle
62546772|NCT03998397|EXPERIMENTAL|patients with alcohol use disorders|
62546773|NCT03998397|EXPERIMENTAL|patients without alcohol use disorders|
62546774|NCT02022878||Attempted PCI of CTO|Attempted PCI of CTO with preprocedural coronary CTA scan
62546775|NCT02031419|EXPERIMENTAL|CC-122 + CC-223 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
62546776|NCT02031419|EXPERIMENTAL|CC-122 + CC-292 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
62546777|NCT02031419|EXPERIMENTAL|CC-292 + CC-223 +/- rituximab|CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
62546778|NCT02031419|EXPERIMENTAL|CC-122 + rituximab|CC-122 administered orally once daily in combination with Rituximab.
62546779|NCT01153295|EXPERIMENTAL|Positive diagnosis|The diagnosis of IBS is based on the international ROME III criteria, few blod tests, and abscence of danger signals
62546780|NCT01153295|ACTIVE_COMPARATOR|Diagnosis of exclusion|The diagnosis of IBS is based on normal extended blood tests, screening for celiac sprue and lactose intolerance, stool for ova and parasites and endoscopy with biopsy
62546781|NCT01199380|ACTIVE_COMPARATOR|Standard Treatment (ST)|Participants will receive a standard, group smoking cessation treatment equated for contact time, based on the most recent clinical practice guideline for treating tobacco. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will complete between group exercises and will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events. Participants will also receive 8 weeks of the transdermal nicotine patch.
62546782|NCT01199380|EXPERIMENTAL|Behavioral Activation for Smoking|Behavioral Activation Treatment for Smoking (BATS) includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Participants will also receive 8 weeks of the transdermal nicotine patch.
62165735|NCT04438369|ACTIVE_COMPARATOR|Erector spinae block|"Group ESPB: Multimodal analgesia comprising of preoperative paracetamol adjusted for weight (2000 milligrams (mg) \>70 kilograms (kg) \<70 years, 1500 mg \<70 kg \>70 years, 1000 mg \<50 kg) and diclofenac adjusted for weight (100 mg \>70 kg \<70 years, 50 mg \<70 kg \>70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodon 1 mg/ml.~Preoperatively positioned bilateral catheters at level T7 injected with ropivacaine 2,5 mg/ml, 30 ml on each side. Postoperative maintenance treatment with injection of 2 mg/ml ropivacaine 30 ml on each side every 6 hours postoperatively. Maximum allowed bolus preoperative ropivacaine dose is 3 mg/kg body weight (BW), while the maximum 24 hour dose postoperatively is 11 mg/kg to avoid local anesthesia systemic toxicity (LAST). The catheter will be discontinued 24 hours after the original procedure. The container with ropivacaine will be masked for blinding of the personnel on the ward."
62546783|NCT04004585|EXPERIMENTAL|Intervention|This was a single arm study with all participants receiving the same intervention. Participants will receive a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour.
62546784|NCT06253806|ACTIVE_COMPARATOR|Experimental: Stellate Ganglion Block|The ultrasound guided stellate ganglion blocks will be performed at the initial visit by a board-certified anesthesiologist and pain management specialist with extensive experience performing these blocks. Laterality of the stellate ganglion blocks will be randomized between the left and right sides of the neck.
62546785|NCT06253806|PLACEBO_COMPARATOR|Placebo: Sham Injection|The ultrasound guided placebo sham injections will be performed at the initial visit by a board-certified anesthesiologist and pain management specialist with extensive experience performing these injections. Laterality of the placebo sham injections will be randomized between the left and right sides of the neck.
62546786|NCT04769531|EXPERIMENTAL|Hip Joint Mobilizations|Hip joint mobilizations Hip strength training Knee exercises
62546787|NCT04769531|EXPERIMENTAL|Hip & Knee Muscles strength training|Hip strength training Knee exercises
62546788|NCT04769531|ACTIVE_COMPARATOR|Knee Muscles strength training|Knee exercises
62546789|NCT02352688|ACTIVE_COMPARATOR|Enhanced Colorectal Geriatric Care|Multidisciplinary team involving in the elderly colorectal cancer patients' pre-, peri- and postoperative care.
62546790|NCT02352688|NO_INTERVENTION|Standard Surgical Care|Standard care given to elderly patients undergoing colorectal cancer resection.
62546791|NCT00486525|EXPERIMENTAL|Arm I: Yoga Therapy|Patients participate in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients are also encouraged to practice yoga at home using the appropriate DVD/video segments for the month.
62546792|NCT00486525|NO_INTERVENTION|Arm II: Wait-List|Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.
62546793|NCT01362543|ACTIVE_COMPARATOR|Stress Management|
62546794|NCT01362543|ACTIVE_COMPARATOR|Cognitive restructuring|
62546795|NCT01078870|EXPERIMENTAL|A|
62546796|NCT01078870|EXPERIMENTAL|B|
62546797|NCT01078870|EXPERIMENTAL|C|
62546798|NCT00822692|ACTIVE_COMPARATOR|Bactrim DS|Trim/sulfa (800/160) two tablets orally (PO) twice a day (BID) x 7 days
62546799|NCT00822692|PLACEBO_COMPARATOR|matched placebo|matched placebo 2 pills orally (PO) twice a day (BID) x 7 days
62546800|NCT00717288|ACTIVE_COMPARATOR|1|Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily
62546801|NCT00717288|ACTIVE_COMPARATOR|2|Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily
62546802|NCT00717288|ACTIVE_COMPARATOR|3|Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily
62546803|NCT03000478|ACTIVE_COMPARATOR|Prolonged Exposure|12 sessions of PE as per protocol
62546804|NCT03000478|EXPERIMENTAL|VRET|12 sessions of Virtual Reality Exposure Therapy
62546805|NCT00594373|EXPERIMENTAL|1|Application of 1% tenofovir gel for 14 consecutive days between menses
62546806|NCT00594373|PLACEBO_COMPARATOR|2|Application of 1% tenofovir placebo gel for 14 consecutive days between menses
62546807|NCT01983241|EXPERIMENTAL|Alpha-1 MP 60 mg/kg|Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
62546808|NCT01983241|EXPERIMENTAL|Alpha-1 MP 120 mg/kg|Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
62546809|NCT01983241|PLACEBO_COMPARATOR|Placebo|0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
62546810|NCT06583057||Thermal ablation group|Patients with clinical T1aN0M0 subcapsular papillary thyroid carcinoma who underwent thermal ablation for treatment.
62546811|NCT06583057||Thyroid lobectomy group|Patients with clinical T1aN0M0 subcapsular papillary thyroid carcinoma who underwent thyroid lobectomy for treatment.
62546812|NCT03277066|EXPERIMENTAL|Diclofenac Sodium Active Topical Patch 1|Diclofenac sodium 1 topical patches will be compared against placebo patches.
62546813|NCT03277066|EXPERIMENTAL|Diclofenac Sodium Active Topical Patch 2|Diclofenac sodium 2 topical patches will be compared against placebo patches.
62546814|NCT02904863|EXPERIMENTAL|patients with HUS|
62546815|NCT01887496||Chickenpox complications|Cases were identified by International Classification of Disease of the Tenth Revision (ICD-10) diagnostic codes for chickenpox infection or chickenpox-associated complications, if available.
62546816|NCT05861297|ACTIVE_COMPARATOR|Control group|The first (control )group includes patients with confirmed diagnosed who received IV pulse (High Dose-Dexamethasone) therapy
62546817|NCT05861297|EXPERIMENTAL|PSL - AZA group|The second group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy
62546818|NCT05861297|EXPERIMENTAL|The RTX group|The third group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy
62546819|NCT05861297|EXPERIMENTAL|The ELTRO group|The fourth group includes patients with confirmed diagnosed who received E therapy
62546820|NCT05861297|EXPERIMENTAL|The ROMP group|The fifth group includes patients with confirmed diagnosed who received Romiplostim therapy
62546821|NCT03180645|OTHER|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
62546822|NCT03180645|OTHER|Test product/ Positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
62546823|NCT03180645|OTHER|Positive control /No treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
62546824|NCT03564392|EXPERIMENTAL|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
62546825|NCT03564392|NO_INTERVENTION|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
62546826|NCT02765763|SHAM_COMPARATOR|Group 1 Sham|Null Formula of the Test System
62546827|NCT02765763|ACTIVE_COMPARATOR|Group 2 Treated|Full Formulas of Test System
62546828|NCT04859452|EXPERIMENTAL|The DDI of DBPR108 tablets and Metformin hydrochloride tablets|Subjects will receive a single dose of metformin hydrochloride on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of metformin hydrochloride on Day 8.
62546829|NCT04859452|EXPERIMENTAL|The DDI of DBPR108 tablets and Glibenclamide tablets|Subjects will receive a single dose of Glibenclamide on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Glibenclamide on Day 8.
62546830|NCT04859452|EXPERIMENTAL|The DDI of DBPR108 tablets and Valsartan Capsules|Subjects will receive a single dose of Valsartan on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Valsartan on Day 8.
62546831|NCT04859452|EXPERIMENTAL|The DDI of DBPR108 tablets and Simvastatin tablets|Subjects will receive a single dose of Simvastatin on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Simvastatin on Day 8.
62546832|NCT04628091|EXPERIMENTAL|Test group|Test group is composed of 20 women of reproductive age devoid of any pathology coming to the hospital for a salpingectomy for contraceptive purposes or for a total hysterectomy.
62546833|NCT04079465|ACTIVE_COMPARATOR|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 24 hours or until weaning from oxygen supplementation
62546834|NCT04079465|NO_INTERVENTION|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic is used in monitoring mode to measure SpO2 continuously.
62546835|NCT00369486|ACTIVE_COMPARATOR|1|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)
62546836|NCT00369486|EXPERIMENTAL|2|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
62546837|NCT00369486|EXPERIMENTAL|3|Anterior peribulbar injection of 20 mg triamcinolone
62546838|NCT00369486|EXPERIMENTAL|4|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
62546839|NCT00369486|EXPERIMENTAL|5|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
62546840|NCT03822104|EXPERIMENTAL|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
62546841|NCT03822104|ACTIVE_COMPARATOR|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
62546842|NCT01108783|EXPERIMENTAL|Bilastine|
62546843|NCT01108783|ACTIVE_COMPARATOR|Desloratadine|
62546844|NCT01108783|PLACEBO_COMPARATOR|Placebo|
62546845|NCT04975204|EXPERIMENTAL|TQB3909 Tablets|Take 100-1200mg once a day; Oral administration on an empty stomach, 28 days as a cycle.
62546846|NCT02871323|EXPERIMENTAL|Treatment (durvalumab)|Patients receive durvalumab IV over approximately 1 hour on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with SD, no new inter-current illness, and no unacceptable toxicity, may continue treatment beyond 3 courses.
62546847|NCT04641052|EXPERIMENTAL|Music Intervention Group|The music intervention group will be listened to the music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
62546848|NCT04641052|NO_INTERVENTION|No Intervention Group|The control group patients will receive standard care only
62546849|NCT00905671|EXPERIMENTAL|LCP+ Bifurcation Lesion|Bifurcating lesions that are positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
62546850|NCT00905671|EXPERIMENTAL|LCP- Bifurcation Lesion|Bifurcating lesions that are not positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
62546851|NCT05835674||Cohort I|500 participants screened by history and interview with parents to assess if they are to proceed to cohort II. This will be assessed by steering committee.
62546852|NCT05835674||Cohort II|"Participants (n=300) who meet the inclusion criteria from Cohort I, is assessed at enrollment visit and will proceed to cohort III if they meet any two of the following criteria:~1. Neuroimaging predictive of a motor disability~2. GMA test with absent fidgety GMs at fidgety age~3. HINE scores \<57 at 3months or \<60 at 6months or \<63 at 9 months or \< 66 at 12 months~Infants will also be included if they meet both of the following criteria:~1. Unilateral brain injury on neuroimaging predictive of CP~2. Clinical signs of asymmetry~Studies/objectives related to Cohort II~1. Evaluation of MRI~2. GMA implementation - To assess the feasibility of GMA in a multi-center Danish hospital setting.~3. Prediction of CP - To determine the clinical utility of the MRI, HINE, HAI, and GMA to predict a confirmed diagnosis of CP at 24 months~4. GMA/HINE/MRI vs. HAI - To compare diagnostic accuracy of HAI and GMA/HINE/MRI."
62546853|NCT05835674||Cohort III|"Participants (n=160) will be included in cohort III if infants are considered CP or at high risk of CP Participants are followed at enrolment, and ages six, 12, 18 and 24 months. Blood sample for trio-whole genome sequencing is offered to participants with definite or high risk of CP.~Studies/objectives related to Cohort III~e) Evaluation of genetics f) GO-PLAY. To analyse the effect of the GO-PLAY intervention with early family-centred set-up for children with definite or high risk of CP.~g) Parents perspective on intervention. To explore parents' perspectives on barriers and facilitators involved in early intervention.~h) Parents perspectives of early diagnosis - To analyse interviews of parents' perspectives of gains and concerns when having an early diagnosis of high risk of CP."
62546854|NCT06471855|EXPERIMENTAL|Technology-based Rehabilitation Group|Patients will undergo conventional treatment and, additionally, virtual reality-based rehabilitation.
62546855|NCT06471855|ACTIVE_COMPARATOR|Conventional Rehabilitation Group|Patients will undergo conventional treatment exclusively.
62546856|NCT01776255|EXPERIMENTAL|Healthy Children, Strong Families (first)|Healthy Children, Strong Families intervention (first). This is a series of monthly educational tool kits mailed to primary caregivers for use with the participating child. This arm crosses over to receive the Child Safety in Year 2.
62546857|NCT01776255|ACTIVE_COMPARATOR|Child Safety (first)|A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
62546858|NCT00396565|EXPERIMENTAL|ER OROS paliperidone|Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
62546859|NCT00396565|PLACEBO_COMPARATOR|Placebo|
62546860|NCT00396565|ACTIVE_COMPARATOR|Olanzapine|
62546861|NCT01157988|EXPERIMENTAL|ibritumomab tuixetan, response, toxicity|
62546862|NCT04712279|ACTIVE_COMPARATOR|Ivermectin 0.6mg/kg/day|
62546863|NCT04712279|ACTIVE_COMPARATOR|Ivermectin 1.0mg/kg/day|
62546864|NCT04712279|PLACEBO_COMPARATOR|Placebo|
62546865|NCT02058329|NO_INTERVENTION|No intervention|Standard of care with no home visit
62546866|NCT02058329|EXPERIMENTAL|Home Visit|After the post hip-fracture patient is discharged to home, there will be home visits by a geriatric fellow assess overall function and response to treatment/s by depression screen, FIM scores, and environmental risk assessment
62546867|NCT05015686|EXPERIMENTAL|Experimental Group with the immunization course of 0,28 days, 0,42 days or 0,56 days|960 subjects (including 480 children aged 13-17 years and 480 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days.
62546868|NCT05015686|ACTIVE_COMPARATOR|Control Group|960 subjects (including 480 children aged 13-17 years and 480 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days.
62546869|NCT05015686|EXPERIMENTAL|Experimental Group with the immunization course of 0, 70 days|320 subjects (including 160 children aged 13-17 years and 160 adults aged 18 years and older) will receive two doses of the experimental vaccine with the immunization course of 0, 70 days.
62546870|NCT05015686|PLACEBO_COMPARATOR|Placebo group|160 subjects (including 80children aged 13-17 years and 80 adults aged 18 years and older) will receive two doses of the placebo with the immunization course of 0, 70 days.
62546871|NCT00948324|ACTIVE_COMPARATOR|CSII|CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.
62546872|NCT00948324|ACTIVE_COMPARATOR|ALA|ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.
62546873|NCT00948324|ACTIVE_COMPARATOR|RSG|RSG:CSII combined with three months rosiglitazoneor 4mg QD.
62546874|NCT00948324|ACTIVE_COMPARATOR|MET|MET:CSII combined with metformin 500mg BID-TID.
62546875|NCT04513366|EXPERIMENTAL|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)~Other Names:~Pegadricase, pegsiticase Drug: SEL-110.36 (0.1 mg/kg) SEL-110.36, ImmTOR"
62546876|NCT04513366|EXPERIMENTAL|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)~Other Names:~Pegadricase, pegsiticase Drug: SEL-110.36 (0.15 mg/kg) SEL-110.36, ImmTOR"
62546877|NCT04513366|PLACEBO_COMPARATOR|Placebo|Normal saline
62546878|NCT00649779|EXPERIMENTAL|1|albuterol sulfate extended-release 8 mg tablets
62546879|NCT00649779|ACTIVE_COMPARATOR|2|VoSpire™ ER 8 mg tablets
62546880|NCT01960335|ACTIVE_COMPARATOR|Whey Protein Only|Ingestion of whey protein only (20 grams per serving) consumed 3X/day along with ad libitum diet for a total of 60 grams per day. One serving was consumed within 1 hour of waking in the morning; a second serving was consumed mid-afternoon; and a third serving was consumed within 2 hours of going to sleep at night.
62546881|NCT01960335|EXPERIMENTAL|Whey Protein and Resistance Exericse|Ingestion of whey protein (20 grams per serving) 3X/day: one serving within an hour of waking in morning; a second serving mid-afternoon or within 1 hour immediately following a resistance exercise bout on exercise days; and a third serving within 2 hours of going to bed at night.
62546882|NCT01960335|EXPERIMENTAL|Whey Protein and RISE exercise routine|Ingestion of whey protein (20 gram serving) 3X/day: one serving within an hour of waking in the morning; a second serving mid-afternoon or within 1 hour immediately following the RISE exercise bout; and a third serving within 2 hours of going to bed at night.
62546883|NCT00626457|EXPERIMENTAL|Maintenance First|
62546884|NCT00626457|ACTIVE_COMPARATOR|Weight Loss First|
62546885|NCT05545124|EXPERIMENTAL|Donafenib+Tislelizumab|Donafenib+Tislelizumab
62546886|NCT04563182||Muscle strength|GMed strength was assessed with the use of a Lafayette Manual Muscle Tester (Lafayette Instruments; Lafayette, Indiana, USA).
62546887|NCT04563182||Horizontal Jumping Performance|Lower extremity horizontal jumping was measured using the single leg hop (SLH) test as previously described
62546888|NCT04563182||Vertical Jumping Performance|To measure the single-leg vertical jump (SLVJ), the participants stood on the ground with their foot flat distributing their weight evenly on both feet.
62546889|NCT04563182||Dynamic Balance|The Y-Balance Test (YBT) was used to dynamic balance
62165736|NCT04438369|PLACEBO_COMPARATOR|Control|"Control group with standard multimodal analgesia: Preoperative paracetamol adjusted for weight (2000 milligrams (mg) \>70 kilograms (kg) \<70 years, 1500 mg \<70 kg \>70 years, 1000 mg \<50 kg) and diclofenac adjusted for weight (100 mg \>70 kg \<70 years, 50 mg \<70 kg \>70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodone 1 mg/ml.~Insertion of bilateral catheters preoperatively. Injection of 30 ml saline preoperatively and every 6 hours postoperatively. The catheter will be discontinued 24 hours after the original procedure. The container with saline will be masked for blinding of the personnel on the ward."
62546890|NCT04563182||Static Balance|The Stork balance test (SBT) was used to measure static balance performance
62546891|NCT04000282|EXPERIMENTAL|Part A: SAR442085 dose escalation|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
62546892|NCT04000282|EXPERIMENTAL|Part B: SAR442085 dose expansion|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
62546893|NCT02886780|EXPERIMENTAL|Concentrated Exposure Treatment (cET)|Please refer to:Havnen, A., Hansen, B., Öst, L.-G. \& Kvale, G. Concentrated ERP delivered in a group setting: An effectiveness study. Journal of Obsessive Compulsive and Related Disorders 3, 319-324 (2014)
62546894|NCT02886780|ACTIVE_COMPARATOR|Self-help|"The self-help condition (SH):~Foa, E.B. \& Kozak, M.J. Mastery of obsessive-compulsive disorder: Client workbook, (Graywind Publications, New York, 1997)."
62546895|NCT02886780|NO_INTERVENTION|Wait list|
62546896|NCT02407639|ACTIVE_COMPARATOR|co2 arm|insufflation with CO2
62546897|NCT02407639|PLACEBO_COMPARATOR|air arm|insufflation with air
62719965|NCT06114719|EXPERIMENTAL|Experimental group|Silymarin 400 mg daily, orally, divided into two doses, for three days preoperatively
62546898|NCT06632275||Prospective Observational Cohort|Patient and family caregiver dyads will be recruited for a prospective cohort observation for at least 24 hours and a maximum of seven days. At inclusion, baseline and self-reported data from admission until inclusion will be collected. After inclusion, data will be collected every 24 hours on self-reported outcomes of the last 24 hours. Patients and family caregiver dyads will be followed until discharge, transfer to another department, death or a maximum of seven days of follow-up. If dyads stay longer than seven days, daily follow-up is ended and they are called once 14 days later to collect outcome data.
62546899|NCT06632275||Time and Motion|Nurses and doctors will be recruited for time-and-motion observations by a trained non-participant observer during their shift on the medicine ward. Observers will use a REDCap to record where, what, for how long and how health workers perform tasks and interactions during their shifts. Observations will take place in sets of two hours each. Approximate equal amounts of observations will be done on all medicine wards. Observations will occur on different days of the week, at different shifts during the day, and at different times during a shift to collect data from different care contexts. Baseline data of the shift is recorded at the start of the observation.
62546900|NCT06632275||Qualitative|The qualitative arm of the study involves interviews and focus group discussions with patients, family caregivers, nurses, doctors and hospital administrators. The FGDs and interviews will be performed in Bengali by a local researcher experienced in qualitative research. An interview guide is used to define themes for the conversations, however, the interviewer is encouraged to follow the flow of the conversation by changing the order of topics or asking additional questions. The main themes of the interview guide are (1) the role of family participation in hospital care, (2) the perceived effect of family participation, (3) the barriers and facilitators for family participation in hospital care, and (4) the opportunities for improving family caregiver participation in hospital care.
62546901|NCT02291640|EXPERIMENTAL|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62546902|NCT02291640|EXPERIMENTAL|Child ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
62546903|NCT06425965|EXPERIMENTAL|Intervention Group 1|The first group will receive advanced life support training with a high reality simulator.
62546904|NCT06425965|EXPERIMENTAL|Intervention Group 2|The second group will receive advanced life support training with web-based simulation method.
62546905|NCT06425965|EXPERIMENTAL|Intervention Group 3|The third group will receive advanced life support training with a hybrid simulation method using both high reality simulator and web-based simulation.
62546906|NCT06228014||Patients with any kind of skin pathologies|Adult patients (≥ 18 years) with skin pathologies seen in the primary care service of health centers referring to Cruces and Basurto University Hospitals. Patients participating in this study did not receive any specific treatment as part of the research protocol. Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study.
62546907|NCT04221230|EXPERIMENTAL|BTRX-335140|BTRX-335140
62546908|NCT04221230|PLACEBO_COMPARATOR|Placebo|Placebo
62546909|NCT05439967|EXPERIMENTAL|Intervention|
62546910|NCT05439967|ACTIVE_COMPARATOR|Conventional Training|
62546911|NCT05911061|EXPERIMENTAL|Experimental group 1|high dose
62719966|NCT06114719|NO_INTERVENTION|Control group|Optimal standard therapy
62546912|NCT05911061|EXPERIMENTAL|Experimental group 2|low dose
62546913|NCT05911061|ACTIVE_COMPARATOR|Control group|Control group
62546914|NCT05911061|PLACEBO_COMPARATOR|Placebo control group|Placebo control group
62546915|NCT00719615||Thyroid Cancer in Remission Group|Thyroid Cancer-Remission Group \& use of Vitamin D
62546916|NCT00719615||Thyroid Cancer with Active Disease Group|Thyroid Cancer-Active Group \& use of Vitamin D
62546917|NCT00719615||Thyroid nodule group (no cancer) & Vit D|Thyroid nodule group without cancer and use of Vitamin D
62546918|NCT01325844|NO_INTERVENTION|G group|G group = General anesthesia group
62546919|NCT01325844|EXPERIMENTAL|G+E group|G+E group = General anesthesia + epidural anesthesia group
62719967|NCT02100293|ACTIVE_COMPARATOR|standard dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.6 mg/kg
62719968|NCT02100293|ACTIVE_COMPARATOR|low dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.45 mg/kg
62719969|NCT02100293|ACTIVE_COMPARATOR|low dose rocuronium plus magnesium group|pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg
62719970|NCT02422329|EXPERIMENTAL|Educational Video|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
62719971|NCT02422329|EXPERIMENTAL|Fact Sheet|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants read educational material describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
62719972|NCT00613184|EXPERIMENTAL|1|Nylon Flocked swab Left Nasal Wash right
62546920|NCT02319278|ACTIVE_COMPARATOR|Myocarditis|
62546921|NCT02319278|ACTIVE_COMPARATOR|Cardiac sarcoid|
62546922|NCT02319278|ACTIVE_COMPARATOR|Cardiac Transplant|
62546923|NCT02319278|PLACEBO_COMPARATOR|Healthy Volunteers|
62546924|NCT03044821|EXPERIMENTAL|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
62546925|NCT05865548|EXPERIMENTAL|Interventional arm|Aspirin 150mg PO daily along with standard of care
62546926|NCT05865548|ACTIVE_COMPARATOR|Standard of care|Standard of care as per the stage of disease and guidelines i.e. Surgery, Surgery with radiation or palliative chemotherapy as per investigators choice
62546927|NCT06551662|EXPERIMENTAL|Device: Paclitaxel drug-coated-balloons|
62546928|NCT06551662|EXPERIMENTAL|Device: Sirolimus drug-coated-balloons|
62546929|NCT06551662|ACTIVE_COMPARATOR|Device: new generation drug-eluting-stents|
62546930|NCT01504997|EXPERIMENTAL|Robot assisted distal gastrectomy|patients who received robot assisted distal gastrectomy
62546931|NCT05800158||SARS-CoV-2|Nasopharyngeal and anterior nasal swabs collected from symptomatic individuals suspected of COVID-19 by their health care provider.
62546932|NCT03324295||cortical cataract|patients with age related cortical cataracts who are otherwise healthy
62546933|NCT03324295||ocular problems|systemically healthy subjects with ocular problems other than cataract
62546934|NCT03324295||impaired renal functions|patients with impaired renal functions and are not on dialysis
62165737|NCT03644277|EXPERIMENTAL|Massed practice training with dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
62546935|NCT02535286|EXPERIMENTAL|TG-1501 + Ublituximab + Umbralisib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Umbralisib oral daily dose TG-1501 IV infusion at scheduled intervals
62546936|NCT05094661|NO_INTERVENTION|Non failure high flow oxygen therapy|The patient is treated with high flow oxygen system throughout the admission in the intermediate respiratory care unit
62546937|NCT05094661|ACTIVE_COMPARATOR|Non-invasive ventilation (CPAP/BiPAP)|If high flow support fails, the patients will be treated with non-invasive respiratory support.
62546938|NCT04876105||Acute-subacute group|According to the duration of low back pain, it is classified as acute pain if it lasts less than a month, subacute pain if it lasts for 1-3 months.
62546939|NCT04876105||Chronic group|According to the duration of low back pain, it is classified as chronic pain if it lasts for more than 3 months.
62546940|NCT02184767|EXPERIMENTAL|ADASUVE®|oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight
62546941|NCT04619212|OTHER|Standard of Care|Standard of Care
62546942|NCT04619212|OTHER|new device|new device
62546943|NCT05871554|NO_INTERVENTION|Waitlist|Participants are allocated to a waitlist condition where they participate in surveys for 11 weeks. Participants receive access to the treatment modules after completing the final survey after the 11th week.
62546944|NCT05871554|EXPERIMENTAL|Treatment|Participants are allocated to a treatment condition where they participate in surveys and online video modules for 11 weeks.
62546945|NCT00663026|EXPERIMENTAL|A|5 mg/week
62546946|NCT00663026|EXPERIMENTAL|B|10 mg/week
62546947|NCT00663026|EXPERIMENTAL|C|Placebo
62546948|NCT01632631||PROcedure rehearsal|PROcedure rehearsal performed before real EVAR procedure No intervention
62546949|NCT01632631||No PROcedure rehearsal|no PROcedure rehearsal performed before real EVAR procedure No intervention
62546950|NCT04370834|EXPERIMENTAL|Other (tocilizumab)|Patients receive tocilizumab IV over 60 minutes. A second dose may be given if there is sustained or recurrent fever, no decrease or not more than a 1-category improvement on the 7-category ordinal scale (only stabilization or partial improvement following first dose), or a \>= 1-category worsening on the 7-category ordinal scale from nadir.
62546951|NCT02234076|EXPERIMENTAL|VRET|"Virtual Reality Exposure Therapy (VRET)~The experimental treatment VRET is offered with the Multi-Modal Memory Restructuring System (3MR system) and a therapy manual. Participants can use this system at home. Note: The 3MR system is offered via a computer screen, no head-mounted display (HMD) equipment is used in this study."
62546952|NCT02234076|ACTIVE_COMPARATOR|TAU|Treatment As Usual
62546953|NCT00595309|ACTIVE_COMPARATOR|A|
62546954|NCT00559533|EXPERIMENTAL|1|
62546955|NCT03594760|EXPERIMENTAL|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
62546956|NCT02268877|EXPERIMENTAL|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
62546957|NCT02268877|ACTIVE_COMPARATOR|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
62546958|NCT03065946||Case series|Early wakening
62546959|NCT03506256|EXPERIMENTAL|Norofloxacin|The recommended dosage of norfloxacin for urinary-tract infections in adults is 400 mg orally every 12 hours; the drug should be given for 7 to 10 days in uncomplicated infections and for 10 to 21 days in complicated ones. Adverse drug effects were mild and included disturbances of the gastrointestinal tract and the central nervous system. The study shall be completed in accordance with the ICH topic E6 (R1)(CPMP/ICH/one hundred thirty five/95) guiding principle for top medical practice and the ideas enunciated within the announcement of Helsinki and the approval by way of an Institutional Ethics Committee.
62546960|NCT03298217|OTHER|Bronchiolitis patients sverity|In patients with bronchiolitis mWCAS / 3-5 : Measurement of the peak tidal inspiratory flow (PTIF)
62546961|NCT00997867|ACTIVE_COMPARATOR|Catheter 0-1cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 0-1cm past the needle tip. The patient will be called the following day by research staff to assess their post-surgical pain.
62546962|NCT00997867|ACTIVE_COMPARATOR|Catheter placed 5-6cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 5-6cm past the needle tip. Patients will be called the following day by research staff to assess their post-surgical pain.
62546963|NCT01408602|EXPERIMENTAL|MRC375 75 mg|MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
62546964|NCT01408602|EXPERIMENTAL|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
62546965|NCT01408602|PLACEBO_COMPARATOR|Placebo|Placebo
62546966|NCT06372184|EXPERIMENTAL|Washed microbiota transplantation|Patients take four capsules containing washed microbiota once a day for five consecutive days
62719973|NCT00613184|EXPERIMENTAL|2|Nylon Flocked swab R Nasal Wash L
62546967|NCT06372184|PLACEBO_COMPARATOR|Placebo|Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
62546968|NCT01121081|PLACEBO_COMPARATOR|Placebo|sugar pills
62546969|NCT01121081|EXPERIMENTAL|Dunaliella|drug
62546970|NCT05863169|EXPERIMENTAL|dlPFC fNIRS-Feedback|Feedback of oxygenation in 4 DLPFC channels
62546971|NCT05863169|EXPERIMENTAL|IFG fNIRS-Feedback|Feedback of oxygenation in 4 IFG channels
62546972|NCT05863169|ACTIVE_COMPARATOR|Control fNIRS-Feedback|Feedback of oxygenation in 4 control channels over temporal areas (unrelated to cognitive control or ADHD)
62546973|NCT04172597|EXPERIMENTAL|Cohort 1|Patients with HER2-positive or HER2-negative BC with a HER2 activating mutation will receive poziotinib 8 milligrams (mg), orally, twice daily (BID) starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
62546974|NCT04172597|EXPERIMENTAL|Cohort 2|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
62546975|NCT04172597|EXPERIMENTAL|Cohort 3|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
62546976|NCT04172597|EXPERIMENTAL|Cohort 4|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
62546977|NCT04172597|EXPERIMENTAL|Cohort 5|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
62546978|NCT00633347|ACTIVE_COMPARATOR|A|A: Antagonist
62546979|NCT00633347|ACTIVE_COMPARATOR|B|Agonist GnRH
62546980|NCT04515381|EXPERIMENTAL|Therapeutic touch group|Each student from the Therapeutic touch (TT) group was given TT sessions via Krieger-Kunz method in a total of 8 times in the manner of twice a week for one group (Monday - Wednesday) and another group (Tuesday - Thursday) for a duration of 1 month (4 week). TT application procedure: The procedure was explained to the student, the student person was concentrated, concentrated practitioner for TT application, the student's entire body was evaluated from head to foot with the practitioner's hands at a distance of about 2 inc, hands were moved regularly and rhythmically to prevent imbalances in the energy field, the energy field was re-evaluated from top to bottom and rebalanced if there was a blocked area, finally, the student was left to rest and response to the treatment was observed. The TT sessions of 20 minutes were applied on the students and they were given a short rest at the end of the session
62546981|NCT04515381|PLACEBO_COMPARATOR|Placebo group|For students in the placebo group, the similar duration (20 minutes) and frequency (2 sessions a week, total of 8 sessions) of TT was applied with hands at a certain distance from the body (approximately 5 cm) and they were moved without a specific order. The application was performed by the other researcher in a separate room to the placebo group.
62546982|NCT04515381|OTHER|Control group|There was no attempt being made towards the students within the control group. At the end of the 4th week, all students were asked to repeat measurements
62546983|NCT06161779|EXPERIMENTAL|Submental artery flap reconstruction group|
62546984|NCT05695066|EXPERIMENTAL|4H group|Patients parents instructed to stop enteral feeding 4 hours before predicted anesthesia induction
62719974|NCT00613184|EXPERIMENTAL|3|Nasal Wash Left Nylon Flocked swab Right
62546985|NCT05695066|ACTIVE_COMPARATOR|6H group|Patients parents instructed to stop enteral feeding 6 hours before predicted anesthesia induction
62546986|NCT06040801|EXPERIMENTAL|Frail group|All patients receive a frailty assessment within 7 days before initiating the first cycle of palliative chemotherapy, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The frail group will receive management and recommendations based on the specific impairment domain.
62546987|NCT06040801|NO_INTERVENTION|Non-frail group|All patients receive a frailty assessment within 7 days before initiating the first cycle of palliative chemotherapy, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The non-frail group will not receive additional interventions, but the clinical physicians will still provide appropriate treatment based on the patient's condition.
62546988|NCT03032679||Single group of patients|Non interventional study. Observational with questionnaires
62546989|NCT01320891|EXPERIMENTAL|balanced|arm in which the subjects received only balanced solutions
62546990|NCT01320891|EXPERIMENTAL|not balanced|arm in which the subjects received only not balanced solutions that means only normal saline and colloid dissolved in normal saline
62719975|NCT00613184|EXPERIMENTAL|4|Nasal Wash R Nylon flocked swab L
62719976|NCT03388892|EXPERIMENTAL|Drug-Eluting Balloon|PTA with DEB at venous anastomotic stenosis of AVG
62719977|NCT03388892|ACTIVE_COMPARATOR|Plain Balloon|PTA with PCB at venous anastomotic stenosis of AVG
62719978|NCT05021952|EXPERIMENTAL|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
62719979|NCT05021952|NO_INTERVENTION|Education brochure|Control group is provided general education through the hospital brochure.
62546991|NCT03778684|EXPERIMENTAL|Normal Body mass index without central obesity|
62546992|NCT03778684|EXPERIMENTAL|High Body mass index with central obesity|
62546993|NCT01244503|EXPERIMENTAL|Sodium Octanoate Breath Test|Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.
62546994|NCT05876637|EXPERIMENTAL|Left Nostril Breathing|The intervention protocol include healthy young females age 18-25 years.. All baseline measurements will be taken , Afterwards, the Cold pressor test would be performed for 1 minutes to induce acute stress while the BP would be monitored for every 30 seconds. At the end of the test, again the BP would be monitored. Out of all the recordings, the BP measuring the highest value would be recorded as final. We will then subtract the normal resting BP by highest value of the recording for each participant. Change in BP of systolic by 25mmHg and diastolic by 20mmHg will be considered hyper reactive. Then the hyper reactive subjects will be divided into two groups. Experimental group will receive left nostril breathing. CPT will be performed again at 4, 8 and 12 weeks to monitor the BP, heart rate and Spo2 likewise to check for any decline in sympathetic activity.
62546995|NCT05876637|ACTIVE_COMPARATOR|Conventional|The conventional protocol include healthy young females age 18-25 years. All baseline measurements will be taken, Afterwards, the Cold pressor test would be performed for 1 minutes to induce acute stress while the BP would be monitored for every 30 seconds. At the end of the test, again the BP would be monitored. Out of all the recordings, the BP measuring the highest value would be recorded as final. We will then subtract the normal resting BP by highest value of the recording for each participant. Change in BP of systolic by 25mmHg and diastolic by 20mmHg will be considered hyper reactive. Then the hyper reactive subjects will be divided into two groups Group A(Experimental) and Group B(Conventional). Controlled group will receive simple deep breathing exercises ,3 sessions per week for 12 weeks. CPT will be performed again at 4, 8 and 12 weeks to monitor the BP, heart rate and Spo2 likewise to check for any decline in sympathetic activity.
62546996|NCT03533309|EXPERIMENTAL|computer guided|"Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.~."
62546997|NCT03533309|ACTIVE_COMPARATOR|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
62546998|NCT02914210|OTHER|Virtual physical therapy|Virtual physical therapy rehabilitation program (VERA) used in the home with care planning and remote support and monitoring by physical therapists
62546999|NCT02914210|OTHER|Traditional physical therapy|No intervention. Standard home health physical therapy and/or outpatient clinic physical therapy as prescribed.
62165738|NCT03644277|EXPERIMENTAL|Massed practice training with Sham dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
62547000|NCT03223701|OTHER|Treatment group|The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.
62547001|NCT01668810||Beijing region|include six hospitals
62547002|NCT01668810||Guangdong Province|include 3 hospitals
62547003|NCT01668810||Jiangsu province|include 3 hospitals
62547004|NCT01668810||Hebei province|include 6 hospitals
62547005|NCT01668810||Hubei Province|include 7 hospitals
62547006|NCT01668810||Shanxi province|include 3 hospitals
62547007|NCT01668810||Jiangxi province|include 3 hospitals
62547008|NCT01668810||Jilin province|include 6 hospitals
62547009|NCT01668810||Sichuan province|include 3 hospitals
62547010|NCT01668810||Shaanxi province|include 3 hospitals
62547011|NCT03981913||Healthy control (HC)|Participants without neurological or psychiatric disturbance (n= 30)
62547012|NCT03981913||Parkinson's disease (PD)|Participants with idiopathic Parkinson's disease but without other neurological or psychiatric disturbance (n= 30)
62547013|NCT01723475|EXPERIMENTAL|BAY2010112 (s.c.)|
62547014|NCT01723475|EXPERIMENTAL|BAY2010112 (c.i.v.)|
62547015|NCT05682612||Survivors|Survivors of COVID-19 induced respiratory failure
62547016|NCT05682612||Nonsurvivors|Nonsurvivors of COVID-19 induced respiratory failure
62547017|NCT05481619|ACTIVE_COMPARATOR|Group of UC patients treated with vedolizumab|Generic Name：vedolizumab Specification：300mg/bottle Dosage and Method of Administration：Usual adult dose for ulcerative colitis.300 mg IV every 30 minutes at weeks 0, 2, and 6, then every 8 weeks
62547018|NCT05481619|NO_INTERVENTION|Normal control group|On the basis of the exclusion criteria, there are no significant intestinal inflammatory, autoimmune or neoplastic disorders.
62547019|NCT01667328|EXPERIMENTAL|Massage therapy|This group will received presurgical massage
62547020|NCT01667328|PLACEBO_COMPARATOR|Control|Standard of care with no massage
62547021|NCT01560741|ACTIVE_COMPARATOR|Telemedicine Group|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be provided with a ventilator outfitted with a wireless transmitter to allow the remote data collection of compliance and efficacy information. While patient sleeps, data is collected. If abnormalities criteria will be detected, remote titration of ventilator settings will be done to optimise therapy. Patient will be monitored again and data analyzed. This procedure will be repeated until we obtained the optimal ventilator parameters for each patient in this group. Nocturnal oximetry under home mechanical non-invasive ventilation will be carried out after one week and one month of treatment. Subjects also receive pre-arranged telephone calls to assist with progress.
62719980|NCT06473532|EXPERIMENTAL|TEXT4HF|In addition to usual care and a standard AHA information packet for patients with HF, participants in the intervention group will receive 5 tailored TMs/week for 12 weeks, targeting health beliefs about medication adherence, heart-healthy diet, self-monitoring of symptoms, and heart failure knowledge.
62719981|NCT06473532|NO_INTERVENTION|Control Group|The control group will receive standard HF medical care, which includes nurse-led patient education about HF self-care before and/or after discharge as well as follow-up visits at the Outpatient Heart Failure Clinic at UIH post-hospital discharge and several times per year or more, depending on the severity of the patient's condition. Participants will also receive the AHA information packet for patients with HF.
62547022|NCT01560741|OTHER|Usual care|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be assessed by a hospital visit scheduled at the end of third month after their initial adaptation. In this hospital visit data provided by the ventilator will be transferred to research team computer so they could evaluate patient compliance and efficacy of ventilation criteria under the parameters used at home present at the time of assessment. If abnormality criteria will be detected, re-titration of ventilator settings will be made. Patients will be encouraged to call their respiratory consultant any time they had a problem or concern.
62547023|NCT05149560|EXPERIMENTAL|Ticagrelor|Ticagrelor 90 mg twice daily for 12 months
62547024|NCT06077474||PTSD QUESTIONNAIRES|The group is anticipated to consist of in 155 patients who have been exposed to traumatic events.
62547025|NCT04563715|ACTIVE_COMPARATOR|Standard of Care|HIV counseling and testing
62547026|NCT04563715|EXPERIMENTAL|Standard of Care plus Network Intervention|Network intervention
62547027|NCT02175901|EXPERIMENTAL|Amoxicillin/metronidazole|Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid
62547028|NCT02175901|ACTIVE_COMPARATOR|Amoxicillin/clarithromycin|Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
62547029|NCT04631536|EXPERIMENTAL|Endothelial Dysfunction Protocol|"Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin, nicorandil, l-arginine, folic acid and nebivolol) in patients already on optimal medical therapy for the treatment of COVID0-19 virus.~Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc).~1. Atorvastatin or continue home statin Atorvastatin will be provided as a 40 mg tablet to be given PO once daily. This dose was suggested because high intensity statin has been associated with a better endothelial profile (Int J Cardiol 2017 Oct 1;244:112-118.-- Eur J Clin Pharmacol 2014 Oct;70(10):1181-93)~2. Nicorandil Nicorandil 10 mg PO BID as the recommended dose for coronary vasodilatation by the manufacturer~3. Nebivolol Nebivolol 2.5-5 mg PO ONCE daily while keeping Heart Rate (HR) between 50-90 bpm~4. Folic Acid Folic Acid 5 mg po once daily~5. L-Arginine L-Arginine 1 g po TID"
62547030|NCT04631536|PLACEBO_COMPARATOR|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
62547031|NCT03539263|EXPERIMENTAL|Group 1|the subjects are treated with probiotics: Bifihappy
62547032|NCT03539263|PLACEBO_COMPARATOR|Group 2|the subjects are treated with a placebo
62547033|NCT01437488|EXPERIMENTAL|Cabazitaxel|Cabazitaxel following platinum-based chemotherapy
62547034|NCT03377257|ACTIVE_COMPARATOR|Active group|The treatment with oral zolmitriptan is 2.5mg when headache attack.
62547035|NCT03377257|EXPERIMENTAL|Experimental group|The treatment with zolmitriptan by sublingual administration is 2.5mg when headache attack.
62547036|NCT05980689|EXPERIMENTAL|Treatment Arm|A total of 33 pMMR/MSS LARC patients will receive long-course chemoradiotherapy plus 2 cycles of AK104, followed by another 3 cycles of AK104, finally received clinical routine manage.
62547037|NCT05644197|OTHER|intervention group|the intervention group of 50 patients will undergo a support program over 12 weeks (1 adapted physical activity session per week, will participate in 5 workshops with the psychologist and 1 workshop with the dietician, plus a visit with the urologist after 6 weeks from prostatectomy
62547038|NCT05644197|NO_INTERVENTION|control group|the control group will only undergo a classic follow-up during its 12 weeks, namely a visit to the urologist after 6 weeks of the prostatectomy
62547039|NCT01098474|EXPERIMENTAL|SB692342 2 dose Group|Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.
62547040|NCT01098474|EXPERIMENTAL|SB692342 1 dose Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.
62547041|NCT01098474|ACTIVE_COMPARATOR|Control Menjugate Group|Subjects received three doses of the control Menjugate™ vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.
62547042|NCT01098474|EXPERIMENTAL|SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group|"Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomintantly with the last two doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered instramuscularly in the right arm, on a 0, 1, 2 months schedule.~All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose."
62547043|NCT01098474|EXPERIMENTAL|SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
62719982|NCT02656667|EXPERIMENTAL|neuromuscular electrical stimulation|conventional pulmonary rehabilitation including exercise training on treadmill and neuromuscular electrical stimulation with a medical device for quadriceps muscle strengthening
62719983|NCT02656667|EXPERIMENTAL|cycle ergometer training|conventional pulmonary rehabilitation including exercise training on treadmill and quadriceps strenghthening on cycle-ergometer
62719984|NCT01152307|EXPERIMENTAL|Decision Aid|Group receiving the decision aid (DVD/booklet)
62719985|NCT01152307|NO_INTERVENTION|Control|Group not receiving the decision aid (DVD/booklet)
62547044|NCT01098474|ACTIVE_COMPARATOR|Control Tritanrix + Prevnar + Polio Sabin Group|Subjects received three doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
62547045|NCT03278691|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Saline 1 ml IV Q6H
62547046|NCT03278691|EXPERIMENTAL|Intervention|Ketorolac 15 mg (15mg/ml) IV Q6H
62547047|NCT03438994|ACTIVE_COMPARATOR|Participants diagnosed with ASD|
62547048|NCT03438994|EXPERIMENTAL|Participants diagnosed with OND|
62547049|NCT03438994|ACTIVE_COMPARATOR|Typically developing participants|
62547050|NCT01670617|OTHER|DeNovo NT Graft|DeNovo NT Graft stratified by lesion location - femur or patella
62547051|NCT06551181|EXPERIMENTAL|RSV OA vaccine Group (China)|Chinese participants receive a single dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until end of study (Month 6 or last ARI visit/contact, whichever is later).
62547052|NCT06551181|PLACEBO_COMPARATOR|Placebo Group (China)|Chinese participants receive a single dose of placebo at Day 1 and are followed up until end of study (Month 6 or last ARI visit/contact, whichever is later).
62547053|NCT06551181|EXPERIMENTAL|RSV OA vaccine Group (Overseas)|Overseas participants receive a single dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until end of study (Month 6).
62547054|NCT05884502|EXPERIMENTAL|Combination therapy|combination of high-dose rosuvastatin and ezetimibe
62547055|NCT05884502|ACTIVE_COMPARATOR|Single therapy|high-dose rosuvastatin single administration group
62547056|NCT03252730|EXPERIMENTAL|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
62547057|NCT05696379||STEMI with high Angio-IMR|Patients with ST segment elevation myocardial infarction and high Angio-IMR
62547058|NCT05696379||STEMI with low Angio-IMR|Patients with ST segment elevation myocardial infarction and low Angio-IMR
62547059|NCT05696379||NSTEMI with high Angio-IMR|Patients with non-ST segment elevation myocardial infarction and high Angio-IMR
62547060|NCT05696379||NSTEMI with low Angio-IMR|Patients with non-ST segment elevation myocardial infarction and low Angio-IMR
62547061|NCT01838473|ACTIVE_COMPARATOR|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
62547062|NCT01838473|ACTIVE_COMPARATOR|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
62547063|NCT01838473|ACTIVE_COMPARATOR|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
62547064|NCT01838473|ACTIVE_COMPARATOR|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
62547065|NCT03630380||Single Arm|All children under five years of age with clinical suspicion of pneumonia (fever or respiratory complaints) who have a chest radiograph ordered will be consented. Clinical history, physical exam findings (temperature, respiratory rate, oxygen saturation, and lung auscultation findings), laboratory findings (white blood cell count, differential, and CRP) will be recorded. Lung ultrasound will be performed on all patients.
62547066|NCT05035277|ACTIVE_COMPARATOR|Acetylsalicylic acid|Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.
62547067|NCT05035277|EXPERIMENTAL|Direct oral anticoagulation (DOAC)|Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.
62547068|NCT03674398|EXPERIMENTAL|Exercise+CT|Aerobic exercise for 30 minutes and smart-phone delivered cognitive training application for 20 minutes, 3 times per week for 4 weeks
62547069|NCT03674398|ACTIVE_COMPARATOR|Exercise only|Aerobic exercise for 30 minutes and smart-phone delivered videos for 20 minutes, 3 times per week for 4 weeks
62547070|NCT00262665|EXPERIMENTAL|Org 24448|ampa receptor potentiator for the treatment of MDD
62547071|NCT00262665|PLACEBO_COMPARATOR|Placebo|matching placebo pill
62547072|NCT03348618|EXPERIMENTAL|IVIG|IVIG dose at 1 g/Kg/body weight
62547073|NCT01144715|EXPERIMENTAL|Hand Mentor Therapy|Use of the Hand Mentor (TM) Stroke Therapy Device at home for 8 weeks
62547074|NCT01144715|ACTIVE_COMPARATOR|Control|Self administered home therapy program
62547075|NCT06582173||Adolescents|Patients aged 12 to 25 years old and diagnosed with SSD by a specialised multidisciplinary team
62547076|NCT06582173||Parents|Parents of an adolescent included
62547077|NCT01442324|EXPERIMENTAL|IRE|Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.
62547078|NCT05379842|NO_INTERVENTION|1- Non-intervention|Non-posterior intervention after randomization
62547079|NCT05379842|ACTIVE_COMPARATOR|2- Traditional advanced intervention model|Motivational workshops, every 3 months and with limited cost
62547080|NCT05379842|ACTIVE_COMPARATOR|3- E-learning advanced intervention model|Educational workshops, every 15 days, with videos -YouTube channel or WhatsApp/text message
62547081|NCT02432053|EXPERIMENTAL|Transplantation|Advagraf
62738996|NCT01042587|ACTIVE_COMPARATOR|bright light|Bright light has been shown to entrain circadian rhythm so our treatment arm will use thirty minutes of early morning exposure to bright blue light for a four week period.
62547082|NCT01837134|NO_INTERVENTION|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
62547083|NCT01837134|EXPERIMENTAL|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
62547084|NCT01837134|EXPERIMENTAL|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
62547085|NCT02620436|EXPERIMENTAL|Core Mother Shelter Model|Existing mother shelters will be renovated, and mother shelters will be built at intervention sites, to meet the Core Mother Shelter Model. This model includes ensuring a safe infrastructure with four walls, a roof, doors and windows that lock, a toilet, running water, and beds.
62547086|NCT02620436|NO_INTERVENTION|Standard of Care|Existing mother shelters with no changes made, except to ensure that they can provide standard of care.
62547087|NCT00511641||Low Risk OVCA|Patient that is participating in an ovarian cancer (OVCA) screening program.
62547088|NCT04246827|EXPERIMENTAL|Enhanced Lifestyle Weight Management Condition|The Enhanced Lifestyle Weight Management condition participants participated in a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors was integrated into a lifestyle behavioral weight loss intervention.
62547089|NCT04246827|NO_INTERVENTION|Standard Care Control|Participants received standard care of rheumatoid arthritis.
62547090|NCT01534169|EXPERIMENTAL|Isotonic Na chloride|The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.
62547091|NCT01860625|EXPERIMENTAL|1(12.5㎠)|"drug : 9 people, 43.75mg/12.5㎠~placebo : 3 people, 12.5㎠"
62547092|NCT01860625|EXPERIMENTAL|2(25㎠)|"drug : 9 people, 87.5mg/25㎠~placebo : 3 people, 25㎠"
62547093|NCT01860625|EXPERIMENTAL|3(50㎠)|"drug : 9 people, 175mg/50㎠~placebo : 3 people, 50㎠"
62547094|NCT05412238|EXPERIMENTAL|Pregnant women receiving fortification sachets|pregnant women receive daily fortified sachets containing micro-and macronutrients for 6-9 months
62547095|NCT05412238|EXPERIMENTAL|6-24 months old children receiving fortification sachets|6-24 months old children receiv daily fortified sachets containing micro-and macronutrients for 6-9 months
62547096|NCT05412238|EXPERIMENTAL|2-5 years old children receiving fortification sachets|2-5 years old children receive daily fortified sachets containing micro-and macronutrients for 6-9 months
62547097|NCT05093829|EXPERIMENTAL|Vaccination at 9 months of age with NmCV-5|Infant participants randomized to receive the NmCV-5 meningococcal vaccination at 9 months of age, while receiving the current Mali EPI schedule of vaccines.
62547098|NCT05093829|ACTIVE_COMPARATOR|Vaccination at 9 months of age with MenACWY-TT|Infant participants randomized to receive the MenACWY-TT meningococcal vaccination at 9 months of age, while receiving the current Mali EPI schedule of vaccines.
62547099|NCT05093829|EXPERIMENTAL|Vaccination at 15 months of age with NmCV-5|Infant participants randomized to receive the NmCV-5 meningococcal vaccination at 15 months of age, while receiving the current Mali EPI schedule of vaccines.
62547100|NCT05093829|ACTIVE_COMPARATOR|Vaccination at 15 months of age with MenACWY-TT|Infant participants randomized to receive the MenACWY-TT meningococcal vaccination at 15 months of age, while receiving the current Mali EPI schedule of vaccines.
62547101|NCT04853095|EXPERIMENTAL|Intervention group (PerFix)|Peritoneal fixation technique
62547102|NCT04853095|ACTIVE_COMPARATOR|Control group (no PerFix)|Standard of care (i.e. no fixation)
62547103|NCT02158715||Smartphone positioning during Chest compression|
62547104|NCT06312566|EXPERIMENTAL|Treatment A-B|Study participants randomized to this arm will receive multiple doses of brivaracetam tablet (Treatment A) as reference and multiple doses of brivaracetam dry syrup (Treatment B) as test in the treatment sequence A-B at pre-specified timepoints.
62719986|NCT06712706||Patients with esophageal cancer receiving neoadjuvant therapy and an jejunal feeding tube|"Included are:~* Adult patients aged 18 years and above at the time of diagnosis.~* Advanced-stage esophageal cancer or cancer of the esophageal junction and treated with curative intent, including neoadjuvant treatment.~* Patients who received an FJT before neoadjuvant treatment or during definitive surgery.~* Patients treated between 2017 and 2024 in the single institution of the City Hospital Zürich Triemli and completed 6 months of follow-up or died by 31.12.2024.~Patients receiving the FJT at staging laparoscopy will be compared to patients receiving FJT at the time of esophagectomy."
62719987|NCT00959907|ACTIVE_COMPARATOR|BoNT A1 (4U)|BoNT A1 (4U): Botulinum toxin A (Dysport®)4 units
62719988|NCT00959907|ACTIVE_COMPARATOR|BoNT-A2 (2U)|BoNT-A2(2U): Botulinum toxin A (Botox®) 2 units
62547105|NCT06312566|EXPERIMENTAL|Treatment B-A|Study participants randomized to this arm will receive multiple doses of brivaracetam tablet (Treatment A) as reference and multiple doses of brivaracetam dry syrup (Treatment B) as test in the treatment sequence B-A at pre-specified timepoints.
62547106|NCT04683016||Periodontitis patients|Patients with a diagnosis of periodontitis, irrespective of its stage and grade.
62547107|NCT00929279|ACTIVE_COMPARATOR|Abciximab bolus plus infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen.
62547108|NCT00929279|EXPERIMENTAL|bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
62719989|NCT05017064|EXPERIMENTAL|Cryotherapy group|An intraoral ice pack will be placed on the mucosal groove during root canal treatment.
62719990|NCT05017064|PLACEBO_COMPARATOR|Control group|No ice pack will be used.
62719991|NCT05095298|NO_INTERVENTION|Control Group|Participants volunteered not to receive the third dose of vaccine, and agreed to be followed-up for 1 year
62719992|NCT05095298|EXPERIMENTAL|Inactivated Vaccine Group|Participants volunteered to receive the third dose of inactivated vaccine
62719993|NCT05095298|EXPERIMENTAL|Recombinant subunit protein vaccine|Participants volunteered to receive the third dose of subunit protein vaccine
62719994|NCT05095298|EXPERIMENTAL|mRNA vaccine Group|Participants volunteered to receive the third dose of mRNA vaccine ( To be enrolled, the vaccine has not been approved in China)
62738997|NCT01042587|SHAM_COMPARATOR|red light|Low level red light is a weak entrainment stimulus of circadian rhythm. Elders in the control group will be exposed to low level red light as a placebo for thirty minutes daily for four weeks.
62165739|NCT03644277|EXPERIMENTAL|Rapael glove with dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
62165740|NCT03644277|ACTIVE_COMPARATOR|Rapael glove with Sham dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
62165741|NCT03644277|PLACEBO_COMPARATOR|No training with dAIH|"Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%.~Hearth rate and pulse oximetry will be continuously monitored throughout, and recording will be taken at each alteration in sequence. Blood pressure will be taken upon completion of the total sequence"
62165742|NCT06121388||health control group|Health control women with similar age, BMI, working environment, education level and regular menstrual cycle in our hospital, and conduct endocrine examination for health examination.
62165743|NCT06121388||premature ovarian failure group|Patients are diagnosed with premature ovarian failure.
62165744|NCT02040532|EXPERIMENTAL|Open-label gabapentin|Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.
62165745|NCT03027999|EXPERIMENTAL|Patient with tight nursing follow-up|Compared as usual, Patient with tight nursing follow-up will be contacted
62165746|NCT03027999|NO_INTERVENTION|Patient without tight nursing follow-up|Compared as usual, Patient without tight nursing follow-up will not have interventions
62165747|NCT01726634|EXPERIMENTAL|Elastic Tapping|
62165748|NCT00358722|EXPERIMENTAL|Fermagate|
62165749|NCT01126177|PLACEBO_COMPARATOR|Placebo|Placebo once daily for 14 days
62165750|NCT01126177|EXPERIMENTAL|SNG001|
62165751|NCT02409888|EXPERIMENTAL|Intervention|Study participants receive either motivational enhancement therapy (MET) or cognitive behavioral therapy (CBT).
62165752|NCT02409888|EXPERIMENTAL|Assessment|IB Assessment study participants receive semi-annual assessments specific to their alcohol and other drug use and FC Assessment study participants receive quarterly assessments specific to diverse areas of functioning (e.g., alcohol and other drug use, social, occupational, legal, psychological/psychiatric, marital).
62165753|NCT02871453|EXPERIMENTAL|Acupuncture combined rehabilitation|"Scalp acupuncture treatment~Rehabilitation treatment"
62165754|NCT02871453|EXPERIMENTAL|Rehabilitation|Rehabilitation treatment
62165755|NCT02236299|PLACEBO_COMPARATOR|saline placebo infusion|30 minute infusion of a saline placebo Right coronary artery percutaneous coronary intervention
62165756|NCT02236299|EXPERIMENTAL|GLP-1 infusion|30 minute infusion of GLP-1 Right coronary artery percutaneous coronary intervention
62165757|NCT00417989|EXPERIMENTAL|722 sensor augmented pump|722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
62165758|NCT00417989|NO_INTERVENTION|Multiple Daily Injections (MDI)|MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year
62165759|NCT06538675||psychoanalytic-psychodynamic therapy|
62165760|NCT06538675||humanistic therapy|
62165761|NCT06538675||systemic therapy|
62165762|NCT06538675||cognitive-behavioral therapy|
62165763|NCT04088500|EXPERIMENTAL|Nivolumab + Ipilimumab (combination)|Nivolumab + Ipilimumab (combination) Q3W for 4 doses
62165764|NCT06240806|ACTIVE_COMPARATOR|Manuka honey interventional arm|Manuka honey used as mouth rinse in treatment of xerostomia
62165765|NCT06240806|PLACEBO_COMPARATOR|Saline mouthwash control group|Saline used as mouth rinse for xerostomia
62165766|NCT04969900|PLACEBO_COMPARATOR|Placebo - Jojoba Oil (100% organic golden expeller-pressed Simmondsia chinensis)|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
62719995|NCT03247634|EXPERIMENTAL|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
62719996|NCT03931187|EXPERIMENTAL|Women intervention arm|Intervention will be applied to the women within the couple.
62719997|NCT03931187|EXPERIMENTAL|Couple intervention arm|Intervention will be applied to the couple, both men and women.
62719998|NCT03931187|NO_INTERVENTION|Control arm|The couple will receive the normal nursing care.
62719999|NCT04855175|ACTIVE_COMPARATOR|Autograft group|The autologous group will receive bone harvested from the patient's own body
62547109|NCT06013098|EXPERIMENTAL|Experimental: 30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 minuets. After successful anesthesia induction, FiO2 will be adjusted to 60% in one lung ventilation and 30% FIO2 in both lungs ventilation, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cm H2O, RR: 1:2. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected for blood gas analysis. Patients in both groups will be extubation the operating room and then sent to the PACU. patients should transfer to 60% Oxygen group if intraoperative oxygen saturation less than 85%.
62547110|NCT06013098|PLACEBO_COMPARATOR|Experimental: 60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 minutes. After successful anesthesia induction, FiO2 will be adjusted to 100% in one lung ventilation and 60% FIO2 in both lungs ventilation, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cm H2O, RR: 1:2. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected for blood gas analysis. Patients in both groups will be extubation the operating room and then sent to the PACU.
62547111|NCT06435442|EXPERIMENTAL|Part 1|Epaminurad 9 mg, Naproxen 500 mg
62547112|NCT06435442|EXPERIMENTAL|Part 2(Test group)|Epaminurad 9 mg
62547113|NCT06435442|PLACEBO_COMPARATOR|Part 2(Control group)|Epaminurad 9 mg placebo
62547114|NCT01495702|EXPERIMENTAL|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
62547115|NCT01495702|ACTIVE_COMPARATOR|NNRTI+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of an NNRTI plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
62547116|NCT01476566|EXPERIMENTAL|Educational intervention|A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented.
62547117|NCT01476566|NO_INTERVENTION|Control group|
62547118|NCT01968564|EXPERIMENTAL|High-dose curcumin pill|
62547119|NCT01968564|EXPERIMENTAL|Low-dose curcumin pill|
62547120|NCT01968564|PLACEBO_COMPARATOR|Placebo pill|
62547121|NCT04550923|EXPERIMENTAL|Investigational device (non-rigid) group|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device.
62547122|NCT04550923|ACTIVE_COMPARATOR|Control device (rigid) group|Use rigid (PEEK) interbody fusion device .
62547123|NCT02369198|EXPERIMENTAL|Single arm, open label TargomiRs|"TargomiRs are IV injected.~Phase 1 Planned dose levels~Dose level 1: 5 billion once a week Dose level 2: 5 billion twice a week Dose level 3: 5 billion once a week with cardiac monitoring Dose level 4: 2.5 billion twice a week with cardiac monitoring Dose level 5: as for dose level #3 with a dexamethasone challenge~All patients begin on a micro dose of one billion and increase their dose over 2 weeks and reach their phase 1 dose level on week 3.~Schedule of assessments includes laboratory and physical assessments in the 24 hours after each treatment as well as periodic assessments such as PET and CT scans for tumour assessment.~100% of the data will be source data verified. Analysis will be simple phase 1 analysis based on a 3+3 model."
62547124|NCT01695642||Microkeratome|mechanical microkeratome
62547125|NCT01695642||Intralase|femtosecond laser
62547126|NCT03062163|EXPERIMENTAL|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
62547127|NCT03062163|EXPERIMENTAL|Placebo|normal saline was loaded on transdermal patch
62547128|NCT01609023||Rituximab|Participants with chronic lymphocytic leukemia treated with rituximab in combination with chemotherapy according to SPC and routine clinical practice will be observed for 24 months.
62547129|NCT04085055|ACTIVE_COMPARATOR|22 Gauge FNB Needle - ProCore|The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.
62720000|NCT04855175|ACTIVE_COMPARATOR|Allograft group (ClearFit)|The allograft group will receive a synthetic bone known as ClearFit
62547130|NCT04085055|ACTIVE_COMPARATOR|22 Gauge FNB Needle - Acquire|The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.
62547131|NCT04085055|ACTIVE_COMPARATOR|22 Gauge FNB Needle - SharkCore|The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.
62547132|NCT04085055|ACTIVE_COMPARATOR|22 Gauge FNB needle - EZ Shot 3 Plus|The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.
62547133|NCT04096040|EXPERIMENTAL|Device Data Engagement Assessment|This arm will assess the endpoints of investigator engagement with the device data.
62547134|NCT04317079|ACTIVE_COMPARATOR|15mg of hydroxytyrosol|15 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given three times daily before main meals (totally 6 capsules daily) in combination with diet
62547135|NCT04317079|ACTIVE_COMPARATOR|5mg of hydroxytyrosol|5 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given in the morning and at night before meals and 2 capsules of placebo before lunch (totally 6 capsules daily) in combination with diet
62547136|NCT04317079|PLACEBO_COMPARATOR|placebo|2 capsules of placebo given 3 times daily before meals (totally 6 capsules daily) in combination with diet
62547137|NCT06356857||re-pet participant|Participant are enrolled for a second pet-scan which will be compared with the initial scan.
62547138|NCT05019287|EXPERIMENTAL|Menstrual blood stem cell secretome group|Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment
62547139|NCT05019287|PLACEBO_COMPARATOR|Control group|Intravenous saline injection (Placebo)+Routine treatment
62720001|NCT02524249|ACTIVE_COMPARATOR|Early caffeine group|55 newborns will be randomized to receive caffeine within 24 hours of life. They will receive 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give PO caffeine if the newborn tolerates \>75% of fluid goals by feeds.
62738998|NCT01591954|EXPERIMENTAL|Video Augmentation|Qualitative assessment of the value of video-based navigation system
62547140|NCT03753191|EXPERIMENTAL|People with Dementia|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. A 2mA direct current for active tDCS (current density : .057 mA/cm2) with a 20 mins stimulation period
62547141|NCT03753191|SHAM_COMPARATOR|Health Control|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. After a fade in period of 10s to mimic initial tDCS peripheral skin sensations, the stimulator will be turned off in order to prevent the induction of any neuromodulatory effect.
62547142|NCT01423123|EXPERIMENTAL|Neratinib|Paclitaxel (80 mg/m2 IV on days 1, 8, and 15 every 28 days) and trastuzumab (4 mg/kg/ loading dose, then 2 mg/kg) IV weekly beginning on day 1 of paclitaxel, neratinib orally daily beginning on day 1 of paclitaxel until disease progression.
62547143|NCT05909280||Observational arm|Patients on VA-ECMO, eligible for weaning
62547144|NCT00537511|EXPERIMENTAL|Dose-finding arm: Pomalidomide + Cisplatin + Etoposide|Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m\^2 and IV etoposide 100 mg/m\^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
62547145|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
62547146|NCT03209310||Control Group|Children with typical development were included in this study
62547147|NCT00808314|ACTIVE_COMPARATOR|LL for CAD|Subjects with \<5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
62547148|NCT00808314|ACTIVE_COMPARATOR|CAD|Subjects with existing mild-moderate ishemia demonstrated by a recent (\< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
62547149|NCT01870440|EXPERIMENTAL|Ozurdex Injection|Ozurdex Intravitreal Injection (0.7 mg)
62547150|NCT03190811|EXPERIMENTAL|Anti-PD-1 plus DC-CIK|
62547151|NCT03190811|ACTIVE_COMPARATOR|Anti-PD-1 alone|
62547152|NCT02455895|ACTIVE_COMPARATOR|iLid Cleanser (Avenova)|iLid Cleanser - applied 2 times per day for 10 days
62547153|NCT02455895|PLACEBO_COMPARATOR|iLid Cleanser Vehicle|iLid Cleanser Vehicle - applied 2 times per day for 10 days
62547154|NCT06021691||Gestational diabetes offspring cohort|The Gestational diabetes(GDM) offspring cohort is to learn about language development assessment in 2-year-old children and causal association with their mother who diagnosed GDM
62547155|NCT06021691||Healthy maternal offspring cohort|Healthy maternal offspring cohort is to learn about language development assessment in 2-year-old children and causal association with their health mother
62547156|NCT03414684|EXPERIMENTAL|Carboplatin + Nivolumab|"* Nivolumab is administered every three weeks intravenously~* Nivolumab dosage is 360mg~* Carboplatin is administered every three weeks intravenously~* Carboplatin dosage is pre-determined by the PI"
62720002|NCT02524249|PLACEBO_COMPARATOR|Late caffeine group|55 newborns will be randomized to receive a placebo (dextrose) in the first 24 hours of life. They will receive a 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give the placebo orally is the newborn tolerates \>75% of fluid goals by feeds.
61978178|NCT00005972|EXPERIMENTAL|gemcitabine + irinotecan|Patients are stratified according to prior response duration (progression 90 days or more after initial therapy vs progression less than 90 days after initial therapy or no response to initial therapy). Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually for 3 years.
62165767|NCT04969900|ACTIVE_COMPARATOR|Investigational Product - A 10% dilute Lavandula angustifolia - jojoba oil essential oil blend|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
62165768|NCT02963922|EXPERIMENTAL|liraglutide 3.0 mg|
62165769|NCT02963922|PLACEBO_COMPARATOR|Placebo|
62165770|NCT04389944|EXPERIMENTAL|convalescent plasma treatment|"After confirmation of negative SARS-CoV-2 polymerase chain reaction (PCR) in two consecutive nasal swabs or 28 days after resolution of symptoms, donor check is performed and plasma donation occurs by apheresis. The plasma is photochemically pathogen reduced using the INTERCEPT Blood System.~In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up."
62165771|NCT06359821|EXPERIMENTAL|Single dose|ZA-001, single dose
62547157|NCT03414684|ACTIVE_COMPARATOR|Carboplatin|"* Carboplatin is administered every three weeks intravenously~* Carboplatin dosage is pre-determined by the PI"
62547158|NCT05178498||Observational (physical exam, questionnaire)|Patients complete physical measurements every 6 months and complete questionnaires annually for 5 years. Patients are followed up annually in years 5-10.
62547159|NCT05406921|EXPERIMENTAL|Intervention Arm: PLWD|150 community-residing PC patients with an ADRD diagnosis will be enrolled and receive MIND coordination services for 3 months to test program implementation feasibility in PC practice settings.
62547160|NCT05406921|NO_INTERVENTION|Data Validation Arm|An additional 100 PLWD will serve as a data validation arm to demonstrate the feasibility of collecting and validating data from large health systems.
62547161|NCT05406921|EXPERIMENTAL|Intervention Arm: PLWD CPs|150 Care Partners (CPs) of the 150 community-residing PC patients with an ADRD diagnosis will be enrolled and receive MIND coordination services for 3 months to test program implementation feasibility in PC practice settings.
62547162|NCT04663191||Full VATS|
62547163|NCT04663191||VATS with conversion|
62547164|NCT04663191||Thoracotomy upfront|
62547165|NCT03991676|EXPERIMENTAL|Values-Based Behavioral Treatment|
62547166|NCT04505254|EXPERIMENTAL|Treatment (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID every 12 hours starting on day 1 of cycle 1, and obinutuzumab IV over 4-6 hours on days 1 and 2 of cycle 3, and day 1 of cycles 4-8. Patients who do not achieve a complete response or remission after cycle 8 may receive single-agent acalabrutinib therapy PO BID for an additional 6 cycles at the discretion of their treating physician. Patients who are in partial response or who have stable disease receive an additional 6 cycles of acalabrutinib PO BID and obinutuzumab IV. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
62547167|NCT02377973||Growth and Development|Growth and Development og healthy young children born by Obese mothers
62547168|NCT02786888||conventional needle|conventional needle used
62547169|NCT02786888||fenestrated needle|fenestrated needle used
62547170|NCT06432855|OTHER|Non-febrile adults of Melanesian and European origin|Saliva samples and 20 mL blood samples from individuals of Melanesian and European origin from NC
62547171|NCT02228850|EXPERIMENTAL|Alprostadil Cream (300mcg)|300 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
62547172|NCT02228850|EXPERIMENTAL|Alprostadil Cream (1000mcg)|1000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
62547173|NCT02228850|EXPERIMENTAL|Alprostadil Cream (3000mcg)|3000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, two dispensers for each administration
62547174|NCT05368116|EXPERIMENTAL|Video Assisted Self Management Program|It is the systematically designed Video Assisted teaching program to educate cancer patients receiving chemotherapy under the experimental group about the management of chemotherapy related side effects at home .It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including Nausea, vomiting, Diarrhea, Constipation, Fever, Mucositis, Skin changes, and Alopecia related distress.
62547175|NCT05368116|ACTIVE_COMPARATOR|Standard of Care|The participants were given video when they come to oncology day care and instruct the participants to watch the video at home. Knowledge, self efficacy and severity of chemotherapy related side effects were assessed after one week.
62547176|NCT04068792|OTHER|Part 1-Observational Phase|Participants will not receive any intervention in the observation phase. All infants will be closely monitored for early signs and symptoms of Respiratory Syncytial Virus (RSV) disease using a mobile RSV application on the parent/caregiver's mobile phone, upon an alert, the RSV will be tested, if RSV negative participants (RSV \[-\] diagnosed at site) will return to the pre-diagnostic phase and RSV positive participants (RSV \[+\] diagnosed at site) can be enrolled in the interventional stage of the study after obtaining informed consent for the interventional stage at that time. RSV (+) participants whose parent(s)/caregiver(s) do not consent for enrollment in the interventional stage and participants who are screening failures in the interventional stage will enter the post-diagnostic phase of the observational stage (hospitalized or outpatients).
62547177|NCT04068792|EXPERIMENTAL|Part 2-Interventional Phase|Participants will be randomized to receive either JNJ-53718678 (for Age Group 1 (greater than or equal to \[\>=\] 28 days and less than \[\<\] 3 months): 2.5 milligram per kilogram \[mg/kg\]; for Age Group 2 (\>=3 and \<6 months): 3 mg/kg and for Age Group 3 (\>=6 months): 4.5 mg/kg) or placebo (Age Group 1, 2 and 3) twice daily for 7 days.
62547178|NCT05167097|EXPERIMENTAL|Deliberative Mindset|Participants receive a paper/pencil questionnaire that evokes a deliberative mindset. The questionnaire asks participants to deliberate upon the positive and negative short- and long-term consequences of acting vs. not acting toward a goal. This procedure is based on previous research on the mindset theory of action phases.
62547179|NCT05167097|EXPERIMENTAL|Implemental Mindset|Participants receive a paper/pencil questionnaire that evokes an implemental mindset. The questionnaire asks participants to plan the when, where, and how of taking five steps toward a goal. This procedure is based on previous research on the mindset theory of action phases.
62547180|NCT05167097|EXPERIMENTAL|Decisional Balance BI|Participants receive the ASSIST-linked Brief Intervention via an interview with a trained interventionist. The decisional balance element describes Steps 6-9 of the ten steps of the manual. They include probing for the positive and negative sides of alcohol consumption, weighing them against each other, focusing on the negative sides, and asking participants how concerned they are regarding the negative sides.
62547181|NCT05167097|EXPERIMENTAL|No Decisional Balance BI|Participants receive the ASSIST-linked Brief Intervention via an interview with a trained interventionist. This is the short-form of the ASSIST-linked Brief Intervention. It drops the decisional balance element that is described above.
62547182|NCT05167097|OTHER|Control Group|Participants perform a filler task in the control group, crossing out a specific letter in paragraphs of nonsense text.
62547183|NCT05644925|EXPERIMENTAL|PICSO+PCI|
62547184|NCT05644925|ACTIVE_COMPARATOR|Standard PCI|
62547185|NCT04770675||Treatment group|Any subject who is scheduled to undergo bronchoscopy as per routine clinical practice
62547186|NCT02716545|EXPERIMENTAL|Endoscopic Intervention Group|Endoscopic therapy
62547187|NCT03335514||STEMI|The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
62738999|NCT05170958|EXPERIMENTAL|LBL-024|LBL-024 injection; Initial dose - MTD; Q3W
62547188|NCT03335514||NSTE-ACS|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
62547189|NCT03335514||SAP|The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
62547190|NCT03335514||CONTROL|20 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
62547191|NCT02291575|EXPERIMENTAL|Training|Of the 304 participants in the study, half will be randomized into the treatment arm in which they will receive training from the Liver Foundation.The objective of the Liver Foundation's training program will be capacity building through information in health sciences, training in referral techniques during emergencies, and maternal and child health care priorities in rural areas. The training will be in the form of two three-hour classes per week and will continue for nine months, with three mid-term exams administered every three. During this time, the evaluation team will only collect the rosters of the attendees of the training classes and conduct sporadic random visits to the sessions to gain a better sense of the training methods and attendance rates.
62547192|NCT02291575|ACTIVE_COMPARATOR|Control|Half of the sample will be randomized into the control group, for whom there will be no training. They will be phased into training the following year. For the current year, the control group will experience no difference in their routine, aside from some (infrequent) opportunities to participate in other public health activities as provided by the Liver Foundation to any provider involved in their various programs.
62547193|NCT00588588|ACTIVE_COMPARATOR|1|Bronchoscopy
62547194|NCT00588588|ACTIVE_COMPARATOR|2|CPIS
62547195|NCT02460679|EXPERIMENTAL|EPI-589|Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
62547196|NCT02304497||DM-CTRL|Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained
62547197|NCT02304497||DM-CP|Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained
62547198|NCT02304497||CP|Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained
62547199|NCT02304497||CTRL|Periodontally and systemically healthy subject Platelet Rich Fibrin obtained
62547200|NCT03327948|EXPERIMENTAL|Treatment group|Urinary Urgency Incontinence
62547201|NCT01516918|EXPERIMENTAL|Quadruple Regimen|All subjects will receive active study drugs (quadruple regimen: VX-222, telaprevir,Peg-IFN, and RBV) for a fixed treatment duration of 24 weeks.
62547202|NCT04684472|EXPERIMENTAL|Modified anti-CD19 CAR T cell therapy|CAR T cell therapy
62547203|NCT05712798||The children with primary ciliary dyskinesia|The children with primary ciliary dyskinesia
62547204|NCT05712798||Healthy controls|Healthy children
62547205|NCT00643812|EXPERIMENTAL|1|"The Early intervention arm received a gun locker at baseline"
62547206|NCT00643812|ACTIVE_COMPARATOR|2|Households in this arm received a gun locker at 12 months following the baseline survey
62547207|NCT03302676|ACTIVE_COMPARATOR|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.~Daily registrations in a patient dairy."
62720003|NCT03674983|EXPERIMENTAL|CEI Group|CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
62720004|NCT03674983|NO_INTERVENTION|SOC Group|SOC Group will receive the standard of care only (information, prescription, free PrEP.)
62547208|NCT03302676|NO_INTERVENTION|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
62547209|NCT01869985|EXPERIMENTAL|HCP1104|HCP1104
62547210|NCT01869985|ACTIVE_COMPARATOR|Mulex Tab. and Airtal Tab.|Eperisone Hydrochloride and Aceclofenac
62547211|NCT06421298|EXPERIMENTAL|Tafolecimab and Sintilimab Combined With Chemotherapy|tafolecimab sintilimab nab-paclitaxel docetaxel gemcitabine
62547212|NCT06287138|EXPERIMENTAL|Experimental arm|Before the trial drug administration, included patients will receive a continuous infusion of remifentanil for analgesia, starting at 0.01 μg/kg/min and adjusting infusion rate to target a Critical-care Pain Observation Tool (CPOT) score of 0-1. The experimental drug was not to be administered until it was confirmed that the patient's baseline sedation level had reached a RASS score of ≥ -2. For sedation, the ciprofol was started at the rate of 0.3 mg/kg/h and maintained for 30 minutes. Then, the initial infusion rate was increased to 0.4, 0.5, 0.6, 0.7, and up to 0.8 mg/kg/h every 30 minutes. The infusion of ciprofol would be stopped if the RASS score ≤ -4, respiratory rate \< 8 breaths/min, or Saturation of pulse oxygen (SpO2) \< 90% before the maximal dose of 0.8 mg/kg/h was achieved.
62720005|NCT01642446|EXPERIMENTAL|surgery|Precise hepatectomy
62720006|NCT01642446|ACTIVE_COMPARATOR|combined intervention|transcatheter hepatic arterial chemoembolization and/or ablation
62720007|NCT06348303|ACTIVE_COMPARATOR|Active 640 mg|Metaxalone (M640) 640 mg tablet, a single-dose at visit 2 of 4 visits.
62720008|NCT06348303|ACTIVE_COMPARATOR|Active 800 mg|Metaxalone 800 mg tablet, a single-dose at Visit 3 of 4 visits.
62720009|NCT04402307|NO_INTERVENTION|Usual care|Usual care to patients with dysphagia
62720010|NCT04402307|EXPERIMENTAL|Training|Chin Tuck Against Resistance to patients with dysphagia
62720011|NCT05457062||large amount of bleeding|large amount of upper GI bleeding after EGD identified
62720012|NCT05457062||no bleeding|no upper GI bleeding after EGD identified
61978179|NCT03833973||Runners|Long-distance runners, marathon runners, 5 km and 10 km runners, both female and male aged 20 - 40 years, participating in regular training and competitions.
62720013|NCT05457062||small amount of bleeding|small amount of upper GI bleeding after EGD identified
62720014|NCT05510518||BMI >30 kg/m2|Singleton pregnant women with normal OGTT at 24-28 weeks of gestation and BMI \>30 kg/m2
62720015|NCT05510518||BMI >35 kg/m2|Singleton pregnant women with normal OGTT at 24-28 weeks of gestation and BMI \>35 kg/m2
62547213|NCT02292095|EXPERIMENTAL|TAPB group|Participants in this group will receive transverse abdominis plane block combined with patient controlled intravenous analgesia.Transverse abdominis plane block will be guided by ultrasound and 0.75% 20 ml ropivacaine will be injected with the sonographic view at the end of the surgery.Participants in this group will also receive patient controlled intravenous analgesia after surgery,the regimens of patient controlled intravenous analgesia are included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total
62547214|NCT02292095|ACTIVE_COMPARATOR|PCIA group|Participants in this group will only receive patient controlled intravenous analgesia after surgery.The formula of the PCIA included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
62547215|NCT06194461||AZD5851|Follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884
62547216|NCT06194461||AZD0754|Follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729
62547217|NCT04420273|EXPERIMENTAL|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
62547218|NCT04420273|ACTIVE_COMPARATOR|Active control: Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
62547219|NCT01366625|EXPERIMENTAL|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
62547220|NCT01366625|NO_INTERVENTION|Maintenance of Medications|Maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
62547221|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score \> 14 on the Insomnia Severity Index, report insomnia for \> 3 months, have sleep difficulties \> 3 nights per week, score \< 3 on the Epworth Sleepiness Scale (ESS), score \> 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
62547222|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score \< 10 on the ESS, score \< 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
62547223|NCT05016609|EXPERIMENTAL|POC HCV antibody group (Arm A)|This group will receive POC HCV antibody testing via fingerprick using the OraQuick HCV antibody test (OraSure) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
62547224|NCT05016609|EXPERIMENTAL|POC HCV RNA group (Arm B)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will receive POC HCV viral load testing via fingerstick using the Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
62547225|NCT05016609|EXPERIMENTAL|Test and treat group (ArmC)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will be provided a starter pack of HCV treatment (epclusa). POC tests results will be confirmed through standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. HCV RNA positive participants will continue treatment. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
62547226|NCT05016609|NO_INTERVENTION|Control|This group will receive the standard of care for HCV testing and treatment. Participants in this group will fill out a short behavioural questionnaire and a clinical questionnaire.
62547227|NCT05594901||Retrospective Cohort|
62547228|NCT05594901||Prospective Cohort|
62547229|NCT01473407|EXPERIMENTAL|Epoetin Hospira|Epoetin Hospira
62547230|NCT01473407|ACTIVE_COMPARATOR|Epogen (Amgen)|Epogen (Amgen)
62547231|NCT02665104||patients without neurological symptoms|carotid endarterectomy patients who dont'have any neurological symptoms after carotid clamping
62547232|NCT02665104||patients with neurological symptoms|carotid endarterectomy patients who have new neurological symptoms after carotid clamping
62547233|NCT02354625|EXPERIMENTAL|ahSC transplantation|Autologous human Schwann cells
62720016|NCT06185426|PLACEBO_COMPARATOR|Healthy Control Group (HCG)|Seven rats will be included randomly in this group. No surgical/medical approach will be applied.
62547234|NCT05574361|EXPERIMENTAL|Hypothermic Machine Perfusion|Hypothermic Machine Perfusion with Organ Recovery Systems LifePort Liver Transporter system
62720017|NCT06185426|ACTIVE_COMPARATOR|Damaged Control Group (DCG):|Facial nerve injury will be created on the right facial nerve. No surgical/medical approach will be applied.
62720018|NCT06185426|EXPERIMENTAL|Laser Group (LG)|Facial nerve injury will be created on the right facial nerve. LLLT (Low-Intensity et al.) willl be applied 3 times a week for 4 weeks postoperatively, at 830 nm with an optical power output of 30 mW, an energy density of 4 J/cm2, an irradiation area of 0.116 cm2 and an exposure time of 16 s per spot.
62720019|NCT06185426|EXPERIMENTAL|Steroid group (SG)|Facial nerve injury will be created on the right facial nerve. Intraperitoneal methylprednisolone (1mg/kg/day) will be administered every day for 1 week postoperatively.
62720020|NCT06185426|EXPERIMENTAL|Laser+Steroid Group (LSG):|Facial nerve injury will be created on the right facial nerve. Laser and steroid treatment will be applied in combination.
62720021|NCT01870869|EXPERIMENTAL|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
62720022|NCT01870869|EXPERIMENTAL|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
62720023|NCT01870869|EXPERIMENTAL|Revision-Augmentation|Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
62720024|NCT01870869|EXPERIMENTAL|Revision-Reconstruction|Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
62720025|NCT05922995|EXPERIMENTAL|Treatment Phase|Tasimelteon will be administered in 20 mg capsules on a nightly basis for 4 weeks during the treatment phase.
62547235|NCT05375253|EXPERIMENTAL|Donor Enriched Activated NK Infusion (DEA-NK)|Infusion of DEA-NK on day +7 post-transplant
62547236|NCT03833778|OTHER|Intervention group|Answering disease related questions during playing a tablet game
62547237|NCT03833778|NO_INTERVENTION|control group|
62547238|NCT00397514||Congenital Heart Surgery Patients|Pacing protocol prior to patient's extubation with 20 min. of either conventional right ventricular (RV) or biventricular (BiV) pacing, preceded and followed by 10 min. of recovery time.
62547239|NCT03062384|EXPERIMENTAL|AT-001|Yeast-selenium supplement
62547240|NCT03062384|PLACEBO_COMPARATOR|Placebo|Yeast supplement devoid of selenium
62547241|NCT06210022||130|"Patients with diagnosis of DRE and DSE will be recruited among patients who are regularly followed at our Epilepsy Outpatients Service (OSR). The diagnosis of DRE and DSE focal cryptogenic epilepsy will be based on the most recent sets of criteria of different types of epilepsy. A small group of NDE patients will be also enrolled~A population of 30 focal cryptogenic epilepsy patients diagnosed with DRE (drug resistant epilepsy) A population of 90 focal cryptogenic epilepsy patients diagnosed with DRE (drug sensitive epilepsy) 10 patients newly diagnosed for focal cryptogenic epilepsy (NDE) will be recruited too."
62547242|NCT01450683|EXPERIMENTAL|Itraconazole|600 mg/day oral (PO)
62547243|NCT06212544|EXPERIMENTAL|Immediate Intervention|The intervention condition builds on our community partners' existing microeconomic intervention of: (1) a one-time emergency cash grant and (2) peer and legal support to obtain legal gender affirmation - plus a 12-week microeconomic intervention that adds: (3) weekly educational sessions and HIV prevention; (4) community mentoring; and (5) weekly posts of job openings in Detroit; and (6) a micro-grant for use towards acquiring self-led or formal employment
62547244|NCT06212544|ACTIVE_COMPARATOR|Delayed Arm|Participants randomized to the control condition will receive UC during the 12-week period following randomization. Usual care consists of emergency assistance and access to legal name/gender marker change. After the RCT follow-up period is complete, waitlist control participants will be offered delayed access to the same intervention that is provided immediately to intervention arm participants.
62547245|NCT02447146|EXPERIMENTAL|Training group|9-week resistance training program
62547246|NCT02447146|OTHER|Control group|'Lectures on the disease'
62547247|NCT02909244||Patients with PID|Biological sampling: collection of feces. In case of blood samples availability in hospital biobank : analyzes of these samples in the frame of this research
62720026|NCT02590289|EXPERIMENTAL|BBI-5000 Dose 1|Low dose of BBI-5000
62547248|NCT02909244||Control patients, with no PID|Biological sampling: collection of feces.
62547249|NCT03252561|EXPERIMENTAL|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
62547250|NCT03252561|ACTIVE_COMPARATOR|Local anaesthetic infiltration|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
62547251|NCT01952314|PLACEBO_COMPARATOR|Control groups with only analgesics|Control groups will receive only analgesics.
62547252|NCT01952314|ACTIVE_COMPARATOR|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
62547253|NCT06482073||Observational|Patients receive genomic counseling and genomic testing education, undergo blood or saliva collection, provide previously collected tissue sample and have medical records reviewed on study. Patients and healthcare providers receive results of any genetic variants found on testing.
62547254|NCT05623683|ACTIVE_COMPARATOR|Intermittent Walking|Intermittent walking on the treadmill
62547255|NCT05623683|ACTIVE_COMPARATOR|Continuous Walking|Continuous walking on the treadmill
62547256|NCT01285297|EXPERIMENTAL|TMR plus BMAC injection|Injection of bone marrow aspirate concentrate into reversibly ischemic myocardium with transmyocardial revascularization during the same open procedure.
62547257|NCT06456866||ChatGPT|
62720027|NCT02590289|EXPERIMENTAL|BBI-5000 Dose 2|Middle dose of BBI-5000
62720028|NCT02590289|EXPERIMENTAL|BBI-5000 Dose 3|High dose of BBI-5000
62720029|NCT02590289|EXPERIMENTAL|BBI-5000 Dose 4|High dose of BBI-5000
62720030|NCT03698279|EXPERIMENTAL|Group 1: QIV-HD 30 μg (US: 6 months to 17 years)|Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62547258|NCT06456866||Anesthesiology expert|
62547259|NCT03105492||Pregnant women|Women who are pregnant
62547260|NCT00328848|EXPERIMENTAL|Intervention care management|post dischsrge care management by a nurse care manager who performs in-home vistis and reports to a interdisciplinary team. Team generates care recommendations based on patient goals. PCP and care manager implement the care plan that is based on patient goals. Includes education, behavioral interventions, and coaching.
62547261|NCT04775303|EXPERIMENTAL|experimental group|Cyclosporine 0.1% (Ikervis®) eye drop - one drop once daily
62547262|NCT03593538|EXPERIMENTAL|Low Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 500 mg and 1 Placebo capsule per day; Days 15-23: Metformin 500 mg and 2 Placebo capsules per day
62547263|NCT03593538|EXPERIMENTAL|High Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 1000 mg per day; Days 15-23: Metformin 1500 mg per day
62547264|NCT03593538|PLACEBO_COMPARATOR|Placebo|Days 1-7: 1 Placebo capsule per day; Days 8-14: 2 Placebo capsules per day; Days 15-23: 3 Placebo capsules per day
62547265|NCT02371473|EXPERIMENTAL|#1 (Acetazolamide-placebo)|The arm #1 consists of 6 eligible patients who receive Acetazolamide 250mg once daily an hour before sleep for first six nights and after two weeks washout they receive placebo for six nights in the same order. After each six-day period they undergo polysomnography.
62547266|NCT02371473|EXPERIMENTAL|#2 (Placebo-acetazolamide)|The arm #2 consists of 6 eligible patients who receive placebo once daily an hour before sleep for first six nights and after two weeks washout they receive acetazolamide 250mg for six nights in the same order. After each six-day period they undergo polysomnography.
62547267|NCT06143852|NO_INTERVENTION|Control|Participants will not receive an intervention. They will receive instructions to use their social media use as usual.
62739000|NCT04114708|OTHER|ACLR|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
62720031|NCT03698279|EXPERIMENTAL|Group 2: QIV-HD 45 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62165772|NCT03332589|EXPERIMENTAL|Monotherapy Safety Run-in: E6201|"E6201 320 mg/m\^2 administered IV over 2 hours twice weekly on Days 1, 4, 8, 11, 15 and 18, repeated every 28 days (=1 cycle).~Dose reductions for toxicity are 240 mg/m\^2 (Dose Level -1) and 160 mg/m\^2 (Dose Level -2) twice weekly."
62165773|NCT03332589|EXPERIMENTAL|Combination Safety Run-in: E6201 Plus Dabrafenib|Dose Level 1: E6201 320 mg/m\^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -1: E6201 240 mg/m\^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -2: E6201 240 mg/m\^2 twice weekly plus dabrafenib 100 mg BID. Dose Level -3: E6201 160 mg/m\^2 twice weekly plus dabrafenib 100 mg BID Dose Level -4: E6201 160 mg/m\^2 twice weekly plus dabrafenib 75 mg BID. Dose Level -5: E6201 160 mg/m\^2 twice weekly plus dabrafenib 50 mg BID.
62165774|NCT03332589|EXPERIMENTAL|Expansion: E6201 Plus Dabrafenib|A total of up to N=18 will be treated at the E6201 plus dabrafenib combined MTD.
62165775|NCT01432678||asthma patients|controlled asthma partly controlled asthma uncontrolled asthma
62165776|NCT06584864|EXPERIMENTAL|Utrasound group|Bedside ultrasound examination of the lumbar spinal canal before lumbar puncture
62165777|NCT06584864|NO_INTERVENTION|Standard group|Standard procedure group
62165778|NCT06503016|EXPERIMENTAL|Phosphocreatine|"Patients randomized to the phosphocreatine group will receive the drug for a maximum of 3 days.~* Patients without renal failure: At the time of randomization (day 0), 4 grams of phosphocreatine will be administered, followed by an additional 4 grams on the same day, with a minimum interval of 20 minutes and a maximum of 4 hours. On day 1 and day 2, after 8 AM, 2 grams of phosphocreatine will be administered twice a day, with a 6-hour interval between doses.~* Patients with history of renal failure: On day 0, patients will receive a single dose of 4 grams of phosphocreatine. On day 1 and day 2, after 8 AM, 2 grams of phosphocreatine will be administered twice a day, with a 6-hour interval between doses.~* Patients with acute kidney injury, without chronic kidney disease: Single dose of 4 grams of phosphocreatine on day 0. No further doses of the drug are planned."
62165779|NCT06503016|PLACEBO_COMPARATOR|Placebo|"Patients randomized to the placebo group will receive saline solution for a maximum of 3 days.~* Patients without renal failure: 200 ml of saline solution twice a day from day 0 to day 2. On day 0, the second bolus should be administered between 20 minutes and 4 hours after the first bolus; on day 1 and day 2, the saline solution should be administered after 8 AM, with the second bolus given 6 hours later.~* Patients with history of renal failure: On day 0, a single infusion of 200 mL of saline solution will be administered. On day 1 and day 2, 200 mL of saline solution will be administered twice a day, after 8 AM, with a 6-hour interval between doses.~* Patients with acute kidney injury, without chronic kidney disease: A single infusion of 200 mL of saline solution on day 0. No further administrations are planned."
62165780|NCT05903118|EXPERIMENTAL|Participants aged 18 to 59 years.|Escalating dose levels
62165781|NCT05903118|EXPERIMENTAL|Participants aged 60 years and older.|Escalating dose levels
62165782|NCT05903118|PLACEBO_COMPARATOR|Placebo|
62165783|NCT03779334|EXPERIMENTAL|Open-label Risdiplam|Participants will be enrolled to receive risdiplam orally once daily at a dose selected to achieve the targeted exposure range.
62165784|NCT03910491|EXPERIMENTAL|Intervention|All participants who enroll in the study will be assigned to a PriCARE group program that will adhere to the approximately 9 hour PriCARE curriculum.The trainings are administered to groups of approximately 4-12 caregivers at a time and are led by 2 mental health providers trained in the PriCARE curriculum. The curriculum will be delivered in 2-6 sessions over a 2-20 week period.
62165785|NCT02626689||β-thalassemia transfusion dependent subjects|Participants will complete 3 quality of life instruments (i.e. FACT-AN, the SF-36v2, and the TranQol) once every 3 weeks, in addition to a TranQol instrument on the day of a RBC transfusion. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
62165786|NCT02626689||β-thalassemia Non Transfusion Dependent (NTD) subjects|Participants will complete 2 quality of life instruments (i.e. FACT-An and the the SF-36v2l) once every 3 weeks, in addition to completing the non-transfusion dependent Patient Recorded Outcome (PRO) tool on a daily basis. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
62165787|NCT00360971|EXPERIMENTAL|Palifermin|Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients.
62165788|NCT00360971|PLACEBO_COMPARATOR|Placebo|Concurrent radiation therapy, cisplatin, and placebo followed by neck dissection for indicated patients.
62165789|NCT03962270|EXPERIMENTAL|Treatment group|
62165790|NCT03962270|SHAM_COMPARATOR|Control group|
62165791|NCT00556296|EXPERIMENTAL|1|
62165792|NCT00556296|EXPERIMENTAL|2|
62165793|NCT00556296|EXPERIMENTAL|3|
62165794|NCT00556296|PLACEBO_COMPARATOR|4|
62165795|NCT04653571||CASPR2 encephalitis|Cohort of patients with a CASPR2 antibody-associated auto-immune encephalitis.
62165796|NCT03915535|ACTIVE_COMPARATOR|MaxSimil|Subjects of group A will receive a constant daily dose of 4.3g of MaxSimil, a combination of EPA + DHA in proportions of 500/200, for a period of 90 days.
62165797|NCT03915535|EXPERIMENTAL|MAG-EPA|Subjects of group B will receive a constant daily dose of 4.4g of MAG-EPA, a purified formulation of EPA with traces of DHA (730/050), for a period of 90 days.
62720032|NCT03698279|EXPERIMENTAL|Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62165798|NCT01642030|OTHER|Methadone Maintenance|
62165799|NCT01642030|OTHER|Buprenorphine Maintenance|
62165800|NCT03296488|EXPERIMENTAL|Nalbuphine Sebacate|receive single dose of NALDEBAIN (150 mg Nalbuphine Sebacate, 75 mg/ml, 2 ml/vial) intramuscularly 24±12 hours before surgery.
62165801|NCT03296488|ACTIVE_COMPARATOR|Fentanyl Citrate|receive intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
62165802|NCT05733013||Participants with refractory thyroid cancer patients|
62165803|NCT01165944|NO_INTERVENTION|Standard diabetes therapy|Standard diabetes therapy with either oral agents or insulin injections
62547268|NCT06143852|EXPERIMENTAL|Mindfulness|"Approximately 12-minute mindfulness-style meditations will be completed daily for one week through the Calm platform. Participants can listen to the exercise on the web-enabled version of Calm, or through the smartphone app. The course is entitled 7 Days of Gratitude and centers around noticing and appreciating things in daily life."
62547269|NCT06143852|EXPERIMENTAL|Social Media Reduction + Exercise|Participants will reduce their social media use by at least 30 minutes daily for one week. Simultaneously, participants will exercise at least 30 minutes daily. Participants are given examples of common exercises (walking, yoga, strength training, etc.), but they are allowed to choose any type, although they are dissuaded from activities with high potential for injury.
62547270|NCT04294628|EXPERIMENTAL|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA, CT or MRI, biopsies, and collection of blood samples throughout the study.
62547271|NCT02009592|ACTIVE_COMPARATOR|Hepatosteatosis|Rifaximin was given to patients with hepatosteatosis in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
62547272|NCT02009592|ACTIVE_COMPARATOR|Steatohepatitis|Rifaximin was given to patients with steatohepatitis patients in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
62547273|NCT02743429|EXPERIMENTAL|Long term infusion of ch14.18/CHO|10 day continuous Infusion of ch14.18/CHO.
62547274|NCT01770717||Pressure Ulcer Formation|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
62547275|NCT03008317|ACTIVE_COMPARATOR|non metallic|PEEK denture base,
62547276|NCT03008317|PLACEBO_COMPARATOR|metallic denture base|cobalt chromium alloy denture base
62547277|NCT03639818|EXPERIMENTAL|experimental group|HIV patients
62547278|NCT04660279|OTHER|Validate|D-WB PET/CT scans + arterial blood sampling.
62547279|NCT00311597|EXPERIMENTAL|Single fractionated radiation adjusted for tumor size|Single fractionated radiation adjusted for volume of tumor tissue encompassed by desired isodose line
62547280|NCT05752825||Acromegalic patients|Subjects with acromegaly
62547281|NCT05752825||Healthy controls|Subjects without acromegaly
62547282|NCT02443597||obese pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~* Fetal nuchal translucency thickness.~* Nasal bone.~* Fetal facio-maxillary angle.~* The flow across the tricuspid valve as normal or regurgitated.~* A-wave in the ductus venosus as normal or reversed."
62547283|NCT02443597||lean pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~* Fetal nuchal translucency thickness.~* Nasal bone.~* Fetal facio-maxillary angle.~* The flow across the tricuspid valve as normal or regurgitated.~* A-wave in the ductus venosus as normal or reversed."
62547284|NCT02248883|EXPERIMENTAL|low TPV/RTV|
62547285|NCT02248883|EXPERIMENTAL|high TPV/RTV|
62547286|NCT02248883|EXPERIMENTAL|Placebo/RTV|
62547287|NCT05671536|EXPERIMENTAL|Motivational interview|Patients on intervention group will receive 4 sessions of motivational interview at least 20 minutes and once a month. Resilience of patients will be evaluated at the beginnig of the study and five months after the beginning of the study.
62547288|NCT05671536|NO_INTERVENTION|Control|Patients on control group will receive standard care. Resilience of patients will be evaluated at the beginnig of the study and five months after the beginning of the study.
62547289|NCT00450801|EXPERIMENTAL|R-MACLO-IVAM-T|Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.
62547290|NCT03778073|EXPERIMENTAL|Cohort A|Cosibelimab (TG-1501) single-agent
62547291|NCT03778073|EXPERIMENTAL|Cohort B|Cosibelimab + Ublituximab + Bendamustine combination
62547292|NCT03778073|EXPERIMENTAL|Cohort C|Cosibelimab + Ublituximab + Bendamustine combination
62547293|NCT02910011|EXPERIMENTAL|Topical Administration of Study Drug|2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
62547294|NCT03958292|EXPERIMENTAL|Patients undergoing routine cataract surgery|"Two eye drops containing PVP-Iodine instillation in the eye undergoing cataract surgery three times for three days before surgery.~Each patient was evaluated for conjunctival flora variation by means of two conjunctival swabs before starting the treatment and at the end of the treatment before the surgery."
62547295|NCT05344131|EXPERIMENTAL|The quantitative part of the study (BETY exercise group)|"intervention group Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model.~Exercise dosage is 60 minute three days a week."
62547296|NCT05344131|NO_INTERVENTION|The quantitative part of the study (Control group)|Control group No intervention
62547297|NCT05344131|EXPERIMENTAL|The qualitative part of the study|"Regularly participated in the BETY program for at least one year Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model.~Exercise dosage is 60 minute three days a week."
62720033|NCT03698279|ACTIVE_COMPARATOR|Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)|Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62165804|NCT01165944|ACTIVE_COMPARATOR|Oral diabetic agents and pramlintide|
62547298|NCT01134432|EXPERIMENTAL|Prednisolone + Rituximab|
62547299|NCT01134432|ACTIVE_COMPARATOR|Prednisolone|
62547300|NCT02757326|EXPERIMENTAL|Phase Ib/II|"For Phase Ib, the planned ABC294640 (Opaganib) doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
62720034|NCT03698279|EXPERIMENTAL|Group 5: QIV-HD, 60 μg (Canada: 6 to <24 months)|Participants from Canada (aged 6 to less than \[\<\] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62720035|NCT03698279|ACTIVE_COMPARATOR|Group 6: Adjuvanted TIV (Canada: 6 to <24 months)|Participants from Canada (aged 6 to \<24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
62165805|NCT01165944|ACTIVE_COMPARATOR|Insulin injection with pramlintide|
62165806|NCT02273856||Treatment naïve patients with CLL|
62165807|NCT02273856||Treatment naïve patients with iNHL|
62165808|NCT02273856||Relapsed/refractory patients with CLL|
62165809|NCT02273856||Relapsed/refractory patients with iNHL|
62165810|NCT03999697|EXPERIMENTAL|CAR-CD22 Cell immunotherapy|Enrolled patients will receive CAR-CD22 cell immunotherapy with a novel specific chimeric antigen receptor targeting CD22 antigen by infusion.
62165811|NCT03278808|EXPERIMENTAL|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
62165812|NCT03278808|ACTIVE_COMPARATOR|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
62165813|NCT03278808|OTHER|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
62165814|NCT03518047|PLACEBO_COMPARATOR|Placebo|Placebo for risankizumab by subcutaneous (SC) injection.
62165815|NCT03518047|EXPERIMENTAL|Risankizumab|Risankizumab by subcutaneous (SC) injection.
62165816|NCT05073835|EXPERIMENTAL|Intervention|Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.
62165817|NCT05073835|PLACEBO_COMPARATOR|Control|Placebo administration, once weekly, subcutaneous injection.
62165818|NCT03656445|ACTIVE_COMPARATOR|Group A - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
62165819|NCT03656445|ACTIVE_COMPARATOR|Group B - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
62165820|NCT03656445|ACTIVE_COMPARATOR|Group C - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively
62165821|NCT05534269|EXPERIMENTAL|Low dose|Already human tested low dose from phase I study
62165822|NCT05534269|EXPERIMENTAL|High dose|First in human dose used for efficacy reasons during phase II
62165823|NCT05105425|ACTIVE_COMPARATOR|NUTRIOSE®|1 sachet to be taken at breakfast during 4 weeks
62165824|NCT05105425|PLACEBO_COMPARATOR|GLUCIDEX® IT21|1 sachet to be taken at breakfast during 4 weeks
62165825|NCT01177228|PLACEBO_COMPARATOR|Placebo|Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
62165826|NCT01177228|EXPERIMENTAL|Vedolizumab 2 mg/kg|Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
62165827|NCT01177228|EXPERIMENTAL|Vedolizumab 6 mg/kg|Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
62165828|NCT01177228|EXPERIMENTAL|Vedolizumab 10 mg/kg|Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.
62165829|NCT02637947|EXPERIMENTAL|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
62165830|NCT02637947|ACTIVE_COMPARATOR|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
62165831|NCT05733793||Cohort A (Retrospective):|"Cohort A (Retrospective):~• All consecutive patients diagnosed with gynecological malignancies who have performed an NGS analysis on tumor sample as for clinical practice or as part of a clinical study from the January 1st 2015 until the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients) will be enrolled."
62165832|NCT05733793||Cohort B (Prospective):|• All consecutive patients diagnosed with a gynecological malignancy who perform an NGS analysis on tumor sample as for clinical practice or as part of a clinical practice from the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients) until 1st January 2025.
62165833|NCT02674555|EXPERIMENTAL|ASP8273|Two Parts - Part A: 14C-radio labeled; Part B: non radio labeled (optional)
62165834|NCT04397432||Elemene plus TKIs|This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
62165835|NCT04397432||TKIs only|This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
62165836|NCT02053402|PLACEBO_COMPARATOR|Placebo|Placebo to be given daily for six months
62165837|NCT02053402|ACTIVE_COMPARATOR|Vitamin D|1200 IU of vitamin D, daily for six months
62165838|NCT04223661|EXPERIMENTAL|Frailty score 1|"Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
62165839|NCT04223661|EXPERIMENTAL|Frailty Score 2 or above|"Starting dose of lenalidomide in frail subjects (frailty score of 2 or higher) will be 5 mg day 1-21 of 28 day cycle, and escalate to 10 mg.~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
62165840|NCT06585176||Gastroesophageal Reflux Disease|Gastroesophageal reflux disease (GERD) is a gastrointestinal motility disorder that results from the reflux of stomach contents into the esophagus or oral cavity resulting in symptoms or complications.
62165841|NCT06223568|EXPERIMENTAL|Arm 1|DC (docetaxel + cisplatin)
62165842|NCT06223568|EXPERIMENTAL|Arm 2|DCP (docetaxel + cisplatin + PRGN-2009)
62547301|NCT01916174|EXPERIMENTAL|Insulin degludec/liraglutide, B5|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
62547302|NCT01916174|EXPERIMENTAL|Insulin degludec/liraglutide, V2|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
62547303|NCT01198132|EXPERIMENTAL|Cholecalciferol|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 3 times a week.
62547304|NCT01198132|PLACEBO_COMPARATOR|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks along with subcutaneous injection of Rebif 3 times weekly.
62547305|NCT02446756|EXPERIMENTAL|acupuncture group|Acupuncture treatment was given once every other day and 20min each time for four weeks.
62547306|NCT02446756|ACTIVE_COMPARATOR|physiotherapy group|Physiotherapy treatment was given five times a week and 30min each time for four weeks.
62547307|NCT00511823|EXPERIMENTAL|Subjects in Part A|Subjects will receive 100 milligrams (mg) of oral dolasetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 100 mg oral dolasetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant on day 1 and 50 mg oral casopitant on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
62165843|NCT00735228|ACTIVE_COMPARATOR|1|Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
62165844|NCT00735228|ACTIVE_COMPARATOR|2|Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
62547308|NCT00511823|EXPERIMENTAL|Subjects in Part B|Subjects will receive 2 mg of oral granisetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 2 mg oral granisetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
62547309|NCT00511823|EXPERIMENTAL|Subjects in Part C|Subjects will receive 4 mg of oral rosiglitazone once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 4 mg oral rosiglitazone once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
62547310|NCT04936165|EXPERIMENTAL|Healthy experimental participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min intervention, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
62547311|NCT04936165|NO_INTERVENTION|Healthy controlled participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min rest, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
62547312|NCT02288026||Arm I|Patients undergo lobectomy
62547313|NCT02288026||Arm II|Patients undergo a wedge resection or anatomical segmentectomy
62547314|NCT03546127||STS|Patients with advanced/metastatic soft-tissue sarcoma
62547315|NCT03546127||CCR|Patients with metastatic colorectal carcinoma
62547316|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
62547317|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
62547318|NCT02381184|ACTIVE_COMPARATOR|Clomiphene Citrate group (Group A)|Group A (n =68) assigned to receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
62165845|NCT04832724|EXPERIMENTAL|Commercial Formulation Dose 1|Dose 1 of RGX-314
62547319|NCT02381184|ACTIVE_COMPARATOR|laparoscopic ovarian drilling (LOD) Group B|Group B (n =68) underwent LOD. Laparoscopy was performed under general anesthesia, using three-puncture technique. Each ovary was cauterized perpendicular to its antimesenteric border at four points, each for 4 seconds at 40 W with a mixed current, using a monopolar electrosurgical needle (Karl Storz, ND, Germany). Each puncture was about 4 mm in diameter and 6-8 mm in depth. The ovary was cooled by irrigation with normal saline solution. Any, intraoperative or postoperative complication was reported. The follow-up was started from the next cycle after ovarian drilling up to 6 months
62547320|NCT05113407||Coronary angioplasty performed using the Shockwave Medical C2 Coronary Lithotripsy System|
62547321|NCT04037709|PLACEBO_COMPARATOR|scaling and root planing (SRP) + PDT placebo|"17 patients will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. SRP will be performed by only one experienced researcher. Periodontal reassessment will be performed after 30 days.~The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application."
62737668|NCT05445921|EXPERIMENTAL|Stellate Ganglion Block|The ultrasound guided stellate ganglion blocks will be performed by a pain management specialist with extensive experience performing these blocks. The first SGB at the initial visit will be performed on the right side, and the second SGB will be on the left side 5-10 days after the first SGB, given that the patient tolerated the first SGB.
62165846|NCT04832724|EXPERIMENTAL|Clinical Formulation Dose 1|Dose 1 of RGX-314
62165847|NCT04832724|EXPERIMENTAL|Commercial Formulation Dose 2|Dose 2 of RGX-314
62547322|NCT04037709|EXPERIMENTAL|scaling and root planing (SRP) + PDT|"17 patients will receive the same scaling and root planing treatment that placebo group.~However the PDT will be done only on one side of the mouth using methylene blue 0.005% - Chimiolux 5, DMC - purified water and methylene blue.The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pocket."
62547323|NCT03854630|ACTIVE_COMPARATOR|Standard dose (20µg)|Three doses of 20µg HBV vaccine given intramuscularly at week 0, 4, 24.
62547324|NCT03854630|EXPERIMENTAL|Double dose (40µg)|Three doses of 40µg HBV vaccine given intramuscularly at week 0, 4, 24.
62547325|NCT05676814|ACTIVE_COMPARATOR|Pecto-intercostal Fascial Block (PIFB)|Subjects in this arm receive standard of care PIFB after surgery
62547326|NCT05676814|EXPERIMENTAL|PIFB with adjuvants|Subjects in this arm receive standard of care PIFB with additional medications after surgery
62547327|NCT03603873||Patients|
62547328|NCT00946517||Parents|Parents or caregivers of type 1 diabetics
62547329|NCT00946517||Child|Type 1 diabetics
62547330|NCT01475045||Turbuhaler inhaler use|
62547331|NCT01475045||Discus inhaler use|
62547332|NCT01475045||Elpenhaler inhaler use|
62547333|NCT03449446|EXPERIMENTAL|Selonsertib (SEL)|Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
62547334|NCT03449446|EXPERIMENTAL|Firsocostat (FIR)|Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
62547335|NCT03449446|EXPERIMENTAL|Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
62547336|NCT03449446|EXPERIMENTAL|Selonsertib (SEL) + Firsocostat (FIR)|Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
62547337|NCT03449446|EXPERIMENTAL|Selonsertib (SEL) + Cilofexor (CILO)|Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
62547338|NCT03449446|EXPERIMENTAL|Firsocostat (FIR) + Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
62547339|NCT03449446|EXPERIMENTAL|Placebo|Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
62547340|NCT04980989|EXPERIMENTAL|Mobile software|Patient with early breast cancer were followed-up by mobile software for the first six months. At six months they crossed-over to be followed-up by telephone calls for the next six months.
62547341|NCT04980989|ACTIVE_COMPARATOR|Telephone calls|Patient with early breast cancer were followed-up by telephone calls for the first six months. At six months they crossed-over to be followed-up by mobile software for the next six months.
62547342|NCT00515918||1|Iron deficient
62547343|NCT00515918||2|Iron sufficient
62547344|NCT00860392|EXPERIMENTAL|1|Biomarker evaluation
62547345|NCT03200717|EXPERIMENTAL|Pazopanib- 2nd line treatment|Participants received pazopanib as 2nd line treatment
62547346|NCT03200717|EXPERIMENTAL|Pazopanib- 3rd line treatment|Participants received pazopanib as 3rd line treatment
62720036|NCT06101368|EXPERIMENTAL|Physical Activity (Combined Aerobic and Resistance Training)|Group A will perform aerobic and resistance exercises at a moderate level. Brisk Walk on treadmill 5 days/week with 40-70% of Vo2max (maximal aerobic capacity) 150 min/week 50-55% humidity and a room temperature of 24-25 °C will maintain. The subject will wear insole proper fitted shoes. Aerobic exercise will be conducted for a total of 30 minutes per session for 5 days for 12 weeks. This protocol will be followed by a 10-minute warm-up and cool-down. Followed by 10-15 minutes of resistance-based exercises at a moderate intensity of three sets with 15 repetitions of upper and lower limbs respectively i.e. Dumbbell biceps curl, Standing dumbbell triceps extension, Dumbbell stiff-legged deadlifts and Dumbbell squats Resistance loads will be 40-50% of one repetition maximum. The resting interval between resistance training sets will be \< 1 min.
62547347|NCT05775133|EXPERIMENTAL|Indocyanine green (ICG)|"Patients in this arm will receive an intravenous injection of indocyanine green (ICG) 45 minutes prior to the start of surgery. This will be used to visualize the biliary anatomy using ActivSight, a device that is FDA 510(k)-cleared for this indication.~The surgeon will perform the procedure in their standard fashion using ActivSight.~ActivInsight artificial intelligence will be used to analyze the surgical video in real time to identify anatomic structures and phases of surgery."
62720037|NCT06101368|OTHER|Control Group|The control group will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
62739001|NCT04114708|OTHER|ACLR with lateral extra-articular tenodesis|All LETs will be performed in a standardized fashion using the modified Lameire technique.
62165848|NCT04832724|EXPERIMENTAL|Clinical Formulation Dose 2|Dose 2 of RGX-314
62547348|NCT05775133|NO_INTERVENTION|Non-Indocyanine Green (Non-ICG)|"The surgeon will perform the procedure in their standard fashion without the use of ICG.~ActivInsight artificial intelligence will be used to analyze the surgical video in real time to identify anatomic structures and phases of surgery."
62547349|NCT05170282||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
62547350|NCT05170282||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
62547351|NCT06557499|EXPERIMENTAL|Polyurethane (PU) male condom-Test condom 1|
62547352|NCT06557499|EXPERIMENTAL|Polyurethane (PU) male condom-Test condom 2|
62547353|NCT06557499|ACTIVE_COMPARATOR|Natural Rubber Latex (NRL) male condom- Control condom|
62739002|NCT00841776|ACTIVE_COMPARATOR|Duac gel|Clindamycin and benzoyl peroxide gel
62547354|NCT00118534|EXPERIMENTAL|Arm 1|Integration of smoking cessation therapy with PTSD therapy.
62547355|NCT00118534|ACTIVE_COMPARATOR|Arm 2|Per standard of care, patients are referred to a smoking cessation clinic for their smoking cessation therapy.
62547356|NCT02027532|ACTIVE_COMPARATOR|Cefazolin|intravenous, weight-based dose (1gm\<80kg, 2gm\>80kg), perioperatively
62547357|NCT02027532|ACTIVE_COMPARATOR|Vancomycin|intravenous, weight-based dose (1gm\<80kg, 2gm\>80kg), perioperatively
62547358|NCT03349346|EXPERIMENTAL|Cohort 1- Participants 12 to less than 18 years of age|"Participants will receive idelalisib monotherapy (from day 1 to day 21), followed by combination therapy with RICE. Upon enrollment, participants will be assigned to one of the 3 dose levels during idelalisib monotherapy (Dose level 1 = 55 mg/m\^2 twice daily (BID), Dose level 2 = 85 mg/m\^2 BID, Dose level 3 = 125 mg/m\^2 BID) administered as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets.~* Day 1: single dose of idelalisib~* Day 2 up to Day 21: initiate and continue idelalisib BID dosing~* Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
62547359|NCT03349346|EXPERIMENTAL|Cohort 2- Participants 1 to less than 12 years of age|"Participants will receive one of the 3 doses of idelalisib monotherapy (from day 1 to day 21) followed by combination therapy with RICE. Idelalisib will be administered as as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets. Participants will will be enrolled at dose level 1 once tolerability is demonstrated in the older cohort (Cohort 1). Thereafter, both age cohorts will be dose escalated independently.~* Day 1: single dose of idelalisib~* Day 2 up to Day 21: initiate and continue idelalisib BID~* Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
62547360|NCT01613430|ACTIVE_COMPARATOR|Printed Educational Material (PEM) only|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
62547361|NCT01613430|EXPERIMENTAL|Coach Training (COACH)|The COACH intervention consists of the Printed Educational Materials (PEM) plus the addition of cancer-related training for participant-designated coaches.
62547362|NCT00645892|ACTIVE_COMPARATOR|A|
62547363|NCT00645892|PLACEBO_COMPARATOR|B|
62547364|NCT00738257|EXPERIMENTAL|Parmidronate|
62547365|NCT02026687|ACTIVE_COMPARATOR|Epidural analgesia|The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
62547366|NCT02026687|EXPERIMENTAL|Intrathecal analgesia|The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.
62547367|NCT00131495|PLACEBO_COMPARATOR|1|Placebo patch
62547368|NCT00131495|EXPERIMENTAL|2|Testosterone patch (300mcg/day, changed twice a week for one year
62547369|NCT03031418||Cohort 1|Enroll up to 500 patients to confirm performance of ExoDx Prostate IntelliScore (EPI) for men scheduled for initial biopsy. The treating physician will collect a urine sample from from a consented subject to test before their scheduled prostate biopsy (during your established clinic visit).
62547370|NCT03031418||Cohort 2|Enroll up to 500 patients to evaluate how the results of the urine test influences the decision process for determining whether to perform a prostate biopsy. The treating physician will collect a urine sample for testing and 2 weeks later discuss whether to perform a prostate biopsy with the subject knowing the results of the urine test and comparing them to the overall consensus report from Cohort 1 as well as other clinical factors the treating physician would otherwise use to determine whether they should have a prostate biopsy.
62547371|NCT05228431|EXPERIMENTAL|Sandwich Regimen|All rectal patients in this group will receive standard surgical resection.
62547372|NCT03680989|PLACEBO_COMPARATOR|Natural Light|"Participants will use a therapy light that provides \~500 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
62547373|NCT03680989|ACTIVE_COMPARATOR|Bright Light|"Participants will receive Bright Light Exposure using a therapy light that provides \~10,000 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
62547374|NCT06171100||First dose tolvapatan|
62547375|NCT06171100||Second dose tolvaptan|
62547376|NCT02729584||Normal weight|
62547377|NCT02729584||Obese|
62547378|NCT03191591|EXPERIMENTAL|First 1,000 Days Program|
62547379|NCT01639157|EXPERIMENTAL|Buspirone|Subjects will be maintained on 30 mg buspirone daily.
62720038|NCT01471964|EXPERIMENTAL|MLN8237 and Erlotinib|"Phase I Erlotinib 100 mg PO daily\* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).~Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I."
62165849|NCT03990909|EXPERIMENTAL|BCAAs|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
62165850|NCT03990909|PLACEBO_COMPARATOR|Rice Protein|Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
62165851|NCT03990909|PLACEBO_COMPARATOR|Microcrystalline Cellulose|Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
62547380|NCT01639157|PLACEBO_COMPARATOR|Placebo|Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).
62720039|NCT05881707|EXPERIMENTAL|Sequence 1|"* Period 1: D064, D702 - A single oral dose of 2 tablets~* Period 2: CKD-828 - A single oral dose of 1 tablet~* Period 3: D064, D702 - A single oral dose of 2 tablets~* Period 4: CKD-828 - A single oral dose of 1 tablet"
62720040|NCT05881707|EXPERIMENTAL|Sequence 2|"* Period 1: CKD-828 - A single oral dose of 1 tablet~* Period 2: D064, D702 - A single oral dose of 2 tablets~* Period 3: CKD-828 - A single oral dose of 1 tablet~* Period 4: D064, D702 - A single oral dose of 2 tablets"
62547381|NCT03709212||Individual semi-structured interview|"20 participants will undergo individual semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.~Participants will be recruited from three ethnic backgrounds; Black African/ Caribbean, South Asian and White Caucasian."
62547382|NCT03709212||Focus Group 1|10 participants female black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
62547383|NCT03709212||Focus Group 2|10 participants male Black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
62547384|NCT03709212||Focus Group 3|10 participants female South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
62547385|NCT03709212||Focus Group 4|10 participants male black South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
62547386|NCT03709212||Focus Group 5|10 participants female White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
62547387|NCT03709212||Focus Group 6|10 participants male White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
62547388|NCT00442455|EXPERIMENTAL|Erlotinib, radiotherapy.|There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation therapy being fixed (63 Gy during 5 days a week during 7 weeks)
62547389|NCT01704274|PLACEBO_COMPARATOR|Placebo|Placebo patch
62547390|NCT01704274|EXPERIMENTAL|Low dose GTN 0.0285 mg/hr|Low dose GTN
62547391|NCT01704274|EXPERIMENTAL|High Dose GTN 0.057 mg/hr|High Dose GTN
62547392|NCT05523466|EXPERIMENTAL|Active-Sham group|will start with 5 sessions (1 per week) of active acupuncture combined with HRV evaluation for 20 min. After a 2-week washout, this group will be reallocated to another 5 sessions (1 per week) of sham acupuncture for 20 min combined with HRV evaluation.
62547393|NCT05523466|EXPERIMENTAL|Sham-Active group|will start an allocated 5 sessions (1 per week) of sham acupuncture combined with HRV evaluation, and after a 1-week washout period will be reallocated to 5 sessions (1 per week) of active acupuncture combined with HRV evaluation.
62547394|NCT03936803|ACTIVE_COMPARATOR|exercise group|Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD) and taking their standard medications in addition to aerobic interval training exercise .Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with heart rate (HR) at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum heart rate HR. The exercise session was terminated by 5 minutes cool-down
62547395|NCT03936803|ACTIVE_COMPARATOR|electro-acupuncture group|"Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD), and taking their standard medications In addition to electro acupuncture (EA) of (2 Hz, 4 mA) was applied at points of: liver 3 (LR3) ,liver 14 (LR14), gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
62547396|NCT06139302|EXPERIMENTAL|BI 1015550 low dose|
62547397|NCT06139302|EXPERIMENTAL|BI 1015550 high dose|
62547398|NCT03385850|EXPERIMENTAL|early enteral nutrition|
62547399|NCT03385850|ACTIVE_COMPARATOR|delayed enteral nutrition|
62547400|NCT02237391|EXPERIMENTAL|CIPAP Program|Complex Interdisciplinary Pain Assessment Program
62547401|NCT02237391|OTHER|Treatment as Usual (TAU)|Treatment as usual control group
62547402|NCT05320887|EXPERIMENTAL|Normal Nicotine Content Vape with all flavor e-liquids|Normal Nicotine Content Vape with all flavor e-liquids
62720041|NCT06718621|EXPERIMENTAL|BL-M08D1|Participants receive BL-M08D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
62165852|NCT05039047||Cohort|
62547403|NCT05320887|EXPERIMENTAL|Normal nicotine content vape with tobacco e-liquids|Normal nicotine content vape with tobacco e-liquids
62547404|NCT05320887|EXPERIMENTAL|Low nicotine content vape with all flavor e-liquids|Low nicotine content vape with all flavor e-liquids
62547405|NCT05320887|EXPERIMENTAL|Low nicotine content vape with tobacco e-liquids|Low nicotine content vape with tobacco e-liquids
62547406|NCT01709539|EXPERIMENTAL|Diagnostiskt Centrum|Investigation at the primary care center followed by further investigation at Diagnostiskt Centrum, Kristianstad General Hospital
62547407|NCT01709539|NO_INTERVENTION|Existing diagnostic procedures|Investigation at the primary care center followed by further investigation at Helsingborg General Hospital
62547408|NCT02289729||All Participants|Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.
62720042|NCT01631721||Cohort 1|Cohort of adolescents recruited in 2012-2013 of study
62720043|NCT01631721||Cohort 2|Cohort of adolescents recruited in year 2013-2014 of study
62720044|NCT01631721||Cohort 3|Cohort of adolescents recruited in year 2014-15 of study
61978180|NCT03833973||Soccer Players|High Level soccer players, both female and male aged 15-30, participating in all games
62739003|NCT00841776|ACTIVE_COMPARATOR|Ziana gel|Clindamycin and tretinoin gel
62547409|NCT01918202|EXPERIMENTAL|Cohort 1 - 20 mg|Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
62547410|NCT01918202|EXPERIMENTAL|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
62547411|NCT01918202|EXPERIMENTAL|Cohort 3 ( adaptive dose, optional)|"Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional"
62720045|NCT05554276|EXPERIMENTAL|neoadjuvant chemotherapy+ PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
62547412|NCT01106014|EXPERIMENTAL|1|Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
62547413|NCT01106014|PLACEBO_COMPARATOR|2|Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed
62547414|NCT04682925|EXPERIMENTAL|skin care arm of where evidence-based practices in the implementation guide|Participants in this arm will be given evidence-based skin care interventions, which are included in the guidelines to prevent medical device-related pressure injuries, and are implemented by the researcher nurse. After the nasogastric tube is inserted by the patient's physician.
62547415|NCT04682925|EXPERIMENTAL|hydrocolloid (Convatec Granuflex-extra thin) dressing|Patients in this arm will be applied a translucent hydrocolloid cover, which is compatible with the sensitive skin structure, can be applied to all body surfaces and nasal mucosa, and allows the underlying mucosa and skin to be observed after the nasogastric tube is inserted by the patient's physician. This cover will be applied to the nasal mucosa and nasal wing under the nasogastric tube.
62547416|NCT04682925|OTHER|control|Participants in the control group will be given no intervention , these patients will receive the routine clinical care(dressing change and nasal skin cleaning once a day) applied in the intensive care unit.
62547417|NCT01881984|EXPERIMENTAL|Ravicti|Open Label Study
62547418|NCT00715624|EXPERIMENTAL|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62547419|NCT00715624|PLACEBO_COMPARATOR|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
62547420|NCT05771948|PLACEBO_COMPARATOR|Group 1 (Control)|1 IA injection of 4 ml Normal Saline solution.
62547421|NCT05771948|EXPERIMENTAL|Group 2 (Study)|1 IA injection of 4 ml CCoat
62547422|NCT00716222||1|Obese adolescent and young adult with sleep disorder
62547423|NCT00716222||2|Obese adolescent and young adult without sleep disorder
62547424|NCT00716222||3|Lean adolescent and young adult with sleep disorder
62547425|NCT01491191|EXPERIMENTAL|PEA|Administration of PEA from 8 days before surgical operation until 30 days after surgery.
62547426|NCT01491191|ACTIVE_COMPARATOR|Sugar pill|Administration of placebo from 8 days before surgical operation until 30 days after surgery.
62547427|NCT06581562|EXPERIMENTAL|Arm 1|Arm 1 - Subjects with Rheumatoid Arthritis
62547428|NCT06581562|EXPERIMENTAL|Arm 2|Arm 2- Pemphigus Vulgaris
62547429|NCT06581562|EXPERIMENTAL|Arm 3|Arm 3 - Systemic Lupus Erythematosus
62547430|NCT06581562|EXPERIMENTAL|Arm 4|Arm 4- Subjects with Granulomatosis with polyangiitis / microscopic polyangiitis
62547431|NCT05698433||high Blood pressure variability team|The group with excessive blood pressure fluctuation during operation is high Blood pressure variability team
62547432|NCT01137071|EXPERIMENTAL|Monoclonal antibody hu3S193|Monoclonal antibody hu3S193 will be administered to 51 patients at the dose of 30mg/m2 every other week (total of 12 infusions) for a total of 23 weeks.
62547433|NCT03451214|EXPERIMENTAL|diet zinc|3 dietary zinc levels: 6 mg/d, 11 mg/d and 25 mg supplemental zinc/d
62720046|NCT06129019|EXPERIMENTAL|Experimental:|Reiki application will be done
61978181|NCT03232801|EXPERIMENTAL|mindfulness group|A multicomponent group-based intervention rooted in mindfulness, administered in 3 sessions over 6 weeks
62547434|NCT04113018|EXPERIMENTAL|KRd-Daratumumab|Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
62547435|NCT02423421|ACTIVE_COMPARATOR|Treatment group|The treatment group will have faecal microbiota transplantation performed using stool from a healthy human donor
62547436|NCT02423421|PLACEBO_COMPARATOR|Placebo group|The placebo group will have autologous faecal microbiota transplantation performed.
62547437|NCT05146648|ACTIVE_COMPARATOR|Real AMPS|AMPS therapy consists of mechanical stimulations applied to two specific points on both feet: the tip of the big toe (hallux) and the first metatarsal joint.
62547438|NCT05146648|SHAM_COMPARATOR|Sham AMPS|AMPS therapy applied to two non-specific points on both feet.
62547439|NCT03132155|EXPERIMENTAL|AMG 337|AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
62547440|NCT04431765|ACTIVE_COMPARATOR|Patient for Eye Movement desensitization Reprocessing therapy|Patient with post-traumatic Stress Disorder will receive Eye Movement Desensitization reprocessing therapy
62547441|NCT04431765|PLACEBO_COMPARATOR|patients for Trauma-Centred Cognitive and Behavioural Therapy|Patients with post-traumatic Stress Disorder will receive Trauma-Centred Cognitive and Behavioural Therapy
62547442|NCT02498028||Cervical Fusion|patients with anterior cerivical decompression and fusion
62547443|NCT02498028||Cervical Disc Prostheses|patients with cervical total disc replacement
62547444|NCT02646605||patients initiating ART|HIV positive men and women initiating ART
62547445|NCT02646605||patients on established ART|HIV positive men and women on established ART
62720047|NCT06129019|NO_INTERVENTION|Control|Reiki application will not be done
62720048|NCT01079325|EXPERIMENTAL|SB-509|
62720049|NCT01079325|PLACEBO_COMPARATOR|Placebo|Saline
62547446|NCT05432661||1 nasal kanul|The data of a total of 60 patients in the group will be recorded. Those with saturation below 92% will be included in the study. The data of the nasal cannula group will be obtained from retrospective file and archive scanning. After providing standard monitoring, preoxygenation was performed for 3 minutes. After preoxygenation, 2-4 L/min oxygen was given to the patients who would receive oxygen support by nasal cannula. Patients were followed for at least 15 minutes after the procedure or until the patient recovered. Our aim is the early recovery of patients without complications.
62547447|NCT05432661||2 HİGH-FLOW NASAL OXYGEN|The data of a total of 60 patients in the group will be recorded. Those with saturation below 92% will be included in the study. After the standard monitoring is established, preoxygenation will be performed for 3 minutes. . After preoxygenation, 40 L/min oxygen will be administered through a HFNO system to patients who will receive oxygen support with HFNO ( Inspired O2 FLO High Flow Oxygen Therapy ). Patients will be followed for a minimum of 15 minutes after the procedure or until the patient recovers.
62547448|NCT04462432||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
62547449|NCT04462432||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
62547450|NCT02131350|EXPERIMENTAL|Ranibizumab with Photocoagulation|
62547451|NCT01024257|EXPERIMENTAL|conjunctival autograft plus beta-irradiation|
62547452|NCT01024257|ACTIVE_COMPARATOR|conjunctival autograft|
62547453|NCT03892499|EXPERIMENTAL|Healthy Volunteers|Period 1: Single dose of olinciguat. Period 2: ITZ is dosed once daily (QD) for 10 days; a single dose of olinciguat is administered 1 hour after the fourth ITZ QD dose.
62547454|NCT01013662|ACTIVE_COMPARATOR|glycemic control between 180 and 220 mg/dl|
62547455|NCT01013662|ACTIVE_COMPARATOR|glycemic control for levels between 80 and 110 mg/dl|
62547456|NCT01964976||Alogliptin + Biguanides|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
62547457|NCT03428711|PLACEBO_COMPARATOR|Placebo Oral Tablet|Placebo comparator twice-a-day, for 12 months
62547458|NCT03428711|EXPERIMENTAL|Mesoglycan Oral Tablet|"a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~50 mg, twice-a-day, for 12 months"
62547459|NCT04873973|NO_INTERVENTION|Control|Participants in this group are routinely treated.
62547460|NCT04873973|ACTIVE_COMPARATOR|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
62547461|NCT01029145||1|Bipolar patients that experience a new episode of any type
62547462|NCT05759013|EXPERIMENTAL|VentFree Respiratory Muscle Stimulator|In the VentFree treatment group, abdominal functional electrical stimulation (FES) will be applied with a frequency of 30 hertz (Hz) and a pulse width of 350µs to cause a strong visible or palpable muscle contraction. The stimulation amplitude will be set to 90% of the participant's maximum tolerable level that does not cause discomfort to the participant. Participant discomfort will be measured using a visual analog pain scale (VAS) with pain ratings from zero (no pain) to ten (worst pain). For participants who are unable to communicate their level of pain, the Behavioral Pain Scale (BPS) will be used. The stimulation will be titrated for each participant and each stimulation session. After the stimulation has been titrated, a visible or palpable contraction of the abdominal wall will be confirmed. The stimulation will be evaluated every 10(± 2) minutes after the start of each stimulation session and adjusted as necessary so that no discomfort is caused to the participant.
62547463|NCT05759013|SHAM_COMPARATOR|Sham Respiratory Muscle Stimulator|In the sham group, abdominal functional electrical stimulation (FES) will be set to cause sensory stimulation but no muscle contraction. Abdominal FES will be applied with a frequency of 30 hertz (Hz), a pulse width of 350 µs and a stimulation amplitude that does not cause abdominal wall muscle contraction. The stimulation amplitude will initially be set at 10 mA and reduced in steps of 2 milliamp (mA) until no muscle contraction is seen.
62720050|NCT06250764||GROUP 1 (periodontally healthy )|An individual to be considered to have periodontal health according to this definition, the percentage of sites with bleeding on probing should be no more than 10%, and the probing depth should be 3 mm or less
62547464|NCT01412086||All Participants|Healthy volunteers. No treatment (intervention) was received.
62547465|NCT04535687|EXPERIMENTAL|Treatment group|Fluzoparib alone
62547466|NCT04892537|ACTIVE_COMPARATOR|CSR|Coronary Sinus Reducer implantation
62547467|NCT04892537|PLACEBO_COMPARATOR|Placebo|Placebo procedure
62547468|NCT02658799|EXPERIMENTAL|diclofenac potassium|"Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
62547469|NCT02658799|ACTIVE_COMPARATOR|placebo|"or placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (placebo) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
62547470|NCT02847988|ACTIVE_COMPARATOR|Neuro-muscular electrical stimulation|"Intervention:Neuromuscular electrical stimulation (NMES)~NMES stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering NMES"
62720051|NCT06250764||GROUP 2 (gingivitis)|Patients with gingivitis had PD ≤3 mm, BOP in ≥30% of the probing sites, and no interproximal AL or radiographic bone loss
62737669|NCT02654821|EXPERIMENTAL|TCR treatment|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
62547471|NCT02847988|SHAM_COMPARATOR|Sham stimulation|"Intervention: sham stimulation~Sham stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering sham-NMES"
62547472|NCT01890525||PROMISE study patients|
62547473|NCT02796638|EXPERIMENTAL|Minute Ventilation Adaptive Servo-Ventilation plus SOC|Patients in this arm will be instructed to use the adaptive servo-ventilation (ASV) device for up to five days of inpatient stay while in the hospital. Patients are encouraged to use the device during any and all hours of sleep, and as needed during waking hours. Apart from this treatment, no other interventions will be administered, and the patient's standard of care will not otherwise be altered for the purposes of the study.Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
62547474|NCT02796638|NO_INTERVENTION|Standard of Care (SOC)|Patients in this arm will not have their standard of care as dictated by their provider altered in any way. Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
62547475|NCT05532709|EXPERIMENTAL|Plyometric training|The plyometric training program progressed from level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
62547476|NCT05532709|EXPERIMENTAL|circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
62547477|NCT01806571|EXPERIMENTAL|Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)|"INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a significant decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy.~CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5, and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
62547478|NCT04510532||Patients with Breast Cancer who use pyrotinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given pyrotinib as having HER2-positive breast cancer with no metastasis.
62547479|NCT04510532||Patients with Breast Cancer who use apatinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given apatinib as having HER2-negative breast cancer with no metastasis.
62547480|NCT04510532||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
62547481|NCT03216863|EXPERIMENTAL|8 weeks Respiratory rehabilitation|
62547482|NCT04015310||PSC patients attending outpatient|Primary sclerosing cholangitis, as defined by EASL and AASLD guidelines.
62547483|NCT06070558|OTHER|Healthy|Healthy volunteers
62547484|NCT06070558|OTHER|Temporomandibular Joint Disorders|Patients with Temporomandibular Joint Disorders
62547485|NCT03305367|NO_INTERVENTION|Screening/Baseline|A standard OGTT with no supplementation/intervention
62547486|NCT03305367|EXPERIMENTAL|Hydrolyzed pine nut oil low dose|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
62547487|NCT03305367|EXPERIMENTAL|Hydrolyzed pine nut oil high dose|Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil
62737670|NCT02520544|ACTIVE_COMPARATOR|Accolade stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
62547488|NCT02548390|EXPERIMENTAL|RXDX-107|
62547489|NCT01730924|OTHER|Contact force available|
62547490|NCT01730924|OTHER|Contact force not available|
62547491|NCT02010515||Sinus rhythm, first ICD implantation|
62547492|NCT02378987||Typical developmental children|Normal children
62547493|NCT02378987||CP children with GMFCS level I and II|Children with CP were classified into Levels I-II based on the Gross Motor Function Classification System (GMFCS).
62547494|NCT02378987||CP children with GMFCS level III and IV|Children with CP were classified into Levels III-IV based on the Gross Motor Function Classification System (GMFCS).
62547495|NCT04084457|PLACEBO_COMPARATOR|Placebo|Matched for macronutrients, micronutrients and fibre
62547496|NCT04084457|ACTIVE_COMPARATOR|Wild Blueberry Powder|Formulation of a 100% blueberry (freeze-dried whole fruit) drink
62547497|NCT05496244||Epidemiological Section|Consecutive enrollment of patients with indications of interest
62547498|NCT05496244||Observational Section|Extended data collection on patients treated via conventional laparoscopy or robotic-assisted surgery
62547499|NCT01384903|EXPERIMENTAL|KW-3357|
62547500|NCT01384903|ACTIVE_COMPARATOR|Plasma-derived antithrombin|
62547501|NCT04639011|ACTIVE_COMPARATOR|Group A Placebo|Participants randomized to Group A will receive placebo (sugar pill) and Boston Medical Center (BMC) standard of care.
62547502|NCT04639011|EXPERIMENTAL|Groups B Intervention|Participants randomized to Group B will receive duloxetine and Boston Medical Center (BMC) standard of care.
62547503|NCT02289456|EXPERIMENTAL|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle~• Carboplatin AUC = 5 mg\*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
62547504|NCT05378555|EXPERIMENTAL|Ketamine|
62547505|NCT00708227||Whites ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
62547506|NCT00708227||Whites ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
62547507|NCT00708227||African American ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
62547508|NCT00708227||African American ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
62547509|NCT00400842|EXPERIMENTAL|L|
62547510|NCT00400842|EXPERIMENTAL|H|
62547511|NCT00400842|PLACEBO_COMPARATOR|P|
62547512|NCT04060446||Observational (smoke cigarettes)|Patients smoke 5 cigarettes separated by 30 minute washout periods. Between 48 hours and 1 week later, patients smoke another 5 cigarettes separated by 30 minute washout period with CReSSMicro topography measurement device and BioRadio device for recording inhalation patterns.
62547513|NCT02233439|PLACEBO_COMPARATOR|Placebo|a placebo identical in appearance to the galactagogue product
62547514|NCT02233439|NO_INTERVENTION|No treatment|Usual care and breastfeeding support
62547515|NCT02233439|EXPERIMENTAL|Herbal galactagogue|A commercially available product containing a combination of Silybum marianum 400 mg and Galega officinalis 150 mg, once a day for 6 weeks
62547516|NCT06538415|EXPERIMENTAL|Pulse Diet|Participants will consume cooked pulse (112 calories -lentils, red kidney beans, black beans, and pinto beans) during 14 weeks.
62547517|NCT06538415|ACTIVE_COMPARATOR|Control Rice Diet|Participants will consume cooked rice (112 calories) during 14 weeks.
62547518|NCT02117739|EXPERIMENTAL|All Participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches twice a week for 21 days followed by a 10 to 17 day rest period then another application of dapsone gel and dapsone gel vehicle by patch.
62547519|NCT00650130||1|drivers of motorised vehicles suspected of being under the influence of psychoactive drugs
62547520|NCT02552121|EXPERIMENTAL|Tisotumab vedotin (HuMax-TF-ADC)|
62547521|NCT01350245|EXPERIMENTAL|TJU 2 Step Regimen|All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.
62547522|NCT03867097|PLACEBO_COMPARATOR|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
62547523|NCT03867097|ACTIVE_COMPARATOR|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
62720052|NCT06250764||GROUP 3(generalized stage I and stage II periodontitis)|Stage I periodontitis was diagnosed with interdental attachment loss (AL) ranging between 1 and 2 mm at the site of greatest loss. Radiographic bone loss (BL) is limited to less than 15% and no tooth loss. Additionally, the maximum probing depth (PD) is equal to or less than 4 mm or primarily involves horizontal bone loss. Stage II periodontitis was diagnosed with interdental attachment loss (AL) is ranging between 3 and 4 mm at the site of greatest loss. Radiographic bone loss (BL) extends to a range of 15% to 33%, there is no tooth loss. The maximum probing depth (PD) is equal to or less than 5 mm or primarily involves horizontal bone loss.
62547524|NCT03537131|ACTIVE_COMPARATOR|arm B1- Dapagliflozin once only dose|Participants who will take one tablet of Dapagliflozin 10 mg on the day of the exercise challenge.
62547525|NCT03537131|ACTIVE_COMPARATOR|arm B2- Dapagliflozin daily administration|Participants who will take a daily dose of Dapagliflozin 10 mg before and after the exercise challenge.
62547526|NCT01399658|EXPERIMENTAL|Image-Guided Brachytherapy|Image-guided brachytherapy
62547527|NCT03810040|ACTIVE_COMPARATOR|Odd-numbered days|Once odd-numbered days the zytoges of IVF cycle were collected. The 140 microns denuding pipette was used.
62547528|NCT03810040|EXPERIMENTAL|Even-numbered days|Once even-numbered days the zytoges of IVF cycle were collected. The 150 microns denuding pipette was used.
62547529|NCT05919615|EXPERIMENTAL|intravenous tranexamic acid|The intervention group comprised patients who went primary unilateral TKA and used two-dose intravenous tranexamic acid that was applied as follows: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride), the first dose 15 minutes before the tourniquet deflation and the second dose at 180 minutes after the first dosage.
62547530|NCT05919615|PLACEBO_COMPARATOR|placebo|The control group comprised primary unilateral TKA patients who did not use TXA, just IV normal saline (0.9% sodium chloride).
62547531|NCT01045668|ACTIVE_COMPARATOR|Clinical VT ablation|
62547532|NCT01045668|ACTIVE_COMPARATOR|clinical VT and substrate ablation|
62547533|NCT03398603||Group 1|25 women with age of 18-25 years
62547534|NCT03398603||Group 2|25 women with age of 26-40 years
62547535|NCT03655314|ACTIVE_COMPARATOR|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
62547536|NCT03655314|PLACEBO_COMPARATOR|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
62547537|NCT03536611|EXPERIMENTAL|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
62547538|NCT03536611|ACTIVE_COMPARATOR|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
62547539|NCT04353895|EXPERIMENTAL|Robotic group (RG)|Patients in the RG group will be operated using the assistance of the Mazor X Stealth robot
62547540|NCT04353895|ACTIVE_COMPARATOR|O-arm navigation group (NV)|Patients in the NV group will be operated using the guidance of the Stealth navigation
61978182|NCT03232801|ACTIVE_COMPARATOR|educational group|A general midlife health and aging educational group, administered in 3 sessions over 6 weeks
62547541|NCT04679493|EXPERIMENTAL|XC7 100 mg single|Cohort 1 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 100 mg (3 subjects) or placebo (1 subject, see placebo single arm)
62165853|NCT05624229|PLACEBO_COMPARATOR|Standard group|"Early treatment is mainly aimed at correcting hypovolemic shock, preventing gastrointestinal bleeding-related complications, effective control of bleeding, monitoring vital signs and urine output.~Medical treatment included initiation and maintenance of vasoactive agents as soon as possible for 2 to 5 days, and prophylactic antibiotics (preferably ceftriaxone sodium or quinolones) by intravenous infusion for 5 days.~Endoscopic intervention was performed within 12 hours after presentation and generally no longer than 24 hours. PPI was stopped immediately after endoscopic treatment.~Early TIPS is determined according to the technology and concept of each unit."
62165854|NCT05624229|EXPERIMENTAL|Standard group+PPI|PPI continued after endoscopic treatment for 5 days.
62165855|NCT04527380|EXPERIMENTAL|Ixekizumab|Ixekizumab given subcutaneously (SC).
62165856|NCT04527380|ACTIVE_COMPARATOR|Adalimumab|Adalimumab given SC. Participants may have the option to switch to ixekizumab given SC during the open label extension period.
62165857|NCT04004169|EXPERIMENTAL|Arm 1: Intervention (stimulation ON)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1), stimulation OFF (arm 2), and Stimulation ON Active Control (sham biomarker) (arm 3) in random order. After 6 months of intervening therapy, this 3-period crossover study will be repeated.
62165858|NCT04004169|SHAM_COMPARATOR|Arm 2: Sham Control (stimulation OFF)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1), stimulation OFF (arm 2), and Stimulation ON Active Control (sham biomarker) (arm 3) in random order. After 6 months of intervening therapy, this 3-period crossover study will be repeated.
62165859|NCT04004169|ACTIVE_COMPARATOR|Arm 3: Active Control (stimulation ON triggered by sham biomarker)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1), stimulation OFF (arm 2), and stimulation ON Active Control (sham biomarker) (arm 3) in random order. After 6 months of intervening therapy, this 3-period crossover study will be repeated.
62165860|NCT03866109|EXPERIMENTAL|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
62165861|NCT01838512||Cohort 1|Participants with relapsed/refractory multiple myeloma (RRMM) followed up for up to 5 years
62165862|NCT01838512||Cohort 2|Participants with newly-diagnosed multiple myeloma (NDMM) followed up for up to 8 years
62165863|NCT02119572|EXPERIMENTAL|peer support|Patients are divided into small groups and assigned with peer leaders for twelve months according to their residence. Besides the same training and follow-ups as the control arm, patients from intervention groups are suggested and encouraged to take part in the group activities with the peer leaders per month. And if possible, casual activities (such as phone call, chatting, short message; physical exercise, group member family visiting，going to supermarket together, etc.)are also recommended
62165864|NCT02119572|ACTIVE_COMPARATOR|usual education|Patients attend the usual self-management education and communicate with the professionals every two months, getting the information on diabetes diet, exercise, glucose monitor, etc. besides that the group members should attend three follow ups at baseline,6 and 12 months.
62165865|NCT02771184|OTHER|Lung-Healthy|Subjects with no diagnosed lung disease. The intervention is the recording of lung sounds with the Lung Sound Recording System.
62165866|NCT02771184|OTHER|Pneumothorax|Subjects with pneumothorax. The intervention is the recording of lung sounds with the Lung Sound Recording System.
62165867|NCT02771184|OTHER|Pulmonary Fibrosis|Subjects with pulmonary fibrosis. The intervention is the recording of lung sounds with the Lung Sound Recording System.
62165868|NCT02543697|EXPERIMENTAL|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
62165869|NCT02449837||Head and Neck Cancer|Patient with locally advanced head and neck cancer but no distant metastasis scheduled to receive radiotherapy to the head and neck region with or without chemotherapy/targeted therapy (palliative or curative intent).
62165870|NCT02449837||Cervical Cancer|Patients with locally advanced cervical cancer without distant metastasis scheduled for radiotherapy to the pelvic region with or without chemotherapy/targeted therapy (palliative or curative intent).
62165871|NCT02449837||Non-Small Cell Lung Cancer|Patients with stage I to III non-small cell lung cancer, without distant metastasis, scheduled to receive stereotactic body radiotherapy for early stage lung disease and/or external beam radiotherapy for locally advanced lung disease, with or without concurrent/sequential chemotherapy and/or targeted therapy (curative intent).
62547542|NCT04679493|EXPERIMENTAL|XC7 200 mg single|Cohort 2 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 200 mg (3 subjects) or placebo (1 subject, see placebo single arm)
62165872|NCT02449837||Rectal Cancer|Patients with locally advanced rectal cancer (no distant metastasis) scheduled to receive neoadjuvant chemoradiotherapy (curative intent).
62165873|NCT02449837||Metastatic Prostate Cancer|Patients with metastatic prostate cancer scheduled for palliative radiotherapy, or biochemically recurrent prostate cancer following radical prostatectomy scheduled for salvage prostatic fossa radiotherapy, with or without androgen deprivation, or with high risk prostate cancer.
62547543|NCT04679493|PLACEBO_COMPARATOR|Placebo single|Placebo comparator arm will consist of 2 subjects (1 subject from Сohorts 1 and 2)
62547544|NCT04679493|EXPERIMENTAL|XC7 200 mg multiple|Cohort 3 - 6 subjects will be randomized in a 6:2 ratio to be treated either XC7 200 mg (6 subjects) or placebo (1 subject, see placebo multiple arm)
62547545|NCT04679493|PLACEBO_COMPARATOR|Placebo multiple|Placebo comparator arm will consist of 2 subjects from cohort 3
62547546|NCT03742947|EXPERIMENTAL|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
62547547|NCT03742947|PLACEBO_COMPARATOR|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL)
62547548|NCT01933477|NO_INTERVENTION|Local Standard of Care|Arm A: Referral of post-partum women from the antenatal clinic to general adult ART services at approximately 4-8 weeks postpartum (the local current standard of care in this setting)
62547549|NCT01933477|ACTIVE_COMPARATOR|MCH-focused ART services|Arm B: Continued receipt of MCH-focused ART services based at the antenatal clinic throughout the period of breastfeeding. Post-partum women will only be referred to general adult ART services after the end of breastfeeding and once infants' final HIV status is determined.
62547550|NCT04990713|PLACEBO_COMPARATOR|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with saline placebo. Local anesthetic administered will be ropivacaine 0.2%.
62547551|NCT04990713|EXPERIMENTAL|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with local anesthetic. Local anesthetic administered will be ropivacaine 0.2%.
62547552|NCT05158543|ACTIVE_COMPARATOR|Control Group|the control group will receive conventional intervention for upper and lower limb motor function \& balance.
62547553|NCT05158543|EXPERIMENTAL|moderate intensity group|this group will get task-oriented training with moderate intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
62547554|NCT05158543|EXPERIMENTAL|high intensity group|this group will get task-oriented training with high intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
62547555|NCT06334224|ACTIVE_COMPARATOR|Low-load resistance training|Twice-daily low load resistance training for four days
62547556|NCT06334224|EXPERIMENTAL|Blood flow restriction training|Twice-daily low load resistance training with blood flow restriction for four days
62547557|NCT04460287|PLACEBO_COMPARATOR|Milk Drink Unfortified (Negative Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days.
62547558|NCT04460287|ACTIVE_COMPARATOR|Milk Drink Unfortified Plus Fish Oil (Positive Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
62547559|NCT04460287|EXPERIMENTAL|Milk Drink Fortified with DHA Used Wet Mixing Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
62547560|NCT04460287|EXPERIMENTAL|Milk Drink Fortified with DHA Used Dry Blending Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
62547561|NCT03245827|ACTIVE_COMPARATOR|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
62547562|NCT03245827|PLACEBO_COMPARATOR|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
62547563|NCT03245827|NO_INTERVENTION|Obese males with normal testosterone|comparison group
62547564|NCT03245827|NO_INTERVENTION|lean males with normal testosterone|comparison group
62547565|NCT05096650|EXPERIMENTAL|platelet rich plasma|Each case will receive 3 sessions of injection therapies with one month interval. The practitioner will inject 2ml of platelet rich plasma with fan and linear method into photoaging areas in one side of the midface in one session of treatment.
62547566|NCT05096650|OTHER|platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. The practitioner will inject 2ml of platelet rich plasma with fan and linear method into photoaging areas in the other side of the midface in one session of treatment.
62547567|NCT05548387|EXPERIMENTAL|Sequence 1|Period 1: RLD2202 +RLD2203 Period 2: HCP2202 Period 3: RLD2202 +RLD2203 Period 4: HCP2202
62547568|NCT05548387|EXPERIMENTAL|Sequence 2|Period 1: HCP2202 Period 2: RLD2202 +RLD2203 Period 3: HCP2202 Period 4: RLD2202 +RLD2203
62547569|NCT01523002|ACTIVE_COMPARATOR|Arm A: metoprolol and pyronaridine-artesunate 90-day redosing|Subjects will take 1 day of metoprolol followed by a 7 day wash out period, then 2 days of pyronaridine-artesunate followed by 1 day of pyronaridine-artesunate + metoprolol, followed by a 87 day follow-up period. Subjects will then receive pyronaridine-artesunate once daily for 3 days followed by a 40 day follow-up period.
62547570|NCT01523002|ACTIVE_COMPARATOR|Arm B: pyronaridine-artesunate 60-day redosing|Subjects will take pyronaridine-artesunate once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take pyronaridine-artesunate once daily for 3 days followed by a 40 day follow-up period.
62547571|NCT03239847|EXPERIMENTAL|EndoPhys Sheath and Radial Arterial Line|This group of patients will have both the EndoPhys sheath and the radial arterial line placed during surgery.
62547572|NCT03239847|EXPERIMENTAL|EndoPhys Sheath|This group of patients will only receive the EndoPhys sheath during surgery.
62547573|NCT06257251||Breast implant capsulectomy|Patients admitted and operated at CHU-Brugmann hospital for surgical revision of their breast implants.
62547574|NCT05341830|EXPERIMENTAL|Recovery Housing|Individuals in this arm will have access to a placement in recovery housing and the associated services. Recovery housing organizations provide individuals recovering from substance use disorders with housing and a variety of services, including transportation, rental assistance, life skills, family services, and educational and employment opportunities.
62547575|NCT05341830|NO_INTERVENTION|No Recovery Housing|Individuals in this arm will not receive a placement in recovery housing. When possible, they will be informed about other available services in their community.
62547576|NCT05294432||Single Group|Patients of Wilderman Medical Clinic diagnosed with symptomatic Osteoarthritis of the Knee who were prescribed with at least one intra-articular corticosteroid injection.
62547577|NCT03043404|EXPERIMENTAL|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
62547578|NCT00862732|ACTIVE_COMPARATOR|1 Cognitive Behavioural Therapy|Intervention group will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
62547579|NCT00862732|ACTIVE_COMPARATOR|2 Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
62547580|NCT05435690|EXPERIMENTAL|Computer-assisted arthroplasty|
62547581|NCT05435690|NO_INTERVENTION|Conventional arthroplasty|
62547582|NCT04582084||Autoimmune Arthritis|Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings
62547583|NCT01662401|EXPERIMENTAL|Peripheral Nerve Block|bilateral rectus sheath and ilioinguinal nerve blocks under ultrasound guidance after induction of general anesthesia administered to subject
62547584|NCT01662401|EXPERIMENTAL|local anesthetic infiltration|local anesthetic infiltration will be administered after induction of general anesthesia
62547585|NCT03561324|EXPERIMENTAL|Use of IntraOperative Imaging Probe|The sterilized (Imaging Beta Probe) IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins.
62547586|NCT04226521|EXPERIMENTAL|Photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
62547587|NCT04226521|NO_INTERVENTION|No prophylactic photopheresis|Standard post-transplant protocol without prophylactic extracorporeal photopheresis
62547588|NCT01478373|EXPERIMENTAL|Dovitinib (TKI258)|Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
62547589|NCT02558439|PLACEBO_COMPARATOR|Placebo|Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
62547590|NCT02558439|EXPERIMENTAL|0.5 mg CNTX-4975|Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
62547591|NCT02558439|EXPERIMENTAL|1.0 mg CNTX-4975|Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
62547592|NCT04912089|EXPERIMENTAL|Cognitive Training Low Dose|Cognitive training completed for 8 sessions
62547593|NCT04912089|EXPERIMENTAL|Cognitive Training High Dose|Cognitive training completed for 16 sessions
62547594|NCT04912089|NO_INTERVENTION|Repeat Assessment|
62547595|NCT05607745|ACTIVE_COMPARATOR|FMT|Fecal transplantation is given 2:1 compared to placebo transplantation via gastroscopy as a fluid of 100-150ml. Similar healthy diet counseling is given to all participants in both FMT and placebo group.
62547596|NCT05607745|PLACEBO_COMPARATOR|Placebo|Placebo is brown-colored water and given the same way than fecal transplantation fluid. All study subjects receive similar dietary advice based on healthy diet. Similar healthy diet counseling is given to all participants in both FMT and placebo group.
62547597|NCT02586155|EXPERIMENTAL|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
62547598|NCT02586155|ACTIVE_COMPARATOR|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
62547599|NCT03512873|EXPERIMENTAL|Tranilast|
62547600|NCT03120325|EXPERIMENTAL|Idiopathic Gastroparesis|Patients with idiopathic gastroparesis and delayed gastric emptying. All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
62547601|NCT03120325|EXPERIMENTAL|Diabetic Gastroparesis|Patients with diabetic gastroparesis and delayed gastric emptying. All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
62547602|NCT03120325|EXPERIMENTAL|Functional Dyspepsia|Patients with functional dyspepsia and normal gastric emptying. All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
62547603|NCT00685386|EXPERIMENTAL|I|
62547604|NCT00685386|PLACEBO_COMPARATOR|II|Room air will be used for insufflation as the placebo comparator arm.
62547605|NCT00534456|EXPERIMENTAL|Active|
62547606|NCT00534456|PLACEBO_COMPARATOR|Placebo|
62547607|NCT05322122|EXPERIMENTAL|Treatment|Side-to-side anastomosis duodeno-ileostomy diversion
62547608|NCT03011593|EXPERIMENTAL|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
62547609|NCT01573299|ACTIVE_COMPARATOR|Early vertical positioning|
62547610|NCT01573299|ACTIVE_COMPARATOR|Progressively vertical positioning|
62547611|NCT01876446|EXPERIMENTAL|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
62547612|NCT04359797|ACTIVE_COMPARATOR|Usual Care|Participants randomized to this arm will remain in their natural choice of position, which is anticipated to favor a supine, semi-recumbent position.
62547613|NCT04359797|ACTIVE_COMPARATOR|Prone|Participants randomized to this arm will be encouraged to lay in a completely prone position for as much time as is tolerable during hospitalization.
62547614|NCT03210792|ACTIVE_COMPARATOR|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
62547615|NCT03210792|EXPERIMENTAL|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
62547616|NCT05986227|EXPERIMENTAL|FOLFOX(D1)was combined with toripalimab(D3)|
62547617|NCT05986227|EXPERIMENTAL|FOLFOX(D1)was combined with toripalimab(D1)|
62547618|NCT05986227|EXPERIMENTAL|FOLFOX(D3) was combined with toripalimab(D1)|
62547619|NCT05986227|ACTIVE_COMPARATOR|FOLFOX(D1)|
62547620|NCT00824343|EXPERIMENTAL|Single P276-00 arm|This is a single experimental arm study
62737671|NCT02520544|ACTIVE_COMPARATOR|Accolade II stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
62547621|NCT04934046|EXPERIMENTAL|DaTSCAN brain scan images from the new CZT SPECT system|All patients will undergo additional SPECT acquisition (30min added time approximately), with no added radiation, with both new multipurpose CZT camera (StarGuide system, GE Healthcare, Haïfa, Israel) and conventional SPECT camera (Discovery 670, GE Healthcare, Haïfa, Israel)
62547622|NCT03423719|EXPERIMENTAL|Verum|This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.
62547623|NCT03423719|PLACEBO_COMPARATOR|Placebo|This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.
62547624|NCT02593643|EXPERIMENTAL|ketamine+TAU - MDD|Ketamine + treatment as usual (TAU) in MDD inpatients with SI
62547625|NCT02593643|ACTIVE_COMPARATOR|midazolam + TAU - MDD|Midazolam + treatment as usual (TAU) in MDD inpatients with SI
62547626|NCT02593643|EXPERIMENTAL|ketamine + TAU - BD|Ketamine + treatment as usual (TAU) in BD inpatients with SI
62547627|NCT02593643|ACTIVE_COMPARATOR|midazolam + TAU - BD|Midazolam + treatment as usual (TAU) in BD inpatients with SI
62547628|NCT03209817|EXPERIMENTAL|Red cherry tomato|300 grams of red cherry tomatoes per day for four weeks (each)
62547629|NCT03209817|EXPERIMENTAL|Yellow cherry tomato|300 grams of yellow cherry tomatoes per day for four weeks (each)
62547630|NCT03209817|NO_INTERVENTION|Control No tomato|No tomato products consumption
62547631|NCT02069548||Cervical dystonia|
62547632|NCT02069548||matched controlled subjects|matched in age (+/- 5 years) and gender
62547633|NCT03305627|EXPERIMENTAL|Short PAP|Perioperative antibiotic prophylaxis will be stopped after 24h
62547634|NCT03305627|ACTIVE_COMPARATOR|Extended PAP|Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
62547635|NCT01308424|EXPERIMENTAL|BTL TML HSV|
62547636|NCT01308424|PLACEBO_COMPARATOR|Matching Placebo|
62547637|NCT04174612|ACTIVE_COMPARATOR|Standard clinical treatment|"Patients will complete 3+7 + Midostaurin induction course."
62547638|NCT04174612|EXPERIMENTAL|Experimental treatment|"The experimental arm will provide 2 main modifications compared to standard:~i) immediate switch to intensified induction with high-doses Cytarabine (on days 5, 6 and 7 of induction) ii) early allocation to high-risk disease category to be refined according to ELN stratification and post induction MRD status"
62547639|NCT04940637|EXPERIMENTAL|Niraparib and Dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
62547640|NCT02210845|ACTIVE_COMPARATOR|Financially incentivized weight loss|Participants can be assigned to the financially incentivized weight loss group in which they can receive 50 dollars at the end of the month if they achieve their monthly weight loss goal.
62168129|NCT01538901|EXPERIMENTAL|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann \& Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
62547641|NCT02210845|PLACEBO_COMPARATOR|Standard of Care|Participants can be assigned to standard of care where they receive no intervention.
62547642|NCT02210845|ACTIVE_COMPARATOR|Supervised Exercise|Participants can be assigned to the supervised exercise arm which they will receive supervised professional training once a week.
62547643|NCT04683224|PLACEBO_COMPARATOR|Placebo Stratum 1: 18 to 59 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
62547644|NCT04683224|EXPERIMENTAL|UB-612 Stratum 1: 18 to 59 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
62547645|NCT04683224|PLACEBO_COMPARATOR|Placebo Stratum 2: ≥60 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
62547646|NCT04683224|EXPERIMENTAL|UB-612 Stratum 2: ≥60 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
62547647|NCT04683224|PLACEBO_COMPARATOR|Placebo Stratum 3: 18 to 59 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
62547648|NCT04683224|EXPERIMENTAL|UB-612 Stratum 3: 18 to 59 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
62547649|NCT04683224|PLACEBO_COMPARATOR|Placebo Stratum 4: ≥60 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
62547650|NCT04683224|EXPERIMENTAL|UB-612 Stratum 4: ≥60 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
62547651|NCT06321614||patients with normal abdominal radiographs|patients with normal abdominal radiographs, which were confirmed by extra imaging examinations and clinical data. The imaging examinations comprised CT, magnetic resonance imaging (MRI) and colonoscopy in the subsequent 72 hours, while clinical data included recent hospital admission information and surgical operation notes.
62547652|NCT06321614||patients with small bowel obstruction radiographs|patients with small bowel obstruction radiographs, which were confirmed by extra imaging examinations and clinical data. The imaging examinations comprised CT, magnetic resonance imaging (MRI) and colonoscopy in the subsequent 72 hours, while clinical data included recent hospital admission information and surgical operation notes. In terms of location, small-bowel obstruction (SBO) involves the duodenum, jejunum, and ileum
62547653|NCT06321614||patients with large bowel obstruction radiographs|patients with large bowel obstruction radiographs, which were confirmed by extra imaging examinations and clinical data. The imaging examinations comprised CT, magnetic resonance imaging (MRI) and colonoscopy in the subsequent 72 hours, while clinical data included recent hospital admission information and surgical operation notes. In terms of location, large-bowel obstruction (SBO), involves the cecum, colon, and rectum.
62547654|NCT06550713|EXPERIMENTAL|TQB3455 tablet and Azacitidine for Injection|"Stage1：TQB3455 tablet, oral, once a day, for 28 consecutive days as a treatment cycle.~Stage2：TQB3455 tablet, oral, once a day, for 28 consecutive days as a treatment cycle.~Azacitidine for injection: A treatment cycle of 4 weeks, with subcutaneous injection of Azacitidine standard dose on the first to seventh day of each cycle."
62737672|NCT00419211|EXPERIMENTAL|Lifestyle counseling|Tailored exercise program
62547655|NCT02708771|EXPERIMENTAL|Intervention|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
62547656|NCT02708771|PLACEBO_COMPARATOR|Control|Capsules of similar appearance and flavor without active drug
62547657|NCT00699998|EXPERIMENTAL|Prasugrel|Prasugrel and Low-dose Commercially-available Aspirin
62547658|NCT00699998|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel and Low-Dose Commercially-available Aspirin
62547659|NCT05501535||pseudophakic patients before and after having ND YAG laser|
62547660|NCT05493501|EXPERIMENTAL|Aumolertinib monotherapy|
62547661|NCT05493501|EXPERIMENTAL|Aumolertinib + platinum-based doublet chemotherapy|"For adenocarcinoma, either:~* Aumolertinib + cisplatin with pemetrexed, or~* Aumolertinib + carboplatin with pemetrexed~For squamous cell carcinoma, one of the following:~* Aumolertinib + cisplatin or carboplatin with paclitaxel;~* Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or~* Aumolertinib + cisplatin or carboplatin with gemcitabine"
62547662|NCT05493501|ACTIVE_COMPARATOR|Osimertinib monotherapy|
62547663|NCT00963066|ACTIVE_COMPARATOR|Pressure Support ventilation|
62547664|NCT00963066|EXPERIMENTAL|NAVA flow triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with flow triggering
62547665|NCT00963066|EXPERIMENTAL|NAVA EMG triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram
62720053|NCT06250764||GROUP 4 (generalized stage III and stage IV periodontitis)|Stage III periodontitis is diagnosed with interdental attachment loss (AL) is ≥ 5, radiographic bone loss (BL) extends to mid-third of the root and beyond, tooth loss may become evident ≤4 teeth. Either PD ≥ 6 mm or vertical BL ≥ 3 mm, or Class II/III furcation involvement, or moderate ridge defect. Stage IV periodontitis is diagnosed with interdental attachment loss (AL) is ≥ 5 mm at the site of greatest loss, radiographic BL extending to mid-third of the root and beyond. ≥5 tooth loss due to periodontitis is evident. In addition to Stage III, either masticatory dysfunction, or secondary occlusal trauma (tooth mobility degree ≥ 2), or severe ridge defect, or bite collapse, or teeth drifting and flaring
62720054|NCT01802099|OTHER|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level \< 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
62720055|NCT01802099|OTHER|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
62720056|NCT06225362|EXPERIMENTAL|Quatera 700|
62720057|NCT06225362|ACTIVE_COMPARATOR|Centurion Vision System|
62720058|NCT05909137||study group|CTV-omitted IMRT+adjuvant immunotherapy
62168130|NCT01538901|ACTIVE_COMPARATOR|imiquimod 5% cream|250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.
62547666|NCT04052620|EXPERIMENTAL|Diclofenac diethylamine (DDEA) 2.32%/ Placebo gel|Participants will receive 4 tubes, DDEA 2.32% gel and Placebo gel (2 each) and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm\^2). DDEA 2.32% gel will be applied in morning and late afternoon and Placebo gel will be applied in noon and late evening for 7 days.
62547667|NCT04052620|ACTIVE_COMPARATOR|DDEA 1.16% gel|Participants will receive 4 tubes of DDEA 1.16% gel and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm\^2) in morning, noon, late afternoon, and late evening for 7 days.
62547668|NCT05209607|EXPERIMENTAL|Interventional group|Participants will be given mobile medical and bundle care
62547669|NCT05209607|OTHER|Control group|Participants will be given mobile medical and standard of care.
62547670|NCT00785148|EXPERIMENTAL|1|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
62547671|NCT04200027||Robotic total mesorectal Excision|robotic assissted total mesorectal excision
62547672|NCT04200027||Transanal total mesorectal excision|Transanally assissted total mesorectal excision
62547673|NCT03993379|EXPERIMENTAL|CX-072 in combination with anti-cancer therapy-front line|histologically or cytologically confirmed solid tumor who have received no prior treatment
62547674|NCT03993379|EXPERIMENTAL|CX-072 in combination with ipilimumab|histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor
62547675|NCT03993379|EXPERIMENTAL|CX-072 in combination with anti-cancer therapy-Progressed|histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy
62547676|NCT03993379|EXPERIMENTAL|CX-072 in combination with anti-cancer therapy-Neoadjuvant|neo-adjuvant study in subjects with histologically confirmed solid tumor
62547677|NCT01090518|ACTIVE_COMPARATOR|Prolonged Exposure therapy with Hydrocortisone|
62547678|NCT01090518|PLACEBO_COMPARATOR|Prolonged Exposure therapy with placebo|
62547679|NCT01654016|ACTIVE_COMPARATOR|Detralex|Detralex 500 mg twice daily for three month prior to surgery
62720059|NCT05909137||control group|CTV-delineated IMRT+adjuvant immunotherapy
62720060|NCT04773548|EXPERIMENTAL|VR-JIT|
62720061|NCT03500211|EXPERIMENTAL|Lidoderm 5% Topical Patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
62720062|NCT03500211|SHAM_COMPARATOR|Sham Topical Patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
62737673|NCT00419211|NO_INTERVENTION|No Intervention|Usual care group
62737674|NCT03745872|EXPERIMENTAL|Testing|This is a preventative study model. All students who choose to participate will receive a pre and post test regarding their sun exposure behaviors and knowledge on sun exposure risk.
62547680|NCT01654016|NO_INTERVENTION|Not taking Detralex|Not taking Detralex for three months prior to surgery
62547681|NCT05497791|EXPERIMENTAL|Experimental Transcranial Laser and Electrical Stimulation|Hemiplegics treated with transcranial laser stimulation (on) associated with neuromuscular electrical stimulation (NMES) (on)
62547682|NCT05497791|PLACEBO_COMPARATOR|Placebo|Hemiplegics treated with placebo transcranial laser stimulation (off) associated with NMES (on)
62547683|NCT02285088|EXPERIMENTAL|GBT440|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
62547684|NCT02285088|PLACEBO_COMPARATOR|Placebo|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
62547685|NCT05500950||Patients with space occupying lesions completed CDU and CT-DCG or CT|Patients who had completed CDU and CT-DCG or CT examination before surgery and were diagnosed with lacrimal sac space occupying lesions during surgery were selected to be included in this study.
62547686|NCT05019443|ACTIVE_COMPARATOR|Conventional balloon predilation|the target lesion can be prepared according to standard clinical practice using SC balloons sized 0.8-1:1. Stenting using a drug-eluting stent (DES) is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
62547687|NCT05019443|EXPERIMENTAL|Scoring balloon predilation|the target lesion must be prepared with a scoring balloon (SC) inflated 3 times at nominal pressure. To allow the scoring balloon to cross the lesion, it might be necessary to predilate with a small compliant balloon. The size of the scoring balloon to be used for is based on the size of the vessel. Stenting using a DES is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
62547688|NCT04671693|EXPERIMENTAL|PASCA intervention|
62547689|NCT06633874|EXPERIMENTAL|Typically Developed Children PLAYING SERIOUS GAME|"The arm describes the data collection process to design an intelligent system that contributes to implementing new innovative tools to assist clinicians and/or other professionals in the complicated screening and diagnostic procedures for communication deficiencies in children.~The main objective of this arm is to feed data from collected responses of TD children to the backend of the SmartSpeech system. The data we collect are Game responses, Speech responses, Gaze data from the tablet camera, and Heart Rate Variability (captured through the smartwatch). The backend system will use the data for training, evaluating, and validating the intelligence system."
62547690|NCT06633874|ACTIVE_COMPARATOR|Non-Typically Developed Children PLAYING SERIOUS GAME|The arm describes the data collection process to design an intelligent system that contributes to implementing new innovative tools to assist clinicians and/or other professionals in the complicated screening and diagnostic procedures for communication deficiencies in children. The main objective of this arm is to feed data from collected responses of Non-TD children to the backend of the SmartSpeech system. The data we collect are Game responses, Speech responses, Gaze data from the tablet camera, and Heart Rate Variability (captured through the smartwatch). The backend system will use the data for training, evaluating, and validating the intelligence system.
62547691|NCT03261492|EXPERIMENTAL|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
62547692|NCT03261492|ACTIVE_COMPARATOR|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
62547693|NCT03001453|ACTIVE_COMPARATOR|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
62547694|NCT03001453|ACTIVE_COMPARATOR|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
62547695|NCT03104855|EXPERIMENTAL|Single pharmacokinetics arm|
62547696|NCT04594824||Term neonates|
62720063|NCT06459102|EXPERIMENTAL|Motor Learning|In addition to the conventional physiotherapy program, motor learning exercise will be performed for 6 weeks, 3 sessions per week. For the exercise, the participant will sit in a chair with back support, in front of a table, with arms on the table. The participant will wear a glove with an IMU sensor on the upper surface and a pressure sensor on the palm, and a cylinder will be placed in the palm. The participant will be asked to bring the wrist into extension and then back into flexion while grasping the cylinder with maximum force. The participant will be asked to maintain maximum strength during the entire movement. The participant will be given visual feedback on muscle strength and range of motion of the wrist on the monitor in front of them throughout the movement. The same protocol will be applied by keeping the size of the cylinder in the participant's palm the same and changing the weight.
62547697|NCT04594824||Preterm neonates|
62547698|NCT06548997|EXPERIMENTAL|GZR18|
62547699|NCT06548997|PLACEBO_COMPARATOR|Placebo|
62547700|NCT03258203|EXPERIMENTAL|diet 1|diet with moderate in fat (40% energy) and protein(15%)
62547701|NCT03258203|EXPERIMENTAL|diet 2|diet with moderate in fat (40% energy) and protein(25%)
62547702|NCT03258203|EXPERIMENTAL|diet 3|diet with low in fat (20% energy) and protein(15%)
62547703|NCT03258203|EXPERIMENTAL|diet 4|diet with low in fat (20% energy) and protein(25%)
62547704|NCT04413201|EXPERIMENTAL|Afatinib|Afatinib followed by osimertinib or ICT depending on T790M status
62547705|NCT04413201|ACTIVE_COMPARATOR|Osimertinib|Osimertinib followed by ICT
62547706|NCT03149276||Limited English Proficiency Group|"LEP persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered limited English proficient when a non-English language was preferred. Interventions included professional interpreter services and occupational therapy."
62547707|NCT03149276||English Speaking Group|"English speaking persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered English speaking when the English language was preferred. Intervention included occupational therapy."
62547708|NCT04939220|ACTIVE_COMPARATOR|Control Group|Deep sedation with propofol and natural airway
62547709|NCT04939220|EXPERIMENTAL|Experimental Group|SGA Placement and maintenance with inhalational anesthetic or propofol
62547710|NCT05099250|PLACEBO_COMPARATOR|Control group: Bupivacaine Group (B group)|Included patients who received 17 mL of 0.25% bupivacaine + 3 mL saline 0.9% in a total volume of 20 ml on each side
62547711|NCT05099250|ACTIVE_COMPARATOR|Magnesium Group (M group)|Included patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side.
62547712|NCT05643872|EXPERIMENTAL|PTX-022|
62547713|NCT03649984|EXPERIMENTAL|Symptom Navi© Program|Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers
62547714|NCT03649984|NO_INTERVENTION|Standard care|Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.
62547715|NCT02202707|OTHER|Gabapentin|Open label single arm study. All participants will receive Gabapentin.
62547716|NCT06019884|EXPERIMENTAL|Intraoral camera, conventional referral|
62547717|NCT06019884|EXPERIMENTAL|Intraoral camera, user fee removal|
62547718|NCT06019884|EXPERIMENTAL|Smartphone camera, conventional referral|
62547719|NCT06019884|EXPERIMENTAL|Smartphone camera, user fee removal|
62547720|NCT01941498|EXPERIMENTAL|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
62547721|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.~Laboratory blood tests will be collected and analyzed"
62547722|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
62547723|NCT05992857|EXPERIMENTAL|Retromesenteric omental flap covering all exposed peripancreatic arteries|A J-shaped omental flap is created by extensive mobilization of the greater omentum, and if needed, lengthening by division of vertical collaterals of gastroepiploic vessels section or thinning it out in patients with visceral obesity. This omental flap is ascended through the retromesentric route to cover all the peri-pancreatic vessels at risk of bleeding after pancreatic resection (hepatic artery, proximal part of the splenic artery, superior mesenteric artery, and right hepatic artery originating from superior mesenteric artery when present)
62547724|NCT05992857|ACTIVE_COMPARATOR|Control|No omental flap or an omental flap not using the retromesenteric route and only interposed between the pancreatic anastomosis and the hepatic artery, or a single round ligament flap wrapping the hepatic artery only.
62720064|NCT06459102|ACTIVE_COMPARATOR|Control|The control group will receive a conventional physiotherapy program for 4 weeks, 5 days a week. Eccentric training for the extensor carpi radialis brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercises for the ECRB muscle will be given. For eccentric training, the weight that the patients can lift in 10 maximal repetitions will be calculated and they will be asked to work with this weight. The best stretching position for the ECRB tendon is extension of the elbow joint, pronation of the forearm and flexion of the wrist with ulnar deviation. Each participant will be taught to perform each exercise for 10 repetitions and 10 seconds. Patients will perform these exercises in a sitting position. In the control group, daily exercises will be performed under the supervision of a physiotherapist.
62720065|NCT01434654||Non Neuro-HAART (low CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
62720066|NCT01434654||Neuro-HAART (high CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
62720067|NCT03100266|EXPERIMENTAL|probiotic|Lactobacillus rhamnosis GG
62720068|NCT03100266|PLACEBO_COMPARATOR|placebo|Inactive capsules
62720069|NCT02636647|ACTIVE_COMPARATOR|FMT|Fecal transplant via enema once
62720070|NCT02636647|NO_INTERVENTION|No treatment|No transplant performed
62547725|NCT01810510|EXPERIMENTAL|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
62547726|NCT01810510|EXPERIMENTAL|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
62547727|NCT06458647|EXPERIMENTAL|Intervention group|Individuals in the intervention group will be shown a video with virtual reality glasses before entering the angiography procedure.
62547728|NCT06458647|NO_INTERVENTION|Control group|No application will be made to the control group before the procedure.
62547729|NCT02460406|OTHER|control group|traditional physiotherapy (stretching, normal range of movement, walking)
62720071|NCT05511402|EXPERIMENTAL|Aerobic exercise|This group will participate in an aerobic training program (8-week, 3 times weekly, and 30-min each time) and conventional physiotherapy program (8-week, 3 times weekly, and 45-min each time).
62720072|NCT05511402|ACTIVE_COMPARATOR|Conventional physiotherapy|This group will participate in a conventional physiotherapy program (8-week, 3 times weekly, and 45-min each time).
62165874|NCT02449837||Oligometastatic Disease|Patients with oligometastatic cancer, defined as any solid malignancy with\< 5 measurable sites of metastatic disease, limited to a maximum of 3 anatomic organ systems, excluding the primary tumor and regional lymph nodes. At least 1 site of metastatic disease, but as many as all 5 sites, in addition to the primary tumor and regional lymph nodes, is amenable to local ablative therapy with external beam radiation, stereotactic cranial radiosurgery or stereotactic body radiotherapy. Treatment will be guided by multi-disciplinary evaluation and may also include surgery, chemotherapy or target agents at the discretion of the primary oncologists. Patients may present with oligometastatic disease or have oligometastatic disease recurrence after definitive therapy for localized disease.
62165875|NCT02449837||Immunotherapy|Melanoma or metastatic NSCLC scheduled to receive ipilimumab, nivolumab, and/or pembrolizumab.
62165876|NCT02449837||Head and Neck Induction chemotherapy|Locally advanced head and neck cancer (HNSCC) scheduled to receive induction chemotherapy followed by radiotherapy.
62165877|NCT02449837||Metastatic Breast Cancer|Patients scheduled to receive any treatment, including radiation therapy, and/or systemic/hormonal therapy
62165878|NCT02449837||Endometrial Cancer|Patients with stage III endometrial cancer, being treated with adjuvant radiation
62165879|NCT05182671||Children diagnosed with bowel and bladder dysfunction|Children who are between the ages of 5-12 and diagnosed with bladder- bowel dysfunction by pediatric urologist.
62165880|NCT05762978|EXPERIMENTAL|Asthmatic Children|NIF will be measured using an In-Check Dial
62165881|NCT01573741|EXPERIMENTAL|ketamine,four hours monitoring hydrochloride injection|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
62165882|NCT03392779|EXPERIMENTAL|ZSP1601(single dose)-25 mg while fasted(Cohort 1)|ZSP1601 25 mg /Placebo
62165883|NCT03392779|EXPERIMENTAL|ZSP1601(single dose)-50 mg while fasted(Cohort 2)|"ZSP1601 50 mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
62165884|NCT03392779|EXPERIMENTAL|ZSP1601(single dose)-100 mg while fasted(Cohort 3)|"ZSP1601 100 mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
62165885|NCT03392779|EXPERIMENTAL|ZSP1601(single dose)-175 mg while fasted(Cohort 4)|"ZSP1601 175 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
62165886|NCT03392779|EXPERIMENTAL|ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)|"ZSP1601 275 mg/Placebo~Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4."
62165887|NCT03392779|EXPERIMENTAL|ZSP1601(single dose)-350 mg while fasted(Cohort 6)|"ZSP1601 350 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5."
62165888|NCT03392779|EXPERIMENTAL|ZSP1601(food effect)-100 mg (Cohort FE)|"Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8."
62165889|NCT03392779|EXPERIMENTAL|ZSP1601(multiple doses)-50 mg (Cohort 7)|"50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE~ZSP1601 50 mg/Placebo for 14 Days."
62165890|NCT03392779|EXPERIMENTAL|ZSP1601(multiple doses)-100 mg (Cohort 8)|"Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.~ZSP1601 100 mg/Placebo for 14 Days."
62165891|NCT03238599|EXPERIMENTAL|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
62165892|NCT00850798|EXPERIMENTAL|1|Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
62165893|NCT00850798|ACTIVE_COMPARATOR|2|Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
62165894|NCT00834483|EXPERIMENTAL|1|Knotless suture for wound closure
62165895|NCT00834483|ACTIVE_COMPARATOR|2|Layered traditional wound closure (monocryl)
62165896|NCT00762554|ACTIVE_COMPARATOR|1|Epidural Depodur after spinal bupivacaine
62165897|NCT00762554|ACTIVE_COMPARATOR|2|Epidural fentanyl infusion after epidural lidocaine or spinal bupivacaine
62165898|NCT04374253|EXPERIMENTAL|Group 1|Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 116 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
62165899|NCT04374253|EXPERIMENTAL|Group 2|Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
62165900|NCT01904253|EXPERIMENTAL|TAS-102|
62165901|NCT01904253|ACTIVE_COMPARATOR|Investigator Choice of Amrubicin or Topotecan|Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)
62165902|NCT05041439|EXPERIMENTAL|Community health worker (CHW) group|Participants in the intervention arm will receive 5 one-on-one sessions over 6 months with a CHW, as well as a manual and written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
62165903|NCT05041439|NO_INTERVENTION|Enhanced care condition (ECC)|Participants in this arm will receive 5 outreach calls at the same interval as the intervention arm, as well as written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
62720073|NCT00087698|EXPERIMENTAL|A|chemotherapy, surgery then chest radiation x 54 gray (Gy)
62720074|NCT03925987|EXPERIMENTAL|Exposure therapy|Participants complete 10 weekly sessions of a group-based exposure therapy class for anxiety disorders.
62720075|NCT00110214|EXPERIMENTAL|Arm I|Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1. Patients also receive oral prednisone once daily on days 1-21.
62547730|NCT02460406|ACTIVE_COMPARATOR|intervention group|progressive functional strength training protocol on lower extremities consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball \& heel-rise exercises.
62547731|NCT01119781|EXPERIMENTAL|peginterferon beta-1a|Single dose of peginterferon beta-1a at either 63 or 125 mcg in renal impaired Participants and healthy volunteers
62547732|NCT02470845|EXPERIMENTAL|Tian Jiu group|The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.
62547733|NCT02470845|SHAM_COMPARATOR|Placebo-control group|The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.
62547734|NCT02470845|NO_INTERVENTION|Waitlist-control group|The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.
62547735|NCT00005957|ACTIVE_COMPARATOR|Standard Breast Irradiation|
62547736|NCT00005957|EXPERIMENTAL|Breast Radiation plus regional radiation|regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
62547737|NCT01810757|ACTIVE_COMPARATOR|Standard planning|Standard planning radiotherapy
62547738|NCT01810757|EXPERIMENTAL|Adaptive planning|Adaptive planning radiotherapy
62547739|NCT05133674|EXPERIMENTAL|0|Blood concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen will be measured.
62547740|NCT02508935|EXPERIMENTAL|XARTEMIS XR|All participants received XARTEMIS XR
62547741|NCT02501018|EXPERIMENTAL|CLI Due to ASO with CLBS12 + SOC|This group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data.
62547742|NCT02501018|ACTIVE_COMPARATOR|CLI Due to ASO with SOC|This group of subjects with CLI due to ASO will be administered with SOC only.
62547743|NCT02501018|EXPERIMENTAL|CLI Due to BD with CLBS12|CLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data.
62547744|NCT03104712|OTHER|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
62547745|NCT03104712|ACTIVE_COMPARATOR|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
62547746|NCT03104712|ACTIVE_COMPARATOR|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
62547747|NCT03104712|ACTIVE_COMPARATOR|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
62547748|NCT03104712|ACTIVE_COMPARATOR|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
62547749|NCT03104712|ACTIVE_COMPARATOR|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
62547750|NCT03104712|ACTIVE_COMPARATOR|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
62547751|NCT03104712|OTHER|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
62547752|NCT03104712|OTHER|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
62547753|NCT05717465|ACTIVE_COMPARATOR|Standard informed consent|Video with audio narration containing information provided in the standard informed consent process for a lumbar puncture
62547754|NCT05717465|EXPERIMENTAL|Visual aid group|Video with identical audio narration (to the control) containing information provided in the standard informed consent process for a lumbar puncture. The video also received statistical information in the form of visual aids; anatomy diagrams, Paling diagrams and Paling scales
62547755|NCT06581367|PLACEBO_COMPARATOR|Control group|Full-course antibiotic therapy based on current guidelines (7 days).
62547756|NCT06581367|ACTIVE_COMPARATOR|Intervention group|In the intervention group, patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment and C-reactive protein rapid testing after completing two full days of antibiotic.
62547757|NCT02759393|EXPERIMENTAL|DEX group|receiving 8-week dexlansoprazole 60 mg per day
62547758|NCT02759393|ACTIVE_COMPARATOR|Double-dose PPI group|receiving 8-week lansoprazole 30 mg twice daily
62547759|NCT04808973|EXPERIMENTAL|Lamivudine plus Dolutegravir in FDC|Single arm of 3TC+DTG for treatment of pregnant women with HIV infection
62547760|NCT01437930|PLACEBO_COMPARATOR|placebo|products (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
62547761|NCT04284059|ACTIVE_COMPARATOR|vitamin AD group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin A 6000 IU/day and vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks.
62547762|NCT04284059|EXPERIMENTAL|vitamin D group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks. After the study, vitamin D group will be administrated with vitamin A on the basis of serum retinol concentration after the study.
62547763|NCT04284059|PLACEBO_COMPARATOR|placebo group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive placebo once a day in addition to methylphenidate for 8 weeks. After the study, the placebo group will be prescribed with vitamin A and vitamin D supplementation on the grounds of retinol and 25 (OH)D concentration.
62547764|NCT03452137|ACTIVE_COMPARATOR|Atezolizumab|Participants will receive Atezolizumab for 16 cycles, or up to 1 year (whichever occurs first)
62547765|NCT03452137|EXPERIMENTAL|Placebo|Participants will receive Placebo for 16 cycles, or up to 1 year (whichever occurs first).
62547766|NCT06281197|EXPERIMENTAL|Conventional Group|In conventional group, Le Fort I osteotomy was made using a piezosurgical saw after nasal mucosa elevation as usual Le Fort I technique.
62547767|NCT06281197|ACTIVE_COMPARATOR|Subspinal Group|In Subspinal group, No dissection was performed between the nasal mucosa and the ANS of the patients. Osteotomy was performed in the subspinal Le Fort I group that is described by Mommaerts . A triangular osteotomy line was created between the maxilla and the ANS with a piezosurgery.
62547768|NCT05445492|EXPERIMENTAL|Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders and compare the reference device measurements to the test device.
62547769|NCT01533012|EXPERIMENTAL|Pressure difference|Peak inspiratory pressures difference between two lungs
62547770|NCT01533012|NO_INTERVENTION|FOB evaluation|FOB evaluation for the optimal position of tubes
62547771|NCT02192398|ACTIVE_COMPARATOR|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
62547772|NCT02192398|ACTIVE_COMPARATOR|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
62547773|NCT02192398|PLACEBO_COMPARATOR|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
62547774|NCT02680951|EXPERIMENTAL|Dose Level 1|"Study participants #1 - #6 receive dose level 1 of dasatinib (60/mg/m2/day) in addition to the standard treatment, for up to 2 courses. Each treatment course is 29 days.~Treatment course 1 consists of:~* Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~* Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~* Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~* Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~* Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
62547775|NCT02680951|EXPERIMENTAL|Dose Level 2|"Study participants # 7 - # 12 receive dose level 2 of dasatinib (80/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 1 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~* Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~* Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~* Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~* Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~* Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
62547776|NCT02680951|EXPERIMENTAL|Dose Level 3|"Study participants # 13 - # 18 receive dose level 3 of dasatinib (100/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 2 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~* Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~* Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~* Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~* Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~* Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
62547777|NCT06133426|OTHER|Cohort group|"Patients will be used a connected scale during the duration of their participation in the study.~Patients will be invited to use the scale once a day. Patient's data will be accesible by medical team via a specific remote plateform.~Alert will be generated according to the evolution of clinical data, permetting a early patient management by the medical team."
62547778|NCT01221610|EXPERIMENTAL|Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter
62547779|NCT01221610|ACTIVE_COMPARATOR|Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter
62547780|NCT05273450|EXPERIMENTAL|Quitline Information with Reinforcement|
62547781|NCT05273450|NO_INTERVENTION|Quitline Information Only|
62547782|NCT02454855|EXPERIMENTAL|"Group Melatonin"|standard anticancer treatment + 3-month of melatonin supplementation
62547783|NCT02454855|PLACEBO_COMPARATOR|"Group Placebo"|standard anticancer treatment + placebo (3 months)
62547784|NCT03643861|EXPERIMENTAL|5 Fraction Breast Stereotactic Body Radiation Therapy|This study will enroll patients that have a confirmed histology of early stage breast cancer. The patient will undergo a lumpectomy and will then receive partial breast 5 fractions stereotactic body radiation therapy at a dose of 6 gy for 5 fractions for treatment. Patients will be followed for 36 total months with specific follow-ups at 3, 6, 9, 12, 18, 24, and 36 months.
62547785|NCT03479801||Conventional Open|Conventional open thyroidectomy group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
62547786|NCT03479801||Transoral Endoscopic Surgery|Transoral endoscopic thyroidectomy via vestibular approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
62547787|NCT03479801||Endoscopic Thyroidectomy via Breast|Endoscopic thyroidectomy via breast approach or bilateral areola approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
62547788|NCT04162678||Diagnostic (blood collection via fluid biopsy, lab analysis)|Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.
62547789|NCT06318312|EXPERIMENTAL|11% FiO2|Hypoxic exposure: fraction of oxygen inspired (FiO2) = 11% (\~5100 m, \~16735 ft)
62547790|NCT06318312|EXPERIMENTAL|13% FiO2|Hypoxic exposure: fraction of oxygen inspired (FiO2) = 13% (\~3800 m, \~12470 ft)
62547791|NCT06318312|EXPERIMENTAL|15% FiO2|Hypoxic exposure: fraction of oxygen inspired (FiO2) = 15% (\~2750 m, \~9000 ft)
62547792|NCT06318312|PLACEBO_COMPARATOR|PLA / 21% FiO2|Hypoxic exposure / placebo condition: fraction of oxygen inspired (FiO2) = 21% (sea level)
62547793|NCT05198180|ACTIVE_COMPARATOR|Potassium hydroxide group|Patients with plantar warts will apply topical 30% potassium hydroxide solutions on warts
62547794|NCT05198180|ACTIVE_COMPARATOR|Hydrogen peroxide group|Patients with plantar warts will use topical 45% hydrogen peroxide solution on warts
62547795|NCT05314088|EXPERIMENTAL|RISE+ Resilience Intervention|Participants in the intervention group will come to the lab for four two-hour weekly sessions in small groups of 3-4. The intervention includes psychoeducational videos and individual written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience. The intervention will be facilitated by a trained research assistant but as in the pilot study, he/she will be minimally involved (i.e., only administering the videos and explaining the activities) to keep the private reflective nature of the program that participants liked. Upon completion of the program, participants will be given handouts with summaries of the program material. We will gather qualitative and quantitative feedback on the intervention at the one-month posttest.
62547796|NCT05314088|PLACEBO_COMPARATOR|Stress Reduction Control|Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games. As with the intervention group, participants in the control group will come to the lab for four two-hour weekly sessions in small groups of 3-4. Facilitator involvement will be the same as the intervention group (e.g., the research assistant will explain computer activities and games but will otherwise not interact with the participant).
62547797|NCT01742858||Adolescents|15-18 years old
62720076|NCT00110214|EXPERIMENTAL|Arm II|Patients receive docetaxel and prednisone as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
62165904|NCT05423015|EXPERIMENTAL|Lactobacillus casei (Probiotic)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product)
62547798|NCT01742858||Young adults I|19-24 years old
62547799|NCT01742858||Young adults II|25-30 years old
62547800|NCT00238355|EXPERIMENTAL|Voriconazole plus Caspofungin|
62547801|NCT01965054|EXPERIMENTAL|Fish Oil Supplement Group|Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
62547802|NCT01965054|NO_INTERVENTION|Control Group|Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
62547803|NCT00352417|EXPERIMENTAL|VIA-2291|
62165905|NCT05423015|EXPERIMENTAL|L. casei strain Shirota plus inulin (Syn-Inulin)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product) and enriched with 3g of inulin.
62165906|NCT05423015|EXPERIMENTAL|L. casei strain Shirota plus fructans from A. salmiana (Syn-A. salmiana)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product) and enriched with 3g of fructans from A. salmiana.
62547804|NCT00352417|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62547805|NCT04753697|EXPERIMENTAL|Administration of CC-93538|CC-93538 360 mg Subcutaneously (SC) once weekly for 24 weeks followed by CC-93538 360 mg SC once weekly for 24 weeks
62547806|NCT04753697|EXPERIMENTAL|Administration of CC-93538 and Placebo|"CC-93538 360 mg SC once weekly for 24 weeks followed by CC-93538 360 mg SC once every other week for 24 weeks.~During the Maintenance Phase, matching placebo will be administered once every other week on alternate weeks to maintain the blind."
62547807|NCT04753697|PLACEBO_COMPARATOR|Administration of Placebo|Matching placebo SC once weekly for 24 weeks followed by matching placebo SC once weekly for 24 weeks
62547808|NCT02165735|EXPERIMENTAL|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification patient concerns and patient behavioral rehearsal for asking about these concerns.
62547809|NCT02165735|EXPERIMENTAL|Usual Care|Usual care for HIV
62547810|NCT02996292|EXPERIMENTAL|Traditional brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19\*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
62547811|NCT02996292|EXPERIMENTAL|Active self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19\*25 stainless steel wires using active self-ligating brackets; American orthodontics active self-ligating Empower® MBT 0.022"
62547812|NCT02996292|EXPERIMENTAL|Passive self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19\*25 stainless steel wires using passive self-ligating brackets; American orthodontics passive self-ligating Empower® MBT 0.022"
62547813|NCT00736437|EXPERIMENTAL|1|ME-609
62547814|NCT00736437|PLACEBO_COMPARATOR|2|Vehicle
62547815|NCT06119594|NO_INTERVENTION|Standard follow-up group|Routine care
62547816|NCT06119594|EXPERIMENTAL|Connected scale group|Routine care + use of connected scale during 6 months
62165907|NCT02259296|EXPERIMENTAL|Lower eGFR for AVF creation|
62547817|NCT02040077|EXPERIMENTAL|Computer + Fluency|Will receive computerized intervention and will be required to periodically demonstrate mastery of information before proceeding to the next module in the computerized intervention.
62720077|NCT01033929|EXPERIMENTAL|0.01µg C-Tb|12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
62720078|NCT01033929|EXPERIMENTAL|0.1µg C.Tb|12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
62720079|NCT00412581|EXPERIMENTAL|Lenalidomide + Dacarbazine|
62547818|NCT02040077|ACTIVE_COMPARATOR|Computer Only|Will receive computerized intervention but will not be required to demonstrate mastery of information as part of the intervention.
62547819|NCT02040077|ACTIVE_COMPARATOR|Treatment as Usual|Will receive publicly available pamphlets that contain same information as the computerized intervention. Will not have access to computerized intervention and will not be required to demonstrate mastery of information as part of the intervention.
62547820|NCT01861912|ACTIVE_COMPARATOR|Arsenic trioxide TACE|Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities.
62547821|NCT01861912|EXPERIMENTAL|Arsenic trioxide TACE+IV|"1. Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities.~2. Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE."
62547822|NCT02100488|ACTIVE_COMPARATOR|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
62547823|NCT02100488|EXPERIMENTAL|Closed-loop insulin infusion system|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the by the software under investigation (CL4M Controls) based on blood glucose estimations from CGM.
62547824|NCT01308801|EXPERIMENTAL|active rTMS + rehabilitation exercise|14 weeks of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
62547825|NCT01308801|PLACEBO_COMPARATOR|placebo rTMS + rehabilitation exercise|14 weeks of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
62547826|NCT04525937||Patients with Severe Aortic Stenosis with Disparities|Patients will complete a survey and their aortic stenosis will be clinically followed at 30 days and one year
62547827|NCT04525937||Medical Providers with Disparities|Referring primary care providers complete a questionnaire on their referral practices for patients with severe aortic stenosis
62547828|NCT05577221|EXPERIMENTAL|Collection of physiological parameters|Installation of the high-flow humidified nasal oxygen therapy device and variation of the inspiratory flow rate (0 L/min, 30 L/min, 50 L/min and 70 L/min) then the weaning test will be performed. During each step of the protocol (= each variation of the inspiratory flow), the intensity of dyspnea will be collected, the esophageal pressure will be measured, the respiratory drive (P0.1) will be measured, the EMG of the respiratory muscles will be measured and the comfort will be measured. Each step lasts about 15 minutes with 5 minutes of wash-out before the next step. Once the 4 steps will be conducted, the weaning test will be performed (without wash-out), for a duration of one hour, 30 minutes with high flow humidified nasal oxygen (50 L/min) and 30 minutes without (both steps being randomized. The whole protocol will last 2h15.
62547829|NCT00782860||unsuccessful termination|unsuccessful termination of early pregnancy failure with Misoprostol
62547830|NCT00782860||successful termination|successful termination of early pregnancy failure with Misoprostol
62547831|NCT03473015|EXPERIMENTAL|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
62547832|NCT03473015|NO_INTERVENTION|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
62547833|NCT02768831|EXPERIMENTAL|Cuffed ETT|
62547834|NCT03742791|EXPERIMENTAL|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
62165908|NCT02259296|ACTIVE_COMPARATOR|Higher eGFR for AVF creation|
62165909|NCT02041897|OTHER|EUS-FNA, Rate of chang on diagnosis|It is a single arm study. We will conclude by calculating the rate of change of diagnosis before and after getting the results of EUS-FNA.
62547835|NCT03742791|PLACEBO_COMPARATOR|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
62547836|NCT01422980|ACTIVE_COMPARATOR|1 = Test product|Arm 1 - intervention 1 (test product)
62547837|NCT01422980|PLACEBO_COMPARATOR|2 = Control product|Arm 2 - intervention 2 (control product)
62547838|NCT04019626|ACTIVE_COMPARATOR|Continue-smoking|The subject's usual brand of combustible cigarette
62547839|NCT04019626|EXPERIMENTAL|myblu Tobacco 2.5%|myblu e-cigarette system with Tobacco flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
62547840|NCT04019626|EXPERIMENTAL|myblu Tobacco 4.0%|myblu e-cigarette system with Tobacco flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
62720080|NCT01543477||Single group|
62165910|NCT02567786|ACTIVE_COMPARATOR|Fresh Frozen Plasma|The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.
62165911|NCT02567786|ACTIVE_COMPARATOR|Plasmalyte|The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.
62737675|NCT04644276|ACTIVE_COMPARATOR|Mask with Mask Adhesive/Arm 1|Patients will be randomized to AF531 if they receive mask adhesive with mask on the first study night then the mask without mask adhesive(Performatrak) on the second study night.
62165912|NCT04673305|EXPERIMENTAL|Arm 1|patients ≥ 70 years, whith haematological malignancy, who need to start a treatment within 3 months
62547841|NCT04019626|EXPERIMENTAL|myblu Honeymoon 2.5%|myblu e-cigarette system with Honeymoon flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
62547842|NCT04019626|EXPERIMENTAL|myblu Honeymoon 4.0%|myblu e-cigarette system with Honeymoon flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
62547843|NCT04019626|ACTIVE_COMPARATOR|JUUL 5%|JUUL® system with Virginia Tobacco Flavor JUULpod, 5.0% nicotine. This arm is only included in the PK sub-study.
62547844|NCT01537939|OTHER|Walking|Quasi-experimental design with one-group, post-test only
62547845|NCT05489614|EXPERIMENTAL|Single Dose Olpasiran Renal Impairment|Participants will be enrolled in 1 of 5 renal function groups based on their renal impairment status, as determined by estimated glomerular filtration rate (eGFR). All participants will receive a single dose of olpasiran on Day 1.
62547846|NCT05489614|EXPERIMENTAL|Single Dose Olpasiran Normal Renal Function|Participants with normal renal function will be enrolled and will receive a single dose of olpasiran on Day 1.
62547847|NCT01015469|ACTIVE_COMPARATOR|Group A|Conventional laparoscopic Roux-en-Y gastric bypass (Golden Standard)
62547848|NCT01015469|EXPERIMENTAL|Group B|Conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
62547849|NCT01331850|EXPERIMENTAL|Previous null responders (Cohort B): Group 4|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
62547850|NCT01331850|EXPERIMENTAL|Previous null responders (Cohort B): Group 5|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 5 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
62547851|NCT01331850|EXPERIMENTAL|Previous null responders (Cohort B): Group 6|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.
62547852|NCT01331850|EXPERIMENTAL|Previous partial responders (Cohort A): Group 1|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 1 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
62547853|NCT01331850|EXPERIMENTAL|Previous partial responders (Cohort A): Group 2|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
62547854|NCT01331850|EXPERIMENTAL|Previous partial responders (Cohort A): Group 3|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 3 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
62547855|NCT02598921|OTHER|Three dimensional ultrasound|Three dimensional ultrasound evaluated the uterine cavity for cavitary lesions
62547856|NCT02598921|OTHER|Office hysteroscopy|Office hystrescopy evaluated the uterine cavity for cavitary lesions
62547857|NCT03597919|ACTIVE_COMPARATOR|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
62547858|NCT03597919|EXPERIMENTAL|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
62547859|NCT01375179|EXPERIMENTAL|KRP203|"Experimental~Edit~Experimental"
62547860|NCT01375179|PLACEBO_COMPARATOR|Placebo|Placebo
62547861|NCT02907879||Ultrasound perfusion imaging|Measuring methods of UPI with phase inversion harmonic imaging
62547862|NCT01607359||dabigatran group|All patients receiving dabigatran as periprocedural anticoagulation during the study time period
62547863|NCT01607359||warfarin group|A randomly selected group of patients treated with warfarin during the study time period matching the number of dabigatran treated patients in the same time period.
62547864|NCT03831204||AHF/HFpEF|AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
62547865|NCT03831204||AHF/HFrEF|AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
62547866|NCT05727098|ACTIVE_COMPARATOR|Bupivacaine|Will receive ultrasound guided ESPB with 0,25% Bupivacaine .
62547867|NCT05727098|ACTIVE_COMPARATOR|Bupivacaine and dexmedetomedine|Will receive ultrasound guided ESPB with 0,25% Bupivacaine + Dexmedetomidine.
62547868|NCT05727098|ACTIVE_COMPARATOR|Bupivacaine and Ketamine|will receive ultrasound guided ESPB with 0,25% Bupivacaine + Ketamine.
62547869|NCT02466841||Patients undergoing cubital tunnel release surgery|Patients undergoing cubital tunnel release surgery will be enrolled. All enrolled subjects will be followed regardless of the technique used by surgeon.
62547870|NCT02624180|EXPERIMENTAL|Colchicine|Colchicine 0.6 mg daily by mouth
62547871|NCT02624180|PLACEBO_COMPARATOR|Placebo|Placebo for colchicine 1 tablet by mouth daily
62547872|NCT01328522|EXPERIMENTAL|SAR153191 drug product 1|"SAR153191 drug product 1 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
62547873|NCT01328522|EXPERIMENTAL|SAR153191 drug product 2|"SAR153191 drug product 2 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
62547874|NCT03419689|EXPERIMENTAL|Sample Collection|"The following samples may be collected during the study:~* Tumour tissue samples~* Blood samples~* Ascites samples~* Other fluids requiring drainage"
62547875|NCT01984827|EXPERIMENTAL|hyper-glycaemic clamp:|hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
62547876|NCT01984827|EXPERIMENTAL|Moxifloxacin|Single oral dose of 400 mg Moxifloxacin
62547877|NCT01984827|PLACEBO_COMPARATOR|Placebo|Placebo
62547878|NCT06259435|EXPERIMENTAL|Low energy dense diet|Subjects will be required to follow time-restricted eating and receive a diet low in energy density
62547879|NCT06259435|ACTIVE_COMPARATOR|Usual diet|Subjects will be required to follow time-restricted eating and receive the usual diet.
62547880|NCT05507736|EXPERIMENTAL|Experimental|"Pre-Post feasibility treatment On the first cycle of irinotecan, the patient does not receive any intervention, we only collect data. This is the control cycle.~There will be a single study group that will be used at the same time as your own control. On the second cycle of irinotecan, the patient receives acupuncture. There will be a single study group that will be used at the same time as your own control."
62547881|NCT02644473|EXPERIMENTAL|Tranexamic acid|Investigators will administer topical (1.5g) TXA during total knee arthroplasty and total hip arthroplasty
62547882|NCT02644473|PLACEBO_COMPARATOR|Control|
62547883|NCT04793594||Tele- Assessment Group|Balance Assessment
62547884|NCT04793594||Face To Face (Clinic) Group|Balance Assessment
62547885|NCT01584817|NO_INTERVENTION|normal education|patients in this arm was educated about bowel preparation on the day of reservation by nurse for 15 minutes and meanwhile a booklet was also sent to them.
62547886|NCT01584817|OTHER|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
62547887|NCT03062761|EXPERIMENTAL|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
62547888|NCT03062761|ACTIVE_COMPARATOR|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
62547889|NCT01917292|OTHER|Periodontal care|
62547890|NCT01917292|EXPERIMENTAL|One-Stage Full-Mouth Disinfection|
62547891|NCT04402840|EXPERIMENTAL|Stellate Ganglion Block (SGB)|Clinical Stellate ganglion block
62547892|NCT01998945|EXPERIMENTAL|Exposure-based Cognitive Behavioral Therapy (ET)|Participants will receive exposure-based cognitive behavioral therapy
61978183|NCT01930747|EXPERIMENTAL|deep neuromuscular block|deep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
62547893|NCT01998945|ACTIVE_COMPARATOR|Relaxation Training (RT)|Participants will receive relaxation training
62547894|NCT01335035|EXPERIMENTAL|ICL670|
62547895|NCT00202930|OTHER|Rituximab|Single Arm
62547896|NCT03469661||Immune Thrombocytopenia Diagnosis|
62547897|NCT03469661||Myelodysplastic Syndrome Diagnosis|
62547898|NCT04291625|OTHER|congenital ptosis|children who had congenital ptosis with levator function of 4mm or better, underwent levator muscle resection guided by intraoperative lagophthalmos formula.
62720081|NCT02312648|ACTIVE_COMPARATOR|Early mobilization Group|Patients will perform deep breaths (3 sets of 10 repetitions), once a day, for 30 minutes until 7th postoperative day. Non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.Early mobilization protocol consist of upper and lower (cycle ergometer) limb exercises, chair transfer, deambulation for 10 to 20 minutes, step exercise (six times).
62720082|NCT02312648|OTHER|Control Group - Respiratory exercise|Respiratory exercises with patient sitting in bed with a high headboard 45, the same breathing exercises will be held
61978184|NCT01930747|EXPERIMENTAL|inhalation with 1 MAC Sevoflurane|1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
62547899|NCT03474458|EXPERIMENTAL|Experimental intervention|doxycycline (100 mg bid)
62547900|NCT03474458|ACTIVE_COMPARATOR|Control intervention|Standard of care therapy
62547901|NCT04987476||ATRT|Children affected by an ATRT at time of surgical resection
62547902|NCT03776916|EXPERIMENTAL|Group 1|"Simethicone administration 20-30 min before the procedure:~Patients intake simethicone solution 20-30 min before the procedure."
62547903|NCT03776916|EXPERIMENTAL|Group 2|"Simethicone administration 31-60 min before the procedure:~Patients intake simethicone solution 31-60 min before the procedure."
62547904|NCT03776916|EXPERIMENTAL|Group 3|Simethicone administration \>60 min before the procedure; Patients intake simethicone solution \>60 min before the procedure.
62547905|NCT00129545|EXPERIMENTAL|WATCHMAN|Implant of WATCHMAN Left Atrial Appendage Closure Technology
62547906|NCT00129545|ACTIVE_COMPARATOR|Warfarin control|Subjects are treated with current standard of care Oral Anticoagulation Therapy with Warfarin
62547907|NCT00129545|OTHER|Roll-in|Implant of WATCHMAN Left Atrial Appendage Closure Technology. Up to 3 non-randomized subjects per site, these subjects were not included in the primary analysis.
62547908|NCT06443723|EXPERIMENTAL|cholecystectomy|Evaluation of hepatosteatosis by hepatobiliary ultrasonography in cholecystectomy patients. Height, hip, waist circumference, blood pressure measurement and hemogram, lipid parameters.
62720083|NCT02722408|EXPERIMENTAL|Gemcabene|Participants with homozygous familial hypercholesterolemia (HoFH) on stable lipid lowering therapy received 300 milligram (mg) of Gemcabene, orally once daily from day 1 to 28 followed by 600 mg of Gemcabene, orally once daily from day 29 to 56 followed by 900 mg of Gemcabene, orally once daily from day 57 to 84. Participants were followed until Day 112.
61978185|NCT01930747|EXPERIMENTAL|remifentanyl|remifentanyl infusion is given after first measurement of lap workspace
61978186|NCT01110707|EXPERIMENTAL|r-hFSH + r-hLH|
62547909|NCT06443723|EXPERIMENTAL|Control|Evaluation of hepatosteatosis by hepatobiliary ultrasonography in participants without cholecystectomy. Height, hip, waist circumference, blood pressure measurement and hemogram, lipid parameters.
62547910|NCT05950308||HC|Healthy control
62547911|NCT05950308||OFA|Received ofatumumab
62547912|NCT05950308||OCR|Received ocrelizumab
62547913|NCT05950308||S1P|Received sphingosine-1-phosphate receptor modulator
62547914|NCT01464632||Primary|Post Market Study
62547915|NCT04322058||Fathers or paternal caregivers to a child 0-18 years of age|Parenting and Healthy Relationship Education (10 Core 24/7 workshops covering- 15 hours of education), financial and economic mobility programming, comprehensive case management, and supplemental workshops utilizing the Within My Reach curriculum.
62547916|NCT04941326|ACTIVE_COMPARATOR|Spinal mobilization group|Spinal mobilization will be applied to the application group for 4 weeks in addition to the treatments applied to the sham group
62547917|NCT04941326|SHAM_COMPARATOR|Sham group|Diaphragmatic stimulation with proprioceptive neuromuscular facilitation techniques (PNF), diaphragmatic breathing techniques, costal mobilization treatments and sham mobilization will be applied to the sham group.
62547918|NCT03953326|EXPERIMENTAL|HeartPhone Intervention|Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.
62547919|NCT01155973|EXPERIMENTAL|EDUCORE intervention|Use of low risk SCORE table. Use of visual impact images. Handing the patient a pamphlet (advice on how to maintain cardiovascular health plus the low risk SCORE table with the patient's current score marked).
62547920|NCT01155973|ACTIVE_COMPARATOR|control group|Use of low risk SCORE table; verbally informing the patient of his/her CVR. Giving advice/verbal information on risk factors.
62547921|NCT01891383||History of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
62547922|NCT01891383||No history of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
62547923|NCT04387942|EXPERIMENTAL|Recombinant Human Interleukin-2|patients were treated with IL-2.
62547924|NCT04387942|NO_INTERVENTION|Traditional therapy|patients were treated with dipyridamole and/or glucocorticoid，immunosuppressor.
62547925|NCT00720382|EXPERIMENTAL|1|0.15% azelastine hydrochloride 1644 mcg
62547926|NCT00720382|EXPERIMENTAL|2|Mometasone furoate 200 mcg
62547927|NCT01165528|ACTIVE_COMPARATOR|Adaptive support ventilation in ARDS|patients of ARDS will be randomized to this arm to receive mechanical ventilation as per ASV protocol
62547928|NCT01165528|ACTIVE_COMPARATOR|conventional ventilation strategy in ARDS|
62547929|NCT04805515|EXPERIMENTAL|Nicotine Corrective Messages|Participants in the nicotine corrective messages condition will receive 8 brief nicotine corrective public education messages delivered online during 4 waves of the 12 week study. The messages will communicate misperceptions about nicotine's role in health harms as well as misperceptions that reduced nicotine content cigarettes are less harmful than tobacco cigarettes and that e-cigarettes contain less nicotine than tobacco cigarettes.
62547930|NCT04805515|NO_INTERVENTION|Delayed Message Control|Participants in the control condition will be exposed to the nicotine corrective messages after the completion of the final assessment at the end of the 12 week study.
62547931|NCT00817518|EXPERIMENTAL|1|
62547932|NCT00817518|EXPERIMENTAL|2|
62547933|NCT05242718|ACTIVE_COMPARATOR|N-Acetyl-L-cysteine (NAC)|600 mg 1 capsule twice daily for 14 days
61976629|NCT06185504|EXPERIMENTAL|the observation group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
61976630|NCT06185504|ACTIVE_COMPARATOR|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
62165913|NCT00027963|EXPERIMENTAL|gabapentin|"Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
62165914|NCT00027963|PLACEBO_COMPARATOR|placebo|"Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
62168131|NCT01403805|EXPERIMENTAL|Oral care and vaccines|Oral care and pneumococcal plus influenza vaccines
62547934|NCT05242718|ACTIVE_COMPARATOR|Echinacea purpurea|252 mg 1 capsule twice daily for 14 days
62547935|NCT05242718|ACTIVE_COMPARATOR|Curcumin|60 mg 3 capsules once daily for 14 days
62547936|NCT05242718|ACTIVE_COMPARATOR|Palmitoylethanolamide|400 mg 3 capsules once daily for 14 days
62547937|NCT06421025||Patients with polycythemia|Patients with polycythemia defined as hematocrit level greater than or equal to 49% in men and 48% in women, whatever the suspected etiology. Primitive and secondary polycythemia are eligible in this observational study. Patients should not have start any cytoreductive therapy prior inclusion.
62547938|NCT03098082|OTHER|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
62547939|NCT02083627|EXPERIMENTAL|1:Single rosuvastatin,multiple fidaxomicin,single rosuvastatin|
62547940|NCT02083627|EXPERIMENTAL|2:Multiple fidaxomicin,single rosuvastatin,single rosuvastatin|
62547941|NCT02049970|EXPERIMENTAL|dexmedetomidine and bupivacaine|Bupivacaine 50 mg and dexmedetomidine 1 microgram/kg
62547942|NCT02049970|EXPERIMENTAL|Bupivacaine and placebo|Bupivacaine 100 mg and SF 10 ml
62547943|NCT03933215||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any injectable DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
62547944|NCT05373199|EXPERIMENTAL|BC Combo THDB0207|Single administration of BC Combo THDB0207
62547945|NCT05373199|ACTIVE_COMPARATOR|Lantus®|Single administration of Lantus®
62547946|NCT05373199|ACTIVE_COMPARATOR|Humalog®|Single administration of Humalog®
62547947|NCT02203409||Laparoscopic ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
62547948|NCT01346293|EXPERIMENTAL|Study Group 1|Participants will receive concomitantly a dose of DTap-IPV, a dose of M-M-R®II, and a dose of VARIVAX® vaccine on Day 0
62547949|NCT01346293|EXPERIMENTAL|Study Group 2|Participants will receive concomitantly a dose of DAPTACEL®, a dose of IPOL®, a dose of M-M-R®II, and a dose of VARIVAX® vaccines on Day 0
62547950|NCT01346293|EXPERIMENTAL|Study Group 3|Participants will receive concomitantly a dose of DTap-IPV with or without a dose of M-M-R®II and a dose of VARIVAX® on Day 0
62547951|NCT01346293|EXPERIMENTAL|Study Group 4|Participants will receive concomitantly a dose of DAPTACEL® vaccine, a dose of IPOL® vaccine with or without a dose of M-M-R®II and a dose of VARIVAX® vaccines on Day 0
62547952|NCT05076461|EXPERIMENTAL|ondansetron group|Children in ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
62547953|NCT05076461|EXPERIMENTAL|Domperidone group|Children in domperidone group, oral suspension of domperidone was given as 0.5 mg per kg body weight
62547954|NCT00626119||Control|
62547955|NCT00626119||diseased|
62547956|NCT04844060||Patients with cognitive impairment|All patients with cognitive disorders observed at the memory center of Strasbourg and in whom a lumbar puncture is performed as part of the patient's diagnosis.
62547957|NCT05706857|EXPERIMENTAL|Ultra fast-track|Patients are extubated in the operating room after the procedure
62547958|NCT05706857|ACTIVE_COMPARATOR|Conventional extubation|Patients are extubated in the intensive unit care
62547959|NCT06353347|EXPERIMENTAL|HTD1801|Administered orally twice daily (BID)
62547960|NCT06353347|PLACEBO_COMPARATOR|Placebo|Administered orally BID
62547961|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
62547962|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
62547963|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
62547964|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
62547965|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
62547966|NCT01117571||open label|iUni® Unicompartmental Knee Resurfacing Device
62547967|NCT04428450|EXPERIMENTAL|Deprexis (unguided)|web-based self-help program without any support from a therapist during the 10-week treatment period
62547968|NCT04428450|EXPERIMENTAL|Deprexis (guided, with therapist)|web-based self-help program plus scheduled e-mail contact with a therapist during the 10-week treatment period
62547969|NCT04428450|NO_INTERVENTION|Wait-list|Wait-list group (subjects receive access to Deprexis after 10 weeks)
62547970|NCT04063085|EXPERIMENTAL|PROTAHERE group|The PROTAHERE group received intra-pelvic PROTAHERE Absorbable Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
62547971|NCT04063085|ACTIVE_COMPARATOR|Hyalobarrier group|The Hyalobarrier group received intra-pelvic Hyalobarrier Gel during the scheduled pelvic surgery and be followed for 24 months.
62547972|NCT04063085|SHAM_COMPARATOR|No treatment group|The no treatment group did not receive any anti-adhesion agent during the scheduled pelvic surgery and be followed for 24 months.
62547973|NCT04063085|ACTIVE_COMPARATOR|Seprafilm group|The Seprafilm group received intra-pelvic Seprafilm Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
62547974|NCT04063085|ACTIVE_COMPARATOR|Interceed group|The Interceed group received intra-pelvic Gynecare Interceed (TC7) Absorbale Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
62547975|NCT04905940|EXPERIMENTAL|Turmeric mouthwash|Evaluation of cost-effectiveness of turmeric mouthwash in controlling halitosis
62547976|NCT04905940|ACTIVE_COMPARATOR|Essential oil mouthwash|Evaluation of cost-effectiveness of essential oil mouthwash in controlling halitosis
62547977|NCT04905940|PLACEBO_COMPARATOR|Placebo mouthwash|Evaluation of cost-effectiveness of placebo mouthwash in controlling halitosis
62547978|NCT04979936|ACTIVE_COMPARATOR|early laparoscopic cholecystectomy|early laparoscopic cholecystectomy
62547979|NCT04979936|ACTIVE_COMPARATOR|percutaneous cholecystostomy|percutaneous cholecystostomy first followed by delayed laparoscopic cholecystectomy
62547980|NCT02074280|EXPERIMENTAL|high dose of rifaximin|rifaximin 600 mg, bid, orally, 2 weeks and conventional treatment
62547981|NCT02074280|EXPERIMENTAL|low dose of rifaximin|rifaximin 400 mg bid,orally, 2 weeks
62547982|NCT02074280|NO_INTERVENTION|control|conventional treatment
62547983|NCT03229200|EXPERIMENTAL|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
62547984|NCT02871492|EXPERIMENTAL|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
62547985|NCT02871492|PLACEBO_COMPARATOR|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
62547986|NCT02871492|ACTIVE_COMPARATOR|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
62547987|NCT01290159||post heat stroke heat tolerant|
62547988|NCT01290159||post heat stroke heat intolerant|
62547989|NCT01290159||healthy controls|
62547990|NCT05076448||1|Group 1.Gonadal veins resection This group includes patients who underwent open retroperitoneal resection of the gonadal veins, endoscopic transperitoneal and retroperitoneal resection of the gonadal veins.
62547991|NCT05076448||2|Group 2. Gonadal veins embolozation This group includes patients who underwent embolization of the gonadal veins with coils.
62547992|NCT05076448||3|Group 3. Stenting of the common iliac vein with or without gonadal veins embolization This group includes patients who underwent isolated iliac vein stenting or iliac vein stenting combined with gonadal vein embolization.
62547993|NCT02487225|EXPERIMENTAL|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
62547994|NCT02487225|PLACEBO_COMPARATOR|Placebo|Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
62547995|NCT00569855|EXPERIMENTAL|1|Receive phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery
62547996|NCT01161485|ACTIVE_COMPARATOR|HIV Testing and Counseling|HIV Testing and Counseling
62547997|NCT01161485|ACTIVE_COMPARATOR|Contingency Management (CM)|Contingency management is based on Skinner's principles of operant conditioning in behavioral psychology, dating back to the 1930s (Skinner 1938). The basis of this model is that behavior is learned and reinforced by environmental contingencies that reward or punish.
62547998|NCT01161485|EXPERIMENTAL|CM with Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community.
62547999|NCT02307773||Case Group|Treated with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope before intubation with conventional pharyngeal anesthesia
62548000|NCT02307773||Control Group|Treated with conventional pharyngeal anesthesia without further treatment.
62548001|NCT00394563|EXPERIMENTAL|1|monoclonal antibody
62548002|NCT00394563|EXPERIMENTAL|2|
62548003|NCT00394563|EXPERIMENTAL|3|
62548004|NCT00394563|EXPERIMENTAL|4|
62548005|NCT00394563|EXPERIMENTAL|5|
62548006|NCT00394563|PLACEBO_COMPARATOR|placebo|
62548007|NCT06630000|EXPERIMENTAL|FACT|Behavioral: Focused Acceptance and Commitment Therapy (FACT) FACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
62548008|NCT06630000|ACTIVE_COMPARATOR|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
62548009|NCT02452437|EXPERIMENTAL|control|Oxycodone will be administered and subjects will undergo hemodialysis
62548010|NCT02452437|EXPERIMENTAL|hemodialysis|Oxycodone will be administered and subjects will undergo hemodialysis
62548011|NCT02657928|EXPERIMENTAL|Treatment (ribociclib and letrozole)|Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62548012|NCT02541968|ACTIVE_COMPARATOR|Face-to-face CBT|16 sessions of individual CBT delivered in 14 weeks.
62548013|NCT02541968|EXPERIMENTAL|Internet-based CBT|Internet-based CBT (ICBT) with therapist support (14 weeks).
62548014|NCT02541968|EXPERIMENTAL|ICBT without therapist support|Internet-based CBT without therapist support (14 weeks).
61976631|NCT02184689|EXPERIMENTAL|Fexinidazole|
62168132|NCT01403805|ACTIVE_COMPARATOR|Vaccine|Influenza vaccine only
61976632|NCT05266742|EXPERIMENTAL|END|Use of web based education
61976633|NCT05266742|NO_INTERVENTION|END free|patient witout of web based education
62548015|NCT03600987|EXPERIMENTAL|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
62548016|NCT02060565||Chronic liver disease|all patients with chronic liver disease followed using non-invasive methods
61976634|NCT01819077||TMMR|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE
61976635|NCT06522048||Non-immune checkpoint inhibitor (non-ICI) drugs group|Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) induced by non-immune checkpoint inhibitor (non-ICI) drugs
62548017|NCT03545204|OTHER|Intervention Clusters|Community based Kangaroo Mother Care,KMC package in low birth weight infants of randomly selected union councils.
62548018|NCT03545204|OTHER|Control clusters|Essential newborn and routine standard care in low birth weight infants of randomly selected union councils.
62548019|NCT03870165|ACTIVE_COMPARATOR|Salmon|After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
62548020|NCT03870165|EXPERIMENTAL|Isolated mixture|After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
62548021|NCT03405922|PLACEBO_COMPARATOR|Placebo|Placebo 40 mL Saline 0.9%
62548022|NCT03405922|ACTIVE_COMPARATOR|Ropivacain|40 mL Ropivacain 0.5%
62548023|NCT02075515|EXPERIMENTAL|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
62548024|NCT02075515|EXPERIMENTAL|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
62548025|NCT02075515|EXPERIMENTAL|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
62548026|NCT03353012|EXPERIMENTAL|Levonorgestrel immediate post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 48-72 hr after child delivery
62548027|NCT03353012|EXPERIMENTAL|Etonogestrel immediate post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 48-72 hr after child delivery
62548028|NCT03353012|ACTIVE_COMPARATOR|Levonorgestrel delayed post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 5-7 weeks after child delivery
62548029|NCT03353012|ACTIVE_COMPARATOR|Etonogestrel delayed post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 5-7 weeks after child delivery
62548030|NCT06072573|EXPERIMENTAL|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
62548031|NCT06072573|PLACEBO_COMPARATOR|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
62548032|NCT02765425|EXPERIMENTAL|Training Group|Subjects will receive the same outcome measures at baseline, after 3 months training and 6 months later. Intervention will comprise of three sessions seated at the AMES device. Each training session will include 15 min of training of each ankle. Training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
62548033|NCT02765425|NO_INTERVENTION|Control Group|Subjects will receive no intervention. Subjects will receive all outcome measures at baseline and at 3 months post enrollment. Subjects will also receive a fall-incidence reporting form 9 months post enrollment. No other intervention - i.e. no treatment - is given.
62548034|NCT03758716|EXPERIMENTAL|FB825|Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.
62548035|NCT06632704||Adults aged 18-70 yrs, if applicable, primary caregiver|The study population will consist of 26 participants, aged 18-70 years old and of record at Penn Dental Medicine.
62548036|NCT04412278||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
62548037|NCT03846193|EXPERIMENTAL|GT005 Dose 1|A single dose of GT005 will be administered via subretinal injection
62548038|NCT03846193|EXPERIMENTAL|GT005 Dose 2|A single dose of GT005 will be administered via subretinal injection
62548039|NCT03846193|EXPERIMENTAL|GT005 Dose 3|A single dose of GT005 will be administered via subretinal injection
62548040|NCT03846193|EXPERIMENTAL|GT005 Dose 1, 2 or 3|A single dose of GT005 will be administered via subretinal injection. This dose will be determined by dose levels determined to be tolerable in Arms 1,2 and 3
62548041|NCT03846193|EXPERIMENTAL|GT005 Dose 2 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
62548042|NCT03846193|EXPERIMENTAL|GT005 Dose 3 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
62548043|NCT03846193|EXPERIMENTAL|GT005 Dose 3 with Orbit Subretinal Delivery Sysem|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
62548044|NCT05494476|ACTIVE_COMPARATOR|2mm under bone level|implant platform will be submerged 2mm under bone level
62548045|NCT05494476|ACTIVE_COMPARATOR|1mm under bone level|implant platform will be submerged 1mm under bone level
62548046|NCT01119365|EXPERIMENTAL|Light|Sequence of bright light flashes of varying durations, interflash intervals, flash lengths, flash brightness, and flash color.
62548047|NCT05397678|EXPERIMENTAL|BCG-Denmark|Infants randomized to receive BCG-Denmark at discharge from the Maternity Ward will receive one 0.05 ml infant dose of Mycobacterium bovis BCG live-attenuated BCG-AJ vaccine by intradermal injection in the left deltoid region. Dependent on national supply, oral polio vaccine will be co-administered.
62548048|NCT05397678|ACTIVE_COMPARATOR|BCG-Bulgaria|Infants randomized to receive BCG-Bulgaria at discharge from the Maternity Ward will receive one 0.05 ml infant dose of Mycobacterium bovis BCG live-attenuated BCG-Bulgaria vaccine by intradermal injection in the left deltoid region. Dependent on national supply, oral polio vaccine will be co-administered.
62548049|NCT03994822|EXPERIMENTAL|pRESET Thrombectomy Device|Mechanical Thrombectomy using the pRESET Thrombectomy Device
62548050|NCT03994822|ACTIVE_COMPARATOR|Solitaire Revascularization Device|Mechanical Thrombectomy using the Solitaire Revascularization Device
62548051|NCT00853099|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
62548052|NCT00853099|EXPERIMENTAL|Adalimumab 80 mg/40 mg|Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
62548053|NCT00853099|EXPERIMENTAL|Adalimumab 160 mg/80 mg|Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
62548054|NCT00682474|EXPERIMENTAL|CI|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
62548055|NCT00682474|ACTIVE_COMPARATOR|II|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
62548056|NCT03921593||Simultaneous Pancreas Kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Simultaneous Pancreas Kidney Transplant (SPK)
62548057|NCT03921593||Pancreas after kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Pancreas after kidney Transplant (PAK)
62548058|NCT03921593||Pancreas Transplant Alone Recipients|Patient affected by Insulin Dependent Diabetes Mellitus with hypoglycemia unawareness undergoing Pancreas Transplant Alone (PTA)
62720084|NCT04362007|EXPERIMENTAL|Phase 1 dose-escalation part|Subjects with r/r PTCL and r/r CTCL will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, \[7 days on/ 7 days off\] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RD is determined.
62720085|NCT04362007|EXPERIMENTAL|Phase 1 ATLL expansion part|Subjects with r/r ATLL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
62548059|NCT04309617||patients with Renal Cell Carcinoma(RCC)|Patients diagnosed with RCC who received a nephrectomy between 01Apr2014 and 31Mar2019
62548060|NCT00658047|EXPERIMENTAL|0.25 mg CH-1504|0.25 mg CH-1504
62548061|NCT00658047|EXPERIMENTAL|0.5 mg CH-1504|0.5 mg CH-1504
62548062|NCT00658047|EXPERIMENTAL|1.0 mg CH-1504|1.0 mg CH-1504
62548063|NCT00658047|ACTIVE_COMPARATOR|Methotrexate|Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks
62548064|NCT01209091||No treatment|
62548065|NCT05534061|EXPERIMENTAL|Connect2Test Intervention + Contingency Management|$10 financial incentive for vaccination and $10 financial incentive for testing plus a brief feedback-based motivational enhancement intervention.
62548066|NCT05534061|ACTIVE_COMPARATOR|Contingency Management Alone|$10 financial incentive for vaccination and $10 financial incentive for testing.
62548067|NCT02006602|EXPERIMENTAL|Arm 1 reference then test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
62548068|NCT02006602|EXPERIMENTAL|Arm 2 test then reference|Subjects will receive the following two treatments administered orally in a fasting state: A= Single dose of candesartan cilexetil (Test formulation) 16mg. B=Single dose of candesartan cilexetil (Reference treatment) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
62548069|NCT05147012||control group|
62548070|NCT05147012||focus group|
62548071|NCT02468050|EXPERIMENTAL|Self Management|In addition to the weekly supervised exercise session, participants in this arm will view an instructional video. The video will deliver theory driven training of cognitive behavioural strategies for self management of exercise. It is expected that this will improve adherence to the exercise program.
62548072|NCT02468050|EXPERIMENTAL|Exercise|Personalized 6 week moderate intensity (50 - 75% of heart rate reserve) facility and home based exercise program including cardiovascular and muscular conditioning.
62548073|NCT02468050|NO_INTERVENTION|Prospective Cohort Control|Eligible, consented participants who are unable to attend the weekly exercise sessions will serve as a cohort control group. Participants will be asked to complete patient reported measures of anxiety, depression, and exercise behaviour within 3 days of biopsy, and 6 weeks post biopsy.
62548074|NCT04959773||COVID+ with exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection.~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.~general conditions."
62548075|NCT04959773||COVID+ without exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life.~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion."
62548076|NCT04959773||Control healthy subjects (CTRL)|Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)). The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.
62548077|NCT04935684|EXPERIMENTAL|Group 1: Fecal Microbiota Transplantation (FMT)|"Patients randomized in the FMT group will received FMT. FMT product will be made by the the pharmacy of the Clermont-Ferrand University Hospital from stools of healthy volunteer donors within 6 hours after defecation in order to preserve the viability of the bacteria. The preparation will be standardized: 50g aliquots will be prepared and diluted in 250mL of 0.9% NaCl containing 10% glycerol, until a homogeneous suspension is obtained. The preparation will be rapidly frozen at -80°C until use, with a maximum shelf life of 18 months."
62548078|NCT04935684|NO_INTERVENTION|Group 2: no intervention|"The comparator group will be constituted by patients randomized in the no FMT group. For ethical reasons, these patients will not receive any FMT and therefore no enema or colic preparation. No placebo will be administered. Prophylactic anti-infective treatments can be introduced at any time."
62548079|NCT05153525|EXPERIMENTAL|Intermittent boluses group|Thirty children with ARDS will be managed with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
62548080|NCT05153525|EXPERIMENTAL|Intravenous infusion for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
62548081|NCT00995176||1|Women residing in areas from defined geographic areas with high HIV prevalence and poverty
62548082|NCT00995176||2|Men residing in areas from defined geographic areas with high HIV prevalence and poverty
62548083|NCT02698111|EXPERIMENTAL|Donafeinib|donafenib 200mg,bid
62548084|NCT01959373|EXPERIMENTAL|patients|
62548085|NCT01959373|EXPERIMENTAL|healthy volunteers|
62548086|NCT02051712|NO_INTERVENTION|Usual care|Usual car accruing to guidelines
62548087|NCT02051712|EXPERIMENTAL|Individualized training|Individualized exercise training program in addition to usual care
62548088|NCT02051712|EXPERIMENTAL|Individualized training plus adherence measures|Individualized exercise training plus measures to increase adherence
61976636|NCT06522048||Immune checkpoint inhibitor (ICIs) group|Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) induced by immune checkpoint inhibitor (ICIs)
62548089|NCT01447043||Group 1|
62548090|NCT04546724|ACTIVE_COMPARATOR|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
62548091|NCT04546724|PLACEBO_COMPARATOR|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
62548092|NCT04439201|EXPERIMENTAL|Treatment (palbociclib)|Patients receive palbociclib PO QD days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
62548093|NCT05860855|ACTIVE_COMPARATOR|Decompressive hemicraniectomy|The procedure of hemicraniectomy is performed in the same way as the augmentative craniotomy from skin incision to dural augmentation. Then, the myo-cutaneous flaps are reapproximated and sealed and the operculum is secured. Then, cranioplasty with autologous bone will be performed within 6-months after the hemicraniectomy.
61976637|NCT00277888|EXPERIMENTAL|Femoral route|
62548094|NCT05860855|EXPERIMENTAL|Augmentative craniotomy|"Surgical incision according to Kempe is performed to obtain a better vascularization of the myo-cutaneous flap, to guarantee a larger surgical exposition and to facilitate the closure. The incision starts from widow's peak and arrives 1 cm upon the inion and it is performed parallel to the midline, 3 cm from it. Then a second incision is performed from the center of the first one and it will be extended inferiorly to the tragus. Burr holes will be performed in the frontal-basal region (keyhole), temporal region and superior and medial to the inion. Supplementary burr holes can be performed. Then, a large frontal-temporal-parietal-occipital craniotomy not smaller than 12x15 cm is performed. Then dural augmentation is performed with the positioning of a dural patch. The operculum is repositioned through the application of 5 titanium clamps secured with screws 1 cm above the margin of the craniotomy. The myo-cutaneous flaps are reapproximated and sealed."
62548095|NCT06551415|ACTIVE_COMPARATOR|Dabigatran|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
62548096|NCT06551415|ACTIVE_COMPARATOR|apixaban|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
62548097|NCT03456505|EXPERIMENTAL|Mindfulness|Participants randomly assigned to the mindfulness meditation condition will meet for five, 15-minute sessions, in which they will receive training in basic mindfulness skills (Wallace, 2006).
62548098|NCT03456505|ACTIVE_COMPARATOR|Active Listening|Participants randomly assigned to the active listening condition will meet for five, 15-minute sessions, in which they will listen to Gilbert White's The Natural History of Selborne.
62548099|NCT00796757|EXPERIMENTAL|1|
62548100|NCT04825340|EXPERIMENTAL|Study vaccine|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
62720086|NCT04362007|EXPERIMENTAL|Phase 2|Subjects with r/r PTCL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
62720087|NCT02170844|EXPERIMENTAL|BIBR 1048 MS (Japanese)|Japanese subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
62720088|NCT02170844|PLACEBO_COMPARATOR|BIBR 1048 MS Placebo (Japanese)|Japanese subjects will receive placebo of BIBR 1048 MS
62720089|NCT02170844|EXPERIMENTAL|BIBR 1048 MS (Caucasian)|Caucasian subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
62720090|NCT02170844|PLACEBO_COMPARATOR|BIBR 1048 MS Placebo (Caucasian)|Japanese subjects will receive placebo of BIBR 1048 MS
62720091|NCT00175929|PLACEBO_COMPARATOR|Placebo|Matching placebo tablets administered twice a day
62720092|NCT00175929|EXPERIMENTAL|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
62720093|NCT00175929|EXPERIMENTAL|Brivaracetam 150 mg/day|Brivaracetam 150 mg/day, 75 mg administered twice a day
62720094|NCT04941105|EXPERIMENTAL|PCSK9 inhibitor (evolocumab)|140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations
62720095|NCT04941105|PLACEBO_COMPARATOR|Usual Care|1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2.
62720096|NCT03678350|EXPERIMENTAL|Treatment (porfimer sodium, IO-PDT)|Participants receive porfimer sodium IV over 3-5 minutes and receive IO-PDT via a light dosimetry system 24-48 hours later.
62720097|NCT05705479|EXPERIMENTAL|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
62720098|NCT05705479|EXPERIMENTAL|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
62720099|NCT03262805|PLACEBO_COMPARATOR|Placebo|Placebo
62720100|NCT03262805|ACTIVE_COMPARATOR|Active|Lanconone(R)
62720101|NCT03815747|EXPERIMENTAL|Treatment Group|Treatment with the investigational device - High- Intensity Focused Electromagnetic (HIFEM) Field Device
62737159|NCT02435667|EXPERIMENTAL|Resistance Exercise Training|Entails 36 supervised resistance exercise training sessions (3 sessions per week for 12 weeks). Each exercise session will be supervised by a trained, certified Exercise Physiologist specializing in Cardiac Rehabilitation. The specific resistance exercise training will include Aerobic Exercise, Resistance Exercise, and Core Strengthening Exercises. Other baseline and follow-up tests include: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
61976638|NCT00277888|EXPERIMENTAL|Jugular route|
61976639|NCT03202797||Patients|
62548101|NCT04825340|PLACEBO_COMPARATOR|Placebo|commercial normal saline
62548102|NCT01351571||Cohort|
62548103|NCT04936399||Cohort 1|Participants with Squamous Cell Oesophageal Carcinoma Receiving Nivolumab
62548104|NCT03513094|EXPERIMENTAL|Without and With Transversus Abdominis|"Without:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, without transversus abdominis contraction.~With:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, with 50% MVIC transversus abdominis contraction."
62548105|NCT04843696|EXPERIMENTAL|NPV group|"The hospital-based maintenance NPV program includes NPV support, breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice. The patients in the NPV group undergo the hospital-based NPV once per week in the maintenance program at least three times per month.~The patients received NPV with breathing training via a cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy) for 60 min, once per week.~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
62548106|NCT04843696|ACTIVE_COMPARATOR|Control group|"Control group receives breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice.~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
62548107|NCT03097991|EXPERIMENTAL|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
62548108|NCT03097991|NO_INTERVENTION|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
62548109|NCT03763474|EXPERIMENTAL|Euglyca|Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
62548110|NCT03763474|NO_INTERVENTION|Control|
62548111|NCT05603403|EXPERIMENTAL|Probiatop|"Probiotic used in the reconstitution and rebalancing of the intestinal microbiota.~Association of probiotic strains containing 1 g/sachet of 1 x 109 Bifidobacterium lactis HN019, 1 x 109 Lactobacillus acidophilus, 1 x 109 Lactobacillus rhamnosus HN001 / Lacticaseibacillus rhamnosus HN001 and 1 x 109 Lactobacillus paracasei Lpc- 37 / Lacticaseibacillus paracasei Lpc-37."
62548112|NCT05603403|PLACEBO_COMPARATOR|Hydrolized collagen|Hydrolyzed collagen is approved by Agência Nacional de Vigilância Sanitária (ANVISA) including for use in infants (ANVISA, IN NO. 28, OF JULY 26, 2018). Its use as a placebo is convenient, as it dissolves well in water, and promotes good masking. Based on literature surveys on hydrolyzed collagen and the intestinal microbiota, it was verified that the dose used (1 g) would not promote relevant functional impact in the context of the habitual Brazilian people diet.
62548113|NCT01691235||Arm 1|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
62720102|NCT04256239|EXPERIMENTAL|Dignity Therapy Group|"Dignity Therapy is a short-term psychotherapy aimed at improving patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress. Therapy sessions, lasting between 20 and 60 minutes, were offered at the patients' bedside and audiotaped, and were conducted by a trained psyco-oncologist. After each therapy session, the audiotaped interview data were transcribed verbatim by a different psycho-oncologist and edited and reshaped into a written narrative by an expert in DT over the course of the next two to three days. Once the editing process was completed, another session was held to allow the therapist to read the generativity document to the patient and to make any editorial changes the patient deemed necessary. The final version of the generativity document was given to the patient to bequeath it to individuals of their choosing"
62165915|NCT04301063||RV3278A arm|"study product RV3278A is applied twice a day on the face during the whole study.~In case of reaction resulting from the use of the product, the subject will inform the investigator who will explain to him/her what to do : application reduction or stop applications for a while"
62165916|NCT05043428|EXPERIMENTAL|Intervention Group|Those randomized to the intervention group will be asked to attend 16 online sessions (2 session/week). Each session will last one hour (total time: 16 hours. The exercise portion will be approximately 30 minutes of each session and led by a certified kinesiologist. These exercises are based on activities related to your daily life. As well, they will take part in peer support sessions. The peer support session will be approximately 30 minutes and be moderated by a behaviour change specialist who will also provide strategies to be active. In this peer support group, particpants will share and learn from other individuals living with COPD to help you stay active during and after the intervention. The online sessions will be video recorded to make sure that the program is delivered as designed.
62165917|NCT05043428|ACTIVE_COMPARATOR|Control Group|Those randomized to the control group will be asked to participate in an 8-week exercise program based on the exercise component of a standard home-based pulmonary rehabilitation program. During week 1 of the program, participants will receive a videocall via Microsoft Teams from the certified kinesiologist who will prescribe an exercise program, supervise the first exercise session, and provide a copy of Living Well with COPD, a list of strength exercises, and a home exercise diary. In weeks 2-8, participant exercises will be performed offline, on their own. Participants will be encouraged to engage in two or more exercise sessions per week, targeting both aerobic capacity and muscular strength, and document their exercise using a home diary. They will also receive a phone call once a week from the certified kinesiologist to discuss their exercise progress.
62165918|NCT02973945|EXPERIMENTAL|High Flow Nasal Cannula|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through High Flow Nasal Cannula (HFNC) while they are training aerobic capacity on the treadmill.
62165919|NCT02973945|ACTIVE_COMPARATOR|The Venturi Mask|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through The Venturi Mask (VM) while they are training aerobic capacity on the treadmill.
62548114|NCT01691235||Arm 2|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
62548115|NCT02503787|OTHER|Open label treatment|Spinal Cord Stimulation (SCS)
62548116|NCT04947917|EXPERIMENTAL|Lymph Node SpotTM Tattoo|"Spot™ ink tattooing will be administered once prior to surgery.~Initial test set of participants with previous sampled lymph nodes positive for metastasis will have SpotTM ink administered at time of standard of care pre-surgery radioseed localization.~A feasibility set of participants will have SpotTM ink administered at time standard of care lymph nodes sampling."
62548117|NCT03423940|EXPERIMENTAL|Evaluation of Treatment Dosage|In Arm 1, we will examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each participant's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across participants, but each individual will receive treatment at each duration. Resurgence will be tested following each treatment duration.
62548118|NCT03423940|EXPERIMENTAL|Evaluation of Size of Decrease in Alternative Reinforcement|In Arm 2, we will evaluate whether smaller, rather than larger, decreases in the availability of alternative reinforcement decreases the magnitude of resurgence. Investigators will counterbalance the order of differently sized decreases in alternative reinforcement with half of the participants in Arm 2 to determine whether the order of such decreases also affects resurgence magnitude.
62548119|NCT03234504||Normal healthy volunteers|
62548120|NCT05432635|EXPERIMENTAL|Treatment (CMV-specific CD19-CAR T cells, triplex vaccine)|"CONDITIONING REGIMEN: Patients receive standard conditioning regimen (typically carmustine, etoposide, cytarabine, melphalan) beginning approximately on day -9 in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION: Patients undergo autoHSCT on day -2.~CAR T-CELLS AND VACCINATION: Patients receive CMV-specific CD19-CAR T cells IV on day 0 and CMV-MVA triplex vaccine IM on days 28 and 56 in the absence of disease progression or unacceptable toxicity."
62548121|NCT06256523|EXPERIMENTAL|GZR18|GZR18 injection s.c.
62548122|NCT06256523|PLACEBO_COMPARATOR|Placebo|Placebo injection s.c.
62548123|NCT05935202|EXPERIMENTAL|Mitapivat|"subjects who enter the Dose Escalation Period will receive an initial dose of 50 mg mitapivat BID. After 4 weeks dose will be increased from 50 mg BID to 100 mg BID unless dose-limiting side effects have occurred or maximum allowed Hb levels have been reached. Subjects who safely tolerate mitapivat may be eligible to continue in two consecutive 24-week Fixed Dose Periods, allowing patients to remain on their tolerated dose of mitapivat for up to 48 weeks after dose escalation. During the Fixed Dose Periods, the dose may not exceed the maximum dose that was used during Dose Escalation Period.~8 weeks: Dose Escalation Period 24-week: Fixed Dose Period 1 24-week: Fixed Dose Period 2"
62548124|NCT03983915|EXPERIMENTAL|Group DR|Patients sedated with dexmedetomidine and remifentanil.
62548125|NCT03983915|EXPERIMENTAL|Group LMA|General anesthesia was applied using laryngeal mask.
62548126|NCT00426439|EXPERIMENTAL|1 Coartem|Treatment of documented malaria in children following the dosages recommended by the manufacturer.
62548127|NCT00426439|ACTIVE_COMPARATOR|2 Chloroquine|The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
62548128|NCT05462197|EXPERIMENTAL|Qigong Wuqinxi group|The Wuqinxi version adopted by this research is the Health Qigong Wuqinxi newly compiled in mainland China in 2003. There are only 10 movements in total. It is practiced three times a week for 3 months, including group practice once a week, 50 minutes each time, and the other two times of independent practice, the same 50 minutes each time, and the practice form must be filled out.
62548129|NCT05462197|NO_INTERVENTION|control group|The control group was carried out according to the original daily activities without any intervention activities
62548130|NCT02004015|EXPERIMENTAL|Atracurium|injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use
62548131|NCT02004015|EXPERIMENTAL|ROCURONIUM|injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus
62548132|NCT02004015|PLACEBO_COMPARATOR|placebo|injection of placebo Injection in Intravenous bolus use
62548133|NCT02186444||PHI Navigator|Personalized Health Information Navigator (PHIN).
62548134|NCT02186444||NCI Information Booklets (IB)|National Cancer Institute (NCI) Information Booklets (IB).
62548135|NCT02084160||CLD from HIS-EX-408/PLT-BID-1108|"Chronic liver disease subjects from previous Exalenz trial HIS-EX-408 and PLT-BID1108"
62548136|NCT01948531|EXPERIMENTAL|Gynomunal® gel|The study will be conducted on 33 healthy volunteers of female sex aged between 35 and 65 years old; each subject will apply a fixed quantity of the Gynomunal gel on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage.
62548137|NCT02420912|EXPERIMENTAL|Cohort I (nivolumab, ibrutinib) Chronic Lymphocytic Leukemia (CLL)|Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62548138|NCT02420912|EXPERIMENTAL|Cohort II (nivolumab, previous ibrutinib) Chronic Lymphocytic Leukemia (CLL)|Patients receive nivolumab as in Cohort I and continue previous ibrutinib treatment.
62548139|NCT02420912|EXPERIMENTAL|Cohort III (nivolumab, ibrutinib) Richters Transformation (RT)|Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
62720103|NCT04256239|NO_INTERVENTION|Control Group (Standard Palliative Care)|Standard Palliative Care was performed by a multidisciplinary care team composed of a palliative doctor, a psycho-oncologist, a nurse, a physiotherapist, a healthcare assistant, a social assistant, a volunteer and a spiritual assistant, tailoring care to the needs of patients and their families.
62720104|NCT06505746||LA/mUC patients|LA/mUC patient record-based survey of medical oncologists and urologists in Saudi Arabia and South Korea.
62548140|NCT05101343|NO_INTERVENTION|Control|Uses Fitbit, does not participate in breathing meditation.
62720105|NCT05232656|NO_INTERVENTION|Pre-intervention|"Usual care on three general medicine units.~Patients/caregivers do no have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
62548141|NCT05101343|EXPERIMENTAL|Meditation|Uses Fitbit and participates in brief, daily breathing meditation.
62548142|NCT02368314|EXPERIMENTAL|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
62548143|NCT02368314|ACTIVE_COMPARATOR|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
62548144|NCT04060186|ACTIVE_COMPARATOR|Balloninflation Group|Patient who will perform a balloninflation after operation
62548145|NCT04060186|SHAM_COMPARATOR|Conservative Group|Patient without performing a balloninflation
62548146|NCT02693860|EXPERIMENTAL|huJ591 followed by 89Zr-J591|Subjects will receive two infusions of unlabeled huJ591 on days 1 and 15 (+/- 1 day). 89Zr-J591 will be administered on day 22 (+/- 1 day) and 5-8 days later. PET/CT will be performed followed by repeat imaging of the prostate. Radical prostatectomy with or without lymph node dissection is performed 2 to 4 weeks after the second dose of J591.
62548147|NCT03068039|ACTIVE_COMPARATOR|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
62548148|NCT03068039|ACTIVE_COMPARATOR|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
62548149|NCT03622424|ACTIVE_COMPARATOR|Gelesis200|Subjects on this ARM will receive Gelesis200
62548150|NCT03622424|PLACEBO_COMPARATOR|Placebo|Subjects on this ARM will receive a placebo device
62548151|NCT03622424|ACTIVE_COMPARATOR|Gelesis200 and Placebo|Subejcts on this ARM will receive both Gelesis200 and placebo.
62548152|NCT02490280|EXPERIMENTAL|Trier Social Stress Test|Participants will be administered the Trier Social Stress Test (TSST). The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
62548153|NCT03077139|EXPERIMENTAL|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
62548154|NCT00616421|EXPERIMENTAL|MenACWY-CRM (1 dose)|1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
62548155|NCT00616421|ACTIVE_COMPARATOR|Licensed polysaccharide vaccine|1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
62548156|NCT00616421|EXPERIMENTAL|MenACWY-CRM (2 doses)|2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.
62548157|NCT04410614|EXPERIMENTAL|Free epithelial graft|Free epithelial graft at implant and teeth sites to increase the band of keratinized mucosa
62548158|NCT03791047|EXPERIMENTAL|Experimental Group: Balance analysis|Sixty older subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
62548159|NCT03791047|ACTIVE_COMPARATOR|Control Group:Balance Analysis|Sixty young subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
62548160|NCT00805675|EXPERIMENTAL|Telbivudine 600 mg monotherapy|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
62548161|NCT00805675|ACTIVE_COMPARATOR|Tenofovir disproxil fumarate 300 mg monotherapy|All patients in this arm were randomized to receive Tenofovir disoproxil fumarate 300 mg(equivalent to tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
62548162|NCT00805675|ACTIVE_COMPARATOR|Telbivudine 600 mg and Tenofovir 300 mg|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD and Tenofovir (TDF) 300 mg (equivalent to Tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
62548163|NCT06341205|ACTIVE_COMPARATOR|Standard-of-care|rituximab treatment 1gram x 2 (day-0, day-15)
62548164|NCT06341205|EXPERIMENTAL|Personalised treatment|"personalized treatment based on the algorithm for assessing the risk of having undetectable rituximab level after 3 months:~* Patients with a risk between 0 and 50% will receive 1gram x2 (day-0, day-15)~* Patients with a risk between 51 and 75% will receive 1gram x 3 (day-0, day-15, day-30)~* Patients with a risk between 76 and 100% will receive 1gram x 4 (day-0, day-15, day-30, day-45)"
62548165|NCT05949697|OTHER|Dry Eye Drink|
62548166|NCT03323242|NO_INTERVENTION|Control group|Recipient hepatectomy using conventional bipolar coagulation devices, surgical suture ligatures, and surgical clips (or any dissecting / coagulating device other than LS)
62548167|NCT03323242|EXPERIMENTAL|LS group|Recipient hepatectomy applying LigaSure.
62548168|NCT03323242|EXPERIMENTAL|USD group|Recipient hepatectomy applying Harmonic Ultrasonic dissector.
62548169|NCT02829476|EXPERIMENTAL|patients with AIS|Patients will have 'Osteoblast sample'
62548170|NCT02829476|EXPERIMENTAL|control patients|
62548171|NCT05805410|EXPERIMENTAL|Robotic hippotherapy|For the robotic training group, each subject will be trained for 40 minutes. Specifically, each participant will sit astride on a robotic horse with the force perturbation will be applied in the anterior-posterior direction and up/down direction.
62548172|NCT05805410|ACTIVE_COMPARATOR|Conventional physical therapy|For the conventional physical therapy group, each subject will be trained for 40 minutes, which will include 10 minutes of stretching, followed by 10 minutes of sitting and 10 minutes of standing balance training, and 10 minutes of treadmill walking.
62720106|NCT05232656|EXPERIMENTAL|Post-intervention|Patients/caregivers have access to the pre-discharge preparation checklist. Providers have access to patient safety dashboard.
62548173|NCT03924687|EXPERIMENTAL|ACT group|ACT group: participants receiving the 8-week bibliotherapy intervention based on Acceptance and Commitment Therapy
62548174|NCT03924687|NO_INTERVENTION|control group|Wait-list control condition: participants placed on a wait-list (and receiving the intervention following the 9 week duration of the intervention)
62548175|NCT02897518|EXPERIMENTAL|endotracheal intubation with Imago V-blade|Patients in this arm will receive endotracheal intubation with the Imago V-Blade videolaryngoscopes.
62548176|NCT02897518|ACTIVE_COMPARATOR|endotracheal intubation with Glidescope|Patients in this arm will receive endotracheal intubation with the glidescope videolaryngoscopes.
62548177|NCT04098510|EXPERIMENTAL|MitoQ|Subjects ingest 160 mg of MitoQ
62548178|NCT05581381|EXPERIMENTAL|Interventional empathy training program|Provide empathy training for the experimental group for a total of 8 weeks (1 time a week, 1 hour each time).In the 8th week, both the experimental group and the control group must fill in the ECRS Empathy Scale; the experimental group must fill in the Learning Satisfaction Scale
62548179|NCT05581381|NO_INTERVENTION|No intervention empathy training program|The control group did not offer empathy training.In the 8th week, both the experimental group and the control group must fill in the ECRS Empathy Scale.
62548180|NCT04860674|EXPERIMENTAL|PD-1+ICE|PD-1 inhibitor combined with icyclophosphamide, carboplatin, etoposide chemotherapy
62548181|NCT04871256|EXPERIMENTAL|Inver|"Intervention: after screening, patient´s obstruction will be evaluated by anterior rhinomanometry (RNMa), and quality of life wil be scored through ESPRINT scale. ESPRINT is a validated Spanish questionnaire about daily life activity, sleep, psychology and perception of affection by allergic rhinitis.~Symptoms will be evaluated with visual analogue scale (VAS) and clinical history. Symptoms like sneezing, itchy nose, ocular symptoms and/or nasal obstruction. Also medication (intranasal corticosteroid, antileukotrienes, antihistamine eye drops, antihistamine) frequency use will be registered"
62548182|NCT01786889|EXPERIMENTAL|Patient with angiosarcoma of the liver|Blood and urine collections, questionnaire and telephone interview
62548183|NCT05921474||Patients with Unbiopsied, Presumed Stage I/IIA NSCLC Undergoing SABR|The first cohort will be comprised of patients with suspected stage I/IIA NSCLC with plans to undergo curative SABR.
62720107|NCT01111162|EXPERIMENTAL|Vaccine|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
62720108|NCT01107639|EXPERIMENTAL|Additional immunotherapy (cetuximab)|All patients in the experimental arm will be given additional immunotherapy (cetuximab) during cycles 1 and 2, during RT and after surgery.
62165920|NCT00647985|EXPERIMENTAL|1|Fexofenadine Tablets 180 mg
62165921|NCT00647985|ACTIVE_COMPARATOR|2|Allegra® Tablets 180 mg
62165922|NCT02682849||Retrospective cohort|
62165923|NCT02682849||Prospective PleuralFlow cohort|
62165924|NCT03480737|EXPERIMENTAL|10 Hz rTMS|
62548184|NCT05921474||Patients with Stage I-IIA NSCLC Undergoing SABR|The second cohort will be comprised of patients with biopsy proven NSCLC, with clinically staged I/IIA disease with a plan to undergo definitive therapy with SABR.
62548185|NCT02404766|EXPERIMENTAL|Intervention group|C0-C1 dorsal glide mobilization in the cervical neutral position.
62548186|NCT02404766|EXPERIMENTAL|Intervention group 2|C7-T1 ventral cranial glide mobilization in the cervical neutral position
62720109|NCT01107639|ACTIVE_COMPARATOR|Without additional immunotherapy|Standard therapy without immunotherapy (cetuximab).
62720110|NCT00888914|ACTIVE_COMPARATOR|Dose A|RT001 Dose A; Active Comparator
61976640|NCT03269942|ACTIVE_COMPARATOR|Endovascular Flow-Diversion|Implantation of flow-diversion device
62165925|NCT03480737|SHAM_COMPARATOR|Sham rTMS|
62165926|NCT03480737|EXPERIMENTAL|iTBS rTMS|
62165927|NCT00996619||People undergoing GI tract endoscopy|
62165928|NCT05472233|ACTIVE_COMPARATOR|2weeks|Suture removal at 2 weeks post intervention
62165929|NCT05472233|EXPERIMENTAL|3+weeks|Suture removal at 3 weeks minimum post intervention
62165930|NCT00312247||Boys taking steroids|Boys who are taking prednisone or deflazacort
62165931|NCT00312247||Boys who are steroid naive|Boys who are not taking steroids for a variety of reasons
62165932|NCT03875794|EXPERIMENTAL|Osteopathic Manipulation|"This research will be carried out as a prospective, non-randomized pilot study in women aged 18-40 who are 2 weeks to 28 weeks postpartum.~The intervention investigated in this study is osteopathic manipulation."
62165933|NCT01444547|EXPERIMENTAL|single-arm Paclitaxel-Cisplatin|
62165934|NCT05750017|EXPERIMENTAL|Cohort1: Low dose sentinel group|Three subjects will be first enrolled into low dose sentinel group in open-label, prior to initiation of dosing in each dose level main group.
62165935|NCT05750017|EXPERIMENTAL|Cohort2: High dose sentinel group|After reviewing the safety through 7 days after the first dose of LZ901, if no safety signals occur, another 3 subjects will be enrolled into high dose sentinel group in open-label.
62165936|NCT05750017|PLACEBO_COMPARATOR|Cohort3: Low dose main group|If also no safety signals occur through 7 days after the first dose of LZ901 in high dose sentinel group, 30 subjects will be randomized in a 2:1 ratio to receive two doses of LZ901 or placebo in a double-blind fashion in low dose main group.
62165937|NCT05750017|PLACEBO_COMPARATOR|Cohort4: High dose main group|Subjects will be enrolled in high dose main group also after the safety review through 7 days after the first dose of LZ901 or placebo in low dose main group.
62165938|NCT04533971|EXPERIMENTAL|WBC group|"Criteria~* documented diagnosis of MS,~* functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3~* no contraindications for WBC treatments found in the medical examination~* no other serious chronic diseases identified that may affect the results of the tests carried out~* readiness to participate in daily WBC~* a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
62548187|NCT02404766|NO_INTERVENTION|Control group|Not receiving any intervention
62548188|NCT02587091|NO_INTERVENTION|Control Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. There was no advertisement of portable ultrasound.
62548189|NCT02587091|EXPERIMENTAL|Intervention Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. In addition, it was advertised that portable ultrasound would be provided free of charge in addition to standard comprehensive antenatal care.
62548190|NCT05389644|EXPERIMENTAL|Dorsal circuit (DLPFC) stimulation|This arm will involve stimulation of the dorsal apathy-relevant circuit. Specifically, a target will be individually selected based on resting-state functional connectivity with a given subject's dorsal striatum.
62548191|NCT05389644|EXPERIMENTAL|Ventral circuit (vmPFC) stimulation|This arm will involve stimulation of the ventral apathy-relevant circuit. Specifically, a target will be individually selected based on resting-state functional connectivity with a given subject's ventral striatum.
62548192|NCT05389644|SHAM_COMPARATOR|Sham stimulation|This arm will involve sham stimulation to a prefrontal target.
62548193|NCT05520125|EXPERIMENTAL|Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles|Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles
62548194|NCT05520125|ACTIVE_COMPARATOR|Patients with bone defects receiving standard treatment|Patients with bone defects receiving standard surgical treatment
62548195|NCT05293821||Positive test subjects|documented medical history of HIV, HBV or HCV. A combination of 2 or 3 conditions is acceptable.
62548196|NCT05293821||Control|no documented medical history of HIV, HBV or HCV and are considered normal.
62548197|NCT04957030|EXPERIMENTAL|ULDCT group|underwent ultralow-dose chest CT(ULDCT)
62548198|NCT04957030|NO_INTERVENTION|LDCT group|underwent conventional chest CT(LDCT)
62548199|NCT04660331|EXPERIMENTAL|Aim I (interview)|Participants participate in a semi-structured interview in-person or via phone over 90 minutes about barriers/facilitators of HPV vaccination in pharmacies.
62548200|NCT04660331|EXPERIMENTAL|Aim 2 (survey, training, communication intervention, and environmental scan)|"Participants provide feedback on survey questions via cognitive testing. Pharmacy staff complete an online survey over 10-15 minutes to assess the acceptability, appropriateness, and feasibility of providing HPV vaccination to children aged 9-17 in their pharmacies. Pharmacy staff then attend two, 60- minute vaccine communication training sessions, consisting of identifying vaccine-eligible children and recommending HPV and other vaccines. Pharmacy staff employ the new communication strategy in their pharmacy up to 6 months, and then complete an online survey over 10-15 minutes.~Pharmacies of which the pharmacy staff participants work undergo an environmental scan to characterize the pharmacy's environment, vaccination workflow, and team dynamics."
62548201|NCT01721317|EXPERIMENTAL|Titration Phase: Ezogabine/Retigabine 300 mg|Subjects receive Ezogabine/Retigabine 300 mg equally divided TID over Wk 1
62548202|NCT01721317|PLACEBO_COMPARATOR|Titration Phase: Placebo 300 mg|Subjects receive matching Placebo
62548203|NCT01721317|EXPERIMENTAL|Titration Phase: Ezogabine/Retigabine 450 mg|Subjects receive Ezogabine/Retigabine 450 mg equally divided TID over Wk 2
62548204|NCT01721317|PLACEBO_COMPARATOR|Titration Phase: Placebo 450 mg|Subjects receive matching Placebo
62548205|NCT01721317|EXPERIMENTAL|Dose-Optimization Phase: Ezogabine/Retigabine 600 mg|Subjects receive Ezogabine/Retigabine 600 mg equally divided (200 mg TID) over Wk 3 or until they achieve their optimal tolerated dose as assessed by the Investigator
62548206|NCT01721317|PLACEBO_COMPARATOR|Dose-Optimization Phase: Placebo 600 mg|Subjects receive matching Placebo
62548207|NCT01721317|EXPERIMENTAL|Dose-Optimization Phase: Ezogabine/Retigabine 750 mg|Subjects receive Ezogabine/Retigabine 750 mg equally or unequally divided TID over Wk 4 or until they achieve their optimal tolerated dose as assessed by the Investigator
62548208|NCT01721317|PLACEBO_COMPARATOR|Dose-Optimization Phase: Placebo 750 mg|Subjects receive matching Placebo
62548209|NCT01721317|EXPERIMENTAL|Dose-Optimization Phase: Ezogabine/Retigabine 900 mg|Subjects receive Ezogabine/Retigabine 900 mg equally or unequally divided TID over Wk 5 or until they achieve their optimal tolerated dose as assessed by the Investigator
62548210|NCT01721317|PLACEBO_COMPARATOR|Dose-Optimization Phase: Placebo 900 mg|Subjects receive matching Placebo
62548211|NCT01721317|EXPERIMENTAL|Dose-Optimization Phase: Ezogabine/Retigabine 1050 mg|Subjects receive Ezogabine/Retigabine 1050 mg equally or unequally divided TID over Wk 6 or until they achieve their optimal tolerated dose as assessed by the Investigator
62548212|NCT01721317|PLACEBO_COMPARATOR|Dose-Optimization Phase: Placebo 1050 mg|Subjects receive matching Placebo
62548213|NCT01721317|EXPERIMENTAL|Dose-Optimization Phase: Ezogabine/Retigabine 1200 mg|Subjects receive Ezogabine/Retigabine 1200 mg equally divided (400 mg TID) over Wk 7 or until they achieve their optimal tolerated dose as assessed by the Investigator
62548214|NCT01721317|PLACEBO_COMPARATOR|Dose-Optimization Phase: Placebo 1200 mg|Subjects receive matching Placebo
62548215|NCT01721317|EXPERIMENTAL|Maintenance Phase:Ezogabine/Retigabine|Subjects receive Ezogabine/Retigabine at the daily dose achieved (equally or unequally divided TID) at the end of the Dose-Optimization Phase for 8 Weeks (600 mg, 750 mg, 900 mg, 1050 mg, or 1200 mg)
62548216|NCT01721317|PLACEBO_COMPARATOR|Maintenance Phase: Placebo|Subjects receive matching Placebo
62548217|NCT05456490|EXPERIMENTAL|Liposomal Bupivacaine 13.3|"Cohort 1 subjects will be dosed 2 mL (26.6 mg) of Liposomal Bupivacaine 13.3.~Cohort 2 subjects randomized to the Liposomal Bupivacaine 13.3 arm will be dosed 3 mL (39.9 mg) of Liposomal Bupivacaine 13.3.~Cohort 3 subjects randomized to the Liposomal Bupivacaine 13.3 arm will be dosed 4 mL (53.2 mg) of Liposomal Bupivacaine 13.3."
62548218|NCT05456490|ACTIVE_COMPARATOR|Bupivacaine IT|"Cohort 1 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg/ 1 mL) of 0.75% bupivacaine.~Cohort 2 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg/ 1 mL) of 0.75% bupivacaine mixed with 1 mL of preservative free normal saline to create a total volume of solution administered of 3 mL.~Cohort 3 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg / 1 mL) of 0.75% bupivacaine mixed with 2 mL of preservative free normal saline to create a total volume of solution administered of 4 mL."
62548219|NCT05456490|PLACEBO_COMPARATOR|Placebo|"Cohort 1 subjects randomized to the placebo arm will be dosed 2 mL of preservative free normal saline.~Cohort 2 subjects randomized to the placebo arm will be dosed 3 mL of preservative free normal saline.~Cohort 3 subjects randomized to the placebo arm will be dosed 4 mL of preservative free normal saline."
62720111|NCT00888914|ACTIVE_COMPARATOR|Dose B|RT001 Dose B; Active Comparator
62720112|NCT00888914|ACTIVE_COMPARATOR|Dose C|RT001 Dose C; Active Comparator
62720113|NCT00888914|ACTIVE_COMPARATOR|Dose D|RT001 Dose D; Active Comparator
61976641|NCT03269942|ACTIVE_COMPARATOR|Cerebral Revascularization|Cerebral revascularization procedure with trapping of aneurysm
61976642|NCT06316141|EXPERIMENTAL|Experimental Group A|Aqua Jogging Group
62548220|NCT04931979|EXPERIMENTAL|Treatment|Pembrolizumab 200mg i.v. three-weekly in combination with salvage radiation therapy (SRT) according to standard of care
62548221|NCT02096744|EXPERIMENTAL|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
62548222|NCT02096744|EXPERIMENTAL|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
62548223|NCT02096744|EXPERIMENTAL|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
62548224|NCT05784025|EXPERIMENTAL|AlterG|Traditional rehabilitation program plus robotic rehabilitation making use of the antigravity AlterG device
62548225|NCT05784025|NO_INTERVENTION|Control|Standard rehabilitation program
62548226|NCT06581991|EXPERIMENTAL|Liquid valine and liquid isoleucine administration|Liquid valine given for 28 days, liquid isoleucine for 28 days
62548227|NCT00979641|EXPERIMENTAL|chemoterapy|docetaxel/paclitaxel + bevacizumab
62548228|NCT06412783|EXPERIMENTAL|blood test group|
62548229|NCT01386255|ACTIVE_COMPARATOR|baclofen|Baclofen suspension
62548230|NCT01386255|PLACEBO_COMPARATOR|placebo|Identical palcebo suspension
62548231|NCT02204085|EXPERIMENTAL|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
62548232|NCT02204085|EXPERIMENTAL|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
62548233|NCT01554319|EXPERIMENTAL|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
62548234|NCT01554319|PLACEBO_COMPARATOR|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
62548235|NCT02658942|ACTIVE_COMPARATOR|Ureteroscopy|Intervention: Flexible ureteroscopy for removal of lower calyceal stones using holmium:YAG laser lithotripsy
62548236|NCT02658942|ACTIVE_COMPARATOR|Shockwave lithotripsy|Intervention: Shockwave lithotripsy for lithotripsy of lower calyceal stones using Siemens Lithostar Lithotriptor
62548237|NCT03917927|EXPERIMENTAL|Eztetic dental implant|Eztetic 3.1mm diameter, lengths 8, 10, 11.5, 13, 16 mm
62548238|NCT05928312|EXPERIMENTAL|Advanced CRC|Patients with Advanced CRC were given Fruquintinib Combine With Chemotherapy.
62548239|NCT02713009|EXPERIMENTAL|Treatment 1|Pregnancy multivitamin + vitamin D daily from \~Week 12 gestation until delivery
62548240|NCT02713009|PLACEBO_COMPARATOR|Treatment 2|Pregnancy multivitamin + placebo daily from \~Week 12 gestation until delivery
62548241|NCT04548765|ACTIVE_COMPARATOR|Standard Letter|The standard letter describes the importance of getting screened and instructs recipients how to use the FIT kit for screening at home.
61976643|NCT06316141|EXPERIMENTAL|Experimental Group B|Land based Jogging Group
62548242|NCT04548765|EXPERIMENTAL|Letter with Risks|The standard letter is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; it also explains why test kits are being sent to disarm skepticism about the program.
62548243|NCT04548765|EXPERIMENTAL|Letter with Risks and Options|In addition to the enhancements added by the letter with risks, the letter also includes a table comparing FIT kit and colonoscopy. Presenting different screening options allows recipients to make the choice that best suits them. In addition, presenting multiple options increases the chance that recipients get screened in one way or another.
62548244|NCT04548765|EXPERIMENTAL|Letter with Risks, Options, and Consequences for Inaction|In addition to the enhancements added by the letter with risk, the comparison table includes comparisons of the consequences of getting screened vs. waiting for symptoms to appear.
62548245|NCT02210624|EXPERIMENTAL|Single arm|"Experimental: HYNR-CS inj.~Treatment group with HYNR-CS inj."
62548246|NCT02258763|EXPERIMENTAL|Amoxicillin-Potassium Clavulanate|Patient will be on amoxicillin-clavulanate 22.5mg/kg/dose bd for 10 days
62548247|NCT02258763|ACTIVE_COMPARATOR|Placebo|Patient will be on amoxicillin-clavulanate 22.5mg/kg/bd for 3 days followed by another 7 days of placebo medication given at the same dose and frequency
62548248|NCT03802071|EXPERIMENTAL|Durvalumab+doxorubicin combination|
62548249|NCT03580473|EXPERIMENTAL|SATURNO II|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
61976644|NCT00300586|SHAM_COMPARATOR|A (supervision)|medical supervision, second line chemotherapy if progression
62548250|NCT03580473|ACTIVE_COMPARATOR|Vigadexa®|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
62548251|NCT03557502|EXPERIMENTAL|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
62548252|NCT03557502|EXPERIMENTAL|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
62548253|NCT00611624|EXPERIMENTAL|Five Days of Mammosite Therapy|Five Days of Mammosite Therapy (Radiotherapy)
62548254|NCT06377618|EXPERIMENTAL|Resistance Training and Core Strengthening Exercises Group|The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.
62720114|NCT00888914|PLACEBO_COMPARATOR|Dose E|RT001 Dose E; Vehicle Comparator
62720115|NCT02647476|EXPERIMENTAL|Study group|Immunomodulating nutrition (Reconvan)
62720116|NCT02647476|ACTIVE_COMPARATOR|Control group|Standard nutrition (Peptisorb)
62720117|NCT01514721|EXPERIMENTAL|DuoTrav|Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks
62548255|NCT06377618|OTHER|Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation|"Identical exercise protocol to Group 1, with three supervised sessions per week.~First Arm Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D status. Typical dosages range from 800 to 2000 IU/day, subject to adjustments as necessary.~Serum 25(OH)D levels and potential supplementation-related adverse effects will be monitored at baseline and after 12 weeks.~Outcome Measures: In addition to the same outcome measures as Group 1, changes in serum 25(OH)D levels will also be assessed."
62548256|NCT01512160|EXPERIMENTAL|PF-04531083 2000 mg|
62548257|NCT01512160|EXPERIMENTAL|PF-04531083 1000 mg|
62548258|NCT01512160|ACTIVE_COMPARATOR|Ibuprofen 400 mg|
62548259|NCT01512160|PLACEBO_COMPARATOR|Placebo|
62548260|NCT03834142|EXPERIMENTAL|Intervention|NSS-2-Bridge auricular therapy will be given in addition to standard of care.
62548261|NCT03834142|NO_INTERVENTION|Control|No intervention, subject receives standard of care
62548262|NCT01425658|ACTIVE_COMPARATOR|clonidine|The clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
62548263|NCT01425658|ACTIVE_COMPARATOR|Fentanyl|The fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
62548264|NCT01425658|PLACEBO_COMPARATOR|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
62548265|NCT00706485|EXPERIMENTAL|Dural brachytherapy plaque|Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.
62548266|NCT05011604|OTHER|Implant Failure|Early peri-implantitis and failed osseointegration.
61976645|NCT00300586|ACTIVE_COMPARATOR|B (gemcitabicine)|Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
62548267|NCT06399744|OTHER|trans-abdominal group|
62548268|NCT06399744|OTHER|trans-vaginal group|
62548269|NCT05309811|EXPERIMENTAL|Group A|RLRL therapy with routine IOP-lowering medications in the 1st-12th weeks then crossing to only routine IOP-lowering medications in the 13th-24th weeks
62548270|NCT05309811|EXPERIMENTAL|Group B|Only routine IOP-lowering medications in the 1st-12th weeks then crossing to RLRL therapy with routine IOP-lowering medications in the 13th-24th weeks
62548271|NCT02302989|NO_INTERVENTION|Observation|No treatment. Observation only
62548272|NCT02302989|ACTIVE_COMPARATOR|Quarterly Ranibizumab 0.5|Quarterly intravitreal injection of 0.5mg Ranibizumab Intervention: Drug: Ranibizumab 0.5mg
62548273|NCT06265259|EXPERIMENTAL|Vasopresin Group|Initiation of vasopressin as the first vasoactive agent (1 amp in 50 mlN/S) up to a maximum dose of 0.03 IU/min (2.3 ml/h). If the patient has MAP \<65 mmHg then noradrenaline will be started.
62548274|NCT06265259|ACTIVE_COMPARATOR|Noradrenaline group|Initiation of noradrenaline first, up to 0,5 mcg/kg/min. If the patient has MAP \<65 mmHg vasopressin will be started (maximum dose of 0.03 IU/min (2.3ml/h)\]. If If the patient has MAP \<65 mmHg, noradrenaline will be further escalated.
62548275|NCT01171261|EXPERIMENTAL|Jackie Chan Studio Fitness|The Jackie Chan Studio Fitness (J-MAT) cartridge includes four types of activities that use a four panel floor mat made of flexible material that functions as the wireless interface game controller. The celebrity actor and choreographer Jackie Chan is the avatar character in the game that demonstrates and guides users in four types of aerobic and anaerobic game modes.
62548276|NCT01171261|EXPERIMENTAL|XaviX Tennis|XaviX Tennis simulates tennis using a tennis racket controller and an infrared sensor to detect speed and timing of the player's swing of the racquet. The Tennis cartridge includes three playing modes. In Tournament Tour players select from eight different characters with different skills and play opponents in a bracketed tournament. In Exhibition mode players choose a computer opponent or play a tennis match with a friend. The Training Games mode includes a) Serving, b) Target Challenge, c) Serve \& Finish, and d) Rally Time.
62548277|NCT01171261|EXPERIMENTAL|XaviX Bowling|XaviX Bowling uses a wireless bowling ball game controller to simulate bowling. The cartridge includes three modes. In Regular Game up to four people can select from 8 preset bowlers with different characteristics. In Tournament Mode up to eight people can play. Challenge Games consists of three games called Against the Clock, Moving Pins, and Panel Crusher.
62548278|NCT01171261|EXPERIMENTAL|XaviX Boxing|XaviX Boxing uses boxing gloves as the game controller and allows players to box against five different computer opponents in Championship and Exhibition modes and to practice boxing skills in Exercise mode. Exercise mode includes Punch Fast, Panel Toucher, Punch the Red Ball, and Combination Training.
62548279|NCT00226291|EXPERIMENTAL|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
62548280|NCT00226291|NO_INTERVENTION|No evidence report|
62548281|NCT02735538||osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
62548282|NCT02735538||osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
62548283|NCT01652989|EXPERIMENTAL|Weight loss maintenance intervention delivered via DVD|Weight loss maintenance intervention delivered via DVD (without a peer facilitator) to employee participants within the respective worksites randomized to this arm. Using DVD technology, a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period will be delivered to the participants of this arm using DVD-produced lessons of PILI Maintenance
62548284|NCT01652989|EXPERIMENTAL|Weight loss maintenance intervention Face-to-Face|The PILI Maintenance delivered face-to-face in a group setting by trained peer facilitators to employee participants within the respective worksites randomized to this arm. The trained peer facilitator will deliver a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period, meeting bi-weekly for the first 2 months and then monthly for the remaining 7 months with a group of 8 to 15 participants.
62548285|NCT04457037|EXPERIMENTAL|MSC|Patients with trophic ulcers received standard treatment and MSC
62548286|NCT00313989|EXPERIMENTAL|Evaluation of implants of patients receiving radiotherapy.|
62548287|NCT02411916|EXPERIMENTAL|intervention cases|patient receiving misoprostol
62548288|NCT02411916|NO_INTERVENTION|controls|patients not receiving misoprostol
62548289|NCT01645787|ACTIVE_COMPARATOR|4-aminopyridine (Ampyra)|10 mg tab/ 1 tab twice daily
62548290|NCT01645787|PLACEBO_COMPARATOR|Sugar pill|Placebo 1 tab /twice daily
62548291|NCT04588389|ACTIVE_COMPARATOR|Group 1 Standard of Care|Group I will receive the standard of care multimodal pharmacological management.
62548292|NCT04588389|EXPERIMENTAL|Group 2 Standard of Care + Quadratus Lumborum Block II|Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.
62548293|NCT04588389|EXPERIMENTAL|Group 2 Standard of Care + Quadratus Lumborum Block III|Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.
62548294|NCT03910673|EXPERIMENTAL|2-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 2 hours after start of third infusion dose. n = 6
62548295|NCT03910673|EXPERIMENTAL|30-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 30 minutes after start of third infusion dose. n = 6
62548296|NCT03910673|EXPERIMENTAL|5-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 5 hours after start of third infusion dose. n = 6
62548297|NCT03910673|EXPERIMENTAL|75-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 75 minutes after start of third infusion dose. n = 6
62548298|NCT03910673|EXPERIMENTAL|8-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 8 hours after start of third infusion dose. n = 6
62548299|NCT02188810|ACTIVE_COMPARATOR|Group 1|Single dose of control vaccine (a single dose of 0.5 mL TIV).
62548300|NCT02188810|EXPERIMENTAL|Group 2|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 0.5x PAL, i.e. 30 μg).
62548301|NCT02188810|EXPERIMENTAL|Group 3|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 1x PAL, i.e. 60 μg).
62548302|NCT02188810|EXPERIMENTAL|Group 4|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 2x PAL (i.e., 120 μg).
62548303|NCT02188810|EXPERIMENTAL|Group 5|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 4x PAL (i.e., 240 μg).
62548304|NCT02188810|EXPERIMENTAL|Group 6|Single dose of the test article (0.125 mL of TIV with 4x PAL i.e., 240 μg).
62548305|NCT03794050|EXPERIMENTAL|resistance training exercise|All participants complete one session of resistance training exercise
62548306|NCT03794050|EXPERIMENTAL|aerobic training exercise|All participants complete one session of aerobic training exercise
62548307|NCT04118023||7T MRI Group|Patient group that receives 7 Tesla Magnetic Resonance Imaging
62548308|NCT05622019||Gingival health|Healthy participants had no sites with inter-proximal attachment loss, probing pocket depth (PPD) of ≤3 mm in all sites, bleeding on probing (BOP) ≤ 10%, and had \<10% of sites with modified gingival index (mGI) ≥ 2
62548309|NCT05622019||periodontitis|Participants were diagnosed with periodontitis if interdental clinical attachment loss (AL) was detected at ≥2 non-adjacent teeth, or buccal or oral AL was ≥3 mm with probing depth ≥3 mm was detected at ≥2 teeth.The participants in this group were divided into subgroups according to their periodontitis stage grade.
62720118|NCT02668341||psoriasis patients in Denmark|non-interventional survey study in psoriasis patients in daily practice care
61978187|NCT01110707|ACTIVE_COMPARATOR|r-hFSH alone|
62548310|NCT04230902|EXPERIMENTAL|Lipogems|The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo harvesting of their own adipose tissue for aMAT then this aMAT will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.
62548311|NCT04230902|ACTIVE_COMPARATOR|Steroid|The cases assigned to this group will be injected intra-articularly in the knee with corticosteroids. No extra preparation of any type is necessary in this case. It will be administered once at the baseline visit of the study.
62548312|NCT01471730|PLACEBO_COMPARATOR|Saline solution|
62548313|NCT01471730|ACTIVE_COMPARATOR|Fibrinogen|
62548314|NCT01471730|ACTIVE_COMPARATOR|Prothrombin complex|
62548315|NCT00061932|EXPERIMENTAL|Stratum 1 (previously untreated)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8.
62548316|NCT00061932|EXPERIMENTAL|Stratum 2 (previously treated)|(closed to accrual as of 9/19/2006): Patients receive bortezomib as in stratum 1.
62548317|NCT02171195|EXPERIMENTAL|Group 1 (20 mg)|
62548318|NCT02171195|EXPERIMENTAL|Group 2 (50 mg)|
62548319|NCT02171195|EXPERIMENTAL|Group 3 (100 mg)|
62548320|NCT02171195|EXPERIMENTAL|Group 4 (200 mg)|
62548321|NCT02171195|EXPERIMENTAL|Group 5 (400 mg)|
62548322|NCT02171195|EXPERIMENTAL|Group 6 (600 mg)|
62548323|NCT02171195|EXPERIMENTAL|Group 7 (900 mg)|
62548324|NCT02171195|EXPERIMENTAL|Group 8 (1200 mg)|
62548325|NCT05558566|EXPERIMENTAL|Neurofeedback from the SMA|
62548326|NCT05558566|ACTIVE_COMPARATOR|Neurofeedback from control region|
62720119|NCT02668341||psoriasis patients in Spain|non-interventional survey study in psoriasis patients in daily practice care
62720120|NCT02668341||psoriasis patients in Poland|non-interventional survey study in psoriasis patients in daily practice care
62720121|NCT02668341||psoriasis patients in Germany|non-interventional survey study in psoriasis patients in daily practice care
62548327|NCT00098774|EXPERIMENTAL|Intensive Combination Chemo & Immunotherapy|"Induction Cycles 1-3: Methotrexate 8gm/m\^2 days 1 \& 15; Leucovorin 100 mg/m\^2 days 2 \& 16; Rituximab 375 mg/m\^2 days 3, 10, 17 \& 24 of cycle 1, days 3 \& 10 of cycle 2; Temozolomide 150 mg/m\^2/day PO days 7-11~Induction Cycle 4: Temozolomide 150 mg/m\^2/day PO days 7-11; Methotrexate 8gm/m\^2 day 15; Leucovorin 100 mg/m\^2 day 16~Consolidation Cycle 5: Methotrexate 8gm/m\^2 days 1; Leucovorin 100 mg/m\^2 days 2; Temozolomide 150 mg/m\^2/day PO days 7-11~Consolidation Cycle 6: Cytarabine 2 g/m\^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m\^2/day starting day 14 until ANC recovers (\>= 500 for 2 consecutive days or \>= 1500 for one day)"
62548328|NCT04524195|EXPERIMENTAL|[18F]F-AraG|A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.
62548329|NCT01822626|EXPERIMENTAL|motivational counseling|
62548330|NCT01822626|NO_INTERVENTION|Usual Care|
62548331|NCT04581330|EXPERIMENTAL|DEKA SmartXide C02 laser|One half of the subject's neck will be treated with ablative fractional CO2 laser.
62548332|NCT04581330|NO_INTERVENTION|Control|The other half of the subject's neck will not be treated with the ablative fractional CO2 laser.
62548333|NCT05082740||Women with a family history of breast cancer|This women are register to the Family History Risk and Prevention clinic and have taken part in the original FH-Risk study. These women will be given the opportunity to learn of their revised breast cancer risk estimate.
62548334|NCT01022697|ACTIVE_COMPARATOR|A|Glucose drink
62548335|NCT01022697|NO_INTERVENTION|B|Fasting
62548336|NCT01524978|EXPERIMENTAL|Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib|Participants with NSCLC will be treated with vemurafenib monotherapy.
62548337|NCT01524978|EXPERIMENTAL|Cohort 2: Ovarian Cancer - vemurafenib|Participants with ovarian cancer will be treated with vemurafenib monotherapy.
62548338|NCT01524978|EXPERIMENTAL|Cohort 3a: Colorectal Cancer - vemurafenib|Participants with colorectal cancer will be treated with vemurafenib monotherapy.
62548339|NCT01524978|EXPERIMENTAL|Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab|Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
62548340|NCT01524978|EXPERIMENTAL|Cohort 4: Cholangiocarcinoma - vemurafenib|Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
62548341|NCT01524978|EXPERIMENTAL|Cohort 6: Multiple Myeloma - vemurafenib|Participants with multiple myeloma will be treated with vemurafenib monotherapy.
62548342|NCT01524978|EXPERIMENTAL|Cohort 7: Other Solid Tumors - vemurafenib|Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.
62548343|NCT06497582|EXPERIMENTAL|Zhan-zhuang group|"The intervention will last 8 weeks and comprise the following~1) Two sessions of Zhan Zhuang training(2 hours per session/week, totally 4 hours) for 2 weeks. (2) self-practice of zhan-zhuang for 6 weeks (daily, at least 20 mins) at home after passing the evaluation by a Zhan-Zhuang master"
62548344|NCT06497582|EXPERIMENTAL|Self-acupressure group|"The intervention will last 8 weeks and comprise the following~1) Two sessions of self-acupressure training (2 hours per session/week, totally 4 hours) for 2 weeks. (2) self-practice of acupressure for 6 weeks (daily, around 20 mins) at home after passing the evaluation by a licensed traditional Chinese medicine doctor."
62548345|NCT06497582|NO_INTERVENTION|Waitlist control group|Usual care only
62548346|NCT05741827|EXPERIMENTAL|Interventional group|Lifestyle intervention with focus on increased physical activity and healthy diet.
62548347|NCT05741827|NO_INTERVENTION|Control group|No lifestyle intervention. No change in physical activity or diet.
62548348|NCT03503695|ACTIVE_COMPARATOR|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
62548349|NCT03503695|NO_INTERVENTION|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
62548350|NCT00803439||Cohort Group 1|Subjects number 1 to 20
62548351|NCT00803439||Cohort Group 2|Subjects number 21 to 40
62548352|NCT00803439||Cohort Group 3|Subjects number 41 to 60
62548353|NCT00803439||Cohort Group 4|Subjects number 61 to 80
62548354|NCT00492778|EXPERIMENTAL|Arm I (brachytherapy, radiation therapy)|Patients undergo EBRT to the pelvis daily on days 1-5 for 5 weeks. After completion of EBRT, patients undergo intracavitary low-dose rate or high-dose rate brachytherapy or low-dose rate interstitial brachytherapy.
62548355|NCT00492778|EXPERIMENTAL|Arm II (brachytherapy, radiation therapy, cisplatin)|Patients undergo EBRT as in Arm I and receive cisplatin IV over 1-2 hours on days 1, 8, 15, 22, and 29. Patients then undergo brachytherapy as in Arm I.
62548356|NCT02933437|EXPERIMENTAL|Healthy Volunteers|Once screened by the investigators, the participants will undergo ajmaline provocation, cardiac magnetic resonance imaging and genotype evaluation
62548357|NCT05018377|ACTIVE_COMPARATOR|Raj'z catheter|
62548358|NCT05018377|ACTIVE_COMPARATOR|NAVI catheter|
62548359|NCT03763305|EXPERIMENTAL|Total intravenous anesthesia (TIVA)|Study participants are anesthetized by total intravenous anesthesia (TIVA) using propofol continuous infusion and remifentanil continuous infusion. During induction of general anesthesia, participants receive 3\~5mcg/mL Propofol Fresenius and 3\~5ng/mL and Remifentanil \[Ultiva\] as initial effect site concentrations. The effect site concentration is controlled with target-controlled infusion to maintain bispectral index (BIS) values between 40 and 60.
62548360|NCT03763305|EXPERIMENTAL|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, sevoflurane inhalant solution \[Sojourn\] is used to maintain 1 age-related minimum alveolar concentration (MAC).
62548361|NCT03763305|EXPERIMENTAL|Desflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane \[Suprane\] is used to maintain 1 age-related minimum alveolar concentration (MAC).
62720122|NCT00956761|EXPERIMENTAL|1|
62548362|NCT06414356|EXPERIMENTAL|Moderate Dose Ketamine|"0.5 mg/kg/hr The total amount of ketamine for each participant is dependent on their body weight in kg per ideal body weight (IBW) formula.~This total ketamine dose will be injected into one 250 ml normal saline 0.9% solution with a rate of 62.5 ml/hr over four hours or until the contents of the bag are infused and flushed with 20 ml of normal saline"
62548363|NCT06414356|EXPERIMENTAL|Moderate dose ketamine + magnesium sulfate|0.50 mg/kg/hr ketamine + 750 mg/hr Mg
62548364|NCT06414356|ACTIVE_COMPARATOR|Magnesium sulfate|750 mg/hr
62548365|NCT00697151|ACTIVE_COMPARATOR|Warfarin|Warfarin (target International Normalized Ratio: 1.4 to 2.8) plus placebo aspirin
62548366|NCT00697151|ACTIVE_COMPARATOR|Aspirin|Aspirin 325 mg plus placebo warfarin
62548367|NCT01940991|PLACEBO_COMPARATOR|Dose B|Dose B: Placebo
62548368|NCT01940991|EXPERIMENTAL|Dose A|Dose A: Botulinum Toxin Type A
62548369|NCT00098618|EXPERIMENTAL|Treatment (sorafenib tosylate and recombinant interferon alfa)|Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
62548370|NCT00067743|OTHER|1|Open Label trial
62548371|NCT03168022|EXPERIMENTAL|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
62548372|NCT03168022|EXPERIMENTAL|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
62548373|NCT03957850|EXPERIMENTAL|Cognitive Reappraisal Training Group|Cognitive Reappraisal Training group will perform 4 training sessions in Cognitive Reappraisal during which, behavioral responses, event-related potentials (ERPs) and eye-tracking data are collected.
62548374|NCT03957850|ACTIVE_COMPARATOR|Control Training Group|Control Training Group will perform 4 control sessions without Cognitive Reappraisal Training during which behavioral responses, ERP and eye-tracking data are collected.
62548375|NCT05036512|PLACEBO_COMPARATOR|Placebo|Placebo as a tablet or capsule with dose based off of preceding cohort's data.
62548376|NCT05036512|EXPERIMENTAL|GBT021601|GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.
62548377|NCT01226394|NO_INTERVENTION|surveillance|
62548378|NCT01226394|EXPERIMENTAL|laparotomy plus HIPEC.|
62548379|NCT03541928|EXPERIMENTAL|Gene Therapy, ADT, RT, and Surgery|"The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10\[11\] virus particles (1.25 x 10\[11\] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.~The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).~The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).~Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months."
62548380|NCT05146843|EXPERIMENTAL|Mitoquinone|MitoQ, 20 mg per day for three months
62548381|NCT05146843|PLACEBO_COMPARATOR|Placebo|Placebo, 20 mg per day for three months
62548382|NCT00411411|PLACEBO_COMPARATOR|Placebo|Placebo treatment, administered as tablets.
62548383|NCT00411411|EXPERIMENTAL|Januvia|Active treatment
62548384|NCT04648787|EXPERIMENTAL|Intervention group: traditional nursing with family-integrated care|traditional nursing with family-integrated care
62548385|NCT04648787|EXPERIMENTAL|Control group: traditional nursing|traditional nursing
62548386|NCT01776931|EXPERIMENTAL|Lysine intake|Dietary supplement:lysine intake
62548387|NCT02975947|ACTIVE_COMPARATOR|Control Group|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
62548388|NCT02975947|EXPERIMENTAL|Study Group|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide delivered into the open peritoneal cavity.
62548389|NCT02336646|EXPERIMENTAL|Low Dose Allogenic MSC|Low dose allogenic mesenchymal stem cells with IM injection
62548390|NCT02336646|EXPERIMENTAL|High Dose Allogenic MSC|High dose allogenic mesenchymal stem cells with IM injection
62548391|NCT02336646|PLACEBO_COMPARATOR|Placebo|normal saline with Intramuscular injection
62548392|NCT04975854|EXPERIMENTAL|Virtual Reality Exposure|Participants complete three 30-40-minute sessions of exposure administered via a virtual reality headset. The exposure involve exposure to various heights and height cues in the virtual city environment. Experimental group also attends 20-minute online information session (prerecorded video).
62548393|NCT04975854|OTHER|Control|Control group attends a single 20-minute information session (prerecorded video) about general principles of exposure therapy and anxiety before the start of the study, but receives no exposure-based intervention.
62548394|NCT04641598|EXPERIMENTAL|Endometrial scratch|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The cervix will be grasped with a single tooth tenaculum and an endometrial biopsy pipelle inserted into the uterine cavity to the depth of the uterine fundus. Suction will be applied and the pipelle will be completely withdrawn in a single pass. All instruments will be removed from the vagina after hemostasis is ensured.
62548395|NCT04641598|SHAM_COMPARATOR|Sham procedure|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The motions of grasping the cervix with a single tooth tenaculum and inserting the biopsy pipelle will be simulated, but not actually performed. All instruments will then be removed from the vagina.
62548396|NCT03840564||Group point of care (POC)|All the analyzes will be done in delocalized
62548397|NCT03840564||control group|the analyzes will be done at the central laboratory
62548398|NCT01500473|EXPERIMENTAL|Females with CCHS > 16 years old on desogestrel|open label studied on drug.
62548399|NCT00199524|ACTIVE_COMPARATOR|1|ureteroscopy with ureteral access sheath
62548400|NCT00199524|NO_INTERVENTION|2|ureteroscopy without ureteral access sheath
62548401|NCT01708668|ACTIVE_COMPARATOR|1|Epidural analgesia (EA) with continuous epidural infusion(CEI)
62548402|NCT01708668|ACTIVE_COMPARATOR|2|Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)
62548403|NCT01708668|ACTIVE_COMPARATOR|3|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
62548404|NCT01708668|ACTIVE_COMPARATOR|4|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
62548405|NCT01708668|ACTIVE_COMPARATOR|5|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
62548406|NCT01708668|ACTIVE_COMPARATOR|6|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
62548407|NCT01708668|ACTIVE_COMPARATOR|7|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
62548408|NCT01708668|ACTIVE_COMPARATOR|8|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
62548409|NCT06228534|EXPERIMENTAL|tunneling technique with connective tissue|GRUPO TEST: THE RECIPIENT BED OF THE CONNECTIVE GRAFT, THE TUNNELING TECHNIQUE IS PREPARED.
62548410|NCT06228534|EXPERIMENTAL|coronal advancement flap technique|GRUPO CONTROL: THE RECIPIENT BED OF THE CONNECTIVE GRAFT, THE CORONAL ADVANCEMENT FLAP TECHNIQUE IS PREPARED
62548411|NCT04812808|EXPERIMENTAL|Bazedoxifene administered in addition to standard chemotherapy protocol|
62548412|NCT02620579|EXPERIMENTAL|Personalized Pharmaceutical and Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive the pain processing education modules as the combined intervention for this arm.
62548413|NCT02620579|PLACEBO_COMPARATOR|Placebo Pharmaceutical, General Education|This group will have the placebo pharmaceutical administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
62548414|NCT02620579|ACTIVE_COMPARATOR|Placebo Pharmaceutical, Personalized Education|This group will have the placebo pharmaceutical administered orally and receive the pain processing education modules as the combined intervention for this arm.
62548415|NCT02620579|ACTIVE_COMPARATOR|Personalized Pharmaceutical, General Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
62548416|NCT02211196|EXPERIMENTAL|Health Services Research (smoking cessation intervention)|Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
62548417|NCT03140787|EXPERIMENTAL|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
62548418|NCT03140787|ACTIVE_COMPARATOR|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
62548419|NCT03928301|ACTIVE_COMPARATOR|Wholetones Intervention|"Wholetones music to help participants sleep. Data collected after listening to the Wholetones music was compared to that collected both at Baseline, and after listening to the other music condition (i.e. Classical music).~Wholetones® 2Sleep is music that is designed to lull the listener into a deep, delta sleep, using frequency-enhanced music and precise tempos. Wholetones® differs from other musical genres in that it employs a proprietary method of tuning and layering the music with a unique frequency underlayment."
62548420|NCT03928301|ACTIVE_COMPARATOR|Classical Intervention|"Classical music was the additional music condition used to compare to both Baseline data and Wholetones data.~The classical music was selected based on the Mayo Clinic and NIH music recommendations for better sleep. More specifically, the classical music consisted of the following six pieces: Beethoven (i.e., Moonlight Sonata, first movement), Marconi Union (i.e., Weightless), Chopin (i.e., Nocturne No.2, Op.9), Ravel (i.e., Piano Concerto in G major, 2nd movement), and J.S. Bach (i.e., Prelude No.1)."
62548421|NCT02459938|EXPERIMENTAL|ZP-Glucagon 0.5 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 0.5 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
62548422|NCT02459938|EXPERIMENTAL|ZP-Glucagon 1.0 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 1.0 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
62548423|NCT02459938|ACTIVE_COMPARATOR|Glucagon by injection, 0.5 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
62548424|NCT02459938|ACTIVE_COMPARATOR|Glucagon by injection, 1.0 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
62548425|NCT05720468|EXPERIMENTAL|Exercise|Participants randomized to the exercise group will receive 26 weeks of home-based, combined endurance and resistance training program under guidance and virtual supervision from exercise trainers. Exercise will be performed 5 days per week, with 3 days of endurance training using treadmill and 2 days of resistance training.
62548426|NCT05720468|PLACEBO_COMPARATOR|Waitlist Control Group|The control group will continue usual level of physical activity the participants were doing prior to enrollment in the study. At the end of the 26 week study period, participants will be offered the chance to participate in the same home-based, combined endurance and resistance training program.
62548427|NCT02028676|EXPERIMENTAL|Clinically Driven Monitoring (CDM)|
62548428|NCT02028676|ACTIVE_COMPARATOR|Laboratory plus Clinical Monitoring (LCM)|
62548429|NCT02028676|ACTIVE_COMPARATOR|Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI|ABC \[abacavir\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC \[lamivudine\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
62548430|NCT02028676|EXPERIMENTAL|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|ZDV \[abacavir\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC \[abacavir\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC \[lamivudine\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
62720123|NCT05886855||PerioMonitor Testing|400 Subject to be tested for Oral Inflammatory Load (OIL) with PerioMonitor. Same subjects to be tested for Oral Inflammation with the BOP method and neutrophil count.
62737676|NCT04644276|PLACEBO_COMPARATOR|Mask without Mask Adhesive/Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then they will receive the mask with the mask adhesive on the second study night.
61976646|NCT00300586|EXPERIMENTAL|C (Erlotinib)|Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression
62548431|NCT02028676|EXPERIMENTAL|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|ZDV \[abacavir\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC \[abacavir\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC \[lamivudine\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
62548432|NCT02028676|EXPERIMENTAL|Once-daily ABC+3TC|ABC \[abacavir\]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC \[lamivudine\]: syrup or tablet, dosed once-daily according to weight-bands following WHO
62548433|NCT02028676|ACTIVE_COMPARATOR|Twice-daily ABC+3TC|ABC \[abacavir\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC \[lamivudine\]: syrup or tablet, dosed twice-daily according to weight-bands following WHO
62548434|NCT02028676|ACTIVE_COMPARATOR|Continued cotrimoxazole prophylaxis|Once-daily doses 5-\<15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-\<30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole \>=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole
62548435|NCT02028676|EXPERIMENTAL|Stopped cotrimoxazole prophylaxis|Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.
62548436|NCT05873790||Serplulimab and chemotherapy|Participants receive 6 cycles of first-line Serplulimab plus chemotherapy, And MRD testing was performed before treatment, after 2 cycles of treatment, after 6 cycles of treatment, 6 months after the end of chemotherapy, and 1 year after the end of chemotherapy.
62548437|NCT03458611|EXPERIMENTAL|Group A|In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
62548438|NCT03458611|EXPERIMENTAL|Group B|In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.
62548439|NCT03957525|EXPERIMENTAL|Orthopaedic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
62548440|NCT03957525|NO_INTERVENTION|Orthopaedic Control group|Gets written and oral preparation for surgery
62548441|NCT03957525|EXPERIMENTAL|Urologic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
62548442|NCT03957525|NO_INTERVENTION|Urologic Control group|Gets written and oral preparation for surgery
62548443|NCT03957525|EXPERIMENTAL|General Paediatric Surgery Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
62548444|NCT03957525|NO_INTERVENTION|General Paediatric Surgery Control group|Gets written and oral preparation for surgery
62548445|NCT05084482||Adult patients admitted to Intensive Care Unit (ICU)|Eligible patients are scored by E-PRE-DELIRIC at admission and PRE-DELIRIC 24 hours after admission.
62548446|NCT06061068|EXPERIMENTAL|Hernia belt compressing group|Patients were given hernia belt compression of the inguinal region after laparoscopic inguinal hernia repair surgery in the operating room. The silicone pad of the hernia belt was placed in the inguinal region of the surgical side for compression for a period of 2 weeks.
62548447|NCT06061068|NO_INTERVENTION|No hernia belt compressing group|"Patients were should not have the intervention Hernia belt compression ."
62548448|NCT01228019||All participants|Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)
62548449|NCT01612065|ACTIVE_COMPARATOR|Misoprostol vaginally, 200 ug|200 ug misoprostol in the posterior vaginal fornix
62548450|NCT01612065|ACTIVE_COMPARATOR|Misoprostol vaginally, 400ug|Misoprostol in the posterior vaginal fornix
62548451|NCT01573104|EXPERIMENTAL|Biomarker group|Patients undergoing CPB having proteomic assays, blood sampling and biomarker assays performed on D0, D1, D2 and D3
62548452|NCT02099565||OPTIMA study patients|The study population will consist of OPTIMA study patients who have not been lost for follow-up and have given a written informed consent.
62548453|NCT06551233|EXPERIMENTAL|dose escalation and expansion|Induction period: once a week, 6 times in total. Maintenance period: once per 28 days, 9 times in total. Intravesical therapy
62548454|NCT04542057|EXPERIMENTAL|Arm 1|Ensifentrine Nebulized Suspension; 3 mg twice daily for 24 weeks
62548455|NCT04542057|PLACEBO_COMPARATOR|Arm 2|Ensifentrine Placebo Nebulized Solution; twice daily for 24 weeks
62548456|NCT05756036||Renal transplant recipients|All incident renal transplant recipients after the commencement of the study
62548457|NCT01228578|EXPERIMENTAL|Multivitamins (B,C,E)|
62548458|NCT01228578|PLACEBO_COMPARATOR|Placebo|
62548459|NCT00520897|EXPERIMENTAL|MK0518 + cART|Raltegravir + standard of care combined antiretroviral therapy
62548460|NCT00520897|PLACEBO_COMPARATOR|Placebo + cART|Placebo + standard of care combined antiretroviral therapy
62548461|NCT05794698||Study group|Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.
62548462|NCT03475108|EXPERIMENTAL|Community Health Worker Group|Patients are assigned a community health worker for one year, in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
62548463|NCT03475108|OTHER|Standard Diabetes Care Group|Patients receive standard diabetes care for one year. They receive a community health worker for the second year (as part of a crossover trial).
62548464|NCT04211116||Pediatric patients indicated to CVC insertion|Paediatric patients indicated to central venous line insertion
62548465|NCT02422797|ACTIVE_COMPARATOR|Current antiretroviral regimen (CAR)|Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitor \[NRTIs\] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) \<50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed-up through the Late Switch Phase, at Week 148 and through the Continuation Phase, after Week 148.
62548466|NCT02422797|EXPERIMENTAL|DTG + RPV|"Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148)."
62548467|NCT04774016|EXPERIMENTAL|Test formula C|
62548468|NCT04774016|EXPERIMENTAL|Test formula B|
62548469|NCT04774016|PLACEBO_COMPARATOR|Test formula A|
62548470|NCT00378144|EXPERIMENTAL|1|Pseudoephedrine/Paracetamol
62548471|NCT01755091|PLACEBO_COMPARATOR|Sugar Pill|Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
62548472|NCT01755091|EXPERIMENTAL|2.5 mg/day|Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
62548473|NCT01755091|EXPERIMENTAL|10 mg/day|Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
62548474|NCT02423629|OTHER|Agili C™|Candidates will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
62548475|NCT05585021|EXPERIMENTAL|Wonderlab Kids instant probiotics|Wonderlab Kids instant probiotics (hawthorn flavor) (4 strains, 20 billion CFU/bottle) 2g/bottle
62548476|NCT05585021|PLACEBO_COMPARATOR|Instant probiotic placebo|Instant probiotic placebo (ET) 2g/bottle
62548477|NCT01314937|EXPERIMENTAL|Deworming at 12 months of age|
62548478|NCT01314937|EXPERIMENTAL|Deworming at 18 months of age|
62548479|NCT01314937|EXPERIMENTAL|Deworming at 12 and 18 months of age|
62720124|NCT01720394|EXPERIMENTAL|Cervical ripening balloon|primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.
62548480|NCT01314937|PLACEBO_COMPARATOR|Usual care|
62548481|NCT06489119||Control group|Patients with angiographic diameter stenosis \<30%.
62548482|NCT06489119||Stable plaque group|Angiographic diameter stenosis between 30% and 70% with no TCFA lesions.
62548483|NCT06489119||Vulnerable plaque group|Angiographic diameter stenosis between 30% and 70% with TCFA lesions.
62548484|NCT06489119||Plaque rupture group|Patient diagnosed as AMI with plaque rupture detected by OCT.
62548485|NCT06489119||Plaque erosion group|Patient diagnosed as AMI with plaque erosion detected by OCT.
62548486|NCT02754843|ACTIVE_COMPARATOR|Naida Q90-SP|Phonak's commercial power Behind-The-Ear (BTE) device, type 1.
62548487|NCT02754843|ACTIVE_COMPARATOR|Naida Q90-UP|Phonak's commercial power Behind-The-Ear (BTE) device, type 2.
62548488|NCT01889147|ACTIVE_COMPARATOR|14C-hRESCAP|Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
62548489|NCT01889147|PLACEBO_COMPARATOR|saline|Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
62548490|NCT01889147|ACTIVE_COMPARATOR|Microdose|Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
62548491|NCT00980525||IL-1 genotype positive|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
62548492|NCT00980525||IL-1 genotype negative|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
62548493|NCT01957761||Clostridium difficile infection|
62548494|NCT02934191|EXPERIMENTAL|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
62548495|NCT02934191|ACTIVE_COMPARATOR|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
62548496|NCT05812534|EXPERIMENTAL|experimental group|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
62548497|NCT01271218|PLACEBO_COMPARATOR|Placebo|Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
62548498|NCT01271218|ACTIVE_COMPARATOR|Active Supplement|Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
62548499|NCT01994850|EXPERIMENTAL|Phase I/II|"Total of six 21-day cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP). Cycle 1 rituximab dose divided between Days 1 and 2 to prevent severe infusion reactions in rituximab naïve patients; brentuximab vedotin and cytotoxic chemotherapy administered on Day 2. Cycles 2 through 6 brentuximab vedotin and R-CHP administered on Day 1. Prednisone (or steroid equivalent) administered Days 1-5 of each cycle (prior to rituximab infusion).~Cycle 1:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 100 mg/m2 IV; Day 2: Rituximab 275 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg or 1.2 mg/kg (Phase I data established a MTD of 1.8 mg/kg brentuximab vedotin)~Cycles 2-6:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 375 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg"
62548500|NCT05175703|OTHER|the infrainguinal arteries disease group|Actual patient group with any atherosclerotic change in the infrainguinal arteries
62548501|NCT05588414|OTHER|Indocyanine Green fluorescence method as first step|Systematic double identification of the sentinel lymph node, by sequential use of ICG fluorescence technique as first step followed by isotopic technique.
62548502|NCT02023294|ACTIVE_COMPARATOR|Lap|Patients candidate to bariatric surgery undergoing Conventional laparoscopic Sleeve Gastrectomy
62548503|NCT02023294|EXPERIMENTAL|SILS|Patients candidate to bariatric surgery undergoing Single Incision Laparoscopic Sleeve Gastrectomy supported by Endograb
62548504|NCT00362336|EXPERIMENTAL|Group 1: DTaP-IPV-Hep B-PRP-T|
62548505|NCT00362336|EXPERIMENTAL|Group 2: CombAct-HIB™ + OPV|
62548506|NCT00362336|ACTIVE_COMPARATOR|Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)|
62548507|NCT06068556|EXPERIMENTAL|Healthy patients|Drug: GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition. A total of 50 people will be randomized and receive the study drug. Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.
62548508|NCT00442871|EXPERIMENTAL|Eltrombopag|Eltrombopag 50 mg oral (single dose)
62548509|NCT04518839||Group with regional anaesthesia|
62548510|NCT04518839||Group with general anaesthesia|
62548511|NCT04201197|ACTIVE_COMPARATOR|Inje Cocktail|Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)
62548512|NCT04201197|EXPERIMENTAL|Inje Cocktail + THC extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 20mg THC
62548513|NCT04201197|EXPERIMENTAL|Inje Cocktail + THC/CBD extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 20mg THC and 640mg CBD
62548514|NCT01072617|EXPERIMENTAL|Safety of rTMS in schizophrenia patients|Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
62548515|NCT05160740|EXPERIMENTAL|ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group
62548516|NCT05160740|PLACEBO_COMPARATOR|No ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group
62548517|NCT01260701|EXPERIMENTAL|Treatment (CLOSED TO ACCRUAL 05/01/13)|Patients receive Akt inhibitor MK2206 PO every other day on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62548518|NCT00330317|EXPERIMENTAL|Letrozole|
62548519|NCT03482973|EXPERIMENTAL|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
62548520|NCT03482973|PLACEBO_COMPARATOR|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
62548521|NCT00996489|EXPERIMENTAL|Coaptite|
62548522|NCT01659125|EXPERIMENTAL|OCFighter|OCFighter
62548523|NCT00456300|EXPERIMENTAL|Exenatide 1.25 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
62548524|NCT00456300|EXPERIMENTAL|Exenatide 2.5 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
62548525|NCT00456300|ACTIVE_COMPARATOR|Insulin|Each subject received a baseline study with insulin alone
62548526|NCT00706589|EXPERIMENTAL|1|Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
62548527|NCT00706589|PLACEBO_COMPARATOR|2|Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
62548528|NCT06582342||Case-crossover group|All patients included in the study will undergo preoperative CT (conventional protocol) and 3D-MSP reconstruction. These results will be compared with the results of the surgery and the anatomopathological study. Each patient will be evaluated by both techniques of the study, thus serving as his or her own control.
62548529|NCT04263025|EXPERIMENTAL|CLARIX CORD 1K|They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP).
62548530|NCT04263025|ACTIVE_COMPARATOR|Controls|They will undergo RARP without adjunctive CLARIX® CORD 1K.
62548531|NCT02176265|EXPERIMENTAL|Qvanteq bioactive coronary stent system|Open-label, single arm, non-randomized study
62548532|NCT06462755||elderly patients (aged ≥ 65 years)|elderly patients undergo surgeries
62548533|NCT02451761||Sequencing|Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
62548534|NCT02740192|EXPERIMENTAL|Adductor Canal Block|Patients in this group received local infiltration of bupivacaine in the adductor canal after surgery, in addition to the periarticular injection intra-op.
62548535|NCT02740192|SHAM_COMPARATOR|Periarticular Injection|Patients in this group received a bandaid at the presumed adductor canal injection site, in addition to the periarticular injection intra-op.
62548536|NCT06581913||Healthy young people|Healthy young people aged 18-30 years
62548537|NCT03390855|EXPERIMENTAL|Broccoli sprout and follow up|Daily consumption of 30 g of raw, fresh, broccoli sprouts, not cooked, during 10 weeks (70 days), followed by other 90 days of no ingestion of broccoli sprouts
62548538|NCT06632886|EXPERIMENTAL|Health Examination Cohort|"Asymptomatic participants in routine health examinations receive abdominal or chest non-contrast CT scans, categorized as follows:~1. Meinian cohort~2. Changhai cohort"
62548539|NCT04306536|EXPERIMENTAL|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
62548540|NCT04306536|NO_INTERVENTION|Control group|Best local diet
62548541|NCT05748951|EXPERIMENTAL|Tear Duct Plug|A device inserted into the tear duct to block tear drainage
62548542|NCT03027024|EXPERIMENTAL|IOL Implantation|Implantation of IOL: PhysIOL POD F GF
62548543|NCT03172195|EXPERIMENTAL|Patients with ulcerative colitis|Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.
62548544|NCT05324124|EXPERIMENTAL|Selpercatinib (Period 1)|Selpercatinib will be administered orally on Day 1 either in fast or fed state.
62548545|NCT05324124|EXPERIMENTAL|Selpercatinib (Period 2)|Selpercatinib will be administered orally on Day 8 either in fast or fed state.
62548546|NCT02972190|EXPERIMENTAL|Bilateral decompression with TLIF|Patients undergoing bilateral decompression with TLIF
62548547|NCT02972190|ACTIVE_COMPARATOR|laminectomy with PLIF|Patients undergoing laminectomy with PLIF
62548548|NCT03689465|ACTIVE_COMPARATOR|PTCy-ATG group|PTCy-ATG group refers to treatment with PTCy-ATG protocol as GVHD prophylaxis at a total dose of 4.5mg/kg ATG, a dose of 50mg/kg/d cyclophosphamide (CTX), a dose of 2.5mg/kg/d Ciclosporin A （CsA）, and a dose of 1.0g/d Mycophenolate Mofetil(MMF).
62548549|NCT03689465|ACTIVE_COMPARATOR|ATG group|ATG group refers to treatment with ATG protocol as GVHD prophylaxis at a total dose of 7.5mg/kg ATG, a dose of 2.5mg/kg/d Ciclosporin A （CsA）, a dose of 1.0g/d Mycophenolate Mofetil(MMF) and methotrexate (MTX, on days +1, +3 and +6).
62548550|NCT02290444|EXPERIMENTAL|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
62548551|NCT02290444|NO_INTERVENTION|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
62548552|NCT03875924||VWD BERHLINGO|Patients with constitutional von Willebrand Disease, of any severity, with or without inhibitor followed in one of the investigator centers
62548553|NCT06416514|EXPERIMENTAL|Patients with high social participation|Patients with high social participation were more active in health management and monitoring due to their high social participation. NPS symptoms were monitored regularly for patients in the different groups, and personalized interventions were developed according to the development of NPS symptoms and patient preferences.
62548554|NCT06416514|EXPERIMENTAL|Patients with low social participation|In the low social participation group, due to the low social participation of patients, their initiative to participate in health management and monitoring is also low. For the patients in the reorganized group, their self-confidence and enthusiasm to participate in activities are first enhanced through health education and health popularization, and NPS symptoms are regularly monitored, and personalized intervention measures are formulated according to the development of NPS symptoms and patient preferences.
62548555|NCT05141617|EXPERIMENTAL|Endoscopic treatment group|Patients in the endoscopic treatment group receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices.
62548556|NCT05141617|EXPERIMENTAL|TIPS group|Patients in the TIPS group receive transjugular intrahepatic portosystem stent-shunt.
62548557|NCT06387355|EXPERIMENTAL|Investigational Treatment Strategy|This arm will have a coronary CTA with FFR-CT with selective coronary artery revascularization plus optimal medical therapy after lower extremity revascularization
62548558|NCT06387355|NO_INTERVENTION|Standard|This arm will have optimal medical therapy after lower extremity revascularization
62548559|NCT05880511|SHAM_COMPARATOR|Group A (Sham)|Participants in group A will take part in 2-4 weeks of treatment with 3-5 sessions per week. Each session will involve both sham repetitive transcranial magnetic stimulation (rTMS) and augmented reality sensorimotor training. Sham repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. Participants will hear and experience the clicking but will not be provided with any stimulation. Sham rTMS will take approximately 11.5 minutes. Immediately following sham rTMS, participants will perform augmented reality sensorimotor training. Participants will perform 20 minutes of sensorimotor training.
62548560|NCT05880511|EXPERIMENTAL|Group B (Active)|Participants in group B will take part in 2-4 weeks of treatment with 3-5 sessions per week. Each session will involve both real repetitive transcranial magnetic stimulation (rTMS) and augmented reality. Repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. rTMS will take approximately 11.5 minutes. Immediately following rTMS, participants will perform augmented reality sensorimotor training. Participants will perform 20 minutes of sensorimotor training.
62720125|NCT01720394|ACTIVE_COMPARATOR|Propess|Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)
62720126|NCT01419119|EXPERIMENTAL|Group 1|Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
62720127|NCT01419119|EXPERIMENTAL|Group 2a|Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
62720128|NCT01419119|EXPERIMENTAL|Group 2b|Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
62720129|NCT01419119|EXPERIMENTAL|Group 3|Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L
62548561|NCT03731442|EXPERIMENTAL|Involved field irradiation|Patients after R0 surgery whose recurrence lesion larger than 5cm in diameter, or largest diameter was less than 5cm but with skip metastasis far from primary tumor or their time-to-recurrence longer than 16 months were assigned to involved field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 60Gy/2Gy/30f, and for lesions close to the thoracic stomach, the prescribed dose is 59.4-61.2Gy/1.8Gy/33-34f. Chest CT scan is planned at 50Gy. Radiation field should be modified according to the tumor response. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF (3-6mg) should be given after 48 hours of chemotherapy.If patients received postoperative chemotherapy of paclitaxel and platinum and went through local-regional recurrence within six months, it is allowed to deliver chemotherapy regimens in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
62548562|NCT03731442|EXPERIMENTAL|Elective field irradiation|Patients after R1/R2 surgery or R0 surgery with the recurrence lesion whose diameter was less than 5cm without skip metastasis far from primary tumor and time-to-recurrence shorter than 16 months were assigned to elective field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a simultaneously integrated boost up to 59.92-62.16Gy/2.14-2.22Gy/28f. For lesions close to the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a sequential boost of 10-12Gy/1.8-2Gy/5-7f. For patients whose planned thoracic stomach V50\>50%, the dose should be lowered to 45Gy/1.8Gy/25f. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF should be given in need. If patients received postoperative chemotherapy of TP and went through local-regional recurrence within 6 months, chemotherapy regimens delivered in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
62548563|NCT02509130||Patients who attended RAAC/SAAC.|Patients who have previously attended the Rapid Access Asthma Clinic (RAAC) will be approached for the quantitative study. Patients who went onto the attend the Severe Asthma Assessment Clinics (SAAC) will also be approached for the quantitative and qualitive parts of the study.
62548564|NCT02509130||Patients eligible for RAAC, but DNA'd|Patients identified by the GP search, who did not attend the previous MISSION clinics will be approached to participate in the quantitative part of the study.
62548565|NCT02509130||Asthma Outpatients|Patients who are attending outpatient clinics as new referrals will be approached to participate in the quantitative part of the study.
62548566|NCT02509130||Healthcare Professionals|Healthcare professionals who performed the MISSION RAAC or SAAC will be approached for qualitative interview part of the study only.
62548567|NCT00299130|ACTIVE_COMPARATOR|Placebo + methotrexate (MTX)|"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
62548568|NCT00299130|EXPERIMENTAL|Rituximab 2 x 0.5 g + MTX|"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
62548569|NCT00299130|EXPERIMENTAL|Rituximab 2 x 1.0 g + MTX|"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
62548570|NCT03647085||Group 1 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, persistent atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
62548571|NCT03647085||Group 2 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, paroxysmal atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
62548572|NCT03647085||Group 3 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, atrial flutter at the time of enrollment and are scheduled for an ablation or cardioversion.
62548573|NCT03406754||Ezera LaMarpeh rehabilitation programs|Participation in a rehabilitation program for 8 weeks
62548574|NCT01380600|OTHER|single arm; Dose escalation|Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
62548575|NCT03752814|EXPERIMENTAL|SYNOSTE Nitinail System|The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
62548576|NCT02072343|EXPERIMENTAL|Mainstream capnometer|
62548577|NCT02072343|EXPERIMENTAL|Microstream capnograph|
62548578|NCT03450473|OTHER|SurgiMend® MP|Patients will not be randomized as this is a case series study involving the evaluation of only 1 type of mesh (SurgiMend MP®).
62548579|NCT02570737||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
62548580|NCT02570737||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
62548581|NCT05281510|EXPERIMENTAL|VRC07523LS + CAP256V2LS + Vesatolimod (VES)|Participants will receive VES 6 mg (or up to 8 mg) every 2 weeks, for a total of 10 doses + VRC07-523LS and CAP256V2LS 20 mg/kg each on Day 7.
62548582|NCT00616512|EXPERIMENTAL|1|GF Strong Water Protocol/ water allowed between meals after oral care for selected clients/ Fraser Water Protocol
62720130|NCT04118543|EXPERIMENTAL|Intervention Group|The intervention group will take part in three 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
62548583|NCT00324220|EXPERIMENTAL|1|MGCD0103 oral administration 3 times per week.
62548584|NCT05475197|EXPERIMENTAL|Kinesio taping Type 1|"For the first group; While the wrist is 30° extension, the forearm is supinated and the elbow is extended, the distance between the 1st metacarpal joint and the medial epicondyles of the patient up to 5 cm below the median epicondyle will be measured. Two strips with width of 2.5 cm will be prepared. For the median nerve, the first band will be adhered along the nerve trachea by stretching of moderate intensity (50%) from the 2nd and 3rd metacarpophalangeal joint to 5 cm below the medial epicondyle.~The second strip will be applied without stretching to a distance of 5 cm under the medial epicondyle from the 4th and 5th metacarpophalangeal joint. In addition, a strip half the length of the wrist circumference will be adhered to the volar face of the wrist by applying tension to the middle 1/3 of it, without applying tension to both ends."
62548585|NCT05475197|EXPERIMENTAL|Kinesio taping Type 2|"For the second group; While the elbow is in full extension and the wrist in the extension and supination position, the distal two free ends of the tape will be adhered to the thenar and hypothenar regions without stretching. The middle 1/3 of the X-shaped tape will be adhered to the forearm volar face by applying moderate stretching.The first half of the two proximal free ends will have adhered to the medial and lateral epicondyle with little or no stretching, and the last half without any stretching.~The I-shaped tape will be adhered to the radial region of the wrist with the elbow in full extension, the wrist in a neutral position, and the palm closed. The middle of the tape will be stretched lightly and moderately, and the last 1/3 of it will be adhered to the ulnar part of the wrist without stretching. Kinesio taping will be applied to both groups once."
62548586|NCT05761899|EXPERIMENTAL|Gene-Corrected Macrophages|Autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments.
62548587|NCT02964312|OTHER|Latera Implant|Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
62548588|NCT06551792||Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection|Transforaminal Epidural Steroid Injection groups
62548589|NCT03296501|EXPERIMENTAL|Autologous ADRC injection|
62548590|NCT01111318|EXPERIMENTAL|BI 10773|50 mg single dose
62548591|NCT03204682|EXPERIMENTAL|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
62548592|NCT05446779||Sudden death|Unexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
62548593|NCT05446779||Control|Death because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
62548594|NCT04860180|EXPERIMENTAL|A, surgery|adrenalectomy
62548595|NCT04860180|NO_INTERVENTION|B, observation|conservative follow up
62548596|NCT00430066|EXPERIMENTAL|Imatinib Mesylate|400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
62548597|NCT00683657|EXPERIMENTAL|Saxagliptin 5 mg + Metformin|
62548598|NCT00683657|PLACEBO_COMPARATOR|Placebo + Metformin|
62548599|NCT03736031|EXPERIMENTAL|Intervention (Promotora)|The intervention group will have three face-to-face meetings with the promotora. Participant will continue to receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
62548600|NCT03736031|NO_INTERVENTION|Self-Education (Control)|Participant will receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
62548601|NCT03440125|EXPERIMENTAL|Healthy|Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.
62548602|NCT03440125|EXPERIMENTAL|LBP patients - CPC Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).
62548603|NCT03440125|EXPERIMENTAL|LBP patients - CPC and ES/M Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.
62548604|NCT02214992|EXPERIMENTAL|Telmisartan/Ramipril|Fixed dose combination tablet
62548605|NCT02214992|ACTIVE_COMPARATOR|Telmisartan + Ramipril capsule|
62548606|NCT02214992|ACTIVE_COMPARATOR|Telmisartan + Ramipril tablet|
62548607|NCT05766137|EXPERIMENTAL|Ridge preservation by filling the socket with autogenous partially demineralized dentin graft|2% HNO3 partial demineralization for 10 minutes
62548608|NCT05766137|EXPERIMENTAL|Ridge preservation by filling the socket with autogenous completely demineralized dentin graft|0.6N HCl for 30 minutes for complete demineralization
62548609|NCT05766137|ACTIVE_COMPARATOR|Ridge preservation by filling the socket with autogenous whole-tooth graft (AWTG).|After cleaning the tooth, it will be ground using bone mill and AWTG particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection , then washed twice in saline and dried using sterile gauze.
62548610|NCT03281876|EXPERIMENTAL|GSK3277511A Group|Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.
62548611|NCT03281876|PLACEBO_COMPARATOR|CONTROL Group|Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.
62548612|NCT03842644|EXPERIMENTAL|Tension Reduction|Tension reduction device for 3 months post surgery
62548613|NCT03842644|NO_INTERVENTION|Control|No tension reduction
62548614|NCT06158919|EXPERIMENTAL|PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sindilizumab: 200mg iv.gtt d1, q3w SOX: Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sindilizumab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable.The longest duration of PD-1 inhibitor treatment is 24 months."
62548615|NCT05012189|ACTIVE_COMPARATOR|Oseltamivir|Nursing homes randomized to receive oseltamivir for treatment and chemoprophylaxis for influenza.
62548616|NCT05012189|EXPERIMENTAL|Baloxavir|Nursing homes randomized to receive baloxavir for treatment and chemoprophylaxis for influenza.
62548617|NCT06372210|EXPERIMENTAL|D-Tect Patch|A D-Tect patch was applied by the clinical staff prior to each IEM tablet ingestion, and directly observed ingestions (DOIs), followed by ingestion of 15 placebo-embedded IEM tablets, 1 every 15 minutes in Cohort 1 on Day 1 and a single dose of Abilify MyCite® tablet in Cohort 2 on Day 1.
62548618|NCT03119779|EXPERIMENTAL|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
62548619|NCT03119779|ACTIVE_COMPARATOR|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
62548620|NCT03532828|EXPERIMENTAL|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
62548621|NCT03532828|EXPERIMENTAL|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
62548622|NCT02819284|ACTIVE_COMPARATOR|KPI-121 0.25% Ophthalmic Suspension|
62548623|NCT02819284|PLACEBO_COMPARATOR|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
62548624|NCT03323398|EXPERIMENTAL|Arm A: mRNA-2416 Alone|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 for six 28-day cycles.
62548625|NCT03323398|EXPERIMENTAL|Arm B: mRNA-2416 in Combination with Durvalumab|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 6 in combination with durvalumab through an intravenous infusion at a fixed dose on Day 1 of Cycles 1 through 6. The duration for each cycle is 28 days.
62548626|NCT06582186|EXPERIMENTAL|individualized maintenance doses|Individualization of first maintenance doses through a multiparametric algorithm integrating CYP2C19 genotype, C reactive protein level and age
62548627|NCT01531660|EXPERIMENTAL|training|step up jogging program
62548628|NCT05105997|ACTIVE_COMPARATOR|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision.
62548629|NCT05105997|PLACEBO_COMPARATOR|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
62548630|NCT03096158|EXPERIMENTAL|Ventilatory Muscle Training (TREMVEN)|The enrolled participants will perform inspiratory muscle training (IMT) for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
62548631|NCT03096158|EXPERIMENTAL|Aerobic Training (AERO)|It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
62548632|NCT03096158|EXPERIMENTAL|Isometric Handgrip Training (ISO)|Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
62548633|NCT00345631|ACTIVE_COMPARATOR|Manual Compression|Manual compression (MC)
62548634|NCT00345631|EXPERIMENTAL|Vascular Closure Device|Vascular Closure Device (VCD)
62548635|NCT03839966|EXPERIMENTAL|Active Treatment|Interpretation Bias Modification for Loneliness
62548636|NCT03839966|ACTIVE_COMPARATOR|Control Treatment|Healthy Habits Psychoeducation and Relaxation.
62548637|NCT02802904|EXPERIMENTAL|Palm olein IV 64|Palm olein IV 64, n= 15, 4 weeks intervention
62548638|NCT02802904|EXPERIMENTAL|Cocoa butter|Cocoa butter, n= 15, 4 weeks intervention
62548639|NCT02802904|EXPERIMENTAL|Virgin olive oil|Virgin olive oil, n= 15, 4 weeks intervention
62548640|NCT04574687|ACTIVE_COMPARATOR|Neurodevelopmental Techniques|Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
62548641|NCT04574687|EXPERIMENTAL|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
62548642|NCT01609205|EXPERIMENTAL|Arm 1|Adalimumab
62548643|NCT01914692|EXPERIMENTAL|Somatostatin group|Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
62548644|NCT01914692|PLACEBO_COMPARATOR|Blank group|Use the normal saline instead of somatostatin.
62548645|NCT03381170|EXPERIMENTAL|Ublituximab|Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
62548646|NCT01185197|EXPERIMENTAL|Myfortic plus low-dose steroid|Not necessary
62548647|NCT01185197|ACTIVE_COMPARATOR|Standard-dose steroid|Not necessary
62548648|NCT05858918|ACTIVE_COMPARATOR|clopidogrel|patient post elective angioplasty and stenting receiving aspirin 80 mg and clopidogrel 75 mg PO daily
62548649|NCT05858918|ACTIVE_COMPARATOR|ticagrelor|patient post elective angioplasty and stenting receiving aspirin 80 mg and ticagrelor 90 mg PO twice daily
62548650|NCT02605915|EXPERIMENTAL|Cohort 1A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks.
62548651|NCT02605915|EXPERIMENTAL|Cohort 1B: Atezolizumab/Trastuzumab emtansine 3.6 mg|Participants will receive atezolizumab in combination with trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
62548652|NCT02605915|EXPERIMENTAL|Cohort 1C: Atezolizumab/Trastuzumab emtansine 3.0 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (3.0 mg/kg) every 3 weeks.
62548653|NCT02605915|EXPERIMENTAL|Cohort 1D: Atezolizumab/Trastuzumab emtansine 2.4 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (2.4 mg/kg) every 3 weeks.
62548654|NCT02605915|EXPERIMENTAL|Cohort 1E: Atezolizumab/ doxorubicin/ cyclophosphamide|Participants with HER2-negative breast cancer will receive atezolizumab (every 2 weeks) in combination with doxorubicin (every 2 weeks) and cyclophosphamide for four cycles. After the completion of four cycles of combination atezolizumab /doxorubicin / cyclophosphamide, atezolizumab will be continued as a single-agent at a dose of 1200 mg every 3 weeks.
62548655|NCT02605915|EXPERIMENTAL|Cohort 1F: Atezolizumab/Trastuzumab/Pertuzumab/ Docetaxel|Participants will receive atezolizumab in combination with trastuzumab, pertuzumab, and docetaxel every 3 weeks.
62548656|NCT02605915|EXPERIMENTAL|Cohort 2A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
62548657|NCT02605915|EXPERIMENTAL|Cohort 2B: Atezolizumab/Trastuzumab emtansine|Participants will receive atezolizumab in combination with trastuzumab emtansine every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
62548658|NCT02605915|EXPERIMENTAL|Cohort 2C: Safety Expansion|Participants with HER2-positive metastatic breast cancer/unresectable locally advanced breast cancer who received prior treatment with trastuzumab and a taxane chemotherapy will receive atezolizumab in combination with trastuzumab emtansine at the dose determined from stage 1, every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
62548659|NCT02605915|EXPERIMENTAL|Cohort 2D: Safety Expansion|Participants with HER2-positive metastatic breast cancer recently progressed on an HP containing regimen will receive atezolimumab in combination with trastuzumab and pertuzumab every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
62548660|NCT02972892|EXPERIMENTAL|Et Control|Subjects, meeting the American Society of Anesthesiologists status classification system 1-3, to undergo a surgical procedure with inhaled anesthesia using the investigational Et Control option intervention. For Subjects under the Et Control option, the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the well being of the subject.
61976647|NCT02107482|ACTIVE_COMPARATOR|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
62548661|NCT02972892|ACTIVE_COMPARATOR|Control Arm|Subjects, meeting the American Society of Anesthesiologists status classification system 1-3, to undergo a surgical procedure with inhaled anesthesia using conventional fresh gas intervention. For subjects under the conventional option, the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature.
62548662|NCT02773602|EXPERIMENTAL|Dexamethasone|Dexamethasone has been used for adult epidurals and nerve blocks and in spine surgeries. It prolongs the duration of pain relief and causes less sedation. It is commonly administered to children during surgery to help decrease nausea and vomiting after surgery. It is also much cheaper than clonidine The patient will receive Ropivacaine plus 200 μgm/kg of dexamethasone in 1 ml saline
62548663|NCT02773602|ACTIVE_COMPARATOR|Clonidine|"Clonidine has been added to caudal analgesia for infants and children for many years. It increases the duration of pain relief of ropivicaine by itself, however, it may lead to prolonged sedation following the surgical procedure (an undesired effect) and it is expensive.~The patient will receive Ropivacaine plus 2 μg/kg of clonidine in 1 ml saline."
62548664|NCT02773602|PLACEBO_COMPARATOR|Normal Saline|The patient only will receive Ropivacaine
62720131|NCT04118543|SHAM_COMPARATOR|Sham-Exercise Group|The shame-exercise group will complete three sham exercise group sessions per week for eight weeks (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
62548665|NCT01988129|EXPERIMENTAL|Intervention|Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
62548666|NCT01988129|NO_INTERVENTION|Control|"Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session."
62548667|NCT05731193|EXPERIMENTAL|Exposed group (EXP)|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.
62548668|NCT06007716|ACTIVE_COMPARATOR|Experimental group|it was planned to apply reflexology massage once a day for each patient for 2 consecutive days, in total 2 sessions.
62548669|NCT06007716|PLACEBO_COMPARATOR|placebo group|placebo massage was applied once a day for each patient for 2 consecutive days, for a total of 2 sessions.
62548670|NCT01992185|ACTIVE_COMPARATOR|Photocil for Vitiligo|Active Drug - Photocil for Vitiligo
62548671|NCT01992185|PLACEBO_COMPARATOR|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
62548672|NCT06400030|OTHER|AH Plus sealer Group (Control Group)|in this group, root canal system was filled with AH Plus sealer in conjunction with lateral condensation.
62548673|NCT06400030|EXPERIMENTAL|BioCeramic Sealer Group (Experimental Group|in this group, root canal system was filled with BioCeramic-based sealer in conjunction with single gutta-percha cone.
62548674|NCT06123455|EXPERIMENTAL|Taurine + Sintilimab + investigator's choice chemotherapy|Taurine + Sintilimab + XELOX or Taurine + Sintilimab + SOX or Taurine + Sintilimab + FOLFOX
62548675|NCT06123455|ACTIVE_COMPARATOR|Sintilimab + investigator's choice chemotherapy|Sintilimab + XELOX or Sintilimab + SOX or Sintilimab + FOLFOX
62548676|NCT06287398|EXPERIMENTAL|Epcoritamab Treatment|Single arm study - All patients undergo same treatment with Epcoritamab for salvage and consolidation phases.
62548677|NCT05860673|EXPERIMENTAL|mini invasive scoliosis surgery (MIS)|This technique involves making small, noncontiguous, midline skin incisions at the levels to be instrumented, usually proximal and distal to the area of arthrodesis. A median fascial incision is then made to expose the vertebral segments on which to thread the screws while the bar is inserted submuscularly in a cranio-caudal direction, after appropriate maneuvers to correct the deformity.
62548678|NCT05860673|ACTIVE_COMPARATOR|posterior spinal fusion technique (PSF)|This technique is the surgical gold standard. It consists of an instrumented arthrodesis with posterior access and requires a wide median incision with extensive muscle dissection.
62548679|NCT06550739||training set|Patients were randomly divided into two groups: a training group of 671 individuals (approximately 70% of the data) and a validation group of 287 individuals (approximately 30% of the data).The nomogram model was developed using the training cohort.
62548680|NCT06550739||validation set|Validate the effectiveness of the model
62548681|NCT04991207|EXPERIMENTAL|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
62548682|NCT04991207|ACTIVE_COMPARATOR|Bosentan|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple (twice daily \[b.i.d.\]) oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
62548683|NCT04991207|EXPERIMENTAL|BIA 5-1058 and Bosentan|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple b.i.d. oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5 1058 400 mg (4 x 100 mg tablets) and bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
62548684|NCT01188512|EXPERIMENTAL|BPZE1 - Low dose|1,000 colony forming units (cfu) of BPZE1
62548685|NCT01188512|EXPERIMENTAL|BPZE1- middle dose|100,000 colony forming units (cfu) of BPZE1
62548686|NCT01188512|EXPERIMENTAL|BPZE1 - High dose|10,000,000 colony forming units (cfu) of BPZE1
62548687|NCT01188512|PLACEBO_COMPARATOR|Placebo|Formulation buffer
62548688|NCT02522923|EXPERIMENTAL|Physical Therapist|Participants randomized to this arm will receive care from a physical therapist first.
62548689|NCT02522923|ACTIVE_COMPARATOR|Primary Care Provider|Participants randomized to this arm will receive care from a primary care provider first.
62548690|NCT01910428|EXPERIMENTAL|L-asparaginase encapsulated in RBC|L-asparaginase encapsulated in RBC dose titration: 50, 100, 150 or 200 IU/kg
62548691|NCT03390803||patients with hemifacial spasm|
62548692|NCT03390803||healthy control subjects|
62548693|NCT01297985|EXPERIMENTAL|BRIDGES Intervention|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a 10-week course to an 8-week course, meeting for 2 1/2 hours once a week.
62548694|NCT01297985|NO_INTERVENTION|Comparison Wait-list Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend the BRIDGES program after their final research interview.
62548695|NCT06553352|EXPERIMENTAL|Zanubrutinib (Z) combined with Obinutuzumab (O)|Zanubrutinib (Z) 160mg bid oral d1-21 Obinutuzumab (O) C1 1000mg d1,8,15 C2-C6 d1 IV, then every 8 weeks until full 20 infusions (1 years maintenance)
62548696|NCT05624645|EXPERIMENTAL|Pelex Upp|In this arm, all patients received the device for use in treatment of stress urinary incontinence.
62548697|NCT01960309|EXPERIMENTAL|1. TnI elevation|TnI 0.06-0.60ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
62548698|NCT01960309|EXPERIMENTAL|2. TnI elevation|TnI 0.61-6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
62548699|NCT01960309|EXPERIMENTAL|3. TnI elevation|TnI\>6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
62548700|NCT01960309|EXPERIMENTAL|4. TnI elevation|TnI \>6.00 ng/ml, ischemia on ECG and Hb\<5.1. Intervention: minimal invasive cardiac imaging
62548701|NCT01960309|EXPERIMENTAL|5. TnI elevation|TnI \>6.00 ng/ml, ischemia on ECG and Hb\>5.0. Intervention: minimal invasive cardiac imaging
62548702|NCT01960309|ACTIVE_COMPARATOR|Control|TnI \<0.06 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
62548703|NCT03064724|EXPERIMENTAL|Smoking Cessation Group|Patients received the interactive mobile doctor (iMD) intervention.
62548704|NCT05086263|NO_INTERVENTION|Standard of Care (No VR) Randomization|Participants would take the same questionnaires as the VR interventional group except the RT questionnaire. Then they will proceed with their MRI.
62548705|NCT05086263|EXPERIMENTAL|VR Randomization|The virtual reality MRI training will be conducted immediately after completion of the questionnaires in a distraction free room. The training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Using audio/visual cues and biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure. The research subject will continue with their regularly scheduled MRI. The modified Yale Preoperative Anxiety Scale (mYPAS) is an observational measure and will be completed by research staff.
62548706|NCT04634279|EXPERIMENTAL|Collaborative Care Plus|Intervention is administered to patients in this arm. Care to be delivered via collaborative care. The supplement intervention adds family involvement in care and Caring Contacts, a suicide prevention method.
62548707|NCT04634279|NO_INTERVENTION|Control|Patients in this arm will receive enhanced usual care.
62548708|NCT02652949|EXPERIMENTAL|Endovascular Repair|Valiant Evo Thoracic Stent Graft System
62548709|NCT06197178|EXPERIMENTAL|Chimeric Antigen Receptor T cell LCAR-G08 Cells|Each subject will receive LCAR-G08 Cells
62548710|NCT00736632|PLACEBO_COMPARATOR|Placebo|Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.
62548711|NCT00736632|ACTIVE_COMPARATOR|Vitamin D|Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.
62548712|NCT00576095||PMD|Patients diagnosed with major depression with psychotic features
62548713|NCT00576095||NPMD|Patients diagnosed with major depression without psychotic features
62548714|NCT00576095||Controls|Participants with no psychiatric or depression history
62548715|NCT02899195|EXPERIMENTAL|Durvalumab|Pemetrexed/cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab every 3 weeks. The first 6 patients who are enrolled and commence treatment will be monitored for safety of the combination. Use of carboplatin in place of cisplatin will be permitted for patients who are ineligible for cisplatin due to impaired renal function at screening. For patients that receive cisplatin, carboplatin may also be substituted after Cycle 1 for cisplatin related toxicity (e.g., grade 3 ototoxicity, grade 3 nausea) at the investigator's discretion. After completion of Cycle 6 of concurrent therapy, patients with stable or responding disease per modified RECIST for malignant mesothelioma will continue on single agent durvalumab every 3 weeks until progression. Maximum duration of durvalumab treatment is 12 months starting from Cycle 1 of concurrent treatment (inclusive of any treatment delays or missed treatments).
62548716|NCT01028482|EXPERIMENTAL|sertraline, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
62548717|NCT01028482|PLACEBO_COMPARATOR|placebo, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
62548718|NCT01016327|EXPERIMENTAL|1|
62548719|NCT02067962|OTHER|Juvenile idiopathic arthritis.|Blood sample
62548720|NCT03608527|EXPERIMENTAL|Active motor treatment (AMT) group|15 people with multiple sclerosis performing a 8 week rehabilitative treatment based on task-oriented voluntary exercises (3 sessions/week).
61976648|NCT02107482|SHAM_COMPARATOR|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
61976649|NCT04665284|EXPERIMENTAL|Empagliflozin|
61976650|NCT04665284|ACTIVE_COMPARATOR|Usual Care Group|
62548721|NCT03608527|ACTIVE_COMPARATOR|Passive motor treatment (PMT) group|15 people with multiple sclerosis performing a 8 week passive mobilization delivered by a physical therapist (3 sessions/week).
62548722|NCT00948155|EXPERIMENTAL|Varenicline before placebo|"Drug (Varenicline (Chantix)): Placebo~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21."
62548723|NCT00948155|EXPERIMENTAL|Placebo then Varenicline|"Placebo: Drug Varenicline (Chantix)~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.~Intervention 'Drug (Varenicline (Chantix)): Placebo'"
62548724|NCT02934243||easy Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven easy
62548725|NCT02934243||difficult Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven difficult
62548726|NCT02833987||Treated with direct oral anticoagulants (DOACs)|Patients who received a new prescription for a DOAC (apixaban, dabigatran, or rivaroxaban) in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
62548727|NCT02833987||Treated with warfarin|Patients who received a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
62548728|NCT00258960|OTHER|Caelyx,Cyclophosphamide,Trastuzumab|Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)
62548729|NCT02567877||levothyroxine in thyroidectomy patients|patients undergoing thyroidectomy for nodular thyroid disease
62548730|NCT05145426|EXPERIMENTAL|Pain Trials|Multi visit - LIFU/Sham application, with quantitative sensory testing (using peltier device).
61976651|NCT04075058|EXPERIMENTAL|Study|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 34Gy in 10 fractions over 2 weeks.
62165939|NCT04533971|NO_INTERVENTION|Control Group|"Criteria~* documented diagnosis of MS,~* functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3~* no contraindications for WBC treatments found in the medical examination~* no other serious chronic diseases identified that may affect the results of the tests carried out~* readiness to participate in daily WBC~* a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
62548731|NCT05179330|EXPERIMENTAL|Group A (no visual feedback-visual feedback)|Participants in group A (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® without visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® plus visual feedback
62548732|NCT05179330|EXPERIMENTAL|Group B (visual feedback-no visual feedback)|Participants in group B (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® plus visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® without visual feedback
62548733|NCT02215967|EXPERIMENTAL|Multiple Myeloma|Dose Escalation with 5 dose levels based on the patients actual bodyweight
62548734|NCT05706584|NO_INTERVENTION|control grup (skill lab.)|"After the control group was determined from the students attending the child health and diseases nursing course in the 2023 -2024 fall semester.~* The control group will be informed and approved.~* The control group will be pre-tested~* The control group will go to the skill laboratory."
62548735|NCT05706584|EXPERIMENTAL|experimental group (metaverse skill lab.)|"After the experimental group was determined from the students attending the pediatric health and diseases nursing course in the fall semester of 2023-2024, respectively.~* Pre-test will be applied to the experimental group.~* Informed consent and demographic data collection form will be obtained from the experimental group.~* The experimental group will be informed about the metaverse and approval will be obtained.~* Premature infant nutrition training will be given to the experimental group in a metaverse-based skill laboratory environment.~* The experimental group will enter the metaverse skill laboratory environment one by one, select their avatar and switch to the patient room in the environment,~* The experimental group will evaluate the feeding pattern of the premature baby on the scenario given first in the metaverse-based skills laboratory."
62548736|NCT02595801||Exposed|Exposure to surgery prior to completion of Early Development Instrument
62548737|NCT02595801||Reference|No exposure to surgery prior to completion of Early Development Instrument
62548738|NCT00334373|EXPERIMENTAL|Post conditioning|Balloon inflations-deflations
62548739|NCT00334373|PLACEBO_COMPARATOR|Standard care|No balloon inflations
62548740|NCT00691717|EXPERIMENTAL|24 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye
62548741|NCT00691717|EXPERIMENTAL|48 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye
62548742|NCT00691717|EXPERIMENTAL|60 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye
62548743|NCT00691717|PLACEBO_COMPARATOR|Anecortave Acetate Vehicle|Single depot administration of 0.8 mL in the study eye
62548744|NCT04884373||Fasted adult patients for elective surgery|"* Age ≥ 18 years~* Fasted according to national guidelines~* Elective surgery~* ASA physical status I-II~* Ability to assume both supine and right lateral decubitus position.~* Able to understand and to sign informed consent"
62548745|NCT02711878|EXPERIMENTAL|Let's Move Program|Participants in this group will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes in their home while wearing a heart rate monitor and a pedometer. Participants will then enter a maintenance exercise period for 65 weeks.
62548746|NCT02711878|ACTIVE_COMPARATOR|Let's Flex Program|Participants in this group will be asked to stretch five times per week for twelve weeks for a minimum of thirty minutes in their home. Participants will then enter a maintenance exercise period for 65 weeks.
62720132|NCT04651205|NO_INTERVENTION|Untreated|This control group will be untreated for 8 weeks as to be a controlled group. Then all participants in the control group will be randomised again to either Mg-B1 or B1-Mg groups for another 8 weeks (delayed-start intervention).
62720133|NCT04651205|EXPERIMENTAL|Mg-B1 early start|Participants in the Mg-B1 are the 'early start' group where they will receive 400 mg of Mg per day for 4 weeks then add on 100 mg of B1 per day for another 4 weeks, a total duration of 8 weeks (MgB1).
62720134|NCT04651205|EXPERIMENTAL|B1-Mg early start|Participants in the B1-Mg are the 'early start' group where they will receive 100 mg of B1 per day for 4 weeks then add on 400 mg of Mg per day for another 4 weeks, a total duration of 8 weeks (B1Mg).
62720135|NCT01544348|PLACEBO_COMPARATOR|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
62720136|NCT01544348|ACTIVE_COMPARATOR|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
62720137|NCT01544348|EXPERIMENTAL|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
62720138|NCT01544348|EXPERIMENTAL|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
62720139|NCT01544348|EXPERIMENTAL|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
62720140|NCT01544348|EXPERIMENTAL|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
62720141|NCT01544348|EXPERIMENTAL|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
62720142|NCT01544348|EXPERIMENTAL|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
62720143|NCT03478670||ADA-SCID subjects treated with Strimvelis|Subjects with ADA-SCID who have received Strimvelis (previously GSK2696273) gene therapy, comprising patients treated prior to marketing authorisation (i.e. clinical studies and compassionate use programs) and those treated after marketing authorisation (including within compassionate use and early access programs).
62720144|NCT03102983|EXPERIMENTAL|Healthy Volonteers|
62720145|NCT06022094|EXPERIMENTAL|Delta of before/after the intervention|Data will be collected before and after the reduced carb intervention
62720146|NCT03941847|EXPERIMENTAL|music|The experimental group will benefit from musical listening during a classic period of induction of anesthesia
62720147|NCT03941847|NO_INTERVENTION|silence|The control group will have a usual care.
62720148|NCT02271061|EXPERIMENTAL|Kinesio Tape|Taping method will be performed in supine position .The taping technique will be started at tibial tuberosity to medial and lateral epicondyles of the femur. The tape will be cut in I shape with 30 cm. The back paper of tape will be removed from the center of tape and both end of the back paper will be placed at each end of tape. Center of the tape will be placed on the tibial tuberosity with no tension. Participants' knee will be bend approximately 20 - 30 degrees. The tape will be pulled at 1/3 of each end with 75% of available tension along the medial and lateral collateral ligaments and the tibia will be pushed to the back. The end of the tape will be placed with no tension toward the medial and lateral aspects of the thigh .
62720149|NCT02271061|SHAM_COMPARATOR|Control tape|Apply tape in same technique without tension.
62720150|NCT01655186|PLACEBO_COMPARATOR|Placebo|Oral, once daily
62720151|NCT01655186|EXPERIMENTAL|Bardoxolone Methyl|Oral, once daily
62720152|NCT03067792|ACTIVE_COMPARATOR|FOLFIRI|2nd palliative chemotherapy with FOLFIRI regimen,In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5- fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle. Response evaluation would be done after 3 cycle of chemotherapy in DP group
62720153|NCT03067792|ACTIVE_COMPARATOR|DP|2nd palliative chemotherapy with Docetaxel/cisplatin regimen, In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle. Response evaluation would be done after 2 cycle of chemotherapy in DP group
62720154|NCT02433912|EXPERIMENTAL|Test - Laterally positioned flap|Incisions were made in mesial and distal aspects of the recession, in order to remove the epithelial attachment. The root surface was then instrumented. The flap design was outlined by two vertical incisions which extended from the horizontal incision which was performed either at the gingival, or 1 - 2mm apically, following the marginal gingival contour. The flap was rotated laterally in order to completely cover the recession defect and extend for approximatelly 1mm coronal to the CEJ. Careful flap suturing was performed in order to position and secure the soft tissues over the root surface by means of sling and simple sutures.
62720155|NCT02433912|ACTIVE_COMPARATOR|Control - Coronally advanced flap|The CAF was designed performing two vertical releasing incisions at both the mesial and distal aspects of the recession to be treated, in such a way that both the proximal papillae were not included as part of the flap. The vertical incisions were joined by an intrasulcular incision. A combined mucoperiosteal-mucosal flap was elevated. Thorough root planning was performed. A complementary horizontal incision was performed on the apical aspect of the flap, releasing it from the attached periosteum. This allowed the elongation and free coronal positioning of the flap. The flap was coronally positioned and maintained in place by means of individual 5.0 monofilament sutures.
62720156|NCT06199024|EXPERIMENTAL|Cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
62720157|NCT06199024|PLACEBO_COMPARATOR|Control group|Patients take 3 placebo pills daily (containing white wheat flour, which is similar to cinnamon pills in terms of size, shape, color and smell, Sagepad Darou Pharmaceutical Company, Iran) 4 weeks before starting the ovarian stimulation/in vitro fertilization (COS/IVF) cycle and 2 weeks during the ovarian stimulation procedure, the ovary will be stimulated
62720158|NCT03121144|EXPERIMENTAL|Masimo Centroid System|Single-arm study. All subjects are enrolled into the test group wherein the noninvasive positional monitoring device will be administered.
62720159|NCT03034707|EXPERIMENTAL|Biotin arm|biotin 10 mg/day for 7 days
62720160|NCT05960838|EXPERIMENTAL|Invervention 1|Immobilization with the Ultrasling® Quadrant shoulder brace after surgical treatment.
62720161|NCT05960838|ACTIVE_COMPARATOR|Intervention 2 (Control)|Immobilization with the Bledsoe ARC® brace after surgical treatment.
62548747|NCT05368493|OTHER|All participants|All participants will be in the same arm.
62548748|NCT00422825|EXPERIMENTAL|Imatinib 800mg|
62548749|NCT00422825|ACTIVE_COMPARATOR|Imatinib 400mg|
62548750|NCT01241110|ACTIVE_COMPARATOR|azitromicin,PID treatment,ofluxacin|
62548751|NCT03638388|ACTIVE_COMPARATOR|Dry Needling (DN)|"Subjects will receive dry needling treatment, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
62548752|NCT03638388|ACTIVE_COMPARATOR|Dry Needling with Intramuscular electrical stimulation (DNES)|"Subjects will receive dry needling treatment with electrical stimulation, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
62548753|NCT02750956||Group 1|Periodontal healthy individuals
62548754|NCT02750956||Group 2|Patients with chronic periodontitis
62548755|NCT02750956||Group 3|the same patients in group 2 after they had been treated with scaling and root planing (SRP) were considered as Group 3.
62548756|NCT05298865|PLACEBO_COMPARATOR|Neutral recall message|Control group will receive a set of messages guiding them to recall neutral life senarios/objects. The messages will contain eight brief paragraphs of neutral text and icon-based pictures to guide participants to recall their life senarios. The text message will include yesterday's meals, yesterday's wearing, home environment and nearby locations. This control condition equated attention and time on task but expect not to induce any emotions in participants.
62548757|NCT05298865|EXPERIMENTAL|Positive imagination stimulation|Positive-affect-priming group (PA) will receive a set of messages guiding participants to imagine positive future life senarios. Prior receiving the PA messages, a brief instruction will also be provided to guide participants to imagine concrete and personal images while browsing the following messages. The PA messages will contain eight pictures representing the life senarios and accompanying with short text to guide participants' imagination. Each senario will contain two pictures, one is used to familiarized participants with the context that they are going to imagine (i.e. imagine one of your best friends); the second one provides richer information to stimulate participants' concrete imagination (i.e. imagine you share a good news with your friend). These intervention messsages aim to intentionally manipulate participants' feelings arousal and mental representation for positive future life.
62548758|NCT00742963|EXPERIMENTAL|1|75 mg/m2 of Doxorubicin administered by bolus injection starting on Day 1 of a 21-day cycle.
62548759|NCT01921686||Gastroesophageal Reflux Disease (GERD)|"History of troublesome symptoms (e.g. heartburn, chest pain, acid regurgitation) secondary to reflux of gastric contents at least three times per week~AND, At least one of the following:~* Mucosal breaks on endoscopy (at least Grade-A esophagitis based on Los Angeles classification)~* Abnormal pH index (pH less than 4 for greater than 6% of study)~* Abnormal MII-pH (greater than 73 episodes of total reflux per 24 hours)"
62548760|NCT01921686||Eosinophilic Esophagitis (EoE)|"* History of troublesome esophageal symptoms (e.g. dysphagia, food impaction, vomiting, upper abdominal or chest pain)~* Greater than or equal to 15 eosinophils in at least one high powered field (HPF) from distal OR proximal esophageal biopsy~* Lack of histological response to 6-8 weeks of high dose Proton Pump Inhibitor (PPI) OR negative pH probe (pH less than 4 for less than 6% of study). Subjects with greater than 15 eosinophils/HPF and abnormal pH results may have an overlap syndrome and will be excluded from the primary analysis."
62548761|NCT01921686||Control|Patients with no history of troublesome esophageal symptoms or esophageal disease AND normal esophagoscopy (for example, patients undergoing evaluation for chronic abdominal pain, inflammatory bowel disease, celiac disease).
62548762|NCT01461538|EXPERIMENTAL|Brentuximab vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
62548763|NCT01461538|EXPERIMENTAL|Brentuximab vedotin 2.4 mg/kg|Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
62548764|NCT01461538|EXPERIMENTAL|Brentuximab vedotin 1.2 mg/kg|Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
62548765|NCT00979199|OTHER|Non invasive cardiac imaging|Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.
62548766|NCT01006798|EXPERIMENTAL|Cohort 1|three vaccinations of 10\^7vp Ad4-H5-Vtn or placebo
62548767|NCT01006798|EXPERIMENTAL|Cohort 2|three vaccinations of the 10\^8vp Ad4-H5-Vtn or placebo
62548768|NCT01006798|EXPERIMENTAL|Cohort 3|three vaccinations of 10\^9 Ad4-H5-Vtn or placebo
62548769|NCT01006798|EXPERIMENTAL|Cohort 4|three vaccinations of 10\^10 Ad4-H5-Vtn or placebo
62548770|NCT01006798|EXPERIMENTAL|Cohort 5|three vaccinations of 10\^11 Ad4-H5-Vtn or placebo
62548771|NCT02729909|EXPERIMENTAL|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
62548772|NCT02729909|PLACEBO_COMPARATOR|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
62548773|NCT01427608|ACTIVE_COMPARATOR|Sertraline + Olanzapine|Randomized to continue with sertraline and olanzapine under double-blind conditions.
62548774|NCT01427608|PLACEBO_COMPARATOR|Sertraline + Placebo|Randomized to continue with sertraline and substitute placebo for olanzapine under double-blind conditions.
62548775|NCT00852202|EXPERIMENTAL|1|0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
62548776|NCT00852202|EXPERIMENTAL|2|1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
62548777|NCT00852202|PLACEBO_COMPARATOR|3|Matching placebo capsules, oral administration, once daily dosing.
62548778|NCT04272424|ACTIVE_COMPARATOR|group A|laparoscopic hernioplasty with no fixation
62548779|NCT04272424|ACTIVE_COMPARATOR|group B|laparoscopic hernioplasty with tacker fixation
62548780|NCT04272424|ACTIVE_COMPARATOR|group C|laparoscopic hernioplasty with histoacryl fixation
62548781|NCT04881487|EXPERIMENTAL|Additional stereotactic body radiation therapy|SBRT in addition to standard of care.
62548782|NCT04881487|NO_INTERVENTION|Standard of care|Treatment according to current clinical practice.
62720162|NCT05578989|EXPERIMENTAL|Group watching video with virtual reality glasses|Women in the intervention group watched a video with virtual reality glasses during the episiotomy. (25 women)
62720163|NCT05578989|NO_INTERVENTION|Comparisongroup that does not use virtual glasses|The women in the control group were treated with without watching videos during the episiotomy. (25 women)
62720164|NCT02449941||Helicobacter pylori(HP) positive|Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
62720165|NCT04464551|EXPERIMENTAL|[14C]D-0316|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (75mg, 50µCi) of \[14C\]D-0316 to healthy Chinese male subjects
62720166|NCT06320704||Complete Denture Group|Completely edentulous patients undergoing complete denture treatment plan effectively balanced using oculosense device
62720167|NCT02246491|OTHER|iPSCs without gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
62720168|NCT02246491|OTHER|iPSCs with gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
62720169|NCT04016701|EXPERIMENTAL|VR Intervention|Eight weeks of training with Floreo's VR Joint Attention Module with two sessions per week
62720170|NCT04016701|ACTIVE_COMPARATOR|Treatment as Usual|Regularly scheduled therapy
62720171|NCT02129712|PLACEBO_COMPARATOR|Non-adaptive cognitive training|Non-adaptive cognitive training
62720172|NCT02129712|EXPERIMENTAL|Adaptive cognitive triaining|Adaptive cognitive training
62720173|NCT00869167|EXPERIMENTAL|1: Ramelteon|
62720174|NCT00869167|PLACEBO_COMPARATOR|2: Placebo|
62720175|NCT06199414||Subjects with Figure-of-eight (F-8) suture|This is the group of subjects for whom Figure-of-eight (F-8) suture is used for their venous closure.
62720176|NCT06199414||Subjects with LockeT Device|This is the group of subjects for whom LockeT device is used for their venous closure.
62720177|NCT04877327|EXPERIMENTAL|Cross-over of ablation technique|Cross-over of cardiac ablation procedures (cryotherapy and radiofrequency; radiofrequency and cryotherapy)
62720178|NCT04877327|NO_INTERVENTION|Repetition of the same technique|Repeat the same procedure (cryotherapy and cryotherapy; radiofrequency and radiofrequency)
62720179|NCT06170567|EXPERIMENTAL|Students' course success|The effect of puzzles on students' course success
62720180|NCT06170567|EXPERIMENTAL|Student scores|The effect of puzzles on students' course success
62720181|NCT02343770|EXPERIMENTAL|idiopathic juvenile arthritis|blood sample
62720182|NCT02343770|OTHER|control|blood sample
62720183|NCT04614844|EXPERIMENTAL|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
62720184|NCT04614844|ACTIVE_COMPARATOR|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
62720185|NCT00326599|EXPERIMENTAL|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and oral AZD2171 once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. Patients achieving stable disease, partial response, or complete response after 6 courses of therapy receive AZD2171 alone as above. Treatment with AZD2171 repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62720186|NCT00326599|ACTIVE_COMPARATOR|Arm II|Patients receive gemcitabine and carboplatin as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62720187|NCT04892186|EXPERIMENTAL|Myo-inositol|30 women with resistance insulin or glucose intolerance will receive myo-inositol 2g + folic acid 200mcg, orally, twice a day for 6 months.
62720188|NCT04892186|ACTIVE_COMPARATOR|Metformin|30 women with resistance insulin or glucose intolerance will receive metformin 850 mg, orally, twice a day for 6 months
62720189|NCT01950728|NO_INTERVENTION|Control group|This group will not receive electrical stimulation. Volunteers will rest during 30 minutes.
62720190|NCT01950728|ACTIVE_COMPARATOR|Interferential current group|Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
62720191|NCT01950728|ACTIVE_COMPARATOR|TENS Group|TENS will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
62720192|NCT01950728|ACTIVE_COMPARATOR|Aussie current group|Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
62720193|NCT01110057|EXPERIMENTAL|Active|GW856553
62720194|NCT01110057|PLACEBO_COMPARATOR|Placebo|Placebo
62720195|NCT00125970|EXPERIMENTAL|1|DNA HIV vaccine administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine administered at Month 6
62720196|NCT00125970|PLACEBO_COMPARATOR|2|DNA HIV vaccine placebo administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine placebo administered at Month 6
62720197|NCT01781884|ACTIVE_COMPARATOR|Gamma Aminobutyric Acid (GABA)|GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
62720198|NCT01781884|ACTIVE_COMPARATOR|Gamma Aminobutyric Acid GABA)|GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
62720199|NCT01781884|PLACEBO_COMPARATOR|placebo|placebo will be given thrice daily for 52 weeks
62720200|NCT00539240|PLACEBO_COMPARATOR|Rabeprazole morning/evening placebo bedtime|AciPhex 20 mg BID and once daily placebo
62720201|NCT00539240|PLACEBO_COMPARATOR|Rabeprazole breakfast, placebo dinner and bedtime|AcipHex 20 mg once daily and BID placebo
62720202|NCT00539240|ACTIVE_COMPARATOR|Rabeprazole breakfast, placebo dinner, nortriptyline bedtime|AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
62720203|NCT02960633|ACTIVE_COMPARATOR|THA with Collar|THA with Collar
62720204|NCT02960633|ACTIVE_COMPARATOR|THA without Collar|THA without Collar
62720205|NCT04236089|NO_INTERVENTION|mirror therapy of healthy adults|Traditional mirror therapy in electroencephalography of healthy adults.
62720206|NCT04236089|EXPERIMENTAL|robotic mirror therapy of healthy adults|Robotic mirror therapy in electroencephalography of healthy adults.
62720207|NCT04236089|NO_INTERVENTION|mirror therapy of stroke patients|Traditional mirror therapy in electroencephalography of stroke patients.
62720208|NCT04236089|EXPERIMENTAL|robotic mirror therapy of stroke patients|Robotic mirror therapy in electroencephalography of stroke patients.
62720209|NCT03904134|OTHER|Donor Search Prognosis: MUD Very Likely|Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a \>90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
62720210|NCT03904134|OTHER|Donor Search Prognosis: MUD Very Unlikely|Patients who are Very Unlikely to find a MUD, defined as having a \<10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
62720211|NCT03904134|OTHER|Donor Search Prognosis: MUD Less Likely|Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
62720212|NCT03928041|OTHER|single prospective study|All subjects who are entered into this trial will receive the EVOS Lumbar Interbody System (EVOS- HA).
62720213|NCT05749640|ACTIVE_COMPARATOR|"Palodent® plus sectional matrix system Control group"|
62720214|NCT05749640|EXPERIMENTAL|"PerForm™ Experimental"|
62720215|NCT05749640|EXPERIMENTAL|"Trimax™ Experimental"|
62720216|NCT05749640|EXPERIMENTAL|"Contact Pro™ Experimental"|
62720217|NCT06237634|ACTIVE_COMPARATOR|control group|First group (30 people): A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side..
62720218|NCT06237634|ACTIVE_COMPARATOR|corticosteroid group|Second group (30 people): In addition to the treatment and recommendations given to the first group, 40 mg (1 ml) triamcinolone acetonide was injected into the wrist under ultrasound guidance.
62720219|NCT06237634|EXPERIMENTAL|ozone group|Third group (30 people): In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
62720220|NCT06375083|EXPERIMENTAL|Cognitive Behavioral Therapy|
62720221|NCT04256187||Healthy group|Caregivers of children who treated with botulinum toxin.
62720222|NCT02058225||Infant Group 1|This group consist of healthy, full-term babies whose mothers have no known medical conditions or complications during pregnancy.
62720223|NCT05962255|EXPERIMENTAL|0.9 % Sodium Chloride solution|Patients receiving an intravenous infusion of 0.9% NaCl
62720224|NCT05962255|ACTIVE_COMPARATOR|5% Glucose solution|Patients receiving an intravenous infusion of 5% glucose
62720225|NCT05231824|ACTIVE_COMPARATOR|BWL-S|1 year of remote gold standard, small group-based behavioral weight loss treatment with an MS-level clinician.
62720226|NCT05231824|EXPERIMENTAL|BWL-AI|1 year of remote weight loss treatment made up of a combination of (1) remote small group-based behavioral weight loss sessions, (2) 12-minute individual video calls, (2) automated text messages. An MS-level clinician will deliver the group treatment. Most video calls will be delivered by a paraprofessional coach, but some by an MS-level clinician. Each week the AI system will select one of the interventions for each participant based on which treatment the participant has responded to the best, within certain time constraints.
62720227|NCT03679104|ACTIVE_COMPARATOR|Endoscopic clips|Closure of mucosotomy using endoscopic clips
62720228|NCT03679104|ACTIVE_COMPARATOR|OverStitch™ suturing device|Closure of mucosotomy using OverStitch™ suturing device
62720229|NCT03332121|EXPERIMENTAL|B001,B001 dose escalation|5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg
62720230|NCT00544856|EXPERIMENTAL|1|cognitive intervention
62720231|NCT00544856|PLACEBO_COMPARATOR|2|
62720232|NCT06117007|ACTIVE_COMPARATOR|Betalains|Daily consumption of 1 betalain capsule (25 mg betalains) for 28 days.
62720233|NCT06117007|PLACEBO_COMPARATOR|Placebo|Daily consumption of 1 placebo capsule (0 mg betalains) for 28 days.
62720234|NCT03479489|EXPERIMENTAL|Human dehydrated amnion/chorion allofraft|Closed hemorrhoidectomy patched with human dehydrated amnion chorion allograft
62720235|NCT01450644|OTHER|Fast track|If patients are randomised to fast-track, their information will be passed to the H2H nurse to organise a case conference within one week of discharge.
62720236|NCT01450644|OTHER|Waiting list|If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
62720237|NCT04708886|EXPERIMENTAL|Females with Chronic SCI|12-month treatment with monthly subcutaneous romosozumab injections (210 mg), followed by 12-month treatment with weekly oral alendronate tablets (70 mg)
62720238|NCT05908838|ACTIVE_COMPARATOR|combination chemotherapy with Modified Banxia Xiexin Decoction|146 patients with gastric cancer were randomly divided into a treatment group of 73 cases and a control group of 73 cases. The treatment group received combination chemotherapy with Modified Banxia Xiexin Decoction
62720239|NCT05908838|PLACEBO_COMPARATOR|combination chemotherapy with Placebo granules|The control group received combination chemotherapy with Placebo granules.
62720240|NCT06307847|EXPERIMENTAL|SP5M001 inj|SP5M001 inj 5 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients
62720241|NCT06307847|ACTIVE_COMPARATOR|Synovian inj|Synovian inj 3 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients
62737677|NCT01508377|EXPERIMENTAL|Treatment of PTSD with cognitive restructuring|"In this arm the PTSD treatment can be divided into three phases.~First phase: self-confrontation (4 essays)~Second phase: cognitive restructuring (4 essays)~Third phase: parting (2 essays)"
62720242|NCT06718881|EXPERIMENTAL|Intervention|In the project, theoretical lessons were given on preeclampsia, postpartum care, and condom counseling, each in a separate week. After each theoretical lesson, an application was made in the laboratory on the subject explained in the same week. The applications were made in the form of a simulation application in a virtual reality environment for the students in the experimental group.
62720243|NCT06718881|NO_INTERVENTION|Control|After classical training, case discussion and role play were conducted.
62720244|NCT03423602|EXPERIMENTAL|Investigational device|To confirm safety and performance of the PerQseal® Closure Device (DP2-FA1-4) and PerQseal® Introducers (DP2-FA1-5 and DP2-FA1-6) to percutaneously close femoral artery punctures and to induce arterial haemostasis in patients undergoing endovascular procedures requiring an arteriotomy created by 12 to 20 F sheaths.
62720245|NCT05364710|EXPERIMENTAL|Group A|Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where he/she will consume the active intervention.
62720246|NCT05364710|EXPERIMENTAL|Group B|Crossover study: Participants will be consuming the active intervention on a clinic day at least 1 week prior to a clinic day where he/she will consume placebo.
62720247|NCT01874392|EXPERIMENTAL|T1DM|Adults aged 21-65 years with type 1 diabetes mellitus for at least one year who are using an insulin infusion pump with rapid-acting insulin for at least six months
62720248|NCT03966040|EXPERIMENTAL|Immunization schedule of day 0-3-7|Three doses of schedule given at day 0, 3 and 7.
62720249|NCT03966040|EXPERIMENTAL|Immunization schedule of day 0/0-3-7|Four doses of schedule given at day 0/0, 3 and 7.
62720250|NCT03966040|EXPERIMENTAL|Immunization schedule of day 0/0-7|Three doses of schedule given at day 0/0 and 7.
62720251|NCT03966040|EXPERIMENTAL|Immunization schedule of day 0/0-7-14|Four doses of schedule given at day 0/0, 7 and 14.
62720252|NCT02945124|EXPERIMENTAL|Normal children with K Tape|
62720253|NCT02945124|NO_INTERVENTION|Normal children without K Tape|
62720254|NCT02945124|EXPERIMENTAL|DCD with K Tape|
61976652|NCT04075058|ACTIVE_COMPARATOR|Control|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 35Gy in 15 fractions over 3 weeks
62720255|NCT02945124|NO_INTERVENTION|DCD without K Tape|
62720256|NCT03348293|EXPERIMENTAL|3D printing patient|Immediate breast reconstruction using 3D printing personalized scaffold
62720257|NCT00942383||IOUS-USEI|Receive intraoperative ultrasound (IOUS) using the Siemens Anteras to acquire ultrasound elasticity imaging (USEI) during standard of care surgical radiofrequency ablation and microwave ablation
62720258|NCT01470183||Lupus Nephritis Patients|"1. Male or female subjects age 18 and older~2. Must have confirmed diagnosis of Class III or Class IV lupus nephritis by biopsy~3. Must have stable disease on medication at time of enrollment"
62720259|NCT01470183||Control Patients|Any patient with an idiopathic glomerular disease who does not have lupus nephritis. This includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy.
62720260|NCT01837680|ACTIVE_COMPARATOR|Levemir|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
62720261|NCT01837680|ACTIVE_COMPARATOR|NPH|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
62720262|NCT05884372|EXPERIMENTAL|Denosumab+Eldecalcitol|Denosumab (subcutaneous injection 60mg/6 months) combined with ELD (oral 0.75μg/day) for 12 months.
62720263|NCT05884372|ACTIVE_COMPARATOR|Denosumab+Native Vitamin D+Calcium|Denosumab (subcutaneous injection 60mg/6 months) combined with native vitamin D (oral 800IU/day) and Calcium (oral 600mg/day) for 12 months.
62720264|NCT03888014||Treatment group|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
62720265|NCT01291966|EXPERIMENTAL|Motivational interview|
62720266|NCT01642550|ACTIVE_COMPARATOR|RM-131|Active study drug - RM-131
62720267|NCT01642550|PLACEBO_COMPARATOR|Placebo|Placebo comparator
62720268|NCT06466525|EXPERIMENTAL|Healthy Volunteers - SAD|Single dose of LBT-3627 administered to healthy volunteers
62720269|NCT06466525|EXPERIMENTAL|Parkinson's disease patients - SAD|Single dose of LBT-3627 administered to Parkinson's disease patients
62720270|NCT06466525|EXPERIMENTAL|Parkinson's disease patients - MAD|Multiple doses of LBT-3627 administered to Parkinson's disease patients
62720271|NCT01941602||prophylactic|Prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Department of neurosurgery at Karolinska Hospital, Stockholm, Sweden
62720272|NCT01941602||non-prophylactic|No use of prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Departments of neurosurgery at University Hospital North Norway (UNN) and St.Olavs University Hospital (Tromsø and Trondheim respectively, both Norway)
62720273|NCT01944020|EXPERIMENTAL|Intervention - CPAP use|Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
62165940|NCT04891809|EXPERIMENTAL|IRd followed by IR|Induction: 8 cycles isatuximab+lenalidomide+dexamethasone; Maintenance: up to 24 cylces isatuximab+lenalidomide
62720274|NCT01944020|NO_INTERVENTION|Control - No CPAP use|Control will be no use of CPAP for 2 months
62548783|NCT02201784|ACTIVE_COMPARATOR|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
62548784|NCT02201784|ACTIVE_COMPARATOR|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
62548785|NCT05868525|ACTIVE_COMPARATOR|Oral Daily Aspirin 81 mg|
62548786|NCT05868525|ACTIVE_COMPARATOR|Oral Daily Aspirin 325 mg|
62165941|NCT04891809|OTHER|Rd followed by R|Induction: 8 cycles lenalidomide+dexamethasone; Maintenance: up to 24 cylces lenalidomide
62548787|NCT02498041|EXPERIMENTAL|Transnasal Endoscopy|Unsedated transnasal endoscopy with biopsies
62548788|NCT02498041|ACTIVE_COMPARATOR|Standard Gastroscopy|Standard endoscopy with biopsies. Patients will decide whether they prefer to have endoscopy with intrevenous sedation or with local anaesthetic only
62548789|NCT00953966|OTHER|Starch 1|Starch 1
62548790|NCT00953966|OTHER|Starch 2|Starch 2
62548791|NCT00953966|OTHER|Starch 3|Starch 3
62548792|NCT00953966|OTHER|Starch 4|Starch 4
62548793|NCT00953966|OTHER|Starch 5|Starch 5
62548794|NCT00953966|OTHER|Starch 6|Starch 6
62548795|NCT00953966|OTHER|Starch 7|Starch 7
62548796|NCT05041920|EXPERIMENTAL|Single arm|The study will have only one study group in a fixed-sequence type of design.
62548797|NCT05029219|EXPERIMENTAL|Virtual reality group|To become proficient in lumbar transforaminal epidural blocks, participants receive additional training using virtual reality programs after audiovisual education.
62548798|NCT05029219|ACTIVE_COMPARATOR|Self study group|In order to become proficient in lumbar transforaminal epidural block, participants have self-study time using books and videos after audiovisual education.
62548799|NCT02387411|ACTIVE_COMPARATOR|Interval group|high-intensity interval exercise training
62548800|NCT02387411|ACTIVE_COMPARATOR|Combined group|combined exercise training
62548801|NCT06004791|PLACEBO_COMPARATOR|Herombopag + CsA|Herombopag 10mg/ day, adjust the dose according to the blood image, the course of treatment is at least 3 months, CsA: 3-5 mg/kg/d, adjust the valley concentration 100-200ng/ml, at least 6 months, effective patients continue to use for 1 year, and then gradually reduce the dose.
62548802|NCT06004791|EXPERIMENTAL|rhTPO combined with Herombopag + CsA|Administer rhTPO (15000U, subcutaneously once daily for 7 days, once a month for 3 months),Herombopag 10mg/day, adjust dose according to blood picture for at least 3 months, CsA: 3-5 mg/kg/d, adjust trough concentration 100-200ng/ml for at least 6 months, continue for 1 year if effective, then gradually reduce dose
62548803|NCT06243276|ACTIVE_COMPARATOR|Diabetic patients|
62548804|NCT06243276|ACTIVE_COMPARATOR|Healthy patient|
62548805|NCT05379244|EXPERIMENTAL|CBT-i|Cognitive Behavioral Therapy for insomnia adjusted for patients with mixed psychiatric disorders
62548806|NCT04514432||When music was available|3 month period during which music was available to patients experiencing agitation
62548807|NCT04514432||When music was not available|3 month period during which music was not available to patients
62548808|NCT03742505|EXPERIMENTAL|Vitamin D|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Vitamin D Group and will receive a single dose of cholecalciferol at enrolment.~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
62548809|NCT03742505|PLACEBO_COMPARATOR|Placebo|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Placebo Group and will receive a single dose of placebo at enrolment.~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
62548810|NCT04435249|EXPERIMENTAL|Treatment Arm|Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula.
62548811|NCT02237092|EXPERIMENTAL|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
62548812|NCT02925039|EXPERIMENTAL|Experimental|Sit to stand training augmented with technology delivered movement feedback
62548813|NCT02925039|ACTIVE_COMPARATOR|Control|Sit to stand training as per normal practice
62548814|NCT04022876|EXPERIMENTAL|Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed|
62548815|NCT04022876|EXPERIMENTAL|Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed|
62548816|NCT04022876|EXPERIMENTAL|Part 1 SCLC: ALRN-6924+Topotecan|
62548817|NCT03900455|EXPERIMENTAL|Hydrocellular polyurethane foam multilayer dressing|
62548818|NCT03900455|ACTIVE_COMPARATOR|standard preventive care|
62548819|NCT00273689|OTHER|I|This is a crossover trial- Patients get randomly assign to albuterol or singulair and then cross overed to the alternate active medication.
62548820|NCT05453890||A sample of adult egyptian population|
62548821|NCT02687347|EXPERIMENTAL|study arm|low dose methadone (1-10mg daily)
62548822|NCT02687347|ACTIVE_COMPARATOR|control arm|low dose morphine (1-10 mg/day)
62548823|NCT05279911|NO_INTERVENTION|Control|Implants were randomly inserted in 20 non-lased T2DM patients (Control)
62548824|NCT05279911|EXPERIMENTAL|Low level laser therapy|Implant were randomly inserted in 20 lased T2DM patients (Intervention)
62548825|NCT01377818|EXPERIMENTAL|ventilation|Group program of positive pressure ventilation noninvasive
62548826|NCT01377818|EXPERIMENTAL|exercise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~d. 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~e. Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
62548827|NCT01377818|EXPERIMENTAL|exercise training and ventilation|Group of exercise training program and noninvasive positive pressure ventilation
62548828|NCT01124578||Control|Existing used daily change-out device
62548829|NCT01124578||Egret|Extended Use Catheter w/BIOSAFE
62548830|NCT03789929||The Emotional Backpack|Healthy adults participating in the offered online-course on their own initiative.
62548831|NCT03789929||Feelings as Powers|Healthy adults participating in the offered online-course on their own initiative.
62548832|NCT06235489|EXPERIMENTAL|Palfique Bulk Flow bulk-fil flowable restorative material|Procedure: restoration of proximal cavities of primary molars with bulk-fil flowable composite removal of proximal caries of primary molars and restoration of the cavities prepared by Palfique bulk flow
61976653|NCT05226325|ACTIVE_COMPARATOR|G0.2|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.2 mcg/kg/hour
62548833|NCT06235489|ACTIVE_COMPARATOR|Glass-hybrid added HVGIC Equia Forte HT Glass-hyrbid-added highly viscous glass ionomer cement|Procedure: Restoration of proximal cavities of primary molars with highly viscous glass ionomer cement removal of proximal caries of primary molars and restoration of the cavities prepared by the Equia forte HT
62548834|NCT04201184|EXPERIMENTAL|Little Holy One intervention|The participants will receive 12 1-hour lessons on parenting, stress, and culture over a period of 16 weeks.
62548835|NCT04201184|ACTIVE_COMPARATOR|Nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes based on seasonal foods, as well as a shopping list for making future meals.
62548836|NCT00732485|ACTIVE_COMPARATOR|Fenofibrate|
62548837|NCT00732485|PLACEBO_COMPARATOR|Placebo|
62548838|NCT03633097|EXPERIMENTAL|Acupuncture + Usual care|Acupuncture with Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
62548839|NCT03633097|ACTIVE_COMPARATOR|Usual care|Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
62548840|NCT02179944||Participants|
62548841|NCT06296485|EXPERIMENTAL|Group Education Sessions|Participants will participate in 3 educational sessions designed to teach about applying and using continuous glucose monitors \[CGMs\] (Session 1) and how to prevent hypoglycemia episodes based on CGM readings and hypoglycemia journal entries (Sessions 2 \& 3).
62548842|NCT06296485|ACTIVE_COMPARATOR|Usual Care|Participants allocated to the control arm will continue with usual care.
62548843|NCT01557517|EXPERIMENTAL|Clobetasol|Patients will rinse oral cavity with 10cc of clobetasol 0.05% for 2 minutes 3 times a day.
62548844|NCT01557517|PLACEBO_COMPARATOR|Placebo|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
62548845|NCT02106234|ACTIVE_COMPARATOR|Control: NO prophylactic iv hydration|"Control group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed."
62548846|NCT02106234|NO_INTERVENTION|Standard care: prophylactic iv hydration|"Standard care group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will receive the standard intravenous prophylactic hydration treatment with normal saline as prescribed."
62548847|NCT03768362|EXPERIMENTAL|Undergoing plication strabismus surgery|
62548848|NCT03768362|ACTIVE_COMPARATOR|Undergoing resection strabismus surgery|
62548849|NCT00208273|EXPERIMENTAL|A|Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
62548850|NCT00208273|EXPERIMENTAL|B|Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.
62548851|NCT02843984|NO_INTERVENTION|A - untreated|The patients will be not treated with vaginal lactoferrin
62548852|NCT02843984|ACTIVE_COMPARATOR|B - 4 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
62548853|NCT02843984|ACTIVE_COMPARATOR|C - 12 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 12 hours prior to mid-trimester genetic amniocentesis.
62548854|NCT00059592|EXPERIMENTAL|Valacyclovir|oral Valacyclovir three times a day for 5 to 10 days.
62548855|NCT02333084|EXPERIMENTAL|Joint Health Product|natural dietary supplement
62548856|NCT02333084|PLACEBO_COMPARATOR|Placebo|vegetable oil placebo
62548857|NCT02333084|ACTIVE_COMPARATOR|Combination with Omega-3|combination with omega-3 fish oil
62548858|NCT04574440||multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap during surgery. The patient's surgery and subsequent medical care will not be altered.
62548859|NCT04736745|EXPERIMENTAL|Dose escalation|"One single injection of study medication (IPN59011 or Placebo) will be injected locally. IPN59011 is injected in a dose-escalation manner.~In total for this stage at least 40 subjects."
62548860|NCT04736745|EXPERIMENTAL|Dose ranging|"Up to two IPN59011dose(s) groups will be included in parallel groups versus Azzalure group and placebo group. One single injection of study medication will be injected locally into several sites.~In total for this stage at least 70 subjects."
62548861|NCT04736745|EXPERIMENTAL|Additional dose ranging|"Dose-ranging for three additional placebo-controlled parallel groups. One single injection of study medication will be injected locally into several sites, concomitantly and non-concomitantly.~In total for this stage at least 110 subjects."
62548862|NCT04736745|EXPERIMENTAL|Total dose for Upper Facial Lines|"One single injection of study medication will be injected locally into Upper Facial Lines.~In total for this stage approximately 48 subjects."
62548863|NCT06208540|ACTIVE_COMPARATOR|Patients group (with interventional treatment)|Patients with persistent smell and taste disorders and treated with cerebrolysin
62548864|NCT06208540|PLACEBO_COMPARATOR|Control|Patients with persistent smell and taste disorders but untreated with cerebrolycin (no intervention)
62548865|NCT02656407|EXPERIMENTAL|Ultrasensitive Doppler|Intraoperative ultrasensitive Doppler acquisitions by using an ultrasound device for functional area detection
62548866|NCT02861014|EXPERIMENTAL|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
62548867|NCT04681716|ACTIVE_COMPARATOR|ELDOA GROUP|ELDOA position was instructed to this group
62548868|NCT04681716|EXPERIMENTAL|CONVENTIONAL PHYSIOTHERAPY|Hot pack,TENS and mobalization was given in this group
62548869|NCT05295576||chronic periodontitis|scaling and root planing
62720275|NCT02070497|EXPERIMENTAL|case management_new|The patients with new-diagnosed lung cancer and accepting case management
62720276|NCT02070497|EXPERIMENTAL|case management_old|the patients with non-new-diagnosed lung cancer and with accepting case management
62720277|NCT02070497|NO_INTERVENTION|control group|The patients with new-diagnosed lung cancer in the period of one year ago and without accepting case management
62720278|NCT00511758||Digital Imaging Device|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.
62720279|NCT02156024|PLACEBO_COMPARATOR|placebo|placebo drink, 1 dose at a time, twice a day, duration: 4 weeks
62720280|NCT02156024|ACTIVE_COMPARATOR|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
62720281|NCT02533310|EXPERIMENTAL|OST treatment with in-vivo spiders|OST consists of increasingly intense interactions with an in-vivo phobic stimuli and human therapist non-phobic behavior modelling.
62720282|NCT02533310|EXPERIMENTAL|VR-OST treatment with virtual spiders|VR-OST consists of simulated OST treatment without the use of live spiders and with the support of a virtual therapist.
62720283|NCT03010943|EXPERIMENTAL|Brain surgery with virtual reality headset|
62720284|NCT06007586|PLACEBO_COMPARATOR|Two antiemetic groups|Placebo 130mg iv d1 30min d1 before chemotherapy (IV time \&gt; 2min);Ondansetron 8mg iv once d1 30min before chemotherapy; Dexamethasone 12mg iv once d1 before chemotherapy 30min, dexamethasone 8mg po qd d2 \~ 4.
62720285|NCT06007586|EXPERIMENTAL|Three antiemetic group|Aprepitant injection 130mg iv d1 30min d1 before chemotherapy (push-back time \&gt; 2min);Ondansetron 8mg iv once d1 30min before chemotherapy;Dexamethasone 12mg iv once d1 30min before chemotherapy, 8mg po qd d2-4.
62720286|NCT02818517||Heart failure|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
62720287|NCT01589224||Healthy people|
62720288|NCT05935059|ACTIVE_COMPARATOR|pregabalin group (group P)|pregabalin group (group P) patients will receive pregabalin (Lyrica, Pfizer, NY) 50 mg with a sip of water one hour before induction of anesthesia and repeated every 8 hours for five days after surgery. The pregabalin capsules will be given to patients by nurses blinded to the study. Neither the researcher allocating the participants, nor the assessing person knew the decoding of the groups in its relation to the allocation sequence. Data will be collected by a junior pain resident blinded to the study protocol.
62720289|NCT05935059|ACTIVE_COMPARATOR|Tianeptine group (group T)|Tianeptine group (group T) patients will receive Tianeptine 12.5 mg (Stablon, Servier, France)with a sip of water one hour before induction of anesthesia and repeated every 8 hours for five days after surgery. The Tianeptine capsules will be given to patients by nurses blinded to the study. Neither the researcher allocating the participants, nor the assessing person knew the decoding of the groups in its relation to the allocation sequence. Data will be collected by a junior pain resident blinded to the study protocol.
62720290|NCT05217459|EXPERIMENTAL|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
62720291|NCT02735018|EXPERIMENTAL|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
62720292|NCT02735018|EXPERIMENTAL|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
62720293|NCT00440817||Patients with lymphoma|Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
62720294|NCT04741932|NO_INTERVENTION|Care as usual|
62720295|NCT04741932|EXPERIMENTAL|Intervention|
62720296|NCT06151119||suspected or confirmed myelofibrosis|Patients with suspected or confirmed myelofibrosis;
62720297|NCT06151119||primary/secondary myelofibrosis|Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib.
62720298|NCT01478022|ACTIVE_COMPARATOR|Isosorbide Dinitrate 20 mg|Isosorbide Dinitrate 10 mg b.i.d
62720299|NCT01478022|ACTIVE_COMPARATOR|Ibuprofen 200 mg|Ibuprofen 200 mg daily, capsule
62720300|NCT01478022|EXPERIMENTAL|Isosorbide dinitrate and Ibuprofen|Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily
62720301|NCT01082614|NO_INTERVENTION|Standard fluid management|standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
62720302|NCT01082614|EXPERIMENTAL|Goal directed therapy|Intraoperative fluid management guided by stroke volume variation determined by arterial pressure pulse wave contour analysis
62720303|NCT03376464|EXPERIMENTAL|single injection technique (SIT)|40 U of Xeomin Cosmetic delivered directly into the region where the three masseter heads overlap.
62720304|NCT03376464|EXPERIMENTAL|multi-injection technique (MIT)|A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
62720305|NCT04632394||Cases|Patients with scar-dependent ventricular tachycardia, requiring ablation. These patients will have satisfied the inclusion/exclusion criteria and be put forward for VT ablation. They will undergo the previously described study protocol, including generation of a computational model of the heart from their cardiac MRI and a VT ablation where we will study the points of interest generated from the MRI model in detail.
62720306|NCT00295607|ACTIVE_COMPARATOR|1|
62720307|NCT00295607|EXPERIMENTAL|2|
62720308|NCT00233532|OTHER|1|
62720309|NCT00233532|OTHER|2|
61976654|NCT05226325|ACTIVE_COMPARATOR|G0.4|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.4 mcg/kg/hour
62720310|NCT00233532|OTHER|3|
62720311|NCT04396821|EXPERIMENTAL|Part A Q2W|Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, multiple dose levels will be tested.
61976655|NCT05226325|ACTIVE_COMPARATOR|G0.6|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.6 mcg/kg/hour
62720312|NCT04396821|EXPERIMENTAL|Part A Q3W|Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg, and multiple dose levels will be tested.
62720313|NCT04396821|EXPERIMENTAL|Part B Cohort A|Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma.
62548870|NCT05295576||Periodontally healthy individuals|no treatment
62548871|NCT06438835|EXPERIMENTAL|PneuFlex AFO Assist|
62548872|NCT04659603|EXPERIMENTAL|Cohort A metastatic breast cancer (mBC)|tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
62548873|NCT04659603|EXPERIMENTAL|Cohort B metastatic pancreatic adenocarcinoma (mPAC)|tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
62548874|NCT04659603|EXPERIMENTAL|Cohort C Metastatic pancreatic adenocarcinoma (mPAC)|tusamitamab ravtansine every 2 weeks combined with gemcitabine on Day 1, Day 8 and Day 15 every 4 weeks administered via intravenous infusion (IV)
62548875|NCT01080183|EXPERIMENTAL|Feedback form|patients receive feedback regarding their prms in addition to doctor receiving report
62548876|NCT01080183|NO_INTERVENTION|usual care|patients do not receive feedback form prior to the encounter, clinicians continue to receive patient reported measures prior to the appointment
62548877|NCT04969731|EXPERIMENTAL|Immuncell-LC/Gemcitabine|Patients will receive 6 cycles Gemcitabine (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle) and Immuncell-LC 16 times during 60 weeks (4 treatments once a week, followed by 4 treatments every other week, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks)
62548878|NCT04969731|ACTIVE_COMPARATOR|Gemcitabine|Patients will receive 6 cycles Gemcitabine alone (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle)
62548879|NCT01284361|EXPERIMENTAL|30 cm Intermittent Catheter|Intervention was the test of a 30 cm catheter compared to standard commercial 40 cm catheter in a cross-over design.
62548880|NCT01284361|ACTIVE_COMPARATOR|40 cm Intermittent Catheter|Active comparator 40 cm commercial catheter was compared to experimental 30 cm catheter in a cross-over design.
62548881|NCT04982302||Non-surgical periodontal treatment NSPT|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets in 2 or 4 appointments
62548882|NCT04215146|ACTIVE_COMPARATOR|Cohort 1|Patients receive paclitaxel alone.
62548883|NCT04215146|EXPERIMENTAL|Cohort 2|Patients receive pelareorep + paclitaxel.
62548884|NCT04215146|EXPERIMENTAL|Cohort 3|Patients receive pelareorep + paclitaxel + avelumab.
62548885|NCT05019300||COVID-19 patients discharged from critical care units|Adults over 18 years of age who have been hospitalized after COVID-19 diagnosis in the critical care units of Red Salud UC Christus who have been cognitively evaluated with Montreal Cognitive Assessment (MoCA) days prior to their discharge. All patients with a previous history of confirmed neurocognitive or psychotic disorders, prior to hospital admission, were excluded.
62548886|NCT03645863|EXPERIMENTAL|Cohort 1|Subject will receive MT-6548 on Day 1, 4, and 7. Subject will receive Iron supplement A on Day 1, 4, or 7. Subject will receive Iron supplement B on Day 1, 4, or 7.
62548887|NCT03645863|EXPERIMENTAL|Cohort 2|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement C on Day 1 or 4.
62548888|NCT03645863|EXPERIMENTAL|Cohort 3|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement D on Day 1 or 4.
62548889|NCT02005835|OTHER|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~* Routine standard clinical care based on the MoH guidelines~* Mentor mothers provide education and psychosocial support at facility~* Weekly support groups provided in clinic~* Phone call, SMS, or home visit for each missed appointment"
62548890|NCT02005835|OTHER|Community-based Peer Support|"Community-based Support from Peer Mothers (Expert mothers):~* Routine standard clinical care based on the MoH guidelines~* Mentor mothers provide education and psychosocial support in community prior to each visit~* Monthly support groups in community~* Home visits for each missed appointment"
62548891|NCT02005835|NO_INTERVENTION|Standard of Care|The Standard of care as outlined in the Malawi HIV integrated Care Guidelines
62548892|NCT02352870|EXPERIMENTAL|Computerised CBT with therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly plus they receive three telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future~In addition to completing the seven online sessions the intervention arm received three 30 minute telephone support calls at weeks two, four, and six to facilitate engagement and understanding of the contents of the website."
62548893|NCT02352870|ACTIVE_COMPARATOR|Computerised CBT without therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly but do not receive any telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future"
62548894|NCT00128401|ACTIVE_COMPARATOR|D-Cycloserine|An antibiotic, d-cycloserine (DCS) was given to one group and the group is evaluated to see if the drug boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.
62548895|NCT00128401|PLACEBO_COMPARATOR|Placebo|Another group was given the placebo and tested for effectiveness of cognitive behavior therapy (CBT) for social anxiety.
62548896|NCT01547702|EXPERIMENTAL|Treatment|This group will have access to the Teacher Help for ADHD intervention program during the randomized controlled trial.
62548897|NCT01547702|NO_INTERVENTION|Waitlist Control|This group will not receive the intervention until all data collection is complete for their study cohort.
62548898|NCT01911273|EXPERIMENTAL|PF 03446962 plus best supportive care (BSC)|
62548899|NCT01911273|PLACEBO_COMPARATOR|Placebo plus best supportive care (BSC)|Placebo, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
62548900|NCT06303700||adolescents|from both sex, age ranged from twelve to seventeen years old, free from mobility disability and Severe cognitive impairment
62548901|NCT06303700||youth|from both sex, age ranged from twenty to twenty-two years old, free from mobility disability and Severe cognitive impairment
62548902|NCT06303700||geriatrics|from both sex, age ranged from sixty to eighty years old, free from mobility disability and Severe cognitive impairment
62548903|NCT04376931|EXPERIMENTAL|Iscador®P as intravenous infusion|"Investigational therapy will be administered in six Dose Groups (DG):~10 mg, 20 mg, 40 mg, 90 mg, 140 mg and 200 mg Iscador®P. The initial dose group of the study is set to 40 mg Iscador®P. The two lower dose groups (20 or 10 mg) will only be used in case of intolerance at 40 mg Iscador®P. Once per week patients receive intravenous infusions of Iscador®P dissolved in 250 ml of sodium chloride solution (0.9 %). After the 4-week period of the MTD estimation phase each subject will immediately be included into a follow up observation in which he/she receives the last well tolerated dosage they had or the next lower dosage than the currently investigated DG in the running phase Ib study depending on the current estimate of the MTD at that time."
62548904|NCT01918462||Alcoholic hepatitis|Patients with alcoholic hepatic; cases.
62548905|NCT01918462||Healthy controls|Persons undergoing hepatic resection; controls.
62548906|NCT05294666|EXPERIMENTAL|cyclosporine group|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
62548907|NCT05294666|EXPERIMENTAL|tacrolimus group|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
62548908|NCT04801511|EXPERIMENTAL|Experimental|"Preoperative concurrent chemoradiotherapy and high-dose intravenous vitamin C :~The eligible subjects will be treated with concurrent chemoradiotherapy and high-dose intravenous vitamin C preoperatively. IMRT will be delivered to PTV-CTV (plan target volume-clinical target volume) with a dose of 45Gy/25fraction/5weeks. If necessary. During IMRT, 2-3 cycles of concurrent chemotherapy (mFOLFOX6) will be delivered. High-dose intravenous vitamin C ( 24g/d，QD ) will be delivered on the day of radiotherapy from the beginning to the end of IMRT.~preoperative consolidation chemotherapy: Three additional cycles of neoadjuvant chemotherapy (mFOLFOX6) will be given after the end of IMRT.~TME （total mesorectal excision）or sphincter preserving surgery will be performed approximately the 10th-12th weeks after the end of IMRT. Whether or not to select watch and wait needs to refer to the tumor location, tumor regression, surgeon's opinion and patient's will."
62548909|NCT06319040||Study Group 1|15 patients who underwent isolated ACLR
62548910|NCT06319040||Study Group 2|15 patients who underwent ACLR with additional intervention
62548911|NCT06319040||Control Group|15 healthy individuals
62548912|NCT04217954|EXPERIMENTAL|OXA, 5-FU and Bev plus Toripalimab|the patients enrolled in this arm would receive hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil and bevacizumab plus intravenous Toripalimab
62548913|NCT03955003|EXPERIMENTAL|Group Drumming|6 week one hour/week drumming sessions. The detailed intervention protocol was created in collaboration with board-certified music therapists. The music used in the intervention will include both recorded percussion music and the use of percussion instruments.
62548914|NCT03955003|OTHER|Attention Control Entertaining Educational Series|6 week one hour/week educational series. The educational group is largely intended to create an attention group control so group effect and time of the drumming intervention can be controlled.
62548915|NCT03142191|EXPERIMENTAL|CC-90001 400 mg PO QD|55 subjects will be randomized to CC-90001 400mg
62548916|NCT03142191|EXPERIMENTAL|CC-90001 200 mg PO QD|55 subjects will be randomized to CC-90001 200mg
62548917|NCT03142191|PLACEBO_COMPARATOR|Placebo PO QD|55 subjects will be randomized to placebo
62548918|NCT03142191|EXPERIMENTAL|CC-90001 400 mg PO QD- Sub-Study|30 subjects will be randomized to CC-90001 400mg
62548919|NCT03142191|PLACEBO_COMPARATOR|Placebo PO QD- Sub-Study|15 subjects will be randomized to placebo
62548920|NCT02371070||Rivaroxaban|N=20
62548921|NCT02371070||Apixaban|N=20
62548922|NCT02371070||Dabigatran|N=20
62548923|NCT05449860|EXPERIMENTAL|Patients with recurrent hepatocellular carcinoma after locoregional treatment|Patients with chronic liver disease have recurrent hepatocellular carcinoma which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
62548924|NCT00916643|EXPERIMENTAL|H.E.L.P. Secura|"The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:~1. Flushing the system with normal saline.~2. Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.~3. Mixing the plasma with an equal volume of acetate buffer containing heparin.~4. Precipitation of LDL as a complex with heparin.~5. Removing the LDL-heparin precipitate by continuous circulation through a filter.~6. Removing heparin with use of a heparin adsorber.~7. Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.~8. Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient."
62548925|NCT02065076|ACTIVE_COMPARATOR|Sodium Polystyrene Sulfonate|30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
62548926|NCT02065076|PLACEBO_COMPARATOR|Lactose with carob gum|30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
62548927|NCT04821193|EXPERIMENTAL|Experimental Group 1|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 5% NaHCO3 water solution group Grup number: 20
62548928|NCT04821193|EXPERIMENTAL|Experimental Group 2|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 2% Chlorhexidine Gluconate solution group Grup number: 21
62548929|NCT04821193|NO_INTERVENTION|Control Group|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 70% Alcohol solution group Grup number: 21
62548930|NCT03863548||Continuation of antithrombotic drugs|operation carried out without stopping anticoagulants
62548931|NCT03863548||Stop anti thrombotic drugs|operation performed with stopping the anticoagulants
62548932|NCT02213653|EXPERIMENTAL|Concomitant iron and I.V. epoietin zeta|
62548933|NCT02213653|EXPERIMENTAL|Iron and I.V. epoietin zeta sequential|
62548934|NCT02213653|ACTIVE_COMPARATOR|Epoietin zeta|
61976656|NCT05125978|EXPERIMENTAL|Canadá association|"The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:~1 tablet Canadá, oral;~1 placebo tablet of tramadol, oral;~1 placebo tablet of dipyrone, oral."
62720314|NCT04396821|EXPERIMENTAL|Part B Cohort B|Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies.
62720315|NCT04396821|EXPERIMENTAL|Part B Cohort C|Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma.
62720316|NCT01220492|EXPERIMENTAL|conventional plus MSC treatment|participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
62720317|NCT01220492|EXPERIMENTAL|conventional plus placebo treatment|participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
62720318|NCT06091358|NO_INTERVENTION|Control|"Participants will arrive at the Laboratory and complete a series of questionnaires: general physical activity, BDI, TDI, PSQI, General health questionnaire, Post COVID fatigue scale, EQ 5D-5L. They will undergo spirometry testing FEV1, MIP and PEF. Participants will undergo a 6 minute walk test and a Sub-maximal exercise test (CPET) using a cycle ergometer (15W/min) until an RPE of 17.~Participants continue usual life between baseline and follow up testing. Participants will have 1 call per week where MIP is measured using a Care fusion hand held spirometer device.~After 4 weeks, participants will return to the Laboratory and repeat baseline testing."
62720319|NCT06091358|EXPERIMENTAL|Inspiratory Muscle training intervention|"Participants will arrive at the Laboratory and complete a series of questionnaires: general physical activity, BDI, TDI, PSQI, General health questionnaire, Post COVID fatigue scale, EQ 5D-5L. They will undergo spirometry testing FEV1, MIP and PEF. Participants will undergo a 6 minute walk test and a Sub-maximal exercise test (CPET) using a cycle ergometer (15W/min) until an RPE of 17.~Participants undergo inspiratory muscle training for 4 weeks between baseline and follow up testing. They will be given a PrO2 device where the intervention will be 3 times per week for 4 weeks. Each session will be 6x6 breaths at 80% MIP. Participants will have 1 call per week where MIP is measured using a Care fusion hand held spirometer device.~After 4 weeks, participants will return to the Laboratory and repeat baseline testing."
62720320|NCT05461586||MR #1/MR #2|Subjects who participated in PCOL-102-AHSF who were bilaterally implanted with TECNIS IOL lenses will be randomized into the (MR #1/MR #2) sequence and receive two different maximum refractive techniques one at a time consecutively.
62720321|NCT05461586||MR#2/MR#1|Subjects who participated in PCOL-102-AHSF who were bilaterally implanted with TECNIS IOL lenses will be randomized into the (MR#2/MR#1) sequence and receive two different maximum refractive techniques one at a time consecutively.
62720322|NCT04955067||Normal control group-Grade 0|Arthroscopic examination of the ankle joint was normal, and the ligament was intact without injury or tear.
62720323|NCT04955067||Ligament injury -Grade 1|Arthroscopic examination of the ankle joint showed ligament degeneration or injury, but no local or complete tear.
62720324|NCT04955067||Ligament tear-Grade 2|Arthroscopy of the ankle joint revealed partial or complete loss of ligaments.
62720325|NCT04674267|EXPERIMENTAL|Intervention Phase - Geriatric Co-Management|"Eligible older adults age 70 and older who score Pre-Frail or Frail will be randomized 2:1 to be offered to meet with a study geriatrician for geriatric co-management in addition to their standard oncology care. Study geriatrician will assist with management of symptoms, additional comorbidities, polypharmacy, and social/emotional concerns in addition to physical care. Geriatrician can make referrals and recommendations for additional supportive services that may be beneficial for more vulnerable older adult patients."
62720326|NCT04674267|NO_INTERVENTION|Intervention Phase - Standard Oncology Care|"This arm is for those older adult patients (age 70+) who score as Pre-Frail or Frail in the fitness assessment questionnaire and are NOT randomized to meet with the study geriatrician. These patients will be followed for the duration of the study as they proceed with their usual oncology care. Study team will evaluate a number of different measures and outcomes, the primary one being unplanned emergency and hospital visits during the course of the study."
62720327|NCT04003298|EXPERIMENTAL|Electric toothbrush and power interdental device|Electric toothbrush and power interdental device
62720328|NCT04003298|ACTIVE_COMPARATOR|Electric toothbrush|Electric toothbrush
62720329|NCT00710944|EXPERIMENTAL|Extraction Sockets|Immediate loading in extraction sockets.
62720330|NCT00710944|EXPERIMENTAL|Healed Ridges|Immediate loading in healed ridges.
62720331|NCT00710944|EXPERIMENTAL|Grafted Sites|Immediate loading of implants placed in grafted sites (four months healing after grafting).
62720332|NCT02588469|EXPERIMENTAL|Interventional group|Physical activity program coupled with compression socks wearing during 3 months.
62720333|NCT02588469|ACTIVE_COMPARATOR|control group|Physical activity program without compression socks during 3 months.
62720334|NCT04753619|EXPERIMENTAL|Niclosamide group: NCS group|NCL + standard therapy
62720335|NCT04753619|NO_INTERVENTION|Control group|Control group
62720336|NCT02267889|EXPERIMENTAL|Image guided GP ablation|Use of cardiac nuclear imaging data to guide GP ablation procedures.
62720337|NCT05038696|EXPERIMENTAL|Single arm|Single arm Phase I Clinical Trial
62720338|NCT00711659||1|all third year medical students starting their pediatric clerkship rotation
62720339|NCT02727322|ACTIVE_COMPARATOR|Nitrofurantoin|Receives once daily nitrofurantoin 100mg
62720340|NCT02727322|PLACEBO_COMPARATOR|Placebo|Receives matching placebo
62720341|NCT01173510|EXPERIMENTAL|Raltegravir plus tenofovir/emtricitabine|
62720342|NCT01173510|ACTIVE_COMPARATOR|Efavirenz/Emtricitabine/Tenofovir|
62720343|NCT00800982|ACTIVE_COMPARATOR|1 (Etanercept only)|Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months. No UVB will be given. Sham UVB will not be used because the subjects are not blinded because they often know they are receiving sham UVB due to differences in light intensity and heat.
62720344|NCT00800982|EXPERIMENTAL|2 (Etanercept + nb-UVB)|"Subjects will receive etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.~In addition, for months 3-6, subjects will receive Narrow Band Ultraviolet B phototherapy three times a week for 12 weeks in addition to the etanercept maintenance dose. The safety and efficacy of the combination therapy will be evaluated by the registered phototherapy nurses at each phototherapy visit and by the study investigator at monthly visits. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff."
62720345|NCT05819476|OTHER|Part 1: Visit 1 (No treatment) followed by Visit 2 (OLP intervention)|In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 2. Visit 1 (No treatment) will be the control of the study intervention.
62720346|NCT05819476|OTHER|Part 1: Visit 1 (OLP intervention) followed by Visit 2 (No treatment)|In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 1. Visit 2 (No treatment) will be the control of the study intervention.
62720347|NCT05819476|OTHER|Part 2/ Group A: 1x OLP (Control)|In Part 2, the Group A (Control) receives just one single OLP injection and no repetition.
62720348|NCT05819476|OTHER|Part 2/ Group B: 2x OLP; booster time fixed|"In Part 2, Group B participants will receive two injections, the first at twenty minutes after start of the experiment, and the second at a time point derived from Part 1 (if data is inconclusive; at 100 minutes).~For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain."
62720349|NCT05819476|OTHER|Part 2/ Group C: 2x OLP; booster on- demand|"In Part 2, Group C participants will receive two injections, the first at twenty minutes after start of the experiment, and the second on demand.~For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain."
62720350|NCT06390956|EXPERIMENTAL|Treatment: All Patients|The study's goal is to investigate the efficacy of the combination of study drugs pirtobrutinib and rituximab.
62720351|NCT03323138|EXPERIMENTAL|Ex-PRESS and phacoemulsification|A treatment session of PACG coexisting cataract treated with phacoemulsification combined with P50 Ex-PRESS miniature glaucoma device (Alcon Laboratories, Fort Worth, Texas, USA).
62720352|NCT06185790|EXPERIMENTAL|LCHF diet|Participants will adhere to a low-carb high-fat diet for 12 weeks,defined by a carbohydrate intake of 50-100 grams per day.
62720353|NCT06185790|NO_INTERVENTION|Control|Participants will follow their usual diet for 12 weeks.
62720354|NCT06547034||Ages 30-45|Women ages 30-45 who have received a mammogram in the past year with negative results and have no history of breast disease.
62720355|NCT06547034||Ages 46-90|Women ages 46-90 who have received a mammogram in the past year with negative results and have no history of breast disease.
62720356|NCT01312480|OTHER|Intervention Group|The smoking cessation intervention is a Public Health Services-approved intervention based on the 5A's Model, which includes (1) Ask if the patient smokes, (2) Advise every patient to quit, (3) Assess readiness to quit, (4) Assist in quitting and finding services and (5) Arrange for cessation services and follow up. Practitioners will complete a 5A checklist for each patient in this arm.
62720357|NCT01312480|OTHER|Control Group|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
62720358|NCT03762161|EXPERIMENTAL|Intervention TAS-102|
62720359|NCT06476288|ACTIVE_COMPARATOR|High-Dose RIC (Remote Ischemic Conditioning) Intervention|Low-intensity resistance exercise training plus high-dose RIC.
62720360|NCT06476288|PLACEBO_COMPARATOR|Low-Dose RIC Intervention|Low-intensity resistance exercise training plus low-dose RIC.
62720361|NCT03606486|EXPERIMENTAL|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
62720362|NCT05816824|EXPERIMENTAL|Symptom Monitoring Telerehabilitation (Intervention) Group|The intervention group will be followed up with the same protocol plus symptom monitoring software called PhysioAnalyst which provides visual feedback. The video exercises given to the participants will include Williams, McKenzie exercises and core strengthening exercises.
62720363|NCT05816824|ACTIVE_COMPARATOR|Telerehabilitation (Control) Group|The control group will receive video exercise-based rehabilitation protocol with telerehabilitation without visual feedback. The video exercises given to the participants will include Williams, McKenzie exercises and core strengthening exercises.
62720364|NCT04407338|EXPERIMENTAL|B-DYN Device|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
62720365|NCT04407338|ACTIVE_COMPARATOR|Conventional bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
62720366|NCT03400241|EXPERIMENTAL|Tiotropium Easyhaler Product A|tiotropium bromide monohydrate 2 inhalations as a single dose
62720367|NCT03400241|EXPERIMENTAL|Tiotropium Easyhaler Product B|tiotropium bromide monohydrate 2 inhalations as a single dose
62720368|NCT03400241|EXPERIMENTAL|Tiotropium Easyhaler Product C|tiotropium bromide monohydrate 2 inhalations as a single dose
62720369|NCT03400241|ACTIVE_COMPARATOR|Spiriva HandiHaler|tiotropium bromide monohydrate 2 Spiriva capsules inhaled via HandiHaler
62720370|NCT03053778|EXPERIMENTAL|Intervention|Early follow-up after discharge
62720371|NCT01929200|EXPERIMENTAL|1-year treatment with icotinib|Patients will receive 1-year treatment with icotinib after operation.
62720372|NCT01929200|EXPERIMENTAL|2-year treatment with icotinib|Patients will receive 2-year treatment with icotinib after operation.
62720373|NCT04298619||Standard cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:~* symptom assessment~* blood tests~* physical examination"
62720374|NCT04298619||Imaging cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:~* symptom assessment~* blood tests~* physical examination~* Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes"
62720375|NCT01652781|EXPERIMENTAL|5-day arm|azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care
62720376|NCT01652781|ACTIVE_COMPARATOR|7-day arm|azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
62720377|NCT01778959|ACTIVE_COMPARATOR|standard OVD|
62720378|NCT01778959|ACTIVE_COMPARATOR|Iris hooks|
62720379|NCT01778959|ACTIVE_COMPARATOR|Malyugin Ring|
62720380|NCT01778959|ACTIVE_COMPARATOR|OVD|
62720381|NCT05329337|EXPERIMENTAL|10 patients with high insulin levels (13.3 ± 9.2 microU/mL) and markers of metabolic syndrome|These are individuals who were isolated from the previous MetACTIV study due to their specific immune profile (Profile 2) defined by 43 immune activation markers and characterized by a high percentage of differentiated T cells and activated T cells.
62720382|NCT05329337|ACTIVE_COMPARATOR|20 patients with other immune profiles|
62720383|NCT00565409|ACTIVE_COMPARATOR|1|
62720384|NCT00565409|ACTIVE_COMPARATOR|2|
62720385|NCT00565409|PLACEBO_COMPARATOR|3|
62720386|NCT00824798||haemophiliacs A and B|haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.
62720387|NCT01664754|EXPERIMENTAL|Treatment (exemestane, pemetrexed disodium, and carboplatin)|Patients receive exemestane PO QD on days 1-28 and pemetrexed disodium IV over 15 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
62720388|NCT01982903||Kidney transplant recipients|Adult recipients of a primary or secondary cadaveric or living donor single renal allograft at the University Hospitals Leuven between July 2014 and June 2016
62720389|NCT02669589|ACTIVE_COMPARATOR|heparin anticoagulation|"Systemic anticoagulation of the continuous renal replacement therapy with heparin.~Dose will be titrated to maintain aPTT (activated partial thromboplastin time) between 45-60s)"
62720390|NCT02669589|EXPERIMENTAL|citrate anticoagulation|"Regional anticoagulation of the continuous renal replacement therapy with citrate.~Target posthemofilter ionized calcium level: 0.25-0.35 mmol/l"
62720391|NCT02006186|EXPERIMENTAL|Bicycle Train Intervention|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
62720392|NCT02006186|NO_INTERVENTION|Control|The control arm does not receive any intervention. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
62720393|NCT03576261|EXPERIMENTAL|Preoperative echo + fluids|20 individuals investigated by preoperative transthoracic echocardiography. Preoperative colloid fluid bolus (Gelofusine, Fresenius Kabi AB, Sweden) 6 ml/kg lean body weight, is infused intravenously immediately before anesthesia induction.
62720394|NCT03576261|ACTIVE_COMPARATOR|Preoperative echo, control|20 individuals investigated by preoperative transthoracic echocardiography. No intravenous fluids are infused before anesthesia induction.
62720395|NCT03924804|EXPERIMENTAL|Group A: 2 ml/kg group|
62720396|NCT03924804|EXPERIMENTAL|Group B: 8 ml/kg group|
62720397|NCT03924804|EXPERIMENTAL|Group C: 16 ml/kg group|
62720398|NCT04474639||with diastolic dysfunction|patients with diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e' \>=8, and lateral e'\>=10 and left atrium \<34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
62720399|NCT04474639||without diastolic dysfunction|patients without diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e'\<8, and lateral e'\<10 and left atrium \>=34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
62720400|NCT01646814|EXPERIMENTAL|PL2200|Investigational product, PL2200
62720401|NCT01646814|ACTIVE_COMPARATOR|Aspirin tablets|Active comparator, 325 mg aspirin tablets
62720402|NCT01444430|EXPERIMENTAL|1|Symbicort
62720403|NCT01444430|ACTIVE_COMPARATOR|2|budesonide
62720404|NCT01459809|EXPERIMENTAL|ARM 1: glimepiride alone|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline \< 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and \> 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
62720405|NCT01459809|EXPERIMENTAL|ARM 2: metformin alone|24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and \> 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
62720406|NCT01459809|EXPERIMENTAL|ARM3: Glimepiride/metformin free combination|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline \< 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.
62720407|NCT01106989|EXPERIMENTAL|Heated lidocaine/tetracaine patch|Active
62720408|NCT04582006||LSG|Patients undergoing laparoscopic sleeve gastrectomy.
62720409|NCT04582006||LRYGB|Patients undergoing laparoscopic Roux-en-Y gastric bypass.
62720410|NCT01675583||Standard Care Group|Subjects who will undergo only standard wound care management.
62720411|NCT01675583||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
62720412|NCT00383071|ACTIVE_COMPARATOR|Cohort 1|H5N1 vaccine - 90 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
62720413|NCT00383071|ACTIVE_COMPARATOR|Cohort 2|H5N1 vaccine - 120 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
62720414|NCT00383071|ACTIVE_COMPARATOR|Cohort 3|H5N1 vaccine - 180 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
62720415|NCT00383071|ACTIVE_COMPARATOR|Cohort 4|H5N1 vaccine - 180 mcg IM every 4 weeks x 2 doses, injection site randomized to either deltoid or gluteus Apheresis - if HAI titer above 1:160
62720416|NCT01070979|EXPERIMENTAL|Estradiol acetate (E3A)|
62720417|NCT01070979|ACTIVE_COMPARATOR|Estradiol|
62720418|NCT01070979|ACTIVE_COMPARATOR|Conjugated equine estrogens (CEE):|
62720419|NCT02263014||Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide to have contralateral prophylactic mastectomy (CPM) along with scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after the surgery is completed.
62720420|NCT02263014||No Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide not to have contralateral prophylactic mastectomy (CPM) performed during scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after unilateral mastectomy or breast conserving surgery is completed.
62720421|NCT06054568||Patient with Mitral stenosis undergoing Percutaneous Mitral trans-luminal commissurotomy|
62720422|NCT05871619|EXPERIMENTAL|Remin Pro with laser application|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye (0.05ml) to 1 mg of the assigned remineralizing agents. The diode laser was irradiated immediately with Average power of 1 W, Exposure time of 10 s, diode 810 nm, continuous and non-contact mode, and Irradiation speed of 1mm/ sec.
62720423|NCT05871619|EXPERIMENTAL|Remin pro without laser application|Used a pea-sized amount with a brush and allowed it to remain on the teeth for at least three minutes as it was recommended by the manufacturer. Instructed the patient to avoid rinsing, eating, and drinking for 30 minutes
62720424|NCT05871619|EXPERIMENTAL|Xpur remin with laser application|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye (0.05ml) to 1 mg of the assigned remineralizing agents. The diode laser was irradiated immediately with Average power of 1 W, Exposure time of 10 s, diode 810 nm, continuous and non-contact mode, and Irradiation speed of 1mm/ sec.
62720425|NCT05871619|EXPERIMENTAL|Xpur remin without laser application|used a thin film of toothpaste on a micro brush and then applied it on the tooth surface for three minutes 2- Do not eat, drink or rinse for 30 minutes
62720426|NCT05871619|EXPERIMENTAL|fluoride varinsh with laser application|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye (0.05ml) to 1 mg of the assigned remineralizing agents. The diode laser was irradiated immediately with Average power of 1 W, Exposure time of 10 s, diode 810 nm, continuous and non-contact mode, and Irradiation speed of 1mm/ sec.
62720427|NCT05871619|EXPERIMENTAL|fluoride varnish without laser application|Used brush applicator to uniformly apply fluoride Varnish, covering the surface to be treated as a thin film.Instructed patient to avoid hard food, alcohol, brushing or flossing for the next 4
62720428|NCT00997789|EXPERIMENTAL|Rebamipide, Serum concentration, Tablet|The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)
62720429|NCT02429817|ACTIVE_COMPARATOR|Aeroneb Solo|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo connected to the high flow nasal cannula.
62720430|NCT02429817|ACTIVE_COMPARATOR|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via the jet nebulizer connected to the high flow nasal cannula.
62720431|NCT02811822|EXPERIMENTAL|Dose 1|
62720432|NCT02811822|EXPERIMENTAL|Dose 2|
62720433|NCT02811822|EXPERIMENTAL|Dose 3|
61976657|NCT05125978|ACTIVE_COMPARATOR|Tramadol|"The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:~1 tablet tramadol, oral;~1 placebo tablet of Canadá, oral;~1 placebo tablet of dipyrone, oral."
61976658|NCT05125978|ACTIVE_COMPARATOR|Dipyrone|"The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:~1 tablet dipyrone, oral;~1 placebo tablet of tramadol, oral;~1 placebo tablet of Canadá, oral."
62720434|NCT02811822|EXPERIMENTAL|Dose 4|
62720435|NCT03502564|ACTIVE_COMPARATOR|CBT for ED only|In this arm, participants will receive CBT for ED following intensive ED treatment (see intervention section for description).
62720436|NCT03502564|EXPERIMENTAL|Concurrent CBT for ED and PTSD|In this arm, participants will receive concurrent CBT for ED and PTSD following intensive treatment. (see intervention section for description).
62720437|NCT05531500|OTHER|Injection|Injection of local anesthetic and steroid to the diseased nerve
62720438|NCT05531500|OTHER|Radiofrequency|Application of radiofrequency to the diseased nerve
62720439|NCT01685814|ACTIVE_COMPARATOR|single stem cell transplant, 3-year lenalidomide maintenance|Arm A
62720440|NCT01685814|EXPERIMENTAL|tandem autologous transplant, lenalidomide maintenance|Arm B
62720441|NCT01685814|ACTIVE_COMPARATOR|allogeneic stem cell transplant, lenalidomide maintenance|Arm C
62720442|NCT01685814|EXPERIMENTAL|tandem autologous transplant|Arm D
62720443|NCT05577026|EXPERIMENTAL|Educational intervention with prescription feedback|Healthcare personnel will participate in a brief educational intervention with information regarding treatment guidelines, recommendations, and risks of prescribing opioids. The presentation will include benchmarking on clinic opioid prescription patterns compared to other primary health centers, followed by targeted feedback on prescription patterns over the subsequent 12 months. Standardized materials will be provided, including a patient-provider agreement, outline of a patient treatment plan, and recommendations of how shared routines at the center can be improved.
62720444|NCT05577026|ACTIVE_COMPARATOR|Written information on guidelines|The manager at each PHC center in the active control group will receive written information on treatment guidelines for pain management. These centers will not receive the intervention, consisting of the onsite educational visit and targeted prescription feedback.
62720445|NCT05577026|NO_INTERVENTION|Standard care|The passive control group will consist of PHC centers that met the eligibility criteria for the study but did not actively participate in the study. Care as usual will proceed at the centers. Prescription data will be gathered directly from regional registers and databases; thus there will be no need to communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
62720446|NCT06320600||Retrospective PDC cohort|The study will include diabetes patients diagnosed within 1 year (including 1 year) from both inpatient and outpatient medical record systems between January 2022 and December 2022. Each center enrolls approximately 1000 new diabetes patients annually, and it is planned to include 30 centers, with an estimated total of 30,000 participants.
62720447|NCT06320600||Prospective PDC cohort|The study centers will enroll diabetes patients diagnosed within 1 year (including 1 year) from both outpatient and inpatient services between January 2024 and December 2024. Each center sees approximately 3000 new diabetes patients annually, and it is planned to include 30 centers, with an estimated total of 90,000 participants. The patients will be followed up for a period of 5 years.
62720448|NCT04795401|EXPERIMENTAL|FRAME Group|"Patients will be enrolled during their hospitalization/consultation in vascular surgery department. After asking questions, his given free, informed and written consent will be collected, and recorded in his medical file by the investigator.~During this hospitalization, the pre-procedure forming part of the usual care is carried out. The specific acts of research are: Cardiac echocardiography and Quality of life survey SF-36 The plication procedure will be performed according to the FRAME FR. All pre-, peri-, and post- operative routine patient management will be carried out as usual.~Follow up visits will be held at 6, 12 months post procedure. All follow up visits will include the assessments as usual.~The specific acts of research are as follows: Cardiac echocardiography at 12 months and quality of life survey SF-36."
62720449|NCT04795401|NO_INTERVENTION|Control Group|"Control group corresponds to the historical patients over a period of time sufficient to have at least 20 patients according to inclusion criteria. The information form will be sent to each patient eligible for the study by post. Without any feedback from him within 30 days, it is considered that the patient does not object to the use of its data.~As part of this research, no additional examination will be performed. The data used correspond to the data collected in the usual care of patients."
62720450|NCT05156411|EXPERIMENTAL|Eccentric Training|This Group will train on the KREHA for 20 Trainings
62720451|NCT02432573|NO_INTERVENTION|Standard care|Postpartum patients that receive physician rounding at current time
62720452|NCT02432573|EXPERIMENTAL|Delayed rounding|Postpartum patients that receive physician rounding at a delayed time
62720453|NCT00917319|EXPERIMENTAL|Infection control measure|Bundling Infection Control Interventions
62720454|NCT02710877|EXPERIMENTAL|Programmed Intermittent bolus (PIEB)|Intervention: epidural analgesia through administration of a mixture of levobupivacaine 0,0625% and sufentanil 4 mcg. Intermittent bolus of 10 ml mixture every 75 minutes. Patient controlled bolus of 5 ml same mixture, lock-out 15 minutes.
62720455|NCT02710877|ACTIVE_COMPARATOR|Manuale epidural bolus (TOP-UP)|Intervention: manual epidural bolus of 15 ml levobupivacaine 0,0625% and sufentanil 5 mcg on maternal request.
62720456|NCT02268110|EXPERIMENTAL|Supervised exercise therapy|Participants will receive 12 sessions with a physiotherapist where they will receive instructions on body mechanics, and be given a progressive abdominal exercise program
62720457|NCT02268110|EXPERIMENTAL|Abdominal binding|Participants will be fitted for an abdominal binder and asked to wear it for a period of 12 weeks.
62720458|NCT02268110|EXPERIMENTAL|Exercise therapy and Abdominal Binding|Participants will attend 12 sessions with a physiotherapist, and receive an abdominal binder
62720459|NCT02268110|NO_INTERVENTION|Control|Participants will not receive an intervention during the study period
62720460|NCT04046393|EXPERIMENTAL|Traditional Chinese Medicine(TCM) group|nasal irrigation with Traditional herbal medicine(licorice) extract-saline isotonic solution
62720461|NCT04046393|PLACEBO_COMPARATOR|Saline control group|nasal irrigation with saline isotonic solution
62720462|NCT05260749|EXPERIMENTAL|Neurofeedback training|Subjects in the neurofeedback training group are instructed to regulate their anterior insula activity based on the visual neurofeedback.
62720463|NCT05260749|SHAM_COMPARATOR|Sham control1|Subjects in the sham control group receive the same instruction but perform the regulation based on neurofeedback from a whole slice of top brain (a controlled sham region).
62720464|NCT05260749|SHAM_COMPARATOR|Sham control2|Subjects in the sham control group receive the same instruction but perform the regulation based on neurofeedback from the middle temporal gyrus (a controlled sham region).
61976659|NCT04876625|EXPERIMENTAL|OA plus MS 8wk|Oral Appliance plus Mouth Shield for 8-weeks
62720465|NCT03470350|EXPERIMENTAL|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer treated with galunisertib and capecitabine
62720466|NCT01631968|EXPERIMENTAL|Cement with erytromycin and colistin|In this group the knee arthroplasty was fixed with cement with erythromycin and colistin.
62720467|NCT01631968|PLACEBO_COMPARATOR|Cement without antibiotic|In this group the knee arthroplasty was fixed with standard cement, without any antibiotics.
62720468|NCT01086696|EXPERIMENTAL|1|subjects with tumor types typically treatedwith taxanes
62720469|NCT01086696|EXPERIMENTAL|2|subjects with tumor types typically treatedwith taxanes
62720470|NCT06709872||Borderline ovarian tumor cohort|Patients with ultrasound discovery of a cyst on the ovary, suspicious for BOT
62720471|NCT06709872||stage I invasive ovarian cancer cohort|Patients with ultrasound discovery of a cyst on the ovary, suspicious for stage I invasive ovarian cancer
62720472|NCT04274595|EXPERIMENTAL|Psoriasis patients|
62720473|NCT04535089|ACTIVE_COMPARATOR|dexmedetomdine|IV bolus dose of 0.5ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5ug/kg/h
62720474|NCT04535089|ACTIVE_COMPARATOR|lidocaine|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
62720475|NCT06459596|EXPERIMENTAL|Communal Coping Intervention|"Experimental: Communal Coping Intervention~The intervention consists of a single session brief communal coping intervention followed by 7 days of intervention prompts delivered via text message to help couples generalize what they have learned into their daily life. There are 9 components to the intervention:~establishment of rapport, shared stressor recollection, communal coping education, application of appraisal to diabetes, we-statements to reframe diabetes as shared, facilitated discussion between couple members to identify each person's needs with active listening, collaborative implementation intentions, EMI (ecological momentary intervention) text messaging for 7 days following intervention"
62720476|NCT06459596|NO_INTERVENTION|Diabetes Education Attention Control|These participants will receive diabetes education via a 15-20 minute videotape (as well the intervention group)
62720477|NCT02481258|EXPERIMENTAL|Ataciguat (HMR1766)|200mg taken daily for 12 months
62720478|NCT02481258|PLACEBO_COMPARATOR|Matching Placebo|Taken Daily for 12 months
62720479|NCT03302143|ACTIVE_COMPARATOR|Control|Guided bone regeneration with Bovine Bone Mineral
62720480|NCT03302143|EXPERIMENTAL|Experimental|Guided bone regeneration with freeze dried bone allograft
62720481|NCT01254448|PLACEBO_COMPARATOR|Placebo|Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).
62720482|NCT01254448|EXPERIMENTAL|TC-5619|Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).
62720483|NCT03172273|EXPERIMENTAL|TIPS with PTFE|Transjugular Intrahepatic portosystemic shunt with PTFE covered stents
62720484|NCT03172273|ACTIVE_COMPARATOR|paracentesis|Paracentesis with albumine invision
62720485|NCT03980392|EXPERIMENTAL|Facility-based Intervention|A group will consist of 5 or 10 persons depending on the size of the study center. Exercise training will be guided by study exercise therapists at a gym and consist of programs for progressive muscle strength training, aerobic exercise, and exercises to improve postural balance and flexibility using elastic bands, floor plate and chairs (three times per week, 60 min per session).The cognitive training program is a program including tasks to be effective in episodic memory, executive function, attention, working memory, calculation, and visuospatial function (twice per week, 60 min per session). The nutritional intervention is conducted by study nutritionists (three individual sessions and seven group sessions). Management of metabolic and vascular risk factors will include additional meetings with the study nurse (at 0, 4, 8, 16, and 20 weeks), and the study physician (at 0 and 12 weeks). Motivational training is conducted by psychologist (four group session).
62720486|NCT03980392|EXPERIMENTAL|Home-based Intervention|The nutritional intervention, management of metabolic and vascular risk factors, social activity, and motivational training in the home-based intervention are similar to the facility-based intervention. The physical exercise programs consist of one group session (60 min) and two home-based sessions (60 min per session) per week in the first 2 months of the trial. During the remaining months of the 6-month study, participants in the home-based intervention attend a 1-h physical exercise group session per two weeks and two or three exercise sessions (60 min per session) alone at home per week. The cognitive training programs consist of one group session (60 min) and one home-based sessions (60 min per session) per week in the first 2 months of the trial. For the remainder of the 6-month study, participants in the home-based intervention attend a 1-h group cognitive training session per two weeks and one or two cognitive training sessions (60 min per session) alone at home per week.
62720487|NCT03980392|NO_INTERVENTION|Controls|They are waiting list controls. They will receive the multi-domain intervention after this study.
62720488|NCT05879952|EXPERIMENTAL|Experimental Group (EG)|"The group consists of 50 patients diagnosed with global developmental delay, randomply assigned.~The patients underwent treatment as usual (TAU) integrated with the use of BTsN pediatric modules, in a 1:1 ratio. All the exercises have been customized by the therapists according to the individual treatment needs, adapting the level of difficulty to the patient's abilities.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
62720489|NCT05879952|ACTIVE_COMPARATOR|Control Group (CG)|"The group consists of 50 patients diagnosed with global developmental delay randomply assigned.~The patients underwent TAU, consisting in standard neuro-psychomotor training. The treatment was tailored according to each child's goals need and preferences.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
62720490|NCT03758807|SHAM_COMPARATOR|Passive treatment|Passive treatment will consist of Manual Therapy with biomechanical explanation of the technique.
62720491|NCT03758807|EXPERIMENTAL|Active Treatment|Active treatment will consist of Manual Therapy with a neuroplasticity explanation of the technique.
62720492|NCT01597726|ACTIVE_COMPARATOR|Misoprostol|
62720493|NCT01597726|EXPERIMENTAL|Laminaria|
62720494|NCT01768949|OTHER|Echocardiography|An echocardiography will be systematically realised in all the patients included in the study in order to evaluate whether any echocardiographic criterion exploring the right ventricle can predict the efficacy and/or safeness of recruitment maneuvers in patients suffering from acute respiratory distress syndrome.
62720495|NCT02797314|OTHER|Type 2 diabetic population|Bone biopsies
62720496|NCT02797314|OTHER|Non-diabetic control population|Bone biopsies
62720497|NCT04340492|EXPERIMENTAL|Adapted Physical Activity group|
62720498|NCT04340492|SHAM_COMPARATOR|control group|
62720499|NCT02987582|EXPERIMENTAL|Emotion-focused mindfulness group|8-week mindfulness group
62720500|NCT03039387|ACTIVE_COMPARATOR|anodal tDCS|transcranial direct current stimulation of the left dlPFC with 1mA
62720501|NCT03039387|PLACEBO_COMPARATOR|Sham stimulation|Double blind sham stimulation (stimulation will be ramped down after 30 sec.)
62720502|NCT03630146|EXPERIMENTAL|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 5-12 weeks.
62720503|NCT03630146|ACTIVE_COMPARATOR|Waitlist Control Group|The control group will receive standard care but without the iPeer2Peer program.
62720504|NCT00613431|EXPERIMENTAL|1|6 dose groups, 9 subjects on active, 3 subjects on placebo in each group
62720505|NCT00613431|PLACEBO_COMPARATOR|2|3 subjects on placebo in each group
62737678|NCT01508377|EXPERIMENTAL|Treatment of PTSD without cognitive restructuring|"In this arm the PTSD treatment can be divided into only two phases. Compared to the other arm the phase dealing with cognitive restructuring is excluded.~First phase: self-confrontation (4 essays)~Second phase: parting (2 essays)"
62720506|NCT02146131|ACTIVE_COMPARATOR|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
62720507|NCT02146131|ACTIVE_COMPARATOR|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
62720508|NCT00517699|EXPERIMENTAL|1|
62720509|NCT01788943||Slow metabolizers|Individuals with an NMR \<0.26 will be classified as slow metabolizers.
62720510|NCT01788943||Normal metabolizers|Participants with an NMR \>= 0.26 will be classified as normal metabolizers.
62720511|NCT00827177|EXPERIMENTAL|ARQ 197 in combination with sorafenib|
62720512|NCT03971929|EXPERIMENTAL|SHR0532 tablet|up to 3 cohorts of subjects will receive multiple dose of oral tablets
62720513|NCT03971929|PLACEBO_COMPARATOR|SHR0532 placebo|up to 3 cohorts of subjects will receive multiple dose of oral SHR0532 placebo
62720514|NCT03971929|ACTIVE_COMPARATOR|Hydrochlorothiazide|up to 3 cohorts of subjects will receive multiple dose of oral Hydrochlorothiazide 25mg
62720515|NCT02777086|EXPERIMENTAL|StaySafe|Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about once per week.
62720516|NCT02777086|NO_INTERVENTION|Comparison|Participants are asked to complete baseline, 3-month and 6-month surveys but are not asked to complete StaySafe sessions or other alternate activities.
62720517|NCT04392973|EXPERIMENTAL|Intervention|Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)
62720518|NCT04392973|NO_INTERVENTION|Control|Standard of Care Treatment for COVID-19 Infection
62720519|NCT03793686|EXPERIMENTAL|Experimental|PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
62720520|NCT03793686|PLACEBO_COMPARATOR|Placebo|Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
62720521|NCT06717087|EXPERIMENTAL|acupuncture+ intensive lifestyle intervention|8 weeks acupuncture+ intensive lifestyle intervention
62720522|NCT06717087|ACTIVE_COMPARATOR|metformin + intensive lifestyle intervention|8 weeks metformin treatment(metformin 500 mg three times a day with meals)+ intensive lifestyle intervention
62720523|NCT05609357|EXPERIMENTAL|Head-up Cardiopulmonary Resuscitation|
62720524|NCT04653974|ACTIVE_COMPARATOR|Needle-free injection group|In needle-free injection techniques, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using the Comfort-In system.
62720525|NCT04653974|ACTIVE_COMPARATOR|Dental injection group|In the conventional dental-injection method, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using a 27G, 40-mm, disposable syringe with a needle.
62720526|NCT06209489|EXPERIMENTAL|İntervention group|"1. White fabric will be covered over the incubator for term newborns during phototherapy.~2. During phototherapy, term newborns will receive a baby massage, including facial massage, chest massage, arm massage, abdominal massage and leg massage, twice a day for 15 minutes."
62720527|NCT06209489|NO_INTERVENTION|Control group|The hospital's clinical routine will be applied to the newborns in the control group.
62720528|NCT03445312||study cohort|All non-ICU medicine and surgery patients at Sinai Health System who have a mid-stream urine culture ordered
62720529|NCT03623438|EXPERIMENTAL|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
62720530|NCT03623438|ACTIVE_COMPARATOR|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
62720531|NCT01776853|PLACEBO_COMPARATOR|Glucose|40g glucose in 500ml water flavoured with lime juice
62720532|NCT01776853|EXPERIMENTAL|Fructose|40g fructose in 500ml water flavoured with lime juice
62720533|NCT01776853|EXPERIMENTAL|Fructans|40g fructans in 500ml water flavoured with lime juice
62720534|NCT05112848|EXPERIMENTAL|Group 1 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
62720535|NCT05112848|EXPERIMENTAL|Group 2 PLWH|Three doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0, Day 21, and Day 70.
62720536|NCT05112848|EXPERIMENTAL|Group 3 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
62720537|NCT05112848|EXPERIMENTAL|Group 4 HIV-Negative Participants|"2 doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
62165942|NCT01827800|EXPERIMENTAL|eHealth weight loss intervention|The 12-month eHealth behavioral intervention includes interactive self-monitoring and feedback, tailored skills training materials, telephone counseling calls from a study coach, and primary care provider counseling.
61976660|NCT04876625|ACTIVE_COMPARATOR|OA Alone 4wk|Oral Appliance is used alone for first 4 weeks followed by 4 weeks of Oral Appliance plus Mouth Shield
61976661|NCT05417061|ACTIVE_COMPARATOR|Saliva and serum collection of patients and samples molecules analysis|
62165943|NCT01827800|NO_INTERVENTION|Usual care|Participants in the usual care arm will receive the usual primary care services offered by their community health center primary care providers.
62165944|NCT04743453|EXPERIMENTAL|Dapagliflozin|
62165945|NCT04743453|PLACEBO_COMPARATOR|Placebo|
62165946|NCT04627259||patient|patients with thumb pain or functional problems
62720538|NCT05112848|EXPERIMENTAL|Group 5 HIV-Negative Participants|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
62548935|NCT00445146|EXPERIMENTAL|EVG+RTV|"EVG 85 mg or 150 mg + RTV + ARV regimen~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their ARV regimen will receive EVG 85 mg and all other participants will receive EVG 150 mg.~Some participants may receive EVG 300 mg during the course of protocol amendment 2."
62548936|NCT02755285|EXPERIMENTAL|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
62548937|NCT03815214|EXPERIMENTAL|Diet Intervention|The diet intervention is a partial meal replacement program using the commercially available OPTAVIA® Optimal Weight 4\&2\&1 Plan™. In the OPTAVIA program, subjects are asked to eat 6 times each day, once every 2 to 3 hours.
62548938|NCT03815214|PLACEBO_COMPARATOR|Enhanced Standard Care|The control group will receive instruction on a healthy diet as defined by the United States Department of Agriculture.
62548939|NCT01998763|PLACEBO_COMPARATOR|Placebo|5 placebo pills per day, 20 weeks
62548940|NCT01998763|EXPERIMENTAL|2000 IU/d Vitamin D3|5 vitamin D3 pills per day, 20 weeks
62548941|NCT04005066||Cohort 1|"* Currently using Elunate® or will use Elunate®(Fruquintinib) within a week;~* Provision of informed consent by the patient."
62548942|NCT05810428|EXPERIMENTAL|GKRS-VR training|GKRS-VR group will undergo GKRS and neuromodulation based on Virtual Reality sensorimotor rehabilitation using an immersive system
62548943|NCT05810428|ACTIVE_COMPARATOR|Control Group|Control group (CT) will undergo only GKRS
62548944|NCT05810428|NO_INTERVENTION|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare neuropsychological,clinical and structural/functional magnetic resonance imaging characteristics at baseline.
62548945|NCT03717012|ACTIVE_COMPARATOR|Nintedanib treatment alone|
62548946|NCT03717012|EXPERIMENTAL|Nintedanib with a pulmonary rehabilitation program|
62548947|NCT02123446|EXPERIMENTAL|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
62548948|NCT02123446|ACTIVE_COMPARATOR|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
62548949|NCT04620408|EXPERIMENTAL|Group A|The subjects in group A did not have breakfast at D1, then were given an SHR4640 tablet. The subjects in group A had a high-fat breakfast on D8. After eating 30min, the subjects in group A were given SHR4640 tablet.
62548950|NCT04620408|EXPERIMENTAL|Group B|Group B had high-fat breakfast on D1, no breakfast on D8, and the rest was the same as group A.
62548951|NCT03791463|EXPERIMENTAL|After meal|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
62548952|NCT03791463|EXPERIMENTAL|Fasting|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered at the end of a 10-hour fast.
62548953|NCT05889312||Non-small cell lung cancer|NSCLC
62548954|NCT05889312||Head and neck squamous cell cancer|HNSCC
62548955|NCT00679133|EXPERIMENTAL|1|
62548956|NCT01804972|ACTIVE_COMPARATOR|Verbal and written infomation|Verbal and written information:Patients will receive both verbal information and written patient information leaflets
62548957|NCT01804972|EXPERIMENTAL|Verbal and electronic information|Patient will receive both verbal information and a web address to access patient information electronically
62548958|NCT02508129|EXPERIMENTAL|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) employs behavioral strategies for managing insomnia and is administered in 4 brief weekly contacts with a therapist via online web conferencing.
62548959|NCT02508129|EXPERIMENTAL|Sleep Healthy Using the Internet (SHUTi)|SHUTi is an automated, interactive, personalized web-based program for improving insomnia through the use of Cognitive-Behavioral Therapy strategies for insomnia.
62548960|NCT02508129|PLACEBO_COMPARATOR|Enhanced Usual Care (EUC)|EUC involves the primary care physician's current treatment; feedback to patients and providers on assessment and treatment recommendations; an educational video from Emmi Solutions, Inc.
62548961|NCT01625988|EXPERIMENTAL|LY2951742|LY2951742: 150 milligrams (mg), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
62548962|NCT01625988|PLACEBO_COMPARATOR|Placebo|Placebo: 0.9% Sodium Chloride, Untied States Pharmacopoeia (USP), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
62548963|NCT00513136|ACTIVE_COMPARATOR|I|10 week group-based mind body medicine intervention
62548964|NCT00513136|EXPERIMENTAL|II|Group-based mind body medicine intervention with a family focus
62548965|NCT04587999|EXPERIMENTAL|bladder stimulation|
62548966|NCT04587999|ACTIVE_COMPARATOR|Quick wee|
62548967|NCT01184443|EXPERIMENTAL|Olanzapine|Those who choose to take olanzapine as part of their treatment (standard practice plus medication).
62548968|NCT01184443|NO_INTERVENTION|Comparison|Those who choose not to take olanzapine as part of their treatment (standard practice).
62548969|NCT05650840|EXPERIMENTAL|Charcoal -based whitening toothpaste|signal charcoal white\& Detox toothpaste Unilever Mashreq - Egypt
62548970|NCT05650840|ACTIVE_COMPARATOR|Calcium carbonate /perlite containing whitening toothpaste|signal whitening moonlight toothpaste Unilever Mashreq - Egypt
62548971|NCT00553735|ACTIVE_COMPARATOR|Cyclosporine A 0.05%|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
62548972|NCT00553735|PLACEBO_COMPARATOR|Artificial Tear|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
62548973|NCT06471374|EXPERIMENTAL|Assessment|Circadian rhythms and light sensitivity
62548974|NCT05354921|EXPERIMENTAL|Indwelling|Foley catheterization upon admission and removed the morning following surgery.
62737679|NCT02973295|EXPERIMENTAL|Group Silymarin|Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
62548975|NCT05354921|EXPERIMENTAL|Intermittent|Intermittent catheterization when post-void residual volume is greater than 400 mL.
62548976|NCT01208805||Candidates for dorsal column stimulation|
62548977|NCT04615351|ACTIVE_COMPARATOR|Metformin|Metformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose
62548978|NCT04615351|NO_INTERVENTION|Routine Care|Discharge information about maintaining a healthy diet
62548979|NCT03744624|EXPERIMENTAL|With 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing both 3D printed model and computed tomography (or/and magnetic resonance imaging)
62548980|NCT03744624|ACTIVE_COMPARATOR|Without 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing only standard medical imaging computed tomography (or/and magnetic resonance imaging) without development of 3D printed model
62548981|NCT05806840|ACTIVE_COMPARATOR|Standard Michigan Model for Health (MMH) Curriculum Implementation|Standard implementation of the MMH (Michigan Model for Health), a universal prevention intervention includes curriculum materials, foundational curriculum training and as-needed technical assistance, provided by the regional school health coordinators.
62548982|NCT05806840|EXPERIMENTAL|Rapid Adaptation to Prevent Drug Use (RAPD)|RAPD is a novel bundle of implementation strategies to improve the responsiveness of an existing evidence-based intervention (EBI), the Michigan Model for Health (MMH) for urgent drug events. These implementation strategies will be deployed in addition to standard implementation components.
62548983|NCT05991869|EXPERIMENTAL|Intervention|
62548984|NCT05991869|NO_INTERVENTION|Usual Care|
62548985|NCT01315327|EXPERIMENTAL|Omega-3 Fatty Acids|Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.
62548986|NCT01315327|PLACEBO_COMPARATOR|Placebo|Olive oil placebo, looks and tastes identical to active intervention.
62548987|NCT02397876|EXPERIMENTAL|partially hydrolyzed whey formula|The group of patients who pass an oral food challenge to partially hydrolyzed whey formula and will be continued on it through out the study
62548988|NCT02397876|NO_INTERVENTION|No intervention|Patients who do not pass an oral food challenge to partially hydrolyzed whey formula will continue on their prior diet of cows milk avoidance.
62548989|NCT00401661|EXPERIMENTAL|1|Alfuzosin for 24 weeks
62548990|NCT00455156|EXPERIMENTAL|150/15 NES/EE CVR|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
62548991|NCT06582667|EXPERIMENTAL|group A: PENG block in hip fracture with antithrombotic therapy|50 patients will receive US guided PENG block and on antithrombotic therapy in hip fracture
62548992|NCT06582667|EXPERIMENTAL|group C: PENG block in hip fracture without antithrombotic therapy|50 patients will receive US guided PENG block without antithrombotic therapy in hip fracture
62548993|NCT02285374|EXPERIMENTAL|Arm 1|Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus Dolutegravir 50mg (one tablet) once daily
62548994|NCT02285374|EXPERIMENTAL|Arm 2|Atripla (efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) one tablet once daily, or Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus efavirenz 600mg one tablet once daily for 4 weeks. At week 4, efavirenz is switched to Dolutegravir 50mg (one tablet) once daily
62548995|NCT00402116|EXPERIMENTAL|A|The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD). Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m\^2 therapy. The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT). If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle. If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles. If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin. The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
62548996|NCT03687840|OTHER|Study Group|Spatio-Temporal gait analysis of subjects with unilateral lower extremity burn injuries due to diabetic polyneuropathy.
62548997|NCT03687840|OTHER|Control Group|Spatio-Temporal gait analysis of subjects with only diabetic polyneuropathy.
62548998|NCT04386395||Immuno Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
62548999|NCT04386395||Cortico Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. According to RECOVERY study, early routine administration of dexamethasone 6 mg/day over 10 days. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
62549000|NCT02229461|EXPERIMENTAL|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
62549001|NCT02229461|EXPERIMENTAL|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
62549002|NCT02229461|EXPERIMENTAL|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
62549003|NCT02229461|ACTIVE_COMPARATOR|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
62737680|NCT02973295|PLACEBO_COMPARATOR|Group Placebo|2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
62549004|NCT02229461|EXPERIMENTAL|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
62549005|NCT02229461|EXPERIMENTAL|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
62549006|NCT06339697|ACTIVE_COMPARATOR|compounded polyethylene glycol electrolyte dispersions|For patients undergoing colonoscopic polypectomy in the morning, 2-3 L should be taken the night before and 1-2 L the morning of the procedure, and for patients undergoing colonoscopy in the afternoon, divided doses should be taken on the same day.
62549007|NCT06339697|ACTIVE_COMPARATOR|compounded sodium pico-sulfate|Oral sodium picolinate/magnesium citrate (PicolaxÒ), 2 sachets, each sachet contains 0.01 g of sodium picolinate, 3.5 g of magnesium oxide, 12.0 g of citric acid, each sachet should be dissolved in 150 ml of water, sachet 1 should be taken at 7:00 p.m.-9:00 p.m. on the first day of the operation, and cite 1,500-2,000 ml of clarified fluids after the dose and before going to bed, sachet 2 should be taken 4-6 hours prior to colonoscopy, and 750 ml of clarified fluids should be taken orally before the colonoscopy. The second bag should be taken 4-6 hours before the colonoscopy and 750 ml of clarified liquid should be taken orally before the colonoscopy.
62549008|NCT02888951||Diabetic Group|A group of diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
62549009|NCT02888951||Non-Diabetic Group|A group of non-diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
62549010|NCT01958138|EXPERIMENTAL|propofol with Isoflurane|Propofol with Isoflurane, Group-I is the intervention arm with combination of two drugs such as low dose propofol and Isoflurane MAC awake.
62549011|NCT01958138|ACTIVE_COMPARATOR|alone isoflurane|The group-II is the control arm of study by using the only Isoflurane 1.2 MAC
62549012|NCT04010552|EXPERIMENTAL|NALIRINOX treatment|Patients will be treated with NALIRINOX, a combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin. Treatment regimen will consist of 8 cycles of neoadjuvant NALIRINOX prior to surgery and trial duration is expected to be 24 months.
62549013|NCT01277159|EXPERIMENTAL|Control Nerve Block. IV Dexamethasone (4 mg).|Control Nerve Block. IV Dexamethasone (4 mg).
62549014|NCT01277159|EXPERIMENTAL|Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
62549015|NCT01277159|EXPERIMENTAL|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
62549016|NCT01277159|EXPERIMENTAL|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
62549017|NCT01277159|EXPERIMENTAL|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
62549018|NCT02091024|EXPERIMENTAL|ECG (Ecklonia cava extract)|ECE 200mg, twice a day
62549019|NCT02091024|PLACEBO_COMPARATOR|Placebo|Placebo 200mg, twice a day
62549020|NCT02720497|EXPERIMENTAL|60-minute Prolonged Exposure|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
62549021|NCT02720497|ACTIVE_COMPARATOR|90-minute Prolonged Exposure|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
62549022|NCT03916705|OTHER|single study arm|All enrolled participants will undergo ultrasound evaluation and chiropractic low back spinal manipulation treatment.
62549023|NCT01662219|EXPERIMENTAL|superficial cervical plexus block|superficial cervical plexus block for experimental group
62549024|NCT01662219|NO_INTERVENTION|No Block|no superficial cervical plexus block for the no intervention group
62549025|NCT05166616|EXPERIMENTAL|Treatment (minnelide, osimertinib)|Patients receive minnelide PO QD on days 1-21 and osimertinib PO QD on days 1-28. Cycles repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
62549026|NCT02523300|EXPERIMENTAL|TEVAR+GC|The patients underwent TEVAR. Then glucocorticoids will be intravenously given after TEVAR
62549027|NCT02523300|PLACEBO_COMPARATOR|TEVAR+Vehicle|The patients underwent TEVAR. Then saline will be given after TEVAR
62549028|NCT05665725|EXPERIMENTAL|Treatment (siltuximab, biospecimen)|Patients receive siltuximab IV prior to CE19.CAR-T cell therapy and as clinically indicated on study. Patients undergo CT scan or PET scan throughout the trial. Patients also undergo blood sample collection during screening and on study.
62549029|NCT05101668|EXPERIMENTAL|Intracranial Thrombosis Aspiration Catheter|Intracranial Thrombosis Aspiration Catheter, product of Sinomed Neurovita Technology Inc.
62549030|NCT02085447|EXPERIMENTAL|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
62549031|NCT04413110||Non-subjective cognitive impaired|Cases of migraine and non-subjective cognitive impaired
62549032|NCT04413110||Subjective cognitive impaired|Cases of migraine and subjective cognitive impaired
62549033|NCT04413110||Control group|Age and sex matched healthy controls
62549034|NCT01128543|ACTIVE_COMPARATOR|lapatinib 1250mg|Patients will receive 1250mg lapatinib once a day for 24 weeks.
62549035|NCT01128543|ACTIVE_COMPARATOR|Vinorelbine 25mg/sqm|Patients will receive vinorelbine 25mg/sqm IV Day 1 and Day 8, every 3 week for 24 weeks.
62549036|NCT02588495|NO_INTERVENTION|Fasting|Participant will remain fasted following initial gastric ultrasound
62549037|NCT02588495|EXPERIMENTAL|Food intake|Participant will ingest either 250mL of clear fluid (apple juice) or 250mL of coffee and a muffin following initial gastric ultrasound
62549038|NCT04799197|EXPERIMENTAL|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
62549039|NCT03076775|EXPERIMENTAL|Intervention|Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.
62549040|NCT03076775|NO_INTERVENTION|Usual Care|Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.
62549041|NCT00866944|EXPERIMENTAL|1|Adecatumumab alone
62549042|NCT00866944|EXPERIMENTAL|2|FOLFOX 4 followed by Adecatumumab
62549043|NCT00866944|ACTIVE_COMPARATOR|3|FOLFOX 4 alone
62549044|NCT02770898|EXPERIMENTAL|Brief Intervention|The brief intervention is individual focus and consists of three main components, which include enhancing the individual personal attributes such as participant's knowledge, values, and behaviors related to physical exercise. Second, the intervention will promote changes in behavioral attributes by providing opportunities and experience in goal setting, skills development in physical exercise and self-monitoring. Finally, the brief intervention promotes family relations and well-being by encouraging individuals to share their knowledge and increase physical activities with other family members. The brief intervention will be delivered by the probation officer during regular monthly consultation.
62549045|NCT02770898|EXPERIMENTAL|Combined Intervention|Participants allocated to the combined intervention will receive the individual brief intervention and participate in a community group program. The components in the brief intervention will also be reinforced in the group program. The group nature is designed to create an environment that is supportive of physical exercise, through role models, peer support, and encourages families to exercise with probationers.
62549046|NCT02770898|NO_INTERVENTION|Care-as-usual|Participants allocated to Care-as-usual arm will receive their usual services. Participants will be offered the combined interventions upon completion of 3-months follow up assessment.
62549047|NCT00298727|ACTIVE_COMPARATOR|1|SHIPS: Face-to-Face Workshop
62549048|NCT00298727|ACTIVE_COMPARATOR|2|ePBL: Online Problem-Based Course
62549049|NCT02489097|ACTIVE_COMPARATOR|Nitrous Oxide|Receives a mixture of 70% Nitrous Oxide in 30% Oxygen
62549050|NCT02489097|PLACEBO_COMPARATOR|Air/Oxygen (placebo)|Receives a mixture of 70% Air in 30% Oxygen
62549051|NCT06037005|EXPERIMENTAL|Cognitive Behavioral Therapy|Expert support was received from the Cognitive Behavioral Psychotherapy Practitioner and Trainer of the Turkish Psychiatric Association in the creation of the sessions. The researcher applying the therapy has a CBT practitioner certificate. Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
62549052|NCT06037005|NO_INTERVENTION|Control|While group therapy was applied to the experimental group, no intervention was made to the control group.
62549053|NCT05725863|NO_INTERVENTION|Control|No psychological intervention was offered. Postpartum mothers in the control condition were informed that they would receive MBCT after a waiting period of 2 months.
62549054|NCT05725863|EXPERIMENTAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
62549055|NCT03059797|EXPERIMENTAL|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
62549056|NCT03059797|PLACEBO_COMPARATOR|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
62549057|NCT04610333|EXPERIMENTAL|School teacher training|"Teacher training programme:~* MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.~* Four-day residental course~* 3 x 2 seminar days~Modified MBSR programme delivered to the students:~- 1hour group session once a week in 10 weeks taught by the educated teachers on class"
62549058|NCT04610333|NO_INTERVENTION|Usual practice|
62549059|NCT03451357||patients with Dependence degree|Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
62549060|NCT00972595|EXPERIMENTAL|A|clinical trial formulation
62549061|NCT00972595|ACTIVE_COMPARATOR|B|non-U.S. marketed formulation
62549062|NCT03288818|EXPERIMENTAL|low dose TSEBT, mechlorethamine hydrochloride gel|Patients undergo low dose TSEBT for 2 weeks. After 30 days of observation, patients receive mechlorethamine hydrochloride gel topically daily at week 7 and then once weekly up to week 54.
62549063|NCT04902937||premenopausal patients|
62549064|NCT04902937||postmenopausal patients|
62549065|NCT00980447|EXPERIMENTAL|UMN-0501 45µg|Recombinant H5N1 vaccine 45µg
62549066|NCT00980447|EXPERIMENTAL|UMN-0501 90µg|Recombinant H5N1 vaccine 90µg
62549067|NCT00980447|EXPERIMENTAL|UMN-0501 135µg|Recombinant H5N1 vaccine 135µg
62549068|NCT03420521|OTHER|Nivolumab plus Ipilimumab|Nivolumab 240 mg IV over 60 minutes every 2 weeks (Q2W) Ipilimumab 1mg/kg IV over 30 minutes every 6 weeks (Q6W)
62549069|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
62720539|NCT05508828||The study group|We retrospectively analysis of 8 consecutive patients with SAP and IPN. SAP was diagnosed with persistent organ failure \>48h. IPN was considered when the following situations occur: ≥38.5℃; increasing WBC, CRP or procalcitonin; rapid clinical deterioration; signs of gas was present in areas of necrosis.
62720540|NCT02431546|EXPERIMENTAL|Mobile Health Application Group|"VIDA is a mobile technology that is well positioned to provide healthcare coaching. After completing the CR program, each participant will have access to the VIDA mobile phone platform for the 12-week intervention, and be instructed to download the app on his/her smart phone. VIDA will assign an individual professional health coach selected from a pool of well-trained and experienced health professionals-nutritionists, fitness trainers, nurses and health educators. Each coach will engage their patient in a productive and meaningful health mentorship on a daily basis. The coach and patient work as a team to successfully set goals and make small changes that add up to significant improvements in the patients' dietary choices, physical activity, medication management, as well as understanding of their health status.~Physical Activity: A goal of total number of steps to attain daily will be provided by the Duke study team to the patient and monitored using a Fitbit activity tracker."
62720541|NCT02431546|NO_INTERVENTION|Usual Care Group|Participants randomized to the usual care control arm will follow standard care as ordered by their individual, treating physician. Participants in the UC control arm will not receive any specific lifestyle recommendations from study personnel. They may, however, receive any lifestyle recommendations deemed appropriate by their usual clinical care providers. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.
62720542|NCT03952403|EXPERIMENTAL|Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
62720543|NCT03952403|EXPERIMENTAL|Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
62720544|NCT03952403|EXPERIMENTAL|Part 2-Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
62720545|NCT03952403|ACTIVE_COMPARATOR|Part 2-Arm C (HLX10 placebo+HLX04 placebo+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 placebo and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
62720546|NCT05030584|ACTIVE_COMPARATOR|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
62720547|NCT05030584|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo orally once daily.
62720548|NCT02946398||elderly patients who visit the ED|elderly patients (65 years and older) who present to the emergency department for internal medicine or gastroenterology
62720549|NCT01055145|ACTIVE_COMPARATOR|levofloxacin|Levofloxacin 750mg po per day for 3 months
62720550|NCT01055145|ACTIVE_COMPARATOR|moxifloxacin|Moxifloxacin 400mg po per day for 3 months
62720551|NCT02039830|EXPERIMENTAL|Group physiotherapy|12 weekly treatment visit + daily home exercise program
62720552|NCT02039830|ACTIVE_COMPARATOR|Individual one-on-one physiotherapy|12 weekly treatment visit + daily home exercise program
62720553|NCT06373211|EXPERIMENTAL|Early immunotherapy|Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone
62720554|NCT06544044|EXPERIMENTAL|Therapist|The only one researcher, an experienced mindfulness practitioner and group therapist, leads groups of 10-15 students in weekly 90-minute sessions to deliver the program.
62720555|NCT06716177||Patients Without Traditional Cardiovascular Risk Factors Experiencing AMI|"This cohort includes patients diagnosed with acute myocardial infarction (AMI) who do not exhibit traditional cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, smoking, or obesity. Participants will undergo comprehensive clinical assessments, including advanced imaging (coronary computed tomography angiography and cardiac magnetic resonance imaging), biomarker profiling, and genetic analyses.~No direct therapeutic interventions will be applied as part of this study; instead, observational methods will be used to analyze clinical characteristics, identify novel biomarkers, and explore mechanisms contributing to AMI pathogenesis in this population. Data collected from this cohort will provide insights into the unique features and risk profiles of AMI patients without conventional risk factors, potentially informing future diagnostic and therapeutic strategies."
62720556|NCT03387215|EXPERIMENTAL|10 mg ITI-214|Single oral dose
62720557|NCT03387215|EXPERIMENTAL|30 mg ITI-214|Single oral dose
62720558|NCT03387215|EXPERIMENTAL|75 mg - 150 mg ITI-214|Single oral dose
62720559|NCT03387215|PLACEBO_COMPARATOR|Placebo|Single oral dose
62720560|NCT01927978||esophageal cancer, 18F-FDG PET|
62720561|NCT04416113|ACTIVE_COMPARATOR|photobiomodulation group|"Laser watch Patients will be subjected to low-level laser (diode laser 980nm) for 30 minutes, the recommended dose based on the previous study is 20 J for 3 to 7 days.~The laser device:~Laser watched applied at the wrist on the radial artery.~Laser acupuncture"
62737681|NCT04701606|EXPERIMENTAL|Artecom® (pyronaridine-artesunate)|Artecom® is treated orally once a day for 3 consecutive days.
62737682|NCT04701606|PLACEBO_COMPARATOR|Placebo|Placebo is treated orally once a day for 3 consecutive days.
62737683|NCT00952861|ACTIVE_COMPARATOR|Doxycycline|Doxycycline 200 mg QD in 5 days
62720562|NCT04416113|ACTIVE_COMPARATOR|photodynamic group|"Methylene blue injection USP 1% will be used as a photosensitizer in PDT.~* 0.1 to 0.2 mL of 1% solution per kilogram of body weight Methylene Blue (methylene blue injection) will be injected intravenously very slowly over a period of several minutes to~* After one hour apply Light dose: 100 - 200 J/cm2 50-100 mW/cm2. (50 mW/cm2 increased the phototoxic response as well as the fractionated light application).~* The session will be done twice per week~Laser watched applied at the wrist on the radial artery."
62720563|NCT04416113|ACTIVE_COMPARATOR|positive control|This group will include patients who are subjected to conventional treatment
62720564|NCT04462601||Patients with Sjögren Syndrome|
62720565|NCT03568747|EXPERIMENTAL|NIV plus oxygen therapy|noninvasive ventilation (dual-limb NIV) is given at peak exercise until the borg scale reaches it's baseline point
62720566|NCT03568747|EXPERIMENTAL|oxygen therapy|oxygen therapy is given at peak exercise until the borg scale reaches it's baseline point
62720567|NCT03618381|EXPERIMENTAL|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
62720568|NCT03618381|EXPERIMENTAL|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
62720569|NCT01298843|OTHER|Study of Blood Levels of Ceftaroline Fosamil|Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
62720570|NCT02465931|OTHER|Comparison Condition|Paper and pencil informed consent
62720571|NCT02465931|EXPERIMENTAL|Intervention condition|Digital informed consent tool
62720572|NCT03313830|EXPERIMENTAL|Whey Protein Hydrolysate (WPH)|The intervention consists of Whey Protein Hydrolysate (WPH) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
62720573|NCT03313830|EXPERIMENTAL|Intact Whey Protein (WHEY)|The intervention consists of Intact Whey Protein (WHEY) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
62720574|NCT04650295|EXPERIMENTAL|Household Remedy|
62720575|NCT04650295|PLACEBO_COMPARATOR|Tap Water|
62720576|NCT02112643|ACTIVE_COMPARATOR|Selenium|100 micrograms of sodium selenate will be taken orally twice daily (total 200 micrograms daily) for 6 months.
62720577|NCT02112643|PLACEBO_COMPARATOR|Sugar pill|A placebo pill will be taken orally twice daily for 6 months.
62720578|NCT05554458|EXPERIMENTAL|Control Group|Paired allocation into intervention group IG (N = 33) and control group CG (N = 33) is based on the number of risk factors identified in the family. IG and CG complete questionnaires at the baseline assessment (T0), at the post-test assessment (T1), and at the follow-up assessments after 6 months (T2) and 12 months (T3).
62720579|NCT05554458|ACTIVE_COMPARATOR|Intervention Group|IG receive the ChildTalks+ intervention within 2 months after T0 and CG after the T3 assessment.
62720580|NCT03757429||RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
62720581|NCT03757429||Non-RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
62720582|NCT01342731|EXPERIMENTAL|Tigecycline|Tigecycline 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 d
62720583|NCT01888861|EXPERIMENTAL|alpha-lipoic acid|the patients in this arm were received 900mg alpha-lipoic acid for 10 days through nasogastric(NG) tube.
62720584|NCT01888861|PLACEBO_COMPARATOR|placebo|the patients in this arm were received 900mg placebo through NG tube.
62720585|NCT00569933|OTHER|A/B/C|Patients are randomized to voice/music/ or no CD
62720586|NCT01437202||high risk group|Identified by the predictive model using 2 genotypes and disease stage
62720587|NCT01437202||intermediate risk group|Identified by the predictive model using 2 genotypes and disease stage
62720588|NCT01437202||Low risk group|Identified by the predictive model using 2 genotypes and disease stage
62720589|NCT01445847|ACTIVE_COMPARATOR|Lidocaine|Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
62720590|NCT01445847|PLACEBO_COMPARATOR|Placebo|Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.
62720591|NCT05986773|ACTIVE_COMPARATOR|group FF|"Group FF will receive a doubled dose Furosemide i.v.~The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v.~Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection."
62720592|NCT05986773|ACTIVE_COMPARATOR|group FM|"Group FM will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o.~The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v.~Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Metolazone will be administered orally."
62720593|NCT05986773|ACTIVE_COMPARATOR|group FA|"Group FA will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v.~The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v.~Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Acetazolamide (500mg) will be administered intravenously as a short infusion."
62720594|NCT01836289|EXPERIMENTAL|High-dose Cyclophosphamide|High-dose Cyclophosphamide
62720595|NCT03731403|EXPERIMENTAL|MI Varnish|
62720596|NCT03731403|ACTIVE_COMPARATOR|Profluorid Varnish|
62720597|NCT01938261|EXPERIMENTAL|Paracetamol effect on ductus|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
62737684|NCT00952861|PLACEBO_COMPARATOR|Placebo|Matching placebo QD i 5 days
62737685|NCT03178136||case group|There is no intervention in case group.
62720598|NCT01938261|EXPERIMENTAL|Paracetamol effect on pain|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
62720599|NCT03984721|EXPERIMENTAL|Amylose typing|Amyloidosis typing by nanoLC-MS/MS in patients diagnosed with Amyloidosis but unable to be typed
62720600|NCT02905578|EXPERIMENTAL|Ascorbate group|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks"
62720601|NCT02905578|ACTIVE_COMPARATOR|Control|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week"
62720602|NCT05245539|EXPERIMENTAL|CVL-231 Dose Level 1|10 mg once daily
62720603|NCT05245539|EXPERIMENTAL|CVL-231 Dose Level 2|30 mg once daily
62720604|NCT03544450|EXPERIMENTAL|Psychosocial counselling + Enhanced usual care (EUC)|This arm receives psychosocial counselling from the counsellor as well as enhanced usual care from health worker
62720605|NCT03544450|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|This arm receives enhanced usual care from health worker
62720606|NCT05046392|EXPERIMENTAL|mHealth Facilitated Adherence Coaching|
62720607|NCT05046392|ACTIVE_COMPARATOR|Control|
62720608|NCT01027039||Patients using noise-reducing headphones|Patients using noise-reducing headphones
62720609|NCT01027039||Patients using no headphones|Patients using no headphones
62720610|NCT01027039||Patients using headphones with music|Patients using headphones with music
62720611|NCT05719207|EXPERIMENTAL|Balloon dilation of eustachian tube|These patient will undergo balloon dilation dilation of the eustachian tube.
62720612|NCT05719207|SHAM_COMPARATOR|Sham procedure|These patients will undergo a sham procedure, where the motions of balloon dilation of the eustachian tube will be simulated.
62720613|NCT04014426|OTHER|Exposed|Healthcare workers participating at two PIPAC
62720614|NCT04014426|OTHER|Non-exposed|Healthy volunteers unexposed to chemotherapy
62720615|NCT02270775||Fibromyalgia Patients|"The central Sensitization questionnaire will be filled in by each patients included.~After One week, patients will filled it the questionnaire again to study the reliability."
62720616|NCT02270775||Ankle sprain Patients|The central Sensitization questionnaire will be filled in by each patients included.
62720617|NCT02270775||Healthy Volunteers|"The central Sensitization questionnaire will be filled in by each volunteer included.~After One week, volunteers will filled it the questionnaire again to study the reliability."
62720618|NCT04470297|PLACEBO_COMPARATOR|Placebo|A placebo with the same physical characteristics of the experimental drug pill will be administered at the same time and daily schedule as the experimental intervention for 10 days.
62720619|NCT04470297|EXPERIMENTAL|Ramelteon|A pill containing ramelteon 8mg will be administered daily at bedtime for 10 days.
62720620|NCT02043990|EXPERIMENTAL|Noninvasive NAVA Ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
62720621|NCT02435654|EXPERIMENTAL|Treatment group|All EOS patients will receive olanzapine treatment with flexible dose(2.5 to 20 mg/day)according to standard body weight,olanzapine will be initiated at 2.5 or 5 mg/day and the dose could be increased by 2.5 or 5 mg/day dose increments at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,the investigator could decrease the dose at any time and in any number of dose decrements if patients experienced an adverse event.
62720622|NCT06717620||UCM students|Measurements before and after the exam period
61976662|NCT05417061|EXPERIMENTAL|Salivary and serum SIRT6, LPXA4 and CASP8 observation|"Saliva and serum samples obtained for each patient were used for cytokine analysis. Prepared samples were analyzed for Lipoxin A4 (LXA4), Caspase 8 (CASP8) and Sirtuin-6 (SIRT6) using commercial ELISA kits~(Elabscience, Houston, Texas, USA and Bioaasay Technology Laboratory (BT-Lab), Shanghai, China, respectively) according to the manufacturer's instructions. The detection limits of ELISA kits were 0.78 - 50ng/ml for LXA4, 0.16 - 10ng/ml for CASP8 and 0.1- 40 ng/ml for SIRT6."
62720623|NCT04934267|EXPERIMENTAL|Eccentric exercise of elbow in order to induce Delayed Onset of Muscle Soreness|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1RM).Both groups will perform 1 set of standing eccentric bicep curls based on their 1RM to failure in order to induce DOMS.The exercise will stop when the participant cannot volitionally keep up with the 5 second count lowering the weight. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
62720624|NCT04868344|EXPERIMENTAL|MRG003|Phase Ia: MRG003 will be administrated by an IV infusion of escalating doses (0.1, 0.3, 0.6, 1.0, 2.0, 2.5, 3.0 mg/kg) on Day 1 of every 3 weeks (Q3W); Phase Ib: MRG003 will be administrated by an IV infusion of MTD/RP2D.
62720625|NCT06263036||Men|Cadavra
62720626|NCT06263036||Women|Cadavra
62720627|NCT05233124|ACTIVE_COMPARATOR|Dual antiplatelet therapy|Acetyl salicylic acid, 100mg once a day + clopidogrel 75mg, once a day.
62720628|NCT05233124|EXPERIMENTAL|Antiplatelet monotherapy + low dose anticoagulant|Clopidogrel 75mg + Rivaroxaban 75mg
62720629|NCT03215043|EXPERIMENTAL|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
62720630|NCT03215043|EXPERIMENTAL|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
62720631|NCT03215043|EXPERIMENTAL|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
62720632|NCT03215043|PLACEBO_COMPARATOR|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
62720633|NCT01709526|OTHER|Improvement after psychiatric inpatient treatment|
62720634|NCT04097652|EXPERIMENTAL|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
62720635|NCT06513533|EXPERIMENTAL|DMF arm|Oral administration of dimethyl fumarate, 480 mg/day, for 36 months
62720636|NCT06513533|PLACEBO_COMPARATOR|Placebo arm|Oral administration of placebo for 24 months, followed by oral dimethyl fumarate, 480 mg/day for 12 months
62737686|NCT03178136||control group|The control group as the contrast for case group.
62720637|NCT03835078|EXPERIMENTAL|methalfilcon A contact lenses / fanfilcon A contact lenses|All subjects will first wear methafilcon A contact lenses for four (4) weeks of daily wear, then be refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
62720638|NCT06414083|ACTIVE_COMPARATOR|Diathermy|
62720639|NCT06414083|ACTIVE_COMPARATOR|CO2 Laser|
62720640|NCT06414083|ACTIVE_COMPARATOR|Argon Beam Coagulator|
62720641|NCT04919720|OTHER|Human Factors Interventions|A 'bundle' of human factors interventions designed to improve response to deteriorating patients.
62720642|NCT01224236|EXPERIMENTAL|iron supplementation|2 mg/kg/day of elemental iron as a multivitamin with iron solution
62720643|NCT01224236|SHAM_COMPARATOR|control|multivitamin solution without iron
62720644|NCT02949011|EXPERIMENTAL|Baloxavir Marboxil|Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of \< 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
62720645|NCT02949011|ACTIVE_COMPARATOR|Oseltamivir|Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
62720646|NCT02949011|PLACEBO_COMPARATOR|Placebo|Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
62720647|NCT04708262|EXPERIMENTAL|Cognitive Analytic Therapy for Containing Self-Harm in Young People|Brief one-to-one psychological therapy using Cognitive Analytic Therapy principles, designed for young people who self-harm
62720648|NCT02399787||infertile patients|Infertile patients with more than 5 oocytes retrieved and no endometriosis
62720649|NCT01864265|ACTIVE_COMPARATOR|Certolizumab Pegol|
62720650|NCT01864265|PLACEBO_COMPARATOR|Placebo|
62720651|NCT00499200|EXPERIMENTAL|SRA-444 + Placebo|Experimental; Placebo
62720652|NCT04815798|EXPERIMENTAL|Bacteriophage-loaded Microcapsule Spray with Standard of Care|Phage therapy (Bacteriophage-loaded Microcapsule Spray) will be administered topically in conjunction with standard of care for pressure ulcers.
62720653|NCT04815798|PLACEBO_COMPARATOR|Placebo with Standard of Care|Placebo, analogous to the experimental arm, will be administered topically in conjunction with standard of care for pressure ulcers.
62720654|NCT02227810|EXPERIMENTAL|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
62720655|NCT02227810|SHAM_COMPARATOR|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
62720656|NCT02459561|EXPERIMENTAL|EndoBarrier Arm|The EndoBarrier Gastrointestinal Liner device received CE Mark for 12 months implant duration on 11 December 2009 and is a single use, minimally invasive device, used to achieve weight loss and improve Type 2 Diabetes status in subjects who are obese. The intent of the EndoBarrier Gastrointestinal Liner is to mimic portions of the standard Roux-en-Y bypass procedure. The device consists of 3 components: the implant, the delivery system, and the removal system. At study visit 4, after eight hours fasting, 80 subjects will arrive to the pre- assessment unit as part of the theatres at St. Mary's Hospital or Southampton Hospital and receive the EndoBarrier TM Gastrointestinal Liner as part of the EndoBarrier Arm Intervention.
62720657|NCT02459561|OTHER|Medical Therapy Arm|"The standard medical therapy arm will be carried out in accordance with the guidelines of the American Diabetes Association. These guidelines have been chosen as they are applicable to an International audience and thus would adhere to the current best worldwide practice that would still be likely to be relevant when the results are published following study completion.~Diabetes reviews appointments with a Diabetologist/Endocrinologist will be performed with the control arm patients at visits 2, 4, 6, 7, 9, 11, 12, 13 and 15.~At study visit 4, 80 subjects will arrive at Mary's Hospital or Southampton Hospital and receive the best Medical Care and dietary advice as part of the Medical Therapy Arm Interventions."
62720658|NCT04933500||Conventional epidural|epidural needle: Tuhoy needle 1.3mm (18 G) with 20G multi-orifice epidural catheter
62720659|NCT04933500||Dural puncture epidural|epidural needle;Tuhoy needle 1.3mm (18G)with 20G multi-orifice epidural catheter and 25G Whitacre spinal needle
62720660|NCT00143559|OTHER|1|
62720661|NCT01334554|EXPERIMENTAL|Sildenafil|Sildenafil 20 mg three times a day
62168133|NCT02592486|ACTIVE_COMPARATOR|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
62720662|NCT01334554|PLACEBO_COMPARATOR|Placebo|placebo
62720663|NCT03465722|EXPERIMENTAL|avapritinib|300 mg PO QD
62720664|NCT03465722|ACTIVE_COMPARATOR|regorafenib|160 mg PO QD
62720665|NCT05775302|EXPERIMENTAL|IASTM Gastrocnemius|"Instrument assisted soft tissue mobilization on gastrocnemius~Conventional therapy:~Cryotherapy for 10 min stretching of calf and plantar fascia strengthning of intrinsic foot muscle"
62720666|NCT05775302|ACTIVE_COMPARATOR|IASTM Achillies Tendon|"Instrument assisted soft tissue mobilization Achillies Tendon~Conventional therapy:~Cryotherapy for 10 min stretching of calf and plantar fascia strengthning of intrinsic foot muscle"
62720667|NCT04550897|EXPERIMENTAL|BM7PE treatment|"The BM7PE treatment will be administered as a 20-minute i.v. infusion. The treatment is repeated after 2 weeks (day 15). The patients will be treated as in-patients and will stay at the hospital until toxicity have decreased to grade 2 and or plasma AST and or ALT levels has started to decrease. For at least a minimum of 3 days.~The dose administered to the patient will be 2.5, 5.0, 7.5, 10.0, 15.0 and 20.0 μg/kg body weight."
62720668|NCT01273571|EXPERIMENTAL|001|Canagliflozin/Metformin Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8 followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
62720669|NCT03024424|EXPERIMENTAL|Early disclosure|Early disclosure group receives results of genetic testing at Week 4
62720670|NCT03024424|ACTIVE_COMPARATOR|Late disclosure|Late disclosure group receives results of genetic testing at final study visit (Month 12)
62720671|NCT05485844||Symptomatic|Individuals reporting increased back pain and/or decreased motor control function in a second questionnaire conducted a year after index pregnancy
62720672|NCT05485844||Controls|Controls reporting no change in their bodily experience between the two questionnaires
62720673|NCT06511687||Newborns|Subjects born between April 1st, and September 31st in 2024
62720674|NCT06511687||Catch-up|Subjects born between October 1st of 2023 and March 31st of 2024
62720675|NCT06511687||High-risk|High-Risk Cohort: Infants born with 29 weeks of gestational age (wga) or less who were born within nine months of the beginning of the RSV season; those born with Bronchopulmonary Dysplasia (BPD), 32 or less wga and/or a birth weight less than 1·5 kgs born within one year of the beginning of the RSV season, and newborns 34 or less wga and/or weight less than 2·5 kgs born during the RSV season.
62720676|NCT05847647|EXPERIMENTAL|1. group: Retrograde Filling Group / RG Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect
62720677|NCT05847647|EXPERIMENTAL|2. Group: Retrograde Filling+L-PRF Group / RG+L-PRF Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect.
62720678|NCT05847647|EXPERIMENTAL|3. Group: Orthograde Filling Group / OG Group|Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect.
62720679|NCT05847647|EXPERIMENTAL|4. Group: Orthograde Filling+L-PRF Group / OG+L-PRF Group|Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect.
62720680|NCT03406403|ACTIVE_COMPARATOR|Laryngeal mask airway group|20 slips of papers will be taken and labeled as group L (LMA) These slips will be placed in an envelope and one slip will be raised for each patient.
62720681|NCT03406403|ACTIVE_COMPARATOR|Magensium sulphate group|20 slips of papers will be taken and labeled as group M (Mgso4) These slips will be placed in an envelope and one slip will be raised for each patient
62720682|NCT03406403|ACTIVE_COMPARATOR|Control group (closure of anesthetics)|20 slips of papers will be taken and labeled as group C (Control) These slips will be placed in an envelope and one slip will be raised for each patient.
62720683|NCT05379699|ACTIVE_COMPARATOR|1|Standard 4-hour live screener training with 1-on-1 live observation by a speech-language pathologist.
62720684|NCT05379699|EXPERIMENTAL|2|New eLearning training with 1-on-1 live observation by a speech-language pathologist.
62720685|NCT05379699|EXPERIMENTAL|3|New eLearning training with 1-on-1 live observation by a competency mentor.
62720686|NCT01745588|EXPERIMENTAL|Clarithromycin + Pomalidomide + Dexamethasone + stem cell|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.
62720687|NCT01745588|EXPERIMENTAL|Clarithromycin + Pomalidomide + Dexamethasone Alone|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.
62720688|NCT05261659|EXPERIMENTAL|TMR group|Patients will receive a sound while they receive a positive feedback for their performance of exposure therapy (ET). They will also receive the sound during REM sleep.
62720689|NCT05261659|ACTIVE_COMPARATOR|Control group|Patients will not receive a sound while they receive a positive feedback for their performance of exposure therapy (ET). They will receive the same sound as the experimental group during REM sleep under the same conditions.
62720690|NCT05566938|OTHER|Tailored nutritional recommendations for each metabotype|Volunteers that will be clustered into metabotypes and will recieve tailored nutritional recommendations according to their metabotype.
62720691|NCT01722929|EXPERIMENTAL|Skin sensor on surgery side|Skin sensor will be placed on the side that had surgery. This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
62720692|NCT01722929|ACTIVE_COMPARATOR|Skin sensor on non-surgery side|Skin sensor will be placed on the contralateral side from surgery site.This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
62720693|NCT00004227|PLACEBO_COMPARATOR|Arm I|"Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups:~* Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~* Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~* Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
62720694|NCT00004227|ACTIVE_COMPARATOR|Arm II|"Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy.~Radiotherapy groups remain the same as in Arm I:~* Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~* Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~* Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
62720695|NCT01023828||TOBACCO SMOKING|Group of patients with diagnosis of NSCLC and exposure to tabacco smoking
62720696|NCT01023828||WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to wood smoke
62720697|NCT01023828||TABACCO SMOKING AND WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to tabacco smoking and wood smoke
62720698|NCT01023828||WHITOUT EXPOSURE|Patients whit diagnosis of NSCLC and whitout exposure to risk factor
62737687|NCT01562392|EXPERIMENTAL|berries and vegetables|subjects include specific berries and vegetables in the diet
62737688|NCT01562392|PLACEBO_COMPARATOR|control product|Control product with equivalent amounts of carbohydrates but without vegetables and berries.
62737689|NCT02590276|EXPERIMENTAL|Evaluation|Characterization
62549070|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
62549071|NCT02441725|OTHER|Pulmonary Rehabilitation Patients|"Validation of the 1-minute sit-to-stand test; for participants who consent including a extended daily assessment period of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients (≥40 years of age) from two pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher Höhenklinik Wald)"
62549072|NCT02441725|OTHER|Acute Care Hospital Patients|"Validation of the 1-minute sit-to-stand test, including daily assessment of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients from two acute care hospitals (≥40 years of age; Stadtspital Waid and Spital Uster)"
62549073|NCT00441220||A|Patients must have lupus nephritis and previously had therapy with intravenous cyclophosphamide.
62549074|NCT00441220||B|Patients must have lupus nephritis and are currently receiving therapy with intravenous cyclophosphamide.
62549075|NCT00351403|EXPERIMENTAL|Individualized therapy|Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
62549076|NCT00351403|OTHER|Historical control|48 week standard therapy
62549077|NCT04468451|EXPERIMENTAL|ROC-48 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 48 hours for a total of 12-week intervention.
62549078|NCT04468451|ACTIVE_COMPARATOR|ROC-24 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 24 hours for a total of 12-week intervention.
62549079|NCT04468451|ACTIVE_COMPARATOR|Control group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. The participant's clinical occupational therapist will be responsible for the regular therapy. The dosage will be their regular dosage for a total of 12-week intervention.
62549080|NCT01517958||Respiratory Distress Group|Neonates 28 weeks GA or greater with respiratory distress
62549081|NCT01517958||Control Group|Neonates 28 weeks GA or greater without respiratory distress.
62549082|NCT03165292|EXPERIMENTAL|Arm A: High administered activity 131I-mIBG radiolabelled with iodine-131 and Topotecan|"The trial will evaluate two randomised arms. Each arm includes~* three cycles of Temozolomide-Irinotecan, similar in both arms,~* a specific consolidation course detailed hereinafter,~* a BuMel sequence, followed by an ASCT, similar in both arms,~* external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
62549083|NCT03165292|EXPERIMENTAL|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes~* three cycles of Temozolomide-Irinotecan, similar in both arms,~* a specific consolidation course detailed hereinafter,~* a BuMel sequence, followed by an ASCT, similar in both arms,~* external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
62549084|NCT06442215||Patients undergoing elective surgery for rectal neoplasm|Patients diagnosed with rectal neoplasia undergoing elective surgery between 2017 and 2021 at medical centers within the national territory.
62549085|NCT04078321|EXPERIMENTAL|Single case design|Single case studies
62549086|NCT04902014|ACTIVE_COMPARATOR|Education|
62549087|NCT04902014|EXPERIMENTAL|Motivational Interviewing|
62549088|NCT04902014|EXPERIMENTAL|Wearable Fitness Tracker|
62549089|NCT04902014|EXPERIMENTAL|Wearable Fitness Tracker+|
62549090|NCT03766607|EXPERIMENTAL|Trastuzumab with Ramucirumab and Paclitaxel|Single arm study of trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) every 21 days + ramucirumab (8 mg/kg) on days 1 \& 15 every 28 days + paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days
62549091|NCT06328465|EXPERIMENTAL|DWB-MRI|Surveillance with diffusion whole body MRI
62549092|NCT02322827||single tablet regimen|Subjects whose most recent antiretroviral therapy consist of a single tablet regimen
62549093|NCT02322827||multiple tablet regimen|Subjects whose most recent antiretroviral therapy consist of multi tablet regimen
62549094|NCT03280381|EXPERIMENTAL|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
62549095|NCT03280381|EXPERIMENTAL|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
62549096|NCT04350450|EXPERIMENTAL|Treatment Group|Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study
62549097|NCT04350450|NO_INTERVENTION|Control Group|Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms
62549098|NCT05880602|PLACEBO_COMPARATOR|Control|Subjects will take two capsule of containing starch, twice a daily for 8 weeks.
62549099|NCT05880602|EXPERIMENTAL|Treatment|Subjects will take two capsule of containing nettle and cranberry complex, twice a daily for 8 weeks.
62549100|NCT04743687|EXPERIMENTAL|Zanuburutinib|Oral Zanuburutinib 160mg twice a day
62549101|NCT01884038|EXPERIMENTAL|Remodulin|Remodulin initiated as a continuous IV infusion at a dose of 2.5 ng/kg/min after subjects have been assessed as hemodynamically stable in the ICU. Dose may be escalated in 1.25- to 2.5-ng/kg/min increments, up to 7.5 ng/kg/min, with a target dose of 5 ng/kg/min, based on tolerability. The dose will be maintained at the maximum tolerated dose, not to exceed 7.5 ng/kg/min for 5 days after the transplantation surgery.
62549102|NCT01884038|PLACEBO_COMPARATOR|Placebo|Matching placebo
62549103|NCT03573830|ACTIVE_COMPARATOR|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
62549104|NCT03573830|EXPERIMENTAL|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
62720699|NCT06715501|EXPERIMENTAL|Cadonilimab combined with Chemoradiotherapy|"Patients with advanced unresectable esophageal squamous cell carcinoma who meet the criteria, will first receive induction therapy with cetuximab combined with paclitaxel and carboplatin chemotherapy for 2 cycles. Within 3 weeks after the second dose, RECIST v1.1 will be used for clinical tumor imaging evaluation. Patients without progression will further receive synchronous radiotherapy and chemotherapy.~PTV-C accepts 50.4Gy, 28 times; Radiotherapy combined with paclitaxel and carboplatin weekly regimen. Within three months after completion, conduct safety assessments and preliminary evaluations of tumor response every three weeks. Consolidate treatment with cetuximab until 1 year or intolerance or disease progression occurs."
62720700|NCT04460183|EXPERIMENTAL|Investigational arm|Participants will receive inhaled RESP301 administered using a nebulizer three times a day for up to 10 days in addition to the standard of care.
62720701|NCT04460183|ACTIVE_COMPARATOR|Control arm|Participants will receive institutional SOC for the treatment of COVID-19
62720702|NCT03940079|EXPERIMENTAL|gross-motor group (GMG)|"The participants of GMG received motor-cognitive dual-task training. The sensors used by the participants were four different colored buttons. The participants wear a suit with two buttons on the shoulders and the other two fasten on the knees by velcros. To accomplish the tasks, the participants had to slap the correct colored buttons. The stretching of upper or lower limbs was demanding while slapping, so the participants of GMG received a training which required cognitive and motor functions at the same time.~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
62720703|NCT03940079|ACTIVE_COMPARATOR|fine-motor group (FMG)|"The participants of FMG received cognitive training only. Four colored sensors used by the participants were the keys on the keyboard of the laptop. The participants simply pressed correct colored keys by fingers to complete the tasks.~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
62720704|NCT04709003||vaccinated|participants who received the Covid-19 vaccine
62720705|NCT04709003||unvaccinated|participants who didn't received the Covid-19 vaccine
62720706|NCT03510130|EXPERIMENTAL|Routine leg movement|Intervention group- In the second stage of labor, attending physician or nurse will help the participant in routine leg movements every 20-30 minutes.
62720707|NCT03510130|NO_INTERVENTION|Control group|Control group which includes women during the second stage of labor with no intervention (routine leg movement).
62720708|NCT05032547|EXPERIMENTAL|Primary Care Online Emotion-Regulation Treatment|The youth component in the experimental condition will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as mindfulness practice and acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective responding to their children's and their own emotions.
62720709|NCT05032547|ACTIVE_COMPARATOR|Supportive Treatment|The intervention will be delivered in a blended treatment format combining asynchronous therapist-guided online modules (text/videos/audio/messaging function) with a synchronous session delivered over video-link.
62720710|NCT01612676|EXPERIMENTAL|Drug|FE 202158
62720711|NCT02155101|ACTIVE_COMPARATOR|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
62720712|NCT02155101|EXPERIMENTAL|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
62720713|NCT00578032||1|Patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.
62720714|NCT00495703|EXPERIMENTAL|1|Exercise
62720715|NCT00495703|ACTIVE_COMPARATOR|2|Usual Care
62720716|NCT06040736||Patients with acute kidney injury|Emergency department patients presenting with acute kidney injury, regardless of their complaint for ED admission. AKI is defined based on increase in serum creatinine (SCr) levels according to Kdigo criteria Patients will undergo both a bedside point of care ultrasonography and a central radiology imaging evaluation of hydronephrosis as part of routine care
62720717|NCT01914250|ACTIVE_COMPARATOR|2|Topical Anesthetic, 2% Tetracaine oral gel - Group A Topical Anesthetic, 20% Benzocaine oral gel - Group B
62720718|NCT02008994|EXPERIMENTAL|Genomic and Proteomic Profiling|"* Reverse Phase Protein Microarray will be used to determine how often there are specific proteins that could make your tumor susceptible or resistant to treatment.~* Immunohistochemistry will look for specific markers of disease in your DNA.~* RNA sequencing will be used to help doctors and scientists understand how your genes are working.~* Low pass whole genome and exome sequencing will be used to help identify variants in your DNA."
62720719|NCT01622296|ACTIVE_COMPARATOR|Sodium Bicarbonate with Lidocaine|
62720720|NCT01622296|PLACEBO_COMPARATOR|Lidocaine with no buffer|
62720721|NCT01166347|EXPERIMENTAL|HeartWare® VAS|Implant of HeartWare® Ventricular Assist System
62720722|NCT01166347|ACTIVE_COMPARATOR|Control LVAD|Implant of FDA-approved LVADs approved for destination therapy
62720723|NCT05945888|EXPERIMENTAL|SRD part: Treatment group|
62720724|NCT05945888|PLACEBO_COMPARATOR|SRD part: Placebo group|
62720725|NCT05945888|EXPERIMENTAL|FE part: Treatment sequence reference (R) - test (T)|
62720726|NCT05945888|EXPERIMENTAL|FE part: Treatment sequence test (T) - reference (R)|
62720727|NCT02724241|EXPERIMENTAL|nicotine|use of an e-cigarette filled with liquid with nicotine
62720728|NCT02724241|EXPERIMENTAL|no nicotine|Use of an e-cigarette filled with liquid without nicotine
62720729|NCT02724241|SHAM_COMPARATOR|sham comparator|Use of empty e-cigarette (sham control)
62720730|NCT04507906|OTHER|Nivolumab + Anlotinib Arm|
62720731|NCT01828840|ACTIVE_COMPARATOR|morphine, epidural|Epidurally administrated morphine
62720732|NCT01828840|ACTIVE_COMPARATOR|fentanyl, epidural|epidurally administrated fentanyl
62720733|NCT01828840|ACTIVE_COMPARATOR|methadone, epidural|epidurally administrated methadone
62720734|NCT01828840|ACTIVE_COMPARATOR|morphine, intervenous|intravenously administrated morphine
62720735|NCT02448134|EXPERIMENTAL|Youth Access|"Youth Engagement in Prosocial Alcohol-Free Activities Participate in the Reward and Reminder program in their community"
62720736|NCT02448134|NO_INTERVENTION|Control|Student will receive regular information and programs.
62720737|NCT01979679|ACTIVE_COMPARATOR|Lurasidone 80 mg per day|Lurasidone 80 mg per day
62720738|NCT01979679|ACTIVE_COMPARATOR|Lurasidone 120 mg per day|Lurasidone 120 mg per day
62720739|NCT01979679|ACTIVE_COMPARATOR|Lurasidone 160 mg per day|Lurasidone 160 mg per day
62720740|NCT05018689|ACTIVE_COMPARATOR|Aevidum curriculum|Curriculum: Aevidum has developed a 5-lesson 3-hour mental health curriculum that can be broken up and integrated into existing school health curricula. The study team in partnership with the Executive Director of Aevidum will collaborate with schools to implement the curriculum to their 9th grade students.
62720741|NCT05018689|ACTIVE_COMPARATOR|Aevidum curriculum + club|Curriculum + club. Schools assigned to the curriculum plus club will also start an Aevidum club at their school. Club basic processes and ideas for events are housed on the Aevidum website. Schools will select faculty and student leaders who will participate in a kickoff web-based training at the start of the academic year. The training is led by current Aevidum student leaders at schools with successful clubs. This is a standard orientation process that Aevidum has run for many years in-person, but has been adapted to a virtual format with the COVID-19 pandemic.
62720742|NCT01628913|EXPERIMENTAL|BEZ235|Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
62720743|NCT01628913|ACTIVE_COMPARATOR|Everolimus|Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
62720744|NCT00305877|EXPERIMENTAL|Arm I (cetuximab, gemcitabine, capecitabine, radiation)|Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions).
62720745|NCT00305877|EXPERIMENTAL|Arm II (bevacizumab, gemcitabine, capecitabine, radiation)|Patients receive bevacizumab IV over 60-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23. Patients also receive gemcitabine hydrochloride and capecitabine and undergo radiotherapy as in arm I.
62720746|NCT04528589||Mothers|Women with adverse childhood experiences referred for treatment in gestational week 20-30
62720747|NCT04528589||Therapists|Clinicians with experience of providing psychotherapy to women with adverse childhood experiences referred for treatment during pregnancy
62720748|NCT03668964|EXPERIMENTAL|Vitamin B2|Daily dose of 75 mg Vitamin B2
62720749|NCT03668964|EXPERIMENTAL|Vitamin C|Daily dose of 500 mg Vitamin C
62720750|NCT03668964|EXPERIMENTAL|Vitamin B2 + C|Daily dose of 75 mg Vitamin B2 and 500 mg Vitamin C
62720751|NCT03668964|EXPERIMENTAL|Vitamin A|Daily dose of 250 µg Vitamin A
62720752|NCT03668964|EXPERIMENTAL|Vitamin D3|Daily dose of 60 µg Vitamin D3
62720753|NCT03668964|EXPERIMENTAL|Vitamin E|Daily dose of 100 mg Vitamin E
62720754|NCT03668964|PLACEBO_COMPARATOR|Placebo|Daily dose of 575 mg microcrystalline cellulose
62720755|NCT02737501|EXPERIMENTAL|Randomized Phase: Brigatinib 90 mg QD/180 QD|Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
62720756|NCT02737501|ACTIVE_COMPARATOR|Randomized Phase: Crizotinib 250 mg BID|Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
62720757|NCT02737501|EXPERIMENTAL|Crossover Phase: Brigatinib 90 mg QD/180 mg QD|Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).
62720758|NCT04445792|EXPERIMENTAL|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
62720759|NCT04445792|OTHER|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
62720760|NCT04445792|EXPERIMENTAL|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
62720761|NCT04445792|OTHER|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
62720762|NCT04445792|EXPERIMENTAL|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
62720763|NCT04445792|OTHER|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
62720764|NCT02157428|PLACEBO_COMPARATOR|saline|patients received 20 ml of saline during 1 minute, after end of surgery.
62720765|NCT02157428|ACTIVE_COMPARATOR|flumazenil|patients received 1 mg of flumazenil, after end of surgery
62720766|NCT02049411|EXPERIMENTAL|Ketamine group|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
62720767|NCT02049411|SHAM_COMPARATOR|physiological solution|Control group: only physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
62720768|NCT06118645|EXPERIMENTAL|cadonilimab combined +paclitaxel (albumin-bound)|cadonilimab combined +paclitaxel (albumin-bound)
62720769|NCT01742884|EXPERIMENTAL|Thealoz|Treatment with Thealoz (Trehalose) 3% for 1 month
62720770|NCT01742884|PLACEBO_COMPARATOR|Treatment with Thealoz´s vehicle|Treatment with Thealoz´s vehicle for 1 month
62737690|NCT01039545|ACTIVE_COMPARATOR|antibiotic|Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
62737691|NCT01039545|EXPERIMENTAL|symptomatic|Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary
62737692|NCT03511014|EXPERIMENTAL|microcurrent|
62720771|NCT05832892|EXPERIMENTAL|surufatinib + KN046 + nab-paclitaxel + gemcitabine|"In the phase Ib of dose escalation, all patients enrolled will receive: nab-paclitaxel at 125 mg/m2 on days 1 and 8, gemcitabine at 1000 mg/m2 on days 1 and 8, KN046 at 5 mg /kg on day 1, plus surufatinib per cohort escalation assignment starting with 200 mg. The combination treatment repeats every 3 weeks, until disease progression, death, intolerable toxicity, or withdrawal of informed consent. Dose-limiting toxicity will be evaluated 28 days after first dose to determine the recommended phase 2 dose (RP2D) of surufatinib.~Patients enrolled in the phase II of dose expansion will receive the combination regimen of nab-paclitaxel plus gemcitabine plus KN046 plus surufatinib as determined in the phase Ib."
62720772|NCT06043336|ACTIVE_COMPARATOR|Group B|Group B received intravenous (IV) dexamethasone 4 mg after intubation \& IV granisetron 1 mg at the end of surgery
62720773|NCT06043336|EXPERIMENTAL|Group A|Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation.
62720774|NCT01328743|NO_INTERVENTION|Treatment as usual|Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
62720775|NCT01328743|EXPERIMENTAL|Brief Alcohol Intervention|Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls
62720776|NCT04979806|EXPERIMENTAL|Cefepime-zidebactam (FEP-ZID)|
62720777|NCT04979806|ACTIVE_COMPARATOR|Meropenem|
62720778|NCT06084351|EXPERIMENTAL|Convalescent Plasma|
62720779|NCT06084351|ACTIVE_COMPARATOR|Standard of care|
62720780|NCT06283277||Singleton pregnant women at gestational age between 37-42 weeks|estimated fetal weight measured by ultrasound using Hadlock IV formula and Youssef's formula compared with the sensitivity of fetal clavicular measurement.
62720781|NCT04123301|ACTIVE_COMPARATOR|Active TBS Arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
62720782|NCT04123301|SHAM_COMPARATOR|Sham TBS Arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
62720783|NCT01899547|EXPERIMENTAL|Arm I|Patients undergo laparoscopic-assisted rectal resection.
62720784|NCT01899547|ACTIVE_COMPARATOR|Arm II|Patients undergo conventional open rectal resection.
62720785|NCT03976297|EXPERIMENTAL|Control Tower Intervention|For participants in the intervention arm, the results of the prediction model will be presented through a GUI interface hereby known as the Control Tower. Participants receive scores from Control Tower (0-100; higher score indicating increased need) for palliative care and are subsequently ranked from highest to lowest. Red (7 or greater) is considered high risk. The intervention will include a Control Tower operator who will interact with the inpatient palliative care consult service. The operator will monitor the Control Tower during weekday normal business hours and select daily a cohort of participants in the intervention units with the highest need of palliative care review. The final list of participants will then be sent to palliative care. The palliative care team who is on service will also assess the need for each participants, and those participants which they agree could benefit they will approach the attending clinical team to suggest a palliative care referral.
62720786|NCT03976297|NO_INTERVENTION|Standard of Care|For participants who are not in an intervention period they will receive the standard of care commensurate with their clinical unit. This is feasible given that this is a pragmatic clinical trial where the investigators can easily control the communication between the control tower operator and palliative care team to prevent any contamination between clusters. In addition to the usual source of care control the investigators intentionally have calibrated the prediction model and the Control Tower review to match the average capacity of the palliative care service, knowing that that the team will still receive palliative care consults through the traditional pathway i.e. the attending care team consulting palliative care directly.
62720787|NCT05330871|EXPERIMENTAL|1. Adolescent booster sentinel group|1 dose of 0.1ml Ad5-nCoV-IH
62720788|NCT05330871|EXPERIMENTAL|2. Adolescent booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
62720789|NCT05330871|EXPERIMENTAL|3. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
62720790|NCT05330871|EXPERIMENTAL|4. Adolescent booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
62720791|NCT05330871|EXPERIMENTAL|5. Adolescent booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
62720792|NCT05330871|EXPERIMENTAL|6. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
62720793|NCT05330871|EXPERIMENTAL|7. Adolescent booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
62720794|NCT05330871|ACTIVE_COMPARATOR|8. Adolesent booster safety group to receive ICV|1 dose of 0.5ml ICV
62720795|NCT05330871|ACTIVE_COMPARATOR|9. Adolescent booster immunopersistency group to receive ICV|1 dose of 0.5ml ICV
62720796|NCT05330871|ACTIVE_COMPARATOR|10. Adolescent booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
62720797|NCT05330871|EXPERIMENTAL|11. Children booster sentinel group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
62720798|NCT05330871|EXPERIMENTAL|12. Children booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
62720799|NCT05330871|EXPERIMENTAL|13. Children booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
62720800|NCT05330871|EXPERIMENTAL|14. Children booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
62720801|NCT05330871|EXPERIMENTAL|15. Children booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
62720802|NCT05330871|EXPERIMENTAL|16. Children booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
62720803|NCT05330871|EXPERIMENTAL|17. Children booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
62720804|NCT05330871|ACTIVE_COMPARATOR|18. Children booster safety group to receive ICV|1 dose of 0.5ml ICV
62720805|NCT05330871|ACTIVE_COMPARATOR|19. Children booster immuno-persistency group to receive ICV|1 dose of 0.5ml ICV
62720806|NCT05330871|ACTIVE_COMPARATOR|20. Children booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
62720807|NCT05330871|EXPERIMENTAL|21. Adolescent primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
62720808|NCT05330871|EXPERIMENTAL|22. Adolescent primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
62720809|NCT05330871|EXPERIMENTAL|23. Children primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
62720810|NCT05330871|EXPERIMENTAL|24. Children primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
62720811|NCT02824523||High-dose aspirin|
62549105|NCT03310749|OTHER|Treatment sequence A|Gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days and gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days.
62168134|NCT02592486|ACTIVE_COMPARATOR|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
62549106|NCT03310749|OTHER|Treatment sequence B|Gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days
62549107|NCT03310749|OTHER|Treatment sequence C|Metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days
62549108|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
62549109|NCT05738278|EXPERIMENTAL|Intervention group|After 2 weeks mapping phase, patient-specific HR-informed intervention from week 3.
62549110|NCT05738278|ACTIVE_COMPARATOR|Control group|After 4 weeks mapping phase, patient-specific HR-informed intervention from week 5.
62549111|NCT04358055|EXPERIMENTAL|WET® gel|"At the screening/baseline visit (Visit 1, Day 1), eligible patients will be assigned to treatment with WET® gel, at the dose of 3-4 nasal applications/day (according to necessity), 1or 2 puff/nostril, for maximum 14 days.~Treatment will be administered according to patient's need without any relation with the time of the day (i.e. day time or night time administration), however within a maximum of 4 applications/day, which must include one administration in the morning upon awakening and one administration in the evening before retiring to bed."
62549112|NCT00880789|EXPERIMENTAL|Dose Level One: 5x10^6/m2|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
62549113|NCT02618525|ACTIVE_COMPARATOR|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
62549114|NCT02618525|ACTIVE_COMPARATOR|Jaw thrust maneuver|Jaw thrust maneuver is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
62549115|NCT04243031||All subjects|Those with TB and those without TB.
62549116|NCT00489255|EXPERIMENTAL|Trimethobenzamide (Tigan®)|
62549117|NCT00489255|PLACEBO_COMPARATOR|Inactive substance|
62549118|NCT03946618|EXPERIMENTAL|Epilepsy|Patients with dominant temporal lobe epilepsy and bilateral temporal lobe epilepsy
62549119|NCT04796298|EXPERIMENTAL|Ballistic Hamstring Stretching Group|Ballistic Hamstring Stretching
62549120|NCT04796298|EXPERIMENTAL|Hamstring Extender Exercise Group|Hamstring Extender Exercise
62549121|NCT04796298|EXPERIMENTAL|Kinesiotape Group|Kinesiotape
62549122|NCT01493921|EXPERIMENTAL|SR-T100 gel|Patient group receiving medication SR-T100 gel with active ingredient under investigation, enrolled subjects randomly assigned to this group to accurately depict statistical significance of the measured outcome.
62549123|NCT01493921|ACTIVE_COMPARATOR|Vehicle gel|Patients given placebo with non-SR-T100 ingredients as they are being administered to patients, subjects are under random assignments from patient pool to depict statistically significant outcome measurement.
62549124|NCT02322905|EXPERIMENTAL|Emotion Regulation Therapy|8 sessions of Emotion Regulation Therapy.
62549125|NCT02322905|NO_INTERVENTION|Usual Medical Care|No planned psychotherapy.
62549126|NCT01598194|EXPERIMENTAL|Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle|The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
62549127|NCT05808478|EXPERIMENTAL|Experimental Group (EG)|The experimental group will undergo treatment with innovative high-tech tools, such as Eye Tracking, for communication purposes. The duration of the treatment will be six months, twice a week, with sessions of 45 minutes.
62549128|NCT05808478|ACTIVE_COMPARATOR|Control Group (CG)|"The control group will undergo conventional AAC treatment, with low-tech tools, such as PECS or sign language.~The duration of the treatment will be six months, twice a week, with sessions of 45 minutes."
62549129|NCT05013125|NO_INTERVENTION|Conventional Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo usual colonoscopy as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
62549130|NCT05013125|ACTIVE_COMPARATOR|ENDO-AID assisted Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo ENDO-AID assisted colonoscopy with all polyps treated as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
62549131|NCT01739049|EXPERIMENTAL|Liraglutide and lifestyle counselling|"Liraglutide 0.6mg od for 1st week, then 1.2mg od for 2nd week then 1.8mg od until 12 weeks.~Diet and Exercise"
62549132|NCT01739049|ACTIVE_COMPARATOR|Lifestyle counselling|Diet and Exercise
62549133|NCT02533180|OTHER|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
62549134|NCT02386124|OTHER|frailty evaluation|"all consecutive patients admitted to hospital for acute cardiac disease aged more than 69 years will be evaluated with Short Portable Mental Status Questionnaire (SPMSQ), handgrip and Short Physical Performance Battery (SPPB).~These three tests (SPMSQ, SPPB and handgrip) are the intervention of the study. They are the assays to establish the frailty status"
61978188|NCT06475950|ACTIVE_COMPARATOR|"Kid'EM app experimental group"|This group uses the Kid'EM app, which guides rehabilitation professionals in setting goals for each child. The app offers a variety of features, including the creation of patient accounts and records, identification of the child's likes and needs, definition of SMART goals, and spaces for exchanges with parents and other professionals. Parents also have access to the application.
62549135|NCT03814655|EXPERIMENTAL|Full digital workflow|"1. Intraoral scan of the partially edentulous site, antagonists and occlusion registration. Radiopaque tray customization over the partially edentulous arch.~2. CBCT with customized radiopaque tray.~3. Merging files in R2 Gate software and implant planning.~4. Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~5. Digital impression for final screw-retained crown/bridge.~6. Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
62549136|NCT03814655|ACTIVE_COMPARATOR|Partially digital workflow|"1. Impression of the edentulous arch and antagonist, occlusion registration. Radiopaque tray customization over the edentulous arch.~2. CBCT with customized radiopaque tray.~3. Stone models alone, maximum intercuspal position and customized radiopaque tray will be scanned using a desktop scanner.~4. Merging files (CBCT and model stl) in R2 Gate software and implant planning.~5. Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~6. Classic impression in customized tray with Impregum.~7. Functional models will be scanned using the same desktop scanner.~8. Final screw-retained crown/bridge manufacturing.~9. Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
62549137|NCT00377832|NO_INTERVENTION|1|
62549138|NCT00377832|ACTIVE_COMPARATOR|2|Acetaminophen 975 mg once
62549139|NCT03739047|EXPERIMENTAL|Desensitization with flipped spoon|Children in this study will receive behavioral feeding treatment. This arm will include desensitization.
62549140|NCT03739047|PLACEBO_COMPARATOR|flipped spoon|Children in this study will receive behavioral feeding treatment.
62549141|NCT02730663|EXPERIMENTAL|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
62549142|NCT02574065|EXPERIMENTAL|L. reuteri DSM 17938 group|"L. reuteri DSM 17938 will be given at a dose of 100000000 colony forming units (CFU) per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.~Each day, at about the same time, the infants will be given 5 drops (1x100000000 CFU) of the study product in connection with feeding."
62549143|NCT02574065|PLACEBO_COMPARATOR|Placebo group|The placebo consists of an identical formulation without L. reuteri. Each day, at about the same time, the infants will be given 5 drops placebo in connection with feeding.
62549144|NCT04590105|EXPERIMENTAL|App Subject|"Users who were assigned to use a smartphone app downloaded a free app from the iOS App or Google Play stores titled SB Colonoscopy Prep. The app informed subjects about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite."
62549145|NCT04590105|ACTIVE_COMPARATOR|Written Instruction Subjects|Subjects in the control group were given a three-page document that described the procedure and instructed users on how to take the preparation medications. The written instructions had a list of frequently asked questions about colonoscopies and the URL of a website where users could view the animated video that was included in the app. The written instructions also contained the time and date of the procedure. All subjects were instructed to arrive one hour before their scheduled procedure.
62549146|NCT03365557|EXPERIMENTAL|Intracuff pressure set by airway peak pressure|
62549147|NCT03365557|OTHER|Intracuff pressure set at 60 mmHg|
62549148|NCT01236443|EXPERIMENTAL|HPPH|3 mg/m2
62549149|NCT04680026|EXPERIMENTAL|Drug: HBI-3000, Stage A Dose Level 1|Stage A Open Label HBI-3000 Dose Level 1: 200 mg
62549150|NCT04680026|EXPERIMENTAL|Drug: HBI-3000, Stage A Dose Level 2|Stage A Open Label HBI-3000 Dose Level 2: 350 mg planned
62549151|NCT04680026|EXPERIMENTAL|Drug: HBI-3000, Stage A Dose Level 3|Stage A Open Label HBI-3000 Dose Level 2: 500 mg planned
62549152|NCT04680026|EXPERIMENTAL|Drug: HBI-3000, Stage B Dose Level 1|Stage B Double-blind placebo controlled, Cohort 1 HBI-3000 Dose Level 1: Selected based on Stage A results
62549153|NCT04680026|EXPERIMENTAL|Drug: HBI-3000, Stage B Dose Level 2|Stage B Double-blind placebo controlled, Cohort 2 HBI-3000 Dose Level 2: Selected based on Stage A, and Stage B Cohort 1 results
62549154|NCT03960463|ACTIVE_COMPARATOR|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
62549155|NCT03960463|NO_INTERVENTION|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
62549156|NCT04520009|ACTIVE_COMPARATOR|Activity Restriction|Discharge orders for activity restriction
62549157|NCT04520009|ACTIVE_COMPARATOR|Activity As Tolerated|Discharge orders written for activity as tolerated
62549158|NCT01256502|OTHER|Implanted Participants|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
62549159|NCT06064578|EXPERIMENTAL|Project SOLVE|Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
62549160|NCT06064578|OTHER|Delayed Receipt of Project SOLVE Control Condition|No intervention for first three months; will receive SOLVE after 3-months and become a second-wave intervention condition.
62549161|NCT03071276|EXPERIMENTAL|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
62549162|NCT05435846|EXPERIMENTAL|Phase 1: Dose Escalation|Patients receive 200 - 400 mg capmatinib orally, twice a day and 1.0 or 1.5 mg trametinib orally once a day on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62720812|NCT00677976||IBS|Children between the ages of 10 and 18 who meet Rome III criteria for IBS as determined by a pediatric gastroenterologist.
62549163|NCT05435846|EXPERIMENTAL|Phase 1b: Dose Expansion|Patients will receive the recommended phase 2 dose (RP2D) or capmatinib in combination with trametinib determined by the safety profile of the Phase 1 group. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
62549164|NCT00842205|ACTIVE_COMPARATOR|1 HCV positive pts|"Patients with chronic HCV infection undergoing liver biopsy followed by antiviral treatment.~peg-IFN alfa 2a 180ug s.c. QW + ribavirin 1000-1200mg p.o. daily 48weeks or peg-IFN alfa 2b 1.5 ug/kg s.c. QW + ribavirin 100-1200mg p.o. daily 48 weeks"
62549165|NCT00842205|NO_INTERVENTION|2 Other liver disease|pts. with NASH (or other liver disease) undergoing liver biopsy.
62549166|NCT03672227|EXPERIMENTAL|Mealtime Matters Training|This group of teachers will get a 3 hour nutrition training, followed by 2 one hour booster sessions.
62549167|NCT03672227|NO_INTERVENTION|Family Style Dining in Head Start|This group of teachers will not get the 3 hour nutrition training until the study has concluded.
62549168|NCT01682811|EXPERIMENTAL|Part 1 Levulan injection|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) injection and 3 hr incubation, and by Levulan treated lesions after 3 or 24 hr incubation.
62549169|NCT01682811|EXPERIMENTAL|Part 1 Levulan painting|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application and 3 hr incubation, and by Levulan treated lesions and 3 or 24 hr incubation.
62549170|NCT01682811|EXPERIMENTAL|Part 1 Levulan painted twice|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation.
62549171|NCT01682811|EXPERIMENTAL|Part 1 Levulan painted twice with microneedling|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation. All lesions prepared with microneedling.
62549172|NCT01682811|EXPERIMENTAL|Part 2 Dose level 1 50 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 - 50 J/cm\^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
62549173|NCT01682811|EXPERIMENTAL|Part 2 Dose level 2 100 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 - 100 J/cm\^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
62549174|NCT01682811|EXPERIMENTAL|Part 2 Dose level 3 200 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 - 200 J/cm\^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
62549175|NCT04607057|EXPERIMENTAL|experimental group (Arm A)|"Preparation of parenteral nutrition (PN): Among winuf(1820cc for central vein, 1,450cc for peripheral vein), smofkabaven(986cc for central vein, 1206cc for peripheral vein), and nutriplex(1875cc for central vein, 1,250cc for peripheral vein) Amount of PN: Total energy expenditure (TEE) of the patients will be calculated with Harris-Benedict Equation, activity factor, and stress factor. The amount of calorie from oral intake will be subtracted from TEE then the remainder will be provided through PN.~Route of PN Injection: PICC (percutaneously-inserted central catheter) will be secured for PN for the central vein. PN for the peripheral vein will be injected directly through peripheral superficial vein.~* Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN"
62549176|NCT04607057|NO_INTERVENTION|control group (Arm B)|"* Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + dextrose 5% water~* POD#3 : Semifluid diet (SFD) + dextrose 5% water~* POD#4-7: Soft blended diet (SBD)"
62549177|NCT03080870|EXPERIMENTAL|Intervention|"Art groups are held once a week, each with the duration of 60 minutes. They begin with a 45 minute art intervention and conclude with a 15 minute discussion. The art groups include music, dance and visual arts, which is psychologically, socially, and physically activating. Music has the main emphasis in art intervention. The preferences of the subjects are taken into consideration in art intervention. Art intervention is conducted by trained and experienced art pedagogues.~Art intervention aims to revive previously learned art-related skills, to learn and enhance new skills, and to improve and intensify physiological, emotional, social, motoric, and cognitive abilities."
62549178|NCT03080870|NO_INTERVENTION|Control|Baseline and follow-up measurements.
62549179|NCT05549531|EXPERIMENTAL|Investigational and interaction treatment|"ACT-1004-1239 (10 mg) will be administered on Day 1 (in Treatment A) and Day 9 (in Treatment B2).~Itraconazole (200 mg, o.d.) will be administered from Day 6 until Day 13. On Day 9, itraconazole will be administered concomitantly with ACT-1004-1239."
62549180|NCT03020771|ACTIVE_COMPARATOR|5 mcg IM|
62549181|NCT03020771|ACTIVE_COMPARATOR|5 mcg SC|
62549182|NCT03020771|PLACEBO_COMPARATOR|5 mcg IM control|0.9% NaCl Solution
62549183|NCT03020771|PLACEBO_COMPARATOR|5 mcg SC control|0.9% NaCl Solution
62549184|NCT03020771|ACTIVE_COMPARATOR|10 mcg IM|
62549185|NCT03020771|ACTIVE_COMPARATOR|10 mcg SC|
62549186|NCT01666769|OTHER|Treatment Dosing|Age group: 0 - \<2y, Micafungin 8 mg/kg/day IV
62549187|NCT01666769|OTHER|Prophylaxis dosing|Age group: 0-\<2y, Micafungin 4 mg/kg/day IV
62549188|NCT01666769|OTHER|Standard of care Dosing|Age group: 2-17.85 y, Micafungin standard of care dosing (decided by treating physician)
62549189|NCT04138043|EXPERIMENTAL|GSK2330811 450 mg|Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter \[mg/mL\]).
62549190|NCT04138043|PLACEBO_COMPARATOR|Placebo|Participants will receive GSK2330811 matching placebo administered as three separate SC injections.
62549191|NCT04931121||Osteoarthritic patients|Subjects are patients referred for knee osteoarthritis and treated with an hyaluronic acid injection (viscosupplementation)
62720813|NCT00677976||Control|Healthy children between the ages of 10 and 18.
62720814|NCT05111145|EXPERIMENTAL|ELX/TEZ/IVA|Participants received ELX 200 mg once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for up to 36 weeks.
62720815|NCT01567033|EXPERIMENTAL|Intervention|Intervention participants received HEALTH, which embedded a lifestyle intervention derived from DPP within the standard PAT curriculum
62720816|NCT00198471|EXPERIMENTAL|Vitrase|A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.
62720817|NCT04555174||Orsiro Mission DES|All subjects will be implanted with the Limus Eluting Orsiro Mission Stent System and followed up until 60 months.
62720818|NCT04794738|EXPERIMENTAL|Treatment group A|
62720819|NCT04794738|EXPERIMENTAL|Treatment group B|
62720820|NCT04794738|PLACEBO_COMPARATOR|Treatment group C|
62720821|NCT04794738|ACTIVE_COMPARATOR|Treatment group D|
62720822|NCT05592821||Test Group: soft tissue level implants|In this study, it was planned to use 20 implants of the same brand, with a single implant in the bilateral posterior regions in 10 patients. While the bone level implant is placed on one side of the patients, the tissue level implant will be used on the other side. The study will be designed as split-mouth. The type of implant to be placed in the regions will be decided according to the amount of keratinized gingival level above the alveolar crest level. Soft tissue level implants are in this group
62720823|NCT05592821||Control Group: bone level implants|In this study, it was planned to use 20 implants of the same brand, with a single implant in the bilateral posterior regions in 10 patients. While the bone level implant is placed on one side of the patients, the tissue level implant will be used on the other side. The study will be designed as split-mouth. The type of implant to be placed in the regions will be decided according to the amount of keratinized gingival level above the alveolar crest level. Bone level implants are in this group
62720824|NCT05711927|EXPERIMENTAL|SNOO group|The SNOO Smart Sleeper will be used in accordance with the manufacturer's programming and instructions.
62720825|NCT05711927|SHAM_COMPARATOR|Traditional bassinet group|The SNOO will remain powered off to mimic the conditions of sleeping in a traditional hospital bassinet.
62720826|NCT00051714|EXPERIMENTAL|Early Primary Prevention|
62720827|NCT01093313|EXPERIMENTAL|Attention training|
62720828|NCT01093313|ACTIVE_COMPARATOR|Cognitive therapy|
62720829|NCT05548764||Prevention Bundles|Patients in which prevention bundles for SSIs have been implemented.
62720830|NCT05548764||No Prevention Bundles|Patients in which prevention bundles for SSIs have not been implemented.
62720831|NCT05783895||Confirmed HIT|Comprehensive collection of patients with suspected and then proven HIT postoperatively from cardiac surgery with bypass surgery during the inclusion period.
62720832|NCT05783895||Absence of HIT|Patients with suspected and unconfirmed HIT postoperatively from cardiac surgery under CEC during the inclusion period.
62720833|NCT00698828|EXPERIMENTAL|Group 1|SUN11031 for injection, low dose, twice daily for 12 weeks
62720834|NCT00698828|EXPERIMENTAL|Group 2|SUN11031 for injection, higher dose, twice daily for 12 weeks
62720835|NCT00698828|PLACEBO_COMPARATOR|Group 3|Placebo injection, twice daily for 12 weeks
62720836|NCT01783210|EXPERIMENTAL|TLC(Therapeutic Lifestyle Changes) group|"Intervention: Specific Therapeutic Lifestyle Changes program in pregnancy. TLC Program includes a diet (with a specific amount of calories and macronutrients) and a mild physical activity."
61978189|NCT06475950|SHAM_COMPARATOR|Kidem app control group|This group uses a control app that offers no guidance or space for exchange with parents. Professionals use their usual strategy to set goals. The functionalities of the control app are more limited, focusing on creating the professional's account, filling in the first letter of the child's first and last name, selecting the child's pathology, identifying the child's tastes, and filling in the objectives without guidance.
62720837|NCT01783210|OTHER|Control group|"Intervention: Dietary and behavioral counselling in pregnancy. The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake."
62720838|NCT04410159|EXPERIMENTAL|Povidone-iodine|gargle with povidone-iodine 10mL, 30 seconds, 3 times per day, 7 days
62720839|NCT04410159|EXPERIMENTAL|Essential Oils|gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days
62720840|NCT04410159|EXPERIMENTAL|Tap water|gargle with tap water 100 mL, 30 seconds, 3 times per day, 7 days
62720841|NCT04410159|NO_INTERVENTION|Control|This group will receive the standard treatment protocol without any additional intervention
62720842|NCT03980639||abatacept|patients with abatacept prescription
62720843|NCT03980639||others bDMARDs|patients with at least one bDMARD prescriptions
62720844|NCT01978483|OTHER|DPCP alone (Cohort 1)|Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
62720845|NCT01978483|EXPERIMENTAL|UVB and denosumab group (Cohort 2)|Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
62720846|NCT01978483|PLACEBO_COMPARATOR|UVB and placebo group (Cohort 2)|Normal saline 1mL subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
62720847|NCT01192126|EXPERIMENTAL|Bausch & Lomb new daily disposable|New daily disposable contact lenses
62720848|NCT01192126|ACTIVE_COMPARATOR|Johnson & Johnson Acuvue Moist|Contact lenses
62720849|NCT06546891|EXPERIMENTAL|Single Group Intervention Arm - Adaptive Rowing|12 supervised and coached sessions of 10-20 minutes of moderate to vigorous exercise using an adaptive rower.
62720850|NCT02330614||bleaching patients|Patients who agreed to be bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the NEO-FFI personality test form, had 30 minutes to answer it.
62720851|NCT02330614||Control group|Patients who refused to be bleached were administered the personality test NEO-FFI, had 30 minutes to answer it.
62720852|NCT05850143|ACTIVE_COMPARATOR|Oral Single dose dexamethsone in acute exacerbation of asthma|
62720853|NCT05850143|ACTIVE_COMPARATOR|Oral Multidose Prednisolone in acute exacerbation of asthma|
62737693|NCT03511014|SHAM_COMPARATOR|control|
62737694|NCT00956137|EXPERIMENTAL|Ultrasound|Use of ultrasound to identify vertebral interspaces for needle insertion.
62720854|NCT03129542|ACTIVE_COMPARATOR|Midodrine Hydrochloride 10 milligrams|Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
62720855|NCT03129542|PLACEBO_COMPARATOR|Placebo oral capsule|For participants randomized to the placebo arm, an identical appearing capsule containing only Lactose Monohydrate powder will be administered every 8 hours for a total of 3 doses.
62720856|NCT05576025|EXPERIMENTAL|Period 1: Shivering intensity 1|During Arm 1 of the study participants will undergo the first cold exposure at either mild or moderate shivering intensity (depending on the randomisation).
62720857|NCT05576025|EXPERIMENTAL|Period 2: Shivering intensity 2|During Arm 2 of the study participants will undergo the second cold exposure at the alternative shivering intensity.
62720858|NCT01196195|EXPERIMENTAL|QD kaletra|Once daily kaletra
62720859|NCT01196195|ACTIVE_COMPARATOR|BID kaletra|twice daily dose of kaletra
62720860|NCT05932173|EXPERIMENTAL|OlyCAR-019 Cell Infusion|OlyCAR-019 cell infusion will be administered by vein after short-time manufacture.
62720861|NCT05866692|EXPERIMENTAL|TY-2699a|"Escalation stage: Multiple doses of TY-2699a as monotherapy for oral administration to find the maximum tolerated dose.~Expansion stage: an optimal dose of TY-2699a for cohort expansion."
62720862|NCT04587037|EXPERIMENTAL|Fascia lata group|
62720863|NCT04587037|EXPERIMENTAL|Dermal allograft group|
62720864|NCT04720378|EXPERIMENTAL|Cohort 1|0.1 ml/kg IV ST266 once a day for 5 days
62720865|NCT04720378|EXPERIMENTAL|Cohort 2|0.25 ml/kg IV ST266 once a day for 5 days
62720866|NCT04720378|EXPERIMENTAL|Cohort 3|0.5 ml/kg IV ST266 once a day for 5 days
62720867|NCT04720378|EXPERIMENTAL|Cohort 4|1.0 ml/kg IV ST266 once a day for 5 days
62720868|NCT01231789|SHAM_COMPARATOR|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
62720869|NCT01231789|EXPERIMENTAL|RIPC treatment|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
62720870|NCT04032145||Observational|All participants who go to the Montreal Museum of Fine Arts will fill out an online questionnaire called: CESAM ( Self Administered Questionnaire). This questionnaire will asse participant's health condition. Moreover, the goal of the questionnaire is to evaluate if art activities may change the participants' health conditions in time.
62720871|NCT04658927|EXPERIMENTAL|Dexamethosone intracanalicular insert|All 30 eyes will undergo iLUX MGD Treatment System for the treatment of evaporative DED secondary to MGD. Patients will have their most symptomatic eye selected to receive the dexamethasone intracanalicular insert at the day of the iLUX MGD Treatment System (study eye).
62720872|NCT04658927|ACTIVE_COMPARATOR|Group 1: Prednisolone actetate 1%|15 fellow eye will undergo iLux and receive topical prednisolone acetate 1% on a 4,3,2,1 taper for 30 days.
62720873|NCT04658927|SHAM_COMPARATOR|Group 2: Sham dilation|"15 fellow eye will undergo ILux and receive punctal sham dilation (control eye)."
62720874|NCT01234493|ACTIVE_COMPARATOR|fixation|Syndesmosis fixation with one 3.5mm fully threaded screw
62720875|NCT01234493|ACTIVE_COMPARATOR|no fixation|No syndesmosis fixation
62720876|NCT03810846|EXPERIMENTAL|Exercise|Walking football exercise program
62720877|NCT01244711|EXPERIMENTAL|Quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
62720878|NCT03522961|ACTIVE_COMPARATOR|Nitrofurantoin prophylaxis/Placebo|Subjects will receive Nitrofurantoin 100mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to Placebo capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
62720879|NCT03522961|ACTIVE_COMPARATOR|Cranberry capsules|Subjects will receive TheraCran® One Cranberry 36mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to another bottle of TheraCran® One Cranberry 36mg capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
62720880|NCT04282850|EXPERIMENTAL|Pulmonary Vein Isolation (PVI) Group|Subjects randomized to this treatment arm will undergo atrial fibrillation ablation, and undergo routine post-procedural follow-up.
62720881|NCT04282850|NO_INTERVENTION|Medical Management|Subjects randomized to this treatment arm will undergo medical management of the arrhythmia, but will not undergo invasive electrophysiologic procedures to address subject's AF.
62720882|NCT05814471|EXPERIMENTAL|Cable fastening system|The knee brace is worn for 2 weeks after adjustment period. The knee brace is held in place by a cable fastening system and 3d printed straps.
62720883|NCT05814471|ACTIVE_COMPARATOR|Velcro straps|The knee brace is worn for 2 weeks after adjustment period. The knee brace is held in place by a velcro straps system.
62720884|NCT02814656|EXPERIMENTAL|Cohort 1, AZD8871 300 μg or placebo|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
62720885|NCT02814656|EXPERIMENTAL|Cohort 2, AZD8871 600 μg or placebo|In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
62720886|NCT02814656|EXPERIMENTAL|Cohort 3, AZD8871 900 μg or placebo|In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
62720887|NCT01382771|ACTIVE_COMPARATOR|Intra-articular corticosteroid injection|Intra-articular corticosteroid injection in conjunction with confirmatory anesthetic medial branch blocks
62720888|NCT01382771|PLACEBO_COMPARATOR|Intra-articular saline injection|Intra-articular saline injections with confirmatory anesthetic medial branch blocks
62720889|NCT04021290|EXPERIMENTAL|Participants receiving DTG/3TC FDC|Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
62720890|NCT04021290|ACTIVE_COMPARATOR|Participants receiving CAR|Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.
62720891|NCT04794348|ACTIVE_COMPARATOR|Fresh Frozen Plasma (FFP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL of fresh frozen plasma. After completion of warfarin dosing, approximately 810 mL of fresh frozen plasma will be intravenously administered to the subject.
62720892|NCT04794348|EXPERIMENTAL|Freeze Dried Plasma (FDP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL, that will be manufactured into freeze dried plasma units. After completion of warfarin dosing, approximately 810 mL of freeze dried plasma will be intravenously administered to the subject.
62720893|NCT04948112|EXPERIMENTAL|Real-time (rt) CGMS with SMBG|Real time continuous glucose monitoring plus self-monitored blood glucose
62720894|NCT04948112|ACTIVE_COMPARATOR|SMBG with blinded CGM|Self monitored blood glucose with blinded continuous glucose monitoring
62720895|NCT03246087|ACTIVE_COMPARATOR|Acupuncture|Patients will receive acupuncture for plantar fasciosis. The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
62720896|NCT03246087|EXPERIMENTAL|Standard of Care|The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
62720897|NCT03246087|EXPERIMENTAL|Crossover|At the end of the study, patients in the Standard of Care group whom are still experiencing pain and symptoms will be rolled into the acupuncture treatment arm of the study.
62720898|NCT03627052|EXPERIMENTAL|Itacitinib|
62720899|NCT03627052|PLACEBO_COMPARATOR|Placebo|
62720900|NCT00246363|EXPERIMENTAL|Silymarin|Silymarin
62720901|NCT00246363|PLACEBO_COMPARATOR|Placebo|Placebo
62720902|NCT03654274|EXPERIMENTAL|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 80 weeks.
62720903|NCT00930449|EXPERIMENTAL|Cogmed Working Memory Training Program|
62720904|NCT00930449|ACTIVE_COMPARATOR|Academy of Math® program|
62720905|NCT00930449|ACTIVE_COMPARATOR|Special Education/Individualized Tutoring|
62720906|NCT02969070|ACTIVE_COMPARATOR|LopiGLIK™ group|4 weeks of LopiGLIK™ therapy 1 capsule/day
62720907|NCT02969070|ACTIVE_COMPARATOR|Armolipid Plus group|4 weeks of Armolipid Plus therapy 1 capsule/day
62720908|NCT00775268|EXPERIMENTAL|Group A - Participants Scanned at Baseline & After Chemotherapy|Patients undergo 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) and fluorodeoxyglucose F 18 (FDG) PET/CT scans at baseline, after 2 courses of chemotherapy, and after completion of chemotherapy. Patients with residual FDG-positive mass after completion of therapy may be enrolled in group B.
62720909|NCT00775268|EXPERIMENTAL|Group B - Participants Scanned in the Evaluation of Residual Masses After Therapy|Patients who have completed treatment in whom FDG-PET shows a remaining tumor mass undergo an FLT PET/CT scan . Patients also undergo a biopsy or fine-needle aspiration, if clinically indicated.
62720910|NCT05857566|EXPERIMENTAL|RDX-002|50 mg oral tablet; 200 mg BID for 7 days
62720911|NCT05857566|OTHER|Olanzapine|10 mg oral tablet; 10 mg QD for 14 days
62720912|NCT04379674|EXPERIMENTAL|Grup 1- Facilitation|It consists of cases that start with the taping of the facilitation.
62720913|NCT04379674|EXPERIMENTAL|Grup 2- İnhibition|It consists of cases that start with the taping of the inhibition.
62720914|NCT04379674|PLACEBO_COMPARATOR|Grup 3- Plasebo|It consists of cases that start with the taping of the placebo.
62720915|NCT00005446||Postmenopausal women with coronary heart disease|
62720916|NCT00005446||Postmenopausal women without coronary heart disease|Matched in age to the women with heart disease
62720917|NCT05450835|EXPERIMENTAL|Arm A|In OGT group,After the enterotomy was made, the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube. Then, the anaesthesiologist continued to pull back the nasogastric tube for 10 cm to ensure that the stapler would not clamp the nasogastric tube. After that, the surgeon began to fire the stapler to perform side-to-side esophagojejunostomy.
62720918|NCT05450835|ACTIVE_COMPARATOR|Arm B|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al. After firing the stapler, two openings were converted into a single entry hole to create an end-to-side oesophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
62720919|NCT01180283|EXPERIMENTAL|lodenafil carbonate (Helleva®)|
62720920|NCT06269510|EXPERIMENTAL|Enhanced usual care (EUC)|Eligible participants randomized will be given this for stage 1 of treatment (three months) and stage 2 (three months) if participants engaged in alcohol treatment during the first stage of treatment.
62720921|NCT06269510|EXPERIMENTAL|ENGAGE-ALD application (app)|Eligible participants randomized to this arm will be given this for stage 1 (three months) of treatment and stage 2 (three months) if participants engaged in alcohol treatment during the first stage of treatment.
62720922|NCT06269510|EXPERIMENTAL|ENGAGE-ALD app then Treatment Facilitation Bundle|Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized and assigned to the Treatment Facilitation bundle for stage 2 (three months).
62720923|NCT06269510|EXPERIMENTAL|Enhanced usual care then Treatment Facilitation Bundle|Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized and assigned to the Treatment Facilitation bundle for stage 2 (three months).
62720924|NCT06269510|EXPERIMENTAL|ENGAGE-ALD app then Enhanced usual care|Eligible participants randomized to this arm will be given this for stage 1 (three months) of treatment. Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized to the EUC arm stage 2 (three months).
62720925|NCT06269510|EXPERIMENTAL|Enhanced usual care then Enhanced usual care|Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be rerandomized to the Enhanced usual care arm stage 2 (three months).
62720926|NCT03678545|ACTIVE_COMPARATOR|Dupilumab|
62720927|NCT03678545|PLACEBO_COMPARATOR|Placebo|
62720928|NCT02908581|ACTIVE_COMPARATOR|Placebo|21 Patients Placebo Each tablet by mouth once daily for 12 weeks
62720929|NCT02908581|EXPERIMENTAL|Iron 150 mg and Folic acid 0.5 mg|21 Patients Iron 150 mg and Folic acid 0.5 mg Each tablet by mouth once daily for 12 weeks
62549192|NCT05295719|PLACEBO_COMPARATOR|Placebo & Flexibility Training (Control)|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period.
62549193|NCT05295719|ACTIVE_COMPARATOR|Placebo & High-Intensity Interval Training|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period.
62549194|NCT05295719|ACTIVE_COMPARATOR|n-3 PUFA & Flexibility Training (Control)|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
62549195|NCT05295719|EXPERIMENTAL|n-3 PUFA & High-Intensity Interval Training|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
62549196|NCT00079430|EXPERIMENTAL|Treatment (adjuvant, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62549197|NCT00619060|EXPERIMENTAL|Myristyl (right), Placebo (Left)|Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
62549198|NCT00619060|EXPERIMENTAL|Myristyl (Left), Placebo (Right)|Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
62549199|NCT01823497|ACTIVE_COMPARATOR|Parent/Nurse Controlled Analgesia|Parent/Nurse Controlled Analgesia will be the method of morphine delivery.
62549200|NCT01823497|ACTIVE_COMPARATOR|Continuous Opioid Infusion|Continuous Opioid Infusion will be the method used to deliver morphine to group 2
62549201|NCT04148573|ACTIVE_COMPARATOR|Arm NFX88 - 1|1.05 g/day NFX88
62549202|NCT04148573|ACTIVE_COMPARATOR|Arm NFX88 - 2|2.10 g/day NFX88
62549203|NCT04148573|ACTIVE_COMPARATOR|Arm NFX88 - 3|4.20 g/day NFX88
62549204|NCT04148573|PLACEBO_COMPARATOR|Arm PLACEBO - 4|Placebo
62549205|NCT00413881|ACTIVE_COMPARATOR|2|Conventional LASIK Enhancement
62549206|NCT00413881|EXPERIMENTAL|1|Wavefront guided LASIK Enhancement
62549207|NCT04306211|ACTIVE_COMPARATOR|Facial mask|facial mask for oxygen delivery
62549208|NCT04306211|EXPERIMENTAL|SuperNO2VA|SuperNO2VA is CPAP device to deliver oxygen with nasal mask rather than with facial mask
62549209|NCT04941079||Immune-related Myopathy Patient (myasthenia gravis and inflammatory myopathy)|
62549210|NCT04941079||Health Control|
62549211|NCT04718831|OTHER|Baseline|Did not take nutritious food
62549212|NCT04718831|EXPERIMENTAL|General dose|Taking 6g spirulina
62549213|NCT04718831|EXPERIMENTAL|Double dose|Taking 12g spirulina
62549214|NCT05859828||Head and Neck Cancer patients|Participants with incurable advanced head and neck cancer. Participants will have histologically or cytologically confirmed squamous cell carcinoma of the head and neck
62549215|NCT05859828||Patient Caregivers|Caregivers to participants in the patient cohort
62549216|NCT04082338|EXPERIMENTAL|VPN Toolkit+TM|The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application) format.
62549217|NCT04082338|ACTIVE_COMPARATOR|Text Messages|Receive TM respectively once a week for 5 weeks for every 6 months in the 18-month study period
62549218|NCT05524337|EXPERIMENTAL|White noise group|"In the white noise group, it will be explained to the mother of the baby that the white noise sound to be used in the research will be used for pain relief. Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db. The loudspeaker will be placed on the tip of the foot, approximately 30 cm from the newborns ear, five minutes before the procedure, and will be played to the baby during the procedure. 5 minutes without taking heel blood. Before, during the procedure and 5 minutes after the end of the procedure, this sound will be played to the baby and the data will be recorded by the observer."
62720930|NCT04470388|EXPERIMENTAL|EDP-514 HBV MAD Cohorts|EDP-514 capsule Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days.
62720931|NCT04470388|PLACEBO_COMPARATOR|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days.
62720932|NCT02039011|ACTIVE_COMPARATOR|Indacaterol|
62720933|NCT02039011|EXPERIMENTAL|Indacaterol & tiotropium|
62737695|NCT00956137|ACTIVE_COMPARATOR|Palpation|Use of manual palpation to identify vertebral landmarks and vertebral interspaces for needle insertion.
62720934|NCT04726891|ACTIVE_COMPARATOR|Continued M2M + SNS for 9 weeks|Participants who successfully watch and exercise at or above 40 minutes per week will continue doing M2M + SNS for the remaining 9 weeks of the study.
62720935|NCT04726891|ACTIVE_COMPARATOR|Augmented M2M + SNS + IBC for 9 weeks|Some participants with sub-optimal adherence in the first treatment stage will be randomized to one of two treatment groups in the second treatment stage. these participants will receive M2M plus social networking support augmented with individualized behavioral coaching. Individualized behavioral coaching involves a weekly coaching session to improve self-regulatory skills based on prior and individualized exercise prescription. The exercise prescriptions are determined by the coach and individual based on their current activity level and a 4-week goal. An example of tailoring the exercise prescribed involves setting a goal of completing the exercise routine one time for the upcoming week instead of three times. The coach will be trained in motivational interviewing to help the participant modify their exercise habits.
62720936|NCT04726891|ACTIVE_COMPARATOR|Switched M2M Live for 9 weeks|The remaining half of participants with sub-optimal adherence in the first treatment stage will switch to another M2M-based home exercise intervention, M2M Live. M2M Live involves one-on-one tele-exercise training with an M2M instructor, which provides accountability and immediate, tailored feedback along with custom movements and music. During the first week of M2M Live, the participant will set a schedule to meet with the M2M instructor 1 time each week for an exercise session. The M2M Live instructors are also trained in motivational interviewing in order to coach participants through any barriers to changing their exercise behavior.
62720937|NCT04726891|ACTIVE_COMPARATOR|Continued M2M + IBC for 6 weeks|Participants who successfully watch and exercise at or above 40 minutes per week will continue doing M2M + SNS for the remaining 6 weeks of the study.
62720938|NCT04726891|ACTIVE_COMPARATOR|Augmented M2M + SNS + IBC for 6 weeks|Some participants with sub-optimal adherence in the first treatment stage will be randomized to one of two treatment groups in the second treatment stage. these participants will receive M2M plus social networking support augmented with individualized behavioral coaching. Individualized behavioral coaching involves a weekly coaching session to improve self-regulatory skills based on prior and individualized exercise prescription. The exercise prescriptions are determined by the coach and individual based on their current activity level and a 4-week goal. An example of tailoring the exercise prescribed involves setting a goal of completing the exercise routine one time for the upcoming week instead of three times. The coach will be trained in motivational interviewing to help the participant modify their exercise habits.
62720939|NCT04726891|ACTIVE_COMPARATOR|Switched M2M Live for 6 weeks|The remaining half of participants with sub-optimal adherence in the first treatment stage will switch to another M2M-based home exercise intervention, M2M Live. M2M Live involves one-on-one tele-exercise training with an M2M instructor, which provides accountability and immediate, tailored feedback along with custom movements and music. During the first week of M2M Live, the participant will set a schedule to meet with the M2M instructor 1 time each week for an exercise session. The M2M Live instructors are also trained in motivational interviewing in order to coach participants through any barriers to changing their exercise behavior.
62720940|NCT02194790|EXPERIMENTAL|community-based Integrated CKD care|Standard CKD care + multidisciplinary team and home visit by community care team
62720941|NCT02194790|NO_INTERVENTION|Conventional CKD care|standard CKD care
62720942|NCT03381287|EXPERIMENTAL|HTD1801 250 mg BID|Subjects received 500 mg/day HTD1801
62720943|NCT03381287|EXPERIMENTAL|HTD1801 500 mg BID|Subjects received 1000 mg/day HTD1801
62720944|NCT03381287|EXPERIMENTAL|HTD1801 1000 mg BID|Subjects received 2000 mg/day HTD1801
62720945|NCT03381287|PLACEBO_COMPARATOR|Placebo|
62720946|NCT00848263|ACTIVE_COMPARATOR|DVR|Volar plate
62720947|NCT00848263|ACTIVE_COMPARATOR|DNP|Dorsal nail plate
62720948|NCT00830050|EXPERIMENTAL|Arm 1|
62720949|NCT00830050|PLACEBO_COMPARATOR|Arm 2|
62720950|NCT02308293|EXPERIMENTAL|High intensity exercise|Subjects will preform a high intensity training exercise (3\* 30 seconds all out sprint on a cycle ergometer) to raise plasma lactate levels
62720951|NCT02308293|SHAM_COMPARATOR|Lay down comfortably|As a control conditions, subjects wil lay down comfortably and rest
62720952|NCT01624935|EXPERIMENTAL|psychotherapy|psychotherapy
62720953|NCT01624935|OTHER|treatment as usual|TAU control
62720954|NCT00670930|ACTIVE_COMPARATOR|omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single use, 5 ml vial that was designed to deliver 150 mg of omalizumab for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The dose administered was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and the number of injections and injection volume was determined using protocol-specified dosing tables. Omalizumab 75 to 375 mg was administered SQ every 2 or 4 weeks depending on the dose for the 78 weeks duration of double-blinded treatment.
62720955|NCT00670930|PLACEBO_COMPARATOR|Placebo|Omalizumab matching placebo was supplied as lyophilized, sterile powder in a single-use, 5 ml vial that was designed to deliver omalizumab matching placebo for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The number of injections and injection volume was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and was determined using protocol-specified dosing tables. Placebo was administered SQ every 2 or 4 weeks for the 78 weeks duration of double-blinded treatment.
62720956|NCT04141319|EXPERIMENTAL|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
62720957|NCT04141319|ACTIVE_COMPARATOR|The control group|In the control group, preoperative peri-incisional scalp infiltration will be performed using 30ml of 60 mg ropivacaine and 0.1mg epinephrine.
62720958|NCT00518050||Specific Aim 1- Focus Group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~* Screening, skin self-examination, sun protection, and other cancer preventive practices;~* Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~* Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
62739004|NCT05633836|EXPERIMENTAL|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreductive surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
62720959|NCT00518050||Specific Aim 2- Survey Study|A separate random sample of melanoma survivors will complete the pilot questionnaire. To enhance completion rates, survey instruments will be developed to be both self-administered and interviewer-administered. The survey will include questions from existing surveys, regarding demographics, sun sensitivity, eye and hair color, color of untanned skin, sun exposure, skin selfexamination, sun protection practices and frequency of sunburns, psychosocial/cognitive factors: skin cancer knowledge, skin awareness, cancer worry, perceived risk of recurrence, cancer risk and screening behaviors, and access to health care and insurance.
62720960|NCT04596683|EXPERIMENTAL|Interested in SDS NSM or SSM|Patients interested same day discharge after NSM or SSM that do not have conditions that would exclude them. Based on discharge outcome after surgery, will be split into SDS group and Admit group.
62720961|NCT00959426|EXPERIMENTAL|PF-04620110|
62720962|NCT00959426|PLACEBO_COMPARATOR|Placebo Comparator|
62720963|NCT03553537|EXPERIMENTAL|Decitabine + CHOP regimen|decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles
62720964|NCT03553537|ACTIVE_COMPARATOR|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles
62720965|NCT01102595|EXPERIMENTAL|1: Temozolomide plus Radiation|"Group 1:~Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy).~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
62720966|NCT01102595|EXPERIMENTAL|2: Temozolomide plus Radiation plus Bevacizumab|"Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles + bevacizumab 10 mg/kg every 15 days.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy) + bevacizumab 10 mg/kg every 15 days.~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
62720967|NCT03401437||Retrospective cohorte|Patients seen in consultation between January 2017 and August 2017, who have already completed the SF-36 questionnaire (pre-operative, M1 and M3), the HAD and ANSM questionnaires (pre-operative and M3)
62720968|NCT03401437||Prospective cohorte|Patients seen in consultation between August 2017
62720969|NCT04305977|OTHER|WAVE-TW Arm|All participants will receive the WAVE-TW intervention.
62720970|NCT04344730|PLACEBO_COMPARATOR|Standard oxygen 1|Standard oxygen and placebo of Dexamethasone
62720971|NCT04344730|EXPERIMENTAL|Standard oxygen 2|Standard oxygen and Dexamethasone
62720972|NCT04344730|EXPERIMENTAL|CPAP 1|CPAP and placebo of Dexamethasone
62720973|NCT04344730|EXPERIMENTAL|CPAP 2|CPAP and Dexamethasone
62720974|NCT04344730|EXPERIMENTAL|HFNO 1|HFNO and placebo of Dexamethasone
62720975|NCT04344730|EXPERIMENTAL|HFNO 2|HFNO and Dexamethasone
62720976|NCT04344730|PLACEBO_COMPARATOR|mechanically ventilated 1|placebo
62720977|NCT04344730|EXPERIMENTAL|mechanically ventilated 2|Dexamethasone
62720978|NCT05361850|ACTIVE_COMPARATOR|Awake Extubation|Removal of the endotracheal tube while the patient is no longer under general anesthesia
62720979|NCT05361850|ACTIVE_COMPARATOR|Deep Extubation|Removal of the endotracheal tube while the patient is under general anesthesia
62720980|NCT02589288|ACTIVE_COMPARATOR|Continuous Infusion|Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
62720981|NCT02589288|EXPERIMENTAL|Automatic Intermittent Bolus|Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).
62720982|NCT01732991|EXPERIMENTAL|prostatic photo-vaporization|prostatic photo-vaporization (PVP) surgery with laser Greenlight
62720983|NCT03289533|EXPERIMENTAL|Experimental 1|Avelumab (MSB0010718C) in combination with axitinib (AG-013736)
62720984|NCT02058979|ACTIVE_COMPARATOR|BOLUS INFUSION|Bolus infusion of antibiotics
62720985|NCT02058979|EXPERIMENTAL|CONTINUOUS INFUSION|Continuous infusion of antibiotics by way of infusion pump
62720986|NCT05579210|EXPERIMENTAL|Online relapse prevention therapy (eRPT)|Online relapse preventiontherapy
62720987|NCT05579210|ACTIVE_COMPARATOR|Face-to-face relapse prevention therapy (RPT)|Face-to-face in-person relapse prevention therapy
62720988|NCT04230967|EXPERIMENTAL|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit InspireTM devices will be set to this goal and notifications will be given on the device for the participants meeting their goals. Upon enrollment, they will be given a pamphlet with instructions to ambulate out of the room at least once per day with a goal of 2,000 steps daily and their Fitbits will be pre-programmed with this goal. Study staff will also remind participants to ambulate via email, text or in-person if they are not meeting their goal of 2,000 steps per day.
62720989|NCT04230967|ACTIVE_COMPARATOR|Routine Care|Participants in the routine care arm will be allowed ad lib activity but no encouragement to walk will be given. They will not have any goals set on their Fitbits. Upon enrollment, they will be given pamphlets with no instruction on whether or not to ambulate and their Fitbits will be pre-programmed to have no goal.
62720990|NCT03433547|EXPERIMENTAL|Buckle|Macular buckling, Limbal paracentesis, and intraocular gas injection.
62720991|NCT03433547|ACTIVE_COMPARATOR|Vitrectomy|Vitrectomy, peeling internal limiting membrane, and gas tamponade.
62720992|NCT05983094|EXPERIMENTAL|cohort 1 Triple-negative breast cancer|Hormone Receptor(HR) negative, Human Epidermal Growth Factor Receptor 2(HER2 )negative breast cancer Drug: Utidelone in combination with carboplatin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin ,Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.
62720993|NCT05983094|EXPERIMENTAL|cohort 2 HR positive, HER2 negative breast cancer|HR positive, HER2 negative, Immunohistochemical(IHC)0,1+; 2+, Fluorescence in situ hybridization(FISH)non-amplification breast cancer Drug: Utidelone in combination with Epirubicin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Epirubicin 75mg/m2 was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.
62737696|NCT06301516|EXPERIMENTAL|Experimental: Impact VR|Participants enrolled into Impact VR will be complete the first of four sessions. The four 20-minute sessions will be completed over 4 weeks (one session per week) either in the lab, at the participant's home, school or a mutual private meeting place
62739005|NCT04053972|EXPERIMENTAL|treatment group|adjuvant lenvatinib
62720994|NCT05983094|EXPERIMENTAL|cohort 3 HER2 positive (IHC 3+; IHC 2+,FISH amplification) breast cancer|"Drug: Utidelone in combination with carboplatin, trastuzumab and pertuzumab Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total. Trastuzumab 8mg/kg iv in first cycle on day 1, then 8mg/kg in the rest cycles; pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles.~One treatment cycle is 21 days, and there are 6 cycles in total."
62720995|NCT02332187|SHAM_COMPARATOR|Sham electrical stimulation|The intervention will consist of sham electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
62720996|NCT02332187|ACTIVE_COMPARATOR|Active electrical stimulation|The intervention will consist of active electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
62720997|NCT01130337|EXPERIMENTAL|1|
62720998|NCT06046248|EXPERIMENTAL|Belumosudil Plus Rituximab|Belumosudil plus Rituximab
62720999|NCT02665546||Case|Patients with diagnosis of LCH based on histopathological or clinical and radiological findings.
62721000|NCT02665546||Controls|Current or ex smokers matched with cases for age, gender and smoking history.
62721001|NCT06282861|EXPERIMENTAL|Trelegy|Trelegy commercial product. 1 inhalation daily for 12 months
62721002|NCT06282861|ACTIVE_COMPARATOR|LABA-LAMA|Any LABA-LAMA combination approved in Spain is accepted. To be used according to product specifications for 12 months.
62721003|NCT03421886|EXPERIMENTAL|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
62721004|NCT03421886|ACTIVE_COMPARATOR|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
62721005|NCT05065593|EXPERIMENTAL|Face-to-Face Training Group|"After completing all assessments, the intervention group will participate in face-to-face exercise training with a physiotherapist for 3 days for 4 months.~In the first week, patients will be taught body awareness; parameters of correct loading on the muscle will be explained and the limits of safe exercise will be drawn. At the beginning and end of all exercises, there will be short-term active stretching and relaxation exercises performed by the patient as a warm-up and cool-down period. In the first 4 weeks, it is planned to increase the physical fitness levels of individuals with progressive resistance exercises and to make them suitable for aerobic loading. For each patient, the PRE, resistance will be increased from 60% to 80% for as long as the person can. At the end of the 1st month, the time allocated to resistance exercise training will be reduced and until the end of the 4th month, an increasing intensity aerobic exercise training will be given on the stationary bike."
62721006|NCT05065593|ACTIVE_COMPARATOR|Home-Based Control Group|After the patients assigned to the control group are evaluated by the physiotherapist with field tests and scales for physical functions, the patients will be informed about the importance of lifestyle changes in disease management, gait training will be given to increase their physical activity level and participants will be asked to follow a 45-minute walking program every day within their own means. All patients in the control group will be followed up regularly and their activity levels will be questioned in interim evaluations by asking them to keep a weekly physical activity diary.
62721007|NCT00761488|EXPERIMENTAL|1|AcrySof® Toric IOL
62721008|NCT02057965|ACTIVE_COMPARATOR|Mesenchymal Stromal Cells + Everolimus|"Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican® (1.5mg/day). Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight.~At the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)"
62721009|NCT02057965|NO_INTERVENTION|Everolimus + Tacrolimus|Patients in the control group will receive Certican® (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks).
62721010|NCT03940807|EXPERIMENTAL|Ultra-long protocol group|All women will receive one intra-muscular administration of 11.25 mg Gonadotropin Releasing Hormone (GnRH) agonist (triptorelin acetate) on luteal phase of their menstrual cycle. Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period. Ovarian stimulation will be started after 90 days desensitization.
62721011|NCT03940807|ACTIVE_COMPARATOR|Long protocol group|All women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous application of 0.1mg of GnRH agonist (triptorelin acetate) started on luteal phase of their menstrual cycle. Ovarian stimulation will begin after 15 days desensitization.
62721012|NCT01245725|EXPERIMENTAL|Tirofiban (Aggrastat)|
62721013|NCT01245725|PLACEBO_COMPARATOR|Placebo|
62721014|NCT04120129|EXPERIMENTAL|TMS treatment|participants receive TMS treatment
62721015|NCT04120129|SHAM_COMPARATOR|sham TMS|participants receive control TMS treatment
62721016|NCT04120129|NO_INTERVENTION|non intervention|control group
62721017|NCT03584815|ACTIVE_COMPARATOR|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
62721018|NCT03584815|ACTIVE_COMPARATOR|Physiotherapy|"1. Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.~2. Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
62721019|NCT03654144|EXPERIMENTAL|Study group|women will receive dienogest
62721020|NCT03654144|ACTIVE_COMPARATOR|control group|women used combined oral contraceptive pills
62721021|NCT06003439|EXPERIMENTAL|Virtual Reality Program|Students in classrooms randomized to this group will receive the Virtual Reality vaping cessation and prevention program.
62721022|NCT06003439|NO_INTERVENTION|Assessment Only|Students in classrooms randomized to this group will not receive the VR intervention but will complete questionnaire assessment only.
62721023|NCT03710889|EXPERIMENTAL|Abaloparatide|Participants self-administered a single daily dose of 80 micrograms (µg) of abaloparatide subcutaneously (SC) during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.
62168135|NCT02503488|EXPERIMENTAL|Program Group|The treatment arm will consist of 20 randomly selected participants who will receive Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) for their traumatic symptomology, aggression, and depression. FORNET consists of a guided exposure of the participant's traumatic experiences in chronological order and integrating them into a coherent biographical memory.The intervention addresses the participant's positive, negative, and violent memories of events that have taken place during their lifetime, and also provides participants an opportunity to asses their current situation and future plans. FORNET can be completed in six sessions and each session lasts 90 minutes on average.
62721024|NCT05238415|NO_INTERVENTION|Control group receiving no Post-/Long-COVID assessment|"Questionnaires at timepoints t1 (screening), t2 (one week later), t3 (before the intervention), t4 (after the intervention), t5 (6 weeks after intervention), t6 (6 months after the intervention)~Patients from Bavaria Germany: Contact to personal pilots and digital health interventions."
62721025|NCT05238415|EXPERIMENTAL|Intervention group receiving a Post-/Long-COVID assessment|"Questionnaires at timepoints t1 (screening), t2 (one week later), t3 (before the intervention), t4 (after the intervention), t5 (6 weeks after intervention), t6 (6 months after the intervention)~Patients from Bavaria Germany: Assessment in clinics for post-/long-COVID, contact to personal pilots and digital health interventions."
62721026|NCT05238415|NO_INTERVENTION|Comparison group receiving no Post-/Long-COVID assessment|"Questionnaires at timepoints t1 (screening), t2 (comparable to t2 in the other groups), t3 (comparable with t4 in the other groups), t3 (comparable to t5 in the other groups)~Patients from Germany: No intervention at all"
62721027|NCT03061292|EXPERIMENTAL|Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation with pectoral nerve block
62721028|NCT03061292|SHAM_COMPARATOR|Without Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation without pectoral nerve block
62721029|NCT06487299|EXPERIMENTAL|Ferrous Lactate|Ferrous lactate is administered via the colon as an injectable solution at a dose of 300 mg per day for 3 days, with saline added to 50ml.
62721030|NCT06487299|ACTIVE_COMPARATOR|Iron Sucrose|Iron sucrose is administered via the colon as an injectable solution at a dose of 300mg per day for 3 days, with saline added to 50ml.
62721031|NCT06487299|PLACEBO_COMPARATOR|Saline|0.9% sodium chloride is administered via the colon as an injectable solution at a dose of 50ml per day for 3 days.
62721032|NCT02222103||Suspected obstructive sleep apnea in adults|Already scheduled in-lab sleep study
62721033|NCT01508208|OTHER|Hypertensive disorder of pregnancy|Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.
62721034|NCT01060254|EXPERIMENTAL|JNJ-42160443|
62721035|NCT01060254|PLACEBO_COMPARATOR|Placebo|
62721036|NCT00508092|ACTIVE_COMPARATOR|A|lanz incision appendectomy
62721037|NCT00508092|ACTIVE_COMPARATOR|B|lanz incision appendectomy
62721038|NCT06155162|EXPERIMENTAL|Original HuggyPuppy doll|The original puppy doll used in Sadeh et al., 2006 is a sad dog with Velcro on its paws will be provided to children allocated to this treatment arm.
62721039|NCT06155162|EXPERIMENTAL|Monkey with velcro on paws, neutral expression|A monkey doll with a neutral expression and with Velcro on its paws will be provided to children allocated to this treatment arm.
62721040|NCT06155162|EXPERIMENTAL|Dog without velcro on paws, neutral expression|A puppy doll with a neutral expression and without Velcro on its paws will be provided to children allocated to this treatment arm.
62721041|NCT06155162|EXPERIMENTAL|Bear, smiling|A smiling bear doll with a neutral expression and without Velcro on its paws will be provided to children allocated to this treatment arm.
62721042|NCT06155162|EXPERIMENTAL|Rabbit, neutral expression|A bunny-rabbit doll with a neutral expression and without Velcro on its paws will be provided to children allocated to this treatment arm.
62721043|NCT02843412||group 1|choose one tumor tissue paraffin blocks
62721044|NCT02843412||group 2|choose two tumor tissue paraffin blocks
62721045|NCT00981903|EXPERIMENTAL|VTE Treatment Group|
62721046|NCT00981903|NO_INTERVENTION|Control|
62721047|NCT00039013|EXPERIMENTAL|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
62721048|NCT00039013|EXPERIMENTAL|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
62721049|NCT00039013|PLACEBO_COMPARATOR|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
62721050|NCT00039013|PLACEBO_COMPARATOR|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
62721051|NCT04572334|OTHER|visual acuity and refractive outcome for Tecnis Eyhance|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
62721052|NCT04572334|OTHER|visual acuity and refractive outcome for Tecnis ZCB00|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
62721053|NCT02609425||STRATAFIX|Anastomosis of esophagus to stomach
62721054|NCT05261828|EXPERIMENTAL|A|Short multidisciplinary program including education and rehabilitation and a personalized follow-up program
62721055|NCT05261828|ACTIVE_COMPARATOR|B|Reassuring messages and advices in agreement with the current recommendations.
62721056|NCT05313763|EXPERIMENTAL|Conventional physical therapy group|Conventional physical therapy is the first line of treatment in cervical spondylosis.
62721057|NCT05313763|ACTIVE_COMPARATOR|Kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Kinesio-tape applications will be applied in 6 sessions during conventional physical therapy, twice a week at four-day intervals.
62721058|NCT05313763|SHAM_COMPARATOR|Sham kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Sham kinesio-tape applications will be applied twice a week at four-day intervals, 6 sessions during conventional physical therapy.
62721059|NCT02073162|ACTIVE_COMPARATOR|Liberal group|At induction-Hartmanns 10 ml/kg During surgery-Hartmanns 8 ml/kg/h After surgery-IV fluids ≥1.5 ml/kg/h Continue IV fluids ≥24hrs
62721060|NCT02073162|EXPERIMENTAL|Restrictive group|At induction-Hartmanns ≤5 ml/kg During surgery-Hartmanns 5 ml/kg/h After surgery-IV fluids, ≤0.8 ml/kg/h Cease IV fluids ASAP,aim for early oral fluids
62721061|NCT03314935|EXPERIMENTAL|Treatment Group A|INCB001158 + FOLFOX
62721062|NCT03314935|EXPERIMENTAL|Treatment Group B|INCB001158 + gemcitabine/cisplatin
62721063|NCT03314935|EXPERIMENTAL|Treatment Group C|INCB001158 + paclitaxel
62721064|NCT02953184|ACTIVE_COMPARATOR|conventional Doxorubicin plus C-T|AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
62721065|NCT02953184|EXPERIMENTAL|PLD plus C -T|Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
62721066|NCT03965182|ACTIVE_COMPARATOR|PEG group|Patients in the PEG group were instructed to take the first sachet of PEG at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
62721067|NCT03965182|ACTIVE_COMPARATOR|PEG plus SPMC group|Patients in the PEG plus SPMC group will be instructed to take the SPMC sachet at 19:00 hours the day before colonoscopy and the PEG sachet at 6:00 hours on the morning of the day of colonoscopy.
62721068|NCT03965182|ACTIVE_COMPARATOR|SPMC group|Patients in the SPMC group were instructed to take the first sachet of SPMC at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
62721069|NCT04298489|EXPERIMENTAL|stage III/IV gastrointestinal cancer patients|The study group (Personalized drug sensitivity test) was treated according to the physician's opinion. Tumor tissues are obtained during the surgery or via biopsy with informed consent, for the purpose of ex vivo assay.
62721070|NCT02951637|EXPERIMENTAL|Group A|Patient will be administrated with Pemetrexed plus carboplatin combined with gefitinib
62721071|NCT02951637|EXPERIMENTAL|Group B|Patient will be administrated with gefitinib
62721072|NCT06718998|EXPERIMENTAL|Arm 1: NNC0519-0130|Participants will receive once-weekly subcutaneous (s.c) injections of NNC0519-0130 following a predetermined dose escalation regimen 1 in the main and extension phase.
62721073|NCT06718998|EXPERIMENTAL|Arm 2: NNC0519-0130|Participants will receive once-weekly s.c injections of NNC0519-0130 following a predetermined dose escalation regimen 2 in the main phase and extension phase.
62721074|NCT06718998|EXPERIMENTAL|Arm 3: NNC0519-0130|Participants will receive twice-weekly s.c injections of NNC0519-0130 following a predetermined dose escalation regimen 3 in the main phase and extension phase.
62721075|NCT06718998|EXPERIMENTAL|Arm 4: NNC0519-0130|Participants will receive once-weekly s.c injections of NNC0519-0130 following a predetermined dose escalation regimen 4 in the main and extension phase.
62721076|NCT00929916||AM dosing of MoviPrep®|Take prep morning of exam
62721077|NCT00929916||PM/AM dosing of MoviPrep®|half of the volume of prep(1L) solution the evening prior, and half (1L) the morning of, colonoscopy.
62721078|NCT01424943|EXPERIMENTAL|Stepping Stones Triple P|10-15 sessions of Level 4 Standard Stepping Stones Triple P delivered in family homes
62721079|NCT01424943|OTHER|BabyNet Services As usual|BabyNet services as usual based on IFSP
62721080|NCT04618588|EXPERIMENTAL|"Sinus elevation using Low Window Sinus Lift technique"|
62721081|NCT05431439||Cohort 1|Participants with cancer or cancer predisposition
62721082|NCT05123300|NO_INTERVENTION|A) Conventional Imaging|Conventional Imaging with NaF (sodium fluoride)-PET/CT used for staging
62721083|NCT05123300|EXPERIMENTAL|B) Interventional Imaging|Staging with the interventional18F-PSMA-1007 PET/CT.
62721084|NCT03848416|EXPERIMENTAL|Ixekizumab (Reference)|Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.
62721085|NCT03848416|EXPERIMENTAL|Ixekizumab (Test 1)|Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
62721086|NCT03848416|EXPERIMENTAL|Ixekizumab (Test 2)|Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
62721087|NCT01632254||Patients with ≥70% carotid artery stenosis|
62721088|NCT03672214|EXPERIMENTAL|Without placement of a catheter|No placement of indwelling catheter prior to Caesarean section
62721089|NCT03672214|ACTIVE_COMPARATOR|With placement of a catheter|Placement of indwelling catheter prior to Caesarean section
62721090|NCT03440866|EXPERIMENTAL|Intervention|Administration of drugs concomitantly.
62721091|NCT03440866|NO_INTERVENTION|Control|Administration of oral Mifepristone 600 mg and after interval of 48 hours administration of oral Misoprostol 400 mcg.
62721092|NCT03893981|EXPERIMENTAL|Proprioception and Balance Training|Proprioception and Balance Program
61976663|NCT05053789|EXPERIMENTAL|Group 1|After enrolment into the study and randomization to the study group (V0) and baseline examinations (V1), patients will receive 1 drop of Lacrimera at the study site and will be instructed to apply one drop of C-NAC into both eyes before bedtime for the following 5 consecutive days and return for a follow-up visit after 7±1 days (V2). Patients will complete a diary describing symptoms during the day, use of Lacrimera and potential side effects until the next visit. If the NEI grading is ≤1 OR the OSDI score \<20 at the next visit, treatment with Lacrimera will be discontinued and one further physical follow-up appointment will be arranged, which will take place 28±2 days after the last physical visit.
62721093|NCT03893981|EXPERIMENTAL|Strengthening Training|Strengthening Program
62721094|NCT03856866|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
62721095|NCT03856866|PLACEBO_COMPARATOR|Placebo|Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
62721096|NCT04580914|EXPERIMENTAL|Treatment with Ablation Catheter|Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
62721097|NCT04815187|EXPERIMENTAL|Montelukast 10 mg|Subjects will be instructed to take one pill at night for 90 days
62721098|NCT04815187|PLACEBO_COMPARATOR|Placebo|Subjects will be instructed to take one pill at night for 90 days
62721099|NCT03249194|EXPERIMENTAL|HCV+ Donor Kidney Recipient|"All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks."
62721100|NCT01203709|EXPERIMENTAL|Combination treatment|treatment arm
62721101|NCT02088125|ACTIVE_COMPARATOR|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
62721102|NCT02088125|ACTIVE_COMPARATOR|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
62721103|NCT06716801||Patients affected by epilepsy with focal-onset seizures with or without secondary generalization|Adult patients affected by epilepsy with focal-onset seizures with or without secondary generalization who have not been adequately controlled despite a history of treatment with 2 or 3 anti-seizure medications (ASMs).
62721104|NCT05180513|OTHER|Teleconference Mindfulness Intervention Group|MBSR training program that has been adapted for use via Zoom teleconferencing and for cultural relevancy
62721105|NCT05180513|OTHER|Smartphone App Mindfulness Intervention Group|MBSR training program that has been adapted for use via smartphone app and for cultural relevancy
62721106|NCT05180513|NO_INTERVENTION|Waitlist Control Group|No intervention; control group
62721107|NCT03483454|EXPERIMENTAL|Exercise classes|This group of children and their parents will participate in an exercise class for 8 weeks.
62721108|NCT03483454|EXPERIMENTAL|Home exercise|"This group of children and their parents will participate in exercise at home for 8 weeks. This is currently the standard of care in the weight management clinic (advise to continue increasing activity at home). This group is considered the control group."
62721109|NCT05759208|EXPERIMENTAL|Placebo|OK-101 Placebo Ophthalmic Solution (vehicle): 1 drop BID in each eye (N = \~80)
62721110|NCT05759208|EXPERIMENTAL|Low Dose OK-101|0.05% OK-101 Ophthalmic Solution: 1 drop BID in each eye (N = \~80)
62721111|NCT05759208|EXPERIMENTAL|High-Dose OK-101|0.1% OK-101 Ophthalmic Solution: 1 drop BID in each eye (N = \~80)
62721112|NCT02314442|ACTIVE_COMPARATOR|ALN-PCSSC|
62721113|NCT02314442|PLACEBO_COMPARATOR|Sterile Normal Saline (0.9% NaCl)|
62721114|NCT03467256|EXPERIMENTAL|experimental|Patients will receive lymphodepleting chemotherapy, one hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV on day 0.
62721115|NCT03007771|EXPERIMENTAL|MR-HIFU|"* Philips 1.5T MRI scanner equipped with a Sonalleve V2 HIFU system will be used~* Will be scanned in the MRI in 1 or more positions to the extremities and/or pelvis while aligned to the HIFU system. The HIFU device will then be used to apply sub-clinical levels (≤ 41°C) of heat to one or more small volumes. Regions will be heated to the desired temperature for variable short durations of time not exceeding 30 minutes.~* After the session is complete, the patient will be removed from the MR-HIFU system and, following a 15-30-minute period of monitoring for any adverse events, allowed to leave.~* Before the scan, after the scan and 5-10 days following the scan, participants will be asked to rate any pain, discomfort, in the area to be heated, as well as any anxiety or claustrophobia on a scale of 1-10 with 1 being minimal/none and 10 being extreme. The skin area to be treated will also be reviewed for any redness/discoloration."
62721116|NCT01176760|EXPERIMENTAL|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
61976664|NCT05053789|ACTIVE_COMPARATOR|Group 2|The study days are conducted in the same way as for the study group. Patients of the control group will receive preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine) for 4 times a day as control.
62168136|NCT02503488|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Participants in the TAU group will receive group and individual psycho-social support from trained peer-support workers, with 10 sessions occurring throughout the course of the intervention for each participant. In addition, there will be sensitisation trainings as well as mentoring for establishing greater financial independence. Last, TAU will include one-day events promoting social cohesion and peace.
62721117|NCT01176760|EXPERIMENTAL|Cardia|Truncally vagotomized subjects (due to cardia resection)
62721118|NCT01176760|EXPERIMENTAL|Ctrl|Healthy matched control subjects
62721119|NCT05017623|EXPERIMENTAL|Intervention/treatment|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
62721120|NCT04406103|EXPERIMENTAL|Sleepwell|Mailed information package includes 2 Sleepwell booklets (How to get your sleep back and How to stop sleeping pills)
62721121|NCT04406103|ACTIVE_COMPARATOR|Empower|Mailed information package includes 2 Empower booklets (You may be at risk AND How to get a good night's sleep without sleeping pills)
62721122|NCT04406103|NO_INTERVENTION|TAU|Treatment-as-usual group: no mailed intervention package.
62721123|NCT06288425||No rejection, normal biopsy (controls)|Normal biopsy - no acute tubular injury (ATI), rejection or any other pathology
62721124|NCT06288425||Acute kidney injury without evidence of rejection|Biopsy features of acute tubular injury but no evidence of rejection
62721125|NCT06288425||Subclinical Rejection|Biopsy features of injury and inflammation but not meeting current diagnostic criteria for acute or chronic rejection
62721126|NCT06288425||Acute rejection|Biopsy features of T-cell mediated, antibody-mediated, or mixed rejection
62721127|NCT06288425||Isolated vascular rejection|Biopsy features of inflammation in the blood vessels only
62721128|NCT06288425||Isolated glomerulitis|Biopsy features of inflammation in the glomeruli only
62721129|NCT06288425||Chronic (active) rejection|Biopsy features of chronic rejection - T-cell, antibody or mixed types
62739006|NCT04053972|NO_INTERVENTION|control group|no intervention
62721130|NCT06288425||BK virus associated nephropathy (BKVAN)|Biopsy features of SV40 positive staining in tubules to diagnose BKVAN
62168137|NCT01389609|EXPERIMENTAL|A|Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
62721131|NCT00245531||+IDU/+HIV or -HIV|
62721132|NCT00245531||-IDU and -HIV (controls)|
62721133|NCT00939107|EXPERIMENTAL|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
62721134|NCT00939107|ACTIVE_COMPARATOR|Spinal manipulation|Spinal manipulation in combination with information of clinical findings and advice about back care
62721135|NCT03942224|EXPERIMENTAL|Arm I (DId)|"INDUCTION: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2 and on days 1 and 15 of cycles 3-8, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.~MAINTENANCE: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
62721136|NCT03942224|EXPERIMENTAL|Arm II (DVd, DId)|"INDUCTION CYCLES 1-3: Patients receive dexamethasone IV and PO on days 1, 8, and 15, daratumumab IV on days 1, 8, and 15, and bortezomib subcutaneously (SC) on days 1, 4, 8, and 11. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~INDUCTION CYCLES 4-8: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1 and 15, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.~MAINTENANCE: Patients receive dexamethasone IV on day 1, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
62721137|NCT02726958||group M|patients who died or suffered from stroke, acute coronary syndrome, heart failure, complete atrioventricular block or life-threatening ventricular arrhythmias within 30 days after the procedure
62721138|NCT02726958||group T|other patients
62721139|NCT02558101|ACTIVE_COMPARATOR|Control invitation materials|Invitation materials and strategy mimicking those of existing UK screening programmes for other cancer types
62721140|NCT02558101|EXPERIMENTAL|Intervention invitation materials|A targeted, stepped and low information burden invitation strategy and materials, specifically designed to improve uptake by reducing barriers to participation among smokers from socioeconomically deprived backgrounds.
62721141|NCT03586271||trifocal lens|trifocal lens implantation(AT Lisa tri 839MP)
62721142|NCT03586271||bifocal lens 1|bifocal lens implantation(Diff-aay)
62721143|NCT03586271||bifocal lens 2|bifocal lens implantation(ReSTOR +3.0D)
62721144|NCT03586271||bifocal lens 3|bifocal lens implantation(ReSTOR +2.5D)
62721145|NCT02266563||Traumatic Brain Injury (TBI) Group|TBI subjects will have a history of one or more concussions and have a memory complaint and objective decline that is considered to be worse than others of the same age (in the absence of an acute medical event). Severity classifications of the subjects selected for past history of TBI will be based upon established criteria used in TBI research (i.e., traumatically induced physiologic disruption of brain function as indicated by at least one of the following: any period of loss of consciousness, any loss of memory for events immediately before or after the accident, any alteration in mental state at the time of the accident, focal neurologic deficits that may or may not be transient). TBI cases will be those with mTBI (single or multiple concussion). Most recent injury must have occurred at least 1 year prior to study enrollment.
62721146|NCT02266563||Mild Cognitive Impairment (MCI) Group|MCI Subjects will have MMSE scores between 24-30 (inclusive), a CDR of 0.5, have no depression, no history of TBI, and no dementia.
62721147|NCT02266563||Healthy Control Group|Healthy control subjects will have no self or informant-reported problems with cognition, no depression, no history of TBI, and no dementia.
62721148|NCT00540696|EXPERIMENTAL|darbepoetin alfa|
62721149|NCT05812326|EXPERIMENTAL|Treatment with AJMUC1--PD-1 knockout CAR-T cells|"Advanced breast cancer patients with positive MUC1 expression are the indications of this clinical study. Current conventional treatments are ineffective for these patients or there is no effective treatment plan available for them. No control group is established and a single arm design is used.~This clinical study is the first application of AJMUC1 in the clinical treatment of MUC1-positive advanced breast cancer patients. The main purpose is to assess the safety and feasibility of the product in clinical use. Therefore, according to the principle of 3+3 dose escalation design, this study explored the maximum tolerated dose of AJMUC1 for the treatment of MUC1-positive advanced breast cancer.~At the same time, the efficacy of AJMUC1 in the treatment of MUC1-positive advanced breast cancer will be observed and factors that could affect the safety and efficacy of the therapy will be exploringly evaluated."
62721150|NCT02067507|NO_INTERVENTION|Control|"LACDPH Site: CDC-developed small media in preferred language~AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation~Northeast Valley Health Corporation Site: Usual care"
62721151|NCT02067507|EXPERIMENTAL|Tailored education and referral|LACDPH Site: Tailored education and referral intervention administered at LACDPH Site
62721152|NCT02067507|EXPERIMENTAL|Staff training and patient reminders|Staff training and patient reminders administered at AltaMed Health Services Corporation Site
62721153|NCT02067507|EXPERIMENTAL|Clinic-level reminder systems|Clinic-level reminders administered at Northeast Valley Health Corporation Site
62739007|NCT03849053|EXPERIMENTAL|Mézières method|
61976665|NCT03036072|ACTIVE_COMPARATOR|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
61978190|NCT00862745|EXPERIMENTAL|Active|fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.
62168138|NCT01389609|EXPERIMENTAL|B|Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
62168139|NCT01389609|EXPERIMENTAL|C|Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
62721154|NCT05285228|ACTIVE_COMPARATOR|Control group: allocation to specific taste of fluoride varnish|allocation to specific taste of fluoride varnish
62721155|NCT05285228|EXPERIMENTAL|Test group: child chooses taste of fluoride varnish|child chooses taste of fluoride varnish before dental treatment
62721156|NCT05930080|EXPERIMENTAL|SKCPT group|
62721157|NCT05930080|ACTIVE_COMPARATOR|Celebrex group|
62721158|NCT05937529|EXPERIMENTAL|Daylight PDT + Cicaplast|Pretreatment with currettage. Metvix cream. Daylight PDT. Application of Cicaplast to test area immediately after dPDT. Cicaplast application twce daily for 14 days.
62721159|NCT05937529|ACTIVE_COMPARATOR|Daylight PDT|Pretreatment with currettage. Metvix cream. Daylight PDT. No post treatment.
62721160|NCT03443687|ACTIVE_COMPARATOR|Pelvic Floor Physical Therapy|If randomized to this arm, women will complete demographic forms and questionnaires. They will then undergo the intervention of 4 pelvic floor physical therapy visits over 3 months. At that time they will return for a follow up visit and complete questionnaires.
62721161|NCT03443687|EXPERIMENTAL|Home Biofeedback|If randomized to this arm, women will complete demographic forms and questionnaires. They will then be given a pelvic floor exercise device that is bluetooth linked to a smartphone application. They will be instructed on how to use the device daily for 3 months and their intervention will be to perform daily exercises with the device in place. At 3 months they will return for a follow up visit and complete questionnaires.
62721162|NCT06323070|ACTIVE_COMPARATOR|Low-fat cookies|Subjects consume 100 kcal of low-fat cookies daily for 4 weeks.
62721163|NCT06323070|EXPERIMENTAL|Watermelon|Subjects consume 100 kcal of watermelon daily for 4 weeks.
62721164|NCT06498115|EXPERIMENTAL|Norepinephrine Bolus|Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
62721165|NCT03911856|EXPERIMENTAL|Non-invasive assesment techniques|We hypothesize that non-invasive indices of right ventricular RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction pulmonary arterial hypertension and heart failure with preserved ejection fraction(PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
62721166|NCT03911856|EXPERIMENTAL|Efficacy of acute-oxygen therapy during exercise|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing pulse volume recording PVR, increasing RV functional reserve, increasing gas diffusion).
62721167|NCT03983330|EXPERIMENTAL|Intervention group|"The trained RA will deliver brief MI to each subject individually via WeChat or WhatsApp in the smart phones throughout the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once per 2-3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering message through WeChat or WhatsApp will be interactive, depended on subjects' actions and responses.~Start from 6 months, minimal messages by merely following the subjects' progress and responding to their questions to maintain contact will be provided to subjects till one-year follow-up.~The readiness of quitting smoking will be assessed at 3-month follow-up. For those who are willing to take further actions to promote their health, i.e. with an intention to quit smoking, health advice on smoking will be given with more emphasis on the health benefits of quitting. The whole intervention will be given through WeChat/WhatsApp."
62721168|NCT03983330|OTHER|Control group|Subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months
62721169|NCT06453031||Patient who underwent Gastric Ischemic Preconditioning Before Esophagectomy|Patient with operable esophageal cancer who underwent embolization of the left gastric artery prior to surgery
62721170|NCT00987714|EXPERIMENTAL|Protocolized Care|Algorithm to manage Pulse Pressure Variation, Cardiac Index, and Mean Arterial Pressure will be used in these donors.
62721171|NCT00987714|NO_INTERVENTION|Standard Care|This is the Organ Procurement Organization current practices.
62721172|NCT01446874|EXPERIMENTAL|Pre-operative brushing (Pilot Portion)|-Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
62721173|NCT01446874|EXPERIMENTAL|Pre-operative & Post-Operative Brushing (Esophageal Resection)|"* Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~* The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
62721174|NCT01446874|EXPERIMENTAL|Pre-operative & Post-Operative Brushing (Lung Resection)|"* Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~* The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
62721175|NCT03952208|EXPERIMENTAL|Concussion Group|Subjects diagnosed with concussion defined as a clinician-diagnosed disease by the International Classification of Diseases (ICD)-10 due to a head injury with a Glasgow Coma Score ≥13 undergoing a planned surgery/anesthetic standard of care will undergo neurocognitive testing pre and post surgery/anesthetic.
62721176|NCT03952208|EXPERIMENTAL|Matched Subjects Group|Matched subjects without concussion undergoing a planned surgery/anesthetic standard of care, matching for procedural type, sex, age ± 2 years, and adherence to the exclusion criteria will undergo neurocognitive testing pre and post surgery/anesthetic.
62721177|NCT03099473|EXPERIMENTAL|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
62168140|NCT05199597|EXPERIMENTAL|All participants|All participants will receive all four drops in randomized order
62168141|NCT04083690|ACTIVE_COMPARATOR|Standard CRT Programming, then ECG CRT Optimization|The control arm patients will have standard CRT programming for the first 6 months, and then will be reprogrammed based on the ECG CRT optimization information for the following 6 months
62168142|NCT04083690|EXPERIMENTAL|ECG CRT Optimization|The experimental arm patients will have CRT device reprogrammed based on the ECG CRT optimization information for 12 months.
62168143|NCT04357587|EXPERIMENTAL|Pembrolizumab|Experimental pembrolizumab and SOC external beam radiation and capecitabine
62549219|NCT05524337|EXPERIMENTAL|therapeutic touch group|"Therapeutic touch steps:~1. Before the application, explaining the study and the intervention to be applied to the mother, obtaining the consent of the mother to participate in the study, and filling the introductory information form will be done at this stage.~2. Immobile touching: Hands will be washed and warmed so that they do not disturb the baby. The researcher will support the babys back and hips with one hand, while holding the baby's chest and abdomen with the other hand. In the meantime, the nurse who will take the heel blood will start the process and continue to touch.~3. Compassionate touch: While the practitioners hands are in the same position; He would caress for 1 minute, rest his hands for 30 seconds, then caress again for 1 minute, rest his hands for 30 seconds, and finally continued to caress for 2 minutes. The caressing process was completed by touching it with circular movements of 1 cm diameter in a clockwise direction every 10 seconds."
62549220|NCT05524337|EXPERIMENTAL|therapeutic touch and white noise group|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time. Meanwhile, the data will be recorded on the form by the observer.
62549221|NCT05524337|NO_INTERVENTION|Control group|Non-pharmacological intervention will not be made for the baby in the control group,
62549222|NCT02310256|NO_INTERVENTION|Usual care|
62549223|NCT02310256|ACTIVE_COMPARATOR|Five Plus|Exercise training
62549224|NCT02852577|ACTIVE_COMPARATOR|Clonazepam|Treatment with clonazepam
62549225|NCT02852577|ACTIVE_COMPARATOR|Paroxetine|Treatment with paroxetine
62549226|NCT06408805||Patients with hereditary angioedema|Patients with documented diagnosis of hereditary angioedema due to C1 inhibitor deficiency with or without prophylactic treatment and aged between 18 and 65 years.
62549227|NCT06408805||Healthy individuals|Healthy individuals with an age between 18 and 65 and matched with patients with hereditary angioedema by age and gender.
62549228|NCT02587078|ACTIVE_COMPARATOR|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
62549229|NCT02587078|ACTIVE_COMPARATOR|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
62549230|NCT00658879||Somavert (Pegvisomant)|Patients taking Somavert (Pegvisomant).
62549231|NCT05637736|EXPERIMENTAL|Mindfulness-based Stress Reduction by Therapeutic VR|
62549232|NCT05637736|ACTIVE_COMPARATOR|mindfulness-based therapy|
62549233|NCT00753311|ACTIVE_COMPARATOR|Rizatriptan|Patients with migraine with and without aura will be enrolled and randomly provided with study drug (rizatriptan 10 mg MLT or placebo, ratio 1:1). Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
62549234|NCT00753311|PLACEBO_COMPARATOR|placebo|Patients who met all the study entry criteria were enrolled and randomly allocated to receive either rizatriptan 10 mg wafer or placebo (ratio 1:1).Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
62549235|NCT00426101|EXPERIMENTAL|Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids|"As compared to the HLH-94 treatment, the main changes are that~1. Cyclosporin A is administered from day 1 and~2. Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below."
62549236|NCT05662839|EXPERIMENTAL|Research Arm|Each group will undergo the same study procedures; Dermoscope Cytological brushing Complete questionnaire on experience of the cytological brushing SoC treatment
62549237|NCT02128321|EXPERIMENTAL|Isavuconazole + Repaglinide + Caffeine|Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16
62549238|NCT05154838||Patients with Pilonidal Abcess|All adult (18+) patients presenting at surgical assessment unit requiring treatment for pilonidal abscess. Wounds will be drained, cleaned and packed as per usual clinical practice. Extra standard wound swabs will be collected for additional microbiological analyses. Control wound dressings will be placed on adjacent, unaffected area of skin for 24 hours.
62549239|NCT02344082|NO_INTERVENTION|Standard of Care|The control arm will receive face-to-face pharmacy clinic visits per usual care.
62549240|NCT02344082|ACTIVE_COMPARATOR|Intervention Arm|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
62549241|NCT01323361|NO_INTERVENTION|Non-immunosupressed|Normal population
62549242|NCT05113784|EXPERIMENTAL|Meplazumab for Injection|First dose: 0.2 mg/kg - Day 1; Second dose: 0.2 mg/kg - Day 8
62549243|NCT05113784|PLACEBO_COMPARATOR|Placebo|First dose: control - Day 1; Second dose: control -Day 8
62549244|NCT02166658|EXPERIMENTAL|Single Arm|Patients receive Cabazitaxel 25 mg/m2 i.v. infusion. This trial is a single arm trial.
62549245|NCT01420965|ACTIVE_COMPARATOR|Arm A|Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)
62549246|NCT01420965|EXPERIMENTAL|Arm B|Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
61976666|NCT03036072|EXPERIMENTAL|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
61976667|NCT03256214|EXPERIMENTAL|Closed suction system|Patients in mechanical ventilation were aspirated with closed suction system.
61976668|NCT03256214|ACTIVE_COMPARATOR|Open suction system|Patients in mechanical ventilation were aspirated with open suction system.
61976669|NCT05560984|EXPERIMENTAL|study population|Women with previous one or more cesarean sections with placenta previa and focal accrete
62549247|NCT01420965|EXPERIMENTAL|Arm C|Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV \[first cycle only\] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
62549248|NCT03613233|ACTIVE_COMPARATOR|traditional glaucoma surgery|glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy
62549249|NCT03613233|ACTIVE_COMPARATOR|microinvasive glaucoma surgery (MIGS)|glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device
62549250|NCT06303531|ACTIVE_COMPARATOR|Eurofer|Ferrous Fumarate - 300 mg
62549251|NCT06303531|ACTIVE_COMPARATOR|FeraMAX|Polysaccharide Iron - 150mg
62549252|NCT06303531|ACTIVE_COMPARATOR|EBMfer|Ferrous Ascorbate - 100 mg
62549253|NCT04913142||control|patients not suffering from COVID-19 hospitalized in intensive care unit
62549254|NCT04913142||patients COVID-19|patients suffering from COVID-19 hospitalized in intensive care unit
62549255|NCT01843738|EXPERIMENTAL|All participants|
62549256|NCT02904941|EXPERIMENTAL|Amniotic Membrane Dressing|Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
62549257|NCT02904941|ACTIVE_COMPARATOR|Synthetic Dressing|Children allocated to this arm will receive skin dressings made out of silicone as part of their wound care. Dressings will be replaced every 72 - 96 hours.
62549258|NCT02796053|PLACEBO_COMPARATOR|Placebo|Placebo to TAB08
62549259|NCT02796053|EXPERIMENTAL|TAB08 Dose 1|Drug: TAB08 biologic
62549260|NCT00321178|EXPERIMENTAL|SR4/CR4|after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
62549261|NCT00321178|ACTIVE_COMPARATOR|SR8|standard treatment consisting of 8 weeks of streptomycin and rifampicin
62549262|NCT01061801|EXPERIMENTAL|Emotional expression, patient present|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the presence of the patient (one session).
62549263|NCT01061801|EXPERIMENTAL|Emotional expression, patient absent|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the absence of the patient (3 sessions).
62549264|NCT01061801|ACTIVE_COMPARATOR|Comparison|Caregivers are asked to talk about their plans for the upcoming week (time management, sessions 1 and 3) and positive aspects of their life (session 2).
62549265|NCT01769287||Surgical operation|The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.
62549266|NCT05771389|ACTIVE_COMPARATOR|Psoriatic arthritis|Patients meeting the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria
62549267|NCT05771389|ACTIVE_COMPARATOR|Axial spondyloarthritis|Patients meeting the ASAS classification criteria for axial spondyloarthritis
62549268|NCT05771389|PLACEBO_COMPARATOR|Healthy controls|Healthy people who do not have inflammatory conditions.
62549269|NCT00098605|EXPERIMENTAL|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62549270|NCT02463357|EXPERIMENTAL|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
62549271|NCT02463357|EXPERIMENTAL|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
62549272|NCT02463357|EXPERIMENTAL|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
62549273|NCT02463357|PLACEBO_COMPARATOR|Placebo|Sugar pill manufactured to look like all other investigational products
62549274|NCT02463357|EXPERIMENTAL|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
62549275|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
62549276|NCT02794727|SHAM_COMPARATOR|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
62549277|NCT02794727|ACTIVE_COMPARATOR|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
62549278|NCT02794727|NO_INTERVENTION|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
62549279|NCT01467440||PGA|Patients under glaucoma treatment with prostaglandines
62549280|NCT01467440||NON-PGA|Patient not recieving prostaglandines to treat their glaucoma
62549281|NCT04363957|OTHER|Standard Consent|Patients only receive the standard brachytherapy consent process
62549282|NCT04363957|EXPERIMENTAL|Standard Consent and Video Intervention|Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
62549283|NCT05560386|EXPERIMENTAL|Text messaging program|Enrolled participants received the pilot text messaging program.
62549284|NCT05560386|EXPERIMENTAL|Virtual peer education|Enrolled participants received a virtual peer education diabetes prevention program.
62549285|NCT01932866|ACTIVE_COMPARATOR|Control - diabetes risk score|the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
62549286|NCT01932866|EXPERIMENTAL|Intervention - diabetes risk score|the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
62549287|NCT00194779|EXPERIMENTAL|Treatment (neoadjuvant therapy, adjuvant therapy)|See Detailed Description.
62721178|NCT03099473|EXPERIMENTAL|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
62721179|NCT03099473|SHAM_COMPARATOR|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
62721180|NCT01227785||INCEPTA ICD and CRT-D|ICD and CRT-D indicated patients were included in the study. Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).
62721181|NCT01739894|EXPERIMENTAL|IP Paclitaxel|Paclitaxel will be administered intraperitoneally at 40mg/m2 on Days 1 and 8 in a 21-day cycle in patients receiving intravenous oxaliplatin 100mg/m2 on Day 1 and capecitabine 1000mg/m2 twice daily on Days 1-14.
62721182|NCT04326062|EXPERIMENTAL|Main Study|A pharmacist will join the practice team for six months.
62721183|NCT04326062|EXPERIMENTAL|PROM Study|A nested Patient Reported Outcome Measure (PROM) study will be undertaken during month four and five of the six-month intervention period to explore the impact of the intervention in older adults (aged ≥65 years).
62721184|NCT05458518|ACTIVE_COMPARATOR|Dressing removal at 24 hours|The wound dressing will be removed 24 hours after emergency cesarean delivery
62721185|NCT05458518|PLACEBO_COMPARATOR|Dressing removal at 48 hours|The wound dressing will be removed 48 hours after emergency cesarean delivery
62721186|NCT03771339|ACTIVE_COMPARATOR|Continuous Epidural Analgesia|Continuous epidural analgesia using ropivacaine 0.375% 3 mL boluses followed by ropivacaine 0.2% with rate 6 mL per hour for 24 hours
62721187|NCT03771339|EXPERIMENTAL|Bilateral Quadratus Lumborum Block|Bilateral Quadratus lumborum block using ropivacaine 0.2% 20 mL each injection after surgery
62721188|NCT00710983|ACTIVE_COMPARATOR|A|Oral polio vaccine
62721189|NCT00710983|NO_INTERVENTION|B|No oral polio vaccine
62721190|NCT04944615|EXPERIMENTAL|Intravascular ultrasound guidance|"All targeted CTO lesions will be examined and documented using a commercially available IVUS catheter (Opticross HD) according to its instructions (if not contraindicated, preoperative vasodilation with nitroglycerin to prevent spasm).~IVUS examination must be performed at least once before and after stent implantation."
62721191|NCT04944615|ACTIVE_COMPARATOR|Angiographic guidance|The patient will choose the appropriate length and diameter of the stent to be implanted by visual estimation. All commercially available drug-eluting stents (except first-generation DES, such as Taxus, Excel, Partner, Firebird, etc.) can be used. DES with high quality clinical evidence is strongly recommended. The type, diameter, and length of the stent are determined by the surgeon. The stent length should be selected to ensure complete coverage of the CTO lesion. If dissection is present, additional stents are implanted. Repeat angiograms were performed immediately after surgery in the same view as before surgery.
62721192|NCT01830348|ACTIVE_COMPARATOR|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
62721193|NCT01830348|PLACEBO_COMPARATOR|Vehicle gel|Vehicle gel comprising HEC with parabens
62721194|NCT02156193|EXPERIMENTAL|Prophylactic clip|Before conventional snare polypectomy, hemoclips will be applied on the base of stalk.
62721195|NCT02156193|ACTIVE_COMPARATOR|No prophylactic management|Conventional snare polypectomy will be performed without any preventive management.
62721196|NCT00002593|ACTIVE_COMPARATOR|5-FU/Leucovorin/Levamisole|levamisole hydrochloride: 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; leucovorin calcium: 20 mg/m\^2/day, IV, Days 1-5 of each cycle; 5-fluorouracil: 425 mg/m\^2/day, IV, Days 1-5 of each cycle;
62721197|NCT00002593|ACTIVE_COMPARATOR|Infusional 5-FU + Levamisole|levamisole hydrochloride : 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; 5-fluorouracil: 250 mg/m\^2/day, continuous infusion, daily for 56 days x 3 cycles of 8 weeks.
62721198|NCT02481193|EXPERIMENTAL|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
62721199|NCT02481193|EXPERIMENTAL|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg
62721200|NCT02481193|EXPERIMENTAL|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg
62721201|NCT02099396|EXPERIMENTAL|docetaxel+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out on the second day; q3wkb"
61978191|NCT00862745|PLACEBO_COMPARATOR|Control|placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.
62721202|NCT02099396|EXPERIMENTAL|gemcitabine+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with gemcitabine 675mg/m2 for 90 min is carried out on the first day and the eighth day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out; intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day; q3wkb"
62721203|NCT03521700|EXPERIMENTAL|Intensive lipid lowering group|10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L
62721204|NCT03521700|OTHER|Conventional lipid lowering group|5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L
62721205|NCT03736148|EXPERIMENTAL|Manual Manipulation|A single manual manipulation was applied to C3/C4 level, on the right side.
62721206|NCT03736148|ACTIVE_COMPARATOR|Instrument-assisted Manipulation|A single instrument-assisted manipulation was applied to C3/C4 level, on the right side.
62739008|NCT03849053|ACTIVE_COMPARATOR|Control Group|
61978192|NCT03143569|ACTIVE_COMPARATOR|aPTT nomogram|aPTT guided heparin management
62549288|NCT03751007|EXPERIMENTAL|AG019 Cohort 1 - Low Dose/Adults|
62549289|NCT03751007|EXPERIMENTAL|AG019 Cohort 2 - High Dose/Adults|
62549290|NCT03751007|EXPERIMENTAL|AG019 Cohort 3 - Low Dose/Adolescents|
62549291|NCT03751007|EXPERIMENTAL|AG019 Cohort 4 - High Dose/Adolescents|
62549292|NCT03751007|EXPERIMENTAL|Combination Cohort 1 - Adults|
62549293|NCT03751007|EXPERIMENTAL|Combination Cohort 2 - Adolescents|
62549294|NCT05531110|ACTIVE_COMPARATOR|Control arm|Bilateral Alcon SN60WF IOL insertion
62549295|NCT05531110|EXPERIMENTAL|Intervention arm|Bilateral Eyhance ICB00 IOL
62549296|NCT05326035|EXPERIMENTAL|Experimental： WJ05129 tablets|Twice daily (except for single dose), 12 hours apart, fixed time is recommended
62549297|NCT03362372|EXPERIMENTAL|INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING|During 2 years a nutritional intervention will be carried out to increase adherence to DiMet based on: annual visit of personalized nutritional education, a telephone contact for intervention reinforcement and computer access to a nutrition blog
62549298|NCT03362372|NO_INTERVENTION|CONTROL GROUP: WITHOUT CHANGES IN DIET|The participants of health centers will carry out the same 5 visits (3 individual visits and 2 phone calls), although no changes are induced in their usual diet and they will not be offered access to the nutritional blog.
62549299|NCT01017627|OTHER|Early anemia management|Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
62549300|NCT01017627|OTHER|case control|"Each case will be data-matched to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm."
62549301|NCT05338931|EXPERIMENTAL|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
62549302|NCT03414216|EXPERIMENTAL|Group1 - early off-loading surgery|"Within 1 week of randomization, offloading surgery:~Tip of toe ulcers will be treated by percutaneous tenotomy. Ulcers under metatarsal heads will be offloaded with minimally invasive floating metatarsal osteotomy.~Ulcers plantar to the interphalangeal joint of the hallux will be treated by a modified Keller resection arthroplasty."
62549303|NCT03414216|ACTIVE_COMPARATOR|Group 2 - off-loading in fiberglass cast|"Tip of toe ulcers and ulcers plantar to the interphalangeal joint of the big toe will be casted in a fiberglass cast with a heel, ending under the metatarsal heads, leaving the toes in the air.~Ulcers under metatarsal heads will be casted in a full foot fiberglass cast with a heel with a window below the ulcer designed to relieve pressure under the metatarsal heads."
62549304|NCT02481869|ACTIVE_COMPARATOR|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
62549305|NCT02481869|PLACEBO_COMPARATOR|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
62549306|NCT03708302|ACTIVE_COMPARATOR|Study Group|Ultrasound guided unilateral serratus plane block and unilateral parasternal infrapectoral block with 0.5% ropivacaine.
62549307|NCT03708302|SHAM_COMPARATOR|Control Group|Ultrasound guided unilateral serratus plane block and unilateral parasternal infrapectoral block with 0.9% saline.
62549308|NCT03893630|ACTIVE_COMPARATOR|Control Group|Patients will receive standard of care.
62549309|NCT03893630|EXPERIMENTAL|Acetylsalicylic Acid 81mg|Patients will receive low dose (81mg) acetylsalicylic acid (Aspirin).
62549310|NCT03893630|EXPERIMENTAL|Acetylsalicylic Acid 162mg|Patients will receive low dose (162mg) acetylsalicylic acid (Aspirin).
62549311|NCT03979755||Study Group|Women cancer survivors living in Campo Belo, Minas Gerais.
62549312|NCT03979755||Control Group|Women in routine follow-up in the public health system in Campo Belo, Minas Gerais.
62549313|NCT03759938|EXPERIMENTAL|Early initiation of DOAC|Early initiation of any direct oral anticoagulant (DOAC) at a dose licensed for stroke prevention in AF, within four days (96hrs) of onset of acute ischaemic stroke
62549314|NCT03759938|ACTIVE_COMPARATOR|Standard Initiation of DOAC|Standard initiation of any DOAC at a dose licensed for stroke prevention in AF, no sooner than day 7 and no later than day 14 after the onset of acute ischaemic stroke (i.e. between 144hrs and 336hrs from onset).
62549315|NCT05407311|EXPERIMENTAL|64Cu-SAR-BBN|Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-BBN.
62549316|NCT03650530|EXPERIMENTAL|The Family Talk Intervention|These families will participate in a psychosocial support program.
62549317|NCT01252277|EXPERIMENTAL|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
62721207|NCT03736148|PLACEBO_COMPARATOR|Placebo|A placebo manipulation was applied on C3/C4 level, on the right side. The neck of th subject was placed in the pre manipulative position but no thrust was made. Then, the cervical was replaced in neutral position.
62721208|NCT03736148|NO_INTERVENTION|Control|No contact was given to the subject.
62721209|NCT00560508|EXPERIMENTAL|Pramipexole Extended Release|patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -\> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
62721210|NCT00560508|ACTIVE_COMPARATOR|Pramipexole Immediate Release|patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -\> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
62721211|NCT06301503|EXPERIMENTAL|1. USG Guided Combined LPB-SNB with Isobaric Bupivacaine|"After completing the surgical procedure under spinal anaesthesia, participants are positioned in the lateral decubitus position with the side to be blocked facing upwards. Identification of the lumbar plexus nerves is carried out with ultrasound guidance using the trident approach. Under aseptic conditions, local anesthetic infiltration with 2% lidocaine (3ml)was given, and a lumbar plexus block (LPB) technique was performed by inserting a 100mm insulated nerve block needle through the transverse process, delivering a bolus of 0.25% isobaric bupivacaine (20ml).~Without changing the participant's position, the sciatic nerve is identified by the gluteal approach. After local anesthetic infiltration with 2% lidocaine (3ml), sciatic nerve block (SNB) was performed by inserting a 100 mm insulated nerve block needle to the sciatic nerve, delivering a bolus of 0.25% isobaric bupivacaine (20ml).~Aspiration is carried out before injecting anaesthetic agent on each puncture sites."
62721212|NCT06301503|ACTIVE_COMPARATOR|2. Control|Postoperatively, participants in this group was positioned in the lateral decubitus position and both the lumbar plexus and sciatic nerves were identified using ultrasound. Local anesthetic infiltration was given at both puncture sites, but participants of this group did not receive a combination of LPB-SNB with bupivacaine.
62721213|NCT02270229||Healthcare providers|
62721214|NCT02270229||PD patients|
62721215|NCT02270229||Primary caregivers of the PD patients|
62721216|NCT02270229||Laboratory personnel|
62721217|NCT05495438||ICU Clinicians|
62721218|NCT06246305|ACTIVE_COMPARATOR|Conventional physical therapy|The conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. In this phase, exercises are done of three sets with 10 repetitions per day. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance using TheraBand, and scapular stabilization exercises. During the off-brace and active mobilization phases, exercises are done of 3-5 sets of exercises with 10 repetitions per day.
62721219|NCT06246305|EXPERIMENTAL|Virtual reality (VR)|During the on-brace phase(0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. This program includes warming and cooling periods with posterior, anterior and inferior capsule stretching and pectoral muscle stretching. Exercise training includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. Resistance training is progressed in the active mobilization phase using TheraBand.
62721220|NCT02626169|ACTIVE_COMPARATOR|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
62721221|NCT02626169|ACTIVE_COMPARATOR|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
62721222|NCT05322278||Single Embryo Transfer|Single Embryo Transfer
62721223|NCT05322278||Double embryo transfer|
62721224|NCT05322278||3 embryo transfer|
62721225|NCT05322278||4 embryo transfer|
62721226|NCT06299592||Participants with asthma|
62721227|NCT06299592||Participants without asthma|
62721228|NCT04100408||Ancillary-Correlative (biospecimen collection)|LCH patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal brushing will be sequenced, genotyped, and analyzed.
62721229|NCT04300387|NO_INTERVENTION|customary care|customary care for CKD
62721230|NCT04300387|ACTIVE_COMPARATOR|multidisciplinary care|multidisciplinary team care for CKD
62721231|NCT04851574||Group I with dose of Sugammadex of 0.5 Mg/kg|After general anesthesia children received one dose of 0.5 Mg/kg of Sugammadex to reverse neuromuscular blockade.
62721232|NCT04851574||Group II with dose of Sugammadex of 1.0 Mg/kg|After general anesthesia children received one dose of 1.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
62721233|NCT04851574||Group III with dose of Sugammadex of 2.0 Mg/kg|After general anesthesia children received one dose of 2.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
62721234|NCT05040646||Patients|Patients who follow the watch-and-wait program for rectal cancer.
62721235|NCT05040646||Experts|Surgeons, radiotherapists, medical oncologist and other medical personnel who are involved in the treatment of rectal cancer and the watch-and-wait program.
62721236|NCT04304079|EXPERIMENTAL|ARssist system|The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist system used by the patient side surgeon.
62721237|NCT06154616|PLACEBO_COMPARATOR|Control|Subjects will consume 250 ml of milk half an hour before bedtime.
62721238|NCT06154616|EXPERIMENTAL|Ashw 250|Subjects will consume 250 ml of milk half an hour before bedtime.
62721239|NCT06154616|EXPERIMENTAL|Ashw 250 + TRP|Subjects will consume 250 ml of milk half an hour before bedtime.
62721240|NCT06154616|EXPERIMENTAL|Ashw 600|Subjects will consume 250 ml of milk half an hour before bedtime.
62721241|NCT04904367|ACTIVE_COMPARATOR|Deep tissue massage|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation(TENS) to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 Megahertz(MHz) and at a dosage of 1 w / cm2. Also, administered DTM to the back and neck region for 20 min in 12 sessions in addition to the conventional physical therapy.
62549318|NCT04464070|EXPERIMENTAL|niacin|"Blood (10 ml) will be drawn from the subject. Immediately before or after the blood draw the subject will collect a urine (3-10 ml) sample. After the baseline blood draw and the urine sample is collected the subject will take 500 mg of niacin. The niacin will not be an extended release formulation. Subjects will be encouraged to drink plenty of water during the study. Subjects are instructed to collect urine 1, 2, 4, 6, 8, and 10 hours after niacin administration. Subjects will collect their urine in separate plastic tubes that will be provided to them.~Approximately 1-2 h after niacin administration a second blood sample (10 ml) will be drawn from the subject."
62549319|NCT04464070|EXPERIMENTAL|niacin + low-dose aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of low-dose aspirin (81 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
61976670|NCT03645980|EXPERIMENTAL|DKN-01 300 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg , depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
62549320|NCT04464070|EXPERIMENTAL|niacin + regular-strength aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of regular-strength aspirin (325 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
62549321|NCT04464070|EXPERIMENTAL|deuterated PGD2|"Volunteers will come to the clinical research center. Volunteers will provide a urine sample. The volunteers will be fitted to record an electrocardiogram (ECG) and blood pressure. ECG will be recorded continuously. Blood pressure will be taken at baseline and every 10 minutes thereafter for one hour. The solution with deuterated PGD2 (10 microgram) will be infused over the course of 30 min. Volunteers will be monitored for 1 h after the end of the infusion, and volunteers will start collecting urine in intervals up to 10 h.~Infusion of the deuterated PGD2 solution will be performed in the presence of a physician. The injection solution will be prepared by Vanderbilt University Medical Center (VUMC) Investigational Drug Services. The solution will be sterile and pyrogen free."
62549322|NCT00378573|EXPERIMENTAL|docetaxel, gemcitabine and bevacizumab|Single arm treatment with docetaxel, gemcitabine and bevacizumab
62549323|NCT00447876|EXPERIMENTAL|Botulinum type A toxin (Dysport®)|
62549324|NCT00447876|PLACEBO_COMPARATOR|Placebo|
62549325|NCT03389516|ACTIVE_COMPARATOR|Polymem breast pads|
62549326|NCT03389516|ACTIVE_COMPARATOR|Lanolin|
62549327|NCT05412953|EXPERIMENTAL|Supportive care (tonation breathing techniques, questionnaire)|Patients participate in tonation breathing techniques twice daily (or more if pain occurs) for 2 weeks. Patients also complete questionnaire at baseline and at 2 weeks.
62549328|NCT02850185|EXPERIMENTAL|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
62549329|NCT02850185|EXPERIMENTAL|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
62549330|NCT04207307|EXPERIMENTAL|Multimodal exercise intervention|Behavioral: Multimodal exercise intervention with machine-based resistance, coordination and endurance training, 1-2 times per week for 30-45 min (increasing amount of training).
62549331|NCT04207307|SHAM_COMPARATOR|Usual Care|General recommendations for healthy ageing, usual physical activity. No machine-based strength training intervention.
62549332|NCT00022113|EXPERIMENTAL|Treatment (cilengitide)|Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
62549333|NCT05600673|EXPERIMENTAL|Bimatoprost + CO2|Each patient received three CO2 fractional laser sessions 3 weeks apart with immediate and subsequent daily Bimatoprost 0.03%,1 drop for each 1cm².
62549334|NCT05600673|ACTIVE_COMPARATOR|CO2|Each patient received only three CO2 fractional laser sessions 3 weeks apart
62549335|NCT01082497|EXPERIMENTAL|Mindfulness|
62549336|NCT01082497|ACTIVE_COMPARATOR|Education|8 - weekly workshops on affect consciousness for all staff
62549337|NCT05098847|EXPERIMENTAL|Cryoablation in combination with Sintilimab plus lenvatinib|
62549338|NCT05870059|EXPERIMENTAL|propolis|5 ml of 20% propolis mouthwash twice a day.
62549339|NCT05870059|ACTIVE_COMPARATOR|chlorhexidine|5 ml of 0.2% chlorhexidine mouthwash twice a day.
62549340|NCT01047527|ACTIVE_COMPARATOR|8 weeks transdermal nicotine|8 weeks of transdermal nicotine
62549341|NCT01047527|ACTIVE_COMPARATOR|24 weeks transdermal nicotine|24 weeks of transdermal nicotine
62549342|NCT01047527|EXPERIMENTAL|52 weeks transdermal nicotine|52 weeks of transdermal nicotine
62549343|NCT05963724|EXPERIMENTAL|Real-Time Computer Aided Detection|
62549344|NCT05963724|ACTIVE_COMPARATOR|Standard Colonoscopy|
62549345|NCT02658760|EXPERIMENTAL|Bupivacaine|30cc of 0.25% bupivacaine
62549346|NCT02658760|ACTIVE_COMPARATOR|Dexmedetomidine and bupivacaine|30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine
62549347|NCT01581125|EXPERIMENTAL|Sleep:wake 2|Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
62549348|NCT01581125|EXPERIMENTAL|Sleep:wake 1|Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
62549349|NCT04778904|EXPERIMENTAL|Group 1 (MVA-HBV)|Day 0: MVA-HBV 1 x 10\^8 pfu IM injection Day 28: MVA-HBV 1 x 10\^8 pfu IM injection
62549350|NCT04778904|EXPERIMENTAL|Group 2 (ChAdOx1-HBV, MVA-HBV)|Day 0: ChAdOx1-HBV 1 x 2.5 10\^10 vp IM injection Day 28: MVA-HBV 1 x 10\^8 pfu IM injection
62549351|NCT04778904|EXPERIMENTAL|Group 3 (ChAdOx1-HBV, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10\^10 vp IM injection Day 28: MVA-HBV 1 x 10\^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
62721242|NCT04904367|EXPERIMENTAL|Conventional physiotherapy|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
62721243|NCT00222976|EXPERIMENTAL|1|A Naproxen PO + placebo PR
62721244|NCT00222976|EXPERIMENTAL|2|B Placebo PO + Naproxen PR
62721245|NCT05073939|EXPERIMENTAL|Oral Oxytocin|Oxytocin orally (24 IU)
62721246|NCT05073939|PLACEBO_COMPARATOR|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
62721247|NCT02234440|EXPERIMENTAL|Metformin|Metformin- 500 mg once daily as a starting dose, can be escalated to 2 g/day to control diabetes
62721248|NCT02234440|ACTIVE_COMPARATOR|Insulin|
62721249|NCT02271529|EXPERIMENTAL|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
62721250|NCT02712996|ACTIVE_COMPARATOR|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
62721251|NCT02712996|PLACEBO_COMPARATOR|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
62721252|NCT02546882|EXPERIMENTAL|stromal vascular fraction|The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).
62721253|NCT02546882|PLACEBO_COMPARATOR|saline|1 ml saline without cells will be used as placebo.
62721254|NCT03578250|EXPERIMENTAL|Study Group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will apply error augmentation force-field to perturbate the arm of the participant away from the straight trajectory line."
62721255|NCT03578250|EXPERIMENTAL|Control group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will not apply any perturbations on the participant's arm."
62721256|NCT00177918||lung transplant patients|
62721257|NCT03289143|EXPERIMENTAL|Dose 1 Semorinemab|
62721258|NCT03289143|EXPERIMENTAL|Dose 2 Semorinemab|
62721259|NCT03289143|EXPERIMENTAL|Dose 3 Semorinemab|
62721260|NCT03289143|PLACEBO_COMPARATOR|Placebo|
62721261|NCT01871025|EXPERIMENTAL|Hospital and home exercise training|Usual care plus hospital exercise training (aerobic and strength) followed by exercise training at home until 30 days to discharge.
62721262|NCT01871025|OTHER|Usual care|Usual care in COPD
62721263|NCT01892371|EXPERIMENTAL|Phase 1 Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62721264|NCT01892371|EXPERIMENTAL|Phase 1 Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62721265|NCT01892371|EXPERIMENTAL|Phase 2 Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62721266|NCT01892371|EXPERIMENTAL|Phase 2 Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62721267|NCT04476758||Fungal Infection Group|Have had a fungal species isolated from sputum and/or BAL culture on \>= 2 separate occasions in the 18 months preceding study visit and do not have a diagnosis of ABPA (N=10).
62721268|NCT04476758||Control Group|Have never previously isolated fungus from sputum, BAL, or OP swab (N=10).
62721269|NCT04476758||ABPA Group|"Previous diagnosis of ABPA as defined by CFF guidelines, regardless of the amount of fungal infection or history thereof.~• ABPA Minimum diagnostic criteria per CFF: Acute or subacute deterioration, total serum IgE \> 500 IU per mL, immediate cutaneous reactivity to Aspergillus or in vitro IgE antibody to A. fumigatus, and either a new or recent chest imaging change that has not responded to antibiotics and standard physiotherapy OR precipitin to A. fumigatus or IgG antibody to A. fumigatus1 (N=5). Culture positive sputum is not required for ABPA diagnosis and is not taken into account for the diagnosis per CFF guidelines."
62721270|NCT05309044|ACTIVE_COMPARATOR|Planetary Health Diet Group|Diet proportional to the EAT-Lancet reference diet, in addition to a behavioral change protocol.
62721271|NCT05309044|ACTIVE_COMPARATOR|Low-fat diet group|Low-fat, low-calorie diet and a behavioral change protocol
62721272|NCT05309044|PLACEBO_COMPARATOR|Waiting list group|Waiting list group
62721273|NCT05305898|EXPERIMENTAL|Metformin group|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
62721274|NCT05305898|NO_INTERVENTION|No metformin group|"Patients form no metformin group will be observed for 2 years and 6 months, which cover the same period like for patients from metformin group."
62721275|NCT05595850|EXPERIMENTAL|Mindfulness|Three-week online mindfulness course followed by one-month social community online interaction.
62721276|NCT05595850|ACTIVE_COMPARATOR|Mindful Learning|Three-week online mindful learning course followed by one-month social community online interaction
62721277|NCT05745649|EXPERIMENTAL|Group A|Resistive exercise
62721278|NCT05745649|ACTIVE_COMPARATOR|group B|Ankle weights
62721279|NCT01226303|EXPERIMENTAL|standard risk|are defined as those patients with a WBC less than 10x10 9 /L at presentation
62721280|NCT01226303|ACTIVE_COMPARATOR|high risk|are defined as those patients whose highest treatment WBC is equal to or greater than 10x10 9 /L at presentation
62721281|NCT06316726|ACTIVE_COMPARATOR|intervention A|full bed silicone mattress plus other measures
61978193|NCT03143569|EXPERIMENTAL|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
62721282|NCT06316726|NO_INTERVENTION|intervention B|full bed silicone mattress plus usual care
62721283|NCT04144114|EXPERIMENTAL|Whey + ProHydrolase®|Subjects received 250mg of ProHydrolase® along with 25g of whey protein mixed in a drink every visit for 4 weeks
62721284|NCT04144114|ACTIVE_COMPARATOR|Whey|Subjects received 25g whey protein in a drink every visit for 4 weeks
62721285|NCT04144114|PLACEBO_COMPARATOR|Placebo|Subjects received 25g maltodextrin in a drink every visit for 4 weeks
62721286|NCT02133469|EXPERIMENTAL|PCV7 (Vaccine)|Randomized group of 1634 subjects to be administered a single dose of PCV7 (Hib vaccine offered at end of study).
62721287|NCT02133469|ACTIVE_COMPARATOR|Hib vaccine|Randomized group of 1634 subjects to be administered a single dose of Hib Vaccine(PCV7 vaccine offered at end of study).
62721288|NCT06718738|EXPERIMENTAL|IM96 CAR-T Cells|After preconditioning with chemotherapy, IM96 CAR-T Cells will be evaluated
62721289|NCT05055076||PODEYE TORIC|Adult patients who have undergone cataract surgery with mono- or bilateral implantation of POD EYE TORIC IOL (POD T 49P) and who meet all the inclusion and exclusion criteria will be invited to participate in the study.
62721290|NCT02172014|EXPERIMENTAL|Fentanyl|midazolam and fentanyl citrate infusion
62721291|NCT02172014|PLACEBO_COMPARATOR|Control|midazolam and normal saline infusion
62721292|NCT00994903|PLACEBO_COMPARATOR|Placebo|Placebo tablets (Inert calcium lactate)
62721293|NCT00994903|EXPERIMENTAL|Simvastatin|40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
62721294|NCT00469833|EXPERIMENTAL|Arm 1|Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).
62721295|NCT01030822|EXPERIMENTAL|Group A|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
62721296|NCT01030822|EXPERIMENTAL|Group B|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
62721297|NCT01030822|EXPERIMENTAL|Group C|Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.
62721298|NCT04601129||patients|undergoing a minimally invasive nephrectomy, eligible to an Enhanced Recovery After Surgery Program.
62721299|NCT02032576|EXPERIMENTAL|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
62721300|NCT04578626|EXPERIMENTAL|dry needling group|Dry needling treatment on right or left side of the face (depending on randomization)
62721301|NCT04578626|NO_INTERVENTION|control group|No treatment on left or right side of the face (depending on randomization)
62721302|NCT06715020|EXPERIMENTAL|68Ga-TTP|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-TTP PET scans
62721303|NCT03601390||PET/CT and EBV DNA|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT protocol 12 weeks after the end of IMRT (primary endpoint).Plasma EBV DNA test will be performed 4, 12, 24 weeks after the end of IMRT. In patients with negative PET/CT results, 2 follow-up visits are required to complement nasopharyngoscope examination and plasma EBV DNA test in the frist year. All patients will undergo annual PET/CT or traditional follow-up examination and plasma EBV DNA test 1 year after completing chemoradiation unless recurrent/residual disease is histopathologically-confirmed.
62721304|NCT06716853|EXPERIMENTAL|Pembrolizumab cohort|At D+30 after Temferon, patients will start to receive pembrolizumab providing they have not received ICI in the 6 months prior to entry into the study. Patients allocated to pembrolizumab will receive pembrolizumab 400mg IV every 6 weeks commencing at D+30.
62721305|NCT06716853|EXPERIMENTAL|Cabozantinib cohort|At D+30 after Temferon, in the event that a patient has received ICI in the 6 months prior to study entry and in case PD occurs (as assessed at D+30 or at subsequent visits), they will be receiving cabozantinib. Patients allocated to cabozantinib cohort will initiate treatment with 40mg QD
62721306|NCT05495880|EXPERIMENTAL|Forearm-supported|forearm-supported head extension during direct laryngoscopy
62721307|NCT05495880|ACTIVE_COMPARATOR|Control|without forearm-support for head extension during direct laryngoscopy
62721308|NCT00200967|EXPERIMENTAL|B16 Arg/Arg|B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
62721309|NCT00200967|EXPERIMENTAL|B16 Gly/Gly|B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
62721310|NCT03257358|OTHER|Cohort 1|RMS patients who were newly prescribed commercially available fingolimod 0.5mg per day
62721311|NCT03257358|OTHER|Cohort 2|RMS patients who had been on commercially available fingolimod 0.5mg per day continuously for ≥ 2 years
62721312|NCT04935255||Single Arm|The participating patients are treated according to local standard treatment (consisting of etoposide 100mg/m2 and cisplatin 20 mg/m2 during 5 consecutive days). Anti-emetic treatment with aprepitant will be given during days 3 to 7.
62721313|NCT02868424|EXPERIMENTAL|fRPE cells|Subretinal transplantation of fRPE cells in experimental eye
61976671|NCT03645980|EXPERIMENTAL|DKN-01 600 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
62721314|NCT05389748|PLACEBO_COMPARATOR|Placebo|Placebo which appears the same as the treatment to investigators, clinicians and subjects.
62721315|NCT05389748|ACTIVE_COMPARATOR|NanO2|A milky white intravenous injectable emulsion
62721316|NCT01213082|EXPERIMENTAL|24GyE + anti-VEGF|
62721317|NCT01213082|EXPERIMENTAL|16GyE + anti-VEGF|
62721318|NCT01213082|SHAM_COMPARATOR|Sham Irradiation + anti-VEGF|
62721319|NCT03975153|EXPERIMENTAL|guselkumab treatment|Treatment with guselkumab for 20 weeks
62721320|NCT03226847|EXPERIMENTAL|Pulmonary Vein Isolation|ablation
62721321|NCT03727035||Group I|Group I :40 Generalized chronic periodontitis subjects without type II diabetes mellitus
62721322|NCT03727035||Group II|Group II: 40 Generalized chronic periodontitis subjects diagnosed with type II diabetes mellitus
62721323|NCT02044679|EXPERIMENTAL|A = Increase water intake 1|+ 1,5 to 2,0 L/day of water
62721324|NCT02044679|EXPERIMENTAL|B = Increase water intake 2|+ 1,0 to 1,5 L/day of water
62721325|NCT02044679|OTHER|C = no change|No change
62721326|NCT03533660|ACTIVE_COMPARATOR|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
62721327|NCT03533660|ACTIVE_COMPARATOR|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
62721328|NCT05465148||ASD|Individuals with Autism Spectrum Disorder indicated by medical records, self diagnosis, or reported by a legally authorized representative. Individuals may be of any age, however, minors (under the age of 18 years) will be required to provide the assent form or a parental permission form, in addition to the Informed Consent Form signed by the parents/guardians prior to any study related activities.
62721329|NCT00414570|EXPERIMENTAL|[18]F-FLT PET scan|Radioactive dose of 2.59 MBq/kg (range 100 - 350 MBq) \[18\]F-FLT per injection prior to Positron Emission Tomography (PET) imaging. \[18\]F-FLT PET scans at baseline/pre-treatment and at disease progression, up to a maximum of two separate \[18\]F-FLT PET scans per participant.
62721330|NCT01643057||Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
62721331|NCT06270238|EXPERIMENTAL|High-Frequency1|"Confirmed responses in TMS-induced MEP: Preserved ipsilateral corticospinal tract.~High-frequency rTMS over ipsilateral primary motor cortex will be applied."
62721332|NCT06270238|ACTIVE_COMPARATOR|cTBS1|"Confirmed responses in TMS-induced MEP: Preserved ipsilateral corticospinal tract.~continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied."
62721333|NCT06270238|EXPERIMENTAL|High-Frequency2|"Absent responses in TMS-induced MEPs, but confirmed corticospinal tract integrity in DTI; Preserved ipsilateral alternative corticospinal tract.~High-frequency rTMS over ipsilateral premotor cortex will be applied."
62721334|NCT06270238|ACTIVE_COMPARATOR|cTBS2|"Absent responses in TMS-induced MEPs, but confirmed corticospinal tract integrity in DTI; Preserved ipsilateral alternative corticospinal tract.~continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied."
62721335|NCT06270238|EXPERIMENTAL|High-Frequency3|"Absent responses in all ipsilateral corticospinal tract.~High-frequency rTMS over contralateral primary motor cortex will be applied."
62721336|NCT06270238|ACTIVE_COMPARATOR|cTBS3|"Absent responses in all ipsilateral corticospinal tract.~continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied."
62721337|NCT05214352||young population with cerebral palsy-Families-Therapist and researchers|The principal group is designed by all people who composed the research and who will work together in the intervention manual elaboration on the participation in the community.
62721338|NCT04800393|EXPERIMENTAL|Inhalation anesthesia|
62721339|NCT04800393|ACTIVE_COMPARATOR|Total intravenous anesthesia|
62721340|NCT01265017|EXPERIMENTAL|Active Treatment|"interventions include Estradiol, medroxyprogesterone, hydrocortisone, GH as follows~* Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection"
62721341|NCT01265017|PLACEBO_COMPARATOR|Placebo|Matching placebo
62721342|NCT03186105|EXPERIMENTAL|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days.
62721343|NCT00052910|ACTIVE_COMPARATOR|Arm I|Patients receive leucovorin calcium IV and fluorouracil (5-FU) IV on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
62721344|NCT00052910|EXPERIMENTAL|Arm II|Patients receive epirubicin IV over 3-15 minutes and cisplatin IV over 1 hour on day 1 and 5-FU IV continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
62721345|NCT00878267||Interview|
62721346|NCT01723969||Colo-rectal cancer|Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
62721347|NCT01103856|EXPERIMENTAL|Patient Mentor Intervention|The patient mentor intervention from TSHC has been adapted to the inpatient setting. Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
62721348|NCT01103856|PLACEBO_COMPARATOR|HIV transmission risk reduction|Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor. We will use a modified version of the RESPECT intervention for our attention control group. Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
62721349|NCT06569121|NO_INTERVENTION|Wait List Control (WLC)|Participants randomized to the wait list control (WLC) will begin the telehealth Group Lifestyle Balance for People post stroke (tGLB-CVA) intervention 6 months after enrolling into the study and completing a baseline assessment.
62737697|NCT06301516|OTHER|Comparative Control|Participants enrolled into the comparative control group will complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others
62721350|NCT06569121|EXPERIMENTAL|Telehealth Group LIfestyle Balance for People with Stroke (tGLB-CVA)|The telehealth Group Lifestyle Balance for People post stroke (tGLB-CVA) is a one-year program with 22 sessions. The tGLB-CVA is a modification of the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) developed by the University of Pittsburgh Diabetes Prevention Support Center (DPSC). It begins with 12 weekly sessions called the Core Program, followed by a Transition phase consisting of 2 bi-weekly and 2 monthly sessions, and a Support Phase consisting of 6 monthly sessions. The goal of the tGLB-CVA program is to help the participant achieve and maintain a 5-7% weight-loss through healthy eating and physical activity.
62721351|NCT05518006|EXPERIMENTAL|PreMama Balance|"Each day, the participants will take 1 packet of Premama Balance, dissolved in one glass (8oz+) of water. Premama Balance may be taken with or without food. Should participants present themselves with a sensitive stomach, it is recommended to take the drink with or after a meal to avoid an upset stomach. Participants will repeat this process daily for 6 months/24 weeks (study period) until the study is complete.~At week 12 and in week 24, the participants will take a survey and a hormone test to track progress. In total there will be 3 surveys and 3 hormone tests. Additionally, participants will fill out a weekly consumption survey to track compliance."
62721352|NCT05518006|PLACEBO_COMPARATOR|Placebo Drink|"Each day, the participants will take 1 packet of Placebo Drink, dissolved in one glass (8oz+) of water. Placebo Drink may be taken with or without food. Should participants present themselves with a sensitive stomach, it is recommended to take the drink with or after a meal to avoid an upset stomach. Participants will repeat this process daily for 6 months/24 weeks (study period) until the study is complete.~At week 12 and in week 24, the participants will take a survey and a hormone test to track progress. In total there will be 3 surveys and 3 hormone tests. Additionally, participants will fill out a weekly consumption survey to track compliance."
62721353|NCT01634217|EXPERIMENTAL|Cohort 1|Administered 3 x 10\^6 iTregs/kg infusion
62721354|NCT01634217|EXPERIMENTAL|Cohort 2|Administered 3 x 10\^7 iTregs/kg infusion
62721355|NCT01634217|EXPERIMENTAL|Cohort 3|Administered 3 x 10\^8 iTregs/kg infusion
62721356|NCT01634217|EXPERIMENTAL|Cohort 4|Administered 10 x 10\^8 iTregs/kg infusion
62721357|NCT01634217|EXPERIMENTAL|Cohort 5 Extension|Administered 10 x 10\^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
62721358|NCT03974074|EXPERIMENTAL|Albumin infusion group|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
62721359|NCT03974074|NO_INTERVENTION|Empty control|Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
62721360|NCT00552071|EXPERIMENTAL|Ultrasound-guided IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months.
62721361|NCT00552071|ACTIVE_COMPARATOR|Regular IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via regular IM gluteal injections every 28 days for 3 months
62721362|NCT04176107|OTHER|Study group- video+questionnaire|"The study group will be exposed to a video at admission to an elective cesarean delivery. The video will have information regarding the admission, pre-operation preparation and post- operation recovery.~All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate the impact of exposure to informative video before caesarean delivery on anxiety and stress measured by State-Trait Anxiety Inventory (STAI)."
62721363|NCT04176107|NO_INTERVENTION|Control group- questionnaire only|All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate anxiety and stress measured by State-Trait Anxiety Inventory (STAI) without intervention.
62721364|NCT05002348|EXPERIMENTAL|Acupoint Laser Group|In the experimental group, the laser pen was turned on, and the acupoint stimulation was performed for about 3-5 minutes. Each acupoint was performed once a day. The patient wore goggles and observed the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
62721365|NCT05002348|NO_INTERVENTION|control group|In the control group, the laser pen does not turn on the energy. The acupoint stimulation is performed for about 3-5 minutes, and each acupoint is performed once a day. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
62737698|NCT00842283||dermatologic diseases|skin tissue sample
62737699|NCT00118638|EXPERIMENTAL|Darbepoetin alfa 500 mcg - Group A|
62737700|NCT00118638|ACTIVE_COMPARATOR|Darbepoetin alfa 2.25 mcg/kg - Group B|
61976672|NCT02969304||Off-Label|Any DMF prescription for MS patients \<18 years of age, or for patients diagnosed with non-MS indications, such as psoriasis.
61976673|NCT02969304||On-Label|Prescriptions for patients who are ≥18 years of age and diagnosed with MS
61976674|NCT01899794|ACTIVE_COMPARATOR|TVT-O|mid-urethral sling
61976675|NCT01899794|ACTIVE_COMPARATOR|Oxytrol|medication
62721366|NCT05065801|EXPERIMENTAL|GABRINOX|"* D1, D8 and D15 GEMBRAX: Albumin bound paclitaxel 125mg / m² followed by Gemcitabine 1000mg / m² followed by 2 weeks of rest~* D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over 46h at 2400mg / m² followed by 2 weeks of rest"
62721367|NCT05065801|ACTIVE_COMPARATOR|FOLFIRINOX|D1, D15, D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400mg / m², 5-fluorouracil 400mg / m² as a bolus followed by continuous administration over 46h at 2.400mg / m² followed by 2 weeks of rest.
62721368|NCT02035514|EXPERIMENTAL|Arm 1|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.
62721369|NCT02035514|EXPERIMENTAL|Arm 2|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0.
62721370|NCT01912573|EXPERIMENTAL|Intranasal (IN) naloxone|Intranasal (IN) naloxone as initial response to suspected opioid overdose
62721371|NCT01912573|ACTIVE_COMPARATOR|Standard of Care (TAU)|Standard of care (intravenous \[IV\], intramuscular \[IM\] or intraosseus \[IO\]delivery of naloxone) as initial response to suspected opioid overdose.
62721372|NCT02077231|EXPERIMENTAL|vitamin A palmitate eye gel|0.1% vitamin A palmitate; Sinqi, Shenyang, China
62721373|NCT02077231|EXPERIMENTAL|carbomer eye gel|0.2% Carbomer 940; Bausch \& Lomb, Aschheim, Germany
62721374|NCT01887405|ACTIVE_COMPARATOR|Adrenaline: Session 1 Jext, 2 Epipen|Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
62721375|NCT01887405|ACTIVE_COMPARATOR|Adrenaline: Session 1 Epipen, 2 Jext|Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
62721376|NCT01482195|EXPERIMENTAL|Subretinal Injection of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|Single arm of 6 patients undergoing subretinal injection of Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus. Each patient received the injection in one eye.
62721377|NCT01482195|NO_INTERVENTION|fellow eye without intervention|fellow eye without intervention
62721378|NCT03789292|EXPERIMENTAL|CT-P17 Subcutaneous(SC) (adalimumab)|CT-P17 SC (adalimumab)
62721379|NCT03789292|ACTIVE_COMPARATOR|Humira SC (adalimumab)|Humira SC (adalimumab)
62721380|NCT01102738||Premature babies (<32 weeks)|All premature babies born at less than 32 completed weeks gestation who are admitted to an Imperial College NHS Healthcare Trust Neonatal Intensive Care Unit (St. Mary's Hospital or Queen Charlotte's \& Chelsea Hospital), and whose parents/guardians have given their consent will be eligible to enter the study.
62721381|NCT01998061|EXPERIMENTAL|Arm A|TKI alone until rapid progression
62721382|NCT01998061|EXPERIMENTAL|Arm B|TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.
62721383|NCT04199585|EXPERIMENTAL|Cohort A: single-ascending oral dose|Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
62721384|NCT04199585|EXPERIMENTAL|Cohort B: (fasting/fed conditions)|"Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.~B1: fed-fasting-fasting condition (spiked dosage)~B2: fasting-fed-fasting condition (spiked dosage)~B3: fasting-fasting-fed condition"
62721385|NCT04144777|EXPERIMENTAL|Treatment|Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.
62721386|NCT04144777|NO_INTERVENTION|Placebo|Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.
62721387|NCT01727388|EXPERIMENTAL|lateral decubitus|The digital rectal examination is performed in lateral decubitus i.e. curled up position . The patient in left lateral decubitus if the examiner is right handed and right lateral decubitus if the examiner is left handed.
62721388|NCT01727388|ACTIVE_COMPARATOR|supine decubitus|The digital rectal examination is performed supine, spread legs, feet on the examination table. The examiner is in the patient's right side if he is right handed and in the patient's left side if he is left-handed.
62721389|NCT05090618||Experimental group:|Patients with Heart Attack
62721390|NCT05090618||Control group|Patients without Heart Attack
62721391|NCT06447766|EXPERIMENTAL|Nutrition Education Videos|Receive weekly nutrition education videos about evidence-based parental feeding practices and food assistance programs.
62721392|NCT01308840|EXPERIMENTAL|Panitumumab|Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
62721393|NCT01341743|ACTIVE_COMPARATOR|A|oral entecavir 1mg daily for 104 weeks
62721394|NCT01341743|ACTIVE_COMPARATOR|B|oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
62721395|NCT01341743|ACTIVE_COMPARATOR|C|oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
62721396|NCT01464749|EXPERIMENTAL|Task-oriented circuit class training|"Functional Circuit include 6 different work-stations in which patients exercise for 5 minutes in each one : 3 minutes exercises and 2 minutes rest. Total training takes about 30 minutes (2 laps/session over 60 minutes).~Walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary.~It is a progressive circuit and subjects, while exercising, receives feedback (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One task oriented session may include up to 3 patients and lasts 120 minutes. At the end of the 2 weeks an exercises brochure will be given to patients so that they can independently train for 3 month. Independent home training takes about 90 minutes."
62721397|NCT01464749|ACTIVE_COMPARATOR|Usual Care|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement (usual care). At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) or do physical rehabilitation in rehabilitative gyms not directly addressed to gait, mobility or balance training such as stretching exercises, active and passive mobilization and Bobath neurorehabilitation or similar.
62721398|NCT00003869|EXPERIMENTAL|Arm I (CAI)|Patients receive oral carboxyamidotriazole daily.
61976676|NCT04988711|EXPERIMENTAL|Hb Oxymeter|Hb mesurment
62721399|NCT00003869|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive oral placebo daily
62721400|NCT00510757||Males|
62721401|NCT00510757||Females|
61976677|NCT05641233|EXPERIMENTAL|Intervention arm|
62721402|NCT06054399|EXPERIMENTAL|Audiovisual educational intervention|Audiovisual educational intervention will be apply within 3 moments of the pregnancy pf patients.
62721403|NCT05784818|EXPERIMENTAL|Intervention + No Booster|This arm will have n=67 participants. The Up To Me behavioral intervention will be administered via 2-hour sessions over three consecutive weeks. During these sessions, participants will complete worksheets from the Up To Me workbook.
62721404|NCT05784818|EXPERIMENTAL|Intervention + Booster|This arm will have n=67 participants. The Up To Me behavioral intervention will be administered via 2-hour sessions over three consecutive weeks. During these sessions, participants will complete worksheets from the Up To Me workbook. Additionally, participants randomized to this arm will complete an additional session 4 weeks after the third session of the intervention.
62721405|NCT05784818|NO_INTERVENTION|Waitlist Control|"This arm will have n=67 participants. Those randomized to this arm will be engaged in treatment as usual, participating in the same services and activities that they were engaged with prior to recruitment into the study."
62721406|NCT03842046|ACTIVE_COMPARATOR|phenylephrine infusion|phenylephrine infusion (30 mL/h corresponding to 50 μg/min)
62721407|NCT03842046|ACTIVE_COMPARATOR|norepinephrine infusion|norepinephrine infusion (30 mL/h corresponding to 4 μg/min)
62721408|NCT05922618|EXPERIMENTAL|I-ONE group|The group will undergo home biophysical treatment with I-ONE® therapy (experimental group) for 4 hours/day for 60 days. Patients will follow standard rehabilitation treatment: patients will perform active and active-assisted range of motion (ROM) recovery exercises and stretching exercises for 30 minutes per day, for 6 weeks.
62721409|NCT05922618|NO_INTERVENTION|Exercise group|The group, not subjected to biophysical therapy, will be controls. Patients will follow standard rehabilitation treatment: patients will perform active and active-assisted ROM recovery exercises and stretching exercises for 30 minutes per day, for 6 weeks.
62721410|NCT01684670|EXPERIMENTAL|Behavioral speech treatment|
62721411|NCT04446403|EXPERIMENTAL|circumflex|patients will undergo ultrasound guided SSN+circumflex
62721412|NCT04446403|EXPERIMENTAL|posterior cord|patients will undergo ultrasound guided SSN+circumflex
62721413|NCT01297283|EXPERIMENTAL|Leadless ECG first|Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device
62721414|NCT01297283|ACTIVE_COMPARATOR|Programmer ECG first|Measurements of pacing thresholds are done first with the support of the programmer ECG
62721415|NCT00805506||Diabetes Insulin Treated|People with type 1 or type 2 diabetes on insulin.
62721416|NCT04049500||Clinicians|Five practices will be selected from NYULH ambulatory practice sites to represent the spectrum of provider settings within the system. These sites will be the clinical partners for the adaptation of the dDPP tool suite
62721417|NCT02025374|EXPERIMENTAL|Hyperbaric levobupivacaine|Group 2 Hyperbaric levobupivacaine % 0.5 plus fentanyl; 2 ml total intrathecally
62721418|NCT02025374|ACTIVE_COMPARATOR|Hyperbaric bupivacaine|Group 1 Hyperbaric bupivacaine % 0.5 plus fentanyl 2 ml intrathecally
62721419|NCT04115462|ACTIVE_COMPARATOR|Morphine|Each participant will receive a single dose of 20 mg morphine tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
61976678|NCT05861856|ACTIVE_COMPARATOR|Virtual reality group|Virtual reality supported core stabilization exercises will be performed.
61976679|NCT05861856|ACTIVE_COMPARATOR|Manual therapy group|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
62721420|NCT04115462|PLACEBO_COMPARATOR|Placebo|Each participant will receive a single dose of an identical placebo tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
62721421|NCT03083782|ACTIVE_COMPARATOR|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
62721422|NCT03083782|EXPERIMENTAL|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
62721423|NCT03083782|EXPERIMENTAL|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
62721424|NCT01790373|EXPERIMENTAL|Suubi+Adherence|"Suubi+Adherence intervention arm provides:~* Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~* Financial education and workshops on asset-building, future planning, and protection from risks~* Mentorship from a young adult/near-peer~* Family-based microenterprise development training~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
62721425|NCT01790373|ACTIVE_COMPARATOR|Bolstered Standard of Care|"Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
62721426|NCT03164005||Group 1|subjects without metabolic diseases
62721427|NCT03164005||Group 2|subjects with metabolic diseases
62721428|NCT05390164||Active vitiligo|
62721429|NCT05390164||Stable vitiligo|
62721430|NCT00105664|OTHER|Arm 1|
62721431|NCT03131908|EXPERIMENTAL|GSK2636771 + Pembrolizumab|"Phase I: Participants receive the lowest dose level of GSK2636771. Each new group receives a higher dose of GSK2636771 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of GSK2636771 is found. Participants receive the same dose level of Pembrolizumab.~Phase II: Participants receive GSK2636771 at the highest dose that was tolerated in Phase 1. Participants receive the same dose level of Pembrolizumab."
62721432|NCT05120050||Patients with confirmed Lung cancer|
62721433|NCT03606291|EXPERIMENTAL|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%\>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
62721434|NCT01571622|PLACEBO_COMPARATOR|Water before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water
62721435|NCT01571622|EXPERIMENTAL|Whey before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\\
62721436|NCT04473781|EXPERIMENTAL|Treatment (interstitial brachytherapy)|Patients undergo interstitial brachytherapy for 1-2 fractions in the absence of disease progression or unacceptable toxicity. Patients who undergo 2 fractions may receive both fractions in the same day or on 2 separate days over 2 weeks.
62721437|NCT04264039|EXPERIMENTAL|anti-CD19 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD19 UCAR-T cells between 1 and 5 ×10\^7 cells/Kg will be evaluated
62721438|NCT00672594|EXPERIMENTAL|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
62721439|NCT02338388|ACTIVE_COMPARATOR|Single-layer unlocked closure|
62721440|NCT02338388|ACTIVE_COMPARATOR|Single-layer locked closure|
62721441|NCT02338388|ACTIVE_COMPARATOR|Double-layer closure|The first layer was continuous and unlocked and a second, continuous non-locking imbricating layer was applied over the first suture.
62721442|NCT04283656|OTHER|Period I|Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone
62721443|NCT04283656|OTHER|Period II|Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo
62721444|NCT04283656|OTHER|Period III|Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone
62721445|NCT01343888|ACTIVE_COMPARATOR|PegIFN/RBV|PegIFN/RBV for 48 weeks
62721446|NCT01343888|EXPERIMENTAL|BI 201335 for 12 or 24 weeks|BI 201335 once daily low dose for 12 or 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
62721447|NCT01343888|ACTIVE_COMPARATOR|Placebo and PegIFN/RBV|Placebo (oral) once daily plus PegIFN/RBV (subcutaneous injection/oral) for 24 weeks, followed by PegIFN/RBV alone up to Week 48.
62721448|NCT03402100|EXPERIMENTAL|0.01% atropine|children who received 0.01% atropine for myopia
62721449|NCT03402100|EXPERIMENTAL|0.005% atropine|children who received 0.005% atropine for myopia
62721450|NCT03402100|EXPERIMENTAL|0.25% Ketorolac|children who received 0.25% Ketorolac for myopia
61976680|NCT05861856|ACTIVE_COMPARATOR|Combine group|Both virtual reality supported core stabilization exercises and manual therapy techniques will be applied.
61976681|NCT01372280|EXPERIMENTAL|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
62721451|NCT03402100|EXPERIMENTAL|0.01% atropine plus 0.25% Ketorolac|children who received 0.01% atropine plus 0.25% Ketorolac for myopia
62721452|NCT03402100|EXPERIMENTAL|0.005% atropine plus 0.25% Ketorolac|children who received 0.005% atropine plus 0.25% Ketorolac for myopia
62721453|NCT00940550|EXPERIMENTAL|Prolonged-release melatonin 2 mg|
62721454|NCT00940550|ACTIVE_COMPARATOR|Temazepam 20 mg|
62721455|NCT00940550|ACTIVE_COMPARATOR|Zolpidem 10 mg|
62721456|NCT00940550|PLACEBO_COMPARATOR|Placebo|
62721457|NCT03027674|EXPERIMENTAL|10% nifedipine cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
62721458|NCT03027674|ACTIVE_COMPARATOR|5% sildenafil cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
62721459|NCT00205439||Fluorescence bronchosopy with sputum cytology|Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.
62721460|NCT06000592|EXPERIMENTAL|transcutaneous spinal stimulation|Transcutaneous spinal cord stimulation (TSCS) protocol to stabilize seated systolic blood pressure in newly injured patients with spinal cord injury and to test the ability of TSCS to reduce the fall in blood pressure when these patients are moved from the supine to the seated position.
62721461|NCT05498584||Post-acute systolic heart failure patients|Patients who received at least one exercise training section within 3 months of acute heart failure discharge are placed in the CR group. Patients will receive a multi-disciplinary disease management program by a qualified HF nursing specialist. A board-certified physiatrist prescribes moderate continuous training according to a cardiopulmonary exercise test.
62721462|NCT05115435|NO_INTERVENTION|control group|No intervention was applied on the control group patients
62721463|NCT05115435|EXPERIMENTAL|experimental group|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
62737160|NCT02435667|PLACEBO_COMPARATOR|Standard Care|No resistance exercise training. Patients will stay on their current healthcare regimen as previously assigned by their physician. Patients will still undergo baseline and follow-up tests similar to the Resistance Exercise Training group, including: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
61976682|NCT01372280|ACTIVE_COMPARATOR|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
61976683|NCT00770289||Single group|
62721464|NCT05545943|EXPERIMENTAL|2-days of calorie restriction with whole body cooling|"Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) with two 10-min whole body cooling practices on separate days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
62721465|NCT05545943|EXPERIMENTAL|6-days of calorie restriction|"Healthy young subjects participated in 6-day CR (0 kcal with water provided ad libitum).~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
62721466|NCT05545943|NO_INTERVENTION|2-days of the usual diet (control)|"During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 2 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
62721467|NCT05545943|NO_INTERVENTION|6 days of the usual diet (control)|"During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 6 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
62721468|NCT05545943|EXPERIMENTAL|2-days of calorie restriction without whole-body cooling|"Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) without whole body cooling.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
62721469|NCT05545943|ACTIVE_COMPARATOR|2-days of usual diet with whole-body cooling|"Healthy young subjects participated two 10-min whole body cooling practices on separate days and were instructed to maintain their previous eating habits for 6 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
62721470|NCT00444925|EXPERIMENTAL|Fesoterodine|Tablets
62721471|NCT00444925|PLACEBO_COMPARATOR|Placebo|Tablets and capsules
62721472|NCT00444925|ACTIVE_COMPARATOR|Tolterodine|Capsules
62721473|NCT05837221||Oral Squamous Cell Carcinoma Saliva Sample Group|"Saliva will be collected at least 30 minutes after subjects stop eating, drinking, chewing gum, and smoking. Subjects will be instructed to spit saliva into a collection tube. The saliva will be split into two aliquots, one that is immediately frozen at~-80C and one that is mixed 1:1 with pre-reduced tryptic soy broth, L-cysteine, and glycerol then frozen at -80C to preserve the viability of microorganisms."
62721474|NCT05837221||Non Oral Squamous Cell Carcinoma Saliva Sample Group|"Saliva will be collected at least 30 minutes after subjects stop eating, drinking, chewing gum, and smoking. Subjects will be instructed to spit saliva into a collection tube. The saliva will be split into two aliquots, one that is immediately frozen at~-80C and one that is mixed 1:1 with pre-reduced tryptic soy broth, L-cysteine, and glycerol then frozen at -80C to preserve the viability of microorganisms."
62721475|NCT05837221||Oral Squamous Cell Carcinoma Stool Sample Group|Stool collection methods may differ depending on the patient. The aim is to collect fresh stool samples, those that are available will be collected during the study visit. If a patient is unable to give a sample at the visit, samples may be collected at home using the OMNIgene-GUT and OMNImet-GUT kits (DNA Genotek, Inc.).
62721476|NCT05837221||Non Oral Squamous Cell Carcinoma Stool Sample Group|Stool collection methods may differ depending on the patient. The aim is to collect fresh stool samples, those that are available will be collected during the study visit. If a patient is unable to give a sample at the visit, samples may be collected at home using the OMNIgene-GUT and OMNImet-GUT kits (DNA Genotek, Inc.).
62721477|NCT02593058|EXPERIMENTAL|PEPS+TAU|Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
62721478|NCT02593058|ACTIVE_COMPARATOR|Treatment As Usual (TAU)|Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
62721479|NCT04892706|EXPERIMENTAL|IDP-126 Gel|
62721480|NCT04892706|PLACEBO_COMPARATOR|IDP-126 Vehicle Gel|
62721481|NCT04892706|ACTIVE_COMPARATOR|Epiduo® Forte Gel|
62721482|NCT00537537|ACTIVE_COMPARATOR|1|Telbivudine
62721483|NCT00537537|ACTIVE_COMPARATOR|2|Telbivudine
62721484|NCT00537537|ACTIVE_COMPARATOR|3|Telbivudine
62721485|NCT03667404|EXPERIMENTAL|Resistant Maltodextrin|Resistant maltodextrin (RM) powder 25 g during days 1-7 and 50g during days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
62721486|NCT03667404|PLACEBO_COMPARATOR|Maltodextrin|Maltodextrin 25g for days 1-7 and 50 g for days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
62721487|NCT01585402|EXPERIMENTAL|Etidronate Treatment for Arterial Calcifications due to Deficiency in CD73 (ACDC)|Participants diagnosed with Arterial Calcifications due to Deficiency in CD73 (ACDC) will receive Etidronate. Etidronate will be administered orally at total dose of 20mg/kg daily x 14 days, followed by 10 weeks off study drug (12 weeks = one cycle). Participants may receive up to 12 cycles of etidronate.
62721488|NCT02385006|OTHER|Arm kidney transplanted|Arm kidney transplanted: all patients who receive kidney transplantation
62721489|NCT02385006|OTHER|Arm pancreas-kidney transplanted|Arm pancreas-kidney transplanted: all patients who receive pancreas-kidney transplantation
62721490|NCT02960425|EXPERIMENTAL|HI Delivra TM Livsport preworkout cream|7 mL topical creatine cream
62721491|NCT02960425|EXPERIMENTAL|LO Delivra TM Livsport preworkout cream|3.5 mL topical creatine + 3.5 mL placebo cream
62721492|NCT01100281||PSP (Progressive supranuclear palsy)|
62721493|NCT01100281||FTD (Frontotemporal lobar degenerative)|
62721494|NCT01100281||Alzheimer's disease|
62721495|NCT02582827|EXPERIMENTAL|ABI-011|IDN 5404 protein-bound particles for injectable suspension
62721496|NCT06220877|ACTIVE_COMPARATOR|Group I|patients were treated using Buccal Pad of Fat for management of OAC.
62721497|NCT06220877|ACTIVE_COMPARATOR|Group II|patients were treated using A-PRF technique for management of OAC.
62721498|NCT06220877|ACTIVE_COMPARATOR|Group III|patients were treated with Fibrin Glue for management of OAC.
62721499|NCT06220877|ACTIVE_COMPARATOR|Group IV|oxidized regenerated cellulose plug have been used for management of OAC.
62721500|NCT00178971|ACTIVE_COMPARATOR|1|buspirone 15-30 mg qd
62721501|NCT00178971|PLACEBO_COMPARATOR|2|placebo
62721502|NCT01428219|EXPERIMENTAL|Cabozantinib (XL184)|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
62721503|NCT03487016|ACTIVE_COMPARATOR|A: Gemcitabine/nab-Paclitaxel (Standard)|"Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
62721504|NCT03487016|EXPERIMENTAL|B: NAPOLI regimen|"On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
62721505|NCT03487016|EXPERIMENTAL|C: seq-NAPOLI-FOLFOX|"The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.~NAPOLI:~On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~mFOLFOX6:~On Day 1 of a 14-day cycle:~Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
62721506|NCT03273907|EXPERIMENTAL|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
62721507|NCT02178800|EXPERIMENTAL|Group 1: GSK1265744|Participants in Cohorts 1 and 2 will receive one GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
62721508|NCT02178800|PLACEBO_COMPARATOR|Group 2: Placebo|Participants in Cohorts 1 and 2 will receive one placebo tablet orally every day from study entry through Week 4. They will then receive an injection of placebo-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
62721509|NCT04624100||All consecutive patients with primary ventral or incisional hernia|
62721510|NCT06000930||marathon runners|Marathon runners
62721511|NCT06000930||myocardial infarction|Patients with Type 1 myocardial infarction
62721512|NCT03694951|EXPERIMENTAL|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of reducing their daily sedentary behaviour to \<7 hours per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for reducing their daily sedentary behaviour. Strategies may include: setting an alarm while studying to break up sedentary behaviour, to stand rather than sit on transit, and/or to achieve an active step profile (i.e., ≥10,000 steps a day) through pedometer self-monitoring.
62721513|NCT03694951|NO_INTERVENTION|Control Group|The control group will not receive any behavioural intervention.
62721514|NCT00950651|EXPERIMENTAL|1 Tramadol HCl Contramid® Once A Day|
62721515|NCT00950651|ACTIVE_COMPARATOR|2 Tramadol HCl Twice a day (SR)|
62721516|NCT00295646|ACTIVE_COMPARATOR|AZ (Arimidex+Zoledronate)|Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)
62721517|NCT00295646|ACTIVE_COMPARATOR|TZ (Tamoxifen+Zoledronate)|Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)
62721518|NCT00295646|ACTIVE_COMPARATOR|AC (Arimidex Control)|Study Drug Arimidex (Anastrozole)
62721519|NCT00295646|ACTIVE_COMPARATOR|TC (Tamoxifen Control)|Study Drug Nolvadex (Tamoxifen)
62721520|NCT01884363|EXPERIMENTAL|Walnuts|This group will receive one ounce of walnuts per day
62721521|NCT01884363|NO_INTERVENTION|Usual diet (no walnuts)|Control group (does not receive walnuts in the diet)
62721522|NCT02890277|EXPERIMENTAL|Treatment group|
62721523|NCT04747262|EXPERIMENTAL|SPACE INTERVENTION|counseling
62721524|NCT03649802|PLACEBO_COMPARATOR|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
62721525|NCT03649802|ACTIVE_COMPARATOR|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
62721526|NCT02471053|EXPERIMENTAL|Moderate Intensity Exercise|All consenting patients will participate in an aerobic training program, twice-weekly over a 12-week period. Assessments will be performed at baseline (pre-training) and post-program (12-weeks). All participants will continue to receive standard care for their cancer diagnosis.
62721527|NCT05853354|EXPERIMENTAL|LY06006|to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.
62721528|NCT05853354|ACTIVE_COMPARATOR|EU Prolia|to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.
62721529|NCT02329093|EXPERIMENTAL|Bone Signal Changes|
62721530|NCT05844228|EXPERIMENTAL|Cohort 1: 8 moderate Renal Impairment (RI) participants and 8 matched healthy participants|
62721531|NCT05844228|EXPERIMENTAL|Cohort 2: 8 severe Renal Impairment (RI) participants and 8 matched healthy participants (optional)|
62721532|NCT03443635|EXPERIMENTAL|Treatment|Subjects receiving hands-on cooking and nutrition education classes
62721533|NCT03443635|NO_INTERVENTION|Control|Subjects not receiving any additional nutrition education aside from that contained in their curricula (for trainees) or medical care (for patients)
62721534|NCT02246010|EXPERIMENTAL|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
62721535|NCT02246010|NO_INTERVENTION|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
62721536|NCT02964806|OTHER|Ordinary Diet|Ordinary Diet
62721537|NCT02964806|OTHER|Modified Atkin's Diet|Modified Atkin's Diet
62721538|NCT02964806|OTHER|Ketogenic Diet|Ketogenic Diet
62721539|NCT01404650|EXPERIMENTAL|AUY922|
62721540|NCT03040128|PLACEBO_COMPARATOR|placebo|normal saline infusion
62721541|NCT03040128|EXPERIMENTAL|minocycline|intravenous minocycline
62721542|NCT04685213|ACTIVE_COMPARATOR|Active E-Stim|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
62721543|NCT04685213|SHAM_COMPARATOR|sham E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
62721544|NCT02553187|EXPERIMENTAL|Treatment group|Kanglaite Injection plus standard therapy.
62721545|NCT02553187|NO_INTERVENTION|Control group|Blank control and standard therapy.
62721546|NCT06439121|EXPERIMENTAL|4-7-8 Breathing Technique|"The Patient Introduction Form comprises three sections. The first section covers sociodemographic characteristics, including gender, age, BMI, education level, smoking status, and family history of obesity (6 questions). The second section addresses medical characteristics such as chronic diseases, ASA score, duration of general anesthesia, type of surgery, surgical complications history, and length of hospital stay (7 questions).~The third section evaluates pain and nausea-vomiting using the Visual Analog Scale, a 10 cm horizontal line where patients mark their severity level. Scores range from 0-10, with higher scores indicating increased symptom severity. The scale is versatile, assessing symptoms like pain, anxiety, fatigue, and nausea-vomiting, with vomiting assessed as present or absent. Patients will be taught the 4-7-8 breathing technique pre-surgery and asked to practice it post-surgery. Their responses to the third section's questions will be recorded."
62721547|NCT06439121|NO_INTERVENTION|Control|"The Patient Introduction Form comprises three sections:~1. Sociodemographic characteristics, encompassing gender, age, BMI, education level, smoking status, and family history of obesity (6 questions).~2. Medical characteristics, including the presence of chronic diseases, ASA score, duration of general anesthesia, type of surgery performed, history of surgical complications, and length of hospital stay (7 questions).~3. Evaluation of pain and nausea-vomiting using the Visual Analog Scale, which entails a 10 cm horizontal line where patients mark their severity level. Scores range from 0-10, with higher scores indicating increased symptom severity. Vomiting will be assessed as present or absent. Patients in the control group will undergo routine monitoring and treatments without interventions, and their responses to the questions from the third section will be recorded."
62721548|NCT01122979|EXPERIMENTAL|group 1: insulin glargine + insulin glulisine|insulin glargine once daily + glulisine at meal times
62721549|NCT01122979|ACTIVE_COMPARATOR|group 2 NPH insulin + regular insulin|NPH insulin (isophane insulin) (2 or more divided doses) + regular insulin at meal times
62721550|NCT03534882|EXPERIMENTAL|Washout|Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
62721551|NCT03534882|NO_INTERVENTION|Control|Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.
62721552|NCT05753514|EXPERIMENTAL|ESWT|Effect of ESWT in alleviating pain
62721553|NCT02603679|ACTIVE_COMPARATOR|A: Weekly Paclitaxel|Patients receive weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for a 12-week period. Thereafter, treatment is switched to endocrine treatment in combination with palbociclib. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during the second 12-week period
62721554|NCT02603679|EXPERIMENTAL|B: Tamoxifen + Palbociclib|Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
62721555|NCT02603679|EXPERIMENTAL|B: Aromatase Inhibitor + Palbociclib|Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
62721556|NCT02603679|EXPERIMENTAL|B: Goserelin + Aromatase Inhibitor + Palbociclib|Pre- or perimenopausal women may be treated with goserelin and an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
62721557|NCT06175780|EXPERIMENTAL|KY-0118|
62721558|NCT06175780|EXPERIMENTAL|Cohort1: KY-0118|
62721559|NCT06175780|EXPERIMENTAL|Cohort2: KY-0118|
62721560|NCT02864264|EXPERIMENTAL|Single Ascending Dose (SAD) - IV Panel|Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184
62721561|NCT02864264|EXPERIMENTAL|Single Ascending Dose (SAD) - SC Panel|Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184
62721562|NCT02864264|EXPERIMENTAL|Multiple Ascending Dose (MAD) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
62721563|NCT02864264|EXPERIMENTAL|Proof of Mechanism (POM) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
62721564|NCT01781377|EXPERIMENTAL|PROPOFOL|PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION
62721565|NCT01781377|EXPERIMENTAL|METOCLOPRAMIDE|METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
62721566|NCT01781377|EXPERIMENTAL|PROPOFOL & METOCLOPRAMIDE|PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
61978194|NCT01316120|EXPERIMENTAL|HPV Dry first|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
62721567|NCT01781377|PLACEBO_COMPARATOR|PLACEBO|SALINE INFUSION
62721568|NCT03583229|OTHER|Aspirin - single arm|1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
62721569|NCT03583229|EXPERIMENTAL|Extracorporeal photopheresis|All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
62721570|NCT03583229|NO_INTERVENTION|Control group|The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.
62721571|NCT02001129|EXPERIMENTAL|Automated Telephone System|In addition to a standardized reminder letter, participants also received a telephone call from an automated system to remind them of a recommended follow-up appointment.
62721572|NCT02001129|EXPERIMENTAL|Personalized Telephone Call|In addition to the usual care letter, a staff member called participants one month prior of recommended follow-up appointment. During this call, participants were given the option to schedule an appointment.
62721573|NCT02001129|ACTIVE_COMPARATOR|Usual Care|"Participants randomized to this arm receive a usual care letter which is a standard reminder letter from the primary eye care office. This is usual practice in many primary eye care facilities."
62721574|NCT04137367|EXPERIMENTAL|Active Affective Bias Modification|Computer based Affective Bias Modification
62721575|NCT04137367|SHAM_COMPARATOR|Sham Affective Bias Modification|Computer based sham Affective Bias Modification
62721576|NCT02706925|EXPERIMENTAL|BI 443651|
62721577|NCT02706925|PLACEBO_COMPARATOR|Placebo|
62721578|NCT02691026|EXPERIMENTAL|Pembrolizumab|200 mg pembrolizumab, i.v. infusion every 3 weeks for up to 10 cycles
62721579|NCT02024412|EXPERIMENTAL|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
62721580|NCT02024412|PLACEBO_COMPARATOR|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
62721581|NCT06718309|EXPERIMENTAL|Treatment group|Treatment group
62721582|NCT04937725||Patients without neurological pathologies|Patients with no history of neurological diseases
62721583|NCT04937725||Patients with neurological pathologies|
62721584|NCT03509818|EXPERIMENTAL|Plyometric|Effects of plyometric acute exercise
62721585|NCT03509818|EXPERIMENTAL|Aerobic|Effects of aerobic acute exercise
62721586|NCT03733938||teeth with failed root canal treatement|endodontic microsurgery will be performed for teeth with failed root canal treatment
62721587|NCT05321459||Comatose patients in intensive care unit|Patient admitted in the intensive care unit (ICU) for post cardiac arrest (CA) coma, persistent for at least 3 days after CA.
62721588|NCT04740580|EXPERIMENTAL|Glycine plus N-acetylcysteine|Glycine and cysteine are amino-acid (protein) precursors of glutathione. Cysteine is provided as N-acetylcysteine
62721589|NCT04740580|PLACEBO_COMPARATOR|Alanine|Alanine is an amino-acid (protein), and not a precursor of glutathione synthesis
62721590|NCT05698303|EXPERIMENTAL|CT103A in patients with RRMM|After lymphodepletion, CT103A will be administered as a single infusion.
62721591|NCT02062515|EXPERIMENTAL|Icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
62721592|NCT04868383|EXPERIMENTAL|Single pilot arm|In this single arm pilot study, all participants will receive access to a novel smartphone app designed to support PrEP uptake and adherence for a 6 month period.
62721593|NCT00295789|ACTIVE_COMPARATOR|1|Drug: chemotherapy: Paclitaxel/Cisplatin
62721594|NCT00295789|EXPERIMENTAL|2|Drug: chemotherapy: Paclitaxel/Carboplatin
62721595|NCT05117814|EXPERIMENTAL|Zanubrtuinib|Zanubrutinib 320mg Qd
62721596|NCT04904107|EXPERIMENTAL|Intervention group|"Chest pain patients in the intervention group will be assessed by EMT personnel by performing the modified HEART score (including POC high sensitive troponin-I measurement (POC HS cTnI)) and the referral policy depends on the result.~* In case of a low modified HEART score (modified HEART 0-3) patients will not be referred to the cardiac ED.~* Patients with a modified HEART score \>3 are directly referred to the cardiac ED after evaluation. These patients will receive standard care."
62721597|NCT04904107|ACTIVE_COMPARATOR|Control group|Chest pain patients in the control group will receive standard triage and standard care according to the local (EMT) protocol.
62721598|NCT03323684|EXPERIMENTAL|Quadratus lumborum block Group (QL)|Quadratus lumborum block will be performed
62721599|NCT03323684|EXPERIMENTAL|Transversus abdominis plane Group (TAP)|Subcostal transversus abdominis plane will be performed
62721600|NCT03323684|EXPERIMENTAL|Control group (C)|Postoperative analgesia will be accomplished with conjunction of paracetamol and ketorolac
62721601|NCT03672149|OTHER|Infection needing cefazolin|a) If a patient requires antimicrobial therapy for a proven or suspected infection at the time of CRRT initiation or at any time receiving CRRT, they are eligible for inclusion. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic and safety data of administering cefazolin via the CRRT solution and infection treatment related data. For this indication, pharmacokinetic and safety data will be obtained for the duration the patient receives cefazolin via the CRRT solution(s) for the proven or suspected infection as dictated by the primary team caring for the patient.
62721602|NCT03672149|OTHER|Infection not needing cefazolin|b) If a patient is deemed a candidate for CRRT and requires therapy with any anti-microbial for a proven or suspected infection not requiring cefazolin as part of the anti-microbial drug regimen, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
62721603|NCT03672149|OTHER|No infection|c) If a patient is deemed a candidate for CRRT and does not require any anti-microbial therapy, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
62721604|NCT00421148|EXPERIMENTAL|Sugammadex 0.5 mg/kg|Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.
62721605|NCT00421148|EXPERIMENTAL|Sugammadex 1 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
62549352|NCT04778904|EXPERIMENTAL|Group 4 (ChAdOx1-HBV and nivolumab, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10\^10 vp IM injection + nivolumab 0.3 mg/kg IV infusion Day 28: MVA-HBV 1 x 10\^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
62549353|NCT02905032|NO_INTERVENTION|Standard Care|Observations in clinical encounter via video, audio or observational notes.
62549354|NCT02905032|ACTIVE_COMPARATOR|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
62549355|NCT03577301|ACTIVE_COMPARATOR|Clinic-based Delivery|Participants will receive the intervention in person following HIV counseling and testing. The intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
62549356|NCT03577301|ACTIVE_COMPARATOR|Remote Delivery|Participants will receive the intervention by remote delivery following HIV counseling and testing. Just as the clinic-based participants, he intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
62549357|NCT03577301|ACTIVE_COMPARATOR|Multi-modal Delivery|A 4 session MI intervention. Session 1 is always delivered in person immediately after baseline. Session 2-4 can be delivered in person or remotely based upon youth preference. This arm is open to enrollment as of 11/15/2019.
62549358|NCT03577301|NO_INTERVENTION|Treatment as Usual|Treatment as usual control = individual HIV testing with referrals and link age to care as provided by the sites under routine circumstances. This arm is open to enrollment as of 11/15/2019.
62549359|NCT06319300|EXPERIMENTAL|AI group|AI-assisted insulin dosage adjustment
62549360|NCT06319300|ACTIVE_COMPARATOR|Doctor group|doctor adjust insulin
62549361|NCT05139888|EXPERIMENTAL|Single wavelength light (red) only|Arm 1 will test the core technology of the ToeFX system; this study reproduces methods well-described in the literature. After application of the formulation, nails affected by onychomycosis are exposed to red light at a wavelength of 630-660 nm intensity of 200 mW/cm2.
62549362|NCT05139888|EXPERIMENTAL|Dual wavelength light (red/blue)|Some research has shown that exposure to mild blue light can have anti-inflammatory effects that would improve patient onychomycosis outcomes. We will assess whether inclusion of blue light in the protocol affects the clinical outcome.
62549363|NCT00794339|EXPERIMENTAL|Copper ATSM|pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT
62549364|NCT03340974|EXPERIMENTAL|GC4419 90mg +50 Gy SBRT|Avasopasem manganese (GC4419) +SBRT
62549365|NCT03340974|EXPERIMENTAL|GC4419 90 mg + 55 Gy SBRT|Avasopasem manganese (GC4419) +SBRT
62549366|NCT03340974|PLACEBO_COMPARATOR|Placebo + 50 Gy SBRT|Placebo +SBRT
62549367|NCT03340974|PLACEBO_COMPARATOR|Placebo + 55 Gy SBRT|Placebo + SBRT
62549368|NCT06550544|ACTIVE_COMPARATOR|Office hysteroscopy|"A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~.Pain intensity will be assessed by visual analogue scale immediately after the procedure."
62549369|NCT06550544|ACTIVE_COMPARATOR|Ultrasound guided|"An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~.Pain intensity will be assessed by visual analogue scale immediately after the procedure."
62549370|NCT04569734||Experimental: Treatment Group|Determination for participation in the study is based on institutional standard of care practice for assessment of WATCHMAN eligibility. Patients that are being considered for LAA Closure with WATCHMAN device implant based on a history of non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2VASc score \>2 but have an appropriate rationale to seek a non-pharmacologic alternative to anti-thrombotic therapy due to risks of anti-thrombotic therapy. Patients should be able to tolerate the WATCHMAN device implant procedure without the need for general anesthesia.
62549371|NCT01665326||Infantile Pompe disease|Individuals with a confirmed diagnosis of Infantile Pompe disease
62549372|NCT02965937|EXPERIMENTAL|Story-Centred Care Intervention Program|A theory-guided approach that emphasises a health-promoting potential of nurse-person dialogue about a health challenge.Participants randomised to the IG will be made to participate in a 4-week long story-centred care intervention program conducted by a trained researcher.
62549373|NCT02965937|ACTIVE_COMPARATOR|Health consultation control condition|Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
62549374|NCT05231434|ACTIVE_COMPARATOR|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol
62549375|NCT05231434|EXPERIMENTAL|Hydration protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery
62549376|NCT06582498|EXPERIMENTAL|Active intervention|Consists of participants (50% of the total recruited) which will receive the Active Intervention.
62549377|NCT06582498|ACTIVE_COMPARATOR|Low-intensity intervention|Consists of participants (50% of the total recruited) which will receive the Low Intensity Intervention.
62549378|NCT00003056|ACTIVE_COMPARATOR|Unselected peripheral blood haemopoietic stem cells (PBSC)|Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control
62549379|NCT00003056|EXPERIMENTAL|CD34+ cells isolated from PBSC|CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine
62549380|NCT03377374|EXPERIMENTAL|Probiotic|L. reuteri ATCC PTA 5289 + L. reuteri DSM 17938 at a dose of 2x10\^8 Colony Forming Units (CFU)
62549381|NCT03377374|PLACEBO_COMPARATOR|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
62549382|NCT05096910|ACTIVE_COMPARATOR|Monofilament Suture Group|Monofilament sutures will be used for uterine closure.
62549383|NCT05096910|ACTIVE_COMPARATOR|Polyfilament Suture Group|Polyfilament sutures will be used for uterine closure.
62549384|NCT00893269|EXPERIMENTAL|Active Medication|Participants receive active hypnotic medication prior to sleep
62549385|NCT00893269|PLACEBO_COMPARATOR|Placebo|Participants receive placebo prior to sleep
62549386|NCT02130622|EXPERIMENTAL|Promethazine|Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
62549387|NCT02130622|PLACEBO_COMPARATOR|Sugar Pill|Placebo P.O. t.i.d. for 4 weeks
62549388|NCT04710615|EXPERIMENTAL|Assistance device|"With prescription assistance device:~During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline)."
62549389|NCT04710615|NO_INTERVENTION|No device|During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, ...
62549390|NCT03442361||Intralipid|Standard soybean oil-based therapy
62549391|NCT03442361||Clinoleic|Olive oil based therapy
62549392|NCT03556124|EXPERIMENTAL|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
62549393|NCT03556124|EXPERIMENTAL|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
62549394|NCT03556124|SHAM_COMPARATOR|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
62549395|NCT03556124|SHAM_COMPARATOR|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
62549396|NCT02702570|OTHER|CASA intervention|Each participant serves as his/her own control. Measures administered before and after an intervention.
62549397|NCT03315078|EXPERIMENTAL|Gene-Modified CD34+ HSCs|Participants will receive palifermin on Days -6, -5, and -4 and then busulfan on Days -3 and -2. On Day 0, participants will undergo the gene transfer treatment with infusion of the gene-modified CD34+ HSCs. They will receive palifermin on Days 1, 2, and 3.
62549398|NCT02358239|EXPERIMENTAL|Efficacy and safety of acupuncture for dizziness and vertigo|To evaluate the efficacy and safety of acupuncture in treating patients with dizziness and vertigo in ED.
62549399|NCT03595007||Phase 1|
62549400|NCT03595007||Phase 2|
62549401|NCT03595007||Phase 3|
62549402|NCT03278626|OTHER|Nivolimumab+Carboplatin/paclitaxel+Radiation|240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation
62549403|NCT02438267||Non-NC group|Enrolled subjects who did not have evidence of NC on renal ultrasound
62549404|NCT02438267||NC group|Enrolled subjects who did have evidence of NC on renal ultrasound
62549405|NCT04653025|EXPERIMENTAL|Test group|Test group patients received an immediate implant with provisional restoration, bone augmentation and soft tissue grafting
62549406|NCT04653025|EXPERIMENTAL|Control group|Patients in the control group received soft tissue grafting after tooth extraction and an implant with bone augmentation after 6 weeks of healing.
62549407|NCT02428439||Increased suicidality|Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
62549408|NCT02428439||Non-increased suicidality|Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
62549409|NCT01160328|NO_INTERVENTION|Control Group|Participants in this group will not receive any treatment.
62549410|NCT01160328|EXPERIMENTAL|Lupron Group|Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels.
62549411|NCT01160328|OTHER|Lupron & Testosterone Group|Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel).
62549412|NCT01860274|EXPERIMENTAL|External Mesh|
62549413|NCT04927845|EXPERIMENTAL|Immediate Intervention Condition|Participants in this condition will receive 7-8 weeks of online intervention modules. Specific modules will be selected based on a campus-wide needs assessment conducted in May 2021.
62549414|NCT04927845|NO_INTERVENTION|Waitlist Condition|Participants in this condition will wait to receive StriveWeekly until after the Immediate Intervention condition is complete and participants from both conditions have completed the posttest survey.
62549415|NCT05178342|OTHER|CA-4948 treatment|Single-arm design. all patients are treated with IMP
62549416|NCT04659759||COVID-19 Positive|Patients diagnosed with COVID-19 during pregnancy or while breastfeeding
62549417|NCT04659759||COVID-19 vaccine|Patients who receive COVID-19 vaccine during pregnancy or while breastfeeding
62549418|NCT04659759||Controls|Reproductive age women exposed to COVID-19 vaccine
62549419|NCT04659759||Pregnant Control|Pregnant women who delivered at TJUH, COVID negative
62549420|NCT01193179|EXPERIMENTAL|OPC-262|
62549421|NCT01587287||Corneal power measurement|All recruited volunteers in present study, that underwent corneal power measurement with 8 different instruments
62549422|NCT03333135|EXPERIMENTAL|HK100 Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
62549423|NCT03333135|SHAM_COMPARATOR|HK100 Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
62549424|NCT03333135|EXPERIMENTAL|UTMB Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
62721606|NCT00421148|EXPERIMENTAL|Sugammadex 2 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.
62721607|NCT00421148|EXPERIMENTAL|Sugammadex 4 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.
62721608|NCT00421148|PLACEBO_COMPARATOR|Placebo|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.
62721609|NCT01490034|EXPERIMENTAL|Energy dense beverage|Metabolic effects of consuming energy dense beverages before and after regular consumption
62721610|NCT01490034|EXPERIMENTAL|Energy dense solid food form|Metabolic effects of consuming energy dense solid foods before and after regular exposure.
62721611|NCT01490034|EXPERIMENTAL|Eenergy dilute beverages|Metabolic effects of consumption of energy dilute beverages on a regular basis.
62721612|NCT01490034|EXPERIMENTAL|Energy dilute solid food form|Metabolic effects of consuming energy dilute sold foods before and after regular exposure.
62721613|NCT04824014|EXPERIMENTAL|4FMFES-PET imaging at 0, 6 and 18 months|Patients burdened with ER+ advanced breast cancers and recruited in the trial will undergo an experimental 4FMFES-PET imaging within a 4-week interval of a medically-prescribed FDG-PET. The 4FMFES-PET procedure will be repeated at 6 and 18 months following the initial scan.
62721614|NCT06388252|ACTIVE_COMPARATOR|Electrochemotherapy with Intratumoral Cysplatin|ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
62721615|NCT06388252|ACTIVE_COMPARATOR|Electrochemotherapy with Intravenous Bleomycin|ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
62721616|NCT03118336|PLACEBO_COMPARATOR|placebo group|
62721617|NCT03118336|EXPERIMENTAL|empaglifozine group|
62721618|NCT02328521|EXPERIMENTAL|Nicorandil group|Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
62721619|NCT02328521|PLACEBO_COMPARATOR|Control group|Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.
62721620|NCT03111316|OTHER|Foley Catheter & Dinoprostone Insert|transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
62721621|NCT03111316|OTHER|Foley Catheter Alone|a Foley catheter alone
62721622|NCT03307538|EXPERIMENTAL|Stereotactic body radiation therapy|
62721623|NCT01630317|EXPERIMENTAL|Peripheral acces|
62721624|NCT01630317|PLACEBO_COMPARATOR|Central access|
62721625|NCT06717945|EXPERIMENTAL|remimazolam besylate|Patients received an initial dose of remimazolam (0.3mg/kg) for induction and a continuous infusion rate of 1 mg/kg/h for anesthesia maintenance.
62721626|NCT06717945|ACTIVE_COMPARATOR|propofol|Patients received an initial dose of propofol (1.0 mg/kg) and a continuous infusion rate of 1-1.5 mg/kg/h
62721627|NCT05346328|EXPERIMENTAL|Single Group Assignment|This study adopts an open research design and selects patients with refractory HER2-positive unresectable locally advanced or metastatic breast cancer who have failed previous ADC drug treatment. The patients who met the enrollment conditions were treated with injection of A166.
62721628|NCT01474304|ACTIVE_COMPARATOR|Acetaminophen|Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.
62721629|NCT01474304|NO_INTERVENTION|No acetaminophen|Patients will receive standard of care with no intraoperative doses of acetaminophen.
62721630|NCT06400628|ACTIVE_COMPARATOR|initial and end|
62721631|NCT06400628|EXPERIMENTAL|Quasi experimental design|quasi
62721632|NCT01462071||Chronic kidney disease|
62721633|NCT03314610||Patients enrolled|Patient with parkinsonian syndromes and lower urinary tract symptoms, age \> 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes. A first record of gait speed will be at strong desire to void. A second record will be after voiding or catheterization Gait records consist on : 3x 10 meter walk test, 1x double task 10 meter walk test, 1x Timed up and Go test and 1x GMT
62721634|NCT06106893|EXPERIMENTAL|Experimental Arm|Participants will receive CD19 Universal CAR-γδ T Cells intravenous infusion
62721635|NCT06460870|EXPERIMENTAL|Mojzisova method|Mobilization of rib, lumbar spine, SI joint and internal rectal work. Stretching and strengthening exercises of pelvic floor, lumbar spine, sacrum and coccyx.
62721636|NCT06460870|ACTIVE_COMPARATOR|Stretching exercises|Stretching exercises cobra pose, child pose and cat/cow pose.
62721637|NCT04541082|EXPERIMENTAL|ONC206|
62721638|NCT02619747|ACTIVE_COMPARATOR|Compound Sodium Alginate Oral Suspension sachet|Single dose of contents of two 10 ml sachets of Compound Sodium Alginate Oral Suspension
62721639|NCT02619747|PLACEBO_COMPARATOR|Matched placebo|Single dose of contents of two 10 ml sachets of matched placebo
62721640|NCT05124717|EXPERIMENTAL|Treatment A|Test Product Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)
62721641|NCT05124717|ACTIVE_COMPARATOR|Treatment B|Reference Product Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
62721642|NCT04933292|EXPERIMENTAL|Methylprednisolone and Mycophenolate mofetil|
62721643|NCT04933292|ACTIVE_COMPARATOR|Methylprednisolone and Azathioprine|
62737906|NCT02697981|NO_INTERVENTION|control group|The control group is comprised of healthy pregnant women, of similar age, smoking behavior and background. No treatment will be given, just follow-up data collection.
62721644|NCT02768285|EXPERIMENTAL|Intervention|Endodontic treatment was performed in posterior teeth with necrotic pulp and periapical periodontitis using a reciprocating single-file system (Reciproc). Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 2.5 % sodium hypochlorite, canal negotiation was done \& apical patency was achieved with #10 K-files in patency group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills was done. The canals were obturated with gutta-percha and epoxy resin sealer. The treatments were carried out in one-visit.
62721645|NCT02768285|NO_INTERVENTION|Control|In the control group, apical patency did not maintained.
62721646|NCT02213068|EXPERIMENTAL|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (\~ 2 weeks into study): 40-60% of the previous dose Day 21 (\~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue~MPA: administered according to SOC"
62721647|NCT02213068|ACTIVE_COMPARATOR|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (\~ 2 weeks into study): 10% of the previous dose Day 21 (\~ 3 weeks into study): 20% of the previous dose Day 30 (\~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
62721648|NCT02213068|OTHER|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
62168144|NCT06401447|EXPERIMENTAL|Treatment Arm|"1. Take one cycle of induction chemo-immunotherapy, two cycle of concurrent chemoradiotherapy 3 weeks later, one cycle of consolidation chemo-immunotherapy 1 month after radiotherapy, and then 1 year of immunotherapy.~2. Radiotherapy: intensity modulated radiotherapy or volume modulated therapy. Modified involving field irradiation. PTV-C of 50.4Gy/28F, and PTV-G of 61.6Gy/28F with simultaneous integrated boost if no deep ulcers.~3. Chemotherapy: paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.~4. Immunotherapy: Sintilimab, 200mg, q3w.~5. Probiotics: Clostridium Butyricum (MIYAIRI 588), 20mg, tid, for 1 year.~6. Thymosin alpha-1: 1.6mg, qd, d1-5 during radiotherapy."
62721649|NCT00848419|ACTIVE_COMPARATOR|Methadone|Epidural methadone bolus 4mg
62721650|NCT00848419|ACTIVE_COMPARATOR|Morphine|Epidural morphine 4mg bolus
62721651|NCT00848419|ACTIVE_COMPARATOR|Fentanyl|Epidural fentanyl 200 microgram bolus
62721652|NCT00848419|PLACEBO_COMPARATOR|Saline|Epidural saline bolus
62721653|NCT04838184||Dental patients|Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible
62721654|NCT04231071|ACTIVE_COMPARATOR|Sutured group|Controlled group: Primary suture repair of the small umbilical hernia defect
62721655|NCT04231071|EXPERIMENTAL|Onlay Mesh group|Intervention group: Primary suture repair of the small umbilical hernia defects + a small Onlay mesh on the closed defect.
62721656|NCT03719807|ACTIVE_COMPARATOR|Control Group|Usual Care No routine outpatient physiotherapy following discharge home post-operatively in line with standard care.
62721657|NCT03719807|EXPERIMENTAL|Intervention Group|12 x Exercise//Rehabilitation sessions Begin at 6 weeks. 6 x weekly sessions Followed by 6 x bi-weekly sessions In line with Accelerated Rehabilitation protocol
62721658|NCT04145076|EXPERIMENTAL|Placebo, Citalopram, Tianeptine|Dose order: Placebo, Citalopram, Tianeptine
62721659|NCT04145076|EXPERIMENTAL|Placebo, Tianeptine, Citalopram|Dose order: Placebo, Tianeptine, Citalopram
62721660|NCT04145076|EXPERIMENTAL|Citalopram, Placebo, Tianeptine|Dose order: Citalopram, Placebo, Tianeptine
62721661|NCT04145076|EXPERIMENTAL|Citalopram, Tianeptine, Placebo|Dose order: Citalopram, Tianeptine, Placebo
62721662|NCT04145076|EXPERIMENTAL|Tianeptine, Placebo, Citalopram|Dose order: Tianeptine, Placebo, Citalopram
62721663|NCT04145076|EXPERIMENTAL|Tianeptine, Citalopram, Placebo|Dose order: Tianeptine, Citalopram, Placebo
62721664|NCT04871477||Observational (audio recording)|Patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the Supportive Care Center.
62721665|NCT05031143|ACTIVE_COMPARATOR|SCTA injection (n=6 eyes)|Suprachoroidal Trimacinolone Acetonide injection 4mg/0.1ml, single dose, follow up for 6 months.
62721666|NCT05031143|NO_INTERVENTION|Non-injected eyes (Standard Treatment) (n=6 eyes)|Non-injected eyes on systemic steroids (standard treatment) and follow up for 6 months
62721667|NCT03930589|PLACEBO_COMPARATOR|Standard of care|no intervention will occur in the standard of care arm
62721668|NCT03930589|ACTIVE_COMPARATOR|Remote Ischemic Conditioning|Remote ischemic conditioning using BP cuff on left arm
62721669|NCT00988793|ACTIVE_COMPARATOR|Laparoscopic distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
62721670|NCT00988793|ACTIVE_COMPARATOR|Open distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
62721671|NCT03571932||Intervention Facilities|Includes 18 health facilities
62721672|NCT03571932||Comparison facilities|Infludes 18 health facilities
62721673|NCT02171689|EXPERIMENTAL|BIBW 2992 MA2|
62721674|NCT01163396|EXPERIMENTAL|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks
62721675|NCT04581785|EXPERIMENTAL|Dose Level 1 Part A|3 year-olds to 12 year-olds
62721676|NCT04581785|EXPERIMENTAL|Dose Level 1 Part B|6 month to 2 year-olds
62721677|NCT04581785|EXPERIMENTAL|Dose Level 1 Part C|6 month to 12 year-olds
62721678|NCT04581785|EXPERIMENTAL|Dose Level 2 Part A|3 year-olds to 12 year-olds
62721679|NCT04581785|EXPERIMENTAL|Dose Level 2 Part B|6 month to 2 year-olds
62168145|NCT04212559||NPV group|Patients who had treated in pulmonary rehabilitation unit with NPV
62168146|NCT06167915|EXPERIMENTAL|Low dose vaccine group|30μg dose of LYB002V14 vaccine IM, on day 0.
62168147|NCT06167915|EXPERIMENTAL|High dose vaccine group|60μg dose of LYB002V14 vaccine IM, on day 0.
62168148|NCT06167915|PLACEBO_COMPARATOR|Placebo group|placebo IM, on day 0.
62549425|NCT03333135|SHAM_COMPARATOR|UTMB Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
62549426|NCT06582420|PLACEBO_COMPARATOR|Standard trauma care|Determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide .
62549427|NCT06582420|EXPERIMENTAL|Standard trauma care plus administration of fibrinogen concentrate (FC).|The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
62549428|NCT01255137|EXPERIMENTAL|Adrenal Cortex Neoplasms|Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
62549429|NCT04768426|EXPERIMENTAL|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day cycles
62549430|NCT04811937|EXPERIMENTAL|Artificial intelligence for real-time Computer decision support of resection of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information about polypectomy procedures.
62549431|NCT04486365|ACTIVE_COMPARATOR|Bifocal bone transport|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
62549432|NCT04486365|ACTIVE_COMPARATOR|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments between osteotomy and defect.
62549433|NCT01153373|PLACEBO_COMPARATOR|Minimal Intervention Control|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only. The reports will not be printed or dynamic referrals generated, and all patients will receive treatment-as-usual by their ED providers."
62549434|NCT01153373|ACTIVE_COMPARATOR|DARSSA Intervention|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
62549435|NCT02892929|EXPERIMENTAL|Motivational Interviewing|The motivational interview is a style of care that evokes the patient their motivations to make behavioral changes in the interests of their own health. It is a technique centered in patient to explore and resolve their ambivalence to modify unhealthy behavior.
62549436|NCT02892929|ACTIVE_COMPARATOR|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation. In this type of consultation the health professional who plans the action plan for the patient and determines how it will be the patient's lifestyle modification.
62549437|NCT06198244|EXPERIMENTAL|Experimental Group|TENS was applied on abdomen along with baseline movements and stretches were given to experimental group.
62549438|NCT06198244|ACTIVE_COMPARATOR|Control Group|Baseline movements and stretches were given to control group
62549439|NCT02203890||Apparently Healthy|Apparently healthy preschool children who attend 3 daycare centers of the Secretariat of Beneficials Works of the First Lady in Guatemalan Western Highlands
62549440|NCT03408171|ACTIVE_COMPARATOR|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
62549441|NCT03408171|ACTIVE_COMPARATOR|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
62549442|NCT04841005|EXPERIMENTAL|Square-Step Exercise group|Square-step exercise for 8 weeks will be applied under the supervision of a physiotherapist.
62549443|NCT04841005|EXPERIMENTAL|Strengthening Exercise Group|Strengthening exercise for 8 weeks will be applied under the supervision of a physiotherapist.
62549444|NCT03893643||pediatric population|Pediatric population aged 0 to 15 years with neurofibromatosis type 2
62549445|NCT03767660|EXPERIMENTAL|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
62549446|NCT05482711|OTHER|Time Restricted Eating intervention|Participants will be asked to stop eating by 7 PM every day and to fast for a target of 16 hours per day for 8 weeks. During the first two weeks of the intervention, participants will gradually ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 8 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Additionally, they will be asked to keep a Fasting and Sleeping diary logging their eating habits and sleep quality.
62549447|NCT05800067|EXPERIMENTAL|Axi-cel|Patients will receive a target dose of 2×10⁶ Axi-cel per kilogram of body weight after receiving a conditioning regimen. The conditioning regimen and dosage will be at investigator's discretion based on patient's status.
62549448|NCT04779879|ACTIVE_COMPARATOR|Sotrovimab (Gen1)|Part A (double-blinded) participants will be randomized to receive 500 mg of an IV infusion of Sotrovimab Gen 1 material or 500 mg of an IV infusion of VIR-7831 Gen 2 material
62549449|NCT04779879|ACTIVE_COMPARATOR|Sotrovimab (Gen2)|"Part B (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or by IM injection~Part C (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or 250 mg by IM injection"
62721680|NCT01103440|OTHER|Conventional Strategy|Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure
62721681|NCT01103440|ACTIVE_COMPARATOR|Aggressive Strategy|Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
62721682|NCT01649713|EXPERIMENTAL|Fluval AB vaccination|In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
62721683|NCT00272220|EXPERIMENTAL|1|receive 6-week intervention of peer-delivered mDOT
62721684|NCT00272220|NO_INTERVENTION|2|
62721685|NCT05357833|EXPERIMENTAL|SPMS Cohort|Subjects will undergo MR imaging of the brain and cervical spine for pre- and post-administration of gadoteridol (0.2 mL/kg), then pre- and post-administration of ferumoxytol (4 mg/kg). Scans will be obtained over the course of two separate imaging visits.
62721686|NCT05141838|EXPERIMENTAL|Group 1 - Vitamin D|Patients receiving vitamin D supplements in therapy
62721687|NCT05141838|EXPERIMENTAL|Group 2 - Oral nutritional supplement|Patients receiving oral nutritional supplement
62721688|NCT05141838|EXPERIMENTAL|Group 3 - Vitamin D+Oral nutritional supplement|Patients receiving vitamin D supplements and oral nutritional supplement in therapy
62721689|NCT05141838|NO_INTERVENTION|Group 4 - No intervention|Patients with dystrophic form of congenital epidermolysis bullosa who have not taken vitamin D supplements and/or oral nutritional supplement
62721690|NCT00547963|EXPERIMENTAL|1|two brief counseling sessions delivered to ED patients who report conjoint alcohol and marijuana use
62721691|NCT04118725|EXPERIMENTAL|Muscular explorations|Pulmonary function test and diaphragmatic electromyography
62721692|NCT02351011|EXPERIMENTAL|Cohort 1|1 x 10\^6 MSCs
62721693|NCT02351011|EXPERIMENTAL|Cohort 2|10 x 10\^6 MSCs
62721694|NCT02351011|EXPERIMENTAL|Cohort 3|50 x 10\^6 MSCs
62721695|NCT01587248|ACTIVE_COMPARATOR|Electrocautery|Raising of the flaps with electrocautery
62721696|NCT01587248|EXPERIMENTAL|Harmonic|Dissection with harmonic scalpel in modified radical mastectomy
62721697|NCT01484457|EXPERIMENTAL|Closed-loop control system|"The objective of this study is to automate glucose control in subjects with type 1 diabetes using a computer control algorithm in a controlled in-clinic research setting.~The controller will be evaluated under two conditions:~1. restoring euglycemia (80-140 mg/dL) when the controller is initiated during a period when the subject's glucose is above the euglycemic range;~2. restoring euglycemia (80-140 mg/dL) when the controller is challenged with a small unannounced meal (\~25 g CHO)."
62721698|NCT01736033|PLACEBO_COMPARATOR|Tamsulosin + Placebo|Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression
62721699|NCT01736033|ACTIVE_COMPARATOR|Tamsulosin + Finasteride|Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression
62721700|NCT00700622|EXPERIMENTAL|TI + Insulin glargine|Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)
62721701|NCT00700622|EXPERIMENTAL|Insulin lispro + Insulin glargine|Humalog (insulin lispro) in combination with Lantus (insulin glargine)
62721702|NCT00441766|EXPERIMENTAL|AGN 203818 3 mg|Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
62721703|NCT00441766|EXPERIMENTAL|AGN 203818 20 mg|Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
62721704|NCT00441766|EXPERIMENTAL|AGN 203818 60 mg|Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
62721705|NCT00441766|PLACEBO_COMPARATOR|Placebo|Part A: Placebo capsule every 12 hours for 4 weeks
62721706|NCT00888225|EXPERIMENTAL|Eccentric exercise|Group exposed to eccentric exercise treatment
62721707|NCT00888225|ACTIVE_COMPARATOR|Concentric exercise|Group exposed to concentric exercise treatment
62721708|NCT00212836|EXPERIMENTAL|Asenapine|
62168149|NCT02905877||Functional neurological disorders|Initially especially patients diagnosed with a functional tremor.
62721709|NCT00212836|ACTIVE_COMPARATOR|Olanzapine|
62721710|NCT03597386||All Participants|
62721711|NCT05035459||Conventional heart failure management group|Patients with ≥ 3 B-lines will be divided into the conventional heart failure management group and the LUS-BL-guided intensive heart failure management group at 1:1 ratio. Patients in the conventional heart failure management group will receive conventional guideline recommended HF therapy post discharge and be followed up at 2-month interval post discharge by clinical visit. LUS-BL will be assessed at 2-month interval post discharge also in this group, but results will be enveloped.
62721712|NCT05035459||LU-BL guided intensive heart failure management group|The group with ≥ 3 B-lines will be divided into the conventional heart failure management group and the LUS-BL-guided intensive heart failure management group at 1:1 ratio. Patients in the LUS-BL-guided intensive heart failure management group will receive optimized HF medication and medication will be adjusted according the status of LUS-BL during the follow-up at 2-month interval.
62721713|NCT00696033|EXPERIMENTAL|1|Oral Lorazepam
62721714|NCT00696033|EXPERIMENTAL|2|Oral Diazepam
62721715|NCT00696033|PLACEBO_COMPARATOR|3|Oral placebo
62721716|NCT06199765|EXPERIMENTAL|Lecture, demonstration, and role play on NSI|this arm will receive intervention regarding needlestick prevention using needlestick prevention educational module. this intervention only involve educational intervention which consist of lecture, demonstration, and role play. This intervention will be done for 1 week duration.
62721717|NCT06199765|SHAM_COMPARATOR|Patient Safety Materials|This arm will receive material regarding patient safety. this material will have some element of needlestick and injury prevention. this intervention will done for 1 week.
62721718|NCT04221633|EXPERIMENTAL|Webinar only|Participants in this arm will attend a webinar training program (3 webinars over the course of 4 to 8 weeks) to receive training in evidence-based engagement strategies, trauma, evidence-based practices, and mental health screening.
62721719|NCT04221633|EXPERIMENTAL|Webinar plus consultation|Participants in this arm will receive the same webinar training as subjects in arm 1, but they will also receive 10 consultation calls over the course of four months to further develop their skills in engaging families and screening for mental health services.
62721720|NCT04221633|NO_INTERVENTION|Delayed training group|This group will not receive any training for the duration of the study year, in order to serve as a waitlist control group. They will be eligible to receive the training after the randomized control trial has been completed.
62721721|NCT00751478|EXPERIMENTAL|A|2 Placebo capsules (whole) + ALO-01 2 x 60 mg capsules (crushed) in apple juice + apple juice (MSIR placebo)
62721722|NCT00751478|EXPERIMENTAL|B|2 x 60 mg ALO-01 (whole) + 2 x placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
62721723|NCT00751478|ACTIVE_COMPARATOR|C|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + 120 mg MSIR in apple juice
62721724|NCT00751478|PLACEBO_COMPARATOR|D|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
62721725|NCT03521154|EXPERIMENTAL|Osimertinib|Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule.
62721726|NCT03521154|PLACEBO_COMPARATOR|Placebo Osimertinib|Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule
62721727|NCT04201639|EXPERIMENTAL|Refit|Refit and dispense patient with Verofilcon A contact lenses and evaluate lens performance.
62721728|NCT03505892||Participants receiving adalimumab|Participants with AS receiving adalimumab
62721729|NCT05110326|EXPERIMENTAL|ERGON Technique Group|Patients in this group will receive ERGON Technique along with conventional therapy
62721730|NCT05110326|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation(PNF) stretching Group|Patients in this group will receive Proprioceptive Neuromuscular Facilitation (PNF) stretching along with conventional therapy
62721731|NCT05515328|EXPERIMENTAL|Part A: Arm 1|
62721732|NCT05515328|EXPERIMENTAL|Part B: Arm 1 - Reference|
62721733|NCT05515328|EXPERIMENTAL|Part B: Arm 2 - Treatment|
62721734|NCT05887037|EXPERIMENTAL|Experimental group|The experimental group was sent for CSF mNGS and traditional microbiological cultures at the same time, and the mNGS results were usually earlier than the traditional microbiological cultures results. The experimental group adjusted or continued the current medication regimen according to the mNGS reporting pathogen and the expert team's opinion. Subsequently, if the CSF traditional microbiological cultures results in the experimental group are consistent with the mNGS results, the current treatment plan of the patient is continued, and if the results are inconsistent with the mNGS results, the expert team needs to discuss and adjust the treatment plan. When no causative organism is detected in mNGS, empiric treatment is continued, and treatment is adjusted pending the pathogen culture results.
62721735|NCT05887037|ACTIVE_COMPARATOR|Control group|After a clinical diagnosis of central nervous system infection, the control group was treated empirically based on only cerebrospinal fluid for traditional microbiological cultures, without mNGS detection, and the treatment plan was adjusted according to the traditional microbiological cultures results. If the patient's culture is negative and empiric therapy does not improve, cerebrospinal fluid is retained for mNGS testing. Treatment is adjusted based on mNGS results and expert team evaluation.
62721736|NCT00249587|EXPERIMENTAL|1|Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
62721737|NCT00249587|ACTIVE_COMPARATOR|2|Methadone plus behavioral counseling consisting of adherence
62721738|NCT00834821|EXPERIMENTAL|1|Participants will undergo the Child Life and Attention Skills (CLAS) Program.
62721739|NCT00834821|ACTIVE_COMPARATOR|2|Participants will undergo parent focused training (PFT).
62721740|NCT00834821|NO_INTERVENTION|3|Participants will receive a list of referrals for clinical services as needed, including professional organizations, support groups, and the community mental health system.
62721741|NCT02886650|EXPERIMENTAL|Thermocoagulation|
62721742|NCT01981798|ACTIVE_COMPARATOR|Training group|Physiotherapy and occupational therapy: Training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour.
62721743|NCT01981798|NO_INTERVENTION|Control Group|Members of the control group were referred to their general practitioner or specialist for further care.
62721744|NCT01459094|EXPERIMENTAL|Treatment Sequence AB|
62721745|NCT01459094|EXPERIMENTAL|Treatment Sequence BA|
62168150|NCT02905877||Organic neurological disorders.|Initially especially patients diagnosed with a an organic action tremor (e.g. essential tremor or dystonic tremor).
62721746|NCT00149786|EXPERIMENTAL|1|Those adolescents receiving family based therapy
62721747|NCT00149786|ACTIVE_COMPARATOR|2|Those adolescents receiving individual therapy
62721748|NCT02848092|EXPERIMENTAL|FOCAL+Training|
62721749|NCT02848092|SHAM_COMPARATOR|Rules of the Road Training|
62721750|NCT06200519||Neonates born at 35 weeks gestation and above|"Stratification of population for recruitment and data analysis~1. Gestational age in weeks~2. Birth weight and centile~3. Small for gestational age (birth weight \<10th centile post-natal)~4. Large for gestational age (birth weight \>90th centile post-natal)~5. Evidence of antenatal Doppler abnormalities~6. Maternal gestational diabetes mellitus or pre-existing diabetes mellitus~7. Maternal pre-eclampsia~8. Signs of maternal chorioamnionitis~9. Mode of delivery~10. Transient Tachypnea of Newborn~11. Pregnancy conceived by assisted reproductive technologies~12. Maternal medication use~13. Suspected or confirmed Trisomy 21~14. Gestational age at birth 35-36+6 gestation group~15. Feeding type~16. Mild neonatal encephalopathy~17. Moderate and severe neonatal encephalopathy receiving therapeutic hypothermia"
62721751|NCT02681081|OTHER|Control|For sessions 2 through 4, maintain normal eating patterns.
62168151|NCT02905877||Healthy control|Healthy age matched controls
62721752|NCT02681081|ACTIVE_COMPARATOR|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
62721753|NCT02681081|ACTIVE_COMPARATOR|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
62721754|NCT04951765|EXPERIMENTAL|Arm A|Cycle1 Day 1：fasting；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：low-fat meal
62721755|NCT04951765|EXPERIMENTAL|Arm B|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：fasting
62721756|NCT04951765|EXPERIMENTAL|Arm C|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：high-fat meal
62721757|NCT04951765|EXPERIMENTAL|Arm D|Cycle1 Day 1：fasting；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：high-fat meal
62721758|NCT04951765|EXPERIMENTAL|Arm E|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：low-fat meal
62721759|NCT04951765|EXPERIMENTAL|Arm F|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：fasting
62721760|NCT02625181|EXPERIMENTAL|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
62721761|NCT05404971|EXPERIMENTAL|Joint integrity exercises|"Tactile stimulation with the various textures will be applied to the patients with three strokes followed by 3 sec rest period.~Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set."
62721762|NCT05404971|ACTIVE_COMPARATOR|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
62721763|NCT01653444|EXPERIMENTAL|GC1119 0.5 mg/kg|0.5 mg/kg biweekly
62721764|NCT01653444|EXPERIMENTAL|GC1119 1.0 mg/kg|1.0 mg/kg biweekly
62721765|NCT01874548||Normal cervix|Control group (n=30) comprising surgical candidates with normal cervical tissue will be collected for comparison.
62721766|NCT01874548||Cervical cancer|"1. 1st year: 30 surgical candidates with cervical cancer tissue collected during operation.~2. 2nd year: Enroll another 30 surgical candidates and complete the data regarding clinical MRS/DWI and tissue high resolution MRS. Together with the 30 cancer subjects in part one there will be in total 60 cancer subjects for analysis.~3. 3rd year: enroll 60 patients primarily treated with CCRT and collect the data using clinical MR and tissue high resolution MRS."
62721767|NCT02026011|EXPERIMENTAL|Naltrexone|Naltrexone 50 mg/day
62721768|NCT02026011|PLACEBO_COMPARATOR|Sugar pill|Matched placebo
62721769|NCT03328832|ACTIVE_COMPARATOR|Combined topical TXA and Floseal|Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
62721770|NCT03328832|ACTIVE_COMPARATOR|Topical TXA alone|Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
62721771|NCT06069609|EXPERIMENTAL|Kalifilcon A Contact Lens for Astigmatism|
62721772|NCT06069609|ACTIVE_COMPARATOR|Commercially available contact lenses: Acuvue Oasys 1-Day for Astigmatism|
62721773|NCT01840488|EXPERIMENTAL|Irosustat (BN83495)|Single oral administration of irosustat
62721774|NCT03001661|ACTIVE_COMPARATOR|Propess|Control intervention: Propess® (dinoprostone) Slow release vaginal drug delivery system (Prostaglandin E2).
62721775|NCT03001661|EXPERIMENTAL|Dilapan-S|Experimental intervention: DILAPAN-S® A synthetic osmotic cervical dilator for insertion into the cervical canal, using as many rods as necessary.
62721776|NCT03345303|EXPERIMENTAL|Bortezomib treatment|'Bortezomib Injectable Solution
62721777|NCT03345303|NO_INTERVENTION|supportive care|supportive care
62721778|NCT02971709|EXPERIMENTAL|Shade Sail|Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
62721779|NCT02971709|NO_INTERVENTION|Unshaded Control|Passive recreation areas in public parks that remained unshaded at pretest and posttest.
62721780|NCT01623934||Phase 1: Pregnant women|
62721781|NCT01623934||Phase 2: Mother-offspring dyad|
62721782|NCT00224081|EXPERIMENTAL|Ferric gluconate|
62721783|NCT00224081|NO_INTERVENTION|standard of care|
62721784|NCT02494154|ACTIVE_COMPARATOR|Conventional flow via nasal prongs|Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.
62721785|NCT02494154|EXPERIMENTAL|High flow nasal cannulas 20L/min|Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.
62721786|NCT02494154|EXPERIMENTAL|High flow nasal cannulas 40L/min|Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
62721787|NCT02494154|EXPERIMENTAL|High flow nasal cannulas 60L/min|Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
62721788|NCT05446935|OTHER|HITOC|HITOC group contains all patients who undergo HIROC in this study.
62721789|NCT06049550||mild thicknening of Bowman's Capsule|
62721790|NCT06049550||severe thickening of Bowman's Capsule|
62721791|NCT00525434|EXPERIMENTAL|A|
62721792|NCT02910141||CSII (subcutaneous insulin infusion)|People with Type 2 diabetes treated by continuous subcutaneous insulin infusion (CSII)
62721793|NCT02910141||MDI (multiple daily insulin injections)|People with type 2 diabetes treated by multiple daily insulin injections
62721794|NCT02559973|EXPERIMENTAL|RBP-6000 - Light MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a light molecular weight (MW) polymer.
62721795|NCT02559973|EXPERIMENTAL|RBP-6000 - Heavy MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a heavy molecular weight (MW) polymer.
62721796|NCT02559973|ACTIVE_COMPARATOR|RBP-6000 - Intermediate MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with an intermediate molecular weight (MW) polymer (reference).
62721797|NCT05725122|ACTIVE_COMPARATOR|ESWL alone|Extracorporeal shock wave lithotripsy will be given to the patient
62721798|NCT05725122|ACTIVE_COMPARATOR|ESWL combined with tamsulosin therapy|Extracorporeal shock wave lithotripsy combined with tamsulosin therapy will be given to the patient
62721799|NCT03761355||medical student of 6th Year|Students of medical faculty of 6th Year in Medical University of Bialystok, Poland.
62721800|NCT00682045||T-SPOT.TB positive|T-SPOT.TB positive patients
62721801|NCT04532515|EXPERIMENTAL|Seal G / Seal-G MIST|"Seal-G Surgical Sealant \[Seal-G\]- will be applied on colonic anastomosis created by extra-corporal approach.~Seal-G MIST System \[Seal-G MIST\]- will be applied on colonic anastomosis created by intra-corporal approach."
62721802|NCT00352859|EXPERIMENTAL|Arm 1|
62721803|NCT00352859|EXPERIMENTAL|Arm 2|
62721804|NCT02261207|EXPERIMENTAL|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
62721805|NCT02802293|ACTIVE_COMPARATOR|Standard rTMS Aiming|Active repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left DLPFC using the standard aiming strategy with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
62721806|NCT02802293|ACTIVE_COMPARATOR|Anterior DLPFC targeting|Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
62721807|NCT02802293|ACTIVE_COMPARATOR|Posterior DLPFC targeting|Active rTMS will be delivered to the left posterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
62721808|NCT05236322||study group|Removal by soft tissue laser of the tumor
62721809|NCT05236322||control group|Removal by ordinary surgical scalpel
62721810|NCT04666974|EXPERIMENTAL|Phase 3: iCBT + Treatment As Usual|CWs in the iCBT group, will be assigned to one the six therapy modules, based on their gender and diagnosis (i.e. Female/Male \* GAD, MDD or PTSD). Each CW will be assigned a specific clinician (a trained psychiatrist/psychologist/ social worker) who would be their care liaison through the study. Each week, the clinician would send one session of the 12-session curriculum to the CW on a pre-determined day of the week. Each weekly session consists of 20-30 slides followed by a homework assignment. It usually takes 40-60 minutes for a participant to complete one weekly session which they have to complete by a specific day of the week. The clinician will review the CW's assignments and provide feedback on their performance. The clinician feedback is structured and takes approximately 15 minutes to complete. The clinician will then send the content for the next session along with the feedback.
62721811|NCT04666974|NO_INTERVENTION|Phase 3: Treatment as Usual|Participants will complete clincally validated questionnaires to measure symptoms while continuing with their regular daily activities and treatments (if any) (i.e., exercise, diet, medications, etc.)
62721812|NCT04666974|EXPERIMENTAL|Phase 4: iCBT + Treatment as Usual|Participants will be randomly assigned to this group and take part in the iCBT module program from phase 3.
62721813|NCT04666974|ACTIVE_COMPARATOR|Phase 4: In-Person CBT + Treatment as Usual|Participants will be randomly assigned to this group and complete in-person CBT with similar content, homework, and feedback as in the iCBT + TAU group. All in-person CBT will be delivered by a trained professional and each session will take approximately 60-75 minutes.
62721814|NCT01949129|EXPERIMENTAL|Flu/Thio/Treo|"Fludarabine/Thiotepa/Treosulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:~* MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.~* MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.~* MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide"
62721815|NCT01949129|ACTIVE_COMPARATOR|TBI/VP16|"TBI (Total Body Irradiation) / VP16 is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients older than 48 months with:~* MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.~* MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.~* MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide.~Patients aged 24-48 months may optionally receive Total Body Irradiation (TBI)."
62721816|NCT01949129|EXPERIMENTAL|Flu/Thio/ivBu|"Fludarabine/Thiotepa/iV Busulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:~* MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.~* MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.~* MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide"
62721817|NCT01949129|EXPERIMENTAL|Bu/VP16/Cy|Busulfan/VP16/Cyclophosphamide is an alternative conditioning arm that may optionally be used for HSCT with MSD/MD and MMD graft in patients aged 0-24 months. Patients undergoing MD HSCT will also receive ATG Thymo- or Grafalon.
62721818|NCT02276742|NO_INTERVENTION|Usual Care (UC)|Participants randomized to UC will receive baseline advice about the value of losing weight, becoming more physically active, and limiting intake of sodium and inorganic phosphates followed by 12 mos of UC. We have elected not to use a control group in which we provide equivalent attention to both study arms. Behaviors are difficult to change and there is no reason to believe that simply giving participants attention would create behavioral changes sufficient to result in weight loss, reduce sodium excretion, or reduce serum phosphorus. Numerous weight loss studies, including Look AHEAD, have used attention control groups that did not demonstrate weight loss.
62168152|NCT04765540|ACTIVE_COMPARATOR|T1: Business as Usual (BAU)|Handwashing station plus standard BRAC programming, i.e. in-person community WASH (water, sanitation and hygiene) demonstrations conducted in households/communal areas, and sticker signs/posters placed on walls in the 'catchment area' of the handwashing station, alerting people to the stations and roughly pointing the way.
61976684|NCT04053023|EXPERIMENTAL|Participants receiving obeticholic acid and linerixibat|In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
62549450|NCT01843296|ACTIVE_COMPARATOR|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
62549451|NCT01843296|ACTIVE_COMPARATOR|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
62549452|NCT01843296|ACTIVE_COMPARATOR|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
62549453|NCT04187170|EXPERIMENTAL|Healthy sedentary subjects exposed to the training program|
62549454|NCT05550506||Duloxetine Group|Patients who use duloxetine at least 3 months for chronic pain or fibromyalgia
62549455|NCT05550506||Healthy Group|Age and sex matched 51 healthy individuals
62549456|NCT02211443|EXPERIMENTAL|Single arm|"Two phase study of Recombinant full human Anti-epidermal growth factor receptor(EGFR) Monoclonal Antibody:~First phase: seven escalating single-dose groups : 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/kg~Second phase: multiple-dose groups 0.5, 1.0, 2.0, 3.0 mg/kg: weekly once for 4 doses; 5.0, 6.0 mg/kg: every two weeks for 2 doses; 4.0 mg/kg: weekly or every two weeks depends on the results of previous dose groups."
62549457|NCT02246114|EXPERIMENTAL|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
62549458|NCT02246114|EXPERIMENTAL|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
62549459|NCT04141982||Suspected of having TB infection|These donors are suspected of having TB infection and live in a high endemic area for TB infection
62549460|NCT04141982||No (or minimal) TB risk factors|These donors must have no previous medical record of TB infection and live in low endemic area for TB infection
62549461|NCT04141982||low/intermediate risk of TB infection population|These donors must live in an low/intermediate endemic area for TB infection
62549462|NCT00316758|EXPERIMENTAL|1|
62549463|NCT02732262|EXPERIMENTAL|Oxycodone, 1.00 mg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
62549464|NCT02732262|EXPERIMENTAL|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
62549465|NCT02732262|EXPERIMENTAL|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
62549466|NCT01970137|EXPERIMENTAL|KPS-0373|
62549467|NCT01477723|EXPERIMENTAL|Experimental Oral Nutrition Supplement|Experimental ONS orally Two 8 fl oz servings/day
62549468|NCT01477723|NO_INTERVENTION|No Product|
62549469|NCT01720888|NO_INTERVENTION|Maximal medical therapy|Maximal medical therapy which comprises of optimal pharmacological therapy
62549470|NCT01720888|EXPERIMENTAL|Maximal medical therapy and BM-MSCs|Autologous Bone marrrow-derived mesenchymal stem cells implantation
62549471|NCT02831426|ACTIVE_COMPARATOR|ADM two-stage reconstruction|Two-stage with Acellular Dermal Matrix (CELLIS® Breast). Tissue Expander A, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by ADM
62549472|NCT02831426|EXPERIMENTAL|TCPM two-stage reconstruction|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra). Tissue Expander B, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by TCPM
62549473|NCT01927575|ACTIVE_COMPARATOR|Standard X-Ray + CT|Standard X-Ray + CT arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
62549474|NCT01927575|ACTIVE_COMPARATOR|Standard X-Ray + MRI|Standard X-Ray + MRI arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
62549475|NCT01927575|EXPERIMENTAL|Tomo|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
62549476|NCT03933566||Ultrasound-Guided|Ultrasound-Guided Superficial Cervical Plexus Block
62549477|NCT03933566||Landmark-Based|Landmark-Based Superficial Cervical Plexus Block
62549478|NCT05316610|EXPERIMENTAL|Body Confident Athletes|Participants in the intervention condition will take part in an in-person program consisting of five sessions over five weeks.
62549479|NCT05316610|NO_INTERVENTION|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
62549480|NCT03214783||Coronary artery disease (CAD) group|Patients enrolled with at least one coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
62549481|NCT03214783||No CAD group|Patients enrolled without coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
62549482|NCT02096432|EXPERIMENTAL|Behavioral: Behavioral Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
62549483|NCT02096432|OTHER|Usual Community Care|Community standard care as usual
62549484|NCT04979351|EXPERIMENTAL|Abdominal Massage Group|Abdominal massage for 15 minutes twice a day application.
62549485|NCT04979351|NO_INTERVENTION|Placebo Group|Abdominal massage was not applied.
62549486|NCT03946852|EXPERIMENTAL|ARP arm|Patients will receive DCD after therapy after the abdominal reperfusion protocol.
62549487|NCT04283422||patintes on mechanical ventilation|
62549488|NCT04283422||patintes not on mechanical ventilation|
62549489|NCT02943590|PLACEBO_COMPARATOR|Placebo|Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
62549490|NCT02943590|EXPERIMENTAL|Atorvastatin|Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
62549491|NCT02290457|EXPERIMENTAL|CSTS|core strength training performed on stable surfaces
62549492|NCT02290457|EXPERIMENTAL|CSTU|core strength training performed on unstable surfaces
62549493|NCT05632926|EXPERIMENTAL|CBL-514 40mg|
62549494|NCT05632926|EXPERIMENTAL|CBL-514 60mg|
62549495|NCT05632926|EXPERIMENTAL|CBL-514 80mg|
62549496|NCT05998876||3-6 HRS|Microneedle electrode array placed into dermis for up to 6 hours. DPV Scans performed at a frequency of 1-20 per hour.
62549497|NCT05998876||12 HRS|Microneedle electrode array placed into dermis for up to 12 hrs. DPV Scans performed at a frequency of 1-20 per hour.
62549498|NCT05998876||3 Days|Microneedle electrode array placed into dermis for up to 3 days. DPV Scans performed at a frequency of 1-20 per hour.
62549499|NCT02859753|EXPERIMENTAL|RFA|
62549500|NCT02859753|ACTIVE_COMPARATOR|MCT|
62549501|NCT01476514|EXPERIMENTAL|1|"In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients."
62549502|NCT06304246||Labor Pain Group (LPG)|LPG; pregnant women who will undergo emergency C-section with labor pain. Labor pain will be defined as having 3 or more regular uterine contractions in 20 minutes or \&gt;120 Montevideo units of uterine performance observed during non-stress testing (NST) conducted at the Obstetrics Clinic.
62549503|NCT06304246||No Pain Group (NPG)|NPG; pregnant women who will undergo elective C-section without labor pain.
62549504|NCT05972369||Exercise Responders|≥30% improvement in pain with 12 weeks of prescribed exercise
62549505|NCT05972369||Exercise Non-responders|\<30% improvement in pain with 12 weeks of prescribed exercise
62549506|NCT00270855|OTHER|Arm Crank Ergometer|Upper body Cycle ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
62549507|NCT00270855|OTHER|FESLCE|Functional Electrical Stimulation Leg Cycle Ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
62549508|NCT01480245|EXPERIMENTAL|Continuous Dosing|GSK2402968 6mg/kg/week
62549509|NCT01480245|EXPERIMENTAL|Intermittent Dosing|GSK2402968 6mg/kg/week
62549510|NCT01480245|NO_INTERVENTION|Natural History Observation|The objective of this arm will be to explore DMD disease progression in a naturalistic setting once discontinuing active treatment
62549511|NCT00600587|EXPERIMENTAL|A|Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
62549512|NCT00600587|ACTIVE_COMPARATOR|B|Non-erlotinib targeted NSCLC population based on EGFR gene analysis
62549513|NCT00324987|EXPERIMENTAL|Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)|Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62549514|NCT00324987|ACTIVE_COMPARATOR|Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)|Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62549515|NCT04003493|EXPERIMENTAL|Intervention group of nutrition|On the basis of a blood test, Mini Nutritional Assessment, food diary and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the caregivers. If the caregivers seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
62549516|NCT04003493|NO_INTERVENTION|Control group of nutrition|The control group has the same examinations as the intervention group, they do not get dietary counseling.
62549517|NCT04003493|EXPERIMENTAL|Intervention group of oral health|After the dental hygienist interview and oral health examination, the caregivers in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
62549518|NCT04003493|NO_INTERVENTION|Control group of oral health|The control group has the same examinations as the intervention group, they do not get oral health counseling.
62549519|NCT05982002|ACTIVE_COMPARATOR|Control group|Group A: (Control group)20 post menopausal women received moderate intensity aerobic exercise in addition to energy restricted diet 2time/week for 6 -weeks
62549520|NCT05982002|EXPERIMENTAL|Shock wave group|Group B: (shock wave group)20 post menopausal women received the same intervention as in group A and 12 sessions of shockwave on abdomen twice/week for 6 -weeks
62549521|NCT06196489|EXPERIMENTAL|telephone|Participants assigned to this group will receive the adapted intervention by telephone.
62549522|NCT06196489|EXPERIMENTAL|Video|Participants assigned to this group will receive the adapted intervention by video telehealth.
62549523|NCT06459492|EXPERIMENTAL|puzzle game strategy study group|Older adults who participate in puzzle game strategies
62549524|NCT06459492|NO_INTERVENTION|older adult control group|Older adults who not participate in puzzle game strategies
62549525|NCT01229137||Right Ventricular Cohort|Right Ventricle wtih SRD-1 conversion
62549526|NCT01229137||Left Ventricular Cohort|Left Ventricle with SRD-1 conversion
62549527|NCT01229137||Right Atrium Cohart|Right atrium cohort with SRD-1 conversion
62549528|NCT04601571|ACTIVE_COMPARATOR|Feeding Tube Placement using CORTRAK stylet|Subjects will already have a feeding tube placed and are undergoing X-rays for placement confirmation.
62549529|NCT04601571|NO_INTERVENTION|Feeding Tube Placement using X-Ray|Routine X-ray is used to confirm feeding tube placement
62549530|NCT05002088||Primary Analysis Population|The primary analysis population will include patients who have signed an Informed Consent Form, and at minimum, the Portico delivery system entered his/her vasculature for an attempted Portico ViV implant. Patients must have met the sizing requirements of the PorticoTM transthoracic aortic valve sizing specification (≥19 mm and ≤27 mm).
62549531|NCT05002088||Exploratory Registry Arm|The exploratory registry arm will collect data for patients that were treated for a failed surgical bioprosthetic aortic valve true inner diameter size of \<19 mm or \>27 mm.
62549532|NCT00973063|NO_INTERVENTION|conventional gloving|
62721819|NCT02276742|ACTIVE_COMPARATOR|Social Cognitive Theory (SCT)|Participants will be exposed to a group behavioral intervention that is based on SCT, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Mastery experiences will include emphasizing past successes; setting incremental, easily achievable goals; identifying modifiable barriers to healthy behavior; receiving positive feedback on goal achievement; and practicing problem solving skills around barriers to adherence.
62721820|NCT02276742|ACTIVE_COMPARATOR|Monitoring|Participants will be taught how to use a lifestyle self-monitoring program to reduce information processing requirements, make readily available the information required to make good self-management decisions, deliver automated, real-time feedback about achievement of behavioral goals, and permit individualized guidance from an interventionist who uses the MyNetDiary® electronic log to provide targeted education and advice. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
62721821|NCT02276742|ACTIVE_COMPARATOR|Combined|Participants randomized to COMBINED will receive all aspects of the SCT and MONITORING intervention conditions. Social Cognitive Theory based behavioral intervention in complex patients is strengthened when technology is used to manage information complexity, and weakened in its absence. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
62721822|NCT04734314|EXPERIMENTAL|conventional treatment of back pain|Group A: received conventional treatment of back pain which included; TENS 20 min and hot packs 10 min .The total treatment session is 30 min three session per week for four weeks
62721823|NCT04734314|EXPERIMENTAL|vojta therapy|received conventional treatment of back pain in addition to Vojta therapy . The total treatment session is 40 min.
62721824|NCT02381964|PLACEBO_COMPARATOR|Placebo|Matched placebo
62721825|NCT02381964|EXPERIMENTAL|1RDA+CoQ10|Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).
62721826|NCT02381964|EXPERIMENTAL|3RDA|Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).
62721827|NCT05162638|OTHER|'In-and-out' catheterization|"Safety and immune-cell profile of lymphatic fluid in MS patients with a single time-point sampling of lymphatic fluids and peripheral blood compared to healthy controls.~Two healthy controls and six patients with early MS (never treated or at least 90 days after discontinued treatment with glatiramer acetate or interferons), who consent to the 'In-and-out' catheter procedure. MS participants can also consent to OMB treatment with 2-year follow-up."
62721828|NCT05162638|OTHER|"Indwelling catheterization"|"immune-biology in people with MS before and during/after OMB treatment within thoracic duct and peripheral blood via indwelling catheter and multiple time-point sampling compared to healthy controls (without drug treatment).~Twelve patients with early MS (never treated or at least 90 days after discontinued treatment with glatiramer acetate or interferons), who consent to treatment with OMB and to the indwelling catheter procedure with serial sampling and up to four healthy controls (no drug treatment)"
62721829|NCT06163976||ICU Survivor|Elderly patients admitted to intensive care unit and discharged alive
62721830|NCT06163976||ICU Mortality|Elderly patients admitted to intensive care unit and died during ICU stay
62721831|NCT01201551|ACTIVE_COMPARATOR|healthy subjects without PVD|healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
62721832|NCT01201551|ACTIVE_COMPARATOR|healthy subjects with PVD|healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
62721833|NCT01405183||Renal Cell Carcinoma patients|Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
62721834|NCT01405183||Colorectal cancer patients|Newly diagnosed (6 months) colon cancer patients
62721835|NCT01626573|EXPERIMENTAL|Itacitinib 400 mg twice a day|Itacitinib 400 mg twice a day
62721836|NCT01626573|PLACEBO_COMPARATOR|Itacitinib 400 mg placebo twice a day|Itacitinib 400 mg placebo twice a day
62721837|NCT01626573|EXPERIMENTAL|Itacitinib 100 mg twice a day|This dose group will be studied twice during the study.
62721838|NCT01626573|PLACEBO_COMPARATOR|Itacitinib 100 mg placebo twice a day|This dose group will be studied twice during the study.
62721839|NCT01626573|EXPERIMENTAL|Itacitinib 100mg once a day|Itacitinib 100mg once a day
62721840|NCT01626573|PLACEBO_COMPARATOR|Itacitinib 100 mg placebo once a day|Itacitinib 100 mg placebo once a day
62721841|NCT01626573|EXPERIMENTAL|Itacitinib 200 mg twice a day|Itacitinib 200 mg twice a day
62721842|NCT01626573|PLACEBO_COMPARATOR|Itacitinib 200 mg placebo twice a day|Itacitinib 200 mg placebo twice a day
62721843|NCT01626573|EXPERIMENTAL|Itacitinib 300 mg once a day|Itacitinib 300 mg once a day
62721844|NCT01626573|PLACEBO_COMPARATOR|Itacitinib 300 mg placebo once a day|Itacitinib 300 mg placebo once a day
62721845|NCT01626573|EXPERIMENTAL|Itacitinib 600 mg once a day|Itacitinib 600 mg once a day
62721846|NCT01626573|PLACEBO_COMPARATOR|Itacitinib 600 mg placebo once a day|Itacitinib 600 mg placebo once a day
62721847|NCT04624516|EXPERIMENTAL|Intervention group|The group received training in self-structured foot exercise and they were encouraged to do self-structure foot exercise 3 times a week. They received usual care
62721848|NCT04624516|NO_INTERVENTION|Control Group|the group received usual care
62721849|NCT04143230|ACTIVE_COMPARATOR|Extended Screening Tool (EST)|The SIAARTI/NCCN (EST) screening tool is, in fact, an instrument validated by many scientific societies, but it is very articulated and its compilation is too much time-consuming.
62721850|NCT04143230|EXPERIMENTAL|Simplified Screening Tool (SST)|The Simplified Screening Tool (SST) has been created through a statistical process in order to include all the critical variables, with the advantage of being shorter and therefore easier to administer in a routinely use.
62737907|NCT05532722|EXPERIMENTAL|ABC008 Dose Level 1 Cohort|"0.25 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
62549533|NCT00973063|EXPERIMENTAL|routine sterile gloving|
62549534|NCT03245411|NO_INTERVENTION|Standard of Care (Control Group)|All participants in this group will receive the standard of care intervention provided by the RN.
62549535|NCT03245411|EXPERIMENTAL|Intervention Group|"In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care~The patient will be asked to watch brief educational videos on Life with oral cancer treatment. The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic."
62549536|NCT05022914||1|Patients affected by biochemical relapse after radical prostatectomy undergoing staging PSMA-PET/CT and baseline blood sample for miRNA panel assessment.
62549537|NCT03714243|EXPERIMENTAL|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
62549538|NCT02559180|EXPERIMENTAL|Single Arm|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
62549539|NCT06365411||Kidney Transplant Recipients|Enrolled at time of transplant or post transplant
62549540|NCT06141343||Veillonella atypica FB0054|Active ingredient dietary supplement group
62549541|NCT06141343||Placebo|No active ingredient
62549542|NCT03980535|EXPERIMENTAL|Device Feasibility (MRI, MRSI)|Patients undergo an additional investigational MRI or MRSI sequence along with the standard MRI or MRSI. Healthy volunteers undergo an investigational MRI or MRSI sequence. Healthy volunteers may also undergo an additional standard sequence if there is one that can be compared to the investigational sequence. All MRI or MRSI procedures, including the standard MRI or MRSI, are no longer than 60 minutes.
62549543|NCT01402687||Mucositis Positive|Participants who developed severe mucositis
62549544|NCT01402687||Mucositis Negative|Participants who did not develop severe mucositis
62549545|NCT05579002||Children with unilateral upper limb malformation|Children born between 2006 and 2012, with a unilateral upper limb deformity. These children are regularly followed at CEREFAM for a unilateral upper limb deformity. During their follow-up, they were fitted with different upper limb prostheses. During a consultation with one of the CEREFAM physicians, they requested a Hero Arm prosthesis following the marketing and reimbursement in France in 2019.
62549546|NCT04198857|NO_INTERVENTION|Standard Care + Telemonitoring: Control|Standard care for GDM will be modifying diet\& exercise and/or medication use. Participants will have consultations with a dietitian and a physical therapist to develop a diet and physical activity plan based on pre-pregnancy weight and disease severity. In addition to verbal information about managing GDM with diet and physical activity, patients will be provided with leaflets and brochures. As per the standard care protocol, GDM patients will be asked to visit the OPD for glucose testing every two weeks, and after each testing, blood glucose levels will be recorded in paper booklets assigned to each patient. In addition, the women will be provided with a glucometer and a blood pressure monitor machine. Participants will be taught to use these devices for self-monitoring and will be provided guidelines to follow at home. The OB/GYN physicians will monitor the blood glucose levels across testing, and will prescribe oral hypoglycemic medications or insulin to the patient if needed.
62549547|NCT04198857|EXPERIMENTAL|Standard Care + GDM-DH app + Telemonitoring|In addition to standard care and telemonitoring, this group will use the GDM-DH app. This group will be provided with the same devices as the control group and in addition, the GDM-DH app will be set up in their cellular device. The app will be on their smart phone and will support self-management by: i) providing health education, ii) helping patients identify and set target health goals (for diet, physical activity, and glucose levels), iii) enhancing their self-efficacy to meet target goals, and iv) facilitating desired support from family members. The core component of the GDM-DH app will be to allow GDM patients to record and self-monitor their carbohydrate intake, physical activity and blood glucose levels. Patients will be able to manually enter their weekly blood glucose levels and blood pressure readings on to the app
62549548|NCT02996773|EXPERIMENTAL|Cyclophosphamide and Bendamustine|"Experimental: Cyclophosphamide and Bendamustine Control: Cyclophosphamide~Interventions:~* Drug: Bendamustine~* Drug: Cyclophosphamide"
62549549|NCT02054286|EXPERIMENTAL|Group 1: THV01 (5.10E+6 TU) or Placebo|5.10E+6 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+6 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
62549550|NCT02054286|EXPERIMENTAL|Group 2: THV01 (5.10E+7 TU) or Placebo|5.10E+7 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+7 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
62549551|NCT02054286|EXPERIMENTAL|Group 3: THV01 (5.10E+8 TU) or Placebo|5.10E+8 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+8 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
62549552|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
62549553|NCT06018038||Breast Cancer Group|Inclusion criteria were to be between 18-65 years of age, to volunteer to participate in the study, to have Stage I-III breast cancer, to have at least 15 months after breast cancer surgery, to have six months after active breast cancer treatment (i.e. surgery/chemotherapy), to have no problems in reading and/or understanding the scales and to be able to cooperate with the tests. Exclusion criteria were the presence of active infection, musculoskeletal and neurologic disease that may affect exercise performance, symptomatic heart disease, neurologic disease or other clinical diagnosis that may affect cognitive status.
62549554|NCT06018038||Control Group|The inclusion criteria were to be between 18-65 years of age, to be willing to participate in the study, to have no problems in reading and/or understanding the scales and to be able to cooperate with the tests. Exclusion criteria were having any orthopedic or neuromuscular condition that would interfere with walking or exercise performance, having any chronic disease, or having psychiatric disorders or mental disorders that might interfere with cooperation or compliance with exercise tests.
62549555|NCT06353698|EXPERIMENTAL|fasting mimicking diet|the intervention group that receive fasting mimicking diet with chemotherapy
62549556|NCT06353698|NO_INTERVENTION|control|the control group that receive chemotherapy without any intervention
62721851|NCT04383093||Combination Therapy|"Patients initial assessment included age, waist circumference, blood pressure, clinical laboratory parameters, digital rectal examination. LUTS were evaluated with total IPSS, focusing also on storage, voiding IPSS sub-scores, and IPSS QoL, and Overactive Bladder questionnaire (OAB-q), while ED with IIEF-515. Each patient underwent uroﬂowmetry and postvoid residual volume (PVR) was measured with abdominal ultrasound immediately after voiding. All patients reporting any intake of therapies for LUTS or ED underwent a 4 weeks treatment-free washout period.~All subjects were treated with tadalafil 5 mg/die plus tamsulosin 0.4 mg/die for 12 weeks. The medications were self-administered every day at the same time, before the night rest, without any limitations or variations of sexual activity timing or food intake. Patients were re-evaluated after 12 weeks of treatment with Uroflowmetry and PVR, IPSS, IPSS QoL, OAB-q and IIEF-5"
62721852|NCT02881736|EXPERIMENTAL|Pateint with chronic stroke|
62721853|NCT02881736|ACTIVE_COMPARATOR|Healthy volunteer|
62721854|NCT04796038|EXPERIMENTAL|Rise SC|All patients will receive the Rise semi-compliant balloon catheter as per treatment.
62721855|NCT04646577|ACTIVE_COMPARATOR|Active|
62721856|NCT04646577|SHAM_COMPARATOR|Sham|
62721857|NCT04144283|EXPERIMENTAL|NAP|The NAP group will undergo a post-learning 2-hour sleep opportunity in Experiment 1.
62721858|NCT04144283|ACTIVE_COMPARATOR|WAKE|The WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness in Experiment 1.
62721859|NCT04896853|EXPERIMENTAL|Treatment|Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells.
62721860|NCT00497900|EXPERIMENTAL|1|Calcium and vitamin D
62721861|NCT00497900|PLACEBO_COMPARATOR|2|Calcium and placebo (cellulose)
62721862|NCT05384899||COVID-19 Patients|The focus will be on patients with AKI in the setting of COVID-19 disease.
62721863|NCT04350801||high risk MCI|MCI patients with amyloid beta positive (based on peripheral blood level)
62721864|NCT04350801||low risk MCI|MCI patients with amyloid beta negative (based on peripheral blood level)
62721865|NCT03461939||ePRIME|"Participants in the study will receive training in using the ePRIME system to report their symptoms and side effects on a weekly basis from home via the internet for 12 weeks while receiving early phase trial treatment. Patients will be sent email/text reminders to enter their symptoms on the system once a week. Patients will be reminded that the data they enter via the online system will not be reviewed promptly by their hospital team and therefore they should continue to contact their treatment team via the contact numbers they have been given.~As part of the research project, we will monitor the number of notifications for severe AE generated by the system to address concerns from the interviews conducted in the first phase of this research project that ePROs will lead to increased workload for clinicians."
62721866|NCT01357343|ACTIVE_COMPARATOR|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping
62721867|NCT01357343|ACTIVE_COMPARATOR|Chiropractic care|Chiropractic adjustments and active and passive physical modalities.
62721868|NCT01357343|ACTIVE_COMPARATOR|Integrated Chiropractic and Acupuncture|
62721869|NCT01343745|PLACEBO_COMPARATOR|Placebo|Placebo pMDI
62721870|NCT01343745|EXPERIMENTAL|Low dose|BDP/formoterol pMDI low dose
62721871|NCT01343745|EXPERIMENTAL|High dose|BDP/Formoterol pMDI high dose
62721872|NCT01309789|EXPERIMENTAL|1|Sequential
62721873|NCT01309789|EXPERIMENTAL|2|Combination
62721874|NCT01309789|EXPERIMENTAL|3 Brentuximab vedotin/CH-P|Combination
62721875|NCT01058239|EXPERIMENTAL|Rituximab plus Bortezomib|This is a single arm trial adding the new drug bortezomib to the standard drug rituximab
62721876|NCT00852410|ACTIVE_COMPARATOR|1% lidocaine with 1:100000 adrenaline|high dose adrenaline
62721877|NCT00852410|ACTIVE_COMPARATOR|1% lidocaine with 1:200,000 adrenaline|low dose
61976685|NCT01808287|EXPERIMENTAL|High risk population|SAPIEN 3 transcatheter heart valve was implanted in high risk patients
61976686|NCT01808287|EXPERIMENTAL|Intermediate risk population|SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients
62721878|NCT01001351|PLACEBO_COMPARATOR|Placebo|
62721879|NCT01001351|EXPERIMENTAL|PRT-201|
62721880|NCT02764996|EXPERIMENTAL|Acupuncture for Migraine|Acupuncture treatments will be subject dependent, and points could include the N point (on scalp); various auricular points to include Shen Men, Point Zero, thalamus and Omega-2; body points to include Liver 2, Liver 3, Gall Bladder 20, bladder 10; and surface release over tense areas in the neck or shoulders
62721881|NCT02622477||Participants with idiopathic pulmonary fibrosis|Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.
62721882|NCT02849002||Interventional Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the brain motion caused by pulsatile blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile blood flow. The system is powered by rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
62721883|NCT00436436|EXPERIMENTAL|O6-benzylguanine & Temozolomide in Glioblastoma|Patients receive O6-benzylguanine intravenous over 1 hour and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
61976687|NCT00363922|EXPERIMENTAL|1|Rehabilitation in institution
61976688|NCT00363922|ACTIVE_COMPARATOR|2|Rehabilitation at home
62721884|NCT04251338||delayed visual maturation|children with delayed visual maturation
62721885|NCT04046640||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
62721886|NCT04046640||Healthy group|This group will include 40 healthy volunteers.
62721887|NCT01506024|ACTIVE_COMPARATOR|THA Direct lateral|Total hip arthroplasty (THA) carried out by direct lateral approach (DLA)
62721888|NCT01506024|EXPERIMENTAL|THA Posterior|Total hip arthroplasty (THA) carried out by posterior approach (DLA)
62721889|NCT01506024|EXPERIMENTAL|THA Anterior|Total hip arthroplasty (THA) carried out by anterior approach (DLA)
62721890|NCT00836771|PLACEBO_COMPARATOR|Materna infant formula 1|milk based infant formula powder
62721891|NCT00836771|EXPERIMENTAL|Materna infant formula 2|Probiotic supplemented infant formula
62721892|NCT00836771|EXPERIMENTAL|Materna infant formula 3|Prebiotic supplemented infant formula
62721893|NCT00836771|EXPERIMENTAL|Materna infant formula 4|Prebiotic+ Probiotic supplemented infant formula
62721894|NCT00836771|OTHER|Human milk|Human Milk
62721895|NCT00962871|ACTIVE_COMPARATOR|1|
62721896|NCT00962871|EXPERIMENTAL|2|
62721897|NCT00962871|EXPERIMENTAL|3|
62721898|NCT00962871|NO_INTERVENTION|4|
62721899|NCT04410965|EXPERIMENTAL|teriflunomide|daily oral administration of teriflunomide 14 mg for 24 weeks
62721900|NCT01541865|OTHER|Renal Denvervation|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.
62721901|NCT01856322|ACTIVE_COMPARATOR|Sulindac|one tablet twice daily
62721902|NCT01856322|PLACEBO_COMPARATOR|Placebo|one tablet twice daily
62721903|NCT01856322|OTHER|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
62721904|NCT05874141|OTHER|type 2 DM|
62721905|NCT02227303|OTHER|Lifestyle counseling|
62721906|NCT01890096|EXPERIMENTAL|HDR 2 fractions|HDR brachytherapy of 27 Gy delivered in 2 fractions one week apart
62721907|NCT01890096|EXPERIMENTAL|HDR 1 fraction|HDR brachytherapy of 19 Gy delivered in a single fraction
62721908|NCT02347592|ACTIVE_COMPARATOR|straight Tenckhoff|The straight Tenckhoff catheter (sT) is the most common used catheter for peritoneal dialysis (PD).
62721909|NCT02347592|ACTIVE_COMPARATOR|self-locating catheter|A new, more expensive, self-locating catheter (sLC) has been developed by Di Paolo.
62721910|NCT00507585|EXPERIMENTAL|Oxaliplatin + Fluorouracil + Leucovorin + Avastin|
62721911|NCT00139958||1|
62721912|NCT00139958||2|
62721913|NCT01603225||Autism|Individuals with autism will have either Anodal, Cathodal, or Sham Transcranial Direct Current Stimulation (tDCS).
62721914|NCT01569412|EXPERIMENTAL|Ertumaxomab|Ertumaxomab administration during two treatment cycles will follow a predefined dose escalation scheme, consisting of 5 ascending doses per cycle with each infusion lasting 3 hours.
62721915|NCT02725333|OTHER|Shoulder Stabilization|Anteroposterior and superoinferior translations were assessed in patients, before and after shoulder stabilization, through a dedicated patient-specific measurement technique based on optical motion capture and computed tomography.
62721916|NCT02472912|EXPERIMENTAL|Treatment A|Single Injection of 40mg / 0.8 mL BMO-2
62721917|NCT02472912|ACTIVE_COMPARATOR|Treatment B|Single Injection of 40mg / 0.8 mL EU-Humira
62721918|NCT02472912|ACTIVE_COMPARATOR|Treatment C|Single Injection of 40mg / 0.8 mL US-Humira
62721919|NCT04527055|ACTIVE_COMPARATOR|The 14-day bismuth-based quadruple therapy group|The patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
62721920|NCT04527055|ACTIVE_COMPARATOR|The 10-day bismuth-based quadruple therapy group|The patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
62721921|NCT04527055|NO_INTERVENTION|The non-H. pylori-infected control|Age- and sex-matched patients who do not have H. pylori infection by endoscopic gastric biopsy are enrolled as the non-H. pylori-infected control.
62721922|NCT04527055|ACTIVE_COMPARATOR|The probiotic therapy group|"The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
62721923|NCT04527055|NO_INTERVENTION|The non-probiotic control group|The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the non-probiotic control therapy and they do not ingest probiotic powder.
62721924|NCT00936663|EXPERIMENTAL|Sitagliptin 100 mg daily|sitagliptin 100 mg daily
62721925|NCT00936663|PLACEBO_COMPARATOR|placebo|placebo
62721926|NCT02847169|ACTIVE_COMPARATOR|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
62721927|NCT02847169|ACTIVE_COMPARATOR|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
62721928|NCT05124353|ACTIVE_COMPARATOR|G1 : Treatment Group (TG)r|Patients in TG receive neuroprotective drug: standard dose of Cerebrolysin 30ml i.v. in the first 6 hours after first symptoms. After EVT the administration is continued for 10 days.
62721929|NCT05124353|NO_INTERVENTION|G2 : Control Group (CG)|Patients in CG receive no additional i.v. treatment.
62721930|NCT01407939||Children, Adults|3- to 15-year old children and their parent (adults
62721931|NCT00381654|EXPERIMENTAL|A|Daily oral administration of AV-412
62721932|NCT03917030|EXPERIMENTAL|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
62721933|NCT03917030|ACTIVE_COMPARATOR|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
62721934|NCT02207543|EXPERIMENTAL|Medical telephonecontact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
62721935|NCT04898478|EXPERIMENTAL|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|This arm will consist of a behavioral intervention to increase treatment seeking among Pacific Islanders with opioid use disorders.
62737908|NCT05532722|EXPERIMENTAL|ABC008 Dose Level 2 Cohort|"0.75 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
62721936|NCT01997645|ACTIVE_COMPARATOR|Rectal advanced mucosal flap|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open."
62721937|NCT01997645|ACTIVE_COMPARATOR|Ligation of intersphincteric fistula tract|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain."
62721938|NCT03111212|ACTIVE_COMPARATOR|Iloprost|
62721939|NCT03111212|PLACEBO_COMPARATOR|control|
62721940|NCT04068454|ACTIVE_COMPARATOR|classical rehabilitation group|
62721941|NCT04068454|EXPERIMENTAL|virtual reality group|
62721942|NCT03657836|EXPERIMENTAL|Dietary supplement and antibiotics|Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
62721943|NCT03657836|OTHER|Antibiotics only|Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
62721944|NCT04024826|EXPERIMENTAL|Early Follicular Phase (EFP)|This group is comprised of participants at the Early Follicular Phase (EFP) of the menstrual cycle.
62721945|NCT04024826|EXPERIMENTAL|Late Follicular Phase|This group is comprised of participants at the Late Follicular Phase (LFP) of the menstrual cycle.
62721946|NCT04024826|EXPERIMENTAL|Early Luteal Phase|This group is comprised of participants at the Early Luteal Phase (ELP) of the menstrual cycle.
62721947|NCT04024826|EXPERIMENTAL|Late Luteal Phase|This group is comprised of participants at the Late Luteal Phase(LLP) of the menstrual cycle.
62721948|NCT02184598|PLACEBO_COMPARATOR|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
62721949|NCT02184598|EXPERIMENTAL|Cognitive training|Cognitive training with 6 different games each of which gets progressively more difficult as children obtain proficiency.
62721950|NCT05979961|EXPERIMENTAL|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
62721951|NCT05979961|ACTIVE_COMPARATOR|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
62721952|NCT03654222||Cardiac surgery|Direct procedures in heart
62721953|NCT03654222||Organ preservation|Mainly renal autograft
62721954|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
62721955|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
62721956|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
62721957|NCT03654222||Other|Any surgery that does not include the previous ones
62721958|NCT01344798|EXPERIMENTAL|Dose level 1|AAV1-gamma-sarcoglycan vector dose level: 3x10e9 vg/100µl
62721959|NCT01344798|EXPERIMENTAL|Dose level 2|AAV1-gamma-sarcoglycan vector dose level: 1.5x10e10 vg/100µl
62721960|NCT01344798|EXPERIMENTAL|Dose level 3|AAV1-gamma-sarcoglycan vector dose level: 4.5x10e10 vg/300µl
62721961|NCT04902209||1- study group- patients after surgical treatment of acetabular fracture|1- study group- patients after surgical treatment of hip acetabular fracture
62721962|NCT04902209||2- control group- healthy subjects|2- control group- healthy subjects age, BMI matched
62721963|NCT02898922|EXPERIMENTAL|HCV group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
62721964|NCT02898922|ACTIVE_COMPARATOR|Healthy control group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
62721965|NCT04061109|EXPERIMENTAL|Prophylactic therapy|Subjects received Recombinant Human Coagulation FVIII for prophylactic therapy with 25 - 35 IU/kg injection once every other day or three times per week for 6 months.
62721966|NCT02779868|EXPERIMENTAL|Omega-3|Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.
62721967|NCT02779868|PLACEBO_COMPARATOR|Olive oil|Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.
62721968|NCT02143349|EXPERIMENTAL|Coleus forskohlii extract|Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks
62721969|NCT02143349|PLACEBO_COMPARATOR|Placebo|Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks
62721970|NCT03165786|EXPERIMENTAL|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
62721971|NCT03165786|NO_INTERVENTION|Control Group|Real-time continuous glucose monitoring
62721972|NCT01692288|EXPERIMENTAL|Offered First Born® Program services|Family and first-born child are selected to be offered First Born® Program home visiting services.
62721973|NCT01692288|NO_INTERVENTION|Not offered First Born® Program services|Family and first-born child are not selected to be offered First Born® Program home visiting services.
62721974|NCT05190679||Cardiomyopathy Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in cardiomyopathy (CM) gene which include inherited CM syndromes.
62721975|NCT05190679||Arrhythmia Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in arrhythmia genes.
62721976|NCT05190679||Controls|No rare variant in CM, arrhythmia, or other atrial fibrillation gene.
62721977|NCT05074225|EXPERIMENTAL|ED&C|The ED\&C arm will receive the standard ED\&C care.
62721978|NCT05074225|EXPERIMENTAL|Excision|The excision arm will undergo standard excision with repair by complex linear closure.
62721979|NCT02938325||No intervention: General Anesthesia|"Thirty patients undergoing elective surgery under general anesthesia who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the surgery, patients will be questioned for awareness under anesthesia by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with general anesthesia as they were supposed to be for their elective surgery. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
62721980|NCT02938325||No intervention: Sedation|"Fourty patients undergoing elective cardiac catheterization under conscious sedation who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the procedure, patients will be questioned for awareness under sedation by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with sedation as they were supposed to be for their elective cardiac catheterization. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
62721981|NCT02938325||No Intervention - Awake Volunteers|EEG and BIS will be recorded in twenty volunteers, for 10 minutes, in supine position, while their eyes are closed. This recording will be utilized as for positive control for recall.
62721982|NCT02917005|EXPERIMENTAL|Palbociclib Arm|Palbociclib (Pfizer) 125mg/day orally for 3 weeks followed by 1 week off plus Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
62721983|NCT02917005|ACTIVE_COMPARATOR|Control Arm|Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
62721984|NCT04039529|NO_INTERVENTION|CT-only guided biopsy|The current standard of care for biopsy at Temple University Hospital.
62721985|NCT04039529|EXPERIMENTAL|SCENERGY-guided Biopsy|The use of the SCENERGY to fuse CT and Ultrasound for biopsy
62721986|NCT05663463|EXPERIMENTAL|booster group|Participants who have undergone a solid organ transplant will receive two doses of an inactivated high dose influenza vaccine
62721987|NCT05663463|ACTIVE_COMPARATOR|Control group|Participants who have undergone a solid organ transplant will receive one dose of inactivated high dose influenza vaccine followed by a placebo injection
62721988|NCT03646760|EXPERIMENTAL|Hybrid Cardiac Rehabilitation (HYCR)|
62721989|NCT03646760|ACTIVE_COMPARATOR|Center Based cardiac Rehabilitation (CBCR)|
62721990|NCT03210701|OTHER|Patients requesting a HIV screening test|
62721991|NCT06538662|EXPERIMENTAL|FID 123320 Ophthalmic Solution|1 drop instilled in each eye at Visit 2 (Day 1), followed by one drop instilled in each eye twice a day (approximately 12 hours apart) Day 2 up to Visit 5 (Day 56), followed by 1 drop instilled in each eye at Visit 5 (Day 56).
62721992|NCT06538662|PLACEBO_COMPARATOR|Vehicle|1 drop instilled in each eye at Visit 2 (Day 1), followed by one drop instilled in each eye twice a day (approximately 12 hours apart) Day 2 up to Visit 5 (Day 56), followed by 1 drop instilled in each eye at Visit 5 (Day 56).
62721993|NCT01061385|EXPERIMENTAL|ReShape Intragastric Balloon|Patients receiving the ReShape Intragastric Balloon
62721994|NCT01061385|OTHER|Control Arm|Weight loss using behavior modification (diet and exercise counseling) alone
62721995|NCT05076344||Group 1: young adults|50 adults aged 18-19 years, with low lifetime noise exposure and audiometric thresholds in the normal range for their age.
62721996|NCT05076344||Group 2: older adults with low noise exposure|50 adults aged 30-50 years, with low lifetime noise exposure and audiometric thresholds in the normal range for their age.
62721997|NCT05076344||Group 3: older adults with high noise exposure|50 adults aged 30-50 years, with high lifetime noise exposure and audiometric thresholds in the normal range for their age.
62721998|NCT05076344||Group 4: older adults with suspected noise-induced hearing loss|50 adults aged 30-50 years, with high lifetime noise exposure and audiometric thresholds above the normal range for their age.
62721999|NCT01873105|EXPERIMENTAL|Health team educational intervention|Agency for Healthcare Research and Quality (AHRQ) TeamSTEPPS approach will be used to redesign health team communication processes regarding preparation for discharge. This redesign will be followed by education for all health team members.
62722000|NCT01873105|NO_INTERVENTION|Control pre-intervention|Usual care control before implementation of the health team communication intervention
62722001|NCT01492088|EXPERIMENTAL|Brentuximab vedotin: Phase 1|Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
62722002|NCT01492088|EXPERIMENTAL|Brentuximab vedotin: Phase 2|Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
62722003|NCT03201640|OTHER|slideshow|Participant receives traditional slideshow presentation for preoperative preparation
62722004|NCT03201640|OTHER|virtual|Participant receives virtual reality presentation for preoperative preparation
62722005|NCT01586689|EXPERIMENTAL|Safe Haven|participants assigned to the Safe haven condition and agree to move into the A Safe Haven residential treatment facility
62722006|NCT01586689|EXPERIMENTAL|Usual aftercare|participants assigned to the control condition, and may or may not seek treatment on their own
62722007|NCT01586689|EXPERIMENTAL|Oxford House|participants who were assigned to the Oxford House condition and agree to move into an Oxford House
62722008|NCT02969642|SHAM_COMPARATOR|Sham|Sham low energy laser using approximately 1/1000 th energy of treatment laser.
62722009|NCT02969642|ACTIVE_COMPARATOR|Treatment|Treatment laser.
62722010|NCT03369366|EXPERIMENTAL|Reconstruction and Dental Rehabilitation|Placement of NobelActive dental implants (minimum of three) using integrated osteotomy and implant placement guide.Placement of provisional screw-retained prosthesis (all while flap is still pedicled to vascular supply). Inset of flap/implant/prosthesis/custom plate construct (KLS Martin Mandibular Reconstruction Implant).
62722011|NCT01288625|EXPERIMENTAL|Cytofos group A|Amifostine 500 mg sc, qod, 3 times per week Radiation treatment 30 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
62722012|NCT01288625|EXPERIMENTAL|Cytofos group B|Amifostine 500mg rinsing wash, qod, 3 times per week Radiation treatment 5 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
62722013|NCT01288625|ACTIVE_COMPARATOR|Control group|Radiation treatment 1.8-2.0 Gy/day × 30-35 times
62722014|NCT02684968|EXPERIMENTAL|Colorectal Surgery with QL block having anesthetic|Bilateral QL catheter with local anesthetic infusion + intravenous patient controlled narcotic medication
62722015|NCT02684968|PLACEBO_COMPARATOR|Colorectal Surgery with QL block having saline|Bilateral QL catheter with normal saline infusion + intravenous patient controlled narcotic medication
62722016|NCT05807373|EXPERIMENTAL|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to MDS criteria (Postuma et al., 2015)
62722017|NCT05807373|EXPERIMENTAL|Multiple system atrophy parkinsonian subtype (MSA-P)|Diagnosis of Multiple Atrophy System (MSA-P) Parkinsonian form possible or probable according to consensus criteria (Gilman et al., 2008)
62722018|NCT05807373|EXPERIMENTAL|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
62722019|NCT04763434|ACTIVE_COMPARATOR|RS group|20 ml mixture of 37.5 mg ropivacaine with 5 mg dexamethasone
62722020|NCT04763434|ACTIVE_COMPARATOR|RM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine
62722021|NCT04763434|EXPERIMENTAL|RSM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group)
62722022|NCT05144828|EXPERIMENTAL|Intercostal Nerve Cryoablation plus Standard of Care (SOC) Pain Control|Intercostal nerve cryoablation using the CryoICE® CRYOS-L cryoablation probe and an intercostal nerve block of nerves 4-9 performed using 0.5% Marcaine with Epinephrine plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
62722023|NCT05144828|ACTIVE_COMPARATOR|Standard of Care (SOC) Pain Control|Intercostal nerve block of nerves 4-9 using 0.5% Marcaine with Epinephrine plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
62722024|NCT06090058||A|Patients with acute ischemic stroke having focal neurological deficits lasting for more than 24 hour with relevant lesion in brain computerized tomography (CT) or magnetic resonance (MR) image
62722025|NCT06090058||B|Patients with chronic ischemic stroke , having these symptoms for 6-12 month
62722026|NCT06090058||C|Healthy controls
62722027|NCT05923697|EXPERIMENTAL|AF-EMDR|Intervention: a total of four 90 min. sessions of AF-EMDR twice per week added to TAU.
62722028|NCT05157061|EXPERIMENTAL|GOS arm|A single daily dose of a food supplement containing GOS for 8 weeks
62722029|NCT05157061|PLACEBO_COMPARATOR|Placebo arm|A single daily dose of maltodextrin, matching in taste, smell, appearance, and solubility, but without active ingredients (i.e. GOS), for 8 weeks
62722030|NCT05000307|EXPERIMENTAL|Volunteers, infected with COVID-19|
62722031|NCT01465035|EXPERIMENTAL|TIV and MVA-NP+M1|"Co-administration group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of 1.5 x108pfu MVA-NP+M1"
62722032|NCT01465035|PLACEBO_COMPARATOR|Saline placebo and seasonal influenza vaccine TIV|"Control group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of a saline placebo"
62722033|NCT03048435||Cervical Cancer Patients|Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
62722034|NCT03048435||Oncologist|Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
62722035|NCT05799391|EXPERIMENTAL|Active treatment (Soothing cream jel)|Soothing cream jel
62722036|NCT05799391|PLACEBO_COMPARATOR|Placebo|Placebo cream jel
62722037|NCT02055950||Kidney perfused by pulsatile machine|
62722038|NCT02055950||Kidney stored in refrigerated solution|
62722039|NCT02469220|EXPERIMENTAL|Low FODMAP diet|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement low in FODMAPS are administered in a blinded fashion.
62722040|NCT02469220|ACTIVE_COMPARATOR|Standardized FODMAP|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement with FODMAPS are administered in a blinded fashion.
62722041|NCT02469220|NO_INTERVENTION|Control|Watchful waiting. No diets or food supplements are administered
62722042|NCT05775211|EXPERIMENTAL|Endometrial composition before and after autologous modulated PBMC administration|The endometrial cell composition in terms of cell quantities and spatial distribution will be compared before and after intrauterine administration of immunomodulated PBMC.
62722043|NCT05749471||Patients with chronic venous disease|Consecutive patients with chronic venous disease (CVD) that will be diagnosed, staged according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification of CVD. ASEX (Arizona Sexual Experience) questionnaire will be administered to CVD patients at time 0 of study inclusion and after treatment of CVD at intervals of 6 months and 12 months after treatment.
62722044|NCT02184065||Meloxicam|
62722045|NCT03895294|EXPERIMENTAL|Health care under the strategic purchase-Clinical pathway|Health care under the strategic purchase and the Clinical pathway for the treatment of chronic Hepatitis C
62722046|NCT03895294|ACTIVE_COMPARATOR|Usual care process prior strategic purchase-clinical pathway|Usual care process prior to the establishment of the strategic purchase and the Clinical Pathway
62722047|NCT00499668|EXPERIMENTAL|ARM A|
62722048|NCT00499668|EXPERIMENTAL|ARM B|
62722049|NCT00776360|EXPERIMENTAL|oxytocin, gastric emptying|Oxytocin is given to study the gastric emptying rate
62722050|NCT00776360|PLACEBO_COMPARATOR|oxytocin|sodium chloride is given to study gastric emptying rate
62722051|NCT04865666|EXPERIMENTAL|movr App Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior for the 8-week intervention period and to avoid any specialized exercise training for that time period, but they were also asked to use the movr app to supplement their current activity.
62722052|NCT04865666|NO_INTERVENTION|Waitlist Control Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior over the 8-week study period and to avoid any specialized exercise training for that time period. Following the 8-week study period, individuals in the control group were permitted to download and use the movr app if they chose to.
62722053|NCT01798381|ACTIVE_COMPARATOR|Essential fatty acids|Omega-3
62722054|NCT01798381|PLACEBO_COMPARATOR|Placebo|Placebo tablet
62722055|NCT00339040|ACTIVE_COMPARATOR|Arm A: QHPV|QHPV at week 0, 8, 24, 96.
62722056|NCT00339040|OTHER|Arm B: Placebo/QHPV|Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.
62722057|NCT01123148|OTHER|Tilt testing|
62722058|NCT05370274|EXPERIMENTAL|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
62722059|NCT05370274|EXPERIMENTAL|Cranial nerve non-invasive neuromodulation (CN-NINM)|CN-NINM will be applied during each session of the strength training intervention
62722060|NCT01718899|EXPERIMENTAL|PVX-410, .4 mg dose|Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
62722061|NCT01718899|EXPERIMENTAL|PVX-410, .8 mg dose|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
62722062|NCT01718899|EXPERIMENTAL|PVX-410 plus lenalidomide|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
62722063|NCT01521598|EXPERIMENTAL|SKL11197|This arm is the experimental drug (SKL11197) arm. Patients will be randomized to this arm.
62722064|NCT01521598|PLACEBO_COMPARATOR|Placebo|This arm is the placebo comparator arm. Patients will be randomized to this arm.
62722065|NCT02793687|EXPERIMENTAL|Mexidol|"Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.~The use of the study drug is held with basic therapy."
62722066|NCT02793687|PLACEBO_COMPARATOR|Placebo|"Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.~The use of a placebo is held with basic therapy."
62722067|NCT00716001|ACTIVE_COMPARATOR|NAC|
62722068|NCT00716001|PLACEBO_COMPARATOR|nonNAC|
62722069|NCT01294852|EXPERIMENTAL|immediate bolus surfactant|
62722070|NCT01294852|EXPERIMENTAL|post-resuscitation surfactant|
62722071|NCT01531998|EXPERIMENTAL|Siltuximab + Bortezomib + Lenalidomide|"Induction: Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1.~If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR (minimum of 4 cycles of therapy and a maximum of 8 cycles of therapy) and then transition to maintenance regimen described below.~Maintenance therapy: Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.~Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly."
62722072|NCT03902795||Group of 62 eyes|Group of 62 eyes with rhegmatogenous retinal detachment who underwent successful vitrectomy with SF6 tamponade
62722073|NCT00202696|EXPERIMENTAL|1|Nalmefene 40 mg
62722074|NCT00202696|EXPERIMENTAL|2|Nalmefene 80 mg
62722075|NCT00202696|OTHER|3|Placebo
62722076|NCT01983592|ACTIVE_COMPARATOR|Homeopathic medicine|The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
62722077|NCT01983592|PLACEBO_COMPARATOR|Unmedicated lactose/sucrose globule|The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
62722078|NCT05573139|EXPERIMENTAL|muscle strength assessment|
62722079|NCT04635202|EXPERIMENTAL|group A|patients (n=30) in this group will receive 16 weeks of elliptical training on elliptical trainer, 3 times per week. the training will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
62722080|NCT04635202|OTHER|Group B (control group)|patients (n=30) in this group will receive general advises on maintaining physical activities
61976689|NCT04824885|EXPERIMENTAL|Acetate free then acetate containing dialysate|Patients in group 1 will first be treated with the acetate-free dialysate (A-D) for 6 months and then the acetate-containing dialysate (A + D) for 6 months.
62722081|NCT01808469|EXPERIMENTAL|NI-0101|NI-0101 is an anti-Toll-like receptor monoclonal antibody.
62722082|NCT01808469|PLACEBO_COMPARATOR|Placebo|The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance.
62722083|NCT00593060|EXPERIMENTAL|Temsirolimus Combined With Cetuximab|
62722084|NCT01790607|EXPERIMENTAL|Subjects with moderate chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
62722085|NCT01790607|EXPERIMENTAL|Healthy subjects matched to moderate hepatic impaired subjects|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
62722086|NCT01790607|EXPERIMENTAL|Subjects with mild chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
62722087|NCT01790607|EXPERIMENTAL|Healthy subjects matched to mild hepatic impaired subjects|Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
62722088|NCT01790607|EXPERIMENTAL|Subjects with severe chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
62722089|NCT04828707|ACTIVE_COMPARATOR|Migraine prevention treatment with active Nerivio|Participants will treat with an active Nerivio device every other day for migraine prevention.
62722090|NCT04828707|SHAM_COMPARATOR|Migraine prevention treatment with sham Nerivio|Participants will treat with a sham (placebo) Nerivio device every other day for migraine prevention.
62722091|NCT01471821|EXPERIMENTAL|simplification|Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
62722092|NCT01471821|ACTIVE_COMPARATOR|Continue with current treatment|
62722093|NCT02078752|EXPERIMENTAL|Part 1|
62722094|NCT04500119|EXPERIMENTAL|Behavioral Testing|Behavioral and Neuronal Recordings
62722095|NCT05189210|PLACEBO_COMPARATOR|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
62722096|NCT05189210|EXPERIMENTAL|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
62722097|NCT05189210|EXPERIMENTAL|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
62722098|NCT03335202||cf patients at the cf centre Kiel|microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.
62722099|NCT01057537|EXPERIMENTAL|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
62722100|NCT01057537|ACTIVE_COMPARATOR|Usual Care|Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
62722101|NCT03644719|EXPERIMENTAL|Cognitive behavior skills training|The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.
62722102|NCT03644719|NO_INTERVENTION|Education as usual|The EAU group received six hours of informational lectures about ketamine, its effects on the brain, relevant regulations and laws, and the risks and modes of transmission of infectious diseases, including HIV and hepatitis C.
62722103|NCT02972229|EXPERIMENTAL|partial body group|10x(3-5) Gy IMRT on partial vertebral body
62722104|NCT02972229|ACTIVE_COMPARATOR|whole body group|10x3 Gy IMRT on whole vertebral body
62722105|NCT00577694|OTHER|single arm study|1
62722106|NCT04285697|EXPERIMENTAL|group 1|During the outpatient clinic visit, an information leaflet will be given about the subjects that should be considered for prevention of SSI before surgery. 2% mupirocin ointment will be applied to the nostrils with the swab twice-daily before surgery and once on the morning of surgery. Body cleaning will be done with 4% chlorhexidine gluconate shower the night before the surgery. Prophylactic antibiotics by weight will be administered within 60 minutes of anesthesia induction. The planned aseptic technique will be applied and a strict draping will be used in the incision site. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form. Before the skin closes, the surgical site will be washed with warm Isotonic NaCl solution. Wound care education will be provided to the patient and family before discharge.
62722107|NCT04285697|NO_INTERVENTION|group 2 control|The pre-operative service sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form.
62722108|NCT03855566|OTHER|Intervention|Enrolled participants will receive the intervention.
62722109|NCT01539447|ACTIVE_COMPARATOR|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
62722110|NCT01539447|PLACEBO_COMPARATOR|Placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
62722111|NCT02725905|EXPERIMENTAL|Multi-Modal Education (MME)|1) The MME is a three year multi-modal educational intervention including a series of interactive learning components and interventions focused on integrated weight management counseling. Prior to its launch, each component of the curriculum will be refined using a school participatory approach to help ensure feasibility and acceptability.
62722112|NCT02725905|ACTIVE_COMPARATOR|Traditional Education (TE)|2) The TE arm of the study includes the school's current curriculum which may include topics related to the treatment of weight management and obesity.
62722113|NCT03273686|EXPERIMENTAL|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
62722114|NCT03273686|NO_INTERVENTION|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
62722115|NCT02529683|EXPERIMENTAL|Nuvaring (only arm)|Nuvaring use for six months, with monthly pickup of rings and returning of used rings, and other behavioral/clinical assessments conducted during the visit on day 21 of the menstrual cycle.
62722116|NCT06230484|ACTIVE_COMPARATOR|IFPE patients|patients receiving IFPE treatment
62722117|NCT06230484|ACTIVE_COMPARATOR|(control group): RME patients|patients receiving conventional rapid maxillary expansion treatment
62722118|NCT03856736|EXPERIMENTAL|MIAT|Composite of the execution of moderated-intensity aerobic training (MIAT) twice week.
62722119|NCT03856736|EXPERIMENTAL|Control|Consisting of two session per week of different activities, such as body relaxation, low-intesity/volume of aerobic exercise to mimic sham group.
62722120|NCT04476667|EXPERIMENTAL|e-Psychotherapy|Participants will receive a 9-week program with CBT, mindfulness, and problem-based therapy, in addition to TAU. The content will be customized to reflect challenges faced through the COVID-19 pandemic and developed into interactive and engaging modules. All sessions and interactions will occur through Online Psychotherapy Tool (OPTT), a secure online platform. Participants will be assigned to a team of psychiatrists and social workers (SWs). The SW working with each patient will assign a pre-designed therapy module to that patient on a specific day of the week through OPTT. Participants will then be able to access the therapy content at any time throughout the week. Each module will highlight a different topic and include general information, an overview of skills, and homework that is to be completed by a specific day that week. This homework will be directly submitted through OPTT to the clinician who will provide personalized feedback to the patient.
62722121|NCT04476667|NO_INTERVENTION|Treatment as Usual|The control group will receive treatment as usual during the first 9 weeks; if they still present significant symptoms (less than 50% response to treatment from baseline), they will be offered the e-psychotherapy program.
62722122|NCT05188638|EXPERIMENTAL|Single dose of up to 5 mL nebulised SIS @ 25 ppm/placebo|
62722123|NCT05188638|EXPERIMENTAL|Single dose of up to 5 mL nebulised SIS @ 50 ppm/placebo|
62722124|NCT05188638|EXPERIMENTAL|Single dose of up to 5 mL nebulised SIS @ 100 ppm/placebo|
62722125|NCT05188638|EXPERIMENTAL|OD dosing of up to 5 mL nebulised SIS @ x ppm/placebo for 5 days|The dose to be administered in the multiple dose groups will depend on the results obtained in the single dose groups and will be decided by the SMC. The dose tested in the first multiple dose group will be the second highest well-tolerated single dose or lower.
62722126|NCT05188638|EXPERIMENTAL|OD dosing of up to 5 mL nebulised SIS @ y ppm/placebo for 5 days|
62722127|NCT05188638|EXPERIMENTAL|BID dosing of up to 5 mL nebulised SIS @ y ppm/placebo, for 4 days + morning dose on Day 5|
62722128|NCT05188638|EXPERIMENTAL|QID dosing of up to 5 mL nebulised SIS @ y ppm/placebo for 4 days + morning dose on Day 5|
62722129|NCT01705340|EXPERIMENTAL|Treatment (MK2206, lapatinib ditosylate, trastuzumab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62722130|NCT04198883|EXPERIMENTAL|Protheracytes|Single arm study : Stem cells injection called Protheracytes
62722131|NCT00891696|ACTIVE_COMPARATOR|Exp 1: AA + Rap|Participants will receive amino acid supplementation and rapamycin.
62722132|NCT00891696|PLACEBO_COMPARATOR|Exp 1: AA|Participants will receive amino acid supplementation and placebo rapamycin.
62722133|NCT00891696|ACTIVE_COMPARATOR|Exp 1: HEx + Rap|Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
62722134|NCT00891696|PLACEBO_COMPARATOR|Exp 1: HEx|Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
62722135|NCT00891696|ACTIVE_COMPARATOR|Exp 1: HEx + AA + Rap|Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
62722136|NCT00891696|PLACEBO_COMPARATOR|Exp 1: HEx + AA|Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
62722137|NCT00891696|ACTIVE_COMPARATOR|Exp 2: LExFR + Rap|Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
62722138|NCT00891696|PLACEBO_COMPARATOR|Exp 2 and 3: LExFR|Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
62722139|NCT00891696|ACTIVE_COMPARATOR|Exp 2: SNP|Participants will receive sodium nitroprusside in a resting state.
62722140|NCT00891696|ACTIVE_COMPARATOR|Exp 2: FR|Participants will undergo blood flow restriction in a resting state.
62722141|NCT00891696|ACTIVE_COMPARATOR|Exp 2: LEx + SNP|Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
62722142|NCT00891696|PLACEBO_COMPARATOR|Exp 3: LEx|Participants will undergo low-intensity resistance exercise.
62722143|NCT00891696|ACTIVE_COMPARATOR|Exp 3: HEx|Participants will undergo high-intensity resistance exercise.
62722144|NCT00891696|ACTIVE_COMPARATOR|Exp 3: HEx + AA|Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
62722145|NCT02538120|ACTIVE_COMPARATOR|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
62722146|NCT02538120|ACTIVE_COMPARATOR|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
62722147|NCT02504372|EXPERIMENTAL|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).
62722148|NCT02504372|PLACEBO_COMPARATOR|Placebo|Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).
62722149|NCT04578756|EXPERIMENTAL|Cariprazine Dose 1|Participants with Schizophrenia (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine.
62722150|NCT04578756|EXPERIMENTAL|Cariprazine Dose 2|Participants with Schizophrenia (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
62722151|NCT04578756|EXPERIMENTAL|Cariprazine Dose 3|Participants with Bipolar I Disorder (age 10 to 12 years and \<40 kg body weight) will receive cariprazine.
62722152|NCT04578756|EXPERIMENTAL|Cariprazine Dose 4|Participants with Bipolar I Disorder (age 10 to 12 years and \>= 40 kg body weight) will receive cariprazine.
62722153|NCT04578756|EXPERIMENTAL|Cariprazine Dose 5|Participants with Bipolar I Disorder (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine.
62722154|NCT04578756|EXPERIMENTAL|Cariprazine Dose 6|Participants with Bipolar I Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
62722155|NCT04578756|EXPERIMENTAL|Cariprazine Dose 7|Participants with Autism Spectrum Disorder ( age 5 to 9 years) will receive cariprazine.
62722156|NCT04578756|EXPERIMENTAL|Cariprazine Dose 8|Participants with Autism Spectrum Disorder (age 10 to 12 years and \<40 kg weight) will receive cariprazine.
62722157|NCT04578756|EXPERIMENTAL|Cariprazine Dose 9|Participants with Autism Spectrum Disorder (age 10 to 12 years and \>=40 kg body weight) will receive cariprazine.
62722158|NCT04578756|EXPERIMENTAL|Cariprazine Dose 10|Participants with Autism Spectrum Disorder (age 13 to 17 years and \<40 kg weight) will receive cariprazine.
62722159|NCT04578756|EXPERIMENTAL|Cariprazine Dose 11|Participants with Autism Spectrum Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
62722160|NCT00183014|EXPERIMENTAL|1|discussion session and exercise class
62722161|NCT00183014|ACTIVE_COMPARATOR|2|exercise class only
62722162|NCT03918382|NO_INTERVENTION|Control group|First phase. 97 participants. This group will continue standard procedure regarding side effect registration and handling. When the 97 patients have been included and have finished their radiotherapy the second phase will be initiated.
62722163|NCT03918382|EXPERIMENTAL|PRO group|Second phase. 194 participants. This group will be assigned to the intervention which is weekly electronic Patient-Reported Outcomes. Patients report the symptoms (PRO) on a tablet before each weekly control visit. The clinician will use the patients PRO answers as part of the consultation. The PRO symptoms consist of head and neck relevant items fra PRO-CTCAE™ (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) and EORTC (European Organisation for Research and Treatment of Cancer) item library.
62722164|NCT06286332|EXPERIMENTAL|Music Therapy|Participants received self-selected music app playback for 30 minutes every day and standard therapy. The entire study duration spans 21 days.
62722165|NCT06286332|NO_INTERVENTION|Standard Care|Participants only received standard care during the entire study duration span of 21 days.
62722166|NCT03396887|EXPERIMENTAL|Smartphone Application Users|"The experimental group will receive the smartphone intervention along with treatment as usual for 3-months. The smartphone application (UControlDrink) includes twice daily text message recovery support, relapse prevention cognitive behavioural therapy, 12 sessions in total, drinking and recovery activity logs where participants detail their abstinence, drinking and recovery activity engagement on a daily basis. Craving intervention in the form of a calm button to deal with cravings and prevent relapse and gamification, a system of encouraging positive behaviour with the awarding of points to achieve various status levels, is used to increase adherence and compliance with treatment recommendations."
62722167|NCT03396887|ACTIVE_COMPARATOR|Control Group|The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
62722168|NCT05921617||Observation group|
62722169|NCT00776529|EXPERIMENTAL|A Sensorimotor first|In each of nine sessions: first sensorimotor exercises, then strengthening exercises
62722170|NCT00776529|EXPERIMENTAL|B Sensorimotor & strength alternated|In each of nine sessions: Strength and sensorimotor exercises alternated
62722171|NCT02294032||Kidney Transplant|Patients who are about to undergo a kidney transplant and are on immunosuppressive agents.
62722172|NCT05743374|OTHER|Normal diet|One arm will be given dietary advice that is always given to patients with ulcerative colitis.
62722173|NCT05743374|ACTIVE_COMPARATOR|E400 elimination|The other arm will be given advice to eliminate E400 substances with special regard to carragenan, CMC and polysorbates.
62722174|NCT01251302||Prospective Cohort|Patient presenting with chest pain or anginal equivalent and receiving a resulted age, sex and gene expression score (ASGES) to assist in diagnosis.
62722175|NCT01251302||Retrospective Cohort|Patients presenting with chest pain or anginal equivalent who did not receive an age, sex and gene expression score (ASGES) to assist in diagnosis. Note: this cohort was historical.
62722176|NCT03334838|EXPERIMENTAL|GRP 1 - Assess relative bioavailability (4-way crossover)|"GROUP 1 (Treatments A, B, C, D) All treatments in Group 1 consisted of a dose of 120 mg nifurtimox (4 x 30 mg tablets).~In Treatment A, dose administration was in a fasted state.~For the other treatments, dose administration was in a fed state:~Treatment B after a low-fat breakfast; Treatment C after a breakfast consisting of dairy products (yogurt+milk); and Treatment D after a high-calorie and high-fat breakfast."
62722177|NCT03334838|EXPERIMENTAL|GRP 2 - Assess relative bioavailability (2-way crossover)|"All subjects in Group 2 received a single dose of nifurtimox in each of the Treatments D and E.~In Treatment D, subjects received 120 mg nifurtimox (4 x 30 mg tablets), and in Treatment E, subjects received 240 mg nifurtimox (8 x 30 mg tablets). Both treatments were administered in a fed state, after a high-calorie and high-fat breakfast."
62722178|NCT03141255|NO_INTERVENTION|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
62722179|NCT03141255|EXPERIMENTAL|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
62722180|NCT03688919|NO_INTERVENTION|Comparison|Adolescents and their families in this group will not receive any of the interventions.
62722181|NCT03688919|EXPERIMENTAL|Self-Regulation Intervention|This arm will use a computer-based working memory training game (NBack) targeting Executive Functioning and in-person relaxation and biofeedback training targeting Emotion Regulation. As well, adolescents will receive Future Orientation training by being asked to envision and describe future events they are looking forward to, using concrete, vivid descriptive language.
62722182|NCT02746406|EXPERIMENTAL|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
62722183|NCT03645538||Parkinson's disease patients|"PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).~The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
62737909|NCT05532722|EXPERIMENTAL|ABC008 Dose Level 3 Cohort|"1.5 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
62722184|NCT03645538||No drug - Control group|PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
62722185|NCT01322256|EXPERIMENTAL|Included patients|"Patients included in the study according to stated inclusion and exclusion criteria~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork"
62722186|NCT00413439|EXPERIMENTAL|Low dose isavuconazole intravenous solution|
62722187|NCT00413439|EXPERIMENTAL|High dose isavuconazole intravenous solution or oral capsules|
62722188|NCT04568603|EXPERIMENTAL|Methadone + ISL|Methadone-maintained participants (20 to 200 mg \[locally-provided\] once daily \[QD\] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9; ISL 60 mg is co-administered with methadone on Day 2.
62722189|NCT05880251|EXPERIMENTAL|Intervention Group|Intervention group receives peripheral stimulation with realtime operant conditioning feedback training.
62722190|NCT05880251|EXPERIMENTAL|Control Group|Control group receives peripheral stimulation but without operant conditioning feedback.
62722191|NCT01154452|EXPERIMENTAL|Arm I (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
62722192|NCT01154452|EXPERIMENTAL|Arm II (vismodegib and gamma-secretase inhibitor RO4929097)|Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
62722193|NCT01165034|NO_INTERVENTION|Usual care|Best usual practice including general respiratory specialist and primary care
62722194|NCT01165034|EXPERIMENTAL|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
62722195|NCT05260320|EXPERIMENTAL|Standardized Protocol|"Premed~1. Acetaminophen PO 15mg/kg~2. Scopolamine patch + PO/IV Midazolam as needed~Induction~1. Lidocaine (1.5 mg/kg), propofol (1-3 mg/kg), and rocuronium (0.6mg/kg)~2. Fentanyl 100 mcg bolus~3. Dexmedetomidine 0.3 mcg/kg bolus~4. Nasotracheal intubation (NTI)~5. Dexamethasone 4-8mg q4-6 hours~6. Tranexamic acid 30mg/kg bolus~7. Ancef 30 mg/kg bolus~Room~1. Bolus line~2. 4 Channel/pump infusion line w/: Maintenance IVFs/Carrier, Dexmedetomidine, TXA, Precedex or Phenylephrine~Maintenance~1. Sevo/isoflurane at 0.5-0.7 MAC with rocuronium boluses as needed~2. Dexmedetomidine 0.3- 0.5 mcg/kg/hour~3. Fentanyl 50 mcg boluses~4. TXA 15 mg/kg/hr~5. Phenylephrine 0.2-1 mcg/kg/min as needed~Emergence~1. Stop dexmedetomidine before emergence~2. Re-dose acetaminophen 15 mg/kg IV~3. Toradol 0.5 mg/kg~4. Zofran 0.15 mg/kg~5. Reverse with sugammadex~6. OGT placement, extubate awake"
62722196|NCT05260320|NO_INTERVENTION|Provider Choice Protocol|Patients will be managed with provider-specific protocols, which may vary.
62722197|NCT02863965||High definition endoscopy and optic enhancement|All the patients underwent routine preparation before the procedure. The detected lesions in high definition endoscopy were observed with optic enhancement mode. The endoscopist was required to give the real-time descriptions of surface pit patterns of the lesions, based on surface pattern classification. After that, biopsy specimens will be obtained respectively by forceps from each detected lesion recorded for histologic diagnosis.
62722198|NCT01719848||Preoperative airway examination|patients undergoing general anesthesia for any surgery
62722199|NCT03763734|EXPERIMENTAL|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
62722200|NCT03763734|ACTIVE_COMPARATOR|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
62722201|NCT05376722|EXPERIMENTAL|pamiparib|Subjects received pamiparib 40 mg orally, twice a day; abiraterone acetate 1000 mg orally, once a day; prednisone acetate tablets (prednisone) 5 mg, once a day; every 30 days Treatment cycle, treatment for 4-6 cycles, that is, 4-6 months. Robot-assisted laparoscopic radical prostatectomy and extended lymph node dissection within 30 days of the end of 4 months of neoadjuvant therapy. If the subjects have intolerable toxic reactions during the treatment period, the dose adjustment can be carried out. Day 1 of cycle 1, day 15 and day 1±3 days of each cycle thereafter, and 1 follow-up within 30 days after the end of treatment and before surgery; 1 prostate MRI during the screening period and within 30 days after the end of treatment and before surgery Scan, PSMA PET/CT scan or CT scan
62722202|NCT06123611|NO_INTERVENTION|Standard Care|In the pre-implementation period, all trauma patients will receive standard routine care. Which may include some screening and counseling on gun safety.
62722203|NCT06123611|EXPERIMENTAL|ACTFAST Intervention|During the implementation and maintenance periods, all trauma patients will receive study activities including firearm access screening, counseling on safe storage practices, and referral to safe storage and other community resources as appropriate.
62722204|NCT04314817||Patients treated for Covid-19|
62722205|NCT00429182|EXPERIMENTAL|High-dose chemotherapy|Carboplatin + Cyclophosphamide + Thiotepa
62722206|NCT03632096|ACTIVE_COMPARATOR|Photobiomodulation group|Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
62722207|NCT03632096|SHAM_COMPARATOR|Sham group|The placebo group will have a simulation of application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
62722208|NCT00670566|EXPERIMENTAL|1|
62722209|NCT04781348|EXPERIMENTAL|Platelet Rich Plasma and fat grafting|Group will receive Platelet Rich Plasma plus fat grafting
62722210|NCT04781348|EXPERIMENTAL|Fat grafting|Group will receive only fat grafting
62722211|NCT03665259|ACTIVE_COMPARATOR|Pure oxygen group|The patients receive 100% oxygen therapy during the induction phase of induction
62722212|NCT03665259|EXPERIMENTAL|Lower oxygen group|The patients received 60% oxygen therapy during the induction phase of induction
62722213|NCT05016258||KONTACT MB|Adult patients needed one or multiple implant-supported fixed restoration(s)
62722214|NCT02148588|EXPERIMENTAL|Pain testing|"Completion of NPSI questionnaire~Sensory mapping of the affected limb~Quantitative Sensory Testing~Patients will have a peripheral nerve blockade"
62722215|NCT03495934|EXPERIMENTAL|single oral administration of 14C-pracinostat in the fas|
62722216|NCT06093399|EXPERIMENTAL|Deep Brain Simulation (DBS) System|The DBS device will be turned on to compare stutter to when the device was off (which would be the control).
62722217|NCT06312189|EXPERIMENTAL|Valbenazine|Capsule, administered orally once daily.
62722218|NCT03984773|NO_INTERVENTION|Control|Clinicians will receive current standard communications regarding serious illness performance.
62722219|NCT03984773|EXPERIMENTAL|Mortality Estimates and Nudges|Clinicians will receive a weekly email with upcoming patients that have high mortality estimates to consider for a serious illness conversation. Clinicians will have the opportunity to review the list and pre-commit (using an opt-out design) to patients appropriate for a conversation. They will receive a nudge on the day of the patient visit through a text message reminding them of their pre-commitment to conduct a serious illness conversation
62722220|NCT01023152|EXPERIMENTAL|Automated cuff-inflator|
62722221|NCT05402254|EXPERIMENTAL|Pharmacovigilance Program|Intensive nursing intervention is carried out for the identification and notification of ADE
62722222|NCT05402254|NO_INTERVENTION|Control|The Usual practice of the nursing care process
62722223|NCT05960487||The patients with a significant decrease in pain severity|Evaluation will be done separately in the 3rd week and 3rd month follow-up periods of the cervical epidural steroid injection. Numerical rating scale (NRS) will be used to evaluate pain severity. A reduction of at least 50 percent in the NRS score will be considered significant.
62722224|NCT05960487||Patients without significant decrease in pain severity|Evaluation will be done separately in the 3rd week and 3rd month follow-up periods of the cervical epidural steroid injection. Numerical rating scale (NRS) will be used to evaluate pain severity. A reduction of at least 50 percent in the NRS score will be considered significant.
62722225|NCT05582681|ACTIVE_COMPARATOR|HCV Education|The intervention of HCV education will be performed at the addiction care setting for video- based patient education. Health care provide delivered patient education is the standard of care referral approach. HCV Education will include HCV disease overview, HCV screening, taking Glecaprevir/Pibrentasivir (G/P), and post study drug assessment and management. Participants may be randomized to either the video-based patient education or the HCV delivered patient education.
62722226|NCT05582681|EXPERIMENTAL|Point of Care (POC) HCV Viremia (RNA) testing|All participants will have standardized laboratory assessments for HCV Viremia (RNA testing) as well as Cepheid POC HCV Viremia (RNA) test. The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
62722227|NCT00639288|EXPERIMENTAL|1|modified CPT-C
62722228|NCT03333694|EXPERIMENTAL|CLL442|Cutaneous Cream application twice daily
62722229|NCT03333694|PLACEBO_COMPARATOR|Placebo|Placebo Cutaneous Cream application twice daily
62722230|NCT00373607|EXPERIMENTAL|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
62722231|NCT00373607|ACTIVE_COMPARATOR|Mefloquine + Artesunate (MAS3)|The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
62722232|NCT02603276|ACTIVE_COMPARATOR|Plant sterols|Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
62722233|NCT02603276|ACTIVE_COMPARATOR|Red Yeast Rice|Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
61976690|NCT04824885|EXPERIMENTAL|Acetate containing dialysate then acetate free dialysate|Group 2 patients will continue on the usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months. Patients will be blinded from study treatment.
62722234|NCT02603276|EXPERIMENTAL|Red Yeast Rice plus Plant sterols|lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
62722235|NCT03819257||Patients with perianal Crohn's disease.|
62722236|NCT06026280|PLACEBO_COMPARATOR|Conventional Job-Search Program|6 weeks of self-guided job-seeking
62722237|NCT06026280|EXPERIMENTAL|DRIVEN App-Based Program|6 weeks of job-seeking guided by the DRIVEN curriculum
62722238|NCT03800030|EXPERIMENTAL|Theta-gamma, Delta-beta, Sham|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS"
62722239|NCT03800030|EXPERIMENTAL|Theta-gamma, Sham, Delta-beta|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS"
62722240|NCT03800030|EXPERIMENTAL|Delta-beta, Theta-gamma, Sham tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS"
62722241|NCT03800030|EXPERIMENTAL|Delta-beta, Sham, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS"
62722242|NCT03800030|EXPERIMENTAL|Sham, Delta-beta, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS"
62722243|NCT03800030|EXPERIMENTAL|Sham, Theta-gamma, Delta-beta tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS"
62722244|NCT05575544|EXPERIMENTAL|Left PVI ablation electroacupuncture group|Patient undergo right pulmonary vein isolation under general anesthesia.After successful isolation of the right pulmonary vein, use a 25-gauge stainless steel millineedle of different lengths to be ordered sequentially according to the acupuncture point prescription.Acupuncture was performed at Hegu and Neiguan points on the left side of the patient.After the manual acupuncture, the point was continuously stimulated by an electrical stimulator to analgesia,the frequency is 200 times / min, the pulse frequency is 3 \~ 4Hz. The output intensity is subject to the patient's tolerance, generally 20mA.The electroneedle stimulates until the end of the left pulmonary vein isolation.
62722245|NCT05575544|EXPERIMENTAL|Right PVI ablation electroacupuncture group|Patient undergo left pulmonary vein isolation under general anesthesia.After successful isolation of the left pulmonary vein, use a 25-gauge stainless steel millineedle of different lengths to be ordered sequentially according to the acupuncture point prescription.Acupuncture was performed at Hegu and Neiguan points on the left side of the patient.After the manual acupuncture, the point was continuously stimulated by an electrical stimulator to analgesia,the frequency is 200 times / min, the pulse frequency is 3 \~ 4Hz. The output intensity is subject to the patient's tolerance, generally 20mA.The electroneedle stimulates until the end of the right pulmonary vein isolation.
62722246|NCT00538057|EXPERIMENTAL|arm 1|study drug
62722247|NCT02539186|EXPERIMENTAL|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
62722248|NCT02539186|ACTIVE_COMPARATOR|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
62722249|NCT02363114||Stroke Prevention Clinic Patients|All consecutive patients presenting to six high volume Regional Stroke Prevention Clinics.
62722250|NCT00648037|EXPERIMENTAL|Rituximab|Patients following a T cell depleted HLA-mis-matched related or unrelated hematopoietic stem cell transplant (HSCT) will be treated with monthly Rituximab.
62722251|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
62722252|NCT03030898|OTHER|respiratory variation of the right internal jugular vein|
62722253|NCT01310530|EXPERIMENTAL|Partial Breast Proton Therapy|Two weeks of daily proton therapy delivered to the lumpectomy site.
62722254|NCT04834726|ACTIVE_COMPARATOR|1: Usual Care|Patients will receive a phone call to schedule their appointment from an Access Center representative. Access Center representatives will make up to 3 attempts to schedule an appointment with the patient. Patients randomized to this arm will not receive any text messaging.
62722255|NCT04834726|EXPERIMENTAL|2A: Call Back + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
62722256|NCT04834726|EXPERIMENTAL|2B: Call Back + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
62722257|NCT04834726|EXPERIMENTAL|2C: Call Back + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
62722258|NCT04834726|EXPERIMENTAL|2D: Call Back + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-outWill include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
62722259|NCT04834726|EXPERIMENTAL|3A: In-Bound Call + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
62722260|NCT04834726|EXPERIMENTAL|3B: In-Bound Call + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
62722261|NCT04834726|EXPERIMENTAL|3C: In-Bound Call + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
62722262|NCT04834726|EXPERIMENTAL|3D: In-Bound Call + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-out. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
62722263|NCT03569943|EXPERIMENTAL|Robotol|
62722264|NCT00718536|EXPERIMENTAL|1|Addition of raltegravir 800 mg QD to HAART
62722265|NCT03192137|EXPERIMENTAL|ISV-305|0.1% dexamethasone in DuraSite® 2
62722266|NCT03192137|PLACEBO_COMPARATOR|Vehicle|DuraSite® 2 Vehicle
62722267|NCT02929641||HDWL and OE with magnification|The polyps found will be observed by HDWL and OE with magnicication model and recorded.
62722268|NCT02664519|EXPERIMENTAL|Exercise training followed by no exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
62722269|NCT02664519|EXPERIMENTAL|No exercise training followed by exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
62722270|NCT02664519|NO_INTERVENTION|Normal Control|Control subjects without CKD will undergo baseline assessment as above.
62722271|NCT03224364|PLACEBO_COMPARATOR|LC & nonsolo approach|The surgical intervention is nonsolo LC
62722272|NCT03224364|ACTIVE_COMPARATOR|LC & solo approach|The surgical intervention is solo LC.
62722273|NCT05501639||tiotropium + inhaled corticosteroids (ICS) group|
62722274|NCT05501639||long-acting β2-agonists (LABA) + inhaled corticosteroids (ICS) group|
62722275|NCT02491281|EXPERIMENTAL|LNA043|LNA043 given intra-articularly
62722276|NCT02491281|PLACEBO_COMPARATOR|Placebo|Placebo given intra-articularly
62722277|NCT06000670|EXPERIMENTAL|knee osteoarhritis|patients with grade 2 and above chondromlacia as well as all grades of osteoarhtritis
62722278|NCT01904721|EXPERIMENTAL|Stage 1: Bimatoprost Solution 1 Twice Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
62722279|NCT01904721|EXPERIMENTAL|Stage 1: Bimatoprost Solution 1 Once Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days.
62722280|NCT01904721|EXPERIMENTAL|Stage 1: Bimatoprost Solution 2 Twice Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
62722281|NCT01904721|EXPERIMENTAL|Stage 1: Bimatoprost Solution 2 Once Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days.
62722282|NCT01904721|EXPERIMENTAL|Stage 2: Bimatoprost Solution 1 Twice Daily|Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
62722283|NCT01904721|EXPERIMENTAL|Stage 2: Bimatoprost Solution 2 Twice Daily|Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
62722284|NCT01904721|PLACEBO_COMPARATOR|Stage 2: Bimatoprost Vehicle Twice Daily|Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months.
62722285|NCT06351826|EXPERIMENTAL|ELLASI|"Polytrauma patients in the intervention group will receive a-6-points structured intervention abbreviated with ELLASI:~1. Evaluasi: Evaluation of airway and cervical control, remove the foreign body, fluid, etc., from the airway~2. Letakkan: patient positioning and give oxygen, head-up.~3. Lakukan: Stabilisasation, including IV insertion, applying pressure and bandage, place monitor, haemodynamic monitoring~4. Assessment: re-assessment of pain and other main complaints~5. Siapkan: make sure informed consents are documented~6. Informasikan: inform patient and family for further intervention"
62722286|NCT06351826|ACTIVE_COMPARATOR|Standard|Polytrauma patients in the control group will receive the usual/standard intervention.
62722287|NCT00439335|EXPERIMENTAL|H5 HA IM|Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.
62722288|NCT00439335|EXPERIMENTAL|H5 HA ID|Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.
62722289|NCT04063917|EXPERIMENTAL|Sequence 1|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device ON for the first half and OFF for the second half."
62722290|NCT04063917|EXPERIMENTAL|Sequence 2|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device OFF for the first half and ON for the second half"
62722291|NCT04495686|EXPERIMENTAL|Caregiver PWD-ADRD TCCI|Participants in the Caregiver PWD-ADRD telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
62722292|NCT04495686|NO_INTERVENTION|Caregiver for PWD-ADRD (BMT)|Participants in the Caregiver PWD-ADRD best medical treatment (BMT) group will not receive care coordination.
62722293|NCT04495686|EXPERIMENTAL|Caregiver for PWD-TBI TCCI|Participants in the Caregiver PWD-TBI telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
62722294|NCT04495686|NO_INTERVENTION|Caregiver for PWD-TBI (BMT)|Participants in the Caregiver PWD-TBI best medical treatment (BMT) group will not receive care coordination.
62722295|NCT00558636|EXPERIMENTAL|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
62722296|NCT00558636|PLACEBO_COMPARATOR|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
62722297|NCT01718158|EXPERIMENTAL|Peginterferon Lambda-1a + Ribavirin + Daclatasvir|"Peginterferon Lambda-1a 180 µg solution for subcutaneous injection, once a week for 24 Weeks~Ribavirin 200 mg tablets \[1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects \< 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food\] by mouth, twice daily, for 24 weeks~Daclatasvir 60 mg tablets by mouth, once a day for 12 weeks"
61976691|NCT00330564|EXPERIMENTAL|SU011248 (Sutent, Sunitinib Malate)|50 mg/day orally for 4 weeks
62722298|NCT01718158|EXPERIMENTAL|Peginterferon Alfa-2a + Ribavirin + Telaprevir|"Peginterferon Alfa-2a 180 µg solution for subcutaneous injection, once a week for 24 to 48 weeks depending on response~Ribavirin 200 mg tablets \[1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects \< 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food\] by mouth, twice daily, for 24 to 48 weeks depending on response~Telaprevir 375 mg tablets \[2250 mg total daily dose: subjects should take 750 mg (two 375 mg tablets) orally three times a day, approximately 7-9 hours apart) for 12 weeks"
62722299|NCT03272555|OTHER|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
62722300|NCT03253718||Healthy Volunteers|Healthy Volunteers between 18 and 68 years of age
62722301|NCT00803361|EXPERIMENTAL|Duloxetine|
62722302|NCT00803361|PLACEBO_COMPARATOR|Placebo|
62722303|NCT05618756|EXPERIMENTAL|Cannabidiol|300 mg CBD (KannaSwiss, Kölliken, Switzerland) dissolved in 1 ml hemp oil. Provided orally in gelatin capsules.
62722304|NCT05618756|PLACEBO_COMPARATOR|Placebo|1 ml hemp oil. Provided orally in gelatin capsules.
62722305|NCT02832193||Study group|"POCD data of study patients of the following studies:~Phydelio - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 ReCosa - EA1/056/13 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 Pain-Long-EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
62722306|NCT02832193||Control group I|"POCD data of prospective control subjects/patients (ASA I+II+III) and POCD data of control subjects/patients of the following studies:~Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 Phydeliostudie - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 BioCog-Studie - EA2/092/14 REACT-Studie - EA2/091/15 PAINLONG-Studie - EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
62722307|NCT00570713|EXPERIMENTAL|MORAb-009|MORAb-009 plus gemcitabine ('MORAb-009'): MORAb-009 was administered at 5 mg/kg on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
62722308|NCT00570713|ACTIVE_COMPARATOR|Placebo|Placebo plus gemcitabine ('Placebo') Placebo was administered on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
62722309|NCT04458740||Patient|Patients with a diagnosis of colorectal cancer after 65 years.
62722310|NCT04458740||The spouse and /or children and /or parents|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
62722311|NCT01936883|ACTIVE_COMPARATOR|LDR boost|After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy
62722312|NCT01936883|ACTIVE_COMPARATOR|HDR boost|Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.
62722313|NCT02315222|ACTIVE_COMPARATOR|Test|Dietary Supplementation
62722314|NCT02315222|PLACEBO_COMPARATOR|Control|Placebo Supplementation
62722315|NCT02136043|EXPERIMENTAL|Group 1|Insertion of catheter into nasal cavity carried out by patient. Fixation of catheter during treatment with patient´s hand.
62722316|NCT02136043|EXPERIMENTAL|Group 2|Insertion of catheter into nasal cavity carried out by health professional. Fixation of catheter during treatment with helmet.
62722317|NCT03406208|EXPERIMENTAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
62722318|NCT03406208|EXPERIMENTAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
62722319|NCT01778998|ACTIVE_COMPARATOR|MICS-group|
62722320|NCT01778998|ACTIVE_COMPARATOR|SICS-group|
62722321|NCT01778998|ACTIVE_COMPARATOR|SICS pre-cut|
62722322|NCT01778998|ACTIVE_COMPARATOR|SICS stab-incision|
62722323|NCT04748692|EXPERIMENTAL|Local exercise therapy|The local exercise therapy group focused on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients trained with the support of a physiotherapist. The physiotherapist gradually increased the intensity of the exercises improving muscle endurance. The exercises were supplemented with mobilisations of the patellofemoral joint. Twice a week, patients trained at home following a prescribed exercise program writing down their work-out in an exercise journal.
62722324|NCT04748692|EXPERIMENTAL|Spinal manual therapy|The spinal manual therapy group was treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots were used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment included manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation was conducted if a restriction of range of motion was found in any of the regions. Patients were also asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
62722325|NCT01147393|EXPERIMENTAL|All subjects|two weekly infusions of 90Y-epratuzumab tetraxetan in combination with four weekly infusions of 200 mg/m2 veltuzumab.
62722326|NCT04450030||Intravenous methyl prednisolone|Patients receiving an additional course of intravenous methyl prednisolone for treatment of a steroid-refractory MS relapse
62722327|NCT04450030||Immunoadsorption|Patients receiving 6 courses of immunadsorption treatment for treatment of a steroid-refractory MS relapse
62722328|NCT05068349|EXPERIMENTAL|A group of patients with ischemic stroke were treated with butylphthalide injection and capsules|Patients eligible for inclusion and exclusion are only divided into one group, no controls or other.
62722329|NCT02546583|EXPERIMENTAL|Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)|2.5x Visit 1 dose
62722330|NCT02546583|EXPERIMENTAL|Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide|Loop diuretic (Bumetanide or Furosemide) dose remains the same as visit 1 dose but now with the addition of 500-1000 mg IV chlorothiazide
62722331|NCT02546583|NO_INTERVENTION|Observational Arm|Subjects taking an IV loop diuretic (Bumetanide or Furosemide) that have sodium output greater than 100 mmol. These subjects will continue to be followed and have data collected on them.
62722332|NCT02916069|ACTIVE_COMPARATOR|Group 1 (Multimodal brain monitoring)|Patients will be monitored with combination of brain monitoring; Nearinfrared Spectroscopy (NIRS), Transcranial Doppler (TCD), and Bispectral index (BIS). Interference will be done to optimize the medical condition based on such monitors.
62722333|NCT02916069|NO_INTERVENTION|Group 2|Patients will be monitored without any interference based on such monitors
62722334|NCT04419545||interstitial pneumonia cases|Chest x-ray diagnosis
62722335|NCT04419545||Negative controls|Chest x-ray Negative for pneumonia
62722336|NCT05278026||HFrEF|heart failure with reduced ejection fraction
62722337|NCT05278026||HFpEF|heart failure with preserved ejection fraction
62722338|NCT05278026||nonfailing control|patients without heart failure
62722339|NCT04277624|EXPERIMENTAL|Fezolinetant: Test Formulation then Reference Formulation|Participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 2.
62722340|NCT04277624|EXPERIMENTAL|Fezolinetant: Reference Formulation then Test Formulation|Participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 2.
62722341|NCT01923766|EXPERIMENTAL|Cytotoxic T lymphocytes (CTLs)|Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
62722342|NCT02525640|EXPERIMENTAL|Hearing Aid|CROS hearing aid
62722343|NCT02185534|EXPERIMENTAL|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
62722344|NCT02185534|ACTIVE_COMPARATOR|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
62722345|NCT02185534|ACTIVE_COMPARATOR|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
62722346|NCT03194399|EXPERIMENTAL|Breast cancer patients|
62722347|NCT00696124|EXPERIMENTAL|Cohort 1|2 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
62722348|NCT00696124|EXPERIMENTAL|Cohort 2|4 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
62722349|NCT00696124|EXPERIMENTAL|Cohort 3|8 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
62722350|NCT00696124|EXPERIMENTAL|Cohort 4|16 mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
62722351|NCT02965066|EXPERIMENTAL|First Coloplast Test catheter; then Speedicath catheter|The subjects allocated to this arm first test Coloplast Test catheter and after cross over test the comparator speedicath catheter
62722352|NCT02965066|EXPERIMENTAL|First Speedicath catheter; then Coloplast Test catheter|The subjects allocated to this arm first test Speedicath catheter and after cross over test the Coloplast test catheter
62722353|NCT01534481|ACTIVE_COMPARATOR|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
62722354|NCT01534481|PLACEBO_COMPARATOR|Preterm Formula|Preterm formula determined by center practice
62722355|NCT00688857|EXPERIMENTAL|A|Diazoxide choline controlled-release coated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 9 through 16).
62722356|NCT00688857|EXPERIMENTAL|B|Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release coated tablets administered orally once daily (Days 9 through 16)
62722357|NCT00786162|EXPERIMENTAL|Intervention|Internet-based hypertension self-management platform
62722358|NCT00786162|ACTIVE_COMPARATOR|Control|Installation of BP cuff for communal use at the worksite
62722359|NCT03757507|EXPERIMENTAL|Optoacoustic imaging|Optoacoustic Imaging before and after tracer administration
62722360|NCT01953211||Healthy reproductive age women|These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
62722361|NCT00954161|EXPERIMENTAL|first aid and helping behaviour|The helping behaviour training is given after 24 hours first aid training and aims to sensitise participants towards a helping reaction and teach participants how to deal with barriers to helping
62722362|NCT00954161|ACTIVE_COMPARATOR|first aid only|This group receives training in first aid only without training in helping behaviour.
61976692|NCT03276884|EXPERIMENTAL|Experimental Infant Formula|Infant formula powder to be fed ad libitum
62722363|NCT05230511|EXPERIMENTAL|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Treatment Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
62737910|NCT05532722|EXPERIMENTAL|ABC008 Dose Level 4 Cohort|"3.0 mg / kg ABC008 Subjects receive ABC008 every 8 weeks OR 1.5 mg / kg Subjects receive ABC008 every 4 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
62722364|NCT05230511|OTHER|Intravesical Bladder Wash (Treatment Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
62722365|NCT05230511|EXPERIMENTAL|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Prophylaxis Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. They will then instill the LGG® mixture every 2 days for the remainder of the 6 months. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
62722366|NCT05230511|OTHER|Intravesical Bladder Wash (Prophylaxis Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. They will then instill the saline BW every 2 days for the remainder of the 6 months. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
62722367|NCT03912610||Health control group|5 health volunteer are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
62722368|NCT03912610||Knee osteoarthritis group|5 patients of knee osteoarthritis accompanied with depression or anxiety are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
62722369|NCT00733486|OTHER|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
62722370|NCT01252589||Adults with CML|Adult patients (18 years of age or older) with confirmed diagnosis of CML
62722371|NCT05197465||Patients undergoing major abdominal surgery|The investigators aim to conduct a prospective observational, cohort study including all patients undergoing a major open abdominal surgery.
62722372|NCT02248896||Hypertensive patients|Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data
62722373|NCT05980754||Healthy group|No intervention
62722374|NCT05980754||pre diabetic patients|No intervention
62722375|NCT05980754||T2DM patients|No intervention
62722376|NCT05630781|ACTIVE_COMPARATOR|Control Arm|80 Volunteers who are between the ages of 18-60 and are non-smokers/vapers. 1. Baseline visit with 1 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
62722377|NCT05630781|EXPERIMENTAL|Nicotine Dependence Arm|140 Volunteers who are between the ages of 18-60 and are daily smokers/vapers. Suvorexant at 10 mg single dose, and Suvorexant at 10 mg daily for approximately 7 days.
62722378|NCT05046626|EXPERIMENTAL|nutritional counseling|Arm with intervention
62722379|NCT00361465||Parkinsonian patients presenting of the dystonia|15 Parkinsonian patients presenting of the dystonia of ONE or OFF at the time of the phases of driving fluctuations. These patients must present a dystonia of the upper limb, mainly localised than the level of the segment brachial or in distality.
62722380|NCT00361465||patients carrying a primary education dystonia affecting|15 patients carrying a primary education dystonia affecting at least one of the two upper limbs, without excessive involuntary movements
62722381|NCT00361465||patients carrying a secondary dystonia|15 patients carrying a secondary dystonia (consecutive with a perinatal suffering) affecting at least one of the two upper limbs, without excessive involuntary movements
62722382|NCT00361465||pilot subjects|30 healthy pilot subjects paired in sex, age (± 5 years), dominant laterality and level of schooling (15 subjects paired with the Parkinsonian patients and 15 subjects paired with the patients dystonic
62722383|NCT02102958|EXPERIMENTAL|Experimental|DSME with Nonvisual Foot Examination
62722384|NCT02102958|ACTIVE_COMPARATOR|Comparison|DSME with Usual Foot Examination Instruction
62722385|NCT04805866||Healthy Age-matched controls|Healthy individuals ages 18-85
62722386|NCT04805866||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-85
62722387|NCT03725956|EXPERIMENTAL|endoscopic sinus surgery|Single group of patients with nasal polyposis eligible for endoscopic sinus surgery
62722388|NCT03815149||patients with intracranial aneurysm(s)|Standard of care elective, unscheduled or emergency procedures for the treatment of an unruptured or ruptured intracranial aneurysm(s) using a Pipeline™ Flex Embolization Device(s) with Shield Technology™
62722389|NCT00894777||1|Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
62722390|NCT03679390|EXPERIMENTAL|10-20 y/o|We will include the teenagers who need intravenous general anesthesia(IVGA), and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
62722391|NCT03679390|EXPERIMENTAL|20-40y/o group|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
62722392|NCT03679390|EXPERIMENTAL|>70 y/o|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
62722393|NCT02581891|EXPERIMENTAL|Early-start T&E / Arm 1|Early-start T\&E arm: test group, early treatment individualization
62722394|NCT02581891|ACTIVE_COMPARATOR|Late-start T&E / Arm 2|Late-start T\&E arm; per label, control group, treatment individualization after Year 1
62722395|NCT01293136||intravenous opioids|
62722396|NCT01293136||femoral nerve block|
62722397|NCT03706365|EXPERIMENTAL|A1. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
62722398|NCT03706365|EXPERIMENTAL|A2. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
62722399|NCT03706365|ACTIVE_COMPARATOR|B1. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
62722400|NCT03706365|ACTIVE_COMPARATOR|B2. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
62722401|NCT03706365|EXPERIMENTAL|A. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
62722402|NCT03706365|ACTIVE_COMPARATOR|B. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
62722403|NCT00532701|ACTIVE_COMPARATOR|Peg-IFN + WB RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
62722404|NCT00532701|ACTIVE_COMPARATOR|Peg-IFN + LD RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
62722405|NCT00532701|ACTIVE_COMPARATOR|Peg-IFN + WB RBV for 24 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
62722406|NCT00532701|ACTIVE_COMPARATOR|Peg-IFN + WB RBV for 48 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
62722407|NCT00532701|ACTIVE_COMPARATOR|Peg-IFN + LD RBV for 24 weeks|Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR
62722408|NCT02255669|ACTIVE_COMPARATOR|partially covered SEMS|Deployment of Partially covered biliary self expandable metal stent
62722409|NCT02255669|ACTIVE_COMPARATOR|fully covered SEMS|Deployment of Fully covered biliary self expandable metal stent
62722410|NCT00362895|EXPERIMENTAL|Tobradex AF|
62722411|NCT00362895|ACTIVE_COMPARATOR|TOBRADEX|
62722412|NCT03991910|PLACEBO_COMPARATOR|control|control patients will be given a placebo
62722413|NCT03991910|EXPERIMENTAL|treatment|Ramipril 5 mg treatment group
62722414|NCT04972188|EXPERIMENTAL|ZYIL1|Capsule administration. Six subjects will be recruited in each cohort. safety data up to day 14 will be evaluated. Single dose will be administered in ascending manner starting from 12.5 mg.
62722415|NCT00598819|EXPERIMENTAL|Healthy Volunteers|Healthy subjects testing the device.
62722416|NCT03857009||Symptomatic|No intervention.
62722417|NCT03857009||Asymptomatic|No intervention.
62722418|NCT01658085||Study group: HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
62722419|NCT01658085||Control group: ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
62722420|NCT05647499|EXPERIMENTAL|The Back 2 School program (B2S) for problematic school absenteeism|The B2S program is a modular trans-diagnostic cognitive behavioral program aimed at helping children and youth with problematic levels of school absenteeism.
62722421|NCT02837718|OTHER|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
62722422|NCT03361488|EXPERIMENTAL|Trained anesthesiologist|Patient interview by anesthesiologists having obtained training to optimize structured communication
62722423|NCT03361488|NO_INTERVENTION|Control anesthesiologist|Patient interview by control anesthesiologists
62722424|NCT02747758|SHAM_COMPARATOR|Control|sham transcranial direct current stimulation (tDCS)
62722425|NCT02747758|EXPERIMENTAL|cathodal stimulation|cathodal transcranial direct current stimulation (tDCS)
62722426|NCT02747758|EXPERIMENTAL|anodal stimulation|anodal transcranial direct current stimulation (tDCS)
62722427|NCT04240886|EXPERIMENTAL|Cohort A: fosmanogepix (APX001)|
62722428|NCT04240886|EXPERIMENTAL|Cohort B: fosmanogepix (APX001)|
62722429|NCT02521974|EXPERIMENTAL|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
62722430|NCT01421966|EXPERIMENTAL|CureXcell®|
62722431|NCT01421966|SHAM_COMPARATOR|Sham injection|
62722432|NCT02126163|EXPERIMENTAL|Treatment Group|The treatment group will receive three interactive Computer Tailored Intervention (CTI) sessions during the course of six months, which will include tailored feedback based on the user's responses, and two assessment only follow-up sessions at twelve and eighteen months.
62722433|NCT02126163|NO_INTERVENTION|Control Group|The control group will receive four assessment only sessions during 18 months.
62722434|NCT03265444|EXPERIMENTAL|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery
62722435|NCT04918147|EXPERIMENTAL|Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper.~* Elotuzumab: 10 mg/kg administered once weekly, intravenously for 4 doses, per protocol.~* Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs)."
62722436|NCT04918147|EXPERIMENTAL|Cohort 1b: Elotuzumab-Twelve-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab over a 48 week period, dose of 10mg/kg IV x 1, at baseline, then at weeks 8, 16, 24, 32 and 40 (for a total of 6 doses), with the prescribed 10-week prednisone taper.~* Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol.~* Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs)."
62722437|NCT04918147|EXPERIMENTAL|Cohort 2: Arm A- Elotuzumab (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).~Assuming no safety signal for Cohort 1, forty-two participants will receive elotuzumab per the regimen prescribed above in Part 1B, with the prescribed 10-week prednisone taper.~* Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol.~* Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that is taken daily by mouth, per protocol. Dosage in milligrams (mgs)."
62737911|NCT05532722|EXPERIMENTAL|ABC008 Dose Level 5 Cohort|"3.0 mg / kg ABC008 Subjects receive ABC008 every 4 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
62737912|NCT06660966|ACTIVE_COMPARATOR|Group M|M TAPA applied group
62737913|NCT06660966|ACTIVE_COMPARATOR|Group E|ESB applied Group
62722438|NCT04918147|PLACEBO_COMPARATOR|Cohort 2: Arm B-Placebo (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).~Twenty-one participants will receive placebo for elotuzumab on day 0, then weeks 8, 16, 24, 32 and 40, and the prescribed 10-week prednisone taper.~* Placebo for elotuzumab: Administered on same schedule as elotuzumab described in Cohort 2 Arm A: intravenously, per protocol.~* Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 taken daily by mouth, per protocol. Dosage in milligrams (mgs)."
62722439|NCT06242847||Insulin Sensitive (IS) with psoriasis|"Patients with plaque psoriasis and overweight/obese (BMI 25-35) found to have:~* Hemoglobin A1c \< 5.7%~* Fasting plasma glucose: \< 95 mg/dL~* Fasting serum insulin: \< 10 micro-international units per milliliter (μIU/mL)"
62722440|NCT06242847||Insulin Intermediate (II) with psoriasis|"Patients with plaque psoriasis and overweight/obese (BMI 25-35) found to have:~* Hemoglobin A1c \< 6.5%~* Fasting plasma glucose: 80-125 mg/dL~* Fasting serum insulin: 10-14 μIU/mL"
62722441|NCT06242847||Insulin Resistant (IR) with psoriasis|"Patients with plaque psoriasis and overweight/obese (BMI 25-35) found to have:~* Hemoglobin A1c \< 6.5%~* Fasting plasma glucose: 80-125 mg/dL~* Fasting serum insulin: ≥ 15 μIU/mL"
62722442|NCT04877678|ACTIVE_COMPARATOR|Treatment group|Participants will be treated with bepotastine.
62722443|NCT04877678|PLACEBO_COMPARATOR|Placebo group|Participants will be treated with identical looking placebo.
62722444|NCT00751712||Back of skull cerebral oximeter sensor|All patients enrolled will receive non-invasive oxygen perfusion monitoring on the back of the skull during their standard of care congenital heart surgery
62722445|NCT00967681|EXPERIMENTAL|A|Oncoxin, a nutritional supplement
62722446|NCT00967681|PLACEBO_COMPARATOR|B|
62722447|NCT05983341||Children (<18 years old) with Berlin Heart EXCOR assisting device.|
62722448|NCT03533088|EXPERIMENTAL|Hospitalized rehabilitation|Patients in this group will recieve rehabilitation program twice in a week at our clinic after the surgical procedure until post-operative 12 weeks.
62722449|NCT03533088|EXPERIMENTAL|Home-based rehabilitation|Patients in his groups will performed home-based rehabilitation in the early stages of the post-op period. They will com to our clinic once in a two weeks and the recieve the exercise program to perform at home until the 6. weeks of the post-operative period. After the 6. week they will come to our clinic once in a week until the post-operative 12. week.
62722450|NCT06364397|EXPERIMENTAL|ERCP group|Participants will undergo ERCP. Indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place. Participants will accept health education and conservative management of clinical routines. Follow-up visits for participants occurred at 3, 6, 9 and 12 months after enrollment.
62722451|NCT06364397|ACTIVE_COMPARATOR|conservative treatment group|Participants will be given health education and conservative management of clinical routines. Follow-up visits for participants occurred at 3, 6, 9 and 12 months after enrollment.
62722452|NCT01595529|EXPERIMENTAL|Active treatment|5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)
62722453|NCT01595529|PLACEBO_COMPARATOR|Placebo treatment|5 days of placebo treatment to match physician-initiated therapy
62722454|NCT06017882||Group A : Usual sleep *2 ; Deprivation *2|V1-\>V3 id. V4 : Usual sleep and test series (easy; difficult; difficult) V5 : Usual sleep and test series (difficult; easy; easy) V6 : Sleep deprivation and test series (easy; easy; difficult) V7 : Sleep deprivation and test series (difficult; difficult; easy)
62722455|NCT06017882||Group B : Usual sleep ; Deprivation; Deprivation ; Usual sleep|V1-\>V3 id. V4 : Usual sleep and test series ( difficult; difficult ; easy) V5 : Sleep deprivation and test series (easy; difficult; difficult) V6 : Sleep deprivation and test series (difficult; easy; easy) V7 : Usual sleep and test series (easy ; easy ; difficult)
62722456|NCT06017882||Group C : Deprivation; Usual sleep ; Deprivation ; Usual sleep|V1-\>V3 id. V4 : Sleep deprivation and test series (easy; easy; difficult) V5 : Usual sleep and test series (difficult; difficult; easy) V6 : Sleep deprivation and test series (easy; difficult; difficult) V7 : Usual and test series (difficult; easy; easy)
62722457|NCT06017882||Group D : Deprivation ; Deprivation ; Usual sleep ; Usual sleep|V1-\>V3 id. V4 : Sleep deprivation and test series (difficult; easy; easy) V5 : Sleep deprivation and test series (easy; difficult; easy) V6 : Usual sleep and test series ( difficult; easy ; easy) V7 : Usual sleep and test series (easy ; difficult; difficult)
62722458|NCT01247064|EXPERIMENTAL|Nebulized 3% Saline|
62722459|NCT01247064|PLACEBO_COMPARATOR|Nebulized 0.9% Normal Saline|
62722460|NCT03323853|EXPERIMENTAL|CARS-SA Report|Emergency care providers for subjects in this group will receive a copy of the subject's CARS-SA summary results.
62722461|NCT03323853|OTHER|No CARS-SA Report|Emergency care providers for subjects in this group will not receive a copy of the subject's CARS-SA summary results.
62722462|NCT01937520|EXPERIMENTAL|acupuncture|acupuncture will be administered after induction for a period of 30 minutes, followed by a 30 minute rest period and then resumption of acupuncture for 30 minutes.
62722463|NCT01937520|PLACEBO_COMPARATOR|device|no acupuncture will be done on this group of subjects
62722464|NCT00720577|ACTIVE_COMPARATOR|1|
62722465|NCT00720577|ACTIVE_COMPARATOR|2|
62722466|NCT00720577|ACTIVE_COMPARATOR|3|
61976693|NCT03276884|ACTIVE_COMPARATOR|Control Infant Formula|Infant formula powder to be fed ad libitum
62722467|NCT01355614|EXPERIMENTAL|QAX576|
62722468|NCT01355614|OTHER|Infliximab|
62722469|NCT03924544|EXPERIMENTAL|Decorin Group|26 patients will receive subconjunctival injection of 100 µg decorin 15 minutes before surgery, 1, 3, and 7postoperatively. A30-gauge needle was used to inject 100 µL of decorin. The needle was placed at the nasal margin of the superior rectus muscle
62722470|NCT03924544|ACTIVE_COMPARATOR|Mitomycin Group|MMC will then be applied in 26 patients to the sclera at a concentration of 0.3 mg/ml using cellulose sponges, which will be removed after 3 minutes followed by copious irrigation with balanced saline solution (BSS).
62722471|NCT02809885|EXPERIMENTAL|Transplanted patients|All patients included are in the same arm.
62722472|NCT04500457|EXPERIMENTAL|Intervention|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 3 days at home (5 treatment sessions total).
62722473|NCT04500457|NO_INTERVENTION|Wait-List Control|Participants in this condition will not receive treatment.
62722474|NCT03661840|EXPERIMENTAL|Acceptance and Commitment Therapy|Participants will receive both the ACT intervention and medication management that is given as usual treatment.
62722475|NCT03661840|ACTIVE_COMPARATOR|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management.
62722476|NCT03982277|EXPERIMENTAL|High dose Rifampin + DTG|High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
62722477|NCT03982277|NO_INTERVENTION|Standard dose Rifampin + DTG|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
62722478|NCT03982277|EXPERIMENTAL|High dose Rifampin + EFV|High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
62722479|NCT03982277|NO_INTERVENTION|Standard dose Rifampin + EFV|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
62722480|NCT06287255|EXPERIMENTAL|Exercise is Medicine Plus|Participants receiving the Exercise is Medicine program along with a smartwatch.
62722481|NCT04819113|EXPERIMENTAL|Nimenrix|Nimenrix
62722482|NCT04130412|ACTIVE_COMPARATOR|Open release of lateral retinaculae|This group was treated by open release of lateral retinaculae after diagnosis of lateral compression syndrome by arthroscopy
62722483|NCT04130412|ACTIVE_COMPARATOR|Arthroscopic release of lateral retinaculae|This group was treated by arthroscopic release
62722484|NCT04256473|EXPERIMENTAL|Intervention|"Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.~Depending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes)."
62722485|NCT04256473|ACTIVE_COMPARATOR|Control|Usual care with alteplase 0.9 mg/kg in 60 minutes
62722486|NCT05480176||Non-COPD high-risk population|The local residents gain a COPD-SQ score \< 16.
62722487|NCT05480176||COPD high-risk population|The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 either with or without bronchodilator administration.
62722488|NCT05480176||Confirmed COPD patients|The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 after administration of bronchodilators.
62722489|NCT01186250|ACTIVE_COMPARATOR|Pioglitazone|Pioglitazone
62722490|NCT01186250|PLACEBO_COMPARATOR|Placebo|Placebo
62722491|NCT05704153|SHAM_COMPARATOR|Sham|Control group to be subjected to sham stimulation.
62722492|NCT05704153|EXPERIMENTAL|30 hertz (Hz) Stimulation|Group of patients treated via 30Hz transcutaneous electrical nerve stimulation
62722493|NCT05704153|EXPERIMENTAL|1Hz Stimulation|Group of patients treated via 1Hz transcutaneous electrical nerve stimulation
62722494|NCT05087498|EXPERIMENTAL|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after process. Cell dose for all patients was 2-10×107 cells per kilogram.
62722495|NCT05087498|PLACEBO_COMPARATOR|control group|Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume per kg.
62722496|NCT03938831|EXPERIMENTAL|dexmedetomidine group|dexmedetomidine mixture with fentanyl-based PCA infusion for 2 days
62722497|NCT03938831|PLACEBO_COMPARATOR|control group|Fentanyl-based PCA infusion for 2 days
62722498|NCT04044014|ACTIVE_COMPARATOR|Arm A|Left arm: Gellan sheet; Right arm: Mepitel One.
62722499|NCT04044014|ACTIVE_COMPARATOR|Arm B|Left arm: Mepitel One; Right arm: Gellan sheet.
62722500|NCT04044014|ACTIVE_COMPARATOR|Arm C|Left arm: Gellan fluid gel; Right arm: Mepitel One.
62722501|NCT04044014|ACTIVE_COMPARATOR|Arm D|Left arm: Mepitel One; Right arm: Gellan fluid gel.
62722502|NCT05078905||Individuals Receiving Vaccine|Individuals receiving a vaccination for an emerging infection, like SARS-CoV-2
62722503|NCT04815200|OTHER|Nickel titanium NiTi arch wire (Gold Standard, control group)|Patient will receive 0.014 round Nickel titanium NiTi archwire and will be ligated using a ligature wire with Follow up for 2 months.
62722504|NCT01135225|ACTIVE_COMPARATOR|PROMUS(TM) Element(TM) Coronary Stent|PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent System
62722505|NCT01135225|EXPERIMENTAL|Evolution Coronary Stent A|Evolution Everolimus-Eluting Monorail Coronary Stent System
62722506|NCT01135225|EXPERIMENTAL|Evolution Coronary Stent B|Evolution Everolimus-Eluting Monorail Coronary Stent System
62722507|NCT03919565|ACTIVE_COMPARATOR|TDF group|80 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 144 weeks.
62722508|NCT03919565|EXPERIMENTAL|Peginterferon alfa group|40 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
62722509|NCT01769976|EXPERIMENTAL|Daily energy restriction|25% reduction in daily energy intake
62722510|NCT01769976|ACTIVE_COMPARATOR|Energy balance diet|Diet provides 100% of energy requirements and is designed to achieve weight stability
62722511|NCT01769976|EXPERIMENTAL|Periodic fasting with weight loss|Fast 3 days per week, and consume 1.5 times usual amount of food on other days
62722512|NCT01769976|EXPERIMENTAL|Periodic fasting without weight loss|Fast 3 days per week, and consume double usual amount of food on other days
62722513|NCT03567603||opioid exposed neonates|prenatal opioid exposure
62722514|NCT03567603||non-opioid exposed neonates|no prenatal opioid exposure
62722515|NCT01052883|EXPERIMENTAL|1|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\] then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
62737914|NCT01903772|EXPERIMENTAL|Inspiratory Muscle Training|Procedure: Inspiratory Muscle Training Three times daily inspiratory muscle training (2x30 breaths) at an intensity of \>50% Pi,max
62722516|NCT01052883|EXPERIMENTAL|2|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
62722517|NCT01052883|EXPERIMENTAL|3|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\] then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
62722518|NCT01052883|EXPERIMENTAL|4|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
62722519|NCT01296503|ACTIVE_COMPARATOR|Dexamethasone (Arm A)|Sixty days (D+60) after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days)
62722520|NCT01296503|EXPERIMENTAL|Thalidomide and Dexamethasone (Arm B)|"D+60 after ASCT: dexamethasone plus thalidomide 200 mg by mouth daily for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
62722521|NCT02340884|EXPERIMENTAL|PRISM|Promoting Resilience In Stress Management Intervention (skills-based intervention designed to teach stress-management, goal-setting, cognitive reframing, and meaning-making skills)
62722522|NCT02340884|NO_INTERVENTION|Control|Standard psychosocial supportive care
62722523|NCT03765047|EXPERIMENTAL|Intervention Arm|"This study arm includes the schools where the School Team (school teachers, coordinator) receives the physical activity intervention. The intervention consists of four parts:~1. School Engagement and Assessment~2. Training~3. Physical Activity Equipment and Resources~4. Ongoing Assessment and Technical Assistance"
62722524|NCT03765047|NO_INTERVENTION|Control Arm|The control arm includes the schools where the School Team does not receive any intervention but all the necessary data will be collected.
62722525|NCT01202240|EXPERIMENTAL|Tasocitinib (CP-690,550) plus Ketoconazole|
62722526|NCT03734822|OTHER|CF|Cystic fibrosis patients undergoing general anesthesia.
62722527|NCT06322667||All Participants|Participants prescribed lecanemab by a physician in routine clinical practice (post-marketing surveillance) will be observed prospectively for up to a maximum of 156 weeks or to the time of discontinuation, whichever occurs first.
62722528|NCT05734664|EXPERIMENTAL|Scan with Pulsify sensor|A trained operator will perform on each volunteer two scans with the Pulsify sensor. Both scans will have a different orientation of the sensor.
62722529|NCT05734664|EXPERIMENTAL|Scan with state-of-the-art ultrasound equipment|Immediately after acquisition with the Pulsify sensor, an echocardiographist will record a complete 2D and 3D ultrasound data set using a state-of-the-art equipment.
62722530|NCT00003873|EXPERIMENTAL|Arm I|Patients receive fluorouracil IV as a continuous infusion for 28 days.
62722531|NCT00003873|EXPERIMENTAL|Arm II|Patients receive eniluracil/fluorouracil orally twice a day for 28 days.
62722532|NCT06332976||Before chemotherapy start|Women candidate to adjuvant or neoadjuvant chemotherapy for breast cancer at the time of informed consent (interview before the start of CT)
62722533|NCT06332976||During chemotherapy|Women who are receiving chemotherapy at the time of informed consent (interview within 1 year from beginning of CT)
62722534|NCT06332976||After chemotherapy end|Women who already received chemotherapy at the time of informed consent (interview after more than 4 years of CT end)
62722535|NCT04357561|EXPERIMENTAL|Exercise group (Schroth best practice)|Exercise program will consists of scoliosis-specific exercises (schroth best practice), which is a pattern specific scoliosis rehabilitation concept and provide three dimensional improvements and include patient education for maintaining corrected posture in daily life. In addition, these exercises provide improvements in neuromuscular control and the endurance of the postural muscles.
62722536|NCT04357561|NO_INTERVENTION|Control group|Due to there is not a standard preoperative exercise protocol, additional exercise program will not be applied in control group. The patients will wait for the surgery in their routine daily life. Measurements will be performed at the same time frame in experimental group.
62722537|NCT04122846|EXPERIMENTAL|Treatment (Emotional Awareness and Expression Therapy)|Internet-based Emotional Awareness and Expression Therapy
62722538|NCT04412681|EXPERIMENTAL|PE Enhanced Screening|"The PE screening program entails the following for all participants:~* provision of additional demographic and risk factors~* provision of mean arterial pressure~* standard nuchal translucency scan as part of their first trimester screening (FTS) with the addition of the measurement of the uterine artery Doppler by a certified sonographer~* standard blood sample (as part of the FTS)~* results of the PE screening (in the format of a screening report) will be provided to the study team and participant's healthcare provider"
62722539|NCT01123226|EXPERIMENTAL|Diversified HVLA spinal manipulation|
62722540|NCT01123226|ACTIVE_COMPARATOR|Trigger point pressure release|
62722541|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation~sputum collection"
62722542|NCT04494685|EXPERIMENTAL|Robotic rehabilitation|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland).
62722543|NCT04494685|ACTIVE_COMPARATOR|Conventional physiotherapy|The protocol will be based on lower limb exercises, aiming at maintaining and gaining muscle strength through passive, assisted or active mobilization, when possible, on the affected side.
62722544|NCT01337778|ACTIVE_COMPARATOR|Primary Care for DILs|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced gender-based violence. A comprehensive health examination for mothers-in-law will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
62737915|NCT01903772|SHAM_COMPARATOR|Sham Inspiratory Muscle Training|Twice daily inspiratory muscle training (3x30 breaths) at an intensity of 5 centimeters of water (H2O)
62722545|NCT01337778|EXPERIMENTAL|Standard Care plus Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the daughter-in-law's (DILs) pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with mothers-in-law (MILs), and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce gender-based violence (GBV) and protect and promote their family's health.
62722546|NCT01212029|EXPERIMENTAL|1/All Subjects|Imaging studies related to functional brain activation
62722547|NCT01335126|EXPERIMENTAL|Test|
62722548|NCT01336348|EXPERIMENTAL|prasugrel|Prasugrel 60 mg loading dose
62722549|NCT01336348|ACTIVE_COMPARATOR|Tirofiban|Tirofiban will be at a bolus only of 25uM or followed by 2 hour infusion
62722550|NCT00561522|EXPERIMENTAL|Intervention treatment|Capecitabine
62722551|NCT00561522|NO_INTERVENTION|No intervention treatment|No other preventive treatment
62722552|NCT02477917|EXPERIMENTAL|Allergovac depot|Allergovac depot with Parietaria judaica pollen extract
62722553|NCT00066053|EXPERIMENTAL|Periodontal Treatment: SRP|Comprehensive scaling \& root planing and subgingival tissue removal; fluorides applied as appropriate; oral hygiene instructions.
62722554|NCT00066053|ACTIVE_COMPARATOR|Community Comparator|Referral to community dentist with copy of x-rays and letter with diagnosis and recomendations for treatment.
62722555|NCT02808429|EXPERIMENTAL|Placebo|
62722556|NCT02808429|EXPERIMENTAL|Atacicept 25 mg|
62722557|NCT02808429|EXPERIMENTAL|Atacicept 75 mg|
62722558|NCT03074188||pre-dialysis patients|
62722559|NCT03074188||end stage renal disease|
62722560|NCT06257225|ACTIVE_COMPARATOR|Patient showing horizontal defect and treated with GBR stabilized with Tacs|Fixation
62722561|NCT06257225|EXPERIMENTAL|Patient showing horizontal defect and treated with GBR stabilized with no Tacs|No Fixation
62722562|NCT04382027|EXPERIMENTAL|Monoacylglycerol|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in monoacylglycerol form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
62722563|NCT04382027|ACTIVE_COMPARATOR|Ethyl ester|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in ethyl ester form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
62722564|NCT05985837||Adolescents and adults|Adolescents from 12 years old and adults with sore throat and/or pharyngitis, who have bought the product.
62722565|NCT05985837||Children 1-6 years|Children from 1 to 6 years old with sore throat and/or pharyngitis, whose parents/caregivers have bought the product.
62722566|NCT05985837||Children 6-12 years|Children from 6 to 12 years old with sore throat and/or pharyngitis, whose parents/caregivers have bought the product.
62722567|NCT03620994||Irritable Bowel Syndrome|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University, Xijing Hospital ,Tangdu Hospital or affiliated hospital of Northwest University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
62722568|NCT04369456|OTHER|Covid-19 kidney transplant patients with moderate symptoms|
62722569|NCT05091411|EXPERIMENTAL|Population Ⅰ|3 doses of experimental vaccine (pilot scale batch) were given at day 0, 30 and 60.
62722570|NCT05091411|EXPERIMENTAL|Population Ⅱ|3 doses of experimental vaccine (process validation lot 1) at day 0, 30 and 60;
62722571|NCT05091411|EXPERIMENTAL|Population Ⅲ|3 doses of experimental vaccine (process validation lot 2) at day 0, 30 and 60;
62722572|NCT05091411|EXPERIMENTAL|Population Ⅳ|3 doses of experimental vaccine (process validation lot 3) were given at day 0, 30 and 60.
62722573|NCT05576324||longitudinal|Inclusion of patients with diagnosed CF prior ETI therapy, follow-up visit after 6 months
62722574|NCT05576324||under ETI|Patients with diagnosed CF already receiving ETI therapy for 6 months
62722575|NCT05576324||no ETI|Patients with diagnosed CF that have refused an ETI treatment or are not eligible for ETI therapy
62722576|NCT05576324||Healthy Individuals|Healthy, age- and gender-matched probands
62722577|NCT01493492||SIRS|"1. temperature \>38 ℃ or \<36℃;~2. pulse rate\>90 beats/min;~3. ventilatory rate\>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)\<32mmHg;~4. white blood cell count\>12,000μL-1 or \<4000μL-1 or \>10% immature cells"
62722578|NCT01493492||sepsis|"Sepsis~1. sepsis: SIRS plus infection;~2. severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~3. septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
62722579|NCT01493492||non-survivors with sepsis|sepsis patients who died within 28 days
62722580|NCT02336061||male|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
62722581|NCT02336061||female|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
62722582|NCT06183489|EXPERIMENTAL|Elranatamab|Participant will receive elranatamab subcutaneously (SC) for 24 cycles (28-day cycle)
62722583|NCT05262413|EXPERIMENTAL|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
62737916|NCT04078958|EXPERIMENTAL|Salmon fishmeal|5 g fishmeal in capsules, single oral dose
62737917|NCT04078958|ACTIVE_COMPARATOR|Whey|5 g whey in capsules, single oral dose
62722584|NCT06131905|ACTIVE_COMPARATOR|Group M (Magnesium sulfate+Propofol)|Includes thirdy patients receive 40mg /kg magnesium sulfate diluted with normal saline to a total volume of 100 ml plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
62722585|NCT06131905|ACTIVE_COMPARATOR|Group N (Propofol)|Includes thirdy patients receive an equal volume of normal saline as a placebo.plus An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
62722586|NCT04610983|EXPERIMENTAL|Control|Control 2 \* Gel Encapsulated Algal Oil Capsules (each containing 200mg DHA) Total dose of 400mg DHA.
62722587|NCT04610983|EXPERIMENTAL|Treatment 1 - Semi-Solid food matrix|Vegetable encapsulated algal oil integrated with a semi-solid food product (soup) to deliver 400 mg DHA.
62722588|NCT04610983|EXPERIMENTAL|Treatment 2 - Solid food matrix|Vegetable encapsulated algal oil integrated with a solid food product (extruded snack) to deliver 400 mg DHA.
62722589|NCT04660175|EXPERIMENTAL|Non-resistance therapy|From the 2nd to 5th day of hospitalization, once a day, 4 times of non-resistance therapy is administered. And non-resistance therapy group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
62722590|NCT04660175|ACTIVE_COMPARATOR|Oriental medicine integrated treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
62722591|NCT01979718|EXPERIMENTAL|Full term intervention|"* random selection~* composed of the daily standard physical treatment and 1 session per one day over two weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality simulating the surgeried knee."
62722592|NCT01979718|ACTIVE_COMPARATOR|Half term intervention|"* random selection~* composed of the daily standard physical treatment over two weeks and 1 session per one day over one weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality stimmulating the surgeried knee )"
62722593|NCT01769053|ACTIVE_COMPARATOR|Variable Ventilation|Patients are ventilated with variable pressure support mode.
62722594|NCT01769053|NO_INTERVENTION|Conventional (non-variable) Ventilation|Patients are ventilated with non-variable(conventional) pressure support ventilation mode.
62722595|NCT04995484|EXPERIMENTAL|Belzutifan in participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single oral 80 mg dose of belzutifan.
62722596|NCT04995484|EXPERIMENTAL|Belzutifan in participants with normal hepatic function|Participants with normal hepatic function will receive a single oral 80 mg dose of belzutifan.
62722597|NCT01458678|ACTIVE_COMPARATOR|Oesophageal Doppler (OD)|Goal directed volume therapy is most often guided by stroke volume measurements by OD.
62722598|NCT01458678|ACTIVE_COMPARATOR|Pleth Variability Index (PVI)|The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.
62722599|NCT05613907||Pre-intervention|This group comprises patients who have been referred into the CLTI clinic service prior to their first assessment. These patients will be given a structured outcome questionnaire like the EuroQoL 5D questionnaire that asks them to describe their symptoms
62722600|NCT05613907||Post-intervention|"This group comprises patients from the pre-intervention group who have undergone a revascularisation procedure. These patients will be given the same structured questionnaire to complete post procedurally.~They will also be invited to complete the same questionnaire at 12 months post revascularisation"
62722601|NCT04624308|EXPERIMENTAL|TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab|TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or \>75%PR. If not, operation is suggested.
62722602|NCT03110484|EXPERIMENTAL|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
62722603|NCT03187509|EXPERIMENTAL|Weight-Based Torsemide Group|Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
62722604|NCT03187509|ACTIVE_COMPARATOR|Standard Outpatient Management Group|Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
62722605|NCT02838043|EXPERIMENTAL|Participant|All participants will be experimental and receive Probio'Stick.
61976694|NCT06332651|EXPERIMENTAL|Methionine in black beans in older men|This group of 7 participants will have 3 test days where they consume black beans with 3 different levels of methionine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of methionine.
62722606|NCT00672230|EXPERIMENTAL|Lut Supp|
62722607|NCT05302310||Older adults (1A)|All older adults visiting/contacting the Information and Advice Center
62722608|NCT05302310||Older adults (1B)|These older adults will receive the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center
62722609|NCT05302310||Older adults (1C)|This group corresponds to a nested sample of older adults who will receive the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center and will participate in interviews with the research team.
62737918|NCT00193791|NO_INTERVENTION|Radiation (RT) Alone|Standard radical radiation therapy alone
61976695|NCT06332651|EXPERIMENTAL|Methionine in black beans in younger men|This group of 7 participants will have 3 test days where they consume black beans with 3 different levels of methionine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of methionine.
62549557|NCT05679271|EXPERIMENTAL|venous stenting|"Venous stenting associated to antiaggregation protocol:~Venous stenting: venous approach can be performed via femoral, brachial or jugular puncture. Autoexpansible stent should delivered at the level of the fistulous sinus. If distal access catheter is wide enough, stent can be delivered directly through it. After partial deployment of the stent, Labbe vein's flow may be restricted. If necessary, several stents can be used in the same procedure to cover the whole length of fistulous sinus area. After stent deployment, ballon angioplasty is compulsory and must be performed using a ballon of equivalent size to the stent. The procedure ends after stent deployment and angiographic arterial post-op controls.~Antiaggregation protocol: aspirin (160mg for 3 months) + clopidogrel (75mg/d 5 days before stenting and 75mg/d for 1 month after stenting) OR ticagrelor (180mg 2h before stenting and 90mg twice a day for 1 month) in case of clopidogrel platelet resistance."
62549558|NCT05679271|ACTIVE_COMPARATOR|no treatment|standard care (no treatment)
62549559|NCT03437473|ACTIVE_COMPARATOR|Active stimulation QD|
62549560|NCT03437473|ACTIVE_COMPARATOR|Active stimulation QID|
62549561|NCT03437473|SHAM_COMPARATOR|No stimulation|
62549562|NCT06579235||Children with neuroborreliosis|
62549563|NCT06579235||Children without neuroborreliosis|
62549564|NCT05709210|OTHER|Memory complaint|
62549565|NCT05709210|OTHER|Mild cognitive decline|
62549566|NCT05709210|OTHER|Alzheimer's Disease|
62549567|NCT05176873|EXPERIMENTAL|Single dose of DZD8586|Single dose of DZD8586
62549568|NCT05176873|PLACEBO_COMPARATOR|Single dose of Placebo|Single dose of Placebo
62549569|NCT02272257|EXPERIMENTAL|Early Direct Access Physical Therapy|All care will be administered by one or more physical therapists employed by Temple University. This arm will be early, direct access, physical therapy (immediately evaluation following contacting the front desk administrator or reporting a work injury). Intervention will include interventions matched to their stratified risk category incorporating biopsychosocially oriented education, therapeutic exercise, and manual therapy tailored to the patient's needs.
62549570|NCT02272257|ACTIVE_COMPARATOR|Physician management|All usual care by physician will be administered by one or more employee health physicians employed by Temple University. Recommendations may or may not include referral to physical therapy.
62549571|NCT03334461|EXPERIMENTAL|high concentration enamel remineralisation agent|first month brushing teeth three times per day: twice per day with high-fluorides gel (Mirafluor K gel cola 6150 ppm F pH 5.1) and once per day without toothpaste and fluoride gel next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
62549572|NCT03334461|EXPERIMENTAL|oral antiseptic|first month brushing teeth without toothpaste three times per day and using oral antiseptic chlorhexidine mouthwash (Curasept ADS 212 a 200ml 0,12%) twice per day next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
62549573|NCT03334461|NO_INTERVENTION|Control|regular oral hygiene without exposure to oral antiseptic or high concentration enamel remineralisation agent three months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
62549574|NCT00704132|EXPERIMENTAL|sitagliptin|Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
62549575|NCT00704132|PLACEBO_COMPARATOR|Placebo|Participants randomized to this arm will be administered matching placebo, daily for six weeks.
62549576|NCT04993066|EXPERIMENTAL|Treatment Arm|All study subjects are to receive treatment with GentleMax Pro Plus device. Subjects will be scheduled to receive as little as one (1) and up to eight (8) treatments with the GentleMax Pro Plus™ Laser System. Up to 2 follow-ups will occur.
62549577|NCT06259097|ACTIVE_COMPARATOR|Misoprostol and Pitocin|Patient receives misoprostol and foley catheter for initial induction of labor, followed by pitocin later on.
62549578|NCT06259097|ACTIVE_COMPARATOR|Pitocin only|Patient receives pitocin and foley catheter for initial induction of labor, followed by more pitocin later on.
62549579|NCT00847964|EXPERIMENTAL|Algisyl-LVR implants|Algisyl-LVR implants to the left ventricular wall
62549580|NCT03003650|EXPERIMENTAL|Symetis ACURATE TF™|Patient implanted with ACURATE TF™Bioprosthesis.
62549581|NCT04698226|ACTIVE_COMPARATOR|ILM peel|Patients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade.
62549582|NCT04698226|EXPERIMENTAL|Inverted flap|Patients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.
62549583|NCT01587157|EXPERIMENTAL|capnography|
62549584|NCT00551512|EXPERIMENTAL|CBP501 and Cisplatin|Dose escalation study
62549585|NCT05054504|OTHER|Intervention|The primary intervention is a multi-phase, mixed methods, implementation research study that will investigate the feasibility and acceptability of the limited introduction of ultrasound via the Butterfly iQ device into routine ANC service delivery at health center level in Blantyre, Malawi. The study will occur in three phases: 1) Training, 2) Iterative Service Delivery, and 3) Final Evaluation.
62549586|NCT05761665||Alzheimer|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
62549587|NCT05761665||Physically Fragile|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
62549588|NCT05761665||Healthy|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
62549589|NCT06228586|EXPERIMENTAL|MenACYW conjugate vaccine|MenACYW conjugate vaccine single injection on Day 01
62549590|NCT05383755|EXPERIMENTAL|Digital intervention|Digital intervention for pregnant adolescents living with HIV.
62549591|NCT02523261|EXPERIMENTAL|ADAPT|
62549592|NCT02523261|ACTIVE_COMPARATOR|Stent Retriever|
62549593|NCT02370524|EXPERIMENTAL|[18F]T807|At the \[18F\]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of \[18F\]T807
62549594|NCT05635487|EXPERIMENTAL|SHR-A1811+Pyrotinib|
62549595|NCT05635487|EXPERIMENTAL|SHR-A1811|
62722610|NCT05302310||Informal caregivers (2)|The informal caregivers of older adults receiving the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center will participate in interviews with the research team.
62722611|NCT05302310||IAC nurse and social worker (3)|The nurse and the social worker who provide the integrated care (intervention) in the Information and Advice Center will participate in bi-weekly meetings with the research team
62722612|NCT05302310||External collaborators (4)|The external collaborators who are involved in the care of the participating older adults and have collaborated with the nurse and the social worker of the Information and Advice Center will complete a survey sent by mail or e-mail.
62722613|NCT01035502|EXPERIMENTAL|Elacytarabine plus idarubicin|
62722614|NCT04301661||ABC/3TC Cohort|"Persons on abacavir/lamivudine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
62722615|NCT04301661||TAF/FTC Cohort|"Persons on tenofovir alafenamide/emtricitabine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
62722616|NCT04301661||Switch Cohort|"Persons switching from abacavir/lamivudine-containing therapy as part of their standard HIV care will change to their newly prescribed regimen.~Participants will be on study for 3 weeks, and will have blood drawn at Days 0, 1, 3, 7, 10, 14, 18, and 21 following their switch."
62722617|NCT03464526|ACTIVE_COMPARATOR|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
62722618|NCT03464526|ACTIVE_COMPARATOR|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
62722619|NCT03464526|ACTIVE_COMPARATOR|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
62722620|NCT03464526|PLACEBO_COMPARATOR|Placebo|Placebo tablet, once daily for 12 weeks
62722621|NCT01129492|PLACEBO_COMPARATOR|Sham Laser|Ten applications of placebo were performed (twice a week) with the same method and Laser equipment, which has a placebo function available with a red ordinary light indistinguishable of the Laser light.
62722622|NCT01129492|ACTIVE_COMPARATOR|Active Laser|Ten applications of low-level Laser therapy (twice a week) were performed with a continuous wave diode laser device (830nm, beam area of 0.2827cm2), using the punctual method, continuous emission mode, output power of de 50 mW and fluence of 70J/cm2.
62722623|NCT02043145||Axillary Hyperhidrosis|Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
62722624|NCT02043145||Focal Spasticity|Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
62722625|NCT02043145||Glabellar Lines|Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
62722626|NCT01074073|OTHER|Lithium/Lurasidone|Schizophrenia Patients
62722627|NCT02101398|EXPERIMENTAL|F7A|Anodal electrode set on the left Broca's area and cathodal electrode set on its right homologue. Active stimulation.
62722628|NCT02101398|EXPERIMENTAL|F7C|Cathodal electrode set on the left Broca's area and anodal electrode set on its right homologue. Active stimulation.
62722629|NCT02101398|EXPERIMENTAL|T5A|Anodal electrode set on the left Wernicke's area and cathodal electrode set on its right homologue. Active stimulation.
62722630|NCT02101398|EXPERIMENTAL|T5C|Cathodal electrode set on the left Wernicke's area and anodal electrode set on its right homologue. Active stimulation.
62722631|NCT02101398|SHAM_COMPARATOR|Sham|Electrodes set on the left Broca's area and its right homologue or electrodes set on the left Wernicke's area and its right homologue, but no stimulation will be delivered.
62722632|NCT02869165|EXPERIMENTAL|Conjugated equine estrogen topical cream|The conjugated equine estrogen topical vaginal cream 0.5 grams per vagina two times per week at nights for 3 months.
62722633|NCT02869165|EXPERIMENTAL|Apricot kernel oil|One teaspoonful per vagina every night for 3 months.
62722634|NCT04319250|ACTIVE_COMPARATOR|Group 1|Ischemic compression and rehabilitation program applied to the group 1
62722635|NCT04319250|ACTIVE_COMPARATOR|Group 2|IASTM and rehabilitation program applied to the group 2
62722636|NCT02257749|EXPERIMENTAL|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
62722637|NCT02257749|ACTIVE_COMPARATOR|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
62722638|NCT01402960|EXPERIMENTAL|Active Anodal HD-tDCS|Subject will receive one 20-minute session of active anodal HD-tDCS.
62722639|NCT01402960|EXPERIMENTAL|Active Cathodal HD-tDCS|Subject will receive one 20-minute session of active cathodal HD-tDCS.
62722640|NCT01402960|SHAM_COMPARATOR|Sham HD-tDCS|Subject will receive one sham session of HD-tDCS
62722641|NCT02797756||Case|CC/GER+ presence of chronic cough and presence of GER evidenced by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
62722642|NCT02797756||Control|CC/GER- presence of chronic cough and absence of GER by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
62722643|NCT04074083|EXPERIMENTAL|Intervention electronic IMCI group|15 primary health care clinics will be randomly allocated to intervention group. One IMCI trained HW will be selected in each intervention facility to be trained in electronic IMCI.
62722644|NCT04074083|ACTIVE_COMPARATOR|Control paper IMCI group|15 primary health care clinics will be randomly allocated to the control group. One IMCI trained HW will be selected in each control facility to receive an IMCI update (designed to mirror eIMCI training).
62722645|NCT01508910|EXPERIMENTAL|Treatment Arm|Targeted intramyocardial delivery of 1 x 10\^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis
62722646|NCT01508910|PLACEBO_COMPARATOR|Active Control Arm|Targeted intramyocardial delivery of placebo after G-CSF mobilization and apheresis
62722647|NCT01508910|OTHER|Unblinded Standard of Care (SOC) Arm|No study-related procedures will be performed.
62722648|NCT05671770||Cohort 1|Patients with chronic kidney disease
62722649|NCT05671770||Cohort 2|Patients with hypertrophic cardiomyopathy
62722650|NCT03484429|EXPERIMENTAL|Group 1|Standard medical therapy and 30 to 60 days of peripheral nerve stimulation starting within 7 days after surgery
62722651|NCT03484429|ACTIVE_COMPARATOR|Group 2|Standard medical therapy only
62722652|NCT03776084||Patients SAHS with CPAP|Continuous Positive Airway Pressure treatment
62722653|NCT02907658|EXPERIMENTAL|PROTECT intervention group|The PROTECT intervention group receives the preventive intervention PROTECT (4 modules in 4 subsequent weeks à 90 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
62722654|NCT02907658|NO_INTERVENTION|Assessment-only control group|The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
62722655|NCT00600067|EXPERIMENTAL|1|
62722656|NCT00600067|PLACEBO_COMPARATOR|2|
62722657|NCT00806260|EXPERIMENTAL|Treatment 1|Dosed first with alcohol, then active VI-0521, and last, VI-0521 placebo
62722658|NCT00806260|EXPERIMENTAL|Treatment 2|First dosed with alcohol placebo (fruit juice), then active VI-0521, and last, placebo VI-0521
62722659|NCT00806260|EXPERIMENTAL|Treatment 3|First dosed with alcohol, then VI-0521 placebo, and last, active VI-0521
62722660|NCT00806260|EXPERIMENTAL|Treatment 4|First dosed with alcohol placebo, then VI-0521 placebo, and last, active VI-0521
62722661|NCT03071861|EXPERIMENTAL|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at \<24 hours of age
62722662|NCT03071861|PLACEBO_COMPARATOR|Placebo|IV, Normal saline (placebo dose), one dose at \<24 hours of age
62722663|NCT03243227|EXPERIMENTAL|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
62722664|NCT03243227|ACTIVE_COMPARATOR|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
62722665|NCT04895371|EXPERIMENTAL|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
62722666|NCT04895371|ACTIVE_COMPARATOR|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
62722667|NCT05554302|EXPERIMENTAL|PET/CT, MRI|All patients will obtain an 18F-Fluciclovine PET/CT scan in addition to the planning MRI at the time of SRS treatment (approximately 2-4 weeks after resection). The value of 18F-Fluciclovine in addition to structural information from the MRI will be analyzed. Patients will continue to undergo 18F-Fluciclovine in addition to MRI during routine follow-up to determine the ability of 18F-Fluciclovine PET/CT to identify areas at risk for marginal failure, monitor resection beds for tumor control, identify patients at risk for disease recurrence, and detect patterns of failure.
62722668|NCT03320187|EXPERIMENTAL|Group A|Nitroglycerin as Nitroderm TTSⓇ skin patch is applied on the upper chest alongside with regular induction of labor protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
62722669|NCT03320187|PLACEBO_COMPARATOR|Group B|Placebo patch is applied on the upper chest alongside with regular induction of labour protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
62722670|NCT04677491|ACTIVE_COMPARATOR|VVA-FSIAD ospemifene group|Women treated with ospemifene 60 mg/day
62722671|NCT04677491|PLACEBO_COMPARATOR|VVA-FSIAD placebo group|Women treated with placebo
62722672|NCT01184976|EXPERIMENTAL|0.6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
62722673|NCT01184976|EXPERIMENTAL|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
62722674|NCT01184976|EXPERIMENTAL|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
62722675|NCT01616277|PLACEBO_COMPARATOR|1|
62722676|NCT01616277|PLACEBO_COMPARATOR|2|
62722677|NCT01616277|PLACEBO_COMPARATOR|3|
62722678|NCT01616277|PLACEBO_COMPARATOR|4|
62722679|NCT01616277|PLACEBO_COMPARATOR|5|Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
62722680|NCT01616277|PLACEBO_COMPARATOR|6|
62722681|NCT01616277|PLACEBO_COMPARATOR|7|
62722682|NCT04469205|EXPERIMENTAL|Intervention Group|intervention group that will receive return-to-work coaching sessions. The intervention consists of 3 individual coaching sessions with a certified professional coach. This personalized accompaniment will complete the standard accompaniment offered to all patients.
62722683|NCT04469205|NO_INTERVENTION|Control Group|"control group who will receive the current care which consists of a psychosocial care.~This care consists in offering the patient regular information meetings organized with social workers of the Health Insurance, to consult a psychologist and to access patients' homes at the frequency of their choice and according to their need."
62722684|NCT05120700|EXPERIMENTAL|Stromal vascular fraction|Treatment of cartilage injury with a tissue engineering construct.The patients will be adults diagnosed with a single, 3 to 6 cm2 full-thickness cartilage lesion, symptomatic and with no improvement with non-operative treatment.
62722685|NCT01899430|ACTIVE_COMPARATOR|metformin|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
62722686|NCT01899430|EXPERIMENTAL|liraglutide|In the LIRA group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
62722687|NCT03444324|EXPERIMENTAL|BT524|Investigational Human Fibrinogen Concentrate
62722688|NCT03444324|ACTIVE_COMPARATOR|Fresh Frozen Plasma (FFP)/Cryoprecipitate (Cryo)|Standard of Care
62722689|NCT04702386||Focus groups|Children aged 8 years or more participating in a focus group with the study psychologist
62722690|NCT04702386||Individual interviews|All children who have an individual interview with the study psychologist
62722691|NCT05265546|EXPERIMENTAL|Experimental|Psilocybin 0-14 mg, before fMRI measurement
62722692|NCT05265546|OTHER|Comparator|Psilocybin 0-14 mg, before fMRI measurement
62722693|NCT05461599|OTHER|SparkRx Mobile App|The 5-week SparkRx app is divided into 5 levels intended to be completed weekly. A character called 'Limbot' is used as a guide. Limbot encourages the user in completing the behavioral activation program and provides personal examples of how they have undertaken behavioral activation therapy. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and Participant Symptom Check (PSC) questionnaire in the mobile app. Tasks in the mobile app progress in a linear fashion-- i.e., each task must be completed to progress to the next task. Certain on-demand resources can be accessed in the app at any time, including crisis resources. Text entries that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support.
62722694|NCT00107276|EXPERIMENTAL|cyclophosphamide and capecitabine|cyclophosphamide orally days 1-14 and capecitabine orally days 15-21 for 8 cycles of 21 days each
62722695|NCT00766519|EXPERIMENTAL|Optimization|volume optimization: continuous monitoring of the respiratory-induced arterial pulse pressure variation during surgery and systematic minimization to 10% or less by volume loading
62722696|NCT00766519|ACTIVE_COMPARATOR|control; standard volume administration|standard volume administration
62722697|NCT01652313|EXPERIMENTAL|Rasagiline|
62722698|NCT06370039|EXPERIMENTAL|INV-102|INV-102 0.7% ophthalmic solution administered for 4 weeks (twice daily \[BID\] for 2 weeks, then once daily \[QD\] for an additional 2 weeks)
62722699|NCT06370039|PLACEBO_COMPARATOR|Vehicle|Vehicle ophthalmic solution administered for 4 weeks (BID for 2 weeks, then QD for an additional 2 weeks)
62722700|NCT05802277|EXPERIMENTAL|Menstrual cycle group|Women who are not currently taking any form of hormonal contraception and who present a regular menstrual cycle.
62722701|NCT05802277|ACTIVE_COMPARATOR|Oral contraceptive group|Women taking a second-generation oral contraceptive estrogen-progestogen pill.
62722702|NCT01056614|EXPERIMENTAL|Treatment (chemotherapy, PBSC transplant)|Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
62722703|NCT00772278|ACTIVE_COMPARATOR|CAS|carotid artery stenting
62722704|NCT00772278|ACTIVE_COMPARATOR|CEA|carotid endarterectomy
62722705|NCT00704067|EXPERIMENTAL|1|Supported employment for 12 months plus cognitive training for the first 12 weeks
62722706|NCT00704067|ACTIVE_COMPARATOR|2|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks
62722707|NCT03593174|EXPERIMENTAL|Ossur Rigid Dressing|Use of ORD, which is a type of Removable Rigid Dressing (RRD), as a post tibial amputation dressing modality.
62722708|NCT03593174|ACTIVE_COMPARATOR|Elastic bandage|Use of the elastic bandage as a post amputation dressing modality.
62722709|NCT02471313|EXPERIMENTAL|[18F] FMISO PET scan|Patients with primary hepatic malignancy who underwent \[18F\] FMISO PET Scan following transarterial chemoembolization (TACE) procedure
62722710|NCT03288844||HOLOCORE Patients|Patients who completed the main HOLOCORE clinical trial will undergo to Ophthalmologic examinations, Digital pictures collection and QoL questionnaires (NEI VFQ 25 and EQ-5D-3L/Y) will be performed/administered at each study visit
62722711|NCT00577369|ACTIVE_COMPARATOR|1|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
62722712|NCT01273038|ACTIVE_COMPARATOR|SenSura|The reference product is the CE marked and launched SenSura product which is commercially available
62722713|NCT01273038|EXPERIMENTAL|Morfeus|The test product is the product with the proposed new Morfeus filter
62722714|NCT05230576||Deep learning training cohort|2/3 of the enrolled patients and their corresponding carotid artery dynamic scan images and expert diagnosis results were randomly selected as the training cohort for deep learning.
62722715|NCT05230576||Deep learning validation cohort|The carotid artery dynamic scan images and expert diagnosis results of the remaining 1/3 patients were used as a validation cohort to evaluate the overall diagnostic accuracy of the deep learning model.
62722716|NCT02859974|EXPERIMENTAL|Respiratory retraining for PVFMD|Single arm study
62722717|NCT02625350|EXPERIMENTAL|Instant noodle without soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes and drained
62722718|NCT02625350|EXPERIMENTAL|Instant noodle with soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes, drained, and given additional 250 ml of water as soup
62722719|NCT02625350|EXPERIMENTAL|Glucose reference|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
62722720|NCT06169163||OSCC group|Patients with histopathology confirmed, treatment naive OSCC
62722721|NCT06169163||Non-cancer controls|"Patients who are undergoing an endoscopy for non-specific upper gastrointestinal (GI) symptoms and are shown to have either:~1. A healthy upper GI tract~2. Benign upper gastrointestinal disease"
62722722|NCT04883255|EXPERIMENTAL|HIV-positive subjects|Adult human subjects seropositive for HIV-1
62722723|NCT04883255|ACTIVE_COMPARATOR|Healthy Comparison Volunteers|Adult human subjects without HIV
62722724|NCT01312519|ACTIVE_COMPARATOR|Manual bone marrow sampling device|Hollow needle with a t-shaped handle manually pushed into the bone for the purpose of bone marrow aspiration and core biopsy collection. Manual Bone Marrow Sampling Device.
62722725|NCT01312519|ACTIVE_COMPARATOR|OnControl Bone Marrow System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest. OnControl Bone Marrow Biopsy and Aspiration System.
62722726|NCT04968392|EXPERIMENTAL|L group|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
62722727|NCT04968392|EXPERIMENTAL|LD group|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
62722728|NCT02274220|EXPERIMENTAL|Rapid Advancement of Feeds|Postoperative feeds are initiated on first postoperative day and rapidly advanced over 27 hours.
62722729|NCT02274220|EXPERIMENTAL|Average feeding protocol|Postoperative feeds are initiated on first postoperative day and advanced in using a standardized protocol that best-reflects current feeding practice. Maximum feeding volume is reached at 60 hours.
62722730|NCT02274220|NO_INTERVENTION|Feeds not affected|Postoperative feeds for patients not eligible for randomization are initiated by the treating clinical team and increased as per clinical team's preference.
62722731|NCT02954458|EXPERIMENTAL|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
62722732|NCT00658489|ACTIVE_COMPARATOR|1|Residents randomized to the promotion of oral health group will receive training consisting of 7 modules (3 on the Bright Futures curriculum and 4 on oral health promotion). They will then enroll 3 patient-child dyads from their practice who present for a well child care visit. Outcomes will be obtained by completing pre- and post-study surveys. Residents will be observed by a faculty preceptor during 3 different patient encounters, and will receive feedback at the end of the 6 month study period.
62722733|NCT00658489|ACTIVE_COMPARATOR|2|Residents randomized to the prevention of iron deficiency group will complete one web-based module.
62722734|NCT01119287|EXPERIMENTAL|Maxidex|Dexamethasone 0.1% ophthalmic suspension, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days \[Visit 4 through Visit 6 morning only\]
62722735|NCT01119287|EXPERIMENTAL|Patanol|Olopatadine hydrochloride 0.1% ophthalmic solution, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days \[Visit 4 through Visit 6 morning only\]
62722736|NCT01119287|PLACEBO_COMPARATOR|Tears Naturale II|Inactive ingredients, used as placebo, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days \[Visit 4 through Visit 6 morning only\]
62722737|NCT00997984|EXPERIMENTAL|Extended-release Guanfacine Hydrochloride (SPD503) AM|
62722738|NCT00997984|EXPERIMENTAL|placebo|
62722739|NCT00997984|EXPERIMENTAL|SPD503 PM|
62722740|NCT03824392|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matched to efzofitimod via intravenous (IV) infusion every 4 weeks until Week 20.
62722741|NCT03824392|EXPERIMENTAL|Efzofitimod 1.0 mg/kg|Participants will receive efzofitimod 1.0 milligrams/kilogram (mg/kg) via IV infusion every 4 weeks until Week 20.
62722742|NCT03824392|EXPERIMENTAL|Efzofitimod 3.0 mg/kg|Participants will receive efzofitimod 3.0 mg/kg via IV infusion every 4 weeks until Week 20.
62722743|NCT03824392|EXPERIMENTAL|Efzofitimod 5.0 mg/kg|Participants will receive efzofitimod 5.0 mg/kg via IV infusion every 4 weeks until Week 20.
62722744|NCT01466465|EXPERIMENTAL|Vigantol|
62722745|NCT01466465|PLACEBO_COMPARATOR|neutral oil (vigantol carrier)|
62722746|NCT03089060|EXPERIMENTAL|Silicone Finger Cap|Patients randomized to this arm will be treated with the novel silicone finger cap for the first two weeks of treatment.
62722747|NCT03089060|ACTIVE_COMPARATOR|Film dressing|Patients randomized to this arm will be treated with conventional film dressings for the first two weeks of treatment.
62722748|NCT03210857|EXPERIMENTAL|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
62722749|NCT01379807|EXPERIMENTAL|panitumumab + docetaxel + cisplatino|
62722750|NCT03371199|ACTIVE_COMPARATOR|Sodium arm|Sodium tablets
62722751|NCT03371199|PLACEBO_COMPARATOR|Placebo arm|Placebo tablets
62722752|NCT05855018|EXPERIMENTAL|Atropine sulfate Concentration A|Subjects will be treated with atropine sulfate eye drop (at dosage Concentration A), administered once daily (QD).
62722753|NCT05855018|EXPERIMENTAL|Atropine sulfate Concentration B|Subjects will be treated with atropine sulfate eye drop (at dosage Concentration B), administered once daily (QD).
62722754|NCT05855018|EXPERIMENTAL|Atropine sulfate Concentration C|Subjects will be treated with atropine sulfate eye drop (at dosage Concentration C), administered once daily (QD).
62722755|NCT00365339|ACTIVE_COMPARATOR|A|
62722756|NCT00365339|EXPERIMENTAL|B|
62722757|NCT00365339|EXPERIMENTAL|C|
62722758|NCT00365339|EXPERIMENTAL|D|
62722759|NCT00365339|EXPERIMENTAL|E|
62722760|NCT02187835||schizophrenia|patients with a diagnosis of schizohrenia
62722761|NCT02187835||control|healthy control group
62722762|NCT03218774|OTHER|Home Group|
62722763|NCT03218774|EXPERIMENTAL|Center Group|
62722764|NCT01020461|EXPERIMENTAL|Venous blood sampling|To use Accuvein to improve the effectiveness of venous blood sampling
62722765|NCT01020461|EXPERIMENTAL|Peripheral IV catheter placement|To use Accuvein to improve the effectiveness of placing peripheral IV catheter
62722766|NCT03729843||CBCT and intraoral digital radiography|simulated bone defects will be detected and measured by 2 techniques using CBCT and using intraoral digital radiography and the all measurements will be compared with the gold standard real measurements on the dry jaws
62722767|NCT04021446|ACTIVE_COMPARATOR|Exercise|Will receive the exercise intervention
62722768|NCT04021446|NO_INTERVENTION|Attention Control|Will not receive the exercise intervention
62722769|NCT02329743|EXPERIMENTAL|RX-10045 0.05% nanomicellar solution|topical eye drops
62722770|NCT02329743|EXPERIMENTAL|RX-10045 0.1% nanomicellar solution|topical eye drops
62722771|NCT02329743|PLACEBO_COMPARATOR|Vehicle|topical eye drops
62722772|NCT04608019|EXPERIMENTAL|Immediate Antibiotics|increased airway clearance plus early initiation of oral antibiotics
62722773|NCT04608019|EXPERIMENTAL|Tailored Therapy|increased airway clearance alone, with addition of antibiotics for worsening symptoms or failure to improve
62722774|NCT00989976|OTHER|8.5 h sleep|Subjects will have normal sleep times
62722775|NCT00989976|OTHER|restricted bedtimes|4.5 h bedtimes
62722776|NCT06393842||Cohort A|"Patients receiving hemodialysis: Primary Objective is to investigate if changes in measures derived by the CPM wearable device correlate with changes in B-lines between dialysis sessions and with the difference in weight between dialysis sessions. The end point would be to demonstrate a change in number of B-Lines on Lung Ultrasound between dialysis sessions and compare it with changes in measures derived by CPM wearable device (thoracic impedance and S3) taken during the same sessions. We would then use correlation coefficient to find how strong a relationship is between measures from Lung Ultrasound and CPM wearable device.~Secondary objective will include correlation of the measures from CPM wearable device with other measures of congestion including Spirometry, Echocardiography, Biomarkers and Physical symptoms and signs including EVEREST and ASCEND congestion score"
62722777|NCT06393842||Cohort B|"Primary Objective- Patients receiving inpatient intravenous diuretic treatment for heart failure. To investigate if measures derived by the CPM wearable device system correlate with B-lines on lung ultrasound before and after exercise during the treatment for HF. The end point would be to demonstrate a change in number of B-Lines on LUS before and after exercise during decongestion treatment for HF and compare it with measures derived by CPM wearable device (thoracic impedance and S3) taken during the same sessions. We would then use correlation coefficient to find how strong a relationship is between measures from LUS and CPM wearable device and whether the correlation improved following exercise.~Secondary objective will include correlation of the measures from CPM wearable device with other measures of congestion including Spirometry, Echocardiography, Biomarkers and Physical symptoms and signs including EVEREST and ASCEND congestion score"
62722778|NCT03186625|EXPERIMENTAL|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
62722779|NCT03186625|PLACEBO_COMPARATOR|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
62722780|NCT04739111|EXPERIMENTAL|Experimental Arms|All participants will receive treatment with LDP combined with CDP1. In the dose-escalation phase, a fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the dose-expansion phase.
62722781|NCT04836442|EXPERIMENTAL|Alcohol-PTSD-PFI (AP-PFI)|Hazardous drinkers with at least subclinical PTSD and elevated AS (N=100) recruited from the community will be randomly assigned to receive Alcohol-PTSD-PFI (AP-PFI) or an active comparison control condition (C-PFI).
62722782|NCT04836442|OTHER|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
62722783|NCT05144672||Patient Group|The patient group will include 60 patients with type II DM. They will be subdivided into three groups according to albumin-creatinine ratio ,normoalbuminuric group(less than 30mg/g),which will include 20 patients, microalbuminuric group (ACR =30-300 mg/), which will include 20 patients, and macroalbuminuric group (ACR more than 300mg/g),which will include 20 patients.
62722784|NCT05144672||Control Group|control group will include 30 apparently healthy age-matched and sex-matched individuals.
62722785|NCT03767439|EXPERIMENTAL|Nivolumab, Vismodegib, Ipilimumab|"Patients will receive a two week run-in of Vismodegib 150 mg PO daily followed by concurrent Nivolumab 480 mg IV every 4 weeks and Vismodegib 150 mg PO daily.~In an exploratory fashion, patients will have the option to receive combination Ipilimumab 1 mg/kg IV every 6 weeks and Nivolumab 360 mg IV every 3 weeks at the time of disease progression."
62722786|NCT01770743|EXPERIMENTAL|AV7909 (Day 0 and 14)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
62722787|NCT01770743|EXPERIMENTAL|AV7909 (Day 0 and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
62722788|NCT01770743|EXPERIMENTAL|AV7909 (Day 0, 14, and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
62722789|NCT01770743|EXPERIMENTAL|AV7909 Reduced Dose|Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
62722790|NCT01770743|ACTIVE_COMPARATOR|BioThrax|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
62722791|NCT05526053|NO_INTERVENTION|Standard|"SBT: PSV 8 cmH2O, PEEP 0 cmH2O for 30 minutes and, when successful, followed by extubation with continuous suctioning.~Patients included in the ultrasound nested study:~* Diaphragm and intercostal thickness and thickening fraction at the beginning and the end of the SBT.~* Modified LUS at the beginning of the SBT, at the end of the SBT and after extubation if successful SBT."
62722792|NCT05526053|EXPERIMENTAL|Lung Volume Preservation|"SBT: PSV 8 cmH2O, PEEP 5 cmH2O for 30 minutes and, when successful, followed by direct extubation without suctioning and connected to the ventilator with PEEP 5 cmH2O.~Patients included in the ultrasound part:~* Diaphragm and intercostal thickness and thickening fraction at the beginning and the end of the SBT.~* Modified LUS at the beginning of the SBT, at the end of SBT and after extubation if successful SBT."
62722793|NCT04764721|EXPERIMENTAL|Patients enrolled in Neurocog-Covid study in Nancy hospital|Young patients (\< 65 year old) who contracted VIDOC 19 and were hospitalized for less than 7 days during the first wave, and who present cognitive disorders may be definitively included in the Neurocog-Covid study if their neuropsychological assessment is abnormal. They will then have a prescription for a cerebral MRI and will be enrolled in the TEP-Covid study. If they accept, they will receive a 18F-FDG PET-CT .
62722794|NCT06373003||Group 1 [APS]|Patients fulfilling the classification criteria for antiphospholipid syndrome (seropositive APS, SN-APS)
62722795|NCT06373003||Group 2 [SN-APS]|Patients with seronegative APS (SN-APS): with clinical criteria (thrombotic or obstetric) for APS, persistently negative for aPL, and with clinical features highly suggestive of APS (recurrent events, thrombotic + obstetrical events, extra-criteria manifestations, other autoimmune diseases)
62722796|NCT06373003||Group 3 [Control Group]|Patients with clinical criteria (thrombotic or obstetric) for APS, negative for aPL, but without clinical features highly suggestive of APS (recurrent events, thrombotic + obstetrical events, extra-criteria manifestations, other autoimmune diseases)
62722797|NCT03489044|EXPERIMENTAL|Active treatment arm (Levetiracetam)|When in the active arm, after a baseline visit, participants will up-titrate Levetiracetam in 250mg steps at intervals of one week to Levetiracetam 500mg twice daily (two tablets twice daily). Participants will be maintained on Levetiracetam 500mg bd for four weeks and have a further full assessment at 8 weeks after being on Levetiracetam. Participants will then down-titrate Levetiracetam by 250mg every week until weaned to nil.
62722798|NCT03489044|PLACEBO_COMPARATOR|Control arm (placebo oral tablets)|When in the control arm, after a baseline visit, participants will up-titrate placebo (manufactured to look identical to Levetiracetam 250mg) in one tablet steps at intervals of one week to two tablets twice daily. Participants will be maintained on placebo for four weeks and have a further full assessment at 8 weeks after being on placebo. Participants will then down-titrate placebo by one tablet every week until weaned to nil.
62722799|NCT04593550||Observational (BrainCheck, 3D-CAM, EEG)|Patients undergo cognitive function assessment BrainCheck over 10 minutes before surgery, day 1 after surgery, and day 2 after surgery (if patients are still admitted to the hospital) and 3D-confusion assessment over 10 minutes BID on day 1 after surgery and day 2 after surgery (if patients are still admitted to the hospital). Patients also undergo EEG during surgery and collection of blood samples 30-60 minutes after surgery.
62722800|NCT03795649|NO_INTERVENTION|The control group (Group K)|The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.
62722801|NCT03795649|ACTIVE_COMPARATOR|Group A, Tranexamic acid|The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later
62722802|NCT03795649|OTHER|Group B, autologous transfusion|The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.
62722803|NCT03795649|OTHER|Group C, alogenous transfusion|The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability.
62722804|NCT00771212||001|
62722805|NCT01010672|EXPERIMENTAL|Ridaforolimus 40 mg|
62722806|NCT04073901|EXPERIMENTAL|Endocrown|Adhesive monoblock restoration for pulpotomized primary molars
62722807|NCT04073901|ACTIVE_COMPARATOR|Zirconia crowns|Prefabricated primary full coverage crown
62722808|NCT01132352|EXPERIMENTAL|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
62722809|NCT01132352|ACTIVE_COMPARATOR|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
62722810|NCT00844103|EXPERIMENTAL|1|
62722811|NCT00844103|PLACEBO_COMPARATOR|2|
62722812|NCT01331681|EXPERIMENTAL|Intravitreal Aflibercept Injection 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
62722813|NCT01331681|EXPERIMENTAL|Intravitreal Aflibercept Injection 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
62722814|NCT01331681|ACTIVE_COMPARATOR|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
62722815|NCT02957513|EXPERIMENTAL|Text Messaging (TM)|The TM intervention will use an extensive text message library focused on 3 key behavioral areas (diet, exercise, and medication adherence). The TM intervention will incorporate supportive cognitive behavioral strategies such as goal setting, positive reinforcement, self-talk and dealing with barriers to change. Messages will encourage social interaction (social support, problem-solving, and feedback), self-monitoring of diet and exercise, diet modification, physical activity advice and prompting and basic self- regulatory skills. Messages will be tailored based on participant demographics, health literacy, and preferences.
62722816|NCT02957513|EXPERIMENTAL|Health Coaching (HC)|The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
62722817|NCT02957513|ACTIVE_COMPARATOR|Enhanced Usual Care (EC)|"All participants in all 3 study arms (TM, HC, and EC) will receive enhanced usual care. Usual care in the participating practices will be supplemented through the following key EC resources:~A. Patient-focused Resources including: 1) MODEL Program Toolkit, and 2) low literacy diabetes educational materials.~B. Availability of diabetes support services including: 1) peer group support sessions, 2) diabetes education, 3) MyDiabetesCenter.org resources, and 4) Diabetes Coalition education hub resources.~C. Practice-focused components including: 1) practice training/continuing medical education, and 2) reporting of diabetes performance measures."
62722818|NCT03771040|EXPERIMENTAL|Masitinib (titration to 6.0 mg/kg/day)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
62722819|NCT03771040|PLACEBO_COMPARATOR|Placebo|Participants receive matched placebo
62722820|NCT05710250|EXPERIMENTAL|Mindfulness based stress reduction (MBSR) program|15 students will follow a 6-week MBSR program with 2h30 sessions per week in group and daily exercises lasting 30-40 minutes per day.
62737919|NCT00193791|EXPERIMENTAL|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
61978195|NCT01316120|EXPERIMENTAL|HPV standard transport medium|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
62722821|NCT05710250|ACTIVE_COMPARATOR|Muscular relaxation program|15 students will follow a 6-week muscular relaxation program with 2h30 group sessions per week in group and daily exercises lasting 30-40 minutes per day.
62722822|NCT02598141|OTHER|Per-op biopsy around material|"Patients included in this study require biopsies for suspicion of infected osteo-articular materials (implants, protheses, nails, screw, plates).~Interventions:~* Biological sampling grinding~* Biological sampling with standard procedures"
62722823|NCT02307448|ACTIVE_COMPARATOR|PRP Group|Patients will receive weekly PRP treatments
62722824|NCT02307448|PLACEBO_COMPARATOR|Standard of Care|Patients will receive weekly standard of care.
62722825|NCT04093960|EXPERIMENTAL|escitalopram plus128|escitalopram (10 mg daily) plus PS128(a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily)
62722826|NCT04093960|ACTIVE_COMPARATOR|escitalopram|10 mg/d of escitalopram
62722827|NCT00394576|EXPERIMENTAL|usual care plus Internet-based nutrition module|usual care plus Internet-based nutrition module
62722828|NCT00394576|ACTIVE_COMPARATOR|usual care|usual care
62722829|NCT01466491|PLACEBO_COMPARATOR|4-site injection|The superior technique of Phase 1 will be compared to a 4-site technique (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
62722830|NCT01466491|ACTIVE_COMPARATOR|2-site Injection|The superior technique of Phase 1 will be compared to a 2-site technique (2 mL injected at the tenaculum site, 18 mL equally distributed between 4 and 8 o'clock) in a randomized fashion (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
62722831|NCT01466491|PLACEBO_COMPARATOR|4-Site PCB followed by 3-minute wait|Women will be randomized to receive a 4-site PCB followed by a 3-minute wait (PCB 20/4/3) prior to dilation
62722832|NCT01466491|ACTIVE_COMPARATOR|4-site PCB followed by no wait|Women will be randomized to receive a 4-site PCB followed by no wait (PCB 20/4/0).
62722833|NCT00088257||Mother-child pairs|Subset of mother-child pairs enrolled in Project Viva, a cohort study of pregnant women and their offspring. 411 mother-child pairs with measures of lymphocyte proliferation in their cord blood samples make up the subset for this study.
62722834|NCT05754476||Brain Diseases|This study does not limit the kinds of brain diseases. The cohort includes patients with suspected or known brain diseases including tumors, vascular disorder, inflammatory disease, neurodegenerative diseases and trauma, follow-up, routine brain, and others requiring MRI exams with GBCAs.
62722835|NCT02830243|EXPERIMENTAL|Sevoflurane|Anesthesia was maintained with sevoflurane.
62722836|NCT02830243|EXPERIMENTAL|Desflurane|Anesthesia was maintained with desflurane.
62722837|NCT05511012|OTHER|motion control fault testing|"Each patient make six motion control fault tests in the same order :~1. waiters bow~2. pelvic tilt~3. one leg stance~4. sitting knee extension~5. rocking 4 point kneeling~6. prone knee bend~This tests are performed three times."
62722838|NCT03271164|EXPERIMENTAL|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
62722839|NCT03271164|ACTIVE_COMPARATOR|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
62722840|NCT03150537|ACTIVE_COMPARATOR|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
62722841|NCT03150537|ACTIVE_COMPARATOR|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
62722842|NCT03150537|ACTIVE_COMPARATOR|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
62722843|NCT03197610|EXPERIMENTAL|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
62722844|NCT03197610|EXPERIMENTAL|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
62722845|NCT06168383|EXPERIMENTAL|Double-blind 80 mg Daily|Patients take double-blind HSK31679 80 mg for 52 weeks
62722846|NCT06168383|EXPERIMENTAL|Double-blind 160 mg Daily|Patients take double-blind HSK31679 160 mg for 52 weeks
62722847|NCT06168383|PLACEBO_COMPARATOR|Placebo|Patients take double-blind placebo for 52 weeks
62722848|NCT02830919|EXPERIMENTAL|Glucosamine and chondroitin sulfate combination (Eurofarma)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
62722849|NCT02830919|ACTIVE_COMPARATOR|Glucosamine and chondroitin sulfate combination (Zodiac)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.
62722850|NCT02135068|EXPERIMENTAL|CL and exercise with proactive snacking|Subject will consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
62722851|NCT02135068|ACTIVE_COMPARATOR|CL and exercise without proactive snacking|Subject will not consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
62722852|NCT01674504|EXPERIMENTAL|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
62722853|NCT01674504|ACTIVE_COMPARATOR|SINGTJLAIR ®|SINGTJLAIR ® (containing Montelukast sodium)chewable tablets 5mg of Merck Sharp \& Dohme Ltd., USA
62722854|NCT06122103||Clareon Monofocal|
62722855|NCT06122103||Light-Adjustable Lens|
62722856|NCT00533429|EXPERIMENTAL|A|Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin
62722857|NCT00533429|PLACEBO_COMPARATOR|B|Pemetrexed + Carboplatin + Bevacizumab + Placebo
62722858|NCT04524260|ACTIVE_COMPARATOR|Painting art therapy|Intervention group
62722859|NCT04524260|SHAM_COMPARATOR|Usual Care|Control group
62722860|NCT01130181|EXPERIMENTAL|Cholecalciferol|
62722861|NCT01130181|PLACEBO_COMPARATOR|Placebo|
62722862|NCT03150381|ACTIVE_COMPARATOR|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (\~5-10% of baseline weight).
62722863|NCT03150381|EXPERIMENTAL|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (\~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
62722864|NCT03150381|ACTIVE_COMPARATOR|Control|Educational materials and optional participation in community-wide cancer awareness activities.
62722865|NCT03569124||Training group|
62722866|NCT03569124||Non-Training group|
62722867|NCT00369837|EXPERIMENTAL|clevidipine|A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.
62722868|NCT04092114|OTHER|Control|Receives Standard of Care (SOC) services established in accordance with the South African Department of Health (DoH) PrEP (Pre-exposure Prophylaxis) guidelines.
62722869|NCT04092114|EXPERIMENTAL|CHARISMA Intervention|"Receives SOC (Standard of care) per control arm plus provider-administration of HEART (HEAlthy Relationship Assessment Tool) and provider-administration of CHARISMA (the Community Health clinic model for Agency in Relationships and Safer Microbicide Adherence) counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning"
62722870|NCT03549741|EXPERIMENTAL|study group|will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
62722871|NCT03549741|ACTIVE_COMPARATOR|control group|will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
62722872|NCT04824703|ACTIVE_COMPARATOR|Conservative oxygen therapy|"* Spo2 alarm limit will be set as follow: - upper limit 94% and lower limit 88%~* If spo2 \>94% Unless fio2 is 0.21%, decrease fio2 by 0.10% at intervals no longer than 5 minutes till spo2 = 94%~* If spo2 within target Decrease fio2 0.05% at intervals no longer than 30 min till fio2 0.21% reached or spo2 = 88 %~* If spo2 \< 88 % return to previous spo2 that achieve target spo2.~* if an arterial blood gas demonstrate that the PaO2 is \< 60 mmHg FiO2 will increased if clinically appropriate irrespective of the SpO2 reading ( target po2 60-100 mmhg )~* During intubation, airway suction, tracheostomy, bronchoscopy, transportation outside of the ICU for radiological or other investigations or for procedures or operations, other critical situations such as hemodynamic collapse, patients will receive standard (non-study)treatment.~* Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
62722873|NCT04824703|PLACEBO_COMPARATOR|Liberal oxygen therapy|"* Spo2 target \> 95%~* No specific measures will be taken to avoid high fio2 or high po2~* Use of upper alarm limit for spo2 will be prohibited~* Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
62722874|NCT03785184|EXPERIMENTAL|Venetoclax + Lenalidomide + Dexamethasone|Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
62722875|NCT00290810|EXPERIMENTAL|Treatment (monoclonal antibody therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62722876|NCT05175274|EXPERIMENTAL|Intervention Group|colchicine 0.5mg every 24 hours for 3 years
62722877|NCT05175274|PLACEBO_COMPARATOR|Control Group|1 placebo tablet every 24 hours for 3 years
62722878|NCT01436110|EXPERIMENTAL|Fluticasone furoate 50 mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
62722879|NCT01436110|ACTIVE_COMPARATOR|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ ACCUHALER
61978196|NCT02834208|EXPERIMENTAL|Schizophrenia subjects|35 patients suffering from schizophrenia
62722880|NCT01436110|PLACEBO_COMPARATOR|Placebo|Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER
62722881|NCT00484783|EXPERIMENTAL|Prospective|Subjects scheduled to receive procedure
62722882|NCT00484783|OTHER|Historical|Chart review control group
62722883|NCT02990650|ACTIVE_COMPARATOR|Standard physical therapist|A combination of nine balance training tasks where the physical therapist provides guarding against loss of balance
62722884|NCT02990650|EXPERIMENTAL|standard robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance
62722885|NCT02990650|EXPERIMENTAL|challenge based robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance while the participant works at a level greater than their current balance capability
62722886|NCT06243614|EXPERIMENTAL|Experimental group|Participants took 60-120 mg/day Buagafuran capsules and Buspirone tablets mimic; 2 times per day, after breakfast and dinner, consecutively for 8 weeks; The dose can be adjusted according to treatment needs and tolerance in the follow-up period( at week 1, week 2 and week 4).
62722887|NCT06243614|ACTIVE_COMPARATOR|Positive-control group|Participants took 10-20mg/day Buspirone tablets and Buagafuran capsules mimic; 2 times per day, after breakfast and dinner, consecutively for 8 weeks; The dose can be adjusted according to treatment needs and tolerance in the follow-up period( at week 1, week 2 and week 4).
62737920|NCT02438683|PLACEBO_COMPARATOR|Placebo under resting/exercise conditions|Participants received matching Placebo oral dose with 240 mL of water after a standardized light breakfast on Day 1 and Day 3 under resting/exercise conditions.
62722888|NCT06243614|PLACEBO_COMPARATOR|Placebo-control group|Participants took Buagafuran capsules mimic and Buspirone tablets mimic; 2 times per day, after breakfast and dinner, consecutively for 8 weeks; The dose can be adjusted according to treatment needs and tolerance in the follow-up period( at week 1, week 2 and week 4).
62722889|NCT04786054|ACTIVE_COMPARATOR|Group BED|Those who are diagnosed with having Binge Eating disorder. These individuals qualified after the questionnaire was administered.
62722890|NCT04786054|NO_INTERVENTION|Group Non-BED|Those who are not diagnosed with having Binge Eating disorder
62722891|NCT05504759|EXPERIMENTAL|Group 1|2 weeks rest protocol + standardized exercise program
62722892|NCT05504759|EXPERIMENTAL|Group 2|local steroid injection + 2 weeks rest protocol + standardized exercise program
62722893|NCT05504759|EXPERIMENTAL|Group 3|dry needling of forearm extensor muscles + 2 weeks rest protocol + standardized exercise program
62722894|NCT04618029|EXPERIMENTAL|Treatment Group|"1. Home Assessment and Modification A two-component individualized home hazards management program will be provided for each participant in the intervention group according to the results of the HOME FAST. Basic home safety strategies and basic modifications are developed and will be prescribed for this study according to the HOME FAST assessment (weeks et al. 2010)~2. Education Education on optimization of functional performance in the home will be provided via pamphlets on fall prevention, including energy conservation techniques (Chumbler et al., 2010), ergonomics (Edwards et al., 2019) and task simplification techniques (Wesson et al., 2013) will be provided. These techniques will also be provided for participants' caregivers."
62722895|NCT04618029|NO_INTERVENTION|Controlled Group|1. Standard Care The standard care defined for this study is any care that are provided from the respective hospital. This will include common therapies and interventions for stroke rehabilitation in general.
62722896|NCT02869672|EXPERIMENTAL|age of 18-50 years old, experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
62722897|NCT02869672|ACTIVE_COMPARATOR|age of 18-50 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
62722898|NCT02869672|EXPERIMENTAL|age of 7-17 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
62722899|NCT02869672|ACTIVE_COMPARATOR|age of 7-17 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
62722900|NCT02869672|EXPERIMENTAL|age of 2-6 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
62722901|NCT02869672|ACTIVE_COMPARATOR|age of 2-6 years old,control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
62722902|NCT05634473|EXPERIMENTAL|Patients with asthma/healthy subjects|
62722903|NCT01952743|ACTIVE_COMPARATOR|AF Ablation alone|Clinical AF ablation performed as deemed appropriate by operator
62722904|NCT01952743|EXPERIMENTAL|AF ablation with Renal Denervation|Renal denervation performed using the same ablation catheter after clinical AF ablation
62722905|NCT00833027|EXPERIMENTAL|1|Sitagliptin
62722906|NCT03358602|EXPERIMENTAL|Radiotherapy|Radiotherapy \& open partial supraglottic laryngectomy(primary tumor)
62722907|NCT03358602|ACTIVE_COMPARATOR|Elective neck dissection|Elective neck dissection \& open partial supraglottic laryngectomy(primary tumor)
62722908|NCT01051037|EXPERIMENTAL|Arm 1|Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.
62722909|NCT06024187|EXPERIMENTAL|Cold Dissection|In this group, the septa between the skin flap and parenchyma was dissected using with scissors or scalpel
62722910|NCT06024187|ACTIVE_COMPARATOR|Electrocautery Dissection|In this group, the septa between the skin flap and parenchyma was dissected using with electrocautery
62722911|NCT04180098|EXPERIMENTAL|Context specific C-mill training|Five week C-mill training on gait adaptability.
62722912|NCT04180098|OTHER|Usual care|Usual care for participants with HSP. May vary per individual.
62722913|NCT00836264||Morphine T & A|"Subjects ages 4-18 years of age who have a Tonsillectomy and Adenoidectomy and receive morphine for pain control and who have also enrolled in the CAG study at CHOP, A Study of the Genetic Causes of Complex Pediatric Disorders (GCPD study), as approved by the CHOP IRB, 2006-7-4886."
62722914|NCT02054065|NO_INTERVENTION|Control|Normal care conditions, no computer-based physician alert.
62722915|NCT02054065|EXPERIMENTAL|CAUTI Decision Support|Decision support aimed at preventing Catheter Associated Urinary Tract Infections (CAUTIs)
62722916|NCT00429143|EXPERIMENTAL|Haploidentical Allogeneic Transplantation|Patients undergoing hematopoietic stem cell transplant from a partially matched related donor
62722917|NCT00465972|PLACEBO_COMPARATOR|Placebo|Placebo
62722918|NCT00465972|ACTIVE_COMPARATOR|2|Doxepin
62722919|NCT00465972|ACTIVE_COMPARATOR|3|Temazepam
62722920|NCT04405440||Healthy controls|The healthy control group will perform a well-validated avoidance (behavioral) task and will fill in some questionnaires about eating behaviors, emotions, and feelings.
62722921|NCT04405440||Anorexia Nervosa patients|As the healthy controls, the participants of the anorexia nervosa group will perform the same behavioral task and will fill in the same questionnaires
62722922|NCT01333410|ACTIVE_COMPARATOR|0.1% tacrolimus ointment|
62722923|NCT01333410|ACTIVE_COMPARATOR|0.1% mometasone furoate cream|
62722924|NCT02982629|PLACEBO_COMPARATOR|Usual Care|Patients in this group do not receive any letters or phone calls after missing follow-up appointment.
62722925|NCT02982629|ACTIVE_COMPARATOR|Reminder Letter Intervention|Patients in this group receive letters and phone calls after missing follow-up appointment to reschedule the appointment.
62722926|NCT01796288|EXPERIMENTAL|Erlotinib & simultaneous radiotherapy|patients started simultaneously radiotherapy for all gross tumors
62722927|NCT01796288|OTHER|Erlotinib & no radiotherapy|patients received no radiotherapy for all gross tumors
62736223|NCT06154148|EXPERIMENTAL|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the premature infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infants's head turns toward the mother's face and is located between the nipple and the clavicle. Their arms and legs are flexed, in a naturally adopted asymmetrical tonic neck posture, according to the infants's term and comfort. The infant is naked and positioned inside the mother's clothes.
62722928|NCT01399112|EXPERIMENTAL|Electronic Decision Support System|The Electronic Decision Support System (EDSS) is a 5-module computer program aimed to assess, motivate, educate, solicit preferences, and provide feedback and referrals for people with severe mental illness. The program provides: a) a personalized assessment of the individual's smoking, b) information to improve knowledge of smoking risks and treatment benefits, c) interactive exercises to personalize the impact of smoking, improve attitudes about quitting, and increase self-efficacy for seeking smoking cessation treatment, and d) a video patient vignette to develop social norms for smoking cessation treatment and increase self-efficacy. Usability testing among people with severe mental illness established that the system was comprehensible, easy to use, and took 30-90 minutes to complete.
62722929|NCT01399112|ACTIVE_COMPARATOR|thetruth.com website|"Participants who are assigned to use the web-based thetruth.com website will be asked to navigate through the website as they wish. The home page of thetruth.com site has links to access video games, fact sheets, and videos that highlight negative aspects of cigarettes or tobacco companies. Thetruth.com website is not structured and participants can utilize whatever aspects of the website they wish and in any order they wish to view them.~Individuals will use the computer with a research staff member present who can provide assistance if needed. The sections of the two programs website that are used and the time spend on each portion of the program will be recorded. Participants who use TheTruth.com will be given a referral for assistance in quitting smoking if requested."
62722930|NCT04878393||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment
62722931|NCT01452477|ACTIVE_COMPARATOR|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
62722932|NCT01452477|PLACEBO_COMPARATOR|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
62722933|NCT04965298|EXPERIMENTAL|Active treatment arm|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
62722934|NCT04965298|PLACEBO_COMPARATOR|Matched-Placebo arm|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
62722935|NCT00710892|EXPERIMENTAL|Dose Level 1-3|Administration of suicide gene-modified allodepleted T cells.
62722936|NCT04068948|ACTIVE_COMPARATOR|Midazolam, Hydroxyzine, Meperidine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, Hydroxyzine 1.0mg/kg, and Meperidine 1.5mg/kg prior to their dental procedure.
62722937|NCT04068948|EXPERIMENTAL|Midazolam, Hydroxyzine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, and Hydroxyzine 1.0mg/kg prior to their dental procedure.
62722938|NCT04818957|EXPERIMENTAL|Vitamin D Oral Thin Film (OTF)|Study subjects will receive vitamin D OTF for a maximum of 12 weeks.
62722939|NCT05634486|EXPERIMENTAL|Multidisciplinary therapeutic approach|"* Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist).~* 12 physiotherapy sessions during one month (three 60-minute sessions per week) administered by a physiotherapist with experience in functional neurological disorders.~* 4 cognitive-behavioral therapy sessions during one month (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy."
62722940|NCT05634486|SHAM_COMPARATOR|Psychoeducation|"* Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist).~* 4 psychoeducational sessions (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy."
62722941|NCT01451749|EXPERIMENTAL|Shenwu Capsule|"Shenwu Capsule:1 capsule contains 451 mg of Shenwu extracts. 5 capsules/time, 3 times/day for 6 months.~Placebo: Placebo identical to donepezil tablets,1 placebo tablet/time, 1 time/day for 6 months."
62722942|NCT01451749|ACTIVE_COMPARATOR|Donepezil|"Donepezil: 1 tablet contains 5 mg of donepezil, 1 tablet/time, 1time/day for 6 months.~Placebo: Placebo identical to shenwu capsules,5 placebo capsules/time,3 times/day for 6 months"
62722943|NCT02597530|EXPERIMENTAL|Long-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.Patients in Long-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and continued until the end of the surgery with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
62722944|NCT02597530|OTHER|Short-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.The patients in Short-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
62722945|NCT02597530|PLACEBO_COMPARATOR|Sham group|Patients in sham group will be pasted electrodes 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
62722946|NCT01738061|NO_INTERVENTION|reference group|They continued their daily routine.
62722947|NCT01738061|EXPERIMENTAL|Multidimensional lifestyle intervention|The multidimensional lifestyle intervention program received motivational activities to improve awareness of the impact of lifestyle on chronic diseases and the importance of self-health management.
62722948|NCT03541499|EXPERIMENTAL|Group 1|800 microliters (10\^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15
62722949|NCT03541499|EXPERIMENTAL|Group 2|800 microliters (10\^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15
62722950|NCT03541499|PLACEBO_COMPARATOR|Group 3|800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15
62722951|NCT03541499|EXPERIMENTAL|Group 4|800 microliters (10\^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5
62722952|NCT05689879|NO_INTERVENTION|REMAIN arm|Infliximab 3 to 5 mg/kg every 4-8 weeks, methotrexate 7.5-10 mg/week (or azathioprine 1 mg/Kg/day), steroids \< or = 10 mg/day
62722953|NCT05689879|OTHER|STOP arm|Methotrexate 0.3 mg/kg/week (or azathioprine 2 mg/kg/day (or 1 mg/kg/day if intermediary metabolism TMPT) (the dose of methotrexate will not exceed 25mg/kg/week wathever the weight of the patient), steroids \< or = 10 mg/d
62722954|NCT02930707|ACTIVE_COMPARATOR|Magnesium group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.
62722955|NCT02930707|PLACEBO_COMPARATOR|control group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
62722956|NCT05999331||Non-SALD group|SALD did not occur in adult patients with sepsis during ICU stay.SALD was diagnosed by the following criteria: (1) ALT or AST≥20 folds upper limit of normal level; or (2) TBIL≥2.0 mg/dL.
62722957|NCT05999331||SALD group|SALD was occured in adult patients with sepsis during ICU stay.SALD was diagnosed by the following criteria: (1) ALT or AST≥20 folds upper limit of normal level; or (2) TBIL≥2.0 mg/dL. SALD is further divided into hypoxic hepatitis and sepsis induced cholestasis (SIC), based on the presence or absence of elevated TBIL. Hypoxic hepatitis is diagnosed when elevated transaminase (\>800 IU/L) is present only; and SIC is diagnosed when TBIL is elevated (≥2.0 mg/dL).
62722958|NCT01107067|EXPERIMENTAL|testosterone replacement therapy|
62722959|NCT03564574|EXPERIMENTAL|Study group|"Inclusion criteria~1. History of consumption of OP compound.~2. Symptom complex consistent with OP poisoning~3. Age \> 18 years~4. Informed consent from the patient or next kin.~Exclusion criteria~1. History of combined poisoning with a non OP compound.~2. All other patients not fitting in the organophosphate symptom complex.~3. Patients with underlying liver and kidney disease.~4. History suggestive of acute pancreatitis in the past.~All patients with history and clinical features of OP compound poisoning admitted to the emergency department in PGIMER during the study period, meeting the inclusion, exclusion criteria and who gave consent were enrolled in the study.~Intervention : Administration of 100mL of 20% Lipid emulsion to all patients in the study group"
62722960|NCT03564574|NO_INTERVENTION|Historic controls|The control arm The study group was compared with data of patients admitted for OP poisoning between the years 2013 and 2014 ( 2 calendar years), fulfilling the inclusion and exclusion criteria as stated above.
62722961|NCT00921050|EXPERIMENTAL|Levothyroxine|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
62722962|NCT00921050|PLACEBO_COMPARATOR|Placebo|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
62722963|NCT02745496|OTHER|TRUS Biopsy|Standard of Care Treatment
62722964|NCT02745496|OTHER|TRUS/FUSION Biopsy|Interventional Treatment
62722965|NCT05323890|EXPERIMENTAL|Tislelizumab arm|Radiotherapy: PTV 41.4Gy in 23 Fractions，5 days per week; Chemotherapy: Paclitaxel (Albumin bound) (100mg/m2) and Cisplatin (75 mg/m2) for 5 weeks, concurrent with radiotherapy; Immunotherapy: Tislelizumab (200mg per 3 weeks)
62722966|NCT05257382|ACTIVE_COMPARATOR|Endoscopy suite|In this arm, ENB procedure will be performed in a classical endoscopy suite equipped by a fluoroscopy.
62722967|NCT05257382|EXPERIMENTAL|CBCT suite|In this arm, ENB procedure will be performed in a n hybrid room equipped by a cone beam CT (CBCT). This will allow to perform a real time visualisation of the lesion, enhanced fluoroscopy and to use the CrossCountry technique if required.
62722968|NCT00913510|EXPERIMENTAL|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
62722969|NCT00913510|ACTIVE_COMPARATOR|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
62722970|NCT04451005||Elderly patients with sarcopenia|Elderly patients with sarcopenia
62722971|NCT01976299|EXPERIMENTAL|Active Treatment|Standard of Care with the AVERT system
62722972|NCT01976299|NO_INTERVENTION|Standard of Care|
62722973|NCT03820284||Group A|Group A inflammatory bowel disease with helicobacter pylori infection
62722974|NCT03820284||Group B|Inflammatory bowel disease without helicobacter pylori infection
62722975|NCT02785692||Combined Radiation/ Surgery|All patients treated with combined radiotherapy and surgery at Balgrist University Hospital and University Hospital Zurich
62722976|NCT04254146|EXPERIMENTAL|Study group|Aerobic exercise will be performed for a single session
62722977|NCT04254146|ACTIVE_COMPARATOR|Control group|Aerobic exercise will be performed to healthy population for a single session
62722978|NCT02272946|OTHER|Safety Arm|In Stage 1: all 10 subjects will receive 150 mg Canakinumab subcutaneous injection. This will be a preliminary safety study (before Stage II).
61978197|NCT02834208|OTHER|Healthy siblings|35 healthy siblings of the patients suffering from schizophrenia
61978198|NCT02834208|OTHER|Healthy controls|"35 healthy controls patients"
62722979|NCT02272946|EXPERIMENTAL|Canakinumab|In Stage II: About 67 subjects will receive 150mg Canakinumab subcutaneous injection.
62722980|NCT02272946|PLACEBO_COMPARATOR|Placebo|In Stage II: About 33 subjects will receive 150mg placebo subcutaneous injection
62722981|NCT04187131|EXPERIMENTAL|augmented reality|
62722982|NCT00811720|PLACEBO_COMPARATOR|Placebo|
62722983|NCT00811720|EXPERIMENTAL|Nalmefene|
62722984|NCT04795375|EXPERIMENTAL|Intervention|The intervention group will receive Physical activity counseling and guidance by a certified Nurse during the six months after the surgery, additional to the routine follow-up after bariatric surgery at Hadassah-Ein Kerem Hospital.
62722985|NCT04795375|NO_INTERVENTION|Control|"The control group will receive the routine follow-up followed at Hadassah-Ein Kerem Hospital after bariatric surgery, which includes long term follow-up with the surgeon and a dietitian.~Participants at the Control group will receive Physical activity counseling by a certified nurse at the end of trial."
62722986|NCT04088968|EXPERIMENTAL|Prehabilitation|Intervention: Patients allocated to the intervention group receive weekly counselling sessions in 6 weeks as an integrated prehabilitation program tailored to meet the individual patient's need for risk reduction at surgery. It is introduced via the surgical 'Engage in the process of change'. The smoking and alcohol cessation intervention follows the Gold Standard Programme and patients in the intervention group are introduced to a standardized exercise training programme taking individualized needs into account. Nutritional support is also individualized.
62722987|NCT04088968|NO_INTERVENTION|Treatment as usual|Treatment as ususal covers shorter interventions, e.g. advice, brief counselling, and handing out the national folders on smoking and alcohol and surgery. Patients are ensured that they are free to access support to lifestyle changes in the community.
62722988|NCT02057926|EXPERIMENTAL|Tetracycline, Without Tetracycline|The study consist in two groups: test group (membrane treated with tetracycline) and control group (membrane no treated with tetracycline).
62722989|NCT01946334|EXPERIMENTAL|patients|
62722990|NCT00643942||1|
62722991|NCT02388880|EXPERIMENTAL|ITPR|Use of the ITPR for 240 minutes.
62722992|NCT05713071|EXPERIMENTAL|BEAM Treatment Patients|Subjects having esophagogastroduodenoscopy (EGD) with Bariatric Endoscopic Antral Myotomy (BEAM) with standard of care lifestyle modification therapy.
62722993|NCT05713071|NO_INTERVENTION|Lifestyle Modification Control Group|Standard of care lifestyle modification therapy only.
62722994|NCT00742625|EXPERIMENTAL|Treatment (daunorubicin hydrochloride and bortezomib)|See Detailed Description
62722995|NCT00619944|EXPERIMENTAL|1|Lumefantrine lopinavir drug interaction arm
62722996|NCT00619944|ACTIVE_COMPARATOR|2|lumefantrine only arm
62722997|NCT03739151|OTHER|Behavioral Obesity Treatment|All participants will receive gold-standard behavioral obesity treatment
62722998|NCT05853588|EXPERIMENTAL|Experimental group|It was determined by lot by the volunteer nurses who accepted to participate in the study.
62722999|NCT05853588|NO_INTERVENTION|Control group|It was determined by lot by the volunteer nurses who accepted to participate in the study.
62723000|NCT04831905|EXPERIMENTAL|Pilote study|Micro-wave ablation of index lesion identified on MRi on prostate cancer
62723001|NCT03116997|EXPERIMENTAL|Neuromuscular blockade reversed with neostigmine/gly|
62723002|NCT03116997|ACTIVE_COMPARATOR|Neuromuscular blockade reversed with sugammadex|
62723003|NCT04222530|EXPERIMENTAL|Linear EUS|patients underwent linear endoscopic ultrasonography followed by magnifying narrowband endoscopy
62723004|NCT04222530|EXPERIMENTAL|ME-NBI|patients underwent magnifying narrowband endoscopy followed by linear endoscopic ultrasonography
62723005|NCT03417583|NO_INTERVENTION|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
62723006|NCT03417583|EXPERIMENTAL|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
62723007|NCT04165863|EXPERIMENTAL|A|treatment of the surgical wound healing process with Platelet-rich-fibrin in patients undergoing total knee replacement surgery
62723008|NCT04165863|ACTIVE_COMPARATOR|B|Gold standard treatment of the surgical wound healing process without Platelet-rich-fibrin in patients undergoing total knee replacement surgery
62723009|NCT06159283|EXPERIMENTAL|IVIG administration|The patients who will meet the inclusion criteria will be administered IVIG at a dose of 1,000 mg/kg, divided over 2-3 days. After administration, the patient's condition will be thoroughly observed. In case of adverse effects from an increased administration rate, the rate will be reduced immediately or suspended until symptom improvement. Other standards of care can be continued.
62723010|NCT06159283|NO_INTERVENTION|Standard Of Care|The same anti-viral, anti-inflammatory, and anti-coagulation treatment criteria are applied to the treatment group. If the primary endpoint will be not reached by day 14 of randomization, IVIG can be given at a dose of 1,000 mg/kg based on clinicians' discretion.
62723011|NCT02996422|EXPERIMENTAL|School-based water campaign|Students who attend middle and high schools in the intervention counties will receive a school-based water campaign. A sample of students from each school will complete surveys before and after the installation of the water refilling stations to measure beverage consumption, knowledge, attitudes, and self-efficacy.
62723012|NCT02996422|NO_INTERVENTION|Comparison schools|A sample of students who attend middle and high schools in the comparison county, which does not receive any intervention components, will complete surveys to measure beverage consumption, knowledge, attitudes, and self-efficacy.
62723013|NCT02996422|EXPERIMENTAL|Community cooking classes|Adults in the same intervention counties as the school-based water campaign will enroll in group cooking classes. They will complete a baseline and two follow-up surveys to measure changes in fruit and vegetable consumption, attitudes, and self-efficacy.
62723014|NCT05373212|EXPERIMENTAL|BC Combo THDB0207 Low dose|Single administration of BC Combo THDB0207 (Low dose)
62723015|NCT05373212|EXPERIMENTAL|BC Combo THDB0207 Medium dose|Single administration of BC Combo THDB0207 (Medium dose)
62723016|NCT05373212|EXPERIMENTAL|BC Combo THDB0207 High dose|Single administration of BC Combo THDB0207 (High dose)
61978199|NCT00728780|EXPERIMENTAL|A|ABT-143 15/135mg
62723017|NCT05373212|ACTIVE_COMPARATOR|Humalog® Mix25|Single administration of Humalog® Mix25
62723018|NCT00225914|EXPERIMENTAL|1|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
62723019|NCT00225914|PLACEBO_COMPARATOR|2|Subjects then enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill
62723020|NCT03068897|ACTIVE_COMPARATOR|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
62723021|NCT03068897|ACTIVE_COMPARATOR|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
62723022|NCT03068897|ACTIVE_COMPARATOR|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
62723023|NCT03068897|PLACEBO_COMPARATOR|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
62723024|NCT04454060||Extracapsular method group|consecutive 43 patients who received extracapsular method treatment for refractory tennis elbow
62723025|NCT05895097|ACTIVE_COMPARATOR|Conventional pacing|
62723026|NCT05895097|EXPERIMENTAL|LBB pacing|
62723027|NCT02042287|EXPERIMENTAL|1: Gynofit®|Vaginal lactic acid gel
62723028|NCT02042287|ACTIVE_COMPARATOR|2: metronidazole|Oral antibiotic
62723029|NCT03920501|EXPERIMENTAL|Tele-Critical Care|Tele-Critical Care + Audit \& Feedback.
62723030|NCT03920501|NO_INTERVENTION|Usual Care|Usual Care.
62723031|NCT05353413|EXPERIMENTAL|Various types of optic neuropathies|Patients with various types of optic neuropathy.
62723032|NCT05353413|OTHER|Healthy volunteers|Healthy volunteers
62723033|NCT05680467|EXPERIMENTAL|"Soft Tissue Mobilization"|Participants allocated to this group will receive six sessions of soft tissue mobilization technique accord to Kaltenborn (2018) .
62723034|NCT05680467|EXPERIMENTAL|"Soft Tissue Mobilization and TECAR"|Participants allocated to this group will receive the same manual therapy protocol with Group 1 in combination with Capacitive and Resistive Electric Transfer Therapy (TECAR).
62723035|NCT05680467|ACTIVE_COMPARATOR|"Control"|Control Group
62723036|NCT01761513|EXPERIMENTAL|Sequence 1|
62723037|NCT01761513|EXPERIMENTAL|Sequence 2|
62723038|NCT01761513|ACTIVE_COMPARATOR|Sequence 3|
62723039|NCT01761513|ACTIVE_COMPARATOR|Sequence 4|
62723040|NCT04904172||Acute ischemic stroke who undergo intravenous thrombolytic and / or endovascular thrombectomy|Patients with acute ischemic stroke who applied to Ege University Emergency Service and decided to undergo intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments by a Neurology Specialist.
62723041|NCT03840213||Patients undergoing chemotherapy treatment|Patients over 18 years of age, followed at the ICLN day hospital or hospitalized and undergoing chemotherapy treatment
62723042|NCT05859139|EXPERIMENTAL|Intervention introduced to group 1|The intervention is introduced to the first group (G1) of clusters.
62723043|NCT05859139|EXPERIMENTAL|Intervention introduced to group 2|The intervention is introduced to the second group (G2) of clusters and G1 remains in intervention conditions.
62723044|NCT05859139|EXPERIMENTAL|Intervention introduced to group 3|The intervention is introduced to the third group (G3) of clusters and G1 and G2 remains in intervention conditions.
62723045|NCT05859139|EXPERIMENTAL|Intervention introduced to group 4|The intervention is introduced to the fourth group (G4) of clusters and G1, G2 and G3 remains in intervention conditions.
62723046|NCT01131897|EXPERIMENTAL|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
62723047|NCT01131897|ACTIVE_COMPARATOR|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
62723048|NCT02126319|EXPERIMENTAL|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
62723049|NCT02126319|ACTIVE_COMPARATOR|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
62723050|NCT01440764|EXPERIMENTAL|F(40), then Saline, then IV.F|"On Test Day 1, participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
62723051|NCT01440764|EXPERIMENTAL|IV.F, then F(40), then Saline|"On Test Day 1, participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes."
62723052|NCT01440764|EXPERIMENTAL|Saline, then F(40), then IV.F|"On Test Day 1, participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 3), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
62723053|NCT01440764|EXPERIMENTAL|F(80), then Saline, then Saline|"On Test Day 1, participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
62723054|NCT01440764|EXPERIMENTAL|Saline, then F(80), then Saline|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
62723055|NCT01440764|EXPERIMENTAL|Saline, then Saline, then F(80)|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes."
62723056|NCT03853044|EXPERIMENTAL|Chidamide plus CHOP|Participants received six 21-day cycles of chidamide, combined with six cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (21-day cycles).
62723057|NCT00283946|EXPERIMENTAL|1|
62723058|NCT00283946|ACTIVE_COMPARATOR|2|
62723059|NCT02535897|PLACEBO_COMPARATOR|CON|500 ml of flavoured water
62723060|NCT02535897|ACTIVE_COMPARATOR|CHO|500 ml of flavoured water containing 80 g carbohydrate
62723061|NCT02535897|ACTIVE_COMPARATOR|CHO-PRO|500 ml of flavoured water containing 40 g carbohydrate and 40 g whey protein
62723062|NCT00498043|EXPERIMENTAL|R-CHOP-14|R-CHOP14 induction regimen
62723063|NCT00498043|EXPERIMENTAL|R-ACVBP14|R-ACVBP14 induction regimen
62723064|NCT01233024|PLACEBO_COMPARATOR|Low fiber control|no treatment dinner bar, no treatment breakfast bar
62723065|NCT01233024|EXPERIMENTAL|Promitor soluble corn fiber|12g in dinner bar, 11g in breakfast bar
62723066|NCT01233024|EXPERIMENTAL|FiberSym resistant starch|12g in dinner bar, 11g breakfast bar
62723067|NCT01233024|EXPERIMENTAL|Orafti P95 fructooligosaccharide|12g in dinner bar, 11g in breakfast bar
62723068|NCT01233024|EXPERIMENTAL|Orafti HPX inulin|12g in dinner bar, 11g in breakfast bar
62723069|NCT06139601|OTHER|Body empowerment intervention program|All study participants will complete a single session body empowerment program.
62723070|NCT06351839|ACTIVE_COMPARATOR|TAU control arm|The treatment-as-usual arm.
62723071|NCT06351839|EXPERIMENTAL|The Sleep-Well intervention|The study arm that receives the Sleep-Well intervention.
62723072|NCT02098304|OTHER|Sound and Unsound Molars|Imaging of unrestored sound molars (ICDAS 0), and third Molars (ICDAS 1,2 or 3) with the Calcivis Caries Activity Imaging System
62723073|NCT06082804|EXPERIMENTAL|A: IPA group|Patients in arm A are followed by the advanced practice nurse and the hematologist.
62723074|NCT06082804|ACTIVE_COMPARATOR|B: Control group|Patients in arm B are followed by the hematologist only (standard of care).
62723075|NCT01267474|EXPERIMENTAL|Nutritional education|
62723076|NCT01267474|NO_INTERVENTION|Control|
62723077|NCT00827814|EXPERIMENTAL|Dutasteride|
62723078|NCT00853892|EXPERIMENTAL|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
62723079|NCT00853892|ACTIVE_COMPARATOR|B|OxyContin® 40 mg tablet
62723080|NCT01490918|PLACEBO_COMPARATOR|Acarbose placebo, Metformin, Sitagliptin|The Acarbose placebo should be changed into real Acarbose from the 16th week.
62723081|NCT01490918|EXPERIMENTAL|Sitagliptin, Metformin, Acarbose|Metformin, Sitagliptin, Acarbose group
62723082|NCT01490918|OTHER|Metformin placebo, Sitagliptin, Acarbose|The Metformin placebo should be changed into real Metformin from the 16th week.
62723083|NCT02592278|EXPERIMENTAL|Fluoride Varnish each 6 months|Fluoride Varnish application every 6 months.
62723084|NCT02592278|EXPERIMENTAL|Fluoride Varnish each 3 months|Fluoride Varnish application every 3 months.
62723085|NCT02592278|ACTIVE_COMPARATOR|Fluoride tooth paste|Control group. Twice a day brush with fluoride toothpaste.
62723086|NCT04718350|ACTIVE_COMPARATOR|Intravenous administration of Levosimendan at a dosage of 6 mcg/kg after induction of anesthesia|in this group, 6 mcg/kg of levosimendan will be administered intravenously after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
62723087|NCT04718350|ACTIVE_COMPARATOR|Inhalational administration of Milrinone at a dosage of 50 mcg/kg after induction of anesthesia|in this group, 50 mcg/kg of milrinone will be administered via inhalation after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
62723088|NCT02054975|EXPERIMENTAL|vitamin D2 + vitamin D3|Vitamin D2 50,000 IU each week x 4 + vitamin D3 4,000 IU each day for 3 months
62723089|NCT02054975|ACTIVE_COMPARATOR|Vitamin D lower dose|800 IU vitamin D3 by mouth each day for 3 months
62723090|NCT00664482|EXPERIMENTAL|1|AGS-006
62723091|NCT01406600|ACTIVE_COMPARATOR|rhCG 250mcg|For final oocyte maturation triggering in ART, rhCG 250mcg will be administrated.
62723092|NCT01406600|EXPERIMENTAL|rhCG 500mcg|For final oocyte maturation triggering in ART, rhCG 500mcg will be administrated.
62723093|NCT01862081|EXPERIMENTAL|Arm A: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
62723094|NCT01862081|EXPERIMENTAL|Arm B: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.
62723095|NCT01862081|EXPERIMENTAL|Arm C: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
62723096|NCT01862081|EXPERIMENTAL|Arm D: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
62723097|NCT01862081|EXPERIMENTAL|Arm E: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
61978200|NCT00728780|ACTIVE_COMPARATOR|B|ABT-335 135mg and rosuvastatin 15mg
62723098|NCT01862081|EXPERIMENTAL|Arm F: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
62723099|NCT01862081|EXPERIMENTAL|Arm G: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
62723100|NCT02405299|EXPERIMENTAL|Experimental Group|neuropsychological reeducation disorder specific of inhibition (bottom-up and top-down protocol): 24 bi-weekly sessions (30 subjects)
62723101|NCT02405299|PLACEBO_COMPARATOR|Control Group|non-specific and general cognitive neuropsychological reeducation (comprehension, syntactic, visuospatial) : 24 bi-weekly sessions (30 subjects)
62723102|NCT06239038|EXPERIMENTAL|scalpel group|"Proceed with following step~1. Using electrocautery for stop bleeding at subcutaneous tissue layer~2. In deep layer still use scalpel for Remove anterior cruciate ligament and posterior cruciate ligament~3. Soft tissue removal and synovial tissue removal~4. No patellar denervation"
62723103|NCT06239038|EXPERIMENTAL|electrocautery group|"Using an electrocautery in following step~1. Stop bleeding at subcutaneous tissue layer~2. Remove anterior cruciate ligament and posterior cruciate ligament~3. Bony mark for further bone cut~4. Patellar denervation~5. Soft tissue removal~6. Synovial tissue removal"
62723104|NCT01908140|EXPERIMENTAL|Aclidinium Bromide / Formoterol Fumarate|Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
62723105|NCT01908140|ACTIVE_COMPARATOR|Salmeterol / Fluticasone propionate|Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
62723106|NCT00616642|EXPERIMENTAL|Group 1 (ACTH-secreting adenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.
62723107|NCT00616642|EXPERIMENTAL|Group 2 (non-secreting macroadenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.
62723108|NCT05827289|EXPERIMENTAL|CAPABLE cohort|Group that receives the CAPABLE application during treatment
62723109|NCT02748681|ACTIVE_COMPARATOR|Telemedicine Group|Patient group with a telemedicine monitoring system
62723110|NCT02748681|ACTIVE_COMPARATOR|Standard Group|Patient Group without a telemedicine monitoring
62723111|NCT05017870|EXPERIMENTAL|KSR-001-01|Participants received KSR-001-01 for 6 days.
62723112|NCT05017870|EXPERIMENTAL|KSR-001-02|Participants received KSR-001-02 for 6 days.
62723113|NCT05017870|EXPERIMENTAL|KSR-001-03|Participants received KSR-001-03 for 6 days.
62723114|NCT05017870|PLACEBO_COMPARATOR|KSR-001-04|Participants received KSR-001-04 for 6 days.
62723115|NCT05715658|EXPERIMENTAL|Evaluating the pharmacokinetics of dabigatran etexilate in elderly healthy subjects|Adult healthy subjects and elderly healthy subjects only took one 110mg dabigatran etexilate capsule orally, and elderly patients with atrial fibrillation took dabigatran etexilate according to routine medical care.
62723116|NCT04240106|EXPERIMENTAL|Niraparib in combination with Aromatase Inhibitors|Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib orally, once daily, flat- fixed, continuously in 28-day cycles plus aromatase Inhibitors.
62723117|NCT02269696|EXPERIMENTAL|Metoprolol|Metoprolol infusion
62723118|NCT02269696|PLACEBO_COMPARATOR|Normal saline|Equal volume of saline.
62723119|NCT03801928||Ulcerative Colitis|Group treated with Inflectra for Ulcerative Colitis
62723120|NCT03801928||Crohn's Disease|Group treated with Inflectra for Crohn's Disease
62723121|NCT01339936|EXPERIMENTAL|Investigational eye drop|Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
62723122|NCT00366210|EXPERIMENTAL|Expanded CI therapy|3.5 hours of training for the more-affected arm set in the laboratory for 15 consecutive weekdays
62723123|NCT00366210|PLACEBO_COMPARATOR|Placebo Control|Stretching, movement exercises, and EMG biofeedback for the same duration as the experimental intervention.
62723124|NCT00366210|NO_INTERVENTION|Usual & Customary Care Control|Treatments available to participants as part of their regular medical care, such as conventional physical or occupational therapy. For some participants, this would involve no treatment, since all participants were more than one year post stroke.f standard clinical care.
62723125|NCT00983034|ACTIVE_COMPARATOR|Membranous nephropathy|Patients with primary membranous nephropathy diagnosed by biopsy
62723126|NCT00983034|ACTIVE_COMPARATOR|IgA nephropathy|Patients with IgA nephropathy diagnosed by biopsy
62723127|NCT00983034|ACTIVE_COMPARATOR|Focal segmental glomerulosclerosis|Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
62723128|NCT04734158||Healthy control|
62723129|NCT04734158||Diabetics with macular edema|
62723130|NCT04734158||Diabetics without macular edema|
62723131|NCT03420144|ACTIVE_COMPARATOR|Standard Medical Therapy|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
62723132|NCT03420144|ACTIVE_COMPARATOR|Growth hormone|Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.
62723133|NCT04348071|EXPERIMENTAL|Ruxolitinib|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
62723134|NCT00839566|EXPERIMENTAL|AV ablation|
62723135|NCT00839566|ACTIVE_COMPARATOR|Rate control|Rate control by drugs
62723136|NCT00839566|NO_INTERVENTION|Sinus rhythm|
62723137|NCT04389866|EXPERIMENTAL|Both Jawline and Lateral (Zygomatic) Cheek Area Injections|JUVÉDERM VOLUMA™ XC 1-3 syringes (each syringe is 1 cc) will be injected bilaterally into the lateral cheek (zygomatic) area plus JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation). Total syringes used per person will have a range of 2-5)
62723138|NCT04389866|EXPERIMENTAL|Jawline Injections|JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected bilaterally into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation). Total syringes used per person will have a range of 1-2)
62723139|NCT04846231|ACTIVE_COMPARATOR|Rosuvastatin|5 mg once per day
62723140|NCT04846231|PLACEBO_COMPARATOR|Placebo|comparable to rosuvastatin 5 mg once per day
62723141|NCT04846231|ACTIVE_COMPARATOR|Fish Oil|Nature Made 2 soft gels per day
62723142|NCT04846231|ACTIVE_COMPARATOR|Cinnamon|1200mg, 2 capsules per day
62723143|NCT04846231|ACTIVE_COMPARATOR|Garlique|Manufactured by Focus Consumer Health Marketgate,1 tablet per day
62723144|NCT04846231|ACTIVE_COMPARATOR|Turmeric|Bio Schwartz Turmeric Curcumin 1500 mg, 3 capsules per day
62723145|NCT04846231|ACTIVE_COMPARATOR|Plant Sterol|Nature Made CholestOff Plus, 2 soft gels twice a day
62723146|NCT04846231|ACTIVE_COMPARATOR|Red Yeast Rice|Arazo Nutrition 1200 mg, 2 capsules per day
62723147|NCT06420193|EXPERIMENTAL|Condition 1|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression).
62723148|NCT06420193|EXPERIMENTAL|Condition 2|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness).
62723149|NCT06420193|EXPERIMENTAL|Condition 3|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance).
62723150|NCT06420193|EXPERIMENTAL|Condition 4|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance); Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness).
62723151|NCT06420193|EXPERIMENTAL|Condition 5|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs).
62723152|NCT06420193|EXPERIMENTAL|Condition 6|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs); Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness).
62723153|NCT06420193|EXPERIMENTAL|Condition 7|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance).
62723154|NCT06420193|EXPERIMENTAL|Condition 8|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance); Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness)
62723155|NCT06420193|EXPERIMENTAL|Condition 9|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values).
62723156|NCT06420193|EXPERIMENTAL|Condition 10|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values); Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness).
62723157|NCT06420193|EXPERIMENTAL|Condition 11|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance).
62723158|NCT06420193|EXPERIMENTAL|Condition 12|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance); Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness).
62723159|NCT06420193|EXPERIMENTAL|Condition 13|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs).
62723160|NCT06420193|EXPERIMENTAL|Condition 14|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs); Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness).
62723161|NCT06420193|EXPERIMENTAL|Condition 15|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance)
62723162|NCT06420193|EXPERIMENTAL|Condition 16|Feeling component of ASCENT (psychoeducation about AYA cancer survivorship and depression); Doing component of ASCENT (an adaptation of behavioral activation that aims to help AYAs engage in enjoyable activities, achieve their goals, and live in accordance with their values); Thinking component of ASCENT (an adaptation of cognitive restructuring that aims to help AYAs identify, evaluate, and restructure their negative automatic thoughts and core beliefs); Being component of ASCENT (an adaptation of mindfulness training that aims to help AYAs maintain contact with the present moment with an attitude of acceptance); and Positivity component of ASCENT (an adaptation of a suite of evidence-based positive psychology interventions that aims to help AYAs savor the good things in life, use their strengths, and practice gratitude and kindness)
62723163|NCT05703217|ACTIVE_COMPARATOR|classical physical therapy and rehabilitation program|In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
62723164|NCT05703217|ACTIVE_COMPARATOR|virtual reality assisted walking and balance exercise program|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds.
62723165|NCT01182298||Hepatitis C|latino participants with Hepatitis C
62723166|NCT01615744||Surgical ORIF calcaneal fx|
62723167|NCT01615744||Conservative treatment calcaneal fx|
62723168|NCT03037866|EXPERIMENTAL|LifeSkills Training for College|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the intervention group (n=2000) will participate in the LST program adapted for college which consists of six 30-minute online sessions (content-specific instruction and skills building activities along with opportunities to apply newly acquired knowledge and practice new skills) and three 60-minute small groups sessions (facilitator-led sessions with fellow incoming students that complement the online modules).
62723169|NCT03037866|NO_INTERVENTION|Treatment as Usual (Control)|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
62723170|NCT00873925|EXPERIMENTAL|Autologous UCB Plus Vit D Omega 3 FA|A single autologous (self) intravenous umbilical cord blood infusion followed by 1 year of daily Vitamin D and Omega 3 Fatty Acid supplementation give as liquid drops and gel capsules that can be swallowed or added to food
62723171|NCT00873925|NO_INTERVENTION|Control|Subjects randomized to be controls will continue to use intensive insulin therapy in order to compare c-peptide production at 1 year in those receiving combination therapy vs those who do not
62723172|NCT01948479|EXPERIMENTAL|Insole optimised with inshoe analysis|
62723173|NCT01948479|ACTIVE_COMPARATOR|Routine insole provision|
62723174|NCT04339413|EXPERIMENTAL|SCarlet RoAD|Participants enrolled from the open label extension (OLE) part of parent study WN25203, received gantenerumab, up to 1200 milligram (mg), subcutaneous (SC) injection, every 4 weeks (Q4W) for up to 129 weeks.
62723175|NCT04339413|EXPERIMENTAL|Marguerite RoAD|Participants enrolled from the OLE part of parent study WN28745, received gantenerumab, up to 1200 mg, SC injection, Q4W for up to 129 weeks.
62723176|NCT02176629|EXPERIMENTAL|Condition virtual reality (VR)|The subject is placed in front of a Barcotm screen capable of displaying high quality images.
62723177|NCT02176629|ACTIVE_COMPARATOR|Condition classic cognitive stimulation (CSC)|It is proposed about using the test dam Zazzo suitable for elderly. This classic test measures sustained attention.
62723178|NCT02193997|EXPERIMENTAL|Fiber 1|Fiber bar containing inulin as fiber soucre taken once daily for 4 weeks
62723179|NCT02193997|EXPERIMENTAL|Fiber 2|Fiber bar containing soluble corn as fiber soucre taken once daily for 4 weeks
62723180|NCT02193997|PLACEBO_COMPARATOR|Placebo|Bar with low fiber content (placebo) once daily for 4 weeks
62723181|NCT02306811|EXPERIMENTAL|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
62723182|NCT02306811|EXPERIMENTAL|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
62723183|NCT02306811|EXPERIMENTAL|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
62723184|NCT02306811|EXPERIMENTAL|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
62723185|NCT05822154||elderly subjects|subjects aged 65 years and over
62723186|NCT02580877|EXPERIMENTAL|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
62723187|NCT02580877|EXPERIMENTAL|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
62723188|NCT04750486|NO_INTERVENTION|Control|No intervention, the patient will be provided routine care at time of epidural placement without use of sequential compression devices.
62723189|NCT04750486|EXPERIMENTAL|Lower Extremity Compression|Patients will have sequential compression devices prior to epidural placement, and maintained for at least one hour following procedure.
62723190|NCT03506620|PLACEBO_COMPARATOR|Control|Subjects will be randomized to receive a single-injection QL block with normal saline (Saline Solution for Injection).
62723191|NCT03506620|EXPERIMENTAL|QL Block|Subjects will be randomized to receive a single-injection QL block with either local anesthetic (0.25% Ropivacaine injection).
62723192|NCT01771874|EXPERIMENTAL|MDMA, bupropion, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject. The four treatment conditions are placebo-placebo, bupropion-placebo, placebo-MDMA, and bupropion-MDMA.
62723193|NCT05833412||Suspected sepsis|These patients will undergo molecular diagnosis by performing the Septicyte Rapid® test on whole blood (EDTA) which allows to know the risk of sepsis (low, intermediate, high) and after 6-8 hours of blood culture incubation, filmarrays blood culture identification (BCID2®) a molecular test approved for direct identification of BSI causing pathogens from blood culture will be performed.
62723194|NCT03679364||LUOTAI group|LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.
62723195|NCT03679364||Control group|Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.
62723196|NCT00726128||VueLock™ Anterior Cervical Plate Group|VueLock™ Anterior Cervical Plate, Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
62723197|NCT01102920|EXPERIMENTAL|Tailored behavioural treatment and CPAP|Tailored behavioural treatment targeting physical activity and eating habits.
62723198|NCT01102920|ACTIVE_COMPARATOR|CPAP-treatment|CPAP-treatment as usual. Advice about benefits of physical activity and weight loss.
62723199|NCT03103854|ACTIVE_COMPARATOR|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
62723200|NCT03103854|EXPERIMENTAL|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
62723201|NCT03103854|EXPERIMENTAL|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
62723202|NCT03103854|EXPERIMENTAL|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
62723203|NCT03007030|EXPERIMENTAL|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62723204|NCT01397227|EXPERIMENTAL|Cohort 1 (Low Dose)|Ad35.CS.01/Ad26.CS.01 - 1 x 10\^10 vp
62723205|NCT01397227|EXPERIMENTAL|Cohort 2 (High Dose)|Ad35.CS.01/Ad26.CS.01 - 5 x 10\^10 vp
62723206|NCT01397227|PLACEBO_COMPARATOR|Cohort 1 - Placebo|
62723207|NCT01397227|PLACEBO_COMPARATOR|Cohort 2 - Placebo|
62723208|NCT01369043|ACTIVE_COMPARATOR|Vitamin E and Vitamin C|4 weeks with Vitamin E and Vitamin C supplementation with no exercise and 4 weeks of supplementation with prescribed exercise.
62723209|NCT01369043|NO_INTERVENTION|Placebo|Placebos instead of the Vitamin E and Vitamin C supplements
62723210|NCT04173182||Inflammation on pCLE|Patients with inflammatory findings in the peridiverticular and colonic mucosa (crypt fusion and distortion, bright epithelium, and dilated-prominent branching vessels)
62723211|NCT04173182||No inflammation on pCLE|Patients with normal findings on pCLE evaluation of the peridiverticular and colonic mucosa (absence of inflammation)
62723212|NCT04023292|EXPERIMENTAL|Arm I (2 weeks preoperative endocrine therapy))|Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
62723213|NCT04023292|ACTIVE_COMPARATOR|Arm II (4 weeks preoperative endocrine therapy)|Patients receive endocrine therapy before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
62723214|NCT04859101|EXPERIMENTAL|Gum|Group 1 will receive gum immediately prior to transport to the operating room. They will be asked to chew the gum for 2 minutes and then spit the gum in the garbage.
62723215|NCT04859101|OTHER|Control|Group 2 will not receive any gum. They will be asked to swallow twice and have no other intervention.
62723216|NCT01193452|EXPERIMENTAL|S-1/LV|S-1 combined with Leucovorin
62723217|NCT01193452|ACTIVE_COMPARATOR|sLV5FU2|5-FU/LV infusion
62723218|NCT03951285|EXPERIMENTAL|NR|"One intervention includes healthy BMI-discordant monozygotic twin pairs, which both are treated with NR. With this unique model, the investigators obtain the information on how beneficial NR is in two different BMI classes (obese and leaner) with an identical genomic background.~The final dose for NR will be 1 g/day. The daily NR dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full NR dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
62723219|NCT03951285|PLACEBO_COMPARATOR|Placebo|"The second intervention includes monozygotic twins concordant for body weight. It's randomized which member of the twin pair is treated with NR while the other co-twin gets placebo.~The final dose for placebo will be 1 g/day. The daily placebo dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full placebo dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
62723220|NCT00815386|EXPERIMENTAL|PTMA implanted|Enrolled patients receiving a PTMA implant
62723221|NCT04222192|SHAM_COMPARATOR|Conventional Epidural application|Epidural catheter insertions with conventional (anatomical landmarks use) method
62723222|NCT04222192|ACTIVE_COMPARATOR|Paramedian sagittal application|Epidural catheter insertions with real time ultrasound guided Paramedian sagittal approach
62723223|NCT04222192|ACTIVE_COMPARATOR|Transverse Interlaminar application|Epidural catheter insertions with real time ultrasound guided Transverse Interlaminar approach
62723224|NCT01735305||Antiplatelet therapy|patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.
62723225|NCT01773928|EXPERIMENTAL|VCIV - Modified manufacturing process (18-49 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
62723226|NCT01773928|EXPERIMENTAL|VCIV - Modified manufacturing process (18-49 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
62723227|NCT01773928|EXPERIMENTAL|VCIV - Modified manufacturing process (18-49 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
62723228|NCT01773928|ACTIVE_COMPARATOR|VCIV manufactured with current process (18-49 Years Old)|Vero cell-derived trivalent influenza vaccine (VCIV)
62723229|NCT01773928|ACTIVE_COMPARATOR|Fluzone® (18-49 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
62723230|NCT01773928|EXPERIMENTAL|VCIV - Modified manufacturing process (≥50 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
62723231|NCT01773928|EXPERIMENTAL|VCIV - Modified manufacturing process (≥50 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
62723232|NCT01773928|EXPERIMENTAL|VCIV - Modified manufacturing process (≥50 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
62723233|NCT01773928|ACTIVE_COMPARATOR|Fluzone® (≥50 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
62723234|NCT04420858|OTHER|Control|The control arm will receive standard education about cell-free DNA screening that would typically be presented during a prenatal visit.
62723235|NCT04420858|EXPERIMENTAL|Experimental|The experimental arm will receive additional education about federal legislation that protects the privacy of genetic information (Genetic Information Nondiscrimination Act, GINA).
62723236|NCT01881789|EXPERIMENTAL|Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
62723237|NCT01881789|EXPERIMENTAL|Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 180 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
62723238|NCT01881789|EXPERIMENTAL|Oprozomib 210 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
62723239|NCT01881789|EXPERIMENTAL|Oprozomib 210 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
62723240|NCT01881789|EXPERIMENTAL|Oprozomib 240 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
62723241|NCT01881789|EXPERIMENTAL|Oprozomib 210 mg 2/7 + Cyclophosphamide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with oral cyclophosphamide 300 mg/m² on days 1, 8, and 15 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 8 cycles, whichever occurred first. After completing 8 cycles of treatment, participants with stable disease or better were to continue on oprozomib with dexamethasone premedication for a total of 24 cycles or until progression of disease or unacceptable toxicity. After completing 24 cycles of treatment, participants without evidence of disease progression could have continued on oprozomib with or without dexamethasone pretreatment.
62723242|NCT03117114|OTHER|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
62723243|NCT03117114|ACTIVE_COMPARATOR|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
62723244|NCT06151470|OTHER|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62723245|NCT06151470|OTHER|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
62723246|NCT01109186||kidney-transplanted patients|
62723247|NCT02607410|ACTIVE_COMPARATOR|sitagliptin|100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
62723248|NCT02607410|ACTIVE_COMPARATOR|NPH insulin|NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
62723249|NCT01323985|EXPERIMENTAL|GSK2315698|Intravenous infusion single dose
62723250|NCT06393803|EXPERIMENTAL|KH607 Cohort 1|Subject received a single KH607 tablets dose of 2mg KH607 tablets or matching placebo.
62723251|NCT06393803|EXPERIMENTAL|KH607 Cohort 2|Subject received a single KH607 tablets dose of 5mg KH607 tablets or matching placebo.
62723252|NCT06393803|EXPERIMENTAL|KH607 Cohort 3|Subject received a single KH607 tablets dose of 10mg KH607 tablets or matching placebo.
62723253|NCT06393803|EXPERIMENTAL|KH607 Cohort 4|Subject received a single KH607 tablets dose of 20mg KH607 tablets or matching placebo.
62723254|NCT06393803|EXPERIMENTAL|KH607 Cohort 5|Subject received a single KH607 tablets dose of 30mg KH607 tablets or matching placebo.
62723255|NCT06393803|EXPERIMENTAL|KH607 Cohort 6|Subject received a single KH607 tablets dose of 40mg KH607 tablets or matching placebo.
62723256|NCT06393803|EXPERIMENTAL|KH607 Cohort 7|Subject received a single KH607 tablets dose of 50mg KH607 tablets or matching placebo.
62723257|NCT06393803|EXPERIMENTAL|KH607 Cohort 8|Subject received a single KH607 tablets dose of 60mg KH607 tablets or matching placebo.
62723258|NCT06393803|EXPERIMENTAL|KH607 Cohort 9|Subject received 10mg KH607 or matching placebo, oncely daily from Day 1 to Day 7.
62723259|NCT06393803|EXPERIMENTAL|KH607 Cohort 10|Subjects receive 20mg KH607 or matching placebo, once daily from Day 1 to Day 7.
62723260|NCT06393803|EXPERIMENTAL|KH607 Cohort 11|Subjects receive 30mg KH607 or matching placebo, once daily from Day 1 to Day 7.
62723261|NCT01518387|EXPERIMENTAL|Arm 1|750-2250mg/day, tid, 8 weeks
62723262|NCT02339805|EXPERIMENTAL|next generation sequencing|Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
62723263|NCT06307392|EXPERIMENTAL|Endotracheal tube plus bougie|
62723264|NCT06307392|ACTIVE_COMPARATOR|Endotracheal tube alone|
62723265|NCT01495325|SHAM_COMPARATOR|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
62723266|NCT01495325|ACTIVE_COMPARATOR|Woodsmoke Exposure|1 hour exposure to dilute woodsmoke at a concentration of 1000µg/m3 during intermittent exercise
62723267|NCT03680885|ACTIVE_COMPARATOR|Reports getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
62723268|NCT03680885|ACTIVE_COMPARATOR|Reports trouble getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
62723269|NCT05160363|EXPERIMENTAL|PYR and PQP Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - \<65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - \<75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg
62723270|NCT05160363|PLACEBO_COMPARATOR|PYR and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - \<65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Matched placebo for piperaquine (3 or 4 tablets based on body weight)
62723271|NCT05160363|PLACEBO_COMPARATOR|PQP and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - \<75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg Matched placebo for pyronaridine (3 or 4 tablets based on body weight)
62723272|NCT05160363|SHAM_COMPARATOR|Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Matched placebo for pyronaridine (3 or 4 tablets dependent on body weight) and matched placebo piperaquine (3 or 4 tablets dependent on body weight)
62723273|NCT00192543|ACTIVE_COMPARATOR|case|diet of fish and fruit addition compared to regular diet
62723274|NCT00192543|PLACEBO_COMPARATOR|control|regular diet
62723275|NCT06307249|EXPERIMENTAL|Carrier First-line Combined Therapy Group C-FL-CT|This group of patients, who are carriers of the risk alleles, will receive combined therapy as the initial first-line treatment without prior chemotherapy.
62723276|NCT06307249|EXPERIMENTAL|Carrier Second-line Combined Therapy Group C-SL-CT|This group of patients, who are carriers of the risk alleles, will receive combined therapy after having undergone prior chemotherapy, making it the second-line treatment.
62723277|NCT06307249|EXPERIMENTAL|Non-carrier First-line Combined Therapy Group NC-FL-CT|This group of patients, who are non-carriers of the risk alleles, will receive combined therapy as the initial first-line treatment without prior chemotherapy.
62723278|NCT06307249|EXPERIMENTAL|Non-carrier Second-line Combined Therapy Group NC-SL-CT|This group of patients, who are non-carriers of the risk alleles, will receive combined therapy after having undergone prior chemotherapy, making it the second-line treatment.
62723279|NCT02240121|EXPERIMENTAL|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
62723280|NCT02240121|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
62723281|NCT03368196|EXPERIMENTAL|DS-8201a|DS-8201a administered by intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W)
62723282|NCT01731795|NO_INTERVENTION|No dexamethasone|Patients will be treated with conventional treatment
62723283|NCT01731795|ACTIVE_COMPARATOR|Dexamethasone|Conventional treatment plus dexamethasone
62723284|NCT00932035|EXPERIMENTAL|Arm I (reverse mapping guided axillary lymph node dissection)|Patients receive isosulfan blue dye SC and then undergo reverse mapping-guided axillary lymph node dissection.
62723285|NCT00932035|ACTIVE_COMPARATOR|Arm II (control)|Patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye SC.
62723286|NCT06426446|EXPERIMENTAL|Connected scale|Patients receiving connected scale
62723287|NCT01762683|EXPERIMENTAL|pre-conceptional obesity with a scheduled cesarean section|
62723288|NCT01762683|ACTIVE_COMPARATOR|non-obese women with a scheduled cesarean section|
62723289|NCT01762683|ACTIVE_COMPARATOR|women entering labour|women entering labour for vaginal delivery and for vaginal delivery
62723290|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
62723291|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
62723292|NCT06136143|ACTIVE_COMPARATOR|Group 1: Autogenous bone graft|The maxillary sinus will treated with autogenous bone graft.
62723293|NCT06136143|EXPERIMENTAL|Group 2: Plenum® Osshp|The maxillary sinus will treated with Plenum® Osshp.
62723294|NCT06136143|EXPERIMENTAL|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will treated with Plenum® Osshp associated with i-PRF (i-PR - injectable platelet-rich fibrin).
62723295|NCT06136143|EXPERIMENTAL|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will treated with Plenum® Osshp associated with autogenous bone graft.
62723296|NCT02625220|EXPERIMENTAL|Prototype toric lens senofilcon A|Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.
62723297|NCT05249205|NO_INTERVENTION|Control|Participants in the control group will be asked to maintain their regular lifestyle for the duration of the study. They will not receive an intervention.
62723298|NCT05249205|EXPERIMENTAL|REHIT1|Participants in the REHIT1 group will perform a single REHIT session per week for 6 weeks.
62723299|NCT05249205|EXPERIMENTAL|REHIT2|Participants in the REHIT2 group will perform 2 REHIT sessions per week for 6 weeks.
62723300|NCT03612089||Low back pain group|Individuals with non-specific chronic low back pain
62723301|NCT03612089||Healthy control group|Healthy individuals without low back pain
62723302|NCT03261895|EXPERIMENTAL|Intervention group|Nurse-led Integrative health and wellness programme
62723303|NCT03261895|NO_INTERVENTION|control group|usual diabetes care
62723304|NCT03767465||PembroHIV|HIV-infected subjects with advanced melanoma or other oncological conditions in which the use of immunological checkpoint inhibitors is clinically indicated
62723305|NCT05452252||study group|adolescents with idiopathic scoliosis
62723306|NCT05452252||control group|healthy individuals
62723307|NCT05295264|EXPERIMENTAL|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy and published by Barakat model.~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
62736224|NCT06154148|ACTIVE_COMPARATOR|Traditional prone position|The infants are placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
62165947|NCT04889833|EXPERIMENTAL|Hypnosis Therapy Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, \& shoulder function. 7 days before surgery, they will receive a pre-recorded video (\~19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Before \& after the video, they will rate pain/anxiety levels. On the day of surgery, they will watch the video again \& answer questions about their average anxiety and pain level. After surgery, they will watch the video each day and report on pain/anxiety, medication use, satisfaction, and sleep disturbance until postoperative day 7. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication \& study doctor will be the same as any shoulder arthroplasty patient regardless of study participation.
62723308|NCT05295264|NO_INTERVENTION|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
62168153|NCT04765540|EXPERIMENTAL|T2: BAU + Low Intensity Nudges|"T1 plus a bundle of 'low-intensity' passive interventions, including:~* Large mirrors installed above handwashing station sinks to attract more people to the station~* 7 to 8 large hand-shaped signposts pointing to the station and leading up to the station, placed on the ground in the vicinity of the station, starting from the nearest 'busy spot'"
62723309|NCT06282718||POS-ARI-PC|"POS-ARI-PC AUDIT:~Anonymous registration of patients of any age presenting at the participating primary care facility with ARI.~POS-ARI-PC CORE:~Patients of any age presenting at the participating primary care facility with ARI.~POS-ARI-PC-001:~Patients 60 and over, or aged 50 to 59 years and have a long-term health condition which makes them eligible for the yearly influenza vaccination under the national influenza vaccination programme, presenting at the participating primary care facility with ARI."
62723310|NCT05807412|EXPERIMENTAL|Experimental half|Each subject will be randomized to have either their right forehead or left forehead treated with 4 units or 0.1 cc of prabotulinumtoxinA 2.5 cm above the orbital rim.
62723311|NCT05807412|ACTIVE_COMPARATOR|Comparator half|Each subject will be randomized to have either their right forehead or left forehead treated with 4 units or 0.1 cc of onabotulinumtoxinA 2.5 cm above the orbital rim.
62723312|NCT02025998|EXPERIMENTAL|Ibudilast|Ibudilast will be administered for 7 days at the target dose of 50 mg/bid
62723313|NCT02025998|PLACEBO_COMPARATOR|Sugar pill|Placebo pills will be administered for 7 days and taken twice daily
62723314|NCT00570323|ACTIVE_COMPARATOR|ARM A / Arimidex with Faslodex|Arimidex with Faslodex in postmenopausal women
62723315|NCT00570323|ACTIVE_COMPARATOR|ARM B Arimidex without Faslodex|Arimidex without Faslodex in postmenopausal women.
62723316|NCT00752492|ACTIVE_COMPARATOR|Study intervention|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. Ventilation will be assisted to maintain tidal volume of 8-10 mL/kg and respiratory rate of 20-25 breaths per minute to achieve minute ventilation of 15-20 L/min. Isocapnia manifold will maintain end-tidal PCO2 in range of 40-50 mm Hg.
62723317|NCT02311881|EXPERIMENTAL|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (\~ 240 mL) of water/dose for 12 weeks.
62723318|NCT02311881|ACTIVE_COMPARATOR|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (\~ 240 mL) of water/dose for 12 weeks.
62723319|NCT02311881|PLACEBO_COMPARATOR|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (\~ 240 mL) of water/dose for 12 weeks.
62723320|NCT01154491|PLACEBO_COMPARATOR|Placebo|Two placebos: placebo for ferric carboxymaltose and placebo for erythropoietin
62723321|NCT01154491|EXPERIMENTAL|FE|Ferric carboxymaltose and placebo for erythropoietin
62723322|NCT01154491|EXPERIMENTAL|EPOFE|Ferric carboxymaltose and erythropoietin
62723323|NCT02235571|NO_INTERVENTION|Control|These subjects are receiving standard patient education
62723324|NCT02235571|EXPERIMENTAL|iChoose Kidney Decision Aid|These subjects receive iChoose Kidney Decision Aid along with standard patient education
62723325|NCT06292377|EXPERIMENTAL|Stroke patients|Patients, hospitalized at the Stroke Unit of CHU Brugmann and UZ Brussel, after the clinical diagnosis of a first-ever ischemic stroke.
62723326|NCT03388541|ACTIVE_COMPARATOR|Dexmedetomidine|Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
62723327|NCT03388541|PLACEBO_COMPARATOR|Placebo|NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
62723328|NCT00912626|EXPERIMENTAL|FU-1 feedback|
62723329|NCT00912626|NO_INTERVENTION|control group|
62723330|NCT01160133|EXPERIMENTAL|Systane|Systane Lubricant Eye Drops
62723331|NCT01160133|EXPERIMENTAL|Refresh Tears|Refresh Tears Lubricant Eye Drops
62723332|NCT03018158|NO_INTERVENTION|dentulous|MR Imaging was collected with condition at the tongue at rest position.
62723333|NCT03018158|NO_INTERVENTION|edentulous without denture wear.|MR Imaging was collected without denture wear.
62723334|NCT03018158|EXPERIMENTAL|edentulous with denture wear.|MR Imaging was collected with denture wear.
62723335|NCT06295380|EXPERIMENTAL|Virtual environment practiced on the Caren|Caren virtual training phase plus conventional physiotherapy phase
62723336|NCT06295380|ACTIVE_COMPARATOR|Conventional physiotherapy|Conventional physiotherapy phase plus Caren virtual training phase
62723337|NCT02048995||Bipolar Depressed|Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
62723338|NCT02048995||Healthy Comparator|Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview
62723339|NCT06110559|EXPERIMENTAL|tDCS active comparator|Active transcranial Direct Current Stimulation (tDCS): Stimulation of 1.5 mA for 30 minutes.
62723340|NCT06110559|SHAM_COMPARATOR|tDCS sham comparator|Sham transcranial Direct Current Stimulation (tDCS): Effective stimulation of 1.5 mA for 30 seconds, then the current is switched off. The complete session lasts 30 minutes, with 29 minutes and 30 seconds without stimulation.
62723341|NCT03540420|EXPERIMENTAL|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
62723342|NCT03540420|NO_INTERVENTION|Observation|standard care after completed chemo-radiotherapy and non-progression
62723343|NCT03631264|EXPERIMENTAL|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
62723344|NCT03631264|NO_INTERVENTION|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
62723345|NCT03317743|EXPERIMENTAL|NOV140101 (IDX-1197)|
62723346|NCT05409703|EXPERIMENTAL|The Effect of Reiki on Executive Nurses on Psychological Empowerment, Happiness|Reiki application will take 45 minutes.
62723347|NCT05409703|NO_INTERVENTION|The Effect of Reiki on Executive Nurses on Emotion Management and Work Engagement|No treatment was applied to the patients in the control group other than their routine care.
62723348|NCT02701205|EXPERIMENTAL|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
62723349|NCT02701205|EXPERIMENTAL|etanercept (half dose)|One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®） 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
62723350|NCT02701205|PLACEBO_COMPARATOR|Placebo|Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 25mg twice a week from Week 12 to Week 24
62723351|NCT05655975|ACTIVE_COMPARATOR|upper gi endoscopy after rygb gastric bypass / weight loss|In all patients undergoing RYGB gastric bypass and success \> %50 EWL , an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
62723352|NCT05655975|ACTIVE_COMPARATOR|upper gi endoscopy after rygb gastric bypass / regain|In all patients undergoing RYGB gastric bypass and regain , an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
62723353|NCT01230320|EXPERIMENTAL|Simplified (S) technique|"Complete dentures fabricated according to a simplified technique, divided into the following four sessions:~1. Maxillary and mandibular casts will be obtained from irreversible hydrocolloid impressions made in stock trays.~2. Record bases will be adjusted according to vertical dimension and centric relation measurements, without facebow transfer. Casts will be mounted in a semi-adjustable articulator using standardized measures and artificial teeth will be selected.~3. Trial dentures will be evaluated for esthetics and maxillomandibular relationships.~4. Insertion of finished dentures."
62723354|NCT01230320|ACTIVE_COMPARATOR|Conventional (C) technique|"Complete dentures fabricated according to a conventional technique:~1. Initial impression and the obtainment of custom trays;~2. Final impression with border molding using compound;~3. Facebow transfer;~4. Determination of maxillomandibular relationship;~5. Try-in of anterior teeth;~6. Try-in of posterior teeth;~7. Insertion of finished dentures."
62723355|NCT05271942|EXPERIMENTAL|Tilt and Tumble|"The patients of this group will undergo cataract surgery using the Tilt and Tumble technique."
62723356|NCT05271942|ACTIVE_COMPARATOR|Divide and Conquer|"The patients of this group will undergo cataract surgery using the Divide and Conquer technique."
62723357|NCT00626535|EXPERIMENTAL|1|20mg once daily
62723358|NCT00626535|PLACEBO_COMPARATOR|2|Oral once daily
62723359|NCT04170088|EXPERIMENTAL|Tranexamic acid|"Left side of face of each participant was selected for intradermal Tranexamic acid injections.~generic name : Tranexamic acid Dose : 4mg / ml tranexamc acid diluted with 0.9 % normal saline Frequency : every 2 weekly total 6 doses. Duration : 6 months"
61976696|NCT06332651|EXPERIMENTAL|Lysine in milk or sorghum in older men|This group of 7 participants will have 3 test days where they consume milk with 3 different levels of lysine, they will have 3 test days where they consume sorghum with 3 different levels of lysine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of lysine.
62723360|NCT04170088|EXPERIMENTAL|0.9% Normal saline|Right side of face of each participant was selected for intradermal normal saline injections generic name : Normal Saline Dose : 0.9 % Normal Saline Dose : Frequency : every 2 weekly total 6 doses. Duration : 6 months
62723361|NCT03413904|EXPERIMENTAL|transanal TME|Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
62723362|NCT03413904|ACTIVE_COMPARATOR|laparoscopic TME|Procedure will consist in 1 team performing laparoscopic TME. Following stapled closure of the rectum below the tumor, and complete mobilization of the rectosigmoid, the specimen is extracted using a Pfannenstiel incision . A stapled (knight-Griffen) colorectal anastomosis or coloanal anastomosis will be created and a temporary diverting stoma will be fashioned which is standard of care following surgery for this type of cancer.
62723363|NCT03091088|ACTIVE_COMPARATOR|Control|walking at an intense pace
62723364|NCT03091088|EXPERIMENTAL|Experimental|osteoporosis specific-oriented training
62723365|NCT02414516|EXPERIMENTAL|OBP-801|
62723366|NCT06252844|EXPERIMENTAL|Intervention|Progressive resistance training (PRT) of lower limb muscles. Frequency of intervention: 2-3 times per week. Duration of intervention: 24 weeks.
62723367|NCT06252844|EXPERIMENTAL|Active control|Flexibility training of the lower limb muscles. Frequency of intervention: 2-3 times per week. Duration of intervention: 24 weeks.
62723368|NCT05609825|EXPERIMENTAL|LY3875383 (Part A)|Single-ascending doses of LY3875383 administered subcutaneously (SC).
62723369|NCT05609825|EXPERIMENTAL|LY3875383 (Part B)|Single doses of LY3875383 administered SC.
62723370|NCT05609825|EXPERIMENTAL|LY3875383 (Part C)|Single doses of LY3875383 administered SC.
62723371|NCT05609825|EXPERIMENTAL|LY3875383 (Part D)|Single doses of LY3875383 administered SC.
62723372|NCT05609825|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered SC.
62723373|NCT05609825|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered SC.
62723374|NCT05609825|PLACEBO_COMPARATOR|Placebo (Part C)|Placebo administered SC.
62723375|NCT05609825|PLACEBO_COMPARATOR|Placebo (Part D)|Placebo administered SC.
62723376|NCT04196725|EXPERIMENTAL|Physical therapy treatment|
62723377|NCT04196725|EXPERIMENTAL|Lifestyle treatment|
62723378|NCT04196725|NO_INTERVENTION|Control|Parallel control group, not undertaking any treatment and not part of the cross-over design
62723379|NCT02563145|EXPERIMENTAL|Real-time fMRI feedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 10 sessions of real-time fMRI feedback of insula- or amygdala activation (dependent on activation patterns during pre-testing), 1 session/week. Each session will last about 1 1/2 hours.~After training completion (10 weeks after the beginning of the treatment phase), subjects will undergo post-treatment assessment and follow up (6 months after the end of the training phase)."
62723380|NCT02563145|ACTIVE_COMPARATOR|Treatment as usual|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator TAU arm will receive several sessions of psychoeducation and counseling with their parents/caregivers or group training over 10 weeks.~Within the sessions, investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, subjects will undergo post-treatment assessment and follow up (6 months after the end of the treatment phase)."
62723381|NCT02563145|NO_INTERVENTION|Typically developing (TD) control group|Healthy typically developing subjects will only participate in pre-training assessment to allow for comparison.
62723382|NCT04157881|OTHER|APO-Dabigatran|Single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
61978201|NCT04599894|SHAM_COMPARATOR|control group|Oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
62723383|NCT04157881|OTHER|APO-Dabigatran and Rabeprazole|4-7 doses of rabeprazole followed by single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
62723384|NCT02394821|EXPERIMENTAL|Metronidazole|metronidazole 0.8% solution - topical
62723385|NCT02394821|EXPERIMENTAL|Polihexanide|Polihexanide 2%
62723386|NCT05911971|EXPERIMENTAL|Specific reeducation|Specific reeducation
62723387|NCT05911971|SHAM_COMPARATOR|Sham comparator|Sham reeducation
62723388|NCT04853914|EXPERIMENTAL|HIFU intervention|Patients will benefit of an HIFU treatment of their Benign Prostatic Hyperplasia.
62723389|NCT05977218|EXPERIMENTAL|Intervention|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping during 26 weeks.
62723390|NCT05977218|NO_INTERVENTION|Control|Access to written dietary advice during 26 weeks.
62723391|NCT02171143|EXPERIMENTAL|ASP2409 Dose Escalation|
62723392|NCT02171143|PLACEBO_COMPARATOR|Placebo Dose Escalation|
62723393|NCT04589897|EXPERIMENTAL|Experimental|Manuka honey sinus rinse
62723394|NCT04589897|ACTIVE_COMPARATOR|Standard|Standard sinus rinse
62723395|NCT01087593|EXPERIMENTAL|Treatment with transdermal 17β-estradiol|
62723396|NCT01087593|PLACEBO_COMPARATOR|Control|
62723397|NCT02450305||Treated with HBO|QOL questionnaires at 5 time points for those having HBO therapy at least one year post radiation therapy for head and neck cancer, daily x6 weeks
62723398|NCT02450305||Not treated with HBO|QOL questionnaires for those at least one year post radiation therapy for head and neck cancer at 5 times points.
62723399|NCT03436901|OTHER|Testicular cancer st. II-III|MRI with DWI vs CT
62723400|NCT04188249||RA patients|"Patients (or a representative) must provide informed consent before any procedures occur.~1. Main Inclusion Criteria:~   * 18 years and older~  * Fulfil the ACR/EULAR classification criteria for RA in 2010~  * Patients able to understand and complete self-evaluation questionnaires.~2. General Exclusion Criteria:~   * Contraindications for golimumab~  * Prior exposure to TNFi/JAKi"
62723401|NCT03938051|EXPERIMENTAL|Experimental group|Multi-component intervention
62723402|NCT03938051|EXPERIMENTAL|Control group|treadmill walk
62723403|NCT02827812|EXPERIMENTAL|Participants Telemedicine Care (PTE)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months~C. Home-Based telemedicine program:"
62723404|NCT02827812|ACTIVE_COMPARATOR|Participants Usual Care (PUC)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months"
62723405|NCT03423433|NO_INTERVENTION|Control condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography.~During the second two visits, participants will have either undergo a 180 minute seated protocol or a 180 minute heel raising protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes in both protocols, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout the 180 minutes. EMG will record muscle activation during heel raises after each 30 minutes.~Ten weeks after these sessions have been completed, participants will return to the laboratory for follow-up a session assessing resting measures in an identical protocol to the first visit."
62723406|NCT03423433|EXPERIMENTAL|Experimental (heel raise) condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography. During the second two visits, participants will have undergo a 180 minute seated or a 180 minute heel raise protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout. EMG will record muscle activation during heel raises after each 30 minutes.~Participants in this arm will be prescribed a ten-week heel-raise programme involving hourly heel raises. Ten weeks later, participants will return to the laboratory for follow-up sessions assessing resting measures in an identical protocol to the first visit."
62723407|NCT05086861|EXPERIMENTAL|Oesophageal Pacing Arm|Patients undergoing atrial fibrillation ablation to isolate the left atrial posterior wall via catheter or staged hybrid ablation.
62723408|NCT04179305|EXPERIMENTAL|Oncolo-GIST Arm - Patients|"Patients assigned to this arm will discuss scan results revealing progressive disease with an Oncolo-GIST trained physician.~Oncolo-GIST: Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis."
62723409|NCT04179305|PLACEBO_COMPARATOR|Usual Care Arm - Patients|"Patients assigned to this arm will will discuss scan results revealing progressive disease with a physician that was not trained with the Oncolo-GIST intervention.~Usual Care Arm: Oncologists will provide care in non-specific manner."
62723410|NCT04179305|EXPERIMENTAL|Oncolo-GIST Arm - Physicians|Physicians assigned to this arm will receive the Oncolo-GIST training intervention.
62723411|NCT04179305|PLACEBO_COMPARATOR|Usual Care Arm - Physicians|Physicians assigned to this arm will not receive the Oncolo-GIST training intervention.
62723412|NCT04357184|EXPERIMENTAL|BFRT with 4 exercises and low resistance loads|Blood flow resistance training will be performed with a standard blood pressure cuff that is placed and inflated by a clinician. The patient will perform 4 exercises with low resistance loads that will produce a muscle burn to enhance promotion of strength. Training will be supervised in the clinic. The cuff is deflated between exercises.
62723413|NCT04522934|EXPERIMENTAL|Pain Neuroscience Education|Patients received 24 sessions, in a 8-week period, of multimodal physiotherapy along with four sessions of pain neuroscience education.
62723414|NCT04522934|ACTIVE_COMPARATOR|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy along with four sessions of biomedical education.
62723415|NCT00652275|EXPERIMENTAL|A|"Biological/Vaccine: 189 volunteers will receive the Malaria vaccine MSP3 Long Synthetic Peptide (LSP)~Arms: MSP3 LSP vaccine Biological/Vaccine:MSP3 LSP 30 micrograms of MSP3 LSP~Arms: I, MSP3 LSP vaccine"
62723416|NCT00652275|ACTIVE_COMPARATOR|B|189 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
62723417|NCT04286152|EXPERIMENTAL|Mirabegron and narcotic analgesia|Drug: Mirabegron 50mg tablet, oral, daily from stent insertion until removal - 7days Drug: Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
62723418|NCT04286152|PLACEBO_COMPARATOR|Placebo|Drug: Placebo for Mirabegron, 1 tablet, oral, daily from stent insertion until removal - 7days Drug:Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
62723419|NCT00435630|OTHER|1|Completing simulator training sessions
62723420|NCT05731271|EXPERIMENTAL|Phase 1a Part - TST003 Dose Escalation|"TST003 administered every 3 weeks at increasing doses~1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg"
62723421|NCT05731271|EXPERIMENTAL|Phase 1b Part - Dose Expansion at Recommended Phase 2 dose|Administer TST003 every 3 weeks to patients with positive GREM1 tumor expression at the recommended Phase 2 Dose,
62723422|NCT06028828|EXPERIMENTAL|Patients with AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT|Patients will be treated with allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on their Hematopoietic Cell Transplant - Composite Risk (HCT-CR), age, and Karnofski performance status (KPS).
62723423|NCT04949945|EXPERIMENTAL|CHF patients who will receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients)(experimental group) will receive guided self help culturally adapted cognitive behavioral therapy.
62723424|NCT04949945|NO_INTERVENTION|CHF patients will not receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients) (control group) will not receive Self Help Culturally Cognitive Behavior Therapy.
62723425|NCT00720694|ACTIVE_COMPARATOR|Verum|"Device: Duolith SD1 (Storz Medical AG) - Focused Extracorporeal shock wave therapy.~The total energy flux density was increased continuously from 0.01 to 0.25 mJ/mm 2 within 500 introductory impulses. Thereafter, 2000 treatment impulses with 0.25 mJ/mm 2 (four impulses per second) were administered per session,and the interventionwas repeated up to a total of three sessions in weekly intervals."
62723426|NCT00720694|SHAM_COMPARATOR|Placebo / Sham|Sham Duolith SD1 (Storz Medical AG). The placebo group received identical sham intervention with an air- filled standoff that prevented the transmission of shock waves. The placebo handpiece was identical in design, shape, and weight to ensure that there was no way for the participants to identify the placebo handpiece.
62723427|NCT02948764|OTHER|single-arm study|This project is designed as a one-armed diagnostic study. Every patient included in the study will undergo the same diagnostic test, the vacuum-assisted biopsy, after NACT and before surgery according to guidelines.
62723428|NCT02835144|EXPERIMENTAL|TIQAAM_therapy|Individuals in this group will receive units from the TIQAAM treatment program
62723429|NCT02835144|ACTIVE_COMPARATOR|active_control|Individuals in this group will receive units of psychoeducation
62723430|NCT04698239|EXPERIMENTAL|Laser application ( BEFORE/AFTER)|"All patients will receive a maximum of 13 laser pulses in each lesion. We are going to make a comparison of the before and after the treatment, it is the patient himself who checks himself.~The number of lesions will be counted before treatment and after treatment(72-hour and 1-week ) . Adverse reactions will be collected at several visits as well, during the 2 weeks that the patient is included in the study."
62723431|NCT05123014|OTHER|ReLex Smile surgery|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery We used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with adenoviral keratitis.
62723432|NCT02757807|EXPERIMENTAL|Utilization of Serenita for Relaxation|Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.
62723433|NCT02438033|EXPERIMENTAL|Treatment Arm|All patients will be implanted with the investigational device in an open-label fashion
62723434|NCT00658541|EXPERIMENTAL|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
62723435|NCT00658541|ACTIVE_COMPARATOR|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
62723436|NCT02870465||CRIF in operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed in the operating room.
62723437|NCT02870465||CRIF outside of operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed outside of the operating room (i.e.: in clinical setting, the emergency department or minor procedures area).
62723438|NCT03874767|ACTIVE_COMPARATOR|10th floor south|"The unit in this arm will be assigned physical therapists plus mobility technicians in the first month and only physical therapists in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~1. On evaluation, a PT will assign a JH-HLM scale rating to the patient~2. If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~3. The mobility technician will then see that patient daily, unless the score is \<4~4. Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~5. The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
62723439|NCT03874767|ACTIVE_COMPARATOR|6th floor Round Wing|"The unit in this arm will be assigned only physical therapists in the first month and physical therapists plus mobility technicians in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~1. On evaluation, a PT will assign a JH-HLM scale rating to the patient~2. If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~3. The mobility technician will then see that patient daily, unless the score is \<4~4. Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~5. The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
62723440|NCT01082081|EXPERIMENTAL|Paracetamol 1000 mg|Paracetamol 1000 mg
62723441|NCT01082081|EXPERIMENTAL|Paracetamol 500 mg|Paracetamol 500 mg
62723442|NCT01082081|PLACEBO_COMPARATOR|Placebo|Placebo
62723443|NCT00648258|ACTIVE_COMPARATOR|Arm 1|
62723444|NCT00648258|ACTIVE_COMPARATOR|Arm 2|
62723445|NCT03920241||MBSR group|Attendants to Mindfulness-Based Stres Reduction programs offered to the community by Complutense University
62723446|NCT03920241||CCT group|Attendants to Compassion Cultivation Training programs offered to the community by Complutense University
62723447|NCT03920241||Control group|Control group matched by age, gender, and meditation experience.
62723448|NCT02490397|EXPERIMENTAL|Exposed to Day light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
62723449|NCT02490397|SHAM_COMPARATOR|Exposed to Room light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.
62723450|NCT02448147|ACTIVE_COMPARATOR|Interval training|
62723451|NCT02448147|ACTIVE_COMPARATOR|Continuous training|
62723452|NCT02448147|NO_INTERVENTION|Control|
62723453|NCT05834049|EXPERIMENTAL|Virtual Parental Presence on Induction of Anesthesia group|Use of Facetime with child and parents during induction
62723454|NCT05834049|EXPERIMENTAL|Midazolam Group|0.5 mg/kg oral midazolam (max 20 mg) will be given preoperatively.
62723455|NCT05197400|ACTIVE_COMPARATOR|supine|operation in the supine position
62723456|NCT05197400|ACTIVE_COMPARATOR|prone|operation in the prone position
62736225|NCT00924612|EXPERIMENTAL|Fasting (Treatment A)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state
61976697|NCT06332651|EXPERIMENTAL|Lysine milk or sorghum in younger men|This group of 7 participants will have 3 test days where they consume milk with 3 different levels of lysine, they will have 3 test days where they consume sorghum with 3 different levels of lysine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of lysine.
62723457|NCT06406530|EXPERIMENTAL|PRF site (test site)|The participants become at least two teeth removed, one site is applied with PRF (test site) while the other is left for natural healing by forming a blood clot (control site). Operator and Investigator as well as the Patient are blinded to to the site of application.
62723458|NCT06406530|ACTIVE_COMPARATOR|Blood clot (control site)|The participants become at least two teeth removed, one site is applied with PRF (test site) while the other is left for natural healing by forming a blood clot (control site). Operator and Investigator as well as the Patient are blinded to to the site of application.
62723459|NCT01476410|EXPERIMENTAL|Treatment (antibody-drug conjugate and combination chemo)|"LEAD-IN: Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
62723460|NCT02132897|OTHER|TR (Test - Reference)|Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
62723461|NCT02132897|OTHER|RT (Reference - Test)|Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
62723462|NCT02164526||No treatment|
62723463|NCT05910515|NO_INTERVENTION|Control|Regular debriefing
62723464|NCT05910515|EXPERIMENTAL|Intervention|Structured debriefing in non-technical skills
62723465|NCT03929432|ACTIVE_COMPARATOR|Active tDCS (with Speech-Language Treatment)|tDCS Stimulation Dose: 1.5 mA for 20-mins
62723466|NCT03929432|SHAM_COMPARATOR|Sham tDCS (with Speech-Language Treatment)|No tDCS stimulation
62723467|NCT02777411|EXPERIMENTAL|Group A1|3 to 6 years
62723468|NCT02777411|EXPERIMENTAL|Group A2|3 to 6 years
62723469|NCT02777411|EXPERIMENTAL|Group A3|3 to 6 years
62723470|NCT02777411|EXPERIMENTAL|Group A4|3 to 6 years
62723471|NCT02777411|EXPERIMENTAL|Group B2|6 to 35 months
62723472|NCT02777411|EXPERIMENTAL|Group B3|6 to 35 months
62723473|NCT02777411|EXPERIMENTAL|Group B4|6 to 35 months
62723474|NCT05246202|EXPERIMENTAL|Anxiety-alcohol personalized feedback intervention (AA-PFI 2.0)|Participants complete the brief (\~20-30 minute) AA-PFI 2.0 at baseline.
62723475|NCT05246202|ACTIVE_COMPARATOR|Control personalized feedback intervention (C-PFI)|Participants complete the brief (\~20-30 minute) C-PFI at baseline.
62723476|NCT01153204|EXPERIMENTAL|Group Psychotherapy (GP)|Time-limited group psychotherapy is a technique based on psychodrama, an in-depth method of group psychotherapy. Active methods are used to enable past, present, and future life events to be explored. Sexual issues and their possible solutions are enacted rather than simply discussed. Time-limited group psychotherapy focuses on a central or core issue or a circumscribed area of conflict (psychogenic erectile dysfunction) as the only or major object of intervention efforts.
62723477|NCT01153204|ACTIVE_COMPARATOR|Sildenafil|Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
62723478|NCT01153204|ACTIVE_COMPARATOR|Group Psychotherapy (GP) plus Sildenafil|The same as above.
62723479|NCT03475342|ACTIVE_COMPARATOR|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
62723480|NCT03475342|PLACEBO_COMPARATOR|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
62723481|NCT02941614||Intervention|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
62723482|NCT02941614||Control|Newly diagnosed breast cancer patients will experience usual care.
62723483|NCT04865289|EXPERIMENTAL|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
62723484|NCT04865289|ACTIVE_COMPARATOR|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
62723485|NCT01510873||Newly Diagnosed pITP|Patients within 3 months from diagnosis.
62723486|NCT01510873||Persistent pITP|Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.
62723487|NCT01510873||Chronic pITP|Patients with ITP lasting for more than 12 months.
62723488|NCT05858177|OTHER|Temozolomide|TMZ was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
62723489|NCT05125146|ACTIVE_COMPARATOR|Pharmacotherapy|Trazodone is the treatment of choice for insomnia and participants allocated to the pharmaceutical intervention group will be prescribed trazodone as a regular treatment for the duration of the study. Participants on trazodone will also visit the psychiatrist every month to ensure their wellbeing is protected, the quality of the data is maintained, the conduct of the trial is in compliance with the approved protocol, and other regulatory requirements. Trazodone is the routine practice for insomnia and is covered through most patients' healthcare. However, if the patient does not have coverage for trazodone, they will be provided financial compensation to offset the cost.
62736226|NCT00924612|EXPERIMENTAL|Very low fat diet (Treatment B)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with very low fat (6-10% fat).
62736227|NCT00924612|EXPERIMENTAL|Low fat diet (Treatment C)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with low fat (20% fat).
62736228|NCT00924612|EXPERIMENTAL|Normal diet (Treatment D)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with normal fat (30% fat).
62723490|NCT05125146|EXPERIMENTAL|e-CBTi|The e-CBTi modules will involve guiding participants to develop constructive and balanced strategies that would help to handle sleep problems. The e-CBTi program is based on the idea that insomnia is caused by thoughts and behaviours that can be changed. The modules aim to adjust negative thinking so patients can think about and adapt to the events that are happening to them, allowing them to adjust their behaviour and thoughts to be more realistic. Continuing, the modules are designed to help patients with insomnia deal with inaccurate thoughts about sleep and negative sleep behaviours, change their lifestyle practices that negatively affect their sleep, and improve relaxation skills to improve healthy sleep patterns. More specifically, the focus of the program is on addressing and exploring the concept of sleep, sleep habits, sleep hygiene, bedtime worries, negative thoughts, and thought examination.
62723491|NCT03046836|EXPERIMENTAL|Oxytocin|Each participant will self-administer 40 international units (IU) intranasal Oxytocin
62723492|NCT03046836|PLACEBO_COMPARATOR|Control|Each participant will self-administer matching saline placebo
62723493|NCT06078527|EXPERIMENTAL|Cancer Survivors|Participants will attend a single 15-30 minute study session during which they will answer questionnaires (5-10 minutes) and undergo laryngopharyngeal sensory testing (10-20 minutes). There will be up to 2 years of medical record follow up after completing the main study.
62723494|NCT05043948||Coronary Artery Disease_collateral flow grade 2|
62723495|NCT05043948||Coronary Artery Disease_collateral flow grade 0|
62723496|NCT05043948||Peripheral Artery Disease_collateral flow grade 2|
62723497|NCT05043948||Peripheral Artery Disease_collateral flow grade 0|
62723498|NCT02394158|ACTIVE_COMPARATOR|Intervention arm Metformin|Metformin (500mg tablets) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
62723499|NCT02394158|PLACEBO_COMPARATOR|Control arm placebo|Matched placebo tablets (500mg) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
62723500|NCT03931226||Departmental cohort|Department level of the Haute-Garonne through the use of the 'POMME' cohort (PrescriptiOns Medicines Mother Children)
62723501|NCT03931226||National cohort|"National level through the use of the EGB database (General Sample of Beneficiaries)"
62723502|NCT01787383|ACTIVE_COMPARATOR|Ingenol mebutate gel 0.05 %|
62723503|NCT01787383|ACTIVE_COMPARATOR|Ingenol mebutate gel 0.015 %|
62723504|NCT05865951|EXPERIMENTAL|chronic neck pain and isometric exercises group:|Group A performed exercises for 12 weeks. Participants performed isometric exercises along with conventional physical therapy treatment ( thermotherapy, manual mobilisation of cervical spine and trigger point therapy). All exercises were performed for 3 sessions per week for a period of 12 weeks.
62723505|NCT05865951|ACTIVE_COMPARATOR|chronic neck pain and isotonic group|Group B performed exercises for 12 weeks. Participants performed isotonic exercises along with conventional physical therapy treatment ( thermotherapy, manual mobilisation of cervical spine and trigger point therapy). All exercises were performed for 3 sessions per week for a period of 12 weeks.
62723506|NCT02308761|EXPERIMENTAL|RO6870810|Participants with RR-AML and HMA-refractory MDS will receive RO6870810, as per schedule described in intervention description.
62723507|NCT03063606|EXPERIMENTAL|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
62723508|NCT03063606|ACTIVE_COMPARATOR|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
62723509|NCT01677871|EXPERIMENTAL|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
62723510|NCT01677871|ACTIVE_COMPARATOR|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
62723511|NCT01677871|EXPERIMENTAL|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
62723512|NCT01677871|ACTIVE_COMPARATOR|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
62723513|NCT04915638|EXPERIMENTAL|Intervention group|Schoolchildren received enriched cookies containing a multiple micronutrients formula. Enriched cookies (20g) with a daily dose of 0.33g of organic mix formula were given in the morning during 4-weeks. The formulation is an industrial secret of UNAM.
62723514|NCT01152801|EXPERIMENTAL|RAD001|
62723515|NCT05517486|EXPERIMENTAL|50 mg GTX-101|
62723516|NCT05517486|EXPERIMENTAL|100 mg GTX-101|
62723517|NCT05517486|EXPERIMENTAL|200 mg GTX-101|
62723518|NCT05517486|ACTIVE_COMPARATOR|Bupivacaine subcutaneous injection|
61976698|NCT01610947|ACTIVE_COMPARATOR|Maintain|Continuation of usual treatment with fixed intervals according to standard recommendations
61976699|NCT01610947|ACTIVE_COMPARATOR|Spacing|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.
62723519|NCT02581436|EXPERIMENTAL|kSORT assay based follow-up|Post Transplant surveillance based on the result of the kSORT assay.
62723520|NCT02581436|ACTIVE_COMPARATOR|Standard follow-up|Post Transplant surveillance based on standard of care.
62723521|NCT04937634|EXPERIMENTAL|Melphalan|
62723522|NCT01864083|EXPERIMENTAL|Local staging patients|Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
62723523|NCT01864083|EXPERIMENTAL|Neoadjuvant chemotherapy patients|Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
62723524|NCT01065025|EXPERIMENTAL|4SC-205|
62723525|NCT01861470||Preterm infants|all \<32 weeks
62723526|NCT00756275|ACTIVE_COMPARATOR|Nicotine Replacement + PLA pill|Nicotine replacement treatment patch plus matched placebo pill
62723527|NCT00756275|ACTIVE_COMPARATOR|Varenicline + PLA patch|Varenicline plus matched placebo patches containing no nicotine
62723528|NCT03073525|EXPERIMENTAL|Part 1: Vigil + Atezo|This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days.
62723529|NCT03073525|EXPERIMENTAL|Part 2: Vigil first then combination Vigil + Atezo|"After Part 1 participants completed completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to Vigil first received two cycles of Vigil alone, then Vigil and atezolizumab given in sequence (Vigil administered first, followed 30 minutes later by atezolizumab)~Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 107 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil~1 cycle = 21 days"
62723530|NCT03073525|EXPERIMENTAL|Part 2: Atezo first then combination of Vigil + Atezo|"After Part 1 participants completed completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to atezolizumab first received two cycles of atezolizumab alone, then Vigil and atezolizumab given in sequence (Vigil administered first, followed 30 minutes later by atezolizumab).~Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 107 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. 1 cycle = 21 days"
62723531|NCT03073525|OTHER|Part 3: Atezo Only|Participants who completed all cycles of Part 2 were pre-approved by the sponsor for inclusion into Part 3. Atezolizumab alone was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days
62723532|NCT00134615|EXPERIMENTAL|RQP-MH|These participants receive the RQP-MH intervention
62723533|NCT01152788|ACTIVE_COMPARATOR|rIL-21|
62723534|NCT01152788|ACTIVE_COMPARATOR|Dacarbazine|
62723535|NCT03420937|EXPERIMENTAL|Deep Neuromuscular Block|"Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min.~Intervention: Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
62723536|NCT03420937|EXPERIMENTAL|Moderate Neuromuscular Block|Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Intervention: Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9.
62723537|NCT05637177|EXPERIMENTAL|Cognitive behavioral therapy (CBT)|"We used the Aging Wisely program for seniors living in the community, which uses elements of CBT and is specifically designed for older people over the age of 65 living in the community who may be in a worried, anxious or depressed mood. The program focuses on psychoeducation to manage these feelings. Seniors learn to change the ways they think and behave that maintain depression and anxiety. The sessions include education on the process of aging, coping with loneliness, improving sleep, coping with worry and avoidance, coping with loss and death. During the sessions, participants learn to track mood, motivation to change, goal setting, planning pleasant activities, identifying thoughts, working with useless thoughts, and practice techniques to replace useless thoughts. The last two sessions are dedicated to assertiveness and communication, and preventing recurrence of problems."
62723538|NCT05637177|EXPERIMENTAL|Reminiscence therapy|Reminiscence is a method of working with memories. Remembering has an irreplaceable place in every person's life. It is a natural activity that can encourage people, make them aware of their own achievements, different moments in life, point out their value, promote self-esteem and contribute to the development of relationships. Self-remembering is a natural form of cognitive stimulation.
62723539|NCT05637177|EXPERIMENTAL|Music therapy|The aim of music therapy is to optimize the quality of life, and to improve psychological, social, communication, emotional and mental health and well-being. Music therapy brings psychological and physical relaxation, reduces stress, improves mood, alleviates anxiety, improves memory and attention, develops and facilitates communication, enables self-expression. For this purpose, a number of activities are used, such as listening to music, singing, playing simple rhythmic instruments, playing the body and a number of other activities that will be carried out with seniors as part of the intervention.
62723540|NCT05637177|EXPERIMENTAL|memory training|"Cognitive training is targeted and structured exercise of cognitive functions (learning, memory, attention, speech, visual-spatial functions, ability to solve problems, plan or manage various tasks and correctly recognize one's surroundings). Regular exercise of cognitive abilities can create a cognitive reserve that can delay the potential aggravation of problems in memory or attention and improve quality of life.~The content of the intervention will be activities developing cognitive functions (primarily memory, attention, imagination, spatial orientation and decision-making speed), practical training and motivation for long-term regular strengthening of cognitive functions using the comprehensive training program MENTEM."
62723541|NCT05637177|EXPERIMENTAL|creation of educational modules (mental health, neural diseases …)|Educational activities will focus on disease prevention in three main directions - cardiovascular diseases, mental health and neurological diseases. Educational activities will take place within the University of the Third Age LF OU.
62723542|NCT05269459|EXPERIMENTAL|Cannabidiol (CBD) as Nantheia ATL5|Cannabidiol (CBD) as Liquid Structure Formulation Nantheia ATL5 400mg BID. Administered in 100mg softgel capsules. Each 100mg softgel contains 10% CBD.
62723543|NCT05269459|PLACEBO_COMPARATOR|Placebo|Matching placebo
62723544|NCT05269459|NO_INTERVENTION|Control Population|Control group for purposes of baseline data collection
62723545|NCT04210492|EXPERIMENTAL|45 Gy|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
62723546|NCT05504512||Parapelvic cyst|
62723547|NCT00443118|ACTIVE_COMPARATOR|Neopuff TM with PEEP|Newborns ventilated for neonatal resuscitation using Neopuff TM with PEEP
62723548|NCT00443118|ACTIVE_COMPARATOR|Self Inflating Bag with PEEP|Newborns ventilated for neonatal resuscitation using Self Inflating Bag with PEEP valve attached
62723549|NCT00443118|ACTIVE_COMPARATOR|Self Inflating Bag without PEEP|Newborns ventilated for neonatal resuscitationusing Self Inflating Bag without PEEP valve attached
62723550|NCT04289558|EXPERIMENTAL|Sodium Nitrite|Single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute)
62723551|NCT02654496||Group 1 (Successful weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had successful weight loss
62723552|NCT02654496||Group 2 (Suboptimal weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had suboptimal weight loss
62723553|NCT02654496||Group 3 (Control group)|A control group who has not had Roux-en-Y gastric bypass surgery and are of similar age, gender, body mass index as the gastric bypass groups.
62723554|NCT06246747|EXPERIMENTAL|Physical therapy treatment in the clinic + telerehabilitation|Patients performed treatments in the clinic in the presence of their physical therapist (PT) as well as perform remote treatment from their homes. The remote treatment included using video chat with their PT as well as performing PD-specific exercises which were stored in a specific library on the platform.
62723555|NCT06246747|EXPERIMENTAL|TR-only|Patients received treatment at their homes using the TR platform. This included video chat with their clinician as well as performing PD-specific exercises which were stored in a specific library on the platform.
62723556|NCT06246747|ACTIVE_COMPARATOR|Control group|Patients received treatment in the clinic in the presence of their PT
62723557|NCT02651116|EXPERIMENTAL|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
62723558|NCT02651116|PLACEBO_COMPARATOR|Placebo|10 mL of Placebo
62723559|NCT01055613|EXPERIMENTAL|Experimental multi-purpose solution|Multi-purpose contact lens care solution.
62723560|NCT01055613|ACTIVE_COMPARATOR|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution.
62723561|NCT06448975|EXPERIMENTAL|The clinically diagnosed patients with mild to severe Alzheimer's Disease|"1. The age ranged from 60 to 80 years, and the time from initial diagnosis to enrollment was more than 12 months~2. The estimated survival time is more than 12 months;~3. The clinically diagnosed patients with mild to severe Alzheimer's Disease;~4. The imaging examination has the correlation diagnosis evidence;~5. Volunteer to participate in the project and sign an informed consent form with the guardian."
62723562|NCT01842672|EXPERIMENTAL|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children \< 3 years age based dosing.
62723563|NCT02724488||Part 1|Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors will have archival tumor specimens requested and used for whole exome sequencing (WES) of tumor DNA. 3 tubes of blood at a single time point will be collected for ctDNA analysis and germ line DNA analysis (to study normal variants) using next generation sequencing.
62723564|NCT02724488||Part 2|Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors (ICIs) or planning to have treatment with ICIs or other immunological therapy as standard of care will have image-guided fresh tumor core needle biopsy at a maximum of 3 time points: 1) prior to commencement of immune checkpoint inhibitors, 2) when disease response to therapy is confirmed using radiology RECIST 1.1 criteria and/or immune related response criteria, and 3) when radiological disease progression is confirmed by using RECIST 1.1. Blood samples for ctDNA analysis will be collected at the commencement of immunotherapy and every 6-12 weeks thereafter until radiological disease progression is confirmed.
62723565|NCT03110029|ACTIVE_COMPARATOR|Efinaconazole 10 % and Nail Polish|Subject will have Efinaconazole 10% solution application and nail polish
62723566|NCT03110029|PLACEBO_COMPARATOR|Efinaconazole 10% without Nail Polish|Subject will have only Efinaconazole 10% application and no nail polish
62723567|NCT04096105|EXPERIMENTAL|CC-93538 in Japanese subjects|Twenty-four Japanese subjects will be randomized into 1 of 2 dose levels in a 1:1 fashion so that 12 subjects will receive a 180 mg or 360 mg dose via SC injection.
62723568|NCT04096105|EXPERIMENTAL|Administration of CC-93538 in Caucasian subjects|Twenty-four Caucasian subjects will be matched to Japanese subjects by weight (± 20%) and receive a 180 mg or 360 mg dose via SC injection
62723569|NCT06568549|NO_INTERVENTION|Non-Randomized Group|Individuals who do not meet eligibility for randomization will continue in the study and continue to follow study related visits. Individuals will continue with their current immunosuppression medication.
62723570|NCT06568549|ACTIVE_COMPARATOR|MMF Maintenance Group|Individuals randomized to the MMF Maintenance Group will not be withdrawn from their MMF and will continue to follow their standard of care immunosuppression medications.
62723571|NCT06568549|EXPERIMENTAL|MMF Withdrawal Group|Individuals randomized to the MMF Maintenance Group will be withdrawn from their MMF immunosuppression medication from Month 4 to Month 10 post-transplant.
62723572|NCT03541278|EXPERIMENTAL|IM-SLNB with MIT|The radiotracer was injected with our modified injection technique (MIT) (periareolar intraparenchymal, high volume and ultrasonographic guidance). Internal mammary sentinel lymph node biopsy (IM-SLNB) was performed for patients with internal mammary visualized.
62723573|NCT02462031|EXPERIMENTAL|KD101|
62723574|NCT02462031|PLACEBO_COMPARATOR|KD101 placebo|
62723575|NCT02274961|EXPERIMENTAL|S-pantoprazole 10mg|S-pantoprazole 10mg Tablet once daily for 4 weeks
62723576|NCT02274961|PLACEBO_COMPARATOR|Placebo|Placebo tablet for the test drug
62723577|NCT04023760|EXPERIMENTAL|Treatment group A: Cyclosporine in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on cyclosporine as part of their immunosuppressive regimen
62723578|NCT04023760|ACTIVE_COMPARATOR|Cyclosporine in healthy subjects|"Results from Treatment group A will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of cyclosporine at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
62723579|NCT04023760|EXPERIMENTAL|Treatment group B: Tacrolimus in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on tacrolimus as part of their immunosuppressive regimen
62723580|NCT04023760|ACTIVE_COMPARATOR|Tacrolimus in healthy subjects|"Results from Treatment group B will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of tacrolimus at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
62723581|NCT04377503|EXPERIMENTAL|Tocilizumab|Patients will receive Tocilizumab, 8 mg / kg diluted in 100 ml of saline and administered IV for 60 minutes. The dose will be repeated only once 12 hours after the first dose.
62723582|NCT04377503|ACTIVE_COMPARATOR|Methylprednisolone|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days in two daily doses. Finally 0.5 mg / kg / day for another 7 days.
62723583|NCT03717623|EXPERIMENTAL|Posaconazole prophylaxis|Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.
62723584|NCT06319781||Atopic dermatitis|"In addition to all other basis assessments, subjects diagnosed with AD are to complete the following forms: EASI, vIGA-AD, SCORAD, TIS, and POEM."
62723585|NCT06319781||Alopecia areata|"In addition to all other basis assessments, subjects diagnosed with AA are to complete the following forms: SALT and PGIS"
62723586|NCT06319781||Psoriasis|"In addition to all other basis assessments, subjects diagnosed with psoriasis are to complete the following forms: PASI, SAPASI, PGA, PLSI"
62723587|NCT06319781||Vitiligo|"In addition to all other basis assessments, subjects diagnosed with vitiligo are to complete the following forms: VASI, VETF, and VIDA"
62723588|NCT04580043|EXPERIMENTAL|cTBS + Habit Override Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Habit Override Training.
62723589|NCT04580043|ACTIVE_COMPARATOR|Sham TBS + Habit Override Training|Sham Transcranial Magnetic Stimulation, paired with Habit Override Training.
62723590|NCT04580043|ACTIVE_COMPARATOR|cTBS + Sham Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Sham Training.
62723591|NCT04580043|SHAM_COMPARATOR|Sham TBS + Sham Training|Sham Transcranial Magnetic Stimulation, paired with Sham Training.
62723592|NCT01352286|EXPERIMENTAL|Autologous Genetically modified T cells|Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose \>0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
62723593|NCT01628068|ACTIVE_COMPARATOR|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
62723594|NCT01628068|NO_INTERVENTION|Oral anticoagulation|Oral anticoagulation
62723595|NCT03084848|EXPERIMENTAL|Active control|
62723596|NCT03084848|EXPERIMENTAL|Inhibitor control|
62723597|NCT04042454|EXPERIMENTAL|Test Product|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
62723598|NCT04042454|ACTIVE_COMPARATOR|Control Product|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
62723599|NCT06525038||Risk of sarcopenia (-) and risk of frailty (-)|
62723600|NCT06525038||Risk of sarcopenia (+) and risk of frailty (-)|
62723601|NCT06525038||Risk of sarcopenia (-) and risk of frailty (+)|
62723602|NCT06525038||Risk of sarcopenia (+) and risk of frailty (+)|
62723603|NCT03417466|EXPERIMENTAL|Study arm|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6).
62723604|NCT05985707|EXPERIMENTAL|A|Arm A will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 treatment.
62723605|NCT05985707|EXPERIMENTAL|B|Arm B will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
62723606|NCT05985707|EXPERIMENTAL|C|Arm C will include HER2-positive treatment-naive metastatic biliary tract cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
62723607|NCT06488274|EXPERIMENTAL|Test formula|The test product is a thickened infant formula containing symbiotic (fibers and probiotics)
62723608|NCT02212665|EXPERIMENTAL|High intense interval training (HIIT)|3 x 20 sec, 3 x week
62723609|NCT02212665|EXPERIMENTAL|Increased daily activity detected by the pedometer|10.000 steps a day
62723610|NCT02212665|EXPERIMENTAL|Increased daily activity detected by te pedometer+HIIT|10.000 steps + 3 x 20 sec, 3 x week
62723611|NCT02212665|EXPERIMENTAL|Increased daily activity (pedometer)+group intervention|10.000 steps + group intervention
62723612|NCT02212665|NO_INTERVENTION|Control group|
62723613|NCT01267786|ACTIVE_COMPARATOR|Sevoflurane|1MAC intraoperatively
62723614|NCT01267786|ACTIVE_COMPARATOR|desflurane|1 MAC intraoperatively
62723615|NCT03142919|EXPERIMENTAL|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
62723616|NCT03142919|ACTIVE_COMPARATOR|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
62723617|NCT03142919|PLACEBO_COMPARATOR|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
62723618|NCT03142919|PLACEBO_COMPARATOR|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
62723619|NCT01562886|EXPERIMENTAL|Rilpivirine and Truvada|TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily
62723620|NCT02611102|EXPERIMENTAL|MCT oil + Butter in Coffee|This group will be provided with MCT oil and butter to add to their daily coffee intake.
62723621|NCT02611102|PLACEBO_COMPARATOR|Low calorie coffee|This group will continue to drink their normal daily coffee with \< 50kcal of creamer and/or sweetener.
62723622|NCT03538093|EXPERIMENTAL|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
62723623|NCT03538093|EXPERIMENTAL|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
62723624|NCT03538093|EXPERIMENTAL|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
62723625|NCT04161690|ACTIVE_COMPARATOR|Group IV|Dexketoprofen 50mg is given intravenous 10 min before the start of the surgery. Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
62723626|NCT04161690|ACTIVE_COMPARATOR|Group Periarticular|Dexketoprofen 50mg is given as part of the local infiltration analgesia with 300mg ropivacaine. Local infiltration analgesia is proceeded by the orthopedic surgeon.
62723627|NCT04161690|PLACEBO_COMPARATOR|Group P|Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
62723628|NCT06059807|EXPERIMENTAL|hyrax group|
62723629|NCT06059807|EXPERIMENTAL|hybrid hyrax group|
62723630|NCT05840835|EXPERIMENTAL|IMX-110 in Combination With Tislelizumab|Patients with advanced solid tumors will be administered a combination of IMX-110 with Tislelizumab
62723631|NCT06016322|EXPERIMENTAL|Before and after study in 6 patients with UC and 6 patients wiht CD|This is a 4-week before-after pilot study to explore the effectiveness of a WholeFiber Trademark (TM) intervention (a dried vegetable rich in prebiotic intrinsic fibers) on inflammation, fecal gut microbiota and metabolites, IBD-complaints and QoL and assesses its feasibility. In this before-after study, 12 patients with IBD will receive WholeFiberTM; of which 6 patients with CD and 6 patients with UC to assess if there is a difference in effect between these groups of patients.
62723632|NCT00335166|EXPERIMENTAL|1|
62723633|NCT00335166|ACTIVE_COMPARATOR|2|
62723634|NCT00335166|PLACEBO_COMPARATOR|3|
62723635|NCT05254756|ACTIVE_COMPARATOR|Traditional plastic 2-blade disposable speculum|Patients assigned to this arm will be evaluated using the traditional plastic 2-blade disposable speculum
62723636|NCT05254756|EXPERIMENTAL|5-petal Bouquet speculum|Patients assigned to this arm will be evaluated using the 5-petal Bouquet speculum
62723637|NCT02399644|EXPERIMENTAL|ACT|Acceptance and Commitment Therapy is a version of Cognitive behavioral Therapy that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
62723638|NCT02399644|EXPERIMENTAL|Physical activity|Participants are going to participate in a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
62723639|NCT02399644|NO_INTERVENTION|Experience based discussion group|Participants are going to discuss their experiences of long term pain. The discussions is supervised by a heath care professional and is based on beforehand defined subjects, i.e. relations, spare time, economics, occupation. The meetings are hold for 7 weeks, 2 hours a week.
62723640|NCT00548457||A|
62723641|NCT02852967|EXPERIMENTAL|Belumosudil 200 mg QD + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening
62723642|NCT02852967|EXPERIMENTAL|Belumosudil 200 mg BID (Twice Daily) + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening
62723643|NCT02852967|EXPERIMENTAL|Belumosudil 400 mg QD + Placebo|Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening
62723644|NCT02852967|EXPERIMENTAL|Belumosudil 600 mg/day|Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening
62723645|NCT02852967|PLACEBO_COMPARATOR|Placebo|Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening
62723646|NCT04451759|ACTIVE_COMPARATOR|healthy controls|
62723647|NCT04451759|EXPERIMENTAL|Anorexia|
62723648|NCT04451759|EXPERIMENTAL|Obesity|
62723649|NCT06487234|ACTIVE_COMPARATOR|Functional band|
62723650|NCT06487234|PLACEBO_COMPARATOR|Nonfunctional band|
62723651|NCT02112539||ADP Blockers|platelet aggregation in response to antiplatelet drugs
62723652|NCT03364231|EXPERIMENTAL|Marginal Zone Lymphoma (MZL): Umbralisib|Participants with non-follicular indolent non-Hodgkin's lymphoma (iNHL) with MZL as the histology type received umbralisib, 800 milligrams (mg), orally, once daily (QD), until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.
62723653|NCT03364231|EXPERIMENTAL|Waldenstrom's Macroglobulinemia (WM): Umbralisib|Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.
62723654|NCT01971684||Refractory Pediatric ITP Patients|Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.
62723655|NCT05807399|EXPERIMENTAL|Arm 1 (Stage 1)|Rifampicin 2,100mg, isoniazid 300mg, pyrazinamide 1,600mg moxifloxacin 600mg; given once daily for 17 weeks (R2100HZM600)
62723656|NCT05807399|EXPERIMENTAL|Arm 2 (Stage 1)|Rifampicin 2,100mg, isoniazid 300mg, pyrazinamide 2,000mg/2,400mg, moxifloxacin 600mg; given once daily for 12 weeks (R2100HZoptM600)
62723657|NCT05807399|ACTIVE_COMPARATOR|Arm 3|Stage 1: control arm (2HRZE-4RH) Stage 2: continuation of control-arm from STAGE 1 (2HRZE-4RH)
62723658|NCT05807399|EXPERIMENTAL|Arm 4 (Stage 2)|Rifampicin, Isoniazid, and Pyrazinamide in weight-banded standard dosages with BTZ-043 1,000mg; given once daily for 17 weeks (RHZT), then rifampicin and isoniazid in weight-banded dosages; given once daily for 9 weeks (RH)
62723659|NCT01537315|PLACEBO_COMPARATOR|Matching Placebo|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
62723660|NCT01537315|EXPERIMENTAL|Hydroxychloroquine|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
62723661|NCT04679038|EXPERIMENTAL|combinational therapy part|SHR-1701 + famitinib
62723662|NCT04679038|EXPERIMENTAL|monotherapy part|famitinib
62723663|NCT04346511|EXPERIMENTAL|Acupuncture|In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.
62723664|NCT04346511|SHAM_COMPARATOR|Sham Acupuncture|Specially designed Sham acupuncture needles that are not actually penetrate the skin and activate the acupoint will be used in an identical procedure to RA. The patient would be able to feel light pressure at the site.
62723665|NCT00066690|ACTIVE_COMPARATOR|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
62723666|NCT00066690|EXPERIMENTAL|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
62723667|NCT00066690|EXPERIMENTAL|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
62723668|NCT06322030|EXPERIMENTAL|Diet|15 week weight management program
62723669|NCT06322030|NO_INTERVENTION|Control|waitlist control
62723670|NCT06322030|EXPERIMENTAL|Exercise|exercise training
62723671|NCT06322030|EXPERIMENTAL|Diet + Exercise|15 week weight management program + exercise training
62723672|NCT01894945||Patients with suspected lymphoma.|
62723673|NCT02822053|EXPERIMENTAL|US-guided laser ablation for refractory neoplasms|The investigators used percutaneously US-guided laser ablation for patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter), Child-Pugh A/B, PLT ≥ 50\*10E9/L and PT ≤ 20s. Then the investigators estimated the safety and efficacy of this treatment through follow-up of US/CEUS/CT/MRI and the tumor markers every three months.
62723674|NCT03115918|ACTIVE_COMPARATOR|Pancreatic Duct Stent Placement|Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.
62723675|NCT03115918|ACTIVE_COMPARATOR|No Pancreatic Duct Stent Placement|Subject will not have a pancreatic Duct stent placed.
62723676|NCT03048773|EXPERIMENTAL|shockwave therapy|"1. 0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece~2. Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
62723677|NCT03048773|PLACEBO_COMPARATOR|placebo|"1. 0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece~2. Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
62723678|NCT01265992||Paricalcitol capsules|Patients with secondary hyperparathyroidism associated with Stage 3 - 5 CKD and not yet on dialysis and prescribed paricalcitol capsules in accordance with the terms of the marketing authorization in Sweden.
62723679|NCT06395116||Conventionl self cure acrylic group|Constructed from heat cured acrylic resin
62723680|NCT06395116||3D printed acrylis resin group|Manufactured by additive manufacturing technique
62723681|NCT06395116||Milled acrylic resin group|Manufactured by milled technique
62723682|NCT03591731|EXPERIMENTAL|Arm A : monotherapy arm|Nivolumab administered IV
62723683|NCT03591731|EXPERIMENTAL|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
62723684|NCT02520492|EXPERIMENTAL|noninvasive method of ICP measurements|"Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do.~Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow."
62723685|NCT01525693||Diagnosed within 6 months|No (test) intervention to be adminisitered
62723686|NCT04536051|EXPERIMENTAL|Group 1a: single dose ChAdOx & paracetamol|Participants will receive a single standard dose of ChAdOx1 nCOV19 vaccine plus paracetamol
62723687|NCT04536051|ACTIVE_COMPARATOR|Group 1b: single dose MenACWY & paracetamol|Participants will receive a single dose of MenACWY plus paracetamol
62723688|NCT04536051|EXPERIMENTAL|Group 1c: two dose ChAdOx & paracetamol|Participants will receive two standard doses of ChAdOx1 nCoV-19 vaccine, 4-12 weeks apart, plus paracetamol
62723689|NCT04536051|ACTIVE_COMPARATOR|Group 1d: two dose MenACWy/saline & paracetamol|Participants will receive MenACWY prime, and Saline Placebo boost (0.5mL) plus paracetamol
62723690|NCT02743767|NO_INTERVENTION|Before interventions|Only observational activity for this arm, to record the frequency and triggering factors of airway complications during general anaesthesia.
62723691|NCT02743767|EXPERIMENTAL|After interventions|After introducing five different treating adaptations in airway management we want to record the frequency of airway complications during general anaesthesia.
62723692|NCT03053934|ACTIVE_COMPARATOR|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
62723693|NCT03053934|EXPERIMENTAL|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
62723694|NCT05298943|OTHER|Subjects with 4 walking situations|
62723695|NCT00524121|EXPERIMENTAL|Oral Erlotinib|Patients receive oral erlotinib hydrochloride once daily for 1 year
62723696|NCT05834985|ACTIVE_COMPARATOR|group (1) endoscopic group|"For patients in EG, we began with assessment of the site \& size of fistula . In this study, OTSC was used in 9 patients .We started deploying the clips perpendicular to the long axis of the defect. If needed, more than one clip was sequentially deployed, starting at edge of the defect towards the center. Standard clips were passed through-the-scope to achieve superficial tissue apposition engaging the mucosa and submucosa (with 1.2-mm-wide and 6-mm-long arms capable of an approximately 12-mm grasp) and were used in conjunction with thermal ablation or mechanical scraping of the tissue around the edges of the defect to achieve a more resilient seal.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
62723697|NCT05834985|NO_INTERVENTION|group (2) surgical group|sigmoid resection after proper colonic preparation with primary anstomosis with circular stapler either open or laparoscopically
62723698|NCT05085483|EXPERIMENTAL|Active intervention (one month)|Nutritional Ketogenic Supplement (NKS) 2 x 12 g of EKS/day
62723699|NCT05085483|PLACEBO_COMPARATOR|Placebo (one month)|Isocaloric placebo supplement
62723700|NCT05075889|EXPERIMENTAL|Benign Bone patients|Patients with Benign Bone tumors requiring intralesional operative management will be administered immunofluorescent indocyanine green 24 hours prior to surgery, imaging of perfused tissues will be performed at the time of tumor removal.
62723701|NCT02118519|ACTIVE_COMPARATOR|mesenchymal stem cells|Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury
62723702|NCT02118519|ACTIVE_COMPARATOR|mesenchymal cells&platelet lysate|Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury
62723703|NCT03225391|EXPERIMENTAL|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
62723704|NCT03225391|EXPERIMENTAL|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
62723705|NCT02218853||Bipolar I disorder, with psychosis|Individuals diagnosed with Bipolar I disorder, with psychotic features
62723706|NCT02218853||Bipolar I disorder, without psychosis|Individuals diagnosed with Bipolar I disorder, without psychotic features
62723707|NCT02218853||Healthy Controls|Must have no personal history of any psychotic or mood disorder, or a family history of psychotic or recurrent mood disorder among their first-degree relatives
62723708|NCT01119144|EXPERIMENTAL|Polycaprolactone / Tricalcium Phosphate|Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
62723709|NCT01119144|ACTIVE_COMPARATOR|Control|Control group with titanium mesh
62723710|NCT04092777|EXPERIMENTAL|Strong Minds Program|This is a 10-session, culturally-adapted intervention, that includes cognitive behavioral therapy techniques combined with mindfulness exercises, led by a Community Health Worker.
62723711|NCT04092777|OTHER|Enhanced Usual Care|Enhanced usual care includes check in calls by a Care Manager 4 times over the course of 6 months and educational materials about depression and anxiety.
62723712|NCT01896687|EXPERIMENTAL|Scrambler therapy|Scrambler therapy applied to region of low back pain for 30 minutes x 10 days
62723713|NCT01896687|SHAM_COMPARATOR|Sham Scrambler treatment|Sham treatment applied to region above low back pain at nontherapeutic dose for 30 minutes x 10 days
62723714|NCT01673646|EXPERIMENTAL|Pasireotide LAR 20mg|Enrolled patients were randomized to 20mg pasireotide LAR.
62723715|NCT01673646|EXPERIMENTAL|Pasireotide LAR 40mg|Enrolled patients were randomized to 40mg pasireotide LAR.
62723716|NCT01673646|EXPERIMENTAL|Pasireotide LAR 60mg|Enrolled patients were randomized to 60mg pasireotide LAR.
62723717|NCT04477460||Infants with BRUE receiving thickened feeds|
62723718|NCT04477460||Infants with BRUE not receiving thickened feeds|
62723719|NCT00521677|EXPERIMENTAL|1|Procedure: Use of protocol that use special suction connected toothbrush to clean the teeth and the oral cavity, use of non alcoholic antiseptic solution and lubrication of the lips and the oral cavity.
62723720|NCT00521677|ACTIVE_COMPARATOR|2|The traditional method of oral care with cleaning of the oral cavity with a sponge soaked with antiseptic non alcoholic solution
62723721|NCT03245346|EXPERIMENTAL|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
62723722|NCT03245346|OTHER|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
62723723|NCT05794737||Participants|60 archived Formalin-fixed Paraffin-embedded tissue blocks of Colorectal Carcinoma will be obtained and sectioned. From each block; Two tissue sections will be prepared, one tissue section will be stained by Hematoxylin and Eosin to detect tumor phenotype and depth of invasion. Other tissue section will be immunohistochemically stained by Anti-Human INHBA.
61978202|NCT04599894|EXPERIMENTAL|study group|Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before operation; oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
62723724|NCT04487197||Cohort 1|"* Adult patients (age ≥ 18 years),~* kidney or pancreas or pancreatic islets transplantation~* transplanted patients (period: 01.01.2020 to 30.06.2020)"
62723725|NCT04487197||Cohort 2|"* Adult patients (age ≥ 18 years),~* kidney or pancreas or pancreatic islets transplantation~* Transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020."
62723726|NCT04590599|EXPERIMENTAL|IBI310+Sintilimab|IBI310+Sintilimab
62723727|NCT04590599|ACTIVE_COMPARATOR|Placebo+Sintilimab|Placebo+Sintilimab
62723728|NCT00889707|EXPERIMENTAL|Active Drug|PRX302
62723729|NCT00889707|PLACEBO_COMPARATOR|Placebo|Placebo
62723730|NCT00196209|EXPERIMENTAL|1|catheter ablation to treat persistent atrial fibrillation
62723731|NCT00196209|EXPERIMENTAL|2|cardioversion and drug prophylaxis to treat persistent atrial fibrillation
62723732|NCT03577262|EXPERIMENTAL|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of \[11C\]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
62723733|NCT03577262|EXPERIMENTAL|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of \[11C\]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
62723734|NCT06139809|OTHER|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using non-invasive positive pressure ventilation (NIPPV) delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the peripheral oxygen saturation (SpO2 \[%\]) and heart rate (HR \[bpm\]).
62723735|NCT04652804|ACTIVE_COMPARATOR|Arm 1: Low Intensity Intervention|4 weeks dispensation + standard adherence counseling
62723736|NCT04652804|ACTIVE_COMPARATOR|Arm 2: Medium Intensity Intervention|4 weeks dispensation + support from patient navigator
62723737|NCT04652804|ACTIVE_COMPARATOR|Arm 3: High Intensity Intervention|Directly Observed Therapy with flexible dispensing and support from patient navigator
62723738|NCT04171505||vaccinated women|"* Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.~* Women who sign informed consent.~* Patients with negative results in the first post-surgery control.~* Patients who have received HPV vaccination and provide vaccination card."
62723739|NCT04171505||non vaccinated woman|"* Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.~* Women who sign informed consent.~* Patients with negative results in the first post-surgery control.~* Patients who have NOT received HPV vaccination and provide vaccination card."
62723740|NCT02861339|EXPERIMENTAL|Keratoconus and IBD|Opthalmologic measure with DM OPD scan III (Nidek)
62723741|NCT03858348||fluticasone / salmeterol treatment|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol (Group A)
62723742|NCT03858348||fluticasone / salmeterol and extra LAMA|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol and extra a long-acting muscarinic receptor antagonist (anticholinergic, LAMA) (Group B).
62723743|NCT04312503||COHORT A: Lurasidone|Patients treated with Lurasidone
62723744|NCT04312503||COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)|Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)
62723745|NCT00588796||Healthy Volunteers|Healthy Volunteers
62723746|NCT00588796||Burn patients|Patients who have sustained burn injury greater than or equal to 20% of total body surface area
62723747|NCT00588796||Trauma patients|Patients who have undergone trauma
62723748|NCT06617286|EXPERIMENTAL|CD30 CAR T-cells|Patients will receive autologous CD30 CAR T-cells post autologous stem cell transplant between days 21-42.
62723749|NCT01913847|EXPERIMENTAL|Sildenafil|Sildenafil 20 mg
62723750|NCT01913847|PLACEBO_COMPARATOR|Placebo|Placebo
62723751|NCT04040062|EXPERIMENTAL|SCC|Subjects will be treated according to their frequency response pattern which may show one or more distinct frequencies of stimulation that generated increased SCC
62723752|NCT06184191|ACTIVE_COMPARATOR|Robotic Hand Rehabilitation|"RHR group received hand rehabilitation through the robotic device. A home-based rehabilitation program was used to these patients for hand and upper extremity rehabilitation in addition to RHR.~Each rehabilitation session consisted of six parts:~1. A sequence of 17 cycles of digital flexion-extension joint motions, from the thumb to the fifth finger (7 min).~2. A sequence of 23 cycles of motion to counting from one to five (7 min).~3. A sequence of 70 cycles of motions including thumb-finger opposition motions from the second to the fifth finger (7 min).~4. A sequence of 28 cycles of motions including wave-like finger motions (7 min).~5. A sequence of 42 cycles of motions including fist opening/closing (7 min).~6. A sequence of 20 cycles of motions including flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min).~The patients underwent Robotic Hand Rehabilitation in the hospital 5 days per week for 1 month."
62723753|NCT06184191|ACTIVE_COMPARATOR|Conventional Rehabilitation|CVR group received 60 minutes of consecutive occupational therapy sessions in the hospital 5 days per week for 1 month. The rehabilitation program involved strength, balance, manual dexterity exercises, and stretching/weight-bearing by the affected arm. Treatments focused on practice of specific functional tasks when possible. These included reach and grasp of various objects, isolated hand motions (writing, playing an instruments, molding putty, cooking), and whole body activities (swinging a racquet, basketball handling skills). The rehabilitation also included training in ADLs. The patients underwent individualized programs based on assessment and patient goals. Manual therapy techniques were used to obtain isometric contractions in weak muscles. The patients received mobilization and stretching exercises to restricted joints as needed to increase range of motion.
62723754|NCT06184191|EXPERIMENTAL|Combined Rehabilitation|The patients underwent 60 minutes of CVR followed by 40 minutes of hand rehabilitation through the robotic device. A home-based rehabilitation was not involve in this group.
62723755|NCT06259318|EXPERIMENTAL|Intervention|
62723756|NCT06259318|NO_INTERVENTION|Control|
62723757|NCT02264743|EXPERIMENTAL|Femoston Conti 0.5mg/2.5mg|"Ultra low dose, film-coated 17β-estradiol (as hemihydrate) 0.5mg \& dydrogesterone 2.5 mg~Once a day~The duration is six months.~Drug intervention: Estradiol\&DydrogesteronevsOestradiol\&Norethisterone acetate"
62723758|NCT02264743|ACTIVE_COMPARATOR|EVOREL® CONTI transdermal patches|"EVOREL CONTI is a transdermal self adhesive patch which is 0.1 mm in thickness and each patch releases 50mcg of oestradiol and 170mcg of norethisterone acetate over 24 hours .~The Evorel Conti patch is cut in half and applied to the lower part of the body for 3.5 days (delivering approx 25mcg of oestradiol over 24 hours ) this is replaced every 3.5 days .~The duration is six months.~Drug intervention: Estradiol\&DydrogesteronevsOestradiol\&Norethisterone acetate"
62723759|NCT05357768||retrospective cohort|"Patients with undifferentiated round cell sarcomas treated from 01 January 1983 to April 2019 will be included.~For retrospective analysis, it is expected to include about 200 patients."
62723760|NCT05357768||prospective cohort|prospective patients with undifferentiated round cell sarcomas will be included in the study. For prospective study, it is expect to include 60 patients.
62723761|NCT00447798|EXPERIMENTAL|Prevention Care Advocate|Prevention Care Advocate (PCA) intervention contains elements based on cognitive-behavioral theories and strengths-based case management. Intervention arm participants will undergo an 8 session intervention comprised of three components: 1) An individual strengths-based case management approach aimed at motivating participants to seek or maintain their engagement with HIV primary care and drug treatment; 2) A cognitive-behavioral, skills-building approach to increase participants' risk reduction knowledge, skills, and perceived self-efficacy as well as intention to change high risk transmission behaviors; and 3) A community placement in which study participants will have the opportunity to practice their advocacy skills in prevention and care setting.
62723762|NCT00447798|NO_INTERVENTION|Standard of Care|"Standard of Care (SOC) condition involves standard practice, consisting of usual inpatient/hospital services provided within normal clinical practice, plus a brief educational session consisting of the review of the topics in the Living with HIV brochure published by the Centers for Disease Control and Prevention (CDC)."
62723763|NCT04227327|EXPERIMENTAL|Abemaciclib + aromatase inhibitors|Abemaciclib will be administered at 150 mg twice daily orally + Letrozole 2,5 mg daily or Anastrozole 1 mg daily
62723764|NCT00833443|ACTIVE_COMPARATOR|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.
62723765|NCT00833443|PLACEBO_COMPARATOR|Sugar Pill|
62723766|NCT01840943|EXPERIMENTAL|CAELYX|Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
62723767|NCT01840943|ACTIVE_COMPARATOR|Topotecan hydrochloride (HCl)|Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
62723768|NCT04013776|ACTIVE_COMPARATOR|Phosphate supplemented diet|All participants will undergo phosphate testing after following a phosphate supplemented diet for 5 days
62723769|NCT04013776|NO_INTERVENTION|Low phosphate diet|All participants will undergo phosphate testing after following a low phosphate diet for 5 days
62723770|NCT03044275|EXPERIMENTAL|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.~New adhesive strip Standard adhesive strip"
62723771|NCT00876252|ACTIVE_COMPARATOR|IC43 100 mcg|IC43 100 mcg with Aluminum hydroxide
62723772|NCT00876252|ACTIVE_COMPARATOR|IC43 200 mcg|IC43 200 mcg with Aluminum hydroxide
62723773|NCT00876252|ACTIVE_COMPARATOR|IC43 100 mcg w/o|IC43 100 mcg without Aluminum hydroxide
62723774|NCT00876252|PLACEBO_COMPARATOR|Placebo|phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant
62723775|NCT02869321|EXPERIMENTAL|Fentanyl|"Administration of Morphine Sulfate Placebo and Fentanyl~1. Morphine Sulfate Placebo: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~   +~2. Fentanyl: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
62723776|NCT02869321|PLACEBO_COMPARATOR|Morphine Sulfate|"Administration of Morphine Sulfate and Fentanyl Placebo~1. Morphine Sulfate: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~   +~2. Fentanyl Placebo: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
62723777|NCT03646058|PLACEBO_COMPARATOR|Placebo|2 placebo pills sublingual during 28 days
62723778|NCT03646058|EXPERIMENTAL|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
62723779|NCT03646058|EXPERIMENTAL|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
62723780|NCT02377414|EXPERIMENTAL|Cohort 1: Retosiban/placebo|Each subject in cohort 1 will receive an intravenous (IV) bolus infusion of 6 milligrams (mg) retosiban or placebo over 5 minutes, followed by a continuous infusion of 6 milligram per hour (mg/h) retosiban or placebo for 24 h. At 24 h of dosing, an additional 6 mg retosiban or placebo will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h. Subjects administered with placebo will receive an equal volume of normal saline as an IV bolus as well as an equal rate of continuous infusion of normal saline as of retosiban.
62723781|NCT02377414|EXPERIMENTAL|Cohort 2: Retosiban|Each subject in cohort 2 will receive a bolus infusion of 6 mg retosiban over 5 minutes, followed by a continuous infusion of 6 mg/h retosiban for 24 h. At 24 h of dosing, an additional 6 mg retosiban will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h.
62723782|NCT02230189|EXPERIMENTAL|Allergen challenge subjects|"Intervention: Segmental airway allergen challenge~Three types of subjects are studied in this arm:~1) Volunteers with neither asthma nor allergy (as established by skin prick testing); 2) Volunteers with allergy (as established by skin prick testing) but without asthma; and 3) Volunteers with both asthma and allergy (as established by skin prick testing)"
62723783|NCT01232439|EXPERIMENTAL|opioid receptor kappa antagonist|
62723784|NCT06507579||Severe aortic valve stenosis|Hydra transcatheter aortic valve (THV) series
62723785|NCT05851885|EXPERIMENTAL|Experimental group|Physicians draft EGD reports with the assistance of the AI-based reporting system.
62723786|NCT05851885|NO_INTERVENTION|Control group|Physicians use the conventional reporting system to draft EGD reports. At the same time, the AI-based reporting system will automatically generate a report of the EGD examination.
62723787|NCT04149171|EXPERIMENTAL|conventional treatment|red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC)
62549596|NCT05503576|EXPERIMENTAL|reminder mobile application group|"The mobile application will be introduced with a video demonstration. Then, with the help of the researcher, the mobile application will be downloaded to his phone. A user name and password will be created for the patient to enter the application. It will be explained that medication and appointment reminders are available in the application. It will be emphasized that the application will direct you to the hospital appointment system to create a control appointment. In addition, it will be announced that the training content prepared with the contribution of experts to increase drug compliance can be accessed through the application. It is thought that the patient will be interviewed for approximately 20 minutes for the information and procedure process. In the next process, the Drug Protocol Information Form, Modified Morisky Scale and Complications Follow-up Form sent to the patient through the application will be filled in at the 1st, 4th, 8th and 12th weeks."
62549597|NCT05503576|NO_INTERVENTION|standard protocol group|"If the patient is in the control group in group assignment; After the first encounter and obtaining consent, the Personal Information Form will be filled in. Next 1., 4.,8. And in the 12th weeks, the Drug Protocol Information Form, Modified Morisky Scale and Complications Follow-up Form will be filled in by telephone interviewing the patient. It is estimated that each phone call with the patient for data collection will take approximately 10 minutes."
62549598|NCT03420586|ACTIVE_COMPARATOR|Nitrous oxide Group|The nitrous oxide group (GN2O) will receive air in 30% O2 during general anesthesia until the last 30 min of surgery, when 70% N2O in 30% O2 will be administered.
62549599|NCT03420586|NO_INTERVENTION|Oxygen Group|The Oxygen group will receive gas carrier mixture consisting of air in 30% O2 during general anesthesia.
62549600|NCT00134901|EXPERIMENTAL|Memantine|Memantine
62549601|NCT00134901|PLACEBO_COMPARATOR|Placebo|Placebo
62549602|NCT03579342|EXPERIMENTAL|App technology and coaching|Participants in the intervention group with app technology and coaching participate in a first meeting with the coach and will thereafter receive active support from the coach every 4 weeks for the duration of the intervention.
62549603|NCT03579342|EXPERIMENTAL|App technology only|Participants in the intervention group with only app technology participate in a first meeting with the coach but do not get any additional support during follow-up.
62549604|NCT03579342|NO_INTERVENTION|Control group|Participants in the control group participate in baseline assessments. The control group will get access to the app and will have a meeting with a coach after 12 weeks of follow-up.
62549605|NCT01332292|ACTIVE_COMPARATOR|COHORT 1 RANDOMISATION A|(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
62549606|NCT01332292|PLACEBO_COMPARATOR|COHORT 1 RANDOMISATION B|(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
62549607|NCT01332292|ACTIVE_COMPARATOR|COHORT 2 RANDOMISATION A|(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
62549608|NCT01332292|PLACEBO_COMPARATOR|COHORT 2 RANDOMISATION B|(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
62549609|NCT02442180|EXPERIMENTAL|G-CSF + steroid in partial responder|Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
62549610|NCT02442180|PLACEBO_COMPARATOR|Placebo + steroid in partial responder|Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
62549611|NCT02442180|EXPERIMENTAL|G-CSF in null responder to steroid|Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
62549612|NCT02442180|PLACEBO_COMPARATOR|Placebo in null responder to steroid|Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.
62549613|NCT01465425||E3/E4 Case Group|The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules.
62549614|NCT01465425||Pulmonary Nodules Case Group|The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules.
62549615|NCT01465425||E1 Control Group|The E1 Control Group will be drawn from the 866 E1 ECF cases from ACRIN 6664 to create a cohort of 260 E1 ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible.
62549616|NCT02490644||MGB1 in valvular heart surgery|Evaluation of the high mobility group box 1 as a prognostic biomarker in patients undergoing valvular heart surgery
62549617|NCT02521805|SHAM_COMPARATOR|PA|Animal protein and no fiber (control)
62549618|NCT02521805|EXPERIMENTAL|PAF|Animal protein added fiber
62549619|NCT02521805|EXPERIMENTAL|PVF|Vegetable protein naturally containing dietary fiber
62549620|NCT02521805|EXPERIMENTAL|PAVM|Animal protein and dietary fiber in meal
62549621|NCT00171951|EXPERIMENTAL|Pasireotide 600 μg BID SC or Ramp up Dose 900 μg BID SC|Participants received pasireotide 600 micrograms (μg) twice daily (BID) subcutaneously (SC) to achieve or maintain urinary free cortisol (UFC) normalization. If UFC levels were increased at any time, participants received 900 μg BID SC, until no safety or tolerability concerns were observed as per investigators assessment. If the participant was unable to tolerate the 900 μg BID, dosing of 600 μg three times a day was given.
62549622|NCT06551883|PLACEBO_COMPARATOR|Group A|Patients in group A were given the 3L PEG in two doses: 1L of PEG was taken from 8:00 pm to 9:00 pm on the night before the examination, and the remaining 2L of PEG were taken from 4:00 am to 6:00 am on the day of the examination, with 250 mL taken every 15 minutes until finished.
62549623|NCT06551883|EXPERIMENTAL|Group B|Patients in group B were given 3L of PEG in a single dose, which was taken gradually from around 3-4 am, 4-6 hours before the examination. Patients in group B were also instructed to take 250 mL every 15 minutes until the 3L were finished.
62549624|NCT03514290|PLACEBO_COMPARATOR|GPLACEBO|the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (HP).
62549625|NCT03514290|EXPERIMENTAL|GLASER|treated with Low-lever laser + tooth bleaching with 35% hydrogen peroxide (HP).
62723788|NCT04149171|ACTIVE_COMPARATOR|conventional treatment added to Crystalloids and TXA|administration of Crystalloids and TXA
62723789|NCT05809427|EXPERIMENTAL|Patient with periodental Disease|Imaging/Scanning and recording by Ultrasonic periodontal probing per operator Manual probing per operator with the OMS probe (part of the routine of care)
62723790|NCT03938818|OTHER|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures
61976700|NCT03406104|EXPERIMENTAL|GS010-treated Eyes|Lenadogene nolparvovec Intravitreal ocular unilateral Injection Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
62549626|NCT04267432|PLACEBO_COMPARATOR|Placebo|Placebo
62549627|NCT04267432|EXPERIMENTAL|TCI633|Testing product
62549628|NCT04267432|ACTIVE_COMPARATOR|Type 2 collagen|Known drug for OA
62549629|NCT02321033|EXPERIMENTAL|low glycemic index|palatinose in soft drinks
62549630|NCT02321033|EXPERIMENTAL|high glycemic index|sucrose plus maltodextrin in soft drinks
62549631|NCT02569918|EXPERIMENTAL|Surface electrical stimulation|Operation of hand prosthesis with surface electrical sensory feedback
62549632|NCT03548727|EXPERIMENTAL|Repeatability of FLT kinetics|Radiotracer: 18F-FLT Dose: 10 mCi Frequency: Two baseline PET/CT at baseline up to 3 days apart.
62549633|NCT03548727|EXPERIMENTAL|Pseudo-Simultaneous FMISO/FLT PET/CT Imaging|Radiotracer: 18F-FLT and 18F-FLT Dose and Frequency: 8 mCi 18F-FLT and 8 mCi 18F-FLT on Day1, the 8mCi 18F-FLT on Day2
62549634|NCT03281759|ACTIVE_COMPARATOR|Active Coil Helmet|The patients will undergo 18 sessions (627 nm, 70 mW/cm2, 10 J/cm2) at four points of the frontal and parietal region for 30 s each, totaling 120 s three times per week for 6 weeks, lasting 30 minutes of transcranial LED stimulation.
62549635|NCT03281759|PLACEBO_COMPARATOR|Inactive Coil Helmet|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions.
62549636|NCT05336188|EXPERIMENTAL|Smartphone|Participants randomized into the Smartphone app arm would use the smartphone app OptiMAT in conjunction with treatment as usual (TAU). Participants would use OptiMAT to complete daily self-assessments of opiate misuse, opiate craving, opiate withdrawal, and mood. The app will personalized feedback for maintaining abstinence goals. The app would also use geographic ecological momentary assessment (GEMA) to intervene via push notification when participants enter areas previously identified as high-risk for opiate use.
62549637|NCT05336188|NO_INTERVENTION|Monitoring Only|Participants randomized into the Monitoring Only arm would undergo treatment as usual (TAU) but without the smartphone app.
62549638|NCT02461251|EXPERIMENTAL|Rotational thromboelastometry (ROTEM)|"Rotational thromboelastometry results are used to guide the treatment of major obstetric hemorrhage, eg. administration of prothrombin complex concentrate, fresh-frozen plasma, fibrinogen concentrate or platelets. In case of massive hemorrhage, shock packs of blood products in 1:1:1 ratio are administered."
62549639|NCT02461251|NO_INTERVENTION|Standard care|"Patients are treated according to clinical decision making and conventional coagulation tests, and in case of massive hemorrhage, shock packs are administered."
62549640|NCT04236934||All included patients|Patients with recurrent unilateral pleural effusion
62549641|NCT03636685|EXPERIMENTAL|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I~Anlotinib combined with pemetrexed and carboplatin, phase II"
62549642|NCT03636685|EXPERIMENTAL|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I~Anlotinib combined with paclitaxel and carboplatin, phase II"
62549643|NCT06432816|ACTIVE_COMPARATOR|NANO-PSO|NANO-PSO or Pomegranate seed oil with nanotechnology, capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast
62549644|NCT06432816|PLACEBO_COMPARATOR|PLACEBO|- Placebo physically identical to NANO-PSO capsules: Soft gelatin capsules 640 mg edible oil 35for PLACEBO being the following information: Oil edible, oval shape, 640 mg.
62549645|NCT02015845|EXPERIMENTAL|Accuvein|Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
62549646|NCT02015845|ACTIVE_COMPARATOR|Routine technique|Routine technique used to insert a peripheral intravenous catheters in obese patients.
62549647|NCT03608397|EXPERIMENTAL|DAXI for injection low dose|Low Dose Group
62549648|NCT03608397|EXPERIMENTAL|DAXI for injection high dose|High Dose Group
62549649|NCT03608397|PLACEBO_COMPARATOR|Placebo|Placebo Group
62549650|NCT00452556|ACTIVE_COMPARATOR|Standard Radiotherapy Sequence Arm|Standard sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) first, then prostate/prostate bed last
62549651|NCT00452556|EXPERIMENTAL|Experimental Radiotherapy Sequence Arm|Experimental sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) last, prostate/prostate bed first
62549652|NCT00741338|EXPERIMENTAL|Cohort 1|Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.
62549653|NCT00741338|EXPERIMENTAL|Cohort 2|TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.
62549654|NCT05733273|ACTIVE_COMPARATOR|Nordic Hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
62549655|NCT05733273|EXPERIMENTAL|Single leg hamstring bridge exercise program|The single-leg hamstring bridge is performed with the athlete lying on the ground with one heel supported by their partner, the hip in approximately 45° and the knee in approximately 20° of flexion. The participants cross their arms across the chest and push down through the heel to lift their buttocks off the ground. The participant should allow their buttocks to touch the ground momentarily and then the hip should be extended to 0°.
62549656|NCT05733273|EXPERIMENTAL|Razor curl|Participants are required to kneel on a gym mat and flex their hips and knees to approximately 90 degrees. They then allow their body to descend towards the ground by extending at the knees and hip simultaneously. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
62549657|NCT03576664|EXPERIMENTAL|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
62549658|NCT03576664|EXPERIMENTAL|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
62549659|NCT00104572|EXPERIMENTAL|(Androgel) testosterone gel|17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
62549660|NCT00104572|EXPERIMENTAL|anastrozole (Aromatase inhibitor)|14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
62549661|NCT00104572|PLACEBO_COMPARATOR|placebo|13 participants will receive a placebo tablet and placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
62549662|NCT00823810|EXPERIMENTAL|Colorectal cancer|
62549663|NCT00039338|EXPERIMENTAL|Chemotherapy followed by surgery|neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)
62549664|NCT00039338|ACTIVE_COMPARATOR|Radio-chemotherapy|Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)
62549665|NCT00006760|EXPERIMENTAL|Treatment (ifosfamide, vinorelbine, filgrastim)|Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5. Patients also receive filgrastim (G-CSF) subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover. Treatment repeats at least every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive a third course of therapy at the discretion of the investigator. Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. Patients with sufficient PBSCs collected may undergo PBSC transplantation on protocol COG-AHOD0121.
62549666|NCT03705429|ACTIVE_COMPARATOR|TC-H Chemotherapy|Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.
62549667|NCT03705429|PLACEBO_COMPARATOR|Paclitaxel(P) + Trastuzumab(T)|Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.
62549668|NCT01235481|EXPERIMENTAL|Exercise DVD|Exercise DVD to be used by participants 30-60 minutes, once daily to facilitate maintenance exercise training
62549669|NCT01235481|OTHER|Usual Care|Participants advised to perform maintenance exercise training 30-60 minutes, once daily without benefit of exercise DVD
62549670|NCT00100308|EXPERIMENTAL|1|Standard treatment plus unfractioned heparin low-dose continuous infusion
62549671|NCT00100308|PLACEBO_COMPARATOR|2|Standard treatment plus placebo
62549672|NCT00911300|ACTIVE_COMPARATOR|Arm 1: fondaparinux|
62549673|NCT00911300|ACTIVE_COMPARATOR|Arm 2: unfractionated heparin + Vitamin-K-Antagonist|
62549674|NCT04278456||general anesthesia|c-section with general anesthesia
62549675|NCT04278456||spinal anesthesia|c-section with spinal anesthesia
62549676|NCT04278456||epidural anesthesia|c-section with epidural anesthesia
62549677|NCT01561846|ACTIVE_COMPARATOR|regular cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trialy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
62549678|NCT01561846|EXPERIMENTAL|CLA enriched cheese|
62549679|NCT02934867|EXPERIMENTAL|CONTARM|Protocol phone advice
62549680|NCT02934867|OTHER|CONTHAB|Usual phone advice
62549681|NCT04045353|NO_INTERVENTION|Standard of care|Subjects will receive standard counseling on obesity as part of routine postpartum care.
62549682|NCT04045353|ACTIVE_COMPARATOR|Low carbohydrate diet education|Subjects will receive educational materials regarding a low carbohydrate diet in addition to the standard counseling on obesity as part of routine postpartum care.
62549683|NCT04045353|ACTIVE_COMPARATOR|Low carbohydrate diet education with behavioral component|Subjects will receive in person instruction regarding a low carbohydrate diet as part of a 12 week course, in addition to receiving educational materials regarding a low carbohydrate diet and the standard counseling on obesity as part of routine postpartum care.
62549684|NCT01545518|EXPERIMENTAL|all subjects|IVIG
62549685|NCT05528601|EXPERIMENTAL|users|app users
62549686|NCT05528601|NO_INTERVENTION|non-users|app non-users
61978203|NCT05553002|EXPERIMENTAL|Deneroll cervical extension traction|The study group will receive 3-point bending cervical extension traction following the protocol of Deed Harrison . The duration of each session will start at approximately three minutes and increased one minute per session until reaching the goal of 20 minutes per session
62549687|NCT01307345|NO_INTERVENTION|Monitoring Alone|Research assistants will phone or text participants and request videorecordings of breathalyzer samples up to 21 times per week. Participants will receive compensation for each valid videorecording that occurs within the requested one-hour time frame, and bonus compensation each time all requested videorecordings are submitted within the timeframe over a 7-day period, and/or if \>90% of prompts are returned over the study period.
62549688|NCT01307345|EXPERIMENTAL|Monitoring plus contingency management for abstinence|Participants assigned to this condition will receive the same monitoring schedule outlined above, plus the same payment for compliance. In addition, they will receive contingent reinforcement for submission of videorecordings that demonstrate negative breath alcohol samples. For each sample submitted that reads below the cut point, participants will receive vouchers for payment.
62549689|NCT02661217|OTHER|Pre-discharge treatment initiation|Patients received first dose at any point after Randomization but no later than 12 h before discharge.
62549690|NCT02661217|OTHER|Post-discharge treatment initiation|Patients received first dose after discharge and up to 14 days thereafter.
62549691|NCT01932918||PCA with morphine in liver transplant|Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
62549692|NCT01932918||PCA with ketorolac in liver transplant|Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
62549693|NCT01932918||Intravenous PCA in thoracic surgery|Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
62549694|NCT01932918||PCEA in thoracic surgery|Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
62549695|NCT05107271||Chronic Liver Disease|
62549696|NCT05107271||Post Liver Transplantation|
62549697|NCT05872022||Participants Exposed to Wegovy|Pregnant women who are exposed to Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition will be observed in this prospective observational study.
62549698|NCT05872022||Participants Unexposed to Wegovy or Other GLP-1 RAs|Pregnant women who have overweight with at least one weight-related comorbid condition or who have obesity at conception and who are not exposed to Wegovy or other GLP-1 RAs at any time during pregnancy but who may be exposed to other products for weight management will be observed in this prospective observational study.
62549699|NCT02940431|EXPERIMENTAL|High Autonomy|Children will choose active video games for use during the study.
62549700|NCT02940431|EXPERIMENTAL|Low Autonomy|Children will be assigned active video games for use during the study.
62549701|NCT06465836|OTHER|O- lreay technique group|Group A: In which 86 patients will have bilateral uterine artery ligations as described by O- lreay technique in addition to standard conservative methods. Briefly, two large vicryl stitches were passed using a large-sized needle below and lateral to the lower edge of the uterine incision angle in an anteroposterior direction and then redirected from back to the front through the avascular window in the posterior leaf of the broad ligament just lateral to the uterine border taking care to avoid injury to bowel posteriorly or bladder/ureter anteriorly. The stitches were tied securely anteriorly
62549702|NCT06465836|OTHER|Modified O- lreay technique group|"Group B: which will include 86 patients we will do our simplified approach which includes;~* After placental separation; try to grasp the lower segment or cervical flap.~* Close uterine cavity by continuous vicryl no 1 suture.~* Do 3 to 4 mattress sutures as the second layer of the uterus.~* Do uterine ligation with compression of the lower uterine segment (Modification of O, lreay suture) as demonstrated below:~  1. Pack Douglas- pouch with a towel.~ 2. Straight the used vicryl needle mostly no 1.~ 3. Try to compress and approximate anterior and posterior uterine walls.~ 4. Start from anterior to posterior 3- 4 cm medial to lateral uterine margin and then pass from posterior to anterior through avascular area in the broad ligament."
62549703|NCT01232933|EXPERIMENTAL|VPS System|Use of navigational VPS system to place catheter
62549704|NCT02763826|EXPERIMENTAL|Determine the Optimal tDCS current|We will invesitigate the optimal curent in range of 1 mA to 4 mA. We hypothesize that 4 mA is tolerable, safe and can induce the highest level of cortical excitability in the lesional motor cortex.
62549705|NCT02763826|EXPERIMENTAL|Determine the optimal tDCS electrode montage|We hypothesize that the bi-hemispheric stimulation with anodal stimulation on the lesional hemisphere and simultaneous cathodal stimulation on the non-lesional hemisphere induces more cortical excitability in the lesional hemisphere than either anodal stimulation on the affected hemisphere or cathodal stimulation on non-lesional hemisphere alone.
62549706|NCT05015257|ACTIVE_COMPARATOR|Standard F100|If the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
62549707|NCT05015257|EXPERIMENTAL|Standard F75+Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Standard F75 during the stabilization phase
62549708|NCT05015257|EXPERIMENTAL|Alternative F75 with CMV +Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Alternative F75 with CMV during the stabilization phase
62549709|NCT05015257|EXPERIMENTAL|Alternative F75 without CMV +Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Alternative F75 without CMV during the stabilization phase
62549710|NCT03070587|EXPERIMENTAL|Positive Affect Training for SAD|The intervention will be conducted in groups with 68 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
62549711|NCT03070587|NO_INTERVENTION|Wait list Control|These participants will not be given an intervention until after they have completed the study.
62549712|NCT00661895|EXPERIMENTAL|Intervention|Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).
62549713|NCT00661895|ACTIVE_COMPARATOR|Control|No intervention
62723791|NCT03938818|EXPERIMENTAL|Tu'Washindi intervention|"Standard of care will include PrEP delivery according to the usual DREAMS procedures. The Tu'Washindi intervention includes the following components:~1. PrEP sensitization for men (community level).~2. Buddy Days (partner level).~3. Adherence support clubs (individual and peer levels)."
62723792|NCT00948077|ACTIVE_COMPARATOR|Treatment A|"Study agents (Rifater+EMB) will be given approximately 45 minutes prior to the breakfast."
62723793|NCT00948077|EXPERIMENTAL|Treatment B|"Study agents (Rifater+EMB) will be given approximately 45 minutes after the breakfast is finished."
62723794|NCT00537472|EXPERIMENTAL|I|
62723795|NCT00537472|ACTIVE_COMPARATOR|II|
62723796|NCT00292526|EXPERIMENTAL|enalapril arm|treatment with enalapril
62723797|NCT00330369|PLACEBO_COMPARATOR|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
62723798|NCT00330369|EXPERIMENTAL|Darusentan 50 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 50 mg administered orally once daily for 14 weeks
62723799|NCT00330369|EXPERIMENTAL|Darusentan 100 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 100 mg administered orally once daily for 14 weeks
62723800|NCT00330369|EXPERIMENTAL|Darusentan 300 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 300 mg administered orally once daily for 14 weeks
62723801|NCT03770858||Crisaborole and wearable sensor|Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.
62723802|NCT02981056|ACTIVE_COMPARATOR|Wash + Lotion regimen|"Johnson's Baby Top-To-Toe Wash (Ideally 7 times a week, at least 5 times a week) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
62723803|NCT02981056|ACTIVE_COMPARATOR|Water + Lotion regimen|"Water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
62723804|NCT02981056|ACTIVE_COMPARATOR|Water only|Water (in lieu of bathing products) only. The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso.
62723805|NCT04762082|EXPERIMENTAL|Treatment A: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
62723806|NCT04762082|ACTIVE_COMPARATOR|Treatment B: Reference|Single oral dose of tadalafil oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
62723807|NCT04762082|EXPERIMENTAL|Treatment C: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
62723808|NCT04762082|EXPERIMENTAL|Treatment D: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with no water, under fasted conditions
62723809|NCT04762082|EXPERIMENTAL|Treatment E: Test|Single oral dose of tadalafil gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
62723810|NCT03420742|EXPERIMENTAL|Midazolam 3 mg + Brigatinib 90 mg|Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
62723811|NCT02874443|EXPERIMENTAL|Intervention centers|"Application of a knowledge translation strategy, of new clinical practice guidelines on labor management, to physicians and nurses caring for women in labor.~Intervention centers will receive knowledge translation of labor management guidelines"
62723812|NCT02874443|NO_INTERVENTION|Control centers|No intervention at control centers
62723813|NCT03800277|EXPERIMENTAL|Cranberry and Agaves|Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)
62723814|NCT03800277|EXPERIMENTAL|Cranberry and placebo|Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)
62723815|NCT03800277|EXPERIMENTAL|Placebo and Agaves|Placebo (2 capsules) + Agaves powder (1 single-dose packet)
62723816|NCT03800277|PLACEBO_COMPARATOR|Placebo and placebo|Placebo (2 capsules) + Placebo powder (1 single-dose packet)
62723817|NCT05367193|EXPERIMENTAL|pars plana vitrectomy performed using NGENUITY® 3D Visualization System (Alcon, TX, USA)|NGENUITY® 3D Visualization System (Alcon, TX, USA)
62723818|NCT05367193|ACTIVE_COMPARATOR|standard binocular microscope pars plana vitrectomy|standard binocular microscope pars plana vitrectomy
62723819|NCT04154605|ACTIVE_COMPARATOR|ClariFix|Cryotherapy of the nasal passages with the ClariFix device.
62723820|NCT04154605|SHAM_COMPARATOR|Sham|Sham cryotherapy of the nasal passages with the ClariFix device
62723821|NCT01525823|EXPERIMENTAL|BMS-754807 + Metformin|
62723822|NCT03440801|EXPERIMENTAL|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
62723823|NCT03440801|ACTIVE_COMPARATOR|Xience|Durable-polymer everolimus-eluting stent Xience
62723824|NCT02321605|EXPERIMENTAL|BPS exercise|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
62723825|NCT02321605|PLACEBO_COMPARATOR|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
62723826|NCT03215498|EXPERIMENTAL|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
62723827|NCT03215498|EXPERIMENTAL|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
62723828|NCT06003777|EXPERIMENTAL|Cohort 1|Single dose administration of PF-06954522 and placebo. Participants will receive up to 5 dose levels of PF-06954522 and up to 2 dose levels of matching placebo.
62549714|NCT02732171|OTHER|Screening Bone Marrow Aspirate|All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs) by immunohistochemistry. The bone marrow sample is also used for other research tests.
62549715|NCT03510390|EXPERIMENTAL|Metformin|Participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days
61978204|NCT05553002|ACTIVE_COMPARATOR|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy to control pain and eliminate the causal role of muscle spasms and/or tightness in changing the posture parameters.
62549716|NCT04316793|EXPERIMENTAL|Dry needling (DN)|Intramuscular insertion
62549717|NCT04316793|SHAM_COMPARATOR|Sham needling (SN)|Intradermal insertion
62549718|NCT02088697|EXPERIMENTAL|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
62549719|NCT02088697|ACTIVE_COMPARATOR|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
62549720|NCT06409819|ACTIVE_COMPARATOR|Intervention phage therapy|Clear 1 milliliter (ml) solution in a plastic needless syringe. Phage therapy will consist of twice daily intravenous (IV) dose of previously selected phage combination of at least 109 plaque forming units (PFU)/ ml concentration per phage but not to exceed 5EU/Kg/hr of total lipopolysaccharide endotoxin for the entire dose as per FDA guidelines.
62549721|NCT06409819|PLACEBO_COMPARATOR|Intervention control arm (normal saline placebo)|Clear 1mL solution in a plastic needless syringe. Placebo will consist of IV normal saline administered in the same manner as the active comparator for 7 days.
62549722|NCT02892552|EXPERIMENTAL|Cone Beam|Patients included will have first a MultiSlice Computed tomography (MSCT) as usual and then a Cone Beam Computed Tomography (CBCT)
62549723|NCT02927470|EXPERIMENTAL|Working memory task|Simple visual stimuli (e.g., dots, colors, lines) will be presented on a computer monitor. The positions of the stimuli must be attended and remembered and decisions about the stimuli and/or their locations must be made. Memory will be probed with a button press or an eye movement towards the remembered locations.
62549724|NCT02465138|PLACEBO_COMPARATOR|Placebo|Normal Saline will be administered prior to procedure.
62549725|NCT02465138|ACTIVE_COMPARATOR|Toradol|Intravenous ketorolac prior to ERCP
62549726|NCT01799044|EXPERIMENTAL|Irreversible electroporation|Single arm study: Irreversible electroporation of colorectal liver metastasis
62549727|NCT01936506|EXPERIMENTAL|Cognitive Training A|emotional memory training exercise
62549728|NCT01936506|ACTIVE_COMPARATOR|Cognitive Training B|memory training exercise
62549729|NCT00012922|OTHER|Arm 1|
62549730|NCT05655130|EXPERIMENTAL|Test Group|Test Group will receive 10mg intravenous dexamethasone at the time of incision, administered by the assigned anesthesiologist. Post-surgery, Test Group patients will be prescribed a 6-day oral methylprednisolone taper course.
62549731|NCT05655130|OTHER|Control Group|Standard of care with no placebo
62549732|NCT03624920|PLACEBO_COMPARATOR|THN102 Dosage A|THN102 Dosage A is a Placebo
62549733|NCT03624920|EXPERIMENTAL|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
62549734|NCT03624920|EXPERIMENTAL|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
62549735|NCT01734161|ACTIVE_COMPARATOR|Dexamethasone|One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
62549736|NCT01734161|PLACEBO_COMPARATOR|Placebo|One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
62549737|NCT04414618|ACTIVE_COMPARATOR|opaganib|Study participants will receive opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
62549738|NCT04414618|PLACEBO_COMPARATOR|placebo|Study participants will receive placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
62549739|NCT00251121|EXPERIMENTAL|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
62549740|NCT02891668||Hypothyroid|Levothyroxine treatment
62549741|NCT02891668||Healthy volunteers|Matched on age and BMI 18 persons
62549742|NCT06198166|EXPERIMENTAL|Cuevas Medek|"This group will receive CME In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. These oscillations will reflexively induce an increase in tone of the body extensors, but also of the lower limbs. Always from the same position, gait movements will be imitated. At the beginning, due to poor coordination between muscle groups, the child may tend to go outside the support base and therefore we have to run following his center of gravity. The action is similar to the one when someone try to maintain balance of a cane in the palm and have to move his hands according to the cane's oscillation until he manage to regain balance"
62549743|NCT06198166|ACTIVE_COMPARATOR|Standard kinetic programs|This group will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
62549744|NCT02108912|EXPERIMENTAL|Traditional outpatient|Traditional outpatient physical therapy
62549745|NCT02108912|EXPERIMENTAL|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
62549746|NCT06353763|EXPERIMENTAL|Intervention. Virtual reality|Immersive virtual reality learning program based on virtual reality glasses
62549747|NCT06353763|NO_INTERVENTION|Control group: Traditional teaching|Self learning theoretical lesson and traditional teaching with a task trainer, supervised by a teacher.
62549748|NCT03536741|EXPERIMENTAL|ALR|
62549749|NCT03536741|ACTIVE_COMPARATOR|EV|
62549750|NCT05927597|EXPERIMENTAL|Part A: Cohort 1 (Dose 1)|Japanese and Caucasian participants will receive INS1007 at Dose 1 or matching placebo, orally, once on Day 1, and Day 4 through Day 30 in Part A under fasted conditions.
62549751|NCT05927597|EXPERIMENTAL|Part A: Cohort 2 (Dose 2)|Japanese and Caucasian participants will receive INS1007 at Dose 2 or matching placebo, orally, once on Day 1, and Day 4 through Day 30 in Part A under fasted conditions.
62723829|NCT06003777|EXPERIMENTAL|Cohort 2|Single dose administration of PF-06954522 and placebo. Participants will receive up to 4 dose levels of PF-06954522 and up to 2 dose levels of matching placebo.
62723830|NCT06003777|EXPERIMENTAL|Cohort 3|Single dose administration of PF-06954522 and placebo. Participants will receive up to 2 dose levels of PF-06954522 and up to 1 dose level of matching placebo.
62723831|NCT06633887||Healthy or people who has indication to conduct polysomnography (PSG).|
62723832|NCT00894699|ACTIVE_COMPARATOR|1|single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
62723833|NCT00894699|PLACEBO_COMPARATOR|2|single dose of sublingual Placebo NanoTab™
62723834|NCT05176951|EXPERIMENTAL|Treprostinil Palmitil|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be titrated up to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
62723835|NCT05176951|PLACEBO_COMPARATOR|Placebo|Participants will be administered a placebo matching TPIP once daily.
62723836|NCT00152204|EXPERIMENTAL|1|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
62723837|NCT00152204|NO_INTERVENTION|2|
62723838|NCT05177419|EXPERIMENTAL|High-dose LSD|High dose of lysergic acid diethylamide
62723839|NCT05177419|ACTIVE_COMPARATOR|Low-dose LSD|Low dose of lysergic acid diethylamide
62723840|NCT00888537|EXPERIMENTAL|Decision Aid|Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid.
62723841|NCT00888537|ACTIVE_COMPARATOR|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
62723842|NCT03841942|OTHER|clinically-based spacing|All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
62723843|NCT03841942|OTHER|Trough level-based spacing|Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
62723844|NCT01887925||breast cancer|breast cancer patients receiving chemotherapy
62723845|NCT02515344|EXPERIMENTAL|A: nominative list|"Providing a list of patients not compliant with CRC sreening~General Practitioners allocated to the intervention group (A) will receive:~* a nominative list of their patients who were not compliant to colorectal cancer screening.~* a document providing general information about colorectal cancer screening"
62723846|NCT02515344|ACTIVE_COMPARATOR|B: general information|"Providing general information about CRC screening~General Practitioners allocated to group (B) will receive:~- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)"
62723847|NCT02515344|NO_INTERVENTION|C: usual practice|General Practitioners allocated to group (C) will not receive any information (as in usual practice)
62723848|NCT05006105|EXPERIMENTAL|PPG-based mHealth on smartphone|Participants used PPG-based mHealth on a smartphone for 6 months. Participants were asked to perform two spot-check measurements and additional measurements in case of symptoms. The use of PPG-based mHealth on a smartphone was initiated on the day of insertable loop recorder insertion.
62723849|NCT05006105|EXPERIMENTAL|PPG-based mHealth on smartwatch|Participants used PPG-based mHealth on a smartwatch for 6 months. Participants were asked to wear the smartwatch continuously (except during battery charging). The use of PPG-based mHealth on a smartwatch was initiated on the day of insertable loop recorder insertion.
62723850|NCT06292663|EXPERIMENTAL|Intervention|Patients allocated to this group are getting the standard information from their anesthesiologist and a supplement of information via. a Virtual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
62723851|NCT06292663|NO_INTERVENTION|Control Group|Patients allocated to this group are only getting standard information from their anesthesiologist.
62723852|NCT00928187|ACTIVE_COMPARATOR|Arm A|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
62723853|NCT00928187|ACTIVE_COMPARATOR|Arm B|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
62723854|NCT00928187|ACTIVE_COMPARATOR|Arm C|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
62723855|NCT03115372|EXPERIMENTAL|Group I (CRC education)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
62723856|NCT03115372|ACTIVE_COMPARATOR|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
62723857|NCT03579758|ACTIVE_COMPARATOR|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62723858|NCT03579758|EXPERIMENTAL|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
62736229|NCT00924612|EXPERIMENTAL|High fat diet (Treatment E)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of \~800 calories with high fat (50% fat).
62723859|NCT05143333||Post acute COVID-19|Severity of COVID-19 will be determined based on patient classification within the PACT (Johns Hopkins Post-acute COVID-19 Team) clinic. Specifically, patients followed in the PACT-ICU clinic required ICU stays of ≥48 hours and high-flow nasal cannula/non-invasive ventilation or mechanical ventilation. Those followed in the PACT-Base clinic have less severe disease that does not necessitate ≥48 hours in the ICU but does qualify for PACT clinic referral based on either (1) ongoing pulmonary and/or rehabilitation needs at the time of hospital discharge, or (2) persistent pulmonary or functional deficits at 4-6 weeks post infection without hospitalization.
62723860|NCT05047133|EXPERIMENTAL|Early Adminstration of TXA + Intraoperative TXA|This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
62723861|NCT05047133|OTHER|Intraoperative only TXA|This group will only receive the intraoperative TXA.
62723862|NCT06308601|EXPERIMENTAL|experimental group|8 sessions of laughter yoga will be applied to the experimental group.
62723863|NCT06308601|NO_INTERVENTION|control group|No application will be made to the control group. After the research is completed, laughter yoga can be applied by the researcher, at the request of the experimental group, within the framework of ethical responsibilities.
62723864|NCT03186430|EXPERIMENTAL|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
62723865|NCT03186430|NO_INTERVENTION|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
62723866|NCT01411423||Group 1|
62723867|NCT03961243|EXPERIMENTAL|YUVA-GT-F901|Gene transfer to treat Hemophilia B
62723868|NCT00893854|EXPERIMENTAL|Diclophenac|
62723869|NCT00893854|EXPERIMENTAL|Triamcinolone|
62723870|NCT05278845|EXPERIMENTAL|Treatment Sequence 1|SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fasted conditions.
62723871|NCT05278845|EXPERIMENTAL|Treatment Sequence 2|SLC SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fed conditions.
62723872|NCT01581684|EXPERIMENTAL|BI 411034 low dose - group 1|Solution for oral administration
62723873|NCT01581684|EXPERIMENTAL|BI 411034 low dose - group 2|Solution for oral administration
62723874|NCT01581684|EXPERIMENTAL|BI 411034 medium dose - group 3|Solution for oral administration
62723875|NCT01581684|EXPERIMENTAL|BI 411034 medium dose - group 4|Solution for oral administration
62723876|NCT01581684|EXPERIMENTAL|BI 411034 medium dose - group 5|Solution for oral administration
62723877|NCT01581684|EXPERIMENTAL|BI 411034 high dose - group 6|Solution for oral administration
62723878|NCT01581684|EXPERIMENTAL|BI 411034 high dose - group 7|Solution for oral administration
62723879|NCT01581684|EXPERIMENTAL|BI 411034 high dose - group 8|Solution for oral administration
62723880|NCT01581684|PLACEBO_COMPARATOR|Placebo|Solution for oral administration
62723881|NCT00965289|EXPERIMENTAL|HDT combined with rituximab before ASCT|The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
62723882|NCT02503085|EXPERIMENTAL|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
62723883|NCT02503085|EXPERIMENTAL|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
62723884|NCT02503085|ACTIVE_COMPARATOR|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
62723885|NCT02503085|ACTIVE_COMPARATOR|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
62723886|NCT01063790|NO_INTERVENTION|Usual care|Patients undergoing elective inguinal hernia repair attend the pre-admission clinic no later than one week prior to surgery. During this visit they receive one-on-one pre-operative education from a registered nurse. It includes both verbal and written information. Verbal information provided to patients includes procedural information such as the admission process, and post-operative care in the post-anaesthetic care uni and day surgery unit. Post-discharge pain management information is minimal and consists of direction to not wait until the pain is severe before taking prescribed analgesics.
62723887|NCT01063790|EXPERIMENTAL|Individualized Education|
62723888|NCT02243683|EXPERIMENTAL|Cohort A|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
62723889|NCT02243683|EXPERIMENTAL|Cohort B|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
62723890|NCT04662931|EXPERIMENTAL|Crizanlizumab|Participants received Crizanlizumab at a dose of 5.0 mg/kg, and standard of care.
62723891|NCT04421404|EXPERIMENTAL|COVID-19 Convalescent Plasma|Subjects in the COVID-19 convalescent plasma group will receive a single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
62723892|NCT04421404|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo group will receive a single infusion of 250 ml of standard fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
62723893|NCT05863403|EXPERIMENTAL|Neuromuscular Training|
62723894|NCT05863403|ACTIVE_COMPARATOR|Traditional Exercise|
62723895|NCT02694601|EXPERIMENTAL|Ketonemia following caffeine intake|"Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.~Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)"
62723896|NCT06012630||group 1: RA without CTS|Rheumatoid arthritis patients without a diagnosis of CTS based on clinical findings and physical examination
62723897|NCT06012630||group 2: RA with CTS|Rheumatoid arthritis patients with a diagnosis of CTS based on clinical findings and physical examination
62723898|NCT06012630||group:3 Healthy Control|Healthy Control without rheumatologic disease and Carpal tunnel syndrome
62723899|NCT01734824|ACTIVE_COMPARATOR|Teriparatide|daily subcutaneous injection of teriparatide 20µg for three months
62723900|NCT01734824|PLACEBO_COMPARATOR|Placebo Teriparatide|daily subcutaneous teriparatide placebo injection
62723901|NCT01734824|ACTIVE_COMPARATOR|Denosumab|one subcutaneous injection of denosumab
62723902|NCT01734824|ACTIVE_COMPARATOR|Placebo Denosumab|one subcutaneous injection of denosumab placebo
62723903|NCT00506779|EXPERIMENTAL|Phase I: Paclitaxel + Imatinib Mesylate|Phase I MTD using oral dose Imatinib Mesylate escalation 400, 500, 600 mg daily; Paclitaxel 175 mg/m\^2 every 21 days
62723904|NCT00506779|EXPERIMENTAL|Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate|"Intended randomization of Paclitaxel alone or Paclitaxel + Imatinib Mesylate; the study was terminated early due to poor enrollment and all patients are no longer being treated or followed. Single treatment arm MTD using oral dose Imatinib Mesylate escalation = 500 mg daily; Paclitaxel 175 mg/m\^2 every 21 days~Phase II, (Arm 1) = Paclitaxel 175 mg/m\^2 every 21 days Phase II, (Arm 2) Paclitaxel 175 mg/m\^2 every 21 days+ Imatinib Mesylate MTD using oral dose Imatinib Mesylate escalation = 500 mg daily"
62723905|NCT03503396|EXPERIMENTAL|BAC feedback|Participants will receive a warning when their BAC is above a set limit (cutpoint is not disclosed by well below legal limit). Warning will notify them that their results indicate it is not safe for them to drive.
62723906|NCT03503396|ACTIVE_COMPARATOR|No Feedback|Participants will not receive any information on their BAC from their device.
62723907|NCT05778994|EXPERIMENTAL|EXPERIMENTAL|Group that performs therapy with intorus
62723908|NCT05778994|NO_INTERVENTION|CONTROL|Group without intervention
62723909|NCT03794440|EXPERIMENTAL|Sintilimab +IBI305|
62723910|NCT03794440|ACTIVE_COMPARATOR|Sorafenib|
62723911|NCT01580774||Post-discharge phone call|All patients in this group will receive a phone call within 72-hours of being discharged from hospital.
62723912|NCT01580774||Usual care (no phone call)|
62723913|NCT02214901|EXPERIMENTAL|BIBW 2948 BS in single rising doses|
62723914|NCT02214901|PLACEBO_COMPARATOR|Placebo|
62723915|NCT06470516|ACTIVE_COMPARATOR|treatment arm|The frequency of the stimulation was 77.5Hz and the intensity was 15mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
62723916|NCT06470516|SHAM_COMPARATOR|sham-treatment arm|The frequency of the stimulation was 77.5Hz and the intensity was 0mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
62723917|NCT06551675|EXPERIMENTAL|Silkworm pupa tablets group|Wanshililongbao silkworm pupa tablets.
62723918|NCT06551675|SHAM_COMPARATOR|Control group|Contains 0.5% of the active ingredient of the study product, indistinguishable in appearance.
62723919|NCT04679961||Experimental|"1. Epidermal inflammations, including eczematous diseases and psoriasis~2. Epidermal tumors, including benign tumors and malignant tumors~3. Pigmented diseases, including hypopigmentation and hyperpigmentation"
62723920|NCT04679961||Control|Healthy skin
62723921|NCT02770131||Group 1|To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
62723922|NCT03446898||Adults Living at Qinghai-Tibet Plateau for Work Purpose|Qinghai-Tibet Plateau is a high altitude area in which human would be exposed in chronic hypoxia environment.
62723923|NCT02186483|EXPERIMENTAL|Metformin|Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration
62723924|NCT02186483|EXPERIMENTAL|Rosuvastatin|Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin
62723925|NCT02186483|EXPERIMENTAL|Co-administration|Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin
62723926|NCT00484796||1|Patients undergoing carotid surgery
62723927|NCT04794868||Culprit vessel of acute coronary syndrome|Culprit vessel of acute coronary syndrome
62723928|NCT04794868||Non-culprit vessel of acute coronary syndrome|Non-culprit vessel of acute coronary syndrome
62723929|NCT01000506|ACTIVE_COMPARATOR|Mepolizumab 750mg|Mepolizumab 750mcg i.v. every 4 weeks
62723930|NCT01000506|ACTIVE_COMPARATOR|Mepolizumab 250mg|Mepolizumab 250mcg i.v. every 4 weeks
62723931|NCT01000506|ACTIVE_COMPARATOR|Mepolizumab 75mg|Mepolizumab 75mcg i.v. every 4 weeks
62723932|NCT01000506|PLACEBO_COMPARATOR|Placebo|Placebo saline every 4 weeks i.v.
62723933|NCT03828760|EXPERIMENTAL|Music Listening|Patients will receive music of choice to listen to using a music-playing device in the waiting room prior to IUD insertion, as well as during the procedure.
62723934|NCT03828760|NO_INTERVENTION|Standard Care|Patients will receive standard care (excluding the use of music) from providers at the clinic to minimize pain and anxiety during the procedure.
62723935|NCT00652171|ACTIVE_COMPARATOR|1|17 Patients - Mean age of 26 years old, 14 female and 3 male - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
62723936|NCT00652171|PLACEBO_COMPARATOR|2|17 Patients - 11 females and 6 males mean age of 29 years old - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
62723937|NCT04980469|EXPERIMENTAL|Vitex negundo + Zingiber officinale|Dosage: 200 mg/ Capsule;1 capsule twice daily Route: Oral
62723938|NCT04980469|PLACEBO_COMPARATOR|Placebo (MCC)|Dosage: 200 mg/ Capsule; 1 capsule twice daily Route: Oral
62723939|NCT01206517|EXPERIMENTAL|Cohort 1|Participants 10 or 11 years of age
62723940|NCT01206517|EXPERIMENTAL|Cohort 2|Participants 10 or 11 years of age
62736230|NCT04601207|EXPERIMENTAL|Solutech™- TC10|10.0mg THC, 12.2 mg CBD liquid emulsion product given orally once in-clinic
62723941|NCT01206517|EXPERIMENTAL|Cohort 3a-d|"Cohort 3a: Participants 10 or 11 years of age~Cohort 3b: Participants 12 or 13 years of age~Cohort 3c: Participants 14 or 15 years of age~Cohort 3d: Participants 16 or 17 years of age"
62723942|NCT04554732|EXPERIMENTAL|Part 1 - Initial group treatment|For part 1 of the study, subjects will be enrolled into a prospective single arm phase where all of them get the study treatment. We plan to enroll up to 25 subjects to have 20 evaluable subjects to this phase.
62723943|NCT03606148||SurePathTM|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In SurePathTM group, subjects who underwent SurePathTM liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
62723944|NCT03606148||Conventional|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePathTM liquid cell test with the second obtained sample."
62723945|NCT01396590|ACTIVE_COMPARATOR|6 x 2 mg perampanel|
62723946|NCT01396590|ACTIVE_COMPARATOR|12 mg Perampanel|
62723947|NCT04271358|EXPERIMENTAL|Peer Coaching|Participant receive a 6 month peer health coaching intervention.
62723948|NCT04271358|NO_INTERVENTION|Education only|Participants receive education-only material (newsletter) biweekly for 6 months
62723949|NCT02015039|ACTIVE_COMPARATOR|Botulinum Toxin Therapy Only|
62723950|NCT02015039|EXPERIMENTAL|Botulinum Toxin Therapy plus Occupational Therapy|Intervention
62723951|NCT06312163||ARM1|The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design)
62723952|NCT06312163||Arm2|The patient's own corneal RGP lens - CE (UKCA) marked class 2 medical devices.
62723953|NCT01406132|EXPERIMENTAL|ASP015K|
62723954|NCT04780529|EXPERIMENTAL|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
62723955|NCT03901638|EXPERIMENTAL|Tllsh2910 to placebo|Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
62723956|NCT03901638|EXPERIMENTAL|Placebo to Tllsh2910|Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks
62723957|NCT06349824|EXPERIMENTAL|Dextrose|
62723958|NCT06349824|EXPERIMENTAL|Steroid|
62723959|NCT06349824|EXPERIMENTAL|PRP|
62723960|NCT05886153|OTHER|Vitaliti CVSM Device|Examine the accuracy of the Cloud DX Vitaliti Continuous Vital Signs Monitor (Model: CVSM-1A) in an ambulatory context with healthy participants to determine the accuracy of continuous non-invasive vital signs metrics including respiration, pulse rate, oxyhemoglobin saturation (SpO2), core temperature, heart rate, and cNIBP against standard comparator devices guided by consensus standards.
62723961|NCT00903422|ACTIVE_COMPARATOR|Eltrombopag|Eltrombopag
62723962|NCT00903422|PLACEBO_COMPARATOR|Placebo|Placebo
62723963|NCT00473889|EXPERIMENTAL|1|vorinostat; IV paclitaxel; IV carboplatin
62723964|NCT00473889|PLACEBO_COMPARATOR|2|Placebo; IV paclitaxel; IV carboplatin
62723965|NCT05658718||glare group.|Patients subjectively complained about glare and Binoptometer examination showed poor visual quality in dark environments, and they were classified as the glare group.
62723966|NCT05658718||non-glare group|The patients did not complain of glare and the Binoptometer examination showed good visual quality in a dark environment, and they were classified as the non-glare group.
62723967|NCT03240562|SHAM_COMPARATOR|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
62723968|NCT03240562|EXPERIMENTAL|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
62723969|NCT01313910|EXPERIMENTAL|ImmunoLin®|8-week treatment course
62723970|NCT04867083|EXPERIMENTAL|Arm 1: 4 days/7|4 days/7 Patients included in this arm will take their ARV treatment 4 consecutive days per week during 48 weeks.
62723971|NCT04867083|ACTIVE_COMPARATOR|Arm 2: 7 days/7|Patients included in this arm will take their ARV treatment 7 days per week during 48 weeks
62723972|NCT03491033||advanced-stage ovarian cancer group|250 patients with pathologically confirmed epithelial ovarian cancer who received at least 1 cycle of NAC at Yonsei Cancer Hospital from 2006 to 2017.
62723973|NCT00622921|OTHER|1|Couples-based behavioral psychotherapy
62723974|NCT03761420||breast cancer postoperative|got surgery for breast cancer in St Olavs Hospital, Trondheim, during 2004-2013
62723975|NCT04845594|EXPERIMENTAL|MySmileBuddy|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will receive a family-focused intervention called MySmileBuddy.
62723976|NCT04845594|NO_INTERVENTION|Control|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will not receive any intervention.
62723977|NCT01603043|EXPERIMENTAL|AL-78898A|1 intravitreal injection per month for up to 12 months
62723978|NCT01603043|SHAM_COMPARATOR|Sham Injection|1 mock injection per month for 12 months
62723979|NCT01280786|EXPERIMENTAL|Elesclomol Sodium|
62723980|NCT03159468|EXPERIMENTAL|Cognitive Restructuring & Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
62723981|NCT03159468|EXPERIMENTAL|Mindfulness & Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
62723982|NCT03159468|EXPERIMENTAL|Nutrition Information & Alcohol Condition|Participants will receive general information about nutrition. They will then consume an alcoholic beverage in the lab.
62723983|NCT03159468|EXPERIMENTAL|Cognitive Restructuring & No Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
62723984|NCT03159468|EXPERIMENTAL|Mindfulness & No Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
62736231|NCT04601207|ACTIVE_COMPARATOR|MCT-diluted Cannabis Product|10.0mg THC, 12.2 mg CBD liquid MCT-diluted oil product given orally once in-clinic
62723985|NCT03159468|NO_INTERVENTION|Nutrition Information & No Alcohol Condition|Participants will receive general information about nutrition. They will then consume a non-alcoholic beverage in the lab.
62723986|NCT01697085|EXPERIMENTAL|Sea buckthorn oil|3 g (6 capsules)/day for three months
62723987|NCT01697085|PLACEBO_COMPARATOR|Placebo oil|3 g (6 capsules)/day for three months
62723988|NCT05029310|EXPERIMENTAL|All patients use both patiromer and tacrolimus|Pharmacokinetic investigation of tacrolimus performed in both the presence and absence of patiromer for all patients.
62723989|NCT03330444||LD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota mainly composed of different species of the genus Lactobacillus, determined by NGS sequencing.
62723990|NCT03330444||NLD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota composed of different pathogenic bacteria such as Streptococcus and Gardnerella, or not dominated by bacteria of the genus Lactobacillus, determined by NGS sequencing.
62723991|NCT01615562||PCOS adolescents|Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
62723992|NCT01615562||PCOS women|Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).
62723993|NCT04991493|PLACEBO_COMPARATOR|Placebo group|5ml normal saline was injected intravenously 15 minutes before anesthesia and 5ml normal saline was injected intravenously when the incision was washed and sutured.
62723994|NCT04991493|EXPERIMENTAL|pre-tramadol group|5ml of tramadol containing 1mg / kg was injected intravenously 15 minutes before anesthesia and 5ml of normal saline was injected intravenously when the incision was washed and sutured.
62723995|NCT04991493|ACTIVE_COMPARATOR|post-tramadol group|5ml of normal saline was injected intravenously 15 minutes before anesthesia and 5ml of tramadol containing 1mg / kg was injected intravenously when the incision was washed and sutured.
62723996|NCT02560727||colonoscope via of FMT|FMT pathway is colonoscope
62723997|NCT02560727||Transendoscopic enteral tubing|FMT was performed via TET tube
62723998|NCT03446963|EXPERIMENTAL|Single arm: Groups 4 Health|Social group intervention. The aim is to practice participating in a social group within a safe environment; to identify groups and social networks which are meaningful for the person; and to understand any barriers people may have to engaging with these groups/networks.
62723999|NCT02640027|NO_INTERVENTION|Treatment in the Clinic Only|Patients in Group A will receive their follow-up care entirely at the investigators institution
62724000|NCT02640027|EXPERIMENTAL|Treatment in the Clinic and at Home|Cast removal at home using a telemedicine tool
62724001|NCT00932074|EXPERIMENTAL|3% KP-413 Ointment|
62724002|NCT00932074|EXPERIMENTAL|1% KP-413 Ointment|
62724003|NCT00932074|PLACEBO_COMPARATOR|Placebo|
62724004|NCT06361004|EXPERIMENTAL|Patients with Treatment-refractory Tourette's syndrome (TR-TS)|Patients will undergo bilateral DBS lead implantation.
62724005|NCT05088044|EXPERIMENTAL|staff nurses|firstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart
62724006|NCT00977483|EXPERIMENTAL|Drug: Thioctic Acid|600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
62724007|NCT00977483|PLACEBO_COMPARATOR|Drug: Placebo|1 tablet once daily throughout the trial
62724008|NCT01361217|EXPERIMENTAL|Fluoxetine DDI|Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
62724009|NCT01573650||group 1|Group 1a (standard): Epineural Suture Group 1b (experimental): Epineural suture and Fibrin Wrap
62724010|NCT01573650||group 2|Group 2a (standard): Epineural suture and autologous nerve transplantation from lateral antebrachial cutaneous nerve (LACN) Group 2b (experimental): Epineural suture and Fibrin Conduit
62724011|NCT02982655|EXPERIMENTAL|Individualized BP lowering|Management policy is to lower the systolic or diastolic BP by 10-15% within 2 hours of randomization and sustained for 7 days. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
62724012|NCT02982655|ACTIVE_COMPARATOR|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the Chinese Society of Neurology (CSN) in 2014. The attending clinician may consider commencing BP treatment and sustained for 7 days if the systolic BP \> 200 mmHg or diastolic BP \>110 mmHg in patients with ischemic stroke, and systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg in patients with cerebral hemorrhage.
62724013|NCT02383862|EXPERIMENTAL|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
62724014|NCT02383862|NO_INTERVENTION|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
62724015|NCT04725019|EXPERIMENTAL|Active tDCS + motor training|In this arm, participants will receive 20 minutes of active tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games.
62724016|NCT04725019|EXPERIMENTAL|Sham tDCS + motor training|In this arm, participants will receive 20 minutes of sham tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games. Children receiving sham tDCS will wear the tDCS device but not receive active stimulation.
62724017|NCT04230616|ACTIVE_COMPARATOR|Conventional total knee arthroplasty|conventional total knee arthroplasty with standard intramedullary alignment guide
62724018|NCT04230616|ACTIVE_COMPARATOR|NAVIO total knee arthroplasty|NAVIO assisted total knee arthroplasty
62724019|NCT04379154|EXPERIMENTAL|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air in patients hospitalised for COVID-19 infection
62724020|NCT03495726|EXPERIMENTAL|Headspace app|Participants randomized to use the mindfulness app for 6 weeks.
62724021|NCT03495726|NO_INTERVENTION|Waitlist control group|This group will receive treatment as usual for 6 weeks. After the completing the 6-week surveys, the waitlist group will receive a subscription to the Headspace app.
62724022|NCT05547386|EXPERIMENTAL|Observational (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and then undergo a PSMA PET/CT scan throughout the trial.
62724023|NCT05177042|EXPERIMENTAL|Oral tablet(s) in combination with abiraterone and a corticosteroid.|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles.
62724024|NCT01992224|EXPERIMENTAL|early mechanical ventilation|"Fulfillment of three or more criteria below:~respiratory rate \> 28 per minute serum lactate \> 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation~Abbreivation: PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SvO2, venous oxygen saturation"
62724025|NCT01992224|EXPERIMENTAL|conventional mechanical ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate \> 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
62724026|NCT06120686|EXPERIMENTAL|biofeedback-based therapy (BBT)|study group - implementing the conventional therapy program supplemented additionally by training with visual and auditory biofeedback on a dynamic balance platform
62724027|NCT06120686|OTHER|conventional therapy program (CT)|control group - implementing only the conventional therapy program
62724028|NCT00680628|PLACEBO_COMPARATOR|2|Saline + Enoxaparin
62724029|NCT00680628|EXPERIMENTAL|1|Tenecteplase + Enoxaparin
62724030|NCT01791517|OTHER|Lens A (senofilcon A)|Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
62724031|NCT01791517|OTHER|Lens B (galyfilcon A)|Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
62724032|NCT01791517|OTHER|Lens C (etafilcon A)|Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
62724033|NCT04361292|ACTIVE_COMPARATOR|Group A: one day abstinence period|Patients allocated into group A had an ejaculatory abstinence period of one day
62724034|NCT04361292|ACTIVE_COMPARATOR|Group B: three days abstinence period|Patients allocated into group B had an ejaculatory abstinence period of three days
62724035|NCT01187654|EXPERIMENTAL|AC133 recipients|intra coronary injection of bone marrow derived AC133+ cells
62724036|NCT01187654|EXPERIMENTAL|MNC recipients|intra coronary injection of bone marrow derived MNC
62724037|NCT01187654|ACTIVE_COMPARATOR|control|injection of autologous serum
62724038|NCT06184178|EXPERIMENTAL|INTERVENTION GROUP|Implementation of socio-health care based on TEC-MED model
62724039|NCT06184178|NO_INTERVENTION|CONTROL GROUP|No intervention
62724040|NCT03415503|PLACEBO_COMPARATOR|placebo|The placebo capsules only contained pullulan and maltodextrin.During the trial period, the participants were instructed to consume 2 Medox® placebo capsules twice daily (30 min after breakfast or supper).
62724041|NCT03415503|EXPERIMENTAL|40mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum). To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (40 mg anthocyanins per capsule) will provid a total daily intake of 40 mg anthocyanins.
62724042|NCT03415503|EXPERIMENTAL|80mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (80 mg anthocyanins per capsule) will provid a total daily intake of 80 mg anthocyanins.
62724043|NCT03415503|EXPERIMENTAL|320mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume two Medox® anthocyanin capsules 30 min after breakfast and after supper.The anthocyanin capsules (80 mg anthocyanins per capsule,4 per day) will provid a total daily intake of 320 mg anthocyanins.
62724044|NCT05140356|EXPERIMENTAL|High amplitude repeated transcranial magnetic stimulation|Applied high amplitude repeated transcranial magnetic stimulation
62724045|NCT05140356|EXPERIMENTAL|Low amplitude repeated transcranial magnetic stimulation|Applied low amplitude repeated transcranial magnetic stimulation
62724046|NCT05140356|NO_INTERVENTION|healthy control group|No intervention
62724047|NCT01637896|EXPERIMENTAL|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
61976701|NCT03406104|SHAM_COMPARATOR|Sham-treated Eyes|Sham Intravitreal ocular unilateral Injection Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
62724048|NCT01637896|ACTIVE_COMPARATOR|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
62724049|NCT05726331|EXPERIMENTAL|Chiropractic Care, Tai Chi, and EUC|Participants assigned to this arm will receive 10 sessions of chiropractic care over 16 weeks, administered by chiropractors at collaborating clinics in the Greater Boston area. Participants assigned to this arm will also be enrolled in a community-based TC program. Participants will also be given a neck-pain self-care book that explains common causes and management strategies for neck pain.
62724050|NCT05726331|ACTIVE_COMPARATOR|Chiropractic care and EUC|Participants assigned to the chiropractic care+EUC arm will receive 10 sessions of chiropractic care over 16 weeks administered by chiropractors at collaborating clinics in the Greater Boston area. Participants will also be given a neck-pain self-care book that explains common causes and management strategies for neck pain.
62737921|NCT02438683|EXPERIMENTAL|BI 409306 50 mg under resting/exercise conditions|Participants received BI 409306 50 mg oral dose with 240 mL of water after a standardized light breakfast on Day 1 and Day 3 under resting/exercise conditions.
62724051|NCT05726331|ACTIVE_COMPARATOR|EUC|Individuals assigned to the EUC alone group will be asked to continue their usual medical care as prescribed by their physician for 16 weeks. In addition, they will be asked to not seek chiropractic care or TC during the study. Participants will also be given a neck-pain self-care book that explains common causes and management strategies for neck pain. We will also provide this arm of participants with increased attention in the form of biweekly calls from the study research assistants.
62724052|NCT03457610|EXPERIMENTAL|Speech and language intervention|
62724053|NCT03386435|EXPERIMENTAL|RIPC|intervention: RIPC groups receive remote ischaemic preconditioning after anaesthesia induction and before surgery started.
62724054|NCT03386435|NO_INTERVENTION|Control|In the control group, the same maneuver was applied but without cuff inflation.
62724055|NCT00810875||hepatitis C|pregnant women with hepatitis C virus infection and their infants
62724056|NCT00810875||controls|pregnant women without hepatitis C infection and their infants
62724057|NCT04160312|EXPERIMENTAL|Mitopure™ (Proprietary Urolithin A)|Fruit flavored food sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
62724058|NCT04160312|EXPERIMENTAL|Pomegranate Juice|100% Pomegranate juice equivalent to a glass of juice
62724059|NCT03758261|OTHER|Erector Spinae Nerve Block|Erector Spinae nerve block
62724060|NCT03758261|OTHER|Paravertebral Nerve Block|Paravertebral nerve block
62724061|NCT03129464|EXPERIMENTAL|Cold Therapy|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. Intervention will include the patient being asked to use a reusable cold gel pack to deliver cold therapy to their abdominal incisions every 6 hours for the first 72 hours.
62724062|NCT03129464|NO_INTERVENTION|Control|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. They will not receive any additional intervention.
62724063|NCT00083980|ACTIVE_COMPARATOR|active antidepressant drug comparator|Venlafaxine ER
62165948|NCT04889833|NO_INTERVENTION|Usual Care Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, \& shoulder function. 7 days before surgery, they will receive a daily questionnaire about their pain \& anxiety over the last 24 hours. On the day of surgery, before they are given any anesthesia, they will answer questions about their average anxiety \& pain levels. Starting the next morning on the day following surgery and every day for the subsequent week, they will be given questionnaires about their pain \& anxiety levels, medication use, satisfaction, and sleep disturbance due to pain. Their postoperative course will be otherwise completely standard of care, including a first postoperative clinic visit at 10 days after surgery, where the patients will be given these same questionnaires. Finally, patients will answer them one more time on postoperative day 49 and this will constitute a study endpoint. The whole process each day should take approximately 10 minutes.
62165949|NCT02366455||Thoracic CT-Scan|Measurement of the length of the right main stem bronchus and of the right upper lobe bronchus antero-posterior angulation on consecutive thoracic CT-Scan reconstruction
62165950|NCT04502888|EXPERIMENTAL|SL-172154|Intratumoral administration
62724064|NCT00083980|PLACEBO_COMPARATOR|Sugar pill|Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
62724065|NCT00083980|EXPERIMENTAL|Herbal treatment kava|Kava
62724066|NCT03723980|ACTIVE_COMPARATOR|Control Group or Group I or Calcium hydroxide Group|
62724067|NCT03723980|EXPERIMENTAL|Experimental Group or Group II or Propolis Group|
62724068|NCT06397378|ACTIVE_COMPARATOR|Group using CDC factsheet|College students in this arm will receive an educational information that made by CDC.
62724069|NCT06397378|EXPERIMENTAL|Group using videos|College students in this arm will watch videos that will make by our research team.
62724070|NCT01059357|EXPERIMENTAL|Transoral Robotic Surgery (TORS)|Transoral Robotic Surgery (TORS) using the Da Vinci Robotic Surgical System
62724071|NCT03589287|EXPERIMENTAL|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
62724072|NCT03589287|EXPERIMENTAL|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
62724073|NCT03589287|EXPERIMENTAL|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
62724074|NCT00104988|EXPERIMENTAL|Thalidomide and Temozolomide|Patients receive oral thalidomide once daily on days 1-56 and temozolomide once daily on days 1-42. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
62724075|NCT01559415|EXPERIMENTAL|Very Low Calorie Diet|
62724076|NCT01559415|ACTIVE_COMPARATOR|Low Calorie Diet|1250 kcal diet in which Modifast is given in combination with a normal diet
62724077|NCT04224922|EXPERIMENTAL|single-arm|weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer
62724078|NCT04951102|EXPERIMENTAL|Group A Patients who receive SDM intervention|Group A patients will complete a pre-visit electronic Asthma SDM App. They may also receive educational information regarding asthma, medication management, smoking cessation, COVID-19 and COVID-19 vaccines.
62724079|NCT04951102|ACTIVE_COMPARATOR|Group B Patients who receive standard care|Group B patients will receive standard care.
62724080|NCT04951102|EXPERIMENTAL|Group A Physicians who receive SDM training and electronic Asthma SDM App data|Group A physicians will view an SDM Physician Training Video and receive the patients' reported data from the pre-visit asthma SDM App prior to the patients' visits.
62724081|NCT04951102|ACTIVE_COMPARATOR|Group B Physicians who provide standard care|Group B physicians will provide standard care.
62724082|NCT00784368|EXPERIMENTAL|SFI (ITCZ Oral Solution Monotherapy)|Participants with deep-seated mycosis (Systemic Fungal Infection \[SFI\]) received itraconazole (ITCZ) oral solution in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks as per Investigator's discretion.
62737922|NCT02438683|EXPERIMENTAL|BI 409306 200 mg under resting/exercise conditions|Participants received BI 409306 200 mg oral dose with 240 mL of water after a standardized light breakfast on Day 1 and Day 3 under resting/exercise conditions.
62724083|NCT00784368|EXPERIMENTAL|SFI (Switched Treatment)|Participants with SFI received 200 milligram (mg) twice daily itraconazole intravenous (into the vein) infusion (ITCZ-IV) for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
62724084|NCT00784368|EXPERIMENTAL|FN (Switched treatment)|Participants with febrile neutropenia (FN) with suspected fungal infection received 200 mg twice daily ITCZ-IV for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
62724085|NCT02360852|EXPERIMENTAL|A4250|A4250 once daily
62724086|NCT01276548|EXPERIMENTAL|Genexol®-PM plus Carboplatin|
62724087|NCT01276548|ACTIVE_COMPARATOR|Genexol® plus Carboplatin|
62724088|NCT03037125|ACTIVE_COMPARATOR|Control Arm|Split crest without PRF
62724089|NCT03037125|EXPERIMENTAL|Intervention Arm|Split crest with PRF
62724090|NCT00968773|EXPERIMENTAL|The Rebound hernia repair device with no fixation|Competent adults who have a unilateral, bilateral inguinal hernia that is primary in nature.
62724091|NCT00968773|ACTIVE_COMPARATOR|Standard Hernia Mesh using fixation|Competent adults who have a unilateral or bilateral inguinal hernia that is primary in nature.
62724092|NCT05137691|EXPERIMENTAL|Experimental|Adapted NHS weight management 1:1 programme. Low carbohydrate dietary focus, enhanced behaviour change via telehealth, daily step target supported by pedometers
62724093|NCT05137691|ACTIVE_COMPARATOR|Active comparator NHS 1:1 weight management programme|12 week NHS 1:1 weight management programme
62724094|NCT01533441|PLACEBO_COMPARATOR|placebo low VKA|
62724095|NCT01533441|PLACEBO_COMPARATOR|Placebo high VKA|Microcrystalline cellulose
62724096|NCT01533441|ACTIVE_COMPARATOR|Vitamin K2 Low VKA|
62724097|NCT01533441|ACTIVE_COMPARATOR|Vitamin K2 high VKA|
62724098|NCT03410069|EXPERIMENTAL|IKORUS UP|
62724099|NCT06393777|EXPERIMENTAL|Effect of Pre-administered honey for Decreasing Pain of Dental Injections|The participants were asked to drink 5 mL of honey solution before injecting on the experimental side, the patient was asked to hold the solution in the mouth for a minute and then to spit it out .
62724100|NCT06393777|OTHER|topical anesthesia|benzocaine 20% gel was applied to the test sites on side of the jaw with a cotton tip applicator which was completely soaked for a period of 5 minutes.
62724101|NCT01266330|ACTIVE_COMPARATOR|Low Dairy|\<0.5 standard dairy servings/day
62724102|NCT01266330|EXPERIMENTAL|Adequate dairy|3.5 standard dairy servings per day
62724103|NCT03132558||CTA|Patients with AIS only receieved cerebral CTA exam.
62724104|NCT03132558||CTA+DSA|Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).
62724105|NCT03775317|EXPERIMENTAL|Video Laryngoscopy|
62724106|NCT03775317|ACTIVE_COMPARATOR|Direct Laryngoscopy|
61978205|NCT06215599||Medical doctors|Medical doctors that specialize in ENT and also mostly work in otology
61978206|NCT06215599||audiologist|Health professionals that specialüze in Audiology
62724107|NCT02965989|EXPERIMENTAL|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
62724108|NCT02965989|NO_INTERVENTION|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
62724109|NCT02733003|EXPERIMENTAL|Women's Health CoOp (WHC)|This is an adapted behavioral intervention for women in South Africa, who use alcohol and other drugs and are living with HIV or at risk of acquiring HIV.
62724110|NCT01590368|OTHER|Marketed electrode|The currently marketed electrodes using the current CE marked adhesive
62724111|NCT01590368|ACTIVE_COMPARATOR|Modified hydrogel|"Electrodes with the new modified adhesive - the test electrodes"
62724112|NCT02159625|EXPERIMENTAL|Abdominal Compression Elastic Support|To compress the abdomen at 15 mmHg for 3 hours during the course of hemodialysis treatment.
62724113|NCT00427011|EXPERIMENTAL|1|
62724114|NCT00976157||Ventilator-associated pneumonia|
62724115|NCT04004767||TRC-PAD Cohort|Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.
62724116|NCT04630925|ACTIVE_COMPARATOR|isCGM-arm|CGM data will be viewed real-time and used to adjust diabetes treatment
62724117|NCT04630925|NO_INTERVENTION|POC-arm|POC glucose readings are used to adjust diabetes treatment. CGM data are blinded to all and only gathered for comparison purposes to intervention group.
62724118|NCT05035043|EXPERIMENTAL|NAFLD patients|Non-Alcoholic Fatty Liver Disease patients
62724119|NCT05745610|EXPERIMENTAL|Shen Hai Long Group|
62724120|NCT05745610|ACTIVE_COMPARATOR|Sheng Jing Group|
62724121|NCT05871580|ACTIVE_COMPARATOR|Laser Group (GL)|The patients will be submitted to eight sessions of low power laser. The radiation emission will be performed according to the protocol.
61978207|NCT05083104||age and sex matched healthy control individuals.|controls divided into groups ,each group match in age and sex with cases
61978208|NCT05083104||mild and severe cases of COVID 19 patients|Covid 19 cases diagnosed by PCR , mild cases have symptoms as fever, dry cough, and diarrhea and severe cases admitted in ICU
61978209|NCT00884208||Group 1|Recommend assistive device
61978210|NCT00884208||Group 2|Consultation for PT assessment
61978211|NCT03072615||1|receiving TE before and 30 min after TIPS
61978212|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
61978213|NCT01952431|EXPERIMENTAL|PulmOne MiniBox PFT|Total Lung Capacity (TLC) testing with PulmOne MiniBoxPFT
62724122|NCT05871580|PLACEBO_COMPARATOR|Control Group (CG)|In these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off.
62724123|NCT03457714||Guided I-CBT for persons with SCI|Persons with spinal cord injury
62724124|NCT03306433|EXPERIMENTAL|UDMA-K18|UDMA-K18 smooth surface sealant
62724125|NCT03306433|PLACEBO_COMPARATOR|UDMA-control|UDMA smooth surface sealant without K18
62724126|NCT03306433|NO_INTERVENTION|Negative control|No intervention to provide baseline
62724127|NCT00222144|EXPERIMENTAL|1|Gleevec and Taxotere
62724128|NCT03248388|EXPERIMENTAL|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
62724129|NCT03175731|EXPERIMENTAL|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
62724130|NCT03175731|PLACEBO_COMPARATOR|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
62724131|NCT04532840|ACTIVE_COMPARATOR|Group A: (control group)|This group includes 30 patients will receive routine medical treatment and routine physical therapy as (Exercising, Positioning and splinting, Pressure Therapy and Massage).
62724132|NCT04532840|EXPERIMENTAL|Group B: (Study group)|This group includes 30 patients will receive cryotherapy (at least 10 minutes at -14 degree , 2 sessions per week , for 10 weeks ) in addition to routine medical and physical therapy treatment.
62724133|NCT05067205|SHAM_COMPARATOR|open release|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using open carpal tunnel release method with duration of 6 months estimated.
62724134|NCT05067205|EXPERIMENTAL|mini CTS releaser|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using mini CTS releaser method with duration of 6 months estimated.
62724135|NCT00825994|EXPERIMENTAL|Omega-3|omega-3 fatty acids, 2grams qd \[every day\] (2 x 1 gram tablets), PO \[by mouth\]
62724136|NCT05527600||assessment of pain in Pediatric Department|2000 children patients admitted in emmergency department
62724137|NCT05696847|EXPERIMENTAL|Tirzepatide|Tirzepatide administered subcutaneously (SC)
62724138|NCT05696847|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
62724139|NCT00856323|EXPERIMENTAL|PEP/CM|Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.
62724140|NCT03673540|EXPERIMENTAL|CBT with smartphone application (EMI on)|CBT with CBT+ smartphone application (EMI on)
62724141|NCT06462287|EXPERIMENTAL|Aprepitant|
62724142|NCT06462287|PLACEBO_COMPARATOR|Placebo|
62724143|NCT04138511|EXPERIMENTAL|Experimental group (ECOFISIO)|Ecofisio Group received the ECOFISIO mobile application after students had received theoretical-practical lessons about ultrasound skills in sports pathologies areas, to study the subject.
62724144|NCT04138511|NO_INTERVENTION|Control Group|Students received theoretical-practical lessons about ultrasound skills in sports pathologies areas and used traditional study models, to study the subject
62724145|NCT05707338|ACTIVE_COMPARATOR|laparoscopic group|
62724146|NCT05707338|ACTIVE_COMPARATOR|open group|
62724147|NCT02797912||CF children and young people|Observational study involving clinical procedures: lung function testing, respiratory muscle strength testing, body composition analysis \& exercise tolerance.
62724148|NCT00753948|EXPERIMENTAL|Chronic Tetraplegia|Individuals with chronic tetraplegia
62724149|NCT00753948|ACTIVE_COMPARATOR|Mild Asthma|Individuals with diagnosed mild asthma
62724150|NCT00753948|PLACEBO_COMPARATOR|Healthy Control|Neurologically intact, otherwise healthy, age-matched control
62724151|NCT02974608||Children 0-10 years|Children living in selected villages surrounding the district of Ouelessebougou
62724152|NCT02974608||Pregnant Women + Newborns|Pregnant women of any age and their newborn children
62724153|NCT02974608||Women of Child Bearing Age Potential|Non-pregnant women of child-bearing age
62724154|NCT05067881||Pneumohematocele|Patients with SARS CoV-2 diagnosis and PHC on imaging studies
62724155|NCT04336241|EXPERIMENTAL|Dose escalation of RP2 - superficial tumors|Dose escalation of RP2 alone in 3 cohorts with IT injections in superficial tumors.
62724156|NCT04336241|EXPERIMENTAL|Dose escalation of RP2 - deep/visceral tumors|Dose escalation of RP2 alone in 3 cohorts with imaging guided IT injections in deep/visceral tumors.
62724157|NCT04336241|EXPERIMENTAL|Dose expansion of RP2 and nivolumab - superficial tumors|Doses of RP2 (IT) in superficial tumors with nivolumab (IV).
62724158|NCT04336241|EXPERIMENTAL|Dose expansion of RP2 and nivolumab - deep/visceral tumors|Imaging guided doses of RP2 (IT) in deep/visceral tumors.
62724159|NCT04336241|EXPERIMENTAL|Seronegative cohort|Doses of RP2 (IT) in HSV seronegative participants.
62724160|NCT04663594|EXPERIMENTAL|Ways of Being online Experience|Ways of Being (WoB) every day for three days
62724161|NCT04663594|OTHER|Ashmolean Website|The Ashmolean Website every day for three days
62724162|NCT06410989||Chronic patients post-stroke|Patients post-stroke, age 40-80, with a unilateral supratentorial ischemic or hemorrhagic stroke
62724163|NCT06410989||Healthy Individuals|Healthy adults, age 40-80, without neurological disorders
61978214|NCT01952431|ACTIVE_COMPARATOR|ZAN500|Total Lung Capacity (TLC) testing with ZAN500.
62724164|NCT03218839|EXPERIMENTAL|HIV+ PrePex|PrePex male circumcision device
62724165|NCT04467814|EXPERIMENTAL|Intervention|
62724166|NCT04467814|ACTIVE_COMPARATOR|Usual Care|
62724167|NCT02264613|EXPERIMENTAL|Dose Regimen A (DR-A)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.
62724168|NCT02264613|EXPERIMENTAL|Dose Regimen B (DR-B)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle
62724169|NCT02264613|EXPERIMENTAL|Dose Regimen C (DR-C)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle
62724170|NCT02264613|EXPERIMENTAL|Combination with palbociclib|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle
62724171|NCT04096586|ACTIVE_COMPARATOR|Red juice|Subjects consume 8 fl oz of red juice daily for 8 weeks
62724172|NCT04096586|EXPERIMENTAL|Watermelon juice|Subjects consume 8 fl oz of watermelon juice daily for 8 weeks
62724173|NCT04923243||Delirium group|Group of patients with postoperative delirium
62724174|NCT04923243||Non delirium group|Group of patients without postoperative delirium
62724175|NCT05358743|EXPERIMENTAL|Probiotic group|
62724176|NCT05358743|PLACEBO_COMPARATOR|Control group|
62724177|NCT00185237|EXPERIMENTAL|Arm 1|
62724178|NCT00185237|PLACEBO_COMPARATOR|Arm 2|
62724179|NCT01900067|ACTIVE_COMPARATOR|Active warming|BARRIER® EasyWarm Active Self-Warming Blanket
62724180|NCT01900067|NO_INTERVENTION|Control|no active warming, standard of care
62724181|NCT01984047|EXPERIMENTAL|GSK3050002 0.1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
62724182|NCT01984047|EXPERIMENTAL|GSK3050002 0.5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
62724183|NCT01984047|EXPERIMENTAL|GSK3050002 1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort
62724184|NCT01984047|EXPERIMENTAL|GSK3050002 5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
62724185|NCT01984047|EXPERIMENTAL|GSK3050002 10 mg|Six subjects in this cohort will receive a single dose of GSK3050002 10 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
62724186|NCT01984047|EXPERIMENTAL|GSK3050002 20 mg|Six subjects in this cohort will receive a single dose of GSK3050002 20 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
62724187|NCT00817934||PREVENTION AND TREATMENT|PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
62724188|NCT03573245||intra-op single dose|intra-operative single dose of tranexamic acid
62724189|NCT03573245||intra-op dose and additional dose|intra-operative dose of tranexamic acid and additional dose 3 hours after
62724190|NCT03573245||intra-op dose and perfusion|intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.
62724191|NCT05634330|EXPERIMENTAL|treatment group|treatment group: core stabilization exercises used to improve balance
62724192|NCT05634330|NO_INTERVENTION|control group|this group members have continued their normal lives
62724193|NCT00375466|EXPERIMENTAL|Tranexamic Acid|
62724194|NCT00375466|PLACEBO_COMPARATOR|placebo|
62724195|NCT00980148|EXPERIMENTAL|Arm2|Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects
62724196|NCT00980148|EXPERIMENTAL|Arm 1|Azithromycin 1 gm oral single dose; 153 subjects
62724197|NCT02616939||Patients with suspected cardiac disease|"Patients eligible for cardiac CT will be included with a focus on symptomatic patients with low-intermediate risk for obstructive coronary artery disease.~Patients will undergo Cardiac CT scanning (with the SpotLight CT)."
62724198|NCT03886493|EXPERIMENTAL|Dupixent Subcutaneous (SQ) Injection|Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.
62724199|NCT02255539|EXPERIMENTAL|CPAP Nasal Mask|Geelong Prototype Mask
62724200|NCT05410418|EXPERIMENTAL|Mosunetuzumab and Polatuzumab Vedotin|Patients receive CD3xCD20 bispecific antibody mosunetuzumab administered subcutaneously in combination with CD79b directed ADC polatuzumab vedotin administered intravenously. Mosunetuzumab and polatuzumab vedotin are given in combination for 6 cycles. Mosunetuzumab is given on Days 1, 8, and 15 of cycle 1 and then Day 1 thereafter, and polatuzumab vedotin is given on Day 1. After 6 cycles, patients continue on mosunetuzumab alone for 2 additional cycles. Patients undergo scans at the end of cycle 8, and if those scans show a complete response, patients will stop any further treatment and will enter follow-up. Patients with a partial response or stable disease on scans at the end of cycle 8 may receive up to 9 additional cycles of mosunetuzumab in the absence of disease progression or unacceptable toxicity. All cycles are planned to be 21 days.
62724201|NCT05171972||Relapsing-remitting Multiple Sclerosis|Enrolled subjects in this group will have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria of the relapsing-remitting form with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and will be treated with Ofatumumab.
62724202|NCT05171972||Healthy Control Subjects|Enrolled subjects must not have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria, any other autoimmune disease, demyelinating co-morbidity, neurological disease or immune system altering disease.
62724203|NCT06235918|EXPERIMENTAL|Neoadjuvant therapy of tislelizumab with chemotherapy|Neoadjuvant Tislelizumab plus double platinum based chemotherapy for 2 cycles
62724204|NCT06103344|EXPERIMENTAL|Intervention|
62724205|NCT06103344|NO_INTERVENTION|Control|
62724206|NCT06512610||Middle Eastern or North Coast of Africa patients with newly AML|Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients
62724207|NCT00142792|ACTIVE_COMPARATOR|A. Cyclic stim|"* Preprogrammed cycles of finger and thumb flexor and extensor stimulation (and flexor stimulation if deemed necessary by the PI) repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~* Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~* Uses NMES device with EMG-triggered and Cyclic capabilities"
62724208|NCT00142792|ACTIVE_COMPARATOR|B. Sensory stim|"Sensory-only electrical stimulation. The stimulation will be cyclic in nature but intensity will be set to a level that can be felt by the patient but not sufficient to cause muscle contraction.~Uses NMES device with EMG-triggered and Cyclic capabilities"
62724209|NCT00142792|ACTIVE_COMPARATOR|C. EMG-Triggered|"EMG-Triggered electrical stimulation. Subjects in this group will attempt to extend their affected wrist and fingers in response to an audio cue. They will be rewarded with stimulation to cause full hand opening once they have generated EMG sufficient to reach a preset threshold level.~Uses NMES device with EMG-triggered and Cyclic capabilities"
62724210|NCT04912544|EXPERIMENTAL|Arm 1|Patient talking with microphone first turned on and then off
62165951|NCT02785302||Adolescents and Young Adults:|Behaviorally-infected, HIV-positive, adolescents and young adults enrolled in ATN 125, aged 18 through 24, inclusive who are transition eligible. All subjects with available endpoint data will be included in the analysis.
62724211|NCT04912544|EXPERIMENTAL|Arm 2|Patient talking with microphone first turned off and then on
62724212|NCT05508646|EXPERIMENTAL|Intervention arm|Twelve participants will be randomized for the intervention. The music therapy intervention takes place once a week for 6 weeks via telemedicine, with the first session reserved for music therapy intake/assessment. There are 5 additional visits, once per week. The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
62724213|NCT05508646|OTHER|Control arm|Twelve participants will be randomized to receive a personalized music CD that they keep and can listen to as they wish.
62724214|NCT02527473|NO_INTERVENTION|Standard Education Group|Control group will receive standard basic life support training for one hour.
62724215|NCT02527473|EXPERIMENTAL|HEROS Group|HEROS group will receive the dispatcher-assisted basic life support training that includes standardized video-based CPR education, interactive role-playing with the dispatcher as well as group discussion for one hour.
62724216|NCT01820806|EXPERIMENTAL|[14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
62724217|NCT04065698|EXPERIMENTAL|RV521|Three single 200 mg oral doses of RV521 administered on Day 1, Day 5 and Day 9 as either the drug in capsule (1 dosing occasion) or the dry powder blend dispersed in water (2 dosing occasions)
62724218|NCT04910152|EXPERIMENTAL|Treatment for aGVHD (BRD4 inhibitor PLX51107)|Patients receive BRD4 inhibitor PLX51107 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62724219|NCT01369199|EXPERIMENTAL|Peginterferon and entecavir|A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.
62724220|NCT06116981|EXPERIMENTAL|Experimental Group|The experimental group consists of individuals who received high-induction magnetic field therapy in addition to conservative treatment (routine rehabilitation sessions including stretching, transcutaneous electrical nerve stimulation, and exercises.).
62724221|NCT06116981|ACTIVE_COMPARATOR|Comparison Group|Conservative Treatment Group: Group with routine rehabilitation sessions including stretching, transcutaneous electrical nerve stimulation, and exercises.
62724222|NCT02271893|EXPERIMENTAL|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
62724223|NCT02271893|PLACEBO_COMPARATOR|placebo|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
62724224|NCT06302465|ACTIVE_COMPARATOR|neoadjuvant chemotherapy|
62724225|NCT06302465|EXPERIMENTAL|narlumosbartmab plus neoadjuvant chemotherapy|
62724226|NCT03159910|EXPERIMENTAL|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
62724227|NCT03159910|ACTIVE_COMPARATOR|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
62724228|NCT05624983|EXPERIMENTAL|Case group (children with language disorder)|Hearing diagnostic test
62724229|NCT05624983|OTHER|controle group (children without language disorder)|Hearing diagnostic test
62724230|NCT02359006|ACTIVE_COMPARATOR|minocycline|200mg minocycline
62724231|NCT02359006|PLACEBO_COMPARATOR|Placebo|Sugar pill
62165952|NCT02785302||AMTU and Adult Clinic Staff|Clinical staff at the Adolescent Medical Trials Units (AMTUs) and at adult clinics where the AMTUs refer their transitioning patients will be recruited to complete quantitative surveys and semi-structured interviews.
62165953|NCT01827202|ACTIVE_COMPARATOR|Aliskiren|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
62724232|NCT05243628|EXPERIMENTAL|Afrezza + Automatic Insulin Delivery|Subjects in this group will use Afrezza for their bolus (mealtime) insulin and a CSII pump with an AID algorithm using RAA for their basal and correction insulin coverage.
62724233|NCT05243628|EXPERIMENTAL|Afrezza + Insulin Degludec|Subjects in this group will use Afrezza for their bolus (mealtime and correction) insulin and insulin degludec for basal insulin coverage.
62724234|NCT05243628|ACTIVE_COMPARATOR|AID Control|Subjects in this group will use a CSII pump with an AID algorithm using RAA for all bolus (mealtime and correction) and basal insulin coverage (control group).
62724235|NCT01082848|EXPERIMENTAL|aripiprazole|
62724236|NCT01082848|PLACEBO_COMPARATOR|placebo|
62165954|NCT01827202|ACTIVE_COMPARATOR|Candesartan|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
62724237|NCT06375525|OTHER|Application (App), a digital tool|Janssen's icon Application (App), a digital tool designed to improve adherence to medication treatment in children with ADHD.
62724238|NCT00856609|ACTIVE_COMPARATOR|Exenatide|10 micrograms subcutaneously twice
62724239|NCT00856609|PLACEBO_COMPARATOR|Placebo|Twice daily
62724240|NCT00548197|EXPERIMENTAL|Intervention group|Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
62724241|NCT00548197|NO_INTERVENTION|Control group|no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy
62724242|NCT01669746|EXPERIMENTAL|Treatment|
62724243|NCT00614133|EXPERIMENTAL|1|Preoperative nutrition.
62724244|NCT00614133|ACTIVE_COMPARATOR|2|Preoperative fasting.
62724245|NCT05996393|EXPERIMENTAL|CsA+ATG+AVA|Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Anti-human thymocyte: rabbit anti-human thymocyte globulin (r-ATG 3mg/kg/d) was administered intravenously for 5 days; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.
62724246|NCT05996393|EXPERIMENTAL|CsA+AVA|Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.
62724247|NCT02051478|EXPERIMENTAL|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied.
62724248|NCT02051478|ACTIVE_COMPARATOR|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
62724249|NCT04268069|PLACEBO_COMPARATOR|Placebo Ophthalmic Solution (vehicle)|vehicle
62724250|NCT04268069|ACTIVE_COMPARATOR|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution
62724251|NCT00811954|EXPERIMENTAL|Arm A: ATV/RTV + FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
62724252|NCT00811954|EXPERIMENTAL|Arm B: RAL + FTC/TDF|FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
62724253|NCT00811954|EXPERIMENTAL|Arm C: DRV/RTV + FTC/TDF|FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
62724254|NCT01327235|ACTIVE_COMPARATOR|Endostar|
62724255|NCT01327235|ACTIVE_COMPARATOR|Cisplatin|
62724256|NCT01327235|EXPERIMENTAL|Endostar and Cisplatin|
62724257|NCT02599480|ACTIVE_COMPARATOR|mirabegron|Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.
62724258|NCT02599480|PLACEBO_COMPARATOR|Placebo|Patients will be orally administererd with a placebo once a day during 12 months.
62724259|NCT00934583|EXPERIMENTAL|Image and Mood (IaM) program|Participants will participate in the IaM program.
62724260|NCT00934583|NO_INTERVENTION|Wait-list control|Participants will be placed on a wait list until after participants in the IaM group have completed all assessments. After that, these participants will be offered the option to complete the IaM program.
62165955|NCT01665014|EXPERIMENTAL|Total marrow irradiation|Double autologous hematopoietic stem cell transplantation using TMI and HD-Mel
62724261|NCT03019887|EXPERIMENTAL|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
62724262|NCT04510467||case group|RMD patients with COVID 19 infection
62724263|NCT04510467||control group|RMD patients without COVID 19 infection
62724264|NCT03565172|EXPERIMENTAL|Children with spastic cerebral palsy|"Children with spastic cerebral palsy will be included. They will have 3 phases:~* Baseline: 4, 5 or 6 evaluations~* Intervention: 9 evaluations before and after every stretching session~* Follow-up: 4, 5 or 6 evaluations~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology."
62724265|NCT04380623|EXPERIMENTAL|Mobile Phone-Based Web-Page: HPV vaccine|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit, tailored education information on the HPV vaccine via a text message with a website link.
62724266|NCT04380623|ACTIVE_COMPARATOR|Mobile Phone-Based Web-Page: Healthy Lifestyles|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit education information on an unrelated topic (e.g., healthy eating and physical activity) via a text message with a website link.
62724267|NCT01024348|ACTIVE_COMPARATOR|Tramadex-OD|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
62724268|NCT01024348|ACTIVE_COMPARATOR|Control group|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
62724269|NCT03372161|EXPERIMENTAL|SP-102|SP-102
62724270|NCT03372161|PLACEBO_COMPARATOR|Placebo|Placebo
62724271|NCT01370304|EXPERIMENTAL|active rTMS and active Venlafaxine|
62724272|NCT01370304|EXPERIMENTAL|active rTMS and sham Venlafaxine|
62724273|NCT01370304|SHAM_COMPARATOR|sham rTMS and active Venlafaxine|
62724274|NCT03154476|EXPERIMENTAL|Sildenafil|Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
62724275|NCT03154476|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo times per day for 12 months.
62165956|NCT00848640|EXPERIMENTAL|Sorafenib|
62724276|NCT01983007|EXPERIMENTAL|high-intensity exercise group|Patients undergoing high-intensity exercise group. Intervention: high-intensity exercise.
62724277|NCT01983007|EXPERIMENTAL|low-intensity exercise group|Patients undergoing low-intensity exercise group Intervention: low-intensity exercise
62724278|NCT02131662|EXPERIMENTAL|VPR 4 mg|
62724279|NCT02131662|EXPERIMENTAL|VPR 2 mg|
62724280|NCT02131662|EXPERIMENTAL|VPR 1 mg|
62724281|NCT02131662|EXPERIMENTAL|VPR 0.5 mg|
62724282|NCT02131662|PLACEBO_COMPARATOR|Placebo|
62724283|NCT03729986||Healthy adults|Healthy subjects without exercise habit that can cooperate with the measurements of this study, loaded inspiratory muscle test.
62724284|NCT02393820|EXPERIMENTAL|pazopanib|Pazopanib per os, 800mg daily until progression
62724285|NCT02356536|EXPERIMENTAL|Experimental|
62724286|NCT03765125|EXPERIMENTAL|collagen peptide test|1 x daily consumption of 1 blister package of the collagen-peptide test powder dissolved in water over a period of 90 days
62724287|NCT03765125|PLACEBO_COMPARATOR|collagen peptide placebo|1y daily consumption of 1 blister package of the placebo powder dissolved in water over a period of 90 days
62724288|NCT03017105|ACTIVE_COMPARATOR|Control|Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
62724289|NCT03017105|EXPERIMENTAL|Experimental|Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm
62724290|NCT00488514|OTHER|Active Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)
62724291|NCT00560092|EXPERIMENTAL|intrathecal magnesium sulfate|
62724292|NCT01973868|EXPERIMENTAL|Regorafenib|"Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.~Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.~The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.~Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
62724293|NCT02548689||Non-scarring hair loss|Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.
62724294|NCT02548689||Control|Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.
62724295|NCT03160456|EXPERIMENTAL|Transcutaneous electrical stimulation|The group of participants receiving continuous transcutaneous electrical stimulation will be trained on the device and settings will be recorded. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Bi-weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At each visit comfort, compliance and adverse reactions will be recorded. At 12-weeks, the patients will be invited for a repeat assessment including polysomnography/home-based respiratory polygraphy during a night of electrical stimulation. Usage time of the device will be discussed with the patients and recorded.
62724296|NCT03160456|ACTIVE_COMPARATOR|Continuous positive airway pressure (usual care)|Participants who will be randomized to the usual care group will be given their own CPAP device, as previously prescribed. Bi-weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At the last visit, the patients will be studied during a repeat inpatient polysomnography/home-based respiratory polygraphy and the initial assessment will be repeated.
62724297|NCT01306643|EXPERIMENTAL|Idelalisib|
62724298|NCT01994681||Pancreatic Cancer|
62724299|NCT01994681||Healthy|
62724300|NCT00746187|EXPERIMENTAL|ASTRA TECH Implant System; Fixture ST|Ø 4.5 cm in lengths 9-13 mm
62724301|NCT00746187|EXPERIMENTAL|Biomet 3i; Osseotite® Implants|Ø 4.0 cm in lengths 8.5-13 mm
62724302|NCT03359369||Septic Patients|
62724303|NCT03359369||Non Septic Patients|
62724304|NCT04691037||CCTA|
62724305|NCT01397383||Vitamin D deficiency|Patients with low serum vitamin D (25-hydroxy vitamin D \< 32 ng/ml)
62724306|NCT01397383||Control group|Patients with normal serum vitamin D level (serum 25-hydroxy vitamin D \> 32 ng/ml)
62724307|NCT01559246||Cardiac Arrhythmia|Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
62724308|NCT05818826|EXPERIMENTAL|early cessation group|The pharmacist uses 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group. The experimental starts after required dose of vasopressor less than 0.1 mcg/kg/min. The nurse serially records capillary blood glucose and serum sodium following the doctor's order.
62724309|NCT05818826|PLACEBO_COMPARATOR|conventional cessation group|The pharmacist prepared hydrocortisone and normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min. The nurse serially records capillary blood glucose and serum sodium following the doctor's order.
62724310|NCT02524561|ACTIVE_COMPARATOR|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
62724311|NCT02524561|ACTIVE_COMPARATOR|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
62724312|NCT02524561|PLACEBO_COMPARATOR|placebo|Placebo tablet, placebo patch, placebo progesterone
62724313|NCT04062084|EXPERIMENTAL|Multifunctional Cataract-assisted Retractor|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
62724314|NCT04062084|EXPERIMENTAL|Capsule Retractor|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
62724315|NCT03116425|EXPERIMENTAL|Verum 1 - Premotor|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the premotor region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
62724316|NCT03116425|EXPERIMENTAL|Verum 2 - Prefrontal|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the prefrontal region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
62724317|NCT03116425|ACTIVE_COMPARATOR|Placebo|Stimulation of a region with normal rCBF and putatively unrelated to catatonic symptoms (parietal cortex).
62724318|NCT02087930||Cow milk allergy children|Children affected by Immunoglobulin E medited cow milk allergy
62724319|NCT02087930||healthy control|healthy infants
62724320|NCT05335252|EXPERIMENTAL|Dronabinol|Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
62724321|NCT05335252|PLACEBO_COMPARATOR|Placebo|Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
62724322|NCT06011265|EXPERIMENTAL|Mirabegron + Isoproterenol|100mg oral + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass
62724323|NCT06011265|PLACEBO_COMPARATOR|Placebo + Isoproterenol|Empty Capsule + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass
62736232|NCT04098887|EXPERIMENTAL|Lattice stereotactic body radiation therapy|Patients with up to 10 chondrosarcoma lesions will undergo radiotherapy to all sites of disease. For lesions less than 4.5 cm, traditional SBRT will be used. For sites 4.5 cm or greater, Lattice SBRT will be used. For Lattice SBRT, radiotherapy will be prescribed to 20 Gy in 5 fractions delivered every other day with a LATTICE simultaneous integrated boost (SIB) to 66.7 Gy in 5 fractions.
62724324|NCT05544435|EXPERIMENTAL|Motivational Interviewing|Intervention In addition to the care they always received, MI sessions were conducted by the researcher for the participants in the experimental group. This intervention was conducted as 30-45 minutes of 12 sessions in total for each patient for a period of 3 months by the academic nurse. In these sessions, the agenda was created in accordance with the nature of MI intervention, efforts were made to resolve the ambivalent feelings in the patient, the patient's change phase was determined, the patient's self-confidence for change was determined, it was questioned how much the patient cared for change and the patient was helped in determining the change plan. In addition, during the sessions, the problems patients experienced about self-care activities, the causes of these problems and the barriers in maintaining self-care activities were discussed and efforts were made to create awareness in patients.
62724325|NCT05257928|EXPERIMENTAL|CARE-CITE GAIT Carepartner|This study arm consists of carepartners (CP) receiving the CARE-CITE Gait intervention. Over a period of one month, alongside the stroke survivor, the CP will receive 2 two-hour home-based therapy visits with a licensed physical therapist to develop therapy goals related to gait, mobility and balance and develop a home exercise plan to improve function. The CP will receive two additional phone calls to discuss the online CARE-CITE educational modules.
62724326|NCT05257928|EXPERIMENTAL|CARE-CITE GAIT Stroke Survivor|This study arm consists of stroke survivors (SS) of carepartners receiving the CARE-CITE Gait intervention. Over a period of one month, along with the CP, the SS will receive 2 two-hour home-based therapy visits with a licensed physical therapist to develop therapy goals related to gait, mobility and balance and develop a home exercise plan to improve function.
62724327|NCT02911142|EXPERIMENTAL|1|Lenalidomide, Rituximab, Prednisone, Etopiside, Doxorubicin, Vincristine and Cyclophosphamide
62724328|NCT06284239|NO_INTERVENTION|Control group|For six weeks, theoretical training on the history of Nursing will be given by the researchers. Then, all the topics learned in the course will be repeated using question-answer and discussion methods, using questions prepared by the researchers, with the control group for four weeks. After this process, carried out by one of the researchers, is completed, the students will be given a nursing history knowledge test (posttest) and a nursing history teaching evaluation form and asked to fill it out.
62724329|NCT06284239|EXPERIMENTAL|Interversion group|For six weeks, theoretical training on the history of Nursing will be given by the researchers. Then, the intervention group will be played the tell-all game with game cards prepared by the researchers for four weeks. After this process, carried out by one of the researchers, is completed, the students will be given a nursing history knowledge test (posttest) and a nursing history teaching evaluation form and asked to fill it out.
62724330|NCT03886467|ACTIVE_COMPARATOR|Nutrition Education|Households will participate in community-based nutrition education program specifically targeting child nutrition and milk consumption, in addition to general community development activities
62724331|NCT03886467|NO_INTERVENTION|Control|community development activities only.
62724332|NCT01122446|PLACEBO_COMPARATOR|Placebo comparator|Two doses of placebo day 1 and 30
62724333|NCT01122446|ACTIVE_COMPARATOR|Alum-GAD (Diamyd)|20 microgram Diamyd day 1 and 30
62724334|NCT05417672||Lung cancer scheduled lobectomy|
62724335|NCT01680926|EXPERIMENTAL|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
62724336|NCT01763333|EXPERIMENTAL|1 BI 1026706 single rising dose part|single rising doses of BI 1026706
62724337|NCT01763333|EXPERIMENTAL|2 BI 1026706 bioavailability part|bioavailability part of BI 1026706
62724338|NCT04203589|EXPERIMENTAL|The Explorer Early Intervention Program|The Explorer Early Intervention Program is used in this group.
62724339|NCT04203589|ACTIVE_COMPARATOR|Neurodevelopmental Therapy|Neurodevelopmental therapy is used in these group by two experienced and certificated physiotherapist
62724340|NCT06460038|EXPERIMENTAL|Tenapanor|Tenapanor 50 mg orally twice daily for 12 weeks
62724341|NCT06460038|PLACEBO_COMPARATOR|Placebo|Placebo orally twice daily for 12 weeks
62724342|NCT02132286|EXPERIMENTAL|Quetiapine -XR (extended release)|Quetiapine-XR (extended release) 150-300mg- treatment in MDD patients with S/Lg alleles in MDD
62724343|NCT02132286|ACTIVE_COMPARATOR|Citalopram|Citalopram 10-20 mgm/day treatment for 8 weeks in MDD with S/Lg alleles
62724344|NCT00256633||Group 1|enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.
62724345|NCT01373190||Epilepsy Group|Individuals diagnosed with Partial/Focal Onset Epilepsy ICD9CM 345.4 and/or 345.5
62724346|NCT01373190||Control Group|Individuals who do not have the diagnosis of Epilepsy and have no history of seizure disorders
62724347|NCT01752556|ACTIVE_COMPARATOR|Hospital diagnosis|diagnosis of Sleep Apnea and therapeutic decision will perform according to polysomnography
62724348|NCT01752556|EXPERIMENTAL|Home diagnosis|diagnosis of Sleep Apnea and therapeutic decision will be perform according to home respiratory polygraphy
62724349|NCT04677543|ACTIVE_COMPARATOR|ALIS + Background Regimen (Azithromycin + Ethambutol)|Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
62724350|NCT04677543|PLACEBO_COMPARATOR|ELC + Background Regimen (Azithromycin + Ethambutol)|Participants will be administered ELC (empty liposome control), a matching placebo to ALIS, once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
62724351|NCT04186325|NO_INTERVENTION|Group C|Group C: the regular mechanical ventilation protocol will be followed.
62724352|NCT04186325|EXPERIMENTAL|Group T|Group T: inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
62724353|NCT01041950|EXPERIMENTAL|Lumbar drainage|
62724354|NCT01041950|NO_INTERVENTION|Control|
62724355|NCT01881282|EXPERIMENTAL|Carraghenates Cream|
62724356|NCT01881282|ACTIVE_COMPARATOR|Mayinglong Musk Hemorrhoid Ointment|
62724357|NCT00609752|ACTIVE_COMPARATOR|1|
62724358|NCT00609752|ACTIVE_COMPARATOR|2|
62724359|NCT04242706|ACTIVE_COMPARATOR|Control group|Endotracheal tube with evacuation lumen without Bactiguard coating.
62724360|NCT04242706|EXPERIMENTAL|Experimental group|Endotracheal tube with evacuation lumen with Bactiguard coating.
62724361|NCT05712980||DTM Cohort|Patients with Failed Back Surgery Syndrome treated with Spinal Cord Stimulation with DTM programming
62724362|NCT05712980||Conventional Cohort|Patients with Failed Back Surgery Syndrome treated with Spinal Cord Stimulation with conventional programming
62724363|NCT04152486|EXPERIMENTAL|Intervention arm|The vaccine Ad26.ZEBOV (5x10\^10 viral particles (vp)) will be given as the first dose and the vaccine MVA-BN-Filo (1x10\^8 infectious units (Inf U)) will be given as the second dose 56 (-14 day +28 day) days later.
62724364|NCT00360958|EXPERIMENTAL|Ultrafiltration|Ultrafiltration treatment
62724365|NCT00360958|ACTIVE_COMPARATOR|Usual treatment|Usual HF treatment
62724366|NCT02921295|ACTIVE_COMPARATOR|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
62724367|NCT02250976|EXPERIMENTAL|Livasupril Cap.160/2mg|"* Fenofibrate pellet ( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~* once a day"
62724368|NCT02250976|ACTIVE_COMPARATOR|Lipilfen cap.160mg, Livaro tab. 2mg|"* Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg~* Coadministariton of Lipilfen cap.160mg and Livaro tab. 2mg, once a day"
62724369|NCT05460897|EXPERIMENTAL|Experimental|12-week intervention consisting of educational sessions and health behaviour change techniques
62724370|NCT05460897|NO_INTERVENTION|Waitlist control group|After the first 12 weeks, this group will receive the same intervention as the experimental group
62724371|NCT06063681|EXPERIMENTAL|SR-8541A Monotherapy|SR-8541A will be orally administered.
62724372|NCT01215656|EXPERIMENTAL|Probiotic|follow on formula with the probiotic Lactobacillus fermentum
62724373|NCT01215656|ACTIVE_COMPARATOR|Control|follow on formula without probiotics
62724374|NCT05214066|EXPERIMENTAL|4-day ATG combined regimen|ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF (Mycophenolate mofetil), CsA (cyclosporin A) and MTX (methotrexate). All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
62724375|NCT05986266|ACTIVE_COMPARATOR|Group A|patients will receive carbetocin, The optimal carbetocin dose(IV or IM) is 100 mcg. The carbetocin group will receive 100 mcg IV carbetocin (Pabal; Ferring Pharmaceuticals) in 10 mL saline solution. The anesthesiologists will administrate carbetocin slowly over 5 minutes (at a rate of 2 mL/min) to maintain hemodynamic stability.
62724376|NCT05986266|EXPERIMENTAL|Group B|patients will receive adrenalin, infiltration of the serosa and/or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine HCL 0.25% and 0.5 mg of adrenaline.The anesthesiologist will be informed prior to the injection of the solution to ensure proper monitoring. The solution will be prepared just before the procedure. Before each infiltration, aspiration will be performed to avoid intravascular injection
62724377|NCT01516632|EXPERIMENTAL|SMS USA|The 6-week smoking cessation intervention
62724378|NCT01516632|NO_INTERVENTION|Attention matched control|Messages aimed at improving one's sleep and increasing one's fitness, along with general messages about the most well known health dangers of smoking. Messages sent on the same schedule as the intervention group.
62724379|NCT03234647|EXPERIMENTAL|AHF patients|AHF patient treatment with the Doraya catheter
62724380|NCT04032925|EXPERIMENTAL|PICSO therapy Group|"This will be the only treatment of the PICSO VIPER study. Within this group patients will be randomised to have cycles of 2 minutes of balloon-induced myocardial schema with PICSO device in ON vs OFF modality."
62724381|NCT03101189|EXPERIMENTAL|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
62724382|NCT03101189|EXPERIMENTAL|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
62724383|NCT03101189|PLACEBO_COMPARATOR|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
62724384|NCT00041340|EXPERIMENTAL|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better continue therapy until disease progression or 1 year after complete response.
62724385|NCT03436498|EXPERIMENTAL|SAR341402/NovoLog|SAR341402 will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of SAR341402 as treatment, patient will switch with NovoLog® as treatment.
62724386|NCT03436498|EXPERIMENTAL|NovoLog/SAR341402|Novolog will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of NovoLog® as treatment, patient will switch with SAR341402 as treatment.
62724387|NCT05750108|ACTIVE_COMPARATOR|Active Transcutaneous Vagal Nerve Stimulation|
62724388|NCT05750108|SHAM_COMPARATOR|Sham Transcutaneous Vagal Nerve Stimulation|
62724389|NCT05695170|ACTIVE_COMPARATOR|Individual intervention condition|"PreventT2 individual lifestyle intervention curriculum (2021 revised National DPP curriculum, freely available from the CDC)"
62724390|NCT05695170|EXPERIMENTAL|Couple-based intervention condition|"PreventT2 Together (couple-based adaptation of PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the National DPP)"
62724391|NCT03256721|EXPERIMENTAL|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
62724392|NCT03256721|ACTIVE_COMPARATOR|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
62724393|NCT01882335|EXPERIMENTAL|Behavioral|Peer support for mothers to encourage them to exclusively breastfeed their babies for 6 months
62724394|NCT01882335|NO_INTERVENTION|Control|No peer support for exclusive breastfeeding
62724395|NCT05207111|EXPERIMENTAL|Revefenacin Inhalation Solution, 175 mcg/3 mL|
62724396|NCT01861665|ACTIVE_COMPARATOR|Marcaine administered pre-incision.|Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
62724397|NCT01861665|ACTIVE_COMPARATOR|Marcaine administered post-incision|Marcaine 0.25% administered post-incision, total amount 5cc per incision.
62724398|NCT04602143|EXPERIMENTAL|Testosterone gel 4 weeks|Patients with low ovarian reserve received 4-week TTG application before controlled ovarian hyperstimulation.
62724399|NCT04602143|EXPERIMENTAL|Testosterone gel 6 weeks|Patients with low ovarian reserve received 6-week TTG application before controlled ovarian hyperstimulation.
62724400|NCT04602143|NO_INTERVENTION|Control group|Patients with low ovarian reserve received no medication before controlled ovarian hyperstimulation.
62724401|NCT02817178|OTHER|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, at 1 month, at 3 months, and 1 month after surgery (if applicable).~Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected. Tissue tumor is collected during surgery if applicable."
62724402|NCT04749745|ACTIVE_COMPARATOR|L-Theanine|Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
62724403|NCT04749745|PLACEBO_COMPARATOR|Placebo|Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
62724404|NCT01288157|EXPERIMENTAL|001|Golimumab Single dose of 50 mg subcutaneously
62724405|NCT01288157|EXPERIMENTAL|002|Golimumab Single dose of 100 mg subcutaneously
62724406|NCT00506467||VRI System|Vibration Response Imaging (VRI) System
62724407|NCT04317235|ACTIVE_COMPARATOR|3 ml ropivacaine|interscalene block using 3 ml under ultrasound put medication on each nerve
62724408|NCT04317235|ACTIVE_COMPARATOR|5 ml ropivacaine|interscalene block using 5 ml under ultrasound put medication on each nerve
62724409|NCT04812431|EXPERIMENTAL|PSA-NCAM(+) NPC|Cells are administered through intrathecal injection. Injection is administered to a total of five areas.
62724410|NCT00955474|EXPERIMENTAL|Quetiapine|Patients assigned to receive Quetiapine
62724411|NCT00955474|ACTIVE_COMPARATOR|Quetiapine and SSRI|Patients assigned to receive Quetiapine and SSRI
62724412|NCT02722213|EXPERIMENTAL|Mindfulness-Based Stress Reduction|"The intervention is an 8-week Mindfulness-Based Stress Reduction (MBSR) course, with 8 weekly 2.5-hour group sessions, and 1 all-day (6.5 hours) retreat, taught per standard protocol in a group setting. The course includes instruction and practice of meditation, breathing techniques, gentle yoga and Tai Chi poses, with shared discussion, brief readings and home practice between sessions. Participants will continue with usual care and receive standard educational materials on healthy lifestyles and stress management.~Note: This study will recruit patients eligible for exercise-based cardiac rehabilitation (CR). Randomization to either MBSR or control (no MBSR) condition will occur within two strata (CR; no CR) will occur based on current enrollment in CR at time of study enrollment."
62724413|NCT02722213|NO_INTERVENTION|Control (No MBSR)|"Those randomized to the control condition will continue with usual care and receive standard educational materials on healthy lifestyles and stress management. At the end of the study control participants will receive a compact disc and workbook on MBSR.~Note: This study will recruit patients who are eligible for traditional exercise-based cardiac rehabilitation (CR). Randomization will be stratified based on whether or not patients are actively enrolled in CR at the time of the study. Within each stratum, participants will be randomized to either the intervention (MBSR) or control (no MBSR) condition."
62724414|NCT04010097|EXPERIMENTAL|Horton group|The test involves chewing a chewing gum for 4 minutes plus a standard Horton disease diagnostic
62724415|NCT04010097|ACTIVE_COMPARATOR|N Horton Group|The test involves chewing a chewing gum for 4 minutes
62724416|NCT05173974|NO_INTERVENTION|Negative Control|Denture adhesive will not be used.
62724417|NCT05173974|ACTIVE_COMPARATOR|Positive Control|A single application of 1 gram of Super Poligrip Free denture adhesive will be applied topically to oral tissues via the upper denture.
62724418|NCT05173974|EXPERIMENTAL|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
62724419|NCT05173974|EXPERIMENTAL|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
62724420|NCT00974155|EXPERIMENTAL|EMC (Early Medication Change)|
62724421|NCT00974155|ACTIVE_COMPARATOR|TAU (Therapy As Usual)|
62724422|NCT02370992||Receiving I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
62724423|NCT00363311|ACTIVE_COMPARATOR|Dutasteride|Dutasteride 0.5mg
62724424|NCT00363311|PLACEBO_COMPARATOR|Placebo|Matching placebo
62724425|NCT00447967|EXPERIMENTAL|1|IOX
62724426|NCT00447967|EXPERIMENTAL|2|FLOX
62724427|NCT03523689||Observational (bronchoscopy, RP-EBUS)|Patients undergo bronchoscopy per standard of care, RP-EBUS of the left and right lungs during bronchoscopy procedure, and RP-imaging over 3-5 minutes at the end of the bronchoscopy procedure.
62724428|NCT06046066|EXPERIMENTAL|Dose Escalation|NM6603, administered orally every day in 28-day cycles
62724429|NCT05309681||Study group|Female patients of the Department of Oral medicine diagnosed with burning mouth syndrome
62724430|NCT05309681||Control group|Age-matched female patients without oral lesions and without burning mouth syndrome
62724431|NCT04343573|EXPERIMENTAL|Proton CSI Followed by Standard of Care (NSCLC & Breast)|Proton CSI (30Gy \[RBE\] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
62724432|NCT04343573|EXPERIMENTAL|Standard of Care|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
62724433|NCT04343573|OTHER|Proton CSI Followed by Standard of Care (Other Solid Tumors)|(Exploratory arm) Patients with solid tumor malignancies other than NSCLC or breast cancer will be enrolled to the exploratory proton CSI arm (Arm C) and will not undergo randomization. Proton CSI (30Gy \[RBE\] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
62724434|NCT02587832|ACTIVE_COMPARATOR|HHHFNC|Randomized to HHHFNC
62724435|NCT02587832|ACTIVE_COMPARATOR|NCPAP|Randomized to NCPAP
62724436|NCT05988918|EXPERIMENTAL|Cohort 1|Pancreatic adenocarcinoma
62724437|NCT05988918|EXPERIMENTAL|Cohort 2|Pancreatic or gastrointestinal neuroendocrine neoplasms with Ki-67 \> 20%
62724438|NCT05988918|EXPERIMENTAL|Cohort 3|Neuroendocrine prostate carcinoma with Ki-67 \> 20%
62724439|NCT05444738|EXPERIMENTAL|oral oxytocin|oral lollipop with oxytocin (24IU)
62724440|NCT05444738|PLACEBO_COMPARATOR|oral lollipop with placebo|Placebo orally (identical ingredients, except the active agent)
62724441|NCT03100318|EXPERIMENTAL|FYU-981|
62724442|NCT03100318|ACTIVE_COMPARATOR|Benzbromarone|
62724443|NCT04831437|EXPERIMENTAL|Hypofractionated|EBRT 40Gy/15fr
62724444|NCT04831437|ACTIVE_COMPARATOR|Control Group|EBRT 45Gy/ 25fr
62724445|NCT04815369||Guidance Clinical Pathway|Facilities will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification to a central point person within the Nursing Home (NH) facility
62724446|NCT04815369||Traditional Clinical Pathway|Facilities will employ their current standard clinical care practices for suspected UTI, including SUC, UA, and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.
62724447|NCT04310696|EXPERIMENTAL|Buteyko group|Buteyko breathing exercises
62724448|NCT04310696|ACTIVE_COMPARATOR|Pursed lip breathing|Pursed lip breathing exercises
62724449|NCT01470222|EXPERIMENTAL|Intervention Group|"Monthly, all-worksite activities will be implemented to raise awareness of healthy nutrition for weight control throughout the worksite. The purpose of the all-worksite activities is: a) to create a supportive worksite-wide atmosphere for the individuals enrolling in the weight loss support group, and b) to provide low-level weight loss support for individuals who wish to prevent weight gain.~Individuals with eligible weight (defined as BMI ≥ 25 kg/m2) without medical contradictions to weight loss, who wish to join a support group to lose weight, may enroll in the worksite weight control support group that will meet weekly for the first 10 weeks and then monthly until the end of the 6-month intervention"
62724450|NCT01470222|EXPERIMENTAL|Control Group (delayed intervention)|At the end of the study period, subjects will receive a 2-month structured intervention that will provide all of the resources and materials given to the intervention worksite as well as weight control support groups for employees interested in losing weight.
62724451|NCT04872569|EXPERIMENTAL|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
62724452|NCT06113003|EXPERIMENTAL|Probiotic and Prebiotic Fiber|
62724453|NCT06405295||Capecitabine|
62724454|NCT06405295||Olaparib|
62724455|NCT06405295||Capecitabine and Olaparib|
62724456|NCT04485845|ACTIVE_COMPARATOR|metformin treated group|A group of patients treated with a daily dose of metformin
62724457|NCT04485845|EXPERIMENTAL|vildagliptin treated group|A group of patients treated with a daily dose of vildagliptin
62724458|NCT01456130|EXPERIMENTAL|Alogliptin|Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
62724459|NCT04523584||Hepatic Steatosis|\<5% liver fat fraction by MRI PDFF
62724460|NCT04523584||No Hepatic Steatosis|\>5% liver fat fraction by MRI PDFF
62724461|NCT02060786|ACTIVE_COMPARATOR|original Clopidogrel Bisulfate (Plavix®)|original Clopidogrel Bisulfate (Plavix®) 600mg loading
62724462|NCT02060786|EXPERIMENTAL|generic Clopidogrel Bisulfate (Plavitor®)|generic Clopidogrel Bisulfate (Plavitor®) 600mg loading
62724463|NCT00368030|EXPERIMENTAL|A|Eszopiclone 3 mg QD
62724464|NCT00368030|PLACEBO_COMPARATOR|B|Placebo tablet
62724465|NCT04892030|EXPERIMENTAL|Intervention|All participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies remotely, through an e-learning platform.
62724466|NCT03202212|EXPERIMENTAL|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
62724467|NCT03202212|ACTIVE_COMPARATOR|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
62724468|NCT03773003|ACTIVE_COMPARATOR|Arm 1: Tumor disease w/o fatigue|Group receiving probiotics.
62724469|NCT03773003|PLACEBO_COMPARATOR|Arm 2: Tumor disease w/o fatigue|Group receiving placebo (corn starch)
62724470|NCT03773003|ACTIVE_COMPARATOR|Arm 3: Healthy control group|Group receiving probiotics
62724471|NCT03773003|PLACEBO_COMPARATOR|Arm 4: Healthy control group|Group receiving placebo (corn starch)
62724472|NCT06416592||Intra-rater and inter-rater validity and reliability|Intra-rater and inter-rater validity and reliability of trunk flexion, extension and right-left lateral flexion isometric muscle strength in cases with AIS will be performed with the Lafeyette hand dynamometer device ((Lafayette Manual Muscle Testing System, Lafayette Instrument Co, Lafayette, Indiana). To avoid systematic error, each participant will perform the isometric handheld dynamometer protocol in a random testing order. In order to determine inter-rater reliability, the same hand dynamometer protocol will be applied to each participant by two different assessors on the first day of the test. Participants will be given a 1-hour rest period between evaluators to prevent fatigue in the evaluations to be held on the same day. To determine inter-rater reliability and agreement, participants will be re-evaluated by the same researchers, at the same protocol, place and day, with a 1-week interval to prevent learning effects.
62724473|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
62724474|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
62724475|NCT03445767|NO_INTERVENTION|Standard Care|All patients will receive perioperative care per the standards of TOH. Standard care relevant to our study consists of a history by a nurse or physician; a best possible medication history performed by a pharmacy technician; and standardized perioperative-specific medication recommendations (e.g., anticoagulant, diabetes agent, and ACE-inhibitor management) based on medical directives. Medication recommendations beyond these medical directives do not occur as standard care in our clinics. Participants will be informed that their medical care will proceed as usual and that they are being recruited for a study to evaluate medication recommendations before surgery
62724476|NCT03445767|EXPERIMENTAL|Intervention|In addition to standard care, the intervention will include a structured preoperative polypharmacy management strategy that consists of: a) input of best possible medication history and comorbidities into our polypharmacy management tool (MedSafer); b) communication of the prioritized deprescribing plan (if indicated) to the patient's active treating physicians (automatically via fax), to the perioperative team (surgeon, anesthesiologist), and to the electronic medical record. During the pre-operative visit, the patient will receive a generalized information flyer about deprescribing. As in the usual care phase, patients will continue to receive usual recommendations from the perioperative team based on medical directives relevant to the perioperative period.
62724477|NCT02826616|EXPERIMENTAL|Trimetazidine group|Trimetazidine 60 mg 30 min before PCI and 20 mg for 12 months after surgery
62724478|NCT02826616|NO_INTERVENTION|The control group|placebo 60 mg 30 min before PCI and 20 mg for 12 months after surgery
62724479|NCT00636844||Group A|Patients receiving chemotherapy (anthracycline and/or adjuvant trastuzumab) for the first time
62724480|NCT05163301|EXPERIMENTAL|Computer delivered RPI|2 session computer delivered counseling to prevent relapse to hazardous drinking
62724481|NCT05163301|EXPERIMENTAL|Person delivered RPI|2 session counselor delivered counseling to prevent relapse to hazardous drinking
62724482|NCT05163301|NO_INTERVENTION|Treatment as Usual|Counseling for alcohol use available in clinic as treatment as usual
62724483|NCT03596788|EXPERIMENTAL|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
62724484|NCT03596788|PLACEBO_COMPARATOR|Placebo Beverage|An artificially-sweetened beverage containing aspartame
62724485|NCT03291132|OTHER|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
62724486|NCT03509961|OTHER|Observational Arm|"Patients are enrolled to the observational arm to proceed with NGS-MRD testing pre-HCT. If NGS-MRD negative, eligible patients may be considered for the Treatment Arm to receive a myeloablative non-TBI conditioning regimen prior to HCT.~If NGS-MRD positive, patients may continue in the observational arm and receive HCT under the direction of their transplant physician and followed on the study for outcome."
62724487|NCT03509961|OTHER|Treatment Arm|Patients enrolled to the observational arm that are NGS-MRD pre-HCT are considered for the Treatment Arm. Patients will receive a myeloablative non-TBI conditioning regimen prior to the transplant consisting on busulfan, fludarabine and thiotepa. Patients will be followed for outcome for up to 5 years.
62724488|NCT01716364|EXPERIMENTAL|Anti-LeY- scFv-CD28-ζ vector.|Anti-LeY- scFv-CD28-ζ vector, a non-pathogenic, replication-incompetent retroviral vector specifically designed for this study and produced by EUFETS under GMP-conditions.
62724489|NCT04729348|EXPERIMENTAL|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment, including evaluations and follow up visits.~* PEMBROLIZUMAB daily, every 3 weeks~* LENVATINIB daily every 3 weeks"
62724490|NCT05922605|EXPERIMENTAL|Group E|the children are given a mixture of 0.2%ropivacaine 0.7 ml／kg and preservative-free S-ketamine 0.5 mg/kg for caudal analgesia.
62724491|NCT05922605|ACTIVE_COMPARATOR|Group C|The children are given 0.2%ropivacaine 0.7 ml／kg and saline of equal volume caudally.
62724492|NCT06167967|EXPERIMENTAL|ctDNA-guided group|ctDNA-negative group in the high-risk cohort were treated with XELOX regimen for 6 months; ctDNA-positive group in the high-risk cohort was treated with cmFOLFOXIRI regimen for 6 months; ctDNA-positive group in the low-risk cohort were treated with XELOX regimen for 3 months; ctDNA-negative group in the low-risk cohort did not receive adjuvant chemotherapy.
62724493|NCT06167967|ACTIVE_COMPARATOR|standard treatment group|The standard treatment group in the high-risk cohort were treated with XELOX regimen for 6 months, and in the low-risk cohort were treated with XELOX regimen for 3 months.
62724494|NCT05663008||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis.
62724495|NCT05663008||Amyotrophic lateral sclerosis patients|Individuals from the Irish population (Irish Motorneuron Disease Register) with possible/probable/definitive diagnosis of ALS.
62724496|NCT05663008||Postpoliomyelitis syndrome|Individuals from the Irish population (Irish Motorneuron Disease Register) with postpoliomyelitis syndrome diagnosis.
62724497|NCT05663008||Spinal Muscular Atrophy|Individuals from the Irish population (Irish Motorneuron Disease Register) with spinal muscular atrophy diagnosis.
62724498|NCT01179308|ACTIVE_COMPARATOR|General-epidural anesthesia|Epidural and general anesthesia
62724499|NCT01179308|ACTIVE_COMPARATOR|General anesthesia|General anesthesia alone
62737923|NCT04313777|EXPERIMENTAL|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
62737924|NCT04313777|ACTIVE_COMPARATOR|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
62737925|NCT01479244|EXPERIMENTAL|NeuVax™|NeuVax™ in WFI solution with Leukine®
62737926|NCT01479244|ACTIVE_COMPARATOR|Leukine®|Leukine® with WFI
61978215|NCT00846131|ACTIVE_COMPARATOR|A: Y-90 alone|Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
62724500|NCT02487953|EXPERIMENTAL|Nicotine ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
62724501|NCT02487953|ACTIVE_COMPARATOR|Nicotine ENDS + Placebo Patch|Participants will initially receive 1 week of placebo skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the placebo patch size will be gradually reduced to mirror standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
62724502|NCT02487953|ACTIVE_COMPARATOR|Placebo ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive placebo ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
62724503|NCT03100448|OTHER|On1 Concept|On1 Concept \& NobelActive implants
62724504|NCT00712517|ACTIVE_COMPARATOR|1|Patients will receive propofol anesthesia during varicose vein stripping surgery.
62724505|NCT00712517|ACTIVE_COMPARATOR|2|Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.
62724506|NCT02439905|EXPERIMENTAL|Dexmedetomidine group|
62724507|NCT02439905|PLACEBO_COMPARATOR|Normal saline group|
62724508|NCT05587660|EXPERIMENTAL|Partially threaded cannulated screw fixation|In Group-A patients, cannulated screw fixation was done using partially threaded screws. In this procedure, first step was insertion of three guide wires under image. The 1st guide wire was inserted immediately above calcar and into femoral head. The second wire was placed posteriorly adjacent to posterior cortex of neck on lateral view. Finally, third guide wire was placed anteriorly and superiorly. Drilling of lateral cortex was done before insertion of screws. Then partially threaded screw fixation was done before removal of guide wires using washers.
62724509|NCT05587660|EXPERIMENTAL|Fully threaded cannulated screws fixation|The surgical approach in fully thread cannulated screws fixation group will remain same but instead of partially threaded screwsm fully threaded screws to be used in this group.
62724510|NCT05723744|EXPERIMENTAL|CS6BP , ECG holter and Blood pressure measurements|The investigational device sensors tracings will be compared to the arrhythmia documented in all patients.
62724511|NCT01951898|ACTIVE_COMPARATOR|Montelukast|
62724512|NCT01951898|SHAM_COMPARATOR|Vitamin B6|
62724513|NCT06014307|EXPERIMENTAL|Plant-Based Meat Alternatives (PBMA)|Up to 2 servings per day of plant-based meat alternatives (Beyond Beef, Impossible Burger, Gardein Chick'n) OR as many plant-based meat alternative servings as available per day in the dining halls.
62724514|NCT06014307|EXPERIMENTAL|Animal|2 servings/day of traditional meat products (beef burger, pork, chicken)
62724515|NCT01117194|EXPERIMENTAL|shoulder training, rehabilitation robot|
62724516|NCT01117194|NO_INTERVENTION|control group|
62724517|NCT01169480|EXPERIMENTAL|Massage Giver|Participants in the experimental group will be asked to give one 50-minute Swedish massage to another volunteer.
62724518|NCT01169480|NO_INTERVENTION|Passive Controls|Participants in this arm will wait in a classroom (as usual) and do nothing out of their ordinary routines.
62724519|NCT05767788|EXPERIMENTAL|Movement with Mobilization (MWM)|Active movement with passive mobilization gliding force
62724520|NCT05767788|SHAM_COMPARATOR|Sham Movement with Mobilization (Sham MWM)|Active movement with passive light touch gliding force
62724521|NCT05225519|EXPERIMENTAL|Experimental arm|Usage of a long-sleeved white shirt impregnated with a long-infrared irradiating bioceramic for a period of 12 weeks.
62165957|NCT03321188|EXPERIMENTAL|HIPEC + adjuvant IV chemotherapy|"HIPEC~* HIPEC will be administered intraoperatively one time only.~  \*HIPEC cisplatin will be administered at rate of 100 milligram per meter squared (mg/m2)~* Administration of HIPEC will have a duration of 90 minutes.~Adjuvant IV chemotherapy~* IV Paclitaxel~  * Dose: 80mg/m2 IV over 1 hour~ * Schedule: Days 1, 8 and 15~ * Cycle Length: 3 weeks (21 days)~* IV Carboplatin~  * Dose: Area under the curve (AUC) 6 IV~ * Schedule: Day 1~ * Cycle Length: 3 weeks (21 days)"
62724522|NCT05225519|PLACEBO_COMPARATOR|Placebo arm|Usage of a long-sleeve white shirt (similar to the one in the experimental arm) but with no long-infrared technology for a period of 12 weeks.
62724523|NCT00429871|EXPERIMENTAL|1|DF
62724524|NCT00429871|EXPERIMENTAL|2|DC
62724525|NCT00284180|EXPERIMENTAL|HER2 Negative Intervention|Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes, repeated every 21 days
62724526|NCT00284180|EXPERIMENTAL|HER2 Positive Intervention|Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/kg, followed by 6 mg/kg IV on day 1 of each subsequent cycle, repeated every 21 days. If no grade 3/4 adverse events were encountered after the first cycle of vinflunine/trastuzumab, the dose of vinflunine could be escalated to 320 mg/m2.
62737927|NCT05709223|EXPERIMENTAL|Participants receiving both Categorical Loudness Scaling Based Fitting and behavioural fitting.|Participants will receive a categorical loudness scaling based fitting (Interventional) and behavioural fitting with 4 weeks experience of both MAPS
62165958|NCT05813132|ACTIVE_COMPARATOR|BeEAM Regimen|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
62165959|NCT05813132|ACTIVE_COMPARATOR|CEM Regimen|CEM (Carboplatin, Etoposide, Melphalan)
62549752|NCT05927597|EXPERIMENTAL|Part A: Cohort 3 (Dose 3)|Japanese and Caucasian participants will receive INS1007 at Dose 3 or matching placebo, orally, up to Day 30 in Part A under fasted conditions. Enrollment will commence in this cohort once the safety and tolerability data in Cohort 2 is deemed acceptable by the principal investigator (PI) and the Sponsor's medical monitor.
62549753|NCT05927597|EXPERIMENTAL|Part B: Treatment Sequence 1|Japanese and Caucasian participants will receive INS1007 at the dose established in Part A after a high-fat and high-calorie breakfast on Day 1 followed by a dose established in Part A on Day 8 under fasted conditions in Part B of the study.
62549754|NCT05927597|EXPERIMENTAL|Part B: Treatment Sequence 2|Japanese and Caucasian participants will receive INS1007 at the dose established in Part A under fasted conditions on Day 1 followed by dose established in Part A on Day 8 after a high-fat and high-calorie breakfast in Part B of the study.
62549755|NCT00739063|EXPERIMENTAL|Tarceva daily|Tarceva oral 150 mg daily.
62549756|NCT01689779|ACTIVE_COMPARATOR|Cholecalciferol|A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
62549757|NCT01689779|PLACEBO_COMPARATOR|Placebo|A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
62549758|NCT01562938|PLACEBO_COMPARATOR|Placebo|Placebo
62549759|NCT01562938|ACTIVE_COMPARATOR|MEDI-557 low-dose|
62549760|NCT01562938|ACTIVE_COMPARATOR|MEDI-557 high-dose|
62549761|NCT01108627|ACTIVE_COMPARATOR|corticosteroid + long acting beta agonist; steroids|
62549762|NCT01108627|PLACEBO_COMPARATOR|placebo + corticosteroid + long acting beta agonist; steroids|
62549763|NCT05737355|EXPERIMENTAL|ANKASCIN 568-P Red yeast rice capsules|ANKASCIN 568-P is a fermented product from the red yeast rice fungus \<Monascus purpureus NTU 568\>. It does not contain Monacolin K, an ingredient that may harm the human body, and is rich in new active ingredients. Take 2 red yeast rice capsules (each containing 440mg ANKASCIN 568-P) every day, and the control group takes 2 placebo capsules (containing equal weight maltodextrin) every day, respectively, at the 0th, 4th , , 12, 24, Collect blood samples for biochemical analysis and record the general body position measurement, blood pressure, blood lipid, blood sugar and other related changes of the subjects, and monitor the liver, kidney, and thyroid functions.
62549764|NCT05737355|PLACEBO_COMPARATOR|Placebo Capsules|Maltodextrin was used as a placebo.
62549765|NCT02536846|EXPERIMENTAL|Second Generation Antipsychotic Drug|Olanzapine; a single 2.5 mg dose PO daily followed by 5 mg dose PO daily for 14 days
62549766|NCT01404676|EXPERIMENTAL|Vildagliptin + Metformin|Adding Vildagliptin to metformin users
62549767|NCT01404676|ACTIVE_COMPARATOR|Glimepiride + Metformin|Adding Glimepiride to metformin users
62549768|NCT01372748|ACTIVE_COMPARATOR|Standard CPR|American Heart Association (AHA)recommended cardiopulmonary resuscitation (CPR) of 30 compressions with brief pause for 2 ventilations
62549769|NCT01372748|EXPERIMENTAL|Continuous chest compressions|Continuous compression CPR
62549770|NCT03691727|EXPERIMENTAL|tirofiban hydrochloride (AGGRASTAT®)|"tirofiban hydrochloride (AGGRASTAT®) administered continuously over the course of 7 days.~MRI Neurological Exam Vital Signs Questionnaires"
62549771|NCT03691727|ACTIVE_COMPARATOR|Standard of Care Control Arm|Standard of Care Treatment MRI Neurological Exam Vital Signs Questionnaires
62549772|NCT02051621|ACTIVE_COMPARATOR|Cavo-tricuspid-isthmus-ablation|Ablation of atrial flutter
62549773|NCT02051621|ACTIVE_COMPARATOR|Pulmonary vein isolation|pulmonary vein isolation
62549774|NCT02051621|ACTIVE_COMPARATOR|Antiarrhythmic drug|"Medical treatment of atrial flutter with either class I antiarrhythmics (flecainide (Tambocor ®) 100 mg twice daily or propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily~cardioversion as needed"
62549775|NCT02315131|EXPERIMENTAL|TV46017- Healthy Volunteers|Stage 1 includes a single-dose treatment period
62549776|NCT02315131|PLACEBO_COMPARATOR|Placebo - Healthy Volunteers|Some healthy subjects will be randomized to receive placebo.
62549777|NCT02315131|EXPERIMENTAL|TV46017 15 μg- COPD|Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered
62549778|NCT02315131|EXPERIMENTAL|TV46017 60 μg- COPD|Stage 2
62549779|NCT02315131|EXPERIMENTAL|TV46017 120 μg- COPD|Stage 2
62549780|NCT02315131|EXPERIMENTAL|TV46017 240 μg- COPD|Stage 2
62549781|NCT04833530||Woman undergoing an gastric ultrasound assessment.|Woman undergoing general anesthesia for oocyte retrieval during in vitro fertilization, will undergo an gastric ultrasound assessment.
62549782|NCT05519176||Cases|Varicose veins of lower extremities inpatients with venous ulceration from The First Affiliated Hospital of Shandong First Medical University \& Shandong Provincial Qianfoshan Hospital.
62549783|NCT05519176||Controls|Varicose veins of lower extremities inpatients without venous ulceration from The First Affiliated Hospital of Shandong First Medical University \& Shandong Provincial Qianfoshan Hospital.
62549784|NCT00346918|ACTIVE_COMPARATOR|1|Treatment of hypertension, cyst infections and flank pain
62549785|NCT00346918|ACTIVE_COMPARATOR|2|Sirolimus plus Standard Treatment
62549786|NCT02494167|EXPERIMENTAL|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for AML or MDS
62549787|NCT02494167|EXPERIMENTAL|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for AML or MDS
62549788|NCT05468801|EXPERIMENTAL|Individualized Homeopathic Remedy plus Standard Pharmacologic Treatment|Each subject receives an individually selected homeopathic remedy (individualized homeopathic remedy) as an add on to the conventional standardized pharmacological treatment he/she is receiving prior and during study. Standardized pharmacological treatment will be monitored and approved at first hospital neurological visit and as a requirement needs to be unchanged within 3 months prior inclusion and throughout the study.
62549789|NCT05468801|PLACEBO_COMPARATOR|Placebo plus Standard Pharmacologic Treatment|Subjects receive an indistinguishable placebo plus the conventional standardized pharmacological treatment he/she is receiving prior and during study. Standardized pharmacological treatment will be monitored and approved at first hospital neurological visit and as a requirement needs to be unchanged within 3 months prior inclusion and throughout the study.
62549790|NCT05440318||mRNA Vaccines Recipients|Participants will wear 2 devices during the specified monitoring period. They will wear both a small patch on their chest that captures continuous electrocardiogram (ECG), accelerometry, and temperature data, and a modified smartwatch measuring continuous photoplethysmography (PPG) and accelerometry data.
62549791|NCT01527409|EXPERIMENTAL|Experimetal Arm|"Providing tailored health care program, which provides various information related to exercise, diet, and posttraumatic growth.~Tailored health partnership program consists of three strategic areas (exercise, diet, and posttraumatic growth). Those areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients who participate in the tailored health partnership program will be received tailored manual and workbook for tele-coaching that help them to lead their healthy life.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life."
62549792|NCT01527409|NO_INTERVENTION|Control Arm|"Providing usual care. Also, patients will be provided a workshop for health education that is dealt with ten areas (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation).~Twelve month later, patients will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth."
62549793|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
62549794|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
62549795|NCT01382537|ACTIVE_COMPARATOR|A|
62549796|NCT01382537|PLACEBO_COMPARATOR|B|
62549797|NCT01794455|EXPERIMENTAL|Phase 1: Sertraline|Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
62549798|NCT01794455|EXPERIMENTAL|Phase 2: Candesartan|For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
62549799|NCT00693095|EXPERIMENTAL|1|CMV-ALT + CMV-DCs
62549800|NCT00693095|EXPERIMENTAL|2|CMV-ALT + Saline
62549801|NCT02181855|OTHER|Atypical GERD syptoms treated with GERD-X|Patients treated by means of full-thickness gastroplication
62549802|NCT03438292|EXPERIMENTAL|Group A - TPGS emulsified with berberine|After an 8-10 hour overnight fast, Group A will receive two soft capsules of TPGS (400mg) emulsified berberine. Following a 7 day wash out period, Group A participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Following another 7 day wash out period, Group A participants will then receive two hard shell capsules of the berberine reference powder 400mg. Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
62549803|NCT03438292|EXPERIMENTAL|Group B - Quillaja extract emulsified with Berberine|After an 8-10 hour overnight fast, Group B will receive four soft capsules of Quillaja extract emulsified berberine (400mg). Following a 7 day wash out period, Group B participants will then receive two hard shell capsules of the berberine reference powder (400mg). Following another 7 day wash out period, Group B participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
62549804|NCT03438292|EXPERIMENTAL|Group C - Berberine reference powder|After an 8-10 hour overnight fast, Group C will receive two hard shell capsules of the berberine reference powder (400mg). Following a 7 day wash out period, Group C participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Following another 7 day wash out period, Group C participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
62549805|NCT06427850|EXPERIMENTAL|Topical tranexamic acid (TXA) injection|receive an injection of topical tranexamic acid (TXA) into the surgical site
62549806|NCT06427850|PLACEBO_COMPARATOR|Placebo group|receive an injection Normal saline into the surgical site
62549807|NCT00577603|ACTIVE_COMPARATOR|2|mesh reinforcement at stoma
62549808|NCT00577603|ACTIVE_COMPARATOR|Arm 1|standard stoma
62549809|NCT03791684|ACTIVE_COMPARATOR|Accelerated Cross Linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 18mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 5 min, delivering a dose of 5.4 J/cm2.
62549810|NCT03791684|ACTIVE_COMPARATOR|Standard Cross linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 3mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 30 min, delivering a dose of 5.4 J/cm2.
62549811|NCT03659929|EXPERIMENTAL|Arm 1: 20 mg/day|Amphetamine Sulfate
62549812|NCT03659929|EXPERIMENTAL|Arm 2: 40 mg/day|Amphetamine Sulfate
62549813|NCT03659929|PLACEBO_COMPARATOR|Arm 3: Placebo|Placebo, no active drug
62549814|NCT05722561|EXPERIMENTAL|Electronic Cigarette|Participants in the Electronic Cigarette (EC) arm will receive telehealth motivational counseling for 5 weeks plus the standardized research e-cigarette (SREC).
62549815|NCT05722561|ACTIVE_COMPARATOR|Nicotine Replacement Therapy|Participants in the Nicotine Replacement Therapy (NRT) arm will receive telehealth motivational counseling plus combination NRT (patch and lozenge).
62549816|NCT05853419||Study population|Adult patients with coronary artery disease and a clinical indication for PCI
62549817|NCT03005665|EXPERIMENTAL|Group A - Acetazolamide|Acetazolamide 5 mg/kg diluted in 10 ml normal saline through orogastric Ryle's Tube soon after the induction of anaesthesia followed by 10 ml normal saline flush.
62549818|NCT03005665|PLACEBO_COMPARATOR|Group s - Normal saline|20 ml normal saline total volume.
62549819|NCT03247179|EXPERIMENTAL|PTSD Coach Condition|PTSD Coach App
62549820|NCT03247179|NO_INTERVENTION|Treatment as Usual Condition|Treatment as Usual
62549821|NCT05376644|EXPERIMENTAL|HER2 positive breast cancer patients|Maximum (15) evaluable subjects with HER2-positive status in primary tumour before chemo/targeted therapy have to be enrolled in the study. Subjects withdrawn from the study for any reason will be replaced
62549822|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
62724527|NCT04038294|EXPERIMENTAL|Protein Supplementation|The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).
62724528|NCT04038294|PLACEBO_COMPARATOR|Placebo Supplementation|Enrolled patients allocated to the control group will receive the same supplementation schedule as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no nutritional benefit).
62724529|NCT05617118||Baclofen|"A cohort of patients who have not previously received baclofen will be offered a course of the drug therapy at a dosage of 10 mg according to the scheme:~1-3 days - 1 tablet per day; 4-6 days - 2 tablets per day; 7-9 days - 3 tablets per day; 10 days and then 4 tablets per day (morning and evening)."
62724530|NCT05617118||BTA|"A cohort of patients who previously received baclofen and canceled the course due to the development of side effects and/or individual intolerance, or who have contraindications to the use of this drug, will receive several injections with a total volume of 100 units. botulinum toxin type A in dilution up to 20 ml, distributed at the trigger points of the pelvic floor muscles."
62724531|NCT05394610|ACTIVE_COMPARATOR|Active Treatment|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies. The device is externally communicating only. The Sana Device will be administered at least twice daily, with one treatment session being just prior to bedtime. Additional PRN sessions with the Sana device will be allowed at the subject's discretion.
62724532|NCT05394610|SHAM_COMPARATOR|Sham Arm|The sham treatment device was designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and ound but should offer no therapeutic effect to the level of the Sana Device. The sham device will run on the same headset, use a matched intensity of light/audio and used on the same schedule as the Sana treatment.
62724533|NCT04564235|EXPERIMENTAL|Indication for a genome-wide analysis in the proband|
62724534|NCT00769795|EXPERIMENTAL|Experimental|Bicalutamide 50 mg daily for 12 weeks Goserelin 10.8 mg SC once IMC-A12 10 mg/kg IV every three weeks for 12 weeks
62724535|NCT01893255||Cohort|
62724536|NCT06121726||Ilioinguinal-Iliohypogastric nerve block|Patients will receive Ilioinguinal-Iliohypogastric nerve block as standard of care
62724537|NCT01027858|EXPERIMENTAL|1|AT (aerobic-based exercise training)
62724538|NCT01027858|ACTIVE_COMPARATOR|2|CON (control; usual care)
62724539|NCT04944771|EXPERIMENTAL|Treatment ABC|Participants will be randomized to receive oral doses of Treatment A, Treatment B and Treatment C.
62724540|NCT04944771|EXPERIMENTAL|Treatment ACB|Participants will be randomized to receive oral doses of Treatment A, Treatment C and Treatment B.
62724541|NCT04944771|EXPERIMENTAL|Treatment BAC|Participants will be randomized to receive oral doses of Treatment B, Treatment A and Treatment C.
62724542|NCT04944771|EXPERIMENTAL|Treatment BCA|Participants will be randomized to receive oral doses of Treatment B, Treatment C and Treatment A.
62724543|NCT04944771|EXPERIMENTAL|Treatment CAB|Participants will be randomized to receive oral doses of Treatment C, Treatment A and Treatment B.
62724544|NCT04944771|EXPERIMENTAL|Treatment CBA|Participants will be randomized to receive oral doses of Treatment C, Treatment B and Treatment A.
62724545|NCT04944771|EXPERIMENTAL|Treatment DEF|Participants will be randomized to receive oral doses of Treatment D, Treatment E and Treatment F.
62724546|NCT04944771|EXPERIMENTAL|Treatment DFE|Participants will be randomized to receive oral doses of Treatment D, Treatment F and Treatment E.
62724547|NCT04944771|EXPERIMENTAL|Treatment EDF|Participants will be randomized to receive oral doses of Treatment E, Treatment D and Treatment F.
62724548|NCT04944771|EXPERIMENTAL|Treatment EFD|Participants will be randomized to receive oral doses of Treatment E, Treatment F and Treatment D.
62724549|NCT04944771|EXPERIMENTAL|Treatment FDE|Participants will be randomized to receive oral doses of Treatment F, Treatment D and Treatment E.
62724550|NCT04944771|EXPERIMENTAL|Treatment FED|Participants will be randomized to receive oral doses of Treatment F, Treatment E and Treatment D.
62724551|NCT03153501|OTHER|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
62724552|NCT00153413|EXPERIMENTAL|Intervention|Receive Cookin' Up Health, a nutrition intervention
62724553|NCT06075875|ACTIVE_COMPARATOR|control=mixed animal and vegetable proteins|"mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group.(average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm)."
62724554|NCT06075875|EXPERIMENTAL|study= pure vegetable proteins|pure vegetable proteins (a study group). (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
62724555|NCT00209144|EXPERIMENTAL|Angioplasty with Insulin|Coming in with acute infarct and received angioplasty with intensive insulin therapy
62724556|NCT00209144|NO_INTERVENTION|Angioplasty w/o Insulin|Coming in with acute infarct and received angioplasty
62724557|NCT01658553|EXPERIMENTAL|GSK1120212 Qtc study|Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
62724558|NCT05781243|EXPERIMENTAL|Lactated Ringer solution (LR)|LR: Lactated Ringer solution. Patients in the LR treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
62724559|NCT05781243|ACTIVE_COMPARATOR|Normal saline (NS)|NS: Normal Saline. Patients in the NS treatment arm will receive fluid therapy based on normal saline for a minimum of 48 hours.
62724560|NCT05196750||Normal vaginal delivery|Maternal delivery of delivery via normal vaginal delivery
62724561|NCT05196750||Lower segment Caesarean section (LSCS)|Maternal delivery of delivery via lower segment Caesarean section (LSCS)
62724562|NCT04595643|EXPERIMENTAL|Specialized dysphagia treatment|Dysphagia treatment is provided by occupational therapists specialized in dysphagia.
62724563|NCT01650948||AMD subjects with GA and/or RPED|All subjects will have AMD and GA and/or RPED.
62724564|NCT01650948||AMD subjects with CNV alone|All subjects will have the CNV form of AMD only.
62724565|NCT02073812|EXPERIMENTAL|Multiple dose of Carbavance (RPX7009/RPX2014)|Multiple dose of Carbavance
62724566|NCT02153437|EXPERIMENTAL|Arm A: BMS-919373|BMS-919373 oral Solution/tablet single dose for one day
62724567|NCT02153437|ACTIVE_COMPARATOR|Arm B: Sotalol|Sotalol oral Tablet single dose for one day
62724568|NCT02153437|PLACEBO_COMPARATOR|Arm C: Placebo for BMS-919373|Oral solution/tablet one single dose for one day
62724569|NCT02652910|EXPERIMENTAL|IL-2 programmed CD19.CAR-T cells|Administrated with IL-2 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
62724570|NCT02652910|EXPERIMENTAL|IL-7/IL-15 programmed CD19.CAR-T cells|Administrated with IL-7/IL-15 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
62724571|NCT01979770||Adolescents|Adolescents who participated in an intervention trial of iron and zinc supplementation and a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast of Thailand.
62724572|NCT02804490|PLACEBO_COMPARATOR|White maize|Conventional maize flour
62724573|NCT02804490|EXPERIMENTAL|Biofortified maize|Provitamin A carotenoid biofortified maize flour
62724574|NCT02804490|ACTIVE_COMPARATOR|Fortified maize|Retinyl palmitate fortified maize flour
62724575|NCT01326806|EXPERIMENTAL|Sex Education + Standard Care|Participating mothers will receive sex education information while their child is having a physical exam.
62724576|NCT01326806|ACTIVE_COMPARATOR|Hygiene & Nutrition Education + Standard Care|Participating mothers will receive information on hygiene and nutrition while their child is having a physical exam.
62724577|NCT01326806|NO_INTERVENTION|No Education + Standard Care|Participating mothers who are passive controls will not receive any additional information while their child is having a physical exam.
62724578|NCT01354223|EXPERIMENTAL|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
62724579|NCT01354223|ACTIVE_COMPARATOR|ocufilcon B contact lens|Randomized to ocufilcon B contact lens worn in a daily wear, daily disposable mode
62724580|NCT02980107|ACTIVE_COMPARATOR|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
62724581|NCT02980107|EXPERIMENTAL|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
62724582|NCT04326218|OTHER|Cohort|All patients included will have to be taken blood samples
62724583|NCT05468645|EXPERIMENTAL|[14C]Hemay005|
62724584|NCT05325762|EXPERIMENTAL|Propofol|
62724585|NCT05325762|ACTIVE_COMPARATOR|Dexmedetomidine|
62724586|NCT05325762|PLACEBO_COMPARATOR|saline|
62724587|NCT02516501|ACTIVE_COMPARATOR|Control|Control group that will not receive advice to follow a ketogenic diet or reduce carbohydrates.
62724588|NCT02516501|EXPERIMENTAL|Intervention group 1|Patients who will receive each radiotherapy (RT) fraction after an overnight fast and subsequently ingest a ketogenic breakfast consisting of (i) up to 250 ml of a medium chain triglyceride drink (betaquik, vitaflo) plus (ii) 10g amino acids (MyAmino, dr. reinwald gmbh + co kg).
62724589|NCT02516501|EXPERIMENTAL|Intervention group 2|Patients who will follow a ketogenic diet throughout the whole period of RT, Patients don't have to fast prior to each RT fraction, but will receive MyAmino analogous to Intervention group 1.
62724590|NCT01969539|EXPERIMENTAL|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
62724591|NCT01969539|EXPERIMENTAL|Combivent Respimat - ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation with /CVT-R via ventilator adapter
62724592|NCT00952705|EXPERIMENTAL|Q/LAIV-BFS (MEDI8662)|Q/LAIV-BFS (quadrivalent influenza vaccine) (MEDI8662) was supplied in the blow-fill-seal delivery system that delivers a nominal dose of 0.2 mL into a single nostril. Each dose contained 10\^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), B/Victoria (B/Malaysia/2506/2004), and B/Yamagata (B/Florida/4/2006).
62724593|NCT00952705|ACTIVE_COMPARATOR|FluMist/B/Yamagata|FluMist/B/Yamagata was administered intranasally using a Becton Dickinson Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10\^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Yamagata (B/Florida/4/2006)
62724594|NCT00952705|ACTIVE_COMPARATOR|FluMist/B/Victoria|FluMist/B/Victoria was administered intranasally using a BD Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10\^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Victoria (B/Malaysia/2506/2004).
62724595|NCT02985177|EXPERIMENTAL|INF2.0 + IBU|The participant will receive a dose of intranasal fentanyl (2.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
62724596|NCT02985177|ACTIVE_COMPARATOR|INF1.0 + IBU|The participant will receive a dose of intranasal (1.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
62724597|NCT04690218||Mastalgia|"Mastalgia group will consist of women with confirmed mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
62724598|NCT04690218||Controls|"Controls group will consist of women attending to general surgery clinic for reasons other than mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
62724599|NCT03412825|EXPERIMENTAL|Nutrition Supplementation|
62724600|NCT03412825|NO_INTERVENTION|Control|
62724601|NCT01623505|EXPERIMENTAL|Champix|
62724602|NCT01623505|EXPERIMENTAL|Long & Combination patch treatment|
62724603|NCT01623505|EXPERIMENTAL|Standard patch treatment|
62724604|NCT00938262|EXPERIMENTAL|Fimasartan, Ketoconazole, Rifampicin|
62724605|NCT03353662||Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years
62724606|NCT03353662||Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6 - 59 months
62724607|NCT03353662||Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years
62724608|NCT03353662||Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between 6 - 59 months
62724609|NCT03353662||Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years
62724610|NCT03353662||Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6 - 59 months
62724611|NCT02970071||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
62724612|NCT01204645||Acute Coronary Syndrome (ACS)|Continuous inclusion at emergency hospitals of patients with acute coronary syndrome (according to ESC/AHA definitions)
62724613|NCT01204645||Follow up|Patients included at 6 or 12 months follow-up visit after an acute coronary event.
62724614|NCT01204645||Coronary|Patients included when undergoing an coronary angiography for suspected or confirmed coronary heart disease
62724615|NCT02818465|EXPERIMENTAL|Patients|
62724616|NCT04005586|EXPERIMENTAL|Light Delivery Device (LDD)|Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.
62724617|NCT01773954|EXPERIMENTAL|Intravitreal Aflibercept Injection More|Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.
62724618|NCT05915611|EXPERIMENTAL|Intervention group|Participants will receive a twelve-week combined physical and psychological intervention.
62724619|NCT05915611|ACTIVE_COMPARATOR|Control group|Participants will receive a twelve-week of standard care of splinting, tendon and nerve gliding exercises.
62724620|NCT04111705|EXPERIMENTAL|Lorlatinib|100 mg once daily
62724621|NCT02746328|EXPERIMENTAL|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
62724622|NCT02131311|EXPERIMENTAL|pessary|disposable, single-use pessary
62724623|NCT00876707|ACTIVE_COMPARATOR|Tecnis|
62724624|NCT00876707|ACTIVE_COMPARATOR|ReSTOR|
62724625|NCT00876707|ACTIVE_COMPARATOR|ReZoom|
62724626|NCT01079364|EXPERIMENTAL|Insulin glargine + Insulin glulisine|Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
62724627|NCT01079364|ACTIVE_COMPARATOR|Premixed insulin|twice daily premixed insulin (before breakfast and evening meal).
62724628|NCT04375956|EXPERIMENTAL|Pembrolizumab|Pembrolizumab 200 mg d1 q 21 iv infusion, until disease progression of disease, unacceptable toxicity or patient's refusal. Pembrolizumab will be administered for a maximum of 2 years.
62724629|NCT02840305|OTHER|Expérience 1|Brain bases of spatial frequencies treatment 30 young adults, 20 old adults 20 children between 4 and 6 years, 20 children between 6 and 12 years and 20 young adults
62724630|NCT02840305|OTHER|Expérience 2|Brain bases of Computer to Film (CtF) analysis 30 young adults, 20 old adults
62724631|NCT02840305|OTHER|Expérience 3|Part of parahippocampal gyrus in Computer to Film (CtF) analysis 30 young adults, 20 old adults.
62724632|NCT04749147|EXPERIMENTAL|Black and White Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in black and white and feature black and white graphics.
62724633|NCT04749147|EXPERIMENTAL|Red Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in red text and feature red graphics.
62165960|NCT04057937|EXPERIMENTAL|Placebo then Apremilast 30mg BID|Participants received matched placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
62165961|NCT04057937|EXPERIMENTAL|Apremilast 30 mg BID then Apremilast 30 mg BID|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
62724634|NCT05254353||Patients with EVD|
62724635|NCT00606645|EXPERIMENTAL|1|XmAb2513
62724636|NCT01126190|ACTIVE_COMPARATOR|Double-Blind Phase: Pegfilgrastim|Participants will receive pegfilgrastim 6 milligrams (mg), administered by subcutaneous (SC) injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
62724637|NCT01126190|EXPERIMENTAL|Double-Blind Phase: Neugranin 40 mg|Participants will receive neugranin 40 mg, administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 administered sequentially by IV infusion on Day 1 of treatment for up to four 21-day cycles.
62724638|NCT01126190|EXPERIMENTAL|Open-Label Phase: Neugranin 40 mg|Participants will receive neugranin 40 mg, administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 administered sequentially by IV infusion on Day 1 of treatment for up to four 21-day cycles.
62724639|NCT00066612|EXPERIMENTAL|Treatment|Irinotecan
62724640|NCT05312606|EXPERIMENTAL|Trial Group|Home treatment with hyaluronic acid.
62724641|NCT05312606|ACTIVE_COMPARATOR|Control Group|Home treatment with chlorhexidine.
62724642|NCT05005221|ACTIVE_COMPARATOR|Unidirectional Text Reminders|"Participants in the unidirectional text reminder arm will receive automated text messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection.~N=15"
62724643|NCT05005221|EXPERIMENTAL|Bidirectional Text Communication|"Participants in the bidirectional text communication arm will also receive automated messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection but they will be asked to confirm the planned day or reschedule. On the day of sample collection participants will also reply with the time the samples are collected to trigger future reminder messages for each of the 4 samples.~N=30"
62724644|NCT05842525|EXPERIMENTAL|study group|Fruquintinib combined with FOLFIRI
62724645|NCT04686344|ACTIVE_COMPARATOR|Hypertonic saline continuous infusion Group|will receive Hypertonic saline continuous infusion
62724646|NCT04686344|ACTIVE_COMPARATOR|Hypertonic saline intermittent boluses Group|will receive Hypertonic saline intermittent boluses for 48 hours
62724647|NCT03637283|EXPERIMENTAL|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
62724648|NCT03637283|ACTIVE_COMPARATOR|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
62724649|NCT00463086|EXPERIMENTAL|1.Isoniazid (INH)|A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
62724650|NCT00463086|PLACEBO_COMPARATOR|2. Placebo|A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
62724651|NCT01823380|OTHER|Amyotrophic lateral sclerosis|Blood test
62724652|NCT01547156|NO_INTERVENTION|Control group|Control group received usual care
62724653|NCT01547156|EXPERIMENTAL|Telemonitoring group|Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
62724654|NCT02117011|OTHER|Physical activity|An 8-week structured, moderate-intensity aerobic training exercise regimen concurrent with their radiation therapy (N=15),
62724655|NCT02117011|NO_INTERVENTION|Control|Patients will continue with usual care, which includes radiation treatment.
62724656|NCT01128725|OTHER|Group Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~* psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~* Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
62724657|NCT01775553|EXPERIMENTAL|Carfilzomib|All patients will receive Carfilzomib
62724658|NCT00673231|EXPERIMENTAL|1|2.5mg
62724659|NCT00673231|EXPERIMENTAL|2|5mg
62724660|NCT00673231|EXPERIMENTAL|3|10mg
62724661|NCT00673231|PLACEBO_COMPARATOR|4|
62724662|NCT04888988|EXPERIMENTAL|Arm 1 Exercise Intervention- EXCAP|"Participants receive a 6-week home-based individually tailored progressive intervention, Exercise for Cancer Patients (EXCAP©®), consisting of walking and resistance band exercises. Participants receive an EXCAP kit, which includes an activity tracker, EXCAP manual, and resistance bands, meet with a certified exercise instructor for \~1 hour, and receive individualized walking and resistance band prescriptions. To enhance adherence to EXCAP intervention, the exercise instructor will conduct 2 additional Booster Meetings, each lasting 15-30 minutes, with participants during weeks 2 or 3 and weeks 4 or 5.~Participants will complete REDCap questionnaires and touch tests at baseline and post-intervention. Participants will also wear activity trackers and complete daily diary during the entire study period.~Participants may optionally complete magnetic resonance imaging (MRI) scans on the study."
62724663|NCT04888988|ACTIVE_COMPARATOR|Arm 2 Control condition (standard care)|"Participants receive their standard care. Participants will complete REDCap questionnaires and touch tests and wear activity trackers at baseline and post-intervention. Participants will also complete daily diary during the entire study period.~Participants may optionally complete magnetic resonance imaging (MRI) scans on the study.~Participants will be provided with the EXCAP©® program (i.e., EXCAP©® kit and all materials, one EXCAP©® teaching session with exercise instructor, and two Booster Meetings) after all study requirements have been completed at no cost to them."
62724664|NCT03780751|EXPERIMENTAL|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
62724665|NCT03780751|EXPERIMENTAL|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
62724666|NCT03780751|NO_INTERVENTION|Waitlist|Participants will receive no immediate treatment but will be able to choose either MIND or COPE after a six months waiting period.
62724667|NCT00893178||CHF with elevated PAP|CHF patients (LVEF \> 35%) with elevated mean pulmonary pressure( \> 20 mmHg ) measured by pa catheter
62724668|NCT00893178||CHF patient without elevated PAP|CHF patients (LVEF \> 35%) with normal mean pulmonary pressure
61978216|NCT00846131|EXPERIMENTAL|B: Sorafenib + Y-90|Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin \> 1.5 x ULN to ≤ 3 x ULN. After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
62724669|NCT00893178||Normal EF with elevated PAP|Patients with normal LVEF \< 60% with elevated mean pulmonary pressure
62724670|NCT00788060|EXPERIMENTAL|RAD001|
62724671|NCT00645840|EXPERIMENTAL|Anakinra|After study enrollment, all subjects started anakinra (Kineret™; Amgen, Thousand Oaks, CA, USA) as a subcutaneous daily injection. Subjects weighing \>25 kg at the time of enrollment received 100 mg daily, whereas those weighing \<25 kg received 50 mg daily. Anakinra was continued for 28 d with no dose adjustment.
62724672|NCT06112470||Interview|Monocentric qualitative study with a descriptive socio-demographic section, a descriptive qualitative section on the experience and perception of allergy, then on the obstacles to allergological assessment, and finally a descriptive quantitative section to evaluate knowledge of antibiotic therapy.
62724673|NCT00742521|ACTIVE_COMPARATOR|1|Euglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
62724674|NCT00742521|ACTIVE_COMPARATOR|2|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
62724675|NCT00742521|ACTIVE_COMPARATOR|3|Euglycemic glucose clamp procedure x 2 with cortisol infusion of 2ug/kg on Day 1 and hypoglycemic glucose clamp procedure on Day 2.
62724676|NCT00742521|ACTIVE_COMPARATOR|4|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
62724677|NCT00363142|ACTIVE_COMPARATOR|FPV/r200|Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
62724678|NCT00363142|EXPERIMENTAL|FPV/r100|Fosamprenavir/ritonavir 1400/100mg QD
62724679|NCT05956847||Gastric precancerous lesions，Normal gastric mucosal tissue and gastric cancer tissues|Normal gastric mucosal tissue Gastric precancerous lesions:Atrophic gastritis, non Atrophic gastritis, intestinal metaplasia, dysplasia gastric cancer tissues
62724680|NCT04572646|OTHER|NRT proposition and exhaled CO measurement|
62724681|NCT02046018|ACTIVE_COMPARATOR|ICCM delivered by VHT|Health Outcomes in Communities where VHT's were trained in ICCM and given drugs.
62724682|NCT02046018|ACTIVE_COMPARATOR|ICCM delivered by VHT with cell phone|Health Outcomes in communities with VHT's who were trained in ICCM and given cell phones
62724683|NCT02046018|ACTIVE_COMPARATOR|Health outcomes in communities with no ICCM|Health outcomes in communities with VHT's who were not trained in ICCM
62724684|NCT00465608|EXPERIMENTAL|1|propranolol
62724685|NCT02636387||Desmopressin|0.2mg tablets, dose titrated to effect
62724686|NCT02636387||Placebo|Placebo Comparator
62724687|NCT01133665|EXPERIMENTAL|Sub Group 1|All Subjects Enrolled in the Trial
62724688|NCT02671006||Patients|Patients with an active Chronic Urticaria according to the EAACI criteria will be included. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
62724689|NCT02671006||Volunteers|Volunteers must no have history of immediate allergy (patients under medical follow up for melanoma in remission for at least 3 months, age (+/- 5 years) and sex matched). Controls should have no history of atopy, urticaria or immediate allergy declared (rhinitis, urticaria, asthma) at the time of the test. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
62724690|NCT02559635|NO_INTERVENTION|No bowel stimulation|Patients undergoing loop ileostomy closures without having had bowel stimulation beforehand
62724691|NCT02559635|EXPERIMENTAL|Bowel stimulation|Patients undergoing loop ileostomy closures having undergone bowel stimulation beforehand
62165962|NCT05840016|EXPERIMENTAL|Experimental: AK112 in Combination With Paclitaxel Plus Carboplatin|AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Carboplatin will be administered at AUC5, Q3W, intravenously (IV) for 4 cycles. Paclitaxel will be administered at 175 mg/m2, Q3W, intravenously (IV) for 4 cycles.
62724692|NCT01530529|EXPERIMENTAL|PF-05180999 Immediate-Release|
62724693|NCT01530529|EXPERIMENTAL|PF-05180999 Modified-Release 1|
61978217|NCT03144388|EXPERIMENTAL|Variable Stepping Training|High intensity stepping training in multiple environments, including overground, on a treadmill and on stairs.
62724694|NCT01530529|EXPERIMENTAL|PF-05180999 Modified-Release 2|
62724695|NCT01530529|EXPERIMENTAL|PF-05180999 Modified-Release 1 With Food|
62724696|NCT02337894|EXPERIMENTAL|Essential amino acids plus arginine|Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
62724697|NCT02337894|PLACEBO_COMPARATOR|Control drink|The control drinks will be indistinguishable from the intervention drinks in taste and volume, but will contain placebo rather than essential amino acids plus arginine.
62724698|NCT02564588|EXPERIMENTAL|Dasotraline|Dasotraline 4, 6, 8 mg
62724699|NCT02564588|PLACEBO_COMPARATOR|Placebo|Placebo Comparator
62724700|NCT00872274|EXPERIMENTAL|1|sumatriptan succinate tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan) manufactured by OHM Laboratories In
62724701|NCT00872274|ACTIVE_COMPARATOR|2|IMITREX® 100 mg tablets (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
62724702|NCT01442337|EXPERIMENTAL|ASP8597 low dose|
61978218|NCT03144388|ACTIVE_COMPARATOR|Variable Non-specific Training|High intensity non-stepping training, including balance, strength, and cycling tasks
62724703|NCT01442337|EXPERIMENTAL|ASP8597 high dose|
62724704|NCT01442337|EXPERIMENTAL|ASP8597 highest dose|
62724705|NCT01442337|PLACEBO_COMPARATOR|Placebo|Placebo comparator used in Part 2 only
62724706|NCT05312840|OTHER|Routine dose group|Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2, Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
62737928|NCT01964495|ACTIVE_COMPARATOR|Common clinical practice|Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
62724707|NCT05312840|OTHER|Low dose group|Low dose group: Every three weeks as a cycle. Gemcitabine 750mg / m2, Cisplatin 56mg / m2 or Carboplatin auc3 were injected intravenously on the first day of each cycle 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
62724708|NCT00736112|EXPERIMENTAL|BMT and food allergy|trial subjects will receive food allergy testing and management in conjunction with BMT (Bilateral Myringotomy with Tympanostomy Tubes). Food allergy management involves parental education on how to avoid the specific offending foods.
62724709|NCT00736112|EXPERIMENTAL|BMT and adenoidectomy|"involves BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and food allergy testing and management.~Food allergy management involves parental education on how to avoid the specific offending foods."
62724710|NCT00736112|ACTIVE_COMPARATOR|BMT alone|The standard protocol for children presenting with initial Chronic OME is to perform a BMT (Bilateral Myringotomy with Tympanostomy Tubes).
62724711|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
62724712|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
62724713|NCT03069066|EXPERIMENTAL|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
62724714|NCT00971282|EXPERIMENTAL|intra-individual comparison|
62724715|NCT00362882|EXPERIMENTAL|Arm 1|Patients receive docetaxel IV over 60 minutes on day 1 and bortezomib IV over 3-5 seconds on days 1 and 8.
62724716|NCT00362882|EXPERIMENTAL|Arm 2|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 2 and 8.
62724717|NCT05135598|EXPERIMENTAL|Health behavior change intervention|Participants will receive a pedometer, workbook, partner, and 15 weekly phone group meetings.
62724718|NCT02398526||Radium-223 dichloride|Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.
62724719|NCT02135744|NO_INTERVENTION|Control|Group of patients undergo standard care as determined by the primary inpatient team
62724720|NCT02135744|EXPERIMENTAL|Bundle|Group of patients that receive the screening and educational tool
62724721|NCT00717847||1|Any patient with NSCLC receiving erlotinib or gefitinib
62724722|NCT00717847||2|Patients with unexpected and/or severe treatment related toxicity whilst receiving EGFR TKI.
62724723|NCT00921726|EXPERIMENTAL|1|Participants will receive treatment in the following order: Study Regimens A, B, C, D
62724724|NCT00921726|EXPERIMENTAL|2|Participants will receive treatment in the following order: Study Regimens B, A, C, D
62724725|NCT01214473|EXPERIMENTAL|Probiotic group|Once daily oral administration of a probiotic preparation (1 billion cells of Lactobacillus plantarum and 150 mg of fructooligosaccharides) for one week to newborn infants
62724726|NCT01214473|PLACEBO_COMPARATOR|Placebo|Once daily oral administration of maltodextrin for one week to newborn infants
62724727|NCT02228161|EXPERIMENTAL|Yoga exercise|Participatants will receive regular 60-minutes yoga classes twice a week for 3 months.
62724728|NCT02228161|NO_INTERVENTION|Regular schedule of daily living|Participants will maintain regular schedule as usual.
62724729|NCT01382914|EXPERIMENTAL|chlorhexidine 0.12 %|
62724730|NCT02992327||Cohort|Patients age ≥ 8 years of age with a GCS \>13 presenting to the emergency department with a diagnosis of concussion.
62724731|NCT04814953||Basal cell carinoma patients|Patients with basal cell carcinoma in history (up to 10 years before inclusion) with or without squamous cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
62724732|NCT04814953||Squamous cell carcinoma patients|Patients with squamous cell carcinoma in history (up to 10 years before inclusion) with or without basal cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
62724733|NCT04814953||Patients with actinic keratoses|Patients with actinic keratosis in history (up to 10 years before inclusion) with or without basal cell carcinoma or squamous cell carcinomas but no other skin cancers (melanoma or non-melanoma skin cancer)
62724734|NCT02563730|EXPERIMENTAL|Lung biopsy|assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
62724735|NCT03683810|EXPERIMENTAL|Lactoferrin|Participants will receive 4gr lactoferrin per day for a duration of 3 months + standard treatment for anemia
62724736|NCT03683810|ACTIVE_COMPARATOR|Standard treatment|Participants will receive only the standard treatment for anemia
62724737|NCT02575144|EXPERIMENTAL|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:~* Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.~* Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min. Patients with a calculated creatinine clearance of \<60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.~* Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
62724738|NCT02575144|ACTIVE_COMPARATOR|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:~* Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.Patients with renal failure will recived an ajusted dose.~* Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously. In patients over 75 years old, dexametasona oral will be given at dose of 20mg on days 1, 8, 15, 22 ."
62724739|NCT02789462||Patients undergoing laser-assisted PCI|Patients of VAMC centers who undergone laser-assisted percutaneous coronary interventions.
62724740|NCT02125344|EXPERIMENTAL|PM(Cb)|"PM(Cb):~paclitaxel 80mg/m² 18 times weekly simultaneously with NPLD (Myocet®)20mg/m² 18 times weekly simultaneously with carboplatin AUC 1.5 18 times weekly (only in patients with TNBC) Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all cycles."
62724741|NCT02125344|ACTIVE_COMPARATOR|ETC|"ETC:~epirubicin 150mg/m² every 2 weeks for 3 cycles followed by paclitaxel 225 mg/m² every 2 weeks for 3 cycles followed cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles. Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all T and C cycles."
62724742|NCT04734262|EXPERIMENTAL|Cohort A|Subjects will receive 70mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62724743|NCT04734262|EXPERIMENTAL|Cohort B|Subjects will receive 100mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62724744|NCT04734262|EXPERIMENTAL|Cohort C|Subjects will receive sitravatinib in combination with 200mg tislelizumab and 100 mg/m2 nab-paclitaxel until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62724745|NCT06465784|ACTIVE_COMPARATOR|Retrograde Ureteroscopic Laser Lithotripsy|In this arm we used the retrograde ureteroscopic Laser lithotripsy to clear the uretric stones. After the end of the procedure, all patients were followed for stone free rate as the primary outcome
62724746|NCT06465784|ACTIVE_COMPARATOR|Antegrade Ureteroscopic Laser Lithotripsy|In this arm we used the antegrade ureteroscopic Laser lithotripsy to clear the uretric stones. After the end of the procedure, all patients were followed for stone free rate as the primary outcome.
62724747|NCT04828135|EXPERIMENTAL|subjects with diagnosis of COVID-19 (Long-hauler)|23 subjects with a confirmed diagnosis of COVID-19 infection, and after 60 days or longer
62724748|NCT01775527|OTHER|blood test|
62724749|NCT01198821|EXPERIMENTAL|Oral sodium bicarbonate and Gemcitabine|
62724750|NCT04893512|EXPERIMENTAL|Orally administered CoV2-OGEN1- 2 dose schedule|50mcg,100mcg and 200mcg will be tested as single oral dose on day 1 and day 15. The dose will be in the form of oral suspension.
62724751|NCT04803474||Klinefelter|Patients with Klinefelter syndrome
62724752|NCT04803474||Turner|Patient with Turner syndrome
62724753|NCT03301337|EXPERIMENTAL|Hydrolyzed meat protein|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
62724754|NCT03301337|EXPERIMENTAL|Minced Meat|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
62724755|NCT03301337|EXPERIMENTAL|Beef|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
62724756|NCT03714607|EXPERIMENTAL|Laser|Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies
62724757|NCT03714607|NO_INTERVENTION|Control|No intervention
62724758|NCT01261364|ACTIVE_COMPARATOR|Treatment as Usual|
62165963|NCT05840016|ACTIVE_COMPARATOR|Active Comparator: Tislelizumab in Combination With Paclitaxel Plus Carboplatin|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) every three weeks (Q3W). Carboplatin will be administered at AUC5, Q3W, intravenously (IV) for 4 cycles. Paclitaxel will be administered at 175 mg/m2, Q3W, intravenously (IV) for 4 cycles.
62165964|NCT05262504||EDOF IOL Group|Patients who were implanted with the novel wavefront shaping extended depth of focus IOL
62165965|NCT05262504||Multifocal IOL group|Patients who were implanted with the multifocal IOL
62724759|NCT01261364|EXPERIMENTAL|Pharmacogenetic guided treatment|
62724760|NCT05497661|EXPERIMENTAL|Effects of Capacitive Resistive Monopolar Radiofrequency in patellar tendon|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant patellar tendon.
62724761|NCT05497661|PLACEBO_COMPARATOR|Placebo Comparator: Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant patellar tendon
62724762|NCT01053533|EXPERIMENTAL|Chinese herbal medicines plus western therapy|
62724763|NCT01053533|ACTIVE_COMPARATOR|western therapy|including supportive therapy and antivirus therapy when necessary
62724764|NCT00711152|EXPERIMENTAL|JADE with CHW|Patients will be enrolled into JADE program and will undergo annual comprehensive assessment (CA) with personalized JADE report with additional support by the CHW.
62724765|NCT00711152|ACTIVE_COMPARATOR|JADE only|Patients will be enrolled into JADE program and undergo annual comprehensive assessment (CA) with personalized JADE report without additional support by the CHW.
62724766|NCT04650438|EXPERIMENTAL|High-creativity|Here participants are allocated to the high-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
62724767|NCT04650438|EXPERIMENTAL|Low-creativity|Here participants are allocated to the low-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
62724768|NCT05771714|EXPERIMENTAL|individuals ages 14 years and older|This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
62724769|NCT05771714|EXPERIMENTAL|individuals aged 2 to 13 years|"This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.~If the subject is under the age of 14, an adult lay-user will collect the sample."
62724770|NCT01537471|OTHER|Placebo|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. On one of three visits, a subject will receive placebo. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
62737929|NCT01964495|EXPERIMENTAL|CRP-guided treatment|Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
62724771|NCT01537471|EXPERIMENTAL|Meclizine|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
62724772|NCT04858542|EXPERIMENTAL|Mask-wearing healthcare workers|All participants in this arm will view the educational health modules and their subjective/objective outcomes will be measure pre/post module viewing.
62724773|NCT01261975|EXPERIMENTAL|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial microincision
62724774|NCT01261975|ACTIVE_COMPARATOR|Coaxial Small Incision Cataract Surgery|2.75 mm standard incision
62724775|NCT05945498|EXPERIMENTAL|TB/Flu-05E vaccine|Single dose of 7.7 lg EID50 vector vaccine
62724776|NCT05945498|PLACEBO_COMPARATOR|Placebo|Single dose of placebo
62724777|NCT00700908|EXPERIMENTAL|1|Automated telephone intervention
62724778|NCT00700908|ACTIVE_COMPARATOR|2|Usual care
62724779|NCT05502003|EXPERIMENTAL|High Intensity Interval Training|With the arm ergometer given to the participants, a telerehabilitation-based upper extremity aerobic exercise program will be applied. Maximum Heart Rate (MHR) will be determined by the formula '220-age', and exercise intensity will be calculated, and exercise will begin with a 5 minute warm-up. Cycle will be created with 4 min MHR (80-95%) high intensity and 3 min MHR (70%) active recovery and exercise will be terminated with 5 min cool down. A total of 35 minutes of exercise program will be given.
62724780|NCT05502003|ACTIVE_COMPARATOR|Moderate Exercise Training|An upper extremity exercise program with telerehabilitation (Zoom/videoconference) will be applied to the moderate-intensity exercise group. Maximum heart rate (MHR) will be determined by the formula 220-Age. A total of 55 minutes of moderate exercise training will be given at 65-70% of MHR, with five minutes of warm-up and cool-down.
62724781|NCT05502003|NO_INTERVENTION|Control|No aerobic exercise program will be applied to this group.
62724782|NCT05350540|EXPERIMENTAL|ICG|This study will use intraoperative ICG imaging to assess recipient pharyngeal tissue perfusion. The ICG is the vascular contrast agent and the SPY Elite is the imaging device. 3mL of ICG will be injected using a peripheral IV access, followed by a 10mL saline flush. The pharyngeal mucosa will be imaged to quantify the tissue perfusion. Poorly perfused areas (less than 25%) will be debrided
62724783|NCT05350540|NO_INTERVENTION|Control|Patients assigned to the observation (control) group will undergo standard of care reconstruction of mucosa
62724784|NCT06133881|EXPERIMENTAL|prilocaine|
62724785|NCT06133881|ACTIVE_COMPARATOR|bupivacaine|
62724786|NCT02982811|NO_INTERVENTION|Control group|Therapy as usual, i.e. occupational therapy, physiotherapy, etc.
62724787|NCT02982811|EXPERIMENTAL|Experimental group|Therapy as usual together with 3x45min training with i-ACT system during 6 weeks.
62724788|NCT02878083|EXPERIMENTAL|VEDOLIZUMAB|300 mg IV
62724789|NCT03469167|EXPERIMENTAL|CEGP003|
62724790|NCT03469167|ACTIVE_COMPARATOR|Injection Tx|
61978219|NCT05985018|ACTIVE_COMPARATOR|Traditional Dietary Advice|Its main elements are to adopt sensible eating habits and avoid excess fatty foods, spicy foods, processed foods, caffeine, fizzy drinks and alcohol.
61978220|NCT05985018|ACTIVE_COMPARATOR|Mediterranean Diet|The principle components is a diet rich in vegetables, pulses, whole grains, and olive oil
61978221|NCT04483011|EXPERIMENTAL|RiaGev|RiaGev, 2000mg, BID
62724791|NCT05255302|ACTIVE_COMPARATOR|Arm A : control Arm|6 months treatment by chemotherapy + pembrolizumab followed by pembrolizumab ± pemetrexed for patients with non-squamous cell carcinoma (SCC) until 2 years max
62724792|NCT05255302|EXPERIMENTAL|Arm B : experimental arm|6 months treatment by chemotherapy + pembrolizumab followed by pemetrexed for patients with non-SCC or observation for patients with SCC
62724793|NCT03783598|EXPERIMENTAL|intervention group|The intervention group received problem solving therapy as 6 modules. Each module was included at least 1 session per week that is nearly 60 minutes, and the amount of weekly sessions was arranged according to the needs of the person.Individuals has an opportunity was provided for identify problems meaningful for themselves and to start their change from the activities they valued by using the COPM.
62724794|NCT03783598|NO_INTERVENTION|control group|Control group had not any intervention we have an education to control group about diabetes and healthy life conditions.
62724795|NCT02901600||Patients with colorectal cancer|Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
62724796|NCT02901600||Patients with adenomatous polyps|Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
62724797|NCT02901600||Control patients|Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
62724798|NCT00871663|EXPERIMENTAL|Advanced solid tumors|Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
62724799|NCT00871663|EXPERIMENTAL|Non-Hodgkin's lymphoma and multiple myeloma|Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
62724800|NCT00871663|EXPERIMENTAL|B cell chronic lymphocytic leukemia|Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts
62724801|NCT02769429||ultrasound-guided CISB|Group 1 will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
62724802|NCT02769429||nerve stimulator-guided CCPVB|Group 2 will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
62724803|NCT02718235||Overall survival HCCIS low risk|HCCIS 2 points
62724804|NCT02718235||Overall survival HCCIS medium risk|HCCIS 1 point
62724805|NCT02718235||Overall survival HCCIS high risk|HCCIS 0 point
62724806|NCT02544347|OTHER|diabetes mellitus group|gingival crevicular fluid was collected
62724807|NCT02544347|OTHER|Control group|gingival crevicular fluid was collected
62724808|NCT02544347|OTHER|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
62724809|NCT02544347|OTHER|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
62549823|NCT01408043|EXPERIMENTAL|Treatment (stem cell supermobilization)|Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
62549824|NCT01971047|ACTIVE_COMPARATOR|Group 1-Regular Insulin|Intravenous Regular Insulin will be administered for a preoperative Blood glucose of greater than 180.
62549825|NCT01971047|ACTIVE_COMPARATOR|Group 2-Humalog|Subcutaneous Humalog will be administered for a preoperative Blood glucose of greater than 180
62549826|NCT05567510|EXPERIMENTAL|BMS-986369|
62549827|NCT01406574|EXPERIMENTAL|OPB-31121 p1|Phase1 step
62549828|NCT01406574|EXPERIMENTAL|OPB-31121 p2|Phase2 step
62549829|NCT01117649|EXPERIMENTAL|1|hyper-oncotic colloid
62549830|NCT01117649|ACTIVE_COMPARATOR|2|iso-oncotic colloid
62549831|NCT01117649|ACTIVE_COMPARATOR|3|crystalloid
62549832|NCT01109810||IVIg and SCIg therapy|Patients receiving Ig therapy by IV or SC route in the home or alternate site setting
62549833|NCT01907256|ACTIVE_COMPARATOR|group A|stair step incisions
62549834|NCT01907256|ACTIVE_COMPARATOR|Group B|inverted V incision
62549835|NCT02532309|EXPERIMENTAL|Rosuvastatin dose adjustment|
62549836|NCT02532309|EXPERIMENTAL|Rosuvastatin fixed dose|
62549837|NCT05567770|ACTIVE_COMPARATOR|Cohort 1|
62549838|NCT05567770|ACTIVE_COMPARATOR|Cohort 2|
62549839|NCT01562860|ACTIVE_COMPARATOR|Carpal Tunnel and Pronator Teres Release|Patients enrolled in this arm of the study will have both surgical procedures performed at the same time
62549840|NCT01562860|ACTIVE_COMPARATOR|Carpal Tunnel Release only|Patients enrolled in this arm will have only Carpal Tunnel Release performed. In they still have symptoms of median nerve neuropathy, they will be scheduled for an additional procedure to release the pronator Teres in a separate surgery.
62549841|NCT04814771|EXPERIMENTAL|[14C] TS-142|Participants will receive oral \[14C\] TS-142 under fasted conditions
62549842|NCT04786587||Pregnant woman|
62549843|NCT01258309|EXPERIMENTAL|1|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
62549844|NCT01258309|ACTIVE_COMPARATOR|2|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
62549845|NCT05257057||Endometrial hyperplasia|These are patients with a diagnosis of endometrial hyperplasia at WellSpan in the study time frame diagnosed via endometrial biopsy, dilation and curettage, or hysterectomy.
62549846|NCT02641158|OTHER|Control Group|
62549847|NCT02641158|EXPERIMENTAL|Care Facilitation Group|
62549848|NCT05298345|EXPERIMENTAL|Primary Workshop Sessions|Participants receive 18 total workshop hours; TYRO Leadership curriculum in 6 2-hour weekly sessions for a subtotal of 12 hours, and Core Communication curriculum in 1-3 sessions for a subtotal of 6 hours.
62549849|NCT05509075||nutraceuticals and neurological disorders|evaluation of nutraceuticals in subjects with memory disorders
62549850|NCT05509075||nutraceuticals and skin disorders|evaluation of nutraceuticals in clinical conditions requiring topical treatment for skin diseases
62549851|NCT05509075||nutraceuticals and gastrointestinal diseases|evaluation of nutraceuticals in clinical conditions requiring systemic treatment for gastrointestinal diseases
62549852|NCT05509075||nutraceuticals and urological diseases|evaluation of nutraceuticals in the management of patients with prostate diseases or with lower tract infectious diseases requiring systemic or local treatment
62549853|NCT05509075||nutraceuticals and immunomediate diseases|evaluation of nutraceuticals in the management of patients with immunomediate disorders
62549854|NCT05509075||nutraceuticals and pain|evaluation of nutraceuticals in the management of patients with acute or chronic pain
62549855|NCT02795247|ACTIVE_COMPARATOR|Hybrid Transtibial Technique|Reconstruction of the ACL using the hybrid transtibial technique
62549856|NCT02795247|ACTIVE_COMPARATOR|Accessory Anteromedial Portal Technique|Reconstruction of the ACL using the accessory anteromedial portal technique
62549857|NCT02795247|ACTIVE_COMPARATOR|Transtibial Technique|Reconstruction of the ACL using the transtibial technique.
62549858|NCT01043887|EXPERIMENTAL|Patients with Moderate Hepatic Insufficiency|Patients with moderate hepatic insufficiency (a score of 7 to 9 on the Child-Pugh's scale) received a single 10 mg dose of ridaforolimus.
62549859|NCT01043887|EXPERIMENTAL|Healthy Control Subjects|Healthy control subjects were matched by race, age, gender, and body mass index (BMI) to the patients with moderate hepatic insufficiency. The healthy control subjects also received a single 10 mg dose of ridaforolimus.
62549860|NCT06222931|EXPERIMENTAL|Triplanar Vibration (synchronous)|Triplanar vibration, performed at 25 Hz and 4 mm peak-to-peak displacement, for 5 minutes each session, three times a week. Participants will be positioned standing, with knees semi-flexed at 30º.
62549861|NCT06222931|EXPERIMENTAL|Side-alternating vibration|Vibration with alternating side of the base, performed at 25 Hz and 4 mm peak-to-peak displacement, for 5 minutes each session, three times a week. Participants will be positioned standing, with knees semi-flexed at 30º.
62549862|NCT06222931|SHAM_COMPARATOR|False vibration|Platform identical to the other two used by the experimental groups, configured at 25 Hz, however, without peak-to-peak displacement. The platform starts the engine and emits an operating sound identical to a vibrating platform in operation, but does not generate any mechanical vibration. Participants will be positioned standing, with knees semi-flexed at 30º and must remain on the equipment for 5 minutes each session, three times a week.
62549863|NCT00858182|EXPERIMENTAL|Group A|
62549864|NCT00858182|EXPERIMENTAL|Group B|
62549865|NCT05949021|EXPERIMENTAL|Liposomal doxorubicin and Carboplatin|"Combination of liposomal doxorubicin 30milligrams per square meter (mg/m2) and carboplatin area under the curve 5 (AUC 5), administered every four weeks for four cycles.~Participants with triple-negative breast cancer (TNBC):~1. Completed breast surgery and sentinel lymph node biopsy~2. Tumor size less than2.5 and NO/ N1mi disease"
62549866|NCT04009707||patients with alcool use desorders|Patient cared for in the addictology department of the University Hospital of Nîmes
62549867|NCT00857350||HIV+, opiod dependent|
62549868|NCT05843747|EXPERIMENTAL|Sampling|
62724810|NCT00439101|EXPERIMENTAL|1|
62724811|NCT00439101|PLACEBO_COMPARATOR|2|Placebo
62724812|NCT04884503|EXPERIMENTAL|Patients diagnosed with BMS traeting with Clonazepam|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
62724813|NCT04884503|ACTIVE_COMPARATOR|Patients diagnosed with BMS treating with tongue pads|patients wearing tongue pads 3 times a day for 20 minutes for 4 weeks to exclude parafunctions
62724814|NCT03263065|EXPERIMENTAL|Nopal added to test meal|test meal including nopal powder
62549869|NCT01140165|ACTIVE_COMPARATOR|butter|Danish butter
61978222|NCT04483011|ACTIVE_COMPARATOR|Comparator|Comparator matched to RiaGev, BID
61978223|NCT03388060|ACTIVE_COMPARATOR|Ultrasound guided SWL|ultrasound guided SWL for Radiolucent stone
62549870|NCT01140165|EXPERIMENTAL|cheese|
62549871|NCT02494661|EXPERIMENTAL|Healthy Cart and Stress Mangement Videos|Healthy Cart and Stress Management Videos: Participants receive two nutritional intervention videos: active comparator and managing stress while food shopping.
62549872|NCT02494661|ACTIVE_COMPARATOR|Healthy Cart Video|Healthy Cart Video: Participants receive one nutritional video intervention on how to shop for healthy foods using My Plate Guidelines.
62549873|NCT05229536|EXPERIMENTAL|High dose Group|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 40μg/dose
62549874|NCT05229536|EXPERIMENTAL|Low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 20μg/dose
62549875|NCT05904002|EXPERIMENTAL|pulmicort inhaler|Group (A) consists of 30 patients. They will receive their inhaled glucocorticoids (pulmicort inhaler) on needs.
62549876|NCT05904002|EXPERIMENTAL|incentive spirometer|Group (B) consists of 30 patients. They will receive the same medical treatment and incentive spirometer program 3 days per week for six weeks.
62549877|NCT02792920|OTHER|CoCr-EES|
62549878|NCT00640315|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) 1.0 mg|Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.
62549879|NCT00640315|EXPERIMENTAL|Riociguat (Adempas, BAY63-2521) 2.5 mg|Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.
62549880|NCT04934059|EXPERIMENTAL|Yuxuebi tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
62549881|NCT04934059|PLACEBO_COMPARATOR|Placebo tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
62549882|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
62549883|NCT00978614|EXPERIMENTAL|Neramexane, Placebo, Moxifloxacin|
62549884|NCT00611260|EXPERIMENTAL|Meditation Cohort|25 patients will be given instruction in vipassana meditation. Vipassana meditation is thought to reduce the incidence of atrial and ventricular arrhythmias in patients with congestive heart failure, and improve their overall psychological profile.
62549885|NCT00611260|ACTIVE_COMPARATOR|Standard Care|25 patients will receive current standard of care to manage their congestive heart failure, implanted cardiac devices, and psychological health.
62549886|NCT05159024||Patients with leak after colorectal anastomosis|Patients who developed anastomotic leak, clinical or radiologic, after colorectal resection and anastomosis
62549887|NCT04342455|NO_INTERVENTION|traditional scanning protocol group|In coronary CTA examination,each subject will be injected 50 ml contrast agent (Iodixanol 320) with the flow rate of 5 ml/s in tube voltage of 120 kVp.
62549888|NCT04342455|EXPERIMENTAL|double-low scanning protocol group|In coronary CTA examination,the tube voltage(70，80,100kVp),contrast agent(Iodixanol 320) volume and flow rate of each subject are adapted to his or her cardiac ejection fraction(EF) and body mass index(BMI).
62549889|NCT00051935|EXPERIMENTAL|1|
62549890|NCT04578535|EXPERIMENTAL|Part 1 Schedule A: TA 1 (Low TDL HYQVIA)|Participants received a subcutaneous (SC) infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
62549891|NCT04578535|EXPERIMENTAL|Part 2 Schedule A: TA 4 (High TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
62549892|NCT04578535|EXPERIMENTAL|Part 1 Schedule B: TA 2 (Low TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
62549893|NCT04578535|EXPERIMENTAL|Part 2 Schedule B: TA 5 (High TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
62549894|NCT04578535|EXPERIMENTAL|Part 1 Schedule C: TA 3 (Low TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
62549895|NCT04578535|EXPERIMENTAL|Part 2 Schedule C: TA 6 (High TDL HYQVIA)|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
62549896|NCT04366947|EXPERIMENTAL|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
62549897|NCT04366947|EXPERIMENTAL|Experimental: IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
62549898|NCT01273896|EXPERIMENTAL|STA-9090|This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
62549899|NCT00621270|EXPERIMENTAL|1|BCI-540 80 mg once a day (q.d.)
62549900|NCT00621270|EXPERIMENTAL|2|BCI-540 80 mg three times a day (t.i.d.)
62549901|NCT00621270|PLACEBO_COMPARATOR|3|Placebo
62724815|NCT03263065|EXPERIMENTAL|Psyllium added to test meal|test meal including psyllium powder
62724816|NCT03263065|EXPERIMENTAL|Bran added to test meal|test meal including bran powder
62724817|NCT05144776||Chronic hepatitis B|300 patients diagnosed with chronic hepatitis B will be enrolled. A fingerstick HBV DNA test will be performed using the Xpert HBV Viral Load assay, and a dried blood spot sample will be collected which will be tested using a gold standard HBV DNA viral load assay. Both results will be compared against the HBV DNA viral load from standard of care venous blood using the gold standard HBV DNA viral load assy. Enrolment of HBV DNA undetectable participants will be capped at 100.
62724818|NCT00003935|EXPERIMENTAL|Treatment|Induction: Patients receive oral etoposide daily on days 1-21 and vincristine sulfate IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiation therapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine sulfate IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter
62724819|NCT02494635||Diagnostic (ultrasound, biomarker studies)|Previously collected tumor tissue samples, bladder washings, and urine cells are stained with calcium dye, washed and immersed in external buffer solution, and then transferred to the ultrasound imaging system. Tissue, bladder wash cells and urine cells samples are also analyzed for biomarkers of invasiveness derived from or related to REST gene via qRT-PCR, Western blot, and FISH.
62724820|NCT03305952|EXPERIMENTAL|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
62724821|NCT03305952|ACTIVE_COMPARATOR|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
62724822|NCT00600717||Pediatric Patients and Healthy Children|Healthy children without dental works. Pediatric patients with epilepsy and migraine (headache).
62724823|NCT00878592|NO_INTERVENTION|Control group|The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education.
62724824|NCT00878592|EXPERIMENTAL|Dietary and Lifestyle counseling|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
62724825|NCT04966234|EXPERIMENTAL|Posaconazole arm|"90 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will receive posaconazole for 12 weeks. Patients in the posaconazole arm will be stratified for body weight and positive sputum cultures for Aspergillus species.~Patients will be followed-up for a total of 12 months post-randomization."
62724826|NCT04966234|NO_INTERVENTION|Control arm|"45 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will not receive the active treatment.~Patients will be followed-up for a total of 12 months post-randomization. If participants in the control arm are deteriorating during the first 3 months after randomization, it is up to the treating physician to consider treatment for the initial asymptomatic Aspergillus infection"
62724827|NCT04548427|EXPERIMENTAL|CKD-352|
62724828|NCT04548427|ACTIVE_COMPARATOR|Diquafosol Sodium 3%|
62724829|NCT03661177|EXPERIMENTAL|Diet intervention|
62724830|NCT03661177|NO_INTERVENTION|Control|
62724831|NCT03909412|EXPERIMENTAL|Carfilzomib Mobilization - Dose Level 0|"Carfilzomib at 20mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
62724832|NCT03909412|EXPERIMENTAL|Carfilzomib Mobilization - Dose Level 1|"Carfilzomib at 27mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
62724833|NCT03909412|EXPERIMENTAL|Carfilzomib Mobilization - Dose Level 2|"Carfilzomib at 36mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
62724834|NCT03909412|EXPERIMENTAL|Carfilzomib Mobilization - Dose Level 3|"Carfilzomib at 45mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
62724835|NCT03909412|EXPERIMENTAL|Carfilzomib Mobilization - Dose Level 4|"Carfilzomib at 56mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
62724836|NCT03909412|EXPERIMENTAL|Carfilzomib Mobilization - Dose Level 5|"Carfilzomib at 70mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
62724837|NCT01736267|EXPERIMENTAL|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
62724838|NCT01941771|ACTIVE_COMPARATOR|Arm A|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
62724839|NCT01941771|EXPERIMENTAL|Arm B|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
62724840|NCT03089047|EXPERIMENTAL|Rejuvenated RBC Transfusion|Washed and Rejuvenated autologous blood
62724841|NCT03089047|SHAM_COMPARATOR|Standard RBC Transfusion|Washed autologous blood (so as to maintain equivalent unit volume and Hct)
62724842|NCT00573391|EXPERIMENTAL|VTD = Velcade, Thal, and Dex|VTD = Velcade, Thalidomide, and Dexamethasone
62724843|NCT00573391|EXPERIMENTAL|VMD = velcade, melphalan, and dex|VMD = velcade, melphalan, and dexamethasone
62724844|NCT06209294|EXPERIMENTAL|Experimental: AK104 combined with nab-paclitaxel and carboplatin|Carboplatin, nab-paclitaxel and AK104 as neoadjuvant treatment before fertility-sparing surgery
62724845|NCT02737319|EXPERIMENTAL|Rosuvastatin|40 mg of Rosuvastatin up to 6 hours before elective percutaneous coronary intervention.
62724846|NCT02737319|NO_INTERVENTION|Control|Use of standard therapy in elective angioplasty.
62724847|NCT05270148|EXPERIMENTAL|HIIT Group|Participants are enrolled in a high-intensity interval training exercise program
62724848|NCT05270148|ACTIVE_COMPARATOR|FatMax Group|Participants who are enrolled in a moderate-intensity continuous training exercise program
62724849|NCT05270148|NO_INTERVENTION|Control|Participants who do not receive an exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
62724850|NCT02578446|EXPERIMENTAL|Uncemented Triathlon Tritanium CR|Primary total knee replacement with Uncemented Triathlon Tritanium CR Total Knee System
62724851|NCT02578446|ACTIVE_COMPARATOR|Cemented Triathlon CR|Primary total knee replacement with Cemented Triathlon CR Total Knee System
62724852|NCT03084705|EXPERIMENTAL|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
62724853|NCT03084705|EXPERIMENTAL|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
62724854|NCT06451874|EXPERIMENTAL|Stage 1 Exercise Treatment|Participants will first be randomized to 6-week exercise treatment (FPT or MBDT)
62724855|NCT06451874|EXPERIMENTAL|Stage 2: Exercise Treatment|At 6-week, responsiveness (change in gait speed = 0.05 m/s) will be evaluated. Responders will continue with their assigned treatment and non-responders will be randomized to either continue assigned treatment or combined treatment for an additional 6 weeks.
62724856|NCT04212130|EXPERIMENTAL|Evaluation of environmental cleanliness|"In this study,~1. fluorescent marking,~2. microbiological sampling and~3. BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
62724857|NCT02002988|EXPERIMENTAL|BT injection|
62724858|NCT04403919|ACTIVE_COMPARATOR|Revision total knee arthroplasty: control|
62724859|NCT04403919|EXPERIMENTAL|Revision total knee arthroplasty: active|
62724860|NCT04403919|ACTIVE_COMPARATOR|Revision Total Hip Arthroplasty: control|
62724861|NCT04403919|EXPERIMENTAL|Revision Total Hip Arthroplasty: active|
62724862|NCT05680493|EXPERIMENTAL|Dry needling|Total 12 sessions of trigger point dry needling at lumbar muscles with Hot pack,with 3 sessions per week
62724863|NCT05680493|ACTIVE_COMPARATOR|manual pressure release|Hot pack for 15 min then manual pressure release
62724864|NCT01816425|EXPERIMENTAL|thermoplastic partial denture|The patients that need oral rehabilitation with partial denture will receive a thermoplastic partial denture as treatment
62724865|NCT01816425|ACTIVE_COMPARATOR|CoCr partial denture|The patients that need oral rehabilitation with partial denture will receive a CoCr partial denture as treatment
62724866|NCT01818843|EXPERIMENTAL|Safety and Adverse Reaction in CO|Inhaled Carbon Monoxide
62724867|NCT05843331|ACTIVE_COMPARATOR|posterior vertical implants|the anterior implants were inserted in the canine/lateral incisor area bilaterally to each other's following the contour of the alveolar bone of the premaxilla. The posterior implants were inserted vertically just anterior to the maxillary sinus (in the area of second premolars) .
62724868|NCT05843331|ACTIVE_COMPARATOR|posterior inclined implants|The anterior implants were inserted in the canine/lateral incisor area bilaterally to each other's and will be inclined 15o labially following the contour of the alveolar bone of the premaxilla. The posterior implants were inserted just anterior to the maxillary sinus (in the area of second premolars) and inclined 15o distally .
62724869|NCT06387069|EXPERIMENTAL|HMPL-306 arm|HMPL-306
62724870|NCT06387069|ACTIVE_COMPARATOR|Salvage treatment arm|Salvage treatment
62724871|NCT05399966|EXPERIMENTAL|Monarda Didyma extract|Monarda Didyma extract
62724872|NCT05399966|PLACEBO_COMPARATOR|Placebo|Maltodextrin
62724873|NCT04335968|EXPERIMENTAL|Experimental group|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery
62724874|NCT04335968|PLACEBO_COMPARATOR|Control group|placebo of this drug with the same schedule, during the same period of time.
62724875|NCT06059677|EXPERIMENTAL|Active Smoked Cannabis|"Participants in this arm will smoke an active cannabis cigarette containing 18.16% Δ9-tetrahydrocannabinol (THC). The smoking will occur at each participant's preferred pace, but will be limited to a maximum ten-minute period. While individual doses vary in this type of paradigm (ad libitum dosing), the anticipated dose of THC within the cannabis condition can be approximated by the following formula: (700 mg of cannabis) x \[% of cigarette smoked; maximum of 70% (allowing room to hold the cigarette)\] x (% THC). Therefore, the maximum dose in this arm is 700 mg x 70% x 18.2% = 89.18 mg of THC. Individual participants will only take part in the study under a single condition and receive the active cannabis once.~Bulk cannabis for this arm will be provided by the National Institute on Drug Abuse Drug Supply Program; cannabis cigarettes will be prepared and prescribed by the Research Pharmacy of the University of California, San Diego."
62739009|NCT03181217|EXPERIMENTAL|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
62724876|NCT06059677|PLACEBO_COMPARATOR|Placebo Smoked Cannabis|"Participants in this arm will smoke a placebo cannabis cigarette containing \<.01 THC. The smoking will occur at each participant's preferred pace, but will be limited to a maximum ten-minute period. Individual participants will only take part in the study under a single condition and receive the placebo cannabis once.~Bulk placebo for this arm will be provided by the National Institute on Drug Abuse Drug Supply Program; placebo cannabis cigarettes will be prepared and prescribed by the Research Pharmacy of the University of California, San Diego."
62724877|NCT06059677|NO_INTERVENTION|Control|Participants in this arm receive no cannabis. Individual participants will only take part in the study under a single condition.
62724878|NCT00038948|ACTIVE_COMPARATOR|A|Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression
62724879|NCT00038948|ACTIVE_COMPARATOR|B|Continued calcineurin inhibitor therapy
62724880|NCT01082627|EXPERIMENTAL|Somatostatin+common daily practice|
62724881|NCT01082627|PLACEBO_COMPARATOR|common daily practice|
62724882|NCT05022173|EXPERIMENTAL|Helmet NIV|Patients randomized to the intervention arm will receive NIV through a phthalate free helmet (CaStar, STARMED) via an ICU ventilator in pressure support (PS) mode.
62724883|NCT05022173|ACTIVE_COMPARATOR|Facemask NIV|Patients in the control arm will be randomized to the traditional facemask interface. The facemask group will use the same ICU ventilator being used for the helmet group.
62724884|NCT01545596|EXPERIMENTAL|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
62724885|NCT01545596|NO_INTERVENTION|No Notification|No additional notification given to anesthesia team apart from the information on their monitors.
62724886|NCT03847831|EXPERIMENTAL|PPASF Group|"Schools enrolled in the post primary active school flag program. All 17 elements are included. Feasibility is measured of the 17 elements.~Student representatives are selected to have accelerometer, physical health measures and perceived health collected for feasibility purposes."
62724887|NCT06287372||Group 1: Calafiore cardioplegia|"Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection:~• Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously."
62724888|NCT06287372||Group 2: del Nido cardioplegia|• Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study).
62724889|NCT01303276||Anti-VEGF group|Patients who are clinically indicated for the intravitreal injection of ranibizumab
62724890|NCT01303276||Age-matched controls|Group of healthy participants who will be age and gender matched
62724891|NCT05228405||1/caregivers of disabled children|1/Caregivers of disabled children will be assessed by the questionnaire of the Disease, Physiotherapy and Sports Awareness
62724892|NCT04098302|ACTIVE_COMPARATOR|dutasteride|two 0.5 mg capsules of dutasteride daily
62724893|NCT04098302|PLACEBO_COMPARATOR|placebo capsule|inactive placebo matched in appearance with dutasteride capsules
62724894|NCT02961270|EXPERIMENTAL|icotinib|patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
62724895|NCT01023217|EXPERIMENTAL|Adefovir plus Entecavir|Adefovir + Entecavir for 104 weeks
62724896|NCT01023217|ACTIVE_COMPARATOR|Adefovir plus Lamivudine|Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
62724897|NCT02457247|EXPERIMENTAL|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) \[A\], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) \[B\], chewable tablets, orally, twice, daily, on Days 15 through 28.
62724898|NCT02457247|EXPERIMENTAL|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
62724899|NCT02457247|EXPERIMENTAL|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) \[C\], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) \[D\], chewable tablets, orally, once, daily, on Days 15 through 28.
62724900|NCT02457247|EXPERIMENTAL|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
62724901|NCT02775266|ACTIVE_COMPARATOR|ALA + Scaling and Root planing|Systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months(group B)
62724902|NCT02775266|PLACEBO_COMPARATOR|Scaling and root planing only|Patients will receive scaling and root planning at baseline and 3 months(group A)
62724903|NCT03076281|EXPERIMENTAL|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
62724904|NCT03076281|EXPERIMENTAL|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
62724905|NCT03076281|EXPERIMENTAL|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
62724906|NCT02881775|EXPERIMENTAL|rTMS and exercise, then Sham rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
62724907|NCT02881775|SHAM_COMPARATOR|Sham rTMS and exercise, then rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
62724908|NCT03908203|OTHER|Treatment Arm|
62724909|NCT04244266||Ideal Body Weight|groups of patients divided according to neostigmine dose weight, ideal body weight (IBW)
62724910|NCT04244266||Total Body Weight|groups of patients divided according to neostigmine dose weight, total body weight (TBW),
62724911|NCT04244266||Adjusted Body Weight|groups of patients divided according to neostigmine dose weight, , adjusted body weight (ABW)
62724912|NCT01484145|ACTIVE_COMPARATOR|6 mA.min, 20 mins|
62724913|NCT01484145|EXPERIMENTAL|6 mA/min, 20 mins, clamping|
62724914|NCT01484145|EXPERIMENTAL|6 mA/min, 20 mins, debridement, clamping|
62724915|NCT01484145|EXPERIMENTAL|15 mA/min, 30 mins, clamping|
62724916|NCT01484145|EXPERIMENTAL|15 mA/min, 50 mins, debridement, clamping|
62724917|NCT05657535|OTHER|Treatment group|Single treatment group for evaluation pain relief before and after LICUS treatment
62724918|NCT03678051|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|Standard of care
62724919|NCT03678051|EXPERIMENTAL|TAU+CBT4CBT|TAU with access to the CBT4CBT program
62724920|NCT01485796|EXPERIMENTAL|Epoch 1 and Epoch 2|In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
62724921|NCT03123770|EXPERIMENTAL|DC Follow T|Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.
62724922|NCT03123770|ACTIVE_COMPARATOR|EC Follow T|Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.
62724923|NCT01059006|EXPERIMENTAL|PresbyLASIK|Male or female patients with presbyopic symptoms who underwent PresbyLASIK.
62724924|NCT00895362|EXPERIMENTAL|Erlotinib + Cetuximab|Erlotinib in Combination with Cetuximab
62724925|NCT04306562|EXPERIMENTAL|Intervention group|Patients in an intervention group will be ask about a history of food consumption in the past seven days to analyze a nutritive value of food consumption with a program (INMUCAL-Nutrients V.4.0, Institute of Nutrition, Mahidol University) and estimate an enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day with nutritional counseling by researchers. Special enteral formula will be selected if patients have specific conditions including renal failure, hyperglycemia/diabetes and liver failure, acute and chronic pulmonary disease and immunocompromised states. Otherwise, standard formula will be provided. Duration of enteral protein supplementation is at least 14 days from a preanesthetic clinic visit to a day of surgery.
62724926|NCT04306562|NO_INTERVENTION|Control group|Patients in a control group will be sent to assess and improve nutritional status by primary doctor as a conventional care pathway.
62724927|NCT03826459|ACTIVE_COMPARATOR|Locked Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running \& locking technique. The second layer will be performed based on surgeon preference.
62724928|NCT03826459|EXPERIMENTAL|Non-Locking Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running \& non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
62724929|NCT02701309||Non-invasive Iron detection|Children between 9months and 5years will be recruited for a non-invasive iron measurement on the lower lip. This study is focusing on the feasability of a non-invasive detection method. There is no intervention planed. The device is tested once for 3-5 Minutes.
62724930|NCT02903823|EXPERIMENTAL|Baclofen injection at designated spinal level|Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
62724931|NCT01991483|EXPERIMENTAL|LY2928057 (No ESA)|Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
62724932|NCT01991483|EXPERIMENTAL|LY2928057 (Reduced ESA)|Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
62724933|NCT01991483|PLACEBO_COMPARATOR|Placebo (No ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
62724934|NCT01991483|PLACEBO_COMPARATOR|Placebo (Reduced ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
62724935|NCT02796833|OTHER|SMOF/Intralipid|"Patients that are randomized to receive for the first 6 months SMOF as a lipid emulsion in their PN, and for the next 6 month (after 28 days of active washout on Intralipid) Intralipid, which is the standard lipid emulsion used in the hospital. SMOF is approved by Health Canada.~The parenteral nutrition bags are compounded individually for each patient based on their specific needs."
62724936|NCT02796833|OTHER|Intralipid/SMOF|Patients that are randomized to receive Intralipid, which is the standard lipid emulsion used in the hospital for the first 6 months, and for the next 6 month (after 28 days of active washout on Intralipid) SMOF as a lipid emulsion in their PN. SMOF is approved by Health Canada.The parenteral nutrition bags are compounded individually for each patient based on their specific needs.
62724937|NCT02092727|NO_INTERVENTION|Control|Standard of care arm will receive no specific interventions, but will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
62724938|NCT02092727|EXPERIMENTAL|Behavioral Intervention|A variety of dialysis facility-level, behavioral interventions will be examined.
62724939|NCT04162470|EXPERIMENTAL|REGN3918|Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 \[NCT03946748\] or R3918-PNH-1853)
62724940|NCT04157699|EXPERIMENTAL|QL-007 100 mg QD + TDF|QL-007 tablet 100 mg QD was combined with TDF tablet 300mg
62724941|NCT04157699|EXPERIMENTAL|QL-007 200 mg QD + TDF|QL-007 tablets 200 mg QD were combined with TDF tablet 300mg
62724942|NCT04157699|EXPERIMENTAL|QL-007 400 mg QD+ TDF|QL-007 tablets 400 mg QD were combined with TDF tablet 300mg
62724943|NCT04157699|EXPERIMENTAL|QL-007 200 mg BID+ TDF|QL007 tablets 200 mg BID were combined with TDF tablet 300mg
62724944|NCT04157699|ACTIVE_COMPARATOR|TDF monotherapy|TDF tablet 300mg
62724945|NCT03108521|EXPERIMENTAL|Sitagliptin group|Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.
62724946|NCT03108521|NO_INTERVENTION|non-T2DM group|Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.
62724947|NCT00305448|EXPERIMENTAL|1|Fulvestrant 250 mg intramuscular injection
62724948|NCT00305448|EXPERIMENTAL|2|Fulvestrant 250mg (Plus 250mg Loading Regimen)
62724949|NCT00305448|EXPERIMENTAL|3|Fulvestrant 500 mg
62724950|NCT01476540|EXPERIMENTAL|Deep Brain Stimulation|Deep Brain Stimulation
62724951|NCT00638729|ACTIVE_COMPARATOR|Midazolam|Pre-anesthetic medication with midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
62724952|NCT00638729|ACTIVE_COMPARATOR|Clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
62724953|NCT00638729|PLACEBO_COMPARATOR|Placebo|Pre-anesthetic medication with an inert tablet, p.o., 60-90 min prior to estimated induction time
62724954|NCT02491177|OTHER|cMM and Text Messaging|Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
62724955|NCT02491177|OTHER|cMM Only|Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
62724956|NCT02491177|OTHER|Text Messaging Only|Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
62724957|NCT02491177|NO_INTERVENTION|Neither cMM nor Text Messaging|Participants randomized to this arm will receive standard of care with no interventions.
62724958|NCT03670849|EXPERIMENTAL|Patients using LapAR system|
62724959|NCT01916486|EXPERIMENTAL|Exercise training|Twice-weekly for the 6-month duration.
62724960|NCT01916486|EXPERIMENTAL|Complex mental and social activities|Twice-weekly for the 6-month duration.
62724961|NCT01916486|ACTIVE_COMPARATOR|Control: stretching and relaxation program|Twice-weekly for the 6-month duration.
62724962|NCT01177124|EXPERIMENTAL|MBSR 6 Weeks Program|
62724963|NCT01177124|NO_INTERVENTION|Usual Care (UC)|
62724964|NCT02572375|EXPERIMENTAL|Codeine Phosphate/Guaifenesin ER Tablet|Patients receiving an extended release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin twice a day for 6 and a half days total. Total dosage \[2 tablets\] is 60 mg Codeine Phosphate and 1200 mg Guaifenesin twice a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
62724965|NCT02572375|ACTIVE_COMPARATOR|Codeine Phosphate/Guaifenesin IR Tablet|Patients receiving an immediate release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin six times a day for 6 and a half days total. Dosage is 20 mg Codeine Phosphate and 400 mg Guaifenesin six times a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
62724966|NCT02059629||Group A: Eluna pacemaker family|Patients with standard indication for pacemaker therapy or Cardiac Resynchronization Therapy (CRT), who will be implanted with a pacemaker or CRT device of the Eluna pacemaker family. Single-, Dual- and Tripple-chamber pacemakers are applicable.
62724967|NCT02059629||Group B: Sentus BP lead|Heart failure patients with indication for Cardiac Resynchronization Therapy (CRT) therapy, who will be implanted with the left ventricular Sentus BP lead. Patients can receive either CRT pacemaker or CRT-D (CRT with defibrillator function).
62724968|NCT02406521|EXPERIMENTAL|Arm A: Pazopanib with Radium-223|"No prior targeted therapy~* Pazopanib oral, daily and at predetermined dosage per cycle~* Radium-223 predetermined dosage via IV, per cycle"
62724969|NCT02406521|EXPERIMENTAL|Arm B: Sorafenib with Radium-223|"At least one line of prior targeted therapy:~* Sorafenib at predetermined dosage, mouth twice daily~* Radium-223 predetermined dosage via IV, per cycle"
62724970|NCT01467336|OTHER|Passive group|Rehabilitation program is immediate. Active range of motion rehabilitation is started at the sixth week.
62724971|NCT01467336|OTHER|Immobilization group|No passive Rehabilitation program is started. An active protocol is started after the sixth week
62724972|NCT01467336|OTHER|Delayed group|Rehabilitation program is delayed to the third week. Active range of motion rehabilitation is started at the sixth week.
62724973|NCT00415870|EXPERIMENTAL|PACE|Received text messages and counseling calls
62724974|NCT00415870|NO_INTERVENTION|Control|
62724975|NCT02990975|ACTIVE_COMPARATOR|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
62724976|NCT02990975|ACTIVE_COMPARATOR|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Transversus Abdominis Plane block.
62724977|NCT02990975|ACTIVE_COMPARATOR|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
62724978|NCT00848458|EXPERIMENTAL|Azelaic Acid Iontophoresis|
62724979|NCT00848458|ACTIVE_COMPARATOR|Azelaic acid topical|
62724980|NCT03663309||study group|"1. Children and adolescents aged 2-17 years, reported to be on gluten free diet for at least a year, diagnosed with celiac disease~2. Children and adolescents aged 2-17 years that are reported to be noncompliant with gluten free diet, diagnosed with celiac disease for at least 1 year."
62724981|NCT03663309||control group|Healthy controls aged 2-17 years old matched for age and sex.
62724982|NCT05386342|OTHER|LeMaitre TufTex Over-the-Wire Embolectomy Catheter|The LeMaitre Over the Wire Embolectomy Catherer is indicated for use in the removal of emboli and thrombi during embolectomy and/or thrombectomy. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
62724983|NCT04916392||liposomal bupivacaine|Nerve block will be preformed using 5ml of 1.33% liposomal bupivacaine with 5ml of 0.9% normal saline.
62724984|NCT01600404||antimuscarinic treatment|antimuscarinic treatment
62724985|NCT01600404||no antimuscarinic treatment (control)|
62724986|NCT02281656|EXPERIMENTAL|Reverse End-to-side|"Surgery: a reverse end-to-side AIN to ulnar nerve transfer whereby the motor branch of the ulnar is left intact and the end of the AIN nerve is coapted to the side of the ulnar motor fascicle(5,6). The advantage of this technique is it preserves the continuity of the ulnar motor branch for axons if they do eventually reinnervate the intrinsic muscles while augmenting or babysitting these muscles during the time period until this occurs."
62724987|NCT02281656|ACTIVE_COMPARATOR|Surgery:standard care|Surgery: the anterior interosseous (AIN) to motor branch of the ulnar nerve transfer has been established as an effective means to reinnervate ulnar innervated intrinsic hand muscles (without loss of function from using the AIN) when nerve injury is too proximal for recovering axons to reach the hand by 18 months. . The procedure (surgery) is presently the standard of care
62724988|NCT04676893|EXPERIMENTAL|Reference-Test|
62724989|NCT04676893|EXPERIMENTAL|Test-Reference|
62724990|NCT05353686|PLACEBO_COMPARATOR|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
62724991|NCT05353686|ACTIVE_COMPARATOR|XEN-D0501|Subjects in the XEN-D050 arm will receive an oral tablet containing 4 mg/tablet of IMP, twice daily
62724992|NCT06073197|ACTIVE_COMPARATOR|erector spinae plane block|Plane blocks implemented on preoperative course on 35 patients for group.
62724993|NCT06073197|ACTIVE_COMPARATOR|combined deep and superficial serratus anterior plane block|Plane blocks implemented on preoperative course on 35 patients for group.
62724994|NCT04778748||Obstructive Sleep Apnea|Participants will be provided with a Withings sleep monitor and instructed to begin using it. Effective data collection via the Withings unit should be confirmed for at least 7 consecutive nights, and the WatchPAT device will be used during one of those same 7 nights.
62724995|NCT05363488||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
62724996|NCT05064046|EXPERIMENTAL|LuCa + Health Disparity module|"Participants will be asked to complete the Health Disparities module that is an interactive CME/CE online course which offers 0.5 continuing education credit hours.~The will also be asked to complete the LuCa course."
62724997|NCT05064046|ACTIVE_COMPARATOR|LuCa only module|"LuCa is a free interactive CME/CE online course entitled, Lung Cancer and the Primary Care Provider. For the purpose of this study, participants will be asked to complete session 1 which offers 1.0 continuing education credit hours, including AMA PRA Category 1 credits, AANP, and AAFP Prescribed credits."
62724998|NCT00087984|EXPERIMENTAL|MB-002-003|
62724999|NCT02250872|ACTIVE_COMPARATOR|Experimental: Gemigliptin and Cisplatin|Gemigliptin 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
62725000|NCT02250872|PLACEBO_COMPARATOR|Control arm|Placebo 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
62725001|NCT03962959|EXPERIMENTAL|Excitatory TBS|Excitatory TBS
62725002|NCT03962959|EXPERIMENTAL|Inhibitory TBS|Inhibitory TBS
62725003|NCT03962959|PLACEBO_COMPARATOR|Sham TBS|Sham TBS
62725004|NCT00649285|EXPERIMENTAL|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
62725005|NCT00649285|ACTIVE_COMPARATOR|2|Macrobid® Capsules 100 mg
62725006|NCT02458872|EXPERIMENTAL|Intervention Arm|Safety huddle alarm intervention.
62725007|NCT02458872|NO_INTERVENTION|Control Arm|Usual care.
62725008|NCT03402932|EXPERIMENTAL|Auditory Amplified-Visual|This arm is designed to test the contrast between auditory amplified and visual conditions.
62725009|NCT03402932|EXPERIMENTAL|Auditory Amplified-Unamplified|This arm is designed to test the contrast between auditory amplified and unamplified conditions.
62725010|NCT03402932|EXPERIMENTAL|Auditory Unamplified-Visual|This arm is designed to test the contrast between auditory unamplified and visual conditions.
62725011|NCT03402932|OTHER|Younger control group|This arm is designed to validate the visual version by comparing to the auditory version in a group of younger normal hearing controls.
62725012|NCT05678166||NTM-LD|Diagnosis is made on the basis of the guidelines produced by the American Thoracic Society . Briefly, Patients have pulmonary symptoms with identified chest image and fit with the microbiology criteria.
62725013|NCT05678166||NTM pulmonary colonizers and others|Those without fulfilling the diagnostic criteria but having at least one set of positive sputum for MAC or patients infected with NTM other than MAC species.
62725014|NCT05678166||Pulmonary tuberculosis (TB)|Those with respiratory specimen culture positive for Mycobacterium tuberculosis or typical TB pulmonary pathology.
62725015|NCT05678166||Healthy control|Healthy control
62725016|NCT00925002|ACTIVE_COMPARATOR|Open-Label|
62725017|NCT00729443|EXPERIMENTAL|1|
62725018|NCT00729443|PLACEBO_COMPARATOR|2|
62725019|NCT03460652|EXPERIMENTAL|Open-Label KP415|"KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
62725020|NCT03776188||no groups - observational study|no groups - observational study
62725021|NCT04698070|ACTIVE_COMPARATOR|Standard|RUTF 130-200 kcal/kg/day for children with nutritional edema or MUAC \< 115 mm or WHZ \<-3 and RUSF 500 kcal/d for children 6-23 months with WHZ between -2 and -3 Z and MUAC 115-124 mm.
62725022|NCT04698070|EXPERIMENTAL|OptiMA|RUTF 170 kcal/kg/d for children with nutritional edema or MUAC \< 115 mm; 125 kcal/kg/d for MUAC 115-119 mm and 75 kcal/kg/d for MUAC 120-124 mm.
62725023|NCT04698070|EXPERIMENTAL|ComPAS|RUTF 1000 kcal/d for children with nutritional edema or MUAC \< 115 mm and 500 kcal/day for MUAC 115-124 mm.
62725024|NCT02606318|EXPERIMENTAL|Adjusted the challenge-skill balance|This group received 10-session occupational therapy with adjustment of challenge-skill balance.This intervention aimed at improving the skill level for the activity has started once the balance were balanced.
62725025|NCT02606318|OTHER|Non-adjusted the challenge-skill balance|This group received 10-session occupational therapy without adjustment of challenge-skill balance. That is conducted the therapy in the normal manner for the day care center.
62725026|NCT05411107|EXPERIMENTAL|Arm I (iloprost)|Patients receive Iloprost PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
62725027|NCT05411107|PLACEBO_COMPARATOR|Arm II (placebo)|Patients receive placebo PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
62725028|NCT05632237|EXPERIMENTAL|Family strengthening program|
62725029|NCT05632237|NO_INTERVENTION|Care as usual|These participants have already been receiving case management from the Child Reintegration Centre prior to the study, and they will continue to receive care as usual, which is to receive normal case management visits without this added Family Strengthening Program component. Case management consists of a social work staff alternating between visiting children at home or at school each month to provide supervision, coaching, counseling, assessments, and identification of additional support needs.
62725030|NCT03954548|EXPERIMENTAL|With CB-17-08 CADe|
62725031|NCT03954548|NO_INTERVENTION|Without CB-17-08 CADe|
62725032|NCT05345548|EXPERIMENTAL|Cold Pressor test|
62725033|NCT05781152|OTHER|Anti-tumor necrosis factor (TNF)|Patients newly diagnosed with pediatric-onset Crohn's disease starting anti-TNF therapy within 6 months of diagnosis
62725034|NCT05439551||Pediatric and adults suspected of acute bacterial or viral infection|ED, Hospital admitted, and urgent care center patients over the age of 90 days, with clinical suspicion of acute bacterial or viral infection.
62725035|NCT04530201|OTHER|Sample collection|Women will self-collect two first-void urine samples at home, the day prior to colposcopy. During the colposcopy visit, the clinician will collect an additional cervical smear. Colposcopy and histology results (when available) will be used as reference test.
62725036|NCT04231097|EXPERIMENTAL|Virtual MBCT|Two cohorts of MBCT participants with approximately 10 participants per cohort.
62725037|NCT04821934|EXPERIMENTAL|Telerehabilitation (TR) at home + Telesurveillance program (TSu)|These COVID-19 patients will enter the usual telesurveillance program together with a specific remote rehabilitation program on exercise activity.
62725038|NCT04821934|ACTIVE_COMPARATOR|Telesurveillance (TSu) alone|These COVID-19 patients will enter the usual remote telesurveillance program
62725039|NCT05011149|EXPERIMENTAL|Selective early medical treatment (SMART) strategy|"Infants who are randomized to experimental group will follow the SMART treatment protocol, which includes echocardiographic screening every 72 hours to categorize PDA disease severity by combining clinical and echocardiographic features. At any evaluation if patients are found to have a severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness, they will receive pharmacotherapy aimed at PDA closure (The PDA severity has been divided into mild, moderate or severe based on pre-defined clinical and echocardiographic criteria)."
62725040|NCT05011149|NO_INTERVENTION|Early conservative management strategy|Infants randomized to this arm will not undergo any further echocardiographic assessment or pharmacological treatment of the PDA regardless of the clinical signs. If the infant gets an echocardiographic assessment for a reason different than PDA assessment (such as hypotension or oxygenation failure) and a PDA is incidentally noted that fits the treatment criteria, the infant will not be initiated on pharmacotherapy. After 7 days of age, decision on PDA assessment and treatment will be at the discretion of the treating physician.
62725041|NCT02861287||Study cohort|patients with Multiple Myeloma who underwent PBSC mobilization since December 2009 and who received plerixafor in line with inclusion criteria
62725042|NCT02861287||Historical cohort|patients with Multiple Myeloma who underwent PBSC mobilization immediately prior to marketing authorization and clinical utilization of Plerixafor which is before December 2009 (over the 2007-2009 period)
62725043|NCT03012334|EXPERIMENTAL|Lasmiditan 50mg (milligrams)|Participants received 50mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
62725044|NCT03012334|EXPERIMENTAL|Lasmiditan 100mg|Participants received 100mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
62725045|NCT03012334|EXPERIMENTAL|Lasmiditan 200mg|Participants received 200mg of Lasmiditan tablets given as single doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
62725046|NCT03012334|ACTIVE_COMPARATOR|Alprazolam 1mg|Participants received 1mg of Alprazolam tablets as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
62725047|NCT03012334|PLACEBO_COMPARATOR|Placebo|Participants received placebo tablets identical to Lasmiditan, administered as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
62725048|NCT01880190|ACTIVE_COMPARATOR|Ringer's Lactate|Crystalloid solution
62725049|NCT01880190|ACTIVE_COMPARATOR|HES 130/0.4 and Ringer's Lactate|Colloid solution
62725050|NCT04001439|OTHER|Clinical trial|the study design is an open-label, single-arm propective clinical trial. In this proof-of-concept study we will assess feasibility safety and potential efficacy of an intervention of FMT in SZ subjects with MD.
62725051|NCT00592631|EXPERIMENTAL|CPAP|Subjects will use CPAP of 8-12 during days 2 through 6 of the study.
62725052|NCT00592631|SHAM_COMPARATOR|SHAM|Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.
62725053|NCT05775484||A|"1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~2. Bio-specimen collection~3. Six-minute walk test~4. Musculoskeletal Analysis~5. Cardiopulmonary exercise test"
62725054|NCT05775484||B|"1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~2. Bio-specimen collection~3. Six-minute walk test~4. Musculoskeletal Analysis"
62725055|NCT05775484||C|"1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~2. Bio-specimen collection~3. Six-minute walk test~4. Musculoskeletal Analysis"
62725056|NCT05775484||D|"1. Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~2. Bio-specimen collection~3. Six-minute walk test (may require separate day visit to complete)~4. Musculoskeletal Analysis~5. Questionnaires"
62725057|NCT04301323|EXPERIMENTAL|BHVI1|BHVI1 eye drops
62725058|NCT04301323|EXPERIMENTAL|BHVI2|BHVI2 eye drops
62725059|NCT04301323|EXPERIMENTAL|BHVI3|Combination of BHVI1 and BHVI2 eye drops
62725060|NCT04301323|NO_INTERVENTION|Non-randomized control group|a separate control group including 105 children enrolled and followed with only single-vision spectacles.
62725061|NCT05407805||Control Group|SCD participants not on disease modifying treatment.
62725062|NCT05407805||SCD Disease Modifying Treatment Group|SCD participants on a stable dose of a SCD disease modifying treatment regimen.
62725063|NCT02959788||Chest pain patients|All patients who present to the ED with chest pain.
62725064|NCT04862559|EXPERIMENTAL|NovaCross|Subjects in this arm are treated with the investigational device, NovaCross micro-cetheter, to facilitate the opening of a chronic total occlusion (CTO)
62725065|NCT05086965|NO_INTERVENTION|Control Group|The nursing process course content prepared by the researchers in the classroom environment will be explained to the students in the control group by the researcher. After the theoretical course content is explained, the appendectomy case prepared by the researchers will be presented to the students and the case-specific nursing care plan will be explained to the students in the classroom environment by the researcher. After explaining the theoretical content and case-specific care plan preparation to the students, a test will be applied to the questions prepared according to the case sample specific to chronic obstructive pulmonary disease prepared by the researchers. Students will be asked to find the nursing diagnoses and goals specific to the presented COPD case and to prioritize the nursing diagnoses they find. Students will be graded in the order of given tests and nursing diagnoses.
62725066|NCT05086965|EXPERIMENTAL|Intervention Group|The nursing process course content prepared by the researchers will be explained to the students in the intervention group by the researcher in the classroom environment. After the theoretical course content is explained, a virtual game simulation specially developed for the appendectomy case will be played in the computer classroom of the school where the study will be conducted. At the end of the game, students will be able to see how many points they got, which questions they answered correctly and which questions they answered incorrectly. After the virtual training simulation game, students will play the virtual assessment simulation game developed for chronic obstructive pulmonary disease in the school's computer classroom. The scoring system in the game developed for COPD will be equal to the scoring system in the test that will be presented to the control group students.
62725067|NCT03346187|EXPERIMENTAL|A|"Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.~Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions."
62725068|NCT03346187|EXPERIMENTAL|B|"Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.~Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions."
62725069|NCT01749527|OTHER|24-hour pad test|decreased activity
62725070|NCT04767672|EXPERIMENTAL|Test product|Food ingredient containing non digestible carbohydrates, in shape of powder
62725071|NCT04767672|PLACEBO_COMPARATOR|Placebo|Food ingredient containing containing 95% of maltodextrin
62725072|NCT00535769|PLACEBO_COMPARATOR|Electronic monitor + no text message|The control or placebo comparator group of subjects will receive the study sunscreen with the attached electronic monitor. They will be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If the subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
62725073|NCT00535769|EXPERIMENTAL|Electronic monitor + Text message|The text message experimental group of subjects will receive the study sunscreen with the attached electronic monitor. In addition, this group will receive daily text messages on their cellular phone to remind them to apply the sunscreen. The text message will also contain the daily weather information. This group will also be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
62725074|NCT01405404|NO_INTERVENTION|No intervention control|Parents complete surveys only
62725075|NCT01405404|EXPERIMENTAL|parent training but no discount|parent enrolled in the parent training intervention but do not receive childcare discounts for attending
62725076|NCT01405404|EXPERIMENTAL|Parent training with discount|parents receive parent training and a childcare discount for attending
62725077|NCT06555341|EXPERIMENTAL|Six Thinking Hats Group|Six Thinking Hats Group
62725078|NCT06555341|OTHER|Video Group|Video Group
62725079|NCT06555341|NO_INTERVENTION|Control Group|Control Group
62725080|NCT05976659|EXPERIMENTAL|tDCS prefrontal cortex + tASC angular gyrus in MDD in the context of AD|Participants will undergo 20 sessions of home-based tDCS over the prefrontal cortex and tACS over the left angular gyrus.These sessions will take place five times a week for four weeks, with one daily stimulation session of no more than 20 minutes. The participant's home will be the setting for the completion of the brain stimulation intervention, which will be delivered by trained caregivers/study companions/administrators.
62725081|NCT05084248|ACTIVE_COMPARATOR|Low-dose|400 IU Per Orem
62725082|NCT05084248|EXPERIMENTAL|High-dose|4000 IU Per Orem
62725083|NCT04895930|EXPERIMENTAL|Furmonertinib Plus Anlotinib|Furmonertinib (80mg) plus Anlotinib (10mg)
62725084|NCT02270281|OTHER|Dexmedetomidine|Before dexmedetomidine infusion
62725085|NCT01709552|EXPERIMENTAL|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
62725086|NCT01709552|SHAM_COMPARATOR|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
62725087|NCT04624789||GM1-Gangliosidosis - Sialidosis|"Confirmed diagnosis of:~* GM1-Gangliosidosis Morquio B Variant~* Sialidosis~* Galactosialidosis"
62725088|NCT04624789||GM2-Gangliosidoses|"Confirmed diagnosis of:~* Tay-Sachs Disease, incl. B1-Variante~* Sandhoff Disease~* GM2-Activator-Deficiency"
62725089|NCT05225883||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
62725090|NCT05837871||Cross sectional arm|Patients with Sickle Cell Anaemia aged 2 to 18 years. Assessed for clinical severity, Complete Blood Count, foetal haemoglobin and Haemoglobin Haplotype
62725091|NCT05837871||Longitudinal arm|"* Patients with Sickle Cell Anaemia recruited at 9 months of age then followed up at 12 months, 18 months and 24 months.~* Assessed for clinical severity, Complete Blood Count, foetal haemoglobin and Haemoglobin Haplotype~* Both parents assesed for Haemoglobin Haplotype~* Genotype - Haplotype assessment to be carried out"
62725092|NCT04642521||Iron deficiency anaemia|Preoperatively, participants who are iron deficient with or without anaemia will receive intravenous iron (Monofer) as per ProPBM protocol.
62725093|NCT04642521||No iron deficiency anaemia|Patient in this group will not be given intravenous iron.
62725094|NCT03011749|EXPERIMENTAL|FLT PET/CT|FLT PET/CT
62725095|NCT01761708||umbilical, epigastric and trocar-site hernia|
62725096|NCT03816722|EXPERIMENTAL|intervention|Patients starting the cross over with 6 weeks of high flow treatment with Airvo2 in addition to usual care
62725097|NCT03816722|EXPERIMENTAL|control|Patients starting the cross over in the usual care Group but after 6 weeks receiving High Flow treatment with Airvo2
62725098|NCT05399927|EXPERIMENTAL|Intervention|The intervention group underwent exposure to relaxing music with sounds from nature
62725099|NCT05399927|NO_INTERVENTION|Control|The control group under the usual transfer conditions.
62725100|NCT02620475|ACTIVE_COMPARATOR|Gold standard of care|The usual gold standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape.
62725101|NCT02620475|EXPERIMENTAL|SutureSafe dressings|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
62725102|NCT05356273|EXPERIMENTAL|Massage Group|The incubator temperature was adjusted between 28-30 C, and it was administered while the baby was awake and one hour after feeding. Before the massage, the hands were washed and warmed. Just before each phototherapy application, 10-minute baby massage was performed by the researcher.Then phototherapy was applied.
62725103|NCT05356273|NO_INTERVENTION|Control Group|Just received phototherapy twice a day
62725104|NCT02192567|EXPERIMENTAL|DS-5573a does escalation (step 1) and expansion (step 2)|"Step 1 of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg.~Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg Step 2: 30 subjects will be enrolled and treated at the dose determined in Step 1."
62725105|NCT01087983|EXPERIMENTAL|Lapatinib + Sirolimus|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Sirolimus starting oral dose 1 mg daily.
62725106|NCT01087983|EXPERIMENTAL|Lapatinib + Metformin|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Metformin Starting oral dose 1000 mg daily.
62725107|NCT03228862|EXPERIMENTAL|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
62725108|NCT03228862|EXPERIMENTAL|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
62725109|NCT03228862|EXPERIMENTAL|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
62725110|NCT03675113|EXPERIMENTAL|upper extremity aerobic group|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be 3 day per a week through 6-weeks.
62725111|NCT03675113|SHAM_COMPARATOR|control group|Deep breathing exercises combination with arm movements will be given as a home program in the control group. Training duration will be 3 day per a week through 6-weeks.
62725112|NCT01365793|EXPERIMENTAL|Rapid rehydration using 0.45% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.45% saline will be used as the replacement fluid for this arm.
62725113|NCT01365793|EXPERIMENTAL|Rapid rehydration using 0.9% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.9% saline will be used as the replacement fluid.
62725114|NCT01365793|EXPERIMENTAL|Slower rehydration using 0.45% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fluid bolus) with 0.45% saline used as the replacement fluid.
62725115|NCT01365793|EXPERIMENTAL|Slower rehydration using 0.9% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fuid bolus) with 0.9% saline used as the replacement fluid.
62725116|NCT04005495|EXPERIMENTAL|Teaching kitchen program|The teaching kitchen model is an innovative, multidisciplinary approach for motivating and establishing healthful habits and behaviors. The program combines didactic information with experiential learning in nutrition, culinary arts, exercise, yoga, and mindfulness.
62725117|NCT02485587|EXPERIMENTAL|Individualized Arousal-Biofeedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 20 sessions of arousal (electrodermal activity) feedback, 1 session/week. Each session will last about 1 hour. After the first 10 sessions (10 weeks after the beginning of the training phase), parents/caregivers will be asked to evaluate behavioral measures of aggression.~After training completion (approximately 20 weeks after the beginning of the training phase), subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the training phase)."
62725118|NCT02485587|ACTIVE_COMPARATOR|Treatment as usual|After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator condition will receive several appointments together with their parents/caregivers or group trainings over a timeframe of 20 weeks. Within the sessions, the investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, parents/caregivers will be asked to evaluate behavioral measures of aggression. After 20 weeks, subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the treatment phase).
62725119|NCT02485587|NO_INTERVENTION|Typically developing (TD) control group|Healthy, typically developing children will only undergo baseline assessment (observational) for comparison
62725120|NCT01144143|EXPERIMENTAL|Infliximab|
62725121|NCT01144143|PLACEBO_COMPARATOR|Salt Water|
62725122|NCT01144143|ACTIVE_COMPARATOR|Methylprednisolone acetate|
62725123|NCT06041009||Patients with PDAC|
62725124|NCT06041009||Individuals at high risk for PDAC|
62725125|NCT06041009||Group of neuroendocrine neoplasm of pancreas|
62725126|NCT06041009||Group of solid pseudopapillary tumor of pancreas|
62725127|NCT06041009||Group of abnormally elevated CA19-9|
62725128|NCT06041009||Controls without pancreatic disease or elevated CA19-9|
62725129|NCT01462929|EXPERIMENTAL|Aclidinium bromide|Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
62725130|NCT01462929|ACTIVE_COMPARATOR|Tiotropium|Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
62725131|NCT01462929|PLACEBO_COMPARATOR|Placebo|Placebo comparator administered during 6 weeks of treatment
62725132|NCT00132301|ACTIVE_COMPARATOR|Arm 1: Docetaxel and Prednisone|Chemotherapy after radical prostatectomy
62725133|NCT00132301|NO_INTERVENTION|Arm 2: Standard of care|Standard of care
62725134|NCT00987285|EXPERIMENTAL|Computer Assisted Self Management plus Social Support|an interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media combined with enhanced support in the form of group Diabetes Care Management visits and live follow up phone calls from Diabetes Care Managers
62725135|NCT00987285|NO_INTERVENTION|Usual care|will receive a health-risk appraisal, interactive CD-ROM program that provides standardized advice on behavior change, but not the hypothesized key intervention processes of goal setting, barriers identification, problem solving, or social environmental support.
62725136|NCT00987285|EXPERIMENTAL|Computer Assisted Self Management|An interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media.
62725137|NCT00777595|EXPERIMENTAL|Treatment A|Single therapeutic dose of CHF 4226 pMDI
62725138|NCT00777595|EXPERIMENTAL|Treatment B|Single supratherapeutic dose of CHF 4226 pMDI
62725139|NCT00777595|PLACEBO_COMPARATOR|Treatment C|Single dose of placebo
62725140|NCT00777595|ACTIVE_COMPARATOR|Treatment D|Single dose of moxifloxacin
62725141|NCT02314676|EXPERIMENTAL|PEG-somatropin|
62725142|NCT02479880|OTHER|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
62725143|NCT02479880|OTHER|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
62725144|NCT02543853|ACTIVE_COMPARATOR|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
62725145|NCT02543853|ACTIVE_COMPARATOR|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
62725146|NCT04475159|EXPERIMENTAL|PIPAC arm|Together with neoadjuvant systemic therpay PIPAC will be performed twice and regional chemotherpay will be administered before planned CRS/HIPEC
62725147|NCT03856359|EXPERIMENTAL|Rifaximin|rifaximin 550 milligrams (mg) orally twice daily for 3 months
62725148|NCT04211454||Migraine|Patients with migraine headaches
62725149|NCT04680624|OTHER|Single Group|
62725150|NCT04875494|EXPERIMENTAL|Physical Exercise|
62725151|NCT04875494|ACTIVE_COMPARATOR|Counseling/support group therapy|
62725152|NCT04875494|NO_INTERVENTION|Control|no intervention
62725153|NCT01726543|ACTIVE_COMPARATOR|Canaloplasty and phacoemulsification|
62725154|NCT01726543|ACTIVE_COMPARATOR|Non-penetrating deep sclerectomy and phacoemulsification|
62725155|NCT01070134|EXPERIMENTAL|Mindfulness-based Behavioural Therapy (MIBT)|
62725156|NCT01070134|ACTIVE_COMPARATOR|PT (psychodynamic therapy)|
62725157|NCT06547762|EXPERIMENTAL|Hybrid rehabilitation|Children will receive one day of remote rehabilitation. All other days children will receive therapy at hospital
62725158|NCT04963023||frequent exacerbation patients|
62725159|NCT04963023||non frequent exacerbation patients|
62725160|NCT04963023||Asthma-and-COPD overlap syndrome|
62725161|NCT04963023||Asthmatic patients (without COPD)|
62725162|NCT02566811|EXPERIMENTAL|Abdominal surgery with lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)\* with lymph node dissection to determine whether lymph nodes are positive or negative:~Positive: patients will receive systemic adjuvant treatment to include chemotherapy Negative: patients will receive vaginal brachytherapy only~Patients will then be followed up, to include assessment of adverse events and quality of life.~\*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, the lymph node dissection will be performed as a separate procedure."
62737930|NCT01964495|EXPERIMENTAL|PCT guided treatment|Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
62737931|NCT01869036|ACTIVE_COMPARATOR|caudal anesthesia|
62725163|NCT02566811|ACTIVE_COMPARATOR|Abdominal surgery, no lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)\*. Patients will receive systemic adjuvant treatment to include chemotherapy.~Patients will then be followed up, to include assessment of adverse events and quality of life.~\*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, no further surgery will be given and the patient will proceed to receive systemic adjuvant treatment to include chemotherapy."
62725164|NCT03605264||Slow Graft Function|Slow Graft function(SGF) is defined as a failure of serum creatinine to fall by 70% at postoperative day 7 after renal transplantation.
62725165|NCT03605264||Immediate Graft Function|Immediate graft function(IGF) is defined as a fall of serum creatinine of 70% at postoperative day 7 after renal transplantation.
62725166|NCT05484466|EXPERIMENTAL|Group A:ZM-H1505R 50 mg QD + Baraclude 0.5 mg QD|"The treatment regimen is as follow:~Group A: ZM-H1505R 50 mg QD + Baraclude 0.5 mg QD 48weeks After 48 weeks of treatment with the corresponding regimen, subjects will continue to take Baraclude 0.5 mg QD, as a monotherapy for a 12-week ."
62725167|NCT05484466|EXPERIMENTAL|Group B:ZM-H1505R 100 mg QD + Baraclude 0.5 mg QD|"The treatment regimen is as follow:~Group B: ZM-H1505R 100 mg QD + Baraclude 0.5 mg QD 48weeks After 48 weeks of treatment with the corresponding regimen, subjects will continue to take Baraclude 0.5 mg QD, as a monotherapy for a 12-week ."
62725168|NCT05484466|PLACEBO_COMPARATOR|Group C:ZM-H1505R placebo QD + Baraclude 0.5 mg QD|"The treatment regimen is as follow:~Group C: ZM-H1505R placebo QD + Baraclude 0.5 mg QD 48weeks After 48 weeks of treatment with the corresponding regimen, subjects will continue to take Baraclude 0.5 mg QD, as a monotherapy for a 12-week ."
62725169|NCT01545765|EXPERIMENTAL|lidocaine 7% and tetracaine 7%|
62725170|NCT02681653|ACTIVE_COMPARATOR|Statin|Atorvastatin, 40 mg for 7 days in patients of septic shock admitted to ICU
62725171|NCT02681653|PLACEBO_COMPARATOR|Placebo|Matched placebo, 40 mg for 7 days in patients of septic shock admitted to ICU
62725172|NCT01787877||Stroke patients reporting to the ER|
62725173|NCT04735653|EXPERIMENTAL|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web-based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second sessions and one call after each subsequent session. Participants can elect to receive any of the following types of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
62725174|NCT04735653|ACTIVE_COMPARATOR|Enhanced standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
62725175|NCT05949918|EXPERIMENTAL|Precontemplation, Contemplation, Preparation, Action, and Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Precontemplation Stage of Change.
62725176|NCT05949918|EXPERIMENTAL|Contemplation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Contemplation Stage of Change.
62725177|NCT05949918|EXPERIMENTAL|Preparation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Preparation Stage of Change.
62725178|NCT05949918|EXPERIMENTAL|Action-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Action Stage of Change.
62725179|NCT05949918|EXPERIMENTAL|Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Maintenance Stage of Change.
62725180|NCT01504100||femoral internal rotation|
62725181|NCT01504100||no femoral internal rotation|
62725182|NCT01789242|EXPERIMENTAL|Carfilzomib|All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (\<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
62725183|NCT02870985|EXPERIMENTAL|BIOTRONIK Orsiro SES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the experimental arm will be implanted with BIOTRONIK sirolimus eluting coronary stent(Orsiro).
62725184|NCT02870985|ACTIVE_COMPARATOR|Abbott Xience Prime™ EES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the comparator arm will be implanted with Abbott everolimus eluting coronary stent(Xience Prime™).
62725185|NCT02946346|EXPERIMENTAL|Vaginal and blood sampling|
62725186|NCT00413660|EXPERIMENTAL|CP 690,550 1 mg BID|
62725187|NCT00413660|EXPERIMENTAL|CP 690,550 10 mg BID|
62725188|NCT00413660|EXPERIMENTAL|CP 690,550 15 mg|
62725189|NCT00413660|EXPERIMENTAL|CP 690,550 3 mg BID|
62725190|NCT00413660|EXPERIMENTAL|CP 690,550 5 mg BID|
62725191|NCT00413660|EXPERIMENTAL|CP-690,550 20 mg QD|
62725192|NCT00413660|PLACEBO_COMPARATOR|Placebo|Dummy tablets
62725193|NCT01526941|EXPERIMENTAL|Treatment period 1|
62725194|NCT01526941|EXPERIMENTAL|Treatment period 2|
61978224|NCT03388060|ACTIVE_COMPARATOR|Dissolution therapy|Dissolution therapy for Radiolucent stone
62725195|NCT00119197|EXPERIMENTAL|1|Killed Whole Cell Oral Cholera Vaccine
62725196|NCT00119197|PLACEBO_COMPARATOR|2|Heat-killed E. coli
61978225|NCT03388060|ACTIVE_COMPARATOR|Combined ultrasound guided SWL and dissolution therapy|Combined treatment for Radiolucent stone.
62725197|NCT03429738|EXPERIMENTAL|Experimental Drug|Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
62725198|NCT03429738|ACTIVE_COMPARATOR|Active Comparator|Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
62725199|NCT01381367|EXPERIMENTAL|Vaccine|Enrolled COPD patients receiving PPSV23 pneumococcal vaccine
62725200|NCT01381367|PLACEBO_COMPARATOR|Normal saline|Enrolled COPD patient receiving placebo normal saline
62725201|NCT04590053|EXPERIMENTAL|COVID-19|Up to 24 subjects, male or female \> 18 and \< 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
62725202|NCT02278315|EXPERIMENTAL|Single|I-131-CLR1404 with or without concurrent dexamethasone
62725203|NCT03704038|ACTIVE_COMPARATOR|PEEP 5|
62725204|NCT03704038|ACTIVE_COMPARATOR|PEEP 0|
62725205|NCT03704038|EXPERIMENTAL|PEEP 10|
62725206|NCT01524393||IVF pregnancy|
62725207|NCT03117959|PLACEBO_COMPARATOR|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
62725208|NCT03117959|EXPERIMENTAL|Stryker shape match|no longer RCT
62725209|NCT06213207|EXPERIMENTAL|Newborn care service providers with simulation-based training and newborns|Newborn care providers will be the subject for receiving intervention. The will receive 5 days training on managing essential newborn care and birth asphyxia using neonatalie. The service providers will be provided monthly mentoring and coaching. The newborn who receive the services
62725210|NCT06213207|NO_INTERVENTION|Controlled health facilities with newborn care service providers with no training and newborns|The newborn care providers from control health facilities will not receive any additional training. They provide usual services.
62725211|NCT02209935|ACTIVE_COMPARATOR|Usual Care|Typically, usual care is when therapies are not initiated until the treating team places an order for each element of care (physical, occupational, speech, and emotional therapy consultation).
62725212|NCT02209935|EXPERIMENTAL|Early Rehabilitation Protocol|Physical, occupational, speech, and emotional evaluation and support personalized to the subject's severity of illness and developmental status.
62725213|NCT00886418|ACTIVE_COMPARATOR|1|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. A muscle relaxant is used to facilitate tracheal intubation; its administration is continued throughout anesthesia.
62725214|NCT00886418|EXPERIMENTAL|2|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. No muscle relaxant is used and a placebo is infused throughout anesthesia.
62725215|NCT02607124|EXPERIMENTAL|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day)
62725216|NCT02607124|EXPERIMENTAL|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day)
62725217|NCT03138785|EXPERIMENTAL|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
62725218|NCT03138785|ACTIVE_COMPARATOR|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
62725219|NCT02631291|EXPERIMENTAL|Lifestyle|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet.
62725220|NCT02631291|NO_INTERVENTION|Usual Care|Participants randomized to this condition will receive the written education provided to all participants.
62725221|NCT02631291|EXPERIMENTAL|LIfestyle + coaching|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet; and behavioral self-monitoring + motivational interviewing lifestyle coaching.
62725222|NCT06160141|EXPERIMENTAL|Training group|The training group performed 48 weeks of resistance training, 3 times per week.
62725223|NCT06160141|NO_INTERVENTION|Control Group|The control group did not performed any kind of resistance exercises.
62725224|NCT01465386|EXPERIMENTAL|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
62725225|NCT03693144|EXPERIMENTAL|Intervention Group 1 Full LIITA3H App|Participants were given the LIITA3H app, which is a combination product consisting of 3 main features that tracked their visits to fast food restaurants (using the ELI feature), sent tailored text messages to prompt healthy choices when they were in a fast food restaurant (using the POP feature), and allowed them to submit pictures of their food (using the SNAP feature).
62725226|NCT03693144|ACTIVE_COMPARATOR|Control Group 2 Partial LIITA3H App|Participants were given the LIITA3H app that tracked their visits to fast food restaurants (using the ELI feature) and they submitted pictures of their food (using the SNAP feature). However, they did not receive tailored text messages.
62725227|NCT03693144|OTHER|Control Group 3 LIITA3H Location only|Participants were given the LIITA3H app that tracked their visits to fast food restaurants (using the ELI feature) but they did not receive tailored messages or submit pictures of their food.
62725228|NCT02574728|EXPERIMENTAL|Oral sirolimus, celecoxib, etoposide, and cyclophosphamide|Participants in this group will receive oral sirolimus and celecoxib in addition to cycles of oral etoposide and cyclophosphamide for up to two years.
61978226|NCT06077292|EXPERIMENTAL|15% THC Potency Reduction Group|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
62725229|NCT02473471|EXPERIMENTAL|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
62725230|NCT02473471|NO_INTERVENTION|control side|No intervention in the other side of maxilla (control side)
62725231|NCT05796388|SHAM_COMPARATOR|Sham VR|Patients in the sham Virtual Reality group will receive the same brand of head mounted device (Oculus Quest 2), but will only have access to sham content. Both groups will receive standard of care linaclotide treatment 290 mcg.
62725232|NCT05796388|ACTIVE_COMPARATOR|Immersive VR|Patients in the immersive Virtual Reality group will receive a head mounted VR device Oculus Quest 2, and will receive active immersive content. Both groups will receive standard of care linaclotide treatment 290 mcg.
62725233|NCT01963988||Transurethral Coagulation (TUC)|This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion
62725234|NCT01963988||Transurethral Resection(TUR)|This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion
62725235|NCT03082677|EXPERIMENTAL|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
62725236|NCT00989508|EXPERIMENTAL|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
62725237|NCT00989508|PLACEBO_COMPARATOR|Placebo marked PEXSIG|Pre-operative administration of placebo tablets according to dosing schedule
62725238|NCT03281629|ACTIVE_COMPARATOR|Active TMS stimulation|Real active rTMS stimulation.
62725239|NCT03281629|SHAM_COMPARATOR|Sham TMS stimulation|Sham repetitive TMS stimulation.
62725240|NCT02905279|ACTIVE_COMPARATOR|Biofeedback|Biofeedback Relaxation Training
62725241|NCT02905279|ACTIVE_COMPARATOR|Standard Exposure|Exposure Therapy
62725242|NCT02905279|EXPERIMENTAL|Exposure with Threat-Relevant OAs.|Exposure with Threat-Relevant Opposite Actions
62725243|NCT02905279|EXPERIMENTAL|Exposure with Threat-Irrelevant OAs|Exposure with Threat-Irrelevant Opposite Actions
62725244|NCT02778984|ACTIVE_COMPARATOR|standard face masks|The standard mask is used in usual care
62725245|NCT02778984|EXPERIMENTAL|QuadraLite face masks|This study will compare tightness of 2 face masks during preoxygenation and after induction of anesthesia with propofol, sufentanil and rocuronium. During preoxygenation, a 10 l.min-1 fresh gas flow and 8 cm H2O PEEP will be applied. After induction of anesthesia, patients will receive pressure-controlled ventilation (fresh gaz flow 3 L.min-1, pressure set to obtain a 7 ml.kg-1 ideal body weight, 10 cpm, peep 5 cm H2O).
62725246|NCT02065492|EXPERIMENTAL|Standard Chelation & Amlodipine|"This arm will receive both chelation and amlodipine.~Amlodipine will be administered as a single daily dose. It will be administered at a dose of 0.1 mg/kg/day or maximum of 2.5 mg/day.~Standard Chelation therapy will be administered either by subcutaneous infusion of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist."
62725247|NCT02065492|ACTIVE_COMPARATOR|Standard Chelation|"Deferasirox or Deferoxamine or Deferiprone. Patients in this arm will be administered only standard chelation therapy,either by subcutaneous infusion of Chelation therapy of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist.~This will serve as the control arm of the study without any additional intervention."
62725248|NCT00644826|EXPERIMENTAL|1|
62725249|NCT00644826|NO_INTERVENTION|2|
62725250|NCT03727971|ACTIVE_COMPARATOR|omalizumab arm|The treatment is initiated with one injection with weight and serum-Immunoglobulin E balanced omalizumab one time per cyclus
62725251|NCT03727971|PLACEBO_COMPARATOR|placebo arm|Participants will be administered placebo (NaCl), one time per cyclus
62725252|NCT02315703|EXPERIMENTAL|Group 1|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
62725253|NCT02315703|EXPERIMENTAL|Group 2|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
62725254|NCT02315703|EXPERIMENTAL|Group 3|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + placebo injection at Week 24 and 48.
62725255|NCT02315703|EXPERIMENTAL|Group 4|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by modified Vaccinia Ankara (MVA)-Mosaic vaccine + gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant at Week 24 and 48.
62725256|NCT02315703|EXPERIMENTAL|Group 5|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
62725257|NCT02315703|EXPERIMENTAL|Group 6|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + placebo injection at Week 24 and 48.
62725258|NCT02315703|EXPERIMENTAL|Group 7|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant + placebo injection at Week 24 and 48.
62725259|NCT02315703|PLACEBO_COMPARATOR|Group 8|Participants will receive 1 placebo injection at Week 0 and 12; followed by 2 placebo injections at Week 24 and 48.
62725260|NCT03069508|EXPERIMENTAL|200 mg TID|200 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
62725261|NCT03069508|EXPERIMENTAL|300 mg TID|300 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
62725262|NCT03069508|EXPERIMENTAL|400 mg TID|400 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
62725263|NCT03069508|EXPERIMENTAL|500 mg TID|500 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
62725264|NCT01123343|ACTIVE_COMPARATOR|LRI Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for LRI.
62725265|NCT01123343|ACTIVE_COMPARATOR|Capsulorhexis Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for Capsulorhexis.
61978227|NCT06077292|EXPERIMENTAL|35% THC Potency Reduction Group|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
62725266|NCT01552837|NO_INTERVENTION|Healthy volunteers|MRI compatible, no present or past DSM-IV diagnosis
62725267|NCT01552837|ACTIVE_COMPARATOR|patients with Bipolar Disorder|MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder
62725268|NCT06432686|SHAM_COMPARATOR|sham stimulation of the tibialis anterior|
62725269|NCT06432686|EXPERIMENTAL|active stimulation of the tibialis anterior|
62725270|NCT06432686|EXPERIMENTAL|active stimulation of the quadriceps|
62725271|NCT06432686|ACTIVE_COMPARATOR|continuous movement of the foot (plantar & dorsiflexion)|
62725272|NCT06432686|SHAM_COMPARATOR|a combination of sham stimulation of the tibialis anterior and movement of the foot|
62725273|NCT06432686|EXPERIMENTAL|a combination of active stimulation of the tibialis anterior and movement of the foot|
62725274|NCT02214069||Patients with Atrial Fibrillation|Patients with Atrial Fibrillation admitted to the hospital for drug loading with Dofetilide or Sotalol willing to record and transmit heart rhythm using AliveCor.
62725275|NCT02118948|EXPERIMENTAL|Abuse-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on the psychological consequences of abuse, current sexual risk behavior, and the link between the two.
62725276|NCT02118948|ACTIVE_COMPARATOR|Sexual behavior-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on current sexual risk behavior.
62725277|NCT04544735|EXPERIMENTAL|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will will integrate two key components: pelvic health PT interventions (i.e., vaginal dilators, Pelvic Floor Muscle Training) and coping skills training for managing symptoms and improving treatment adherence. The intervention aims to improve women's sexual function after pelvic radiation
62725278|NCT06004297|ACTIVE_COMPARATOR|Group 1|Single bundle group
62725279|NCT06004297|ACTIVE_COMPARATOR|Group 2|Double bundle only group
62725280|NCT06004297|EXPERIMENTAL|Group 3|Double bundle with lateral release group
62725281|NCT02175277|EXPERIMENTAL|Darbepoetin Alfa|Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.
62725282|NCT04799002|ACTIVE_COMPARATOR|Topotecan|Topotecan intraocular injection during chemotherapy
62725283|NCT04799002|EXPERIMENTAL|Melphalan|Melphalan intraocular injection during chemotherapy
62725284|NCT02151656|EXPERIMENTAL|F17464|Oral administration - During 6 weeks - 4 capsules daily
62725285|NCT02151656|PLACEBO_COMPARATOR|Placebo|Oral administration - During 6 weeks - 4 capsules daily
62725286|NCT02890459|ACTIVE_COMPARATOR|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
62725287|NCT02890459|EXPERIMENTAL|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
62725288|NCT02890459|EXPERIMENTAL|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
62725289|NCT02890459|ACTIVE_COMPARATOR|Aim 2 - Standard Care|Standard care Travel voucher
62725290|NCT02890459|EXPERIMENTAL|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
62725291|NCT02890459|EXPERIMENTAL|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
62725292|NCT02890459|EXPERIMENTAL|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
62725293|NCT02890459|NO_INTERVENTION|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
62725294|NCT02890459|EXPERIMENTAL|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
62725295|NCT02890459|EXPERIMENTAL|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
62725296|NCT02890459|NO_INTERVENTION|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
62725297|NCT05223998|EXPERIMENTAL|Full-thickness skin microcolumns Implantation|implantation of FTSM on open wound
62725298|NCT02692963|EXPERIMENTAL|BCG vaccination|
62725299|NCT02692963|NO_INTERVENTION|Control|
62725300|NCT04719221|PLACEBO_COMPARATOR|Statin+Ezetimibe|Drug: Statin + Ezetimibe (combined cholesterol therapy)
62725301|NCT04719221|ACTIVE_COMPARATOR|Statin+Ezetimibe+Evolocumab|Drug: Statin + Ezetimibe (combined cholesterol therapy) and Drug: Evolocumab
62725302|NCT04122872||Patients with bone or soft tissue sarcomas or carcinosarcomas|Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone \[GCTB\], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
62725303|NCT01866748|EXPERIMENTAL|Part A (single dose)|
62725304|NCT01866748|EXPERIMENTAL|Part B (multiple dose)|
62725305|NCT01235663|EXPERIMENTAL|advisory support|advisory support for six months to prolong the breast-feeding period
62725306|NCT02512445|EXPERIMENTAL|Trauma Informed Guilt Reduction Therapy|6-session psychotherapy intervention
62725307|NCT02512445|ACTIVE_COMPARATOR|Supportive Care Therapy|6-session psychotherapy intervention
62725308|NCT01550601|OTHER|bariatric surgery 1|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with conservation of gastric antrum.
62725309|NCT01550601|EXPERIMENTAL|bariatric surgery 2|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with ablation of gastric antrum.
62725310|NCT01428310|ACTIVE_COMPARATOR|Anatabloc(TM)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
62725311|NCT01428310|ACTIVE_COMPARATOR|CigRx(R)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
62725312|NCT05745766||Canines assessed using 2D images|The 2D-based assessments of the impacted maxillary canine.
62725313|NCT05745766||Canines assessed using 3D images|The 3D-based assessments of the impacted maxillary canine.
62725314|NCT05745766||Canines assessed intra-operatively or post-operatively|The gold standard-based assessments are based on surgical exposure.
62725315|NCT04718740|EXPERIMENTAL|fluzoparib|"* Experimental: group A Intervention: Drug: fluzoparib, caffeine, vitamin K, warfarin, omeprazole, and midazolam~* Experimental: group B Intervention: Drug: fluzoparib, repaglinide and bupropion"
62737932|NCT01869036|ACTIVE_COMPARATOR|caudal anesthesia supplemented with morphine|
62725316|NCT03618667|EXPERIMENTAL|single group|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.
62725317|NCT05533632|EXPERIMENTAL|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.) injection once weekly in a dose escalation manner for 24 weeks: 0.25 milligrams (mg) (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24).
62725318|NCT04472169||Severe haemophila A patients with or without inhibitors|
62725319|NCT04199065|EXPERIMENTAL|Good Practice Guidelines group|Implementation of Good Practice Guidelines
62725320|NCT04199065|NO_INTERVENTION|usual practices group|Not Implementation of Good Practice Guidelines, so working as the usual way
62725321|NCT05922345|EXPERIMENTAL|TQB2450 injection + docetaxel injection matching placebo + AL2846 capsules|TQB2450 injection combined with docetaxel injection matching placebo and AL2846 capsules 21 days as a treatment cycle.
62725322|NCT05922345|ACTIVE_COMPARATOR|TQB2450 matching placebo + docetaxel injection + AL2846 matching placebo|TQB2450 matching placebo combined with docetaxel injection and AL2846 matching placebo 21 days as a treatment cycle.
62725323|NCT05687981|ACTIVE_COMPARATOR|Patients will receive 10 ml of 0.5% bupivacaine|A 2mg dexamethasone will be added
62725324|NCT05687981|ACTIVE_COMPARATOR|Patients will receive 10 ml of 0.25% bupivacaine|A 2mg dexamethasone will be added
62725325|NCT00118274|EXPERIMENTAL|Arm I|Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
62725326|NCT00118274|EXPERIMENTAL|Arm II|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
62725327|NCT00118274|EXPERIMENTAL|Arm III|Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
62725328|NCT00118274|EXPERIMENTAL|Arm IV|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
62725329|NCT00399074|NO_INTERVENTION|chloroquine|Weekly CQ
62725330|NCT00399074|NO_INTERVENTION|Sulfadoxine-pyrimethamine|Monthly SP
62725331|NCT06364917|EXPERIMENTAL|single agent immune checkpoint blockade (ICB) + chemotherapy (CT)|"200 mg of Pembrolizumab will be administered intravenously (IV) every 3 weeks (Q3W) for 4 cycles.~Combination chemotherapy:~For squamous NSCLC: Carboplatin (dose according to area under the curve (AUC) 6) + paclitaxel 200 mg/m².~For non-squamous NSCLC: Carboplatin (AUC 5) + pemetrexed 500 mg/m². Maintenance Therapy for Non-Squamous NSCLC: Pembrolizumab 200 mg + pemetrexed 500 mg/m² Q3W for up to 2 years."
62725332|NCT06364917|EXPERIMENTAL|dual agent immune checkpoint blockade (ICB) + chemotherapy (CT)|"Drug 1: 360 mg of Nivolumab will be administered intravenously (IV) every 3 weeks (Q3W).~Drug 2: 1 mg/kg of Ipilimumab will be administered intravenously (IV) every 6 weeks (Q6W) for 2 cycles.~Combination Chemotherapy:~For squamous NSCLC: Carboplatin (AUC 6) + paclitaxel 200 mg/m². For non-squamous NSCLC: Carboplatin (AUC 5) + pemetrexed 500 mg/m². Maintenance Therapy for Non-Squamous NSCLC: Nivolumab 360 mg Q3W + Ipilimumab 1mg/kg Q6W for up to 2 years."
62725333|NCT01151020|EXPERIMENTAL|Arm 1|Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
62725334|NCT04541485|EXPERIMENTAL|Experimental: Cohort 1 (96 mg)|24 mg/0.1 mL x 4 sites
62725335|NCT04541485|EXPERIMENTAL|Experimental: Cohort 2 (288 mg)|72 mg/0.3 mL x 4 sites
62725336|NCT04541485|EXPERIMENTAL|Experimental: Cohort 3 (480 mg)|120 mg/0.5 mL x 4 sites
62725337|NCT04541485|EXPERIMENTAL|Experimental: Cohort 4 (672 mg)|168 mg/0.7 mL x 4 sites
62725338|NCT04541485|EXPERIMENTAL|Experimental: Cohort 5 (960 mg)|240 mg/1.0 mL x 4 sites
62725339|NCT01206829|ACTIVE_COMPARATOR|Audiological rehabilitation|16 hours of psychosocial rehabilitation course
62725340|NCT05010083|EXPERIMENTAL|diet and lifestyle program|
62725341|NCT00808392|EXPERIMENTAL|1|
62725342|NCT00808392|ACTIVE_COMPARATOR|2|
62725343|NCT02112305|EXPERIMENTAL|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) on three occasional at 20 minutes interval
62725344|NCT02112305|ACTIVE_COMPARATOR|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
62725345|NCT01955460|EXPERIMENTAL|Treatment (chemotherapy, autologous T-cell immunotherapy)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
62725346|NCT05865301||Arm A (Retrospective data)|Participants who have undergone standard of care tisagenlecleucel therapy, Participants will received a questionnaire study using patient reported outcomes.
62725347|NCT05865301||Arm B (Prospective data)|Patients enrolled in ARM B will be asked to participate in the biological sample collection. Participants will received a questionnaire
62725348|NCT01563900|SHAM_COMPARATOR|sham-CPAP group|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp).
62725349|NCT01563900|ACTIVE_COMPARATOR|Auto-titration CPAP|This group will received an auto-titration CPAP, which will have a pressure range of 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
62725350|NCT04408677|EXPERIMENTAL|Normative data|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye
62725351|NCT04408677|EXPERIMENTAL|Repeatability|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye. After a 15 to 30 minutes break, same measurements repeated.
62725352|NCT04408677|EXPERIMENTAL|Inter-eye variability|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye. After a 15 to 30 minutes break, same measurements repeated in the left eye.
62725353|NCT03255889|ACTIVE_COMPARATOR|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
62725354|NCT03255889|PLACEBO_COMPARATOR|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
62725355|NCT02479204|EXPERIMENTAL|Part A ACT-334441 + atenolol|4 subjects will receive 50 mg of atenolol once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
62725356|NCT02479204|EXPERIMENTAL|Part A ACT-334441 + diltiazem|4 subjects will receive 240 mg of diltiazem once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
62725357|NCT02479204|EXPERIMENTAL|Part B ACT-334441 + atenolol|12 subjects will receive 50 mg of atenolol (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
62725358|NCT02479204|EXPERIMENTAL|Part B ACT-334441 + diltiazem|12 subjects will receive 240 mg of diltiazem (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
62725359|NCT03154671|EXPERIMENTAL|Intervention group|At study enrollment participants allocated to the intervention arm will complete a comprehensive geriatric assessment with the study intervention team (nurse and physician). Based on these findings a care plan tailored to the needs of the older adult with cancer will be developed and implemented. The study intervention nurse will call the participant at least monthly to follow up and evaluate the care (e.g. whether adjustments are required) and more if needed. All participants will receive a monthly healthy aging newsletter.
62725360|NCT03154671|NO_INTERVENTION|Control group|The participant will receive usual care from their treating oncology team. All participants will receive a monthly healthy aging newsletter.
62725361|NCT02126046|OTHER|Hi-HSC-CBT|
62725362|NCT00728156|ACTIVE_COMPARATOR|C|Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
62725363|NCT00728156|PLACEBO_COMPARATOR|P|Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
62725364|NCT00127881|EXPERIMENTAL|Zanolimumab|
62725365|NCT01907607|EXPERIMENTAL|PD-0332991|"Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib.~PD-0332991 is formulated as gelatin capsules of 100 mg and 25 mg respectively."
62725366|NCT00983866|EXPERIMENTAL|Tailored Telephone Counseling|
62725367|NCT00983866|NO_INTERVENTION|Standard Trial Recruitment Procedures|
62725368|NCT05555342|EXPERIMENTAL|IRE ablation and radiation therapy|Patients will be treated with IRE ablation directed at the target lesion on day 1. Moderate-dose, single-fraction radiation therapy will be delivered to the target lesion on day 8 to day 15.
62725369|NCT05860348||Device: Barostim™ System|Implantation of the Barostim™ System
62725370|NCT02969915|ACTIVE_COMPARATOR|Integrated care centers|Participants in the active comparator arm have access to integrated care centers (ICCs)
62725371|NCT02969915|EXPERIMENTAL|ICC + incentives|Participants in the experimental arm have access to the ICC intervention and the incentive intervention
62725372|NCT04105959|EXPERIMENTAL|RIST4721 300mg|RIST4721 as once-daily 300mg oral solution for 6 days with a placebo crossover.
62725373|NCT04105959|EXPERIMENTAL|RIST4721 150mg|RIST4721 as once-daily 150mg oral solution for 6 days with a placebo crossover.
62725374|NCT00539123|EXPERIMENTAL|NCB|Participants receive Physician Management (PM) and non-contingent provision of take-home doses of buprenorphine-naloxone (NCB).
62725375|NCT00539123|EXPERIMENTAL|ACB|Participants receive Physician Management (PM) and abstinence-contingent provision of take-home doses of buprenorphine-naloxone (ACB).
62725376|NCT06029062|EXPERIMENTAL|tACS Sham, tACS 10Hz, tACS 20Hz|"tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
62725377|NCT06029062|EXPERIMENTAL|HD-tACS 20Hz, HD-tACS 10Hz, HD-tACS Sham|"tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
62725378|NCT06029062|EXPERIMENTAL|HD-tACS 10Hz, HD-tACS 20Hz, HD-tACS Sham|"tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
62736233|NCT05151510|EXPERIMENTAL|Trigger point with 1% Lidocaine|The physician will withdraw 1cc of 1% lidocaine in a 25g needle, sterilely prep the field with a Chloraprep applicator, use index, and middle finger to squeeze the borders of the trigger point and raise the central aspect of the trigger point, insert the needle at 90-degree angle up to 5/8' deep, inject 1cc of the 1% lidocaine after ensuring needle is not in a blood vessel, removing the needle, and then covering the insertion site with a sterile bandage.
62736234|NCT05151510|ACTIVE_COMPARATOR|5% Lidocaine Patch|5% lidocaine patch will be placed at the point of maximal tenderness upon palpation. Location of placement will be described and instructed by physician and placed by nursing staff.
62725379|NCT03751826|EXPERIMENTAL|Incentivised network delivery HIV-ST|Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
62725380|NCT03751826|EXPERIMENTAL|Peer Navigator distributed HIV-ST|Peer navigators will directly distribute HIV-ST kits to females aged 18-24 years over a period of six months. Each person recruited will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV-ST. The packs include referral slips with information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
62725381|NCT03751826|ACTIVE_COMPARATOR|Standard of care|Peer navigators will encourage females aged 18-24 years to test for HIV at clinics, and link to services/care. Each female aged 18-24 approached by a peer navigator will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. They will then be given a referral slip for HIV testing through the clinic. The referral slips include information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
62725382|NCT01308255|EXPERIMENTAL|Infliximab Arm|For those randomised to the infliximab arm, infliximab will be administered at a dose of 3mg/kg according to the standard treatment protocol.
62725383|NCT01308255|PLACEBO_COMPARATOR|Steroid/Placebo Arm|Patients randomised to this arm will receive an IV infusion of 250mg methylprednisolone at week 0 \& those without an adequate clinical response after 26 wks will receive additional steroid as IM methylprednisolone 120mg. Patients on this arm will receive an IV placebo infusion of 250ml of 9mg/l NaCl.
62725384|NCT02308267||Cystic fibrosis|Cystic fibrosis patients More than 18 years old DF508/DF508 mutation colonized or not with Pseudomonas aeruginosa
62725385|NCT02308267||Controls|Controls patients More than 18 years old Without CF Smokers or nonsmokers
62725386|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
62725387|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
62725388|NCT04636567|EXPERIMENTAL|Nerindocianine for injection|One Arm: Nerindocianine for Injection (0.055 mg/kg body weight); solution, intravenous, one time administration during surgery.
62725389|NCT02141672|EXPERIMENTAL|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
62725390|NCT02141672|EXPERIMENTAL|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
62725391|NCT02141672|PLACEBO_COMPARATOR|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
62725392|NCT02664480||study group|Reproductive age women with polycystic ovary syndrome and irregular menses (Salivary Alpha-amylase Levels of 3rd and 24th day of menstrual cyclus)
62725393|NCT02664480||control group|Reproductive age women with regular menses (Salivary Alpha-amylase level of 3rd and 24th day of menstrual cyclus)
62725394|NCT00599352|EXPERIMENTAL|1|Magnesium infusion
62725395|NCT02688192|ACTIVE_COMPARATOR|Arm I (Intervention)|"Assessment including~1. Wear an electronic accelerometer~2. Quality of life assessment~3. Physical fitness evaluation~4. Participate in a fitness program which includes:~   * 8 group meetings of 90 minutes weekly~  * Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
62725396|NCT02688192|ACTIVE_COMPARATOR|Arm II (Waitlist Control [WLC])|"Assessment including~1. Wear an electronic accelerometer~2. Quality of life assessment~3. Physical fitness evaluation~After waiting 6 months they will begin the fitness program as described in Arm I"
62725397|NCT04791293||Group 1|Patients with postoperative complications
62725398|NCT04791293||Group 2|Patients without postoperative complications
62725399|NCT02954224|EXPERIMENTAL|CPAP therapy arm|Auto-titrating Continuous Positive Airway Pressure (CPAP)) treatment will be given on postoperative days 1, 2, and 3.
62725400|NCT02954224|NO_INTERVENTION|Control arm|no auto-titrating CPAP, standard care
62725401|NCT00703742|EXPERIMENTAL|A,1|A: Escitalopram, 20 mg/day,8weeks
62725402|NCT01598714|OTHER|Darco shoe|Darco walking shoe provided
62725403|NCT01598714|OTHER|Podalux Shoe|Podalus shoe
62725404|NCT01598714|OTHER|Standard dressing shoe|Standard dressing shoe
62725405|NCT01883700|EXPERIMENTAL|Low-GI, High-GL Meal|Boiled Pasta
62725406|NCT01883700|EXPERIMENTAL|Low-GI, High GL Meal|Boiled Chickpeas with Oil
62725407|NCT01883700|EXPERIMENTAL|High-GI, High-GL Meal|Instant Mashed Potatoes
62725408|NCT01883700|EXPERIMENTAL|High-GI, Low-GL Meal|Instant Mashed Potatoes with Egg Whites
62725409|NCT03775499|OTHER|Period 1: Placebo - Period 2: BL NCC 2705|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
62725410|NCT03775499|OTHER|Period 1: BL NCC 2705 - Period 2: Placebo|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
62725411|NCT02343848|EXPERIMENTAL|treatment|smart bracelet.
62725412|NCT01885650|EXPERIMENTAL|Normal airway clearance|The patients usual airway clearance technique
62725413|NCT01885650|EXPERIMENTAL|Non-Invasive Ventilation|The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique
62725414|NCT00375674|EXPERIMENTAL|A|
62725415|NCT00375674|PLACEBO_COMPARATOR|B|
62725416|NCT02393339|ACTIVE_COMPARATOR|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
62725417|NCT02393339|PLACEBO_COMPARATOR|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
62725418|NCT04164810|EXPERIMENTAL|Hydrotherapy|Hydrotherapy intervention will receive the treatment for 9 weeks (2 days per week) , resulting in a total of 18 sessions of Hydrotherapy. Each session will be held for a duration of 45 minutes to 1 hour.
62725419|NCT04164810|ACTIVE_COMPARATOR|Physical therapy|Physical therapy inthervention will have 18 standard physical therapy treatment sessions during 9 weeks. Each session will be held for a duration of 45 minutes to 1 hour.
62725420|NCT01722344|EXPERIMENTAL|Individual Placement and Support (IPS)|
62725421|NCT01722344|EXPERIMENTAL|IPS plus|Individual Placement and Support plus cognitive remediation and work-related social skills training
62725422|NCT01722344|NO_INTERVENTION|Standard intervention|
62725423|NCT06193564|EXPERIMENTAL|Combined CSE with tDCS|Combined cervical stabilzation exercises with tDCS
62725424|NCT06193564|EXPERIMENTAL|control group|Only cervical stabilzation exercises
62725425|NCT06193564|PLACEBO_COMPARATOR|placebo tDCS and CSE|Placebo tDCS and cervical stabilzation exercises
62725426|NCT04202666|NO_INTERVENTION|not convex skin barrier|no intervention
62725427|NCT04202666|EXPERIMENTAL|convex skin barrier|intervention
62725428|NCT01509846|EXPERIMENTAL|Cohort 1|Received one oral dose of 2.6±0.8 x 10\^8 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
62725429|NCT01509846|EXPERIMENTAL|Cohort 2|Received three oral doses of 2.6±0.8 x 10\^9 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
62725430|NCT01509846|EXPERIMENTAL|Cohort 3|Received three oral doses of 2.6±0.8 x 10\^10 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
62725431|NCT01509846|EXPERIMENTAL|Cohort 4|Received three oral doses of 2.6±0.8 x 10\^11 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
62725432|NCT01509846|PLACEBO_COMPARATOR|Placebo|Received oral dose of placebo concurrent with Cohort 1 (one dose), 2, 3, or 4 (3 doses).
62725433|NCT01822769|EXPERIMENTAL|Cardiopulmonary rehabilitation|The subjects will attend 2 sessions each week for 12 weeks. Each session will be approximately 2 hours in duration, consisting of both exercise (aerobic and strength,\~60 minutes) and education. In addition, subjects will be directed to participate in 3 weekly \~40 minute home exercise training sessions, personalized to their level of aerobic conditioning.
62725434|NCT01822769|OTHER|Standard of care|Subjects randomized to standard of care will not be enrolled in a rehabilitation program, but may receive any other clinically indicated exercise training or other intervention (e.g., an exercise prescription).
62725435|NCT06406244|EXPERIMENTAL|TEAS group|Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS）or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6), Hegu (L14), Yanglingquan (GB34), Zusanli (ST 36) and Renying (ST9) acupoints. Patients will receive 30 min TEAS before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
62725436|NCT06406244|PLACEBO_COMPARATOR|Sham group|Patients in the sham group will receive electrodeattachment but without stimulation.
62725437|NCT01145963|EXPERIMENTAL|experimental pasta B|Past B
62725438|NCT01145963|EXPERIMENTAL|experimental pasta C|Pasta C
62725439|NCT01145963|PLACEBO_COMPARATOR|Control pasta|Control
62725440|NCT04132414|EXPERIMENTAL|NIRS open|Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia
62725441|NCT04132414|NO_INTERVENTION|NIRS blinded|NIRS monitoring applied and masked for caregiver.
62725442|NCT02901691|EXPERIMENTAL|Deaf children|
62725443|NCT02901691|PLACEBO_COMPARATOR|healthy volonteer children|
62725444|NCT04003844|EXPERIMENTAL|Experimental|Investigational product (IP)
62725445|NCT02733744|EXPERIMENTAL|Fecal Microbiota Transplant|"Each participant will undergo allogeneic hematopoietic stem cell transplantation, according to institutional standards.~Participants will receive a single standard dose of oral Fecal Microbiota Transplantation (FMT), which is 15 capsules per day for two consecutive days, for a total of 30 capsules. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Capsules will be individually handed to participants by a research nurse or physician. Each capsule will be taken with a sip of water."
62725446|NCT04414540|EXPERIMENTAL|Arm 1: Metformin before Pembrolizumab|Metformin ER 1000mg daily D-14 to D-7. Metformin ER 2000mg daily D-7 to D1. D1 Begin Pembrolizumab 200mg every 3 weeks, while continuing Metformin ER 2000mg daily.
62725447|NCT04414540|EXPERIMENTAL|Arm 2: Metformin after Pembrolizumab|D-21 Begin Pembrolizumab 200mg. D-7 begin Metformin ER 1000mg daily. D1 begin Metformin ER 2000mg daily. Continue Pembrolizumab 200mg every 3 weeks.
62725448|NCT02922946|EXPERIMENTAL|Entinostat 5mg in 2-Way Crossover|"Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast."
62725449|NCT02922946|EXPERIMENTAL|Entinostat 5mg in 3-Way Crossover|"Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal.~Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast."
62725450|NCT02489149|EXPERIMENTAL|Multi-sector interventions|"Multi-sector interventions~* Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights."
62725451|NCT02489149|PLACEBO_COMPARATOR|Control|Conventional approach of current public food and nutrition policies.
62725452|NCT01774773|EXPERIMENTAL|Group A|E5501 5mg, then 20mg, then 40 mg, then 5mg
62725453|NCT01774773|EXPERIMENTAL|Group B|E5501 20mg, then 40mg, then 5 mg, then 5mg
62725454|NCT01774773|EXPERIMENTAL|Group C|E5501 40mg, then 5mg, then 20 mg, then 5mg
62725455|NCT05741892|EXPERIMENTAL|3D fracture reposition guide group|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
62725456|NCT01737762|EXPERIMENTAL|HP802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
62725457|NCT01737762|PLACEBO_COMPARATOR|Vehicle|Vehicle Control(fibrinogen solution \& thrombin solution without cells)
62725458|NCT01849315|PLACEBO_COMPARATOR|Control|Sedentary intervention
62725459|NCT01849315|ACTIVE_COMPARATOR|AKIDS II|Physically active group
62725460|NCT03751371|EXPERIMENTAL|Walking Training with the HWA Device|Training with HWA device
62725461|NCT03751371|OTHER|Usual Care|Usual Care
62725462|NCT02605356|EXPERIMENTAL|Radium-223 dichloride [Phase 1, dose 1]|Phase 1: Radium-223 dichloride; 30 kiloBecquerel (kBq)/kg body weight (33 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
62725463|NCT02605356|EXPERIMENTAL|Radium-223 dichloride [Phase 1, dose 2]|Phase 1: Radium-223 dichloride; 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
62725464|NCT02605356|EXPERIMENTAL|Radium-223 dichloride [Phase 1, dose 3]|Phase 1: Radium-223 dichloride; 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
62725465|NCT02605356|PLACEBO_COMPARATOR|Placebo +SoC [Phase 2]|Phase 2: Matching placebo (isotonic saline) every 4 weeks for a total of 6 doses plus SoC (Standard of care) bortezomib/dexamethasone.
62725466|NCT02605356|EXPERIMENTAL|Radium-223 dichloride + SoC [Phase 2]|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 4 weeks for 6 doses plus SOC bortezomib/dexamethasone
62725467|NCT03040089|EXPERIMENTAL|picosecond laser & 2% hydroquinone cream|PICO+4 laser system and Neoquine Cream 2% (2% hydroquinone cream) for melasma
62725468|NCT03040089|SHAM_COMPARATOR|2% hydroquinone cream|Only Neoquine Cream 2% (2% hydroquinone cream) for melasma
62725469|NCT06493175|EXPERIMENTAL|Large Language Model Diagnostic|Patients interacted with the large-language model triage system MedGuide-V5 during the waiting period before or after routine triage in the emergency department. During this phase, MedGuide-V5 will automatically record data and metrics during communication with patients.
62725470|NCT06493175|ACTIVE_COMPARATOR|Routine diagnostic and therapeutic procedure|After the artificial intelligence system evaluation, the patients will receive the diagnosis and treatment according to the normal procedure. The overall time of artificial triage, the triage of patients, and other data will be recorded. Patient visits should not be delayed by the use of artificial intelligence systems for evaluation.
62725471|NCT06377384|EXPERIMENTAL|FLIGHT Intervention|
62725472|NCT03384186|EXPERIMENTAL|Danicopan Modified Release Prototype Tablets|"Participants received danicopan once each period as a single oral dose as follows:~Period 1: Danicopan Modified Release Prototype 1 under fasted conditions. Period 2: Danicopan Modified Release Prototype 2 under fasted conditions. Period 3: Danicopan Modified Release Prototype 3 under fasted conditions. Period 4: Danicopan Modified Release Prototype 2 under fed conditions.~There was a washout period of at least 14 days between each danicopan dosing."
62725473|NCT00038090|EXPERIMENTAL|Thalidomide + Dexamethasone|
62725474|NCT01715428||Liraglutide|administration of liraglutide at 1.2 mg/daily
62725475|NCT02621476|EXPERIMENTAL|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
62725476|NCT02621476|EXPERIMENTAL|Usual care|Usual care
62725477|NCT02379195|EXPERIMENTAL|A|"All patients receive the same treatment.~All patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy are administered on day 0 to day 5.~Interleukin-2 are administered in an i.v. continuous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days~Subcutaneous injections of peginterferon alpha 2b are administered three time (day -2, day 7 and day 14)"
62725478|NCT05410496|EXPERIMENTAL|TAF switching therapy cohort|A prospective single-arm cohort to evaluate the safety, drug adherence, and efficacy of TAF switching therapy in kidney or liver or transplant patients with chronic HBV infection.
62725479|NCT06260605|EXPERIMENTAL|nursing students|Nursing students\&#39; education
62725480|NCT01187095|EXPERIMENTAL|counselling|Does couples in IVF treatment benefit from emotional disclosure
62725481|NCT01187095|ACTIVE_COMPARATOR|Control|Neutral writing exercise
62725482|NCT01714323|OTHER|Standard care|At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
62725483|NCT01714323|EXPERIMENTAL|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
62725484|NCT01853891|NO_INTERVENTION|usual condition|sleep in usual room light condition for 5 nights
62725485|NCT01853891|EXPERIMENTAL|dLAN|sleep with dim light at night for 5 nights
62725486|NCT01027650|EXPERIMENTAL|Stage 1 Cohort 1|AGN208397 intravitreal injection 75 ug on Day 1.
62725487|NCT01027650|EXPERIMENTAL|Stage 1 Cohort 2|AGN208397 intravitreal injection 300 ug on Day 1.
62725488|NCT01027650|EXPERIMENTAL|Stage 1 Cohort 3|AGN208397 intravitreal injection 600 ug on Day 1.
62725489|NCT01027650|EXPERIMENTAL|Stage 1 Cohort 4|AGN208397 intravitreal injection 900 ug on Day 1.
62725490|NCT01027650|EXPERIMENTAL|Stage 2 Arm 1|AGN208397 intravitreal injection 600 ug on Day 1.
62725491|NCT01027650|EXPERIMENTAL|Stage 2 Arm 2|AGN208397 intravitreal injection 450 ug on Day 1.
62725492|NCT01027650|EXPERIMENTAL|Stage 2 Arm 3|AGN208397 intravitreal injection 300 ug on Day 1.
62725493|NCT01027650|ACTIVE_COMPARATOR|Stage 2 Arm 4|Dexamethasone 700 ug intravitreal implant on Day 1.
62725494|NCT03033680|EXPERIMENTAL|Multiple System Atrophy (MSA)|Eight subjects with a probable MSA diagnosis will be recruited for this study. Each subject will undergo a \[F-18\]PBR06 PET scan at baseline, and at 9 months follow-up.
62725495|NCT01471223||Patients receiving Belatacept in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
62725496|NCT01471223||Patients receiving CNI in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
62165966|NCT04476849|EXPERIMENTAL|Fezolinetant: Mild renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
62165967|NCT04476849|EXPERIMENTAL|Fezolinetant: Moderate renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
62725497|NCT04967066||children with febrile convulsions|"* Inclusion criteria~* Age from 6 months to 6 years.~* Seizures.~* Fever (≥38°C).~* Exclusion criteria~* Central nervous system infection.~* Epilepsy.~* Previous neurological abnormalities.~* Inborn errors of metabolism.~* Immunological diseases.~* Endocrinal diseases (e.g., diabetes mellitus).~* Obesity.~* Eating disorders.~* Gastrointestinal disorders (e.g., diarrhea)."
62725498|NCT04967066||Febrile children without convulsions|"* Inclusion criteria~* Age from 6 months to 6 years.~* Fever (≥38°C) due to acute infection.~* Exclusion criteria~* Seizures.~* Central nervous system infection.~* Previous neurological abnormalities.~* Inborn errors of metabolism.~* Immunological diseases.~* Endocrinal diseases (e.g., diabetes mellitus).~* Obesity.~* Eating disorders.~* Gastrointestinal disorders (e.g., diarrhea)."
62725499|NCT04967066||Healthy control children|"* Inclusion criteria~* Age from 6 months to 6 years.~* Presented for routine check-up.~* Exclusion criteria~* Fever.~* Seizures.~* Central nervous system infection.~* Previous neurological abnormalities.~* Inborn errors of metabolism.~* Immunological diseases.~* Endocrinal diseases (e.g., diabetes mellitus).~* Obesity.~* Eating disorders.~* Gastrointestinal disorders (e.g., diarrhea).~* Any illness in the last month."
62725500|NCT00198328|ACTIVE_COMPARATOR|Surgery Control|Patients receive surgical excision of their tumor.
62725501|NCT00198328|EXPERIMENTAL|MedPulser EPT|Patients receive electroporation with injection of Bleomycin Sulfate.
62725502|NCT03667989|OTHER|123I-MIBG CZT SPECT|Patients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.
62725503|NCT02840279|EXPERIMENTAL|BPN14770|An oral dose of BPN14770
62725504|NCT02840279|PLACEBO_COMPARATOR|Placebo|An oral dose of placebo matching BPN14770
62725505|NCT04011592|EXPERIMENTAL|Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)
62725506|NCT04011592|EXPERIMENTAL|Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)
62725507|NCT05593315|OTHER|Mindfulness and Buteyko techniques|A Mindfulness relaxation program and a Buteyko technique respiratory rehabilitation program will be administered individually and weekly, in 10 sessions (5 face-to-face and 5 telematic sessions afterwards).
62725508|NCT06231706|PLACEBO_COMPARATOR|Phase 1: Control|A commercially available bread crouton product. To be consumed as 2 x 14g portions per day for 6 weeks.
62725509|NCT06231706|EXPERIMENTAL|Phase 1: Intervention treatment|Prebiotic-like nut and seed mix. To be consumed as 2 x 15g portions per day for 6 weeks
62725510|NCT06231706|OTHER|Phase 1: Secondary Intervention treatment.|Probiotic capsule. To be consumed as one capsule per day for 6 weeks.
62725511|NCT06231706|PLACEBO_COMPARATOR|Phase 2: Control|Control breakfast consisting of White bread (3 slices; 128g approx.) and low fat spread (10-15g)
62725512|NCT06231706|EXPERIMENTAL|Phase 2: Intervention|Intervention breakfast consisting of White bread (3 slices; 128g approx.) and low fat spread (10-15g) + Prebiotic-like nut and seed mix (2 x 15g portions)
62725513|NCT05529251|EXPERIMENTAL|ARM A|RADIOTHERAPY boost 20 to 30 Gy on lymph nodes
62725514|NCT05529251|EXPERIMENTAL|ARM B|One cycle of CARBOPLATIN AUC7
62725515|NCT05529251|OTHER|ARM C|3 cycles of ETOPOSIDE and CISPLATIN
62725516|NCT05529251|NO_INTERVENTION|OBSERVATIONAL COHORT|STANDARD RADIOTHERAPY on lymph nodes
62725517|NCT01106157|EXPERIMENTAL|Anti-Thymocyte Globin plus pegylated GCSF|Subjects will receive an infusion of Anti-Thymocyte Globin (ATG) followed by 6 doses of pegylated GCSF every 2 weeks for 10 weeks.
62725518|NCT01106157|PLACEBO_COMPARATOR|Placebo|Saline infusion will be given on both Day 1 and Day 2 followed by placebo injection given in identical volumes in identical syringes in the identical subcutaneous manner
62725519|NCT01724216|EXPERIMENTAL|pulse sequence software|The central aim of this study is to acquire a set of images and associated technical and clinical information to facilitate regulatory submission of the pulse sequences being studied by GEHC. Segment 1 allows to collect a minimum of 10 subjects then evaluate if additional scans/enrollment needed Segment 2 will allow an additional 90 subjects if data needed
62725520|NCT02478112|EXPERIMENTAL|Biodegradable Balloon Implant|Biodegradable balloon implanted before radiotherapy
62725521|NCT00443703|EXPERIMENTAL|1|Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
62725522|NCT00443703|ACTIVE_COMPARATOR|2|Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)
62725523|NCT06450015|EXPERIMENTAL|Vacuum Assisted Closure therapy|Diabetic wounds managed wit VAC dressing
62725524|NCT06450015|EXPERIMENTAL|Saline Dreesing|Saline dressing was done in these patients
62725525|NCT01704508|ACTIVE_COMPARATOR|Artemether-lumefantrine|6-dose regime will be used:
62725526|NCT01704508|ACTIVE_COMPARATOR|Dihydroartemisinin-piperaquine|A 3 dose regime will be used
62725527|NCT04790747|EXPERIMENTAL|radiotherapy and CAR-T therapy|sequential radiotherapy and CAR-T cell therapy
62725528|NCT03811522||Carbon Dioxide Insufflation|Received CO2 insufflation during procedure
62725529|NCT03811522||Air Sufflation|Received ambient insufflation during procedure
62725530|NCT02953561|EXPERIMENTAL|Treatment (azacitidine, avelumab)|Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62165968|NCT04476849|EXPERIMENTAL|Fezolinetant: Severe renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
62165969|NCT04476849|EXPERIMENTAL|Fezolinetant: Normal renal function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
62725531|NCT00705770|PLACEBO_COMPARATOR|1|Placebo treatment with vehicle
62725532|NCT00705770|EXPERIMENTAL|2|Low dose of study medication
62725533|NCT00705770|EXPERIMENTAL|3|Middle dose of study medication
62725534|NCT00705770|EXPERIMENTAL|4|High dose of study medication
62725535|NCT03519997|EXPERIMENTAL|Pembro + Bavi|Pembrolizumab 200 mg IV every 3 weeks plus, Bavituximab 3mg/kg IV weekly
62725536|NCT02353858|EXPERIMENTAL|RtChx + Hyperthermia|Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week
62725537|NCT02967679|EXPERIMENTAL|MD1003|MD1003 100mg capsules, 1 capsule tid for 48 weeks
62725538|NCT02615977|EXPERIMENTAL|Intervention|"In the verum treatment condition, i.e. Zooming Joystick Task, 90% of all alcohol-related pictures appear in the landscape format and hence are trained to be pushed away."
62725539|NCT02615977|PLACEBO_COMPARATOR|Placebo Intervention|In the placebo condition, i.e. Zooming Joystick Task (Placebo), alcohol picture are as often pushed away as pulled towards the subject.
62725540|NCT00666081|EXPERIMENTAL|Cohort 1|GSK690693 for injection. This is a dose escalation study.
62725541|NCT05794880|EXPERIMENTAL|Alpha/Beta T cell depletion (TCD) plus CD19+ depletion|Alpha beta T cell and B cell depleted allogeneic transplantation with individualized dosing of ATG for patients with hematologic malignancies
62725542|NCT03888378|ACTIVE_COMPARATOR|0.3% Topical Minocycline Ointment|Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
62725543|NCT03888378|ACTIVE_COMPARATOR|1% Topical Minocycline Ointment|Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
62725544|NCT03888378|PLACEBO_COMPARATOR|Topical Vehicle Ointment|Topical administration of Topical Vehicle Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
62725545|NCT02081313|ACTIVE_COMPARATOR|Netherton syndrome|Patients with Netherton syndrome
62725546|NCT02081313|ACTIVE_COMPARATOR|Healthy controls|healthy controls
62725547|NCT03149146|EXPERIMENTAL|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
62725548|NCT03149146|ACTIVE_COMPARATOR|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
62725549|NCT00006695|EXPERIMENTAL|Arm I|Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)
62725550|NCT04463940||Umbilical cord arterial blood|participant's umbilical cord arterial blood will be obtained
62725551|NCT04463940||Umbilical cord venus blood|participant's umbilical cord Venus blood will be obtained
62725552|NCT04463940||Maternal blood|participant's blood will be obtained
62725553|NCT00701025||1|35 asthmatic participants with EIB
62725554|NCT00701025||2|35 without EIB
62725555|NCT03030729||Intermediate AMD|
62725556|NCT03030729||Advanced AMD|
62725557|NCT03030729||DR without macular edema|
62725558|NCT03030729||DR with macular edema|
62725559|NCT03599518|EXPERIMENTAL|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1000 mg, 1200 mg) in combination with daily 250 mg oral dose of gefitinib
62725560|NCT04735315||Born preterm|"Inclusion :~Born preterm ≤29 weeks Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
62725561|NCT04735315||Born term|"Inclusion :~Born full-term at 37-41 weeks Birthweight ˃2500g Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
62725562|NCT05274412|ACTIVE_COMPARATOR|Control group|Participants in this group will receive protocolized hemodynamic management based on advanced hemodynamic monitoring and dynamic parameters.Keep pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
62725563|NCT05274412|EXPERIMENTAL|HPI group|Participants in this group will receive protocolized hemodynamic management based on advanced hemodynamic monitoring, hypotension prediction index (HPI), and dynamic parameters.Keep HPI \<85; pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
62725564|NCT05600829|EXPERIMENTAL|Intervention|Patients participate in a traditional 12-week outpatient CR program with added weekly behavioural weight loss classes.
62725565|NCT05600829|OTHER|Control|Patients participate in a traditional 12-week outpatient CR program.
62725566|NCT05820048|ACTIVE_COMPARATOR|proton pump inhibitor|"1. medication : Lanston~2. capacity : 15mg~3. Number of times : QD~4. period : 6 month~5. Injection path : oral"
62725567|NCT05820048|NO_INTERVENTION|non-administered army|No Intervention
62725568|NCT01647698|EXPERIMENTAL|Early training group|The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).
62736235|NCT02729116|EXPERIMENTAL|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
62736236|NCT02729116|ACTIVE_COMPARATOR|Ertapenem group|Ertapenem 1 gm IV every 24 h
62725569|NCT01647698|EXPERIMENTAL|Late training group|The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.
62725570|NCT01647698|PLACEBO_COMPARATOR|No training group|The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
62725571|NCT00992056|EXPERIMENTAL|Metoprolol/Nebivolol|Metoprolol/Nebivolol: Metoprolol 50 mg titrated to 100 mg then nebivolol 5 mg titrated to 10 mg
62725572|NCT00992056|EXPERIMENTAL|Nebivolol/Metoprolol|Metoprolol 50 mg titrated to 100 mg then Nebivolol 5 mg titrated to 10 mg
62725573|NCT04532346|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine in a dose of 10 mg/kg\*d, p.o., bid for 12 months. The maximum daily dose is 400mg.
62725574|NCT04532346|NO_INTERVENTION|control|control group which do not take hydroxychloroquine for treatment.
62725575|NCT04078269|EXPERIMENTAL|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIXNEO-LUNG autologous DC vaccine
62725576|NCT05214430|EXPERIMENTAL|3 months exclusive enteral nutrition after surgery|3 months exclusive enteral nutrition after surgery
62725577|NCT05214430|EXPERIMENTAL|less than 1 months exclusive enteral nutrition after surgery|less than 1 months exclusive enteral nutrition after surgery
62725578|NCT04963816|ACTIVE_COMPARATOR|Group A Quadratus Lumborum Block with dexamethasone IV|QLB with (0.5 mL/kg of bupivacaine 0.25%) and IV dexamethasone (0.1-0.3 mg/kg with a maximum dose 10 mg) added to 5 mL normal saline
62725579|NCT04963816|ACTIVE_COMPARATOR|Group B Quadratus Lumborum Block with dexamethasone locally|QLB with (0.5 mL/kg of bupivacaine 0.25% plus dexamethasone 0.1 mg/kg), and IV 5 mL normal saline
62725580|NCT04963816|PLACEBO_COMPARATOR|Group C Quadratus Lumborum Block with bupivacaine alone|Patients will receive QLB (0.5 mL/kg of bupivacaine 0.25%) and IV 5 mL normal saline.
62725581|NCT02140970|EXPERIMENTAL|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
62725582|NCT02140970|PLACEBO_COMPARATOR|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
62725583|NCT03284983|EXPERIMENTAL|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
62725584|NCT05250921|EXPERIMENTAL|Corticision|Corticision will be performed on the lower anterior teeth using a surgical blade and a hammer.
62725585|NCT05250921|ACTIVE_COMPARATOR|Conventional method|A fixed appliance will be applied using conventional braces without any surgical procedure.
62725586|NCT01007175|EXPERIMENTAL|Cohort 1|
62725587|NCT01007175|EXPERIMENTAL|Cohort 2|
62725588|NCT01007175|EXPERIMENTAL|Cohort 3|
62725589|NCT01007175|EXPERIMENTAL|Cohort 4|
62725590|NCT01007175|EXPERIMENTAL|Cohort 5|
62725591|NCT03133494|ACTIVE_COMPARATOR|Laparoscopic cholecystectomy in smokers|ABG analysis of patients with history of smoking posted for laparoscopic cholecystectomy was collected
62725592|NCT03133494|PLACEBO_COMPARATOR|Laparoscopic cholecystectomy nonsmokers|ABG analysis of patients without history of smoking posted for laparoscopic cholecystectomy was collected
62725593|NCT03765580|PLACEBO_COMPARATOR|Control group|No fish
62725594|NCT03765580|EXPERIMENTAL|1 portion of fish per week|140g fish/week
62725595|NCT03765580|EXPERIMENTAL|2 portions of fish per week|280g fish/week
62725596|NCT03369665|EXPERIMENTAL|Mavenclad®|
62725597|NCT05940506|EXPERIMENTAL|KX-826-2.5 mg BID|treatment dose groups of 2.5 mg BID (0.25%)
62725598|NCT05940506|EXPERIMENTAL|KX-826-5 mg QD|treatment dose groups of 5 mg QD (0.5%)
62725599|NCT05940506|EXPERIMENTAL|KX-826-5 mg BID|treatment dose groups of 5 mg BID (0.5%)
62725600|NCT05940506|PLACEBO_COMPARATOR|Placebo|Placebo
62725601|NCT04292197|EXPERIMENTAL|18-MC SAD Study|In Part 1, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice in 1 day.
62725602|NCT04292197|EXPERIMENTAL|18-MC MAD Study|In Part 2, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice a day for 7 consecutive days.
62725603|NCT03549286||pregnant women in the first trimester ultrasound consultation|Participation in the study will be offered to all pregnant patients, presenting for their first trimester ultrasound consultation in the obstetrics and gynecology department of the University Hospital of Reims. The study includes the consultations of all the certified doctors of the Maternity Department of the Reims University Hospital carrying out the first trimester ultrasounds. It will concern all the ranges of consultation regardless of the doctor who performs the consultation.
62725604|NCT00414076|ACTIVE_COMPARATOR|Letrozole|Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks.
62725605|NCT00414076|NO_INTERVENTION|Standard of Care|Patients receive no treatment. Follow up every 3 months.
62725606|NCT04035343|ACTIVE_COMPARATOR|Conventional face down positioning|Patients in third arm will be treated with the current standard of care, that is, they will be kept supine in the ophthalmic surgery chair after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will transition to face down positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
62725607|NCT04035343|EXPERIMENTAL|Supine positioning|Patients in the second arm will be kept supine after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will maintain supine positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
62725608|NCT02477488|EXPERIMENTAL|Allopurinol HS|Allopurinol at bedtime compared to AM administration
62725609|NCT00595296||1|All eligible patients.
62725610|NCT03188263|EXPERIMENTAL|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
62725611|NCT03188263|PLACEBO_COMPARATOR|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
62725612|NCT00556803|EXPERIMENTAL|1|TACE after RFA within one month as an adjuvant therapy
62725613|NCT00556803|ACTIVE_COMPARATOR|2|RFA alone
62725614|NCT00682279|NO_INTERVENTION|This is a single-arm, dose escalation|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
62725615|NCT02351492|ACTIVE_COMPARATOR|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography (IOC) to investigate bile ducts.
62725616|NCT02351492|ACTIVE_COMPARATOR|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography (MRCP) first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
62725617|NCT02945163|EXPERIMENTAL|Arm 1|Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die
62725618|NCT02945163|ACTIVE_COMPARATOR|Arm 2|Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die
62725619|NCT04155528|EXPERIMENTAL|Study group|The intervention group will receive routine hospital care alongside 30 minutes of music therapy per day for three consecutive days. The music therapy will be initiated on the second day postoperatively. The assessment of baseline data and the music therapy will be applied at least three hours after analgesics administration.
62725620|NCT04155528|NO_INTERVENTION|Control group|Patients in the control group will receive routine hospital care only.
62725621|NCT01222819|EXPERIMENTAL|IV filgrastim|as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg) in bolus IV injection, as per manufacturer's recommendations.
62725622|NCT01222819|ACTIVE_COMPARATOR|SC filgrastim|given as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg)
62725623|NCT05621122||Omnivours|100 subjects (comparison group)
62725624|NCT05621122||Vegans|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
62725625|NCT05621122||Lacto-ovo-vegetarians|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
62725626|NCT05621122||Pesco-vegetarians|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
62725627|NCT05621122||Pro-vegetarians|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
62725628|NCT03204877|ACTIVE_COMPARATOR|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
62725629|NCT03204877|PLACEBO_COMPARATOR|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
62725630|NCT05821452|EXPERIMENTAL|Immumotherapy plus Chemotherapy|"Paclitaxel: 175mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of 3 cycles.~Cisplatin: 75mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of 3 cycles.~Camrelizumab: 200mg was administered intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), for a total of 3 cycles."
62725631|NCT05821452|EXPERIMENTAL|chemoradiotherapy|"Paclitaxel: 175mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of two cycles~Cisplatin: 75mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of two cycles~Radiotherapy: Irradiation mode and dose: three-dimensional conformal or intensity modulated radiotherapy technology was adopted, 41.4Gy, 1.8Gy each time, 5 times a week."
62725632|NCT05605548|EXPERIMENTAL|MitoQ|Participants will take 1 pill each day for 6 weeks
62725633|NCT05605548|PLACEBO_COMPARATOR|Placebo|Participants will take 1 pill each day for 6 weeks
62725634|NCT00401843|EXPERIMENTAL|Part 1: Siltuximab Plus Bortezomib|Siltuximab 6 milligram per kilogram (mg/kg) will be administered as intravenous infusion once every 2 weeks along with bortezomib 1.3 milligram per square meter (mg/m\^2) during cycle 1.
62725635|NCT00401843|EXPERIMENTAL|Part 2: Bortezomib + Placebo|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
62725636|NCT00401843|EXPERIMENTAL|Part 2: Bortezomib + Siltuximab|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
62725637|NCT02242058||High frequency pain group|39 pediatric or adult patients with high pain frequency (greater than or equal to 3 ER visits and/or hospitalizations for pain per year over the last two years)
62725638|NCT02242058||Low Pain Frequency group|39 pediatric or adult patients with low pain frequency (less than or equal to 1 severe pain episode for the last two years)
62725639|NCT02242058||Healthy control group|39 pediatric or adult relatives of sickle cell disease patients, who do not have the sickle cell trait of SCD.
62725640|NCT02242058||Pain Crisis group|30 patients with sickle cell disease with severe phenotype (HbSS, HbSβ0 thalassemia, HbSOArab)
62725641|NCT02242058||Pain Service group|10 patients without sickle cell disease admitted to the pain service.
62725642|NCT02177630||Magnetic resonance imaging and endomyocardial biopsy|Magnetic resonance imaging and endomyocardial biopsy
62725643|NCT02056028||Bile leak after hepatic resection|
62725644|NCT02074943|EXPERIMENTAL|PRP/Saline|Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
62725645|NCT03703934||Psoriatic Arthritis|Patients with painful psoriatic arthritis
62725646|NCT03703934||Hand Osteoarthritis|Patients with painful nodal non-erosive hand osteoarthritis
62725647|NCT03703934||Healthy Controls|Patients without a painful condition
62725648|NCT00589797|EXPERIMENTAL|Investigational|Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
62725649|NCT00589797|ACTIVE_COMPARATOR|Control|Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
62725650|NCT01908543|EXPERIMENTAL|Iron treatment|"INTERVENTION: Ferrous sulphate 200mg oral tablet~This is a single arm study. Individuals in this arm will~* have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods~* receive a single tablet of ferrous sulphate 200mg~* fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months~* have a second blood sample later that day (20 mls of blood~Total number of participants in arm = 100"
62725651|NCT05681338|EXPERIMENTAL|the medium intensity coughing technique|Immediately before the subcutaneous heparin injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
62725652|NCT05681338|NO_INTERVENTION|the standard injection technique|During the subcutaneous heparin injection, patients were not asked to perform any action, and the injection was given by the standard technique.
62725653|NCT04797377|EXPERIMENTAL|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
62725654|NCT01718821||Advanced upper GI cancer patients|Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
62725655|NCT03269773|EXPERIMENTAL|FURESTEM-AD Inj.|hUCB-MSC 5.0x10\^7 cells
62725656|NCT03269773|PLACEBO_COMPARATOR|Placebo|
62725657|NCT00194467|EXPERIMENTAL|1|
62725658|NCT00194467|PLACEBO_COMPARATOR|2|
62725659|NCT06486766|NO_INTERVENTION|Control|Standard care: Influenza vaccination is generally recommended to all individuals aged 65 or older, but there is no systematic individual invitation/reminding/scheduling for vaccination by SMS or any other mode. The control arm is applicable to all three populations (general population, immigrants born in Poland, immigrants born in Ukraine)
62725660|NCT06486766|EXPERIMENTAL|Norwegian SMS|
62725661|NCT06486766|EXPERIMENTAL|Polish/Ukrainian SMS|
62725662|NCT02164344|EXPERIMENTAL|Probiotics|HIV-1 infected patients take daily dietary supplement with probiotics for at least 3 months
62725663|NCT03859037|EXPERIMENTAL|Umbilical cord milking|One group will have umbilical cord milking and will ba assessed for blood pressure,oxygen saturation and heart rate by monitor
62725664|NCT03859037|PLACEBO_COMPARATOR|Immediate cord clamping|One group will have immediate cord clamping and will be assessed for bloob pressure,heart rate,oxygen saturation by monitor
62725665|NCT00659841|ACTIVE_COMPARATOR|1|Ciclesonide 200µg
62725666|NCT00659841|PLACEBO_COMPARATOR|2|Placebo
62725667|NCT02514291|EXPERIMENTAL|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
61978228|NCT02409992|EXPERIMENTAL|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting intervention.
62725668|NCT02514291|NO_INTERVENTION|Standard care|Standard pediatric neurology care
62725669|NCT06070818|EXPERIMENTAL|Intervention|Healthy Body \& Mind Program: In summary, the program includes two visits to the University of New South Wales (UNSW) Medicine \& Health Lifestyle Clinic at the beginning and end of the program for Initial and Final Assessments, and two weekly sessions for 12 weeks (24 sessions in total) to the UNSW Medicine \& Health Lifestyle Clinic to complete the Healthy Body \& Mind Program. Participants will also be invited to take part in a focus group either at the clinic or online (via Teams/ zoom) at the end of the program.
62725670|NCT06070818|NO_INTERVENTION|Wait-list control|Usual care. Participants will not be recruited if they are taking part in another research intervention or receiving treatment other than usual care.
62725671|NCT02225652|EXPERIMENTAL|FEC + filgrastim x 3 cycles q 14-21 days and Weekly Paclitaxel|"FEC (FLUOROURACIL 500 mg/m2 IV infusion of 30 minutes + EPIRUBICIN 60 mg/m2 IV infusion of 1 hour + CYCLOPHOSPHAMIDE 500 mg/m2 IV infusion of 30 minutes).~From day 7 until hematological recovery = Filgrastim 300 microg s.c. After 21 days from the last FEC cycle = Paclitaxel 100 mg/m2 IV infusion of 1hour (weekly for 8 cycles, at day 1)."
62725672|NCT01165125|OTHER|FF/GW642444 and keto|Ketoconazole (400mcg) administered on Days 1-11, with co-administration of fFF / GW642444 (200mcg/25mcg) on Days 5-11
62725673|NCT01165125|OTHER|Ketoconazole Placebo to match & FF/GW642444|ketoconazole placebo to match administered on days 1-11. FF/GW642444 (200mcg/25mcg) co-administered on Days 5-11
62725674|NCT04316559|PLACEBO_COMPARATOR|Placebo|Placebo capsule
62725675|NCT04316559|EXPERIMENTAL|TRV734|TRV734 at different doses vs. oxycodone for withdrawal suppression
62725676|NCT05763680||Infants suspect of neonatal sepsis (early and late onset) up to 90 days postnatally|Infants who are suspect of sepsis, either based on risk factors for infection or on clinical assessment. No restrictions in terms of gestational age
62725677|NCT00495235||Endometrial Cancer Group|Participants who have had endometrial cancer (cases).
62725678|NCT00495235||Control Group|Participants who have not had endometrial cancer (controls).
62725679|NCT05575700|EXPERIMENTAL|Ibuprofen|Participants received ibuprofen 400 mg tablet administered orally three times daily, with eight hour intervals, for eight days after surgery.
62725680|NCT05575700|PLACEBO_COMPARATOR|Placebo|Participants received identical placebo tablet administered orally three times daily, with eight hour intervals, for eight days after surgery.
62725681|NCT02374541|EXPERIMENTAL|Patient Navigation|Assistance from Autism Patient Navigator (APN) to obtain diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
62725682|NCT02374541|NO_INTERVENTION|Control|Standard referral for diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
62725683|NCT00777959|EXPERIMENTAL|Open Label|ridaforolimus (MK8669)+ bicalutamide
62725684|NCT00777959|EXPERIMENTAL|Ridaforolimus|ridaforolimus (MK8669)+ bicalutamide
62725685|NCT00777959|PLACEBO_COMPARATOR|Placebo|Placebo + bicalutamide
62725686|NCT02879513|ACTIVE_COMPARATOR|Switch to CEF|Epirubicin 75 mg/m² IV push on day 1 every 3 weeks for 4 cycles. Cyclophosphamide 500 mg/m² IV push on day 1 every 3 weeks. 5-fluoruracil 500 mg/m² IV push on day 1 every 3 weeks.
62725687|NCT02879513|EXPERIMENTAL|Continue the neoadjuvant regimen|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
62725688|NCT02879513|EXPERIMENTAL|Pathological complete response group with chemotherapy|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
62725689|NCT02879513|NO_INTERVENTION|Pathological complete response group with no chemotherapy|
62725690|NCT04009239|EXPERIMENTAL|Early Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 1 hour after habitual wake time.
62725691|NCT04009239|EXPERIMENTAL|Mid-day Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 6 hours after habitual wake time.
62725692|NCT03955328|EXPERIMENTAL|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
62725693|NCT03961555|EXPERIMENTAL|SYN023+Rabies vaccine|"SYN023:~* Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~* SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~* Dosage form: 6mg/2mL, liquid,~* Dosage: 0.3 mg/kg of SYN023~* Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~* Interventions: should be administered in deltoid muscle~* Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~* Dosage: 1 mL after reconstitution~* Frequency/duration: at Day 1, 4, 8, 15, 29"
62725694|NCT03961555|ACTIVE_COMPARATOR|HRIG+Rabies vaccine|"HRIG:~* Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~* Dosage form: 150 IU/mL or 300 IU/mL, liquid,~* Dosage: 20 IU/kg of HyperRab (HRIG)~* Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~* Interventions: should be administered in deltoid muscle~* Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~* Dosage: 1 mL after reconstitution~* Frequency/duration: at Day 1, 4, 8, 15, 29"
62725695|NCT02775630|EXPERIMENTAL|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
62725696|NCT02775630|NO_INTERVENTION|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
62725697|NCT03759600|EXPERIMENTAL|Niraparib 300 mg|Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 to 28 of each 28-day treatment cycle for up to 50 cycles.
62725698|NCT01616212|EXPERIMENTAL|TX1|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
62725699|NCT01616212|EXPERIMENTAL|TX 2|Motivational Enhancement Therapy for adolescents
62725700|NCT01616212|EXPERIMENTAL|TX3|Drug Education for adolescents, Parenting Wisely for parents
62725701|NCT01616212|EXPERIMENTAL|TX4|Drug Education for adolescents
62725702|NCT06475768||Premenopausal Female Athletes|
62725703|NCT06475768||Postmenopausal Female Athletes|
62725704|NCT06475768||Male Athletes|
62725705|NCT02354261|EXPERIMENTAL|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
62725706|NCT04436445|ACTIVE_COMPARATOR|dry cupping|Dry cupping is considered to be a noninvasive and inexpensive technique, used worldwide to treating patients with pain syndromes It is in fact a type of physical therapy which is applied by the specialists of acupuncture or other individuals. It improves the subcutaneous blood flow and, as a result, stimulates the autonomic nervous system and reduces the pai
62725707|NCT04436445|ACTIVE_COMPARATOR|Life style modification|"lifestyle modifications in the form of dietary recommendations, exercises and sleep quality improvement for 8 weeks.The life style modification followed in the treatment: Avoid consumption of all kinds of alcohol beverages. Avoid consumption of spicy foods, pepper, chili and coffee Follow a correct diet assuming each day 50% carbohydrates,30% fats and 20% proteins Increase your intake of fruits, vegetables and foods rich of natural fibers (dark bred, vegetables, spinaches).~8 hour sleep at night 40 minutes of walking 3time per week."
62725708|NCT05845619|EXPERIMENTAL|Pilot|
62725709|NCT05845619|NO_INTERVENTION|Controls - prospectively enrolled|
61978229|NCT02409992|ACTIVE_COMPARATOR|Parent Training Only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
62725710|NCT05845619|NO_INTERVENTION|Controls - abstracted from records|
62725711|NCT02970591|EXPERIMENTAL|Diet A|Low carbohydrate diet
62725712|NCT02970591|ACTIVE_COMPARATOR|Medical treatment|Optimized Medical treatment
62725713|NCT02970591|EXPERIMENTAL|Diet B|Traditional dietary advice and low FODMAP content
62725714|NCT02537730|ACTIVE_COMPARATOR|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
62725715|NCT02537730|ACTIVE_COMPARATOR|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
62725716|NCT00005739||Community-based therapy (case)|Community-based directly observed therapy (DOT) - A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
62725717|NCT00005739||Self-administered treatment (control)|Clinic directly observed therapy (DOT) - Traditional self-administered preventive treatment
62725718|NCT00953810|NO_INTERVENTION|control|General heart failure population staying under regular care of their primary care physician
62725719|NCT00953810|ACTIVE_COMPARATOR|Intervention|Like control plus one education training regarding heart failure aspects and management
62725720|NCT05521126||high risk/ACL repair cohort|The high risk cohort will be subjects who have had an ACL reconstruction procedure 9-24 months prior to enrollment.
62725721|NCT05521126||control group|The control group will be individuals who have not had an ACL reconstruction procedure.
62725722|NCT02877069|EXPERIMENTAL|VYC-12 Injectable Gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection on Day 0 in the face and if applicable neck areas. Participants are eligible to receive up to 3 treatments including an optional top-up and an optional second treatment.
62725723|NCT02067143|EXPERIMENTAL|Study population|In this phase II multicentric trial, eligible patients with Ph- ALL/LL will receive homogeneous supportive care and chemotherapy and will be homogeneously analyzed for response at prefixed timepoints from induction day 1. For risk-/MRD-oriented therapy, CR patients will be stratified by risk class according to diagnostic characteristics, MRD study and CT/PET (LL only) results during early consolidation.
62725724|NCT01541488|EXPERIMENTAL|BI 1021958|Single rising dose (SRD) part
62725725|NCT01541488|EXPERIMENTAL|BI 1021958 (Food effect)|Food effect part (FE)
62725726|NCT01541488|PLACEBO_COMPARATOR|Placebo to BI 1021958|Matching placebo as drinking solution and tablets
62725727|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
62725728|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
62725729|NCT04592471||Orthosis Group 1|Use of kneeMID500 device
62725730|NCT04592471||Control Group 1|Control Group of the kneeMID500 Orthosis Group - No use of the device
62725731|NCT04592471||Orthosis Group 2|Use of kneeSTRONG700 device
62725732|NCT04592471||Control Group 2|Control Group of the kneeSTRONG700 Orthosis Group - No use of the device
62725733|NCT04299386|EXPERIMENTAL|NeoPhylaxis|Nanocrystalline gel for nonsurgical cleaning of implants
62725734|NCT04299386|EXPERIMENTAL|ImplanTreat|Nanocrystalline gel for surgical cleaning of Implants
62725735|NCT04299386|NO_INTERVENTION|Nonsurgical cleaning without gel|Cleaning dental implants non-surgically using the electric brush without the gel
62725736|NCT04299386|NO_INTERVENTION|Surgical cleaning without gel|Cleaning dental implants surgically using the electric brush without the gel
62725737|NCT06118424|EXPERIMENTAL|deepfake group|The experimental group was trained and monitored with deep fake videos every week for 6 weeks.
62725738|NCT06118424|NO_INTERVENTION|Control group|The control group was given a pre-test before the study and a post-test at the end of the study, without any intervention.
62725739|NCT05384834|EXPERIMENTAL|AYA participants|AYA participants will complete a brief initial survey consisting of demographic information and the Visual Analog Scale (VAS) and the #HerHeart tool in clinic. AYA participants will the rate the usability of the #HerHeart tool using the Website Analysis and Measurement Inventory (WAMMI), the likelihood they would recommend the app to their friends, and the likelihood of behavior change. AYA participants will then be offered the opportunity to continue into the 3-month intervention phase.
62725740|NCT04476381|EXPERIMENTAL|Dry needling of a trigger point in the infraspinatus muscle|Insertion a a acupuncture type needle into a trigger point in the infraspinatus muscle on the painful side to decrease the stiffness and tone and increase the elasticity
62725741|NCT01296750|ACTIVE_COMPARATOR|Early Physiotherapy|Physiotherapy to begin within 1 day post op.
62725742|NCT01296750|NO_INTERVENTION|Late Physiotherapy|Physiotherapy to start 6 weeks post op
62725743|NCT01725802|EXPERIMENTAL|Treatment sequence A|Period 1. ND0612; Period 2. Placebo
62725744|NCT01725802|EXPERIMENTAL|Treatment sequence B|Period 1. Placebo; Period 2. ND0612
62725745|NCT04078204|EXPERIMENTAL|Butylphthalide Soft Capsules|Two Butylphthalide soft capsules will be taken three times a day before meals.
62725746|NCT04078204|PLACEBO_COMPARATOR|Placebo Soft Capsules|Two placebo soft capsules will be taken three times a day before meals.
62725747|NCT01665911|OTHER|Arm 1|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
62725748|NCT01665911|OTHER|Arm 2|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
62725749|NCT01665911|OTHER|Arm 3|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
62725750|NCT01665911|OTHER|Arm 4|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
62725751|NCT01665911|ACTIVE_COMPARATOR|Arm 5|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
62725752|NCT06085235|EXPERIMENTAL|exercise|15min of cycling at moderate intensity
62725753|NCT06085235|NO_INTERVENTION|video control|watching a video on healthy living
62725754|NCT05756023|ACTIVE_COMPARATOR|PCOs Patients|To compare the pregnancy rate at IVF / ICSI cycles in patients with PCOs
62725755|NCT05756023|ACTIVE_COMPARATOR|Non PCOs Patients|To compare the pregnancy rate at IVF / ICSI cycles in patients with without PCOs
62725756|NCT03449849|OTHER|Base diet|Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
62725757|NCT03449849|OTHER|Kale Treatment|Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
62725758|NCT02825446|ACTIVE_COMPARATOR|angioplasty tibial arteries|
62725759|NCT02825446|EXPERIMENTAL|radio frequency denervation popliteal artery by the use|"radio frequency denervation popliteal artery Vessix Renal Denervation System Balloon"
62725760|NCT04880239|ACTIVE_COMPARATOR|Sacralcolpopexy with posterior colpoperineorrhaphy|
62725761|NCT04880239|NO_INTERVENTION|Sacralcolpopexy without posterior colpoperineorrhaphy|
62725762|NCT00642707|ACTIVE_COMPARATOR|Arm 1|PRO 140 for three single SC doses: Days 1, 8, and 15
62725763|NCT00642707|ACTIVE_COMPARATOR|Arm 2|PRO 140 for three single SC doses: Days 1, 8 and 15
62725764|NCT00642707|ACTIVE_COMPARATOR|Arm 3|PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
62725765|NCT00642707|PLACEBO_COMPARATOR|Arm 4|PBO for three single SC doses: Days 1, 8 and 15
62725766|NCT06522477|EXPERIMENTAL|High-intensity followed by low-intensity virtual reality gait training|Individuals randomized to this group will first perform high-intensity virtual reality gait training and following a 4-week washout period will complete low-intensity virtual reality gait training.
62725767|NCT06522477|EXPERIMENTAL|Low-intensity followed by high-intensity virtual reality gait training|Individuals randomized to this group will first perform low-intensity virtual reality gait training and following a 4-week washout period will complete high-intensity virtual reality gait training.
62725768|NCT00049257|EXPERIMENTAL|Treatment|Please see intervention descriptions
62725769|NCT03679676|OTHER|Cohort A: Omalizumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with placebo
62725770|NCT03679676|OTHER|Cohort B: Omalizumab/Dupilumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab.
62725771|NCT03679676|OTHER|Cohort C: Dupilumab|Participants will be treated with placebo for 8 weeks, followed by 24 weeks of treatment with dupilumab.
62725772|NCT01495039|ACTIVE_COMPARATOR|Nystatin|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
62725773|NCT01495039|PLACEBO_COMPARATOR|Control|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.
62725774|NCT04233528|EXPERIMENTAL|healthy volunteers|metabolically healthy eutrophic individuals (BMI ≥18.5 and \<25 kg / m2) without any IDF criteria for metabolic syndrome
62725775|NCT04233528|EXPERIMENTAL|metabolically healthy obesity|obese individuals (BMI ≥ 30.0 kg / m2) meeting the criteria for metabolically healthy obesity
62725776|NCT04233528|EXPERIMENTAL|metabolically unhealthy obesity|volunteers diagnosed with metabolically unhealthy obesity
62725777|NCT04729933|EXPERIMENTAL|Treatment|V-Wave Shunt Placement
62725778|NCT05598905|EXPERIMENTAL|Oxycodone + Pregabalin|Participants will visit twice. On one visit they will take a 10mg oxycodone tablet and 90 minutes later a 150mg pregabaline capsule.
62725779|NCT05598905|EXPERIMENTAL|Oxycodone + Lacosamide|Participants will visit twice. On one visit they will take a 10mg oxycodone tablet and 90 minutes later a 150mg Lacosamide capsule.
62725780|NCT05598905|OTHER|Oxycodone|"Amendment:~one open label arm.~In order to get an impression of the effect of 10 mg oxycodone per se, one open label arm of just 10 mg oxycodone as a visit 3 was added."
62725781|NCT01050725||Radiation therapy patients|Individuals receiving radiation therapy as definitive or neo-adjuvant therapy for selected malignancies, including head and neck, lung, esophageal, rectal cervical and prostate cancers.
62725782|NCT02918669|EXPERIMENTAL|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
62725783|NCT06440603||Group I|Age and sex matched healthy Control
62725784|NCT06440603||Group 2|50 patients with β-thalassemia major
62725785|NCT06440603||Group 3|50 patients with β-thalassemia intermedia
62725786|NCT01096108|EXPERIMENTAL|Standard Contest|Smoking abstinence, 1 prize award (month 1)
62725787|NCT01096108|EXPERIMENTAL|Standard Contest plus MAPS|Smoking abstinence, 1 prize award (month 1) plus motivational and problem-solving counseling (MAPS - Counseling phone calls); 20 weeks.
62725788|NCT01096108|EXPERIMENTAL|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
62725789|NCT01096108|EXPERIMENTAL|Extended Contests plus MAPS|Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.
62725790|NCT06095869|EXPERIMENTAL|progressive relaxation exercise group|intervention group with progressive relaxation exercise
62725791|NCT06095869|EXPERIMENTAL|relaxation background music group|intervention group with relaxation background music
62725792|NCT06095869|EXPERIMENTAL|control group|group receiving routine health protocol and no intervention
62725793|NCT01718522||Intervention Group|Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).
62725794|NCT01135160||TKA/THA|All patients receiving TKA/THA meeting inclusion but not exclusion criteria
62725795|NCT01810900|EXPERIMENTAL|Protescal|Protescal is applied to this arm.
62725796|NCT01810900|NO_INTERVENTION|non-treatment|
62725797|NCT05036161||Predicting treatment failure of Nasal High Flow in newborns|newborns with respiratory distress treated with NHF
62725798|NCT05036161||Predicting treatment failure of Continuous Positive Airway Pressure in newborns|newborns with respiratory distress treated with CPAP
62725799|NCT04495946|EXPERIMENTAL|Sepsis Transition and Recovery (STAR) Program|Virtual sepsis navigation delivered across the peri-hospital discharge interval
62725800|NCT04495946|ACTIVE_COMPARATOR|Usual Care|Standard of care received through Atrium Health facilities for patients hospitalized with sepsis. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
62725801|NCT05998486||Tremor of rest|Patient with a diagnosis of Parkinson's disease and who performed surface EMG recordings of wrist flexor-pronators and extensor-supinators analysis in Laboratories
62725802|NCT05998486||Cerebellar tremor|Patient with a diagnosis of cerebellar tremor and who performed surface EMG recordings of wrist flexor-pronators and extensor-supinators analysis in Laboratories
62725803|NCT06319404||negative lymph node|
62725804|NCT06319404||postive lymph node|
62725805|NCT02492243|EXPERIMENTAL|Group 1|Patients with documented myocardial infarction in the 7days prior to enrolment and left ventricular ejection fraction \>=40% as assessed by echocardiography within 7 days window after MI,who are not candidate to ICD/CRT/IPG implantation after PCI undergo ILR implantation
62725806|NCT05309967|EXPERIMENTAL|GLUMA|Glutaraldehyde + Hydroxyethyl methacrylate (GLUMA® Desensitizer)
62725807|NCT05309967|PLACEBO_COMPARATOR|PLACEBO|DISTILLED WATER
62725808|NCT04570618|SHAM_COMPARATOR|Standard of Care|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines.
62725809|NCT04570618|EXPERIMENTAL|Standard of Care + AlgoDx Sepsis Prediction Algorithm|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines, and sepsis prediction algorithm alerts are unblinded to clinical staff.
62725810|NCT02115035|EXPERIMENTAL|Vermurafenib|Vermurafenib dosing will be given twice daily by oral administration in cycles of 28 days
62725811|NCT02916511|EXPERIMENTAL|Chemo-radiation group|"A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw\*5"
62725812|NCT05252208|EXPERIMENTAL|Stretching|Stretching
62725813|NCT05252208|EXPERIMENTAL|Walking|Walking
62725814|NCT05229809|EXPERIMENTAL|Yiqi Wenyang Jiedu prescription Group|
62725815|NCT05229809|PLACEBO_COMPARATOR|Simulation agent of Yiqi Wenyang Jiedu prescription Group|
62725816|NCT01138085|EXPERIMENTAL|Dose Escalation|Dose escalation will proceed until unacceptable toxicity is observed. Dose escalation decisions will take into account all available data, including PK data and the safety profile of prior cohorts and will occur following review of these data by the investigator(s), GSK medical monitor, pharmacokineticist, and statistician.
62725817|NCT01138085|EXPERIMENTAL|Expansion Cohorts|"Enrollment into expansion cohort(s) in Part 2A may begin once a recommended dosing regimen(s) is identified in Part 1A utilizing a once daily continuous dosing schedule for both GSK1120212 and GSK2141795. Enrolment to cohorts utilizing this daily dosing schedule may proceed in parallel with enrolment in Part 1B. Expansion cohort(s) will preferentially enroll subjects with treatment-refractory, measurable and biopsiable triple negative breast cancer or BRAF- wild type melanoma. Subjects selected for enrollment into Part 2A or Part 2B will be tested for PTEN deficiency and must agree to provide paired tumor biopsies (at baseline and once while on- treatment). An additional tumor biopsy at the time of disease progression should also be collected if feasible.~In Part 2A and Part 2B, up to 35 additional subjects per tumor type and schedule (i.e., a total of up to 70 subjects per schedule tested) may be enrolled in a two-stage design to better characterize safety, PK and PD."
62725818|NCT04834908|EXPERIMENTAL|Equine COVID-19 Antiserum [F(ab')2] (BSVEQAb) Along with Standard of care|"Dose of BSVEQAb - 5 mg/kg or 10 mg/kg body weight. It is administered as a single dose intravenously after diluting in 100 -150 ml saline. The infusion will be done over 1 to 2 hours.~Standard of care for treatment of COVID-19 positive patients"
62725819|NCT04834908|ACTIVE_COMPARATOR|Standard of care.|Treatment as per current treatment guidelines and institutional practice for COVID-19 positive patients will be administered
62725820|NCT03349255|EXPERIMENTAL|intravenous (i.v.) arm|autologous ET1402L1-CART cells administered by intravenous (IV) infusion
62725821|NCT03349255|EXPERIMENTAL|intra-hepatic artery (i.a.) arm|autologous ET1402L1-CART cells administered by intra-hepatic artery (IA) infusion
62725822|NCT04522050|OTHER|Induction chemotherapy + IMRT and concurrent gemcitabine|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m²,d1) every 3weeks for 2 cycles before radiotherapy, and then receive intensity modulated radiotherapy (IMRT) concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. Patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
62725823|NCT05844202|EXPERIMENTAL|Low dose|0.5 mg Alveavax-v1.2 in one ID injection
62725824|NCT05844202|EXPERIMENTAL|Standard dose|2 mg Alveavax-v1.2 in one ID injection
62725825|NCT05844202|EXPERIMENTAL|High dose|8mg Alveavax-v1.2 in four ID injections
62725826|NCT05844202|ACTIVE_COMPARATOR|Comparator|0.5ml Janssen Ad26.COV2.S COVID-19 vaccine in one IM injection
62725827|NCT05844202|EXPERIMENTAL|Subcutaneous|8mg Alveavax-v1.2 in one SC injection
62725828|NCT02776046|EXPERIMENTAL|High FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs\> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.8 FiO2 and individualized CPAP"
62725829|NCT02776046|ACTIVE_COMPARATOR|Conventional FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.3. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs\> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.3 FiO2 and individualized CPAP"
62725830|NCT03926910|EXPERIMENTAL|VESAP|patient receiving stimulation test to detect hypovolemia
62725831|NCT01014806|EXPERIMENTAL|Low dose|
62725832|NCT01014806|EXPERIMENTAL|High dose|Investigational Influenza VLP Vaccine 60ug/strain
62725833|NCT01014806|ACTIVE_COMPARATOR|TIV|Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced
62725834|NCT04342091|EXPERIMENTAL|Microneedling|Participants with fibrosing alopecia will receive microneedling with a tattoo machine.
62725835|NCT02377024|EXPERIMENTAL|TF 600mg|TF 600mg/day
62725836|NCT02377024|EXPERIMENTAL|TF 1200mg|TF 1200mg/day
62725837|NCT02377024|PLACEBO_COMPARATOR|placebo|placebo
62725838|NCT00432068|EXPERIMENTAL|Octreotide pamoate|
62725839|NCT02584712|NO_INTERVENTION|Control|This group do not participated in the intervention protocol (exercise training), and was followed throughout the entire process. Autonomic activity was assessed before and after 4 weeks.
62725840|NCT02584712|ACTIVE_COMPARATOR|Exercise Training|This group undergone exercise training intervention during 4 weeks.
62725841|NCT01968538||Prostate Cancer Patients|Prostate cancer patients who underwent radiation therapy
62725842|NCT01968538||Healthy control|age-matched male who has no known prostate cancer
62725843|NCT03251027|EXPERIMENTAL|Treatment (IM-SRT)|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
62725844|NCT01973010|EXPERIMENTAL|Massage|To treat low back pain with massage
62725845|NCT01973010|ACTIVE_COMPARATOR|Ibuprofen|Medicine control group
62725846|NCT02484443|EXPERIMENTAL|Treatment (sargramostim and dinutuximab)|Patients receive sargramostim SC QD on days 1-14 and dinutuximab IV over 10 hours on days 4-7 (dinutuximab infusion may be extended up to a total of 20 hours per day for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
62725847|NCT01753817||Study cohort|Cohort of patients who have previously undergone transradial catheterization with the use of a 7F vascular sheath
62725848|NCT05003908|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62725849|NCT00843440|EXPERIMENTAL|Bevacizumab|Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
62725850|NCT00318240|EXPERIMENTAL|1|High Intensity Focused
62725851|NCT04571060|EXPERIMENTAL|Zavegepant|Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar Unidose System (UDS) liquid spray device.
62725852|NCT04571060|PLACEBO_COMPARATOR|Placebo|Participants administered a single intranasal dose of zavegepant matching placebo on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar UDS liquid spray device.
62725853|NCT00956358||Pre-HSCT|Haematological conditions requiring haemopoietic stem cell transplantation
62725854|NCT00956358||Post-HSCT with BOS|Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
62725855|NCT00956358||Control|Healthy HSCT donors
62725856|NCT02065323|ACTIVE_COMPARATOR|ADT alone|Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
62725857|NCT02065323|EXPERIMENTAL|ADT plus Dovitinib|"Standard androgen deprivation therapy (LHRH analogue or orchiectomy)~Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons."
62725858|NCT06205446|EXPERIMENTAL|abdominal breathing|The relationship between respiration and the autonomic nervous system (ANS) is closely intertwined, as the phrenic nerve, responsible for controlling the movement of the diaphragm, is connected to the vagus nerve of the parasympathetic nervous system.The respiratory cycle reflects the balance between the parasympathetic and sympathetic nervous systems in the Autonomic Nervous System (ANS), which can be observed through Heart Rate Variability (HRV). The ANS state shifts from the parasympathetic nervous system to the sympathetic nervous system during inhalation, while it transitions from the sympathetic nervous system to the parasympathetic nervous system during exhalation. In HRV, an increase in heart rate indicates enhanced sympathetic nervous system activity during inhalation, whereas a decrease in heart rate signifies increased parasympathetic nervous system activity during exhalation.
62725859|NCT01602263||Controls|Healthy Controls with no known cognitive impairment will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
62725860|NCT01602263||Individuals with schizophrenia|Individuals with schizophrenia and first-degree relatives will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
62725861|NCT01602263||Individuals with aphasia|Individuals with aphasia will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
62725862|NCT01602263||Individuals with high-functioning autism|Individuals with high-functioning autism will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
62725863|NCT03270059|EXPERIMENTAL|Group I (gadolinium, ferumoxytol, MRI)|Patients receive gadolinium IV and then ferumoxytol IV and undergo MRI over 60 minutes on day 1.
62725864|NCT03270059|EXPERIMENTAL|Group II (ferumoxytol, gadolinium, MRI)|Patients receive ferumoxytol IV and then gadolinium IV and undergo MRI over 60 minutes on day 1.
62725865|NCT04603469||Trisomy 21 patients|Children \<18 years old requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3
62725866|NCT06286449|OTHER|Alcohol Use Disorder cohort and Healthy controls cohort|"Alcohol Use Disorder Cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of healthy controls. Study participants with Alcohol Use Disorder (AUD) are recruited from other previous or ongoing clinical trials performed within the research group: NordAlc (PI Andrea de Bejczy), IV-ASA (PI Bo Söderpalm), GlycinA (PI Bo Söderpalm) and COMB (PI Bo Söderpalm).~Healthy controls cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of participants with Alcohol Use Disorder. Healthy controls will be continuously recruited via advertisements in media, and onsite at the Sahlgrenska University Hospital and the University of Gothenburg"
62725867|NCT01277822|EXPERIMENTAL|Losartan/amlodipine Treatment Arm|One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.
62725868|NCT01277822|ACTIVE_COMPARATOR|Amlodipine Treatment Arm|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.
62725869|NCT03199677|EXPERIMENTAL|apatinib with 500mg qd po|Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
62725870|NCT06004206|EXPERIMENTAL|nPSV first|Patients will follow the pattern: nPSV -\> PSV -\> nPSVo -\> PSVo
62725871|NCT06004206|EXPERIMENTAL|PSV first|Patients will follow the pattern: PSV -\> nPSV -\> PSVo -\> nPSVo
62725872|NCT01899781|EXPERIMENTAL|with antibiotic and without antibiotic|
62725873|NCT02690766|OTHER|Physical Activity Group|The Success Study's Standard Behavioral Weight Change Intervention consists of 75 minute group sessions held monthly which include 30 minutes of physical activity with a licensed Physical Activity Instructor. Web Lessons that include information on Physical Activity, Nutrition and Healthy Behaviors will also be provided to participants on the study's website.
62725874|NCT03161210|EXPERIMENTAL|Dextrose Prolotherapy|
62725875|NCT03161210|ACTIVE_COMPARATOR|Local Anaesthetic|
62725876|NCT03161210|PLACEBO_COMPARATOR|Saline|
62725877|NCT04858438|ACTIVE_COMPARATOR|Standard Insufflation Group|Patients will receive standard insufflation during surgery (15 mm Hg).
62725878|NCT04858438|EXPERIMENTAL|Low Insufflation Group|Patients will receive a lower level of insufflation during surgery (12 mm Hg or lower).
62725879|NCT01116388|OTHER|test product|product free of gluten and casein
62725880|NCT01116388|OTHER|control product|product containing gluten and milk protein
62725881|NCT01664247|EXPERIMENTAL|IDeg + Lira|
62725882|NCT01664247|EXPERIMENTAL|Placebo + Lira|
62725883|NCT04054336|EXPERIMENTAL|Inhibition group|The inhibition group gets the instructions to respond to pictures containing soft drinks by swiping/pulling them towards themselves, whereas pictures with alcoholic content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
62725884|NCT04054336|EXPERIMENTAL|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon soft drinks by swiping/pulling towards themselves the picture. Pictures containing alcoholic content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
62725885|NCT04054336|SHAM_COMPARATOR|Control group|This type of active control group receives the instructions to swipe alcohol pictures to the left and soft drink pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
62725886|NCT04684615||AmBiGen|Individuals who are enrolled in AmBiGen over the last 3 years
62725887|NCT00972023|EXPERIMENTAL|DHEA, surgical resection|Day-14 (approx. 2 wks prior to surgery): begin a 2 week course of DHEA; Day-7 (approx. 1 wk after starting treatment): answer question about pill diary; Day 0 (approx. 2 wks after starting treatment, within 48 hours prior to surgery;
62725888|NCT02003443|PLACEBO_COMPARATOR|Sham Acupressure|Participants assigned to sham acupressure will receive similar instruction as those assigned to pain-relief acupressure, except that they will be taught to apply pressure to 10 acupoints that are unrelated to pain. That is, they will conduct self-administered acupressure 5 days/week for 8 weeks, as the pain-relief acupressure group does, but on 'sham' acupoints.
62725889|NCT02003443|NO_INTERVENTION|Usual Care|Participants assigned to the UC group will receive no intervention.
62725890|NCT02003443|EXPERIMENTAL|Pain-Relief Acupressure|Participants assigned to pain-relief acupressure will be taught to apply physical pressure, using a wooden hand-held device designed for acupressure, to 10 acupoints on their body.That is, they will conduct self-administered acupressure 5 days/week for 8 weeks,on acupoints that are relevant to pain reduction.
62725891|NCT04524221|EXPERIMENTAL|PTG-100|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
62725892|NCT04524221|PLACEBO_COMPARATOR|Placebo|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
62725893|NCT04782349|EXPERIMENTAL|high intensity laser group|
62725894|NCT04782349|EXPERIMENTAL|low intensity laser group|
62725895|NCT04782349|OTHER|control group|
62725896|NCT05934383|EXPERIMENTAL|Renal sympathetic denervation|
62725897|NCT02735603|EXPERIMENTAL|Nalterxone/Bupropion + Placebo + Moxifloxacin|Naltrexone hydrochloride (HCl) 8 milligram (mg)/bupropion HCl 90 mg (NB) placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
62725898|NCT02735603|EXPERIMENTAL|Placebo + Moxifloxacin + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
62725899|NCT02735603|EXPERIMENTAL|Moxifloxacin + Naltrexone/Bupropion + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Day 4 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in the treatment period 3.
62725900|NCT02735603|EXPERIMENTAL|Naltrexone/Bupropion + Moxifloxacin + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 3.
62736237|NCT05544201|EXPERIMENTAL|40 Hz HD-tACS|The stimulation parameters of HD-tACS include: 20 minutes at 40 Hz, 2 milliamps.
62736238|NCT05544201|ACTIVE_COMPARATOR|HD-tDCS|The stimulation parameters of HD-tDCS include: 20 minutes at 2 milliamps, 20 seconds fade-in and 20 seconds fade-out.
62736239|NCT05544201|SHAM_COMPARATOR|Sham HD-tCS|In sham condition, the stimulation only last for 30 seconds with the electrodes left in place for a further 20 minutes. This procedure mimics the transient skin sensation of tingling induced by active HD-tACS and HD-tDCS without producing any sustainable effects.
62725901|NCT02735603|EXPERIMENTAL|Placebo + Naltrexone/Bupropion + Moxifloxacin|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
62725902|NCT02735603|EXPERIMENTAL|Moxifloxacin + Placebo + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
62725903|NCT06290492|ACTIVE_COMPARATOR|real stimulation|Participants will receive active HD-tDCS daily for 10 consecutive days. The anode electrode was placed on the DMPFC (Fz) surrounded by four cathodes with a 1cm diameter (FPz, F3, Cz, and F4). The stimulation direct current magnitude was set at 2 mA with a 30-s immediate decline at the beginning and end of each phase.
62725904|NCT06290492|SHAM_COMPARATOR|sham stimulation|In the sham intervention phase, the sensation was simulated by applying a 30-s rising current until 2 mA was reached, with a 30-s immediate decline at the beginning and end of each phase.
62725905|NCT06111638|EXPERIMENTAL|Arm of BBM-H803|The dose of BBM-H803 will be calculated according to participant's weight
62725906|NCT00709150|EXPERIMENTAL|1|Patients will receive collaborative depression care management.
62725907|NCT00709150|ACTIVE_COMPARATOR|2|Patients will receive enhanced usual care.
62725908|NCT02168101|EXPERIMENTAL|MLN9708 - 2.3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 2.3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
62725909|NCT02168101|EXPERIMENTAL|MLN9708 - 3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
62725910|NCT02168101|EXPERIMENTAL|MLN9708 - 4 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
62725911|NCT05550961||Retrospective Cohort|About 1000 patients with NSCLC pre-treated with innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
62725912|NCT05550961||Prospective Cohort|About 200 patients with NSCLC planned to start an innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
62725913|NCT02015481|EXPERIMENTAL|Cabaletta 30gr.|weekly IV of Cabaletta 30gr.
62725914|NCT05940064|EXPERIMENTAL|Elderly Treatment-naive Diffuse Large B-cell Lymphoma|Elderly Treatment-naive Diffuse Large B-cell Lymphoma
62725915|NCT05496361|EXPERIMENTAL|Tianyi Revascularization Device|
62725916|NCT05496361|ACTIVE_COMPARATOR|Solitaire FR Revascularization Device|
62725917|NCT05407207|ACTIVE_COMPARATOR|Intervention group|The intervention group will take part in a 12-week plantar electrical stimulation intervention using the proposed technology 3 times per week during HD either in a sitting or supine position under the supervision of a research staff member. The duration of each treatment session will be one hour. Patients who receive an activated electrical stimulation unit will receive a standard dose of 30 milliamps as described in the following during each HD session (3 times per week for 12 weeks).
62725918|NCT05407207|SHAM_COMPARATOR|Control group|Placebo controls will have an electrical stimulation unit programmed not to provide any electrical current, while all other lights and programming indicators will be functional. Both active and inactive electrical stimulation units will be programmed to download the period that they are used on a weekly basis in order to verify that the units are used for the prescribed time period.
62725919|NCT02573571||Clostridium difficile infection|Patients with Clostridium difficile-associated diarrhea for development of biomarkers
62725920|NCT01237431|EXPERIMENTAL|liver transplanted patients|Target group to confirm the hypothesis. Transplantation has to be between 6 an 24 Month before participation.
62725921|NCT01237431|ACTIVE_COMPARATOR|kidney transplanted patients|Control group, age, gender and medication matched. Transplantation has to be between 6 an 24 Month before participation.
62725922|NCT02448355|EXPERIMENTAL|Patient undergoing carotid endarterectomy|"All patients undergoing carotid endarterectomy in Shaare Zedek Medical Center Visual acuity measurement (Snellen) SS-OCT (DRI-Atlantis, Topcon) 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.~* On pre-op visit (Monday)~* Day 1 post-surgery~* Discharge day~* Week 1 post-surgery~* Month 1 post-surgery"
62725923|NCT05115370||Patients with an inflammatory disease taking immune-suppressing medication|
62725924|NCT05938348|EXPERIMENTAL|pain scores of patients before and after (6h, 12h, 24h, 48h, 72h) angiopuncture.|investigators done angiopuncture on perforators in human. Pain score will be assessed on both before and after the treatment.
62725925|NCT03756116|EXPERIMENTAL|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
62725926|NCT03756116|ACTIVE_COMPARATOR|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope; followed by octreotide.
62725927|NCT04915508|EXPERIMENTAL|Treatment (SBRT, hormone therapy)|Patients undergo SBRT every other day or on consecutive days for up to 14 days. Patients may receive hormonal therapy at the discretion of the treating physician.
61978230|NCT05527145|ACTIVE_COMPARATOR|surgery|Oper or minimally invasive surgery
62165970|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
62725928|NCT01918865|EXPERIMENTAL|ISIS-PTP1BRx|Weekly Dosing for 26 Weeks
62725929|NCT01918865|PLACEBO_COMPARATOR|Placebo|Weekly Dosing for 26 Weeks
62725930|NCT00682175||Observation|Adult (age \> 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.
62725931|NCT01558596|PLACEBO_COMPARATOR|Sham|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
62725932|NCT01558596|EXPERIMENTAL|RIPC|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
62725933|NCT01730911|NO_INTERVENTION|ParaGard, paper diaries|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries on paper.
62725934|NCT01730911|ACTIVE_COMPARATOR|ParaGard, text message|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries via text message.
62725935|NCT01730911|NO_INTERVENTION|Mirena, paper diaries|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries on paper.
62725936|NCT01730911|ACTIVE_COMPARATOR|Mirena, text message|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries via text message.
62725937|NCT02098525||HIV associated CM patients|The study population is all adult HIV positive patients with CM at Ramathibodi Hospital.
62725938|NCT05152251||Study Group|Down Syndrome
62725939|NCT05152251||Control Group|Typically Developing Children
62725940|NCT04649658||Prone position|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to prone position
62725941|NCT04649658||Standard care|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to standard care
62725942|NCT04877860|EXPERIMENTAL|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Access to the PaiNEd system.
62725943|NCT04877860|ACTIVE_COMPARATOR|Multimodal rehabilitation program + traditional biomedical information|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Dossier with traditional biomedical recommendations on the management of pain and disability.
62725944|NCT04877860|ACTIVE_COMPARATOR|Control group|Information dossier with recommendations on pain control and dysfunction improvement.
62725945|NCT05614752||Treatment group|treated with Fexuclue Tablet 40mg
62725946|NCT06186583|EXPERIMENTAL|[14C]ABSK021 Suspension|On Day 1, subjects will receive a single oral dose of approximately 50 mg ABSK021 containing approximately 100 μCi of \[14C\] ABSK021 in the fasted state.
62725947|NCT05573698|EXPERIMENTAL|Multiple Dose: DT-216|Participants will be administered multiple doses of DT-216
62725948|NCT05573698|PLACEBO_COMPARATOR|Multiple Dose: DT-216 matching placebo|Participants will be administered multiple doses of placebo
62725949|NCT04974463||Persistent Opioid Use at 3 months|Patients who continue to use opioids about 3 months after their joint replacement surgery
62725950|NCT04974463||No Persistent Opioid Use at 3 months|Patients who do not use opioids after about 3 months following joint replacement surgery
62725951|NCT04381299||Intervention|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
62725952|NCT04381299||Control|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
62725953|NCT04335448||Arterial Switch Operation - Transposition of Great Arteries|Patients with previous arterial switch operation for the treatment of a transposition of great arteries will constitute the sole group of the cohort.
62725954|NCT04069312|ACTIVE_COMPARATOR|Roflumilast arm|Participants will receive prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
62725955|NCT04069312|ACTIVE_COMPARATOR|Azithromycin arm|Participants will receive prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
62725956|NCT02673983|EXPERIMENTAL|Patients undergoing endoscopic full-thickness biopsy|
62725957|NCT05968248|EXPERIMENTAL|MLR-DBS（Deep brain stimulation of the mesencephalic locomotor region）|The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
62725958|NCT05968248|SHAM_COMPARATOR|Conventional rehabilitation group|The arm will l also have DBS surgery and receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
62725959|NCT02407743||Surgical patients' clinical progression|Patients undergoing non-ambulatory surgery will be asked questions and complete surveys in an effort to characterize postoperative pain experience profiles. A blood sample will be obtained for genetic markers exploring a variety of pain-related genes.
62725960|NCT01891981|EXPERIMENTAL|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
62725961|NCT02685826|EXPERIMENTAL|Cohort A: High risk, TNE|"High risk, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were administered~* Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~* Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\]) value on Days 1 to 21 of each 28-day treatment cycle~* Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle"
62725962|NCT02685826|EXPERIMENTAL|Cohort B: >=65 years old, TNE|"\>= 65 years old, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered~* Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~* Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\]) value on Days 1 to 21 of each 28-day treatment cycle~* Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles"
62725963|NCT02685826|EXPERIMENTAL|Cohort C: High risk, Post-transplant|"High risk, post-transplant NDMM participants were administered the following as maintenance therapy:~* Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~* Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
62725964|NCT06337981|EXPERIMENTAL|Test group 1|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
62725965|NCT06337981|EXPERIMENTAL|Test group 2|(AJU-S56 5%), 1drop/1times, 6times in a day
62725966|NCT06337981|PLACEBO_COMPARATOR|Comparator group|Placebo(Vehicle), 1drop/1times, 6times in a day
62725967|NCT00355030|EXPERIMENTAL|1|
62725968|NCT00355030|EXPERIMENTAL|2|
62725969|NCT04563767||Infinitome|All patients will be in the same cohort. No intervention will be administered. Patients will undergo a structural magnetic resonance imaging (MRI) as part of their standard of care. Added on will be the resting state fMRI (rs-fMRI). The rs-fMRI data will be analyzed.
62725970|NCT05219253|EXPERIMENTAL|HZ/su Group|Participants randomized to the HZ/su group received two doses of HZ/su vaccine, administered at Day 1 and Month 2.
62725971|NCT05219253|PLACEBO_COMPARATOR|Placebo Group|Participants randomized to the Placebo group received two doses of Placebo, administered at Day 1 and Month 2.
62725972|NCT03284060|EXPERIMENTAL|Cognitive remediation program|
62725973|NCT00579423|EXPERIMENTAL|vaccine|Patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administrated at the standard dose of 100ug.
62725974|NCT01158443|EXPERIMENTAL|Behavioral activation therapy|The Behavioral Activation Program for Energy and Productivity (BA-PEP) is a manualized, 8-session intervention, scheduled to coincide with maintenance armodafinil treatment. It is a structured counseling program with homework, short-term activities and goals, and includes problem-solving, identification of barriers and strategies for their resolution, with an ongoing focus on achieving employment or training.
62725975|NCT01158443|PLACEBO_COMPARATOR|supportive counseling (SC)|Supportive counseling is designed to create an empathic, accepting environment, to direct attention to the patient's feelings and to facilitate acceptance of affective experience using supportive statements, reflective listening and empathic communications.
62725976|NCT05134610|NO_INTERVENTION|Control|Standard of care for pre- and post-op pulmonary care
62725977|NCT05134610|EXPERIMENTAL|OPEP Therapy|14 days pre- and and post-op OPEP device usage
62725978|NCT01809886|EXPERIMENTAL|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
62725979|NCT01809886|ACTIVE_COMPARATOR|Neostigmina|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
62725980|NCT02063685|OTHER|GROUP 1 - STANDARD|R-CHOP or R-bendamustine + Standard Maintenance
62725981|NCT02063685|EXPERIMENTAL|GROUP 2|FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance
62725982|NCT02063685|EXPERIMENTAL|GROUP 1a|FDG-PET NEGATIVE (score 1-3) AND MRD NEGATIVE R-CHOP or R-bendamustine + Observation
62725983|NCT02063685|EXPERIMENTAL|GROUP 1b|FDG-PET NEGATIVE (score 1-3) AND MRD POSITIVE R-CHOP or R-bendamustine + Maintenance weekly x4
62725984|NCT01478464|NO_INTERVENTION|Control group|Control group, does not receive any intervention
62725985|NCT01478464|EXPERIMENTAL|Massage group|Massage will be performed on the left or right hamstring muscle (randomized) for ten minutes with a massage roller. The contralateral leg will not be massaged, but serve as a non-massaged control leg to assess possible cross-over effects from the massaged leg
62725986|NCT05370365|EXPERIMENTAL|4 week cast|Patients over 65 years old with a distal radius fracture will be treated conservatively with a cast for 4 weeks. Once the immobilization will be removed, the standard rehabilitation protocol of our center used in these fractures will be carried out. The usual clinical and radiological follow-up will be performed at 3, 6 and 12 months.
62165971|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
62725987|NCT05370365|EXPERIMENTAL|6 week cast|Patients over 65 years old with a distal radius fracture will be treated conservatively with a cast for 6 weeks. Once the immobilization will be removed, the standard rehabilitation protocol of our center used in these fractures will be carried out. The usual clinical and radiological follow-up will be performed at 3, 6 and 12 months.
62725988|NCT04456205||Dual Therapy|Dual Therapy (long-acting muscarinic antagonist \[LAMA\] + long-acting beta-agonist \[LABA\])
62725989|NCT04456205||Triple Therapy|Triple Therapy (inhaled corticosteroid \[ICS\]/ long-acting beta-agonist \[LABA\] + long-acting muscarinic antagonist \[LAMA\])
62165972|NCT03190317||Providers and staff of HIV-infected veteran|This groups represents the population of providers and staff who utilize the MHV portal to deliver care for HIV-infected veterans.
62725990|NCT01149330|EXPERIMENTAL|Adapalene-BPO Gel|
62725991|NCT02162654|ACTIVE_COMPARATOR|Remote ischemic preconditioning|Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
62725992|NCT02162654|SHAM_COMPARATOR|Sham preconditioning|Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
62725993|NCT03102294|ACTIVE_COMPARATOR|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with \~50% of maximum inspiratory pressure
62725994|NCT03102294|PLACEBO_COMPARATOR|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
62725995|NCT02848456|ACTIVE_COMPARATOR|Spinal Manipulation SM|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
62725996|NCT02848456|ACTIVE_COMPARATOR|Max Voluntary Isometric Contraction MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
62725997|NCT02848456|ACTIVE_COMPARATOR|SM+MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
62725998|NCT03712774||neoadjuvant chemoradiation|Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
62725999|NCT03712774||definitive chemoradiation|Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
62726000|NCT02251496|ACTIVE_COMPARATOR|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
62726001|NCT02251496|ACTIVE_COMPARATOR|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
62726002|NCT03890523|EXPERIMENTAL|Segmented Airway Stent for Gastro-Respiratory fistula|Segmented covered metallic airway stent modified with 3D printing was used for gastro-respiratory fistula.
62726003|NCT04084535|ACTIVE_COMPARATOR|High intensity interval training|It will apply a HIIT program for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
62726004|NCT04084535|ACTIVE_COMPARATOR|Inspiratory muscle training|It will apply an inspiratory muscle training for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
62726005|NCT04384068||Chinese RA patients|Chinese RA patients who used tocilizumab in real world clinical practice
62726006|NCT04830943|EXPERIMENTAL|Olfactory and gustatory disorders after covid 19 infection (n = 150)|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 40 treatments (for at least 8 weeks after presentation), after which the cycle was repeated again according to the each patient response to therapy for a maximum of 24 weeks.
62726007|NCT04830943|NO_INTERVENTION|control group (n = 100)|no drug intervention, just olfactory training using at least 4 strong odors to smell twice daily for at least 15 minutes (every time), for at least 8 weeks after presentation.
62726008|NCT03128489|EXPERIMENTAL|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
62726009|NCT03512574|EXPERIMENTAL|Group PD|combination of pregabalin and dexmedetomidine
62726010|NCT03512574|ACTIVE_COMPARATOR|Group P|pregabalin +placebo
62726011|NCT03512574|ACTIVE_COMPARATOR|Group D|placebo + dexmedetomidine
62726012|NCT03512574|PLACEBO_COMPARATOR|Group C|placebo + placebo
62726013|NCT03853967|EXPERIMENTAL|screening|participants performed lung cancer screening by Low Dose CT scan
62726014|NCT04942132|EXPERIMENTAL|Treatment|A Smartphone self-administered cognitive-behavioral based intervention
62726015|NCT01389986|EXPERIMENTAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
62726016|NCT01389986|NO_INTERVENTION|Conventional|Conventional postoperative feeding schedule
62726017|NCT01588119||Dabigatran|in atrial fibrillation
62726018|NCT01588119||Rivaroxaban|in atrial fibrillation and VTE
62726019|NCT01588119||Apixaban|in atrial fibrillation and VTE
62726020|NCT01588119||Edoxaban|in atrial fibrillation and VTE
62726021|NCT05338762||Current COVID-19 symptoms or SARS-CoV-2 in the last 30 days with a positive RT-PCR test|"75 subjects will be enrolled who were diagnosed as SARS-CoV-2 with a positive RT-PCR nasal pharangeal test or are suspected of having a COVID-19 infection with symptom onset in the last 30 days. (Symptom onset 0-30 days)~This group of subjects will receive:~1. a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test~2. a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)~3. a nasal-pharangeal RT-PCR test"
62726022|NCT05338762||Diagnosed with SARS-CoV-2 (COVID-19) in the past 3 months with a positive RT-PCR test|"30 subjects will be enrolled who have been diagnosed with COVID-19 in the past 3 months and had a prior positive RT-PCR nasal pharangeal test. (Symptom onsent 31-90 days)~This group of subjects will receive:~1. a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test~2. a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)"
62726023|NCT00480740|EXPERIMENTAL|Cardiac Transplant|diagnostic cardiac catheterization in children with a transplanted heart
62726024|NCT00480740|EXPERIMENTAL|Fontan procedure|diagnostic cardiac catheterization in children with a transplanted ventricle
62726025|NCT00480740|OTHER|Normal Physiology|diagnostic cardiac catheterization in children with normal cardiac physiology
62726026|NCT02461199||Fecal microbiota transplantation|Patients with proven gut colonization status with following bacteria: Klebsiella pneumoniae resistant to carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis VRE (vancomycin-resistant enterococcus), Enterococcus faecium VRE, Enterobacter cloacae resistant to carbapenems or other MDR species. Gut colonization proven by conventional microbiological culture and/or molecular methods.
62726027|NCT03941418|EXPERIMENTAL|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
62726028|NCT03941418|PLACEBO_COMPARATOR|Placebo|Patients will be administered with placebo as an addition to their standard therapy.
62726029|NCT01503814|NO_INTERVENTION|Control (Usual Care)|Control
62726030|NCT01503814|EXPERIMENTAL|Intervention|"Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a2+2model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable"
62726031|NCT02863393|EXPERIMENTAL|Diaphragmatic breathing exercise|The aim of this study is to ameliorate hepatic inflammation by using diaphragmatic breathing exercises instead of aerobic exercise to reduce the fat in liver inflammation.
62726032|NCT06183281|EXPERIMENTAL|Intervention|The INSPIRE chronic pain management system has three primary components: 1) a patient facing smartphone app that collects and interprets a comprehensive intake and patient reported outcomes (PROs), provides health education, and a tailored, modular self-management program that includes cognitive-behavioral therapy (CBT), physical therapy (PT), and mindfulness-based interventions (MBI), 2) a weekly telehealth visit with a pain coach that uses the PRO data and module engagement measures to guide the visit, and 3) enhanced primary care coordination achieved through pain coaching notes and alerts integrated into the electronic health record (EHR).
62726033|NCT06183281|NO_INTERVENTION|Control|Control participants will receive educational materials about chronic pain and full workbook with non-pharmacologic strategies.
62726034|NCT03579693|ACTIVE_COMPARATOR|CoQ10|Coenzyme Q10, 2 - 250 mg tablets twice a day (1000 mg total daily dose) for 6 weeks
62726035|NCT03579693|ACTIVE_COMPARATOR|Nicotinamide riboside|Nicotinamide riboside, 1 - 600 mg tablet twice a day (1200 mg total daily dose) for 6 weeks
62726036|NCT03579693|PLACEBO_COMPARATOR|Placebo|Placebo, inactive sugar pill for 6 weeks
62726037|NCT01384851|EXPERIMENTAL|Next Generation Emulsion|Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
62726038|NCT01384851|ACTIVE_COMPARATOR|Refresh Dry Eye Therapy|A preserved multi-dose formulation for use in treating dry eye symptomatology. The key ingredients are Castor oil, Polysorbate 80, Carbomer 1342 and Glycerin. Refresh Dry Eye Therapy® Lubricant Eye Drops contains emulsified castor oil, which enhances the natural oily superficial tear layer on the ocular surface. By stabilizing and supplementing the lipid layer, castor oil may retard evaporation of surface moisture.
62726039|NCT01384851|ACTIVE_COMPARATOR|Refresh Contacts|Solution contains carboxymethylcellulose sodium (carmellose), sodium chloride, boric acid, sodium borate, potassium chloride, calcium chloride, magnesium chloride, Purite®, sodium hydroxide, and purified water. This product is registered as a CE Mark medical device. Refresh Contacts Comfort drops providing soothing relief from tired, dry eyes. Although intended for contact lens wearers, the primary indication is for relief of dry eyes as is being studied in this investigation.
62726040|NCT04288856|EXPERIMENTAL|Cohort A: BIIB078 First Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
62726041|NCT04288856|EXPERIMENTAL|Cohort B: BIIB078 Second Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
62726042|NCT04288856|EXPERIMENTAL|Cohort C: BIIB078 Third Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
62726043|NCT04288856|EXPERIMENTAL|Possible Cohort D: BIIB078 Fourth Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
62726044|NCT03056833|EXPERIMENTAL|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
62726045|NCT03341637|EXPERIMENTAL|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
62726046|NCT03341637|PLACEBO_COMPARATOR|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
62726047|NCT04032886|EXPERIMENTAL|classic kinesio tape|this group will receive mechanical correction tape with classic tape plus exercise.
62726048|NCT04032886|EXPERIMENTAL|performance kinesio tape|this group will receive mechanical correction tape with performance tape plus exercise.
62726049|NCT04032886|OTHER|control|this group will receive only exercise.
62726050|NCT05915585|EXPERIMENTAL|High-Intensity Laser Therapy (HILT)|
62726051|NCT06379828||eDelphi panel/participants|The eDelphi panels will consist of approximately 100 healthcare professionals from various European countries from the following fields: neonatology, midwifery, (neonatal) care, obstetrics, parent representing institutions, psychology, and physiotherapy. 20-30 of them will be invited for a final consensus workshop.
62726052|NCT06379828||Pilot hospitals|10 hospitals with neonatal units from Germany, UK, France, Italy, Sweden, Portugal, and Spain.
62726053|NCT00553631|EXPERIMENTAL|GA-GCB|VPRIV™ ,velaglucerase alfa
62726054|NCT00553631|ACTIVE_COMPARATOR|imiglucerase|
62726055|NCT05238519|EXPERIMENTAL|Motivational Interview|Motivational interview arm will receive a message to schedule a follow up motivational interview via telephone or video after the baseline survey as well as follow up surveys.
62726056|NCT05238519|NO_INTERVENTION|Usual Care|Usual care arm will receive baseline and follow up surveys only.
62726057|NCT04609605|EXPERIMENTAL|patients with acute pulmonary embolism|speckle tracking echocardiography for patient with acute pulmonary embolism
62726058|NCT05058729||Cohort 1|Participants with multiple sclerosis (MS) or clinically isolated syndrome (CIS) who are enrolled in MS PATHS under Study 888MS001 and have completed at least one COVID-19 questionnaire administered by a participating healthcare institution.
62726059|NCT03814928|EXPERIMENTAL|Caregivers eCourse|Education post-hip fracture delivered via eCourse.
62726060|NCT02782845|EXPERIMENTAL|Pegfilgrastim|Participants will receive CT or ICT for 6 cycles on Days 1-6, as per standard of care. Protocol does not specify any choice of CT or ICT drugs. Participants will receive pegfilgrastim at a fixed dose of 6 mg subcutaneously, 24 hours after the last dose of CT or ICT in each treatment cycle. CT or ICT cycles of 21 days, as per standard of care.
62726061|NCT04584398|EXPERIMENTAL|Intervention|The intervention group (A) will perform respiratory muscle training and steam inhalation with WellO2 device for 30 days.
62726062|NCT04584398|NO_INTERVENTION|Control|The control group (B) will continue on their conventional treatment without respiratory muscle training or steam inhalation with WellO2. After 30 days, the group B performs the same 30-day intervention with the WellO2 device (test) as the group A.
62726063|NCT03530150|ACTIVE_COMPARATOR|Pirfenidone 600 mg|Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
62726064|NCT03530150|NO_INTERVENTION|Usual Care|Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
62726065|NCT05461339|EXPERIMENTAL|TAB014|intravitreal injection at 1.25mg once every 4 week
62726066|NCT05461339|ACTIVE_COMPARATOR|Ranibizumb|intravitreal injection at 0.5mg once every 4 week
62726067|NCT02770027|PLACEBO_COMPARATOR|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62726068|NCT02770027|ACTIVE_COMPARATOR|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
62726069|NCT02909660|EXPERIMENTAL|Support-seeking intervention|Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
62726070|NCT02909660|ACTIVE_COMPARATOR|Family accommodation reduction intervention|Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.
62726071|NCT05186935|EXPERIMENTAL|Single arm|This is a multi-center, pivotal, non-randomized, prospective, open-label clinical investigation.
62726072|NCT01408277|ACTIVE_COMPARATOR|Santyl|2mm Santyl applied once daily.
62726073|NCT01408277|ACTIVE_COMPARATOR|Control|Standard Care
62726074|NCT06457477|EXPERIMENTAL|PD-1 antibody therapy|
62726075|NCT05585073||qualified of D2 Lymph node dissection group|
62726076|NCT05585073||not-qualified D2 Lymph node dissection group|
62726077|NCT05580354|EXPERIMENTAL|Arm 1|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
62726078|NCT05415553|EXPERIMENTAL|IOBT group|For IOBT, the whole belly of inferior oblique muscle is anchored to the sclera 5 mm behind the temporal insertion of the inferior rectus muscle.
62726079|NCT05415553|ACTIVE_COMPARATOR|IO-Rec group|For IO-Rec, the insertion of inferior oblique muscle is excised and anchored to the sclera 4 mm behind and 2 mm beside the temporal insertion of the inferior rectus muscle.
62726080|NCT04878601|EXPERIMENTAL|hbART|Home-Based ART initiation and continuation for 3-months with male-specific counseling and assisted facility navigation at 4-months.
62726081|NCT04878601|ACTIVE_COMPARATOR|fbART|Facility-Based ART initiation and continuation with male-specific counseling.
62726082|NCT04232943|ACTIVE_COMPARATOR|Inactivated Poliomyelitis Vaccine (IPV)|Participants will receive a single intramuscular injection of 0.5 mL inactivated poliomyelitis vaccine (IPV) on Day 1 followed by a single dose (2 drops) of bivalent oral polio vaccine (bOPV) 28 days later.
62726083|NCT04232943|EXPERIMENTAL|Inactivated Poliomyelitis Vaccine + dmLT|Participants will receive a single intramuscular injection of 0.5 mL IPV co-administered with 0.5 μg of dmLT on Day 1 followed by a single dose (2 drops) of bOPV 28 days later.
62726084|NCT04232943|ACTIVE_COMPARATOR|Bivalent Oral Polio Vaccine|Participants will receive one dose (2 drops) of bOPV on Day 1 followed by a second dose of bOPV 28 days later.
62726085|NCT04543916|EXPERIMENTAL|Dose Level 1|Venetoclax 50mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
62726086|NCT04543916|EXPERIMENTAL|Dose Level 2|Venetoclax 100mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
62726087|NCT04543916|EXPERIMENTAL|Dose Level 3|Venetoclax 200mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
62726088|NCT04543916|EXPERIMENTAL|Dose Level 4|Venetoclax 400mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
62726089|NCT04543916|EXPERIMENTAL|Dose Level 5|Venetoclax 600mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
62726090|NCT04543916|EXPERIMENTAL|Phase 2 Expansion Cohort|Venetoclax recommended phase 2 dose (RP2D) by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
62726091|NCT05434494|ACTIVE_COMPARATOR|remifentanil group|"Start the continuous infusion of 25cc of remifantanil (labeled as a test drug) by TCI mode ( the target effect site concentration is 2.0).~While slowly injecting the prescribed dose of remimazolam over 30 seconds, observe whether it responds to the investigator's oral commands and the disappearance of the eyelash reflex for 3 minutes after administering the drug. Success in inducing loss of consciousness during anesthesia is defined as the loss of both verbal command response and eyelash reflex within 3 minutes after infusion, otherwise it is considered a failure.~The dose of remimazolam is initially 0.15 mg/kg and the next experimental dose is determined according to the biased coin design up-and-down sequential method. The standard deviation of this study is 0.05 mg."
62736240|NCT03981640|EXPERIMENTAL|African American Adults|African American adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
62726092|NCT05434494|PLACEBO_COMPARATOR|control group|"Start the continuous infusion of 25cc of normal saline (labeled as a test drug).~While slowly injecting the prescribed dose of remimazolam over 30 seconds, observe whether it responds to the investigator's oral commands and the disappearance of the eyelash reflex for 3 minutes after administering the drug. Success in inducing loss of consciousness during anesthesia is defined as the loss of both verbal command response and eyelash reflex within 3 minutes after infusion, otherwise it is considered a failure.~The dose of remimazolam is initially 0.15 mg/kg and the next experimental dose is determined according to the biased coin design up-and-down sequential method. The standard deviation of this study is 0.05 mg."
62726093|NCT04579666|EXPERIMENTAL|1,080 mg pegcetacoplan (APL-2)|administered subcutaneously twice weekly
62726094|NCT04579666|PLACEBO_COMPARATOR|Placebo administered subcutaneously twice weekly|
62726095|NCT03130998|ACTIVE_COMPARATOR|Control - Group A|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
62726096|NCT03130998|EXPERIMENTAL|Intervention - Group B|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive individualized support through a remote knowledge broker (rKB) communicating via interactive technology. The rKB will be certified in tobacco cessation counseling through CAMH's TEACH program and will have completed a specialty course on tobacco addiction treatment in those with mental illness. The rKB will have access to the CAMH network of KBs (e.g. Evidence Exchange Network ) for guidance and support, as this has been shown to be important for KB success.
62726097|NCT00973336|EXPERIMENTAL|Calcium and vitamin D|Intervention
62726098|NCT00973336|NO_INTERVENTION|No treatment (control)|
62726099|NCT00761982|OTHER|bone marrow stem cells|Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.
62726100|NCT01448538||Group 1|
62726101|NCT01022970|PLACEBO_COMPARATOR|Placebo|
62726102|NCT01022970|ACTIVE_COMPARATOR|QAX576|
62726103|NCT00715247||Affected Population|Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
62726104|NCT00715247||Healthy Female Controls|Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
62726105|NCT00504439|EXPERIMENTAL|Cohort 1|Subjects in Cohort 1 will receive 20 milligrams (mg) of SB-656933-AAA once daily or matching placebo once daily for 14 days.
62726106|NCT00504439|EXPERIMENTAL|Cohort 2|Subjects will be administered 40 mg simvastatin on day 1 followed by a washout period of two days. From day 3, the subjects will receive 50 mg of SB-656933-AAA once daily or matching placebo once daily for 14 days. On day 17, subjects will be administered 40 mg simvastatin along with SB-656933-AAA to assess statin interaction.
62726107|NCT00504439|EXPERIMENTAL|Cohort 3|Subjects will be administered 100 mg SB-656933-AAA/ day or matching placebo for 14 days. Dosing will initiate after cohort I and II have completed dosing.
62726108|NCT02389465|NO_INTERVENTION|Control|This arm is for participants who are not depressed.
62726109|NCT02389465|EXPERIMENTAL|Experimental - treatment|Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.
62726110|NCT03007420|EXPERIMENTAL|Occipital Nerve Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a \> or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit \< 50% pain reduction, the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
62726111|NCT03007420|EXPERIMENTAL|Cervical Medial Branch Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a \> or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit \< 50% pain reduction the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
61978231|NCT05527145|ACTIVE_COMPARATOR|percutaneous|percutaneous non-surgical insertion of interspinous device
62726112|NCT06295900|ACTIVE_COMPARATOR|Intervention 1 Group|In this group, application is made with chamomile, lavender and neroli oil.
62726113|NCT06295900|SHAM_COMPARATOR|Intervention 2 Group|In this group, application is made with lavender oil.
62726114|NCT06295900|PLACEBO_COMPARATOR|Placebo Control Group|In this group, application is made only with almond oil.
62726115|NCT04133025|ACTIVE_COMPARATOR|Conventional vestibular rehabilitation|Conventional vestibular rehabilitation
62726116|NCT04133025|ACTIVE_COMPARATOR|Vestibular rehabilitation with software|
62726117|NCT04906031|EXPERIMENTAL|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
62726118|NCT01266889||study group, control group|
62726119|NCT05320484|EXPERIMENTAL|clinical pilates exercises|clinical pilates exercises applied to 1st group,for 3 days / week for 6 weeks.
62726120|NCT05320484|OTHER|classical posture exercises|classical postural exercises applied to 2 nd group,for 3 days / week for 6 weeks.
62726121|NCT01745653|EXPERIMENTAL|Low level laser therapy|Low level laser (970nm) will be delivered on the mucous membrane in regard to the first molar teeth on which rings of the quadhelix have been settled.
62726122|NCT01745653|SHAM_COMPARATOR|sham procedure|Same procedure than experimental arm except that the laser is not activated.
62726123|NCT01745653|NO_INTERVENTION|no intervention|no intervention : Patient received the quadhelix with nothing else
62726124|NCT06094309|ACTIVE_COMPARATOR|Active Comparator: botulinum toxin|The botulinum toxin injection will be carried out by a doctor with experience in this therapeutic modality, which in turn is not part of the group of doctors who observe patients in the initial and subsequent phases. 100 Units (U) of botulinum toxin type A, in each lower limb (200 U in total), in muscle proximal thigh, once, at a moment that will be defined as T0. This group of 10 participans.
62726125|NCT06094309|PLACEBO_COMPARATOR|Active Comparator: Placebo|In the control group, patients will be subject to the same protocol, with the difference in that the injections will be saline, although they look the same on the outside. You doctors carrying out therapy and evaluating progress during face-to-face visits will not have access to the distribution of groups. This group of 10 participans.
62726126|NCT00437268|EXPERIMENTAL|enzastaurin + irinotecan + cetuximab|
62726127|NCT00437268|ACTIVE_COMPARATOR|irinotecan + cetuximab|
62726128|NCT05619120|EXPERIMENTAL|Giant T-wave electrical alternans conventional plus mexiletine therapy|It is proposed that patients presenting with giant TWA-triggered VT/VF patients to be randomized to conventional treatment and conventional plus mexiletine treatment, respectively.
62726129|NCT05619120|ACTIVE_COMPARATOR|Giant T-wave electrical alternans conventional therapy|Conventional treatment in the control group according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
62726130|NCT00835289|PLACEBO_COMPARATOR|Placebo (corn oil)|Each participant will be taking 3 capsules of a matching placebo (corn oil).
62726131|NCT00835289|EXPERIMENTAL|PUFA (Omax3)|Omax3\[TM\] (Cenestra Health), or dietary supplement: n-3 polyunsaturated fatty acids, is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3\[TM\].
62726132|NCT03339310|EXPERIMENTAL|Optimizer Smart System with 2-leads|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
62726133|NCT04245709|EXPERIMENTAL|Open label Arm|This is an open label pilot trial in which 25 people with ALS will take clenbuterol orally at 40-80 micrograms twice daily for 24 weeks.
62726134|NCT04945525|EXPERIMENTAL|Care Continuity Program + Education|Participating clinics (and their prescribers and patients) will be randomly selected to implement the Care Continuity Program (CCP) intervention, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients will receive welcome letters and be required to complete CCP self-assessments before each appointment. Prescribers will begin using the generated CCP summary page at each appointment to help make decisions about initiating or maintaining an opioid prescription for an individual patient.
62726135|NCT04945525|NO_INTERVENTION|Education Alone|Participating clinics (and their prescribers and patients) will be randomly selected to the control group, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients and prescribers will continue treatment as usual in their clinic.
62726136|NCT00915889|ACTIVE_COMPARATOR|Group I|Patients receive a survivorship booklet in the mail that contains information about cervical cancer. Patients then receive a follow-up telephone call at 3 months to clarify any issues relevant to the survivorship booklet.
62726137|NCT00915889|EXPERIMENTAL|Group II|Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
62726138|NCT05500651|EXPERIMENTAL|Experimental group|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
62726139|NCT05500651|NO_INTERVENTION|Control group|
62726140|NCT03954912|ACTIVE_COMPARATOR|MAKO robotic assisted UKA|image base (MAKO) robotic assisted UKA
62726141|NCT03954912|ACTIVE_COMPARATOR|NAVIO robotic assisted UKA|imageless (NAVIO) robotic assisted UKA
62726142|NCT02082964|EXPERIMENTAL|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
62726143|NCT02082964|EXPERIMENTAL|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course.
62726144|NCT03982017|ACTIVE_COMPARATOR|Usual care|Consists of routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
62726145|NCT03982017|EXPERIMENTAL|Application|Participants will be provided a special link to navigate to the online content and resources.
62726146|NCT05675826||Donor infected with covid19|This includes donors who have been infected or are infected with COVID19 at the time of hematopoietic stem cell collection.
62726147|NCT05675826||Donor not infected with covid|Including donors not yet infected with COVID19 at the time of hematopoietic stem cell collection.
62726148|NCT05812352|EXPERIMENTAL|"Audio recording and instructional flashcard with tourniquet (audio kit) - 6 month follow-up"|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application, used for tourniquet application attempt. Participants repeat the tourniquet application attempt with the audio kit at 6 month follow-up
62726149|NCT05812352|EXPERIMENTAL|Instructional flashcard with tourniquet - 6 month follow-up|Instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application, used for tourniquet application attempt. Participants repeat the tourniquet application attempt with the instructional flashcard at 6 month follow-up
62726150|NCT05812352|EXPERIMENTAL|In-person training with tourniquet - 6 month follow-up|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt. Participants repeat the tourniquet application attempt without any POC instruction or re-training at 6 month follow-up
62726151|NCT05812352|NO_INTERVENTION|Control group with no in-person training and no point-of-care instruction access - 6 month follow-up|There is no in-person training or point-of-care (POC) instructional interventions for this group for tourniquet application attempt. Participants repeat the tourniquet application attempt without any in-person training or POC instructional interventions at 6 month follow-up
62726152|NCT04347343|EXPERIMENTAL|COMBO|Neuromuscular Electrical Stimulation and Blood Flow Restriction (COMBO) in addition to standard postoperative rehabilitation.
62726153|NCT04095702|EXPERIMENTAL|Weighted Pacifier|Patient will receive a weighted pacifier for 48 hours of their stay in the NICU.
62726154|NCT04095702|PLACEBO_COMPARATOR|Non-Weighted Pacifier|Patient will receive a standard non-weighted pacifier for 48 hours of their stay in the NICU.
62726155|NCT06515015|EXPERIMENTAL|Experimental Group|All subjects will be assigned to the treatment group to receive the endobronchial silicon spigot treatment.
62726156|NCT06160596||PDAC STAGE IV SURVIVORS & CONTROLS|Metastatic pancreatic ductal adenocarcinoma (PDAC) (Other histologies such as adenosquamous carcinoma, hepatoid carcinoma, anaplastic undifferentiated carcinoma and medullary carcinoma, acinar cell carcinoma, neuroendocrine tumors, Solid pseudopapillary neoplasm, Pancreatoblastoma, Serous cystadenocarcinoma are excluded)
62726157|NCT06160596||SMALL CELL LUNG CANCER EXTENSIVE STAGE SURVIVORS & CONTROLS|Extensive small cell lung cancer (SCLC) (Other histologies excluded: combined SCLC with some areas of non-small cell lung cancer (NSCLC), carcinoid tumors, typical and atypical, large cell neuroendocrine carcinoma of the lung).
62726158|NCT06160596||GLIOBLASTOMA SURVIVORS & CONTROLS|Glioblastoma (GBM) (IDH mutated excluded)
62726159|NCT01673659|EXPERIMENTAL|Test product|Mometasone furoate 50 mcg/actuation Nasal Spray
62726160|NCT01673659|ACTIVE_COMPARATOR|Reference product|Nasonex Nasal Spray
62726161|NCT01673659|PLACEBO_COMPARATOR|Placebo Nasal Spray|vehicle of the test product
62726162|NCT02014805|EXPERIMENTAL|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
62726163|NCT02014805|NO_INTERVENTION|observation|no treatment after radical resection for thymoma
62726164|NCT00459641|EXPERIMENTAL|1|I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
62726165|NCT00459641|ACTIVE_COMPARATOR|2|Standard of care (bone marrow aspirate or steroids)
62726166|NCT06512779|SHAM_COMPARATOR|Control Group|Participants who are unwilling to undergo surgery, use a mandibular advancement device, utilize continuous positive airway pressure (CPAP) devices, or undergo oropharyngeal training. They will receive sleep hygiene education.
62726167|NCT06512779|EXPERIMENTAL|Surgical Intervention|Remove excessive soft tissue from the base of the tongue, soft palate, and/or tonsil.
62726168|NCT06512779|EXPERIMENTAL|Oropharyngeal Training (face-to-face)|Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
62726169|NCT06512779|EXPERIMENTAL|Oropharyngeal Training (telerehabilitation )|Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
62726170|NCT06512779|EXPERIMENTAL|Continuous Positive Airway Pressure|Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
62726171|NCT01330095|ACTIVE_COMPARATOR|Eearly administration|Administration of Bifidobacterium within 48h after birth
62726172|NCT01330095|ACTIVE_COMPARATOR|Late administration|Administration of Bifidobacterium more than 48h after birth
62726173|NCT02391324|EXPERIMENTAL|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
62726174|NCT02391324|EXPERIMENTAL|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
62726175|NCT02391324|EXPERIMENTAL|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
62726176|NCT02391324|NO_INTERVENTION|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
62726177|NCT02546726|EXPERIMENTAL|Heat & Aerobic Training (HEAT) Condition|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the HEAT condition will be asked to sit quietly on the bench in the steam-room within their same-sex locker room for no more than 20 minutes. They will start at 11 minutes to get acclimated to the mild heat stress, and gradually work up to 20 minutes. A trained research staff member will be stationed outside the room.
61978232|NCT04975360|EXPERIMENTAL|Caffeine|Administration of a time-controlled, pulsatile-release caffeine formulation (160 mg caffeine) at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
62726178|NCT02546726|ACTIVE_COMPARATOR|Exercise Only|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the Exercise Only condition will be asked to sit quietly on the bench in the lobby of the fitness facility, initially for 11 minutes and then gradually working up to 20 minutes.
62726179|NCT06071598||CRC|CRC-affected patients stratified according to tumor stage (T0/T1-T4, M0/M1, N0/N1/N2)
62726180|NCT04665804|EXPERIMENTAL|Experimental Group A (Creatine Supplementation)|
62726181|NCT04665804|EXPERIMENTAL|Experimental Group B (Glucosamine and Chondroitin sulfate Supplementation)|
62726182|NCT01905189|EXPERIMENTAL|Hemodynamic study, cardiac pacing|We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.
62726183|NCT00661830|EXPERIMENTAL|1|Gemcitabine + Sorafenib
62726184|NCT00661830|PLACEBO_COMPARATOR|2|Gemcitabine + Placebo
62726185|NCT03619993|EXPERIMENTAL|Arm A: Start with On-body injector|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)
62726186|NCT03619993|EXPERIMENTAL|Arm B: Start with pre-filled syringe|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)
62726187|NCT02980757|ACTIVE_COMPARATOR|Gliclazide 120 mg MR Tablets Formula A|Single oral dose of one tablet containing 120 mg gliclazide
62726188|NCT02980757|ACTIVE_COMPARATOR|Gliclazide 120 mg MR Tablets Formula B|Single oral dose of one tablet containing 120 mg gliclazide
62726189|NCT02980757|ACTIVE_COMPARATOR|DIAMICRON MR® 60 mg x 2|Two x oral dose of one tablet containing 60 mg gliclazide
62726190|NCT00503425|EXPERIMENTAL|1|
62726191|NCT03456219|EXPERIMENTAL|Shift workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the normal protein diet.
62726192|NCT03456219|EXPERIMENTAL|Night workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the high-protein diet.
62726193|NCT04731896|NO_INTERVENTION|Late Amniotomy|Initiating induction of labor with oxytocin infusion followed by amniotomy 4-6 hours later
62726194|NCT04731896|ACTIVE_COMPARATOR|Early Amniotomy|Early amniotomy initiating induction of labor followed by oxytocin infusion 30 minutes later
62726195|NCT03463837|EXPERIMENTAL|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%,Virginia Tobacco \[5 days\] in confinement.
62726196|NCT03463837|EXPERIMENTAL|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, Cool Mint \[5 days\] in confinement.
62726197|NCT03463837|EXPERIMENTAL|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, Mango \[5 days\] in confinement.
62726198|NCT03463837|EXPERIMENTAL|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, Creme Bruele \[5 days\] in confinement.
62726199|NCT03463837|ACTIVE_COMPARATOR|Combustible cigarette|Exclusive use of combustible cigarette \[5 days\] in confinement.
62726200|NCT03463837|SHAM_COMPARATOR|Smoking cessation (no smoking)|Smoking cessation (no smoking).
62726201|NCT02358993|EXPERIMENTAL|Methenamine|Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
62726202|NCT02358993|ACTIVE_COMPARATOR|Ciprofloxacin|Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
62726203|NCT00355368|ACTIVE_COMPARATOR|Succinylcholine|
62726204|NCT00355368|ACTIVE_COMPARATOR|Rocuronium|
62726205|NCT01963767|EXPERIMENTAL|NT-020|Participants received two pills of NT-020 plus Biovin (900 mg proprietary formulation of blueberry, carnosine, green tea, plus 200 U Vitamin D3, 40 mg Biovin), with one to be taken in the morning and the other in the evening.
62726206|NCT01963767|PLACEBO_COMPARATOR|Placebo|Subjects took two pills, one in the morning and one in the evening, that were matched in size and shape to the active compound.
62726207|NCT01194245|EXPERIMENTAL|Lispro-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
62726208|NCT01194245|EXPERIMENTAL|Aspart-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
62726209|NCT00400855|EXPERIMENTAL|Arm 1|study drug
62726210|NCT06000488|NO_INTERVENTION|Control|No intervention
62726211|NCT06000488|EXPERIMENTAL|Reflective Writing Workshop Sessions (RWW)|Participants will participate in three 75-minute RWW sessions scheduled to take place after students finish their 1st, 3rd, and 5th clinical rotations during the study period. reflective writing workshops
62726212|NCT05939752||patient|Patients with an indication for ibrutinib treatment for hematologic reasons
62726213|NCT03448016|EXPERIMENTAL|Alcohol use disorders|\[C-11\]NOP-1A PET Scan
62726214|NCT03448016|EXPERIMENTAL|Controls|\[C-11\]NOP-1A PET Scan
62726215|NCT03667313|EXPERIMENTAL|sirolimus-eluting balloon (SEB)|treatment of bare-metal (BMS) or drug-eluting in-stent restenosis (DES-ISR) with SEB
62726216|NCT03667313|ACTIVE_COMPARATOR|paclitaxel-eluting balloon (PEB)|treatment of BMS- or DES-ISR with PEB
62726217|NCT04619667|ACTIVE_COMPARATOR|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher \& Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
62726218|NCT04619667|ACTIVE_COMPARATOR|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
62726219|NCT04619667|ACTIVE_COMPARATOR|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
62726220|NCT04961138|EXPERIMENTAL|Neoadjuvant group|
62726221|NCT04961138|ACTIVE_COMPARATOR|Surgery group|
62726222|NCT06028698|EXPERIMENTAL|Positive emotion music fatigue group|After mental fatigue inducement, participants will be instructed listening to music pieces for inducing positive emotion music.
62726223|NCT06028698|PLACEBO_COMPARATOR|Fatigue control group|After mental fatigue inducement, participants will be instructed to sit and relax for the same duration as intervention group.
62726224|NCT06028698|PLACEBO_COMPARATOR|No Fatigue positive emotion music group|participants will not be induced mental fatigue, but will be instructed listening to music pieces for inducing positive emotion music.
62726225|NCT06028698|NO_INTERVENTION|No fatigue control group|participants will not be induced mental fatigue. Also, participants will not receive music intervention，just sit and relax.
62726226|NCT04576910|EXPERIMENTAL|"Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
62726227|NCT04576910|EXPERIMENTAL|"Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
62726228|NCT04576910|EXPERIMENTAL|"Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
62726229|NCT04576910|EXPERIMENTAL|"Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
61978233|NCT04975360|PLACEBO_COMPARATOR|Placebo|Administration of a placebo formulation at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
62165973|NCT04010981|EXPERIMENTAL|study grup-Virtual reality- Nintendo Wii Fit exercise group|in this group patients will complete 12 sessions of virtual reality exercise - Nintendo Wii Fit Plus, 30-minute training sessions with strengthening exercises for the lower extremities and upper extremities, aerobic and balance exercises, two days a week. They will do 5 minute warm-up exercises before stretching, stretching exercises and 5 minute cooling exercises at the end of the session, as well as breathing exercises and will attend a total of 50 minutes of treatment.
62726230|NCT04576910|EXPERIMENTAL|"Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
62726231|NCT01825330|ACTIVE_COMPARATOR|NeuroAD|NeuroAD treatment, synchronized TMS and cognitive training stimulation
62726232|NCT01825330|SHAM_COMPARATOR|Sham TMS+Cog|Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
62726233|NCT03768089|PLACEBO_COMPARATOR|Part A: Pooled Placebo (Cohorts A1-5; Except A3)|Participants received single dose of placebo matched to VX-121.
62726234|NCT03768089|EXPERIMENTAL|Part A: VX-121 (Cohort A1)|Participants received single dose of VX-121 10 milligrams (mg).
62726235|NCT03768089|EXPERIMENTAL|Part A: VX-121 (Cohort A2)|Participants received single dose of VX-121 20 mg.
62726236|NCT03768089|EXPERIMENTAL|Part A: VX-121 (Cohort A3)|Participants received single dose of VX-121 5 mg or matched placebo without milk, followed by open label VX-121 5 mg with milk.
62726237|NCT03768089|EXPERIMENTAL|Part A: VX-121 (Cohort A4)|Participants received single dose of VX-121 40 mg.
62726238|NCT03768089|EXPERIMENTAL|Part A: VX-121 (Cohort A5)|Participants received single dose of VX-121 60 mg.
61978234|NCT00003644|EXPERIMENTAL|Carboplatin, paclitaxel, low dose paclitaxel|carboplatin, paclitaxel followed by low dose paclitaxel 4 weeks later
61978235|NCT00003644|ACTIVE_COMPARATOR|Carboplatin, paclitaxel|carboplatin, paclitaxel
61978236|NCT03999450|EXPERIMENTAL|Behavioral intervention|Patients admitted to Strong Hospital with opioid use will be given 1 to 3 brief motivational interventions and computer based cognitive behavioral therapy
61978237|NCT02746016|EXPERIMENTAL|Infant Formula supplemented with Oligosaccharides|Ready to feed infant formula ; Feed ad libitum.
61978238|NCT01335581|EXPERIMENTAL|Laser treatment|Laser treatment and microdermabrasion and topical lightening agent regimen
62726239|NCT03768089|EXPERIMENTAL|Part A: VX-121 (Cohort A9)|Participants received single dose of VX-121 10 mg suspension on Day 1, VX-121 10 mg tablet on Day 9, followed by VX-121 10 mg tablet with milk on Day 17.
62726240|NCT03768089|PLACEBO_COMPARATOR|Part B: Pooled Placebo (Cohorts B1-4)|Participants received placebo matched to VX-121 for 10 days.
62726241|NCT03768089|EXPERIMENTAL|Part B: VX-121 (Cohort B1)|Participants received VX-121 10 mg once daily (qd) for 10 days.
62726242|NCT03768089|EXPERIMENTAL|Part B: VX-121 (Cohort B2)|Participants received VX-121 20 mg qd for 10 days.
62726243|NCT03768089|EXPERIMENTAL|Part B: VX-121 (Cohort B3)|Participants received VX-121 40 mg qd for 10 days.
62726244|NCT03768089|EXPERIMENTAL|Part B: VX-121 (Cohort B4)|Participants received VX-121 60 mg qd for 10 days.
62726245|NCT03768089|PLACEBO_COMPARATOR|Part C: Pooled Placebo (Cohorts C1-3)|Participants received placebo matched to VX-121/TEZ/IVA for 14 days.
62726246|NCT03768089|EXPERIMENTAL|Part C: VX-121 (Cohort C1)|Participants received VX-121 10 mg qd/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) for 14 days.
62726247|NCT03768089|EXPERIMENTAL|Part C: VX-121 (Cohort C2)|Participants received VX-121 20 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.
62726248|NCT03768089|EXPERIMENTAL|Part C: VX-121 (Cohort C3)|Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.
62726249|NCT03768089|PLACEBO_COMPARATOR|Part D: Placebo|Participants received placebo matched to VX-121/TEZ/IVA for 4 weeks.
62726250|NCT03768089|EXPERIMENTAL|Part D: VX-121/TEZ/IVA|Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks.
62726251|NCT01219101|EXPERIMENTAL|clomiphene citrate and ethinyl estradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
62726252|NCT01219101|ACTIVE_COMPARATOR|clomiphene citrate and placebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
62726253|NCT02390492|EXPERIMENTAL|Ipatasertib/[14C]-ipatasertib|
62726254|NCT04244071|ACTIVE_COMPARATOR|Group C|"Usual care (Group C): The patients in this group received routine hospital care.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
62726255|NCT04244071|EXPERIMENTAL|Group A|"The patients in Group A were warmed up using a gown blowing warm air starting at least 30 min prior to the surgery until they were anesthetized.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
62726256|NCT04244071|EXPERIMENTAL|Group B|"Routine care was provided for the patients in Group B in the preoperative and intraoperative periods. In the postoperative period, patients were warmed up using a gown blowing warm air after they were transferred to the post-anesthesia care unit, and continued to be warmed up on the basis of the temperature set by themselves until they wore their own clothes in the ward.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
61978239|NCT01335581|ACTIVE_COMPARATOR|Control|Microdermabrasion and topical lightening agent regimen
61978240|NCT06413342|EXPERIMENTAL|Sintilimab group|Patients in treatment group receive sintilimab (for patients with a weight \<60 kg: 3 mg/kg IV on Day 1 every 3 weeks; for patients with a weight ≥60 kg: 200 mg IV on Day 1 every 3 weeks) .
61978241|NCT06413342|NO_INTERVENTION|Observation group|Patients in the observation group receive regular follow-up and observation.
62726257|NCT00251693|EXPERIMENTAL|Dexlansoprazole MR 60 mg QD|
62726258|NCT00251693|EXPERIMENTAL|Dexlansoprazole MR 90 mg QD|
62726259|NCT00251693|ACTIVE_COMPARATOR|Lansoprazole 30 mg QD|
62726260|NCT04074226|EXPERIMENTAL|Ultrasound-guided ESP block with liposomal bupivacaine|For the ESP block, the transducer will be placed parasagittally at the level of the tip of the scapula and the anesthesiologist will scan in a craniocaudal manner to identify the ipsilateral T10 transverse process and overlying erector spinae muscle. Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the muscle and transverse process. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site.
62726261|NCT04074226|ACTIVE_COMPARATOR|Ultrasound-guided QL block with liposomal bupivacaine|"For the QL block, the transducer will be placed transversely over the lumbar spine at the level of the iliac crest. Then, the anesthesiologist will scan laterally to identify the ipsilateral L3 transverse process, psoas muscle, and quadratus lumborum muscle to identify the Shamrock Sign (7). Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the quadratus lumborum muscle and psoas muscle. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the two muscles. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site."
62726262|NCT04276194|EXPERIMENTAL|Treatment (intensity modulated proton therapy)|Patients undergo intensity modulated proton therapy once daily over 30 fractions and also undergo MRI over 20 minutes during fractions 7, 13, 20, and 30 of radiation in the absence of disease progression or unacceptable toxicity.
62726263|NCT01447745||Observational, longitudinal study|Adult men and women representative of the population of asymptomatic adult men and women aged from 35-65 years living in the Québec City metropolitan area
62726264|NCT05406128|ACTIVE_COMPARATOR|preoperative group|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
62726265|NCT05406128|ACTIVE_COMPARATOR|intraoperative group|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
62726266|NCT03432494|EXPERIMENTAL|Transcaval access and closure with the transcaval closure device (TCD) test article.|All participants undergo transcaval access for transcatheter aortic valve replacement (TAVR) followed by implantation of the transcaval closure device (TCD).
62726267|NCT05644717|EXPERIMENTAL|Ertugliflozin|Ertugliflozin 5/15mg once daily with standard of care
62726268|NCT05011175||Individuals with Parkinson's Disease|Individuals that have been diagnosed with Parkinson's Disease will be enrolled to participant in the survey research.
62726269|NCT00310375|EXPERIMENTAL|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets - 50mg, 100mg or 300mg
62726270|NCT02661152|EXPERIMENTAL|Radio-/Chemoradiotherapy + nimorazole|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole but receiving the drug, which is normal standard radiotherapy of HNSCC in Denmark.
62726271|NCT02661152|NO_INTERVENTION|Radio-/Chemoradiotherapy|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole and not receiving the drug, that is normally part of standard radiotherapy of HNSCC in Denmark.
62726272|NCT02989116|EXPERIMENTAL|Preterm Inhibition|"In children born very preterm:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
62726273|NCT02989116|EXPERIMENTAL|Full-term Inhibition|"In children born full-term:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
62726274|NCT02989116|EXPERIMENTAL|Full-term Working memory|"In children born full-term:~Working memory training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
62726275|NCT02989116|EXPERIMENTAL|Full-term Mindfulness|"In children born full-term:~Mindfulness training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
62726276|NCT02989116|ACTIVE_COMPARATOR|Full-term Active control|"In children born full-term:~Active control training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
62726277|NCT02855658|EXPERIMENTAL|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
62726278|NCT02855658|PLACEBO_COMPARATOR|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
62726279|NCT03569358|EXPERIMENTAL|Virtual Reality and EEG Interventions|In the interventional arm, 20 subjects will receive twice daily sessions of immersive virtual reality for a maximum of 15 minutes, with EEG headband recording starting 5 minutes prior to and 5 minutes after the intervention, for a maximum of 4 consecutive days.
62726280|NCT03569358|ACTIVE_COMPARATOR|EEG Intervention group|In the control arm, 10 subjects would have EEG recorded for 25 mins twice daily, with a minimum of 4 hours intervening, for 3 consecutive days, with the EEG headband. There would be no immersive virtual reality sessions.
62726281|NCT03569358|ACTIVE_COMPARATOR|Healthy Volunteers|At the completion of the above intensive care study recruitment, demographic data of the interventional immersive virtual reality arm would analysed to recuit 10 age-matched healthy volunteers with no known cognitive disorders or visual impairment. This is to compare study data with healthy controls. A 25 minute session consisting of 15 minutes of immersive virtual reality and 5 minutes of EEG recording with the EEG headband before and after the intervention would be performed. Eye-tracking and EEG data from these groups of patients would be compared against subjects in both arms of the study performed in the intensive care unit to investigate for exploratory differences.
62726282|NCT02708316||schizophrenia group|schizophrenia patients in the group
62726283|NCT02708316||control group|healthy population
62726284|NCT00794846|EXPERIMENTAL|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62726285|NCT00794846|EXPERIMENTAL|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
62726286|NCT00792090|EXPERIMENTAL|1|Fermented milk
62726287|NCT00792090|ACTIVE_COMPARATOR|2|Standard milk
62726288|NCT02819531|ACTIVE_COMPARATOR|Rotational atherectomy|RA protocol: After IVUS protocol, patients who are randomized to RA will undergo coronary wiring of the target lesion and subsequent advancement of the RA burr. The RA system is performed using standard technique under intravenous infusion of heparin. The atherectomy burr size will be determined by the operator.
62726289|NCT02819531|ACTIVE_COMPARATOR|Orbital atherectomy|OAS protocol: After IVUS protocol, patients who are randomized to OAS will undergo coronary wiring of the target lesion and subsequent advancement of the OAS according to the manufacturer's guidelines.
62726290|NCT02819531|ACTIVE_COMPARATOR|Scoring balloon system|SBS protocol: After IVUS protocol, patients who are randomized to SBS will undergo coronary wiring of the target lesion and balloon inflation with SBS performed by standard technique under intravenous infusion of heparin. SBS will be used according to the manufacturer's guidelines.
62726291|NCT02988726|EXPERIMENTAL|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
62726292|NCT01770405||pancreatic cysts|Patient indicated for a first endoscopic ultrasound fine needle aspiration (EUS-FNA) for a pancreatic cyst,
62726293|NCT04758481|EXPERIMENTAL|Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy|The patients, in whom disease stabilisation/partial regression will be achieved, will undergo primary tumour radiotherapy and stereotactic body radiotherapy, followed with maintenance radiotherapy.
62726294|NCT01179269|EXPERIMENTAL|Pazopanib plus Paclitaxel|Pazopanib daily and weekly Paclitaxel IV.
62726295|NCT02348580|NO_INTERVENTION|Treatment as usual|Schools in which regular curriculum is delivered and teachers do not receive any additional training in child centered methodologies.
62726296|NCT02348580|EXPERIMENTAL|Child centered teaching of life-skills|Training of teachers and weekly implementation of hour long sessions based on child centered teaching of life-skills education over the course of the school year in P6 and S3 classes as designed by Aflatoun Stichting Child Savings International and the Association of Microfinance Institutions in Rwanda (AMIR). The life-skills curriculum is known as Aflatoun's Child Social and Financial Education program. The training of teachers element of the intervention is known as Aflatoun Academy, which trains teachers in active learning, child centered methodologies as well as how to implement the life-skills curriculum of Aflatoun Child Social and Financial Education.
62726297|NCT01842373|EXPERIMENTAL|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
62726298|NCT01842373|ACTIVE_COMPARATOR|BLT|3 g of BLT will be applied to half of face for 60 minutes
62726299|NCT01515579|EXPERIMENTAL|Formulation 3|
62726300|NCT01515579|EXPERIMENTAL|Formulation 4|
62726301|NCT00003846|EXPERIMENTAL|Treatment|See detailed description.
62726302|NCT05607602||1|Women with uterine fibroids, not requiring any medical or surgical treatment.
62726303|NCT05607602||1a|Women with uterine fibroids undergoing myomectomy or hysterectomy for uterine fibroids
62726304|NCT05607602||Group 2|Women with no uterine fibroids or uterine pathology on ultrasound scan
62726305|NCT06418737|EXPERIMENTAL|Sleep Training Group:|Sleep Intervention: A 60-minute sleep hygiene education session will be delivered to the participants by an expert with experience in providing education in the areas of sports and sleep. Subsequently, interventions will be implemented to improve the sleep environments of the athletes who are staying at the facility
62726306|NCT06418737|NO_INTERVENTION|Control Group|"No training will be provided If offered by the control group participants, sleep hygiene training will be given after all the data collected from the Sleep Training Group"
62726307|NCT00364650|PLACEBO_COMPARATOR|I|Placebo
62726308|NCT00364650|EXPERIMENTAL|II|Probiotic supplement
62726309|NCT03542019|ACTIVE_COMPARATOR|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
62726310|NCT03542019|ACTIVE_COMPARATOR|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
62726311|NCT03542019|ACTIVE_COMPARATOR|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
62726312|NCT05842486||Real-world cohort|The real-world cohort consists of patients with diagnosis of paroxysmal nocturnal hemoglobinuria and anemia initiating anti-C5 therapy.
62726313|NCT02682459|EXPERIMENTAL|Lisinopril|Patients will receive, in addition to standard immunosuppressive therapy, lisinopril starting with 5 mg/day, then progressively up-titrated to reach the maximum tolerable dose (target dose) for 18 months.
62726314|NCT02682459|NO_INTERVENTION|No intervention|Patients will receive only the standard immunosuppressive therapy.
62726315|NCT03367169|ACTIVE_COMPARATOR|minimally invasive method|The patients are treated with minimally invasive method
62726316|NCT03367169|ACTIVE_COMPARATOR|open reduction method|The patients are treated with open reduction method
62726317|NCT01853462|EXPERIMENTAL|Proprioceptive Neuromuscular Facilitation (PNF)|Supervised PNF training
62726318|NCT01853462|EXPERIMENTAL|Balance|Supervised balance training
62726319|NCT02088853|EXPERIMENTAL|high fat diet|
62726320|NCT02088853|ACTIVE_COMPARATOR|high carb diet|
62726321|NCT01518790|EXPERIMENTAL|Polyethylene glycol 3350|
62726322|NCT00343564|EXPERIMENTAL|Phase 1 Dose Escalation|Phase 1 dose escalation without and with GCSF support
62726323|NCT00343564|EXPERIMENTAL|Phase 2 Fixed Dose|Phase 2 fixed dose based on Phase I findings stratified by NHL type
62726324|NCT05679349|EXPERIMENTAL|Group A (Providers): (survey, online educational activity)|Participants complete survey on study. Participants undergo online educational activity on study. Participants undergo distance learning on study.
62726325|NCT05679349|ACTIVE_COMPARATOR|Group B (Providers): (survey)|Participants complete survey at baseline and end of study survey.
62726326|NCT05679349|EXPERIMENTAL|Group A (Patients): (EHR, educational activity, counseling))|Patients undergo EHR review on study. Patients undergo educational activity on study. Patients also undergo SDM counseling once on study.
62726327|NCT05679349|ACTIVE_COMPARATOR|Group B (Patients): (survey)|Patients undergo EHR review on study and complete telephone survey throughout the trial.
62726328|NCT01242631|EXPERIMENTAL|Everolimus 10 mg daily|
62726329|NCT02253082|ACTIVE_COMPARATOR|OctaplasLG®|replacement to bleeding
62726330|NCT02253082|PLACEBO_COMPARATOR|Standard fresh frozen plasma|replacement to bleeding
62726331|NCT03159975|EXPERIMENTAL|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
62726332|NCT03159975|EXPERIMENTAL|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
62726333|NCT03159975|EXPERIMENTAL|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
62726334|NCT00763256|ACTIVE_COMPARATOR|A|
62726335|NCT00763256|PLACEBO_COMPARATOR|B|
62726336|NCT01352208|EXPERIMENTAL|ASP9521|
62726337|NCT05115565|NO_INTERVENTION|Control group|When the patients are admitted to the clinic, the patient identification form and the SF-36 Quality of Life Scale will be filled by face-to-face interview method. On the morning of the operation, before the operation, the GCS, EHA and WOMAC index will be filled. After the operation, the pain during rest and movement (24., 48., 72., 96. hours and 15. days) will be evaluated with VAS. The total amount of analgesics used by the patients will be recorded by looking at the nurse observation form records where the nurses recorded the drugs they administered at the 24th, 48th, 72nd, and 96th hours after the surgery, and by asking the patients on the 15th day after discharge. The WOMAC Index will be re-administered at discharge and on the 15th day, and the VCS, ROM, and the SF-36 Quality of Life Scale on the 15th day.
62726338|NCT05115565|EXPERIMENTAL|Intervention group|Unlike the control group, the patients in the intervention group will be informed about TENS and the application will be made. The electrodes of TENS will be placed 2 cm below and 2 cm above the incision site. TENS settings Frequency: 100 Hz; Pulse width (duration): 150 μs; Flow Intensity (Amplitude): By adjusting it to be 30 mA, TENS will be applied 3 times a day (09.00, 13.00, 17.00) for 20 minutes during the time the patients stay in the clinic (3 days).It is planned to start the TENS application the day after the surgery.
62726339|NCT01964378|EXPERIMENTAL|Cebranopadol|Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.
62726340|NCT01964378|ACTIVE_COMPARATOR|Morphine Prolonged Release|Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
62726341|NCT05123989|EXPERIMENTAL|Personalized move goals|Participants will be sent daily messages in the Welltory mobile app with personalized move goals that are based on each participant's historical physical activity data and their daily wellbeing
62726342|NCT05123989|ACTIVE_COMPARATOR|Constant move goals|Participants will be sent daily messages in the Welltory mobile app with a static move goal of 10,000 steps per day
62726343|NCT05123989|NO_INTERVENTION|No intervention|Participants will not be sent any messages with move goals in the Welltory mobile app
62726344|NCT00120627|EXPERIMENTAL|Arm 1: Mantram + Usual Care|Mantram Repetition Program for PTSD delivered in this study as 6-week, 90-minute per week that targeted PTSD symptoms. It was offered as an adjunct to usual care consisting of medication and case-management.
62726345|NCT00120627|ACTIVE_COMPARATOR|Arm 2: Usual Care alone|Usual care alone is defined as receiving 6 weeks of medication and case management, as needed by each patient. No group meetings.
62726346|NCT04754269|EXPERIMENTAL|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children. Parents will receive that reinforce and expand on the messages in the video.
62726347|NCT04754269|EXPERIMENTAL|Reading Intervention|Parents will watch a video that promotes reading to children. Parents will receive text messages that reinforce and expand on the messages in the video.
62726348|NCT03036852|EXPERIMENTAL|SOF/VEL|SOF/VEL for 12 weeks
62726349|NCT01786681|EXPERIMENTAL|Positive pressure before surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour before bariatric surgery.
62726350|NCT01786681|EXPERIMENTAL|Positive pressure during the surgery|Individuals treated with 10 cm H2O of PEEP (Positive End Expiratory Pressure) during the surgical procedure.
62726351|NCT01786681|EXPERIMENTAL|Positive pressure after surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour after bariatric surgery.
62726352|NCT01786681|NO_INTERVENTION|Control|Individuals treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
62726353|NCT04684212|EXPERIMENTAL|Device Arm|The LAmbre PlusTM Left Atrial Appendage Closure System (LAmbre device)
62726354|NCT04684212|ACTIVE_COMPARATOR|Control Arm|Market approved oral anticoagulation (OAC)
62726355|NCT04684212|OTHER|Roll-in Arm|225 roll-in subjects
62726356|NCT03019757||Alzheimer's disease|Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
62726357|NCT03019757||Lewy Body dementia|Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
62726358|NCT03019757||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
62726359|NCT04466384|OTHER|Propofol|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Propofol will be started at a concentration of 0.5 µg/ml followed by incremental increases in the target effect-site concentrations of 1.5, 2, 2.5, 3, 4, 6, and 8 µg/ml until a MOAA/S score less than 2 is reached.
62726360|NCT04466384|OTHER|Propofol with Remifentanil|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Approximately 2 minutes before starting propofol, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, remifentanil will be given by a continuous infusion. Within approximately 7 minutes, the infusion rate of Remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml throughout the study.
62726361|NCT04163653||Fontan Group|Fontan patients operated at the two centres between 1991 and 2014.
62726362|NCT04163653||Healthy Control Group|Age, gender and weight matched healthy controls.
62726363|NCT02138812|EXPERIMENTAL|BAY1161909 + Paclitaxel|Participants received oral doses of BAY1161909 starting from 0.75 mg twice daily, from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in combination with weekly intravenous paclitaxel on D1, D8, and D15 of the 28-day cycles. For single-dose Pharmacokinetic (PK) cohort: in Cycle 1, participants received a single oral dose of 6 mg BAY1161909 on C1D1 with no BAY1161909 dosing for the remainder of Cycle 1.
62726364|NCT02553928|EXPERIMENTAL|Memantine (once daily)|Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
62726365|NCT02553928|EXPERIMENTAL|Memantine (twice daily)|Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally
62726366|NCT02487160|EXPERIMENTAL|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
62726367|NCT02487160|ACTIVE_COMPARATOR|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
62726368|NCT03345446||Patients with HF-rEF|These patients have Heart Failure with Reduced Ejection Fraction (EF \< 55% per the protocol).
62726369|NCT03345446||Patients with HF-pEF|These patients have Heart Failure with Preserved Ejection Fraction (EF \> 55% per the protocol).
62726370|NCT04982471||First relapsed/refractory diffuse large B-cell lymphoma|First relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants must have been diagnosed with relapsed/refractory (R/R) disease within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
62726371|NCT04982471||First relapsed/refractory follicular lymphoma|First relapsed/refractory (R/R) follicular lymphoma (FL) participants must have been diagnosed with R/R disease (grade 1 to 3B or transformed) within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
62726372|NCT05727046||Children with cerebral palsy and Children with other diagnoses|"Of the children with special needs included in the study, 60% were parents of children with cerebral palsy.~40% of the children with special needs included in the study had Hydrocephalus, Arthrogryposis, Multiplex Congenita, Down Syndrome, Microcephaly, Alpha-thalassemia mental retardation syndrome (ATRX), Spinal Muscular Atrophy (SMA) Type 1, Spinal Muscular Atrophy (SMA) Type 2, L2 hydroxy glutaric aciduria, Prader Willi syndrome, Periventricular leukomalacia grade 1, Hypotonia, Angelman syndrome, Genetic chromosomal abnormality, Dandy-walker syndrome, Western syndrome, Infantile epileptic encephalopathy, Stroke-like migraine attacks after radiation therapy (SMART syndrome), Trigonocephaly, Motor developmental delay, Lissencephaly, Spina bifida, Leigh syndrome and Epilepsy."
62726373|NCT01302327|EXPERIMENTAL|Exenatide|
62726374|NCT02948582|EXPERIMENTAL|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
62726375|NCT02948582|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
62726376|NCT02948582|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
62726377|NCT02948582|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
62726378|NCT02948582|EXPERIMENTAL|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
62726379|NCT02948582|PLACEBO_COMPARATOR|Placebo 0.5mL|Placebo 0.5mL via e-flow nebulizer, once daily
62726380|NCT03571360|OTHER|Pembrolizumab|Pembrolizumab 200 mg i.v., every 3 weeks, maximum of 2 years
62726381|NCT00892008||Open-Label|This study was open-label with only one treatment group. Pregabalin was prescribed in accordance with usual clinical practice.
62726382|NCT04475107|EXPERIMENTAL|Arm A|Pyramax (Pyronaridine 180mg/ Artesunate 60mg)
62726383|NCT04475107|PLACEBO_COMPARATOR|Arm B|Placebo
62726384|NCT01196013|EXPERIMENTAL|Clofarabine|
62726385|NCT02862977|EXPERIMENTAL|EMS association|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h.
62726386|NCT02862977|ACTIVE_COMPARATOR|Miosan Caf®|The patient will take 2 tablets (combination of Cyclobenzaprine and caffeine), oral, per day, each 12h.
62726387|NCT01018654|EXPERIMENTAL|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
61978242|NCT05849103|ACTIVE_COMPARATOR|A) Standard BP Control, Clinician Monitoring|Target blood pressure will be less than 150/100. Participants will be instructed to check their blood pressures twice a day for two weeks and daily for weeks 3-6 after delivery and report abnormal blood pressures or symptoms to their obstetric clinicians. Additional postpartum visits beyond the blood pressure check will be directed by their obstetric clinician.
62726388|NCT01018654|ACTIVE_COMPARATOR|Standard Cognitive-Behavioral Treatment|Standard Cognitive-Behavioral Treatment for Substance Abuse
62726389|NCT02615119|EXPERIMENTAL|Anorexia nervosa|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
62726390|NCT02615119|EXPERIMENTAL|Generalized anxiety disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
62726391|NCT02615119|EXPERIMENTAL|Panic disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
62726392|NCT02615119|EXPERIMENTAL|Major depressive disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
62726393|NCT02615119|EXPERIMENTAL|Brain injury|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
62726394|NCT02615119|ACTIVE_COMPARATOR|Healthy comparison|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
62726395|NCT02574039|EXPERIMENTAL|Oat bran|66g oat bran made up in 350ml skimmed milk
62726396|NCT02574039|PLACEBO_COMPARATOR|Control|Refined grain product and 350ml skimmed milk
62726397|NCT05531006||pandemic time group|The surgeries performed during the COVID-19 pandemic and the anesthesia techniques applied for these surgeries
62726398|NCT05531006||normal time group|The surgeries performed during the non-pandemic period and the anesthesia techniques applied in these surgeries
62726399|NCT05529407|EXPERIMENTAL|Simple Vaginal Tampon|Dilation exercises will be performed with tampon
62726400|NCT05529407|EXPERIMENTAL|Glass Vaginal Dilator|Dilation exercises will be performed with vaginal dilator
62726401|NCT00881985|ACTIVE_COMPARATOR|continuous positive airway pressure|
62726402|NCT00881985|NO_INTERVENTION|observation|
62726403|NCT02455102|ACTIVE_COMPARATOR|Electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive an electronic warning alert.
62726404|NCT02455102|NO_INTERVENTION|No electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive no electronic warning alert.
62726405|NCT02332785||Composite Data Collection of Endoscopy of Serrated Polyps|Goal is to collect data from endoscopy reports \& electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025.
62726406|NCT04143581|EXPERIMENTAL|IMP|
62726407|NCT01466205|EXPERIMENTAL|DAR 0-100A|The examination of SPD subjects, who are more likely than schizophrenia patients to show significant cognitive improvement after the use of single doses of dopamine agonists, such as DAR-0100A provides an excellent opportunity to demonstrate the effectiveness of D1 agonists on cognition in the schizophrenia spectrum.
62726408|NCT01466205|PLACEBO_COMPARATOR|Placebo|Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
62726409|NCT02523287|ACTIVE_COMPARATOR|Fluad - 5 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
62726410|NCT02523287|ACTIVE_COMPARATOR|Fluad - 3 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
62726411|NCT02523287|PLACEBO_COMPARATOR|Saline - 5 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
62726412|NCT02523287|PLACEBO_COMPARATOR|Saline - 3 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
62726413|NCT02020473||WLS group|patients with informed consents for withholding/withdrawing life support
62726414|NCT02020473||non-WLS group|patients without informed consents for withholding/withdrawing life support
62726415|NCT03762460|EXPERIMENTAL|Online eHealth Tool|Participants randomized to this group will use a personally-owned smartphone, tablet, or computer to access the online eHealth tool.
62726416|NCT03762460|PLACEBO_COMPARATOR|Informational website (control)|Participants randomized to this group will receive information about online resources for mental health
62726417|NCT02276430||Cases|Patients who developed cardiovascular disease after testicular cancer treatment
62726418|NCT02276430||Subcohort members|A random selection out of the total cohort of testicular cancer patients per participating hospital
62726419|NCT03336190|EXPERIMENTAL|Intervention|Receives the full program, including the toolkit training and avatar interaction
62726420|NCT01239771|EXPERIMENTAL|1|TC-5214
62726421|NCT01239771|PLACEBO_COMPARATOR|2|Placebo matched to TC-5214
62726422|NCT01435174|EXPERIMENTAL|Ranolazine|End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
62726423|NCT03441529|EXPERIMENTAL|Treatment Sequence 1 (AB)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4\*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4\*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
62726424|NCT03441529|EXPERIMENTAL|Treatment Sequence 2 (BA)|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
62726425|NCT03392428|EXPERIMENTAL|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
62726426|NCT03392428|ACTIVE_COMPARATOR|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
62726427|NCT00906412||ET Group|Total of 25 participants with ET
62726428|NCT00906412||Controls|25 controls without ET
62726429|NCT06287021|EXPERIMENTAL|Jump System Traser® cup|25 patients receiving unilateral primary total hip arthroplasty with the Jump System Traser® acetabular cup, a 3D-printed highly-porous titanium cup
62726430|NCT06287021|ACTIVE_COMPARATOR|Jump System HAX-Pore® cup|25 patients receiving unilateral primary total hip arthroplasty with the Jump System HAX-Pore® acetabular cup, a standard hydroxyapatite/titanium plasma-sprayed cup
62726431|NCT04355195||Cohort before training|500 patients should be asked to participate in the project in the phase of zero value measurement. The documentation of the routine data before the training phase relates to patients aged ≥70 years, male and female, who are undergoing surgery.
62726432|NCT04355195||Cohort after training 1|From October 1st, 2020, the documentation of the routine data will begin after the training phase: 2,500 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2023.
62726433|NCT04355195||Cohort after documentation of routine data until June 2023|From July 1st, 2023, the documentation of the routine data will go on: 1,700 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2028.
62726434|NCT05703724|OTHER|Subjects|A fundus picture will be acquired without pupil dilation. This examination will be followed by an intra-ocular pressure measurement. The results will be discussed with the participating subject by the present physician. For each subject, both eyes will be evaluated. In case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.
62726435|NCT03400410|EXPERIMENTAL|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
62726436|NCT03400410|NO_INTERVENTION|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
62726437|NCT00129285|EXPERIMENTAL|Low Dose Modafinil|Low Dose Modafinil 200 mg daily
62726438|NCT00129285|EXPERIMENTAL|High Dose Modafinil|High dose modafinil 400 mg daily
62726439|NCT00129285|PLACEBO_COMPARATOR|Placebo|Placebo
62726440|NCT06536543||Study group|"Patients with moderate or severe ARDS treated with PP equipped with EIT will be included.~Measurement of EIT data and ventilator spirometry in supine position and just after turning the patient in PP during a decremental PEEP-EIT titration, will be done, and blood gases and finally haemodynamic data"
62736241|NCT03981640|EXPERIMENTAL|White Adults|White adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
62736242|NCT02483442||No CT Pulmonary Angiography|Low Clinical Pretest Probability with D-dimer \< 1000 ug/L and Moderate Clinical Pretest Probability with D-dimer \< 500ug/L
62736243|NCT02483442||CT Pulmonary Angiography Required|Low Clinical Pretest Probability with D-dimer \> or = 1000ug/L and Moderate Clinical Pretest Probability with D-dimer \> or = 500 ug/L and High Clinical Pretest Probability
62726441|NCT06163196|EXPERIMENTAL|accupressure|In the study group (n:19), blood pressure, pulse and oxygen saturation were measured, and the acupressure points determined (large intestine meridian 4. Point: LI 4, large intestine meridian 11. Point: LI 11, Heart Meridian 7. Point: HT 7 ) acupressure was applied for only one session by applying light pressure with the thumb of the practitioner's hand, in two directions as the right and left arms, for 2 minutes to each point for a total of 12 minutes. Blood was drawn immediately after the procedure. In order to evaluate the child's pain immediately after the blood collection procedure, the child was asked to mark the most appropriate face on the Wong Baker Faces Pain Rating Scale. In addition, the child's pain was evaluated by the researcher and the parent using the Wong Baker Faces Pain Rating Scale. After the pain assessment, the child's heart rate, oxygen saturation and blood pressure were re-evaluated by the researcher and recorded in the Procedure Record Form.
62726442|NCT06163196|SHAM_COMPARATOR|control|The point used in our research is the point located in the middle of the third and fourth metacarpal bones on the back of the hand. Children in the placebo control group (n:20) were touched by the researcher for one minute without applying pressure or massage to the determined placebo point immediately after their physiological parameters were evaluated. Immediately after blood collection, the child was asked to mark the most appropriate facial expression on the Wong Baker Faces Pain Rating Scale so that he or she could assess his pain. In addition, the child's pain was evaluated by the researcher and the parent using the Wong Baker Faces Pain Rating Scale.
62726443|NCT00937495|EXPERIMENTAL|Treatment (vorinostat, bortezomib)|Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m\^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62726444|NCT05052944||Cochlear implant recipients|Patients with single-sided deafness undergoing cochlear implantation
62726445|NCT01043744|EXPERIMENTAL|Artemether-Lumefantrine|Receive artemether-lumefantrine with direct observation of am dose on days 0, 1, and 2 of study
62726446|NCT01043744|NO_INTERVENTION|No treatment|No antimalarial treatment given on day 0.
62726447|NCT02644824|EXPERIMENTAL|Biventricular Pacing (BiVp)|Consented infants with wide QRS randomized to receive standard of care and BiVp.
62726448|NCT02644824|NO_INTERVENTION|Control (wide QRS)|Consented infants with wide QRS randomized to receive standard of care alone.
62726449|NCT02644824|NO_INTERVENTION|Control (narrow QRS)|This is an observation control group. Consented infants with narrow QRS will enter control group 2 without randomization.
62726450|NCT04308018|ACTIVE_COMPARATOR|S1|Caudal end of the instrumentation at S1
62726451|NCT04308018|ACTIVE_COMPARATOR|S2alar-iliac|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
62726452|NCT05369364|EXPERIMENTAL|Zanubrutinib and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and Zanubrutinib 80mg qd po, 6 consecutive weeks
62726453|NCT05369364|ACTIVE_COMPARATOR|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
62726454|NCT00581022||1|Patients with Chronic Orthostatic Intolerance
62726455|NCT04226625|ACTIVE_COMPARATOR|Propofol|Patients will receive Propofol as an intravenous (IV) agent, which is administered into a vein through an IV line as a continuous infusion.
62726456|NCT04226625|ACTIVE_COMPARATOR|Desflurane|Patients will receive Desflurane as a gas that is administered through an anesthesia machine.
62726457|NCT04011735||Respimat SMI-experienced: Switching to re-usable Respimat|patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry.
62726458|NCT04011735||Respimat SMI-naïve|patients who have not previously used a Respimat SMI product and receive their first prescription at study entry
62726459|NCT04011735||Respimat SMI-experienced: Maintenance treatment|patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry.
62726460|NCT02085421|ACTIVE_COMPARATOR|Active tDCS|The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 20 minutes of each CRT session in the active condition.
62726461|NCT02085421|SHAM_COMPARATOR|Sham tDCS|In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.
62726462|NCT04188990|ACTIVE_COMPARATOR|Intervention arm|"The Intervention arm includes an intervention in the groups of patients who, after screening, are identified as having disease-related malnutrition (DRM) or at risk of DRM, and a follow-up of the rest of the patients"
62726463|NCT04188990|PLACEBO_COMPARATOR|By demand arm|"The By demand arm will include patients in whom the nutritional intervention, if given, is performed by demand by the medical staff responsible for each patient."
62726464|NCT04188990|PLACEBO_COMPARATOR|Usual care arm|"In the Usual care arm usual hospital practice is followed without any explicit nutritional intervention"
62726465|NCT04264923|EXPERIMENTAL|All patients enrolled|All patients enrolled with receive the HyGIeaCare Prep with a new lab sampling technique to be used on all patients enrolled in the study.
62726466|NCT01504295|EXPERIMENTAL|Metadoxine|Metadoxine 500mg tablet t.i.d.for 12 weeks
62726467|NCT01504295|PLACEBO_COMPARATOR|Sugar pill|Placebo group
62726468|NCT03395496|EXPERIMENTAL|Biodentine|Dental materials
62726469|NCT03395496|EXPERIMENTAL|ProRoot MTA|Dental Materials
62726470|NCT04708808|EXPERIMENTAL|MVA case undergone music therapy|case undergone manual vacuum aspiration are randomised to receive music therapy during the procedure.
62726471|NCT04708808|NO_INTERVENTION|Control|Routine Care
62726472|NCT02906410|NO_INTERVENTION|Control 1|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for numeric labeling conditions.
62726473|NCT02906410|EXPERIMENTAL|Numeric individual|Features Item-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices.
62726474|NCT02906410|EXPERIMENTAL|Numeric individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices. Additionally, an aggregated numeric calorie count for the entire meal will be dynamically updated as items are added or removed from the meal.
62736244|NCT05820841|ACTIVE_COMPARATOR|Standard arm|6x R-miniCHOP + 2x Rituximab.
62726475|NCT02906410|NO_INTERVENTION|Control 2|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for light labeling conditions.
62726476|NCT02906410|EXPERIMENTAL|Light individual|Features Item-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices.
62726477|NCT02906410|EXPERIMENTAL|Light individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices. Additionally, an aggregated traffic light label for the entire meal will be dynamically updated as items are added or removed from the meal.
62726478|NCT02041299|EXPERIMENTAL|Deferiprone|Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication. Deferiprone is taken orally, at a dosage that is calculated in terms of milligrams per kilogram of body weight (mg/kg) and is divided into 3 equal doses taken approximately 8 hours apart. The daily dosage is 75 mg/kg (25 mg/kg per dose) for patients with less severe iron load, and 99 mg/kg (33 mg/kg per dose) for those with more severe iron load.
62726479|NCT02041299|ACTIVE_COMPARATOR|Deferoxamine|Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information. Deferoxamine is administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week. The dosage is 20 mg/kg (children) or 40 mg/kg (adults) in patients with less severe iron load, and up to 40 mg/kg (children) or 50 mg/kg (adults) in those with more severe iron load.
62726480|NCT05608954||Physical Therapy Modalities|Children diagnosed with cerebral palsy will be followed longitudinally in their therapies within the physiotherapeutic treatment.
62726481|NCT01621555||PSOASS Patients|Patients undergoing elective arthroscopic shoulder surgery
62726482|NCT02949024|EXPERIMENTAL|TX Naïve Arm|Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
62726483|NCT02949024|EXPERIMENTAL|Previous TX Arm|Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
62726484|NCT02955238|EXPERIMENTAL|Special Intervention|The Special Intervention (SI) is designed to modify multiple, modifiable CVD risk factors that affect atherosclerosis and can be measured by sonography of the carotid intimal thickness. The SI is designed to address multiple, modifiable CVD risk factors that involve medication therapy, including hypertension, diabetes, and dyslipidemia.
62726485|NCT02955238|NO_INTERVENTION|Usual Care|Usual care (UC) reflects current practices by the primary care providers in the adult medicine department. Participants randomized into the UC group will continue with their regular medical visits and referrals to the health educator as they were before randomization.
62726486|NCT05257486||NMSC Treatment|Patients who completed Xoft eBx treatment at least five years from the last treatment.
62726487|NCT04262479|EXPERIMENTAL|GAD-vaccination with vitamin D suppletion|"Each study participant will receive 3 injections of 4 µg GAD-alum (Diamyd). The first, second and third injection will be one month apart.~Vitamin D (Divisun 2000 IE) will be given from one month before the first injection of GAD-alum until one month after the third injection (120 days in total)."
62726488|NCT00002798|EXPERIMENTAL|Arm I (combination chemotherapy)|"Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.~See Detailed Description"
62726489|NCT00002798|EXPERIMENTAL|Arm II (combination chemotherapy)|"Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.~Intensification: See Detailed Description"
62726490|NCT00002798|EXPERIMENTAL|Arm III (combination chemotherapy, aldesleukin)|Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.
62726491|NCT00002798|ACTIVE_COMPARATOR|Arm IV (combination chemotherapy)|No further treatment
62726492|NCT00002798|EXPERIMENTAL|Arm V (combination chemotherapy, radiotherapy)|Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.
62726493|NCT00689897|EXPERIMENTAL|1|In acupuncture treatment, immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation, the needles are retained for 30 minutes.
62726494|NCT00689897|ACTIVE_COMPARATOR|2|In acupuncture treatment, immediately after insertion of a needle, it is NOT manually rotated backwards or forwards to induce the DeQi sensation, and retained for 30 minutes.
62726495|NCT05896943||Ulcerative colitis patients treated with ustekinumab|Patients with Ulcerative Colitis treated with ustekinumab
62726496|NCT00410189|EXPERIMENTAL|ZD6474|ZD6474 300 mg by mouth daily for 28 Days.
62726497|NCT05473455|EXPERIMENTAL|Follicular aspiration with addition of follicular flushing.|All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle)
62726498|NCT05473455|NO_INTERVENTION|Follicular aspiration only.|All follicles will be aspirated and no flushing will be applied.
62726499|NCT00755807|PLACEBO_COMPARATOR|Placebo|
62726500|NCT00755807|EXPERIMENTAL|Duloxetine|
62726501|NCT01440673|ACTIVE_COMPARATOR|aprepitant 125mg|NK1 receptor antagonist
62726502|NCT01440673|ACTIVE_COMPARATOR|Aprepitant 80 mg|
62726503|NCT04694118|EXPERIMENTAL|15 hemiparetic cerebral palsy,walking back group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
62726504|NCT04694118|EXPERIMENTAL|15 hemiparetic cerebral palsy,rebound therapy group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
62726505|NCT01565473||Parkinson disease patients|
62726506|NCT01565473||Healthy normal controls|
62726507|NCT00841061|ACTIVE_COMPARATOR|Cereal L|Rice cereal with electrolytic iron
62726508|NCT00841061|ACTIVE_COMPARATOR|Cereal M|Rice cereal with ferrous fumarate
62726509|NCT01189344|EXPERIMENTAL|Not surgical group|The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.
62726510|NCT01189344|EXPERIMENTAL|Surgical group|The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
62726511|NCT06554249|ACTIVE_COMPARATOR|Vulsellum group|"The patients are asked to empty the bladder before IUD insertion. The vulsellum is applied on the cervix, sounding of the uterus is done and the IUD is inserted according to the standard technique of IUD insertion.~Pain intensity is assessed after the procedure using a visual analogue scale."
62726512|NCT06554249|ACTIVE_COMPARATOR|Ultrasound group|"During the two hour period before IUD insertion, the patients are asked to drink about one liter of water and to avoid micturition.~Abdominal ultrasound is used to obtain a sagittal view of the uterus and the IUD is introduced into the uterine cavity under ultrasound guidance.~The vulsellum and uterine sound are not used during IUD insertion. Pain intensity is assessed after the procedure using a visual analogue scale."
62726513|NCT02336815|EXPERIMENTAL|Part 1|Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).
62726514|NCT02336815|EXPERIMENTAL|Part 2|Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).
62726515|NCT04295837|EXPERIMENTAL|ABLE - A Better everday LifE|A home-based occupational therapy intervention addressing ADL task performance issues among persons living with chronic conditions. The ABLE intervention is occupation-focused and -based, and follows a structured process of assessment, goalsetting, intervention and evaluation.
62726516|NCT04295837|ACTIVE_COMPARATOR|Usual care|Community-based occupational therapy addressing ADL task performance issues among persons living with chronic conditions
62726517|NCT02307240|EXPERIMENTAL|CUDC-907 - five days on/two days off|60 mg/day CUDC-907, oral administration, five days on/two days off until disease progression or other discontinuation criteria are met.
62726518|NCT01107964|ACTIVE_COMPARATOR|Omega-3-acid ethyl esters|
62726519|NCT01107964|PLACEBO_COMPARATOR|Corn oil capsule|
62726520|NCT03971175|ACTIVE_COMPARATOR|Forceps group|
62726521|NCT03971175|EXPERIMENTAL|Cryobiopsy group|
62726522|NCT00921388|EXPERIMENTAL|1|Exercise program
62726523|NCT00921388|OTHER|2|Relaxation program
62726524|NCT06481345||MPN patients with IDH1/2 mutation|
62726525|NCT06481345||MPN patients with SRSF2 mutation|
62726526|NCT06481345||MPN patients with SF3B1 mutation|
62726527|NCT00533130||1|Pediatric patients under 16 years old with long bones fractures
62726528|NCT02909088|EXPERIMENTAL|Ecopipam 50mg|50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
62726529|NCT02909088|EXPERIMENTAL|Ecopipam 100mg|If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
62726530|NCT03486782|ACTIVE_COMPARATOR|Dual stimulation|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area ii) anodal stimulation on ipsilesional dorsolateral prefrontal cortex and cathodal stimulation of contralesional supraorbital area
62726531|NCT03486782|ACTIVE_COMPARATOR|Single stimulation 1|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional inferior frontal cortex
62726532|NCT03486782|ACTIVE_COMPARATOR|Single stimulation 2|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area
62726533|NCT01634607||HIV uninfected|HIV negative patients
62726534|NCT01634607||HIV-infected, HAART naïve, high CD4 count|HIV positive patients with high CD4 and not on HIV treatment
62726535|NCT01634607||HIV-infected with planned to start HAART group|HIV positive patients who will start HIV treatment
62726536|NCT04793282|PLACEBO_COMPARATOR|Control|Post-test satisfaction
62726537|NCT04793282|EXPERIMENTAL|Experimental|Treatment and satisfaction
62726538|NCT03235882||observational group|"Infants born 24-32 weeks.~Inclusion criteria:~* Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:~  * a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or~ * a nasogastric tube inserted as part of routine management of preterm infants.~* Written informed consent has been obtained"
62726539|NCT04153695|EXPERIMENTAL|Experimental|To listen flamenco music during 30 minuts per day, during 2 weks
62726540|NCT04153695|NO_INTERVENTION|Control|No intervention
62726541|NCT04832529|ACTIVE_COMPARATOR|Perianal abscess cavity packing|
62726542|NCT04832529|EXPERIMENTAL|Perianal abscess cavity no packing|
62726543|NCT01872975|ACTIVE_COMPARATOR|Group 1A Lumpectomy: no regional nodal XRT with WBI|Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
62726544|NCT01872975|NO_INTERVENTION|Group 1B Mastectomy: No regional nodal or chestwall XRT|Mastectomy patients do not undergo radiation therapy.
62726545|NCT01872975|EXPERIMENTAL|Group 2A lumpectomy: Regional nodal XRT with WBI|Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
62726546|NCT01872975|EXPERIMENTAL|Group 2B Mastectomy: Regional nodal XRT and chestwall XRT|Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.
62736245|NCT05820841|EXPERIMENTAL|Experimental arm|6x R-miniCHOP + 2x Rituximab + Acalabrutinib.
62726547|NCT05207748||patients with a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
62726548|NCT05207748||patients without a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
62726549|NCT01446887|NO_INTERVENTION|non-prophylactic anticoagulation|without prophylactic anticoagulation
62726550|NCT01446887|EXPERIMENTAL|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
62726551|NCT04176393|EXPERIMENTAL|Ivosidenib (CS3010) tablet|Ivosidenib (CS3010) tablet
62726552|NCT00253916|NO_INTERVENTION|Control Arm|No exercise measured
62726553|NCT00253916|EXPERIMENTAL|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
62726554|NCT00253916|EXPERIMENTAL|Resistance Exercise Program|Resistance Exercise Program
62726555|NCT01847092|ACTIVE_COMPARATOR|AZD1722|AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
62726556|NCT01847092|PLACEBO_COMPARATOR|Placebo|Placebo capsule BID PO for 12 Weeks
62726557|NCT06292767||Not ventilated|Non-ventilated patient group.Patients will be placed in the cardiac bypass mode of the anesthesia machine. Only 150 ml of free air flow will be provided and mechanical ventilation will be turned off.
62726558|NCT06292767||Ventilated|Patients will continue to be ventilated at Fraction of inspired oxygen(FiO2): 40%, Tidal volume(TV): 3 ml/kg, frequency 12 breaths/min, Positive end expiratory pressure (Peep): 5 cm/H2O.
62726559|NCT05878977|OTHER|Immune checkpoint inhibitors|
62726560|NCT04712123||relapse due to S. aureus|patients having had an initial infection due to S. aureus and who present a relapse with persistence of S. aureus
62726561|NCT03286192|EXPERIMENTAL|Single-Arm Intervention|All participants in this arm receive compassion cultivation training
62726562|NCT05412043|EXPERIMENTAL|Persons with MS - Dance group|12 pwMS in the Dance Therapy intervention
62726563|NCT05412043|ACTIVE_COMPARATOR|persons with MS - excercise group|12 pwMS in the exercise (placebo) group
62726564|NCT05412043|PLACEBO_COMPARATOR|Healthy controls|
62726565|NCT00710398|EXPERIMENTAL|Control|A group consuming twice daily (post-exercise and in morning/afternoon) drinks containing no dairy protein or calcium. Daily protein intake (15% total kcals) should be from non-dairy sources (i.e. meat, egg, fish, chicken, wheat gluten).
62726566|NCT00710398|EXPERIMENTAL|Dairy Protein|A group consuming twice daily drinks (post-exercise and morning) containing 1% chocolate milk (in 1.5 cup servings = 3 cups/d). Daily protein intake is set at 15% total kcals with \~8% coming from dairy sources.
62726567|NCT00710398|EXPERIMENTAL|High Dairy Protein|A group consuming twice daily drinks of 1% artificially sweetened chocolate milk (in 1.5 cup servings = 3 cups/d). Their diet contains 30% protein (as opposed to only 15% in the Con and DairyPro groups) with at least 50% of that coming from dairy sources.
62726568|NCT03951610|EXPERIMENTAL|Test lens|Subjects wearing the test lens for one week, either randomized as the first or second pair.
62726569|NCT03951610|ACTIVE_COMPARATOR|Control lens|Subjects wearing the control lens for one week, either randomized as the first or second pair.
62726570|NCT04728646|EXPERIMENTAL|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
62726571|NCT04728646|OTHER|Dissolvable intracanalicular plug|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
62726572|NCT04313738|EXPERIMENTAL|Intervention group|Experimental: Intervention group Intervention group: Home visit, health education, telephone counseling At the intervention group; the researcher firstly made spirometry meausurement in hospital. After, the researcher made pretest (baseline measurement) before nursing interventions at the first home visit. At the first home visit, the researcher was offered education and guide smoking cessation. Second, Third and fourth home visit were made 15 days later, one and six months after visit first visit. During the second, third and fourth home visits, firstly the patient's stage of change was determined and then appropriate nursing intervention was performed in accordance with the guidelines.Between the third and fourth home visits, the participants were contacted through telephone calls once a month. At fourth home visit, the researcher made posttest. After the patient was invited to the hospital and spirometry measurements were repeated.
62726573|NCT04313738|NO_INTERVENTION|Control Group|At the control group; No home visits were paid to the control group. The researcher made measurements twice at in the first and sixth months in the hospital. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
62726574|NCT03680534|EXPERIMENTAL|Reciproc Blue|Patients in which root canal from a lower premolar was prepared with the Reciproc Blue technique.
62726575|NCT03680534|EXPERIMENTAL|WaveOne Gold|Patients in which root canal from a lower premolar was prepared with the WaveOne Gold technique.
62726576|NCT03680534|EXPERIMENTAL|XP EndoShaper|Patients in which root canal from a lower premolar was prepared with the XP EndoShaper technique.
62726577|NCT03578107|OTHER|Improvement intervention1|receive the following improvement intervention for 18 months：
62726578|NCT03578107|OTHER|Improvement intervention2|receive the following improvement intervention for 12 months：
62726579|NCT03578107|OTHER|Improvement intervention3|receive the following improvement intervention for 6 months：
62726580|NCT04861779|EXPERIMENTAL|Phase 1a Dose Escalation|Multiple dose levels of HSK29116 to be evaluated; determination of MTD/Phase 1b recommended dose
62726581|NCT04861779|EXPERIMENTAL|Phase 1b Dose Expansion in R/R CLL or SLL|CLL/SLL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
62726582|NCT04861779|EXPERIMENTAL|Phase 1b Dose Expansion in R/R MCL|MCL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
62726583|NCT04861779|EXPERIMENTAL|Phase 1b Dose Expansion in other R/R B-cell Malignancy|Patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
62726584|NCT00737932|EXPERIMENTAL|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
62726585|NCT00737932|PLACEBO_COMPARATOR|Placebo|Matching placebo
62726586|NCT05372393|ACTIVE_COMPARATOR|Local infiltration anaesthesia in carpal tunnel release|The investigators allocate 59 patients in this arm. It serves as the control group, who receives local infiltration anaesthesia.
62726587|NCT05372393|EXPERIMENTAL|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The investigators allocate 59 patients in this arm. It serves as the experimental group, who receives local infiltration anaesthesia and distal median nerve block.
62726588|NCT02263872|EXPERIMENTAL|Minocycline|Minocycline 200mg perday
62726589|NCT02263872|PLACEBO_COMPARATOR|comparison group with placebo|Placebo provide
62726590|NCT06100146|PLACEBO_COMPARATOR|Control group|Teenage girls randomly assigned to the control group will receive a standard bag of unfortified cereal flours every week for six months.
62726591|NCT06100146|EXPERIMENTAL|folic acid & vit B12 fortified flour|Teenage girls randomly assigned to the control group will receive a standard bag of cereal flours fortified with folic acid and Vit B12 every week for six months.
62726592|NCT05063929|EXPERIMENTAL|Fruits|Participants will receive 2 cup eq fruits per day
62726593|NCT05063929|OTHER|Fruit restriction|Participants will receive 1/2 cup eq fruits per day
62726594|NCT06288204|EXPERIMENTAL|Propolis+Royal Jelly|4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.
62726595|NCT06288204|EXPERIMENTAL|Royal Jelly|Conservative Group will receive 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
62726596|NCT06288204|PLACEBO_COMPARATOR|Placebo|4 capsules a day of placebo.
62726597|NCT04125329|EXPERIMENTAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
62726598|NCT02897115|EXPERIMENTAL|Treat-to-Target (T2T)|Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
62726599|NCT02897115|ACTIVE_COMPARATOR|Standard of Care (SOC)|Participants received treatment as prescribed by their physician according to the local standard of care.
62726600|NCT01170234||Eosinophilic esophagitis (EoE)|Treatment-naïve EoE patients, age 7 -65
62726601|NCT06275828|NO_INTERVENTION|control|
62726602|NCT06275828|EXPERIMENTAL|intervention|
62726603|NCT03355248|ACTIVE_COMPARATOR|Control Group - 28|The control group (post-operative cesarean section) will be prescribed 28 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
62726604|NCT03355248|EXPERIMENTAL|Experimental - 20|The experimental group (post-operative cesarean section) will be prescribed 20 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
62726605|NCT04190680|EXPERIMENTAL|Kokkerelli Learning Street|The classes included in this group will participate in the Kokkerelli Learning Street; a school-based nutrition education programme included classroom-based lessons, a visit to a grower's farm and a cooking workshop.
62726606|NCT04190680|NO_INTERVENTION|Control group|The classes included in this group will not participate in the Kokkerelli Learning Street and will continue with their regular curriculum.
62726607|NCT03738722|EXPERIMENTAL|High-flow-nasal-cannula-therapy (HFNCT)|100% Oxygen at 80 l/min with flow reductions of 20 l/min, jaw thrust, with opened and closed mouth, using different flow rates (80l/min, 60l/min, 40l/min, 20l/min, 1l/min) within each subject.
62726608|NCT01999686|EXPERIMENTAL|Treatment I : DLBS3233|DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
62726609|NCT01999686|ACTIVE_COMPARATOR|Treatment II : Metformin|Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
62726610|NCT01999686|EXPERIMENTAL|Treatment III : Combination DLBS3233 and Metformin|DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
62726611|NCT02248766|ACTIVE_COMPARATOR|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
62726612|NCT02248766|EXPERIMENTAL|somofilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
62726613|NCT03018860|EXPERIMENTAL|"Moderate management"|Women are encouraged by physicians to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration.
62726614|NCT03018860|ACTIVE_COMPARATOR|"Intensive management"|Usual obstetrical care in France
62726615|NCT05412264|EXPERIMENTAL|Website intervention|Website access: 12 Weekly emails, access to website with goal setting and recording steps
62726616|NCT05412264|NO_INTERVENTION|Delayed access|Will not receive access to the program/website until they complete their 16 week assessments
62726617|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia~* Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.~* Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
62726618|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.~1. Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.~2. Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.~3. Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
62726619|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:~1. Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.~2. After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.~3. Ocular and systemic health data will be extracted from the study participant's medical record."
62726620|NCT01746446|EXPERIMENTAL|Care team|Patients are offered the support and services of the care team.
62726621|NCT01746446|NO_INTERVENTION|Usual Care|Patients receive usual care.
62726622|NCT02642211|ACTIVE_COMPARATOR|phako|eyes receiving phakoemulsification for cataract surgery
62726623|NCT02642211|ACTIVE_COMPARATOR|MSICS|Eyes undergoing manual small incision cataract surgery
62726624|NCT02232971|PLACEBO_COMPARATOR|Placebo|Isotonic Saline
62726625|NCT02232971|EXPERIMENTAL|Glucagon 0.1 mg|GlucaGen(r) 0.1 mg administration
62726626|NCT02232971|EXPERIMENTAL|Glucagon 0.2 mg|GlucaGen(r) 0.2 mg administration
62726627|NCT02232971|EXPERIMENTAL|Glucagon 0.3 mg|GlucaGen(r) 0.3 mg administration
62726628|NCT03950258|EXPERIMENTAL|endovascular embolization|patients under the age of 18 years with arteriovenous shunts manifested by systemic or neurological manifestations will undergo endovascular embolization
62726629|NCT01118780|EXPERIMENTAL|Duloxetine 30 milligrams (mg) -120 mg|
62726630|NCT01118780|PLACEBO_COMPARATOR|Placebo|
62726631|NCT00702832|EXPERIMENTAL|Vestibular rehabilitation|early supported vestibular rehabilitation
62726632|NCT00702832|ACTIVE_COMPARATOR|standard|standard treatment
62726633|NCT02973997|EXPERIMENTAL|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
62726634|NCT03822637|EXPERIMENTAL|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC coadministered with albuterol and delivered via nebulizer three times per day for fourteen days.
62726635|NCT03822637|PLACEBO_COMPARATOR|0.9% saline|Normal saline will be coadministered with albuterol as the placebo agent via a nebulizer three times per day for fourteen days.
62726636|NCT06106906|EXPERIMENTAL|Experimental Arm|Participants will receive CD19 CAR-T cell intravenous infusion
62726637|NCT02141165|EXPERIMENTAL|Primary.|Diagnosis, autoCPAP, follow up.
62726638|NCT02141165|ACTIVE_COMPARATOR|Hospital|Diagnosis, autoCPAP, follow up
62726639|NCT03127696|EXPERIMENTAL|FMT + LMP|FMT and lifestyle modification program
62726640|NCT03127696|EXPERIMENTAL|FMT alone|Fecal Microbiota Transplantation
62726641|NCT03127696|SHAM_COMPARATOR|Sham + LMP|Sham and lifestyle modification program
62726642|NCT03190798|ACTIVE_COMPARATOR|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
62726643|NCT03190798|PLACEBO_COMPARATOR|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
62726644|NCT05596734|EXPERIMENTAL|SSA: qIRV + bivalent BNT162b2 (dose level combination 1)|Administered intramuscularly into the deltoid muscle of the right arm
62726645|NCT05596734|EXPERIMENTAL|SSA: qIRV + bivalent BNT162b2 (dose level combination 2)|Administered intramuscularly into the deltoid muscle of the right arm
62726646|NCT05596734|EXPERIMENTAL|SSA: qIRV + bivalent BNT162b2 (dose level combination 3)|Administered intramuscularly into the deltoid muscle of the right arm
62726647|NCT05596734|EXPERIMENTAL|SSA: qIRV (dose level 1)|Administered intramuscularly into the deltoid muscle of the right arm
62726648|NCT05596734|EXPERIMENTAL|SSA: qIRV (dose level 2)|Administered intramuscularly into the deltoid muscle of the right arm
62726649|NCT05596734|EXPERIMENTAL|SSA: bivalent BNT162b2 (dose level 1) + QIV|BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm
62726650|NCT05596734|EXPERIMENTAL|SSB: QIV + bivalent BNT162b2 (original/Omi BA.4/BA.5)|BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm
62726651|NCT05596734|EXPERIMENTAL|SSB: QIV + bIRV/bivalent BNT162b2 (original/Omi BA.4/BA.5)|BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm
62726652|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 1|Administered intramuscularly into the deltoid muscle of the right arm
62726653|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 2|Administered intramuscularly into the deltoid muscle of the right arm
62726654|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 3|Administered intramuscularly into the deltoid muscle of the right arm
62726655|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 4|Administered intramuscularly into the deltoid muscle of the right arm
62726656|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 5|Administered intramuscularly into the deltoid muscle of the right arm
62726657|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 6|Administered intramuscularly into the deltoid muscle of the right arm
62726658|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 7|Administered intramuscularly into the deltoid muscle of the right arm
62726659|NCT05596734|EXPERIMENTAL|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 8|Administered intramuscularly into the deltoid muscle of the right arm
62726660|NCT05596734|EXPERIMENTAL|SSB: tIRV/bivalent BNT162b2(original/Omi\BA.4/BA.5)|Administered intramuscularly into the deltoid muscle of the right arm
62726661|NCT05596734|EXPERIMENTAL|SSB: qIRV|Administered intramuscularly into the deltoid muscle of the right arm
62726662|NCT02148068||Bariatric Surgery - Gastric Bypass|This population will undergo a laparoscopic roux-en-y gastric bypass
62726663|NCT02148068||Bariatric Surgery - Sleeve Gastrectomy|This group will undergo a laparoscopic sleeve gastrectomy
62726664|NCT04848480|EXPERIMENTAL|Insulin icodec + insulin aspart|insulin icodec once a week in combination with 2-4 times daily injections of insulin aspart at meal times.
62726665|NCT04848480|ACTIVE_COMPARATOR|Insulin degludec + insulin aspart|insulin degludec once a day in combination with 2-4 times daily injections of insulin aspart at meal times.
62726666|NCT04414553|EXPERIMENTAL|Community-AHF|Participants in this arm will receive the Community Active and Healthy Families Intervention
62726667|NCT06285045|EXPERIMENTAL|Roujin Formula group|Roujin Formula : angelica, bupleurum, radix paeoniae alba, etc. Medication method : oral 1 bag ( 150ml ) each time, 2 times a day. Treatment course : 8 weeks.
62726668|NCT06285045|NO_INTERVENTION|Control group|Placebo : According to the internationally accepted standard, one-tenth of the dose of Roujin Formula was used to prepare a placebo, which was similar to Roujin Formula in appearance, color, taste or smell, and packaging. Medication method : oral 1 bag ( 150ml ) each time, 2 times a day. Treatment course : 8 weeks.
62726669|NCT00777348|EXPERIMENTAL|1|DSCG + Reproterol
62726670|NCT00777348|ACTIVE_COMPARATOR|2|DSCG
62726671|NCT00777348|ACTIVE_COMPARATOR|3|Reproterol
62726672|NCT00777348|PLACEBO_COMPARATOR|4|Placebo
62726673|NCT00924001|EXPERIMENTAL|Metastatic Melanoma|Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.
62726674|NCT01462526||Control|Participants who do not have glaucoma in either eye
62726675|NCT01462526||Glaucoma|Participants who have glaucoma in one or both eyes
62726676|NCT00845247|PLACEBO_COMPARATOR|Control|Control group patients will receive usual medical plus usual supportive treatment.
62726677|NCT00845247|ACTIVE_COMPARATOR|Case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
62726678|NCT06176846|EXPERIMENTAL|Immersive Virtual Reality Exergaming Group|Patients in this group will be included in an exergaming program using Oculus Quest 3 glasses.
62726679|NCT06176846|EXPERIMENTAL|Home-Based Exercise Group|Patients in this group will be included in a home-based exercise program.
62726680|NCT05816746|EXPERIMENTAL|Treatment group|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
62726681|NCT05989438|ACTIVE_COMPARATOR|Premature that the family receives only orientation.|The orientations will happen once a month via telephone, and once a week a reminder will be sent. Follow-up will occur from 4 to 12 corrected months.
62726682|NCT05989438|ACTIVE_COMPARATOR|Premature who receive intervention by a specialized professional more orientation for the family|The frequency of stimulation by a specialized professional will vary according to the degree of prematurity, from approximately 1 to 8 times per month. The guidelines will take place on the days of the calls. Follow-up will occur from 4 to 12 corrected months.
62726683|NCT01980199|EXPERIMENTAL|Fexinidazole|"600mg tablets~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days"
62726684|NCT01172444|EXPERIMENTAL|Test|Sandoz Mesalamine 1 g Suppository
62726685|NCT01172444|ACTIVE_COMPARATOR|Reference|Canasa 1 g Suppository
62726686|NCT01172444|PLACEBO_COMPARATOR|Placebo|Sandoz 1 g Placebo Suppository
62726687|NCT06300177|EXPERIMENTAL|D-1553 Tablet|D-1553 Tablet，21 days as a treatment cycle.
62726688|NCT06300177|ACTIVE_COMPARATOR|Docetaxel Injection|Docetaxel Injection，21 days as a treatment cycle.
62726689|NCT02163577|EXPERIMENTAL|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W). Dose was determined by the participant's weight and prescribed dose by their study doctor.
62726690|NCT02163577|EXPERIMENTAL|Burosumab Q4W Then Q2W|Burosumab SC injections every 4 weeks (Q4W). Dose was determined by the participant's weight and prescribed dose by their study doctor. Participants in Q4W were to switch to Q2W beginning with Week 64 dosing.
62726691|NCT01890265|EXPERIMENTAL|Pamrevlumab|Participants will receive pamrevlumab 30 milligram/kilogram (mg/kg) by intravenous (IV) infusion every 3 weeks for a total of 16 infusions over 45 weeks.
62726692|NCT01890265|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 16 infusions over 45 weeks.
62726693|NCT01890265|ACTIVE_COMPARATOR|Sub-Study: Pamrevlumab+Pirfenidone or Nintedanib|"Participants will receive pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with pamrevlumab in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
62726694|NCT01890265|PLACEBO_COMPARATOR|Sub-Study: Placebo+Pirfenidone or Nintedanib|"Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
62726695|NCT01042158|OTHER|Tadalafil and ambrisentan upfront therapy|This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD).
62726696|NCT05561933|PLACEBO_COMPARATOR|Choice Group|Participants assigned to the Choice group will receive a list of digital (i.e., links to TED talks) and hard-copy (i.e., books) resources that focus on the science of well-being and may support well-being. It is up to participants whether and to what extent they choose to engage with these resources. A study library with 10 copies of each recommended book will be accessible to participants should they wish to read any of the suggested books. After follow-up testing, Choice group participants will be provided free access to the HMP training.
62726697|NCT05561933|EXPERIMENTAL|Healthy Minds Program (HMP) Group|"Participants in the experimental arm will be assigned to the Healthy Minds Program Foundations training (HMP) which consists of 30-days of didactic and experiential content in a scientifically-derived model of well-being.~A second random assignment will occur among intervention participants in which participants will receive the standard Foundations training or the Foundations training plus once per day push notifications (i.e., a micro-interventions) that provide a very brief opportunity to practice with the HMP content of that day. HMP participants will not be made aware of this second assignment."
62726698|NCT02453893|EXPERIMENTAL|oral iloperidone|2\~12mg/day for 2 weeks,12\~24mg/day for 6 weeks.
62726699|NCT02453893|ACTIVE_COMPARATOR|oral risperidone|1\~3mg/day for 2 weeks,3\~6mg/day for 6 weeks.
62726700|NCT03135431|EXPERIMENTAL|Salpingectomy|Bilateral salpingectomy following cesarean delivery
62726701|NCT03135431|ACTIVE_COMPARATOR|Tubal Ligation|Bilateral tubal ligation following cesarean delivery via Parkland or modified Pomeroy methods.
62726702|NCT04455828||Hospitalized Heart Failure subjects|Subjects hospitalized for heart failure exacerbation will be enrolled, prior to discharge from hospital, to wear the WHOOP device for 90 days.
62726703|NCT04455828||Non-hospitalized Heart Failure subjects|Subjects who have not been hospitalized in the past 1 year, but have a diagnosis of heart failure, will be enrolled during routine outpatient care to wear the WHOOP device for 90 days.
62726704|NCT00972517|EXPERIMENTAL|Group A|Subjects receiving alternative dose of GSK23440272A vaccine
62726705|NCT00997854|ACTIVE_COMPARATOR|Group 1 Bolus Feeds|This group will receive feeds administered by bolus method over no more than 30 minutes per feed.
62726706|NCT00997854|EXPERIMENTAL|Group 2- Slow Infusion Feeds|This group will receive feeds administered by slow infusion over pump for 2 hours.
62726707|NCT02789085|NO_INTERVENTION|Control|without tens stimulation
62726708|NCT02789085|EXPERIMENTAL|Test|with tens stimulation
62726709|NCT04177537||Pre-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work with traditional therapies selected from one rehabilitation facility
62726710|NCT04177537||Post-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies selected from one rehabilitation facility
62726711|NCT02781571|EXPERIMENTAL|SOF/VEL|SOF/VEL FDC for 12 weeks
62726712|NCT02140021|EXPERIMENTAL|Screening (biospecimen collection)|Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
62726713|NCT05558488|EXPERIMENTAL|Meatless restrictive ketogenic diet|Diet was designed to be isoproteic (1.8 g x Kg- 1 x body weight- 1 x day-1) with three meals a day., restrictive (EER minus 500 kcal / day). The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 g x Kg-1 x body weight- 1 x day-1 (\~ 25-30%), fats (\~ 65-70%, with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\< 30 g x day- 1; \< 10%).
62726714|NCT00941525|OTHER|Ocular hypertensives|"This study includes two groups.~1. Subjects with ocular hypertension and~2. Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment."
62726715|NCT00648648|EXPERIMENTAL|adavosertib 325 mg Single Dose|Participants received adavosertib 325 mg, orally, on Day 1.
62726716|NCT00648648|EXPERIMENTAL|adavosertib 650 mg Single Dose|Participants received adavosertib 650 mg, orally, on Day 1.
62726717|NCT00648648|EXPERIMENTAL|adavosertib 1300 mg Single Dose|Participants received adavosertib 1300 mg, orally, on Day 1.
62726718|NCT00648648|EXPERIMENTAL|adavosertib 100 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m\^2 as an intravenous (IV) infusion on Days 1, 8, and 15 in each 4-week cycle plus adavosertib 100 mg single dose, orally, on Day 2 of each cycle.
62726719|NCT00648648|EXPERIMENTAL|adavosertib 200 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion on Days 1, 8, and 15 in each 4-week cycle plus adavosertib 200 mg single dose, orally, on Day 2 of each cycle.
62726720|NCT00648648|EXPERIMENTAL|adavosertib 100 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 100 mg single dose orally, on Day 2 of each cycle.
62726721|NCT00648648|EXPERIMENTAL|adavosertib 200 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 200 mg single dose orally, on Day 2 of each cycle.
62726722|NCT00648648|EXPERIMENTAL|adavosertib 100 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5) as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 100 mg single dose orally, on Day 2 of each cycle.
62726723|NCT00648648|EXPERIMENTAL|adavosertib 200 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 200 mg single dose orally, on Day 2 of each cycle.
62726724|NCT00648648|EXPERIMENTAL|adavosertib 325 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 325 mg single dose orally, on Day 2 of each cycle.
62726725|NCT00648648|EXPERIMENTAL|adavosertib 25 mg BID x2.5 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion on Days 1, 8, and 15 of each 4-week cycle plus adavosertib 25 mg orally twice daily (BID) for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of adavosertib 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each cycle.
62726726|NCT00648648|EXPERIMENTAL|adavosertib 50/25 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 doses of adavosertib 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
62726727|NCT00648648|EXPERIMENTAL|adavosertib 50 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion given once weekly for 3 consecutive weeks of a 4 week cycle plus adavosertib 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of adavosertib 50 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
62726728|NCT00648648|EXPERIMENTAL|adavosertib 100 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 100 mg orally once daily (QD) on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
62726729|NCT00648648|EXPERIMENTAL|adavosertib 125 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 125 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
62726730|NCT00648648|EXPERIMENTAL|adavosertib 150 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 150 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
62726731|NCT00648648|EXPERIMENTAL|adavosertib 175 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion given on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
62726732|NCT00648648|EXPERIMENTAL|adavosertib 200 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m\^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 200 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
62726733|NCT00648648|EXPERIMENTAL|adavosertib 50 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 50 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726734|NCT00648648|EXPERIMENTAL|adavosertib 100 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 100 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726735|NCT00648648|EXPERIMENTAL|adavosertib 125 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 125 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726736|NCT00648648|EXPERIMENTAL|adavosertib 150 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 150 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726737|NCT00648648|EXPERIMENTAL|adavosertib 200 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 200 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726738|NCT00648648|EXPERIMENTAL|adavosertib 250 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m\^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 250 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726739|NCT00648648|EXPERIMENTAL|adavosertib 75 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 75 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726740|NCT00648648|EXPERIMENTAL|adavosertib 150 mg BID x 2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 150 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726741|NCT00648648|EXPERIMENTAL|adavosertib 225 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 225 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62726742|NCT00648648|EXPERIMENTAL|adavosertib 325 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 325 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
62736246|NCT04979026|NO_INTERVENTION|active ankle pumping without any reminders|In group 1, active ankle pumping exercise for the operative limb was performed without any reminder during hospitalization and at home after being discharged.
61978243|NCT05849103|ACTIVE_COMPARATOR|B) Tight BP Control, Clinician Monitoring|Target blood pressure will be less than 140/90. Participants will be instructed to check their blood pressures twice a day for two weeks and daily for weeks 3-6 after delivery and report abnormal blood pressures or symptoms to their obstetric clinicians. Additional postpartum visits beyond the blood pressure check will be directed by their obstetric clinician.
62726743|NCT04188132|EXPERIMENTAL|EEG BCI closed loop feedback for rehabilitation of upper limb|"This study is a pilot study to examine the feasibility of a SMR based EEG BCI using motor task and motor imagery and involve a gaming feedback for same.~The first two days will be used for calibrating the BMI using commands in computer screen followed by further two days for testing the BMI and feedback control during gaming in computer to move the ball in the computer screen."
62726744|NCT05545592|EXPERIMENTAL|Low oestrogen|The patients take orally estradiol tablets 2 mg (Femoston) q.d. during the HRT-FET cycles
62726745|NCT05545592|NO_INTERVENTION|Regular oestrogen|The patients take orally estradiol tablets 2 mg (Femoston) t.i.d. during the HRT-FET cycles
62726746|NCT01838460|EXPERIMENTAL|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
62726747|NCT01838460|ACTIVE_COMPARATOR|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
62726748|NCT01838460|ACTIVE_COMPARATOR|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
62726749|NCT01838460|ACTIVE_COMPARATOR|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
62726750|NCT01838460|ACTIVE_COMPARATOR|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
62726751|NCT03184883|EXPERIMENTAL|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
62726752|NCT03184883|ACTIVE_COMPARATOR|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
62726753|NCT03685981|EXPERIMENTAL|Incentives information provided|
62726754|NCT03685981|NO_INTERVENTION|No incentives information provided|
62726755|NCT00361972|ACTIVE_COMPARATOR|Lansoprazole therapy|Lansoprazole 30 mg orally twice daily
62726756|NCT00361972|PLACEBO_COMPARATOR|Placebo|placebo orally twice daily
62726757|NCT03595735|EXPERIMENTAL|Treatment Group|Receives treatment with the Zenflow Spring System
62726758|NCT04587882|EXPERIMENTAL|Telehealth|Participants will be provided with a smartwatch, have access to activity tracking and goal setting through the VALENTINE app, receive micro-randomized, contextually tailored notifications, and receive weekly activity summaries via email, which will be provided to participants and to their exercise physiologist while enrolled in cardiac rehabilitation.
62726759|NCT04587882|ACTIVE_COMPARATOR|Control|Participants will continue to receive usual care and a smartwatch but without access to the micro-randomized notifications or weekly activity summaries.
62726760|NCT00763724||1|Duloxetine
62726761|NCT00763724||2|Venlafaxine
62726762|NCT00763724||3|SSRI
62726763|NCT00763724||4|TCA
62726764|NCT00763724||5|Multiple Antidepressants
62726765|NCT00763724||6|Depressed (not antidepressant treated)
62726766|NCT00763724||7|General population
62726767|NCT00836394|EXPERIMENTAL|Intervention Group|Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
62726768|NCT00836394|NO_INTERVENTION|Control|Will follow daily habitual activities
62726769|NCT01896830|EXPERIMENTAL|Vaccine Group|Participants will receive the candidate C. difficile toxoid vaccine
62726770|NCT01896830|PLACEBO_COMPARATOR|Placebo Group|Participants will receive a placebo vaccine
62726771|NCT00754689|ACTIVE_COMPARATOR|Arm 1|Metformin 500mg twice daily (bid) + placebo
62726772|NCT00754689|ACTIVE_COMPARATOR|Arm 2|Metformin 1000mg bid + placebo
62726773|NCT00754689|ACTIVE_COMPARATOR|Arm 3|Rimonabant 20mg once daily (od) + placebo
62726774|NCT00754689|EXPERIMENTAL|Arm 4|Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid
62726775|NCT00754689|EXPERIMENTAL|Arm 5|Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid
62726776|NCT01127932|EXPERIMENTAL|CBT for suicide|
62726777|NCT01127932|ACTIVE_COMPARATOR|Enhanced care control group|This group is designed to be an active control which provides detailed information about substance use, suicide risk, and depression without providing any CBT or other specific therapy.
62726778|NCT05595343||Early adopting surgeons|Surgeons who started performing LDP during phase 3 of the IDEAL framework; the Assessment phase. They received training in the form of fellowships, proctoring, and courses
62726779|NCT05595343||Pioneering surgeons|Surgeons who started performing LDP during phase 2 of the IDEAL framework; the Development and Exploration phase. They did not receive any specific form of training and were therefore considered self-taught.
62726780|NCT05462106|PLACEBO_COMPARATOR|Placebo for Study Part 1 (Prodromal AD)|Prodromal AD participants receive placebo at predefined time points over 48 weeks
62726781|NCT05462106|EXPERIMENTAL|ACI-24.060 at Dose A|Prodromal AD participants receive dose A of ACI-24.060 at predefined time points over 48 weeks
62726782|NCT05462106|EXPERIMENTAL|ACI-24.060 at Dose B (Optional)|Prodromal AD participants receive dose B of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
62726783|NCT05462106|EXPERIMENTAL|ACI-24.060 at Dose C (Optional)|Prodromal AD participants receive dose C of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
62726784|NCT05462106|EXPERIMENTAL|ACI-24.060 at Dose D (Optional)|Prodromal AD participants receive dose D of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
62726785|NCT05462106|PLACEBO_COMPARATOR|Placebo for Study Part 2 (Down syndrome)|Participants with Down syndrome receive placebo at predefined time points over 74 weeks
62726786|NCT05462106|EXPERIMENTAL|ACI-24.060 at Dose X|Participants with Down syndrome receive dose X of ACI-24.060 at predefined time points over 74 weeks. Dose X will be a dose already tested in Study Part 1.
62726787|NCT05462106|EXPERIMENTAL|ACI-24.060 at Dose Y (Optional)|Participants with Down syndrome may optionally receive a dose Y of ACI-24.060 at predefined time points over 74 weeks.
62726788|NCT04833335|EXPERIMENTAL|Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versus|Inclusion visit, 1 month later, 6 month later
62726789|NCT00286299|EXPERIMENTAL|Aerobic interval training (AIT)|AIT is 4x4 minutes interval training on a treadmill at 85 to 95 % HRpeak interspersed with 3 min of active resting periods at a work load corresponding to 70 % HRpeak between each interval. Patients performed the intervals walking or running with a minimum of 5 % inclination.
62726790|NCT00286299|ACTIVE_COMPARATOR|Computer game training (CG)|36 minutes playing supervised computer games, Tetris, Xbox
62726791|NCT00286299|EXPERIMENTAL|Maximal strength training (MST)|MST is performed in a leg press machine. The weight is lowered in a controlled manner in the eccentric phase until the patient reached 90 degrees in the knee joint. Then the patients has a short stop (\~0.5 second) before the weight is moved as rapidly as possible to complete extension. The training volume is 4 sets of 4RM (i.e. 85-90 % 1RM). The training load is increased with 2.5-5 kg each time patients managed to perform 4 sets with the determined load or each training session.
62726792|NCT02854995|OTHER|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce.
62726793|NCT02854995|OTHER|preputioplasty with intralesional injection of triamcinolone|(ii) preputioplasty with intralesional injection of triamcinolone: longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile.
62726794|NCT01494324|EXPERIMENTAL|CT guided percutaneous ablation|The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.
62726795|NCT06319209||Preoperative resolved COVID-19|Patients who had a history of SARS-CoV-2 infection prior to surgery underwent limited breast cancer operations in the Breast Surgery Department of our hospital after recovering from SARS-CoV-2 infection between January 2023 and March 2023.
62726796|NCT06319209||Preoperative COVID-19 negative|Patients undergoing limited surgery for breast cancer in our Breast Surgery Department between June and August 2022 had no history of SARS-CoV-2 infection prior to surgery. However, they were diagnosed with COVID-19 after the first tumor evaluation following surgery, which occurred at least 90 days after the surgery.
62726797|NCT01880151|EXPERIMENTAL|Prodromal AD|Presence of memory impairment Absence of impairment in activities of daily life EEG
62726798|NCT01880151|EXPERIMENTAL|Mild AD dementia|Presence of memory impairment Presence of impairment in activities of daily life EEG
62726799|NCT01880151|EXPERIMENTAL|Healthy control group|Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG
62726800|NCT02994966|EXPERIMENTAL|Surrosense|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear as well as wear SurroSense Rx® in-shoe pressure-sensing arrays, which provide visual and auditory/vibratory feedback alerts (relating to high plantar pressures) and offloading guidance to a watch display intended to assist in the recurrence of diabetic foot ulcers. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
62726801|NCT02994966|ACTIVE_COMPARATOR|Standard care|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
62726802|NCT03110718|EXPERIMENTAL|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
62726803|NCT03110718|ACTIVE_COMPARATOR|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
62726804|NCT01740778||Study Group 1|Aurora vs. Microlet 2
62726805|NCT01740778||Study Group 2|Aurora vs. SoftClix
62726806|NCT01740778||Study Group 3|Aurora vs. One Touch Comfort
62726807|NCT01740778||Study Group 4|Aurora vs. Multiclix
62726808|NCT02638714|EXPERIMENTAL|Stem Cells|Intervention: Transplantation of autologous purified stem cells
62726809|NCT00344175|EXPERIMENTAL|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
62726810|NCT00344175|ACTIVE_COMPARATOR|Simvastatin 40mg/80mg|Simvastatin 40 mg or 80 mg once daily
62726811|NCT03345355||patient with axial spondyloarthritis|
62726812|NCT01337193|ACTIVE_COMPARATOR|Pelvic floor muscle exercises|Three pelvic floor muscle exercises will be performed with verbal cueing from the instructor.
62726813|NCT01337193|EXPERIMENTAL|Pelvic floor exercises with biofeedback|Pelvic floor exercises will be performed with biobeedback cueing.
62726814|NCT03167138|EXPERIMENTAL|Autologous micro-fragmented adipose tissue|Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems® system.
62726815|NCT05827705||Group H|General anaesthesia was induced by Propofol (2 mg/kg) IV, Rocuronium (0.6 mg/kg) and Fentanyl (2 μg/kg) IV, and maintained with sevoflurane and Epidural anesthesia, intraoperative Hypotensive patients
62726816|NCT05827705||Group N|General anaesthesia was induced by Propofol (2 mg/kg) IV, Rocuronium (0.6 mg/kg) and Fentanyl (2 μg/kg) IV, and maintained with sevoflurane and Epidural anesthesia, intraoperative Non-Hypotensive patients
62726817|NCT02229708|NO_INTERVENTION|Usual Care|The Usual Obstetric Care group will receive usual advice about nutrition and activity during pregnancy from their obstetrician along with some additional information about pregnancy and childbirth through readings from The American College of Obstetricians and Gynecologists. In addition, participants will receive weekly text messages to maintain contact and ensure follow-up.
62737933|NCT05322291|EXPERIMENTAL|Experimental Group|The developed mobile application will be installed on the phones of hemodialysis patients in the experimental group. Online consultancy and training will be provided with the application.
62726818|NCT02229708|EXPERIMENTAL|Healthy Lifestlye Group|The Healthy Lifestyle Group will take part in an individual, technology-based behavioral intervention program which will include specific information about nutrition and physical activity, and strategies for helping them make changes to their diet, physical activity, and weight-related behaviors during pregnancy. Participants will receive information through print materials, text messages, a private Facebook group, and in-person visits and phone calls from a health coach who is part of our research team.
62726819|NCT06285552|EXPERIMENTAL|Parenting newborn|Program aimed at community families with children enrolled in Early Childhood Care Centers (from 0 to 2 years old).
62726820|NCT06285552|EXPERIMENTAL|Parenting Toddlers|Program aimed at community families with children from 2 to 5 years old.
62726821|NCT06285552|EXPERIMENTAL|Parenting Children|Program aimed at community families with children from 6 to 12 years old.
62726822|NCT06285552|EXPERIMENTAL|Parenting Adolescents|Program aimed at community families with children from 12 to 18 years old.
62726823|NCT06285552|EXPERIMENTAL|Active and Health Families|Program aimed at targeted families due identified needs for healthy lifestyle habits
62726824|NCT06285552|EXPERIMENTAL|Functional diversity Parenting|Program aimed at targeted families whose children and/or adolescents exhibit functional diversity characteristics
62726825|NCT06285552|NO_INTERVENTION|Control|Families that are not participating in any program as they live in a comparable area where any of the intervention is offered
62726826|NCT06285552|EXPERIMENTAL|Parenting as as Father|Program aimed at fathers from the community population
62726827|NCT02530476|EXPERIMENTAL|Phase I Group 1 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
62726828|NCT02530476|EXPERIMENTAL|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
62726829|NCT02530476|EXPERIMENTAL|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
62726830|NCT02530476|EXPERIMENTAL|Phase I Group 2 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle."
62726831|NCT03745638|PLACEBO_COMPARATOR|VC Period: Vehicle Cream BID|Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
62726832|NCT03745638|EXPERIMENTAL|VC Period: Ruxolitinib 0.75% Cream BID|Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
62726833|NCT03745638|EXPERIMENTAL|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
62726834|NCT03745638|EXPERIMENTAL|LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID|Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the Long-term Safety (LTS) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62726835|NCT03745638|EXPERIMENTAL|LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID|Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62726836|NCT03745638|EXPERIMENTAL|LTS Period: Ruxolitinib 0.75% Cream|Arm description: Participants who applied ruxolitinib 0.75% cream during VC Period, continued applying ruxolitinib 0.75% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62726837|NCT03745638|EXPERIMENTAL|LTS Period: Ruxolitinib 1.5% Cream|Arm description: Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
62726838|NCT00719992|EXPERIMENTAL|1|positive ETT, High HS-CRP
62726839|NCT00719992|ACTIVE_COMPARATOR|2|positive ETT, Low HS-CRP
62726840|NCT02826408|ACTIVE_COMPARATOR|Active group|Will receive Rabeprazole sodium (Proton pump inhibitor 20 mg once daily)
62726841|NCT02826408|PLACEBO_COMPARATOR|Placebo group|Will receive Folic acid 5 mg once daily
62726842|NCT03346083|EXPERIMENTAL|Cohort 1: Betrixaban 40 mg|Participants received a single, oral dose of betrixaban at 40 mg in a fed state, and had 10 PK blood sampling time points.
62726843|NCT03346083|EXPERIMENTAL|Cohort 2: Betrixaban 80 mg|Participants received a single, oral dose of betrixaban at 80 mg in a fed state, and had 5 PK sampling time points.
62726844|NCT00483678|EXPERIMENTAL|Intimacy-Enhancing Couples Therapy|Patients and their partners receive Intimacy-Enhancing Couples Therapy over 6 weeks comprising the following four 90-minute sessions: the Story of Cancer; Understanding the Couple, Ways of Relating and Key Influences; Intimacy; and Coping, Support, and Adaptation. Patients and their partners complete treatment satisfaction questionnaires after completion of study intervention.
62737934|NCT05322291|NO_INTERVENTION|Control Group|No intervention will be made. They will continue to receive routine care.
62726845|NCT00483678|ACTIVE_COMPARATOR|standard psychosocial care|Patients and their partners receive standard psychosocial care. All participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention
62726846|NCT04973358|EXPERIMENTAL|BuccoTherm|buccotherm mouthwash
62726847|NCT04973358|PLACEBO_COMPARATOR|Placebo|placebo mouthwash
62726848|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
62726849|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
62726850|NCT03584126||Patients with AF|Patients with atrial fibrillation visiting the outpatient clinic; examined by general examination, electrocardiography, ecocardiography and MRI.
62726851|NCT03584126||Control|Healthy adult volunteers; examined by the study physicians by general examination, electrocardiography, ecocardiography and MRI.
62726852|NCT04762836|EXPERIMENTAL|Augmented learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of DCS two hours prior to conditioning and fMRI
62726853|NCT04762836|PLACEBO_COMPARATOR|Baseline learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of placebo two hours prior to conditioning and fMRI
62726854|NCT05730946||Egyptian parents of cleft lip and/ or palate (CLP) patients|Egyptian parents of CLP patients presented to the cleft lip \& palate clinic at Ain Shams university.
62726855|NCT02100930|EXPERIMENTAL|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
62726856|NCT06251622||People with Cystic fibrosis treated with CFTR modulators|Children (over 10 years old) and adults with cystic fibrosis, with a stable clinical condition and no contraindications to engaging in moderate-intensity physical activities (PA).
62726857|NCT06251622||Healthy individuals|Healthy children (over 10 years old) and adults without known diseases (chronic respiratory, cardiovascular, metabolic, renal, or neuromuscular diseases) that may affect their peripheral muscle strength.
62726858|NCT05771805|EXPERIMENTAL|Vagus nerve stimulation with task oriented training|Vagus nerve stimulation with task oriented training
62726859|NCT05771805|ACTIVE_COMPARATOR|Task oriented training|Task oriented training alone
62726860|NCT00652015||1|Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
62726861|NCT00652015||2|Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
62726862|NCT04930315|EXPERIMENTAL|neoadjuvant and adjuvant group|Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles
62726863|NCT04930315|ACTIVE_COMPARATOR|adjuvant group|Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 12 cycles
62726864|NCT05521009|EXPERIMENTAL|endotracheal tube fixation|Tube fixation will be performed using a bandage in one of the groups. The patients identified with the bandage will form the control group of the study. The group of the patients to be included in the groups will be determined by drawing lots. Except for the different fixation material, no different application will be made to the patients in oral care. As soon as the patients are intubated, a swab will be taken twice, from the outer surface of the endotracheal tube from the fixation distance, and from the same area 3 days after intubation
62726865|NCT05521009|EXPERIMENTAL|Enfection|Tube fixation will be performed with adhesive tube fixation material to one of the groups. In which group the patients to be included in the groups will be will be determined by drawing lots. Except for the different fixation material, no different application will be made to the patients in oral care. As soon as the patients are intubated, a swab will be taken twice, from the outer surface of the endotracheal tube from the fixation distance, and from the same area 3 days after intubation.
62726866|NCT04892719|OTHER|Participants who underwent a lung transplant at Duke|Participants will undergo fluoroscopic chest imaging with 4Dx technology software analysis
62726867|NCT01444911|EXPERIMENTAL|Vaginal Renewal Program|
62726868|NCT01444911|ACTIVE_COMPARATOR|Standard of care|This will consist of still vaginal dilator and/or lubricant.
62726869|NCT03293303|EXPERIMENTAL|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
62726870|NCT03293303|NO_INTERVENTION|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
62726871|NCT03475069|EXPERIMENTAL|Individual intervention|This exercise program was prepared specific to each patient in this group according to his/her physiotherapy assessment, functional performance tests and body analysis results. This exercise type focuses on patients' physical demands. Exercises were applied by a researcher physiotherapist.
62726872|NCT03475069|EXPERIMENTAL|Plates intervention|Plates exercises were applied as a group treatment. This exercise type contains non-impact exercises to develop strength, flexibility, balance, and inner awareness.Plates exercises were applied as a group treatment. Exercises were applied by a researcher physiotherapist.
62726873|NCT03475069|EXPERIMENTAL|Chalistenics intervention|These exercises included range of motion exercises of neck (flexion, extension, lateral flexion and rotation), shoulder (flexion, extension, abduction, adduction, internal and external rotation), elbow (flexion and extension), forearm (pronation and supination), wrist (flexion and extension), hip (flexion, extension, abduction and adduction, internal and external rotation), knee (flexion and extension), foot (dorsi and plantar flexion, pronation and supination) and trunk (flexion, extension, lateral flexion and rotation). Exercises were applied by a researcher physiotherapist.
62736247|NCT04979026|ACTIVE_COMPARATOR|intermittent pneumatic compression|In group 2, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
62737935|NCT00879151|EXPERIMENTAL|Psychotherapy|Patients are randomized to one of three different types of psychotherapy: Cognitive-Behavioral Therapy for adolescents, Family-Based Therapy for Bulimia Nervosa, and Supportive Psychotherapy. All treatments consist of 18 sessions over a period of approximately 6 months.
62726874|NCT04207515|EXPERIMENTAL|Removal of wisdom tooth under conscious sedation|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure, oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia , intraoperative time-after extraction , postoperative time . In this group removal of wisdom teeth was done under conscious sedation. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
62726875|NCT04207515|ACTIVE_COMPARATOR|Removal of wisdom tooth under local anesthesia|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure , oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia, intraoperative time-after extraction, postoperative time. In this group, removal of wisdom teeth was done under local anesthesia. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
62165974|NCT04010981|ACTIVE_COMPARATOR|control group-home based video exercise group|Patients will be join home based exercises two days a week during 12 sessions .we will prepare for the lower and upper extremity features similar to Nintendo Wii Fit exercises 30 minutes of video game exercise practices, 5 minutes warm-up exercises, 5 minutes cooling exercises and complete the 50-minute training session with the breathing exercises we will teach them. In addition to exercise sessions, patients will record their activities (walking, cycling, swimming ına) in daily life schedules with their pedometers. Thus, changes in physical activity levels will be monitored.
62165975|NCT05418335||stroke group|stroke history at least 3 months ago
62726876|NCT00996658|EXPERIMENTAL|Linagliptin|Linagliptin tablets once daily
62726877|NCT00996658|PLACEBO_COMPARATOR|Placebo|Placebo tablets once daily
62726878|NCT02709720|EXPERIMENTAL|1 Experimental group|"2 cycles of metronomic Vinorelbine 50 mg + cisplatin, followed by 2 cycles of Vinorelbine 30 mg + cisplatin concomitant with radiotherapy~Induction chemotherapy:~* Cisplatin: 80 mg/m2 day 1 every 21 days, for 2 cycles.~* Metronomic oral vinorelbine: 50mg/day, 3 days of each week for 2 cycles.~Concomitant chemotherapy and radiotherapy:~* Cisplatin: 80 mg/m2 day 1 every 21 days, for 2 cycles.~* Metronomic oral vinorelbine: 30mg/day, 3 days of each week for 2 cycles. 1 cycle equals 21 days~Radiotherapy treatment:~Patients will receive concomitant thoracic radiation therapy, using a technique three-dimensional conformal radiation therapy, using an accelerator linear that operates with energy rays ≥ 6 MV. The total target RTT dose will be 66 Gy in 33 daily fractions of 2 Gy, which will be prescribed in accordance with the document of ICRU reference 50 of ICRU."
62726879|NCT03814356|EXPERIMENTAL|IV MPH|All patients will receive IV Methylphenidate (MPH). Patients will receive escalating daily doses of IV MPH starting at 0.5 mg/kg, increasing stepwise to 1.0mg/kg and 2.0 mg/kg unless an adverse event (AE) necessitates dose de-escalation or a serious adverse event (SAE) necessitates that the patient stop participation in the study.
62726880|NCT03652389|EXPERIMENTAL|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
62726881|NCT03652389|NO_INTERVENTION|Usual Care|Standard Diabetes Treatment
62726882|NCT01312727|OTHER|HTIN|HTIN
62726883|NCT02250469|ACTIVE_COMPARATOR|Axium SCS System|Implantation with the Axium Neurostimulator
62726884|NCT02250469|ACTIVE_COMPARATOR|Medtronic SCS System|Implantation with the Medtronic Prime Advanced Dorsal Column Stimulation System
62726885|NCT06455878|EXPERIMENTAL|Full usage of diet management app group and with the full usage of an intelligent weight scale|"Full usage of the diet management app means subjects can use all functions of the application (including personal information, food record, weight record, exercise record, step count, daily dietary intake, distribution and analysis of dietary structure, and recommended foods and their structural distribution).~Full usage of the intelligent weight scale means subjects can use all functions of the scale (including the report of heart rate, total body water, body fat rate, muscle mass, protein mass, bone mass, visceral fat index, basal metabolic rate, subcutaneous fat rate, and skeletal muscle rate)."
62726886|NCT06455878|ACTIVE_COMPARATOR|Limited usage of diet management app group and with the limited usage of an intelligent weight scale|"Limited usage of the diet management app means subjects can use some functions of the application (including personal information, food record, weight record, exercise record, and step count).~Limited usage of the intelligent weight scale means subjects can use a few functions of the scale (including the weight record, lower limb impedance value, and BMI)."
62726887|NCT00500461|EXPERIMENTAL|Subjects receiving GSK233705|Each subject will receive one or more ascending doses given as a constant rate IV infusion over 30 minutes and a single oral dose of 250 microgram GSK233705 solution. IV doses will include 30, 70, 110 microgram of GSK233705 at specified time points.
62726888|NCT02508545|OTHER|perceived egocentric distance measurements - parabolic flight|perceived egocentric distance (PED) measurements during parabolic flight
62726889|NCT03204604|EXPERIMENTAL|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
62726890|NCT03204604|EXPERIMENTAL|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
62726891|NCT00106041|OTHER|Arm 1|Palliative Care Nurse Case Management
62726892|NCT03513913|EXPERIMENTAL|IVF|Oocytes fertilized by conventional in vitro fertilization (IVF) method
62726893|NCT03513913|EXPERIMENTAL|ICSI|Oocytes fertilized by intracytoplasmic sperm injection (ICSI) method
62726894|NCT00524888|ACTIVE_COMPARATOR|1|suturing lacerations of the hand
62726895|NCT00524888|ACTIVE_COMPARATOR|2|using bioadhesive on lacerations of hand
62165976|NCT05418335||Control group|Healthy control
62165977|NCT03925298||group 1|participants with elevated serum troponin level (≥0.01μg/L)
62165978|NCT03925298||group 2|those with normal serum troponin level (\<0.01μg/L)
62726896|NCT03782064|EXPERIMENTAL|Nivolumab+DC/myeloma fusions/GM-CSF|"* Nivolumab will be given every two weeks~* The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle"
62726897|NCT00790543||Observation|Children newly diagnosed with Crohn's disease.
62726898|NCT02419378|EXPERIMENTAL|alemtuzumab|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
62726899|NCT04190823|EXPERIMENTAL|RC98|
62726900|NCT03269357|OTHER|Intervention|"Clinics randomized to intervention will provide structured LARC centered counselling"
62726901|NCT03269357|NO_INTERVENTION|Routine counselling|Clinics randomized to routine counselling
62726902|NCT00756353||Wave 1|
62726903|NCT00756353||Wave 2|
62726904|NCT01189786|EXPERIMENTAL|Cohort 2: CD34+ cells as a top off|"Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a topoff without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse."
62726905|NCT01189786|EXPERIMENTAL|Cohort 1: CD34+ Cells for transplant|Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
62726906|NCT04891913|EXPERIMENTAL|15mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 15mg SY-007 or placebo twice a day for seven consecutive days.
62726907|NCT04891913|EXPERIMENTAL|30mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 30mg SY-007 or placebo twice a day for seven consecutive days.
62726908|NCT04891913|EXPERIMENTAL|60mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 60mg SY-007 or placebo twice a day for seven consecutive days.
62726909|NCT02523989||study group|children confirmed to have developmental delays
62726910|NCT02523989||control group|children with typical development
62726911|NCT03729635|EXPERIMENTAL|PIFB performed to treat PSP|Pectoral-intercostal fascial plane block (PIFB) is performed on patients with severe post-sternotomy pain (PSP) after coronary artery bypass graft surgery (CABG).
62726912|NCT03659110||1000 subjects receive the HPV 4 vaccine|
62726913|NCT00130039|EXPERIMENTAL|cilostazol|cilostazol 100mg bid plus placebo of clopidogrel
62726914|NCT00130039|ACTIVE_COMPARATOR|Clopidogrel|clopidogrel 75mg qd and matching placebo of cilostazol
62726915|NCT05340530|EXPERIMENTAL|The injectable TQD3606|received a single dose of 0.75g TQD3606 for injection
62726916|NCT05340530|ACTIVE_COMPARATOR|The injectable TQD3606+ meropenem|First, a single dose of 0.5g of meropenem for injection was administered for 0.5h intravenous infusion; after washout for at least 2 days, 0.75g of TQD3606 for injection was administered for 1h intravenous infusion; for at least 2 days of washout, 0.75g was administered A single dose of TQD3606 for injection was administered for 2 hours, and the elution time was at least 2 days. Finally, a single dose of 0.75 g of TQD3606 for injection was administered, and the duration of intravenous infusion was 3 hours.
62726917|NCT05340530|ACTIVE_COMPARATOR|The injectable TQD3606+ meropenem+ Avibactam Sodium|According to the random table, they were divided into two groups, A and B, Group A was given 1.0g meropenem for injection (Mepin) in the first cycle, and 0.5g avibactam sodium for injection in the second cycle. The third cycle was given 1.5g TQD3606 for injection; group B was given 0.5g avibactam sodium for injection in the first cycle, 1.0g meropenem (Mepin) for injection in the second cycle, and 1.5g for injection in the third cycle TQD3606.
62726918|NCT05340530|EXPERIMENTAL|The injectable TQD3606-1|First, 0.75g TQD3606 for injection was administered multiple times (Dosing every 8 hours, 3 consecutive doses), and at least 2 days were washed out after the last dose; then 1.125g TQD3606 for injection was administered multiple times (Dosing every 12 hours, 2 consecutive doses) times), wash out at least 2 days after the last administration; finally, a single administration of 2.25 g of TQD3606 for injection (Dosing every 12 hours, once administered). Intravenous infusion for 3 hours.
62726919|NCT05340530|PLACEBO_COMPARATOR|The injectable TQD3606/ Placebo|First, a single dose of 3.0g TQD3606 for injection/placebo was administered, intravenous infusion for 3hours, and washout for at least 3 days; then multiple doses of 3.0g TQD3606 for injection/placebo were administered (Dosing every 8 hours, 10 consecutive doses) , the intravenous infusion duration is 3hours.
62726920|NCT01728285|ACTIVE_COMPARATOR|Electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
62726921|NCT01728285|NO_INTERVENTION|No electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
62726922|NCT03375931|EXPERIMENTAL|prayer group|
62726923|NCT03375931|ACTIVE_COMPARATOR|non-prayer group|
62726924|NCT02791347|NO_INTERVENTION|Control|"Upon discharge from the medical center, patients would be advised on a qualitative, neutropenic diet. Participants' quality of life, physical activity level, functional and nutritional status would be assessed at days +30, +60 and +100 post transplantation.~These participants will not receive nutritional counseling by the dietitian as outpatients except if referred by the medical team."
62726925|NCT02791347|EXPERIMENTAL|Nutrition Intervention Group|"Upon discharge from the medical center, NIG patients will receive tailored nutrition counseling with the provision of patient education material and oral nutritional supplements if needed. Patients will be advised on a diet high in energy and proteins and tailored to their medical condition in the hospital before discharge.~Patients will be followed up at days +30, +60 and +100 post transplantation. Compliance will be measured at each visit by comparing patients caloric and protein needs to their actual protein and energy intake. Compliance will be reinforced to meet patients' goals using nutritional tips, oral supplementation, and artificial nutrition use."
62726926|NCT05068986|OTHER|single arm intervention|
62726927|NCT04704713|EXPERIMENTAL|Afamelanotide|Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
62726928|NCT04704713|PLACEBO_COMPARATOR|Placebo|Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
62726929|NCT04651465|EXPERIMENTAL|Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
62726930|NCT04651465|NO_INTERVENTION|Business as usual|"control groups have business as usual, and then get offered the intervention program after one year follow-up assessment."
62726931|NCT04971967|EXPERIMENTAL|Crowdsourced HIV PS Group|Participants in the intervention group will receive crowdsourced partner services intervention, including postcards from the crowdsourcing contest that promote PS, provider referral and dual referral services, and take-home HIV self testing kits.
62726932|NCT04971967|NO_INTERVENTION|Conventional HIV PS Group|Participants in the control group will receive traditional partner services intervention, including referral cards that encourage the index patient to notify their partners by themselves.
62726933|NCT03500289|EXPERIMENTAL|Ketamine|
62726934|NCT03500289|PLACEBO_COMPARATOR|Midazolam|
62726935|NCT05468281||Before Period|The before period (12 months) serves as the control period prior to implementation; data will be collected by health records review.
62726936|NCT05468281||After Period|The after period (12 months) will be when patients are prospectively enrolled, and outcomes assessed.
62726937|NCT01603173|EXPERIMENTAL|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
62726938|NCT01603173|ACTIVE_COMPARATOR|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
62726939|NCT06073080|EXPERIMENTAL|Protein Nutrition Even|Volunteers will consume 1.6 g protein/kg/d as an even (\~0.4/0.4/0.4/0.4 g/kg) distribution across breakfast, lunch, dinner, and a snack.
62726940|NCT06073080|ACTIVE_COMPARATOR|Protein Nutrition Skewed|Volunteers will consume 1.6 g protein/kg/d as a skewed (\~0.11/0.27/1.15/0.07 g/kg) distribution across breakfast, lunch, dinner, and a snack.
62726941|NCT03554018|EXPERIMENTAL|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
62726942|NCT03554018|ACTIVE_COMPARATOR|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
62726943|NCT01063348|ACTIVE_COMPARATOR|N-Acetyl Cysteine|N-Acetyl Cysteine - 600mg tablets by mouth (dosing 1200mg - 3000mg qd)
62726944|NCT01063348|PLACEBO_COMPARATOR|Placebo|Matching placebo taken daily
62726945|NCT04621994|ACTIVE_COMPARATOR|Steri Strips Arm|
62726946|NCT04621994|EXPERIMENTAL|Dermabond Arm|
62726947|NCT05762042|EXPERIMENTAL|Femal|Patients in this arm will receive FEMAL (2 cp/die) for three months long
62726948|NCT05762042|PLACEBO_COMPARATOR|Placebo|Patients in this arm will receive PLACEBO (2 cp/die) for three months long
62726949|NCT03547908|EXPERIMENTAL|B/F/TAF|B/F/TAF + placebo to match DTG + placebo to match F/TDF for 96 weeks.
62726950|NCT03547908|ACTIVE_COMPARATOR|DTG+F/TDF|DTG + F/TDF + placebo to match B/F/TAF for 96 weeks.
62726951|NCT03547908|EXPERIMENTAL|Open-label Extension Phase: B/F/TAF|After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
62726952|NCT02986633||Patients with heart failure and CRT|Heart failure with left ventricular ejection fraction less than 35 % treated with CRT
62726953|NCT04927481|EXPERIMENTAL|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced HER2 negative breast cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for about 6 cycles.
62726954|NCT06090123|EXPERIMENTAL|TPN171H and Itraconazole|Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
62726955|NCT06090123|EXPERIMENTAL|TPN171H and Rifampicin|Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
62726956|NCT00243191|OTHER|imatinib mesylate|
62726957|NCT03819387|EXPERIMENTAL|NBF-006|
62726958|NCT02560090|PLACEBO_COMPARATOR|Control Group|Survey assessments as well as collection of medical records and billing information.
62726959|NCT02560090|ACTIVE_COMPARATOR|Telephonic Nurse Intervention|Survey assessments as well as collection of medical records and billing information. A nurse will communicate with participants via telephone to support diabetes self-management practices.
62726960|NCT02560090|ACTIVE_COMPARATOR|In-person Community Health Worker Intervention|Survey assessments as well as collection of medical records and billing information. A community health worker will work with participants in person to support diabetes self-management practices.
62726961|NCT04169178|EXPERIMENTAL|HLX55, dose finding stage, advanced solid tumor|Participants will receive HLX55 at assign dose level, e.g. 2.5, 5, 15 and 25 mg/kg every three weeks followed by a 21-day DLT observation period.
62726962|NCT04169178|EXPERIMENTAL|HLX55, dose expansion stage, gastric cancer|Participants diagnosed with gastric cancer with will receive HLX55 in recommended phase 2 dose (RP2D) every three weeks.
62726963|NCT04169178|EXPERIMENTAL|HLX55, dose expansion stage, NSCLC|Participants diagnosed with non-small cell lung cancer (NSCLC) with will receive HLX55 in RP2D every three weeks.
62726964|NCT04169178|EXPERIMENTAL|HLX55, dose expansion stage, colorectal cancer|Participants diagnosed with colorectal cancer (CRC) with will receive HLX55 in RP2D every three weeks.
62726965|NCT04169178|EXPERIMENTAL|HLX55, dose expansion stage, other solid cancer|Participants diagnosed with other solid cancer with will receive HLX55 in RP2D every three weeks.
62726966|NCT01862406|EXPERIMENTAL|Generic Label|Purportedly generic version of the analgesic presented
62726967|NCT01862406|ACTIVE_COMPARATOR|Brand-name Label|actual brand-name analgesic presented
62726968|NCT01611740||Preterm infants|Telemonitoring system prototype developed by INSERM U-642
62737936|NCT03241277|EXPERIMENTAL|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
62737937|NCT03241277|EXPERIMENTAL|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
62726969|NCT05110781|EXPERIMENTAL|Treatment (atezolizumab, surgery, radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Beginning 6 weeks after surgery, patients with residual disease undergo standard of care radiation therapy and receive atezolizumab IV over 30-60 minutes on day 1. Treatment with atezolizumab repeats every 21 days for up to 15 cycles in the absence of disease progression and unacceptable toxicity.
62726970|NCT03381664|EXPERIMENTAL|AVP-923-20/10 capsule|Participants will receive a single AVP-923-20/10 (dextromethorphan hydrobromide \[DM\] 20 milligram \[mg\]/quinidine sulfate \[Q\] 10 mg) capsule administered orally.
62726971|NCT03381664|EXPERIMENTAL|AVP-923-20/10 via applesauce|Participants will receive the contents from a single AVP-923-20/10 capsule mixed and consumed in 1 tablespoon of applesauce.
62726972|NCT03381664|EXPERIMENTAL|AVP-923-20/10 via nasogastric feeding tube|Participants will receive the contents from a single AVP-923-20/10 capsule solubilized in feeding solution and administered through a nasogastric feeding tube.
62726973|NCT00348946|ACTIVE_COMPARATOR|Oxandrolone|Androgen oxandrolone: Oxandrolone, 0.6 \> mg/kg/day, orally, for 2 years.
62726974|NCT00348946|PLACEBO_COMPARATOR|Placebo|An inactive substance.
62726975|NCT02091635|ACTIVE_COMPARATOR|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
62726976|NCT02091635|PLACEBO_COMPARATOR|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
62726977|NCT06351982|EXPERIMENTAL|Hand and ultrasonic scalers and curettes|Hand and ultrasonic scalers and curettes will be used for supra- and subgingival instrumentation.
62726978|NCT06351982|ACTIVE_COMPARATOR|Electro Medical Systems AIRFLOW® Prophylaxis Master Device With Erythritol Powder|An erythritol powder will be used by Electro Medical Systems AIRFLOW® Prophylaxis Master Device.
62726979|NCT02877576|EXPERIMENTAL|Epileptic patient|micro-electrode recordings interventions: Implantation of mixed intracerebral electrodes Face detection Face individualization
62726980|NCT05325229|EXPERIMENTAL|Docetaxel combined with Bevacizumab|Docetaxel for Injection (Albumin-bound) will be administrated once every 3 weeks at a dose of 75 mg/m\^2 or 100 mg/m\^2; Bevacizumab will be administrated once every 3 weeks at a dose of 15mg/kg.
62726981|NCT03752203|EXPERIMENTAL|Sodium-Fluorescein Resection|This study will employ the use of sodium fluorescein and an FDA approved operative microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
62726982|NCT00953953||Acutely Decompensated Systolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
62726983|NCT00953953||Chronic HF Patients on Dialysis|Patients who have heart failure (defined as NYHA class II, III, or IV) and are on dialysis.
62726984|NCT00953953||Ambulary Chronic HF|Patients with diagnosis of chronic heart failure (NYHA class II and III) who are on optimal medical therapy.
62726985|NCT00953953||Acutely Decompensated Diastolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
62726986|NCT02382991|OTHER|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
62726987|NCT02382991|OTHER|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
62726988|NCT05528406|EXPERIMENTAL|HLX208|
62726989|NCT04787731|ACTIVE_COMPARATOR|Lidocaine|Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent. It exists in liquid form in cartridges. Lidocaine is a FDA approved marketed anesthetic drug.
62726990|NCT04787731|ACTIVE_COMPARATOR|Bupivacaine|Bupivacaine HCI (1.8mL) 5% concentration, with epinephrine (1:200,000) is the investigational product. It exists in liquid form in cartridges. Bupivacaine is a FDA approved marketed anesthetic drug and meets IND Exemption.
62726991|NCT05854537|ACTIVE_COMPARATOR|Sphenopalatine ganglion block using bupivacaine: xylocaine mixture for maxillofacial surgeries|Patients will have the cotton swab soaked in the LA medication (bupivacaine: lidocaine) introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication. Then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
62726992|NCT05854537|PLACEBO_COMPARATOR|Sphenopalatine ganglion block using normal saline for maxillofacial surgeries|Patients will undergo the same procedure but the cotton swab will be soaked into a normal saline solution, and the injection will be done by normal saline as well.
62726993|NCT05001971|EXPERIMENTAL|Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
62726994|NCT04514731|EXPERIMENTAL|Group M|Patients in the magnesium sulfate group received magnesium sulfate 50 mg/kg for 15 minutes after spinal anesthesia and then 15 mg/kg/hour by continuous intravenous infusion until the end of surgery
62726995|NCT04514731|PLACEBO_COMPARATOR|Group S|Patients in the saline group received the same volume of isotonic saline over the same period with magnesium infusion protocol
62726996|NCT01393899|PLACEBO_COMPARATOR|Placebo BID|
62726997|NCT01393899|EXPERIMENTAL|5mg BID|
62726998|NCT01393899|EXPERIMENTAL|10mg BID|
62726999|NCT05442567|EXPERIMENTAL|Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 150 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
62727000|NCT05442567|EXPERIMENTAL|Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 100 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
62727001|NCT05442567|EXPERIMENTAL|Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 200 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \>15 to \<30 kg will receive vedolizumab 200 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
62737938|NCT03241277|ACTIVE_COMPARATOR|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
62727002|NCT05442567|EXPERIMENTAL|Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 100 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \>15 to \<30 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
62727003|NCT05442567|EXPERIMENTAL|Treatment Cohort: Participants ≥30 kg, Vedolizumab 300 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 300 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
62727004|NCT05442567|EXPERIMENTAL|Treatment Cohort: Participants ≥30 kg, Vedolizumab 150 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
62727005|NCT05442567|OTHER|Observational Cohort: Early Terminated Participants From Parent Studies|Participants will have assessment visits at Day 1 and Weeks 8, 34, 60, and 86 as part of a long-term follow-up period to assess prespecified safety events of interest and to monitor growth and pubertal development for approximately 2 years after their last dose of study drug in parent study.
62727006|NCT06457113|EXPERIMENTAL|TMR group|Patients will receive a sound S1 and sound S2 while they generate a correct outcome of Emotional Attention Bias Modification(EABM). They will also receive the sound S1 and sound S2 during REM sleep.
62727007|NCT06457113|ACTIVE_COMPARATOR|Control group|Patients will not receive the sound S1 and sound S2 while they generate a correct outcome of Emotional Attention Bias Modification(EABM). During REM sleep, they will receive the same sound as the experimental group (S1 and S2) under the same conditions.
62727008|NCT04717921||Patients|Subjects with unipolar depression
62727009|NCT04717921||Healthy|Healthy Control Group
62727010|NCT05208008||With service dog|Veterans living with a certified service dog
62727011|NCT05208008||Without service dog|Veterans living without a certified service dog
62727012|NCT00190333|ACTIVE_COMPARATOR|A|
62727013|NCT05409469||Chinese patients with aortic dissection|Clinical characteristics, management patterns and outcomes of type A aortic dissection in China.
62727014|NCT05409469||American patients with aortic dissection|Clinical characteristics, management patterns and outcomes of type A aortic dissection in the United States.
62727015|NCT03774797||Pre-Implementation Patients|Enrolled patients will take online surveys following a prenatal or a postpartum visit.
62727016|NCT03774797||Post-Implementation Patients|All enrolled patients will take online surveys following a prenatal or a postpartum visit. A subset will be interviewed after the postpartum survey.
62727017|NCT03774797||Post-Implementation Providers|All enrolled providers will take online surveys at 6-12 months after program implementation, and a subset will be interviewed.
62727018|NCT01033084|EXPERIMENTAL|Sham stimulation / sertraline|In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
62727019|NCT01033084|SHAM_COMPARATOR|Sham stimulation / placebo pill|"Placebo pills are sugar pills having the same size and shape of the active pills.~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation."
62727020|NCT01033084|EXPERIMENTAL|Active stimulation / Sertraline|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Patients will receive Sertraline 50mg/day."
62727021|NCT01033084|EXPERIMENTAL|Active stimulation / placebo pill|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Placebo pills are sugar pills having the same size and shape of the active pill"
62727022|NCT04899726|EXPERIMENTAL|Intervention|Oncology patients candidate for rectal surgery (tumors located up to 15 cm from the anal margin) and meet inclusion criteria. Rectoscope (P201630551) allows the identification of the distal section margin.
62727023|NCT05694663||Patients Undergoing Vagal Nerve Stimulation for Stroke Recovery|"Individuals undergoing vagal nerve stimulation (VNS) paired rehabilitation will be included in this cohort.~This is a registry study with no active intervention outside standard of care. Patients with chronic ischemic stroke will be implanted with the Vivistim vagal nerve stimulation device per standard of care."
62727024|NCT03513315|EXPERIMENTAL|Intervention Community Clusters|For the community-based arm of the study, 16 clusters will be randomized into intervention and control groups. Those in the intervention group will receive implementation of community-based Home Heat Bundle. This Bundle includes education from community health workers on the signs and symptoms of heat-related illness, how to prevent the illness, and when to seek treatment. In addition, the intervention group will receive SMS messaging with information about heatwaves. The education and Short Message Service (SMS) messaging will occur in March and April via meetings in households and in public spaces. There will be a total of 40 activities, each lasting approximately two hours.
62727025|NCT03513315|EXPERIMENTAL|Control Community Clusters|Eight community clusters of 1000 population each where regular community-based healthcare services will be provided without focused interventions on identification and management of heat-related illnesses. These clusters will receive regular community healthcare provision.
62727026|NCT02994745|EXPERIMENTAL|A fixed dose combination group|A fixed dose combination of Fimasartan/Atorvastatin
62727027|NCT02994745|ACTIVE_COMPARATOR|Co-administration group|Co-administration of Fimasartan and Atorvastatin
62727028|NCT05118113|OTHER|Healthy donors|
62727029|NCT03396627||muller muscle|muller muscle and conjunctiva excised during muller muscle conjunctival resection
62727030|NCT04789720|EXPERIMENTAL|SyMon-SAYS Intervention (Group A)|Group A participants will receive the SyMon-SAYS intervention every week for 16 weeks.
62727031|NCT04789720|OTHER|SyMon-SAYS Waitlist Control (Group B)|The waitlist control group participants (Group B) will receive their usual care during weeks 1-8 and will receive the SyMon-SAYS intervention every week during weeks 9-16.
62727032|NCT03048201|OTHER|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
62727033|NCT03048201|OTHER|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
62727034|NCT03048201|OTHER|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
62727035|NCT03048201|OTHER|Physica CR with LMC Liner|Subjects that receive the Physica Cruciate Retaining Knee System with LMC Liner
62727036|NCT01460069|ACTIVE_COMPARATOR|Victoza treatment|
62727037|NCT01460069|PLACEBO_COMPARATOR|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
62727038|NCT00933439|EXPERIMENTAL|Duloxetine|
62727039|NCT03087604|ACTIVE_COMPARATOR|Traditional Technique Group|In the traditional loss of resistance technique group, the epidural catheter will be placed after achieving loss of resistance to air. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.
62727040|NCT03087604|EXPERIMENTAL|Electric Stimulation Group|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.Thoracic epidural block with Electrical Nerve stimulation
62727041|NCT06425653|EXPERIMENTAL|Exercise Program|"In the control group the standard protocol was applied. The standard protocol included routine care and treatment practices conducted by the same physician at the same institution. In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"
62727042|NCT06425653|NO_INTERVENTION|Standart Protocol|The standard protocol included routine care and treatment practices conducted by the same physician at the same institution.
62727043|NCT00958477|EXPERIMENTAL|EMD 525797|
62727044|NCT06117345|EXPERIMENTAL|Parents/Caregivers|Parents/caregivers of children hospitalized in the PICU at Monroe Carell Jr. Children's Hospital at Vanderbilt who will participate in the PICU journal intervention
62727045|NCT06117345|NO_INTERVENTION|Patients|Pediatric patients ages 8 to 18 years whose parents/caregivers participated in the PICU journal intervention
62727046|NCT06117345|NO_INTERVENTION|PICU providers and staff|PICU providers and staff who observed or participated in the PICU journal intervention during its use with parents/caregivers
62727047|NCT05814718|EXPERIMENTAL|modified BEAM conditioning regimen|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
62727048|NCT05814718|ACTIVE_COMPARATOR|BEAM conditioning regimen|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
62727049|NCT02526303|EXPERIMENTAL|Anticoagulation|Drug: Nadroparin Calcium and Warfarin Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,along with Nadroparin Calcium 85IU／kg，subcutaneous, q12h,for the first 5 days at least.
62727050|NCT02526303|NO_INTERVENTION|Non-anticoaglated|No anticoagulatoin or other treatment for PVT will be used in this group of patients.
62727051|NCT05673824|EXPERIMENTAL|Huaier Granule Group|Huaier Granule+VEGFR-TKIs
62727052|NCT04156334|EXPERIMENTAL|computer-controlled intraosseous anaesthesia|Patients will receive the local anaesthetic using computer-controlled intraosseous anaesthesia (Quicksleeper 5) before the tooth extraction in general anaesthesia.
62727053|NCT04156334|EXPERIMENTAL|infiltrative or conductive local anaesthesia|Patients will receive a local anaesthetic using carpule before the tooth extraction in general anaesthesia.
62727054|NCT01050751|EXPERIMENTAL|Lersivirine (new formulation)|
62727055|NCT01050751|ACTIVE_COMPARATOR|Lersivirine (old formulation)|
62727056|NCT01345929|EXPERIMENTAL|CXA-201 as treatment for cUTI|CXA-201 IV infusion (1500mg q8) for 7 days
62727057|NCT01345929|ACTIVE_COMPARATOR|Levofloxacin as treatment for cUTI|Levofloxacin IV infusion (750mg qd) for 7 days
62727058|NCT02441101|EXPERIMENTAL|RV pacing optimization on/off|RBBB pacing Arm 1 is RV pacing optimization on/off
62727059|NCT02441101|PLACEBO_COMPARATOR|RV pacing optimization off/on|Standard demand pacing Arm 2 is RV pacing optimization off/on
62727060|NCT04593368|EXPERIMENTAL|FMT|
62727061|NCT01706653|ACTIVE_COMPARATOR|Intervention 1|Polyphenol-enriched fruit-based drink - low
62727062|NCT01706653|ACTIVE_COMPARATOR|Intervention 2|Polyphenol-enriched fruit-based drink - medium
62727063|NCT01706653|ACTIVE_COMPARATOR|Intervention 3|Polyphenol-enriched fruit-based drink - high
62727064|NCT01706653|PLACEBO_COMPARATOR|Intervention 4|Very low polyphenol fruit based drink (control)
62727065|NCT04620889||PVP (peripheral vascular disease)|Bypass or reconstruction of diseased or occluded blood vessels
62727066|NCT04620889||AV Access (arteriovenous access)|Arteriovenous shunting for blood access and bypass.
62727067|NCT01143961|EXPERIMENTAL|NBL with one-way valve|NBL performed with one-way valve in ventilator circuit during procedure
62727068|NCT01143961|NO_INTERVENTION|Standard NBL|Performance of standard NBL with recording of changes in regional ventilation by electrical impedance tomography
62727069|NCT05494268||Experimental ( Carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. The Carb Group will consume carbohdrate fluid and Non-carb Group will consume equal amount of water at night and two hours before the surgery.
62727070|NCT05494268||Standart Care (Non-carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. The Carb Group will consume carbohdrate fluid and Non-carb Group will consume equal amount of water at night and two hours before the surgery.
62727071|NCT05934110|EXPERIMENTAL|EMP16-120/40|EMP16 120 mg orlistat/40 mg acarbose (referred to as EMP16-120/40), 80 participants.
62727072|NCT05934110|ACTIVE_COMPARATOR|MR orlistat|MR orlistat 120 mg, 80 participants.
62727073|NCT05934110|ACTIVE_COMPARATOR|Conventional orlistat|Conventional orlistat 120 mg, 80 participants.
62727074|NCT05934110|EXPERIMENTAL|EMP16-60/20|EMP16 60 mg orlistat/20 mg acarbose (referred to as EMP16-60/20), 40 participants.
62727075|NCT05934110|PLACEBO_COMPARATOR|Placebo|Placebo, 40 participants
62727076|NCT00506454|ACTIVE_COMPARATOR|Lipidose|Dosage of 1.5 mL/kg of Lipidose over a 2-hour period.
62727077|NCT00506454|PLACEBO_COMPARATOR|Placebo|Dosage of 1.5 mL/kg of Placebo over a 2-hour period.
62727078|NCT04738175|EXPERIMENTAL|COVI-AMG|40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
62727079|NCT04738175|PLACEBO_COMPARATOR|Placebo|Placebo will be administered
62727080|NCT05160506|EXPERIMENTAL|Hydrocortisone|Patients in this arm will be administered 100 mg of hydrocortisone in 50 milliliters of saline solution by nursing staff every 8 hours for 72 hours as per standard clinical procedures (9 administrations)
62727081|NCT05160506|PLACEBO_COMPARATOR|Placebo|Patients in this arm will be given matching placebo (50ml 0.9%NACL) by nursing staff every 8 hours for 72 hours (9 administrations)
62727082|NCT00442416|EXPERIMENTAL|RO0503821|Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta \[Mircera\]) subcutaneously (SC) every month for eight months (6 months of titration period \[TP\] and two months of evaluation period \[EP\] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of \>=10.0 gram per decilitre (g/dL) and \<=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
62727083|NCT00442416|ACTIVE_COMPARATOR|Epoetin Alfa|Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.
62727084|NCT02235792|EXPERIMENTAL|Deep Brain Stimulation 37604 Activa PC+S|All subjects will undergo DBS using the 37604 Activa PC+S device (single arm study).
62727085|NCT03455894|EXPERIMENTAL|Smart carpet|
62727086|NCT05204095||Referral group|The patients with severe cataracts in this group need a referral to a higher-level hospital for further treatment.
62727087|NCT05204095||Observation group|The patients with mild cataracts or transparent lenses in this group do not need a referral to a higher-level hospital for further treatment and keep regular examinations.
62727088|NCT02590536|EXPERIMENTAL|sildenafil citrate|Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery
62727089|NCT02590536|PLACEBO_COMPARATOR|placebo|Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.
62727090|NCT00633763||1|Healthy individuals with normal C-peptide levels following i.v. glucagon challenge. These individuals will be administered 18F-fallypride and then subjected to PET-CT scanning of the pancreas and brain. The subject will be positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen carried out (with subjects breathing normally). A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame). The subject will then be repositioned for a low-dose CT scan of the head (15-20 secs) following which a 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).
62727091|NCT00633763||2|Patients with longstanding T1DM and \<20% C-peptide levels following i.v. glucagon challenge will be consented. 18F-Fallypride injected intravenously and subjects allowed to wait for approx 1 hr for the uptake.(b) Subject positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen (pancreas) carried out (with subjects breathing normally).(c) A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame).(d) Subject repositioned for a low-dose CT scan of the head (15-20 secs).(e) A 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).(f) End of PET/CT scanning procedures. Subject taken out of the scanner.
62727092|NCT05198076|NO_INTERVENTION|G1 ( Conventional Physical Therapy Program group)|Patients in (G1) will be treated by a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration was 40min to 1 hour.
62727093|NCT05198076|EXPERIMENTAL|G2 ( High Frequency rTMS group)|Patients in (G2) will be treated by high frequency repetitive transcranial magnetic stimulation (HF-rTMS) in addition to the same physiotherapy program as in G1. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration for rTMS will be 20-30 minutes, the physiotherapy session will be 40-45 min.
62727094|NCT00731861|EXPERIMENTAL|1|Paclitaxel plus PTK787
62727095|NCT02491047|EXPERIMENTAL|BonyPid-1000|Implantation of BonyPid-1000 medical device, constructed of bone filler coated with controlled release antibiotic formulation, concomitantly with standard of care treatment (SOC)
62727096|NCT02491047|OTHER|Study control arm|Standard of care treatment (SOC) only
62727097|NCT03650868|NO_INTERVENTION|Control Group|No intervention will be applied to control group
62727098|NCT03650868|EXPERIMENTAL|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
62727099|NCT02655718|OTHER|Patients with ACS|Patients with ACS who underwent coronary angiography within 72 hours from the onset of disease. In identifying nonobstructive coronary atherosclerosis , patients underwent cardiac contrast MRI.
62727100|NCT04210661|ACTIVE_COMPARATOR|classic prediction software|test with classic precition software
62727101|NCT04210661|EXPERIMENTAL|prediction software with spell checker|test with prediction software with spell checker
62727102|NCT03567889|EXPERIMENTAL|Daromun plus Surgery and Adjuvant therapy (Arm 1)|Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks and adjuvant therapy (Arm 1).
62727103|NCT03567889|ACTIVE_COMPARATOR|Surgery and adjuvant therapy (Arm 2)|Patients in the control arm (Arm 2) will receive direct surgery within 4 weeks from randomization, followed by adjuvant therapy.
62727104|NCT05837039||Healthcare Provider and Caregiver Perception of Discomfort|Participants will be providing demographic information about you (age, sex/gender, race, ethnicity, educational level, if the participant are in the same household as the patient, if participants are the primary caregiver of the patient, and whether you live in a rural, suburban, or urban environment) Your feelings about your loved one's comfort level Your feelings about symptoms you think affect comfort level Behaviors seen while at the bedside of your loved one
62727105|NCT04983771||Expert in ultrasound-guided regional anaesthesia|"At least 15 UGRA experts, member of a relevant professional society (e.g., RA-UK, ESRA, ASRA) and meeting at least 3 of the following criteria) will be recruited from centres in the UK.~* Completed advanced training in UGRA or have \>10 years of independent practice in UGRA~* Hold a qualification related to UGRA (e.g., EDRA, higher degree or equivalent)~* Regularly delivers direct clinical care using UGRA, including for 'awake' surgery where indicated~* Regularly teaches UGRA in the course of their clinical work, including advanced techniques (Plan B/C/D blocks) where indicated"
62727106|NCT01993134|EXPERIMENTAL|Cefazolin|2g of Cefazolin, 20minutes before sugery. After surgery, 1g of cefazolin 06/06h.
62727107|NCT01993134|ACTIVE_COMPARATOR|Cefazolin Single Dose|2g of Cefazolin, 20minutes before sugery. After surgery, no drugs.
62727108|NCT01419600|EXPERIMENTAL|Group 1 - 4, single ascending dose AZD 8683|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
62727109|NCT01419600|PLACEBO_COMPARATOR|Group 1-4 single ascending dose Placebo|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
62727110|NCT01757301|ACTIVE_COMPARATOR|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
62727111|NCT01757301|EXPERIMENTAL|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
62727112|NCT03551613|ACTIVE_COMPARATOR|honey group|malnourished children supplemented with honey in dose of 2ml/kg
62727113|NCT03551613|PLACEBO_COMPARATOR|malnourished control group|no honey supplementation only nutrition rehabilitation
62727114|NCT03551613|NO_INTERVENTION|healthy children|healthy children with no suplementation
62727115|NCT00938613|EXPERIMENTAL|Captisol-Enabled Budesonide|32 ug/spray
62727116|NCT00938613|ACTIVE_COMPARATOR|Rhinocort Aqua|32 ug/spray
62727117|NCT00938613|PLACEBO_COMPARATOR|Placebo|posphate buffered saline
62727118|NCT01146613|ACTIVE_COMPARATOR|Varenicline|Varenicline Tartrate
62727119|NCT01146613|PLACEBO_COMPARATOR|Sugar Pill|
62727120|NCT00838812|OTHER|clindamicin and tretinoin gel|
62727121|NCT05224466||A|defined as patients survived on PD for more than 10 years
62727122|NCT05224466||B|defined as patients survived on PD for 5-10 years
62727123|NCT05224466||C|defined as patients survived on PD within 5 years
62727124|NCT06199128||CONTROL GROUP|For the duration of the study, standard clinical practice will be followed wait and see strategy, without administering carboxymethyl-b-glucan treatment.
62727125|NCT06199128||TREATMENT GROUP|For a period of three months, patients will be administered once daily treatment with Carboxymethyl β-glucan and Polycarbophil
62727126|NCT01722994|EXPERIMENTAL|Group 1 Punch Biopsy Wound with chromic gut suture|One of two absorbable sutures is used to close punch wounds.
62727127|NCT01722994|EXPERIMENTAL|Group 2 Punch Biopsy Wound with PDS|This is one of two absorbable sutures used to close punch biopsy wounds.
62727128|NCT00699413|ACTIVE_COMPARATOR|1 - nutrition education plus active supplement|nutrition education plus active supplement
62727129|NCT00699413|PLACEBO_COMPARATOR|2 - nutrition education plus inactive supplement|nutrition education plus inactive supplement
62727130|NCT02613520|EXPERIMENTAL|Group 1a (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 9 x 10\^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
62727131|NCT02613520|PLACEBO_COMPARATOR|Group 1a (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
62727132|NCT02613520|OTHER|Group 1a (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).
62727133|NCT02613520|EXPERIMENTAL|Group 1b (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
62727134|NCT02613520|PLACEBO_COMPARATOR|Group 1b (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
62727135|NCT02613520|OTHER|Group 1b (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).
62727136|NCT02613520|EXPERIMENTAL|Group 2a (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
62727137|NCT02613520|PLACEBO_COMPARATOR|Group 2a (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
62727138|NCT02613520|EXPERIMENTAL|Group 2b (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart.
62727139|NCT02613520|PLACEBO_COMPARATOR|Group 2b (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
62727140|NCT02613520|EXPERIMENTAL|Group 3a (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
62727141|NCT02613520|PLACEBO_COMPARATOR|Group 3a (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
62727142|NCT02613520|EXPERIMENTAL|Group 3b (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 1.8 x 10\^6 PfSPZ Vaccine given 8 weeks apart.
62727143|NCT02613520|PLACEBO_COMPARATOR|Group 3b (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
62727144|NCT02613520|EXPERIMENTAL|Group 4a (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 4.5 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
62727145|NCT02613520|PLACEBO_COMPARATOR|Group 4a (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
62727146|NCT02613520|EXPERIMENTAL|Group 4b (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
62727147|NCT02613520|PLACEBO_COMPARATOR|Group 4b (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
62727148|NCT02613520|EXPERIMENTAL|Group 5a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 2.7 x 10\^5 PfSPZ Vaccine.
62727149|NCT02613520|EXPERIMENTAL|Group 5b (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 4.5 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
62727150|NCT02613520|PLACEBO_COMPARATOR|Group 5b (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
62727151|NCT02613520|EXPERIMENTAL|Group 5c (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 9.0 x 10\^5 PfSPZ Vaccine given 8 weeks apart.
62727152|NCT02613520|PLACEBO_COMPARATOR|Group 5c (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
62727153|NCT02172391|EXPERIMENTAL|Tiotropium|Tiotropium inhalation powder capsules 18 mcg, one capsule once daily for 28 days
62727154|NCT02172391|PLACEBO_COMPARATOR|Placebo|Placebo inhalation powder capsules, one capsule once daily for 28 days
62727155|NCT01224327|EXPERIMENTAL|umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
62727156|NCT01224327|ACTIVE_COMPARATOR|Conserved therapy|Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
62727157|NCT05066126|EXPERIMENTAL|High-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a high-mixed presentation of content.
62727158|NCT05066126|EXPERIMENTAL|Low-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a low-mixed presentation of content.
62727159|NCT05066126|EXPERIMENTAL|High-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a high-mixed presentation of content.
62727160|NCT05066126|EXPERIMENTAL|Low-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a low-mixed presentation of content.
62727161|NCT03943290|EXPERIMENTAL|Part 1 Cohort 1a|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for FSHD patients
62727162|NCT03943290|EXPERIMENTAL|Part 1 Cohort 1b|ACE-083 240 mg/muscle administered bilaterally by injection into the BB muscle every 4 weeks for up to 6 doses for FSHD patients
62727163|NCT03943290|EXPERIMENTAL|Part 1 Cohort 1c|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for CMT patients
62727164|NCT03943290|EXPERIMENTAL|Part 2 Cohort 2a|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for FSHD patients
62727165|NCT03943290|EXPERIMENTAL|Part 2 Cohort 2b|ACE-083 Administered into the BB muscle q4w for up to 24 months (24 doses) for FSHD patients
62727166|NCT03943290|EXPERIMENTAL|Part 2 Cohort 2c|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for CMT patients
62727167|NCT03943290|EXPERIMENTAL|Part 2 Cohort 3a|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for FSHD patients
62727168|NCT03943290|EXPERIMENTAL|Part 2 Cohort 3b|ACE-083 Administered into the BB muscle q8w for up to 24 months (12 doses) for FSHD patients
62727169|NCT03943290|EXPERIMENTAL|Part 2 Cohort 3c|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for CMT patients
62727170|NCT00529243|EXPERIMENTAL|MK-0518 (raltegravir)|Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
62727171|NCT00860626|EXPERIMENTAL|1|At the twelfth week of interferon α treatment, HBV DNA is detectable(\>1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.
62727172|NCT00860626|ACTIVE_COMPARATOR|2|At the twelfth week of interferon α treatment, HBV DNA is detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
62727173|NCT00860626|ACTIVE_COMPARATOR|3|At the twelfth week of interferon α treatment, HBV DNA is undetectable (\<1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.
62727174|NCT06261008|NO_INTERVENTION|Standard Care|An automated noninteractive short message service (SMS) text reminder, used by the Program as standard care (SC), is delivered to participants who are due for repeat FIT.
62727175|NCT06261008|EXPERIMENTAL|Telehealth Intervention group|Subjects randomized to the Telehealth Intervention (TI) group will receive the SC as well as an interactive TI with interactive health education messages via a WhatsApp-based chatbot on the repeat FIT due date. All subjects will be followed up on WhatsApp at 3 months after their repeat FIT due date and asked about their repeat FIT status.
62727176|NCT01490255|ACTIVE_COMPARATOR|Ranolazine|Patients will receive ranolazine (750 mg bid) for 15 days
62727177|NCT01490255|ACTIVE_COMPARATOR|Amlodipine|Patients will receive amlodipine (10 mg once daily) for 15 days
62727178|NCT02146053|ACTIVE_COMPARATOR|Ferrous sulfate|ferrous sulfate taken at mealtimes twice daily during 1 week of the treatment period.
62727179|NCT02146053|PLACEBO_COMPARATOR|Placebo|placebo taken at mealtimes twice daily during 1 week of the treatment period.
62727180|NCT01469481|EXPERIMENTAL|1|
62727181|NCT03552107||Observational Group - Lorcaserin Treated|The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
62727182|NCT00581048|EXPERIMENTAL|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
62727183|NCT01559545|ACTIVE_COMPARATOR|Metronidazole|Immediate release metronidazole
62727184|NCT01559545|EXPERIMENTAL|Metronidazole-DRF1|Modified release metronidazole (DRF1)
62727185|NCT01559545|EXPERIMENTAL|Metronidazole-DRF2|Modified release metronidazole (DRF2)
62727186|NCT03137953|EXPERIMENTAL|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
62727187|NCT00654225|EXPERIMENTAL|1|Rosuvastatin
62727188|NCT00654225|ACTIVE_COMPARATOR|2|Atorvastatin
62737939|NCT06523764|EXPERIMENTAL|tegoprazan and minocycline dual theropy|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
62727189|NCT01922882|EXPERIMENTAL|Amagugu Counseling Intervention|"The 'Amagugu' intensive 6 session home-based intervention. All 6 visits will be undertaken by a lay counsellor over a period of 8-10 weeks. The intervention includes 3 stages linked to the outcomes of the intervention:~* family engagement, personal preparation, disclosure practice using intervention materials~* health promotion training and a mother-child visit~* play-for-communication and custody care planning"
62727190|NCT01922882|NO_INTERVENTION|Standard of Care|"There is currently no Standard of Care in the South African DoH addressing the issue of parental disclosure of HIV status to HIV-uninfected children, beyond a recommendation to 'counsel to disclose'.~Therefore, for women who are randomized to the control group, we will ensure a Standard of Care for all mothers including a one-hour counselling session, focused specifically on disclosure, delivered at the primary health care facility as part of the HIV Programme.~We will orientate all health professionals in the enrolment clinic, including nurses, counsellors and community health care workers, on parental HIV disclosure, and provide a one-day training workshop (including training manual, role-plays and competency testing."
62727191|NCT03623698||Before treatment|Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)
62727192|NCT03623698||After treatment|Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)
62727193|NCT04938284|EXPERIMENTAL|PAS and VNS|
62727194|NCT04938284|ACTIVE_COMPARATOR|PAS and sham VNS|
62727195|NCT04938284|ACTIVE_COMPARATOR|PAS|
62727196|NCT04938284|ACTIVE_COMPARATOR|VNS|
62727197|NCT02424058||Neck pain|Patients aged between 18 and 65 years with persistent neck pain for more than 3 months
62727198|NCT02424058||Healthy|Acceptance to participate in the study, no previous neck oain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected
62727199|NCT05267535|EXPERIMENTAL|Piromelatine 20 mg|Piromelatine 20 mg tablets once daily taken before going to bed, preferably between 2100h and 2300h, and after food consumption.
62727200|NCT05267535|PLACEBO_COMPARATOR|Placebo|Matched placebo tablets, with identical features to the piromelatine tablets, will be used as control treatment
62727201|NCT01918241|EXPERIMENTAL|pegfilgrastim,30mcg/kg|On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.
62727202|NCT01918241|EXPERIMENTAL|pegfilgrastim, 60mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.
62727203|NCT01918241|EXPERIMENTAL|pegfilgrastim,100mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.
62727204|NCT01918241|EXPERIMENTAL|filgrastim,5mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10\^9/L, but at least 7 days.
62727205|NCT01078792||COPD exacerbation|Patients admitted to hospital with COPD exacerbation
62727206|NCT04538131|ACTIVE_COMPARATOR|conventional SCS|
62727207|NCT04538131|EXPERIMENTAL|sensor-driven position-adaptive SCS|
62727208|NCT03468777|EXPERIMENTAL|Part 1: Treatment Sequence (ABC)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4\*250 mg tablets) under fasted condition on Day 1 of period 1 then Treatment B as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment C (optional Part 2) as a single dose of 150 mg ranitidine administered after 2 hours of single dose of 1000 mg lumicitabine (4\*250 mg tablets) under fasted condition on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
62727209|NCT03468777|EXPERIMENTAL|Part 1: Treatment Sequence (BAC)|Participants will receive Treatment B on Days 1 to 5 of period 1 then Treatment A on Day 1 of period 2 followed by Treatment C (optional Part 2) on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
61976702|NCT03886233||Traditional Treatment for Autoimmune uveitis|Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
62727210|NCT03468777|EXPERIMENTAL|Optional Part 3: Treatment Sequence (DEF)|Participants will receive Treatment D as a single oral dose of 1000 mg lumicitabine (4\*250 mg tablets) after standardized breakfast on Day 1 of period 1 then Treatment E as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment F as a single oral dose of 150 mg ranitidine administered after 2 hours after a single oral dose of 1000 mg lumicitabine (4\*250 mg tablets) after standardized breakfast on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
62727211|NCT03468777|EXPERIMENTAL|Optional Part 3: Treatment Sequence (EFD)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment F on Day 1 of period 2 followed by Treatment D on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
62727212|NCT03468777|EXPERIMENTAL|Optional Part 3: Treatment Sequence (FDE)|Participants will receive Treatment F on Days 1 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
62727213|NCT03468777|EXPERIMENTAL|Optional Part 3: Treatment Sequence (FED)|Participants will receive Treatment F on Day 1 of period 1 then Treatment E on Days 1 to 5 of period 2 followed by Treatment D on Days 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
62727214|NCT03468777|EXPERIMENTAL|Optional Part 3: Treatment Sequence (EDF)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment F on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
62727215|NCT03468777|EXPERIMENTAL|Optional Part 3: Treatment Sequence (DFE)|Participants will receive Treatment D on Day 1 period 1 then Treatment F on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
62727216|NCT03856463|EXPERIMENTAL|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay patient navigator who will provide information regarding early advance care planning, documentation of goals of care, and coordinating home-based care. The intervention arm will also receive usual care as provided by their local oncologists.
62727217|NCT03856463|ACTIVE_COMPARATOR|Control Group Arm|The control group will receive usual care as provided by their local oncologists.
62727218|NCT02063984|EXPERIMENTAL|Intensive Outpatient Treatment (IOP) + Contingency Management (CM) + Working Memory Training (WMT)|IOP + CM + WMT
62727219|NCT02063984|ACTIVE_COMPARATOR|IOP + CM|IOP + CM
62727220|NCT04671563|EXPERIMENTAL|Viproof Film Coated Tablets 300mg|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
62727221|NCT04671563|ACTIVE_COMPARATOR|Viread Tablets|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
62727222|NCT04868942|EXPERIMENTAL|Participant assisting to the event|Attending to musical event protected by established protection measures (protection kit, distancing, flow management, health mediation).
62727223|NCT04868942|NO_INTERVENTION|Participant with no other constraints than national recommendations|A group control participant will not attend to the event
62727224|NCT04393662||Tenodesis group|Tenodesis as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
62727225|NCT04393662||Tenotomy group|Tenotomy as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
62727226|NCT05773495|EXPERIMENTAL|Usual Care Followed by I-SITE Intervention|
62727227|NCT02748499|EXPERIMENTAL|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
62727228|NCT02748499|ACTIVE_COMPARATOR|Control|The control group maintains daily activities.
62727229|NCT00845481|EXPERIMENTAL|all patients apply all products|
62727230|NCT05362357|EXPERIMENTAL|Prevention Group|Web-app with five weekly substance modules. Each module is approximately 15 minutes long.
62727231|NCT05362357|ACTIVE_COMPARATOR|Comparison Group|Web-app with single abbreviated module combining all five substances. Module is approximately 20 minutes long.
62727232|NCT05362357|NO_INTERVENTION|Control Group|No access to web-app.
62727233|NCT00638911||Patients with hypertention|
62727234|NCT03497468|ACTIVE_COMPARATOR|Control group|Patients in this group will receive combined exercise training included aerobic and strengthening exercises, 3 times a week for 6 weeks. All exercise sessions will be performed under the supervision of a physiotherapist.
62727235|NCT03497468|EXPERIMENTAL|Training group|Patients in this group will receive task-oriented training additional to combined exercise training 3 times a week for 6 weeks. Task-oriented training included more functional daily life mobility activities like reaching, obstacle walking, stairs climbing. All exercise sessions will be performed under the supervision of a physiotherapist.
62727236|NCT04085978||Pre implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2014 - November 30, 2016 who qualify for hypoglycemia protocol
62727237|NCT04085978||Post implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2018 - November 30 2018 who qualify for hypoglycemia protocol
62727238|NCT03749824|EXPERIMENTAL|Omega-3|Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure.
62727239|NCT03749824|PLACEBO_COMPARATOR|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
62727240|NCT06432400|OTHER|Substance use disorders|Group composed of patients suffering from disorders related to the use of alcohol, cannabis, opiates, inhalants, sedatives, hypnotics, anxiolytics, stimulants, hallucinogens (all of these disorders will have been diagnosed by a doctor before or during follow-up according to Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM 5) criteria)
62727241|NCT04853771|EXPERIMENTAL|experiment|28-29. Between the weeks of gestation, one-time progressive muscle relaxation exercise training prepared by the researcher will be given to the pregnant women. Exercise will be demonstrated in training. Later, pregnant women will be asked to explain and practice the exercise. Women will be repeated until they do the exercise completely correctly (Check-list 1). After the training, pregnant women will be asked to do progressive relaxation exercises at least 3 times a week (every other day). With the progressive muscle relaxation exercise daily follow-up schedule prepared by the researcher, the pregnant women will be followed for 8 weeks and weekly reminders will be made (via whatsapp® or text message). The final test application (36-37 weeks) will be done online at the end of 8 weeks to the pregnant women. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
62727242|NCT04853771|NO_INTERVENTION|control|No intervention will be applied to pregnant women, other than the routine training given in the pregnancy school. In the maternity school, training is given on physiological and psychological changes that occur during pregnancy, baby care, postpartum period, family planning. However, pregnant women are not given any information about RLS, coping methods, creating a healthy lifestyle, and progressive muscle relaxation exercises. Final test application to pregnant women; 36-37. It will be held online between weeks. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
62727243|NCT05629455|EXPERIMENTAL|individuals ages 14 years and older|This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
62727244|NCT05629455|EXPERIMENTAL|individuals aged 2 to 13 years|"This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.~If the subject is under the age of 14, an adult lay-user will collect the sample."
62727245|NCT04209374||HMB-DMR-HA|Primary total hip arthroplasty with hemispherical dual-mobility acetabular cup
62727246|NCT04298294|EXPERIMENTAL|injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with i-PRF\& bone graft
62727247|NCT04298294|NO_INTERVENTION|no injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with bone graft
62727248|NCT03706027|ACTIVE_COMPARATOR|Stereotactic body radiotherapy- 3 fractions|
62727249|NCT03706027|ACTIVE_COMPARATOR|Stereotactic body radiotherapy- 5 fractions|
62727250|NCT05782985||Myeloproliferative neoplasms Cases|The myeloproliferative neoplasms Cases will be tested for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes
62727251|NCT05782985||Controls|Healthy controls will be tested for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes
62727252|NCT00995098|EXPERIMENTAL|Early enteral nutrition|Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
62727253|NCT00995098|ACTIVE_COMPARATOR|Control: Parenteral Nutrition|Twenty patient will be enrolled into this arm. PN administration will start within 24 hours after admission and continue for 7 days after admission.Parenteral nutrition will be administered through subclavian central venous catheter.
62727254|NCT03450239|EXPERIMENTAL|Recovered from anorexia nervosa|Women who have recovered from Anorexia Nervosa for over a year. BMI over 18.5, aged 18-40, scores on Eating Disorder Examination (EDE) within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
62727255|NCT03450239|EXPERIMENTAL|Healthy controls|Healthy control women. BMI over 18.5, aged 18-40, scores on EDE within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
62727256|NCT06379633|EXPERIMENTAL|Virtual reality exposure (VRE)|Participants in the VRE condition will be exposed to various VR-based one-on-one and group social interactions which tend to elicit anxiety. That is, commonly feared situations and events (e.g., raising your hand in class, saying no to a friend, ordering food at a restaurant, calling a classmate to invite them to hang out) will be recreated in the virtual environments. Exercises will be tailored to the participant and provided by clinical psychologists under supervision of experienced CBT therapists (and supervisors). To deliver VRE we will utilize a dynamic and interactive VR-software called 'Social Worlds' developed by CleVR. It has various functions and capabilities (e.g., role-playing, walking around, change of perspective, alteration of dialogue style, number of avatars present in the virtual environment) which enables individualized exposure.
62727257|NCT06379633|ACTIVE_COMPARATOR|In vivo exposure (IVE)|Similarly to VRE, participants in the IVE condition will be exposed to various one-on-one and group social interactions which tend to elicit anxiety, but they will do so in real-life. The exposure exercises here also will be determined in consultation with the participant. Depending on the given exposure exercise, exposure will either take place at the training location or in its neighborhood (e.g., nearby supermarkets, subway stations, cafes, buses). Exercises will be tailored to the participant and provided by clinical psychologists under supervision of experienced CBT therapists (and supervisors). Importantly, participants will undergo the same amount of exposure sessions as in the VRE condition (to keep exposure time constant).
62727258|NCT06379633|NO_INTERVENTION|Waitlist|The participants in the WL condition will complete the assessments at the same time points as in the active conditions but will not receive any of the sessions until post-assessment has been completed. Then they will be randomly assigned to one of the two active conditions (VRE or IVE).
62727259|NCT03243565|ACTIVE_COMPARATOR|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
62727260|NCT03243565|PLACEBO_COMPARATOR|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
62727261|NCT05282875||kidney transplant patients returning to dialysis after graft loss|"This cohort contains kidney transplant patients returning to dialysis after graft loss in Lorraine between 1 January 2007 and 31 December 2019. They are identified by the REIN registry of the Lorraine region.~The REIN registry is a national database that contains multiple information on patients with chronic end-stage renal disease (type of nephropathy, type of replacement therapy, comorbidities)."
62727262|NCT05041998|EXPERIMENTAL|Unmodified Socket + 8 Socket Modifications in Random Order|The sequence of the 9 different interventions (original socket and 8 versions derived from it) is randomized for each participant. The number of participants is smaller than the number of possible permutations. Therefore the enacted ordering is randomly selected from the pool of possible orderings. Participants walk for less than 10 minutes with every socket type while data is being collected.
62727263|NCT02288000|ACTIVE_COMPARATOR|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
62727264|NCT02288000|PLACEBO_COMPARATOR|Placebo|The placebo will be presented as capsule comparable to memantine
62727265|NCT06360653|EXPERIMENTAL|Experimental arm|Patients with endometrial cancer (stage IB-IIIC1) with histological and molecular features that require adjuvant external beam radiotherapy alone or in combination with chemotherapy and/or brachytherapy. Adjuvant radiotherapy will be performed with stereotactic body radiotherapy schedule of 30 Gy in 5 sessions.
62727266|NCT01799343|EXPERIMENTAL|Immersion into water|Normal healthy singleton pregnant women. The case serves as its own control. Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion (Baseline), during immersion (Immersion) and after immersion (Post-immersion).
62737940|NCT06523764|ACTIVE_COMPARATOR|Bismuth-containing quadruple therapy|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
62727267|NCT03759639|EXPERIMENTAL|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~* Patients aged 6-12 years weighing 15 to \<25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~* Patients aged 6-12 years weighing 25 to \<35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~* Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
62727268|NCT03759639|NO_INTERVENTION|Post-Treatment Washout|After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
62727269|NCT04554459|EXPERIMENTAL|ponatinib plus reduced-intensity chemotherapy|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
62727270|NCT04998227||suspect acute coronary syndrome|"Subjects with the diagnosis of suspected acute coronary syndrome (ACS), age between 20 to 80.~Exclusion criteria: pregnant women, patients with end-stage renal disease (eGFR \<15 mL/min/1.73 m2), cardiogenic shock."
62727271|NCT05542446|EXPERIMENTAL|Critically ill patients with ECMO|The subjects connected to ECMO will be treated with colistin ain approved dosing - a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours. Only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours.
62727272|NCT05542446|ACTIVE_COMPARATOR|Critically ill patients without ECMO|The subjects not connected to ECMO will be treated with colistin ain approved dosing - a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours. Only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours.
62727273|NCT02118454|EXPERIMENTAL|Daily IVR calls|"The Daily IVR Calls Intervention: consisting of two (2) automated voice calls (intervention messages) each day for six months, PLUS one IVR assessment call (consisting of four \[4\] questions) every week for 6 months"
62727274|NCT02118454|ACTIVE_COMPARATOR|Weekly IVR Survey Only|The Weekly IVR Survey Only control condition: consisting of standard care, PLUS one IVR assessment call (consisting of four \[4\] questions) every week for 6 months.
62727275|NCT01692106|EXPERIMENTAL|peroral endoscopic myotomy (POEM)|The Procedure: per oral endoscopic myotomy (POEM)will be performed on all patients in this single arm study.
62727276|NCT03805854|EXPERIMENTAL|Transcranial alternating current stimulation (tACS)|
62727277|NCT03170570|EXPERIMENTAL|treatment|retreatment using intensity-modulated radiotherapy for cervical cancer patients with in-field recurrence
62727278|NCT01747915|EXPERIMENTAL|Study Drug Level 1|
62727279|NCT01747915|EXPERIMENTAL|Study Drug Level 2|
62727280|NCT01747915|PLACEBO_COMPARATOR|Placebo|
62727281|NCT00693927|ACTIVE_COMPARATOR|1|Unmanipulated PBSC
62727282|NCT00693927|EXPERIMENTAL|2|CD8-Depleted PBSC
62727283|NCT06438185|EXPERIMENTAL|Enlarged Inferior Turbinate(s) will be reduced by ENTire IRE System.|The bi-polar IRE System locally applies short, high-voltage (HV) pulses, increasing the permeability of tissue cells, creating non-thermal irreversible electroporation (NTIRE). The energy is transferred via bipolar forceps and causes irreversible cell membrane perforation and apoptosis. This results in tissue reduction within 2-4 weeks after treatment.
62727284|NCT01132703|PLACEBO_COMPARATOR|Matching Placebo|Matching placebo (glyburide excipients without active) is administered as a bolus followed by continuous infusion for 72 hours.
62727285|NCT01132703|EXPERIMENTAL|Glyburide for Injection: Dose 1|Glyburide is administered as a bolus followed by a infusion for 72 hours
62727286|NCT01132703|EXPERIMENTAL|Glyburide for Injection: Dose 2|Glyburide is administered as a bolus followed by a infusion for 72 hours
62727287|NCT01132703|EXPERIMENTAL|Glyburide for Injection: Dose 3|Glyburide is administered as a bolus followed by a infusion for 72 hours.
62727288|NCT03579069||Ductus venosus Doppler realized|Ductus venosus Doppler realized
62727289|NCT03579069||Ductus venosus Doppler unrealized|Ductus venosus Doppler unrealized
62727290|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
62727291|NCT03180112||control group|Healthy children of matching age and sex.
62727292|NCT04384471||People living with Type 1 Diabetes|People from all ages living with type 1 diabetes in the Province of Quebec
62727293|NCT02245321|PLACEBO_COMPARATOR|Letter Group- No information|Receive a thank you letter after each blood donation.
62727294|NCT02245321|EXPERIMENTAL|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
62727295|NCT02245321|PLACEBO_COMPARATOR|Ferrous gluconate- 0 mg|Receive pills to take daily that contain no iron (a placebo or inert pill).
62727296|NCT02245321|EXPERIMENTAL|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
62727297|NCT02245321|EXPERIMENTAL|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
62727298|NCT03134859|EXPERIMENTAL|0 to 30 min/day tummy time|Group tasked to engage in an accumulation of 0 to 30 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
62727299|NCT03134859|EXPERIMENTAL|31-60 min/day tummy time|Group tasked to engage in an accumulation of 31 to 60 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
62727300|NCT03134859|EXPERIMENTAL|>61 min/day tummy time|Group tasked to engage in an accumulation of 61 or more minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
62727301|NCT02795299|ACTIVE_COMPARATOR|Gerilimzumab 5/2 mg/Methotrexate/folate|• 5 mg gerilimzumab loading dose followed by 2 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
62727302|NCT02795299|ACTIVE_COMPARATOR|Gerilimzumab 10/5mg/Methotrexate/folate|• 10 mg gerilimzumab loading dose followed by 5 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
62727303|NCT02795299|ACTIVE_COMPARATOR|Gerilimzumab 20/10mg/Methotrexate/folate|• 20 mg gerilimzumab loading dose followed by 10 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
62727304|NCT02795299|PLACEBO_COMPARATOR|Placebo/Methotrexate/folate|• Placebo every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
62727305|NCT06059612|EXPERIMENTAL|Experimental|Superior cluneal nerve entrapment (SCN) will be treated with local steroid injection
62727306|NCT05483959|EXPERIMENTAL|BIPAP group|Mechanically ventilated ARDS patients on BIPAP mode of ventilation
62727307|NCT05483959|EXPERIMENTAL|SIMV PC group|Mechanically ventilated ARDS patients on SIMV PC mode of ventilation
62727308|NCT05243979||Group (A)|40 patients with CKD (1-3) not on renal replacement therapy.
62727309|NCT05243979||Group (B)|40 persons with normal kidney function and GFR ( control ).
62727310|NCT04103281||Sepsis Patients|
62727311|NCT04103281||Control Patients|
62727312|NCT05669040|ACTIVE_COMPARATOR|Patient experience|
62727313|NCT05669040|ACTIVE_COMPARATOR|Adherence to drug treatment|
62727314|NCT05669040|ACTIVE_COMPARATOR|Positive mental health|
62727315|NCT03666988|EXPERIMENTAL|Part 1: GSK3368715 dose escalation|Eligible participants with solid relapsed/refractory tumors will receive escalating doses of GSK3368715 at a starting dose of 50 mg, administered orally once daily.
62727316|NCT03666988|EXPERIMENTAL|Part 1: GSK3368715 PK/PD/Metabolite/Biomarker|Additional participants in Part 1, treated at or close to the expected the maximum tolerated dose (MTD)/RP2D, will be evaluated for metabolic and biomarker profiling. Participants may be enrolled into this cohort(s) even after MTD/RP2D has been identified and Part 2 has been initiated.
62727317|NCT03666988|EXPERIMENTAL|Part 1: GSK3368715 Food effect|Eligible participants will receive single dose of GSK3368715 at starting dose of 50 mg tablet orally in fasted state followed by fed state in Period 1 and Fed followed by fasted state in Period 2.
62727318|NCT03666988|EXPERIMENTAL|Part 2:GSK3368715 dose expansion - DLBCL participants|Eligible participants with relapsed/refractory DLBCL will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
62727319|NCT03666988|EXPERIMENTAL|Part 2:GSK3368715 dose expansion-solid tumor participants|Eligible participants with relapsed/refractory solid tumors (pancreas cancer, NSCLC, and bladder cancer) will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
62727320|NCT02547103|EXPERIMENTAL|Chlorhexidine gluconate|Chlorhexidine gluconate-soaked cloths, clean topical area around catheter exit site with CHG 2% soaked cloths
62727321|NCT02547103|ACTIVE_COMPARATOR|Normal saline (usual care)|Normal saline, clean topical area around catheter exit site
62727322|NCT02547103|ACTIVE_COMPARATOR|Mupirocin ointment|Mupirocin ointment 2%, clean topical area around catheter exit site with Mupirocin ointment
62727323|NCT02154165|ACTIVE_COMPARATOR|Blue light wavelenght 460 nm|
62727324|NCT02154165|ACTIVE_COMPARATOR|Turquoise light wavelength 499 nm|
62727325|NCT05172635||Patients, who received a VEGF antibody|We distinguished between patients who received a VEGF antibody therapy and patients who received a EGFR antibody therapy.
62727326|NCT05172635||Patients, who received a EGFR antibody|We distinguished between patients who received a VEGF antibody therapy and patients who received a EGFR antibody therapy.
62727327|NCT04041557||adults with CHD|Adults with congenital heart disease 18-32 years of age
62727328|NCT04041557||controls|healthy peers
62727329|NCT05895123|EXPERIMENTAL|Rosuvastatin group|patients will receive Rosuvastatin orally (20 mg) at night once daily
62727330|NCT05895123|EXPERIMENTAL|Atorvastatin group|patients will receive Atorvastatin orally (40 mg) at night once daily
62727331|NCT05975346||(K) Ketamine group|40 patients will receive ketamine 50mg (1.0 ml with 4.0 ml of the saline) nebulization
62727332|NCT05975346||(S) Saline group|40 patients will receive saline nebulization (5ml).
62727333|NCT04202185||G1a|infants under 3 years deaf severe to deep
62727334|NCT04202185||G1b|children under 16 years of age with audiologically proven auditory neuropathy
62727335|NCT04202185||G2|patients \<25 years old with one or two Otoferlin mutations
62727336|NCT01640015|EXPERIMENTAL|low frequency diet|Participants will be assigned to a low frequency diet (fixed energy intake)
62727337|NCT01640015|EXPERIMENTAL|High frequency diet|
62727338|NCT02054039|EXPERIMENTAL|Incentive spirometry (IS)|Group I
62727339|NCT02054039|ACTIVE_COMPARATOR|Breath stacking (BS)|Group II
62727340|NCT06371157|EXPERIMENTAL|Arm A|AK104+ Lenvatinib in Combination With Transarterial Chemoembolization (TACE)
62727341|NCT06371157|PLACEBO_COMPARATOR|Arm B|Placebo for AK104 + Placebo for Lenvatinib in Combination With TACE
62727342|NCT06371157|OTHER|Arm C|AK104 + Placebo for Lenvatinib in Combination With TACE
62727343|NCT02808897|ACTIVE_COMPARATOR|Standard drainage|The control arm consist of consecutively enrolled cardiac surgery patients receiving one standard chest tube in the mediastinum and at most three (3) commercially available standard or silastic chest tubes in the mediastinal, right or left pleural space.
62727344|NCT02808897|EXPERIMENTAL|Active Tube Clearance drainage|The test arm consists of consecutively enrolled cardiac surgery patients receiving one (1) chest tube using active tube clearance (PleuraFlow®) in the mediastinum and at most three (3) other commercially available standard or silastic chest tubes in the mediastinal, right or left pleural space.
62727345|NCT03993665||affected|All patients with a histologically confirmed squamous cell carcinoma in the head and neck region
62727346|NCT03993665||control|Whartin tumour or pleomorphic adenoma of the parotid gland without malignant transformation
62727347|NCT02465476|NO_INTERVENTION|normal care|patient who will have normal treatment pathway
62727348|NCT02465476|EXPERIMENTAL|telemedicine|patient who will have telemedicine
62727349|NCT01904929|EXPERIMENTAL|Reconditioning in the effort|
62727350|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
62727351|NCT03111004||Comparator Group|The comparator group receives usual care
62727352|NCT04774380|EXPERIMENTAL|Durvalumab - (cisplatin or carboplatin) - Etoposide|Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.
62727353|NCT01590745|PLACEBO_COMPARATOR|Sham Ultrasound regimen|A switch in the transducer circuit allows mock ionisation as a result no ultrasound emitted.
62727354|NCT01590745|ACTIVE_COMPARATOR|Real Ultrasound therapy|Pulsed mode ultrasound therapy
62727355|NCT05040698|EXPERIMENTAL|Open Label Fostamatinib|Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1
62727356|NCT00807183|PLACEBO_COMPARATOR|Tx1|Inactive air filter
62727357|NCT00807183|EXPERIMENTAL|Tx2|New EPA-certified woodstove
62727358|NCT00807183|EXPERIMENTAL|Tx3|Active air filter
62727359|NCT03191942|EXPERIMENTAL|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
62727360|NCT03191942|ACTIVE_COMPARATOR|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
62727361|NCT00939887|EXPERIMENTAL|Treatment|
62727362|NCT03168893|EXPERIMENTAL|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
62727363|NCT03168893|EXPERIMENTAL|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
62727364|NCT06388239|EXPERIMENTAL|Apixaban 5 mg FCT|Apixaban 5 mg Film-coated tablets Each tablet contains 5 mg apixaban
62727365|NCT06388239|ACTIVE_COMPARATOR|ELIQUIS|Apixaban 5 mg Film-coated tablets Each tablet contains 5 mg apixaban
62727366|NCT00417768|ACTIVE_COMPARATOR|Tissue Plasminogen Activator|tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
62727367|NCT00417768|SHAM_COMPARATOR|Instillation of Normal Saline|Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
62727368|NCT01062698|ACTIVE_COMPARATOR|IV thrombolysis + thrombectomy|
62727369|NCT01062698|ACTIVE_COMPARATOR|IV thrombolysis|
62727370|NCT04509570|OTHER|Treatment: ILI(Intralesional injection)|5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
62727371|NCT03336086|OTHER|experimental|This group underwent a weight loss program
62727372|NCT03336086|NO_INTERVENTION|control|This group underwent adlibitum diet + physical activity
62727373|NCT06425510|EXPERIMENTAL|Viviendo las ventajas de la Asistencia Tecnológica (VIVE-AT)|The VIVE-AT program consists of a six-week, once-a-week, 2-hour group educational intervention guided by the social cognitive model. It is facilitated by primary care and community health workers in a primary healthcare clinic. The intervention aims to teach older Latinos self-management strategies to increase the adoption and use of assistive technology devices that enhance their function in daily activities. VIVE-AT is designed to support behavioral change by providing up to five assistive technology devices to participants, along with information, instruction, demonstration, action planning, and guided practice in using the devices.
62727374|NCT06425510|ACTIVE_COMPARATOR|Waitlist Control|Participants in the waitlist control group will receive weekly attention calls providing general health advice during the 6-week intervention period. They will also receive usual care for the initial 6 months post-randomization, followed by crossover to the VIVE-AT intervention.
62727375|NCT03003754|EXPERIMENTAL|High Intensity Training (HIT) + Resistance Training (RT)|"To HIT program will be use cycle ergometers adapted for children (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Each participant performed a range of 8 to 14 cycling intervals during the intervention period. The time of each work interval cycling will be increased progressively weekly, and ranged between 40-60 s (40 s weeks 1-2; 50 s weeks 3-5; 60 s week 6), with 120 s of passive rest (over the bicycle without movement) between each interval of work.~The RT will consist in voluntary concentric/eccentric exercise during 1 minute until to get a high subjective effort perception (i.e., between 8-10 points based on the modified and subjective Borg scale of 1 to 10 points. Subjects will perform 4 exercises (biceps curl, leg-extension, shoulders press, and upper row exercise) during 6-weeks."
62727376|NCT03003754|ACTIVE_COMPARATOR|Control group|We will compare within each group (G)-1, G-2, and G-3 sub-group according to both RT and HIT intervention both pre-post changes as well as if are there some anthropometric, cardiovascular, and performance variable predicting changes in homeostasis model assessment (HOMA-IR).
62727377|NCT00407602|OTHER|Implant of Argus II Retinal Prosthesis|This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.
62727378|NCT01029912|EXPERIMENTAL|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) Electrical Stimulator
62727379|NCT01029912|ACTIVE_COMPARATOR|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) Electrical Stimulator
62727380|NCT06453343|ACTIVE_COMPARATOR|Cochleostomy|When employing the cochleostomy approach, a carefully positioned opening will be drilled anterior-inferior to the eRW membrane.
62727381|NCT06453343|ACTIVE_COMPARATOR|extended Round Window|In case of the extended round window approach, the scala tympani will be accessed through the extended round window technique, involving the creation of a round window margin cochleostomy.
62727382|NCT04796129||patients with hip osteoarthritis|the patients who aged 45 and older and have paint in the hips. and also without having any other comorbidities about inflammatory status.
62727383|NCT04796129||control|the participants who have any other comorbidities for impact on the inflammatory status and also no hip pain.
62727384|NCT01158755|ACTIVE_COMPARATOR|Standard dose rifampisin|"Subjects in this arm receive 450 mg rifampicin orally.~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
62737941|NCT02706418|OTHER|Clinical Massage Therapy|
62737942|NCT01505036|EXPERIMENTAL|SMARTCARE service|U-Health service
62727385|NCT01158755|EXPERIMENTAL|High dose rifampisin|"Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
62727386|NCT01015755|EXPERIMENTAL|thirst intervention|
62727387|NCT01715389|EXPERIMENTAL|Intervention|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
62727388|NCT01715389|NO_INTERVENTION|Control|The control group will be signed up for MyChart but not use the MyAsthma Patient Portal. This group will be referred to asthma educational content on the CHOP website, complete study measures and otherwise, receive standard care.
62727389|NCT03409952|ACTIVE_COMPARATOR|Group A: LaseMD and DUAL 1927nm Laser|Group A subjects will receive split-side study treatments comparing two devices: LaseMD compared to the DUAL 1927nm laser.
62727390|NCT03409952|ACTIVE_COMPARATOR|Group B: LaseMD Optimized|Group B subjects will receive LaseMD Optimized Treatments based on Group A treatment data.
62727391|NCT01590472||Mesothelioma|Individuals who have been diagnosed with mesothelioma
62727392|NCT02840253|EXPERIMENTAL|NIRS|Non-invasive near infrared spectroscopy to assess changes in tissue and cerebral oxygenation.
62727393|NCT05448729|SHAM_COMPARATOR|Strain ratio Elastography EUS|The solid pancreatic lesion will be assessed by using strain ratio elastography EUS
62727394|NCT05448729|ACTIVE_COMPARATOR|Shear Wave Elastography EUS|The solid pancreatic lesion will be assessed by using shear wave elastography EUS
62727395|NCT01460810|EXPERIMENTAL|1000CsK Silicon Oil Tamponade|In 20 patients, a standard three-port vitrectomy will be performed. Following a standard air-fluid exchange, the eye will be filled with Silikon-1000 silicone oil in standard fashion. At a subsequent surgery, a standard two-port pars plana vitrectomy will be performed to remove the silicone oil and replace it with saline. The removed silicone oil will be tested onsite for traces of radiation.
62727396|NCT03948893|EXPERIMENTAL|MORE|
62727397|NCT03948893|ACTIVE_COMPARATOR|CBT|
62727398|NCT01465438|EXPERIMENTAL|Adalimumab|Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
62727399|NCT05672368|EXPERIMENTAL|Device feasibility (da Vinci SP1098 robotic system)|Patients undergo surgery using the da Vinci SP1098 robotic system on study.
62727400|NCT01742728||Nagasaki|Sample collection
62727401|NCT01742728||Tokushima|Oxidative stress, cytokine
62727402|NCT01742728||Kanagawa|oxidative stress
62727403|NCT05576298|EXPERIMENTAL|TR sequence|Experimental:Insulin degludec injection (RD15003)+Tresiba Subjects receive Insulin degludec injection(RD15003) in the first cycle and Tresiba in the second cycle.
62727404|NCT05576298|EXPERIMENTAL|RT sequence|Experimental:Tresiba+Insulin degludec injection (RD15003) Subjects receive Insulin Tresiba in the first cycle and degludec injection(RD15003) in the second cycle.
62727405|NCT03930381|EXPERIMENTAL|Intervention Arm|This group will download the ASTHMAXcel application and use it for the duration of the study
62727406|NCT03930381|NO_INTERVENTION|Usual Care Arm|This group will just receive normal provider care
62727407|NCT02202967|ACTIVE_COMPARATOR|Misoprostol|Misoprostol
62727408|NCT02202967|PLACEBO_COMPARATOR|Placebo|Placebo
62727409|NCT01797757|ACTIVE_COMPARATOR|Fish oil enriched with EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
62727410|NCT01797757|ACTIVE_COMPARATOR|MAG-EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
62727411|NCT01797757|ACTIVE_COMPARATOR|MAG-EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
62727412|NCT01797757|ACTIVE_COMPARATOR|Fish oil enriched with EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
62727413|NCT01069393|ACTIVE_COMPARATOR|Standard DAFNE|Usual DAFNE course taught over 5 consecutive days in one week
62727414|NCT01069393|EXPERIMENTAL|DAFNE 5x1 day|DAFNE course taught 1 day a week for 5 consecutive weeks
62727415|NCT04645992|ACTIVE_COMPARATOR|study group|study group will receive only one session of yoga eye exercise for 20 minutes followed by transcutaneous electrical nerve stimulation by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
62727416|NCT04645992|SHAM_COMPARATOR|control group|control group will be treated with the same protocol as the study group but with the unit of transcutaneous electrical nerve stimulation is off .
62727417|NCT03685058|ACTIVE_COMPARATOR|The control group|A total of 88 non-cavitated proximal carious lesions treated with standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish (Vanish 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate, 3M ESPE, St. Paul, MN, U.S.A.), oral hygiene instruction, and dietary counseling applied at initial, six-months follow-up, and 12-months follow-up visits.
62727418|NCT03685058|EXPERIMENTAL|The test group|Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
62737943|NCT01505036|NO_INTERVENTION|Usual care|Usual care
62727419|NCT00724659|EXPERIMENTAL|Ultrasound Pre-Arthrogram|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
62727420|NCT00724659|EXPERIMENTAL|Ultrasound Post-Arthrogram|Ultrasound of the joint(s) after the clinically scheduled arthrogram of the same joint(s), performed while the body still has a contrast agent in it from the arthrogram. The contrast agent varies with different joint areas, but is usually iodine based (like Ultravist.)
62727421|NCT05697653|EXPERIMENTAL|intervention group (skin-to-skin contact group)|skin-to-skin contact: It is the laying of the newborn in the prone position on the mother's bare chest area with only a diaper on.
62727422|NCT05697653|NO_INTERVENTION|control group|The routine applications of the hospital were applied to the pregnant women in the control group.
62727423|NCT05475977||First Group|Thirty patients of COPD smokers patients.
62727424|NCT05475977||Second group|Thirty patients of COPD ex-smokers patients.
62727425|NCT05475977||Third group|Thirty patients of COPD non-smokers patients.
62727426|NCT03482986|EXPERIMENTAL|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
62727427|NCT03482986|EXPERIMENTAL|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
62727428|NCT05280821|ACTIVE_COMPARATOR|Consecutive Day Dosing|This arm will daily receive iron capsules for 3 months, followed by daily placebo capsules for 3 months.
62727429|NCT05280821|EXPERIMENTAL|Alternate Day Dosing|This arm will receive iron capsules alternating with placebo capsules for 6 months.
62727430|NCT02621437|EXPERIMENTAL|Intervention group (osteopathy)|Patients will have three sessions of osteopathy and 6 phone questionnaires.
62727431|NCT02621437|OTHER|control group|Patients will have 6 phone questionnaires.
62727432|NCT04481607|EXPERIMENTAL|TQB3454 tablets|TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.
62727433|NCT04888806|EXPERIMENTAL|Camrelizumab+ablation +chemotherapy|The enrolled patients received ablation of liver metastases/pulmonary metastasis first, followed by chemotherapy (standard treatment plan for advanced colorectal cancer, determined by the investigator) and camrelizumab treatment (200mg, iv, q3w) one week later. If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times. Sequential chemotherapy and camrelizumab is administered one week after each ablation therapy. Treatment will continue until disease progression, unacceptable toxicity, or voluntary patient withdrawal.
62727434|NCT02065349|PLACEBO_COMPARATOR|Placebo|oral
62727435|NCT02065349|ACTIVE_COMPARATOR|ASP8477|oral
62727436|NCT04643847|EXPERIMENTAL|Stereotactic radiosurgery with Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions
62727437|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
62727438|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
62727439|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
62727440|NCT01738633|EXPERIMENTAL|nutritional + respirology counseling|patients will receive both nutritional and respirology counseling
62727441|NCT01738633|EXPERIMENTAL|nutritional counseling|patients will receive nutritional counseling alone
62727442|NCT01738633|EXPERIMENTAL|respirology counseling|patients will receive respirology counseling alone
62727443|NCT01738633|NO_INTERVENTION|standard care|patients will receive standard care
62727444|NCT00790582|EXPERIMENTAL|lithium carbonate|
62727445|NCT02378285|ACTIVE_COMPARATOR|PRP group|ACP infiltration: 2 mL at 0 and 4 weeks with ultrasound guidance
62727446|NCT02378285|PLACEBO_COMPARATOR|Saline solution group|Saline solution infiltration: 2mL at 0 and 4 weeks with ultrasound guidance
62727447|NCT04458246|EXPERIMENTAL|Intervention|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will receive an online home-based aerobic training, three times a week, during 3 months.
62727448|NCT04458246|NO_INTERVENTION|Control|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will be advised to maintain their daily routine.
62727449|NCT05237362|EXPERIMENTAL|Intervention|Receives the Saga Stories health promotion talk as well as take-home material
62727450|NCT05237362|NO_INTERVENTION|Control|Receives standard health promotion talk
62727451|NCT00910494|EXPERIMENTAL|12 Gray IORT|
62727452|NCT00910494|EXPERIMENTAL|15 Gray IORT|
62727453|NCT04284501||Study|children with Migraine headache
62727454|NCT04284501||Control|Healthy children
62727455|NCT04453826|EXPERIMENTAL|Camrelizumab plus chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy with concurrent and adjuvant camrelizumab therapy.
62727456|NCT04453826|ACTIVE_COMPARATOR|Chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy.
62727457|NCT02499627|EXPERIMENTAL|Bendamustine + Brentuximab for 6 cycles|Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
62727458|NCT03366025||Oocyte donors|Healthy oocyte donors undergoing ovarian stimulation with recombinant Follicular stimulating hormone
62727459|NCT05302427|EXPERIMENTAL|Massage group|The massage group will be shown live one-to-one baby massage training via Microsoft Teams by the researcher, and the mother will be asked to apply it to her baby at the same time. Baby massage training; It consists of leg massage, face-abdominal massage, arm-chest massage and back massage and will be completed in four weeks.
62727460|NCT05302427|NO_INTERVENTION|Control group|Infant massage training will not be given to the mothers of the babies in the control group until the 20th week.
62727461|NCT01445613|OTHER|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
62727462|NCT04232982|EXPERIMENTAL|MicroPulse Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered by micropulse waves will be given 4-8 weeks before the Boston keratoprosthesis surgery.
62727463|NCT04232982|EXPERIMENTAL|G-Probe Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered with a diode laser using the G-Probe device, will be given 4-8 weeks before the Boston keratoprosthesis surgery.
62727464|NCT04232982|NO_INTERVENTION|Historical Cohort|"An historical cohort composed of patients who received a Boston keratoprosthesis between january 2017 and january 2019 will be included. Only patients who did not receive any glaucoma treatment 3 months before their surgery will be included. A total of 10 patients will be selected with the goal of matching the preoperative characteristics of the interventional patients.~This group will serve as the control group in our study. Retrospective chart review will be performed for this branch."
62727465|NCT03943576|EXPERIMENTAL|GXCPC1|GXCPC1 contains 6.7×10\^6 or 4×10\^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL
62727466|NCT03943576|ACTIVE_COMPARATOR|hyaluronic acid|Hya Joint Plus synovial fluid supplement 3mL
62727467|NCT01354522|ACTIVE_COMPARATOR|TAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
62727468|NCT01354522|EXPERIMENTAL|TCX|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
62727469|NCT03961191||Benign group|Patients with benign cervical histology, including normal findings, inflammation and LSIL
62727470|NCT03961191||HSIL group|Patients with cervical histology of HSIL
62727471|NCT03961191||Cancer group|Patients with cervical histology of cancer
62727472|NCT01072721|OTHER|Fibrosis group|a single arm with the two interventions (elastometry and biopsy)
62727473|NCT00712478||A|
62727474|NCT03440554|EXPERIMENTAL|Whole Body Non-Contrast MRI|
62165979|NCT00138645|EXPERIMENTAL|MicroDiet|Participants randomized to the MicroDiet group (1200 kcal/day) will be instructed by a Registered Dietitian to consume (one shake and 3 cookies; 240 kcal) for two meals each day for Months 1 through 3. They will be provided with meal plans for the meal that they do not replace with MicroDiet. During Months 4 through 6, participants in the MicroDiet group will be instructed to replace one meal per day with MD (the energy content of the meal plan will still be 1200 kcal/day). Participants will also be encouraged to eat or drink MD for snacks. The rest of the diet will consist of healthy foods, as outlined above. To help participants adhere to the MicroDiet regimen, they will meet with a registered dietitian for one hour at Week 0 and 30 minutes at Weeks 2 and 4, and every month thereafter.
62727475|NCT01004536|NO_INTERVENTION|no treatment|The other half of cesarean section wound that is to be left untreated.
62727476|NCT01004536|EXPERIMENTAL|silicone gel|Randomly-designated half of cesarean section wound that is to be subject to application ot silicone gel
62727477|NCT06391580|EXPERIMENTAL|Poly-L-lactin Acid (PLLA) Based Facial Injectable|Poly-L-lactin Acid (PLLA) Based Facial Injectable
62727478|NCT06391580|NO_INTERVENTION|No treatment control|No treatment control
62727479|NCT06270446|OTHER|Outpatient|Usual care, outpatient physiotherapy
62727480|NCT06270446|ACTIVE_COMPARATOR|CRC|Community based physiotherapy
62727481|NCT01530646|PLACEBO_COMPARATOR|Control|Carbohydrate \& 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of maltodextrin (no protein) for 14 days. Weight loss.
62727482|NCT01530646|EXPERIMENTAL|Whey|Whey protein \& 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of WPI for 14 days. Weight loss.
62727483|NCT01530646|EXPERIMENTAL|Soy|Soy protein \& 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of SPC for 14 days. Weight loss.
62727484|NCT01321853|EXPERIMENTAL|Machine and NCC|Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
62727485|NCT01321853|EXPERIMENTAL|Medplanner and NCC|Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
62727486|NCT01321853|NO_INTERVENTION|Usual Care Group|Admitted post home health care with no intervention.
62727487|NCT02843438|OTHER|Subjects suspected of toxoplasmosis chorioretinitis infection|Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
62727488|NCT04631315|EXPERIMENTAL|Intervention|Difluprednate Ophthalmic Emulsion 0.05%
62727489|NCT04631315|ACTIVE_COMPARATOR|Comparator|Prednisolone Acetate 1% - Phenylephrine 0.12% Ophthalmic Suspension
62727490|NCT01823081|ACTIVE_COMPARATOR|Intravitreal bevacizumab (Avastin)|Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks
62727491|NCT01823081|ACTIVE_COMPARATOR|Combined intravitreal fasudil and bevacizumab (Avastin)|Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks
62727492|NCT01791491|EXPERIMENTAL|Belatacept|
62727493|NCT04280016|EXPERIMENTAL|Exercise Added to Off-loading|Participants in this arm will participate in exercise at the healthcare facility one time a week (away from where wound care is provided) and be instructed in a home exercise program that they will be encouraged to perform at least three days per week with no more than two days between sessions. Wound care will continue at the facility as is standard, utilizing off-loading.
62727494|NCT02804633|ACTIVE_COMPARATOR|IV acetaminophen group|In addition to PCA (morphine or hydromorphone) all patients receive 1 gram of IV acetaminophen (100 ml ) 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge.
62727495|NCT02804633|PLACEBO_COMPARATOR|Placebo Group|In addition to PCA (morphine or hydromorphone) all patients received placebo (100 ml normal saline) given 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge
62727496|NCT06107543||Intravenous lidocaine|Patients who received lidocaine intravenously before induction of anesthesia will be considered in this group.
62727497|NCT06107543||Nebulized lidocaine|Patients who received lidocaine by inhalation with a nebulizer before induction of anesthesia will be considered in this group.
62727498|NCT06072625|ACTIVE_COMPARATOR|Olive oil group|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
62727499|NCT06072625|NO_INTERVENTION|Control group|
62727500|NCT04952428||Peri-implant group|It is based on clinical and radiographic bone loss. Implants should have clinical inflammation in combination with bleeding on probing and/or suppuration, also progressive bone loss when compared with baseline radiograph shall be demonstrable, as well as an increase in probing pocket depth (PPD) from the baseline examination (Baseline record are referred to those obtained after definitive prosthesis delivery). In those cases where no baseline records were available, marginal bone loss \> 3mm and probing \> 6mm were stated as requirements (2).
62727501|NCT04952428||Peri-implant mucositis group|The case definition of peri-implant mucositis it is based on clinical inflammation in combination with profuse bleeding on probing and/or suppuration with increasing of probing pocket depths and absence of bone loss beyond crestal bone level (initial remodelling) (2).
62727502|NCT04952428||Healthy patients group|The case definition of peri-implant health was based on absence of clinical inflammation, lack of bleeding on probing and absence of bone loss following initial healing (\< 2mm) (2).
62727503|NCT03782623||Intensive care patients after elective open aortic surgery|
62727504|NCT03782623||Intensive care patients after bilateral lung transplantation|
62727505|NCT03782623||Anesthetic intensive care patients, unplanned admission|
62727506|NCT02297633||Stability in patients with COPD|Those patients diagnosed COPD according to the GOLD guideline and without acute exacerbation within one month.
62727507|NCT02297633||AECOPD|the diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.
62727508|NCT02297633||Healthy persons without smoking|The healthy people who do not smoke
62727509|NCT02297633||Healthy persons with smoking|Healthy persons who smoke
62727510|NCT03301779|EXPERIMENTAL|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
62727511|NCT03301779|NO_INTERVENTION|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
62727512|NCT03216720|ACTIVE_COMPARATOR|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
62727513|NCT03216720|ACTIVE_COMPARATOR|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
62727514|NCT06069830|EXPERIMENTAL|Interim PET and EBV DNA-directed therapy|According to the interim PET and EBV DNA results, patients are divided into three cohorts: 1) cohort A: Deauville score 1-3 and EBV DNA negativity; 2) cohort B: Deauville score 1-3 and EBV DNA positivity; 3) cohort C: Deauville score 4-5.
62727515|NCT01284959|EXPERIMENTAL|risperidone|Drug: risperidone 3mg, PO two times Groups: risperidone
62727516|NCT01284959|PLACEBO_COMPARATOR|placebo|drug: lactose, PO 3 times group: placebo
62727517|NCT01284959|EXPERIMENTAL|paliperidone ER|drug : Paliperidone ER 6mg PO, two times group: paliperidone ER
62727518|NCT04256278|EXPERIMENTAL|Intervention Group|
62727519|NCT04256278|PLACEBO_COMPARATOR|Control Group|
62727520|NCT02409433|EXPERIMENTAL|lacosamide|The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
62727521|NCT02409433|ACTIVE_COMPARATOR|phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.
62727522|NCT00003631|EXPERIMENTAL|Arm I|(0-1 adverse prognostic factors): Patients receive ifosfamide by 24 hour infusion on day 2. Carboplatin is administered on day 2. Etoposide IV is administered once daily on days 1-3. Patients then receive filgrastim (G-CSF) subcutaneously or IV on days 5-12. Patients receive another course of ICE chemotherapy 2-3 weeks after the first course.
62727523|NCT00003631|EXPERIMENTAL|Arm II|(2 adverse prognostic factors): Patients receive the first course of ICE as in Arm I
62727524|NCT00003631|EXPERIMENTAL|Arm III|Arm III (3 adverse prognostic factors): Patients receive cyclophosphamide IV daily for 2 days, then G-CSF beginning on day 4 until blood stem cells are collected
62727525|NCT02786563||Participants with RA receiving adalimumab|This group contains participants in China with RA receiving adalimumab
62727526|NCT05746182||Participants with Pancreatic Neuroendocrine Neoplasms|
62727527|NCT01569815|EXPERIMENTAL|LCZ696 400 mg|LCZ696 400 mg once daily for 5 days
62727528|NCT02663336||CKD patients|Patients with chronic kidney disease, with diagnosed arterial hypertension and normal blood pressure during office blood pressure measurement. Comparison of ambulatory blood pressure (ABPM) with office blood pressure measurements (OBPM).
62727529|NCT01198782|EXPERIMENTAL|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
62727530|NCT00456625|EXPERIMENTAL|Group Engerix™-B|Subjects received a dose of Hepatitis B vaccine approximately 20 years after the primary neonatal vaccination
62727531|NCT00585637|ACTIVE_COMPARATOR|1|No Vitamin D
62727532|NCT00585637|ACTIVE_COMPARATOR|2|1000 IU of Vitamin D
62727533|NCT00585637|ACTIVE_COMPARATOR|3|2000 IU of Vitamin D
62727534|NCT00585637|ACTIVE_COMPARATOR|4|4000 IU of Vitamin D
62727535|NCT00943631|EXPERIMENTAL|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
62727536|NCT00943631|EXPERIMENTAL|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
62727537|NCT04406402|EXPERIMENTAL|Acute glucose tolerance test|A standard oral glucose tolerance test (75 grams of dextrose in 180 cc of water)
62727538|NCT04406402|EXPERIMENTAL|Acute protein load test|A protein-rich, vanilla-flavored powder (Pro-gym, Telpharma, Is
62727539|NCT04406402|EXPERIMENTAL|Acute fat load test|a 100-gram portion of sweet cream containing 300 Kacls, of which 94% of the ingested calories were fat
62727540|NCT04406402|EXPERIMENTAL|Acute alcohol load test|Vodka (100 cc, 40% alcohol)
62727541|NCT04406402|EXPERIMENTAL|Acute exercise|30 minutes of supervised graded walking on a treadmill according to each subject's individual ability. A goal heart rate was calculated as 70% of the age-adjusted maximal allowable heart rate.
62727542|NCT04406402|EXPERIMENTAL|Lifestyle modification program - 12 weeks|12 weeks of weight-loss dietary program constructed according to the guidelines of the American Diabetes Association. Based on weight, gender, and age, daily dietary allowance varied at 1200-1800 Kcal, 50% carbohydrates, 20% protein, and 30% fat. Participants were also asked to engage in moderate physical activity comprised of a 40-minute walk three times a week. A weekly clinic visit alternating with a weekly telephone contact was also required.
62727543|NCT05792163|EXPERIMENTAL|A (SNP318)|"Drug: SNP318, Dose level: Start from 1mg for single ascending dose and from 30mg for multiple ascending dose. Dose levels can be adjusted based on emerging safety, tolerability, pharmacokinetics data of previous cohorts.~Dosage form: Capsule Route of administration: Oral"
62727544|NCT05792163|PLACEBO_COMPARATOR|B (Placebo)|Placebo comparator taken by participants randomized to the placebo arm in each cohort in Part 1 and Part 2.
62727545|NCT02056444|EXPERIMENTAL|Topical tranexamic acid (TXA)|Single dose 1.5 grams topical TXA infiltrated into the surgical field at time of arthrotomy closure.
62727546|NCT02056444|ACTIVE_COMPARATOR|Intravenous TXA|Single 20 mg/kg dose of intravenous TXA administered prior to skin incision.
62727547|NCT06172816||PLWH|the people living with HIV
62727548|NCT06172816||HC|the people without disease
62727549|NCT04451408|EXPERIMENTAL|LY3372993 (Part A)|LY3372993 administered as multiple doses either intravenously (IV) or subcutaneously (SC).
62727550|NCT04451408|EXPERIMENTAL|LY3372993 (Part B)|LY3372993 administered as single dose IV or SC.
62727551|NCT04451408|PLACEBO_COMPARATOR|Placebo (Part A)|Placebo administered as multiple doses IV or SC.
62727552|NCT04451408|PLACEBO_COMPARATOR|Placebo (Part B)|Placebo administered as single dose IV or SC.
62727553|NCT03666338|ACTIVE_COMPARATOR|Early, goal-directed mobilization|Early goal-directed mobilization with (1) SOMS algorithm and (2) facilitator
62727554|NCT03666338|NO_INTERVENTION|Standard of Care|Standard of Care regarding mobilization
62727555|NCT01684839|OTHER|new surgical treatment|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap taken from the homolateral dorsal branch of the digital nerve.
62727556|NCT05424835|EXPERIMENTAL|SHR-A1811|
62727557|NCT05424835|EXPERIMENTAL|Pyrotinib in combination with Capecitabine.|
62727558|NCT00901251||1|
62727559|NCT00252512|EXPERIMENTAL|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are negative, they receive a chance to draw tokens from a bowl. Some tokens are social reinforcement. Others have monetary value.
62727560|NCT00252512|PLACEBO_COMPARATOR|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
62727561|NCT05065073|ACTIVE_COMPARATOR|Iso-Osmolar Contrast Media|Will receive iso-osmolar media first, low-osmolar media second
62727562|NCT05065073|ACTIVE_COMPARATOR|Low-Osmolar Contrast Media|Will receive low-osmolar media first, iso-osmolar media second
62727563|NCT02505373|EXPERIMENTAL|Intervention Group ASSIP|Intervention Group ASSIP (Brief Therapy)
62727564|NCT02505373|ACTIVE_COMPARATOR|Control Group CG|Control Group CG (structured interview)
62727565|NCT04200092|EXPERIMENTAL|Cohort 1|Single orally-inhaled dose
62727566|NCT04200092|EXPERIMENTAL|Cohort 2|Single orally-inhaled dose
62727567|NCT04200092|EXPERIMENTAL|Cohort 3|Single orally-inhaled dose
62727568|NCT04200092|EXPERIMENTAL|Sequence 1|Single orally-inhaled dose
62727569|NCT04200092|ACTIVE_COMPARATOR|Sequence 2|Single IV administered dose
62727570|NCT01887964|OTHER|Community-1|Received control flour first and then Resistant starch type 4 (RS4) flour
62727571|NCT01887964|OTHER|Community-2|Received RS4 flour first and then control flour
62727572|NCT01520467|EXPERIMENTAL|Anastrozole|stratification according to the rare disease. Oral administration of Anastrozole (1mg/day) for 18 months
62727573|NCT01520467|PLACEBO_COMPARATOR|Placebo|stratification according to the rare disease. Oral administration of 1 placebo tablet /day for 18 months
62727574|NCT00114127|PLACEBO_COMPARATOR|Duloxetine 60mg + Placebo for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
62727575|NCT00114127|ACTIVE_COMPARATOR|Duloxetine 120mg for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
62727576|NCT00114127|ACTIVE_COMPARATOR|Duloxetine 60mg/day for 6 Weeks|In Phase 1 all participants entered an open trial.
62727577|NCT06198062|EXPERIMENTAL|Paraffin wax bath therapy|Heat therapy for the relief of joint pain and stiffness was established using paraffin and prolonged stretching. When used as a treatment method, paraffin wax is heated to a temperature between 115 and 118 degrees. One step of the paraffin treatment is cleaning. (1) Drying the damaged area and making sure the skin is covered in plastic, (2) Wrapping any small open wounds in plastic, (3) Applying paraffin wax to the affected area, (4) Stretching the affected extremity for 20 minutes, (5)Covering the area with an ACE bandage or a towel to prevent the wax from cooling too quickly
62727578|NCT06198062|EXPERIMENTAL|Muscle energy technique|Reciprocal inhibition, hypertonic antagonists can reflexively inhibiting their agonist muscle. Therefore, in the presence of short and tight antagonist muscles, restoring normal muscle tone and length should be first addressed. MET involves the subject to voluntarily contract the muscle in a precisely controlled direction against the therapist's counter force. Its therapeutic effects are to reduce pain, reduce muscle tone, stretch tightened muscles, strengthen the weak muscles, improve local circulation and mobilize joint restrictions. Anatomical structures that contribute to stiffness at the joint states that the joint capsule, surrounding inter-muscular fasciae and muscles, tendons and skin tissue account for restriction at the joint. Relaxation of the antagonist muscle occurs due to actively contracting the agonist muscle
62727579|NCT04280991|EXPERIMENTAL|Moderate intensity exercise under mild normobaric hypoxia|The participants will perform moderate intensity exercise at heart rate corresponding with 50%WMAX (determined during maximal workload test) under mild normobaric hypoxia (FiO2: 15%), two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge will be performed at day 5 to determine fasting/postprandial substrate oxidation.
62727580|NCT04280991|PLACEBO_COMPARATOR|Moderate intensity exercise under normoxia|The participants will perform moderate intensity exercise at 50% WMAX (determined during maximal workload test) under normoxia (FiO2: 21%) two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge test will be performed at day 5 to determine fasting/postprandial substrate oxidation.
62727581|NCT05238350|EXPERIMENTAL|Acupressure (intervention group)|The intervention group was performed with 45 patients. Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
62727582|NCT05238350|NO_INTERVENTION|Control group|Thecontrol group was performed with 45 patients. Any application was not performed for the control group.
62727583|NCT03864146|EXPERIMENTAL|Pioglitazone|Pioglitazone titrated to 45mg by mouth each day
62727584|NCT03864146|PLACEBO_COMPARATOR|Placebo|placebo, identical 45mg pill
62727585|NCT05901571|SHAM_COMPARATOR|sham-acupuncture/placebo-pill|sham-acupuncture protocol plus escitalopram placebo
62727586|NCT05901571|ACTIVE_COMPARATOR|sham-acupuncture/escitalopram|sham-acupuncture protocol plus escitalopram
62727587|NCT05901571|ACTIVE_COMPARATOR|active acupuncture/placebo-pill|acupuncture protocol plus escitalopram placebo
62727588|NCT05901571|EXPERIMENTAL|active acupuncture/escitalopram|acupuncture protocol plus escitalopram
62727589|NCT04770688|EXPERIMENTAL|Osimertinib + Anlotiib|Escalating doses and expanding doses of Anlotinib administered with Osimertinib
62727590|NCT00169702|OTHER|Standard|standard information
62727591|NCT00169702|ACTIVE_COMPARATOR|Intervention|weight management program, 12 sessions, 2 weekly, psychoeducational program, interactive topics like healthy food, diet behavior, physical activity, stress reduction.
62727592|NCT03531814|EXPERIMENTAL|Adult Participants|Questionnaires and use of the medication event monitoring system (MEMS\^TM)
62727593|NCT03531814|EXPERIMENTAL|Pediatric Participants 8+ Years|Questionnaires and use of the medication event monitoring system (MEMS\^TM)
62727594|NCT02544750|EXPERIMENTAL|GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
62727595|NCT00276406|EXPERIMENTAL|Pyridostigmine|Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
62727596|NCT00276406|PLACEBO_COMPARATOR|Placebo|Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.
62727597|NCT04149483|EXPERIMENTAL|Atorvastatin|Atorvastatin tablets, 20mg once a day, for six months.
62727598|NCT04149483|PLACEBO_COMPARATOR|Placebo|Same color and size coated tablet, 20mg once a day, for six months.
62727599|NCT03091790|ACTIVE_COMPARATOR|Synthetic Mesh|Synthetic mesh (mid-density polypropylene (generic) Bard soft mesh) will be used in open ventral hernia repair
62727600|NCT03091790|ACTIVE_COMPARATOR|Biologic Mesh|Biologic mesh (non cross linked porcine acellular dermal matrix: Strattice) will be used in open ventral hernia repair
62727601|NCT05034809|EXPERIMENTAL|Treatment Group|Other than the guided management of Dengue Fever with warning signs, the treatment group will receive a standard dose of 20mg/day of melatonin20-21 for 5 days. The dosing was based on the study by Leiberman et al and Malhotra et al. If a patient is unable to tolerate the whole or punctured tablet, it will be given with milk or water. There is no known interaction between melatonin and milk known to date. Daily complete blood count will be done and be recording in an electronic record using Microsoft Excel.
62727602|NCT05034809|NO_INTERVENTION|Control Group|Other than the guided management of Dengue Fever with warning signs, the control group will be manage according the Department of Health Dengue Management Guideline. No placebo will be given.
62727603|NCT02871817||Normal Vision|Patients without significant vision deficit (20/20 vision), when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
62727604|NCT02871817||Age-related macular degeneration|Patients presenting with dry AMD or neovascular (wet) AMD, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
62727605|NCT02871817||Diabetic retinopathy|Patients presenting with Diabetic Retinopathy, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
62727606|NCT02944838|ACTIVE_COMPARATOR|Advocacy|"The Senior Change Makers Advocacy Program consists of weekly meetings, 1 hour each, for 8-weeks. The program will be led by graduate level students and will address topics such as how the environment affects walking, potential pedestrian hazards and solutions, how to conduct an audit of the walking environment, what advocates do, local examples of successful advocacy projects, creating an advocacy action plan, creating a fact sheet about the advocacy issue, writing letters to representatives, and making an advocacy presentation. The program will culminate with the presentation of the advocacy issue to a decision maker (e.g., a city planner, engineer, city council member, etc.)."
62165980|NCT00138645|ACTIVE_COMPARATOR|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet. The Healthy Diet will consist of the same foods that are used in the meal plans for the MicroDiet group. The Healthy Diet group will be instructed not to use meal replacements such as shakes (e.g., Slim Fast®), nutrition bars (e.g., Balance Bar®), or portion-controlled meals (e.g., Healthy Choice entrees).
62165981|NCT03660254|EXPERIMENTAL|one group has exercise intervention|tai chi exercise intervention，two times a week and each time costs one hour
62165982|NCT03660254|NO_INTERVENTION|no intervention|no intervention
62165983|NCT03138356|EXPERIMENTAL|Cohort 1 Treatment A|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
62737944|NCT04182477||Patients with at least one general anesthesia in anamnesis|Patients who underwent during their life at least one anesthesia in anamnesis
62727607|NCT02944838|ACTIVE_COMPARATOR|Physical Activity|The Senior Change Makers Physical Activity Program consists of weekly meetings, 1 hour each, for 8 weeks. The program provides participants with information about safe physical activity, strategies to increase physical activity, and guided walks. Topics will focus on walking, but we will also include information and activities relating to strength training, flexibility, and balance. Behavioral skills such as goal setting, addressing barriers, and social support will also be addressed.
62727608|NCT04041232|EXPERIMENTAL|PBA treatment of ATF6-/- Achromatopsia|Patients will be monitored at the baseline visit, followed by a second and third visit that will be 1 and 3 months after the initial visit. Patients will complete a standard visual functioning questionnaire and undergo a complete ophthalmic evaluation at each visit. Other visual assessments will consist of color vision testing, contrast sensitivity, retinal imaging, and macular sensitivity testing using microperimetry. Full-field electroretinogram will also be performed at the baseline visit and after 1 and 3 months of PBA use. If improvement in retinal function is observed, an additional ophthalmic evaluation will be conducted after 6 months of PBA use. A blood draw will be performed at each visit to test for any indications of adverse effects from drug use.
62727609|NCT00002548|ACTIVE_COMPARATOR|HDCTX and PBSC|"High dose chemotherapy with peripheral blood stem cells~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7"
62727610|NCT00002548|EXPERIMENTAL|HDCTX with PBSC and Autologous BMT|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Auto Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0"
62727611|NCT00002548|EXPERIMENTAL|HDCTX with PBSC and interferon|"High dose chemotherapy with peripheral blood stem cells and interferon~Experimental: HDCTX with PBSC and interferon High dose chemotherapy with peripheral blood stem cells and interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7~IFN: IFN 3 million units/m2 MWF SQ"
62727612|NCT00002548|EXPERIMENTAL|HDCTX with PBSC and transplant plus IFN|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~Experimental: HDCTX with PBSC and transplant plus IFN High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0~IFN: 3 million units/m2 MWF SQ"
62727613|NCT02385903|OTHER|Standard dressing procedure|One arm receive standard dressing procedure according to the wound
62727614|NCT02385903|ACTIVE_COMPARATOR|Flammacerium|"Necrosis covering with Flammacerium 3 mm thick each day during one week then one day on two.~On each dressing, remove excess and add flammacerium. Not to remove crust forming until eliminating furrow appears.~Cover Flammacerium by compress."
62727615|NCT04020471||Experimental|All subjects who have completed their standard of care total knee arthroplasty will undergo pharmacogenomics testing and will complete a daily pain and medication diary for 30 days post discharge from the hospital. Subjects will be offered a consultation visit with a member of the Pharmacogenomics Team to discuss results.
62727616|NCT04750343|EXPERIMENTAL|Test group 1 - Stage 1 Low dose-level Cohort|2 doses of GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.
62727617|NCT04750343|EXPERIMENTAL|Test group 2 - Stage 1 Low dose-level Cohort|2 doses of GBP510 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
62727618|NCT04750343|PLACEBO_COMPARATOR|Placebo group - Stage 1 Low dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
62727619|NCT04750343|EXPERIMENTAL|Test group 3 - Stage 1 High dose-level Cohort|2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
62727620|NCT04750343|EXPERIMENTAL|Test group 4 - Stage 1 High dose-level Cohort|2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
62727621|NCT04750343|PLACEBO_COMPARATOR|Placebo group - Stage 1 High dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
62727622|NCT04750343|EXPERIMENTAL|Test group 1 - Stage 2|2 doses of GBP510 adjuvanted with AS03 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
62727623|NCT04750343|EXPERIMENTAL|Test group 3 - Stage 2|2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
62727624|NCT04750343|EXPERIMENTAL|Test group 4 - Stage 2|2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
62727625|NCT04750343|PLACEBO_COMPARATOR|Placebo group - Stage 2|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
62727626|NCT01433406|EXPERIMENTAL|TAK-875 25 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
62727627|NCT01433406|EXPERIMENTAL|TAK-875 50 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
62727628|NCT05952297|EXPERIMENTAL|Sleep Wellness Device|The wearable sleep wellness device that contains specially designed coils that generate micro electromagnetic stimulation located in the neckband and is worn around the neck like headphones for at least 3 hours per day.
62727629|NCT05952297|SHAM_COMPARATOR|Inactive Sleep Wellness Device|This sleep wellness device is running an inactive program in the application (no electromagnetic stimulation).
62727630|NCT00678288|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously.
62727631|NCT00678288|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
62165984|NCT03138356|EXPERIMENTAL|Cohort 1 Treatment B|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
62165985|NCT03138356|ACTIVE_COMPARATOR|Cohort 1 Treatment C (Reference product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
62727632|NCT06549465|EXPERIMENTAL|Part 1: 148 ± 37 MBq In-111 rosopatamab tetraxetan|
62727633|NCT06549465|EXPERIMENTAL|Part 2: 55 KBq/kg Ac-225 rosopatamab tetraxetan|
62727634|NCT06549465|EXPERIMENTAL|Part 2: 60 KBq/kg Ac-225 rosopatamab tetraxetan|
62727635|NCT06549465|EXPERIMENTAL|Part 3: Dose Escalation|Participants previously treated with Lu-177-PSMA-radioligand therapy will be assigned to receive one of the three dose levels (45 KBq/kg, 55 KBq/kg, or 60 KBq/kg) depending on the dose limiting toxicities (DLTs) observed.
62727636|NCT00331032|EXPERIMENTAL|1: 3% w/w SPL7013 Gel|40 subjects VivaGel™.
62727637|NCT00331032|PLACEBO_COMPARATOR|2: Placebo|20 subjects placebo.
62727638|NCT01720303|EXPERIMENTAL|Rep + NPH|
62727639|NCT01720303|ACTIVE_COMPARATOR|Premixed insulin/NPH|
62727640|NCT03526094|ACTIVE_COMPARATOR|Flavanols-capsules|Capsules containing 541 mg cocoa flavanols (75 mg epicatechin) and 315 g of milk (1% fat)
62727641|NCT03526094|EXPERIMENTAL|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 638 mg cocoa flavanols (88 mg epicatechin)
62727642|NCT03526094|EXPERIMENTAL|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 565 mg cocoa flavanols (78 mg epicatechin)
62727643|NCT03526094|EXPERIMENTAL|Flavanol-berry blend|Fruit blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 484 mg cocoa flavanols (68 mg epicatechin)
62727644|NCT03526094|EXPERIMENTAL|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 565 mg cocoa flavanols (78 mg epicatechin)
62727645|NCT03526094|EXPERIMENTAL|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 653 mg cocoa flavanols (85 mg epicatechin) and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
62727646|NCT03526094|EXPERIMENTAL|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 653 mg cocoa flavanols (85 mg epicatechin)
62727647|NCT03526094|EXPERIMENTAL|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 484 mg cocoa flavanols (68 mg epicatechin)
62727648|NCT03526094|ACTIVE_COMPARATOR|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 638 mg cocoa flavanols (88 mg epicatechin)
62727649|NCT03526094|EXPERIMENTAL|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 638 mg cocoa flavanols (88 mg epicatechin) Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
62727650|NCT01970228|ACTIVE_COMPARATOR|Adverse reaction to metal debris|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with adverse tissue reactions to metal debris
62727651|NCT01970228|ACTIVE_COMPARATOR|Periprosthetic joint infection|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with periprosthetic joint infection
62727652|NCT01970228|ACTIVE_COMPARATOR|Aseptic mechanical implant loosening|68Ga-citrate and 19F-FDG PET/CT imaging of patients with aseptic mechanical loosening of hip prosthesis
62727653|NCT00843336|EXPERIMENTAL|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that measures urinary estrogen and LH and provides users with low, high, or peak fertility readings.
62727654|NCT00843336|ACTIVE_COMPARATOR|Cervical mucus monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
62727655|NCT04078503||Case|All patients aspected to stay in ICU for at least 3 days who will develop delirium
62727656|NCT04078503||Control|All patients aspected to stay in ICU for at least 3 days who will not develop delirium (1:1 matched with the controls with a propensity score method).
62727657|NCT06266559|EXPERIMENTAL|Initial Drink Group|Consume one bottle of Chang Geng Healthy Drink per day for the first eight weeks of the trial.
62727658|NCT06266559|EXPERIMENTAL|Subsequent Drink Group|Consume one bottle of Chang Geng Healthy Drink per day for the last eight weeks of the trial.
62727659|NCT04973995||Patients with shoulder pain who received ER lag sign|
62727660|NCT04973995||Patients with shoulder pain who received External rotation resistence strength test|
62727661|NCT04973995||Patients with shoulder pain who received Patte's test|
62727662|NCT04973995||Patients with shoulder pain who received Errsair test|
62727663|NCT04973995||Patients with shoulder pain who received speed test|
62727664|NCT04973995||Patients with shoulder pain who received Yergason test|
62727665|NCT04973995||Patients with shoulder pain who received backward traction test|
62727666|NCT04973995||Patients with shoulder pain who received Cui's test|
62727667|NCT01464645||Primary|Post Market Study
62727668|NCT02296710|EXPERIMENTAL|Echocardiographic and sleep apnea test|Echocardiographic Evaluation of systolic and diastolic function of both ventricles and evaluation of apnea-hypopnea index and type of apnea
62727669|NCT02460068|ACTIVE_COMPARATOR|fotemustine|fotemustine alone
62727670|NCT02460068|EXPERIMENTAL|fotemustine and ipilimumab|fotemustine in combination with ipilimumab
62727671|NCT02460068|EXPERIMENTAL|ipilimumab and nivolumab|ipilimumab in combination with nivolumab
62727672|NCT00837161|EXPERIMENTAL|Philips MR guided HIFU system|Patient receiving HIFU treatment
62727673|NCT05216939|EXPERIMENTAL|Flannel mask with earl loops|Participants will wear a flannel mask with earl loops
62727674|NCT05216939|EXPERIMENTAL|Flannel mask with ties|Participants will wear a flannel mask with earl ties
62727675|NCT05216939|EXPERIMENTAL|Twill mask with ear loops|Participants will wear a twill mask with ear loops
62727676|NCT05216939|EXPERIMENTAL|Twill mask with ties|Participants will wear a twill mask with ties
62727677|NCT04168567|EXPERIMENTAL|Obese patients|Patients who have BMI higher than 30
62727678|NCT04168567|EXPERIMENTAL|Normal weight patients|Patients who have BMI between 20 and 25.
62727679|NCT01877681|EXPERIMENTAL|Assisted Care|Assisted care (Tele=assistance) provided by an expert nurse through a informatic online application
62727680|NCT01877681|ACTIVE_COMPARATOR|Active comparator|Usual care as stated by the Clinical Practice Guidelines for Pressure Ulcers treatment
62727681|NCT02109289|EXPERIMENTAL|Methotrexate and Etanercept|Patients already taking Methotrexate prior to the study will continue taking 15 mg weekly and start Etanercept 50 mg every week for 16 weeks
62727682|NCT04099498|NO_INTERVENTION|Standard Control group|This group will not partake in the intervention but will be assessed with the same protocol at the same moments.
62727683|NCT04099498|EXPERIMENTAL|Online-Intervention group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator.
62727684|NCT04099498|EXPERIMENTAL|Enhanced-online-Intervention Group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator. In addition, gamification strategies (e.g., points for each complete activity, feedback) will be implemented in order to promote engagement with the program and activities.
62727685|NCT01490216|OTHER|lisdexamfetamine|open label
62727686|NCT04379453|EXPERIMENTAL|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses
62727687|NCT05850442||FIBROMIYALGIA GROUP|Patients aged between 18-65 who are diagnosed as FMS according to AACR 2016 criterias willing to take part in the study.
62727688|NCT03884153|EXPERIMENTAL|CRP apheresis|"CRP apheresis by means of selective apheresis using the PentraSorb-CRP adsorber"
62727689|NCT01295307|EXPERIMENTAL|Single Arm|Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available
62727690|NCT03506139|EXPERIMENTAL|Radiation Therapy|External beam radiation therapy delivered to target volume.
62727691|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
62165986|NCT03138356|EXPERIMENTAL|Cohort 2 Treatment D|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
62165987|NCT03138356|EXPERIMENTAL|Cohort 2 Treatment E|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
62727692|NCT00375427|EXPERIMENTAL|Every 3 months|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
62727693|NCT00375427|EXPERIMENTAL|Every 4 weeks|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.
62727694|NCT02897687|EXPERIMENTAL|Facebook Group|Social skills training within an online group.
62727695|NCT02897687|ACTIVE_COMPARATOR|Book Club Group|An in-person Book Club discussing material related to Autism Spectrum Disorder.
62727696|NCT00572104|EXPERIMENTAL|resistance exercise|12 month resistance exercise training
62727697|NCT00572104|EXPERIMENTAL|plyometric exercise|12 month plyometric exercise training
62727698|NCT03744195|EXPERIMENTAL|Group I Experimental Kinesotaping|Application of kinesotaping along with conventional treatment
62727699|NCT03744195|ACTIVE_COMPARATOR|Group II conventional training group|Application of conventional treatment
62727700|NCT03604497|EXPERIMENTAL|beacon alerts|active intervention - participants are receiving alerts to warn them about distracted pedestrian behavior near intersections
62727701|NCT03604497|NO_INTERVENTION|no alerts baseline|baseline - participants do not receive any alerts on their mobile smartphone when near intersections
62727702|NCT03604497|OTHER|no alerts retention|retention phase - alerts have stopped after active intervention and behavior is monitored to test retention of learned behavior
62727703|NCT03843151|EXPERIMENTAL|All subjects: Reference followed by Test treatments|Reference - BI 1358894 alone. Test - BI 1358894 + Itraconazole
62727704|NCT02135627|EXPERIMENTAL|Control group|Current standard endoscopic therapy such as epinephrine injection, sclerotherapy, mechanical (endoclip). contact electrocautery/thermal, and non-contact electrocalcautery (APC) ± radiation therapy, angioembolization, and/or surgery.
62727705|NCT02135627|ACTIVE_COMPARATOR|TC-325|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
62727706|NCT06237036||patients diagnosed with any of the specified chronic dermatological conditions|"The study encompasses patients diagnosed with any of the specified chronic dermatological conditions that meet the inclusion criteria. These patients are attended at the Dermatology Department of the Hospital Universitario de Torrejón.~Treatment Patients participating in this study did not receive any specific treatment as part of the research protocol.~Concomitant Medication/Treatment Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study.~Follow-Up Duration The follow-up period extended for seven months. Throughout this duration, patients underwent a minimum of two follow-up visits, which could be conducted either remotely or in-person, as per the study\&amp;#39;s protocol."
62727707|NCT04106544|OTHER|Acid Sphingomyelinase Deficiency (ASMD) Cohort|Patients across the full spectrum of chronic ASMD who have fulfilled the eligibility criteria and who have performed the inclusion visit
62727708|NCT00542126|ACTIVE_COMPARATOR|1|GnRH analog administration following embryo transfer
62727709|NCT00542126|NO_INTERVENTION|2|
62727710|NCT00730756|ACTIVE_COMPARATOR|Arm A|Fluticasone Furoate Nasal Spray 110mcg intranasally once daily
62727711|NCT00730756|PLACEBO_COMPARATOR|Arm B|Matching placebo nasal spray intranasally once daily
62727712|NCT01356862|EXPERIMENTAL|PASIREOTIDE|INTRAMUSCULAR INJECTION OF PASIREOTIDE 60 MG
62727713|NCT01356862|PLACEBO_COMPARATOR|PLACEBO|INTRAMUSCULAR INJECTION OF PLACEBO
62727714|NCT01367379||Physician of internal medicine in Taipei city hospital|
62727715|NCT04513769|EXPERIMENTAL|Study participants|This is a single-arm study so all participants receive the same intervention.
62727716|NCT00994825|PLACEBO_COMPARATOR|Placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
62727717|NCT00994825|EXPERIMENTAL|Levosimendan|Levosimendan
62727718|NCT04144738||Individuals eligible for CRC Screening|Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy.
62727719|NCT06411613|EXPERIMENTAL|CC Program Received Intervention|The CC Program will be delivered through the existing HBPC infrastructure at VA Puget Sound Health Care System. Each HBPC team is comprised on a lead physician or nurse practitioner, nurse, pharmacist, nutritionist, social worker, psychologist, therapist, and chaplain. At a minimum, subsequent clinical encounters and assessments for each Veteran will be scheduled no less than on a quarterly basis and more often as needed based on the HBPC team's clinical judgment. On a monthly basis, the entire HBPC team will conduct MDC meetings to review each Veteran's medical plan. The Program aims to provide patient-centered, whole-person and team-based care, shared decision-making, active symptom management, advance care planning and end-of-life care.
62727720|NCT06411613|NO_INTERVENTION|Usual Care|Does not receive intervention.
62727721|NCT04858113|PLACEBO_COMPARATOR|Baby Shampoo|Conventional Baby shampoo
62727722|NCT04858113|NO_INTERVENTION|No intervention|Baseline condition without intervention
62727723|NCT04858113|EXPERIMENTAL|Blephaclean|Intervention
62727724|NCT04294225|EXPERIMENTAL|Treatment (anastrozole, letrozole)|Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 \>= 1.3 pg/ml and E2 \>= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
62165988|NCT03138356|ACTIVE_COMPARATOR|Cohort 2 Treatment F (Reference Product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
62727725|NCT01285024|NO_INTERVENTION|Control|No Vitagel used during total hip arthroplasty
62727726|NCT01285024|EXPERIMENTAL|Vitagel|Vitagel applied just prior to closure during total hip arthroplasty
62727727|NCT05895305|EXPERIMENTAL|Single arm treated by Airiver Pulmonary DCB|subject will be treated by Airiver Pulmonary Drug Coated Balloon (DCB) catheter. The balloon is coated with a paclitaxel drug (3.5ug/mm2).
62727728|NCT04968626|EXPERIMENTAL|IS GROUP|Patients who received an operation to treat their isthmic spondylolisthesis (IS, Meyerding grade I-II)
62727729|NCT04968626|NO_INTERVENTION|AS GROUP|The asymptomatic adults had no history of severe back pain or spinal trauma
62727730|NCT05072054|EXPERIMENTAL|Atorvastatin arm|Tablet Atorvastatin 40mg once daily at bed-time given for 6 months
62727731|NCT05072054|ACTIVE_COMPARATOR|Rosuvastatin arm|Tablet Rosuvastatin 20mg once daily at bed-time given for 6 months
62727732|NCT00961272||HIV-infected, pre-menopausal women|
62727733|NCT05163314|EXPERIMENTAL|Soticlestat|Participants with DS and LGS will receive:Participants weighing \<45kg:Soticlestat,mini-tablets,titrated from lower dose level(60mg to 140mg) to higher dose(100mg to 200mg) twice daily(BID),based on body weight,orally/via enteral feeding tubes including but not limited to nasogastric(NG)-tube,gastrostomy tube(G-tube),MIC-KEY button,upto 2 weeks in Titration Period. Will continue to receive dose they are on at end of Titration Period,for approximately 4 years in Maintenance Period.Dose will be tapered down to lower dose(not less than lowest dose level based on weight)every 3 days until study drug is discontinued(upto 1week) in Taper Period.Participants weighing ≥45kg/adults:Soticlestat mini-tablets/tablets with starting dose of 200mg BID followed by 300mg BID,up to 2 weeks in Titration Period.Will continue to receive 300mg BID for approximately 4 years in Maintenance Period.Dose will be tapered down upto 100mg every 3 days until study drug is discontinued(up to 1 week) in Taper Period.
62727734|NCT00803595|EXPERIMENTAL|CS-8958 Low Dose|CS-8958 powder to be inhaled - low-dose arm
62727735|NCT00803595|EXPERIMENTAL|CS-8958 High Dose|CS-8958 powder to be inhaled - high-dose arm
62727736|NCT00803595|ACTIVE_COMPARATOR|Oseltamivir phosphate|oseltamivir phosphate oral capsules
62727737|NCT00041470|EXPERIMENTAL|Weekly paclitaxel, vinorelbine and GCSF|"Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.~Paclitaxel weekly. Dose levels:~50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2~Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:~20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2~Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.~G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily"
62727738|NCT06209463||Study group|The inclusion of 40 children diagnosed with Autism Spectrum Disorder (ASD) and their parents/caregivers is planned. Parents/caregivers of children diagnosed with ASD will undergo assessments including a demographic information form; sensory processing (Dunn Sensory Profile); nutrition (Screening Tool for Eating Problems (STEP), Brief Autism Mealtime Behavior Inventory (BAMBI)); quality of life (Pediatric Quality of Life Inventory (PedsQL 4.0)); assessments for children, including balance (Pediatric Berg Balance Scale); head posture (Craniovertebral angle method), hand functions (Jebsen Taylor Hand Function Test); grip strength (Jamar Hand Dynamometer); and evaluations for parents, including depression, anxiety, and stress levels (Beck Depression Inventory, Beck Anxiety Inventory, Spielberger State-Trait Anxiety Inventory).
62727739|NCT06209463||Control group|The inclusion of 40 typically developing children and their parents/caregivers is planned. Parents/caregivers of typically developing children will undergo assessments including a demographic information form; sensory processing (Dunn Sensory Profile); nutrition (Screening Tool for Eating Problems (STEP), Brief Autism Mealtime Behavior Inventory (BAMBI)); quality of life (Pediatric Quality of Life Inventory (PedsQL 4.0)); assessments for children, including balance (Pediatric Berg Balance Scale); head posture (Craniovertebral angle method), hand functions (Jebsen Taylor Hand Function Test); grip strength (Jamar Hand Dynamometer); and evaluations for parents, including depression, anxiety, and stress levels (Beck Depression Inventory, Beck Anxiety Inventory, Spielberger State-Trait Anxiety Inventory).
62727740|NCT03183752|EXPERIMENTAL|Metformin|patients randomized to Metformin group
62727741|NCT03183752|PLACEBO_COMPARATOR|Placebo|patients randomized to placebo group
62727742|NCT02780934|ACTIVE_COMPARATOR|Pressure Dressing|Participants randomized to this group will receive the standard post-operative dressing following their Mohs procedure: a pressure dressing consisting of high absorbency gauze and retention tape.
62727743|NCT02780934|EXPERIMENTAL|Simple Adhesive Dressing|Participants randomized to this group will receive the experimental post-operative dressing following their Mohs procedure: a simple adhesive dressing consisting of a non-adherent pad and transparent dressing.
62727744|NCT00889850|ACTIVE_COMPARATOR|1|Oral fasted administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
62727745|NCT00889850|ACTIVE_COMPARATOR|2|Oral fasted administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
62727746|NCT00889850|ACTIVE_COMPARATOR|3|Oral fed administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
62727747|NCT00889850|ACTIVE_COMPARATOR|4|Oral fed administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
62727748|NCT05946161|EXPERIMENTAL|testing the digital intervention|Prostate cancer survivors (n=20) randomly assigned to this arm will complete a digital psychosexual intervention and will be accompanied weekly by a certified clinical psychologist to monitor progress (synchronous or asynchronous). Pre and Post testing involve questionnaires collecting data on psychosexual variables. At post-testing a 30-minute interview will be conducted to collect information on the usability
62727749|NCT05946161|NO_INTERVENTION|waiting list|Prostate cancer survivors (n=20) randomly assigned to this arm will not be accompanied or get access to the intervention during the six week period in which the experimental group is completing the intervention. Pre and Post testing involved questionnaires collecting data on psychosexual variables. After post testing the control arm will gain access to the intervention as compensation for their participation
62727750|NCT01396187|EXPERIMENTAL|Treatment|
62727751|NCT01396187|PLACEBO_COMPARATOR|Placebo|
62727752|NCT04692012|OTHER|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
62727753|NCT04454346|EXPERIMENTAL|Double Foley Catheter|The patients allocated to this arm were randomly and did not differ from the Single Foley Catheter or Cook Balloon arm regard to patients' demographic features and characteristics. The connected FCs were inserted into the cervix using long forceps and advanced to the internal os level. One of the Foley balloons was inflated with 80 ml of saline, and the other FC, now the cervicovaginal balloon, was pulled out with mild traction until the balloon could be visualized and inflated with 20 ml of saline. The vaginal speculum was removed, and the cervicovaginal balloon was inflated further to a total of 80 ml of saline. Both catheters were taped to the inner aspect of the thigh without tension
62727754|NCT04454346|EXPERIMENTAL|Single Foley Catheter|The patients allocated to this arm were randomly and did not differ from the Double Foley Catheter or Cook Balloon arm regard to patients' demographic features and characteristics. a 16-F FC was inserted into the cervix using long forceps. Then, the balloon was inflated with 80 ml of saline using a standard 20 ml syringe. The catheter was then pulled out until the balloon covered the internal os. The speculum was removed, and the catheter was fixed under slight tension to the inner aspect of the thigh
62727755|NCT04454346|EXPERIMENTAL|Cook Balloon|The patients allocated to this arm were randomly and did not differ from the Double Foley Catheter or Single Foley Catheter arm regard to patients' demographic features and characteristics. Cook cervical ripening group, the device was applied according to the manufacturer's instructions, and each balloon was inflated with 80 ml saline. The catheter was taped to the inner aspect of the thigh without tension.
62727756|NCT00781443|EXPERIMENTAL|A|
62727757|NCT00781443|PLACEBO_COMPARATOR|B|
62727758|NCT06191692|ACTIVE_COMPARATOR|3 months of daily rifampicin plus isoniazid regimen (Arm A)|"Participants will receive rifampicin (dosage based on their weight\*, 10mg/kg/day, maximum 600mg), 300 mg of isoniazid, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day from week 1 to week 12 for a total of 90 doses.~\* Weight will be monitored and dosing adjusted as needed during treatment"
62737945|NCT04182477||Patient without general anesthesia in anamnesis|Patients who never underwent general anesthesia during their life
61976703|NCT03886233||Biological Treatment for Autoimmune uveitis|Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
62727759|NCT06191692|EXPERIMENTAL|1 month of daily rifapentine plus isoniazid regimen (Arm B)|"Participants will receive rifapentine (dosage based on their weight\* 300 mg daily for participants body weight of 30kg -\&amp;amp;lt;35 kg, 450 mg daily for a weight of 35 to 45 kg, and 600 mg for a weight of \&amp;amp;gt;=45 kg), 300 mg of isoniazid, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day from week 1 to week 4 for a total of 28 days.~\* Weight will be monitored and dosing adjusted as needed during treatment"
62727760|NCT02626936|ACTIVE_COMPARATOR|Dual-hormone CL with overestimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 95g of carbohydrates.
62727761|NCT02626936|ACTIVE_COMPARATOR|Dual-hormone CL with adequate estimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
62727762|NCT03972618|EXPERIMENTAL|School and village|Simultaneous installation of filters in schools and the village
62727763|NCT03972618|EXPERIMENTAL|School only|Initial installation in school only
62727764|NCT03972618|EXPERIMENTAL|Village only|Initial installation in village only
62727765|NCT03972618|NO_INTERVENTION|Control|Control group. No filter installation initially.
62727766|NCT00347932|EXPERIMENTAL|ISV-403|0.6% ISV-403 ophthalmic suspension
62727767|NCT00347932|PLACEBO_COMPARATOR|Vehicle|Vehicle of ISV-403 ophthalmic suspension
62727768|NCT02993627|EXPERIMENTAL|Spirulina|daily intake of spirulina tablets weight reduction diet therapy
62727769|NCT02993627|PLACEBO_COMPARATOR|placebo|daily intake of placebo tablets weight reduction diet therapy
62727770|NCT01813695||Preemptive|Patients with genotype testing entered into electronic medical record for consideration and opioid administration postoperatively.
62727771|NCT01813695||Control|Genetic sample taken but withheld from electronic medical record.
62727772|NCT02345655|EXPERIMENTAL|Urine Drug Testing|GPs of the intervention group will dedicate an average 5 minutes during the consult to perform OS-UDT. Patients will be asked to collect a urine sample at the GP's medical office. GP will read and communicate the results immediately to the patients. GPs will keep free of their management according to OS-UDT results.
62727773|NCT02345655|OTHER|No test|Patients will not have to performed the OS-UDT test
62727774|NCT06059456||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
62727775|NCT06059456||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
62727776|NCT01416740|EXPERIMENTAL|Indirect MRA|After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
62727777|NCT06138808||Stereoelectroencephalography (SEEG)|Participants undergoing SEEG as part of standard of care.
62727778|NCT06138808||Control Group|Participants not undergoing SEEG as part of standard of care.
62727779|NCT06424821|EXPERIMENTAL|Trial group|Cadonilimab (10 mg/kg, IV, every 3 weeks) plus platinum-based chemotherapy (carboplatin \[area under the curve (AUC) 5 mg/mL per min, IV\] and paclitaxel \[175 mg/m2, IV\] for squamous NSCLC, or carboplatin \[AUC 5 mg/mL per min, IV\] and pemetrexed \[500 mg/m2, IV\] for non-squamous NSCLC) for up to four cycles, followed by maintenance therapy with cadonilimab for squamous NSCLC, and intravenous cadonilimab plus pemetrexed for non-squamous NSCLC
62727780|NCT02963883|EXPERIMENTAL|SVO2 group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells by the individual value of ScvO2, whose value must be greater than 70% after elimination of hypovolemia, hypotension or hypoxemia.
62727781|NCT02963883|ACTIVE_COMPARATOR|control group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells based on the hemoglobin values, as recommended by the National Health Authority for Anesthesiology, Surgery, Emergency (November 2014 ): transfusion threshold of \<9 g / dl for patients with cardiovascular antecedents.
62727782|NCT06375239||Part A|5-10 patients will initially be assessed on a battery of tests to determine operational feasibility
62727783|NCT06375239||Part B|The same patients from Part A and the remainder of the study cohort (15-35) patients to quantify measurement properties of each test modality
62727784|NCT05060692||LONGCOVID|Patient with Long-COVID Syndrom
62727785|NCT05060692||CONTROLS|Healthy individials
62727786|NCT00825695|ACTIVE_COMPARATOR|flavanol-rich cocoa|
62727787|NCT00825695|PLACEBO_COMPARATOR|flavanol-poor cocoa|
62727788|NCT04335630||Cases|Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR.
62727789|NCT04335630||Controls|Age- and gender-matched subjects admitted to the hospital with similar symptoms but negative PCR testing for SARS-CoV-2 (one negative PCR test for patients of low clinical suspicion and two negative tests, 24 hours apart from each other, for patients of high clinical suspicion).
62727790|NCT05101811|EXPERIMENTAL|Control women without polycystic ovary syndrome|Normal fertile women without polycystic ovary syndrome
62727791|NCT05101811|EXPERIMENTAL|Case women with polycystic ovary syndrome|Women with polycystic ovary syndrome
62727792|NCT03299478||NSCLC patients|Resected NSCLC patients with curative intent
62727793|NCT04836611|OTHER|regular cannabis consumer patients|
62727794|NCT04439864|EXPERIMENTAL|MyIDEA|Research Participants interacted with MyIDEA program both in the hospital and in the follow up cardiology appointment.
62737946|NCT06655363||Anatomical arm|
62727795|NCT04439864|NO_INTERVENTION|Treatment as normal|The research participants were given the chance to play games on the tablet and received normal clinical education.
62727796|NCT02030106||Prior Preterm Birth Patients|All obstetrical patients eligible for the study that have had a prior preterm birth.
62727797|NCT02030106||Term Birth Patients|All obstetrical patients eligible for the study that have not had a prior preterm birth.
62727798|NCT05401539|EXPERIMENTAL|Group 1: VR- Operating Theater Tour Group|The 7-minute operating theatre tour, which describes the preparation process for the surgery, covers the following process: 6-12-year-old children's leaving their room, entering the operating theatre, and meeting the surgery team after they are taken to the operating theatre. The tour ends in the postoperative recovery unit. The actual operating theatre tour also will include information about how and when the child would wear the surgical gown, and how he or she would go to the operating theatre. In order to shoot the operating theatre tour scenes in the most appropriate way, all the procedures to be applied to the children to be operated will observe by the researcher in the pre-, intra- and post-operative periods. The scenario created for the scene shots will reviewe by experts in the field of filming and the final version will decide. The children who will have surgery will watch the real operating theatre tour with the cardboard VR headset.
62727799|NCT05401539|EXPERIMENTAL|Group 2: VR- Documentary Film Group|The children in this group will watch the 5-minute musical documentary film featuring farm animals suitable for their age group with a cardboard VR headset. This group will form as a parallel group to determine whether the VR-Operating theatre Tour or the VR- Documentary Film is more effective.
62727800|NCT02453698|EXPERIMENTAL|Methylphenidate|
62727801|NCT02453698|PLACEBO_COMPARATOR|Control Group|
62727802|NCT00286091|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
62727803|NCT00286091|EXPERIMENTAL|Denosumb|Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
62727804|NCT03855345|EXPERIMENTAL|Control group|In this group, the participants will be submitted to the conventional treatment. The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
62727805|NCT03855345|EXPERIMENTAL|aPDT group|In this group, besides the conventional treatments, patients will also receive aPDT. aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
62727806|NCT01881009|EXPERIMENTAL|Inpatient overnight|Participants in this group will have an overnight evaluation to test safety of the closed-loop system therapy device.
62727807|NCT01881009|EXPERIMENTAL|Summer Camp Session|Participants in this group will receive either the sensor augmented pump or the close loop controller on the first night, then alternated treatment type each night for the duration of the study.
62727808|NCT05340673|EXPERIMENTAL|Arm I (Aquaphor)|Beginning on day 1 of radiation therapy, patients apply Aquaphor BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
62727809|NCT05340673|EXPERIMENTAL|Arm II (Miaderm)|Beginning on day 1 of radiation therapy, patients apply Miaderm BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
62727810|NCT04212715|EXPERIMENTAL|Experimental arm|SABR 35Gy/5 to prostate, up to 50Gy/5 to MR nodule, and 25Gy/5 to pelvic nodes and SVs
62727811|NCT06239883||Patients with OSA|Patients with diagnosed OSA will be included in this study group.
62727812|NCT04390269||Infected group|The infected group will be classified according to the severity whether mild ,moderate or severe
62727813|NCT04390269||susceptible (non infected|This group either exposed and not infected .
62727814|NCT04390269||control group|normal control subject
62727815|NCT05290662||Participants having received oNKord® as part of the WiNK clinical trial|WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable disease and not currently proceeding to hematopoietic stem cell transplantation
62727816|NCT02148263|EXPERIMENTAL|Full-Time Senofilcon A Contact Lens Wear|This group will start wearing contact lenses 8 or more hours per day on the first day of wear
62727817|NCT02148263|EXPERIMENTAL|Graduated Senofilcon A Contact Lens Wear|This group will start wearing contact lenses on a graduated schedule (day 1 = 2 hours, day 2 = 4 hours, day 3 = 6 hours, day 4 = 8 hours, day 5 = 8 or more hours).
62727818|NCT02867228|OTHER|Single Observational Group|Patients receiving mechanical ventilation and subject to the intervention: changes in ventilator settings.
62736248|NCT04979026|EXPERIMENTAL|active ankle pumping with a regular watch alarm|In group 3, in addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge. The watch was continuously used until the 14th day when the patients returned to the hospital for examination.
62737947|NCT06655363||Radiological arm|
62727819|NCT01282385|EXPERIMENTAL|simvasatin|"a) patients responding to treatment with beta-blockers, in which she was treated with nadolol Subsequently randomized into two treatment arms, double-blind:~a.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~a.2: placebo capsules with external characteristics similar to simvastatin.~b) non-responders to treatment with beta blockers, receive treatment with carvedilol.Subsequently randomized into two treatment arms, double-blind~b.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~b.2: placebo capsules with external characteristics similar to simvastatin."
62727820|NCT01282385|PLACEBO_COMPARATOR|placebo|
62727821|NCT03573388||Optical coherence tomography (OCT)|
62727822|NCT00001964|EXPERIMENTAL|single arm|ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months
62727823|NCT00001964|EXPERIMENTAL|single arm 2|ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF
62727824|NCT06521814|EXPERIMENTAL|Globus-tethering HUD patients|The implantation of the REFLECT scoliosis tethering system in patients diagnosed with idiopathic scoliosis.
62727825|NCT01227226|ACTIVE_COMPARATOR|Refresh tears|Allergan's Refresh tears artificial tear
62727826|NCT01227226|ACTIVE_COMPARATOR|Systane Ultra|Alcon's Systane Ultra artificial tear
62727827|NCT01227226|ACTIVE_COMPARATOR|Visine|Visine artificial tear
62727828|NCT01227226|ACTIVE_COMPARATOR|Blink tears|AMO's blink tears artificial tear
62727829|NCT02895516|OTHER|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
62727830|NCT03940989|EXPERIMENTAL|3-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, 5 days/week for three weeks.
62727831|NCT03940989|EXPERIMENTAL|15-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, one day/week for 15 weeks.
62727832|NCT01135992|EXPERIMENTAL|IGlar/IDeg|
62727833|NCT01135992|EXPERIMENTAL|IDeg 3TW|
62727834|NCT05043181|EXPERIMENTAL|Homozygous Familial Hypercholesterolemia|
62727835|NCT02147795||Control cohort|Standard care before implementation (pre-implementation)
62727836|NCT02147795||PBM cohort|After implementation of PBM program (post-implementation)
62727837|NCT04463537|EXPERIMENTAL|experiment group|"Firstly, patients selected with convenience sampling. In the sampling method, the order of the patients' enrollment to the emergency room was used. Then, patient's age, sex and presence of otitis media were recorded in the Personal Information Form.~After recording, measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale. The auricle on the same side was used during both measurements."
62727838|NCT04616170|ACTIVE_COMPARATOR|Usual care|Patients in this arm will be randomized to the routine positioning instructions given at the time of crowning of the fetal vertex during vaginal delivery.
62727839|NCT04616170|EXPERIMENTAL|Hip extension|Patients in this arm will be randomized to hip extension at the time of crowning of the fetal vertex during vaginal delivery.
62727840|NCT05949580||People with RRMS|Participants with relapsing-remitting multiple sclerosis (RRMS) will have to complete various questionnaire from which data will be collected for patient-reported outcomes (PROs) using the icompanion patient app and the HCPs will complete various questionnaires using the icompanion HCP portal.
62727841|NCT03949868|EXPERIMENTAL|High Mindfulness|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions (all including questions about memory performance) twice daily for six days.
62727842|NCT03949868|EXPERIMENTAL|Low Mindfulness|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (some related to memory performance) twice daily for six days.
62727843|NCT03949868|ACTIVE_COMPARATOR|Active control|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (none about memory performance) twice daily for six days.
62727844|NCT06049147|EXPERIMENTAL|MBF-015 4mg oral single dose|Drug: MBF-015 oral single dose. MBF-015 4 mg strength hard gelatin capsules
62727845|NCT06049147|EXPERIMENTAL|MBF-015 8 mg oral single dose|Drug: MBF-015 oral single dose. Two 4 mg strength hard gelatin capsules
62727846|NCT06049147|EXPERIMENTAL|MBF-015 16 mg oral single dose|Drug: MBF-015 oral single dose. One 16 mg strength hard gelatin capsules
62727847|NCT06049147|EXPERIMENTAL|MBF-015 32 mg oral single dose|Drug: MBF-015 oral single dose. Two 16 mg strength hard gelatin capsules
62727848|NCT06049147|EXPERIMENTAL|MBF-015 64 mg oral single dose|Drug: MBF-015 oral single dose. Four 16 mg strength hard gelatin capsules
62727849|NCT06049147|EXPERIMENTAL|MBF-015 8 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. Two 4 mg strength hard gelatin capsules
62727850|NCT06049147|EXPERIMENTAL|MBF-015 16 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. One 16 mg strength hard gelatin capsules
62727851|NCT06049147|EXPERIMENTAL|MBF-015 32 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. Two 16 mg strength hard gelatin capsules
62727852|NCT06049147|EXPERIMENTAL|MBF-015 64 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. Four 16 mg strength hard gelatin capsules
62727853|NCT06049147|PLACEBO_COMPARATOR|Placebo single dose|Placebo Hard gelatin capsules filled with cellulose microcrystalline. One single administration
62727854|NCT06049147|PLACEBO_COMPARATOR|Placebo multiple dose|Placebo Hard gelatin capsules filled with cellulose microcrystalline. Single daily dose during five days
62736249|NCT02286804|EXPERIMENTAL|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
62727855|NCT04588636|ACTIVE_COMPARATOR|Behavioral and self-care therapy control group|Subjects received verbal and written information on the etiology and prognosis of TMDs. In addition, advice on habits and behavior changes, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
62727856|NCT04588636|ACTIVE_COMPARATOR|Rigid occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a rigid occlusal splint
62727857|NCT04588636|ACTIVE_COMPARATOR|Soft occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a soft occlusal splint
62727858|NCT04588636|PLACEBO_COMPARATOR|Non-occlusive splint group|Subjects in this group received behavioral and self-care therapy, in combination with a non-occlusive splint
62727859|NCT00705874|EXPERIMENTAL|1|CGC-11047 in combination with Gemcitabine
62727860|NCT00705874|EXPERIMENTAL|2|CGC-11047 in combination with Docetaxel
62727861|NCT00705874|EXPERIMENTAL|3|CGC-11047 in combination with Bevacizumab
62727862|NCT00705874|EXPERIMENTAL|4|CGC-11047 in combination with Erlotinib
62727863|NCT00705874|EXPERIMENTAL|5|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
62727864|NCT00705874|EXPERIMENTAL|6|CGC-11047 in combination with 5-Flurouracil / Leucovorin
62727865|NCT00705874|EXPERIMENTAL|7|CGC-11047 in combination with Sunitinib
62727866|NCT06032858|EXPERIMENTAL|Apremilast 30 mg twice daily|
62727867|NCT02318836|ACTIVE_COMPARATOR|Normal Hepatic function|
62727868|NCT02318836|ACTIVE_COMPARATOR|Mild Hepatic Impairment|(Child-Pugh score 5-6)
62727869|NCT02318836|ACTIVE_COMPARATOR|Moderate Hepatic Impairment|(Child-Pugh score 7-9)
62727870|NCT02318836|ACTIVE_COMPARATOR|Severe Hepatic Impairment|(Child-Pugh score 10-15)
62727871|NCT06199804|EXPERIMENTAL|Experimental Group|"A program was created to be given to the mothers in the experimental group in line with the content of the Toy Hygiene Guide Book prepared by the researchers."
62727872|NCT06199804|NO_INTERVENTION|Control Group|The researcher did not apply anything other than the clinical routine to the control group during the first three days of hospitalization.
62727873|NCT01439737||asthma|
61976704|NCT01830699|ACTIVE_COMPARATOR|Rilonacept|160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
62727874|NCT05014373|ACTIVE_COMPARATOR|Experimental: Favipiravir + Best supportive Care|Favipiravir (or Avigan) 1800 mg tablet 2x a day on Day 1 then 800 mg 2x a day from Day 2 to maximum of Day 14
62727875|NCT05014373|PLACEBO_COMPARATOR|Comparator: Best Supportive Care|Best supportive care or Standard Treatment includes oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases
62727876|NCT06419439|OTHER|Open label, single arm pilot|Initial phase: A small open-label, single arm pilot study (n=5) will be conducted to develop and assess initial feasibility of study procedures and obtain participant feedback through semi-structured exit interviews. All participants in this open-label single arm pilot will receive the intervention (ketamine infusions followed by the brief behavioral intervention). There will be no control condition, randomization, or blinding.
62727877|NCT06419439|EXPERIMENTAL|Intervention + Minimally Enhanced Usual Care|"Second phase: Intervention arm of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT.~Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression."
62727878|NCT06419439|ACTIVE_COMPARATOR|Minimally Enhanced Usual Care Only|"Second phase: Control arm of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT.~Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression."
62727879|NCT00634140|EXPERIMENTAL|1|ezetimibe
62727880|NCT00634140|PLACEBO_COMPARATOR|2|placebo for 4-6 weeks
62727881|NCT02628444|EXPERIMENTAL|STAGE-I Group 1: CYD Dengue Vaccine|Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).
62727882|NCT02628444|EXPERIMENTAL|STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)|Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).
62727883|NCT02628444|EXPERIMENTAL|STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)|Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).
62727884|NCT02628444|EXPERIMENTAL|STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)|Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
62727885|NCT02628444|EXPERIMENTAL|STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
62727886|NCT02628444|EXPERIMENTAL|STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
62727887|NCT02628444|EXPERIMENTAL|STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)|Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
62727888|NCT02628444|EXPERIMENTAL|STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
62727889|NCT02628444|EXPERIMENTAL|STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
62727890|NCT02374060|ACTIVE_COMPARATOR|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0~Second injection permitted at Week 8 IF:~* Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~* IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
62727891|NCT02374060|ACTIVE_COMPARATOR|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0~Second injection permitted at Week 8 IF:~* Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~* IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
62727892|NCT02374060|ACTIVE_COMPARATOR|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0~Second injection permitted at Week 12 IF:~* Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~* IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
62727893|NCT00650052|EXPERIMENTAL|1|Zonisamide Capsules 100 mg
62727894|NCT00650052|ACTIVE_COMPARATOR|2|Zonegran® Capsules 100 mg
62727895|NCT00618735|EXPERIMENTAL|1|Subjects in Schedule A will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (Beginning at midnight).
62727896|NCT00618735|EXPERIMENTAL|2|Subjects in Schedule B will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (beginning at midnight). The second dose will be taken, following at least a 2-hour fast, 12 hours (+/- 2 hours) after the first dose, except on Day 1 of Cycle 1 and Day 1 of Cycle 2.
62727897|NCT00551031|EXPERIMENTAL|Influenza Virus Vaccine Formulation 1|Influenza Virus Vaccine Formulation 1
62727898|NCT00551031|EXPERIMENTAL|Influenza Virus Vaccine Formulation 2|Influenza Virus Vaccine Formulation 2
62727899|NCT00551031|ACTIVE_COMPARATOR|Fluzone® Elderly Group|
62727900|NCT00551031|ACTIVE_COMPARATOR|Fluzone® High-dose Group|Participants enrolled at age ≥ 65 years
62727901|NCT00551031|ACTIVE_COMPARATOR|Fluzone® Adults Group|Participants enrolled at age 18-49 years.
62727902|NCT03710356|EXPERIMENTAL|Danazol|Danazol
62727903|NCT05922007||Validation study|A total of 150 patients with chronic pain (18-65 years) will be included in the validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ). The reliability and validity study will have a cross-sectional design.
62727904|NCT05922007||Prospective quantitative study|For 150 patients with chronic pain aged 18-65 years, a questionnaire survey will be carried out using the questionnaire set three times, during the first regular check-up at the outpatient clinic and after at least 3 and 6 months, also during a regular check-up.
62727905|NCT02709577|EXPERIMENTAL|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
62727906|NCT02709577|EXPERIMENTAL|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
62727907|NCT02002507||park bench position|Comparing jugular venous flow in supine and park bench position in neurosurgical patients requiring their surgery in park bench position
62727908|NCT02002507||prone position|Comparing the jugular venous flow in the supine and prone position in patients requiring their surgery to be done in the prone position.
62727909|NCT01679938|EXPERIMENTAL|primary obesity prevention|"The intervention will involve four main components:~1. Training of child care providers.~2. Curriculum sessions for children.~3. Family outreach activities.~4. Maintenance activities."
62727910|NCT01679938|NO_INTERVENTION|Control group|For the control group, usual care will be provided
62727911|NCT05346276|EXPERIMENTAL|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
62727912|NCT04345484|EXPERIMENTAL|GMT Intervention + Health Lifestyle Program|The intervention group will participate in GMT, a standardized cognitive rehabilitation program which will be given as per the manual and which consists of 9 sessions each 2-hours in duration. They will also participate in the Healthy Lifestyle Program (HLP), which includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
62727913|NCT04345484|ACTIVE_COMPARATOR|Health Lifestyle Program|The control group enters directly into the HLP without any other study visits. The HLP includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
62727914|NCT00178997||Good blood flow|Group without ischemia to the small intestine
62727915|NCT00178997||Poor blood flow|Groups that have partial ischemia to their small intestine
62727916|NCT01232816||Delayed graft function|These are patients in whom dialysis is required following transplantation.
62727917|NCT01232816||Immediate function|These are patients in whom no dialysis is required and creatinine declines by \>20% in the first 24 hours following transplantation.
62727918|NCT03691298||Arthroscopic hip repair|
61976705|NCT01830699|PLACEBO_COMPARATOR|Corticosteroid|80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once
61976706|NCT00703079||Group A|\>15 patients treated only with SSA (octreotide-LAR or lanreotide depot)
61976707|NCT00703079||Group B|\>15 patients treated with surgery after a period of SSA treatment of 6-24 months
62727919|NCT03005730|EXPERIMENTAL|Group 1|Submitted to a session of phototherapy with 39,27 Joules per point in muscle masseter and temporal bilateral.
62727920|NCT03005730|PLACEBO_COMPARATOR|Group 2|Submitted to a session of phototherapy placebo with 0,0 Joules per point in muscle masseter and temporal bilateral.
62727921|NCT06511947|EXPERIMENTAL|Part 1, Cohort A|A single dose inhaled dose of 6 mg GH001 administered via a proprietary aerosol delivery device in eight subjects.
62727922|NCT06511947|EXPERIMENTAL|Part 1, Cohort B|A single dose inhaled dose of 12 mg GH001 administered via a proprietary aerosol delivery device in eight subjects.
62727923|NCT06511947|EXPERIMENTAL|Part 1, Cohort C|A single dose inhaled dose of 18 mg GH001 administered via a proprietary aerosol delivery device in eight subjects.
62727924|NCT06511947|EXPERIMENTAL|Part 1, Cohort D (optional)|A single inhaled intermediate dose of 8, 9, 10, 14, 15, or 16 mg GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD and safety data from Cohorts A, B, and C).
62727925|NCT06511947|EXPERIMENTAL|Part 1, Cohort E (optional)|A single inhaled intermediate dose of 8, 9, 10, 14, 15, or 16 mg GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on SSG review of PK, PD and safety data from Cohorts A, B, and C).
62727926|NCT06511947|EXPERIMENTAL|Part 2, Cohort F|Up to three escalating inhaled doses of GH001 (doses as determined by Part 1, maximum single inhaled dose of 18 mg) administered via a proprietary aerosol delivery device in 12 subjects.
62727927|NCT03191162|ACTIVE_COMPARATOR|B300/60|Benznidazole 300mg/day p.o. divided in two doses for 60 days
62727928|NCT03191162|EXPERIMENTAL|B150/60|Benznidazole 150mg/day p.o. divided in two doses for 60 days
62727929|NCT03191162|EXPERIMENTAL|B400/15|Benznidazole 400mg/day p.o. divided in two doses for 15 days
62727930|NCT06009250||CKD patients|CKD patient who are not DM are investigated for the presence of NAFLD
62727931|NCT06009250||normal control group|normal population are investigated to know the prevalence of NAFLD in contrast to patients with CKD.
62727932|NCT02331953||delirium group|the patients with delirium after spine surgery
62727933|NCT02331953||no delirium group|the patients without delirium after spine surgery
62727934|NCT00148031|EXPERIMENTAL|1|On-site (MMT Clinic) HCV evaluation and treatment
62727935|NCT00148031|ACTIVE_COMPARATOR|2|Off-site (GI Clinic) HCV evaluation and treatment
62727936|NCT05879809|EXPERIMENTAL|The clinical response of the MT|To assess the efficacy of music therapy of MT group compared to control group in depressive symptoms.
62727937|NCT05879809|EXPERIMENTAL|The alterations of acoustic features in the MT|To understand the possible biological mechanism underlying the efficacy of music therapy by analyzing alterations of acoustic features.
62727938|NCT05879809|EXPERIMENTAL|The alterations of neuroimaging features in the MT|To investigate potential neurobiological mechanisms underlying the effectiveness of music therapy by analyzing alterations in neuroimaging features.
62727939|NCT02309658|EXPERIMENTAL|Interventional|Treatment consisted of gemcitabine at a dose of 1000 mg/m2, followed by cisplatin 35 mg/m2 administered on day 1 and 8, for two cycles. After that, weekly cisplatin 40mg/m2 is administered concomitant with radiotherapy (45-55Gy) in 1,8-2,0 daily fractions and a 10Gy boost when there was parametrial involvement. Low-dose rate brachytherapy, in 4 fractions of 7Gy, in a total of 28Gy will complete the protocol.
62727940|NCT00876863|EXPERIMENTAL|CERE-110|CERE-110: Adeno-Associated Virus Delivery of NGF
62727941|NCT00876863|SHAM_COMPARATOR|Placebo|Placebo Surgery
62727942|NCT04364815|EXPERIMENTAL|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine oral loading dose of 400mg two times per day on Day 1 then 400 mg once a day for Day 2-10 plus standard preventive measures as defined by PGH Hospital Infection Control Unit (HICU)
62727943|NCT04364815|PLACEBO_COMPARATOR|Placebo plus standard preventive measure|Placebo tablet plus standard preventive measures as defined by PGH-HICU
62727944|NCT05749367|ACTIVE_COMPARATOR|Suprainguinal Fascia Iliaca Block Group|Patients will undergo SIFIB with ropivacaine and PENG plus LFCNB with saline solution.
62727945|NCT05749367|EXPERIMENTAL|PENG Block + Lateral Femoral Cutaneous Nerve Block Group|Patients will undergo SIFIB with saline solution and PENG plus LFCNB ropivacaine.
62727946|NCT02681367|NO_INTERVENTION|fresh embryo transfer|Patient with RIF underwent ICSI cycle followed by Day 5 fresh embryo transfer.
62727947|NCT02681367|EXPERIMENTAL|Freeze all|Patient with RIF. All of them underwent ICSI cycle, all their embryos were cryopreserved at Day 5 and transferred in a consecutive natural cycle.
62727948|NCT04114071|EXPERIMENTAL|Physical Activity intervention group|Older overweight or obese Black women who participate in the physical activity intervention group will receive a daily text message from the TOSS study for 12 weeks, a Fitbit device plus have access to the Fitbit community option on their Fitbit app as an opportunity for virtual peer support. They will also receive an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention.
62727949|NCT04114071|ACTIVE_COMPARATOR|Control group|The control will only receive a weekly neutral text message during the 12-week intervention. For this project, a neutral text message is defined as a message that only provides facts about a topic.They will also receive a Fitbit device, an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention
62727950|NCT02454530||Cancer patients treated with Nivestim®|
62727951|NCT01125410|EXPERIMENTAL|Dequalinium chloride 10mg|
62727952|NCT01125410|ACTIVE_COMPARATOR|clindamycin vaginal cream 2%|
62727953|NCT01699126|EXPERIMENTAL|CPAP, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP on OSA
62727954|NCT01699126|ACTIVE_COMPARATOR|CPAP and statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP plus statin on OSA patients
62727955|NCT01699126|ACTIVE_COMPARATOR|OSA, statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after statin treatment on OSA
62727956|NCT01699126|NO_INTERVENTION|Placebo|We will also measure the FMD, blood pressure and inflammation on patients with only life style modification as in all other patients
62727957|NCT01994746|EXPERIMENTAL|Nasal Glucagon|At one visit, a glucagon dose of 3 mg was administered in a nostril with a prefilled delivery device that delivers a single dose upon activation.
62727958|NCT01994746|ACTIVE_COMPARATOR|Intramuscular Glucagon|At a separate visit, 1 mg of glucagon was administered into the deltoid muscle of the non-dominant arm (intramuscular \[IM\]).
62727959|NCT02103127|EXPERIMENTAL|755nm Alexandrite laser with lens array|
62727960|NCT05973708|ACTIVE_COMPARATOR|Group A: Clamshell Exercise|"Group B will be given frog pumps exercises in their regular training program.~These exercises are given as:~* In (0-2) week ,2 sets 10 repetitions~* In (2-4)week, 3 sets of 10 repetitions~* In (4-6)week, 3 sets of 15 repetitions"
62727961|NCT05973708|ACTIVE_COMPARATOR|Group B: Frog Pump Exercise|"Group B will be given frog pumps exercises in their regular training program.~These exercises are given as:~* In (0-2) week ,2 sets 10 repetitions~* In (2-4)week, 3 sets of 10 repetitions~* In (4-6)week, 3 sets of 15 repetitions"
62727962|NCT03079531|EXPERIMENTAL|Secukinumab arm|Participants receive secukinumab (7 doses over a 16-week study period).
62727963|NCT00644943|ACTIVE_COMPARATOR|1|
62727964|NCT00644943|ACTIVE_COMPARATOR|2|
62727965|NCT04452123|EXPERIMENTAL|Argon plasma|Patients with endometrioma treated with laparoscopic argon plasma energy.
62727966|NCT04452123|EXPERIMENTAL|Stripping and suture/coagulation|Patients with endometrioma treated with laparoscopic excision with suture or gentle coagulation of the rest of ovary.
62727967|NCT02377843|EXPERIMENTAL|Participatory|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the participatory study arm will receive a 1-hour in-person communication training.
62727968|NCT02377843|EXPERIMENTAL|Efficient|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the efficient study arm will receive a 1-hour in-person communication training.
62727969|NCT02377843|NO_INTERVENTION|Control|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
62727970|NCT01580410|EXPERIMENTAL|Arm I (mitomycin C)|Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
62727971|NCT01580410|EXPERIMENTAL|Arm II (oxaliplatin)|Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
62727972|NCT01101672|EXPERIMENTAL|Single-port laparoscopic colectomy|
62727973|NCT01101672|ACTIVE_COMPARATOR|Conventinal laparoscopic colectomy|
62727974|NCT02534883|ACTIVE_COMPARATOR|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
62727975|NCT02534883|PLACEBO_COMPARATOR|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
62727976|NCT05545410|OTHER|healthy volunteers|
62727977|NCT00383669|ACTIVE_COMPARATOR|Multiple RDA multivitamins|Multivitamins (including B, C, and E)
62727978|NCT00383669|ACTIVE_COMPARATOR|Single RDA Multivitamins|Multivitamins (including B, C, and E)
62727979|NCT00587808||HFpEF|Patients with a history of HFpEF
62727980|NCT00587808||control|Patients with a without a history of CHF
62727981|NCT01481350|EXPERIMENTAL|Sildenafil|All patient will be treat with a intravenous administration of the drug from the beginning of the intervention, for a maximum of 72 hours.
62727982|NCT05869968||Individuals with Chronic Spinal Cord Injury who receive either Flu or COVID-19 vaccine|18-89 years old with traumatic SCI, AIS grade A-D, Neurological injury level of C1-T10 who are choosing to receive a vaccine against the flu or COVID-19 and demonstrate capacity to provide informed consent.
62727983|NCT05869968||Uninjured Controls who receive the Flu vaccine or COVID-19 vaccine|18-89 years old without traumatic Spinal Cord Injury (SCI) who are choosing to receive a vaccine against either the Flu or COVID-19 and demonstrate the capacity to provide informed consent.
62727984|NCT02902445||Case group|250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration
62727985|NCT02902445||Control group|"250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.~Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.~oral swab for polymorphism exploration"
62727986|NCT04963283|EXPERIMENTAL|Cabozantinib 40 mg orally daily in combination with nivolumab 480 mg IV every 28 days.|"Cabozantinib is supplied as 20-mg tablets and will be administered orally at a dose of 40 mg/day.~Nivolumab is supplied in 100 mg/Vial (10 mg/mL) vials and will be administered IV at a dose of 480 mg every 28 days."
62727987|NCT03929354|EXPERIMENTAL|Risk Factors Modification Programme|"* Patients in the intervention arm will attend the 12-week intensive lifestyle programme which includes healthy lifestyle change such as smoking cessation, healthy food choices and increasing physical activity levels, as well as management of cholesterol, diabetes, and blood pressure.~* The 12-week programme will consist of 12 sessions of 2.5 hours each per week.~* Each of the weekly sessions will incorporate an individualised meeting between the multidisciplinary healthcare team and each patient to review the progress and health goals.~* The weekly sessions will also include a one-hour group exercise programme and an educational workshop."
62727988|NCT03929354|ACTIVE_COMPARATOR|Standard Care|Standard care is defined as giving information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
62737948|NCT01713647|EXPERIMENTAL|LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon|"Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
62727989|NCT03487484||With protective stoma|Patients in which intraoperatively the decision was made to add a protective stoma (following a risk algorithm) to total mesorectal excision. In patients quality of life, the Gastrointestinal Quality of Life Index (GIQLI) questionnaire, Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.
62727990|NCT03487484||No stoma|"Patients in which intraoperatively the decision was made to refrain from adding a protective stoma (following a risk algorithm) to total mesorectal excision.~In patients quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index), Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied."
62727991|NCT03805061|ACTIVE_COMPARATOR|Aerobic exercise group|Group 1 was 'aerobic exercise group'. Patients in this group were included in an aerobic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise.
62727992|NCT03805061|ACTIVE_COMPARATOR|Isokinetic exercise group|Group 2 was 'isokinetic exercise group'. Patients in this group were included in an isokinetic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study.
62727993|NCT03218280|ACTIVE_COMPARATOR|Antioxidant Therapy|
62727994|NCT03218280|NO_INTERVENTION|Antioxidant Free|
62727995|NCT04356300|EXPERIMENTAL|The exosome of MSC arm|Exosome of MSC at a dose of 150mg will be given intravenously to Patients in the exosome of MSC arm once a day for 14 times.
62727996|NCT04356300|NO_INTERVENTION|The control arm|Patients in the control arm will not be given exosome of MSC.
62727997|NCT04406207||Patients|Patients relapsing or not after hematopoietic stem cell transplantation.
62727998|NCT04067791|EXPERIMENTAL|Prolonged-Release melatonin then Immediate-release melatonin|
62727999|NCT04067791|EXPERIMENTAL|Immediate-Release Melatonin then Prolonged-Release Melatonin|
62728000|NCT05651763|EXPERIMENTAL|Stimulation and exercise group|30-minute exercise program (based on Pilates method) associated with active transcranial direct current stimulation.
62728001|NCT05651763|SHAM_COMPARATOR|Exercise and sham stimulation group|30-minute exercise program (based on Pilates method) associated with sham transcranial direct current stimulation.
62728002|NCT02691416|EXPERIMENTAL|propofol postconditioning|1.2mg/L propofol
62728003|NCT02691416|EXPERIMENTAL|sevoflurane|0.5%-2% sevoflurane
62728004|NCT06305585|EXPERIMENTAL|Primal Reflex Release Technique|"The subject will lay on their back with their eyes closed. Palmar Reflex Release The subject will actively raise arms overhead (palm facing the floor) with a pen squeezed between their fingers.~Epicranial Release The clinician will grasp the subject's hair near the front of the hairline with one hand, just above the ear on the right side and gently pull.~Frontalis Release The clinician will instruct the subject to raise their eyebrows and keep them raised. The clinician will use their thumbs to gently flick downward on the inside portion of the subject's eyebrows.~Orbicularis Oculi Release The clinician will place their thumb below the eye resting on the cheek bone and with the other hand will lightly rest on the subject's eyelid The clinician will then gently and lightly attempt to quickly open the subject's eyelids~Suboccipital Release The participant will rest their head in clinicians hands while they provide a slight traction at the base of the skull"
62728005|NCT06305585|NO_INTERVENTION|Control|For the control, the subject will watch another 5-minute video of fish in an aquarium.
62728006|NCT04212078|ACTIVE_COMPARATOR|A-Levofloxacin|0.1 ml/0.5mg of levofloxacin 0.5% ophthalmic solution
62728007|NCT04212078|ACTIVE_COMPARATOR|B-Intracameral Cefuroxime|0.1 ml/1mg of Cefuroxime
62728008|NCT03318445|EXPERIMENTAL|Rucaparib and irinotecan|"Rucaparib will be taken twice daily by mouth for 7-14 days in 21 or 28 day cycles. Irinotecan will be administered by IV for 90 minutes every 14 days, or every 21 days if not tolerated.~During the dose escalation phase, the maximum tolerated dose for combining Rucaparib and irinotecan will be determined. The dose for rucaparib during dose escalation will range from 300 mg to 600 mg, depending on the progression of study. The dose for irinotecan during dose escalation may range from 40 mg/m2 to 150 mg/m2.~During the dose expansion phase, patients who have received prior PARP inhibitors will be given rucaparib and irinotecan at the maximum tolerated dose levels determined during the dose escalation phase."
62728009|NCT03318445|EXPERIMENTAL|Rucaparib only|During the dose expansion phase, patients who have not received prior PARP inhibitor therapy will take 600 mg of rucaparib by mouth daily. Patients who progress on single-agent rucaparib will be given the option to cross-over to the combination treatment arm and receive rucaparib in combination with irinotecan at the maximum tolerated dose levels determined during dose escalation.
62728010|NCT05757180|EXPERIMENTAL|Intervention group|Classes that will follow Positive Events Training.
62728011|NCT05757180|ACTIVE_COMPARATOR|Control group|Classes that will follow Bogus Control Training.
62728012|NCT05959317|OTHER|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
62728013|NCT05959317|OTHER|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
62728014|NCT02588417|ACTIVE_COMPARATOR|dexamethasone|dexamethasone 4 mg administered intrathecally during active stage of labor once only in combination with levobupivacaine
62728015|NCT02588417|ACTIVE_COMPARATOR|levobupivacaine|levobupivacaine 2.5 mg in 2 ml administered intrathecally during active stage of labor once and alone and then epidural levobupivacaine 7ml of 2.5 mg concentrationis administered till the end of labor
62728016|NCT03773666|EXPERIMENTAL|Durvalumab|-Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
62728017|NCT03773666|EXPERIMENTAL|Durvalumab + Oleclumab|"* Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle~* Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle"
61976708|NCT00703079||Group C|\>15 patients cured after surgery only
62728018|NCT05113654||IPF|Patients with idiopathic pulmonary fibrosis
62728019|NCT05113654||COPD|Patients with chronic obstructive pulmonary disease
62728020|NCT05113654||Healthy|Healthy controls
62728021|NCT05329753|EXPERIMENTAL|Intervention group|Mobile application
62728022|NCT05329753|NO_INTERVENTION|Control group|Usual education
62728023|NCT03410719|EXPERIMENTAL|<55 (Low-GI group)|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals:Low-GI - pasta, barley, parboiled rice, legumes.
62728024|NCT03410719|EXPERIMENTAL|>70 (Hi-GI group).|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals: Hi-GI - rice, potato,
62728025|NCT02567799|EXPERIMENTAL|Single-arm|Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
62728026|NCT02714491|ACTIVE_COMPARATOR|Music|Erigo + Music: During each stepping verticalization session the patient receives auditory stimulation (earphones) with previously preferred music
62728027|NCT02714491|ACTIVE_COMPARATOR|Metronome|Erigo + Metronome: During each stepping verticalization session the patient receives auditory stimulation (earphones) with a metronome (rhythmic with the stepping movement)
62728028|NCT02714491|ACTIVE_COMPARATOR|Silence|Erigo + Silence: During each stepping verticalization session the patient does note receive any auditory stimulation.
62728029|NCT03139032|EXPERIMENTAL|APD334|APD334 active treatment for 12 weeks.
62728030|NCT03843528|EXPERIMENTAL|Combined therapy|"Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design.~Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle."
62728031|NCT00610259|EXPERIMENTAL|1|brief behavioral therapy for insomnia (bBT-I) in addition to treatment as usual (TAU)
62728032|NCT00610259|ACTIVE_COMPARATOR|2|Treatment as usual (TAU)
62728033|NCT03686878|EXPERIMENTAL|Intervention Group|Lifitegrast 5% ophthalmic solution group
62728034|NCT05863390|EXPERIMENTAL|McKenzie exercise|
62728035|NCT05863390|OTHER|Trochanteric belt|
62728036|NCT03343678|EXPERIMENTAL|Venetoclax + BI 836826|
62728037|NCT02524145|ACTIVE_COMPARATOR|Healthy Seniors|"Fifteen healthy senior volunteers \> 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) \<30, with exercise histories of less than 3 days per week of aerobic exercise.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
62728038|NCT02524145|EXPERIMENTAL|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction \> 0.50; and c) objective evidence of diastolic dysfunction.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
62728039|NCT02524145|ACTIVE_COMPARATOR|Healthy Young|"Fifteen volunteers \<45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI \<30.~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
62728040|NCT01701960||Group 1|This cohort will be injected with 1% lidocaine with 1:100,000 of epinephrine into the nasal mucosa at the time of nasal surgery
62728041|NCT01701960||Group 2|This group will be injected with 1% lidocaine with 1:200,000 of epinephrine into the nasal mucosa at the start of nasal surgery.
62728042|NCT03335150|ACTIVE_COMPARATOR|Supportive Care|Support Group for PD-MCI
62728043|NCT03335150|EXPERIMENTAL|CogSMART-PD|Cognitive Rehabilitation for PD-MCI
62728044|NCT04430608|OTHER|Fingerprick glucose|Standard care with fingerprick glucose + blinded CGM stratification on COVID-19 status
62728045|NCT04430608|EXPERIMENTAL|Open continous glucose monitoring (CGM)|Standard care with fingerprick glucose + un-blinded CGM stratification on COVID-19 status
62728046|NCT00412191|EXPERIMENTAL|Subjects in treatment regimen A|Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.
62728047|NCT00412191|EXPERIMENTAL|Subjects in treatment regimen B|Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.
62728048|NCT00412191|EXPERIMENTAL|Subjects in treatment regimen C|Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.
62728049|NCT03807050|EXPERIMENTAL|Astaxanthin|Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
62728050|NCT00403013|EXPERIMENTAL|1|lateral, head-down position during axillary plexus block
62728051|NCT00403013|ACTIVE_COMPARATOR|2|standard position during axillary plexus block
62728052|NCT05833035|EXPERIMENTAL|All participants|
62728053|NCT03211819|EXPERIMENTAL|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.~Then in implants with primary stability \> 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
62736250|NCT01111734|EXPERIMENTAL|Treatment Group|The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
62728054|NCT03211819|ACTIVE_COMPARATOR|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability \> 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
62728055|NCT03151122|EXPERIMENTAL|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
62728056|NCT03151122|ACTIVE_COMPARATOR|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
62728057|NCT03051295|ACTIVE_COMPARATOR|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
62728058|NCT03051295|EXPERIMENTAL|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
62728059|NCT03051295|ACTIVE_COMPARATOR|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
62728060|NCT03051295|EXPERIMENTAL|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
62728061|NCT04303429|NO_INTERVENTION|observation group|Patients enrolled in the observation group will not receive any chemotherapy drugs
62728062|NCT04303429|EXPERIMENTAL|adjuvant chemotherapy group|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
62728063|NCT02168062|ACTIVE_COMPARATOR|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
62728064|NCT02168062|EXPERIMENTAL|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
62728065|NCT04133350|EXPERIMENTAL|Active Patient Engagement|All patients are enrolled into the Active Patient Engagement (APE) arm. This arm will receive the APE intervention.
62728066|NCT03974126|EXPERIMENTAL|40 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
62728067|NCT03974126|EXPERIMENTAL|80 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
62728068|NCT06069180|EXPERIMENTAL|Busulfan included group|The conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
62728069|NCT06069180|OTHER|Control group|The conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
62728070|NCT01619761|EXPERIMENTAL|Treatment Plan 1 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -8 to -2, fludarabine phosphate IV over 1 hour on days -7 to -4, and melphalan IV over 30 minutes on day -4. CD20 positive patients also receive rituximab IV over 6 hours on days -8 to -4.
62728071|NCT01619761|EXPERIMENTAL|Treatment Plan 2 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -7 to -2, cyclophosphamide IV over 3 hours on day -7, and undergo TBI on day -3. Patients also receive rituximab and fludarabine phosphate as in Treatment Plan 1.
62728072|NCT01759342|EXPERIMENTAL|Comprehensive exercise program|Moderate to high intensity aerobic, resistance, flexibility, posture and balance exercise program
62728073|NCT01759342|ACTIVE_COMPARATOR|Usual care exercise|30 minutes/day of self selected mode and intensity of aerobic exercise
62728074|NCT02449811||Perindopril|Treatment period 1: Perindopril 5mg, oral, once daily, for 4 weeks Treatment period 2: Perindopril 10mg, oral, once daily, for 4 weeks
62728075|NCT02449811||Olmesartan|Treatment period 1: Olmesartan 20mg, oral, once daily, for 4 weeks Treatment period 2: Olmesartan 40mg, oral, once daily, for 4 weeks
62728076|NCT02449811||Amlodipine|Treatment period 1: Amlodipine 5mg, oral, once daily, for 4 weeks Treatment period 2: Amlodipine 10mg, oral, once daily, for 4 weeks
62728077|NCT02449811||Hydrochlorothiazide|Treatment period 1: Hydrochlorothiazide 25mg, oral, once daily, for 4 weeks Treatment period 2: Hydrochlorothiazide 50mg, oral, once daily, for 4 weeks
62728078|NCT04373343|OTHER|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
62728079|NCT04015011|EXPERIMENTAL|Low Calorie Diet (LCD) diet intervention|In person or video conference
62728080|NCT02870062|EXPERIMENTAL|Chlorhexidine|Intervention: daily baths with chlorhexidine wipes, oral spray and shampoo. This arm will receive daily bathing with chlorhexidine wipes at 2% (CLORHEXI-WIPES ONE-STEP, G70 Antisepsis, León, México) plus an oral spray application of chlorhexidine chlorhydrate at 0.12%. For scalp washing, a chlorhexidine shampoo at 0.12% concentration will be applied.
62736251|NCT01111734|EXPERIMENTAL|Control|40 healthy age-matched peers with undergo the same baseline testing as the NAC subjects as well as baseline fMRI. They will not engage in any follow up visits.
61976709|NCT00703079||Group D|\>15 patients treated with surgery first and then with SSA after 6-12 months
62728081|NCT02870062|PLACEBO_COMPARATOR|Placebo|Intervention: daily baths with placebo wipes, oral spray and standard shampoo. This arm will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in arm #1.
62728082|NCT04430361|EXPERIMENTAL|Megestrol|Palonosetron 2.5mg, Dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, Megestrol acetates 160mg orally every morning on the day of the beginning of chemotherapy for 10 days.
62728083|NCT04430361|OTHER|Control|Palonosetron 2.5mg, Dexamethasone12mg on the first day, 8mg on the 2nd-4th day
62728084|NCT02882191|EXPERIMENTAL|LevoCept IUD|LevoCept IUD placement
62728085|NCT03882593||Analysis of arterial filters during CPB|This is a clinical and observational study to investigate of blood cells addesion to surfaces of arterial filters during CPB and the impact in coagulations laboratory exams
62728086|NCT02574559|EXPERIMENTAL|Caregiver of Child With Autism Spectrum Disorder|Caregivers attending eight weekly sessions of Cognitive Based Compassion Training Sessions and Meditation.
62728087|NCT02536144|EXPERIMENTAL|MCCES|Magnetic -controlled capsule endoscopy system (MCCES) is a robot system that the capsule would be swallowed to observe the mucosa of the human alimentary canal especially the colon under the control of the magnetic-manipulator.
62728088|NCT02536144|ACTIVE_COMPARATOR|Colonoscopy|Colonoscopy has now been in use for many years to visualize and diagnose abnormalities of the colon and it is the gold standard for detecting colorectal lesions.In this study,the additional utility of the colonoscopy is to monitor the movement of the Magnetic -controlled capsule endoscopy.
62728089|NCT01898286|EXPERIMENTAL|DiaPep277®|Administration of DiaPep277® to patients previously enrolled in the Phase 3 Study 1001 (NCT01103284)
62728090|NCT03610854|EXPERIMENTAL|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
62728091|NCT05025410||General anesthesia using remimazolam and remifentanil|Adult female patients scheduled for gynecological surgery under general anesthesia using remimazolam and remifentanil
62728092|NCT01738685|OTHER|Control.|Nutritional Education.
62728093|NCT01738685|OTHER|Behavioral Intervention|Behavioral Intervention.
62728094|NCT01484652|EXPERIMENTAL|COV795|
62728095|NCT01484652|PLACEBO_COMPARATOR|Placebo|
62728096|NCT05393999|EXPERIMENTAL|BMS-986414 and BMS-986413|"1. Broadly neutralising antibody:BMS-986414 This long-acting antibody will be prescribed to all participants and given as one subcutaneous injection of 200 mg.~2. Broadly neutralising antibody: BMS-986413 This long-acting antibody will be prescribed to all participants and given as one subcutaneous injection of 200 mg"
62728097|NCT00355355|EXPERIMENTAL|Litx|Drug: Talaporfin Sodium (1 mg/kg iv), Device: Interstitial Light Emitting Diodes (200 J/cm) 3 treatments within 6 months
62728098|NCT00355355|ACTIVE_COMPARATOR|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
62728099|NCT03399942|EXPERIMENTAL|DBS-ACC ON|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
62728100|NCT03399942|EXPERIMENTAL|DBS-ACC OFF|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
62728101|NCT00047502|EXPERIMENTAL|Gleevec + SCH 66336|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day, and SCH66336 100 mg by mouth twice a day."
62728102|NCT00335309|EXPERIMENTAL|1|The Investigational arm is treated with sinus irrigation with normal saline 0.9% and intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
62728103|NCT00335309|ACTIVE_COMPARATOR|2|The control arm is treated with the same intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. There is no sinus irrigation with normal saline for this arm. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
62728104|NCT02822742|OTHER|DE-117 ophthalmic solution and Latanoprost|DE-117 is Experimental. Latanoprost is Active Comparator.
62728105|NCT00608049|EXPERIMENTAL|1|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/high GI, and low carbohydrate/low GI
62728106|NCT00608049|EXPERIMENTAL|2|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/low GI, and low carbohydrate/high GI
62728107|NCT00608049|EXPERIMENTAL|3|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/high GI, and low carbohydrate/low GI
62728108|NCT00608049|EXPERIMENTAL|4|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/low GI, and low carbohydrate/high GI
62728109|NCT00608049|EXPERIMENTAL|5|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/high GI, and high carbohydrate/low GI
62728110|NCT00608049|EXPERIMENTAL|6|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/low GI, and high carbohydrate/high GI
62728111|NCT00608049|EXPERIMENTAL|7|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/high GI, and high carbohydrate/low GI
62728112|NCT00608049|EXPERIMENTAL|8|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/low GI, and high carbohydrate/high GI
62728113|NCT03384459|EXPERIMENTAL|Experimental group|"For a total period of 12 months, perform the 308-nm excimer laser treatment once a month.~At this time, the dose of the 308-nm excimer laser is based on the 50% of the maximum dose that the patient received for the treatment.~Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
62728114|NCT03384459|NO_INTERVENTION|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
62728115|NCT02069873|EXPERIMENTAL|16-Week Group Treatment|The 16-week treatment group will contain 3 blocks of treatment (exposure, cognitive, skills) with order randomized within the treatment. The first and last group session are considered inactive treatment sessions. The group treatment will be provided weekly.
62728116|NCT02069873|NO_INTERVENTION|Wait List Control|The Wait List Control group will receive minimal attention, as they will meet bi-monthly for supportive sessions with the study psychologist. The study psychologist will not introduce any active treatment in the individual sessions.
62728117|NCT05748301||ICU Clinicians|ICU doctors at the senior registrar, ICU fellow or consultant level will evaluate the AI Clinician system.
62728118|NCT05748301||Septic patients|Septic patients meeting the inclusion criteria will be included on the system.
62728119|NCT06384846||Control-Cohort|Subjects with suspected ACS but exclusion of a culprit lesion during coronary angiography.
62728120|NCT06384846||Case-Cohort|Subjects with suspected ACS and identification of a culprit lesion during coronary angiography.
62728121|NCT06384846||Supplementary cohort|Subjects with no or stable angina pectoris and no indication for revascularization during coronary angiography.
62728122|NCT00988156|ACTIVE_COMPARATOR|Eslicarbazepine acetate|To receive Eslicarbazepine acetate in addition to concomitant therapy
62728123|NCT00988156|PLACEBO_COMPARATOR|Placebo|To receive placebo in addition to concomitant therapy
62728124|NCT02529111|EXPERIMENTAL|intervention|"The Echonavigator software will be used on all patients. It will be used after the introduction of the percutaneous closure of ASD prosthesis. The image fusion on fluoroscopy will then be applied."
62728125|NCT03710265|EXPERIMENTAL|SHR-1701|
62728126|NCT02849834|ACTIVE_COMPARATOR|healthy volunteers|
62728127|NCT02849834|EXPERIMENTAL|Patients with resistant pain|
62728128|NCT03344783||mother-children pairs|
62728129|NCT01843166|ACTIVE_COMPARATOR|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
62728130|NCT01843166|PLACEBO_COMPARATOR|Control group|These patients will utilize a pessary with an inactive placebo cream.
62728131|NCT06375395|EXPERIMENTAL|Active tACS|Those who participate in the treatment group will receive tACS, which lasts for 40 minutes per day on 3 consecutive days.
62728132|NCT06375395|PLACEBO_COMPARATOR|Sham tACS|Those who participate in the control group will receive sham tACS, which lasts for 40 minutes per day on 3 consecutive days.
62728133|NCT01970644||Brain metastases (>= 4)|Patients with pathologically proven solid tumour malignancy who have \>=4 brain metastases will be treated with gamma knife radiosurgery.
62728134|NCT04543877|EXPERIMENTAL|Inulin and Ty21a Vaccine|Participants will consume 12 grams/day of inulin for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
62728135|NCT04543877|PLACEBO_COMPARATOR|Maltodextrin and Ty21a Vaccine|Participants will consume 12 grams/day of maltodextrin (control) for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
62728136|NCT05173012|PLACEBO_COMPARATOR|SAGE-324 Matched Placebo|"Participants will receive SAGE-324 matched placebo, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324 matched placebo, oral tablets, once daily (QD), in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324 matched placebo, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 milligrams (mg) of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
62728137|NCT05173012|EXPERIMENTAL|SAGE-324 15 mg|"Participants will receive SAGE-324, 15 mg, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324, 15 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324, 15 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 mg of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
62728138|NCT05173012|EXPERIMENTAL|SAGE-324 30 mg|"Participants will receive SAGE-324, 30 mg, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324, 30 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324, 30 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 mg of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
62728139|NCT05173012|EXPERIMENTAL|SAGE-324 60 mg|"Participants will receive SAGE-324: 15 mg, 30 mg, 45 mg, and 60 mg, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324, 15 mg from Day 1 to 14, followed by up-titration to 30 mg from Day 15 to 28, then to 45 mg from Day 29 to 42, and then to 60 mg from Day 43 to 90, oral tablets, QD, in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324, 15 mg from Day 1 to 14, followed by up-titration to 30 mg from Day 15 to 28, then to 45 mg from Day 29 to 42, and then to 60 mg from Day 43 to 90, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 mg of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
62728140|NCT04204850|EXPERIMENTAL|Cabozantinib|Cabozantinib, at a dose of 60 mg orally (by mouth), once a day (at bedtime), continuously.
62728141|NCT05174338||AL and TTR amyloidosis|immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR)
62728142|NCT02094118|ACTIVE_COMPARATOR|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
62728143|NCT02094118|EXPERIMENTAL|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
62728144|NCT02517398|EXPERIMENTAL|MSB0011359C (M7824)|
62728145|NCT05841719|OTHER|Population from Cantalupo, locality of the Municipality of Cerro Maggiore (MI).|capillary sampling and questionnaires to test feasibility and acceptability
62728146|NCT00614419|ACTIVE_COMPARATOR|1|The Lichtenstein tension-free hernioplasty with polypropylene mesh
62728147|NCT00614419|EXPERIMENTAL|2|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
62728148|NCT02173405|ACTIVE_COMPARATOR|Treatment Group|20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.
62728149|NCT02173405|PLACEBO_COMPARATOR|Placebo group|20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.
62728150|NCT01741493|EXPERIMENTAL|Healthy Volunteers (ABT-494)|Multiple dosing of ABT-494 in healthy volunteers
62728151|NCT01741493|EXPERIMENTAL|Rheumatoid Arthritis Patients|Multiple dosing of ABT-494 in patients with rheumatoid arthritis
62728152|NCT01741493|PLACEBO_COMPARATOR|No treatment|Placebo administration in healthy volunteers and patients with rheumatoid arthritis
62728153|NCT01741493|OTHER|Healthy Volunteers (tofa)|Multiple dosing of tofacitinib in healthy volunteers
62728154|NCT03858517||ReUnion TSA System|"Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System:~* Aseptic necrosis of the humeral head~* Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis~* Failed previous total shoulder replacement, resurfacing or other procedure"
62728155|NCT06363695|ACTIVE_COMPARATOR|Care as Usual|Community Health Volunteers will continue their usual services with families. This is typically done on a monthly basis focused on physical health needs of the mother and/or child.
62728156|NCT06363695|EXPERIMENTAL|SafeCare Kenya In-Person|Community Health Volunteers randomized to SafeCare Kenya will be trained to deliver this program either virtually or in-person. The Community Health Volunteer's families enrolled in the study will be randomized to receive the program either virtually or in-person. For in-person families, the Community Health Volunteer will deliver the session in the mother's home. The SafeCare Kenya curriculum will be the same in both the virtual and in-person.
62728157|NCT06363695|EXPERIMENTAL|SafeCare Kenya Virtual|Community Health Volunteers randomized to SafeCare Kenya will be trained to deliver this program either virtually or in-person. The Community Health Volunteer's families enrolled in the study will be randomized to receive the program either virtually or in-person. For in-person families, the Community Health Volunteer will deliver the session via a virtual platform (e.g., Zoom). The SafeCare Kenya curriculum will be the same in both the virtual and in-person.
62728158|NCT03390517|EXPERIMENTAL|ICG group|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice with the addition of intraoperative imaging using fluorescence angiography with indocianyne green to assess colon and rectal tissue perfusion.
62728159|NCT03390517|NO_INTERVENTION|Standard|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice.
62728160|NCT02398201|EXPERIMENTAL|Interventional|Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
62728161|NCT05020301|EXPERIMENTAL|Control group|Participants who have never practiced mindfulness
62728162|NCT05020301|EXPERIMENTAL|Beginner Practitioner|Participants with less than two years of mindfulness practice
62728163|NCT05020301|EXPERIMENTAL|Advanced Practitioner|Participants with more than two years of mindfulness practice
62728164|NCT01651286|EXPERIMENTAL|nasal mask|when the patient is apneic after the injection of anesthetics in the operating room, a nasal mask will be applied with positive pressure ventilation for 1 min. Then the nasal mask will be replaced with a full face mask for 1 min. Subsequently, the face mask will be replaced with the nasal mask.
62728165|NCT01651286|ACTIVE_COMPARATOR|full face mask|when the patient is apneic after the injection of anesthetics in the operating room, a full face mask will be applied with positive pressure ventilation for 1 min. Then the full face mask will be replaced with a nasal mask for 1 min. Subsequently, the nasal mask will be replaced with the full face mask.
62728166|NCT04114916|EXPERIMENTAL|Apigenin, luteonin, grapefruit extract and citrolive|One capsules a day. It will be consumed at breakfast for eight weeks.
62728167|NCT04114916|PLACEBO_COMPARATOR|maltodextrina|One capsules a day. It will be consumed at breakfast for eight weeks.
62728168|NCT06401499|EXPERIMENTAL|etoricoxib 60mg|tablet etoricoxib 60mg once daily for four weeks
62728169|NCT06401499|EXPERIMENTAL|pregabalin 75mg|tablet pregabalin 75mg once daily for 4 weeks tablet etoricoxib 60mg once daily for four weeks
62728170|NCT05408273||Postmenopausal women|Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated.
62728171|NCT04138563||Case|Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
62728172|NCT04138563||Control|Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years
62728173|NCT04483258|ACTIVE_COMPARATOR|Sedation with Insufflation|Sedation induction via oxygen mask %8 sevoflurane and reducing %3 concentration after rediotherapy start
62728174|NCT04483258|ACTIVE_COMPARATOR|İntravenous sedation|Midazolam+ Ketamine sedation
62728175|NCT00668473||1|Subjects with diffuse scleroderma
62728176|NCT00668473||2|Healthy controls
62728177|NCT03096639|ACTIVE_COMPARATOR|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
62728178|NCT03096639|NO_INTERVENTION|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
62728179|NCT00765401||Group A|The subject with positive breath Test for H.pylori and/or positive stool antigen test
62728180|NCT00765401||Group B|The subject with negative breath Test for H.pylori and negative stool antigen test
62728181|NCT02122146|EXPERIMENTAL|PF-06664178|Experimental
62728182|NCT04855240|EXPERIMENTAL|Drug - ACP-044 Dose A|ACP-044 Dose A
62728183|NCT04855240|EXPERIMENTAL|Drug - ACP-044 Dose B|ACP-044 Dose B
62728184|NCT04855240|PLACEBO_COMPARATOR|Placebo|Placebo
62728185|NCT03672851|EXPERIMENTAL|anti-CD123 CAR-T treatment|
62728186|NCT01774812|ACTIVE_COMPARATOR|Vitamin D Sequence 1|6 weeks - alfacalcidol 0.25mcg + placebo 3x per week, 12 week washout, 6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days)
62728187|NCT01774812|ACTIVE_COMPARATOR|Vitamin D Treatment Sequence 2|6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days), 12 week washout, 6 weeks - alfacalcidol 0.25mcg + placebo 3x per week
62728188|NCT00625586|EXPERIMENTAL|RAV12 plus gemcitabine|
62728189|NCT00411385|EXPERIMENTAL|1|900 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
62728190|NCT00411385|EXPERIMENTAL|2|1200 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
62728191|NCT00411385|ACTIVE_COMPARATOR|3|180 mcg PEG-IFNx2a every 1 week (24 doses)+ Ribavirin 800 micrograms per day
62728192|NCT02287194||SpyGlass Direct Visualization System|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of biliary tract diseases.
62728193|NCT04556526|EXPERIMENTAL|Group A: Ad26.ZEBOV, MVA-BN-Filo|Participants will receive intramuscular (IM) injection (0.5 milliliter \[mL\]) of Adenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5\*10\^10 viral particle(s) \[vp\]) on Day 1, followed by modified vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1\*10\^8 infectious unit(s) \[Inf U\]) on Day 57.
62728194|NCT04556526|OTHER|Group B: No vaccination during pregnancy|Participants (pregnant women) in control Group B will not receive any vaccination during pregnancy. However, women in this group will receive the 2-dose vaccination regimen at the earliest 6 weeks after delivery/termination of pregnancy that is Dose 1 of Ad26.ZEBOV vaccine (0.5 mL) (5\*10\^10 vp) on Day 1 by IM injection followed by 0.5 mL of MVA-BN-Filo (1\*10\^8 Inf U) vaccine by IM injection 56 days after Dose 1.
62728195|NCT00131352|EXPERIMENTAL|Synvisc|Participants with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL hylan G-F 20 (Synvisc).
62728196|NCT00131352|PLACEBO_COMPARATOR|Saline Control|Participants (control group) with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL phosphate buffered saline.
62728197|NCT04845672|EXPERIMENTAL|2% chlorhexidine gluconate|4% Chlorhexidine gluconate solution and one to one water will be used to create a 2% Chlorhexidine gluconate solution.
62728198|NCT04845672|ACTIVE_COMPARATOR|soap-free body cleaning solution|It supports and protects the natural barrier function of the skin's natural protective layer.
62728199|NCT03008070|EXPERIMENTAL|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
62728200|NCT03008070|EXPERIMENTAL|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
62728201|NCT03008070|PLACEBO_COMPARATOR|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
62728202|NCT01947335|NO_INTERVENTION|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention
62728203|NCT01947335|ACTIVE_COMPARATOR|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
62728204|NCT01234181|EXPERIMENTAL|BMSCs transplantation|
62728205|NCT01234181|SHAM_COMPARATOR|No BMSCs transplantation|
62728206|NCT02522169|ACTIVE_COMPARATOR|Conventional treatment|"The patients of the control group undergo Infliximab-maintenance according to the approved dosing scheme, initially with 5 mg/kg body weight Infliximab. Before each administration laboratory parameters will be controlled (Albumin, CrP, Calprotectin) and disease activity scores will be obtained (PCDAI / PUCAI). Infliximab trough levels will be assessed but not have any implication. In the presence of clinical signs of a disease exacerbation and after exclusion of other causes an adjustment of the dosage will follow for the next Infliximab-infusion:~A) interval shortening, or B) Dose increase to 10 mg / kg body weight. With a clinical stable course of the disease without signs of deterioration, the dosage and the eight-week interval will be maintained."
62728207|NCT02522169|EXPERIMENTAL|Intervention Group|Aiming to maintain the therapeutic window of Infliximab a de- or increase of the dose or infusion interval will be carried out for the following administration, provided the patient shows no signs of a clinical worsening. With good trough levels and clinically stable conditions the therapy will be continued without modification until next check-up. In the case of an eminent disease exacerbation Infliximab trough levels and the search for anti - Infliximab antibodies should guide further treatment decisions. With trough levels below the target range antibody testing should be performed.
62728208|NCT03632460|ACTIVE_COMPARATOR|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
62728209|NCT03632460|ACTIVE_COMPARATOR|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
62728210|NCT02578160|EXPERIMENTAL|Tell-Show-Do Behavior Technique|This technique will involve verbal explanations related to the inferior alveolar and lingual nerve block procedure in phrases appropriate to the developmental level of the patient (tell);demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do).
62728211|NCT02578160|ACTIVE_COMPARATOR|"Conventional Technique"|The operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child's field of view by hand during the inferior alveolar and lingual nerve block.
62728212|NCT06301308|SHAM_COMPARATOR|Intraurethral lidocaine gel alone|Participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
62728213|NCT06301308|EXPERIMENTAL|Intraurethral lidocaine gel + lidocaine 2% injection|Participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
62728214|NCT06301308|EXPERIMENTAL|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
62728215|NCT05287776|EXPERIMENTAL|15 patients with vitiligo subjected to NB-UVB|Patients will be subjected to NB-UVB sessions 3 times weekly. The UVB dosing scheme in the patients receiving only NB-UVB treatment entailed initial dosing at 0.5 J/cm2 with increasing increments by 0.3 J/cm 2 every other session until faint erythema occurs.
62728216|NCT05445258|EXPERIMENTAL|InnoCath AB® Balloon|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
62728217|NCT01565408|EXPERIMENTAL|NNC0114-0006|
62728218|NCT01565408|PLACEBO_COMPARATOR|Placebo|
62728219|NCT02735421|EXPERIMENTAL|Part 1: ABPO Forte Gel|
62728220|NCT02735421|PLACEBO_COMPARATOR|Part 1: ABPO Forte Vehicle Gel|
62728221|NCT02735421|EXPERIMENTAL|Part 2: ABPO Forte Gel|
62728222|NCT02735421|PLACEBO_COMPARATOR|Part 2: ABPO Forte Vehicle Gel|
62728223|NCT01686971||questionaire|patients will receive a questionaire and speak to a nurse regarding their needs and/ or demands.
62728224|NCT04170998|EXPERIMENTAL|Evogliptin 5mg group|Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
62728225|NCT04170998|PLACEBO_COMPARATOR|Evogliptin Placebo group|Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
62728226|NCT05459441|EXPERIMENTAL|Treatment of glioma|For patients with glioma, after the patient's general condition was stable, contraindications were excluded and RAK cells were injected into Ommaya sac.
62728227|NCT05459441|EXPERIMENTAL|Treatment of brain metastases|For patients with brain/meninges metastasis, Ommaya capsule was placed subcutaneously after puncture under local anesthesia. Two days after surgery, chemotherapy was started when the intracranial pressure was stable and the condition was stable, and the conjunctivitis was eliminated. Intracapsular injection of autoimmune cells was started in the second week after chemotherapy.
62728228|NCT02695914||Control group|Conventional treatment methods will be given to cases in control group.
62728229|NCT02695914||Experiment group|On the base of control group, Compound Qingre Granule will be added to in experiment group.
62728230|NCT02645032|EXPERIMENTAL|Test group|Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
62728231|NCT02645032|ACTIVE_COMPARATOR|Comparator group|"Biological/Vaccine:~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28)."
62728232|NCT05271747|ACTIVE_COMPARATOR|AB- Kolicare|Probiotic multi-strain formulation comprising Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 in sunflower oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
62728233|NCT05271747|ACTIVE_COMPARATOR|Reuteri gotas|Probiotic single-strain formulation comprising Lactobacillus reuteri DSM17938 in sunflower oil and medium-chain triglyceride oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
62728234|NCT01188941|NO_INTERVENTION|Standard of Care|
62728235|NCT01188941|EXPERIMENTAL|Assigned a Health System Navigator|
62728236|NCT00740753|OTHER|Treatment|yttrium 90 (TheraSphere) administration
62728237|NCT05080439|EXPERIMENTAL|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis in the teres major muscle
61976710|NCT05743179|EXPERIMENTAL|Zoledronate|Zoledronate intravenous infusion (5mg) once and usual care will be provided to the patient and mark the start of 12-month follow-up period
62728238|NCT05080439|EXPERIMENTAL|Dry needling|Dry needling based on fast-in fast-out technique in the teres major muscle
62728239|NCT00420381|EXPERIMENTAL|A|
62728240|NCT00750230|EXPERIMENTAL|NEM Treatment|NEM, 500 mg, once daily, orally for 30 days.
62728241|NCT03549338|EXPERIMENTAL|Arm A (Sym004)|"Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.~For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover."
62728242|NCT03549338|EXPERIMENTAL|Arm B (Futuximab)|Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
62728243|NCT03549338|EXPERIMENTAL|Arm C (Modotuximab)|Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.
62728244|NCT03150147|EXPERIMENTAL|Non-ischemic preservation.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
62728245|NCT03150147|OTHER|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
62728246|NCT00808522|EXPERIMENTAL|hCG|Patients at high risk for breast cancer will be treated with hCG
62728247|NCT00808522|NO_INTERVENTION|routine care|Patients receiving routine care will be followed
62728248|NCT02175485|EXPERIMENTAL|Fexofenadine HCl|2 tablets of Dellegra Combination Tablets (Fexofenadine Hydrochloride 30 mg+Pseudoephedrine Hydrochloride 60 mg/tablet), oral, administrated 2 hours after start of exposure with 8,000 grains/cubic meter of Japanese cedar pollen
62728249|NCT05276128|OTHER|WWB Reference|White wheat bread (WWB) without lipid supplements. The effects of this high glycaemic product on postprandial glucose and insulin responses are well studied.
62728250|NCT05276128|EXPERIMENTAL|WWB 5g active lipids|WWB supplemented with 5 g active lipids, and 10 g control lipids
62728251|NCT05276128|EXPERIMENTAL|WWB 10g active lipids|WWB supplemented with 10g active lipids, and 5 g control lipids
62728252|NCT05276128|EXPERIMENTAL|WWB 15g active lipids|WWB supplemented with 15g active lipids, and 0 g control lipids
62728253|NCT05276128|ACTIVE_COMPARATOR|WWB 15 g control lipids|WWB supplemented with 15g control lipids
62728254|NCT01202890|EXPERIMENTAL|Arm 1|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
62728255|NCT00334568|EXPERIMENTAL|Rosi XR|Rosi XR
62728256|NCT00334568|PLACEBO_COMPARATOR|Placebo|Placebo (matched)
62728257|NCT05402007|NO_INTERVENTION|Control|The control group will not receive intervention during the study.
62728258|NCT05402007|ACTIVE_COMPARATOR|Face-to-face intervention|The face-to-face intervention group will perform pulmonary rehabilitation at the professional-oriented Rehabilitation Center.
62728259|NCT05402007|ACTIVE_COMPARATOR|Home intervention|The home intervention group will carry out home intervention through a self-explanatory exercise booklet.
62728260|NCT05557994|ACTIVE_COMPARATOR|Blood clotting|Blood clotting protocol for pulp regeneration of mature teeth
62728261|NCT05557994|EXPERIMENTAL|Disinfection technique|Compare different disinfection technique
61976711|NCT05743179|NO_INTERVENTION|Control|Only usual care will be provided to the patient with 12-month follow-up period.
62728262|NCT05875844|OTHER|Wrist Splint|
62728263|NCT05875844|EXPERIMENTAL|Occupational Therapy|
62728264|NCT04982705|EXPERIMENTAL|[Part 1.1] IDG-16177|6 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
62728265|NCT04982705|PLACEBO_COMPARATOR|[Part 1.1] Placebo of IDG-16177|2 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
62728266|NCT04982705|EXPERIMENTAL|[Part 1.2] IDG-16177|8 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo.
62728267|NCT04982705|PLACEBO_COMPARATOR|[Part 1.2] Placebo|2 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo (QD).
62728268|NCT04982705|EXPERIMENTAL|[Part 2] IDG-16177|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
62728269|NCT04982705|PLACEBO_COMPARATOR|[Part 2] Placebo|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
62728270|NCT04982705|ACTIVE_COMPARATOR|[Part 2] Sitagliptin|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator (1:1:1 ratio).
62728271|NCT06499103|EXPERIMENTAL|Interventional group|The interventional group (n=22) will receive TENS sessions in addition to the prescribes medication (Gabapentinoids). The assessment will be performed at three time points also; before the begging of the intervention, after 5 days, and after the last session.
62728272|NCT06499103|NO_INTERVENTION|Control group|The control group The control group (n=22) will stay on the prescribed oral medication (Gabapentinoids) for at least 4 weeks (Hirayama et al.,2015). The assessment will be performed at three time points by the primary investigator using the Arabic version of CIPNAT . The first assessment will take place prior to the start of the trial, after two weeks of taking the medication, and the final assessment will be done after 4 weeks of receiving oral agents.
62728273|NCT06510179|ACTIVE_COMPARATOR|Conventional toothbrush group|Patients are instructed with the modified Bass technique. In this technique, the toothbrush bristles are positioned 45° to the long axis of the tooth towards the base of the tooth at the gum line with a gentle back-and-forth rolling motion, then swept towards the occlusal surface of the teeth. To adapt to orthodontic braces, the same movement is repeated with the bristles positioned just occlusal to the brackets.
62728274|NCT06510179|EXPERIMENTAL|Orthodontic toothbrush group|The patients in this group are instructed to brush with the Bass technique. In this technique, the toothbrush is placed on the gingival margin with its bristles at 45° to the long axis of the tooth. It is demonstrated by making back-and-forth movements and vibrating the brush at short intervals without lifting the bristles.
62728275|NCT06510179|EXPERIMENTAL|Single-tufted toothbrush group|In this group, a single-tooth circular brushing technique first developed by Jiri Sedelmayer was explained, and dental plaque removal is demonstrated with circular movements around the brackets and following the gingival margin of each tooth.
62728276|NCT05042648|NO_INTERVENTION|Control group (Group A)|Group A will receive no intervention
62728277|NCT05042648|EXPERIMENTAL|Buprenorphine group (Group B)|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest.
62728278|NCT02808923|EXPERIMENTAL|Foam rolling|"Participants in the foam rolling group will perform unilateral rolling of the hamstring musculature from ischial tuberosity to posterior knee in supine for 2 repetitions of 1 minute with 15 second rest between repetitions at a consistent cadence of 1 second superiorly and 1 second inferiorly. Subjects will be asked to adjust pressure as needed to maintain a consistent moderate pressure on the treatment area. Participants will use new and individually issued high density foam rollers that are 6 diameter x 36 length."
62728279|NCT02808923|EXPERIMENTAL|Static stretching|Participants in the static stretching group will perform sustained static hamstring stretching for 2 repetitions of 1 minute bouts for the same leg before switching sides using moderate pressure in supine against the wall. Subjects will rest for 15 seconds between repetitions and adjust distance from the wall to perceive moderate intensity.
62728280|NCT02808923|NO_INTERVENTION|Control|The control group will perform their regular baseline activities without the addition of a specific lower extremity flexibility program. If the subjects are currently performing stretching of any mode at baseline, they will be allowed to continue with that activity.
62728281|NCT03719963||cochlear implant|Cochlear implantation is a powerful tool for helping children with severe to profound sensorineural hearing loss to gain the ability to hear, and to achieve age appropriate communication skills. Evaluating the development of auditory, speech, language skills and the personality of implanted child is useful for the parent, the teacher, the therapist, and the subsequent rehabilitation progress
62728282|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
62728283|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
62728284|NCT05789459||Stapler group|closure with a stapler
62728285|NCT05789459||Hand-sewn group|closure with suture
62728286|NCT00870480|EXPERIMENTAL|A|Finasteride 5 mg single dose tablet, single dose
62728287|NCT00870480|ACTIVE_COMPARATOR|B|Proscar® 5 mg Tablet, single dose
62728288|NCT02593903|EXPERIMENTAL|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
62728289|NCT02593903|NO_INTERVENTION|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
62728290|NCT00912574|ACTIVE_COMPARATOR|Saline|first of 4 arms: injection: 1 ml saline
62728291|NCT00912574|ACTIVE_COMPARATOR|GM-CSF|Second of 4 arms: injection: specified dose of GM-CSF in 1 ml saline
62728292|NCT00912574|ACTIVE_COMPARATOR|0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline|Third of 4 arms: injection: 0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline
62728293|NCT00912574|ACTIVE_COMPARATOR|GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant|Fourth of 4 arms: injection: specified dose of GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant
62728294|NCT03417310|EXPERIMENTAL|"H joystick"|"Patients are treated with the H joystick on a traction table"
62728295|NCT03417310|ACTIVE_COMPARATOR|Common reduction methods|Patients are treated with common reduction methods on a traction table
62728296|NCT02528942|EXPERIMENTAL|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
62728297|NCT02342769||Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
62728298|NCT06192290|NO_INTERVENTION|Control Group|(1) aged 60 years or older; (2) diagnosed with CAD and were recommended to undergo elective CABG by a cardiologist; (3) intact cognitive function; (4) agree to be visited by the researchers at home; and (5) didn't have previous experiences with CABG. These Patients receive the usual care only.
62728299|NCT06192290|EXPERIMENTAL|Intervention Group|(1) aged 60 years or older; (2) diagnosed with CAD and were recommended to undergo elective CABG by a cardiologist; (3) intact cognitive function; (4) agree to be visited by the researchers at home; and (5) didn't have previous experiences with CABG. These Patients will receive the Video film presentations and content (16 parts)
62728300|NCT01783197|EXPERIMENTAL|Paclitaxel and carboplain plus selumetinib|"Cohort 1: Standard Chemotherapy (paclitaxel and carboplatin) plus selumetinib~If you are registered to Cohort 1, you will receive two commonly-used chemotherapy drugs called paclitaxel and carboplatin, plus you will be given the experimental drug selumetinib."
62728301|NCT01783197|EXPERIMENTAL|pemetrexed and cisplain plus selumetinib|"Cohort 2: Standard Chemotherapy (pemetrexed and cisplatin) plus selumetinib (cohort closed)~If you are registered to Cohort 2, you will receive two commonly-used chemotherapy drugs called pemetrexed and cisplatin, plus you will be given the experimental drug selumetinib."
62728302|NCT01783197|EXPERIMENTAL|pemetrexed plus selumetinib|"Cohort 3: Standard Chemotherapy (pemetrexed) plus selumetinib (cohort closed)~If you are registered to Cohort 3, you will receive one commonly-used chemotherapy drug called pemetrexed, plus you will be given the experimental drug selumetinib."
62728303|NCT05531552||Group I (control group)|"was collect data without any interference (without clinical pharmacy guidelines).~Subgroup: 10 outpatient, 25 inpatient, 15 patient in CCU."
62728304|NCT05531552||Group II (observation group)|application of clinical pharmacy guidelines and management CAD. Subgroup: 10 outpatient, 25 inpatient, 15 patient in CCU.
62728305|NCT03804242|EXPERIMENTAL|Black Youth M.A.T.T.E.R.|The session topics are as follows: (1) Debunking the Stigma of Mental Health in the Black Community, (2) School to Prison Pipeline, (3) Achievement Gap, (4) Cultural Barrier that Black Students Experience with Teachers, (5) Trauma 101, (6) Trauma 102, (7) Actions of Today, Blueprints for Tomorrow: Youth Organizing to Transform Education film, (8) My Voice Will Be Heard (Part I), and (9) My Voice Will Be Heard (Part II). The intervention will be conducted in 2-hour weekly group sessions.
62728306|NCT03804242|NO_INTERVENTION|Usual Care|All participants already participate in Youth Justice Coalition's Free LA High School. Those in control condition will participate in educational activities as usual.
62728307|NCT04194879||Cancer|Case subjects (at least 50) will be men and women age 40-74 who are recently diagnosed, through colonoscopy, with different stages of colorectal cancer and have not yet had surgical intervention.
62728308|NCT04194879||Negative|Approximately 250 prospectively enrolled subjects will be men and women age 40-74 who are at average risk of developing colorectal cancer and eligible for colonoscopy. About 150 Control subjects will be enrolled prospectively, who have no colorectal neoplasia detected on colonoscopy, including cancer, advanced adenoma, sessile serrated lesions and small, non-advanced adenoma.
62728309|NCT00786305|EXPERIMENTAL|1: nebulized ceftazidime and amikacin|
62728310|NCT00786305|ACTIVE_COMPARATOR|2: intravenous ceftazidime and amikacin|
62728311|NCT04103112|NO_INTERVENTION|Standard clinical care|Standard clinical care (anticoagulation) with no graduated compression stocking
62728312|NCT04103112|EXPERIMENTAL|Graduated compression stocking and standard clinical care|A graduated compression stocking and the standard clinical care (anticoagulation)
62728313|NCT01016288||22 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 22 G needle
62728314|NCT01016288||25 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 25 G needle
62728315|NCT03020004|EXPERIMENTAL|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg) for 12 weeks.
62165989|NCT03138356|EXPERIMENTAL|Cohort 3 Treatment G|"Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
62728316|NCT02962245|ACTIVE_COMPARATOR|berberine group|regular treatment and receive oral berberine 300mg three times daily untill recurrence in one year
62728317|NCT02962245|PLACEBO_COMPARATOR|regular treatment group|regular treatment untill recurrence in one year
62728318|NCT04751227||1|Modafinil 100-200 mg daily for wakefulness in a cohort of adult patients admitted to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020
62728319|NCT01882387|EXPERIMENTAL|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect. Treatment dose is 300 mcg/kg/day TXA127.
62728320|NCT04352543|EXPERIMENTAL|Older adults group|Group of older adults \>60 years old.
62728321|NCT05026151||non-CO|Consecutive persistent critically ill patients requiring more than 10 days of mechanical ventilation, admitted just before the first COVID-19 wave
62728322|NCT05026151||COVID|Consecutive persistent critically ill COVID-19 patients requiring more than 10 days of mechanical ventilation, admitted during the first COVID-19 wave
62728323|NCT01034501|ACTIVE_COMPARATOR|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
62728324|NCT01034501|SHAM_COMPARATOR|sham procedure|Not activation of laser device
62728325|NCT01527877|EXPERIMENTAL|BKM120|
62728326|NCT05394506|OTHER|Collection of biological material|"Patients carrying LMNA mutation with no contrindication for skin and/or muscle biopsy:~* from large families with striking intrafamilial phenotypic variability (3 families identified).~* patients carrying p.Arg453Trp or p.Glu358Lys LMNA gene mutations"
62728327|NCT04716608|ACTIVE_COMPARATOR|Group 1 INT (= intervention)|"physiotherapy program with~* Myofascial Release Massage (quadriceps)~* Foam Rolling lower extremity~* Knee Isometrics in knee extension (sitting position)~* Dynamic and static stretching (quadriceps) in half knee position~* Core Stability (planks)~* Strengthening (calf raises, good morning,squats, squat jump)~* Balance (single leg stance)"
62728328|NCT04716608|PLACEBO_COMPARATOR|Group 2 USC (= usual care)|"usual care treatment with~* Core Stability (prone plank)~* Strengthening: (Hip extension, abduction; Calf raises)~* Stretching (M. rectus femoris (static) in standing position; Hamstring in sitting position)~* Balance (single leg stand)"
62728329|NCT02199093|EXPERIMENTAL|Functional Rehabilitation of apraxia|The participants will be randomly assigned to an experimental group, to receive intervention in upper limb apraxia at home since two approaches, a rehabilitative and another compensatory (providing adaptive strategies at home). The treatment will be performed three times a week, 30 minutes a day, during a 4-week period.
62728330|NCT02199093|ACTIVE_COMPARATOR|Traditional health educative protocol|Control group will receive treatment with a traditional health educative protocol to improve his functionality in activities of daily living. The treatment will be performed twice in two month.
62728331|NCT04504630|ACTIVE_COMPARATOR|Active HD-tDCS|Participants will receive 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting dorsal anterior cingulate region for 20 minutes) across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
62728332|NCT04504630|SHAM_COMPARATOR|Sham HD-tDCS|Participants will receive 10 sessions of sham stimulation across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
62728333|NCT01308359|EXPERIMENTAL|glucose 5%|glucose 5%
62728334|NCT01308359|ACTIVE_COMPARATOR|saline|saline
62165990|NCT03138356|EXPERIMENTAL|Cohort 3 Treatment H|"Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
62728335|NCT01201928||Technosphere Insulin Inhalation Powder|
62728336|NCT01201928||Comparator|Based on parent trial
62728337|NCT02596139||Healthy people|
62728338|NCT06308744|EXPERIMENTAL|Mindfulness conditions|Participants will engage in a 15-minute mindfulness meditation session. Within this framework, four distinct experimental conditions will be introduced, each showcasing a unique mindfulness exercise: Body Scan, Mindful Breathing, Mindful Walking, and Loving-Kindness Meditation. The audio tracks of the mindfulness experimental conditions is embedded in the Qualtrics survey.
62728339|NCT06308744|ACTIVE_COMPARATOR|Listening of a story|Participants in the active control condition listened to a 15-minute story. The audio track of the control condition is embedded in the Qualtrics survey.
62728340|NCT02981862|EXPERIMENTAL|CaptHPV method|
62728341|NCT05765058|PLACEBO_COMPARATOR|SDF solution|Subjects will receive one of the available non-operative treatment methods for root caries, namely silver diamine fluoride solution (SDF \[38% F-, 38,000 ppm F\]) twice yearly applied professionally by a dentist, Placebo Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, \[0.32% F-, 1,450 ppm F\]) twice daily.
62728342|NCT05765058|PLACEBO_COMPARATOR|NaF Varnish|Subjects will receive one of the available non-operative treatment methods for root caries, namely sodium fluoride varnish (NaF, \[5% F-, 22,600 ppm F\]) twice yearly applied professionally by a dentist, Placebo Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, \[0.32% F-, 1,450 ppm F\]) toothpaste twice daily.
62728343|NCT05765058|EXPERIMENTAL|Tooth mousse|Subjects will receive placebo varnish (water-based) twice yearly applied professionally by a dentist, Biosmalto Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, \[0.32% F-, 1,450 ppm F\]) toothpaste twice daily.
62728344|NCT05765058|SHAM_COMPARATOR|Placebo varnish|Subjects will receive placebo varnish (water-based) twice yearly applied professionally by a dentist, Placebo tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, \[0.32% F-, 1,450 ppm F\]) toothpaste twice daily.
62728345|NCT00405730|EXPERIMENTAL|Nepafenac|One drop in the study eye 3 times daily for 23 days
62728346|NCT00405730|ACTIVE_COMPARATOR|Ketorolac Trometamol|One drop in the study eye 3 times daily for 23 days
62728347|NCT00405730|PLACEBO_COMPARATOR|Nepafenac Vehicle|One drop in the study eye 3 times daily for 23 days
62728348|NCT01244035|EXPERIMENTAL|Part I - Sequence ABC|Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
62728349|NCT01244035|EXPERIMENTAL|Part I - Sequence ACB|Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
62728350|NCT01244035|EXPERIMENTAL|Part I - Sequence BCA|Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
62728351|NCT01244035|EXPERIMENTAL|Part I - Sequence BAC|Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
62728352|NCT01244035|EXPERIMENTAL|Part I - Sequence CAB|Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
62728353|NCT01244035|EXPERIMENTAL|Part I - Sequence CBA|Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
62728354|NCT01244035|EXPERIMENTAL|Part II - Sequence DEF|Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
62728355|NCT01244035|EXPERIMENTAL|Part II - Sequence DFE|Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
62728356|NCT01244035|EXPERIMENTAL|Part II - Sequence EFD|Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
62728357|NCT01244035|EXPERIMENTAL|Part II - Sequence EDF|Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
62728358|NCT01244035|EXPERIMENTAL|Part II - Sequence FDE|Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
62728359|NCT01244035|EXPERIMENTAL|Part II -Sequence FED|Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3
62728360|NCT05598853|EXPERIMENTAL|Intrathecal nivolumab and intrathecal ipilimumab|The experimental treatment will be combined from cycle 2 with systemic nivolumab and systemic ipilimumab
62728361|NCT01427218|EXPERIMENTAL|Medication Therapy Management (MTM)|Medication Therapy Management visits with a pharmacotherapist will occur at a minimum of 6-9 weeks, 20-24 weeks, and 28-32 weeks. Additional interim face to face and telephonic visits may be scheduled based on patient's progress with meeting treatment goals and need for follow-up physical assessment and laboratory analysis.
62728362|NCT01427218|PLACEBO_COMPARATOR|Usual Care|Visits with a pharmacotherapist to create an accurate list of medications for those patients randomized to placebo (who receive usual care by their cardiologist and primary care provider).
62728363|NCT04907253|ACTIVE_COMPARATOR|Quercetin|Patients receiving 500 mg quercetin twice daily
62728364|NCT04907253|PLACEBO_COMPARATOR|Placebo|Patients receiving placebo twice daily
62728365|NCT04361448|OTHER|Health Care Workers with Covid-19 symptoms|3 samples (2 nasopharyngeasl swabs, 1 oropharyngeal swab) willl be taken from each volunteer
62728366|NCT02333812||copd patients|Adult patients with COPD
62728367|NCT02333812||healthy smokers|Adult patients with smoking history and no clinical manifestation of COPD who will be recruited form the institute of pulmonary medicine and the otolaryngology outpatient clinic.
62728368|NCT02333812||Adult patients with lung disease unrelated to smoking|Adult patients with lung disease unrelated to smoking
62728369|NCT02881424||alcohol-dependent patients|a group of 34 alcohol-dependent patients, currently abstinent
62728370|NCT02881424||healthy controls|a group of control subjects, without neurologic or psychiatric disease, matched for age and sex with the alcohol-dependent participants
62728371|NCT05100355|ACTIVE_COMPARATOR|Opacification|Contrast agent injection
62728372|NCT05100355|EXPERIMENTAL|Physiological serum injection|Physiological serum injection
62728373|NCT02662426|EXPERIMENTAL|Drugs for experimental group|Lingdancao granules, 4 packs per time (3g/pack), three times per day; analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
62728374|NCT02662426|ACTIVE_COMPARATOR|Drugs for positive control group|Oseltamivir phosphate capsule (tamiflu), 1 capsule per time (75mg), twice per day; analogous Lingdancao granules, 4 packs per time, three times per day.Drugs must be used on the day of fever and last for five days continuously.
61976712|NCT04926350|NO_INTERVENTION|Control|Tracking of outcomes during a normal week
62728375|NCT02662426|PLACEBO_COMPARATOR|Drugs for placebo control group|Analogous Lingdancao granules, 4 packs per time, three times per day, analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
62728376|NCT02341651|EXPERIMENTAL|"Multicomponent combination"|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
62728377|NCT02341651|NO_INTERVENTION|Usual Care|No active intervention
62728378|NCT04114175|ACTIVE_COMPARATOR|Control Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
62728379|NCT04114175|EXPERIMENTAL|Spinal Stabilization Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
62728380|NCT01279876|ACTIVE_COMPARATOR|Melatonin|
62728381|NCT01279876|PLACEBO_COMPARATOR|Placebo|
62728382|NCT04545879|EXPERIMENTAL|Raw garlic juice|Raw garlic juice treatment group
62728383|NCT00373048|PLACEBO_COMPARATOR|Placebo, tablet|
62728384|NCT00373048|EXPERIMENTAL|mefloquine, tablet|
62737949|NCT01713647|ACTIVE_COMPARATOR|NORVASC & HYZAAR (100/12.5 mg)|"Subjects will be fasted overnight and receive one tablet of Norvasc \&HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
61976713|NCT04926350|EXPERIMENTAL|Resistance Exercise|Tracking of outcomes during a normal week with the addition of daily resistance exercise breaks (8 breaks per day)
62728385|NCT05721781|EXPERIMENTAL|Participants receiving a dental cleaning and oral hygiene instruction|Participants randomized to this arm will receive a standard dental cleaning and education on proper toothbrushing and flossing technique and asked to follow these toothbrushing and flossing techniques for the duration of the study period. They will receive periodic phone call reminders to maintain these practices during the study period.
62728386|NCT05721781|NO_INTERVENTION|Control|Participants randomized to this arm will be instructed to continue with their usual oral hygiene practices for the duration of the study period.
61976714|NCT06420843|EXPERIMENTAL|low FODMAP milk|Patients will receive one week of low FODMAP diet supplemented with fermented milk followed by one week of low FODMAP diet supplemented with fermented beans.
61976715|NCT06420843|ACTIVE_COMPARATOR|low FODMAP beans|The second group will receive low FODMAP diet supplemented for one week with fermented beans followed by a second week of low FODMAP diet supplemented with fermented milk.
62728387|NCT01791621|EXPERIMENTAL|Elimination/Challenge Diet|Once non-IgE mediated food allergy testing has been administered, study participants will follow food choices according to a pre-specified elimination diet for three weeks (Elimination phase). After the Elimination phase, study participants will introduce one food every three days (Challenge phase)and monitor their symptoms. Eight different foods will be introduced in the Challenge phase of the study.
62728388|NCT02975804|EXPERIMENTAL|Interactive computer play (ICP)|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
62728389|NCT02975804|NO_INTERVENTION|Standard Therapy|Children in the control group will continue their usual therapy.
62728390|NCT04941469|EXPERIMENTAL|Specifically optimized off-the-counter foot orthosis|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type."
62728391|NCT04941469|ACTIVE_COMPARATOR|Plain off-the-counter foot orthosis|The control device for this study would be the plain original Formthotics (Original Dual Hard).
62728392|NCT06231407|EXPERIMENTAL|Recovery Oriented CBTp Med Check|Resident physicians will provide medication appointments, supervised by their attending physician (Stovall) and CT-R supervisor (Brinen). They will conduct their appointment per protocol detailed in a treatment manual. No additional/special information needs to be recorded in medical record, beyond the clinical notes expected per VAPOC policy. Appointments will be a standard length.
62728393|NCT06231407|ACTIVE_COMPARATOR|Treatment as Usual|Patient will attend traditional medication management check appointments with psychiatry residents.
62728394|NCT02538536|EXPERIMENTAL|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
62728395|NCT04115124|EXPERIMENTAL|E-PAR Arm|Exposed to media, information and communication technology through ethnographic participatory action research.
62728396|NCT02360072||AR group|Allergic rhinitis without any typical asthma symptoms
62728397|NCT02360072||Asthma|Accompanied by typical asthma symptoms and Δ FEV1≥12% in response to a short-acting bronchodilator or bronchial hyperreactivity(BHR) in the methacholine provocation test (PC20≤2.504mg)
62728398|NCT02360072||AR+Asthma|Diagnosed allergic rhinitis concomitant asthma symptoms
62728399|NCT02360072||Control group|non-atopic subjects with neither a history of rhinitis nor asthma
62728400|NCT02446821|EXPERIMENTAL|VeraCept IUD System|All women will receive VeraCept.
62728401|NCT04754971|EXPERIMENTAL|Table|
62728402|NCT02359032|EXPERIMENTAL|Part 1: ASP6858 single ascending dose|ASP6858 arm
62728403|NCT02359032|PLACEBO_COMPARATOR|Part 1: Placebo single ascending dose|Placebo arm
62728404|NCT02359032|EXPERIMENTAL|Part 1: ASP6858 single ascending dose (fasting cohort)|ASP6858 arm
62728405|NCT02359032|EXPERIMENTAL|Part 2, Sequence 1: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
62728406|NCT02359032|EXPERIMENTAL|Part 2, Sequence 2: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
62728407|NCT02722005|EXPERIMENTAL|Financial Coaching & Access to Services|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
62728408|NCT02722005|ACTIVE_COMPARATOR|Access to Services|Participants will have access to a host of referrals to social services (this is the intervention for this group)
62728409|NCT05593354||MPTLT patients|All UK patients undergoing MPTLT
62728410|NCT00883948|EXPERIMENTAL|1|Participants will receive initial minimal (trophic) enteral feeding.
62728411|NCT00883948|EXPERIMENTAL|2|Participants will receive initial full-calorie enteral feeding.
62728412|NCT00115193|ACTIVE_COMPARATOR|Arm A|Pegfilgrastim
62728413|NCT00115193|ACTIVE_COMPARATOR|Arm B|Pegfilgrastim
62728414|NCT00442923|PLACEBO_COMPARATOR|CTRL|
62728415|NCT00442923|EXPERIMENTAL|TREAT|
62728416|NCT02226224||early gastric cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
62728417|NCT02226224||Locally Advanced Gastric Cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
62728418|NCT02226224||early esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
62728419|NCT02226224||locally advanced esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
62728420|NCT04063891|PLACEBO_COMPARATOR|Placebo-Controlled|Placebo group will have placebo treatment by standing on the LMHFV platform for 20 minutes/day
62728421|NCT04063891|EXPERIMENTAL|Vibration Group|Vibration group is treated with LMHFV at 35Hz, 0.3g, for 20 minutes/day, 5 times/week
62728422|NCT03345511|EXPERIMENTAL|Ultrasound Guided Caudal Block|30 minutes before benign canal anal surgery, a 18 G tuohy needle guided with an ultrasound probe to visualize the caudal space, a solution of bupivacaine 0.25%, Lidocaine 1% and dexamethasone 8mg was injected and needle removed.
62728423|NCT05135572|ACTIVE_COMPARATOR|control group|Fibromiyalgia patients with foot pain.
62728424|NCT05135572|EXPERIMENTAL|study group|Patients with foot pain
62728425|NCT01191515||Near visual outcomes with Monofocal IOL|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
62728426|NCT01191515||Intermediate Visual outcomes|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
62728427|NCT06169618||cervical radiculopathy group|thirty participants with cervical radiculopathy due to discogenic lesions.
62728428|NCT06169618||normal group|thirty participants in normal without any discogenic lesion
62728429|NCT04644510||Lung ultrasonography group|Patient which benefited from a Lung ultrasonography during the medical consultation
62728430|NCT01350050|ACTIVE_COMPARATOR|articaine|Pharyngeal anesthesia with articaine 4% or placebo should randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of Articaine 4%solution or placebo (NaCl 0,9%) will be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with articaine (or placebo) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
62728431|NCT01350050|PLACEBO_COMPARATOR|placebo|Pharyngeal anesthesia with placebo or articaine 4% should be randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of placebo or Articaine 4% solution should be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with placebo(or articaine) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
62728432|NCT06512077|EXPERIMENTAL|Clinical Validation of mμSORS for Noninvasive Blood Glucose Detection in healthy subjects|Enrolled subjects will perform oral glucose tolerance test or hyperinsulin-hypoglucose clamp test. A measurement session of blood glucose consists of plasma sample and a measurement by mμSORS will be conducted synchronously.
62728433|NCT05369598|ACTIVE_COMPARATOR|ABF fitting followed by standard fitting|
62728434|NCT05369598|ACTIVE_COMPARATOR|Standard fitting followed by ABF fitting|
62728435|NCT00898170|EXPERIMENTAL|myoma, with or without hypertension|those with myoma with or without hypertension in holter monitoring
62728436|NCT01484496|PLACEBO_COMPARATOR|Placebo plus standard therapy|Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
62728437|NCT01484496|EXPERIMENTAL|Belimumab 200 mg SC plus standard therapy|Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
62728438|NCT01382576||PCOS patients|
62728439|NCT01382576||PCOS patients and healthy controls|There are two groups in this study. One group is PCOS patients and other group is healthy controls.
62728440|NCT05140135|EXPERIMENTAL|Recovery Oriented Cognitive Therapy (CT-R)|Therapists implement CT-R in weekly sessions for approximately 9 months while supported by a clinical supervisor. Therapists will have completed a supervised CT-R training case prior to the initiation of the randomized controlled trial. CT-R will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. The therapist will use techniques to engage the patient in the adaptive mode, which involves activating cognitions, affects, motivation, and behaviors by engaging the individual in personally meaningful activities.
62728441|NCT05140135|ACTIVE_COMPARATOR|Continued Usual Care|
62728442|NCT00650663|EXPERIMENTAL|Ezetimibe + Simvastatin|
62728443|NCT00650663|ACTIVE_COMPARATOR|Simvastatin|
62728444|NCT01027962|OTHER|ICBT Program|Intensive Computerized Brain Training using software packages donated by Posit Science.
62728445|NCT01027962|NO_INTERVENTION|Control Intervention|Commercially available computer games that do not contain violent stimuli but are appealing to youth between 10 and 19 years of age.
62728446|NCT01027962|NO_INTERVENTION|Healthy Control Group|No participation in computer activity.
62728447|NCT05296317|EXPERIMENTAL|Arm 1 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of G-CSF|"2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
62728448|NCT05296317|EXPERIMENTAL|Arm 2 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF|"2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
62728449|NCT06090955|EXPERIMENTAL|Dexmedetomidine group|Patients in the dexmedetomidine group will be administered a bolus of 0.3 ug/kg intravenous dexmedetomidine over 10 min before anesthetic induction. After bolus injection, a continuous infusion of 0.3 ug/kg/hr of intravenous dexmedetomidine will be administered until the end of surgery.
62728450|NCT06090955|EXPERIMENTAL|Lidocaine group|Patients in the lidocaine group will receive a bolus of 1.5 mg/kg intravenous lidocaine over 10 min before induction of anesthesia. A continuous infusion of 1.5 mg/kg/hour of systemic lidocaine will be administered until the end of the surgery.
62728451|NCT06090955|PLACEBO_COMPARATOR|Control group|Patients in the control group will be administered equal volumes of 0.9% saline using the identical application scheme.
62728452|NCT00291031|EXPERIMENTAL|IRT|Patients randomly assigned to the IRT condition receive Imagery Rehearsal Therapy after 4 weeks since the entrance into the trial next to their treatment as usual.
62728453|NCT00291031|NO_INTERVENTION|TAU|Patients that are randomly assigned to the waiting list control condition get treatment as usual (TAU) and complete the daily nightmare logs for a period of three months. These patients get the IRT intervention after waiting for 6 months.
62728454|NCT03877003|EXPERIMENTAL|Egg Intake|Consumption of 3 eggs per day for breakfast during 4 weeks
62728455|NCT03877003|EXPERIMENTAL|Choline Supplement Intake|Consumption of choline supplement 1.5 tablets (approx. 400 mg) with breakfast for 4 weeks
62728456|NCT05509062|ACTIVE_COMPARATOR|Light Tactile Pressure|light tactile pressure with 5-10 mmHg without skin stretch
62728457|NCT05509062|ACTIVE_COMPARATOR|Medium Tactile Pressure|medium tactile pressure of 11-20 mmHg and medium skin stretch with therapist in a stationary position
62728458|NCT05509062|ACTIVE_COMPARATOR|Firm Tactile Pressure|firm tactile pressure (\> 21 mmHg) and maximal skin stretch with therapist weight shift
62728459|NCT03177018|EXPERIMENTAL|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
62728460|NCT02859831||with construction work|
62728461|NCT02859831||without construction work|
62728462|NCT05317026|EXPERIMENTAL|V-SBRT|Vertebroplasty followed by Stereotactic Body Radiation Therapy (SBRT)
62728463|NCT05317026|OTHER|SBRT|SBRT is the actual standard of care.
62728464|NCT06009822||Patients with Medial Patellofemoral Ligament reconstruction|"Must have undergone unilateral medial patellofemoral ligament (MPFL) reconstruction.~At least 2 years post MPFL reconstruction surgery. Absence of patellar instability subsequent to the surgical procedure. Exclusion of patients with any orthopedic or neurological issues that might impact functionality, except for those who have undergone unilateral MPFL reconstruction."
62728465|NCT06074237|EXPERIMENTAL|Interactive Vaccine Education Program for resident providers|Resident providers in pediatric, pediatric/medicine and family medicine clinics will be given interactive educational interventions using online training modules combined with standardized patient encounters to teach and refine vaccine counseling skills
62728466|NCT02705612|OTHER|control group|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
62728467|NCT02705612|EXPERIMENTAL|experimental group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group. Patients also receive nimotuzumab during the external radiotherapy.
62728468|NCT06224907|EXPERIMENTAL|Valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
62728469|NCT00820144|EXPERIMENTAL|1|voie nasale 0.25 mg
62728470|NCT00820144|EXPERIMENTAL|2|0.5mg of CTB by oral way
62728471|NCT00820144|EXPERIMENTAL|3|1mg of dukoral by oral way
62728472|NCT00820144|EXPERIMENTAL|4|0.25mg of CTB by sublingual way
62728473|NCT00820144|EXPERIMENTAL|5|1mg of CTB by sublingual way
62728474|NCT02811120||single arm|single venepuncture
62728475|NCT03525002|PLACEBO_COMPARATOR|FTO SNP rs8050136 (AA), Placebo|Participants with FTO SNP rs8050136 AA receiving matching Placebo
62728476|NCT03525002|ACTIVE_COMPARATOR|FTO SNP rs8050136 (AA), Bromocriptine|Participants with FTO SNP rs8050136 AAreceiving Bromocriptine up to 5 mg
62728477|NCT03525002|PLACEBO_COMPARATOR|FTO SNP rs8050136 (CA), Placebo|Participants with FTO SNP rs8050136 CA receiving matching Placebo
62728478|NCT03525002|ACTIVE_COMPARATOR|FTO SNP rs8050136 (CA), Bromocriptine|Participants with FTO SNP rs8050136 CA receiving Bromocriptine up to 5 mg
62728479|NCT03525002|PLACEBO_COMPARATOR|FTO SNP rs8050136 (CC), Placebo|Participants with FTO SNP rs8050136 CC receiving matching Placebo
62728480|NCT03525002|ACTIVE_COMPARATOR|FTO SNP rs8050136 (CC), Bromocriptine|Participants with FTO SNP rs8050136 CC receiving Bromocriptine up to 5 mg
62728481|NCT03183765|EXPERIMENTAL|MMR vaccine|Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
62728482|NCT03183765|ACTIVE_COMPARATOR|Cryotherapy|patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
62728483|NCT05433701|ACTIVE_COMPARATOR|RFA group|"* RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.~* RFA procedures are continued by modifying the output power based on the location and size of the tumor until the entire tumor and border area sizes of greater than 0.5 cm are included in the detected target lesion on ultrasound or CT."
62728484|NCT05433701|EXPERIMENTAL|SBRT group|A total dose of 45 Gy is presecribed using 15 Gy per fraction over 3 consecutive days.
62728485|NCT02805959||Constipated, Elderly|Investigation with MTS for motility
62728486|NCT02805959||Constipation, Young|Investigation with MTS for motility
62728487|NCT02805959||Normal Bowel, Elderly|Investigation with MTS for motility
62728488|NCT02805959||Normal Bowel, Young|Investigation with MTS for motility
62728489|NCT05255692|EXPERIMENTAL|Complete evaluation UDO and fMRI|Evaluation including both urodynamic evaluation and functional MRI testing
62728490|NCT04535973||study group|female postmenopausal women with burning mouth syndrome
62728491|NCT04535973||control group|female postmenopausal women without burning mouth syndrome
62728492|NCT05182450|EXPERIMENTAL|Active capsule|Colored capsule containing 300 mg mango leaf extract (Zynamite®) standardized to contain ≥ 60% mangiferin. Supplied by PLT Health Solutions, Inc.
62728493|NCT05182450|PLACEBO_COMPARATOR|Placebo capsule|Colored capsule, appearance-matched to the active experimental capsule
62728494|NCT02990715|ACTIVE_COMPARATOR|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
62728495|NCT02990715|EXPERIMENTAL|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
62728496|NCT05522283||CMV colitis|Patients with the detection of either cytomegalic cells or IHC-CMV cells were diagnosed with CMV colitis.
62728497|NCT05522283||Non-CMV colitis|Symptomatic patients were not detected with either cytomegalic cells or IHC-CMV cells.
62728498|NCT05522283||Healthy volunteers|Asymptomatic patients underwent colonoscopy for screening.
62728499|NCT04970173||1|patients taking very low-volume 1L-PEG plus ascorbate (plenvu) for open access colonoscopy
62728500|NCT04970173||2|patients taking low-volume 2L-PEG plus ascorbate (moviprep) for open access colonoscopy
62728501|NCT03215381|OTHER|[11C]AZD1390 Microdose|\[11C\]AZD1390 single dose not exceeding 10 ug by IV bolus
62728502|NCT04244240||Sickle cell disease patient|Adults with sickle cell disease (homozygous SS or heterozygous SC, Sβ0 or Sβ+) with cognitive complaint.
62728503|NCT05641012||metastatic melanoma group|adult with metastatic melanoma treated by immunotherapy
62728504|NCT02339844|ACTIVE_COMPARATOR|antipsychotic treatment|individual doses of aripiprazole for all patients
62728505|NCT02339844|NO_INTERVENTION|no treatment|no treatment for all healthy controls
62728506|NCT03023306|ACTIVE_COMPARATOR|preemptive group|"The preemptive group will receive the anti-emetic regimen i.v. (4 mg of ondansetron) 1h before the start of surgery. During surgery, 30 min before the end of operation, this group will receive i.v. 0.9% NaCl in equal volumes.The intervention consists of the different time points of antiemetic treatment, thus 1h before surgery vs intraopertively.~Intervention: Antiemetic treatment 1h before surgery"
62728507|NCT03023306|OTHER|intraoperative group|"The preventive group will receive i.v. 0.9% NaCl 1h before surgery and ondansetron 4 mg 30 min before the end of surgery at equal volumes.~Intervention: Antiemetic treatment intraoperatively"
62728508|NCT04277546|EXPERIMENTAL|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
62728509|NCT04277546|EXPERIMENTAL|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
62728510|NCT00618007|EXPERIMENTAL|30 mg QD|
62728511|NCT00618007|EXPERIMENTAL|20 mg QD|
62728512|NCT00618007|PLACEBO_COMPARATOR|Placebo|
62728513|NCT03587896|EXPERIMENTAL|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
62728514|NCT03587896|NO_INTERVENTION|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
62728515|NCT03123900|EXPERIMENTAL|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
62728516|NCT03123900|EXPERIMENTAL|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
62728517|NCT03123900|EXPERIMENTAL|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
62728518|NCT03123900|NO_INTERVENTION|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
62728519|NCT04130893|EXPERIMENTAL|A stimulation of G13 then G15|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G13 auricular stimulation At the Third session: Cold water hand immersion + G15 auricular stimulation
62728520|NCT04130893|EXPERIMENTAL|B: stimulation of G15 then G13|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G15 auricular stimulation At the Third session: Cold water hand immersion + G13 auricular stimulation
62728521|NCT04847570|EXPERIMENTAL|Music listening experience|It is a single-arm non-randomised study. The same inclusion and exclusion criteria applies to all the participants.
62728522|NCT00418093|EXPERIMENTAL|Chemotherapy|All patients received oxaliplatin, gemcitabine, and bevacizumab
62728523|NCT04844541||Sub-population A Infected Cases|Symptomatic SARS-CoV-2 infected adults or adults meeting the ILI case definition (hospitalized and non-hospitalized)
62728524|NCT04844541||Sub-population B Contacts|Asymptomatic adult contacts of positive cases, defined as indoor exposure to the symptomatic case or cases within 6 feet (2 meters) for greater than or equal to 15 minutes over a 24-hour period without the use of personal protective equipment
62728525|NCT01479764|EXPERIMENTAL|Sugammadex|Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
62728526|NCT01479764|ACTIVE_COMPARATOR|Neostigmine/glycopyrrolate|Participants receive neostigmine/glycopyrrolate per usual practice
62728527|NCT00604552|OTHER|Lifeline Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by the Foundation of Society for the Vascular Surgery (SVS)
62728528|NCT00604552|OTHER|PS Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by Medtronic
62728529|NCT01396356||ablation procedure|
62728530|NCT02477527|EXPERIMENTAL|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
62728531|NCT04902430|EXPERIMENTAL|En-Masse Retraction using sliding mechanics (Friction)|6 anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
62728532|NCT04902430|EXPERIMENTAL|En-Masse Retraction using segmental mechanics (Frictionless)|6 anterior teeth (en-Masse) retracted using a T- loop
62728533|NCT04887194|EXPERIMENTAL|Phase 1, Part 1: Sitravatinib monotherapy (DDI cohort)|To evaluate the potential for drug-drug interactions (DDI) with sitravatinib monotherapy. To determine the effect of sitravatinib on the pharmacokinetics (PK) of midazolam (CYP3A4 probe substrate), warfarin (CYP2C9 probe substrate), dextromethorphan (CYP2D6 probe substrate), rosuvastatin (BCRP probe substrate), and digoxin (P-gp probe substrate).
62728534|NCT04887194|EXPERIMENTAL|Phase 1, Part 1: Sitravatinib monotherapy (QTc cohort)|To evaluate the QTc prolongation risk for sitravatinib in patients with advanced/metastatic solid tumors via C-QTc modeling.
62728535|NCT04887194|EXPERIMENTAL|Phase 1, Part 2: Combination Therapy (both DDI and QTc cohorts)|To evaluate safety and tolerability of Sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.
62728536|NCT05045859|EXPERIMENTAL|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning.
62728537|NCT05045859|NO_INTERVENTION|No Intervention: Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 15-weeks waiting period. At the end of that period received the exact intervention as the study group.
62728538|NCT03725072|EXPERIMENTAL|Evobrutinib|
62728539|NCT02432937|PLACEBO_COMPARATOR|Corever middle dose|
62728540|NCT02432937|PLACEBO_COMPARATOR|Corever high dose|
61976716|NCT00558025|EXPERIMENTAL|Pramipexole Extended Release (ER)|Pramipexole Extended Release (ER) once daily
62728541|NCT02432937|PLACEBO_COMPARATOR|Placebo|
62728542|NCT01941927|EXPERIMENTAL|Trametinib, GSK2141795|"Trametinib (GSK1120212)~* Oral~* 2 mg~* Daily~* Number of Cycles: until progression or unacceptable toxicity develops~GSK2141795~* Oral~* 25 mg~* Daily~* Number of Cycles: until progression or unacceptable toxicity develops"
62728543|NCT02599311|OTHER|the efficacy|transvaginal synthetic mesh
62728544|NCT02599311|NO_INTERVENTION|the recurrence rate|transvaginal synthetic mesh
62728545|NCT02599311|NO_INTERVENTION|the quality of life|transvaginal synthetic mesh
62728546|NCT02599311|OTHER|the rate of the LUTS|We use Tolterodine to improve patients' LUTS
62728547|NCT04672148||A|Patient who died in the 30 days after receiving mechanical thrombectomy, no matter the mortality cause
62728548|NCT04672148||B|Non-30-day-mortality group after receiving mechanical thrombectomy
62728549|NCT05659914|EXPERIMENTAL|olaparib +durvalumab|olaparib+durvalumab
62728550|NCT00628498|EXPERIMENTAL|Defibrotide|Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
62728551|NCT00809926|EXPERIMENTAL|Valsartan/aliskiren|
62728552|NCT00809926|ACTIVE_COMPARATOR|Valsartan|
62728553|NCT03174626|EXPERIMENTAL|WLSCC Intervention|Williams LifeSkills framework on stress management and cancer care
62728554|NCT03174626|OTHER|Usual Care|No intervention is provided
62728555|NCT05449041||Glaucoma patients|Patients diagnosed with Glaucoma of both gender; passed the age of 18 years; without any other eye disease; suffering from other know serious disease but have a health situation in accordance with expectations related to the age.
62728556|NCT05449041||Glaucoma controlls|Gender- and age-matched controls to the Glaucoma patients, passed the age of 18 years without any eye diseases; not suffering from other know serious disease and have a health situation in accordance with expectations related to the age.
62728557|NCT05449041||Cateract patients|Patients diagnosed with Cataract of both gender; passed the age of 18 years; without any other eye disease; suffering from other know serious disease but have a health situation in accordance with expectations related to the age.
62728558|NCT05449041||Cataract controlls|Gender- and age-matched controls to the Cataract patients, passed the age of 18 years without any eye diseases; not suffering from other know serious disease and have a health situation in accordance with expectations related to the age.
62728559|NCT03202433|EXPERIMENTAL|Virtual Reality Distractor|The objective is to apply a technique, using virtual reality lenses, with relaxing audio-visual contents of no more than ten minutes, to reduce stress before and during the blood donation process and to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle
62728560|NCT03202433|NO_INTERVENTION|Traditional Blood Donation Process|The objective is to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle, without virtual reality support
62728561|NCT02365181|EXPERIMENTAL|IAL|intra-articular local anesthetic infiltration with catheter
62728562|NCT02365181|ACTIVE_COMPARATOR|ISB|interscalene block with catheter
62728563|NCT01760616|EXPERIMENTAL|Test group|Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
62728564|NCT01760616|NO_INTERVENTION|Control group: adjuvant therapy|Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.
62728565|NCT06513039|EXPERIMENTAL|study group|Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months
62728566|NCT06513039|NO_INTERVENTION|control|Patient will have extraction of teeth only and followup
62728567|NCT06513039|ACTIVE_COMPARATOR|positive control|Patient will have extraction of teeth and placement of chitosan carrier only for six months
62728568|NCT03971162|EXPERIMENTAL|Group A|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 3 months. Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
62728569|NCT03971162|EXPERIMENTAL|Group B|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 6 months.Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
62728570|NCT02343601|NO_INTERVENTION|Control group|Control group using a hemodynamic standard protocol
62728571|NCT02343601|OTHER|Photoplethysmography group|Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)
61976717|NCT00558025|EXPERIMENTAL|Pramipexole Immediate Release (IR)|Pramipexole Immediate Release (IR) once daily
62728572|NCT00180557|EXPERIMENTAL|Active fixation lead|Active fixation lead was implanted
62728573|NCT00180557|ACTIVE_COMPARATOR|Passive fixation lead|Passive fixation lead was implanted
62728574|NCT03130725|EXPERIMENTAL|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
62728575|NCT03130725|ACTIVE_COMPARATOR|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
62728576|NCT00886327||Postoperative patients|Patients with CD who recently underwent bowel resection
62728577|NCT00964951|EXPERIMENTAL|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
62728578|NCT00964951|EXPERIMENTAL|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
62728579|NCT00964951|EXPERIMENTAL|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
62728580|NCT00964951|EXPERIMENTAL|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
62728581|NCT00964951|EXPERIMENTAL|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
62728582|NCT06114940|EXPERIMENTAL|Experimental group|Subjects received Toripalimab combined with tyrosine kinase inhibitors TKI (Lenvatinib) followed by enucleation of renal tumor or partial nephrectomy or radical nephrectomy.
62728583|NCT06302803|EXPERIMENTAL|The mTRE group|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
62728584|NCT06302803|EXPERIMENTAL|The CR group|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
62728585|NCT06302803|NO_INTERVENTION|Control|usual health care
62728586|NCT01977898|EXPERIMENTAL|Morphine|Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
62728587|NCT01977898|PLACEBO_COMPARATOR|Saline|Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
62728588|NCT02931838|EXPERIMENTAL|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
62728589|NCT02931838|EXPERIMENTAL|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
62728590|NCT02931838|EXPERIMENTAL|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
62728591|NCT02931838|EXPERIMENTAL|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
62728592|NCT02931838|EXPERIMENTAL|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
62728593|NCT02931838|PLACEBO_COMPARATOR|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
62728594|NCT03274947|ACTIVE_COMPARATOR|Hypothesis 2 Protocol 2 Low dose TMS|Low level cerebellar TMS. Delivered once per day for 3 days.
62728595|NCT03274947|ACTIVE_COMPARATOR|Hypothesis 2 Protocol 2 High dose TMS|High level cerebellar TMS. Delivered twice per day for 5 days.
62728596|NCT03274947|SHAM_COMPARATOR|Hypothesis 2 Protocol 2 Sham|Sham cerebellar TMS. Delivered twice a day for 5 days.
62728597|NCT03274947|ACTIVE_COMPARATOR|Hypothesis 2 Protocol 1 Cerebellar TMS|Cerebellar TMS at 10Hz, 250 pulses.
62728598|NCT03274947|SHAM_COMPARATOR|Hypothesis 2 Protocol 1 Sham|Sham cerebellar TMS
62728599|NCT03634111|ACTIVE_COMPARATOR|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
62728600|NCT03634111|PLACEBO_COMPARATOR|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
62728601|NCT05912491||Urinary stress incontinence (UI)|Women with clinical symptoms of stress urinary incontinence
62728602|NCT05912491||No Urinary stress incontinence (no-UI)|Women without clinical symptoms of stress urinary incontinence
62728603|NCT04067089|EXPERIMENTAL|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
62728604|NCT04067089|ACTIVE_COMPARATOR|Surgical aortic valve replacement|Surgical aortic valve replacement
62728605|NCT01962428|EXPERIMENTAL|high loading dose of ticagrelor|Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
62728606|NCT01962428|ACTIVE_COMPARATOR|conventional loading dose of ticagrelor|Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
62728607|NCT03474263|EXPERIMENTAL|IC14 (monoclonal anti-CD14 antibody)|Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
62728608|NCT02634242|EXPERIMENTAL|Si-Wu-Tang (SWT)|Subjects are recommended to drink 125 mL of SWT (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
62728609|NCT02634242|PLACEBO_COMPARATOR|placebo|Subjects are recommended to drink 125 mL of Placebo (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
62728610|NCT02476604|EXPERIMENTAL|Electronic Messaging|Subjects randomized to the intervention arm will receive health coaching and electronic messages at the rate of up to six times per week over an 8 week period.
62728611|NCT02476604|NO_INTERVENTION|Control|Subjects randomized to the control arm will undergo all of the same measurements for baseline and follow up data but will not receive the intervention of health coaching and electronic messaging.
62728612|NCT01021176|PLACEBO_COMPARATOR|0mg 0 spray|No Diltiazem
62728613|NCT01021176|ACTIVE_COMPARATOR|2mg 2 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 2mg/2 spray Diltiazem
62728614|NCT01021176|ACTIVE_COMPARATOR|4mg 4 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 4mg/4 spray Diltiazem
62728615|NCT01021176|ACTIVE_COMPARATOR|8mg 8 spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 8mg/8 spray Diltiazem
62728616|NCT02474303|OTHER|HIV Pre-exposure Prophylaxis (PrEP)|Truvada
62728617|NCT01424358|EXPERIMENTAL|Web-based Educational|
62728618|NCT02215057|EXPERIMENTAL|Group 2|topical anesthetic drops patients were prepared for bilateral ICL/TICL procedure on the same day.Group I (1 eye) received topical anesthetic drops
62728619|NCT02215057|EXPERIMENTAL|Group 1|received topical anesthesia plus intracameral lidocaine 1% topical anesthesia plus intracameral lidocaine 1%'
62728620|NCT05842746|PLACEBO_COMPARATOR|Stupp Protocol|Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Placebo that has the same appearance and flavor with Elemene is given 20ml orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.
62728621|NCT05842746|EXPERIMENTAL|Ele-Stupp Protocol|Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Elemene is given 20ml:176mg orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.
62728622|NCT02655276|EXPERIMENTAL|100 mg microencapsulated Glycine and then Placebo tablets|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the first three weeks and then Placebo t.i.d. from Biotiki® for the second three weeks.
62728623|NCT02655276|EXPERIMENTAL|Placebo tablets and then 100 mg microencapsulated Glycine|Placebo t.i.d. from Biotiki® for the first three weeks and then 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the second three weeks.
62728624|NCT03841851|NO_INTERVENTION|temporization without soft tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area~* traditional drilling for immediate implant placement .~* immediate temporization ."
62728625|NCT03841851|ACTIVE_COMPARATOR|temporization with soft tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area~* traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate ."
62728626|NCT00787241||Mild preeclampsia|Preeclampsia without eclampsia or HELLP syndrome
62728627|NCT00787241||Severe preeclampsia|Severe preeclampsia with eclampsia and/or HELLP syndrome
62728628|NCT00787241||Mild preeclampsia superimposed on chronic hypertension|Mild preeclampsia in association with chronic hypertension
62728629|NCT01673776|NO_INTERVENTION|K group|commonly used therapy
62728630|NCT01673776|EXPERIMENTAL|M group|multimodal intervention
62728631|NCT00572429|PLACEBO_COMPARATOR|A|
62728632|NCT01108328|EXPERIMENTAL|PolyGlycopleX (PGX)|5 grams of PGX 3 times per day with each main meal (breakfast, lunch and dinner)
62728633|NCT01108328|PLACEBO_COMPARATOR|Rice flour|5 grams of rice flour 3 times per day at each main meal (breakfast, lunch and dinner)
62728634|NCT01152125|EXPERIMENTAL|Autologous bone marrow stem cells|
62728635|NCT01316458|EXPERIMENTAL|imatinib mesylate|
62728636|NCT00043745|EXPERIMENTAL|1|Participants will receive moderate dose soy isoflavone (80 mg/day) tablets, extracted from soy protein
62728637|NCT00043745|EXPERIMENTAL|2|Participants will receive high dose soy isoflavone (120 mg/day) tablets, extracted from soy protein
62728638|NCT00043745|PLACEBO_COMPARATOR|3|Participants will receive soy extract devoid of isoflavones to serve as placebo
62728639|NCT04657185||Before OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place but without OR PathTrac feedback optimization.
62728640|NCT04657185||After OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place AND OR PathTrac feedback optimization.
62728641|NCT01591265|ACTIVE_COMPARATOR|Compensatory Extraction|Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
62728642|NCT01591265|ACTIVE_COMPARATOR|No Compensatory Extraction|Patients allocated to this group, only the lower FPM tooth will be extracted.
62728643|NCT05131412||mesenchymal stromal cell|Patients treated with mesenchymal stromal cell
62728644|NCT05131412||non-mesenchymal stromal cell|Patients treated without mesenchymal stromal cell
62728645|NCT05039866||Subjects who received ST-920|Subjects who received ST-920 in a separate parent trial
62728646|NCT04059068||NASH (non-alcoholic steatohepatitis)|Patients diagnosed with non-alcoholic steatohepatitis.
62728647|NCT04059068||NAFLD (non-alcoholic fatty liver disease)|Patients diagnosed with non-alcoholic fatty liver disease.
62728648|NCT04059068||Control|Patients with normal liver tissue.
62728649|NCT04059068||obese / high WAT inflammation and fibrosis|Patients who are obese with inflammed white adipose tissue and evidence of fibrosis.
62728650|NCT04059068||obese / low WAT inflammation and fibrosis|Patients who are obese with no evidence of inflammed white adipose tissue and no evidence of fibrosis.
62728651|NCT04059068||non- obese controls|Patients who are not obese.
62728652|NCT00589173|EXPERIMENTAL|Intervention|Patients referred to the IPHR
62728653|NCT00589173|ACTIVE_COMPARATOR|Control|"Patients receiving standard preventive care"
61976718|NCT02123745|EXPERIMENTAL|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
61976719|NCT01432886|EXPERIMENTAL|1|
62728654|NCT02829996|EXPERIMENTAL|trabodenoson 6.0% /latanoprost 0.005% QD|trabodenoson 6.0% / latanoprost 0.005% QD FDC
62728655|NCT02829996|EXPERIMENTAL|trabodenoson 3.0% /latanoprost 0.005% QD|trabodenoson 3.0% / latanoprost 0.005% QD FDC
62728656|NCT02829996|EXPERIMENTAL|trabodenoson 6.0% /latanoprost 0.0025%QD|trabodenoson 6.0% /latanoprost 0.0025% QD FDC
62728657|NCT02829996|ACTIVE_COMPARATOR|latanoprost 0.005% QD|latanoprost 0.005% ophthalmic solution QD
62728658|NCT02829996|ACTIVE_COMPARATOR|latanoprost 0.0025% QD|latanoprost 0.0025% ophthalmic solution QD
62728659|NCT04263766|EXPERIMENTAL|Healthy Adult Volunteers|The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.
62728660|NCT04256174|EXPERIMENTAL|Part 1:15mg cohort|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.
62728661|NCT04256174|EXPERIMENTAL|Part 1: 50mg cohort|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.
62728662|NCT04256174|EXPERIMENTAL|Part 1: 150mg cohort|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.
62728663|NCT04256174|EXPERIMENTAL|Part 1: 300 mg cohort|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.
62728664|NCT04256174|EXPERIMENTAL|Part 1: 600 mg cohort|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.
62728665|NCT04256174|EXPERIMENTAL|Part 2: low dose cohort|Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
62737950|NCT05894304|ACTIVE_COMPARATOR|Excercise therapy group|The group that recived scapular muscle training exercises
62728666|NCT04256174|EXPERIMENTAL|Part 2: medium dose cohort|Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
62728667|NCT04256174|EXPERIMENTAL|Part 2: high dose cohort|Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
62728668|NCT04256174|EXPERIMENTAL|Part 2: Loading dose cohort|A loading dose followed by multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
62728669|NCT04665427|OTHER|Patient in whom a bilioenteric anastomosis is performed for any etiology.|Patient in whom a bilioenteric anastomosis is performed for any etiology..
62728670|NCT04570306||Belimumab-treated SLE patients|SLE patients with active disease who will be started on add-on treatment with belimumab on top of standard of care.
62728671|NCT02790840|EXPERIMENTAL|Gefapixant + Omeprazole|Gefapixant oral tablets (15mg and 30 mg) administered twice daily for 15 days + Omeprazole oral capsules (20 mg or 40 mg) administered once or twice daily for 10 days
62728672|NCT06488690|OTHER|All patients who are pregnant and undergo cesarean section|We included all patients who were pregnant and underwent cesarean section and calculated maternal early warning scores.
62728673|NCT04297150||Patients that satisfy inclusion criteria|Patients who satisfy the inclusion criteria and sign the informed consent.
62728674|NCT00742170|ACTIVE_COMPARATOR|Active electroacupuncture|In the active electroacupuncture condition, the current is set at 2 times threshold (approximately 6-10 mA), which typically produces muscle twitching.
62728675|NCT00742170|SHAM_COMPARATOR|Sham electroacupuncture|In the sham electroacupuncture condition, the current is set at 1 mA, the lowest intensity possible before the HANS device shuts off; this is undetectable stimulation.
62728676|NCT02653339|EXPERIMENTAL|Qufeng Shengshi Fang and Loratadine|Qufeng Shengshi Fang is a traditional Chinese medicine form 8 kinds of herbs. Loratadine is the second generation antihistamines, after converted into its active metabolite Carrie period (carebastine), its antihistamines and allergy effect has been demonstrated in vitro and in vivo tests, also received data from clinical trials.
62728677|NCT02653339|ACTIVE_COMPARATOR|Loratadine|Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough\[needs update\] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
62728678|NCT01534286|ACTIVE_COMPARATOR|Theramine|Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
62728679|NCT01534286|PLACEBO_COMPARATOR|Theramine-like Placebo|Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.
62728680|NCT03980782|EXPERIMENTAL|Music Intervention|Each participant will receive a 30 minute individual music intervention twice daily.
62728681|NCT03980782|NO_INTERVENTION|Care as usual|Each participant will receive care as usual.
62728682|NCT02415244||Age 0 - 18|TEE visualization of the spinal cords in patients age between 0 - 18
62728683|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
62728684|NCT03810014|EXPERIMENTAL|Arm 1|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
62728685|NCT03810014|EXPERIMENTAL|Arm 2|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
62728686|NCT03810014|EXPERIMENTAL|Arm 3|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
62728687|NCT03810014|EXPERIMENTAL|Arm 4|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
62728688|NCT01042067||Warfarin treatment group|Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
62728689|NCT02244372|EXPERIMENTAL|Cordyceps sinensis mycelium culture extract 0.76 g|Cordyceps sinensis mycelium culture extract 0.76 g
62728690|NCT02244372|EXPERIMENTAL|Cordyceps sinensis mycelium culture extract 1.15 g|Cordyceps sinensis mycelium culture extract 1.15 g
62728691|NCT02244372|PLACEBO_COMPARATOR|Placebo|Placebo
62728692|NCT01540786|EXPERIMENTAL|Part 1: OAB subjects|
62165991|NCT03138356|ACTIVE_COMPARATOR|Cohort 3 Treatment I (Reference Product)|"Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
62728693|NCT01540786|EXPERIMENTAL|Part 2: Healthy subjects|
62728694|NCT01540786|EXPERIMENTAL|Part 2: OAB subjects|
62728695|NCT05706207|EXPERIMENTAL|Arm 1|Treatment with 0.03 mg/kg HB0030 injection administered intravenously
61976720|NCT06479798|OTHER|FDG PET and EBUS TBNA arm|It is a single arm in which all patients undergo FDG PET and EBUS-TBNA
62165992|NCT03614923|EXPERIMENTAL|Etokimab 300 mg + 150 mg Q4W|Participants received a 300 mg loading dose of etokimab administered by subcutaneous injection at Week 0 then 150 mg etokimab by subcutaneous injection every 4 weeks (Q4W) up to Week 12 (Weeks 4, 8, and 12). Participants also used mometasone furoate nasal spray (MFNS) of 2 actuations (50 μg/actuation) in each nostril twice daily (BID).
62728696|NCT05706207|EXPERIMENTAL|Arm 2|Treatment with 0.3 mg/kg HB0030 injection administered intravenously
61976721|NCT01516424|EXPERIMENTAL|Blonanserin|Antipsychotics
62728697|NCT05706207|EXPERIMENTAL|Arm 3|Treatment with 1 mg/kg HB0030 injection administered intravenously
62728698|NCT05706207|EXPERIMENTAL|Arm 4|Treatment with 3 mg/kg HB0030 injection administered intravenously
62728699|NCT05706207|EXPERIMENTAL|Arm 5|Treatment with 10 mg/kg HB0030 injection administered intravenously
62728700|NCT05706207|EXPERIMENTAL|Arm 6|Treatment with 20 mg/kg HB0030 injection administered intravenously
62728701|NCT05706207|EXPERIMENTAL|Arm 7|Treatment with 30 mg/kg HB0030 injection administered intravenously
62728702|NCT05706207|EXPERIMENTAL|Arm 8|Treatment with 40 mg/kg HB0030 injection administered intravenously
62728703|NCT02342353|EXPERIMENTAL|Phase I (pacritinib and erlotinib)|"* Pacritinib will be administered orally twice a day; dosing will depend on the dose level the patient is enrolled.~* Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~* A 28-day interval is defined as a cycle"
62728704|NCT02342353|EXPERIMENTAL|Phase II (pacritinib and erlotinib)|"* Pacritinib will be administered orally twice a day; the dose used will be the dose determined to be the MTD in phase I.~* Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~* A 28-day interval is defined as a cycle"
62728705|NCT02904369|EXPERIMENTAL|F/TAF 200/10|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/10 mg)
62728706|NCT02904369|EXPERIMENTAL|F/TAF 200/25|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/25 mg)
62728707|NCT02904369|ACTIVE_COMPARATOR|F/TDF 200/300|Emtricitabine (FTC) + Tenofovir Disoproxil Fumarate (TDF) (200/300 mg)
62728708|NCT04312477|EXPERIMENTAL|Experimental group|Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
62728709|NCT04312477|ACTIVE_COMPARATOR|Control group|Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
62728710|NCT01575808|EXPERIMENTAL|GP1101|Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
62728711|NCT01575808|NO_INTERVENTION|Retrospective Surgical Bypass Outcomes|Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.
62728712|NCT05591638||GROUP 1|There will be 45 patients diagnosed with preeclampsia in the study group
62728713|NCT05591638||GROUP 2|There will be 45 normal pregnant women in the control group
62728714|NCT05270018|EXPERIMENTAL|Bacterial Lysate group|Oral / gastric administration of bacterial lysate once a day on an empty stomach, 14.0mg each time for at least 5 days
62728715|NCT05270018|PLACEBO_COMPARATOR|Control group|Oral / gastric administration of normal saline once a day, 14.0ml each time
62728716|NCT02444507|ACTIVE_COMPARATOR|Reference Drug: Nexium|Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
62728717|NCT02444507|ACTIVE_COMPARATOR|Test Drug: Esomelone|Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
62728718|NCT01768910|EXPERIMENTAL|Healthy controls|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
62728719|NCT01768910|EXPERIMENTAL|MS with OAB|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
62728720|NCT01768910|EXPERIMENTAL|MS without OAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
62728721|NCT01768910|EXPERIMENTAL|NNOAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
62728722|NCT01768910|EXPERIMENTAL|SCI with neurogenic detrusor overactivity|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
62728723|NCT04532125|EXPERIMENTAL|ARGX-117 IV|Subjects receiving ARGX-117 IV
62728724|NCT04532125|PLACEBO_COMPARATOR|Placebo IV|Subjects receiving placebo IV
62728725|NCT04532125|EXPERIMENTAL|ARGX-117 PH20 SC|Subjects receiving ARGX-117 PH20 SC
62728726|NCT04532125|PLACEBO_COMPARATOR|Placebo PH20 SC|Subjects receiving placebo PH20 SC
62728727|NCT04532125|EXPERIMENTAL|ARGX-117 + rHuPH20|Subjects receiving ARGX-117 + rHuPH20
62728728|NCT04532125|PLACEBO_COMPARATOR|Placebo + rHuPH20|Subjects receiving placebo + rHuPH20
62728729|NCT05334472||Kesimpta|Patients or caregivers of patients administered Kesimpta
62728730|NCT01162473|ACTIVE_COMPARATOR|Delayed Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 16 and continue thru Week 50. Total active participation will last 51 weeks.
62728731|NCT01162473|ACTIVE_COMPARATOR|Immediate Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 3 and continue thru Week 35. Total active participation will last 38 weeks.
62728732|NCT00529438|EXPERIMENTAL|Bardoxolone methyl capsules|"Bardoxolone methyl to be taken orally for 21 consecutive days, once a day, in the morning prior to food intake.~Patients to continue to receive treatment for the first 21 days of each 28-day cycle until they experience intolerable toxicity, show evidence of disease progression, or receive a maximum of 18 cycles (18 months)."
62728733|NCT03102450|EXPERIMENTAL|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
62728734|NCT06107985|EXPERIMENTAL|Structured exercise group|Group A (Experimental Group) will receive structured exercises protocol, will be given approximately for two days per week for twelve weeks.
62728735|NCT06107985|ACTIVE_COMPARATOR|Conventional Exercise group|Group B (control group) will receive conventional exercise program for two days per week for twelve weeks.
62728736|NCT00690794|EXPERIMENTAL|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
62728737|NCT00690794|ACTIVE_COMPARATOR|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
62728738|NCT02569567||US elastography|"Participants who have the plan of liver transplantation or liver biopsy within 4 weeks will be screened from the outpatient clinic.~Two types of ultrasonographic elastography(US elastography) techniques including Smart-Shear Wave(SSW) imaging and transient elastography(TE) will be performed as a diagnostic method for hepatic fibrosis."
62728739|NCT02753478|EXPERIMENTAL|intracoronary hypothermia group|Patients who will receive intracoronary hypothermia before and during percutaneous coronary intervention
62728740|NCT01297803|ACTIVE_COMPARATOR|Mitomycin_c application before sclera flap dissection|
62728741|NCT01297803|ACTIVE_COMPARATOR|Mitomycin_c application after sclera flapdissection|
62728742|NCT01198574|EXPERIMENTAL|Iron group|
62728743|NCT01198574|EXPERIMENTAL|Vitamin A group|Vitamin A group
62728744|NCT01198574|EXPERIMENTAL|Iron and Vitamin A group|Iron and Vitamin A group
62728745|NCT01198574|EXPERIMENTAL|Placebo group|Placebo group with folic acid
62728746|NCT05216718|EXPERIMENTAL|Conventional flap|BABA robotic-thyroidectomy that using conventional flap
62728747|NCT05216718|ACTIVE_COMPARATOR|Mini-flap|BABA robotic-thyroidectomy that using Mini-flap
62728748|NCT02059564|EXPERIMENTAL|Cohort A|The weekly treatment of the 6 mg HM11260C or placebo will be maintained
62728749|NCT02059564|EXPERIMENTAL|Cohort B|The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg
62728750|NCT02059564|EXPERIMENTAL|Cohort C|The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg
62728751|NCT02099084|EXPERIMENTAL|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
62728752|NCT02099084|PLACEBO_COMPARATOR|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
62728753|NCT02798744|EXPERIMENTAL|Empagliflozin 25mg once daily|Empagliflozin (Jardiance™) 25mg once daily (orally)
62728754|NCT02798744|EXPERIMENTAL|Empagliflozin 25mg once daily + diet|Empagliflozin (Jardiance™) 25mg once daily (orally) + energy restriction diet
62728755|NCT02798744|PLACEBO_COMPARATOR|Placebo once daily|Placebo once daily (orally)
62728756|NCT02798744|ACTIVE_COMPARATOR|Placebo once daily + diet|Placebo once daily (orally) + energy restriction diet
62728757|NCT02776683|EXPERIMENTAL|All patients|
62728758|NCT05643781||Co-TB Group|Follow up all participants from hospital discharge until 12 months post-Covid-19 infection. Conduct investigations assessing cardiopulmonary, socioeconomic, quality of life outcomes. No interventions.
62728759|NCT04328896|EXPERIMENTAL|Intervention|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Dexcom G5/6) that communicates via smart phone to a Tidepool designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes \<54 mg/dl. Tidepool dashboard automatically emails daily alerts to the Certified Diabetes Educator (CDE). If alerts occurred, the CDE performed telemedicine outreach based on type of alert.
62728760|NCT01176877|OTHER|keloid scar|Those with a diagnosis of keloid scar.
62728761|NCT02013349|OTHER|DESyne Novolimus Eluting CSS|approved device continued access
62728762|NCT04645511|EXPERIMENTAL|Chronic sinusitis: Balloon sinuplasty|30 patients with chronic maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
62728763|NCT04645511|SHAM_COMPARATOR|Chronic sinusitis: Placebo|30 patients with chronic maxillary sinusitis that are randomized to be treated with sham surgery.
62728764|NCT04645511|EXPERIMENTAL|Recurrent sinusitis: Balloon sinuplasty|30 patients with recurrent maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
62728765|NCT04645511|SHAM_COMPARATOR|Recurrent sinusitis: Placebo|30 patients with recurrent maxillary sinusitis that are randomized to be treated with sham surgery.
62728766|NCT03565341|EXPERIMENTAL|Melasma|Treatment of Melasma Using PiQo4 Laser System
62728767|NCT01668160|EXPERIMENTAL|Revision Total Hip|patients recieving a revision total hip replacement will be assessed for implant stability and wear using RSA. Tantalum beads will be placed in the polyethylene and surrounding pelvic and femoral bone.
62728768|NCT01431898|EXPERIMENTAL|Multiple-dose, dose-escalation study of GS-9669|Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
62728769|NCT03886948|EXPERIMENTAL|125 mg LY3074828 Prefilled Syringe (PFS)|"Reference 1: Participants received 125 mg LY3074828 solution formulation subcutaneously (SC) via 1-mL pre-filled syringe (PFS) administered in the arm.~Reference 2: Participants received 125 mg LY3074828 solution formulation SC via 1-mL PFS administered in the thigh.~Reference 3: Participants received 125 mg LY3074828 solution formulation SC via 1-mL PFS administered in the abdomen."
62728770|NCT03886948|EXPERIMENTAL|125 mg LY3074828 Autoinjector (AI)|"Test 1: Participants received 125 mg LY3074828 solution formulation SC via 1-mL Autoinjector (AI) administered in the arm.~Test 2: Participants received 125 mg LY3074828 solution formulation SC via 1-mL AI administered in the thigh.~Test 3: Participants received 125 mg LY3074828 solution formulation SC via 1-mL AI administered in the abdomen."
62728771|NCT00049322|EXPERIMENTAL|Arm I-bevacizumab|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization at a dose of 10 mg/kg. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
62728772|NCT00049322|NO_INTERVENTION|Arm II-chemoembolization|chemoembolization as part of standard of care
62728773|NCT02069977|EXPERIMENTAL|Aripiprazole|"* Dose level: 2, 5, 10, 15 mg/day~* Starting dose: 2 mg/day~* Dose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.~* Target dose: 5-15 mg/day~* Maximum dose: 15 mg/day~* Flexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals"
62728774|NCT02462187|EXPERIMENTAL|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
62728775|NCT02462187|EXPERIMENTAL|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
62728776|NCT02462187|EXPERIMENTAL|NVN1000 16% Once daily|NVN1000 16% Gel once daily
62728777|NCT02462187|PLACEBO_COMPARATOR|Vehicle Gel|Vehicle Gel at frequency to match active
62728778|NCT02462187|EXPERIMENTAL|NVN1000 24% once daily|NVN1000 24% once daily
62728779|NCT01163305||metastatic colorectal cancer|
62728780|NCT02116842|EXPERIMENTAL|0.075% bupivacaine|Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.
62728781|NCT02116842|EXPERIMENTAL|0.1% bupivacaine|Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.
62728782|NCT00976638|ACTIVE_COMPARATOR|Chromogenic Arm|Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
62728783|NCT00976638|ACTIVE_COMPARATOR|Molecular Arm|Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
62728784|NCT03069833|EXPERIMENTAL|Computer-aided diagnosis|
62728785|NCT03069833|NO_INTERVENTION|traditional diagnosis|
62728786|NCT03507296||Chronic low back pain patients|
62728787|NCT03507296||Asymptomatic subjects|
62728788|NCT00083460|ACTIVE_COMPARATOR|1|
62728789|NCT00083460|ACTIVE_COMPARATOR|2|
62728790|NCT04620616|EXPERIMENTAL|Product Use Sequence 1|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - RELX ENDS menthol flavor Period 3 - Usual Brand ENDS"
62728791|NCT04620616|EXPERIMENTAL|Product Use Sequence 2|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS tobacco flavor"
62728792|NCT04620616|EXPERIMENTAL|Product Use Sequence 3|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS tobacco flavor Period 3 - RELX ENDS menthol flavor"
62728793|NCT04620616|EXPERIMENTAL|Product Use Sequence 4|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS menthol flavor Period 3 - RELX ENDS tobacco flavor"
62728794|NCT04620616|EXPERIMENTAL|Product Use Sequence 5|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS menthol flavor"
62728795|NCT04620616|EXPERIMENTAL|Product Use Sequence 6|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - RELX ENDS tobacco flavor Period 3 - Usual Brand ENDS"
62728796|NCT04871828|EXPERIMENTAL|Treatment|"Zafirlukast plus the standard treatment according to Saudi CDC protocol (combination experimental arm)~Description of investigational drug Zafirlukast is leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet and is usually dosed twice daily. It is approved by USFDA and currently commercially marketed under the name of Accolate 20 mg oral tablet. The drug will be acquired from the pharmacy and will be received by the patient during the hospital admission via research coordinator. The study drug will be stored in at room temperature (15 - 25 c) in the hospital's pharmacy and a delegated pharmacist will be responsible for dispensing and return of any drugs.~The study drug will be administrated to the patient in the dose of 20 mg orally twice daily for 10 days (fixed dose with no staring or escalating dose)."
62728797|NCT04871828|PLACEBO_COMPARATOR|Control|placebo plus the standard treatment according to Saudi CDC protocol
62728798|NCT05793359||Modified monthly regimen|Treatment with 3 pulses of 3 infusions of 500 mg methylprednisolone on 3 consecutive months with intramuscular administration of 125 mg methylprednisolone per week between the pulses. Additional low dose peroral treatment after completion of the pulses.
62728799|NCT05793359||Weekly regimen|Treatment with 6 infusions of 500 mg methylprednisolone during the first 6 weeks, followed by 6 infusions of 250 mg methylprednisolone during the next 6 weeks.
62728800|NCT04071431|NO_INTERVENTION|Control|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
62728801|NCT04071431|EXPERIMENTAL|Risk shown|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are known by the endoscopists before and during the endoscopy."
62728802|NCT03338400|ACTIVE_COMPARATOR|Dexamethasone|Patients in the Dexamethasone arm will be administered the drug at the time of induction.
62728803|NCT03338400|PLACEBO_COMPARATOR|Normal Saline|The placebo arm patients will receive normal saline at the time of induction.
62728804|NCT06493045|EXPERIMENTAL|IRL757|
62728805|NCT06493045|PLACEBO_COMPARATOR|Placebo Comparator|
62728806|NCT06015360|EXPERIMENTAL|Fat Grafting|The fat grafting procedure will be conducted as per local standard RM protocol. All procedures will be conducted by the study Principal Investigator (PI) who is well practiced in performing this procedure in Head \& Neck and breast cancer patients and also in scar revision patients.
62728807|NCT03813875||TEE (transesophageal echocardiography)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~TEE group: the routine sedation medication for the procedure include midazolam (approximately 1\~5mg per patient), alfentanil (200\~1000mcg per patient) and propofol (small boluses of 10\~20mg on demand, total dose usually below 100mg per patient depending on the overall examination timespan) all in intravenous boluses. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
62728808|NCT03813875||LMA (laryngeal mask airway)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~LMA group: routine induction medications include propofol (50\~200mg per patient), fentanyl (50\~150mcg per patient) and sevoflurane (machine setting at 1.5% to 3% according to clinical needs). Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
62728809|NCT02315040|ACTIVE_COMPARATOR|IUI|standard intrauterine insemination method
62728810|NCT02315040|EXPERIMENTAL|EVIE|Slow release insemination method (SRI)
62728811|NCT03109743|EXPERIMENTAL|Sisters-GPS: Group Clinical Visits|Those randomized to the Sisters-GPS arm will be expected to attend a total of seven group clinical visits, once a week for \~1.5 hours. Groups visits will include education, self-management skills development, and a clinical assessment by a medical provider with a focus on HIV treatment and adherence. Additionally, Sisters-GPS participants will be encouraged to participate in a private social media site specifically designed for the study, where participants will be able communicate with one another and with research staff. Group size will be 8-10 participants.
62728812|NCT03109743|ACTIVE_COMPARATOR|Control: One-on-one Adherence Counseling|Those randomized to the control condition will receive an appointment with a HIV treatment adherence counselor and will be expected to attend a minimum of three adherence counseling visits. .
62728813|NCT03149159|EXPERIMENTAL|Nivolumab + Ipilimumab + SRT|
62728814|NCT05953298|EXPERIMENTAL|Patients with COPD|Patients with COPD in stable condition fitted with long-term NIV
62728815|NCT03118505|EXPERIMENTAL|Group 1|Infuse Bone Graft \[4.2 mg per operative level\] + Mastergraft Strip + local bone autograft + posterior fixation
62728816|NCT03118505|EXPERIMENTAL|Group 2|Infuse Bone Graft \[6 mg per operative level\] + Mastergraft Strip + local bone autograft + posterior fixation
62728817|NCT03118505|EXPERIMENTAL|Group 3|Infuse Bone Graft \[12 mg per operative level\] + Mastergraft Strip + local bone autograft + posterior fixation
62728818|NCT03118505|ACTIVE_COMPARATOR|Control|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.
62728819|NCT06512870||Known ACS|Patients, aged 18 to 75 years, with diagnosis of unilateral tibial fracture, complicated by Acute Compartment syndrome and/or acute vascular compromise (leg ischemia, absent pulses below the knee), as diagnosed and confirmed by ED physician, orthopedic surgeon and/or vascular surgeon. Only patients with depth to anterior compartment \<2.5 cm as measured by the ultrasound will be enrolled.
62728820|NCT05024253|EXPERIMENTAL|patient is receiving Tranexemic acid (TXA )|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare TXA injection at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion at a dose of 5mg/kg/hour will be given until wound closure."
62728821|NCT05024253|PLACEBO_COMPARATOR|standard treatment (saline)|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare 50 ml of 0.9% saline or TXA at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion of saline will be given until wound closure."
62728822|NCT02705482|EXPERIMENTAL|Arm A: MEDI0562 and durvalumab|MEDI0562 and durvalumab
62728823|NCT02705482|EXPERIMENTAL|Arm B: MEDI0562 and tremelimumab|MEDI0562 and tremelimumab
62728824|NCT01531582|EXPERIMENTAL|Children with Angelman Syndrome|Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
62728825|NCT01072136|PLACEBO_COMPARATOR|Placebo|Placebo.
62728826|NCT01072136|EXPERIMENTAL|Azithromycin/Cefixime|A single dose of cefixime 400 mg (1 tablet oral at 400 mg) and azithromycin 1 gram (2 tablets oral at 500 mg each).
62728827|NCT00856635|EXPERIMENTAL|Glatiramer acetate|Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.
62728828|NCT00856635|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once a day for up to 6 months.
62728829|NCT02845986|EXPERIMENTAL|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed laparoscopic spleen-preserving No.10 lymph node dissections.After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
62728830|NCT02099773||support workers & AAC users|Support workers who use KeyWordSigning in the communication with their client who has an intellectual disability
62728831|NCT02099773||support workers & KWS users|Support workers who use aided AAC in the communication with their client who has an intellectual disability
62728832|NCT01543919|EXPERIMENTAL|PH-787904 (arm1)|
62728833|NCT01543919|EXPERIMENTAL|PH-787904 (arm2)|
62728834|NCT01543919|EXPERIMENTAL|PH-787904 (arm3)|
62728835|NCT01543919|EXPERIMENTAL|PH-787904 (arm4)|
62728836|NCT01543919|EXPERIMENTAL|PH-787904 (arm5)|
62728837|NCT01543919|EXPERIMENTAL|Placebo|
62728838|NCT03370211|EXPERIMENTAL|experimental intervention|The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums (RM).The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
62728839|NCT03370211|NO_INTERVENTION|control group|The control group did not perform any type of physical exercise during the intervention period.
62728840|NCT01206634|EXPERIMENTAL|Regenerative injection therapy|
62728841|NCT01206634|ACTIVE_COMPARATOR|Exercise|
62728842|NCT06365658||General population/control group|Polish adults (age 18 to 60 y.o).
62728843|NCT06365658||Neurologically recognized aphasic syndromes|Polish adults (age 18 to 60 y.o) with neurologically recognized aphasic syndromes.
62728844|NCT06365658||Seniors (over 60 y.o)|Polish adults (over 60 y.o.)
62728845|NCT03072043|EXPERIMENTAL|Phase 1b Dose Escalation|Participants will receive intravenous infusions of APR-246 as a lead-in phase on days -14 to -11 starting at Dose Level 1 prior to starting cycle #1 of combination therapy with azacitidine. Combination therapy will consist of APR-246 on days 1-4 and azacitidine on days 4-10 (or days 4-5 and 8-12) of a 28 day cycle.
62728846|NCT03072043|EXPERIMENTAL|Phase 2 Treatment|Participants will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing schedule as in Phase 1b.
62728847|NCT05671523|EXPERIMENTAL|Dry needling|The patients will receive ten sessions, twice a week, for five weeks of dry needling in addition to their conventional physical therapy program (splinting and ultrasound therapy.)
62728848|NCT05671523|ACTIVE_COMPARATOR|conventional treatment|The patients will receive conventional treatment (splinting and ultrasound therapy) for 5 weeks
62728849|NCT02648009|OTHER|Healthy Volunteers|"Arm 1~* Group 1A: control male volunteers between 19 and 50 years of age.~* Group 1B: control female volunteers between 19 and 50 years of age.~* Group 1C: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice~* Group 1D: control male volunteers between 19 and 50 years of age.~* Group 1E: control female volunteers between 19 and 50 years of age.~* Group 1F: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice"
62728850|NCT02648009|OTHER|Hypertension Hypertrophy Volunteers|"Arm 2~* Group 2A: patients aged 30 to 75 with hypertension and hypertrophy~* Group 2B: patients aged 30 to 75 with non-obstructive hypertrophic cardiomyopathy (HCM).~* Group 2C: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.~* Group 2D: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents.~* Group 2E: patients aged 30 to 75 with hypertrophy~* Group 2F: patients aged 30 to 75 with hypertrophic cardiomyopathy (HCM).~* Group 2G: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.~* Group 2H: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents."
62728851|NCT01016067|EXPERIMENTAL|INFUSE/MASTERGRAFT|Patients received INFUSE/MASTERGRAFT granules with rigid internal fixation.
62728852|NCT01016067|ACTIVE_COMPARATOR|Autograft bone|Patients received autograft bone with rigid internal fixation.
62728853|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 1 Group|Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
62728854|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 2 Group|Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
62728855|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 3 Group|Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
62728856|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 4 Group|Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
62728857|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 5 Group|Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
62728858|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 6 Group|Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
62728859|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 7 Group|Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
62728860|NCT00540592|EXPERIMENTAL|Influenza vaccine GSK576389A formulation 8 Group|Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
62728861|NCT00540592|ACTIVE_COMPARATOR|Fluarix elderly Group|Subjects aged ≥65 years received one dose of Fluarix vaccine.
62728862|NCT00540592|ACTIVE_COMPARATOR|Fluarix young Group|Subjects aged 18-40 years received one dose of Fluarix vaccine.
62728863|NCT01261273||Stable angina|Patient admitted with stable angina
62728864|NCT01261273||Acute Coronary Syndrome|Patients admitted with Acute Coronary Syndrome
62728865|NCT01261273||Female|Participant female patients
62728866|NCT01261273||Bifurcation|One or more lesions treated during the baseline in bifurcation
62728867|NCT01261273||Insulin Dependent Diabetes Mellitus|Patients that were insulin-dependent diabetes mellitus at admission
62728868|NCT01261273||Non-Insulin Dependent Diabetes Mellitus|Patients that were non-insulin-dependent diabetes mellitus at admission
62728869|NCT01261273||Small Vessels|vessels smaller or equal to 2.75mm
62728870|NCT01261273||NOBORI Long Lesions|Lesions longer or equal to 20mm
62728871|NCT01261273||Renal Insufficiency|Patients that at admission had renal insufficiency (\> 2.0 mg/dL - 176 µmol/mL) at admission
62728872|NCT01261273||Elderly|Patients more or equal 80 years old
62728873|NCT01261273||Restenosis|One or more lesions treated during the baseline in were restenotic lesions
62728874|NCT01261273||Multivessel Treatment|Patients who underwent the treatment of more than 1 vessel during the index procedure
62728875|NCT01261273||Complex Lesions|Patients who underwent a PCI on the Left Main Trunk, on a Chronic Total Occluded lesion or located on a Saphenous Vein Graft
62728876|NCT01261273||Overall|Total Population
62728877|NCT01632852|EXPERIMENTAL|CSL362|See Intervention Description
62728878|NCT03456700|EXPERIMENTAL|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
62728879|NCT02938247|EXPERIMENTAL|Single-arm study|High caloric, high protein ONS, three portions daily, total dose of 400 kcal/day for 7 consecutive days, oral administration
62728880|NCT00912782|PLACEBO_COMPARATOR|Placebo|Placebo one time per week for 3 weeks
61976722|NCT01516424|ACTIVE_COMPARATOR|Risperidone|Antipsychotics
62728881|NCT00912782|EXPERIMENTAL|Cholecalciferol|Vitamin D 200,000 IU per week for 3 weeks
62728882|NCT03724279|EXPERIMENTAL|ByCross Atherectomy and Thrombectomy|Percutaneous intervention including ByCross atherectomy and Thrombectomy potentially followed with PTA and/or stent placement
62728883|NCT02027727||No intervention|No intervention- this is an observational study of patients receiving Infliximab.
62737951|NCT05894304|EXPERIMENTAL|Suspension group|The group that recived scapular muscle training using suspension system
62728884|NCT06363474|EXPERIMENTAL|Group A - Decompressive Craniectomy|Patients allocated to Group A will undergo decompressive craniectomy, a neurosurgical procedure involving the removal of a section of the skull (bone flap). This procedure aims to alleviate intracranial pressure (ICP) and provide additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. Following the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
62728885|NCT06363474|ACTIVE_COMPARATOR|Group B - Cisternostomy|Arm Description: Patients allocated to Group B will undergo cisternostomy, a microsurgical technique used in neurosurgery. This procedure involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Postoperatively, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
62728886|NCT02678962|ACTIVE_COMPARATOR|SN6AD1 group|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
62728887|NCT02678962|ACTIVE_COMPARATOR|SBL-3 group|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
62728888|NCT02678962|ACTIVE_COMPARATOR|LS-313 MF30 group|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
62728889|NCT02678962|ACTIVE_COMPARATOR|AT LISA tri 839 MP group|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
62728890|NCT02678962|ACTIVE_COMPARATOR|ART group|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
62728891|NCT02678962|ACTIVE_COMPARATOR|LS-313 MF30T group|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
62728892|NCT01399229||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
62728893|NCT01399229||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
62728894|NCT01399229||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
62728895|NCT04122989|EXPERIMENTAL|MS-SUPPORT|Group receives access to an online shared decision making tool (an interactive decision aid) for multiple sclerosis.
62728896|NCT04122989|NO_INTERVENTION|Control|Usual care
62728897|NCT05429580|OTHER|postpartum bleeding risks as low-risk|The patients were divided into two groups according to their postpartum bleeding risks as low-risk (240 patients) and high-risk (240 patients), and then the patients in each group were randomly divided into two groups, and some of these pregnant women were given intravenous tranexamic acid and some were given placebo.
62728898|NCT05429580|OTHER|postpartum bleeding risks as high-risk|The patients were divided into two groups according to their postpartum bleeding risks as low-risk (240 patients) and high-risk (240 patients), and then the patients in each group were randomly divided into two groups, and some of these pregnant women were given intravenous tranexamic acid and some were given placebo.
62728899|NCT05196373|EXPERIMENTAL|Part 1: Group 1|10ug Intrascar injection
62728900|NCT05196373|EXPERIMENTAL|Part 1: Group 2|20ug Intrascar injection
62728901|NCT05196373|EXPERIMENTAL|Part 1: Group 3|40ug Intrascar injection
62728902|NCT05196373|EXPERIMENTAL|Part 1: Group 4|60ug Intrascar injection
62728903|NCT05196373|EXPERIMENTAL|Part 1: Group 5|80ug Intrascar injection
62728904|NCT05196373|EXPERIMENTAL|Part 1: Group 6|100ug Intrascar injection
62728905|NCT05280665||The non-specialized group|"Patients who were operated by a non-specialized surgeon. Non-specialized surgeons were defined as general surgeon who does not have the characteristics of a specialized gastric cancer surgeon.~The non-specialized group will be divided into two subgroups (high-volume vs low-volume) for further analysis."
62728906|NCT05280665||The specialized group|"Patients who were operated by a specialized gastric cancer surgeon. Specialized gastric cancer surgeons were defined as surgeons who meet all of the criteria for a specialized gastric cancer surgeon.~* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21"
62728907|NCT03259243|PLACEBO_COMPARATOR|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
62728908|NCT03259243|EXPERIMENTAL|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
62728909|NCT03259243|EXPERIMENTAL|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
62728910|NCT03259243|EXPERIMENTAL|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
62728911|NCT03645278|EXPERIMENTAL|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
62728912|NCT03645278|EXPERIMENTAL|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
62728913|NCT03310359|ACTIVE_COMPARATOR|Astaxanthin (12 mg)|Subjects will be given capsules containing a set oral dose of astaxanthin (12 mg) and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
62728914|NCT03310359|PLACEBO_COMPARATOR|Placebo|Subjects will be given capsules containing placebo and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
62728915|NCT03069040|EXPERIMENTAL|nerve-sparing radical hysterectomy|The patient recived surgury of nerve-sparing radical hysterectomy.
62728916|NCT03069040|ACTIVE_COMPARATOR|radical hysterectomy|The patient recived surgury of radical hysterectomy.
62728917|NCT01184677|PLACEBO_COMPARATOR|Group size 4|
62728918|NCT01184677|EXPERIMENTAL|Group size 3|ProSeal LMA size 3 is inserted to the patients of Group size 3.
62728919|NCT02872870||Control adults|lexical tests and electroencephalogram (EEG).
62728920|NCT02872870||Dyslexic patients|lexical tests
62728921|NCT02872870||Dysphasic patients|lexical tests
62728922|NCT04486547|NO_INTERVENTION|Follow up Posttest and HbA1c|56.0% of the adolescents with type 1 diabetes were aged 12-14 years and 52.0% were male in the control group (n=25)
62728923|NCT04486547|EXPERIMENTAL|Information Motivation Behavioral Skills Based Intervention|52.0% of the adolescents with type 1 diabetes were aged 15-18 years and 52.0% were female(n=25)
62728924|NCT05653401|ACTIVE_COMPARATOR|Magnesium Sulfate|Intravenous Magnesium Sulfate combined to Diclofenac
62728925|NCT05653401|ACTIVE_COMPARATOR|Lidocaine|Intravenous lidocaine combined to Diclofenac
62728926|NCT05653401|ACTIVE_COMPARATOR|Diclofenac|Intramuscular Diclofenac alone
62728927|NCT03998800|EXPERIMENTAL|L-arginine and L-citrulline|10 days of supplementation with 1.5 g of L-arginine and 1.5 g of L-citrulline per day
62728928|NCT03998800|EXPERIMENTAL|L-arginine|10 days of supplementation with 3 g of L-arginine per day
62728929|NCT03998800|PLACEBO_COMPARATOR|Placebo (corn-starch)|10 days of supplementation with corn-starch
62728930|NCT04037098|EXPERIMENTAL|Magnesium|Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
62728931|NCT04037098|PLACEBO_COMPARATOR|Control|2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.
62728932|NCT03263325||AKI Group|Patients developing AKI after surgery
62728933|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
62728934|NCT00502580||1|Patients with lesions of the oral cavity mucosa.
62728935|NCT00004891|EXPERIMENTAL|primary resectable rectal cancer|
62728936|NCT02824393|EXPERIMENTAL|Mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
62728937|NCT02824393|NO_INTERVENTION|Control patients|The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell.
62728938|NCT06084000|EXPERIMENTAL|Drug-coated balloon dominant strategy|"* Patients will receive DCB (Bingo©, Yinyi Ltd., China) only if pre-dilation of the lesion was successful, or otherwise receive bailout stenting.~* If bailout stenting is indicated, patients will receive any type of commercially available 2nd Gen DES at physician's preference."
62728939|NCT06084000|ACTIVE_COMPARATOR|Drug-eluting stent only strategy|-For conventional stenting, patients will receive any type of commercially available 2nd Gen DES at physician's preference.
62728940|NCT02782585|EXPERIMENTAL|Experimental group 1|Cervical Manipulation
62728941|NCT02782585|EXPERIMENTAL|Experimental group 2|Cervical lateral glide
62728942|NCT02782585|PLACEBO_COMPARATOR|Control group|Cervical Mobilisation
62728943|NCT04318054|EXPERIMENTAL|Immediate intervention group|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, in the 2 months following the randomization, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
62728944|NCT04318054|OTHER|Deferred intervention group|Deferred intervention group : fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, one year after the inclusion, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
62728945|NCT03182283|NO_INTERVENTION|Pre-intervention|All patients at the psychosis wards receive care as usual before staff goes through educational intervention.
62728946|NCT03182283|OTHER|Post-intervention|After staff attended educational intervention and implemented Person-centered psychosis care in the wards all patients admitted will receive person-centered care.
62728947|NCT02574988||SCAR Patients|Patients diagnosed with severe cutaneous adverse reactions with be recruited
62728948|NCT04124094|EXPERIMENTAL|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg|Test Product
62728949|NCT04124094|ACTIVE_COMPARATOR|SERETIDE DISKUS 100/50|reference Product
62728950|NCT05631171|EXPERIMENTAL|Solution group|The study sample will consist of 60 patients, 30 of whom will be randomly assigned to a control group and 30 to the experimental group. Validated questionnaires will be administered to the participants of both groups, at the beginning of the study, at 1 month and 3 months by Microsoft Forms. In addition, the experimental group will be given a smartwatch to each person which will collect real-time data on activity, training and sleep in a completely anonymous way. Also, through a mobile application, the patient of the experimental group will answer questionnaires about health status perception. The application has also been trained to provide educational content and motivational messages to support the patient's self-management. The data provided by patients in both groups of the study will be coded, in order to maintain the confidentiality of the individual.
62728951|NCT05631171|NO_INTERVENTION|Control group|The study sample will consist of 60 patients, 30 of whom will be randomly assigned to a control group and 30 to the experimental group. Validated questionnaires will be administered to the participants of both groups, at the beginning of the study, at 1 month and 3 months by Microsoft Forms.
62728952|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points~Phone follow-up"
62728953|NCT02185261|EXPERIMENTAL|interferon Alfa-2b group|Acute leukemia patients who are minimal residual disease positive after hematopoietic stem cell transplantation receive interferon Alfa-2b
62728954|NCT04684940|EXPERIMENTAL|Valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg in Active Inhibitor Population (Part A) and Prior Inhibitor Population (Part B).
62728955|NCT01360814||GROUP A (multidisciplinary intervention)|Patients receive six 90-minute sessions of a multidisciplinary structured intervention comprising physical therapy, education, a cognitive-behavioral intervention, discussion and support, spiritual reflection, and a relaxation exercise over 2-4 weeks. Caregivers are invited to sessions 1, 3, 4, and 6. Patients may also receive brief telephone contact during the 6 month follow-up period.
62728956|NCT01360814||GROUP B (standard medical care)|Patients receive standard medical care only. Patients may also receive brief telephone contact during the 6 month follow-up period.
62728957|NCT05163327||Healthy Volunteer|10 Volunteers (Male or Female), aged18 or over, with no known history of Coronary Artery Disease
62737952|NCT02253433|EXPERIMENTAL|Enhanced Clinic Care|This arm receives enhanced in-clinic care only.
62728958|NCT05163327||Known Coronary Artery Disease|10 Volunteers (Male orFemale), aged 18 or over,with a known significant (defined as =\> 70% stenosis) single or 2 vessel Coronary Artery Disease
62728959|NCT01558115|EXPERIMENTAL|Denosumab - Group #1|Receive active drug for year 1 and year 2 of the study
62728960|NCT01558115|PLACEBO_COMPARATOR|Placebo - Group #2|Receive placebo for year 1 and active drug for year 2 of the study
62728961|NCT05321017|EXPERIMENTAL|MEP Wrist Extensor Up-Conditioning|
62728962|NCT01901484|ACTIVE_COMPARATOR|Drug: Praziquantel|Praziquantel 40mg/Kg - single dose
62728963|NCT01901484|ACTIVE_COMPARATOR|Praziquantel|double dose
62728964|NCT05547087|EXPERIMENTAL|Group 1: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a.
62728965|NCT05547087|EXPERIMENTAL|Group 2: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
62728966|NCT05547087|EXPERIMENTAL|Group 3: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
62728967|NCT05547087|EXPERIMENTAL|Group 4: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
62728968|NCT05547087|EXPERIMENTAL|Group 5: VN-0200 medium dose|Healthy elderly subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a.
62728969|NCT05547087|EXPERIMENTAL|Group 6: VN-0200 medium dose|Healthy elderly subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
62728970|NCT05547087|ACTIVE_COMPARATOR|Group 7: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a.
62728971|NCT05547087|EXPERIMENTAL|Group 8: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
62728972|NCT05547087|EXPERIMENTAL|Group 9: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
62728973|NCT05547087|EXPERIMENTAL|Group 10: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
62728974|NCT05716867||Children with early childhood caries aged between 36-71 month|
62728975|NCT05716867||Caries free children aged between 36-71 month|
62728976|NCT05496985|EXPERIMENTAL|Patients in coma|Patients in coma were assessed by the SECONDs and CRS-R for five days.
62728977|NCT05496985|EXPERIMENTAL|Patients in unresponsive wakefulness syndrome|Patients in unresponsive wakefulness syndrome were assessed by the SECONDs and CRS-R for five days.
62728978|NCT05496985|EXPERIMENTAL|Patients in minimally conscious state|Patients in minimally conscious state were assessed by the SECONDs and CRS-R for five days.
62728979|NCT05496985|EXPERIMENTAL|Patients in emerge from the minimally conscious state|Patients in emerge from the minimally conscious state were assessed by the SECONDs and CRS-R for five days.
62728980|NCT00881530|ACTIVE_COMPARATOR|Sitagliptin|100 mg
62728981|NCT00881530|ACTIVE_COMPARATOR|Metformin|2000 mg
62728982|NCT00881530|EXPERIMENTAL|BI 10773 X mg|lower dose
62728983|NCT00881530|EXPERIMENTAL|BI 10773 Y mg|higher dose
62728984|NCT05604144|OTHER|Active Treatment|As a Proof of Concept Study, 5 subjects will follow the same protocol, with one cryoanalgesic treatment (iovera°®) with a 6 month clinical follow-up.
62728985|NCT00399607||Aim 1|Participants previously randomized for the parent study will be eligible for a portion of the adjunct biomarker study.
62728986|NCT00399607||All aims|Participants entering the parent study will be eligible for all sample collections of the adjunct biomarker study.
62728987|NCT06023121||Cases|Gastric cancer cases from two medical centers in China
62728988|NCT06023121||Controls|Controls from two medical centers in China
62728989|NCT00486356|EXPERIMENTAL|Capecitabine, Epirubicin, and Carboplatin|Determine the recommended phase II dose of capecitabine when given together with epirubicin and carboplatin in treating patients with progressive, unresectable, or metastatic cancer.
62728990|NCT03411018||Conventional respiratory managed group.|Preterm infants born with less than 32 weeks gestational age (wGA) that entered in the neonatal Intensive care unit (NICU) from January 1 2012 to December 31 2013. These preterm infants were managed according to prior ventilatory protocol: Prophylactic Continuous positive airway pressure (CPAP) in delivery room, early surfactant administration by INSURE technique and volume target mechanical ventilation with rescue high frequency ventilation when needed. Mechanical ventilation exposure will be analyzed
62728991|NCT03411018||Less invasive managed group|Preterm Infants born with less than 32wGA that entered the NICU from January 1 2014 to December 31 2017. This infants are managed according to the actual ventilatory protocol. Prophylactic CPAP in delivery room, early surfactant administration by less invasive technique, nasal Synchronized positive pressure ventilation for CPAP failure and early rescue high frequency ventilation with minimally target volume.Mechanical ventilation exposure will be analyzed
62728992|NCT04194892|EXPERIMENTAL|Pegilodecakin Vial|Pegilodecakin administered subcutaneously (SQ) in one of two study periods.
62728993|NCT04194892|EXPERIMENTAL|Pegilodecakin Pre-filled syringe (PFS)|Pegilodecakin administered SQ in one of two study periods.
62728994|NCT04420052|EXPERIMENTAL|OMT group|
62728995|NCT04420052|PLACEBO_COMPARATOR|Placebo group|
62728996|NCT05253742||Pregnant women presenting for MRI|Alternative motion-robust MR imaging sequences and procedures for automatic positioning while be tested during fetal brain imaging
62728997|NCT03761589|EXPERIMENTAL|AFL Intervention Group|The AFL intervention consisted of twice a week physical activity and nutrition sessions for children and twice a week educational and physical activity sessions for parents. Each session lasted 90 minutes and all sessions were conducted in a municipal recreation center. The child program was delivered in English while the parent program was delivered in separate English-only or Spanish-only classes.
62728998|NCT03761589|OTHER|Wait-List Control Group|The wait-list control group received the 12-week AFL intervention after all follow-up data had been completed.
62728999|NCT01168843||normal pregnant|
62729000|NCT06554600|EXPERIMENTAL|Pola-ZBR treatment|Relapsed/refractory DLBCL were treated with 4 courses of Pola-ZBR regimen. Subjects achieving PR or CR were consolidated with autologous transplantation consolidation or the original regimen for 2 additional courses, and then given Zanubrutinib maintenance therapy for 1 year.
62729001|NCT03862612|ACTIVE_COMPARATOR|Erector Spinae Plane Block|This group will receive an Erector Spinae Plane Block under ultrasound guidance while under General Anaesthesia
62729002|NCT03862612|EXPERIMENTAL|Serratus Anterior Plane Block|This group will receive a Serratus Anterior Plane Block under ultrasound guidance while under General Anesthesia
62729003|NCT03399864|EXPERIMENTAL|Experimental group|Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
62729004|NCT03399864|OTHER|Control group|The subjects will receive usual care, such as medical follow-up according to the schedule of the oncology units.
62729005|NCT00792311|EXPERIMENTAL|Tsui test|Tsui test administration.
62729006|NCT05071612|EXPERIMENTAL|AD109 Dose 1|
62729007|NCT05071612|EXPERIMENTAL|AD109 Dose 2|
62729008|NCT05071612|EXPERIMENTAL|AD504 Dose 1|
62729009|NCT05071612|EXPERIMENTAL|AD504 Dose 2|
62729010|NCT05071612|ACTIVE_COMPARATOR|Atomoxetine 1|
62729011|NCT05071612|ACTIVE_COMPARATOR|Atomoxetine 2|
62729012|NCT05071612|PLACEBO_COMPARATOR|Placebo 1|
62729013|NCT05071612|PLACEBO_COMPARATOR|Placebo 2|
62729014|NCT03122145|EXPERIMENTAL|Healthy Volunteers - Experiment 1|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo voluntary and reflexive cough testing. The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
62729015|NCT03122145|EXPERIMENTAL|Healthy Volunteers - Experiment 2|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
62729016|NCT06448130|EXPERIMENTAL|Henagliflozin5mg + lifestyle intervention|Henagliflozin 5mg+ placebo 10mg po qd + lifestyle intervention for 6 months
62729017|NCT06448130|EXPERIMENTAL|Henagliflozin10mg+ lifestyle intervention|Henagliflozin 10mg+ placebo 5mg po qd + lifestyle intervention for 6 months
62729018|NCT06448130|PLACEBO_COMPARATOR|placebo+ lifestyle intervention|placebo 10mg + placebo 5mg po qd + lifestyle intervention for 6 months
62729019|NCT02284256|EXPERIMENTAL|Fibrocaps|"Human fibrinogen and thrombin powder. Single application during surgery~Other Names:~* Raplixa~* PRO-0601~* Fibrin sealant~Device: Gelatin sponge. Single application during surgery~Other Name: Spongostan"
62729020|NCT02284256|ACTIVE_COMPARATOR|TachoSil|Human fibrinogen and thrombin powder. Single application during surgery
62729021|NCT03686930|ACTIVE_COMPARATOR|Cohort 1 - FP-045 oral solution|FP-045 powder for oral solution, will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
62729022|NCT03686930|PLACEBO_COMPARATOR|Cohort 1 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
62729023|NCT03686930|ACTIVE_COMPARATOR|Cohort 2 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
62729024|NCT03686930|PLACEBO_COMPARATOR|Cohort 2 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
62729025|NCT03686930|ACTIVE_COMPARATOR|Cohort 3 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
61978250|NCT05264155|PLACEBO_COMPARATOR|Control: one-size-fits-all|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the control group, the parameter values of the dynamic tasks were based on national guidelines."
62729026|NCT03686930|PLACEBO_COMPARATOR|Cohort 3 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
62729027|NCT04650997|EXPERIMENTAL|Combined|12 weeks eccentric exercise combined with 6 sessions of extracorporeal shockwave therapy in the initial 6 weeks
62729028|NCT04650997|SHAM_COMPARATOR|Exercise|12 weeks eccentric exercise combined with 6 sessions of sham extracorporeal shockwave therapy in the initial 6 weeks
62729029|NCT00815048|ACTIVE_COMPARATOR|Remifentanil|"Atropine~Remifentanil"
62729030|NCT00815048|PLACEBO_COMPARATOR|Fentanyl|"Atropine~Fentanyl~Succinylcholine"
62729031|NCT04980586||Non-OSA Groups|Participants with apnea-hypopnea index \< 5 events per hour of sleep.
62729032|NCT04980586||Mild OSA Group|Participants with apnea-hypopnea index \> 5 \< 15 events per hour of sleep.
62729033|NCT04980586||Moderate OSA group|Participants with apnea-hypopnea index \> 15 \< 30 events per hour of sleep.
62729034|NCT04980586||Severe OSA Group|Participants with apnea-hypopnea index \> 30 events per hour of sleep.
62729035|NCT01789359|OTHER|anthocyanin-free diet|Maintain anthocyanin-free diet throughout study. Day 1 to day 30, consume daily 250 ml single strength blueberry juice containing 229 mg anthocyanins, taken either as 1 morning dose or 1/3 dose morning, 1/3 mid-day and 1/3 evening. At d 31-38 continue anthocyanin-free diet. On d 39 consume daily dose.
62729036|NCT06011317|EXPERIMENTAL|Part A: Healthy Volunteer (Ages ≥ 18 to < 60 years) Single Ascending Dose|Single oral ascending dose in healthy volunteers ages ≥ 18 to \< 60 years
62729037|NCT06011317|EXPERIMENTAL|Part B: Healthy Volunteer (Ages ≥ 18 to < 60 years) Multiple Ascending Doses|Multiple oral ascending doses in healthy volunteers ages ≥ 18 to \< 60 years
62729038|NCT06011317|EXPERIMENTAL|Part D: Healthy Volunteer Food Effect and Relative Bioavailability|Crossover food effect (fed versus fasted) single oral dose in healthy volunteers and relative bioavailability of liquid versus solid formulation
62729039|NCT03298698|EXPERIMENTAL|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
62729040|NCT03298698|ACTIVE_COMPARATOR|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
62729041|NCT04981964|EXPERIMENTAL|Conventional physical therapy plus forward walking|25 minutes of the forward walking training program It is based on methods as described by Grecco et al. (2013) The children were instructed to walk at a comfortable, self-selected speed during the first and final five minutes of the session and encouraged to increase the speed during the other 15 minutes.
62729042|NCT04981964|EXPERIMENTAL|Conventional physical therapy plus backward walking|25minutes of the backward walking training It is based on methods as described by Davis (1992) Firstly, the subject is asked to take a step backwards within the parallel bar and can support him or herself with the unaffected hand as required. The therapist provides help to move the subject's leg in the correct pattern, preventing subject from moving the leg back in full extension, when the subject can move the leg back with the correct pattern, the therapist gradually reduces the amount of assistance. Secondly, as the movement components have been practiced and the subjects has taken over actively with only slight help, the therapist facilitates walking backward within the parallel bars. Thirdly, the subject walks backwards actively away from the parallel bars. Finally, the distance and speed of walking backwards is progressively increased.
62729043|NCT05920811|ACTIVE_COMPARATOR|conventional obturator|maxillary obturator fabricated from cast metal framework, heat-cured acrylic resin
62729044|NCT05920811|EXPERIMENTAL|3 d printed obturator|3d printed obturator with full digital workflow ( intraoral scanning, made of selective laser melting, 3d printed resin
62729045|NCT04763889|EXPERIMENTAL|CBT workshop|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. In the intervention group participants will attend a day workshop or two half day workshops focused on using CBT to manage their anxiety and stress.
62729046|NCT04763889|NO_INTERVENTION|Self-help control treatment as usual group|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. Participants in the treatment as usual group will receive the workshop materials after the active treatment group have completed their final follow-up at 3 months
62729047|NCT03225248|EXPERIMENTAL|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
62729048|NCT03225248|ACTIVE_COMPARATOR|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
62729049|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
62729050|NCT03343340|EXPERIMENTAL|Early CRRT|Early Continous Renal Replacement Therapy within 6 hours + Standard Medical Therapy
62729051|NCT03343340|ACTIVE_COMPARATOR|Late CRRT|Late Continous Renal Replacement Therapy + Standard Medical Therapy
62729052|NCT02012036||TUR-B|TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).
62729053|NCT04165551|EXPERIMENTAL|Probiotic|Volunteers will take 1 capsule per day containing 6x109 cfu of Lactobacillus BSL_PS71 in maltodextrin.
62729054|NCT04165551|PLACEBO_COMPARATOR|Placebo|Volunteers will take 1 capsule per day containing maltodextrin.
62729055|NCT01393210|ACTIVE_COMPARATOR|low-calorie diet|Intervention was low-calorie diet only for 12 weeks.
62729056|NCT01393210|ACTIVE_COMPARATOR|low calorie diet plus beta-glucan|Intervention was low-calorie diet plus BETA-GlLUCAN 1.3D-1.6D 500 mg daily for 12 weeks.
62729057|NCT04929353|OTHER|ARM A|Self-Reporting by electronic survey consisting of 14 items selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0)
62729058|NCT04929353|OTHER|Arm B|Standard symptom reporting following the conventional modalities of clinical oncology practice
62729059|NCT04878107|EXPERIMENTAL|SBRT/LDRT + Camrelizumab +Apatinib|SBRT（8Gy×3f） LDRT（2Gy×5f） Camrelizumab（200mg，q3w） Apatinib （250mg，qd）
62729060|NCT04878107|ACTIVE_COMPARATOR|SBRT + docetaxel|docetaxel 75mg/m2 SBRT（8Gy×3f）
62729061|NCT04531956|NO_INTERVENTION|Before group|In the before group (BG) GPs will execute care as usual in the decision-making process for a diagnostic trajectory for memory complaints.
62729062|NCT04531956|ACTIVE_COMPARATOR|After group|In the after group (AG), a patient decision aid will be added to the decision-making process provided by the GP.
62729063|NCT01456793|EXPERIMENTAL|Teen Options to Prevent Pregnancy|
62729064|NCT01456793|NO_INTERVENTION|Usual care services|
62729065|NCT02569463|EXPERIMENTAL|Low-does rhIL-2 therapy|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks
62729066|NCT04202068|EXPERIMENTAL|Ceftriaxone sodium and Sulbactam Sodium for injection|combinations of β-Lactamase inhibitors
62729067|NCT03069742|EXPERIMENTAL|Decision Aid|Women at high risk for developing breast cancer will use a decision support tool, RealRisks, that facilitates discussion of breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
62729068|NCT03069742|NO_INTERVENTION|Control Group|Women at high risk for developing breast cancer will receive standard breast health education brochures.
62729069|NCT01487486||Normal patients|Women with infertility diagnosis of male factor only or women who are oocyte donors
62729070|NCT01487486||Polycystic Ovary Syndrome, High BMI|Women with Polycystic Ovary Syndrome with a BMI between 30-35
62729071|NCT01487486||Polycystic Ovary Syndrome, Low BMI|Women with Polycustic Ovary Syndrom with a BMI between 20 \& 25
62737161|NCT04381624|EXPERIMENTAL|Transcutaneous Vagal Stimulation|TVS will be applied through a portable electrostimulation equipment during the whole session in each of the treatment sessions. The electrodes will be placed in the left ear, specifically in the auricular concha. The device will be programmed with a biphasic square current at an intensity that produces a clear tingling sensation that is neither uncomfortable nor painful, with pulses of 300 microseconds, at 25 Hertz, the stimulus will be present for 30 seconds and will be followed by a 30-second rest period repeating this for approximately one hour.
62729072|NCT05605730|ACTIVE_COMPARATOR|Traditional exercise management|"1. Prone back extension.~2. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~3. Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~4. Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~5. Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~6. Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
62729073|NCT05605730|EXPERIMENTAL|Maitland mobilization for thoracic spine|This group will receive the previously mentioned exercises protocol targeting shoulder joint in addition to Maitland mobilization for thoracic spine.
62729074|NCT05605730|EXPERIMENTAL|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Treatment would be administered at the vertebral level revealed during the evaluation of thoracic SNAG.
62729075|NCT04714866|EXPERIMENTAL|Interventional group|Cognitive behavioral therapy for ADHD
62729076|NCT04714866|NO_INTERVENTION|waiting list group|No Intervention for the waiting list group
62729077|NCT02445014|EXPERIMENTAL|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
62729078|NCT00330304|EXPERIMENTAL|Isoniazid preventive therapy|HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
62729079|NCT00330304|PLACEBO_COMPARATOR|Placebo|HIV infected children living in a high TB prevalence area receive placebo once daily
62729080|NCT00612976||1|Patients with COPD treated with budesonide/formoterol
62729081|NCT04021316|ACTIVE_COMPARATOR|Standard care arm|Compression bandaging therapy as per standard care
62729082|NCT04021316|EXPERIMENTAL|DCD Arm|DCD graft plus compression bandaging therapy as per standard care
62729083|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
62729084|NCT02060929|EXPERIMENTAL|Sequence 1|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal (through nose) device with a nasal guide on Day 1 of period 1 as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
62729085|NCT02060929|EXPERIMENTAL|Sequence 2|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide on Day 1 of period 1 as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device with a nasal guide as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
62729086|NCT02648594|EXPERIMENTAL|Intervention: Hook wire CT guided|"There is only one arm. When patient undergo surgery , the radiologist will place a CT-guided Hook wire in order to localize it in patient lung. The intervention consists to place a CT-guided hook wire in contact with the pulmonary nodule under local anesthesia.~Then, the thoracoscopy will be realised. Then, the surgery piece will be examined to confirm if the node is in the surgery piece"
62729087|NCT01056081|EXPERIMENTAL|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
62729088|NCT02688270|EXPERIMENTAL|Treatment Sequence A|Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream
62729089|NCT02688270|EXPERIMENTAL|Treatment Sequence B|Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vehicle cream, Vascana® (0.9% nitroglycerin cream)
62729090|NCT02688270|EXPERIMENTAL|Treatment Sequence C|Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream)
62729091|NCT02688270|EXPERIMENTAL|Treatment Sequence D|Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vascana® (0.9% nitroglycerin cream), Vehicle cream
62729092|NCT00386620||Survey + ED|"Part 1: Survey + Electronic Diaries (ED)~Part 2: 3 Month, 6 Month Survey + ED"
62729093|NCT06368843||the 1st group (K group)|the 1st group (K group) consisted of 46 patients who were instructed to gargle with a ketamine solution
62729094|NCT04075305||Brain cancer|
62729095|NCT04075305||Lung cancer|
62729096|NCT04075305||Esophageal cancer|
62729097|NCT04075305||Breast Cancer|
62729098|NCT04075305||Head and Neck Cancer|
62729099|NCT04075305||Pancreatic cancer|
62729100|NCT04075305||Gynecological cancer|
62729101|NCT04075305||Rectal cancer|
62729102|NCT04075305||Prostate cancer|
62729103|NCT04075305||Bladder cancer|
62729104|NCT04075305||Oligometastases|
62729105|NCT04075305||Liver cancer|
62729106|NCT04075305||Other types of cancer|
62729107|NCT01815424|PLACEBO_COMPARATOR|Placebo BID|
62729108|NCT01815424|EXPERIMENTAL|5mg BID CP-690,550|
62729109|NCT01815424|EXPERIMENTAL|10mg BID CP-690,550|
62729110|NCT05957458|EXPERIMENTAL|Moderate irradiance of PBM therapy to myopia|The PBM therapy irradiance is about 0.60mW. It is asked subjects to look at the light binocularly with fusion through the pupils with natural pupils. The distance between the light and the pupils is about 5\~10cm. The treatment of each session is 3 minutes and twice daily administration while the interval time between two session is equal or larger than 4 hours with twice daily administration.
62729111|NCT05957458|SHAM_COMPARATOR|Extra low irradiance PBM therapy group|The PBM therapy irradiance is about 0.37mW. It is asked subjects to look at the light binocularly with fusion through the pupils with natural pupils. The distance between the light and the pupils is about 5\~10cm. The treatment of each session is 3 minutes and twice daily administration while the interval time between two session is equal or larger than 4 hours with twice daily administration.
62729112|NCT05957458|EXPERIMENTAL|high lever PBM therapy group|The PBM therapy irradiance is about 1.20mW. It is asked subjects to look at the light binocularly with fusion through the pupils with natural pupils. The distance between the light and the pupils is about 5\~10cm. The treatment of each session is 3 minutes and twice daily administration while the interval time between two session is equal or larger than 4 hours with twice daily administration.
62729113|NCT05957458|NO_INTERVENTION|Control|Without PBM therapy group.
62729114|NCT01791660|EXPERIMENTAL|Zeltiq Coolsculpting System|non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
62729115|NCT03483792||PCOS group|
62729116|NCT03483792||Control group|
62729117|NCT04363242|EXPERIMENTAL|Part A|Dose escalation of SYN125. Each dose level (low, medium, high) will be tested in a cohort of 3 patients. If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next SYN125 dose level.
62729118|NCT04363242|EXPERIMENTAL|Part B|Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated). Once cohorts with low and medium dose levels in Part A are completed and no DLTs are observed per cohort, Part B with the SYN125 low dose level + SYN004 will start and run in parallel with Part A. The high dose of SYN125 in a cohort in Part A will begin along with Part B.
62729119|NCT06046092|EXPERIMENTAL|Vaccinated|Participants will be allocated to one of 3 dose groups, each receiving two intradermal (i.d.) vaccinations with 0.12 mg, 0.60 mg, or 3.00 mg of H7HLAII, respectively.
62729120|NCT01295944|EXPERIMENTAL|1/Carboplatin and Bevacizumab for Recurrent Ependymoma|The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician.
62729121|NCT02594007|EXPERIMENTAL|discharge home|SEEQ for 28 days. Cardiocom for 30 days
62729122|NCT02594007|EXPERIMENTAL|discharge to skilled nursing facility|SEEQ for 28 days, DocView for 30 days
62729123|NCT02501681|ACTIVE_COMPARATOR|crystalloid|Group A (n=20); crystalloid as priming solution used in patients,
62729124|NCT02501681|ACTIVE_COMPARATOR|colloid|Group B (n=20); colloids as priming solution used in patients
62729125|NCT02110485|EXPERIMENTAL|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
62729126|NCT02110485|NO_INTERVENTION|Standard Consultation|Patients and their caregivers will receive standard consultation alone
62729127|NCT05370027|EXPERIMENTAL|1st Group|With the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be taken and the application will be made from the right ear. Then, the application will be performed on both ears with a 48-hour break.
62729128|NCT05370027|EXPERIMENTAL|2nd Group|With the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the right ear with a break for 48 hours.
62729129|NCT05370027|EXPERIMENTAL|3rd Group|With the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be taken and the application will be made from the left ear. Then, the application will be performed on both ears with a 48-hour break.
62729130|NCT05370027|EXPERIMENTAL|4th Group|With the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the left ear with a break for 48 hours.
62729131|NCT05370027|EXPERIMENTAL|5th Group|With the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the left ear. Then, the application will be performed on the right ear with a break for 48 hours.
62729132|NCT05370027|EXPERIMENTAL|6th Group|With the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the right ear. Then, the application will be performed on the left ear with a break for 48 hours.
62729133|NCT00858351|EXPERIMENTAL|Thermal Biofeedback Assisted Relaxation|
62729134|NCT00858351|ACTIVE_COMPARATOR|Discussion|
62729135|NCT00841412|EXPERIMENTAL|Immediate Intervention Group|Immediate Intervention: Long term care units assigned to the Immediate Intervention group were first to receive the staff training and management intervention to improve nutritional care processes.
62729136|NCT00841412|ACTIVE_COMPARATOR|Delayed Intervention Group|Delayed Intervention: Long term care units assigned to the Delayed Intervention group were monitored under usual care conditions to serve as a control for the Immediate Intervention group. Then, these units received the staff training and management intervention at a later date.
62729137|NCT04792034|EXPERIMENTAL|Active|Active: FDA Approved Golprelto (Cocaine Hydrochloride Topical Solution)
62729138|NCT03973112|EXPERIMENTAL|HLX10 3 mg/kg + HLX04 5 mg/kg|HLX10 3 mg/kg + HLX04 5 mg/kg, as second-line treatment or above
62729139|NCT03973112|EXPERIMENTAL|HLX10 3 mg/kg + HLX04 10 mg/kg|HLX10 3 mg/kg + HLX04 10 mg/kg,as second-line treatment or above
62729140|NCT03973112|EXPERIMENTAL|HLX10|HLX10 3mg/kg, as second-line treatment or above
62729141|NCT03973112|EXPERIMENTAL|HLX10+HLX04 1L treatment|HLX10 3 mg/kg + HLX04 10 mg/kg: as first-line treatment
62729142|NCT05524636|EXPERIMENTAL|Experimental|Exercise with peripheral magnetic stimulation of the abdominal wall muscles
62729143|NCT05524636|ACTIVE_COMPARATOR|Control|Exercise without peripheral magnetic stimulation of the abdominal wall muscles
62737162|NCT04381624|PLACEBO_COMPARATOR|Sham Transcutaneous Vagal Stimulation|The device will be configured with the same parameters and intensity of the real TVS. However the device will be located in the left ear lobe.
62737163|NCT06400589|EXPERIMENTAL|0.25% tanfanercept|0.25% tanfanercept ou bid for 12 weeks
62729144|NCT00730353|EXPERIMENTAL|1|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.~* Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.~* Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion."
62729145|NCT04755764||Beta blockade|Beta blocker (labetalol or atenolol) will be given for a cardiac output \>8 l/min.
62729146|NCT04755764||Nifedipine|Nifedipine will be given for a mean arterial pressure \>100.
62729147|NCT03072472|EXPERIMENTAL|Endocuff-assisted Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope
62729148|NCT03072472|NO_INTERVENTION|Standard Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope
62729149|NCT06473298|EXPERIMENTAL|Visual light tracking program|Visual light tracking program
62729150|NCT06473298|EXPERIMENTAL|Selective physical therapy program|Selective physical therapy program
62729151|NCT04661111|EXPERIMENTAL|Hymovis ONE Arm|Hymovis® ONE (32 mg/4 ml) intra-articular mono injection. Patients will be followed during 12 months including 6 visits.
62729152|NCT01869634|ACTIVE_COMPARATOR|HIV positive naive to ART|HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
62729153|NCT01869634|NO_INTERVENTION|normal control volunteers|HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
62729154|NCT02725476|EXPERIMENTAL|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
62729155|NCT01218217|EXPERIMENTAL|SQ109 75 mg|75 mg SQ109 monotherapy daily
62729156|NCT01218217|EXPERIMENTAL|SQ109 150 mg|150 mg SQ109 daily
62729157|NCT01218217|EXPERIMENTAL|SQ109 300 mg|300 mg SQ109 daily
62729158|NCT01218217|EXPERIMENTAL|SQ109 150 mg + RIF|150 mg SQ109 + RIF standard dose daily
62729159|NCT01218217|EXPERIMENTAL|SQ109 300 mg + RIF|300 mg SQ109 + RIF standard dose daily
62729160|NCT01218217|ACTIVE_COMPARATOR|RIF Mono|Standard dose Rifampicin monotherapy daily
62729161|NCT01943786||FOLFIRI + Cetuximab|Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
62729162|NCT03614598|ACTIVE_COMPARATOR|LMA-UNIQUE™|
62729163|NCT03614598|ACTIVE_COMPARATOR|LMA-SUPREME™|
62729164|NCT03614598|ACTIVE_COMPARATOR|I-GEL®|
62729165|NCT03267784|EXPERIMENTAL|Experimental: allo-APZ2-DFU|Application of IMP on patients wound
62729166|NCT04388215|EXPERIMENTAL|Treatment group|"Drug: CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg~- CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
62729167|NCT04388215|ACTIVE_COMPARATOR|Comparator group 1|"Drug: CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D013(placebo) 80mg~- CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D337(placebo) 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
62729168|NCT04388215|ACTIVE_COMPARATOR|Comparator group 2|"Drug: CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg~- CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg, orally, 1 tablet once a day for 8 weeks"
62729169|NCT05980065|EXPERIMENTAL|Dose level 1|C1K 150mg
62729170|NCT05980065|EXPERIMENTAL|Dose level 2|C1K 300mg or placebo
62729171|NCT05980065|EXPERIMENTAL|Dose level 3|C1K 600mg or placebo
62729172|NCT05980065|EXPERIMENTAL|Dose level 4|C1K 900mg or placebo
62729173|NCT05980065|EXPERIMENTAL|Dose level 5|C1K 1200mg or placebo
62729174|NCT06149923||cases|Patients that histopathologically confirmed gastric and/or colorectal cancer, males and females.
62729175|NCT02733822|EXPERIMENTAL|IMP: buccal naloxone (single dose)|0.8 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
62729176|NCT02733822|EXPERIMENTAL|IMP: buccal naloxone (double dose)|1.6 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
62729177|NCT02733822|ACTIVE_COMPARATOR|Intramuscular (IM) reference|0.8 mg IM injection of 1 mg/ml Naloxone Hydrochloride Injection
62729178|NCT02733822|ACTIVE_COMPARATOR|Intravenous (IV) reference|0.8 mg IV injection of 1 mg/ml Naloxone Hydrochloride Injection
62729179|NCT04451200|EXPERIMENTAL|busulfan treatment|Personalized BU administration
62729180|NCT02941328|EXPERIMENTAL|Pyridostigmine|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
62729181|NCT02941328|PLACEBO_COMPARATOR|Placebo|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
62729182|NCT04365426|EXPERIMENTAL|Oral contraceptive (OC)|Oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
62729183|NCT04365426|EXPERIMENTAL|No oral contraceptive (No OC)|No oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
62729184|NCT06057805|EXPERIMENTAL|Blinded CGM|Blinded continuous glucose monitor Dexcom G7
62729185|NCT02549989|EXPERIMENTAL|LY3023414|This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.
62729186|NCT01618240||Long term ventilated subjects|Muscle Strength Measurement, ventilator
62737164|NCT06400589|EXPERIMENTAL|1.0% tanfanercept|1.0% tanfanercept ou bid for 12 weeks
62729187|NCT02039765|EXPERIMENTAL|Brimonidine tartrate|One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
62729188|NCT03976050|EXPERIMENTAL|Dose escalation|Subjects in the dose escalation cohorts will receive ascending doses of HL-085 until the MTD is determined. The first three subjects will receive twice-daily doses (BID) of HL-085 6 mg. Additional cohorts may receive doses of HL-085 9, 12 or 18 mg BID respectively and sequentially. If DLTs are observed in \<33.3% of subjects at the 18 mg dose.
62729189|NCT05050292|EXPERIMENTAL|Experimental Group|"Activities are designed to target specific cognitive skills (attention, perception, inhibition).~An internal algorithm of the cognitive stimulation platform will adjust the activities' difficulty depending on the participant's performance, always demanding a maximum cognitive effort."
62729190|NCT05050292|ACTIVE_COMPARATOR|Control Group|"Painting and artistic activities not designed to target specific cognitive skills.~The internal algorithm will be deactivated, so the cognitive stimulation activities will be of constant difficulty throughout the intervention."
62729191|NCT04494828|EXPERIMENTAL|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/ kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
62729192|NCT04494828|PLACEBO_COMPARATOR|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
62729193|NCT02127554||Electric coagulation|Patients with anterior epistaxis, treated with electric coagulation
62729194|NCT02127554||Chemical coagulation|Patients with anterior epistaxis, treated with chemical coagulation
62729195|NCT02127554||Outpatient tamponade|Patients with posterior epistaxis, treated with tamponade as an outpatient
62729196|NCT02127554||Inpatient tamponade|Patients with posterior epistaxis, treated with tamponade and kept in the hospital.
62729197|NCT02127554||Surgery|Patients with posterior epistaxis, treated with surgery as inpatients
62729198|NCT02127554||Foley balloon catheter|Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter
62729199|NCT02127554||Combined treatment|Patients with posterior epistaxis, treated as inpatients with a combination of methods
62729200|NCT01542463||IDet users|
62729201|NCT03110211|EXPERIMENTAL|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
62729202|NCT03110211|EXPERIMENTAL|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
62729203|NCT02075086|EXPERIMENTAL|Chemotherapy treatment|Chemotherapy treatment with Xelox or Xeliri and bevacizumab
62729204|NCT05318495|EXPERIMENTAL|Standard Colonoscopy+CAD-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
62729205|NCT05318495|ACTIVE_COMPARATOR|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
62729206|NCT05318495|EXPERIMENTAL|Standard Colonoscopy+CAD-EYE+G-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
62729207|NCT05318495|ACTIVE_COMPARATOR|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE+G-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
62729208|NCT03902392|ACTIVE_COMPARATOR|NATUR-OX Group (A)|Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
62729209|NCT03902392|PLACEBO_COMPARATOR|Placebo Group (B)|Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
62729210|NCT04089852|EXPERIMENTAL|Inhaled nitrous oxide anesthesia|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The treatment group will receive inhaled N2O/O2. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2. N2O/O2 will be administered per Boston Children's Hospital (BCH) N2O sedation protocol. Prior to speculum placement, treatment group participants will receive the inhaled gas until minimal sedation is achieved per BCH sedation guidelines, such that the patient is cooperative, oriented, and tranquil. Inhaled N2O will be administered throughout the duration of the procedure."
62737165|NCT06400589|PLACEBO_COMPARATOR|Vehicle|Vehicle ou bid for 12 weeks
62737166|NCT05743127|EXPERIMENTAL|Group Conventional Expander|Conventional Laboratory Fabricated Hyrax Expander
62729211|NCT04089852|PLACEBO_COMPARATOR|Inhaled oxygen placebo|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The control group will receive inhaled O2 alone. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered throughout the duration of the procedure."
62729212|NCT01715363|EXPERIMENTAL|FOLFOX + surgery + FOLFOX|"* Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery~* resection of the colorectal tumor during surgery~* Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
62729213|NCT02137642|ACTIVE_COMPARATOR|RM-131|
62729214|NCT02137642|PLACEBO_COMPARATOR|Placebo|
62729215|NCT04744220|EXPERIMENTAL|Yoga Training Group|"Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session.~During the program, the perceived fatigue intensity of the patients will be questioned with the Modified Borg Scale.~Yoga Session~1-8 weeks and duration~* Breathing Exercises 5 min~* Instant Relaxation Technique 2 min~* Warm-up Exercises 10 min~* Quick Relaxation Technique 3 min~* Asanas (Posture Exercises) 15 min~* Alternative Breathing Exercises 10 min~* Deep Relaxation Technique 3 min"
62729216|NCT04744220|NO_INTERVENTION|Control group|"Training: The exercise program will include respiration exercises that they can do at home.~Before the exercise program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters and tests used in the evaluation. Respiratory control, breathing exercises, relaxation techniques and the reasons, importance and effects of exercise training in the treatment program will be explained.~Breathing Exercises (10 min) Pursed-lip breathing training, Chest breathing exercise (10 repetitions), Diaphragmatic breathing exercise (10 repetitions), Bilateral basal expansion breathing exercises (10 repetitions)"
62729217|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
62729218|NCT02948699|EXPERIMENTAL|Nutrition support|Nutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
62729219|NCT02948699|NO_INTERVENTION|Regular diet|Regular diet without other nutritional intervention.
62729220|NCT01795014||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an IOP above 21 mmHg that could suggest possible glaucoma suspects.
62729221|NCT01795014||Primary open-angle Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of \>21 mmHg required
62729222|NCT01795014||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of \< 21 mmHg
62729223|NCT02855879||CAD patients|
62729224|NCT06128850||Peri-implantitis|
62729225|NCT06128850||Peri-implant mucositis|
62729226|NCT06128850||Peri-implant health|
62729227|NCT05289089|EXPERIMENTAL|Positive Psychology Intervention Group|Participants will complete 9 weekly phone sessions with a study trainer and positive psychology exercises between phone sessions. Study trainers will review the positive psychology exercises with the participant on the phone each week. Participants will receive this intervention in addition to their treatment as usual.
62729228|NCT05289089|ACTIVE_COMPARATOR|Wait list Control Group|After waiting for 9 weeks, participants will complete 9 weekly phone sessions with a study trainer and positive psychology exercises between phone sessions. Study trainers will review the positive psychology exercises with the participant on the phone each week. Participants will receive this intervention in addition to their treatment as usual.
62729229|NCT03492502|EXPERIMENTAL|Allo-SCT patients with GI related GVHD|"Allo-SCT patients above 18 years of age with acute steroid-resistant GI-related GVHD grade III-IV.~The diagnosis of GVHD will be made on clinical grounds (in line with the major associations' recommendations) - the appearance of characteristic mucoid diarrhea within 100 days after Allo-SCT, with or without associated skin/liver involvement. In cases of atypical presentation - we will recommend biopsy or endoscopy for diagnosis. Patients suspected to have Clostridium difficille associated diarrhea will be tested for toxin (CDT).~Steroid-resistant GI-related GVHD will be defined as lack of improvement (same stage) or worsening of GI symptoms after 7 days of steroid therapy (≥ 2 ml/kg of IV methylprednisolone)."
62729230|NCT01926444|EXPERIMENTAL|GIC-1001 low dose|GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)
62729231|NCT01926444|EXPERIMENTAL|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
62729232|NCT01926444|EXPERIMENTAL|GIC-1001 , high dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
62729233|NCT01926444|PLACEBO_COMPARATOR|GIC-1001 matching placebo|Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)
62729234|NCT01583114|EXPERIMENTAL|perindopril|
62729235|NCT01583114|PLACEBO_COMPARATOR|placebo|same form, administration, posology, frequency and duration as perindopril
62729236|NCT05360251|EXPERIMENTAL|Pulsed dye laser(PDL)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
62729237|NCT05360251|EXPERIMENTAL|IPL(Delicate Pulsed Light)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
62729238|NCT05360251|EXPERIMENTAL|IPL(M22 590)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
62729239|NCT05360251|EXPERIMENTAL|IPL(M22 vascular filter)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
62729240|NCT05481983|OTHER|control group|Walk exercise
62729241|NCT05481983|ACTIVE_COMPARATOR|study group|One-on-one clinical exercise training
62729242|NCT02070328||Radiation therapy Registry|Cancer patients who have received proton therapy
62729243|NCT05822037|EXPERIMENTAL|CT0594CP CAR-T Cells[BCMA-UCAR-T(CT0594) and CD9-UCAR-T(CT7590)]|CT0594CP
62729244|NCT05881681|EXPERIMENTAL|App-Delivered Mindfulness Training (MT)|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
62729245|NCT02052869|OTHER|esophagus intubation|all patients will be intubated in the trachea first, with subsequent intubation in the esophagus. measurements will be performed on both tubes in a blinded manner.
62729246|NCT01251562|EXPERIMENTAL|Cohort 1|"5.62 mg/kg~Sterile Compound C31510 for Injection"
62729247|NCT01251562|EXPERIMENTAL|Cohort 2|"11.25 mg/kg~Sterile Compound C31510 for Injection"
62729248|NCT01251562|EXPERIMENTAL|Cohort 3|"22.5 mg/kg~Sterile Compound C31510 for Injection"
62729249|NCT01251562|EXPERIMENTAL|Cohort 4|33.0 mg/kg
62729250|NCT01251562|EXPERIMENTAL|Cohort 5|"44.0 mg/kg~Sterile Compound C31510 for Injection"
62729251|NCT01251562|EXPERIMENTAL|Cohort 6|"58.7 mg/kg~Sterile Compound C31510 for Injection"
62729252|NCT01251562|EXPERIMENTAL|Cohort 7|"78.2 mg/kg~Sterile Compound C31510 for Injection"
62729253|NCT01251562|EXPERIMENTAL|Cohort 8|"104.3 mg/kg~Sterile Compound C31510 for Injection"
62729254|NCT01251562|EXPERIMENTAL|Cohort 9|"139.0 mg/kg~Sterile Compound C31510 for Injection"
62729255|NCT02288299|EXPERIMENTAL|non invasive mechanical ventilation|Patients suffering from neuromuscular disease with NIV indication and cough inefficiency
62729256|NCT04826783|EXPERIMENTAL|Diode laser|
62729257|NCT04826783|EXPERIMENTAL|Er,Cr:YSGG laser|
62729258|NCT04826783|EXPERIMENTAL|Er:YAG LAser|
62729259|NCT03833557|ACTIVE_COMPARATOR|Nanohydroxyapatite Pulpotomy|"Biphasic calcium phosphate. Straumann BoneCeramic Regenerative Pulpotomy of 24 mandibular second primary molars using Nanohydroxyapatite~In Group 1: 24 mandibular second primary molars Caries removal and deroofing of pulp chamber Following the manufacturer's instructions, Nanohydroxyapatite was mixed with distilled water to homogeneous consistency then introduced into the pulp chamber and condensed properly against the pulp orifices.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six \& 12 months after the pulpotomy"
62729260|NCT03833557|ACTIVE_COMPARATOR|MTA Pulpotomy|"Angelus Grey MTA , Regenerative Pulpotomy Pulpotomy of 24 mandibular second primary molars using MTA Caries removal and deroofing of pulp chamber The MTA powder was mixed with sterile water in a 3:1 powder/water ratio according to the manufacturer's instructions to obtain a thick creamy paste, then placed on the floor of the pulp chamber using a messing gun and compacted against the pulp orifices with a condenser over a moist cotton pellet.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation at one, three ,six \& 12 months after pulpotomy."
62729261|NCT03833557|ACTIVE_COMPARATOR|Formocresl Pulpotomy|"Buckley' s Formocresol , Fixation pulpotomy Pulpotomy of 24 mandibular second primary molars using Formocresol Caries removal and deroofing of pulp chamber~A cotton pellet with formocresol was placed on the pulp stumps then removed and ZO/E dressing was condensed against the pulp stumps.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six \& 12 months after the pulpotomy for clinical and radiographic evaluation. Independently, two examiners evaluated the teeth clinically and radiographically."
62729262|NCT03302403|EXPERIMENTAL|CAR T cell|"In this study, autologous T cells transduced with a chimeric antigen receptor are used to treat patients with malignant tumors:~CAR-CD19 T cell is for the treatment of B-cell Leukaemia/Lymphoma; CAR-BCMA T cell is for the treatment of Myeloma; CAR-GPC3 T cell is for the treatment of Hepatocellular Carcinoma; CAR-CLD18 T cell is for the treatment of Pancreatic Carcinoma and Adenocarcinoma of Esophagogastric Junction.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR T cell infusion, which may improve in vivo cell count and survival of T cells.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
62729263|NCT05324592|EXPERIMENTAL|9MW0813|
62729264|NCT05324592|ACTIVE_COMPARATOR|aflibercept|
62729265|NCT04839653|NO_INTERVENTION|Control group: standard care|Patients in the standard care group will be prospectively evaluated to determine pre-defined clinical outcomes.
62729266|NCT04839653|EXPERIMENTAL|Selective digestive decontamination group|"1. Oral paste (0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B q6h~2. In the NGT 10 ml of suspension containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B and 500 mg of vancomycin q6h~3. A 3-day course of intravenous cefotaxime 1 g q6h/ceftriaxone 1 qd"
62729267|NCT00758940|EXPERIMENTAL|1|Acrysof ReSTOR multifocal IOL
62729268|NCT02955108|EXPERIMENTAL|music first then no music|
62729269|NCT02955108|EXPERIMENTAL|no music first then music|
62729270|NCT03689569|EXPERIMENTAL|Exercise|Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.
62729271|NCT03689569|EXPERIMENTAL|Resistant Starch|Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training
62729272|NCT03689569|EXPERIMENTAL|Exercise & Resistant Starch|Exercise \& resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period
62729273|NCT03689569|PLACEBO_COMPARATOR|Starch|Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks
62729274|NCT04263844|ACTIVE_COMPARATOR|Dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine 1 mcg/kgBB thirty minutes before induction
62729275|NCT04263844|ACTIVE_COMPARATOR|Midazolam|subject will receive premedication with intranasal midazolam 0,1 mg/kgBB thirty minutes before induction
62729276|NCT04175340|EXPERIMENTAL|BL-300-PFM04|
62729277|NCT04175340|ACTIVE_COMPARATOR|Lubricating and rewetting drops|
62729278|NCT01148901|EXPERIMENTAL|Remicade|Infliximab 5 mg/kg was administered as specified in the Summary of Product Characteristics for patients with ankylosing spondylitis
62729279|NCT03765216|ACTIVE_COMPARATOR|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
62729280|NCT03765216|EXPERIMENTAL|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
62729281|NCT05892497|EXPERIMENTAL|Tecartherpay Group|A single 25-minute tecartherapy procedure will be performed in both legs with the T-Plus Wintecare® machine. The configuration of the tecartherapy programme will be in 40 watts resistive mode for each muscle.
62729282|NCT05892497|SHAM_COMPARATOR|Sham group|The same procedure of the intervention group will be performed but with the tecartherapy machine without power (sham). The machine will be on but no power will be supplied.
62729283|NCT05519111|EXPERIMENTAL|Dronabinol|BID for 8 weeks. Dosage will be individualized per patient. In days 1-4 of the study each patient will be titrated from 5mg bid to a minimum dose of 2.5 mg bid to a maximum dose of 10 mg bid depending on patient preference.
62729284|NCT05519111|PLACEBO_COMPARATOR|Placebo|A placebo comparator
62729285|NCT00691457|EXPERIMENTAL|1|Opti-Free contact lens solution
62729286|NCT00691457|ACTIVE_COMPARATOR|2|ReNu Multiplus contact lens solution
62729287|NCT00691457|ACTIVE_COMPARATOR|3|Clear Care contact lens solution
62729288|NCT02228044|EXPERIMENTAL|Prevention Program|This is a cognitive-behavioral substance abuse, suicide, and HIV prevention program delivered in a workshop format to adolescent participants and their parents/legal guardians.
62729289|NCT02228044|NO_INTERVENTION|Assessment Only|
62729290|NCT06396702|EXPERIMENTAL|EASE-SOT Intervention Arm|"Participants in the intervention group receive EASE plus usual care. Each participant will participate in 8 EASE-psy sessions, starting twice a week during the inpatient stay and once every 1-2 weeks thereafter. They will also be screened for physical symptoms using electronic patient-reported outcome measures (ePROMs) twice a week while in-patient and once a week during the rest of the 8-week intervention period (EASE-phys). Participants will receive an output report that provides graphic representation of their current and previous scores on the various domains of health (e.g., depression, fatigue, etc.). If scoring above threshold for any symptom assessed during routine screening, participants will be referred/re-referred to a symptom control team. Additional ePROMs will be completed at baseline, 4, 8, 12 and 20 weeks."
62729291|NCT06396702|NO_INTERVENTION|Control Arm|Participants in the control group receive usual care alone. Additional ePROMs will be completed at baseline, 4, 8, 12 and 20 weeks.
62729292|NCT03329625|EXPERIMENTAL|Pathways Triple P|Families randomized to the Pathways Triple P received a 14 week home based intervention.
62729293|NCT03329625|ACTIVE_COMPARATOR|Services as Usual|Families randomized to the services as usual condition received services as usual through the Missouri Children's Division
62729294|NCT01816776|EXPERIMENTAL|Treatment Group|Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
62729295|NCT01816776|OTHER|Control group|Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
62729296|NCT02869542||Patients with lymphoma diagnosis|
62729297|NCT02425787||Parents of deceased children (no BMT)|"Participants will be parents who have lost a child at St. Jude Children's Research Hospital (SJCRH). They will participate in a 60-90 minute interview.~(Not recruiting)"
62729298|NCT02425787||Parents of deceased children (haploidentical BMT)|Participants will be parents whose child died after receiving a haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
62729299|NCT02425787||Parents of deceased children (non-haploidentical BMT)|Participants will be parents whose child died after receiving a non-haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
62729300|NCT02425787||Parents of deceased children (not interviewed)|Participants will be parents who have lost a child at SJCRH, who have not previously participated in an interview through this study.They will participate in a 30-90 minute focus group.
62729301|NCT02425787||Hematology/Oncology Fellows|Participants will be Hematology/Oncology Fellows at SJCRH. They will participate in a 30-90 minute focus group.
62729302|NCT02425787||Legacy-Building|Participants will be parents who have lost a child at SJCRH and received legacy items. They will participate in a 30-90 minute interview.
62729303|NCT03268889|EXPERIMENTAL|treatment group|In this arm, patients would be given the regimen composed of Chidamide, Cyclophosphamide, epirubicin, Vincristine and Prednisone.
62729304|NCT05013021|OTHER|Sedentary participants|"Series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT).~These measurements consist of physiological measurements (VO2max), neuromuscular capacities (force-speed profile), autonomic nervous system responses (heart rate variability) and blood markers (lactate, CK, cytokinases, µRNA)."
62729305|NCT03715725||Registry cohort|Registries in Norway are nation-wide and provision of the information is mandatory, which eliminates the risk of both selection and re-call bias. The large and detailed dataset also makes it possible to adjust for other risk factors on which information is available.
62729306|NCT03715725||Electronic Medical Records (EMR) cohort|Patients with NVAF diagnosis will be identified through extraction of patient-level data from EMRs from a number of hospitals in Norway, in order to describe these patients more closely regarding their clinical characteristics that are not available in nation-wide registers (e.g., in-patient treatments, anthropometric data and laboratory test results).
62729307|NCT03107728|EXPERIMENTAL|Advanced orthotic brace|
62729308|NCT03107728|ACTIVE_COMPARATOR|Conventional orthotic brace|
62729309|NCT01743612|EXPERIMENTAL|Sclerodermic patients|patients with systemic sclerosis according to Leroy's classification
62729310|NCT01743612|EXPERIMENTAL|Primary Raynaud's phenomenon|without secondary disease
62729311|NCT01743612|EXPERIMENTAL|Healthy subjects|18 years old or more
62729312|NCT01619293||Epidural H.|patients with hematoma epidurale
62729313|NCT01619293||Subdural H.|patients with hematoma subdurale
62729314|NCT01619293||Subarachnoidal H.|patients with hematoma subarachnoidale
62729315|NCT01619293||Intracerebral H.|patients with hematoma intracerebrale
62729316|NCT01619293||E. cerebri|patients with edema cerebri
62729317|NCT01619293||Concussion|patients with concussion
62729318|NCT06227533|EXPERIMENTAL|PRF group|Five ml blood will be drawn from the patient's right median cubital vein into a test tube without the addition of an anticoagulant and centrifuged immediately at 3000 rpm for 10 minutes
62729319|NCT06227533|EXPERIMENTAL|CGF group|Ten ml of intravenous blood sample from the patient will be obtained and placed in centrifuge tubes without anticoagulants; accelerated for 30 seconds; centrifuged at 2700 rpm for 2 min, 2400 rpm for 4 min, 2700 rpm for 4 min, and 3000 rpm for 3 min; and decelerated for 36 secs to stop
62729320|NCT03947268|EXPERIMENTAL|Short-course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation technique.
62729321|NCT03464513|OTHER|Patients with GIT bleeding|Patients with active lower Gastrointestinal bleeding
62729322|NCT02006108|EXPERIMENTAL|Feraheme|"Intravenous injection of Feraheme, 5 mg Fe/kg~Interventions:~Drug: Feraheme Procedure: MR Scan"
62729323|NCT04608292|ACTIVE_COMPARATOR|Single-voxel MRS|MRS
62729324|NCT04608292|ACTIVE_COMPARATOR|Multi-voxel MRSI|MRSI
62729325|NCT04608292|ACTIVE_COMPARATOR|Magnetization Transfer Imaging|MTI
62729326|NCT04608292|ACTIVE_COMPARATOR|Single-voxel MRS + ClearMate|MRS+CM
62729327|NCT04608292|ACTIVE_COMPARATOR|Multi-voxel MRSI + ClearMate|MRSI+CM
62729328|NCT04608292|ACTIVE_COMPARATOR|Magnetization Transfer Imaging + ClearMate|MTI+CM
62729329|NCT04608292|ACTIVE_COMPARATOR|Single-voxel MRS + ClearMate + Blood Sampling|MRS+CM+B
62729330|NCT04608292|ACTIVE_COMPARATOR|Multi-voxel MRSI + ClearMate + Blood Sampling|MRSI+CM+B
62729331|NCT04608292|ACTIVE_COMPARATOR|Magnetization Transfer Imaging + ClearMate + Blood Sampling|MTI+CM+B
62729332|NCT01596855|EXPERIMENTAL|FG-4592|Active Drug
61978251|NCT05264155|ACTIVE_COMPARATOR|Treatment: personalized|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the treatment group, these parameters were tailored to the users' self-reported capabilities and health goals."
62729333|NCT01596855|ACTIVE_COMPARATOR|Epoetin alfa|Standard of care
62729334|NCT06174155|ACTIVE_COMPARATOR|Control group|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist.
62729335|NCT06174155|ACTIVE_COMPARATOR|Study group A|The study group A will receive Botulinum toxin-A injection in addition to physical therapy program as control group
62729336|NCT06174155|ACTIVE_COMPARATOR|Study group B|The study group B will receive shock wave therapy in addition to physical therapy program as control group.
62729337|NCT00200707|EXPERIMENTAL|The treatment group|Intracoronary Injection of Autologous Bone Marrow Mononuclear C
62729338|NCT00200707|NO_INTERVENTION|the control group|
62729339|NCT06043180||Severe aortic stenosis|Aortic valve area \<1.0 cm2/\<0.6cm2/m2 or mean gradient \>40mmHg or jet velocity \>4.0 m/s.
62729340|NCT04346147|EXPERIMENTAL|Imatinib 400 mg|Imatinib 400 mg 1 tablet 24 hours
62729341|NCT04346147|EXPERIMENTAL|Baricitinib 4 mg|Baricitinib 4 mg 1 tablet 24 hours
62729342|NCT04346147|EXPERIMENTAL|Supportive treatment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
62729343|NCT05631314||operative treatment|This group will consist of patients who underwent operative treatment for a distal radius fracture.
62729344|NCT05631314||non-operative treatment|This group will consist of patients who underwent non-operative treatment for a distal radius fracture.
62729345|NCT00941291||vitrectomy in pseudophakic eyes|
62729346|NCT00941291||vitrectomy and cataract:combined procedure|
62729347|NCT00941291||vitrectomy followed by cataract extraction|
62729348|NCT00941291||vitrectomy on phakic eyes|
62729349|NCT03073863|ACTIVE_COMPARATOR|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
62729350|NCT03073863|EXPERIMENTAL|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
62729351|NCT03015155|EXPERIMENTAL|Hypothermia|Infusion of Cold Saline into Local Infarction Myocardium. A standard working guide-wire, Runthrough NS (Terumo, Japan), is advanced into the distal part of the target coronary artery by using angiography. Compared to the standard PPCI after the balloon expansion, the aspirated catheter (Diver C.E. MAX, Italy) is firstly placed at the location of the distal occlusion lesion to achieve local myocardial hypothermia by infusing the cold saline (4℃, 2.5ml/min, 5min). Then we retract the aspirated catheter, following the balloon expansion and the drug eluting stent implanting. Subsequently, the infusion catheter is tautologically placed at the location of the opened occlusion, within the stent, to persistently perfuse the infarct myocardium with cold saline (4℃, 2.5ml/min, 15min).
62729352|NCT03015155|NO_INTERVENTION|Standard treatment|We place a standard working guide-wire, Runthrough NS (Terumo Corporation, Japan), crossover the criminal lesion of to the distal of the target coronary artery after angiography. Then the pre-dilated balloon is placed at the occluded lesion site to expand the criminal vessel without hypothermia intervention. The operation will be completed when the flow of target coronary artery achieves TIMI class 3 after the drug eluting stent implanting.
62737167|NCT05743127|EXPERIMENTAL|Group 3-D Printed Expander|3D-Printed Hyrax Expander
62729353|NCT05079347|EXPERIMENTAL|Healer led HIV testing|"Traditional healers will offer HIV testing to their patients. They will provide the test result to patients. If the patient is positive they will refer their patients to the health facility via referral form and/or walk them to the clinic (based on patient preference). If the patient is negative, the healer will encourage them to re-test at the health facility in 6 months during an open house event where healers will attend to try and de-stigmatize going to the health facility."
62729354|NCT04389905|EXPERIMENTAL|Motivational Interviewing Oral Health Education Group|The intervention group focused on the mothers from before birth until their child reached the age of 3 years. They received repeated questionnaires and repeated oral health education using the Motivational Interviewing (MI) technique.
62729355|NCT04389905|NO_INTERVENTION|Local Control Group|The local control group included other mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
62729356|NCT04389905|NO_INTERVENTION|Similar Socio-economics Control Group|This control group is from a Public Dental Clinic with similar socioeconomics (among the families in the catchment area of the clinic) as in the intervention group. This control group included mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
62729357|NCT01538576||Insulin aspart users|
62729358|NCT06281977|ACTIVE_COMPARATOR|Dexmedetomidine|Participants randomized to receive dexmedetomidine will be started at a dose of 0.3 mcg/kg/hr and titrated to a target dose of 1.0 mcg/kg/hr. Once the participant reaches their maximum tolerated dose (as decided by the blinded treating physician), they will continue treatment for 48 ± 6 hours. This will be followed by a weaning phase that will similarly be at the discretion of the treating physician.
62729359|NCT06281977|PLACEBO_COMPARATOR|Placebo|Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.
62729360|NCT00170326|ACTIVE_COMPARATOR|Dual Chamber pacing|conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex
62729361|NCT00170326|EXPERIMENTAL|Biventricular pacing|Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle
62729362|NCT05809323|EXPERIMENTAL|Exercise Intervention Group|Group of up to 50 patients will randomly allocated into an experimental group at a 4:1 ratio intervention to controls. The experimental group will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
62729363|NCT05809323|OTHER|Control Group|Control group will be randomly allocated at a 4:1 ratio, intervention to controls.. The control group will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) and will be instructed to continue with baseline physical activities. They will be asked to return for a reassessment of all baseline procedures (cardiovascular, musculoskeletal, and psychological screening).
62729364|NCT05498740|EXPERIMENTAL|drug eluting balloon catheter|use drug eluting balloon catheter to treat the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
62729365|NCT05536882|EXPERIMENTAL|Benzoyl peroxide|topical benzoyl peroxide 10% (vehicle choice per patient preference) applied 1-2x daily as tolerated until complete clearance or 12 week follow up
62729366|NCT05536882|ACTIVE_COMPARATOR|Adapalene|adapalene 0.1% gel applied 1-2x daily as tolerated until complete clearance or 12 week follow up
62729367|NCT01222988|OTHER|very low calorie diet program|
62729368|NCT06045065||patients with primitive tumor|Patient samples will be collected during routine care neurosurgical resection.
62729369|NCT06045065||patients with brain metastasis|Patient samples will be collected during routine care neurosurgical resection.
62165993|NCT03614923|EXPERIMENTAL|Etokimab 300 mg + 150 mg Q8W|Participants received a 300 mg loading dose of etokimab administered by subcutaneous injection at Week 0 then etokimab 150 mg by subcutaneous injection every 8 weeks (Q8W) up to Week 12 and placebo at Weeks 4 and 12. Participants also used MFNS of 2 actuations (50 μg/actuation) in each nostril BID.
62165994|NCT03614923|PLACEBO_COMPARATOR|Placebo|Participants received placebo subcutaneous injection once every 4 weeks up to Week 12. Participants also used MFNS of 2 actuations (50 μg/actuation) in each nostril BID.
62165995|NCT00472056|EXPERIMENTAL|BEAM + Standard Rituximab|"Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Standard Rituximab: 375 mg/m\^2 IV Days +1, +8 after Stem Cell Infusion on Day 0."
62729370|NCT03443089|EXPERIMENTAL|Test formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
62729371|NCT03443089|ACTIVE_COMPARATOR|Reference formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
62729372|NCT01495533|ACTIVE_COMPARATOR|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
62729373|NCT01495533|ACTIVE_COMPARATOR|drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
62729374|NCT03633955|ACTIVE_COMPARATOR|Standard therapy - Acute leukemia cohort|The Arm will accrue patients receiving standard therapy from the high-risk acute leukemia cohort (18 patients).
62729375|NCT03633955|EXPERIMENTAL|Immunotherapy - Acute leukemia cohort|The Arm will accrue patients receiving immunotherapy from the high-risk acute leukemia cohort (18 patients).
62729376|NCT03633955|ACTIVE_COMPARATOR|Standard therapy - Myeloma cohort|The Arm will accrue patients receiving standard therapy from the myeloma cohort (9 patients).
62729377|NCT03633955|EXPERIMENTAL|Immunotherapy - Myeloma cohort|The Arm will accrue patients receiving immunotherapy from the myeloma cohort (9 patients).
62729378|NCT00078806|EXPERIMENTAL|Part 1: Etanercept|"Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months."
62729379|NCT00078806|PLACEBO_COMPARATOR|Part 2: Placebo|Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
62729380|NCT00078806|EXPERIMENTAL|Part 2: Etanercept|Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
62729381|NCT00078806|EXPERIMENTAL|Part 3:|Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.
62729382|NCT01340664|EXPERIMENTAL|Canagliflozin 50 mg bid|Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
62729383|NCT01340664|EXPERIMENTAL|Canagliflozin 150 mg bid|Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
62729384|NCT01340664|PLACEBO_COMPARATOR|Placebo|Each patient will receive matching placebo twice daily for 18 weeks
62729385|NCT00945373|EXPERIMENTAL|Erythematotelangiectatic Rosacea|2.5% gel calcium dobesilate and pulsed dye laser
62729386|NCT01119443|OTHER|Treatment sequence A|V4: PPX ER 1.5mg x 1 fed, V5: PPX ER 0.375mg x 4 fed, V6:: PPX ER 1.5mg x 1 fasted, V5: PPX ER 0.375mg x 4 fasted
62729387|NCT01119443|OTHER|Treatment sequence B|V4: PPX ER 0.375mg x 4 fed, V5: PPX ER 1.5mg x 1 fed, V6:: PPX ER 0.375mg x 4 fasted, V5: PPX ER 1.5mg x 1 fasted
62729388|NCT05424965||normal weight without gestational diabetes|BMI \< 25; normal glucose tolerance
62729389|NCT05424965||normal weight with gestational diabetes|BMI \< 25; impaired oral glucose tolerance
62729390|NCT05424965||overweight without gestational diabetes|BMI 25 - 29.9; normal glucose tolerance
62729391|NCT05424965||overweight with gestational diabetes|BMI 25 - 29.9; impaired glucose tolerance
62729392|NCT05424965||obese without gestational diabetes|BMI \>= 30; normal glucose tolerance
62729393|NCT05424965||obese with gestational diabetes|BMI \>= 30; impaired glucose tolerance
62729394|NCT02420184|EXPERIMENTAL|CPAP Therapy|Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).
62729395|NCT02420184|PLACEBO_COMPARATOR|No CPAP|Participants will receive standard medical care for CKD.
62729396|NCT01212471|EXPERIMENTAL|Bromfenac Ophthalmic Solution A|Bromfenac ophthalmic solution A
62729397|NCT01212471|EXPERIMENTAL|Bromfenac Ophthalmic Solution B|Bromfenac ophthalmic solution B
62729398|NCT01212471|PLACEBO_COMPARATOR|Placebo Comparator|Placebo Comparator
62729399|NCT01635998|EXPERIMENTAL|Intervention arm|These subjects will undergo routine catheter ablation of atrial fibrillation PLUS renal sympathetic denervation with the Boston Scientific Vessix Renal Denervation System.
62729400|NCT01635998|NO_INTERVENTION|Control arm|These subjects will undergo routine catheter ablation of atrial fibrillation only.
62729401|NCT06311773|EXPERIMENTAL|Treated with Boomerang Catheter|
62729402|NCT00161616|ACTIVE_COMPARATOR|A|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage +surgical fixation
62729403|NCT00161616|OTHER|B|Standard of Care: Surgical fixation only
62729404|NCT02134301|EXPERIMENTAL|Oritavancin|Single-Dose IV Oritavancin Diphosphate
62729405|NCT04868305|ACTIVE_COMPARATOR|Intramedullary nail|Intramedullary nail with proximal lagscrew and distal locking screw(s)
62729406|NCT04868305|ACTIVE_COMPARATOR|Hip arthroplasty|Hemiarthroplasty (HA) or Total hip arthroplasty (THA). A cemented dual-mobility cup will be utilized in THA. Addition of cerclage/trochanter claw plate to fixate trochanter major will be used when suitable.
62729407|NCT05807152|NO_INTERVENTION|Control Group|Furosemide infusion (standard treatment)
62729408|NCT05807152|EXPERIMENTAL|RenalGuard group|Furosemide infusion with matched de-hydration
62729409|NCT04368377|EXPERIMENTAL|Tirofiban|"1. Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0.15 microgram/kg/minute for 48 hours.~2. Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75 mg daily for 30 days.~3. Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75 mg daily for 30 days~4. Patents will receive concurrent fondaparinux 2.5 mg s/c per day for the duration of the hospital stay"
62729410|NCT00271908||Cohort #1|Venue-tracking survey subjects recruited annually for 4 years: N= 320-640 (10-20 members of the population of focus per site, per year). The purpose of this cohort is to identify and track venues at which the population of focus congregates.
62729411|NCT00271908||Cohort #2|HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody \[Ab\] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
62729412|NCT02988544|EXPERIMENTAL|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
62729413|NCT02988544|NO_INTERVENTION|Control group|No intervention on blastocoelic
62729414|NCT03627949|EXPERIMENTAL|Intervention group 1|Students in the intervention group 1 received first 4-week treatment on physical activity followed by 4-week treatment on healthy dietary behaviour.
62729415|NCT03627949|EXPERIMENTAL|Intervention group 2|Students in the intervention group 2 received first 4-week treatment on healthy dietary behaviour followed by 4-week treatment on physical activity.
62729416|NCT03627949|NO_INTERVENTION|Control group|Students in the control group were not provided with any supportive treatments on physical activity or healthy dietary behaviour.
62729417|NCT01798095|EXPERIMENTAL|Aplisol|To confirm the response of PPD materials
62729418|NCT01798095|ACTIVE_COMPARATOR|PPD Standard|Determine equivalent specificity for new material compared to standard material.
62729419|NCT02615418|ACTIVE_COMPARATOR|Fully active treatement|
62729420|NCT02615418|SHAM_COMPARATOR|partially active|first 2.5 weeks will receive sham treatment followed by active
62729421|NCT01946659|EXPERIMENTAL|Adherence to Sleep Apnea Treatment|The intervention arm of the study receives tailored education regarding Sleep Apnea by the study health educator via telephone.
62729422|NCT01946659|OTHER|Standard Care Group|The standard care group gets the standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine.
62729423|NCT02532582||Living Liver Donor Transplant Donors|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital (same surgical setup is used for living liver donor surgery and liver surgery (e.g. retractors, arterial line for monitoring, surgeons). Living liver donors and liver surgery patients for enrollment to receive neuromuscular monitoring)
62729424|NCT01053507|ACTIVE_COMPARATOR|Treximet|In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
62729425|NCT01053507|PLACEBO_COMPARATOR|Placebo|In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
62729426|NCT04923334|EXPERIMENTAL|Brief Pain Teleconsult|Participants randomized to Brief Pain Teleconsult will receive the brief teleconsult intervention in Phase 1 (1-12 weeks) Responder status to the Phase 1 treatment will be examined at the 12 week assessment. Participants determined to be non-responders will receive the Telehealth Physical Therapy intervention. Responders receive no additional treatment.
62729427|NCT04923334|EXPERIMENTAL|Brief Pain Teleconsult plus Telehealth Physical Therapy|Participants randomized to Brief Pain Teleconsult plus Telehealth Physical Therapy will receive the brief teleconsult intervention in Phase 1 followed by the 10-week physical therapy intervention. No additional treatment is provided after the 12 week assessment.
62729428|NCT03880045|ACTIVE_COMPARATOR|Topical TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
62729429|NCT03880045|ACTIVE_COMPARATOR|placebo to TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus placebo to tranexamic acid
62729430|NCT00221546|ACTIVE_COMPARATOR|DHA-rich supplement|
62729431|NCT00221546|PLACEBO_COMPARATOR|Placebo|
62729432|NCT01239173|ACTIVE_COMPARATOR|1|Post-traumatic stress disorder patient receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
62729433|NCT01239173|PLACEBO_COMPARATOR|2|Post-traumatic stress disorder receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
62729434|NCT01239173|ACTIVE_COMPARATOR|3|Controls receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
62729435|NCT01239173|PLACEBO_COMPARATOR|4|Controls receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
62729436|NCT06361966|ACTIVE_COMPARATOR|Laminate socket|control intervention as standard treatment for transtibial amputees requiring a lower limb prosthesis
62729437|NCT06361966|EXPERIMENTAL|3d printed socket|trial intervention for transtibial amputees requiring a lower limb prosthesis
62729438|NCT05247684|EXPERIMENTAL|arm 1(AK112)|Neoadjuvant therapy was 3-4 cycles of AK112(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
62729439|NCT05247684|EXPERIMENTAL|arm 2(AK112+Carboplatin/cisplatin + paclitaxel)|Neoadjuvant therapy was 3-4 cycles of AK112 plus Carboplatin/cisplatin + paclitaxel(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
62729440|NCT00638300|EXPERIMENTAL|1|large pore dialyzers (FX80, Fresenius, Germany)
62729441|NCT00638300|EXPERIMENTAL|2|small pore dialyzers ( F8HPS, Fresenius, Germany)
62729442|NCT00638300|EXPERIMENTAL|A|dialysate bicarbonate concentration of 33 mEq/l
62729443|NCT00638300|EXPERIMENTAL|B|dialysate bicarbonate concentration of 40 mEq/l
62729444|NCT00638300|EXPERIMENTAL|I|dialysate calcium concentration of 3 mEq/L
62729445|NCT00638300|EXPERIMENTAL|II|dialysate calcium concentration of 2.5 mEq/L
61978252|NCT01988857|EXPERIMENTAL|dTpa Group|
62729446|NCT05145699|EXPERIMENTAL|Right hemispheric stroke with hemineglect|
62729447|NCT05145699|ACTIVE_COMPARATOR|Right hemispheric stroke without hemineglect|
62729448|NCT05145699|OTHER|Normal people|
62729449|NCT04192266|EXPERIMENTAL|Prolonged Exposure (PE) therapy with estradiol|A 2.0 mg pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD. A single dose of estradiol 2mg or placebo will be taken at home by the study participant 5-6 hours before each of 5 PE treatment sessions (sessions 2 to 6)
62729450|NCT04192266|PLACEBO_COMPARATOR|Prolonged Exposure (PE) therapy with placebo|A 2.0 mg placebo pill will be given with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD.
62729451|NCT06199908|EXPERIMENTAL|Arm 1|AMT-562 Dose Escalation
62729452|NCT06386926|EXPERIMENTAL|Experimental group 1|23 subjects will Receive radial shockwave by ( Storz Medical /SN:BS.3517 ) for 3 sessions one session per week for four consecutive weeks and conventional physical therapy
62729453|NCT06386926|EXPERIMENTAL|Experimental group 2|23 subjects will receive Ultrasound phonophoresis using diclofenac Na+( voltaren) by ( Sonopuls 490 / SN : 36 602 ) for 12 session, 3 sessions per week and same conventional physical therapy
62729454|NCT06386926|OTHER|Control group|"23 subjects will receive conventional physical therapy modalities in the for 3 sessions per week for 4 weeks in form of Stretching Exercise in form of exercise of posterior shoulder capsule, strengthening exercises all have been recommended as essential for any shoulder rehabilitation program. These exercise include shoulder flexion, scaption.~,Tens applied for 20 minutes per session using (Enraf Nonius (Endomed 482) SN : 36853 )"
62729455|NCT03942198|EXPERIMENTAL|Oral Chinese medicine|Participants in experimental group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
62729456|NCT03942198|PLACEBO_COMPARATOR|Oral Chinese medicine placebo|Participants in placebo group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
62729457|NCT01658605|EXPERIMENTAL|GSK1605786|Administered orally for 16 weeks in a 2:1 ratio
62729458|NCT01658605|PLACEBO_COMPARATOR|Placebo|Administered orally for 16 weeks in a 2:1 ratio
62729459|NCT05722366|ACTIVE_COMPARATOR|Active Video Game İntervention|"The active video games intervention will be carried out with a virtual reality system (XBOX360, Microsoft, USA) consisting of a console and a sensor.~Active video games consist of Bowling, River Rush, Rally Ball and Reflex Ridge games.~Participants will exercise for a total of 25 minutes with light-paced games for warm-up for the first 5 minutes, then brisk games with different body movements until the 15 minutes are complete, and light-paced games for 5 minutes to cool down.~Participants will complete active video games in the same order."
62729460|NCT05722366|ACTIVE_COMPARATOR|Aerobic Exercise Intervention|The exercise intervention will consist of a continuous moderate intensity walking session on the treadmill. After the first 5 minutes of warm-up,a at 55-70% of the peak heart rate reserve(HRR)with a 15-minute walking session, and 5 minutes of cooling down total of 25 minutes of exercise will be performed.
62729461|NCT02872597|EXPERIMENTAL|Treatment|Inhaled ipratropium bromide 250mcg given via nebulization every 6 hours for up to 5 days
62729462|NCT02872597|PLACEBO_COMPARATOR|Placebo|Inhaled normal saline 1.25mL given via nebulization every 6 hours for up to 5 days
62729463|NCT06062381|EXPERIMENTAL|Intervention Group|experimental group will receive abdominal massage of 20 minutes duration for 3 days.
62729464|NCT06062381|NO_INTERVENTION|Control Group|control group will receive only routine care
62729465|NCT01900522|EXPERIMENTAL|Multiple Rising Dose (MRD) Phase: Ascending ITI-214 Doses|ITI-214 Doses (A, B, C, D, matching placebo), solution, orally, once daily for 14 days.
62729466|NCT01900522|EXPERIMENTAL|Neuroimaging Phase: ITI-214 Doses|ITI-214 (E,F, G, H, matching Placebo) Oral solution, once daily for 7 days in 3 periods with placebo and two of the ITI-214 Doses (E, F, G and H) in a cross-over fashion with minimum 7 days washout between periods
62729467|NCT02623205|ACTIVE_COMPARATOR|Escitalopram|Active Comparator: Escitalopram (Lexapro) 10mg Week 1, 20mg Weeks 2 and 3, and 30mg for Weeks 4 to 8 (or until 12 for patients close to remission)
62729468|NCT02623205|PLACEBO_COMPARATOR|Placebo|Lactose pill manufactured to mimic Escitalopram pill
62729469|NCT05745103|EXPERIMENTAL|The Eleos Health Platform|Therapists in the AI group will use the HIPAA-compliant, secure, password-protected Eleos Health platform. This AI tool was designed for behavioral health to support clinical decision-making and automation of administrative tasks. The platform captures the therapist and patient's utterances during a treatment session, analyzes the data, and offers feedback on the implementation of EBPs. The platform also incorporates a measurement-based care component, wherein standardized assessment scales completed by clients are immediately summarized and graphed for the therapist, who can use these data to inform therapy and share them with the patient. Insights and key indicators from the session data and MBC are summarized into a progress note draft which the therapist can then submit or edit as needed.
62729470|NCT05745103|ACTIVE_COMPARATOR|Treatment as Usual|Participants randomized to the control group will receive the routine services provided in the center. Therapists providing TAU will be permitted to use the strategies they deen would be most successful.
62729471|NCT02217813|EXPERIMENTAL|1. Tafamidis|
62729472|NCT02217813|EXPERIMENTAL|2. Tafamidis|
62729473|NCT01986894|PLACEBO_COMPARATOR|Treatment 1 (placebo)|Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1
62729474|NCT01986894|EXPERIMENTAL|Treatment 2 (4 mg pomalidomide)|Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1
62729475|NCT01986894|EXPERIMENTAL|Treatment 3 (20 mg pomalidomide)|Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1
62729476|NCT01986894|ACTIVE_COMPARATOR|Treatment 4 (moxifloxacin)|One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1
62729477|NCT01672879|EXPERIMENTAL|SIM 200 mg|During the Randomized Double-Blind Phase, participants will receive SIM 200 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
62729478|NCT01672879|EXPERIMENTAL|SIM 700 mg|During the Randomized Double-Blind Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
62729479|NCT01672879|PLACEBO_COMPARATOR|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM administered via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg administered via intravenous infusion every 2 weeks for up to an additional 240 weeks.
62729480|NCT00451958|EXPERIMENTAL|Degarelix 80 mg / Degarelix 80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
62729481|NCT00451958|EXPERIMENTAL|Degarelix 160 mg / Degarelix 160 mg|"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
62737168|NCT03851627|ACTIVE_COMPARATOR|Testosterone undecanoate|intramuscular Testosterone undecanoate 1000mg/4ml
62737169|NCT03851627|PLACEBO_COMPARATOR|Testosterone like Placebo|intramuscular Testosterone undecanoate like Placebo
62737170|NCT06242990|EXPERIMENTAL|Y-PATH Intervention Group|Participants will receive the Y-PATH NI intervention programme which is an adapted form of physical education classes.
62729482|NCT00451958|EXPERIMENTAL|Leuprolide 7.5 mg / Degarelix 80 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
62729483|NCT00451958|EXPERIMENTAL|Leuprolide 7.5 mg / Degarelix 160 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
62729484|NCT02421848||Cirrhotic Patients With Ascites|Cirrhotic Patients With Ascites
62729485|NCT05246878|EXPERIMENTAL|EDP-235 SAD Cohorts|EDP-235 Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5, orally, once daily in one single administration
62729486|NCT05246878|EXPERIMENTAL|EDP-235 MAD Cohorts|EDP-235 Dose 1, Dose 2 and Dose 3 orally, once daily for 7 days
62729487|NCT05246878|PLACEBO_COMPARATOR|EDP-235 SAD Placebo Cohorts|Matching placebo, orally, once daily in one single administration
62729488|NCT05246878|PLACEBO_COMPARATOR|EDP-235 MAD Placebo Cohorts|Matching placebo, orally, once daily for 7 days
62729489|NCT00211172|EXPERIMENTAL|Beta-blocker adherence after an AMI|Patients received two mailings about the importance of beta blocker use.
62729490|NCT00211172|NO_INTERVENTION|Usual care|Patients received usual care.
62729491|NCT05498532||PUJS patients|Patients between 0 and 17 years old treated or followed for pyelo-ureteral junction syndrome.
62729492|NCT00153673|ACTIVE_COMPARATOR|1|Celecoxib + Famotidine
62729493|NCT00153673|ACTIVE_COMPARATOR|2|Dologesics + Famotidine
62729494|NCT03502915|EXPERIMENTAL|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
62729495|NCT03502915|PLACEBO_COMPARATOR|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
62729496|NCT04310319|OTHER|Normal salt, low protein treatment period|6 grams of sodium chloride daily / Placebo
62729497|NCT04310319|OTHER|Normal salt, normal protein treatment period|6 grams of sodium chloride daily / 40 grams of protein daily
62729498|NCT04310319|OTHER|Low salt, low protein treatment period|Double placebo
62729499|NCT04310319|OTHER|Low salt, normal protein treatment period|Placebo / 40 grams of protein daily
62729500|NCT04914156|EXPERIMENTAL|Personalised, genetic-based advice for sport performance|This group will receive personalised nutrition advice for sports performance based on their genetic test results and tailored to their current dietary intake.
62729501|NCT04914156|ACTIVE_COMPARATOR|Personalised nutrition advice for sport performance based on population-based evidence|This group will receive personalised nutrition advice on key nutrients relating to sports performance based on current best practice, population-based sport nutrition guidelines. These will be tailored to their current dietary intake
62729502|NCT03462641|EXPERIMENTAL|Sequence A - (Flumazenil at Visit 1)|A detailed 90 minute clinical assessment was conducted before and after treatment administration for each visit. Flumazenil 1mg in 10cc normal saline was given intravenously (iv) over 5-10 minutes on the first visit as treatment. 10 cc of normal saline placebo was given intravenously (iv) over 5-10 minutes on the second visit as treatment.
62729503|NCT03462641|EXPERIMENTAL|Sequence B - (Placebo at Visit 1)|A detailed 90 minute clinical assessment was conducted before and after treatment administration for each visit. 10 cc of normal saline placebo was given intravenously (iv) over 5-10 minutes on the first visit as treatment. Flumazenil 1mg in 10cc normal saline was given intravenously (iv) over 5-10 minutes on the second visit as treatment.
62729504|NCT00325507|EXPERIMENTAL|TroVax|TroVax given as first or second line treatment in conjuntion with low dose IL-2.
62729505|NCT00848887|EXPERIMENTAL|1|
62729506|NCT01607125|EXPERIMENTAL|Vortioxetine|
62729507|NCT01607125|PLACEBO_COMPARATOR|Placebo|
62729508|NCT02113774|NO_INTERVENTION|no therapy|
62729509|NCT02113774|ACTIVE_COMPARATOR|antimicrobial treatment according to in-vitro susceptibility|
62729510|NCT00235183|ACTIVE_COMPARATOR|Quarantined FFP|Quarantined FFP
62729511|NCT00235183|ACTIVE_COMPARATOR|Methylene blue FFP|Methylene blue FFP
62729512|NCT00235183|ACTIVE_COMPARATOR|Solvent detergent FFP|Solvent detergent FFP
62729513|NCT06184685|EXPERIMENTAL|Sahasthara Microemulsion|The extract of Sahasthara remedy was obtained by maceration with 95% ethanol for 3 days. The marc was re-extracted using the same process two more times. After that, the extract was filtered, concentrated using a rotary evaporator at 40 degree C and vacuum (Rotavapor R-205, Buchi, Switzerland), to gave a yield of 10.3% w/w. Finally, SHT ethanolic extract was formulated into a microemulsion with 1% (w/w) of extract and was stored in 50 ml bottles.
62729514|NCT06184685|EXPERIMENTAL|Diclofenac Microemulsion|DF-ME, which consists of 2% diclofenac sodium, was compounded according to the published instructions by RS Therapeutics Inc. (Canada) and stored in the same containers as SHT-ME.
62729515|NCT03551834|ACTIVE_COMPARATOR|doing scleral patch graft glaucoma implantation|
62729516|NCT03551834|ACTIVE_COMPARATOR|Using short tunnel small flap technique|
62729517|NCT03074201|EXPERIMENTAL|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
62729518|NCT05427123||Youth with or at clinical high risk for Bipolar Spectrum Disorder|Youth included in the study will have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of Bipolar I or II, Cyclothymic Disorder, or Other Specified Bipolar Disorder (per Course and Outcome of Bipolar Youth study definition)
62729519|NCT00737724|EXPERIMENTAL|Group 1|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
62729520|NCT00737724|EXPERIMENTAL|Group 2|Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy
62729521|NCT05439343|EXPERIMENTAL|Adductor canal block|Allocation of which limb is to receive adductor canal block is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, adductor canal block will be performed by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following skin infiltration, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through a 3-inch, 23-gauge, short bevel block needle.
62729522|NCT05439343|EXPERIMENTAL|Local infiltration|Allocation of the other limb to receive local infiltration is determined after randomization of the knee allocated for adductor canal block in the same patient. The chosen knee is infiltrated by the orthopedic surgeon intraoperatively with a 150-ml mixture of 150 mg bupivacaine, 10 mg morphine, 30 mg ketorolac, and 0.5 mg epinephrine. The posterior capsule is infiltrated before placement of the prosthesis, and the periarticular and superficial soft tissues are infiltrated after the prosthesis is in place and before wound closure.
62729523|NCT01010451|EXPERIMENTAL|Antimicrobial pulpotomy|Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste
62729524|NCT01010451|ACTIVE_COMPARATOR|Calcium hydroxide pulpectomy|Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication
62729525|NCT04809493||patients will be receiving conventional dialysis|Patients will be receiving conventional dialysis treatment followed by isonatremic dialysis treatment during an observational period of 2 months for each treatment
62729526|NCT04422691||Covid-19 suspected|Emergency department patients with suspected or diagnosed COVID-19 disease. All patients will be screened at triage and put into isolation if suspected disease. Ultrasound of the patients lungs will be performed after patient consent and findings will be recorded and categorized (Soldati et al., 2020). The use of ultrasound and registration of data will not affect the regular patient evaluation, treatment or logistics.
62729527|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
62729528|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
62729529|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
62729530|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
62729531|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
62729532|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
62729533|NCT02974829||All patients|Continuing with marketed anti-HBV or off-treatment in real-life setting
62729534|NCT00358033|EXPERIMENTAL|group intervention|pharmacist-led group intervention in behavioral and pharmacologic therapy
62729535|NCT00358033|ACTIVE_COMPARATOR|individual|pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction
62729536|NCT00358033|NO_INTERVENTION|usual care|usual care
62729537|NCT06183151||Participants|All participants to undergo the same study method. Where all participants are to donate capillary blood to complete 2 tests on the investigational system and the remnant blood sample from routine CBC testing will also be tested on the investigational system. The routine CBC results will be compared to the results obtained by the investigational system.
62729538|NCT05252286|EXPERIMENTAL|video watching|In the video-watching group, a patient will follow the exercise instructions from watching the video. The exercise content in video are set during the patient conducting the rehabilitation program. Then, the therapist will select 3 to 5 groups of movements pattern needed to be enhanced catching from the video for the patient to practice when returning the bedside after the rehabilitation programs.
62729539|NCT05252286|ACTIVE_COMPARATOR|paper sheet|For the paper sheet group, the therapist will prepare the exercise leaflet, suitable for the patients, in advance, and select three to five groups of movement exercises on the leaflet that his/her therapist deem the patients needed to be enhanced. When the patients ends his/her rehabilitation program, they can practice following the instructions on the leaflet for them-self in bedside.
62729540|NCT05252286|PLACEBO_COMPARATOR|oral health education group|In the oral health education group, the program is similar to the paper sheet group without providing any exercise paper sheet the patient but oral education.
62729541|NCT04345692|EXPERIMENTAL|Hydroxychloroquine|Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5
62729542|NCT04345692|NO_INTERVENTION|Usual Care|usual care for hospitalized patients diagnosed with COVID-19
62729543|NCT04088799||FSGS requiring LDL-apheresis|Pediatric patients with FSGS requiring LDL-apheresis with the Liposorber
62729544|NCT04060004|OTHER|Control group|Electrotherapy + therapeutic exercise
62729545|NCT04060004|EXPERIMENTAL|Experimental group 1|Electrotherapy + therapeutic exercise + dry needling
62729546|NCT04060004|PLACEBO_COMPARATOR|Experimental group 2|Electrotherapy + therapeutic exercise + sham dry needling
62729547|NCT01594840|EXPERIMENTAL|Changing chat|Diapers will have tips on them
62729548|NCT01594840|ACTIVE_COMPARATOR|Control|Normal diapers
62729549|NCT00243867|EXPERIMENTAL|Arm A|(Taxoprexin® + carboplatin)
62729550|NCT00243867|ACTIVE_COMPARATOR|Arm B- Paclitaxel and carboplatin|(Paclitaxel and carboplatin)
62729551|NCT06513390|ACTIVE_COMPARATOR|healthys received intelligent mode first|healthy subjects received exoskeleton with intelligent mode first
62729552|NCT06513390|PLACEBO_COMPARATOR|healthys received default mode first|healthy subjects received exoskeleton with intelligent mode first
62729553|NCT03369015|EXPERIMENTAL|Placebo, then 10 mg d-amphetamine, then 20mg d-amphetamine|
62729554|NCT03369015|EXPERIMENTAL|Placebo, then 20 mg d-amphetamine, then 10mg d-amphetamine|
62729555|NCT03369015|EXPERIMENTAL|10 mg d-amphetamine, then placebo, then 20mg d-amphetamine|
62729556|NCT03369015|EXPERIMENTAL|10 mg d-amphetamine, then 20mg d-amphetamine, then placebo|
62729557|NCT03369015|EXPERIMENTAL|20 mg d-amphetamine, then 10mg d-amphetamine, then placebo|
62729558|NCT03369015|EXPERIMENTAL|20 mg d-amphetamine, then placebo, then 10mg d-amphetamine|
62729559|NCT01119066|EXPERIMENTAL|Total Body Irradiation, Thiotepa and Cyclophosphamide|Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
62729560|NCT01119066|EXPERIMENTAL|Busulfan, Melphalan and Fludarabine|Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)
62729561|NCT01119066|EXPERIMENTAL|Clofarabine, Melphalan and Thiotepa|Clofarabine (20mg/m2/ day x 5) (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
62729562|NCT01119066|EXPERIMENTAL|Melphalan, Fludarabine and Thiotepa|Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
62729563|NCT06221410|NO_INTERVENTION|Control Group|The control group will only receive traditional teaching methods (PowerPoint).
62729564|NCT06221410|EXPERIMENTAL|Funny Scenario-Based Group|"The Funny Scenario-Based approach is an educational approach where humor is integrated with scenario-based learning. Using this teaching strategy, comedic elements are incorporated into realistic or hypothetical scenarios to engage students and make learning more fun.~In such scenarios, students may encounter a wide range of characters, situations, and challenges designed to entertain and engage students with different types of medical terms. It is common to incorporate humor into the educational process, helping to maintain educational relevance while appealing to the student's sense of enjoyment."
62729565|NCT06221410|EXPERIMENTAL|Mind-mapping Group|"The term Mind-mapping Group refers to a collaborative educational setting in which students use mind-mapping as an instructional strategy. A mind map is a visual thinking tool that involves diagramming tasks, words, concepts, or items that are related to and arranged around a central concept."
62729566|NCT03235193|EXPERIMENTAL|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
62729567|NCT03235193|ACTIVE_COMPARATOR|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
62729568|NCT04981847|EXPERIMENTAL|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
62729569|NCT04981847|EXPERIMENTAL|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern. There is also less calcium and vitamin D because it includes fewer dairy foods.
62729570|NCT04981847|EXPERIMENTAL|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
62729571|NCT02995512|EXPERIMENTAL|Myocardial Infarction (MI) Patients|
62729572|NCT00610844|EXPERIMENTAL|1|pulmonary radiofrequency ablation
62729573|NCT01899131|OTHER|platform-switch tapered internal implants|2 platform-switch tapered internal implants placed in 10 participants.clinical and radiographic assessment in 6,12,24, month post implant insertion
62729574|NCT04227626|EXPERIMENTAL|GlucoSTAT|Type 1 diabetes and Type 2 diabetes with a total daily dose (TDD) of insulin that is \> 0.75 u/kg or ≥ 2 u/kg.
62729575|NCT01333722|PLACEBO_COMPARATOR|Placebo|placebo, 1 oral tablet every 12 hours
62729576|NCT01333722|EXPERIMENTAL|Hydrocodone/Acetaminophen Extended Release|hydrocodone/acetaminophen extended release, 1 oral tablet every 12 hours
62729577|NCT01320345|EXPERIMENTAL|Fenofibrate|145 mg tablet of fenofibrate administered daily for 36 months.
62729578|NCT01320345|PLACEBO_COMPARATOR|Placebo|Inert lactose tablet (otherwise matching active) administered daily for 36 months.
62729579|NCT01664117||bDMARD Monotherapy|Patients with moderate to severe rheumatoid arthritis (RA) will be treated with bDMARD (biologic disease-modifying antirheumatic drug) monotherapy under routine clinical practice conditions at rheumatology clinics
62729580|NCT03456258|EXPERIMENTAL|Lactoferrin|To measure hemoglobin difference and serum ferritin
62729581|NCT03456258|EXPERIMENTAL|Ferrous sulphate|To measure hemoglobin difference and serum ferritin
62729582|NCT01672086||Stelkast Surpass Patients|
62729583|NCT05685420|EXPERIMENTAL|open-label|Herombopag plus standard of care
62729584|NCT01804049|PLACEBO_COMPARATOR|Placebo|60 participants will be randomized to placebo pills.
62729585|NCT01804049|ACTIVE_COMPARATOR|Metformin|60 enrolled participants will be randomized to metformin.
62729586|NCT02130674|EXPERIMENTAL|Dipeptiven|0.75 g/ kg/ d Dipeptiven ( L- alanine- L- glutamine; 82 mg/ ml L- alanine, 134.6 mg/ ml L- glutamine; Fresenius Kabi, Switzerland) continuous intravenous infusion
62729587|NCT03896477|EXPERIMENTAL|Pneumosil|Infants received two primary vaccinations with Pneumosil, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
62729588|NCT03896477|ACTIVE_COMPARATOR|Synflorix|Infants received two primary vaccinations with Synflorix, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
62729589|NCT03896477|ACTIVE_COMPARATOR|Prevenar 13|Infants received two primary vaccinations with Prevenar 13, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
62729590|NCT02835703|ACTIVE_COMPARATOR|Deep hypothermic arrest|Surgical repair of coarctation of aorta under deep hypothermic circulatory arrest
62729591|NCT02835703|ACTIVE_COMPARATOR|Selective antegrade cerebral perfusion|Surgical repair of coarctation of aorta using selective antegrade cerebral perfusion
62729592|NCT02835703|ACTIVE_COMPARATOR|Double arterial cannulation|Surgical repair of coarctation of aorta using cerebral antegrade perfusion with descending aortic cannulation
62729593|NCT04462029|OTHER|sequence 1|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~* R(Reference): BR4002-1 (oral intake) 5mg single-dose~* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 1: R - T1 - T2"
62729594|NCT04462029|OTHER|sequence 2|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~* R(Reference): BR4002-1 (oral intake) 5mg single-dose~* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 2: R - T2 - T1"
62729595|NCT04462029|OTHER|sequence 3|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~* R(Reference): BR4002-1 (oral intake) 5mg single-dose~* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 3: T1 - R - T2"
62729596|NCT04462029|OTHER|sequence 4|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~* R(Reference): BR4002-1 (oral intake) 5mg single-dose~* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 4: T1 - T2 - R"
62729597|NCT04462029|OTHER|sequence 5|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~* R(Reference): BR4002-1 (oral intake) 5mg single-dose~* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 5: T2 - R - T1"
62729598|NCT04462029|OTHER|sequence 6|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~* R(Reference): BR4002-1 (oral intake) 5mg single-dose~* T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~* T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 6: T2 - T1 - R"
62729599|NCT01845246|NO_INTERVENTION|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
62729600|NCT01845246|EXPERIMENTAL|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
62729601|NCT02970136|EXPERIMENTAL|Home Based Screening|The participant will be receiving home-based screening tests (OraQuick Swab, OraQuick Fingerstick, Human Papillomavirus (HPV) Self-Sampling Test, Fecal Immunochemical Test) delivered by the community health worker
62729602|NCT02970136|ACTIVE_COMPARATOR|Clinic Based Screening|The participant will meet the Community Health Worker and will be navigated to a clinic appointment for standard screening tests
62729603|NCT02186782|ACTIVE_COMPARATOR|Clomiphene citrate-Estradiol group|Women will receive clomiphene citrate and estradiol
62729604|NCT02186782|ACTIVE_COMPARATOR|Clomiphene citrate group|Women will receive clomiphene citrate and placebo
62729605|NCT01669525||No treatment|Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
62729606|NCT04195490|OTHER|children with disorders of sex development|children with disorders of sex development needing feminizing genitoplasty
62729607|NCT00094926|EXPERIMENTAL|001|
62729608|NCT00094926|PLACEBO_COMPARATOR|002|
62729609|NCT06056206|ACTIVE_COMPARATOR|Plain Balloon Angioplasty|Plain Balloon Angioplasty will be used to treat lesions.
62729610|NCT06056206|ACTIVE_COMPARATOR|Sirolimus-coated Balloon Angioplasty|Sirolimus-coated Balloon Angioplasty will be used to treat lesions after preparing vessel with plain balloon angioplasty.
62729611|NCT05211193||eTNM arm|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1- 42.
62729612|NCT05912595|ACTIVE_COMPARATOR|EXOPULSE Mollii Suit Stimulation Active.|This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes.
62729613|NCT05912595|SHAM_COMPARATOR|EXOPULSE Mollii Suit Stimulation Sham.|This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes.
62729614|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 1.8 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
61978253|NCT03716882||Infant at the birth|"Infant at the birth will be included. Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights.~At every cry, parent should answer the questionnaire of cry in infant."
61978254|NCT04857515||Cigarette Smokers|Adult cigarette smokers who only smoke combustible cigarettes
62729615|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 1.95 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729616|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 1.98 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729617|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 2.04 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729618|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 2.10 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729619|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 2.14 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729620|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 2.19 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729621|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 2.22 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729622|NCT02257242|EXPERIMENTAL|Vincristine sulfate liposome injection 2.24 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
62729623|NCT03723798|EXPERIMENTAL|Group 1|SA001 Low dose
62729624|NCT03723798|EXPERIMENTAL|Group 2|SA001 Mid dose
62729625|NCT03723798|EXPERIMENTAL|Group 3|SA001 High dose
62729626|NCT03723798|PLACEBO_COMPARATOR|Placebo|Placebo
62729627|NCT00959491||Colonoscopy indication|All outpatients referred to colonoscopy according to inclusion criteria in the specified period time of one year .
62729628|NCT01247454|OTHER|academic detailing|All arms will receive this intervention
62729629|NCT01247454|EXPERIMENTAL|Electronic Health Record (EHR) prompt|One intervention arm will receive the EHR prompt along with the academic detailing
62729630|NCT01247454|EXPERIMENTAL|EHR prompt and patient prompt|The final arm will receive this combined intervention plus the academic detailing
62729631|NCT01444001|EXPERIMENTAL|Pneumococcal Vaccine Dose 1 (Low dose)|Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.
62729632|NCT01444001|EXPERIMENTAL|Pneumococcal Vaccine Dose 2 (Middle dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.
62729633|NCT01444001|EXPERIMENTAL|Pneumococcal Vaccine Dose 3 (High dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.
62729634|NCT01591408|EXPERIMENTAL|EEG biofeedback|Subjects will receive EEG biofeedback according to their own brain rhythms
62729635|NCT01591408|SHAM_COMPARATOR|sham EEG biofeedback|Subjects will receive feedback according to someone else's brain rhythms collected during a different session.
62729636|NCT05340998||Crossover Group|Patients with Transradial access failure for percutaneous coronary procedures necessitating vascular crossover
62729637|NCT05340998||Non Crossover Group|Patients with successful transradial access for percutaneous coronary procedures
62729638|NCT00334737|EXPERIMENTAL|Darbepoetin alfa injection|Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
62729639|NCT00334737|ACTIVE_COMPARATOR|erythropoietin alfa injection|Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
62729640|NCT00334737|PLACEBO_COMPARATOR|placebo/control|Sham injection
62729641|NCT02440139|NO_INTERVENTION|Arm 1|Participating radiologists will perform clinical reading on \~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
62729642|NCT02440139|ACTIVE_COMPARATOR|Arm 2|Participating radiologists will perform clinical reading on \~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
62729643|NCT02076854|EXPERIMENTAL|Text-Message Intervention|Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder.
62729644|NCT02076854|NO_INTERVENTION|No Text Message Phase|Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder.
62729645|NCT03103646|EXPERIMENTAL|Lu AF35700|Day 1: Single dose of Lu AF35700. Extensive metabolisers (EMs): 10mg. Poor metabolisers (PMs): 5 mg
62729646|NCT03103646|EXPERIMENTAL|Lu AF35700 AND itraconazole|Days 29 to 31: once-daily dosage of 200 mg itraconazole. Day 32: Single dose of Lu AF35700 (EMs: 10 mg, PMs: 5 mg) and 300 mg itraconazole Days 33 to 42: once-daily dosage of 200 mg itraconazole
62729647|NCT02216916|EXPERIMENTAL|HM781-36B|
62729648|NCT03439046|EXPERIMENTAL|ribociclib+letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
62729649|NCT03439046|EXPERIMENTAL|alpelisib+fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
62737171|NCT06242990|NO_INTERVENTION|Control Group|Participants will continue to receive their usual physical education classes.
62729650|NCT05540626|NO_INTERVENTION|Standard of Care Arm|Baseline tremor power without stimulation (SOC arm) over the first month of the study. Subjects in the SOC arm will be asked to measure their tremor severity by doing daily postural holds with the Cala Trio device without actual stimulation.
62729651|NCT05540626|EXPERIMENTAL|Intervention with the Cala Trio device (CTD) arm|Tremor power after stimulation with Cala Trio. Subjects in the intervention arm will wear the device at home for a period of 12 months, during which they will deliver 40 min stimulation sessions, which can be started and stopped on demand.
62729652|NCT04633135|NO_INTERVENTION|Control|Households enrolled in the control arm of the study did not receive either improved cookstove
62729653|NCT04633135|EXPERIMENTAL|Gyapa/Gyapa|Households enrolled in the Gyapa/Gyapa arm of the study received two Gyapa stoves for free
62729654|NCT04633135|EXPERIMENTAL|Gyapa/Philips|Households enrolled in the Gyapa/Philips arm of the study received one Gyapa stove and one Philips stove for free
62729655|NCT04633135|EXPERIMENTAL|Philips/Philips|Households enrolled in the Philips/Philips arm of the study received two Philips stoves for free
62729656|NCT06156852|ACTIVE_COMPARATOR|Mindfulness-based stress reduction group (MBSR)|Medical faculty students who volunteered to participate in the study were assessed by a senior psychiatry resident. The students who were found to be eligible to take part in the study were randomized to two groups (MBSR and CBSR groups).
62729657|NCT06156852|ACTIVE_COMPARATOR|Cognitive behavioral based stress reduction group (CBSR)|Medical faculty students who volunteered to participate in the study were assessed by a senior psychiatry resident. The students who were found to be eligible to take part in the study were randomized to two groups (MBSR and CBSR groups).
62729658|NCT00550342|EXPERIMENTAL|Rituximab|Rituximab (375 mg/m2) will be administered intravenously as per current package label in a facility capable of handling infusion reactions. Subjects would be pre dosed with diphenhydramine and acetaminophen. Solu-Medrol, 1.5 mg/kg would be dosed 1 hour prior to the first dose of rituximab. Three subsequent doses of rituximab will be given at weekly intervals.
62729659|NCT02820844|EXPERIMENTAL|GSK1358820 Injection 100 U|"Initially, subjects will receive a single (double-blind) treatment with GSK1358820 (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment with GSK1358820 (open-label). A third treatment with GSK1358820 (open-label) may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
62729660|NCT02820844|PLACEBO_COMPARATOR|Placebo Injection|"Initially, subjects will receive a single (double-blind) treatment with Placebo (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment, this time with open-label GSK1358820. A third treatment with open-label GSK1358820 may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
62729661|NCT06075134|EXPERIMENTAL|EMG-guided Botox injection|Botox injection in patients with gummy smile will be done under electromyography guidance to target the most hyperactive and effective muscle that is the chief factor causing the condition.
62729662|NCT06075134|ACTIVE_COMPARATOR|Conventional Botox injection in Yonsei point|Conventional injection of Botox is located in Yonsei point, which is the center of a triangle formed by the convergence of Levator labii superioris alaeque nasi (LLSAN), levator labii superioris (LLS), zygomaticus minor (ZMn), muscles, and is located 1 cm lateral to the ala of the nose horizontally and 3 cm above the lip line vertically.
62729663|NCT00323531|ACTIVE_COMPARATOR|1|Video assisted thoracoscopic decortication
62729664|NCT00323531|EXPERIMENTAL|2|Fibrinolysis through the chest tube
62729665|NCT03742570||CBBDQ|A Questionnaire
62729666|NCT03516175|ACTIVE_COMPARATOR|Tight fitting mask|Pre oxygenation with tight facemask with 100% oxygen
62729667|NCT03516175|EXPERIMENTAL|High flow nasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange is used for pre oxygenation
62729668|NCT01735383|EXPERIMENTAL|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
62729669|NCT01735383|ACTIVE_COMPARATOR|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
62729670|NCT05976152|EXPERIMENTAL|dl-3-butylphthalide|Routine treatment and dl-3-butylphthalide
62729671|NCT05976152|PLACEBO_COMPARATOR|dl-3-butylphthalide Placebo|Routine treatment and dl-3-butylphthalide Placebo
62729672|NCT03374735|EXPERIMENTAL|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
62729673|NCT01569737||ella|
62729674|NCT04921852|ACTIVE_COMPARATOR|costoclavicular group|
62729675|NCT04921852|ACTIVE_COMPARATOR|lateral sagittal group|
62729676|NCT03497039|EXPERIMENTAL|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm\^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
62729677|NCT03497039|PLACEBO_COMPARATOR|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm\^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
62729678|NCT05231850|EXPERIMENTAL|Tislelizumab|Tislelizumab
62729679|NCT01154335|EXPERIMENTAL|Dose Level 1|"combination of OSI-906 and everolimus~OSI-906: 50 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
62729680|NCT01154335|EXPERIMENTAL|Dose Level 2|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 10mg Daily, cycle-28 days"
62729681|NCT01154335|EXPERIMENTAL|Dose Level 2a|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
62729682|NCT04312139||Fast progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated fast progression from moderate to severe aortic valve stenosis: echocardiographic dVmax\>0.25 m/sec/year (difference in transaortic Vmax).
62737953|NCT02253433|EXPERIMENTAL|Enhanced Clinic Care + Home Intervention|This arm receives the enhanced in-clinic care intervention, as well as a home-based intervention.
62165996|NCT00472056|EXPERIMENTAL|BEAM + High Rituximab|"BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~High Dose Rituximab: 1000 mg/m\^2 IV Days +1, +8 after Stem Cell Infusion on Day 0"
62165997|NCT05935098|EXPERIMENTAL|Phase 1a Part A: Dose Escalation (BGB-A3055 Monotherapy)|Different groups of participants will receive increasing doses of BGB-A3055 alone to determine the most appropriate dosage levels.
62165998|NCT05935098|EXPERIMENTAL|Phase 1a Part B: Dose Escalation (BGB-A3055 + tislelizumab)|Different groups of participants will receive increasing doses of BGB-A3055 in combination with tislelizumab to determine the most appropriate dosage levels.
62165999|NCT05935098|EXPERIMENTAL|Phase 1b (Dose Expansion):|Participants will receive the recommended dose for expansion phase (RDFE) of BGB-A3055 in combination with tislelizumab to provide additional information on the safety, tolerability, and potential benefits of the recommended dose.
62166000|NCT03055819|EXPERIMENTAL|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
62166001|NCT01780584|ACTIVE_COMPARATOR|Oral T3 low dose & placebo|Oral T3 low dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) starting on induction of anesthesia and then every 24 hours alternating with placebo, which was given 12 hours after the first dose of oral T3 and then every 24 hours until 60 hours post anesthesia induction (3 doses oral T3, 3 doses placebo)
62166002|NCT01780584|PLACEBO_COMPARATOR|Placebo|Placebo (saccharin lactic) administer through nasogastric tube, given starting on induction of anesthesia and then every 12 hours until 60 hours post-anesthesia induction (6 doses total)
62166003|NCT01780584|EXPERIMENTAL|Oral T3 high dose|Oral T3 high dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) q12h starting on induction of anesthesia until 60 hours post-anesthesia (6 doses oral T3)
62166004|NCT06069596|ACTIVE_COMPARATOR|Study group|obstetric lubricant gel was applied to patients in the study groups, which had 47 nulliparous and 50 primiparous patients.
62166005|NCT06069596|NO_INTERVENTION|Control group|obstetric lubricant gel was not applied to patients in the control groups, which had 55 nulliparous and 43 primiparous patients.
62166006|NCT05055141|EXPERIMENTAL|Care to Share Poster|"The intervention was an 18x18 poster board with a large blank surface for patients to share information about who they are as people and what is important to them. The Care to Share poster was co-designed with ten medicine inpatients during pilot testing. The goal of the poster was to equip Caregivers with humanizing information about their patients, thereby provoking more genuine empathetic interactions. Based on input from pilot testing, the researcher wrote on the poster for the patient to ensure ease of completion and legibility. The posters were displayed on the wall behind patients' beds, so Caregivers entering the room could easily see the information when facing the patient."
62166007|NCT05055141|NO_INTERVENTION|Control|Study participants hospitalized on the two control units had no Care to Share poster.
62166008|NCT02176317|EXPERIMENTAL|Autologous Umbilical Cord Blood (UCB)|All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
62166009|NCT01828749||CT abdomen and pelvis|blunt trauma patients without suspected fractures of the pelvis, hip or lumbar spine in two age groups: ages 3-17 years and 18-60 years
62166010|NCT02653066|NO_INTERVENTION|Control|Participant is recruited via usual avenues including flyers and physician referral. This includes participants who received a HealtheRx with advertisement for phone survey but did not call in based on advertisement.
62729683|NCT04312139||Slow progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated slow progression from moderate to severe aortic valve stenosis: echocardiographic dVmax\<0.15 m/sec/year (difference in transaortic Vmax).
62166011|NCT02653066|EXPERIMENTAL|Intervention with consent form|After completing survey, participant in HealtheRx+ group receives $5 bill with their survey check and blank registry consent form.
62166012|NCT02653066|EXPERIMENTAL|Intervention with return of consent form|After returning signed consent form, participant in HealtheRx++ group is mailed $5 bill.
62166013|NCT02927288||Military subjects with mTBI|mTBI/concussion only Group: Participants must have been clinically diagnosed with mTBI/concussion according to criteria outline by the World Health Organization (WHO; Holm et al., 2005) and be at least three month post-injury. Participants in the mTBI/concussion only group must not have a concurrent diagnosis of PTSD and must score below 25 on the Post-traumatic stress Check List for Civilians (PCL-C).
62166014|NCT02927288||Military subjects with PTSD|Participants in the PTSD only group must have a clinical diagnosis of PTSD, following criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR). Proof of diagnosis will be obtained from participants via a request for release of pertinent medical records. Participants in this group must not have a history of mTBI or concussion.
62166015|NCT02927288||Military subjects with mTBI and PTSD|Participants in the mixed group must meet criteria for mTBI/concussion and PTSD as outlined above.
62166016|NCT02927288||Military healthy control|Participants in the military control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above. Participants in this group will include service members on Active Duty and those currently serving with National Guard or Reserve forces.
62166017|NCT02927288||Civilian healthy control|Participants in the civilian control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above.
62166018|NCT06266065|EXPERIMENTAL|Coronary Sinus Reducer|
62166019|NCT04200547|EXPERIMENTAL|Immunomonitoring-based follow-up|Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum.
62729684|NCT04312139||Prospective Moderate Aortic Valve Stenosis|100 consecutive prospectively enrolled patients with moderate aortic valve stenosis. Plus 20 patients accounting for 20% drop-out rate, total prospective cohort = 120 patients.
62166020|NCT04200547|ACTIVE_COMPARATOR|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. This strategy is the standard strategy for post-operative follow-up of Crohn's disease patients.
62166021|NCT00563433|ACTIVE_COMPARATOR|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
62166022|NCT00563433|ACTIVE_COMPARATOR|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
62166023|NCT05789927||Patient who received antibiotic prophylaxis|"Severe T2-High asthmatics treated with biotherapy"
62166024|NCT01596634|EXPERIMENTAL|Supportive care (bovine lactoferrin)|Patients receive bovine lactoferrin PO (rinse or tablet) TID for 1 month. Treatment continues in the absence of unacceptable toxicity.
62166025|NCT03953209|EXPERIMENTAL|spironolactone 50 mg|Oral administration of spironolactone 50 mg once daily for 12 weeks
62166026|NCT03953209|EXPERIMENTAL|spironolactone 100 mg|Oral administration of spironolactone 100 mg once daily for 12 weeks
62166027|NCT03953209|EXPERIMENTAL|spironolactone 200 mg|Oral administration of spironolactone 200 mg once daily for 12 weeks
62166028|NCT06646315|EXPERIMENTAL|Early intervention|Participants will be assessed using ESAS, ENP and adhoc sociofamiliar questions just before entering their Phase I Clinical Trial (T0). Responses of this assessment will be discussed in a multidisciplinary committee comprised of a palliative physician, a clinical psychologist, a social worker, an oncologist, an hematologist and the Phase 1 Unit referent nurse. According to the patient responses, the committee will decide which needs will be addressed and this will be cited to the corresponding professional (palliative, psychologist and/or social worker) within the following 15 days. The same cycle (assessment - committee - attention) will take place a month after the T0 (T1), and during the following 2 other months (T2 and T3).
62166029|NCT06646315|NO_INTERVENTION|TAU|Participants will be assessed using ESAS, ENP and adhoc sociofamiliar questions just before entering their Phase I Clinical Trial (T0), one month after (T1), two months after (T2) and three months after (T3).
62166030|NCT04915456|EXPERIMENTAL|Systemic steroid (Prednisolone)|Prednisolone 50mg (tapered down until postoperative day (POD) 14, then 5mg for 14 days), tablets
62166031|NCT04915456|PLACEBO_COMPARATOR|Placebo|Lactose monohydrate, tablets
62166032|NCT02971683|ACTIVE_COMPARATOR|Abatacept subcutaneous + Standard Treatment|Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
62166033|NCT02971683|PLACEBO_COMPARATOR|Placebo of Abatacept subcutaneous + Standard Treatment|Placebo of Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
62166034|NCT05473221|EXPERIMENTAL|CD33 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
62166035|NCT01901302|EXPERIMENTAL|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
62166036|NCT01901302|PLACEBO_COMPARATOR|Placebo|Placebo BID for a 12-week treatment period
62166037|NCT02843542|OTHER|Control Group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT)
62166038|NCT02843542|OTHER|Study group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT) and in addition will also undergo the PET-MR
62166039|NCT05308199|EXPERIMENTAL|experimental|thoracic manipulation group
62166040|NCT05308199|ACTIVE_COMPARATOR|control|MET group
62166041|NCT04443881|EXPERIMENTAL|Anakinra Arm|Standard of care plus Anakinra (100mg) administered as 4-times daily i.v. infusions for a maximun of 15 days
62166042|NCT04443881|NO_INTERVENTION|Control Arm|Standard of care
62166043|NCT06585475|EXPERIMENTAL|Experimental group|The intervention group received a 3-session PMS symptom map-structured training by the responsible and first author (ADK). Before the training, pre-test data were collected using data collection tools (VAS pain scoring, DAS depression stress anxiety assessment scale, premenstrual syndrome assessment scale and premenstrual syndrome-specific life satisfaction scale). After the training, post-test data were collected on the last day of the 1nd cycle.
62166044|NCT06585475|NO_INTERVENTION|Control group|No intervention was applied to the control group. After the participants were divided into groups by randomization, pre-test data were collected using data collection tools (VAS pain scoring, DAS depression stress anxiety rating scale, premenstrual syndrome rating scale and premenstrual syndrome specific life satisfaction scale). After the pre-test, post-test data were collected on the last day of the cycle after 1 menstrual cycles.
62166045|NCT02286297|EXPERIMENTAL|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
62166046|NCT02286297|EXPERIMENTAL|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
62166047|NCT05558241|EXPERIMENTAL|Combined MRI and micro-ultrasound guided prostate biopsy.|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
62729685|NCT04312139||Negative calcium score group|50 patients at intermediate to high risk for Cardiovascular Disease (CVD) and negative aortic valve and coronary calcium score at CT scan, prospectively followed-up. Plus 10 patients accounting for 20% drop-out rate, total control cohort = 60 patients.
62729686|NCT01807325||pancreas cysts and solid masses|patents referred for solid and cystic lesions of the pancreas who will have a biopsy for usual medical care.
61978255|NCT04857515||Dual-Users|Adult smokers who smoke both combustible cigarettes and vape
62166048|NCT01066897|EXPERIMENTAL|Pramipexole|Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (\> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.
62166049|NCT01066897|NO_INTERVENTION|Healthy Controls|Non depressed, non-intervention comparison group
62166050|NCT03924596|EXPERIMENTAL|Luban Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
62166051|NCT03924596|ACTIVE_COMPARATOR|Uralyt-U Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)
62166052|NCT03924596|EXPERIMENTAL|Luban Uric acid|25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
62166053|NCT03924596|ACTIVE_COMPARATOR|Uralyt-U Uric acid|25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2
62166054|NCT01114217|EXPERIMENTAL|Ferumoxytol|Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 \[NCT01114139\]. Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin \<11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) \<20% at any evaluation visit, (except study termination visit). Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV). The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1. The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
62166055|NCT03435809|ACTIVE_COMPARATOR|Pozzi for intrauterine insemination|Treatment done with a pozzi tenaculum forceps
62166056|NCT03435809|ACTIVE_COMPARATOR|No Pozzi for intrauterine insemination|Treatment done without a tenaculum forceps
62166057|NCT01607099|EXPERIMENTAL|Pico Prep|Arm in which sodium- picosulfate/magnesium citrate is used for bowel cleansing
62166058|NCT01607099|NO_INTERVENTION|Standard|The standard drug macrogol is used for bowel cleansing
62166059|NCT05348642|EXPERIMENTAL|Experimental group receiving pasteurized Akkermansia muciniphila|pasteurized Akkermansia muciniphila - daily oral dose
62166060|NCT05348642|PLACEBO_COMPARATOR|Control group|Control group receiving placebo, identical to verum regarding the form, size, taste, color and intake.
62166061|NCT01532830|EXPERIMENTAL|Active|n-VNS active therapy
62166062|NCT04304898||Single Group Assignment|Intervention group without a control group
62166063|NCT05288504|EXPERIMENTAL|AVTX-002|Approximately 40 subjects will receive AVTX-002 at a dose of 600 mg three times during the study.
62166064|NCT05288504|PLACEBO_COMPARATOR|Placebo|Approximately 40 subjects will receive placebo sourced as normal saline three times during the study.
62166065|NCT01598688|ACTIVE_COMPARATOR|Blood collection immediately after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
62166066|NCT01598688|EXPERIMENTAL|Blood collection five minutes after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
62166067|NCT01198899||left ventricular hypertrophy|Patients with left ventricular hypertrophy will be used.
62166068|NCT02169245|EXPERIMENTAL|Average Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and fiber for this age group for 2 weeks.
62166069|NCT02169245|EXPERIMENTAL|Average Protein and High Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and higher than average amount of fiber for this age group for 2 weeks.
62729687|NCT00534768|ACTIVE_COMPARATOR|1|debridement on 1st, 3-5th and 7th postoperative days
62166070|NCT02169245|EXPERIMENTAL|High Protein and Average Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of fiber and higher than average amount of protein for this age group for 2 weeks.
62166071|NCT02169245|EXPERIMENTAL|Higher Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with a higher than average amount of protein and fiber for this age group for 2 weeks.
62166072|NCT03942861||Severe Ulcerative Colitis|Consecutive patients admitted as in-patients to the Department of Gastroenterology at four University Hospitals in Denmark, with acute severe UC defined as an affirmed diagnosis of UC according to well established criteria, combined with a Mayo score of 8 or more (i.e. severe disease activity) and the need for intravenous corticosteroid treatment will be screened for participation in the study after informed consent.
62166073|NCT02154893|EXPERIMENTAL|Device and exercise|Device with ultrasound and laser associated with therapeutic exercise
62166074|NCT02154893|EXPERIMENTAL|Device|Device with ultrasound and laser
62729688|NCT00534768|ACTIVE_COMPARATOR|2|
62166075|NCT02154893|PLACEBO_COMPARATOR|Placebo|Without any treatment
62166076|NCT05889221|EXPERIMENTAL|Combination isatuximab SC, lenalidomide, bortezomib and dexamethasone|
62166077|NCT03599934|EXPERIMENTAL|LiFE training and home safety assessment|The participants will receive Lifestyle Integrated Functional Exercise Program and Home safety assessment
62729689|NCT00625534|EXPERIMENTAL|1|Laparoscopic repair
62729690|NCT00625534|ACTIVE_COMPARATOR|2|Open tension free inguinal hernia mesh repair
62729691|NCT02895178|EXPERIMENTAL|Exercise in breast cancer survivors|Combined aerobic and strength exercise training for 12 weeks under supervision
62166078|NCT03599934|NO_INTERVENTION|Control group|The control group will continue their usual daily routine.
62166079|NCT00998387||medical ICU|admitted to medical ICU at Seoul National University Hospital longer than 24 hours
62166080|NCT05813249|ACTIVE_COMPARATOR|NAFLD1|Hepatic steatosis
62166081|NCT05813249|ACTIVE_COMPARATOR|NAFLD2|Hepatic steatosis
62166082|NCT05813249|ACTIVE_COMPARATOR|NAFLD3|Hepatic steatosis
62166083|NCT06470347|EXPERIMENTAL|pyrrolitinib|Subjects will receive 52 weeks (approximately 1 year) of continuous oral administration of piretinib, 400 mg administered once daily, within 30 minutes of breakfast.
62166084|NCT03925402||Ertapenem|Patients who received ertapenem as an empirical antibiotic
62166085|NCT03925402||Other carbapenems|Patients who received carbapenems other than ertapenem as an empirical antibiotic
62166086|NCT03418701|ACTIVE_COMPARATOR|Patient Centered Culturally Sensitive WLM|This program is designed to enable physicians to: (a) talk with their patients about their weight, weight loss goals, goal barriers, strategies for overcoming these barriers, and deliver this talk in patient-centered, culturally sensitive ways, (b) assist their patients with engaging in self-identified strategies for achieving and sustaining their self selected goals for weight loss and overall health, (c) be knowledgeable about health-smart behaviors, (d) use behaviors and display attitudes in physician-patient interactions with patients that are provider cultural sensitivity indicators in published literature, and (e) say and display behaviors and attitudes that patients identified as important when discussing obesity and losing weight.
62166087|NCT03418701|ACTIVE_COMPARATOR|Standard Behavioral WLM|This program is designed to enable physicians to: (a) implement motivational interviewing approaches when talking with their patients about their weight loss goals and behavioral strategies to achieve these goals, (b) become knowledgeable about empirically supported behavioral change principles that have been used to help patients maintain weight loss in previous interventions, (c) communicate how to use these empirically supported behavioral change principles to have patients initiate or maintain their self-selected health-smart goals related to weight loss and/or weight loss maintenance, and (d) use motivational interviewing approaches to communicate empathy and understanding with patients who are struggling to maintain their weight loss and/or accomplish a behavioral goal.
62166088|NCT06247878||Sleep apnea/hypopnea detection|Ability of Skiin underwear chest band in detecting sleep apnea or hypopnea will be tested against polysomnography.
62166089|NCT03360071|EXPERIMENTAL|Allergen Immunotherapy Group|
62166090|NCT03360071|PLACEBO_COMPARATOR|Control Group|
62166091|NCT02553616|EXPERIMENTAL|Behavioral intervention|Intervention to promote healthy behaviors.
62166092|NCT05099978||NGS analysis of ctDNA|"This study consists of 6 cohorts; cervical cancer(n=100), ovarian clear cell cancer(n=50), nasopharyngeal cancer(n=96), ovarian cancer(n=100), breast cancer(n=100), endometrial cancer(n=60).~In each cohort, the blood samples will be collected within 2weeks after registration. ctDNA will be extracted from blood samples and somatic gene abnormalities will be analyzed using NGS, PCR, and Sanger sequencing. In addition, the analysis of DNA methylation and RNA sequencing may be performed to obtain information related to gene expression."
62166093|NCT05685251|EXPERIMENTAL|Health Coaching|
62166094|NCT05685251|NO_INTERVENTION|Standard of Care|
62166095|NCT00796497|EXPERIMENTAL|ondansetron|
62166096|NCT06232941|EXPERIMENTAL|Odontocem pulpotomy agent|calcium silicate-based technology containing 0.2% of the low steroid triamcinolone acetonide and has outstanding biocompatibility, handling properties and least amount of staining potential
62166097|NCT06232941|ACTIVE_COMPARATOR|NeoPutty bioceramic|premixed format of tricalcium silicate-based material (Bioceramic). It's composed of tantalum oxide, tricalcium silicate, calcium aluminate, dicalcium silicate, tricalcium aluminate, and calcium sulfate
62166098|NCT06232941|ACTIVE_COMPARATOR|Mineral Trioxide Aggregate material|hydrophilic and biocompatible endodontic biomaterial, capable of stimulating healing and osteogenesis
62166099|NCT00148616|ACTIVE_COMPARATOR|Memantine plus Risperidone|24 weeks memantine add on treatment to risperidone
62166100|NCT00148616|PLACEBO_COMPARATOR|Placebo plus Risperidone|24 weeks placebo add on treatment to risperidone
62166101|NCT05879822|EXPERIMENTAL|Part 1: INCB099280 Dose 1|Participants will receive INCB099280 dose 1 twice daily (BID) for up to 2 years.
62166102|NCT05879822|EXPERIMENTAL|Part 1: INCB099280 Dose 2|Participants will receive INCB099280 dose 2 twice daily (BID) for up to 2 years.
62166103|NCT05879822|EXPERIMENTAL|Part 1: INCB099280 Dose 3|Participants will receive INCB099280 dose 3 twice daily (BID) for up to 2 years
62166104|NCT05879822|EXPERIMENTAL|Part 2: INCB099280 Dose selected from Part 1|Participants will receive INCB099280 dose selected from Part 1 twice daily (BID) for up to 2 years.
62729692|NCT02895178|NO_INTERVENTION|No exercise in breast cancer survivors|Lifestyle counseling and standard of care follow up for 12 weeks
61978256|NCT00735592||A|Children discharged with the recommendation of performing a follow up X rays after lobar pneumonia
62166105|NCT03362684|EXPERIMENTAL|FOLFOX-4 plus Cetuximab|
62166106|NCT03362684|ACTIVE_COMPARATOR|FOLFOX-4|
62166107|NCT02868788|OTHER|high fat high calorie meal (HFHC)|Subjects in this arm will receive high fat high calorie (HFHC) meal only
62166108|NCT02868788|EXPERIMENTAL|HFHC plus fiber|Subjects in this arm will receive HFHC meal plus dietary fiber supplementation
62166109|NCT06248021|EXPERIMENTAL|Ecological Footprint Awareness Program Group|The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature.
62166110|NCT06248021|NO_INTERVENTION|Control Group|No intervention was applied to the group
62166111|NCT01942538|EXPERIMENTAL|rTMS-rTMS|subjects receiving real rTMS treatment and real rTMS maintenance sessions
62166112|NCT01942538|SHAM_COMPARATOR|sham - sham|subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
62166113|NCT01942538|SHAM_COMPARATOR|rTMS-sham|subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
62166114|NCT01942538|EXPERIMENTAL|rTMS|real rTMS for 3 weeks but without clinical improvement
62166115|NCT01942538|SHAM_COMPARATOR|sham|sham treatment for 3 weeks without clinical improvement
62166116|NCT04006652|EXPERIMENTAL|Recipient|"* Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy which will be administered at the discretion of the treating physician~* Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines"
62166117|NCT04006652|NO_INTERVENTION|Donor|-Donors will undergo apheresis from peripheral blood after daily G-CSF administration (for up to 5 days prior to Day -1)
62166118|NCT03892122|OTHER|Propofol group|"Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient~. The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group"
62166119|NCT03892122|OTHER|Dexmedetomidine group|For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.
62166120|NCT06301529|ACTIVE_COMPARATOR|100mg|Participants assigned to this arm will be taking 100mg daily, up to 7 times, for study duration.
62166121|NCT06301529|EXPERIMENTAL|150mg|Participants assigned to this arm will be taking 150mg, every other day, up to 4 times, for study duration.
62166122|NCT00702234||Women/Expectant Mothers - Corifollitropin Alfa 150 µg|In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin (\[rec\]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
62166123|NCT05530928|NO_INTERVENTION|Control Group|This group will receive the standard care (standard family planning counseling)
62166124|NCT05530928|OTHER|Intervention Group|This group will receive the standard family planning counseling + reproductive life plan counseling.
62166125|NCT05326802||U.S. Embryologists|U.S. embryologists of all ages, career levels, and other sociodemographic groups will be asked questions about their physical and mental health related to their occupational characteristics using the nationally validated surveys and questionnaires, and also about their working conditions in the ART/IVF laboratories using a custom occupational questionnaire and the single-item work unit grade (A-F).
62166126|NCT03971799|EXPERIMENTAL|CD33CART autologous|Patients who receive an autologous CD33CART cell infusion
62166127|NCT03971799|EXPERIMENTAL|CD33 CART allogeneic|Patients who receive an allogeneic CD33CART cell infusion
62166128|NCT02686983|EXPERIMENTAL|Active|Betamethasone and local anesthetic.
62166129|NCT02686983|PLACEBO_COMPARATOR|Placebo|Saline with local anesthetic.
62166130|NCT01248078|ACTIVE_COMPARATOR|Cefazolin A|administered before skin incision
62166131|NCT01248078|ACTIVE_COMPARATOR|Cefazolin B|after umbilical cord clamping
62166132|NCT01248078|PLACEBO_COMPARATOR|saline solution|administered before skin incision
62166133|NCT06375018|PLACEBO_COMPARATOR|Control group|After data collection, each volunteer will undergo a simulated technique within this group. The investigator will mimic the contacts of the phrenic nerve inhibition technique without applying traction or compression to the tissue, merely maintaining the contacts for the same duration as described in the technique performed in the experimental group, along with the same rest period afterward. Subsequently, new data will be collected following the simulated intervention.
62166134|NCT06375018|EXPERIMENTAL|Experimental group|After collecting data from each volunteer, a Diaphragm Stretching technique will be administered to individuals in this group. The technique will be executed for a maximum duration of 4 minutes. Following the technique, volunteers will be required to rest for 5 minutes. Subsequently, another round of data collection will be conducted.
62166135|NCT03320941|EXPERIMENTAL|LIK066 2.5 mg|Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
62166136|NCT03320941|EXPERIMENTAL|LIK066 10 mg|Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
62166137|NCT03320941|EXPERIMENTAL|LIK066 25 mg|Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
62729693|NCT02895178|SHAM_COMPARATOR|Exercise in healthy subjects|Age-matched healthy subjects. Combined aerobic and strength exercise training for 12 weeks under supervision
61978257|NCT06327867|ACTIVE_COMPARATOR|Direct Laryngoscopy|All participants who are intubated from Direct laryngoscopy is enrolled in this arm.
62166138|NCT03320941|EXPERIMENTAL|LIK066 50 mg|Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
62166139|NCT03320941|PLACEBO_COMPARATOR|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
62166140|NCT03684278|ACTIVE_COMPARATOR|Infusion of 5 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 5 mg of Infliximab, per kg of patient body weight.
62166141|NCT03684278|ACTIVE_COMPARATOR|Infusion of 10 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 10 mg of Infliximab, per kg of patient body weight.
62166142|NCT03684278|PLACEBO_COMPARATOR|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) 0.9% Sodium Chloride to be administered as a one time intravenous infusion over a period of 2 hours.
62729694|NCT01694433|EXPERIMENTAL|Calcipotriene Cream|The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
62166143|NCT03308383|EXPERIMENTAL|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
62166144|NCT00003611|EXPERIMENTAL|acitretin|"Patients receive oral acitretin daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
62166145|NCT00003611|PLACEBO_COMPARATOR|placebo|"Patients receive placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
62166146|NCT05168826||Transcatheter Aortic Valve Implantation (TAVI)|
62166147|NCT02840812|EXPERIMENTAL|Renal function impaired|Subject with Severe Impaired Renal Function. Nemonoxacin Malate Capsules 500mg single dose oral
62166148|NCT02840812|EXPERIMENTAL|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
62166149|NCT05285696|EXPERIMENTAL|[68Ga]-NOTA-hGZP (CSB-111) Injection|Eligible participants will receive a single IV injection of CSB-111 up to 40 micro grams
62166150|NCT06029920|EXPERIMENTAL|Subjects|
62166151|NCT01702155|EXPERIMENTAL|DFP-10917|"1. 7-day continuous infusion (in the vein): Starting dose 4 mg/m\^2~2. 14-day continuous infusion (in the vein): Starting dose 10 mg/m\^2~3. Phase II Only: 6 mg/m\^2 for the 14-day continuous infusion (in the vein)"
62166152|NCT02420938|EXPERIMENTAL|Rituximab + Urelumab|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course. Urelumab 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the course. Urelumab doses administered approximately 24 hours after the Rituximab doses. Up to two 12-week courses of treatment administered (total of maximum 12 doses of Rituximab and 8 doses of Urelumab).
62166153|NCT02924532||Patients with total thiroidectomy|
62166154|NCT01269190|EXPERIMENTAL|Diagnostic (widefield multispectral imaging and HRME)|Patients undergo evaluation of oral cavity using a widefield multispectral imaging device and a high-resolution optical system (HRME) at baseline, after induction of general anesthesia, and prior to surgery.
62166155|NCT03282071|EXPERIMENTAL|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
62166156|NCT03282071|NO_INTERVENTION|Control|No intervention will be provided to control groups during study period.
62729695|NCT01694433|PLACEBO_COMPARATOR|Placebo|The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
62729696|NCT05242341|EXPERIMENTAL|app use teaching|"Intervention includes teach the subjects one-on-one to use the My Health Bank for 30 minutes (such as download, register, test, find information, etc.), and provide pre-recorded 1-minute instructional videos for viewing when needed at home. The intervention group also accepts to follow the use of My Health Bank app at home every two weeks for a period of two months. Both groups will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety (prohibited medicines and concomitant medications)."
62729697|NCT05242341|NO_INTERVENTION|B|will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety
62166157|NCT00647374||1|
62166158|NCT01038128|EXPERIMENTAL|Memantine|Memantine, 10-40 mg daily
62166159|NCT01810640|NO_INTERVENTION|Control|In this group a liver biopsy will not be performed. All management would be as per standard of practice
62166160|NCT01810640|ACTIVE_COMPARATOR|Percutaneous liver biopsy|In this group a percutaneous biopsy of the liver will be performed prior to organ recovery
62166161|NCT02475499||Treated with incretins|Ever-use of incretin-based drugs ((DPP-4 inhibitors \[sitagliptin, vildagliptin, and saxagliptin\] or GLP-1 analogs \[exenatide, liraglutide\]) between (and including) base cohort entry and the index day - 365 days.
62166162|NCT02475499||Treated with sulfonylureas|Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
62166163|NCT02475499||Treated with other antidiabetic agents|Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
62166164|NCT05899673|EXPERIMENTAL|Fazirsiran 200 mg|Participants who are currently taking part in or who have completed their treatment in parent studies AROAAT2001 (NCT03945292) and AROAAT2002 (NCT03946449) may rollover in this study to receive fazirsiran, 200 milligrams (mg), injection, subcutaneously on Day 1 and once every 12 weeks (Q12W) thereafter for up to 96 weeks or until participant withdraws from the study or the sponsor terminates the study.
62166165|NCT00203502|EXPERIMENTAL|Intervention: Dtx Cyclophosphamide Bev|Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg
62166166|NCT03336749|EXPERIMENTAL|Sensory group|Sensory re-learning in combination with task-specific training
62166167|NCT03336749|ACTIVE_COMPARATOR|Control group|Traditional task-specific training
62166168|NCT05118009|EXPERIMENTAL|Intervention|Patients randomized to intervention will have access to the screening tool.
62166169|NCT05118009|NO_INTERVENTION|Control|Patients randomized to control will continue routine practice.
62166170|NCT06646250||Feasibility study - Healthy neonates|Neonates born with gestational week \< 32 weeks, gestational week 32-37 and at term. Will will include 20-30 of each sex in each group.
62166171|NCT06646250||Patients with patent ductus arteriosus (premature infants)|Preterm neonates with patent ductus arteriosus (n=20)
62166172|NCT06646250||Different groups of sick neonates|Neonates with different medical conditions such as perinatal asphyxia, stroke, pulmonary hypertension and congenital heart disease will be conducted. We will include 5-30 neonates in each group.
62166173|NCT06646250||Neonates/infants undergoing procedures|Neonates/infants undergoing procedures such as intubation, anesthesia, spinal puncture, peripheral and central arterial and venous catheter. We will include 20-30 neonates.
62166174|NCT06646250||Neonates with infection/sepsis|Infants with infection/sepsis and/or meningitis (n=40).
62166175|NCT05283200|EXPERIMENTAL|Yoga|"The goal for the yoga intervention is to provide participants with instructor-guided safe, gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, anxiety symptoms, disability, and improve quality of life.~Participants enrolled in the Yoga intervention group will receive one month of Instructor-Guided 70-minute virtual live yoga classes, twice per week, led by an experienced yoga therapist and co-instructor. During Months 2-3 participants in the Yoga Intervention will receive one 70-minute virtual live yoga class per week. Each session will have a set of specific poses, breathing exercises, meditation, and yoga philosophies developed by our yoga experts."
62166176|NCT05283200|EXPERIMENTAL|Cognitive Behavioral Therapy|"The goal of the Cognitive Behavioral Therapy (CBT) intervention is to provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, depression and anxiety symptoms, disability and improve quality of life.~Participants enrolled in the CBT intervention group will receive 3 months of Instructor-Guided 90-minute, virtual group counseling session, once per week, led by a psychologist and a co-therapist."
62166177|NCT05283200|EXPERIMENTAL|Music|"The aim of this intervention is for participants to learn and develop skills to reduce stress which may, in turn, decrease seizure frequency and improve quality of life. Participants will be exposed to a variety of ways that they might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.~Participants enrolled in the Music Intervention group will receive one month of Instructor-Guided Intervention 70-minute virtual live music therapy sessions, twice per week, led by an experienced music therapist and co-instructor. An two months of a 70-minute virtual live music therapy session once per week."
62166178|NCT05283200|NO_INTERVENTION|Standard of Care|Participants randomized to the Standard of Care Control Group will receive their usual standard epilepsy care. For Months 1-3 participants will receive weekly online surveys as well as brief monthly calls checking-in and collecting their seizure frequency. Participants will continue to receive brief monthly calls for checking-in and collection of seizure frequency Months 4-12. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
62166179|NCT05283200|NO_INTERVENTION|Enhanced Standard of Care|Participants randomized to the Enhanced Standard of Care Control Group will receive their usual standard epilepsy care and weekly scheduled, scripted, follow-up phone calls from a study team member to check-in on their health, epilepsy management, and seizure frequency. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
62166180|NCT03570996|ACTIVE_COMPARATOR|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
62166181|NCT03570996|ACTIVE_COMPARATOR|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
62166182|NCT04488809|EXPERIMENTAL|Deep Water Running|Participants in this group will perform running in a vertical position in water. The sessions will be held in deep pool where the feet of the participants will not touch the ground.
62166183|NCT04488809|ACTIVE_COMPARATOR|Treadmill Running|Participants in this group will perform running on a treadmill.
62166184|NCT04488809|NO_INTERVENTION|Control|Participants in this group will not interfere regular exercise for 8 weeks.
62166185|NCT01129011|EXPERIMENTAL|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
62166186|NCT01129011|ACTIVE_COMPARATOR|Naproxen|Naproxen 500 mg dosed twice daily
62166187|NCT03199495|EXPERIMENTAL|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
62166188|NCT03199495|SHAM_COMPARATOR|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
62166189|NCT02465775|EXPERIMENTAL|UltraShape treatment in all subjects|UltraShape treatment for fat reduction to unilateral flank for all subjects with untreated flank as control.
62166190|NCT00764855||1|Patients undergoing a surgery with general anesthesia
62166191|NCT02245971|ACTIVE_COMPARATOR|Whole precutting group|
62166192|NCT02245971|ACTIVE_COMPARATOR|Partial precutting group|
62166193|NCT03600922|EXPERIMENTAL|Intervention group|
62166194|NCT03734614||Patients with adjuvant aspirin|After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
62166195|NCT03734614||Patients without adjuvant aspirin|After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
62166196|NCT05041478|EXPERIMENTAL|Cold EMR with adjuvant STSC to margins|Standard cold EMR technique with adjuvant snare tip soft coagulation to defect margins
62166197|NCT05041478|ACTIVE_COMPARATOR|Cold EMR|Standard Cold EMR resection technique
62729698|NCT05626179|OTHER|[14C] IBI351|Recommended dose of \[14C\] IBI351
62166198|NCT04117256|ACTIVE_COMPARATOR|Transcranial Stimulation|Transcranial stimulation on the primary motor cortex (M1) with anode located on the point C3 (10/20 EEG system), and the cathode on contralateral supraorbital zone.
62166199|NCT04117256|ACTIVE_COMPARATOR|Suboccipital Stimulation|Suboccipital stimulation with anode located at the upper cervical level and cathode was placed on the lateral part of right shoulder.
62166200|NCT03244202|EXPERIMENTAL|Decision Aid Plus Counselling|Participants will use a decision aid to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing. After using the decision aid the participants will speak with a genetic counsellor over the phone about their choice.
62166201|NCT03244202|ACTIVE_COMPARATOR|Genetic Counselling Only|Participants will a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
62166202|NCT00988429|ACTIVE_COMPARATOR|800 mg QD Eslicarbazepine acetate|tablets
62166203|NCT00988429|ACTIVE_COMPARATOR|1200 mg QD Eslicarbazepine acetate|tablets
62166204|NCT00988429|PLACEBO_COMPARATOR|Placebo|tablets
62166205|NCT03651271|EXPERIMENTAL|"Hot tumors for Advanced Metastatic Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
62166206|NCT03651271|EXPERIMENTAL|"Cold tumors for Advanced Metastatic Cancer"|Participants with \< 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
62166207|NCT03651271|EXPERIMENTAL|"Hot tumors for Advanced Prostate Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
62166208|NCT03651271|EXPERIMENTAL|"Cold tumors for Advanced Prostate Cancer Cohort A"|Participants with \< 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
62166209|NCT03651271|EXPERIMENTAL|"Cold tumors for Advanced Prostate Cancer Cohort B"|Participants with \< 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
62166210|NCT02725359|PLACEBO_COMPARATOR|Placebo|Group Placebo (Group P) will receive placebo 1 hour before surgery and bilateral superficial cervical block with saline 10 ml each side
62166211|NCT02725359|EXPERIMENTAL|Tizanidine|Group Tizanidine (Group T) will receive 6 mg tizanidine 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
62166212|NCT02725359|ACTIVE_COMPARATOR|Bupivacaine|Group Bupivacaine will receive placebo 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
62166213|NCT02357355|ACTIVE_COMPARATOR|CMT 1A Group|Patients with CMT 1A will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
62166214|NCT02357355|ACTIVE_COMPARATOR|Control Group|Patients without CMT 1A who are our normal controls will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
62166215|NCT00889733|EXPERIMENTAL|IP Cisplatin|Patients with epithelial ovarian cancer who have undergone optimal debulking surgery receive IP Cisplatin with IV Paclitaxel.
62166216|NCT00662415|OTHER|1|12 non-amputee control subjects will be scanned at 0, 2 and 4 weeks but will not recieve mirror therapy.
62166217|NCT00662415|EXPERIMENTAL|2|24 unilateral lower extremity amputee subjects will recieve daily mirror therapy for phantom limb pain and will be scanned at 0, 2, and 4 weeks.
62166218|NCT06275087|EXPERIMENTAL|TIVA group|"The study involves patients in an operating room undergoing standard procedures. The induction procedure for anesthesia is the same for both groups, using sufentanil, propofol, and cisatracurium.~In the TIVA group, anesthesia is maintained with continuous propofol infusion and intermittent cisatracurium doses, guided by neuromuscular and electroencephalogram monitoring. At the end of surgery, neuromuscular block is reversed, and extubation occurs when the train-of-four (TOF) index is over 90%.~Muscle strength and bite force are measured at different intervals before and after anesthesia, using specific instruments. Additionally, patients fill out the Quality of recovery-40 (Qor-40) questionnaire at various time points to assess the quality of recovery after surgery and anesthesia."
62166219|NCT06275087|ACTIVE_COMPARATOR|Volatile group|In the volatile group, anesthesia is maintained with inhaled sevoflurane and intermittent cisatracurium doses. Cisatracurium is repeated based on TOF ratio, and anesthesia depth is controlled by BIS, maintaining values between 25 and 50. Drug doses are adjusted according to TOF and BIS values.
62166220|NCT05302271|EXPERIMENTAL|First Dose Cohort|AAVrh.10hFXN will be administered intravenously.
62166221|NCT05302271|EXPERIMENTAL|Second Dose Cohort|AAVrh.10hFXN will be administered intravenously.
62166222|NCT05302271|EXPERIMENTAL|Third Dose Cohort|AAVrh.10hFXN will be administered intravenously.
62166223|NCT05302271|EXPERIMENTAL|Maximum Tolerated Dose Cohort|AAVrh.10hFXN will be administered intravenously.
62166224|NCT04038034|PLACEBO_COMPARATOR|group A|35 patients treated with pressure lowering drugs and placebo
62166225|NCT04038034|EXPERIMENTAL|group B|35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
62166226|NCT05664061|EXPERIMENTAL|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals|Test (T)
62166227|NCT05664061|ACTIVE_COMPARATOR|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|Reference (R)
62166228|NCT05664061|PLACEBO_COMPARATOR|Placebo|Placebo
62166229|NCT05374408|OTHER|BBN pilot|Deployment of BBN for patient use, self-paced
62166230|NCT05803525|ACTIVE_COMPARATOR|• Group I: BC scaffold and 0.5% concentration of NaOCl irrigant solution.|BC will be made \& use 0.5 NaOCl conc
62166231|NCT05803525|ACTIVE_COMPARATOR|• Group II: BC scaffold and 2.5% concentration of NaOCl irrigant solution. •|BC will be made \& use 2.5 NaOCl conc
62166232|NCT05803525|ACTIVE_COMPARATOR|• Group III: PRF scaffold and 0.5% concentration of NaOCl irrigant solution. •|PRF will be made \& use 0.5 NaOCl conc
62166233|NCT05803525|ACTIVE_COMPARATOR|Group IV: PRF scaffold and 2.5% concentration of NaOCl irrigant solution. •|PRF will be made \& use 2.5 NaOCl conc
62166234|NCT05803525|ACTIVE_COMPARATOR|• Group V: Collagen scaffold and 0.5% concentration of NaOCl irrigant solution.|Collagen will be made \& use 0.5 NaOCl conc
62166235|NCT05803525|ACTIVE_COMPARATOR|• Group VI: Collagen scaffold and 2.5% concentration of NaOCl irrigant solution.|Collagen will be made \& use 2.5 NaOCl conc
62166236|NCT03681171|EXPERIMENTAL|Children with CP|Children with CP (9-15 years old) participated in a therapeutic dance program to improve physical, physiological and cognitive outcomes.
62166237|NCT00789399|ACTIVE_COMPARATOR|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
62166238|NCT00789399|PLACEBO_COMPARATOR|Placebo|
62166239|NCT02650388|OTHER|Post TAVI neurocognitive outcome|"TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective Eyeball test, Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced."
62166240|NCT01985945|OTHER|Yoga|
62166241|NCT01985945|NO_INTERVENTION|Without Yoga|
62166242|NCT04872166|EXPERIMENTAL|BTX-A51 Dose Cohort 1|Starting dose (SD) of BTX-A51 administered orally 5 times per week in a 28-day cycle
62166243|NCT04872166|EXPERIMENTAL|BTX-A51 Dose Cohort 2|Up to 2-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
62166244|NCT04872166|EXPERIMENTAL|BTX-A51 Dose Cohort 3|Up to 3.5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
62166245|NCT04872166|EXPERIMENTAL|BTX-A51 Dose Cohort 4|Up to 5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
62166246|NCT04872166|EXPERIMENTAL|BTX-A51 Dose Cohort 5|Up to 7-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
62166247|NCT04872166|EXPERIMENTAL|BTX-A51 Dose Cohort 6|Up to 10-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
62166248|NCT05080803||Early DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
62166249|NCT05080803||Advanced DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
62166250|NCT05080803||Severe DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
62166251|NCT05080803||Atrophic diabetic maculopathy|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
62166252|NCT00555334|EXPERIMENTAL|1|nucleoid antiviral therapy after RFA
62166253|NCT00555334|ACTIVE_COMPARATOR|2|RFA only
62166254|NCT02623400||Preterm infants and their parents|Preterm infants born before 34 weeks gestational age and/or with a birth weight lower than 1500g and their parents.
62166255|NCT00741689|EXPERIMENTAL|1|AZD1656 in 6 increasing oral single doses given to 6 groups (5 on active and 1 on placebo in each group)
62166256|NCT02350127|EXPERIMENTAL|Immediate Start|The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
62166257|NCT02350127|ACTIVE_COMPARATOR|Delayed Start|Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
62166258|NCT03750175||Colorectal cancer patients|"Clinical utility of ctDNA analysis for treatment decision~Use of ctDNA for KRAS, NRAS and BRAF testing prior to potential anti-EGFR monoclonal antibody treatment for metastatic colorectal cancer"
62166259|NCT00679419||Group 0 (Controllgroup)|eGFR \>= 90 ml/min/1.73m\^2 and no proteinuria
62166260|NCT00679419||Group 1|eGFR \>= 90 ml/min/1.73m\^2 and proteinuria
62166261|NCT00679419||Group 2|eGFR 60 - 89 ml/min/1.73m\^2
62166262|NCT00679419||Group 3|eGFR 30 - 59 ml/min/1.73m\^2
62166263|NCT00679419||Group 4|eGFR 15 - 29 ml/min/1.73m\^2
62166264|NCT00679419||Group 5|eGFR \< 15 ml/min/1.73m\^2 or requiring dialysis
61978258|NCT06327867|EXPERIMENTAL|Video Laryngoscopy|All participants who are intubated from Video laryngoscopy is enrolled in this arm.
62166265|NCT02039297|OTHER|No Intervention: Baseline arm|Pre and post design (same arm)
62166266|NCT00829517|ACTIVE_COMPARATOR|STI kiosk|computer-assisted provision of screening for chlamydia
62166267|NCT00829517|EXPERIMENTAL|contraceptive kiosk|computer-assisted provision of hormonal contraception
62166268|NCT06386575|OTHER|control group|
62166269|NCT06386575|ACTIVE_COMPARATOR|suprainguinal fascia iliaca block|
62166270|NCT05188729|EXPERIMENTAL|Part 1 LTX-315 Safety Run-in|Part 1: Starting total daily dose of LTX-315 will be 2 mg for the first subject. Subjects will receive ascending once daily doses increasing in 1 mg increments for up to 3 days in a 7-day treatment week until the first lesion is necrosed or a DLT occurs
62166271|NCT05188729|EXPERIMENTAL|Part 2 VP-315 Regimen Finding|"Part 2: VP-315 once-daily dosing; total daily dose of 8 mg in up to 5 cohorts~* Cohort 1: VP-315 once-daily dosing of 8 mg with half the target dose of 8 mg only on W1D1; all remaining doses will be the full target dose~* Cohort 2: VP-315 once-daily dosing of 8 mg on all treatment days for up to 3 consecutive daily doses/week.~* Cohort 3: has been removed, advance from Cohort 2 to 4 and 5.~Cohorts 4 and 5, the total daily dose of VP-315 (8.0 mg) will be divided into a split dose; the first dose is not to exceed 2.4 mg (30% of 8 mg dose), and the remaining dose will not exceed 5.6 mg (70% of 8 mg dose) and administered 15 minutes apart (not to exceed 30 minutes).~* Cohort 4: (Two times weekly dosing) VP-315 once-daily dosing of 8 mg, administered on 2 consecutive days in one week.~* Cohort 5: (Three times weekly dosing) VP-315 once-daily dosing of 8 mg, administered on 3 consecutive days in one week.~PK data will be collected in the Cohorts 4 and 5 expansion groups."
62166272|NCT04477954|EXPERIMENTAL|Experimental HBOT|Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
62166273|NCT04477954|NO_INTERVENTION|Standard care|
62166274|NCT03082196|EXPERIMENTAL|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
62166275|NCT03082196|ACTIVE_COMPARATOR|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
62166276|NCT06379763|EXPERIMENTAL|group one|diaphragmatic breathing exercise in addition to conventional physiotherapy such as ROM, stretching exercises for superficial neck muscles
62166277|NCT06379763|ACTIVE_COMPARATOR|group two|conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
62166278|NCT01580462||Children and Adolescent with type 1 diabetes on CSII|
62166279|NCT02135419|EXPERIMENTAL|Arm I (treatment)|Patients are directed to receive either topical or ablative treatment at the discretion of the clinician. Patients receiving topical treatment apply imiquimod intra-anally, peri-anally or both thrice weekly for up to 16 weeks, fluorouracil twice daily for 5 days every 2 weeks for up to 16 weeks, or trichloroacetic acid every 3 weeks up to 12 weeks. Patients receiving ablative treatment using infrared photocoagulation therapy, hyfrecation/electrocautery (thermal ablation therapy), or laser therapy. Patients may undergo excision under anesthesia if the clinician believes none of the other treatment approaches will be effective. The number and timing of such treatments will be at the discretion of the investigator. Patients with persistent HSIL should continue a protocol-approved treatment or a new protocol treatment should be considered. All participants will have samples collected for laboratory biomarker analysis.
62166280|NCT02135419|ACTIVE_COMPARATOR|Arm II (active monitoring) (closed since SEP2021)|Patients undergo active monitoring with examinations for clinical observation every 6 months. Every 12 months, patients undergo biopsies of visible lesions. Patients have cytology sampling performed at every visit. All participants will have samples collected for laboratory biomarker analysis.
62166281|NCT01855997||Adult CHB Participants Treated With Peg-IFN Alfa-2a|Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
62166282|NCT02136797|EXPERIMENTAL|CMVpp65-CTL T-cells|The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10\^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
62166283|NCT00145496|EXPERIMENTAL|asenapine|
62166284|NCT00145496|ACTIVE_COMPARATOR|olanzapine|
62166285|NCT04271956|EXPERIMENTAL|Tislelizumab + Zanubrutinib|"Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib~Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib~Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation"
62166286|NCT04271956|EXPERIMENTAL|Tislelizumab + Zanubrutinib + Sonrotoclax|"Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax~Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax~Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) + Sonrotoclax until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation"
62166287|NCT00082784|EXPERIMENTAL|Treatment|Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62166288|NCT01161706|NO_INTERVENTION|Control|0 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
62166289|NCT01161706|EXPERIMENTAL|8 fluid ounces vegetable juice|8 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
62166290|NCT01161706|EXPERIMENTAL|16 fluid ounces vegetable juice|16 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
62166291|NCT03167645|EXPERIMENTAL|Human albumin|Substitution of human albumin until serum albumin \>30g/l; dosage: (30 g/l - serum albumin \[g/l\] ) x 0,04 l/kg x body weight \[kg\] x 2
62166292|NCT03167645|NO_INTERVENTION|Control|Standard clinical care
62166293|NCT02745184|EXPERIMENTAL|lung stem cells|Patients will receive 0.5-5x10\^6 (0.5-5 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
62166294|NCT04422509|EXPERIMENTAL|lanadelumab|20 Patients will receive an intravenous dose of 300 mg lanadelumab on day 1, followed by a second dose of lanadelumab 300mg iv on day 4 (if needed).
62166295|NCT04422509|OTHER|controls|20 patients will received standard of care In additiona, for every index patient we will match one historical controls. Controls will be matched based on age, bodyweight and gender.
62166296|NCT05692414|EXPERIMENTAL|Preoperative carbohydrate loaded patients|
62166297|NCT05692414|NO_INTERVENTION|Conventional fasting protocol|
62166298|NCT05618054|OTHER|Adolescents with POTS|
62166299|NCT05618054|OTHER|Adolescents without POTS|
62166300|NCT06289036||favorable prognosis|modified Rankin scale (mRS) ≤ 2
62166301|NCT06289036||poor prognosis|modified Rankin scale (mRS) \> 2
62166302|NCT06041334|OTHER|Study volunteers|
62166303|NCT03652792|EXPERIMENTAL|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
62166304|NCT03652792|ACTIVE_COMPARATOR|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
62166305|NCT03652792|EXPERIMENTAL|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
62166306|NCT03652792|ACTIVE_COMPARATOR|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
62729699|NCT05982912||Patients that developed Invasive Pulmonary Aspergillosis|All patients sampled who later on developed IPA
62729700|NCT05490277|ACTIVE_COMPARATOR|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
62729701|NCT05490277|SHAM_COMPARATOR|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
62729702|NCT01656707|EXPERIMENTAL|ACRA|Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
62729703|NCT01656707|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
62729704|NCT04889248|EXPERIMENTAL|Intervention|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual
62729705|NCT04889248|NO_INTERVENTION|Control|Without inspiratory muscle training. Treatment as usual.
62729706|NCT02452385|EXPERIMENTAL|CM082 tablet|Escalating dose of CM082 tablet starting at 25mg once a day
62729707|NCT06485726|ACTIVE_COMPARATOR|valproate arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000 mg daily for three months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. Treatment safety was evaluated by monitoring and documenting patients' treatment-emergent adverse events (TEAE) through regular follow-up procedures for three months.
62729708|NCT06485726|ACTIVE_COMPARATOR|Propranolol group|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive propranolol 160 mg once daily for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
62729709|NCT01871545|EXPERIMENTAL|Magnetic Resonance Imaging|dynamic contrast-enhanced MRI measuring arterial and portal flow
62729710|NCT01871545|NO_INTERVENTION|Healthy Controls|
62729711|NCT02432781|EXPERIMENTAL|Carbohydrate group|Carbohydrate-rich drink 400 mL 3 h before surgery
62729712|NCT02432781|ACTIVE_COMPARATOR|Control group|10% dextrose solution mixed with insulin 16 unit 100 mL/h
62729713|NCT04951219|EXPERIMENTAL|Double-blind 80 mg Daily|For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 80 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
62729714|NCT04951219|EXPERIMENTAL|Double-blind 100 mg Daily|For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 100 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
62729715|NCT04951219|EXPERIMENTAL|Open-label|For patients assigned to open-label treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, open-label resmetirom at same dose as MGL-3196-14 for an additional 52 weeks. NASH cirrhosis patients may receive open-label resmetirom for an additional 52 weeks (ie, 52 weeks in MGL-3196-14 and 104 weeks in MGL-3196-18).
62729716|NCT04951219|EXPERIMENTAL|Open-Label 80 mg|For patients with NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 80 mg for 104 weeks
62729717|NCT04951219|EXPERIMENTAL|Open Label 100 mg|For patients without NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 100 mg for 52 weeks
62729718|NCT04951219|EXPERIMENTAL|Open-Label 40 mg|For NASH cirrhosis patients who enter MGL-3196-18 directly or were screen failures from MGL-3196-19, open-label resmetirom 40 mg for 104 weeks
62729719|NCT02656394|ACTIVE_COMPARATOR|GL101|GL101 topical gel
62729720|NCT02656394|PLACEBO_COMPARATOR|Placebo|Placebo topical gel
62729721|NCT01324960|EXPERIMENTAL|Ceplene® / IL2 + Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
62729722|NCT01324960|ACTIVE_COMPARATOR|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
62729723|NCT05882760|EXPERIMENTAL|Tetric N Bond Universal®|Cavities in this group will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Technique using Tetric N Bond Universal®.
62729724|NCT05882760|ACTIVE_COMPARATOR|Self Etch Tetric N Bond Universal®|Cavities in this group will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Technique using Tetric N Bond Universal®.
62729725|NCT05882760|ACTIVE_COMPARATOR|GC Fuji IX, GC, Japan®|Cavities in this group will be restored with GC Fuji IX, GC, Japan®
62729726|NCT05882760|ACTIVE_COMPARATOR|Activa TM Bioactive Restorative ®|Cavities in this group will be restored with Activa TM Bioactive Restorative ®
62729727|NCT00697528||Group control with healthy subjects|Healthy subjects without thyroid disease, ocular disease and previous surgery in the orbit or eye used in the study.
62729728|NCT00697528||Graves' Ophthalmopathy - fibrotic phase|Patients that are clinically inactive (CAS equal or lower than 2). This group will be subdivided in the miogenic and lipogenic groups.
62729729|NCT00697528||Graves' Ophthalmopathy - active phase|Patients that are clinically active, presenting a CAS of 4 or more points, with or without disthyroid optic neuropathy.
62729730|NCT01480726||Open vein harvest|Conventional open vein harvest from the lower leg
62729731|NCT01480726||Endoscopic vein harvest|Endoscopic vein harvest from the calf
62729732|NCT05892991|ACTIVE_COMPARATOR|standard physical therapy group|this group will receive 4 physical therapy sessions per week for 4 weeks. The session will consist of intermittent neuromuscular inhibition which is composed of 3 manual approaches (positional release, muscle energy technique, and progressive pressure release).
62729733|NCT05892991|EXPERIMENTAL|amplitude modulated frequency (AMF) 130Hz group|"1. Chattanooga (Intellect© Advanced, USA) multi-current device will be used to apply the IFC sessions. Carrier frequency 4000Hz, 2 pole placement (pre-modulated), the intensity will be raised till the patient feels a strong but comfortable tingling sensation, AMFs 130. Two vacuum electrodes of medium size will be placed at both sides of the trigger point. The duration of the session will be 30 minutes and will be repeated 3 times per week for 4 weeks.~2. standard physical therapy treatment as in the first group"
62729734|NCT05892991|EXPERIMENTAL|amplitude modulated frequency (AMF) 80Hz group|"1. Chattanooga (Intellect© Advanced, USA) multi-current device will be used to apply the IFC sessions. Carrier frequency 4000Hz, 2 pole placement (pre-modulated), the intensity will be raised till the patient feels a strong but comfortable tingling sensation, AMFs 80Hz. Two vacuum electrodes of medium size will be placed at both sides of the trigger point. The duration of the session will be 30 minutes and will be repeated 3 times per week for 4 weeks.~2. standard physical therapy treatment as in the first group"
62729735|NCT05892991|EXPERIMENTAL|amplitude modulated frequency 4Hz group|"1. Chattanooga (Intellect© Advanced, USA) multi-current device will be used to apply the IFC sessions. Carrier frequency 4000Hz, 2 pole placement (premodulated), the intensity will be raised till muscle twitching is visible under electrodes, AMFs 4 Hz. Two vacuum electrodes of medium size will be placed at both sides of the trigger point. The duration of the session will be 30 minutes and will be repeated 3 times per week for 4 weeks.~2. standard physical therapy treatment as in the first group"
62729736|NCT05672940|EXPERIMENTAL|Aerobic plus resistance training group|Receive three one-hour supervised group sessions weekly for 12 weeks, in which Sections 1 and 3 were AT plus RT sessions, including 5-minute warm-up, 30-minute AT exercises on a bicycle (Comfort 408, Horizon Fitness) or a treadmill (832T, Horizon Fitness), 20-minute RT, and 5-minute cool-down; whereas Section 2 was an AT-only session, including 5-minute warm up, 50-minute aerobic exercises (bicycling or treadmill walking), and 5-minute cool-down.
62729737|NCT05672940|EXPERIMENTAL|Stretching plus breathing training group|Receive three one-hour sessions of weekly supervised group training combining Tongtze Gymnastics (童子體操) and breathing exercises for 12 weeks.
62729738|NCT00921115|EXPERIMENTAL|Arimidex + Faslodex|"Patients will have an Oncotype Dx performed and if the RS is \<25, they will receive Anastrazole and Fulvestrant for 16 weeks.~On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery."
62729739|NCT05266846|EXPERIMENTAL|Pembrolizumab plus Bevacizumab and Chemotherapy|Pembrolizumab Plus Bevacizumab and Chemotherapy was used for ALK-rearranged NSCLC With Persistent 5'ALK.
62729740|NCT05266846|EXPERIMENTAL|Bevacizumab plus Chemotherapy|Bevacizumab plus Chemotherapy was used for ALK-rearranged NSCLC With Persistent 5'ALK.
62729741|NCT02649452|EXPERIMENTAL|vibration|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between. After exercise, this group had to undergo vibration exercise by using whole body vibration machine.
62729742|NCT02649452|ACTIVE_COMPARATOR|Exercises|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between
62729743|NCT03538886|ACTIVE_COMPARATOR|Percutaneous coronary intervention (PCI)|Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
62729744|NCT03538886|EXPERIMENTAL|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.
62729745|NCT00657137|EXPERIMENTAL|A|apricoxib + lapatinib + capecitabine
62729746|NCT00657137|PLACEBO_COMPARATOR|B|placebo + lapatinib + capecitabine
62729747|NCT02413476|EXPERIMENTAL|Robotic-assisted Gastrectomy(RAG)|Robotic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
62729748|NCT02413476|ACTIVE_COMPARATOR|Laparoscopic-assisted Gastrectomy(LAG)|Laparoscopic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
62729749|NCT06119516|EXPERIMENTAL|Esophageal pressure-guided strategy,|The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used to monitor esophageal and gastric pressures during several days. Ventilator settings will be adjusted to the evaluated esophageal pressure-guided strategy, aiming to obtain a slightly positive transpulmonary pressure at the end of expiration.
62729750|NCT04650230|ACTIVE_COMPARATOR|high flow nasal cannula (HFNC)|Participants in the HFNC group received heated and humidified gas flow with the Fisher \& Paykel Healthcare HFNC system. The flow rate was usually started at the maximum flow rate for the size of cannula and a constant flow temperature of 37 °C.The flow rate will be progressively decreased when inspired fraction of oxygen (FiO2) was inferior to 30 percent (%).
61978259|NCT03907293||Phase-III Cardiac Rehabilitation|Eight weeks of supervised exercise sessions (one session per week).
61978260|NCT03907293||Phase-III and Phase IV Cardiac Rehabilitation|Twenty weeks of supervised exercise sessions (one session per week for first eight weeks \[phase-III\], session frequency determined by participant for remaining twelve weeks \[phase-IV\].
62729751|NCT04650230|ACTIVE_COMPARATOR|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)|Participants in the CPAP/NPPV group received for first CPAP using a neonatal ventilator. The recommended starting pressure for CPAP was +6 centimeter of water (cmH2O). Positive continuous pressure could be increased to a maximum of +8 cmH2O. Optimal positive end expiratory pressure (PEEP) was what could maintain SpO2 at 94 per cent using the lowest fraction of inspired oxygen. PEEP will be decreased progressively of 1cmH2O every 6 hours from the optimal PEEP when FiO2 was inferior to 30% and there is no increase of work of breath.
62729752|NCT06524271|EXPERIMENTAL|Fermented soybean supplementation|The intervention supplement composed of Lactobacillus delbrueckii FSB, hydrogen-ated palm kernel oil, sodium caseinate, isolated soy protein, brown rice, inulin, digestive enzymes blend (lactase, protease, cellulase, lipase, amylase, pectinase, papain, and bromelain), galacto-oligosaccharides (GOS), and Bifidobacterium longum, powder form packaged in individual sachets (NattomeTM, Nattome, Kuala Lumpur, Malaysia). The dosage of FSB in each sachet was 1g.
62729753|NCT06524271|PLACEBO_COMPARATOR|Placebo control|The placebo supplement had the exact composition of ingredients but excluding FSB.
62729754|NCT03700164|EXPERIMENTAL|Cold exposure|Participants will be wrapped in a water-perfused suit. The temperature of the suit will be lowered to 10°C. From the onset of shivering, the participants will remain in the suit for 1 hour.
62729755|NCT03700164|OTHER|Thermoneutral (Control)|"Participants will be wrapped in a water-perfused suit. The temperature of the suit will remain at a thermoneutral temperature (32°C) to avoid shivering and excessive sweating.~The duration will be matched to that during the cold exposure."
62729756|NCT01681667|ACTIVE_COMPARATOR|ibuprofen|liquid ibuprofen 400mg compared to tablet ibuprofen 400mg
62729757|NCT01681667|PLACEBO_COMPARATOR|sugar pill or liquid|
62729758|NCT03112291|EXPERIMENTAL|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
62729759|NCT06397859||Hepatis Delta|Bulevirtide (BLV) at a dose of 2 mg/day subcutaneously
62729760|NCT04342676|EXPERIMENTAL|patients|LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
62729761|NCT05508178|EXPERIMENTAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Participants 18-40 years of age, 2-dose regimen: Norovirus bivalent GI.4 (50 μg) / GII.4 (50 μg) virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1 and Day 29
62729762|NCT05508178|EXPERIMENTAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Participants 18-40 years of age, 2-dose regimen: Norovirus bivalent GI.4 (150 μg) / GII.4 (150 μg) virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1 and Day 29
62729763|NCT05508178|PLACEBO_COMPARATOR|Placebo|Participants 18-40 years of age, 2-dose regimen: Placebo (norovirus vaccine vehicle without antigens), intramuscularly (IM), on Day 1 and Day 29
62729764|NCT04888416|EXPERIMENTAL|Acute care|Acute care practitioners who will receive the I-STROM intervention
62729765|NCT04888416|EXPERIMENTAL|Inpatient|Inpatient practitioners who will receive the I-STROM intervention
62729766|NCT04888416|EXPERIMENTAL|Outpatient|Outpatient practitioners who will receive the I-STROM intervention
62729767|NCT01698931|EXPERIMENTAL|Treatment period 1|
62729768|NCT01698931|ACTIVE_COMPARATOR|Treatment period 2|
62729769|NCT01698931|PLACEBO_COMPARATOR|Treatment period 3|
62729770|NCT04169646|OTHER|Intervention|Multi-component intervention
62729771|NCT04169646|OTHER|Control|Control
62729772|NCT06288633|ACTIVE_COMPARATOR|Cardioneuroablation|Radiofrequency catheter transmyocardial ablation of the ganglion plexuses (GP) of the atria - cardioneuroablation. The procedure is performed under local anesthesia using intracardiac catheters. Radiofrequency applications will be applied to the endocardial surface of the left and/or right atria in places of typical localization of the densest GPs network in order to destroy nerve fibers and ganglia: in patients with sinus bradycardia - in the left and right atria (5 places with the highest concentration of ganglia); in patients with impaired atrioventricular conduction - in the right atrium and in the left atrium (1 place in the right atrium - at the ostium of the coronary sinus; 2 places in the left atrium - opposite the ostium of the coronary sinus and opposite the Marshall ligament/vein).
62729773|NCT06288633|SHAM_COMPARATOR|Sham group|"In the control (sham) group, endocardial electrophysiological study will be performed, but patients will not know which procedure they performed (they are blinded in relation to the distribution group). The monitoring will be performed according to the same protocol as in the cardioneuroablation group. In case of recurrence of symptomatic bradycardia and/or (with) syncopal condition without traumatization of the patient in the control group, a transition to the cardioneuroablation group (cross-over) will be proposed. In case of disagreement, a pacemaker is implanted."
62729774|NCT04901663|ACTIVE_COMPARATOR|Omeprazole Group|Omeprazole 20 mg BD Amoxicillin 1000 mg BD Clarithromycin 500 mg BD
62729775|NCT04901663|EXPERIMENTAL|Vonoprazan Group|Vonoprazan 20 mg BD Amoxicillin 1000 mg BD
62729776|NCT03288454|EXPERIMENTAL|Cohort 1|ciraparantag (60 mg)
62729777|NCT03288454|EXPERIMENTAL|Cohort 2|ciraparantag (120 mg)
62729778|NCT03288454|EXPERIMENTAL|Cohort 3|ciraparantag (30 mg)
62729779|NCT03288454|PLACEBO_COMPARATOR|Placebo|placebo (saline for injection)
62729780|NCT01303952|EXPERIMENTAL|Eculizumab|
62729781|NCT01698203|EXPERIMENTAL|ropivacaine|
62729782|NCT01698203|PLACEBO_COMPARATOR|placebo|
62729783|NCT03440567|EXPERIMENTAL|Cohort I (avelumab, utomilumab, RICE)|Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, utomilumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo autologous hematopoietic stem cell transplantation.
62729784|NCT03440567|EXPERIMENTAL|Cohort II (avelumab, utomilumab, rituximab, ibrutinib)|Patients receive rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, and ibrutinib PO QD or rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, utomilumab IV on day 2, and ibrutinib PO QD. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. (Closed as of 12/12/2019)
62729785|NCT02556281|EXPERIMENTAL|Patient with colorectal cancer|Blood sampling is done for patient with colorectal cancer
62729786|NCT03699566||Healthy volunteers|"Individuals aged 18-65 without chronic disease.~Interventions: Assessment of Respiratory Muscle Strength, Spirometer, Trunk Muscles Endurance Tests"
62729787|NCT02748876|EXPERIMENTAL|His-Ventricular (HV)-optimised|His-Ventricular (HV) optimised atrioventricular delay
62729788|NCT02748876|NO_INTERVENTION|Non-optimised|Standard atrioventricular delay
62729789|NCT03620032|OTHER|Standard treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
62729790|NCT03620032|EXPERIMENTAL|Experimental treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
62729791|NCT06377280|EXPERIMENTAL|All subjects|The investigational subjects are persons with anal incontinence or outlet problems and deemed suitable for and in need of low-volume TAI as assessed by the investigator or designee
62729792|NCT02357199|EXPERIMENTAL|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
62729793|NCT02357199|NO_INTERVENTION|Standard oral care|Standard oral care protocol consisting of referral by staff in the Department of Nephrology to general dental practitioner followed by patient self-administration of tooth brushing, fluoride toothpaste and oral lubricants.
62729794|NCT06289946|PLACEBO_COMPARATOR|Placebo arm|Subject will get placebo
62729795|NCT06289946|EXPERIMENTAL|Nitro arm|Subject will get Nitrobid
62729796|NCT05530902|EXPERIMENTAL|Patients with musculoskeletal pain|Patients with musculoskeletal pain
62729797|NCT03644810|ACTIVE_COMPARATOR|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
62729798|NCT03644810|ACTIVE_COMPARATOR|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
62729799|NCT00553410|ACTIVE_COMPARATOR|Continuous letrozole|Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
62729800|NCT00553410|EXPERIMENTAL|Intermittent letrozole|Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
62729801|NCT05120583|EXPERIMENTAL|study group|Patients in the study group received Pilates exercises (25 minutes/ session). There are different types of equipment to be used in Pilates exercises to achieve different purposes; mat, Pilates band or elastic bands, and Pilate's ball were used.
62729802|NCT05120583|EXPERIMENTAL|control group|Participants in control group received the traditional physical therapy program program (60 minutes/session, three sessions /week for three months).
62729803|NCT03974932|EXPERIMENTAL|Cohort 1|HTX-011 + MMA
62729804|NCT03974932|EXPERIMENTAL|Cohort 2|HTX-011 + MMA
62729805|NCT03974932|EXPERIMENTAL|Cohort 3|HTX-011 + MMA
62729806|NCT03974932|EXPERIMENTAL|Cohort 4|HTX-011 + MMA
62729807|NCT03187405|NO_INTERVENTION|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
62729808|NCT03187405|EXPERIMENTAL|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
62729809|NCT01206140|EXPERIMENTAL|Arm I (selumetinib and temsirolimus)|Patients receive selumetinib PO twice daily on days 1-28 and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22.
62729810|NCT01206140|EXPERIMENTAL|Arm II (selumetinib)|Patients receive selumetinib as in arm I. Patients who experience disease progression may cross over to arm I.
62729811|NCT00986791|NO_INTERVENTION|Control group|Treatment as usual
62729812|NCT00986791|EXPERIMENTAL|GSP-A|Gold-Standard-Program for Alcohol cessation intervention (GSP-A): 6-week intensive patient education program with pharmaceutical support
61978261|NCT03907293||No Cardiac Rehabilitation|Participants who declined to take part in a cardiac rehabilitation programme.
61978262|NCT01778829|ACTIVE_COMPARATOR|CPAP ventilation mode|Once the patient is extubated, CPAP ventilation mode is inmediately administered in order to prevent reintubation
61978263|NCT01778829|EXPERIMENTAL|NIPPV ventilation mode|NIPPV: Non Invasive Ventilation mode is administered inmediately after extubation to prevent reintubation
62729813|NCT01136525|EXPERIMENTAL|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
62729814|NCT01136525|ACTIVE_COMPARATOR|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
62729815|NCT00572416|EXPERIMENTAL|1 Individual Sleep Promotion Plan|Four component behavioral sleep intervention comprised of activity-rest, sleep-wake, psychological distress and symptom management. Four components of the Individual Sleep Promotion Plan are: stimulus control, sleep restruction, relaxation, and sleep hygiene.
62729816|NCT00572416|PLACEBO_COMPARATOR|2 Healthy Eating Control|Equal time and attention, information about healthy eating and general conversation
62729817|NCT06343272|EXPERIMENTAL|Sperimental|
62729818|NCT06343272|PLACEBO_COMPARATOR|Isocaloric placebo|
62729819|NCT00752921|ACTIVE_COMPARATOR|A|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
62729820|NCT00752921|PLACEBO_COMPARATOR|B|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
62729821|NCT03632707|OTHER|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial PD,T2 and PD-SPIR weighted images, and correlate the results with Knee Arthroscopy.while the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing.
62729822|NCT01393795|PLACEBO_COMPARATOR|Tegaderm|
62729823|NCT01393795|ACTIVE_COMPARATOR|Qutenza|
62729824|NCT04683406|EXPERIMENTAL|ZSP1273 600 mg + Oseltamivir Placebo BID|Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
62729825|NCT04683406|ACTIVE_COMPARATOR|Oseltamivir 75mg + ZSP1273 Placebo|Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days
62729826|NCT04683406|PLACEBO_COMPARATOR|Placebo Comparator|Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
62729827|NCT04014894|EXPERIMENTAL|ET019003-T Cells|The trial will enroll 9 patients with leukemia and 9 patients with lymphoma. Each disease has 3 dose-levels.
62729828|NCT04081662|EXPERIMENTAL|compACT Intervention|"At every time-point of the study, participants will complete self-reports of stress, (as measured by the PSS-4) distress (as measured by the PHQ-2), and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
62729829|NCT04801485|ACTIVE_COMPARATOR|D-chiro inositol|500 mg twice a day
62729830|NCT04801485|PLACEBO_COMPARATOR|Placebo|500 mg twice a day
62729831|NCT04565912|EXPERIMENTAL|Sage extract mouthwash|Natural product mouthwash
62729832|NCT04565912|ACTIVE_COMPARATOR|Chlorohexidine mouthwash|Synthetic mouthwash
62729833|NCT02550444|PLACEBO_COMPARATOR|Control|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
62729834|NCT02550444|EXPERIMENTAL|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
62729835|NCT02550444|EXPERIMENTAL|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
62729836|NCT03053557|EXPERIMENTAL|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
62729837|NCT03053557|NO_INTERVENTION|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
62729838|NCT05302895||single-group|The health monitoring data of all the resident participants are measured using traditional device and the all-in-one health monitoring device on the same day for 12 weeks
62729839|NCT04826263|EXPERIMENTAL|ESWT Group|The patients in the ESWT group will receive ESWT treatment and a home exercise program.
62729840|NCT04826263|EXPERIMENTAL|LLLT Group|The patients in the LLLT Group will receive LLLT treatment and a home exercise program.
62729841|NCT05849350|EXPERIMENTAL|Protein|Participants will receive a whey protein supplement.
62729842|NCT05849350|PLACEBO_COMPARATOR|Maltodextrin|Participants will receive an isocaloric maltodextrin supplement.
62729843|NCT04220580|OTHER|Cold Pressor Test|The participants are instructed to keep the non-dominant hand submerged in ice-water for as long as possible with a maximum of 10 minutes.
62729844|NCT01795976|EXPERIMENTAL|NY-ESO-1 T cells|"NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype A serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg.."
62729845|NCT05113199|EXPERIMENTAL|Virtual Dignity Therapy|
62729846|NCT01009905||A|
62729847|NCT02014662|OTHER|Arm 1|Healthy subjects aged 18 to 35 years
62729848|NCT05272722||Infants (under age of 1 year old)|ECG assessment and Holter monitoring
62729849|NCT05272722||1 - 5 years old children|ECG assessment and Holter monitoring
62729850|NCT05272722||6 -12 years old children|ECG assessment and Holter monitoring
62729851|NCT05272722||13-18 years old adolescents|ECG assessment and Holter monitoring
62729852|NCT04643366|EXPERIMENTAL|Concurrent Chemotherapy/ Radiation Therapy|5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) four 14-day cycles will be given before CRT starts. Pelvic Intensity-modulated radiation therapy (IMRT): 25 Gy in 5 fractions over 5 days + Continuous infusion 5-fluorouracil (5-FU) for 4 days (96 hours) followed by four 14-day cycles of (mFOLFOX6) to be given after CRT ends.
62729853|NCT02345616|EXPERIMENTAL|Nitric oxyde|
62729854|NCT04404101|ACTIVE_COMPARATOR|1). EUS-FNA plus MFB|A 19-G needle plus micro-forceps will be used for FNA plus MFB.
62729855|NCT04404101|ACTIVE_COMPARATOR|2). EUS-FNA Alone|A 19-G needle will be used for FNA alone.
62729856|NCT05010070|EXPERIMENTAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindful eating.
62729857|NCT01696773|EXPERIMENTAL|Tangerine tomato juice|Tangerine tomato juice will be fed
62729858|NCT01696773|EXPERIMENTAL|Red tomato juice|Red tomato juice will be fed
62729859|NCT06374888|EXPERIMENTAL|Single-arm|Cohort A: : Patients with brain metastases who had not previously received central nervous system radiotherapy, distance from the last systemic treatment junction The beam should be longer than 2 weeks. Cohort B: Patients with disease progression or new lesions after whole brain radiotherapy or stereotactic radiotherapy; For accepted offices For partially treated lesions, there is clear evidence of progress in imaging examination, and the lesions that have received radiotherapy can be selected as target diseases
62729860|NCT03497273|EXPERIMENTAL|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
62729861|NCT02103062|EXPERIMENTAL|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
62729862|NCT02630069|EXPERIMENTAL|CDP-choline+supportive psychotherapy|CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
62729863|NCT02630069|PLACEBO_COMPARATOR|Placebo+supportive psychotherapy|Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
62729864|NCT02630069|NO_INTERVENTION|Healthy control|No intervention
62729865|NCT02031003|OTHER|Control|Standard infant formula
62729866|NCT02031003|EXPERIMENTAL|Experimental 1|Standard infant formula containing a new fat blend
62729867|NCT02031003|EXPERIMENTAL|Experimental 2|Standard infant formula containing a new fat blend and fiber
62729868|NCT02031003|NO_INTERVENTION|Human Milk (HM)|Non-randomized Human Milk group
62729869|NCT02727816|EXPERIMENTAL|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
62729870|NCT02727816|EXPERIMENTAL|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
62729871|NCT02727816|EXPERIMENTAL|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
62729872|NCT02727816|EXPERIMENTAL|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
62729873|NCT01440114|ACTIVE_COMPARATOR|fentanyl group|First arm: intervention group. Patient in this group received fentanyl 1 mcg/kg (concentration 10mcg/ml) intravenous route 15 minutes before the end of surgery.
62729874|NCT01440114|PLACEBO_COMPARATOR|controlled group|patient in this group received NSS 0.1 ml/kg 15 minutes before the end of surgery
62729875|NCT03731052|EXPERIMENTAL|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
62729876|NCT03731052|PLACEBO_COMPARATOR|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
62729877|NCT01290042|ACTIVE_COMPARATOR|Placebo arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
62729878|NCT01290042|ACTIVE_COMPARATOR|Active arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
62729879|NCT01899638|EXPERIMENTAL|UMEC/VI 125/25 mcg|Combination in high dose
62166307|NCT03380143|EXPERIMENTAL|Wellscapes Intervention|The wellness landscape intervention (Wellscapes) will establish a multi-level system infrastructure (Community Hub, Organization Wellness Teams, Activity Setting/Leaders) and provide training and support for population health quality improvement cycle processes targeting two evidence-based practices (EBPs): (1) stacking time segments of PA episodes within an organization's daily routine, and (2) improving the quality of PA episodes (% time in PA).
62166308|NCT03380143|ACTIVE_COMPARATOR|Standard Practice|The standard collective impact public health practice intervention will establish a multi-level system infrastructure and provide training on community development.
62729880|NCT01899638|EXPERIMENTAL|UMEC/VI 62.5/25 mcg|Combination in low dose
62729881|NCT01899638|EXPERIMENTAL|UMEC 125 mcg|LAMA mono in high dose
62729882|NCT01899638|EXPERIMENTAL|UMEC 62.5 mcg|LAMA mono in low dose
62729883|NCT01899638|EXPERIMENTAL|VI 25 mcg|LABA mono
62729884|NCT05096637|NO_INTERVENTION|control group|Patients receive the best medical care according to current guideline recommendations without access to the app
62729885|NCT05096637|EXPERIMENTAL|intervention group|Patients receive the best medical care according to current guideline recommendations with full access to the app. This includes access to relevant findings including ultrasound images of the carotid artery, lipid profile, blood pressure values, and weight.
62729886|NCT05936957||Acute heart failure|These are acutely decompensated heart failure
62729887|NCT05936957||Chronic heart failure|These are stable heart failure patients being followed up in the outpatient clinic
62729888|NCT06554119||TVR|tricuspid valve replacement group，
62729889|NCT06554119||TVP|tricuspid valvuloplasty group
62729890|NCT00292045|EXPERIMENTAL|NY-ESO-1 protein + CpG 7909|Patients received immunization with intradermal injections of the NY-ESO-1 protein combined with CpG 7909.
62729891|NCT00400517|EXPERIMENTAL|GM-CSF Injections and Oral Thalidomide|taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
62729892|NCT01269554||Children with diarrhea in Bissau|
62729893|NCT01269554||Children without diarrhea in Bissau|
62729894|NCT01269554||Children without diarrhea in Finland|
62729895|NCT01269554||Children with diarrhea in Finland|
62729896|NCT01269554||Adults without diarrhea in Finland|
62729897|NCT01269554||Adults with diarrhea in Finland|
62729898|NCT01269554||Adults without diarrhea in Bissau|
62729899|NCT01269554||Adults with diarrhea in Bissau|
62729900|NCT06084533||Parkinson Disease|
62729901|NCT06084533||Healthy Control|
62729902|NCT02044029||Age- and gender-matched controls|
62729903|NCT02044029||Patients with spinal muscular atrophy|
62729904|NCT04746664|OTHER|Nutrition counselling|The intervention will be home-to-home-visit once per week lasting 30 minutes to one hour for one month period. The convenience day and time will be selected in the discussion.
62729905|NCT02832102||Retrospective cohort|"A total of 1000 SCCHN patients will be enrolled in a retrospective observational study treated in the period 2008-2014.~Standard treatment of SCCHN patients The patients will be managed as foreseen by best clinical practice and international guidelines for SCCHN."
62729906|NCT02832102||Prospective cohort|"A total of 450 SCCHN patients will be enrolled in a study. Each participating Center will select consecutive patients according to the selection criteria (inclusion/exclusion criteria) for one year and will be followed up for two years or more.~Standard treatment of SCCHN patients: patients will be administered current best clinical practice treatments."
62729907|NCT03005236|EXPERIMENTAL|Envarsus|Basiliximab induction with maintenance therapy of Envarsus, mycophenolate mofetil and corticosteroids. Envarsus constitutes the experimental component of immunosuppression in older kidney transplant recipients.
62729908|NCT03005236|ACTIVE_COMPARATOR|Standard twice daily tacrolimus|Basiliximab induction with maintenance therapy of standard tacrolimus, mycophenolate mofetil and corticosteroids. Standard tacrolimus constitutes the control component of immunosuppression in older kidney transplant recipients.
62729909|NCT04998500|EXPERIMENTAL|GH intervention - control intervention|Participants will receive daily subcutaneous injections of growth hormone for 7 days. Approximately 1-4 months later, the participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant).
62729910|NCT04998500|EXPERIMENTAL|Control intervention - GH intervention|Participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant). Approximately 1-4 months later, the participants will receive daily subcutaneous injections of growth hormone for 7 days.
62729911|NCT00532311|EXPERIMENTAL|Lapaquistat Acetate 50 mg QD|(and stable statin therapy)
62729912|NCT00532311|ACTIVE_COMPARATOR|Stable statin therapy|
62729913|NCT05218941|EXPERIMENTAL|Passive robotic group|Implant surgery without flap assisted by passive robotics
62729914|NCT05218941|ACTIVE_COMPARATOR|Control group|Implant surgery with flap
62729915|NCT03268408||Intervention|"Intervention aimed at improving self-efficacy parenting which consists in sending to new parents, during the first year of life of their son, eight newsletters with advices and recommendations on child care and development (project Baby Newsletter)."
62729916|NCT03268408||Control|Usual care
62729917|NCT02589197||Group 1 (Medial-Pivot)|Group 1 will be implanted with the EVOLUTION® MP System with Cruciate Sacrificing (CS) tibial inserts.
62729918|NCT02589197||Group 2 (Posterior-Stabilized)|Group 2 will be implanted with the Zimmer® NexGen® PS TKA system.
62729919|NCT02589197||Group 3 (Control Group)|Non-implanted control subjects
61978264|NCT04882267|NO_INTERVENTION|Determination of attitudes and perceived barriers to exercise|Adults with CF will take part in a quantitative modified Exercise Benefits/Barriers Scale (EB/BS) survey to identify universal and unique benefits and barriers to regular exercise activity. Subjects will be surveyed on potential ways to engage in exercise, including perceptions and prior use of smart device exercise technology. Qualitative input will be incorporated to better understand potential solutions to barriers, and develop more personalized plans for exercise engagement.
62166309|NCT03709485|EXPERIMENTAL|prostate biopsy patients|a cohort o consecutive patients referred to prostate biopsies. In all patients, a rectal swab will be taken prior to biopsy and antimicrobial treatment. The swab will be cultured and analyzed in the lab for characterization of the microbiome.
62729920|NCT00703963|ACTIVE_COMPARATOR|Usual Care|Subjects will be having their INR tested by their Primary Care Provider as often as their Care Provider dictates. This study phase is twelve weeks long beginning at the day of discharge from our hospital.
62729921|NCT00703963|ACTIVE_COMPARATOR|Patient Self Testing|Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
62729922|NCT03266744|OTHER|Main study group|"Patients will have repeat CT (Computerised Tomography) scans and WB-MRI (Whole Body Magnetic Resonance Imaging) every 12 weeks until disease progression. A baseline bone scan (99mTc-MDP) will be performed.~At the point of disease progression, a repeat bone scan will be obtained in addition to the CT and WB-MRI."
62729923|NCT03266744|OTHER|WB-MRI sub-study group|Patients will be given the opportunity to participate in a sub-study of WB-MRI reproducibility. This involves a repeat scan of the Whole Body Magnetic Resonance Imaging (WB-MRI) diffusion-weighted sequences. This will be shorter in duration than the full WB-MRI scan and will take place within one hour of completing the full WB-MRI scan.
62729924|NCT01960283|ACTIVE_COMPARATOR|Group I|"The group I will receive the intervention :~Methotrexate + anti-H1"
62729925|NCT01960283|PLACEBO_COMPARATOR|Group II|The intervention in group II will include : placebo + anti-H1
62729926|NCT03495141|ACTIVE_COMPARATOR|Supervised|Participants first take part in supervised/coached colonoscopy module session twice (case one and case two) and then transition to performing an unassisted colonoscopy module twice (case three and case four).
62729927|NCT03495141|ACTIVE_COMPARATOR|Unsupervised|Participants will either first partake in an unsupervised colonoscopy module twice (case one and case two) and then transition to a supervised/coached colonoscopy module session twice (case three and case four).
62729928|NCT01166217|EXPERIMENTAL|ABCE, ACBD, BACD, BCAE, CABE and CBAD|
62729929|NCT00475592|EXPERIMENTAL|Capsule Endoscopy|
62729930|NCT00475592|ACTIVE_COMPARATOR|Upper Gastrointestinal Endoscopy|
62729931|NCT04133662|EXPERIMENTAL|Group 1|Restricted sleep condition first, longer sleep condition second
62729932|NCT04133662|EXPERIMENTAL|Group 2|Longer sleep condition first, restricted sleep condition second
62729933|NCT04660695||Group 1|Patients included will undergo an EUS-guided gastroenterostomy with a 15x10mm or a 20x10mm lumen apposing metal Stent (Axios, Boston Scientific, Mass).
62729934|NCT04029428|ACTIVE_COMPARATOR|90Y DOTATATE|Therapy 90Y DOTATATE, total activity 4x3.7GBq (14.8 GBq), i.v. infusion of 90Y DOTATATE administered for 20 min. via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
62729935|NCT04029428|EXPERIMENTAL|177Lu DOTATATE or mix 90Y and 177Lu DOTATATE (50% each)|Therapy 177Lu DOTATATE, total activity 4x5.55GBq (22.2 GBq), i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution (AA) 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other or therapy 90Y and 177Lu DOTATATE, 4x3.7GBq total activity 14.8 GBq, (mix 50% each 90Y and 177Lu), i.v. infusion of mix 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y and 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
62729936|NCT05015647|EXPERIMENTAL|LP group|LP group (n=17) was prescribed high calories/low proteins diet (30 Kcal/kg and 0.6-0.7gr/kg respectively) supplemented with commercial protein free products (protein content \<2%).
62729937|NCT05015647|ACTIVE_COMPARATOR|NP group|NP group (n=18) was prescribed high calories/normal proteins diet (30 kcal/kg and 0.8 gr/kg respectively)
62729938|NCT03350451|EXPERIMENTAL|Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M|"Participants enrolling from study 001B (NCT02706886), received lumasiran, subcutaneous (SC) injection, at a starting dose of 1.0 milligrams per kilograms (mg/kg) once monthly (QM) or 3.0 mg/kg once every 3 months \[Q3M\]) from Day 1 up to a maximum of Month 6. By Month 6, all participants were approved to change dose and/or dosing regimen to receive lumasiran, SC injection at a dose of 3.0 mg/kg, Q3M, up to Month 51 of the treatment period.~All 3 participants who began treatment at 1 mg/kg QM transitioned to 3 mg/kg Q3M regimen by Month 6. As the cumulative dose administered over 6 months was the same for both 1 mg/kg QM \& 3 mg/kg Q3M, these participants were pooled into one arm as recommended by the Safety Review Committee (SRC)."
62729939|NCT03350451|EXPERIMENTAL|Lumasiran (ALN-GO1): 3.0 mg/kg QM|Participants enrolling from study 001B, received lumasiran, SC injection, at a starting dose of 3.0 mg/kg, QM, from Day 1 up to a maximum of Month 21. By Month 21, all participants were approved to change dosing regimen to receive lumasiran, SC injection, at a dose of 3.0 mg/kg, Q3M, up to Month 51 of the treatment period.
62729940|NCT05879731||Participants|"Potential participants for the study will be approached by phone on the day prior to their surgery. Details of the study will be explained to the potential participant by a member of the study team, who will also verify inclusion/exclusion criteria. The morning of the surgery, co-investigators will meet the patients to address any concerns. Written informed consent will be obtained by a member of the study team who is not a member of the patient's treating team.~Participants will then receive the interventions described in the ''Interventions'' section."
62729941|NCT05874505|EXPERIMENTAL|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
62729942|NCT05874505|EXPERIMENTAL|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
62729943|NCT01981265||Hand osteoarthritis|
62729944|NCT02084498|ACTIVE_COMPARATOR|ACC|Training in advanced carbohydrate counting
62729945|NCT02084498|EXPERIMENTAL|ACC + ABC|Training in advanced carbohydrate counting plus the use of an automated bolus calculator.
62729946|NCT01504893|EXPERIMENTAL|Protective|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg PBW, peak airway pressure ≤ 25 cm H2O, I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 4 mL / kg PBW, peak airway pressure ≤ 35 cmH2O, respiratory rate \<30, I:E = 1:2 / 1:3.~During OLV in case of desaturation (before increasing the FiO2) and every 60 minutes alveolar recruitment maneuvers followed by the setting of PEEP to 5 cmH2O"
62729947|NCT01504893|NO_INTERVENTION|Conventional|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg PBW, peak airway pressure ≤ 25 cmH2O; I: E = 1:2; after lung re-expansion to the closure of the chest PEEP set to 5 cmH2O~OLV (OLV): 6 mL / kg PBW, peak airway pressure ≤ 35 cmH2O; I: E = 1:2."
62729948|NCT05930847|EXPERIMENTAL|Digital game group|In addition to routine drug use, children of the digital game group were followed up with 15 sessions of 15 minutes of digital games for respiratory training.
62729949|NCT05930847|ACTIVE_COMPARATOR|Routine medical treatment group|The children continued their current asthma treatment in the same way. They did not receive any extra treatment.
62729950|NCT01883154||IUGR pregnancies|Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile
62729951|NCT01883154||pregnancies with Gestational Diabetes|Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test
62729952|NCT01883154||Pre Gestational Diabetes|A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.
62729953|NCT01883154||IVF pregnancies|
62729954|NCT05756920|EXPERIMENTAL|ABL301|
62729955|NCT05756920|PLACEBO_COMPARATOR|Placebo|
62729956|NCT04721158|OTHER|CGM Arm|Children with type 2 diabetes will wear a continuous glucose monitor for 10 days.
62729957|NCT03466398|EXPERIMENTAL|Intervention Arm|Patients will use the Vivify Health RPM protocol as part of their diabetes management. They required to complete the Care Plan questions on a daily basis, and will upload blood glucose readings directly to the tablet twice a day. They will also have scheduled video conferences with study team physicians or advanced practice nurses on a weekly basis, to discuss ongoing diabetes management and educational objectives.
62729958|NCT03466398|NO_INTERVENTION|Control Arm|Patients in this arm will manage their diabetes at home per normal standard of care, without any extra intervention from the study investigators.
62729959|NCT05568563|EXPERIMENTAL|Ethyl chloride|
62729960|NCT05568563|EXPERIMENTAL|Honey|
62729961|NCT05568563|NO_INTERVENTION|Control|
62729962|NCT04058015||adult patients with thoracoabdominal injuries|adult patients with moderate to severe thoracoabdominal injuries
62729963|NCT00326001|EXPERIMENTAL|Gold tip catheter|Gold tip catheter
62729964|NCT00326001|ACTIVE_COMPARATOR|Platinum-iridium tip catheter|Platinum-iridium tip catheter
62729965|NCT01993381||CINV of FOLFOX, FOLFIRI|moderate emetogenic chemotherapy
62729966|NCT03987711|EXPERIMENTAL|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
62729967|NCT03987711|ACTIVE_COMPARATOR|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
62729968|NCT03987711|ACTIVE_COMPARATOR|No oral anticoagulation|Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.
62729969|NCT04471376|ACTIVE_COMPARATOR|Sugammadex group|
62729970|NCT04471376|NO_INTERVENTION|control group|
62729971|NCT02413944|EXPERIMENTAL|healthy volunteers|ACTH stimulation test
62729972|NCT01489709||Vesicare group|Who receive vesicare
62729973|NCT00712387|NO_INTERVENTION|A|General surgical trainees who will receive the 'traditional' training programme; i.e. will receive whatever clinical training on a patient their supervising consultant deems appropriate. This is the way junior surgeons are currently trained. They will also receive the standard didactic teaching on the School for Surgeons e-learning resource.
62729974|NCT00712387|ACTIVE_COMPARATOR|B|Surgical trainees who are assigned to the 'proficiency-based progression' training programme. These trainees will be required to train on the virtual reality simulator (Lap Sim™) for a laparoscopic cholecystectomy. Trainees will have objectively set goals to reach on the simulator and will have to demonstrate proficiency before they are permitted to progress to the next, more challenging level. Group B will also receive the standard School for Surgeons instruction but, unlike Group A, they will have to demonstrate proficiency on the didactic module before they progress to the operating theatre
62729975|NCT06204588|EXPERIMENTAL|Test group-1|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
62729976|NCT06204588|EXPERIMENTAL|Test group-2|Single flap approach along with diode laser (SFA+LLLT).
62729977|NCT06204588|EXPERIMENTAL|Control group|using single flap approach only
62729978|NCT01670669|ACTIVE_COMPARATOR|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
62729979|NCT05512481|EXPERIMENTAL|Neoadjuvant/adjuvant therapy|"Drug: Camrelizumab~Drug: Apatinib mesylate~Drug: Temozolomide Injection"
62729980|NCT00005097|EXPERIMENTAL|Polyphenon E & Placebo|"Each subject will receive both the Polyphenon E and placebo, one on each arm.~One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks."
62729981|NCT03009162|EXPERIMENTAL|Renal impaired participants|Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
62729982|NCT03009162|EXPERIMENTAL|Healthy participants|Participants received single 200 mg oral tablet of lasmiditan.
62729983|NCT03326635||frailty group|frailty score ≤ 3
62729984|NCT03326635||non-frailty group|frailty score \>3
62729985|NCT01527045|EXPERIMENTAL|Prevention (donor statin treatment)|See Detailed Description
62729986|NCT03743545|ACTIVE_COMPARATOR|conventional drilling with irrigation|
62729987|NCT03743545|EXPERIMENTAL|low speed without irrigation|
62729988|NCT01716130||IM vaccine in the past 3 years|Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
62729989|NCT01716130||no IM vaccine in the past 3 years|Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
62729990|NCT01716130||vaccine administrators|Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
62729991|NCT02423525|EXPERIMENTAL|Afatinib|Afatinib tablets are taken by mouth. Dose Level 1: 80 mg every 4 days Dose Level 2: 120 mg every 4 days Dose Level 3: 180 mg every 4 days Dose Level 4: 280 mg every 7 days
62729992|NCT03915444|EXPERIMENTAL|NabCG|nab-paclitaxel 125mg/m2 cisplatin 25 mg/m2 gemcitabine 1000 mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days
62729993|NCT05524519|ACTIVE_COMPARATOR|WT group|This group will include 30 patients with MDD. Patients in this group will not receive IA treatment during the study period. When the study is over, they will receive 6 weeks of the same IA treatment as in the CCA group.
62729994|NCT05524519|EXPERIMENTAL|CCA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. LR3, PC6, SP6, and HT7 will be selected for IA.
62729995|NCT05524519|EXPERIMENTAL|TSA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. TSA selected in the first part of the study will be stimulated.
62729996|NCT05524519|EXPERIMENTAL|PSA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. PSA selected in the first part of the study will be stimulated.
62729997|NCT03186092|ACTIVE_COMPARATOR|Intervention Group|inspiratory muscle training with load
62729998|NCT03186092|SHAM_COMPARATOR|Control Group|unloaded inspiratory muscle training
62729999|NCT01170273|PLACEBO_COMPARATOR|Placebo Arm|placebo capsule
62730000|NCT01170273|EXPERIMENTAL|Cholecalciferol 4000 IU|cholecalciferol 4000 IU daily
62730001|NCT02176200|EXPERIMENTAL|Berodual® Respimat®|
62730002|NCT02176200|ACTIVE_COMPARATOR|Berodual® HFA-MDI|
62730003|NCT04873440|EXPERIMENTAL|Manganese plus Radiotherapy|Subject received standard-of-care radiotherapy or stereotactic body radiation therapy (SBRT) to one metastatic site. Manganese inhalation began 1 week after the start of radiotherapy and lasted up to 6 months. The same systemic therapy before the enrollment will be maintained.
62730004|NCT02089932|PLACEBO_COMPARATOR|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally
62730005|NCT02089932|EXPERIMENTAL|Group B-DEX 25 : Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally
62730006|NCT02089932|EXPERIMENTAL|Group B-DEX 50:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally
62730007|NCT02089932|EXPERIMENTAL|Group B-DEX 75:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally
62730008|NCT03990532|EXPERIMENTAL|treatment group|
62730009|NCT02122497||abdominal aortic aneurysm (AAA) endovascular|endovascular aortic repair
62730010|NCT02122497||abdominal aortic aneurysm (AAA) open|open surgical repair
62730011|NCT02122497||abdominal aortic occlusive disease (AOD)|open surgical repair
62730012|NCT03162133|EXPERIMENTAL|Exercise group|After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
62730013|NCT03162133|EXPERIMENTAL|Waiting list Control group|"Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise.~After their post-assessment they were able to attend the Baduanjin classes."
62730014|NCT05130684|EXPERIMENTAL|Neo-CRT|"* Nivolumab 240 mg, 30-min IVF, Q2W on days -14, 1, 15, and 29;~* Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8, 15, 22, and 29;~* Cisplatin 30 mg/m2,1h-IVF,on days 1, 8,15, 22, and 29;~* RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."
62730015|NCT03965104|EXPERIMENTAL|Intervention pharmacists|Will receive the HC-PCP prior to starting enrollment, and then will provide care to their patients, which will include risk assessment, prescribing of antihypertensive medications, and follow-up monthly according to the Hypertension Canada Guidelines.
62730016|NCT03965104|NO_INTERVENTION|Control pharmacists|Will provide usual pharmacist care. All patients with blood pressure above target will be entered into the study database and serve as the control group. No specific interventions or follow-up will be mandated other than usual pharmacist care, although all patients will be assessed at 3 months to determine change in BP since enrollment (the primary outcome).
62730017|NCT03183063|EXPERIMENTAL|4DCT and SPECT/CT|Anticipated 15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing. Data will be analyzed for objectives 1, 4 and 5.
62730018|NCT03183063|EXPERIMENTAL|4DCT with BiPAP and SPECT/CT|Anticipated 5 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. The second of the two 4DCT scans will be obtained with positive airway breathing via BiPAP. Results in these patients will be analyzed for objective 6 only.
62730019|NCT03183063|EXPERIMENTAL|4DCT with CTA in suspected PE|Anticipated 124 participants with CTA ordered/performed for suspected PE will be enrolled to have 4DCT. Goal for analysis is 62 with positive CTA results for PE and 62 with negative CTA results for PE. Data will be analyzed for objectives 2 and 3.
62730020|NCT00583674|EXPERIMENTAL|B|
62730021|NCT00583674|EXPERIMENTAL|A|
62730022|NCT00583674|ACTIVE_COMPARATOR|C|
62730023|NCT03576014|EXPERIMENTAL|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
62730024|NCT02923531|EXPERIMENTAL|X4P-001 Plus Nivolumab|Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study medication will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
62730025|NCT05421299||Abatacept Group|Participants with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS), hodgkin lymphoma (HL), or non-hodgkin lymphoma (NHL) who have a bone marrow (BM) or peripheral blood (PB) stem cell donor who is HLA-matched at 7/8 loci (A, B, C, DRB1) who received abatacept.
62730026|NCT05421299||Comparator Group|Participants with AML, ALL, CML, MDS, HL, or NHL who have a BM or PB stem cell donor who is HLA-matched at 7/8 loci (A, B, C, DRB1) who did not receive abatacept.
62730027|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
62730028|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
62730029|NCT05831904|EXPERIMENTAL|20 healthy children|20 healthy children aged 5 to 15 years , without any congenital or developmental abnormalities of their hip joint
62730030|NCT05515406|EXPERIMENTAL|Dose Escalation Phase (Part 1)|Up to 4 dose levels will be evaluated. Eligible patients will be assigned to a dose level cohort according to a traditional 3+3 dose escalation design.
62730031|NCT05515406|EXPERIMENTAL|Dose Expansion Phase (Part 2)|Eligible patients will be assigned to the recommended dose level(s) selected from Part 1.
62730032|NCT03313635||Men presenting with low-T|Men presenting with low-t will undergo a blood draw for evaluation of prealbumin levels.
62730033|NCT01928290|EXPERIMENTAL|Arm A: FOLFIRINOX (HER2-negative)|"Irinotecan 180 mg/m2 IV on Days 1 \& 15.~Oxaliplatin 85 mg/m2 IV on Days 1 \& 15.~Leucovorin 400 mg/m2 IV on Days 1 \& 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
62730034|NCT01928290|EXPERIMENTAL|Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)|"Trastuzumab 8 mg/kg on Cycle 1 Day 1 then 4 mg/kg on Day 15 and Day 1 of all future cycles.~Irinotecan 180 mg/m2 IV on Days 1 \& 15.~Oxaliplatin 85 mg/m2 IV on Days 1 \& 15.~Leucovorin 400 mg/m2 IV on Days 1 \& 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
62730035|NCT00888706|ACTIVE_COMPARATOR|1|
62730036|NCT00888706|ACTIVE_COMPARATOR|2|
62730037|NCT00888706|ACTIVE_COMPARATOR|3|
62730038|NCT00888706|EXPERIMENTAL|4|
62730039|NCT00776542|EXPERIMENTAL|1|Minocycline 100 mg tablets of ranbaxy
62730040|NCT00776542|ACTIVE_COMPARATOR|2|Minocin 100mg tablets
62730041|NCT03560583|EXPERIMENTAL|Metoclopramide 10 mg BID|
62730042|NCT03560583|PLACEBO_COMPARATOR|Placebo 10 mg BID|
62730043|NCT05139927|EXPERIMENTAL|Condition 1|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - ON Component D: Navigation
62730044|NCT05139927|EXPERIMENTAL|Condition 2|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - ON Component D: Self-test kit
62730045|NCT05139927|EXPERIMENTAL|Condition 3|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - ON Component D: Navigation
62730046|NCT05139927|EXPERIMENTAL|Condition 4|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - ON Component D: Self-test kit
62730047|NCT05139927|EXPERIMENTAL|Condition 5|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Navigation
62730048|NCT05139927|EXPERIMENTAL|Condition 6|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Self-test kit
62730049|NCT05139927|EXPERIMENTAL|Condition 7|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Navigation
62730050|NCT05139927|EXPERIMENTAL|Condition 8|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Self-test kit
62730051|NCT05139927|EXPERIMENTAL|Condition 9|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Navigation
62730052|NCT05139927|EXPERIMENTAL|Condition 10|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Self test kit
62730053|NCT05139927|EXPERIMENTAL|Condition 11|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Navigation
62730054|NCT05139927|EXPERIMENTAL|Condition 12|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Self test kit
62730055|NCT05139927|EXPERIMENTAL|Condition 13|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Navigation
62730056|NCT05139927|EXPERIMENTAL|Condition 14|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Self test kit
62730057|NCT05139927|EXPERIMENTAL|Condition 15|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Navigation
62730058|NCT05139927|EXPERIMENTAL|Condition 16|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Self test kit
62730059|NCT00133263|EXPERIMENTAL|1|
62730060|NCT00133263|ACTIVE_COMPARATOR|2|
62730061|NCT01552512|NO_INTERVENTION|MSPP Integrated Package|Participants in this arm only receive the standard care offered by the Ministry of Health (MSPP)called the Integrated Package. During the trial, they do not receive Nutributter.
62730062|NCT01552512|EXPERIMENTAL|Nutributter 3 Months, Integrated Package|Participants receive a one-month supply for the first 3 months of the 6-month trial in addition to the Integrated Package.
62730063|NCT01552512|EXPERIMENTAL|Nutributter 6 Months, Integrated Package|Participants receive a one-month supply for each month of the 6-month trial in addition to the Integrated Package.
62730064|NCT05317650|NO_INTERVENTION|Control group|Control group, no exercise was performed, and the measurements were repeated at the end of 4 weeks.
62730065|NCT05317650|EXPERIMENTAL|M-Gravity group|Intervention group performed the exercise with the M-Gravity, 2 sessions per week, for 4 weeks, at the Outpatient Clinic of Department of Physical Therapy, Baskent University, one session for 60 minutes.
62730066|NCT01223339|EXPERIMENTAL|Single Dose Japanese Cohort|This will be a single dose Cohort in which Japanese healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin or placebo through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
62730067|NCT01223339|EXPERIMENTAL|Single dose Western cohort|This will be a single dose Cohort in which Western healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
62730068|NCT01223339|EXPERIMENTAL|Multiple Dose Japanese Cohort|This will be a multiple dose Cohort in which Japanese healthy participants will receive once-daily 25 mg ertugliflozin or placebo for 7 days.
62730069|NCT00675831|EXPERIMENTAL|CD25+ Treg depleted DLI dose schema|"Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema:~* Dose level -C: 3x10\^7 (CD3+Dose (#cells/kg\*))~* Dose level -B: 1x10\^7 (CD3+Dose (#cells/kg\*))~* Dose level -A: 1x10\^6 (CD3+Dose (#cells/kg\*)) \*Recipient's body weight in Kg"
62730070|NCT00996957|EXPERIMENTAL|ACE-041|Patients assigned to 1 of 9 possible dosing groups
62730071|NCT02270658|EXPERIMENTAL|Continuous positive airway pressure|Continuous positive airway pressure therapy (CPAP)
62730072|NCT02270658|PLACEBO_COMPARATOR|Nasal strips|Nasal strips applied to the outside surface of the nose with adhesive.
62730073|NCT01687881|SHAM_COMPARATOR|Sham Chiropractic|Sham Chiropractic manipulative therapy.
62730074|NCT01687881|NO_INTERVENTION|Control group|No intervention: Control group.
62730075|NCT01687881|ACTIVE_COMPARATOR|Chiropractic Spinal Manipulative Therapy|Active intervention: Chiropractic Spinal Manipulative Therapy
62730076|NCT00496431|EXPERIMENTAL|ITF2357|Patients were provided with the appropriate number of 50 mg hard gelatine capsules for oral administration for 7 days treatment, i.e. at the daily dose of 100 mg, 14 capsules 50 mg each, plus 2 spare capsules suitable in case of accidental loss.
62730077|NCT02021786|EXPERIMENTAL|Mobile phone based intervention|The intervention in the present study is a web- and mobile phone based intervention aiming to develop healthy lifestyle behaviors regarding physical activity and dietary habits in 4-year-olds. The intervention will be delivered to the parents and it is available to the parents during six months.
62730078|NCT02021786|NO_INTERVENTION|Control|The control group receive a pamphlet on healthy eating and physical activity in pre-school children based on the existing guidelines. The information is similar to what parents receive from the Swedish child healthcare system
62730079|NCT04349358|OTHER|FDG and FCH PET/CT|
62730080|NCT02623777|EXPERIMENTAL|AXOS as first intervention|AXOS as first intervention
62730081|NCT02623777|EXPERIMENTAL|SCFA as first intervention|SCFA as first intervention
62730082|NCT04306458|EXPERIMENTAL|Robot assisted minimally invasive esophagectomy|Robot assisted minimally invasive esophagectomy
62730083|NCT04306458|ACTIVE_COMPARATOR|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
62730084|NCT02325024|EXPERIMENTAL|Renally Impaired Subjects|"Treatment group consists of subjects with severe renal impairment or ESRD and in accordance with the following criteria;~* Clinically significantly abnormal creatinine and creatinine clearance (CLcr \<30 mL/min) and not requiring dialysis.~* Onset of renal impairment must have been documented at least 3 months prior to study start."
62730085|NCT02325024|EXPERIMENTAL|Matched subjects with Normal Renal Function|Group consists of healthy subjects (as determined by medical history, physical examination, biochemistry, hematology, urinalysis, hepatitis B and C, and HIV testing) who demonstrate normal renal function (CLcr \> 80 mL/min) and are individually matched to renally impaired subjects with respect to age (within the decile or five years, whichever is less), gender, and Body Mass Index (BMI) (+/- 10% BMI).
62730086|NCT04550780||The study population|The study population will comport all beneficiaries in the national French SNDS database who were prescribed mepolizumab and for whom health resource use data is available for the 12 months preceding and following a first filled prescription for mepolizumab.
62730087|NCT01489865|EXPERIMENTAL|ABT-888 and mFOLFOX-6|ABT-888 orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
62730088|NCT05155124|EXPERIMENTAL|Cetuximab and trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
62730089|NCT03536325|EXPERIMENTAL|Cohort 1: Guselkumab Dose 1 or Placebo|Participants will receive Dose 1 of guselkumab or matching placebo as an intravenous (IV) infusion on Day 1.
62730090|NCT03536325|EXPERIMENTAL|Cohort 2: Guselkumab Dose 2 or Placebo|Participants will receive Dose 2 of guselkumab or matching placebo as an IV infusion on Day 1.
62730091|NCT03536325|EXPERIMENTAL|Cohort 3: Guselkumab Dose 3 or Placebo|Participants will receive Dose 3 of guselkumab or matching placebo as an IV infusion on Day 1 based on safety data results received from Cohort 1 and 2.
62730092|NCT06196996|EXPERIMENTAL|Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus|
62730093|NCT01196897|EXPERIMENTAL|Implantable device|WATCHMAN LAA Closure Technology (Gen 4.0)
62730094|NCT04219449||study group|Diagnosed beta-thalassemia patients at Assiut University Hospital.
62730095|NCT02955888|EXPERIMENTAL|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
62730096|NCT02955888|PLACEBO_COMPARATOR|Placebo|Four 200 mg capsules (total 800 mg) administered orally, once daily.
62730097|NCT02920307|EXPERIMENTAL|TEP without fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair without mesh fixation
62730098|NCT02920307|ACTIVE_COMPARATOR|TEP with fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair
62730099|NCT02920307|EXPERIMENTAL|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) hernia repair without mesh fixation
62730100|NCT02920307|ACTIVE_COMPARATOR|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) hernia repair
62730101|NCT02049346|ACTIVE_COMPARATOR|Epoetin alpha or beta (Epoetin group)|Patients in that arm were continued on the previous same dose and route of administration of Epoetin alpha/ beta (Epoetin group).
62730102|NCT02049346|ACTIVE_COMPARATOR|Darbepoetin alpha|subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol.
62730103|NCT02049346|EXPERIMENTAL|Methoxy polyethylene glycol-epoetin beta|Patients in that arm received Intravenous Methoxy polyethylene glycol-epoetin beta monthly.
62730104|NCT06543459|EXPERIMENTAL|Group A, Sequence 1, Dose 1|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62730105|NCT06543459|EXPERIMENTAL|Group A, Sequence 2, Dose 2|Participants randomized to receive MY008211A tablets or placebo on Day 7.
62730106|NCT06543459|PLACEBO_COMPARATOR|Group B, Sequence 1, Dose 1|Participants randomized to receive MY008211A tablets or placebo on Day 1.
62730107|NCT06543459|PLACEBO_COMPARATOR|Group B, Sequence 2, Dose 2|Participants randomized to receive MY008211A tablets or placebo on Day 7.
62730108|NCT04012827|EXPERIMENTAL|Apatinib Mesylate Combined With Doxorubicin and Ifosfamide|A course of treatment every 21 days. For patients with disease control (CR+ PR+SD) and tolerable adverse reactions after 6 courses of treatment, continuous drug use was considered by the researchers as inappropriate for patients to continue drug use or when the efficacy was assessed as disease progression (PD).No other antitumor treatment can be given during the treatment.
62730109|NCT00466947|EXPERIMENTAL|Synflorix Group|Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
62730110|NCT00466947|ACTIVE_COMPARATOR|Control Group|Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.
62730111|NCT01412125||Patient|Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status
62730112|NCT01412125||Healthy subject|Voluntary controls with no family history of huntington's disease
62730113|NCT05490316|PLACEBO_COMPARATOR|Placebo tablet|
62730114|NCT05490316|EXPERIMENTAL|IBI353 (Orismilast) dose 2|
62730115|NCT05490316|EXPERIMENTAL|IBI353 (Orismilast) dose 1|
62730116|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.~Fatigue will be assessed with the FIS and 6 Minute Walk Test.~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
62730117|NCT05985798|EXPERIMENTAL|Sin-Bev-TACE|Sintilimab, bevacizumab plus TACE
62730118|NCT05985798|ACTIVE_COMPARATOR|Len-TACE|Lenvatinib plus TACE
62730119|NCT05701553||Anti-PD-1/PD-L1 antibodies and S-adenosyl-methionine combination|"Drug: Anti-PD-1/PD-L1 Intravenous injection for at least 6 months~Drug: S-adenosyl-methionine Taken orally for at least 6 months"
62730120|NCT02095392|EXPERIMENTAL|P1000/Ca0|
62730121|NCT02095392|EXPERIMENTAL|P1000/Ca500|
62730122|NCT02095392|EXPERIMENTAL|P1000/Ca1000|
62730123|NCT02095392|PLACEBO_COMPARATOR|Placebo|
62730124|NCT04858607||Immunocompromised individuals|Patients with primary or secondary immunodeficiency planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
62730125|NCT04858607||Healthy individuals|Healthy people planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
62730126|NCT05299177|EXPERIMENTAL|Automated Insulin Delivery|The components of the automated insulin delivery system are the Dexcom G6 continuous glucose monitor (CGM), the InControl algorithm and an insulin pump (Ypsomed Ypsopump). The Dexcom G6 continuous glucose monitoring device is an approved device and is licensed to be used to inform insulin dosing decisions without confirmation. The algorithm (inControl 1.0) is approved when used embedded in the Tandem X2 insulin pump. We are using the algorithm for its intended purpose but are implementing it in a smartphone app to be installed in a compatible smartphone (Android). We are additionally assessing incremental benefit with the next software version of the algorithm. This will be the first time this updated software has been assessed in people with type 1 diabetes. The compatible insulin pump is a continuous subcutaneous insulin infusion device and is being used in line with its intended purpose, according to the manufacturer's instructions (YpsoMed Ypsopump).
62730127|NCT02340169|EXPERIMENTAL|Topicort® Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25%, twice a day for 28 days
62730128|NCT00590122|EXPERIMENTAL|Randomization Group b|Parcopa at equivalent dosage to subjects current stable dose
62730129|NCT00590122|ACTIVE_COMPARATOR|Randomization Group a|Carbidopa-levodopa (Sinemet)at subjects current stable dose
62730130|NCT01558037||Main study|Main study patients are enrolled before or at time of solid organ transplant. Qualifying subjects either have tested positive for Cytomegalovirus or have a donor who has tested positive for Cytomegalovirus.
62730131|NCT01558037||Sub study|Subjects are enrolled to this arm who have begun replicating Cytomegalovirus post transplant. These subjects may or may not have been on the main study arm.
62730132|NCT06138353|EXPERIMENTAL|Shuxuening injection treatment group|Group1: Shuxuening injection treatment group (N1=25): Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
62730133|NCT06138353|PLACEBO_COMPARATOR|Placebo control group|Group2: Placebo control group (N2=25): Shuxuening injection simulant (0.9% sodium chloride injection, specification: 10 ml/cartridge, Kunming Yusi Pharmaceutical Co., Ltd.), 20 ml (2 cartridges) + 5% dextrose injection 250 ml, intravenously dripped once a day, from the first day of postoperative, treatment for 1 course of treatment, for a total of 10-14 days.
62730134|NCT00700193|OTHER|Group A|Equal to or greater 6 months to less than 3 years old
62730135|NCT00700193|OTHER|Group B|Equal to or greater 3 years to less than 9 years old
62730136|NCT01030120|ACTIVE_COMPARATOR|etanercept|etanercept 50mg BIW
62730137|NCT01030120|PLACEBO_COMPARATOR|placebo|matching placebo
62730138|NCT05897073|EXPERIMENTAL|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
62730139|NCT05897073|EXPERIMENTAL|Supervised exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
62730140|NCT05897073|NO_INTERVENTION|Usual-care control group|Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion.
62730141|NCT05897073|EXPERIMENTAL|Time-restricted eating plus Supervised exercise|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). Moreover, participants will receive an individualized moderate-intensity goal-
62730142|NCT05742412|EXPERIMENTAL|Intervention Group|"Intervention group: EMS dispatcher using video-based communication in emergency calls.~In the intervention arm, the EMS Dispatchers are requested to use video in all emergency calls during the 4-month study period."
62730143|NCT05742412|ACTIVE_COMPARATOR|Control Group|"Control group: EMS dispatcher using telephone-only (audio-only) communication in emergency calls.~In the control arm, the EMS Dispatchers continue using standard telephone communication (usual care)."
62730144|NCT06184230|OTHER|Revaccinated at 32 Years|
62730145|NCT01202201||Study Cohort|Subjects hospitalized with acute gastroenteritis or rotavirus gastroenteritis
62730146|NCT04594629|SHAM_COMPARATOR|nitroglycerine group|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
62730147|NCT04594629|ACTIVE_COMPARATOR|PGI2 group|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres.
62730148|NCT03870464||Prospective arm|Quality of Life questionnaires EORTC-QoL30 and Euro EQ-5D-5L questionnaires are distributed. Blood samples are collected consecutively during ICI and at a follow-up period of one year. CT-scans extended of thorax, abdomen and the lower extremities are performed at baseline and at 6 months. MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.Prospective registration of irAEs are registered during ICI and for one year of follow-up.Enrolment period 1th of April 2018- 31th of April 2021.
62730149|NCT01813201|ACTIVE_COMPARATOR|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)
62730150|NCT01813201|PLACEBO_COMPARATOR|Saline isotonic solution (Placebo)|Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).
62730151|NCT01930604|ACTIVE_COMPARATOR|Palmar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
62730152|NCT01930604|PLACEBO_COMPARATOR|Palmar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
62730153|NCT01930604|ACTIVE_COMPARATOR|Plantar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
62730154|NCT01930604|PLACEBO_COMPARATOR|Plantar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
62730155|NCT01930604|ACTIVE_COMPARATOR|Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
62730156|NCT01930604|PLACEBO_COMPARATOR|Inguinal (groins/buttocks) hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
62730157|NCT01930604|ACTIVE_COMPARATOR|Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)|Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.
62730158|NCT01930604|PLACEBO_COMPARATOR|Craniofacial hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
62730159|NCT01930604|ACTIVE_COMPARATOR|Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)|Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.
62730160|NCT01930604|PLACEBO_COMPARATOR|Truncal hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
62730161|NCT04884763|ACTIVE_COMPARATOR|Arm A|Arm A: erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
62730162|NCT04884763|PLACEBO_COMPARATOR|Arm B|Arm B: placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
62730163|NCT04770558|EXPERIMENTAL|Exergame group|The exergame group will receive exergame training for 12 weeks, 2 times a week and 60 min per session.
62730164|NCT04770558|NO_INTERVENTION|Control group|The control group will not receive any intervention and maintain their lifestyle for 12 weeks.
62730165|NCT03394742|EXPERIMENTAL|Intervention group|Peer support group received, in addition to usual care, peer support via telephone 1-5 times according to their own preference. Peer support was started at the time between diagnosis and the beginning of treatments.
62730166|NCT03394742|NO_INTERVENTION|Control group|The control group received usual care only. For ethical reasons, participants in the control group were not discouraged from seeking peer support by themselves if they felt a need for it.
62730167|NCT06162273||IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
62730168|NCT05640362|PLACEBO_COMPARATOR|Benzydamine mouthwash|
62730169|NCT05640362|EXPERIMENTAL|Natural enzymes mouthwash|
62730170|NCT05179278|EXPERIMENTAL|Intervention Group: post-surgical face-to-face follow up consultation|
62730171|NCT05179278|EXPERIMENTAL|Control Group: post-surgical telephone follow up consultation|
62730172|NCT05715138|EXPERIMENTAL|GPi-DBS|The DBS electrodes are implanted into posteroventral GPi bilaterally.
62730173|NCT05715138|EXPERIMENTAL|STN-DBS|The DBS electrodes are implanted into dorsolateral STN bilaterally.
62730174|NCT03360240||Cases|Cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
62730175|NCT03360240||controls|Are patients with pregnancy that starts before the age of 19 that without develops (preeclampsia mild), severe preeclampsia, gestational hypertension or eclampsia) that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
62730176|NCT04118075|EXPERIMENTAL|PT-CY-FK +/- ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
62730177|NCT06226597|EXPERIMENTAL|Fitbit monitoring|Individuals in this arm will wear a fitbit device consistently throughout the duration of their pregnancy, and monitor fitbit data using a platform that connects to their phone. The remainder of prenatal care will be per standard procedure.
62730178|NCT06226597|NO_INTERVENTION|Routine prenatal care|Individuals in this arm will receive standard prenatal care without the addition of wearing a fitbit device.
62730179|NCT02136004|EXPERIMENTAL|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
62730180|NCT05908981|ACTIVE_COMPARATOR|The effects of sandalwood oils on anxiety levels of pediatric|first group sandalwood aromatherapy
62730181|NCT05908981|ACTIVE_COMPARATOR|The effects of Lavender oils on anxiety levels of pediatric|second group lavender oil
62730182|NCT00430989|OTHER|70% Nitrous Oxide|General anaesthesia using 70% Nitrous Oxide with fraction of inspired oxygen at 30%
62730183|NCT00430989|OTHER|No Nitrous Oxide|General anaesthesia not containing Nitrous oxide with fraction of inspired oxygen at 30%
62730184|NCT00841243|ACTIVE_COMPARATOR|nutritional advise/support|Nutritional advise and support
62730185|NCT00841243|NO_INTERVENTION|control|Control
62730186|NCT00532129|EXPERIMENTAL|Rituximab plus Chlorambucil|Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.
62730187|NCT01492426|EXPERIMENTAL|Daclatasvir + Peginterferon alfa-2a + Ribavirin|
62730188|NCT01492426|EXPERIMENTAL|Telaprevir + Peginterferon alfa-2a + Ribavirin|
62730189|NCT04816981|EXPERIMENTAL|EBUS-Elastography|
62730190|NCT05183074|EXPERIMENTAL|MR-linac group|Pts received ultra-hypofractionated RT for primary w/o adjacent oligo-metastatic diseases on 1.5-Tesla MR-Linac
62730191|NCT05525039|PLACEBO_COMPARATOR|Control Group|Subjects assigned to Contro Group will not receive VT or HMB. They will receive daily protein supplement for 6 months.
62730192|NCT05525039|ACTIVE_COMPARATOR|HMB only Group|Subjects assigned to HMB only Group will receive HMB supplement at 3g/day and daily protein supplement for 6 months.
62730193|NCT05525039|ACTIVE_COMPARATOR|VT only Group|Subjects assigned to VT only Group will receive VT (0.3g, 35Hz, at least 3 times/week) and daily protein supplement for 6 months
62730194|NCT05525039|EXPERIMENTAL|HMB + VT Group|Subjects assigned to HMB + VT Group will receive HMB supplement at 3g/day, VT at least 3 times/week and daily protein supplement for 6 months.
62730195|NCT01724229|OTHER|treatment with OTC drug products|"* Body Wash \& Shampoo applied directly to the skin or cloth; soiled area gently wiped clean. No rinsing necessary.~* Moisture Barrier Cream: Once area cleansed and dried thoroughly, a thin coat is gently applied to the area of the skin exposed to moisture twice daily for two weeks or as directed by doctor.~* 2-in-1 Cleanser: applied directly to the skin or a cloth and skin gently wiped clean. No rinsing necessary.~* Antifungal Cream: Once reddened area cleansed and dried thoroughly a thin layer is applied over the affected area twice daily for two weeks or as directed by doctor."
62730196|NCT00854789|EXPERIMENTAL|Vaccine|HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
62730197|NCT00854789|NO_INTERVENTION|Control/observation|HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.
62730198|NCT00636103|EXPERIMENTAL|CUF2|
62730199|NCT00636103|PLACEBO_COMPARATOR|Placebo|
62730200|NCT00745290|ACTIVE_COMPARATOR|Bupivacaine HCl|Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration
62730201|NCT00745290|OTHER|SKY0402|Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
62730202|NCT01799486|EXPERIMENTAL|Telbivudine|Telbivudine,600mg/d,oral,100patients,2 years.
62730203|NCT01799486|EXPERIMENTAL|Adefovir|Adefovir,10mg/d,oral,100 patients,2years.
62730204|NCT01799486|EXPERIMENTAL|Enecavir|Enecavir,0.5mg/d,oral,100 patients,2 year
62730205|NCT01080924|EXPERIMENTAL|Low frequency ultrasound spectroscopy|Low frequency ultrasound spectroscopy after broncholysis
62730206|NCT00099502|EXPERIMENTAL|Arm 1|
62730207|NCT00099502|EXPERIMENTAL|Arm 2|
62730208|NCT00099502|ACTIVE_COMPARATOR|Arm 3|
62730209|NCT02408679||All subjects|300 eligible subjects will perform a blood sampling for a dosage of serum vitamin D and will fill up a study questionnaire during one visit.
62730210|NCT00778167|EXPERIMENTAL|Arm I (Enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
62730211|NCT00778167|EXPERIMENTAL|Arm II (Enzyme inhibitor and monoclonal antibody therapy)|Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.
62730212|NCT03976505|ACTIVE_COMPARATOR|textual prescription healthy volunteers|
62730213|NCT03976505|ACTIVE_COMPARATOR|table prescription healthy volunteers|
62730214|NCT03976505|EXPERIMENTAL|textual prescription Parkinson's disease patients|
62730215|NCT03976505|EXPERIMENTAL|table prescription Parkinson's disease patient|
62730216|NCT04525144|EXPERIMENTAL|Tebonin Forte|Treatment: 120mg, twice a day, 52 weeks
62730217|NCT04525144|NO_INTERVENTION|Control|No Treatment
62730218|NCT01731847|EXPERIMENTAL|The combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
62730219|NCT05002933|EXPERIMENTAL|Insulin glargine 300 U/ml|Insulin glargine 300 U/ml once daily for 24 weeks. Participants may continue for an additional 12 week extension period or switch to other anti-diabetic treatment, insulin dose will be adjusted according to the recommended dose titration algorithm
62730220|NCT06497751|EXPERIMENTAL|Couple-based Dyadic Coping Group|The investigators will deliver three sessions (we-disease appraisal, communication skills, and dyadic coping skills) once per week. The first two sessions last 30 mins, and the final session lasts one hour.
62730221|NCT06497751|NO_INTERVENTION|Usual Care Group|Participants received routine care from health providers.
62730222|NCT03021603|EXPERIMENTAL|Intervention Group|"This is a 4-week Brief Hope Intervention~Four sessions in total:~two face-to-face sessions (1-hour) and two telephone follow up sessions (30 mins) in between.~Homework : A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
62166310|NCT03279172|EXPERIMENTAL|Group Direct Laryngoscope|direct laryngoscope (macintosh laryngoscope) is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Macintosh laryingoscope, BIS monitoring and tonometry would be used in Group Direct Laryngoscope.
62166311|NCT03279172|EXPERIMENTAL|Group videolaryngoscope|Videolaryngoscope is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Video laryingoscope, BIS monitoring and tonometry would be used in Group Video Laryngoscope.
62730223|NCT03021603|EXPERIMENTAL|Control Group|"Standard care:~Clinic follow up and normal hospital care. Logistic call and social communication On completion of the 4-week standard care, the 4-session brief hope intervention will be offered"
62730224|NCT02977910|EXPERIMENTAL|with repair of deltoid ligament|open reduction and internal fixation with repair of deltoid ligament
62730225|NCT02977910|NO_INTERVENTION|without repair of deltoid ligament|open reduction and internal fixation without repair of deltoid ligament
62730226|NCT02025634|EXPERIMENTAL|Intravenous acetaminophen|Infusion of Intravenous acetaminophen (Ofirmev)
62730227|NCT02025634|PLACEBO_COMPARATOR|Placebo (0.9% Normal Saline Infusion)|Infusion of 100 ml of 0.9 NS Normal Saline
62730228|NCT05921591|EXPERIMENTAL|Dose A IRL201104|IRL201104 or placebo IV on days 1 and 7
62730229|NCT05921591|EXPERIMENTAL|Dose B IRL201104|IRL201104 or placebo IV on days 1 and 7
62730230|NCT05921591|EXPERIMENTAL|Dose C IRL201104|IRL201104 or placebo IV on days 1 and 7
62730231|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
62730232|NCT01435694|EXPERIMENTAL|Robot-assisted gait training|Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
62730233|NCT01435694|ACTIVE_COMPARATOR|Conventional Therapy|Training sessions will focus on locomotor function improvements. Subjects will receive 45 minutes of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that they will be trained on walking abilities (like walking at different speeds, rapid changes directions) for 30 minutes with or without assistive aids.
62730234|NCT02807389|EXPERIMENTAL|MSC Fistula plug: Single Treatment Group|All patients received treatment of a stem cell coated fistula plug.
62730235|NCT05551156|EXPERIMENTAL|Animal-assisted interaction|A dog-handler team will visit participants in their hospital room
62730236|NCT05551156|EXPERIMENTAL|Conversational interaction|Conversational interaction with the participants and the dog-handler
62730237|NCT05551156|NO_INTERVENTION|Treatment as usual|Participants will received the regular services currently being received in the hospital
62730238|NCT06488937||RA patients|Patients that are diagnosed rheumatoid arthritis by their rheumatologist according to the 2010 European League Against Rheumatism/American College of Rheumatology classification criteria.
62730239|NCT06488937||Contorol group|The control group will be patients recruited from among regular patients visiting hospital for annual systematic examination in the same hospital.
62730240|NCT05074823|ACTIVE_COMPARATOR|Ketamine 0.1|Group I: will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
62730241|NCT05074823|ACTIVE_COMPARATOR|Ketamine 0.2|Group II will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
62730242|NCT05074823|ACTIVE_COMPARATOR|Ketamine 0.3|Group III will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
62730243|NCT00693446|OTHER|2|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time."
62730244|NCT00693446|OTHER|1|Patients receive Tacrolimus from day 0 to the end of the study (Arm Tacrolimus).
62730245|NCT01945996|ACTIVE_COMPARATOR|TExT-MED only|Patients will receive TExT-MED intervention, but supporters will not receive additional messages
62730246|NCT01945996|EXPERIMENTAL|TExT-MED FANS|Patients get TExT-MED intervention, supporter gets FANS curriculum
62730247|NCT01194219|ACTIVE_COMPARATOR|Apremilast|Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
62730248|NCT01194219|PLACEBO_COMPARATOR|Placebo|Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
62730249|NCT01194219|ACTIVE_COMPARATOR|Apremilast 30 mg|Apremilast 30 mg by mouth (PO) twice a day (BID). Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost). At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study. Non-responders or partial responders (PASI response \<75) received additional topical therapies or phototherapy beginning at Week 32.
62730250|NCT06024551|EXPERIMENTAL|Intervention Group|Patients who receive telerehabilitation
62730251|NCT06024551|OTHER|Control Group|Patients who receive home exercise program
62730252|NCT05140772|ACTIVE_COMPARATOR|group I|Patient were received 0.5gm/kg/day IV glutamine infusion (dipeptiven 100ml contains 20 g N(2)-L-alanyl-L-glutamine (= 8.20 g L-alanine, 13.46 g L-glutamine) Water for Injections).
62730253|NCT05140772|PLACEBO_COMPARATOR|group II|Patients received an equivalent volume of normal saline daily for 7 days.
62730254|NCT01744067|ACTIVE_COMPARATOR|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.
62730255|NCT01744067|PLACEBO_COMPARATOR|Placebo|Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.
62730256|NCT05359315||Experimental|Ingaron + basic TB therapy 500,000 IU once daily for 3 months followed by 3 months follow-up
62730257|NCT05359315||No Intervention|only basic anti-tuberculosis therapy
62730258|NCT02558062|EXPERIMENTAL|BAC ONE administration|All participants in this clinical study will be dosed on one occasion with BAC ONE. The final dosage will be 80 µg (± 25%).
62730259|NCT01138696||Stryker Dacron synthetic graft|
62730260|NCT01138696||Trevira synthetic graft|
62730261|NCT05532228||Obstructive sleep apnea|children with adenotonsillar hypertrophy and reports of nocturnal arousals/gasp/respiratory abnormalities
62730262|NCT05532228||No obstructive sleep apnea|children without adenotonsillar hypertrophy and no reports of nocturnal arousals/gasp/respiratory abnormalities
62730263|NCT05532228||Recurrent infections|Children with recurrent upper respiratory infections
62730264|NCT05532228||no recurrent infections|Children without recurrent upper respiratory infections
62730265|NCT02512289|ACTIVE_COMPARATOR|Real stimulation|real tDCS associated with robot-assisted therapy (RAT)
62730266|NCT02512289|SHAM_COMPARATOR|Sham stimulation|Sham tDCS associated with RAT
62730267|NCT05568160|EXPERIMENTAL|Intervention|
62730268|NCT05568160|ACTIVE_COMPARATOR|Control|
62730269|NCT04760483|EXPERIMENTAL|Transperineal Laser Ablation for BPH|"Ceftriaxone 250 mg IM as antibiotic prophylaxis. Local Anesthesia: perineal skin will be infiltrated with 10 cc of Lidocaine 2% and then each neurovascular bundle will be infiltrated with 5 - 10 cc. Nitrous self-administered anesthesia will be available.~One or two laser fibers from Echolaser x4 will be placed in each of the two prostate lobes using the plan. Treatment will be executed following Echolaser smart Interface planning, needles will follow targeted location using stepper grid under a transperineal approach in a sagittal plane. Ablation with 5 watts power per fiber, a total of \~ 1800 J will be delivered. We will evaluate pain measures and procedure tolerance using visual analog pain scale Upon completion we will measure coagulation zone with TRUS. Before discharge, trial of void will be conducted. Patients with a residual greater than 200 cc will have an indwelling catheter placed and will be discharged with it."
62730270|NCT02628041|ACTIVE_COMPARATOR|Permanent Iodine-125 seed implant|Prostate brachytherapy using Iodine-125 seed implant to a prescription dose of 144 Gy delivered to the Target volume defined as Clinical Target volume (CTV)+ 0-3 mm margin.
62730271|NCT02628041|EXPERIMENTAL|High-dose-Rate Prostate brachytherapy|"Prostate brachytherapy implant using Iridium-192 to a prescription dose of 19 Gy delivered to the CTV in one fraction. Greater than 95% coverage of the CTV with the prescription dose is considered per protocol, 90-95% coverage is considered a minor deviation and, \< 90% coverage is considered a major deviation.~Attempts should be made to achieve these other dosimetric values:~* D90: 105-115%~* V150 ≤ 35%~* V200 ≤ 12%"
62730272|NCT06219915|EXPERIMENTAL|Carbidopa Monotherapy and Carbidopa-Levodopa|Participants will begin by taking 25mg of Carbidopa monotherapy three times per day (TID) for 3 days. On day four, participants will begin taking 1 tablet of Carbidopa-Levodopa (25/100mg) TID in addition to the Carbidopa monotherapy. On day seven, participants will increase to 1.5 tablets of Carbidopa-Levodopa (25/100mg) TID while maintaining 25mg Carbidopa monotherapy TID. The intervention will end after ten days of supplementation.
62730273|NCT06219915|PLACEBO_COMPARATOR|Placebo|Participants will begin by taking a 25mg placebo tablet three times per day (TID) for 3 days. On day four, participants will begin taking a separate placebo tablet TID in addition to the original placebo. On day seven, participants will increase to 1.5 tablets of the second placebo TID while maintaining 25mg original placebo TID. The intervention will end after ten days of supplementation.
62730274|NCT05670639|OTHER|Pilot|
62730275|NCT02327585|EXPERIMENTAL|Executive function training|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
62730276|NCT01060748|EXPERIMENTAL|ACE527|"First cohort: ACE527 vaccine doses of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis.~Second cohort: ACE527 vaccine dose of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis."
62730277|NCT01060748|PLACEBO_COMPARATOR|Placebo vaccine|"First cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis.~Second cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis."
62736252|NCT01625416|EXPERIMENTAL|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
62730278|NCT05173844|EXPERIMENTAL|Treatment|Participants will be instructed to use SleepFix mobile application for 3 weeks with an optional 3 weeks of additional therapy. Participants will complete daily sleep diary entries (which take less than 1 min) which are used to calculate the sleep window titration. SleepFix incorporates sleep restriction and stimulus control which have been shown to be the most powerful components of cognitive-behavioural therapy for insomnia - CBTi. It has been shown to produce rapid, clinically-meaningful insomnia symptom reduction in a shorter period of time compared with both face-to-face and digital CBTi. SleepFix does not require the user to complete modules and multiple components such as other digital CBTi programs (e.g. Sleepio). Further, it is personalised to the individual's current sleep patterns and requires minimal engagement compared to full CBTi.
62730279|NCT05173844|NO_INTERVENTION|Control|Participants randomised to the control group will gain access to the first Sleep Health Education module immediately following completion of baseline questionnaires. There are 3 modules provided bi-weekly and the information in these modules is presented as a subdomain through the study website. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study.
62730280|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
62730281|NCT01403779|ACTIVE_COMPARATOR|1-Hypofractionated IMRT|hypofractionated IMRT for right sided breast cancer
62730282|NCT01403779|ACTIVE_COMPARATOR|2-Normofractioated IMRT|normofractionated IMRT for left sided breast cancer
62730283|NCT01123031|ACTIVE_COMPARATOR|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
62730284|NCT01123031|ACTIVE_COMPARATOR|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
62730285|NCT01642056|EXPERIMENTAL|EPI-743, then Placebo|Received EPI-743, 15mg/kg up to a maximum dose of 200 mg orally or via gastric tube three times daily with meals, then placebo three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
62730286|NCT01642056|PLACEBO_COMPARATOR|Placebo, then EPI-743|Received Placebo three times daily orally or via gastric tube with meals, then EPI-743, 15mg/kg up to a maximum dose of 200 mg three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
62730287|NCT01840813|ACTIVE_COMPARATOR|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
62730288|NCT01840813|PLACEBO_COMPARATOR|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
62730289|NCT00046189||1|Patients with XP
62730290|NCT00046189||2|Family members from XP families with known DNA repair gene mutations
62730291|NCT03276728|PLACEBO_COMPARATOR|Part A: Placebo|Healthy participants were administered placebo either intravenously (IV) or by mouth (PO) to match the 5 IV cohorts and 6 PO cohorts of AMG 986.
62730292|NCT03276728|EXPERIMENTAL|Part A: AMG 986|Healthy participants were administered a single dose of AMG 986 either IV or PO. The 5 IV cohorts started at a 0.5 mg loading dose over one hour up to to the Cohort 5 IV dosage consisting of a 60 mg loading dose over 1 hour and a 360 mg maintenance dose lasting 23 hours. The 6 PO cohorts started at a single 5 mg dose up to the Cohort 6 PO dose of 650 mg.
62730293|NCT03276728|PLACEBO_COMPARATOR|Part B: Placebo|Healthy participants were administered placebo either IV for 4 consecutive days or PO for 7 days to match the 2 IV cohorts and 6 PO cohorts of AMG 986.
62730294|NCT03276728|EXPERIMENTAL|Part B: AMG 986|Healthy participants were administered AMG 986 either IV or PO. IV cohort 1 was administered a loading dose of 6 mg over one hour followed by maintenance doses of 36 mg lasting 23 hours on Day 1 and 38 mg lasting 24 hours on Days 2-4. IV cohort 2 was administered a loading dose of 60 mg over one hour followed by maintenance doses of 360 mg lasting 23 hours on Day 1 and 376 mg lasting 24 hours on Days 2-4. The 6 PO cohorts started at 5 mg for 7 days up to Cohort 6 PO dose of 650 mg for 7 days.
62730295|NCT03276728|PLACEBO_COMPARATOR|Part C: HFrEF Placebo|Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO placebo tablet daily from Days 1-21.
62730296|NCT03276728|PLACEBO_COMPARATOR|Part C: HFpEF Placebo|Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO placebo tablet daily from Days 1-21.
62730297|NCT03276728|EXPERIMENTAL|Part C: HFrEF AMG 986|Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.
62730298|NCT03276728|EXPERIMENTAL|Part C: HFpEF AMG 986|Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.
62730299|NCT04981301|ACTIVE_COMPARATOR|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.
62730300|NCT04981301|NO_INTERVENTION|Group C = Control group|"Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group."
62730301|NCT01544101|EXPERIMENTAL|Vegan Diet|
62730302|NCT01544101|PLACEBO_COMPARATOR|Supplement|
62730303|NCT03754556||Women with IUD|Women with an intrauterine device (IUD) and electronic health records in the Kaiser Permanente Northern California (KPNC), Kaiser Permanente Southern California (KPSC), Kaiser Permanente Washington (KPWA) and the Regenstrief Institute (RI) databases.
62730304|NCT02229786|EXPERIMENTAL|Buscopan® plus|
62730305|NCT02229786|ACTIVE_COMPARATOR|Buscopan®|
61978394|NCT02377466|EXPERIMENTAL|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
62730306|NCT02229786|ACTIVE_COMPARATOR|Paracetamol|
62730307|NCT02229786|PLACEBO_COMPARATOR|Placebo|
62730308|NCT05042401|EXPERIMENTAL|Treatment group A|
62730309|NCT05042401|PLACEBO_COMPARATOR|Treatment group B|
62730310|NCT05042401|EXPERIMENTAL|Treatment group C|
62730311|NCT05042401|PLACEBO_COMPARATOR|Treatment group D|
62730312|NCT02785783|ACTIVE_COMPARATOR|Standard colonoscopy|A standard colonoscope will be used to complete the procedure
62730313|NCT02785783|ACTIVE_COMPARATOR|EndoRings™|An EndoRings™ device will be placed at the distal end of a standard colonoscope
62730314|NCT04954300||open|open: open ICU
62730315|NCT04954300||negative|negative: negative-pressure laminar flow ward
62730316|NCT04954300||positive|positive: laminar flow ward
62730317|NCT04587206|EXPERIMENTAL|Experimental: Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
62730318|NCT04587206|EXPERIMENTAL|Experimental: Sequence2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
62730319|NCT05474456|EXPERIMENTAL|SNAGs Group|Group A sustained natural apophyseal glides will be provided to wrestlers in the sitting position. SNAG technique applied on the dorsal side of the neck. The treatment will be given for 6 weeks, 2 sessions per week.
62730320|NCT05474456|ACTIVE_COMPARATOR|Manipulation Group|group bWrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
62730321|NCT04405999|EXPERIMENTAL|Bromhexine hydrochloride Group|medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride
62730322|NCT04405999|NO_INTERVENTION|Control Group|medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride
62730323|NCT02178319|ACTIVE_COMPARATOR|open group|the patients under go the open esophagogastric devascularization and splenectomy
62730324|NCT02178319|EXPERIMENTAL|laparoscopic group|the patients under go the laparoscopic esophagogastric devascularization and splenectomy
62730325|NCT00565396|ACTIVE_COMPARATOR|1|Fosinopril 10mg/day(oral)
62730326|NCT00565396|ACTIVE_COMPARATOR|2|Fosinopril 20mg/day(oral)
62730327|NCT00565396|ACTIVE_COMPARATOR|3|Losartan 50mg/day(oral)
62730328|NCT00565396|ACTIVE_COMPARATOR|4|Losartan 100mg/day(oral)
62730329|NCT02492308|EXPERIMENTAL|SVF-MSC induction|"1. collection of autologous SVF~2. culture of SVF to abstain MSC~3. infusion of MSC during and after living-relative kidney transplantation"
62730330|NCT02492308|ACTIVE_COMPARATOR|Basiliximab induction|The control group will be inducted with Basiliximab
62730331|NCT04498286||Amsterdam MS Cohort|
62730332|NCT02565693|EXPERIMENTAL|Apixaban|"Apixaban: oral, 5 mg twice daily. If two of the three following criteria are met, the dose will be reduced to 2.5 mg twice daily:~* Age ≥ 80 years~* Body weight ≤ 60 kg~* Serum creatinine ≥ 133 μmol. Additionally, if the creatinin clearance is below 30 ml per minute, the dose will be reduced to 2.5 mg twice daily."
62730333|NCT02565693|OTHER|Avoiding oral anticoagulants|"The following treatment regimens are allowed in the comparator arm:~- No antithrombotic treatment~or:~* Acetylsalicylic acid 80 mg once daily~* Carbasalate calcium 100 mg once daily~* Clopidogrel 75 mg once daily~* Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily~* Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily"
62730334|NCT06030973||Healthcare professionals involved in neuromodulation|
62730335|NCT05870462|EXPERIMENTAL|Semaglutide|Participants will receive once-weekly semaglutide subcutaneous injection \[Ozempic\] at escalating doses from 0.25 mg/week, 0.5 mg/week, to 1.0 mg/week.
62730336|NCT05870462|NO_INTERVENTION|Usual care|Participants will continue to receive other usual medications, rehabilitation, procedures, and interventions as recommended by their healthcare providers.
62730337|NCT04083703|EXPERIMENTAL|Simple lumbar discectomy|
62730338|NCT04083703|EXPERIMENTAL|Lumbar discectomy with inter vertebral cage|
62730339|NCT00758693|EXPERIMENTAL|1|Bendamustine + Rituximab
62730340|NCT03391986|ACTIVE_COMPARATOR|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
62730341|NCT03391986|PLACEBO_COMPARATOR|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
62730342|NCT03391986|NO_INTERVENTION|Routine Care|This arm will receive no intervention.
62730343|NCT00298298|EXPERIMENTAL|1|5 million autologous, DNP-modified NSCLC cells
62730344|NCT00298298|EXPERIMENTAL|2|2.5 million autologous, DNP-modified NSCLC cells
62730345|NCT00298298|EXPERIMENTAL|3|0.5 million autologous, DNP-modified NSCLC cells
62730346|NCT01458301|PLACEBO_COMPARATOR|Placebo|
62730347|NCT01458301|EXPERIMENTAL|TAK-385 10 mg QD|
62730348|NCT01458301|EXPERIMENTAL|TAK-385 20 mg QD|
62730349|NCT01458301|EXPERIMENTAL|TAK-385 40 mg QD|
62730350|NCT01458301|OTHER|Leuplin|
62730351|NCT04758286|ACTIVE_COMPARATOR|Successful outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
62730352|NCT04758286|ACTIVE_COMPARATOR|Complicated outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
62730353|NCT01663207||obese individuals with prediabetes|
62730354|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
62730355|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
62736253|NCT01625416|NO_INTERVENTION|Usual Care|Usual care control patients will be given a list of available community resources and encouraged to proceed using all resources available to them.
61978395|NCT02377466|PLACEBO_COMPARATOR|Placebo|The placebo control will be a normal saline (0.9% sodium chloride \[NaCl\]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
62730356|NCT05123339||Case group|Marfan disease according to Ghent criteria revised in 2010 with dural ectasia Patients followed at the CNMR in Bichat Adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies) No history of lumbar surgery \<1 year and without specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism)
62730357|NCT05123339||Control group|Marfan disease according to Ghent criteria revised in 2010 without dural ectasia Patients followed at the CNMR in Bichat Adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies) No history of lumbar surgery \<1 year and without specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism)
62730358|NCT03181971|EXPERIMENTAL|Water Access and Promotion - Students|Intervention group will receive installation of water stations in high traffic areas, schoolwide promotion, and 4th graders will receive a curricula focused on increasing intake of water.
62730359|NCT03181971|NO_INTERVENTION|Control - Students|Participants do not receive an intervention
62730360|NCT03181971|NO_INTERVENTION|School Personnel|School administrators and food service managers provide information on school policies and procedures.
62730361|NCT06525610|EXPERIMENTAL|Periprosthetic Fracture Knee Repaired|The one and only group will be participants that have recently undergone revision surgery for their periprosthetic distal knee fracture.
62730362|NCT01290146|ACTIVE_COMPARATOR|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
62730363|NCT01290146|EXPERIMENTAL|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min"
62730364|NCT03806530|ACTIVE_COMPARATOR|Gabapentin + Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
62730365|NCT03806530|PLACEBO_COMPARATOR|Gabapentin + Placebo Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
62730366|NCT03806530|PLACEBO_COMPARATOR|Ropinirole + Placebo Gabapentin|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
62730367|NCT03806530|PLACEBO_COMPARATOR|Placebo Gabapentin + Placebo Ropinirole|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
62730368|NCT02267291|EXPERIMENTAL|All patients|Ventilatory support to alter intrathoracic pressure
62730369|NCT05836831|EXPERIMENTAL|Intervention Arm|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes. Intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive agents (intravenous and/or oral) which is to be achieved within one hour and has to be maintained over seven days. BP monitoring is done every 15 minutes in the first hour and thereafter every hour for the next six hours after the initiation of intensive BP control. The choice of antihypertensive will depend on the clinician's preference.
62730370|NCT05836831|NO_INTERVENTION|Control Arm|The control arm will receive a standard of care management as per the institutional practice. Intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive (intravenous and/or oral) which is to be achieved within one hour and has to be maintained over seven days. BP monitoring is done for every 15 minutes in the first hour and thereafter every hour for the next six hours after the initiation of intensive BP control. The choice of antihypertensive will depend on the clinician's preference.
62730371|NCT04819529|EXPERIMENTAL|Experimental Group - Early and intensive Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
62730372|NCT04819529|NO_INTERVENTION|Control group - Standard Analgesia,Sedation, Delirium and Mobilization (ASDM) Protocol|The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.
62730373|NCT05761808|ACTIVE_COMPARATOR|Exercise Group|Lumbar stabilization exercises constitute the first step of treatment in chronic low back pain.
62730374|NCT05761808|ACTIVE_COMPARATOR|NMES Group|NMES will be applied in addition to lumbar stabilization exercises.
62730375|NCT01732705|EXPERIMENTAL|HIT (trained leg) DM|High intensity interval training for one leg (trained leg) (randomized) in patient with type 2 diabetes
62730376|NCT01732705|NO_INTERVENTION|Control leg, DM|Control leg (untrained leg)in patient with type 2 diabetes
62730377|NCT01732705|EXPERIMENTAL|HIT (trained leg), Control subject|High intensity interval training for one leg (trained leg) (randomized) in control subject
62730378|NCT01732705|NO_INTERVENTION|Control leg, Control subject|Control leg (untrained leg)in control subject
62730379|NCT05674227||Robotic surgery|Patients who have undergone pulmonary robotic surgery
62730380|NCT05674227||VAT surgery|Patients who have undergone pulmonary video-assisted thoracoscopy surgery (VATS)
62730381|NCT05674227||Open surgery|Patients who have undergone pulmonary open surgery
62736254|NCT01208324|ACTIVE_COMPARATOR|Estrogen patch|Vivelle Dot® 0.10 - 0.15 mg/day for 8 weeks
62736255|NCT01208324|ACTIVE_COMPARATOR|Amino Acids|L-Isoleucine (4.2 g), L-Leucine (6.6 g), L-Lysine (4.8 g), L-Methionine (1.5 g), L-Phenylalanine (6.6 g), L-Threonine (3.0 g), L-Valine (4.8 g)
62736256|NCT01208324|PLACEBO_COMPARATOR|Placebo Patch|Placebo
62736257|NCT01208324|PLACEBO_COMPARATOR|Placebo pills|31.5 g of lactose or microcellulose
61978396|NCT04321148|OTHER|standard of care PCI|
61978397|NCT04321148|EXPERIMENTAL|Impella-protected PCI|
62736258|NCT01523743|EXPERIMENTAL|Compact catheter|Compact intermittent catheter
62736259|NCT01523743|ACTIVE_COMPARATOR|Standard Care|Standard Care: Coated intermittent catheter normally used by subject
62730382|NCT04830839|EXPERIMENTAL|Recovery after Stress Toolkit (ReSeT)|"ReSeT is comprised of interactive web-based psychoeducational modules that are developmentally tailored for school age children (8-17 years) for use with synchronous e-health therapy sessions with a trained therapist.~Participants in the ReSeT treatment will complete 8 modules and therapy sessions. Parents will also have access to 4 modules During the study, children/youth will be asked to complete all eight sessions of the online treatment together with the therapist over an 8 -12 week time period (to allow for scheduling/cancellations). For younger children, parents will participate in the beginning and end of each session. Sessions will last approximately 30-60 minutes and will occur approximately every week for an anticipated 4-8 hour time commitment. Parents of older children will be permitted to review the content independently and participate in feedback sessions."
62730383|NCT03352999|OTHER|ROHCA rescued by vaECMO|Patients experiencing a ROHCA despite advanced CPR and finally rescued with a va ECMO device.
62730384|NCT04779307|EXPERIMENTAL|Induction Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of ≥30 kg are included in this arm.
62730385|NCT04779307|EXPERIMENTAL|Induction Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of \>15 to \<30 kg are included in this arm.
62730386|NCT04779307|EXPERIMENTAL|Induction Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of 10 to 15 kg are included in this arm.
62730387|NCT04779307|EXPERIMENTAL|Maintenance Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
62730388|NCT04779307|EXPERIMENTAL|Maintenance Period: Participants ≥30 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
62730389|NCT04779307|EXPERIMENTAL|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
62730390|NCT04779307|EXPERIMENTAL|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
62730391|NCT04779307|EXPERIMENTAL|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
62730392|NCT04779307|EXPERIMENTAL|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
62730393|NCT01470131|EXPERIMENTAL|Masitinib|Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone
62730394|NCT01470131|PLACEBO_COMPARATOR|Placebo|Placebo in combination with Bortezomib and Dexamethasone
62730395|NCT03981744|EXPERIMENTAL|Group 1: Ustekinumab|Participants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
62730396|NCT03981744|PLACEBO_COMPARATOR|Group 2: Placebo|Participants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
62730397|NCT02864212||Glucose monitoring|Glucose will be monitor in patients using fast-acting insulin.
62730398|NCT02864212||Depth of anesthesia monitoring|Depth of anesthesia will be monitor in patients undergoing cardiac surgery.
62730399|NCT02864212||Blood pressure monitoring|Invasive blood pressure will be monitor in patients undergoing cardiac surgery.
62730400|NCT04739930|EXPERIMENTAL|Bone Marrow Aspiration Group|A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.
62730401|NCT04739930|SHAM_COMPARATOR|Control|The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation.
62730402|NCT02413996|EXPERIMENTAL|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS) in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
62730403|NCT02413996|ACTIVE_COMPARATOR|traditional rehabilitation|exercise therapy through a traditional rehabilitation training in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
62730404|NCT05117151||Observation|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
62730405|NCT01417221|EXPERIMENTAL|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with essential hypertension.
62730406|NCT01417221|NO_INTERVENTION|Absolute medicine therapy|Maintenance of anti-hypertensive medications only
62730407|NCT00008411|EXPERIMENTAL|Docetaxel Weekly|Arm I: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days.
62730408|NCT00008411|EXPERIMENTAL|Docetaxel Every 3 Weeks|Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
62730409|NCT03706768|OTHER|Glycocalyx|degree of glycocalyx breakdown in patients with aSAH
62730410|NCT04903574|EXPERIMENTAL|Sedentary behavior smartphone app|This arm will be assigned to download and use a smartphone app that prompts you to stand up when your smartphone detects 30 minutes of sitting.
62730411|NCT04903574|ACTIVE_COMPARATOR|Pregnancy smartphone app|This arm will download and use a commercially available pregnancy smartphone app that does not attempt to change activity behavior.
62730412|NCT02904174|EXPERIMENTAL|Healthy Living Programme|6 weeks program, with 45 minutes weekly session over 6 weeks.Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies.
62730413|NCT04863053||Stable CHD patient|Patients aged ≥ 18 years who have a history of stable coronary heart disease (CHD) receiving long-term mono-antiplatelet therapy with aspirin (80 mg once daily)
62730414|NCT04424459||Patients included from 10/01/19 to 12/31/19.|Patients included from 10/01/19 to 12/31/19. (the study will be extended to a larger number of patients according to the first results), continued according to the first results. DCNC patients treated at the Montpellier Pain Assessment and Treatment Center hospitalized during the period from 10/01/19 to 12/31/19, for misuse of opioid treatment.
62730415|NCT05250167||CKD patients stage 2|
62730416|NCT05250167||CKD patients stage 3a|
62730417|NCT05250167||CKD patients stage 3b|
62730418|NCT05250167||CKD patients stage 4|
62730419|NCT05250167||Controls without CKD|
62730420|NCT04961281|ACTIVE_COMPARATOR|Dexmeditomidine group|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
62730421|NCT04961281|ACTIVE_COMPARATOR|triamcinolone group|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
62730422|NCT00848237|EXPERIMENTAL|Treatment|All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
62730423|NCT03000556|EXPERIMENTAL|experience|
62730424|NCT03000556|NO_INTERVENTION|control|
62730425|NCT02750046|EXPERIMENTAL|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
62730426|NCT02750046|SHAM_COMPARATOR|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
62730427|NCT02466477|EXPERIMENTAL|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
62730428|NCT02466477|EXPERIMENTAL|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
62730429|NCT02466477|ACTIVE_COMPARATOR|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
62730430|NCT01669694||Women with Pelvic Pain|Women with Pelvic Pain undergoing pelvic floor PT in the Beaumont Women's Urology Center
62730431|NCT06164691|EXPERIMENTAL|Blue light|This cohort will be exposed to bright (1700 lux) blue (peak 442 nm) light for 4 hours each morning for 3 days prior to and 3 days following each chemotherapy infusion.They will be exposed to bright (1700 lux) blue (peak 442 nm) light for 1 hour each morning during radiation treatments.
62730432|NCT06164691|EXPERIMENTAL|Amber light|This cohort will be exposed to bright (1700 lux) amber (peak 617 nm) light for 4 hours each morning for 3 days prior to and 3 days following each chemotherapy infusion.They will be exposed to bright (1700 lux) amber (peak 617 nm) light for 1 hour each morning during radiation treatments
62730433|NCT06164691|ACTIVE_COMPARATOR|Ambient white light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments.
62730434|NCT04715841||group A|Group A (Study group ) : 25 adolescent females suffering patellofemoral pain syndrome were recruited from the outpatient clinic of the faculty of physical therapy delta university in addition to the medical diagnosis was confirmed by consultant orthopedist using clinical and radiographic investigations .
62730435|NCT04715841||group B|Group B (Control Group):25 adolescent females with healthy knee joints with no clinical and radiographic evidence of patellofemoral pain syndrome , were recruited from the students of the faculty of physical therapy delta university .
62730436|NCT06404242||MCA stroke patient|"The investigators would include patients who had ischemic stroke due to middle cerebral artery (MCA) stenosis (\>50%). The investigators collect plaque characteristics such as plaque enhancement, T1 hyperintense, remodeling ratio, surface irregularity, correlation with the origin of perforating branches, percent stenosis, upstream angle, and downstream angle. The patients were followed up for stroke recurrence for 6 months.~For each culprit-plaque characteristic, the investigators would divide the patients into groups of patients with culprit-plaque characteristics and groups without culprit-plaque characteristics. The two groups will compare the type of ischemic lesions and the recurrent stroke rate in the same vascular territory. These results will be presented by Kaplan-Meier curve and binary logistic regression."
62730437|NCT00660972|EXPERIMENTAL|1|Oral RAL and FTC/TDF for 72 weeks
62730438|NCT00839280|EXPERIMENTAL|Arm 1|
62730439|NCT00839280|ACTIVE_COMPARATOR|Arm 2|
62730440|NCT06487637|EXPERIMENTAL|Determine the impact of CardioCare Quest's telehealth interventions|This project will employ a mixed methods approach, combining quantitative and qualitative data collection methods within quarters 4 to 8. The quantitative method includes using the Motivation, Engagement, and Thriving in User Experience (METUX), health measures (i.e., blood pressure measurements), and telemetry to assess user engagement, adherence rates, and health outcomes in CardioCare Quest. The qualitative method will be used to identify key constructs such as motivation, engagement, and overall well-being and choose relevant metrics for each construct, including surveys for motivation, thematic analysis of quotes for engagement, and experience sampling for well-being.
62730441|NCT02837471|EXPERIMENTAL|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
62730442|NCT02837471|NO_INTERVENTION|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
62730443|NCT05770297|ACTIVE_COMPARATOR|Propolis|the subjects were asked to consume propolis 1 drop/10 kgbw/time given 2 times a day for 12 weeks. the dose will be calculated based on body weight by the certified nutritionist during the interview after the subject signs the informed consent form
62730444|NCT05770297|PLACEBO_COMPARATOR|Placebo|the subjects were asked to consume placebo (glucose-only contained) 1 drop/10 kgbw/time given 2 times a day for 12 weeks. the dose will be calculated based on body weight by the certified nutritionist during the interview after the subject signs the informed consent form
62730445|NCT01195818|EXPERIMENTAL|RAS Inhibitors|RAS Inhibitors
62730446|NCT01271842||Extra corporeal oxygenation|Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
62730447|NCT01271842||No extracorporeal oxygenation|Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
62730448|NCT04904029|EXPERIMENTAL|1. Digital Assessment Routing Tool (DART) 2. Physiotherapy-led remote triage|Participants complete the Digital Assessment Routing Tool (DART), which is followed by physiotherapy-led remote triage with the usual care clinician.
62730449|NCT04904029|EXPERIMENTAL|1. Physiotherapy-led remote triage 2. Digital Assessment Routing Tool (DART)|Participants complete their physiotherapy-led remote triage with the usual care clinician, which is followed by the Digital Assessment Routing Tool.
62730450|NCT04426773|EXPERIMENTAL|tDCS treatment|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
62730451|NCT01141998|PLACEBO_COMPARATOR|Placebo|
62730452|NCT01141998|ACTIVE_COMPARATOR|Vitamin D administered orally|
62730453|NCT01141998|EXPERIMENTAL|Vitamin D administered via UVB|
62730454|NCT04963075|EXPERIMENTAL|Unilaterally blind Subjects will be exposed to visual-auditory stimulation|The over-arching objective is to evaluate the functional recovery of vision in hemianopic patients engaged with a multisensory training paradigm. Unilaterally blind participants will participate in weekly training sessions in which they are exposed to high-density spatiotemporally congruent and consistent visual-auditory stimulation. The participants will be tested on a battery of visual tasks probing different levels of function in different environments in a longitudinal study to track recovery.
62730455|NCT04464811||Heart failure with diuretic resistance|This group includes acute heart failure patients who has diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have received oral furosemide before. Diuretic resistance was defined as urine output \<250 hr at 2 hours after furosemide administration.
62730456|NCT04464811||Heart failure without diuretic resistance|This group includes acute heart failure patients who do not have diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide before. Patients will be defined not to have diuretic resistance if their urine output ≥250 hr at 2 hours after furosemide administration.
62730457|NCT03180580|EXPERIMENTAL|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
62730458|NCT06092112|EXPERIMENTAL|CD-801 treatment|The subjects with advanced HCC will be treated by CD-801 through the hepatic artery injection.
62730459|NCT05312684||High anticholinergic burden|ACB scale score 1 or \>1 as a high anticholinergic buden
62730460|NCT05312684||Normal anticholinergic burden|ACB scale score \<1 as a control group
62730461|NCT04181229|EXPERIMENTAL|DBS Treatment|Patients in the treatment arm will receive DBS of bilateral centromedian nucleus (2 electrodes per patient). DBS is a standard of care treatment option for drug-resistant epilepsy patients who have previously failed VNS at 12 months or more after instigation and optimization of therapy.
62730462|NCT04181229|NO_INTERVENTION|Continued VNS (control)|For the control arm, the patients will be monitored for one year with the same standard assessments used for the measurement of seizure frequency and severity. No changes will be made to these patients' treatment plan. These patients will be placed on a wait list for CM-DBS treatment of seizures if that is the desire of the patient and/or their family. After the 12 months of observation, these patients can choose to undergo DBS surgery.
62730463|NCT03353987|NO_INTERVENTION|Control|Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
62730464|NCT03353987|EXPERIMENTAL|Cognitive Training|Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.
62730465|NCT01633840|ACTIVE_COMPARATOR|Elemental E028 with added food allergens|
62730466|NCT01633840|PLACEBO_COMPARATOR|Elemental E028|
62730467|NCT04082650|EXPERIMENTAL|Vitamin D|Participants in the intervention group will be treated with vitamin D 4000IU (800IU per pill, take five pills once each day) per day for around 12 weeks (till the triggering day).
62730468|NCT04082650|PLACEBO_COMPARATOR|Placebo|Participants in the control group will be treated with equal amount of placebo tablets per day for the same duration.
62730469|NCT01295151|EXPERIMENTAL|TNF-blocking drug|
62730470|NCT01295151|EXPERIMENTAL|Abatacept|
62730471|NCT01295151|ACTIVE_COMPARATOR|Rituximab|
62730472|NCT01951196||Chronic kidney disease, CKD III+IV|150 patients with Chronic kidney disease, CKD stage III+IV.
62730473|NCT01951196||Healthy subjects|75 healthy subjects.
62730474|NCT04470882|EXPERIMENTAL|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
62730475|NCT04470882|ACTIVE_COMPARATOR|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
62730476|NCT04470882|EXPERIMENTAL|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
62730477|NCT01453491|EXPERIMENTAL|50mg SRT2104|Single oral administration of 50mg SRT2104 study drug will be supplied as 25 mg and 250 mg capsules and will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
62730478|NCT01453491|EXPERIMENTAL|500mg SRT2104|Single oral administration of 500mg SRT2104 will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
62730479|NCT02159209||Drug Induced Renal Injury (DIRI)|This is a prospective observational cohort study of patients who have developed acute kidney injury Stage 2 or a glomerular disorder following exposure to specific drugs that have been associated with DIRI.
62730480|NCT05689489|EXPERIMENTAL|Puzzle|
62730481|NCT05689489|ACTIVE_COMPARATOR|control group|
62730482|NCT01179984|EXPERIMENTAL|PTA and study stent|Bard® LifeStent® Vascular Stent System
62730483|NCT00984594|OTHER|Primary injury site|CR-Plug will be placed in the site of the primary injury
62730484|NCT00984594|OTHER|Backfill site|Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site
62730485|NCT00288886|EXPERIMENTAL|Contracts, Prompts and Reinforcement arm|Participants were provided with contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
62730486|NCT00288886|ACTIVE_COMPARATOR|Control Arm|Participants were provided with routine care- they did not receive contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
62730487|NCT02585115||Non-pregnant women with symptoms|Non-pregnant women with one or more symptoms of UTI. All women will make a paired urine sample (first void and midstream void) of the same urine sample.
62730488|NCT00260728|EXPERIMENTAL|Arm 1|
62730489|NCT05308303||All cause OHCA|
62730490|NCT05308303||OHCA of non-cardiac origin|
62730491|NCT01751672|ACTIVE_COMPARATOR|SBIRT|Screening, Brief Intervention, and Referral to Treatment
62730492|NCT01751672|EXPERIMENTAL|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment
62730493|NCT03952767|EXPERIMENTAL|Digital Physical Measures and Survey Assessments|Digital physical measure data will be collected in clinic and at home and survey assessments will be collected
62730494|NCT03565822|OTHER|interview|There are two data collection phases (individual interviews +/- focus groups) with parents of children with esophageal atresia, congenital diaphragmatic hernia or short bowel syndrome.
62730495|NCT03644225|OTHER|Healthy Control|Healthy controls, who signed an informed consent, age ≥18 years old will be age and sex matched to the SSc patients
62730496|NCT03644225|OTHER|Systemic sclerosis patients|"SSc patients who signed an Informed consent~* Age ≥18 years old~* Diagnosis of systemic sclerosis according to the ACR/EULAR 2013 criteria~* Skin thickening diagnosed by clinical expert"
62730497|NCT01423695|EXPERIMENTAL|paclitaxel/trastuzumab|Single experimental arm in a phase II trial
62730498|NCT01990976||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) and the FSHD2 study (NCT01689480) can be included in this study.
62730499|NCT00924794||Cohort A|Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.
62730500|NCT03570242|NO_INTERVENTION|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
62730501|NCT03570242|EXPERIMENTAL|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
62730502|NCT03570242|NO_INTERVENTION|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
62730503|NCT03570242|EXPERIMENTAL|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
62736260|NCT05018195|ACTIVE_COMPARATOR|Benign|Women who receive surgery for benign lesions including leiomyoma, adenomyosis, or ovarian cysts. We will obtain one 5\*5 cm omental fat and one 3\*3 cm subcutaneous adipose tissue during surgery.
62730504|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
62730505|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
62730506|NCT03238703|EXPERIMENTAL|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
62730507|NCT06447155|ACTIVE_COMPARATOR|The babies fed with bolus feeding during TH|The babies were randomized into three groups; Group 1.The neonates who received bolus feeding,Group 2. The neonates who received continuous feeding Group 3. The control group who were not fed during TH. The control group was composed of historical newborns. Three groups were compared in terms of demographic characteristics and clinical outcomes.
62730508|NCT06447155|ACTIVE_COMPARATOR|The babies fed with continuous feeding during TH|The babies were randomized into three groups; Group 1.The neonates who received bolus feeding,Group 2. The neonates who received continuous feeding Group 3. The control group who were not fed during TH. The control group was composed of historical newborns.Three groups were compared in terms of demographic characteristics and clinical outcomes.
62730509|NCT06447155|PLACEBO_COMPARATOR|The babies who were not fed|The babies were randomized into three groups; Group 1.The neonates who received bolus feeding,Group 2. The neonates who received continuous feeding Group 3. The control group who were not fed during TH. The control group was composed of historical newborns.Three groups were compared in terms of demographic characteristics and clinical outcomes.
62730510|NCT04090957|EXPERIMENTAL|Estetrol 15 mg - Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for up to 53 weeks.
62730511|NCT04090957|EXPERIMENTAL|Estetrol 20 mg - Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 53 weeks.
62730512|NCT04090957|PLACEBO_COMPARATOR|Placebo - Efficacy Part|Placebo will be administered orally once daily for up to 53 weeks.
62730513|NCT04090957|EXPERIMENTAL|Estetrol 20 mg - Safety Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 53 weeks.
62730514|NCT00714506|EXPERIMENTAL|Intervention|lifestyle weight reduction - low fat eating, low calorie and physical activity
62730515|NCT00714506|ACTIVE_COMPARATOR|Control|physical activity plus successful aging health education
62730516|NCT00709319||Primary|Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness \>300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
62730517|NCT01805687|OTHER|Zileuton extended release|Oral, 1200 mg (2 x 600 mg tablets)
62730518|NCT03696550|EXPERIMENTAL|Cohort 1|"Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age.~Age group (years) Dose (mg/kg) 12 to \<18 (Cohort 1) 1.50"
62730519|NCT03696550|EXPERIMENTAL|Cohort 2|"Eravacycline will be administered as a single 60 minute IV infusion according to age.~Age group (years) Dose (mg/kg) 8 to \<12 (Cohort 2) 1.75"
62730520|NCT04399200||Sleep-disordered breathing group|Sleep-disordered breathing (SDB) patients (AHI\>15/h, measured by polysomnography performed 3 months after stroke)
62730521|NCT04399200||Control group|Control patients with no SDB (AHI\<15/h, measured by polysomnography performed 3 months after stroke)
62730522|NCT04900844|EXPERIMENTAL|CGuard group|Single experimental arm compared vs. objective performace goal
62730523|NCT01340222|OTHER|Patients|
62730524|NCT01340222|OTHER|Volunteers|
62730525|NCT03743714|EXPERIMENTAL|males|healthy, sedentary males
62730526|NCT03743714|EXPERIMENTAL|females|healthy, sedentary females
62730527|NCT00429715|EXPERIMENTAL|Alum-ALM + BCG|Alum-ALM + BCG
62730528|NCT00429715|ACTIVE_COMPARATOR|BCG|BCG
62730529|NCT00429715|PLACEBO_COMPARATOR|BCG diluent|Diluent
62730530|NCT03472495|ACTIVE_COMPARATOR|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
62730531|NCT03472495|ACTIVE_COMPARATOR|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR \<110 (Diltiazem Injectable Product)
62730532|NCT02644889||Patients advanced NSCLC EGFR mutated|This is an observational study, there is no intervention.
62730533|NCT05740046|EXPERIMENTAL|experimental group|Group that will receive the intervention sessions using the Intorus tool
62730534|NCT05740046|NO_INTERVENTION|control group|Group that will receive the intervention sessions without using the Intorus tool
62730535|NCT05646225|EXPERIMENTAL|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning,self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
62730536|NCT05646225|ACTIVE_COMPARATOR|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes.
62736261|NCT05018195|EXPERIMENTAL|Endometrial cancer|Women who receive surgery(staging or cytoreductive surgery) for endometrial cancer. We will obtain one 5\*5 cm omental fat and one 3\*3 cm subcutaneous adipose tissue during surgery.
62736262|NCT01645735|EXPERIMENTAL|Ceftaroline|Ceftaroline fosamil 600 mg Intravenous (IV) administration over 60 minutes, every 8 hours (q8h); dosing to be adjusted for renal function; treatment duration 5 to 14 days
62730537|NCT04767061|ACTIVE_COMPARATOR|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually uptitrating until reaching their home dose and finally during Period 4, we will again conduct a dose reduction until off of beta blockers."
62730538|NCT04767061|ACTIVE_COMPARATOR|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers and finally during Period 4, we will uptitrate them back to their home dose of beta blockers."
62730539|NCT03402139||IUGR infants|Intrauterine growth restricted infants will be enrolled. There are no interventions.
62730540|NCT03402139||AGA infants|Appropriate for gestational age infants will be enrolled. There are no interventions.
62730541|NCT05989139|EXPERIMENTAL|NPPV|non-invasive positive-pressure ventilation arm
62730542|NCT05989139|EXPERIMENTAL|HFNC|High-flow nasal cannulae arm
62730543|NCT02151903|EXPERIMENTAL|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m\^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
62730544|NCT02151903|EXPERIMENTAL|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m\^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
62730545|NCT02866162||patients with neutropenia|
62730546|NCT05604573||pancreatic cancer|patients with pancreatic cancer
62730547|NCT05604573||control|patients without any malignancy
62730548|NCT06374927||Stroke patients|Stroke patients at different time points after stroke (acute, subacute, and chronic), aged over 18 years.
62730549|NCT00690430|ACTIVE_COMPARATOR|Pasireotide LAR|Patients assigned to pasireotide LAR will receive a 60 mg dose of pasireotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 40 mg is permitted if tolerability issues arise. In addition, after 24 hours of the first LAR injections the patients were permitted to use pasireotide s.c. formulation for breakthrough symptoms as needed.
62730550|NCT00690430|ACTIVE_COMPARATOR|Octreotide LAR|Patients assigned to octreotide LAR will receive a 40mg dose of octreotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 30 mg is permitted if tolerability issues arise. Patients requiring a dose reduction are to return to the higher dose once the tolerability issue is resolved, if required for efficacy In addition, after 24 hours of the first LAR injections the patients were permitted to use octreotide s.c. formulation for breakthrough symptoms as needed.
62730551|NCT03114111|ACTIVE_COMPARATOR|Application of ALA|The treatment will consist of split-face comparisons of no application of aminolevulinic acid (ALA) vs ALA application to either half of the face. Prior to ALA application, the face will be swabbed for microbiome analysis. After the ALA application, the subjects will incubate with the ALA on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
62730552|NCT03114111|PLACEBO_COMPARATOR|No Application of ALA|For the placebo, Demo Levulan Kerastick, which contains no active ingredient and is enclosed in same cardboard sleeve and cap, will be applied to the other side of the face to mimic the surface of the ALA application stick. After the placebo application, the subjects will incubate with the placebo on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
62730553|NCT03911999||Non-prostate cancer subjects|No clinical evidence of prostate cancer
62730554|NCT03911999||Subjects with pathologically insignificant prostate cancer|Insignificant prostate cancers were organ confined with tumor volumes less than 0.5 cc and Gleason score \< 7.
62730555|NCT03911999||Subjects with pathologically significant prostate cancer|Significant cancers are those with either Gleason score \> 7, evidences of extra-prostatic extension with positive margins, or seminal vesicles / lymph nodes involvement.
62730556|NCT00930917|EXPERIMENTAL|cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
62730557|NCT00930917|ACTIVE_COMPARATOR|wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
62730558|NCT00930917|OTHER|conventional group|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
62730559|NCT02019953|OTHER|Yoga 3 times per week|Yoga participation 3 x per week for 24 weeks; 48 week follow-up.
62730560|NCT02019953|OTHER|Yoga 2 times per week|Yoga participation 2 x per week for 24 weeks; 48 week follow-up
62730561|NCT02019953|OTHER|Yoga 1 time per week|Yoga participation 1 x per week for 24 weeks; 48 week follow-up
62730562|NCT02019953|OTHER|Walking 3 times per week|Walking 3x per week for 24 weeks; 48 week follow-up
62730563|NCT02019953|OTHER|Healthy Lifestyles Education|Healthy Lifestyles Education Participation 1 x per week for 24 weeks; 48 week follow-up
62730564|NCT03056235|EXPERIMENTAL|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
62730565|NCT03056235|PLACEBO_COMPARATOR|Saline control|Saline
62730566|NCT05545787|EXPERIMENTAL|Cold snare endoscopic mucosal resection (CS-EMR)|Eligible colorectal polyps sized 10-19mm will be resected by CS-EMR
62730567|NCT05545787|EXPERIMENTAL|Hot snare endoscopic mucosal resection (HS-EMR)|Eligible colorectal polyps sized 10-19mm will be resected by HS-EMR
62730568|NCT02253095|EXPERIMENTAL|Multiple Intervention Arm|single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
62730569|NCT02253095|PLACEBO_COMPARATOR|Placebo|three placebos
62730570|NCT04140786|EXPERIMENTAL|Daily IV Gentamicin|Once daily (for 24 days) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
62730571|NCT04140786|EXPERIMENTAL|Biweekly IV Gentamicin|Twice weekly (for 3 months or 24 total) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
62730572|NCT02372695|EXPERIMENTAL|Treatment|Patient will take one pill of paricalcitol a day.
62730573|NCT02372695|NO_INTERVENTION|Usual treatment.|Patient allocated to this arm will only take his/her habitual treatment
62730574|NCT02614339|EXPERIMENTAL|metformin|
62730575|NCT02614339|ACTIVE_COMPARATOR|control|
62730576|NCT01253369|EXPERIMENTAL|Pazopanib|Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
62730577|NCT05386147|EXPERIMENTAL|Study group|"Women with recurrent BV use the Flourish HEC Vaginal Care System, consisting of three components: 1) Balance external wash; 2) BioNourish vaginal moisturizing gel (an FDA 510k cleared class II medical device); and 3) BiopHresh homeopathic vaginal suppository with probiotics. All system components are currently available to the public at national retailers. Women will use the system for six months. They will have vaginal microbiome composition (next-generation sequencing and Nugent score) and vaginal pH tested at baseline, 3 months, and 6 months. At each timepoint they will also complete the vulvovaginal symptoms questionnaire (VSQ)."
62730578|NCT01121055|PLACEBO_COMPARATOR|Control|Placebo 1T by mouth (po) at night one day before FB and placebo 1T po 30min before the FB
62730579|NCT01121055|EXPERIMENTAL|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
62730580|NCT05524077|EXPERIMENTAL|Ablation|"Patients will be expected to have a catheter ablation procedure within 2 weeks post randomisation and no longer than 30 days post randomisation.~Medical therapy can be used as a temporising measure before catheter ablation, as is standard of care. If there is breakthrough VT during the period before the clinical procedure, standard practice will be followed in stabilising the ventricular tachycardia (VT) including intravenous short acting anti-arrhythmic drugs (AAD), admission to hospital, internal or external cardioversion. However, preference will be given to scheduling the procedure within 24-48 hours in this situation."
62730581|NCT05524077|ACTIVE_COMPARATOR|Anti-arrhythmic drugs (AAD)|Patients managed with medical therapy alone by their usual medical practitioners. A protocol aligned with standard clinical care/current clinical guidelines will be provided for guidance, the objective being that the control arm replicates what would constitute standard of care for patients with ventricular tachycardia managed with a non-interventional approach.
62730582|NCT04757571|EXPERIMENTAL|Paroxetine|Paroxetine 20 mg daily plus standard therapy
62730583|NCT04757571|PLACEBO_COMPARATOR|Placebo|Placebo tablet daily plus standard therapy
62730584|NCT04449107|EXPERIMENTAL|Intervention Arm|The intervention arm in addition to the standard counselling will include receiving text messages, voice messages, pictorial messages and video messages regarding vaccination once a week till the child turns 14 weeks
62730585|NCT04449107|NO_INTERVENTION|Control Arm|The control group will receive one-time standard verbal counselling at the time of initial visit for on-time EPI vaccines at 10 and 14 weeks of age as recommended by EPI, government of Pakistan.
62730586|NCT00924677|SHAM_COMPARATOR|lidocaine|Local injection with lidocaine through the RF cannula without activation of RF generator.
62730587|NCT00924677|ACTIVE_COMPARATOR|lidocaine, radiofrequency current|After lidocaine injection through the RF cannula, the temperature of the electrode tip was raised to 70℃ for 90 seconds by RF generator.
62730588|NCT04119752|ACTIVE_COMPARATOR|Curcumin powder|Curcumin powder - 10g
62730589|NCT04119752|PLACEBO_COMPARATOR|Placebo ( curcumin depleted)|Placebo- sucralose -1g
62730590|NCT04023383|PLACEBO_COMPARATOR|Control|The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
62730591|NCT04023383|EXPERIMENTAL|HyaRegen NCH gel group|In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
62730592|NCT05005273|EXPERIMENTAL|Arm A|
62730593|NCT05005273|EXPERIMENTAL|Arm B|
62730594|NCT00603941|EXPERIMENTAL|Cohort 1; 0.15 mg CS-7017|Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 \[Dose Level 1a\] or 175 \[Dose Level 1b\] mg/m\^2 intravenous (IV) paclitaxel once every 3 weeks.
62730595|NCT00603941|EXPERIMENTAL|Cohort 2; 0.30 mg CS-7017|Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m\^2 IV paclitaxel once every 3 weeks.
62730596|NCT00603941|EXPERIMENTAL|Cohort 3; 0.50 mg CS-7017|Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m\^2 IV paclitaxel once every 3 weeks.
62730597|NCT02279550||hip fracture|aged \>65 with hip fracture
62730598|NCT04091191|ACTIVE_COMPARATOR|Specialized nutraceutical|Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
62730599|NCT04091191|PLACEBO_COMPARATOR|Placebo|Identical placebo formulated without active ingredients in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
62730600|NCT04855630|EXPERIMENTAL|Sleep Only Group|Participants in this group will wear the DREEM 2 headband for 12 weeks.
62730601|NCT04855630|ACTIVE_COMPARATOR|Exercise Only Group|Participants in this group will workout twice a week for 12 weeks.
62730602|NCT04855630|ACTIVE_COMPARATOR|Exercise and Sleep Group|Participants in this group will take part in a guided exercise program in additional to wearing the DREEM 2 headband for 12 weeks.
62730603|NCT05272397|ACTIVE_COMPARATOR|Drug Session|"In this arm of the study participants receive the drug (Methylphenidate - 20mg), administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
62730604|NCT05272397|PLACEBO_COMPARATOR|Placebo Session|"In this arm of the study participants receive the a placebo, administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
62730605|NCT05272397|OTHER|Intake Session|In this arm of the study participants are screened for suitability to participate in the experiment based on specified inclusion and exclusion criteria. They also complete some baseline tasks to assess working memory capacity, impulsiveness, and subjective mood.
62730606|NCT05069727|ACTIVE_COMPARATOR|Group 1, Regular Protocol|Participants will bolus (insulin), based on carbohydrate content in each meal
62730607|NCT05069727|EXPERIMENTAL|Group 2, Simplified protocol|Participants will bolus (insulin), based on three sets of meal set of meals announcement
62730608|NCT01530503|EXPERIMENTAL|capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food
62730609|NCT01530503|EXPERIMENTAL|capecitabine plus mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion Mitomycin 6 mg/m2 day 1
62730610|NCT02189148||Cohort|"Each participant will :~* give consent~* provide a blood sample (10 ml)~* be measured (weight and height for BMI calculation)~* undergo a blood pressure measurement~* have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)~* answer to a short questionnaire (5 pages)"
62730611|NCT01584414||normal samples|
62730612|NCT01584414||premalignant/carcinoma samples|
62730613|NCT01296971|EXPERIMENTAL|A|genotype 1, treatment-naive
62730614|NCT01296971|EXPERIMENTAL|B|genotype 2 and 3, treatment-naive
62730615|NCT01296971|EXPERIMENTAL|C|all genotypes, non-responders or relapses
62730616|NCT01084343|ACTIVE_COMPARATOR|Panel 1|Subjects in this panel receive the low dose of vaccine (10 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
62730617|NCT01084343|ACTIVE_COMPARATOR|Panel 2|Subjects in this panel receive the high dose of vaccine (50 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
62730618|NCT01553292|EXPERIMENTAL|ECALMIST|Large volume 5ml/kg surfactant administered by vascular catheter while maintaining CPAP or ECALMIST; Early CPAP (continuous positive airway pressure) And Large volume Minimal Invasive Surfactant Therapy
62730619|NCT02540512|PLACEBO_COMPARATOR|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
62730620|NCT02540512|EXPERIMENTAL|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
62730621|NCT02540512|EXPERIMENTAL|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
62730622|NCT04774068|EXPERIMENTAL|Treatment (romidepsin, parsaclisib)|"PRE-PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~INDUCTION PHASE: Patients receive romidepsin IV over 4 hours on days 1,8, and 15 and parsaclisib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and parsaclisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62730623|NCT05934149||New Onset|Individuals with a new diagnosis of SLE
62730624|NCT05934149||LN Active|Individuals with a recent diagnosis of Lupus Nephritis
62730625|NCT05934149||Extra-renal Flare|Individuals who have experienced a recent flare
62730626|NCT05934149||Prevalent|Individuals with lupus who do not meet the criteria for one of the other cohorts
62730627|NCT04703192|EXPERIMENTAL|Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible peripheral T-cell lymphoma subtype that was confirmed by independent hematopathology central review.
62730628|NCT04703192|EXPERIMENTAL|Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible adult T-cell leukemia/lymphoma subtype that was confirmed by the local pathologist/investigators and by documented positive anti-human T-cell leukemia virus type 1 (HTLV-1) antibody.
62730629|NCT01889108|NO_INTERVENTION|Control|Usual care
62730630|NCT01889108|EXPERIMENTAL|Intervention group|Intervention with SPEEDI
62730631|NCT03480893|EXPERIMENTAL|Small size interarcuair decompression|Patients will undergo small size interarcuair decompression
62730632|NCT03480893|ACTIVE_COMPARATOR|Laminectomy|Patients will undergo laminectomy
62730633|NCT02749201|EXPERIMENTAL|Analysis|Light Intensity and gastric wall thickness analysis
62730634|NCT06105515|EXPERIMENTAL|Interventional arm|The group that will receive the active treatment
62730635|NCT00804050|EXPERIMENTAL|Infusion A: rEPO|rEPO for 4 mounths consequently
62730636|NCT00804050|EXPERIMENTAL|Infusion B combined r-EPO|rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently
62730637|NCT03211663||Interventional : MOTO Medial® UKA|Interventional : Patients who are planned to undergo a primary medial UKA using the MOTO Medial® will be enrolled.
62730638|NCT06372509||Patients with migraine|Consecutive patients admitted for non coronary disease, will follow their clinical pathway. They will be classified into symptomatic for migraine with aura (group 1, N=45) and free from migraine (N=45) and will be enrolled in the study.
62730639|NCT06372509||Patients w/o migraine|Consecutive patients admitted for non coronary disease, will follow their clinical pathway. They will be classified into free from migraine (group 2, N=45) and will be enrolled in the study.
62730640|NCT00283101|EXPERIMENTAL|1|SGN-40
62730641|NCT03977545|OTHER|Newborn with risk of neonatal opioid abstinence syndrome|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 7 days
62730642|NCT03977545|OTHER|Eutrophic term newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
62730643|NCT03977545|OTHER|Term newborn with low birth weight|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
62730644|NCT03977545|OTHER|Eutrophic premature newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
62730645|NCT05111197|EXPERIMENTAL|A. (Immunotherapy + SRT)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy, started at least 6 months ago, associated with Stereotactic Radiation Therapy (SRT)
62730646|NCT05111197|ACTIVE_COMPARATOR|B (Immunotherapy alone)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy alone (started at least 6 months ago)
62730647|NCT06008262|EXPERIMENTAL|Cold Application Group|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
62730648|NCT06008262|NO_INTERVENTION|Control Group|In the control group, the severity of nausea and pain will be determined by using a numerical evaluation scale in patients with postoperative nausea. Vital signs will be recorded at this stage. Normal procedures will be applied to these patients within the scope of nursing practices.
62730649|NCT02386787|EXPERIMENTAL|SEMI EMERGENCY SURGERY PATIENT|patient undergoing a non-elective surgery and having a preoperative fasting period of six hours.
62730650|NCT06110949||At home hospitalization cohort|Participants admitted with acute medical diseases to at home hospitalization units will be included in a prospective registry in order to investigate the 90 days incidence of thromboembolic disease. A group of such patients will be controlled with triaxial accelerometer in order to collect raw data regarding patient mobility during admission.
62730651|NCT06110949||Conventional hospitalization cohort|Participants admitted with acute medical diseases to a conventional hospitalization unit will be included in a prospective registry in order to investigate the 90 days incidence of thromboembolic disease. A group of such patients will be controlled with triaxial accelerometer in order to collect raw data regarding patient mobility during admission.
62730652|NCT06335069|EXPERIMENTAL|Additional 68Ga-FAPI-46 PET/CT and PET/MRI exam|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
62730653|NCT02012855|EXPERIMENTAL|Exercise only|90 minutes of exercise
62730654|NCT02012855|EXPERIMENTAL|Exercise and high glycemic index meal|90 minutes of exercise followed by a high glycemic index meal matched for calories expended during the exercise
62730655|NCT02012855|EXPERIMENTAL|Exercise and low glycemic index meal|90 minutes of exercise followed by a low glycemic index meal matched for calories expended during the exercise
62730656|NCT02012855|NO_INTERVENTION|No exercise and no meal|No exercise and no meal
62730657|NCT05922228|EXPERIMENTAL|Neural flossing with proprioceptive neuromuscular facilitation|nerve flossing technique protocol along with contract relax technique of proprioceptive neuromuscular facilitation is used
62730658|NCT05922228|ACTIVE_COMPARATOR|Neural flossing without proprioceptive neuromuscular facilitation|only nerve flossing technique protocol is used
62730659|NCT05320354||Patients suspected of PJI|Adult patients, both male and female, scheduled for a puncture or surgery of their prosthetic joint due to suspected PJI.
62730660|NCT01283438|EXPERIMENTAL|Barricaid Device|Intervention: Barricaid Device
62730661|NCT01283438|ACTIVE_COMPARATOR|Standard of Care|Standard (Limited) Discectomy Only
62730662|NCT02497222|EXPERIMENTAL|RNS60|RNS60 4 ml, inhaled twice daily by nebulization for 21 days.
62730663|NCT02497222|PLACEBO_COMPARATOR|Normal Saline|Normal Saline 4 ml, inhaled twice daily by nebulization for 21 days.
62730664|NCT05480735|EXPERIMENTAL|Prehabilitation group|"The intervention group will participate in a prehabilitation program of approximately 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. A dietician will provide nutritional support and give dietary advice to increase protein intake, including a supplement containing 30 g of whey-protein daily and after supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychologist. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke.~Patients will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation."
62730665|NCT05480735|NO_INTERVENTION|Control group|Patients randomized to the control group will receive care as usual according to local ERAS guideline implementation. In addition, they will receive a leaflet with the recent guidelines regarding physical activity, dietary advice, and smoking cessation. Their actual physical activity level will be obtained via questionnaire.
62730666|NCT01349205|EXPERIMENTAL|Caffeine and Sodium Benzoate 10 mg/kg IV|Group 1 of randomized study.
62730667|NCT01349205|EXPERIMENTAL|Caffeine and Sodium Benzoate 20 mg/kg IV|Group 2 of randomized study
62730668|NCT01349205|PLACEBO_COMPARATOR|0.9 NS Saline|Control group of randomized study.
62730669|NCT01941654|EXPERIMENTAL|preemptive local ablative therapy|
62730670|NCT05592990|EXPERIMENTAL|NGI226|single peritendon injection
62730671|NCT05592990|PLACEBO_COMPARATOR|Placebo|single peritendon injection
62730672|NCT06257446|EXPERIMENTAL|Motivation|Trials in which participants are motivated by agency or not in a within-subjects design
62730673|NCT02663427|EXPERIMENTAL|PG(-) and Hp(-) Group|PG negative （pepsinogen（PG）Ⅰ \> 70ng/ml or PGⅠ/PGⅡ \>7.0）and Hp (helicobacter pylori) negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
62730674|NCT02663427|EXPERIMENTAL|PG(-) and Hp(+) Group|PG negative and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
62730675|NCT02663427|EXPERIMENTAL|PG(+) and Hp(-) Group|PG positive (PGⅠ ≤ 70ng/ml and PGⅠ/PGⅡ≤7.0) and Hp negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
62730676|NCT02663427|EXPERIMENTAL|PG(+) and Hp(+) Group|PG positive and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
62730677|NCT01976871|EXPERIMENTAL|Oral Dopamine Agonist to Rotigotine|During the study, we will switch patients who are not satisfied with their current oral dopamine agonist to rotigotine. Cross-titration will allow determination of the lowest effective dose of rotigotine. We will use as initial guidance the equivalence determined from the Parkinson's Disease trials, in which 1 mg rotigotine was shown to be approximately equivalent to 1-1.5 mg ropinirole or 0.25 -0.375 mg pramipexole. Tolerability, adverse events, and RLS symptom control will be evaluated. These data will provide clinicians with practical guidance to optimize RLS treatment while minimizing adverse events.
62730678|NCT04771689|ACTIVE_COMPARATOR|Buprenorphine/Naloxone|Subjects will take a maximum dose of 4 mg buprenorphine and 1 mg naloxone with concurrent administration of other intravenous or oral opioids needed.
62730679|NCT04771689|NO_INTERVENTION|Standard Medication Regiment|Subjects will take conventional intravenous or oral opioid management.
62730680|NCT02575729|EXPERIMENTAL|Inject betamethasone by sonography|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease by sonography- guided. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
62730681|NCT02575729|ACTIVE_COMPARATOR|Inject betamethasone directly|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease directly. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
62730682|NCT05165732|EXPERIMENTAL|Experimental Group 1|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co.,Ltd.
62730683|NCT05165732|EXPERIMENTAL|Experimental Group 2|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co.,Ltd.
62730684|NCT05165732|EXPERIMENTAL|Experimental Group 3|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd.
62730685|NCT05165732|EXPERIMENTAL|Experimental Group 4|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research \& Development Co.,Ltd.
62730686|NCT05165732|EXPERIMENTAL|Experimental Group 5|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.
62730687|NCT05296746|EXPERIMENTAL|Responder (ROR-low)|Ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years
62730688|NCT05296746|OTHER|Non-responder (ROR-medium/high)|"Adjuvant chemotherapy. 3 regimens are permitted.~Regimen 1:~- Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles, followed by Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks.~Regimen 2:~- Docetaxel 75-100 mg/m2 IV day 1 and Cyclophosphamide 600-830 mg/m2 day 1 every 21 days for 4-6 cycles.~Regimen 3:~- Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks followed by Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles.~Then, patients will receive ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years"
62730689|NCT03388762|ACTIVE_COMPARATOR|GlucoSupreme™ Herbal|Each daily serving of four GlucoSupreme™ Herbal tablets includes extracts from: cinnamon bark (Cinnamomum cassia) 500 mg, banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid) 200 mg, kudzu root (Pueraria lobata standardized to 40% isoflavones) 200 mg, fenugreek seed (Trigonella foenum-graceum standardized to contain 60% saponins) 200 mg, and gymnema leaf (Gymnema sylvestre standardized to contain 25% gymnemic acid). Additionally, American ginseng root (Panax quinquefolius standardized to contain 5% ginsenosides) 200 mg, and berberine HCl derived from bark (Berberis aristata) 500 mg. Other ingredients include Cellulose (capsule), microcrystalline cellulose, silicon dioxide, and vegetable stearate.
62730690|NCT03388762|PLACEBO_COMPARATOR|Control|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
62730691|NCT04918381|EXPERIMENTAL|CellFX Procedure|Treatment of the BCC with CellFX System
62730692|NCT01741298|EXPERIMENTAL|Lifestyle counseling|CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
62730693|NCT00847899|ACTIVE_COMPARATOR|1|AR9281
62730694|NCT00847899|ACTIVE_COMPARATOR|2|AR9281
62730695|NCT00847899|PLACEBO_COMPARATOR|3|Placebo
62730696|NCT00847899|PLACEBO_COMPARATOR|4|Placebo
62730697|NCT03462758|OTHER|Control Group|IUD placed 6-8 weeks postpartum (standard of care, interval placement)
62730698|NCT03462758|EXPERIMENTAL|Intervention Group|IUD placed 2-4 weeks postpartum (early postpartum placement, EPP)
62730699|NCT05961683|NO_INTERVENTION|Infants receiving non invasive ventilation without NIV plus|
62730700|NCT05961683|EXPERIMENTAL|Infants receiving non invasive ventilation with NIV plus|
62730701|NCT06443333||neuroimmune diseases patient|Patients diagnosed with neuroimmune diseases by a neurologist.
62730702|NCT06443333||Health Volunteers|Healthy adults undergoing medical examinations at the Xuanwu Hospital Physical Examination Center.
62730703|NCT03313999|OTHER|Durometer Measurement|All patients participating in the study will receive standard of care treatment for their lymphedema. As part of the study they will be measured by the durometer in addition to other, standard diagnostics to further characterize their lymphedema progression.
62730704|NCT04812535|EXPERIMENTAL|Arm A: IFX-1 monotherapy|IFX-1 monotherapy
62730705|NCT04812535|EXPERIMENTAL|Arm B: IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
62730706|NCT02474576|EXPERIMENTAL|Percutaneous aponeurotomy|Treatment of Dupuytrens-induced finger flessum using percutaneous aponeurotomy
62730707|NCT00782899||1|Schizophrenic patients with a acute episode treated in outpatients clinics
62730708|NCT02409641|EXPERIMENTAL|30 healthy male and female subjects|30 healthy male and female subjects , age 18-35 years
62730709|NCT01142076|PLACEBO_COMPARATOR|placebo|Dose treatment group, 10%
62730710|NCT01142076|ACTIVE_COMPARATOR|Xinju Xiaogao Prescription|treatment group
62730711|NCT03166852|EXPERIMENTAL|Home-training group|High-intensity training at home 3 times/week for 5 weeks
62730712|NCT02905838|ACTIVE_COMPARATOR|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
62730713|NCT02905838|ACTIVE_COMPARATOR|CAD/CAM CARES Abutment|Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
62730714|NCT01568281|EXPERIMENTAL|1|2 way crossover
62730715|NCT01568281|EXPERIMENTAL|2|2 way crossover
62730716|NCT01568281|EXPERIMENTAL|3|2 way crossover
62730717|NCT01568281|EXPERIMENTAL|4|2 way crossover
62730718|NCT06309602|OTHER|Control / Standard Care|Standard care provided for patients with orders for thickened liquids.
62730719|NCT06309602|EXPERIMENTAL|Free Water Protocol|Standard care provided for patients with orders for thickened liquids. Additionally, participant will be allowed to have plain, un-thickened water after the following have taken place: 1) Wait 30 minutes after meal or medication administration; 2) Complete oral care according to instructions posted at bedside.
62730720|NCT04111796|EXPERIMENTAL|group in nature|they participate in nature based-program during work hours
62730721|NCT04111796|NO_INTERVENTION|control group|they participate don't in nature based-program during work hours and perform their normal work schedule
62730722|NCT04068077||Experimental|Patients with amyloidosis and other indistinguishable diseases
62730723|NCT01970241|EXPERIMENTAL|NPH with steroid dose|"Receive NPH with each corticosteroid dose during the study duration (2-5 days).~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg"
62730724|NCT01970241|ACTIVE_COMPARATOR|Control - Background and correction insulin|Receive usual care with background insulin and correction factor for duration of study (2-5 days)
62730725|NCT00852579|EXPERIMENTAL|1|Active treatment.
62730726|NCT00852579|PLACEBO_COMPARATOR|2|Placebo control group.
62730727|NCT04497597||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
62730728|NCT00711282|EXPERIMENTAL|A|
62730729|NCT00711282|EXPERIMENTAL|B|
62730730|NCT05582512||Clinical Characteristics of pediatric COVID-19 by the retrospective research group|Analyze all clinically visible data of hospitalized children with COVID-19 infection (different virus strains), and then find the cause of severe disease and related risk factors for disease
62730731|NCT05582512||acute case receiving group (including children with multisystem inflammatory syndrome)|"1. The correlation between the microbial flora of the respiratory tract and the central nervous system and the severity of SARS-CoV2 pneumonia and host immunity (host inflammatory biomarkers, antibody library/cell receptor library, chemokines, cytokines, cell-regulated immune responses, table Epitope mapping, host transcriptome studies)~2. To explore the correlation between the clinical manifestations of gastrointestinal tract and liver and SARS-CoV-2 infection and the analysis of gut microbiota~3. To analyze the host gene factors of COVID-19 patients.~4. To explore the changes of brain injury biomarkers (Biomarker) in acute and chronic phases, and to analyze the correlation with changes in brain structure and other clinical factors (e.g. severity of neurological symptoms)"
62730732|NCT05582512||children's long COVID-19 tracking group|"1. Clarify the incidence and persistent impact of COVID-19 symptoms in children through outpatient assessment, and further analyze the factors related to preventing the development of COVID-19. / Conduct long-term follow-up through brain MRI and neurophysiological examinations to explore the effects of COVID-19 infection on children brain structure and peripheral nerve function, and analyze the association of risk factors and other clinical symptoms. A psychiatric clinical diagnostic interview was also conducted to establish a psychiatric diagnosis. The emotional and behavioral assessment scale was used to fully evaluate the mental state and family social function.~2. To analyze the correlation between host genes and antibody repertoire/receptor repertoire, epitope mapping, microbial phase, and prognosis of severe COVID-19 patients"
62730733|NCT05582512||seroepidemiological research group|Through the antibody test and the content of the questionnaire, we can better understand the epidemiology of the COVID-19. Including the proportion of asymptomatic infections, the scale of infection, the speed of transmission, etc. Vaccinated people can also learn about the speed of antibody decline
62730734|NCT05582512||healthy control group|"Provide a sample of the normal population of the Acute Reception Unit. To carry out respiratory microbial flora, host inflammatory biomarkers, antibody library/receptor library, chemokines, cytokines, cell-mediated immune responses, epitope mapping, brain MRI, neurophysiological examinations (neurophysiological examinations) Conduction, brain waves, sleep watch checks, etc.), brain injury biomarkers (Biomarker), healthy control group studies of host transcriptome"
62730735|NCT03674970|EXPERIMENTAL|Random Nicotine Delivery|One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.
62730736|NCT03674970|ACTIVE_COMPARATOR|Steady State Nicotine Delivery|One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
62730737|NCT03674970|PLACEBO_COMPARATOR|Placebo Control|One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
62730738|NCT05991583|EXPERIMENTAL|Phase Ia - Dose escalation|The goal of the Dose Escalation Phase (Part A) is to initially characterize the safety and tolerability of IBB0979, and more specifically to describe the DLTs for each dose level studied and to define the MTD based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.
62730739|NCT05991583|EXPERIMENTAL|Phase Ib - Dose extension|During the Dose Expansion Phase , patients will be enrolled to receive IBB0979 at the MTD established from the Dose Escalation Phase of the study.
62730740|NCT05991583|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage|After finishing Phase 1, invesigators will discuss with the sponsor about how to carry out the Phase IIa due to the results acheived from Phase I.
62730741|NCT01048398|EXPERIMENTAL|Remifentanil|
62730742|NCT01048398|ACTIVE_COMPARATOR|Paracetamol|intravenous paracetamol 1g
62730743|NCT03842774|EXPERIMENTAL|Test group|taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks
62730744|NCT03842774|PLACEBO_COMPARATOR|Control group|taken 3 tablets of placebo once a day for 12 weeks
62730745|NCT03045588|EXPERIMENTAL|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
62730746|NCT03045588|ACTIVE_COMPARATOR|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
62730747|NCT04253210|EXPERIMENTAL|Sexualized images / High photo modification|
62730748|NCT04253210|EXPERIMENTAL|Sexualized images / Low photo modification|
62730749|NCT04253210|EXPERIMENTAL|Nonsexualized images / High photo modification|
62730750|NCT04253210|EXPERIMENTAL|Nonsexualized images / Low photo modification|
62730751|NCT04253210|EXPERIMENTAL|Control images|
62730752|NCT01037998|ACTIVE_COMPARATOR|A|Iressa 250 mg daily treatment plus UFUR twice daily treatment
62730753|NCT01037998|NO_INTERVENTION|B|Gefitinib 250 mg daily treatment
62730754|NCT04909840|EXPERIMENTAL|dental floss|Instructions of oral hygiene with toothbrush plus dental floss
62730755|NCT04909840|ACTIVE_COMPARATOR|without dental floss|Individuals who will use only toothbrush
62730756|NCT01059864|EXPERIMENTAL|Arm 1|
62730757|NCT01059864|EXPERIMENTAL|Arm 2|
62730758|NCT03058198|EXPERIMENTAL|High Grade Glioma|"We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from thehot-spot on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies."
62730759|NCT03653234|EXPERIMENTAL|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
62730760|NCT03653234|NO_INTERVENTION|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
62730761|NCT05100771||Experimental group|The experimental group will be made up of patients with focal epilepsy
62730762|NCT04798222|EXPERIMENTAL|Group 1: Treatment Sequence ABECD|Participants will receive a single oral dose of Treatments A, B, E, C, and D in Treatment periods 1 to 5 on Day 1 of the study.
62730763|NCT04798222|EXPERIMENTAL|Group 1: Treatment Sequence BACED|Participants will receive a single oral dose of Treatments B, A, C, E, and D in Treatment periods 1 to 5 on Day 1 of the study.
62730764|NCT04798222|EXPERIMENTAL|Group 1: Treatment Sequence CDBEA|Participants will receive a single oral dose of Treatments C, D, B, E, and A in Treatment periods 1 to 5 on Day 1 of the study.
62730765|NCT04798222|EXPERIMENTAL|Group 1: Treatment Sequence EADBC|Participants will receive a single oral dose of Treatments E, A, D, B, and C in Treatment periods 1 to 5 on Day 1 of the study.
62730766|NCT04798222|EXPERIMENTAL|Group 2: Treatment Sequence AFHG|Participants will receive a single oral dose of Treatments A, F, H, and G in Treatment periods 1 to 4 on Day 1 of the study.
62730767|NCT04798222|EXPERIMENTAL|Group 2: Treatment Sequence FGAH|Participants will receive a single oral dose of Treatments F, G, A, and H in Treatment periods 1 to 4 on Day 1 of the study.
62730768|NCT04798222|EXPERIMENTAL|Group 2: Treatment Sequence GHFA|Participants will receive a single oral dose of Treatments G, H, F, and A in Treatment periods 1 to 4 on Day 1 of the study.
62730769|NCT04798222|EXPERIMENTAL|Group 2: Treatment Sequence HAGF|Participants will receive a single oral dose of Treatments H, A, G, and F in Treatment periods 1 to 4 on Day 1 of the study.
62730770|NCT05354492|EXPERIMENTAL|Active Program Participant|You will actively take part in the group program via Zoom with our program facilitators.
62730771|NCT05354492|NO_INTERVENTION|Program Wait List|You will be placed on a wait list to take part in the program.
62730772|NCT04797455|EXPERIMENTAL|PI+ Inpatient Treatment as Usual|"Standard inpatient treatment delivered in the context of an adolescent psychaitric inpatient unit plus an 4 session DBT-based parenting intervention PI)~Intervention: Behavioral: DBT-Based Parenting Intervention"
62730773|NCT04797455|ACTIVE_COMPARATOR|Inpatient Treatment alone|"No parenting intervention provided beyond what is part of the inpatient treatment as usual.~Intervention: Behavioral: Treatment as Usual"
62730774|NCT05963243||Healthy Volunteers|Healthy adult (18+ years old) volunteers
62730775|NCT00844142|OTHER|1|etanercept 25mg twice weekly
62730776|NCT00844142|ACTIVE_COMPARATOR|2|Sulfasalazine 2000- 3000mg daily
62730777|NCT01746381|EXPERIMENTAL|IVAPS mode of non-invasive ventilation|Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
62730778|NCT01746381|ACTIVE_COMPARATOR|BIST mode of non-invasive ventilation|Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
62730779|NCT02548910|EXPERIMENTAL|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
62730780|NCT02548910|NO_INTERVENTION|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
62730781|NCT05859646|EXPERIMENTAL|Probiotics|Group A-Probiotics group: Patients who started using probiotic drops after general anesthesia procedure
62730782|NCT05859646|NO_INTERVENTION|Control|Group B-Control group: Patients who did not use any probiotics after general anesthesia procedure
62730783|NCT01803971|EXPERIMENTAL|vascular access in out-of-hospital cardiac arrest patients|Obtention of vascular access according to the current strategy, ie after one unsuccessful attempt to obtain a peripheral venous access, use of an intra osseous device
62730784|NCT01032187|ACTIVE_COMPARATOR|Meglumine antimoniate|20mg/kg/day IV for 20 days
62730785|NCT01032187|EXPERIMENTAL|Anfo B|Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days
62730786|NCT01777048|EXPERIMENTAL|Omega-3 Fatty Acids|1g of Omega-3 per day \[400mg DHA \& 600mg EPA\] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
62730787|NCT01777048|PLACEBO_COMPARATOR|Omega-3 Placebo|1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
62730788|NCT06442904|EXPERIMENTAL|Intervention group|Access to a digital education program for three months.
62730789|NCT06442904|NO_INTERVENTION|Control group|The control group is not offered any intervention.
62730790|NCT06269692|EXPERIMENTAL|Implantable Loop Recorder|Patients identified at very low-risk of VT/VF randomized to be implanted with an ILR (experimental strategy). Following randomization, these patients will be followed using remote ILR monitoring.
62730791|NCT06269692|OTHER|Implantable Cardioverter Defibrillator|Patients identified at very low-risk of VT/VF randomized to be implanted with an ICD (reference strategy), which corresponds to the currently recommended treatment in post-MI patients with a LVEF ≤35% (European Society of Cardiology guidelines 2015) (Zeppenfeld et al., 2022).
62730792|NCT02941770|NO_INTERVENTION|Control group|"Clinic standard care protocol:~* Baseline evaluation session with a Pediatrician for initial screening;~* Appointment with a Dietitian;~* A brochure with physical activity guidelines for youth with examples of physical exercises."
62730793|NCT02941770|EXPERIMENTAL|Intervention group I|"* Clinic standard care protocol;~* Physical activity consultation (Physical activity behavior change);"
62730794|NCT02941770|EXPERIMENTAL|Intervention group II|"* Clinic standard care protocol;~* Physical activity consultation;~* 2 exercise sessions per week (≈60 min/session) directed by one Exercise Physiologist."
62730795|NCT04165408|EXPERIMENTAL|Device Use|Only one arm
62730796|NCT02873455|EXPERIMENTAL|watching video|Short video clip including the circumstance of operation theater, and surgeon's interview
62730797|NCT02752490|ACTIVE_COMPARATOR|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
62730798|NCT02752490|EXPERIMENTAL|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
62730799|NCT00481455|EXPERIMENTAL|1|
62730800|NCT03230318|EXPERIMENTAL|derazantinib|Oral administration
62730801|NCT03611218|OTHER|Hemodiafiltration HDF|Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.
62730802|NCT03413033||Group 1|43 participants will produce the vowel /a:/ three times as baseline during 5 seconds in habitual, comfortable speaking pitch and loudness. Thereafter, participants will produce series of a semi-occluded vocal tract exercises (resonance tube or lip trill). Afterwards, subjects will produce the vowel /a:/ three times once again. Electroglottographic signals will be captured before and after each exercise. A 15 minutes voice rest will be taken between exercises by all subjects.
62730803|NCT01627626|EXPERIMENTAL|0.1% pilocarpine mouthwash|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline
62730804|NCT01627626|PLACEBO_COMPARATOR|0.9% saline mouthwash|0.9% saline as a mouthwash
62730805|NCT02659813|EXPERIMENTAL|Firewire|Experimental Group 1. Novel orthodontic archwire.
62730806|NCT02659813|EXPERIMENTAL|CNiTi|Experimental Group 2. Current best available orthodontic archwire
62730807|NCT05945381|EXPERIMENTAL|GIC on MIH|see below
62730808|NCT04392674|EXPERIMENTAL|using the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
62730809|NCT05077839|EXPERIMENTAL|experimental group|In the experimental group, the treatment regimen is trifluridine/tipiracil 35mg/m2 orally taken on d1-5 and d8-12, oxaliplatin 85mg/m2 and bevacizumab 5mg/kg intravenously infused on d1 and d15 every 4 weeks, up to 6 cycles. Then patients will be given trifluridine/tipiracil and bevacizumab maintenance treatment.
62730810|NCT05077839|NO_INTERVENTION|control group|The control group was XELOX plus bevacizumab regimen, bevacizumab 7.5mg/kg, d1 oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 3 weeks, up to 8 cycles. Then patients will be given capecitabine and bevacizumab maintenance treatment.
62730811|NCT03953677|EXPERIMENTAL|Dexmedetomidine|
62730812|NCT03953677|PLACEBO_COMPARATOR|Placebo|
62730813|NCT02620033|NO_INTERVENTION|Standard Care|Those assigned to the standard care group will follow the routine pre- and post-operative care for patients whose undergoing radical prostatectomy.
62730814|NCT02620033|ACTIVE_COMPARATOR|Yoga therapy group|Those assigned to the yoga therapy group will be asked to participate in yoga session three times in a week for 6 weeks prior to the scheduled surgery and then re-initiated 3 weeks after the surgery for another 6 weeks. Each session will be approximately 60 - 75 minutes. These yoga session will be held at Nydia's Yoga Therapy Studio, located in San Antonio, TX, under the guidance of certified yoga instructor, Dr. Nydia Tijerina Darby, PT, DPT, MS, who's the owner of the studio and co-investigator of this study. The yoga exercise will be tailored to patient's comfort level.
62730815|NCT06187779|EXPERIMENTAL|Segmental thickness measurement|This population's lower segment will be measured.
62730816|NCT06187779|NO_INTERVENTION|Segmental thickness no measurement|No measurements of lower segment.
62730817|NCT04859348|EXPERIMENTAL|Group-A ( RPT+ Insulin Therapy)|Group A includes participants received the routine physical therapy only.
62730818|NCT04859348|EXPERIMENTAL|Group-B (RPT+ Antenatal Exercises+ Insulin therapy)|Group B includes participants were given antenatal exercise program from 20- 24 weeks of gestation to till the date of delivery, with addition of the routine physical therapy plan.
62730819|NCT06156878|EXPERIMENTAL|Anti-EGFR and PD-1 inhibitor arm|Two cycles of TP (docetaxel+cisplatin), TPF(docetaxel+cisplatin+5-FU), TPX (docetaxel+cisplatin+capecitabine) or GP regimen (gemcitabine+cisplatin) followed by radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week) when responses to induction chemotherapy are less than 50% Partial Response (PR) or EBVDNA copy number decreased by less than 50%.
62730820|NCT02816515||Ectoin® mouth wash|The treatment will be started on the first day of radio- and/or chemotherapy, before development of mucositis
62730821|NCT02816515||Ectoin mouth wash|The treatment will be started after oral mucositis development in patients receiving radio- and/or chemotherapy
62730822|NCT02816515||Supersaturated electrolyte mouth rinse|The treatment will be started after oral mucositis development in patients receiving radio and/or chemotherapy
62730823|NCT04672980|EXPERIMENTAL|RTX-321 Dose Escalation|Phase 1: RTX-321 administered intravenously on Day 1 of each cycle monotherapy dose escalation
62730824|NCT04672980|EXPERIMENTAL|RTX-321 Dose Expansion|Phase 1: RTX-321 administered intravenously on Day 1 of each cycle.
62730825|NCT01453972|EXPERIMENTAL|Long distanse moderate training|40 minutes moderate treadmill running
62730826|NCT01453972|EXPERIMENTAL|Long interval training|4x4min interval treadmill running
62730827|NCT01453972|EXPERIMENTAL|Short interval training|10x1min interval treadmill running
62730828|NCT04058899|ACTIVE_COMPARATOR|, Dexmedetomidine group(DEX group)|dexmedetomidine group (DEX)group who will receive 0.5 µg/kg dexmedetomidine diluted in 50 ml of normal saline 0.9% to be given by IV infusion over 10 minutes after induction of anesthesa then 5ml of 0.9% normal saline IV ,
62730829|NCT04058899|ACTIVE_COMPARATOR|Nalbuphine group(NAL group)|nalbuphine group (NAL)group will receive IV infusion of 50 ml of 0,9%normal saline by IV infusion over 10 minutes then 0.1mg/kg nalbuphine diluted in 5ml of 0.9%normal saline IV after induction of anesthesia.
62730830|NCT01489501|EXPERIMENTAL|only one arm available|Caomecs transplantation on eye cornea.
62730831|NCT03374358|NO_INTERVENTION|No intervention arm.|Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).
62730832|NCT03374358|EXPERIMENTAL|Raltegravir arm.|Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).
62730833|NCT06094608|EXPERIMENTAL|Morning light treatment|A 1 hour per day morning light treatment starting at average wake time, or up to 1 hour earlier to accommodate the morning schedule. The daily treatment continues for 4 weeks.
62730834|NCT06094608|ACTIVE_COMPARATOR|Treatment-as-usual|Participants will be instructed to continue to follow their usual sleep schedule for 4 weeks.
62730835|NCT00886769|EXPERIMENTAL|Canakinumab|Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\>37.5 kg) received two sc injections.
62730836|NCT00886769|PLACEBO_COMPARATOR|Placebo|Patients received a single dose matching placebo of canakinumab on day 1.
62736263|NCT01645735|ACTIVE_COMPARATOR|Ceftriaxone plus vancomycin|Ceftriaxone 2 g IV over 30 minutes once per day (q24h) plus vancomycin 15 mg/kg IV every 12 hours (q12h) initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
62736264|NCT05197933|EXPERIMENTAL|Laparoscopic resection|laparoscopic resection for GIST at unfavorable anatomic sites of stomach
62736265|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
62730837|NCT03749928|EXPERIMENTAL|OstiSense biosensor - active|Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
62730838|NCT03749928|PLACEBO_COMPARATOR|OstiSensor biosensor - not activated|Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
62730839|NCT05551351||Coronary CT|The single cohort consists of all patients enrolled in the study. All participants performs cardiac CT and coronary angiography as part of routine care.
62730840|NCT01973231|EXPERIMENTAL|Metformin + liraglutide 1.8 mg|
62730841|NCT01973231|ACTIVE_COMPARATOR|Metformin + lixisenatide 20 microg|
62730842|NCT00470262|OTHER|Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD|Treatment with pioglitazone and fenofibrate in subjects with pre diabetes
62730843|NCT00470262|OTHER|Fenofibrate 145 mg PO QD|Treatment with fenofibrate in subjects with pre diabetes
62730844|NCT05932576||The HPV vaccine group|Women aged 9-45 years who received the last dose of HPV vaccine within the past 12 months were included, and each subject was evaluated within 3-12 months after the last dose of HPV vaccine. Adverse reaction symptoms were queried by telephone follow-up and face-to-face, and peripheral blood tube (3ml) was collected to detect the concentration of comprehensive antibody to HPV vaccine.
62730845|NCT05318300|EXPERIMENTAL|Tested formula LP-2018|infant formula containing fibers
62730846|NCT05318300|PLACEBO_COMPARATOR|Placebo formula CT-2018|infant formula without fibers
62730847|NCT01906411||subjecst with different BMI|
62730848|NCT06526312|EXPERIMENTAL|SMS/Text (CAMPI)|"Receives interactive content with prompts via SMS (text) message to participant cellular phones developed within this project using the CAMPI platform.~Receives Family Check-Up 4 Health (FCU4Health) parenting intervention."
62730849|NCT06526312|EXPERIMENTAL|Fidelity Monitoring System (Lyssn)|"Receives automated fidelity monitoring and interactive feedback reports.~Receives Family Check-Up 4 Health (FCU4Health) parenting intervention."
62730850|NCT06526312|EXPERIMENTAL|SMS/Text (CAMPI) and Fidelity Monitoring System (Lyssn)|"Receives interactive content with prompts via SMS (text) message to participant cellular phones developed within this project using the CAMPI platform.~Receives automated fidelity monitoring and interactive feedback reports.~Receives Family Check-Up 4 Health (FCU4Health) parenting intervention."
62730851|NCT06526312|EXPERIMENTAL|No CAMPI or Lyssn|"Receives neither SMS/Text (CAMPI) or Fidelity Monitoring System (Lyssn).~Receives Family Check-Up 4 Health (FCU4Health) parenting intervention."
62730852|NCT01255839|ACTIVE_COMPARATOR|Double-balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
62730853|NCT01255839|ACTIVE_COMPARATOR|Prostglandin E2|The prostaglandin 2 minprostin (3mg) was applied vaginally
62730854|NCT02298309|NO_INTERVENTION|Usual Care|Patients in the usual care arm will be screened for tuberculosis (TB) on a mobile unit and referred for treatment according to the current standard of care in South Africa
62730855|NCT02298309|ACTIVE_COMPARATOR|Test-and-Treat Intervention|Patients in the intervention arm will partake in a Test-and-Treat TB strategy involving mobile GeneXpert MTB/RIF testing, facilitated TB treatment initiation, SMS reminders for clinic visits, and cashless incentives.
62730856|NCT00848276||1|Hypogonadal Men before and after starting testosterone replacement therapy
62730857|NCT00848276||2|Post-menopausal women before and after starting Estrogen Replacement Therapy
62730858|NCT00550186|PLACEBO_COMPARATOR|1|No preload
62730859|NCT00550186|ACTIVE_COMPARATOR|2|Preload with cristalloid infusion
62730860|NCT00550186|ACTIVE_COMPARATOR|3|Preload with collid infusion
62730861|NCT06511960|ACTIVE_COMPARATOR|Astaxanthin (12 mg/day) group|In this group, participants ingested either 12 mg/day (AX12) for 4 weeks.
62730862|NCT06511960|ACTIVE_COMPARATOR|Astaxanthin (36 mg/day) group|In this group, participants ingested either 36 mg/day (AX36) for 4 weeks.
62730863|NCT06511960|PLACEBO_COMPARATOR|Placebo|In this group, participants ingested the placebo capsules that were identical in appearance and dimensions to the astaxanthin supplement.
62730864|NCT04656808|EXPERIMENTAL|Guilt focused intervention|Following literature on factors associated with guilt experiences in caregivers (Gonyea et al., 2008; Gallego-Alberto et al., 2019; Losada et al., 2014; Prunty \& Foli, 2019; Romero-Moreno et al., 2014; Spillers et al., 2008) and previous intervention studies testing an Acceptance and Commitment Therapy intervention for dementia family caregivers (Losada et al., 2015; Márquez-González et al., 2020), a guilt focused intervention was specifically designed for caregivers who experienced high levels of guilt and emotional distress. The program is based on CBT (Márquez-González et al., 2007) and Acceptance and Commitment Therapy (ACT) approaches (Losada et al., 2005; Márquez-González et al., 2010), combined with techniques of Compassion-Focused Therapy (CFT; Gilbert, 2009), which were adapted to work with guilt experienced by family dementia caregivers.
62736266|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
62730865|NCT04656808|ACTIVE_COMPARATOR|Cognitive behavioral therapy|Following the cognitive behavioral model adapted to caregiving (Losada et al., 2006) and considering other previous CBT intervention studies with dementia caregivers (Gallagher-Thompson et al., 2003), a CBT intervention developed and tested for dementia family caregivers (Márquez-González et al., 2007) was used for this study. Specifically, this intervention consists of different components that are described in more detail in Losada et al. (2011) and Márquez-González et al. (2007): a) a cognitive restructuring module aimed at modifying caregivers' dysfunctional thoughts about caregiving into other, more appropriate thoughts which promote the use of more adaptive coping strategies for caregivers; b) increasing pleasant activities or behavioral activation; c) asking for help skills; and d) relaxation techniques for reducing physiological activation.
62730866|NCT03330678|EXPERIMENTAL|Probiotic (VSL#3)|Probiotics will be given to women included in study arm
62730867|NCT03925571|EXPERIMENTAL|music-listening group|patient will listen to music during the dental surgery (1 to 1h30 hours).
62730868|NCT03925571|NO_INTERVENTION|non music-listening group|patient will receive their dental intervention without music-listening.
62730869|NCT04804696|EXPERIMENTAL|TPC treatment|Neoadjuvant treatment of toripalimab, paclitaxel and cisplatin
62730870|NCT00693069|ACTIVE_COMPARATOR|1|Clopidogrel 300 mg the day before PCI
62730871|NCT00693069|EXPERIMENTAL|2|Clopidogrel 600 mg the day before PCI
62730872|NCT00693069|EXPERIMENTAL|3|300 mg followed by 75 mg daily started one week prior to angiography
62730873|NCT00693069|EXPERIMENTAL|4|300 mg followed by 150 mg daily started one week prior to angiography
62730874|NCT04442633|ACTIVE_COMPARATOR|conventional therapy|topical corticosteroid plus antifungal
62730875|NCT04442633|EXPERIMENTAL|Glutamine with a topical corticosteroid plus antifungal|Glutamine therapy in combination with a topical corticosteroid plus antifungal
62730876|NCT02919163|EXPERIMENTAL|Visible light exposure Red 30 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730877|NCT02919163|EXPERIMENTAL|Visible light exposure Red 120 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730878|NCT02919163|EXPERIMENTAL|Visible light exposure Blue 30 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730879|NCT02919163|EXPERIMENTAL|Visible light exposure Blue 120 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730880|NCT02919163|EXPERIMENTAL|Visible light exposure Green 30 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730881|NCT02919163|EXPERIMENTAL|Visible light exposure Green 120 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730882|NCT02919163|EXPERIMENTAL|Visible light exposure White 30 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730883|NCT02919163|EXPERIMENTAL|Visible light exposure White 120 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
62730884|NCT04916977||FD patients|
62730885|NCT02018029||cardiac resynchronisation therapy|
62730886|NCT01145781|ACTIVE_COMPARATOR|Single-freeze cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw.
62730887|NCT01145781|ACTIVE_COMPARATOR|Double-freeze cryotherapy|Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
62730888|NCT00869635|EXPERIMENTAL|1|"Treatment by combination of photodynamic therapy and S-1~1. PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~2. S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment"
62730889|NCT00869635|ACTIVE_COMPARATOR|2|"Treatment by photodynamic therapy only~1. PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~2. Other managements except systemic chemotherapy were added freely."
62730890|NCT00869635|OTHER|3|Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label
62730891|NCT00143624|EXPERIMENTAL|1|The first group will receive 8 mg of the study drug (rosiglitazone).
62730892|NCT00143624|PLACEBO_COMPARATOR|2|The second group will be given a placebo.
62730893|NCT03577834|EXPERIMENTAL|Liquid vinegar|Participants in this arm were instructed to drink 2 tablespoons of red wine vinegar (provided) mixed with water twice each day for weeks 1 to 8 of the trial.
62730894|NCT03577834|PLACEBO_COMPARATOR|Vinegar pill|Participants in the control group were instructed to take one vinegar pill (provided) each day for weeks 1-8 of the trial.
62730895|NCT05701839|EXPERIMENTAL|face mask airway management without oxygen reserve index monitoring|Participants inhale oxygen through face mask at a flow rate of 5 L/min and will be monitored with oxygen saturation.
62730896|NCT05701839|EXPERIMENTAL|face mask airway management with oxygen reserve index monitoring|Participants inhale oxygen through face mask at a flow rate of 5 L/min and will be monitored with oxygen reserve index.
62730897|NCT05701839|EXPERIMENTAL|nasopharyngeal tube airway management without oxygen reserve index monitoring|Participants inhale oxygen through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min and will be monitored with oxygen saturation.
62730898|NCT05701839|EXPERIMENTAL|nasopharyngeal tube airway management with oxygen reserve index monitoring|Participants inhale oxygen through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min and will be monitored with oxygen reserve index.
62730899|NCT02709512|EXPERIMENTAL|Drug: ADI-PEG 20 plus Pem Platinum|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~ADI-PEG 20 plus Pem Platinum: Investigational Drug in combination approved standard of care treatment for this indication"
62730900|NCT02709512|PLACEBO_COMPARATOR|Drug: Placebo plus Pem Platinum|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~Placebo plus Pem Platinum: Placebo in combination approved standard of care treatment for this indication"
62730901|NCT05955664|PLACEBO_COMPARATOR|MRI including DTI|"MR imaging will be performed on 3T MRI scanner (Skyra, Avanto) in supine position with no rectal contrast. The patients will undergo pelvic MRI with additional diffusion tensor (DTI) sequences dedicated for assessment of the fibres in the pelvic floor muscles.~DTI will be processed with the use of special software. The images will be assessed separately by two clinicians who will not know patients' symptoms or results of the US."
62730902|NCT05955664|ACTIVE_COMPARATOR|Pelvic floor ultrasound.|"Internal pelvic floor ultrasound will be performed with the use of high-frequency transducers with automatic 3D image acquisition by one of the Consultant Radiologists involved in the study.~No preparation is required. No vaginal or rectal contrast is used. The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound."
62730903|NCT03557957|EXPERIMENTAL|Standard care plus targeted correction of hyponatremia|Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.
62730904|NCT03557957|ACTIVE_COMPARATOR|Standard care|Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
62730905|NCT04980625|ACTIVE_COMPARATOR|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China.
62730906|NCT04980625|PLACEBO_COMPARATOR|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China.
62730907|NCT05232214||short eyes|Axial length under 22.5 mm
62730908|NCT05232214||long eyes|Axial length under 25.5 mm
62730909|NCT05960045|ACTIVE_COMPARATOR|Patients receiving direct milk antigen (Group A)|Patients with cow milk protein allergy after 6 month of elimination diet will receive direct milk antigen and will be followed up for 2 months for the development of any symptoms of milk intolerance
62730910|NCT05960045|ACTIVE_COMPARATOR|Patients subjected to gradual reintroduction of milk through a milk ladder (Group B)|Patient with cow milk protein allergy after 6 month of elimination diet will be offered indirect milk antigen through a ladder starting by baked milk products and will be followed up for also for 2 months to detect any symptoms of intolerance.
62730911|NCT00562432|EXPERIMENTAL|Plexisyl-AF|Plexisyl-AF implants
62730912|NCT00562432|SHAM_COMPARATOR|No Treatment|Surgery without experimental treatment
62730913|NCT04544644|EXPERIMENTAL|treatment arm|AK104+anlotinib
62730914|NCT04116177|ACTIVE_COMPARATOR|Standard Stimulation|Standard stimulation using contact 3-6 to achieve best therapeutic stimulation
62730915|NCT04116177|EXPERIMENTAL|Flexible stimulation|Flexible stimulation using all available stimulation strategies provided by the VerciseTM system including stimulation of contacts 1-8 and variable pulse width and frequency.
62730916|NCT01596322||UARTO|
62730917|NCT03933683||Pathologic Group|Patients affected by Fecal Incontinence
62730918|NCT03933683||Control Group|Healty volunteers cohort
62730919|NCT02526810|ACTIVE_COMPARATOR|GROUP A|using continuous subcutaneous insulin injection with insulin lispro, Humalog, initiating with 0.5-0.8 IU/kg.
62730920|NCT02526810|EXPERIMENTAL|GROUP B|using glargine combined with oral drugs: insulin glargine, Lantus( initiating with 0.2 IU/kg) with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd.
62730921|NCT03235921|OTHER|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
62730922|NCT03235921|OTHER|control group|no drug given to the patients in control group
62730923|NCT01721486|EXPERIMENTAL|Study Group|IV acetaminophen 15 mg/kg (up to 1000 mg) administered intraoperatively over a 15 minute infusion.
62730924|NCT01721486|ACTIVE_COMPARATOR|Control Group|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30 minutes) prior to induction of anesthesia in the pre-operative area.
62730925|NCT05553769|EXPERIMENTAL|10 week training, 10 week detraining, 10 week retraining|Participants (healthy untrained men and women, age 18-40) will conduct 10-week RT intervention and a 10-week DT period and the exact same 10-week RT intervention again. RT consists of two training sessions per week of total body workouts.
62730926|NCT05553769|EXPERIMENTAL|10 week non-training, 20 week continuous training|Participants (healthy untrained men and women, age 18-40) start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts.
62730927|NCT04560686|EXPERIMENTAL|Treatment (bintrafusp alfa, surgical resection)|Patients receive bintrafusp alfa IV on days 1, 15, and 29 in the absence of unacceptable toxicity. Within 4-6 weeks after last dose of bintrafusp alfa, patients undergo surgery at the discretion of the treating surgeon. Within 8 weeks after surgery, patients may receive chemotherapy or undergo radiation therapy at the discretion of the treating physician.
62730928|NCT02576548|EXPERIMENTAL|MEDI4276 0.05 mg/kg|Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730929|NCT02576548|EXPERIMENTAL|MEDI4276 0.1 mg/kg|Participants received IV dose of 0.1 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730930|NCT02576548|EXPERIMENTAL|MEDI4276 0.2 mg/kg|Participants received IV dose of 0.2 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730931|NCT02576548|EXPERIMENTAL|MEDI4276 0.3 mg/kg|Participants received IV dose of 0.3 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730932|NCT02576548|EXPERIMENTAL|MEDI4276 0.4 mg/kg|Participants received IV dose of 0.4 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730933|NCT02576548|EXPERIMENTAL|MEDI4276 0.5 mg/kg|Participants received IV dose of 0.5 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730934|NCT02576548|EXPERIMENTAL|MEDI4276 0.6 mg/kg|Participants received IV dose of 0.6 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730935|NCT02576548|EXPERIMENTAL|MEDI4276 0.75 mg/kg|Participants received IV dose of 0.75 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730936|NCT02576548|EXPERIMENTAL|MEDI4276 0.9 mg/kg|Participants received IV dose of 0.9 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
62730937|NCT03226327|EXPERIMENTAL|hypertension patients|
62730938|NCT01037335|PLACEBO_COMPARATOR|control group|10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly.
62730939|NCT01037335|ACTIVE_COMPARATOR|intramuscular morphine|10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly
62730940|NCT01037335|ACTIVE_COMPARATOR|donor site morphine|5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
62730941|NCT04294381|EXPERIMENTAL|pilot of SMART-goal-setting health behavior decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
62730942|NCT06554106|EXPERIMENTAL|Neuromuscular Electrical Stimulation Group|All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
62730943|NCT06554106|EXPERIMENTAL|Control group|Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
62730944|NCT04917367||Conventional surgery group|Conventional surgery with Preoperative foreign body localization
62730945|NCT04917367||New surgery group|new surgery with Intraoperative localization of foreign body
62730946|NCT00566046|EXPERIMENTAL|Levetiracetam|
62730947|NCT00566046|PLACEBO_COMPARATOR|Placebo|
62730948|NCT00556439|EXPERIMENTAL|A and C|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to abatacept at this point will be in Group A for giant cell arteritis and Group C for Takayasu arteritis.
62730949|NCT00556439|PLACEBO_COMPARATOR|B and D|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to placebo at this point will be in Group B for giant cell arteritis and Group D for Takayasu arteritis.
62730950|NCT00156104|EXPERIMENTAL|1|Asenapine 5 mg BID
62730951|NCT00156104|EXPERIMENTAL|2|Asenapine 10 mg BID
62730952|NCT00156104|ACTIVE_COMPARATOR|3|Haloperidol 4m mg BID
62730953|NCT00156104|PLACEBO_COMPARATOR|4|placebo
62730954|NCT02589028|EXPERIMENTAL|premeal protein bar first|"intervention: premeal protein-enriched bar intake~* protein enriched bar(total serving: 30g, 43.28% carbohydrate; 1.29% fat; 40.39% protein; 42.63% fiber) will be given 30 minutes before breakfast~* protein enriched bar is provided with 150 ml of water~* amount of protein bar : 30g~* breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
62730955|NCT02589028|OTHER|breakfast first|"intervention: breakfast follows by protein bar~* protein enriched bar is provided with 150 ml of water shortly after breakfast~* amount of protein bar : 30g~* breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
62730956|NCT05790044|ACTIVE_COMPARATOR|Group Placebo|Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side.
62730957|NCT05790044|ACTIVE_COMPARATOR|Group Clonidine|Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% and clonidine 1 ug/kg after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side.
61978398|NCT02703389|EXPERIMENTAL|Video|An innovative video will be developed to explain the nature of non-severe acute otitis media and the rationale for watchful waiting and antimicrobial stewardship. This video will be viewed at recruitment and will be available online for further viewing later.
62730958|NCT06187220||Therapeutic Plasma Exchange (PEX)|Patients receiving in addition to Standard Medical Therapy (SMT) at least one treatment with Therapeutic Plasma Exchange (PEX)
62730959|NCT06187220||Standard Medical Therapy (SMT)|Patients receiving only Standard Medical Therapy (SMT) of Amanita Toxin associated acute liver failure, including intensive care support (invasive ventilation, vasopressors, renal replacement therapy), silibinin and n-acetylcystein. Included in this group are also patients receiving albumine dialysis or other extracorporeal liver assist therapies excluding therapeutic plasma exchange.
62730960|NCT01766037|EXPERIMENTAL|Aspiration Therapy|Aspiration Therapy and Lifestyle Therapy
62730961|NCT01766037|ACTIVE_COMPARATOR|Lifestyle Therapy|Lifestyle Therapy only
62730962|NCT04194944|EXPERIMENTAL|Selpercatinib - Treatment A (TRT A)|160 milligram (mg) Selpercatinib administered orally twice daily (BID) continuously in 21-day cycles.
62730963|NCT04194944|ACTIVE_COMPARATOR|Pemetrexed and Platinum with or without Pembrolizumab - (TRT B)|Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose of 750 mg\] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.
62730964|NCT01294137|ACTIVE_COMPARATOR|ventilatory polygraphy|
62730965|NCT05275088|EXPERIMENTAL|Treatment|Transcatheter atrioventricular valve replacement with the Prizvalve® system
62730966|NCT00422188|EXPERIMENTAL|Deoxycholic Acid Injection 0.5%|Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
62730967|NCT00422188|EXPERIMENTAL|Deoxycholic Acid Injection 1.0%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
62730968|NCT00422188|EXPERIMENTAL|Deoxycholic Acid Injection 2.0%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
62730969|NCT00422188|EXPERIMENTAL|Deoxycholic Acid Injection 4.0%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
62730970|NCT00422188|PLACEBO_COMPARATOR|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
62730971|NCT04684576|EXPERIMENTAL|Explorer Mini First (AB Arm)|Children randomized into this arm will first trial a Permobil Explorer Mini powered mobility device over an 8-week intervention period, then trial a modified ride-on car over a second 8-week intervention period in their home and community environments.
62730972|NCT04684576|ACTIVE_COMPARATOR|Modified Ride On Car First (BA Arm)|Children randomized into this arm will first trial a modified ride-on car over an 8-week intervention period, then trial a Permobil Explorer Mini powered mobility device over a second 8-week intervention period in their home and community environments.
62730973|NCT01875393|EXPERIMENTAL|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
62730974|NCT05070793|OTHER|Culturally adapted interpersonal psychotherapy|Individual psychotherapy intervention based on Brief Interpersonal Psychotherapy (IPT-B) with additional cultural adaptation for transgender and nonbinary individuals.
62730975|NCT00647244|ACTIVE_COMPARATOR|1|Tenofovir
62730976|NCT00647244|ACTIVE_COMPARATOR|2|Abacavir
62730977|NCT02468440|EXPERIMENTAL|ESPAIR|Patients with an educational therapy's program since registration in transplant list.
62730978|NCT02468440|NO_INTERVENTION|normal care|Patients without educational therapy
62730979|NCT00885183|EXPERIMENTAL|acupuncture therapy|Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy
62730980|NCT00885183|OTHER|Usual care|Control group (usual care) receives standard chemotherapy alone
62730981|NCT01460706|EXPERIMENTAL|68Ga-DOTATOC|
62730982|NCT04237181|OTHER|Acute diarrhoea or colitis presumed to be of infectious origin|
62730983|NCT05313607|EXPERIMENTAL|conventional group|received conventional physical therapy program
62730984|NCT05313607|EXPERIMENTAL|plyometric group|received a plyometric physical therapy program
62730985|NCT01165411||Patients with CVCs and PICC lines placed|This group will have either Standard of Care (control) or Process Improvement infection control changes administered.
62730986|NCT02261064|EXPERIMENTAL|Telmisartan/Amlodipine low dose, fed|Telmisartan low dose/Amlodipine fixed-dose combination
62730987|NCT02261064|ACTIVE_COMPARATOR|Telmisartan/Amlodipine low dose, fasted|Telmisartan low dose/Amlodipine fixed-dose combination
62730988|NCT02261064|EXPERIMENTAL|Telmisartan/Amlodipine high dose, fed|Telmisartan high dose/Amlodipine fixed-dose combination
61978399|NCT02703389|ACTIVE_COMPARATOR|Pamphlet|Informative pamphlet containing the same information as the video.
62730989|NCT02261064|ACTIVE_COMPARATOR|Telmisartan/Amlodipine high dose, fasted|Telmisartan high dose/Amlodipine fixed-dose combination
62730990|NCT05677477|EXPERIMENTAL|Intervention/Treatment|In the implementation process of the research, knowledge tests will be applied as pre-test and post-test, and training will be given to the mother who has a baby with physiological jaundice. In the study, the scenario of the mother with a baby with jaundice will be implemented only with the intervention group
62730991|NCT05677477|NO_INTERVENTION|Control|During the application process of the research, knowledge tests will be applied as pre-test and post-test.
62730992|NCT02628405|EXPERIMENTAL|Treatment (R2-ICE)|Patients receive lenalidomide PO daily on days 1-14, rituximab IV on day 1, ifosfamide IV over 24 hours on day 2, carboplatin IV over 1-2 hours on day 2, and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CMR, PMR, or NMR may receive 2 more cycles per physician discretion. After completion of 2 cycles of R2ICE treatment, patients achieving objective status of CMR, PMR or NMR may proceed to SCT during the event monitoring phase.
62730993|NCT02508363|ACTIVE_COMPARATOR|Health Fair Alone (Control)|"No Follow Up Participant does not require referrals or assistance and was not advised to see a provider in the next three months.~Regular follow-up call within two weeks of health fair by IHCD intern or staff. Participant has abnormal values, requires referrals or assistance or was advised to see a provider in the next three months.~Up to 3 call attempts to get participant into needed care. Further contact only by participant request.~Urgent follow-up call or in-person assistance within 1 day of health fair by IHCD intern or staff Participant advised to seek urgent care within one week.~Three total call or in-person attempts to get participant into needed care. Further contact only by participant request The follow up call attempts may extend up to 3 months past the date of health fair to complete any needs the driver may have."
62730994|NCT02508363|EXPERIMENTAL|Health Fair + Navigator Case Management|"• Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.~Navigator Case Management by trained staff~* Tailored assistance for any health needs a minimum of once a month 12 months. Assistance includes pre-appointment reminder calls, post-appointment follow up calls, and health promotion reminders.~* NCM case management will continue follow-up at a minimum of once per month or as requested by the participant for the study duration and will consistently offer appointment reminders and follow-ups."
62730995|NCT02508363|EXPERIMENTAL|Health Fair + Taxi Health Improvement Promoters|"Health Fair standard services Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.~Taxi health Improvement Promoters (TIPs)~* Weekly check-ins with each participant, in person or by phone, about scheduling of, and attendance at, primary care appointments along with other health or study questions Mosio Text Messaging Program~* Send primary care provider recommendations to participant up to three times~* Two pre-appointment reminders \& one post-appointment check-in~* Twice weekly health promotion reminders after primary care appointment"
62730996|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
62730997|NCT00635141|EXPERIMENTAL|1|
62730998|NCT00635141|EXPERIMENTAL|2|
62730999|NCT03879928|PLACEBO_COMPARATOR|Placebo for SAD|Placebo comparator for SAD
62731000|NCT03879928|EXPERIMENTAL|FM101 75 mg for SAD|Single ascending doses of FM101
62731001|NCT03879928|EXPERIMENTAL|FM101 150 mg for SAD|Single ascending doses of FM101
62731002|NCT03879928|EXPERIMENTAL|FM101 300 mg for SAD|Single ascending doses of FM101
62731003|NCT03879928|EXPERIMENTAL|FM101 600 mg for SAD|Single ascending doses of FM101
62731004|NCT03879928|EXPERIMENTAL|FM101 1200 mg for SAD|Single ascending doses of FM101
62731005|NCT03879928|EXPERIMENTAL|FM101 2400 mg for SAD|Single ascending doses of FM101
62731006|NCT03879928|PLACEBO_COMPARATOR|Placebo for MAD|Placebo comparator for MAD
62731007|NCT03879928|EXPERIMENTAL|FM101 150 mg (QD) for MAD|Multiple ascending doses of FM101
62731008|NCT03879928|EXPERIMENTAL|FM101 450 mg (QD) for MAD|Multiple ascending doses of FM101
62731009|NCT03879928|EXPERIMENTAL|FM101 600 mg (BID) for MAD|Multiple ascending doses of FM101
62731010|NCT03879928|EXPERIMENTAL|FM101 300 mg under fasted condition for FE|Food Effect of FM101
62731011|NCT03879928|EXPERIMENTAL|FM101 300 mg under fed condition for FE|Food Effect of FM101
62731012|NCT03797066|OTHER|Single arm|"A phase 4, open label, non-randomised study, conducted in hostels and homeless shelters in London; as well as mobile clinics in collaboration with the Hep C trust and the NHS Find and Treat program.~Treatment: 12 or 16 weeks of Zepatier, based on genotypes; with Ribavarin for certain subtypes. The study drug is administered as a single tablet; which is a combination of 100 mg of grazoprevir and 50 mg of elbasvir; as outlined below:~Genotypes 1a/b and 4: once daily dose for 12 weeks, taken with / without food. Genotype 1a and 4: (HCV RNA\> 800,000 iu/ml or baseline NS5A resistance): once daily dose for 16 weeks, taken with / without food.~NO dose modifications with the study drug."
62731013|NCT05597358|ACTIVE_COMPARATOR|High Intensity Laser Therapy (HILT)|Active high intensity laser therapy for 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
62731014|NCT05597358|SHAM_COMPARATOR|Sham High Intensity Laser Therapy|Sham high-intensity laser therapy for 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
62731015|NCT01802593|EXPERIMENTAL|Immunomodulator therapy 26 weeks|IFX 5mg/kg for 76 weeks, continuing immunomodulator for 6 months from first infusion
62731016|NCT01802593|EXPERIMENTAL|Immunomodulator therapy 2 weeks|IFX 5mg/kg induction for 76 weeks, discontinuing immunomodulator on day of second infusion( after 14 days).
62731017|NCT06279117|EXPERIMENTAL|Therapeutic touch group|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
62731018|NCT06279117|NO_INTERVENTION|control group|No treatment will be performed on individuals in the control group.
62731019|NCT02594228|EXPERIMENTAL|Whey Protein and exercise training|Six meals per day of 20 grams of protein, two of which were whey protein and 4 days per week of exercise training..
62731020|NCT02594228|EXPERIMENTAL|Food Protein and exercise training|Six meals per day of 20 grams of protein, all of which were whole food protein and 4 days per week of exercise training.
62731021|NCT05779228|EXPERIMENTAL|Color Contrast|Test patch is surrounded spatially by different colors
62731022|NCT05779228|EXPERIMENTAL|Color Adaptation|Test patch is surrounded temporally (preceded) by different colors
61978400|NCT02703389|NO_INTERVENTION|No intervention|This is the reference standard currently.
62731023|NCT05779228|EXPERIMENTAL|Neuroimaging|Functional MRI and Electroencephelography data are acquired for multiple test colors
62731024|NCT05779228|EXPERIMENTAL|Red Room|Participants are tested in a red-illuminated room
62731025|NCT05779228|EXPERIMENTAL|Dark Room|Participants are tested in a completely darkened room
62731026|NCT05779228|EXPERIMENTAL|Gradual Change|Participants view a gradual change in tint, presented on a head-mounted display
62731027|NCT01266226|EXPERIMENTAL|ACP treated|The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
62731028|NCT01266226|PLACEBO_COMPARATOR|Control group|The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
61978401|NCT01338545||Cohort|
62731029|NCT05679596|EXPERIMENTAL|Exogenous ketone monoester (KET)|KET will be provided at a dose of 360 mg kg-1 body mass per serving at 2 servings per day between each main meal (ΔG®; TΔS Ltd, UK, Oxford, UK).
62731030|NCT05679596|ACTIVE_COMPARATOR|Energy matched control (CON)|CON will be provided at a dose energy matched to the KET supplement and consist of both carbohydrate (i.e., fructose) and fat (i.e., corn and canola oil 50:50 ratio). 1/3 of the supplemental energy will come from carbohydrate while 2/3 will come from fat. We have excluded protein from the CON supplement since it is well established to influence our primary outcome measure (MPS rates). A non-caloric sweetener will also be added to the CON supplement.
62731031|NCT01144624|EXPERIMENTAL|1|"AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1):~AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2)"
62731032|NCT01144624|PLACEBO_COMPARATOR|2|
62731033|NCT03869567|EXPERIMENTAL|Cone beam CT|A cone beam CT wll be performed just after thrombectomy on patients with acute ischemic stroke
62731034|NCT03277001|ACTIVE_COMPARATOR|Enoxaparin|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score \> 4
62731035|NCT03277001|EXPERIMENTAL|Rivaroxaban|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score \> 4
62731036|NCT04257643|EXPERIMENTAL|Experimental group|water-based exercise was conducted at a hydrotherapy pool for the Eden Heelth Care,Cairo The pool measures 8 × 15 m and ranges from 1 to 1.8 m in depth with access via steps. Interventions were conducted predominately in the deeper section of the pool so participants immerse their neck in water. Thermo neutral water temperature, 30-32 °C at room temperature. Females were instructed to adjust water depth completely covering clavicles from standing position. Diaphragmatic breathing during exercise routine to assist with lymph fluid clearance. Exercise continuously for 40 to 45 min Full-body warm-up exercise for 10 min and cooling down for 10 minutes. Plus land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.
62731037|NCT04257643|ACTIVE_COMPARATOR|Control group|Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles
62731038|NCT06429709||Algorithm Development|Ultrasound and signal information and visual otoscopic images will be collected with an engineering prototype otoscope device for children scheduled for tympanostomy tube surgery. Images of each of the child's ears will be taken by the advanced ultrasound otoscope device. Data collected will include ear laterality, surgical and lab findings of the effusion (present or absent) and characteristics as reported by the surgeon. The middle ear fluid which is usually suctioned will be collected in a trap chamber- Tympap- and this collected fluid will be send for analysis to microbiology. The pathology results will be recorded to correlate ultrasound signals to surgical findings
62731039|NCT06429709||Clinical Validation|The clinical validation phase includes the same procedures as the algorithm development phase only, the clinical validation phase is a double blind study where ultrasound score is compared to surgical findings and lab analysis.
62731040|NCT04573790||Trained in eFONA|Trained participants completed our eFONA workshop within the last six month prior to participating in this study
62731041|NCT04573790||Untrained in eFONA|Untrained participants had never taken part in our institutional eFONA workshop
62731042|NCT02226588|EXPERIMENTAL|Secondary prevention|Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
62731043|NCT02226588|ACTIVE_COMPARATOR|Universal prophylaxis|Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby
62731044|NCT03799952|EXPERIMENTAL|Intervention|Participants are offered to attend a 12-week exercise program, classes offered twice a week, each class 60 minutes in length.
62731045|NCT03799952|NO_INTERVENTION|Control|"Participants are instructed to continue with their daily activities and their normal physical activity levels for 12-weeks."
62731046|NCT06458621||Underweight group (A):|This group will be underweight group according to BMI- for age percentile growth chart ranged from BMI-for-age \< 5th percentiles.
62731047|NCT06458621||Normal weight group (B):|This group will be with normal weight according to BMI- for age percentile growth chart which ranged from BMI-for-age 5th to 85th percentiles
62731048|NCT06458621||Overweight group (C):|This group will be an overweight group according to BMI- for age percentile growth chart which ranged from BMI-for-age 85th to 95th percentiles
62731049|NCT06458621||Obese group (D):|This group will be obese group according to BMI- for age percentile growth chart which ranged from BMI-for-age \> 95th percentiles and \<99th percentile
62731050|NCT04615624|EXPERIMENTAL|Furosemide|When patient meets inclusion criteria and is randomized to treatment drug, she receives 40mg /4 milliliters (mL) IV furosemide in addition to usual antihypertensive.
62731051|NCT04615624|PLACEBO_COMPARATOR|Placebo|When patient meets inclusion criteria and is randomized to placebo, she receives one dose of 4mL normal saline in addition to usual antihypertensive.
62731052|NCT05242835|ACTIVE_COMPARATOR|biliopancreatic diversion with duodenal switch|Patient randomized for a the standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
62731053|NCT05242835|EXPERIMENTAL|Single-anastomosis duodeno-ileal anastomosis|Patient randomized for a single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
62731054|NCT02008942|EXPERIMENTAL|PL2200 Aspirin Capsules|PL2200 Aspirin Capsules
62731055|NCT02008942|ACTIVE_COMPARATOR|Enteric-coated aspirin caplets|Enteric-coated aspirin caplets
62731056|NCT02998879|EXPERIMENTAL|Velmanase Alfa|velmanase alfa 1mg/kg body weight infusion
62731057|NCT01160393|OTHER|Miniaturized bypass system|Miniaturized bypass system and the incidence of atrial fibrillation after cardiac surgery
62731058|NCT03083665|PLACEBO_COMPARATOR|Placebo|"* 12 weeks Treatment Period: Subjects will receive Placebo~* 4 weeks Down-Titration Period: Subjects will receive Placebo"
61978265|NCT04882267|NO_INTERVENTION|Determination of baseline exercise activity (Baseline Period)|Adults with CF who identify as 'willing to use technology' and own compatible smart phones/tablets will undergo the Short General Health Questionnaires (GHQ 12) to establish baseline levels of general and mental health. Subjects will be fitted with wrist actigraphy and monitored for four weeks to establish baseline levels of exercise activity at home. Anticipated outcomes: Access to actigraphy will encourage personal accountability, and physical activity will increase during the first two weeks before reaching a plateau.
62731059|NCT03083665|EXPERIMENTAL|BRV 50 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 50 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period"
62731060|NCT03083665|EXPERIMENTAL|BRV 200 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 200 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period"
62731061|NCT06080763||Non-Responders|Individuals who do not respond to physical therapy are determined by the absence of significant improvements, with no change in pain or function exceeding 50%, and with an absolute change of less than 20%.
62731062|NCT06080763||Responders|Individuals who respond to physical therapy are determined by the presence of significant improvements, with changes in pain or function exceeding 50%, and with an absolute change of more than 20%.
62731063|NCT04725045|ACTIVE_COMPARATOR|Standard clinical pulse shape|Standard clinical pulse shape as used in clinical practice (cathodic stimulation).
62731064|NCT04725045|EXPERIMENTAL|Complex pulse shape|Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse)
62731065|NCT05456997||Cushings syndrome|Patients with Cushing's syndrome treated medically prior to adrenalectomy
62731066|NCT05456997||Phaeochromocytoma and paraganglioma (PPGL)|Patients with PPGL treated medically prior to adrenalectomy
62731067|NCT05456997||Conn's syndrome|Patients with Conn's syndrome treated medically prior to adrenalectomy
62731068|NCT04145726||Patients undergoing esophageal resection|All patients undergoing esophageal resection will be included and tested if frail or non-frail. Which means there is no intervention
62731069|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
62731070|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
62731071|NCT00613548|ACTIVE_COMPARATOR|1|CABG Alone
62731072|NCT00613548|ACTIVE_COMPARATOR|2|CABG + Mitral repair
62731073|NCT06472323||PRF+PRP|The puncture point was located 3cm outside the corners of the mouth of the affected side, using the Hartel technique. Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion. After accurately puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times. After removing the RF electrode in the combined treatment group, 2 ml of LP-PRP mixture was injected slowly into the Gasserian ganglion and mandibular nerve.
62731074|NCT06472323||PRF|The puncture point was located 3cm outside the corners of the mouth of the affected side, using the Hartel technique. Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion. After accurately puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times.
62731075|NCT05231759||Navigable Percutaneous Plasma Disc Decompression (L'DISQ)|The L'DISQ (U\&I Co., Uijeongbu, Korea) is one of the minimally invasive disc decompression procedures which was introduced in 2011. The L'DISQ uses a navigable tip and flexible handle allowing resection of the posterolateral or posterior median disc tissue without thermal damage.
62731076|NCT02254044|EXPERIMENTAL|bivatuzumab mertansine|dose escalation
62731077|NCT02669394|EXPERIMENTAL|Resistance Training (RT)|"The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
62731078|NCT02669394|ACTIVE_COMPARATOR|Stretching and Relaxation (CON)|"The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
62731079|NCT00579553|ACTIVE_COMPARATOR|Intramuscular Progesterone|Intramuscular Progesterone
62731080|NCT00579553|EXPERIMENTAL|Vaginal Progesterone|Vaginal Progesterone
62731081|NCT02656966|ACTIVE_COMPARATOR|Auricular acupuncture + standard therapy|Patients, who will wish acupuncture, will receive this intervention, in addition to standard therapy
62731082|NCT02656966|NO_INTERVENTION|Standard therapy alone|Patients who do not wish acupuncture will be asked if they will fill in the study questionnaire
62731083|NCT04338607||All study patients|All study patients will be in one group.
62731084|NCT03783962|EXPERIMENTAL|Active Intervention - Cooking|Twelve cooking classes will be run every other week after the in-person weight loss meetings. These lessons will be patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for individuals specifically interested in weight loss. Classes will begin with a brief lecture on the day's topic, followed by a laboratory session. Participants work in teams of two in the Nutrition and Food Sciences (NFS) foods lab to actively practice skills and cook a meal. Subjects will receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. Classes will be taught by a chef trained in the pedagogy by Dr. Trubek and participants will have the opportunity to sample the food they prepared at the end of class.
62731085|NCT03783962|ACTIVE_COMPARATOR|Demonstrations - Cooking|"The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All participants will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."
62731086|NCT00993863|PLACEBO_COMPARATOR|Placebo|
62731087|NCT00993863|EXPERIMENTAL|ADL5859 30 mg|
62731088|NCT00993863|EXPERIMENTAL|ADL5859 100 mg|
62731089|NCT00993863|EXPERIMENTAL|ADL5859 200 mg|
62731090|NCT00993863|ACTIVE_COMPARATOR|ibuprofen 400 mg|
62731091|NCT05365789|ACTIVE_COMPARATOR|Study Device and Standard of Care|"1 to 2 sprays per nostril of Sterimar Blocked Nose Baby for a minimum of 2 times (morning and evening) and, as needed, up to a maximum of 6 times per day (i.e. maximum 12 sprays per nostril each day) until nasal symptoms are resolved, up to a maximum of 10 days.~Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary."
62731092|NCT05365789|OTHER|Standard of Care|Standard of care consists of hydration, rest at home and antipyretic medication paracetamol as necessary.
62731093|NCT00548626|ACTIVE_COMPARATOR|A|Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
62731094|NCT00548626|EXPERIMENTAL|B|Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
62731095|NCT02544867|EXPERIMENTAL|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies \[17,18\] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
62731096|NCT02544867|EXPERIMENTAL|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions \[26-28\]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
62731097|NCT05388604|EXPERIMENTAL|Treatment|Subjects are to be treated with the RF device, followed by the microneedling device. Parameters may be adjusted throughout the treatment and will determined by the Clinician. Subjects will receive up to 4 treatments, spaced approximately 4 weeks apart.
62731098|NCT03798639|EXPERIMENTAL|Arm I (nivolumab, radiation therapy)|Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
62731099|NCT03798639|ACTIVE_COMPARATOR|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes at week 0. Treatments repeat every 2 weeks for nivolumab and 6 weeks for ipilimumab for up to 1 year in the absence of disease progression or unacceptable toxicity.
62731100|NCT03838211|EXPERIMENTAL|stimulation group|Anodal tDCS + intensive cognitive Training
62731101|NCT03838211|SHAM_COMPARATOR|sham group|Sham tDCS + intensive cognitive Training
62731102|NCT01632592|EXPERIMENTAL|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
62731103|NCT01632592|PLACEBO_COMPARATOR|Placebo|
62731104|NCT06044233|EXPERIMENTAL|TR group|Subjects in the TR group will take the test preparation (T) 200 mg/ pill × 1 pill on day 1 (D1) and the reference preparation (R) 200 mg/ pill × 1 pill on day 8 (D8).
62731105|NCT06044233|EXPERIMENTAL|RT group|Subjects in the RT group will take the reference preparation (R) 200 mg/ pill × 1 pill on day 1 (D1) and the test preparation (T) 200 mg/ pill × 1 pill on day 8 (D8).
62731106|NCT06227312|EXPERIMENTAL|warm-up intervention|"Each participant performed all warm-up variants one week apart, without the possibility of repeating:~CTRL 5 sets of 30 s calf raises on the platform but without vibration with 30 s rest intervals between sets; WBV 5 sets of 30 s calf raises on the vibration platform with 30 s rest intervals between sets; DJ 6 modified drop jump with a 30 s rest interval between sets (DJ); WBV + DJ 5 sets of 30 s calf raises on the vibration platform followed by 6 drop jumps with a 30 s rest interval between sets"
62731107|NCT06003218|EXPERIMENTAL|Dexmedetomidine-esketamine combined with oxycodone|Dexmedetomidine-esketamine combination will be infused in addition to oxycodone; the target is to maintain a Richmond Agitation and Sedation Scale between -2 and -1 during surgery.
62731108|NCT06003218|ACTIVE_COMPARATOR|Remifentanil combined with oxycodone|Remifentanil will be infused in addition to oxycodone; the target is to maintain a Richmond Agitation and Sedation Scale between -2 and -1 during surgery.
62731109|NCT05719779|ACTIVE_COMPARATOR|MAD-active|MAD = mandibular advancement appliance, in 60-70% forward position from maximum possible jaw advancement for a given participant
62731110|NCT05719779|SHAM_COMPARATOR|Neutral MAD- control|Mandibular advancement appliance in neurtral-control position, 10-20% of advancement - a non functional position to open upper airway
62731111|NCT05978674|EXPERIMENTAL|Experimental Group: rocking bed group|Preterms in the intervention group will lie in a rocking bed for a consecutive two-hour period without treatment and invasive procedures. During 30 minutes of this period, the rocking bed will be in the rocking mode and will stop at the end of 30 minutes.
62731112|NCT05978674|NO_INTERVENTION|Control Group|Newborns in the control group will be followed in a fixed bed (open bed or incubator).
62731113|NCT04279119|EXPERIMENTAL|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks
62731114|NCT02144571|EXPERIMENTAL|Lifestyle|Diet and physical activity intervention group. Measurements taken at baseline, 12 weeks and 1 year.
62731115|NCT02144571|NO_INTERVENTION|Wait-list control|No-treatment control group. Measurements taken at baseline, 12 weeks and 1 year. People in the control condition can elect to take the intervention after 1 year.
62731116|NCT05265858||Patients with hip osteoarthritis|Patients with hip osteoarthritis who will undergo total hip arthroplasty
62731117|NCT02134561|OTHER|All subjects|psychological interview, MRI, neurological tests, cognitive tests
62731118|NCT04444271|EXPERIMENTAL|Mesenchymal stem cells|10 patients will be given mesenchymal stem cells at dose 2x10\^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
62731119|NCT04444271|PLACEBO_COMPARATOR|Placebo|Only supportive care will be given to 10 patients
62731120|NCT00720967|ACTIVE_COMPARATOR|1|Control Group (Open heart surgery alone)
62731121|NCT00720967|EXPERIMENTAL|2|Intraoperative Modified Ultrafiltration (MUF) Group (Open heart surgery with intraoperative MUF)
62731122|NCT00720967|EXPERIMENTAL|3|Preoperative Hemodialysis Group (Open Heart Surgery after preoperative hemodialysis)
62731123|NCT01692743|NO_INTERVENTION|Standard of Care|Participants undergo usual follow up (routine and as needed office visits and telephone calls) and receive educational fact sheets from the Crohn's and Colitis Foundation of America.
62731124|NCT01692743|EXPERIMENTAL|Weekly Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
62731125|NCT01692743|EXPERIMENTAL|Home Monitoring Every Other Week|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
62731126|NCT01958255|OTHER|Tobacco cessation counseling|planned intervention for tobacco cessation counseling
62731127|NCT05107063||Dyslipidemic participants with Type 2 diabetes|Dyslipidemic participants with Type 2 diabetes who received a routine initiation dose of pravastatin 10 mg, 20 mg or 40 mg single dose once daily and maintained a low cholesterol diet throughout the study period.
62731128|NCT03292003||Journey II BCS Total Knee System|Subjects having TKA with Journey II BCS Total Knee System
62731129|NCT01413711|EXPERIMENTAL|Vigabatrin|
62731130|NCT01448889|ACTIVE_COMPARATOR|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
62731131|NCT01448889|PLACEBO_COMPARATOR|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
62731132|NCT04780802|OTHER|Ballloon catheter|Balloon-assisted transarterial therapy will be performed in the first treatment session only
62731133|NCT03822143|EXPERIMENTAL|Fetus anemia diagnosis|Diagnosis of anemia in the fetus through use of ultrasound data collection
62731134|NCT03019523|PLACEBO_COMPARATOR|Sugar Pill|Maltodextrin (\~2 grams to match weight of active treatment) placebo pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
62731135|NCT03019523|ACTIVE_COMPARATOR|Caffeine Blend|75 mg caffeine, 75 mg theanine, and 2g tyrosine pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
62731136|NCT02742233|EXPERIMENTAL|saxagliptin|"saxagliptin \& Regular treatment:~saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd"
62731137|NCT02742233|PLACEBO_COMPARATOR|placebo|"placebo \& Regular treatment:~placebo, dose: 5mg, po, qd"
62731138|NCT03857932|EXPERIMENTAL|SLNB and non-slns resection|"1. Participants only receive SLNB~2. preoperative CT lymphography~3. SLNB with stained non-SLN resection~4. SLNB with ARM dissection"
62731139|NCT03857932|EXPERIMENTAL|SLNB group|Participants only receive SLNB
62731140|NCT00147017||Smokers|All subjects had a smoking history of \>15 pack years
62731141|NCT00147017||Ex-smokers|Ex-smokers had ceased smoking for \>6 months.
62731142|NCT00147017||Emphysema lung transplant|The emphysema subjects were all undergoing lung transplants.
62736267|NCT05587179|EXPERIMENTAL|Lateral side-lying recovery position with extended arm|The lateral side-lying recovery position with extended arm is directly based on the revised 2021 ERC guidelines recommending to extend the dependent arm and placing it next to the creased upper lying arm, which supports the head.
62736268|NCT05587179|ACTIVE_COMPARATOR|Lateral side-lying recovery position with bent arms|In the lateral side-lying recovery position with bent arms, the elbow of the dependent arm will now be bent with palm up and the far knee still flexed.
62736269|NCT01756573|ACTIVE_COMPARATOR|Bupivacaine|Control
62731143|NCT05634824|EXPERIMENTAL|IVIg plus low dose rhTPO|Patients were randomized into experimental and control groups. For the experimental patients, the initial combination therapy consisted rhTPO at an initial does of 150U/kg once daily subcutaneously for 28 days and IVIg 400mg/kg per day for 5 days. If the platelet count was in the range of 30 to 50 × 10\^9/L, the combination therapy was repeated. To reduce the risk for thrombocytosis, patients received maintenance therapy consisting rhTPO at a dose of 150U/kg per day if the platelet count rose above 50 × 10\^9/L, and treatment discontinued when platelet counts exceeded 100 × 10\^9/L. After delivery, the treatment consisted rhTPO 150U/kg per day, and maintained the dose if the platelet count exceeded 30 × 10\^9/L. In addition, IVIg 400mg/kg per day for 5 days was added if the platelet count could not maintain above 30 × 10\^9/L. If patients did not achieve 30 × 10\^9/L within 4 weeks treatment was also discontinued.
62731144|NCT05634824|ACTIVE_COMPARATOR|IvIg treatment|Patients would be treated with IVIg 400mg/kg per day for 5 days monthly. And treatment discontinued when platelet counts exceeded 100 × 10\^9/L.
62731145|NCT03804892|EXPERIMENTAL|Acipimox ingestion|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
62731146|NCT03804892|OTHER|No drug|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
62731147|NCT03576781|EXPERIMENTAL|Real iTBS to the DLPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
62731148|NCT03576781|SHAM_COMPARATOR|Sham iTBS to the DLPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
62731149|NCT03576781|EXPERIMENTAL|Real cTBS to the MPFC|One session of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
62731150|NCT03576781|SHAM_COMPARATOR|Sham cTBS to the MPFC|One session of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
62731151|NCT02485509|EXPERIMENTAL|20 mg VM-1500/Placebo Healthy group|VM-1500 20 mg or placebo single dose.
62731152|NCT02485509|EXPERIMENTAL|40 mg VM-1500/Placebo Healthy group|VM-1500 40 mg or placebo single dose.
62731153|NCT02485509|EXPERIMENTAL|20 mg VM-1500/Placebo Patient group|VM-1500 20 mg or placebo once daily for 7 days.
62731154|NCT02485509|EXPERIMENTAL|40 mg VM-1500/Placebo Patient group|VM-1500 40 mg or placebo once daily for 7 days.
62731155|NCT03660592||operator 1|ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
62731156|NCT03660592||operator 2|a different ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
62731157|NCT06005558|ACTIVE_COMPARATOR|Normal saline|30 patients will receive placebo of 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of Nacl for 72 hours.
62731158|NCT06005558|ACTIVE_COMPARATOR|methylene blue low dose|30 patients will receive a bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
62731159|NCT06005558|ACTIVE_COMPARATOR|methylene blue high dose|30 patients will receive a bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
62731160|NCT02480088|EXPERIMENTAL|ramosetron|patients receiving ramosetron for prophylaxis of postoperative nausea and vomiting
62731161|NCT02480088|ACTIVE_COMPARATOR|palonosetron|patients receiving palonosetron for prophylaxis of postoperative nausea and vomiting
62731162|NCT03475446|PLACEBO_COMPARATOR|sham tES healthy elderly|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
62731163|NCT03475446|PLACEBO_COMPARATOR|sham tES MCI|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
62731164|NCT03475446|PLACEBO_COMPARATOR|sham tES AD|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
62731165|NCT03475446|EXPERIMENTAL|real anodal tDCS healthy elderly|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62731166|NCT03475446|EXPERIMENTAL|real anodal tDCS MCI|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62736270|NCT01756573|EXPERIMENTAL|Bupivacaine with Dexamethasone|Dexamethasone will be mixed with bupivacaine
62736271|NCT01756573|ACTIVE_COMPARATOR|Intravenous Dexamethasone|Dexamethasone will be given intravenously
61978381|NCT03484884||Thyroid cancer/nodal metastasis|Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
62731167|NCT03475446|EXPERIMENTAL|real anodal tDCS AD|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62731168|NCT03475446|EXPERIMENTAL|real tACS healthy elderly|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62731169|NCT03475446|EXPERIMENTAL|real tACS MCI|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62731170|NCT03475446|EXPERIMENTAL|real tACS AD|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
62731171|NCT01404728||Pelvic Malignancies|Women with Vaginal Stenosis
62731172|NCT03700840|OTHER|Clinical examination and sample|"Cross-sectional observational study~Measure of 6 indices:~* Bleeding on Intergental Brush Index (BOIB)~* Gingivitis Score (GI)~* Plaque index score (PI)~* ICDAS~* Salivary test~Individual caries risk assessment~Determination of interdental brushes adapted to each interdental site~Recovery of the interdental brush passed through the 4 sites (between 15-16, 25-26, 35-36, 45-46) on which the interdental biofilm was fixed during the passage in the interdental space.~The interdental brush is immediately put in a sterile tube and then sent in dry ice to maintain the integrity of the genetic material.~Quantitative PCR experiments will be performed and a qualitative and quantitative analysis of the interdental flora will be made."
62731173|NCT03584048||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, residing in the Charlotte Metropolitan Area and with at least a single entry in the EHR in the last 2 years.
62731174|NCT06006936|EXPERIMENTAL|Intervention Condition|This arm will receive the Coping with Infertility intervention.
62731175|NCT06006936|NO_INTERVENTION|Waitlist/Treatment as Usual Control Condition|This arm will continue with everyday life-including their attempts to conceive.
62731176|NCT01292122|EXPERIMENTAL|VCT-01-treated STSG donor site wound|Application of VCT-01 to STSG donor site wound at Day 0
62731177|NCT04538599|EXPERIMENTAL|RD13-01 cell infusion|
62731178|NCT04930146|EXPERIMENTAL|Intervention group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~1. Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~2. Evaluating the meridian energy by M.E.A.D"
62731179|NCT04930146|NO_INTERVENTION|Control group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~1. Conventional treatment.~2. Evaluating the meridian energy by M.E.A.D"
62731180|NCT04930146|EXPERIMENTAL|Intervention group (Moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~1. Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~2. Evaluating the meridian energy by M.E.A.D"
62731181|NCT04930146|NO_INTERVENTION|Control group (moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~1. Conventional treatment.~2. Evaluating the meridian energy by M.E.A.D"
62731182|NCT01798147|ACTIVE_COMPARATOR|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
62731183|NCT01798147|EXPERIMENTAL|SIRT|Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)
62731184|NCT04185077|EXPERIMENTAL|Experimental|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
62731185|NCT04185077|ACTIVE_COMPARATOR|Control|a bolus dose of 100 U/kg Heparin was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
62731186|NCT02954887|EXPERIMENTAL|GWP42003-P|"Administered orally, up to the target dose recommended by the data safety monitoring committee.~Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment."
62731187|NCT04073862|OTHER|Stepped-Care TF-CBT|The study participants will receive Stepped-Care Trauma-Focused Cognitive-Behavioral-Therapy (SC-TF-CBT).
62731188|NCT00383331|EXPERIMENTAL|A|
62731189|NCT00383331|EXPERIMENTAL|B|
62731190|NCT05339399||4 cm cervical os dilatation|Low risk women with cervical os dilatation of 4 cm at amniotomy and whether they need oxytocin augmentation and analgesia.
62731191|NCT05339399||6 cm cervical os dilatation|Low risk women with cervical os dilatation of 6 cm at amniotomy and whether they need oxytocin augmentation and analgesia.
62731192|NCT01546233||multidisiplinary self care program|Patient with Lung cancer will be participated in group education with multidisiplinary self care program
62731193|NCT01546233||Conventional education|Lung cancer patient will be received standard education
62731194|NCT05480982|EXPERIMENTAL|Cognitive functional therapy (CFT) via tele rehabilitation|"Cognitive Functional Therapy (CFT) is a physiotherapy-led intervention which has evolved from an integration of foundational behavioral psychology and neuroscience within the physiotherapy practice directed at the multidimensional biopsychosocial nature of low back pain. The clinical journey is adapted to the individual's profile following three main components: (i) making sense of pain, (ii) exposure with control and (iii) lifestyle changes.~The first 2 one-hour treatment sessions of CFT will be delivered individually and via videoconference in a weekly basis. The following one-hour treatment sessions (from 6 to 9 sessions) will be delivered in groups (up to 6 participants). One group booster session will be delivered 20 weeks after randomization"
62736272|NCT06660758|EXPERIMENTAL|Healthy Adults|An Entarik feeding tube will be introduced and subjects will receive a meal administered through the feeding tube. Ultrasound and other data will be recorded before, during and after the meal is administered.
62736273|NCT04166370|ACTIVE_COMPARATOR|Standard of Practice|Current Standard of Practice
62731195|NCT05480982|ACTIVE_COMPARATOR|Pilates|"Participants in the comparison group will receive Pilates method using classic principles and exercises recommended by Joseph Pilates. No specific accessories or equipment will be used, allowing the exercises to be performed under any circumstances. Based on Pilates, 10 exercises were selected: Leg Pull Front, One Leg Circle, One Leg Kick, One leg stretch, Shoulder bridge, Side bend, Spine Stretch , Swimming, The hundred and The Saw. The main objective of the exercises is to improve physical capacities, including mobility, flexibility, muscle strength and activation of the power house center of force, with the therapeutic aim of a positive evolution of chronic non-specific low back pain. The one-hour sessions will be delivered once a week. Participants will be instructed to perform the set of exercises once a week without the supervision of the physiotherapist. The number of group sessions (up to 6 participants) will vary between 8 to 12."
62731196|NCT00633087|EXPERIMENTAL|2-deoxyglucose|
62731197|NCT02812238|EXPERIMENTAL|Arm 1|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
62731198|NCT02812238|EXPERIMENTAL|Arm 2|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
62731199|NCT05415423|ACTIVE_COMPARATOR|Study 1 Low-Intensity Group|Control group which receives less intense electrical stimuli than the other.
62731200|NCT05415423|EXPERIMENTAL|Study 1 High-Intensity Group|Group which receives more intense electrical stimuli than the other.
62731201|NCT05415423|ACTIVE_COMPARATOR|Study 2 Low-Intensity Group|Control group which receives less intense heat stimuli than the other.
62731202|NCT05415423|EXPERIMENTAL|Study 2 High-Intensity Group|Group which receives more intense heat stimuli than the other.
62731203|NCT05415423|PLACEBO_COMPARATOR|Study 3 Placebo group|A group that receives a placebo cream.
62731204|NCT05415423|EXPERIMENTAL|Study 3 Painkiller group|A group that receives a topical analgesic such as EMLA cream.
62731205|NCT05415423|NO_INTERVENTION|Study 4 test-retest reliability group|Participants who participated in either Study 1 or 2 are recruited. They will experience both electrical and heat stimuli.
62731206|NCT01693250|EXPERIMENTAL|fitbit ultra|Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
62731207|NCT01693250|ACTIVE_COMPARATOR|Pedometer|After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
62731208|NCT05009576|ACTIVE_COMPARATOR|vac with silver|wounds of patients will be covered with a vac dressing with single layer of Ag+ hydrocolloid dressings. Such pattern of dressing will be followed in every change of dressing in 48 hours.
62731209|NCT05009576|ACTIVE_COMPARATOR|simple VAC without silver alginate|wounds of patients will be covered with VAC dressings only. Such pattern of dressing will be followed in every change of dressing in 48 hours.
62731210|NCT06502522|EXPERIMENTAL|Intervention group|Whole-body neuromuscular electrical stimulation will be administered for three times week for eight weeks, totaling 24 sessions.
62731211|NCT06502522|NO_INTERVENTION|Control group|No intervention will be carried out.
62731212|NCT00382265|ACTIVE_COMPARATOR|Tamsulosin|Tamsulosin 0.4mg PO qd for 28 days
62731213|NCT00382265|PLACEBO_COMPARATOR|Placebo|Placebo PO qd for 28 days
62731214|NCT02596256|EXPERIMENTAL|control group|Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
62731215|NCT02596256|ACTIVE_COMPARATOR|contrast group|Docetaxel (60mg/m2, i.v. d1 q21d)
62731216|NCT02277574|EXPERIMENTAL|Crossover Group 1|Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo
62731217|NCT02277574|EXPERIMENTAL|Crossover Group 2|Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week
62731218|NCT00422877|EXPERIMENTAL|Taxoprexin|Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.
62731219|NCT02194946|ACTIVE_COMPARATOR|CKD-related management group|"Patients in basic care group are provided with basic western medicine treatment according to Kidney Disease: Improving Global Outcomes(KDIGO) and The National Kidney Foundation Kidney Disease Outcomes Quality Initiative(KDOQI) guidelines but not prescribed any Chinese herbal medicine.~The basic western medicine treatment mainly includes dietary protein restriction(0.6g/kg·d, for Chinese), Blood pressure control, treating anemia with erythropoietin,treatment of abnormal calcium-phosphate metabolism, and treatment of fluid, electrolyte and acid-base disorders."
62731220|NCT02194946|EXPERIMENTAL|CM therapies group|Participants will receive CM therapies and CKD-related management concurrently. One or several the following CM patterns will be allowed: a. Chinese herbal formula via oral administration; b. Chinese patent medicine via oral administration; c. Chinese herbal formula via colonic administration; d. Chinese patent medicine via colonic administration.
62731221|NCT03136653|EXPERIMENTAL|Single arm Study MP0250 plus BOR + DEX|Single arm study of MP0250 plus bortezomib + dexamethasone
62731222|NCT03542266|EXPERIMENTAL|CC486 +CHOP|CC486 +CHOP
62731223|NCT02807220|EXPERIMENTAL|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
62731224|NCT00187538|ACTIVE_COMPARATOR|1|
62731225|NCT00187538|ACTIVE_COMPARATOR|2|
62731226|NCT00187538|ACTIVE_COMPARATOR|3|
62731227|NCT00187538|ACTIVE_COMPARATOR|4|
61978382|NCT02867189|EXPERIMENTAL|atlas of micro-instrument|anterior chamber cell counts and visual and intraocular pressures on postoperative days 1,3,7,14 by atlas of micro-instrument training method.
62731228|NCT01545297|ACTIVE_COMPARATOR|Propofol-Remifentanil|Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
62731229|NCT01545297|EXPERIMENTAL|Dexmedetomidine|Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
62731230|NCT04614012|EXPERIMENTAL|hyperimmune plasma|treated with hyperimmune plasma
62731231|NCT02391311|ACTIVE_COMPARATOR|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
62731232|NCT02391311|EXPERIMENTAL|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
62731233|NCT03353038|ACTIVE_COMPARATOR|Off-The-Shelf Pillbox vs 3D Printed Pillbox|Participants in the study were pillbox users at baseline. Participants described their experiences and preferences with their own pillbox. Then participants will be given a 3D printed pillbox. Researchers will compare participants' experiences and preferences between their off-the-shelf pillbox used at baseline and the customized 3D printed pillbox delivered to participants as part of the study.
62731234|NCT04152954|ACTIVE_COMPARATOR|Traditional cannula|Cervical Medial Branch Radiofrequency Neurotomy using a conventional cannula, the patient lying prone with a posterior approach.
62731235|NCT04152954|EXPERIMENTAL|Multi-tined cannula|Cervical Medial Branch Radiofrequency Neurotomy using a Multi-Tined cannula, the patient lying in lateral decubitus with a lateral approach
62731236|NCT05353114|NO_INTERVENTION|Standard Therapeutic Footwear prescription group|1) Patients that will acquire the therapeutic footwear size and model according to aesthetic preferences
62731237|NCT05353114|EXPERIMENTAL|Therapeutic Footwear prescription based on a 3D Foot scanner|2) Patients that will acquire a specific size and model according to result of a novel mobile app 3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).
62731238|NCT05147753|EXPERIMENTAL|Group|0.6 mg moxonidine daily
62731239|NCT03773900|EXPERIMENTAL|Chitin-Glucan supplementation|
62731240|NCT03773900|PLACEBO_COMPARATOR|Placebo supplementation|
62731241|NCT04113356||ST-Elevation Myocardial Infarction|Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
62731242|NCT05657899|ACTIVE_COMPARATOR|Cerclage|Intervention by cerclage fixation.
62731243|NCT05657899|ACTIVE_COMPARATOR|Tension Band Wiring|Intervention by tension band wiring
62731244|NCT04538300|ACTIVE_COMPARATOR|Group Gum|"Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.~Degree of nausea and Abramowitz Emezis score were evaluated as the interventions. If PONV persists second chewing gum was gived. 15 minutes later PONV was evaluated. If PONV was persisted ondansetron 4 mg, then dexamethasone 4 mg , then propofol 10 mg intravenously were given, respectively."
62731245|NCT04538300|ACTIVE_COMPARATOR|Group Control|In Group Control, Degree of nausea and Abramowitz Emezis score were evaluated as the interventions in recovery room. If patients with moderate and severe nausea were given 4 mg ondansetron intravenously. If PONV continues, we planned to give dexamethasone 4 mg and propofol 10 mg intravenously, respectively.
62731246|NCT05797051||diabetic nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
62731247|NCT05797051||minimal change nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
62731248|NCT05797051||IgA nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
62731249|NCT05797051||idiopathic membranous nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
62731250|NCT06374680||C3 laminectomy|laminectomy at C3 level and laminoplasty at C4-6 level
62731251|NCT06374680||C3 laminoplasty|laminoplasty at C3-6 level
62731252|NCT02364037|OTHER|Phase 1: Enhanced Care|Women in Phase 1 of the prospective study will receive the CHOICE Project structured contraceptive counseling in addition to usual care by their health care provider. Contraceptive coverage will be by the usual mechanism such as insurance or financial assistance programs.
62731253|NCT02364037|OTHER|Phase 2: Complete CHOICE|Women in Phase 2 of the prospective study (Complete CHOICE) will receive the CHOICE Project structured contraceptive counseling. Immediately prior to the start of Phase 2, health care providers in participating health centers will undergo a contraceptive education session with a focus on evidence-based guideline for LARC provision and same-day insertion. Participating women will receive cost support for IUDs and implants if she chooses either as her contraceptive method and does not have appropriate insurance coverage.
62731254|NCT01364129|EXPERIMENTAL|Telemedicine|Participants in this group have digital images of their retina captured with a non-mydriatic camera and are encouraged to see an eye care provider yearly.
62731255|NCT01364129|NO_INTERVENTION|Traditional Surveillance|Participants in this group are encouraged to see an eye care provider each year for a diabetic eye exam.
62731256|NCT05551793|EXPERIMENTAL|Dupilumab|Dupilumab: weekly 300mg SC injections Manufacturer: Regeneron
62731257|NCT05551793|PLACEBO_COMPARATOR|Placebo|Placebo: weekly SC injections of equivalent volume Manufacturer: Regeneron
62731258|NCT00413673|EXPERIMENTAL|1|PRK
62731259|NCT02381314|EXPERIMENTAL|enoblituzumab plus ipilimumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
62731260|NCT02645565|ACTIVE_COMPARATOR|Low dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
62731261|NCT02645565|ACTIVE_COMPARATOR|High Dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
62731262|NCT02140606|EXPERIMENTAL|Cafusertib Hydrochloride + Cytarabine|Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.
62731263|NCT04901806|EXPERIMENTAL|Phase 1 Dose Escalation|
62731264|NCT04901806|EXPERIMENTAL|Phase 2 Cohort Expansion|
62731265|NCT03121300||High Risk Lung Cancer Patients|
62731266|NCT02317497|EXPERIMENTAL|Moderate sedation (M)|1. Moderate sedation defined by target RASS of \>= -3. The intervention (M) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of \>= -3 (patient responds to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be deepened below the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the intervention group again.
62731267|NCT02317497|ACTIVE_COMPARATOR|Deep sedation (D)|2. Deep sedation defined by target RASS of \< -3. The control (D) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of \< -3 (patient does not respond to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be reduced above the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the control group again.
62731268|NCT05965245|EXPERIMENTAL|Suubi-Mhealth|Participants in this condition will receive the Suubi-Mhealth intervention delivered via a smart phone app.
62731269|NCT05965245|OTHER|Waitlist Control|Participants in this condition will receive the Suubi-Mhealth intervention after the active treatment group. They will also receive a smart phone without the Suubi-Mhealth app at the same time as the intervention group.
62731270|NCT06013722|EXPERIMENTAL|Patients of groups III and IV|Patients who are categorized after calcium score determination as presenting an intermediate risk to produce atheromatous plaques (group III : between the 40th percentile and the 65th percentile) or presenting a high risk to produce such plaques (group IV: \>65th percentile).
62731271|NCT04209023|EXPERIMENTAL|navigated TMS|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest; these areas will provide the cerebral coordinates to be validated by TMS.
62731272|NCT02244307||Patients with BPH treated with alpha-andrenergic blockade|
62731273|NCT03925272|EXPERIMENTAL|Patients with Suppurated Hidradenitis|"Human biological samples :~Whole blood and derived products (DNA, RNA), urine, stool, saliva, tears, skin and mouth swabs, lesion samples: swab for microbiological analyzes, cutaneous biopsies (lesion skin and peri-lesional healthy skin), surgical lesion excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: Ethno-geographical, family and personal antecedents and current events in particular related to Verneuil's disease and any associated diseases (chronic auto-inflammatory ...)"
62731274|NCT03925272|EXPERIMENTAL|Patients with Alzheimer disease|"Human biological samples :~stool, blood (20 ml), nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: healthy or sick status,cognitive, memory and psychometric abilities evaluated by different tests example: MMSE (for Alzheimer's) and MST (minor memory disorders), Psychometric abilities assessed by the Geriatric Depression Scale GDS, Nutritional status assessed by the MNA test"
62731275|NCT03925272|EXPERIMENTAL|Patients with familial adenomatous polyposis|"Human biological samples :~whole blood (30 to 100 mL), optional stool collection~bio-clinical data: Age, Gender, Ethnicity, Personal and Family Medical History, Current Treatment, Type of PAF Mutation"
62731276|NCT03925272|EXPERIMENTAL|Patients with chronic inflammatory diseases (SPA, Crohn, ...)|"Human biological samples :~whole blood and derived products (DNA, RNA, PBMC, plasma, serum), (100 mL), stool; as part of the treatment, occasionally: lesions, urine, saliva, tears~Bio-clinical data :~Ethno-geographical origin, Personal and family history, History of the disease, Associated or concomitant diseases, Treatments in progress."
62736274|NCT04166370|EXPERIMENTAL|Strengthened Services and Social Behavioral Change (SBCC)|Increase referrals to health services, strengthen health services, and provide enhanced social and behavior change communication (SBCC)
62731277|NCT03925272|EXPERIMENTAL|Healthy cases|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
62731278|NCT03925272|EXPERIMENTAL|Healthy cases relatives|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
62731279|NCT03925272|EXPERIMENTAL|Subjects vaccinated against COVID-19|"Human biological samples :~whole blood and derived products: serum, DNA, PBMCs, saliva, nasopharyngeal swab~Bio-clinical data :~ethno-geographical origin, family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases, specific history of otorhinolaryngology and broncho-pulmonary and treatments, specific COVID-19 history, risk factor for a severe form of COVID-19, symptoms of COVID-19 or positive test for SarsCov-2 positive"
62731280|NCT01461746|EXPERIMENTAL|Chemotherpay and radiation therapy|Docetaxel plus cisplatin followed by radiation therapy
62731281|NCT02457650|EXPERIMENTAL|Anti-NY ESO-1 TCR-transduced T cells|Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.
62731282|NCT05176340|EXPERIMENTAL|Intervention group|Participants in the experimental group were provided an education program through the Care Action Module during their hospitalization period, and follow-up was conducted one and two months after discharge.
62731283|NCT05176340|NO_INTERVENTION|Control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
62731284|NCT01094977|EXPERIMENTAL|Low Dose|TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure
62731285|NCT01094977|EXPERIMENTAL|High Dose|TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure
62731286|NCT01094977|PLACEBO_COMPARATOR|Placebo|Normal saline 10 ml before skin incision and infusion according to weight until skin closure
62731287|NCT05195086||Cyc group|
62731288|NCT05195086||MMF group|
62731289|NCT01683136|EXPERIMENTAL|Deep TMS treatment|
62731290|NCT01683136|SHAM_COMPARATOR|inactive stimulation|
62731291|NCT01230190|ACTIVE_COMPARATOR|Probiotic mixture|participants daily ingest a selected probiotic mixture for a period of 3 months
62731292|NCT01230190|PLACEBO_COMPARATOR|Placebo mixture|controls daily ingest a placebo mixture for a period of 3 months.
62731293|NCT01232127|OTHER|Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI|The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
62731294|NCT01232127|OTHER|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
62731295|NCT01232127|OTHER|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
62731296|NCT03440515|EXPERIMENTAL|prednisone|prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -\> 10mg/day-\>7.5mg/day-\>5mg/day-\>stop
62731297|NCT01946633|EXPERIMENTAL|Esophagogastroduodenoscopy（ECG）|n=15
62731298|NCT01083069||COOL|Patients after therapy with mild hypothermia
62731299|NCT01083069||UnCool|Patients without therapy with mild hypothermia due to non-operational cooling-devices
62731300|NCT04773288|EXPERIMENTAL|Live feedback provided on display during handwashing|
62731301|NCT04773288|NO_INTERVENTION|No live feedback provided during handwashing|
62731302|NCT04054921|EXPERIMENTAL|Interventions|PTG-300
62731303|NCT00771927||Lacosamide|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with add-on Vimpat
62731304|NCT00771927||Other AED|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with other approved AED as add-on therapy
62731305|NCT02386462|EXPERIMENTAL|Dexmedetomidine|After an injection of pre-determined bolus dose of dexmedetomidine over 10 min, anaesthesia was induced with propofol 2.0 mg/kg. The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg).
62731306|NCT04224233|EXPERIMENTAL|Home-based physical activity group|The experimental group will receive the iLiFE.
62731307|NCT04224233|ACTIVE_COMPARATOR|Control group|The control group will receive a leaflet with exercises and PA recommendations.
61978383|NCT02867189|NO_INTERVENTION|traditional training|anterior chamber cell counts and visual and intraocular pressures on postoperative days1,3,7,14 by traditional training method.
62731308|NCT01150786|EXPERIMENTAL|selenium|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
62731309|NCT01150786|PLACEBO_COMPARATOR|placebo capsule|The patients in this arm took one placebo capsule daily for 12 weeks.
62731310|NCT00833469|EXPERIMENTAL|Escitalopram|Flexible dose escitalopram 10mg
62731311|NCT04339790||New study participant|Individuals who respond to study website or advertisements for the study who have not previously been a NIMH study participant
62731312|NCT04339790||NIMH Study Participant|Individuals who have previously consented for a NIMH study
62731313|NCT02402530|PLACEBO_COMPARATOR|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
62731314|NCT02402530|EXPERIMENTAL|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
62731315|NCT02402530|EXPERIMENTAL|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
62731316|NCT00768261|NO_INTERVENTION|Very Mild to Mild DAT Untreated|Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine
62731317|NCT00768261|ACTIVE_COMPARATOR|Very Mild-Mild DAT Treated W/ Donepezil|Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with Donepezil (Aricept®).
62731318|NCT00768261|ACTIVE_COMPARATOR|Very Mild-Mild DAT Treated W/Combination|Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of Donepezil (Aricept®) and Memantine (Namenda®)
62731319|NCT00768261|NO_INTERVENTION|Nondemented Comparison Subjects|Group 4) nondemented comparison subjects.
62731320|NCT01162252|ACTIVE_COMPARATOR|Mindfulness-Based Stress Reduction|
62731321|NCT01162252|ACTIVE_COMPARATOR|Living Well|
62731322|NCT02994485|ACTIVE_COMPARATOR|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks
62731323|NCT02994485|NO_INTERVENTION|no treatment|no treatment
62731324|NCT04803864|EXPERIMENTAL|Roxadustat|Early and short-term Roxadustat treatment
62731325|NCT04803864|NO_INTERVENTION|Control|Patients only receive conventional therapies as recommended by guidelines.
62731326|NCT05128071|ACTIVE_COMPARATOR|Progesterone Arm|Randomized to receive progesterone
62731327|NCT05128071|PLACEBO_COMPARATOR|Placebo Arm|Randomized to receive placebo
62731328|NCT00739310|EXPERIMENTAL|Vest Treatment (HFCWO)|Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
62731329|NCT02368600|EXPERIMENTAL|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
62731330|NCT02368600|NO_INTERVENTION|Usual care|Women will have their first AN booking visit generally on or before 12 week gestation. For women who are primigravida, their AN visit appointments will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-28 weeks, and every 2 weeks after 28 weeks. For women who are multigravida, the corresponding schedules will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-36 weeks, and every 2 weeks after 36 weeks. Body weight of the pregnant woman will be monitored by nurses and basic nutrition advice will be briefly given by nurses in case she is slightly overweight. They will be provided with an educational pamphlet on diet and exercise during pregnancy. They will also be offered optional antenatal classes which subjected to quotas availability.
62731331|NCT02008149|NO_INTERVENTION|Standard of care group|SCI individuals receiving conventional rehab
62731332|NCT02008149|EXPERIMENTAL|FES-rowing group|Individuals with SCI participating in an FES-rowing program
62731333|NCT05190978|EXPERIMENTAL|Acellular Dermal Matrix|Patients will receive ADM during their initial tissue expander placement.
62731334|NCT05190978|ACTIVE_COMPARATOR|Control|Patients will not receive ADM during their initial tissue expander placement.
62731335|NCT00439595|EXPERIMENTAL|1|Hemocue 210 meter
62731336|NCT00439595|EXPERIMENTAL|2|Copack HBCS
62731337|NCT00439595|NO_INTERVENTION|3|Control
62731338|NCT03469622|ACTIVE_COMPARATOR|EndoRings|Colonoscopy is performed with the EndoRings attached
62731339|NCT03469622|ACTIVE_COMPARATOR|Standard Colonoscopy|Standard colonoscopy without any additional devices
62731340|NCT02043418||children VIH+|children infected with HIV
62731341|NCT02043418||Chlidren VIH-|uninfected children born from HIV-positive or HIV-negative mothers
62731342|NCT00530634|EXPERIMENTAL|Gemcitabine + Cisplatin|Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.
62731343|NCT01621984|EXPERIMENTAL|Therapeutic Riding/ Hippotherapy|12 week Therapeutic Riding program that focused on gross motor function, gross motor performance, balance, spasticity, posture and quality of life
62731344|NCT01621984|NO_INTERVENTION|without Therapeutic Riding/ Hippotherapy|
62731345|NCT05918965|ACTIVE_COMPARATOR|Vagus Nerve Stimulation with 10 Hertz|"Twelve weeks home therapy with transcutaneous electrical neurostimulation (TENSeco®, CE197, Schwa-Medico Gmbh), transcutaneous 2-channel nerve stimulator.~Matching ear electrode 3 DTS.~* Stimulation frequency: 10 Hertz~* Intensity: sensitive threshold; clearly perceptible, but pleasant~* Form of stimulation: biphasic~* Duration: 30 min~* Position: left ear~* Frequency: daily, in the evening, when all daily activities are done"
62731346|NCT05918965|ACTIVE_COMPARATOR|Vagus Nerve Stimulation with 25 Hertz|"Twelve weeks home therapy with transcutaneous electrical neurostimulation (TENSeco®, CE197, Schwa-Medico Gmbh), transcutaneous 2-channel nerve stimulator.~Matching ear electrode 3 DTS.~* Stimulation frequency: 25 Hertz~* Intensity: sensitive threshold; clearly perceptible, but pleasant~* Form of stimulation: biphasic~* Duration: 30 min~* Position: left ear~* Frequency: daily, in the evening, when all daily activities are done"
62731347|NCT05918965|EXPERIMENTAL|Vagus Nerve Stimulation with 2 Hertz|"Twelve weeks home therapy with transcutaneous electrical neurostimulation (TENSeco®, CE197, Schwa-Medico Gmbh), transcutaneous 2-channel nerve stimulator.~Matching ear electrode 3 DTS.~* Stimulation frequency: 2 Hertz~* Intensity: sensitive threshold; clearly perceptible, but pleasant~* Form of stimulation: biphasic~* Duration: 30 min~* Position: left ear~* Frequency: daily, in the evening, when all daily activities are done"
62731348|NCT06026605|EXPERIMENTAL|WTX212A|WTX212A infusion once every 21 days
62731349|NCT00961740|OTHER|Cognitive Behavioral Therapy|Design: 49 children (aged 8-12)with obesity was recruited, the children were randomly assigned to a group that started a cognitive behavioural intervention immediately after recruitment, and another group that received the same treatment after a 12-week wait list condition. For further description of the treatment, see summary. Arm 1 (this arm) started receiving a cognitive behavioural intervention immediately after randomization.
62731350|NCT00961740|OTHER|12-weeks waitlist condition|After an initial pre-assessment no contact were made before assessment after 12-weeks and start of intervention after this assessment. After the 12-week waitlist condition the families were offered the same familibased cognitive behavioral intervention as in arm one.
62731351|NCT05257421|EXPERIMENTAL|shockwave group|
62731352|NCT05257421|ACTIVE_COMPARATOR|exercise group|
62731353|NCT05257421|ACTIVE_COMPARATOR|combined group|
62731354|NCT03026296|EXPERIMENTAL|Participators in HLCs|Adults with high risk of non-communicable diseases (musculoskeletal disease, obesity, physical distress) about to start a 3 months structural support for lifestyle change in a Healthy Life Center (HLC) in Norway
62731355|NCT04522856||Endovascular thrombectomy|there is only one group of the subjects that had stroke and went under thrombectomy procedure and to see how anaesthesiologists support endovascular thrombectomy with regard to anaesthetic technique,choice of substances, haemodynamic management, and ventilation.
62731356|NCT00843258|NO_INTERVENTION|Active Sonographic surveillance|Follow-up at 1.5 and 3 months (Ultrasound,Clinical examination), at 6 and 12 months (clinical examination, pelvic X-ray)
62731357|NCT00843258|EXPERIMENTAL|Abduction treatment|Treatment (abduction splint) from 0-6 weeks, follow-up at 1.5 and 3 months (clinical examination and ultrasound) and at 6 and 12 months (clinical examination and pelvic x-ray)
62731358|NCT04105686|ACTIVE_COMPARATOR|Control Infant Formula|Milk-based study product
62731359|NCT04105686|EXPERIMENTAL|Experimental Infant Formula|Milk-based study product with oligosaccharides
62731360|NCT04105686|NO_INTERVENTION|Reference Group|Human milk-fed group
62731361|NCT06196151|EXPERIMENTAL|Experimental|
62731362|NCT06196151|NO_INTERVENTION|No intervention|
62731363|NCT01740258|EXPERIMENTAL|Bevaczimab, Radiation Therapy, Temozolomide|"In Part A, newly-diagnosed patients with Grade 4 malignant gliomas will receive standard radiation therapy, daily Temodar 75mg/M for 6-8 weeks. Bevacizumab will be given concurrently with radiation therapy and Temodar, 10 mg/kg every two weeks.~If they are stable at the end of Part A, they will continue to Part B. In Part B patients will receive up to 12 cycles of bevacizumab and Temodar. Bevacizumab will be given on Days 1 and 15 of a 28-day cycle. Temodar will be 200 mg/meter squared daily for 5 days (days 1-5) of each cycle.~If they have not progressed, patients will start Part C. In Part C, patients will receive bevacizumab 10mg/kg approximately every 2 weeks or 15 mg/kg approximately every 3 weeks.~If patients progress during Part B or C, they will start Part D. In Part D, patients will receive bevacizumab-based therapy containing bevacizumab in combination with a chemotherapy and/or biologic agent, as determined by the Duke treating physician."
62731364|NCT05121298|EXPERIMENTAL|Upadacitinib|The administration of upadacitinib 15mg/day
62731365|NCT04776161|NO_INTERVENTION|Control|Patients in the control arm will not receive any intervention (but will receive electronic pill bottles to monitor their adherence).
62731366|NCT04776161|EXPERIMENTAL|Cue-Reward Intervention|Patients in this intervention arm will choose an event-based cue and receive reminder text messages reminding them of their cue. Additionally, a donation will be made to a local charity every time they take their medication.
62731367|NCT04776161|EXPERIMENTAL|Cue-Reward Intervention with possible intensification.|Patients in this intervention arm will choose an event-based cue. Additionally, a donation will be made to a local charity every time they take their medication. Those who show no improvement in adherence after 6 weeks will start receiving reminder text messages reminding them of their cue.
62731368|NCT01559337|OTHER|Nerve repair|the dorsal branch of the proper digital nerve was used as a pedicle nerve for reconstructing PDN defects
62731369|NCT01648023|EXPERIMENTAL|Randomization to LC OR ONCOZENE Bead with Gem-Cis or Gem-Carbo|Transarterial Chemoembolization (LC or ONCOZENE Bead) with Gem-Cis or Gem-Carbo
62731370|NCT01648023|ACTIVE_COMPARATOR|Randomization to Gem-Cis or Gem-Carbo|Gem-Cis or Gem-Carbo alone
62731371|NCT05156944|EXPERIMENTAL|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including two exercises for daily self-guided therapy.
62731372|NCT05156944|NO_INTERVENTION|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
62731373|NCT00816010|EXPERIMENTAL|1|Lifestyle and compliance counseling via telephone contact with structured set of questions and reinforcements provided
62731374|NCT00816010|NO_INTERVENTION|2|Control arm with usual care as per local hospital practice
62731375|NCT03619434|ACTIVE_COMPARATOR|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
61977724|NCT05883930|EXPERIMENTAL|"Transtheoretical Model (TTM)-based Let's Move mobile software program"|"Transtheoretical Model (TTM)-based Let's Move mobile software program developed for the experimental group will be applied for 12 weeks. Students will be given smart wristbands. Smart wristband data (step numbers) will be integrated into the program. Through this program, students will fill in the pre-test, post-test and follow-up test (at 6 months) and the sedentary lifestyle TTM Sedentary Life Scales (Stages of Change questionnaire, Self-Efficacy and Decision Making scales) and daily step count values.The body mass index, fat and muscle ratios of the students will be evaluated by the researcher. They will be asked to add these values to the program."
62731376|NCT03619434|EXPERIMENTAL|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
62731377|NCT01794624|ACTIVE_COMPARATOR|Cognitive Therapy|Cognitive Therapy for Catastrophizing
62731378|NCT01794624|ACTIVE_COMPARATOR|Behavioral Therapy|Behavioral Therapy for Sleep Continuity Disturbance
62731379|NCT01794624|NO_INTERVENTION|TMJD Education|6-sessions of TMJD disease education/support control
62731380|NCT04807166|EXPERIMENTAL|Anlotinib Combined With Carboplatin/Paclitaxel|Anlotinib Combined With Carboplatin/Paclitaxel
62731381|NCT02440204|ACTIVE_COMPARATOR|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
62731382|NCT02440204|ACTIVE_COMPARATOR|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
62731383|NCT02440204|ACTIVE_COMPARATOR|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
62731384|NCT00868829|EXPERIMENTAL|Firebird2|
62731385|NCT01094834|EXPERIMENTAL|DWP05195|
62731386|NCT05227495|EXPERIMENTAL|VR group|
62731387|NCT05227495|ACTIVE_COMPARATOR|control group|
62731388|NCT05407116|EXPERIMENTAL|Experimental|Patients receiving standard or hypofractionated radiotherapy for curative intent to a pelvic malignancy with an intended total dose of 25-60 Gy.
62731389|NCT03609502|EXPERIMENTAL|behavioral|Adults with and without language impairment will be given three different types of behavioral training, and assessments of learning through those trainings, at two time points.
62731390|NCT03609502|EXPERIMENTAL|neuroimaging|Following speech sound behavioral training, adults with and without language impairment will undergo post-training perceptual assessments in an MRI scanner before and after post-training sleep.
62731391|NCT01474785|EXPERIMENTAL|RYGB|Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.
62731392|NCT01474785|EXPERIMENTAL|VSG|Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.
62731393|NCT01474785|EXPERIMENTAL|Low Calorie Diet|Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.
62731394|NCT01127984|EXPERIMENTAL|treatment with tissucol|patients treated with tissucol, local application in the pocket of PM / ICD
62731395|NCT01127984|ACTIVE_COMPARATOR|vacuum drainage system|patients treated with application of vacuum drainage system.
62731396|NCT04491903|EXPERIMENTAL|REBOA|
62731397|NCT03635632|EXPERIMENTAL|Arm A: High-risk group of patients with lung metastases|"Patients will be treated at 2 dose levels without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated at the next dose level with C7R.GD2.CART cell infusion without lymphodepletion chemotherapy.~The protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Each arm will undergo separate dose escalation."
62731398|NCT03635632|EXPERIMENTAL|Arm B: Standard risk group of all other patients|"Patients will be treated at 2 dose levels without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated at the next dose level with C7R.GD2.CART cell infusion without lymphodepletion chemotherapy.~The protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Each arm will undergo separate dose escalation."
62731399|NCT04051749||Patients submitted to VS|
62731400|NCT02097628|ACTIVE_COMPARATOR|pressure-controlled ventilation|pressure-controlled ventilation: a peak airway pressure that provided a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column, respiratory rate 12-16 times per minute.
62731401|NCT02097628|EXPERIMENTAL|volume-controlled ventilation|volume-controlled ventilation: tidal volume 8-12ml/kg, respiratory rate 12-16 times per minute.
62731402|NCT01927263|EXPERIMENTAL|NI-071|
62731403|NCT01927263|ACTIVE_COMPARATOR|Infliximab|
62731404|NCT06207552|EXPERIMENTAL|Arm of BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
62731405|NCT05656222|EXPERIMENTAL|VIA treatment Group|
62731406|NCT03203577|ACTIVE_COMPARATOR|Hospital initiation|Initiation of mechanical ventilation in hospital initiation of Home Mechanical ventilation takes place in a hospital; this makes this arm the standard care.
62731407|NCT03203577|EXPERIMENTAL|Home initiation|Initiation of mechanical ventilation at home Initiation of mechanical ventilation in a patient's home setting with telemonitoring
62731408|NCT01739608|EXPERIMENTAL|CT Colonography (CTC)|Invitation to screening. Subject who consent to participate in the study undergo to low dose CTC examination with limited bowel preparation.
62731409|NCT01739608|ACTIVE_COMPARATOR|Sigmoidoscopy (FS)|Invitation to screening. Subjects who consent to participate in the study undergo to FS.
62731410|NCT00040742|PLACEBO_COMPARATOR|Placebo|Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
62731411|NCT00040742|EXPERIMENTAL|0.5g ginger|Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
62731412|NCT00040742|EXPERIMENTAL|1.0g ginger|Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
62731413|NCT00040742|EXPERIMENTAL|1.5g ginger|Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
62731414|NCT02761473||Patients with Urticaria Pigmentosa|This group will undergo skin biopsy, blood and buccal swab analyses
62731415|NCT02761473||Family members of affected patients|This group will undergo blood and buccal swab analyses
62731416|NCT04742777|EXPERIMENTAL|Rapamycin|Rapamycin 1mg for 8 weeks
62731417|NCT01344486|EXPERIMENTAL|Full conditioing|Intervention by alteration of laparoscopic gas with addition of oxygen and nitrous oxide, regulation of humidification and temperature (32°C), injection of 5mg Dexamethasone and application of Hyalobarrier Gel Endo (Nordic Pharma) at the surgical wound
62731418|NCT01344486|ACTIVE_COMPARATOR|carbon dioxide|induction pneumoperitoneum with carbon dioxide 100%
62731419|NCT01643408|EXPERIMENTAL|Open-Label Erwinaze|
62731420|NCT02655757|ACTIVE_COMPARATOR|Sitagliptin|Sitagliptin 100mg QD
62731421|NCT02655757|PLACEBO_COMPARATOR|Placebo|Placebo
62731422|NCT06104007||Genoss® DCB|Patients with coronary in-stent restenosis (ISR) who underwent percutaneous coronary intervention using the Genoss® DCB
62166312|NCT05306223|EXPERIMENTAL|Bedaquiline-containing Short-course Regimen (SCR)|Participants will receive an oral dose of bedaquiline 400 milligrams (mg) once daily for first 2 weeks followed by bedaquiline 200 mg thrice a week for 22 weeks (with at least 48 hours between doses) in combination with oral doses of levofloxacin (LFX) up to 1000 mg (weight-based), cycloserine (CS) up to 750 mg (weight-based), clofazimine (CFZ) 100 mg daily for 40 weeks and linezolid \[LZD\] 600 mg daily for at least 24 weeks . If a participant is still sputum culture-positive for Mycobacterium tuberculosis by Week 16, bedaquiline treatment will be extended from Week 24 to Week 40.
62166313|NCT05306223|EXPERIMENTAL|Non-bedaquiline-containing Short-course Regimen (SCR)|Participants will receive oral doses of LFX up to 1000 mg (weight-based), CS up to 750 mg (weight-based), CFZ 100 mg, Pyrazinamide (PZA) up to 2000 mg (weight-based), Protionamide (PTO) up to 800 mg (weight-based) daily for first 16 weeks and LZD 600 mg daily for at least 24 weeks.
62166314|NCT02710578|ACTIVE_COMPARATOR|Alcohol|Alcohol
62166315|NCT02710578|PLACEBO_COMPARATOR|Placebo|Tonic water
62166316|NCT01386411||Women with Breast Cancer|The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
62166317|NCT05067972|EXPERIMENTAL|Monotherapy dose escalation (Part 1)|Participants will receive PF-07260437
62166318|NCT05067972|EXPERIMENTAL|Dose Expansion (Part 2A) - Tumor specific Arm A|Participants will receive PF-07260437
62166319|NCT05067972|EXPERIMENTAL|Dose Expansion (Part 2B) - Tumor specific Arm B|Participants will receive PF-07260437
62166320|NCT05067972|EXPERIMENTAL|Dose Expansion (Part 2C) - Tumor specific Arm C|Participants will receive PF07260437
62166321|NCT01721759|EXPERIMENTAL|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, intravenously over 60 minutes every 2 weeks (on Day 1 of each cycle) until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. Every 2-week treatment period was considered to be a cycle.
62166322|NCT05104957|EXPERIMENTAL|Dynamic tape|Experimental group will use a special dynamic tape on the lumbar extensor muscles
62166323|NCT05104957|SHAM_COMPARATOR|Paper tape|Control group will use a paper tape on the lumbar extensor muscles
62166324|NCT04564027|EXPERIMENTAL|Cohort A|Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.
62166325|NCT04564027|EXPERIMENTAL|Cohort B|Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.
62166326|NCT03089502|EXPERIMENTAL|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
62166327|NCT03089502|NO_INTERVENTION|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
62166328|NCT00653419|EXPERIMENTAL|A|Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
62166329|NCT00653419|ACTIVE_COMPARATOR|B|Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
62166330|NCT04393779|OTHER|HARPOON™ MVRS|Subjects who were treated with the HARPOON MVRS.
62166331|NCT06646588|EXPERIMENTAL|Fruquintinib in Combination With Tislelizumab followed by radiotherapy|Fruquintinib in Combination With Tislelizumab followed by radiotherapyin Relapsed or Progressive Esophageal Squamous Cell Carcinoma
62166332|NCT05115721||Pre-ductal SpO2|
62166333|NCT05115721||Post-ductal SpO2|
62166334|NCT04208815|EXPERIMENTAL|MPL-rich dairy beverage|Daily consumption of 100 g of dairy powder containing 5.3 g MPL for 4 weeks
62166335|NCT04208815|PLACEBO_COMPARATOR|Control dairy beverage|Daily consumption of 100 g of dairy powder containing 0.3 g MPL for 4 weeks
62166336|NCT01860222|ACTIVE_COMPARATOR|SR|
62166337|NCT01860222|EXPERIMENTAL|PLAT|
62166338|NCT03936309|EXPERIMENTAL|Scar Deactivation Surface Release|Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
62166339|NCT03936309|EXPERIMENTAL|Scar Infiltration with 0.25-1% Lidocaine|Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
62166340|NCT03936309|EXPERIMENTAL|Physical Therapy|Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
62166341|NCT04946656|EXPERIMENTAL|SPG block|The sphenopalatine ganglion will be blocked with bipuvacaine for this study
62731423|NCT02598869|ACTIVE_COMPARATOR|Intravitreal triamcinolone|subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)
62731424|NCT02598869|ACTIVE_COMPARATOR|posterior subtenon triamcinolone|subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)
62166342|NCT02064361|EXPERIMENTAL|High intensity exercise|A dive to 18 meters sea water for a duration of 41 minutes preceded by high intensity cycling
62166343|NCT03234842|EXPERIMENTAL|Proton|Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
62166344|NCT03234842|ACTIVE_COMPARATOR|Photon|Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
62166345|NCT00747149|EXPERIMENTAL|Rosuvastatin 1|titrated
62166346|NCT00747149|EXPERIMENTAL|Rosuvastatin 2|Non-titrated
62166347|NCT00928876|EXPERIMENTAL|Anakinra group|Anakinra 150 mg/day during four weeks
62166348|NCT00928876|PLACEBO_COMPARATOR|Placebo|Placebo during four weeks
62166349|NCT02665806|EXPERIMENTAL|Ciclesonide|
62166350|NCT02665806|ACTIVE_COMPARATOR|Fluticasone|
62166351|NCT06285383|OTHER|control group|Participants in the control group will receive classical physiotherapy 5 days a week for 4 weeks (Tens 20 min, ultrasound 5 min, hotpack 20 min).
62166352|NCT06285383|EXPERIMENTAL|Music group|Participants in the music group will be played Pachabel Canon D major (30 minutes) during the classical physical therapy session, free from external sounds (max 70 dB through headphones).
62166353|NCT04427397|EXPERIMENTAL|Sulcular Bristle Tip Technique (SBTT)|This test group will receive formal instruction on the Sulcular Bristle Tip Technique (SBTT).
62166354|NCT04427397|NO_INTERVENTION|User manual of the electric toothbrush (DFU)|This control group will be asked to read and use the instructions found in the user manual of the electric toothbrush (DFU). No formal instruction will be provided. The DFU accompany the electric toothbrush regardless of the subject's participation in the research.
62166355|NCT05832216|EXPERIMENTAL|Daratumumab|
62166356|NCT00642499|EXPERIMENTAL|1|
62166357|NCT00642499|PLACEBO_COMPARATOR|2|
62166358|NCT02103426|EXPERIMENTAL|Part 1: ASP0113 CMV-seropositive healthy cohort|5 mg single dose IM injection
62166359|NCT02103426|EXPERIMENTAL|Part 1: ASP0113 CMV-seronegative healthy cohort|5 mg single dose IM injection
62166360|NCT02103426|PLACEBO_COMPARATOR|Part 1: Placebo CMV-seropositive healthy cohort|single dose IM injection
62166361|NCT02103426|PLACEBO_COMPARATOR|Part 1: Placebo CMV-seronegative healthy cohort|single dose IM injection
62166362|NCT02103426|EXPERIMENTAL|Part 2: ASP0113 CMV-seropositive healthy cohort|4 IM injections of ASP0113
62166363|NCT02103426|EXPERIMENTAL|Part 2: ASP0113 CMV-seronegative healthy cohort|4 IM injections of ASP0113
62166364|NCT02103426|EXPERIMENTAL|Part 2: ASP0113 CMV-seronegative dialysis cohort|4 IM injections of ASP0113
62166365|NCT02103426|PLACEBO_COMPARATOR|Part 2: Placebo CMV-seropositive healthy cohort|4 placebo IM injections
62166366|NCT02103426|PLACEBO_COMPARATOR|Part 2: Placebo CMV-seronegative healthy cohort|4 placebo IM injections
62166367|NCT02103426|PLACEBO_COMPARATOR|Part 2: Placebo CMV-seronegative dialysis cohort|4 placebo IM injections
62166368|NCT04635241|EXPERIMENTAL|Inhaled heparin|Inhaled nebulised unfractionated heparin in addition to standard care Dose 25,000 IU every 6 hours for up to 21 days
62166369|NCT04635241|NO_INTERVENTION|Standard care|Standard care
62166370|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 1|SARS-CoV-2 beta S vaccine Antigen dose 1, no adjuvant, IM
62166371|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 2|SARS-CoV-2 beta S vaccine Antigen dose 1, no adjuvant, IN
62166372|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 3|SARS-CoV-2 beta S vaccine Antigen dose 2, adjuvant dose 1, IM
62166373|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 4|SARS-CoV-2 beta S vaccine Antigen dose 2, adjuvant dose 1, IN
62166374|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 5|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 1, IM
62166375|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 6|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 1, IN
62166376|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 7|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 2, IM
62166377|NCT05385991|EXPERIMENTAL|SARS-CoV-2 beta S vaccine arm 8|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 2, IN
62166378|NCT01039597|EXPERIMENTAL|Active study drug|ORE1001 300 mg oral capsules
62166379|NCT01039597|PLACEBO_COMPARATOR|Placebo control|300 mg oral capsules containing placebo material
62166380|NCT00966056|ACTIVE_COMPARATOR|Mitomycin C|Cases recruited into this arm receive topical application of mitomycin c (1mg/ml)following surgical synechiolysis
62166381|NCT00966056|ACTIVE_COMPARATOR|Teflon septal splint|Cases recruited into this arm receive insertion of teflon internal nasal septal splint following surgical synechiolysis
62166382|NCT01464671|ACTIVE_COMPARATOR|Bivalirudin|Anticoagulation during percutaneous coronary intervention
62166383|NCT01464671|ACTIVE_COMPARATOR|Unfractionated Heparin|Anticoagulation during percutaneous coronary intervention
62166384|NCT05644236|EXPERIMENTAL|experimental group|CPC-containing mouthwash solution
62166385|NCT02931994|NO_INTERVENTION|Group A Phase 1|50% of sample are randomly assigned to Group A and are to utilise conventional flossing technique in the first phase of 6-weeks
62166386|NCT02931994|ACTIVE_COMPARATOR|Group B Phase 1|50% of sample are randomly assigned to Group B and are to utilise knotted floss technique in the phase 1 of 6-weeks
62166387|NCT02931994|ACTIVE_COMPARATOR|Group A Phase 2|After a washout period of 2 weeks, those from Group A will use the knotted floss technique for a period of 6 weeks.
62166388|NCT02931994|NO_INTERVENTION|Group B Phase 2|After a washout period of 2 weeks, those from Group B will use the conventional floss technique for a period of 6 weeks.
62166389|NCT05068687|EXPERIMENTAL|intraoperative high-resolution PET-CT imaging of resected malignancy|
62166390|NCT05954156|EXPERIMENTAL|injectable restorative resin composite material used for cementation|Highly filled injectable composites display properties in a manner similar to resin cements due to their unique viscosities. This with the added benefits of higher filler content, thus improved mechanical and physical properties with the easy placement and handling properties which can improve clinical performance and durability of indirect restorations. (Fugimoto et al., 2019)
62166391|NCT05954156|ACTIVE_COMPARATOR|dual cured resin cement|Dual cured resin cement is chosen as a comparator (gold standard )for the cementation of indirect restorations. (Sadighpour et al., 2018) Resin cement is insoluble and has superior mechanical and physical properties, compared with other previous luting materials. The clinical advantages of resin cement include high resistance to compression forces, low thermal expansion coefficients, high flexural strengths, and hardness. In addition, resin cement is characterized by adhesion to many materials, the ability to modify shade and color, high retention, resistance to wear at the margin of the restoration, and low marginal permeability. Resin cement provides optimal bond with resin composite indirect restorations and evenly distributes the compression force along all contact surfaces. (Gurdal et al., 2018
62166392|NCT05229549|ACTIVE_COMPARATOR|A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16|
62166393|NCT05229549|ACTIVE_COMPARATOR|B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16|
62166394|NCT05229549|PLACEBO_COMPARATOR|C. One day treatment with 3 self-administrations of free AAs|
62166395|NCT05229549|PLACEBO_COMPARATOR|D. One day treatment with 2 self-administrations of free AAs|
62166396|NCT05493605|OTHER|Cases|The intervention consists in setting up a morphological and rhythmological cardiological follow-up patients with confirmed Wilson disease. It will require the wearing of a long Holter duration (21 days) and for some patients the installation of an implantable cardiac monitor.The long-time ECG holter is used to record heart rhythm for 21 days and detect possible arrhythmias (accelerations of the heart) or conduction disorders (slowdowns of the heart).
62166397|NCT00615355|OTHER|Body location|Different body locations receive specific treatments
62166398|NCT00615355|ACTIVE_COMPARATOR|Control|Treatment with narrow-band UVB
62166399|NCT03886688|EXPERIMENTAL|single ascending|Drug or placebo, oral, fast, single dose ascending
62166400|NCT03886688|EXPERIMENTAL|multiple ascending|Drug or placebo, oral, fast, multiple dose ascending
62166401|NCT03886688|EXPERIMENTAL|Food Effect|Drug or placebo, oral, fed or fast, single dose
62166402|NCT02792296|EXPERIMENTAL|Daily measurement|This arm will be asked to use the Project: EVO Monitor once a day for four weeks..
62166403|NCT02792296|EXPERIMENTAL|Multiple times per day measurement|This arm will be asked to use the Project: EVO Monitor at least once per day and six times over the day every three days for four weeks.
62166404|NCT02792296|EXPERIMENTAL|Weekly measurement|This arm will be asked to use the Project: EVO Monitor once a week for eight weeks.
62166405|NCT01347281|EXPERIMENTAL|[18F]HX4 PET|Injection of \[18F\]HX4
62166406|NCT00422786|EXPERIMENTAL|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
62166407|NCT05990309|ACTIVE_COMPARATOR|non-segmental vitiligo|patients with non-segmental vitiligo
62166408|NCT05990309|ACTIVE_COMPARATOR|control group|
62166409|NCT03606759|EXPERIMENTAL|Traitment as usual adjusted on ATI information|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
62166410|NCT03606759|ACTIVE_COMPARATOR|Traitment as usual|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
62166411|NCT05229848|ACTIVE_COMPARATOR|3D electroanatomical mapping alone|Patients who are diagnosed with typical right sided flutter who are scheduled for an ablation procedure will be enrolled. Informed consent will be obtained from each of them prior to the procedure. Patients will be randomly assigned to undergo either 3D electroanatomical mapping alone vs ICE plus 3D electroanatomical mapping guided CTI ablation. Operators will plan to alternate each case with the use of ICE + 3D mapping and 3D mapping alone with one method followed by the other for randomization. All patients will have the standard access sheaths placed in the right femoral vein.
62166412|NCT05229848|EXPERIMENTAL|ICE plus 3D electroanatomical mapping|Patients who are diagnosed with typical right sided flutter who are scheduled for an ablation procedure will be enrolled. Informed consent will be obtained from each of them prior to the procedure. Patients will be randomly assigned to undergo either 3D electroanatomical mapping alone vs ICE plus 3D electroanatomical mapping guided CTI ablation. Operators will plan to alternate each case with the use of ICE + 3D mapping and 3D mapping alone with one method followed by the other for randomization. All patients will have the standard access sheaths placed in the right femoral vein. The group randomized to ICE catheter placement will have a left femoral 11F sheath placed in addition.
62166413|NCT04458376|EXPERIMENTAL|Follows the internet-based self-help program|
62166414|NCT05414656|EXPERIMENTAL|Group A : Saddle contoured metal matrix|The prepared teeth received the Saddle contoured metal matrix. The saddle clip of matrix connect the band and secured around prepared cavity wall. The anatomical wedge placed into the gingival embrasure to maintain the height of gingival floor and ensure the optimal adaptation of the matrix band in the cervical region.
62166415|NCT05414656|ACTIVE_COMPARATOR|Group B:pre-contoured self-adhesive matrix|Teeth received the Pre-contoured self adhesive matrix with anatomical wedges. The adhesive end of band closed around the prepared cavity.
62166416|NCT00191984|EXPERIMENTAL|Pemetrexed + Irinotecan|
62166417|NCT05063292|NO_INTERVENTION|Control group|Patients covered with a 41 centigrade degrees double layered cotton cloth
62166418|NCT05063292|EXPERIMENTAL|Prewarmed group|Patients receive active prewarming with an air forced blanket ( full body blanket) 30 minutes prior to the operation
62166419|NCT05910502|NO_INTERVENTION|Treatment As Usual Group|This group will receive treatment as usual.
62166420|NCT05910502|EXPERIMENTAL|Coaching Group|Coaching Group will receive Project AFECT intervention, in addition to treatment as usual.
61978384|NCT00449540|ACTIVE_COMPARATOR|Active Transcranial Magnetic Stimulation (TMS) Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
62166421|NCT01256645|NO_INTERVENTION|restrictive transfusion|No transfusion given to correct anemia unless vital indication is given
62166422|NCT01256645|EXPERIMENTAL|liberal transfusion|transfusions are given in single units until Hb is \> 12 mg/dl
62166423|NCT03002233|EXPERIMENTAL|TRK-820|PartA: 5 μg PartB: 2.5-10 μg
62166424|NCT00185848|EXPERIMENTAL|[18F]FHBG arm|
62166425|NCT01084356||hand|patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
62166426|NCT01084356||thyroid|patients admitted for Tc thyroid scan
62166427|NCT01084356||parathyroid|patients investigated for parathyroid adenoma
62166428|NCT01084356||sentinel node|patients who are due to sentinel node biopsy
62166429|NCT01511744|EXPERIMENTAL|Inactivated influenza split vaccine|Biological: Experimental: influenza split vaccine of 15 μg HA, one dose regime
62166430|NCT01511744|NO_INTERVENTION|Blank control|
62166431|NCT04891263|EXPERIMENTAL|Suture-Septoplasty|Participants will receive suture-septoplasty technique, and will be followed for three months postoperatively.
62166432|NCT04050306||Adolescents and young adults|Participants 12-19 years old without chronic diseases.
62166433|NCT04118088|EXPERIMENTAL|Darvadstrocel|Participants who have previously received darvadstrocel would receive a single repeat dose of darvadstrocel 120 million cells (5 million cells/mL), by local injection into the fistula.
62166434|NCT05717647||Paediatric patients with severe traumatic brain injury undergoing multimodality monitoring|"* Patients admitted with brain injury requiring ventilation and ICP monitoring~* Age group: 3 years and 16 years (children under the age of three years are excluded as the triple bolt for multimodality monitoring is not currently used for this age group)"
62166435|NCT02877745||no SDB|apnea-hyponea index \<15/hour
62166436|NCT02877745||SDB|apnea-hyponea index \>=15/hour
62166437|NCT02383121||No patients|Study has been withdrawn
62166438|NCT03468387|ACTIVE_COMPARATOR|Primary realignment|
62166439|NCT03468387|ACTIVE_COMPARATOR|Suprapubic cystostomy|
62166440|NCT00961597|EXPERIMENTAL|Meniscus repair with PRP|Meniscus repair for tears extending into the red/white region with PRP
62166441|NCT00961597|ACTIVE_COMPARATOR|Meniscus repair without PRP|
62166442|NCT04990128|EXPERIMENTAL|Bone marrow aspirate concentrate|Bone marrow that is aspirated then concentrated using a device.
62166443|NCT04990128|ACTIVE_COMPARATOR|Triamcinolone|Triamcinolone is a corticosteroid.
62166444|NCT01106586|EXPERIMENTAL|Stribild|
62166445|NCT01106586|ACTIVE_COMPARATOR|ATV/r + FTC/TDF|
62166446|NCT01461343|EXPERIMENTAL|pulmonary hypertension|Patients with Group I pulmonary arterial hypertension and exercise-induced pulmonary hypertension to undergo CT imaging, functional PET imaging
62166447|NCT01461343|ACTIVE_COMPARATOR|healthy controls|healthy adults to serve as controls and to undergo the same study procedures: CT imaging, functional PET imaging
62166448|NCT02409732|EXPERIMENTAL|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
62166449|NCT01314014|EXPERIMENTAL|Imexon|Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.
62166450|NCT00912275|EXPERIMENTAL|Lapatinib plus Oral Vinorelbine|Oral vinorelbine on day 1 and day 8 q3w plus lapatinib 1000mg/day.
62166451|NCT06477887|EXPERIMENTAL|Allogeneic Dentin Matrix|"Steps of Allogenic Dentin Processing:~1. Wash with distilled water for 30-120 minutes.~2. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~3. Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~4. Demineralization with 0.5N HCL for 10-60 min.~5. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~6. Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin."
62166452|NCT06477887|ACTIVE_COMPARATOR|Autogenous Partially Demineralized Dentine Matrix|The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size of 400-800 μm. The extracted socket will be filled with partially demineralized autogenous dentin graft covered by a collagen membrane.
62166453|NCT04631341|EXPERIMENTAL|Melatonin Group|Take melatonin supplements
62166454|NCT04631341|NO_INTERVENTION|Normal Control Group|Don't take melatonin supplements
62166455|NCT04512560|EXPERIMENTAL|Structured Remote Surgical Coaching|Participants randomized to the intervention group will participate in a 3-month SRSC program in addition to CST. Participants will be asked to provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon prior to the coaching session. Each coach will review the video recording and will identify key themes for discussion. Coaching sessions will be structured using the modified PRACTICE model, will be conducted outside of the clinical environment, and will employ facilitative coaching methods to encourage participants to define specific intra-operative problems and conceptually troubleshoot various solutions.
62166456|NCT04512560|ACTIVE_COMPARATOR|Conventional Surgical Training|Participants randomized to the control group will continue of their usual general surgery residency training including attending scheduled teaching sessions, and continuing with assigned responsibilities on the ward and in the OR.
62166457|NCT04730570|EXPERIMENTAL|Essential Coaching for Every Mother Intervention|Women in the intervention arm will receive the Essential Coaching for Every Mother messages up to six-weeks postpartum. No changes in standard care.
62166458|NCT04730570|NO_INTERVENTION|Standard care|Women in the control group will receive no content messages. No changes in standard care.
62731425|NCT03067402|OTHER|Observation|Patient receives standard observation, i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years.
62731426|NCT03067402|EXPERIMENTAL|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
62166459|NCT04593641|EXPERIMENTAL|Cohort 1 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
62166460|NCT04593641|EXPERIMENTAL|Cohort 2 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
62166461|NCT04593641|EXPERIMENTAL|Cohort 3 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
62166462|NCT01225705|EXPERIMENTAL|Raltegravir|45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine
62166463|NCT01225705|ACTIVE_COMPARATOR|Atazanavir/ritonavir|45 patients will receive open label atazanavir/ritonavir
62166464|NCT03096496||GIMEMA APL0406 patients|APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.
62166465|NCT04643496||Patients requiring ileocolic resection for Crohn disease.|All consecutive patients requiring an ileocolic resection for Crohn disease, between January 2010 and March 2020 at the Digestive Surgery Units of CHU Montpellier.
62166466|NCT01239056||Pancreatic Pseudocysts|All adult patients who have a clinical indication to undergo an endoscopic drainage of a pancreatic pseudocyst.
62166467|NCT05938959|ACTIVE_COMPARATOR|Sham group|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% Normal Saline
62166468|NCT05938959|ACTIVE_COMPARATOR|ESPB group|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
62166469|NCT01459523|ACTIVE_COMPARATOR|Imaging technique|In one substudy, subjects will be randomly assigned to either short axis or long axis target ultrasound imaging for perineural catheter insertion. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
62166470|NCT01459523|ACTIVE_COMPARATOR|Catheter location|In another substudy, subjects will be randomly assigned to receive their perineural catheters either proximally or distally along the same target nerve or plexus.
62166471|NCT01874717|EXPERIMENTAL|oral midazolam|oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.
62166472|NCT01874717|OTHER|intravenous midazolam|intravenous administration of midazolam at the individual dose determined in session 1
62166473|NCT04934124|EXPERIMENTAL|Cohort 1: 0.03 mg ITI-333 or placebo|
62166474|NCT04934124|EXPERIMENTAL|Cohort 2: 0.09 mg ITI-333 or placebo|
62166475|NCT04934124|EXPERIMENTAL|Cohort 3: 0.25 mg ITI-333 or placebo|
62166476|NCT04934124|EXPERIMENTAL|Cohort 4: 0.75 mg ITI-333 or placebo|
62166477|NCT04934124|EXPERIMENTAL|Cohort 5: 2.25 mg ITI-333 or placebo|
62166478|NCT04934124|EXPERIMENTAL|Cohort 6: 6.75 mg ITI-333 or placebo|
62166479|NCT02146859||general anesthesia|Patient having general anesthesia
62166480|NCT02478762|ACTIVE_COMPARATOR|Normal glycemic control|GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
62166481|NCT02478762|EXPERIMENTAL|Low glycemic control|GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
62166482|NCT06226896||Dapagliflozin + RAS inhibitor|In addition to ACEI/ARB treatment, patients will receive dapagliflozin 10mg once daily for 24 months.
62166483|NCT06226896||RAS inhibitor only|Patients will continue ACEI/ARB treatment for 24 months.
62166484|NCT00967915|EXPERIMENTAL|Frenotomy|Group of neonates that will receive frenotomy for tongue-tie
62166485|NCT00967915|SHAM_COMPARATOR|No frenotomy|Group of infants that will undergo sham procedure (no frenotomy performed)
62166486|NCT01073774|EXPERIMENTAL|Side by Side|
62166487|NCT01073774|ACTIVE_COMPARATOR|couples control condition|
62166488|NCT01098929||Congenital Diaphragmatic Hernia (CDH)|Individuals affected with congenital diaphragmatic hernia (CDH)
62166489|NCT01098929||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
62166490|NCT01114334|ACTIVE_COMPARATOR|Guideline-based Medical Management|"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.~The evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications"
62166491|NCT01114334|EXPERIMENTAL|Motivational Interview with GBMM|Motivational Interviewing for Depression combined with guideline-based medical management for depression
62166492|NCT04655222||All Participants|Pregnant Multiple Sclerosis (MS) participants treated with SC interferon beta therapy or an IM interferon beta therapy in the German PSP of the MSSC.
62166493|NCT04788472|EXPERIMENTAL|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
61976723|NCT05725811|ACTIVE_COMPARATOR|Intervention group 1|"A myofascial release technique will be performed using a foam roller (Blackroll Standard, 30 x 15 cm) on the dominant lower limb.~For the IG 1, the technique will be applied to the hamstrings muscles. In this group, participants will sit on the floor on a mat with the roller under their thighs. Their hands will be placed on the floor with their fingers pointing downwards. The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers. The limb that will not be tested will function as a lever, it will remain bent to the side, which will allow the simple realization of the glide.~A cycle of the procedure will be defined as a proximal to distal rolling movement, so the frequency in this study will be 25 cycles per minute measured with a metronome from a mobile application (Smart Metronome \& Tuner v.11.8 IOS)."
61976724|NCT05725811|ACTIVE_COMPARATOR|Intervention group 2|"A myofascial release technique will be performed using a foam roller (Blackroll Standard, 30 x 15 cm) on the dominant lower limb.~The IG 2 will perform the same technique on a different muscle group: the quadriceps. In this way, the positioning will be different, the participants will be in the prone position, in a plank position, leaning on the forearms, the body well aligned and the studied lower limb well stretched. However, the participant will also perform a self-massage in the direction of the muscle fibers until they feel slight pain. The duration of the procedure will be set at 4 minutes in this study; 3 rounds of 1 minute (30 s rest).~A cycle of the procedure will be defined as a proximal to distal rolling movement, so the frequency in this study will be 25 cycles per minute measured with a metronome from a mobile application (Smart Metronome \& Tuner v.11.8 IOS)."
61976725|NCT05725811|NO_INTERVENTION|Control group|The participants will remain at rest in a chair for 4 minutes.
61976726|NCT00696176|EXPERIMENTAL|A|STAT 3 decoy administration
61976727|NCT05761977||Patient with extensive small-cell lung cancer|extensive small-cell lung cancer
61976728|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
62166494|NCT01448447|EXPERIMENTAL|Sole method|patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS
62166495|NCT01448447|EXPERIMENTAL|Boost|patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS
62166496|NCT05659745|PLACEBO_COMPARATOR|Vaginal Suppository Capsule|In the VM-02 Vaginal Suppository Capsule Placebo Arm, participants will take the test vaginal suppository capsule placebo as directed.
62166497|NCT05659745|EXPERIMENTAL|Vaginal Suppository Capsule Active|In the VM-02 Vaginal Suppository Capsule Active Arm, participants will take a test vaginal suppository capsule as directed.
62166498|NCT05659745|EXPERIMENTAL|Vaginal Suppository Tablet Active|In the VM-02 Vaginal Suppository Tablet Active Arm, participants will take a test vaginal suppository tablet as directed.
62166499|NCT05659745|EXPERIMENTAL|Oral Capsule Active|In the VM-02 Oral Capsule Active Arm, participants will take a test oral capsule as directed.
62166500|NCT05659745|OTHER|Commercial Oral Vaginal Probiotic Competitor|In the Commercial Over-The-Counter (OTC) Oral Probiotic Competitor Arm, participants will take an over-the-counter competitor product as directed.
62166501|NCT01446042|EXPERIMENTAL|TBS-1 - b.i.d.|5.5 mg per nostril of 4.5% TBS-1 BID
62166502|NCT01446042|EXPERIMENTAL|TBS-1 - t.i.d.|5.5 mg per nostril of 4.5% TBS-1 TID
62166503|NCT03336684|EXPERIMENTAL|Patient Education Group|Patients will be provided with disease education literature
62166504|NCT03336684|NO_INTERVENTION|Normal Group|Patients will not be provided with disease education literature
62166505|NCT02109718|EXPERIMENTAL|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with Open Dressing with Petrolatum Jelly
62166506|NCT02109718|ACTIVE_COMPARATOR|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed with Silver Sulfadiazine Gauze Dressing.
62166507|NCT01498406|EXPERIMENTAL|high dose vitamin D3|4,000 IU of vitamin D3 daily for 8 months
62166508|NCT01498406|ACTIVE_COMPARATOR|low dose vitamin D3|400 IU of vitamin D3
62166509|NCT01283971|EXPERIMENTAL|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
62166510|NCT01283971|ACTIVE_COMPARATOR|Adalimumab + Methotrexate|Adalimumab 40 mg SC every 2 weeks + Placebo to tocilizumab IV every 4 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
62166511|NCT02574949|ACTIVE_COMPARATOR|Conventional rate fluoroscopy|Radiation: 15 FPS Cine 15 PPS
62166512|NCT02574949|EXPERIMENTAL|Intermediate frame rate 7.5 fps|Radiation: 7.5 low Frame rate
62166513|NCT02574949|EXPERIMENTAL|Low frame rate|Low Cine 10 PPS
62166514|NCT04174378||GnRH agonist with progestogen support|
62166515|NCT04174378||progestogen support only|
62166516|NCT03928171|EXPERIMENTAL|Intra-abdominal pressure of 8 mmHg|The laparoscopy insufflator is set to a pressure of 8 mmHg
62166517|NCT03928171|EXPERIMENTAL|Intra-abdominal pressure of 12 mmHg|The laparoscopy insufflator is set to a pressure of 12 mmHg
62166518|NCT03928171|EXPERIMENTAL|Intra-abdominal pressure of 16 mmHg|The laparoscopy insufflator is set to a pressure of 16 mmHg
62166519|NCT03869411|EXPERIMENTAL|aerobic exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness. The aerobic exercise group will arranged to the supervised aerobic dance program, it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
62166520|NCT03869411|EXPERIMENTAL|home exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness.The home exercise group will give the exercise recommendation based on ACSM's guideline, and it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
62166521|NCT03869411|ACTIVE_COMPARATOR|health control group|This study will recruit subjects without type 2 diabetes and the age matched to the diabetes groups.
62166522|NCT02841176|EXPERIMENTAL|Experimental|Thermography and Golimumab (solution for subcutaneous injection, 50 or 100 mg, monthly)
62166523|NCT03490942|EXPERIMENTAL|CSGI high infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
62166524|NCT03490942|EXPERIMENTAL|CSGI low infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
62166525|NCT03490942|PLACEBO_COMPARATOR|Placebo high infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
62166526|NCT03490942|PLACEBO_COMPARATOR|Placebo low infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
62166527|NCT02520414|EXPERIMENTAL|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
62166528|NCT01976156|EXPERIMENTAL|Phopsholean dietary supplement|Subjects in the Phospholean group will receive six capsules of PhosphoLean orally daily (total of 180 mg of NOPE and 120 mg of EGCG), ); two capsules consumed one hour before lunch, two capsules one hour prior to dinner, and two capsules two hours after dinner.
62166529|NCT01976156|PLACEBO_COMPARATOR|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule).
62166530|NCT05347602|OTHER|Phase 1: double-blinded placebo-controlled Supplement vs Placebo|Phase 1 (8 weeks): Supplement and Placebo groups ingested 3 oz of Supplement and Placebo per day respectively for the first four weeks as a loading dose, and then switched to 2 oz per day for weeks 5 - 8. This phase was double-blinded.
62166531|NCT05347602|NO_INTERVENTION|Washout Phase|"Phase 2 (4 weeks): Both groups underwent a month-long wash out period, during which they did not ingest any of the Supplement or Placebo. This lasted from weeks 9-12. This phase was not double-blinded as all participants and the researchers were aware of the wash-out procedure."
62166532|NCT05347602|ACTIVE_COMPARATOR|Phase 3: Supplement|Phase 3 (8 weeks): Both groups took the Supplement at 3 oz per day as a loading dose for four weeks (weeks 13 - 16), and then 2 oz per day for the final four weeks (weeks 17 - 20). This phase was open labeled, as all participants and the researchers were aware that all participants were ingesting the Supplement.
62166533|NCT06074055|OTHER|Programmed FET Protocol|Patients in this arm of the study will proceed with another programmed FET protocol which involves taking exogenous estrogen by mouth to stimulate the uterine lining to grow and develop. Once the lining has reached ≥ 7 mm and an endometrial pattern of type 1 or type 2, intramuscular progesterone in oil (50mg/ml daily) will be started at 8am on the morning that progesterone is initiated and continued per routine.
62166534|NCT06074055|OTHER|Modified Natural FET Protocol|Following development of at least one dominant follicle and endometrial proliferation ≥ 7 mm during cycle monitoring, patient will undergo administration of human chorionic gonadotropin (hCG) trigger shot followed by initiation of vaginal progesterone administration in accordance with institutional protocols.
62166535|NCT04994314|ACTIVE_COMPARATOR|orthodontic primer containing calcium fluoride nanoparticles|Fixed appliance for ten maxillary teeth and the contralateral mandibular teeth will be bonded using orthodontic primer containing calcium fluoride nanoparticles
62731427|NCT04556357|ACTIVE_COMPARATOR|Control group|Phenylephrine infusion simultaneous with subarachnoid block
62166536|NCT04994314|PLACEBO_COMPARATOR|Control primer|Fixed appliance for ten maxillary teeth (contralateral to experimental ten side)and the contralateral mandibular teeth will be bonded using conventional primer (TransbondTM XT orthodontic primers (3M-Unitek, Monrovia, USA)
62166537|NCT02884219|ACTIVE_COMPARATOR|Early Treatment with cyclooxygenase inhibitors|Treatment of PDA that starts within the first 3 days of life using cyclooxygenase-inhibitors (Ibuprofen or Indomethacin)
62166538|NCT02884219|SHAM_COMPARATOR|Expectative Treatment|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
62166539|NCT01125735|EXPERIMENTAL|MIST Therapy|MIST Therapy is a low energy, low intensity ultrasound delivered through a saline mist to the wound bed.
62166540|NCT01125735|OTHER|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
62166541|NCT05577663|OTHER|Spontaneous healing|Routine treatment of the extraction socket. Extraction of the tooth and suturing of the extraction socket with resorbable suture PGA 5/0 (polygalactic acid 5/0 sutures; PGA, medipac, Greece).
62166542|NCT05577663|ACTIVE_COMPARATOR|Free gingival graft|Extraction of the tooth, placement of a Free Gingival Graft taken from the palate and adjusted to seal the socket opening and stabilize it by resorbable sutures PGA 5/0 (polygalactic acid 5/0 sutures; PGA, medipac, Greece).
62166543|NCT05577663|EXPERIMENTAL|Polylactic-Glycolic Acid membrane|Extraction of the tooth, adjustment of the Polylactic-Glycolic Acid membrane (PLGA,Tisseos®, Biomedical Tissues, Septodont, France) over the socket opening resting by 1 mm over the alveolar crest of the extraction socket. Tissues are sutured over the barrier by resorbable sutures PGA 5/0 (polygalactic acid 5/0 sutures; PGA, medipac, Greece).
62166544|NCT05527054||AKI Group|
62166545|NCT05527054||Non-AKI Group|
62166546|NCT06003478||Hypertrophic Obstructive Cardiomyopathy Patients|
62166547|NCT02599987|EXPERIMENTAL|Inspiratory Muscle Training Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The training group will carry with IMT load of 50% of MIP. Weekly, patients attend the Cardiopulmonary Physical Therapy Laboratory for evaluation of MIP and load adjustment, performing a training session in the presence of the therapist, while other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
62166548|NCT02599987|SHAM_COMPARATOR|Sham Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The sham group will carry without load, but will be subjected to the same procedures in the experimental group (simulation of load adjustment in the Cardiopulmonary Physical Therapy Laboratory) to ensure blinding of the study, other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
62166549|NCT01955720|EXPERIMENTAL|healthy subjects aged 45-64|Sequential Crossover to Placebo or BI 655075
62731428|NCT04556357|EXPERIMENTAL|Norepinephrine group|Norepinephrine infusion simultaneous with subarachnoid block
62166550|NCT01955720|EXPERIMENTAL|healthy elderly subjects aged 65-80 year|Sequential Crossover to Placebo or BI 655075
62166551|NCT01955720|EXPERIMENTAL|mild renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
62166552|NCT01955720|EXPERIMENTAL|mod renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
62166553|NCT01631825|EXPERIMENTAL|SPM 962|SPM 962 transdermal patch
62166554|NCT06450275|EXPERIMENTAL|Dolutegravir Film Coated Tablet|Dolutegravir 50mg Film Coated Tablet
62166555|NCT06450275|ACTIVE_COMPARATOR|Tivicay film-coated tablets|Tivicay 50mg, film-coated tablets
62166556|NCT02095938|EXPERIMENTAL|Solian|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician
62166557|NCT04891159||Shared decision making|During the first consultation (V1), the doctor will present the patient on the therapeutic treatment information related to diabetes according to the shared decision making (options, benefits, risks) with the assistance of decision support tools. The decision-making visit will take place after a reflection period of 8 to 15 days after V1. A discussion based on the feedback from this period of reflection will take place between the two actors and either there is a common agreement on the decision taken (shared decision-making), or the decision is taken by the patient, or the decision is made by the physician at the request of the patient. A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing. After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires: SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire
62166558|NCT04891159||Control group|"Decision-making for insulin therapy is based on the usual practice defined in each Cystic Fibrosis Centers Competences with decision-making procedures specific to each center and doctor. The decision-making process is generally carried out in two consultations.~A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing.~After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires (SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire)."
62731429|NCT05729113|EXPERIMENTAL|Distraction technique|
62731430|NCT05729113|NO_INTERVENTION|Pain monitor|
62731431|NCT01102491|EXPERIMENTAL|Ramosetron prophylaxis|ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery
62731432|NCT01102491|NO_INTERVENTION|Control|no antiemetic prophylaxis
62731433|NCT06469190|EXPERIMENTAL|KN5501|
62731434|NCT05551845||Subject use both KD-595 Arm Automatic Electronic BPM and mercury sphygmomanometers|
62166559|NCT04293055|EXPERIMENTAL|Maintenance program+possibility of phone coaching|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. Some participants randomized to this condition will also receive 4 consecutive weeks of phone coaching at some point over the 1-year intervention period (this is determined by a weight-based algorithm).
62166560|NCT04293055|ACTIVE_COMPARATOR|Maintenance program only|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. No participants in this condition will receive phone coaching.
62166561|NCT06487897|EXPERIMENTAL|Single arm treatment with the VIS Optimal Keratoplasty (Opti-K™) System|Subjects who accept monovision will receive Opti-K™ treatment in the non-dominant eye. The fellow eye will not receive Opti-K™ treatment in this Pivotal Study. Eligible subjects will undergo a single retreatment
62166562|NCT05243498||no acute GVH, no chronic GVH|
62166563|NCT05243498||acute GVH without chronic GVH|
62166564|NCT05243498||chronic GVH without acute GVH|
62166565|NCT05243498||acute and chronic GVH|
62166566|NCT02351609|EXPERIMENTAL|Intervention|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 6-month period. Patients will receive financial incentives for biochemically confirmed smoking cessation.
62166567|NCT02351609|ACTIVE_COMPARATOR|Enhanced Traditional Care control|Patients receive information about smoking cessation resources and an educational brochure developed by the Massachusetts Department of Public Health.
62166568|NCT00310024|EXPERIMENTAL|Treatment (vorinostat, bortezomib)|"Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.~Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies."
62166569|NCT01103271|EXPERIMENTAL|Open-label Placebo Immediate Treatment|Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.
62166570|NCT01103271|PLACEBO_COMPARATOR|Open-label Placebo Waitlist Treatment|Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.
62166571|NCT03343509|EXPERIMENTAL|Group A - Oral|Oral metronidazole 400mg 3 times a day for 7 days Placebo ointment applied 3 time times a day for 7 days to affected region
62166572|NCT03343509|EXPERIMENTAL|Group B - Topical|Topical metronidazole ointment 10% 3 times a day for 7 days Oral placebo tablets 3 times a day for 7 days
62166573|NCT00840788|EXPERIMENTAL|Skin adhesive|perineal skin repair with octyl-2-cyanoacrylate skin adhesive
62166574|NCT00840788|ACTIVE_COMPARATOR|subcuticular suture|continuous subcuticular suture of perineal skin using rapidly absorbable polyglactin 910
62166575|NCT06311448||Treated with immunomodulation|Adult patients with COVID-19 ARDS admitted to ICU and requiring mechanical ventilation and receiving standard of care treatment (including steroids) and single-target immunomodulation, for example Toculizimab, Anakinra, etc.
62166576|NCT06311448||Not treated with immunomodulation|Adult patients with COVID-19 ARDS admitted to ICU and requiring mechanical ventilation and receiving standard of care treatment (including steroids).
62166577|NCT06402916|EXPERIMENTAL|Blueberry drink|46g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.
62166578|NCT06402916|PLACEBO_COMPARATOR|Placebo drink|46g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
62166579|NCT05740371|OTHER|Argatroban|
62166580|NCT03427645|NO_INTERVENTION|Control Surrogate Arm|Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques. This group will not be asked to use the decision making tool.
62166581|NCT03427645|EXPERIMENTAL|Surrogate Decision Tool Arm|This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
62166582|NCT01938209|EXPERIMENTAL|seated general thoracic spine manipulation|seated general thoracic spine manipulation
62166583|NCT01938209|EXPERIMENTAL|supine specific thoracic spine manipulation|Specific supine manipulation
62166584|NCT01670032|EXPERIMENTAL|CD07223 1.5 % Topical Gel BID|Drug: 1.5% CD07223 Topical Gel applied BID for 7 days
62166585|NCT01670032|EXPERIMENTAL|CD07223 1.5% Topical Gel TID|Drug: 1.5% CD07223 Topical Gel applied TID for 7 days
62166586|NCT01670032|PLACEBO_COMPARATOR|CD07223 vehicle gel BID|Drug: CD07223 Vehicle Topical Gel applied BID for 7 days
62166587|NCT01670032|PLACEBO_COMPARATOR|CD07223 vehicle gel TID|Drug: CD07223 Vehicle Topical Gel applied TID for 7 days
62166588|NCT02181751||Treatment Group|Children in the Treatment Group will receive treatment for a Trauma Focused Cognitive Behavioural Therapy Group.
62166589|NCT05673421|EXPERIMENTAL|Exergaming Training Group|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks.
62166590|NCT05673421|ACTIVE_COMPARATOR|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb. Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
62166591|NCT02332434|EXPERIMENTAL|sleeve gastrectomy|bariatric surgery procedure based exclusively on the gastric restriction (the sleeve gastrectomy).
62166592|NCT02332434|EXPERIMENTAL|gastric bypass|bariatric surgery procedure associating a malabsorption (the gastric bypass).
62166593|NCT01394263|ACTIVE_COMPARATOR|Zoladex goserelin implant.|Zoladex goserelin implant: D, L-lactic and glycolic acids copolymer. Injected subcutaneously into the upper abdominal wall.
62166594|NCT01394263|EXPERIMENTAL|Histrelin Acetate implant|Histrelin hydrogel implant, 3 cm x 3.5 mm, containing 50 mg of histrelin acetate, surgically placed subdermally into the inner aspect of the upper arm.
62166595|NCT05905445|EXPERIMENTAL|ozone gel with conventional scaling and root planning|administered ozone gel in the probing pocket depth after scaling and root planning by a disposable plastic syringe with a blunt tip until the access ozone became out of the pocket. this procedure is made at baseline and in the first month. instructed the patient not to eat or drink for at least 30 minutes
62166596|NCT05905445|NO_INTERVENTION|only conventional scaling and root planning|only scaling and root planning without any intervention.
62166597|NCT01803789|ACTIVE_COMPARATOR|Single Kirschner Wire|Antegrade intramedullary fixation of with a single Kirschner wire.
62166598|NCT01803789|ACTIVE_COMPARATOR|Double Kirschner Wire|Antegrade intramedullary fixation with double Kirschner wire.
62166599|NCT02596178|EXPERIMENTAL|EIT Guided PEEP Therapy|
62166600|NCT04900545||beta blocker navie patients with acute coronary syndrome|
62166601|NCT06584617|EXPERIMENTAL|Berovenal®|
62166602|NCT06584617|ACTIVE_COMPARATOR|NU-GEL Hydrogel with Alginate|
62166603|NCT05740904|EXPERIMENTAL|New defocus spectacle lens|The children in the experimental group will wear new defocus spectacle lens and receive follow-up examinations every half year.
62166604|NCT05740904|ACTIVE_COMPARATOR|Conventional aspheric single-vision spectacle lenses|The children in the control group will wear conventional aspheric single-vision spectacles and receive follow-up examinations every half year.
62166605|NCT03427879|PLACEBO_COMPARATOR|Low flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, low flavonoid, sports nutrition recovery beverage 14 days.
62166606|NCT03427879|ACTIVE_COMPARATOR|High flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, high flavonoid, sports nutrition recovery beverage 14 days.
62166607|NCT01330719|EXPERIMENTAL|Diseased periodontal treatment|Scaling and root planing along with systemic antibiotics (Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days).
62166608|NCT01330719|ACTIVE_COMPARATOR|Conventional periodontal treatment|Standard periodontal prophylaxis
62166609|NCT01870999|EXPERIMENTAL|400 mg Aripiprazole IM Depot|400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
62166610|NCT01870999|EXPERIMENTAL|300 mg Aripiprazole IM Depot|300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
62166611|NCT01870999|EXPERIMENTAL|200 mg Aripiprazole IM depot|200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
62166612|NCT02732899|EXPERIMENTAL|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
62166613|NCT02732899|ACTIVE_COMPARATOR|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
62166614|NCT00390936|NO_INTERVENTION|1|4 dosages
62166615|NCT02931240|EXPERIMENTAL|Treatment|Treatment with the Revivent TC System
62735176|NCT02964273|EXPERIMENTAL|Phase B: Prior Placebo|Qualified participants (defined as those who were willing to continue in the trial and who did not have any AEs that would require IMP discontinuation) who received matching-placebo and completed Phase A, were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), based on their current body weight as per following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.
62166616|NCT02931240|NO_INTERVENTION|Control Pool|Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
62166617|NCT04225234|ACTIVE_COMPARATOR|Weight loss incentive|Participants will receive incentive rewards based on WEIGHT LOSS outcomes.
62166618|NCT04225234|EXPERIMENTAL|Weigh-in incentive|Participants will receive incentive rewards based on WEIGH-INs frequency
62166619|NCT04225234|EXPERIMENTAL|Combination incentive|Participants will receive half of the incentive from WEIGHT LOSS and WEIGH-INs
62166620|NCT04225234|EXPERIMENTAL|Choice option incentive|Participants will choose one out of the three incentive programs (Weight-loss, Weigh-ins, and Combination).
62166621|NCT01882088|EXPERIMENTAL|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
62166622|NCT03044951|EXPERIMENTAL|cryoballoon ablation|patients who accept cryoballoon ablation
62166623|NCT03044951|ACTIVE_COMPARATOR|radiofrequency ablation|patients who accept radiofrequency ablation
62166624|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
62166625|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
62731435|NCT05113316|EXPERIMENTAL|Messy Memories App Group|"Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days (affect rating sliders), their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.~The Messy Memories app will also collect data on how frequently and for how long each participant uses the app. Each response will trigger a prompt within the app, and will be recorded with a timestamp (date and time) to indicate when the participant provided a particular response. For all participants, self-report measures will be collected at weeks 4, 8, 12, and 16."
62731436|NCT05113316|NO_INTERVENTION|Treatment as usual (TAU) Group|Subjects will not receive any study treatments or have access to the app but may seek standard treatment if they choose, in addition to completing self-report measures. For 8 weeks, TAU group will participate in the study under treatment as usual. For weeks 9-16, the TAU group will then switch and have full access to the Messy Memories App to review and use for a limited amount of time. Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days, their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.
62731437|NCT04304053|ACTIVE_COMPARATOR|No Intervention- SARS-CoV-2 surveillance|"Study 1- Contacts will complete a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and day 14.~Study 2- Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3 and 7.~Isolation of patient and contact tracing as per national guidelines."
62731438|NCT04304053|EXPERIMENTAL|Testing, treatment and prophylaxis of SARS-CoV-2|"Study 1- Contacts receive Hydroxychloroquine prophylaxis. Contacts will complete a survey collecting demographic, epidemiological and clinical and provides a swab for RT-PCR testing at baseline and day 14.~Study 2- Index case receives Hydroxychloroquine. Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3, and 7.~Isolation of patient and contact tracing as per national guidelines."
62731439|NCT01274598|EXPERIMENTAL|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|Lactobacillus rhamnosus GG ATCC 53103 1 x 10\^10 twice a day for 28 days
62731440|NCT03042429|EXPERIMENTAL|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
62731441|NCT03042429|ACTIVE_COMPARATOR|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
62731442|NCT04404673||Open rectal resection|
62731443|NCT04404673||Laparoscopic rectal resection|
62731444|NCT04404673||Robotic rectal resection|
62731445|NCT04404673||Trans-anal TME (Ta-TME)|
62731446|NCT03915990|OTHER|control group|60 healthy pregnant women will be included
62731447|NCT03915990|ACTIVE_COMPARATOR|controlled diabetics|30 diabetic pregnant women with controlled Diabetes (i.e. HbA1C less than 6.5 %)
62731448|NCT03915990|ACTIVE_COMPARATOR|uncontrolled diabetics|30 diabetic pregnant women with uncontrolled Diabetes (i.e. HbA1C equal or more to 6.5 %)
62731449|NCT01101893|EXPERIMENTAL|Period 1|In period 1 all subjects will receive Raltegravir 400mg q12h from Day 1 to Day 5
62731450|NCT01101893|EXPERIMENTAL|Period 2|In period 2 all subjects will receive GSK2248761 200mg q24h from Day 1 to Day 5.
62731451|NCT01101893|EXPERIMENTAL|Period 3|Day 1 of Period 3 will be the day after Day 5 of Period 2. Subjects will receive GSK2248761 200mg q24h + raltegravir 400mg q12h from Day 1 to Day 5.
62731452|NCT04884880|EXPERIMENTAL|Luo-Fu-Shan Plaster 10g|10g，once daily，4 weeks
62731453|NCT04884880|PLACEBO_COMPARATOR|Placebo|10g，once daily，4 weeks
62731454|NCT02100423|EXPERIMENTAL|Treatment (curcumin, cholecalciferol)|Patients receive curcumin PO daily on days 1-28 and cholecalciferol PO daily on days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving partial response or better may receive treatment for a total of 2 years.
62731455|NCT03785353|EXPERIMENTAL|PNE Group|A group of Spanish-speaking individuals will listen to a translated lecture related to PNE (PNE lecture). They will fill out the R-NPQ pre and post the lecture.
62731456|NCT00358319|EXPERIMENTAL|Phase I|Dose escalation phase
62731457|NCT00358319|EXPERIMENTAL|Phase II|All patients enrolled in the Phase II will be treated with Valproic Acid (VPA) and Karenitecin using the dosing schedule determined to be the Maximum Tolerated Dose (MTD) in Phase I.
62731458|NCT02075424|EXPERIMENTAL|salivery sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call For each participant, a serie of control-samples will be taken during a day off and during a security break."
62731459|NCT00628459|ACTIVE_COMPARATOR|1|
62731460|NCT00628459|EXPERIMENTAL|2|
62731461|NCT00628459|EXPERIMENTAL|3|
62731462|NCT02779777|EXPERIMENTAL|Regimen 1: Tipifarnib|600 mg twice daily (bid) for 7 days on Days 1-7 in 28 day cycles.
62731463|NCT02779777|EXPERIMENTAL|Regimen 2: Tipifarnib|300 mg bid for 21 days on Days 1-21 in 28 day cycles.
62731464|NCT04994665|ACTIVE_COMPARATOR|Sleeve gastrectomy|realization of a sleeve gastrectomy alone
62731465|NCT04994665|EXPERIMENTAL|sleeve gastrectomy with omentopexy|realization of a sleeve gastrectomy followed by an omentopexy
62166626|NCT04719273|EXPERIMENTAL|Treatment (onapristone, anastrozole)|Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
62166627|NCT02056873|EXPERIMENTAL|Continuous Deep Brain Stimulation (DBS)|"Subjects' DBS surgical intervention requires implantation of a DBS system: two CM thalamic leads (one in each brain hemisphere), two ECOG strip leads (one in each brain hemisphere), and two neurostimulators implanted in the chest.~The ECOG strip lead is implanted into the brain to provide an interface through which stimulation can be delivered or activity of the brain can be monitored by the device, or observed by a clinician using a programmer.~Neurostimulator and leads system includes a programmer, which includes a wand and telemetry interface, and a patient remote control to check battery status and whether the device is on or off. The programmer is used to set up the device, including setup of stimulation and recording, as well as to retrieve data for subsequent review."
62166628|NCT02056873|EXPERIMENTAL|Responsive Brain Stimulation (RBS Setting)|Eligible participants from Arm 1 will be switch to the RBS intervention.
62166629|NCT01975259||Cystic Fibrosis|"Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions:~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring"
62166630|NCT01975259||Controls|"Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance.~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich)"
62166631|NCT01951105|NO_INTERVENTION|Observation|Individuals identified as having a recovering phenotype (SBPp) will be assigned to the observational arm and will be asked to continue his/her normal regime and return for the week 12 and week 24 visits for follow-up.
62166632|NCT01951105|ACTIVE_COMPARATOR|Carbidopa/Levodopa & Naproxen|"Individuals identified as having a persisting phenotype (SBPr) will be treated with Carbidopa/Levodopa on a flexible dose-titration designed intervention based on dose-response TID throughout the 12 week treatment period.~Naproxen (250mg) capsules will be administered orally, one capsule TID, throughout the 12 week treatment period."
62166633|NCT01951105|PLACEBO_COMPARATOR|Placebo & Naproxen|Individuals identified as having a persisting phenotype (SBPr) will be treated with placebo capsule plus 250mg naproxen tablet three times a day for 12 weeks.
62731466|NCT03326063|ACTIVE_COMPARATOR|Ifetroban|Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.
62166634|NCT03154827|EXPERIMENTAL|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
62166635|NCT02330861|OTHER|Normal coronary artery|
62166636|NCT06080178|ACTIVE_COMPARATOR|Static group|"When during surgery systolic blood pressure (SBP) is below 100mmHg:~* give a fluid bolus (Plasmalyte A) until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg~* if the 5ml/kg/h crystalloid limit is already reached: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.~When SBP remains below 100mmHg after reaching a vasopressor dose of 0.2mcg/kg/min: the anaesthetist can decide to give a bolus of 6mg ephedrine intravenous (IV) (with a maximum dose of 12mg ephedrine iv per hour)."
62166637|NCT06080178|EXPERIMENTAL|Dynamic group|"After insertion of an arterial line, a pulse contour analysis system will be installed (Acumen IQ sensor, Edwards) for measuring PPV and cardiac index (CI).~When during surgery SBP is below 100mmHg and PPV is above 12%:~• give a fluid bolus (Plasmalyte A) until PPV is below or equal to 12% or SBP is above 100mmHg~When during surgery SBP is below 100mmHg and PPV is below or equal to 12%:~• start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min) When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.~When SBP remains below 100mmHg after reaching a vasopressor dose of 0.2mcg/kg/min, and CI is \< 2.2 L/min/m², a bolus of 6mg ephedrine iv will be given (with a maximum dose of 12mg ephedrine iv per hour)."
62166638|NCT03816202||Sundt Carotid Shunt|Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt.
62166639|NCT06006754||Cardiogenic shock|
62166640|NCT00512941||1|HBV: Carrier
62166641|NCT00512941||2|HBV: cure
62166642|NCT00512941||3|HBV: isolate anti-HBc
62166643|NCT00512941||4|HBV: vaccinated
62166644|NCT00512941||5|HCV: anti-HCV positive test
62166645|NCT00512941||6|HBV/HCV co-infection
62166646|NCT00512941||7|Susceptible individuals
62166647|NCT05134948|EXPERIMENTAL|Cohort A: BMS-986213 Fixed Dose Combination|
62166648|NCT05134948|EXPERIMENTAL|Cohort B: BMS-986213 Fixed Dose Combination|
62166649|NCT02811302|OTHER|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
62166650|NCT02775175|NO_INTERVENTION|Fasting as Usual|This group will continue to practice their usual fasting regimen during Ramadan
62166651|NCT02775175|EXPERIMENTAL|Modified Ramadan Fasting|This group will receive an educational intervention providing knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
62166652|NCT03266003|OTHER|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
62166653|NCT03266003|OTHER|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
62731467|NCT03326063|PLACEBO_COMPARATOR|Placebo|Subjects will be randomized to receive placebo for 4 weeks.
62731468|NCT00510445|EXPERIMENTAL|Single Arm Trial|Patients will be enrolled in the order of confirmation of eligibility. Dose cohorts will be filled sequentially with a minimum of 3 patients. Once assigned to a dose cohort, each patient will continue to be treated at the same dose level throughout the course of the study.
62166654|NCT00598156|EXPERIMENTAL|1|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
62166655|NCT00598156|EXPERIMENTAL|2|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
62166656|NCT05928689|EXPERIMENTAL|Memory Reminder followed by Propranolol Hydrochloride|This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a propranolol hydrochloride tablet.
62166657|NCT05928689|PLACEBO_COMPARATOR|Memory reminder followed by Placebo|This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a placebo tablet.
62166658|NCT05928689|EXPERIMENTAL|No memory reminder followed by Propranolol Hydrochloride|This arm aims to have 30 participants with a pharmacological manipulation. They will not receive a reminder to reactivate their memory of a misophonia sound and only receive a propranolol hydrochloride tablet.
62166659|NCT05928689|EXPERIMENTAL|Memory reminder followed by counterconditioning|This arm aims to have 30 participants with a behavioral manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger and then will undergo counterconditioning.
62166660|NCT05928689|EXPERIMENTAL|No memory reminder followed by counterconditioning|This arm aims to have 30 participants with a behavioral manipulation. They will not receive a reminder to reactivate their memory of a misophonia trigger and then undergo counterconditioning.
62166661|NCT01174862||Aspirin responder|Normal aspirin responsiveness in ASPI test (Multiplate)
62166662|NCT01174862||Aspirin non-responder|Reduced aspirin responsiveness in ASPI test (Multiplate)
62166663|NCT00860899|ACTIVE_COMPARATOR|clonidine|Clonidine is an alpha2-adrenergic agonist with sedative, analgesic and hemodynamic properties. It inhibits transmission of nociceptive stimuli in the dorsal horn of the spinal cord, acting on the inhibitory descending pathways.
62166664|NCT00860899|ACTIVE_COMPARATOR|levobupivacaine|Levobupivacaine is long-acting local anesthetic, S-enantiomer of bupivacaine, with identical anesthetic potency.
62166665|NCT05456113|PLACEBO_COMPARATOR|Placebo|Vehicle control, does not contain cannabidiol
62166666|NCT05456113|EXPERIMENTAL|Cannabidiol|Active ingredient experimental arm, contains full spectrum connabidiol
62166667|NCT03630783|EXPERIMENTAL|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
62166668|NCT03630783|PLACEBO_COMPARATOR|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
62166669|NCT05268185|ACTIVE_COMPARATOR|Moderna Booster Recommendation|Participants assigned to this arm will be recommended to receive the Moderna vaccine for their Covid-19 booster shot.
62166670|NCT05268185|ACTIVE_COMPARATOR|Pfizer Booster Recommendation|Participants assigned to this arm will be recommended to receive the Pfizer vaccine for their Covid-19 booster shot.
62166671|NCT03386799||Patient in wheelchair|Patient in wheelchair with E-motion device
62166672|NCT05887479|ACTIVE_COMPARATOR|Study Group|This is the group that will be injected with botulinum toxin for spasticity and stretching exercises will be given.
62166673|NCT05887479|PLACEBO_COMPARATOR|Control Group|This is the group that will be injected with %0,9 NaCl for spasticity and stretching exercises will be given.
62166674|NCT00449033|EXPERIMENTAL|Sorafenib (Nexavar, BAY43-9006) + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m\^2 infusion (IV), followed by cisplatin 75 mg/ m\^2 IV; Day 8: gemcitabine 1250 mg/ m\^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
62166675|NCT00449033|PLACEBO_COMPARATOR|Placebo + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m\^2 infusion (IV), followed by cisplatin 75 mg/ m\^2 IV; Day 8: gemcitabine 1250 mg/ m\^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
62166676|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy +/- bilateral salpingo-oophorectomy for endometrial or ovarian cancer or precursors
62166677|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
62166678|NCT02042625|OTHER|nasopharyngeal|The nasopharyngeal probe will be inserted into the nostril. The nasopharyngeal temperature will initially be recorded 45 minutes after anesthetic induction. The nasopharyngeal probe will then be withdrawn 2 cm and after a 3-minute equilibration period, nasopharyngeal temperatures will again be recorded. The nasopharyngeal probe withdrawal sequence will be repeated, 2 cm at a time, until only 2 cm remains in the nostril. There will be a total of 10 sets of nasopharyngeal temperatures obtained.
62731469|NCT02373046|EXPERIMENTAL|Treatment A|1 × 400-mg LX4211 tablet (fasted conditions)
62731470|NCT02373046|EXPERIMENTAL|Treatment B|2 × 200-mg LX4211 tablets (fasted conditions)
62731471|NCT00651014|EXPERIMENTAL|Ezetimibe|
62731472|NCT00651014|PLACEBO_COMPARATOR|Placebo|
62731473|NCT03046446|EXPERIMENTAL|FX006 32 mg|Single intra-articular injection
62731474|NCT04512001|EXPERIMENTAL|MSB11456|
62731475|NCT04512001|ACTIVE_COMPARATOR|RoActemra®|
62166679|NCT03392688|EXPERIMENTAL|Patellofemoral pain group|"Diagnosis of PFP was established based on symptoms, physical examination performed by an orthopedic surgeon. Patients were also screened through physical examination to rule out ligamentous or meniscal injuries, patellar tendinitis and knee joint effusion by an orthopedic surgeon. All patients also underwent a radiologic examination consisting of AP, lateral and tangential radiograms.~Surface EMG, Kujala patellofemoral pain scale, Q angle measurement were administered to the PFP group."
62166680|NCT03392688|ACTIVE_COMPARATOR|Control Group|"Control group had similar demographic characteristics with PFP group, and neither one of the controls had any knee pathology or current knee pain or effusion that would effect the gait.~Surface EMG, Q angle measurement were administered to the control group."
62166681|NCT03661749|EXPERIMENTAL|Clean catch|women in this group will collect urine for PR/CR using a clean catch technique
62166682|NCT03661749|PLACEBO_COMPARATOR|Non-clean catch|women in this group will not employ clean catch technique
62166683|NCT05893225|ACTIVE_COMPARATOR|Treatment group|The treatment group will receive Metformin Hydrochloride oral tablets 850mg tid or bid, during a maximum of 96 weeks.
62166684|NCT05893225|PLACEBO_COMPARATOR|Control group|The control group will receive a matching placebo, during a maximum of 96 weeks.
62166685|NCT03911141|NO_INTERVENTION|Control|Participants receive a daily text message stating whether or not they achieved their step goal on the prior day during the 12 months of intervention and 6 months of follow-up.
62166686|NCT03911141|EXPERIMENTAL|Gamification Intervention|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
62166687|NCT03911141|EXPERIMENTAL|Financial Incentive Intervention|"Participants are informed that each week that money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
62166688|NCT03911141|EXPERIMENTAL|Gamification and Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
62166689|NCT03367845|EXPERIMENTAL|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
62166690|NCT03367845|EXPERIMENTAL|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity; with COVID-19, we now conduct remote visits using Zoom
62166691|NCT03367845|EXPERIMENTAL|Couples Intervention|Home visits to enhance constructive couples' communication; with COVID-19, we now conduct remote visits using Zoom
62166692|NCT03367845|EXPERIMENTAL|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions; with COVID-19, we now conduct remote visits using Zoom
62166693|NCT03191526|EXPERIMENTAL|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
62166694|NCT03191526|PLACEBO_COMPARATOR|Placebo (saline)|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
62166695|NCT02784535|PLACEBO_COMPARATOR|placebo|placebo capsules
62166696|NCT02784535|ACTIVE_COMPARATOR|atomoxetine|atomoxetine capsules 10 mg or 18 mg
62166697|NCT02547025|EXPERIMENTAL|rabeprazole+3 antibiotics|patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days
62166698|NCT02547025|EXPERIMENTAL|rabeprazole+bismuth+2 antibiotics|patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days
62166699|NCT02547025|ACTIVE_COMPARATOR|rabeprazole+amox+tetr+levo|patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days
62166700|NCT06329544|EXPERIMENTAL|Fructose Dietary then Glucose Dietary|Participants that will be randomized to the 12-day isocaloric weight-maintaining high fructose diet, then will change to the 12-day isocaloric weight-maintaining high glucose diet after a 10-day washout period.
62166701|NCT06329544|EXPERIMENTAL|Glucose Dietary then Fructose Dietary|Participants that will be randomized to the 12-day isocaloric weight-maintaining high glucose diet, then will change to the12-day isocaloric weight-maintaining high fructose diet after a 10-day washout period.
62166702|NCT04925245|EXPERIMENTAL|Clinical Reminder|
62166703|NCT04925245|NO_INTERVENTION|No Reminder|
62166704|NCT00866502|EXPERIMENTAL|sNN0031|Continuous ICV infusion for two weeks at one of three dose levels
62166705|NCT00866502|PLACEBO_COMPARATOR|Placebo|Continuous ICV infusion
62166706|NCT05389254|EXPERIMENTAL|real-time CGM group|Participants in this group will be implanted with sensors of SISENSING® GS1 continuous glucose monitoring system in their left upper arm within 24 hours after hospitalization. According to the real-time CGM blood glucose data and clinical needs, researchers will carry out individualized in-hospital blood glucose standard management.
62166707|NCT05389254|OTHER|Capillary blood glucose monitoring group|Participants in this group will be implanted with sensors of SISENSING® GS1 continuous glucose monitoring system in their left upper arm within 24 hours after hospitalization. But these patients will be blind to the CGM data. They'll receive 8-point capillary blood glucose monitoring simultaneously, which are 6am, 9am, 11am, 1pm, 4pm, 7pm, 9pm, 2am. According to the 8-point glucose data and clinical needs, researchers will carry out individualized in-hospital blood glucose standard management.
62166708|NCT04786431||Controls, CVD, IS, SLE|"Control (n = 85) were taken from the population of the Coimbra and Lisbon, Portugal, regions. They satisfied the criterion that they had never had any CVD- or SLE-related health complaints.~The CVD patients (n = 238) were divided into 6 groups. CVD1 (n = 61) contains individuals who went to the hospital with chest pain but had no indicators for stable angina pectoris, unstable angina pectoris or myocardial infarction.~Acute ischemic stroke (IS) (n = 21) were patients admitted at the emergency room of the Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, who suffered from acute ischemic stroke.~The SLE cohort (n = 104) were patients from Hospital Dr. Fernando Fonseca, Amadora, Portugal."
62166709|NCT02854436|EXPERIMENTAL|Niraparib|Participants will receive 300 milligram (mg) niraparib (3 capsules\*100 mg) orally once daily.
62166710|NCT04178096|OTHER|Quality Improvement Intervention|Twelve low-performing sites will receive a package of strategies which have been empirically determined to be associated with successful implementation of evidence based practices that lead to improved health outcomes for Veterans with cirrhosis.
62166711|NCT04178096|NO_INTERVENTION|Control Arm|All sites besides the pre-selected twelve, a total of one hundred eighteen sites, will not receive the intervention and will provide care as usual.
62166712|NCT04260282||Neutrophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils \<300/mm3 in blood and \<3% in induced sputum
62166713|NCT04260282||Eosinophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils \>300/mm3 in blood and/or \>3% in induced sputum
62166714|NCT05311956|EXPERIMENTAL|Experimental|Patients will receive tDCS delivered over the motor cortex, at an intensity of 2mA, delivered for 20 minutes 5 times each week over eight consecutive weeks (40 applications in total).
62166715|NCT05311956|SHAM_COMPARATOR|Sham Comparator|Sham treatment will consist of 30 seconds of the direct current at 2mA and 0 current for the remaining time of the 20-minute application 5 times per week over eight consecutive weeks (40 applications in total).
62166716|NCT03748680|ACTIVE_COMPARATOR|A|Intensified follow-up schedule
62166717|NCT03748680|EXPERIMENTAL|B|Adjuvant chemotherapy + intensified follow-up schedule
62166718|NCT05550584|EXPERIMENTAL|THRIVE|Ventilatory management during surgery provided by transnasal humidified rapid-insufflation ventilatory exchange.
62166719|NCT05550584|ACTIVE_COMPARATOR|Control|Ventilatory management during surgery provided by mechanical ventilation through laringeal mask
62166720|NCT01825018|EXPERIMENTAL|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be taught to endorse compliance with medical guidelines, safer behaviors, and effective ways to communicate these concepts to social network members.
62166721|NCT01825018|ACTIVE_COMPARATOR|Comparison Group|Members of social networks assigned to this group will receive only HIV counseling at the baseline session.
62166722|NCT03740932||Study group (group A):|It will consist of 30 subjects who will have cyclic pelvic pain
62166723|NCT03740932||Study group (group B):|It will consist of 30 subjects who will have non cyclic pelvic pain.
62166724|NCT03740932||Control group (group C):|It will consist of 30 subjects normal women who will not having pelvic pain.
62166725|NCT02232919|EXPERIMENTAL|Deep Brain Stimulation|The design of this translation trial is a single-center, single cohort, open-label and non-masked study. The aim is to evaluate tolerability of chronic low-frequency electrical stimulation of the VMH, while achieving weight loss in morbidly obese subjects. The subjects must have a body-mass index \[BMI\] greater than 40, and no obesity co-morbidities, such as diabetes or cardiopulmonary abnormalities. Up to six subjects will be implanted in this protocol.
62166726|NCT03535493|ACTIVE_COMPARATOR|Acceptance and Commitment Therapy (ACT)|
62166727|NCT03535493|ACTIVE_COMPARATOR|Float REST|
62166728|NCT03535493|EXPERIMENTAL|ACT + Float REST|
62166729|NCT03169530|ACTIVE_COMPARATOR|Alcohol|One standard serving of alcohol (\~15 gm) daily
62166730|NCT03169530|NO_INTERVENTION|Abstention|Abstention from alcohol
62166731|NCT05974371|EXPERIMENTAL|Emotional memory updating paradigm|All participants will encode AB/AC word pairs shown with images that have differing emotional valence (positive, negative, or neutral)
62166732|NCT06275906|EXPERIMENTAL|Intervention arm 1|"The 1st arm involves a low-calorie diet, which respects the criteria of the Mediterranean diet, with the following macronutrient percentage: carbohydrates 50% of total calories, lipids 30% of total calories, proteins 20% of total calories.~The dietary intervention will be combined with moderate intensity exercise (outdoor walking)."
62166733|NCT06275906|EXPERIMENTAL|Intervention arm 2|"The 2nd arm involves a low-calorie diet, which respects the criteria of the Mediterranean diet, with the following percentage of macronutrients: carbohydrates 30% of total calories, lipids 50% of total calories, proteins 20% of total calories.~The dietary intervention will be combined with moderate intensity exercise (outdoor walking)."
62166734|NCT02884921|ACTIVE_COMPARATOR|Preemptive Paracetamol|Preemptive Paracetamol
62166735|NCT02884921|ACTIVE_COMPARATOR|Post surgery Paracetamol|Post surgery Paracetamol
62166736|NCT02884921|PLACEBO_COMPARATOR|Placebo|Placebo
62166737|NCT00073788||Subjects with PTSD|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Study group subjects will be PTSD positive. Overt CVD is exclusionary.
62166738|NCT00073788||Control Group|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Control subjects will be PTSD negative. For both groups: overt CVD is exclusionary.
62166739|NCT05852171|EXPERIMENTAL|Baricitinib|Baricitinib，2mg QD，oral use.
62166740|NCT05018871|EXPERIMENTAL|Treatment Group|Single intravenous infusion of 100 million cells
62731476|NCT03748589|EXPERIMENTAL|airway type 1|The children weighed between 2-5kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1
62166741|NCT03558750|EXPERIMENTAL|Treatment (nivolumab, rituximab, lenalidomide)|Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
62166742|NCT03826225||Study Cohort|All participants are considered to be in the study cohort and will have the study device placed externally on their skin in order to collect human ECG data.
62166743|NCT00972114|EXPERIMENTAL|CABG combined cardiomyoplasty|Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
62166744|NCT00972114|ACTIVE_COMPARATOR|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
62166745|NCT00972114|ACTIVE_COMPARATOR|CABG alone|Coronary artery bypass graft surgery alone
62166746|NCT02101554|EXPERIMENTAL|Embeda|One arm, open label, active
62166747|NCT03239171|ACTIVE_COMPARATOR|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (\> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62166748|NCT03239171|ACTIVE_COMPARATOR|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62166749|NCT03239171|EXPERIMENTAL|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (\> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
62166750|NCT03239171|NO_INTERVENTION|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
62166751|NCT04715711|ACTIVE_COMPARATOR|Active Cooling|Participants will be actively cooled during rest breaks
62166752|NCT04715711|PLACEBO_COMPARATOR|No Intervention|"Participants will participant in passive cooling where they sit in a chair during rest."
62166753|NCT02946788|EXPERIMENTAL|BPX-01 1%|BPX-01 1% minocycline topical gel
62166754|NCT02946788|EXPERIMENTAL|BPX-01 2%|BPX-01 2% minocycline topical gel
62166755|NCT02065895|EXPERIMENTAL|HIGH error, LOW error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control equal blood glucose (NO error).
62166756|NCT02065895|EXPERIMENTAL|HIGH error, NO error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
62166757|NCT02065895|EXPERIMENTAL|NO error, HIGH error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-values-used-for-control higher than blood glucose (HIGH error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
62166758|NCT02065895|EXPERIMENTAL|NO error, LOW error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
62166759|NCT02065895|EXPERIMENTAL|LOW error, NO error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
62166760|NCT02065895|EXPERIMENTAL|LOW error, HIGH error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third glucose-value-used-for-control higher than blood glucose (HIGH error),
62166761|NCT04260984|ACTIVE_COMPARATOR|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
62166762|NCT04260984|ACTIVE_COMPARATOR|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
62166763|NCT05194813|EXPERIMENTAL|Hydrophilic sandblasted and acid-etched dental implants|
62166764|NCT05194813|ACTIVE_COMPARATOR|Conventional hydrophobic sandblasted and acid-etched dental implant|
62166765|NCT01671826||above 65 years old|
62166766|NCT04746690|ACTIVE_COMPARATOR|Slider neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch on one nerve end and slackness on the other end.
62731477|NCT03748589|EXPERIMENTAL|airway type 1.5|The children weighed between 5-12kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1.5
62166767|NCT04746690|ACTIVE_COMPARATOR|Tensioner neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch of both nerve ends.
62166768|NCT04746690|ACTIVE_COMPARATOR|Stretching exercises of back extensors, hamstrings and gastrocnemius muscles|Stretching exercises of back extensors, hamstrings and gastrocnemius to relief the pressure on the nerve.
62166769|NCT03520790|EXPERIMENTAL|Gemcitabine + Nab-paclitaxel + Placebo|"* Gemcitabine and Nab-paclitaxel is administered intravenously 3 times/cycle.~* Placebo is administered orally on a daily basis"
62166770|NCT03520790|EXPERIMENTAL|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"* Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~* Paricalcitol is administered intravenously once weekly."
62166771|NCT03520790|EXPERIMENTAL|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"* Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~* Paricalcitol is administered orally on a daily basis"
62166772|NCT05304884|ACTIVE_COMPARATOR|single dose ozone|Group 1 received a single dose ozone injection (n:36)
62166773|NCT05304884|ACTIVE_COMPARATOR|three doses of ozone|Group 2 (n:36) received three doses of ozone injection (n :36).
62166774|NCT05304884|ACTIVE_COMPARATOR|corticosteroid|Group 3 (n:36) was treated with a corticosteroid injection
62166775|NCT02331771|ACTIVE_COMPARATOR|donepezil|Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
62166776|NCT02331771|PLACEBO_COMPARATOR|Placebo|Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
62166777|NCT05189288|EXPERIMENTAL|Reference-Test|D418 Tab. - CKD-388 Tab.
62166778|NCT05189288|EXPERIMENTAL|Test-Reference|CKD-388 Tab. - D418 Tab.
62166779|NCT06456788||Healthcare workers|Healthcare workers at King's College Hospital NHS Foundation Trust (KCH) who have direct patient contact and fall within one of four groups: 1) they are not immune to measles (have not had measles in the past and have not been vaccinated with both doses of the MMR vaccine), 2) they have not completed the full vaccination schedule (they have received only 1 dose of the MMR vaccine), 3) they do not know their immunity status, and 4) they received the MMR vaccine after joining KCH
62166780|NCT01719068||Workers exposed to asbestos|
62166781|NCT00853203||Part 1|Interviews + Questionnaire + Electronically Activated Recorder (EAR)
62166782|NCT00853203||Part 2, Expressive Disclosure Group|Group Meetings + Written Materials
62166783|NCT00853203||Part 2, Standard Care Control Group|Written Materials
62166784|NCT01112371|EXPERIMENTAL|Contractubex|
62166785|NCT01112371|NO_INTERVENTION|Non treatment|
62166786|NCT04117477|EXPERIMENTAL|Xylitol wipes|
62166787|NCT04117477|PLACEBO_COMPARATOR|Placebo wipes|
62166788|NCT00729508|EXPERIMENTAL|1|
62166789|NCT00729508|EXPERIMENTAL|2|
62166790|NCT00729508|EXPERIMENTAL|3|
62731478|NCT03748589|EXPERIMENTAL|airway type 2|The children weighed between 10-25kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2
62166791|NCT00729508|EXPERIMENTAL|4|
62166792|NCT00729508|PLACEBO_COMPARATOR|5|
62166793|NCT05651334|EXPERIMENTAL|Active repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered with a MagPro R-30 magnetic stimulator (MagVenture, Farum, Denmark) Cool-B65 A/P (Active/Placebo). Participants will receive 900 pulses of 20 Hz rTMS per session at 110% of the Motor threshold (MT) (45 20-pulse trains of 1 second duration with an inter-train interval of 20 seconds). MT will be established to determine the intensity of stimulation for each participant, as recommended by safety guidelines. MT will be defined as the amount of energy required to induce a visible twitch in contralateral hand in at least 50% of stimulations. The target stimulation site will be the left DLPFC, specifically: located 6 cm anterior of the MT site identified with assistance from the neuro-navigation system to ensure that the target is located in the middle of the frontal gyrus, in the lateral part of Brodmann Area (BA) 9, near the border of BA 46.
62166794|NCT05651334|SHAM_COMPARATOR|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS will appear identical to active treatment, with the exception that the sham side of the coil will be used resulting in no stimulation being applied to the participant, while providing a sensation of stimulation.
62166795|NCT01745380|EXPERIMENTAL|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
62166796|NCT01745380|PLACEBO_COMPARATOR|Placebo|Placebo - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
62166797|NCT00739700||A|There is only one cohort of subjects, the critically ill. The NIBP will be correlated with the IABP in each subject.
62166798|NCT04263909|EXPERIMENTAL|sufentanil SL arm|Each patient will receive 30mcg of sufentanil SL prior to extubation in the operating room, and then as needed in the recovery room, guided by pain scores.
62166799|NCT00843245||heart failure|Heart failure attending a HF clinic with or without clinical decompensation
62166800|NCT05593016|EXPERIMENTAL|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
62166801|NCT05593016|EXPERIMENTAL|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer and otherwise continue their usual care."
62166802|NCT01189994|EXPERIMENTAL|Acupuncture|Patients will receive acupuncture treatment in addition to standard care, coming to twelve weekly acupuncture sessions
62166803|NCT01189994|ACTIVE_COMPARATOR|Orientation|Patients will receive standard care only, coming to three monthly orientation sessions
62731479|NCT03748589|EXPERIMENTAL|airway type 2.5|The children weighed between 25-35kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2.5
62731480|NCT01233908||PTSD|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and developed an associated posttraumatic stress disorder
62731481|NCT01233908||PTSD - negative|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and did not develope an associated posttraumatic stress disorder
62166804|NCT04310800|EXPERIMENTAL|LIFT-plug|The LIFT-plug procedure was performed as followings. A portion of the fistula tract was excised from ei¬ther end within the intersphincteric space. One porcine small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures.
62166805|NCT04310800|EXPERIMENTAL|LIFT|The LIFT procedure was performe as followings. The curvilinear incision and dissection of the intersphincteric tract were made as in the LIFT-plug technique. After the tract was isolated, the tract was doubly-ligated and suture-ligated with absorbable sutures as close as possible to the lateral margin of the internal anal sphincter and the medial margin of the external anal sphincter. The tract was then divided between the two sutures. A portion of the fistula tract was excised after ligation of ei¬ther end within the intersphincteric space. The medial ligature was very close to the internal opening, and nearly obliterated the internal opening. The external opening was then enlarged to allow adequate drainage. The internal and external sphincters were then re-approximated, and the skin was closed loosely with interrupted 3/0 absorbable suture.
62166806|NCT02270606|EXPERIMENTAL|Treatment(IMRT,fluorouracil,chemotherapy,surgery)|"CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours.~PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity.~SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery.~POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity."
62166807|NCT04566744|EXPERIMENTAL|Physical tool use, tool making and construction|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a physical tool, making a physical tool or building a construction. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools as well as when we build constructions.
62166808|NCT04566744|EXPERIMENTAL|Use of modern physical tools and stone tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a modern physical tool or a stone tool. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools irrespective of whether they are modern or old (i.e., stone tools).
62166809|NCT04566744|EXPERIMENTAL|Use of modern physical, arbitrary and digital tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when watching video clips of individuals using either a modern physical tool, an arbitrary tool (e.g., a washing machine) or a digital tool (e.g., a touchscreen). Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we observe others using different kinds of tools, which have appeared progressively over technological evolution.
62166810|NCT04566744|EXPERIMENTAL|Physical tool use and Internet|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when estimating the capacity to solve a mechanical problem with modern physical tools either alone or with the help of a Internet Tutorial. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we imagine and estimate solving a mechanical problem alone or with the help of the Internet;
62166811|NCT05639166|EXPERIMENTAL|Active|IBIO123 10 mg
62166812|NCT05639166|PLACEBO_COMPARATOR|Placebo|Matching Placebo
62166813|NCT03071341|EXPERIMENTAL|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
62166814|NCT01366144|EXPERIMENTAL|Treatment (veliparib, paclitaxel, carboplatin)|"Patients receive veliparib\* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~NOTE: \* All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day)."
62166815|NCT03939793|PLACEBO_COMPARATOR|Usual Clinical Support|Participants will continue with their usual diabetes care provided by their clinic. Participants will receive a free wireless glucometer on the day of enrollment if they do not already have one.
62731482|NCT03075306|NO_INTERVENTION|usual care|usual care and materials on healthy weight
62731483|NCT03075306|EXPERIMENTAL|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
62731484|NCT06323850|EXPERIMENTAL|Experimental Group|The experimental group will receive the intervention first then a 2-month follow-up
62731485|NCT06323850|EXPERIMENTAL|Waitlist Group|The waitlist group receives no intervention (Phase 1) at first. After the 2-month intervention period, the waitlist group will receive the intervention, while the experimental group participates in a 2-month follow-up
61976729|NCT01690247|EXPERIMENTAL|Conventional plus UC-MSC|Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
62731486|NCT00140712|EXPERIMENTAL|Ropinirole|single dose .25mg of IR formulation, .05mg of RLS controlled release
62731487|NCT02554799|EXPERIMENTAL|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
62731488|NCT02554799|EXPERIMENTAL|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
62166816|NCT03939793|ACTIVE_COMPARATOR|DFI Alone|Participants will receive a free wireless glucometer on the day of enrollment if they don't already have one. To encourage habit formation, for the first 6 weeks of the trial, participants will be eligible for a daily lottery incentive for every day that they use their glucometer. Investigators will use an approach similar to what we have used in prior DFI trials: the lottery will provide infrequent large payoffs (a 1 in 100 chance of a US$50 reward) and more frequent small payoffs (an 18 in 100 chance of a US $5 reward). Participants who draw the winning lottery number, but did not check their glucose the day prior will receive an automated text or e-mail message informing them what earnings they would have won had they used their glucometer. After 6 weeks, investigators will terminate the lottery but continue to monitor patients' adherence to glucose self-monitoring.
62166817|NCT03939793|EXPERIMENTAL|Hybrid DFI CHW|Participants in the hybrid intervention will receive a wireless glucometer if they don't already have one and financial incentives just as in the DFI intervention. However, any individuals who have low adherence (no self-monitoring) or elevated glucose readings (\>300 mg/dL) for \>30% of days over any 2 week period in the first 12 weeks of the study will be assigned to receive ongoing community health worker (CHW) support for the duration of the 24-week study period.
62166818|NCT02852486|EXPERIMENTAL|Pioglitazone|Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation
62166819|NCT05400525|ACTIVE_COMPARATOR|YMETA|Y META is a combination of gut health focused bioactives that target both the metabolic activity of existing microbiota (Bifidobacterium spp. targeting prebiotic galacto-oligosaccharides mixture)
62166820|NCT05400525|PLACEBO_COMPARATOR|Maltodextrin|
62166821|NCT01347099|EXPERIMENTAL|Internet CBT|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks.
62166822|NCT01347099|PLACEBO_COMPARATOR|Support therapy|10 weeks. Therapist support contact through e-mail.
62166823|NCT01838499|EXPERIMENTAL|MEDI8968|
62166824|NCT01838499|PLACEBO_COMPARATOR|Saline|
62166825|NCT06192693|EXPERIMENTAL|1|FMT (from healthy lean euglycemic non-obese donors)
62166826|NCT06192693|PLACEBO_COMPARATOR|2|Placebo of FMT
62166827|NCT05183997|PLACEBO_COMPARATOR|Group (A) : 30 patients (control group):|Patient will receive 20 to 30 ml bupivacaine plus 2 ml of normal saline .
62166828|NCT05183997|EXPERIMENTAL|Group (B) : 30 patients (verapamil group):|Patient will receive 20 to 30 ml bupivacaine plus 5 mg of verapamil diluted in 2 ml of normal saline.
62166829|NCT04107688|EXPERIMENTAL|PROP non-taster subjects|This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
62166830|NCT04107688|EXPERIMENTAL|PROP super-taster subjects|This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
62166831|NCT05016674|EXPERIMENTAL|Laser-assisted liposuction|Laser-Assisted Liposuction with the LipoLife system.
62166832|NCT02823171|EXPERIMENTAL|Sequence I|Sequence I: treatment A/B
62166833|NCT02823171|EXPERIMENTAL|Sequence II|Sequence II: treatment B/A
62166834|NCT01202305||HIV negative|
62166835|NCT01202305||HIV positive|
62166836|NCT03617016|EXPERIMENTAL|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
62166837|NCT03617016|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
62166838|NCT03048058|EXPERIMENTAL|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
62166839|NCT03048058|ACTIVE_COMPARATOR|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
62166840|NCT00665392|EXPERIMENTAL|cetuximab|Cetuximab by intravenous (IV) infusion over 1-2 h on day
62731489|NCT02554799|EXPERIMENTAL|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
62166841|NCT01624012|ACTIVE_COMPARATOR|NIV NAVA|Noninvasive ventilation in this group is practiced with NIV NAVA
62166842|NCT01624012|ACTIVE_COMPARATOR|ncpap|Patients randomized to this arm will receive noninvasive ventilation with continuous nasal CPAP as routinely in neonatal intensive care unit.
62166843|NCT00984347|ACTIVE_COMPARATOR|Oxytocin induction|women in need for induction of labor due to medical indications, will receive continuous IV oxytocin
62166844|NCT00984347|ACTIVE_COMPARATOR|Breast Stimultion|nipple stimulation with a breast pump, calibrated at the lowest suction strength,operated alternately: 15 min one breast, 15 min second breast, 15 min rest, till appearance of regular uterine contractions (3 contractions in 10 min). the manipulation will continue for 3 hours of regular contractions.
62166845|NCT02260583|EXPERIMENTAL|extracorporeal CO2 removal device|"the patients will be enroll to start a one shot session of extracorporeal CO2 removal. The patient will be connected to the device via a double lumen catheter inserted in the femoral vein An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used. Blood flow is driven by a roller nonocclusive pump (0-450 mL/min) through a polypropylene oxygenator ; priming volume, 100 mL; contact surface area, 1.35 m2; maximum blood flow rate, 7 L/min) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the oxygenator, blood is driven to a hemofilter."
62166846|NCT01377688||Diabetics with PKD|Diagnoses of diabetes type 2 with progressive kidney disease (slope of eGFR decline between -15 to -3 ml/min/1.73m2 per year, estimated by calculating an eGFR for each creatinine using the 4-variable Modification of Diet in Renal Disease Study \[MDRD\] equation and conducting a simple ordinary least squares regression from these values to evaluate changes over time to derive each individuals' slope of eGFR, annualized using test dates)
62166847|NCT02035488|EXPERIMENTAL|Tobramycin|Patients with bronchiectasis
62731490|NCT01356498|EXPERIMENTAL|q2 RCT|Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
62166848|NCT05499117|ACTIVE_COMPARATOR|Antidepressant and light treatment group|
62166849|NCT05499117|PLACEBO_COMPARATOR|Antidepressants and pseudo-light therapy|
62166850|NCT05200299|EXPERIMENTAL|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 12 cycles as adjuvant chemotherapy. They can change the regimen to mFOLFOX6 or CapeOx after accepting not less than two complete chemotherapy regimen, if can not tolerate the adverse reaction of mFOLFOXIRI. Total 24 weeks.
62166851|NCT05200299|ACTIVE_COMPARATOR|mFOLFOX6 or CapeOx adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 12 cycles as adjuvant chemotherapy or CapeOx once every three weeks for 8 cycles as adjuvant chemotherapy. Total 24 weeks.
62166852|NCT04892004|NO_INTERVENTION|Control group|Standard information defined as the standard care, unplanned, provided for Heart Failure patients and not personalized.
62166853|NCT04892004|EXPERIMENTAL|Interventional group|A nurse provides the intervention with expertise in Heart Failure and addresses reinforcements on: a) an explanation on signs and symptoms of Heart Failure and how to recognise them; b) importance on daily fluid management, by planning 1.5-2 litres of liquids per day (e.g., soup, milk, coffee, water, tea and yoghurts); and c) when doctors or nurses should be contacted (when symptoms escalation or a weight gain of 2 kg in three days or 5 kg in a week were detected).
62166854|NCT06135883||Case|Singleton pregnant women over the age of 18 and under the age of 45 who have at least one of the risk factors for neural tube defects (family history, MTHFR gene mutation, birth history with aneuploidy, history of GDM or known DM).
62166855|NCT06135883||Control|Singleton pregnant women over 18 years of age and under 45 years of age who do not have any risk factors for neural tube defects
62166856|NCT02842125|EXPERIMENTAL|Ad-p53 with Xeloda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
62166857|NCT02842125|EXPERIMENTAL|Ad-p53 with Keytruda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
62166858|NCT02842125|EXPERIMENTAL|Ad-p53 with Opdivo 33.3% of patients|Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
62166859|NCT01425697|ACTIVE_COMPARATOR|2% Chlorhexidine Gluconate cloths|2% Chlorhexidine Gluconate wipes will be used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery
62166860|NCT01425697|OTHER|Standard of Care Preoperative Preparation|Subject will receive standard of care preoperative preparation for the clinical site.
62166861|NCT03533803|ACTIVE_COMPARATOR|Group A (Indomethacin)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
62166862|NCT03533803|PLACEBO_COMPARATOR|Group B (Control)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
62166863|NCT01747616|EXPERIMENTAL|12 subjects wearing soft contact lenses|The medical test device will be administered with the contact lenses inserted
62166864|NCT01747616|EXPERIMENTAL|12 subjects wearing rigid contact lenses|The medical test device will be administered with the contact lenses inserted
62166865|NCT01747616|EXPERIMENTAL|12 subjects with soft contact lenses|The medical test device will be administered before insertion of the contact lenses
62166866|NCT01747616|EXPERIMENTAL|12 subjects with rigid contact lenses|The medical test device will be administered before insertion of the contact lenses
62166867|NCT03052478|EXPERIMENTAL|vismodegib arm|. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
62166868|NCT06533020||Complex Total Hip Arthroplasty|Participants who have undergone complex total hip arthroplasty within the last 10 years
62166869|NCT06533020||Conversion Total Hip Arthroplasty|Participants who have undergone conversion total hip arthroplasty within the last 5 years
62166870|NCT03078699|EXPERIMENTAL|stereotactic body radiation therapy|
62166871|NCT04242342|EXPERIMENTAL|Experimental arm|Patient with a localized primary tumor (hepatocellular carcinoma or cholangiocarcinoma) or a secondary hepatic localization of a solid carcinoma, with one to three hepatic lesions accessible to a treatment by stereotactic radiotherapy.
62166872|NCT05788406|EXPERIMENTAL|Short Foot Exercises Group|İnsole+Short Foot Exercises group
62166873|NCT05788406|EXPERIMENTAL|Balance Exercises Group|İnsole+Balance exercises group
62166874|NCT05788406|EXPERIMENTAL|Control Group|İnsole group
62166875|NCT06317311|EXPERIMENTAL|Dostarlimab- Carboplatin-Paclitaxel followed by Dostarlimab Monotherapy|
62166876|NCT02653001|EXPERIMENTAL|Experimental arm|Stool sample collection: Stool samples collected from study participants will be introduced into the colon model to enhance our understanding of the colonic bacterial ecosystem in response to various food components, drugs or biological therapies, and/or to allow investigation the impact of the bacterial ecosystem itself on these added components
62166877|NCT01190228|EXPERIMENTAL|Group 1: JE-CV Vaccine Booster|Participants previously vaccinated with JE-CV vaccine will receive a booster dose of JE-CV vaccine on Day 0.
62166878|NCT01190228|EXPERIMENTAL|Group 2: JE-CV Vaccine First Dose|JE-CV vaccine naïve participants will receive a single dose of JE-CV vaccine on Day 0.
62166879|NCT01190228|ACTIVE_COMPARATOR|Group 3: Varicella Vaccine|JE-CV vaccine naïve participants will receive one dose of Varicella vaccine on Day 0.
62166880|NCT02794428|ACTIVE_COMPARATOR|Eflornithine|
62166881|NCT02794428|PLACEBO_COMPARATOR|Eflornithine Placebo|
62166882|NCT06153836|ACTIVE_COMPARATOR|ARM I (control)|Patients undergo standard of care NSM on study.
62166883|NCT06153836|EXPERIMENTAL|ARM II (neurotization)|Patients undergo neurotization during standard of care NSM on study.
62166884|NCT03171389|EXPERIMENTAL|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
62166885|NCT03171389|EXPERIMENTAL|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
62166886|NCT03171389|EXPERIMENTAL|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
62166887|NCT05487937||Toleriane Ultra|Participants are asked to apply the study product twice daily (morning and evening) at home for 28 days.
62166888|NCT01767636|EXPERIMENTAL|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62166889|NCT03987672|OTHER|Assess Nutritional Effects of Nutritional Formula|Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.
62166890|NCT02775123|NO_INTERVENTION|Control|Conventional cardio-pulmonary bypass
62166891|NCT02775123|EXPERIMENTAL|Cytosorb|Cytosorb added to cardio-pulmonary bypass
62166892|NCT01357564|EXPERIMENTAL|Tailored Activity Program|Occupational therapists assess the person's home environment, preserved capabilities, daily routines, interests and the caregiver's readiness and ability to use activities. Activities are developed that reflect the Veteran's previous or current interests and are modified to match their preserved capabilities without taxing the most impaired areas of cognition (e.g., memory, new learning). TAP-VA provides caregivers with the knowledge and skills to use activities. The overall goal is to provide predictability, familiarity, and structure in the daily life of the Veteran and establish a level of environmental stimulation appropriate to that person's abilities.
62166893|NCT01357564|ACTIVE_COMPARATOR|Attention Control|Caregivers in this group receive bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers are provided important information about dementia and strategies for disease management. Each telephone contact begins with a brief overview of the specific purpose of the session, followed by a description of the key facts about the session topic, and concludes with a question and answer period. The attention control group intervention is delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
62166894|NCT03985826||Childhood ALL survivors|The cohort of childhood ALL survivors will be identified in the Danish part of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-Register .
62166895|NCT03985826||Comparison cohort|A reference cohort (comparison cohort) of individuals will be sampled randomly from the source population matched by age and sex and without a history of childhood cancer in the calendar year where the case was diagnosed (density sampling). For each childhood ALL-patient we will choose ten comparison subjects.
62166896|NCT03624023|EXPERIMENTAL|TWB-103|(Mixture of TWB-102 cell and TWB-103 hydrogel)
62166897|NCT05649904|EXPERIMENTAL|IRRAflow with Active Fluid Exchange System (IRRAflow)|Subjects may be randomized to receive the IRRAflow with Active Fluid Exchange System (intervention) for intracranial pressure monitoring and for externally draining intracranial fluid as a means of reducing intracranial pressure.
62166898|NCT05649904|ACTIVE_COMPARATOR|External Ventricular Drainage (EVD)|Subjects may be randomized to receive an External Ventricular Drain (control) for intracranial pressure monitoring and for externally draining intracranial fluid as a means of reducing intracranial pressure.
62166899|NCT06288750|EXPERIMENTAL|Indocyanine green group|Identification of parathyroid glands (PGs) Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
62166900|NCT06288750|ACTIVE_COMPARATOR|Traditional surgery group|Conventional means of identification and assessment of PGs are mainly based on surgeon-dependent identification of their anatomical location and appearance (color, shape, etc.) by the naked eye.
62166901|NCT05805033|EXPERIMENTAL|Ultra-polished zirconia abutment|
61976730|NCT01690247|PLACEBO_COMPARATOR|Conventional plus placebo|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
62166902|NCT05805033|EXPERIMENTAL|Machined zirconia abutment|
62166903|NCT05805033|ACTIVE_COMPARATOR|Titanium abutment|
62166904|NCT04371471||Patient with COVID-19|Patient with clinical signs of CoV-2-SARS infection and signs of severity
62166905|NCT02980198|EXPERIMENTAL|IFN-Kinoid|IFN-Kinoid + ISA 51
62166906|NCT02980198|PLACEBO_COMPARATOR|Placebo|Placebo + ISA 51
62166907|NCT02827851|EXPERIMENTAL|SVF injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
62166908|NCT05797220||Botulinum toxin group|The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters.
62166909|NCT05797220||Botulinum toxin plus topical diltiazem group|The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters. After BT injection, topical 2% diltiazem gel was prescribed, applied 2 times per day for 10 days (2 doses of 1 gr each per day). No selection criteria were used when recommending this treatment; it was randomly suggested to some for a while during the cohort since the surgeon believed it might enhance the efficacy of BT.
62166910|NCT05053256||HFpEF|Heart failure with preserved ejection fraction
62166911|NCT05053256||HFrEF|Heart failure with reduced ejection fraction
62166912|NCT05750121|EXPERIMENTAL|Treatment group|The intervention group will receive home-based motor-cognitive training and usual emergency care.
62166913|NCT05750121|NO_INTERVENTION|Usual care group|Usual care includes wound care, community nurse service, medications and on-site physiotherapy, occupational therapy, community nurse service, medical social work service, and geriatric nurse follow-up service will be referred when necessary.
62166914|NCT02709798|EXPERIMENTAL|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
61976731|NCT03325361|EXPERIMENTAL|TD|
62166915|NCT02709798|PLACEBO_COMPARATOR|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
62166916|NCT01142154|EXPERIMENTAL|oral, liquid solution|
62166917|NCT02828592|EXPERIMENTAL|Flu/Cy/TBI|Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 \& 4.
62166918|NCT03997409|EXPERIMENTAL|Low Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the LCD intervention will consume 25-35% of total daily intake from carbohydrates, 45-65% from fat and 10-30% from protein.
62166919|NCT03997409|ACTIVE_COMPARATOR|Standard Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the SCD intervention will consume 45-65% of total daily caloric intake from carbohydrates, 25-35% from fat and 10-30% from protein.
62166920|NCT03997409|NO_INTERVENTION|No Dietary Recommendations|This group will serve as a control that receives the same number of education sessions as LCD and SCD group to teach general diabetes management but without specific dietary recommendations.
62166921|NCT01527500|EXPERIMENTAL|LFG316 higher dose|LFG316 10 mg/100 μL
62166922|NCT01527500|SHAM_COMPARATOR|Sham|Sham injection
62166923|NCT01527500|EXPERIMENTAL|LFG316 lower dose|LFG316 5 mg/ 50 μL
62166924|NCT02821689|EXPERIMENTAL|pirfenidone|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on. Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. Investigators were allowed to adjust the dose according to the participants' tolerance.
62166925|NCT02821689|NO_INTERVENTION|Blank|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on.
62166926|NCT05662878||Patient Group|Hemiplegic Patients
62166927|NCT05662878||Control Group|Healthy Individuals
62166928|NCT03491774|EXPERIMENTAL|Montessori Intervention|Participants will receive Montessori intervention for three months,twice weekly sessions over the period of three months.
62166929|NCT06646198|EXPERIMENTAL|DoTH: TIPS plus half-dose donafenib|TIPS plus half-dose donafenib
62166930|NCT00946088|ACTIVE_COMPARATOR|Progesterone|Progesterone 400mg per vagina qhs.
62166931|NCT00946088|PLACEBO_COMPARATOR|Polyethylene glycol&hydrogenated vegetable oil|Polyethylene glycol\&hydrogenated vegetable oil per vagina
62166932|NCT01286376|ACTIVE_COMPARATOR|symbiotic|
62166933|NCT01286376|PLACEBO_COMPARATOR|placebo|
62166934|NCT01824719||Allergic group|All patients who used Reduning Injection have anaphylaxis.
62166935|NCT01824719||Control group|All patients who used Reduning Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
62166936|NCT01038206|EXPERIMENTAL|Family Function Intervention|Familias Unidas Intervention Program
62166937|NCT01038206|NO_INTERVENTION|Treatment as Usual|The Public School system mandates that all high school students receive at least 5 lessons (55 minutes each) per year of HIV prevention.
62166938|NCT04723784|EXPERIMENTAL|Person with disability|"* Initial assessment.~* Implementation of AT in the daily life of participants~* Application of outcome measures and analysis of the data"
62166939|NCT02211599|EXPERIMENTAL|15% protein meal and sweetened beverage|Breakfast and lunch will each contain 15% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
62166940|NCT02211599|EXPERIMENTAL|30% protein meal and sweetened beverage|Breakfast and lunch will each contain 30% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
62166941|NCT02166788|OTHER|Arm 1: Inguinal Lymphadenectomy|Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes
62166942|NCT02166788|OTHER|Arm 2: Ilio-inguinal Lymphadenectomy|Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.
62166943|NCT01503515|EXPERIMENTAL|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
62166944|NCT01503515|ACTIVE_COMPARATOR|Arm II (fluconazole or voriconazole)|Patients receive fluconazole IV over 1-2 hours QD or PO QD; or voriconazole IV over 1-2 hours QD or PO BID beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
62166945|NCT02157688||case|Patient with a folliculitis Decalvans
62166946|NCT02157688||control|Control without folliculitis decalvans
62166947|NCT05842278|ACTIVE_COMPARATOR|4 session rTMS|Four sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62166948|NCT05842278|ACTIVE_COMPARATOR|6 session rTMS|Six sessions of active TMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62166949|NCT05842278|ACTIVE_COMPARATOR|8 session rTMS|Eight sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62166950|NCT05842278|ACTIVE_COMPARATOR|10 session rTMS|Ten sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
62166951|NCT05842278|SHAM_COMPARATOR|sham rTMS|Subjects were randomized to receive 4 sessions or 6 sessions or 8 sessions or 10 sessions of sham rTMS to the left DLPFC daily in a 1:1:1:1 ratio.
62166952|NCT03614351|EXPERIMENTAL|Physical Therapy plus Protein Supplement|Participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
62166953|NCT03614351|ACTIVE_COMPARATOR|Physical Therapy Control|Participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
61976732|NCT03325361|NO_INTERVENTION|NTD|
62166954|NCT03015961|ACTIVE_COMPARATOR|EXPAREL admixed with bupivacaine HCl|EXPAREL 266 mg + bupivacaine HCl
62166955|NCT03015961|PLACEBO_COMPARATOR|Bupivacaine HCl|Bupivacaine HCl
62166956|NCT05066230|EXPERIMENTAL|KSI-301 - Treatment Group A|Intravitreal injection of KSI-301 (5 mg): three initiating doses, and then every 24 weeks through Week 92
62166957|NCT05066230|SHAM_COMPARATOR|Treatment Group B|Sham injection on the same schedule as Treatment Group A
62166958|NCT03455153||Most active|COPD patients with higher physical activity levels as defined by daily step counts.
62166959|NCT03455153||Least active|COPD patients with lower physical activity levels as defined by daily step counts.
62166960|NCT04545021||Cognitive Behavioral Stress Management (CBSM) - PC Survivor|Participant receives standard cognitive behavioral stress management from the Parent study NCT03344757.
62166961|NCT04545021||CBSM - PC Survivor Partner|The survivor partner does not receive any intervention.
62166962|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor|Participant receives culturally adapted cognitive behavioral stress management from the Parent study NCT03344757.
62166963|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor Partner|The survivor partner does not receive any intervention.
62166964|NCT02542293|EXPERIMENTAL|Combination Therapy|Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
62166965|NCT02542293|ACTIVE_COMPARATOR|Standard of Care|Standard of Care chemotherapy treatment
62166966|NCT05766124|EXPERIMENTAL|Low dose tPA|Patients with pleural infection and will receive a starting dose of tPA at 2.5mg
62166967|NCT05766124|ACTIVE_COMPARATOR|Standard dose tPA|Patients with pleural infection and will receive a starting dose of tPA at 10mg
62166968|NCT03937076|NO_INTERVENTION|intercostal block|patients will get intercostal block at the end of the surgery, control group
62166969|NCT03937076|EXPERIMENTAL|PECS II block|patients with get PECS II block at the end of the surgery, research group
62166970|NCT04682223|EXPERIMENTAL|Aphasia Remote Therapy (ART)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done remotely with a speech-language pathologist through an online platform using therapy applications. Participants will be provided with teletherapy kits (including an Internet hotspot if needed) to complete the therapy tasks."
62166971|NCT04682223|ACTIVE_COMPARATOR|In-Clinic Therapy (I-CT)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done in person with a speech-language pathologist at the UofSC Aphasia Lab."
62166972|NCT05544539|EXPERIMENTAL|drug arm|In the study group the (0.5 ml) of Ozone oil (perio3®, Hoffmann, German) was placed inside the socket of the extracted tooth filling it completely following suturing of the flap
62166973|NCT05544539|PLACEBO_COMPARATOR|placebo arm|the ozone oil syringe was placed inside the patient mouth without applying the oil.
62166974|NCT02295293|EXPERIMENTAL|Rhus|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
62166975|NCT02295293|PLACEBO_COMPARATOR|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
62166976|NCT06154798|ACTIVE_COMPARATOR|World Digital Detox Women's Health Program|The intervention is a 6-week World Digital Detox Program designed to help participants reduce their dependence on digital devices and foster a healthier balance between technology use and overall well-being.
62166977|NCT06154798|NO_INTERVENTION|Control Group|Participants assigned to the control group will continue with their regular, unrestricted digital device usage throughout the 6-week study period.
62166978|NCT04890158|EXPERIMENTAL|Prone positioning for a total of 6 hours daily by study protocol|Patients will be positioned prone for 3 hours then placed supine for 3 hours then prone again for 3 additional hours. The change in position from prone to supine and back is to more reliably document possible changes in ventilation, oxygenation, other vital signs and respiratory support required.
62166979|NCT04890158|NO_INTERVENTION|usual positioning|"Patients in the newborn intensive care unit are physically handled usually every 3-4 hours. Those study participants who are randomly assigned to usual position may rest in a variety of positions in any order based on nursing or perceived patient preference. Positions may include supine, right lateral, left lateral, and prone as well."
62166980|NCT02333747|EXPERIMENTAL|the TEAS group|Patients in the TEAS group received pre-operative TEAS for 30 min before the induction of anesthesia using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China) in the holding area. TEAS was applied to two pairs of acupoints: bilateral Hegu (LI4) and Neiguan (PC6).
62166981|NCT02333747|SHAM_COMPARATOR|the sham group|In the sham group, the patients were connected to the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China), but electronic stimulation was not applied.
62166982|NCT05988385|ACTIVE_COMPARATOR|3-month OSA treatment|"A 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an effective AHI3a\<15 (rapid multi-modal treatment RMMT)."
62166983|NCT05988385|OTHER|Waitlist control group|A waitlist control group to receive treatment at the conclusion of the 3-month intervention period.
62166984|NCT04364035|EXPERIMENTAL|CCMM+GS-9620|ChAdOx1.HTI 2 doses, MVA.HTI 2 doses, GS-9620 10 doses.
62166985|NCT04364035|PLACEBO_COMPARATOR|PLACEBO|ChAdOx1.HTI placebo 2 doses, MVA.HTI placebo 2 doses, GS-9620, placebo 10 doses.
62166986|NCT00648271|EXPERIMENTAL|1|Metoprolol Tartrate Tablets 25 mg
62731491|NCT01356498|EXPERIMENTAL|q4 RCT|Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
61976733|NCT00710710|EXPERIMENTAL|BI 2536 High dose|Day 1
61976734|NCT00710710|EXPERIMENTAL|BI 2536 Low dose|Day 1 - 3
62166987|NCT00648271|ACTIVE_COMPARATOR|2|Lopressor® Tablets 50 mg
62731492|NCT01356498|EXPERIMENTAL|Placebo in RCT|Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
62166988|NCT04919330|EXPERIMENTAL|ACT Group|One four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP) and routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation.
62166989|NCT04919330|OTHER|Wait-list Control Group|Routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation
62166990|NCT03856424|OTHER|Modality 1 - Washout - Modality 2 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
62166991|NCT03856424|OTHER|Modality 1 - Washout - Modality 3 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
62166992|NCT03856424|OTHER|Modality 2 - Washout - Modality 1 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
62166993|NCT03856424|OTHER|Modality 2 - Washout - Modality 3 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
62166994|NCT03856424|OTHER|Modality 3 - Washout - Modality 2 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
62166995|NCT03856424|OTHER|Modality 3 - Washout - Modality 1 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
62166996|NCT04288778|EXPERIMENTAL|Canagliflozin + Metformin Hydrochloride Immediate Release (IR)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.
62166997|NCT02612116|ACTIVE_COMPARATOR|pulverized ticagrelor sublingually|Pulverized ticagrelor 180 mg (Brilique) administered sublingually
62166998|NCT02612116|ACTIVE_COMPARATOR|pulverized ticagrelor orally|Pulverized ticagrelor 180 mg (Brilique) administered orally
62166999|NCT02612116|ACTIVE_COMPARATOR|Integral ticagrelor orally|Ticagrelor 180 mg (Brilique) administered orally in integral tablets
62167000|NCT03787719|EXPERIMENTAL|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment (Monday and Friday or Tuesday and Saturday).
61976735|NCT04106986|EXPERIMENTAL|PEMF and PRE|The PEMF and PRE group received 24 sessions (3 sessions/week for 8 weeks) of combined treatment group (pulsed electromagnetic field with PRE training)
62167001|NCT03787719|NO_INTERVENTION|Thrice per week dialysis|Standard thrice-weekly 4 hour dialysis treatment (Monday, Wednesday and Friday or Tuesday, Thursday and Staurday)
62167002|NCT00254722|EXPERIMENTAL|I|single arm study
62167003|NCT03916159|EXPERIMENTAL|Extrauterine Placental Transfusion EPT|Intervention group
62167004|NCT03916159|ACTIVE_COMPARATOR|Delayed cord clamping DCC|Control group
62167005|NCT02625922|EXPERIMENTAL|Serelaxin followed by Placebo|On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
62167006|NCT02625922|EXPERIMENTAL|Placebo followed by Serelaxin|On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
62167007|NCT02849509||Switch Patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
62167008|NCT02849509||New Patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
62167009|NCT03115879|PLACEBO_COMPARATOR|Placebo Group|Hip manipulation simulation
62167010|NCT03115879|EXPERIMENTAL|Manipulation Group|Hip manipulation
62167011|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
62167012|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
62167013|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
62167014|NCT02746497|ACTIVE_COMPARATOR|Group E (early intervention)|One weekly treatment with acupuncture in five consecutive weeks. In trial week 1-5 Group E will receive treatment and Group L will act as control group.
62167015|NCT02746497|ACTIVE_COMPARATOR|Group L (late intervention)|After trial week five the Groups must cross-over. Group L will then receive treatment for five weeks (trial week 6-11) and Group E will act as follow up group.
62167016|NCT04745455|OTHER|Cow's milk based infant formula containing prebiotics, probiotics and postbiotics|
62167017|NCT01682447|EXPERIMENTAL|Extensive Pulmonary Rehabilitation (ERP)|Participants in this group are measured on primary and secondary outcome measures before and after a 12 week extensive pulmonary rehabilitation program.
62167018|NCT01682447|NO_INTERVENTION|Waiting List Control group|Participants in the waiting list control group are measured on primary and secondary outcome measures before and after waiting time for the extensive pulmonary rehabilitation program and start with this program after the second moment of measurement.
62731493|NCT01104545|EXPERIMENTAL|Panel A - Healthy|Healthy participants receive single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast except for Period 3. Period 3 dose was administered after the ingestion of a high-fat breakfast.
62167019|NCT04322864|ACTIVE_COMPARATOR|In-person supervised intervention|
62167020|NCT04322864|EXPERIMENTAL|Web-based instrument intervention|
62167021|NCT06270849||Female with LUTS|Females who has symptoms of lower urinary tract symptoms
62167022|NCT06270849||Normal control group|Females who no history of LUTS or urinary tract disease
62735177|NCT01607463|EXPERIMENTAL|active TENS group|Two electrodes were attached to the radial side of dominant forearm. In the active TENS group, TENS was delivered via two electrodes on the venous cannulation site
62167023|NCT03816332|EXPERIMENTAL|Treatment (tacrolimus, prednisone, nivolumab, ipilimumab)|"Patients receive tacrolimus PO BID and prednisone PO QD. Within 28 days, patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 24 cycles (96 weeks) in the absence of disease progression or unacceptable toxicity.~Patients who experience PD or patients who have experienced allograft loss at 16 weeks receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Patients also receive tacrolimus PO BID and prednisone PO QD. Cycles repeat every 3 weeks for 4 cycles (12 weeks) in the absence of disease progression or unacceptable toxicity. Starting 6 weeks later, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 21 cycles (84 weeks) in the absence of disease progression or unacceptable toxicity."
62167024|NCT03050372|EXPERIMENTAL|Active Low Field Magnetic Stimulation|LFMS - Active
62167025|NCT03050372|SHAM_COMPARATOR|Sham Low Field Magnetic Stimulation|LFMS - Sham
62167026|NCT03172897|EXPERIMENTAL|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
62167027|NCT03172897|PLACEBO_COMPARATOR|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
62167028|NCT03786783|EXPERIMENTAL|Treatment(chemotherapy, dinutuximab, sargramostim, ASCT, EBRT)|See Detailed Description
62167029|NCT03347773|EXPERIMENTAL|Intervention|The subjects will be assigned to receive nutritional supplement consisting of one can of ReGen 18% (19.1 g protein, 425 Kcal) daily and standard care.
62167030|NCT03347773|NO_INTERVENTION|Control|The subjects will be assigned to receive standard care alone.
62167031|NCT03159065|EXPERIMENTAL|Bilberry|A bilberry-based beverage with fermented oatmeal
62167032|NCT03159065|EXPERIMENTAL|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
62167033|NCT03159065|EXPERIMENTAL|Mango|A mango-based based beverage with fermented oatmeal
62167034|NCT03159065|EXPERIMENTAL|Beetroot|A beetroot-based based beverage with fermented oatmeal
62167035|NCT03159065|EXPERIMENTAL|Rose hip|A rose hip-based based beverage with fermented oatmeal
62167036|NCT03159065|ACTIVE_COMPARATOR|Glucose drink|A reference glucose drink
62167037|NCT02829411|ACTIVE_COMPARATOR|Employment Services only|'Workforce Readiness Program'. job readiness workshop, organized into ten daily sessions over two weeks. The main content of these sessions will be a program-developed workforce readiness training, developed with funding from a DOL Career Pathways Bridge grant.
62167038|NCT02829411|EXPERIMENTAL|Employment Services with HMRE content|'Workforce Readiness Program supplemented with Relationship Education': job readiness workshop, organized into ten daily sessions over two weeks. Program will add approximately 17 hours of content from the Within My Reach relationship education curriculum to the two-week job readiness workshop - and add up to eight additional one-hour relationship skills education sessions that customers can attend in the five weeks after completing the initial two-week job readiness workshop
62167039|NCT03982082|EXPERIMENTAL|Device feasibility (MuscleSound technology)|Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.
62167040|NCT00068718|EXPERIMENTAL|Treatment (DLI)|Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
62167041|NCT03490747|EXPERIMENTAL|Co-developed referral scheme|A physical activity referral scheme co-developed by multidisciplinary stakeholders to incorporate behaviour change support and ensure pragmatic relevance and feasibility.
62167042|NCT03490747|ACTIVE_COMPARATOR|Usual care referral scheme|Comparative, usual care exercise referral scheme.
62167043|NCT03490747|NO_INTERVENTION|No treatment control|Lifestyle advice leaflet only (provided to participants in all arms during baseline assessments).
62167044|NCT06646029|EXPERIMENTAL|Orthosis + standard hand therapy care|Patients will receive a custom splint/orthosis will be made by the hand therapist for patients to wear through the day for the length of the treatment as much as possible in additional to standard of care hand therapy. Patients will be encouraged use the orthosis during the day (at least 6-8 hours) for 6 weeks.
62167045|NCT06646029|ACTIVE_COMPARATOR|Standard of care|Standard of care (control group) will only complete the routine treatment. This consists of physical therapy exercises, stretches, manual therapy and use of therapeutic modalities.
62167046|NCT04372186|PLACEBO_COMPARATOR|Placebo|Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
62167047|NCT04372186|EXPERIMENTAL|Tocilizumab|Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
62167048|NCT04539938|EXPERIMENTAL|Single Arm|Tucatinib + trastuzumab deruxtecan
62167049|NCT02977468|EXPERIMENTAL|Single Arm open label|"Participants receive 'Merck 3475 Pembrolizumab' by vein one to two times before Intraoperative radiation therapy (IORT).~The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial."
62167050|NCT06195150||VHL patients|Patients with hereditary Von Hippel-Lindau (VHL) with genetic diagnosis of VHL disease who have at least three tumors larger than 3cm that have to be surgically removed. The procedure involves standard surgery with the additional collection of 15ml of blood.
62167051|NCT04734171|PLACEBO_COMPARATOR|Informational sheet (IS)|participant receives an informational sheet about COVID-19
62167052|NCT04734171|ACTIVE_COMPARATOR|IS + Video Solo|participants an informational sheet about COVID-19 and a 90 seconds video aimed at sensitizing participants to COVID-19 related stigma
62167053|NCT04734171|ACTIVE_COMPARATOR|IS + Video Friends|participants an informational sheet about COVID-19 and a 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends.
62167054|NCT04734171|NO_INTERVENTION|Control|No intervention
62167055|NCT03959735|EXPERIMENTAL|High Intensity Interval Training (HIIT)|"50% of participants (inpatients with a diagnosis of severe mental illness) will be randomised to HIIT. HIIT will be conducted twice a week for 12 weeks using a stationary bike. Each session will have the following structure: 4-minute warm-up, followed by 5X1 minute intervals at 85-95% of maximum heart rate, interspersed with active pauses of 90 seconds cycling at approximately 60-70% of maximum heart rate, and a 4-minute cool-down. Each exercise session will take 19 minutes to complete (11 minutes of HIIT + warm-up and cool-down). However, the amount of HIIT will be adapted for people who may be unable to complete the above target and gradually build up until they can complete the recommended amount.~All exercise sessions will be conducted in a 1:1 environment with a participant and a member of the research team who will supervise the exercise session."
62167056|NCT03959735|NO_INTERVENTION|Treatment As Usual (TAU)|50% of participants will be randomised to TAU. They will be provided with details of the local hospital gym availability and instructed to maintain their usual dietary habits
62167057|NCT02567227|EXPERIMENTAL|Cognitive Remediation|An individualized computerized cognitive remediation program.
62167058|NCT02567227|ACTIVE_COMPARATOR|Active control|Individualized computer based exposure and interactive health education classes.
62167059|NCT04466293|NO_INTERVENTION|Standard of care study arm|"Providers will receive training on benefits, indications, and contra-indications for TPT. Providers will use the standard approach of the default being to not prescribe. Only if providers specifically write for TPT will it be dispensed by a pharmacy or the provider."
62167060|NCT04466293|EXPERIMENTAL|Choice Architecture study arm|"Clinic staff will be responsible for strategy delivery for all patient interactions. Research staff will provide training and guidance for the choice architecture arm. Research staff will also work with the clinics to develop appropriate clinical stationary, ink stamps, stickers, or EMR modifications for prescribing, and reminder systems (e.g. written by pharmacy in clinic file, post-it on clinic file, post-it on lab results). The goal of this approach is for TPT prescribing to occur routinely and as part of ART prescribing. This is in contrast to considering prescribing only at the end of a long algorithm that includes TB and other assessments. With this approach, a patient will automatically be prescribed TPT unless the clinician specifically decides patients are not candidates due to active TB treatment or other clinical reasons."
62167061|NCT01154699|EXPERIMENTAL|Usual Care first, then Bilevel PAP|"Subjects will begin the study by continuing their usual care for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period. After a Washout Period of an additional 4 weeks of usual care, they will then start Bilevel PAP therapy for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests."
61976736|NCT04106986|EXPERIMENTAL|PRE|The PRE group received 24 sessions (3 sessions/week for 8 weeks) of only progressive resistance exercise
61976737|NCT01230268|EXPERIMENTAL|Mulberry fruit extract|Daily 1000 mg oral Mulberry fruit extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
61976738|NCT00170716|ACTIVE_COMPARATOR|Control|
61976739|NCT00170716|EXPERIMENTAL|Investigational|
61976740|NCT05205421|EXPERIMENTAL|Oncolytic Virus Injection(RT-01)|RT-01 will be administered by intravenously;
61976741|NCT02936791||Individuals diagnosed with PKD|Individuals that have been diagnosed and meet the study's definition of early stage PKD.
61976742|NCT02936791||Individuals with a family history of PKD|Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD
61976743|NCT02936791||Normal individuals for the comparison|Normal volunteers with no family history of PKD or other kidney diseases.
61976744|NCT00970333|EXPERIMENTAL|assess [18F]-FEPPA PET imaging|
61976745|NCT04090840|EXPERIMENTAL|Intermittent Fasting|Patients will follow intermittent fasting for 16 hours with time restricted eating during an 8 hour window. The subjects are also advised to minimize sugar intake to \<15g per serving.
61976746|NCT03435744|EXPERIMENTAL|Simvastatin with TAU|Participants will receive Simvastatin 20 mg added to TAU for 3 months
61976747|NCT03435744|PLACEBO_COMPARATOR|Placebo Oral Tablet with TAU|Participants will receive placebo added to TAU for 3 months
61976748|NCT05244577|EXPERIMENTAL|Olanzapine|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Olanzapine 5mg Po D1-7
61976749|NCT05244577|PLACEBO_COMPARATOR|Placebo|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Placebo 5mg Po D1-7
61976750|NCT00252954|PLACEBO_COMPARATOR|1|
61976751|NCT05573945|EXPERIMENTAL|Family Education Only|"Family Education Only. Parents will be asked to participate in an evidence based program s that includes 6-8 visits with a a trained healthcare provider.~This program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~Active listening Visits includes a cycle of 5-6 consecutive meetings lasting about an hour. The meetings will take place in a defined and dedicated space (private room) or if possible (if no other parents are present) at the baby's cradle. The meeting will take place between a single parent and a trained direct operator. This is not a psychotherapeutic intervention but a support that is provided to the parent. The support is mainly based on active listening, on the problems posed by the parent and on the subject's empowerment."
61976752|NCT05573945|ACTIVE_COMPARATOR|Family Education and Active Listening|"Family Education and Active Listening. Parents of infants will be asked to participate in an evidence based program for parents of NICU infants that includes 6-8 visits with a a trained healthcare provider operator.~This evidence-based program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~The program takes its conceptual basis from the Mother Infant Transaction Program (MITP).~It involves about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalisation in the NICU directly at the child's bed between the operator and one or both parents."
61976753|NCT01414907|ACTIVE_COMPARATOR|Health Promotion activities|
61976754|NCT01414907|NO_INTERVENTION|No Intervention|
61976755|NCT01859533|EXPERIMENTAL|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
62167062|NCT01154699|EXPERIMENTAL|Bilevel PAP first, then Usual Care|"Subjects will begin the study by starting on Bilevel PAP for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests. After a 4 week Washout Period of usual care, they will start a Usual Care period for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period."
62167063|NCT00771238|EXPERIMENTAL|P500 Mattress|The new P500 Low Air Loss mattress will be used to replace the standard mattress for this study arm.
62167064|NCT00771238|NO_INTERVENTION|Standard of Care Mattress|Cardiovascular ICU patients that receive standard of care mattress (Total Care Treatment Mattress) and standard pressure ulcer prevention care. All patients had daily skin assessments, as per normal care.
62167065|NCT03823261|EXPERIMENTAL|CBT|
62167066|NCT00689520|EXPERIMENTAL|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months.
62167067|NCT00689520|ACTIVE_COMPARATOR|acenocoumarol|tinzaparin for 1 weeks followed by acenocoumarol for 6 months
62167068|NCT06646887|ACTIVE_COMPARATOR|Varipluse,|Varipulse Arm - Participants in this arm will undergo ablation using the Varipulse system
62167069|NCT06646887|ACTIVE_COMPARATOR|PulseSelect|PulseSelect Arm - Participants in this arm will receive treatment with the PulseSelect system
62167070|NCT06646887|ACTIVE_COMPARATOR|Farpulse|"Farapulse Arm - Participants in this arm will undergo ablation using the Farapulse electroporation system.~."
62167071|NCT03130127|EXPERIMENTAL|Continuous infusion of terlipressin|In our clinical practice, continuous infusion of terlipressin is being employed.
62167072|NCT03130127|ACTIVE_COMPARATOR|Bolus infusion of terlipressin|Traditionally, a bolus infusion of terlipressin is recommended.
62167073|NCT04260776|EXPERIMENTAL|Phase 1|Participants will be randomly assigned to one of the two text message programs that correspond with the web-based intervention (MyWebQuit): 1) standard, 1-way text messages, or 2) interactive, 2-way text messages
62731494|NCT01104545|EXPERIMENTAL|Panel B - Healthy|Healthy participants receive single oral dose of MK-3614 0.5 mg. 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast
62167074|NCT04260776|EXPERIMENTAL|Phase 2|"For the first 5 weeks after randomization, engagement with the website will be monitored. Participants who continue to engage with the website will continue with the same Phase 1 treatment components until the 3-month follow-up.~Participants who disengage with the website will be randomly assigned to receive one of three re-engagement strategies: 1) interactive, re-engagement text messages, 2) re-engagement email, or 3) no re-engagement strategy"
62167075|NCT03395873|EXPERIMENTAL|Single arm|"* Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days"
62167076|NCT05709145|EXPERIMENTAL|Written recommendation|Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within 1 year.
62167077|NCT05709145|NO_INTERVENTION|Non Written recommendation|Patients in the control group will receive a report of the colonoscopy without a written recommendation that the colonoscopy should be repeated within 1 year.
62167078|NCT06646783|EXPERIMENTAL|dose escalation|subgroups mass does escalation
62167079|NCT05213559|EXPERIMENTAL|wheat-based biscuit enriched with plant proteins|Subjects follow a hypocaloric dietary intervention supplemented with certain amount of wheat-based biscuits enriched with plant proteins daily.
62167080|NCT05213559|ACTIVE_COMPARATOR|wheat biscuit|Subjects follow a hypocaloric dietary intervention supplemented with certain isocaloric amount of common wheat biscuits daily.
62167081|NCT05623761|ACTIVE_COMPARATOR|Group 1 - toothpaste containing thermal water of Castera-Verduzan and 1450 ppm Sodium fluoride|Subjects will receive thermal water/sodium fluoride toothpaste (BUCCOTHERM® Sensitive Gums with Fluoride)
62167082|NCT05623761|ACTIVE_COMPARATOR|Group 2 - toothpaste containing thermal water of Castera-Verduzan|Subjects will receive thermal water toothpaste (BUCCOTHERM® Sensitive Gums Fluoride-Free)
62167083|NCT00125619|ACTIVE_COMPARATOR|Arm 1: Therapist assisted|Therapist assisted locomotor training (partial body-weight supported)
62167084|NCT00125619|EXPERIMENTAL|Arm 2: Robot-assisted|Robot-assisted locomotor training (partial body-weight supported)
62167085|NCT02176018|ACTIVE_COMPARATOR|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
62167086|NCT02176018|PLACEBO_COMPARATOR|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
62167087|NCT00830284|EXPERIMENTAL|Recruitment|Patients with hypoxic respiratory failure
62167088|NCT06376344|EXPERIMENTAL|Study|
62167089|NCT06376344|NO_INTERVENTION|Control|
62167090|NCT00244751|EXPERIMENTAL|GI262570 0.5 mg|Participants received GI262570 0.5 milligrams (mg) tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
62167091|NCT00244751|EXPERIMENTAL|GI262570 1.0 mg|Participants received GI262570 1.0 mg tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
62167092|NCT00244751|PLACEBO_COMPARATOR|Placebo|Participants received matching placebo tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
62167093|NCT06440980|EXPERIMENTAL|Part A: Relative bioavailability study: Cohort 1 and 2: Orforglipron|Participants will receive different sequences of orforglipron doses administered as either tablet or capsule at different dose levels.
62167094|NCT06440980|EXPERIMENTAL|Part B: BE (bioequivalence) study: Cohort 1 and 2: Orforglipron|Participants will receive different sequences of orforglipron doses administered as either tablet (different dose levels) or capsule (test dose levels 1 to 6).
62731495|NCT01104545|EXPERIMENTAL|Panel C - Hypertensive|Hypertensive participants receive single oral dose of MK-3614 0.75 mg. 0.5 mg. 0.75 mg, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing period. All doses were administered after an 8-hour fast
62731496|NCT01007188|ACTIVE_COMPARATOR|1.5PD|average American diet plus 1.5 oz per day almonds
62167095|NCT02826759||serum sphingolipid metabolites in healthy subjects|Healthy subjects are classified according to BMI into three subgroups: healthy normal weight subjects, healthy overweight subjects and healthy subjects with obesity. Age and sex are matched among three subgroups. serum sphingolipid metabolites including sphingosine-1-phosphate will be compared.
62167096|NCT02826759||serum sphingolipid metabolites in diabetic subjects|Diagnosed diabetic patients are divided into three subgroups: diabetic patients with normal weight, overweight and obesity. age and sex are matched.
62167097|NCT02826759||serum sphingolipid metabolites in the progression of diabetes|serum sphingolipid metabolites are compared among three age-, sex- and body mass index-matched subgroups: healthy subjects, subjects with pre-diabetes, subjects with diabetes
62167098|NCT02826759||serum sphingolipid metabolites and HbA1c|diabetic subjects are divided by HbA1c level. the cut-offs are 7% and 9%. serum sphingolipid metabolites will be tested among diabetic patients with HbA1c \<7%, 7%-9% and \>9%
62167099|NCT02826759||serum sphingolipid metabolites in insulin-resistant subjects|comparison of serum sphingolipid metabolites in newly diagnosed insulin-resistant subjects and age-, sex- and BMI-matched healthy controls.
62167100|NCT06584669|ACTIVE_COMPARATOR|0.5 KO|This group receives 500 mg Krill Oil + 1.5 g medium-chain triglycerides (MCT) Oil daily during a 4-cycle supplementation phase.
62167101|NCT06584669|ACTIVE_COMPARATOR|1 KO|This group receives 1 g Krill Oil + 1 g MCT Oil daily during a 4-cycle supplementation phase.
62167102|NCT06584669|ACTIVE_COMPARATOR|2 KO|This group receives 2 g Krill Oil daily during a 4-cycle supplementation phase.
62167103|NCT06584669|ACTIVE_COMPARATOR|0.5 KO+A|This group receives 500 mg Krill Oil + 2mg astaxanthin + 1.5 g MCT Oil daily during a 4-cycle supplementation phase.
62167104|NCT06584669|PLACEBO_COMPARATOR|Placebo|This group receives medium-chain triglyceride (MCT) oil daily during a 4-cycle supplementation phase.
62167105|NCT04225247|ACTIVE_COMPARATOR|Group-I Single Bond Universal|"it is a seventh generation bonding agent used as desensitizer, manufactured by 3M ESPE.~applied on the affected surface of the group-I participants."
62167106|NCT04225247|ACTIVE_COMPARATOR|Group-II Xeno V+|"it is a seventh generation bonding agent used as desensitizer, manufactured by Dentsply.~applied on the affected surface of the group-II participants."
62167107|NCT04225247|PLACEBO_COMPARATOR|Group-III Bifluorid 12|it is a fluoride varnish used as desensitizer, manufactured by VOCO. applied on the affected surface of the group-III participants.
62167108|NCT01799993|EXPERIMENTAL|Amikacin inhale (BAY41-6551)|Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.
62167109|NCT01799993|PLACEBO_COMPARATOR|Placebo|Participants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.
62167110|NCT00588042|ACTIVE_COMPARATOR|1|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
62167111|NCT00588042|SHAM_COMPARATOR|2|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
62167112|NCT03743597|EXPERIMENTAL|SOCKNLEG|"Group of participant who will conduct the examinations first with the SOCKNLEG compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
62167113|NCT03743597|ACTIVE_COMPARATOR|Sigvaris COTTON|"Group of participant who will conduct the examinations first with the Sigvaris COTTON compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
62167114|NCT05757063|ACTIVE_COMPARATOR|Propofol|Sedation procedure with propofol
62167115|NCT05757063|ACTIVE_COMPARATOR|Dexmedetomidine|Sedation procudure with dexmedetomidine
62167116|NCT06320535|EXPERIMENTAL|Group 1: Escalating dose R21/Matrix M™|12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, and 56 via intramuscular (IM) injection in the deltoid region of the same arm
62167117|NCT06320535|EXPERIMENTAL|Group 2: Escalating dose R21/Matrix M™ with delayed booster|12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, 168 via intramuscular (IM) injection in the deltoid region of the same arm
62167118|NCT06320535|EXPERIMENTAL|Group 3: Standard dose R21/Matrix-M™|12 volunteers receiving two 10mcg doses of R21 in 50mcg of Matrix M™ adjuvant at days 0 and 56 via intramuscular (IM) injection in the deltoid region of the same arm
62167119|NCT05180526|EXPERIMENTAL|Experimental|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
62167120|NCT03302559|EXPERIMENTAL|Retinol Complex 0.5|During a 2-week washout period the participant used a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin were made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.
62167121|NCT00303017|EXPERIMENTAL|flavocoxid|medical food
62167122|NCT00303017|ACTIVE_COMPARATOR|naproxen|NSAID
62167123|NCT01090856|NO_INTERVENTION|No pre-dilation side branch|
62167124|NCT01090856|ACTIVE_COMPARATOR|Pre-dilation side branch|
62167125|NCT02001649|OTHER|Inpatient group SNP Genotyping|"Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.~Individuals will be genotyped at a total of 96 SNPs"
62167126|NCT02001649|OTHER|Control group SNP Genotyping|Control subjects are young adults without suicide attempt and without mental disorders
62167127|NCT05029271|OTHER|InPen with Guardian 4 System Arm|"All subjects will move from phase 1 to phase 4 of the study.~Phase 1:~Blinded Continuous Glucose Monitoring (CGM) will be utilized while subjects are on their current MDI therapy.~Phase 2:~All subjects will utilize a smart bolus insulin pen injector (InPen™) and app with dose calculator (InPen™ Diabetes Management App).~Phase 3:~Subjects will continue on the InPen and InPen App utilizing the HCP insights gained during the titration follow-up visit.~Phase 4:~All subjects will utilize the InPen™ with the Guardian™ 4 system."
62167128|NCT02431832|EXPERIMENTAL|Augmentin tab|
62167129|NCT04128514||Enrolled subjects|"Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation.~The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects."
62167130|NCT05476978||Pancreas-EUS|Patients since 2014 with EUS pictures of normal pancreas or pancreatic solid lesions have been included in this cohort.
62167131|NCT02880306||RA cohort|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria.
62167132|NCT02880306||Non-RA cohort|Participants who were ≥18 years of age, without a RA diagnosis
62167133|NCT03873714|EXPERIMENTAL|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
62167134|NCT03949699|OTHER|Resistance Training|. Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down. Performance during exercise sessions will be monitored by study staff who will progress the participant to exercises of greater intensity (increasing number of repetitions, sets, or resistance load; on an individual basis over the 8-week intervention period according to the participant's level of readiness). This progression will also be guided by a strength training protocol. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise
62167135|NCT02316821|EXPERIMENTAL|bardoxolone methyl|bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
62167136|NCT02316821|PLACEBO_COMPARATOR|Placebo|Placebo capsules, once daily for 16 weeks
62167137|NCT04175834|OTHER|diphenhydramine|25 mg diphenhydramine capsule, generic, sourced from Major Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
62167138|NCT04175834|ACTIVE_COMPARATOR|cetirizine|10 mg cetirizine tablet, generic, sourced from Mylan Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
62167139|NCT01136733|EXPERIMENTAL|Lenvatinib|
62167140|NCT01136733|EXPERIMENTAL|Lenvatinib plus Everolimus|
62167141|NCT01136733|ACTIVE_COMPARATOR|Everolimus|
62167142|NCT01637337|ACTIVE_COMPARATOR|laparoscopic pyelolithotomy|
62167143|NCT01637337|SHAM_COMPARATOR|percutaneous nephrolithotomy|
62167144|NCT04809545|EXPERIMENTAL|Intervention|The study intervention consists of the delivery of a soundscape in the private rooms of the participant during the morning and evening. The soundscape is personalized and consists of a collection of natural sounds, birdsongs, kitchen sounds, music, bell sound, outdoor sounds, water/rain sounds, and similar.
62167145|NCT04809545|ACTIVE_COMPARATOR|Treatment as Usual|As part of usual care, patients on the Specialized Dementia Unit receive a comprehensive assessment of their health and symptoms of dementia involving consultation by a geriatric psychiatrist, geriatrician, physical therapist, occupational therapist, and recreation therapist, and pharmacological and non-pharmacological treatment plans are developed and executed. All participants in the study will receive this standard of care
62167146|NCT01563445|EXPERIMENTAL|activated recombinant human factor VII|
62167147|NCT01563445|PLACEBO_COMPARATOR|Placebo|
62167148|NCT05018455|EXPERIMENTAL|Fall prevention intervention program conducted through telehealth|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. Each participant will practice from home, using a zoom system. The duration of each training will be one hour, the frequency of training will be twice a week for three months.
62167149|NCT05018455|ACTIVE_COMPARATOR|Similar fall prevention intervention program conducted through face to face group training|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. The training sessions will be delivered at the local community center, twice a week for one hour for three months.
62167150|NCT05986799|ACTIVE_COMPARATOR|Amway Herbal Drink|"Amway Herbal Drink: 5g/sachet, containing the following active ingredients:~* Extract of Phyllanthus emblica~* Sophora flower extract~* Wild cherry extract~* Flower extract of Dendrobium candidum~* Pomegranate extract~* Resistant dextrin~* γ-cyclodextrin"
62167151|NCT05986799|PLACEBO_COMPARATOR|Placebo Drink|"Placebo Drink: 5g/sachet, containing the following active ingredients:~* Maltodextrin~* Sugar~* Honey"
62167152|NCT05711017|EXPERIMENTAL|Huashibaidu|"During the study, subjects diagnosed as community-acquired pneumonia in children according to Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version) will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS."
62167153|NCT05711017|PLACEBO_COMPARATOR|Placebo|"During the study, subjects diagnosed as community-acquired pneumonia in children according to Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version) will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS."
62167154|NCT02010749||Control|Control: Children who had received Standard formula (SF) as infants
62167155|NCT02010749||Experimental|Experimental: Children who had received lower protein formula as infants
62167156|NCT00087919||Maywood|The were 743 subjects were sampled from Maywood, Il. There was no intervention.
62167157|NCT00087919||Nigeria|There were 1188 Nigerian sampled from Igbo-Ora and Ibadan, Nigeria. There was no intervention.
62167158|NCT03247985|ACTIVE_COMPARATOR|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
62167159|NCT03247985|ACTIVE_COMPARATOR|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
62731497|NCT01007188|OTHER|Base|average American diet without almonds
62167160|NCT00991133|EXPERIMENTAL|Clofarabine|Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.
62167161|NCT02033499|NO_INTERVENTION|No testing|No testing
62731498|NCT01007188|ACTIVE_COMPARATOR|3.0PD|average American diet plus 3.0 oz per day almonds
62167162|NCT02033499|OTHER|standard messaging|SMBG standard messaging
62167163|NCT02033499|OTHER|enhanced messaging|SMBG enhanced messaging
62167164|NCT05465499||Patient|Patient baseline data were taken from the examination at the anesthesiology outpatient clinic. (N=41)
62167165|NCT05465499||Doctor|Consists of specialist and resident anesthesiology, orthopaedic surgery and traumatology, obstetrics and gynaecology, urology. (N=110)
62167166|NCT05465499||Healthcare worker|Consists of nutritionists, pharmacists, surgical nurses, anesthesiologists, and recovery room nurses.(N=56)
62167167|NCT05727553||Breast cancer patients|Breast cancer patients treated with postoperative radiotherapy in an online adaptive workflow on Ethos.
62167168|NCT05984147|EXPERIMENTAL|AUR108, 50mg to 300mg|Currently, planned dose levels are 50,90,150,220,300 mg will be administered in 3+/4- regimen.
62167169|NCT03453489|EXPERIMENTAL|Treatment (AMT-PET, telotristat etiprate)|Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.
62167170|NCT04611724|EXPERIMENTAL|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
62167171|NCT01443546|ACTIVE_COMPARATOR|hCG|standard dose of hCG for ovulation trigger
62167172|NCT01443546|ACTIVE_COMPARATOR|Lupron Trigger|Leuprolide acetate 2 mg ovulation trigger
62167173|NCT01443546|EXPERIMENTAL|Dual Trigger|Lupron and hCG combined ovulation trigger
62167174|NCT00938288|OTHER|1|Single group
62167175|NCT03915951|EXPERIMENTAL|Treatment Period|"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.~Patients will receive the following per 28-day (± 3 days) cycle:~* Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)~* Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)"
62167176|NCT06292832|ACTIVE_COMPARATOR|Obese Spinae Plane Block|Spinae Plane Block for pain control
62167177|NCT06292832|ACTIVE_COMPARATOR|Obese Transversus Abdominis Plane Block|Transversus Abdominis Plane Block for pain control.
62167178|NCT06292832|ACTIVE_COMPARATOR|Morbidly Obese Spinae Plane Block|Spinae Plane Block for pain control
62167179|NCT06292832|ACTIVE_COMPARATOR|Morbidly Obese Transversus Abdominis Plane Block|Transversus Abdominis Plane Block for pain control.
62167180|NCT06646107||Type 1 Diabetes Mellitus|patients aged \>12 years old with T1DM who are on multiple daily injections or insulin pump and are scheduled to start using MiniMed 780G
62167181|NCT03595826|EXPERIMENTAL|1. Neurostimulant pharmaceutical drugs..|1.Participants receiving medicinal drugs, such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.
62167182|NCT03595826|EXPERIMENTAL|2. Exercise Intervention|Participants receiving a minimum of 8 sessions of exercise intervention, for the duration of an hour each session. Exercises will be to build muscle tone, improve core stability, enhance balance, improve fine and gross motor skills and visual motor integration.
62167183|NCT03595826|EXPERIMENTAL|3. Neurostimulants + Exercise intervention|See Arms 1 and 2 above. Both interventions administered together: Pharmaceutical drugs plus exercise intervention
62167184|NCT03595826|EXPERIMENTAL|4. Control Group|Participants will not receive any intervention during the research process. They will be given an intervention after the research is completed.
62167185|NCT01846988|ACTIVE_COMPARATOR|Group 1 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.
62167186|NCT01846988|ACTIVE_COMPARATOR|Group 2 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.
62167187|NCT01846988|ACTIVE_COMPARATOR|APAP pressurized comparison|randomization periods for 6-8 weeks. An in-hospital APAP titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.
62167188|NCT04369547|EXPERIMENTAL|Roflumilast|Participants will ingest a capsule containing 250mcg of the phosphodiesterase-4 inhibitor roflumilast. Their baseline TMS evoked potentials (TEP) will be recorded over 100 single TMS pulses prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the left dorsolateral prefrontal cortex (DLPFC). TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
62167189|NCT04369547|PLACEBO_COMPARATOR|Placebo|Participants will ingest a capsule identical to that containing the study medication, however, this capsule will be contain a placebo. Their baseline TEP will be recorded over 100 single TMS pulses prior to receiving TBS to the left DLPFC. TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
62167190|NCT05968911||Trauma brain injury|Patients with acquired brain injury of traumatic etiology.
62167191|NCT05968911||Non-trauma brain injury|Patients with acquired brain injury of non-traumatic etiology.
62167192|NCT00586430|ACTIVE_COMPARATOR|1|single 2 mg dose of lorazepam
62167193|NCT00586430|PLACEBO_COMPARATOR|2|single dose of placebo
62731499|NCT01896778|EXPERIMENTAL|Arm I (B-WARM for 30 minutes)|Patients undergo B-WARM at 39 degrees C for 30 minutes.
62731500|NCT01896778|EXPERIMENTAL|Arm II (B-WARM for 2 hours)|Patients undergo B-WARM at 39 degrees C for 2 hours.
62731501|NCT02507596|EXPERIMENTAL|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
62731502|NCT02507596|SHAM_COMPARATOR|Open flap debridement|an open periodontal flap without adding bone graft.
62167194|NCT03866434|EXPERIMENTAL|SPD422 + Omeprazole|Participants will receive 1 milligram (mg) of SPD422 (Anagrelide hydrochloride) (2\*0.5 mg) capsule orally on Day 1 in fasted state (10 hours prior to and until 4 hours following administration of anagrelide), followed by 40 mg of Omeprazole capsule orally once daily (prior to breakfast) on Days 2 to Day 7, followed by 1 mg of Anagrelide in fasted state in combination with Omeprazole 40 mg on Day 8.
62167195|NCT03472859|EXPERIMENTAL|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
62167196|NCT03472859|EXPERIMENTAL|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
62167197|NCT00527371|EXPERIMENTAL|PVP|Photoselective vaporization of the prostate.
62167198|NCT00527371|ACTIVE_COMPARATOR|TURP|Transurethral resection of the prostate.
62167199|NCT03287375|EXPERIMENTAL|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 4-6 weeks interval (6-7 weeks if combined with systemic chemotherapy).
62167200|NCT02490059|ACTIVE_COMPARATOR|Standard size bronchoscopy|ll procedures were started using SB with an external diameter of 5.0-6.0 mm with a biopsy channel of 2.2-2.8 mm (models Olympus BF-30 and BF-1T160, Olympus, Tokyo, Japan). If during SB the lesion was endoscopically visible the bronchoscopy was continued as standard diagnostic procedure and the patients were excluded from the analysis. Only if no tumour was visible during complete inspection of the bronchial tree using the SB, a participant was randomised by opening a numbered sealed opaque envelope. Randomisation was performed using sequentially numbered (1-40) sealed opaque envelopes (block randomisation: block size 4). For subjects allocated to the SB group, the examination was immediately continued with the same SB bronchoscope.
62167201|NCT02490059|EXPERIMENTAL|Ultrahin bronchoscopy|For subjects randomised to UB, the instrument was changed immediately to an Olympus BF-XP 40 ultrathin bronchoscope with an outer diameter of 2.8 mm and a working channel 1.2 mm during the same bronchoscopy session.
62167202|NCT05198323|EXPERIMENTAL|LT3001 Drug Product|Administered by intravenous infusion
62167203|NCT05198323|PLACEBO_COMPARATOR|Placebo|Administered by intravenous infusion
62167204|NCT00149071|ACTIVE_COMPARATOR|A|rTMS
62167205|NCT00149071|SHAM_COMPARATOR|B|sham rTMS
62167206|NCT01535625|OTHER|Momo stent|Patients with PCI
62167207|NCT03314116|EXPERIMENTAL|video group|guided by a 7-minute video that explains the importance of using ear plugs and correct installation.
62167208|NCT03314116|NO_INTERVENTION|control group|instructed to use earplugs properly, including practical exercises by a medic
62167209|NCT02464306|EXPERIMENTAL|SOT Recipients|SOT recipients (heart, lung, kidney, liver, kidney-pancreas, and pancreas) with a first-episode of CDI. Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days. The rate of sustained clinical response (SCR; cure without recurrence at 30 days) will be assessed.
62167210|NCT02464306|NO_INTERVENTION|Historical Cohort|Historical cohort of SOT recipients who received standard of care therapy for CDI at our institution.
62167211|NCT05082441|EXPERIMENTAL|experimental|Exparel group
62167212|NCT05082441|ACTIVE_COMPARATOR|control|plain bupivacaine
62167213|NCT03878290|EXPERIMENTAL|8-week RiSE|Participate in 8-week Resilience, Stress, and Ethnicity (RiSE) group based stress reduction program in which participants meet every week for approximately 2 hours for 8 consecutive weeks.
62167214|NCT03878290|NO_INTERVENTION|Control|Treatment as usual
62167215|NCT03340766|EXPERIMENTAL|Cohort Ia: Blinatumomab 9/28 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion (CIVI) for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days then 28 µg/day for the remaining days of treatment.~Starting on Day 15 participants also received 200 mg pembrolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) until disease progression or for up to 35 cycles."
62167216|NCT03340766|EXPERIMENTAL|Cohort IIa: Blinatumomab 9/28/56 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 56 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
62167217|NCT03340766|EXPERIMENTAL|Cohort IIIa: Blinatumomab 9/28/112 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 112 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
62167218|NCT03340766|EXPERIMENTAL|Expansion Cohort|This cohort will test the maximum tolerated dose of blinatumomab in combination with pembrolizumab identified in Part 1 of the study.
62167219|NCT05466968|EXPERIMENTAL|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
62731503|NCT03194308|OTHER|HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
62731504|NCT02880111||group 1|CF patients with Pseudomonas aeruginosa chronic colonization.
62731505|NCT02880111||group 2|CF patients without a Pseudomonas aeruginosa chronic colonization.
62167220|NCT05466968|PLACEBO_COMPARATOR|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
62167221|NCT06644391||Radiographs Analyzed Using AI and Radiologist Review|This cohort consists of 600 radiographs collected from pediatric and adult patients, aged 1 to 99 years, who underwent X-ray imaging for musculoskeletal conditions. The radiographs include various body parts such as the foot, ankle, knee, hand, wrist, elbow, shoulder, and pelvis. Fractures were present in 95 cases, while 453 cases showed no fractures.
62167222|NCT03344900||Phase I|It is estimated that 100 participants with SCD will be enrolled for the Phase I portion which will identify barriers to hydroxyurea utilization.
62167223|NCT03344900||Phase II|It is estimated that 72 participants with SCD will be enrolled for the Phase II portion of the study which will evaluate the degree of feasibility and acceptance of mHealth intervention on hydroxyurea adherence.
62167224|NCT01169571||Group I - No loading dose|No loading dose to be administered during the loading-dose paradigms
62167225|NCT01169571||Group II - Loading dose over 10 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 10 minutes during the loading-dose paradigms
62167226|NCT01169571||Group III - Loading dose over 20 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 20 minutes during the loading-dose paradigms
62167227|NCT06063564|ACTIVE_COMPARATOR|Wait-List Control|Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered immediately following their clinic visit and at 6-months after the clinic visit electronically and by mail. A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement.
62167228|NCT06063564|EXPERIMENTAL|PREVENT Intervention|"Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered immediately following the clinic visit, and monthly for 6-months after the clinic visit electronically and by mail~At the clinic visit, the provider will use the PREVENT tool to discuss CVH risk. A community health worker (CHW) will deliver a tailored behavioral change plan inclusive of patient-centered community resources. The CHW will provide ongoing support with goals and social needs for 6-months."
62167229|NCT03013725||The Homocysteine Study|Conducted in 1992-93, ca. 18000 participated.
62167230|NCT03013725||The Hordaland Health Study (HUSK)|Conducted in 1997-99, ca. 26000 participated.
62167231|NCT01350102|ACTIVE_COMPARATOR|Bacitracin wound care dressing alone|Bacitracin wound care dressing alone
62167232|NCT01350102|ACTIVE_COMPARATOR|Bacitracin with Vit C|Bacitracin wound care dressing with Vitamin C supplementation
62167233|NCT01350102|ACTIVE_COMPARATOR|AmeriGel® wound care dressing alone|AmeriGel® wound care dressing alone
62167234|NCT01350102|ACTIVE_COMPARATOR|AmeriGel® with Vit C|AmeriGel® wound care dressing with Vitamin C supplementation
62167235|NCT04232475|NO_INTERVENTION|Control|Seated control
62167236|NCT04232475|EXPERIMENTAL|1 minute SCD|1 minute of stair climbing and descending
62167237|NCT04232475|EXPERIMENTAL|3 minute SCD|3 minute of stair climbing and descending
62167238|NCT04232475|EXPERIMENTAL|10 minute SCD|10 minute of stair climbing and descending
62167239|NCT02198885||Control|This group receives the standard prehospital care en route to hospital, and they do not receive the FAST ultrasound en route.
62167240|NCT02198885||FAST|This group receives the FAST ultrasound en route to hospital.
62167241|NCT04861974||Robotic Distal Pancreatectomy|
62167242|NCT04861974||Laparoscopic Distal Pancreatectomy|
62167243|NCT04861974||Robotic Gastrectomy|
62167244|NCT04861974||Laparoscopic Gastrectomy|
62167245|NCT04861974||Robotic Funduplication|
62167246|NCT04861974||Laparoscopic Funduplication|
62167247|NCT04861974||Robotic Hernioplasty|
62731506|NCT05754411|EXPERIMENTAL|[14C]STI-1558|
62735178|NCT01607463|PLACEBO_COMPARATOR|Placebo group|"Two electrodes were attached to the radial side of dominant forearm. In the placebo group the TENS device had no current output although the power on indicator light remained active."
62737172|NCT04098653|EXPERIMENTAL|Decitabine + BUCY|For myeloid tumors undergoing allo-HSCT, Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
62167248|NCT04861974||Laparoscopic Hernioplasty|
62167249|NCT04861974||Robotic Rectal Resection|
62167250|NCT04861974||Laparoscopic Rectal Resection|
62167251|NCT05079958|EXPERIMENTAL|Stage2 - cognitive-behavioral education|A quasi-experimental design will be used to determine the effects of a four-week cognitive-behavioral education course related to smoking cessation on the participants' smoking cessation behavior, smoking decision-making, and self-efficacy in smoking cessation.
62167252|NCT05079958|EXPERIMENTAL|Stage 3- 12-week brisk walking|"Subjects who are at the preparation  and action stage will be recruited and randomly divided into experimental or control group to identify the effect of a 12-week brisk walking on improving the participants' immediate (short-term), three-month, and six month (long-term) health status."
62167253|NCT02623686|EXPERIMENTAL|Aroma group|"* two massages delivered within a two day period~* the patient will choose the essential oils used from blend A and blend B (if no choice is made, therapist will choose blend A and B alternately). One drop of the essential oil blend will be added to 5 mls of grapeseed base oil.~* an Inhalation Patch with the same blend of oils as used in the massage will be left by the therapist for use on each of the two nights following the aromatherapy massage intervention. Its use will be explained to the patient and to the member of nursing staff. The Inhalation Patch will be applied to the patient's upper chest when it is time to sleep at approximately 11 pm and will be removed the following morning at approximately 6 am."
62167254|NCT02623686|NO_INTERVENTION|Control Group|Normal Care
62167255|NCT05852496|ACTIVE_COMPARATOR|Vitamin D supplement|Vitamin D supplement intake for 6 months
62167256|NCT05852496|PLACEBO_COMPARATOR|Placebo group|Group with no vitamin D supplement treatment
62167257|NCT04397822||COVID-19 GROUP Intensive care unit|Patients suffering from COVID-19 hospitalized in intensive care unit
62167258|NCT04397822||COVID-19 GROUP Standard care unit|Patients suffering from COVID-19 hospitalized in standard care unit.
62167259|NCT01757171|EXPERIMENTAL|Arm A (taxane naïve)|No prior Taxane treatment. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
62731507|NCT05238272|EXPERIMENTAL|tRNS-augmented unilateral MT|"A battery driven multi-channel electrical stimulator will deliver alternating electrical current over the scalp through sailine-soaked sponge electrodes (surface area = 25 cm2). The stimulation electrodes were directly positioned on an adult sized cap that will be worn by the participants, and labeled according to the 10-20 EEG system of electrode positioning. The stimulation intensity will be ramp up to 1.5 to 2 mA.~For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
62167260|NCT01757171|EXPERIMENTAL|Arm B (prior taxane therapy)|Subject previously treated with taxane. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
62167261|NCT06291584|EXPERIMENTAL|Face-to-Face Exercise Group|In the face-to-face exercise group called Group 1, students will apply an exercise program of respiratory exercises and resistance exercises with the physiotherapist.
62167262|NCT06291584|EXPERIMENTAL|Telehealth Exercise Group|In the online (telehealth) exercise group, group 2 will be applied by the students with the help of the physiotherapist.
62167263|NCT06291584|NO_INTERVENTION|Control Group|In the control group called Group 3, students will not be given any exercise program.
62167264|NCT05052333||Examining the psychosocial impacts of COVID-19 in Pakistan.|This is exploratory research and data will be obtained on a set of measures using a bilingual (Urdu-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
62167265|NCT05052333||Examining the psychosocial impacts of COVID-19 in Iraq.|This is exploratory research and data will be obtained on a set of measures using a bilingual (Arabic-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
62167266|NCT05052333||Examining the psychosocial impacts of COVID-19 in Türkiye.|This is exploratory research and data will be obtained on a set of measures using a unilingual (Turkish) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
62167267|NCT05052333||Examining the psychosocial impacts of COVID-19 in Iran.|This is exploratory research and data will be obtained on a set of measures using a Bilingual (Persian-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
62167268|NCT05052333||Examining the psychosocial impacts of COVID-19 in Malaysia.|This is exploratory research and data will be obtained on a set of measures using a bilingual (Malay-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
62167269|NCT05052333||Examining the psychosocial impacts of COVID-19 in Indonesia.|This is exploratory research and data will be obtained on a set of measures using a unilingual (Indonesian) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
62167270|NCT05052333||Examining the psychosocial impacts of Covid-19 in Somaliland.|This is exploratory research and data will be obtained on a set of measures using a unilingual (Somalia) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
62167271|NCT05024578|SHAM_COMPARATOR|Sham|In the sham condition, participants will wear the EEG headband monitor (DREEM2, Dreem, Paris, France) for 1 week, but the sound stimulation feature will be deactivated.
62167272|NCT05024578|EXPERIMENTAL|Auditory Stimulation|In the active experimental condition, participants will complete 1 week of slow oscillation (SO) stimulation with the EEG headband monitor (DREEM2, Dreem, Paris, France) in the form of auditory stimuli (100ms pink noise pulses, i.e., below the waking threshold as established in prior work) sent on the ascending phase of the SO during N3 sleep.
62167273|NCT03553459|EXPERIMENTAL|Trendelenburg Maneuver|Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
62167274|NCT02658032|OTHER|Standard Care/No Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the non bio feedback arm.
62167275|NCT02658032|OTHER|Standard Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the bio feedback arm.
62167276|NCT02658032|OTHER|Personalized Care/ No Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the non bio feedback arm.
62167277|NCT02658032|EXPERIMENTAL|Personalized Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the bio feedback arm.
62167278|NCT03861078|EXPERIMENTAL|Cigarette smokers|"Each participant will participate in 5 sessions. During each session, participants will complete a 10-puff, directed product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.~Session 1: Own brand cigarette use Session 2: ECIG 15 mg nicotine, sweetened Session 3: ECIG Lab Session ECIG 15 mg nicotine, unsweetened Session 4: ECIG Lab Session ECIG 0 mg nicotine, sweetened Session 5: ECIG Lab Session ECIG 0 mg nicotine, unsweetened"
62167279|NCT00494286|EXPERIMENTAL|AF-CBT|Participants will receive abused-focused cognitive behavioral therapy
62167280|NCT00494286|ACTIVE_COMPARATOR|TAU|Participants will receive treatment as usual
62167281|NCT02469051|OTHER|Breathhold SPECT-MPI vs. standard freebreathing SPECT-MPI|
62167282|NCT05474378|EXPERIMENTAL|Dose escalation|All subjects will be assigned to a dose level. Does escalation will proceed sequentially via a standard 3+3 dose escalation design in subjects who receive at least one infusion of B7-H3CART. Each dose level will include 3 to 6 subjects, starting at Dose Level 1. If Dose Level 1 is considered too toxic, the dose may be de-escalated to Dose Level -1. If Dose Level 4 is completed with no dose limiting toxicity (DLT) in six subjects, a maximum tolerated dose (MTD) may not be determined, and Dose Level 4 will instead be the maximum administered dose (MAD). T
62736275|NCT04166370|EXPERIMENTAL|Strengthened Services and SBCC plus Conditional Cash Transfer|Increase referrals to health services, strengthenhealth services, provide enhanced SBCC, as well as cash transfers that are conditional on a mother attending antenatal care (ANC) and monthly nutrition education SBCC group sessions.
62736276|NCT02585986|ACTIVE_COMPARATOR|Probiotic|daily intake of 1 capsule containing probiotic.
62167283|NCT05474378|EXPERIMENTAL|Dose Expansion|After Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is established, a total of 12 evaluable subjects (including the 6 subjects infused during the dose escalation phase) will be enrolled at the RP2D to further explore safety of repeat administrations at MTD/RP2D and conduct a preliminary assessment of benefit.
62167284|NCT01502605|EXPERIMENTAL|5-ALA|This arm will receive the investigational agent, 5-ALA.
62167285|NCT00005914||Probands and family members|Individuals with major depressive disorder who meet study criteria, and members of their families. No intervention. This is a genetic study only.
62167286|NCT05547503|PLACEBO_COMPARATOR|Placebo Control|Double blind placebo control
62167287|NCT05547503|EXPERIMENTAL|AFA-281|"Part 1: AFA-281 administered as an oral capsule at 5 dose levels for one day.~Part 2: AFA-281 administered as an oral capsule at 3 dose levels twice daily for 14 consecutive days. Doses will be determined after completion of Part 1."
62167288|NCT04093583|ACTIVE_COMPARATOR|Simple suture|
62167289|NCT04093583|EXPERIMENTAL|PRGF-Endoret|
62167290|NCT02429037|EXPERIMENTAL|rAd-p53 plus radiation and chemotherapy|rAd-p53 tumor injection combined with radio- and chemo-therapy.
62167291|NCT02429037|ACTIVE_COMPARATOR|radiation and chemotherapy|radiation combined with chemotherapy
62167292|NCT05143437|EXPERIMENTAL|Writing Intervention|Couples will take part in three 7-minute online writing sessions over the course of four weeks.
62167293|NCT05414071|EXPERIMENTAL|NMS Assist|NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.
62167294|NCT02007421|OTHER|HIV positive homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
62167295|NCT02007421|OTHER|HIV negative homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
62167296|NCT02241642|EXPERIMENTAL|Treatment|VIVASURE CLOSURE DEVICE™
62167297|NCT03918733|EXPERIMENTAL|surgical treatment|surgical treatment of failed root canal treated teeth following secondary root canal treatment.
62167298|NCT03918733|EXPERIMENTAL|Non surgical retreatment|Non surgical retreatment of failed root canal treated teeth
62167299|NCT03296423|PLACEBO_COMPARATOR|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
62167300|NCT03296423|ACTIVE_COMPARATOR|Vaccination|One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)
62167301|NCT02618109|OTHER|Relapse Group|"* Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.~* Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis."
62167302|NCT02618109|OTHER|Control Group|"* Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.~* Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.~* These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients."
62167303|NCT05256914|EXPERIMENTAL|Peri-implant mucositis sites|Peri-implant mucositis sites will be randomly assigned to ozone treatment.
62167304|NCT05256914|EXPERIMENTAL|Contralateral peri-implant mucositis sites|Contralateral peri-implant mucositis sites with respect to those treated with ozone will be assigned to chlorhexidine treatment.
62167305|NCT00079599|EXPERIMENTAL|1|
62167306|NCT00079599|PLACEBO_COMPARATOR|2|
62167307|NCT03022734|EXPERIMENTAL|chemotherapy with radiotherapy|Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy
62167308|NCT02635711|EXPERIMENTAL|Adapted Taekwondo training|An adapted TKD training regime which was developed by our research team \[16\] will be used in this study. This training programme is designed to train balance control, eye-hand coordination and facilitate skeletal development for children with DCD. The high-impact striking techniques (e.g., punching and blocking) incorporated in the programme may stimulate bone growth \[15\]. Subjects who are assigned to the TKD training group will attend a weekly 1-h session of TKD training that will be held at the University of Hong Kong for 12 weeks. All TKD training sessions will be conducted by a qualified World Taekwondo Federation black belt coach.
62167309|NCT02635711|ACTIVE_COMPARATOR|Control|Subjects who are assigned to the DCD-control group will receive no TKD training during the study period. Instead, they will participate in jogging exercise daily (one hour per day) for 12 weeks. Participants will be encouraged to jog to school or other places every day, as appropriate. Pedometers will be used to monitor their exercise level and enhance habitual physical activity. The pedometer count (steps per day) will be documented in a log book by the parents. Signed log books will be returned to our research personnel after the intervention period. In addition, children with DCD in this group will receive an adapted TKD training menu and 12 training/demonstration sessions immediately after the follow-up testing is completed.
62167310|NCT06086665||Observation cohort (Cohort A)|All patients who did not receive any kind of maintenance therapy for primary epithelial ovarian cancer from Dec 2019 to Dec 2022
62167311|NCT06086665||Cohort B|All patients who received or who are receiving niraparib maintenance therapy for primary epithelial ovarian cancer in 1st line setting
62731508|NCT05238272|EXPERIMENTAL|tRNS-augmented bilateral MT|"A battery driven multi-channel electrical stimulator will deliver alternating electrical current over the scalp through sailine-soaked sponge electrodes (surface area = 25 cm2). The stimulation electrodes were directly positioned on an adult sized cap that will be worn by the participants, and labeled according to the 10-20 EEG system of electrode positioning. The stimulation intensity will be ramp up to 1.5 to 2 mA.~For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
62731509|NCT05238272|SHAM_COMPARATOR|sham tRNS with unilateral MT|"For the sham tRNS condition, the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds .~For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
62736277|NCT02585986|PLACEBO_COMPARATOR|Placebo|daily intake of 1 capsule containing placebo
62736278|NCT00969605|ACTIVE_COMPARATOR|Pressure support ventilation|
62736279|NCT00969605|ACTIVE_COMPARATOR|Adaptive support ventilation|
61976756|NCT01859533|NO_INTERVENTION|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
61976757|NCT01509430|EXPERIMENTAL|Early training patient|12 weeks of Progressive Resistance Training followed by 12 weeks of a self chosen level of physical activity
61976758|NCT01509430|EXPERIMENTAL|Late training patients|12 weeks of a self chosen level of physical activity followed by 12 weeks of progressive resistance training
61976759|NCT04711408|EXPERIMENTAL|Virtual reality|women allocated to undergo ultrasound for the diagnosis of endometriosis with Virtual reality System
61976760|NCT04711408|NO_INTERVENTION|Standart care|women allocated to undergo ultrasound for the diagnosis of endometriosis without VR
61976761|NCT02584335|ACTIVE_COMPARATOR|"Lidocaine solution (A)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient)."
61976762|NCT02584335|PLACEBO_COMPARATOR|"Saline solution (B)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution."
61976763|NCT00432107|EXPERIMENTAL|2-stage mono therapy of APO866|The treatment period consists of 3 consecutive 28 day cycles. Each cycle starts with a 4 day continuous infusion of the study medication followed by a 24 day break
61976764|NCT06204718|EXPERIMENTAL|Standard pelvic floor exercises|Standard pelvic floor exercises in addition to Global Postural Reeducation training
61976765|NCT06204718|EXPERIMENTAL|Involuntary reflexive pelvic floor exercises|Involuntary reflexive pelvic floor exercises in addition to Global Postural re-education training
61976766|NCT02905331|EXPERIMENTAL|Group 1 (Guselkumab: Placebo)|Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
61976767|NCT02905331|EXPERIMENTAL|Group 2 (Placebo: Guselkumab)|Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
61976768|NCT01434069|EXPERIMENTAL|Combination Therapy: FOLFIRI and SOM 230|"Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of \> 10% from baseline.~SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days."
61976769|NCT03557151|ACTIVE_COMPARATOR|Usual Care|Usual Care participants will receive the same excellent multidisciplinary care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
61976770|NCT03557151|EXPERIMENTAL|Transdisciplinary Care-In Person & Telehealth|In addition to all elements of Usual Care, TC-IP participants will have follow-up clinic visits in-person or by telehealth at approximately 3 month intervals during the study that will consist of simultaneous involvement of an advanced practice nurse, dietitian and psychologist who will see the parent and adolescent together. TC team members will have passed a competency exam following completion of a training course on each of the TC team professional disciplines.
61976771|NCT02562794|EXPERIMENTAL|Intervention|Family Strengthening Intervention-Refugees. A total of 20 Somali Bantu and 20 Bhutanese refugee families will participate in a Family Strengthening Intervention adapted for use with refugees.
61976772|NCT02562794|NO_INTERVENTION|Control|A total of 20 Somali Bantu and 20 Bhutanese refugee families will receive services as usual.
61978385|NCT00449540|SHAM_COMPARATOR|Sham TMS Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
62167312|NCT06086665||Cohort C|All patients who received or who are receiving niraparib maintenance therapy for recurrent epithelial ovarian cancer in 2nd or 3rd line setting
62167313|NCT06086665||Cohort D|All patients who received or who are receiving salvage niraparib therapy for recurrent epithelial ovarian cancer in 4th line or more line setting
62167314|NCT01481701|EXPERIMENTAL|intravenous chemotherapy|treatment of ovarian carcinoma in relapse
62167315|NCT05635994||Single arm|There is only one arm. Initially, a tentative diagnosis would be performed by the clinician, only taking into account patients's clinical information and angiography images. After applying AID strategy, a final diagnosis will be reached and compared with the tentative one.
62167316|NCT02589678|OTHER|MMR/Tdap-IPV|Participants receiving MMR vaccine (Measles, mumps, and rubella) at 0 months/at enrollment, followed by Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 3 months.
62167317|NCT02589678|OTHER|Tdap-IPV/MMR|Participants receiving Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 0 months/at enrollment, followed by MMR vaccine (Measles, mumps, and rubella) at 3 months.
62167318|NCT03555708|EXPERIMENTAL|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
62167319|NCT03555708|EXPERIMENTAL|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
62167320|NCT03555708|EXPERIMENTAL|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
62167321|NCT02577848|EXPERIMENTAL|GLP-1 group|liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
62167322|NCT02577848|PLACEBO_COMPARATOR|placebo|placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
62167323|NCT00975130|EXPERIMENTAL|SC-GLM50|In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.
62167324|NCT00975130|EXPERIMENTAL|IV GLM 2 mg/kg + GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.
62167325|NCT00975130|EXPERIMENTAL|GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.
62167326|NCT01482871|EXPERIMENTAL|Arm 1.5 mg ALG-1001|Group Using 1.5 mg per 100 ul of ALG-1001
62167327|NCT01482871|EXPERIMENTAL|Arm 2.5 mg ALG-1001|Group Using 2.5 mg per 100 ul of ALG-1001
62167328|NCT01482871|EXPERIMENTAL|Arm 5.0 mg ALG-1001|Group Using 5.0 mg per 100 ul of ALG-1001
62167329|NCT01482871|EXPERIMENTAL|Arm 7.5 mg ALG-1001|Group Using 7.5 mg per 100 ul of ALG-1001
62167330|NCT02165696|EXPERIMENTAL|Manual lymphatic drainage and compression bandaging|Experimental group: 30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
62167331|NCT02165696|ACTIVE_COMPARATOR|Manual lymphatic drainage|Control group: 30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
62167332|NCT04950790|EXPERIMENTAL|Test group|Shuxuening injection + basic treatment
62167333|NCT04950790|PLACEBO_COMPARATOR|Control group|placebo (sterilized water for injection) + basic treatment
62167334|NCT02876393||Cases|Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
62167335|NCT02876393||Control definition|Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.
62736280|NCT00033423|EXPERIMENTAL|Cohort 1|First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
62736281|NCT00033423|EXPERIMENTAL|Cohort II|Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
61978386|NCT05641051|EXPERIMENTAL|Metoclopramide group|Patients will receive 10 mg intravenous metoclopramide / 6 hours.
62167336|NCT06098443|EXPERIMENTAL|Acupressure|The acupressure points will be determined, patients are informed that they will feel soft vibrations and pain during acupressure application. Patients are advised that it is sufficient for them to feel the vibrations of the acupressure device slightly. It be felt first symmetrically right knee, right leg, left knee, left leg Patients will receive acupressure 24 sessions three times a week for eight weeks. After application the patient will be asked about the severity of pain half an hour after administration (Çevik \& Taşcı, 2020).
62167337|NCT06098443|ACTIVE_COMPARATOR|Transcutaneous electrical nerve stimulation|"• Placement electrodes applied on the painful area lower leg.~Settings:~* Intensity up to patient tolerance.~* Duration 30min."
62167338|NCT00396721|ACTIVE_COMPARATOR|A|
62167339|NCT00396721|EXPERIMENTAL|B|
62167340|NCT04673071|ACTIVE_COMPARATOR|Thread Embedding Acupuncture (TEA)|TEA once a month for 4 months + AEDs
62167341|NCT04673071|SHAM_COMPARATOR|Sham-TEA (STEA)|STEA once a month for 4 months + AEDs
62167342|NCT06183944||Patient with acute pulmonary embolism|Patient with acute pulmonary embolism in Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, hospitalised or not since 2019
62167343|NCT03548272|EXPERIMENTAL|BiOSS LIM C|"Intervention: Percutaneous coronary intervention (PCI) with BiOSS LIM C stent implantation.~The BiOSS LIM C® is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 µm) releasing sirolimus (1.4 µg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids (PGLA). The degradation of the polymer lasts approximately 8 weeks. The BiOSS LIM C® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller. The proximal part is always a bit shorter than the distal one (avg. 1 mm)."
62167344|NCT03548272|ACTIVE_COMPARATOR|regular 2nd generation DES|"Intervention: Percutaneous coronary intervention (PCI) with regular drug-eluting stent implantation (rDES).~rDES well-tested and available on the market. Xience, Orsiro, Resulte Integrity"
62167345|NCT04546971|ACTIVE_COMPARATOR|Brief intervention|A brief alcohol intervention lasting about 10 minutes, delivered after the baseline assessments.
62167346|NCT04546971|EXPERIMENTAL|Brief Intervention plus Telehealth Counseling|A brief alcohol intervention followed by referral to a telehealth counseling protocol including 5 sessions of counseling based on Motivational Interviewing and delivered by videoconferencing. Telehealth counseling extends for up to two years and also includes a text messaging intervention to encourage reductions in drinking.
62167347|NCT00597025|ACTIVE_COMPARATOR|Group A|Center Hemodialysis patients
62167348|NCT00597025|ACTIVE_COMPARATOR|Group B|Center hemodialysis patients
62167349|NCT00597025|NO_INTERVENTION|Group C|Center Hemodialysis Patients
62167350|NCT00597025|ACTIVE_COMPARATOR|Group D|Peritoneal dialysis patients
62167351|NCT00597025|NO_INTERVENTION|Group E|Peritoneal dialysis patients
62167352|NCT02831751|EXPERIMENTAL|30 µg/strain of Quadrivalent VLP Vaccine|
62167353|NCT02831751|EXPERIMENTAL|60 µg/strain of Quadrivalent VLP Vaccine|
62167354|NCT02831751|ACTIVE_COMPARATOR|FluLaval® Tetra (15 µg/strain)|
62167355|NCT02831751|ACTIVE_COMPARATOR|Fluzone® High-Dose (60 µg/strain)|
62167356|NCT04695249|EXPERIMENTAL|Exposure intervention|Eleven individual sessions.
62167357|NCT04399798|EXPERIMENTAL|Baricitinib active treatment|Baricitinib 4 mg/day
62167358|NCT02061189|EXPERIMENTAL|Swimming pool training group|"10 patients will be selected to perform a 6 months training in a swimming pool, from M12 to M18 or M18 to M24 or M24 to M36, in defined and reproducible conditions.~* M0, M6, M12 and M18 or M0, M6, M12, M18 and M24 or M0, M6, M12, M18, M24 and M30 assessments: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis.~* M12 to M18 or M18 to M24 or M24 to M30: Physical exercise in a swimming pool (3 times per week).~* M24 or M30 or M36: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis."
62167359|NCT02061189|NO_INTERVENTION|Control group|"20 patients with same assessments at M0, M6, M12 and M18, but:~* without swimming pool training.~* without M24 assessment."
62167360|NCT03101098|EXPERIMENTAL|Retroperitoneal hysterectomy|In subjects allocated to the experimental group, which the uterine vessels were ligated where it originates from the internal iliac artery,
62167361|NCT03101098|ACTIVE_COMPARATOR|Classical hysterectomy|The operative technique of classical total laparoscopic hysterectomy (TLH) performed in the control group was comparable to that of retroperitoneal TLH, except for one that coagulation and transection of uterine artery was achieved using an energy device alongside the cervix
62167362|NCT00731276|OTHER|Four Regimens|"The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.~Four Regimens are:~1. Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly~2. Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~3. Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~4. Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly"
62167363|NCT02752789||Pediatric Heart Transplant Recipients|CTOTC-04 (ClinicalTrials.gov ID NCT01005316) participants who consent to long-term follow-up as part of this study as well as candidates less than 21 years of age who are listed for isolated orthotopic heart transplantation at one of the participating sites
62167364|NCT01550783|EXPERIMENTAL|Group I (home-based HPV screening)|Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
62167365|NCT01550783|EXPERIMENTAL|Group II (clinic-based standard of care screening)|Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.
62167366|NCT04868734|EXPERIMENTAL|Supportive Psychotherapy|Supportive Psychotherapy do to subjects
62167367|NCT04868734|NO_INTERVENTION|Casual Treatment|Do Casual Intervention
62167368|NCT04593771|EXPERIMENTAL|Experimental group|80 healthy people were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD once.
62167369|NCT04593771|OTHER|control group|80 healthy people were randomly assigned to the experimental group and the control group. The control group was injected with BCG-PPD was marketed once.
62167370|NCT00752999|EXPERIMENTAL|A|150 mg tablet, oral, twice-a-day
62167371|NCT00752999|PLACEBO_COMPARATOR|B|Placebo tablet, oral, twice-a-day
62167372|NCT03053908|EXPERIMENTAL|Elderly Patients|
62167373|NCT06336707|EXPERIMENTAL|HS-20089 and Adebrelimab|
62167374|NCT06336707|EXPERIMENTAL|HS-20089, Adebrelimab and cisplatin / carboplatin|
62167375|NCT06336707|EXPERIMENTAL|HS-20089 and Bevacizumab|
62167376|NCT06336707|EXPERIMENTAL|HS-20089, Bevacizumab and cisplatin / carboplatin|
62167377|NCT05961488|EXPERIMENTAL|Patients|
62167378|NCT02243488|EXPERIMENTAL|12 month menstrual hygiene programme|This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
62167379|NCT02243488|EXPERIMENTAL|6 month menstrual hygiene programme|This is the second group to receive the intervention. They will act as a control group for the first 6 months then receive intervention at 6 months.
62167380|NCT01349699|ACTIVE_COMPARATOR|Iron loading|Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.
62167381|NCT01349699|ACTIVE_COMPARATOR|Iron chelation|Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.
62167382|NCT01349699|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration
62167383|NCT01350388|ACTIVE_COMPARATOR|Febuxostat|80 mg/day of febuxostat for 24 weeks
62167384|NCT01350388|PLACEBO_COMPARATOR|Placebo|1 placebo tablet per day for 24 weeks
62167385|NCT05765409|EXPERIMENTAL|TIMCA|The intervention will combine elements of motivational interviewing, cognitive and behavioral therapy and an attachment-based intervention. Sessions with both the adolescent and his parents are planned.
62167386|NCT05765409|ACTIVE_COMPARATOR|Treatment as Usual|"The comparator, an active control, will be Treatment As Usual (TAU) group, i.e., the therapy usually practiced in the services. Given the multiplicity of investigating centers and the different treatments offered according to the patient's problems, it seems difficult to choose a single reference treatment for the control arm. Each investigating center undertakes to adopt the treatment that seems most effective and appropriate for each patient"
62167387|NCT05723029|EXPERIMENTAL|Group A: Bowen Technique|The subjects will receive Bowen Technique. The treatment session will be 3 times per week for 4 weeks for 20 minutes. The Bowen technique is a subtle and precise mobilization called Bowen moves. The mobilization is applied by using the fingers and thumbs over muscles, tendon, nerves and fascia. Only gentle non-invasive pressure is applied. A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position. The therapist has a sense of tissue tension, and this enables his/her to feel where stress has built up in the tissue.
62167388|NCT05723029|EXPERIMENTAL|Group B: Post Isometric Relaxation Technique|The subjects will receive Post Isometric Relaxation Technique. Treatment session includes 3 times per week for 4 weeks for 20 minutes. Evaluation will be done before and after the treatment at the end of the 4th week. The outcome will be measured by the Active Knee Extension test, Numeric pain Rating Scale, and Goniometer. Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles. The intervention is performed three times in a single session with 30 seconds rest intervals.
62167389|NCT01212952|EXPERIMENTAL|Arm I|Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62167390|NCT03731572|EXPERIMENTAL|Power Training|Hip abductor-adductor resistance exercises at 75% maximum strength and maximum execution speed, 3, 1-hour training sessions per week for 12 weeks.
62167391|NCT03731572|ACTIVE_COMPARATOR|Strength Training|Hip muscle abductor-adductor resistance exercises at maximum strength at reduced execution speed (2s concentric/3s eccentric), 3, 1-hour training sessions per week for 12 weeks.
62167392|NCT01698216||Consta Sustenna switching|The patients group who switched to paliperidone palmitate from risperidone long acting injection
62167393|NCT00728832|ACTIVE_COMPARATOR|1|No test dose + DepoDur + flush with 1 mL normal saline
62167394|NCT00728832|EXPERIMENTAL|2|Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline
62167395|NCT00728832|EXPERIMENTAL|3|Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline
62167396|NCT00728832|EXPERIMENTAL|4|Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline
62167397|NCT00728832|EXPERIMENTAL|5|Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline
62167398|NCT05455554||CLI (Critical Limb Ischemia)|CLI cohort is a population of individuals with CLI, at least one active lower extremity wound and planned lower extremity revascularization. CLI cohort patients will receive Flowmet-D measurements in addition to standard of care therapy following intervention.
62167399|NCT05455554||HBO (Hyperbaric Oxygen)|HBO cohort is a subset of the CLI cohort who will undergo hyperbaric oxygen therapy in the post-operative setting who will receive Flowmet-D measurements before and after their therapy.
62167400|NCT03441737|EXPERIMENTAL|Exercise|Aerobic exercise intervention
62736282|NCT00033423|EXPERIMENTAL|Cohort III|Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
62736283|NCT00033423|EXPERIMENTAL|Cohort IV|Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
61978387|NCT05641051|PLACEBO_COMPARATOR|Control group|Patients will receive the same volume of intravenous placebo / 6 hours.
62167401|NCT03441737|ACTIVE_COMPARATOR|Non-Exercise|Non-aerobic exercise intervention
62167402|NCT01714414|EXPERIMENTAL|FZD 600mg twice daily|FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
62167403|NCT01714414|EXPERIMENTAL|FZD 800mg once daily|FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
62167404|NCT01714414|EXPERIMENTAL|FZD 1200mg once daily|FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
62167405|NCT01714414|ACTIVE_COMPARATOR|AZT twice daily|1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
62167406|NCT02029027|EXPERIMENTAL|GYNEFFIK(R)|30 min-session of vaginal electro-stimulation by GYNEFFIK thrice a week for 6 months (except during menstrual periods)
62167407|NCT02029027|OTHER|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
62167408|NCT05292170|EXPERIMENTAL|Males|10 consecutive day heat acclimation in males
62167409|NCT05292170|EXPERIMENTAL|Females + high hormones|10 consecutive day heat acclimation in females with high hormonal dose
62167410|NCT05292170|EXPERIMENTAL|Females + low hormones|10 consecutive day heat acclimation in females with low hormonal dose
62167411|NCT02951416||Idiopathic Pulmonary Fibrosis (IPF)|"IPF diagnosis according to the guidelines of 2011 (AJRCCM 2011; 183:788). For patients diagnosed prior to 2011, the criteria of the consensus statement 2000 apply (AJRCCM 2000;161:646).~Patient registry (observation and biomaterial sampling)."
62167412|NCT02951416||Non-specific interstitial pneumonia|"Non-specific interstitial pneumonia (NSIP) based on the histopathological demonstration of an NSIP pattern.~Patient registry (observation and biomaterial sampling)."
62167413|NCT02951416||Cryptogenic organising pneumonia (COP)|"COP characterised histologically by an organising pneumonia with intraluminal organising fibrosis in the alveolar ducts and alveolar spaces.~Patient registry (observation and biomaterial sampling)."
62167414|NCT02951416||Acute interstitial pneumonia (AIP)|"Histological pattern of diffuse alveolar damage (DAD), characterised by hyaline membranes, alveolar oedema and a marked interstitial and alveolar inflammatory reaction.~Patient registry (observation and biomaterial sampling)."
62167415|NCT02951416||Lymphoid interstitial pneumonia (LIP)|"Histological pattern of LIP primary or secondary (e.g. rheumatoid arthritis, Sjögren's syndrome, pernicious anaemia, chronic active hepatitis, systemic lupus erythematosus (SLE), primary biliary cirrhosis, myasthenia gravis, severe immune deficiency syndromes (AIDS)).~Patient registry (observation and biomaterial sampling)."
62167416|NCT02951416||respiratory bronchiolitis-ILD (RB-ILD)|Histological pattern of RB-ILD or typical clinical and radiological findings. Patient registry (observation and biomaterial sampling).
62167417|NCT02951416||Desquamative Interstitial Pneumonia|"Histological pattern of Desquamative Interstitial Pneumonia (DIP). The picture is similar to RB-ILD, but the distribution pattern is much more homogeneous and does not even have the bronchiolocentric distribution.~Patient registry (observation and biomaterial sampling)."
62167418|NCT02951416||Hypersensitivity Pneumonitis|"Hypersensitivity Pneumonitis (HP) characterized by exposure to inhaled organic antigens and development of antibodies. Typical clinical and radiological findings, lymphocytosis in bronchoalveolar lavage (BAL) or histology showing HP granulomas.~Patient registry (observation and biomaterial sampling)."
62167419|NCT02951416||Sarcoidosis|"Histological pattern with sarcoid granulomas or typical clinical and radiological findings with a lymphocytosis in BAL.~Patient registry (observation and biomaterial sampling)."
62167420|NCT02951416||Lung Cancer|"Histological confirmation of Lung Cancer. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
62167421|NCT02951416||Chronic Obstructive Pulmonary Disease|"Obstructive spirometry and physical history suggesting Chronic Obstructive Pulmonary Disease (COPD). Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
62167422|NCT02951416||Pulmonary Hypertension|"Pulmonary Hypertension (PH) diagnosed through right heart catheterisation. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
62167423|NCT02951416||Sleep Apnea|"Sleep Apnea diagnosed by polysomnography. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
62167424|NCT02951416||Asthma|"Asthma diagnosed by positive bronchoprovocation test and typical history or bronchoreversibility in the lung function measurement or through peak flow measurement. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
62167425|NCT02951416||Control/Health Individuals|Healthy volunteers not suffering from any lung disease as control group. Patient registry (observation and biomaterial sampling).
62167426|NCT00518310|PLACEBO_COMPARATOR|0|Placebo
62167427|NCT00518310|ACTIVE_COMPARATOR|1|Azathiprine Prednisone
62167428|NCT01573897||Foot-wound without SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
62167429|NCT01573897||Foot-wound with SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome
62167430|NCT01753323|EXPERIMENTAL|Part 1 - Cohort 1: P. vivax: KAF156 400mg QD|Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
62167431|NCT01753323|EXPERIMENTAL|Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD|Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
62167432|NCT01753323|EXPERIMENTAL|Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose|Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
62167433|NCT06647160|EXPERIMENTAL|Intervention|Blue star MAX-5 spectacle lens
62167434|NCT06647160|ACTIVE_COMPARATOR|Control|Single-vision spectacle lens
62167435|NCT01700634||OA patients with HIGH central sensitization|Central sensitization will be defined by the presence of both spreading sensitization and temporal summation to repeated pressure pain stimulation (Arendt-Nielsen et al. 2010, Graven-Nielsen et al. 2010, Woolf 2010, Imamura et al. 2008, Nijs et al. 2010).
62167436|NCT01700634||OA patients with LOW central sensitization|
62167437|NCT01700634||Control subjects|
62167438|NCT04553029||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
62167439|NCT04553029||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
62167440|NCT04553029||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
62167441|NCT04553029||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
62167442|NCT05858047|PLACEBO_COMPARATOR|Group I (Placebo)|Placebo will be administered orally (PO) for 12 weeks.
62167443|NCT05858047|EXPERIMENTAL|Group Ⅱ (SYHX1901 60 mg)|SYHX1901 will be administered orally (PO) for 12 weeks.
62167444|NCT05858047|EXPERIMENTAL|Group III (SYHX1901 90 mg)|SYHX1901 will be administered orally (PO) for 12 weeks.
62167445|NCT05858047|EXPERIMENTAL|Group Ⅳ (SYHX1901 180 mg)|SYHX1901 will be administered orally (PO) for 12 weeks.
62167446|NCT04958629||non-FH Group|
62167447|NCT04958629||FH Group|
62167448|NCT04034914|EXPERIMENTAL|Yoga Therapy|
62167449|NCT06585501||GC/GEJC|Patients diagnosed with locally advanced unresectable or metastatic HER2-positive GC/GEJC
62167450|NCT05313178|PLACEBO_COMPARATOR|Milk Protein|25-gram dose of milk protein concentrate
62167451|NCT05313178|EXPERIMENTAL|Milk Protein and Probiotic|25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
62167452|NCT05936905|EXPERIMENTAL|Acupuncture therapy|This study aims to compare acupuncture therapy administered one time per month
62167453|NCT05936905|EXPERIMENTAL|Chiropractor therapy|This study aims to compare chiropractic therapy administered one time per month
62167454|NCT06036797|EXPERIMENTAL|Group 1|Group 1 will be administered with 15 ug/ml hydromorphone and 0.08% ropivacaine
62167455|NCT06036797|EXPERIMENTAL|Group 2|Group 2 will be administered with 17.5 ug/ml hydromorphone and 0.08% ropivacaine
62167456|NCT06036797|EXPERIMENTAL|Group 3|Group 3 will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine
62167457|NCT06036797|ACTIVE_COMPARATOR|Group 4|Group 4 will be administered with 0.4 ug/ml sufentanil and 0.08% ropivacaine
62167458|NCT00672100|ACTIVE_COMPARATOR|A|Initial Bolus 5 ml Ropivacaine
62167459|NCT00672100|ACTIVE_COMPARATOR|B|Initial Bolus 10 ml Ropivacaine
62167460|NCT00672100|ACTIVE_COMPARATOR|C|Initial Bolus 20 ml Ropivacaine
62167461|NCT01544309|EXPERIMENTAL|Atorvastatin administration group|
62167462|NCT01544309|EXPERIMENTAL|Rosuvastatin administration group|
62167463|NCT03378895|EXPERIMENTAL|adults aged 35 to 55 years|
62736284|NCT00033423|EXPERIMENTAL|Cohort V|MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
62167464|NCT03575572|EXPERIMENTAL|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
62167465|NCT00781677||MDD|
62167466|NCT04419961|NO_INTERVENTION|Control|Routine care.
62167467|NCT04419961|EXPERIMENTAL|Intervention|Routine care plus participation in an educational program including a group discussion and a booklet.
62167468|NCT02399982|ACTIVE_COMPARATOR|CBT-GSH|Traditional CBT-GSH with paper and pencil self-monitoring
62167469|NCT02399982|EXPERIMENTAL|CBT-GSH + Noom Monitor|CBT-GSH with smartphone application for self-monitoring
62167470|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
62167471|NCT00692523|ACTIVE_COMPARATOR|1|The control group will receive 8 recreational therapy sessions over a 2-week (14 day) period, to be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
62167472|NCT00692523|EXPERIMENTAL|2|Patients randomized to Wii technology will receive an intensive program consisting of 8 Wii gaming sessions, 60 minutes each, over a 2-week (14 day) period. These 8 sessions can be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
62167473|NCT00412802|EXPERIMENTAL|1|dose adaptation of Enoxaparine at the renal deficient patients
62167474|NCT00412802|ACTIVE_COMPARATOR|2|No dose adaptation of Enoxaparine at renal normal patients
62167475|NCT01769352|ACTIVE_COMPARATOR|PredA q1h WA + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
62167476|NCT01769352|ACTIVE_COMPARATOR|PredA qid + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
62167477|NCT04266366|ACTIVE_COMPARATOR|Face-to Face rehabilitation program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience. This program will be developed in the rehabilitation service of the study health centers. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
62167478|NCT04266366|EXPERIMENTAL|Telemedicine Program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 8 weeks, with a total of 24 sessions
62167479|NCT06318364||Patients staying in the PACU|Patients staying in the PACU
62167480|NCT01631799|ACTIVE_COMPARATOR|Femoral Block|One group received a femoral block for analgesia after surgery. Ropivacain was administered continuously for three days.
62167481|NCT01631799|ACTIVE_COMPARATOR|Epidural Analgesia|One group received an epidural analgesia after surgery for three days.
62167482|NCT00255515|EXPERIMENTAL|1|quetiapine fumarate
62737173|NCT04098653|ACTIVE_COMPARATOR|BUCY|For myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
62167483|NCT00255515|ACTIVE_COMPARATOR|2|Conventional treatment for schizophrenia
62167484|NCT00255515|EXPERIMENTAL|3|quetiapine fumarate + Cognitive Remediation Therapy
62167485|NCT03802513|OTHER|Individualized Physiotherapy|This study has 1 health-related intervention. Veterans with somatosensory tinnitus will receive individualized physiotherapy.
62167486|NCT03722485|EXPERIMENTAL|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|V.A.C. VeraFlo Cleanse Choice Dressing, V.A.C.Ulta Therapy Unit and saline solution
62167487|NCT03722485|ACTIVE_COMPARATOR|Collagenase Ointment|Collagenase Ointment
62167488|NCT05312190|EXPERIMENTAL|Zhenqi Buxue Oral Liquid|Zhenqi Buxue Oral Liquid, 10 ml each time, 2 times a day for 3 menstrual cycles, orally
62167489|NCT05312190|EXPERIMENTAL|Zhenqi Buxue Oral Liquid and Progesterone Capsules|Zhenqi Buxue Oral Liquid was taken orally, 10 ml at a time, twice a day for 3 menstrual cycles + orally from the second half of menstrual cycle, Progesterone Capsules 200mg, once a day for 10 days for 3 menstrual cycles
62167490|NCT05312190|ACTIVE_COMPARATOR|Progesterone Capsules|Progesterone Capsules 200mg, qd\*10 days\*3 menstrual cycles, orally
62167491|NCT06194786|EXPERIMENTAL|Group A|Dietary and physical activity
62167492|NCT06194786|EXPERIMENTAL|Group B|Dietary only
62167493|NCT06194786|EXPERIMENTAL|Group C|Physical activity only
62167494|NCT00909922||Lower Limb Amputees|Unilateral Above knee amputees
62167495|NCT06154733|EXPERIMENTAL|Photobiomodulation with low level laser therapy|This group will be subjected to photo biomodulation by low level laser therapy. Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions. During the laser treatments, both the volunteer and operator will use protective eyewear and all rules of safety will be obeyed.
62167496|NCT06154733|ACTIVE_COMPARATOR|light cured resin-based sealant|This group will receive light cured resin-based sealant (Fissured Novo Plus). Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
62167497|NCT06154733|ACTIVE_COMPARATOR|glass ionomer sealant|This group will receive glass ionomer sealant. Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
62167498|NCT04312971|PLACEBO_COMPARATOR|Placebo|Infusion of normal Saline 0.9%will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
62167499|NCT04312971|ACTIVE_COMPARATOR|Norepinephrine|Infusion of norepinephrine (40 µg/ml) will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
62167500|NCT05973357|EXPERIMENTAL|Sub-crestal group|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
62167501|NCT05973357|EXPERIMENTAL|Equi-crestal grouo|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
62167502|NCT02131155|EXPERIMENTAL|Afatinib (BIBW2992)|Once daily
62167503|NCT02131155|PLACEBO_COMPARATOR|Placebo|Once daily
62167504|NCT02375243|EXPERIMENTAL|cases|children who receive midazolam 0.05 mg/kg/h + morphine 10 mcg/kg/h + dexmedetomidne 0.5 mcg/kg/h. Midazolam in administered until extubation, while morphine and dexmedetomidine are administered until removal of surgical drains.
62167505|NCT02375243|NO_INTERVENTION|controls|standard care: children who receive midazolam 0.1 mg/kg/h + morphine 20 mcg/kg/h. Midazolam in administered until extubation, while morphine is administered until removal of surgical drains.
62167506|NCT02367664|EXPERIMENTAL|0.5ml experimental vaccine on day 0,7|0.5ml experimental vaccine on day 0,7 and a booster dose 12 months later
62167507|NCT02367664|EXPERIMENTAL|0.5ml experimental vaccine on day 0,28|0.5ml experimental vaccine on day 0,28 and a booster dose 12 months later
62167508|NCT02367664|ACTIVE_COMPARATOR|0.5ml active comparator vaccine on day 0,7|0.5ml active comparator vaccine on day 0,7 and a booster dose 12 months later
62167509|NCT03895892|PLACEBO_COMPARATOR|Water Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
62167510|NCT03895892|EXPERIMENTAL|Experimental 1|Ketone salts supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
62167511|NCT03895892|EXPERIMENTAL|Experimental 2|Ketone salts/caffeine supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
62167512|NCT05422040|EXPERIMENTAL|Dry needling|"Dry needling is performed with a 4cm needle (APS Dry Needles®) on the most symptomatic side of the patient on palpation. To perform the technique, the patient is positioned in prone position on the couch. The physiotherapist palpates the lateral border of the lumbar iliocostalis muscle and performs the tapping technique in a latero-medial direction parallel to the stretcher.~The technique is performed by applying 12 incisions. After the application of the technique, ischaemic compression shall be performed for 1 minute.~Patients will complete a home exercise program"
62167513|NCT05422040|EXPERIMENTAL|Diathermy treatment|"Diathermy treatment will be applied using the TCaRe Power diathermy instrument (PRIM Physio©), using a capacitive system with an intensity of 50%, with slight variation depending on patient tolerance and 500khz. The therapy will be applied for 10 minutes on each side of the patient's lumbar region, who will be positioned in prone decubitus during the intervention.~Patients will complete a home exercise program"
62167514|NCT05116865|EXPERIMENTAL|Single Ascending Dose Cohort A1|Subjects will receive a single dose of either dose level 1 of HH-120 or placebo
62167515|NCT05116865|EXPERIMENTAL|Single Ascending Dose Cohort A2|Subjects will receive a single dose of either dose level 2 of HH-120 or placebo
62167516|NCT05116865|EXPERIMENTAL|Single Ascending Dose Cohort A3|Subjects will receive a single dose of either dose level 3 of HH-120 or placebo
62167517|NCT05116865|EXPERIMENTAL|Multiple Ascending Doses Cohort B1|Subjects will receive multiple doses of either Dose level 1of HH-120 or placebo
62167518|NCT05116865|EXPERIMENTAL|Multiple Ascending Doses Cohort B2|Subjects will receive multiple doses of either Dose level 2 of HH-120 or placebo
62167519|NCT05116865|EXPERIMENTAL|Multiple Ascending Doses Cohort B3|Subjects will receive multiple doses of either Dose level 3 of HH-120 or placebo
62167520|NCT02939859|EXPERIMENTAL|Microcannula Harvest Adipose|Acquisition AD-tSVF via closed syringe microcannula
62167521|NCT02939859|EXPERIMENTAL|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
62167522|NCT02939859|EXPERIMENTAL|Sterile Normal Saline|Re-suspension of Autologous AD-cSVF pellet in Normal Saline deployment via IV
62167523|NCT00341588||Cases|Male U.S. serviceman, age 18-45 years old with TGCT
62167524|NCT00341588||Controls|Male U.S. serviceman, age 18-45 years old without TGCT
62167525|NCT04581356|EXPERIMENTAL|voxelotor|Voxelotor 1500mg daily orally
62167526|NCT03409276|EXPERIMENTAL|Group 1 (Treatment): Protein Vaccine/GLA-SE|Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.
62167527|NCT03409276|PLACEBO_COMPARATOR|Group 1 (Control)|Participants will receive placebo at Day 0 and Month 2.
62167528|NCT03409276|EXPERIMENTAL|Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
62167529|NCT03409276|PLACEBO_COMPARATOR|Group 2 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
62167530|NCT03409276|EXPERIMENTAL|Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE|Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.
62167531|NCT03409276|PLACEBO_COMPARATOR|Group 3 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
62167532|NCT04757961|EXPERIMENTAL|Lifestories|Participants in this condition will be actively participating in the online intervention for 4 weeks.
62167533|NCT04757961|NO_INTERVENTION|Waitlist Control Condition|Participant in the waitlist group will be asked to not use other self-help websites or books for four weeks, after which they will be given weekly access to LifeStories modules. All participants will be asked to continue their antidepressant treatment as usual as directed by their primary care provider.
62167534|NCT02646644||Metastasized intestinal NET|We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
62167535|NCT00600223||1|Patients undergoing laryngectomy and pharyngeal reconstruction
62167536|NCT05527509|ACTIVE_COMPARATOR|Standard Training Condition (STC)|"The STC has received the standard RCMP Depot Division (Depot) Cadet Training Program as has been provided to cadets prior to June 2022. The STC and the ATC will complete the same standardized self-report assessments, clinical interview assessments, and biometric assessments, and receive the same feedback and reporting based on those assessments."
62167537|NCT05527509|EXPERIMENTAL|Augmented Training Condition (ATC)|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based cognitive-behavioral intervention designed to cultivate constructive approach-oriented emotional engagement. The 13-week Emotional Resilience Training (ERST) is an adaptation of the UP designed for use as a proactive training course. The ERST frames emotional experiences as natural responses to threat, rather than pathological occurrences to avoid; as such, the ERST is well-suited for mitigating health challenges and the skills may also help PSP to support persons in distress, including other PSP and the community members they all serve. The ERST training materials include an instructor guide, didactic PowerPoints, and a trainee workbook. The ERST was designed for seamless integration with the Cadet Training Program, effective June 2022, which is what creates the augmented training arm (i.e., the ATC).
62167538|NCT06365177|OTHER|Physical consultation followed by Teleconsultation|"First, patients take the Five Time Sit To Stand in the presence of the physiotherapist. Then, patients perform the test in a room away from the physiotherapist (there are a computer with a webcam is set up on a desk).~There will be a 5-minute rest period between the 2 test conditions (physical consultation and teleconsultation).~Each test is performed 2 times. The best time will be retained for analysis."
62167539|NCT06365177|OTHER|Teleconsultation followed by physical consultation|"First, patients perform the Five Time Sit To Stand in a room away from the physiotherapist (there are a computer with a webcam is set up on a desk). Then, patients take the test in the presence of the physiotherapist. There will be a 5-minute rest period between the 2 test conditions (teleconsultation and physical consultation).~Each test is performed 2 times. The best time will be retained for analysis."
62167540|NCT00647387|EXPERIMENTAL|1|Implantation with the device
62167541|NCT05128227|ACTIVE_COMPARATOR|Pharm-SAVES|This is an approximately 30-minute self-guided online module that covers basic information about suicide prevention gatekeeper skills training that is relevant to community pharmacists.
62167542|NCT05128227|EXPERIMENTAL|Interactive video case|An approximately 30-minute self-guided online suicide prevention gatekeeper skills training module, plus two approximately 5-minute interactive video cases in which participants are asked to respond to patients who exhibit suicidal warning signs.
62167543|NCT04074304|OTHER|I-HoME prototype|Participants will be shown prototype of I-HoME and provide feedback as part of the user-center design process.
62167544|NCT06646835|NO_INTERVENTION|Control Group|Pregnant women in the control group will not receive any intervention other than routine general care before cesarean section.
62731510|NCT05238272|SHAM_COMPARATOR|sham tRNS with bilateral MT|"For the sham tRNS condition, the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds .~For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
62167545|NCT06646835|EXPERIMENTAL|Intervention Group|Pregnant women in the intervention group will be explained how to use the stress ball in the obstetric ward before cesarean section. During the practice, pregnant women will be asked to demonstrate the movements of squeezing and loosening the stress ball to ensure correct use. It will be emphasized to the pregnant women that they should squeeze the ball once after counting to three, inhale when they squeeze the ball, exhale when they loosen their grip and focus only on the ball. In the obstetrics ward, this practice will cover the period starting from the time when the patient is waiting in her room to be taken to the operating room for cesarean section, until she is taken from the preop room to the operating room. In this process, the researcher will monitor whether the stress ball is applied correctly or not. In addition, in order to minimize the risk of infection in the hospital environment, the stress balls used will be disinfected with disposable aseptic wipes before being given
62167546|NCT04257786|ACTIVE_COMPARATOR|Group 1|1ry surgery
62167547|NCT04257786|ACTIVE_COMPARATOR|Group 2|Neoadjuvant Chemotherapy followed by surgery
62167548|NCT00212979||non intervention study|
62167549|NCT05358184|EXPERIMENTAL|High frequency percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to oxygen therapy at high flow through nasal cannula
62167550|NCT01026116|ACTIVE_COMPARATOR|EC-wP|epirubicin/cyclophosphamide followed weekly paclitaxel
62167551|NCT01026116|EXPERIMENTAL|EP-wP|epirubicin/paclitaxel followed by weekly paclitaxel
62167552|NCT04542083||COVID-19 period|Admissions from January to December 2020
62167553|NCT04542083||Control period|Admissions from January 2018 to December 2019
62167554|NCT03807271|EXPERIMENTAL|Smart Pilot(R) View|Anesthesia provided by standard procedure, additionally guided by Smart Pilot(R) View, a device with calculated and graphically produced depth of anesthesia.
62167555|NCT03807271|NO_INTERVENTION|Standard|Anesthesia provided by standard procedure.
62167556|NCT03902145||Intervention Group|Children previously in the intervention group received one egg per day for 6 months beginning when the child was between 6-9 months of age.
62167557|NCT03902145||Control Group|
62167558|NCT00901966||Agricultural workers and spouses|Melanoma risk factors among Ag workers and spouses who use pesticides.
62167559|NCT04747717|EXPERIMENTAL|Mitomycin C and cisplatin regimen|mitomycin C at 10 mg/m2 and cisplatin at 100 mg/m2
62167560|NCT04747717|ACTIVE_COMPARATOR|Paclitaxel and carboplatin regimen|paclitaxel at 175 mg/m2 and carboplatin AUC5-6
62167561|NCT02108483|EXPERIMENTAL|All participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches on Day 1.
62167562|NCT04870814|ACTIVE_COMPARATOR|SOFTT® Gen 4 tactical tourniquet|The SOFTT® Gen 4 (Tactical Medical Solutions, Anderson) tactical tourniquet will be assessed.
62167563|NCT04870814|ACTIVE_COMPARATOR|CAT® Gen 7 tactical tourniquet|The CAT® Gen 7 (C-A-T® Resources, Rock Hill) tactical tourniquet will be assessed.
62167564|NCT04870814|ACTIVE_COMPARATOR|SAM XT® tactical tourniquet|The SAM XT® (SAM Medical Products®, Wilsonville) tactical tourniquet will be assessed.
62167565|NCT04870814|ACTIVE_COMPARATOR|RMT® 1.5 tactical tourniquet|The RMT® 1.5 (m2®, Winooski) tactical tourniquet will be assessed.
62167566|NCT04568304|EXPERIMENTAL|Toripalimab Injection + chemotherapy group|
62167567|NCT04568304|PLACEBO_COMPARATOR|Placebo + chemotherapy group|
62167568|NCT02683213|ACTIVE_COMPARATOR|Fluoxetine|One capsule Fluoxetine 20mg once daily for 6 months.
62167569|NCT02683213|PLACEBO_COMPARATOR|Placebo|One matching capsule placebo once daily for 6 months.
62167570|NCT00645320|EXPERIMENTAL|A|
62167571|NCT04929483|EXPERIMENTAL|BIO89-100 - 15 mg once weekly (QW)|BIO89-100 - 15 mg QW
62167572|NCT04929483|EXPERIMENTAL|BIO89-100 - 30 mg QW|BIO89-100 - 30 mg QW
62167573|NCT04929483|EXPERIMENTAL|BIO89-100 - 44 mg once every 2 weeks (Q2W)|BIO89-100 - 44 mg Q2W
62167574|NCT04929483|PLACEBO_COMPARATOR|Placebo QW|Placebo QW
62167575|NCT04929483|PLACEBO_COMPARATOR|Placebo Q2W|Placebo Q2W
62167576|NCT04929483|EXPERIMENTAL|Placebo QW (Main study)/ BIO89-100 - 30 mg QW (Extension)|Placebo QW (Main study)/ BIO89-100 - 30 mg QW (Extension)
62167577|NCT00881972|EXPERIMENTAL|exercise|
62167578|NCT03813602|EXPERIMENTAL|Cannabis sativa|a 750 mg cannabis cigarette with 12.5% THC
62167579|NCT00572299||glucocorticoids|patients receiving glucocorticoid treatment
62167580|NCT00572299||glucocorticoids and bisphosphonates|patients receiving both glucocorticoids and bisphosphonates
62167581|NCT06645587|ACTIVE_COMPARATOR|Arm Pre-SMA|"Active cathodal HD-tDCS over pre-SMA cortex. For HD-tDCS a 4 × 1 montage, small circular electrodes (diameter 1 cm) will be used with the cathode placed centrally over Fz with a current intensity of 0.5 mA for a total of 20 minutes (30 s ramp up/down).~For the electrodes' placement, the investigators will follow the recommended guidelines for children."
62167582|NCT06645587|ACTIVE_COMPARATOR|Arm left-dlPFC|"Active cathodal HD-tDCS over left dlPFC cortex. For HD-tDCS a 4 × 1 montage, small circular electrodes (diameter 1 cm) will be used with the cathode placed centrally over F3 with a current intensity of 0.5 mA for a total of 20 minutes (30 s ramp up/down).~For the electrodes' placement, the investigators will follow the recommended guidelines for children."
62167583|NCT06645587|SHAM_COMPARATOR|Arm Sham|Sham HD-tDCS will be delivered over pre-SMA or left-dlPFC cortex. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness.
62167584|NCT04342442||Steroid-refractory a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-refractory a GvHD
62167585|NCT04342442||Steroid-responsive a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-responsive a GvHD
62167586|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
62167587|NCT04915157|OTHER|Group A: High Density stimulation - No Stimulation|Patients in this group will receive high density stimulation (parasthesia free form of stimulation) during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive no stimulation during the final 6 months of the study period.
62731511|NCT05055609|EXPERIMENTAL|Open Label|In the dose escalation portion, will enroll up to 42 subjects in six or more cohorts. The dose expansion portion will enroll up to 36 subjects. The actual number of subjects enrolled will depend on the safety data and additional evidence of antitumor activity but will not exceed an aggregate total of 85, including both the dose escalation and expansion phases.
62731512|NCT01005641|EXPERIMENTAL|A|phase II
62731513|NCT04251832|EXPERIMENTAL|Ultrasound guided percutaneous lavage with STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using sodium thiosulfate 25 %: a volume of 1 mL of sodium thiosulfate will be prepared in a syringe and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. At the end of the procedure 1 mL (250 mg) of thiosulfate will be injected inside the calcific deposit. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.~Only a single procedure will be performed and the outcomes measured after 1 week, 1 month and 3 months."
62731514|NCT04251832|ACTIVE_COMPARATOR|Ultrasound guided percutaneous lavage without STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using of saline solution and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.~Only a single procedure will be performed and the outcomes measured after 1week, 1month and 3months"
62731515|NCT03279159|EXPERIMENTAL|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
62731516|NCT06491225|EXPERIMENTAL|GTE001 injection treatment group|
62731517|NCT01772550|EXPERIMENTAL|20 Gauge BD Nexiva Diffusics|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch).
62731518|NCT01772550|ACTIVE_COMPARATOR|18 Gauge Conventional Catheter|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the non-fenestrated 18GA Conventional Catheter (18 GA x 1.25 inch Smiths Medical Jelco® IV Catheter).
62731519|NCT01772550|EXPERIMENTAL|BD Nexiva Diffusics - Nonrandomized|Subjects whose veins were not suitable for an 18 GA IV Catheter were assigned to this non-randomized arm. During their routinely scheduled CECT procedure, subjects receive IV contrast medium injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch)
62731520|NCT06511544|EXPERIMENTAL|Active TMS|All participants will receive active TMS to the VMPFC for 20 sessions
62731521|NCT00827645||Uterine artery embolization|Women with symptomatic uterine fibroids scheduled for uterine artery embolization
62731522|NCT01350258|EXPERIMENTAL|Transplant Treatment Group|All patients treated on this research study.
62731523|NCT03232827|ACTIVE_COMPARATOR|Flavored-sweetened|Flavored-sweetened (FS) WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
62731524|NCT03232827|ACTIVE_COMPARATOR|Unflavored-sweetened|Unflavored-sweetened (US) WP will be associated with the second longest and slightly less frequent puffing than FS resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
62731525|NCT03232827|ACTIVE_COMPARATOR|Unflavored very low sweetened|Unflavored-very low sweetened (UU) WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
62731526|NCT03232827|ACTIVE_COMPARATOR|Flavored-very low sweetened waterpipe|Flavored-very low sweetened WP will be associated with the third longest and slightly less frequent puffing than US resulting in the third greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
62731527|NCT06402929|EXPERIMENTAL|Honest Open Proud - College (HOP-C)|
62731528|NCT06402929|NO_INTERVENTION|Waitlist Control|Participants randomized to the waitlist control condition complete the study measures at the same timepoints as the experimental group while remaining on a waiting list for the program. Following this, participants randomized to the waitlist are invited to participate in HOP-C without completing study measures.
62731529|NCT05733637||Vascular Access|Patients undergo vascular access procedure.
62731530|NCT01836536|OTHER|BEVACIZUMAB|BEVACIZUMAB standard of care
62731531|NCT04385316||Gastric Cancer|
62731532|NCT04385316||Colorectal Cancer|
62731533|NCT04385316||Bladder Cancer|
62731534|NCT03146663|EXPERIMENTAL|Arm A|NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
62731535|NCT03146663|EXPERIMENTAL|Arm B|NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
62731536|NCT03835481|EXPERIMENTAL|25 mg BI 730357|25 mg BI 730357 + placebo under fasted conditions.
62731537|NCT03835481|EXPERIMENTAL|50 mg BI 730357|50 mg BI 730357 + placebo under fasted conditions.
62731538|NCT03835481|EXPERIMENTAL|100 mg BI 730357|100 mg BI 730357 + placebo under fasted conditions.
62731539|NCT03835481|EXPERIMENTAL|200 mg BI 730357|200 mg BI 730357 + placebo under fasted conditions
62731540|NCT03835481|EXPERIMENTAL|400 mg BI 730357|400 mg BI 730357 + placebo under fasted conditions.
62737174|NCT02371785|EXPERIMENTAL|CorPath 200 System|CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
62731541|NCT03619577|EXPERIMENTAL|Sequential training-high frequency|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
62731542|NCT03619577|EXPERIMENTAL|Sequential training-low frequency|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
62731543|NCT04711239||Two types of samples (TE and SCM) will be collected for all blastocysts included in the study|
62731544|NCT01833858|PLACEBO_COMPARATOR|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
62731545|NCT01833858|ACTIVE_COMPARATOR|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
62731546|NCT01971671||Chinese lactating mother|no intervention.
62731547|NCT02572297||video-EEG|Patients suffering from drug-resistant partial epilepsy for whom a video-EEG monitoring of their seizures was scheduled as part of pre-surgical assessment
62731548|NCT04766320|EXPERIMENTAL|Tumor Infiltrating Lymphocytes (TIL)|1x10\^9-3x10\^11 in vitro expanded autologous TILs will be infused i.v. to patients with relapsed/refractory malignant gynecological tumors after NMA lymphodepletion treatment with fludarabine and cyclophosphamide. PD-1 checkpoint inhibitor would be applied as combination treatment to those patients.
62731549|NCT03794427|EXPERIMENTAL|unilateral lumbosacral nerve block|Sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
62731550|NCT03794427|ACTIVE_COMPARATOR|Spinal anesthesia|spinal anesthesia will be performed
62731551|NCT05761288|EXPERIMENTAL|Surgery days with intraoperative microbreaks and exercises|Surgery days randomized to intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. The exercises will be performed just before surgical time-out, at a surgically safe and convenient time 45-75 mins after the start of the case and at the end of the case. A surgically safe and convenient time means the surgeon feels that it is safe to take an approximately 1.5-2 minute break during the procedure at that time. Surgeons will skip the microbreak if there is no surgically convenient or safe time during the case. Surgeons will stop the microbreak at any point if needed to ensure patient safety.
62731552|NCT05761288|NO_INTERVENTION|Surgery days without intraoperative microbreaks and exercises|Surgery days without intraoperative microbreaks and exercises will include no intervention. Surgeons will perform the surgeries as they are normally performed and surgeons will not take microbreaks or perform exercises.
62731553|NCT02946177|EXPERIMENTAL|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
62731554|NCT02946177|PLACEBO_COMPARATOR|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
62731555|NCT02076529|EXPERIMENTAL|Ramosetron 0.6mg|Ramosetron 0.6mg intravenous injection 30min before chemotherapy
62731556|NCT02076529|EXPERIMENTAL|Ramosetron 0.45mg|Ramosetron 0.45mg intravenous injection 30min before chemotherapy
62731557|NCT02076529|ACTIVE_COMPARATOR|Ramosetron 0.3mg|Ramosetron 0.3mg intravenous injection 30 min before chemotherapy
62731558|NCT06090630|EXPERIMENTAL|Diagnostic (DWI, magnetic resonance spectroscopic imaging)|Participants undergo DWI over 15 minutes and MR spectroscopic imaging over 45 minutes.
62731559|NCT04377958|OTHER|Asthmatics|Asthmatic group from which serum samples will be collected for analysis
62731560|NCT05712577||MFS_PT+|MFS patients who followed psychological support/psychotherapy
62731561|NCT05712577||MFS_PT-|MFS patients who never followed psychological support/psychotherapy
62731562|NCT06493643||Perfusion index at the blocked & unblocked limb|"The Perfusion Index was recorded at baseline and at 10, 20, and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters.~In every patient , a comparison between the blocked and unblocked limb was performed ."
62731563|NCT04649216|EXPERIMENTAL|Mass Balance|Subjects will receive a single oral dose of \[14C\]PCO371 Oral Solution.
62731564|NCT04649216|EXPERIMENTAL|Absolute Bioavailability and Mass Balance|Subjects will receive a single oral dose of PCO371 capsules, followed by a single IV infusion of \[14C\]PCO371 over 10 min, starting 2 h post-oral dose.
62731565|NCT00792740|PLACEBO_COMPARATOR|Placebo|Oral matching placebo capsules, administered bid.
62731566|NCT00792740|EXPERIMENTAL|ITF2357|Oral ITF2357 50 mg bid
62731567|NCT01486355|EXPERIMENTAL|Early measles vaccine|Receives an early measles vaccine in addition to the standard measles vaccine at 9 months of age
62731568|NCT01486355|NO_INTERVENTION|No early measles vaccine|Receives only the standard measles vaccine at 9 months of age
62731569|NCT03276832|EXPERIMENTAL|Treatment (pembrolizumab, imiquimod)|Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Cycles repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline, 6 weeks, and 12 weeks and CT, PET/CT, or MRI throughout the trial.
62731570|NCT05253755|ACTIVE_COMPARATOR|DBI-001 Gel|"DBI-001 Gel: Topical application of DBI-001 gel on skin affected with atopic dermatitis.~(This study is a within-subject bilateral controlled study)"
62731571|NCT05253755|PLACEBO_COMPARATOR|Aqueous Gel|"Aqueous Gel: Topical application of aqueous gel on skin affected with atopic dermatitis.~(This study is a within-subject bilateral controlled study)"
62731572|NCT06014151||The candidate to gamete donation|All candidate to gamete donation at the CECOS centers in France
62731573|NCT04808713|EXPERIMENTAL|Treatment condition|
62731574|NCT04808713|NO_INTERVENTION|Waitlist condition|
62731575|NCT06291311||NIPP treatment|Treatment with cold physical Plasma
62731576|NCT06291311||Control group|No treatment with cold physical Plasma
62731577|NCT04994639|EXPERIMENTAL|HPI group|Managing intraoperative hemodynamic condition under the HPI guidance
62731578|NCT04994639|NO_INTERVENTION|Standard care group|Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
62731579|NCT04340388|ACTIVE_COMPARATOR|Switch from a non-integrase based regimen to dolutegravir|Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.
62731580|NCT04340388|ACTIVE_COMPARATOR|Continue on non-integrase inhibitor based regimen|Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.
62731581|NCT05257590|EXPERIMENTAL|Nivolumab + CVM-1118|"1 Cycle = 28 days~Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.~CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID.~Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3~Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
62731582|NCT02443337|EXPERIMENTAL|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
62731583|NCT01309204|EXPERIMENTAL|Brinz/Brim|Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
62731584|NCT01309204|ACTIVE_COMPARATOR|Brinz+Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
62731585|NCT04791657||Patients without complications|Patients with uneventful recovery
62731586|NCT04791657||Patients with complications|Patients experiencing complications within 30 days postoperatively
62731587|NCT06348641|EXPERIMENTAL|experimental group|"Babies in intervention classes will receive baby massage before the examination. Pre-examination baby massage will be applied by a single nurse = researcher. Video recording will be taken before and during the ROP examination, and evaluations will be made by two neonatal nurses other than the researcher.~Babies will be massaged by the researcher in accordance with IAIM rules and massage techniques. The total massage time will be equal for each baby."
62731588|NCT06348641|NO_INTERVENTION|control group|"For the control group, the routine retinopathy examination of the unit will be performed without any intervention.~Video recording will be taken before and during the ROP examination, and evaluations will be made by two neonatal nurses other than the researcher."
62731589|NCT03154255|EXPERIMENTAL|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
62731590|NCT03154255|NO_INTERVENTION|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
62731591|NCT06517368||benign solid renal masses|
62731592|NCT06517368||malignant solid renal masses|
62731593|NCT02997865|EXPERIMENTAL|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.
62731594|NCT02997865|NO_INTERVENTION|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
62731595|NCT04096950|EXPERIMENTAL|MT-3921|Intravenous, single dose
62731596|NCT02678403|EXPERIMENTAL|1 - TENS group|The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
62731597|NCT02678403|SHAM_COMPARATOR|2 - SHAM group|SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
62731598|NCT01597648|EXPERIMENTAL|Sequence 1|Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast Washout Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
62737175|NCT05139745|EXPERIMENTAL|Histological evaluation of BTL-899 device´s effect on fat tissue|This group will be treated with 100% of the treatment parameter settings
62731599|NCT01597648|EXPERIMENTAL|Sequence 2|"Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.~Washout Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast"
62731600|NCT01564823|EXPERIMENTAL|Metronidazole + Azathioprine.|Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
62731601|NCT01564823|ACTIVE_COMPARATOR|Metronidazole + Adalimumab|Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.
62731602|NCT01589146|NO_INTERVENTION|short heparin|
62731603|NCT01589146|EXPERIMENTAL|extended heparin|
62731604|NCT03741907|EXPERIMENTAL|FAUCS|French Ambulatory C-section
62731605|NCT03741907|ACTIVE_COMPARATOR|MLC|Gold Standard
62731606|NCT02439307|ACTIVE_COMPARATOR|Rifaximin|Patients will receive per day 1200 mg of rifaximin
62731607|NCT02439307|PLACEBO_COMPARATOR|Placebo|Patients will receive a placebo of rifaximin
62731608|NCT02915627|ACTIVE_COMPARATOR|Healthy participants|Non chronic kidney disease (CKD) participants. Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
62731609|NCT02915627|ACTIVE_COMPARATOR|CKD patients not on dialysis|CKD 4/5 patients not on Dialysis- Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
62731610|NCT02915627|ACTIVE_COMPARATOR|CKD patients on Dialysis|Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
62731611|NCT06503822|EXPERIMENTAL|Intervention group|In the intervention group, a new long peripheral venous catheter was selected by the puncture operator according to the puncture location and venous conditions, and was placed using aseptic technology. After blood return, the catheter could be easily rinsed with 0.9% sodium chloride solution, which was considered to be placed in the correct position and could be used normally. Intravenous infusion therapy begins immediately after successful catheterization. Check the condition of the catheter at least 3 times a day, and rinse with 10 ml.9% sodium chloride solution before each intravenous treatment; After disconnection of any infusion, pulse flushing with 0.9% sodium chloride solution 10ml and positive pressure sealing tube flushing to seal the catheter. Collect patient information, including sociodemographic information, duration of intravenous therapy, and details about catheter failure.
62731612|NCT06503822|ACTIVE_COMPARATOR|Control group|The control group will receive a new 24G or 22G short peripheral venous catheter with direct view aseptic technique puncture, see blood return and rinse easily with 0.9% sodium chloride solution. The catheter is considered to be in the correct position and can be used normally. Check the condition of the catheter at least 3 times a day, and rinse with 10 ml.9% sodium chloride solution before each intravenous treatment; After disconnection of any infusion, pulse flushing with 0.9% sodium chloride solution 10ml and positive pressure sealing tube flushing to seal the catheter. Collect patient information, including sociodemographic information, duration of intravenous therapy, and details about catheter failure.
62731613|NCT06007508|NO_INTERVENTION|Standard of Care|Subjects presenting to ED with diagnosis of DKA and receiving intravenous short acting insulin will not have orders for subcutaneous insulin glargine placed for research purposes.
62731614|NCT06007508|ACTIVE_COMPARATOR|Intervention|Subjects presenting to ED with diagnosis of DKA will receive study medication set to begin within 2 hours after initiation of the IV insulin infusion. The dose will come from IV pharmacy and dispensed in a 1 mL insulin syringe. If the patient was not taking basal insulin prior to admission, the patient will receive 0.2 units/kg insulin glargine. If the patient was taking basal insulin prior to admission, the patient will receive their home insulin glargine dose.
62731615|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
62731616|NCT05597540|EXPERIMENTAL|7 day-duration antibiotic treatment|
62731617|NCT05597540|ACTIVE_COMPARATOR|14 day-duration antibiotic treatment|
62731618|NCT01343836|EXPERIMENTAL|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte implantation) injection with eccentric exercises
62731619|NCT01343836|PLACEBO_COMPARATOR|Saline injection|Intratendinous saline injection with eccentric exercises
62731620|NCT05226832|EXPERIMENTAL|Injection Group|
62731621|NCT01778075|EXPERIMENTAL|Treatment sequence AB|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
62731622|NCT01778075|EXPERIMENTAL|Treatment sequence BA|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
62731623|NCT03011112||KL 1|All patients (\>50 years) are classified to be Kellgrence/Lawrence grade 1 according to Kellgrence/Lawrence score.
62731624|NCT03011112||KL 2|All patients (\>50 years) are classified to be Kellgrence/Lawrence grade 2 according to Kellgrence/Lawrence score.
62731625|NCT03011112||KL 3|All patients (\>50 years) are classified to be Kellgrence/Lawrence grade 3 according to Kellgrence/Lawrence score.
62731626|NCT03011112||KL 4|All patients (\>50 years) are classified to be Kellgrence/Lawrence grade 4 according to Kellgrence/Lawrence score.
62731627|NCT01875081|NO_INTERVENTION|Control group|Best Supportive care
62731628|NCT01875081|EXPERIMENTAL|1-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
62731629|NCT01875081|EXPERIMENTAL|2-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
62731630|NCT01819363||Study group|Patients with Malignant pleural effusion according to inclusion and exclusion criteria.
62731631|NCT05028699|EXPERIMENTAL|Snack|32 g of a common bean baked snack per day for 28 days.
62731632|NCT05028699|NO_INTERVENTION|Control|
62731633|NCT02366676|EXPERIMENTAL|treatment group|-Intervention: combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IALURIL®) ( 1st month: once a week, 2nd\~5th month:once a month)
62731634|NCT00093262|EXPERIMENTAL|clevidipine|Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
62731635|NCT00093262|PLACEBO_COMPARATOR|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
62731636|NCT03116906|EXPERIMENTAL|BI 685509|multiple rising doses of BI 685509
62731637|NCT03116906|PLACEBO_COMPARATOR|Placebo|matching placebo
62731638|NCT03939338||Participates|
62731639|NCT03085134|EXPERIMENTAL|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
62731640|NCT03085134|ACTIVE_COMPARATOR|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
62731641|NCT01127633|EXPERIMENTAL|Solanezumab|
62731642|NCT01127633|PLACEBO_COMPARATOR|Placebo|
62731643|NCT00508105|ACTIVE_COMPARATOR|subscapularis peel|
62731644|NCT00508105|ACTIVE_COMPARATOR|osteotomy|
62731645|NCT01331746|EXPERIMENTAL|APD515|Active APD515 treatment 20 mg qds for 7 days
62731646|NCT01331746|PLACEBO_COMPARATOR|Placebo|
62731647|NCT05533944|ACTIVE_COMPARATOR|Simulation group|Trainees will undergo routine hands-on clinical ERCP training. In addition, trainees from Simulation Group have coached simulation training, by participating in three two-days intensive courses during the first three months of training, with a monthly basis.
62731648|NCT05533944|NO_INTERVENTION|Control group|Trainees will undergo routine hands-on clinical ERCP training.
62731649|NCT05361382|EXPERIMENTAL|Individuals across the aging and Alzheimer's disease (AD) spectrum|Approximately 620 individuals (40 young healthy, 280 cognitively unimpaired older, 200 mild cognitive impairment, and 100 Alzheimer's disease dementia) will be enrolled in the HEAD study.
62731650|NCT00869544||HIV|Those positive for HIV and those negative but at high risk for HIV. Both positive and negative for HIV who smoke and those who do not smoke. Both HIV positive and negative with and without asthma and/or COPD
62731651|NCT06005012|EXPERIMENTAL|Semaglutide|2.4 mg weekly for 52 weekly in a 3 ml PDS290 pen-injector containing Semaglutide 3.0 mg/ml for subcutaneous use
62731652|NCT06005012|PLACEBO_COMPARATOR|Placebo|2.4 mg weekly for 52 weekly in a 3 ml PDS290 pen-injector containing 3.0 mg/ml of a placebo solution for subcutaneous use
62731653|NCT00964483|EXPERIMENTAL|DASH materials|Participant randomized to a 12-week, group-based lifestyle intervention using modified DASH materials and intervention delivery approaches to help them adopt the DASH diet. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium.
62731654|NCT00964483|ACTIVE_COMPARATOR|Delayed intervention|"The intervention participants will receive an NHLBI brochure entitled Your Guide to Lowering Blood Pressure. They will then receive the modified DASH materials and the intervention at the end of the study, following the intervention group's completion of the study."
62731655|NCT04118751||parents of preterm babies (born before 37 weeks of pregnancy|
62731656|NCT04118751||parents of full-term babies (over 37 weeks of pregnancy)|
62731657|NCT00922246|NO_INTERVENTION|control group|Conscript used their own ankle boots instead of custom made insoles.
62731658|NCT00922246|EXPERIMENTAL|shoe insoles|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length. The insole was strong enough to fill the arch area thus providing support to the mid foot. It also influences the position of the foot. The insoles were individually customized by heating the polyethylene in form of individual foot with standing and walking in them. The conscripts were advised to use these insoles in their ankle boot.
62731659|NCT03810547|ACTIVE_COMPARATOR|Spinal anesthesia|Patients undergoing abdominoplasty under spinal anesthesia may need to drug administration like propofol or ketamine or change anesthesia to general anesthesia.
62731660|NCT03810547|NO_INTERVENTION|General anesthesia|General anesthesia for abdominoplasty
62731661|NCT01433042|EXPERIMENTAL|capsule endoscopy|
62731662|NCT01606904|EXPERIMENTAL|Weight loss counseling|Cognitive behavioral therapy - based weight loss program
62731663|NCT01606904|OTHER|Control|Short term weight loss counseling, control group
62731664|NCT03938987|EXPERIMENTAL|CAR T cells|Patients with relapsed/refractory B-cell ALL or NHL.
62731665|NCT02236572|EXPERIMENTAL|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
62731666|NCT02837523||Observation|Patients with a Cystinosis disease or high-grade suspicion for Cystinosis disease
62731667|NCT01673854|EXPERIMENTAL|Vemurafenib, 960 mg + Ipilimumab, 10 mg/kg|Participants received vemurafenib, 960 mg, twice daily for 6 weeks (Vem1 Phase). After a washout period of 3-10 days, patients received ipilimumab, 10 mg/kg, every 3 weeks for a maximum of 4 doses. At Week 24, participants received ipilimumab, 10 mg/kg, every 12 weeks until disease progression or unacceptable toxicity. Patients who did not progress or have unacceptable toxicity in the Vem1 Phase were retreated with vemurafenib (Vem 2 Phase) at the last dose level identified at the end of the Vem1 Phase until disease progression or unacceptable toxicity.
62731668|NCT01508559||HIV infected|HIV infected MSM 18-50 years old
62731669|NCT01508559||HIV uninfected|HIV uninfected MSM 18-50 years old
62731670|NCT05350215|PLACEBO_COMPARATOR|Placebo oral capsules|Placebo (2 pills) before sleep for a week
62731671|NCT05350215|ACTIVE_COMPARATOR|Atomoxetine and DAW2020 oral capsules|DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep
62731672|NCT01886235|EXPERIMENTAL|Diagnosis (intravital microscopy)|Patients receive fluorescein sodium IV followed by intravital microscopic observation over 10-15 minutes during excision of the melanoma.
62731673|NCT04744948|PLACEBO_COMPARATOR|low caloric diet|low caloric diet 1200cal/day
62731674|NCT04744948|EXPERIMENTAL|treadmill|treadmill aerobic exercise training
62731675|NCT00124969|ACTIVE_COMPARATOR|1|Amlodipine
62731676|NCT00124969|PLACEBO_COMPARATOR|2|Placebo
62731677|NCT00147992|EXPERIMENTAL|implants|
62731678|NCT01135459|EXPERIMENTAL|CEP-33457|Participants will receive CEP-33457 200 mcg SC every 4 weeks for 20 weeks (Day 1, Weeks 4, 8, 12, 16, and 20).
62731679|NCT01135459|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching to CEP-33457 SC every 4 weeks for 20 weeks (Day 1, Weeks 4, 8, 12, 16, and 20).
62731680|NCT00803738|EXPERIMENTAL|Test Product|Terconazole Vaginal Suppository
62731681|NCT00803738|ACTIVE_COMPARATOR|Reference Product|Terazol Vaginal Suppository
62731682|NCT00749788|EXPERIMENTAL|1|JTT-302, 200 mg
62731683|NCT00749788|EXPERIMENTAL|2|JTT-302, 400 mg
62731684|NCT00749788|PLACEBO_COMPARATOR|3|Matching placebo tablets
62731685|NCT02936869|NO_INTERVENTION|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
62731686|NCT02936869|EXPERIMENTAL|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
62731687|NCT04799457|NO_INTERVENTION|Classical caesarean group|Care providers are applying standard caesarean procedure for participants.
62731688|NCT04799457|EXPERIMENTAL|Study caesarean group|Care providers are applying additional sutures to standard caesarean procedure for participants.
62731689|NCT05850819|EXPERIMENTAL|Group A|Application of Gelatamp in the extraction socket
62731690|NCT05850819|ACTIVE_COMPARATOR|Group B|Extraction socket allowed to heal without application of Gelatamp
62731691|NCT00923351|EXPERIMENTAL|Arm A - Participants who did not receive rhIL-7|Six patients with Ewings sarcoma family or tumors (ESFT) participants will receive cytotoxic/lympholytic therapy with cyclophosphamide and fludarabine (if cluster of differentiation 4 (CD4) count \> 200 cells/mcl). Participant will receive Tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccine followed by Infusion of 8H9/CD25 depleted autologous lymphocyte infusion on Day 1, followed by Tumor lysate/KLH pulsed dendritic cell vaccine on week 4, 6, 8, 10, and 12.
62731692|NCT00923351|EXPERIMENTAL|Arm B - Participants who received rhIL-7|"Eight patients with rhabdomyosarcoma, fifteen patients with Ewings sarcoma family or tumors (ESFT), two patients with desmoplastic small round cell tumor, and one patient with synovial cell sarcoma participants will receive CYT107 20 mcg/kg/dose subcutaneous (SQ) (approx. 48h prior to vaccine\[Day 0\]), Tumor lysate/KLH pulsed dendritic cell vaccine followed by Infuse 8H9/CD25 depleted autologous lymphocyte infusion on Day 2, followed by CYT107 20 mcg/kg/dose SQ on days 14, 28 and 42 (± 7 days), and Tumor lysate/KLH pulsed dendritic cell vaccine on Days 16, 30, 44, 56, and 70 (± 7 days).~Apheresis/flow cytometry/delayed type of hypersensitivity (DTH) responses for immune endpoint monitoring (skin tests) will be performed on Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (+/- 7 days) (Arm B); and radiographic studies for clinical restaging will be performed on Week 8 and 20 (Arm A) and Days 42 and 126 (+/- 7 days) (Arm B)."
62731693|NCT05709704||Postpartum Women WITH DRA|Participants who have the diagnosis of diastasis rectus abdominis
62731694|NCT05709704||Postpartum Women WITHOUT DRA|Participants who do not have a diagnosis of diastasis rectus abdominis
62731695|NCT01101763||All Subjects|Healthy males
62731696|NCT01599598|ACTIVE_COMPARATOR|Progressive Muscle Relaxation|A stress intervention where subjects will learn to regulate stress based on the tensing and releasing of the major muscle groups in the body, accompanied with relaxed breathing techniques.
62731697|NCT01599598|ACTIVE_COMPARATOR|Coherence Advantage|A stress intervention where subjects will learn to regulate stress by focusing on breathing and mindfulness techniques while recognizing physiological coherence by way of a portable biofeedback device.
62731698|NCT05129163|PLACEBO_COMPARATOR|Exercise|The control group received weekly one-hour group exercise training for 3 months.
62731699|NCT05129163|EXPERIMENTAL|Exercise and nutrition|The intervention group had weekly one-hour group exercise training the same as the control and an additional weekly one-hour group nutrition session for 3 months.
62731700|NCT04037891|EXPERIMENTAL|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in an open-label manner at intervals of 1 week and will have weekly clinic visits until Day 14, after which the visit will be every two weeks. When the first 3 patients have completed two weeks of treatment and the safety and tolerability data has been reviewed by the PI and an independent clinician, provided the data is favourable the randomisation process will begin (Part 2). The first 3 patients will continue treatment for a total of 8 weeks and will be assessed throughout the trial by the Principal Investigator according to the Schedule of Events Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
62731701|NCT04037891|PLACEBO_COMPARATOR|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
62731702|NCT00434993|ACTIVE_COMPARATOR|Albuterol Sulfate|
62731703|NCT00434993|PLACEBO_COMPARATOR|Placebo|
62731704|NCT01109108||Children <2 years of age|Children \<2 years of age with and without respiratory tract infection
62731705|NCT01109108||Children 2<5 years of age|Children 2\<5 years of age with and without respiratory tract infection
62731706|NCT04106128|EXPERIMENTAL|ultrasound examination|Assess the prevalence of acute diaphragmatic dysfunction by ultrasound
62731707|NCT01143909|EXPERIMENTAL|No FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to omitting transfusion of fresh frozen plasma before they undergo an intervention.
62731708|NCT01143909|NO_INTERVENTION|FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to transfusion of fresh frozen plasma before they undergo an intervention. This is considered standard care.
62731709|NCT06431191|EXPERIMENTAL|Study group|lateral raw repair for full tear rotator cuff combined microfracture procedure
62731710|NCT06431191|PLACEBO_COMPARATOR|Control group|double raw repair for full tear rotator cuff combined microfracture procedure
62731711|NCT01370941|ACTIVE_COMPARATOR|Drug A: Chymosin|A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
62731712|NCT01370941|PLACEBO_COMPARATOR|Drug B: Placebo|B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
62731713|NCT01582009|EXPERIMENTAL|Arm I: Oral Panobinostat and Oral Everolimus|Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
62731714|NCT04281420|EXPERIMENTAL|ATG-019 Alone|A starting does of 30 mg QoD×3 ATG-019
62731715|NCT04281420|EXPERIMENTAL|ATG-019 + Niacin ER|A starting dose of 60 mg ATG-019 and 500 mg niacin ER
62731716|NCT00325130|EXPERIMENTAL|Group 1|Concomitant Administration
62731717|NCT00325130|EXPERIMENTAL|Group 2|Non-concomitant administration
62731718|NCT02827760|PLACEBO_COMPARATOR|Maltodextrin DE19|Placebo
62731719|NCT02827760|ACTIVE_COMPARATOR|Prebiotic Synergy1|Effective prebiotic
62731720|NCT02942888|ACTIVE_COMPARATOR|Healthy control|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
62731721|NCT02942888|EXPERIMENTAL|MCI|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.
62731722|NCT02478814|EXPERIMENTAL|Active, Young Adult Males|Subjects will receive different levels of amino acid intakes varying from 0.2 to 2.6 g/kg/day.
62731723|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
62731724|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
62731725|NCT02001324|ACTIVE_COMPARATOR|Paper-based data collection|Paper-based data collection
62731726|NCT02001324|ACTIVE_COMPARATOR|Web-based data collection|Web-based data collection
62731727|NCT00003587|EXPERIMENTAL|carboplatin/gemcitabine/paclitaxel|IV carboplatin AUC=5.5 day 1 every 21 days X 3 IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3 IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
62731728|NCT00003587|EXPERIMENTAL|cisplatin/vinorelbine/docetaxel|IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3 IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3 IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
62731729|NCT02977364|EXPERIMENTAL|HS-10241 100mg|HS-10241 100mg daily
62731730|NCT02977364|EXPERIMENTAL|HS-10241 200mg|HS-10241 200mg daily
62731731|NCT02977364|EXPERIMENTAL|HS-10241 400mg|HS-10241 400mg daily
62731732|NCT02977364|EXPERIMENTAL|HS-10241 600mg|HS-10241 600mg daily
62731733|NCT02977364|EXPERIMENTAL|HS-10241 800mg|HS-10241 800mg daily
62731734|NCT02977364|EXPERIMENTAL|HS-10241 1000mg|HS-10241 1000mg daily
62731735|NCT04062747|ACTIVE_COMPARATOR|I-gel LMA|After standard anesthesia i-Gel was placed into the patient.
61978388|NCT02743806|EXPERIMENTAL|Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) that maybe reduced to once every 4 weeks (Q4W) based on the investigator's judgment of participant's clinical status and acknowledged by the medical monitor for up to 6 years.
62731736|NCT04062747|ACTIVE_COMPARATOR|Ambu Aura-i|After standard anesthesia Ambu Aura-i was placed into the patient.
62731737|NCT03134391|ACTIVE_COMPARATOR|vapocoolant spray|Subjects received Vapocoolant spray before spinal anesthesia
62731738|NCT03134391|ACTIVE_COMPARATOR|EMLA|Subjects received EMLA before spinal anesthesia
62731739|NCT04267887|EXPERIMENTAL|Treatment (apalutamide, abiraterone acetate, prednisone, ADT)|Patients receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive androgen deprivation therapy per standard of care. Patients undergo CT scan, bone scan and blood sample collection throughout the study.
62731740|NCT06138938|NO_INTERVENTION|Control Group|In the control group, abdominal irrigation as described in the study group was not performed.
62731741|NCT06138938|EXPERIMENTAL|Study Group|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
62731742|NCT03925103|EXPERIMENTAL|3D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a three-dimensional display system
62731743|NCT03925103|ACTIVE_COMPARATOR|2D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a two-dimensional display system
62731744|NCT02016495|ACTIVE_COMPARATOR|Magnesium + Lipoic Acid|
62731745|NCT02016495|PLACEBO_COMPARATOR|Placebo|
62731746|NCT04308655||Patient participants|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until five days postpartum.
62731747|NCT04308655||Provider participants|This cohort will include clinicians who provide care for pregnant patients with OUD. Providers will be interviewed and will complete one survey cross-sectionally.
62731748|NCT06341595|EXPERIMENTAL|combination therapy|sintilimab combined with chemotherapy and radiotherapy
62731749|NCT06513754|EXPERIMENTAL|Ozone, High Intensity|Participants will exercise for 45 minutes in the heavy intensity domain while exposed to 180 ppb ozone
62731750|NCT06513754|EXPERIMENTAL|Ozone, Moderate Intensity|Participants will exercise for 75 minutes in the moderate intensity domain while exposed to 180 ppb ozone
62731751|NCT06513754|SHAM_COMPARATOR|Filtered Air, Heavy Intensity|Participants will exercise for 45 minutes in the heavy intensity domain while exposed to filtered air.
62731752|NCT06513754|SHAM_COMPARATOR|Filtered Air, Moderate Intensity|Participants will exercise for 75 minutes in the moderate intensity domain while exposed to filtered air
61978389|NCT03695679|EXPERIMENTAL|Intervention group|Interactive computer-based intervention
62731753|NCT04531280|EXPERIMENTAL|Home hospital care|Patients receive hospital-level care in their home, as a substitute to traditional hospital care.
62731754|NCT02819297|EXPERIMENTAL|BLI400 Laxative|BLI400 Laxative
62731755|NCT02819297|PLACEBO_COMPARATOR|Placebo|BLI400 placebo
62731756|NCT00773643|EXPERIMENTAL|Tissue Sample|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
62731757|NCT04981106|EXPERIMENTAL|Elastic Band Exercise|"All the participants were subjected to walking training and a standard postoperative care and exercise protocol until discharged from the hospital. During discharging, all the participants in both groups were provided with explanation and illustration about how to perform the exercises. In order to prevent any problem, the participants in both groups were recommended to start the at-home rehabilitation programs, which incorporate knee movement exercises, to be ready 2 weeks (14 days) after the surgery and they were asked to continue their current exercise programs thus far.~The patients in intervention group were recommended to do, in addition to the at-home exercise program given to the patients in control group, elastic band exercises and researchers showed them how to use the elastic bands by making use of instructions."
62731758|NCT04981106|NO_INTERVENTION|Exercise|The patients in control group were recommended to maintain only an at-home exercise program incorporating knee flexion and extension exercises.
62731759|NCT04975659|ACTIVE_COMPARATOR|Nocebo|"We informed subjects in the N group a negative suggestion, using the following script: During the local anaesthetic injection, you are going to feel a sharp prick at your back; this is usually the painful part of the procedure"
62731760|NCT04975659|PLACEBO_COMPARATOR|Placebo|"We informed subjects in the P group a positive suggestion, using the following script: We will administer some local anaesthetic to numb your back; this will allow the procedure to be more comfortable and tolerable for you."
62731761|NCT01888068||No treatment|
62731762|NCT02205268|EXPERIMENTAL|Neurofeedback training|20 sessions of near infrared spectroscopy neurofeedback training to increase activation to bilateral prefrontal cortex. Two sessions per week.
62731763|NCT01608737|EXPERIMENTAL|2. BI 201335 for 24 weeks|BI 201335 once daily low dose for 24 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
62731764|NCT01608737|EXPERIMENTAL|3. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
62731765|NCT01608737|ACTIVE_COMPARATOR|1. PegIFN/RBV|PegIFN/RBV for 48 weeks in treatment-naive patients
62731766|NCT01608737|ACTIVE_COMPARATOR|4. PegIFN/RBV|PegIFN/RBV for 48 weeks in prior relapser patients
62731767|NCT01608737|EXPERIMENTAL|5. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in prior relapser patients
62731768|NCT02100254|EXPERIMENTAL|Arm I (personal narrative)|Participants view videos with information about CRC and screening delivered by personal narrative.
62731769|NCT02100254|ACTIVE_COMPARATOR|Arm II (fact-based message)|Participants view videos with information about CRC and screening delivered by informative fact-based message.
62731770|NCT00910910|EXPERIMENTAL|1 - Lenalidomide|1 - Lenalidomide
62731771|NCT00910910|ACTIVE_COMPARATOR|2- Chlorambucil|2- Chlorambucil
62731772|NCT03730714|ACTIVE_COMPARATOR|Ggroup LAM|Patients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
62731773|NCT03730714|ACTIVE_COMPARATOR|Ggroup LAMG|Patients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
62731774|NCT03730714|ACTIVE_COMPARATOR|Group CG|Patients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
62731775|NCT04373148||COVID-19|Participants diagnosed with COVID-19
62731776|NCT04373148||Controls|Participants not diagnosed with COVID-19
62731777|NCT04148703|EXPERIMENTAL|Active group|in-office follow-up at 30 days post-implantation and after by remote monitoring (daily) without scheduled in-office follow-up during the study period (48 months). A remote FU will be planned every 9 months.
62731778|NCT04148703|ACTIVE_COMPARATOR|Control group|The patients randomized in the control group will be followed accordingto the guidelines; i.e. with an in-office follow-up at 30 days post-implantation and after followed with in-office follow-ups according to clinical practice.
62731779|NCT03096392|EXPERIMENTAL|HDV insulin lispro 100 UNT/mL|insulin lispro with 0.8 ml HDV added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
62167588|NCT04915157|OTHER|Group B: No Stimulation - High Density Stimulation|Patients in this group will receive no stimulation during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive high density stimulation (parasthesia free form of stimulation) during the final 6 months of the study period.
62167589|NCT03713437||Cystic Fibrosis|Serum sample will be drawn once
62167590|NCT03713437||Healthy, age-matched controls|Serum sample will be drawn once
62167591|NCT03735147|EXPERIMENTAL|All children|Administration of live attenuated influenza vaccine (LAIV)
62731780|NCT03096392|ACTIVE_COMPARATOR|insulin lispro 100 UNT/ML|insulin lispro with 0.8 ml sterile water for injection added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
62731781|NCT03323216||No diabetes|Patients without diabetes
62731782|NCT03323216||Type 2 diabetes|Patients with diagnosis of type 2 diabetes (new/established)
62731783|NCT03323216||Prediabetes|Patients with an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.
62731784|NCT02613663|EXPERIMENTAL|immediate implants with nanobone graft|Nano-hydroxyapatite bone graft fill the gap between immediate implant and labial bone wall.
62731785|NCT02613663|ACTIVE_COMPARATOR|immediate implants with autogenous bone graft|Autogenous graft fill the gap between immediate implant and labial bone wall.
62731786|NCT01803685||Surgical treatment|Surgical resection of intracranial arteriovenous malformations.
62731787|NCT01803685||Stereotaxic radiosurgery|Deliver a relatively high dose of focused radiation precisely to the arteriovenous malformations.
62731788|NCT01803685||Endovascular treatment|Deliver embolic materials to the feeding arteries or the nidus by microcatheters
62731789|NCT01803685||Comprehensive treatment|Use two or three methods ( Surgical treatment stereotaxic radiosurgery endovascular treatment ) to cure the intracranial arteriovenous malformations
62731790|NCT01803685||Conservative treatment|Patients refused to any of the treatment above
62731791|NCT03685318|ACTIVE_COMPARATOR|Conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
62731792|NCT03685318|ACTIVE_COMPARATOR|Shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo for two weeks. The shortened mouthguard is designed with the palatal margin at 2 mm from the cervical line.
62731793|NCT01861561|EXPERIMENTAL|Low-dose intravenous cyclophosphamide|Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
62731794|NCT01861561|ACTIVE_COMPARATOR|High-dose intravenous cyclophosphamide|High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
62731795|NCT05940389|EXPERIMENTAL|NAM appliance Group|The NAM appliance is constructed according to the Grayson technique \[8\] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed. The surgical lip repair technique involved will be done by one surgeon using the Delare technique without the blind dissection of the alar cartilage.
62731796|NCT05940389|EXPERIMENTAL|Taping with nasal elevator:|"For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.~The surgical lip repair technique involved will be done by one surgeon using the Delare technique without the blind dissection of the alar cartilage."
62731797|NCT06503627|ACTIVE_COMPARATOR|dissection of bladder flap for CS|
62731798|NCT06503627|NO_INTERVENTION|no dissection of bladder flap for CS|
62731799|NCT06144294|EXPERIMENTAL|Group 2 - Cohort 2a|Healthy women or transgender men 18-50 years of age, \<6 months postpartum
62731800|NCT06144294|EXPERIMENTAL|Group 2 - Cohort 2b|Women and transgender men 18-50 years of age, \<6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI
62731801|NCT06144294|EXPERIMENTAL|Group 2 - Cohort 2c|Healthy adults of both sexes 18-50 years of age
62731802|NCT06144294|EXPERIMENTAL|Group 2 - Cohort 2d|Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the MINI
62731803|NCT06144294|EXPERIMENTAL|Group 3 - Cohort 2a|Healthy women or transgender men 18-50 years of age, \<6 months postpartum
62731804|NCT06144294|EXPERIMENTAL|Group 3 - Cohort 2b|Women and transgender men 18-50 years of age, \<6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI
62731805|NCT06144294|EXPERIMENTAL|Group 3 - Cohort 2c|Healthy adults of both sexes 18-50 years of age
62731806|NCT06144294|EXPERIMENTAL|Group 3 - Cohort 2d|Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the MINI
62731807|NCT06353048|ACTIVE_COMPARATOR|group A|patients with tibial plateau fractures Schatzker type II fixed by screws only
62731808|NCT06353048|ACTIVE_COMPARATOR|group B|patients with tibial plateau fractures Schatzker type II fixed by plate and screws
62731809|NCT05600361|OTHER|Patients having 13C Pyruvate DNP for lymphoma early treatment response evaluate|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
62731810|NCT00119028|OTHER|Arm 1|Non-experimental QI intervention - No comparator
62731811|NCT04178928|ACTIVE_COMPARATOR|group A|patiWill receive L-T4 treatment at a dose 1 µg/kg/day for 12 weeks. And the dose will be titrated every 4 weeksents with SCH will be subjected to clinical, laboratory and imaging assessment and
62731812|NCT04178928|NO_INTERVENTION|Group B|.pWill not receive treatment.atients with SCH will be subjected to clinical, laboratory and imaging assessment and
62731813|NCT00821158|PLACEBO_COMPARATOR|1|Placebo tablet and iv
62731814|NCT00821158|EXPERIMENTAL|2|Placebo tablet and intervention iv
62731815|NCT00821158|EXPERIMENTAL|3|Intervention tablet and placebo iv
62731816|NCT05090878||1. Patients with and without carotid IPH|Among patients with carotid artery atherosclerosis (stenosis 30-99%), patients with and without IPH, as assessed by MR-Plaque Imaging, are compared in terms of apoB, Lp(a) levels and other cardiovascular risk factors.
62731817|NCT05090878||2. Patients with and without first-ever ischemic stroke at baseline|Among patients with carotid artery atherosclerosis (stenosis 30-99%), the risk of first-ever ischemic stroke in relation to apoB, Lp(a) levels, and presence of IPH is assessed, after adjusting for the cardiovascular factors.
62731818|NCT05090878||3. Patients with and without recurrent ischemic stroke|Among patients with carotid artery atherosclerosis (stenosis 30-99%) with an ipsilateral ischemic stroke at baseline, the risk of recurrent ipsilateral ischemic stroke in relation to apoB, Lp(a) levels, and presence of IPH is assessed, after adjusting for the cardiovascular factors.
62731819|NCT03740399|ACTIVE_COMPARATOR|Group sitting|we are performing spinal anesthesia in sitting position pregnant patients
62731820|NCT03740399|ACTIVE_COMPARATOR|Group lateral decubitus position|we are performing spinal anesthesia in lateral decubitus position pregnant patients
62731821|NCT03740399|ACTIVE_COMPARATOR|Group Modified 45-degree head-up tilt|we are performing spinal anesthesia in Modified 45-degree head-up tilt position pregnant patients
62731822|NCT02289365|PLACEBO_COMPARATOR|Group I|Totally 3000 mg of PEG-400 per day. 3 capsules of 500 mg PEG-400 per time, twice a day.
62731823|NCT02289365|EXPERIMENTAL|Group II|Totally 2000 mg of JBM-TC4 per day. 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400 per time, twice a day.
62731824|NCT02289365|EXPERIMENTAL|Group III|Totally 3000 mg of JBM-TC4 per day. 3 capsules of 500 mg JBM-TC4 per time, twice a day.
62731825|NCT03599778|EXPERIMENTAL|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
62731826|NCT03599778|ACTIVE_COMPARATOR|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
62731827|NCT03844087|EXPERIMENTAL|multiplanar neuromuscular training arm|The intervention arm will be involved in the training intervention outlined. Briefly, each participant will be asked to train on the TopSpin360 3 times per week for 3-5 sets for the duration of the study. Each set will take roughly 15-30 seconds to perform and training will take part during regularly scheduled training sessions.
62731828|NCT01623167|EXPERIMENTAL|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 6
62731829|NCT01623167|EXPERIMENTAL|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 3
62731830|NCT01623167|EXPERIMENTAL|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18months, and receive eltrombopag day 1 to month 6
62731831|NCT01623167|EXPERIMENTAL|Extrension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
62731832|NCT04755998|EXPERIMENTAL|Experimental Group|The Experimental Group watched cartoons with virtual reality glasses during vaccination applications.
62731833|NCT04755998|NO_INTERVENTION|Control Group|Pre-test and post-tests were applied to the non-intervention group
62731834|NCT06556082|EXPERIMENTAL|Training Group|In addition to the standard training programs in the off-season period; PNF-based upper extremity strengthening training will be performed 3 days a week for 8 weeks in addition to core stabilization training.
62731835|NCT06556082|EXPERIMENTAL|Control Group|The amputee football players in the control group will be trained 3 days a week for 8 weeks with isotonic strengthening exercises of the upper extremity muscles with free weights and core stabilization training.
62731836|NCT01088295|EXPERIMENTAL|Telmisartan|Telmisartan 40mg po daily for 24 weeks
62731837|NCT00255723|EXPERIMENTAL|Cytoreductive chemotherapy group 1|Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
62731838|NCT00255723|EXPERIMENTAL|Cytoreductive chemotherapy group 2|Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.
62731839|NCT04413058||Female healthcare workers|Healthy female healthcare workers at Covid 19 clinic in Istanbul, Turkey
62731840|NCT05933967|EXPERIMENTAL|orelabrutinib+R-CHOP|
62731841|NCT05792007|ACTIVE_COMPARATOR|Patients with acute leukemias|Children with acute lymphoid leukemia B, acute lymphoid leukemia -T or acute myeloid leukemia
62731842|NCT05792007|OTHER|Control group|Children without blood diseases
62731843|NCT04695470|EXPERIMENTAL|Fruquintinib with Sintilimab|Patients who met the eligibility criteria took fruquintinib 5mg qd for 2 weeks on and 1 week off Q3w plus Sintilimab 200mg iv, Q3w.
62731844|NCT06453382|EXPERIMENTAL|'Whole of government' and 'whole of society' approach|Sub-district level potential human resources engagement to control and prevent NCDs
62731845|NCT05547919|EXPERIMENTAL|Gastrointestinal tumors histologically positive for PSMA|Tumor biopsy at baseline to establish diagnosis and to identify PSMA expression in an ex-vivo setting. Patients with ex-vivo PSMA expression receive a multimodal imaging approach: This includes a PSMA-targeted PET/CT (18F-PSMA) at baseline and conventional imaging.
62731846|NCT03415425|ACTIVE_COMPARATOR|Usual Care|The current version of the alert will fire for this arm of the study.
62731847|NCT03415425|ACTIVE_COMPARATOR|Alert Iteration|A modified version of the alert will fire for this arm of the study.
62731848|NCT03522415|EXPERIMENTAL|HLX01+MTX|
62731849|NCT03522415|PLACEBO_COMPARATOR|Placebo+MTX|
62731850|NCT05396339|EXPERIMENTAL|Phase Ia - Dose escalation(Acceleration Stage)|Phase Ia is an open, non-random, single-arm dose escalation design.
62731851|NCT05396339|EXPERIMENTAL|Phase Ia - Dose escalation(3+3 Stage)|Phase Ia is an open, non-random, single-arm dose escalation design.
62731852|NCT05396339|EXPERIMENTAL|Phase Ib - Dose extension|Phase Ib is an open, non-random, single-arm, multi-center research design.
62731853|NCT05396339|EXPERIMENTAL|Phase IIa - Clinical Exploratory Stage|The Phase IIa is planned to be divided into three indication groups, all of which are open, non-randomized, single-arm research design.
62731854|NCT02968498|ACTIVE_COMPARATOR|Study arm 1|Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water
62731855|NCT02968498|ACTIVE_COMPARATOR|Study arm 2|Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water
62731856|NCT03705559|EXPERIMENTAL|Vaporized Marijuana|Participants will receive non-therapeutic, experimental doses of active or placebo. vaporized marijuana. Active marijuana/placebo will be administered once per session and will be administered via a vaporizer.
62731857|NCT03705559|EXPERIMENTAL|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intranasally (snorting).
62731858|NCT03705559|EXPERIMENTAL|Opioid Agonist/Marijuana Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with non-therapeutic, experimental doses of active vaporized marijuana/placebo. Opioid/placebo and marijuana/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
62731859|NCT04783311|EXPERIMENTAL|Phase 1 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
62731860|NCT04783311|EXPERIMENTAL|Phase 1 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
62731861|NCT04783311|EXPERIMENTAL|Phase 2 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
62731862|NCT04783311|EXPERIMENTAL|Phase 2 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
62731863|NCT04783311|ACTIVE_COMPARATOR|Phase 2 - Placebo comparator group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
62731864|NCT04085146|EXPERIMENTAL|Optimal PEEP|Individualized optimal PEEP will be provided during the laparoscopic period of surgery. Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
62731865|NCT04085146|ACTIVE_COMPARATOR|Conventional PEEP|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
62731866|NCT04295811|EXPERIMENTAL|EsoCheck and EsoGuard vs. EGD with or without biopsies|All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
62731867|NCT06451367|EXPERIMENTAL|Intervention|Regular football training and neuromuscular training program for 12 weeks
62731868|NCT06451367|NO_INTERVENTION|Controle|Regular football training
62731869|NCT06482827|SHAM_COMPARATOR|Group A (Sham)|Participants in group A will take part in 4 weeks of treatment with 5 sessions per week. Each session will involve sham repetitive transcranial magnetic stimulation (rTMS). Sham rTMS will be delivered at 10 Hz, 2004 pulses targeting the leg representation of the primary motor cortex. Participants will hear and experience the clicking but will not be provided with any stimulation. Sham rTMS will take approximately 11.5 minutes.
62731870|NCT06482827|ACTIVE_COMPARATOR|Group B (Active)|Participants in group B will take part in 4 weeks of treatment with 5 sessions per week. Each session will involve real repetitive transcranial magnetic stimulation (rTMS). rTMS will be delivered at 10 Hz, 2004 pulses targeting the leg representation of the primary motor cortex. rTMS will take approximately 11.5 minutes.
62731871|NCT04378101||Anorexia Nervosa Case|Participants in this group have a life-time history of anorexia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
62731872|NCT04378101||Bulimia Nervosa Case|Participants in this group have a life-time history of bulimia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa.
62731873|NCT04378101||Binge-Eating Disorder Case|Participants in this group have a life-time history of binge-eating disorder as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa or bulimia nervosa.
62731874|NCT04378101||Control|Participants in this group have no history of disordered eating behaviors as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
62731875|NCT02562846||ECT patients|Depressive patients receiving electroconvulsive therapy.
62731876|NCT04894539|EXPERIMENTAL|TENS1|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
62731877|NCT04894539|EXPERIMENTAL|TENS2|TENS with 80/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
62731878|NCT04894539|SHAM_COMPARATOR|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
62731879|NCT00925665||Glidescope|Patients intubated with the Glidescope technique
62731880|NCT00925665||Macintosh|Patients intubated via the conventional direct laryngoscopy with a Macintosh laryngoscope
62731881|NCT03926377|OTHER|Clobetasol propionate treatment|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
62731882|NCT06197152||100 patients with RSV diagnosis|Patients with acute respiratory infection and positive nasopharyngeal PCR or other respiratory specimen for RSV.
62731883|NCT06197152||33 control patients|Patient admitted for acute respiratory syndrome with no diagnosis of respiratory infection or immunosuppression.
62731884|NCT00924014|ACTIVE_COMPARATOR|Conivaptan|Conivaptan will be given via IV bolus
62731885|NCT00924014|ACTIVE_COMPARATOR|Furosemide|Furosemide will be given via IV bolus
62731886|NCT00924014|ACTIVE_COMPARATOR|conivaptan and furosemide|on day 3 subjects will receive both study drugs
62731887|NCT05710133|OTHER|alectinib-d6|Patients will receive one single dose of alectinib-d6 (100 µg) orally on day 1 and 9.
62731888|NCT01503346|EXPERIMENTAL|herbal medicine|"Intervention group~* 1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~* 2. each package was given to each patient four times a day (three time after meal and one time before sleep);~* 3. each patient received the usual medication of the hospice ward at the same time;~* 4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~* 5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
62731889|NCT05340478||AF-CBT|Adjunctive Family -CBT for family members of Veterans with anxiety
62731890|NCT02213497|EXPERIMENTAL|Dose Escalation of Neoadjuvant Proton Radiotherapy in Esophageal Cancer|Patients with esophageal cancer to be treated with concurrent preoperative chemoradiation with carboplatin and paclitaxel.
62731891|NCT03017339|EXPERIMENTAL|Laser Group|The subjects participated in a functional exercise program associated with low level laser therapy applied in the quadriceps, hamstrings and triceps sural
62731892|NCT03017339|PLACEBO_COMPARATOR|Placebo Group|The subjects participated in a functional exercise program associated with placebo low level laser therapy applied in the quadriceps, hamstrings and triceps sural
62731893|NCT05483023|EXPERIMENTAL|18F-fluorofuranylnorprogesterone PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
62731894|NCT00848835||control|all patients in the control group
62731895|NCT05733741|EXPERIMENTAL|Preservative-free topical anesthetics group|Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free topical anesthetics for pain control following single-step transepithelial PRK surgery in one eye.
62731896|NCT05733741|PLACEBO_COMPARATOR|Preservative-free artificial tears group|Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free artificial tears as a placebo following single-step transepithelial PRK surgery in the other eye.
62731897|NCT05572736|EXPERIMENTAL|Conduction system pacing|Patients will be randomized 1:1 to either conduction system pacing or biventricular pacing.
62731898|NCT05572736|ACTIVE_COMPARATOR|Biventricular pacing|Patients will be randomized 1:1 to either conduction system pacing or biventricular pacing.
62731899|NCT01844297|OTHER|TDF+3TC+EFV|
62731900|NCT01321242||achieving resting HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
62731901|NCT01321242||non-achieving HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
62731902|NCT05006976|ACTIVE_COMPARATOR|NSAC health only|Treatment as usual (TAU) at NSAC, following a digital survey of health problems and the provision of a condensed report of this survey to clinician prior to consultation.
62731903|NCT05006976|EXPERIMENTAL|NSAC health + MBW|Treatment as usual (TAU) at NSAC, following a digital survey of health problems as well as Motivation, Barriers for return to work and Work environment (MBW), and the provision of a condensed report of this survey to clinician prior to consultation.
62731904|NCT01803880|ACTIVE_COMPARATOR|Mechanical Debridement|Mechanical shaver removes areas of damaged tissue
62731905|NCT01803880|ACTIVE_COMPARATOR|RF-based Debridement|Electrical energy removes areas of damaged tissue (Coblation®)
62731906|NCT04784793|NO_INTERVENTION|Phase1: Design and development|"We conducted focus group meetings to discuss the content, features and design of the app.~The focus group consisted of physiotherapists and young adults. The focus group members discussed the variety of topics in subgroups (login parameters, self-monitoring, exercises content, video or animation types, exercise diary, reminders, encouragement, method, etc)."
62731907|NCT04784793|NO_INTERVENTION|Phase 2: Testing the app|We tested the prototype version app interface in the 2nd phase. All participants downloaded the prototype app and used the app for one week.
62731908|NCT04784793|NO_INTERVENTION|Phase 3: Usability evaluation|"We conduct a think-aloud interview and evaluate the quantitative usability in the third phase.~The quantitative usability was assessed by the System Usability Scale (SUS), and the adapted Usability, Satisfaction and Ease to Use (USE) Questionnaire."
62731909|NCT04784793|ACTIVE_COMPARATOR|Phase 4: Pilot randomized controlled trial/ The app-based group|"The app-based group:~Participants in the intervention group received their smartphone-based- home exercise program."
62731910|NCT04784793|EXPERIMENTAL|Phase 4: Pilot randomized controlled trial/ The control group|"The control group:~Participants in the control group received their home exercise programs as a paper handout."
62731911|NCT01780805||Young adult alcohol drinkers|Young adults between the ages of 21-25 who regularly drink alcohol
62731912|NCT03689608|EXPERIMENTAL|Intermittent Fasting (IF)|3 days fasting per week
62731913|NCT03689608|EXPERIMENTAL|Daily Restriction (DR)|daily energy restriction
62731914|NCT03689608|OTHER|standard care (SC)|usual care
62731915|NCT04005391|EXPERIMENTAL|Postpartum Contraceptives offered to Intervention Clusters|"Women will have postpartum contraceptive options (condoms vive amor, birth control pills segura plus, injectable cyclofem, contraceptive implant jadelle) offered to them at their routine forty day postpartum visit after routine care is provided, first."
62731916|NCT04005391|NO_INTERVENTION|Routine Care offered to Control Clusters|Women will receive routine postpartum care
62731917|NCT03367403|EXPERIMENTAL|Donanemab Monotherapy (Donanemab-M)|Participants received 700 milligram (mg) donanemab intravenously (IV) every 4 weeks (Q4W) x 3 doses, then 1400 mg donanemab IV Q4W for up to 72 weeks.
62731918|NCT03367403|PLACEBO_COMPARATOR|Placebo|Participants received placebo IV Q4W for up to 72 weeks.
62731919|NCT03367403|EXPERIMENTAL|Donanemab in Combination With LY3202626 (Donanemab-C)|"Participants received 700 mg donanemab IV Q4W x 3 doses, then 1400 mg donanemab IV Q4W in combination with 12 mg of LY3202626 orally for up to 72 weeks.~As per protocol amendment (d) approved on Oct 9, 2018, donanemab in combination with LY3202626 (donanemab-C) arm discontinued as there was a low probability of identifying a statistically significant effect of 12mg of LY3202626 slowing cognitive decline."
62731920|NCT04911647|ACTIVE_COMPARATOR|The Plastic stent|Patient group with plastic stent inserted in biliary obstruction through endoscope
62731921|NCT04911647|EXPERIMENTAL|The metal stent|Patient group with metal stent inserted in biliary obstruction through endoscope
62731922|NCT03792555|EXPERIMENTAL|Paltusotine|
62731923|NCT03792555|PLACEBO_COMPARATOR|Placebo|
62731924|NCT00920361||1|Patients who underwent IVF
62731925|NCT04236050|EXPERIMENTAL|rocuronium is administered via continuous infusion|"40 patients. General anesthesia is maintained with propofol and remifentanil, with standard anesthetic monitoring, bispectral index (BIS) and train-of-four(TOF). In experimental group, rocuronium was administered via continuous infusion so that theTOF ratio was 5%. Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
62736285|NCT01279291|EXPERIMENTAL|KHK2866 as monotherapy|Groups of subjects will receive a weekly infusions of KHK2866 as treatment for advanced cancer. If there no severe side effects, the dose will be increased for future subjects. A total of four groups are anticipated. Once an acceptable dose is determined an additional seven subjects will be treated at that dose.
62737176|NCT05139745|SHAM_COMPARATOR|Sham treatment|This group will be treated with 5% of the treatment parameter settings
62737177|NCT06175598||Acquire Aganglionosis (AA)|
62731926|NCT04236050|ACTIVE_COMPARATOR|rocuronium is administered in bolus doses|"40 patients. General anesthesia was maintained with propofol and remifentanil, with standard anesthetic monitoring, BIS and TOF. In this group, rocuronium was administered in separate bolus doses with the TOF ratio of 5%.~Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
62731927|NCT01384565|ACTIVE_COMPARATOR|G-CSF+EPO|
62731928|NCT01384565|PLACEBO_COMPARATOR|Placebo|
62731929|NCT05388227||Pole Walking|Attending pole walking sessions.
62731930|NCT04048889|EXPERIMENTAL|Popliteal plexus block and continuous femoral nerve block|
62731931|NCT04048889|ACTIVE_COMPARATOR|continuous femoral nerve block|
62731932|NCT04358146|EXPERIMENTAL|Test|new thickened infant formula containing fibres
62731933|NCT04358146|ACTIVE_COMPARATOR|Control|infant formula thickened with locust bean
62731934|NCT03585725|EXPERIMENTAL|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
62731935|NCT05491096|EXPERIMENTAL|Proprioceptive Neuromuscular Training|It consists of 13 patients who will receive conventional exercises and proprioceptive training with 2 sessions per week for 8 weeks.
62731936|NCT05491096|PLACEBO_COMPARATOR|Conventional Physical Therapy|It consists of 13 patients who will receive conventional exercises i.e; strengthening exercises, 2 sessions per week for 8 weeks
62731937|NCT04633369|EXPERIMENTAL|Fructo-oligosaccharide|Fructo-oligosaccharide 20g
62731938|NCT04633369|EXPERIMENTAL|Arabinogalactan|Arabinogalactan 12g
62731939|NCT04633369|EXPERIMENTAL|Glucomannan|Glucomannan 4g
62731940|NCT06398002|ACTIVE_COMPARATOR|Dialysate calcium 1.25 mmol/L (standard)|
62731941|NCT06398002|EXPERIMENTAL|Dialysate calcium 1.50 mmol/L (high)|
62731942|NCT06436222|OTHER|HVNI (Intervention Group)|The infant was given therapy using HVNI with an initial flow of 6 L/min. Inspiratory fraction of oxygen (FiO2) started with 30% following the SpO2 target. The maximum flow is 8L/min. FiO2 can be increased by 5% until the target SpO2 is reached.
62731943|NCT06436222|OTHER|CPAP(Control Group)|The infant was given therapy using CPAP with an initial pressure of 7 cmH20. Inspiratory fraction of oxygen (FiO2) starting with 30% following the SpO2 target.The maximum of CPAP pressure is 8 cmH2O. FiO2 can be increased by 5% until the target SpO2 is reached.
62731944|NCT06137885||PCI group|Patients who received percutaneous coronary intervention (PCI) at the Department of cardiology of Peking University Third Hospital will be included in the PCI group.
62731945|NCT06137885||Heart failure group|Patients with heart failure who hospitalized at the Department of cardiology of Peking University Third Hospital will be included in the heart failure group.
62731946|NCT06137885||Cardiometabolic syndrome group|Patients with cardiometabolic syndrome who hospitalized at the Department of cardiology of Peking University Third Hospital will be included in the cardiometabolic syndrome group.
62731947|NCT06137885||Structural heart disease group|Patients with structural heart disease who hospitalized at the Department of cardiology of Peking University Third Hospital will be included in the structural heart disease group.
62731948|NCT05293600|PLACEBO_COMPARATOR|Placebo|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
62731949|NCT05293600|ACTIVE_COMPARATOR|Interventional arm|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
62731950|NCT05395039|NO_INTERVENTION|Usual Care: Control Group|No interventions administered. Participant will receive usual care in the hospital.
62731951|NCT05395039|EXPERIMENTAL|VCHIPS: Intervention Group|Individuals in this group will work with a study nurse to schedule the intervention.
62731952|NCT02961504|EXPERIMENTAL|HLCM051 (MultiStem)|single dose of 1.2 billion HLCM051 cells
62731953|NCT02961504|PLACEBO_COMPARATOR|Placebo|a single dose of placebo
62731954|NCT05746091|EXPERIMENTAL|Arthroscopic partial Trapezictomy With Hematoma Distraction|
62731955|NCT02365610|EXPERIMENTAL|GWP42006|GWP42006
62731956|NCT02365610|PLACEBO_COMPARATOR|Placebo control|Placebo
62731957|NCT01413295|EXPERIMENTAL|Dendritic Cells Vaccine|Dendritic Cells Vaccine after 2 lines of chemotherapy
62731958|NCT01413295|OTHER|Supportive treatment|Supportive treatment after 2 lines of chemotherapy
62731959|NCT00295282|EXPERIMENTAL|1|patients will receive active MDX-1100
62731960|NCT02363777|ACTIVE_COMPARATOR|Standard of Care|Epidural placed for postoperative pain control
62731961|NCT02363777|EXPERIMENTAL|Experimental Intervention|Bilateral paravertebral catheters placed for postoperative pain control
62731962|NCT02509936|ACTIVE_COMPARATOR|Standard of Care Arm|In this arm enrolled children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement.
62731963|NCT02509936|EXPERIMENTAL|Home-based Education|In the intervention arm, children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement. In addition, they will receive monthly home visits from a community health promoter who will provide detailed dietary assessments and individualized dietary coaching and education to parents.
62737178|NCT06175598||Intestinal Dysmotility (ID)|
61978390|NCT03695679|NO_INTERVENTION|Control group|An one-page online information about procedures and tips of condom use with minimal intervention
62731964|NCT05623748||Cancer for CTC culture|participants are cancer patients with transitional cell carcinoma
62731965|NCT05623748||Healthy for CTC culture|enroll participants without cancer
62731966|NCT04396795|EXPERIMENTAL|PRP group|Participants in this group will receive 2 sessions of autologous PRP penile injection, each administered 1 month apart ± 7 days
62731967|NCT04396795|PLACEBO_COMPARATOR|Placebo group|Participants in this group will receive 2 sessions of placebo injection, each administered 1 month apart ± 7 days.
62731968|NCT04858841|EXPERIMENTAL|Levetiracetam|The group receives oral levetiracetam.
62731969|NCT04858841|EXPERIMENTAL|Perampanel|The group receives oral perampanel.
62731970|NCT04858841|PLACEBO_COMPARATOR|Placebo|The group receives oral placebo.
62731971|NCT01833494|EXPERIMENTAL|PA21|
62731972|NCT01650831|ACTIVE_COMPARATOR|Clinical Suspicion of Hpylori|All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
62731973|NCT01591434|ACTIVE_COMPARATOR|AQUACEL®|A sterile non-woven sheet of sodium carboxymethylcellulose (NaCMC).
62731974|NCT01591434|ACTIVE_COMPARATOR|AQUACEL® Extra™|A sandwiched construction of two layers of optimally textiled non-woven fabric, stitch-bonded together using Lyocel (Tencel™ regenerated cellulose) yarns.
62731975|NCT00942370||accelerometric device|
62731976|NCT00407836|EXPERIMENTAL|Vaccination|One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
62731977|NCT03732716||Elderly with sarcopenia|50 patients aged 75 or older with sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
62731978|NCT03732716||Elderly without sarcopenia|50 patients aged 75 or older without sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
62731979|NCT04365686|ACTIVE_COMPARATOR|Group K|Ketofol group
62731980|NCT04365686|ACTIVE_COMPARATOR|Group P|propofol group
62731981|NCT01467466|ACTIVE_COMPARATOR|Saline & oral placebo|IV isotonic saline and oral placebo drug capsule
62731982|NCT01467466|ACTIVE_COMPARATOR|Saline & oral N-acetylcysteine|IV isotonic saline and oral N-acetylcysteine drug capsule
62731983|NCT01467466|ACTIVE_COMPARATOR|Bicarbonate & oral placebo|IV isotonic bicarbonate and oral placebo drug capsule
62731984|NCT01467466|ACTIVE_COMPARATOR|Bicarbonate & oral N-acetylcysteine|IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
62731985|NCT01784679||Natural History Prospective Observational Group|
62731986|NCT01784679||Online Registry Patient Reported Group|
62731987|NCT03896854|EXPERIMENTAL|CD19 positive relapsed or refractory acute myeloid leukemia|MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia
62731988|NCT02655952|EXPERIMENTAL|Foxy-5|"Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly for three weeks.~There will be a maximum of 8 dose cohorts. Cohorts 1-4 will be conducted in the United Kingdom and Denmark whereas cohorts 5-8 will only be conducted in Denmark. As doses in cohort 1 and 2 have been investigated in the previous phase I study, cohorts 1+2 and 3 can be run in parallel with dose escalation approved by the DSMB at all times.~DK+UK: Cohort 1: 0.8 mg/kg DK+UK: Cohort 2: 1.3 mg/kg DK+UK: Cohort 3: 1.8 mg/kg DK+UK: Cohort 4: 2.3 mg/kg DK only: Cohort 5: 3.0 mg/kg DK only: Cohort 6: 4.0 mg/kg DK only: Cohort 7: 5.3 mg/kg DK only: Cohort 8: 7.0 mg/kg"
62731989|NCT04311112|PLACEBO_COMPARATOR|ZA placebo|
62731990|NCT04311112|ACTIVE_COMPARATOR|ZA low dose|
61978391|NCT00412022|ACTIVE_COMPARATOR|A|Triptorelin 3.75 mg IM every 4 weeks and Tamoxifen 20 mg daily, for 5 years
61978392|NCT00412022|ACTIVE_COMPARATOR|B|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily, for 5 years
62731991|NCT04311112|ACTIVE_COMPARATOR|ZA high dose|
62731992|NCT05625295||Patients with non-face-to-face consultation|A sample of 500 patients who have undergone non-face-to-face consultation with dermatology
62731993|NCT05625295||Patients with face-to-face consultation|A sample of 500 patients who have undergone face-to-face consultation with dermatology
62731994|NCT02342860|EXPERIMENTAL|WASH in Schools (WinS) programme|Schools in the intervention group will receive the UNICEF/Department of Foreign Affairs and Trade (DFAT)-supported WinS programme that includes a new water supply, 3 latrines (boys, girls, handicapped), and handwashing facilities. It will also include behavior change education.
62731995|NCT02342860|NO_INTERVENTION|Control|Schools in the control group will receive no additional WinS programming.
62731996|NCT04887727|EXPERIMENTAL|Healthy, recreationally-active adult males - Muscle Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-\[1-13C\]leucine and L-ring-\[2H5\]phenylalanine with a primed-constant infusion of L-\[555-2H3\]leucine to assess myofibrillar protein synthesis rates
62731997|NCT04887727|EXPERIMENTAL|Healthy, recreationally-active adult males - Whole Body Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-\[1-13C\]leucine with a primed-constant infusion of L-\[555-2H3\]leucine to whole-body protein turnover, amino acid oxidation, and net protein balance
62731998|NCT01564251|EXPERIMENTAL|Stage 1 Arm 1: GDC-0575 Monotherapy|Participants will receive escalating doses of GDC-0575, administered orally, for 3 consecutive days, starting on Days 1, 8, and 15 of each 21-day cycle.
62731999|NCT01564251|EXPERIMENTAL|Stage 1 Arm 2a: GDC-0575 + Gemcitabine (750 or 1000 mg/m^2)|Participants will receive gemcitabine 750 milligrams per meter square (mg/m\^2) or 1000 mg/m\^2, intravenously, on Days 1 and 8 followed by escalating doses of GDC-0575 orally, on Days 2 and 9 of each 21-day cycle.
62732000|NCT01564251|EXPERIMENTAL|Stage 1 Arm 2b: GDC-0575 plus Gemcitabine (500 mg/m^2)|Participants will receive gemcitabine 500 mg/m\^2, intravenously, once weekly for approximately 2 consecutive weeks of any 3-week period and escalating doses of GDC-0575 orally approximately 24-hours after each gemcitabine dose.
62732001|NCT01564251|EXPERIMENTAL|Stage 2: GDC-0575 plus Gemcitabine|Participants will receive GDC-0575 in combination with gemcitabine intravenously (1000 mg/m\^2 and/or 500 mg/m\^2), at or below the MTDs for the combination treatments that are determined during Stage 1.
62732002|NCT03592771|NO_INTERVENTION|Usual Care|Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
62167592|NCT04661189|EXPERIMENTAL|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
62167593|NCT04661189|EXPERIMENTAL|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
62732003|NCT03592771|ACTIVE_COMPARATOR|THRIVE App|Participants use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants receive reminders via text or email to use the app once per week during the 6-month intervention phase. Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
62732004|NCT03592771|ACTIVE_COMPARATOR|THRIVE App+Feedback|Participants use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants receive reminders via text or email to use the app once per week during the 6-month intervention phase. In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase. Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
62732005|NCT04719481|EXPERIMENTAL|pravastatin 80mg/d|Oral administration of pravastatin at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
62732006|NCT04719481|PLACEBO_COMPARATOR|placebo|Oral administration of placebo at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
62732007|NCT03034005|EXPERIMENTAL|Patients with asthma|6 weeks treatment with 1600 ug budesonide
62732008|NCT03034005|NO_INTERVENTION|Healthy Controls|Healthy controls to establish baseline level of Na/K pumps.
62732009|NCT01754246|EXPERIMENTAL|Alexandrite Laser for Skin Toning|755 nm Alexandrite Laser for Skin Toning
62732010|NCT01754246|EXPERIMENTAL|Alexandrite Laser for Pigmented Lesions|755nm Alexandrite Laser for Epidermal Pigmented Lesions
62732011|NCT04414813|EXPERIMENTAL|hAESCs treatment|50 millions hAESCs are transplanted to participants with PD.
62732012|NCT05710731|EXPERIMENTAL|low-reality simulation Group|In this group, urinary catheterization will be performed through a plastic half-hip model.
62732013|NCT05710731|EXPERIMENTAL|Computer Based Simulation Group|In this group, urinary catheterization will be performed through a computer-based full-body model.
62732014|NCT05710731|EXPERIMENTAL|Virtual Reality Simulation Group|In this group, urinary catheterization will be performed through a software based on virtual reality technology.
62732015|NCT06133556|ACTIVE_COMPARATOR|control arm|"Busulfan/Cyclophosphamide, standard conditioning regimen as a control group. including Bu3.2mg/kg -5\~-3d; Cy 80mg/kg，-2\~-1d。 or alternative Bu/Cy regimen, Bu3.2mg/kg -9\~-7d；Flu 30mg/m2 -6\~-4d；Ara-C 2g/m2 -6\~-4d；Cy 80mg/kg -3\~-2d。"
62732016|NCT06133556|EXPERIMENTAL|MCBC group|using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
62732017|NCT03303053|EXPERIMENTAL|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
62732018|NCT03303053|EXPERIMENTAL|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
62732019|NCT03303053|ACTIVE_COMPARATOR|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
62732020|NCT02973139|ACTIVE_COMPARATOR|Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
62732021|NCT02973139|ACTIVE_COMPARATOR|Fibrinolytic group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
62732022|NCT06090812||acute brain injury|The included population was patients with acute brain injury, protected from acute cerebrovascular events, traumatic brain injury, and acute cerebral edema. Assessment of stress levels, Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
62732023|NCT04742530|EXPERIMENTAL|Fasted Evening Exercise|Exercise will take place in the evening, following a 7 hour period of fasting.
62167594|NCT00582192||1|Participants with certain types of cancers that are eligible for studies at Memorial Sloan-Kettering Cancer Center.
62167595|NCT01411176|ACTIVE_COMPARATOR|Menthol|20 ml NPO-11
62167596|NCT01411176|PLACEBO_COMPARATOR|Placebo|20 ml NPO-11(Placebo)
62732024|NCT04742530|ACTIVE_COMPARATOR|Fed Evening Exercise|Exercise will take place in the evening, after having consumed a carbohydrate-containing meal 2 hours prior.
62167597|NCT06091982||AKI-RRT|Post cardiovascular surgery patients with condition of acute kidney injury postoperative; and with an exposure of renal replacement therapy (intermittent haemodialysis or continuous renal replacement therapy) which is indicated postoperatively.
62167598|NCT06091982||AKI non RRT|Post cardiovascular surgery patients with condition of acute kidney injury postoperative; but without exposure of renal replacement therapy.
62167599|NCT00665106|EXPERIMENTAL|cohort 1|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
62167600|NCT00665106|EXPERIMENTAL|cohort 2|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
62167601|NCT00665106|EXPERIMENTAL|cohort 3|5 up to 6 patients per arm. Emulsion at 3.2% of drug product.
62732025|NCT04742530|ACTIVE_COMPARATOR|Fed Morning Exercise|Exercise will take place in the morning, after having consumed a carbohydrate-containing meal 2 hours prior.
62732026|NCT04512677|NO_INTERVENTION|No Interventions: Control|Conventional clinical treatment and using the ventilatory weaning protocol and standard extubation with the spontaneous breathing test (SBT) with the T-piece in 30 minutes.
62732027|NCT04512677|EXPERIMENTAL|Experimental: Intervention|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
62732028|NCT02463396|EXPERIMENTAL|Mindfulness Based Cognitive Therapy (MBCT) for ADHD|Adapted MBCT for ADHD
62732029|NCT02463396|NO_INTERVENTION|Treatment as usual (TAU)|Usually medication \& psycho-education
62732030|NCT01084577|ACTIVE_COMPARATOR|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
62732031|NCT01084577|ACTIVE_COMPARATOR|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
61977725|NCT05883930|EXPERIMENTAL|control group|No intervention will be made in the control group. A smart bracelet will be given as a gift in order to follow the step counts of the students. Students will fill in pre-test, post-test and follow-up test (at 6 months) and sedentary lifestyle TTM Sedentary Life Scales (Stages of Change questionnaire, Self-Efficacy and Decision Making scales) and daily step count values via online forms. The body mass index, fat and muscle ratios of the students will be evaluated by the researcher. These values will be recorded.
62732032|NCT04710498|EXPERIMENTAL|Atezolizumab|Subjects will receive neoadjuvant atezolizumab intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 (+/- 3 days) of each 21-day cycle for a total of 3 doses prior to surgery, unless there is clinical or radiographic evidence of disease progression.
62732033|NCT02383186|ACTIVE_COMPARATOR|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
62732034|NCT02383186|ACTIVE_COMPARATOR|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
62732035|NCT00075764|ACTIVE_COMPARATOR|Arm I|Patients receive oral anastrozole once daily on days 1-28.
62732036|NCT00075764|EXPERIMENTAL|Arm II|Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.
62732037|NCT00974506|ACTIVE_COMPARATOR|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine therapy by general practitioner
62732038|NCT00974506|ACTIVE_COMPARATOR|Routine care therapy|Routine care therapy by general practitioner
62732039|NCT01585779||Contour 3D® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Contour 3D® ring will occur in conjunction with another concomitant surgical repair procedure
62732040|NCT01585779||Tri-Ad® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Tri-Ad® ring will occur in conjunction with another concomitant surgical repair procedure
62732041|NCT02141230|EXPERIMENTAL|Alli® 60 mg|Participants purchasing Alli®
62732042|NCT05247450|EXPERIMENTAL|FES-t along with conventional physiotherapy|Combined conventional physiotherapy and functional electrical stimulation therapy (FES-t) along with task-specific training
62732043|NCT05247450|ACTIVE_COMPARATOR|Conventional physiotherapy alone|Conventional physiotherapy alone (current standard of care)
62732044|NCT00725946|EXPERIMENTAL|Iodine-124 PET-CT scan|
62732045|NCT04723498|OTHER|Patients|male and female patients, handled on an ambulatory basis in Psychiatric University Clinics, Department of Child and Adolescent Psychiatrythe ages from 8 - 18 years during the study
62732046|NCT04380909|EXPERIMENTAL|Internet-based self-help|The self-help program consists of six text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
62732047|NCT04380909|OTHER|Waiting control group|Access to internet-based intervention after 3 weeks.
62732048|NCT02668705|NO_INTERVENTION|Human RA|A sham research informed consent form will be explained by a research assistant
62732049|NCT02668705|EXPERIMENTAL|ECA|A sham research informed consent form will be explained by an ECA (embodied conversational agent as presented on a touch screen computer)
62732050|NCT02668705|EXPERIMENTAL|ECA + Human RA|A sham research informed consent form will be explained by an ECA and then questions will be answered by a research assistant
62732051|NCT03376711|NO_INTERVENTION|Standard Care Group|Participants in this arm of the study will not have access to the online peer support program until the end of the 12-week trial.
62732052|NCT03376711|EXPERIMENTAL|Online Peer Support Program|Participants in the online peer support program arm of the intervention will have access to the website for 12 weeks.
62732053|NCT03900728|ACTIVE_COMPARATOR|Auriculotherapy with needles (acupuncture) + usual care|A designated trained therapist will perform auriculotherapy with 1mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place until removal at the 1-week follow-up visit
62732054|NCT03900728|ACTIVE_COMPARATOR|Auriculotherapy with gold beads (acupressure) + usual care|A designated trained therapist will perform auriculotherapy with beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place until removal at the 1-week follow-up visit.
62732055|NCT03900728|SHAM_COMPARATOR|Placebo group + usual care|A designated trained therapist will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place until removal at the 1-week follow-up visit.
62732056|NCT03926949|ACTIVE_COMPARATOR|Intervention group|Participants will receive parenteral nutrition (Olimel 7.6% E 1000 ml), infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
62732057|NCT03926949|OTHER|Control group|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively
62732058|NCT03931499||Study cohort|Patients undergoing surgery under cardiopulmonary bypass
62732059|NCT02805634|EXPERIMENTAL|Multiple sclerosis|Patients with multiple sclerosis, followed by Dr Dachy within the CHU Brugmann Hospital.
62732060|NCT02805634|OTHER|Control group|Control group without neurological pathology
62732061|NCT01078194||Weight regain / weight loss failure|Weight regain of more than 10 kg from or weight loss of less than 50% EWL 18 months after lap. gastric bypass
62732062|NCT02689206|EXPERIMENTAL|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
62732063|NCT02689206|EXPERIMENTAL|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
62732064|NCT02689206|EXPERIMENTAL|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
62732065|NCT02689206|EXPERIMENTAL|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
62732066|NCT02689206|PLACEBO_COMPARATOR|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
62732067|NCT00661726|EXPERIMENTAL|1|Participants will receive injected decitabine for 12 weeks.
62732068|NCT05135039|EXPERIMENTAL|Lifestyle interventions + Canagliflozin|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of canagliflozin 100mg.
62732069|NCT05135039|PLACEBO_COMPARATOR|Lifestyle interventions + Placebo|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of placebo 100mg.
62732070|NCT06422624|EXPERIMENTAL|Semaglutide ER Injectable Suspension, 1 mg|Participants receive a single of semaglutide ER injectable suspension at a lower dose 1 mg for safety, tolerability and pharmacokinetics assessements
62732071|NCT06422624|EXPERIMENTAL|Semaglutide ER Injectable Suspension, 4 mg|Participants receive a single of semaglutide ER injectable suspension at a medium dose 4 mg for safety, tolerability and pharmacokinetics assessements
62732072|NCT06422624|EXPERIMENTAL|Semaglutide ER Injectable Suspension, 8 mg|Participants receive a single of semaglutide ER injectable suspension at a higher dose 8 mg for safety, tolerability and pharmacokinetics assessements
62732073|NCT04875468|ACTIVE_COMPARATOR|Zirconia crown cemented by adhesive resin cement|MultiRein link adhesive resin cement (non MDP, non-calcium and fluoride releasing cement)
62732074|NCT04875468|EXPERIMENTAL|Zirconia crown cemented by self-adhesive resin cement|TheraCem self-adhesive resin cement (MDP, calcium and fluoride releasing cement)
62732075|NCT01107392|EXPERIMENTAL|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
62732076|NCT01107392|PLACEBO_COMPARATOR|Placebo (Normal saline)|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
62732077|NCT00579969|EXPERIMENTAL|Latanoprost Effects on Aqueous Humor Dynamics in Ocular Hypertensive Patients|Evaluating the Effects of Latanoprost on Aqueous Humor Dynamics in Ocular Hypertensive Patients (prostaglandin analogue)
62732078|NCT00579969|EXPERIMENTAL|Timolol Effects on Aqueous Humor Dynamics in Ocular Hypertensive Patients|Evaluating the Effects of Timolol on Aqueous Humor Dynamics in Ocular Hypertensive Patients (prostaglandin analogue)
62732079|NCT01628523||All ED patients requiring mechanical ventilation|
62732080|NCT01602601||Cohort 1|Patients will have a single blood draw for the analysis of antibodies induced by idursulfase. Samples will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro.
62732081|NCT03534505|EXPERIMENTAL|Ketorolac injections|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
62732082|NCT03534505|ACTIVE_COMPARATOR|bupivacaine|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
62732083|NCT04695353|EXPERIMENTAL|Study group|These patients will receive telemedicine by using Telecommunication Platform videoconferences/messages.
62732084|NCT04695353|NO_INTERVENTION|Control group|The patients will receive in-office clinical care
62732085|NCT03815448|EXPERIMENTAL|Methotrexate|Methotrexate 2.5mg/ tablet, oral, once a week, 2-6 tablets each time
62732086|NCT03815448|PLACEBO_COMPARATOR|Placebo|Placebo 2.5mg/ tablet,oral,once a week,2-6 tablets each time
61978393|NCT00412022|EXPERIMENTAL|C|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily for 5 years + zoledronic acid 4 mg every 6 months.
62167602|NCT00665106|EXPERIMENTAL|cohort 4|5 up to 6 patients per arm. Oily solution at 3.4% of drug product.
62732087|NCT04456478|ACTIVE_COMPARATOR|pH 7.38 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.38 ± 0.02
62732088|NCT04456478|EXPERIMENTAL|pH 7.22 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.22 ± 0.02
62732089|NCT06089031||BELmicro|No intervention foreseen.
62732090|NCT05356988|EXPERIMENTAL|Physical Activity Group|Physical activity (PA) group participants will receive behavioral nudge e-mails with links to a web-based platform which will provide: physical activity information, at-home exercise demonstrations/videos for survivors of all fitness levels, articles, blog posts, physical activity/sitting recommendations, a space for goal setting, a platform for physical activity tracking, a discussion board, automatic syncing of their Fitbit to the leaderboard, etc.
62732091|NCT05356988|ACTIVE_COMPARATOR|Balance and Flexibility Group|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure. They will receive access to the HEALED website at the end of the 12-month intervention period.
62732092|NCT06045273|EXPERIMENTAL|Elders' Resilience Curriculum Recipients|Youth aged 9-14 who receive the Elders' Resilience Curriculum
62732093|NCT01326091|NO_INTERVENTION|Standard Positioning|
62732094|NCT01326091|ACTIVE_COMPARATOR|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
62732095|NCT04469088|EXPERIMENTAL|Dry Needling Group|
62732096|NCT04469088|ACTIVE_COMPARATOR|Manual Therapy Treatment|
62732097|NCT00938912|EXPERIMENTAL|Lacosamide|Subjects and their caregivers may chose to receive Lacosamide oral solution (syrup) or Lacosamide tablets. The maximum duration of LCM administration will be approximately 2 years.
62737179|NCT06175598||Anastomotic Complications (AC)|
62732098|NCT06333002||Derivation cohort|It will contain 800 patients randomly selected (80% of 1,000 patients with AHRF)
62732099|NCT06333002||Validation cohort|It will contain 200 patients randomly selected (20% of 1000 patients with AHRF
62732100|NCT06333002||Confirmatory cohort|It will contain the remaining 241 patients randomply selected (por external validation)
62732101|NCT02180204|EXPERIMENTAL|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum dose: 25 mg
62732102|NCT02180204|ACTIVE_COMPARATOR|Alteplase|Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg
62732103|NCT02786212|EXPERIMENTAL|dexmedetomidine|Patients receiving intraoperative dexmedetomidine infusion. Infusion duration: from 10 minutes after anesthetic induction to the end of surgery.
62732104|NCT02786212|PLACEBO_COMPARATOR|control|control group, receiving same volume of normal saline infusion.
62732105|NCT02283892|EXPERIMENTAL|Checklist|2 checklists available for consultation by the attending physician: (1) dyspnea evaluation checklist and (2) cough evaluation checklist. The checklists are available on computers and mobile devices (smartphone, PDA or tablet computer).
62732106|NCT02283892|ACTIVE_COMPARATOR|Conventional assessment|Evaluation of patients reporting dyspnea or cough made by the attending physician, without the use of the checklists for dyspnea or cough evaluation.
62732107|NCT03396302|EXPERIMENTAL|Experimental|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education).
62732108|NCT03396302|NO_INTERVENTION|Control|The control group will receive Hospital treatment as usual.
62732109|NCT06353152|EXPERIMENTAL|Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection|The subjects enrolled will be sequentially assigned to the corresponding dose level.
62732110|NCT00620373|EXPERIMENTAL|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.
62732111|NCT00922402|EXPERIMENTAL|Treatment|All patients will be submitted to a shared intensive protocol of insulin infusion supported by continuous glucose monitoring
62732112|NCT03351868|EXPERIMENTAL|Gene-modified autologous stem cells|Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo
62732113|NCT03849664|EXPERIMENTAL|Cytoflavin®|Patients of group I will receive the experimental drug Cytoflavin®, manufactured by POLYSAN (Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Cytoflavin® solution(Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered IV for 7 days, and Cytoflavin® enteric-coated tablets (Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered for 25 days (in total 32 days of treatment).
62732114|NCT03849664|PLACEBO_COMPARATOR|Placebo|Patients of group II will receive placebo (manufactured by POLYSAN, Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Placebo solution will be administered IV for 7 days, and placebo enteric-coated tablets will be administered for 25 days (in total 32 days of treatment).
62732115|NCT03598049|EXPERIMENTAL|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
62732116|NCT03598049|ACTIVE_COMPARATOR|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
62732117|NCT05253937||Intracoronary Epinephrine administration during cardiac arrest|
62732118|NCT05253937||Peripheral intravenous Epinephrine administration during cardiac arrest|
62732119|NCT05253937||Central intravenous Epinephrine administration during cardiac arrest|
62732120|NCT05096143||Naive Sacubitril/valsartan|Participants who were prescribed with Naive Sacubitril/valsartan
62732121|NCT05096143||Naive ACEi/ARB|Participants who were prescribed with Naive Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
62732122|NCT02078024|ACTIVE_COMPARATOR|Annual Ivermectin|Ivermectin 200 µg/kg body weight given orally at 0, 12 and 24 months
62732123|NCT02078024|EXPERIMENTAL|Biannual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months.
62732124|NCT02078024|EXPERIMENTAL|Annual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg given at 0, 12 and 24 months; vitamin pills at given at 6 and 18 months.
62732125|NCT02078024|EXPERIMENTAL|Biannual IVM 200 µg/kg|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months.
62732126|NCT02078024|EXPERIMENTAL|IVM 200 µg/kg plus ALB 400 mg|IVM 200 µg/kg plus ALB 400 mg given at 0, 6, 12, 18, and 24 months.
62732127|NCT02487147|ACTIVE_COMPARATOR|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
62732128|NCT02487147|EXPERIMENTAL|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
62732129|NCT04648917|EXPERIMENTAL|Arm A|In Arm A: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval (weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
62732130|NCT04648917|PLACEBO_COMPARATOR|Arm B|In Arm B: 40 patients will receive the placebo tablets: 100-200mg, tid, po, 2 weeks treated then 1 week black interval.
62732131|NCT03899025|OTHER|Suspected scaphoid fracture|Patients with a suspected scaphoid fracture
61978402|NCT04200456|EXPERIMENTAL|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
62732132|NCT01963247||Healthy Athletes|
62732133|NCT01963247||Concussed Athletes|
62732134|NCT05168046|EXPERIMENTAL|Parkinson Mindfullness Based Stress Reduction|Patients who have an assessment before and after a mindfulness based stress reduction intervention for 6 months
62732135|NCT05168046|NO_INTERVENTION|Parkinson controls|Patients who have an assessment before and after 6 monthswithout intervention
62732136|NCT03836846|PLACEBO_COMPARATOR|Treatment As Usual|Standard of care as usual with follow-up at 1-, 3-, and 6-months
62732137|NCT03836846|ACTIVE_COMPARATOR|Intervention with CBT Mobile App|Treatment as usual with additional treatment using cognitive behavioral therapy (CBT) mobile apps (ie What's Up?)
62732138|NCT03634098|EXPERIMENTAL|Volunteers|"Exams performed on volunteers with other purpose than liver disease or diabetes in two centers:~* MRI~* Ultrasound AixPlorer These examinations are carried out in 2 differents centers at 1month intervals"
62732139|NCT03634098|EXPERIMENTAL|T2D liver test abnormalities's participants|"Exams performed on type 2 diabetic patients with liver test abnormalities :~* sample for analysis and biocollection~* MRI +/-Primovist~* Ultrasound AixPlorer +Sonovue"
62732140|NCT03634098|NO_INTERVENTION|T2D participants without liver test abnormality|type 2 diabetic participants without liver test abnormality and not undergoing liver biopsy
62732141|NCT01637532|OTHER|Group 1|Carboplatin/Caelyx
62732142|NCT01637532|EXPERIMENTAL|Group 2|Carboplatin/Caelyx or doxorubicin plus Tocilizumab
62732143|NCT01637532|EXPERIMENTAL|Group 3|Carboplatin/Caelyx or doxorubicin plus Tocilizumab plus Peg-Intron
62732144|NCT00229697|EXPERIMENTAL|1|ZD1839 + Nolvadex
62732145|NCT00229697|OTHER|2|Nolvadex + placebo
62732146|NCT04961346|EXPERIMENTAL|Ultrapro®|Participants received incisional hernia repair with an Ultrapro mesh in a sublay technique.
62732147|NCT04961346|EXPERIMENTAL|Premilene®|Participants received incisional hernia repair with a Premilene mesh in a sublay technique.
62732148|NCT03601065||Routine colonoscopy Cohort|
62732149|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
62732150|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
62732151|NCT02661204||Population A|Consecutive women in the age range 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2, referring to our department for breast evaluation with ultrasound, will be invited to participate to the study. During the interview, before imaging examination, women will be questioned about family history as well as other relevant personal information (e.g. previous surgery or biopsy for benign breast disease).
62732152|NCT02661204||Population B|Consecutive women with a new breast cancer diagnosis and undergoing pre-operative MRI examination for local staging will be invited to participate to the study. ABUS will be performed within two weeks before the scheduled surgery.
62732153|NCT02661204||Population C|Consecutive women with BI-RADS 3 and 4 lesions detected in a routine breast imaging examination will be invited to participate to the study. ABUS will be performed just after the routine HH-US examination.
62732154|NCT02661204||Population D|Consecutive women undergoing breast MRI examination for the evaluation of breast implants integrity will be invited to participate to the study. ABUS will be performed just after the breast MRI.
62732155|NCT01978145|EXPERIMENTAL|Regimen A|Placebo administered BID by multi-dose inhaler followed by FSC (250/50 mcg) administered BID by capsule-based inhaler.
62732156|NCT01978145|EXPERIMENTAL|Regimen B|FSC (250/50 mcg) administered BID by multi-dose inhaler followed by placebo administered BID by capsule-based inhaler.
62732157|NCT00945568|EXPERIMENTAL|Aminolaban EN|Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
62732158|NCT00945568|NO_INTERVENTION|Control|The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.
62732159|NCT03775824||MTX start|Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
62732160|NCT03775824||TNF start|Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
62732161|NCT01894724|EXPERIMENTAL|NeuroSave Device|Targeted Hypothermia with NeuroSave Device
62732162|NCT01520155||Systemic lupus erythematosus with renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
62732163|NCT01520155||Systemic lupus erythematosus without renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
62732164|NCT01520155||Non-autoimmune kidney disease|Patients with non-systemic, non-autoimmune kidney disease
62732165|NCT01679678|EXPERIMENTAL|PolyHeal 2|Negatively charged 5-micron polystyrene microspheres in Water For Injection
62732166|NCT01679678|ACTIVE_COMPARATOR|PolyHeal|Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)
62732167|NCT02967549|EXPERIMENTAL|NAVA then PAV|Infants randomised to NAVA then PAV
62732168|NCT02967549|EXPERIMENTAL|PAV then NAVA|Infants randomised to PAV then NAVA
62732169|NCT04213469|EXPERIMENTAL|PD1-CD19-CART|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of PD1-CD19-CART will be infused on day 0.
62732170|NCT02424500|EXPERIMENTAL|d-Nav Device|"d-Nav Device: daily use to provide insulin dosage updates weekly - or sooner when needed based on analyzes and evaluates the historical blood glucose patterns.~Insulin dosage is adjusted as required"
62732171|NCT02424500|ACTIVE_COMPARATOR|Blood Glucose Monitoring System|"Patient's personal Over the Counter Blood Glucose Monitoring System (OTC BGMS) for daily glucose testing to determine insulin dosage needed.~Insulin dosage is adjusted as required"
62732172|NCT03890900|OTHER|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
62732173|NCT00402324|EXPERIMENTAL|1|olanzapine and divalproex
62732174|NCT00402324|PLACEBO_COMPARATOR|2|placebo and divalproex
62732175|NCT02453750|EXPERIMENTAL|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
62736286|NCT01279291|EXPERIMENTAL|KHK2866, gemcitabine+carboplatin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with gemcitabine and carboplatin. The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
62732176|NCT05434793|EXPERIMENTAL|The meridian effect of sham testing from mechanical stimulation|The effects of sham acupuncture at Tsu San Li (St-36) were examined by analyzing noninvasive 30-sec. recordings of the radial arterial pulses for 3 groups of patients treated with different probes (blunt, sharp, and patch) on the superficial skin of the acupuncture point. The 3 groups were then treated with the sharp probe for 3 different periods (16, 30, and 50 seconds). Then we compared the harmonics of the radial arterial pulse after Fourier transformation before and after the treatment.
62732177|NCT04361539||Elite adolescent badminton players|The population was all the elite adolescent badminton players from a high-level club. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed from September 2018 to May 2019.
62732178|NCT00626886|EXPERIMENTAL|1|Two, 5x5cm bupivacaine collagen sponges implanted during surgery
62732179|NCT00626886|PLACEBO_COMPARATOR|2|Placebo collagen sponge implanted during surgery
62732180|NCT06202352|EXPERIMENTAL|Intervention Group|The group which yoga and meditation are implemented
62732181|NCT06202352|NO_INTERVENTION|Control|The group which has no implementation
62732182|NCT03274011|EXPERIMENTAL|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
62732183|NCT03559517|EXPERIMENTAL|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
62732184|NCT03559517|EXPERIMENTAL|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
62732185|NCT03559517|PLACEBO_COMPARATOR|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
62732186|NCT00222755|EXPERIMENTAL|1|Behavioral Care Management
62732187|NCT00222755|NO_INTERVENTION|2|Usual Care
62732188|NCT02956746|EXPERIMENTAL|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
62732189|NCT02956746|ACTIVE_COMPARATOR|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
62732190|NCT02956746|EXPERIMENTAL|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
62732191|NCT02956746|ACTIVE_COMPARATOR|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
62732192|NCT05340946|EXPERIMENTAL|Group (G)|received general anaesthesia followed by IV patient-controlled analgesia (IV PCA).
62732193|NCT05340946|EXPERIMENTAL|Group (F)|received spinal anaesthesia followed by continuous ultrasound guided femoral never block once the anaesthesia-induced motor block resolved.
62732194|NCT00755963|EXPERIMENTAL|1|
62732195|NCT00755963|EXPERIMENTAL|2|
62732196|NCT00755963|PLACEBO_COMPARATOR|3|Placebo
62732197|NCT03399279|EXPERIMENTAL|Open flap debridement & perforated&Nano|Perforated collagen membrane and nano-hydroxyapatite and open flap debridement
62732198|NCT03399279|ACTIVE_COMPARATOR|Open flap debridment &Occlusive&Nano|Occlusive membrane and nano-hydroxyapatite and open flap debridement
62732199|NCT04635150|EXPERIMENTAL|Post-intervention parents and staff|An educational intervention for the multidisciplinary staff of a neonatal intensive care unit.
62732200|NCT01784367|EXPERIMENTAL|ECLA-group|Treatment with a pump driven, venovenous extracorporeal lung assist
62732201|NCT01574287|EXPERIMENTAL|FACBC|
62732202|NCT02931409|EXPERIMENTAL|Optimal PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O. Optimal PEEP is considered as a PEEP value resulting the highest possible Cstat measured by ventilator. After PEEP titration procedure a lung protective mechanical ventilation will be performed using optimal PEEP and low tidal volumes (6 mL/Kg IBW).
62732203|NCT02931409|ACTIVE_COMPARATOR|Standard PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/Kg).
62732204|NCT01525862|EXPERIMENTAL|Balloon sinus dilation|Balloon dilation of the maxillary sinus using a transnasal approach.
62732205|NCT01654874|EXPERIMENTAL|Preparation A|20 (±3) mCi 99mTc-MIP-1404 (preparation A)
62732206|NCT01654874|EXPERIMENTAL|Preparation B|20 (±3) mCi 99mTc-MIP-1404 (preparation B)
62732207|NCT04910386|EXPERIMENTAL|Envafolimb|"Envafolimab plus Gemcitabine\&Cisplatin Envafolimab: 300 mg on Day 1 of each cycle, subcutaneous injection. Every 21 days is a treatment cycle.~Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
62732208|NCT04910386|ACTIVE_COMPARATOR|Gemcitabine&Cisplatin|"Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
62732209|NCT01097096|ACTIVE_COMPARATOR|CAD106 150μg + Adjuvant 1 at middle dose|
62732210|NCT01097096|ACTIVE_COMPARATOR|CAD106 150μg + Adjuvant 1 at low dose|
62732211|NCT01097096|PLACEBO_COMPARATOR|Placebo + Adjuvant 1 at middle dose|
62732212|NCT01097096|ACTIVE_COMPARATOR|CAD106 150μg + Adjuvant 2 at middle dose|
62732213|NCT01097096|ACTIVE_COMPARATOR|CAD106 150μg + Adjuvant 2 at low dose|
62732214|NCT01097096|PLACEBO_COMPARATOR|Placebo + Adjuvant 2 at middle dose|
62732215|NCT01097096|ACTIVE_COMPARATOR|CAD106 450μg + either Adjuvant 1 or 2 at middle dose|
62737180|NCT06175598||Intestinal Neurodevelopmental Impairment (INI)|
62732216|NCT01097096|ACTIVE_COMPARATOR|CAD106 450μg + either Adjuvant 1 or 2 at low dose|
62732217|NCT01097096|PLACEBO_COMPARATOR|Placebo + either Adjuvant 1 or 2 at middle dose|
62732218|NCT02018484|EXPERIMENTAL|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
62732219|NCT01645774|EXPERIMENTAL|10s injections duration|10s injections duration
62732220|NCT01645774|EXPERIMENTAL|10s injection duration , waiting 10s|10s injection duration and waiting 10s before withdrawing the needle
62732221|NCT01645774|EXPERIMENTAL|15s injection duration,waiting 5s|15s injection duration and waiting 5s before withdrawing the needle
62732222|NCT01645774|EXPERIMENTAL|5s injection duration , waiting 15s|5s injection duration and waiting 15s before withdrawing the needle
62732223|NCT01487538|EXPERIMENTAL|intervention group|The intervention will be delivered through action plans, videos, discussion boards and health behavior tracking (weight, calories in and out, pedometer steps) to facilitate health management, resourcefulness and health status.
62732224|NCT01487538|ACTIVE_COMPARATOR|Standard Advice Group|Standard advice group receives newsletters and health behavior tracking (weight) to initiate, increase, or sustain physical activity for weight maintenance.
62732225|NCT04172350|EXPERIMENTAL|Intervention group: iCareBreast plus routine care|Participants in the intervention group will receive the routine care provided by the hospital (the same as the control group) plus the iCareBreast mobile app, which provides i) pre-surgery education and instructions; ii) post-surgery education, instructions, and recovery plan; iii) positive psychological support; and iv) social support. The total intervention period is 29 days (14 days before surgery, operation day, and 14 days after the surgery).
62732226|NCT04172350|ACTIVE_COMPARATOR|Control group: Routine care|Participants in the control group will only receive routine care provided by the attending Hospital. Participants being allocated to the control group may freely use the Internet to search for information regarding breast cancer but will not be granted to access the iCareBreast app.
62732227|NCT03167788|EXPERIMENTAL|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period.
62732228|NCT03167788|ACTIVE_COMPARATOR|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
62732229|NCT04130438|ACTIVE_COMPARATOR|Beta Blocker (nebivolol)|
62732230|NCT04130438|ACTIVE_COMPARATOR|Calcium Channel Blocker (diltiazem)|
62732231|NCT04130438|PLACEBO_COMPARATOR|Placebo|
62732232|NCT01279811|OTHER|Single Arm|Vasopressor Crossover - Dopamine \& NORepinephrine
62732233|NCT01901614|EXPERIMENTAL|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
62732234|NCT01901614|ACTIVE_COMPARATOR|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
62732235|NCT04741412||Hypohidrotic Ectodermal Dysplasia|all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder
62732236|NCT04741412||Control|individuals of the same age group, but without HED, including pregnant women
62732237|NCT02522429|EXPERIMENTAL|Low Intensity Focused Ultrasound Device|15 acute DOC patients, 15 chronic DOC patients
62732238|NCT04892472|EXPERIMENTAL|Arm 1: Treatment Group|Pembrolizumab (MK-3475) and TTFields
62732239|NCT04892472|EXPERIMENTAL|Arm 2: Control Group|Pembrolizumab (MK-3475)
62732240|NCT00787839||Group 1|Atlanta VA Medical Center patients who meet criteria for screening for prediabetes and early diabetes based on standard guidelines of the VA, the American Diabetes Association, and the National Institutes of Health
62732241|NCT03198091|EXPERIMENTAL|Dun Ye Guan Xin Ning mono-therapy|
62732242|NCT06339086|EXPERIMENTAL|Semaglutide Injection|"Semaglutide 0.25mg、0.5mg、1.0mg~Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day"
62732243|NCT06339086|ACTIVE_COMPARATOR|Ozempic®|"Ozempic® 0.25mg、0.5mg、1.0mg~Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day."
62732244|NCT06513741|EXPERIMENTAL|Workshop Participants|Educate faculty members to develop personal development plans for becoming effective mentors and mentees
62732245|NCT00302744|EXPERIMENTAL|Psilocybin|Single, 6-hour treatment with 0.2 mg/kg active psilocybin capsule.
62732246|NCT00302744|ACTIVE_COMPARATOR|Active Niacin Placebo|Each subject functioned as their own control, receiving niacin placebo capsule in a single 6-hour session.
62732247|NCT03375086|EXPERIMENTAL|Single arm|Patients will receive APX3330 orally, twice per day until disease progression
62732248|NCT04792788|ACTIVE_COMPARATOR|NAVA/PSV/NAVA|6 patients
62732249|NCT04792788|ACTIVE_COMPARATOR|PSV/NAVA/PSV|6 patients
62732250|NCT06170190|EXPERIMENTAL|Open-label：IBI133 monotherapy|
62732251|NCT04120246|EXPERIMENTAL|Treatment (alpha-TEA, trastuzumab)|Patients receive one of 4 doses of alpha-TEA PO on days 1-14 of each cycle. Patients also receive trastuzumab on day 1 of cycle 1 and then every 3 weeks per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62732252|NCT04808791|EXPERIMENTAL|Single Arm iTTO treatment|"Patients will receive the combination of irinotecan, TAS-102, and Oxaliplatin on a 28 day cycle with the following doses;~* Irinotecan 160mg/m2 IV infusion over 60-90 mins on day 1~* Oxaliplatin 100mg/m2 IV infusion over 2 hours on day 1~* TAS-102 (Trifluridine/Tipiracil) 25mg/m2 twice a day, on days 1-5 and 8-12 every 28days."
62732253|NCT01720875|EXPERIMENTAL|Vorinostat Velcade Dexamethasone (VVD)|"Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.~Cycles 1-8 (21-day cycle)~* Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11~* Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12~* Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)~* Vorinostat: 400mg PO on 1-4 and 15-18"
62732254|NCT01008761|ACTIVE_COMPARATOR|Zithromax, 100 mgmgs; 5mls suspension|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
62732255|NCT01008761|PLACEBO_COMPARATOR|Suspension placebo,|placebo (suspension produced by CDC Edmonton.) given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days.
62732256|NCT01147159|OTHER|Skin Prick Test|
62732257|NCT06289387||Individuals with or without diabetes|
62732258|NCT00940290|OTHER|GRADE system|A clinical recommendation built and graded with the GRADE working group system
62732259|NCT00940290|OTHER|SIGN grading system|A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
62732260|NCT00940290|OTHER|NICE grading system|A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
62732261|NCT00940290|OTHER|CEBM-Oxford|A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system
62732262|NCT04716686|EXPERIMENTAL|Niraparib as maintenance therapy for Endometrial Serous Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
62732263|NCT04716686|EXPERIMENTAL|Niraparib as recurrent therapy for Endometrial Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
62732264|NCT06093269|EXPERIMENTAL|Cefazolin|20mg/kg to be administered in the hemodialysis circuit at the end of the 4-hour dialysis period, with no dosage adjustment planned afterwards.
62732265|NCT00480831|EXPERIMENTAL|1|
62732266|NCT00480831|PLACEBO_COMPARATOR|2|
62732267|NCT02544035|EXPERIMENTAL|36-71 month-old Play Partner|36-71 month-olds (1.5-2 year olds)
62732268|NCT02544035|EXPERIMENTAL|72-107 month-old Play Partner|72-107 month-olds (6-8 year-olds)
62732269|NCT02544035|EXPERIMENTAL|12-18 month-old Toy Type|12-18 month-olds (1-1.5 year olds)
62732270|NCT02544035|EXPERIMENTAL|19-35 month-old Toy Type|19-35 month-olds (1.5-2 year-olds)
62732271|NCT02544035|EXPERIMENTAL|36-71 month-old Toy Type|36-71 month-olds (3-5 year-olds)
62732272|NCT02544035|EXPERIMENTAL|72-107 month-old Toy Type|72-107 month-olds (6-8 year-olds)
62732273|NCT02544035|EXPERIMENTAL|12-18 month-old Play Partner|12-18 month-olds (1-1.5 year olds)
62732274|NCT02544035|EXPERIMENTAL|19-35 month-old Play Partner|19-35 month-olds (1.5-2 year olds)
62732275|NCT00817323|EXPERIMENTAL|Quetiapine fumurate (Seroquel)|See Detailed description
62732276|NCT05254236|EXPERIMENTAL|Medium-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using medium-dose COVID-19 Vaccine (Vero Cell), Inactivated
61978403|NCT04200456|PLACEBO_COMPARATOR|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
62732277|NCT05254236|EXPERIMENTAL|High-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using high-dose COVID-19 Vaccine (Vero Cell), Inactivated
62732278|NCT06315972|EXPERIMENTAL|Experimental intervention|Application of double-blind add-on clemastine at a dosage of 8 mg/day (morning: 4 mg; evening: 4 mg) + aerobic exercise training 50 min 3x/week over a period of 3 months
62732279|NCT06315972|PLACEBO_COMPARATOR|Control intervention|Application of double-blind add-on placebo (morning and evening) + aerobic exercise training 50 min 3x/week
62732280|NCT04922853|EXPERIMENTAL|2 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have TME operation after reevaluation and randomization.
62732281|NCT04922853|OTHER|4 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have two more cycles chemotherapy and TME operation after reevaluation and randomization.
62732282|NCT00472654|PLACEBO_COMPARATOR|WL|
62732283|NCT00472654|EXPERIMENTAL|WL + D|
62732284|NCT00472654|PLACEBO_COMPARATOR|WM|
62732285|NCT00472654|ACTIVE_COMPARATOR|WM + D|
62732286|NCT01104402|NO_INTERVENTION|Standard Care|Subjects will receive education about signs and symptoms indicative of worsening CF.
62732287|NCT01104402|ACTIVE_COMPARATOR|Home monitoring|Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
62732288|NCT06525688||Postmenopausal Female Patient with subcapital hip osteoporotic fracture|Postmenopausal Female Patient with subcapital hip osteoporotic fracture
62732289|NCT06525688||Postmenopausal Female Patient with hip osteoarthritis|Postmenopausal female patient with hip osteoarthritis who will undergo total hip replacement.
62732290|NCT06181838|ACTIVE_COMPARATOR|Intervention|Standard therapy and lesion extraction
62732291|NCT06181838|PLACEBO_COMPARATOR|Control|Standard therapy without lesion extraction
62732292|NCT05695794|OTHER|the group with a bed head height of 45 degrees|The bed head height of the patients in this group will be adjusted to 45 degrees. This group was determined as the control group since the patients were given a 45-degree head height as a standard in the hospital where the study would be conducted.
62732293|NCT05695794|EXPERIMENTAL|the group with a bed head height of 30 degrees|The bed head height of the patients in this group will be adjusted to 30 degrees. This group was determined as the experimental group since the patients were given a 45-degree head height as a standard in the hospital where the study would be conducted.
62732294|NCT02777359|EXPERIMENTAL|the closure group|In the closure group, the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA, in combination of clopidogrel(50mg/d, 3mon) and aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
62732295|NCT02777359|NO_INTERVENTION|the medication group|In the medication group, in combination of clopidogrel (50mg/d, 3mon) and aspirin (0.1g/d, 6mon), current medication resumed, including conventional prescription for migraine as β-receptor blockers, calcium-ion antagonists, antiepileptics, antidepressants and non-steroid anti-inflammatory drugs (NSAID).
62732296|NCT01737983|EXPERIMENTAL|Lactobacillus reuteri (LR) ATCC55730|The tested probiotic, Lactobacillus reuteri, was administered in 5 drops per day (10\^10 colony-forming units) for 6 months
62732297|NCT01737983|PLACEBO_COMPARATOR|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation for 6 months During the test period, patients were not allowed to consume any other product that contained probiotics or prebiotics
62732298|NCT05094063|EXPERIMENTAL|experimental group|Training will be given to the patients in the experimental group.
62732299|NCT05094063|NO_INTERVENTION|control group|untrained patient group
62732300|NCT03621072|OTHER|Reference|Fluconazole 150mg Capsule Originator
62732301|NCT03621072|EXPERIMENTAL|Experimental|Fluconazole 150mg Capsule Localized Originator
62732302|NCT02782351|EXPERIMENTAL|CAR-T|In interventional studies, patients enrolled will receive autologous 2nd generation CAR-T cells, which contain a humanized single chain antibody sequence against CD19.
62732303|NCT05989672|EXPERIMENTAL|HSVTI_F1 group|HSV-2 seronegative participants randomized in this group will receive 2 doses of HSVTI Formulation 1 of the study intervention at Day 1 and Day 29.
62732304|NCT05989672|EXPERIMENTAL|HSVTI_F2 group|HSV-2 seronegative participants randomized in this group will receive 2 doses of HSVTI Formulation 2 of the study intervention at Day 1 and Day 29.
62732305|NCT05989672|PLACEBO_COMPARATOR|Placebo group|HSV-2 seronegative participants randomized in this group will receive 2 doses of placebo as control at Day 1 and Day 29.
62732306|NCT03233139|EXPERIMENTAL|Cemiplimab|Part 1
62732307|NCT03233139|EXPERIMENTAL|Cohort A|Part 2
62732308|NCT03233139|EXPERIMENTAL|Cohort B|Part 2
62732309|NCT03233139|EXPERIMENTAL|Cohort C|Part 2
62732310|NCT03233139|EXPERIMENTAL|Cohort D|Part 2
62732311|NCT03233139|EXPERIMENTAL|Cohort E|Part 2
62732312|NCT05497739|EXPERIMENTAL|Intraperitoneal chemotherapy group|In this study, patients with positive peritoneal lavage fluid cancer cell DNA will be given intraperitoneal chemotherapy followed by adjuvant systemic chemotherapy.
62732313|NCT06237712|ACTIVE_COMPARATOR|Sodium chloride|40 mmol of oral sodium chloride daily for 5 days
62732314|NCT06237712|ACTIVE_COMPARATOR|Sodium bicarbonate|40 mmol of oral sodium bicarbonate daily for 5 days
62732315|NCT06237712|ACTIVE_COMPARATOR|Potassium chloride|40 mmol of oral potassium chloride daily for 5 days
62732316|NCT06237712|ACTIVE_COMPARATOR|Potassium bicarbonate|40 mmol of oral potassium bicarbonate daily for 5 days
62732317|NCT06237712|ACTIVE_COMPARATOR|Potassium gluconate|40 mmol of oral potassium gluconate daily for 5 days
62732318|NCT06237712|PLACEBO_COMPARATOR|Placebo|
62732319|NCT01496053|ACTIVE_COMPARATOR|AndoSan|AndoSan given to IBD patients
62732320|NCT01496053|SHAM_COMPARATOR|Sugar extract|Sugar extract to IBD patients
62732321|NCT01680354|ACTIVE_COMPARATOR|ReLEx|One eye is treated with ReLEx the other with LASIK
62732322|NCT01680354|ACTIVE_COMPARATOR|LASIK|One eye is treated with ReLEx the other with LASIK
62732323|NCT04575545||HIV positive patients|
62732324|NCT04575545||Patients taking PrEP|
62732325|NCT03840044|OTHER|Healthy volunteers|Healthy volunteers will perform the same protocol as foreseen for asthmatic patients. Both will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
62732326|NCT03840044|OTHER|Asthmatic subjects|Asthmatic patients will perform the same protocol as foreseen for healthy volunteers. They will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
62732327|NCT06006715||DanFunD baseline|The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).
62732328|NCT06006715||DanFunD 5-years follow-up investigation|The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).
62732329|NCT04189302|EXPERIMENTAL|palatal connective tissue graft harvest with KPM blade|palatal connective tissue graft is harvested using single incision technique using KPM blade
62732330|NCT04189302|ACTIVE_COMPARATOR|palatal connective tissue graft harvest with 15C blade|palatal connective tissue graft is harvested using single incision technique using 15 C blade
62732331|NCT04965792||HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients|Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.
62732332|NCT05400850|EXPERIMENTAL|YOGA|sEMG values will record during different 5 YOGA Asana's
62732333|NCT05088434|ACTIVE_COMPARATOR|donor FMT|Fresh stool samples were obtained immediately from close family member (donor) before being re-transplanted into the patient through a gastroscope.
62732334|NCT05088434|ACTIVE_COMPARATOR|ACHIM|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
62732335|NCT05088434|PLACEBO_COMPARATOR|Placebo|Fresh stool samples were obtained from the patients themselves immediately before transplantation and re-transplanted through a gastroscope.
62732336|NCT00742222|OTHER|single arm, treatment with FDA cleared technology|Patients who have early stage breast cancer, and are candidate for intracavitary accelerated partial breast irradiation may be considered for this study.
62732337|NCT04625400|EXPERIMENTAL|post intubation tracheal stenosis patients|all ICU patients who were mechanically ventilated will be assessed for the possibility of presence of tracheal stenosis using spirometery and dyspnea will be assessed using (mMRC) score, chest X-ray to assess the location of tracheal stenosis and finally flexible bronchoscopy to confirm the presence of stenosis and identify the proper management.
62732338|NCT02337101|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Clinical psychiatric and neurological assessment. Information and advice.
62732339|NCT02337101|EXPERIMENTAL|EUC + Early intervention programme|Clinical psychiatric and neurological assessment. Information and advice. Individually targeted treatment programme.
62732340|NCT01883622||Type 1 diabetes|Pregnant women affected by type 1 diabetes mellitus
62732341|NCT01883622||GDM|Pregnant women affected by gestational diabetes mellitus
62732342|NCT01883622||Healthy|Healthy pregnant women
62732343|NCT00135330|EXPERIMENTAL|Exenatide Arm|
62732344|NCT00135330|EXPERIMENTAL|Exenatide plus Rosiglitazone Arm|
62732345|NCT00135330|EXPERIMENTAL|Rosiglitazone Arm|
62732346|NCT04777006|EXPERIMENTAL|Cluster 1 (First Cluster of Clinics Randomized to Receive Care)|Arm 1 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 3 of the trial
62732347|NCT04777006|EXPERIMENTAL|Cluster 2 (Second Cluster of Clinics Randomized to Receive Care)|Arm 2 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 6 of the trial
62732348|NCT04777006|EXPERIMENTAL|Cluster 3 (Third Cluster of Clinics Randomized to Receive Care)|Arm 3 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 9 of the trial
62732349|NCT04777006|EXPERIMENTAL|Cluster 4 (Fourth Cluster of Clinics Randomized to Receive Care)|Arm 4 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 12 of the trial
62732350|NCT04777006|EXPERIMENTAL|Cluster 5 (Fifth Cluster of Clinics Randomized to Receive Care)|Arm 5 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 15 of the trial
62732351|NCT03169868|EXPERIMENTAL|Enhanced Medication reconciliation|Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
62732352|NCT03169868|NO_INTERVENTION|Standard Medication reconciliation|Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only
62732353|NCT04346186||Hospital Staff in the Capital Region of Denmark|
62732354|NCT04346186||Healthy volunteer blood donors|
62732355|NCT05559905|EXPERIMENTAL|Panel A: Molnupiravir Prophylaxis|Participants received molnupiravir 800 mg every 12 hours for 5 days beginning on Day -1, and are inoculated with RSV-A Memphis 37b on Day 0. Participants switch to placebo beginning on the evening of Day 4 to the morning of Day 10.
62732356|NCT05559905|EXPERIMENTAL|Panel B: Molnupiravir Triggered Treatment|Participants received placebo on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue to receive placebo until testing positive for RSV. Participants then received 800 mg of molnupiravir every 12 hours for 5 days.
62732357|NCT05559905|PLACEBO_COMPARATOR|Panel C: Matched Placebo|Participants received placebo beginning on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue receiving placebo until the morning of Day 10.
62732358|NCT06417827|EXPERIMENTAL|SP patients-actors|"The actors (n=10) will be trained in one of 5 scenarios: depression, anxiety, PTSD with cannabis abuse, psychosis, and control patients with no diagnosis. Each scenario will have 2 levels of severity.~The actors will present demographic and medical backgrounds, symptoms and signs, including disorders of thought and affect. based on the interview, the AI (LIV) will present a differential diagnosis and treatment plan. Immediately afterward, the actors will be interviewed by a board-certified psychiatrist, who will also give a differential diagnosis and a treatment plan."
62732359|NCT06417827|EXPERIMENTAL|Patients|The patients (n=150) will be recruited for the study from patients who applied to the psychiatric clinic in Sheba, new patients, old patients and patients on the waiting list. In addition, patients from the various psychiatric departments and the psychiatric and general ER at the Sheba Medical Center - Tel Hashomer. In addition, a recruitment ad will be published on social networks.
62732360|NCT06417827|OTHER|Control group- patients|Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history. They will be offered to participate in the study and be examined by the AI (LIV) and a psychiatrist while waiting for the ER physician. In addition, a recruitment ad will be published on social networks for patient with no psychiatric conditions.
62732361|NCT00818402||Non-small cell lung cancer patients|
62732362|NCT01302626||1: Surgery alone or combined with (chemo)radiotherapy|"* Fresh frozen tumor tissue and normal tissue;~* Recording of clinical characteristics, imaging, surgery features.~After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery"
62732363|NCT01302626||2: Radiotherapy alone|"(including stereotactic radiotherapy)~* Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~* Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features;~* Day 8-12 (during RT): Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
62732364|NCT01302626||3: Sequential chemotherapy and radiotherapy|"* Day -30 (before start CT):~  * Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~ * Recording of clinical characteristics, imaging, and chemotherapy features.~* Day 0 (before start RT):~  * Recording of clinical characteristics, imaging, and radiotherapy features.~ * Scoring of toxicity.~* Day 8-12 (during RT):~  * Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
62732365|NCT01302626||4: Concurrent chemoradiotherapy with induction chemotherapy|"* Day -30 until-18 (before start CT):~  * Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~ * Recording of clinical characteristics, imaging, and chemotherapy features.~* Day 0 (before start RT):~  * Recording of clinical characteristics, imaging, and radiotherapy features.~ * Scoring of toxicity.~* Day 8-12 (during RT):~  * Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
62732366|NCT01302626||5: Concurrent chemoradiotherapy without induction chemotherapy|"* Day 0 (before start CRT):~  * Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~ * Recording of clinical characteristics, imaging, chemotherapy features, and radiotherapy features.~* Day 8-12 (during CRT):~  * Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
62732367|NCT01302626||6: Stage IV lungcancer, any systemic therapy & supportive care|"Day 0:~* Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~* Recording of clinical characteristics, imaging, surgery or any systemic (MoAb) features.~After treatment: FU at 2-3 weeks post treatment, 3,6,12,24 and 36 months post-treatment"
62732368|NCT04077489|OTHER|MT|Macular thickness
62732369|NCT01814865|EXPERIMENTAL|Abiraterone Acetate + Prednisone|Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
62732370|NCT01814865|ACTIVE_COMPARATOR|Aromatase Inhibitor|Anastrozole 1mg PO OD x 2 weeks
62732371|NCT04685980||Failed spinal anaesthesia group|Failed spinal anaesthesia: failure of anaesthetic level of blockade both sensory and motor blockage, and consequently receive general anaesthesia
62732372|NCT04685980||Control Group|Patient receiving spinal anaesthesia and successfully finish the cesarean section
62732373|NCT05948904|EXPERIMENTAL|Ex Vivo Cryo|Multiple procedures will be performed to each model in order to accomplish the objectives of the study. Tissue samples will be taken from the models and images will be performed. This will allow us to determine which configuration is the optimal for obtaining the more effective and stable models that could offer the best quality specimens as well.
62732374|NCT00130104|EXPERIMENTAL|MCB|randomized to receive the metacarpal block for anesthesia
62732375|NCT03882437|EXPERIMENTAL|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of three dose levels depending on the cohort.
62732376|NCT05971992|EXPERIMENTAL|Prebiotic|Adult women and men (N = 35) with mild psoriasis (Psoriasis Area and Severity Index; PASI \< 10) will receive 15g of prebiotic (chicory-derived inulin-type β-fructans) daily for 8 weeks
62732377|NCT05971992|PLACEBO_COMPARATOR|Placebo|Adult women and men (N = 35) with mild psoriasis (Psoriasis Area and Severity Index; PASI \< 10) will receive 15g of placebo (maltodextrin) daily for 8 weeks
62732378|NCT05971992|NO_INTERVENTION|Control|Healthy adult women and men (N = 30) will not receive any dietary intervention
62732379|NCT00245453|ACTIVE_COMPARATOR|1 Azithromycin|
62732380|NCT00245453|ACTIVE_COMPARATOR|2 Clarythromycin|
62732381|NCT00245453|ACTIVE_COMPARATOR|3 Telithromycin|
62732382|NCT03138551|EXPERIMENTAL|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.~A: Baseline - typical mealtimes in the home.~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
62732383|NCT05648877|EXPERIMENTAL|43 semirigid ureteropyeloscopy|43 Patients underwent semirigid ureteropyeloscopy
62732384|NCT05648877|ACTIVE_COMPARATOR|34 flexible ureteropyeloscopy|34 patients with flexible ureteropyeloscopy
62732385|NCT05156437|EXPERIMENTAL|Group I (Experimental)|Two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of oral therapy with outpatient follow-up.
62732386|NCT05156437|ACTIVE_COMPARATOR|Group II (Control Group)|Conventional two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of IV antibiotic therapy (inpatient or facility supervised if indwelling catheter utilized).
62732387|NCT02641756|EXPERIMENTAL|Study Population|"This is a single arm study. The investigators will include 10 HIV positive patients under chronic CART (combined antiretroviral therapy).~The intervention will consist on treatment interruption after in depth sampling under CART"
62732388|NCT04548700|EXPERIMENTAL|Dose-finding and dose-expansion|"Dose-finding stage: Patients with treatment-naïve PTCL will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 12 mg/m2.~Dose-expansion stage: Patients with treatment-naïve PTCL will receive liposomal mitoxantrone hydrochloride at RP2D in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 or 21 days per cycle)."
62732389|NCT03235453|EXPERIMENTAL|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
62732390|NCT03235453|EXPERIMENTAL|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
62732391|NCT03075280|EXPERIMENTAL|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
62732392|NCT03075280|NO_INTERVENTION|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
62732393|NCT01624961|EXPERIMENTAL|50 PfSPZ IV|PfSPZ Challenge
62732394|NCT01624961|EXPERIMENTAL|200 PfSPZ IV|PfSPZ Challenge
62732395|NCT01624961|EXPERIMENTAL|800 PfSPZ IV|PfSPZ Challenge
62732396|NCT01624961|EXPERIMENTAL|3200 PfSPZ IV|PfSPZ Challenge
62732397|NCT01624961|EXPERIMENTAL|2500 PfSPZ ID|PfSPZ Challenge
62732398|NCT03556670|EXPERIMENTAL|Total Worker Health Intervention|
62732399|NCT03556670|ACTIVE_COMPARATOR|Control|
62732400|NCT02924259|EXPERIMENTAL|Foam Roll Group|Subjects will undergo a 2-minute video-guided foam roll intervention on the left quadriceps muscle using the GRID foam roll.
62732401|NCT02951234|EXPERIMENTAL|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
62732402|NCT02951234|ACTIVE_COMPARATOR|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
62732403|NCT04805476|EXPERIMENTAL|Non invasive mechanical ventilation|The subjects in the immediate intervention group (GI) will be extubated and placed in NIV the moment they enter the recovery room through a portable ventilator (Esprit ® or BiPAP Vision ®, Respironics) in face mask. The parameters will be adjusted as follows: FiO2 = 50%, positive expiratory pressure (EPAP, starting at 4-6 cmH2O and adjusting 1-2 cmH2O to avoid snoring, apnea, paradoxical breathing and desaturations) and adjusted inspiratory positive pressure (IPAP) to maintain a tidal volume of 400 to 500 ml, maintaining IPAP \<15cmH2O17. Individuals will receive this ventilatory support for 1 hour. After this period the patients will be submitted to the same care of GP patients.
62732404|NCT04805476|ACTIVE_COMPARATOR|Usual care|Subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to the team routine and patient need.
61978404|NCT04576832|EXPERIMENTAL|Group A (MT group)|Participants will receive 4 weeks of mindfulness training during the first training interval between the first (T1) and second (T2) assessment sessions.
62737181|NCT06175598||Incomplete Resection of Affected Intestinal Segments (IRAIS)|
62732405|NCT02676648|EXPERIMENTAL|Experimental: Condition 1|1) core program; 2) breath meter; 3) text messages; 4) diet-appropriate food and cookbooks
62732406|NCT02676648|EXPERIMENTAL|Experimental: Condition 2|1) core program
62732407|NCT02676648|EXPERIMENTAL|Experimental: Condition 3|1) core program; 2) breath meter
62732408|NCT02676648|EXPERIMENTAL|Experimental: Condition 4|1) core program; 2) text messages
62732409|NCT02676648|EXPERIMENTAL|Experimental: Condition 5|1) core program; 2) diet-appropriate food and cookbooks
62732410|NCT02676648|EXPERIMENTAL|Experimental: Condition 6|1) core program; 2) breath meter; 3) text messages
62732411|NCT02676648|EXPERIMENTAL|Experimental: Condition 7|1) core program; 2) breath meter; 3) diet-appropriate food and cookbooks
62732412|NCT02676648|EXPERIMENTAL|Experimental: Condition 8|1) core program; 3) text messages; 4) diet-appropriate food and cookbooks
62732413|NCT02075294||youth|"\<45years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
62732414|NCT02075294||middle age|"≥45years and\<65years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
62732415|NCT02075294||elderly|"≥65 years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
62732416|NCT00293228|EXPERIMENTAL|A|Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
62732417|NCT00293228|ACTIVE_COMPARATOR|B|B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
62732418|NCT00293228|EXPERIMENTAL|C|C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
62732419|NCT00293228|ACTIVE_COMPARATOR|D|D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
62732420|NCT05079802|EXPERIMENTAL|Group 1|study group
62732421|NCT05079802|OTHER|Group 2|control group
62732422|NCT02748252||HIV patients|HIV patients admitted in Stroke units for the first occurence of acute stroke
62732423|NCT02748252||non HIV patients|non HIV patients admitted in Stroke units for the first occurence of acute stroke
62732424|NCT03520296||Patients hospitalized in the cardiology unit|
62732425|NCT03520296||Patients hospitalized in the orthopedic surgery unit|
62732426|NCT03520296||Patients hospitalized in the endocrinology unit|
62732427|NCT02044224|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine infusion during anaesthesia for IRE procedure
62732428|NCT04317339|EXPERIMENTAL|Zhigancao Tang granule group|Participants in experimental group will receive Zhigancao Tang granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters, diuretics as needed.
62732429|NCT04317339|PLACEBO_COMPARATOR|Zhigancao Tang placebo group|Participants in experimental group will receive Zhigancao Tang placebo granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
62732430|NCT05096975||Control group|"ADHD without emotion dysregulation (Control group) The group is composed of children with ADHD and with a score ≤ 180 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
62732431|NCT05096975||Deficit Emotion Self Regulation group|"ADHD without moderate emotion dysregulation (Deficit Emotion Self Regulation group) The group is composed of children with ADHD and with a score ≥180 and ≤ 210 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
62732432|NCT05096975||Dysregulation Profile Group|"ADHD with severe emotion dysregulation (Dysregulation Profile Group) The group is composed of children with ADHD and with a score ≥ 210 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
62732433|NCT00272831|ACTIVE_COMPARATOR|Cilostazol|Cilostazol 100 mg twice daily
62732434|NCT00272831|PLACEBO_COMPARATOR|Placebo|
62732435|NCT05695040|EXPERIMENTAL|dietary workshop conducted on the 15th postoperative day|
62732436|NCT05695040|NO_INTERVENTION|Standard care|
62732437|NCT00778076|ACTIVE_COMPARATOR|HAG|Patients that will receive a Hyaluronic acid treatment course consisting of 3 consecutive injections one week apart.
62732438|NCT00778076|PLACEBO_COMPARATOR|PG|Those patients that receive 3 consecutive placebo injections one week apart.
62732439|NCT03582046|NO_INTERVENTION|Monitoring Group|Patients that sustain intra-abdominal pressure of \< 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
62732440|NCT03582046|ACTIVE_COMPARATOR|Mean Arterial Pressure (MAP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
62732441|NCT03582046|EXPERIMENTAL|Abdominal Perfusion Pressure (APP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
62732442|NCT02231398||Women who participated in nuMoM2b|
62732443|NCT03398941|EXPERIMENTAL|Combined group|
62732444|NCT03226249|EXPERIMENTAL|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
62732445|NCT02882438|ACTIVE_COMPARATOR|Infected group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
62732446|NCT02882438|PLACEBO_COMPARATOR|Control group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
62732447|NCT00122616|ACTIVE_COMPARATOR|Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy|Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
62732448|NCT00122616|PLACEBO_COMPARATOR|HIV antiretroviral therapy|Day0 to week 96: HIV antiretroviral therapy
62732449|NCT04239261|ACTIVE_COMPARATOR|Nutritional therapy|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
62732450|NCT04239261|PLACEBO_COMPARATOR|Placebo|Hydrolyzed gelatin 10.0 grams once daily
62732451|NCT03098433|EXPERIMENTAL|Liothyronine|Each participant will receive a single dose of lithyronine
62732452|NCT03098433|ACTIVE_COMPARATOR|Levothyroxine|Each participant will receive a single dose of levothyroxine
62732453|NCT03098433|PLACEBO_COMPARATOR|Placebo|Each participant will receive a single dose of placebo
62732454|NCT02649920|EXPERIMENTAL|Cervical ripening balloon|Prospective
62732455|NCT02649920|ACTIVE_COMPARATOR|Dinoprostone|Retrospective
62732456|NCT04945473|EXPERIMENTAL|Revision|"BMI≥30 or total weight loss (TBWL) \< 10% and relaxation of gastric tubulisation at 6 months after ESG.~Additional stitches will be placed during the follow-up gastroscopy at 6 months."
62732457|NCT04945473|NO_INTERVENTION|Without revision|The control gastroscopy will be performed without any additional procedure (no additional stitches).
62732458|NCT02788032|OTHER|EnergieShake Intervention|Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
62732459|NCT01390298||Observational|Adult patients scheduled for elective unicompartmental or total knee replacement surgery or total hip replacement will be consented to participate
62732460|NCT04741841|PLACEBO_COMPARATOR|Placebo|The placebo product is identical to active product in taste and appearance but without probiotic
62732461|NCT04741841|ACTIVE_COMPARATOR|Treatment high dose|High dose GutMagnific™
62732462|NCT04741841|ACTIVE_COMPARATOR|Treatment low dose|Low dose GutMagnific™
62732463|NCT04738994|EXPERIMENTAL|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
62732464|NCT04738994|ACTIVE_COMPARATOR|Control group|Standard hospital diet
62732465|NCT03715140|EXPERIMENTAL|Patients who will recieve crucumin|patients who prescribing crucumin 80 mg daily for three months will be evaluated. A sample will be taken before taking the drug.
62732466|NCT03715140|PLACEBO_COMPARATOR|Patients who will receive placebo|Patients who prescribing placebo daily for three months will be evaluated. A sample will be taken before taking the placebo.
62732467|NCT03748706|EXPERIMENTAL|Simufilam (PTI-125)|Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)
62732468|NCT02680938|ACTIVE_COMPARATOR|oxytocin group|10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
62732469|NCT02680938|PLACEBO_COMPARATOR|control group|1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
62732470|NCT05205616|PLACEBO_COMPARATOR|Reciprocating saw|The traditional surgical instrument used for cutting bilateral sagittal split osteotomies
62732471|NCT05205616|ACTIVE_COMPARATOR|Sonopet ultrasonic saw|This instrument is being compared to the reciprocating saw
62732472|NCT03441022|EXPERIMENTAL|Cardioversion|Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.
62732473|NCT00566553|ACTIVE_COMPARATOR|Grape Seed Extract # 1|200 mg \[1 pill\]
62732474|NCT00566553|ACTIVE_COMPARATOR|Grape Seed Extract # 2|200 mg \[2 pills\]
62732475|NCT00566553|ACTIVE_COMPARATOR|Grape Seed Extract # 3|200 mg \[3 pills\]
62732476|NCT00566553|ACTIVE_COMPARATOR|Grape Seed Extract # 4|200 mg \[4 pills\]
62732477|NCT04830306|ACTIVE_COMPARATOR|6MST|Six minute step test
62732478|NCT04830306|ACTIVE_COMPARATOR|6MWT|Six minute walk test
62732479|NCT04830306|ACTIVE_COMPARATOR|CPET|Cardiopulmonary exercise test
62732480|NCT03763695||Retrospective control group|Patients admitted in our PICU before the implementation of the protocol for VAP prevention (from 01/01/2016 to 12/31/2017)
62732481|NCT03763695||Prospective group|Patients admitted to our PICU since the VAP bundle has been introduced in the clinical practice (from 01/01/2018)
62732482|NCT03587428|EXPERIMENTAL|Zinc-A toothpaste|In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
62732483|NCT03587428|EXPERIMENTAL|Zinc-B toothpaste|In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
62732484|NCT03587428|OTHER|Mineral Water|In this arm, participants received mineral water.
62732485|NCT06514274|EXPERIMENTAL|Berberine-containing triple therapy|vonoprazan 20 mg , amoxicillin 1000 mg , and berberine 500 mg by mouth,twice daily for 14 days.
62732486|NCT06514274|ACTIVE_COMPARATOR|Bismuth-containing quadruple therapy|Bismuth potassium citrate 220 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
62732487|NCT06188598|EXPERIMENTAL|Time-restricted eating (TRE)|Participants in the TRE group are instructed to restrict eating to an 8-hr window but were not asked to change the type or amount of food typically consumed. The 8-hour window (e.g., 10am - 6pm) has to be the same each day starting at least 2 hours after wake and ending at least 2 hours before bed.
62732488|NCT06188598|NO_INTERVENTION|Unrestricted eating|Participants are instructed to continue their diet as normal without changing the type, amount or timing of food typically consumed.
62732489|NCT04217707|OTHER|Pre- and Post-Surgical Transgender Therapeutic Support Groups|
62732490|NCT00369850|EXPERIMENTAL|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomisation.
62732491|NCT00369850|EXPERIMENTAL|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomisation.
62732492|NCT00369850|EXPERIMENTAL|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
62732493|NCT00369850|EXPERIMENTAL|Letrozole 2 years plus tamoxifen 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
62732494|NCT01220401|EXPERIMENTAL|ERRT-M|Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
62732495|NCT06064006|EXPERIMENTAL|NNC0487-0111|Participants will be randomized to receive NNC0487-0111. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD)
62732496|NCT06064006|PLACEBO_COMPARATOR|Placebo|Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B,C,D and E: Multiple ascending dose (MAD).
62737182|NCT00810771|EXPERIMENTAL|Preference-tailored (PT) intervention|"Intervention:~Behavioral: Standard Information Behavioral: Preference-tailored Information"
62732497|NCT02370368|EXPERIMENTAL|Dance Group|"Training: participants will engage in dance training with the Xbox Kinect 360 using the Just Dance 2014 disc.~Duration : 45 minutes per session. Frequency: three times per week for six weeks."
62732498|NCT02370368|ACTIVE_COMPARATOR|Ladder Drills|Intervention: Agility ladder drill training. Duration: 45 minutes per session. Frequency: three times per week for six weeks
62732499|NCT04729153||Chronic HCV patients previously treated by DAADs.|
62732500|NCT04729153||Chronic HCV patients not treated by DAADs yet.|
62732501|NCT02104531||Shoulder Pain|No intervention. Subjects will have a standard static MRI taken of their shoulder, and also complete a series of shoulder motions using video fluoroscopy.
62732502|NCT02104531||Healthy Subjects|No intervention. Subjects will receive a standard shoulder MRI and perform shoulder motions while being measured with video fluoroscopy.
62732503|NCT02777450||Block group|Lumbar facet block. Levobupivacaine 0,25% and corticosteroids
62732504|NCT02382731|NO_INTERVENTION|Usual care|Usual care (no intervention)
62732505|NCT02382731|EXPERIMENTAL|Usual care + letters|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians)
62732506|NCT02382731|EXPERIMENTAL|Usual care + letters + automated calls|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians), plus automated reminder interactive voice response phone calls to identify patients at being at risk for non-adherence and a trained lay health worker to provide additional support and navigation for such patients via telephone.
62732507|NCT06554561|EXPERIMENTAL|PRM treatment|Experimental arm will be treated with PRM regimen (pomadomide in combination with rituximab and methotrexate) for 4 cycles as initiate induction. If the patients achieved complete remission（CR）or partial remission（PR）, They would be consolidated by autologous transplantation consolidation regimen or the original regimen for additional 2 courses, and then were given pomadomide maintenance therapy for 12 cycles.
62732508|NCT04177615|EXPERIMENTAL|Thromboectomy and rTPA|use thromboectomy and rtpa for patient with basilar artery occlusion stroke in 24 hour
62732509|NCT04177615|NO_INTERVENTION|rTPA( recombinant tissue plasminogen activator )|use rtpa for patient with basilar artery occlusion stroke in 24 hour
62732510|NCT06287541|EXPERIMENTAL|Urine biomarker -Guided without reTURBT|Participants in this arm will proceed without reTURBT.
62732511|NCT06287541|NO_INTERVENTION|Standard Care with reTURBT|Participants in this arm will receive standard care, which undergo reTURBT
62732512|NCT03012191|EXPERIMENTAL|Gentamicin|Topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
62732513|NCT01925768|EXPERIMENTAL|Apremilast 30 mg|30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.
62732514|NCT01925768|PLACEBO_COMPARATOR|Placebo|Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is \<10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.
62732515|NCT05711875|EXPERIMENTAL|Virtual Reality Glasses|Virtual Reality (VR) glasses applied group
62732516|NCT05711875|NO_INTERVENTION|Standard of care|group without Virtual Reality (VR) glasses
62732517|NCT03757624|ACTIVE_COMPARATOR|Gastric specimen measurements after 24 hours from % 10 formol|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after formol solution
62732518|NCT03757624|ACTIVE_COMPARATOR|Gastric specimen measurements after surgery in operating room|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after surgery in operating room peroperatively
62732519|NCT02000024|EXPERIMENTAL|Lifestyle coaching|The existing Weight Watchers lifestyle modification program including the online support tools.
62732520|NCT02000024|ACTIVE_COMPARATOR|Lifestyle counseling|Brief advice regarding risk factors and strategies to reduce them by lifestyle modification guided by National Diabetes Education Program (NDEP) materials.
62732521|NCT04490213||hydrofibre, Aquacel|Study participants were previously treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
62732522|NCT04490213||polyurethane foam, Allevyn|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
62732523|NCT04490213||porcine xenograft, Mediskin|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
62732524|NCT06121076|EXPERIMENTAL|SDM-EBP training|the group received SDM combined with EBP training
62732525|NCT06121076|OTHER|control|the group received received SDM without EBP training
62732526|NCT03760198|EXPERIMENTAL|botulinum toxin type A|
62732527|NCT03760198|PLACEBO_COMPARATOR|Placebo|
62732528|NCT03173989|EXPERIMENTAL|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
62732529|NCT03173989|ACTIVE_COMPARATOR|Orientation|Patients received orientation for home.
62737183|NCT00810771|ACTIVE_COMPARATOR|Standard information (SI) intervention|Behavioral: Standard Information
62732530|NCT04833660|EXPERIMENTAL|rTMS group|"Each patient will receive five consecutive sessions (Monday to Friday for 1 week).~Patients in the rTMS group will administer rTMS over the optimal scalp site at 10 Hz, with an intensity of 90% of the MT and a duration of 5 seconds, for a total of 20 trains separated by 55-second intertrain pauses (a total of 1,000 pulses). The coil will be placed tangentially to the scalp at an approximate angle of 45° tilted backward and laterally. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods."
62732531|NCT04833660|SHAM_COMPARATOR|sham group|Patients in the sham group will administer sham stimulation using the same protocol, except that the angle of the coil is 90° (i.e., perpendicular, rather than tangential) to the skull. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods.
62732532|NCT03936907|EXPERIMENTAL|Orally Disintegrating MGC-ODT Tablet|Administration of a single tablet of Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5mg THC and 5 mg CBD
62732533|NCT03936907|ACTIVE_COMPARATOR|Sativex®|Sativex® spray X 2 actuations (1 under the tongue and 1 inside the cheek administered within 2 min) - Reference Product \[Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 5.4 mg THC and 5.0 mg CBD\]
62732534|NCT05737823|EXPERIMENTAL|Carers-ID online support programme|Participants in this arm will receive access to the Carers-ID online programme. Participants will be able to access the online programme for 2 weeks.
62732535|NCT05737823|OTHER|Wait-list Control|Wait-list control arm
62732536|NCT02053922|ACTIVE_COMPARATOR|Syntocinon|Drug is given just after delivery of the neonate during cesarean section.
62732537|NCT02053922|ACTIVE_COMPARATOR|Carbetocin|Drug is given just after delivery of the neonate during cesarean section.
62732538|NCT02053922|ACTIVE_COMPARATOR|Misoprostol|Drug is given just after delivery of the neonate during cesarean section.
62732539|NCT02277249|OTHER|Transvaginal digoxin|Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
62732540|NCT02277249|OTHER|Transabdominal digoxin|Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
62732541|NCT02536716|ACTIVE_COMPARATOR|Platform-matched dental implant|Platform-matched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
62732542|NCT02536716|EXPERIMENTAL|Platform-switched dental implant|Platform-switched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
62732543|NCT04206631|PLACEBO_COMPARATOR|Doxycycline Group|Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
62732544|NCT04206631|ACTIVE_COMPARATOR|Comedone Extraction Group|Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.
62732545|NCT03577327||Adults with vitiligo|
62732546|NCT03577327||Healthy adults|
62732547|NCT00282087|OTHER|gemcitabine/docetaxel then doxorubicin|Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).
62732548|NCT00631124|EXPERIMENTAL|Arm 1|
62732549|NCT00631124|EXPERIMENTAL|Arm 2|
62732550|NCT05711706|EXPERIMENTAL|Su Jok Application|"I. Interview: One Day Before Surgery:~II. Interview: Post-Surgery - After Transfer to the Clinic III. Interview: Postoperative Day 1 IV. Interview: Postoperative Day 2 V. Interview (Post-Operative Day 10"
62732551|NCT05711706|NO_INTERVENTION|Standard care|"I. Interview: One Day Before Surgery:~II. Interview: Post-Surgery - After Transfer to the Clinic III. Interview: Postoperative Day 1 IV. Interview: Postoperative Day 2 V. Interview (Post-Operative Day 10"
62732552|NCT05034042|EXPERIMENTAL|Fezolinetant: low dose (15 mg)|Participants will receive low dose of fezolinetant once daily for 12 weeks.
62732553|NCT05034042|EXPERIMENTAL|Fezolinetant: high dose (30 mg)|Participants will receive high dose of fezolinetant once daily for 12 weeks.
62732554|NCT05034042|PLACEBO_COMPARATOR|Placebo|Participants will receive matching placebo once daily for 12 weeks.
62732555|NCT01055717|PLACEBO_COMPARATOR|Placebo muffin made with no oats|
62732556|NCT01055717|ACTIVE_COMPARATOR|Test muffin made with AV-enriched oats|
62732557|NCT02674464|ACTIVE_COMPARATOR|Standard of Care Plus|The standard of care plus arm will include audit and feedback of blood pressure control rates at the provider level along with web-based training about: 1) barriers to blood pressure and cardiovascular disease (CVD) risk factors management in at-risk patient populations; 2) strategies to address healthcare disparities in clinical settings; and 3) appropriate blood pressure (BP) measurement techniques for all clinical staff. The Hopkins research team will help clinics develop audit and feedback mechanisms if they are lacking and will provide all blood pressure measurement and web-based training.
62732558|NCT02674464|EXPERIMENTAL|Collaborative Care/Stepped Care (CC/SC)|The CC/SC arm includes: -BP training -Audit and feedback dashboard, data stratified by race, ethnicity, payor status -A 4 hour workshop for organizational leaders in quality improvement and disparities reduction, with follow up meetings for problem-solving and support, and web-based, patient-centered communication skills training program for providers and staff -Support and guidance in establishing collaborative care model (CCM): team-based care targeting health behaviors and medication adherence. The primary care provider (PCP), care manager, CHW, and specialists in: medication management, psychosocial/behavioral, and self-management will make up the CCM team -Community health workers (CHW) working on contextualized patient interactions focused on problem-solving skills and patient self-management. CHWs will visit their patients in their homes and communities -Provider access to on-call specialists for help with patients who do not achieve BP control under the CC/SC
62732559|NCT03027518|OTHER|Group 1|Group 1 will be active in the WILD 5 Wellness program the first 30 days and inactive the 2nd 30 days.
62732560|NCT03027518|OTHER|Group 2|Group 2 will be inactive in the WILD 5 Wellness program the first 30 days and active the 2nd 30 days.
62732561|NCT03147378|EXPERIMENTAL|arm A Fasting-Fed condition|ModraDoc006/r will be administered in fasting condition week 1 and in fed condition week 2
62732562|NCT03147378|EXPERIMENTAL|arm B Fed-Fasting condition|ModraDoc006/r will be administered in fed condition week 1 and in fasting condition week 2
62732563|NCT04248712|EXPERIMENTAL|Treatment Group|Participants receive Famotidine 40 mg tab twice daily by mouth and Loratadine 10 mg tab once daily by mouth for 12 weeks.
62732564|NCT04248712|PLACEBO_COMPARATOR|Placebo Group|Participants receive Famotidine placebo tablet matching Famotidine orally twice daily for 12 weeks, and Loratadine placebo tablet matching Loratadine orally daily for 12 weeks.
62732565|NCT04265248|EXPERIMENTAL|Virtual Reality|"The subjects will use Fulldive VR as the first degree of difficulty where only tilt movements are necessary, for the second degree of difficulty the game VR Ocean Aquarium 3D will be used, where bending, extension and rotation movements will be integrated, also introducing a sensory element to integrate the sound of the sea.~For these patients to perform the same work as group 2, the physiotherapist will have to count and control in each exercise the number of movements that the patient performs so as not to exceed the proposed dose in the active comparator group (3 sets of 10 repetitions of each exercise)."
62732566|NCT04265248|ACTIVE_COMPARATOR|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
62732567|NCT04047368|ACTIVE_COMPARATOR|Rotablation|
62732568|NCT04047368|EXPERIMENTAL|Coronary Lithoplasty|
62732569|NCT05124028|EXPERIMENTAL|Orelabrutinib|Orelabrutinib 50mg po qd 6 weeks
62732570|NCT04644198|ACTIVE_COMPARATOR|Convalescent Plasma Treatment|Convalescent Plasma
62732571|NCT04644198|NO_INTERVENTION|Control|Standard of care
62732572|NCT04294940|OTHER|Group A: standard of care|The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.
62732573|NCT04294940|OTHER|Group B: standard of care + mobile application CardiCare™|The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™
62732574|NCT02079909|EXPERIMENTAL|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
62732575|NCT02079909|EXPERIMENTAL|T-817MA-L|224 mg T-817MA once daily
62732576|NCT02079909|PLACEBO_COMPARATOR|Placebo|Placebo once daily
62732577|NCT01281384|ACTIVE_COMPARATOR|Standard imaging (echocardiography)|Subjects will undergo their clinically indicated echocardiogram as ordered by their attending physician.
62732578|NCT01281384|ACTIVE_COMPARATOR|Advanced Imaging (Cardiac MRI)|Subjects will undergo their clinically indicated echo as ordered by their attending physician, plus a cardiac MRI, which will be scheduled within 14 days of the echo.
62732579|NCT02113423|EXPERIMENTAL|recurrent T1-2 NPC,no treatment|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
62732580|NCT06467071|EXPERIMENTAL|Self Help Plus (SH+) combined with a session for Post Migration Living Difficulties (PMLD)|The intervention integrates Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. Participants will be randomly assigned to the SH+ combined with the PMLD session (n = 105). The participants in the experimental arm will receive SH+ combined with the PMLD session, by non-specialist facilitators.
62732581|NCT06467071|NO_INTERVENTION|Treatment-As-Usual (TAU)|105 participants will be randomly allocated to the Treatment as Usual (TAU) group. Mental health services for asylum seekers in Turkey are provided by the Ministry of Health and different non-governmental organizations. These services include psychosocial support, counseling, mental health screenings, and psychotherapy (AIDA, 2020). As usual, treatment includes usual mental health support and assessment following the standard procedures of the Refugees Association Mental Health Unit.
62732582|NCT01420224||Healthy volunteers|
62732583|NCT01420224||Chuvash polycythaemia|
62732584|NCT02782234|NO_INTERVENTION|not contract management|monthly follow-up phone or family visit completed as regulation, and instruct them proper healthy training.
62732585|NCT02782234|EXPERIMENTAL|Contract management|In accordance with the contract content, researchers and participants should manage and maintain the liquid balance of the participants. Signed doctors and nurses should undergo the follow-up phone or family visit on time, instruct them proper healthy training, and provided necessary information data. By telephone, SMS, wechat, remind and urge the participants to take the lifestyle and behavior regulate in the contract. Participants should supervise and manage the fluid unbalance (Edema, hypertension, heart failure, and fluid imbalance of intake and output etc.), and feedback the Management and supervision to researchers according to contract.
62732586|NCT06200168|EXPERIMENTAL|True acupuncture + standard quadruple antiemetic therapy|"Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment."
62732587|NCT06200168|PLACEBO_COMPARATOR|Sham acupuncture + standard quadruple antiemetic therapy|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive olanzapine-contained four-drug antiemetic therapy. All the antiemetic drugs used are the same as those in the true acupuncture group."
62732588|NCT01225133|ACTIVE_COMPARATOR|Complex Ayurvedic Treatment|In the Āyurveda arm treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
62732589|NCT01225133|ACTIVE_COMPARATOR|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
62732590|NCT01047917|EXPERIMENTAL|Meditation DVD|All participants will receive a Meditation DVD to practice at home daily for a total of 4 weeks.
62732591|NCT03618771|EXPERIMENTAL|Medacta GMK Sphere|Half of the patients will be implanted with the Medacta GMK Sphere total knee arthroplasty
62732592|NCT03618771|EXPERIMENTAL|DePuy Synthes Attune|Half of the patients will be implanted with the DePuy Attune total knee arthroplasty
62732593|NCT00454740|EXPERIMENTAL|1|
62732594|NCT01696799|EXPERIMENTAL|Econazole Nitrate Foam|Investigational Drug Product
62732595|NCT01696799|PLACEBO_COMPARATOR|Vehicle Foam|Vehicle Foam Comparator
62732596|NCT01696799|ACTIVE_COMPARATOR|Econazole Nitrate Cream|Active comparator cream product
62732597|NCT02446769|EXPERIMENTAL|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
62732598|NCT02446769|NO_INTERVENTION|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
62732599|NCT04401150|EXPERIMENTAL|Vitamin C|Vitamin C: 50 mg/kg of weight administered intravenously every 6 hours for 96 hours (16 doses).
62732600|NCT04401150|PLACEBO_COMPARATOR|Control|Normal saline (0.9% NaCl) or dextrose 5% in water (D5W) in a volume to match the vitamin C.
62732601|NCT03102515|OTHER|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
62732602|NCT03102515|OTHER|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
62732603|NCT00394329|EXPERIMENTAL|Daily ICS + Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
62732604|NCT00394329|ACTIVE_COMPARATOR|Daily ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
62732605|NCT00394329|EXPERIMENTAL|Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
62732606|NCT00394329|PLACEBO_COMPARATOR|Placebo|Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
62732607|NCT01315613||Acute pancreatitis|Patients admitted in our institution for an episode of acute pancreatitis
62732608|NCT06123273|EXPERIMENTAL|Intervention group|The intervention group was given an exercise-oriented training
62732609|NCT06123273|NO_INTERVENTION|Control group|The control group was given only routine recommendations
62732610|NCT02689414|EXPERIMENTAL|Remote ischaemic preconditioning|Four episodes of 5 minutes of ischaemia are performed. Between all the episodes there is a 5-minute period of reperfusion.
62732611|NCT02689414|SHAM_COMPARATOR|Control to RIPC|Four episodes of 5 minutes during which the pressure in the cuff is equal to venous pressure are performed. Between all the episodes there is a 5-minute pause.
62732612|NCT03311581|EXPERIMENTAL|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
62732613|NCT03311581|ACTIVE_COMPARATOR|Sevoflurane group|sevoflurane 2\~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
62732614|NCT04069949|EXPERIMENTAL|sorafenib plus toripalimab|"Stage I：Subjects (n=3) in cohort A received oral sorafenib (400 mg qd), in combination with intravenous toripalimab (240 mg d1, q3w). Subjects (n=3) in cohort B received oral sorafenib (400 mg bid) and the administration of toripalimab is consistent with cohort A. If dose-limiting toxicity (DLT) does not occur within 42 days of the first administration, the dose is escalated.~Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39."
62732615|NCT02334072|EXPERIMENTAL|Classical|Laryngeal mask airway (LMA) is manufactured from medical grade silicone rubber and is reusable. It consists of 3 main components: An airway tube, inflatable mask and mask inflation line. The airway tube is slightly curved to match the oropharyngeal anatomy, semirigid to facilitate atraumatic insertion and semitransparent, so that condensation and regurgitated material is visible. The distal aperture of the airway tube opens into the lumen of an inflatable mask and is protected by two flexible vertical rubber bars, called mask aperture bars, to prevent the epiglottis from entering and obstructing the airway. The laryngeal mask classical application will be done following anesthesia induction.
62732616|NCT02334072|EXPERIMENTAL|I-Gel|I-Gel LMA is anatomically designed mask made of a gel-like thermoplastic elastomer. It has a drain tube for gastric aspiration. I-gel laryngeal mask application will be done following anesthesia induction.
62732617|NCT02334072|EXPERIMENTAL|Cobra|Cobra LMA consists of a translucent silicone airway tube with an inflatable cuff sited approximately two-thirds of the way to the tip, a 15-mm standard adapter and an expanded distal end with a smooth posterior surface. The cuff forms a seal in the upper pharynx and the distal end sits in the laryngopharynx. The distal grill is designed to sit over the laryngeal inlet.Cobra laryngeal mask application will be done following induction of anesthesia
62732618|NCT02334072|EXPERIMENTAL|Supreme|The Supreme LMA is a single-use polyvinyl chloride supraglottic device. High oropharyngeal leak pressures are important as they indicate airway protection, feasibility of positive pressure ventilation and likelihood of successful LMA placement.Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia.
62732619|NCT02334072|EXPERIMENTAL|Proseal|The ProSeal LMA is the most complex of the specialized laryngeal mask devices.The primary design goal was to construct a laryngeal mask with improved ventilatory characteristics that also offered protection against regurgitation and gastric insufflation. The principal new features are a modified cuff and a drain tube.Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia.
62732620|NCT01861704|ACTIVE_COMPARATOR|Lyric|Silver Lyric device
62732621|NCT01861704|ACTIVE_COMPARATOR|Lyric2|Lyric2 (Barracuda) device
62732622|NCT02041390|EXPERIMENTAL|SMS group|Patients in SMS group will receive reminding by additional SMS messages monthly after stent implantation.
62732623|NCT02041390|ACTIVE_COMPARATOR|Conventional reminder group|Patients in control group will not receive additional SMS reminder monthly after stent implantation.
62732624|NCT01580709|ACTIVE_COMPARATOR|Multimodality Approach|Patients in the multimodality arm will undergo a single brushing for routine cytology, a second brush sample for Fluorescence In Situ Hybridization and a cholangioscopy with site-directed biopsies for histology.
62732625|NCT01580709|ACTIVE_COMPARATOR|Multiple brush samples|In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
62732626|NCT03125330|EXPERIMENTAL|One-to-One Coaching|"Participants randomized to One-to-One Coaching meet for an initial 2-hour coaching session, followed by seven 1-hour coaching sessions every 3-weeks. These eight sessions take place over the course of 6 months.~Additional requirements for One-to-One Coaching:~* Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~* Complete a 15-minute VIA Character Strengths Test online prior to One-to-One Coaching.~* Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
62732627|NCT03125330|ACTIVE_COMPARATOR|Group Coaching|"Participants meet for 90-minutes each month for 6 months for facilitated professional coaching with a group of colleagues.~Additional requirements:~* Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~* Complete a 15-minute VIA Character Strengths Test online prior to Group Coaching.~* Prior to your initial group coaching session, participate in a 75-minute private phone interview with the primary investigator to discuss the how you make decisions and make sense of the world.~* Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
62732628|NCT03125330|NO_INTERVENTION|Group Coaching Waitlist|"Participants are offered group coaching at the completion of the 12-month study period. Six 90-minute group coaching sessions will occur over the course of six months.~Additional requirements:~• Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment (b) and at 6-months after study enrollment."
62732629|NCT04875455|EXPERIMENTAL|Experimental: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|PhysIOL POD F GF: 50 (bilateral implantation) PhysIOL POD F: 50 (bilateral implantation) Alcon PanOptix: 20 (bilateral implantation) In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
62732630|NCT01570517|EXPERIMENTAL|Device implantation|Subjects are implanted with the study device.
62732631|NCT00129090|EXPERIMENTAL|R-CHOEP14 with 12x Rituximab|8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )
62732632|NCT01268540|EXPERIMENTAL|NHT15|Aspheric Toric Intraocular Lens Models NHT15
62732633|NCT01268540|ACTIVE_COMPARATOR|FY-60AD|Aspheric Non-toric Intraocular Lens: Model FY-60AD
62732634|NCT01268540|EXPERIMENTAL|NHT30|Aspheric Toric Intraocular Lens Model NHT30
62732635|NCT01268540|EXPERIMENTAL|NHT53|Aspheric Toric Intraocular Lens Models NHT53
62732636|NCT06343545|OTHER|Standard of Care|Standard of care provided by participating hospitals
62732637|NCT06343545|EXPERIMENTAL|Rehabilitation|An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
62732638|NCT06425913|ACTIVE_COMPARATOR|Kinesio Taping|KT was applied to the symptomatic shoulder of participants.
62732639|NCT06425913|ACTIVE_COMPARATOR|Cold Therapy|Ice packs were applied to the symptomatic shoulder of participants.
62732640|NCT05447390|ACTIVE_COMPARATOR|Pulmonary Hypertension|
62732641|NCT05447390|ACTIVE_COMPARATOR|Healthy Control|
62732642|NCT01095991|EXPERIMENTAL|1|AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
62732643|NCT01095991|EXPERIMENTAL|2|Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
62732644|NCT04661423|EXPERIMENTAL|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last between 5 and 7 days during the post-ICU hospitalization, at rest and during rehabilitation exercises.
62732645|NCT00699946|ACTIVE_COMPARATOR|1|
62732646|NCT00699946|PLACEBO_COMPARATOR|2|
62732647|NCT03766464||with sleep bruxism, apnea and DTM|"Patients who will undergo analysis of:~Evaluation of TMD and pain sensitivity Evaluation of SB Evaluation of AB"
62732648|NCT04285554|EXPERIMENTAL|Hepatic Denervation|
62732649|NCT05833308||POD group|Patients who were determined to have incident postoperative delirium by a positive confusion assessment method (CAM) questionnaire after operation were defined as the POD group.
62732650|NCT05833308||Non-POD group|Patients who did not suffer from delirium after surgery consisted of the Non-POD group.
62732651|NCT04894019|EXPERIMENTAL|Continuous monitoring group|In patients randomized to the continuous monitoring group, continuous invasive arterial blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
62732652|NCT04894019|ACTIVE_COMPARATOR|Intermittent monitoring group|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous invasive arterial blood pressure monitoring.
62732653|NCT06027619|EXPERIMENTAL|Regimen A|Apply topical aminolevulinic acid gel and incubate for 10 minutes prior to red light source
62732654|NCT06027619|EXPERIMENTAL|Regimen B|Apply topical aminolevulinic acid gel and incubate for 20 minutes prior to red light source
62732655|NCT06027619|EXPERIMENTAL|Regimen C|Apply topical aminolevulinic acid gel and incubate for 60 minutes prior to red light source
62732656|NCT01139541|NO_INTERVENTION|Control|Participants in the control condition will be asked to refrain from using the WalkStations during the study period.
62732657|NCT01139541|EXPERIMENTAL|Individual|In the individual condition, participants will not be part of a team. They will receive weekly email feedback on their Walkstation performance (e.g. number of time slots they signed up for, and number of times they showed up for the time slot.)
62732658|NCT01139541|EXPERIMENTAL|Pairs|In the pair condition, participants will be randomly assigned to a partner. They will receive the same feedback as those in the individual condition, for both themselves AND their partner.
62732659|NCT01139541|EXPERIMENTAL|Groups|In the group condition, participants will be randomly assigned to a group of 5 people. They will receive the same feedback as those in the individual condition, for both themselves AND each member of their group.
62732660|NCT01279044|ACTIVE_COMPARATOR|1|HIV testing with adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
62732661|NCT01279044|PLACEBO_COMPARATOR|2|HIV testing with information only
62732662|NCT04362800|EXPERIMENTAL|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
62732663|NCT04362800|PLACEBO_COMPARATOR|Control|10 days of care and classic activities
62732664|NCT04612829|EXPERIMENTAL|Intervention- Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic 1 Lozenge after every 2 hours, 5 times a day. Mode of Administration: Oral Duration of Treatment: 5 days
62732665|NCT02445729|ACTIVE_COMPARATOR|Dressing Removal at 24 Hours|These patients are randomly assigned to have their dressing removed 24 hours after cesarean section.
62732666|NCT02445729|ACTIVE_COMPARATOR|Dressing Removal at 48 Hours|These patients are randomly assigned to have their dressing removed 48 hours after cesarean section.
62732667|NCT02523092|EXPERIMENTAL|Acthar gel|After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.
62732668|NCT05881486|EXPERIMENTAL|Fosaprepitant|Participants undergoing thoracoscopic pneumonectomy will receive 150 mg of fosaprepitant and 100 ml of normal saline, administer intravenously after the induction of general anesthesia.
62732669|NCT05881486|ACTIVE_COMPARATOR|Ondansetron|Participants undergoing thoracoscopic pneumonectomy received 8 mg of ondansetron and 100 ml of normal saline, administer intravenously after the induction of general anesthesia.
62732670|NCT03663569||subjects with COPD|
62732671|NCT01663766|EXPERIMENTAL|Milatuzumab|Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
62732672|NCT01901289|EXPERIMENTAL|Drug-Eluting Stent|
62732673|NCT01415297|EXPERIMENTAL|NKP-1339|"NKP-1339 will be administered in single patient cohorts until ≥ Grade 2 toxicity encountered, at which time cohorts converted to a standard 3 + 3 dose escalation scheme.~When MTD is reached, an expanded cohort of up to 25 patients will be enrolled at the MTD."
62732674|NCT06352697|ACTIVE_COMPARATOR|Probiotic lysate (postbiotic and metabiotc) group|oral, 2 capsules per day (BID) for 3 month treatment
62732675|NCT06352697|PLACEBO_COMPARATOR|Placebo group|placebo, oral, 2 capsules per day (BID) for 3 month treatment
62732676|NCT03032419|EXPERIMENTAL|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
62732677|NCT03032419|ACTIVE_COMPARATOR|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
62732678|NCT00891488||Fit|
62732679|NCT00891488||Unfit|
62732680|NCT00288015|EXPERIMENTAL|Bevacizumab|Bevacizumab treatment until disease progression or intolerance
62732681|NCT01388179|ACTIVE_COMPARATOR|Real rTMS treatment|low-frequency rTMS to the left DLPFC (Dorsa-Lateral Pre-Frontal Cortex) prior to high-frequency deep rTMS to the FFA (Fusi-Form Area) through the STS(Superior Temporal Sulcus).
62732682|NCT01388179|SHAM_COMPARATOR|Sham rTMS treatment|Sham coil which simulate the real coil action
62732683|NCT03451487|PLACEBO_COMPARATOR|Reference drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg\*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
62732684|NCT03451487|EXPERIMENTAL|Test drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg\*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
62732685|NCT03451487|PLACEBO_COMPARATOR|Reference drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg\*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
62732686|NCT03451487|EXPERIMENTAL|Test drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg\*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study"
62732687|NCT03451487|PLACEBO_COMPARATOR|Reference drug 2 tablets Q6H (28,000mg)|"Eligible subjects were randomly assigned to either of the two treatment stage.Each treatment will be completed when there are at least 7 evaluable subjects. The evaluable subjects are randomized into period V.~Panadol® oral dosage form (500mg\*2 tablets =1000mg) will be orally administered with 240 ml of water every 6 hours daily in each of the multiple-dose study period (Q6H, total 28 dosages, 56 tablets)."
62732688|NCT03451487|EXPERIMENTAL|Test drug 2 tablets Q6H (28,000mg)|"Eligible subjects were randomly assigned to either of the two treatment stage.Each treatment will be completed when there are at least 7 evaluable subjects. The evaluable subjects are randomized into period V.~SafeTynadol® oral dosage form (500mg\*2 tablets =1000mg) will be orally administered with 240 ml of water every 6 hours daily in each of the multiple-dose study period (Q6H, total 28 dosages, 56 tablets)."
62732689|NCT04841785||CKD4/5|Patients with chronic kidney disease stage G4-G5 without dialysis or with a kidney transplant
62732690|NCT04841785||Dialysis|Patients on hemodialysis and peritoneal dialysis
62732691|NCT04841785||Kidney transplant|Patients with a kidney transplant at least 6 weeks after transplantation
62732692|NCT04669860||calcium oxalate urolithiasis group|Participants with CO urolithiasis scheduled for definitive endoscopic stone removal will be evaluated to identify bacterial and fungal microbiome in mid-stream voided urine sample, urine sample collected from the bladder, kidney stone fragment, and a renal papillae biopsy specimen.
62732693|NCT04669860||renal cell carcinoma group|Participants with RCC scheduled for definitive kidney removal surgery will be evaluated to identify bacterial and fungal microbiome in a catheterized urine specimen from the bladder, a biopsy of the tumor, and a biopsy of normal-appearing renal papillae specimen.
62732694|NCT04669860||healthy control group|The participants will provide a clean-catch voided midstream urine sample to identify bacterial and fungal microbiome.
62732695|NCT02452216|EXPERIMENTAL|Ferumoxytol group|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
62732696|NCT03040739||case|
62732697|NCT03040739||control|
62732698|NCT05078931|EXPERIMENTAL|Pembrolizumab + Lenvatinib in PD-L1 Positive TKI resistant NSCLC patients|The PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC will receive the combination of pembrolizumab and lenvatinib.
62732699|NCT02526212|EXPERIMENTAL|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
62732700|NCT02526212|ACTIVE_COMPARATOR|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
62732701|NCT03061877||Anxiety or depression|
62732702|NCT03061877||Non-anxiety or depression|
62732703|NCT00175916|EXPERIMENTAL|Brivaracetam|Flexible dosing, can up and down titrate as needed.
62732704|NCT00389376|OTHER|Group 1|Placebo and 140 mg single dose + every 8 hours
62732705|NCT00389376|OTHER|Group 2|Placebo and 280 mg single dose
62732706|NCT00389376|OTHER|Group 3|Placebo and 280mg every 8 hours
62732707|NCT00389376|OTHER|Group 4|Placebo and 280 single dose + every 8 hours
62732708|NCT00389376|OTHER|Group 5|Placebo and 560 mg single dose + every 8 hours
62732709|NCT00389376|OTHER|Group 6|Placebo and 560 mg single dose + every 8 hours
62732710|NCT00389376|OTHER|Group 7|Placebo and 700 mg single dose + every 8 hours
62732711|NCT03168165|NO_INTERVENTION|Usual Care|Usual care, no intervention
62732712|NCT03168165|EXPERIMENTAL|Pain Neuroscience Education Training|The region of clinics randomized to this arm will receive PNE education, which consists of 6 weeks online training followed by an on-site training day.
62732713|NCT00711594|EXPERIMENTAL|BIBW 2992 MA2|Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally. Escalating doses of BIBW 2992 starting at 20mg daily.
62732714|NCT00711594|EXPERIMENTAL|BIBW 2992 QD|Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
62732715|NCT02740244|ACTIVE_COMPARATOR|active iTBS|Participants will receive 10 to 30 sessions of active intermittent theta burst stimulation (iTBS) consisting in delivering 2 s train of bursts containing three pulses at 50 Hz repeated each 200 ms every 10 s (iTBS). Each iTBS session contained 990 pulses and lasted 6 min. Stimulation intensity will be set at 80% of the patient's resting motor threshold. iTBS will be applied twice per day, with at least three hours between each session. Ten to 30 sessions will be delivered until patient achieved remission (i.e., 13-item Beck Depression Inventory (BDI13) score \< 10). iTBS will be applied over the left dorsolateral prefrontal cortex (DLPFC) according to the individual's 3D-T1 MRI.
62732716|NCT02740244|SHAM_COMPARATOR|sham iTBS|The same protocol (location, intensity, parameters of stimulation) will be applied using a commercial sham coil.
62732717|NCT01405703||percuataneous plate fixation|an approach with three small longitudinal incisions
62732718|NCT01405703||open plate fixation|large transverse incision
62732719|NCT00298389||Non smokers|Non smokers included no history of respiratory or allergic disease, normal baseline spirometry
62732720|NCT00298389||Smokers|Smoking history of at least 10 pack years
62732721|NCT00298389||COPD|Patients with stable COPD
62732722|NCT04517344|EXPERIMENTAL|Arm 1, HFNC 1 L/kg/min|The infant that is randomized to the HFNC therapy arm 1 will be placed on high flow at 1 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If oxygen saturation (SpO2) is \<90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
62732723|NCT04517344|EXPERIMENTAL|Arm 2, HFNC 1.5 L/kg/min|The infant that is randomized to the HFNC therapy arm 2 will be placed on high flow at 1.5 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is \<90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
62732724|NCT04517344|EXPERIMENTAL|Arm 3, HFNC 2 L/kg/min|The infant that is randomized to the HFNC therapy arm 3 will be placed on high flow at 2 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is \<90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
62732725|NCT06291337|EXPERIMENTAL|Treatment of sweet taste receptors with Ibuprofen oral rinse|Participants were tested for sweetness perception without and with an oral rinse of ibuprofen.
62732726|NCT06291337|EXPERIMENTAL|Treatment of sweet taste receptors with naproxen oral rinse|Participants were tested for sweetness perception without and with an oral rinse of naproxen.
62732727|NCT06367660|ACTIVE_COMPARATOR|Bupivacaine with Fentanyl (BF)|In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml . Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
62732728|NCT06367660|ACTIVE_COMPARATOR|Bupivacaine with Dexmedetomidine (BD)|In patients undergoing elective LSCS under subarachnoid block, group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
62732729|NCT01098253|EXPERIMENTAL|Adherence Intervention|Factors affecting adherence to oral hypoglycemic agents and antidepressants were addressed using a problem solving process.
62732730|NCT01098253|NO_INTERVENTION|Usual Care|
62732731|NCT03569787||Patients with hyperprolactinaemia|Patients undergoing subfertility studies with at least one high prolactin reading (\>500mU/L).
62732732|NCT06099223|EXPERIMENTAL|Acupuncture|Preoperative acupuncture
62732733|NCT06099223|NO_INTERVENTION|Control|No acupuncture
62732734|NCT03355950|ACTIVE_COMPARATOR|TEP group|Patients who undergo totally extraperitoneal hernia repair, TEP Repair.
62732735|NCT03355950|ACTIVE_COMPARATOR|Lichtenstein group|Patients who undergo Lichtenstein repair.
62732736|NCT03504891|EXPERIMENTAL|MRI Prior to CRT for Upgrades|MRI will be performed prior to CRT upgrade.
62732737|NCT03504891|ACTIVE_COMPARATOR|MRI Prior to de novo CRT Implants|MRI will be performed prior to de novo CRT implants.
62732738|NCT02695017|EXPERIMENTAL|Iso inertial|Subjects should do 12 exercise repetition with Iso inertial machine
62732739|NCT02695017|EXPERIMENTAL|Conventional machine|Subjects should do 12 exercise repetition with conventional machine
62732740|NCT01328028||Group A|Subjects diagnosed with invasive cervical cancer
62732741|NCT00750035|EXPERIMENTAL|1|total abdominal hysterectomy and
62732742|NCT00750035|EXPERIMENTAL|2|Subtotal hysterectomy
62732743|NCT05365958|EXPERIMENTAL|African American Heterosexuals|
62732744|NCT01957293|EXPERIMENTAL|Salbutamol|
62732745|NCT01957293|PLACEBO_COMPARATOR|Sugar Syrup|
62732746|NCT05894356||Men undergoing sperm DNA fragmentation test|Men presenting at the clinic for infertility evaluation
62732747|NCT03293355|NO_INTERVENTION|Control|Standard of care
62732748|NCT03293355|EXPERIMENTAL|Intervention|"The VPN intervention has 2 in-person sessions:~1) Providing training on service integration and team building for CHW and tools for them to network more effectively with OPC and MMT treatment providers as well as reach out to their patients; and 2) Learning to use effective communication tools such as motivational ruler and decision balance sheet to work more effectively with their patients and use Facebook group to facilitate collaboration among providers and e-chat for patient engagements. Sessions will occur once a week for two weeks, with each session featuring a different set of themes and relevant activities."
62732749|NCT04314245||Urothelial carcinoma group|Subjects who diagnosed with incident or recurrent urothelial carcinoma (including bladder/ureter/renal pelvis) by surgical pathology.
62732750|NCT04314245||interference group|Subjects who diagnosed with incident or recurrent bladder cancer other than urothelial carcinoma (including bladder squamous cell carcinoma/bladder adenocarcinoma/other bladder-related cancers/prostate cancer/rectal cancer) by surgical pathology.
62732751|NCT04314245||Control group|Subjects who clinically diagnosed with benign disease of the urinary system, such as Urinary calculi, urinary tract infection (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis.
62732752|NCT04314245||Healthy volunteers group|Volunteers who have a normal routine urine test / ultrasound examination of the urinary system and do not carry suspected tumors of other organs.
62732753|NCT02783547|EXPERIMENTAL|SyB C-1101 and Azacytidine|
62732754|NCT03937388|EXPERIMENTAL|Cochlear implant recipients|
62732755|NCT04328545|EXPERIMENTAL|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 mins duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
62732756|NCT04328545|ACTIVE_COMPARATOR|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
62732757|NCT04328545|SHAM_COMPARATOR|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
62732758|NCT03498131|EXPERIMENTAL|3 mg Melatonin|Subjects will receive 3 mg melatonin once a day.
62732759|NCT03498131|EXPERIMENTAL|5 mg Melatonin|Subjects will receive 5 mg melatonin once a day.
62732760|NCT04574180|ACTIVE_COMPARATOR|Group 1|Zirconia crown anterior (NuSmile, Houston, Texas, USA).
62732761|NCT04574180|ACTIVE_COMPARATOR|Group 2|Zirconia crown posterior (NuSmile, Houston, Texas, USA).
62732762|NCT04574180|ACTIVE_COMPARATOR|Group 3|Stainless steel crown (3M-ESPE, St. Paul, Minnesota, USA)
62732763|NCT04574180|ACTIVE_COMPARATOR|Group 4|Strip Crown (3M-ESPE, St. Paul, Minnesota, USA)
62732764|NCT02466425|EXPERIMENTAL|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
62732765|NCT02466425|PLACEBO_COMPARATOR|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
62732766|NCT00521209|EXPERIMENTAL|Clinic 1 - intervention|Clinic 1 will feature the Self-Care Stimulating Disease Prevention Program (SCSDPP) intervention
62732767|NCT00521209|OTHER|Clinic 2 - no intervention|Clinic 2 will continue with standard procedures no intervention
62732768|NCT02014259|EXPERIMENTAL|Subjects with renal impairment|
62732769|NCT02014259|ACTIVE_COMPARATOR|Subjects with normal renal function|
62732770|NCT02626156|EXPERIMENTAL|Cooling gel pack|A cooling pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
62732771|NCT02626156|ACTIVE_COMPARATOR|Cooling cotton pack|A cooling cotton pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
62732772|NCT02192892|EXPERIMENTAL|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from Corn Soy Blend drum dried with α-amylase
62732773|NCT02192892|PLACEBO_COMPARATOR|CSB drum dried - α-amylase|CSB drum dried - α-amylase: Porridge from Corn Soy Blend drum dried without α-amylase
62732774|NCT02192892|EXPERIMENTAL|CSB + α-amylase|CSB + α-amylase: Porridge from Corn Soy Blend with α-amylase
62732775|NCT02192892|PLACEBO_COMPARATOR|CSB - α-amylase|CSB - α-amylase: Porridge from Corn Soy Blend without α-amylase
62732776|NCT02192892|EXPERIMENTAL|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
62732777|NCT02192892|PLACEBO_COMPARATOR|RSB - α-amylase|RSB - α-amylase: Porridge from Rice Soy Blend without α-amylase
62732778|NCT02192892|ACTIVE_COMPARATOR|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
62732779|NCT02192892|ACTIVE_COMPARATOR|Commercial porridge flour|Porridge from commercial porridge flour
62732780|NCT02192892|ACTIVE_COMPARATOR|Commercial porridge bar|Porridge from commercial porridge bar
62732781|NCT02192892|EXPERIMENTAL|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from Corn Soy Blend PLUS drum dried with α-amylase
62732782|NCT02192892|PLACEBO_COMPARATOR|CSB PLUS drum dried - α-amylase|CSB PLUS drum dried - α-amylase: Porridge from Corn Soy Blend PLUS drum dried without α-amylase
62732783|NCT02192892|EXPERIMENTAL|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
62732784|NCT02192892|PLACEBO_COMPARATOR|CSB PLUS - α-amylase|CSB PLUS - α-amylase: Porridge from Corn Soy Blend PLUS without α-amylase
62732785|NCT02192892|EXPERIMENTAL|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
62732786|NCT02192892|PLACEBO_COMPARATOR|RSB PLUS - α-amylase|RSB PLUS - α-amylase: Porridge from Rice Soy Blend PLUS without α-amylase
62732787|NCT02192892|EXPERIMENTAL|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
62732788|NCT02192892|PLACEBO_COMPARATOR|WSB PLUS - α-amylase|WSB PLUS - α-amylase: Porridge from Wheat Soy Blend PLUS without α-amylase
62732789|NCT02192892|ACTIVE_COMPARATOR|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
62732790|NCT03283488|EXPERIMENTAL|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
62732791|NCT03283488|ACTIVE_COMPARATOR|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
62732792|NCT01771991|EXPERIMENTAL|Topical Sodermix Dismutase|Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to applying Topical Sodermix Dismutase in the form of Sodermix(SOD) to the area of neck skin fibrosis twice a day for 12 weeks.
62732793|NCT01771991|PLACEBO_COMPARATOR|Placebo group|Cetaphil cream
62732794|NCT04021485|OTHER|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire"
62732795|NCT02846792|EXPERIMENTAL|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62732796|NCT02531139|EXPERIMENTAL|MAP maintained at 80 mmHg|During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
62732797|NCT02531139|ACTIVE_COMPARATOR|MAP maintained at 60 mmHg|During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
62732798|NCT01683630||Confirmed influenza A and B cases|Cases of influenza A and B as diagnosed by PCR, viral culture or florescence microscopy
62737184|NCT00810771|NO_INTERVENTION|Usual Care|Due to budget and time constraints this group was not powered as a true study arm but was used to assess the impact of our baseline physician information letter and to control for any other interventions of system-wide initiatives that may occur during the study timeframe and impact rated of CRC screening. Data was not collected on every participant in this arm.
62732799|NCT00335738|EXPERIMENTAL|Group 1 (identified by central review as high risk)|Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
62732800|NCT00335738|NO_INTERVENTION|Group 2 (identified by central review as not high risk)|Patients undergo observation periodically for at least 5 years.
62732801|NCT02036580|EXPERIMENTAL|Low Dose|Investigational product Tralokinumab
62732802|NCT02036580|EXPERIMENTAL|High Dose|Investigational product Tralokinumab
62732803|NCT02036580|PLACEBO_COMPARATOR|Placebo|Placebo
62732804|NCT04403607||COVID-19|Patients with confirmed COVID-19 meeting the eligibility criteria specified in the protocol.
62732805|NCT04403607||Control|COVID-19 negative. Age/sex matched to the COVID-19 cohort. Age range 40-80 years. At least one cardiovascular risk factor by ASSIGN criteria.
62732806|NCT00057759|EXPERIMENTAL|Sildenafil citrate|Sildenafil with dose escalation as needed from 50 mg to 100 mg/day prn for 12 weeks.
62732807|NCT00057759|PLACEBO_COMPARATOR|Placebo|"Placebo with similar dose escalation opportunity for 12 weeks."
62732808|NCT03130907|ACTIVE_COMPARATOR|Stent|
62732809|NCT03130907|EXPERIMENTAL|No stent|
62732810|NCT04512820|EXPERIMENTAL|TRUCLEAR TREATMENT|patients up to 10 weeks of gestation with missed miscarriage undergoing evacuation of products of conception using the TRUCLEAR tissue removal system under direct hysteroscopic visualization
62732811|NCT02997696|EXPERIMENTAL|Experimental arm 1|ONO-4474 low dose every day for 4 weeks
62732812|NCT02997696|EXPERIMENTAL|Experimental arm 2|ONO-4474 high dose every day for 4 weeks
62732813|NCT02997696|PLACEBO_COMPARATOR|Placebo arm|Placebo matching ONO-4474 every day for 4 weeks
62732814|NCT01465880|NO_INTERVENTION|Part B. Healthy Caucasian adult non-smokers|Non-smokers
62732815|NCT01465880|EXPERIMENTAL|Part A.Healthy Caucasian adult smokers|No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
62732816|NCT01249755||delirious patients|The cohort is divided in delirious and non-delirious patients
62732817|NCT00735553|ACTIVE_COMPARATOR|25 mg Proellex|25 mg oral daily dose of Proellex
62732818|NCT00735553|ACTIVE_COMPARATOR|50 mg Proellex|50 mg oral daily dose of Proellex
62732819|NCT00735553|PLACEBO_COMPARATOR|placebo|oral daily dose of placebo
62732820|NCT01934907|EXPERIMENTAL|washed RBC|Packed RBCs are Washed and then, transfused.
62732821|NCT01934907|NO_INTERVENTION|pack RBC|Packed RBCs are transfused.
62732822|NCT00593177|EXPERIMENTAL|Treatment Group 1|0.05% PTH (1-34) Gel
62732823|NCT00593177|EXPERIMENTAL|Treatment Group 2|0.10% PTH (1-34) Gel
62732824|NCT00593177|PLACEBO_COMPARATOR|Treatment Group 3|Placebo (Vehicle) Gel
62732825|NCT05271734|EXPERIMENTAL|Single arm -lid retractor placement|Placement of a lid retractor the find out if the corneal limbus is exposed to 360 degrees
62732826|NCT05795673|OTHER|Group Peer support|Intervention of mentor to provide peer support
62732827|NCT05795673|NO_INTERVENTION|Group Control|Usual practices of accompaniment of the pediatric-adult transition
62732828|NCT04713410|EXPERIMENTAL|Group A|Steroids will be given for short duration of time i-e 12 weeks
62732829|NCT04713410|ACTIVE_COMPARATOR|Group B|Steroid will be given for longer duration i-e 20 weeks
62732830|NCT02422069||Study Population|Gynecology outpatients who meet eligibility criteria will be enrolled and evaluated for the presence of PMO at screening. Women diagnosed with PMO will complete an additional visit to document the prescribed management plan.
62732831|NCT03423303|EXPERIMENTAL|Screening arm|Invitation to prostate cancer screening and questionnaires.
62732832|NCT03423303|NO_INTERVENTION|Control arm|Registry-based follow-up and a questionnaire.
62732833|NCT05729555|EXPERIMENTAL|Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
62732834|NCT05729555|ACTIVE_COMPARATOR|Motrin® IB (ibuprofen tablets USP) 200mg and BENADRYL® (diphenhydramine hydrochloride tablet) 25 mg|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading~Distributed by: Johnson \& Johnson Consumer Inc., McNeil Consumer Healthcare Division Usage and dosage：Once a day, two tablets at a time"
62732835|NCT01977196|EXPERIMENTAL|DTP/HepatitisB/Hib vaccine|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
62732836|NCT03376139|EXPERIMENTAL|Zonisamide (up to 400 mg/day)|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
62732837|NCT03376139|PLACEBO_COMPARATOR|Placebo|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
62732838|NCT06285565|EXPERIMENTAL|Nurse-led supported group|"A supportive program consisting of the following elements will be provided:~1. Pre-discharge educational meeting. After the patient is deemed stable, an in-hospital educational intervention will be provided by a trained nurse not involved in the clinical pathway. Key topics of self-care management recognized by the European Society of Cardiology will be discussed.~2. Telephone nurse-led coaching sessions. In this phase, patients will be encouraged to focus on their values and progress towards their goals. The intervention will be customized based on the objectives identified during the initial meeting. The scheduled sessions will occur weekly during the first months and then transition to twice a month thereafter.~3. Patients will receive education on measuring weight, blood pressure, heart rate, and oxygen saturation at rest, every morning before breakfast. All participants will be provided with a telemonitoring system that transmits data to a web platform via Bluetooth."
62732839|NCT06285565|NO_INTERVENTION|Controlled group|The controlled group will receive usual care
62732840|NCT06331039|EXPERIMENTAL|PFMT+Balance Group|PFMT+Otago group was included in the program that includes Otago exercises and pelvic floor muscle training. Otago exercises combined with pelvic floor muscle training will be performed 3 days a week (with a 1-day rest gap between 2 sessions) for 45 minutes per day. Otago exercises consist of strengthening, balance exercises and walking program. Warm-up exercises were performed before each program and cooling exercises were performed at the end of the program. Exercises were performed for 45-60 minutes in each session.
62732841|NCT06331039|EXPERIMENTAL|PFMT Group|PFMT group was included in a program that includes pelvic floor muscle training, 3 days a week (with 1 day of rest between 2 sessions) and 45 minutes per day.
62732842|NCT00625391|PLACEBO_COMPARATOR|Placebo pill|24 weeks of placebo.
62732843|NCT00625391|ACTIVE_COMPARATOR|Green Tea Polyphenols (GTP)|24 weeks of green tea polyphenols
62732844|NCT00625391|ACTIVE_COMPARATOR|Placebo+Tai Chi (TC)|24 weeks of placebo plus Tai Chi exercise.
62732845|NCT00625391|ACTIVE_COMPARATOR|GTP+TC|24 weeks of green tea polyphenols plus Tai Chi exercise.
62732846|NCT00740454||A|Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography
62732847|NCT05645796|ACTIVE_COMPARATOR|Fixed group|They received a fixed amount of contrast media prior to CT scan
62732848|NCT05645796|ACTIVE_COMPARATOR|body composition tailored group|They received a body tailored amount of contrast media prior to CT scan
62732849|NCT04354948|EXPERIMENTAL|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 3 min wall squat exercise
62732850|NCT04354948|PLACEBO_COMPARATOR|No pain (Hypotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 3 min wall squat exercise
62732851|NCT02510469|EXPERIMENTAL|Apatinib Maintenance Therapy After Adjuvant Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
62732852|NCT02510469|NO_INTERVENTION|Only Adjuvant Chemotherapy|No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
62732853|NCT00786968|EXPERIMENTAL|intrathecal laronidase|drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
62732854|NCT05944588||Extubation Success|Patients who don't need a new intubation in the 7 days following the extubation
62732855|NCT05944588||Extubation Failure|Patients who need a new intubation in the 7 days following the extubation
62732856|NCT01135888||HED children|
62732857|NCT01135888||HED adolescents|
62732858|NCT01135888||Control children|
62732859|NCT01135888||Control adolescents|
62732860|NCT01457664|PLACEBO_COMPARATOR|Placebo|
62732861|NCT01457664|EXPERIMENTAL|RO4995819|
62732862|NCT04413214|EXPERIMENTAL|Test Group|The 3x3 dose escalation design will be adopted, including 200mg, 400mg and 600mg of Carrimycin; and three subjects at each dose level initially. If there is no DLT in the dose level of 200mg, the dose level of 400mg will be followed; if there is one DLT in the dose level of 200mg, another three patients will be added in the dose level of 200mg; if there is no DLT occurs in the another three patients, the dose level of 400mg will also be followed; if there is one DLT in the another three patients, the trial will be closed. The same condition to the dose level of 400mg and 600mg.
62732863|NCT04447235|PLACEBO_COMPARATOR|ARM A: Placebo|Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
62732864|NCT04447235|EXPERIMENTAL|ARM B: Ivermectin plus losartan|Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days
62732865|NCT00631280|EXPERIMENTAL|Choice|
62732866|NCT00631280|ACTIVE_COMPARATOR|Recommendation|
62732867|NCT06513923|EXPERIMENTAL|Remimazolam group|Patients will receive remimazolam for induction and maintenance of anesthesia.
62732868|NCT06513923|EXPERIMENTAL|Remimazolam + Flumazenil group|Patients will receive remimazolam for induction and maintenance, followed by flumazenil to reverse its effects.
62732869|NCT06513923|EXPERIMENTAL|Propofol group|Patients will receive propofol for induction and maintenance of anesthesia.
62732870|NCT00237666|EXPERIMENTAL|Ziprasidone|Ziprasidone monotherapy, 20-60 mg BID.
62732871|NCT06383169||observation group|
62732872|NCT06383169||control group|
62732873|NCT02318368|EXPERIMENTAL|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
62732874|NCT02318368|ACTIVE_COMPARATOR|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
62732875|NCT03162796|EXPERIMENTAL|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
62732876|NCT03162796|EXPERIMENTAL|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
62732877|NCT03162796|EXPERIMENTAL|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
62732878|NCT05879393|EXPERIMENTAL|Multistrain Probiotic OMNi-BiOTiC® Active|Lacticaseibacillus casei W56, Lactobacillus acidophilus W37, Ligilactobacillus salivarius W24, Levilactobacillus brevis W63, Lactococcus lactis W58, Lactococcus lactis W19, Bifidobacterium animalis subsp. lactis W52, Bifidobacterium longum subsp. longum W108, Bifidobacterium breve W25, Bifidobacterium animalis subsp. lactis W51 and Bifidobacterium bifidum W23. Additional ingredients:corn starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate and vanillin
62732879|NCT05879393|PLACEBO_COMPARATOR|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
62732880|NCT02310737|ACTIVE_COMPARATOR|sharp incision|the patients who were included as the control group (Group 1) with sharp fascia incision
62732881|NCT02310737|ACTIVE_COMPARATOR|blunt incision|the patients who were included as the another group (Group 2) with blunt fascia incision
62732882|NCT00819156|EXPERIMENTAL|Degarelix 200/80|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
62732883|NCT00819156|EXPERIMENTAL|Degarelix 200/120|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
62732884|NCT00819156|EXPERIMENTAL|Degarelix 200/160|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
62732885|NCT00819156|EXPERIMENTAL|Degarelix 240/80|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
62732886|NCT00819156|EXPERIMENTAL|Degarelix 240/120|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
62732887|NCT00819156|EXPERIMENTAL|Degarelix 240/160|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
62732888|NCT00287001|OTHER|1|1= cool air cooling
62732889|NCT01882712|EXPERIMENTAL|CD07805/47 Gel 0.5%|active arm
62732890|NCT01882712|PLACEBO_COMPARATOR|CD07805/47 Gel Placebo|Comparator arm
62732891|NCT02220803|ACTIVE_COMPARATOR|Acetazolamide and CPAP|"Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.~CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks."
62732892|NCT02220803|ACTIVE_COMPARATOR|CPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
62732893|NCT02220803|EXPERIMENTAL|Acetazolamide|Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
62732894|NCT05373758|EXPERIMENTAL|Standard of Care|In Uganda, participants will receive management per Uganda Ministry of Health (MOH) guidelines. A reflex genotypic resistance test (GRT) is performed by MOH for individuals with a second viral load \>1,000 while on TLD. Participants will continue enhanced adherence counseling (EAC) and TLD while awaiting the GRT result. Participants will have an additional Week 24 visit for specimen collection. Participants will return for a visit after GRT results are received and a treatment decision has been made by the regional switch committee. In South Africa, participants will receive management per South Africa Department of Health guidelines. At enrollment, participants will undergo EAC and continue on TLD. At Week 24, participants will undergo repeat viral load testing. If viral load \>1,000, the participant will continue TLD and EAC. If resuppressed, participants will be maintained on TLD. All participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
62732895|NCT05373758|EXPERIMENTAL|Individualized Care|Participants will undergo routine EAC, point-of-care urine tenofovir (TFV) testing, and genotypic resistance testing (GRT) at enrollment. Participants will return when GRT results are available for a treatment decision. Side effects and tolerance will also be assessed. All information will be used to make an optimal treatment recommendation with participant input. Participants will have an additional study visit at Week 24 and will continue to have routine care visits, adherence counseling by the clinic, and viral load monitoring at intervals determined by the clinic per national guidelines. Participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
62732896|NCT05373758|EXPERIMENTAL|Immediate Switch|Participants will undergo routine EAC and a switch from TLD to PI-based second-line ART at the enrollment visit (Week 0). Participants will have an additional study visit at Week 24. Participants will continue to have routine care visits and viral load monitoring at intervals determined by the clinic per national guidelines. At study completion, participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
62732897|NCT02018523|EXPERIMENTAL|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
62732898|NCT01491061|ACTIVE_COMPARATOR|Ranolazine|Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)
62732899|NCT01491061|PLACEBO_COMPARATOR|Placebo|Placebo
62732900|NCT06075719||Stroke Survivor|Survivor of acute ischemic stroke or intracerebral hemorrhage in the last 6 weeks
62732901|NCT06075719||Caregiver|Primary caregiver of stroke survivor
62737185|NCT04931914||Group c|Patients admitted from June 9, 2020 to june 31, 2021.
62737186|NCT02265185||ED Patients|Children aged 2-10 visiting the Emergency Department.
61978405|NCT04576832|ACTIVE_COMPARATOR|Group B (Wait-list group)|Participants will not receive 4 weeks of mindfulness training during the first training interval; they will receive 4 weeks of mindfulness training during the second training interval between the second (T2) and third (T3) assessment sessions.
61978406|NCT05691296|EXPERIMENTAL|Home-school training group|There was a Letter Chart Accomodative Rock Training for accommodation facility at home and school everyday. This training usually lasted 2 minutes each time.
62732902|NCT02252640|ACTIVE_COMPARATOR|Group 1|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
62732903|NCT02252640|ACTIVE_COMPARATOR|Group 2|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
62732904|NCT02252640|ACTIVE_COMPARATOR|Group 3|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) \& ChAd63 ME-TRAP (5 x 10\^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) \& MVA ME-TRAP (2 x 10\^8 pfu), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) \& MVA ME-TRAP (2 x 10\^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
62732905|NCT02252640|ACTIVE_COMPARATOR|Group 4|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) \& ChAd63 ME-TRAP (5 x 10\^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) \& MVA ME-TRAP (2 x 10\^8 pfu), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01) \& MVA ME-TRAP (2 x 10\^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
62732906|NCT02252640|NO_INTERVENTION|Group 5|Week 11: Controlled Human Malaria Infection
62732907|NCT02252640|NO_INTERVENTION|Group 6|Week 31-39: Controlled Human Malaria Infection
62732908|NCT04803175||Sacubitril/valsartan|Patients undergoing continued treatment with sacubitril/valsartan after improvement of LVEF \>40% with \> 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
62732909|NCT04803175||Valsartan|Patients undergoing continued treatment with valsartan after improvement of LVEF \>40% with \> 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
62732910|NCT01118403|EXPERIMENTAL|Sultamicillin, Antibiotic Prophylaxis|Sultamicillin, Antibiotic Prophylaxis
62732911|NCT01118403|PLACEBO_COMPARATOR|Placebo|Physiologic Sodium Chloride Solution
62732912|NCT05639309||Case (hemodynamically significant patent ductus arteriosus)|Hemodynamically significant patent ductus arteriosus (hsPDA) diagnosed by echocardiographic criteria including pulsatile left-to-right shunt through patent ductus arteriosus, enlarged left atrium and/or left ventricle, increased left pulmonary artery velocity, absent or reversed end-diastolic flow of anterior cerebral artery and/or renal artery
62732913|NCT05639309||Control (no hemodynamically significant patent ductus arteriosus)|no hsPDA based on the same echocardiographic criteria described for the Case group
62732914|NCT02448992|EXPERIMENTAL|PCI via hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian-iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole-brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
62732915|NCT02448992|NO_INTERVENTION|observation without PCI|
62732916|NCT03885154|ACTIVE_COMPARATOR|Valproic Acid|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
62732917|NCT03885154|ACTIVE_COMPARATOR|Dihydroergotamine|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours.
62732918|NCT03885154|ACTIVE_COMPARATOR|Cross-Over to Dihydroergotamine|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours.
62732919|NCT03885154|ACTIVE_COMPARATOR|Cross-Over to Valproic Acid|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose \>1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
62732920|NCT05802420|EXPERIMENTAL|MRD-guided|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
62732921|NCT05802420|NO_INTERVENTION|Routine treatment|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
62732922|NCT02676674|EXPERIMENTAL|Dose 1|Three topical applications of 100,000 units for a total of 300,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
62732923|NCT02676674|EXPERIMENTAL|Dose 2|Three topical applications of 300,000 units for a total of 900,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
62732924|NCT04074070||Psoriasis with and without musculoskeletal complains|psoriasis with and without musculoskeletal complains
62732925|NCT04074070||Healthy individuals|
62732926|NCT04074070||Psoriatic arthritis|
62732927|NCT02229825|EXPERIMENTAL|Duloxetine 60 mg|Duloxetine 60 mg
62732928|NCT02229825|EXPERIMENTAL|Duloxetine 120 mg|Duloxetine 120 mg
62732929|NCT03238274||Arm 1|Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
62737187|NCT04239066|EXPERIMENTAL|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
62737188|NCT04239066|EXPERIMENTAL|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
62732930|NCT03238274||Arm 2|Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
62732931|NCT03238274||Arm 3|Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
62732932|NCT03880370||group 1(group without low back pain)|Participants inclusion criteria an age 18 to 55 years of age who practice sports equal to greater than three hours per week who have not had low back pain or ciatalgia in the last 12 months.
62732933|NCT03880370||group 2 (low back pain group)|Participants inclusion criteria an age 18 and 55 years of age who practice sports equal to greater than three hours a week, with a history of at least one episode of low back pain and / or ciatalgia in the last 12 months lasting no longer than three months and diagnosis of hernia lumbar disc using MRI.
62732934|NCT03200431|EXPERIMENTAL|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
62732935|NCT03678337||Observational cohort with plasma samples|
62732936|NCT06254092|EXPERIMENTAL|tourniquet|The investigators use tourniquets to bind the cervical for intervention groups to block venous return to the lower uterine segments to reduce the inflow of amniotic fluid into the uterus.
62732937|NCT00037440||BHS Whites|Whites from Bogalusa, Louisiana; initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
62732938|NCT00037440||BHS African Americans|African Americans from Bogalusa, Louisiana, initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
62732939|NCT02595866|EXPERIMENTAL|Treatment (pembrolizumab and cART)|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients continue receiving their recommended combination antiretroviral therapy PO QD. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT and blood sample collection throughout the trial. Patients may also undergo biopsies during screening and on study.
62732940|NCT03544905|EXPERIMENTAL|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
62732941|NCT00791050|EXPERIMENTAL|1 Thermo|
62732942|NCT00791050|NO_INTERVENTION|2 Control|
62732943|NCT03372720|EXPERIMENTAL|Arm I (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart.
62732944|NCT03372720|SHAM_COMPARATOR|Arm II (sham laser therapy)|Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I.
62732945|NCT00511628||001|Risperidone As prescribed
62732946|NCT02227030|EXPERIMENTAL|BIIB 722 CL single rising dose|
62732947|NCT02227030|EXPERIMENTAL|BIIB 722 CL cross over|
62732948|NCT02227030|PLACEBO_COMPARATOR|Placebo solution|
62732949|NCT02227030|PLACEBO_COMPARATOR|Placebo tablet|
62732950|NCT04087031|ACTIVE_COMPARATOR|control arm|Ten traditional treatment sessions divided into 2 training sessions per week for 5 weeks
62732951|NCT04087031|EXPERIMENTAL|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
62732952|NCT04087031|EXPERIMENTAL|robotic treadmill arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
62732953|NCT02201329|EXPERIMENTAL|A|Volasertib escalating doses + azacitidine
62732954|NCT02357537|ACTIVE_COMPARATOR|Traditional|"Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
62732955|NCT02357537|ACTIVE_COMPARATOR|Remote|"Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
62732956|NCT03930771|EXPERIMENTAL|All Patients|"All subjects will receive:~1. Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.~2. Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14.~After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity)."
62732957|NCT04348812|EXPERIMENTAL|tDCS Active|Transcranial direct current stimulation with ABMT
62732958|NCT04348812|SHAM_COMPARATOR|tDCS sham|Transcranial direct current sham stimulation with ABMT
62732959|NCT02533544||tenofovir disoproxil fumarate monotherapy|a group which treated with tenofovir disoproxil fumarate
62732960|NCT05947916|EXPERIMENTAL|Intervention group|The intervention group will wear real-time CGM (120 cases) to monitor blood glucose and is required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
62732961|NCT05947916|NO_INTERVENTION|Control group|The control group will be followed up with traditional SMBG (120 cases) monitoring.
62737189|NCT01709617|EXPERIMENTAL|Glucose-glucose|Glucose ingestion
62732962|NCT06018207|EXPERIMENTAL|An Up-and-Down Sequential Allocation|An Up-and-Down Sequential Allocation is that the dose is varied based on the hypnosis response of the previous patient after taking midazolam oral solution for 1 hour.
62732963|NCT05712265|EXPERIMENTAL|Miricorilant - Fluvoxamine/Miricorilant|Participants will receive a single oral dose of miricorilant 600 mg on Days 1 and 10 and a single oral dose of fluvoxamine 50 mg on Days 4 to 12.
62732964|NCT04797689|EXPERIMENTAL|Trauma Informed Yoga|Participants will receive 12 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
62732965|NCT04797689|EXPERIMENTAL|Trauma Informed Psychotherapy|Participants will receive 12 x 120 min group-based psychotherapy sessions, delivered synchronously over Zoom.
62732966|NCT04797689|NO_INTERVENTION|Control|These participants will not receive an intervention.
62732967|NCT03770208|PLACEBO_COMPARATOR|Control: Standard Care + Placebo|"Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV placebo (Lactated Ringers). Lactated Ringers will be delivered as a initial bolus and then run as a continuous infusion to mimic the volume (as per Kg) of study drug for 72-96 hours. Standard care will be determined by the care team with no limitations introduced by the research team. Medications utilized and dosing regimes will be recorded after the intervention."
62732968|NCT03770208|EXPERIMENTAL|Intervention: Lidocaine|Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV lidocaine. IV lidocaine will be administered as a bolus dose of 2 mg/kg (maximum dose 100 mg) followed by a 2 mg/kg/hr infusion for 72-96 hrs.
62732969|NCT06354530|EXPERIMENTAL|neoadjuvant immunotherapy plus chemotherapy and anlotinib|neoadjuvant immunotherapy plus chemotherapy and anlotinib
62732970|NCT06354530|EXPERIMENTAL|neoadjuvant immunotherapy combined with concurrent chemoradiotherapy|neoadjuvant immunotherapy combined with concurrent chemoradiotherapy
62732971|NCT05331053|EXPERIMENTAL|Atorvastatin|"Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.~Atorvastatin acts as a systemic LOX inhibitor."
62732972|NCT04983693|EXPERIMENTAL|Dementia-friendly Worship Service|Caregiver and persons living with dementia dyads attending six dementia-friendly worship services in person or online.
62732973|NCT05365516|NO_INTERVENTION|Medical Safety Huddles - Pre-implementation|
62732974|NCT05365516|EXPERIMENTAL|Medical Safety Huddles - Post-implementation|
62732975|NCT05799703|ACTIVE_COMPARATOR|Group (A)|will receive RES in addition to the traditional exercise program.
62732976|NCT05799703|ACTIVE_COMPARATOR|Group (B)|will receive KT in addition to the traditional exercise program.
62732977|NCT06215365|EXPERIMENTAL|Adult cancer survivors (until 74 years old) who have completed their heavy treatments|"Adult cancer survivors (until 74 years old) who have completed their heavy treatments (chemotherapy, radio-chemotherapy, ...) and that are taking part in the JUMP post-cancer day which is a multidisciplinary evaluation carried out at the end of treatments.~They must not have cognitive disorders that limit their ability to understand and complete the questionnaire. Also, they have to speak, read and write French language.~The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
62732978|NCT05628870|EXPERIMENTAL|HRS-1358|Daily oral dosages of HR-1358； Daily oral dosages of HR-1358 and Dalpiciclib Isethionate Tablets
62732979|NCT04984343|EXPERIMENTAL|5 radiation treatments - ARM 1|Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.
62732980|NCT04984343|ACTIVE_COMPARATOR|2 radiation treatments - ARM 2|Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.
62732981|NCT04105192|EXPERIMENTAL|experimental group (Lippia citriodora + sabdariffa)|"Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days."
62732982|NCT04105192|PLACEBO_COMPARATOR|control group Placebo (sucrose)|Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg or Placebo (sucrose) Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days.
62732983|NCT05657938||DMD Patients|Ambulatory males aged 4 to \<13 years with Duchenne Muscular Dystrophy
62732984|NCT05657938||Age Matched Controls|Normal male age-matched controls
62732985|NCT00955643|EXPERIMENTAL|hyperbaric therapy|Hyperbaric therapy by oxygen
62732986|NCT00955643|EXPERIMENTAL|dental scaling and root planing|dental scaling and cleaning
62732987|NCT04709679|EXPERIMENTAL|Constant dwell time but varying power and duration|The laser dwell time will be constant but the laser power and duration will be varied for patients
62732988|NCT04709679|EXPERIMENTAL|Constant power but varying dwell time and duration|The laser power will be constant but the laser dwell time and duration will be varied for patients
62732989|NCT04709679|EXPERIMENTAL|Constant duration but varying dwell time and power|The laser duration will be constant but the laser dwell time and power will be varied for patients
62732990|NCT01500785|ACTIVE_COMPARATOR|levosimendan|
62732991|NCT01500785|PLACEBO_COMPARATOR|placebo|
62732992|NCT02435459|PLACEBO_COMPARATOR|No lining|No lining material placed under amalgam dental restoration
62732993|NCT02435459|ACTIVE_COMPARATOR|Calcium hydroxide cement|Placement of calcium hydroxide cement under amalgam dental restorations
62732994|NCT02435459|ACTIVE_COMPARATOR|Bonding agent|Placement of Resin bonding agent under amalgam dental restorations
62732995|NCT02435459|ACTIVE_COMPARATOR|RMGI cement|Placement of rmgi lining under amalgam dental restorations
62732996|NCT03144336|EXPERIMENTAL|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
62737190|NCT01709617|ACTIVE_COMPARATOR|Glucose-Fructose|glucose-fructose ingestion
62732997|NCT03144336|ACTIVE_COMPARATOR|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
62732998|NCT02204423|EXPERIMENTAL|Trans-Radial PCI|
62732999|NCT02291133|EXPERIMENTAL|Electrochemotherapy treatment|
62733000|NCT03861416|EXPERIMENTAL|Unifuzol® 1.4% 500 ml|Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days
62733001|NCT03861416|EXPERIMENTAL|Unifuzol® 1.4% 250 ml|Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days
62733002|NCT03861416|PLACEBO_COMPARATOR|Placebo 500 ml|Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.
62733003|NCT05233501|SHAM_COMPARATOR|non-surgical perıodontal treatment|
62733004|NCT05233501|EXPERIMENTAL|non-surgical treatment+ low level laser therapy|
62733005|NCT05954208|EXPERIMENTAL|VAGT-WHCM|Vısual Arts Group Therapy Based On Watson's Human Care Model
62733006|NCT05954208|ACTIVE_COMPARATOR|Control group|Routine follow-up, treatment in the institution
62733007|NCT04850924||children impact by the Alex storm|
62733008|NCT03580538|EXPERIMENTAL|elastic tube group|
62733009|NCT00861692|EXPERIMENTAL|Argatroban|
62733010|NCT02011230|NO_INTERVENTION|Control|Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
62733011|NCT02011230|EXPERIMENTAL|Hoist|Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer
62733012|NCT03687775||DSG-Stabi|The group consists of patients with primary trapeziometacarpal osteoarthritis and an indication for trapeziectomy alone or in combination with the resection-suspension-interposition arthroplasty.
62733013|NCT03995095|NO_INTERVENTION|Control group|Group of participants that received usual psychological attention.
62733014|NCT03995095|EXPERIMENTAL|Experimental group|Group of participants that received usual psychological attention plus attention of spiritual needs following the Kibo protocol (intervention).
62733015|NCT04290247|EXPERIMENTAL|Ultrasound + X-ray|Ultrasound first then x-ray examination
61978407|NCT05691296|EXPERIMENTAL|School training group|There was a Letter Chart Accomodative Rock Training for accommodation facility only at school everyday. This training usually lasted 2 minutes each time.
62733016|NCT04501939|EXPERIMENTAL|Cirmtuzumab + Venetoclax|All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.
62733017|NCT02691910|ACTIVE_COMPARATOR|CONCURRENT CHLOROQUINE+PRIMAQUINE|"The infected individuals were treated with the standard chloroquine (CQ)+primaquine(PQ) regimen to malaria caused by Plasmodium vivax.~* Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~* Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
62733018|NCT02691910|EXPERIMENTAL|CHLOROQUINE|"The infected individuals were initially treated with chloroquine (CQ) alone and the primaquine(PQ) was introduced on day 28.~* Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~* Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 28 of CQ treatment. Total dose, 3.5mg/kg.~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
62733019|NCT00677183||SN###.#1|All children in this cohort will have biopsy-proven NASH.
62733020|NCT00677183||SN###.#2|This cohort will be parents (mother and father when possible) of child subjects with biopsy-proven NASH.
62733021|NCT04504539|EXPERIMENTAL|mOPV with FIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
62733022|NCT04504539|EXPERIMENTAL|bOPV with FIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
62733023|NCT04504539|EXPERIMENTAL|mOPV with fIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
62733024|NCT04504539|EXPERIMENTAL|bOPV with fIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
62733025|NCT06018077||Colorectal Cancer Group|Individuals aged 18-65 years, who applied to Ankara City Hospital Oncology Hospital Medical Oncology Outpatient Clinic, newly diagnosed with colorectal cancer as a result of the necessary examinations, at least 3 weeks after the surgical procedure and without metastasis (except for Stage IV)
62733026|NCT06018077||Healthy Group|A healthy adult between the ages of 18-65 who has not been diagnosed with any malignant disease and consented to participate in the study.
62733027|NCT03979469|EXPERIMENTAL|opiod free general anesthesia|In group A opioid free anesthesia is administered. Anesthesia and analgesia were achieved with ketamine(1mg/kg, bolus), dexmedetomidine(1mcg/kg, over 10 minutes), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg). Anesthesia induction with ketamine(1mg/kg), propofol 1% 2-3mg/kg, rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
62733028|NCT03979469|ACTIVE_COMPARATOR|opioid based general anesthesia|In group B opioid based anesthesia is administered.Anesthesia and analgesia were achieved with remifentanil(0.3mcg/kg/minute), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg).Anesthesia induction with propofol 1% 2-3mg/kg,fentanyl(2mcg/kg), rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
62733029|NCT05562557|NO_INTERVENTION|Services as Usual|Randomly assigned to receive services as usual
62733030|NCT05562557|EXPERIMENTAL|Enhanced Fatherhood Services through Regional Partnership Grant Round 7 (RPG7)|Randomly assigned to receive enhanced RPG7 services (motivational enhancement, fatherhood engagement services, contingency management, case management)
62733031|NCT04244695|EXPERIMENTAL|Dexamethasone 16 mg|Dexamethasone (4mg) 4 tab oral once daily in the morning
62733032|NCT04244695|ACTIVE_COMPARATOR|Dexamethasone 8 mg|Dexamethasone (4mg) 2 tab and placebo 2 tab oral once daily in the morning
62733033|NCT04244695|PLACEBO_COMPARATOR|Placebo|Placebo 4 tab oral once daily in the morning
62733034|NCT04062981|EXPERIMENTAL|Cohort I|"Subjects ≥ 18 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
62733035|NCT04062981|EXPERIMENTAL|Cohort II|"Subjects 12 to \<18 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
62733036|NCT04062981|EXPERIMENTAL|Cohort III|"Subjects 6 to \<12 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
62733037|NCT04062981|EXPERIMENTAL|Cohort IV|"Subjects 2 to \<6 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
62733038|NCT03438708|EXPERIMENTAL|Axitinib Oral Tablet [Inlyta]|Axitinib 5 mg PO BID for 8-10 weeks
62733039|NCT03563755|EXPERIMENTAL|Cognitive Bias Modification (CBM) + Treatment as usual|Participants will receive access to a 3-week online training programme alongside their usual treatment.
62733040|NCT03563755|NO_INTERVENTION|Treatment as usual|Participants will continue to receive their usual treatment.
62733041|NCT03978611|EXPERIMENTAL|Part 1: Dose Escalation Phase|
62733042|NCT06216327|EXPERIMENTAL|intervention arm|There is a single intervention arm with no comparator for this pilot study
62733043|NCT03641807|EXPERIMENTAL|Acupuncture|
62733044|NCT03641807|SHAM_COMPARATOR|Sham acupuncture|
62733045|NCT02509364||AE-IPF|"Diagnosis criteria for AE-IPF:~* Diagnosed IPF patient experiences unexplained dyspnea within 1 month~* With objective evidence of hypoxia and new onset of pulmonary infiltration based on imaging examination~* With other diagnosis like pulmonary embolism, pneumothorax or heart failure excluded."
62733046|NCT02509364||Stable-IPF|"Diagnosis criteria for Stable-IPF:~* Exclusion of other known causes of ILDs~* Presence of a usual interstitial pneumonitis (UIP) pattern on high-resolution computed tomography (HRCT)~* Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy."
62733047|NCT02509364||Health control|Healthy volunteer
62733048|NCT01539070|EXPERIMENTAL|Eating and physical activity counseling|Participants randomized to intervention received a 6 week curriculum focused on obesity awareness and prevention. A trained nutritionist led diet, healthy growth and physical activity workshops, while a health educator led workshops on instilling healthy habits and routines in childhood. The nurse provided child care and developed relevant games and activities for children while parents attended the workshops.
62733049|NCT01539070|NO_INTERVENTION|Usual care|According to the existing clinical practice guide within IMSS, obese children may be referred to a nutritionist if the physician considers it necessary, given general dietary advice by the attending physician, or, if necessary, sent for laboratory analyses of blood lipids and glucose. We gave the parents the height and weight results from the measurement of their child and recommended they share results with their physician in their next medical consultation.
62733050|NCT04539054|EXPERIMENTAL|Pre-Workout Condition|This condition consisted of the ingestion of one serving of the pre-workout supplement.
62733051|NCT04539054|EXPERIMENTAL|Caffeine Condition|This condition consisted of the ingestion of 6 mg of caffeine per kg of body mass.
62733052|NCT04539054|PLACEBO_COMPARATOR|Placebo condition|This condition consisted of the ingestion of a placebo.
62733053|NCT03150290|OTHER|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
62733054|NCT03150290|OTHER|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
62733055|NCT01488461||patients ataxic|
62733056|NCT03948802||STROKE GROUP|Cerebral ischemic stroke patients treated.
62733057|NCT03948802||CONTROL GROUP|Ambulatory healthy patients
62733058|NCT00286624|EXPERIMENTAL|1|Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
62733059|NCT06422221|NO_INTERVENTION|No Intervention|Receiving no prophylaxis
62733060|NCT06422221|ACTIVE_COMPARATOR|Clindamycin|Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
62733061|NCT06422221|ACTIVE_COMPARATOR|Doxycycline|Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
62733062|NCT01047007|EXPERIMENTAL|Part 1: adavosertib 65 mg BID|Participants received 65 mg of adavosertib administered orally twice a day (BID) on Days 1-5 of a 21-day cycle.
62733063|NCT01047007|EXPERIMENTAL|Part 2 A1: adavosertib 20 mg BID+5-FU 1000 mg|Participants received 20 mg of adavosertib administered orally BID on Days 1-5 of a 21-day cycle and 1000 mg/m\^2/day of 5-FU administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle.
62733064|NCT01047007|EXPERIMENTAL|Part 2 A2: adavosertib 20 mg QD+5-FU 1000 mg|Participants received 20 mg of adavosertib administered orally once a day (QD) on Days 1-5 of a 21-day cycle and 1000 mg/m\^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle.
62733065|NCT01047007|EXPERIMENTAL|Parts 2B +3: adavosertib+5-FU+CDDP|Participants were to receive 20 mg or 65 mg of adavosertib administered either BID or QD on Days 1-5 of a 21-day cycle; 1000 mg/m\^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle; and 60 mg/m\^2 to 100 mg/m\^2 of CDDP administered as an IV infusion on Day 1.
62733066|NCT02229981|EXPERIMENTAL|ABC294640|Patients will receive ABC294640 orally in gelatin capsules BID.
62733067|NCT02511795|EXPERIMENTAL|AZD1775 (6 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 3 days (6 doses) on Days 1-3 of Week 1 and Days 8-10 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
62737191|NCT01709617|ACTIVE_COMPARATOR|disaccharide|Disaccharide ingestion
62733068|NCT02511795|EXPERIMENTAL|AZD1775 (10 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 5 days (10 doses) on Days 1-5 of Week 1 and Days 8-12 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
62733069|NCT03423238|ACTIVE_COMPARATOR|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI\<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
62733070|NCT03423238|EXPERIMENTAL|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI\<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
62733071|NCT03897465|EXPERIMENTAL|Lomatuell Pro|Lomatuell Pro® is a wound contact layer consisting of wide-meshed tulle, impregnated with a polymer matrix, which form a gel on contact with wound exudate to facilitate moist wound healing.
62733072|NCT03897465|ACTIVE_COMPARATOR|UrgoTul|UrgoTul® is a flexible contact layer with TLC healing matrix comprised of a conformable polyester mesh impregnated with hydrocolloid and petroleum jelly particles.
62733073|NCT00887159|ACTIVE_COMPARATOR|Arm A (CE)|Patients receive cisplatin IV over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
62733074|NCT00887159|EXPERIMENTAL|Arm B (CE + GDC-0449)|Patients receive cisplatin and etoposide as in Arm A and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
62733075|NCT00887159|EXPERIMENTAL|Arm C (CE + IMC-A12)|Patients receive cisplatin and etoposide as in Arm A and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity.
62733076|NCT02403063|ACTIVE_COMPARATOR|sugammadex|Selective relaxant binding agent
62733077|NCT02403063|ACTIVE_COMPARATOR|neostigmine|Acetylcholinesterase inhibitor
62733078|NCT02403063|EXPERIMENTAL|neostigmine-sugammadex|Acetylcholinesterase inhibitor followed by a selective relaxant binding agent
62733079|NCT00851890|EXPERIMENTAL|ABT-333 (300 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 300 mg ABT-333 BID for 2 days followed by 300 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62733080|NCT00851890|EXPERIMENTAL|ABT-333 (600 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 600 mg ABT-333 BID for 2 days followed by 600 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62733081|NCT00851890|EXPERIMENTAL|ABT-333 (1200 mg) once daily (QD) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 1200 mg ABT-333 QD for 2 days followed by 1200 mg ABT-333 QD with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
62733082|NCT00851890|PLACEBO_COMPARATOR|Placebo + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naïve participants received matching placebo once daily (QD) or twice daily (BID) for 2 days followed by placebo QD or BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
61978408|NCT05691296|NO_INTERVENTION|No training group|There was no such treatment for students.
62733083|NCT05016024|OTHER|Colilen IBS + Placebo|First Period: Colilen IBS Second Period: Placebo
62733084|NCT05016024|OTHER|Placebo + Colilen IBS|First Period: Placebo Second Period: Colilen IBS
62733085|NCT01520649|EXPERIMENTAL|NSI-189 Phosphate|There will be 3 ascending cohorts. The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
62733086|NCT01520649|PLACEBO_COMPARATOR|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
62733087|NCT03818906|ACTIVE_COMPARATOR|Control Group|Patients with first or second molars where the extractions will be performed in a conventional way without any additional local treatment to be done in the alveolus. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
62733088|NCT03818906|EXPERIMENTAL|Test Group 1|Patients with first or second molars where the extractions will be performed in a conventional way and after extraction will be performed aPDT inside the alveolus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
62733089|NCT03818906|EXPERIMENTAL|Test Group 2|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia, the fresh socket will receive local application of infrared in the outer vestibular portion. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
61978409|NCT01529346|EXPERIMENTAL|PF-05089771 1600 mg|
62733090|NCT03818906|EXPERIMENTAL|Test Group 3|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia the approaches from the previous groups (Test Group 1 and 2 (aPDT + infrared) will be done. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
62733091|NCT04476446|EXPERIMENTAL|Intranasal Esketamine|Induction Phase: Participants will self-administer esketamine intranasally 56 milligram (mg) on Day 1 followed by 56 mg or 84 mg (as a flexible dose regimen) twice per week for 4 weeks. Participants greater than or equal to (\>=) 65 years old will start at a dose of 28 mg on Day 1. Maintenance Phase: Participants will self-administer esketamine 56 mg or 84 mg intranasally once per week from Week 5 to Week 9. Subsequently from Week 9, based on the investigator's clinical judgment, participants will self-administer esketamine 56 mg or 84 mg intranasally once or twice a week.
62733092|NCT03774771|PLACEBO_COMPARATOR|Placebo|In Part 1 participants received placebo capsules orally once a day for 6 weeks. In Part 2 participants received placebo capsules twice a day for 15 days.
62733093|NCT03774771|EXPERIMENTAL|Cinacalcet 50 mg QD|In Part 1 participants received 50 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 30 mg cinacalcet capsules twice a day for 15 days.
62733094|NCT03774771|EXPERIMENTAL|Cinacalcet 75 mg QD|In Part 1 participants received 75 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 40 mg cinacalcet capsules twice a day for 15 days.
62733095|NCT03774771|EXPERIMENTAL|Cinacelcet 100 mg QD|In Part 1 participants received 100 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 50 mg cinacalcet capsules twice a day for 15 days.
62733096|NCT06386055|EXPERIMENTAL|Intervention group 1|This is the physical intervention group 1(n=8).
62733097|NCT06386055|EXPERIMENTAL|Intervention group 2|This is the physical intervention group 2(n=8).
62733098|NCT06386055|NO_INTERVENTION|Control group|This is the control group (n=8).
62733099|NCT03240861|EXPERIMENTAL|Treatment (Genetically engineered PBMC and PBSC)|"G-CSF AND PLERIXAFOR MOBILIZED LEUKAPHERESIS: Between 6 months and 3 weeks before infusion of cells, patients undergo G-CSF and plerixafor mobilization of CD34+ peripheral blood stem cells. Patients receive G-CSF SC on mobilization days 1-8 and plerixafor SC on mobilization days 4-7. Patients also undergo an unmobilized leukapheresis on day -5 before infusion of cells.~CHEMOTHERAPY CONDITIONING REGIMEN: Patients receive busulfan IV on days -4 to -2 and fludarabine IV over 30 minutes on days -3 to -2.~Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0, and after approximately 24 hours, patients receive RV-NYESO TCR PBMC IV on day 1. Beginning on day 2, patients receive aldesleukin SC BID for up to 7 days. Patients undergo blood collection for safety and immune monitoring on days 0, 1, 3, 5, 7, 14, 30, 60, 90, and 120. Patients receive 18F-FHBG IV, and after 1 hour, undergo PET/CT on days 25 and 120."
62733100|NCT06035952||Intervention|This study will have one cohort. This group of patients will undergo 3D scanning with a smartphone, and will also have standard of care diagnostics, such as an X-ray.
62733101|NCT01541735|PLACEBO_COMPARATOR|Placebo|Placebo of calcined magnesia, capsules
62733102|NCT01541735|EXPERIMENTAL|Pantoprazole|The pantoprazole will be administered in 40mg capsules
62733103|NCT00306839|OTHER|1|Tissel group
62733104|NCT00306839|OTHER|2|Suture group
62733105|NCT03697161|EXPERIMENTAL|OV101 (gaboxadol) Regimen 1|Once Daily
62733106|NCT03697161|EXPERIMENTAL|OV101 (gaboxadol) Regimen 2|Twice Daily
62733107|NCT03697161|EXPERIMENTAL|OV101 (gaboxadol) Regimen 3|Three Times Daily
62733108|NCT02165943||Vitoss Bone Graft with BMA|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage age was recommended and who received Vitoss bone graft with BMA to fill the cavity.
62733109|NCT02165943||Vitoss bone graft|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage was recommended and who received Vitoss bone graft to fill the cavity.
62733110|NCT03047811|EXPERIMENTAL|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 \* 10 \^ 7 / kg - 1 \* 10 \^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1\* 10 \^ 8 / kg - 10 \* 10 \^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
62733111|NCT03673280|PLACEBO_COMPARATOR|Classical spinal anesthesia|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + placebo quadratus lumborum block.
62733112|NCT03673280|EXPERIMENTAL|Spinal anaesthesia with block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg + quadratus lumborum block.
62733113|NCT03673280|EXPERIMENTAL|Classical anaesthesia plus block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + quadratus lumborum block.
62733114|NCT05815433|EXPERIMENTAL|Donor Human Milk|Infants randomized to the intervention group will receive DHM each time supplementation is required for the first 7 days of life.
62733115|NCT05815433|NO_INTERVENTION|Standard Care (Infant Formula)|Infants randomized to the standard care group will receive formula each time supplementation is required for the first 7 days of life.
62733116|NCT05844735|EXPERIMENTAL|Part I SAR441566 Dose A|Participants will receive repeated low dose of SAR441566 for 7.5 days
62733117|NCT05844735|EXPERIMENTAL|Part I SAR441566 Dose B|Participants will receive repeated high dose of SAR441566 for 7.5 days
62733118|NCT05844735|PLACEBO_COMPARATOR|Part I Placebo|Participants will receive repeated SAR441566 matching placebo tablets for 7.5 days
62733119|NCT05844735|ACTIVE_COMPARATOR|Part II Ciprofloxacin|Participants will receive repeated ciprofloxacin 500 mg twice-daily (BID) for 5.5 days
62733120|NCT01662830||MWCC clients|This study will be a systematic retrospective chart review of clients participating in the Jump Start (5 \& 1) Plan at three different MWCC locations in Texas during the years 2007 - 2010.
62733121|NCT01789086|EXPERIMENTAL|Liraglutide|
62733122|NCT01789086|PLACEBO_COMPARATOR|Placebo|
62733123|NCT02018536|EXPERIMENTAL|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
61978410|NCT01529346|EXPERIMENTAL|PF-05089771 450 mg|
62733124|NCT02018536|EXPERIMENTAL|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
62733125|NCT02018536|EXPERIMENTAL|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
62733126|NCT02018536|EXPERIMENTAL|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
62733127|NCT02018536|EXPERIMENTAL|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
62733128|NCT02018536|EXPERIMENTAL|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
62733129|NCT02018536|EXPERIMENTAL|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
62733130|NCT03047967|EXPERIMENTAL|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
62733131|NCT03047967|EXPERIMENTAL|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
62733132|NCT03617718|EXPERIMENTAL|Cystic Fibrosis|All Cystic Fibrosis participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
62733133|NCT03617718|EXPERIMENTAL|Asthma|All Asthma participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
62733134|NCT03617718|EXPERIMENTAL|Healthy Control|All Healthy Control participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
62733135|NCT00703846|OTHER|KETOCONAZOLE|
62733136|NCT02704624|ACTIVE_COMPARATOR|Vitamin D|Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.
62733137|NCT02704624|PLACEBO_COMPARATOR|Placebo|The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.
62733138|NCT03220646|EXPERIMENTAL|A:recurrent IDH wildtype RB1 intact grade II and III gliomas|The main study cohort will consist of patients with recurrent IDH wildtype, RB1 wildtype, WHO grade II and III gliomas that have failed previous therapy. This arm is currently on hold.
62733139|NCT03220646|EXPERIMENTAL|B:Recurrent glioma any grade|Ten patients who require standard of care cytoreductive surgery for recurrent astrocytoma, oligodendroglioma, or glioblastoma, will be offered pre-surgical abemaciclib and then resume the drug following recovery from surgery, continuing until disease progression or unacceptable toxicity analogous to the non-surgical patients in cohort A and C. This arm is closed to accrual.
62733140|NCT03220646|EXPERIMENTAL|C:All other recurrent brain tumors|This is an exploratory cohort including patients with recurrent IDH mutant glioma, meningioma, recurrent ependymoma, and recurrent PCNSL,and other primary brain tumors.
62733141|NCT04700085|EXPERIMENTAL|ReMotion Knee|The ReMotion Knee (mechanical prosthetic knee type) was used during measurements
62733142|NCT04700085|NO_INTERVENTION|Current prosthetic knee|The participant's current prosthetic knee was used during measurements
62733143|NCT01234038|EXPERIMENTAL|Part 1 Cohort 1|
62733144|NCT01234038|EXPERIMENTAL|Part 1 Cohort 2|
62733145|NCT01234038|EXPERIMENTAL|Part 2 Arm A|
62733146|NCT01234038|EXPERIMENTAL|Part 2 Arm B|
62733147|NCT03320837||Breastfeeding group|Infant are exclusively fed with breast milk
62733148|NCT03320837||Mixed feeding group|Infants are fed with mixed nutrition with breast milk and Rontamil Complete 1®
62733149|NCT03320837||Infant formula group|Infant are fed exclusively with Rontamil Complete 1®
62733150|NCT01976546||airway|Patients with one or more predictors of diffucult airway
62733151|NCT02334020|EXPERIMENTAL|Training course|12 hour training course in Mental Health First-aid
62733152|NCT02334020|OTHER|Waiting list|Waiting list design, hence delayed offering of Mental Health First-aid
62733153|NCT06552845||Observational Group|"Inclusion Criteria~1. Adult patients (≥18 years old) who are willing to participate in this study and can sign informed consent;~2. Atrial fibrillation was diagnosed and catheter ablation was proposed Exclusion criteria~a) Left atrial thrombus or left atrial appendage thrombus; b) Severe chronic obstructive pulmonary disease (FEV1/ FVC\<70%, FEV1\<50% predicted value); c) Absolute contraindications of anticoagulation therapy; d) Currently pregnant; e) Contraindications for LGE-MRI (claustrophobia, pacemaker implantation, eGFR\<30ml/min for renal insufficiency, severe obesity, pregnancy, gadolinium chelating agent allergy, etc.); f) refuse to participate in the study; g) other physical or mental incapacity to participate in the study."
62733154|NCT00353301|EXPERIMENTAL|Erlotinib and Sirolimus|"Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day.~Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day."
62733155|NCT02033681|EXPERIMENTAL|"One-per-mil Tumescent Solution"|
62733156|NCT02033681|PLACEBO_COMPARATOR|Saline Solution|
62733157|NCT02131610||Obstructive slep apnea patients|Patients with OSA
62733158|NCT02131610||Control group|Subjects without OSA
62736287|NCT01279291|EXPERIMENTAL|KHK2866, weekly paclitaxel|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with weekly paclitaxel (80 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
62733159|NCT05506072|EXPERIMENTAL|BFR group with standard therapy|Participants will be randomized into their assigned group of receiving standard therapy with BFR by a blinded therapist within the study. Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of Blood Flow Restriction Training with the standard rehabilitation exercises. Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training.
62733160|NCT05506072|ACTIVE_COMPARATOR|standard therapy group|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
62733161|NCT01496287|EXPERIMENTAL|Tube placement group|
62733162|NCT02956252||Spinal anesthesia group|patients underwent laparoscopic cholecystectomy under spinal anesthesia
62733163|NCT02956252||General anesthesia|Patients underwent laparoscopic cholecystectomy under general anesthesia
62733164|NCT03964168||Biologic Therapy|Patient's who received and discontinued a biologic therapy
62733165|NCT01132053||PML|These are subjects who have confirmed PML.
62733166|NCT01132053||Control|These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV.
62733167|NCT06117033|EXPERIMENTAL|experimental group|Preoperative routine patient education and video-assisted mobilization training were given to patients undergoing coronary artery bypass graft surgery.
62733168|NCT06117033|NO_INTERVENTION|control group|Patients in the control group received only routine patient education.
62733169|NCT03115411|EXPERIMENTAL|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
62733170|NCT01457404|EXPERIMENTAL|Integrated Cognitive Behavioral Therapy|Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
62733171|NCT01457404|ACTIVE_COMPARATOR|Treatment-as-usual|Treatment-as-usual (TAU) is the typical outpatient treatment that patients would receive ordinarily at the PVAMC Substance Abuse Treatment Program (SATP) or PTSD Clinic.
62733172|NCT02198859|EXPERIMENTAL|Lithium|Oral lithium carbonate dose escalation: Level 1 of 600 mg/day, then escalating to Level 2 of 900 mg/day, then the final Level 3 of 1200 mg/day.
62733173|NCT03644498||Adults treated with a CPI therapy for cancer|
62733174|NCT04941430|EXPERIMENTAL|Diagnostic (7T MRI)|Within 2 weeks of initial standard of care 3T MRI, patients undergo 7T MRI scan with and without contrast over 1-2 hours.
62733175|NCT02030769|EXPERIMENTAL|Pronase|Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
62733176|NCT02030769|SHAM_COMPARATOR|control|No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
62733177|NCT03825640|EXPERIMENTAL|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
62733178|NCT02565875|EXPERIMENTAL|SLL Presentation|"Intervention: Standardized Language of Laparoscopy (SLL) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation on the use of a SLL for communication between the primary and assistant surgeons during laparoscopy as previously determined by a national survey of Canadian experts and a modified delphi technique."
62733179|NCT02565875|PLACEBO_COMPARATOR|Control Presentation|"Intervention: Surgical Anatomy (SA) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation of similar duration as the intervention group on laparoscopy but not related to communication (laparoscopic anatomy). The simulated laparoscopic task will be identical to the SLL group."
62733180|NCT02967419||RIF group|People who were diagnosed as repeated implantation failure after IVF-ET
62733181|NCT02967419||Control group|People who had normal pregnancy
62733182|NCT00375505|EXPERIMENTAL|Zometa|Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
62733183|NCT00375505|PLACEBO_COMPARATOR|Placebo|Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
62737420|NCT00570778|ACTIVE_COMPARATOR|indacaterol 600 μg|Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
61978411|NCT01529346|EXPERIMENTAL|PF-05089771 150 mg|
62733184|NCT00800696|EXPERIMENTAL|oral care|intervention: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx.
62733185|NCT00800696|NO_INTERVENTION|control|continue to receive oral care as performed today.
62733186|NCT02702609|EXPERIMENTAL|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
62733187|NCT02702609|ACTIVE_COMPARATOR|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
62733188|NCT01062789|OTHER|Use of an optical breath-hold control device|This is a feasibility study that will use this new device in place of a different bellows-based breath-hold control device for a series patients undergoing CT-guided lung biopsy. The new belt will be used in all patients in our study.
62733189|NCT05870969||Patients with very high risk for HCC according local guideline|
62733190|NCT05870969||Patients with high risk for HCC according local guideline|
62733191|NCT05870969||Patients with medium risk for HCC according local guideline|
62733192|NCT05870969||Patients with low risk for HCC according local guideline|
62733193|NCT04091932|EXPERIMENTAL|Pembrolizumab treatment|Pembrolizumab dosage form:100mg/4ml dosage:2mg/kg weight frequency: once per 4 weeks duration:12 weeks
62733194|NCT02026947|PLACEBO_COMPARATOR|Placebo|In both arms, one capsule at the morning for the first week. One capsule at the morning and one at the evening for the weeks 2-12.
62733195|NCT02026947|EXPERIMENTAL|Sodium benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
62733196|NCT01014767|EXPERIMENTAL|Standard Arm (1)|Alternating chemotherapy cycles with etoposide 100 mg/m2 over 1 hour on days 1-5, carboplatin 350 mg/m2 over 2 hours on day 2 and 3, vincristine 1.5 mg/m2 on day 5 alternating with: etoposide 100 mg/m2 over 1 hour on days 1-5, cyclophosphamide 1 g/m2 over 1 hour on day 2 and 3, vincristine 1.5 mg/m2 on day 5. Six blocks are given in 4 week intervals (day1 to day1). Radiation is given between the second and the third cycle only to a small subgroup of patients defined by age histology staging and response to the first to cycles of chemotherapy.
62733197|NCT01014767|EXPERIMENTAL|Doxorubicin/cisplatin arm (2)|Doxorubicin 25 mg/m²/day over 12 hrs on days 1-3, Dactinomycin 45 µg/kg/day (max. 2 mg), i.v. on day 1, and Cisplatin 70 mg/m²/d over 6 hrs on day 4, and Vincristine 1.5 mg/m²/day (max. 2 mg), i.v. on days 8, 15. An identical second cycle is started on day 28 if the side effects allow it. The further treatment is identical to the standard arm with four more cycles of chemotherapy following radiation in some of the patients in all treatment arms.
62733198|NCT01014767|EXPERIMENTAL|Methotrexate Arm (3)|Methotrexate 5g/m\^2 over 24 hours with leucovorin rescue at hour 42 given three times on days 1 15 and 29. The further treatment is identical in all four treatment arms.
62733199|NCT01014767|EXPERIMENTAL|Temozolomide Irinotecan arm (4)|Temozolomide is given at 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day x 5 days as one hour infusions. Two of these cycles are followed by the common radiation - four cycle chemotherapy protocol.
62733200|NCT02713113|ACTIVE_COMPARATOR|group 1|patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
62733201|NCT02713113|ACTIVE_COMPARATOR|group II|patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
62733202|NCT02713113|ACTIVE_COMPARATOR|group III|patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
62733203|NCT00853710|EXPERIMENTAL|rapid PSA assay on whole blood|
62733204|NCT05978349|EXPERIMENTAL|experimental group|Select adjuvant chemotherapy scheme according to 3D drug sensitivity test results of micro tumor (PTC) in vitro
62733205|NCT05978349|NO_INTERVENTION|control group|Formulate adjuvant chemotherapy strategy based on clinical experience
62733206|NCT05111431|EXPERIMENTAL|Dexmedetomidine Hydrochloride Nasal Spray|
62733207|NCT05111431|PLACEBO_COMPARATOR|Dexmedetomidine hydrochloride nasal spray blank preparation|
62733208|NCT06282445|EXPERIMENTAL|Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab|"The enrolled patients with microsatellite stable (MSS) initially unresectable metastatic colorectal cancer will receive a chemotherapy with XELOX and Bevacizumab in combination with Adebrelimab in first-line treatment.~XELOX: Oxaliplatin 130 mg/m2, day 1, q3w; Capecitabine 1000 mg/m2, bid, d1-d14, q3w; Bevacizumab: 7.5mg/kg, intravenous infusion, day 1. q3w. Adebrelimab: intravenously guttae, 1200mg, day 1, q3w. 4 cycles.~Imaging assessment of tumor remission was performed every 8 weeks. Patients who received 4-6 months of treatment and achieved disease control entered the maintenance treatment stage, receiving maintenance treatment:~Bevacizumab: 7.5mg/kg, intravenous infusion, d1, Q3W; Capecitabine: 1250mg/ m2, orally, bid, Q3W; Adebrelimab: 1200mg, intravenous infusion, day 1, Q3W."
62733209|NCT03684837|ACTIVE_COMPARATOR|D vitamine|a dose for week
62733210|NCT03684837|PLACEBO_COMPARATOR|D vitamine placebo|a dose for week
62733211|NCT05402215|EXPERIMENTAL|experimental group|The flipped classroom model was used in teaching the clinical practice skills of the students in the experimental group. First of all, videos for clinical applications were prepared by the researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
62733212|NCT05402215|ACTIVE_COMPARATOR|control group|"To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher. While the students were doing the applications, one of the researchers observed the application and marked only the skill level in the checklists (applied, incompletely applied and did not apply) without making any comments or directions."
62733213|NCT01453036|ACTIVE_COMPARATOR|Conventional AOC group|The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks
62737421|NCT00570778|ACTIVE_COMPARATOR|indacaterol 300 μg|One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
62733214|NCT01453036|ACTIVE_COMPARATOR|Mutation test group|Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
62733215|NCT01453036|ACTIVE_COMPARATOR|Conventional AOM group|The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
62733216|NCT00594607|ACTIVE_COMPARATOR|1: AN69ST|Hemodialysis sessions with use of the dialysis filter AN69ST.
62733217|NCT00594607|ACTIVE_COMPARATOR|2:Fx8|Hemodialysis sessions with use of the dialysis filter Fx8
62733218|NCT03287323|NO_INTERVENTION|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
62733219|NCT03287323|OTHER|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
62733220|NCT01941381||Type B tympanogram|Patients with a clinical diagnosis of acute otitis media and a B type curve with tympanometry.
62733221|NCT01941381||Type A/C tympanogram|Patients with a clinical diagnosis of acute otitis media and a type A or C curve with tympanometry
62733222|NCT05798546|EXPERIMENTAL|Treament of Neo-T|"Part A dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with MEL or NSCLC at escalating doses of 1.2×10\^9 cells and 2.4×10\^9 cells.~Part B will enroll 15 patients with MEL and 5 patients with NSCLC. The administration dose will be identified by the safty of Part A."
62733223|NCT02108756|EXPERIMENTAL|L-pantoprazole sodium|
62733224|NCT02108756|ACTIVE_COMPARATOR|Panmeilu|
62733225|NCT06471699|EXPERIMENTAL|Continous Glucose Monitoring|Participants will be randomized to intervention Continous Glucose Monitoring (CGM)
62733226|NCT06471699|ACTIVE_COMPARATOR|Self Monitoring Blood Glucose|Participants will be randomized to control Self Monitoring Blood Glucose (SMBG)
62733227|NCT02944708|ACTIVE_COMPARATOR|Conventional chemotherapy|Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
62733228|NCT02944708|EXPERIMENTAL|Maintenance chemotherapy 1|Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.
62733229|NCT02944708|EXPERIMENTAL|Maintenance chemotherapy 2|Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.
62733230|NCT01689987|EXPERIMENTAL|Treatment (HCQ, sirolimus, cy/dex)|Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
62733231|NCT04154644|EXPERIMENTAL|Cervical Cytology|100 women with abnormal cervical cytology will receive cryotherapy with the experimental CryoPop device
62733232|NCT04434547|EXPERIMENTAL|PRP group|In the PRP group autologous platelets rich plasma was prepared from the blood using the two step centifuge process .Under ultrasound guidance and complete aseptic procedure , 1 ml of PRP was infused inside the uterus while performing the mock embryo transfer
62733233|NCT04434547|NO_INTERVENTION|Control group|In the control group mock embryo transfer was performed without injecting anything inside the uterus.
62733234|NCT05056558|EXPERIMENTAL|Baricitinib|Continued SOC together with oral 4 mg Baricitinib from day 1 to day 14
62733235|NCT05056558|PLACEBO_COMPARATOR|Placebo|Continued SOC according as mentioned in operational definition in the protocol
62733236|NCT02535013|PLACEBO_COMPARATOR|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose at the end of surgery and 6 to 12 hours after surgery in the intensive care unit.
62733237|NCT02535013|ACTIVE_COMPARATOR|Ultrasound|Perform lung ultrasound three times during the perioperative period; after the induction of general anesthesia, at the end of surgery, and 6 to 12 hours after surgery in the intensive care unit. According to the lung ultrasound finding, conduct appropriate interventions such as, alveolar recruitment maneuver for atelectasis, or chest tube insertion for pneumothorax.
62733238|NCT03506412|EXPERIMENTAL|Low Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml
62733239|NCT03506412|EXPERIMENTAL|High Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP greater than or equal to 0.9 ng/ml
62733240|NCT03275090|ACTIVE_COMPARATOR|Intralipid injectable product (MOFS)|20 preterm infants receive parenteral nutrition containing 20% MOFS lipid emulsion (Smoflipid ®)
62733241|NCT03275090|NO_INTERVENTION|Pure Soybean oil lipid emulsion|20 preterm infants with sepsis receive the usual parenteral nutrition containing soybean oil based lipid emulsion (20% Intralipid ®) at daily increasing doses guided by serum triglycerides.
62733242|NCT01258556|EXPERIMENTAL|Probiotic yogurt|
62733243|NCT01258556|PLACEBO_COMPARATOR|Placebo yogurt.|
62733244|NCT04839250|EXPERIMENTAL|cataract surgery performed by heads-up method|3D heads-up surgery was performed under the NGENUITY® 3D visualization system
62733245|NCT04839250|NO_INTERVENTION|Traditional surgery|Traditional surgery was performed under a surgical microscope.
62733246|NCT03472820|EXPERIMENTAL|Intervention Group|The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.
62733247|NCT03472820|NO_INTERVENTION|Control Group|The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.
62733248|NCT01169701|ACTIVE_COMPARATOR|Tacrolimus|Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).
62737422|NCT00570778|PLACEBO_COMPARATOR|placebo|Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
62733249|NCT01169701|EXPERIMENTAL|Everolimus|Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.
62733250|NCT00804895|EXPERIMENTAL|1|subcutaneous injection of Cortivazol ALTIM, 3,375mg
62733251|NCT00804895|PLACEBO_COMPARATOR|2|PROAMP, subcutaneous serum physiological saline
62733252|NCT05542498|ACTIVE_COMPARATOR|Mindfulness Training|5-lesson audio-guided mindfulness training program delivered over 5 consecutive days, with two additional writing activities on day 1 and day 5
62733253|NCT05542498|ACTIVE_COMPARATOR|Relaxation Training|5-lesson audio-guided relaxation training program delivered over 5 consecutive days, with two additional writing activities on day 1 and day 5
62733254|NCT03022864||Chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain more than 3 points according the Numerical Rating Scale, then it can be considered that the patient has chronic pain.
62733255|NCT03022864||No chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain no more than 3 points according the Numerical Rating Scale, then it can be considered that the patient doesn't have chronic pain.
62733256|NCT00127491|EXPERIMENTAL|EPVent|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The intervention group will undergo transpulmonary pressure-directed controlled mechanical ventilation using parameters directed by the initial balloon measurements. Driving pressures will be adjusted to maintain a transpulmonary plateau pressure of less then 30. The PEEP setting will be set to achieve a transpulmonary end expiratory pressure of 0. Repeat PES measurements will be done at 24, 48 and 72 hours following the initial measurements. Additional measurements will be taken as clinically indicated. Ventilator management by PES measurements will continue for a period of 72 hours.
62733257|NCT00127491|ACTIVE_COMPARATOR|Control|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The control group will be managed using the low tidal volume strategy laid out by the NIHBLI ARDSnet study. These recommendations include a set tidal volume of 6 ml/ kg. Respiratory rate and PEEP are set to maintain adequate ventilation and oxygenation. These settings will be continued for a period of 72 hours.
62733258|NCT04879108|EXPERIMENTAL|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation approaches after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~TENS therapy was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
62733259|NCT04879108|ACTIVE_COMPARATOR|Physiotherapy rehabilitation Group|"This group was enrolled only physiotherapy and rehabilitation program after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
62733260|NCT00460655|ACTIVE_COMPARATOR|BTX|
62733261|NCT00460655|PLACEBO_COMPARATOR|Placebo|
62733262|NCT00909441|EXPERIMENTAL|SNB + ALND|Intervention: Sentinel Lymph Node Biopsy followed by Axillary Node Dissection.
62733263|NCT02552095|OTHER|Triathlon PKR|Patient who receives the Triathlon.
62733264|NCT02303210|OTHER|hearing aid NaidaUP|Within subject design: compare frequency lowering one with frequency lowering two.
62733265|NCT02303210|OTHER|hearing aid NaidaSP|Within subject design: compare frequency lowering one with frequency lowering two.
62733266|NCT04293276|EXPERIMENTAL|Treatment group|Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
62733267|NCT02871349|EXPERIMENTAL|Propanolol and MRI|Participants will receive propranolol via oral capsule, crushed tablet, or liquid daily. The drug dosage will be titrated slowly to ensure the drug is tolerated well. Those aged 15-24 will have an MRI before starting drug.
62733268|NCT02871349|PLACEBO_COMPARATOR|Placebo and MRI|Participants will receive placebo via oral capsule, crushed tablet, or liquid daily. Those aged 15-24 will have an MRI before starting drug.
62733269|NCT05710796||All population|The total population reported to Cardiology department during enrollment period
62733270|NCT05710796||COVID recovered|Patient having history of COVID 19 disease
62733271|NCT05710796||No history of COVID|Population those who never exposed to COVID 19 disease and never suffers
62733272|NCT01354730||Exposed cohort|The woman received AdimFlu-S (A/H1N1) vaccination between 2009/10 and 2010/02. The woman was pregnant at the time of vaccination.
62733273|NCT01354730||Unexposed cohort|The woman was gestation after April 2009.
62733274|NCT05449912||Patients registered in the RICO database|Patients hospitalized for myocardial infarction between 01/01/2002 and 31/12/2008
62733275|NCT06057597|EXPERIMENTAL|Experimental group|"This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery.~Laparoscopic OAGB will be performed with long and narrow gastric pouch (30cc) and 150 cm biliopancreatic limb"
62733276|NCT06057597|ACTIVE_COMPARATOR|Control Groupe|"This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery.~Standard laparoscopic RYGB will be performed with a gastric pouch (30cc) and 150 cm antecolic Roux limb and a 50 cm biliopancreatic limb."
62733277|NCT02998671|EXPERIMENTAL|Group 1: CJM112 high dose|CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
62733278|NCT02998671|EXPERIMENTAL|Group 2: CJM112 low dose|CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
62733279|NCT02998671|PLACEBO_COMPARATOR|Group 3: Placebo, CJM112 low dose or high dose|Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
62733280|NCT03419312|EXPERIMENTAL|Study sequence A|"Proclaim™ Elite 5: Burst - Washout - Sham~1. 14 days of burst stimulation.~2. 7 days washout.~3. 14 days of sham stimulation."
62733281|NCT03419312|EXPERIMENTAL|Study sequence B|"Proclaim™ Elite 5: Sham - Washout - Burst~1. 14 days of sham stimulation.~2. 7 days washout.~3. 14 days of burst stimulation."
62733282|NCT04198766|EXPERIMENTAL|Part 1 INBRX-106 Escalation (Not Recruiting)|INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.
62733283|NCT04198766|EXPERIMENTAL|Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)|INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.
62733284|NCT04198766|EXPERIMENTAL|Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)|Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106
62733285|NCT04198766|EXPERIMENTAL|Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC|Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106
62733286|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (alternating)|Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts.
62733287|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC|Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts.
62733288|NCT04198766|ACTIVE_COMPARATOR|Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)|Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.
62733289|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (concurrent)|Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.
62733290|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab|Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks.
62733291|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting|Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks
62733292|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma|Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks
62733293|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC|Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks
62733294|NCT04198766|EXPERIMENTAL|Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC|Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks
62733295|NCT04198766|EXPERIMENTAL|Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC|Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given
62733296|NCT04171908|ACTIVE_COMPARATOR|Conventional therapy|Conventional Physical therapy for the upper limb
62733297|NCT04171908|EXPERIMENTAL|semi-inmersive VR technology plus conventional therapy|Conventional Physical therapy for the upper limb plus semi-inmersive VR technology
62733298|NCT00920348||Group 1|COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC\<0.70 and FEV1\<80% of pred.)
62733299|NCT00920348||Group 2|COPD mild (GOLD1)(post-BD FEV1/FVC\<0.70 AND FEV1\>=80% of pred.)
62733300|NCT00920348||Group 3|COPD at risk (ever smoker with post-BD FEV1/FVC\>=0.70)
62733301|NCT00920348||Group 4|"Healthy control never smokers without respiratory disease (post-BD FEV1/FVC\>=0.70."
62733302|NCT04800575|EXPERIMENTAL|Semi-permeable film dressing|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
62733303|NCT04800575|OTHER|sterile gauze and tape dressing|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
62733304|NCT05730868|EXPERIMENTAL|group 1 myofascial release|soft tissue release technique to release tension from muscles which relieves pain and increase range of motion
62733305|NCT05730868|EXPERIMENTAL|group 2 muscle energy technique|soft tissue release technique to release tension from muscles which relieves pain and increase range of motion
62733306|NCT05730868|EXPERIMENTAL|group 3 MFR & MET|combination of two soft tissue release techniques to release tension from muscles which relieves pain and increase range of motion
62733307|NCT05730868|EXPERIMENTAL|group 4 conventional therapy|combination of traditional techniques to relieve pain and spasm
62733308|NCT03012828|EXPERIMENTAL|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
62733309|NCT03012828|EXPERIMENTAL|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
62733310|NCT03012828|EXPERIMENTAL|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
62733311|NCT03012828|EXPERIMENTAL|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
62733312|NCT03012828|EXPERIMENTAL|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
62733313|NCT03012828|PLACEBO_COMPARATOR|Placebo|10 subjects will receive a single oral dose of placebo
62733314|NCT01599247||Suicidal ideation/behavior|
62733315|NCT02317601|ACTIVE_COMPARATOR|Methylprednisolone sodium succinate|125 mg iv, as single dose, preoperative.
62733316|NCT02317601|PLACEBO_COMPARATOR|physiological saline|5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi
62733317|NCT01618058||ARV-Treated Participants|Those participants who received dapivirine during HIV seroconversion
62733318|NCT01618058||ARV-Naive Participants|Those participants who received placebo during HIV seroconversion
62733319|NCT04821414||trial group|anakinra canakinumab
62733320|NCT04821414||control group|conventional treatment
62733321|NCT06102512|EXPERIMENTAL|[¹⁴C]-LOXO-783 (Part 1)|Single dose of \[¹⁴C\]-LOXO-783 administered orally
62733322|NCT06102512|EXPERIMENTAL|LOXO-783 + [¹⁴C]-LOXO-783 (Part 2)|Single dose of LOXO-783 administered orally followed by single dose of \[¹⁴C\]-LOXO-783 administered intravenously (IV)
62733323|NCT01455922|EXPERIMENTAL|ITCA 650 60 mcg/day|
62733324|NCT01455922|ACTIVE_COMPARATOR|glimepiride|
62733325|NCT05070455|EXPERIMENTAL|Asceniv|Asceniv™ will be given as an intravenous infusion at the same dose, or higher dose where medically appropriate, as the subject's previous IV Immunoglobulin G treatment (300-800 mg/kg) every 21 or 28 days.
62733326|NCT00637624|ACTIVE_COMPARATOR|1|N-Acetylcysteine
62733327|NCT00637624|PLACEBO_COMPARATOR|2|Placebo
62733328|NCT01177085|EXPERIMENTAL|Mushroom|Mushroom enriched weight loss diet. Participants will be given a personalized diet plan, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
62733329|NCT01177085|ACTIVE_COMPARATOR|No mushroom diet|Participants will be given a personalized diet plan, without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
62733330|NCT01251718||Donepezil Hydrochloride|
62733331|NCT01288170|OTHER|Nebcinal Tobi|crossover design
62733332|NCT01288170|OTHER|Tobi Nebcinal|crossover design
62733333|NCT01166789|ACTIVE_COMPARATOR|Lubiprostone|Lubiprostone 48ug taken daily for 14 days.
62733334|NCT01166789|PLACEBO_COMPARATOR|Placebo|2 capsules containing a substance with no active ingredient taken daily for 14 days.
62733335|NCT05082766|EXPERIMENTAL|DefenAge 8-in-1 BioSerum supplemented with enhanced concentration of defensins|Enrolled subjects will all receive enhanced DefenAge 8-in-1 BioSerum to be applied on the face including periorbital area.
62733336|NCT05708573|EXPERIMENTAL|Cohort 1|Participants will receive a single dose of rosuvastatin in the morning of Day 1 in Treatment Period 1. Following a washout period of 5 days, participants will receive ALXN2040 three times daily on Days 1 through 7 in treatment period 2.
62733337|NCT02295228||Adults undergoing total hip arthroplasty|No intervention will be administered, this is an observational trial. The study population includes adults 50+ who are undergoing elective total hip arthroplasty for osteoarthritis.
62733338|NCT03394781|EXPERIMENTAL|DUR-928 10 mg|10 mg oral suspension
62733339|NCT03394781|EXPERIMENTAL|DUR-928 50 mg|50 mg oral suspension
62733340|NCT05541822|EXPERIMENTAL|Cohort 1: ABN401|Subjects will receive ABN401 800 mg, monotherapy, administered orally once daily in 21-day cycles
62733341|NCT02998684|ACTIVE_COMPARATOR|Active Transcranial Direct Current Stimulation|Participants will receive active Transcranial Direct Current Stimulation
62733342|NCT02998684|SHAM_COMPARATOR|Sham Transcranial Direct Current Stimulation|Participants will receive sham Transcranial Direct Current Stimulation
62733343|NCT00615719||ED patients undergoing coronary CTA|Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.
62733344|NCT04732923|EXPERIMENTAL|Experimental arm|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks~STEP 2 : monitoring at 6 months after cardiac rehabilitation program~STEP 3 : monitoring at one year after cardiac rehabilitation program"
62733345|NCT05744856|NO_INTERVENTION|Standard GDM care|"After being diagnosed with GDM, standard care includes counseling on nutrition and physical activity. All patients are referred to an endocrinologist at the General Hospital, yet this is not covered by insurance unless the patients have received a referral letter from a health station. The endocrinologist will perform blood glucose measurements (venous blood sample) once every four weeks at the General Hospital until gestational week 36, after which it will be monitored once a week until delivery. The cut-off for c-section is 3800g (no matter the mother's GDM status).~Treatment recommended by the endocrinologist may include home-monitoring of blood glucose and insulin treatment in the most severe cases. The home-monitoring requires that the women are able to buy the glucometer and test strips themselves."
62733346|NCT05744856|EXPERIMENTAL|Self-care with informal support|"Standard care + Self-care/informal support intervention~The detailed content of the self-care/informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
62733347|NCT03525600|EXPERIMENTAL|APL-2 15mg 0.1 mL monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
62733348|NCT03525600|EXPERIMENTAL|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
62733349|NCT03525600|EXPERIMENTAL|Sham Procedure Monthly for 24 months|Sham Procedure for 24 months
62733350|NCT03525600|EXPERIMENTAL|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
62733351|NCT05361538|EXPERIMENTAL|MTA Group|Use true circular microwave needle for ultrasound-guided thermal ablation in MSA （microwave spherical ablation） group.
62733352|NCT05361538|NO_INTERVENTION|MWA Group|Use normal microwave needle for ultrasound-guided thermal ablation in MTA （microwave ablation） group.
62733353|NCT03360682|EXPERIMENTAL|HIV-1-infected solid organ transplant patients 1|"The patient or donor is not a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is not a carrier of the hepatitis B virus.~treatment 48 weeks"
62733354|NCT03360682|EXPERIMENTAL|HIV-1-infected solid organ transplant patients 2|"The patient or donor is a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is a carrier of the hepatitis B virus.~treatment 48 weeks"
62733355|NCT05703425|EXPERIMENTAL|Sulfasalazine|Pregnant persons will receive sulfasalazine daily with 500 mg/daily and increasing by 500 mg/day every week until they reach a therapeutic dose of 1,000 mg twice daily. Drug will be started at 24 weeks estimated gestational age and ended at 36 weeks or earlier if preterm birth occurs.
62733356|NCT05703425|NO_INTERVENTION|Standard Care|Pregnant persons will receive standard care in pregnancy.
62733357|NCT01322724|ACTIVE_COMPARATOR|Warm water|Body temperature (95-100 degrees F) water
62733358|NCT01322724|EXPERIMENTAL|Cool water|Room temperature (68-73 degrees F) water
62733359|NCT05244655||Patients without painscores available during hospital stay|
62733360|NCT05244655||Patients with painscores available during hospital stay|
62733361|NCT00582712|EXPERIMENTAL|Lithium Capsules|Lithium carbonate
62733362|NCT02705105|EXPERIMENTAL|Dose-Finding Cohort|"Cycle 1 Days 1, 8, 15, and 22: Dose Level 1 of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Dose Level 1 of Mogamulizumab + Nivolumab~If \>1 patient has a DLT at first dose level, then the following cohort will be enrolled:~Cycle 1 Days 1, 8, 15, and 22: Optional Dose Level of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Optional Dose Level of Mogamulizumab + Nivolumab"
62733363|NCT02705105|EXPERIMENTAL|Expansion Cohort|"Cycle 1 Days 1, 8, 15, and 22: Maximum Tolerated Dose of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Maximum Tolerated Dose of Mogamulizumab + Nivolumab~Subjects will be separated further into cohorts by tumor type"
62733364|NCT01773967|EXPERIMENTAL|LGG|LGG 10\^10 cfu PO bid x 5 days
62733365|NCT01773967|PLACEBO_COMPARATOR|Placebo|micro-crystalline cellulose PO bid x 5 days
62733366|NCT01510990|EXPERIMENTAL|Gefitinib|"After a baseline 18F FDG-PET, patients are treated with gefitinib 250mg/d as 1st line treatment for 7 days. And follow up 18F-FDG PET image is acquired after 1 week's treatment of gefitinib (with window period +/- 2 days).~If % decrease of peak SUV of main lesion is 20% or more, gefitinib treatment is continued till progression, unacceptable toxicities or patient's refusal. But if % decrease of peak SUV of main lesion less than 20% or peak SUV increase, gefitinib treatment is stopped, and changed to Pemetrexed/Cisplatin chemotherapy."
62733367|NCT05370976|EXPERIMENTAL|Experimental group|
62733368|NCT04635709|EXPERIMENTAL|behavioral therapy|applying biofeedback training on the pelvic floor muscles
62733369|NCT04635709|EXPERIMENTAL|interferential therapy (IF)|Interferential current was applied to the body using four surface electrodes placed on the lower abdomen and lower buttocks.
62733370|NCT05833009|EXPERIMENTAL|Acupuncture Group|They receive actual acupuncture on purpose acupoints.
62733371|NCT05833009|SHAM_COMPARATOR|Sham Group|They receive actual acupuncture on points but not an acupoint around the purpose acupoints.
62733372|NCT05833009|SHAM_COMPARATOR|non-Acupuncture Group|They receive fake acupuncture (no needle) on purpose acupoints.
62733373|NCT05372978|EXPERIMENTAL|Cash|Participants will receive a one-time unconditional cash transfer of $8,500 CAD.
62733374|NCT05372978|NO_INTERVENTION|Control|Participants will not receive a cash transfer.
62733375|NCT02840435|ACTIVE_COMPARATOR|North Carolina Quit Line: Quit for Life|Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
62733376|NCT02840435|EXPERIMENTAL|Sit to Quit|Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
62733377|NCT03533699|ACTIVE_COMPARATOR|Propranolol|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
62733378|NCT03533699|PLACEBO_COMPARATOR|placebo|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
62733379|NCT06080074|EXPERIMENTAL|participants receiving the Cardiohelp device according to a standardized management guideline|participants receiving the Cardiohelp device for severe heart failure will be managed according to a standardized treatment guideline to estimate the safety and effectiveness of the device for up to 30 days of support.
62733380|NCT06554977||Patient with Aki|acute kidney injury that will be divided into transient and persistent Aki according to follow up within 48hr and 72hr with kidney function (urea \& creatine)
62733381|NCT06554977||Non Aki patients|
62733382|NCT00193011|EXPERIMENTAL|1|Docetaxel
62733383|NCT00193011|EXPERIMENTAL|2|Cyclophosphamide + Methotrexate + 5-fluorouracil
62733384|NCT01926951|EXPERIMENTAL|Renal Denervation|Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.
62733385|NCT00958087||Sarcoidosis with cardiac involvement|
62733386|NCT00958087||Dilated cardiomyopathy|
62733387|NCT00958087||Sarcoidosis without cardiac involvement|
62733388|NCT00958087||Healthy controls|
62733389|NCT00205153|EXPERIMENTAL|TEAM Care|Intervention pharmacies implement 6-month TEAM program.
62733390|NCT00205153|NO_INTERVENTION|Usual Care|"Control pharmacies provide usual care only."
62733391|NCT03190135|EXPERIMENTAL|BOKS: 2 day per week|
62733392|NCT03190135|EXPERIMENTAL|BOKS: 3 day per week|
62733393|NCT03190135|NO_INTERVENTION|Non-BOKS|
62733394|NCT01746355|ACTIVE_COMPARATOR|rTMS-active|patients undergoing of rTMS real
62733395|NCT01746355|SHAM_COMPARATOR|rTMS-Sham|patients undergoing to placebo rTMS
62733396|NCT04013269|ACTIVE_COMPARATOR|CytoSorb-Therapy|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy in combination with haemadsorption using CytoSorb-Adsorber
62733397|NCT04013269|NO_INTERVENTION|Standard of care|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy
62733398|NCT00880269|EXPERIMENTAL|Stratum A|patients with refractory acute myelogenous leukemia (AML) initially diagnosed as de novo AML received 60 mg of panobinostat per day on three discontinuous days per week.
62733399|NCT00880269|EXPERIMENTAL|Stratum B|patients with refractory AML initially diagnosed as AML secondary to myelodysplastic syndrome (MDS)/antecedent hematologic disorder (AHD) received 60 mg of panobinostat per day on three discontinuous days per week.
62733400|NCT01229683||Shoulder Surgery|Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas.
62733401|NCT02204046|EXPERIMENTAL|BIWA 4|"Generic Name: Bivatuzumab~186Re-labelled humanised monoclonal antibody BIWA 4"
62733402|NCT02020798|PLACEBO_COMPARATOR|Nutrient formulations without active ingredient|4 nutrient formulations without active ingredient and variable level of available placebo ingredient
62733403|NCT02020798|EXPERIMENTAL|Nutrient formulation with active ingredien|4 nutrient formulations with increasing amount of active ingredient
62733404|NCT04059081|EXPERIMENTAL|GC chemotherapy|"Before administration of GC chemotherapy, all patients must undergo pretreatment bone marrow biopsy. The pretreatment BM biopsy must include at least 1 long core biopsy samples and 10 cc of aspirate.~Obinutuzumab 1000mg fixed dose will be administered intravenously (Day 1,8,15 for cycle 1 and D1 for subsequent cycles). Chlorambucil 0.5mg/kg will be administered orally (D1,15 for all cycles).~28 days are considered as one cycle, and cycles will be repeated every 4-weeks for a total of 6 cycles."
62733405|NCT04833946|ACTIVE_COMPARATOR|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
62733406|NCT04833946|PLACEBO_COMPARATOR|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
62733407|NCT06373900|ACTIVE_COMPARATOR|Group A|wound closure with polypropylene
62733408|NCT06373900|ACTIVE_COMPARATOR|Group B|wound closure with polyglactin 910 suture
62733409|NCT02886910|EXPERIMENTAL|Clinical observation|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. They will receive a limited evaluation (blood culture, complete blood count), and a clinical observation. Antibiotics will be started only if sepsis-related signs or symptoms are present.
62733410|NCT02886910|ACTIVE_COMPARATOR|Standard management|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. The will receive a limited evaluation (blood culture, complete blood count), a clinical observation and antibiotics at birth.
62733411|NCT04089527|EXPERIMENTAL|CC-95775|Escalating dose finding part A of study and extension Part B of the study. In Part A, subjects will be treated with oral capsules of CC-95775 with a schedule of 4d on/ 24d off (Q4W) and a starting dose of 100 mg/day on a 28-day cycle. Dose increments between cohorts will not exceed 100% of the dose in previous cohort. Patients in Part B will be treated with a schedule of 4d on/24d off (Q4W) at the Maximum tolerated dose (MTD) established from Part A.
62733412|NCT01389674|EXPERIMENTAL|2D-strain echo|After myocard vitality diagnostics with MRI follows a stress echocardiography to determine the LV volumes and EF. The received Data are compare with the MRI-Data(reference)to identify the ideal strain-parameters and Cut-Off-Result for an intraprocedural vitality diagnostic of the different films (endocardial, myocardial and epicardial).
62733413|NCT00396786|EXPERIMENTAL|Arm 1|
62733414|NCT00396786|EXPERIMENTAL|Arm 2|
62733415|NCT00396786|EXPERIMENTAL|Arm 3|
62733416|NCT00396786|EXPERIMENTAL|Arm 4|
62733417|NCT00396786|EXPERIMENTAL|Arm 5|
62733418|NCT00396786|ACTIVE_COMPARATOR|Arm 6|
62733419|NCT00886860|ACTIVE_COMPARATOR|conventional oral misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 centimeters
62733420|NCT00886860|EXPERIMENTAL|titrated oral misoprostol|misoprostol 20 micrograms oral every hour until cervical dilatation 3 centimeters
62733421|NCT06243328|EXPERIMENTAL|conventional dressing|The surface of the PU will be cleaned with normal saline and packed with sterilised gauze to cover the wound. Dressing changes will be performed once or twice daily depending on the soakage of the dressing
62733422|NCT06243328|EXPERIMENTAL|negative pressure wound therapy|We will place a nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister. Continuous pressure of 200 mm Hg will be applied. The dressing will be changed three times a week.
61978412|NCT01529346|ACTIVE_COMPARATOR|Ibuprofen 400 mg|
62733423|NCT00162214|ACTIVE_COMPARATOR|1|
62733424|NCT04930835|ACTIVE_COMPARATOR|Conventional Loading|implants are loaded at least after two months of healing
62733425|NCT04930835|EXPERIMENTAL|Immediate Loading|implants are loaded the same day of surgery
62733426|NCT05671406|EXPERIMENTAL|Sensor-controlled digital game|The intervention group will receive a sensor-controlled digital game (SCDG) app and physical activity tracker.
62733427|NCT05671406|ACTIVE_COMPARATOR|Sensor-only|The control group will receive only the physical activity tracker.
62733428|NCT04910529|EXPERIMENTAL|Yoga group|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students. This application includes the most basic yoga exercises and does not pose any health risks for practitioners. During the yoga practice in the online environment, the cameras of the students in the yoga group will be turned on and the researcher who has the application will be able to see each student. Yoga will be applied to this group twice a week for 60 minutes each for three menstrual cycles (12 weeks).
62733429|NCT04910529|NO_INTERVENTION|Control group|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
62733430|NCT03578926|EXPERIMENTAL|fanfilcon A toric lens|Randomized participants will wear fanfilcon A toric contact lenses bilaterally for two weeks then switch to senofilcon A toric contact lenses for another two weeks.
62733431|NCT03578926|ACTIVE_COMPARATOR|senofilcon A toric lens|Randomized participants will wear senofilcon A toric contact lenses bilaterally for two weeks then switch to fanfilcon A toric contact lenses for another two weeks.
62733432|NCT00678171|EXPERIMENTAL|OP-1 Putty|Patients randomized to the OP-1 Putty Spinal System arm will receive OP-1 Putty with AVS™TL PEEK Spacer System and XIA® Spinal System.
62733433|NCT00678171|ACTIVE_COMPARATOR|Autograft|Patients randomized to the Autograft Spinal System arm will receive iliac crest autograft with AVS™TL PEEK Spacer System and XIA® Spinal System.
62733434|NCT00631813|ACTIVE_COMPARATOR|1|Prucalopride 0.5 mg
62733435|NCT00631813|ACTIVE_COMPARATOR|2|Prucalopride 1 mg
62733436|NCT00631813|ACTIVE_COMPARATOR|3|Prucalopride 2 mg
62733437|NCT00631813|PLACEBO_COMPARATOR|4|
62733438|NCT05003323||High Knee Pain with Osteoarthritis|Adults 45-80 years old who have moderately severe knee osteoarthritis and rate their daily knee pain at \>=6 on a 0-10 numeric rating scale
62733439|NCT05003323||Low Knee Pain with Osteoarthritis|Adults 45-80 who have moderately severe knee osteoarthritis and rate their daily knee pain at \<=5 on a 0-10 numeric rating scale
62733440|NCT05003323||Healthy Controls|Age matched, BMI matched adults who do not have knee osteoarthritis or chronic pain
62733441|NCT03903549|EXPERIMENTAL|Brain uptake and kinetics in Parkinson patients|
62733442|NCT03903549|EXPERIMENTAL|Brain uptake and kinetics in healthy volunteers|
62733443|NCT03903549|EXPERIMENTAL|Dosimetry in healthy volunteers|
62733444|NCT01229046|ACTIVE_COMPARATOR|ticarcillin-clavulanate|5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
62733445|NCT02092636|EXPERIMENTAL|NIR/US Diagnostic Group|These patients will include women who have breast lumps/lesions visible by ultrasound and are prescribed follow up with an ultrasound-guided biopsy at the UCHC Cancer Center for evaluation and diagnosis of actual/suspected breast abnormalities.
62733446|NCT02092636|EXPERIMENTAL|NIR/US Neoadjuvant Chemotherapy Group|These patients will include women who have breast lumps/lesions visible by ultrasound and have been diagnosed with breast cancers and will undergo neoadjuvant chemotherapy. These patients may be identified from the diagnostic group or after initial diagnosis. Patients will only be enrolled to one of the two groups.
62733447|NCT02092636|OTHER|NIR/US Process Validation Group|This group will contain data from about five women who did not have ultrasound visible lumps on the day of the planned biopsy. Data from the NIR/US scan will be used to validate instrument measurements.
62733448|NCT04545424|EXPERIMENTAL|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
62733449|NCT04545424|ACTIVE_COMPARATOR|Usual Temperature Management|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
62733450|NCT02346903|OTHER|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. The patients will be asked follow-up questions concerning their experiences with chest pain in the past and their tolerance of spicy foods. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion."
62733451|NCT02659033|ACTIVE_COMPARATOR|ceftriaxone|healthy volunteer who receive ceftriaxone
62733452|NCT02659033|ACTIVE_COMPARATOR|cefotaxime|healthy volunteer who receive cefotaxime
62733453|NCT03522935|EXPERIMENTAL|Elafin 0.03 mg/kg|5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
62733454|NCT03522935|EXPERIMENTAL|Elafin 0.06 mg/kg|5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
62733455|NCT03522935|EXPERIMENTAL|Elafin 0.10 mg/kg|5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
62733456|NCT03522935|EXPERIMENTAL|Elafin 0.15 mg/kg|5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
62733457|NCT03522935|EXPERIMENTAL|Elafin 0.18 mg/kg|5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
62733458|NCT03522935|PLACEBO_COMPARATOR|Placebo Drug|5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
62733459|NCT05233488|EXPERIMENTAL|Low US dose|Pulsed US, 1 W/cm2, 10% duty cycle.
62733460|NCT05233488|EXPERIMENTAL|Intermediate US dose|Pulsed US, 1 W/cm2, 50% duty cycle.
62733461|NCT05233488|EXPERIMENTAL|High US dose|Pulsed US, 3 W/cm2, 10% duty cycle.
62733462|NCT05233488|EXPERIMENTAL|Higher US dose|Pulsed US, 3 W/cm2, 50% duty cycle.
61978413|NCT01529346|PLACEBO_COMPARATOR|Placebo|
61978414|NCT05601258||patients with higher lipase level|patients with higher lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
61978415|NCT05601258||Control|patients with normal lipase levels in the course of SARS-CoV-2 infection
61978416|NCT00531817|EXPERIMENTAL|Tocilizumab 8 mg/kg + DMARDs|
62733463|NCT04621266|EXPERIMENTAL|Online Home-based peer support intervention|Participants will receive intervention on top of standard usual care.
62733464|NCT04621266|NO_INTERVENTION|Standard usual care|Participants will receive standard usual care.
62733465|NCT03873727|EXPERIMENTAL|Prevenar13/ Pneumovax|Prime-boost strategy combining a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar 13, PCV13) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12).
62733466|NCT03873727|PLACEBO_COMPARATOR|Placebo / Pneumovax|Standard strategy combining a single dose of placebo vaccine (Prevenar 13 placebo) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12)
62733467|NCT05508542|EXPERIMENTAL|Intervention group: Progressive relaxation exercises|"Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.~After these trainings are completed, a booklet will be given to the patients that will contribute to the correct practice of relaxation exercises on their own. Patients will be asked to practice relaxation exercises by listening to the programs downloaded to their phones at least three times a week for 4 weeks.~In the final test phase; Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be re-administered 4 weeks after the start of exercise practices."
62733468|NCT05508542|NO_INTERVENTION|No Intervention: Standard care group|Standard care group.
62733469|NCT00770562|ACTIVE_COMPARATOR|Dexamethasone|Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10\^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m\^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
62733470|NCT00770562|EXPERIMENTAL|Dexamethasone plus Rituximab|Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (\<) 20 x10\^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
62733471|NCT03519724|EXPERIMENTAL|SUG|
62733472|NCT03519724|ACTIVE_COMPARATOR|NEO|
62733473|NCT04482439|EXPERIMENTAL|Vivity mini-monovision|Subjects will have bilateral Vivity IOL implanted, with a target of slight myopia in the non-dominant eye.
62733474|NCT03458325|EXPERIMENTAL|Furoscix Infusor Prospective Treatment|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
62733475|NCT03458325|NO_INTERVENTION|Propensity-Matched Historical Control|The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
62733476|NCT00758069|PLACEBO_COMPARATOR|1|Placebo
62733477|NCT00758069|EXPERIMENTAL|2|Sitagliptin 100 mg
62733478|NCT00758069|EXPERIMENTAL|3|Sitagliptin 50 mg
62733479|NCT01890824||Breast Cancer Patients|Breast cancer patients to be studied before and after chemotherapy
62733480|NCT01890824||Healthy Female Controls|Healthy female controls will be compared to breast cancer patients before and after chemotherapy and to healthy male controls
62733481|NCT01890824||Healthy Male Controls|Healthy male controls will be compared to healthy female controls to determine gender differences
62733482|NCT05290506|ACTIVE_COMPARATOR|Prediabetes Low GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
62733483|NCT05290506|ACTIVE_COMPARATOR|Prediabetes High GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
62733484|NCT05290506|ACTIVE_COMPARATOR|Diabetes Low GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
62733485|NCT05290506|ACTIVE_COMPARATOR|Diabetes High GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
62733486|NCT02078050|OTHER|Phrenic nerves magnetic stimulations|
62733487|NCT00581399|EXPERIMENTAL|NO-NUMO Chest Tube|The NO-NUMO™ High Vacuum Body Cavity Drainage System consist of disposable NO-NUMO™ body cavity drainage tubes, disposable Vario™ fluid management canisters Vario™ portable vacuum pump
61978417|NCT00531817|PLACEBO_COMPARATOR|Placebo + DMARDs|
62733488|NCT00581399|ACTIVE_COMPARATOR|Standard Chest Tube|Classic PVC Chest Tube
62733489|NCT05535023|EXPERIMENTAL|SAR444245 plus Cemiplimab|Participants will receive SAR444245 and Cemiplimab by vein on Day 1 of Cycles 1 and 2. Each drug's infusion should take about 30 minutes.
62733490|NCT00506402|EXPERIMENTAL|1|
62733491|NCT01817842|EXPERIMENTAL|mEX support|Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support. Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
62733492|NCT01817842|ACTIVE_COMPARATOR|Device Control|Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
62733493|NCT02408172|EXPERIMENTAL|OSA-amlodipine|To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
62733494|NCT02408172|EXPERIMENTAL|OSA-metoprolol|To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment
62733495|NCT00075855|EXPERIMENTAL|testosterone|"Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
62733496|NCT00075855|OTHER|placebo|"Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
62737954|NCT06568003|EXPERIMENTAL|: LuX-Valve Plus transvenous tricuspid valve and delivery system(LuX-Valve Plus System)|The LuX-Valve Plus System is intended for the treatment of patients with severe TR who are determined by a Heart Team to be at high risk of traditional open-heart surgery.
61976773|NCT03520374|OTHER|Healthy adult volunteers|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. Each novice will assess the gastric contents of 3 healthy adult volunteers using the clinical algorithm for gastric ultrasound and aspiration risk assessment - giving an antral grade for each subject (a score of 0-2). Each novice ultrasound assessment will be video recorded. In the weeks following this evaluation, expert ultrasonographers will observe each video and give their own scores for each subject using the antral grading system.
62737955|NCT02456207|EXPERIMENTAL|Experimental|SCT400:375 mg/m2, iv, one infusion
62737956|NCT02456207|ACTIVE_COMPARATOR|Active Comparator|Rituximab: 375 mg/m2, iv, one infusion
62737957|NCT03084094|EXPERIMENTAL|M1|Transcranial direct current Stimulation in primary motor cortex
62737958|NCT03084094|EXPERIMENTAL|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
62737959|NCT03084094|SHAM_COMPARATOR|Sham|sham stimulation
62737960|NCT03544424||Study cohort|People over 60 years of age with a Medtronic CareLink® compatible CIED in situ recruited from the Manchester University NHS Foundation Trust, England, UK
62737961|NCT06433687||HekaHeart-based medication optimization and remote monitoring|Patients will onboard to the HekaHeart platform, which will recommend a GDMT management plan that has been validated by a Yale-based clinician, with consideration given to eligibility for GDMT, past medical history, and patient preference. Participants will also be provided with an at-home blood pressure cuff, weight scale, and heart rate monitor and be instructed to use these devices on a regular cadence. Measurements will be electronically transmitted in real-time to the HekaHeart platform and uploaded to a web-based portal for review. Weekly/bi-weekly scheduled remote check-ins will be used by clinicians to monitor patient progress with GDMT management, to evaluate whether additional medications or dose adjustments are necessary, monitor symptoms, identify issues, offer medical education, and provide continued assistance with remote patient monitoring (RPM) devices. A final patient offboarding visit will occur once the patient has been on the platform for 45 days.
62737962|NCT01267864|ACTIVE_COMPARATOR|Metoclopramide|Metoclopramide 10mg IVSS
62737963|NCT01267864|ACTIVE_COMPARATOR|Ketorolac|Ketorolac 30mg IV
62737964|NCT01267864|ACTIVE_COMPARATOR|Valproate|1gm IV
62737965|NCT02262026|EXPERIMENTAL|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
62737966|NCT02262026|EXPERIMENTAL|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
62737967|NCT02262026|EXPERIMENTAL|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
62737968|NCT02262026|EXPERIMENTAL|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
62737969|NCT02262026|EXPERIMENTAL|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
62737970|NCT02262026|EXPERIMENTAL|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
62737971|NCT02262026|ACTIVE_COMPARATOR|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
62737972|NCT02262026|ACTIVE_COMPARATOR|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
62737973|NCT02262026|ACTIVE_COMPARATOR|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
62737974|NCT02262026|ACTIVE_COMPARATOR|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
62737975|NCT02262026|ACTIVE_COMPARATOR|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
62737976|NCT02262026|ACTIVE_COMPARATOR|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
62737977|NCT02470585|ACTIVE_COMPARATOR|Placebo + Carboplatin + Paclitaxel -> Placebo|Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
62737978|NCT02470585|EXPERIMENTAL|Veliparib + Carboplatin + Paclitaxel -> Placebo|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
62737979|NCT02470585|EXPERIMENTAL|Veliparib + Carboplatin + Paclitaxel -> Veliparib|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles.
62737980|NCT00353808|EXPERIMENTAL|s, s reboxetine|
62737981|NCT04254692|ACTIVE_COMPARATOR|Liposomal Bupivacaine|Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall.
62737982|NCT04254692|OTHER|Bupivacaine|Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.
62737423|NCT00795444|EXPERIMENTAL|Maraviroc|Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc.
62737424|NCT02363972|EXPERIMENTAL|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
62737425|NCT02283905|OTHER|Amphotericin-B and Voriconazole|Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. \~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.
62737426|NCT01500252|EXPERIMENTAL|Patellar Resurfacing|These subjects received a Profix TKR including an all polyethylene patellar implant.
62737427|NCT01500252|ACTIVE_COMPARATOR|Patellar Retention|This group received a Profix TKR, but retained their native patella
62737428|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
62737429|NCT03972462|EXPERIMENTAL|NPC-12G Gel 0.2% (Period 1)|A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.
62737430|NCT03972462|ACTIVE_COMPARATOR|Rapamune Tablet (Period 2)|Rapamune® (sirolimus) 2 mg tablet for oral dosing.
62737431|NCT01884324|NO_INTERVENTION|Late delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
62737432|NCT01884324|EXPERIMENTAL|Early delivery|The early group will undergo induction of labor at 34 weeks with cesarean delivery reserved for obstetrical indications.
62737433|NCT05905224|ACTIVE_COMPARATOR|Group 1 (Control)|
62737434|NCT05905224|EXPERIMENTAL|Group 2 (Experimental)|
62737983|NCT06565780|OTHER|Aktiia.product-G0 device under test|Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.
62737984|NCT02566187|OTHER|Group 1|Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
62737985|NCT02566187|OTHER|Group 2|Subjects of Group 2 take a Fimasartan/Atorvastatin Combination Tablet at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 2 take Fimasartan and Atorvastatin Individual Tablets at 8th day.
62737986|NCT04763252||Canadian|
62737987|NCT01697475|EXPERIMENTAL|Intervention Group|Motivational text messaging
62737988|NCT01697475|NO_INTERVENTION|Control Group|Step count
62737989|NCT02660593|EXPERIMENTAL|SanGrow|Patients will be given SanGrow Decoction 150 ml per day for 3 months.
62737990|NCT05366816|EXPERIMENTAL|Group A: KIT Exon 13 receiving Sunitinib|Participants with KIT mutation on exon 13 will receive Sunitinib. Participants showing disease progression after first-assigned Sunitinib therapy have the option to receive Regorafenib therapy. Total allotted time for treatment is up to 12 months.
62737991|NCT05366816|EXPERIMENTAL|Group B: KIT Exon 17 receiving Regorafenib|Participants with KIT mutation on exon 17 will receive Regorafenib. Participants showing disease progression after first-assigned Regorafenib therapy have the option to receive Sunitinib therapy. Total allotted time for treatment is up to 12 months.
62737992|NCT06321445||Experts|ASA scores provided by anesthesiologists
62737993|NCT06321445||ChatGpt|ASA scores provided by ChatGpt
62737994|NCT05852938|EXPERIMENTAL|BION-1301|600mg subcutaneous administration every 2 weeks for 104 weeks
62737995|NCT05852938|PLACEBO_COMPARATOR|Placebo|subcutaneous administration every 2 weeks for 104 weeks
62737996|NCT02442986||Septic Shock or severe sepsis|Septic patients on ICU with severe sepsis or septic shock.
62737997|NCT02442986||Non-Septic, Surgical Patients|Non-septic patients after surgical treatment and anesthesia on ICU.
62737998|NCT02442986||Non-Septic, Non-Surgical Patients|Patients without sepsis criteria treated on ICU, non-surgical patients.
62737999|NCT02110355|EXPERIMENTAL|AMG 232 with Trametinib and Dabrabenib|Arm 1 of Part 1 and 2 and Part 3
62738000|NCT02110355|EXPERIMENTAL|AMG 232 with Trametinib|Arm 2 of Part 1 and 2
62738001|NCT02110355|ACTIVE_COMPARATOR|Trametinib and Dabrafenib|Part 3
62738002|NCT04739319||Age-Related Macular Degeneration|Participants with Age-Related Macular Degeneration
62738003|NCT02248649|EXPERIMENTAL|Physical Activity|Structured walking program
62738004|NCT02248649|ACTIVE_COMPARATOR|Control|Health education attention control
62738005|NCT06657846||Quality of life assessment|Quality of life questionnaires
62738006|NCT00752739|PLACEBO_COMPARATOR|Arm I|Patients receive oral placebo once daily for 48 months in the absence of disease progression or unacceptable toxicity.
62738007|NCT00752739|EXPERIMENTAL|Arm II|Patients receive low-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
62738008|NCT00752739|EXPERIMENTAL|Arm III|Patients receive high-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
62738009|NCT00958347|OTHER|Omnifit HA Hip Stem|Participants underwent total hip replacement surgery using the Omnifit HA Hip Stem.
62738010|NCT04343534||Original Shared Decision Making Process scale|Patients receive the original version of the Shared Decision Making Process scale.
62738011|NCT04343534||Revised Shared Decision Making Process scale|This group completes a new version of the scale with different wording for several items.
62738012|NCT04075513|EXPERIMENTAL|Toujeo|Toujeo (Insulin Glargine, 300 U/ml) subcutaneous (SC) injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
62738013|NCT04075513|ACTIVE_COMPARATOR|Tresiba|Tresiba (Insulin Degludec, 100U/ml) SC injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
62738014|NCT06458062|EXPERIMENTAL|Pocket Assisted Colposcopy|Pocket-Assisted Visual Inspection with Acetic Acid (PA-VIA): The cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied using a spray bottle or fox swab. After approximately 1-minute, using the Pocket Colposcope any changes to the cervix will be noted. Using the Calla Health image acquisition software, both white and green images of the cervix will be captured at low-resolution. Acetic acid may be reapplied between white and green imaging at the provider's discretion if acetowhitening diminishes. Images will be acquired. A biopsy will be obtained using the pocket. Random biopsies will be obtained from 2 quadrants in the absence of a visible lesion.
62738015|NCT04887584|EXPERIMENTAL|Group 1|"Order of treatments:~A: Control diet B: Low pulse diet C: High pulse diet"
62738016|NCT04887584|EXPERIMENTAL|Group 2|"Order of treatments:~A: Control diet C: High pulse diet B: Low pulse diet"
62738017|NCT04887584|EXPERIMENTAL|Group 3|"Order of treatments:~B: Low pulse diet A: Control diet C: High pulse diet"
62738018|NCT04887584|EXPERIMENTAL|Group 4|"Order of treatments:~B: Low pulse diet C: High pulse diet A: Control diet"
62738019|NCT04887584|EXPERIMENTAL|Group 5|"Order of treatments:~C: High pulse diet A: Control diet B: Low pulse diet"
62738020|NCT04887584|EXPERIMENTAL|Group 6|"Order of treatments:~C: High pulse diet B: Low pulse diet A: Control diet"
62738021|NCT02358200|EXPERIMENTAL|Treatment|BMN-673: Oral, every day, Days 1-21; Carboplatin: intravenous, every week, 750 μg/day; Paclitaxel: intravenous, every week, 0.75 x Maximum Tolerated Dose μg/day
62738022|NCT04143152||Diagnostic/prognostic cohort|Patients being evaluated for a potential pancreatic abnormality or for potential treatment for pancreatic adenocarcinoma.
62738023|NCT04143152||Surveillance Cohort|Patients who are being monitored for recurrence following surgical or medical treatment for pancreatic adenocarcinoma
62738024|NCT01543282|ACTIVE_COMPARATOR|EUS 22 gauge needle|EUS 22 g needle is the most common needle used in clinical practice. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
62738025|NCT01543282|EXPERIMENTAL|EUS 25 gauge needle|25 gauge needle is usually used less frequently but nowadays is increasingly used and is as well a valid option. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
62738026|NCT06444854|EXPERIMENTAL|Early Chest Tube Removal|early chest tube removal at 3 hours
62738027|NCT06444854|NO_INTERVENTION|Standard of Care|Routine post operative chest tube care
62738028|NCT03500016|EXPERIMENTAL|Acute exercise and high intensity interval training|Euglycemic-hyperinsulinemic clamp, IVGTT, DXA scan, VO2max, plasma samples, fat and muscle biopsies before and after 8 weeks supervised high intensity interval training (HIIT). Before the 8 weeks HIIT-protocol the participants will also perform an 1-h acute exercise with plasma samples and musce samples before and immediately after the exercise bout and 4 hours into recovery
62738029|NCT03254628|EXPERIMENTAL|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
62738030|NCT03254628|EXPERIMENTAL|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
62738031|NCT03254628|ACTIVE_COMPARATOR|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
62738032|NCT00856596|OTHER|Males and females with athlete's foot|Male and female subjects with athlete's foot inbetween their toes without nail involvement
62738033|NCT03248167|EXPERIMENTAL|Cannabidiol (CBD 600 mg daily)|6 weeks, such that both participants and study staff are blind to treatment condition.
62738034|NCT03248167|PLACEBO_COMPARATOR|Placebo|6 weeks, such that both participants and study staff are blind to treatment condition.
62738035|NCT01644669|EXPERIMENTAL|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
62738036|NCT02200757|EXPERIMENTAL|Aldoxorubicin|
62738037|NCT02200757|ACTIVE_COMPARATOR|Topotecan|
62738038|NCT00090779|ACTIVE_COMPARATOR|IT arm|IT (immediate treatment) arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily
62738039|NCT00090779|NO_INTERVENTION|DT arm|DT (deferred treatment) arm participants received no treatment
62738040|NCT04400916|EXPERIMENTAL|Topical tranexamic acid|
62738041|NCT04400916|PLACEBO_COMPARATOR|Topical BSS|
61976774|NCT03520374|OTHER|Pediatric patients|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. Each novice will assess the gastric contents of 3 pediatric patients undergoing surgery in the preoperative area or the in-patient unit using the clinical algorithm for gastric ultrasound and aspiration risk assessment - giving an antral grade for each subject (a score of 0-2). Each novice ultrasound assessment will be video recorded. In the weeks following this evaluation, expert ultrasonographers will observe each video and give their own scores for each subject using the antral grading system.
61976775|NCT05489809|EXPERIMENTAL|Endotracheal extubation with suctioning|Suctioning is applied to the endotracheal tube while removing it.
62738042|NCT00128024|ACTIVE_COMPARATOR|Statins|
62738043|NCT00128024|NO_INTERVENTION|No statins|
62738044|NCT01601756|EXPERIMENTAL|navigated revision total knee arthroplasty|revision total knee arthroplasty with the aid of a navigation system
62738045|NCT01601756|ACTIVE_COMPARATOR|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
62738046|NCT04772352|EXPERIMENTAL|Experimental group: Lifestyle intervention + febuxostat (40mg, once a day, orally)|participants accept febuxostat treatment in addition to lifestyle intervention for 0-48 week.
62738047|NCT04772352|ACTIVE_COMPARATOR|Control group: Lifestyle intervention|participants receive lifestyle intervention for 0-24 week. If the results of the 0-24 week study showed that the liver fat content of subjects in the experimental group was significantly lower than that in the control group, control group will accept febuxostat treatment in addition to lifestyle intervention in the next 25-48 week.
62738048|NCT02279368|EXPERIMENTAL|Intervention Group|Nurses delivered the supportive intervention along with family counselling from last term of pregnancy through three months and then were followed till the first birthday of the child.
62738049|NCT02279368|NO_INTERVENTION|Control Group|Control group families were followed in usual care.
62738050|NCT05911360|EXPERIMENTAL|Participants Receiving DTG/3TC FDC|
62738051|NCT02062229||Halthy controls|Subjects not affected by any disease and with normal seminal fluid characteristics
62738052|NCT02062229||Oligospermia|Infertile subjects with oligospermia
62738053|NCT02062229||Varicocele|Infertile subjects with varicocele
62738054|NCT02062229||Asthenospermia|Infertile subjects with asthenospermia
62738055|NCT01110525|EXPERIMENTAL|1|AZD1981 + Oral contraceptive
62738056|NCT01110525|PLACEBO_COMPARATOR|2|Placebo + Oral contraceptive
62738057|NCT02739386||Cohort Population|Individuals included in a large US-based administrative medical claims database with underlying autoimmune disorder exposed to ipilimumab for the treatment of melanoma.
62738058|NCT06097078||Eso-SPONGE®|endoluminal vacuum therapy to prevent anastomotic leakage after esophagectomy due to esophageal cancer
62738059|NCT01140867|EXPERIMENTAL|1|
62738060|NCT06233162|EXPERIMENTAL|Sequence 1-Febuxostat test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Febuxostat 80 mg tablets test product, treatment 2= Febuxostat 80 mg tablets reference product.
62738061|NCT06233162|EXPERIMENTAL|Sequence 2-Febuxostat reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Febuxostat 80 mg tablets test product, treatment 2= Febuxostat 80 mg tablets reference product.
62738062|NCT01832493|EXPERIMENTAL|Cardiac Resynchronization Therapy|Patients implanted with a cardiac resynchronization therapy device
62738063|NCT06566170||Donanemab Group + Usual Care|Participants will receive open-label (unblinded) donanemab intravenously (IV) and Usual Care
62738064|NCT06566170||Usual Care Group|Participants will receive usual care.
62738065|NCT00416494|EXPERIMENTAL|Initial Cohort|
62738066|NCT00416494|EXPERIMENTAL|Second cohort|
62738067|NCT04554693|EXPERIMENTAL|Metronidazole|Metronidazole
62738068|NCT04554693|PLACEBO_COMPARATOR|Placebo|Halal and Kosher certified gelatin placebo capsules
62738069|NCT03358875|EXPERIMENTAL|BGB-A317|100 mg per vial, 200mg intravenous (IV), Q3W
62738070|NCT03358875|EXPERIMENTAL|Docetaxel|75 mg/m2 IV Q3W
62738071|NCT00442494|OTHER|Study couldn´t start due to investigator|Study couldn´t start due to investigator
62738072|NCT05322811||Participants|Adults patients with neurological disorder
62738073|NCT01144169|EXPERIMENTAL|Hydroxychloroquine (HC)|HC orally for 14 days prior to nephrectomy
62738074|NCT02499913|ACTIVE_COMPARATOR|breath alcohol monitoring|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use.
62738075|NCT02499913|EXPERIMENTAL|breath monitoring plus prize contingency management|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use. Participants of this group earn opportunities to draw cards from a prize bowl for negative breath samples.
62738076|NCT04982341||HFNC/prone|awake patients with COVID-19 and severe acute respiratory failure receiving HFNC in prone position
62738077|NCT00617097|ACTIVE_COMPARATOR|paracervical block with lidocaine|Subjects who receive pain control using paracervical block with lidocaine during first trimester surgical abortion
62738078|NCT00617097|EXPERIMENTAL|paracervical block with ketorolac and lidocaine|Subjects who receive pain control using paracervical block with ketorolac and lidocaine during first trimester surgical abortion
62738079|NCT06187766||University Students|University students will be categorized with Bergen Social Media Addiction Scale.
62738080|NCT04904406|EXPERIMENTAL|dolutegravir/lamivudine|50 mg dolutegravir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
62738081|NCT04904406|NO_INTERVENTION|dolutegravir/abacavir/lamivudine|50 mg dolutegravir, 600 mg abacavir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
62738082|NCT04803292||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
62738083|NCT04803292||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
62738084|NCT04803292||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
62738085|NCT04769271|ACTIVE_COMPARATOR|Scaling and Root Planing (SRP)|
62738086|NCT04769271|EXPERIMENTAL|Scaling and Root Planing with tea tree oil|
61976776|NCT05489809|EXPERIMENTAL|Endotracheal extubation with positive pressure|Positive pressure is applied to the endotracheal tube while removing it.
61976777|NCT02432404|ACTIVE_COMPARATOR|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
61976778|NCT02432404|EXPERIMENTAL|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
61976779|NCT02309489|EXPERIMENTAL|Intervention|"* Receive standard maternity care~* Woman and partner attend one extra couple counselling session during pregnancy (A)~* Partner attends one group education session for men (B)~* Partner participates in pre-discharge consultation (C)"
62733497|NCT05869253|EXPERIMENTAL|children diagnosed with ADHD|After completing an eligibility assessment, adequate participants will go through baseline assessment and 12 weeks of waiting without receiving intervention; b) pre-test, before first treatment session, end of 12 week waiting period; c) post-test after 12 weeks of intervention; d) post intervention assessment, three months follow up
62733498|NCT02676895|EXPERIMENTAL|1790GAHB 25 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 25 μg of S. sonnei.
62733499|NCT02676895|EXPERIMENTAL|1790GAHB 100 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 100 μg of S. sonnei.
62733500|NCT02676895|ACTIVE_COMPARATOR|Control Group|Subjects who received one dose of Menveo vaccine and a second dose of Boostrix vaccine.
62733501|NCT06526182|EXPERIMENTAL|Lebrikizumab|Participants with moderate-to-severe AD will receive loading doses of lebrikizumab 500 milligrams (mg) subcutaneous (SC) injection (2 injections) at Day 1 and Week 2 followed by 250 mg (1 injection) every 2 weeks (Q2W) after Week 4 to Week 16 followed by 250 mg (1 injection) every 4 weeks (Q4W) after Week 16 to Week 24.
62733502|NCT02038751||Index proband|moderate to severe OSA (AHI\>30 or AHI\>15 needing CPAP intervention) age 20-99 y/o
62733503|NCT02038751||Index family|first-degree, second-degree, or spouse of index proband age \>20 y/o
62733504|NCT02038751||Control proband|friends of index proband, living in the same environment as index proband age \> 20 y/o
62733505|NCT02038751||Control family|first-degree, second-degree, or spouse of control proband age \>20 y/o
62733506|NCT01219478||control|0 metabloil risk
62733507|NCT01219478||1|1 metabloil risk
62733508|NCT01219478||2|2 metabloil risk
62733509|NCT01219478||3|3 metabloil risk
62733510|NCT04094324||Children and youth at obesity clinic|Children 11-18 who are patients at obesity clinics in region Skåne SUS.
62733511|NCT04094324||Children and youth at a pediatric gastrointestinal clinic|Children 11-18 who are patients at a gastrointestinal clinic i region Skåne SUS.
62733512|NCT04009018|OTHER|Psycometric analyses|It will be a validation study of the Perioperative Satisfaction Scale in Regional Anesthesia. This study is not experimental research. This is a psychometric assessment study of a questionnaire and data will collect pencil-paper survey and face to face from the patients who will get regional anesthesia in the postoperative second day.
62733513|NCT00529776|ACTIVE_COMPARATOR|1|Continuous lateral rotation therapy
62733514|NCT00529776|NO_INTERVENTION|2|Standard manual positioning (Supine position)
62733515|NCT03215628|ACTIVE_COMPARATOR|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
62733516|NCT03215628|EXPERIMENTAL|Group B - TCEUS with HLM|Surgery of the aortic arc
62733517|NCT03215628|ACTIVE_COMPARATOR|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
62733518|NCT01922362|EXPERIMENTAL|Negative pressure drainage system|Negative pressure drainage system
62733519|NCT01922362|ACTIVE_COMPARATOR|Indirect wet dressing group|Indirect wet dressing
62733520|NCT03544801||sample group ,300|CSVD patients after symptomatic stroke
62733521|NCT03544801||control group,100|community population
62733522|NCT01378650|EXPERIMENTAL|Cilostazol group|Administration of Cilostazol 100mg twice a day for 4 weeks
62733523|NCT01378650|PLACEBO_COMPARATOR|Placebo group|placebo drug twice a day for 4 weeks.
62733524|NCT06368414|OTHER|Asciminib arm|
62733525|NCT02936518|EXPERIMENTAL|Intervention|
62733526|NCT02776605|EXPERIMENTAL|Ponatinib|"1. Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)~2. Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.~3. Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT.~4. HSCT (performed ideally within 1 month from the end of consolidation).~5. Post HSCT therapy (MRD monitoring)"
62733527|NCT05679960|ACTIVE_COMPARATOR|Patients low gastrointestinal tract bleeding|Patients presenting in the surgical outpatients or emergency department with low gastrointestinal tract bleeding
62733528|NCT05679960|ACTIVE_COMPARATOR|Participants who are high risk due to a family history of CRC|First degree relatives of patients diagnosed with colorectal cancer
62733529|NCT05679960|ACTIVE_COMPARATOR|Patients with a diagnosis of stage I-III CRC who have no evidence of disease|Patients previously diagnosed of stage I-III CRC and managed in the hospital but are now having no evidence of disease
62733530|NCT00981162|EXPERIMENTAL|Treatment (sorafenib tosylate and everolimus)|Patients receive everolimus PO once daily and sorafenib tosylate PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
62733531|NCT04408391||COVID-19 patients with anosmia|Patients reporting loss of smell and scoring \< 30 on a VAS 0-100 for ability to detect n-Butanol diluted 1/1000
62733532|NCT04408391||COVID-19 patients without anosmia|Patients reporting no loss of smell and scoring \> 80 on a VAS 0-100 for ability to detect n-Butanol diluted 1/16000
62733533|NCT00289289|ACTIVE_COMPARATOR|On-Off|Subjects have intervention pacing features turned On according to randomization assignment in the first crossover period then Off in the second period.
62733534|NCT00289289|ACTIVE_COMPARATOR|Off-On|Subjects have intervention pacing features turned Off according to the randomization assignment for the first crossover period and then On in the second period.
62733535|NCT00289289|NO_INTERVENTION|Non-randomized|Subjects that did not have device recorded episodes of atrial tachycardia/atrial fibrillation during the 3 month observation period post-implant did not qualify for randomization but were continued to be followed in the study. There were no programming requirements and symptom activations were not collected.
62733536|NCT04482777||ITP|Patient newly diagnosied with ITP
62733537|NCT04482777||Treated|Patients with ITP recived treatment
62733538|NCT04482777||Control|Healthy people
62733539|NCT05656183|EXPERIMENTAL|Single Arm|To investigate the diagnostic efficacy of WGS and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.
62733540|NCT03256669|EXPERIMENTAL|umbilical incision|neonates undergone surgery by umbilical incision
62733541|NCT02840942|NO_INTERVENTION|Non-robot|Patients will interact with Child Life as per usual routine, no robot condition
62733542|NCT02840942|EXPERIMENTAL|Coping Robot|Robot will play coping game with children. Robot will speak and child will respond by touching tablet. Child life still present.
62733543|NCT02840942|EXPERIMENTAL|Non-coping Robot|Robot will play distraction only game, in addition to Child Life and routine cares
62733544|NCT02881411|ACTIVE_COMPARATOR|Self-soft tissue therapy|Intervention group: Fibromyalgia coping skills programme plus self-soft tissue therapy (SSTT) SSTT consists of MTrP therapy on TrP sites in either the lower leg/foot or forearm/hand. MTrP therapy will be administered by the researcher for only two sessions which will include training to teach the participant how to do SSTT on themselves. All participants in the intervention group will also receive an advice booklet for SSTT.
62733545|NCT02881411|ACTIVE_COMPARATOR|Fibromyalgia coping skills programme|Control group:Fibromyalgia coping skills programme only. The FCSP is a non-pharmacological, multidisciplinary exercise and education group programme. Its main aims are to provide condition-specific, patient centred, self-management education and advice, in line with national drivers for long-term conditions and international FMS clinical guidelines.
62733546|NCT00969163|EXPERIMENTAL|1|2.5 mg testosterone gel
62733547|NCT00969163|EXPERIMENTAL|2|300 ug testosterone gel
62733548|NCT00969163|PLACEBO_COMPARATOR|3|placebo gel
62733549|NCT04019964|EXPERIMENTAL|Nivolumab in biochemically recurrent prostate cancer|"Participants with previous prostatectomy or radiation therapy who subsequently developed detectable prostate specific antigen (PSA) levels (biochemically recurrent prostate cancer)."
62733550|NCT03612128|OTHER|control group|Children continued their traditional physiotherapy
62733551|NCT03612128|ACTIVE_COMPARATOR|intervention group|We applied mirror therapy in addition to traditional physiotherapy
62733552|NCT06307990||RTH Syndromes|Patients with THRA or THRB gene mutations
62733553|NCT05053074|EXPERIMENTAL|NHF - NHF/CO2|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) alone, then NHF (30l/min) plus 1% CO2.
62733554|NCT05053074|EXPERIMENTAL|NHF/CO2 - NHF|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) plus 1% CO2 , then NHF (30l/min) alone.
62733555|NCT04579406||non-diabetic group|The non-diabetic patients undergoing non-cardiac surgery.
62733556|NCT04579406||Diabetic group|The diabetic patients without peripheral neuropathy undergoing non-cardiac surgery.
62733557|NCT04579406||Diabetic neuropathic group|The diabetic patients with peripheral neuropathy undergoing non-cardiac surgery.
62733558|NCT00426868|EXPERIMENTAL|Treatment|
62733559|NCT00426868|PLACEBO_COMPARATOR|Placebo|
62733560|NCT02947802|EXPERIMENTAL|Consumer Support|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale.
62733561|NCT02947802|EXPERIMENTAL|Consumer Support with Effectiveness Info|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
62733562|NCT01821092|ACTIVE_COMPARATOR|standard implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in healed ridge, prosthetic connection with switching platform
62733563|NCT01821092|ACTIVE_COMPARATOR|immediate implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in immediate post-extraction sites, prosthetic connection with switching platform
62733564|NCT05503979||Substances Users|Substances users confirmed with Viral Load for HCV. after that will be evaluated through laboratory studies (CBC and blood chemistry), HIV/HBV (Hepatitis B Virus) serology, fibrosis status will be evaluated through APRI (AST to Platelet Ratio Index) and FIB-4. The antiviral treatment (sofosbuvir/Velpatasvir) will be chosen according to the characteristics of each patient and follow-up will be maintained according to the national plan with a visit at the end of treatment and 12 weeks after its end to assess SVR. The importance of this project is characterized by minimal monitoring, patients and doctors education by telementoring, multidisciplinary teams and integral treatment.
62733565|NCT00393991|EXPERIMENTAL|1|FlutiForm 100/10 μg
62733566|NCT00393991|ACTIVE_COMPARATOR|2|Fluticasone 100 μg
62733567|NCT00393991|ACTIVE_COMPARATOR|3|Formoterol 10 μg
62733568|NCT00393991|PLACEBO_COMPARATOR|4|Placebo
62733569|NCT04263116|EXPERIMENTAL|BAM group|Balloon assisted maturation
62733570|NCT04263116|EXPERIMENTAL|NO BAM|NO Balloon assisted maturation
62733571|NCT03389698||Cohort A|Cognitively normal control participants aged 20 - 40 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.
62733572|NCT03389698||Cohort B|Cognitively normal control participants aged 65 - 85 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.
62733573|NCT03389698||Cohort C|Amnestic mild cognitive impairment (aMCI) patients aged 65 and older. Participants in Cohort C will be matched by age and gender to participants in Cohort B. Participants in Cohort C will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 9 minutes of scan time.
62733574|NCT03419546||Bronchoscopic procedures|Bronchoscopies performed in different sites to evaluate the level of satisfaction of the operators with the device Ambu® aScope™ 4
62733575|NCT01274234|EXPERIMENTAL|COMBO Stent|COMBO Stent
62733576|NCT03060915|OTHER|Polysomnography and actigraphy|Polysomnography and actigraphy
62733577|NCT04779450|EXPERIMENTAL|Synchronous Telemonitoring|The sessions will be supervised by a therapist and conducted via video call using the WhatsApp® application, lasting 50 minutes, 3 times a week, for 6 consecutive weeks, the exercises will basically consist of active stretching, mobilization and scapular stabilization, and active shoulder exercises with gradual range of motion.
62733578|NCT04779450|EXPERIMENTAL|Asynchronous Telemonitoring|An explicative schedule with the exercises to be performed asynchronously during the week will be delivered weekly via e-mail and WhatsApp®. The exercises will be the same as those performed by the synchronous telemonitoring group, and the participant will be free to ask any questions about the protocol to the therapist at any time via text message or e-mail.
62733579|NCT04779450|ACTIVE_COMPARATOR|Control Group|Will receive only a booklet of usual guidelines for women after breast cancer, such as skin care, return to activities, upper limb functionality, self-care, lymphedema and physical activity practice.
62733580|NCT02674113|ACTIVE_COMPARATOR|regional anesthesia bupivacaine|regional anesthesia (a single shot fascia iliaca block using bupivacaine) prior to hip arthroscopy
62733581|NCT02674113|PLACEBO_COMPARATOR|regional anesthesia placebo|subcutaneous injection procedure placebo (0.9% sodium chloride in water)
62733582|NCT01060904|EXPERIMENTAL|1|brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
62733583|NCT01060904|EXPERIMENTAL|2|brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)
62733584|NCT06495320|EXPERIMENTAL|Experimental group|Rational drug use education will be applied to the experimental group.
62733585|NCT06495320|NO_INTERVENTION|Control group|No action will be taken
62733586|NCT01876680|EXPERIMENTAL|Group 1: Stretching and aerobic exercise|Group 1 undertook a stretching programme for neck/shoulder muscles three times weekly and performed aerobic exercise för 30 minutes three times weekly.
62733587|NCT01876680|EXPERIMENTAL|Group 2: Strength training|Group 2 undertook a stretching programme for neck/shoulder muscles three times weekly, performed aerobic exercise three times weekly and performed weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
62733588|NCT05525130|EXPERIMENTAL|Food supplement|Two doses (sachets) a day during 4 weeks before the ESWL. After the ESWL, one dose a day during 6 weeks.
62733589|NCT05525130|PLACEBO_COMPARATOR|Placebo|Two doses (sachets) a day during 4 weeks before the ESWL. After the ESWL, one dose a day during 6 weeks.
62733590|NCT01736423|EXPERIMENTAL|Female Patients with D-IBS|
62733591|NCT02831127|EXPERIMENTAL|short message service group|Patients in this arm received conventional instructions plus short message reminder.
62733592|NCT02831127|ACTIVE_COMPARATOR|conventional group|Patients in this arm just received conventional instructions.
62733593|NCT01780844|ACTIVE_COMPARATOR|Standard of Care|Basiliximab induction + Tacrolimus + MMF + Corticosteroids
62733594|NCT01780844|EXPERIMENTAL|CNI avoidance|Basiliximab induction + ASKP1240 + MMF + Corticosteroids
62733595|NCT01780844|EXPERIMENTAL|CNI minimization-MMF avoidance|Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
62733596|NCT04809519|EXPERIMENTAL|UHTINuM|UHTINuM is an acronym that defines multimodal interventions consisting of three components. These interventions are as follows: (1) Structured yoga program including meditation and breathing techniques (2) Hypertensive Treatment Compliance Training (3) Teaching blood pressure measurement and monitoring at home.
62733597|NCT04809519|ACTIVE_COMPARATOR|Control group|Control group will be receive information notes and standard brochures related to physical activity, healthy lifestyle behaviors advice, stop smoking etc. and will be referred to a specialist physician.
62733598|NCT03345030||Unexplained infertile group|Patients diagnosed as unexplained infertility (UI) were recruited to the study. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. If the results of all this tests were normal, patients were accepted as UI.
62733599|NCT03345030||Control group|The control group received in vitro fertilization (IVF) for tubal factor and included only those women who had salpingectomy for ectopic pregnancy or proximal tubal obstruction because of low-grade infection or fimbrial occlusion with or without mild peritubal adhesions. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease were excluded. Patients with male factor except oligoasthenospermia were also recruited for the study.
62733600|NCT05760027|EXPERIMENTAL|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
62733601|NCT05760027|OTHER|Regular exercise|The group of athletes will their usual exercise for 30 days.
62733602|NCT01430143|EXPERIMENTAL|600 kcal/day|Exercise combusting 600 kcal/day, 7 days/week for 12 weeks.
62733603|NCT01430143|EXPERIMENTAL|300 kcal/day|Exercise combusting 300 kcal/day, 7 days/week for 12 weeks.
62733604|NCT01430143|NO_INTERVENTION|Sedentary|Continued sedentary living.
62733605|NCT00797264|EXPERIMENTAL|A|Ketamine pre and per operative, and morphine postoperative
62733606|NCT00797264|ACTIVE_COMPARATOR|B|NaCl pre and per operative, and morphine postoperative
62733607|NCT00797264|EXPERIMENTAL|C|Ketamine and morphine postoperative
62735179|NCT03572959|ACTIVE_COMPARATOR|comparison group (active control)|0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application. Patients used the medication for 4 weeks , and if extension of treatment was required after that period , patients were instructed to apply miconazole oral gel (JANSSEN-CILAG Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Australia) four times a day for one week to protect from superimposed fungal infections.15
62733608|NCT05085041|EXPERIMENTAL|Intervention Group|"The participants in this group will receive 8 sessions of a multi-component online education intervention. The education curriculum will be focused on addressing evidence-based healthy habits that are related to preventing childhood obesity: more vegetables and fruits, less screen time, and more physical activity. Topics may include age-appropriate nutrition and eating, picky eating, positive parental feeding practices, active playtime, and screen time. Strategies for eating healthy on a budget will be also provided to the participants.~The intervention will incorporate multi-component as follow: instructional YouTube videos, online cooking activities, reminder text messages with key information, and telephone consultation. Each session will include a lifestyle component regarding eating, feeding, and physical activity, aimed at equipping parents with knowledge and skills to improve fruit and vegetable intake and physical activity levels of young children."
62733609|NCT05085041|NO_INTERVENTION|Control Group|The participants in the control group will receive no intervention. However, the investigators will provide the control group with a copy of the booklet that includes 2020 USDA dietary guidelines for a healthy diet for young children. This will enable the investigators to see if the multi-component education intervention (stated above) is more effective on behavior changes than the written booklet in the control group.
62733610|NCT01268046|EXPERIMENTAL|Young postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
62733611|NCT01268046|EXPERIMENTAL|Older postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
62733612|NCT01268046|PLACEBO_COMPARATOR|Young postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
62733613|NCT01268046|PLACEBO_COMPARATOR|Older postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
62733614|NCT03024112|EXPERIMENTAL|Heated humidified high-flow nasal cannula (HHFNC) oxygen|The intervention group received HHFNC O2 at a set flow of 40L/min. FiO2 was titrated by respiratory therapists to maintain SpO2 ≥ 90%. The HHFNC O2 apparatus included: 1) Air-Oxygen blender - capable of delivering 21-100% FiO2 at flow rates up to 60L/min, 2) Heated Humidifier - providing active heating and humidification to the delivered air-O2 blend, 3) Nasal cannula - larger diameter, slightly elongated nasal cannula with single limb connection to humidifier
62733615|NCT03024112|ACTIVE_COMPARATOR|Standard oxygen Therapy|The standard O2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO2 ≥ 90%.
62733616|NCT05828615|ACTIVE_COMPARATOR|Group A|Alternate nostril breathing exercise 2 times a day, 10 min duration of exercise each time, for 5 days
62733617|NCT05828615|ACTIVE_COMPARATOR|Group B|Breathing control exercise 2 times a day, 10 min duration of exercise each time, for 5 days
62733618|NCT05415254|EXPERIMENTAL|treatment group|calcitriol 0.25ug daily for 10 days + COVID-19 routine treatment
62733619|NCT05415254|NO_INTERVENTION|control group|COVID-19 routine treatment
62733620|NCT04022525||leflunomide responsive vs non-responsive|
62733621|NCT03081663|EXPERIMENTAL|Quads-Sparing Approach with Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and a tourniquet.
62733622|NCT03081663|ACTIVE_COMPARATOR|Medial Para-Patellar with Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and a tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
62733623|NCT03081663|ACTIVE_COMPARATOR|Quads-Sparing Approach w/o Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and no tourniquet.
62733624|NCT03081663|ACTIVE_COMPARATOR|Medial Para-Patellar w/o Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and no tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
62733625|NCT05263570||Stage II-III HR+/HER2+ Early Breast Cancer|Stage II-III HR+/HER2+ Early Breast Cancer
62733626|NCT05813184||Control|Women not exposed to antibiotics throughout the entire duration of pregnancy
62733627|NCT05813184||Prenatal antibiotics|Women exposed to antibiotics for at least 7 days from the 32nd week of gestation
62733628|NCT01652053||Disc Nucleus Replacement|Disc Nucleus Replacement (InterCushion DNP)
62733629|NCT01596712|EXPERIMENTAL|QGE031 Dose 1|QGE031 Dose 1: subcutaneous injection, single dose
62733630|NCT01596712|EXPERIMENTAL|QGE031 Dose 2|QGE031 Dose 2: subcutaneous injection, single dose
62733631|NCT01596712|EXPERIMENTAL|QGE031 Dose 3|QGE031 Dose 3: subcutaneous injection, single dose
62733632|NCT01596712|PLACEBO_COMPARATOR|Placebo|Placebo to QGE031 : subcutaneous injection, single dose
62733633|NCT01346943|EXPERIMENTAL|AAA Stent Graft System|Altura Medical AAA Stent Graft System
62733634|NCT05116397|EXPERIMENTAL|4% CO2|Inspired gas containing 4% CO2, 21% O2, balance N2
62733635|NCT05116397|EXPERIMENTAL|2% CO2|Inspired gas containing 2% CO2, 21% O2, balance N2
62733636|NCT05116397|SHAM_COMPARATOR|0% CO2|Inspired gas containing 0% CO2, 21% O2, balance N2
62733637|NCT02569424|EXPERIMENTAL|ventilated patients|Patient's position (Supine or Trendelenburg strict -20°)
62733638|NCT05401344||dry nose patients|
62733639|NCT05401344||normal controls|
62733640|NCT03815630|EXPERIMENTAL|PD-1 and dc-cik treatment group|
62733641|NCT04372550|ACTIVE_COMPARATOR|Standard of Care|"Standard of care treatment:~- including passive / assisted / active movements, stretching, functional exercise, scar treatment~Duration: 6-12 weeks"
62733642|NCT04372550|EXPERIMENTAL|Exercise|"Standard of care + added exercises~Exercise type: resistance and aerobic exercise~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)~Duration: 6-12 weeks"
62735824|NCT05202899|NO_INTERVENTION|Control Group|general anesthesia without rocuronium
62736288|NCT01279291|EXPERIMENTAL|KHK2866, pegylated liposomal doxorubicin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with monthly PLD (40 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
62733643|NCT05822947|EXPERIMENTAL|Active manual therapy|Active manual therapy intervention involved mobilization of the lumbar paraspinal musculature. With participants laying prone on a chiropractic table, the intervention provider administered hand-reinforced circumferential movements to six focal areas, using continuous ischemic compression strokes, and adjusting the pressure to participants' tolerability.
62733644|NCT05822947|SHAM_COMPARATOR|Control manual therapy|Control MT intervention included light touch to six distal, broad areas of the thoracic region, with a synchronized breathing exercise.
62733645|NCT03265145|EXPERIMENTAL|Stiolto Respimat|
62733646|NCT03265145|ACTIVE_COMPARATOR|ICS plus LABA plus LAMA (triple therapy)|ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)
62733647|NCT04505644|EXPERIMENTAL|lidocaine patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
62733648|NCT04505644|ACTIVE_COMPARATOR|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
62733649|NCT04505644|PLACEBO_COMPARATOR|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
62733650|NCT01588041||Vitreoretinal Interface Disease Group|A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
62733651|NCT01588041||Macular Hole Group|A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
62733652|NCT01588041||Retinal Detachment Group|A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
62733653|NCT01588041||Diabetic Retinopathy Group|A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
62733654|NCT01588041||Rare Related Macular Disease Group|Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
62733655|NCT01588041||Generation 2 MIOCT Transition Group|80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
62733656|NCT01588041||Endothelial Keratoplasty Group|150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
62733657|NCT01588041||Anterior Lamellar Keratoplasty Group|150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
62733658|NCT03820336|EXPERIMENTAL|Extra Virgin Olive Oil|
62733659|NCT03820336|PLACEBO_COMPARATOR|Control Oil|
62733660|NCT01939522|EXPERIMENTAL|Prevenar13® (13-valent pneumococcal conjugate vaccine)|Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.
62733661|NCT06260449|EXPERIMENTAL|Surgical removal|Surgical removal of the whitish granuloma
62733662|NCT06260449|NO_INTERVENTION|Medical treatment|Topical and systemic steroid
62733663|NCT06260449|EXPERIMENTAL|Laser treatment|Argon laser
62733664|NCT04717271|EXPERIMENTAL|Movement Guidance Group (MVG)|In the MVG Group, the physiotherapist will provide kinesthetic stimuli by assisting manually the participant movements.
62733665|NCT04717271|EXPERIMENTAL|No Movement Guidance Group (NO-MVG)|In the NO-MVG, the involvement of the physiotherapist will be restricted to guarantee the safety of the participant.
62733666|NCT04211285||community dwelling elderly|community dwelling elderly patients (60 years or older), can read and write, able to use the android software applications
62733667|NCT01963793|OTHER|placebo (left) / aprepitant (right)|placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)
62733668|NCT01963793|OTHER|aprepitant (left) / placebo (right)|aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)
62733669|NCT03443856|OTHER|chemotherapy arm|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
62733670|NCT03443856|EXPERIMENTAL|immunotherapy arm|Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
62733671|NCT05811754||HZ/su-Exposed Group|Pregnant adult women diagnosed with immunocompromised (IC) conditions exposed to HZ/su vaccine during pregnancy.
62733672|NCT05811754||Comparison (Unexposed) Group|Pregnant adult women diagnosed with immunocompromised (IC) conditions who were not vaccinated with HZ/su vaccine (i.e., not receiving at least one dose of HZ/su vaccine during pregnancy).
62733673|NCT04822818|EXPERIMENTAL|Bevacizumab + SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
62733674|NCT04822818|ACTIVE_COMPARATOR|SOC|SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
62733675|NCT03138317|EXPERIMENTAL|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
62733676|NCT03138317|EXPERIMENTAL|Plasma|Group 2: knee injection of Plasma
62733677|NCT03138317|PLACEBO_COMPARATOR|Placebo|Group 3: knee injection of placebo (saline solution)
62733678|NCT05752097||Renal inflammatory or fibrotic disease|\[18F\]AIF-NOTA-FAPI-04 (4.81MBq/Kg) will be injected intravenously according to the patient's body weight. PET/CT examination will be performed 50-60 minutes after the injection of radiotracer. The patients will undergo renal puncture biopsy one day after PET/CT examination.
62733679|NCT03088787||Patients for TAVR|Patients for TAVR
62733680|NCT03191643||differentiated thyroid cancer|Patients with locally recurrent thyroid cancer, treated with radical radiotherapy after total thyroidectomy +/- central compartment and/or laterocervical lymphadenectomy, previously treated with one or more cycles of 131 Iodine-ablation (RAI) and TSH suppression.
62733681|NCT02104791||procalcitonin in blood|-Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
62733682|NCT02104791||plasma of blood|-Group 2: Preterm premature rupture of membrane Group include 50 pregnant women
62733683|NCT02104791||procalcitonin,prematureruptureofmembrane in blood|"Complete history including (special habits like smoking and alcohol taking, menstrual history especially LMP, medical diseases, past obstetric history including duration, mode of delivery for each pregnancy, and if there were fetal or maternal complications).~Physical examination including (general condition, height, weight, vital signs).-Ultrasound to execlude multiple pregnancies, IUFD and to confirm oligohydraminos in group2.~The venous blood samples will be taken for measuring of -Procalcitonin in mothors -CRP and WBCs in mothers to detect infection -CRP in neonates of mothers of group 2.~They will be asked for their permission and consent."
62733684|NCT02266199||conservative patients|in-patients on pneumology, cardiology, neurology, gastroenterology, endocrinology
62733685|NCT02266199||operative patients|inpatient on Traumatology, Plastic Surgery, Cardiothoracic Surgery, Gynecology, Abdominal Surgery
62733686|NCT01480583|EXPERIMENTAL|GRN1005|GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
62733687|NCT01480583|EXPERIMENTAL|GRN1005 with trastuzumab|GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
62733688|NCT03271320||systemic sclerosis|patients with systemic sclerosis
62733689|NCT03271320||control|Healthy subjects
62733690|NCT05296551|EXPERIMENTAL|Dual Task One|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is simple.
62733691|NCT05296551|EXPERIMENTAL|Dual Task Two|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is complex.
62733692|NCT05296551|ACTIVE_COMPARATOR|Control|Participants perform only a motor-task that is the same for all groups (no simultaneous cognitive task).
62733693|NCT00738608||1|33 pat. with verum
62733694|NCT00738608||2|33 Pat. with placebo
62733695|NCT01174979|EXPERIMENTAL|Caroverin|
62733696|NCT01174979|PLACEBO_COMPARATOR|Placebo|
62733697|NCT04231682|EXPERIMENTAL|Denosumab receiving group.|Patients in this arm will receive denosumab injection 60 mg subcutaneously every 6 months. (A total of 4 injections)
62733698|NCT04231682|PLACEBO_COMPARATOR|Placebo receiving group.|Patients in this arm will receive Placebo injection subcutaneously every 6 months. (A total of 4 injections)
62733699|NCT03823105|EXPERIMENTAL|Nocturnal Recording|Recording of photoplethysmographic pulse wave and accelerometry with two devices (OHR Tracker, PulseWatch) in parallel to the standard polysomnography
62733700|NCT04504344|EXPERIMENTAL|Active tDCS|Active tDCS
62733701|NCT04504344|SHAM_COMPARATOR|Sham tDCS|Sham tDCS
62733702|NCT01312025|PLACEBO_COMPARATOR|conventional laparoscopic cholecystectomy|
62733703|NCT01312025|ACTIVE_COMPARATOR|modified laparoscopic cholecystectomy|
62733704|NCT00598923|EXPERIMENTAL|1|Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
62733705|NCT00598923|EXPERIMENTAL|2|topiramate for 3 months after loading dose of phenytoin
62733706|NCT00598923|PLACEBO_COMPARATOR|3|Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
62733707|NCT05777785|EXPERIMENTAL|Active|VIZO Glasses- personalized
62733708|NCT01282255|EXPERIMENTAL|A|
62733709|NCT01282255|PLACEBO_COMPARATOR|B|
62733710|NCT00241176|EXPERIMENTAL|Aripiprazole|
62733711|NCT03786926|EXPERIMENTAL|Treatment|All patients take HMPL-689 taken daily
62733712|NCT01835301||DES|Patients who received a DES stent \> 3 years ago.
62733713|NCT01835301||BMS|Patients who received BMS stents \> 3 years ago.
62733714|NCT06032559|EXPERIMENTAL|MORE|Eight group sessions of Mindfulness-Oriented Recovery Enhancement plus methadone treatment as usual (TAU)
62733715|NCT06032559|ACTIVE_COMPARATOR|Scripted Mindfulness Practice (SMP)|Eight group sessions of scripted mindfulness practice plus TAU.
62733716|NCT06032559|ACTIVE_COMPARATOR|Treatment-as-Usual|Methadone treatment as usual.
62733717|NCT02516397|EXPERIMENTAL|Omnia group|After 2 weeks of run-in period, subjects take 2 Omnia pills per meal (3 meals a day) for 12 weeks.
62733718|NCT02516397|PLACEBO_COMPARATOR|Placebo group|After 2 weeks of run-in period, subjects take 2 Placebo pills per meal (3 meals a day) for 12 weeks.
62733719|NCT04944238||Patients implanted with Ankoris IOL|To assess the IOL stability, slitlamp photos of the consecutive 30 patients with respect to time will then be analysed with a 5% confidence interval.
62733720|NCT05954949||Ileoanal pouch adenomas detection assessment|Every patient who needs follow up lower digestive examination for familial adenomatous polyposis after colectomy can join this study with ileal pouch adenomas detection by experienced endoscopist.
62733721|NCT03249324|EXPERIMENTAL|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
62736289|NCT05645237||Applied radiotherapy protocol (subcohort) 1|60 Gy in 20 fractions of 3 Gy external beam radiotherapy
62736290|NCT05645237||Applied radiotherapy protocol (subcohort) 2|42.7 Gy in 7 fractions of 6.1 Gy external beam radiotherapy
62733722|NCT03249324|ACTIVE_COMPARATOR|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
62733723|NCT00515528|EXPERIMENTAL|Vaccine Alone|Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression.
62733724|NCT00515528|EXPERIMENTAL|Vaccine plus Ontak|Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration
62733725|NCT02015949|ACTIVE_COMPARATOR|Methylphenidate|2 weeks of 0.3mg/kg twice daily of methylphenidate to the nearest 5mg
62733726|NCT02015949|PLACEBO_COMPARATOR|Sugar pill|2 weeks of twice daily placebo
62733727|NCT00610792|EXPERIMENTAL|1|
62733728|NCT05976568|EXPERIMENTAL|Arm 1|QL1706 in combination with bevacizumab and chemotherapy
62733729|NCT05976568|EXPERIMENTAL|Arm 2|QL1706 in combination with bevacizumab
62733730|NCT05976568|EXPERIMENTAL|Arm 3|QL1706 in combination with chemotherapy
62733731|NCT05976568|ACTIVE_COMPARATOR|Arm 4|Sintilimab in combination with bevacizumab
62733732|NCT04015570|EXPERIMENTAL|High Volume Plasma Exchange with SMT|"PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity.~Standard Medical Treatment (Albumin + High Caloric Diet)"
62733733|NCT04015570|ACTIVE_COMPARATOR|Standard Medical Treatment|Standard Medical Treatment (Albumin + High Caloric Diet)
62733734|NCT01637584|EXPERIMENTAL|Prazosin|Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
62733735|NCT01637584|PLACEBO_COMPARATOR|Placebo|A placebo is a sugar pill, which will be used to compare with the results of the active medication
62733736|NCT04262882|EXPERIMENTAL|Multilevel Family Planning Intervention|A multi-level, community-based intervention delivered in groups of couples to increase contraceptive uptake, reduce discontinuation, and reduce the incidence of unintended pregnancy, and improve intermediate outcomes (knowledge, attitudes, norms, communication, equity).
62733737|NCT04262882|ACTIVE_COMPARATOR|Time and attention-matched control|A community sanitation intervention delivered in groups of couples to increase at-home and community hygiene practices.
62733738|NCT01119196|NO_INTERVENTION|glucose-based dialysate|most frequently used Standard of Care (SOC) dialysate
62733739|NCT01119196|OTHER|Icodextrin dialysate|alternate SOC dialysate
62733740|NCT04594135|EXPERIMENTAL|anti-CD5 CAR T cells|Experimental: anti-CD5 CAR T cells Dose escalation phase: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells with an escalation approach, 1e6 to 5e6 CAR-T cells/kg
62733741|NCT05474703||AUK with Dydrogestrone|Patients who applied for abnormal uterine bleeding and received oral dydrogesterone therapy for at least 6 months
62733742|NCT05474703||AUK with Levonorgestrel releasing intrauterin device|Patients who applied for abnormal uterine bleeding and were administered levonorgestrel-releasing intrauterine device at least 6 months ago
62733743|NCT02651324|EXPERIMENTAL|Treatment Group|A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.
62733744|NCT02651324|PLACEBO_COMPARATOR|Placebo|A placebo (saline) will be given in place of ketamine
62733745|NCT01151384|EXPERIMENTAL|LE-DT|
62733746|NCT00544024||Reference|Lariam was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
62733747|NCT00544024||T1|Mephaquin was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
62733748|NCT00544024||T2|Mefloquine-AC Farma was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
62733749|NCT04397367|EXPERIMENTAL|Ruxolitinib10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
61976780|NCT02309489|NO_INTERVENTION|Control|"* Receive standard maternity care~* No active encouragement of partner involvement, no extra sessions offered"
62736291|NCT05645237||Applied radiotherapy protocol (subcohort) 3|38 Gy in 4 fractions of 9 Gy stereotactic external beam radiotherapy
62733750|NCT04397367|EXPERIMENTAL|Ruxolitinib5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
62733751|NCT04397367|EXPERIMENTAL|Ruxolitinib5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
62733752|NCT04397367|EXPERIMENTAL|Ruxolitinib 2.5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
62733753|NCT05722834|EXPERIMENTAL|SOAR intervention|The SOAR intervention will be a remote intervention that will follow a self-regulation process in which the participant first selects a specific problem to address and researches how asthma is preventing resolution of the problem, and finally identifies and develops a plan to achieve the objective.
62733754|NCT01034982|EXPERIMENTAL|1|tosylate salt tablet
62733755|NCT01034982|EXPERIMENTAL|2|free suspension
62733756|NCT01034982|EXPERIMENTAL|3|tosylate salt tablet
62733757|NCT01034982|EXPERIMENTAL|4|free suspension
62733758|NCT02467192|EXPERIMENTAL|Low dose CT|All patients will have Thoracic CT scan
62733759|NCT05521347|EXPERIMENTAL|caffeine|capsules with 3 mg/kg of caffeine
62733760|NCT05521347|PLACEBO_COMPARATOR|placebo|The placebo capsule contained flour
62733761|NCT04420832|ACTIVE_COMPARATOR|Surgical treatment|Patients with a distance of 5 mm or more between tendon ends will be treated surgically and with physiotherapy
62733762|NCT04420832|OTHER|Non-surgical treatment|Patients with a distance of less than 5 mm between tendon ends will be treated non-surgically and with physiotherapy
62733763|NCT02195700|EXPERIMENTAL|SD-809|SD-809 tablets taken twice daily for 12 weeks.
62733764|NCT02195700|PLACEBO_COMPARATOR|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
62733765|NCT04566952|EXPERIMENTAL|Anlotinib combined With dose-reduced olaparib|Anlotinib-olaparib combination therapy until disease progression
62733766|NCT04192669||Anxio-depressive patients|Patients with a depressive or anxious disorder going to the Psychiatry Department of the CHU Brugmann Hospital.
62733767|NCT03549494|EXPERIMENTAL|Ocoxin-Viusid®|
62733768|NCT03902015|EXPERIMENTAL|Nuance Phone case|"Nuance Hearing has developed a technology enabling focused hearing. The Selective Noise Cancellation (SNC) technology consists of an advanced beam-forming algorithm that tones down the ambient sound by up to 15 decibels (dB) in order to focus on a primary audio source. The device consists of a special phone case(for iPhone) containing microphone array. Controlling the direction of focus is enabled through the use of a designated app. The user can place the phone case on his/hers table and can choose the direction of preferred listening, without having to ask the talker to hold the device."
62733769|NCT03402191|ACTIVE_COMPARATOR|L-arginine|l-arginine for pulmonary hypertension in patients with thalassemia.
62733770|NCT03402191|ACTIVE_COMPARATOR|Sildenafil|Sildenafil for pulmonary hypertension in patients with thalassemia.
62733771|NCT03402191|NO_INTERVENTION|Control|No pulmonary hypertension
62733772|NCT04508933||Typical ARDS|ARDS due to non Covid19 causes
62733773|NCT04508933||C-ARDS|ARDS due to Covid19
62733774|NCT05561439||Cardiology: Coronary/Valvular|
62733775|NCT05561439||Cardiology: Rhythmology|
62733776|NCT05561439||Cardiology: Mixed|
62733777|NCT05561439||Radiology: Simple Vascular|
62733778|NCT05561439||Radiology: Complex Vascular|
62733779|NCT05561439||Radiology: Mixed Vascular|
62733780|NCT05561439||Radiology: Simple Osteoarticular|
62733781|NCT05561439||Radiology: Complex Osteoarticular|
62733782|NCT05561439||Radiology: Mixed Osteoarticular|
61976781|NCT01711177|SHAM_COMPARATOR|Normal control|Normal patient placebo
61976782|NCT01711177|SHAM_COMPARATOR|Glaucoma suspect|Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
61976783|NCT01711177|EXPERIMENTAL|Newly diagnosed glaucoma|Treated with Travoprost (0.04%)
62733783|NCT05561439||Radiology: Simple Neuroradiology|
62733784|NCT05561439||Radiology: Complex Neuroradiology|
62733785|NCT05561439||Radiology: Mixed Neuroradiology|
62733786|NCT05561439||Radiology: Mixed|
62733787|NCT05561439||Radiology: Simple Oncology|
62733788|NCT05561439||Radiology: Complex Oncology|
62733789|NCT05561439||Radiology: Mixed Oncology|
62733790|NCT02819986|EXPERIMENTAL|Progressive Goal Attainment Program|10 one hour weekly therapy sessions focused on behavioural interventions
62733791|NCT04884750|EXPERIMENTAL|High engagement mechanisms, tailed content|During this time the investigators will conduct a 2x2 factorial RCT (with the individual the unit of random assignment and measurement) to assess the impact of two app design features on engagement and outcomes: (1) the investigators will manipulate engagement mechanisms (ENGAGEMENT), including reminder notifications and trust-building dialogue by the ECA and, (2) independently manipulate cultural tailoring of vaccination promotion counseling language used by the agent (TAILORING) to either adaptive religiosity (tailored) or secular (non-tailored). The investigators' primary hypotheses are that participants with have significantly greater vaccination completion rates in the high engagement and tailored conditions at 6 months (H1) and 12 months (H2) compared to other conditions.
62733792|NCT04884750|EXPERIMENTAL|Low engagement mechanisms, tailed content|manipulate low engagement mechanisms while provide adaptive religiosity (tailored) content
62733793|NCT04884750|EXPERIMENTAL|High engagement mechanism, non-tailed content|manipulate high engagement mechanisms while provide secular (non-tailored) content
62733794|NCT04884750|EXPERIMENTAL|Low engagement mechanism, non-tailed content|manipulate low engagement mechanisms and provide secular (non-tailored) content
62733795|NCT01816191|EXPERIMENTAL|Diltiazem Hydrochloride|Topical cream and oral pill
62733796|NCT05223023||1/Assessment of the opinions of the physiotherapists|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
62733797|NCT03449563|PLACEBO_COMPARATOR|Placebo group (group G)|
62733798|NCT03449563|ACTIVE_COMPARATOR|Ultrasound-guided TPVB group (group U)|
62733799|NCT03449563|EXPERIMENTAL|open TPVB group(group E)|
62733800|NCT03496064||Anterior circulation LVO patients with ASPECTS <6|
62733801|NCT03496064||Anterior circulation LVO patients with NIHSS<8|
62733802|NCT03496064||Posterior versus anterior circulation LVO patients|
62733803|NCT03496064||LVO patients with isolated PCA or ACA occlusions|
62733804|NCT03496064||Tandem lesions versus non-tandem lesion|
62733805|NCT03496064||Bridging vs Direct MT|
62733806|NCT03137680|NO_INTERVENTION|Control Arm|No specific exercise regime for the control group. Usual hospital SOP will be adhered to
62733807|NCT03137680|EXPERIMENTAL|Exercise Arm|The exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of 6 weeks. This will be performed at least 6 weeks prior to the creation of the AV fistula
62733808|NCT01101958|OTHER|Chartis System-EBV Treatment|Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
62733809|NCT06228482|EXPERIMENTAL|[177Lu]Lu DOTA-ABM-5G single dose therapy study|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy.
62733810|NCT03776318||Safety Group|STX-015-18-01 Clonidine Micropellet long-term safety follow-up
62733811|NCT03776318||Sham Control|STX-015-18-01 Sham control long-term safety follow-up
62733812|NCT05084079|EXPERIMENTAL|Formula-based|Initial insulin regimen was decided according to the formula developed by the investigators previously.
62733813|NCT05084079|PLACEBO_COMPARATOR|Weight-based|Initial insulin regimen was decided according to current guidelines.
62733814|NCT04633395|EXPERIMENTAL|Music before bedtime|Participants will be listening to music before bedtime for a duration of up to 1 hour each night, in a total treatment period of 4 weeks. Participants will also receive the sleep hygiene guidelines, and be told to follow these.
62733815|NCT04633395|ACTIVE_COMPARATOR|Sleep hygiene|Participants will be given sleep hygiene guidelines, and be asked to follow these during the total treatment period of 4 weeks.
62733816|NCT00995436|ACTIVE_COMPARATOR|Extraoral anchorage|The intervention is the placement of Headgear, to be worn 100 hours per week
62733817|NCT00995436|ACTIVE_COMPARATOR|Miniscrews|The intervention is the of miniscrews to supplement anchorage
62733818|NCT00995436|ACTIVE_COMPARATOR|Nance palatal arch|Anchorage supplemented by Nance palatal arch fixing molars together with an arch
62733819|NCT02110186|EXPERIMENTAL|Discectomy and dynamic stabilization|Discectomy with posterior dynamic stabilization
62733820|NCT02110186|ACTIVE_COMPARATOR|Discectomy alone|Discectomy
62733821|NCT02110186|ACTIVE_COMPARATOR|Discectomy and fusion|Discectomy with internal fixation and fusion
62733822|NCT04920084|EXPERIMENTAL|Plant-based meals|Patients who will be administered a whole-foods plant-based diet for 12 weeks with nutrition counselling for 24 weeks.Participants will be asked to complete a survey via MSK Engage and a notification will be sent via email notification.
62733823|NCT03427593|EXPERIMENTAL|Patients|Patients with the phenotype (PID and Neutropenia and lymphoproliferation)
62733824|NCT03427593|OTHER|relatives (parents)|
62733825|NCT03427593|SHAM_COMPARATOR|Controls|
62733826|NCT02949050|EXPERIMENTAL|Treatment Group|the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.
62733827|NCT02949050|NO_INTERVENTION|Control Group|Control patient group only used antihistamines/nasal steroids but no SCIT
62733828|NCT04667676|EXPERIMENTAL|TENS Therapy Group|patients received acupoint TENS
62733829|NCT04667676|SHAM_COMPARATOR|Control group|patients received shame acupoint TENS
62733830|NCT05223569|EXPERIMENTAL|Home OCT monitoring model|"Participants will receive a home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester. For each home service, participants will undergo the following:~1. Smartphone-assisted online instruction provided by a virtual specialist~2. Visual acuity self test using a smartphone~3. Self-testing OCT imaging"
62733831|NCT05223569|ACTIVE_COMPARATOR|Hospital-based monitoring with a staff-administrated OCT|Participants will be instructed to come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators every month.
62733832|NCT02399124|OTHER|single arm, open label, treatment|single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance
62733833|NCT02219061||GMT|
62733834|NCT02088099|EXPERIMENTAL|Complex clinical intervention|
62733835|NCT02088099|ACTIVE_COMPARATOR|Treatment as usual|
62733836|NCT04216849|EXPERIMENTAL|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5\*10\^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.
62733837|NCT04216849|PLACEBO_COMPARATOR|control group|The control group will be given the same dose of saline containing human albumin.
62733838|NCT01248572|EXPERIMENTAL|Softec HD IOL|
62736292|NCT05645237||Applied radiotherapy protocol (subcohort) 4|27 Gy in 2 fractions of 13.5 Gy brachytherapy
62736293|NCT05645237||Applied radiotherapy protocol (subcohort) 5|72 Gy in 36 fractions of 2 Gy postoperative external beam radiotherapy
62733839|NCT02342847||Pateints with metastatic pancreatic cancer|"Patients diagnosed with metastatic pancreatic cancer confirmed histologically or cytologically, who will be treated with chemotherapy as first-line treatment of metastatic pancreatic cancer.~This study is designed to observe patients treated in routine clinical practice, without the exclusion limitations of a clinical trial. The decision to treat patients will be performed prior to the decision to include the patient in the study.~The follow-up of patients will be performed according to standard clinical practice of each site"
62733840|NCT03200483|EXPERIMENTAL|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
62733841|NCT03200483|EXPERIMENTAL|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
62733842|NCT03200483|EXPERIMENTAL|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
62733843|NCT05178836|EXPERIMENTAL|F520+F007|"Treatment period：~F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 14-day cycle for 8 cycles.~F520 (200mg) administered intravenously (IV) on Day 2 of each 14-day cycle for cycle 1.~F520 (200mg) administered intravenously (IV) on Day 1 of each 14-day cycle for cycle 2 to 8.~Maintenance period：~F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 56-day cycle for 10 cycles.~F520 (200mg) administered intravenously (IV) on Day 1/15/29/43 of each 56-day cycle for 10 cycles."
62733844|NCT05848466|EXPERIMENTAL|A/ Accelerated titration 0.8mg/kg of BAT8010|Drug: BAT8010, Dosage: 0.8mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733845|NCT05848466|EXPERIMENTAL|B/ Standard 3+3 1.2mg/kg of BAT8010|Drug: BAT8010, Dosage: 1.2mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733846|NCT05848466|EXPERIMENTAL|C/ Standard 3+3 2.4mg/kg of BAT8010|Drug: BAT8010, Dosage: 2.4mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733847|NCT05848466|EXPERIMENTAL|D/ Standard 3+3 3.6mg/kg of BAT8010|Drug: BAT8010, Dosage: 3.6mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733848|NCT05848466|EXPERIMENTAL|E/ Standard 3+3 4.8mg/kg of BAT8010|Drug: BAT8010, Dosage: 4.8mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733849|NCT05848466|EXPERIMENTAL|F/ Standard 3+3 6.0mg/kg of BAT8010|Drug: BAT8010, Dosage: 6.0mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733850|NCT05848466|EXPERIMENTAL|G/ Standard 3+3 7.2mg/kg of BAT8010|Drug: BAT8010, Dosage: 7.2mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733851|NCT05848466|EXPERIMENTAL|H/ Standard 3+3 8.4mg/kg of BAT8010|Drug: BAT8010, Dosage: 8.4mg/kg, Frequency: once every 3 weeks, Duration: 1year
62733852|NCT02531360|EXPERIMENTAL|[18F]MNI-815 (MNI-815)|At the \[18F\]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of \[18F\]MNI-815
62733853|NCT04823728||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
62733854|NCT06004258|EXPERIMENTAL|Intervention group (IG)|Welcoming the child and his or her guardians Invite them to participate, explain the study, and collect informed consent Recording of vaccinations in the medical record Safety check-list and identification Structural and environmental adaptation of the office Decorated nursing uniforms Use of distracting and rewarding elements according to age Preparation of vaccines out of sight of children Apply antalgic measures according to age and preferences. If the skin is dirty, clean it with physiological saline solution. Administer vaccines from least painful to most painful Only cover the puncture site if there is bleeding. Give post-vaccination recommendations Measure pain before, during and after vaccination with validated scales according to age
62733855|NCT06004258|NO_INTERVENTION|Control group (CG)|"The right 5+2 might be identified (patient, vaccine, interval, dose, route of administration, anatomical site, record) might be identified In infants, a non-pressing but secure breastfeeding position is recommended \>3 years old: they sit on the tutor's lap, encouraging their collaboration to hold the child without compressing ensuring to avoid movements, and try to distract them 6-12 years old: they sit in the chair with the tutor sitting next to him/her and they are vaccinated asking for the child's collaboration. If necessary, they might be held to avoid movements Vaccines will be administered following The 2021 Vaccination Protocol Tutors will receive recommendations on adverse effects Queries might be solved The atmosphere of the immunization clinic is similar to the rest of the clinics in the health centre (white walls and no child decoration) The uniform used by the nurses is white and the vaccination techniques are the same as those previously used in these centres"
62733856|NCT06370624|EXPERIMENTAL|Newborns|
62733857|NCT05594771|EXPERIMENTAL|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion.
62733858|NCT05594771|ACTIVE_COMPARATOR|epidural catheter|the loading dose for labor analgesia administrated via the epidural catheter.
62733859|NCT00879723|EXPERIMENTAL|Vitamin and mineral supplementation|Intravenous micronutrient solution or an oral micronutrient supplementation twice per day for 14 days. Treatment is determined by percent total body surface area burned.
62733860|NCT00879723|NO_INTERVENTION|Control|current vitamin regimen as listed on the Memorial medical Center Order Set for burn unit admission.
62733861|NCT04177004|EXPERIMENTAL|Group A (conditioning, goat milk, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
62733862|NCT04177004|ACTIVE_COMPARATOR|Group B (conditioning, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
62733863|NCT05232279|EXPERIMENTAL|Testofen 300mg|Testofen in capsule form - taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
61976784|NCT01744990|OTHER|Interventional single arm|Single group of children undergoing the same investigations and follow up
61976785|NCT00539448|EXPERIMENTAL|1|combination of insulin Glargine \& insulin Glulisine as basal bolus regimen
61976786|NCT02299479|EXPERIMENTAL|Intervention|Volunteers will wear a Dexcom G4 Platinum CGM device as well as an activity monitor. Data will be uploaded to study investigators on a regular basis, and recommendations will be made to adjust insulin dosing based upon analysis of these data.
61976787|NCT03108027|EXPERIMENTAL|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
62733864|NCT05232279|EXPERIMENTAL|Testofen 600mg|Testofen in capsule form - taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
62733865|NCT05232279|PLACEBO_COMPARATOR|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
62733866|NCT05003973|EXPERIMENTAL|home-based anti-resistance exercise|
62733867|NCT05003973|EXPERIMENTAL|usually care|
62733868|NCT03990402||Malawi group|500 young people with asthma symptoms in Malawi
62733869|NCT03990402||South Africa group|500 young people with asthma symptoms in South Africa
62733870|NCT03990402||Uganda group|500 young people with asthma symptoms in Uganda
62733871|NCT03990402||Nigeria|500 young people with asthma symptoms in Nigeria
62733872|NCT03990402||Zimbabwe group|500 young people with asthma symptoms in Zimbabwe
62733873|NCT03990402||Ghana group|500 young people with asthma symptoms in Ghana
62733874|NCT02869581||Patients with diagnosis of Pancreatic neoplasms|
62733875|NCT01320852|ACTIVE_COMPARATOR|Milan Criteria|Patients meeting the Milan Criteria
62733876|NCT01320852|OTHER|No Milan Criteria|Patients not meeting the Milan Criteria
62733877|NCT04898348|PLACEBO_COMPARATOR|Placebo|3 capsules twice a day dosing of Placebo
62733878|NCT04898348|EXPERIMENTAL|KBL697|3 capsules twice a day dosing of KBL697
62733879|NCT04224441|EXPERIMENTAL|Standard protocol plus chlorpromazine (CPZ)|Combination of chlorpromazine to the standard treatment with temozolomide in the sole adjuvant phase of the standard protocol.Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide (TMZ)
62733880|NCT00817453||1|Clinically diagnosed Early iPD
62733881|NCT00817453||2|Age/gender matched controls without neurodegenerative diagnosis
62733882|NCT00817453||atypical or late Parkinsonian Syndromes|Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.
62733883|NCT03093948|EXPERIMENTAL|Remote Ischemic post-conditioning|
62733884|NCT03093948|NO_INTERVENTION|standard of care|
62733885|NCT05141175|EXPERIMENTAL|Hypertension patients|Patients with documented diagnosis of hypertension and their most recent office systolic BP average measured using automated office BP is ≥140 mmHg systolic or ≥90 mmHg diastolic and they are currently prescribed at least one BP-lowering medication will be recruited.
62733886|NCT05200416|EXPERIMENTAL|Test Product - Heylo|The arm includes the test product Heylo
62733887|NCT05200416|ACTIVE_COMPARATOR|Standard of Care|The arm includes Standard of Care
62733888|NCT03910725||Obesity|Patients with BMI \>40 awaiting stapled bariatric surgery, without a history of or concomitant ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication, will be recruited prospectively from the bariatric surgery preoperative assessment clinics.
62733889|NCT03910725||Rheumatoid arthritis|Patients with RA without diagnosed or known ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication will be recruited prospectively from rheumatology clinics, prior to initiation of biologic or diseased modifying anti-rheumatic drugs.
62733890|NCT03910725||Dilated cardiomyopathy|TTNtv-positive and -negative DCM patients from the Royal Brompton Hospital biobank have provided informed consent to be contacted for research
62733891|NCT00452075|EXPERIMENTAL|arm 1 medicine|erlotinib daily
62733892|NCT05070312|EXPERIMENTAL|MEDI3506 dose 1|MEDI3506 dose1
62733893|NCT05070312|EXPERIMENTAL|MEDI3506 dose 2|MEDI3506 dose 2
62733894|NCT05070312|PLACEBO_COMPARATOR|Placebo|Placebo 2 mL and 4 mL
62733895|NCT03461562|EXPERIMENTAL|Experimental|
62733896|NCT03461562|ACTIVE_COMPARATOR|Control|
62733897|NCT00070109|EXPERIMENTAL|Trabectedin 1.3 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. A cohort of 6 patients will be enrolled at the 1.3 mg/m2 dose level.
62733898|NCT00070109|EXPERIMENTAL|Trabectedin 1.5 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Six toxicity-evaluable patients are assigned this treatment.
62733899|NCT00070109|EXPERIMENTAL|Trabectedin at 1.5 mg/m2 to assess efficacy in Ewing sarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62733900|NCT00070109|EXPERIMENTAL|Trabectedin at 1.5 mg/m2 - assess efficacy in rhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62733901|NCT00070109|EXPERIMENTAL|Trabectedin 1.5 mg/m2 - assess efficacy in nonrhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
62733902|NCT06322550|EXPERIMENTAL|Migraine Patient|"122 migraine patients assigned the role of patient"
62733903|NCT06322550|EXPERIMENTAL|Migraine Healthy|"122 migraine patients assigned the role of healthy participant"
62733904|NCT06322550|NO_INTERVENTION|headache-free controls|122 headache-free controls with no cover story
62733905|NCT02110433|OTHER|Placebo group|Patients will be managed per consensus guidelines Clinicians could see the patients as many times as necessary in order to optimize their therapy and could make BNP measurement (but not using Home BNP monitoring)
62733906|NCT02110433|EXPERIMENTAL|Cordiva System (R)|Patient will see their cardiologist every three months and benefit from telemonitoring of their weight and general well being through a specific communicant device.
62733907|NCT02110433|ACTIVE_COMPARATOR|BNP and Cordiva (R) monitoring system|In this group, patients and doctors have access to the platform detailed above (Cordiva (R) monitoring system) and had also access to BNP home monitoring (BNP heartcheck).
62733908|NCT02225704|EXPERIMENTAL|Radium-223 and enzalutamide|Radium-223 50kBq/kg by intravenous injection on day 1 of every 4 week cycle for maximum of 6 cycles Enzalutamide 160mg orally daily
62733909|NCT00483054|EXPERIMENTAL|Efavirenz|Efavirenz 600 mg/day + stavudine +lamivudine
62733910|NCT00483054|EXPERIMENTAL|Nevirapine|Nevirapine 400 mg/day + stavudine +lamivudine
62733911|NCT05382884|EXPERIMENTAL|Intervention|Fifty participants will be randomized to the intervention group, receiving immediate access to postpartumcare.ca for a period of 4 weeks. Intervention group participants may use postpartumcare.ca as often as desired for the duration of the 4-week intervention period. Following the 4-week intervention period and a 2-week follow-up period, intervention group participants will retain access to postpartumcare.ca.
62733912|NCT05382884|NO_INTERVENTION|Waitlist Control|Fifty participants will be randomized to a waitlist control group, receiving treatment as usual (TAU) for a period of 4 weeks. Following the 4-week intervention period and a 2-week follow-up period, waitlist control participants will receive access to postpartumcare.ca.
62733913|NCT04495530||Patient|Patients will be considering commencing or discontinuing parenteral nutrition, or will be receiving home parenteral nutrition
62733914|NCT04495530||Carer|Carers will be those caring for a patient with advanced cancer who is considering commencing or discontinuing parenteral nutrition, or already receiving parenteral nutrition. Carers will also be recruited if they previously cared for a person with advanced cancer receiving parenteral nutrition in the last 12 months
62733915|NCT03941964|EXPERIMENTAL|Venetoclax 400 mg + azacitidine 75 mg|Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Azacitidine (75 mg/m\^2) was administered subcutaneously or intravenously per investigator's choice and institutional practice for 7 days beginning on Day 1 of each 28-day cycle.
62733916|NCT03941964|EXPERIMENTAL|Venetoclax 400 mg + decitabine 20 mg|Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Decitabine (20 mg/m\^2) was administered intravenously per investigator's choice and institutional practice for 5 days beginning on Day 1 of each cycle.
62733917|NCT01454505|EXPERIMENTAL|Stage B/AL-53817|Stage B: AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
62733918|NCT01454505|PLACEBO_COMPARATOR|Stage B/Vehicle|Stage B: Vehicle nasal spray, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
62733919|NCT02016716|EXPERIMENTAL|Romosozumab 90 mg/mL|Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
62733920|NCT02016716|EXPERIMENTAL|Placebo 90 mg/mL|Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
62733921|NCT02016716|EXPERIMENTAL|Romosozumab 70 mg/mL|Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
62733922|NCT02016716|PLACEBO_COMPARATOR|Placebo 70 mg/mL|Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
62733923|NCT00003566|EXPERIMENTAL|video-thorascopy + surgery|Patients will undergo ipsilateral video-thorascopic evaluation. Patients may undergo surgery at the discretion of the surgeon and treating physicians.
62733924|NCT02704949|EXPERIMENTAL|Low-dose|The intervention is to use 1/4 fluoroscopy dose while the ureteroscopy is being performed
62733925|NCT02704949|ACTIVE_COMPARATOR|Full-dose|The intervention is to use full fluoroscopy dose while the ureteroscopy is being performed
62733926|NCT01475643|EXPERIMENTAL|Loteprednol etabonate|Loteprednol etabonate 0.5%
62733927|NCT01475643|ACTIVE_COMPARATOR|Prednisolones acetate|Prednisolone acetate 1.0%
62733928|NCT02322580||Psoriasis patients who receive Enbrel® therapy|
62733929|NCT01798901|EXPERIMENTAL|Treatment (HDAC inhibitor AR-42, decitabine)|"INDUCTION THERAPY: Patients receive HDAC inhibitor AR-42 PO daily on days 1, 3, and 5 or 1, 3, 4, 5 and decitabine IV over 1 hour on days 6-15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving CR or CRi receive HDAC inhibitor AR-42 as in Induction Therapy and decitabine IV over 1 hour on days 6-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62733930|NCT01936454||Cohort 1|n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
62733931|NCT01936454||Cohort 2|n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
62733932|NCT01936454||Cohort 3|n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
62733933|NCT01936454||Cohort 4|n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
62733934|NCT02575872|EXPERIMENTAL|Exercise Intervention|Participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. Participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks.
62733935|NCT02575872|NO_INTERVENTION|wait-list for intervention|Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.
62733936|NCT04848467|EXPERIMENTAL|Group 1: Co-ad group|Participants will receive CVnCoV at the same visit as QIV: first dose of CVnCoV and a dose of QIV in opposite arms at Day 1, the second dose of CVnCoV at Day 29, and a placebo injection at Day 57.
62733937|NCT04848467|EXPERIMENTAL|Group 2: Control group|Participants will receive QIV and CVnCoV at two different visits: one dose of placebo and one dose of QIV in opposite arms at Day 1, the first dose of CVnCoV at Day 29 and the second dose of CVnCoV at Day 57.
62733938|NCT00335283|ACTIVE_COMPARATOR|Lansoprazole|
62733939|NCT00335283|PLACEBO_COMPARATOR|Sugar Pill|
62733940|NCT06264908|EXPERIMENTAL|Early intervention arm|8 weeks integrated self-management programme delivered by occupational therapists and rheumatology nurse
62733941|NCT06264908|NO_INTERVENTION|Routine Clinical care (Control)|Patients will receive routine clinical care for hand osteoarthritis for 26 weeks, then cross-over to the integrated programme after 26 weeks.
61976788|NCT03108027|EXPERIMENTAL|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
62733942|NCT06089733|EXPERIMENTAL|ABSK201 and Itraconazole/Rifampicin|"Part A: Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.~Part B: Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg."
62733943|NCT05323604||Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
62733944|NCT05650463|EXPERIMENTAL|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns with darker skin types using Picterus JP.
62733945|NCT02434653|EXPERIMENTAL|Postpartum anemia diagnosis following symptoms|Post partum anemia will be assessed by taking hemoglobin level following symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL in the first 5 days following delivery
62733946|NCT02434653|EXPERIMENTAL|Postpartum anemia diagnosis following patients screening|Post partum anemia will be assessed by taking hemoglobin level in patients at increased risk to develop post-partum anemia in the first 5 days following delivery, defined as patients with initial (before or immediately after delivery) hemoglobin level of 10.5 g/dl or less regardless of symptoms, or in cases of severe post partum hemorrhage.
62733947|NCT01063062|EXPERIMENTAL|tocilizumab|Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
62733948|NCT01322854|EXPERIMENTAL|IMRT + integrated boost|28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost
62733949|NCT01322854|OTHER|Conventional RT + sequential boost|Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy
62733950|NCT04704297|ACTIVE_COMPARATOR|Standard Therapy (ST)|ST will consist of 975mg of Acetaminophen PO and either 30mg of Ketorolac IM or 15 mg IV. Upon discharge ST will consist of prescriptions for acetaminophen 650mg every 4 hours by mouth, Ibuprofen 400mg every 4 hours by mouth, and 10 mg of cyclobenzaprine nightly by mouth. Additionally, participants will be provided a handout going over these medications and the use of heat for low back pain and instructions on the performance of McKenzie stretching exercises for low back pain.4
62733951|NCT04704297|ACTIVE_COMPARATOR|ST plus Trigger Point Injections (TPI) with 8 mL of 0.5 percent Bupivacaine|ST plus TPI with 8 mL of 0.5 percent Bupivacaine
62733952|NCT04704297|ACTIVE_COMPARATOR|ST plus TPI with 8 mL of Normal Saline (NS)|ST plus TPI with 8 mL of Normal Saline
62733953|NCT03789123|EXPERIMENTAL|Study Group (patients with OMA)|"I) Untreated patients (n=142)~II) Dienogest (n=142)~III) Dienogest/Estradiol valerate+Dienogest (n=142)"
62733954|NCT03789123|SHAM_COMPARATOR|Control Group(patients without OMA)|"I) Untreated patients (n=142)~II) Dienogest/Estradiol valerate+Dienogest (n=142)"
62733955|NCT01661751|EXPERIMENTAL|ACYW135 Meningococcal Vaccine|0.5 ml/ dose, containing 50 μg of each antigen; lot No.: 20040601, manufacturing date: June 9, 2004 and the expiration date: till June 2006
62733956|NCT01661751|ACTIVE_COMPARATOR|A+C Meningococcal Vaccine|0.5 ml/ dose; each ampoule or dose contains 100 μg (one single human dose) and 50 μg of each antigen; lot No.: 20050805 and the expiration date: Aug. 24, 2007
62733957|NCT05580263|EXPERIMENTAL|aerobic exercise(AE) preceding resistance exercise(RE)|at least moderate intensity of AE 30 minutes than RE 15 minutes, with a break of 5 minutes between two modalities of training.
62733958|NCT05580263|EXPERIMENTAL|RE preceding AE|RE 15 minutes than at least moderate intensity of AE 30 minutes, with a break of 5 minutes between two modalities of training.
62733959|NCT05580263|NO_INTERVENTION|Control group|Participants maintain their usual life without any exercise intervention.
62733960|NCT03192293|EXPERIMENTAL|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:~1. Metformin: 850mg (one tablet) twice a day~2. Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~1. Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~2. Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
62733961|NCT04565340||Induction of labor with Foley catheter|Induction of labor with Foley catheter
62733962|NCT04565340||Induction of labor with Propess|Induction of labor with Propess
62733963|NCT04014699|EXPERIMENTAL|modified 2.2mm micoincision|
62733964|NCT04014699|ACTIVE_COMPARATOR|conventional 2.2mm microincision|
62733965|NCT01407952|OTHER|HydroCoil Embolic System|Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
62733966|NCT01407952|OTHER|Control|Aneurysm treatment using bare platinum coil(s)
62733967|NCT05842941|EXPERIMENTAL|DNL343|
62733968|NCT05842941|PLACEBO_COMPARATOR|Matching Placebo|
62733969|NCT01248728|ACTIVE_COMPARATOR|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
62733970|NCT01248728|PLACEBO_COMPARATOR|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
62736294|NCT05645237||Applied radiotherapy protocol (subcohort) 6|70 Gy in 35 fractions of 2 Gy on prostate combined with 52 Gy in 28 fractions of 2 Gy on pelvic lymph node areas, external beam radiotherapy.
62736295|NCT04077424|ACTIVE_COMPARATOR|Fluzone-High Dose|FDA approved high dose inactivated influenza vaccine (HD-Fluzone)
62733971|NCT05802472|EXPERIMENTAL|Polyphenolic beverage|Thirty subjects were randomly assigned (Visit 1), and weight and height will be evaluated, as body composition and blood sampling to assess glucose, liver, and kidney function. During Visit 2, and before the administration (1.2 mg/kg of weight) of a single infusion of the polyphenolic extract, glucose in the blood will be quantified (basal; with 12 hours of fasting); later, administer a load of 75 g of oral sucrose and after 30 minutes, the blood sample will begin at different intervals: 20, 40, 60, 90 and 120 minutes. The participant solves the food consumption frequency questionnaires during this procedure. A second blood sample will be taken 48 hours later (Visit 3). Finally, a urine sample will be taken to rule out acute kidney damage through the sensitive kidney damage biomarker (KIM-1). In addition, the participant will be interviewed to answer the adverse effects questionnaire.
62733972|NCT05802472|PLACEBO_COMPARATOR|Water|Thirty subjects were randomly assigned (Visit 1), and weight and height will be evaluated, as body composition, and blood sampling to assess glucose, liver, and kidney function. During Visit 2, and before the administration of a single water as placebo, glucose in the blood will be quantified (basal; with 12 hours of fasting); later, administer a load of 75 g of oral sucrose and after 30 minutes, the blood sample will begin at different intervals: 20, 40, 60, 90 and 120 minutes. The participant solves the food consumption frequency questionnaires during this procedure. A second blood sample will be taken 48 hours later (Visit 3). Finally, a urine sample will be taken to rule out acute kidney damage through the sensitive kidney damage biomarker (KIM-1). In addition, the participant will be interviewed to answer the adverse effects questionnaire.
62733973|NCT05074511||healthy|Children in this group will be healthy category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 5th to 85th percentiles
62733974|NCT05074511||overweight|Children in this group will be overweight category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 85th to 95th percentiles .
62733975|NCT05074511||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age \> 95th percentiles
62733976|NCT05074511||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age \< 5th percentiles
62733977|NCT01030952|EXPERIMENTAL|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
62733978|NCT01030952|ACTIVE_COMPARATOR|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
62733979|NCT00683930|EXPERIMENTAL|Mycophenolate Mofetil (MMF) 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
62733980|NCT00683930|EXPERIMENTAL|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
62733981|NCT00683930|PLACEBO_COMPARATOR|Placebo|
62733982|NCT01056406|NO_INTERVENTION|Control Group|Overweight and obese pregnant women who are randomly assigned to the control group will receive the current standard of optimal care in addition to 1 nutrition education session with the study nutritionist (a registered dietitian) at 6-16 weeks gestation.
62733983|NCT01056406|EXPERIMENTAL|Nutrition Education Group|Overweight and obese pregnant women randomly assigned to the nutrition education group, in addition to the current standard of optimal care, will receive twice monthly interaction with the study nutritionist (a registered dietitian) from 6-16 weeks gestation through 6 months postpartum.
62733984|NCT01132846|ACTIVE_COMPARATOR|Low dose Dopamine|"Drug: Dopamine~Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study"
62733985|NCT01132846|PLACEBO_COMPARATOR|Placebo|Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
62733986|NCT01132846|ACTIVE_COMPARATOR|Low Dose Nesiritide|Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
62733987|NCT05439278|EXPERIMENTAL|Hypofractionated radiochemotherapy|Radiotherapy: 40.05 Gy in 15 fractions (daily treatment, 5 per week) Temozolomide: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
62733988|NCT05439278|EXPERIMENTAL|Conventional radiochemotherapy|Radiotherapy: 60 Gy in 30 fractions (daily treatment, 5 per week) Temozolomide: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
62733989|NCT01131806|ACTIVE_COMPARATOR|MD Flu/Sal|fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
62733990|NCT01131806|EXPERIMENTAL|HD Flu/Sal|fluticasone 250 mcg/salmeterol 25 mcg 2puffs (high dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
62733991|NCT06285032|EXPERIMENTAL|Cognitive Behavioral Therapy (CBT)|Participants will be randomized to the CBT group (N=34). CBT groups will meet for 1 hour via Zoom, for 8 weeks.
62733992|NCT06285032|EXPERIMENTAL|Social Navigation Group|Participants will be randomized to the social navigation group (N=34). Social navigation group will meet for 30 mins via Zoom, for 8 weeks.
62733993|NCT06285032|EXPERIMENTAL|Usual Care Group|Participants will be randomized to the usual care group (N=34). Participants in this group will resume to their usual standard of care for 8 weeks.
62733994|NCT00194077|ACTIVE_COMPARATOR|Aripiprazole|Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
62733995|NCT00194077|PLACEBO_COMPARATOR|Placebo|in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks
62733996|NCT02250131|NO_INTERVENTION|Control|Routine cardiopulmonary bypass technique. Flow adjusted on BSA and temperature
62733997|NCT02250131|ACTIVE_COMPARATOR|Goal Directed Perfusion|Perfusion targeted at oxygen delivery
62733998|NCT02959294|EXPERIMENTAL|Microcannula Harvest Adipose|Acquisition Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via close syringe microcannula harvest from subdermal fat deposits
62733999|NCT02959294|EXPERIMENTAL|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
62734000|NCT02959294|EXPERIMENTAL|Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline deployment via IV
62736296|NCT04077424|ACTIVE_COMPARATOR|Fluad|Adjuvanted (MF59) inactivated influenza vaccine (Fluad)
62734001|NCT04807608||Healthy Users|Each subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).
62734002|NCT01262560|ACTIVE_COMPARATOR|Supportive Care|Standard supportive care
62734003|NCT01262560|EXPERIMENTAL|Liquid Manuka Honey|Manuka honey in liquid form
62734004|NCT01262560|EXPERIMENTAL|Lozenge Manuka Honey|Manuka honey in lozenge form
62734005|NCT04555863|EXPERIMENTAL|haMSter app|Patients receiving the app for personal use for 6 months
62734006|NCT03992716|EXPERIMENTAL|SmofKabiven® extra Nitrogen|Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
62734007|NCT03992716|ACTIVE_COMPARATOR|Olimel N9E|Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
62734008|NCT04625101|EXPERIMENTAL|NBI-827104|NBI-827104 administered orally for 13 weeks.
62734009|NCT04625101|PLACEBO_COMPARATOR|Placebo|Placebo administered orally for 13 weeks.
62734010|NCT02473094|EXPERIMENTAL|Neoadjuvant capecitabine and metformin|"* Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~* Metformin 2500mg/d for five weeks;~* 3D radiotherapy 50,4Gy divided in 25 fractions"
62734011|NCT02473094|PLACEBO_COMPARATOR|Neoadjuvant capecitabine and placebo|"* Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~* Placebo 2500mg/d for five weeks;~* 3D radiotherapy 50,4Gy divided in 25 fractions"
62734012|NCT01013324|EXPERIMENTAL|Single Arm|All subjects will receive single-agent XL147 dosed daily
62734013|NCT03442556|EXPERIMENTAL|Treatment (docetaxel, carboplatin, rucaparib camsylate)|"INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
62734014|NCT01461499|ACTIVE_COMPARATOR|Direct renin inhibitor|
62734015|NCT01461499|ACTIVE_COMPARATOR|Angiotensin receptor blockers|
62734016|NCT01266278|EXPERIMENTAL|Kinesiotape|Kinesiotape will be applied to the correct shoulder position of the participants.
62734017|NCT05429320|EXPERIMENTAL|Part I|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT to determine if ablation to all sites of disease leads to acceptable rates of mean VAF reduction, thus indicating a discernible molecular/clinical response in this subgroup of patients with metastatic disease.
62734018|NCT05429320|ACTIVE_COMPARATOR|Part II - standard of care|If the appropriate criteria are met in part I,, in part II 60 patients with NR-VAF but without radiographic progression of disease will be randomized to one of two arms: continuation of systemic therapy (standard of care) vs. ablation to all sites of disease (experimental arm), with a primary endpoint of progression free survival.
62734019|NCT05429320|EXPERIMENTAL|Part II - ablation to all sites of disease (experimental arm)|If the appropriate criteria are met in part I,, in part II 60 patients with NR-VAF but without radiographic progression of disease will be randomized to one of two arms: continuation of systemic therapy (standard of care) vs. ablation to all sites of disease (experimental arm), with a primary endpoint of progression free survival.
62734020|NCT05993988|NO_INTERVENTION|control group|The participants in the control group did not receive any intervention.
62734021|NCT05993988|EXPERIMENTAL|Exercise group|The participants in the exercise group performed Jacobson muscle relaxation exercises with a specialist physiotherapist through the Zoom program (https://zoom.us). The exercises were applied 4 days a week for 4 weeks.
62734022|NCT01942824|EXPERIMENTAL|Intervention|Text Message
62734023|NCT01942824|NO_INTERVENTION|Usual Care|
62734024|NCT05487690|EXPERIMENTAL|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries.
62734025|NCT05487690|ACTIVE_COMPARATOR|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
62734026|NCT05800353|EXPERIMENTAL|early treatment group|Participants in the early treatment group will receive a YAG laser vitreolysis immediately and a sham laser treatment three months later.
62734027|NCT05800353|EXPERIMENTAL|delayed treatment group|Participants in the delayed treatment group will receive a sham laser treatment immediately and a YAG laser vitreolysis three months late.
62734028|NCT01769950|EXPERIMENTAL|Choline-PET arm|Every eligible patient will be scanned with Choline-PET at the time of diagnosis of prostate cancer. MRI will also be obtained as it is the current standard of care. CT scan will be obtained as part of the same procedure while procuring the Choline-PET scan with PET-CT dual imaging hardware.
62734029|NCT00000407|ACTIVE_COMPARATOR|Enrollment Intervention|The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the vocational rehabilitation (VR) program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively.
62734030|NCT00000407|PLACEBO_COMPARATOR|Usual Care|
62734031|NCT05175131|EXPERIMENTAL|Mebeverine+Simethicone combination|three times a day per os
62734032|NCT05175131|ACTIVE_COMPARATOR|mebeverine|three times a day per os
62734033|NCT05175131|ACTIVE_COMPARATOR|simethicone|80 mg (2 capsules 40 mg) three times a day per os
62734034|NCT04222894|ACTIVE_COMPARATOR|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 12 weeks
62734035|NCT04222894|ACTIVE_COMPARATOR|Control diet|Half of the participants will be asked to continue their usual diets for the 12-week study period.
62734036|NCT00652314|EXPERIMENTAL|1 - Thrombi-gel treatment|Thrombi-gel treatment
62734037|NCT00652314|ACTIVE_COMPARATOR|2 - Gelatin Sponge (Gelfoam)|Gelatin Sponge (Gelfoam) plus thrombin
62736297|NCT04077424|ACTIVE_COMPARATOR|Recombinant Hemagglutinin vaccine (Flublok)|Recombinant hemagglutinin vaccine
62736298|NCT02789358|ACTIVE_COMPARATOR|Control Arm|"Conventional protocol for cryoablation:~At least 2 applications of 180s each"
62736299|NCT02789358|EXPERIMENTAL|Study Arm|"Experimental protocol for cryoablation:~Time to effect + 1 minute and a bonus application of 120s"
62734038|NCT04905706||3D laparoscopic adrenalectomy|Operations are done with an high definition 3D laparoscopic system (Olympus, Tokyo, Japan); all personnel wear polarized glasses to achieve stereoscopic imaging in the operating room. Dissection is realized using a hybrid energy system (Thunderbeat, Olympus Europe Se \& Co, Hamburg, Germany).
62734039|NCT03626012|EXPERIMENTAL|Cohort 1: BIIB078 First Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
62734040|NCT03626012|EXPERIMENTAL|Cohort 2: BIIB078 Second Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
62734041|NCT03626012|EXPERIMENTAL|Cohort 3: BIIB078 Third Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
62734042|NCT03626012|EXPERIMENTAL|Cohort 4: BIIB078 Fourth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
62734043|NCT03626012|EXPERIMENTAL|Cohort 5: BIIB078 Fifth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
62734044|NCT03626012|EXPERIMENTAL|Cohort 6: BIIB078 Sixth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
62734045|NCT03626012|PLACEBO_COMPARATOR|Cohorts 1-6: Placebo|Matching placebo will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days (Cohorts 1 through 3) and five maintenance doses on five later days (Cohorts 4 through 6).
62734046|NCT03396497|EXPERIMENTAL|LYC-55716 + pembrolizumab|Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
62734047|NCT05948527|EXPERIMENTAL|with mild Hypercapnia (Pco2 range 45-60 mmhg and power of hydrogen not less 7.30)|with mild Hypercapnia (Pco2 range 45-60 mmhg and power of hydrogen not less 7.30) of different pulmonary disorders
62734048|NCT05059301|EXPERIMENTAL|RSV OA_Lot 1|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at Day 1 and were followed up until the study end (Month 6).
62734049|NCT05059301|EXPERIMENTAL|RSV OA_Lot 2|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at Day 1 and were followed up until the study end (Month 6).
62734050|NCT05059301|EXPERIMENTAL|RSV OA_Lot 3|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1 and were followed up until the study end (Month 6).
62734051|NCT02869126|EXPERIMENTAL|Patients|Patients with abnormalities of myocardial perfusion detected with stress tomoscintigraphy, undergo double isotope myocardial tomoscintigraphy using Thallium-201 and 99mTc-sestamibi and traditional myocardial tomoscintigraphy using 99mTc-sestamibi with a semiconductor camera
62734052|NCT02707965|ACTIVE_COMPARATOR|Sequence 1|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
62734053|NCT02707965|ACTIVE_COMPARATOR|Sequence 2|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
62734054|NCT00100568|EXPERIMENTAL|1|All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.
62734055|NCT02715830|EXPERIMENTAL|One Artery|In this arm after obtain the good result after the angioplasty of one artery the procedure stops
62734056|NCT02715830|EXPERIMENTAL|More than one artery|In this arm, after obtain a good result of the angioplasty of one artery, we continue trying one or two more arteries
62734057|NCT04434430|ACTIVE_COMPARATOR|Gabapentin|Patient will receive preemptive oral gabapentin 600 mg
62734058|NCT04434430|PLACEBO_COMPARATOR|Placebo|Patient will receive oral placebo
62734059|NCT06293534||Patients with major psychiatric disorders|Patients diagnosed with major psychiatric disorders according to the Diagnostic Statistical Manual version 5 (DSM 5-TR), admitted to the psychiatry department in Assiut University Hospital.
62734060|NCT05475028||HFpEF|We will recruit HFpEF (LVEF \> 50%)
62734061|NCT05475028||HFrEF|We will recruit HFrEF (LVEF \< 40%)
62734062|NCT05475028||Healthy controls|We will recruit volunteer blood donors
62734063|NCT04428255|EXPERIMENTAL|HBM9161 Dose A|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
62734064|NCT04428255|EXPERIMENTAL|HBM9161 Dose B|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
62734065|NCT04428255|PLACEBO_COMPARATOR|Placebo|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
62734066|NCT03415581|PLACEBO_COMPARATOR|Doxazosin (Placebo First)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, followed by 4-week maintenance on active doxasozin (up to 16mg/day or the highest tolerated dose. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
62734067|NCT03415581|ACTIVE_COMPARATOR|Doxazosin (Active First)|Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
62734068|NCT03028129|EXPERIMENTAL|Treatment|Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.
62734069|NCT03028129|PLACEBO_COMPARATOR|Control|Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).
62734070|NCT03038971|OTHER|Concentration 1: Short and Tall Ragweed Mix|
62734071|NCT03038971|OTHER|Concentration 2: Short and Tall Ragweed Mix|
62734072|NCT03038971|OTHER|Placebo: Saline with 0.4% Phenol|
62734073|NCT06245005||OPAC|Feasibility to conduct brain exercise gameplay on a portable electronic device at Ohio State Preoperative Assessment Clinic (OPAC)
62734074|NCT06245005||PREOP|Feasibility to conduct brain exercise gameplay on a portable electronic device at The Wexner Medical Center Preoperative Holding Areas.
62734075|NCT04830215|OTHER|Brexpiprazole|Participants received brexpiprazole as a flexible dose; 0.5 mg to 2 mg, orally (PO), QD, and continued on the stable dose of ADT up to 8 weeks.
62734076|NCT02058004|EXPERIMENTAL|Cricoid pressure|Patients randomized to receive cricoid pressure during endotracheal intubation.
62734077|NCT02058004|NO_INTERVENTION|No cricoid pressure|Patients randomized to receive no cricoid pressure during endotracheal intubation.
62734078|NCT01888783|EXPERIMENTAL|CRPS Type I|Patients diagnosed with complex regional pain syndrome type I of the upper limb
62734079|NCT01888783|ACTIVE_COMPARATOR|Median Nerve Neuropathy|Patients diagnosed with a neuropathy of the median nerve of the upper limb.
62734080|NCT01888783|ACTIVE_COMPARATOR|Healthy Controls|Healthy adult persons.
62734081|NCT04570878|EXPERIMENTAL|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
62734082|NCT04570878|ACTIVE_COMPARATOR|Control|No regional block is provided at the end of surgery.
62734083|NCT05248178|EXPERIMENTAL|CO-OP and tDCS group|Each session will consist of 20 minutes of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. This will be followed by 45 minutes of the assigned CO-OP.
62734084|NCT05248178|ACTIVE_COMPARATOR|CO-OP and sham tDCS group|Each session will consist 20 minutes of sham tDCS followed by 45 minutes of the assigned CO-OP.
62734085|NCT05248178|ACTIVE_COMPARATOR|Computer cognitive training and tDCS group|Each session will consist of 20 minutes of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. This will be followed by 45 minutes of the assigned computer cognitive training.
62734086|NCT05248178|ACTIVE_COMPARATOR|Computer cognitive training and sham tDCS group|Each session will consist 20 minutes of sham tDCS followed by 45 minutes of the assigned computer cognitive training.
62734087|NCT06190470|EXPERIMENTAL|Experimental group|The participants will receive cannabis product for 2 weeks. The participants will receive the cannabis product (THC 30mg / 1 ml) manufactured by Faculty of pharmaceutical science KhonKaen University. The participants will gradually increase using the product starting from 1 drop (1.5 mg THC) per day sublingually and can increase using not more than 1 drop per day, until pain or spasticity can be controlled.
62734088|NCT06190470|PLACEBO_COMPARATOR|Placebo group|The participants will receive placebo product manufactured by Faculty of Pharmaceutical Science KhonKaen University for 2 weeks. The participants will gradually increase using the product starting from 1 drop per day sublingually and can increase using not more than 1 drop per day,
62734089|NCT02316353|EXPERIMENTAL|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
62734090|NCT02316353|EXPERIMENTAL|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
62734091|NCT02456753||trans-perineal ultrasonography|"Patients included are women about to give birth, they undergo a clinical examination done by midwives. Followed by a trans-perineal ultrasonography examination done by a technical operator in order to measure the perineal-cephalic distance.~These examination are done the day of enrollment, they last for a few minutes and no further tests will be done afterwards."
62734092|NCT04976790|EXPERIMENTAL|Chinese Tuina group (CTG)|The participants in Chinese Tuina group will receive the traditional Chinese Tuina therapy on the basis of health education and home-exercise. All the treatment will cost 20-25 minutes. Patients in this group received 4 treatments over 14 days.
62734093|NCT04976790|ACTIVE_COMPARATOR|Flurbiprofen Cataplasms group (FCG)|The FCG group received flurbiprofen gel on the basis of the health education and home-exercise, twice daily, for 14 days.
62734094|NCT00824889|OTHER|1|Healthy volunteer
62734095|NCT00824889|OTHER|2|atopic dermatitis patient
62734096|NCT00824889|OTHER|3|contact dermatitis patient
62734097|NCT00824889|OTHER|4|psoriasis patient
62734098|NCT00824889|OTHER|5|lichen planus patient
62734099|NCT00824889|OTHER|6|GVH patient
62734100|NCT00824889|OTHER|7|melanoma patient
62734101|NCT05044650|EXPERIMENTAL|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days combined with background treatment
62734102|NCT05044650|NO_INTERVENTION|NON-KOVIR|Only background treatment
62734103|NCT04727996|EXPERIMENTAL|Sitravatinib/Tislelizumab|All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
62734104|NCT06039215|EXPERIMENTAL|Experimental group|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
62734105|NCT06039215|NO_INTERVENTION|Control group|The ventilator settings are adjusted in line with the centre's usual practice. No change from usual management of acute respiratory distress syndrome.
62734106|NCT00109213|ACTIVE_COMPARATOR|1|Lumbar Laminectomy without Fusion
62734107|NCT00109213|ACTIVE_COMPARATOR|2|Lumbar Laminectomy with Pedicle Screw Instrumented Fusion
62734108|NCT05511506|OTHER|first-eye group|
62734109|NCT05511506|OTHER|second-eye group|
62734110|NCT03233828|EXPERIMENTAL|Intralesional IL-2 Injection|Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
62734111|NCT03233828|PLACEBO_COMPARATOR|Saline Injection|Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
62734112|NCT06149676|EXPERIMENTAL|Probiotic with or without antibiotic|All patients will receive probiotics for this, only those with a UTI will get ciprofloxacin.
62734113|NCT06149676|NO_INTERVENTION|Control|Patients will get standard of care treatment.
62736300|NCT04784351||Training|A subset of patients that are used to train the machine learning algorithm.
62736301|NCT04784351||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
62734114|NCT00626782|EXPERIMENTAL|A: Ranibizumab 0.5mg (0.05mL) injection|Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriorly to the limbus as an antifibrotic agent.
62734115|NCT00626782|ACTIVE_COMPARATOR|B: Mitomycin C 0.4 mg/ml sponge|Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
62734116|NCT00428181|ACTIVE_COMPARATOR|1 Brief Intervention|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
62734117|NCT00428181|ACTIVE_COMPARATOR|2) Booster|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
62734118|NCT05054491|EXPERIMENTAL|Group ANC|Intervention period in stepped wedge design where women are receiving antenatal care in a group setting
62734119|NCT05054491|NO_INTERVENTION|Individual ANC (routine)|Pre-intervention time period (control period) where the intervention is not being implemented yet (women are receiving individual antenatal care as is currently offered)
62734120|NCT00978419|ACTIVE_COMPARATOR|Rosuvastatin|Rosuvastatin
62734121|NCT00978419|PLACEBO_COMPARATOR|Placebo|Placebo
62734122|NCT01239277|EXPERIMENTAL|protein (elderly)|
62734123|NCT01239277|EXPERIMENTAL|protein and carbohydrate (elderly)|
62734124|NCT01239277|EXPERIMENTAL|protein and carbohydrate (young)|
62734125|NCT01239277|EXPERIMENTAL|protein and leucine (elderly)|
62734126|NCT01607762|EXPERIMENTAL|Cohort A: Aripiprazole|
62734127|NCT01607762|EXPERIMENTAL|Cohort B: Quetiapine|
62734128|NCT01607762|EXPERIMENTAL|Cohort C: Olanzapine|
62734129|NCT01607762|EXPERIMENTAL|Cohort D: Risperidone|
62734130|NCT01607762|EXPERIMENTAL|Cohort E: Paliperidone|
62734131|NCT01048242|EXPERIMENTAL|Ramelteon|Ramelteon 8 mg oral before bedtime
62734132|NCT01048242|PLACEBO_COMPARATOR|sugar pill|
62734133|NCT06534047|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation (rTMS) Intervention|Treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.
62734134|NCT06534047|ACTIVE_COMPARATOR|Treatment as Usual|Treatment with Nicotine Replacement Therapy (NRT) and/or adjunctive counselling will be provided by their clinical team through the Smoking Treatment for Ontario Patients (STOP) Program. All treatments will be delivered by study physicians in the Nicotine Dependence Clinic at CAMH, all of whom administer NRT through the STOP program.
62734135|NCT03387709|EXPERIMENTAL|Pistachio-enriched diet|Participants in this group will be individually counseled on a lower calorie diet, receive pistachios to be consumed daily for four months, and receive print materials on incorporating pistachios into their diet.
62734136|NCT03387709|ACTIVE_COMPARATOR|General dietary guidance diet|Participants in this group will receive general dietary guidance as part of a 4-month long group intervention.
62734137|NCT03657784|EXPERIMENTAL|Cohort 1|P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
62734138|NCT03657784|EXPERIMENTAL|Cohort 2|P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
62734139|NCT03657784|EXPERIMENTAL|Cohort 3|P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
62734140|NCT03657784|EXPERIMENTAL|Cohort 4|P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
62734141|NCT03657784|EXPERIMENTAL|Cohort 5|P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
62734142|NCT01098331|OTHER|Arm Rx1: Radical Prostatectomy|Arm Rx1: Radical Prostatectomy
62734143|NCT01098331|OTHER|Arm Rx2: Brachytherapy|Arm Rx2: Brachytherapy
62734144|NCT05842434|EXPERIMENTAL|Felix|
62734145|NCT02412189|NO_INTERVENTION|control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
62734146|NCT02412189|ACTIVE_COMPARATOR|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
62734147|NCT02506855|EXPERIMENTAL|Group A|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and anesthetic will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight \<70kg: Ropivacaine 75mg - 150 mg on each side (20mL ropivacaine 3.75mg/ml each side)~Weight greater than or equal to 70kg: Ropivacaine 100mg - 200mg on each side (20mL ropivacaine 5mg/ml each side"
62734148|NCT02506855|PLACEBO_COMPARATOR|Group B|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and the placebo solution will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight \<70kg: 20mL each side~Weight greater than or equal to 70kg: 20mL each side"
62734149|NCT01916824|EXPERIMENTAL|Participants with Major Depressive Disorder|Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
62734150|NCT01916824|NO_INTERVENTION|Healthy Controls|Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness
62734151|NCT03782259|PLACEBO_COMPARATOR|Placebo|10mg tabs placebo matching dapagliflozin.
62734152|NCT03782259|ACTIVE_COMPARATOR|Active|10mg tabs of dapagliflozin
62734153|NCT06386978|ACTIVE_COMPARATOR|TAP Group|TAP (Transverse Abdominis Plane Block) Block was performed in Group 1 patients after negative aspiration on both sides, under aseptic conditions with bupivacaine under ultrasonography guidance.
62734154|NCT06386978|ACTIVE_COMPARATOR|TFP Group|TFP (Transversalis facia plane block ) Block was performed in Group 2 patients after negative aspiration on both sides, under aseptic conditions with bupivacaine under ultrasonography guidance.
62734155|NCT06386978|ACTIVE_COMPARATOR|Control Group|Patients in the Third group will be considered the control group and no block will be performed
62734156|NCT04923633||Phase I Instrument-Assisted Soft Tissue Manipulation (IASTM) Stroke Pattern Analysis|Fifteen (n=15) experienced clinicians, each with 8 or more years experiences in instrument-assisted soft tissue manipulation (IASTM), will participate in an observational studying analyzing their application of basic stroke patterns (linear, curved) to a consistent research assistant/model. IASTM is a type of massage that uses rigid devices. A Quantifiable Soft Tissue Manipulation (QSTM) device system will be used for determining objective metrics of stroke parameters (e.g. stroke force, rate, angle) and results will be compared between participants to determine characteristic stroke profile patterns for use in training and research.
62734157|NCT04923633||Phase II Consistency of IASTM Force Application|"The reproducibility of applying a targeted STM stroke force will be determined within and between therapists, both with and without visual monitoring of the QSTM metrics and graphic display. Two novice and two experienced therapists will be trained using QSTM. A novice is defined as a clinician with \<1 year and an experienced with \>8 years of practice. Fifty (n=50) healthy, non-obese subjects will be enrolled that meet the inclusion/exclusion criteria. First, the clinicians will apply a self-perceived moderate force for 15sec (non-therapeutic dose), within subject tolerance, without using QSTM feedback. Then, the clinician will apply a targeted force of 10N with visual monitoring of QSTM feedback. This process will be repeated 5-7 days later to determine repeatability. After testing, subjects will participate in simple back and/or leg stretches and an ice pack applied."
62734158|NCT04923633||Phase III Reliability of Dynamic Pressure Pain Threshold Assessment|"The reliability of dynamic pressure pain threshold (DPPT) assessment over a specified area will be determined. Two novice and two experienced clinicians will be trained using QSTM. Subjects (n=50) will be recruited that meet the inclusion/exclusion criteria of healthy, non-obese, younger (≥18 but ≤30yo) and older individuals (≥50 but ≤75yo) (males and females). The clinicians will apply force to standardized areas of the back and thigh regions for 1 min, using the Quantifiable Soft Tissue Manipulation (QSTM) device system. The force applied will be applied up to but below the threshold of when a subject says to stop when they feel the pressure change into any sort of irritating discomfort/pain. Secondary clinical outcomes will be assessed before and after testing since testing could have effects on the soft tissue, pain, and physical performance measures. After testing, the subject will be instructed in simple back and/or leg stretches and an ice pack applied."
62734159|NCT05077540|ACTIVE_COMPARATOR|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
62734160|NCT05077540|EXPERIMENTAL|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
62734161|NCT02574767|EXPERIMENTAL|Lifestyle counseling + PUFA supplement|Home-based Diet and Physical activity plus n3LC-PUFAs supplementation
62734162|NCT02574767|EXPERIMENTAL|Routine diet & PA + PUFA Supplementation|Routine Diet \& Physical Activity counseling care plus n3LC-PUFAs supplementation.
62734163|NCT02574767|EXPERIMENTAL|Lifestyle counseling + PUFA placebo|Home-based Diet and Physical Activity plus placebo for n3LC-PUFAs supplementation.
62734164|NCT02574767|PLACEBO_COMPARATOR|Routine diet & PA + PUFA placebo|Routine Diet \& Physical Activity counseling plus placebo for n3LC-PUFAs supplementation.
62734165|NCT03391830|ACTIVE_COMPARATOR|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
62734166|NCT03391830|PLACEBO_COMPARATOR|Placebo|Placebo
62734167|NCT04389710|EXPERIMENTAL|Intervention Group|Participants included in the experimental group will receive 200-600 milliliters of convalescent plasma, administered at a rate of 100-250 mL/hr
62734168|NCT02584062|EXPERIMENTAL|no-touch fluid-air exchange group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will not touch the macular area,especially the area of the macular hole and investigator will not have the fluid-air exchange of the macular area.
62734169|NCT02584062|EXPERIMENTAL|the tradional group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will touch the macular area and investigator will have the fluid-air exchange.
62734170|NCT02620800|EXPERIMENTAL|FABLOx|5 fluorouracil (5-FU ) (180 mg/m\^2/day for 14 days), by continuous intravenous infusion (CIVI) via ambulatory pump, nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15, bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15, calcium leucovorin (20 mg/m\^2) IV bolus on Days 1, 8, 15, and oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15. First bevacizumab infusion is given over 90 minutes.
62734171|NCT02487758|EXPERIMENTAL|Ridge preservation Flap|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
61976789|NCT03108027|EXPERIMENTAL|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
61976790|NCT03108027|EXPERIMENTAL|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
62734172|NCT02487758|EXPERIMENTAL|Ridge preservation Flapless|The test will be a flapless technique with tunneling and an intramucosal vertical incision on the buccal.
62734173|NCT03184662|EXPERIMENTAL|HIPA group|"Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.~The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study."
62734174|NCT03184662|ACTIVE_COMPARATOR|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
62734175|NCT02366923|EXPERIMENTAL|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
62734176|NCT02366923|ACTIVE_COMPARATOR|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
62734177|NCT02325570|EXPERIMENTAL|KLOX BioPhotonic OraLum Gel + SRP|Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
62734178|NCT02325570|OTHER|Scaling and Root Planing (SRP)|The second half-mouth will be treated with SRP alone.
62734179|NCT02038946|EXPERIMENTAL|Arm 1: Nivolumab|Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity
62734180|NCT04452747|ACTIVE_COMPARATOR|Dino-first|Labour will be induced by the use of the vaginal Dinoprostone system (Propess®) first.
62734181|NCT04452747|ACTIVE_COMPARATOR|Balloon-first|Labour will be induced by the use of a cervix dilatation balloon first.
62734182|NCT05626140|PLACEBO_COMPARATOR|Diclofenac plus placebo|Oral tablet diclofeanc sodium 50 mg was given with tab folic acid 5 mg as placebo ,12 hourly for 15 days
62734183|NCT05626140|ACTIVE_COMPARATOR|Diclofenac plus codeine|Oral tablet diclofeanc sodium 50 mg was given with tab codeinephosphate 30 mg ,12 hourly for 15 days
62734184|NCT05626140|EXPERIMENTAL|Diclofenac plus lacosamide|Oral tablet diclofeanc sodium 50 mg was given with tab lacosamide 50 mg as placebo ,12 hourly for 15 days
62734185|NCT00801112||1|PD patients with residual renal function \>200ml with BIA monitor.
62734186|NCT00801112||2|PD patients with residual renal function \<200ml with BIA monitor.
62734187|NCT00801112||3|PD patients with residual renal function \>200ml without BIA monitor
62734188|NCT00801112||4|PD patients with residual renal function \<200ml without BIA monitor
62734189|NCT02578134|EXPERIMENTAL|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
62734190|NCT02578134|SHAM_COMPARATOR|Sham US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of sham US-guided percutaneous electrolysis. In this case, the acupuncture needle will be inserted in the soft tissue, in this case the plantar fascia insertion without the application of the galvanic electrical current. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
62734191|NCT01518725|EXPERIMENTAL|Vitamin D Supplementation|The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day.
62734192|NCT01518725|PLACEBO_COMPARATOR|Gel-like Substance|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
62734193|NCT03964987||Control group|Women with normoevolutionary gestation.
62734194|NCT03964987||Problem group|Patients with GDM.
62734195|NCT04496908|ACTIVE_COMPARATOR|Early Amniotomy|Women in the Early AROM group will under amniotomy one hour from Foley Catheter expulsion. Labor augmentation will continue per study protocol. Refer to Appendix A for protocol regimen.
62734196|NCT04496908|ACTIVE_COMPARATOR|Delayed Amniotomy|Women in the Delayed AROM group will undergo amniotomy at the discretion of the obstetrician or labor provider. No specific instructions will be given.
62734197|NCT04706312|EXPERIMENTAL|hAMSCs injection|hAMSCs were injected via venous in the dorsum of hand.
62734198|NCT03533959||alirocumab therapy group|patients with 10mg daily rosuvastatin and alirocumab at least 75mg every 2 weaks
62734199|NCT03533959||standard statin therapy group|patient with 10mg daily rosuvastatin and never use alirocumab or other PCSK-9 inhibitor
62734200|NCT00876096|OTHER|1|precocious diagnosis and taken care therapeutics of the systematic athlete's feet
62734201|NCT03050450|EXPERIMENTAL|dose level 1|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
62734202|NCT03050450|EXPERIMENTAL|dose level 2|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
62734203|NCT03050450|EXPERIMENTAL|dose level 3|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
62734204|NCT03050450|EXPERIMENTAL|dose level 4|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
62734205|NCT03050450|EXPERIMENTAL|dose level 5|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
62734206|NCT00322049|EXPERIMENTAL|Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )|"Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;~DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection."
62734207|NCT00322049|ACTIVE_COMPARATOR|Cohort B: Control vaccines|Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine
62734208|NCT00322049|EXPERIMENTAL|Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )|Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years
62734209|NCT03088644|EXPERIMENTAL|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
62734210|NCT03088644|EXPERIMENTAL|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
62734211|NCT03088644|EXPERIMENTAL|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V\[t\]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
62734212|NCT03088644|EXPERIMENTAL|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram \[mg\]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
62734213|NCT04221503|EXPERIMENTAL|Cohort A|Cohort A is for subjects with recurrent glioblastoma who do not have clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort A will initiate and continue TTFields therapy for 5-7 days prior to starting niraparib.
62734214|NCT04221503|ACTIVE_COMPARATOR|Cohort B|Cohort B is for subjects with recurrent glioblastoma who have a clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort B will receive TTFields for 5-7 days prior to planned surgical resection, undergo surgical resection, resume TTFields postoperatively, and initiate niraparib 5- 7 days after starting TTFields postoperatively.
62734215|NCT03612063|EXPERIMENTAL|Fitbit Iconic HR and Garmin Vivosmart HR|
62734216|NCT03612063|EXPERIMENTAL|Fitbit Iconic HR and TomTom Spark 3|
62734217|NCT03612063|EXPERIMENTAL|Garmin Vivosmart HR and TomTom Spark 3|
62734218|NCT03612063|EXPERIMENTAL|Fitbit Iconic HR and Apple Watch III|
62734219|NCT03612063|EXPERIMENTAL|Apple Watch III and Garmin Vivosmart HR|
62734220|NCT03612063|EXPERIMENTAL|Apple Watch III and TomTom Spark 3|
62734221|NCT03687242|EXPERIMENTAL|SPR001|SPR001 at Dose A
62734222|NCT03278795|ACTIVE_COMPARATOR|PSV mode|PSV weaning group
62734223|NCT03278795|EXPERIMENTAL|VSV mode|VSV weaning group
62734224|NCT03049579|EXPERIMENTAL|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
62734225|NCT03049579|PLACEBO_COMPARATOR|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
62734226|NCT01527591|OTHER|vaccine|pneumococcal conjugated vaccine
62734227|NCT03954886|EXPERIMENTAL|Induced myopic defocus|Subjects will view a television through a lens that induces blur to the retina for one hour. Images of the eye will be captured every 10 minutes
62734228|NCT03954886|NO_INTERVENTION|No defocus|Subjects will view a television through a lens that induces no blur to the retina for one hour. Images of the eye will be captured every 10 minutes
62734229|NCT05860907|EXPERIMENTAL|Huaier Granule+Standard treatment|The subject is administered according to the clinical dosage and method of medication until disease progression occurs or the subject is unable to tolerate treatment.Subjects receiving routine diagnosis and treatment simultaneously.
62734230|NCT05860907|NO_INTERVENTION|Standard treatment|Subjects receive routine diagnosis and treatment without taking Huaier granules.
62734231|NCT05561816|EXPERIMENTAL|Dioxidin|Patients will apply Dioxidin® 3 times a day (in the morning, afternoon and evening) by spraying (4 pressings of the spray nozzle on each affected area corresponding to 1% of the body area) on the affected skin areas from a distance of about 10 cm, so that the entire affected surface is covered with the solution. After application, you should wait until the preparation is completely dry. The therapy duration will be 10 days.
62734232|NCT05561816|ACTIVE_COMPARATOR|Miramistin|Patients will apply Miramistin® to the affected areas of the skin by wiping with sterile gauze swabs liberally moistened with the preparation three times a day (in the morning, lunchtime, and evening). The therapy duration will be 10 days.
62734233|NCT02110849||Prostate Cancer Patients|Prostate cancer patients who received proton radiation therapy
62734234|NCT00931125|ACTIVE_COMPARATOR|vitrectomy with ranibizumab|Patients receiving adjunct preoperative intravitreal ranibizumab (3±1 days) before vitrectomy surgery
62734235|NCT00931125|PLACEBO_COMPARATOR|vitrectomy without ranibizumab|Patients receiving sham treatment before vitrectomy as a comparator arm
62734236|NCT03694769||All participants|Semi-structured interview and drop attack diary
62734237|NCT03200197|EXPERIMENTAL|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
62734238|NCT03200197|ACTIVE_COMPARATOR|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
61976791|NCT03108027|EXPERIMENTAL|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
62734239|NCT04359524|ACTIVE_COMPARATOR|Intervention|Received vitamin D3 capsules (1200 IU/30µg).
62734240|NCT04359524|PLACEBO_COMPARATOR|Control|Received placebo (oil capsules).
62734241|NCT00276055|EXPERIMENTAL|Cohort 1|1000mg/m2 gemcitabine
62734242|NCT00276055|EXPERIMENTAL|Cohort 2|1250 mg/m2 gemcitabine
62734243|NCT00276055|EXPERIMENTAL|Cohort 3|1500 mg/m2 gemcitabine
62734244|NCT01183429|EXPERIMENTAL|3F8 and 13-cis-retinoic acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(8), patients no longer receive high dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles.
62734245|NCT05183516|EXPERIMENTAL|Tdap|Open label study, no placebo comparator
62734246|NCT02342782|EXPERIMENTAL|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
62734247|NCT03042650|EXPERIMENTAL|Intensive Referral Intervention Group|Intensive Referral Intervention will by done by trained probation officers
62734248|NCT03042650|ACTIVE_COMPARATOR|Standard Practice Facilitated Group|Standard Current Practice will be provided by untrained probation officers
62734249|NCT01059045|EXPERIMENTAL|Cryocontact therapy|
62734250|NCT01059045|NO_INTERVENTION|Control|
62734251|NCT02350075|EXPERIMENTAL|Short implants group|Patients receive short dental implants installation (6mm) without additional augmentation procedures.
62734252|NCT02350075|OTHER|Standard implants with OSFE group|Patients receive standard dental implants installation (10mm) combined with osteotome sinus floor elevation.
62734253|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(single dose) 12.5 mg (Cohort 1)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
62734254|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo((single dose) 37.5 mg Cohort(Cohort 2)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
62734255|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(single dose) 75 mg (Cohort 3)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
62734256|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(single dose) 125 mg(Cohort 4)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
62734257|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(single dose and food effect) 175mg (Cohort 5)|"Period 1 (Day1 to Day4): Group A and Group B receive IMM-H014 /Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day11): Group A and Group B receive IMM-H014 /Placebo under the fed or fasting condition ,respectively on Day8."
62734258|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(single dose) 225 mg (Cohort 6)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
62734259|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(single dose) 275mg (Cohort 7)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
62734260|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(single dose) 325 mg (Cohort 8)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
62734261|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(multiple dose) tentative 37.5 mg(Cohort 9)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
62734262|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(multiple dose) tentative 75 mg(Cohort 10)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
62734263|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(multiple dose) tentative 125 mg(Cohort 11)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
62734264|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(multiple dose) tentative 175 mg(Cohort 12)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
62734265|NCT06216041|EXPERIMENTAL|IMM-H014 /Placebo(multiple dose) tentative 225 mg(Cohort13)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
62734266|NCT00050557|EXPERIMENTAL|1|Participants will receive immediate Multi-Family Psychoeducation Group treatment and ongoing treatment as usual
62734267|NCT00050557|ACTIVE_COMPARATOR|2|Participants will receive treatment as usual and waitlist Multi-Family Psychoeducation Group treatment
62734268|NCT03703232|OTHER|Lower extremity amputees|Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.
62734269|NCT02082444|EXPERIMENTAL|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
62734270|NCT06407453|ACTIVE_COMPARATOR|control|No intervention will be made
62734271|NCT06407453|EXPERIMENTAL|exercise|exercise program will be applied
62734272|NCT04245449|EXPERIMENTAL|e learning+therapy (TEAACH)|TEAACH-Training to Empower Activity-dependent plasticity-based Arm-use habits in the Community and at Home
62734273|NCT06159244|EXPERIMENTAL|sAH patients|the recruitment of patients with sAH will be carried out from the Hepatogastroenterology Service of the University Hospital of Amiens.
62734274|NCT06159244|EXPERIMENTAL|Alcohol controls without liver complications|the recruitment of alcohol controls will concern patients followed for alcohol addiction without sAH in the antecedents or evolutionary. It will be carried out by the Hospital of Roye-Montdidier. The total number of controls will be equivalent to the number of sAH patients, matched for age and sex.
62734275|NCT06159244|ACTIVE_COMPARATOR|Healthy non-alcoholic witnesses|the general population will be called with a matching on age
62734276|NCT02827344||Stage IV non-small cell lung cancer|"Intervention to be done are :~- Blood sample collection for CTC and MDSC analysis"
61976792|NCT03108027|EXPERIMENTAL|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
61976793|NCT02007018|EXPERIMENTAL|Negative Pressure Wound Therapy|This group will receive the usual care of surgical wound AND Negative Pressure Wound Therapy (NPWT). The Prevena™ Incision Management System (PIMS) is placed in a sterile fashion over the closed surgical site prior to leaving the operating room. The PIMS is to remain in place until the completion of therapy at five days.
61976794|NCT02007018|ACTIVE_COMPARATOR|Usual Care of Surgical Wound|This group will receive the usual care of a surgical wound.
61976795|NCT01464385|EXPERIMENTAL|Nutritional Beverage #2|Nutritional Beverage with an amino acid Oral 237 ml
61976796|NCT01464385|EXPERIMENTAL|Nutritional Beverage #3|Nutritional Beverage with an amino acid Oral 237 ml
61976797|NCT01464385|PLACEBO_COMPARATOR|Nutritional Beverage #1|Nutritional Beverage Oral 237 ml
61976798|NCT03183375|EXPERIMENTAL|Hydroxyurea arm|This arm will be given investigational drug that is Hydroxyurea .This intervention will be given along with the standard treatment that is blood transfusion and iron chelation.
61976799|NCT03183375|NO_INTERVENTION|Standard arm|this arm will only receive the standard treatment which is blood transfusion and iron chelation
61976800|NCT05076526|ACTIVE_COMPARATOR|HA|Patients will receive 2 intra-articular injections of 2mL Synolis VA (20 mg/mL HA and 40 mg/mL sorbitol), with an interval of 1 month between both injections.
61976801|NCT05076526|EXPERIMENTAL|PRP-HA|Patients will receive 2 intra-articular injections of 5mL CM-PRP-HA combination (3mL of autologous PRP, 2mL of 16mg/mL HA), with an interval of 1 month between both injections.
61976802|NCT03666845||Sciatic nerve block|Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic kidney disease
61978244|NCT05849103|ACTIVE_COMPARATOR|C) Standard BP Control, Care Navigation|Target blood pressure will be less than 150/100. Participants will check blood pressures twice daily for 14 days and daily for weeks 3-6. A nurse navigator will review their blood pressures M-F for Weeks 1-2 and weekly for weeks 3-6 and will provide feedback on blood pressure values and recommend initiating or escalating medications as needed. The nurse navigator will communicate progress to the participant's clinicians and will remind the participant of their appointments. The nurse navigator will facilitate a visit around 3 months with a primary care clinician or a cardiologist for hypertension follow up.
61976803|NCT03935906|EXPERIMENTAL|Reach Pathway|Community pharmacist will explain the risks of contracting HCV from current or historical intravenous drug use. OST patients will then meet with an outreach hepatology nurse specialist who will perform a diagnostic point-of-care (PoC) HCV test along with venepuncture for safety blood tests and confirmatory HCV RNA on the pharmacy premises. The nurse will return for a subsequent visit to prescribe (in the UK; in Australia prescribing is undertaken by qualified medic) and deliver HCV medication for participants who test positive, which will be dispensed alongside their OST schedule by their community pharmacist. The outreach nurse will return after approximately 14 days to confirm negative results, dispense medication for new patients with positive results (PCR positive but below limit of detection of POC test) and confirm follow up appointments where required. The RNA and PoC test will also be administered for sustained viral response at 12 weeks post treatment (SVR12).
61976804|NCT03935906|EXPERIMENTAL|Education-only Pathway|The community pharmacist will discuss the risks of contracting HCV through current or historical intravenous drug use. The community pharmacist will then advise participants on the nearest centre for HCV testing and treatment, as is standard of care for the countries included in this study. If they are referred from a REACH pharmacy, they will present a reply slip and/or the Patient Information Sheet to the nurse who will then consent the participant, perform HCV and safety blood tests, and complete the study paperwork. The participant's medication will be delivered to, and dispensed from, their community pharmacy alongside their OST. Participants will return to the local BBV clinic for an SVR12 test after completing treatment.
61976805|NCT03910608|EXPERIMENTAL|DLPFC+10 IPL|Stimulation of dorsolateral prefrontal cortex (DLPFC) 10 ms before inferior parietal lobule (IPL) presumes that the DLPFC to IPL input facilitates insula postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
61976806|NCT03910608|EXPERIMENTAL|IPL+10 DLPFC|Stimulation of IPL 10 ms before DLPFC presumes that the IPL to DLPFC input inhibits insula postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
61976807|NCT03910608|EXPERIMENTAL|IPL+4 DPLFC|Stimulation of IPL 4 ms before DLPFC is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula inhibits insula postsynaptic output by weakening the IPL to insula input, thereby impairing cognition response.
61976808|NCT03910608|EXPERIMENTAL|DLPFC+4 IPL|Stimulation of DLPFC 4 ms before IPL is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula potentiates insula postsynaptic output by strengthening the IPL to insula input, thereby improving cognition response.
61976809|NCT03910608|EXPERIMENTAL|DLPFC+4 MPFC|Stimulation of DLPFC 4 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
61976810|NCT03910608|EXPERIMENTAL|MPFC+4 DLPFC|Stimulation of MPFC 4 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
61976811|NCT03910608|EXPERIMENTAL|DLPFC+10 MPFC|Stimulation of DLPFC 10 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
61976812|NCT03910608|EXPERIMENTAL|MPFC+10 DLPFC|Stimulation of MPFC 10 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
61976813|NCT01512082|EXPERIMENTAL|Active pulsed electromagnetic field|
61976814|NCT01512082|SHAM_COMPARATOR|Non-active pulsed electromagnetic field|
61976815|NCT00774319|ACTIVE_COMPARATOR|1|Induction Chemotherapy with TPF Then: cisplatin 100 mg/m2 on day 1, 22 and 43 combined with conventional radiotherapy
61976816|NCT00774319|ACTIVE_COMPARATOR|2|Induction chemotherapy with TPF Then cisplatin 40mg/m2 on day 1,8,15,22,29 and 35 combined with accelerated radiotherapy
61976817|NCT01001611|EXPERIMENTAL|CKD-501 0.5mg|
61976818|NCT01001611|PLACEBO_COMPARATOR|Placebo|
61976819|NCT00948623|EXPERIMENTAL|1|
61976820|NCT00948623|SHAM_COMPARATOR|2|
61976821|NCT04101981||healthy subjects|10 subjects
61976822|NCT04101981||oncological patients|10 subjects
61976823|NCT00611286|EXPERIMENTAL|1|treatment with Aspirin and clopidogrel for 24 months after coronary intervention with stents. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent.
61976824|NCT00611286|ACTIVE_COMPARATOR|2|Treatment with aspirin and clopidogrel for minimum 1 or 6 month(s) after BMS or DES implantation, respectively. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent
61976825|NCT02938871|ACTIVE_COMPARATOR|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
61976826|NCT02938871|PLACEBO_COMPARATOR|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
61976827|NCT02288559|EXPERIMENTAL|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
61976828|NCT02288559|EXPERIMENTAL|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
61976829|NCT02288559|EXPERIMENTAL|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
61976830|NCT02288559|SHAM_COMPARATOR|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
61976831|NCT03271112|OTHER|Exercise program|Participation to the 12-wks exercise program
61976832|NCT02312895|EXPERIMENTAL|Dry Needling|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive dry needling, patient education, and a home exercise program.
61976833|NCT02312895|EXPERIMENTAL|Manual Therapy|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive manual therapy, patient education, and a home exercise program.
61976834|NCT02566226|PLACEBO_COMPARATOR|Bupivacaine with normal saline|
61976835|NCT02566226|ACTIVE_COMPARATOR|Bupivacaine with intrathecal morphine|
61976836|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
61976837|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
61976838|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
61976839|NCT02597348|EXPERIMENTAL|Liver Transplantation|Arm LT+C: patients will be treated by experimental liver transplantation preceding the non experimental standard chemotherapy (according to usual practices).
61976840|NCT02597348|NO_INTERVENTION|No intervention|Arm C: patients will receive non experimental standard chemotherapy according to usual practices in the context of definitively unresectable CLM.
61976841|NCT05138575|ACTIVE_COMPARATOR|Empagliflozin + Potassium Chloride (KCl)|"Empagliflozin (10 mg daily) + Potassium Chloride (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
61976842|NCT05138575|ACTIVE_COMPARATOR|Empagliflozin + Potassium Nitrate (KNO3)|"Empagliflozin (10 mg daily) + Potassium Nitrate (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
61976843|NCT05138575|PLACEBO_COMPARATOR|Potassium Chloride (KCl) + Placebo for Empa|"Potassium Chloride (6 mmol three times daily) + Placebo for Empagliflozin~Placebo arm will be 6 weeks in duration followed by a 2 week washout period."
61976844|NCT05534997|EXPERIMENTAL|Group A|will receive the post covid protocol conventional treatment in form of medication and 24 sessions of combined rehabilitation exercise program in the form of Graded exercise therapy (GET) and cognitive behavioral therapy (CBT). Patients will attend two sessions per week for 12 weeks. Sessions will be taken at Modern university for technology and information physical therapy rehabilitation center . A home exercise program will be prescribed on at least five days a week. Patients will be contacted by phone daily for the 12 weeks treatment sessions, for following up the home exercise program.
61976845|NCT05534997|NO_INTERVENTION|Group B|will receive the post covid protocol conventional treatment in form of medication and specialist medical care provided by doctors with specialist experience in CFS. All patients will be given a leaflet explaining the illness and the nature of this treatment. Treatment will consist of an explanation of chronic fatigue syndrome, generic advice such as to avoid extremes of activity and rest, specific advice on self-help and symptomatic pharmacotherapy (especially for insomnia, pain and mood) .
61976846|NCT03686163|EXPERIMENTAL|IN-NGF group|Patients who underwent acute ischemic stroke will be chosen to receive NGF randomly
61976847|NCT03686163|PLACEBO_COMPARATOR|Control group|Patients who underwent acute ischemic stroke will be chosen to receive normal saline randomly
61976848|NCT01330589|EXPERIMENTAL|AB: Placebo (A); St. Johns Wort (B)|Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort
61976849|NCT01330589|EXPERIMENTAL|BA: St. Johns Wort (B); Placebo (A)|Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo
61976850|NCT01404845|ACTIVE_COMPARATOR|B: patients with wet AMD in one eye.|group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.
61976851|NCT01404845|ACTIVE_COMPARATOR|A :patients without retinal pathology|"group A :patients without retinal pathology who underwent cataract surgery 1 month previously.~In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin."
61976852|NCT01479153|ACTIVE_COMPARATOR|Subclavian catheterization|
61976853|NCT01479153|ACTIVE_COMPARATOR|Internal Jugular catheterization|
61976854|NCT01479153|ACTIVE_COMPARATOR|Femoral Catheterization|
61976855|NCT01720992|EXPERIMENTAL|Group A|A theory-based action planning toolkit will be distributed to Group A participants.
61976856|NCT01720992|OTHER|Group B|Group B is a wait list control
61976857|NCT05778825|EXPERIMENTAL|Oral Minoxidil|Patients receive oral minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day for 8 months
61976858|NCT05778825|ACTIVE_COMPARATOR|Placebo followed by oral Minoxidil|Patient receive placebo for 4 months followed by oral minoxidil for 4 months
61976859|NCT05490745|EXPERIMENTAL|Immediate Intervention Group (IIG)|Participants receive initially one session for psychological assessment. At the end of the session, the second session is scheduled for the following week, where feedback about the assessment will be provided. If in the second session participants agree to proceed with the psychological intervention, then the remaining 4-6 sessions of Skills4Parenting+ are conducted.
61976860|NCT05490745|OTHER|Delayed Intervention Group (DIG)|Waiting-list Comparator (nocebo): Participants initially receive one session for psychological assessment. At the end of the session, participants are informed that they will be contacted to schedule the second session, where feedback about the assessment will be provided. Participants are contacted during the same week, to schedule the second session 8 weeks after the first session. If in the second session participants agree to proceed with the psychological intervention, then the remaining 4-6 sessions of Skills4Parenting+ are conducted.
61976861|NCT04924647|EXPERIMENTAL|RD|lenalidomide and dexamethasone
61976862|NCT01267812|EXPERIMENTAL|Treatment (bortezomib and rituximab)|Doses of bortezomib given is 1.3 mg/m2 weekly x 4 weeks given every 3 month x 8 cycles. Doses of RITUXAN given is 375 mg/m2 give weekly x 4 weeks given every 6 month for 4 cycles.
61976863|NCT04277078||Intubated asthma attack|Patients who had been hospitalised with asthma attack, then intubated during hospitalisation.
61976864|NCT04277078||Non-Intubated asthma attack|Patients who had been hospitalised with asthma attack without intubation during hospitalisation.
61976865|NCT02107027|ACTIVE_COMPARATOR|nMARQ catheter (circular catheter)|Group treated with the circular ablation catheter for atrial fibrillation ablation
61976866|NCT02107027|ACTIVE_COMPARATOR|Navistar catheter (conventional catheter)|Group treated with the conventional ablation catheter for atrial fibrillation ablation
61976867|NCT02986789|NO_INTERVENTION|Control Group|Clinicians will be performing blood transfusions using hospital standard of care procedures.
61976868|NCT02986789|EXPERIMENTAL|Evaluation Group|Clinicians will be guiding blood transfusions using SpHb with In vivo feature as a trigger for laboratory blood draws and PVi to inform fluid administration decisions in addition to hospital standard of care procedures.
61976869|NCT01327885|EXPERIMENTAL|Arm A|
61976870|NCT01327885|ACTIVE_COMPARATOR|Arm B|
61976871|NCT02200445|EXPERIMENTAL|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~* Cohort 1: 0.3x10\^6 IU/m\^2/day.~* Cohort 2: 1.0x10\^6 IU/m\^2/day.~* Cohort 3: 1.5x10\^6 IU/m\^2/day.~Up to 6 subjects will be recruited to each dose cohort.~Once the maximum effective dose has been identified, a further 10 subjects will receive IL-2 at the maximum effective dose."
61976872|NCT03905187|OTHER|Control Group|Group received education only
61976873|NCT03905187|OTHER|Traditional CR Group|Group received cardiac rehabilitation including education and exercise
61976874|NCT03905187|EXPERIMENTAL|Stress-Modified CR Group|Group received cardiac rehabilitation including education, exercise and stress management
61976875|NCT05584176|EXPERIMENTAL|Subject 14-65+ years of age|Participants will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the Rapid SARS-CoV-2 Antigen Test. The participant will then self-collect or, if both are over 18, collect from another study participant an anterior nasal swab sample and test using the Rapid SARS-CoV-2 Antigen Test.
61976876|NCT05584176|EXPERIMENTAL|At least 30 children between 2 and 13 years of age|Participants 2-13 years of age will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the Rapid SARS-CoV-2 Antigen Test. The parent or legal guardian of the child will collect an anterior nasal swab sample from the child and perform the Rapid SARS-CoV-2 Antigen Test.
61976877|NCT03969394|EXPERIMENTAL|Heart Failure Patients|Patients with Heart Failure
61976878|NCT03864250|EXPERIMENTAL|Tacrolimus monotherapy|
61976879|NCT03864250|ACTIVE_COMPARATOR|Tacrolimus combined with hormone therapy|
61976880|NCT06518135||SLNB group|Standard sentinel lymph node biopsy group, if frozen pathology SLNs are negative, no ALND will be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If the frozen pathology is false negative, it is recommended to complete ALND within 12 weeks after SLNB surgery.
61976881|NCT05830201|ACTIVE_COMPARATOR|Control Group|Dog will not be in room when child has elbow pins removed
61976882|NCT05830201|EXPERIMENTAL|Therapy Dog Group|The dog will come in a few minutes before to meet with you and your child and ensure ease. The therapy dog will be present throughout the procedure and is able to sit on the exam table if desired.
61976883|NCT03103633|EXPERIMENTAL|Individualized Goal-Directed Therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.
61976884|NCT03103633|SHAM_COMPARATOR|Controlled|no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
61976885|NCT01667757||low post DES FFR group (<0.9)|the patient with FFR values less than 0.9 after DES procedure
61976886|NCT01667757||high post DES FFR group (≥0.9)|the patient with FFR values greater than 0.9 after DES procedure
61976887|NCT05436951|EXPERIMENTAL|No-nap, then brief 45-minute nap|Participants will be monitored for a total of 48 hours, including a 12-hour simulated night shift. At baseline (consent), participants are randomized to a crossover study design with two study arms (no nap, brief 45-minute nap). In this sequence, participants will perform the 12-hour simulated night shift with no nap first, undergo a minimum of 1-week washout, then return complete the 48-hour protocol again with the brief 45-minute nap.
61976888|NCT05436951|EXPERIMENTAL|The brief 45-minute nap, then no-nap|Participants will be monitored for a total of 48 hours, including a 12-hour simulated night shift. At baseline (consent), participants are randomized to a crossover study design with two study arms (no nap, brief 45-minute nap). In this sequence, participants will perform the 12-hour simulated night shift with the brief 45-minute nap, undergo a 1-week minimum washout, then return to complete the 48-hour protocol again with the no-nap
61976889|NCT02157298|EXPERIMENTAL|dapagliflozin 5mg|dapagliflozin tablet 5mg
61976890|NCT02157298|PLACEBO_COMPARATOR|Placebo|dapagliflozin tablet 5mg placebo
61976891|NCT03502044|ACTIVE_COMPARATOR|Arm 1, active KOS treatment|Patients in arm 1 receive active KOS treatment throughout study, which means 16 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
61976892|NCT03502044|PLACEBO_COMPARATOR|Arm 2, 8 inactive KOS treatments then 8 active KOS treatments|Patients in arm 2 receive inactive KOS treatment during the first 8 KOS treatments of the study. Thereafter patients in arm 2 receive 8 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
61976893|NCT02338531|EXPERIMENTAL|Therapeutic regimen|oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
61976894|NCT03957707|EXPERIMENTAL|stereotactic surgery with drugs treatment|
61976895|NCT03957707|SHAM_COMPARATOR|drugs treatment alone|
61976896|NCT03724539|EXPERIMENTAL|STRIPA intervention|"GPs in the intervention group will perform a STRIPA analysis for each of their 8-10 patients after the recruitment of the patient into the OPTICA trial, so that the results can be discussed in the next consultation and a shared decision-making can be performed.~STRIPA is a structured method to perform pharmacotherapy optimization. The STRIPA intervention in the OPTICA trial consists of 4 steps:~1. recording medication and diagnoses in STRIPA (upload from data from the 'Family medicine ICPC Research using Electronic medical records' (FIRE) database)~2. structured drug review through the GP based on the STRIPA with the integrated STOPP/START criteria~3. shared decision-making between GP and patient with possible adaptation of the recommendation~4. follow-up through study team"
61976897|NCT03724539|SHAM_COMPARATOR|Sham intervention|Patients in the control group will receive a sham intervention, which consists of a usual medication review by their GP as well as a shared decision making of the latter.
61976898|NCT01912651|NO_INTERVENTION|No antibiotic treatment|Withholding post-operative antibiotics following reconstructive surgery necessitating skin grafting for defects of the face or nose.
61976899|NCT01912651|EXPERIMENTAL|Antibiotics|All patients will receive peri-operative antibiotics per standard practice. This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week).
61976900|NCT01064401|EXPERIMENTAL|Daclizumab High Yield Process 150 mg SC|Daclizumab High Yield Process (DAC HYP) 150mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks
61976901|NCT01064401|ACTIVE_COMPARATOR|IFN β-1a 30 µg IM|Interferon beta-1a (IFN β-1a) 30 µg IM once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks
61976902|NCT02589574|NO_INTERVENTION|Control|Subjects of the control group will receive the usual announcement on the dates and times of offering free influenza vaccination, and reminder from hospital, and access to informational flyers posted at the hospital
61976903|NCT02589574|EXPERIMENTAL|Intervention|Subjects of the intervention group besides the usual information same as those stated in the control group, will receive four reminders on dates and details for free influenza vaccine. Together with the reminder, electronic text messages of educational information will be received
61976904|NCT01101347|EXPERIMENTAL|Aneurysm-Embolization System|
61976905|NCT02730455|EXPERIMENTAL|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
61976906|NCT02730455|EXPERIMENTAL|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
61976907|NCT02730455|EXPERIMENTAL|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
61976908|NCT01503281|EXPERIMENTAL|Hospital-based exercise program|Exercise monitored at the hospital
61976909|NCT01503281|EXPERIMENTAL|Home-based exercise program|Participants perform exercise at home
61976910|NCT01503281|NO_INTERVENTION|Control|Control Group participants maintained their usual levels of daily activity, with no additional exercise components.
61976911|NCT00549523|PLACEBO_COMPARATOR|Placebo|Placebo (capsule filled with inert materials)
61976912|NCT00549523|EXPERIMENTAL|Low Dose|400 mg bid Lessertia Frutescens
61976913|NCT00549523|EXPERIMENTAL|Mid Dose|800 mg bid Lessertia Frutescens
61976914|NCT00549523|EXPERIMENTAL|High Dose|1200 bid Lessertia Frutescens
61976915|NCT01735513|EXPERIMENTAL|Transaortic TAVI with EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation with the use of the embolic protection device EmbolX"
61976916|NCT01735513|ACTIVE_COMPARATOR|Transaortic TAVI without EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation without the use of the embolic protection device EmbolX"
61976917|NCT04811833||Monoplus®|Adult patients undergoing an elective, primary surgery within the gastrointestinal tract with the need for anastomosis.
61976918|NCT01953133|NO_INTERVENTION|Control|"Couples do not receive intervention (counseling sessions) during study period. They do undergo one group-based session.~Upon completion of 9 month follow-up, participants in this arm can undergo a condensed, 2 session version of the intervention."
61976919|NCT01953133|EXPERIMENTAL|Couples' Counseling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
61976920|NCT00315198|ACTIVE_COMPARATOR|Near activities|2 hours of daily patching combined with near visual activities while patching
61976921|NCT00315198|ACTIVE_COMPARATOR|Distance activities|2 hours of daily patching combined with distance visual activities while patching
61976922|NCT05063669|EXPERIMENTAL|Cognitive Occupational Therapy|Occupational therapy applications were carried out 40 minutes, twice a week (one individual session and one group intervention session) and total of 8 weeks. In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
61976923|NCT05063669|NO_INTERVENTION|Control|No intervention was performed in this group.
61976924|NCT02573727|EXPERIMENTAL|Nor Adrenaline + Albumin|"Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.~In case of no response the dose of the terlipressin will be progressively increased to the maximum infusion dose of 12 mg/24 hour.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
61976925|NCT02573727|ACTIVE_COMPARATOR|Terlipressin + Albumin|"Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours designed to achieve an increase in MAP of at least 10 mmHg or an increase in 4-h urine output of more than 200 ml. When one of these goals was not achieved, the noradrenaline dose was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
61976926|NCT04204954|OTHER|Group 1: Topical 0.3% Ciprofloxacin [Cipro]|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.
61976927|NCT04204954|ACTIVE_COMPARATOR|Group 2: Cipro + 50% diluted baby shampoo|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.
61976928|NCT04204954|ACTIVE_COMPARATOR|Group 3: Cipro + Blephaclean|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.
62736619|NCT05376059|NO_INTERVENTION|Control Condition|Participants in this group will not receive any oureach at all
61976929|NCT04204954|EXPERIMENTAL|Group 4: Cipro + Tea tree oil.|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.
61976930|NCT05893407||Patients with acute brain injuries when a contrast ultrasound imaging is requested by the physician|Contrast-enhanced ultrasound perfusion imaging (PerCEUS)
61976931|NCT06146426|EXPERIMENTAL|Early diet|The patients of early group will be performed water swallowing test at bedside after 2 hours of extubation. Before performing the Water Swallow Test, the patient must be evaluated for readiness.This interventional group of patients will be initiated with sips of water (warm or cold as patient prefers) at 2 hours of extubation (post-operative day 0) followed by clear liquid diet (tea, clear juice/ soup, gelatin) at 4 hours. If well tolerated, then slowly progress to a full liquid and solid diet as the patient preferred pace.
61976932|NCT06146426|NO_INTERVENTION|Conventional diet|Patients in this group will receive the existing standard (conventional) post-operative diet regimen that is sips of water on the day of surgery and initiation of solid oral diet on next day (post-operative day 1)
61976933|NCT05682105||Development dataset|Slit-lamp images collected from the Department of Hepatobiliary Surgery of the Third Affiliated Hospital of Sun Yat-sen University(HTH)， Affiliated Huadu Hospital of Southern Medical University(HDH)， and Nantian Medical Centre of Aikang Health Care (NMC).
61976934|NCT05682105||Testing dataset|Slit-lamp and smartphone images collected from the Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University（ITH）， Huanshidong Medical Centre of Aikang Health Care， the Medical Centre of the Third Affiliated Hospital of Sun Yat-sen University(MCH).
61976935|NCT04035928|EXPERIMENTAL|3D digital scanning for maxillofacial prosthetics|
61976936|NCT02846922||catheter ablation group|atrial fibrillation patients with heart failure who received catheter ablation for rhythm control
61976937|NCT02846922||rate control group|atrial fibrillation patients with heart failure who received pharmacological approaches for rate control
61976938|NCT01569711||Deep brain stimulation|
61976939|NCT04410224|EXPERIMENTAL|ASN004 ascending doses|Patients will receive escalating doses of ASN004 to identify the best dose for further study.
61976940|NCT02853578|EXPERIMENTAL|Busonid (budesonide 200mcg and 400mcg)|"It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture.~Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug.~The duration of treatment may be 12 weeks."
61976941|NCT02415881|EXPERIMENTAL|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.
61976942|NCT01942291|EXPERIMENTAL|Niacin/Laropiprant|Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
61976943|NCT01942291|EXPERIMENTAL|Niacin|Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
61976944|NCT02477254||SLE patients|SLE patients who received HPV vaccination
61976945|NCT02477254||Control subjects|Healthy subjects who received HPV vaccination
61976946|NCT01304901|ACTIVE_COMPARATOR|1-Montelukast|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
61976947|NCT01304901|PLACEBO_COMPARATOR|2- Placebo|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
61976948|NCT01108705|EXPERIMENTAL|Brivanib|
61976949|NCT01108705|PLACEBO_COMPARATOR|Placebo|
61976950|NCT05002855||Enhanced Recovery After Surgery (ERAS)|
61976951|NCT05002855||Conventional Recovery Strategy (pre-ERAS)|
61976952|NCT05944809|EXPERIMENTAL|prophylactic TPO|Prophylactic TPO combined with BMS-IMRT in the esophageal cancer patients undergoing concurrent chemoradiotherapy
61976953|NCT01326689|EXPERIMENTAL|KW-2246|
61976954|NCT01326689|PLACEBO_COMPARATOR|Placebo|
61976955|NCT02235012|EXPERIMENTAL|Ketamine then placebo|Infusion of low dose Ketamine then infusion of a saline solution
61976956|NCT02235012|EXPERIMENTAL|Placebo then ketamin|Infusion of a saline solution then infusion of low dose Ketamine
61976957|NCT01941641|EXPERIMENTAL|neoadjuvant FOLFOXIRI|
61976958|NCT04290884|EXPERIMENTAL|Local administration of tranexamic acid|"1. All patients hip fracture will be treated according to the hospital standard procedure~2. Check complete blood count on admission and Day 3 post-operation.~3. 10ml tranexamic acid injected under the deep fascia around the fracture site under x-ray control~4. Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.~5. Transfusion when clinically indicated or Hb \< 8g/dL~6. Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)~7. Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.~8. After discharge, patients will be seen in 6 weeks and 3 months"
61976959|NCT04290884|NO_INTERVENTION|Control group|"1. All patients hip fracture will be treated according to the hospital standard procedure~2. Check complete blood count on admission and Day 3 post-operation.~3. 10ml normal saline injected under the deep fascia around the fracture site under x-ray control~4. Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.~5. Transfusion when clinically indicated or Hb \< 8g/dL~6. Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)~7. Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.~8. After discharge, patients will be seen in 6 weeks and 3 months"
61976960|NCT02781922|EXPERIMENTAL|Autologous cardiac stem cells (JRM-001)|
61976961|NCT02781922|NO_INTERVENTION|Usual care|
61976962|NCT05721963||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.
61976963|NCT03622307|EXPERIMENTAL|S-ICD therapy combined with VT Ablation|To evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients
61976964|NCT06119360|OTHER|Group Conventional|Conventional approach using group in lightwand intubation
61976965|NCT06119360|OTHER|Group Face-to-Face|Face-to-face approach using group in lightwand intubation
61976966|NCT05951868|EXPERIMENTAL|Continuum of support on breastfeeding|"Content of counselling intervention will be on ideal breast feeding practices,benefits of breastfeeding, weaning, myths \& common problems faced during breastfeeding with their solutions,Latching techniques,feeding positions, ways to express milk \& storage techniques. Discussion and Q\&A session~1. Women with her female family member of support invited for antenatal visit will be counselled by a trained doctor on breastfeeding in 2 -sessions between 32 \& 40 weeks of gestation.~2. Readable booklet \& whats app videos having same content in local Urdu language will be shared with the women during antenatal visit and at discharge from hospital.~3. At time of delivery skin to skin contact, early initiation, proper latching ,positioning and reemphasising on exclusive breastfeeding done by a trained nurse.~4. Follow up by trained community lady health workers to visit mothers home to reinforce learned information and support mothers at 0,1,2 weeks \& 1,3,4,6 months"
61976967|NCT05951868|NO_INTERVENTION|Control group/Routine care|The control group will receive routine care in terms of routine counselling done on breastfeeding in the hospital \& when mothers at home by lady health workers.
61976968|NCT04465539|PLACEBO_COMPARATOR|control group|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
61976969|NCT04465539|EXPERIMENTAL|Hydroxyethyl starch group):|Patients will start therapy with Hydroxyethyl starch instead of normal saline (6% hetastarch 600/0.75 in 0.9% sodium chloride) with a dose of 500 cc in 6 hours. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
61976970|NCT04465539|EXPERIMENTAL|Combined Hydroxyethyl starch and hydrocortisone group|Patients will start therapy with combined Hydroxyethyl starch (Voluven®, fresenius kabi, Germany) and hydrocortisone (SOLU-CORTEF 100 mg ampoule) instead of normal saline of normal saline as follow: Hydroxyethyl starch dose is 6% hetastarch 600/0.75 in 0.9% sodium chloride with a dose of 500 cc in 6 hours. Hydrocortisone dose is 200-300 mg /day intravenously until normalization of blood pressure. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
61976971|NCT03468257|ACTIVE_COMPARATOR|Progressive Muscle Relaxation only|Condition 1: 7-dose control - Progressive Muscle Relaxation only
61976972|NCT03468257|EXPERIMENTAL|Pairs Progressive Muscle Relaxation with fruit|Condition 2: 5-dose - Pairs Progressive Muscle Relaxation with fruit 5 consecutive days; Condition 3: 7-dose - Pairs Progressive Muscle Relaxation with fruit 7 consecutive days; Condition 4: 9-dose - Pairs Progressive Muscle Relaxation with fruit 9 consecutive days
61976973|NCT05937191|EXPERIMENTAL|IPH Patients|Leflunomide+Steroid treatment
61976974|NCT05937191|ACTIVE_COMPARATOR|Control Group|Steroid treatment
61976975|NCT02711540||Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
61976976|NCT02711540||No Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did not receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
61976977|NCT02068833||Gastrectomy|Subjects in this group will undergo a gastrectomy only.
61976978|NCT02068833||BPD-DS|Subjects in this group will undergo a BPD-DS surgery.
61976979|NCT05548231|EXPERIMENTAL|LY3437943|LY3437943 administered subcutaneously (SC)
61976980|NCT05548231|PLACEBO_COMPARATOR|Placebo|Placebo administered SC
61976981|NCT01636401|ACTIVE_COMPARATOR|aclidinium bromide|
61976982|NCT01636401|PLACEBO_COMPARATOR|Placebo|
61976983|NCT00824603||primary care provider|attending insulin CME Training
61976984|NCT05353231|EXPERIMENTAL|Intervention 1 - Attention Feedback Awareness and Control Training|
61976985|NCT05353231|EXPERIMENTAL|Intervention 2 - Mindful Disengagement from Thoughts Training|
61976986|NCT05353231|PLACEBO_COMPARATOR|Placebo|
61976987|NCT04322253|EXPERIMENTAL|Neladenoson bialanate, mild hepatic impairment|Subjects with Child Pugh score 5 or 6 received a single immediate-release (IR) tablet dose of 10 mg neladenoson bialanate in the fasted state
61976988|NCT04322253|EXPERIMENTAL|Neladenoson bialanate, moderate hepatic impairment|Subjects with Child Pugh score 7-9 received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
61976989|NCT04322253|EXPERIMENTAL|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
61976990|NCT02211521|EXPERIMENTAL|PRP group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
61976991|NCT02211521|ACTIVE_COMPARATOR|Hyaloronan group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)
61976992|NCT02275650|EXPERIMENTAL|nbUVB|2 SED dose of nbUVB will be given every other week for this intervention group.
61976993|NCT02275650|NO_INTERVENTION|control|No nbUVB illumination will be given for the control group.
61976994|NCT05020990|EXPERIMENTAL|Lens A, then Lens B|Participants wore Lens A for one week, then crossed over to wear Lens B for one week.
61976995|NCT05020990|EXPERIMENTAL|Lens B, then Lens A|Participants wore Lens B for one week, then crossed over to wear Lens A for one week.
61976996|NCT01020851|EXPERIMENTAL|tailored intervention|Participants in this arm will receive 6 monthly telephone calls of a behaviorally tailored intervention based on the transtheoretical model.
61976997|NCT01020851|ACTIVE_COMPARATOR|attention placebo|Participants in this arm will receive 6 monthly telephone delivered counseling sessions about general health topics
61976998|NCT03479606|EXPERIMENTAL|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
61976999|NCT03479606|ACTIVE_COMPARATOR|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
61977000|NCT02392741|NO_INTERVENTION|Control|The control group will follow the IMIP prenatal routine.
61977001|NCT02392741|EXPERIMENTAL|Physical exercise program|The intervention group witch will be submitted to an exercise program consisting of daily post prandial, 10' after breakfast, lunch and dinner.
61977002|NCT03447756|EXPERIMENTAL|ABX-1431|One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431. Each patients dose will be determined by the Investigator based on assessment of adverse events.
61977003|NCT03447756|PLACEBO_COMPARATOR|Placebo oral capsule|One or more oral capsules containing placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of placebo. Each patients dose will be determined by the Investigator based on assessment of adverse events.
61977004|NCT06493695|EXPERIMENTAL|Chatbot & CES|Exercise Chatbot intervention with Cranial Electrical Stimulation intervention
61977005|NCT06493695|EXPERIMENTAL|Chatbot|Exercise Chatbot intervention without Cranial Electrical Stimulation intervention
61977006|NCT06493695|EXPERIMENTAL|CES|Cranial Electrical Stimulation intervention without Exercise Chatbot intervention
61977007|NCT02348606|ACTIVE_COMPARATOR|37.5 mg of JZP-110|Once Daily Dosing
61977008|NCT02348606|ACTIVE_COMPARATOR|75 mg of JZP-110|Once Daily Dosing
61977009|NCT02348606|ACTIVE_COMPARATOR|150 mg of JZP-110|Once Daily Dosing
61977010|NCT02348606|ACTIVE_COMPARATOR|300 mg of JZP-110|Once Daily Dosing
61977011|NCT02348606|ACTIVE_COMPARATOR|Placebo|Once Daily Dosing
61977012|NCT02533830|ACTIVE_COMPARATOR|gum chewing group.|"Group A (81 Women) Who Received One Stick of Sugarless Gum (Samara for food \& Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
61977013|NCT02533830|PLACEBO_COMPARATOR|Placebo group|Group B (81 Women) had Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
61977014|NCT05855460||Mycosis fungoides patients|Blood sample and skin biopsy for assessment of IL35 by ELISA
61977015|NCT05855460||Normal healthy controls|Blood sample and skin biopsy for assessment of IL35 levels by ELISA
61977016|NCT00946959|EXPERIMENTAL|cardiac surgery|This arm will include patients older than 18 years and candidate to cardiac surgery.
61977017|NCT00946959|NO_INTERVENTION|cardiac angiography|Patients older than 18 years who undergo coronary angiogram. This arm will include patients with coronary revascularization and patients without coronary revascularization.
61977018|NCT02025244|ACTIVE_COMPARATOR|Key Hole Biopsy|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
61977019|NCT02025244|ACTIVE_COMPARATOR|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
61977020|NCT06087666|EXPERIMENTAL|FICare intervention|FICare implementation model will be demonstrated by setting 5 pilots in non-FICare-experienced NICUs from NL, TR, RO, UK, ZM (AMC, GU, CLUJ, UHS, and UNZA, partners, respectively) and 2 pilots in clinical sites who have recently implemented FICare from ES and NL (SERMAS and OLVG).
61977021|NCT06087666|NO_INTERVENTION|control intervention|A cohort of patients born at the non-FICare clinical sites (AMC, GU, CLUJ, UHS, and UNZA) from the start of the study (November 2022) to the time assigned to start the intervention. A 3-month washout period will be established for staff training and site readiness.
61977022|NCT05755685|EXPERIMENTAL|Group1|The preoperative clinical stage was M1c colon or peritoneal retroflex superior rectum adenocarcinoma
61977023|NCT06265740|OTHER|cohort of pregnant women at -risk of preterm delivery|vaginal swab
61977024|NCT01057602||Normal community dwelling elders|Individuals age 65 and older who live in the community
61977025|NCT05999136|EXPERIMENTAL|Pulses Diet (PulD)|Subjects will follow a Pulses-enriched diet for 2 months.
61977026|NCT05999136|EXPERIMENTAL|Plant Proteins Diet (PPD)|Subjects will follow a Plant protein-enriched diet for 2 months.
61977027|NCT05999136|ACTIVE_COMPARATOR|Habitual Diet (HabD)|Subjects will follow a habitual diet for two months.
61977028|NCT02793102|EXPERIMENTAL|Olfactory workshop + Somesthesia workshop|Olfactory workshop, Twenty odorants. Somesthesia workshop, time for moving the body, Talk Time
61977029|NCT02793102|EXPERIMENTAL|Auditory workshop + Somesthesia workshop|Auditory workshop, Twenty extracts of music tracks. Somesthesia workshop, time for moving the body, Talk Time
61977030|NCT04056676|ACTIVE_COMPARATOR|Intraoperative modified PEC block only|Intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
61977031|NCT04056676|EXPERIMENTAL|Adding preoperative thoracic paravertebral nerve block|Preoperative thoracic paravertebral nerve block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug and intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
61977032|NCT05273138||Systemic sclerosis patients|Patients fulfilling the ACR/EULAR criteria for systemic sclerosis
61977033|NCT05273138||Healthy subjects|
61977034|NCT03963362|EXPERIMENTAL|Administration of GLA5PR 75 mg as 60~89 mL/min|Administration of GLA5PR 75 mg as 60\~89 mL/min(CLcr)
61977035|NCT03963362|EXPERIMENTAL|Administration of GLA5PR 75 mg over 90 mL/min|Administration of GLA5PR 75 mg over 90 mL/min(CLcr)
61977036|NCT03963362|EXPERIMENTAL|Administration of GLA5PR 150 mg as 60~89 mL/min|Administration of GLA5PR 150 mg as 60\~89 mL/min(CLcr)
61977037|NCT03963362|EXPERIMENTAL|Administration of GLA5PR 150 mg over 90 mL/min|Administration of GLA5PR 150 mg over 90 mL/min(CLcr)
61977038|NCT03963362|EXPERIMENTAL|Administration of GLA5PR 75 mg as 30~59 mL/min|Administration of GLA5PR 75 mg as 30\~59 mL/min(CLcr)
61977039|NCT03648060|EXPERIMENTAL|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
61977040|NCT02187484|EXPERIMENTAL|Single rising doses of BIBR 277|
61977041|NCT00006903|EXPERIMENTAL|Treatment (fulvestrant)|Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
61977042|NCT02736409|EXPERIMENTAL|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
61977043|NCT02736409|PLACEBO_COMPARATOR|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
61977044|NCT02736409|EXPERIMENTAL|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
61977045|NCT02736409|EXPERIMENTAL|Arm D Placebo Completers|Arm D Placebo Completers
61977046|NCT00853801|EXPERIMENTAL|Provider/Patient Intervention Arm|Lifestyle modification education and counseling for intervention patients. Diagnosis and treatment education and feedback on performance for providers of intervention patients.
61977047|NCT00853801|NO_INTERVENTION|Provider/Patient Control Arm|Pts will be informed that they have MetSyn and asked to speak with their PCP with any questions.
61977048|NCT04761289|ACTIVE_COMPARATOR|Control group. Health education program|The participants in this group will undergo the usual clinical practice: compliance and adherence to the prescribed drug treatment will be explained, as well as the established guidelines for individualized health care. A Health Education Program will also be added at discharge, mainly aimed at reinforcing and promoting an active and healthy life.
61977049|NCT04761289|EXPERIMENTAL|Experimental Group. Multimodal Exercise and Functional Rehabilitation Program|"1. Prescription of multimodal physical exercise. A supervised and structured home program will be carried out for one month. It will be carried out daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. Each session will be structured in a warm-up, a main part and a cool-down and relaxation (14).~2. Reeducation of Activities of Daily Living (ADL). Specific training will be carried out after the evaluation and before the discharge of the patients from the university healthcare complex. It is intended to identify the factors that are interfering with the performance of activities of daily living. The intervention will consist of three parts: Direct intervention on Activities of Daily Living (ADL), carried out in situ in the hospitalization and generalizable to their daily environment; teaching in Energy Saving Techniques (APR).~3. Prescription of support products and adaptations of the environment."
61977050|NCT04566211|EXPERIMENTAL|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
61977051|NCT04566211|ACTIVE_COMPARATOR|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
61977052|NCT04332354||T2D diabetes obese subjects|Patients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery
61977053|NCT03038958|ACTIVE_COMPARATOR|Isobaric 2-chloroprocaine|The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy
61977054|NCT03038958|ACTIVE_COMPARATOR|Hyperbaric prilocaine 2%|The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy
61977055|NCT01486914|EXPERIMENTAL|NN2000|
61977056|NCT01486914|ACTIVE_COMPARATOR|IAsp|
61977057|NCT00531050|EXPERIMENTAL|Part 1: Sequence A, Part 2: Sequence A|"Part 1: Sequence 'A' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus dry powder inhaler (DPI). Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'A' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
61977058|NCT00531050|EXPERIMENTAL|Part 1 : Sequence B, Part 2: Sequence B|"Part 1: Sequence 'B' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'B' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
61978245|NCT05849103|ACTIVE_COMPARATOR|D) Tight BP Control, Care Navigation|Target blood pressure will be less than 140/90. Participants will check blood pressures twice daily for 14 days and daily for weeks 3-6. A nurse navigator will review their blood pressures M-F for Weeks 1-2 and weekly for weeks 3-6 and will provide feedback on blood pressure values and recommend initiating or escalating medications as needed. The nurse navigator will communicate progress to the participant's clinicians and will remind the participant of their appointments. The nurse navigator will facilitate a visit around 3 months with a primary care clinician or a cardiologist for hypertension follow up.
61977059|NCT00531050|EXPERIMENTAL|Part 1: Sequence C, Part 2: Sequence C|"Part 1: Sequence 'C' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus DPI. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'C' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device . In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
61977060|NCT00531050|EXPERIMENTAL|Part 1; Sequence D, Part 2: Sequence D|"Part 1: Sequence 'D' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'D' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
61977061|NCT00531050|EXPERIMENTAL|Part 1: Sequence E, Part 2: Sequence E|"Part 1: Sequence 'E' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'E' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
61977062|NCT00531050|EXPERIMENTAL|Part 1: Sequence F, Part 2: Sequence F|"Part 1: Sequence 'F' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'F' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
61977063|NCT03454581|EXPERIMENTAL|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.~18 individuals"
61977064|NCT03454581|EXPERIMENTAL|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.~16 individuals."
61977065|NCT03454581|EXPERIMENTAL|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
61977066|NCT05104164|EXPERIMENTAL|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
61977067|NCT01131923|EXPERIMENTAL|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
61977068|NCT01131923|ACTIVE_COMPARATOR|Norvasc Tablets, 10 mg|
61977069|NCT00556036||1|lean healthy women, age 18-45
61977070|NCT00556036||2|overweight healthy women, age 18-45
61977071|NCT00556036||3|women with hypothalamic amenorrhea (have not had a period in three months), age 18-45
61977072|NCT00556036||4|women with anorexia nervosa, age 18-45
61977073|NCT05721989|EXPERIMENTAL|Ziltivekimab B (manual syringe)|Participants will receive a single subcutaneous (s.c.) injection of 15 milligram (mg) ziltivekimab B (15 milligrams per milliliter \[mg/mL\]) by single-use pre-filled manual syringe on Day 1.
61977074|NCT05721989|EXPERIMENTAL|Ziltivekimab D (manual syringe)|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
61977075|NCT05721989|EXPERIMENTAL|Ziltivekimab C (pen-injector)|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
61977076|NCT06405061|EXPERIMENTAL|Study arm|Adebrelimab: 1200 mg, IV, q3w Bevacizumab: 7.5 mg/kg, IV, q3w HAIC: (FOLFOX regimen:oxaliplatin 65 mg/m2, folinic acid 200 mg/m2, 5-Fu 200 mg/m2 push, followed by continuous infusion for 24h 1200 mg/m25-Fu), Q3W) every 3 weeks until 6 treatments have been completed or HAIC treatment is terminated when patients with fewer than 6 treatments develop intolerable adverse effects
61977077|NCT05928897|EXPERIMENTAL|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin (2.5mg/kg, ivgtt, Q3W) Combined With Sintilimab (200mg, ivgtt, Q3W) untill diseases progress
61977078|NCT04427774|EXPERIMENTAL|Surufatinib plus Sintilimab|
61977079|NCT02411474||With or without newly diagnosed chronic GVHD after SCT|The patients developed chronic GVHD after SCT/ The patients did not developed chronic GVHD after SCT
61977080|NCT01945177|NO_INTERVENTION|white light endoscopy|white light endoscopy
61977081|NCT01945177|ACTIVE_COMPARATOR|narrow band imaging|narrow band imaging
61977082|NCT05890040||patients watching surgery video|Situational and trait anxiety test will be applied to patients.
61977083|NCT05890040||patients who did not watch the surgery video|Situational and trait anxiety test will be applied to patients.
61977084|NCT06372782|EXPERIMENTAL|Restylane Skinboosters Vital Lidocaine|Subjects' hands treated by Restylane Skinboosters Vital Lidocaine
61977085|NCT06372782|ACTIVE_COMPARATOR|Restylane Vital|Subjects' hands treated by Restylane Vital
61977086|NCT04535960|EXPERIMENTAL|Liraglutide|Liraglutide Subcutaneous Total Dose 1.8mg daily for 6 weeks
61977087|NCT04535960|EXPERIMENTAL|Empagliflozin|Empagliflozin Tablets Total Dose 25mg daily for 6 weeks
61977088|NCT03005028||Control|
61977089|NCT06244225|EXPERIMENTAL|HAIC + Sintilimab + Donafenib|HAIC combine with Sintilimab and Donafenib
61977090|NCT06458608|EXPERIMENTAL|group that watched virtual reality videos|"Pre-test data for all participants before treatment in the waiting room of the hemodialysis unit, Structured Patient Introduction Form (Annex-1), Dialysis Symptom Index (DSI) (Appendix 2), Vital Signs Monitoring Form (Appendix). 3),''Hemodialysis Comfort Scale Version II'' (Appendix 4) face to face interview for approximately 15 minutes is run as learning pre-test data. The intervention group was also given information about the use of virtual reality and the video content to be watched. Videos are transferred to virtual reality glasses and presented with the headset. After the hemodialysis treatment starts, the intervention psychologist researcher will watch 30 scan videos of approximately half an hour during the dialysis period, 2 sessions a week for 8 weeks, and a Turkey promotional short film presented by the researchers visually and audibly in VR (VR Shineco 3d)."
61977091|NCT06458608|EXPERIMENTAL|The group that is not allowed to watch virtual reality videos|The hemodialysis patients in this group were not shown anything. Only data collection forms were administered to the patients before the study (pretest) and at the end of the study.
61977092|NCT05956860||radial access for abdominopelvic vascular intervention|abdominopelvic vascular intervention through the radial artery access
61977093|NCT01890551|OTHER|affected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
61977094|NCT01890551|OTHER|unaffected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
61977095|NCT03970161|EXPERIMENTAL|T2DM Patients|Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
61977096|NCT03970161|EXPERIMENTAL|healthy control subjects|All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
61977097|NCT04617444|EXPERIMENTAL|Intervention group|
61977098|NCT04617444|ACTIVE_COMPARATOR|Control group|
61977099|NCT05767892|EXPERIMENTAL|YK-029A Group (Arm A)|
61977100|NCT05767892|ACTIVE_COMPARATOR|Platinum-based Chemotherapy Group (Arm B)|
61977101|NCT05714657|EXPERIMENTAL|Shortened Course Adjuvant Radiotherapy|"The volume treated to the regional lymphatics will be according to the characteristics of the primary site and involved lymph nodes. The dose of radiotherapy delivered will be 30 Gy, over the course of 10 treatments (5 daily treatments/week).~Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In patients requiring treatment of the primary site, reduced dose (30 Gy) will be delivered."
61977102|NCT06427031|EXPERIMENTAL|TJO-083|TJO-083 : 1 drop 3 times a day
61977103|NCT06427031|ACTIVE_COMPARATOR|Diquas-s Ophthalmic solution 3% 0.4mL|1 drop 6 times a day
61977104|NCT04544098|EXPERIMENTAL|PRRT with 177Lu-DOTATATE|Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration.
61977105|NCT04247360|OTHER|cuff pressure with 20cmH2O|continuous monitoring and maintaining cuff pressure with 20 cmH2O during surgery
61977106|NCT04247360|OTHER|cuff pressure with 30cmH2O|continuous monitoring and maintaining cuff pressure with 30 cmH2O during surgery
61977107|NCT05741567||transobturator cystocele repair by vaginal plastron|patients who underwent surgery using the transobturator repair by vaginal plastron for correction of anterior prolapse
61977108|NCT00758082|ACTIVE_COMPARATOR|1|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support
61977109|NCT00758082|EXPERIMENTAL|2|PDA-phone + phone consultations + standard visit at 3 months
61977110|NCT01432353|EXPERIMENTAL|Single Arm|
61977111|NCT00224055|EXPERIMENTAL|IV iron|Sodium ferric gluconate
61977112|NCT00224055|ACTIVE_COMPARATOR|oral iron|ferrous sulfate
61977113|NCT02329561|ACTIVE_COMPARATOR|Tramadol extended release and CP/T|Tramadol extended release: 200mg Single-dose, extended-release, once-daily, tablet; Current Perception and Tolerance (CP/T)
61977114|NCT02329561|PLACEBO_COMPARATOR|Placebo and CP/T|Single-dose, placebo identical in appearance to an extended release once-daily tablet; Current Perception and Tolerance (CP/T)
61977115|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
61977116|NCT01748643|EXPERIMENTAL|Deep neuromuscular blockade, reversal with sugammadex|a continuous rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with Sugammadex 4mg/kg. Patients are extubated when the train of four ratio is \> 0.9.
61977117|NCT01748643|ACTIVE_COMPARATOR|normal neuromuscular blockade, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when TOF ratio \> 0.9.
61977118|NCT05232240||Non-hypertensive patients with Ischemic Cerebrovascular Disease|The patients are diagnosed as ischemic cerebrovascular disease (ICVD) and less than 90 days after the onset of ischemic stroke or transient ischemic attack. The patients have no definite diagnosis of hypertension, and are not under anti-hypertension treatment. The blood pressure measured 5\~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥ 2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).
61977119|NCT05527392|EXPERIMENTAL|HINT Synchronous Intervention Group (HINT-S)|a virtual, synchronous version of the 5 HINT-S navigator sessions + HINT booklet
61977120|NCT05527392|EXPERIMENTAL|HINT Asynchronous Intervention Group (HINT-A)|a prerecorded, asynchronous version of the 5 HINT-S navigator sessions + HINT booklet
61977121|NCT05527392|NO_INTERVENTION|Enhanced Usual Care|HINT Booklet
61977122|NCT05390879|EXPERIMENTAL|Meditation Post-OSCE|One half of the students will watch a 6 minutes auto-guided video of meditation, just after the OSCE.
61977123|NCT05390879|SHAM_COMPARATOR|Control|One half of the students will watch a 6 minutes control video, just after the OSCE
61977124|NCT01057550|ACTIVE_COMPARATOR|Autologous Fascial Sling|Retropubic, bottom up autologous sling
61977125|NCT01057550|ACTIVE_COMPARATOR|TVT|Standard retropubic TVT
61977126|NCT01057550|ACTIVE_COMPARATOR|Pelvicol|Retropubic mid urethral sling made from Pelvicol
61977127|NCT05543525||Male Athletes|Athletes who underwent a pre-participation medical evaluation in the Nancy University Hospital between January 1st, 2013, and January 1st, 2020.
61977128|NCT05543525||Control Group|A subgroup of 161 participants in a population-based cohort (STANISLAS Cohort) restricted by age and sex to create a control group in the current analysis.
61977129|NCT02724475|EXPERIMENTAL|LA group|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated.
61977130|NCT02724475|EXPERIMENTAL|3D-CRT group|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times.
61977131|NCT01929850|ACTIVE_COMPARATOR|Surgery|Sleeve gastrectomy laparoscopic surgery plus Weight Watchers for morbidly obese patients
61977132|NCT01929850|OTHER|Control|Weight Watchers Program for morbidly obese patients.
61977133|NCT01169610|EXPERIMENTAL|Varenicline|
61977134|NCT03084029|EXPERIMENTAL|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
61977135|NCT03084029|EXPERIMENTAL|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
61977136|NCT03084029|PLACEBO_COMPARATOR|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
61977137|NCT03084029|PLACEBO_COMPARATOR|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
61977138|NCT01737788|EXPERIMENTAL|Therapeutic Trial|Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (\<25mm)
61977139|NCT01737788|EXPERIMENTAL|Prophylactic Trial|Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency
61977140|NCT02977689|EXPERIMENTAL|IDH305|IDH305 550 mg, oral, two times per day
61977141|NCT01389544|EXPERIMENTAL|Single Arm|
61977142|NCT05962970|ACTIVE_COMPARATOR|CACB|continuous adductor canal block
61977143|NCT05962970|PLACEBO_COMPARATOR|Control group|sham continuous adductor canal block - ShACB
61977144|NCT06021782||All subjects|Patients scheduled to have their transvaginal ultrasound for medical reasons at the fetal care center and gynecology clinic will be asked to participate in this study. Also, patients undergoing pelvic floor surgery at either the Main OR or outpatient surgery center at UVA will be asked to participate.
61977145|NCT00513474|EXPERIMENTAL|Rasburicase Group|Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
61977146|NCT00513474|OTHER|Control Group|Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.
61977147|NCT03251079|EXPERIMENTAL|Continuous Glucose Monitoring Device|Senseonics continuous glucose monitoring system
61977148|NCT05276544|EXPERIMENTAL|phone counseling|dietary intervention via phone counseling
61977149|NCT05276544|EXPERIMENTAL|video counseling|dietary intervention via video counseling
61977150|NCT05276544|EXPERIMENTAL|Traditional follow up|dietary intervention via traditional follow up
61977151|NCT03350633|EXPERIMENTAL|Tocilizumab|Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
61977152|NCT03350633|ACTIVE_COMPARATOR|Azathioprine|Imuran
61977153|NCT00503009|ACTIVE_COMPARATOR|Arm 1|
61977154|NCT00503009|ACTIVE_COMPARATOR|Arm 2|
61977155|NCT00503009|PLACEBO_COMPARATOR|Arm 3|
61977156|NCT04350788|PLACEBO_COMPARATOR|Survivorship Care Plan (SCP)|The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
61977157|NCT04350788|EXPERIMENTAL|Enhanced SCP (ESCP)|ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
61977158|NCT01721382|EXPERIMENTAL|Sitagliptin|Treatment with sitagliptin
61977159|NCT01321268|EXPERIMENTAL|dietary supplement for cellulite|PUFA, resveratrol, lycopene, beta carotene, lutein
61977160|NCT01321268|ACTIVE_COMPARATOR|Control|Vitamin E
61977161|NCT04071730|EXPERIMENTAL|Immulina Dietary Supplementation|Immulina Dietary Supplementation - 200 mg capsules; 800 mg/day; 2 (200 mg) capsules given by mouth in the morning and 2 (200 mg) capsules given by mouth in the evening for 4 weeks duration
61977162|NCT04071730|PLACEBO_COMPARATOR|Placebo|Placebo - inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 4 weeks duration
61977163|NCT04159025|EXPERIMENTAL|Endobronchial ultrasound guided miniforceps biopsy|"* Standard of care convex-probe endobronchial ultrasound and transbronchial needle aspiration followed by rapid on-site evaluation. If evaluation yields a diagnosis of nonsmall cell lung cancer then EBUS-MFB will be performed.~* With the EBUS bronchoscope, 6 needle punctures will be made into the targeted lymph node with the 22 gauge aspiration needle. The needle will be removed and the 1mm miniforceps will be passed through the working channel of the EBUS-bronchoscope into the targeted lymph node through the puncture site made using the 22 gauge needle using continuous endobronchial ultrasound guidance. The miniforceps will be used to obtain a core biopsy of the targeted lymph node - 8 core biopsies will be obtained from each targeted lymph node using this technique"
61977164|NCT05938543|EXPERIMENTAL|Active cerebellum rTMS|Cerebellar targeted iTBS, once daily, one week
61977165|NCT02610179|ACTIVE_COMPARATOR|Standard Glucola GCT|A prospective cohort of 617 women who will undergo screening for gestational diabetes with the standard glucola GCT between 24 and 28 weeks gestational age.
61977166|NCT02610179|EXPERIMENTAL|Twizzlers challenge|At a later date, the same prospective cohort of 617 women Participants will receive their Twizzlers challenge between 24 and 28 weeks gestational age.
61977167|NCT04803097||pediatric cataract group|Children who underwent cataract surgery and primary IOL implantation at the Eye Hospital of Wenzhou Medical University (Hangzhou, China) between 2016 and 2019 were included in the study. Every surgery included posterior capsulorhexis or capsulotomy and anterior vitrectomy. Patients accept slit-lamp-adapted anterior segmental photography at 1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
61977168|NCT02014844|EXPERIMENTAL|250 mg/m2 aldoxorubicin|Subjects received 250 mg/m2 aldoxorubicin IV.
61977169|NCT02014844|EXPERIMENTAL|350 mg/m2 aldoxorubicin|Subjects received 350 mg/m2 aldoxorubicin IV.
61977170|NCT02484963|EXPERIMENTAL|zolpidem|Tablet zolpidem 5mg once daily will be given for 4 weeks
61977171|NCT02484963|PLACEBO_COMPARATOR|Placebo|One tablet of placebo will be given for 4 weeks
61977172|NCT01484873|EXPERIMENTAL|Exenatide|All patients received exenatide 10mcg BID x 50 weeks
61977173|NCT01133301|ACTIVE_COMPARATOR|Naltrexone-Placebo|In the first three weeks of the study, 50 mg Naltrexone will be administrated, the following three three weeks placebo will be administrated.
61977174|NCT01133301|PLACEBO_COMPARATOR|Placebo-Naltrexone|The first three weeks, placebo will be administrated, the following three weeks 50 mg Naltrexone will be administrated.
61977175|NCT02670954|EXPERIMENTAL|Dexmedetomidine,tramadol and flurbiprofen|Both routine analgesic and sedation(dexmedetomidine,tramadol and flurbiprofen) are applied for this group of patients.
61977176|NCT02670954|ACTIVE_COMPARATOR|Tramadol and flurbiprofen|Only routine analgesic(Tramadol and flurbiprofen) is applied for this group of patients.
61977177|NCT02850393|EXPERIMENTAL|patients with obsessive compulsive disorder|Functional magnetic resonance imaging behavioral measures physiological measurements
61977178|NCT02850393|EXPERIMENTAL|healthy participants|Functional magnetic resonance imaging behavioral measures physiological measurements
61977179|NCT00789451|SHAM_COMPARATOR|1|no ischaemia - only sham. Blood pressure cuff inflation up till 10 mmHg on the upper arm for 20 mins.
61977180|NCT00789451|ACTIVE_COMPARATOR|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated around the upper arm for 20 minutes to induce ischaemia.
61977181|NCT00905554|EXPERIMENTAL|warm water|warm water irrigation during the insertion phase of colonoscopy
61977182|NCT00905554|ACTIVE_COMPARATOR|air|air insufflation during the insertion phase of colonoscopy
61977183|NCT03562104|EXPERIMENTAL|Minimally consciousness Patient|Wessex Head Injury Matrix scale and Videofluoroscopy for characterization of swallowing disorders in Minimally consciousness Patient
61977184|NCT02136186|NO_INTERVENTION|Standard of care|patients will receive standard of care discharge instructions
61977185|NCT02136186|ACTIVE_COMPARATOR|Philips Telehealth|patients will be discharged with a telemonitoring device for 30 days
61977186|NCT03226392|ACTIVE_COMPARATOR|QAW039|QAW039 once daily
61977187|NCT03226392|PLACEBO_COMPARATOR|Placebo|Placebo once daily
61977188|NCT03061331|EXPERIMENTAL|Treatment Sequence 1|LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
61977189|NCT03061331|EXPERIMENTAL|Treatment Sequence 2|Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
61977190|NCT03927664||Peritoneal Tuberculosis|Patients diagnosed with peritoneal tuberculosis and who have undergone a computed tomographic examination
61977191|NCT01190709|OTHER|unreamed Intramedullary Nailing|tibial fracture fixed with unreamed Intramedullary Nailing
61977192|NCT01190709|OTHER|Dynamic Compression Plate|tibial fracture fixed with Dynamic Compression Plate
61977193|NCT00353561|ACTIVE_COMPARATOR|1, Boric acid|600 mg vaginal pessaries for 14 days
61977194|NCT00353561|OTHER|2, Fluconazole|
61977195|NCT00232817|EXPERIMENTAL|1|Propofol anesthetic with and without nicotine
61977196|NCT00232817|EXPERIMENTAL|2|isoflurane anesthetic with and without nicotine
61977197|NCT01453712|NO_INTERVENTION|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
61977198|NCT01453712|EXPERIMENTAL|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
61977199|NCT02118012|ACTIVE_COMPARATOR|Chlorcyclizine and RBV|Chlorcyclizine HCl and Ribavirin
61977200|NCT02118012|ACTIVE_COMPARATOR|Chlorcyclizine HCl only|Chlorcyclizine HCl only
61977201|NCT05072561|EXPERIMENTAL|Experimental|
61977202|NCT02064647|EXPERIMENTAL|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool, uses a formula based on the patients Insulin Sensitivity Factor (ISF) to allow adjustments to meal time insulin boluses, based on CGM trend arrows.
61977203|NCT02064647|ACTIVE_COMPARATOR|10/20% bolus adjustment|10-20% increase/decrease of the total original recommended bolus dose (10% for one arrow up or down, and 20% for two arrows up or down), with the original bolus dose calculated by the pump calculator (i.e. Bolus Wizard).
61977204|NCT02064647|NO_INTERVENTION|No adjustment/ignore trend arrows|Subjects will ignore the CGM trend arrows, meal time bolus insulin as per Bolus Wizard
61977205|NCT01138631|ACTIVE_COMPARATOR|Embryoscope|
61977206|NCT01138631|NO_INTERVENTION|Conventional incubator|
61977207|NCT02532790|EXPERIMENTAL|group 1|Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.
61977208|NCT02532790|EXPERIMENTAL|group 2|Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)
61977209|NCT04170257|EXPERIMENTAL|Opportunistic screening cohort|This opportunistic screening cohort is constructed among patients aged 45-69 years who undergo endoscopic examinations at the endoscopy center in any of the five hospitals included in this study. Enrolled participants are requested to complete a computer aided one-on-one questionnaire regarding demographic factors, smoking and alcohol drinking status, dietary habits，digestive tract symptoms and family history of ESCC. Then experienced endoscopists will perform the upper gastrointestinal endoscopic examination for each participant, and the entire esophagus will be visually examined with the white light, NBI and iodine staining endoscopic examination.
61977210|NCT01151644|ACTIVE_COMPARATOR|VACCINATION OF PATIENTS|
61977211|NCT01151644|ACTIVE_COMPARATOR|VACCINATION OF HEALTHY CONTROLS|
61977212|NCT02289690|EXPERIMENTAL|Phase 1: Veliparib + Carboplatin + Etoposide|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of veliparib in combination with carboplatin/etoposide for up to four 21-day cycles.~Participants without evidence of disease progression will continue on veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity."
61977213|NCT02289690|EXPERIMENTAL|Phase 2: Veliparib + Carboplatin + Etoposide -> Veliparib|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity.
61977214|NCT02289690|EXPERIMENTAL|Phase 2: Veliparib + Carboplatin + Etoposide -> Placebo|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
61977215|NCT02289690|ACTIVE_COMPARATOR|Phase 2: Placebo + Carboplatin + Etoposide -> Placebo|Participants will receive placebo in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
61977216|NCT03703765|EXPERIMENTAL|Lower limb volume estimation|"Patients referred for a preoperative venous assessment as part of an indication for interventional management, whether by conventional or endovascular surgery, of a chronic venous pathology.~Intervention is measurement of lower limb volume with scanner 3D system before and after surgery or vascular intervention."
61977217|NCT04468204|EXPERIMENTAL|SinuSonic Device|SinuSonic device used for 1 min three times a day for 8 weeks.
61977218|NCT04468204|SHAM_COMPARATOR|Sham|Sham SinuSonic device used for 1 min three times a day for 8 weeks.
61977219|NCT01698047|EXPERIMENTAL|Resiliency Class|"Resiliency Classes (study group) Study participant randomized to the Resiliency classes will be offered and assigned a time and date to attend the classes. Each class will have up to 10 participants. Classes will be 90-120 minutes in duration and will be held weekly for six weeks. At the classes, participants will be offered a copy of the Resiliency Class Manual. And at each class, light snacks and refreshments will be offered.~The Resiliency Class manual covers the following topics:~Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation"
61977220|NCT01698047|ACTIVE_COMPARATOR|Case Management|Case management phone calls (control group) Study participants randomized to the case management phone calls will be told that they will receive two calls over two months by study staff to offer them referrals based on their perceived need for services to local health care, mental health, substance use, social services, child welfare, housing, and food. In addition, study participants in this arm of the study will be told that if the study determines that the resiliency classes are better at improving mood than the case management calls, they will receive a call to invite them to participate in resiliency classes for free at the B-RICH partner agencies.
61977221|NCT03051607|EXPERIMENTAL|Tozadenant|120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.
61977222|NCT03293550||patients over 65 years undergoing elective surgery|patients over 65 years undergoing elective cardiac surgery or elective hip or knee surgery
61977223|NCT02614950|EXPERIMENTAL|Treatment interuption|
61977224|NCT06017440|EXPERIMENTAL|adolescents with obesity|There is only one arm as this is an acute randomized study comparing two differents conditions within the same sample of participants.
61977225|NCT00634166|OTHER|Historical Control|Treated within the last 5 years (if possible) with topical prophylactic therapies that did not include mafenide acetate or mafenide salt forms. These are considered the Topical Antimicrobial/Antifungal Medications
61977226|NCT00634166|EXPERIMENTAL|Prospective Patients/Active Drug|Prospective subjects with thermal injuries of 20-60% TBSA on the chest, abdomen, or proximal upper and lower extremities requiring meshed autografts on these areas will receive SS5% as the initial topical moist dressing over the meshed autograft(s) placed at the initial graft procedure (Day 1). Intervention is Sulfamylon® For 5 % Topical Solution.
61977227|NCT05067829|ACTIVE_COMPARATOR|Ideal Body weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR IDEAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR IDEAL BODY WEIGHT WILL BE GIVEN."
61977228|NCT05067829|ACTIVE_COMPARATOR|Total Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR TOTAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR TOTAL BODY WEIGHT WILL BE GIVEN."
61977229|NCT05067829|ACTIVE_COMPARATOR|Corrected Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR CORRECTED BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR CORRECTED BODY WEIGHT WILL BE GIVEN."
61977230|NCT04762797||Non-neoplastic group|"Gallbladder polyps with pathological diagnosis of cholesterol polyps or inflammatory polyps are classified into Non-neoplastic group."
61977231|NCT04762797||Neoplastic group|"Gallbladder polyps pathologically diagnosed as adenocarcinoma, adenoma, adenomyosis, or other malignancies are classified into Neoplastic group."
61977232|NCT02213016|SHAM_COMPARATOR|Transcranial magnetic stimulation|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
61977233|NCT02213016|ACTIVE_COMPARATOR|Transcraneal magnetic stimulation|Active repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
61977234|NCT02213016|SHAM_COMPARATOR|Sham Comparator|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
61977235|NCT02213016|ACTIVE_COMPARATOR|Active Comparator|Active repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
61977236|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: Arctic Front® \& Arctic Front Advance® Cardiac CryoAblation Catheter System.~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
61977237|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
61977238|NCT04466254|EXPERIMENTAL|Arm A|CPGJ602 325mg/m2 IV Q2W； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks.
61977239|NCT04466254|EXPERIMENTAL|Arm B|CPGJ602 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
61977240|NCT04466254|ACTIVE_COMPARATOR|Arm C|cetuximab 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
61977241|NCT01898728|ACTIVE_COMPARATOR|Liquid preoperative medications|Liquid preoperative medications
61977242|NCT01898728|ACTIVE_COMPARATOR|Gel preoperative medications|Gel preoperative medications
61977243|NCT02047760||MS patients|All MS sub-types
61977244|NCT02047760||Controls|sex- and age-matched controls
61977245|NCT00799487|EXPERIMENTAL|1|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
61977246|NCT00799487|EXPERIMENTAL|2|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
61977247|NCT04458233|ACTIVE_COMPARATOR|long axis|
61977248|NCT04458233|ACTIVE_COMPARATOR|short axis|
61977249|NCT04394104||COVID-19 Survey Group|Group of individuals participating in the survey via self-selection. There is not intervention being administered. The group is simply answering questions on their health behaviors before COVID-19 and their health behaviors in the past 7-30 days, during the COVID-19 outbreak in the United States.
61977250|NCT01229059||lipid infusion in untrained humans|healthy lean humans before and after lipid infusion
61977251|NCT01229059||lipid infusion in athletes|endurance trained atheletes
61977252|NCT05783115|ACTIVE_COMPARATOR|Tibial Transportation|Tibial Transportation
61977253|NCT05783115|EXPERIMENTAL|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion
61977254|NCT00860964|PLACEBO_COMPARATOR|Placebo|
61977255|NCT00860964|EXPERIMENTAL|estradiol valerate|
61977256|NCT03641651|EXPERIMENTAL|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
61977257|NCT01851564|EXPERIMENTAL|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
61977258|NCT01851564|ACTIVE_COMPARATOR|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
61977259|NCT01851564|EXPERIMENTAL|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
61977260|NCT01851564|ACTIVE_COMPARATOR|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
61977261|NCT01320462|EXPERIMENTAL|Smoking cessation group|Counselling, Pharmacotherapy and Smokers Help Line
61977262|NCT01320462|OTHER|Control group|Brief informatin about quitting and smokers help line
61977263|NCT03398291|ACTIVE_COMPARATOR|Standard treatment|Patients continue to receive standard chemotherapy.
61977264|NCT03398291|EXPERIMENTAL|Surgical exploration|Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.
61977265|NCT05947370|EXPERIMENTAL|Berberine Chloride|This study employed a randomized, double-blind, placebo-controlled, two-period crossover design: subjects were randomized into two groups of equal size. The random allocation was conducted by asking volunteers to select the randomized number generated by computer. Each number represented placebo or BBR, and each group has the same number of numbers. The dosing sequence in the first group was oral BBR in the first cycle and oral placebo in the second cycle. The second group was administered placebo in the first cycle and BBR in the second cycle. Take the second dose 14 days after the first dose. After the last dose, continue to observe for 14 days to watch for side effects. On each experimental day, after an overnight fast, the subjects received a single oral dose of 1 g of BBR or a corresponding dose of the placebo.
61977266|NCT05947370|PLACEBO_COMPARATOR|Placebo control|This study employed a randomized, double-blind, placebo-controlled, two-period crossover design: subjects were randomized into two groups of equal size. The random allocation was conducted by asking volunteers to select the randomized number generated by computer. Each number represented placebo or BBR, and each group has the same number of numbers. The dosing sequence in the first group was oral BBR in the first cycle and oral placebo in the second cycle. The second group was administered placebo in the first cycle and BBR in the second cycle. Take the second dose 14 days after the first dose. After the last dose, continue to observe for 14 days to watch for side effects. On each experimental day, after an overnight fast, the subjects received a single oral dose of 1 g of BBR or a corresponding dose of the placebo.
61977267|NCT04691284|EXPERIMENTAL|Observational arm|Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including miR and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S rRNA gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used. Moreover, we might be able to characterized potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.
61977268|NCT06387745|EXPERIMENTAL|Investigational Arm|Single arm study protocol
61977269|NCT03867929||STUDY|Patient with serum 25-Hydroxy vitamin D level \<27.32
61977270|NCT03867929||CONTROL|Patient with serum 25-Hydroxy vitamin D level \>27.32
61977271|NCT05291247||Heavily calcified femoropopliteal disease|"* Subject must be between 21 and 85 years old~* Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5~* Willing to comply with the specified follow-up evaluation~* Written informed consent prior to any study procedures"
61977272|NCT01632969||families or next-of-kin of deceased patients|The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
61977273|NCT01361386||1|
61977274|NCT05328791|EXPERIMENTAL|Mindfulness+Diet intervention|Diet and mindfulness intervention
61977275|NCT05328791|EXPERIMENTAL|Diet intervention|Diet intervention
61977276|NCT05980650|EXPERIMENTAL|Reiki group|Reiki will be implied to this group and this group will have routine nursing care given in the hospital during their hospitalization such as medical treatment implication and measuring vital signs
61977277|NCT05980650|NO_INTERVENTION|Routine Nursing Care|This group will have just routine nursing care given in the hospital during their hospitalization such as medical treatment implication and measuring vital signs
61977278|NCT05513495|ACTIVE_COMPARATOR|Drip Group|Each infant received the same amount of feed via continuous administration for 3 hours, and subsequent feeding resumed 1 hour after the end of continuous feeding. All of the infants were fed through an orogastric tube that was attached to a syringe infusion pump for continuous feeding. Once a full enteral feed of 120 mL/kg/day was achieved, the drip feeding was stopped.
61977279|NCT05513495|ACTIVE_COMPARATOR|Intermittent Group|Every 3 hours (×8/day), each infant received a 10-minute gravity bolus of milk/preterm formula via orogastric tube.
61977280|NCT04797793|EXPERIMENTAL|Adapalene gel 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
61977281|NCT04797793|ACTIVE_COMPARATOR|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
61977282|NCT04797793|PLACEBO_COMPARATOR|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
61977283|NCT02568150|OTHER|Intervention|Onset time of improvement effect of glabellar lines at maximum frown of botulinum toxin treatment
61977284|NCT05792371|EXPERIMENTAL|with induced membrane|operation of stage I and II
61977285|NCT05792371|EXPERIMENTAL|without induced membrane|only stage II
61977286|NCT04326907|EXPERIMENTAL|CAT injection group|After fistulectomy for complex anal fistula, CAT (harvested from abdominal subcutaneous adipose tissue by Coleman's procedure) was injected into the tissue surrounding the internal opening, and inside the perianal wound obtained after fistulectomy.
61977287|NCT04326907|NO_INTERVENTION|No CAT injection group|Patients of this group were treated with anal fistulectomy without CAT injection.
61977288|NCT04270123||Group 1|Group 1 consists of breast cancer patients with local or locally advanced disease. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. A subgroup of participants within this group (those who have changed disease or treatment status) will be asked to complete the above questionnaires again, three months later (+-1 week). They will also complete an anchor question. Completing twice is for the responsiveness to change analysis.
61977289|NCT04270123||Group 2|Group 2 consists of metastatic breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires at one time point only.
61977290|NCT04270123||Group 3 - follow up|Group 3 consists of follow up breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. One-to two weeks later, a subgroup of participants in this group (with no evidence of disease and /or change in health status) will complete the above questionnaires, as well as an anchor question. Completing twice is for the test-retest analysis.
61977291|NCT01406431|ACTIVE_COMPARATOR|Pitavastatin + Valsartan|Intervention: Drug: Pitavastatin, Valsartan
61977292|NCT01406431|EXPERIMENTAL|Livalo fixed combination drug|Intervention: Drug: Livalo® fixed combination drug
61978246|NCT03930576||Early Legal Terminations|Participants who receive a legal termination at \<10 weeks gestation at a recruiting facility.
61978247|NCT03930576||Late Legal Terminations|Participants who receive a legal termination at 10+ weeks gestation at a recruiting facility.
61978248|NCT03930576||Turn-aways: Termination outside Legal Setting|Participants who receive a termination at another facility or outside the formal healthcare sector.
61978249|NCT03930576||Turn-aways: Birth|Participants who ultimately carry the pregnancy to term
62167603|NCT02978846||Observational (side effects evaluation using cards)|Patients are shown two groups of cards on the last day of radiation treatment. Group A lists 48 physical side effects and group B lists 27 psychosocial side effects. The cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. Patients rank the selected cards from each group by order of severity. The top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.
62167604|NCT03352661||Endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
62167605|NCT03352661||No endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
62167606|NCT04339543|OTHER|Longitudinal assessment|Participants will take part in a baseline study session, followed by a year of weekly reports of their number of near falls and falls. The same participants will repeat the same study session six months and twelve months after the baseline session.
62167607|NCT02804347||Patient|Patients will be receiving either ECT or iTBS as a depression management. Olfactory functioning will be assessed at pre-treatment and 6 weeks later at post-treatment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
62167608|NCT02804347||Control|Controls will have their olfactory functioning assessed at baseline and 6 weeks after the baseline assessment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
62167609|NCT04342910|EXPERIMENTAL|camrelizumab (SHR-1210) combined with apatinib|Participants will receive camrelizumab on Day 1 and Day 15 of each 28-day cycle and apatinib mg/day up to 2 years.
62167610|NCT04342910|ACTIVE_COMPARATOR|Paclitaxel or Irinotecan|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle, or irinotecan on Days 1 and 15 of each 28-day cycle.
62167611|NCT05599516|EXPERIMENTAL|Cohort 1 LIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months
62167612|NCT05599516|EXPERIMENTAL|Cohort 1 BIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months
62167613|NCT05599516|PLACEBO_COMPARATOR|Cohort 1 placebo control group|Subject vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months
62167614|NCT05599516|EXPERIMENTAL|Cohort 2 LIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months
62167615|NCT05599516|EXPERIMENTAL|Cohort 2 BIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months
62167616|NCT06045364|EXPERIMENTAL|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously to participants.
62167617|NCT06045364|ACTIVE_COMPARATOR|Anisodamine Group|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection
62167618|NCT00927316|ACTIVE_COMPARATOR|Active arm|E. coli 83972 bacteriuria
62167619|NCT00927316|PLACEBO_COMPARATOR|Placebo arm|Monitoring
62167620|NCT01159990|EXPERIMENTAL|Recombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C|Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
62167621|NCT01159990|ACTIVE_COMPARATOR|rAd5 gag/pol|Participants will receive one intramuscular injection of rAd5 gag/pol.
62167622|NCT05560945|ACTIVE_COMPARATOR|0.32% Sodium Fluoride Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
62167623|NCT05560945|EXPERIMENTAL|1.5% Arginine Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
62167624|NCT05560945|EXPERIMENTAL|8.0% Arginine Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
62167625|NCT00187135|ACTIVE_COMPARATOR|1|Fentanyl-1mcg/kg in 3 ml of Normal Saline
62167626|NCT00187135|ACTIVE_COMPARATOR|2|Fentanyl - 0.5 mcg/kg in 3 ml normal saline
62167627|NCT00187135|PLACEBO_COMPARATOR|3|normal saline
62167628|NCT03011671|EXPERIMENTAL|Acetazolamide with Temozolomide|Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
62167629|NCT04960436|EXPERIMENTAL|Meniscus Allograft Transplantation|The patient underwent Meniscus Allograft Transplantation
62167630|NCT04960436|ACTIVE_COMPARATOR|Meniscectomy|The patient underwent Meniscectomy
62167631|NCT04497753||Can't fell bitterness|"1. The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.~2. Record whether the subject feels bitterness, if there is no feeling, the test is over."
62167632|NCT04497753||Can fell bitterness|"1. The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.~2. Record whether the subject feels bitterness, If there is a sensation, put the adhesive strip on the upper edge of the subject's mask and put on the hood to carry out the above fitness test again.~3. Record whether the subject feels bitterness, if not, the test is over. If there is any sensation, ask the subject to change to a medical surgical mask, and put an adhesive strip on the upper edge of the mask, and put on the hood to carry out the above fitness test again."
62167633|NCT05125016|EXPERIMENTAL|Module 1- Monotherapy|REGN4336
62167634|NCT05125016|EXPERIMENTAL|Module 2-Combo Therapy|REGN4336 + Cemiplimab
62167635|NCT05125016|EXPERIMENTAL|Module 3-Combo Therapy|REGN4336 + REGN5678
62167636|NCT05959109|EXPERIMENTAL|Peresolimab (Test 1)|Peresolimab administered subcutaneously (SC).
62167637|NCT05959109|EXPERIMENTAL|Peresolimab (Test 2)|Peresolimab administered SC.
62167638|NCT05959109|EXPERIMENTAL|Peresolimab (Test 3)|Peresolimab administered SC.
62167639|NCT05959109|EXPERIMENTAL|Peresolimab (Reference)|Peresolimab administered SC.
62167640|NCT01198067|EXPERIMENTAL|Treatment (pomalidomide)|Patients receive pomalidomide PO on days 1-28 or 1-21. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
62167641|NCT05497037|SHAM_COMPARATOR|Sham Control Group|Subject receiving fake stimulation (no stimulation but same device procedure with PRF group)
62167642|NCT05497037|ACTIVE_COMPARATOR|PRF Group|Subject receiving 500 KHz PRF stimulation for 15 min
62167643|NCT06415747||Brachial Plexus Birth Injury|It was determined that 76 babies with BPBI and their families applied to our hospital for their first medical check or examination. Inclusion criteria: a diagnosis of BPBI, initial evaluation and not having started treatment before, being in the age range of 15-90 days old, and consent to participate in the study. Exclusion criteria: Children with BPBI who are older than 90 days or younger than 15 days and have started regular physical therapy or home program before applying to our hospital. In addition, causes of pseudo-paralysis that are diseases that may show symptoms similar to BPBI were excluded. Seventeen children who were excluded because they did not meet the inclusion criteria. Hence, 59 children with BPBI were included in the study.
62167644|NCT06645782|EXPERIMENTAL|Virtual, group CF-CBT|
62167645|NCT06042270|PLACEBO_COMPARATOR|Placebo|10 participants will be given rice-flour as a placebo
62167646|NCT06042270|ACTIVE_COMPARATOR|Betaine|10 participants will be given betaine
62167647|NCT04406142|EXPERIMENTAL|treatment feasibility|feasibility, safety and effectiveness assessment
62167648|NCT01799785|EXPERIMENTAL|Aerobic exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
62167649|NCT01799785|PLACEBO_COMPARATOR|Usual care group|These patients will continue with their normal daily activity and will not be provided with supervised aerobic exercise training during the study period.
62167650|NCT04573257||normotensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
62167651|NCT04573257||Prehypertension group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
62167652|NCT04573257||hypertensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
62167653|NCT00705042|EXPERIMENTAL|A|25 mg
62167654|NCT00705042|EXPERIMENTAL|B|50 mg
62167655|NCT00168805|EXPERIMENTAL|dabigatran etexilate 220 mg|220 mg once daily
62167656|NCT00168805|EXPERIMENTAL|dabigatran etexilate 150 mg|150 mg once daily
62167657|NCT00168805|ACTIVE_COMPARATOR|enoxaparin|40 mg once daily
62167658|NCT06164041|NO_INTERVENTION|Control Group|The control group did not use any of the research mobile applications, but were measured at pre, post and post 2. They continued attending physical education classes normally and practicing their sports activities.
62167659|NCT06164041|EXPERIMENTAL|"Cardiovascular training through the application MapMyWalk"|"The adolescents who used this application were required to record their weekly workouts. To do this, before starting the workout, they entered the application, selected walking and started the record. The application included different warnings and alerts to encourage the practice of physical activity. Each week they had to make a weekly report with the distance covered."
62167660|NCT06164041|EXPERIMENTAL|"Cardiovascular training through the application Strava"|"The adolescents who used this application were required to record their weekly workouts. To do this, before starting the workout, they entered the application, selected walking and started the record. The application included different warnings and alerts to encourage the practice of physical activity. Each week they had to make a weekly report with the distance covered."
62167661|NCT06164041|EXPERIMENTAL|"Cardiovascular training through the application Pacer"|"The adolescents who used this application were required to record their weekly workouts. To do this, before starting the workout, they entered the application, selected walking and started the record. The application included different warnings and alerts to encourage the practice of physical activity. Each week they had to make a weekly report with the distance covered."
62167662|NCT06164041|EXPERIMENTAL|"Cardiovascular training through the application Pokémon Go"|This application is considered immersive as teenagers enter a virtual world. In it, the distance traveled in the real world was accounted for in the video game, also appearing different Pokémon that they could capture, making the gaming experience more playful. In the same way, the teenagers had to keep a weekly record of the distance traveled.
62167663|NCT03237741|EXPERIMENTAL|Treatment Sequence 1: ABC1D1|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
62167664|NCT03237741|EXPERIMENTAL|Treatment Sequence 2: ABC2D2|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
62167665|NCT03237741|EXPERIMENTAL|Treatment Sequence 3: BAC1D1|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
62736620|NCT05376059|EXPERIMENTAL|How incentive receive|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues, including an incentive if they seek out mental health treatment (if they visit a therapist within 30 days, they will receive a gift card).
62167666|NCT03237741|EXPERIMENTAL|Treatment Sequence 4: BAC2D2|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
62167667|NCT04761341|EXPERIMENTAL|AMD|
62167668|NCT04761341|ACTIVE_COMPARATOR|healthy control|
62167669|NCT04091945|ACTIVE_COMPARATOR|LT3001 Drug Product|
62167670|NCT04091945|PLACEBO_COMPARATOR|Placebo|
62167671|NCT06465615|EXPERIMENTAL|Experimental group|self-rehabilitation at home. Intervention 25 min/day, 5 days a week for 6 weeks at home (weekly load of 125 minutes), on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and patient's optical correction (if applicable).
62167672|NCT06465615|ACTIVE_COMPARATOR|Control group|The control group will receive conventional treatment consisting of 12 sessions of 25 minutes each over 6 weeks of rehabilitation with an orthoptist in the ophthalmology department of Montpellier University Hospital.
62167673|NCT06538818|EXPERIMENTAL|Study group|This group will include 30 patients who will receive Ultra Phonophoresis with a hyaluronic acid-containing gel 5 sessions per week for 3 weeks in addition to their physical therapy program and medical treatment.
62167674|NCT06538818|NO_INTERVENTION|Control group:|This group will include 30 patients who will receive only their traditional physical therapy program and medical treatment.
62167675|NCT00819676||subjects with asthma|
62167676|NCT00819676||healthy subjects|
62167677|NCT03178318|OTHER|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
62167678|NCT01132222|EXPERIMENTAL|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
62167679|NCT01132222|ACTIVE_COMPARATOR|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
62167680|NCT02392429|EXPERIMENTAL|Diagnostic (anthracycline, cytarabine, FLT PET/CT)|Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment. Patients also undergo bone marrow biopsy and aspiration and blood sample collection during screening and on the trial.
62167681|NCT01953471||Allergic rhinitis|
62167682|NCT01509937|EXPERIMENTAL|BCM Arm|BCM measured every 2 months
62167683|NCT01509937|SHAM_COMPARATOR|Control arm|patients care according to standard of care
62167684|NCT04881396||All haemodialysed patients with a medical prescription of BTN162b2 mRNA Cov-19 vaccine|Serological response is defined by a 4 fold increase of IgG anti-spike protein of SARS-Cov2 between Day 0 (before vaccination) and after complete vaccination (evaluated at Day 7 - 14 post-boost).
62167685|NCT03340818|EXPERIMENTAL|Bone Marrow Concentrate|Patients in this group will receive injection of autologous bone marrow concentrate into the suspected painful intervertebral discs.
62167686|NCT03340818|SHAM_COMPARATOR|Placebo Group|Patients in this group will receive an injection of normal saline dorsal to the transverse process. The bone marrow aspiration will be simulated for these patients.
62167687|NCT05769361|EXPERIMENTAL|Unstable (UNST)|12-week training protocol with unstable devices, twice a week.
62167688|NCT05769361|EXPERIMENTAL|Stable (ST)|12-week training protocol with stable devices, twice a week
62167689|NCT05769361|NO_INTERVENTION|Control (CTRL)|No administration of training protocols.
62167690|NCT02785900|EXPERIMENTAL|33A + HMA|33A plus azacitidine or decitabine
62167691|NCT02785900|ACTIVE_COMPARATOR|placebo + HMA|placebo plus azacitidine or decitabine
62167692|NCT05246618|EXPERIMENTAL|TUM012|Ex-vivo infusion
62167693|NCT05246618|PLACEBO_COMPARATOR|Placebo|Ex-vivo infusion
62167694|NCT04538534|EXPERIMENTAL|nicardipine and isosorbide dinitrate|"A Cocktail of 1 mg of Isosorbide Dinitrate associated to 1 mg of nicardipine will be put in a syringe than diluted in saline serum to have a volume of 3cc.~The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization."
62167695|NCT04538534|ACTIVE_COMPARATOR|isosorbide dinitrate|Isosorbide Dinitrate: 1 mg will be diluted in saline solution as to have a 3cc volume The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization
62167696|NCT03825614|EXPERIMENTAL|training gruop|The plates exercise program is concerned with the following main principles: efficient breathing, mental concentration, relaxation, correct spine elongation and posture, correct abdominal muscle control over spine stability and mobility, correct function of each upper and lower limb, precision, lowing integrated movement, and achieving muscle strength and stamina.
62167697|NCT03825614|ACTIVE_COMPARATOR|training group|Therapeutic exercise program was designed according to the American Collage of Sports Medicine's recommendations for healthy people. The exercise program was conducted using low- to moderate-intensity therapeutic exercises. These therapeutic exercises included a short educational talk that provided information on proper body mechanics, the benefits of exercise, realistic goal-setting, and overcoming common barriers (such as fear) when developing an exercise routine.
62167698|NCT03825614|NO_INTERVENTION|Control group|Participants in the control group have no exercise in this study.
62167699|NCT03829072|EXPERIMENTAL|cooking Education and adapted physical activity|
62167700|NCT02581371|EXPERIMENTAL|Cerebrolysin infusion|Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
62167701|NCT02581371|PLACEBO_COMPARATOR|Placebo infusion|Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
62167702|NCT01594697|EXPERIMENTAL|metformin|
62167703|NCT05463445||A|"patients diagnosed with Primary Sclerosing Cholangitis which met the PSC criteria according to The European Association for the Study of the Liver Clinical Practice Guidelines Management of cholestatic liver diseases in 2009."
62167704|NCT05463445||B|patients diagnosed with IgG4-related Sclerosing Cholangitis which met initially using the Japan Pancreas Society criteria and confirmed using HISORt criteria.
62167705|NCT03600090|EXPERIMENTAL|Arm EOC202 + Paclitaxol|"Biological: EOC202 This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Two EOC202 dose levels (6 mg and 30 mg) will be evaluated in two cohorts of 18 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 48 weeks (12 s.c. injections in total), separated by 13-day intervals free of EOC202 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
62167706|NCT05118737|ACTIVE_COMPARATOR|colchicine|Intervention arm: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
62167707|NCT05118737|PLACEBO_COMPARATOR|Control|COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab according to local protocol
62167708|NCT00908245|EXPERIMENTAL|Preconditioning|Surgery with ischemic preconditioning
62167709|NCT00908245|ACTIVE_COMPARATOR|Control|Surgery without preconditioning ischemia
62167710|NCT06244706|OTHER|Peristent Pain Patients|"Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment), will be included.~Evaluation of drug combination pain relief and its impact on daily life activities as therapeutic effects, and on drug-induced sedation and drug-induced cognitive dysfunction (memory and attention) as adverse effects will be evaluated through online (REDCap) patient-reported outcomes at the beginning of the study (day 0), 10 days and 3 months."
62167711|NCT00842699||1|patients receiving IL-2 receptor antagonist (Simulect) as induction treatment
62167712|NCT00842699||2|patients receiving Thymoglobulin as induction treatment
62167713|NCT00953199|EXPERIMENTAL|Lidocaine|Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
62167714|NCT00953199|ACTIVE_COMPARATOR|Normal Saline|The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
62167715|NCT06023134||Control group|Participants met the indication for right heart catheterization but did not meet the diagnostic criteria for pulmonary hypertension and right heart failure.
62167716|NCT06023134||Pulmonary Hypertension group|Participants were classified according to the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension, meaning that a mean pulmonary artery pressure (mPAP) ≥20 mmHg was defined as PH.
62167717|NCT06023134||Right heart failure group|Right heart failure was considered present when RV fractional area change (FAC) was \<35% or tricuspid annular systolic velocity (RV S') was \<9.5 cm/s or tricuspid annular plane systolic excursion (TAPSE) \<17mm.
62167718|NCT06554288|EXPERIMENTAL|Trihexyphenidyl|"Participants receive trihexyphenidyl following the dose escalation schedule below:~Week 1: 0.05 mg/kg BID Week 2: 0.05 mg/kg TID Week 3: 0.1 mg/kg TID Week 4: 0.15 mg/kg TID Week 5: 0.20 mg/kg TID Week 6-15: 0.25 mg/kg TID"
62167719|NCT03697070|ACTIVE_COMPARATOR|Routine Care|Continued routine antibiotic stewardship strategies.
62167720|NCT03697070|ACTIVE_COMPARATOR|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for PNA in non-ICU patients in the first 3 days of hospitalization.
62167721|NCT05829278|EXPERIMENTAL|Acupuncture group|Subjects in the acupuncture group will undergo acupuncture treatment, which is administered 3 times a week for 4 weeks.
62167722|NCT05829278|NO_INTERVENTION|Waiting list group|No intervention will be provided for the waiting list group and the subjects in this group will be followed during the 4-week observation period.
62167723|NCT06647212|EXPERIMENTAL|study arm|patients randomized to the study arm will receive a breathing exercise program with standard diatonic mouth harmonica
62167724|NCT06647212|NO_INTERVENTION|control arm|patients randomized to the control arm will follow standard cardiac rehabilitation program with breathing exercises only
62167725|NCT03341312|EXPERIMENTAL|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
62167726|NCT03341312|EXPERIMENTAL|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
62167727|NCT03341312|ACTIVE_COMPARATOR|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
62167728|NCT03341312|ACTIVE_COMPARATOR|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
62167729|NCT06480396|EXPERIMENTAL|High-intensity radiological surveillance|"High/intermediate grade histology: 3-4 monthly CT scan up to 2-years postoperatively, 6-monthly CT scan from 2-5 years postoperatively (schedule 1)~Low grade histology: 6-monthly CT scan up to 2-years postoperatively, annual CT scan from 2-5 years postoperatively (schedule 2)"
62167730|NCT06480396|ACTIVE_COMPARATOR|Lower-intensity radiological surveillance|"High intermediate grade histology: 6-monthly CT scan up to 2-years postoperatively, annual CT scan from 2-5 years postoperatively (schedule 2)~Low grade histology: Annual CT scan up to 2-years postoperatively, 18 monthly CT scan from 2-5 years postoperatively (schedule 3)"
62167731|NCT03682237|NO_INTERVENTION|A) Standard diabetes training (control)|"More specifically, group training in general diabetes health issues, how to do experienced based dosing, how to handle sick days, exercise etc. in general terms. The group will not be taught in carbohydrate counting or bolus calculation. They will be encouraged to measure SMBG at least 4 times daily with patients own preferred glucose meter.~Patients will be offered 6 months treatment with FGM after study end."
62167732|NCT03682237|ACTIVE_COMPARATOR|B) Carbohydrate counting, automated bolus calculation|
62167733|NCT03682237|ACTIVE_COMPARATOR|C) Flash glucose monitoring (FGM)|Group training with same content as for group A.
62736621|NCT05376059|EXPERIMENTAL|How incentive holdout|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues. This group is eligible for an incentive but not randomly assigned to it.
62167734|NCT03682237|ACTIVE_COMPARATOR|D) Carbohydrate counting, automated bolus calculation, FGM|Group training as group B. A more sophisticated education concept will be developed for how FGM should be used to adjust settings and suggestions from the automated bolus calculator (MySugr app).
62167735|NCT00828542|EXPERIMENTAL|etonogestrel implant|Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
62167736|NCT00828542|ACTIVE_COMPARATOR|depot medroxyprogesterone acetate|At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).
62167737|NCT01145547|ACTIVE_COMPARATOR|low glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.
62167738|NCT01145547|ACTIVE_COMPARATOR|high glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.
62167739|NCT04872842||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
62167740|NCT04872842||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
62167741|NCT05584709|EXPERIMENTAL|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
62167742|NCT01920399|PLACEBO_COMPARATOR|Placebo|IV infusions of 0.9% normal saline
62167743|NCT01920399|EXPERIMENTAL|CAZ-AVI|IV infusion of AVI 500 mg + CAZ 2000 mg.
62167744|NCT06412900||Adults investigated with CT for suspected urinary stone disease|"Newly occurring colic pain and clinical suspicion of kidney stones or known kidney stone with new/increasing symptoms.~Age ≥ 18 years"
62167745|NCT05127122|PLACEBO_COMPARATOR|Placebo Saline|Saline
62167746|NCT05127122|EXPERIMENTAL|10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
62167747|NCT05127122|EXPERIMENTAL|15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
62167748|NCT05797116||Anaesthesiologists in the Netherlands|The participants in this study are anesthesiologists in the Netherlands, preferably those in charge of preoperative screening. One anesthesiologist per anesthesiology department may be included.
62167749|NCT05122078|EXPERIMENTAL|ANI group|Investigator will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
62167750|NCT05122078|NO_INTERVENTION|Control group|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. We will not monitor ANI in this group.
62167751|NCT05307120|EXPERIMENTAL|Intervention|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on smartphones that enables continuous monitoring of nutrition (via food diary), physical activity (via activity tracker Fitbit and self-reported activities) and blood glucose values (via Freestyle libre 2 sensors). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
62167752|NCT02956876|EXPERIMENTAL|Nurse practitioner consultation|standard chemotherapy for colorectal cancer
62167753|NCT02956876|OTHER|Standard consultation|standard chemotherapy for colorectal cancer
62167754|NCT00652496|EXPERIMENTAL|1|Bimatoprost 0.01% ophthalmic solution
62167755|NCT00652496|EXPERIMENTAL|2|Bimatoprost 0.015% formulation 1 ophthalmic solution
62167756|NCT00652496|EXPERIMENTAL|3|Bimatoprost 0.015% formulation 2 ophthalmic solution
62167757|NCT00652496|EXPERIMENTAL|4|Bimatoprost 0.02% ophthalmic solution
62167758|NCT00652496|ACTIVE_COMPARATOR|5|Bimatoprost 0.03% ophthalmic solution
62167759|NCT01846637|EXPERIMENTAL|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
62167760|NCT01846637|ACTIVE_COMPARATOR|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
62167761|NCT04481334|EXPERIMENTAL|One group|One group pre-test, post-test design
62167762|NCT01598389|EXPERIMENTAL|Low energy-dense preload|
62167763|NCT01598389|EXPERIMENTAL|High energy-dense preload|
62167764|NCT01598389|EXPERIMENTAL|No preload|
62167765|NCT01007721|EXPERIMENTAL|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 25 mg plus 2 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
62167766|NCT01007721|EXPERIMENTAL|BI 671800 ED 400 mg|2 capsules of BI 671800 ED 100 mg plus 2 capsules of placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
62167767|NCT01007721|ACTIVE_COMPARATOR|Montelukast 10 mg|1 over-encapsulated montelukast 10 mg tablet (qd in the morning) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
62167768|NCT01007721|ACTIVE_COMPARATOR|Fluticasonepropionate nasal spray 200¿g|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 ¿g per nostril) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 overencapsulated montelukast placebo tablet (qd in the morning)
62167769|NCT01007721|PLACEBO_COMPARATOR|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening), plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
62167770|NCT01007721|EXPERIMENTAL|BI 671800 ED 800 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
62167771|NCT05417555|ACTIVE_COMPARATOR|LIFUP Dose Group 1|Administration of low intensity focused ultrasound (LIFUP) dose level 1 to the entorhinal cortex.
62734277|NCT05684692|EXPERIMENTAL|Sub-study A: Siltuximab|"The treatment period includes a double-blind treatment period (days 1-84) and an open-label treatment period (days 85-168).~All participants will receive siltuximab during this drug sub-study. Twenty (20) participants will be randomized to receive either Siltuximab or matching placebo during the double-blind treatment period. All participants will receive siltuximab during the open-label treatment period. Participants will complete study procedures as outlined:~* Double-Blind Treatment period: Administration of Siltuximab versus matching placebo in pre-determined dose once every 21 days (for 4 cycles).~* Open-Label Treatment period: Administration of Siltuximab in pre-determined dose once every 21 days (for 4 cycles)."
62734278|NCT05684692|EXPERIMENTAL|Sub-study B: Erenumab-Aooe|"The treatment period includes a single-blind treatment period (days 1-84) and an open-label treatment period (days 85-168).~All participants will receive erenumab-aooe during this drug sub-study. Twenty (20) participants will receive a randomization assignment to receive either Erenumab-Aooe or matching placebo during the single-blind treatment period. All participants will receive erenumab-aooe during the open-label treatment period. Participants will complete study procedures as outlined:~* Single-Blind treatment period (days 1 - 84): Administration of Erenumab-Aooe versus matching placebo in pre-determined dose once every 28 days (for 3 cycles).~* Open-Label Treatment period (days 85-168): Administration of Erenumab-Aooe in pre-determined dose once every 28 days (for 3 cycles)."
62734279|NCT03086408|EXPERIMENTAL|THRIVE|high flow nasal oxygen
62734280|NCT03086408|ACTIVE_COMPARATOR|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
62734281|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
62734282|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
62734283|NCT06110364|EXPERIMENTAL|Low-Level Tragus Stimulation|The Low-Level Tragus Stimulation will be done with TENS.
62734284|NCT06110364|EXPERIMENTAL|Heart Rate Variability- Biofeedback|Heart Rate Variability-Biofeedback will be done with a phone application. Practice sessions are at least 10-15 minutes twice a daily.
62734285|NCT06110364|ACTIVE_COMPARATOR|Conventional Medical Therapy|Subjects without beta blockers will be initiated on a usual/standard care medication of beta blockers to determine the efficacy of this standard medication therapy for Premature Ventricular Contraction suppression.
62734286|NCT03299244|ACTIVE_COMPARATOR|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
62734287|NCT03299244|EXPERIMENTAL|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
62734288|NCT01823198|EXPERIMENTAL|Treatment (NK cells, PBSC transplant)|Patients receive fludarabine phosphate IV over 1 hour and busulfan IV over 3 hours on days -13 to -10. Patients then receive allogeneic CD56-positive CD3-negative natural killer cells IV over 1 hour on day -8. Patients also receive aldesleukin SC QD on days -8 to -4. Patients then undergo allogeneic PBSC transplant on day 0.
62734289|NCT05744778|EXPERIMENTAL|Physical therapy and rehabilitation|The patient group who underwent physical therapy and rehabilitation.
62734290|NCT05744778|EXPERIMENTAL|Dry needling|The patient group who underwent dry needling for trigger points in the upper trapezius muscle along with physical therapy and rehabilitation.
62734291|NCT03611881|EXPERIMENTAL|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
62734292|NCT03611881|EXPERIMENTAL|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
62734293|NCT03611881|EXPERIMENTAL|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
62734294|NCT03611881|EXPERIMENTAL|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
62734295|NCT03611881|EXPERIMENTAL|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
62734296|NCT03611881|EXPERIMENTAL|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
62734297|NCT03611881|EXPERIMENTAL|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
62734298|NCT03611881|EXPERIMENTAL|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
62734299|NCT00648921|EXPERIMENTAL|1|Olanzapine Tablets 5 mg
62734300|NCT00648921|ACTIVE_COMPARATOR|2|Zyprexa® Tablets 5 mg
62734301|NCT00292071|OTHER|1|IV caspofungin acetate (50 mg/m²/day)
62734302|NCT00292071|OTHER|2|IV caspofungin acetate (70 mg/m²/day)
62734303|NCT02173639|EXPERIMENTAL|BI 1356/metformin|
62734304|NCT02173639|EXPERIMENTAL|BI 1356 + Metformin|
62734305|NCT02725450|EXPERIMENTAL|Motor Imagery + Psychomotor Battery of fine motor skills|Application of Motor Imagery together with normal practice improves fine motor skills in disabled individuals.
62734306|NCT06094244|EXPERIMENTAL|Group I Patients who were not taking statins prior to the occurrence of SICH|Patients who were not taking statins prior to the occurrence of SICH.
62734307|NCT06094244|EXPERIMENTAL|Group II Patients who were taking statins prior to the occurrence of SICH|Patients who were taking statins prior to the occurrence of SICH.
62734308|NCT06094244|EXPERIMENTAL|Subgroup Ia Patients were not diagnosed to dyslipidemia. They did not receive statins.|Patients who were not diagnosed to have dyslipidemia during hospitalization. They did not receive statins.
62736622|NCT05376059|EXPERIMENTAL|How incentive ineligible|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues. This group is not eligible for an incentive.
61977293|NCT03472469|ACTIVE_COMPARATOR|Original MMPR - descending dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
61977294|NCT03472469|ACTIVE_COMPARATOR|MAST MMPR - escalating dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
61977295|NCT04892888||COVID-19 Vaccine Intramuscular Injection 0.5 mL|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
61977296|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
61977297|NCT04307693|EXPERIMENTAL|Lopinavir/ritonavir|Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days
61977298|NCT04307693|ACTIVE_COMPARATOR|Hydroxychloroquine|Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days
61977299|NCT04307693|NO_INTERVENTION|Control|No lopinavir/ritonavir and hydroxychloroquine
61977300|NCT05514691|ACTIVE_COMPARATOR|Anterior nasal swab sample tested on iStatis Covid-19 Antigen Testing diagnostic device|An anterior nasal swab was collected using the swab provided with the iStatis test kit and will be used for the iStatis Covid-19 Antigen Testing at the site.
61977301|NCT05514691|ACTIVE_COMPARATOR|Anterior nasal swab sample tested with RT-PCR|Another anterior nasal swab sample was collected to be tested with RT-PCR at the central research laboratory.
61977302|NCT02352714|ACTIVE_COMPARATOR|Paracervical Nerve Block|Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
61977303|NCT02352714|SHAM_COMPARATOR|Sham Paracervical Block|To perform the sham cervical block, the cervix will be touched with the blunt end of a Q-tip at the three locations described above for the paracervical block. The cervical mucosa will not be broken during the sham block. A 3 minute waiting period will again occur between administration of the sham block and IUS insertion to be consistent with the procedure used for the nerve block.
61977304|NCT06189651|EXPERIMENTAL|Wrist splint treatment|The same type of wrist splint was given
61977305|NCT06189651|EXPERIMENTAL|Wrist splint treatment+ %5 dextrose injection|The same type of wrist splint was given and 5% dextrose injection using USG-guided nerve hydrodissection method was applied
61977306|NCT02090660|EXPERIMENTAL|VATS wedge lung resection|
61977307|NCT02943720|PLACEBO_COMPARATOR|placebo|5 SC injections in 2 months
61977308|NCT02943720|EXPERIMENTAL|AllerT 50 ug|5 SC injections in 2 months
61977309|NCT02943720|EXPERIMENTAL|AllerT 10 ug|5 SC injections in 2 months
61977310|NCT04890223|EXPERIMENTAL|Intervention group|The participants in the intervention group will be asked to identify an unfavourable behaviour that they wish to change when filling out the baseline questionnaire. The research nurse will conduct the individual face-to-face brief MI interviews for this purpose, which will last for approximately five to ten minutes. After the face-to-face brief MI interviews, the participants in the intervention group will receive brief MI messages individually by means of mobile instant messaging for six months from the baseline. After six months, the brief MI messages will cease to be delivered to the participants in the intervention group, with whom the research team will then maintain only minimal contact until the 12-month follow-up.
61977311|NCT04890223|PLACEBO_COMPARATOR|Control group|Participants in the control group will be asked to identify an unfavourable behaviour that they want to change at the baseline but, rather than brief MI interviews delivered face-to-face, received generic health advice consultations on the selected unfavourable behaviour that lasted approximately five to ten minutes. Each participant will receive a self-help smoking cessation booklet titled Be Smart, Quit Smoking! published by the Hong Kong Council on Smoking and Health with information about the negative health consequences of smoking, reasons to quit, strategies for quitting, and smoking cessation services available in Hong Kong along with a public quitline number (specifically, 1833183). Those who express the intention to quit at follow-ups will receive usual smoking cessation support.
61977312|NCT01980875|EXPERIMENTAL|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
61977313|NCT01980875|EXPERIMENTAL|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
61977314|NCT01980875|ACTIVE_COMPARATOR|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
61977315|NCT05639374|EXPERIMENTAL|BASICS_HealthyClassroom|"Students assigned to the IG will receive the peer-led preventive program. The preventive program consists of a single face-to-face session, lasting about 45-50 minutes. First, the participant will receive, from the Research Staff in Training, the individualized feedback sheet prepared from the baseline information obtained through the BASICS_HealthyClassroom Questionnaire. Subsequently, they will have a motivational interview with the counsellor. The content of the intervention will be adapted to the interests and level of motivation of each participant."
61977316|NCT05639374|NO_INTERVENTION|Control Group|Students assigned to the CG will not receive any type of intervention, they will only receive the usual information and messages that students receive in their daily environments and at the University.
61977317|NCT03316131|EXPERIMENTAL|Treatment A|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin;"
61977318|NCT03316131|EXPERIMENTAL|Treatment B|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin matched placebo"
61977319|NCT05443932|OTHER|Washout Phase and treatment arms|"At first there will be wash-out phase I with daily placebo administration for all participants. All patients will receive blood- and 24h-urine screenings in week 0 and 6 to get baseline data and also a low-dose native CT of the urinary tract in week 6. In preparation of the HCT phase all participants will daily receive an oral placebo.~In week 7 the HCT phase will start and all patients will receive an oral therapy with 50mg of HCT daily; the treatment response will be evaluated by blood- and urine test after 4 weeks of therapy (week 10).~After that, in washout phase II, the same test as before will be performed in week 0 and 6 (weeks 15 and 20).~At the end another therapy phase with an oral administration of 10mg dapagliflozin daily will be performed; the treatment response will be evaluated by blood- and urine test after 4 weeks of therapy (week 25).~Finally, the same tests as before will be performed in wash-out phase III in week 0 and 6 (weeks 29 and 34)."
61977320|NCT00782145|EXPERIMENTAL|Arm I|"Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.~The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant."
61977321|NCT00782145|ACTIVE_COMPARATOR|Arm II|Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
61977322|NCT00603551||Chemotherapy|Postmenopausal women who have been diagnosed with a breast or gynecological cancer and who have undergone chemotherapy as a result of that diagnosis
61977323|NCT06095427|EXPERIMENTAL|LY06006|60 mg LY006006
61977324|NCT06095427|ACTIVE_COMPARATOR|US-Prolia|60 mg US-Prolia
61977325|NCT06095427|ACTIVE_COMPARATOR|EU-Prolia|60 mg EU-Prolia
61977326|NCT01922089|EXPERIMENTAL|LCZ696 Condensed|Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
61977327|NCT01922089|EXPERIMENTAL|LCZ696 Conservative|Up-titration to LCZ696 200 mg bid over 6 weeks
61977328|NCT02549183|ACTIVE_COMPARATOR|Arm 1|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz
61977329|NCT02549183|ACTIVE_COMPARATOR|Arm 2|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz
61977330|NCT02549183|ACTIVE_COMPARATOR|Arm 3|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz
61977331|NCT02549183|ACTIVE_COMPARATOR|Arm 4|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz
61977332|NCT00775151|EXPERIMENTAL|1|amlodipine 10 mg tablet of Ranbaxy
61977333|NCT00775151|ACTIVE_COMPARATOR|2|Norvasc® 10 mg tablets
61977334|NCT03952000|EXPERIMENTAL|Experimental: Exercise|Exercise: Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1.
61977335|NCT03952000|NO_INTERVENTION|No Intervention: Control|Participants will rest on day 1.
61977336|NCT03913793|ACTIVE_COMPARATOR|Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction with peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
61977337|NCT03913793|ACTIVE_COMPARATOR|Non-Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction without peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
61977338|NCT03913793|NO_INTERVENTION|Control group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction, not enrolled into exercise program.
61977339|NCT03612297||ATOUTBIO|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
61977340|NCT03612297||EVOLAB|Complete reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
61977341|NCT03696511|ACTIVE_COMPARATOR|group 1:maxillary insertion|Orthodontic miniscrew insertion; maxillary insertion. buccal
61977342|NCT03696511|ACTIVE_COMPARATOR|group 2: mandible insertion|Orthodontic miniscrew insertion; mandible insertion.
61977343|NCT03696511|ACTIVE_COMPARATOR|group 3: palatal insertion|Orthodontic miniscrew insertion; palatal insertion
61977344|NCT00271609|OTHER|Anaplastic Glioma (AG)|Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mixed oligoastrocytoma Malignant astrocytoma (not otherwise specified) 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
61977345|NCT00271609|OTHER|Glioblastoma Multiforme (GBM)|Glioblastoma multiforme Gliosarcoma 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
61977346|NCT00197730|EXPERIMENTAL|Multivitamins|Vitamin E, Vitamin C, and Vitamin B complex
61977347|NCT00197730|PLACEBO_COMPARATOR|Placebo|Placebo
61977348|NCT01455142|EXPERIMENTAL|Formulation 1|
61977349|NCT01455142|EXPERIMENTAL|Formulation 2|
61977350|NCT05688189|EXPERIMENTAL|37 degree centigrade|The 37°C arm implies the setting of the temperature immediately at 37°C.
61977351|NCT05688189|EXPERIMENTAL|34-37 degree centigrade|The 34-37°C arm implies the setting of the temperature at 34°C and after 15 minutes at 37°C.
61977352|NCT05688189|EXPERIMENTAL|31-34-37 degree centigrade|The 31-34-37°C arm implies setting the temperature initially at 31°C, after 15 minutes at 34°C and after another 15 minutes at 37°C.
61977353|NCT03021239|ACTIVE_COMPARATOR|1) Echo Guided Testing -|This testing uses echocardiography to create images of the heart and make measurements while gradually increasing the heart pump speed. The final pump speed and medical treatment are determined using the echo measurements. This will take about 45 minutes.
61977354|NCT03021239|ACTIVE_COMPARATOR|2) Hemodynamic-Echo Ramp Testing -|This testing is performed during a right heart catheterization procedure which provides hemodynamic measurements (pressure and blood flow) in addition to the echocardiography measurements. With this method, more echo images and measurements are taken. The final pump speed and medical treatment adjustments are made using the hemodynamic measurements as well as the information from the echo. This test will take about 1 hour and 45 minutes.
61977355|NCT04358666|ACTIVE_COMPARATOR|surgery and focal radiosurgery of the surgical site|
61977356|NCT04358666|ACTIVE_COMPARATOR|hypofractionned radiosurgery|
61977357|NCT03523754|OTHER|Misoprostol only|This group will receive Intravaginal Misoprostol only.
61977358|NCT03523754|OTHER|Isosorbide Mononitrate & Misoprostol|This group will reveive intravaginal Isosorbide Mononitrate \& Misoprostol.
61977359|NCT00967798|EXPERIMENTAL|Sitagliptin|"CF patients receiving Sitagliptin.~Intervention: Dose is 100 mg taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
61977360|NCT00967798|PLACEBO_COMPARATOR|Sugar pill|"CF patients receiving placebo.~Intervention: Placebo is taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
61977361|NCT05415085|EXPERIMENTAL|Culprit-first PCI|In this arm, primary PCI with stent implantation will be performed prior to the demonstration of the whole coronary tree. The suspected culprit artery will be demonstrated first and the PCI will be performed.
61977362|NCT05415085|NO_INTERVENTION|Culprit-last PCI|In this arm, primary PCI with stent implantation will be performed after the demonstration of the whole coronary tree. The suspected culprit artery will be demonstrated after the contralateral side and then PCI will be performed. This is the common approach.
61977363|NCT00877058|EXPERIMENTAL|1.Preventive home visit|Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
61977364|NCT00877058|EXPERIMENTAL|2. Senior meetings|The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
61977365|NCT00877058|NO_INTERVENTION|3. Control group|The control group had access to the ordinary range of services if requested from the urban districts for the aged. The aim of the municipal provision of care for the older persons is to ensure the ability to live as independently as possible. This includes remaining in their homes. When an older person in Sweden has difficulties managing independently, she or he can apply for assistance from the district. The extent of such support is subject to an assessment of needs and includes meals on wheels, help with cleaning and shopping, assistance with personal care, safety alarms and transportation service. The older person are also offered healthcare, provided either by municipal home help or home medical care services.
61977366|NCT05789979|EXPERIMENTAL|The resident-handling device|This group will use the resident-handling device during the 4-week trial.
61977367|NCT00341835||High risk lung cancer families|Individuals from families with a high risk of lung cancer, both affected and unaffected family members
61977368|NCT01503268|ACTIVE_COMPARATOR|Percutaneous ablation|
61977369|NCT01503268|ACTIVE_COMPARATOR|Surgical ablation|
61977370|NCT01503268|ACTIVE_COMPARATOR|DCCV|Direct current cardioversion
61977371|NCT04239820||RRMS patients initiating cladribine|Patients will be imaged using PET and MRI at baseline prior the cladribine treatment initiation and 18 months after baseline
61977372|NCT02360956|EXPERIMENTAL|Olmesartan medoxomil|Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
61977373|NCT02360956|ACTIVE_COMPARATOR|Antihypertensive medication|"Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).~The drug dose must be individualized."
61977374|NCT03896776|EXPERIMENTAL|Community Based Organization (CBO) Delivery|"CBOs will be selected through a Request for Proposal (RFP) process. The RFP will describe research and KIU! delivery activities to be conducted as part of the study and allowable budget to carry out the activities. The RFP will ask CBOs to describe past experience providing HIV services for YMSM. Selected CBOs will recruit participants into the intervention and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the CBO delivery arm will receive baseline HIV and STI testing at a CBO. Participants will receive an at-home STI test kit at 12 Week Follow-up if testing is not provided at their CBO site."
61977375|NCT03896776|EXPERIMENTAL|Direct to Consumer (DTC) Delivery|"In the DTC arm, participants will be recruited online via paid social media advertising (e.g., Facebook, Instagram). Advertisements will target placements by age, gender, sexual orientation, racial background, likes that are relevant to YMSM (e.g., local LGBT organizations, out celebrities), and location (i.e., target county). Dating/sex-seeking apps (e.g., Grindr) will also be used to recruit YMSM, using a similar advertising approach as social media. These online recruitment strategies will be supplemented by referrals from local organizations and participant registries, and snowball recruitment. Study staff at Northwestern University will manage this recruitment process and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the DTC delivery arm will receive at-home HIV and STI test kits at baseline. Participants will receive an at-home STI test kit at 12 Week Follow-up."
61977376|NCT02529514|ACTIVE_COMPARATOR|Baclofen|Baclofen 25 mg per os for 7 days at 10 pm every day
61977377|NCT02529514|PLACEBO_COMPARATOR|Placebo|Placebo per os for 7 days at 10 pm every day
61977378|NCT01800864|OTHER|Normal|Normal weight subjects
61977379|NCT01800864|OTHER|Over weight /obese subjects|Overweight and obese subjects
61977380|NCT03670550|EXPERIMENTAL|Knee Brace|"ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy.~Dynamic X-ray imaging of the knee will take place prior to surgery, and again upon clearance from physical therapy 7-9 months after surgery. The injured knee will be imaged with and without the brace, and the contralateral limb will be imaged for use as a control."
61977381|NCT02769247|EXPERIMENTAL|Placebo|Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
61977382|NCT02769247|EXPERIMENTAL|Naproxen/Normal saline|Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
61977383|NCT02769247|EXPERIMENTAL|Placebo oral medication/Lidocaine|Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
61977384|NCT02769247|EXPERIMENTAL|Naproxen/Lidocaine|Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
61977385|NCT03808051|EXPERIMENTAL|Physiological-based cord clamping|Stabilisation of the infant is performed while the cord is intact and the cord will be clamped after the infant is cardiopulmonary stable. Stable is defined as the establishment of heart rate greater than 100 bpm and oxygen saturation above 85% while using supplemental oxygen lower than 40%. The maximum cord clamping time is 10 minutes and prior to cord clamping a trial of weaning from PPV to CPAP is performed. With the exception that the infant is stabilised close to the mother and the cord is clamped later, the infant will receive standard resuscitation interventions.
61977386|NCT03808051|ACTIVE_COMPARATOR|Time-based cord clamping|Infants are clamped first and then moved to the standard resuscitation table for further treatment and intervention needed for cardiopulmonary stabilisation. Clamping is time based and performed immediately or delayed at 30-60 seconds, depending on the clinical condition of the infant. Uterotonic drugs are administered immediately after cord clamping.
61977387|NCT02867033|OTHER|Study procedure|Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
61977388|NCT04658095|ACTIVE_COMPARATOR|Ab-interno canaloplasty and trabeculotomy (both up to 360 degrees) using the OMNI Surgical System|
61977389|NCT04658095|ACTIVE_COMPARATOR|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System|
61977390|NCT04658095|ACTIVE_COMPARATOR|Ab-interno implantation of iStent inject (2 microstents)|
61977391|NCT06377254|EXPERIMENTAL|Inactivity|Participants in this group will reduce their physical activity (increase sitting time to 7hrs/day and decrease step count to \<4500/day) for 6 months
61977392|NCT06377254|EXPERIMENTAL|Activity|Participants in this group will have moderate intensity physical activity levels increased for 6 months, through attending 3x 45 min supervised exercise sessions/week.
61977393|NCT05630612|EXPERIMENTAL|Sparsentan|"20 participants with ANCA-associated vasculitis in long-term disease remission.~Participants will undergo a forearm blood flow study where forearm vasodilatation will be assessed in response to acetylcholine (7.5, 15 and 30ug/min) and sodium nitroprusside (1, 2 and 4ug/min). Participants will also receive bradykinin (100, 300 and 1000pmol/min) in order to assess tPA release to measure fibrinolytic capacity.~Participants will also have 24h blood pressure assessed as well as measurements of arterial stiffness, systemic haemodynamics and measures of urinary protein.~After these baseline measures have been obtained the subject will receive 6 weeks of sparsentan. Finally the subject will undergo the same investigations listed above and we will compare to see if measurements obtained differ after treatment."
61977394|NCT05630612|ACTIVE_COMPARATOR|Irbesartan|"20 participants with ANCA-associated vasculitis in long-term disease remission.~Participants will undergo a forearm blood flow study where forearm vasodilatation will be assessed in response to acetylcholine (7.5, 15 and 30ug/min) and sodium nitroprusside (1, 2 and 4ug/min). Participants will also receive bradykinin (100, 300 and 1000pmol/min) in order to assess tPA release to measure fibrinolytic capacity.~Participants will also have 24h blood pressure assessed as well as measurements of arterial stiffness, systemic haemodynamics and measures of urinary protein.~After these baseline measures have been obtained the subject will receive 6 weeks of irbesartan. Finally the subject will undergo the same investigations listed above and we will compare to see if measurements obtained differ after treatment."
61977395|NCT04931355|EXPERIMENTAL|Acupuncture treatment group|Method: Acupuncture at Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi. The acupuncture treatment starts on the 5th day of the menstrual cycle and lasts to the days before IVF-ET
61977396|NCT04931355|ACTIVE_COMPARATOR|Western medicine group|The western medicine group will be treated with conventional western medicine
61977397|NCT04225728|ACTIVE_COMPARATOR|Iron sucrose IV arm|Perfusion of diluted iron sucrose i.v. in two weeks. Half of the total dose at Day 0 and the other half at Day 14
61977398|NCT04225728|ACTIVE_COMPARATOR|Ferric polymaltose hydroxide complex IM arm|Injection in two series, begin at Day 0 and the second at Day 14. In each series, we administered 300 mg of iron IM until reach half of the dose
61977399|NCT04225728|PLACEBO_COMPARATOR|Placebo arm|100 ml i.v. of normal saline administered at Day 0 and at day 14.
61977400|NCT02985307|EXPERIMENTAL|Short Message Text Service|Participants receive short messages daily via their mobile phone
61977401|NCT02985307|ACTIVE_COMPARATOR|Standard Weight Management Group|Participants attend standard group weight management sessions
61977402|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
61977403|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
61977404|NCT04759703|EXPERIMENTAL|Pramipexole|Medication arm; 0.25 or 0.5 mg of pramipexole
61977405|NCT04759703|PLACEBO_COMPARATOR|Placebo|Placebo arm; 0.25 or 0.5 mg of placebo
61977406|NCT04763915|EXPERIMENTAL|GeneSHARE|Access to GeneSHARE, a web-based toolkit including interactive and narrative components to enhance FC of genetic test results.
61977407|NCT04763915|EXPERIMENTAL|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
61977408|NCT04763915|ACTIVE_COMPARATOR|Standard-of-care|Receive standard-of-care from their treating healthcare provider.
61977409|NCT04763915|EXPERIMENTAL|Variants of Uncertain Significance (VUS) Pilot Study|Participants are provided access to VUS educational resources including video and written education and assistance for speaking with family members.
61977410|NCT02658357|EXPERIMENTAL|600 mg|Two, 300 mg Risperidone Implants
61977411|NCT02658357|EXPERIMENTAL|900 mg|Three, 300 mg Risperidone Implants
61977412|NCT03884218|OTHER|Thermal Comfort|Infra red thermal image
61977413|NCT02063412||XELOX|Capecitabine (Xeloda) 1000mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
61977414|NCT02063412||XP|Cisplatin (CDDP) 80 mg/m2 iv over 3 hrs d1 Capecitabine (Xeloda) 1000 mg/m2 po bid d1-14, Q3w
61977415|NCT02063412||FOLFOX|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and d2 5-FU 400mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d1 and d2 Q2w
61977416|NCT02063412||FP|Cisplatin (CDDP) 100 mg/m2 iv d1 5-FU 1000 mg/m2/d civi d1-5, Q4w
61977417|NCT03876912|EXPERIMENTAL|GnRH antagonist|Administration of GnRH antagonist (subcutaneous injection, 240 mg) after baseline 18F-PSMA 1007 PET/CT.Then 18F-PSMA 1007 PET/CT is repeated 3 weeks after ADT and at development of CRPC
61977418|NCT02747901|EXPERIMENTAL|Kinesiotaping Group|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
61977419|NCT02747901|ACTIVE_COMPARATOR|Cold Therapy Group|Cold Therapy group received cold pack immediately after operation and following postoperative days.
61977420|NCT02747901|NO_INTERVENTION|Control Group|Control group have no intervention.
61977421|NCT02902965|EXPERIMENTAL|Ibrutinib+ Bortezomib+ Dexamethasone|
61977422|NCT01994460|ACTIVE_COMPARATOR|Arm 1 (control arm)|Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)
61977423|NCT01994460|EXPERIMENTAL|Arm 2 (experimental arm 1)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)
61977424|NCT01994460|EXPERIMENTAL|Arm 3 (experimental arm 2)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)
61977425|NCT01214954|ACTIVE_COMPARATOR|Control group|Standard rehabilitation
61977426|NCT01214954|EXPERIMENTAL|Resistance training|10 weeks of supervised progressive resistance training initiated within the first week after total hip replacement.
61977427|NCT02248389|EXPERIMENTAL|Ablation arm|Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
61977428|NCT04519125|EXPERIMENTAL|Intervention|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
61977429|NCT04519125|PLACEBO_COMPARATOR|Placebo|(1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
61977430|NCT06363968|EXPERIMENTAL|ERG, all participants|All participants undergo ERG recording before and after a single dose of sertraline 50 mg.
61977431|NCT00795756|EXPERIMENTAL|Intrathecal DepoCyte|I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
61977432|NCT00795756|ACTIVE_COMPARATOR|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
61977433|NCT00940394|OTHER|standard care|Families receive routine community and family mental health care services
61977434|NCT00940394|EXPERIMENTAL|mutual support group|bi-weekly, 12-session, family-led mutual support group
61977435|NCT00940394|ACTIVE_COMPARATOR|psychoeducation group|bi-weekly, 12-session, family psychoeducation group program
61977436|NCT01157936|ACTIVE_COMPARATOR|Allopurinol treatment|
61977437|NCT01157936|PLACEBO_COMPARATOR|Placebo|
61977438|NCT00807157|PLACEBO_COMPARATOR|2|Every morning subjects will consume a stick of placebo during 30 days
61977439|NCT00807157|EXPERIMENTAL|1|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
61977440|NCT01364207|EXPERIMENTAL|Caffeinated Coffee 1st Visit, Decaffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of caffeinated coffee on their first visit and 8 oz cup of decaffeinated coffee on their second visit.
61977441|NCT01364207|EXPERIMENTAL|Decaffeinated Coffee 1st Visit, Caffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of decaffeinated coffee on their first visit and 8 oz cup of caffeinated coffee on their second visit.
61977442|NCT05439512|EXPERIMENTAL|orbital floor fracture|orbital floor fracture
61977443|NCT06061653|EXPERIMENTAL|IPT plus HD-tDCS|
61977444|NCT06061653|SHAM_COMPARATOR|IPT plus sham HD-tDCS|
61977445|NCT04279951|EXPERIMENTAL|Omega 3|"Intake of 1 gram omega-3 (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
61977446|NCT04279951|PLACEBO_COMPARATOR|Placebo|"Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
61977447|NCT04279951|NO_INTERVENTION|Control|No intervention
61977448|NCT05982275|EXPERIMENTAL|CARTemis-1|Dose escalation sequential cohorts CARTemis-1 will be self-administered intravenously one or two days, depending on the dose administered.
61977449|NCT01907204|ACTIVE_COMPARATOR|Oral|Oral drug (methylprednisolone) administration
61977450|NCT01907204|EXPERIMENTAL|Metered dose inhaler|
61977451|NCT01907204|EXPERIMENTAL|Nebulized|
61977452|NCT01096121|PLACEBO_COMPARATOR|2|
61977453|NCT01096121|EXPERIMENTAL|1|Enalapril
61977454|NCT04905446|OTHER|Healthy male subjects|
61977455|NCT00649623|EXPERIMENTAL|1|Olmesartan Medoxomil Tablets 40 mg
61977456|NCT00649623|ACTIVE_COMPARATOR|2|Benicar® Tablets 40 mg
61977457|NCT04993989||Pharmacy based survey|Patients received a questionnaire, which was filled out and returned to the Contract Research Organization (CRO) or, alternatively to the pharmacy.
61977458|NCT06242249|EXPERIMENTAL|Relapsed or Refractory Multiple Myeloma|
62167772|NCT05417555|ACTIVE_COMPARATOR|LIFUP Dose Group 2|Administration of low intensity focused ultrasound (LIFUP) dose level 2 to the entorhinal cortex.
61977459|NCT05631886|EXPERIMENTAL|TP53-EphA-2-CAR-DC plus anti-PD-1 antibody/anti-CTLA4 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and TP53-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, TP53-EphA-2-CAR-DC vaccine is infused one dose every 8 weeks since Week 5.~Anti-PD-1 antibody and anti-CTLA4 antibody are administered 2 days after the first dose of TP53-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 3 weeks afterwards for four doses, followed by anti-PD-1 antibody once every 3 weeks, until:~1. Unacceptable toxicity occurred or disease progression; or 2. Reactive T cells are undetected repeatedly after the last vaccine dose; or 3. Vaccine exhaustion."
61977460|NCT00745147|EXPERIMENTAL|A|Chinese herbal formula + Placebo of duphalac
61977461|NCT00745147|ACTIVE_COMPARATOR|B|Duphalac + Placebo of Chinese herbal formula
61977462|NCT01338493||lumbar spinal arthroplasty + Maverick™|Patients requiring total disc replacement
61977463|NCT05473338||CRPS (Complex Regional Pain Syndrome)|Participants with CRPS (Complex Regional Pain Syndrome))
61977464|NCT05473338||Healthy|Healthy individuals
61977465|NCT05924750|EXPERIMENTAL|Study treatment|Participants receive BL-M11D1 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
61977466|NCT02326753|EXPERIMENTAL|No. 7 oral airway|
61977467|NCT02326753|EXPERIMENTAL|No. 8 oral airway|
61977468|NCT02326753|ACTIVE_COMPARATOR|No. 9 oral airway|
61977469|NCT05164224||No secondary suture|The participants who will develop post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
61977470|NCT05164224||secondary suture|The participants who will develop post-cesarean surgical site infection and need a secondary suture for their wound care
61977471|NCT01256554|EXPERIMENTAL|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
61977472|NCT02187601|EXPERIMENTAL|CLD with MPBA and BID|Chronic Liver Disease (CLD) patients of all degrees will be offered to be tested on the MPBA (multi purpose breath analyzer) and BID (BreathID) on a walk- in basis with , proving they meet inclusion/exclusion criteria.
61977473|NCT02187601|EXPERIMENTAL|HV with MPBA and BID|Healthy volunteers (HV) with no known liver disease will undergo the breath test with the MPBA and the BID before and after substrate ingestion.
61977474|NCT04379089||Children <18|"Infants, children, and young adults age \< 18 years~Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)"
61977475|NCT05688046||IA group|Immune checkpoint inhibitors plus angiogenesis inhibitors group
61977476|NCT05688046||NIA group|Immune checkpoint inhibitors without angiogenesis inhibitors group
61977477|NCT06494683|EXPERIMENTAL|Pueraria lobata radix group|Pueraria lobata radix will be made into granules.
61977478|NCT06494683|PLACEBO_COMPARATOR|Placebo group|The dosage form, specifications and packaging of the placebo will be no different from those of Pueraria lobata radix granules, and the smell and taste will be basically the same.
61977479|NCT03857243|EXPERIMENTAL|dTDCS plus physical therapy|active dual transcranial direct current stimulation (TDCS) arm (M1-M1)
61977480|NCT03857243|PLACEBO_COMPARATOR|Sham dTDCS plus physical therapy|Non-effective dose dual TDCS stimulation arm, identical with intervention arm except for the stimulation intensity/duration used.
61977481|NCT04971473|EXPERIMENTAL|rhTSH+Thyroid hormone withdrawal|"rhTSH: rhTSH(0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH.Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration.~Thyroid hormone withdrawal: Patients stop taking thyroid hormone for 14 days, and then monitor the level of thyroid stimulating hormone every week. When TSH\>30mU/L, an ablative activity of 131I was administered.and scanning was done 48 hours after the radioiodine administration."
61977482|NCT04517253|EXPERIMENTAL|Baricitinib|"CANDLE:~Participants with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~SAVI:~Participants with STING-associated vasculopathy with onset during infancy (SAVI) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~Aicardi-Goutières Syndrome (AGS):~Participants with Aicardi-Goutières Syndrome (AGS) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR)."
61977483|NCT01179945|EXPERIMENTAL|sodium benzoate containing|
61977484|NCT01179945|ACTIVE_COMPARATOR|non sodium benzoate containing|
61977485|NCT03218553|EXPERIMENTAL|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
61977486|NCT03218553|PLACEBO_COMPARATOR|placebo|Standard cares plus postoperative administrations of placebo
61977487|NCT02066233|ACTIVE_COMPARATOR|Subjects with Barrett's Esophagus|All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
61977488|NCT02066233|ACTIVE_COMPARATOR|Subjects with Reflux and/or Heartburn|All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
61977489|NCT01026792|EXPERIMENTAL|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. For complete responders, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or for 2 courses after complete response criteria are first met. For other patients, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
61977490|NCT00708162|EXPERIMENTAL|Elvitegravir|"EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg."
61977491|NCT00708162|ACTIVE_COMPARATOR|Raltegravir|"RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg."
61977492|NCT03184415|EXPERIMENTAL|DWC20155/DWC20156 Combination Therapy|
61977493|NCT03184415|ACTIVE_COMPARATOR|DWC20155 Monotherapy|
61977494|NCT03184415|ACTIVE_COMPARATOR|DWC20156 Monotherapy|
61977495|NCT02785354||NOAC|New oral anticoagulant groups
61977496|NCT02785354||VKA|VKA group
61977497|NCT04242615||Prognostic score cohort|323 patients included between January 1, 2001 to December 31, 2004
61977498|NCT04242615||Prognostic score validation cohort|534 patients included between January 1, 2010 to December 31, 2013
61977499|NCT03349749||Patients undergoing fluid resuscitation|Adult patients in the intensive care unit (ICU) undergoing fluid resuscitation guided by the LiDCOplus haemodynamic monitor.
61977500|NCT03589950|EXPERIMENTAL|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
61977501|NCT03589950|ACTIVE_COMPARATOR|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
61977502|NCT02070692|EXPERIMENTAL|Tamoxifen|Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
61977503|NCT02070692|PLACEBO_COMPARATOR|Placebo|Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
61977504|NCT06135701|EXPERIMENTAL|COPD-patients|The participants will be instructed to abstain from caffeine, nicotine, alcohol, and strenuous exercise all known to affect blood flow to the limb for 12 hours prior to the study day. After being placed on the one-leg kicking chair, baseline measurements will be performed, followed by passive leg movement for 2 minutes. Then participants will perform one-legged knee-extension exercise at submaximal intensity, first at 10% and then at 20% of the previously measured WLpeak, remaining 3.5 minutes at each level, while femoral blood flow is measured. This study day will be repeated within 2-10 days.
61977505|NCT06135701|EXPERIMENTAL|Matched healthy volunteers|The participants will be instructed to abstain from caffeine, nicotine, alcohol, and strenuous exercise all known to affect blood flow to the limb for 12 hours prior to the study day. After being placed on the one-leg kicking chair, baseline measurements will be performed, followed by passive leg movement for 2 minutes. Then participants will perform one-legged knee-extension exercise at submaximal intensity, first at 10% and then at 20% of the previously measured WLpeak, remaining 3.5 minutes at each level, while femoral blood flow is measured. This study day will be repeated within 2-10 days.
61977506|NCT04933942|ACTIVE_COMPARATOR|Control group|Lomustine alone
61977507|NCT04933942|EXPERIMENTAL|Experimental group|Lomustine plus Romiplostim
61977508|NCT06218355|ACTIVE_COMPARATOR|Intensive Education|"Women enrolled in the intensive education care model participate in intensive in-person education as well as ongoing virtual education via the electronic health record web portal in the form of strategically timed pushes of relevant and digestible educational elements via a Care Companion. These virtual education pushes will include to do list reminders to check vital signs and submit them for review to the care team. Positive reinforcement will be provided when tasks are completed."
61977509|NCT06218355|ACTIVE_COMPARATOR|Enhanced Virtual Care|"Women in the enhanced virtual care model will receive scheduled telehealth visits on the platform of their choice - either via video or audio-only synchronous visits. Patients in the virtual care model will check vital signs with home devices during the telehealth visit and report them directly to the provider. This pull approach to data collection directly contrasts with the push approach of comparator #1."
61977510|NCT02561650|EXPERIMENTAL|COV155|
61977511|NCT04537507||Patients underwent coronary angiography|We reviewed medical notes of patients hospitalized for coronary angiography because of exacerbated angina (recurrent chest pain, classical stable angina, long history of chest pain/angina or other symptoms such as dyspnea). We excluded patients with acute coronary syndromes (ACS), Tako-tsubo cardiomiopathy and history of ischemic heart disease, as well as those referred for coronary angiography before heart valve surgery. Prior cardiosurgical valve replacement was also the exclusion criterion.
61977512|NCT00633386|EXPERIMENTAL|A|
62167773|NCT05417555|ACTIVE_COMPARATOR|LIFUP Dose Group 3|Administration of low intensity focused ultrasound (LIFUP) dose level 3 to the entorhinal cortex.
61977513|NCT00633386|PLACEBO_COMPARATOR|B|
61977514|NCT01053611|ACTIVE_COMPARATOR|Group 1 BIS value 30|
61977515|NCT01053611|ACTIVE_COMPARATOR|Group 2 BIS value 30|
61977516|NCT01053611|ACTIVE_COMPARATOR|Group 3 BIS value 30|
61977517|NCT01053611|ACTIVE_COMPARATOR|Group 4 BIS valaue 30|
61977518|NCT01053611|ACTIVE_COMPARATOR|Group 1 BIS value 50|
61977519|NCT01053611|ACTIVE_COMPARATOR|Group 2 BIS value 50|
61977520|NCT01053611|ACTIVE_COMPARATOR|Group 3 BIS value 50|
61977521|NCT01053611|ACTIVE_COMPARATOR|Group 4 BIS value 50|
61977522|NCT01053611|ACTIVE_COMPARATOR|Group 1 BIS value 70|
61977523|NCT01053611|ACTIVE_COMPARATOR|Group 2 BIS value 70|
61977524|NCT01053611|ACTIVE_COMPARATOR|Group 3 BIS value 70|
61977525|NCT01053611|ACTIVE_COMPARATOR|Group 4 BIS value 70|
61977526|NCT01882621|ACTIVE_COMPARATOR|Monosialoganglioside(GM1)|Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
61977527|NCT01882621|PLACEBO_COMPARATOR|normal saline|placebo 80mg + N.S 250ml,qd,D0-D3
61977528|NCT06376110|ACTIVE_COMPARATOR|Topical Antioxidant Serum containing Silymarin CF (Left Face)|"14 day application of topical antioxidant serum containing Silymarin CF~Subjects will be given study drug and instructed to topically apply to the treatment area, the respectively randomized half of the face, once daily for 14 consecutive days."
61977529|NCT06376110|ACTIVE_COMPARATOR|Topical Antioxidant Serum containing Silymarin CF (Right Face)|"14 day application of topical antioxidant serum containing Silymarin CF~Subjects will be given study drug and instructed to topically apply to the treatment area, the respectively randomized half of the face, once daily for 14 consecutive days."
61977530|NCT04991155|EXPERIMENTAL|PART 1 (400 mg BIA 5-1058)|Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3): Part 1: 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 1, 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 2, and 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 3.
61977531|NCT04991155|EXPERIMENTAL|PART 2 (800 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 2: 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 1, 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 2, and 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 3."
61977532|NCT04991155|EXPERIMENTAL|PART 3 (1200 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 3: 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 1, 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 2, and 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 3."
61977533|NCT04487639|EXPERIMENTAL|Cohort : patients needing oncofertility preservation|
61977534|NCT05200533|EXPERIMENTAL|Task-sharing and shifting|In the task-sharing and shifting group, family physicians shifted acute low back pain consultations to physiotherapists. Patients with acute low back pain are seen by the physiotherapist instead of family physician. Physiotherapist diagnose acute low back pain, identify red and yellow flags, prescribe sick leave and medications and can refer the patient to additional physical therapy treatment.
61977535|NCT05200533|ACTIVE_COMPARATOR|Usual care|In the usual care group, patients with acute low back pain are seen by their family physician.
61977536|NCT03097874|EXPERIMENTAL|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
61977537|NCT03097874|EXPERIMENTAL|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment plus Intensive Parental Coaching if weight milestones are not met by session 4.
61977538|NCT03530111||Sedentary|Sedentary individuals will be classified as achieving \< 75 minutes of moderate-intensity or \< 37 minutes of vigorous-intensity aerobic physical activity per week.
61977539|NCT03530111||Very Physically Active|Very Physically Active individuals will be classified as achieving \> 225 minutes of moderate-intensity or \> 112 minutes of vigorous-intensity aerobic physical activity per week.
61977540|NCT03020680|EXPERIMENTAL|ubiquinol|It is the reduced form of coenzyme Q10
61977541|NCT03020680|ACTIVE_COMPARATOR|ubiquinone|It is the oxidized form of coenzyme Q10
61977542|NCT01970111|EXPERIMENTAL|KPS-0373|
61977543|NCT05711849|EXPERIMENTAL|Treatment arm|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.
61977544|NCT05711849|SHAM_COMPARATOR|Sham arm|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).
61977545|NCT05042349||Elite athletes|Pregnant female elite athletes
61977546|NCT05042349||Controls|Moderately physical active pregnant females
61977547|NCT05042349||Sponsors|Sponsors of the athletes
61977548|NCT05042349||Coaches/tema leaders|Coaches or team leaders of the atheltes
61977549|NCT03596528|OTHER|Lung biopsy|Lung biopsy
61977550|NCT01721642|EXPERIMENTAL|Apica Cardiovascular ASC Device|Access, stabilisation and closure with the Apica Cardiovascular ASC Device
61977551|NCT02260479|ACTIVE_COMPARATOR|Preheated chlorhexidine|Preheated skin disinfection with 36ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
61977552|NCT02260479|NO_INTERVENTION|Room temperature chorhexidine|Room temperature skin disinfection with 20ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
61977553|NCT01252940|EXPERIMENTAL|FTC/RPV/TDF|Participants will switch from their existing treatment regimen to the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) at the beginning of the study.
61977554|NCT01252940|EXPERIMENTAL|SBR/Delayed Switch|Participants will stay on baseline regimen (SBR; their existing treatment regimen of PI+RTV plus 2 NRTIs) at the beginning of the study through Week 24, and may switch to the FTC/RPV/TDF STR (Delayed Switch) at the Week 24 visit.
61977555|NCT02859675||Crohn and anti-TNF treatment|Tests at 3 or 4 weeks after the beginning of anti-TNF treatment
61977556|NCT02859675||Crohn and without anti-TNF treatment|tests performed according to patient availability
61977557|NCT02859675||Control|tests performed according to patient availability
61977558|NCT03027726|ACTIVE_COMPARATOR|Control group|Family-based lifestyle education and psycho-educational program
61977559|NCT03027726|EXPERIMENTAL|Exercise group|Supervised exercise plus family-based lifestyle education and psycho-educational program
61977560|NCT03254927|EXPERIMENTAL|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
61977561|NCT01417520||ECD|ECD patients of any gender and ethnicity age 2-80 years are eligible to enroll in this protocol
61977562|NCT00834860|ACTIVE_COMPARATOR|CHC, HCC|100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
61977563|NCT00834860|ACTIVE_COMPARATOR|CHC, LC|100 naïve CHC patients without malignancy
61977564|NCT04566081|ACTIVE_COMPARATOR|iTALKbetter: deterministic|"Participants will receive the deterministic version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter:deterministic version will randomise the order all of the words that are to be trained and participants will cycle through all of these words regardless of their performance until complete at which point the order is re-randomised and participants begin the cycle again."
61977726|NCT05461677|EXPERIMENTAL|SAIRE smart walker|"The investigational device used in this clinical investigation is called the SAIRE smart walker. This first prototype version is equipped with a depth camera and two cheaper cameras. The depth camera is used to acquire high-quality data to train artificial intelligence (AI) models which then can run on the cheaper camera modules. Additionally, two ultrasonic sensors are applied to estimate the distance. A touch monitor is used to provide audiovisual feedback and display the user interface. Two LED strips are also attached to the walker to provide additional visual feedback to the patient.~The SAIRE smart walker gives feedback to the patient in terms of cadence using a metronome, and foot placement using the LED strips and the video stream presented on the monitor. Additionally, the walker will give information about step length and step width through AI-models."
61977565|NCT04566081|ACTIVE_COMPARATOR|iTALKbetter: reactive|"Participants will receive the reactive version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter reactive version is identical to the deterministic version for the first cycle only. From then on the words participants are trained on can change depending on their performance on that word over a number of cycles. Words that participants are failing to retrieve over a number of cycles will be retired from the therapy as they are deemed too difficult for a given participant. Similarly words that are correctly retrieved over a number of consecutive cycles are also retired from the therapy as they are deemed to have been learned. In this way iTALKbetter reactive version will gradually give each participant a personalised corpus of words that they can train on, focusing on the words where they stand to make the most improvements."
61977566|NCT01156311|EXPERIMENTAL|Glatiramer acetate (GA) and dimethyl fumarate|Participants taking a stable dose of GA for at least 12 months prior to the study remain on that dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
61977567|NCT01156311|EXPERIMENTAL|Interferon beta (IFNβ) and dimethyl fumarate|Participants taking a stable dose of one of the IFNβ products for at least 12 months prior to the study remain on that product and dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
61977568|NCT05481645|EXPERIMENTAL|Group one|"First-line treatment: TQB2450 injection 1200mg,d1/Q3W+Carboplatin Injection, AUC=5 mg/ml.min,d1/Q3W + Paclitaxel Injection 175mg/m2,d1/Q3W;6-8 cycles;~Maintenance treatment: TQB2450 injection, 1200mg，d1/Q3W"
61977569|NCT05481645|EXPERIMENTAL|Group two|First-line treatment: TQB2450 Injection 1200mg, d1/Q3W + Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W + Carboplatin Injection AUC=5 mg/ml.min, d1/Q3W + Paclitaxel Injection 175mg/m2, d1/Q3W ; 6-8 cycles; Maintenance treatment: TQB2450 injection+ Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W
61977570|NCT05481645|EXPERIMENTAL|Group three|"First-line treatment stage:~TQB2450 injection 1200mg, d1/Q3W + anlotinib hydrochloride capsules 8mg/qd, d8-21/Q3W+ chemotherapy（① Doxorubicin Hydrochloride Injection 60mg/㎡，d1/Q3W; or ② Gemcitabine Hydrochloride Injection 900mg/㎡, d1, d8/Q3W+ Docetaxel Injection 75mg/㎡, d8/Q3W）; 6-8 cycles;~Maintenance phase:~TQB2450 injection 1200mg, d1/Q3W+ Anlotinib hydrochloride capsules 10mg/qd, d8-21/Q3W"
61977571|NCT04980859|EXPERIMENTAL|Zebutinib Combined With CIT arm|Zebutinib Combined With FCR( under 60 years of age) or BR (over 60 years of age )
61977572|NCT01313767|EXPERIMENTAL|Meditoxin®|Botulinum toxin type A
61977573|NCT01313767|ACTIVE_COMPARATOR|Botox®|Botulinum Toxin type A
61977574|NCT02921698||FRED®|
61977575|NCT01659463|EXPERIMENTAL|ICON - low viscosity resin|APPLICATION OF A LOW VISCOSITY RESIN IN EARLY PROXIMAL CARIES LESIONS
61977576|NCT01659463|ACTIVE_COMPARATOR|INSTRUCTIONS ORAL HYGIENE|INSTRUCTION ORAL HYGIENE AND DIET AND TOOPICAL FLUORIDE APPLICATIONS
61977577|NCT04415255|EXPERIMENTAL|EPABI & IABPI|extrapleural autologous blood injection (EPABI) along with intraparenchymal autologous blood patch injection (IABPI)
61977578|NCT04415255|ACTIVE_COMPARATOR|IABPI-alone|intraparenchymal autologous blood patch injection (IABPI)
61977579|NCT05327686|ACTIVE_COMPARATOR|Arm I (standard of care immunotherapy)|Patients receive one of the following immunotherapy regimens per physician discretion: nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes every 3 weeks for 4 doses followed by nivolumab IV over 30 minutes every 2 or 4 weeks; pembrolizumab IV over 30 minutes every 3 or 6 weeks and axitinib PO BID; avelumab IV over 60 minutes every 2 weeks and axitinib PO BID; nivolumab IV over 30 minutes every 2 or 4 weeks and cabozantinib PO QD; OR pembrolizumab IV over 30 minutes every 3 or 6 weeks and lenvatinib PO QD. Treatment with immunotherapy continues in the absence of disease progression or unacceptable toxicity.
61977580|NCT05327686|EXPERIMENTAL|Arm II (SABR, standard of care immunotherapy)|Patients undergo SABR on 3 different days over 1-3 weeks and receive immunotherapy as in Arm I.
61977581|NCT04615663||face-to-face patients|During this visit, the investigator will complete the SMI score.
61977582|NCT04615663||Email patients|this visit at M0 + 7d will correspond to the emailing of the Mc_QoL and Burden_MCD questionnaires completed by the patient.
61977583|NCT01907880|ACTIVE_COMPARATOR|Pamidronate and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
61977584|NCT01907880|ACTIVE_COMPARATOR|Zoledronic acid and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
61977585|NCT03675607||Caregivers infants <2years old|Caregivers of infants under 2 years of age (parents or other), of any gender, who prepare complementary feeding regularly (more than once a week).
61977586|NCT05001074|EXPERIMENTAL|de novo cohort, extended release tacrolimus|de novo cohort, extended release tacrolimus
61977587|NCT05001074|ACTIVE_COMPARATOR|de novo cohort, immediate release tacrolimus|de novo cohort, immediate release tacrolimus
61977588|NCT05001074|EXPERIMENTAL|conversion cohort, extended release tacrolimus|conversion cohort, extended release tacrolimus
61977589|NCT05001074|ACTIVE_COMPARATOR|conversion cohort, immediate release tacrolimus|conversion cohort, immediate release tacrolimus
61977590|NCT02442960|ACTIVE_COMPARATOR|Cohort 1|Herbal treatment (SA100) 500 mg/day (250 mg twice per day)
61977591|NCT02442960|ACTIVE_COMPARATOR|Cohort 2|Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)
61977592|NCT04685915|EXPERIMENTAL|Addition of copanlisib to either ibrutinib or acalabrutinib|"During the 28-day study treatment cycles, participants will:~* Continue to take ibrutinib (daily) or acalabrutinib (twice a day) at a predetermined dose for as long as there are no serious side effects and disease progression~* Receive intravenous infusion of copanlisib at a predetermined dose days 1, 8 and 15 for cycles 1-6."
61977593|NCT02715076|EXPERIMENTAL|Ambient Temp 19°C & Passive Insulation|Ambient Temperature 19°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
61977727|NCT05461677|ACTIVE_COMPARATOR|Standard walker|The comparator device consist of a standard 4-wheeled walker
61977728|NCT05461677|ACTIVE_COMPARATOR|No walking aid|
61977594|NCT02715076|EXPERIMENTAL|Ambient Temp 19°C & Forced-air Warming|Ambient Temperature 19°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
61977595|NCT02715076|EXPERIMENTAL|Ambient Temp 21°C & Passive Insulation|Ambient Temperature 21°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
61977596|NCT02715076|EXPERIMENTAL|Ambient Temp 21°C & Forced-air Warming|Ambient Temperature 21°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
61977597|NCT02715076|EXPERIMENTAL|Ambient Temp 23°C & Passive Insulation|Ambient Temperature 23°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
61977598|NCT02715076|EXPERIMENTAL|Ambient Temp 23°C & Forced-air Warming|Ambient Temperature 23°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
61977599|NCT01075724|ACTIVE_COMPARATOR|Forced air|Forced Air Warming
61977600|NCT01075724|EXPERIMENTAL|Resistive HotDog Warming|Warming by resistive Warming
61977601|NCT01437215|EXPERIMENTAL|Fenestrated Endografting|
61977602|NCT03892590||Stable patient|Stable patients who admitted to ICU for observation.
61977603|NCT04729569|OTHER|Tested finish line preparation|Feather edge finish line preparation (Intervention)
61977604|NCT04729569|ACTIVE_COMPARATOR|Comparator finish line preparation|Deep chamfer finish line preparation (Comparator)
61977605|NCT06493396|EXPERIMENTAL|Opioid-free group|
61977606|NCT06493396|ACTIVE_COMPARATOR|Opioid group|
61977607|NCT04392947|ACTIVE_COMPARATOR|combined iTBS/cTBS|"Combined theta burst stimulation (TBS) of the left (intermittent TBS, iTBS) and right (continuous TBS, cTBS) dorsolateral prefrontal cortex (dlPFC; F3 and F4 according to EEG10/20 system). Each stimulation session will comprise 2 trains of 600 stimuli each applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s. In the same session, stimulation with cTBS will be applied continuously for 40 s. Intensity of iTBS/cTBS will be standardized at 80 % of the resting motor threshold (rMT).~Additionally, patients receive an electrical co-stimulation of the forehead. One electrode is fixed to FZ and the 2nd one is either fixed to the left forehead (iTBS) or the right forehead (cTBS), rectangular aligned to the upper edge of the FZ-electrode with a distance of 0.5 cm. Intensity of the co-stimulation is applied with 50% of TBS-intensity."
61977608|NCT04392947|SHAM_COMPARATOR|sham stimulation|Setup is identical to combined active iTBS/cTBS but TBS is not actively delivered
61977609|NCT04333784||exercise with BFR|Patients with rotator cuff tendinopathy will perform the exercises with a pneumatic cuff and blood flow restricted.
61977610|NCT04333784||Control|Patients with rotator cuff tendinopathy will perform the exercises without a pneumatic cuff.
61977611|NCT01093547|ACTIVE_COMPARATOR|Dianeal only|Patients in Dianeal during the daily exchanges and randomised to Dianeal during the long-dwell exchange
61977612|NCT01093547|ACTIVE_COMPARATOR|Dianeal; Extraneal long-dwell exchange|Patients in Dianeal during the daily exchanges and randomised to Extraneal during the long-dwell exchange
61977613|NCT00157950|EXPERIMENTAL|Gardasil™|Gardasil™ 3 dose regimen
61977614|NCT00157950|PLACEBO_COMPARATOR|Placebo|Gardasil™ matching placebo 3 dose regimen
61977615|NCT01355731||Registered Nurse|This is quality improvement study that is descriptive and is utilizing a convenience sample of direct care registered nurses employed full-time for at least one year at St. Jude Children's Research Hospital.Participants will take a onetime researcher generated therapeutic boundaries questionnaire which will describe behaviors and attitudes regarding therapeutic boundaries.
61977616|NCT01119131|ACTIVE_COMPARATOR|Arm 1|Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
61977617|NCT01119131|PLACEBO_COMPARATOR|Arm 2|Will be on placebo and 1000mg of calcium.
61977618|NCT05162131|EXPERIMENTAL|1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)|PB2452 Infusion
61977619|NCT05162131|EXPERIMENTAL|1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)|PB2452 Infusion
61977620|NCT05162131|EXPERIMENTAL|1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
61977621|NCT05162131|EXPERIMENTAL|2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
61977622|NCT05162131|EXPERIMENTAL|3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
61977623|NCT05162131|EXPERIMENTAL|4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
61977624|NCT05162131|EXPERIMENTAL|5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
62167774|NCT05417555|SHAM_COMPARATOR|Sham LIFUP|"No administration of LIFUP. The device will be affixed to the user's head but not turned on.~Additionally, if at the end of the study, the treatment has been shown to be effective, placebo subjects will be offered a free session using the optimally effective dose, if they consented to being contacted for this purpose."
62167775|NCT02281214|EXPERIMENTAL|blood sample, biopsy|
62167776|NCT03549299|EXPERIMENTAL|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10\^4 cells per patient
61977625|NCT02632539|ACTIVE_COMPARATOR|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
61977626|NCT02632539|EXPERIMENTAL|Manual air-impingement operation|A method which we invented to clear subglottic secretion
61977627|NCT00128778|EXPERIMENTAL|Arm A: PLD|Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
61977628|NCT00128778|NO_INTERVENTION|Arm B: Observation|Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.
61977629|NCT04263207||anti-Tat Ab positive subjects|
61977630|NCT04263207||anti-Tat Ab negative subjects|
61977631|NCT03009565||study patients|Study participants will be individuals aged 30-80 arriving to Rabin Medical Center with suspected CAD and able to provide informed consent. Participants will provide medical, lifestyle, and nutritional questionnaires. Blood pressure and heart-rate measurements will be taken during hospitalization as well as blood tests and fecal samples and/or rectal swabs. In order to evaluate and/or treat suspected atherosclerotic disease patients will undergo cardiac CT and/or cardiac catheterization in accordance with the standard of care and based upon the decision of the treating cardiologist. Diagnostics and treatment options will be based only on their medical condition and regardless of the aforementioned study protocol.
61977632|NCT03009565||control|The control group will be selected to represent an age, sex and cardiovascular risk factors -matched group without current CAD. Further exclusion criteria in the control group will be antibiotic consumption in the following 3 months, inflammatory bowel disease, or other significant chronic disease that may influence the microbiota (such as cancer, autoimmune disease, and chronic immunosuppressive treatment). The control group will undergo cardiac CT or coronary angiography according to clinical suspicion in order to rule-out CAD and irrespective of the study protocol.
61977633|NCT03116607|NO_INTERVENTION|Control|The control group will receive the usual hospital care. In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
61977634|NCT03116607|EXPERIMENTAL|Intervened|"The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge.~In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.~patient education/ recommendations to the health team"
61977635|NCT03451344|EXPERIMENTAL|Integrated rehabilitation group|Participants will receive the standardized community-based rehabilitation and simultaneously receive a 6-month integrated rehabilitation based on the Community-based Addiction Rehabilitation Electronic System.
61977636|NCT03451344|ACTIVE_COMPARATOR|Community-based rehabilitation group|Participants will receive the standardized community-based rehabilitation.
61977637|NCT03758144|ACTIVE_COMPARATOR|study|
61977638|NCT03758144|NO_INTERVENTION|CONTROL GROUP|
61977639|NCT00561080|EXPERIMENTAL|Single Dose of Zostavax|Zostavax 0.65mL intramuscular injection administered on Day 0
61977640|NCT00561080|EXPERIMENTAL|Zostavax - Day 0 and Month 1|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
61977641|NCT00561080|EXPERIMENTAL|Zostavax - Day 0 and Month 3|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
61977642|NCT06014489|EXPERIMENTAL|single arm arm extension phase|prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1
62167777|NCT03549299|EXPERIMENTAL|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10\^5 cells per patient
62167778|NCT03549299|EXPERIMENTAL|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10\^5 cells per patient
62167779|NCT03549299|EXPERIMENTAL|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10\^6 cells per patient
62167780|NCT05834647|EXPERIMENTAL|Group P|Drug: prilocaine 2% Dosage : 50 mg prilocaine 2% (2.5 mL volume)
62167781|NCT05834647|ACTIVE_COMPARATOR|Group L|Drug: hyperbaric lidocaine 5% Dosage : 50 mg hyperbaric lidocaine 5% (1 mL volume)
62167782|NCT01270217|EXPERIMENTAL|Brief motivational interview|
62167783|NCT01270217|NO_INTERVENTION|No discussion|
62167784|NCT02030847|EXPERIMENTAL|Arm1|"phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia."
62167785|NCT02965599|EXPERIMENTAL|GSK3117391|Subjects will receive GSK3117391 (Dose A) for 28 days.
62167786|NCT02965599|PLACEBO_COMPARATOR|Placebo|Subjects will receive placebo for 28 days.
62167787|NCT00016978|EXPERIMENTAL|Arm I|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium and fluorouracil IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a confirmed complete response for 2 consecutive courses may discontinue study treatment at the investigators discretion. Quality of life is assessed at baseline, approximately every 6-8 weeks during treatment, and then after the last course of treatment.
62167788|NCT03775278|EXPERIMENTAL|Experimental|PHP-303, multiple oral dose, up to 5 ascending dose cohorts
61977643|NCT05642754|ACTIVE_COMPARATOR|GRADE + margin of error|"Overall uncertainty using GRADE\* language AND margin of error around main result~\* Based on the Cochrane Effective Practice and Organisation of Care Group's guidance for communicating the certainty of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assessing the certainty of evidence"
61977644|NCT05642754|ACTIVE_COMPARATOR|Colloquial language AND margin of error|Colloquial language developed to describe overall study uncertainty AND margin of error around main result
61977645|NCT05642754|ACTIVE_COMPARATOR|No overall uncertainty language AND margin of error|No overall uncertainty language AND margin of error around main result
61977646|NCT05642754|ACTIVE_COMPARATOR|GRADE -No margin of error|"Overall uncertainty using GRADE\* language and NO margin of error around main result~\* Based on the Cochrane Effective Practice and Organisation of Care Group's guidance for communicating the certainty of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assessing the certainty of evidence"
61977647|NCT05642754|ACTIVE_COMPARATOR|Colloquial - No margin of error|Colloquial language developed to describe overall study uncertainty and NO margin of error around main result
62167789|NCT03775278|PLACEBO_COMPARATOR|Placebo|Placebo, multiple oral dose, up to 5 ascending dose cohorts
62167790|NCT03436433|ACTIVE_COMPARATOR|Lacosamide|Enrolled subjects will be randomized to receive Lacosamide.
62167791|NCT03436433|ACTIVE_COMPARATOR|Levetiracetam|Enrolled subjects will be randomized to receive Levetiracetam.
62167792|NCT03436433|NO_INTERVENTION|No anti-epileptic|Enrolled subjects will be randomized to not receive anti-epileptic drugs.
62167793|NCT02756299|ACTIVE_COMPARATOR|Device and Standard Care|Positive Airway Pressure Device and Standard Support
62167794|NCT02756299|ACTIVE_COMPARATOR|Device and Educational Care|Positive Airway Pressure Device and Educational Support
62167795|NCT06584721|ACTIVE_COMPARATOR|Anti-pronation taping (Low dye taping) + Conventional therapy|Anti-pronation taping and conventional
62167796|NCT06584721|OTHER|Short Foot Exercises + Conventional Study|Short foot exercises + Conventional therapy
62167797|NCT00626158|EXPERIMENTAL|Gem/Cape|
62167798|NCT01374971|OTHER|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks with arthroscopic synovial tissue biopsy pre- and post-treatment.
62167799|NCT03323983||Normal lung clearance index|
62167800|NCT03323983||Elevated lung clearance index|
62167801|NCT03514745|ACTIVE_COMPARATOR|GlideScope group|After the induction of anesthesia, endobronchial intubation is performed using the GlideScope.
62167802|NCT03514745|EXPERIMENTAL|Lighted stylet group|After the induction of anesthesia, endobronchial intubation is performed using a lighted stylet.
62167803|NCT02209688|EXPERIMENTAL|ESR 1150 CL dose escalation fasted|
62167804|NCT02209688|EXPERIMENTAL|ESR 1150 CL fed|
62167805|NCT02209688|PLACEBO_COMPARATOR|Placebo|
62167806|NCT06645509|EXPERIMENTAL|Victorhy (dose 1) (TTB gel)|Participants will receive Victorhy (TTB, dose 1) topically to both hands, once daily for 28 days (20 participants)
62167807|NCT06645509|EXPERIMENTAL|Victorhy (dose 2) (TTB gel)|Participants will receive Victorhy (TTB, dose 2) topically to both hands, once daily for 28 days (20 participants)
62167808|NCT06645509|PLACEBO_COMPARATOR|Vehicle gel|Participants will receive a vehicle gel topically to both hands, once daily for 28 days (20 participants)
62167809|NCT05076955|EXPERIMENTAL|Treatment of Diabetic Foot Ulcer|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
62167810|NCT05312021|EXPERIMENTAL|IMR-687|Participants randomly assigned to this arm will take IMR-687 orally with food BID for 16 weeks. IMR-687 dosing will be 300 mg BID for participants weighing less than 100 kg and 400 mg BID for participants weighing 100 kg or more.
62167811|NCT05312021|PLACEBO_COMPARATOR|Placebo|Participants randomly assigned to this arm will take placebo orally with food BID for 16 weeks.
62167812|NCT06244745|EXPERIMENTAL|Study group: Oral administration of letrozole|Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture. day for 5 days starting the night of the follicular puncture.
62167813|NCT06244745|NO_INTERVENTION|Control group: No specific treatment of letrozole|No specific treatment with letrozol
62167814|NCT06388785||QDENGA Vaccinated|Participants who have received QDENGA vaccine will be prospectively surveyed and regularly contacted to obtain data for up to 15 months post-vaccination.
62167815|NCT03261713|EXPERIMENTAL|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
62167816|NCT03261713|ACTIVE_COMPARATOR|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
62167817|NCT05399082|EXPERIMENTAL|Standard forceps biopsy then research cryoprobe biopsy|Subjects scheduled for a biopsy of lung lesions using robotic bronchoscopy as part of their standard of care will have the lung lesion biopsied using forceps first followed by cryoprobe.
62167818|NCT05399082|EXPERIMENTAL|Research cryoprobe biopsy then standard forceps biopsy|Subjects scheduled for a biopsy of lung lesions using robotic bronchoscopy as part of their standard of care will have the lung lesion biopsied using the cryoprobe first followed by forceps.
62167819|NCT00614536||001|
62167820|NCT02604147|SHAM_COMPARATOR|Simulated inspiratory muscle training|Inspiratory muscle training with load of 15% of maximal inspiratory pressure.
62167821|NCT02604147|EXPERIMENTAL|Inspiratory muscle training group|Inspiratory muscle training with initial load of 50% of maximal inspiratory pressure.
62167822|NCT04759599|ACTIVE_COMPARATOR|Group 1|Group 1 will undergo Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks
62167823|NCT04759599|ACTIVE_COMPARATOR|Group 2|Group 2 will undergo Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
62167824|NCT04061967|OTHER|HPV self sampling test ordered|An invitation to order a HPV self sampling test through an online application will be sent by SMS or electronic letter.
62167825|NCT01088347|EXPERIMENTAL|Advanced cervical cancer patients|
62167826|NCT03165344|EXPERIMENTAL|hydrocortisone group|
62167827|NCT03165344|PLACEBO_COMPARATOR|prednisone grope|
62167828|NCT03997708|ACTIVE_COMPARATOR|Group A|MED-LFD Diet (diet A) for 2 - 6 weeks. After this period there will be a reintroduction phase protocol that will last 6 - 8 weeks.
62167829|NCT03997708|ACTIVE_COMPARATOR|Group B|Diet according to guidelines from the National Institute for Health and Care Excellent (NICE) Managing IBS (diet B) for 4 weeks.
62167830|NCT00747578||1|"AS patients who fit the modified New York criteria (1984)~Exclusion criteria :~1. Patients who have cognitive impairment.~2. Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~3. Patients who are less than 18 years old or older than 65 years old.~4. Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
62167831|NCT00747578||2|"RA patients who fit the American College of Rheumatology (ACR) criteria (1987)~Exclusion criteria :~1. Patients who have cognitive impairment.~2. Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~3. Patients who are less than 18 years old or older than 65 years old.~4. Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
62167832|NCT00747578||3|"SLE patients who fit the ACR revised criteria for the classification of SLE (1997)~Exclusion criteria :~1. Patients who have cognitive impairment.~2. Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~3. Patients who are less than 18 years old or older than 65 years old.~4. Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
62167833|NCT01114659||Women with PCOS|
62167834|NCT01114659||Normal Control|
62167835|NCT04978688|EXPERIMENTAL|Relugolix|Participants received relugolix 40 milligrams (mg) alone for 6 weeks.
62167836|NCT04978688|EXPERIMENTAL|Relugolix + E2/NETA|Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks.
62167837|NCT05453292|EXPERIMENTAL|EUS guided RFA|This group is comprised by patients with diagnosis of resectable GISTs with/without liver metastasis. The patients included are naïve (without previous treatment) or patients with stable/progressive disease following systemic therapy with tyrosine kinase inhibitors.
62167838|NCT01109602|EXPERIMENTAL|Arm 1: Yoga Group|"Yoga Group, 8 week bi-weekly in-person yoga training focused on strength, flexibility, and balance~Yoga focused on strength, flexibility, and balance"
62167839|NCT01109602|EXPERIMENTAL|Arm 2: Yoga Group Plus|"Yoga Group Plus: 8 week, bi-weekly in-person yoga training focused on strength, flexibility, and balance paired with almost daily at home yoga focused on breathing and relaxation.~Yoga focused on strength, flexibility, and balance~Data for both yoga groups were combined for analyses as there were not any differences between these two groups."
62167840|NCT01109602|NO_INTERVENTION|Arm 3: Wait list control group|wait-list control: will be assessed before and after 8 weeks. Will then be offered the 8 week yoga intervention.
62167841|NCT02943109|EXPERIMENTAL|High tech, high touch|Patient receives the full version of MyChart Bedside. Patient receives training/intervention from technology navigator
62167842|NCT02943109|EXPERIMENTAL|Low tech, high touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives training/intervention from technology navigator
62167843|NCT02943109|EXPERIMENTAL|High tech, low touch|Patient receives the full version of MyChart Bedside. Patient receives online training, only
62167844|NCT02943109|EXPERIMENTAL|Low tech, low touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives online training, only
62167845|NCT02977780|ACTIVE_COMPARATOR|Temozolomide|"* Daily Radiation for a maximum of 49 days.~* Temozolomide will be administered orally on a daily dosing schedule~* Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~* Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)"
62167846|NCT02977780|EXPERIMENTAL|Neratinib with Temozolomide|"* Daily Radiation for a maximum of 49 days.~* Temozolomide will be administered orally on a daily dosing schedule~* Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~* Neratinib will be taken post radiation at a daily oral pre-determine dose"
62167847|NCT02977780|EXPERIMENTAL|QBS10072S|"Daily Radiation for a maximum of 49 days.~QBS10072S will be administered on Day 1 of Radiation Treatment~QBS10072S will be administered post- radiation for up to 6 cycles"
62167848|NCT06544421|EXPERIMENTAL|1 week : What is Stroke, Taking Care of the Individual with Physical Needs-1|Session 1 What is Stroke, The Importance of Post-Stroke Rehabilitation, Obtaining accurate health information, Contacting the Health Team, Difficult caregiving behaviors Support mechanisms in stroke patient care
62167849|NCT06544421|EXPERIMENTAL|Week 1: What is a Stroke, Caring for Someone with Physical Needs-2|Session 2 Personal Care, Prevent pressure sores Position and handling techniques Pain In-bed exercises Self-care Nutrition Sleep Speech \& Communication Medication Management Emotional and Cognitive Changes in the Stroke Individual
62167850|NCT06544421|EXPERIMENTAL|Week 2: Stress of Care, Becoming resistant to stress Coping with stress-1|Session 1 Caregiving role barriers and facilitators Positive Aspects of Caregiving Care Stress and Its Causes, Reaction to Stress Maintaining emotional balance in the caregiving process
62167851|NCT06544421|EXPERIMENTAL|Week 2: Stress of Care, Becoming resistant to stress Coping with stress-2|Self-knowledge and motivation Maintenance and Time Management Controlling the Body in the Caregiving Process Breathing and relaxation
62167852|NCT06544421|EXPERIMENTAL|Week 3: Supporting oneself in the caregiving process and becoming resistant to stress-1|"Session 1:~Personal space and comfort in the care process Taking time for yourself Unreasonable beliefs and mental regulation technique Tackling anxieties"
62167853|NCT06544421|EXPERIMENTAL|Week 3: Supporting oneself in the caregiving process and becoming resistant to stress-2|The importance of nutrition The importance of physical activity Regulation of sleep
62167854|NCT06544421|EXPERIMENTAL|4 week: Control of emotions and spirituality in the process of care-1|Anger management Unleashing emotions and social relationships Use of humor
62167855|NCT06544421|EXPERIMENTAL|4 week: Control of emotions and spirituality in the process of care-2|Communication and Empathy Spirituality and religious coping Pray Be happy
62167856|NCT02208271||Control|pre-operative total hip patients with no existing total hip implant
62167857|NCT02208271||Metal on polyethylene|patients who have a failed metal on polyethylene total hip implant and are presenting for revision surgery
62167858|NCT02208271||Metal on Metal|patients who have a failed metal on metal total hip implant and are presenting for revision surgery
62167859|NCT00724750|EXPERIMENTAL|G-SUC|Gauze suction (G-SUC) Negative Pressure Wound Therapy, continuous wall suction at 75 to 80 mm Hg was applied and dressings were changed daily.
62167860|NCT00724750|ACTIVE_COMPARATOR|Vacuum Assisted Closure|Vacuum Assisted Closure Device (VAC) Negative Pressure Wound Therapy, continuous suction at 75 to 125 mm Hg and the dressing was changed every 48 hours.
62167861|NCT05865782|EXPERIMENTAL|Schoolyard reconstruction|Schools undertaking schoolyard reconstruction will act as both control and intervention schools. Each year, a cross-sectional sample of 2nd and 5th grade children will be measured in all participating schools.
62167862|NCT04089332|EXPERIMENTAL|Enrolled, eligible|Single arm for eligible subjects
62734309|NCT06094244|EXPERIMENTAL|Subgroup Ib Patients with dyslipidemia Received statins, recommended to take medicine for 90 days.|Patients with dyslipidemia diagnosed during hospitalization who received statins and were recommended to take this medicine for 90 days since they occurrence of SICH.
62167863|NCT00701506|EXPERIMENTAL|1|"15 Patients (may be expanded) will receive stimulation with the following parameters:~* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings."
62167864|NCT00701506|PLACEBO_COMPARATOR|2|"5 Patients (may be expanded) will receive stimulation with the following parameters:~* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings."
62167865|NCT02950870|EXPERIMENTAL|group treated|this group will be treated with Ombitasvir-Paritaprevir-Ritonavir (12,5 mg/75 mg/50 mg) and Dasabuvir ( 250 mg) with or without Ribavirina every day , for 12 weeks.
62167866|NCT02950870|NO_INTERVENTION|group untreated|Control group
62167867|NCT03092323|EXPERIMENTAL|Treatment|Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.
62167868|NCT03092323|NO_INTERVENTION|Standard of Care|Neoadjuvant radiotherapy followed by surgical resection.
62167869|NCT02409823||patients on atypical antipsychotics|
62167870|NCT01236963|EXPERIMENTAL|Essential oils mouthrinse|Subjects use the essential oils mouthrinse
62167871|NCT01236963|ACTIVE_COMPARATOR|Dental floss|Subjects use dental floss
62167872|NCT02338206|ACTIVE_COMPARATOR|Long + Growth hormone|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously along with Growth hormone (Norditropin, Novo nordisk) co-treatment daily in a dose of 2.5 mg S.C. till the day of hCG administration.. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG and growth hormone, were continued till the day of hCG administration.
62167873|NCT02338206|NO_INTERVENTION|Long protocol only|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG, were continued till the day of hCG administration.
62167874|NCT05562492|EXPERIMENTAL|Closed-loop insulin delivery (CamAPS FX)|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) A smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data.~Participants will use the closed-loop system for the next 26 weeks at home"
62167875|NCT05562492|ACTIVE_COMPARATOR|Conventional insulin therapy with CGM|Usual insulin therapy (injections or pump) and study CGM for 26 weeks at home.
62167876|NCT04357522|EXPERIMENTAL|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose
62167877|NCT04357522|ACTIVE_COMPARATOR|Positive control group|Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose
62167878|NCT02648282|EXPERIMENTAL|Cyclophosphamide, Pembrolizumab, GVAX Pancreas Vaccine, SBRT|
62167879|NCT02544841|EXPERIMENTAL|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is the treatment condition. SSI is an in-person, individual-level, clinic-based intervention that aims to reduce risky sexual behaviors among sexually active adolescent females.
62167880|NCT02544841|ACTIVE_COMPARATOR|Female Sexual Health|Female Sexual Health is the control counterfactual condition. It is an individual-level, information-only sex education program that aims to increase participants' knowledge on various topics related to STIs.
62167881|NCT05264649|EXPERIMENTAL|acupuncture group|Stainless steel, disposable, sterile needles choosing based on the needs of different body parts (0.22 gauge x 25mm, 0.22 gauge x 40mm, or 0.25 gauge x 100mm) were inserted to acupoints at traditional depths and angles.
62167882|NCT05264649|EXPERIMENTAL|Chinese medicine group|The Chinese medicine group used Guizhi-Shaoyao-Zhimu decoction (GZSD) as their medical intervention. The GZSD samples were made and packed by Sun Ten Pharmaceutical Co. Ltd., a firm that meets the requirements of the good manufacturing practice (GMP) certification in Taiwan. Every 4g of concentrated GZSD was sealed in an isolated paper drug bag.
62167883|NCT05264649|EXPERIMENTAL|combined group|The combined group would have both acupuncture and Chinese medicine interventions.
62167884|NCT02573883|EXPERIMENTAL|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate
62167885|NCT02573883|ACTIVE_COMPARATOR|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate.
62167886|NCT02445781|EXPERIMENTAL|90 mg/dl glucose clamp|Glucose clamp intervention of 90 mg/dl maintained for 90 minutes.
62167887|NCT02445781|EXPERIMENTAL|70 mg/dl glucose clamp|Glucose clamp intervention of 70 mg/dl maintained for 90 minutes.
62167888|NCT02445781|EXPERIMENTAL|60 mg/dl glucose clamp|Glucose clamp intervention of 60 mg/dl maintained for 90 minutes.
62167889|NCT02445781|EXPERIMENTAL|50 mg/dl glucose clamp|Glucose clamp intervention of 50 mg/dl maintained for 90 minutes.
62167890|NCT02346942||Patients who have no history of bDMARD therapy use|
62167891|NCT02346942||Patients who have a prior history of bDMARD therapy use|
62167892|NCT03300661|EXPERIMENTAL|Mediterranean Style|Educational intervention with personalized suggestions to improve diet and physical activity
62167893|NCT01568021||OZURDEX®|Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.
62167894|NCT03845517|PLACEBO_COMPARATOR|Placebo|Placebo
62167895|NCT03845517|EXPERIMENTAL|PF-06700841 15 mg|PF-06700841 15 mg
62167896|NCT03845517|EXPERIMENTAL|PF-06700841 30 mg|PF-06700841 30 mg
62167897|NCT03845517|EXPERIMENTAL|PF-06700841 45 mg|PF-06700841 45 mg
62167898|NCT00957671|EXPERIMENTAL|Human Growth Hormone|recombinant human growth hormone (rhGH) self administered daily for one year
62167899|NCT00274846|EXPERIMENTAL|Intent-to-Treat|All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10\^7/kg.)
62167900|NCT04809298|OTHER|Free-hand lumbar punction|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the free-hand method.
62167901|NCT04809298|ACTIVE_COMPARATOR|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
62167902|NCT02125656|NO_INTERVENTION|Regular Sleep|A single night of regular sleep
62167903|NCT02125656|NO_INTERVENTION|Sleep Deprivation|A single night of sleep deprivation
62167904|NCT02125656|EXPERIMENTAL|HIIT + Regular Sleep|2 weeks of HIIT and after a single night of regular sleep.
62167905|NCT02125656|EXPERIMENTAL|HIIT + Sleep Deprivation|2 weeks of HIIT and after a single night of sleep deprivation
62167906|NCT05291585|EXPERIMENTAL|the dedicated venous sinus thrombectomy stent|Patients diagnosed with acute or subacute venous sinus thrombosis within 28days from the onset of symptoms to endovascular treatment, regardless of whether anticoagulation has been performed. The dedicated venous sinus thrombectomy stent can be used to remove the thrombus to restore sinus blood flow.
62167907|NCT05291585|ACTIVE_COMPARATOR|balloon catheter thrombectomy|Intracranial thrombectomy was balloon catheter in conjunction with aspiration performed with a control product
62167908|NCT06646055|EXPERIMENTAL|Cadonilimab(q4w) + AK112 + nab-paclitaxel + gemcitabine(phase Ib)|Cadonilimab will be administered at a selected dose every 4 weeks (q4w). AK112 will be administed at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.
62167909|NCT06646055|EXPERIMENTAL|Cadonilimab(q2w) + AK112 + nab-paclitaxel + gemcitabine(phase Ib)|Cadonilimab will be administered at a selected dose every 2 weeks (q2w). AK112 will be administed at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.
62167910|NCT06646055|EXPERIMENTAL|Cadonilimab + AK112 + nab-paclitaxel + gemcitabine(phase II)|Cadonilimab will be administered at a selected dose and frequency from phase Ib. AK112 will be administered at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.
62167911|NCT06646055|EXPERIMENTAL|AK112 + nab-paclitaxel + gemcitabine(phase II)|AK112 will be administered at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.
62167912|NCT06646055|ACTIVE_COMPARATOR|nab-paclitaxel + gemcitabine(phase II)|Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.
62167913|NCT00421122|ACTIVE_COMPARATOR|1|Bricasol®
62167914|NCT00421122|EXPERIMENTAL|2|Bricasol® + Pulmicort®
62167915|NCT00421122|EXPERIMENTAL|3|Bricasol® + Symbicort®
62167916|NCT04501107|EXPERIMENTAL|BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Subcutaneous administration of Biochaperone insulin lispro formulation made from a freeze-dried of BioChaperone reconstituted with Humalog® at a dose of 0.2 U/Kg Body Weight (BW).
62167917|NCT04501107|EXPERIMENTAL|Ready-to-use BioChaperone insulin lispro (IMP2)|Subcutaneous administration of ready-to-use Biochaperone insulin lispro formulation at a dose of 0.2 U/Kg BW.
62167918|NCT04501107|ACTIVE_COMPARATOR|US-approved Humalog® (IMP3)|Subcutaneous administration of US-approved Humalog® at a dose of 0.2 U/Kg BW.
62167919|NCT04501107|ACTIVE_COMPARATOR|EU-approved Humalog® (IMP4)|Subcutaneous administration of EU-approved Humalog® at a dose of 0.2 U/Kg BW.
62167920|NCT05731414|EXPERIMENTAL|Individual CBTp + Group Sham CR|"Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness.~Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion."
62167921|NCT05731414|EXPERIMENTAL|Group CR + Individual Befriending (Sham CBTp)|"Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials.~Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth."
62167922|NCT05731414|EXPERIMENTAL|Individual CBTp + Group CR|"Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness.~Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials."
62167923|NCT06366724|ACTIVE_COMPARATOR|Pyridostigmine/LDN|Pyridostigmine will be taken as liquid suspension three times a day, scaling up from 20mg (1.67mL) to 60mg (5mL) (180mg/day). Low dose naltrexone will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL (4.5mg/day).
62167924|NCT06366724|ACTIVE_COMPARATOR|Pyridostigmine/Placebo|Pyridostigmine will be taken as liquid suspension three times a day, scaling up from 20mg (1.67mL) to 60mg (5mL) (180mg/day). Placebo will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL.
62167925|NCT06366724|ACTIVE_COMPARATOR|Placebo/LDN|Placebo will be taken as liquid suspension three times a day, scaling up from 1.67mL to 5mL. Low dose naltrexone will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL (4.5mg/day).
62167926|NCT06366724|PLACEBO_COMPARATOR|Placebo/Placebo|Placebo will be taken as liquid suspension three times a day, scaling up from 1.67mL to 5mL. Placebo will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL .
62167927|NCT05895110|EXPERIMENTAL|Experimental group|1 dose of the test recombinant novel coronavirus vaccine (CHO cell) was injected into the deltoid muscle of the subject's upper arm
62167928|NCT02511171|NO_INTERVENTION|No intervention|Subjects do not receive osteopathic care
62167929|NCT02511171|EXPERIMENTAL|Cranial osteopathic manipulative treatment|Subjects receive individualised osteopathic treatment
62167930|NCT06159114|EXPERIMENTAL|Ningmitai Capsule Group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules and celexcoib placebo, 0.2 g/ capsule, 1 capsule, qd each time, after meals, for 6 weeks.
62167931|NCT06159114|ACTIVE_COMPARATOR|Celecoxib Capsule Group|Patients take celexcoib capsule, 0.2 g/capsule, qd, 1 capsule and Ningmitai placebo, 0.38 g/ capsule, 4 cpsule, tid each time, after meals, for 6 weeks.
62167932|NCT06159114|EXPERIMENTAL|Combined Group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules and celexcoib capsule, 0.2 g/ capsule, 1 capsule, qd each time, after meals, for 6 weeks.
62167933|NCT04614285|EXPERIMENTAL|Partial excavation|The treatment will be performed after applying local anesthetic according to individual needs. The intervention group will receive partial removal of the carious lesion; In the inner part of the lesion, the caries removal will be limited to reach leathery or slightly soft dentin by probing. The restorations will be placed according to evidence based methods and the material used according to the operators material of choice.
62167934|NCT04614285|ACTIVE_COMPARATOR|Complete excavation|The treatment will be performed after applying local anesthetic according to individual needs. The control group will receive the same treatment procedure as the intervention group, but the excavation procedure will include total removal of the carious tissue. The total caries removal will be ensured with hardness on probing and the visual examination. Photographs will be used as benchmark.
62167935|NCT02222844|NO_INTERVENTION|Preoperative CT scan|CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)
62167936|NCT02222844|EXPERIMENTAL|Preoperative MRI scan|Standard treatment plus an additional MRI scan before surgery
62167937|NCT02222844|NO_INTERVENTION|Observational|Observational only
61977648|NCT05642754|PLACEBO_COMPARATOR|No overall uncertainty language AND no margin of error|No overall uncertainty language and NO margin of error around main result
61977649|NCT03779789|EXPERIMENTAL|vortioxetine|
61977650|NCT03779789|ACTIVE_COMPARATOR|SSRIs|
61977651|NCT04388267||Septic shock|Patients with septic shock, according to the Sepsis 3 definition, regardless of the origin
61977652|NCT04388267||Major vascular surgery|Patients who underwent elective or emergent major vascular surgery abdominal aortic surgery (open or endovascular surgery)
61977653|NCT01839773|EXPERIMENTAL|DHP107 (oral paclitaxel)|DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
61977654|NCT01839773|ACTIVE_COMPARATOR|Taxol® (IV paclitaxel)|Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
61977655|NCT02251002||Control|no history of TBI or neurologic disorder
61977656|NCT02251002||mTBI|documented past mild to moderate TBI
61977657|NCT01739478|EXPERIMENTAL|Non-packing of abscess cavity|
61977658|NCT01739478|OTHER|Packing of abscess cavity|Current practice
61977659|NCT05898815||Healthy subjects and stroke patients|Healthy subjects and stroke patients
61977660|NCT03930043||Health Control|
61977661|NCT03930043||Non-gastrointestinal Lymphoma|
61977662|NCT03930043||Gastric Lymphoma|
61977663|NCT03930043||Intestinal Lymphoma|
61977664|NCT05404919|OTHER|Recipient of Hepatitis B NAT+ Donor|All subjects will then be treated with Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide (choice of specific drug to be based on long-term cost, clinical response, and renal function)
61977665|NCT03022344|SHAM_COMPARATOR|Healthy|Patients in this cohort consist of 100 healthy patients
61977666|NCT03022344|SHAM_COMPARATOR|Diabetes mellitus|Newly diagnosed (\< 1 year) diabetes patients clinically classified as type-2 diabetes patients of both sex
61977667|NCT01914744|EXPERIMENTAL|entecavir|entecavir 0.5 mg/day PO
61977668|NCT01914744|ACTIVE_COMPARATOR|lamivudine|lamivudine 100 mg/day PO
61977669|NCT02255981|EXPERIMENTAL|Acupuncture group|"Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months~."
61977670|NCT04107233|EXPERIMENTAL|Intervention|Audit and feedback directed at family physicians, including reports a one-on-one meeting.
61977671|NCT04107233|NO_INTERVENTION|Control|Usual care; may receive the intervention at the end of the study if successful
61977672|NCT04715763|ACTIVE_COMPARATOR|Telmisartan (80 mg)|Telmisartan 80 mg (given as two 40 mg encapsulated tablets) given orally each day x 21 days
61977673|NCT04715763|PLACEBO_COMPARATOR|Placebo|Two placebo capsules given orally each day x 21 days
61977674|NCT02006381||Age 3-6|This will include 10 typically developing boys age 3-6
61977675|NCT02006381||Age 7-12|This will include 10 typically developing boys age 7-12
61977676|NCT02006381||Age 13-17|This will include 10 typically developing boys age 13-17
61977677|NCT04961645|EXPERIMENTAL|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants will have two study visits. During the first visit, participants will have an fMRI scan to identify the OPA location in each individual participant. During the second visit, participants will receive rTMS. Each visit lasts approximately 90 minutes.
61977678|NCT06471894||CD|Crohn's disease
61977679|NCT06471894||UC|ulcerative colitis
61977680|NCT06471894||HC|healthy controls
61977681|NCT05366803|EXPERIMENTAL|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults. Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times.
61977682|NCT05366803|NO_INTERVENTION|Usual Activity Control|Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times. Participants carry about their normal activities during this period.
61977683|NCT01865539|ACTIVE_COMPARATOR|Custom Foot Orthotic|Custom foot orthotic
61977684|NCT01865539|SHAM_COMPARATOR|Sham Orthotic|Will be a sham orthotic that will be the same as the actual orthotic without the custom support pads.
61977729|NCT02237950|EXPERIMENTAL|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
62167938|NCT02948205|EXPERIMENTAL|3D group|infertility patient get TU-LESS by 3D Laparoscopy
62167939|NCT02948205|OTHER|normal group|infertility patient get normal laparoscopic surgery
62167940|NCT04472442|EXPERIMENTAL|High Intensity Training with Intermittent Hypoxia|The primary goal will be provide acute intermittent hypoxia (9% PO2; 1 min on 1 min off) prior to stepping training while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into \~10 minute increments (\~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
62167941|NCT04472442|SHAM_COMPARATOR|High Intensity Training with Sham Hypoxia|The primary goal will be provide sham intermittent hypoxia (20% PO2) prior to performing continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into \~10 minute increments (\~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
62167942|NCT01737034|EXPERIMENTAL|low GI, low GI|low GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
62167943|NCT01737034|EXPERIMENTAL|low GI, high GI|low GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
62167944|NCT01737034|EXPERIMENTAL|high GI, low GI|high GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
62167945|NCT01737034|EXPERIMENTAL|high GI, high GI|high GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
62734310|NCT02665559||Hypogonadism group|a cross-sectional and prospective study, in HIV-infected men less than 50 years old, with HIV-RNA ≤ 50 cop/mL under ART who had never presented AIDS
62167946|NCT05156216|EXPERIMENTAL|Experimental video|Knee OA educational video based on an empowerment discourse delivered online and embedded within the survey.
62167947|NCT05156216|ACTIVE_COMPARATOR|Control video|Knee OA educational video based on a disease and impairment discourse delivered online and embedded within the survey.
62167948|NCT04403178||Children who develops hip displacement|Patient group 1 includes children who developed a Migration Percentage of \> 40 % in either hip over a follow-up period of three years.
62167949|NCT04403178||Children who do not develops hip displacement|Patient group 2 includes children who did not develop a Migration Percentage of \> 40 % on either hip over a follow-up period of three years
62167950|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
62167951|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
62167952|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
62167953|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
62167954|NCT02113540|PLACEBO_COMPARATOR|placebo group|taking atorvastatin like placebo 12 hours before the procedure
62167955|NCT02113540|NO_INTERVENTION|long term statin group|taking atorvastatin for a long time before entering the study (their routine treatment)
62167956|NCT02113540|EXPERIMENTAL|preoperation statin group|taking atorvastatin 12 hours before the procedure
62167957|NCT01309256||R-robot group|retrospective robot group
62167958|NCT01309256||P-robot group|prospective robot group
62167959|NCT01309256||P-laparoscopic group|prospective laparoscopic group
62167960|NCT05272787|EXPERIMENTAL|Left face TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home. The choice of the half face on which the product will be applied will be defined by a randomization list, prepared by the statistician in charge. If the TH Facial Moisturizer will be applied on the left side of the face, then the Facial Moisturizer B (Control) will be applied on the right side of the face. Lip moisturizer, facial wash and sunscreen will be applied in all arms of the study.
62167961|NCT05272787|EXPERIMENTAL|Right face TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home. The choice of the half face on which the product will be applied will be defined by a randomization list, prepared by the statistician in charge. If the TH Facial Moisturizer will be applied on the right side of the face, then the Facial Moisturizer B (Control) will be applied on the left side of the face. Lip moisturizer, facial wash and sunscreen will be applied in all arms of the study.
62167962|NCT02321371|EXPERIMENTAL|Lactulose + Rifaximin|Continuation of Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route.
62167963|NCT02321371|ACTIVE_COMPARATOR|Lactulose therapy|
62167964|NCT06001814|EXPERIMENTAL|One-Mind One-Heart|One-Mind One-Heart (OM-OH) is intended to be a mindfulness-based, behavior change intervention to reduce psychological and behavioral cardiovascular disease risk.
62167965|NCT06001814|ACTIVE_COMPARATOR|Education|The education session will provide information on behaviors important for cardiovascular disease risk reduction.
62167966|NCT03175835|EXPERIMENTAL|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
62167967|NCT06358339|EXPERIMENTAL|Routine Tracker, Mind Care, Social Connectivity, and Achievement & Rewards|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker, Mind Care, Social Connectivity, and Achievement \& Rewards."
62167968|NCT06358339|EXPERIMENTAL|Routine Tracker, Mind Care and Social Connectivity|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker, Mind Care and Social Connectivity."
62167969|NCT06358339|EXPERIMENTAL|Routine Tracker, Social Connectivity, and Achievement & Rewards|"At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group.~The TEEM app with the intervention condition of Routine Tracker, Social Connectivity, and Achievement \& Rewards."
62734311|NCT06262191|EXPERIMENTAL|Study group|Participants will walk with the new AFO, their own AFOs, and no AFOs.
62734312|NCT01687543|EXPERIMENTAL|Probiotics|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
62734313|NCT01687543|PLACEBO_COMPARATOR|Control|Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
62734314|NCT00062491|EXPERIMENTAL|1|Karenitecin (BNP1350)
62734315|NCT04437550|EXPERIMENTAL|high-intensity|
62734316|NCT04437550|EXPERIMENTAL|low-intensity|
62734317|NCT05274516|EXPERIMENTAL|Single Ascending Doses, 6 dose levels|HRS-2261 oral tablet Matching placebo to HRS-2261
62734318|NCT05274516|EXPERIMENTAL|Multiple Ascending Doses, 3 dose levels|HRS-2261 oral tablet Matching placebo to HRS-2261
62734319|NCT03714984|EXPERIMENTAL|Pre operative exercise|The educational pelvic floor intervention group will receive one months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction. Patients and care giver will receive a daily exercise diary to fill at home and will be advised to follow the exercise program.
62734320|NCT03714984|ACTIVE_COMPARATOR|Control group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
62734321|NCT02816268|OTHER|Conventional Pulmonary vein isolation|Conventional pulmonary vein isolation was gained by using an irrigated tip ablation catheter
62734322|NCT02816268|OTHER|Contact force pulmonary vein isolation|Contact force was meassured by using the SMART-Touch ablation catheter (Biosense-Webster®)
62734323|NCT00935506|EXPERIMENTAL|Clopidogrel + Aspirin|
62734324|NCT00982046|ACTIVE_COMPARATOR|ACUVUE OASYS|Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
62734325|NCT00982046|ACTIVE_COMPARATOR|AIR OPTIX AQUA|Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
62734326|NCT00982046|ACTIVE_COMPARATOR|Biofinity|Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
62734327|NCT01441947|EXPERIMENTAL|Cabozantinib plus fulvestrant|Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)
62734328|NCT04818307|EXPERIMENTAL|Macquarie Injury Management group|
62734329|NCT04818307|ACTIVE_COMPARATOR|Mulligan Mobilization with Movement|
62734330|NCT03608241|EXPERIMENTAL|Treatment sequence 1|Treatment sequence 1 will receive a single dose of an oral contraceptive during the first period of the study (period 1) and then continue to the second period (Period 2) of the study where they will receive PF-06651600 every day for 11 days and a single dose of an oral contraceptive towards the end of the period.
62734331|NCT03608241|EXPERIMENTAL|Treatment Sequence 2|Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
62734332|NCT00255918|EXPERIMENTAL|Dimethoxybenzylidene anabaseine 75 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)
62734333|NCT00255918|PLACEBO_COMPARATOR|Placebo|Participants will take placebo.
62734334|NCT00255918|EXPERIMENTAL|Dimethoxybenzylidene anabaseine 150 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)
62734335|NCT00513084|EXPERIMENTAL|SDT Intervention|This arm will follow main experimental intervention, as described elsewhere
62734336|NCT00513084|NO_INTERVENTION|Comparison Group|Comparison Group receiving standard care health promotion intervention
62734337|NCT00803231||Retrospective cohort|Patient treated with Xigris between January 2006 and November 2008.
62734338|NCT00803231||Prospective cohort|Patient treated with Xigris between November 2008 and November 2009.
62734339|NCT00436046|ACTIVE_COMPARATOR|Group 1: 0.6 ml of IVV|30 subjects to receive 0.6 ml of inactivated influenza virus vaccine (IVV).
62734340|NCT00436046|EXPERIMENTAL|Group 3: 0.7 ml of IVV + 10M units of IFN|30 subjects to receive 0.7 ml of IVV containing 10M units of interferon (IFN).
62734341|NCT00436046|EXPERIMENTAL|Group 2: 0.6 ml of IVV + 1M unit of IFN|30 subjects to receive 0.6 ml of IVV containing 1M units of interferon (IFN).
62734342|NCT01061723|PLACEBO_COMPARATOR|Placebo|Placebo (for sarilumab) weekly (qw) for 12 weeks.
62734343|NCT01061723|EXPERIMENTAL|Sarilumab 100 mg q2w|Sarilumab 100 mg Subcutaneous (SC) injection alternating with placebo every other week (q2w) for 12 weeks.
62734344|NCT01061723|EXPERIMENTAL|Sarilumab 150 mg q2w|Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks.
62734345|NCT01061723|EXPERIMENTAL|Sarilumab 100 mg qw|Sarilumab 100 mg SC injection qw for 12 weeks.
62734346|NCT01061723|EXPERIMENTAL|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks.
62734347|NCT01061723|EXPERIMENTAL|Sarilumab 150 mg qw|Sarilumab 150 mg SC injection qw for 12 weeks.
62734348|NCT01527240|EXPERIMENTAL|Ciclosporin A|Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
62734349|NCT01527240|PLACEBO_COMPARATOR|Placebo|Injectable Saline Solution.
62734350|NCT01705327||Parkinson's Disease Subjects|
62734351|NCT01705327||Healthy Control Subjects|
62739010|NCT03181217|EXPERIMENTAL|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
62734352|NCT05373095|EXPERIMENTAL|Adapted Adherence Counseling (PKC) and Conditional Cash Transfers|Eligible and consenting participants randomized to the intervention arm will receive the same standard HIV clinical services according Tanzania's National Guidelines for the Management of HIV as the comparison arm, which includes provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions adapted for study purposes (PKC sessions). Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. A minimum of three sessions are required. In addition to enhanced adherence counseling, intervention participants will receive the offer of a cash transfer paired with attendance at each of the three enhanced adherence counseling sessions. The first payment will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining enhanced adherence counseling sessions.
62734353|NCT05373095|NO_INTERVENTION|Enhanced Adherence Counseling only for those who qualify|Eligible and consenting participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the Management of HIV. For those who meet clinic eligibility criteria for enhanced adherence counseling, this includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of a detectable viral load result and for two months after. Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. A minimum of three sessions are required.
62734354|NCT00932438|EXPERIMENTAL|LC Beads loaded with Irinotecan and FOLFOX6|"Device: LC Beads loaded with 100mg Irinotecan~Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician"
62734355|NCT00932438|ACTIVE_COMPARATOR|FOLFOX6 and Bevacizumab|Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
62734356|NCT03454997|ACTIVE_COMPARATOR|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
62734357|NCT03454997|ACTIVE_COMPARATOR|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
62734358|NCT01555970|EXPERIMENTAL|NAC|Patients allocated in this group will receive N-acetylcysteine 1200 mg (one 600 mg capsule twice a day) during the first week of the study. On day 8 this will increase to 4 capsules per day (2400 mg NAC; 2 capsules twice a day). Finally, on day 15 (after 1 week at 2400 mg) the dose will be increased to the target dose of 5 capsules per day (3000 mg; 2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
62734359|NCT01555970|PLACEBO_COMPARATOR|Placebo|Patients allocated in this group will receive one capsule of placebo twice a day during the first week of the study. On day 8 this will increase to 4 capsules per day (2 capsules twice a day). Finally, on day 15 the dose will be increased to the target dose of 5 capsules per day (2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
62734360|NCT04583124|EXPERIMENTAL|ATENTO-B|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed before the begining of medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
62734361|NCT04583124|ACTIVE_COMPARATOR|ATENTO-T|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed throughout medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
62734362|NCT03641781|ACTIVE_COMPARATOR|Isometric strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
62734363|NCT03641781|ACTIVE_COMPARATOR|Isokinetic strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOK group isokinetic training group randomly. ISOk group participants were involved in Training at speed of 30 deg/sec, 90deg/sec, 150/deg/sec 210deg/sec, 270deg/sec 5 repetition for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
62734364|NCT03641781|NO_INTERVENTION|Healthy control group|Data for outcome parameters including Peak torque average peak torque average power agonist antagonist ratio by using biodex isokinetic system for both by isometric contraction method and isokinetic method. For performance test were recorded for healthy control of same age group to compare the training effect with healthy control values.
61977685|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study~Inclusion criteria:~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
61977686|NCT06152757|EXPERIMENTAL|BGT007H injection|Intravenous infusion
62734365|NCT05045430|EXPERIMENTAL|Assigned Intervention|Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silver II Non-Woven Dressing
62734366|NCT02085044|EXPERIMENTAL|12 months RUSF|Children between 6 to 24 months received ready-to-used supplementary food every months during the whole year.
62734367|NCT02085044|ACTIVE_COMPARATOR|4 months RUSF|children between 6 to 24 months of one zone received a ready-to-used supplement food during the 4 months of the hunger gap period (june to september)
62734368|NCT03595150|ACTIVE_COMPARATOR|Diclofenac|100 mg Diclofenac rectally prior to the ERCP
62734369|NCT03595150|NO_INTERVENTION|No prophylaxis|No prophylaxis
62734370|NCT01948154||children with CP|Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. 2-12 years old (n=60-80)
62734371|NCT01948154||normal child|normal child 2-12 years old (50 subjects)
62734372|NCT05088759|EXPERIMENTAL|Alert|"an on-screen electronic alert will prompt the responsible inpatient provider (inpatient cohort) or the cardiologist of record for the clinic visit (outpatient cohort) as follows:~1. All patients whose LDL-C is not less than 70 mg/dL and not taking a maximally tolerated statin dose will prompt a recommendation for statin intensification~2. All patients whose LDL-C is within 20% of 70 mg/dL and who are on a maximally tolerated statin dose but not on ezetimibe or PCSK9 inhibitor will receive a prompt for adding ezetimibe~3. All patients whose LDL-C is greater than 20% of goal, and on a maximally tolerated statin (±ezetimibe) but not on PCSK9 inhibitor will receive a prompt for initiating PCSK9 inhibitor"
62734373|NCT05088759|NO_INTERVENTION|No Alert|No notification will be issues
62734374|NCT05523557|EXPERIMENTAL|Urban Training Group|The PA will consist of the following components: motivational interview, exercise following a dossier containing various maps of Urban Training walking trails (at least 30 minutes per day/5 days per week) and use of a Fitbit Inspire (FitBit, San Francisco) and motivational follow-up visit, in group, once per month during the follow-up period.
62734375|NCT05523557|NO_INTERVENTION|Control Group|The intervention will consist of a general recommendation to perform regular physical activity .
62734376|NCT05498935||CPB time ≥ 90 minutes|No intervention, regular therapy
62734377|NCT05498935||CPB time < 90 minutes|No intervention, regular therapy
62734378|NCT04888026|EXPERIMENTAL|Automated QST procedure|The QST robot will autonomously perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. All verbal information is giving through the computer
62734379|NCT04888026|ACTIVE_COMPARATOR|Manual QST procedure|The research assistant will perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. All tests are performed manually without using the robot.
62734380|NCT04888026|ACTIVE_COMPARATOR|Semi-automated QST procedure|The QST robot will with guidance from the research assistant perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. However and in contrast to the first arm, all verbal information and procedure guiding is given by a research assistant.
62734381|NCT02010593|EXPERIMENTAL|Dapivirine Vaginal Ring|Safety study of a vaginal ring containing Dapivirine in a postmenopausal female population
62734382|NCT02010593|PLACEBO_COMPARATOR|Placebo|The placebo VR is a flexible, platinum-catalyzed-cured matrix ring, identical to Dapivirine Ring-004, containing no active-drug
62734383|NCT05952973|EXPERIMENTAL|SkillTalk|"Educators in the treatment group will receive access to an online educator microskill training platform. Parents/caregivers of students in the educators' classes will be assigned to treatment and receive access to a parent-specific online educator microskill training platform. Students in this group will receive business as usual."
62734384|NCT05952973|NO_INTERVENTION|Business as usual|Business as usual.
62734385|NCT04005469|EXPERIMENTAL|Trepostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
62734386|NCT00069134|EXPERIMENTAL|Sulfur Amino Acids|12 children with edematous severe malnutrition will be assigned to receive 0.65 mmol/kg/d of sulfur amino acids. Supplements will be added to the children's daily diets.
62734387|NCT00069134|PLACEBO_COMPARATOR|Alanine|12 children with edematous severe malnutrition are assigned to receive 0.65 mmol/kg/d of alanine as placebo. Supplements will be added to the children's daily diets.
62734388|NCT02193009|EXPERIMENTAL|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
62734389|NCT02193009|ACTIVE_COMPARATOR|Move More, behavioral intervention|Aimed at physical activity promotion
62734390|NCT04560816|EXPERIMENTAL|Treatment Sequence 1|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: ALXN1840.~Period 2: Placebo-matching ALXN1840.~Period 3: Moxifloxacin."
62734391|NCT04560816|EXPERIMENTAL|Treatment Sequence 2|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: ALXN1840.~Period 2: Moxifloxacin.~Period 3: Placebo-matching ALXN1840."
62734392|NCT04560816|EXPERIMENTAL|Treatment Sequence 3|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Placebo-matching ALXN1840.~Period 2: ALXN1840.~Period 3: Moxifloxacin."
62734393|NCT04560816|EXPERIMENTAL|Treatment Sequence 4|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Placebo-matching ALXN1840.~Period 2: Moxifloxacin.~Period 3: ALXN1840."
62734394|NCT04560816|EXPERIMENTAL|Treatment Sequence 5|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Moxifloxacin.~Period 2: ALXN1840.~Period 3: Placebo-matching ALXN1840."
62734395|NCT04560816|EXPERIMENTAL|Treatment Sequence 6|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Moxifloxacin.~Period 2: Placebo-matching ALXN1840.~Period 3: ALXN1840."
62734396|NCT06176781|EXPERIMENTAL|Sequential group|Edaravone Dexborneol concentrated solution for injections 37.5 mg BID administered intravenously for 5 - 10 days, and then followed by Edaravone Dexborneol Sublingual Tablets 30 mg BID administered sublingually for the last days, the total duration of treatment was 14 days
62734397|NCT06176781|PLACEBO_COMPARATOR|Placebo group|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
62734398|NCT01861691|ACTIVE_COMPARATOR|Open surgery|Open colectomy
62734399|NCT01861691|EXPERIMENTAL|Laparoscopic surgery|Laparoscopic colectomy
62734400|NCT02565147|EXPERIMENTAL|PPCI with Bivalirudin|Bivalirudin was administered as a bolus (0.75 mg/kg) and an infusion (1.75 mg/kg/h) for the duration of the PPCI and continued for the first 4 h after completion of the procedure.
62734401|NCT02565147|ACTIVE_COMPARATOR|PPCI with Heparin|UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
62734402|NCT01185951|ACTIVE_COMPARATOR|Achilles tendinopathy|Patients suffering both, insertional and midportion Achilles tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
62734403|NCT01185951|ACTIVE_COMPARATOR|Patella tendinopathy|Patients suffering patella tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
62734404|NCT01185951|ACTIVE_COMPARATOR|Epikondylitis|Patients suffering both, lateral (tennis elbow) or medial (golfers' elbow) elbow tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
62734405|NCT06390046|ACTIVE_COMPARATOR|TIVA|total intravenously anesthetized (infusion of Propofol, Ketamine, Lignocaine and Dexmedetomidine)
62734406|NCT06390046|EXPERIMENTAL|Inhalation agent|combined general anesthesia (infusion of Ketamine, Lignocaine and Dexmedetomidine and inhalation of Sevoflurane)
62734407|NCT06390046|ACTIVE_COMPARATOR|Conventional|traditional laryngoscope for the first laryngoscopy
62734408|NCT06390046|EXPERIMENTAL|Video-Laryngoscope|video laryngoscope will be used to intubate half of the people
62734409|NCT06129461|EXPERIMENTAL|Treatment|The intervention group will participate in a single-session, self-guided online intervention imparting skills grounded in Acceptance and Commitment Therapy. The one-hour workshop guides participants through evidence-based exercises, brief video clips, and reflection activities designed to clarify values and teach skills to foster acceptance, defusion, and present-moment awareness.
62734410|NCT06129461|NO_INTERVENTION|Control|Participants in the control group will not receive any intervention; they will complete assessments on the same schedule as the intervention group (baseline, 1 month, at full term)
62734411|NCT05451589|EXPERIMENTAL|RESET intervention|Participants will engage in a 7-week positive psychology and self-management group telephone-based program.
62734412|NCT05451589|ACTIVE_COMPARATOR|Wellness check control|Participants will receive educational information and an individual wellness check phone call from a Community Health Worker to screen for unmet social needs.
62734413|NCT03917875|NO_INTERVENTION|Control|
62734414|NCT03917875|EXPERIMENTAL|PFI|
62734415|NCT00935493|EXPERIMENTAL|Guanfacine 0.1 mg po qhs|
62734416|NCT00935493|EXPERIMENTAL|Guanfacine 0.5 mg po qhs|
62734417|NCT00935493|PLACEBO_COMPARATOR|Placebo po qhs|
62734418|NCT04812782|EXPERIMENTAL|EVOO-Butter|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with EVOO and the second with butter.
62734419|NCT04812782|EXPERIMENTAL|Butter-EVOO|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with Butter and the second with EVOO
62734420|NCT05788666|EXPERIMENTAL|Geriatric Assessments using GeriKit App|Participants will receive comprehensive geriatric assessment via GeriKit app at baseline. All participants will complete a follow-up assessment via phone at 6 months. 20 of the 150 enrolled participants will continue onto a qualitative questionnaire after the completion of the 6-month follow up call.
62734421|NCT00269113|EXPERIMENTAL|1|
62734422|NCT00269113|ACTIVE_COMPARATOR|2|
62734423|NCT03144128|PLACEBO_COMPARATOR|Control (Ctl)|Standard of Care resistance exercise and timed protein supplementation with placebo capsule daily for 12 weeks
62734424|NCT03144128|EXPERIMENTAL|Vitamin D|Standard of Care resistance exercise and timed protein supplementation with 5,000IU vitamin D supplementation daily for 12 weeks
62734425|NCT02505022||Treatment seeking patients|Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
62734426|NCT04234347|ACTIVE_COMPARATOR|Long Axis approach|Utilize the longitudinal orientation when placing an USGPIV.
62734427|NCT04234347|ACTIVE_COMPARATOR|Short axis approach|Utilize the transverse orientation when placing an USGPIV.
62734428|NCT00694577|EXPERIMENTAL|Irradiation using 32 Gy / 8 fractions|Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions BID in one week
62734429|NCT00694577|EXPERIMENTAL|Irradiation using 36 Gy / 9 fractions|Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions BID in one week
62734430|NCT00694577|EXPERIMENTAL|Irradiation using 40 Gy / 10 fractions|Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions BID in one week
62734431|NCT02220192|EXPERIMENTAL|Focal LEEP|All patients will undergo focal treatment of high-grade cervical intraepithelial neoplasia using LEEP. A two-week follow-up assessment will evaluate the side effects of the treatment and any unusual symptoms. This will be done through a phone survey. At six months a clinic visit is required to assess whether there are any precancerous cells of the patient's cervix.
61977730|NCT02237950|PLACEBO_COMPARATOR|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
61978074|NCT06249412|EXPERIMENTAL|MI-E with Positive expiratory pressure during pause (PEP)|With the MI-E EOVE-70 device, it is possible to enable the setting of PEP (Positive Expiratory Pressure) during the pause. When this setting is activated, PEP can be adjusted between 1 and 20 cmH2O. The MI-E session will last, depending on patient tolerance, between 8 and 15 minutes. In this study, the MI-E will be set in automatic or semi-automatic mode with settings proposed by the physiotherapists based on the effectiveness and tolerance of the patient. To titrate PEP, the practitioner will start at 8 cmH2O; the setting can be decreased or increased at the discretion of the practitioner to optimize it, based on the inspiratory volume and peak expiratory flow (PEF) measured by the device at each cycle (usual clinical practice). The practitioner can adjust PEP between a minimum of 4 and a maximum of 15 cmH2O. A wash-out period of 30 minutes is planned between each INEX session with and without the PEP function activated (Experimental arm and comparative arm)
61978075|NCT06249412|ACTIVE_COMPARATOR|MI-E without Positive expiratory pressure during pause (PEP)|The MI-E session will last, depending on patient tolerance, between 8 and 15 minutes. In this study, the MI-E will be set in automatic or semi-automatic mode with settings proposed by the physiotherapists based on the effectiveness and tolerance of the patient. The PEP function will not be used by the practitioner (ie. 0 cmH2O of PEP during the pause). A wash-out period of 30 minutes is planned between each INEX session with and without the PEP function activated (Experimental arm and comparative arm)
61978076|NCT00237757|EXPERIMENTAL|Arm 1|The experimental arm consisted of a six month staff training period with an emphasis on effective team functioning to improve patient outcomes. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing
61978077|NCT00237757|ACTIVE_COMPARATOR|Arm 2|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
61978078|NCT02891460|EXPERIMENTAL|40 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
61978079|NCT02891460|EXPERIMENTAL|80 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
61978080|NCT05748977|EXPERIMENTAL|SABA,SAMA ICS|
61978081|NCT05748977|EXPERIMENTAL|LABA,LAMA ICS|
61978082|NCT00815009|NO_INTERVENTION|A (Std of Care)|Standard of Care/Control, including Lifestyle Advice (attend a basic healthy nutrition class as well as follow up appointments with GI MD).
61978083|NCT00815009|EXPERIMENTAL|B (Low Fat)|Standard of Care, plus Low Fat Diet and Moderate Exercise
61978084|NCT00815009|EXPERIMENTAL|C (Mod Fat)|Standard of Care, plus Moderate Fat/Low Processed Carbohydrate Diet and Moderate Exercise
61978085|NCT00815009|EXPERIMENTAL|D (Exercise only)|Standard of Care plus Moderate Exercise only
61978086|NCT05611879|EXPERIMENTAL|Neoadjuvant therapy of Tislelizumab with chemotherapy+surgery|Participants will receive neoadjuvant Tislelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection.
61978087|NCT01693575|EXPERIMENTAL|Pupil expansion with APX 100 device|Use of APX 100 device during standard phacoemulsification cataract extraction surgery in patients with small pupil diameter (\<4.5 mm) or with documented intraoperative floppy iris syndrome in previous eye.
61978088|NCT00268996|EXPERIMENTAL|Subjects with ACS and evidence of MN:SB-480848|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
61978089|NCT00268996|PLACEBO_COMPARATOR|Subjects with ACS and evidence of MN: placebo|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
61978090|NCT00268996|EXPERIMENTAL|Non-ACS and ACS subjects without evidence of MN: SB-480848|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
61978091|NCT00268996|PLACEBO_COMPARATOR|Non-ACS and those ACS subjects without evidence of MN: placebo|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
61978092|NCT03654651|EXPERIMENTAL|Evening Peanut Consumption|Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).
61978093|NCT03654651|ACTIVE_COMPARATOR|Evening Snack|Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).
61978094|NCT01683955|EXPERIMENTAL|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
61978095|NCT01683955|PLACEBO_COMPARATOR|Placebo|100mL 0.9% sterile saline, applied topically
61978096|NCT00840554|ACTIVE_COMPARATOR|Physical Therapy|
61978097|NCT00840554|EXPERIMENTAL|Home Exercise|
61978098|NCT03764137|EXPERIMENTAL|[89Zr]Panitumumab-PET/MRI patients|All study patients will receive \[89Zr\]Panitumumab-PET/MRI imaging.
61978099|NCT02003612||All subjects|All subjects
61978100|NCT05312398|EXPERIMENTAL|single arm|"This is an open-label phase II study investigating the efficacy and safety of a bio-marker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line. Based on dynamic and longitudinal liquid biopsy assessment of RAS/BRAF status, that will be prospectively performed before each line of treatment, mCRC patients will be treated with cetuximab in combination with chemotherapy throughout three lines of therapy, as follows:~* FOLFIRI plus cetuximab (first line);~* FOLFOX plus cetuximab (second line);~* irinotecan plus cetuximab (third line).~If at progression after the first line or after the second line, the liquid biopsy assessment indicates RAS and or BRAF mutant status, patients will be treated with FOLFOX plus bevacizumab as second line of therapy, or with regorafenib or with trifluridine-tipiracil (investigator's choice) as third line therapy."
61978347|NCT05487638|EXPERIMENTAL|experimental Group|Training was given to the patients once a week, starting on the second day after discharge, four times in total. Increasing the level of knowledge about infection control, wound care, post-CABG care, using drugs as prescribed, hygiene, excretion (things to be done to avoid constipation), nutrition (diet and diet compliance after CABG), bleeding control, proper sleep and rest positions, deep breathing and coughing exercises, maintaining a healthy weight, what to pay attention to while taking a bath, pain management and methods of coping with pain, relaxation techniques, walking and exercise, returning to social life, reducing anxiety and depression, using elastic stockings and chest corsets, controlling Training was given on the subjects of notifying the due dates, emotional adjustment and coping methods with symptoms. After 1 month of training, at the end of the 4th week, the patients were asked to fill out the Discharge Education Satisfaction Scale and the Self-Care Strength Scale.
61978348|NCT05487638|NO_INTERVENTION|Control Group|On the other hand, no intervention was made in the control group and after discharge, the personal information form, the Discharge Training Satisfaction Scale and the Self-Care Strength Scale were filled. At the end of the 4th week, the patients were asked to fill out the Discharge Education Satisfaction Scale and the Self-Care Strength Scale.
61978349|NCT01433601|NO_INTERVENTION|Self Supervised Treatment (SST)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
61978350|NCT01433601|EXPERIMENTAL|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
61978351|NCT06336460|EXPERIMENTAL|Pericapsular Nerve Group (PENG) Block|
61978352|NCT06336460|EXPERIMENTAL|Fascia Iliaca Compartment (FIC) Block|
61978353|NCT01946425|EXPERIMENTAL|Age 6 Months to <36 Months (Study Group 1)|Participants at 6 months to \< 36 months of age at enrollment
61978354|NCT01946425|EXPERIMENTAL|Age 3 Years to <9 Years Group (Study Group 2)|Participants at 3 years to \< 9 years of age at enrollment
61978355|NCT03267186|EXPERIMENTAL|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
61978356|NCT04563689|EXPERIMENTAL|actve|oral rinse
61978357|NCT04563689|PLACEBO_COMPARATOR|placebo|distilled water,
61978358|NCT03966703|EXPERIMENTAL|conventional denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
61978359|NCT03966703|EXPERIMENTAL|implant fixed denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
61978360|NCT06020365|EXPERIMENTAL|sequential antibiotics treatment and fecal + small intestinal microbiota transplant|
61978361|NCT00893191||Sildenafil|Treated with 50 mg of Sildenafil at night
61978362|NCT00893191||Placebo|Treated with placebo at night
61978363|NCT01770548|EXPERIMENTAL|Autism|Analysis of the glutamate synapse in autism
61978364|NCT01770548|OTHER|Relative|Analysis of the glutamate synapse in autism
61978365|NCT01770548|OTHER|Major control|DNA collection
61978366|NCT01770548|OTHER|Minor control|auditory evoked potentials
61978367|NCT04122092||MM patients have curative effect at least VGPR|We will detect cfDNA CIN of multiple myeloma patients who have the curative effect at least very good partial response (VGPR) after front line therapy, and then monitoring cfDNA CIN every two treatment cycles or every three months during follow up，the result will be compared with bone marrow aspiration MFC.
61978368|NCT05608109|EXPERIMENTAL|Alcohol personalized normative feedback (APNF)|"Participants will receive feedback about their consumption, what they think the average student at their university drinks, and actual drinking statistics at their university.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
61978369|NCT05608109|EXPERIMENTAL|Social media personalized normative feedback (SMPNF)|"Participants will receive feedback about their consumption and alcohol related consumption posts, what they think the average student at their university drinks, and actual drinking statistics at their university.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
61978370|NCT05608109|EXPERIMENTAL|Alcohol and social media personalized normative feedback (APNF + SMPNF)|"Participants will go through the alcohol personalized normative feedback process and the social media personalized normative feedback.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
61978371|NCT05608109|NO_INTERVENTION|Attention control|"Participants will receive feedback about their consumption of desserts, what they think their peers consume, and actual dessert consumption statistics are for individuals in their age group in the United States.~Participants in this condition will participate in a baseline survey/feedback intervention. They will then complete follow-up surveys and feedback interventions at 3-months and 6-months."
61978372|NCT01491503|EXPERIMENTAL|Montelukast and levocetirizine|
61978373|NCT01491503|ACTIVE_COMPARATOR|Montelukast|
61978374|NCT01491503|ACTIVE_COMPARATOR|Levocetirizine|
61978375|NCT06469866|EXPERIMENTAL|low-pressure pneumoperitoneum (LPP) with deep NMB affect quality of recovery|low-pressure pneumoperitoneum (LPP) with deep NMB.
61978376|NCT06469866|EXPERIMENTAL|standard-pressure pneumoperitoneum (SPP) with moderate NMB affect quality of recovery|standard-pressure pneumoperitoneum (SPP) with moderate NMB.
61978377|NCT01848002|EXPERIMENTAL|rFXIII|
61978378|NCT01848002|PLACEBO_COMPARATOR|Placebo|
61978379|NCT05536258||RI-Monitoring|"The investigator will evaluate the feasibility of a RI-guided fluid ministration for improving perioperative characteristics.~Feasibility will be defined by:~The investigators will titrate fluid administration to maintain a RI \> 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI \> 90 over at least 85% of the intraoperative period;"
61978380|NCT01727973|EXPERIMENTAL|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
62735148|NCT04247893|PLACEBO_COMPARATOR|Blood flow restriction exercises + placebo photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted. Photobiomodulation turned off with a mesh composed of multiple diodes containing 50 Infrared LEDs.
62735149|NCT06293716|EXPERIMENTAL|part1:treatment group|Patients were given CVL237 tablets, 100 mg/ day, QD, for 4 weeks (28 days), and safety assessment was performed on day 28 of the first cycle. If there was no safety risk, patients could take CVL237 tablets, 200 mg/ day, QD, for 4 weeks (28 days).
62735150|NCT06293716|EXPERIMENTAL|part2:treatment group|Patients were randomly assigned to the trial and placebo groups in a ratio of 2:1 to take an oral CVL237 tablet once daily.
62735151|NCT06293716|PLACEBO_COMPARATOR|part 2:placebo group|Patients were randomly assigned to the trial and placebo groups in a ratio of 2:1 to take a placebo CVL237 simulant once daily.
62735152|NCT00682929|ACTIVE_COMPARATOR|1) Inhaled Cannabis|Inhaled cannabis is compared to oral placebo.
62735153|NCT00682929|ACTIVE_COMPARATOR|2) Oral THC|Inhaled placebo is compared to oral THC.
62735154|NCT00682929|PLACEBO_COMPARATOR|3) Placebo|Inhaled placebo is compared to oral placebo.
62735155|NCT04893317|EXPERIMENTAL|Ablation in the ventricle with the Adagio VT cryoablation system|all study subjects will receive an ablation procedure using the Adagio Medical VT Cryoablation System
62735156|NCT03163134|NO_INTERVENTION|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
62735157|NCT03163134|EXPERIMENTAL|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
62735158|NCT02072252|EXPERIMENTAL|App teaching cognitive behavioral skills|"App teaching cognitive behavioral skills. This mobile phone application (app) teaches cognitive behavioral techniques to help participants manage their mood, for example by providing information, interactive tools and tips, and a mood tracker. A coach will support participants as they use the app via phone calls and email contacts."
62735159|NCT02072252|NO_INTERVENTION|Wait-list with referrals|10-week wait-list control condition in which participants will be provided with and encouraged to use mental health referrals to resources in the community. After the 10-week waiting period, control group participants will have the option to receive the mobile phone application and coaching.
62735160|NCT02051751|EXPERIMENTAL|BYL719 and paclitaxel|All patients enrolled in the study will receive BYL719 once daily plus weekly paclitaxel
62735161|NCT03777046|NO_INTERVENTION|Screen fail subjects|Mothers and their babies that meet inclusion criteria for the study, but score less than 10 on the Edinburgh Postpartum Depression Scale (EPDS)
62735162|NCT03777046|ACTIVE_COMPARATOR|PPD Control subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
62735163|NCT03777046|EXPERIMENTAL|PPD Intervention subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
62735164|NCT03400358||Medical abortion|150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
62735165|NCT03282344|EXPERIMENTAL|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
62735166|NCT03282344|EXPERIMENTAL|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
62735167|NCT01848067|EXPERIMENTAL|Treatment (alisertib, abiraterone acetate, prednisone)|Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
62735168|NCT00688467|EXPERIMENTAL|Navarixin → Placebo|Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2
62735169|NCT00688467|EXPERIMENTAL|Placebo → Navarixin|Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2
62735170|NCT04031898||full analysis set|All eligible patients who meet all inclusion criteria and none of the exclusion criteria
62735171|NCT02052115|OTHER|Exercise and weight loss|12 month exercise and weight loss intervention
62735172|NCT06467786|EXPERIMENTAL|Experimental administration group|Irinotecan hydrochloride liposome injection: 70mg/m2, intravenous infusion CISPLATIN: 60mg/m2, intravenous infusion or carboplatin: AUC=5, intravenous infusion
62735173|NCT02964273|EXPERIMENTAL|Phase A: Tolvaptan|Participants received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting doses based on their weight as per the following specifications: ≥20 to 45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.
62735791|NCT05691790|ACTIVE_COMPARATOR|Control Group|Participants who are allocated to the control group will receive a pamphlet about recommendation for influenza vaccines, pneumococcal vaccines, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. This group will receive six control telephone care visits over six weeks. We will purposively balance the characteristics of the student helpers who do the control telephone visits and the patient activation interviews. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health. In the last telephone care visit, the interviewer will give a summary for how to live a healthy lifestyle and a reminder of taking the recommended vaccinations for older people shown in the pamphlet.
62735792|NCT05691790|EXPERIMENTAL|Intervention Group|"Intervention development and delivery The interventions will involve deliver a booklet designed based on MMA and six telephone interviews for patient activation.~Design of booklet for older people's preventive care: The booklet will be framed as one series of Positive aging via preventive care-vaccination. According to MMA, the booklet will be aimed to translate expert knowledge into information that can fit to older people's mental models (e.g., misperceptions and knowledge deficits revealed in our previous qualitative studies) regarding vaccinations to facilitate cognitive process of the information.~Patient activation sections: We will design six telephone-based patient activation sections with accommodation for older people's mental models and decision-making preference. The motivation interviewing (MI) techniques will be incorporated into the design of patient activation sections."
62735793|NCT00855777|EXPERIMENTAL|Etoricoxib|Etoricoxib 120 mg/day x 3 days
62735794|NCT00855777|ACTIVE_COMPARATOR|Ibuprofen|Ibuprofen 1800 mg/day x 3 days
62735795|NCT04883749|EXPERIMENTAL|Acalabrutinib|Acalabrutinib will be administered up to 24 cycles (= approx. 24 months total) until progression of disease (PD) or intolerable toxicity
62735796|NCT06468891||women with stress urinary incontinence|This group includes 62 participants with chronic stress urinary incontinence.
62735797|NCT06468891||women without stress urinary incontinence|This group includes 62 participants who are free from urinary incontinence symptoms and pelvic floor dysfunction.
62735798|NCT02596568|EXPERIMENTAL|Active tDCS stimulation|Anodal tDCS will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
62735799|NCT02596568|SHAM_COMPARATOR|Sham tDCS stimulation|tDCS electrodes will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor, however stimulation will never be turned on.
62735800|NCT01918605|EXPERIMENTAL|Diluted spacer|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
62735801|NCT01918605|ACTIVE_COMPARATOR|Non-diluted spacer|Single dose of DuraSeal product injected between rectum and prostate
62735802|NCT01749280||Abdominal Aortic Aneurysms|Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
62735803|NCT00422448|EXPERIMENTAL|Nevi from participants|Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis
62735804|NCT04550520|EXPERIMENTAL|study part 1: healthy adult volunteers|22 Healthy volunteers: The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
62735805|NCT04550520|EXPERIMENTAL|study part 2: adult patients with primary polydipsia or central diabetes insipidus|If results of study part 1 suggest that glucagon stimulates copeptin (proof of concept),10 patients with primary polydipsia and 10 patients with central diabetes insipidus will be additionally included (study part 2): The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
62735806|NCT01140594|ACTIVE_COMPARATOR|Wavefront-guided PRK|Wavefront-guided PRK
62735807|NCT01140594|ACTIVE_COMPARATOR|Wavefront-guided LASIK|Wavefront-guided LASIK
62735808|NCT01156025|EXPERIMENTAL|GV550|(Ganciclovir 1.5 mg/g ophtalmic gel)
62735809|NCT01156025|PLACEBO_COMPARATOR|Placebo|Placebo ophtalmic gel
62735810|NCT05006989|EXPERIMENTAL|Intervention Group|Participants will be provided pre-made whole blueberry freeze-dried powder to be consumed.
62735811|NCT05006989|PLACEBO_COMPARATOR|Placebo Group|Participants will be provided placebo powder to be consumed.
62735812|NCT04764097|EXPERIMENTAL|Dapagliflozin|Dapagliflozin, Oral Tablet,10mg, od, 24 months.
62735813|NCT04764097|PLACEBO_COMPARATOR|Placebo|Placebo, Oral Tablet, od, 24 months.
62735814|NCT05332392|EXPERIMENTAL|INVSENSOR00040|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00040 device.
62735815|NCT03626064|OTHER|PROMPT Participants|80 participants who are homeless or at-risk for homelessness, smoke tobacco, and identify as People Who Use Drugs in Ottawa.
62735816|NCT05764252||BioEP|The EEG will be analysed using the BioEP algorithm
62735817|NCT01864967||carbon dioxide infusion|Group I: receive carbon dioxide infusion
62735818|NCT01864967||control|did not receive carbon dioxide
62735819|NCT00574392||1|Multiwavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented lesions on skin in vivo
62735820|NCT01628484|OTHER|Skin Preparation Testing|The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
62735821|NCT00824252||Spousal Support|Questionnaire for Head and Neck Cancer Patients + Spouses
62735822|NCT06271681|OTHER|All participants|This will be a single population open label trial evaluating immune response to PCV15 followed by PPSV23 8 weeks later in subjects with immunocompromising conditions or receiving immunosuppressive medications.
62735823|NCT05202899|EXPERIMENTAL|Sugammadex Group|rocuronium-induced general anesthesia，use of sugammadex antagonism
62736192|NCT05210088|ACTIVE_COMPARATOR|PHASE 2 - Intermittent hypoxia group|"Group exposed to an intermittent hypoxic stimulus (n=20, target pulsed saturation in dioxygen 75%).~The device used is a gas mixer already in use in the unit and used in current clinical practice and research in our team (Altitrainer®, Sport and Medical TEChnologies S.A. (SMTEC S.A.), Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the FiO2 will be set individually to achieve the targeted level of desaturation."
62736193|NCT05210088|SHAM_COMPARATOR|PHASE 2 - Sham (Normoxia) group|Normoxia group (n=10, FiO2 = 21%). The same setting will be used as in the Intermittent hypoxia group, but subjects will breathe ambient air throughout the conditioning procedure.
62736194|NCT06158464|NO_INTERVENTION|Care-as-usual|In standard care, persons on sick leave/work disability are invited by the medical advisor for a consultation. If the patient is allocated to the control group (or if the patient did not agree to participate in the study), the medical advisor takes decisions based on the information at his disposal, e.g. start a return-to-work trajectory, to temporarily prolong sickness absence and disability, or to confirm definitive work disability. If they agree to participate, they are asked to complete four questionnaires: at baseline, at 3 months, 6 months, and 9 months.
62736195|NCT06158464|EXPERIMENTAL|Care-as-usual supplemented by a Functional Capacity Evaluation|"In the intervention group, participants are referred to an occupational therapist to receive an FCE. Afterwards, the occupational therapist completes a standardized FCE-template, and conveys these recommendations to the medical advisor. This template includes a list of ICF categories important to the work context. The conclusion of the FCE includes: 1) The facilitators and barriers related to work-related physical, cognitive or psychological functioning, or related to environmental and/or psychosocial factors. 2) A recommendation on the current or last occupation or a reference occupation with or without adaptation and/or on reorientation, training, coaching.~Based on the FCE results, the medical advisor can adapt his advice and communicate to the person on sick leave/work disability to advise him/her, or refer the person on sick leave/work disability to other partners (such as VDAB, FOREM, Actiris, or the RTW-coordinator)."
62736196|NCT04768205|ACTIVE_COMPARATOR|Study group|The therapy and Kinesio tex gold tape that was affixed to stretched and neck localised were applied
62736197|NCT04768205|PLACEBO_COMPARATOR|Sham control group|The therapy and Kinesio tex gold tape that was affixed to different neck localised as no-stretched were applied
62736198|NCT00832598|EXPERIMENTAL|PET imaging|We will perform \[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc.
62736199|NCT01297608|EXPERIMENTAL|treatment|
62736200|NCT01297608|PLACEBO_COMPARATOR|placebo|
62736201|NCT00729911|ACTIVE_COMPARATOR|AF ablation|"Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting."
62736202|NCT00729911|ACTIVE_COMPARATOR|Amiodarone|Amiodarone is taken orally on a daily basis.
62736203|NCT01062724|NO_INTERVENTION|Trophamine|This group of neonates will be receive the Trophamine amino acids solution from Pisa laboratories as an active comparator with Primene. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
62736204|NCT01062724|EXPERIMENTAL|Primene 10% from Baxter|This group of neonates will be receive the Primene amino acids solution (10 %) from Baxter laboratories as other active comparator with Trophamine. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
62736205|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
62736206|NCT03334981||exposed mother and child|mother and child who have been exposed to methadone or to buprenorphine during pregnancy
62736207|NCT02396108|EXPERIMENTAL|Paclitaxel + Carboplatin + ASLAN001|"Phase I:~A modified 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdraws consent. In the presence of intolerable toxicities to one or more of the drugs in the regimen (but not all 3), the drug in question may be discontinued and the other drugs continued with the patient remaining in the study, if the patient is deemed to be benefiting, after discussion with the Principal Investigator.~Phase II:~Patients with stage I-III HER2-positive breast cancer with a primary breast tumour of 2cm or greater will receive up to 4 cycles of pre-operative ASLAN001 and weekly paclitaxel/ carboplatin delivered in 21-day cycles. Prior to administration of chemotherapy, there will be lead-in dosing of single-agent ASLAN001 administered daily for 2 weeks at the recommended phase II dose."
62736208|NCT02676700|ACTIVE_COMPARATOR|Pelvic floor muscle training and Kaatsu|"Participants are instructed in the PFMT program by primary investigator and instructed in Kaatsu training by a research nurse. The Kaatsu training is performed 4 times a week before PFMT. The program includes 2 x 15 knee extensions with partly occlusion of the blood supply to the thigh. Training level is \>12 RM. Training is performed sitting on a chair and rubber bands are used to increase resistance. Training adherence and bother with the training is reported in a training diary. At week 6 the research nurse adjusts the training program.~The PFMT program includes three sets of 10 contractions with an intensity of \>12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
62736209|NCT02676700|ACTIVE_COMPARATOR|pelvic floor muscle training|"Participants perform the same PFMT program as the intervention group. The PFMT program includes three sets of 10 contractions with an intensity of \>12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
62736210|NCT05291546|EXPERIMENTAL|Part A|Single ascending dose (SAD) of REGN9035 or matching placebo given by intravenous (IV) administration.
62736578|NCT03107052|EXPERIMENTAL|Fremanezumab 225 mg Monthly|Participants with ECH or CCH who received fremanezumab at 900 mg intravenous (IV) infusion at Week 0 and fremanezumab at 225 mg subcutaneous (SC) injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056 or TV48125-CNS-30057, and participants with CCH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab at 225 mg SC injection monthly (approximately every 4 weeks, administered as single SC injection of fremanezumab at 225 mg \[225 mg/1.5 milliliter {mL}\] at Week 0 and 36; and 2 placebo SC injections at Weeks 0, 12, 24, and 36 for blinding in participants rolled over from Study TV48125-CNS-30056; fremanezumab at 225 mg as a single SC injection (225 mg/1.5 mL) at Week 0, 12, 24, and 36; 2 SC injections of placebo at Week 0 for blinding in participants rolled over from Study TV48125-CNS-30057) through Week 36 in this study.
62736579|NCT03107052|EXPERIMENTAL|Fremanezumab 675/225 mg Monthly|Participants with CCH who received placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab 675 mg SC injection as loading dose (administered as 3 SC injections of fremanezumab at 225 mg \[225 mg/1.5 mL\] at Week 0) followed by monthly (approximately every 4 weeks) fremanezumab at 225 mg SC injection (administered as single SC injection of fremanezumab at 225 mg \[225 mg/1.5 mL\] at Weeks 12, 24, and 36) through Week 36.
62736580|NCT03107052|EXPERIMENTAL|Fremanezumab 675 mg Quarterly|Participants with ECH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study; or placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056; will receive fremanezumab at 675 mg SC injection quarterly (approximately every 12 weeks, administered as 3 SC injections of fremanezumab at 225 mg \[225 mg/1.5 mL\] at Weeks 0 an 36; and single placebo SC injections at Weeks 4, 8, 16, 20, 28, and 32 for blinding) through Week 36.
62736581|NCT03154515|EXPERIMENTAL|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
62736582|NCT03154515|PLACEBO_COMPARATOR|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
62736583|NCT06186908|EXPERIMENTAL|Healthy periodontium|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62736584|NCT06186908|EXPERIMENTAL|Gingivitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62736585|NCT06186908|EXPERIMENTAL|Periodontitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
62736586|NCT06651775|EXPERIMENTAL|HILT group|Receiving Hotpack+TENS+Exercises+HILT
62736587|NCT06651775|SHAM_COMPARATOR|Sham group|Receiving Hotpack+TENS+Exercises+ sham HILT
62736588|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
62736589|NCT01864681|EXPERIMENTAL|Arm A|Gefitinib and metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for metformin loading.
62736590|NCT01864681|PLACEBO_COMPARATOR|Arm B|Gefitinib and placebo. Placebo was given to patients in the same way as that of metformin in Arm A.
62736591|NCT06290531|EXPERIMENTAL|Buzzy device (cold and vibration)|
62736592|NCT06290531|EXPERIMENTAL|Buzzy device (vibration only)|
62736593|NCT06290531|EXPERIMENTAL|Precooling|
62736594|NCT06290531|ACTIVE_COMPARATOR|Flavored Benzocaine topical anesthetic gel 20%|
62736595|NCT03371576||2 different torical intraocular lenses|
62736596|NCT03395782||Age group 40-49|30 patients will be stratified to this age group.
62736597|NCT03395782||Age group 50-59|30 patients will be stratified to this age group.
62736598|NCT03395782||Age group 60-69|30 patients will be stratified to this age group.
62736599|NCT03395782||Age group 70-79|30 patients will be stratified to this age group.
62736600|NCT00606411|ACTIVE_COMPARATOR|Topiramate|Study medication arm, 25-300mg of Topiramate
62736601|NCT00606411|PLACEBO_COMPARATOR|Placebo|Placebo arm of study, 25-300mg of sugar pill
62736602|NCT00956722|EXPERIMENTAL|Treatment|Active treatment with Bovine colostrum
62736603|NCT01130909|EXPERIMENTAL|AZD6765 75 mg|
62736604|NCT01130909|EXPERIMENTAL|AZD6765 150 mg|
62736605|NCT01130909|ACTIVE_COMPARATOR|Ketamine 0.5 mg/kg|
62736606|NCT01130909|PLACEBO_COMPARATOR|125 mL sterile NaCl 0.9%|
62736607|NCT03636672|EXPERIMENTAL|experimental|Perturbation training during stationary bicycle riding
62736608|NCT03636672|ACTIVE_COMPARATOR|control|stationary bicycle riding training
62736609|NCT05358262|EXPERIMENTAL|Intervention using the Airvo device|Patients randomized to this group will receive the standard of care as well as wear the Airvo (equipment to provide high heated humidity) starting on Day 0 of their transplant for a minimum of 4 hours a day (to be worn in one continuous block of time). The humidity is delivered by nasal cannula that goes into your nose, similar to wearing oxygen. The equipment stands on a pole and plugs into a power outlet. Patients may take off the equipment for short periods of time. Eg to go to the bathroom.
62736610|NCT05358262|NO_INTERVENTION|Standard of Care|"Patients randomized into this group will receive the usual standard of care for mucositis.~The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes."
62736611|NCT02469987|EXPERIMENTAL|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
62736612|NCT02469987|ACTIVE_COMPARATOR|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
62736613|NCT02469987|ACTIVE_COMPARATOR|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
62736614|NCT02297815||Broad-spectrum antibiotics|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
62736615|NCT02297815||Narrow-spectrum|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.
62736616|NCT01032434|EXPERIMENTAL|sertraline|sertraline: 50-200mg/day
62736617|NCT00800527|ACTIVE_COMPARATOR|1|Gabapentin
62736618|NCT00800527|ACTIVE_COMPARATOR|2|Diclofenac
62736826|NCT03226886||All patients|"In London renal cell carcinoma patients undergo nephrectomy at centres for urological oncology, including the Royal Marsden, Guy's and St Thomas', St Georges, Charing Cross and Kings Hospitals. It is not uncommon for the same patients to undergo palliative resection for metastatic sites of disease. The majority of tissue from these resections does not undergo routine histopathological examination. As such, it is ethically feasible to use these specimens for laboratory research in the presence of patient consent. Practically, these specimens are often large, thereby offering considerable scope for a range of molecular analyses.~CAPTURE Sub-study:~We plan to enrol patients/participants into three groups:~Group A: patients with confirmed or suspected COVID-19 and a history of cancer Group B: patients without a history of COVID-19 infection and a history of cancer Group C: Hospital staff with or without a history of COVID-19"
62736827|NCT00915759|ACTIVE_COMPARATOR|ProKera|
62736828|NCT00915759|PLACEBO_COMPARATOR|Bandage contact lens|
62736829|NCT06554535|EXPERIMENTAL|Serplulimab + Chemotherapy + Aspirin|
62736830|NCT00540241||Second-line pemetrexed treatment in NSCLC|Patients with NSCLC who will start second-line treatment with pemetrexed.
62736831|NCT01498744|EXPERIMENTAL|5 days postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
62736832|NCT01498744|EXPERIMENTAL|1 day postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
62736833|NCT00342628|EXPERIMENTAL|Vi-rEPA plus DTP|Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
62736834|NCT00342628|ACTIVE_COMPARATOR|Hib-TT plus DTP|Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
62736835|NCT00342628|ACTIVE_COMPARATOR|EPI|DTP at 2,4 and 6 months
62736836|NCT02293967|EXPERIMENTAL|MT-1303|\[14C\] MT-1303 after a single oral dose
62736837|NCT01996488|EXPERIMENTAL|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
62736838|NCT05672641|EXPERIMENTAL|Inertial training group|13 young men, physical education students. Inertial training was performed three times a week (Monday, Wednesday, Friday, between 7:00 a.m. and 8:30 a.m.) for 6 weeks using Cyklotren device (Inerion, Poland).
62736839|NCT05672641|EXPERIMENTAL|Body building training group|13 young men, physical education students. Body building training was performed three times a week (Monday, Wednesday, Friday, between 7:00 a.m. and 8:30 a.m.) for 6 weeks using traditional free weights.
62736840|NCT02552173||stem anteversion|intraoperative surgeon's estimation and postopertive CT sacn were taken to measure stem anteversion
62736841|NCT02329977||Recurrent group|Patients with history of recurrent common bile duct stone after successfully ERCP stone remove.
62736842|NCT02329977||Control group|Patients without history of recurrent common bile duct stone after successfully ERCP stone remove.
62736843|NCT02594930|EXPERIMENTAL|undirected and directed biopsy|Via an antero-lateral incision of the knee samples are taken without visual control; Afterwards an arthroscope is inserted and samples are taken from 5 defined regions of the knee (suprapatellar pouch, medial and lateral gutter, notch, Hoffa's fat pad)
62736844|NCT06662175|EXPERIMENTAL|Group A Hyperbaric Bupivicaine|Group A (Unexposed) will received 2 ml of intrathecal bupivacaine.
62736845|NCT06662175|EXPERIMENTAL|GROUP B Hyperbaric Bupivacaine and Dexmedetomidine|Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion.
62736846|NCT02345408|EXPERIMENTAL|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
62736847|NCT02013778|EXPERIMENTAL|TACE + HCQ|Subjects will receive HCQ plus standard of care TACE.
62736848|NCT05464940|ACTIVE_COMPARATOR|Group assigned to receive caffeine|
62736849|NCT05464940|PLACEBO_COMPARATOR|Group assigned to receive masked placebo|
62736850|NCT02319460||Retrospective|Retrospective cohort of adults hospitalized for major bleeding during 2008 to 2013 who receive plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
62736851|NCT02319460||Prospective|Prospective parallel cohort of adults hospitalized for major bleeding during 2014 to 2020 who either receive Kcentra® or plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
62736852|NCT01325051|NO_INTERVENTION|Raltegravir|To test raltegravir to see if it can be detected in gastrointestinal tissue of healthy men.
62736853|NCT06519240|ACTIVE_COMPARATOR|Patients with a diagnosis of cardiac rejection|Based on heart muscle biopsy findings. Subjects must have no significant coronary disease within the last 12 months (with a confirmatory angiogram, computed tomography coronary angiogram, myocardial perfusion scan, cardiac magnetic resonance imagining, or other coronary ischaemia test.
62736854|NCT06519240|ACTIVE_COMPARATOR|Patients with no evidence of cardiac rejection|Based on heart muscle biopsy findings
62736855|NCT06661252||Healthy Controls|Healthy volunteers.
62736856|NCT06661252||COPD sufferers|Previously diagnosed COPD sufferers.
62736857|NCT06661252||Asthma sufferers|Previously diagnosed asthma sufferers of various subtypes.
62736858|NCT06661252||Allergic rhinitis sufferers|Previously diagnosed seasonal or perennial allergic rhinitis sufferers.
62736859|NCT06661252||Chronic sinusitis sufferers|Previously diagnosed chronic sinusitis sufferers with/without nasal polyps.
62736860|NCT00703274|EXPERIMENTAL|Navigation Group|Participants enrolled in this group will receive education concerning primary and secondary PROTECT DC goals. Primary PROTECT DC goals adhere to the following medication directives: 1) Anti-hypertensive, 2) Lipid Lowering, 3) Anti-Coagulant, and 4) Anti-Diabetic. PROTECT DC secondary goals include the following behaviors 1) Smoking Cessation, 2) Consuming an AHA Diet, 3) Regular Exercise, and 4) Knowledge of Stroke Risk and Warning Signs. Participants will also receive assistance with overcoming resource-related barriers to the PROTECT DC goals.
62736861|NCT00703274|NO_INTERVENTION|Control Group|Participants enrolled in this group will receive periodic follow up through mailings, phone calls etc to ensure availability for 1 year assessment.
62739011|NCT03181217|EXPERIMENTAL|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
62736961|NCT05221567|ACTIVE_COMPARATOR|High intensity high dosage inpatient short-term psychodynamic psychotherapy (affect phobia therapy)|APT and VITA psychotherapy was carried out in accordance with treatment manuals. In addition to weekly individual sessions the inpatient program at both groups contained two 75 min group sessions each week. In addition, VITA had shorter group meetings each morning (15 minutes). Patients in both treatments participated in two physical exercise sessions per week, weekly psycho-educational lectures and art-therapy groups, and both groups finish each week with end of the week status groups. On average, patients in both treatments received seven sessions of therapeutic activity each week. All treatment components, with the exception of the physical exercises, adhered to the APT or VITA treatments, and thus the two intensive treatments were similar in dose but different in content. Medication was managed by psychiatrists, aiming to optimize the psychotropic medication regime, typically by reducing medication use.
62736962|NCT05221567|OTHER|Treatment-as-usual|TAU through public services locally, either outpatient treatment from a psychologist/psychiatrist and/or treatment/support from their local general practitioner.
62736963|NCT05221567|ACTIVE_COMPARATOR|High intensity high dosage inpatient short-term psychodynamic psychotherapy (VITA)|APT and VITA psychotherapy was carried out in accordance with treatment manuals. In addition to weekly individual sessions the inpatient program at both groups contained two 75 min group sessions each week. In addition, VITA had shorter group meetings each morning (15 minutes). Patients in both treatments participated in two physical exercise sessions per week, weekly psycho-educational lectures and art-therapy groups, and both groups finish each week with end of the week status groups. On average, patients in both treatments received seven sessions of therapeutic activity each week. All treatment components, with the exception of the physical exercises, adhered to the APT or VITA treatments, and thus the two intensive treatments were similar in dose but different in content. Medication was managed by psychiatrists, aiming to optimize the psychotropic medication regime, typically by reducing medication use.
62736964|NCT05450224|OTHER|Telehealth Massed Imaginal Exposure Therapy|
62736965|NCT02040922||Post-Campylobacter|Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
62736966|NCT01997593|EXPERIMENTAL|ropivacaine|Preincisional wound intraperitoneal infiltration of 1% ropivacaine 0.3ml/kg was performed in group I patients before surgery.
62736967|NCT01095081||Group 1|
62736968|NCT01976702|EXPERIMENTAL|Enhanced Behavioral Skills Training|The Enhanced Behavioral Skills Training (E-BST) will include four 90-minute group sessions and two 60-minute individual sessions regarding HIV prevention and diminishing risk behavior, enhancing communication skills, improving the use of support services, and enhancing the use of resources in their community.
62736969|NCT01976702|ACTIVE_COMPARATOR|Health Promotion Comparison|The Health Promotion Comparison (HPC)condition will receive one video-based HIV prevention session, 3 video-based 90-minute group sessions and an additional 2 60-minute sessions with discussions on relevant topics unrelated to HIV.
62736970|NCT06659042|EXPERIMENTAL|Tislelizumab plus platinum doublet chemotherapy|
62736971|NCT00586716|OTHER|Group 1 intravenous immune globulin|Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
62736972|NCT00586716|OTHER|Group 2 intravenous immune globulin|Intravenous immune globulin for patients who have living donors with positive crossmatch results.
62736973|NCT03898271|EXPERIMENTAL|Virtual World Training|Synchronous PTSD training in a virtual world environment
62736974|NCT03898271|ACTIVE_COMPARATOR|Web-based Video Training|Asynchronous web-based PTSD training
62736975|NCT02752919|EXPERIMENTAL|Part A Galunisertib - 1 tablet|Single oral dose of galunisertib in Japanese participants
62736976|NCT02752919|EXPERIMENTAL|Part A Galunisertib - 2 tablets|Single oral dose of galunisertib in Japanese participants
62736977|NCT02752919|EXPERIMENTAL|Part B Galunisertib - 1 tablet|Single oral dose of galunisertib in non-Japanese participants
62736978|NCT02752919|EXPERIMENTAL|Part B Galunisertib - 2 tablets|Single oral dose of galunisertib in non-Japanese participants
62736979|NCT06659146|EXPERIMENTAL|Head and neck squamous cell carcinoma|1) HNSCC i) Inoperable/incurable or recurrent/metastatic HNSCC with no previous radiotherapy treatment ii) Inoperable/incurable or recurrent/metastatic HNSCC with previous radiotherapy treatment (re-irradiation)
62736980|NCT06659146|EXPERIMENTAL|Cutaneous squamous cell carcinoma|2) cSCC i) Inoperable/incurable or recurrent/metastatic cSCC with no previous radiotherapy treatment ii) Inoperable/incurable or recurrent/metastatic cSCC with previous radiotherapy treatment (re-irradiation)
62736981|NCT06659146|EXPERIMENTAL|Locally recurrent breast cancer|3) LRBC locally recurrent breast cancer with previous radiotherapy treatment (re-irradiation)
62736982|NCT06196658|EXPERIMENTAL|anti-EX02 CAR T cells|
62736983|NCT05533294|EXPERIMENTAL|ARO-RAGE|single or multiple doses of ARO-RAGE by subcutaneous (sc) injection
62736984|NCT05533294|PLACEBO_COMPARATOR|Placebo|placebo calculated volume to match active treatment by sc injection
62736985|NCT00420082|EXPERIMENTAL|1|Bilastine 20 mg
62736986|NCT00420082|ACTIVE_COMPARATOR|2|Fexofenadine 120 mg
62736987|NCT00420082|ACTIVE_COMPARATOR|3|Cetirizine 10 mg
62736988|NCT00420082|PLACEBO_COMPARATOR|4|Placebo
62736989|NCT05170477|EXPERIMENTAL|Apical aptency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically
62736990|NCT05170477|ACTIVE_COMPARATOR|Non-apical patency|in Gp B apical patency will not be maintained
62736991|NCT03920462|OTHER|Programme of intelligent electric bike for health (single arm)|All volunteers will realise the programme of intelligent electric bike for health with connected vests.
62736992|NCT03719001|EXPERIMENTAL|Phenylephrine|Phenylephrine (100 ug/ml) infusion will be used to increase blood pressure by 20 mmHg
62736993|NCT03719001|EXPERIMENTAL|Dexmedetomidine|Dexmedetomidine infusion will be used to increase blood pressure by 20 mmHg
62736994|NCT03719001|EXPERIMENTAL|Clevidipine|Clevidipine infusion will be used to increase blood pressure by 20 mmHg
62736995|NCT03719001|EXPERIMENTAL|Calcium Chloride|Calcium Chloride will be administered to increase blood pressure and to increase blood calcium concentration
62736996|NCT03719001|EXPERIMENTAL|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be used to increase peripheral vascular tone
62737107|NCT02672189|EXPERIMENTAL|EVA-Online guided group|"The CBT/Relaxation program (EVA-Online) consists of 6 online sessions intended to be completed weekly over a 6 week period. The program comprises the following elements: (1) information and advice about symptoms (e.g., hot flushes, night sweats and sexual functioning); (2) monitoring and modifying precipitants; (3) relaxation and stress reduction; (4) cognitive restructuring of unhelpful thoughts and (5) encouraging helpful behavioral strategies (e.g., pacing activities). Throughout the program women will be asked to spend an hour a week to read the session and fill in the assignments and to spend 30 minutes per day on homework exercises (eg, filling in a hot flush/night sweats diary, practicing relaxation techniques).~Participating women will first undergo a 30 minute phone interview with a trained therapist before they start the online program. The same therapist will provide weekly feedback and support."
62737108|NCT02672189|EXPERIMENTAL|EVA-Online self-management group|The content of the self-management CBT/Relaxation program is the same as the guided version of the program as described above, but without weekly guidance by a trained therapist. The women allocated to the self-management intervention will work through the program independently.
62737109|NCT06169787||Sentinel Lymph Node|Sentinel lymph node biopsy in patients with early stage cervical cancer
62737110|NCT06169787||Lymphadenectomy|Comprehensive lymphadenectomy in patients with early stage cervical cancer
62737111|NCT00907322|EXPERIMENTAL|Dimbeon 20 mg|
62737112|NCT00907322|EXPERIMENTAL|Dimebon 40 mg|
62737113|NCT00907322|EXPERIMENTAL|Dimebon 60 mg|
62737114|NCT00907322|EXPERIMENTAL|Placebo|
62737115|NCT03148379|EXPERIMENTAL|Customized patient instruments|Experimental group: Patients randomized into this group will undergo surgery utilizing single-use Efficiency Instruments with patient-specific technique (MyKnee® patient-matched cutting blocks)
62737116|NCT03148379|ACTIVE_COMPARATOR|Traditional metal instruments|Control Group: Patients will undergo conventional surgical technique
62737117|NCT05294484|ACTIVE_COMPARATOR|Fasting group|Following an overnight fast of at least 10 hours, subjects should be administered single dose of indapamide 1.5 mg SR with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.
62737118|NCT05294484|ACTIVE_COMPARATOR|Fed group|"Following an overnight fast of at least 10 hours, subjects should start the recommended meal 30 minutes prior to administration of the drug. Study subjects should eat this meal in 30 minutes or less; however, indapamide 1.5 mg SR should be administered 30 minutes after start of the meal. The drug should be administered with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.~All subjects should abstain from the consumption of fruit juices during the study period. All the subjects are to be under complete medical supervision."
62737119|NCT06130475|EXPERIMENTAL|Oral Rehydration Solution|Oral rehydration solution with carbohydrate
62737120|NCT06130475|EXPERIMENTAL|Water|Water with flavor
62737121|NCT05828589|EXPERIMENTAL|Part 1 (Cohort A1): Dose escalation in patients with B-cell non-Hodgkin lymphoma (NHL)|Participants with R/R B-cell NHL (including diffuse large B-cell lymphoma \[DLBCL\], follicular lymphoma \[FL\], marginal zone lymphoma \[MZL\], transformed B-cell NHL (B-NHL), and Richter's transformation to DLBCL) will receive BGB-21447 once a day.
62737122|NCT05828589|EXPERIMENTAL|Part 1 (Cohort B): Dose escalation in R/R CLL/SLL participants with low tumor burden|Participants with relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) will receive BGB-21447 once a day.
62737123|NCT05828589|EXPERIMENTAL|Part 2 (Cohort A2): BGB-21447 Monotherapy Dose Expansion|Participants will receive BGB-21447 with up to two dose levels from Cohort A1 for further evaluation of safety and efficacy.
62737124|NCT05252494|EXPERIMENTAL|animal assisted therapy group|Animal assisted therapy group will watch aquarium fish while bloodletting prosedure.
62737125|NCT05252494|NO_INTERVENTION|Control Group|Control group will not watch aquarium fish while bloodletting prosedure.
62737126|NCT04196855|EXPERIMENTAL|Intervention - Teriparatide Treatment|Teriparatide 20ug/day from confirmation of stress fracture for 16 weeks, with the potential to extend to 24 weeks if required.
62737127|NCT04196855|NO_INTERVENTION|Control - Standard Care|Standard rehabilitation care with additional monitoring to assess healing.
62737128|NCT06221761|EXPERIMENTAL|Non antibiotic group|Not using antibiotics within 72 hours after burns
62737129|NCT06221761|ACTIVE_COMPARATOR|antibiotic group|Using antibiotics within 72 hours after burns
62737130|NCT02441907|OTHER|aflibercept treatment|aflibercept, 40 mg/mL Solution for Intravitreal Injection
62737131|NCT05466136|EXPERIMENTAL|Mental fatigue condition|Performing a completed incongruent version of Stroop task for 30min.
62737132|NCT05466136|EXPERIMENTAL|Control condition|Performing a completed congruent version of Stroop task for 30min.
62737133|NCT03727022|EXPERIMENTAL|0.07 mg SM04690|Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle
62737134|NCT03727022|PLACEBO_COMPARATOR|Vehicle|Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
62737135|NCT06221943|EXPERIMENTAL|experimental group|ASD preschoolers who receive group-based NDBIs intervention (aged 2-6y)
62737136|NCT06221943|ACTIVE_COMPARATOR|active control group|ASD preschoolers who receive one-on-one NDBIs intervention (aged 2-6y)
62737137|NCT06245486|EXPERIMENTAL|Probiotic Young Group (Women aged 18-29 years)|Participants in this group will take probiotic Crispact® (20 Bld CFU/Stick of Lactobacillus crispatus M247) as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
62737138|NCT06245486|ACTIVE_COMPARATOR|Control Young Group (Women aged 18-29 years)|Participants in this group will take Placebo as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
62737139|NCT06245486|EXPERIMENTAL|Probiotic Lady Group (Women aged 30-64 years)|Participants in this group will take probiotic Crispact® (20 Bld CFU/Stick of Lactobacillus crispatus M247) as 1 sachet oral per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
62737140|NCT06245486|ACTIVE_COMPARATOR|Control Lady Group (Women aged 18-29 years)|Participants in this group will take Placebo as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
62737387|NCT02514811|EXPERIMENTAL|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
62737388|NCT02514811|NO_INTERVENTION|Control Group|Students in the control condition receive a benign intervention called the Community Voices (CV) program, which like TOP, meets in a group setting. The CV students are convened four times during the program year. Sessions are the same length as the TOP sessions. The first and last CV sessions are primarily focused on survey data gathering. At the two other sessions, CV students are convened to discuss current issues among young people in their community. The CV program specifically does not include any sexuality education or community service learning opportunities.
62737389|NCT01826539|OTHER|Innervated finger flap|donor nerve attached with the flap for finger pulp reconstruction
62737390|NCT00104728|EXPERIMENTAL|Neoadjuvant ZD1839 Preoperative Therapy|"The ZD1839 250-mg tablet will be taken once a day, every day about the same time. It can be taken with or without food.~At the time of surgery, investigators will collect tissue from the participant's tumor once it has been removed. This tissue will be used to study the effect of ZD1839 on tumor growth."
62737391|NCT06552975||Bacterial infection|Individuals with acute fever whose positive bacteria isolated from sterile or non-sterile sites have pathological characteristics.
62737392|NCT06552975||Viral infection|Individuals with acute fever whose viral nucleic acid test and/or serological positive compatible with acute syndrome#(e.g. serology, PCR).
62737393|NCT06552975||non-infectious group|Individuals with acute fever whose have negative findings in cultures and PCR; negative image modality findings suspected for infection; confirmed or highly likely other diagnosis; improvement without antibiotics.
62737394|NCT02620878|EXPERIMENTAL|AP|"Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.~Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence"
62737395|NCT02620878|ACTIVE_COMPARATOR|SAP|"Active Comparator: Sensor Augmented Pump (SAP teraphy : CGM + insulin pump) will be used for 72 hours during day and night (3 days).~Patients will be randomly assigned to receive either 3 days of SAP (Control) followed by 3 days of automated closed-loop insulin delivery (intervention), or the inverted sequence"
62737396|NCT01521923|EXPERIMENTAL|CZP 200 mg Q2W + Methotrexate|
62737397|NCT01521923|EXPERIMENTAL|CZP 200 mg Q4W + Methotrexate|
62737398|NCT01521923|PLACEBO_COMPARATOR|Placebo + Methotrexate|
62737399|NCT05912894||Videolaparoscopic cholecystectomy|Patients undergoing Videolaparoscopic cholecystectomy
62737400|NCT03136224|EXPERIMENTAL|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
62737401|NCT03136224|ACTIVE_COMPARATOR|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
62737402|NCT03136224|SHAM_COMPARATOR|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
62737403|NCT01788397|EXPERIMENTAL|Physical activity|Physical activity 2-4 times pr. day
62737404|NCT01788397|NO_INTERVENTION|Control group|No intervention in the control group
62737405|NCT03403530|ACTIVE_COMPARATOR|case group|'IgM rich immunoglobulin' intravenous infusion in the dose of 5 ml/ kg/ dose over 3 hours once a day for 3 days.
62737406|NCT03403530|PLACEBO_COMPARATOR|control group|antibiotics only
62737407|NCT00107900|EXPERIMENTAL|15mg BID|15mg edoxaban administered twice daily (BID)
62737408|NCT00107900|EXPERIMENTAL|30mg QD|30mg edoxaban administered once daily (QD)
62737409|NCT00107900|EXPERIMENTAL|30mg BID|30mg edoxaban administered twice daily (BID)
62737410|NCT00107900|EXPERIMENTAL|60mg QD|60mg edoxaban administered once daily (QD)
62737411|NCT00107900|EXPERIMENTAL|60mg BID|60mg edoxaban administered twice daily (BID)
62737412|NCT00107900|EXPERIMENTAL|120mg QD|120mg edoxaban administered once daily (QD)
62737413|NCT01574820|PLACEBO_COMPARATOR|placebo|
62737414|NCT01574820|EXPERIMENTAL|rosiglitazone (4 mg)/day|
62737415|NCT02801682||Healthy Controls|
62737416|NCT02801682||Invasive Candidiasis|
62737417|NCT02801682||Bacterial Sepsis (Bacteremia)|
62737418|NCT02801682||ICU patients without infectious disease|
62737419|NCT00570778|EXPERIMENTAL|indacaterol/glycopyrrolate 300/50 μg|One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
62737621|NCT02601638|EXPERIMENTAL|Arm 1|"* Demographics and Health History Questionnaire (5-10 minutes to complete)~* Pre-Class Laryngectomy Survey (5-10 minutes to complete)~* Attend a preoperative counseling session with a speech pathologist. It will take 30-60 minutes~* Attend the Total Laryngectomy Preoperative Education Class. Participants will attend within 1-2 weeks of providing written consent and prior to their scheduled surgery. The preoperative education class will take one hour.~* Complete the Day of Hospital Discharge Laryngectomy Survey at the time of discharge from the hospital (5-10 minutes to complete)~* Perform the day of discharge practicum assessing the minimal competency skills for laryngectomy care prior to discharge from the hospital.~* Complete the Laryngectomy Education Study Exit survey. Participants will perform an exit survey at the first clinic appointment after 30 days after hospital discharge (15-30 minutes to complete)"
62737622|NCT06125171|EXPERIMENTAL|Tucidinostat+Apatinib|
62737623|NCT01545869|EXPERIMENTAL|Fractional carbon dioxide laser|
62737624|NCT05645393|ACTIVE_COMPARATOR|EstroGel® 0.06%|EstroGel® 0.06% (1.25 g of gel)
62737625|NCT05645393|ACTIVE_COMPARATOR|Biest cream|Biest cream (equivalent dose to EstroGel®)
62737626|NCT03960060|EXPERIMENTAL|CCT301-59|The safety and preliminary therapeutic efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation rule. Three dose levels of CAR T will be administered in this study: 1x10\^6, 3x10\^6, 1x10\^7 CCT301-59 CAR positive T cells/kg weight, intravenous infusion.
62737627|NCT04262466|EXPERIMENTAL|Brenetafusp Monotherapy|Participants receive brenetafusp.
62737628|NCT04262466|EXPERIMENTAL|Brenetafusp and Anti-PD(L)1 Agent|Participants receive brenetafusp and pembrolizumab.
62737629|NCT04262466|EXPERIMENTAL|Brenetafusp and Chemotherapy|Participants receive brenetafusp and chemotherapy. Choice of chemotherapy is dependent on cohort.
62737630|NCT04262466|EXPERIMENTAL|Brenetafusp and Targeted Therapy|Participants receive brenetafusp and a selected targeted therapy. Receipt of kinase inhibitor is dependent on histology.
62737631|NCT04262466|EXPERIMENTAL|Brenetafusp and Multimodal Therapy|Participants receive brenetafusp, biologics (eg, pembrolizumab, bevacizumab) IV infusions and chemotherapy IV infusions based on histology.
62737632|NCT00887367|PLACEBO_COMPARATOR|Placebo to match GSK598809|Placebo to match GSK598809.
62737633|NCT00887367|PLACEBO_COMPARATOR|Placebo to match ethanol infusion|Glucose solution to be given in the same way as ethanol.
62737634|NCT01849692|EXPERIMENTAL|ESBA1008 1.2 mg/10 μL|Cohort 1: One intravitreal injection on Day 0, followed by one intravitreal (IVT) injection of ESBA1008 6 mg/50 μL on Day 28
62737635|NCT01849692|EXPERIMENTAL|ESBA1008 1 mg/8.3 μL|Cohort 2: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
62737636|NCT01849692|EXPERIMENTAL|ESBA1008 0.6 mg/10 μL|Cohort 3: One intravitreal injection on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
62737637|NCT01849692|EXPERIMENTAL|ESBA1008 0.5 mg/8.3 μL|Cohort 4: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
62737638|NCT01849692|ACTIVE_COMPARATOR|Ranibizumab 0.5 mg in 50 μL|Cohorts 1-4: One intravitreal injection on Day 0, followed by another intravitreal injection on Day 28
62737639|NCT03614741|ACTIVE_COMPARATOR|Control group|Bolus of 4500 IU tinzaparin
62737640|NCT03614741|ACTIVE_COMPARATOR|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
62737641|NCT02798315||Participants With Hepatitis C Virus (HCV) Genotype 1 or 4|"Participants with HCV genotype 1 or 4 receiving paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
62737642|NCT06554782|EXPERIMENTAL|manual u-shaped toothbrush|manual u-shaped toothbrush with arm angled 45 degrees to brush upper and lower arch at the same time
62737643|NCT06554782|EXPERIMENTAL|manual toothbrush|manual toothbrush with soft bristles and circular movement to clean each quadrant separately
62737644|NCT04963855|ACTIVE_COMPARATOR|CT300|GT300 capsule given once daily
62737645|NCT04963855|PLACEBO_COMPARATOR|Placebo|Microcrystalline cellulose capsule given once daily
62737646|NCT00834600|EXPERIMENTAL|HCTZ , ARB|Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA \>.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
62737647|NCT00834600|ACTIVE_COMPARATOR|Conventional antihypertensive therapy|All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP \> 140 mmHg
62737648|NCT03628105|EXPERIMENTAL|CR Before Exposure|Participants in this arm will receive 15 minutes of CR (preparation) before engaging in exposure and will complete the 15-minute questionnaire filler task after exposure.
62737649|NCT03628105|EXPERIMENTAL|CR After Exposure|Participants in this arm will complete the 15-minute questionnaire filler task before exposure and receive 15 minutes of CR (consolidation) after engaging in exposure.
62737650|NCT04079231|EXPERIMENTAL|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
62737651|NCT04079231|ACTIVE_COMPARATOR|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
62737652|NCT05273372|EXPERIMENTAL|Oxaloacetate|500 mg anhydrous enol-oxaloacetate in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
62737653|NCT05273372|PLACEBO_COMPARATOR|Placebo|500 mg white rice flour in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
62737654|NCT06179810|EXPERIMENTAL|Baduanjin exercise in addition to medical treatment|30 patients with metabolic syndrome do baduanjin exercise in addition to traditional medical treatment
62737655|NCT06179810|EXPERIMENTAL|Traditional medical treatment|30 patients with metabolic syndrome taking traditional medical treatment
62737656|NCT01127464|EXPERIMENTAL|.3 dose level of DCVax -001|.3 dose level of DCVax plus fixed dose of 1.6 ml Poly ICLC
62737657|NCT01127464|EXPERIMENTAL|1 mg dose level of DCVax -001|1 mg dose level of DCVax -001 plus 1.6 ml of poly ICLC
62737658|NCT01127464|EXPERIMENTAL|3 mg dose level of DCVax-001|3 mg dose level of DCVax-001 plus poly ICLC
62737880|NCT06208293|EXPERIMENTAL|KPZ Program (KPZ)|Participants in this group will receive the KPZ program in addition to EUC. This group will receive the culturally adapted suicide prevention package (KPZ) of services delivered by trained Peers. The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level. A Peer will be assigned an eligible mother and visit her within no less than 48 hours of enrollment. The first session will be delivered within two days of detection, and follow up contacts conducted by a trained Peer at 24 hours, every two days (for one week), weekly (for 1 month), and monthly (for 5 months), totaling 13 KPZ sessions in all. Contact assesses how the participant is coping, if the safety plan is helpful, adjustments to the safety plan, assessment of the suicide ideation and depression, and providing basic motivational interviewing and referral as needed.
62737881|NCT06208293|ACTIVE_COMPARATOR|Enhanced Usual Care (EUC)|Participants in this group will receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
62737882|NCT03420755|EXPERIMENTAL|MB 1-on-1 Only|Mothers and Babies 1-on-1. MB 1-on-1 -12-session intervention Each MB session lasts 15-20 minutes and is delivered as part of a regularly scheduled home visit (English or Spanish).
62737883|NCT03420755|EXPERIMENTAL|MB 1-on-1 Plus TEXT|Mothers and Babies Plus Text. MB 1-on-1 along with text enhancements both in English and Spanish.
62737884|NCT05966090|EXPERIMENTAL|RSV+ HZ/su Co-administration Group|Participants will be administered first dose of HZ/su vaccine and the RSVPreF3 OA investigational vaccine together on Day 1. A second dose of the HZ/su vaccine will be administered at Day 61.
62737885|NCT05966090|ACTIVE_COMPARATOR|RSV+HZ/su Control Group|Participants will be administered first dose HZ/su vaccine on Day 1, followed by the RSVPreF3 OA investigational vaccine on Day 31, and then second dose of HZ/su vaccine on Day 61.
62737886|NCT05335304|ACTIVE_COMPARATOR|intervention group 1|Kinesio taping and standard treatment program
62737887|NCT05335304|ACTIVE_COMPARATOR|intervention group 2|Rigid taping and standard treatment program
62737888|NCT05335304|ACTIVE_COMPARATOR|intervention group 3|Thoracic Mobilization and standard treatment program
62737889|NCT05335304|ACTIVE_COMPARATOR|intervention group 4|Core Stabilization and standard treatment program
62737890|NCT05335304|OTHER|Control group|No intervention, only standard treatment program
62737891|NCT04568486|OTHER|Rural-dwelling older adults (seed) and Key players (alter|Rural-dwelling older adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. This group will be paired with their key players (identified during interviews) to receive the diabetes education. The pair complete the intervention as a dyad.
62737892|NCT06574880|EXPERIMENTAL|Lu-PSMA-617 + SBRT|"* Lu-PSMA-617: 7.4GBq intravenous infusion once with cycle 1, followed by 7.4GBq cycle 2 that is delivered 6 weeks after SBRT , and potentially 7.4GBq cycle #3 delivered 6 weeks after cycle #2 pending dose escalation~* Radiation therapy: 5 fractions to prostate and elective nodal irradiation, SBRT, delivered 6 weeks after cycle 1 of 177Lu-PSMA-617"
62737893|NCT01835977|ACTIVE_COMPARATOR|Focal ablation|Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE
62737894|NCT01835977|ACTIVE_COMPARATOR|Extended ablation|Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE
62737895|NCT02177331|EXPERIMENTAL|Lacidipine|
62737896|NCT04093193|EXPERIMENTAL|Debridement group|Patients receive routine post-operative debridement at their Day 6, 30 and 60 follow up appointments.
62737897|NCT04093193|NO_INTERVENTION|Non Debridement Group|Patients will not receive debridement at any follow up visit after surgery. They will continue with saline irrigation.
62737898|NCT00970723|EXPERIMENTAL|intensive treatment|with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected
62737899|NCT00970723|ACTIVE_COMPARATOR|conventional treatment|in accordance with national guidelines
62737900|NCT05631340|EXPERIMENTAL|case group|Recieving additional discharge education by the researcher and supported by a booklet and mobile app
62737901|NCT05631340|ACTIVE_COMPARATOR|control group|Recieving standart hoapital discharge education
62737902|NCT04733118|EXPERIMENTAL|Patient HER 2+ IHC 3+|Patients ≥18 years of age with previously untreated HER2-positive (HER2\[+\]) (Immunohistochemistry \[IHC\] 3+) invasive carcinoma according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and tumor size between \>5 to 25 mm by breast magnetic resonance imaging (MRI) and node-negative status by clinical exam, MRI, and ultrasound. Patients must have not been previously treated with chemotherapy, anti-HER2 therapy, radiation therapy, or endocrine therapy (ET) for invasive breast cancer. Patients with metastatic disease are not eligible. In patients with suspected axillary node involvement, a negative fine needle aspiration biopsy (FNAB) will be mandatory
62737903|NCT05974384|PLACEBO_COMPARATOR|No Music|Intervention without music
62737904|NCT05974384|ACTIVE_COMPARATOR|Music|Intervention while listening to music
62737905|NCT02697981|EXPERIMENTAL|intervention group|Pregnant post bariatric surgery women will receive nutritional counseling from a specialist dietitian, to ensure a healthy balanced diet including adequate daily servings from all food groups, intake of essential nutrient during pregnancy such as iron and folic acid and limitation of high-sugar and fatty foods. Patients will also be advised concerning eating at scheduled times (e.g., 4-6 times daily), supplements, preference of water. Advice concerning healthy cooking methods will also be given, as well as advised to avoid soft drinks, drinking during meals, grazing and emotional eating, and fast foods. Subject of lifestyle in general - encouraged to incorporate suitable physical activity on most days, refraining from alcohol, and smoking. intervention: nutrition counseling
62738365|NCT05304975|ACTIVE_COMPARATOR|intervention|"Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline and review study visits.~The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise resource that has been designed for older adults.~Cognitive stimulation will be delivered using Brain HQ®, a computer based cognitive training platform, which utilises visuospatial and auditory games to enhance attention, mental processing speed, learning, memory, and low mood.~Participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary.~The 4-month active intervention will be followed by a 2-month self-directed consolidation phase and all participants will be left to their own initiative for a further 3 months"
62738366|NCT05304975|OTHER|control|this will be routine management of the diabetes condition as per current recommended practice
62738367|NCT02642393|EXPERIMENTAL|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
62738368|NCT02642393|PLACEBO_COMPARATOR|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
62738369|NCT02019615|ACTIVE_COMPARATOR|anodal stimulation|Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
62738370|NCT02019615|SHAM_COMPARATOR|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session.
62738371|NCT02797301|EXPERIMENTAL|synthetic test & computerised test|Seventeen preschool children (G1), with no motor impairments, from a private school. The children in G1 performed the synthetic test before the computerised test.
62738372|NCT02797301|EXPERIMENTAL|computerised test & synthetic test|Sixteen preschool children (G2), with no motor impairments, from a private school. The children in G2 performed the computerised test before the synthetic test.
62738373|NCT02797301|EXPERIMENTAL|computerised test|Seven volunteers (G3), two males and five females, with moderate mobility impairment, patients from the Physical Therapy and Rehabilitation Clinic.
62738374|NCT01157572|ACTIVE_COMPARATOR|Metoprolol|
62738375|NCT01157572|PLACEBO_COMPARATOR|Placebo|
62738376|NCT02476032|EXPERIMENTAL|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter \& Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
62738377|NCT02476032|ACTIVE_COMPARATOR|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter \& Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
62738378|NCT02476032|SHAM_COMPARATOR|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter \& Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
62738379|NCT05051670|EXPERIMENTAL|SP group|patients group underwent gastrectomy using da vinci SP
62738380|NCT05502718|ACTIVE_COMPARATOR|Study Group|The patients in the study group will be given stretching, strengthening, breathing and rhythmic coordination exercises for the muscles involved. (Personalized exercise program)
62738381|NCT05502718|PLACEBO_COMPARATOR|Control Group|The patients in the control group will be given only breathing and rhythmic coordination exercises.
62738382|NCT02810769|PLACEBO_COMPARATOR|Control|Sugar matched control containing no phytochemicals
62738383|NCT02810769|EXPERIMENTAL|Juiced berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
62738384|NCT02810769|EXPERIMENTAL|Powdered berry drink|Berry drink made up from a powdered concentrate. each drink will be standardised to contain 500mg of polyphenols
62738385|NCT04812769|EXPERIMENTAL|Intervention|Two nursing homes will receive the eCARE-ID intervention
62738386|NCT04812769|PLACEBO_COMPARATOR|Control|One control nursing home will receive infectious disease consultations and antibiotic stewardship services per routine practice.
62738387|NCT03462927|EXPERIMENTAL|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
62738388|NCT03462927|ACTIVE_COMPARATOR|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
62738389|NCT03796390|EXPERIMENTAL|CD123 CAR-T cells|Patients will be be treated with CD123 CAR-T cells
62738390|NCT02374281|EXPERIMENTAL|Glucose sucking|"The newborn will receive one minute before the painful care either a compress with sucrose.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Glucose 30% by oral route (1 ml)."
62738391|NCT02374281|ACTIVE_COMPARATOR|Water sucking|"The newborn will receive one minute before the painful care either a compress with water.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Sterile water by oral route (1 ml)."
62738392|NCT02374281|PLACEBO_COMPARATOR|No sucking|The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
62738393|NCT03982784|EXPERIMENTAL|single-injection TQLB(transmuscular quadratus lumborum block)|Single-injection of TQLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
62738394|NCT03982784|ACTIVE_COMPARATOR|Control|postoperative IPCA is given alone
62739012|NCT03181217|EXPERIMENTAL|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
62738395|NCT05936619|EXPERIMENTAL|Mind Extender (MindEx)|MindEx consists of two Neuroport Multi-Port Arrays, described in detail in the intervention description. Each NeuroPort Multi-Port Array comprises two electrode arrays implanted into human brain tissue, for a total of four electrode arrays. These will be in 1) prefrontal cortex, a brain area involved in scene comprehension, action selection, and error signaling, 2) premotor cortex, a brain area involved in planning ongoing and upcoming actions, 3) posterior parietal cortex, a brain area involved in processing sensory-to-motor transformations during movements, and 4) primary motor cortex, responsible for controlling movement. The pair of electrode arrays in each NeuroPort Multi-Port Array connect to a single percutaneous pedestal attached to the skull during a surgical procedure. Following recovery from the surgical placement, subjects will participate in study sessions up to 5 times a week. They will learn to use thought to control applications on a computer, a laptop, or a tablet.
62738396|NCT06661460|EXPERIMENTAL|Internet-Delivered Cognitive-Behavioral Therapy|Includes the intervention Internet-Delivered Cognitive-Behavioral Therapy.
62738397|NCT04748679|EXPERIMENTAL|Worry Intervention|The Worry Intervention uses cognitive-behavioral therapy (CBT) techniques to support the patient in reducing the amount of time they worry throughout the week. It is an 8-week manualized treatment with 5 modules. Each session is 45-60 minutes.
62738398|NCT04748679|ACTIVE_COMPARATOR|Befriending|Befriending therapy controls for the general factors of therapy (warmth, engagement) without any 'active' interventions. Individuals in the befriending arm will spend sessions talking with the therapist about things that interest them. It will also be conducted over 8-weeks with 45-60 minute sessions.
62738399|NCT06631469|EXPERIMENTAL|Personalised behavioural sustainable and healthy dietary recommendations|Personalised dietary plan, standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus personalised behavioural support and strategies aimed at meeting personalised dietary recommendations.
62738400|NCT06631469|ACTIVE_COMPARATOR|Personalised sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice) aimed at meeting personalised dietary recommendations.
62738401|NCT05029128|OTHER|Exercise|All participants engage in exercise training
62738402|NCT00863044|ACTIVE_COMPARATOR|High frequency ventilation|high frequency ventilation
62738403|NCT00863044|PLACEBO_COMPARATOR|Apnea|lung ventilation will be stopped during distal anastomosis as is commonly done
62738404|NCT04797273|EXPERIMENTAL|Internet-based cognitive behavior therapy|
62738405|NCT04797273|ACTIVE_COMPARATOR|Internet-based structured treatment-as-usual|
62738406|NCT06521385|EXPERIMENTAL|Device Arm|Subjects with both the reference and experimental device placed for paired data collection
62738407|NCT05363501|ACTIVE_COMPARATOR|Naloxone IM Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
62738408|NCT05363501|ACTIVE_COMPARATOR|Intranasal Naloxone Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
62738409|NCT05363501|EXPERIMENTAL|Single 8 mg naloxone nasal swab-Swirl method|Single 8 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
62738410|NCT05363501|EXPERIMENTAL|Single 4 mg naloxone nasal swab-Swirl method|Single 4 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
62738411|NCT05363501|EXPERIMENTAL|Single 12 mg naloxone nasal swab-Swirl method|Single 12 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
62738412|NCT05363501|EXPERIMENTAL|Single 12 mg naloxone nasal swab-Squeeze method|Single 12 mg naloxone nasal swab administered into the nasal cavity - administered in one nostril and using two fingers to squeeze outside of both nostrils.
62738413|NCT05363501|EXPERIMENTAL|Single 12 mg naloxone nasal swab in each nostril-Squeeze method|Two 12 mg naloxone nasal swabs in both nostrils- administered one per nostril and using two fingers to squeeze outside of both nostrils (two doses given sequentially)
62738414|NCT05363501|EXPERIMENTAL|Single 8 mg naloxone nasal swab in each nostril-Squeeze method|Two 8 mg naloxone nasal swab in both nostrils - administered one per nostril and using two fingers to squeeze outside of both nostrils (two doses given sequentially)
62738415|NCT05363501|EXPERIMENTAL|Single 12.5 mg naloxone nasal swab-Squeeze method|Single target naloxone nasal swab dose identified in Phase 1(12.5 mg) administered as one swab in one nostril, using the insert into nostril and squeeze method of administration
62738416|NCT05363501|EXPERIMENTAL|Single 12.5 mg naloxone nasal swab in each nostril-Squeeze method|Single target naloxone nasal swab dose identified in Phase 1 (12.5 mg) using the insert into each nostril and squeeze method of administration (two doses given in total).
62738417|NCT04802031|EXPERIMENTAL|Treatment (isatuximab)|Participants receive their first rapid infusion of isatuximab IV over 30 minutes. If a \>=Grade 2 iRR occurs, then participants will revert to a SOC infusion time and be removed from the study. If a Grade 1 or no IRR occurs, then participants will receive another rapid infusion of 30 minutes. Participants will continue to receive RI and IRR assessment after each dose up to at least 6 doses or until a grade 2 or higher IRR occurs.
62738418|NCT04631198|NO_INTERVENTION|No Intervention: GROUP CONTROL|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, expiratory flow acceleration, fractional inspiration in times, diaphragmatic breaths and aspiration when required
62738419|NCT04631198|EXPERIMENTAL|Active Comparator: INTERVENTION GROUP|The patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
62738420|NCT01312805|ACTIVE_COMPARATOR|CHICA Control|This arm received CHICA without the asthma module
62738421|NCT01312805|EXPERIMENTAL|CHICA Asthma Module|This arm received the CHICA asthma module
62738422|NCT05469425|EXPERIMENTAL|Preoperative home-based exercise training|Patients allocated to this group will receive usual care plus a preoperative home-based exercise program consisting of aerobic and resistance exercise. In addition, a physical therapist will carry out weekly telephone supervision with all participants.
62738744|NCT06012084|EXPERIMENTAL|iCF-PWR Intervention|"Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program is comprised of five text/voice-delivered, animated, interactive modules. The pathways are comprised of the same modules that take approximately 15 to 20 minutes to complete. Modules are comprised of web pages and/or screens with numerous illustrations and interactive components. Written module content will be presented verbally as well as in text format.~The program modules include: (1) What is CF? (i.e., physiological explanation of CF, prevalence rate); (2) How does my sibling with CF stay healthy? (i.e., review of medication, nutrition, physiotherapy treatment, and why treatment is important); (3) How does CF affect me?; (4) Mental health awareness (i.e., introduction to cognitive behaviour model of emotions-thoughts, feelings, bodily sensations, and behaviours); and (5) Strategies (i.e., ways to challenge unhelpful thoughts, talking about emotions, relaxation)."
62738745|NCT05625516||Patients with acute syndesmotic injuries|The patients undergo a bilateral external torque CT.
62738746|NCT05625516||Patients with asymptomatic chronic syndesmotic injuries|The patients undergo a bilateral external torque CT.
62738747|NCT05625516||Patients with symptomatic chronic syndesmotic injuries|The patients undergo a bilateral external torque CT.
62738748|NCT03550443|EXPERIMENTAL|RTA 402(Bardoxolone methyl)|Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
62738749|NCT03550443|PLACEBO_COMPARATOR|Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
62738750|NCT04637776||Patients with Heart Failure|Patients with heart failure who were discharged within the past month after hospitalization for any reason.
62738751|NCT00758368|EXPERIMENTAL|Ambulatory Pump|Participants will receive apomorphine via a pump. Participants in the Continuous Delivery Arm will self-administer apomorphine continuously (12-14 hours a day) using a portable pump.
62738752|NCT00758368|ACTIVE_COMPARATOR|Subcutaneous Injections|Participants will receive apomorphine via an injection pen. Participants in the Intermittent Delivery Arm will self-administer apomorphine at intervals, via a injection, using pen injector.
62738753|NCT03143153|EXPERIMENTAL|Nivolumab + Ipilimumab|
62738754|NCT03143153|EXPERIMENTAL|Nivolumab + Cisplatin + Fluorouacil|
62738755|NCT03143153|ACTIVE_COMPARATOR|Cisplatin + Fluorouracil|
62738756|NCT05088915|EXPERIMENTAL|BREATHE Primary Care Intervention for PTSD (PCIP)|"BREATHE PCIP is a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms for use with individuals who have a diagnosis of PTSD or probable PTSD. The treatment will be considered delivered when patients have learned and practiced breathing retraining and have discussed the symptoms of PTSD (Sessions 1 through 3)."
62738757|NCT05088915|ACTIVE_COMPARATOR|Treatment As Usual|Receive standard care treatment and provided information on free or low cost mental health care referrals in the Los Angeles Area.
62738758|NCT01282242|EXPERIMENTAL|IV rt-PA|open-label
62738759|NCT02222688|EXPERIMENTAL|Cirmtuzumab 0.015 - 0.03 mg/kg|Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
62738760|NCT02222688|EXPERIMENTAL|Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg|Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
62738761|NCT02222688|EXPERIMENTAL|Cirmtuzumab 0.5 - 1.0 mg/kg|Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
62738762|NCT02222688|EXPERIMENTAL|Cirmtuzumab 2.0 - 4.0 mg/kg|Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
62738763|NCT02222688|EXPERIMENTAL|Cirmtuzumab 8 mg/kg|Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
62738764|NCT02222688|EXPERIMENTAL|Cirmtuzumab 16 mg/kg|Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
62738765|NCT02222688|EXPERIMENTAL|Cirmtuzumab 20 mg/kg|Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
62738766|NCT00789152|EXPERIMENTAL|desloratadine followed by levocetirizine|Subjects in this arm received desloratadine 5 mg daily for 8 days, followed by 10 day washout period, then followed by levocetirizine 5 mg daily for 8 days
62738767|NCT00789152|EXPERIMENTAL|levocetirizine followed by desloratadine|Subjects in this arm received levocetirizine 5 mg daily for 8 days, followed by 10 day washout period, then followed by desloratadine 5 mg daily for 8 days
62738768|NCT00933608|EXPERIMENTAL|memantine|after a period of gradual dose increase from 5 mg/day, participants will be asked to take memantine (20mg/day) for 16 weeks 10 mg in the morning, 10 mg at night
62738769|NCT00933608|PLACEBO_COMPARATOR|Placebo|dose increase to match active drug, after that 1 tablet in the morning, 1 tablet at night, to match active drug
62738770|NCT00600106|ACTIVE_COMPARATOR|Hormone replacement therapy|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
62738771|NCT00600106|PLACEBO_COMPARATOR|Placebo|1mg placebo
62738772|NCT00224120|EXPERIMENTAL|Silodosin|Silodosin 8 mg/Day with food
62738773|NCT00224120|PLACEBO_COMPARATOR|Placebo|Matching placebo capsule once daily with food
62738774|NCT06419959|EXPERIMENTAL|NightWare active|Intervention with NightWare Therapeutic System
62738775|NCT06419959|SHAM_COMPARATOR|NightWare Sham|NightWare app disabled; device will not deliver an intervention
62738776|NCT06549504|EXPERIMENTAL|AG2202T|
62738777|NCT06549504|ACTIVE_COMPARATOR|AG2202R|
62738778|NCT03753360|OTHER|Intervention Group|internet-based mindfulness meditation program
62738779|NCT03753360|OTHER|Active Control Group|relaxing music
62738780|NCT00319202|EXPERIMENTAL|1|
62738781|NCT00319202|PLACEBO_COMPARATOR|2|
62738782|NCT06416878|EXPERIMENTAL|Intervention|All participants
62738783|NCT02289911|ACTIVE_COMPARATOR|Class|Traditional learning form
62738784|NCT02289911|ACTIVE_COMPARATOR|Web|Didactic training using internet
62738785|NCT06420349|EXPERIMENTAL|Treatment (NXP800)|Patients receive NXP800 according to assigned treatment schedule. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or PET at baseline and on study. Patients may optionally undergo ultrasound-guided liver biopsy and/or collection of blood samples on study and during follow up.
62738955|NCT03490292|EXPERIMENTAL|Run-In Phase|"6 patients enrolled will receive weekly carboplatin (AUC2) and paclitaxel (50 mg/m2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\] while undergoing radiation therapy \[23 fractions, M-F, estimated completion day 35\].~Avelumab combined with Chemoradiation - Avelumab (10 mg/kg IV) every 2 weeks starting on the day of the last chemotherapy infusion (day 29). A total of 3 doses administered during the pre-operative period and an additional 6 doses of avelumab post-operatively.~Trial enrollment will resume after at least 5 patients do not have a dose-limiting toxicity (DLT) during the DLT evaluation period or until all 6 patients are seen for post-operative evaluation. If 2 or more patients experience dose limiting toxicities associated with the proposed treatments, further accrual of the subjects will be halted and trial will be suspended. Trial may be reopened in the future with appropriate schedule and dose modifications of the proposed treatment."
62738956|NCT03490292|EXPERIMENTAL|Expansion Cohort|Following a determination of safe and tolerable treatment outcome of the Run-In Phase, Part 2 of the trial will enroll 18 additional patients to evaluate activity of the proposed treatment and to obtain further safety information (carboplatin, paclitaxel, radiation \& Avelumab combined with Chemoradiation).
62738957|NCT00595881||Ultrasound|One group of patients will undergo emergency bedside ultrasound in addition to the clinical examination.
62738958|NCT03122899|OTHER|SIJ fusion with iFuse 3D with 6 mo CT|These subjects will get pelvic CT at 6 months post-operatively.
62738959|NCT03122899|OTHER|SIJ fusion with iFuse 3D with 12 mo CT|These subjects will get pelvic CT at 12 months post-operatively.
62738960|NCT06446596|EXPERIMENTAL|Telerehabilitation-based exercises|Home therapeutic exercise intervention scheduled through a software of digital physiotherapy and telerehabilitation
62738961|NCT06446596|ACTIVE_COMPARATOR|Standard home-based exercise|Home therapeutic exercise program scheduled through a dossier and an exercise diary
62738962|NCT03989375|EXPERIMENTAL|experiment group|
62738963|NCT03989375|NO_INTERVENTION|control group|
62738964|NCT06053151|EXPERIMENTAL|experiemental group|The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy.
62738965|NCT06053151|NO_INTERVENTION|control group|The control group will receive standard antenatal treatments without intervention.
62738966|NCT05645107|EXPERIMENTAL|XEMBIFY + Standard Medical Treatment (SMT)|"Participants will receive a loading dose of 150 milligrams per kilograms per day (mg/kg/day) (Week 1, Days 1 to 5) subcutaneously (SC) for 5 consecutive daily doses followed by biweekly infusions of 300 mg/kg/2-week starting Week 3 (Day 15) through Week 51 (end of Treatment Phase).~The SMT will include the active treatments and the other supportive treatments that the participants will need during their participation."
62738967|NCT05645107|PLACEBO_COMPARATOR|Placebo + SMT|"Participants will receive sterile 0.9 percent Sodium Chloride Injection (commercially available in the corresponding country) starting at Week 1 (Days 1 to 5) SC for 5 consecutive daily doses followed by biweekly infusions starting at Week 3 (Day 15) through Week 51.~The SMT will include the active treatments and the other supportive treatments that the participants will need during their participation."
62738968|NCT01518686|NO_INTERVENTION|one arm|observational study, no cohort, single group of different ages
62738969|NCT05139719|EXPERIMENTAL|HEC585 tables does A|
62738970|NCT05139719|EXPERIMENTAL|HEC585 tables does B|
62738971|NCT05139719|PLACEBO_COMPARATOR|placebo|Placebo once daily up to 24 weeks in main stage; HEC585 dose A once daily up to 96 weeks in extended stage
62738972|NCT05464771||Patients experiencing adverse event while in hospital|Patients that have experienced a patient safety incident according to the Patient Safety Indicators (PSIs) developed by the U.S. Agency for Healthcare Research and Quality (AHRQ)
62738973|NCT04642118|EXPERIMENTAL|Pulmonary recruitment maneuver 30 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver \[balloon bag\] from anesthesiologist 5 times of setting pressure 30 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
62738974|NCT04642118|ACTIVE_COMPARATOR|Pulmonary recruitment maneuver 40 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver \[balloon bag\] from anesthesiologist 5 times of setting pressure 40 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
62738975|NCT04642118|NO_INTERVENTION|Control|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will not be received any positive pressure from Pulmonary recruiment maneuver \[balloon bag\] from anesthesiologist."
62738976|NCT05292495|EXPERIMENTAL|Cohort one: mild renal insufficiency|
62738977|NCT05292495|EXPERIMENTAL|Cohort two: moderate renal insufficiency|
62738978|NCT05292495|EXPERIMENTAL|Cohort three: severe renal insufficiency|
62738979|NCT05292495|EXPERIMENTAL|Cohort four: end-stage renal disease|
62738980|NCT05292495|EXPERIMENTAL|Cohort five: normal renal function|
62738981|NCT05961111|EXPERIMENTAL|R130 Treatment Group|Every 7-14 days,1-2 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors
62738982|NCT00577707|EXPERIMENTAL|Patients With Stage IB-IIIA NSCLC With EGFR Mutations|This is a open label, single center, phase II trial for patients with clinical stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable tumors that harbor EGFR activating mutations. Patients will receive erlotinib x 3 weeks prior to initiation of concurrent erlotinib and chemotherapy.
62738983|NCT05740527|OTHER|Testing closed-loop system in an ambulatory setting|Closed-loop system feasibility testing
62738984|NCT05688202|ACTIVE_COMPARATOR|Left face|The face's left side is treated with simultaneous combination therapy, in which fractional CO2 laser is performed immediately following subcision
62738985|NCT05688202|PLACEBO_COMPARATOR|Right face|The face's right side receives sequential combination therapy with fractional CO2 laser conducted two weeks after subcision.
